Dossier zur Nutzenbewertung gemäß § 35a SGB V

Tezepelumab (Tezspire®)

AstraZeneca GmbH

Modul 4 A – Anhang 4-G-9

Add-on-Erhaltungstherapie bei Erwachsenen und Jugendlichen ab 12 Jahren mit schwerem Asthma, das trotz hochdosierter inhalativer Kortikosteroide plus eines weiteren Arzneimittels zur Erhaltungstherapie unzureichend kontrolliert ist

Zusätzlicher Datenschnitt

Studie PATHWAY

RCT mit dem zu bewertenden Arzneimittel

Stand: 11.11.2022

Table PT2BA_IOOB0: Baseline age
DITT

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline age	Tezepelumab	137	137	52.7 (12.7)	21	46.0	55.0	61.0	75
	Placebo	138	138	52.3 (11.7)	20	45.0	54.0	61.0	74

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years.
Source Data: ASL, created on: 11AUG2022

Table PT2BAG1_IOOA0: Baseline age - categorical
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline age - categorical	< 18 years	137	0 (0.0)	138	0 (0.0)
	18 to < 65 years	137	114 (83.2)	138	118 (85.5)
	>= 65 years	137	23 (16.8)	138	20 (14.5)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2BS_IOOA0: Sex
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Sex	Male	137	50 (36.5)	138	44 (31.9)
	Female	137	87 (63.5)	138	94 (68.1)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2BRC_IOOA0: Race
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Race	White	137	128 (93.4)	138	123 (89.1)
	Black or African American	137	3 (2.2)	138	6 (4.3)
	Asian	137	5 (3.6)	138	6 (4.3)
	Other	137	1 (0.7)	138	3 (2.2)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2DRG_IOOA0: Region
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Region	Europe	137	78 (56.9)	138	80 (58.0)
	America	137	10 (7.3)	138	9 (6.5)
	Asia/Pacific	137	5 (3.6)	138	6 (4.3)
	Rest of the world	137	44 (32.1)	138	43 (31.2)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Europe = Austria, Denmark, UK, France, Germany, Slovakia, Bulgaria, Czech Republic, Hungary, Latvia, Lithuania, Poland.
America = North and South. Asia/Pacific = South Korea, Japan, Taiwan, Vietnam, Australia. Rest of the world = all others.
Source Data: ASL, created on: 11AUG2022

Table PT2BW_IOOB0: Baseline weight
DITT

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline weight	Tezepelumab	137	137	80.15 (16.18)	45.5	70.00	78.00	88.00	133.0
	Placebo	138	138	79.09 (15.40)	45.1	68.70	80.15	90.00	119.8

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in kg.
Source Data: ASL, created on: 11AUG2022

Table PT2BM_IOOB0: Baseline BMI
DITT

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline BMI	Tezepelumab	137	137	28.50 (4.91)	19.8	24.77	28.26	31.89	39.5
	Placebo	138	138	28.45 (5.55)	18.0	24.09	27.98	31.74	44.4

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in kg/m**2.
Source Data: ASL, created on: 11AUG2022

Table PT2BMG_IOOA0: Baseline BMI - categorical
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline BMI - categorical	< 18.5 kg/m**2	137	0 (0.0)	138	1 (0.7)
	18.5 - < 25.0 kg/m**2	137	39 (28.5)	138	43 (31.2)
	25.0 - < 30.0 kg/m**2	137	45 (32.8)	138	47 (34.1)
	>= 30.0 kg/m**2	137	53 (38.7)	138	47 (34.1)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CEX_IOOA0: Number of exacerbations past 12 months
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Number of exacerbations in the past 12 months	1	137	3 (2.2)	138	3 (2.2)
	2	137	102 (74.5)	138	107 (77.5)
	3	137	21 (15.3)	138	12 (8.7)
	4	137	3 (2.2)	138	6 (4.3)
	5	137	3 (2.2)	138	3 (2.2)
	6	137	3 (2.2)	138	5 (3.6)
	7	137	0 (0.0)	138	1 (0.7)
	10	137	2 (1.5)	138	1 (0.7)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CEXG_IOOA0: Number of exacerbations past 12 months - categorical
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Number of exacerbations in the past 12 months - categorical	<= 2	137	105 (76.6)	138	110 (79.7)
	> 2	137	32 (23.4)	138	28 (20.3)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CEO_IOOB0: Baseline eosinophils
DITT

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline eosinophils	Tezepelumab	137	136	366.8 (351.6)	0	160.0	285.0	475.0	3180
	Placebo	138	138	383.3 (332.6)	0	150.0	285.0	490.0	1870

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in cells/ul.
Source Data: ASL, created on: 11AUG2022

Table PT2CEOG_IOOA0: Baseline eosinophils - categorical
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline eosinophils - categorical	< 150 cells/uL	137	27 (19.7)	138	33 (23.9)
	150 - < 300 cells/uL	137	42 (30.7)	138	39 (28.3)
	>= 300 cells/uL	137	67 (48.9)	138	66 (47.8)
	Missing	137	1 (0.7)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CFE_IOOB0: Baseline FeNO
DITT

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline FeNO	Tezepelumab	137	135	31.5 (29.8)	4	12.7	22.0	36.5	153
	Placebo	138	137	37.8 (39.7)	4	12.5	22.0	46.5	276

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in ppb.
Source Data: ASL, created on: 11AUG2022

Table PT2CFEG_IOOA0: Baseline FeNO - categorical
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline FeNO - categorical	< 25 ppb	137	78 (56.9)	138	74 (53.6)
	25 - < 50 ppb	137	33 (24.1)	138	30 (21.7)
	>= 50 ppb	137	24 (17.5)	138	33 (23.9)
	Missing	137	2 (1.5)	138	1 (0.7)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CIG_IOOB0: Baseline total serum IgE
DITT

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline total serum IgE	Tezepelumab	137	137	483.88 (1402.46)	2.0	62.90	135.40	334.90	11429.6
	Placebo	138	138	475.10 (1271.51)	6.0	83.70	148.15	400.00	11859.6

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in IE/ml.
Source Data: ASL, created on: 11AUG2022

Table PT2CIGG_IOOA0: Baseline total serum IgE - categorical
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline total serum IgE - categorical	Low	137	35 (25.5)	138	32 (23.2)
	Normal	137	95 (69.3)	138	98 (71.0)
	High	137	7 (5.1)	138	8 (5.8)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CPF_IOOA0: Perennial FEIA status at baseline
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Perennial FEIA status	All negative	137	57 (41.6)	138	66 (47.8)
	Any positive	137	71 (51.8)	138	63 (45.7)
	Missing	137	9 (6.6)	138	9 (6.5)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CID_IOOA0: ICS dose level at study entry
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
ICS dose level at study entry	Medium/Low	137	70 (51.1)	138	73 (52.9)
	High	137	67 (48.9)	138	65 (47.1)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
No patients with low dose levels reported.
Source Data: ASL, created on: 11AUG2022

Table PT2CMB_IOOA0: LABA use at baseline
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
LABA use at baseline	Yes	137	135 (98.5)	138	138 (100.0)
	No	137	2 (1.5)	138	0 (0.0)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CML_IOOA0: LAMA use at baseline
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
LAMA use at baseline	Yes	137	11 (8.0)	138	6 (4.3)
	No	137	126 (92.0)	138	132 (95.7)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CMT_IOOA0: Tiotropium use at baseline
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Tiotropium use at baseline	Yes	137	9 (6.6)	138	3 (2.2)
	No	137	128 (93.4)	138	135 (97.8)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CMO_IOOA0: OCS use at baseline
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
OCS use at baseline	Yes	137	9 (6.6)	138	13 (9.4)
	No	137	128 (93.4)	138	125 (90.6)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CMC_IOOA0: Montelukast/Cromoglicic acid use at baseline
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Montelukast/Cromoglicic acid use at baseline	Yes	137	29 (21.2)	138	37 (26.8)
	No	137	108 (78.8)	138	101 (73.2)
	Missing	137	0 (0.0)	138	0 (0.0)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CD_IOOB0: Time since asthma diagnosis
DITT

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Time since asthma diagnosis	Tezepelumab	137	137	18.7 (14.2)	1	7.0	16.0	26.0	66
	Placebo	138	138	16.9 (13.0)	1	7.0	14.0	23.0	69

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years.
Source Data: ASL, created on: 11AUG2022

Table PT2CA_IOOB0: Age at asthma diagnosis
DITT

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Age at asthma diagnosis	Tezepelumab	137	137	33.9 (17.9)	0	22.0	36.0	48.0	71
	Placebo	138	138	35.4 (16.3)	2	23.0	38.0	46.0	67

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years.
Source Data: ASL, created on: 11AUG2022

Table PT2DFS_IOOB0: Duration of study period
DITT

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Duration of study period	Tezepelumab	137	121	411.5 (111.9)	15	446.0	449.0	450.0	471
	Placebo	138	115	438.3 (56.2)	96	447.0	449.0	451.0	464

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in days.
Source Data: ASL, created on: 11AUG2022

Table PT2DFT_IOOB0: Duration of on-treatment period
DITT

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Duration of on-treatment period	Tezepelumab	137	121	411.5 (111.9)	15	446.0	449.0	450.0	471
	Placebo	138	115	438.3 (56.2)	96	447.0	449.0	451.0	464

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in days.
Source Data: ASL, created on: 11AUG2022

Table PT2DFE_IOOB0: Duration of exposure
DITT

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Duration of exposure	Tezepelumab	137	137	323.5 (87.0)	1	350.0	351.0	351.0	358
	Placebo	138	138	339.8 (52.2)	18	350.0	351.0	352.0	356

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in days.
Source Data: ASL, created on: 11AUG2022

Table PT2DIS_IOOO: Patient disposition
DITT

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Patients in analysis set		137	137 (100.0)	138	138 (100.0)
Patients completing study		137	106 (77.4)	138	107 (77.5)
Patients withdrawn from study		137	15 (10.9)	138	8 (5.8)
Reasons for withdrawal	Lost To Follow-Up	137	1 (0.7)	138	0 (0.0)
	Other	137	7 (5.1)	138	4 (2.9)
	Withdrawal Of Consent	137	7 (5.1)	138	4 (2.9)

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of affected patients.
In case of ongoing patients at time of data-cut, the number of patients completing study and patients withdrawn from study do not add up to N.
Source Data: ASL, created on: 11AUG2022

Table PT2BA_ILOB0: Baseline age
DITTL

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline age	Tezepelumab	66	66	52.0 (12.9)	21	46.0	54.0	61.0	74
	Placebo	65	65	52.2 (13.1)	20	44.0	54.0	62.0	74

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years.
Source Data: ASL, created on: 11AUG2022

Table PT2BAG1_ILOA0: Baseline age - categorical
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline age - categorical	< 18 years	66	0 (0.0)	65	0 (0.0)
	18 to < 65 years	66	57 (86.4)	65	55 (84.6)
	>= 65 years	66	9 (13.6)	65	10 (15.4)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2BS_ILOA0: Sex
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Sex	Male	66	19 (28.8)	65	20 (30.8)
	Female	66	47 (71.2)	65	45 (69.2)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2BRC_ILOA0: Race
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Race	White	66	60 (90.9)	65	58 (89.2)
	Black or African American	66	2 (3.0)	65	2 (3.1)
	Asian	66	3 (4.5)	65	3 (4.6)
	Other	66	1 (1.5)	65	2 (3.1)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2DRG_ILOA0: Region
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Region	Europe	66	40 (60.6)	65	36 (55.4)
	America	66	6 (9.1)	65	4 (6.2)
	Asia/Pacific	66	3 (4.5)	65	3 (4.6)
	Rest of the world	66	17 (25.8)	65	22 (33.8)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Europe = Austria, Denmark, UK, France, Germany, Slovakia, Bulgaria, Czech Republic, Hungary, Latvia, Lithuania, Poland.
America = North and South. Asia/Pacific = South Korea, Japan, Taiwan, Vietnam, Australia. Rest of the world = all others.
Source Data: ASL, created on: 11AUG2022

Table PT2BW_ILOB0: Baseline weight
DITTL

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline weight	Tezepelumab	66	66	80.15 (16.18)	45.5	70.00	78.06	88.40	126.0
	Placebo	65	65	77.39 (14.47)	45.1	68.00	80.00	85.00	116.0

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in kg.
Source Data: ASL, created on: 11AUG2022

Table PT2BM_ILOB0: Baseline BMI
DITTL

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline BMI	Tezepelumab	66	66	28.72 (4.91)	19.8	25.10	28.53	32.13	38.9
	Placebo	65	65	28.32 (5.47)	19.2	24.09	28.37	31.74	40.1

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in kg/m**2.
Source Data: ASL, created on: 11AUG2022

Table PT2BMG_ILOA0: Baseline BMI - categorical
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline BMI - categorical	< 18.5 kg/m**2	66	0 (0.0)	65	0 (0.0)
	18.5 - < 25.0 kg/m**2	66	15 (22.7)	65	21 (32.3)
	25.0 - < 30.0 kg/m**2	66	24 (36.4)	65	20 (30.8)
	>= 30.0 kg/m**2	66	27 (40.9)	65	24 (36.9)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CEX_ILOA0: Number of exacerbations past 12 months
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Number of exacerbations in the past 12 months	1	66	0 (0.0)	65	1 (1.5)
	2	66	44 (66.7)	65	44 (67.7)
	3	66	15 (22.7)	65	6 (9.2)
	4	66	1 (1.5)	65	5 (7.7)
	5	66	3 (4.5)	65	3 (4.6)
	6	66	3 (4.5)	65	5 (7.7)
	7	66	0 (0.0)	65	1 (1.5)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CEXG_ILOA0: Number of exacerbations past 12 months - categorical
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Number of exacerbations in the past 12 months - categorical	<= 2	66	44 (66.7)	65	45 (69.2)
	> 2	66	22 (33.3)	65	20 (30.8)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CEO_ILOB0: Baseline eosinophils
DITTL

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline eosinophils	Tezepelumab	66	65	342.2 (233.1)	50	170.0	290.0	440.0	1080
	Placebo	65	65	390.2 (339.5)	0	180.0	280.0	480.0	1510

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in cells/ul.
Source Data: ASL, created on: 11AUG2022

Table PT2CEOG_ILOA0: Baseline eosinophils - categorical
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline eosinophils - categorical	< 150 cells/uL	66	11 (16.7)	65	14 (21.5)
	150 - < 300 cells/uL	66	22 (33.3)	65	20 (30.8)
	>= 300 cells/uL	66	32 (48.5)	65	31 (47.7)
	Missing	66	1 (1.5)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CFE_ILOB0: Baseline FeNO
DITTL

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline FeNO	Tezepelumab	66	66	31.4 (28.5)	4	12.0	21.0	37.0	122
	Placebo	65	64	43.5 (46.6)	5	14.3	26.8	59.0	276

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in ppb.
Source Data: ASL, created on: 11AUG2022

Table PT2CFEG_ILOA0: Baseline FeNO - categorical
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline FeNO - categorical	< 25 ppb	66	39 (59.1)	65	30 (46.2)
	25 - < 50 ppb	66	15 (22.7)	65	16 (24.6)
	>= 50 ppb	66	12 (18.2)	65	18 (27.7)
	Missing	66	0 (0.0)	65	1 (1.5)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CIG_ILOB0: Baseline total serum IgE
DITTL

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline total serum IgE	Tezepelumab	66	66	373.31 (1258.28)	7.9	46.80	100.30	260.00	10017.0
	Placebo	65	65	545.48 (1139.88)	6.0	85.30	133.70	458.90	7265.3

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in IE/ml.
Source Data: ASL, created on: 11AUG2022

Table PT2CIGG_ILOA0: Baseline total serum IgE - categorical
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline total serum IgE - categorical	Low	66	23 (34.8)	65	14 (21.5)
	Normal	66	40 (60.6)	65	44 (67.7)
	High	66	3 (4.5)	65	7 (10.8)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CPF_ILOA0: Perennial FEIA status at baseline
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Perennial FEIA status	All negative	66	27 (40.9)	65	29 (44.6)
	Any positive	66	34 (51.5)	65	33 (50.8)
	Missing	66	5 (7.6)	65	3 (4.6)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CID_ILOA0: ICS dose level at study entry
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
ICS dose level at study entry	Medium/Low	66	0 (0.0)	65	0 (0.0)
	High	66	66 (100.0)	65	65 (100.0)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CMB_ILOA0: LABA use at baseline
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
LABA use at baseline	Yes	66	66 (100.0)	65	65 (100.0)
	No	66	0 (0.0)	65	0 (0.0)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CML_ILOA0: LAMA use at baseline
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
LAMA use at baseline	Yes	66	7 (10.6)	65	3 (4.6)
	No	66	59 (89.4)	65	62 (95.4)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CMT_ILOA0: Tiotropium use at baseline
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Tiotropium use at baseline	Yes	66	6 (9.1)	65	2 (3.1)
	No	66	60 (90.9)	65	63 (96.9)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CMO_ILOA0: OCS use at baseline
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
OCS use at baseline	Yes	66	9 (13.6)	65	13 (20.0)
	No	66	57 (86.4)	65	52 (80.0)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CMC_ILOA0: Montelukast/Cromoglicic acid use at baseline
DITTL

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Montelukast/Cromoglicic acid use at baseline	Yes	66	17 (25.8)	65	21 (32.3)
	No	66	49 (74.2)	65	44 (67.7)
	Missing	66	0 (0.0)	65	0 (0.0)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CD_ILOB0: Time since asthma diagnosis
DITTL

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Time since asthma diagnosis	Tezepelumab	66	66	20.7 (15.1)	1	9.0	16.0	30.0	57
	Placebo	65	65	18.1 (14.3)	1	8.0	16.0	24.0	69

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years.
Source Data: ASL, created on: 11AUG2022

Table PT2CA_ILOB0: Age at asthma diagnosis
DITTL

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Age at asthma diagnosis	Tezepelumab	66	66	31.3 (18.0)	0	15.0	31.5	46.0	66
	Placebo	65	65	34.1 (17.8)	2	23.0	36.0	45.0	65

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years.
Source Data: ASL, created on: 11AUG2022

Table PT2DFS_ILOB0: Duration of study period
DITTL

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Duration of study period	Tezepelumab	66	56	406.8 (117.5)	29	448.0	449.0	451.0	470
	Placebo	65	54	427.8 (80.1)	96	448.0	449.0	450.0	464

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in days.
Source Data: ASL, created on: 11AUG2022

Table PT2DFT_ILOB0: Duration of on-treatment period
DITTL

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Duration of on-treatment period	Tezepelumab	66	56	406.8 (117.5)	29	448.0	449.0	451.0	470
	Placebo	65	54	427.8 (80.1)	96	448.0	449.0	450.0	464

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in days.
Source Data: ASL, created on: 11AUG2022

Table PT2DFE_ILOB0: Duration of exposure
DITTL

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Duration of exposure	Tezepelumab	66	66	320.9 (89.5)	15	350.0	351.0	351.0	358
	Placebo	65	65	328.2 (74.4)	18	350.0	351.0	352.0	354

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in days.
Source Data: ASL, created on: 11AUG2022

Table PT2DIS_ILOO: Patient disposition
DITTL

Category		Tezepelumab N	Tezepelumab n (%)	Placebo N	Placebo n (%)
Patients in analysis set		66	66 (100.0)	65	65 (100.0)
Patients completing study		66	49 (74.2)	65	48 (73.8)
Patients withdrawn from study		66	7 (10.6)	65	6 (9.2)
Reasons for withdrawal	Other	66	4 (6.1)	65	2 (3.1)
	Withdrawal Of Consent	66	3 (4.5)	65	4 (6.2)

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of affected patients.
In case of ongoing patients at time of data-cut, the number of patients completing study and patients withdrawn from study do not add up to N.
Source Data: ASL, created on: 11AUG2022

Table PT2BA_IBOB0: Baseline age
DITTB

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline age	Tezepelumab	12	12	49.2 (12.2)	29	39.5	51.0	55.5	74
	Placebo	9	9	54.9 (12.0)	42	44.0	52.0	64.0	74

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years.
Source Data: ASL, created on: 11AUG2022

Table PT2BAG1_IBOA0: Baseline age - categorical
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline age - categorical	< 18 years	12	0 (0.0)	9	0 (0.0)
	18 to < 65 years	12	11 (91.7)	9	7 (77.8)
	>= 65 years	12	1 (8.3)	9	2 (22.2)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2BS_IBOA0: Sex
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Sex	Male	12	2 (16.7)	9	1 (11.1)
	Female	12	10 (83.3)	9	8 (88.9)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2BRC_IBOA0: Race
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Race	White	12	10 (83.3)	9	8 (88.9)
	Black or African American	12	2 (16.7)	9	1 (11.1)
	Asian	12	0 (0.0)	9	0 (0.0)
	Other	12	0 (0.0)	9	0 (0.0)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2DRG_IBOA0: Region
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Region	Europe	12	10 (83.3)	9	5 (55.6)
	America	12	2 (16.7)	9	2 (22.2)
	Asia/Pacific	12	0 (0.0)	9	0 (0.0)
	Rest of the world	12	0 (0.0)	9	2 (22.2)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Europe = Austria, Denmark, UK, France, Germany, Slovakia, Bulgaria, Czech Republic, Hungary, Latvia, Lithuania, Poland.
America = North and South. Asia/Pacific = South Korea, Japan, Taiwan, Vietnam, Australia. Rest of the world = all others.
Source Data: ASL, created on: 11AUG2022

Table PT2BW_IBOB0: Baseline weight
DITTB

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline weight	Tezepelumab	12	12	85.57 (16.73)	58.6	74.50	82.10	98.00	115.0
	Placebo	9	9	72.56 (17.41)	46.0	54.20	79.38	83.00	95.0

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in kg.
Source Data: ASL, created on: 11AUG2022

Table PT2BM_IBOB0: Baseline BMI
DITTB

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline BMI	Tezepelumab	12	12	30.62 (4.77)	20.8	27.54	31.86	34.11	37.1
	Placebo	9	9	27.68 (6.53)	19.7	24.09	26.61	31.24	39.5

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in kg/m**2.
Source Data: ASL, created on: 11AUG2022

Table PT2BMG_IBOA0: Baseline BMI - categorical
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline BMI - categorical	< 18.5 kg/m**2	12	0 (0.0)	9	0 (0.0)
	18.5 - < 25.0 kg/m**2	12	1 (8.3)	9	4 (44.4)
	25.0 - < 30.0 kg/m**2	12	4 (33.3)	9	2 (22.2)
	>= 30.0 kg/m**2	12	7 (58.3)	9	3 (33.3)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CEX_IBOA0: Number of exacerbations past 12 months
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Number of exacerbations in the past 12 months	2	12	7 (58.3)	9	5 (55.6)
	3	12	4 (33.3)	9	2 (22.2)
	4	12	1 (8.3)	9	2 (22.2)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CEXG_IBOA0: Number of exacerbations past 12 months - categorical
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Number of exacerbations in the past 12 months - categorical	<= 2	12	7 (58.3)	9	5 (55.6)
	> 2	12	5 (41.7)	9	4 (44.4)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CEO_IBOB0: Baseline eosinophils
DITTB

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline eosinophils	Tezepelumab	12	12	140.0 (49.2)	50	100.0	155.0	170.0	230
	Placebo	9	9	196.7 (92.5)	30	180.0	220.0	260.0	290

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in cells/ul.
Source Data: ASL, created on: 11AUG2022

Table PT2CEOG_IBOA0: Baseline eosinophils - categorical
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline eosinophils - categorical	< 150 cells/uL	12	5 (41.7)	9	2 (22.2)
	150 - < 300 cells/uL	12	7 (58.3)	9	7 (77.8)
	>= 300 cells/uL	12	0 (0.0)	9	0 (0.0)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CFE_IBOB0: Baseline FeNO
DITTB

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline FeNO	Tezepelumab	12	12	14.1 (5.4)	8	8.8	13.5	19.4	23
	Placebo	9	9	14.7 (6.2)	5	9.5	17.5	19.5	21

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in ppb.
Source Data: ASL, created on: 11AUG2022

Table PT2CFEG_IBOA0: Baseline FeNO - categorical
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline FeNO - categorical	< 25 ppb	12	12 (100.0)	9	9 (100.0)
	25 - < 50 ppb	12	0 (0.0)	9	0 (0.0)
	>= 50 ppb	12	0 (0.0)	9	0 (0.0)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CIG_IBOB0: Baseline total serum IgE
DITTB

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline total serum IgE	Tezepelumab	12	12	27.76 (17.69)	7.9	12.45	23.85	38.05	61.5
	Placebo	9	9	525.18 (1008.78)	11.1	20.30	41.60	50.00	2727.2

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in IE/ml.
Source Data: ASL, created on: 11AUG2022

Table PT2CIGG_IBOA0: Baseline total serum IgE - categorical
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Baseline total serum IgE - categorical	Low	12	12 (100.0)	9	7 (77.8)
	Normal	12	0 (0.0)	9	0 (0.0)
	High	12	0 (0.0)	9	2 (22.2)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CPF_IBOA0: Perennial FEIA status at baseline
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Perennial FEIA status	All negative	12	7 (58.3)	9	5 (55.6)
	Any positive	12	2 (16.7)	9	3 (33.3)
	Missing	12	3 (25.0)	9	1 (11.1)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CID_IBOA0: ICS dose level at study entry
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
ICS dose level at study entry	Medium/Low	12	0 (0.0)	9	0 (0.0)
	High	12	12 (100.0)	9	9 (100.0)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CMB_IBOA0: LABA use at baseline
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
LABA use at baseline	Yes	12	12 (100.0)	9	9 (100.0)
	No	12	0 (0.0)	9	0 (0.0)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CML_IBOA0: LAMA use at baseline
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
LAMA use at baseline	Yes	12	0 (0.0)	9	1 (11.1)
	No	12	12 (100.0)	9	8 (88.9)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CMT_IBOA0: Tiotropium use at baseline
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Tiotropium use at baseline	Yes	12	0 (0.0)	9	1 (11.1)
	No	12	12 (100.0)	9	8 (88.9)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CMO_IBOA0: OCS use at baseline
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
OCS use at baseline	Yes	12	0 (0.0)	9	0 (0.0)
	No	12	12 (100.0)	9	9 (100.0)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CMC_IBOA0: Montelukast/Cromoglicic acid use at baseline
DITTB

		Tezepelumab		Placebo	
	Category	N	n (%)	N	n (%)
Montelukast/Cromoglicic acid use at baseline	Yes	12	0 (0.0)	9	1 (11.1)
	No	12	12 (100.0)	9	8 (88.9)
	Missing	12	0 (0.0)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients in category.
Source Data: ASL, created on: 11AUG2022

Table PT2CD_IBOB0: Time since asthma diagnosis
DITTB

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Time since asthma diagnosis	Tezepelumab	12	12	19.1 (17.2)	3	8.0	13.0	26.0	57
	Placebo	9	9	17.7 (11.9)	1	11.0	18.0	24.0	41

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years.
Source Data: ASL, created on: 11AUG2022

Table PT2CA_IBOB0: Age at asthma diagnosis
DITTB

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Age at asthma diagnosis	Tezepelumab	12	12	30.1 (19.6)	1	15.0	33.5	43.0	66
	Placebo	9	9	37.2 (14.0)	20	28.0	34.0	41.0	64

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years.
Source Data: ASL, created on: 11AUG2022

Table PT2DFS_IBOB0: Duration of study period
DITTB

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Duration of study period	Tezepelumab	12	10	382.5 (137.7)	71	422.0	449.0	450.0	454
	Placebo	9	8	448.8 (3.3)	441	449.0	449.5	450.0	452

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in days.
Source Data: ASL, created on: 11AUG2022

Table PT2DFT_IBOB0: Duration of on-treatment period
DITTB

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Duration of on-treatment period	Tezepelumab	12	10	382.5 (137.7)	71	422.0	449.0	450.0	454
	Placebo	9	8	448.8 (3.3)	441	449.0	449.5	450.0	452

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in days.
Source Data: ASL, created on: 11AUG2022

Table PT2DFE_IBOB0: Duration of exposure
DITTB

	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Duration of exposure	Tezepelumab	12	12	305.2 (109.6)	57	350.0	351.0	352.5	358
	Placebo	9	9	350.1 (4.6)	338	351.0	351.0	352.0	353

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in days.
Source Data: ASL, created on: 11AUG2022

Table PT2DIS_IBOO: Patient disposition
DITTB

Category		Tezepelumab N	Tezepelumab n (%)	Placebo N	Placebo n (%)
Patients in analysis set		12	12 (100.0)	9	9 (100.0)
Patients completing study		12	8 (66.7)	9	7 (77.8)
Patients withdrawn from study		12	2 (16.7)	9	1 (11.1)
Reasons for withdrawal	Other	12	1 (8.3)	9	1 (11.1)
	Withdrawal Of Consent	12	1 (8.3)	9	0 (0.0)

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of affected patients.
In case of ongoing patients at time of data-cut, the number of patients completing study and patients withdrawn from study do not add up to N.
Source Data: ASL, created on: 11AUG2022

Table PT2E_IOMN0: AAER during planned treatment period
DITT

AAER during planned treatment period					Adjusted rates		Rate ratio		
Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Tezepelumab	137	25	126.5	0.20	0.20	(0.12, 0.33)	0.241	(0.129, 0.449)	<0.001 *
Placebo	138	97	130.7	0.74	0.84	(0.58, 1.21)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model.
A negative binomial model was applied with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNK: AAER during planned treatment period by key subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Sex	Tezepelumab									0.821	
Male	Tezepelumab	50	8	47.3	0.17	0.17	(0.07, 0.41)	0.274	(0.091, 0.824)	0.021	*
Male	Placebo	44	24	41.6	0.58	0.63	(0.32, 1.25)				
Female	Tezepelumab	87	17	79.3	0.21	0.22	(0.12, 0.41)	0.235	(0.111, 0.498)	<0.001	*
Female	Placebo	94	73	89.1	0.82	0.94	(0.61, 1.45)				
Age	Tezepelumab									0.430	
< 65 years	Tezepelumab	114	20	106.5	0.19	NE		NE		NE	
< 65 years	Placebo	118	87	111.3	0.78	NE					
>= 65 years	Tezepelumab	23	5	20.1	0.25	0.25	(0.07, 0.90)	0.427	(0.077, 2.362)	0.330	
>= 65 years	Placebo	20	10	19.4	0.51	0.59	(0.19, 1.83)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNK: AAER during planned treatment period by key subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Exacerbations in the year before study	Tezepelumab									0.470	
<= 2	Tezepelumab	105	11	98.2	0.11	0.11	(0.06, 0.22)	0.287	(0.127, 0.653)	0.003	*
<= 2	Placebo	110	39	106.6	0.37	0.39	(0.25, 0.62)				
> 2	Tezepelumab	32	14	28.3	0.49	0.50	(0.27, 0.94)	0.193	(0.090, 0.414)	<0.001	*
> 2	Placebo	28	58	24.1	2.41	2.61	(1.69, 4.03)				
Race	Tezepelumab	N<10	any level							NE	
White	Tezepelumab	128	23	117.8	0.20						
White	Placebo	123	71	117.2	0.61						
Black or African American	Tezepelumab	3	0	2.9	0.00						
Black or African American	Placebo	6	9	5.5	1.65						
Asian	Tezepelumab	5	2	4.9	0.41						
Asian	Placebo	6	4	5.8	0.69						
Other	Tezepelumab	1	0	1.0	0.00						
Other	Placebo	3	13	2.3	5.64						

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNK: AAER during planned treatment period by key subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Region	Tezepelumab									0.016	i
Europe	Tezepelumab	78	17	72.8	0.23	0.24	(0.13, 0.45)	0.483	(0.217, 1.075)	0.075	
Europe	Placebo	80	36	78.2	0.46	0.50	(0.30, 0.82)				
America	Tezepelumab	10	4	9.0	0.44	0.44	(0.14, 1.39)	0.286	(0.070, 1.174)	0.082	
America	Placebo	9	12	8.3	1.44	1.55	(0.68, 3.57)				
Asia/Pacific	Tezepelumab	5	2	4.9	0.41	0.44	(0.02, 8.39)	0.533	(0.011, 26.826)	0.753	
Asia/Pacific	Placebo	6	4	5.8	0.69	0.82	(0.06, 10.79)				
Rest of the world	Tezepelumab	44	2	39.8	0.05	0.05	(0.01, 0.22)	0.038	(0.008, 0.185)	<0.001	*
Rest of the world	Placebo	43	45	38.4	1.17	1.34	(0.74, 2.42)				
BMI	Tezepelumab	N<10	any level							NE	
< 18.5 kg/m**2	Tezepelumab	0									
< 18.5 kg/m**2	Placebo	1	0	1.0	0.00						
18.5 - < 25.0 kg/m**2	Tezepelumab	39	5	38.3	0.13						
18.5 - < 25.0 kg/m**2	Placebo	43	33	40.8	0.81						
25.0 - < 30.0 kg/m**2	Tezepelumab	45	10	41.1	0.24						
25.0 - < 30.0 kg/m**2	Placebo	47	32	44.7	0.72						
>= 30.0 kg/m**2	Tezepelumab	53	10	47.1	0.21						
>= 30.0 kg/m**2	Placebo	47	32	44.2	0.72						

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNK: AAER during planned treatment period by key subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline eosinophils - Low	Tezepelumab									0.426	
< 150 cells/uL	Tezepelumab	27	4	25.5	0.16	0.17	(0.05, 0.57)	0.150	(0.035, 0.637)	0.010	*
< 150 cells/uL	Placebo	33	29	31.2	0.93	1.12	(0.52, 2.37)				
>= 150 cells/uL	Tezepelumab	109	21	100.0	0.21	0.21	(0.12, 0.37)	0.282	(0.142, 0.561)	<0.001	*
>= 150 cells/uL	Placebo	105	68	99.6	0.68	0.75	(0.50, 1.14)				
Baseline eosinophils - High	Tezepelumab									0.814	
< 300 cells/uL	Tezepelumab	69	11	61.9	0.18	0.18	(0.08, 0.40)	0.261	(0.100, 0.682)	0.006	*
< 300 cells/uL	Placebo	72	41	67.6	0.61	0.70	(0.40, 1.24)				
>= 300 cells/uL	Tezepelumab	67	14	63.6	0.22	0.22	(0.12, 0.43)	0.227	(0.101, 0.512)	<0.001	*
>= 300 cells/uL	Placebo	66	56	63.1	0.89	0.98	(0.61, 1.58)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNK: AAER during planned treatment period by key subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline FENO	Tezepelumab									0.119	
< 25 ppb	Tezepelumab	78	16	72.0	0.22	0.23	(0.12, 0.44)	0.398	(0.171, 0.926)	0.032	*
< 25 ppb	Placebo	74	38	71.5	0.53	0.58	(0.34, 0.99)				
>= 25 ppb	Tezepelumab	57	9	52.6	0.17	0.17	(0.08, 0.38)	0.148	(0.059, 0.375)	<0.001	*
>= 25 ppb	Placebo	63	59	58.2	1.01	1.17	(0.72, 1.89)				
Baseline specific perennial FEIA status	Tezepelumab									0.512	
All negative	Tezepelumab	57	12	52.9	0.23	0.23	(0.12, 0.47)	0.286	(0.124, 0.661)	0.003	*
All negative	Placebo	66	47	63.0	0.75	0.81	(0.51, 1.29)				
Any positive	Tezepelumab	71	10	64.8	0.15	0.16	(0.07, 0.36)	0.180	(0.062, 0.519)	0.002	*
Any positive	Placebo	63	43	59.0	0.73	0.87	(0.46, 1.68)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNK: AAER during planned treatment period by key subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Total serum IgE	Tezepelumab									0.840	
Low	Tezepelumab	35	6	32.2	0.19	0.19	(0.08, 0.49)	0.231	(0.074, 0.724)	0.012	*
Low	Placebo	32	23	30.4	0.76	0.83	(0.44, 1.60)				
Normal	Tezepelumab	95	18	88.3	0.20	0.21	(0.11, 0.38)	0.234	(0.110, 0.497)	<0.001	*
Normal	Placebo	98	72	92.5	0.78	0.89	(0.57, 1.39)				
High	Tezepelumab	7	1	6.1	0.16	0.16	(0.01, 2.08)	0.605	(0.024, 15.276)	0.760	
High	Placebo	8	2	7.9	0.25	0.27	(0.04, 2.01)				
OCS at baseline	Tezepelumab									0.980	
Yes	Tezepelumab	9	4	7.6	0.53	0.52	(0.16, 1.71)	0.265	(0.068, 1.040)	0.057	
Yes	Placebo	13	20	10.8	1.86	1.98	(0.99, 3.94)				
No	Tezepelumab	128	21	119.0	0.18	0.18	(0.10, 0.31)	0.250	(0.127, 0.493)	<0.001	*
No	Placebo	125	77	119.9	0.64	0.72	(0.48, 1.08)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNK: AAER during planned treatment period by key subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
ICS dose level (at study entry)	Tezepelumab									0.337	
Medium/Low	Tezepelumab	70	9	65.3	0.14	0.14	(0.07, 0.29)	0.358	(0.144, 0.892)	0.027	*
Medium/Low	Placebo	73	27	71.9	0.38	0.39	(0.23, 0.65)				
High	Tezepelumab	67	16	61.3	0.26	0.27	(0.14, 0.51)	0.196	(0.089, 0.434)	<0.001	*
High	Placebo	65	70	58.8	1.19	1.37	(0.86, 2.19)				
LAMA use at baseline	Tezepelumab									0.679	
Yes	Tezepelumab	11	5	10.8	0.46	0.47	(0.17, 1.32)	0.356	(0.083, 1.533)	0.166	
Yes	Placebo	6	7	5.6	1.25	1.32	(0.47, 3.74)				
No	Tezepelumab	126	20	115.8	0.17	0.18	(0.10, 0.31)	0.216	(0.110, 0.426)	<0.001	*
No	Placebo	132	90	125.1	0.72	0.82	(0.55, 1.20)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNK: AAER during planned treatment period by key subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Tiotropium use at baseline	Tezepelumab									0.686	
Yes	Tezepelumab	9	5	8.8	0.57	0.57	(0.23, 1.43)	0.392	(0.095, 1.618)	0.196	
Yes	Placebo	3	4	2.8	1.44	1.46	(0.49, 4.32)				
No	Tezepelumab	128	20	117.8	0.17	0.17	(0.10, 0.30)	0.211	(0.107, 0.413)	<0.001	*
No	Placebo	135	93	127.9	0.73	0.83	(0.56, 1.21)				
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab									0.471	
Yes	Tezepelumab	29	11	24.3	0.45	0.45	(0.21, 0.97)	0.352	(0.140, 0.888)	0.027	*
Yes	Placebo	37	40	34.4	1.16	1.28	(0.77, 2.15)				
No	Tezepelumab	108	14	102.3	0.14	0.14	(0.07, 0.27)	0.209	(0.092, 0.478)	<0.001	*
No	Placebo	101	57	96.4	0.59	0.68	(0.41, 1.10)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNP: AAER during planned treatment period by study specific subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Race (cat. P)	Tezepelumab									0.307	
White	Tezepelumab	128	23	117.8	0.20	0.20	(0.12, 0.33)	0.302	(0.160, 0.567)	<0.001	*
White	Placebo	123	71	117.2	0.61	0.66	(0.45, 0.96)				
Non-white	Tezepelumab	9	2	8.8	0.23	0.24	(0.04, 1.50)	0.101	(0.012, 0.836)	0.033	*
Non-white	Placebo	15	26	13.6	1.92	2.34	(0.84, 6.50)				
Region (cat. P)	Tezepelumab									0.883	
North America/Western EU	Tezepelumab	10	4	9.0	0.44	0.44	(0.14, 1.39)	0.286	(0.070, 1.174)	0.082	
North America/Western EU	Placebo	9	12	8.3	1.44	1.55	(0.68, 3.57)				
Rest of world	Tezepelumab	127	21	117.5	0.18	0.18	(0.11, 0.32)	0.233	(0.118, 0.460)	<0.001	*
Rest of world	Placebo	129	85	122.4	0.69	0.79	(0.53, 1.18)				
Baseline eosinophils (cat. P)	Tezepelumab									0.498	
< 250 cells/uL	Tezepelumab	61	8	58.9	0.14	0.14	(0.06, 0.31)	0.184	(0.067, 0.501)	<0.001	*
< 250 cells/uL	Placebo	60	37	56.4	0.66	0.75	(0.42, 1.31)				
>= 250 cells/uL	Tezepelumab	76	17	67.6	0.25	0.26	(0.14, 0.49)	0.286	(0.129, 0.634)	0.002	*
>= 250 cells/uL	Placebo	78	60	74.3	0.81	0.91	(0.56, 1.47)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNP: AAER during planned treatment period by study specific subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline FENO (cat. P)	Tezepelumab									0.101	
< 24 ppb	Tezepelumab	75	15	69.0	0.22	0.23	(0.11, 0.45)	0.423	(0.172, 1.038)	0.060	
< 24 ppb	Placebo	72	34	69.7	0.49	0.53	(0.30, 0.95)				
>= 24 ppb	Tezepelumab	60	10	55.5	0.18	0.18	(0.09, 0.38)	0.152	(0.064, 0.363)	<0.001	*
>= 24 ppb	Placebo	65	63	60.1	1.05	1.19	(0.76, 1.89)				
Baseline FENO (cat. M)	Tezepelumab									0.156	
< 22.0 ppb	Tezepelumab	65	13	59.1	0.22	0.23	(0.11, 0.50)	0.414	(0.150, 1.143)	0.089	
< 22.0 ppb	Placebo	62	30	59.8	0.50	0.56	(0.29, 1.07)				
>= 22.0 ppb	Tezepelumab	70	12	65.4	0.18	0.19	(0.09, 0.36)	0.171	(0.077, 0.380)	<0.001	*
>= 22.0 ppb	Placebo	75	67	69.9	0.96	1.08	(0.71, 1.66)				
Baseline all FEIA status	Tezepelumab									0.213	
All negative	Tezepelumab	50	12	45.9	0.26	0.27	(0.13, 0.54)	0.378	(0.155, 0.923)	0.033	*
All negative	Placebo	50	31	47.7	0.65	0.71	(0.41, 1.22)				
Any positive	Tezepelumab	77	10	70.8	0.14	0.14	(0.07, 0.32)	0.157	(0.060, 0.410)	<0.001	*
Any positive	Placebo	80	59	75.3	0.78	0.91	(0.53, 1.56)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNP: AAER during planned treatment period by study specific subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Th2 status	Tezepelumab									0.204	
Low	Tezepelumab	70	10	64.7	0.15	0.16	(0.07, 0.34)	0.153	(0.060, 0.387)	<0.001	*
Low	Placebo	62	51	57.5	0.89	1.04	(0.61, 1.78)				
High	Tezepelumab	65	14	59.9	0.23	0.24	(0.12, 0.48)	0.346	(0.147, 0.810)	0.015	*
High	Placebo	75	46	72.2	0.64	0.69	(0.42, 1.14)				
Baseline Periostin	Tezepelumab									0.724	
Low (< 20.9 ng/ml)	Tezepelumab	62	12	56.9	0.21	0.22	(0.10, 0.48)	0.273	(0.104, 0.714)	0.008	*
Low (< 20.9 ng/ml)	Placebo	67	43	62.4	0.69	0.81	(0.45, 1.44)				
High (>= 20.9 ng/ml)	Tezepelumab	74	13	68.6	0.19	0.19	(0.10, 0.37)	0.220	(0.097, 0.497)	<0.001	*
High (>= 20.9 ng/ml)	Placebo	71	54	68.3	0.79	0.87	(0.54, 1.39)				
Current post-BD FEV1 reversibility	Tezepelumab									0.491	
Yes	Tezepelumab	114	17	106.2	0.16	0.16	(0.09, 0.29)	0.248	(0.126, 0.490)	<0.001	*
Yes	Placebo	126	73	120.1	0.61	0.66	(0.45, 0.96)				
No	Tezepelumab	23	8	20.4	0.39	0.40	(0.15, 1.06)	0.143	(0.035, 0.589)	0.007	*
No	Placebo	12	24	10.6	2.27	2.77	(1.00, 7.67)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_IOSNP: AAER during planned treatment period by study specific subgroups
DITT

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Maintenance OCS use at baseline	Tezepelumab									0.710	
Yes	Tezepelumab	9	4	7.6	0.53	0.52	(0.15, 1.80)	0.201	(0.049, 0.830)	0.027	*
Yes	Placebo	14	27	11.4	2.36	2.60	(1.30, 5.21)				
No	Tezepelumab	128	21	119.0	0.18	0.18	(0.11, 0.31)	0.280	(0.143, 0.545)	<0.001	*
No	Placebo	124	70	119.3	0.59	0.65	(0.43, 0.96)				
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab									0.454	
Yes	Tezepelumab	108	16	101.4	0.16	0.16	(0.09, 0.29)	0.278	(0.136, 0.564)	<0.001	*
Yes	Placebo	115	60	110.9	0.54	0.58	(0.39, 0.87)				
No	Tezepelumab	29	9	25.1	0.36	0.36	(0.15, 0.86)	0.166	(0.054, 0.513)	0.002	*
No	Placebo	23	37	19.8	1.86	2.17	(1.06, 4.41)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOMN0: Severe AAER during planned treatment period
DITT

Severe AAER during planned treatment period					Adjusted rates		Rate ratio			
Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Tezepelumab	137	3	127.5	0.02	0.02	(0.01, 0.09)	0.139	(0.027, 0.720)	0.019	*
Placebo	138	19	134.5	0.14	0.17	(0.07, 0.42)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model.
A negative binomial model was applied with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNK: Severe AAER during planned treatment period by key subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Sex	Tezepelumab									0.548	
Male	Tezepelumab	50	1	47.6	0.02	0.02	(0.00, 0.15)	0.447	(0.041, 4.934)	0.511	
Male	Placebo	44	2	42.6	0.05	0.05	(0.01, 0.19)				
Female	Tezepelumab	87	2	79.9	0.03	0.03	(0.00, 0.14)	0.116	(0.016, 0.848)	0.034	*
Female	Placebo	94	17	91.9	0.19	0.22	(0.08, 0.61)				
Age	Tezepelumab									0.477	
< 65 years	Tezepelumab	114	2	107.2	0.02	0.02	(0.00, 0.10)	0.102	(0.014, 0.759)	0.026	*
< 65 years	Placebo	118	17	114.6	0.15	0.18	(0.06, 0.54)				
>= 65 years	Tezepelumab	23	1	20.3	0.05	0.05	(0.01, 0.35)	0.490	(0.044, 5.405)	0.560	
>= 65 years	Placebo	20	2	19.9	0.10	0.10	(0.03, 0.40)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNK: Severe AAER during planned treatment period by key subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Exacerbations in the year before study	Tezepelumab									0.570	
<= 2	Tezepelumab	105	1	98.6	0.01	0.01	(0.00, 0.07)	0.274	(0.031, 2.450)	0.247	
<= 2	Placebo	110	4	108.1	0.04	0.04	(0.01, 0.10)				
> 2	Tezepelumab	32	2	28.9	0.07	0.07	(0.01, 0.39)	0.104	(0.013, 0.846)	0.034	*
> 2	Placebo	28	15	26.4	0.57	0.67	(0.20, 2.18)				
Race	Tezepelumab	N<10	any level							NE	
White	Tezepelumab	128	3	118.6	0.03						
White	Placebo	123	10	119.9	0.08						
Black or African American	Tezepelumab	3	0	2.9	0.00						
Black or African American	Placebo	6	1	6.0	0.17						
Asian	Tezepelumab	5	0	5.0	0.00						
Asian	Placebo	6	0	6.0	0.00						
Other	Tezepelumab	1	0	1.0	0.00						
Other	Placebo	3	8	2.6	3.07						

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNK: Severe AAER during planned treatment period by key subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio		
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Region	Tezepelumab									NE
Europe	Tezepelumab	78	3	73.4	0.04	0.04	(0.01, 0.16)	1.070	(0.159, 7.197)	0.944
Europe	Placebo	80	3	79.8	0.04	0.04	(0.01, 0.15)			
America	Tezepelumab	10	0	9.2	0.00					NE
America	Placebo	9	1	9.0	0.11					
Asia/Pacific	Tezepelumab	5	0	5.0	0.00					NE
Asia/Pacific	Placebo	6	0	6.0	0.00					
Rest of the world	Tezepelumab	44	0	39.9	0.00					NE
Rest of the world	Placebo	43	15	39.7	0.38					
BMI	Tezepelumab	N<10	any level							NE
< 18.5 kg/m**2	Tezepelumab	0								
< 18.5 kg/m**2	Placebo	1	0	1.0	0.00					
18.5 - < 25.0 kg/m**2	Tezepelumab	39	1	38.5	0.03					
18.5 - < 25.0 kg/m**2	Placebo	43	2	42.2	0.05					
25.0 - < 30.0 kg/m**2	Tezepelumab	45	1	41.4	0.02					
25.0 - < 30.0 kg/m**2	Placebo	47	5	46.0	0.11					
>= 30.0 kg/m**2	Tezepelumab	53	1	47.6	0.02					
>= 30.0 kg/m**2	Placebo	47	12	45.3	0.27					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNK: Severe AAER during planned treatment period by key subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline eosinophils - Low	Tezepelumab									0.936	
< 150 cells/uL	Tezepelumab	27	1	25.6	0.04	0.04	(0.00, 0.49)	0.134	(0.007, 2.624)	0.185	
< 150 cells/uL	Placebo	33	8	32.2	0.25	0.29	(0.06, 1.43)				
>= 150 cells/uL	Tezepelumab	109	2	100.9	0.02	0.02	(0.00, 0.10)	0.154	(0.022, 1.094)	0.061	
>= 150 cells/uL	Placebo	105	11	102.3	0.11	0.13	(0.04, 0.38)				
Baseline eosinophils - High	Tezepelumab									0.568	
< 300 cells/uL	Tezepelumab	69	1	62.4	0.02	0.02	(0.00, 0.14)	0.084	(0.007, 0.960)	0.046	*
< 300 cells/uL	Placebo	72	11	69.0	0.16	0.19	(0.06, 0.56)				
>= 300 cells/uL	Tezepelumab	67	2	64.1	0.03	0.03	(0.00, 0.22)	0.216	(0.019, 2.483)	0.219	
>= 300 cells/uL	Placebo	66	8	65.5	0.12	0.15	(0.03, 0.66)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNK: Severe AAER during planned treatment period by key subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline FENO	Tezepelumab									0.277	
< 25 ppb	Tezepelumab	78	2	72.6	0.03	0.03	(0.01, 0.12)	0.396	(0.064, 2.436)	0.318	
< 25 ppb	Placebo	74	5	72.9	0.07	0.07	(0.02, 0.20)				
>= 25 ppb	Tezepelumab	57	1	52.9	0.02	0.02	(0.00, 0.20)	0.063	(0.004, 0.945)	0.045	*
>= 25 ppb	Placebo	63	14	60.5	0.23	0.30	(0.08, 1.13)				
Baseline specific perennial FEIA status	Tezepelumab									NE	
All negative	Tezepelumab	57	3	53.2	0.06	0.06	(0.01, 0.25)	0.336	(0.054, 2.092)	0.242	
All negative	Placebo	66	9	64.8	0.14	0.17	(0.06, 0.51)				
Any positive	Tezepelumab	71	0	65.3	0.00					NE	
Any positive	Placebo	63	9	60.7	0.15						

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNK: Severe AAER during planned treatment period by key subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio		
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Total serum IgE	Tezepelumab									NE
Low	Tezepelumab	35	1	32.4	0.03	0.03	(0.00, 0.28)	0.122	(0.010, 1.517)	0.102
Low	Placebo	32	7	31.2	0.22	0.26	(0.07, 0.90)			
Normal	Tezepelumab	95	2	89.0	0.02	0.02	(0.00, 0.13)	0.145	(0.017, 1.263)	0.080
Normal	Placebo	98	12	95.3	0.13	0.16	(0.05, 0.54)			
High	Tezepelumab	7	0	6.1	0.00					NE
High	Placebo	8	0	8.0	0.00					
OCS at baseline	Tezepelumab									NE
Yes	Tezepelumab	9	0	7.8	0.00					NE
Yes	Placebo	13	5	11.6	0.43					
No	Tezepelumab	128	3	119.7	0.03	0.03	(0.01, 0.10)	0.187	(0.034, 1.035)	0.055
No	Placebo	125	14	122.9	0.11	0.14	(0.05, 0.36)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNK: Severe AAER during planned treatment period by key subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
ICS dose level (at study entry)	Tezepelumab									NE	
Medium/Low	Tezepelumab	70	0	65.7	0.00					NE	
Medium/Low	Placebo	73	2	72.8	0.03						
High	Tezepelumab	67	3	61.8	0.05	0.05	(0.01, 0.19)	0.148	(0.028, 0.775)	0.024	*
High	Placebo	65	17	61.6	0.28	0.33	(0.13, 0.83)				
LAMA use at baseline	Tezepelumab									NE	
Yes	Tezepelumab	11	3	10.9	0.28					NE	
Yes	Placebo	6	0	6.0	0.00						
No	Tezepelumab	126	0	116.6	0.00					NE	
No	Placebo	132	19	128.5	0.15						

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNK: Severe AAER during planned treatment period by key subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Tiotropium use at baseline	Tezepelumab									NE	
Yes	Tezepelumab	9	3	8.9	0.34					NE	
Yes	Placebo	3	0	3.0	0.00						
No	Tezepelumab	128	0	118.6	0.00					NE	
No	Placebo	135	19	131.5	0.14						
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab									0.790	
Yes	Tezepelumab	29	1	24.7	0.04	0.04	(0.00, 0.70)	0.200	(0.006, 6.238)	0.359	
Yes	Placebo	37	6	36.0	0.17	0.20	(0.03, 1.40)				
No	Tezepelumab	108	2	102.8	0.02	0.02	(0.00, 0.10)	0.125	(0.019, 0.818)	0.030	*
No	Placebo	101	13	98.5	0.13	0.16	(0.06, 0.42)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNP: Severe AAER during planned treatment period by study specific subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Race (cat. P)	Tezepelumab									NE	
White	Tezepelumab	128	3	118.6	0.03	0.03	(0.01, 0.10)	0.257	(0.047, 1.418)	0.119	
White	Placebo	123	10	119.9	0.08	0.10	(0.04, 0.27)				
Non-white	Tezepelumab	9	0	8.9	0.00					NE	
Non-white	Placebo	15	9	14.6	0.62						
Region (cat. P)	Tezepelumab									NE	
North America/Western EU	Tezepelumab	10	0	9.2	0.00					NE	
North America/Western EU	Placebo	9	1	9.0	0.11						
Rest of world	Tezepelumab	127	3	118.3	0.03	0.03	(0.01, 0.11)	0.146	(0.026, 0.809)	0.028	*
Rest of world	Placebo	129	18	125.5	0.14	0.18	(0.07, 0.46)				
Baseline eosinophils (cat. P)	Tezepelumab									0.877	
< 250 cells/uL	Tezepelumab	61	1	59.2	0.02	0.02	(0.00, 0.14)	0.126	(0.012, 1.320)	0.084	
< 250 cells/uL	Placebo	60	7	57.9	0.12	0.13	(0.05, 0.39)				
>= 250 cells/uL	Tezepelumab	76	2	68.3	0.03	0.03	(0.00, 0.20)	0.153	(0.014, 1.633)	0.120	
>= 250 cells/uL	Placebo	78	12	76.6	0.16	0.19	(0.05, 0.78)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNP: Severe AAER during planned treatment period by study specific subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline FENO (cat. P)	Tezepelumab									0.268	
< 24 ppb	Tezepelumab	75	2	69.6	0.03	0.03	(0.01, 0.13)	0.402	(0.065, 2.471)	0.325	
< 24 ppb	Placebo	72	5	70.9	0.07	0.07	(0.03, 0.20)				
>= 24 ppb	Tezepelumab	60	1	55.9	0.02	0.02	(0.00, 0.19)	0.062	(0.004, 0.919)	0.043	*
>= 24 ppb	Placebo	65	14	62.5	0.22	0.29	(0.08, 1.10)				
Baseline FENO (cat. M)	Tezepelumab									0.136	
< 22.0 ppb	Tezepelumab	65	2	59.6	0.03	0.03	(0.01, 0.13)	0.683	(0.114, 4.089)	0.676	
< 22.0 ppb	Placebo	62	3	61.1	0.05	0.05	(0.02, 0.15)				
>= 22.0 ppb	Tezepelumab	70	1	65.9	0.02	0.02	(0.00, 0.15)	0.054	(0.004, 0.710)	0.026	*
>= 22.0 ppb	Placebo	75	16	72.4	0.22	0.28	(0.08, 0.93)				
Baseline all FEIA status	Tezepelumab									NE	
All negative	Tezepelumab	50	3	46.3	0.06	0.07	(0.02, 0.27)	0.291	(0.048, 1.757)	0.179	
All negative	Placebo	50	9	48.8	0.18	0.22	(0.08, 0.67)				
Any positive	Tezepelumab	77	0	71.3	0.00					NE	
Any positive	Placebo	80	9	77.7	0.12						

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNP: Severe AAER during planned treatment period by study specific subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Th2 status	Tezepelumab									NE	
Low	Tezepelumab	70	2	65.1	0.03	0.03	(0.01, 0.15)	0.081	(0.013, 0.490)	0.006	*
Low	Placebo	62	19	59.2	0.32	0.38	(0.16, 0.92)				
High	Tezepelumab	65	1	60.4	0.02					NE	
High	Placebo	75	0	74.3	0.00						
Baseline Periostin	Tezepelumab									0.736	
Low (< 20.9 ng/ml)	Tezepelumab	62	1	57.4	0.02	0.02	(0.00, 0.19)	0.098	(0.006, 1.539)	0.098	
Low (< 20.9 ng/ml)	Placebo	67	9	64.1	0.14	0.18	(0.04, 0.74)				
High (>= 20.9 ng/ml)	Tezepelumab	74	2	69.1	0.03	0.03	(0.01, 0.16)	0.179	(0.023, 1.368)	0.097	
High (>= 20.9 ng/ml)	Placebo	71	10	70.3	0.14	0.16	(0.05, 0.51)				
Current post-BD FEV1 reversibility	Tezepelumab									NE	
Yes	Tezepelumab	114	3	106.8	0.03	0.03	(0.01, 0.09)	0.478	(0.109, 2.092)	0.327	
Yes	Placebo	126	7	123.2	0.06	0.06	(0.03, 0.14)				
No	Tezepelumab	23	0	20.7	0.00					NE	
No	Placebo	12	12	11.3	1.06						

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IOSNP: Severe AAER during planned treatment period by study specific subgroups
DITT

Severe AAER during planned treatment period						Adjusted rates		Rate ratio		
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Maintenance OCS use at baseline	Tezepelumab									NE
Yes	Tezepelumab	9	0	7.8	0.00					NE
Yes	Placebo	14	10	12.3	0.81					
No	Tezepelumab	128	3	119.7	0.03	0.03	(0.01, 0.09)	0.310	(0.061, 1.572)	0.157
No	Placebo	124	9	122.1	0.07	0.08	(0.03, 0.21)			
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab									NE
Yes	Tezepelumab	108	3	102.0	0.03	0.03	(0.01, 0.10)	0.531	(0.113, 2.502)	0.424
Yes	Placebo	115	6	113.3	0.05	0.06	(0.02, 0.14)			
No	Tezepelumab	29	0	25.5	0.00					NE
No	Placebo	23	13	21.2	0.61					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOMN0: Non-severe AAER during planned treatment period
DITT

Non-severe AAER during planned treatment period					Adjusted rates		Rate ratio			
Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Tezepelumab	137	22	126.7	0.17	0.18	(0.11, 0.30)	0.277	(0.146, 0.525)	<0.001	*
Placebo	138	78	131.8	0.59	0.64	(0.44, 0.93)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model.
A negative binomial model was applied with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNK: Non-severe AAER during planned treatment period by key subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Sex	Tezepelumab									0.935	
Male	Tezepelumab	50	7	47.3	0.15	0.15	(0.06, 0.40)	0.269	(0.078, 0.924)	0.037	*
Male	Placebo	44	22	41.7	0.53	0.56	(0.26, 1.22)				
Female	Tezepelumab	87	15	79.4	0.19	0.19	(0.10, 0.36)	0.286	(0.135, 0.606)	0.001	*
Female	Placebo	94	56	90.1	0.62	0.68	(0.44, 1.04)				
Age	Tezepelumab									0.533	
< 65 years	Tezepelumab	114	18	106.6	0.17	0.17	(0.10, 0.31)	0.257	(0.129, 0.512)	<0.001	*
< 65 years	Placebo	118	70	112.2	0.62	0.68	(0.46, 1.00)				
>= 65 years	Tezepelumab	23	4	20.1	0.20	0.20	(0.05, 0.76)	0.447	(0.076, 2.617)	0.372	
>= 65 years	Placebo	20	8	19.6	0.41	0.45	(0.14, 1.43)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNK: Non-severe AAER during planned treatment period by key subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Exacerbations in the year before study	Tezepelumab									0.693	
<= 2	Tezepelumab	105	10	98.3	0.10	0.10	(0.05, 0.21)	0.298	(0.127, 0.696)	0.005	*
<= 2	Placebo	110	35	106.9	0.33	0.34	(0.22, 0.55)				
> 2	Tezepelumab	32	12	28.4	0.42	0.43	(0.22, 0.84)	0.236	(0.104, 0.536)	<0.001	*
> 2	Placebo	28	43	24.9	1.73	1.83	(1.14, 2.95)				
Race	Tezepelumab	N<10	any level							NE	
White	Tezepelumab	128	20	117.9	0.17						
White	Placebo	123	61	117.8	0.52						
Black or African American	Tezepelumab	3	0	2.9	0.00						
Black or African American	Placebo	6	8	5.5	1.46						
Asian	Tezepelumab	5	2	4.9	0.41						
Asian	Placebo	6	4	5.8	0.69						
Other	Tezepelumab	1	0	1.0	0.00						
Other	Placebo	3	5	2.7	1.85						

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNK: Non-severe AAER during planned treatment period by key subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio		
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Region	Tezepelumab									0.134
Europe	Tezepelumab	78	14	72.9	0.19	0.20	(0.10, 0.40)	0.432	(0.176, 1.062)	0.067
Europe	Placebo	80	33	78.3	0.42	0.46	(0.26, 0.81)			
America	Tezepelumab	10	4	9.0	0.44	0.44	(0.14, 1.37)	0.316	(0.078, 1.273)	0.105
America	Placebo	9	11	8.4	1.31	1.41	(0.62, 3.21)			
Asia/Pacific	Tezepelumab	5	2	4.9	0.41	0.44	(0.02, 8.39)	0.533	(0.011, 26.826)	0.753
Asia/Pacific	Placebo	6	4	5.8	0.69	0.82	(0.06, 10.79)			
Rest of the world	Tezepelumab	44	2	39.8	0.05	0.05	(0.01, 0.21)	0.063	(0.014, 0.296)	<0.001 *
Rest of the world	Placebo	43	30	39.3	0.76	0.80	(0.46, 1.37)			
BMI	Tezepelumab	N<10	any level							NE
< 18.5 kg/m**2	Tezepelumab	0								
< 18.5 kg/m**2	Placebo	1	0	1.0	0.00					
18.5 - < 25.0 kg/m**2	Tezepelumab	39	4	38.4	0.10					
18.5 - < 25.0 kg/m**2	Placebo	43	31	41.0	0.76					
25.0 - < 30.0 kg/m**2	Tezepelumab	45	9	41.2	0.22					
25.0 - < 30.0 kg/m**2	Placebo	47	27	45.0	0.60					
>= 30.0 kg/m**2	Tezepelumab	53	9	47.1	0.19					
>= 30.0 kg/m**2	Placebo	47	20	44.8	0.45					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNK: Non-severe AAER during planned treatment period by key subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline eosinophils - Low	Tezepelumab									0.450	
< 150 cells/uL	Tezepelumab	27	3	25.5	0.12	0.12	(0.03, 0.47)	0.167	(0.037, 0.763)	0.021	*
< 150 cells/uL	Placebo	33	21	31.6	0.66	0.75	(0.35, 1.57)				
>= 150 cells/uL	Tezepelumab	109	19	100.1	0.19	0.19	(0.11, 0.34)	0.316	(0.155, 0.644)	0.002	*
>= 150 cells/uL	Placebo	105	57	100.2	0.57	0.61	(0.40, 0.94)				
Baseline eosinophils - High	Tezepelumab									0.528	
< 300 cells/uL	Tezepelumab	69	10	62.0	0.16	0.17	(0.08, 0.36)	0.351	(0.136, 0.905)	0.030	*
< 300 cells/uL	Placebo	72	30	68.2	0.44	0.47	(0.27, 0.83)				
>= 300 cells/uL	Tezepelumab	67	12	63.7	0.19	0.19	(0.10, 0.39)	0.233	(0.099, 0.551)	<0.001	*
>= 300 cells/uL	Placebo	66	48	63.6	0.75	0.82	(0.50, 1.35)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNK: Non-severe AAER during planned treatment period by key subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline FENO	Tezepelumab									0.231	
< 25 ppb	Tezepelumab	78	14	72.1	0.19	0.20	(0.10, 0.40)	0.407	(0.168, 0.985)	0.046	*
< 25 ppb	Placebo	74	33	71.8	0.46	0.49	(0.28, 0.87)				
>= 25 ppb	Tezepelumab	57	8	52.6	0.15	0.15	(0.07, 0.35)	0.186	(0.072, 0.479)	<0.001	*
>= 25 ppb	Placebo	63	45	59.1	0.76	0.83	(0.51, 1.35)				
Baseline specific perennial FEIA status	Tezepelumab									0.875	
All negative	Tezepelumab	57	9	53.0	0.17	0.18	(0.08, 0.39)	0.274	(0.104, 0.721)	0.009	*
All negative	Placebo	66	38	63.6	0.60	0.64	(0.37, 1.09)				
Any positive	Tezepelumab	71	10	64.8	0.15	0.16	(0.07, 0.34)	0.245	(0.091, 0.658)	0.005	*
Any positive	Placebo	63	34	59.4	0.57	0.64	(0.35, 1.17)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNK: Non-severe AAER during planned treatment period by key subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Total serum IgE	Tezepelumab									0.873	
Low	Tezepelumab	35	5	32.2	0.16	0.16	(0.06, 0.43)	0.288	(0.086, 0.968)	0.044	*
Low	Placebo	32	16	30.8	0.52	0.56	(0.28, 1.11)				
Normal	Tezepelumab	95	16	88.4	0.18	0.18	(0.10, 0.34)	0.263	(0.122, 0.568)	<0.001	*
Normal	Placebo	98	60	93.1	0.64	0.70	(0.45, 1.10)				
High	Tezepelumab	7	1	6.1	0.16	0.16	(0.01, 2.08)	0.605	(0.024, 15.276)	0.760	
High	Placebo	8	2	7.9	0.25	0.27	(0.04, 2.01)				
OCS at baseline	Tezepelumab									0.792	
Yes	Tezepelumab	9	4	7.6	0.53	0.52	(0.16, 1.73)	0.369	(0.091, 1.506)	0.165	
Yes	Placebo	13	15	11.1	1.35	1.42	(0.67, 3.00)				
No	Tezepelumab	128	18	119.1	0.15	0.15	(0.09, 0.27)	0.275	(0.136, 0.554)	<0.001	*
No	Placebo	125	63	120.7	0.52	0.56	(0.37, 0.85)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNK: Non-severe AAER during planned treatment period by key subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
ICS dose level (at study entry)	Tezepelumab									0.397	
Medium/Low	Tezepelumab	70	9	65.3	0.14	0.14	(0.07, 0.30)	0.388	(0.154, 0.979)	0.045	*
Medium/Low	Placebo	73	25	72.0	0.35	0.36	(0.21, 0.61)				
High	Tezepelumab	67	13	61.4	0.21	0.22	(0.11, 0.43)	0.225	(0.096, 0.523)	<0.001	*
High	Placebo	65	53	59.8	0.89	0.97	(0.59, 1.60)				
LAMA use at baseline	Tezepelumab									0.551	
Yes	Tezepelumab	11	2	10.9	0.18	0.19	(0.04, 0.99)	0.139	(0.016, 1.229)	0.076	
Yes	Placebo	6	7	5.6	1.25	1.36	(0.33, 5.64)				
No	Tezepelumab	126	20	115.8	0.17	0.18	(0.10, 0.30)	0.290	(0.149, 0.565)	<0.001	*
No	Placebo	132	71	126.2	0.56	0.61	(0.41, 0.90)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNK: Non-severe AAER during planned treatment period by key subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Tiotropium use at baseline	Tezepelumab									0.679	
Yes	Tezepelumab	9	2	8.9	0.22	0.23	(0.05, 1.13)	0.151	(0.015, 1.529)	0.109	
Yes	Placebo	3	4	2.8	1.44	1.53	(0.28, 8.19)				
No	Tezepelumab	128	20	117.8	0.17	0.17	(0.10, 0.30)	0.279	(0.143, 0.543)	<0.001	*
No	Placebo	135	74	129.0	0.57	0.62	(0.42, 0.91)				
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab									0.511	
Yes	Tezepelumab	29	10	24.3	0.41	0.41	(0.19, 0.89)	0.394	(0.156, 0.992)	0.048	*
Yes	Placebo	37	34	34.7	0.98	1.04	(0.63, 1.74)				
No	Tezepelumab	108	12	102.3	0.12	0.12	(0.06, 0.24)	0.245	(0.103, 0.581)	0.001	*
No	Placebo	101	44	97.1	0.45	0.49	(0.30, 0.82)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNP: Non-severe AAER during planned treatment period by study specific subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Race (cat. P)	Tezepelumab									0.582	
White	Tezepelumab	128	20	117.9	0.17	0.17	(0.10, 0.30)	0.313	(0.159, 0.614)	<0.001	*
White	Placebo	123	61	117.8	0.52	0.56	(0.37, 0.83)				
Non-white	Tezepelumab	9	2	8.8	0.23	0.23	(0.04, 1.29)	0.172	(0.025, 1.188)	0.074	
Non-white	Placebo	15	17	14.0	1.22	1.36	(0.55, 3.38)				
Region (cat. P)	Tezepelumab									0.913	
North America/Western EU	Tezepelumab	10	4	9.0	0.44	0.44	(0.14, 1.37)	0.316	(0.078, 1.273)	0.105	
North America/Western EU	Placebo	9	11	8.4	1.31	1.41	(0.62, 3.21)				
Rest of world	Tezepelumab	127	18	117.7	0.15	0.16	(0.09, 0.28)	0.267	(0.132, 0.543)	<0.001	*
Rest of world	Placebo	129	67	123.4	0.54	0.59	(0.39, 0.89)				
Baseline eosinophils (cat. P)	Tezepelumab									0.495	
< 250 cells/uL	Tezepelumab	61	7	58.9	0.12	0.12	(0.05, 0.28)	0.209	(0.074, 0.589)	0.003	*
< 250 cells/uL	Placebo	60	30	56.8	0.53	0.57	(0.32, 1.02)				
>= 250 cells/uL	Tezepelumab	76	15	67.7	0.22	0.23	(0.12, 0.44)	0.330	(0.145, 0.750)	0.008	*
>= 250 cells/uL	Placebo	78	48	75.0	0.64	0.69	(0.43, 1.13)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNP: Non-severe AAER during planned treatment period by study specific subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline FENO (cat. P)	Tezepelumab									0.192	
< 24 ppb	Tezepelumab	75	13	69.1	0.19	0.20	(0.09, 0.40)	0.437	(0.170, 1.123)	0.085	
< 24 ppb	Placebo	72	29	69.9	0.41	0.45	(0.25, 0.82)				
>= 24 ppb	Tezepelumab	60	9	55.6	0.16	0.16	(0.08, 0.35)	0.188	(0.078, 0.457)	<0.001	*
>= 24 ppb	Placebo	65	49	60.9	0.80	0.87	(0.55, 1.37)				
Baseline FENO (cat. M)	Tezepelumab									0.356	
< 22.0 ppb	Tezepelumab	65	11	59.2	0.19	0.19	(0.09, 0.44)	0.397	(0.138, 1.140)	0.086	
< 22.0 ppb	Placebo	62	27	60.0	0.45	0.49	(0.25, 0.96)				
>= 22.0 ppb	Tezepelumab	70	11	65.5	0.17	0.17	(0.08, 0.34)	0.219	(0.097, 0.496)	<0.001	*
>= 22.0 ppb	Placebo	75	51	70.8	0.72	0.77	(0.50, 1.20)				
Baseline all FEIA status	Tezepelumab									0.290	
All negative	Tezepelumab	50	9	46.0	0.20	0.20	(0.09, 0.46)	0.420	(0.146, 1.205)	0.107	
All negative	Placebo	50	22	48.3	0.46	0.48	(0.25, 0.92)				
Any positive	Tezepelumab	77	10	70.8	0.14	0.14	(0.07, 0.31)	0.196	(0.079, 0.488)	<0.001	*
Any positive	Placebo	80	50	75.7	0.66	0.73	(0.44, 1.21)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNP: Non-severe AAER during planned treatment period by study specific subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Th2 status	Tezepelumab									0.542	
Low	Tezepelumab	70	8	64.8	0.12	0.13	(0.06, 0.28)	0.214	(0.080, 0.568)	0.002	*
Low	Placebo	62	32	58.6	0.55	0.59	(0.34, 1.03)				
High	Tezepelumab	65	13	59.9	0.22	0.22	(0.11, 0.45)	0.321	(0.134, 0.769)	0.011	*
High	Placebo	75	46	72.2	0.64	0.69	(0.42, 1.15)				
Baseline Periostin	Tezepelumab									0.590	
Low (< 20.9 ng/ml)	Tezepelumab	62	11	56.9	0.19	0.20	(0.09, 0.44)	0.336	(0.126, 0.895)	0.029	*
Low (< 20.9 ng/ml)	Placebo	67	34	62.9	0.54	0.60	(0.33, 1.08)				
High (>= 20.9 ng/ml)	Tezepelumab	74	11	68.7	0.16	0.16	(0.08, 0.33)	0.237	(0.101, 0.555)	<0.001	*
High (>= 20.9 ng/ml)	Placebo	71	44	68.9	0.64	0.68	(0.42, 1.10)				
Current post-BD FEV1 reversibility	Tezepelumab									0.681	
Yes	Tezepelumab	114	14	106.3	0.13	0.13	(0.07, 0.25)	0.229	(0.110, 0.479)	<0.001	*
Yes	Placebo	126	66	120.5	0.55	0.59	(0.40, 0.87)				
No	Tezepelumab	23	8	20.4	0.39	0.40	(0.15, 1.03)	0.330	(0.081, 1.350)	0.123	
No	Placebo	12	12	11.3	1.06	1.20	(0.43, 3.41)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IOSNP: Non-severe AAER during planned treatment period by study specific subgroups
DITT

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Maintenance OCS use at baseline	Tezepelumab									0.839	
Yes	Tezepelumab	9	4	7.6	0.53	0.53	(0.17, 1.64)	0.357	(0.095, 1.333)	0.125	
Yes	Placebo	14	17	12.0	1.41	1.47	(0.76, 2.85)				
No	Tezepelumab	128	18	119.1	0.15	0.16	(0.09, 0.27)	0.282	(0.139, 0.572)	<0.001	*
No	Placebo	124	61	119.8	0.51	0.55	(0.36, 0.84)				
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab									0.900	
Yes	Tezepelumab	108	13	101.6	0.13	0.13	(0.07, 0.25)	0.254	(0.117, 0.552)	<0.001	*
Yes	Placebo	115	54	111.2	0.49	0.52	(0.34, 0.79)				
No	Tezepelumab	29	9	25.1	0.36	0.36	(0.16, 0.83)	0.282	(0.095, 0.831)	0.022	*
No	Placebo	23	24	20.6	1.17	1.28	(0.64, 2.55)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ER_IOMI0: Patients without exacerbations during planned treatment period
DITT

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Patients without exacerbations during planned treatment period	137	101 (73.7) [65.5, 80.9]	138	91 (65.9) [57.4, 73.8]	1.118 [0.956, 1.307]	1.449 [0.863, 2.433]	7.8 [-3.8, 19.3]	0.189

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with events. A patient will be considered as without exacerbation, if no exacerbations was observed in considered timeframe and the patient has completed the planned treatment period.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: atte, created on: 11AUG2022

Table PT2ER_IOSIK: Patients without exacerbations during planned treatment period by key subgroups
DITT

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex								0.995	
Male	50	38 (76.0) [61.8, 86.9]	44	30 (68.2) [52.4, 81.4]	1.115 [0.864, 1.438]	1.478 [0.596, 3.662]	7.8 [-12.5, 28.1]	0.490	
Female	87	63 (72.4) [61.8, 81.5]	94	61 (64.9) [54.4, 74.5]	1.116 [0.916, 1.359]	1.420 [0.754, 2.674]	7.5 [-7.1, 22.1]	0.337	
Age								0.071	
< 65 years	114	86 (75.4) [66.5, 83.0]	118	75 (63.6) [54.2, 72.2]	1.187 [0.999, 1.410]	1.761 [0.998, 3.107]	11.9 [-0.7, 24.5]	0.064	
>= 65 years	23	15 (65.2) [42.7, 83.6]	20	16 (80.0) [56.3, 94.3]	0.815 [0.563, 1.181]	0.469 [0.117, 1.885]	-14.8 [-45.7, 16.1]	0.327	
Exacerbations in the year before study								0.036	i
<= 2	105	83 (79.0) [70.0, 86.4]	110	84 (76.4) [67.3, 83.9]	1.035 [0.897, 1.195]	1.168 [0.613, 2.223]	2.7 [-9.4, 14.7]	0.743	
> 2	32	18 (56.3) [37.7, 73.6]	28	7 (25.0) [10.7, 44.9]	2.250 [1.106, 4.579]	3.857 [1.278, 11.638]	31.3 [4.4, 58.1]	0.019	*
Race		N<10 any level						NE	
White	128	94 (73.4) [64.9, 80.9]	123	84 (68.3) [59.3, 76.4]					
Black or African American	3	2 (66.7) [9.4, 99.2]	6	2 (33.3) [4.3, 77.7]					
Asian	5	4 (80.0) [28.4, 99.5]	6	5 (83.3) [35.9, 99.6]					
Other	1	1 (100.0) [2.5, 100.0]	3	0 (0.0) [0.0, 70.8]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_IOSIK: Patients without exacerbations during planned treatment period by key subgroups
DITT

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Region								0.078	
Europe	78	56 (71.8) [60.5, 81.4]	80	60 (75.0) [64.1, 84.0]	0.957 [0.793, 1.155]	0.848 [0.419, 1.720]	-3.2 [-18.2, 11.8]	0.720	
America	10	5 (50.0) [18.7, 81.3]	9	2 (22.2) [2.8, 60.0]	2.250 [0.572, 8.858]	3.500 [0.473, 25.901]	27.8 [-24.0, 79.5]	0.350	
Asia/Pacific	5	4 (80.0) [28.4, 99.5]	6	5 (83.3) [35.9, 99.6]	0.960 [0.545, 1.690]	0.800 [0.037, 17.196]	-3.3 [-67.7, 61.0]	1.000	
Rest of the world	44	36 (81.8) [67.3, 91.8]	43	24 (55.8) [39.9, 70.9]	1.466 [1.086, 1.979]	3.563 [1.345, 9.438]	26.0 [5.0, 47.0]	0.011	*
BMI		N<10 any level						NE	
< 18.5 kg/m**2	0		1	1 (100.0) [2.5, 100.0]					
18.5 - < 25.0 kg/m**2	39	32 (82.1) [66.5, 92.5]	43	26 (60.5) [44.4, 75.0]					
25.0 - < 30.0 kg/m**2	45	33 (73.3) [58.1, 85.4]	47	31 (66.0) [50.7, 79.1]					
>= 30.0 kg/m**2	53	36 (67.9) [53.7, 80.1]	47	33 (70.2) [55.1, 82.7]					
Baseline eosinophils - Low								0.538	
< 150 cells/uL	27	21 (77.8) [57.7, 91.4]	33	21 (63.6) [45.1, 79.6]	1.222 [0.881, 1.696]	2.000 [0.632, 6.327]	14.1 [-11.9, 40.2]	0.270	
>= 150 cells/uL	109	79 (72.5) [63.1, 80.6]	105	70 (66.7) [56.8, 75.6]	1.087 [0.910, 1.299]	1.317 [0.734, 2.362]	5.8 [-7.4, 19.1]	0.376	
Baseline eosinophils - High								0.547	
< 300 cells/uL	69	50 (72.5) [60.4, 82.5]	72	49 (68.1) [56.0, 78.6]	1.065 [0.859, 1.320]	1.235 [0.599, 2.548]	4.4 [-12.1, 20.9]	0.586	
>= 300 cells/uL	67	50 (74.6) [62.5, 84.5]	66	42 (63.6) [50.9, 75.1]	1.173 [0.932, 1.475]	1.681 [0.798, 3.539]	11.0 [-6.1, 28.1]	0.192	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_IOSIK: Patients without exacerbations during planned treatment period by key subgroups
DITT

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO								0.092
< 25 ppb	78	58 (74.4) [63.2, 83.6]	74	55 (74.3) [62.8, 83.8]	1.000 [0.830, 1.206]	1.002 [0.484, 2.075]	0.0 [-15.2, 15.2]	1.000
>= 25 ppb	57	42 (73.7) [60.3, 84.5]	63	35 (55.6) [42.5, 68.1]	1.326 [1.013, 1.737]	2.240 [1.036, 4.843]	18.1 [-0.3, 36.6]	0.056
Baseline specific perennial FEIA status								0.954
All negative	57	41 (71.9) [58.5, 83.0]	66	43 (65.2) [52.4, 76.5]	1.104 [0.869, 1.403]	1.371 [0.636, 2.955]	6.8 [-11.2, 24.8]	0.444
Any positive	71	53 (74.6) [62.9, 84.2]	63	43 (68.3) [55.3, 79.4]	1.094 [0.881, 1.358]	1.370 [0.645, 2.909]	6.4 [-10.4, 23.2]	0.447
Total serum IgE								0.433
Low	35	27 (77.1) [59.9, 89.6]	32	20 (62.5) [43.7, 78.9]	1.234 [0.893, 1.705]	2.025 [0.698, 5.875]	14.6 [-10.1, 39.4]	0.285
Normal	95	69 (72.6) [62.5, 81.3]	98	64 (65.3) [55.0, 74.6]	1.112 [0.920, 1.345]	1.410 [0.763, 2.604]	7.3 [-6.7, 21.4]	0.281
High	7	5 (71.4) [29.0, 96.3]	8	7 (87.5) [47.3, 99.7]	0.816 [0.477, 1.396]	0.357 [0.025, 5.109]	-16.1 [-70.0, 37.9]	0.569
OCS at baseline								0.926
Yes	9	4 (44.4) [13.7, 78.8]	13	5 (38.5) [13.9, 68.4]	1.156 [0.424, 3.151]	1.280 [0.228, 7.187]	6.0 [-45.3, 57.3]	1.000
No	128	97 (75.8) [67.4, 82.9]	125	86 (68.8) [59.9, 76.8]	1.101 [0.945, 1.284]	1.419 [0.816, 2.469]	7.0 [-4.8, 18.8]	0.261

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_IOSIK: Patients without exacerbations during planned treatment period by key subgroups
DITT

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)								0.310
Medium/Low	70	54 (77.1) [65.6, 86.3]	73	54 (74.0) [62.4, 83.5]	1.043 [0.865, 1.257]	1.188 [0.553, 2.551]	3.2 [-12.3, 18.6]	0.701
High	67	47 (70.1) [57.7, 80.7]	65	37 (56.9) [44.0, 69.2]	1.232 [0.947, 1.603]	1.778 [0.868, 3.644]	13.2 [-4.6, 31.0]	0.148
LAMA use at baseline								0.786
Yes	11	7 (63.6) [30.8, 89.1]	6	3 (50.0) [11.8, 88.2]	1.273 [0.509, 3.182]	1.750 [0.233, 13.159]	13.6 [-48.3, 75.6]	0.644
No	126	94 (74.6) [66.1, 81.9]	132	88 (66.7) [57.9, 74.6]	1.119 [0.956, 1.310]	1.469 [0.856, 2.521]	7.9 [-3.9, 19.8]	0.174
Tiotropium use at baseline								0.652
Yes	9	5 (55.6) [21.2, 86.3]	3	1 (33.3) [0.8, 90.6]	1.667 [0.303, 9.157]	2.500 [0.162, 38.599]	22.2 [-62.4, 100.0]	1.000
No	128	96 (75.0) [66.6, 82.2]	135	90 (66.7) [58.0, 74.5]	1.125 [0.963, 1.314]	1.500 [0.877, 2.566]	8.3 [-3.4, 20.0]	0.175
Montelukast/ Cromoglicic acid use at baseline								0.467
Yes	29	13 (44.8) [26.4, 64.3]	37	18 (48.6) [31.9, 65.6]	0.921 [0.547, 1.553]	0.858 [0.323, 2.274]	-3.8 [-31.1, 23.5]	0.807
No	108	88 (81.5) [72.9, 88.3]	101	73 (72.3) [62.5, 80.7]	1.127 [0.970, 1.311]	1.688 [0.879, 3.240]	9.2 [-3.2, 21.6]	0.139

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_IOSIP: Patients without exacerbations during planned treatment period by study specific subgroups
DITT

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)								0.195	
White	128	94 (73.4) [64.9, 80.9]	123	84 (68.3) [59.3, 76.4]	1.075 [0.917, 1.261]	1.284 [0.744, 2.216]	5.1 [-6.9, 17.2]	0.406	
Non-white	9	7 (77.8) [40.0, 97.2]	15	7 (46.7) [21.3, 73.4]	1.667 [0.875, 3.173]	4.000 [0.616, 25.964]	31.1 [-14.9, 77.1]	0.210	
Region (cat. P)								0.306	
North America/Western EU	10	5 (50.0) [18.7, 81.3]	9	2 (22.2) [2.8, 60.0]	2.250 [0.572, 8.858]	3.500 [0.473, 25.901]	27.8 [-24.0, 79.5]	0.350	
Rest of world	127	96 (75.6) [67.2, 82.8]	129	89 (69.0) [60.3, 76.8]	1.096 [0.941, 1.276]	1.392 [0.803, 2.414]	6.6 [-5.1, 18.3]	0.265	
Baseline eosinophils (cat. P)								0.235	
< 250 cells/uL	61	48 (78.7) [66.3, 88.1]	60	38 (63.3) [49.9, 75.4]	1.242 [0.985, 1.568]	2.138 [0.954, 4.791]	15.4 [-2.2, 33.0]	0.073	
>= 250 cells/uL	76	53 (69.7) [58.1, 79.8]	78	53 (67.9) [56.4, 78.1]	1.026 [0.830, 1.269]	1.087 [0.549, 2.151]	1.8 [-14.1, 17.7]	0.863	
Baseline FENO (cat. P)								0.048	i
< 24 ppb	75	56 (74.7) [63.3, 84.0]	72	55 (76.4) [64.9, 85.6]	0.977 [0.813, 1.175]	0.911 [0.429, 1.934]	-1.7 [-17.0, 13.5]	0.850	
>= 24 ppb	60	44 (73.3) [60.3, 83.9]	65	35 (53.8) [41.0, 66.3]	1.362 [1.038, 1.787]	2.357 [1.111, 4.999]	19.5 [1.4, 37.6]	0.027	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_IOSIP: Patients without exacerbations during planned treatment period by study specific subgroups
DITT

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. M)								0.039	i
< 22.0 ppb	65	48 (73.8) [61.5, 84.0]	62	48 (77.4) [65.0, 87.1]	0.954 [0.783, 1.162]	0.824 [0.365, 1.856]	-3.6 [-20.1, 12.9]	0.683	
>= 22.0 ppb	70	52 (74.3) [62.4, 84.0]	75	42 (56.0) [44.1, 67.5]	1.327 [1.040, 1.692]	2.270 [1.123, 4.588]	18.3 [1.7, 34.9]	0.024	*
Baseline all FEIA status								0.394	
All negative	50	34 (68.0) [53.3, 80.5]	50	34 (68.0) [53.3, 80.5]	1.000 [0.764, 1.309]	1.000 [0.432, 2.317]	0.0 [-20.3, 20.3]	1.000	
Any positive	77	59 (76.6) [65.6, 85.5]	80	53 (66.3) [54.8, 76.4]	1.157 [0.948, 1.412]	1.670 [0.827, 3.370]	10.4 [-4.9, 25.7]	0.162	
Th2 status								0.312	
Low	70	54 (77.1) [65.6, 86.3]	62	39 (62.9) [49.7, 74.8]	1.226 [0.975, 1.543]	1.990 [0.931, 4.254]	14.2 [-2.8, 31.3]	0.087	
High	65	46 (70.8) [58.2, 81.4]	75	51 (68.0) [56.2, 78.3]	1.041 [0.835, 1.297]	1.139 [0.554, 2.345]	2.8 [-14.0, 19.5]	0.854	
Baseline Periostin								0.685	
Low (< 20.9 ng/ml)	62	47 (75.8) [63.3, 85.8]	67	44 (65.7) [53.1, 76.8]	1.154 [0.924, 1.443]	1.638 [0.759, 3.536]	10.1 [-7.0, 27.3]	0.248	
High (>= 20.9 ng/ml)	74	53 (71.6) [59.9, 81.5]	71	47 (66.2) [54.0, 77.0]	1.082 [0.869, 1.348]	1.289 [0.637, 2.609]	5.4 [-11.0, 21.9]	0.590	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_IOSIP: Patients without exacerbations during planned treatment period by study specific subgroups
DITT

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.407
Yes	114	89 (78.1) [69.4, 85.3]	126	84 (66.7) [57.7, 74.8]	1.171 [1.001, 1.370]	1.780 [0.999, 3.173]	11.4 [-0.6, 23.4]	0.061
No	23	12 (52.2) [30.6, 73.2]	12	7 (58.3) [27.7, 84.8]	0.894 [0.482, 1.659]	0.779 [0.190, 3.190]	-6.2 [-47.1, 34.7]	1.000
Maintenance OCS use at baseline								0.804
Yes	9	4 (44.4) [13.7, 78.8]	14	5 (35.7) [12.8, 64.9]	1.244 [0.452, 3.429]	1.440 [0.260, 7.961]	8.7 [-41.4, 58.9]	1.000
No	128	97 (75.8) [67.4, 82.9]	124	86 (69.4) [60.4, 77.3]	1.093 [0.938, 1.273]	1.383 [0.793, 2.411]	6.4 [-5.4, 18.2]	0.262
No chronic OCS use and current post-BD FEV1 reversibility								0.576
Yes	108	86 (79.6) [70.8, 86.8]	115	79 (68.7) [59.4, 77.0]	1.159 [0.992, 1.355]	1.781 [0.966, 3.285]	10.9 [-1.3, 23.2]	0.068
No	29	15 (51.7) [32.5, 70.6]	23	12 (52.2) [30.6, 73.2]	0.991 [0.586, 1.678]	0.982 [0.328, 2.937]	-0.4 [-31.7, 30.8]	1.000

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ET_IOMT0: Time to first asthma exacerbation
DITT

Time to first asthma exacerbation			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Tezepelumab	137	21 (15.3)	NE		0.411	(0.243, 0.696)	<0.001 *
Placebo	138	42 (30.4)	NE				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least on event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year.
Source Data: atte, created on: 11AUG2022

Figure PF2ET_IOMK0: Time to first asthma exacerbation - Kaplan-Meier plot
DITT



Note: DITT = Dossier Intent-to-Treat Set.
Reference table: PT2ET_IOMT0
Source Data: atte, created on: 11AUG2022

Table PT2ET_IOSTK: Time to first asthma exacerbation by key subgroups
DITT

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Tezepelumab							0.480	
Male	Tezepelumab	50	6 (12.0)	NE		0.285	(0.102, 0.797)	0.017	*
Male	Placebo	44	12 (27.3)	NE					
Female	Tezepelumab	87	15 (17.2)	NE		0.464	(0.249, 0.864)	0.015	*
Female	Placebo	94	30 (31.9)	NE					
Age	Tezepelumab							0.155	
< 65 years	Tezepelumab	114	16 (14.0)	NE		0.351	(0.196, 0.630)	<0.001	*
< 65 years	Placebo	118	39 (33.1)	NE					
>= 65 years	Tezepelumab	23	5 (21.7)	NE		1.132	(0.236, 5.435)	0.877	
>= 65 years	Placebo	20	3 (15.0)	NE					
Exacerbations in the year before study	Tezepelumab							0.536	
<= 2	Tezepelumab	105	11 (10.5)	NE		0.480	(0.234, 0.985)	0.045	*
<= 2	Placebo	110	23 (20.9)	NE					
> 2	Tezepelumab	32	10 (31.3)	NE		0.358	(0.166, 0.773)	0.009	*
> 2	Placebo	28	19 (67.9)	24.6	(7.9, 43.7)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_IOSTK: Time to first asthma exacerbation by key subgroups
DITT

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Race	Tezepelumab	N<10	any level					NE	
White	Tezepelumab	128	20 (15.6)						
White	Placebo	123	35 (28.5)						
Black or African American	Tezepelumab	3	0 (0.0)						
Black or African American	Placebo	6	3 (50.0)						
Asian	Tezepelumab	5	1 (20.0)						
Asian	Placebo	6	1 (16.7)						
Other	Tezepelumab	1	0 (0.0)						
Other	Placebo	3	3 (100.0)						
Region	Tezepelumab							0.008	i
Europe	Tezepelumab	78	15 (19.2)	NE		0.836	(0.421, 1.660)	0.609	
Europe	Placebo	80	18 (22.5)	NE					
America	Tezepelumab	10	3 (30.0)	NE		0.433	(0.107, 1.758)	0.242	
America	Placebo	9	6 (66.7)	43.4	(5.9, NE)				
Asia/Pacific	Tezepelumab	5	1 (20.0)	NE		0.000	(0.000,)	0.999	
Asia/Pacific	Placebo	6	1 (16.7)	NE					
Rest of the world	Tezepelumab	44	2 (4.5)	NE		0.066	(0.015, 0.297)	<0.001	*
Rest of the world	Placebo	43	17 (39.5)	NE					
BMI	Tezepelumab	N<10	any level					NE	
< 18.5 kg/m**2	Tezepelumab	0							
< 18.5 kg/m**2	Placebo	1	0 (0.0)						
18.5 - < 25.0 kg/m**2	Tezepelumab	39	4 (10.3)						
18.5 - < 25.0 kg/m**2	Placebo	43	16 (37.2)						
25.0 - < 30.0 kg/m**2	Tezepelumab	45	8 (17.8)						
25.0 - < 30.0 kg/m**2	Placebo	47	14 (29.8)						
>= 30.0 kg/m**2	Tezepelumab	53	9 (17.0)						
>= 30.0 kg/m**2	Placebo	47	12 (25.5)						

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_IOSTK: Time to first asthma exacerbation by key subgroups
DITT

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eosinophils - Low	Tezepelumab							0.475	
< 150 cells/uL	Tezepelumab	27	4 (14.8)	NE		0.279	(0.086, 0.906)	0.034	*
< 150 cells/uL	Placebo	33	11 (33.3)	NE					
>= 150 cells/uL	Tezepelumab	109	17 (15.6)	NE		0.454	(0.251, 0.822)	0.009	*
>= 150 cells/uL	Placebo	105	31 (29.5)	NE					
Baseline eosinophils - High	Tezepelumab							0.921	
< 300 cells/uL	Tezepelumab	69	9 (13.0)	NE		0.432	(0.195, 0.959)	0.039	*
< 300 cells/uL	Placebo	72	19 (26.4)	NE					
>= 300 cells/uL	Tezepelumab	67	12 (17.9)	NE		0.390	(0.193, 0.790)	0.009	*
>= 300 cells/uL	Placebo	66	23 (34.8)	NE					
Baseline FENO	Tezepelumab							0.277	
< 25 ppb	Tezepelumab	78	13 (16.7)	NE		0.521	(0.251, 1.082)	0.080	
< 25 ppb	Placebo	74	18 (24.3)	NE					
>= 25 ppb	Tezepelumab	57	8 (14.0)	NE		0.308	(0.138, 0.687)	0.004	*
>= 25 ppb	Placebo	63	24 (38.1)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_IOSTK: Time to first asthma exacerbation by key subgroups
DITT

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline specific perennial FEIA status	Tezepelumab							0.379	
All negative	Tezepelumab	57	11 (19.3)	NE		0.513	(0.248, 1.060)	0.071	
All negative	Placebo	66	22 (33.3)	NE					
Any positive	Tezepelumab	71	8 (11.3)	NE		0.352	(0.148, 0.835)	0.018	*
Any positive	Placebo	63	16 (25.4)	NE					
Total serum IgE	Tezepelumab							0.490	
Low	Tezepelumab	35	5 (14.3)	NE		0.362	(0.127, 1.030)	0.057	
Low	Placebo	32	12 (37.5)	NE					
Normal	Tezepelumab	95	15 (15.8)	NE		0.393	(0.209, 0.742)	0.004	*
Normal	Placebo	98	29 (29.6)	NE					
High	Tezepelumab	7	1 (14.3)	NE		1.000	(0.063, 15.988)	1.000	
High	Placebo	8	1 (12.5)	NE					
OCS at baseline	Tezepelumab							0.603	
Yes	Tezepelumab	9	3 (33.3)	NE		0.359	(0.089, 1.444)	0.149	
Yes	Placebo	13	7 (53.8)	13.9	(3.1, NE)				
No	Tezepelumab	128	18 (14.1)	NE		0.431	(0.243, 0.763)	0.004	*
No	Placebo	125	35 (28.0)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_IOSTK: Time to first asthma exacerbation by key subgroups
DITT

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
ICS dose level (at study entry)	Tezepelumab							0.652	
Medium/Low	Tezepelumab	70	8 (11.4)	NE		0.476	(0.205, 1.103)	0.083	
Medium/Low	Placebo	73	17 (23.3)	NE					
High	Tezepelumab	67	13 (19.4)	NE		0.360	(0.183, 0.709)	0.003	*
High	Placebo	65	25 (38.5)	NE					
LAMA use at baseline	Tezepelumab							0.217	
Yes	Tezepelumab	11	4 (36.4)	NE		0.999	(0.214, 4.674)	0.999	
Yes	Placebo	6	3 (50.0)	NE					
No	Tezepelumab	126	17 (13.5)	NE		0.363	(0.204, 0.645)	<0.001	*
No	Placebo	132	39 (29.5)	NE					
Tiotropium use at baseline	Tezepelumab							0.668	
Yes	Tezepelumab	9	4 (44.4)	NE		0.536	(0.093, 3.096)	0.486	
Yes	Placebo	3	2 (66.7)	43.4	(2.6, NE)				
No	Tezepelumab	128	17 (13.3)	NE		0.376	(0.213, 0.665)	<0.001	*
No	Placebo	135	40 (29.6)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_IOSTK: Time to first asthma exacerbation by key subgroups
DITT

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab							0.216	
Yes	Tezepelumab	29	9 (31.0)	NE		0.666	(0.297, 1.496)	0.325	
Yes	Placebo	37	17 (45.9)	NE					
No	Tezepelumab	108	12 (11.1)	NE		0.312	(0.154, 0.630)	0.001	*
No	Placebo	101	25 (24.8)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_IOSTP: Time to first asthma exacerbation by study specific subgroups
DITT

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Race (cat. P)	Tezepelumab							0.309	
White	Tezepelumab	128	20 (15.6)	NE		0.450	(0.259, 0.784)	0.005	*
White	Placebo	123	35 (28.5)	NE					
Non-white	Tezepelumab	9	1 (11.1)	NE		0.136	(0.016, 1.129)	0.065	
Non-white	Placebo	15	7 (46.7)	NE					
Region (cat. P)	Tezepelumab							0.806	
North America/Western EU	Tezepelumab	10	3 (30.0)	NE		0.433	(0.107, 1.758)	0.242	
North America/Western EU	Placebo	9	6 (66.7)	43.4	(5.9, NE)				
Rest of world	Tezepelumab	127	18 (14.2)	NE		0.398	(0.225, 0.706)	0.002	*
Rest of world	Placebo	129	36 (27.9)	NE					
Baseline eosinophils (cat. P)	Tezepelumab							0.442	
< 250 cells/uL	Tezepelumab	61	7 (11.5)	NE		0.321	(0.134, 0.770)	0.011	*
< 250 cells/uL	Placebo	60	18 (30.0)	NE					
>= 250 cells/uL	Tezepelumab	76	14 (18.4)	NE		0.458	(0.234, 0.894)	0.022	*
>= 250 cells/uL	Placebo	78	24 (30.8)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_IOSTP: Time to first asthma exacerbation by study specific subgroups
DITT

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline FENO (cat. P)	Tezepelumab							0.257	
< 24 ppb	Tezepelumab	75	12 (16.0)	NE		0.543	(0.252, 1.171)	0.120	
< 24 ppb	Placebo	72	16 (22.2)	NE					
>= 24 ppb	Tezepelumab	60	9 (15.0)	NE		0.315	(0.147, 0.673)	0.003	*
>= 24 ppb	Placebo	65	26 (40.0)	NE					
Baseline FENO (cat. M)	Tezepelumab							0.229	
< 22.0 ppb	Tezepelumab	65	10 (15.4)	NE		0.592	(0.256, 1.368)	0.220	
< 22.0 ppb	Placebo	62	13 (21.0)	NE					
>= 22.0 ppb	Tezepelumab	70	11 (15.7)	NE		0.320	(0.159, 0.643)	0.001	*
>= 22.0 ppb	Placebo	75	29 (38.7)	NE					
Baseline all FEIA status	Tezepelumab							0.068	
All negative	Tezepelumab	50	11 (22.0)	NE		0.705	(0.324, 1.537)	0.380	
All negative	Placebo	50	15 (30.0)	NE					
Any positive	Tezepelumab	77	8 (10.4)	NE		0.263	(0.116, 0.596)	0.001	*
Any positive	Placebo	80	23 (28.8)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_IOSTP: Time to first asthma exacerbation by study specific subgroups
DITT

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Th2 status	Tezepelumab							0.476	
Low	Tezepelumab	70	9 (12.9)	NE		0.324	(0.148, 0.709)	0.005	*
Low	Placebo	62	21 (33.9)	NE					
High	Tezepelumab	65	11 (16.9)	NE		0.473	(0.226, 0.991)	0.047	*
High	Placebo	75	21 (28.0)	NE					
Baseline Periostin	Tezepelumab							0.918	
Low (< 20.9 ng/ml)	Tezepelumab	62	9 (14.5)	NE		0.390	(0.175, 0.871)	0.022	*
Low (< 20.9 ng/ml)	Placebo	67	19 (28.4)	NE					
High (>= 20.9 ng/ml)	Tezepelumab	74	12 (16.2)	NE		0.431	(0.214, 0.868)	0.019	*
High (>= 20.9 ng/ml)	Placebo	71	23 (32.4)	NE					
Current post-BD FEV1 reversibility	Tezepelumab							0.141	
Yes	Tezepelumab	114	15 (13.2)	NE		0.344	(0.187, 0.633)	<0.001	*
Yes	Placebo	126	37 (29.4)	NE					
No	Tezepelumab	23	6 (26.1)	NE		1.256	(0.363, 4.348)	0.719	
No	Placebo	12	5 (41.7)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_IOSTP: Time to first asthma exacerbation by study specific subgroups
DITT

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Maintenance OCS use at baseline	Tezepelumab							0.488	
Yes	Tezepelumab	9	3 (33.3)	NE		0.328	(0.084, 1.282)	0.109	
Yes	Placebo	14	8 (57.1)	11.7	(3.1, NE)				
No	Tezepelumab	128	18 (14.1)	NE		0.443	(0.250, 0.787)	0.005	*
No	Placebo	124	34 (27.4)	NE					
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab							0.512	
Yes	Tezepelumab	108	14 (13.0)	NE		0.367	(0.194, 0.694)	0.002	*
Yes	Placebo	115	32 (27.8)	NE					
No	Tezepelumab	29	7 (24.1)	NE		0.573	(0.214, 1.531)	0.267	
No	Placebo	23	10 (43.5)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_IOMT0: Time to first severe asthma exacerbation
DITT

Time to first severe asthma exacerbation			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Tezepelumab	137	3 (2.2)	NE		0.318	(0.086, 1.177)	0.086
Placebo	138	9 (6.5)	NE				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least on event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year.
Source Data: atte, created on: 11AUG2022

Figure PF2EST_IOMK0: Time to first severe asthma exacerbation - Kaplan-Meier plot
DITT



Note: DITT = Dossier Intent-to-Treat Set.
Reference table: PT2EST_IOMT0
Source Data: atte, created on: 11AUG2022

Table PT2EST_IOSTK: Time to first severe asthma exacerbation by key subgroups
DITT

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Tezepelumab	n<10	all levels					NE
Male	Tezepelumab	50	1 (2.0)					
Male	Placebo	44	2 (4.5)					
Female	Tezepelumab	87	2 (2.3)					
Female	Placebo	94	7 (7.4)					
Age	Tezepelumab	n<10	all levels					NE
< 65 years	Tezepelumab	114	2 (1.8)					
< 65 years	Placebo	118	7 (5.9)					
>= 65 years	Tezepelumab	23	1 (4.3)					
>= 65 years	Placebo	20	2 (10.0)					
Exacerbations in the year before study	Tezepelumab	n<10	all levels					NE
<= 2	Tezepelumab	105	1 (1.0)					
<= 2	Placebo	110	4 (3.6)					
> 2	Tezepelumab	32	2 (6.3)					
> 2	Placebo	28	5 (17.9)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_IOSTK: Time to first severe asthma exacerbation by key subgroups
DITT

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Race	Tezepelumab	N<10	any level					NE
White	Tezepelumab	128	3 (2.3)					
White	Placebo	123	6 (4.9)					
Black or African American	Tezepelumab	3	0 (0.0)					
Black or African American	Placebo	6	1 (16.7)					
Asian	Tezepelumab	5	0 (0.0)					
Asian	Placebo	6	0 (0.0)					
Other	Tezepelumab	1	0 (0.0)					
Other	Placebo	3	2 (66.7)					
Region	Tezepelumab	n<10	all levels					NE
Europe	Tezepelumab	78	3 (3.8)					
Europe	Placebo	80	2 (2.5)					
America	Tezepelumab	10	0 (0.0)					
America	Placebo	9	1 (11.1)					
Asia/Pacific	Tezepelumab	5	0 (0.0)					
Asia/Pacific	Placebo	6	0 (0.0)					
Rest of the world	Tezepelumab	44	0 (0.0)					
Rest of the world	Placebo	43	6 (14.0)					
BMI	Tezepelumab	N<10	any level					NE
< 18.5 kg/m**2	Tezepelumab	0						
< 18.5 kg/m**2	Placebo	1	0 (0.0)					
18.5 - < 25.0 kg/m**2	Tezepelumab	39	1 (2.6)					
18.5 - < 25.0 kg/m**2	Placebo	43	2 (4.7)					
25.0 - < 30.0 kg/m**2	Tezepelumab	45	1 (2.2)					
25.0 - < 30.0 kg/m**2	Placebo	47	2 (4.3)					
>= 30.0 kg/m**2	Tezepelumab	53	1 (1.9)					
>= 30.0 kg/m**2	Placebo	47	5 (10.6)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_IOSTK: Time to first severe asthma exacerbation by key subgroups
DITT

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eosinophils - Low	Tezepelumab	n<10	all levels					NE
< 150 cells/uL	Tezepelumab	27	1 (3.7)					
< 150 cells/uL	Placebo	33	3 (9.1)					
>= 150 cells/uL	Tezepelumab	109	2 (1.8)					
>= 150 cells/uL	Placebo	105	6 (5.7)					
Baseline eosinophils - High	Tezepelumab	n<10	all levels					NE
< 300 cells/uL	Tezepelumab	69	1 (1.4)					
< 300 cells/uL	Placebo	72	6 (8.3)					
>= 300 cells/uL	Tezepelumab	67	2 (3.0)					
>= 300 cells/uL	Placebo	66	3 (4.5)					
Baseline FENO	Tezepelumab	n<10	all levels					NE
< 25 ppb	Tezepelumab	78	2 (2.6)					
< 25 ppb	Placebo	74	4 (5.4)					
>= 25 ppb	Tezepelumab	57	1 (1.8)					
>= 25 ppb	Placebo	63	5 (7.9)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_IOSTK: Time to first severe asthma exacerbation by key subgroups
DITT

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline specific perennial FEIA status	Tezepelumab	n<10	all levels					NE
All negative	Tezepelumab	57	3 (5.3)					
All negative	Placebo	66	5 (7.6)					
Any positive	Tezepelumab	71	0 (0.0)					
Any positive	Placebo	63	3 (4.8)					
Total serum IgE	Tezepelumab	n<10	all levels					NE
Low	Tezepelumab	35	1 (2.9)					
Low	Placebo	32	4 (12.5)					
Normal	Tezepelumab	95	2 (2.1)					
Normal	Placebo	98	5 (5.1)					
High	Tezepelumab	7	0 (0.0)					
High	Placebo	8	0 (0.0)					
OCS at baseline	Tezepelumab							NE
Yes	Tezepelumab	9	0 (0.0)	NE		NE		NE
Yes	Placebo	13	2 (15.4)	NE				
No	Tezepelumab	128	3 (2.3)	NE				
No	Placebo	125	7 (5.6)	NE				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_IOSTK: Time to first severe asthma exacerbation by key subgroups
DITT

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
ICS dose level (at study entry)	Tezepelumab							NE
Medium/Low	Tezepelumab	70	0 (0.0)	NE		NE		NE
Medium/Low	Placebo	73	1 (1.4)	NE				
High	Tezepelumab	67	3 (4.5)	NE				
High	Placebo	65	8 (12.3)	NE				
LAMA use at baseline	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	11	3 (27.3)					
Yes	Placebo	6	0 (0.0)					
No	Tezepelumab	126	0 (0.0)					
No	Placebo	132	9 (6.8)					
Tiotropium use at baseline	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	9	3 (33.3)					
Yes	Placebo	3	0 (0.0)					
No	Tezepelumab	128	0 (0.0)					
No	Placebo	135	9 (6.7)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_IOSTK: Time to first severe asthma exacerbation by key subgroups
DITT

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	29	1 (3.4)					
Yes	Placebo	37	2 (5.4)					
No	Tezepelumab	108	2 (1.9)					
No	Placebo	101	7 (6.9)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_IOSTP: Time to first severe asthma exacerbation by study specific subgroups
DITT

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Race (cat. P)	Tezepelumab	n<10	all levels					NE
White	Tezepelumab	128	3 (2.3)					
White	Placebo	123	6 (4.9)					
Non-white	Tezepelumab	9	0 (0.0)					
Non-white	Placebo	15	3 (20.0)					
Region (cat. P)	Tezepelumab							NE
North America/Western EU	Tezepelumab	10	0 (0.0)	NE		NE		NE
North America/Western EU	Placebo	9	1 (11.1)	NE				
Rest of world	Tezepelumab	127	3 (2.4)	NE				
Rest of world	Placebo	129	8 (6.2)	NE				
Baseline eosinophils (cat. P)	Tezepelumab	n<10	all levels					NE
< 250 cells/uL	Tezepelumab	61	1 (1.6)					
< 250 cells/uL	Placebo	60	5 (8.3)					
>= 250 cells/uL	Tezepelumab	76	2 (2.6)					
>= 250 cells/uL	Placebo	78	4 (5.1)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_IOSTP: Time to first severe asthma exacerbation by study specific subgroups
DITT

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline FENO (cat. P)	Tezepelumab	n<10	all levels					NE
< 24 ppb	Tezepelumab	75	2 (2.7)					
< 24 ppb	Placebo	72	4 (5.6)					
>= 24 ppb	Tezepelumab	60	1 (1.7)					
>= 24 ppb	Placebo	65	5 (7.7)					
Baseline FENO (cat. M)	Tezepelumab	n<10	all levels					NE
< 22.0 ppb	Tezepelumab	65	2 (3.1)					
< 22.0 ppb	Placebo	62	3 (4.8)					
>= 22.0 ppb	Tezepelumab	70	1 (1.4)					
>= 22.0 ppb	Placebo	75	6 (8.0)					
Baseline all FEIA status	Tezepelumab	n<10	all levels					NE
All negative	Tezepelumab	50	3 (6.0)					
All negative	Placebo	50	5 (10.0)					
Any positive	Tezepelumab	77	0 (0.0)					
Any positive	Placebo	80	3 (3.8)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_IOSTP: Time to first severe asthma exacerbation by study specific subgroups
DITT

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Th2 status	Tezepelumab							NE
Low	Tezepelumab	70	2 (2.9)	NE				
Low	Placebo	62	9 (14.5)	NE				
High	Tezepelumab	65	1 (1.5)	NE		NE		NE
High	Placebo	75	0 (0.0)	NE				
Baseline Periostin	Tezepelumab	n<10	all levels					NE
Low (< 20.9 ng/ml)	Tezepelumab	62	1 (1.6)					
Low (< 20.9 ng/ml)	Placebo	67	4 (6.0)					
High (>= 20.9 ng/ml)	Tezepelumab	74	2 (2.7)					
High (>= 20.9 ng/ml)	Placebo	71	5 (7.0)					
Current post-BD FEV1 reversibility	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	114	3 (2.6)					
Yes	Placebo	126	6 (4.8)					
No	Tezepelumab	23	0 (0.0)					
No	Placebo	12	3 (25.0)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_IOSTP: Time to first severe asthma exacerbation by study specific subgroups
DITT

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Maintenance OCS use at baseline	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	9	0 (0.0)					
Yes	Placebo	14	3 (21.4)					
No	Tezepelumab	128	3 (2.3)					
No	Placebo	124	6 (4.8)					
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	108	3 (2.8)					
Yes	Placebo	115	5 (4.3)					
No	Tezepelumab	29	0 (0.0)					
No	Placebo	23	4 (17.4)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IOMT0: Time to first non-severe asthma exacerbation
DITT

Time to first non-severe asthma exacerbation			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Tezepelumab	137	19 (13.9)	NE		0.410	(0.236, 0.712)	0.002 *
Placebo	138	39 (28.3)	NE				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least on event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year.
Source Data: atte, created on: 11AUG2022

Figure PF2ENT_IOMK0: Time to first non-severe asthma exacerbation - Kaplan-Meier plot
DITT



Note: DITT = Dossier Intent-to-Treat Set.
Reference table: PT2ENT_IOMT0
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IOSTK: Time to first non-severe asthma exacerbation by key subgroups
DITT

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Tezepelumab							0.570	
Male	Tezepelumab	50	5 (10.0)	NE		0.271	(0.088, 0.837)	0.023	*
Male	Placebo	44	10 (22.7)	NE					
Female	Tezepelumab	87	14 (16.1)	NE		0.461	(0.243, 0.873)	0.017	*
Female	Placebo	94	29 (30.9)	NE					
Age	Tezepelumab							0.286	
< 65 years	Tezepelumab	114	15 (13.2)	NE		0.366	(0.200, 0.669)	0.001	*
< 65 years	Placebo	118	36 (30.5)	NE					
>= 65 years	Tezepelumab	23	4 (17.4)	NE		0.757	(0.137, 4.185)	0.750	
>= 65 years	Placebo	20	3 (15.0)	NE					
Exacerbations in the year before study	Tezepelumab							0.325	
<= 2	Tezepelumab	105	11 (10.5)	NE		0.528	(0.254, 1.094)	0.086	
<= 2	Placebo	110	21 (19.1)	NE					
> 2	Tezepelumab	32	8 (25.0)	NE		0.308	(0.133, 0.710)	0.006	*
> 2	Placebo	28	18 (64.3)	38.3	(13.0, NE)				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IOSTK: Time to first non-severe asthma exacerbation by key subgroups
DITT

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Race	Tezepelumab	N<10	any level					NE	
White	Tezepelumab	128	18 (14.1)						
White	Placebo	123	32 (26.0)						
Black or African American	Tezepelumab	3	0 (0.0)						
Black or African American	Placebo	6	3 (50.0)						
Asian	Tezepelumab	5	1 (20.0)						
Asian	Placebo	6	1 (16.7)						
Other	Tezepelumab	1	0 (0.0)						
Other	Placebo	3	3 (100.0)						
Region	Tezepelumab							0.054	
Europe	Tezepelumab	78	13 (16.7)	NE		0.746	(0.362, 1.537)	0.426	
Europe	Placebo	80	17 (21.3)	NE					
America	Tezepelumab	10	3 (30.0)	NE		0.433	(0.107, 1.758)	0.242	
America	Placebo	9	6 (66.7)	43.4	(5.9, NE)				
Asia/Pacific	Tezepelumab	5	1 (20.0)	NE		0.000	(0.000,)	0.999	
Asia/Pacific	Placebo	6	1 (16.7)	NE					
Rest of the world	Tezepelumab	44	2 (4.5)	NE		0.092	(0.021, 0.408)	0.002	*
Rest of the world	Placebo	43	15 (34.9)	NE					
BMI	Tezepelumab	N<10	any level					NE	
< 18.5 kg/m**2	Tezepelumab	0							
< 18.5 kg/m**2	Placebo	1	0 (0.0)						
18.5 - < 25.0 kg/m**2	Tezepelumab	39	4 (10.3)						
18.5 - < 25.0 kg/m**2	Placebo	43	15 (34.9)						
25.0 - < 30.0 kg/m**2	Tezepelumab	45	7 (15.6)						
25.0 - < 30.0 kg/m**2	Placebo	47	13 (27.7)						
>= 30.0 kg/m**2	Tezepelumab	53	8 (15.1)						
>= 30.0 kg/m**2	Placebo	47	11 (23.4)						

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IOSTK: Time to first non-severe asthma exacerbation by key subgroups
DITT

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eosinophils - Low	Tezepelumab							0.494	
< 150 cells/uL	Tezepelumab	27	3 (11.1)	NE		0.286	(0.078, 1.048)	0.059	
< 150 cells/uL	Placebo	33	10 (30.3)	NE					
>= 150 cells/uL	Tezepelumab	109	16 (14.7)	NE		0.452	(0.245, 0.835)	0.011	*
>= 150 cells/uL	Placebo	105	29 (27.6)	NE					
Baseline eosinophils - High	Tezepelumab							0.511	
< 300 cells/uL	Tezepelumab	69	9 (13.0)	NE		0.509	(0.226, 1.143)	0.102	
< 300 cells/uL	Placebo	72	17 (23.6)	NE					
>= 300 cells/uL	Tezepelumab	67	10 (14.9)	NE		0.339	(0.159, 0.720)	0.005	*
>= 300 cells/uL	Placebo	66	22 (33.3)	NE					
Baseline FENO	Tezepelumab							0.310	
< 25 ppb	Tezepelumab	78	12 (15.4)	NE		0.532	(0.250, 1.130)	0.101	
< 25 ppb	Placebo	74	17 (23.0)	NE					
>= 25 ppb	Tezepelumab	57	7 (12.3)	NE		0.303	(0.129, 0.712)	0.006	*
>= 25 ppb	Placebo	63	22 (34.9)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IOSTK: Time to first non-severe asthma exacerbation by key subgroups
DITT

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline specific perennial FEIA status	Tezepelumab							0.642	
All negative	Tezepelumab	57	8 (14.0)	NE		0.459	(0.199, 1.057)	0.067	
All negative	Placebo	66	18 (27.3)	NE					
Any positive	Tezepelumab	71	9 (12.7)	NE		0.375	(0.165, 0.851)	0.019	*
Any positive	Placebo	63	17 (27.0)	NE					
Total serum IgE	Tezepelumab							0.794	
Low	Tezepelumab	35	5 (14.3)	NE		0.428	(0.146, 1.254)	0.122	
Low	Placebo	32	10 (31.3)	NE					
Normal	Tezepelumab	95	13 (13.7)	NE		0.385	(0.197, 0.752)	0.005	*
Normal	Placebo	98	27 (27.6)	NE					
High	Tezepelumab	7	1 (14.3)	NE		1.000	(0.063, 15.987)	1.000	
High	Placebo	8	2 (25.0)	NE					
OCS at baseline	Tezepelumab							0.867	
Yes	Tezepelumab	9	3 (33.3)	NE		0.436	(0.111, 1.716)	0.235	
Yes	Placebo	13	7 (53.8)	55.7	(3.1, NE)				
No	Tezepelumab	128	16 (12.5)	NE		0.422	(0.231, 0.771)	0.005	*
No	Placebo	125	32 (25.6)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IOSTK: Time to first non-severe asthma exacerbation by key subgroups
DITT

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
ICS dose level (at study entry)	Tezepelumab							0.265	
Medium/Low	Tezepelumab	70	9 (12.9)	NE		0.584	(0.258, 1.322)	0.197	
Medium/Low	Placebo	73	16 (21.9)	NE					
High	Tezepelumab	67	10 (14.9)	NE		0.296	(0.140, 0.627)	0.001	*
High	Placebo	65	23 (35.4)	NE					
LAMA use at baseline	Tezepelumab							0.444	
Yes	Tezepelumab	11	1 (9.1)	NE		0.214	(0.022, 2.115)	0.187	
Yes	Placebo	6	3 (50.0)	NE					
No	Tezepelumab	126	18 (14.3)	NE		0.444	(0.251, 0.784)	0.005	*
No	Placebo	132	36 (27.3)	NE					
Tiotropium use at baseline	Tezepelumab							0.194	
Yes	Tezepelumab	9	1 (11.1)	NE		0.000	(0.000,)	0.999	
Yes	Placebo	3	2 (66.7)	43.4	(2.6, NE)				
No	Tezepelumab	128	18 (14.1)	NE		0.454	(0.258, 0.799)	0.006	*
No	Placebo	135	37 (27.4)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IOSTK: Time to first non-severe asthma exacerbation by key subgroups
DITT

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab							0.189	
Yes	Tezepelumab	29	9 (31.0)	NE		0.689	(0.304, 1.559)	0.371	
Yes	Placebo	37	16 (43.2)	NE					
No	Tezepelumab	108	10 (9.3)	NE		0.302	(0.142, 0.642)	0.002	*
No	Placebo	101	23 (22.8)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IOSTP: Time to first non-severe asthma exacerbation by study specific subgroups
DITT

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Race (cat. P)	Tezepelumab							0.338	
White	Tezepelumab	128	18 (14.1)	NE		0.456	(0.255, 0.816)	0.008	*
White	Placebo	123	32 (26.0)	NE					
Non-white	Tezepelumab	9	1 (11.1)	NE		0.138	(0.017, 1.146)	0.067	
Non-white	Placebo	15	7 (46.7)	NE					
Region (cat. P)	Tezepelumab							0.837	
North America/Western EU	Tezepelumab	10	3 (30.0)	NE		0.433	(0.107, 1.758)	0.242	
North America/Western EU	Placebo	9	6 (66.7)	43.4	(5.9, NE)				
Rest of world	Tezepelumab	127	16 (12.6)	NE		0.401	(0.220, 0.732)	0.003	*
Rest of world	Placebo	129	33 (25.6)	NE					
Baseline eosinophils (cat. P)	Tezepelumab							0.421	
< 250 cells/uL	Tezepelumab	61	6 (9.8)	NE		0.311	(0.121, 0.796)	0.015	*
< 250 cells/uL	Placebo	60	16 (26.7)	NE					
>= 250 cells/uL	Tezepelumab	76	13 (17.1)	NE		0.482	(0.242, 0.959)	0.038	*
>= 250 cells/uL	Placebo	78	23 (29.5)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IOSTP: Time to first non-severe asthma exacerbation by study specific subgroups
DITT

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline FENO (cat. P)	Tezepelumab							0.292	
< 24 ppb	Tezepelumab	75	11 (14.7)	NE		0.558	(0.252, 1.238)	0.151	
< 24 ppb	Placebo	72	15 (20.8)	NE					
>= 24 ppb	Tezepelumab	60	8 (13.3)	NE		0.314	(0.141, 0.700)	0.005	*
>= 24 ppb	Placebo	65	24 (36.9)	NE					
Baseline FENO (cat. M)	Tezepelumab							0.711	
< 22.0 ppb	Tezepelumab	65	8 (12.3)	NE		0.446	(0.181, 1.096)	0.078	
< 22.0 ppb	Placebo	62	13 (21.0)	NE					
>= 22.0 ppb	Tezepelumab	70	11 (15.7)	NE		0.383	(0.189, 0.777)	0.008	*
>= 22.0 ppb	Placebo	75	26 (34.7)	NE					
Baseline all FEIA status	Tezepelumab							0.124	
All negative	Tezepelumab	50	8 (16.0)	NE		0.711	(0.286, 1.768)	0.463	
All negative	Placebo	50	11 (22.0)	NE					
Any positive	Tezepelumab	77	9 (11.7)	NE		0.286	(0.131, 0.623)	0.002	*
Any positive	Placebo	80	24 (30.0)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IOSTP: Time to first non-severe asthma exacerbation by study specific subgroups
DITT

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Th2 status	Tezepelumab							0.888	
Low	Tezepelumab	70	8 (11.4)	NE		0.374	(0.161, 0.867)	0.022	*
Low	Placebo	62	17 (27.4)	NE					
High	Tezepelumab	65	10 (15.4)	NE		0.400	(0.187, 0.854)	0.018	*
High	Placebo	75	22 (29.3)	NE					
Baseline Periostin	Tezepelumab							0.633	
Low (< 20.9 ng/ml)	Tezepelumab	62	9 (14.5)	NE		0.469	(0.208, 1.060)	0.069	
Low (< 20.9 ng/ml)	Placebo	67	17 (25.4)	NE					
High (>= 20.9 ng/ml)	Tezepelumab	74	10 (13.5)	NE		0.374	(0.177, 0.792)	0.010	*
High (>= 20.9 ng/ml)	Placebo	71	22 (31.0)	NE					
Current post-BD FEV1 reversibility	Tezepelumab							0.027	i
Yes	Tezepelumab	114	13 (11.4)	NE		0.311	(0.163, 0.593)	<0.001	*
Yes	Placebo	126	35 (27.8)	NE					
No	Tezepelumab	23	6 (26.1)	NE		2.085	(0.551, 7.892)	0.279	
No	Placebo	12	4 (33.3)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IOSTP: Time to first non-severe asthma exacerbation by study specific subgroups
DITT

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Maintenance OCS use at baseline	Tezepelumab							0.867	
Yes	Tezepelumab	9	3 (33.3)	NE		0.413	(0.109, 1.575)	0.196	
Yes	Placebo	14	8 (57.1)	29.7	(3.1, NE)				
No	Tezepelumab	128	16 (12.5)	NE		0.429	(0.234, 0.788)	0.006	*
No	Placebo	124	31 (25.0)	NE					
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab							0.327	
Yes	Tezepelumab	108	12 (11.1)	NE		0.348	(0.176, 0.690)	0.002	*
Yes	Placebo	115	29 (25.2)	NE					
No	Tezepelumab	29	7 (24.1)	NE		0.656	(0.245, 1.762)	0.403	
No	Placebo	23	10 (43.5)	NE					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2E_ILMN0: AAER during planned treatment period
DITTL

AAER during planned treatment period					Adjusted rates		Rate ratio		
Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Tezepelumab	66	16	60.3	0.27	0.27	(0.14, 0.52)	0.200	(0.090, 0.441)	<0.001 *
Placebo	65	70	58.8	1.19	1.37	(0.86, 2.19)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model.
A negative binomial model was applied with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNK: AAER during planned treatment period by key subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Sex	Tezepelumab									0.680	
Male	Tezepelumab	19	4	17.5	0.23	0.23	(0.06, 0.84)	0.264	(0.053, 1.329)	0.106	
Male	Placebo	20	14	17.9	0.78	0.88	(0.33, 2.31)				
Female	Tezepelumab	47	12	42.7	0.28	0.29	(0.14, 0.60)	0.183	(0.074, 0.452)	<0.001	*
Female	Placebo	45	56	40.8	1.37	1.58	(0.93, 2.70)				
Age	Tezepelumab									0.629	
< 65 years	Tezepelumab	57	13	52.2	0.25	0.26	(0.13, 0.52)	0.183	(0.077, 0.437)	<0.001	*
< 65 years	Placebo	55	60	49.3	1.22	1.40	(0.84, 2.34)				
>= 65 years	Tezepelumab	9	3	8.0	0.37	0.37	(0.08, 1.76)	0.315	(0.045, 2.188)	0.243	
>= 65 years	Placebo	10	10	9.5	1.06	1.18	(0.37, 3.78)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNK: AAER during planned treatment period by key subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Exacerbations in the year before study	Tezepelumab									0.329	
<= 2	Tezepelumab	44	6	41.6	0.14	0.15	(0.05, 0.39)	0.301	(0.087, 1.043)	0.058	
<= 2	Placebo	45	18	42.4	0.42	0.48	(0.23, 1.02)				
> 2	Tezepelumab	22	10	18.6	0.54	0.54	(0.27, 1.09)	0.163	(0.073, 0.363)	<0.001	*
> 2	Placebo	20	52	16.4	3.18	3.35	(2.22, 5.06)				
Race	Tezepelumab	N<10	any level							NE	
White	Tezepelumab	60	14	54.4	0.26						
White	Placebo	58	46	53.1	0.87						
Black or African American	Tezepelumab	2	0	2.0	0.00						
Black or African American	Placebo	2	8	1.5	5.26						
Asian	Tezepelumab	3	2	2.9	0.69						
Asian	Placebo	3	4	2.8	1.43						
Other	Tezepelumab	1	0	1.0	0.00						
Other	Placebo	2	12	1.3	8.96						

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNK: AAER during planned treatment period by key subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Region	Tezepelumab	N<10	any level							NE	
Europe	Tezepelumab	40	12	36.4	0.33						
Europe	Placebo	36	24	34.7	0.69						
America	Tezepelumab	6	1	5.3	0.19						
America	Placebo	4	9	3.5	2.59						
Asia/Pacific	Tezepelumab	3	2	2.9	0.69						
Asia/Pacific	Placebo	3	4	2.8	1.43						
Rest of the world	Tezepelumab	17	1	15.7	0.06						
Rest of the world	Placebo	22	33	17.9	1.85						
BMI	Tezepelumab									0.965	
18.5 - < 25.0 kg/m**2	Tezepelumab	15	4	14.4	0.28	0.28	(0.09, 0.84)	0.231	(0.066, 0.807)	0.022	*
18.5 - < 25.0 kg/m**2	Placebo	21	22	19.3	1.14	1.21	(0.67, 2.19)				
25.0 - < 30.0 kg/m**2	Tezepelumab	24	5	21.3	0.24	0.24	(0.07, 0.75)	0.171	(0.040, 0.735)	0.018	*
25.0 - < 30.0 kg/m**2	Placebo	20	22	18.0	1.22	1.38	(0.57, 3.38)				
>= 30.0 kg/m**2	Tezepelumab	27	7	24.6	0.28	0.31	(0.10, 0.92)	0.204	(0.049, 0.860)	0.030	*
>= 30.0 kg/m**2	Placebo	24	26	21.5	1.21	1.49	(0.59, 3.77)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNK: AAER during planned treatment period by key subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline eosinophils - Low	Tezepelumab									0.379	
< 150 cells/uL	Tezepelumab	11	2	9.6	0.21	0.23	(0.04, 1.24)	0.100	(0.015, 0.672)	0.018	*
< 150 cells/uL	Placebo	14	24	12.4	1.94	2.31	(0.94, 5.65)				
>= 150 cells/uL	Tezepelumab	54	14	49.7	0.28	0.29	(0.14, 0.57)	0.257	(0.107, 0.615)	0.002	*
>= 150 cells/uL	Placebo	51	46	46.4	0.99	1.11	(0.65, 1.90)				
Baseline eosinophils - High	Tezepelumab									0.888	
< 300 cells/uL	Tezepelumab	33	8	30.3	0.26	0.28	(0.11, 0.72)	0.215	(0.066, 0.702)	0.011	*
< 300 cells/uL	Placebo	34	33	29.9	1.10	1.29	(0.63, 2.64)				
>= 300 cells/uL	Tezepelumab	32	8	29.0	0.28	0.28	(0.12, 0.67)	0.193	(0.066, 0.561)	0.003	*
>= 300 cells/uL	Placebo	31	37	28.9	1.28	1.45	(0.78, 2.68)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNK: AAER during planned treatment period by key subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline FENO	Tezepelumab									0.045	i
< 25 ppb	Tezepelumab	39	12	35.4	0.34	0.36	(0.15, 0.84)	0.444	(0.134, 1.467)	0.183	
< 25 ppb	Placebo	30	20	28.2	0.71	0.80	(0.35, 1.85)				
>= 25 ppb	Tezepelumab	27	4	24.8	0.16	0.16	(0.05, 0.48)	0.085	(0.025, 0.285)	<0.001	*
>= 25 ppb	Placebo	34	50	29.6	1.69	1.91	(1.14, 3.19)				
Baseline specific perennial FEIA status	Tezepelumab									0.931	
All negative	Tezepelumab	27	7	24.6	0.28	0.29	(0.12, 0.69)	0.212	(0.078, 0.576)	0.002	*
All negative	Placebo	29	34	26.6	1.28	1.38	(0.82, 2.33)				
Any positive	Tezepelumab	34	8	30.7	0.26	0.26	(0.09, 0.76)	0.193	(0.050, 0.748)	0.017	*
Any positive	Placebo	33	33	29.4	1.12	1.37	(0.58, 3.24)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNK: AAER during planned treatment period by key subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Total serum IgE	Tezepelumab									NE	
Low	Tezepelumab	23	6	20.6	0.29	0.30	(0.12, 0.71)	0.174	(0.060, 0.505)	0.001	*
Low	Placebo	14	20	12.5	1.60	1.71	(0.92, 3.16)				
Normal	Tezepelumab	40	10	37.5	0.27	0.27	(0.11, 0.64)	0.190	(0.065, 0.552)	0.002	*
Normal	Placebo	44	48	39.5	1.22	1.43	(0.76, 2.68)				
High	Tezepelumab	3	0	2.1	0.00					NE	
High	Placebo	7	2	6.9	0.29						
OCS at baseline	Tezepelumab									0.778	
Yes	Tezepelumab	9	4	7.6	0.53	0.52	(0.16, 1.71)	0.265	(0.068, 1.040)	0.057	
Yes	Placebo	13	20	10.8	1.86	1.98	(0.99, 3.94)				
No	Tezepelumab	57	12	52.7	0.23	0.24	(0.11, 0.50)	0.194	(0.075, 0.498)	<0.001	*
No	Placebo	52	50	48.0	1.04	1.22	(0.69, 2.17)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNK: AAER during planned treatment period by key subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
LAMA use at baseline	Tezepelumab									0.630	
Yes	Tezepelumab	7	5	6.8	0.74	0.74	(0.30, 1.81)	0.323	(0.095, 1.099)	0.070	
Yes	Placebo	3	6	2.6	2.28	2.30	(0.99, 5.34)				
No	Tezepelumab	59	11	53.5	0.21	0.21	(0.10, 0.45)	0.161	(0.065, 0.399)	<0.001	*
No	Placebo	62	64	56.2	1.14	1.32	(0.79, 2.20)				
Tiotropium use at baseline	Tezepelumab	N<10	any level							NE	
Yes	Tezepelumab	6	5	5.8	0.87						
Yes	Placebo	2	3	1.8	1.65						
No	Tezepelumab	60	11	54.5	0.20						
No	Placebo	63	67	57.0	1.18						

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNK: AAER during planned treatment period by key subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab									0.588	
Yes	Tezepelumab	17	8	13.7	0.58	0.58	(0.24, 1.41)	0.281	(0.098, 0.809)	0.019	*
Yes	Placebo	21	35	18.5	1.89	2.06	(1.16, 3.68)				
No	Tezepelumab	49	8	46.5	0.17	0.18	(0.07, 0.44)	0.174	(0.056, 0.539)	0.002	*
No	Placebo	44	35	40.3	0.87	1.03	(0.52, 2.05)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNP: AAER during planned treatment period by study specific subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Race (cat. P)	Tezepelumab									0.251	
White	Tezepelumab	60	14	54.4	0.26	0.26	(0.14, 0.51)	0.275	(0.121, 0.626)	0.002	*
White	Placebo	58	46	53.1	0.87	0.96	(0.59, 1.57)				
Non-white	Tezepelumab	6	2	5.9	0.34	0.35	(0.07, 1.76)	0.073	(0.012, 0.462)	0.005	*
Non-white	Placebo	7	24	5.6	4.25	4.74	(1.98, 11.36)				
Region (cat. P)	Tezepelumab									0.410	
North America/Western EU	Tezepelumab	6	1	5.3	0.19	0.19	(0.02, 1.52)	0.067	(0.006, 0.696)	0.024	*
North America/Western EU	Placebo	4	9	3.5	2.59	2.83	(0.97, 8.26)				
Rest of world	Tezepelumab	60	15	55.0	0.27	0.28	(0.14, 0.55)	0.222	(0.096, 0.516)	<0.001	*
Rest of world	Placebo	61	61	55.3	1.10	1.27	(0.77, 2.10)				
Baseline eosinophils (cat. P)	Tezepelumab									0.456	
< 250 cells/uL	Tezepelumab	30	5	28.6	0.18	0.18	(0.06, 0.50)	0.137	(0.039, 0.475)	0.002	*
< 250 cells/uL	Placebo	29	29	25.7	1.13	1.29	(0.65, 2.55)				
>= 250 cells/uL	Tezepelumab	36	11	31.7	0.35	0.36	(0.16, 0.82)	0.253	(0.089, 0.717)	0.010	*
>= 250 cells/uL	Placebo	36	41	33.1	1.24	1.43	(0.76, 2.70)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNP: AAER during planned treatment period by study specific subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline FENO (cat. P)	Tezepelumab									0.036	i
< 24 ppb	Tezepelumab	38	12	34.4	0.35	0.37	(0.16, 0.86)	0.457	(0.138, 1.509)	0.199	
< 24 ppb	Placebo	30	20	28.2	0.71	0.80	(0.35, 1.85)				
>= 24 ppb	Tezepelumab	28	4	25.8	0.15	0.16	(0.05, 0.46)	0.081	(0.024, 0.273)	<0.001	*
>= 24 ppb	Placebo	34	50	29.6	1.69	1.91	(1.14, 3.19)				
Baseline FENO (cat. M)	Tezepelumab									0.048	i
< 22.0 ppb	Tezepelumab	32	11	28.5	0.39	0.41	(0.17, 0.99)	0.454	(0.133, 1.551)	0.208	
< 22.0 ppb	Placebo	27	20	25.2	0.79	0.89	(0.39, 2.07)				
>= 22.0 ppb	Tezepelumab	34	5	31.8	0.16	0.16	(0.06, 0.43)	0.090	(0.029, 0.279)	<0.001	*
>= 22.0 ppb	Placebo	37	50	32.6	1.53	1.75	(1.03, 2.97)				
Baseline all FEIA status	Tezepelumab									0.752	
All negative	Tezepelumab	25	7	22.6	0.31	0.32	(0.14, 0.72)	0.248	(0.092, 0.672)	0.006	*
All negative	Placebo	22	24	20.0	1.20	1.27	(0.73, 2.22)				
Any positive	Tezepelumab	35	8	31.7	0.25	0.26	(0.09, 0.71)	0.184	(0.052, 0.653)	0.009	*
Any positive	Placebo	41	43	36.9	1.16	1.39	(0.66, 2.94)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNP: AAER during planned treatment period by study specific subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Th2 status	Tezepelumab									0.101	
Low	Tezepelumab	41	8	37.2	0.22	0.22	(0.10, 0.49)	0.111	(0.042, 0.296)	<0.001	*
Low	Placebo	30	45	25.8	1.75	1.99	(1.14, 3.46)				
High	Tezepelumab	25	8	23.1	0.35	0.35	(0.12, 1.00)	0.405	(0.111, 1.473)	0.170	
High	Placebo	34	25	32.0	0.78	0.87	(0.41, 1.87)				
Baseline Periostin	Tezepelumab									0.925	
Low (< 20.9 ng/ml)	Tezepelumab	26	7	24.4	0.29	0.31	(0.11, 0.89)	0.211	(0.057, 0.776)	0.019	*
Low (< 20.9 ng/ml)	Placebo	31	33	26.8	1.23	1.46	(0.68, 3.14)				
High (>= 20.9 ng/ml)	Tezepelumab	40	9	35.9	0.25	0.25	(0.11, 0.56)	0.196	(0.073, 0.528)	0.001	*
High (>= 20.9 ng/ml)	Placebo	34	37	32.0	1.16	1.29	(0.72, 2.30)				
Current post-BD FEV1 reversibility	Tezepelumab									0.280	
Yes	Tezepelumab	57	11	51.5	0.21	0.22	(0.11, 0.46)	0.238	(0.098, 0.576)	0.001	*
Yes	Placebo	60	46	55.2	0.83	0.92	(0.56, 1.52)				
No	Tezepelumab	9	5	8.8	0.57	0.57	(0.24, 1.37)	0.085	(0.032, 0.223)	<0.001	*
No	Placebo	5	24	3.6	6.69	6.69	(4.49, 9.98)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2E_ILSNP: AAER during planned treatment period by study specific subgroups
DITTL

AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Maintenance OCS use at baseline	Tezepelumab									0.879	
Yes	Tezepelumab	9	4	7.6	0.53	0.52	(0.15, 1.80)	0.201	(0.049, 0.830)	0.027	*
Yes	Placebo	14	27	11.4	2.36	2.60	(1.30, 5.21)				
No	Tezepelumab	57	12	52.7	0.23	0.24	(0.11, 0.49)	0.228	(0.090, 0.580)	0.002	*
No	Placebo	51	43	47.4	0.91	1.03	(0.58, 1.84)				
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab									0.398	
Yes	Tezepelumab	51	10	46.7	0.21	0.22	(0.10, 0.48)	0.278	(0.105, 0.734)	0.010	*
Yes	Placebo	49	33	46.0	0.72	0.80	(0.45, 1.42)				
No	Tezepelumab	15	6	13.5	0.44	0.45	(0.17, 1.18)	0.142	(0.045, 0.449)	<0.001	*
No	Placebo	16	37	12.8	2.88	3.15	(1.69, 5.84)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILMN0: Severe AAER during planned treatment period
DITTL

Severe AAER during planned treatment period					Adjusted rates		Rate ratio			
Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Tezepelumab	66	3	60.8	0.05	0.05	(0.01, 0.20)	0.150	(0.029, 0.790)	0.025	*
Placebo	65	17	61.6	0.28	0.33	(0.13, 0.83)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model.
A negative binomial model was applied with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNK: Severe AAER during planned treatment period by key subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Sex	Tezepelumab									0.503	
Male	Tezepelumab	19	1	17.7	0.06	0.06	(0.01, 0.40)	0.527	(0.048, 5.808)	0.601	
Male	Placebo	20	2	18.6	0.11	0.11	(0.03, 0.43)				
Female	Tezepelumab	47	2	43.2	0.05	0.05	(0.01, 0.25)	0.114	(0.015, 0.853)	0.034	*
Female	Placebo	45	15	43.0	0.35	0.41	(0.14, 1.21)				
Age	Tezepelumab									0.438	
< 65 years	Tezepelumab	57	2	52.7	0.04	0.04	(0.01, 0.21)	0.106	(0.014, 0.824)	0.032	*
< 65 years	Placebo	55	15	51.8	0.29	0.36	(0.12, 1.11)				
>= 65 years	Tezepelumab	9	1	8.1	0.12	0.12	(0.02, 0.87)	0.605	(0.055, 6.676)	0.682	
>= 65 years	Placebo	10	2	9.9	0.20	0.20	(0.05, 0.81)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNK: Severe AAER during planned treatment period by key subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio		
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Exacerbations in the year before study	Tezepelumab									0.707
<= 2	Tezepelumab	44	1	41.9	0.02	0.02	(0.00, 0.17)	0.258	(0.029, 2.304)	0.225
<= 2	Placebo	45	4	43.1	0.09	0.09	(0.03, 0.25)			
> 2	Tezepelumab	22	2	19.0	0.11	0.10	(0.02, 0.64)	0.127	(0.014, 1.171)	0.069
> 2	Placebo	20	13	18.5	0.70	0.83	(0.23, 3.01)			
Race	Tezepelumab	N<10	any level							NE
White	Tezepelumab	60	3	54.8	0.05					
White	Placebo	58	8	55.1	0.15					
Black or African American	Tezepelumab	2	0	2.0	0.00					
Black or African American	Placebo	2	1	2.0	0.51					
Asian	Tezepelumab	3	0	3.0	0.00					
Asian	Placebo	3	0	3.0	0.00					
Other	Tezepelumab	1	0	1.0	0.00					
Other	Placebo	2	8	1.6	4.98					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNK: Severe AAER during planned treatment period by key subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio		
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Region	Tezepelumab	N<10	any level							NE
Europe	Tezepelumab	40	3	36.7	0.08					
Europe	Placebo	36	1	35.9	0.03					
America	Tezepelumab	6	0	5.3	0.00					
America	Placebo	4	1	4.0	0.25					
Asia/Pacific	Tezepelumab	3	0	3.0	0.00					
Asia/Pacific	Placebo	3	0	3.0	0.00					
Rest of the world	Tezepelumab	17	0	15.8	0.00					
Rest of the world	Placebo	22	15	18.7	0.80					
BMI	Tezepelumab									0.659
18.5 - < 25.0 kg/m**2	Tezepelumab	15	1	14.6	0.07	0.07	(0.01, 0.49)	0.696	(0.063, 7.673)	0.767
18.5 - < 25.0 kg/m**2	Placebo	21	2	20.3	0.10	0.10	(0.02, 0.39)			
25.0 - < 30.0 kg/m**2	Tezepelumab	24	1	21.4	0.05	0.05	(0.00, 0.58)	0.148	(0.006, 3.391)	0.232
25.0 - < 30.0 kg/m**2	Placebo	20	5	19.0	0.26	0.32	(0.05, 2.09)			
>= 30.0 kg/m**2	Tezepelumab	27	1	24.9	0.04	0.04	(0.00, 0.38)	0.080	(0.006, 1.092)	0.058
>= 30.0 kg/m**2	Placebo	24	10	22.4	0.45	0.50	(0.13, 1.88)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNK: Severe AAER during planned treatment period by key subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio		
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Baseline eosinophils - Low	Tezepelumab									0.897
< 150 cells/uL	Tezepelumab	11	1	9.6	0.10	0.10	(0.01, 1.60)	0.190	(0.007, 5.252)	0.327
< 150 cells/uL	Placebo	14	6	13.3	0.45	0.54	(0.08, 3.44)			
>= 150 cells/uL	Tezepelumab	54	2	50.2	0.04	0.04	(0.01, 0.20)	0.149	(0.022, 1.016)	0.052
>= 150 cells/uL	Placebo	51	11	48.3	0.23	0.27	(0.10, 0.77)			
Baseline eosinophils - High	Tezepelumab									0.614
< 300 cells/uL	Tezepelumab	33	1	30.6	0.03	0.03	(0.00, 0.29)	0.095	(0.008, 1.130)	0.062
< 300 cells/uL	Placebo	34	9	31.1	0.29	0.34	(0.11, 1.10)			
>= 300 cells/uL	Tezepelumab	32	2	29.3	0.07	0.07	(0.01, 0.46)	0.221	(0.020, 2.432)	0.217
>= 300 cells/uL	Placebo	31	8	30.5	0.26	0.31	(0.07, 1.35)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNK: Severe AAER during planned treatment period by key subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio		
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Baseline FENO	Tezepelumab									0.239
< 25 ppb	Tezepelumab	39	2	35.9	0.06	0.06	(0.01, 0.22)	0.540	(0.090, 3.234)	0.500
< 25 ppb	Placebo	30	3	29.1	0.10	0.10	(0.03, 0.32)			
>= 25 ppb	Tezepelumab	27	1	25.0	0.04	0.04	(0.00, 0.43)	0.072	(0.005, 1.054)	0.055
>= 25 ppb	Placebo	34	14	31.6	0.44	0.56	(0.16, 2.00)			
Baseline specific perennial FEIA status	Tezepelumab									NE
All negative	Tezepelumab	27	3	24.7	0.12	0.12	(0.03, 0.53)	0.395	(0.061, 2.574)	0.331
All negative	Placebo	29	7	27.9	0.25	0.31	(0.10, 1.00)			
Any positive	Tezepelumab	34	0	31.1	0.00					NE
Any positive	Placebo	33	9	30.8	0.29					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNK: Severe AAER during planned treatment period by key subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Total serum IgE	Tezepelumab									NE	
Low	Tezepelumab	23	1	20.8	0.05	0.05	(0.01, 0.39)	0.082	(0.007, 0.906)	0.041	*
Low	Placebo	14	7	13.2	0.53	0.59	(0.18, 1.91)				
Normal	Tezepelumab	40	2	37.9	0.05	0.05	(0.01, 0.34)	0.175	(0.018, 1.725)	0.136	
Normal	Placebo	44	10	41.4	0.24	0.30	(0.08, 1.15)				
High	Tezepelumab	3	0	2.1	0.00					NE	
High	Placebo	7	0	7.0	0.00						
OCS at baseline	Tezepelumab									NE	
Yes	Tezepelumab	9	0	7.8	0.00					NE	
Yes	Placebo	13	5	11.6	0.43						
No	Tezepelumab	57	3	53.1	0.06	0.06	(0.01, 0.23)	0.200	(0.035, 1.136)	0.069	
No	Placebo	52	12	50.0	0.24	0.29	(0.10, 0.80)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNK: Severe AAER during planned treatment period by key subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio		
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
LAMA use at baseline	Tezepelumab									NE
Yes	Tezepelumab	7	3	6.9	0.44					NE
Yes	Placebo	3	0	3.0	0.00					
No	Tezepelumab	59	0	54.0	0.00					NE
No	Placebo	62	17	58.6	0.29					
Tiotropium use at baseline	Tezepelumab	N<10	any level							NE
Yes	Tezepelumab	6	3	5.9	0.51					
Yes	Placebo	2	0	2.0	0.00					
No	Tezepelumab	60	0	55.0	0.00					
No	Placebo	63	17	59.6	0.29					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNK: Severe AAER during planned treatment period by key subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab									0.828	
Yes	Tezepelumab	17	1	14.1	0.07	0.07	(0.00, 1.16)	0.197	(0.007, 5.747)	0.346	
Yes	Placebo	21	6	20.0	0.30	0.36	(0.05, 2.37)				
No	Tezepelumab	49	2	46.8	0.04	0.04	(0.01, 0.21)	0.137	(0.020, 0.922)	0.041	*
No	Placebo	44	11	41.6	0.26	0.31	(0.11, 0.88)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNP: Severe AAER during planned treatment period by study specific subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Race (cat. P)	Tezepelumab									NE	
White	Tezepelumab	60	3	54.8	0.05	0.05	(0.01, 0.22)	0.318	(0.056, 1.824)	0.199	
White	Placebo	58	8	55.1	0.15	0.17	(0.06, 0.50)				
Non-white	Tezepelumab	6	0	6.0	0.00					NE	
Non-white	Placebo	7	9	6.6	1.37						
Region (cat. P)	Tezepelumab									NE	
North America/Western EU	Tezepelumab	6	0	5.3	0.00					NE	
North America/Western EU	Placebo	4	1	4.0	0.25						
Rest of world	Tezepelumab	60	3	55.5	0.05	0.05	(0.01, 0.23)	0.161	(0.028, 0.922)	0.040	*
Rest of world	Placebo	61	16	57.7	0.28	0.34	(0.13, 0.91)				
Baseline eosinophils (cat. P)	Tezepelumab									0.806	
< 250 cells/uL	Tezepelumab	30	1	28.7	0.03	0.03	(0.00, 0.28)	0.124	(0.012, 1.238)	0.075	
< 250 cells/uL	Placebo	29	7	26.9	0.26	0.28	(0.10, 0.78)				
>= 250 cells/uL	Tezepelumab	36	2	32.1	0.06	0.06	(0.01, 0.47)	0.173	(0.014, 2.185)	0.175	
>= 250 cells/uL	Placebo	36	10	34.7	0.29	0.36	(0.08, 1.70)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNP: Severe AAER during planned treatment period by study specific subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline FENO (cat. P)	Tezepelumab									0.223	
< 24 ppb	Tezepelumab	38	2	34.9	0.06	0.06	(0.01, 0.23)	0.556	(0.093, 3.327)	0.520	
< 24 ppb	Placebo	30	3	29.1	0.10	0.10	(0.03, 0.32)				
>= 24 ppb	Tezepelumab	28	1	26.0	0.04	0.04	(0.00, 0.40)	0.069	(0.005, 1.002)	0.050	
>= 24 ppb	Placebo	34	14	31.6	0.44	0.56	(0.16, 2.00)				
Baseline FENO (cat. M)	Tezepelumab									0.187	
< 22.0 ppb	Tezepelumab	32	2	28.9	0.07	0.07	(0.02, 0.28)	0.602	(0.101, 3.603)	0.578	
< 22.0 ppb	Placebo	27	3	26.1	0.12	0.12	(0.04, 0.36)				
>= 22.0 ppb	Tezepelumab	34	1	32.0	0.03	0.03	(0.00, 0.32)	0.061	(0.004, 0.868)	0.039	*
>= 22.0 ppb	Placebo	37	14	34.6	0.41	0.51	(0.14, 1.86)				
Baseline all FEIA status	Tezepelumab									NE	
All negative	Tezepelumab	25	3	22.7	0.13	0.13	(0.03, 0.54)	0.323	(0.052, 2.020)	0.227	
All negative	Placebo	22	7	20.9	0.33	0.41	(0.13, 1.32)				
Any positive	Tezepelumab	35	0	32.1	0.00					NE	
Any positive	Placebo	41	9	38.8	0.23						

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNP: Severe AAER during planned treatment period by study specific subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Th2 status	Tezepelumab									NE	
Low	Tezepelumab	41	2	37.4	0.05	0.05	(0.01, 0.25)	0.074	(0.013, 0.436)	0.004	*
Low	Placebo	30	17	27.3	0.62	0.72	(0.30, 1.76)				
High	Tezepelumab	25	1	23.4	0.04					NE	
High	Placebo	34	0	33.3	0.00						
Baseline Periostin	Tezepelumab									0.906	
Low (< 20.9 ng/ml)	Tezepelumab	26	1	24.6	0.04	0.04	(0.00, 0.49)	0.127	(0.007, 2.463)	0.172	
Low (< 20.9 ng/ml)	Placebo	31	7	28.3	0.25	0.32	(0.06, 1.60)				
High (>= 20.9 ng/ml)	Tezepelumab	40	2	36.2	0.06	0.06	(0.01, 0.29)	0.163	(0.023, 1.176)	0.072	
High (>= 20.9 ng/ml)	Placebo	34	10	33.4	0.30	0.34	(0.11, 1.04)				
Current post-BD FEV1 reversibility	Tezepelumab									NE	
Yes	Tezepelumab	57	3	51.8	0.06	0.06	(0.02, 0.18)	0.663	(0.159, 2.776)	0.574	
Yes	Placebo	60	5	57.3	0.09	0.09	(0.04, 0.21)				
No	Tezepelumab	9	0	9.0	0.00					NE	
No	Placebo	5	12	4.3	2.78						

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_ILSNP: Severe AAER during planned treatment period by study specific subgroups
DITTL

Severe AAER during planned treatment period						Adjusted rates		Rate ratio		
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Maintenance OCS use at baseline	Tezepelumab									NE
Yes	Tezepelumab	9	0	7.8	0.00					NE
Yes	Placebo	14	10	12.3	0.81					
No	Tezepelumab	57	3	53.1	0.06	0.06	(0.02, 0.21)	0.368	(0.073, 1.858)	0.226
No	Placebo	51	7	49.3	0.14	0.15	(0.06, 0.41)			
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab									NE
Yes	Tezepelumab	51	3	47.1	0.06	0.06	(0.02, 0.20)	0.756	(0.169, 3.377)	0.714
Yes	Placebo	49	4	47.4	0.08	0.08	(0.03, 0.22)			
No	Tezepelumab	15	0	13.8	0.00					NE
No	Placebo	16	13	14.2	0.91					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILMN0: Non-severe AAER during planned treatment period
DITTL

Non-severe AAER during planned treatment period					Adjusted rates		Rate ratio			
Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Tezepelumab	66	13	60.4	0.22	0.22	(0.11, 0.44)	0.228	(0.098, 0.532)	<0.001	*
Placebo	65	53	59.8	0.89	0.97	(0.59, 1.59)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model.
A negative binomial model was applied with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNK: Non-severe AAER during planned treatment period by key subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio		
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Sex	Tezepelumab									0.923
Male	Tezepelumab	19	3	17.6	0.17	0.18	(0.03, 0.92)	0.244	(0.030, 1.998)	0.189
Male	Placebo	20	12	18.1	0.66	0.72	(0.20, 2.62)			
Female	Tezepelumab	47	10	42.8	0.23	0.24	(0.11, 0.51)	0.223	(0.089, 0.556)	0.001 *
Female	Placebo	45	41	41.7	0.98	1.08	(0.64, 1.82)			
Age	Tezepelumab									0.861
< 65 years	Tezepelumab	57	11	52.3	0.21	0.22	(0.10, 0.46)	0.221	(0.088, 0.556)	0.001 *
< 65 years	Placebo	55	45	50.2	0.90	0.99	(0.57, 1.69)			
>= 65 years	Tezepelumab	9	2	8.1	0.25	0.25	(0.04, 1.43)	0.275	(0.033, 2.285)	0.232
>= 65 years	Placebo	10	8	9.6	0.84	0.91	(0.27, 3.00)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNK: Non-severe AAER during planned treatment period by key subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Exacerbations in the year before study	Tezepelumab									0.388	
<= 2	Tezepelumab	44	5	41.7	0.12	0.12	(0.04, 0.36)	0.338	(0.087, 1.321)	0.119	
<= 2	Placebo	45	14	42.7	0.33	0.36	(0.16, 0.81)				
> 2	Tezepelumab	22	8	18.7	0.43	0.43	(0.20, 0.92)	0.184	(0.077, 0.439)	<0.001	*
> 2	Placebo	20	39	17.1	2.28	2.36	(1.53, 3.65)				
Race	Tezepelumab	N<10	any level							NE	
White	Tezepelumab	60	11	54.5	0.20						
White	Placebo	58	38	53.7	0.71						
Black or African American	Tezepelumab	2	0	2.0	0.00						
Black or African American	Placebo	2	7	1.5	4.52						
Asian	Tezepelumab	3	2	2.9	0.69						
Asian	Placebo	3	4	2.8	1.43						
Other	Tezepelumab	1	0	1.0	0.00						
Other	Placebo	2	4	1.7	2.31						

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNK: Non-severe AAER during planned treatment period by key subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Region	Tezepelumab	N<10	any level							NE	
Europe	Tezepelumab	40	9	36.5	0.25						
Europe	Placebo	36	23	34.7	0.66						
America	Tezepelumab	6	1	5.3	0.19						
America	Placebo	4	8	3.5	2.28						
Asia/Pacific	Tezepelumab	3	2	2.9	0.69						
Asia/Pacific	Placebo	3	4	2.8	1.43						
Rest of the world	Tezepelumab	17	1	15.7	0.06						
Rest of the world	Placebo	22	18	18.8	0.96						
BMI	Tezepelumab									0.845	
18.5 - < 25.0 kg/m**2	Tezepelumab	15	3	14.4	0.21	0.21	(0.06, 0.74)	0.197	(0.048, 0.801)	0.023	*
18.5 - < 25.0 kg/m**2	Placebo	21	20	19.4	1.03	1.07	(0.57, 2.01)				
25.0 - < 30.0 kg/m**2	Tezepelumab	24	4	21.3	0.19	0.19	(0.05, 0.69)	0.181	(0.035, 0.931)	0.041	*
25.0 - < 30.0 kg/m**2	Placebo	20	17	18.3	0.93	1.04	(0.38, 2.87)				
>= 30.0 kg/m**2	Tezepelumab	27	6	24.6	0.24	0.26	(0.09, 0.80)	0.314	(0.073, 1.357)	0.121	
>= 30.0 kg/m**2	Placebo	24	16	22.0	0.73	0.83	(0.32, 2.15)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNK: Non-severe AAER during planned treatment period by key subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline eosinophils - Low	Tezepelumab									0.256	
< 150 cells/uL	Tezepelumab	11	1	9.6	0.10	0.11	(0.01, 0.94)	0.072	(0.007, 0.692)	0.023	*
< 150 cells/uL	Placebo	14	18	12.7	1.42	1.57	(0.70, 3.56)				
>= 150 cells/uL	Tezepelumab	54	12	49.8	0.24	0.24	(0.12, 0.51)	0.304	(0.118, 0.786)	0.014	*
>= 150 cells/uL	Placebo	51	35	47.1	0.74	0.80	(0.45, 1.45)				
Baseline eosinophils - High	Tezepelumab									0.645	
< 300 cells/uL	Tezepelumab	33	7	30.3	0.23	0.24	(0.09, 0.63)	0.283	(0.087, 0.920)	0.036	*
< 300 cells/uL	Placebo	34	24	30.4	0.79	0.85	(0.42, 1.72)				
>= 300 cells/uL	Tezepelumab	32	6	29.1	0.21	0.21	(0.08, 0.57)	0.190	(0.056, 0.642)	0.007	*
>= 300 cells/uL	Placebo	31	29	29.4	0.99	1.10	(0.55, 2.20)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNK: Non-severe AAER during planned treatment period by key subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline FENO	Tezepelumab									0.086	
< 25 ppb	Tezepelumab	39	10	35.5	0.28	0.30	(0.12, 0.74)	0.447	(0.125, 1.595)	0.215	
< 25 ppb	Placebo	30	17	28.3	0.60	0.67	(0.27, 1.62)				
>= 25 ppb	Tezepelumab	27	3	24.9	0.12	0.12	(0.04, 0.42)	0.095	(0.025, 0.366)	<0.001	*
>= 25 ppb	Placebo	34	36	30.4	1.18	1.27	(0.74, 2.17)				
Baseline specific perennial FEIA status	Tezepelumab									0.524	
All negative	Tezepelumab	27	4	24.7	0.16	0.17	(0.05, 0.52)	0.160	(0.044, 0.580)	0.005	*
All negative	Placebo	29	27	27.1	1.00	1.06	(0.56, 2.00)				
Any positive	Tezepelumab	34	8	30.7	0.26	0.26	(0.10, 0.70)	0.287	(0.082, 1.010)	0.052	
Any positive	Placebo	33	24	29.9	0.80	0.92	(0.42, 2.03)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNK: Non-severe AAER during planned treatment period by key subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Total serum IgE	Tezepelumab									NE	
Low	Tezepelumab	23	5	20.7	0.24	0.25	(0.09, 0.65)	0.232	(0.069, 0.778)	0.018	*
Low	Placebo	14	13	12.9	1.01	1.07	(0.51, 2.23)				
Normal	Tezepelumab	40	8	37.6	0.21	0.22	(0.09, 0.54)	0.208	(0.069, 0.632)	0.006	*
Normal	Placebo	44	38	40.0	0.95	1.04	(0.55, 1.97)				
High	Tezepelumab	3	0	2.1	0.00					NE	
High	Placebo	7	2	6.9	0.29						
OCS at baseline	Tezepelumab									0.591	
Yes	Tezepelumab	9	4	7.6	0.53	0.52	(0.16, 1.73)	0.369	(0.091, 1.506)	0.165	
Yes	Placebo	13	15	11.1	1.35	1.42	(0.67, 3.00)				
No	Tezepelumab	57	9	52.8	0.17	0.18	(0.08, 0.40)	0.206	(0.074, 0.571)	0.002	*
No	Placebo	52	38	48.6	0.78	0.86	(0.47, 1.58)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNK: Non-severe AAER during planned treatment period by key subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
LAMA use at baseline	Tezepelumab									0.661	
Yes	Tezepelumab	7	2	6.9	0.29	0.30	(0.06, 1.44)	0.123	(0.015, 1.025)	0.053	
Yes	Placebo	3	6	2.6	2.28	2.40	(0.59, 9.82)				
No	Tezepelumab	59	11	53.5	0.21	0.21	(0.10, 0.45)	0.235	(0.095, 0.579)	0.002	*
No	Placebo	62	47	57.1	0.82	0.90	(0.54, 1.51)				
Tiotropium use at baseline	Tezepelumab	N<10	any level							NE	
Yes	Tezepelumab	6	2	5.9	0.34						
Yes	Placebo	2	3	1.8	1.65						
No	Tezepelumab	60	11	54.5	0.20						
No	Placebo	63	50	58.0	0.86						

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNK: Non-severe AAER during planned treatment period by key subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab									0.648	
Yes	Tezepelumab	17	7	13.8	0.51	0.51	(0.20, 1.27)	0.311	(0.105, 0.923)	0.035	*
Yes	Placebo	21	29	18.8	1.54	1.63	(0.91, 2.94)				
No	Tezepelumab	49	6	46.6	0.13	0.14	(0.05, 0.36)	0.206	(0.060, 0.704)	0.012	*
No	Placebo	44	24	40.9	0.59	0.66	(0.32, 1.36)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNP: Non-severe AAER during planned treatment period by study specific subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Race (cat. P)	Tezepelumab									0.549	
White	Tezepelumab	60	11	54.5	0.20	0.21	(0.10, 0.44)	0.271	(0.107, 0.685)	0.006	*
White	Placebo	58	38	53.7	0.71	0.77	(0.44, 1.33)				
Non-white	Tezepelumab	6	2	5.9	0.34	0.35	(0.07, 1.64)	0.131	(0.022, 0.760)	0.023	*
Non-white	Placebo	7	15	6.1	2.47	2.64	(1.16, 6.05)				
Region (cat. P)	Tezepelumab									0.401	
North America/Western EU	Tezepelumab	6	1	5.3	0.19	0.19	(0.02, 1.52)	0.076	(0.007, 0.801)	0.032	*
North America/Western EU	Placebo	4	8	3.5	2.28	2.50	(0.83, 7.53)				
Rest of world	Tezepelumab	60	12	55.1	0.22	0.23	(0.11, 0.47)	0.259	(0.105, 0.640)	0.003	*
Rest of world	Placebo	61	45	56.3	0.80	0.87	(0.51, 1.49)				
Baseline eosinophils (cat. P)	Tezepelumab									0.465	
< 250 cells/uL	Tezepelumab	30	4	28.6	0.14	0.14	(0.04, 0.44)	0.153	(0.039, 0.596)	0.007	*
< 250 cells/uL	Placebo	29	22	26.1	0.84	0.92	(0.44, 1.92)				
>= 250 cells/uL	Tezepelumab	36	9	31.8	0.28	0.30	(0.12, 0.71)	0.292	(0.098, 0.873)	0.028	*
>= 250 cells/uL	Placebo	36	31	33.7	0.92	1.01	(0.52, 1.96)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNP: Non-severe AAER during planned treatment period by study specific subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Baseline FENO (cat. P)	Tezepelumab									0.072	
< 24 ppb	Tezepelumab	38	10	34.5	0.29	0.31	(0.12, 0.77)	0.460	(0.129, 1.640)	0.231	
< 24 ppb	Placebo	30	17	28.3	0.60	0.67	(0.28, 1.61)				
>= 24 ppb	Tezepelumab	28	3	25.9	0.12	0.12	(0.03, 0.40)	0.092	(0.024, 0.351)	<0.001	*
>= 24 ppb	Placebo	34	36	30.4	1.18	1.27	(0.74, 2.17)				
Baseline FENO (cat. M)	Tezepelumab									NE	
< 22.0 ppb	Tezepelumab	32	9	28.6	0.31						
< 22.0 ppb	Placebo	27	17	25.3	0.67						
>= 22.0 ppb	Tezepelumab	34	4	31.8	0.13						
>= 22.0 ppb	Placebo	37	36	33.4	1.08						
Baseline all FEIA status	Tezepelumab									0.875	
All negative	Tezepelumab	25	4	22.7	0.18	0.18	(0.06, 0.54)	0.212	(0.058, 0.773)	0.019	*
All negative	Placebo	22	17	20.5	0.83	0.86	(0.43, 1.72)				
Any positive	Tezepelumab	35	8	31.7	0.25	0.26	(0.10, 0.67)	0.249	(0.075, 0.819)	0.022	*
Any positive	Placebo	41	34	37.4	0.91	1.03	(0.51, 2.07)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNP: Non-severe AAER during planned treatment period by study specific subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Th2 status	Tezepelumab									0.305	
Low	Tezepelumab	41	6	37.3	0.16	0.16	(0.07, 0.40)	0.147	(0.051, 0.428)	<0.001	*
Low	Placebo	30	28	26.7	1.05	1.12	(0.62, 2.01)				
High	Tezepelumab	25	7	23.1	0.30	0.31	(0.10, 0.94)	0.354	(0.091, 1.386)	0.136	
High	Placebo	34	25	32.0	0.78	0.87	(0.39, 1.94)				
Baseline Periostin	Tezepelumab									0.894	
Low (< 20.9 ng/ml)	Tezepelumab	26	6	24.4	0.25	0.27	(0.09, 0.80)	0.248	(0.064, 0.958)	0.043	*
Low (< 20.9 ng/ml)	Placebo	31	26	27.2	0.96	1.07	(0.49, 2.35)				
High (>= 20.9 ng/ml)	Tezepelumab	40	7	36.0	0.19	0.20	(0.08, 0.47)	0.221	(0.075, 0.647)	0.006	*
High (>= 20.9 ng/ml)	Placebo	34	27	32.6	0.83	0.89	(0.48, 1.65)				
Current post-BD FEV1 reversibility	Tezepelumab									0.985	
Yes	Tezepelumab	57	8	51.6	0.16	0.16	(0.07, 0.37)	0.199	(0.073, 0.541)	0.002	*
Yes	Placebo	60	41	55.5	0.74	0.81	(0.47, 1.39)				
No	Tezepelumab	9	5	8.8	0.57	0.57	(0.22, 1.50)	0.197	(0.057, 0.676)	0.010	*
No	Placebo	5	12	4.3	2.81	2.91	(1.34, 6.34)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_ILSNP: Non-severe AAER during planned treatment period by study specific subgroups
DITTL

Non-severe AAER during planned treatment period						Adjusted rates		Rate ratio			
Subgroup	Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value	
Maintenance OCS use at baseline	Tezepelumab									0.635	
Yes	Tezepelumab	9	4	7.6	0.53	0.53	(0.17, 1.64)	0.357	(0.095, 1.333)	0.125	
Yes	Placebo	14	17	12.0	1.41	1.47	(0.76, 2.85)				
No	Tezepelumab	57	9	52.8	0.17	0.18	(0.08, 0.41)	0.213	(0.075, 0.605)	0.004	*
No	Placebo	51	36	47.7	0.75	0.84	(0.45, 1.57)				
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab									0.966	
Yes	Tezepelumab	51	7	46.9	0.15	0.16	(0.06, 0.39)	0.228	(0.073, 0.707)	0.010	*
Yes	Placebo	49	29	46.2	0.63	0.69	(0.36, 1.32)				
No	Tezepelumab	15	6	13.5	0.44	0.45	(0.17, 1.14)	0.239	(0.078, 0.736)	0.013	*
No	Placebo	16	24	13.6	1.76	1.86	(1.00, 3.45)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model. * = significant treatment effect.
A negative binomial model was applied per subgroup with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
To investigate interaction, the interaction effect is determined by the same model adding subgroup and subgroup*treatment interaction. i = significant interaction effect.
Source Data: aaer, created on: 16AUG2022

Table PT2ER_ILMI0: Patients without exacerbations during planned treatment period
DITTL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Patients without exacerbations during planned treatment period	66	46 (69.7) [57.1, 80.4]	65	37 (56.9) [44.0, 69.2]	1.224 [0.940, 1.595]	1.741 [0.848, 3.571]	12.8 [-5.1, 30.7]	0.149

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with events. A patient will be considered as without exacerbation, if no exacerbations was observed in considered timeframe and the patient has completed the planned treatment period.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: atte, created on: 11AUG2022

Table PT2ER_ILSIK: Patients without exacerbations during planned treatment period by key subgroups
DITTL

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex								0.428	
Male	19	13 (68.4) [43.4, 87.4]	20	13 (65.0) [40.8, 84.6]	1.053 [0.676, 1.640]	1.167 [0.307, 4.430]	3.4 [-31.3, 38.1]	1.000	
Female	47	33 (70.2) [55.1, 82.7]	45	24 (53.3) [37.9, 68.3]	1.316 [0.946, 1.832]	2.063 [0.876, 4.858]	16.9 [-4.9, 38.6]	0.133	
Age								0.195	
< 65 years	57	41 (71.9) [58.5, 83.0]	55	30 (54.5) [40.6, 68.0]	1.319 [0.986, 1.764]	2.135 [0.974, 4.680]	17.4 [-2.0, 36.8]	0.077	
>= 65 years	9	5 (55.6) [21.2, 86.3]	10	7 (70.0) [34.8, 93.3]	0.794 [0.390, 1.617]	0.536 [0.081, 3.533]	-14.4 [-68.1, 39.2]	0.650	
Exacerbations in the year before study								0.028	i
<= 2	44	34 (77.3) [62.2, 88.5]	45	34 (75.6) [60.5, 87.1]	1.023 [0.812, 1.288]	1.100 [0.413, 2.929]	1.7 [-18.2, 21.6]	1.000	
> 2	22	12 (54.5) [32.2, 75.6]	20	3 (15.0) [3.2, 37.9]	3.636 [1.197, 11.043]	6.800 [1.537, 30.077]	39.5 [8.7, 70.4]	0.011	*
Race		N<10 any level						NE	
White	60	41 (68.3) [55.0, 79.7]	58	35 (60.3) [46.6, 73.0]					
Black or African American	2	2 (100.0) [15.8, 100.0]	2	0 (0.0) [0.0, 84.2]					
Asian	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]					
Other	1	1 (100.0) [2.5, 100.0]	2	0 (0.0) [0.0, 84.2]					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_ILSIK: Patients without exacerbations during planned treatment period by key subgroups
DITTL

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Region		N<10 any level						NE
Europe	40	26 (65.0) [48.3, 79.4]	36	25 (69.4) [51.9, 83.7]				
America	6	4 (66.7) [22.3, 95.7]	4	1 (25.0) [0.6, 80.6]				
Asia/Pacific	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Rest of the world	17	14 (82.4) [56.6, 96.2]	22	9 (40.9) [20.7, 63.6]				
BMI								0.569
18.5 - < 25.0 kg/m**2	15	10 (66.7) [38.4, 88.2]	21	9 (42.9) [21.8, 66.0]	1.556 [0.845, 2.863]	2.667 [0.672, 10.580]	23.8 [-13.8, 61.4]	0.192
25.0 - < 30.0 kg/m**2	24	17 (70.8) [48.9, 87.4]	20	12 (60.0) [36.1, 80.9]	1.181 [0.760, 1.834]	1.619 [0.462, 5.679]	10.8 [-21.9, 43.6]	0.532
>= 30.0 kg/m**2	27	19 (70.4) [49.8, 86.2]	24	16 (66.7) [44.7, 84.4]	1.056 [0.726, 1.534]	1.188 [0.363, 3.881]	3.7 [-25.8, 33.2]	1.000
Baseline eosinophils - Low								0.534
< 150 cells/uL	11	8 (72.7) [39.0, 94.0]	14	7 (50.0) [23.0, 77.0]	1.455 [0.770, 2.749]	2.667 [0.492, 14.461]	22.7 [-22.5, 68.0]	0.414
>= 150 cells/uL	54	37 (68.5) [54.4, 80.5]	51	30 (58.8) [44.2, 72.4]	1.165 [0.870, 1.560]	1.524 [0.684, 3.392]	9.7 [-10.5, 29.9]	0.318
Baseline eosinophils - High								0.605
< 300 cells/uL	33	24 (72.7) [54.5, 86.7]	34	19 (55.9) [37.9, 72.8]	1.301 [0.904, 1.874]	2.105 [0.757, 5.852]	16.8 [-8.7, 42.4]	0.204
>= 300 cells/uL	32	21 (65.6) [46.8, 81.4]	31	18 (58.1) [39.1, 75.5]	1.130 [0.765, 1.670]	1.379 [0.497, 3.825]	7.6 [-19.5, 34.7]	0.609

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_ILSIK: Patients without exacerbations during planned treatment period by key subgroups
DITTL

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO								0.037	i
< 25 ppb	39	27 (69.2) [52.4, 83.0]	30	22 (73.3) [54.1, 87.7]	0.944 [0.699, 1.275]	0.818 [0.284, 2.354]	-4.1 [-28.5, 20.3]	0.793	
>= 25 ppb	27	19 (70.4) [49.8, 86.2]	34	14 (41.2) [24.6, 59.3]	1.709 [1.068, 2.736]	3.393 [1.162, 9.910]	29.2 [2.0, 56.4]	0.038	*
Baseline specific perennial FEIA status								0.276	
All negative	27	19 (70.4) [49.8, 86.2]	29	14 (48.3) [29.4, 67.5]	1.458 [0.930, 2.284]	2.545 [0.846, 7.654]	22.1 [-6.5, 50.7]	0.111	
Any positive	34	23 (67.6) [49.5, 82.6]	33	21 (63.6) [45.1, 79.6]	1.063 [0.751, 1.504]	1.195 [0.435, 3.279]	4.0 [-21.7, 29.7]	0.800	
Total serum IgE								0.276	
Low	23	16 (69.6) [47.1, 86.8]	14	5 (35.7) [12.8, 64.9]	1.948 [0.917, 4.136]	4.114 [1.006, 16.827]	33.9 [-3.3, 71.0]	0.086	
Normal	40	28 (70.0) [53.5, 83.4]	44	26 (59.1) [43.2, 73.7]	1.185 [0.861, 1.629]	1.615 [0.654, 3.992]	10.9 [-11.8, 33.6]	0.364	
High	3	2 (66.7) [9.4, 99.2]	7	6 (85.7) [42.1, 99.6]	0.778 [0.331, 1.830]	0.333 [0.014, 8.182]	-19.0 [-100.0, 64.1]	1.000	
OCS at baseline								0.946	
Yes	9	4 (44.4) [13.7, 78.8]	13	5 (38.5) [13.9, 68.4]	1.156 [0.424, 3.151]	1.280 [0.228, 7.187]	6.0 [-45.3, 57.3]	1.000	
No	57	42 (73.7) [60.3, 84.5]	52	32 (61.5) [47.0, 74.7]	1.197 [0.919, 1.561]	1.750 [0.777, 3.943]	12.1 [-7.2, 31.5]	0.219	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_ILSIK: Patients without exacerbations during planned treatment period by key subgroups
DITTL

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline								0.980
Yes	7	3 (42.9) [9.9, 81.6]	3	1 (33.3) [0.8, 90.6]	1.286 [0.209, 7.892]	1.500 [0.089, 25.392]	9.5 [-79.0, 98.1]	1.000
No	59	43 (72.9) [59.7, 83.6]	62	36 (58.1) [44.8, 70.5]	1.255 [0.965, 1.632]	1.941 [0.904, 4.167]	14.8 [-3.6, 33.2]	0.126
Tiotropium use at baseline	N<10 any level							NE
Yes	6	2 (33.3) [4.3, 77.7]	2	1 (50.0) [1.3, 98.7]				
No	60	44 (73.3) [60.3, 83.9]	63	36 (57.1) [44.0, 69.5]				
Montelukast/ Cromoglicic acid use at baseline								0.793
Yes	17	7 (41.2) [18.4, 67.1]	21	8 (38.1) [18.1, 61.6]	1.081 [0.492, 2.376]	1.138 [0.308, 4.204]	3.1 [-33.5, 39.7]	1.000
No	49	39 (79.6) [65.7, 89.8]	44	29 (65.9) [50.1, 79.5]	1.208 [0.935, 1.559]	2.017 [0.793, 5.130]	13.7 [-6.5, 33.8]	0.164

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_ILSIP: Patients without exacerbations during planned treatment period by study specific subgroups
DITTL

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)								0.139	
White	60	41 (68.3) [55.0, 79.7]	58	35 (60.3) [46.6, 73.0]	1.132 [0.864, 1.484]	1.418 [0.665, 3.022]	8.0 [-10.9, 26.9]	0.443	
Non-white	6	5 (83.3) [35.9, 99.6]	7	2 (28.6) [3.7, 71.0]	2.917 [0.857, 9.926]	12.500 [0.839, 186.299]	54.8 [-5.5, 100.0]	0.103	
Region (cat. P)								0.380	
North America/Western EU	6	4 (66.7) [22.3, 95.7]	4	1 (25.0) [0.6, 80.6]	2.667 [0.446, 15.959]	6.000 [0.354, 101.568]	41.7 [-35.9, 100.0]	0.524	
Rest of world	60	42 (70.0) [56.8, 81.2]	61	36 (59.0) [45.7, 71.4]	1.186 [0.908, 1.549]	1.620 [0.764, 3.437]	11.0 [-7.6, 29.6]	0.255	
Baseline eosinophils (cat. P)								0.113	
< 250 cells/uL	30	24 (80.0) [61.4, 92.3]	29	15 (51.7) [32.5, 70.6]	1.547 [1.042, 2.295]	3.733 [1.178, 11.833]	28.3 [1.7, 54.8]	0.029	*
>= 250 cells/uL	36	22 (61.1) [43.5, 76.9]	36	22 (61.1) [43.5, 76.9]	1.000 [0.692, 1.446]	1.000 [0.388, 2.580]	0.0 [-25.3, 25.3]	1.000	
Baseline FENO (cat. P)								0.029	i
< 24 ppb	38	26 (68.4) [51.3, 82.5]	30	22 (73.3) [54.1, 87.7]	0.933 [0.688, 1.266]	0.788 [0.273, 2.273]	-4.9 [-29.5, 19.7]	0.790	
>= 24 ppb	28	20 (71.4) [51.3, 86.8]	34	14 (41.2) [24.6, 59.3]	1.735 [1.090, 2.762]	3.571 [1.229, 10.382]	30.3 [3.5, 57.0]	0.022	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_ILSIP: Patients without exacerbations during planned treatment period by study specific subgroups
DITTL

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. M)								0.048	i
< 22.0 ppb	32	21 (65.6) [46.8, 81.4]	27	19 (70.4) [49.8, 86.2]	0.933 [0.657, 1.324]	0.804 [0.267, 2.420]	-4.7 [-32.0, 22.5]	0.784	
>= 22.0 ppb	34	25 (73.5) [55.6, 87.1]	37	17 (45.9) [29.5, 63.1]	1.600 [1.069, 2.396]	3.268 [1.203, 8.877]	27.6 [2.9, 52.3]	0.029	*
Baseline all FEIA status								0.306	
All negative	25	17 (68.0) [46.5, 85.1]	22	10 (45.5) [24.4, 67.8]	1.496 [0.880, 2.544]	2.550 [0.778, 8.362]	22.5 [-9.4, 54.5]	0.148	
Any positive	35	24 (68.6) [50.7, 83.1]	41	26 (63.4) [46.9, 77.9]	1.081 [0.783, 1.494]	1.259 [0.484, 3.273]	5.2 [-18.8, 29.1]	0.809	
Th2 status								0.052	
Low	41	30 (73.2) [57.1, 85.8]	30	13 (43.3) [25.5, 62.6]	1.689 [1.078, 2.646]	3.566 [1.313, 9.688]	29.8 [4.6, 55.0]	0.015	*
High	25	16 (64.0) [42.5, 82.0]	34	23 (67.6) [49.5, 82.6]	0.946 [0.650, 1.376]	0.850 [0.287, 2.523]	-3.6 [-31.6, 24.3]	0.788	
Baseline Periostin								0.374	
Low (< 20.9 ng/ml)	26	20 (76.9) [56.4, 91.0]	31	17 (54.8) [36.0, 72.7]	1.403 [0.957, 2.056]	2.745 [0.865, 8.708]	22.1 [-5.3, 49.5]	0.101	
High (>= 20.9 ng/ml)	40	26 (65.0) [48.3, 79.4]	34	20 (58.8) [40.7, 75.4]	1.105 [0.770, 1.586]	1.300 [0.506, 3.337]	6.2 [-18.7, 31.1]	0.636	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ER_ILSIP: Patients without exacerbations during planned treatment period by study specific subgroups
DITTL

Patients without exacerbations during planned treatment period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.212
Yes	57	41 (71.9) [58.5, 83.0]	60	37 (61.7) [48.2, 73.9]	1.166 [0.902, 1.508]	1.593 [0.732, 3.466]	10.3 [-8.4, 28.9]	0.327
No	9	5 (55.6) [21.2, 86.3]	5	0 (0.0) [0.0, 52.2]	6.600 + [0.438, 99.429]	13.444 + [0.575, 314.287]	55.6 [7.5, 100.0]	0.086
Maintenance OCS use at baseline								0.914
Yes	9	4 (44.4) [13.7, 78.8]	14	5 (35.7) [12.8, 64.9]	1.244 [0.452, 3.429]	1.440 [0.260, 7.961]	8.7 [-41.4, 58.9]	1.000
No	57	42 (73.7) [60.3, 84.5]	51	32 (62.7) [48.1, 75.9]	1.174 [0.903, 1.527]	1.663 [0.733, 3.769]	10.9 [-8.4, 30.3]	0.300
No chronic OCS use and current post-BD FEV1 reversibility								0.383
Yes	51	38 (74.5) [60.4, 85.7]	49	32 (65.3) [50.4, 78.3]	1.141 [0.880, 1.479]	1.553 [0.656, 3.676]	9.2 [-10.7, 29.1]	0.385
No	15	8 (53.3) [26.6, 78.7]	16	5 (31.3) [11.0, 58.7]	1.707 [0.717, 4.063]	2.514 [0.581, 10.882]	22.1 [-18.3, 62.5]	0.285

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
A patient will be considered to be without exacerbations, if no exacerbations were observed in the considered timeframe and the patient has completed the planned treatment period.
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: atte, created on: 11AUG2022

Table PT2ET_ILMT0: Time to first asthma exacerbation
DITTL

Time to first asthma exacerbation			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Tezepelumab	66	13 (19.7)	NE		0.364	(0.185, 0.716)	0.003 *
Placebo	65	25 (38.5)	NE				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least on event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year.
Source Data: atte, created on: 11AUG2022

Figure PF2ET_ILMK0: Time to first asthma exacerbation - Kaplan-Meier plot
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
Reference table: PT2ET_ILMT0
Source Data: atte, created on: 11AUG2022

Table PT2ET_ILSTK: Time to first asthma exacerbation by key subgroups
DITTL

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Tezepelumab							0.910	
Male	Tezepelumab	19	3 (15.8)	NE		0.353	(0.085, 1.461)	0.151	
Male	Placebo	20	6 (30.0)	NE					
Female	Tezepelumab	47	10 (21.3)	NE		0.359	(0.166, 0.779)	0.010	*
Female	Placebo	45	19 (42.2)	NE					
Age	Tezepelumab							0.355	
< 65 years	Tezepelumab	57	10 (17.5)	NE		0.316	(0.149, 0.672)	0.003	*
< 65 years	Placebo	55	22 (40.0)	NE					
>= 65 years	Tezepelumab	9	3 (33.3)	NE		0.600	(0.093, 3.871)	0.592	
>= 65 years	Placebo	10	3 (30.0)	NE					
Exacerbations in the year before study	Tezepelumab							0.183	
<= 2	Tezepelumab	44	6 (13.6)	NE		0.631	(0.224, 1.772)	0.382	
<= 2	Placebo	45	9 (20.0)	NE					
> 2	Tezepelumab	22	7 (31.8)	NE		0.249	(0.101, 0.613)	0.002	*
> 2	Placebo	20	16 (80.0)	13.4	(3.7, 38.3)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_ILSTK: Time to first asthma exacerbation by key subgroups
DITTL

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Race	Tezepelumab	N<10	any level					NE	
White	Tezepelumab	60	12 (20.0)						
White	Placebo	58	20 (34.5)						
Black or African American	Tezepelumab	2	0 (0.0)						
Black or African American	Placebo	2	2 (100.0)						
Asian	Tezepelumab	3	1 (33.3)						
Asian	Placebo	3	1 (33.3)						
Other	Tezepelumab	1	0 (0.0)						
Other	Placebo	2	2 (100.0)						
Region	Tezepelumab	N<10	any level					NE	
Europe	Tezepelumab	40	10 (25.0)						
Europe	Placebo	36	10 (27.8)						
America	Tezepelumab	6	1 (16.7)						
America	Placebo	4	3 (75.0)						
Asia/Pacific	Tezepelumab	3	1 (33.3)						
Asia/Pacific	Placebo	3	1 (33.3)						
Rest of the world	Tezepelumab	17	1 (5.9)						
Rest of the world	Placebo	22	11 (50.0)						
BMI	Tezepelumab							0.547	
18.5 - < 25.0 kg/m**2	Tezepelumab	15	3 (20.0)	NE		0.184	(0.048, 0.696)	0.013	*
18.5 - < 25.0 kg/m**2	Placebo	21	11 (52.4)	43.7	(14.3, NE)				
25.0 - < 30.0 kg/m**2	Tezepelumab	24	4 (16.7)	NE		0.526	(0.152, 1.816)	0.310	
25.0 - < 30.0 kg/m**2	Placebo	20	7 (35.0)	NE					
>= 30.0 kg/m**2	Tezepelumab	27	6 (22.2)	NE		0.541	(0.178, 1.650)	0.280	
>= 30.0 kg/m**2	Placebo	24	7 (29.2)	NE					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_ILSTK: Time to first asthma exacerbation by key subgroups
DITTL

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eosinophils - Low	Tezepelumab							0.096	
< 150 cells/uL	Tezepelumab	11	2 (18.2)	NE		0.112	(0.019, 0.651)	0.015	*
< 150 cells/uL	Placebo	14	7 (50.0)	NE					
>= 150 cells/uL	Tezepelumab	54	11 (20.4)	NE		0.453	(0.213, 0.963)	0.040	*
>= 150 cells/uL	Placebo	51	18 (35.3)	NE					
Baseline eosinophils - High	Tezepelumab							0.998	
< 300 cells/uL	Tezepelumab	33	6 (18.2)	NE		0.380	(0.141, 1.021)	0.055	
< 300 cells/uL	Placebo	34	12 (35.3)	NE					
>= 300 cells/uL	Tezepelumab	32	7 (21.9)	NE		0.340	(0.133, 0.871)	0.025	*
>= 300 cells/uL	Placebo	31	13 (41.9)	NE					
Baseline FENO	Tezepelumab							0.040	i
< 25 ppb	Tezepelumab	39	9 (23.1)	NE		0.711	(0.259, 1.951)	0.507	
< 25 ppb	Placebo	30	7 (23.3)	NE					
>= 25 ppb	Tezepelumab	27	4 (14.8)	NE		0.174	(0.058, 0.519)	0.002	*
>= 25 ppb	Placebo	34	18 (52.9)	38.3	(13.0, NE)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_ILSTK: Time to first asthma exacerbation by key subgroups
DITTL

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline specific perennial FEIA status	Tezepelumab							0.619	
All negative	Tezepelumab	27	6 (22.2)	NE		0.453	(0.175, 1.174)	0.103	
All negative	Placebo	29	15 (51.7)	43.7	(13.9, NE)				
Any positive	Tezepelumab	34	6 (17.6)	NE		0.394	(0.128, 1.217)	0.105	
Any positive	Placebo	33	9 (27.3)	NE					
Total serum IgE	Tezepelumab							NE	
Low	Tezepelumab	23	5 (21.7)	NE		0.366	(0.119, 1.131)	0.081	
Low	Placebo	14	9 (64.3)	32.2	(7.9, NE)				
Normal	Tezepelumab	40	8 (20.0)	NE		0.276	(0.110, 0.690)	0.006	*
Normal	Placebo	44	15 (34.1)	NE					
High	Tezepelumab	3	0 (0.0)	NE		NE		NE	
High	Placebo	7	1 (14.3)	NE					
OCS at baseline	Tezepelumab							0.689	
Yes	Tezepelumab	9	3 (33.3)	NE		0.359	(0.089, 1.444)	0.149	
Yes	Placebo	13	7 (53.8)	13.9	(3.1, NE)				
No	Tezepelumab	57	10 (17.5)	NE		0.390	(0.179, 0.850)	0.018	*
No	Placebo	52	18 (34.6)	NE					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_ILSTK: Time to first asthma exacerbation by key subgroups
DITTL

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
LAMA use at baseline	Tezepelumab							0.886	
Yes	Tezepelumab	7	4 (57.1)	44.1	(0.4, NE)	0.385	(0.053, 2.823)	0.348	
Yes	Placebo	3	2 (66.7)	7.9	(2.6, NE)				
No	Tezepelumab	59	9 (15.3)	NE		0.307	(0.141, 0.667)	0.003	*
No	Placebo	62	23 (37.1)	NE					
Tiotropium use at baseline	Tezepelumab	N<10	any level					NE	
Yes	Tezepelumab	6	4 (66.7)						
Yes	Placebo	2	1 (50.0)						
No	Tezepelumab	60	9 (15.0)						
No	Placebo	63	24 (38.1)						
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab							0.705	
Yes	Tezepelumab	17	6 (35.3)	NE		0.490	(0.183, 1.311)	0.155	
Yes	Placebo	21	12 (57.1)	24.6	(3.7, NE)				
No	Tezepelumab	49	7 (14.3)	NE		0.314	(0.123, 0.801)	0.015	*
No	Placebo	44	13 (29.5)	NE					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_ILSTP: Time to first asthma exacerbation by study specific subgroups
DITTL

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Race (cat. P)	Tezepelumab							0.296	
White	Tezepelumab	60	12 (20.0)	NE		0.437	(0.212, 0.900)	0.025	*
White	Placebo	58	20 (34.5)	NE					
Non-white	Tezepelumab	6	1 (16.7)	NE		0.000	(0.000,)	0.998	
Non-white	Placebo	7	5 (71.4)	24.6	(3.7, NE)				
Region (cat. P)	Tezepelumab							0.442	
North America/Western EU	Tezepelumab	6	1 (16.7)	NE		0.107	(0.008, 1.377)	0.086	
North America/Western EU	Placebo	4	3 (75.0)	19.6	(7.1, NE)				
Rest of world	Tezepelumab	60	12 (20.0)	NE		0.400	(0.196, 0.813)	0.011	*
Rest of world	Placebo	61	22 (36.1)	NE					
Baseline eosinophils (cat. P)	Tezepelumab							0.176	
< 250 cells/uL	Tezepelumab	30	4 (13.3)	NE		0.220	(0.070, 0.688)	0.009	*
< 250 cells/uL	Placebo	29	12 (41.4)	NE					
>= 250 cells/uL	Tezepelumab	36	9 (25.0)	NE		0.521	(0.221, 1.230)	0.137	
>= 250 cells/uL	Placebo	36	13 (36.1)	NE					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_ILSTP: Time to first asthma exacerbation by study specific subgroups
DITTL

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline FENO (cat. P)	Tezepelumab							0.036	i
< 24 ppb	Tezepelumab	38	9 (23.7)	NE		0.722	(0.263, 1.988)	0.529	
< 24 ppb	Placebo	30	7 (23.3)	NE					
>= 24 ppb	Tezepelumab	28	4 (14.3)	NE		0.170	(0.057, 0.507)	0.001	*
>= 24 ppb	Placebo	34	18 (52.9)	38.3	(13.0, NE)				
Baseline FENO (cat. M)	Tezepelumab							0.034	i
< 22.0 ppb	Tezepelumab	32	8 (25.0)	NE		0.748	(0.267, 2.091)	0.580	
< 22.0 ppb	Placebo	27	7 (25.9)	NE					
>= 22.0 ppb	Tezepelumab	34	5 (14.7)	NE		0.184	(0.067, 0.502)	<0.001	*
>= 22.0 ppb	Placebo	37	18 (48.6)	NE					
Baseline all FEIA status	Tezepelumab							0.571	
All negative	Tezepelumab	25	6 (24.0)	NE		0.455	(0.170, 1.220)	0.118	
All negative	Placebo	22	12 (54.5)	41.1	(9.6, NE)				
Any positive	Tezepelumab	35	6 (17.1)	NE		0.309	(0.108, 0.885)	0.029	*
Any positive	Placebo	41	12 (29.3)	NE					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_ILSTP: Time to first asthma exacerbation by study specific subgroups
DITTL

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Th2 status	Tezepelumab							0.350	
Low	Tezepelumab	41	7 (17.1)	NE		0.271	(0.111, 0.663)	0.004	*
Low	Placebo	30	16 (53.3)	38.6	(13.1, NE)				
High	Tezepelumab	25	6 (24.0)	NE		0.460	(0.154, 1.372)	0.164	
High	Placebo	34	9 (26.5)	NE					
Baseline Periostin	Tezepelumab							0.949	
Low (< 20.9 ng/ml)	Tezepelumab	26	5 (19.2)	NE		0.373	(0.129, 1.083)	0.070	
Low (< 20.9 ng/ml)	Placebo	31	11 (35.5)	NE					
High (>= 20.9 ng/ml)	Tezepelumab	40	8 (20.0)	NE		0.357	(0.148, 0.860)	0.022	*
High (>= 20.9 ng/ml)	Placebo	34	14 (41.2)	NE					
Current post-BD FEV1 reversibility	Tezepelumab							0.201	
Yes	Tezepelumab	57	10 (17.5)	NE		0.395	(0.183, 0.852)	0.018	*
Yes	Placebo	60	20 (33.3)	NE					
No	Tezepelumab	9	3 (33.3)	NE		0.000	(0.000,)	0.997	
No	Placebo	5	5 (100.0)	3.7	(1.3, 9.6)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ET_ILSTP: Time to first asthma exacerbation by study specific subgroups
DITTL

Time to first asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Maintenance OCS use at baseline	Tezepelumab							0.560	
Yes	Tezepelumab	9	3 (33.3)	NE		0.328	(0.084, 1.282)	0.109	
Yes	Placebo	14	8 (57.1)	11.7	(3.1, NE)				
No	Tezepelumab	57	10 (17.5)	NE		0.411	(0.187, 0.903)	0.027	*
No	Placebo	51	17 (33.3)	NE					
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab							0.329	
Yes	Tezepelumab	51	9 (17.6)	NE		0.455	(0.197, 1.051)	0.065	
Yes	Placebo	49	15 (30.6)	NE					
No	Tezepelumab	15	4 (26.7)	NE		0.250	(0.076, 0.824)	0.023	*
No	Placebo	16	10 (62.5)	8.7	(3.1, NE)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Figure PF2ET_ILSKK20: Kaplan-Meier Plot of time to first asthma exacerbation by baseline FENO
DITTL

Baseline FENO: < 25 ppb



Note: DITTL = Dossier Label Intent-to-Treat Set.
Reference table: PT2ET_ILSTK
Source Data: atte, created on: 11AUG2022

Figure PF2ET_ILSKK20: Kaplan-Meier Plot of time to first asthma exacerbation by baseline FENO DITTL

Baseline FENO: >= 25 ppb



Note: DITTL = Dossier Label Intent-to-Treat Set.
Reference table: PT2ET_ILSTK
Source Data: atte, created on: 11AUG2022

Figure PF2ET_ILSKK23: Kaplan-Meier Plot of time to first asthma exacerbation by baseline FENO
DITTL

Baseline FENO (cat. P): < 24 ppb



Note: DITTL = Dossier Label Intent-to-Treat Set.
Reference table: PT2ET_ILSTK
Source Data: atte, created on: 11AUG2022

Figure PF2ET_ILSKK23: Kaplan-Meier Plot of time to first asthma exacerbation by baseline FENO DITTL

Baseline FENO (cat. P): >= 24 ppb



Note: DITTL = Dossier Label Intent-to-Treat Set.
Reference table: PT2ET_ILSTK
Source Data: atte, created on: 11AUG2022

Figure PF2ET_ILSKK24: Kaplan-Meier Plot of time to first asthma exacerbation by baseline FENO DITTL

Baseline FENO (cat. M): Low



Placebo	27	24	23	23	22	22	21	20	20	20	20	19	19	19
Tezepelumab	32	31	29	27	26	25	23	23	23	23	23	22	21	21

Note: DITTL = Dossier Label Intent-to-Treat Set.
Reference table: PT2ET_ILSTK
Source Data: atte, created on: 11AUG2022

Figure PF2ET_ILSKK24: Kaplan-Meier Plot of time to first asthma exacerbation by baseline FENO DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
Reference table: PT2ET_ILSTK
Source Data: atte, created on: 11AUG2022

Table PT2EST_ILMT0: Time to first severe asthma exacerbation
DITTL

Time to first severe asthma exacerbation			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Tezepelumab	66	3 (4.5)	NE		0.367	(0.097, 1.383)	0.139
Placebo	65	8 (12.3)	NE				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least on event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year.
Source Data: atte, created on: 11AUG2022

Figure PF2EST_ILMK0: Time to first severe asthma exacerbation - Kaplan-Meier plot
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
Reference table: PT2EST_ILMT0
Source Data: atte, created on: 11AUG2022

Table PT2EST_ILSTK: Time to first severe asthma exacerbation by key subgroups
DITTL

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Tezepelumab	n<10	all levels					NE
Male	Tezepelumab	19	1 (5.3)					
Male	Placebo	20	2 (10.0)					
Female	Tezepelumab	47	2 (4.3)					
Female	Placebo	45	6 (13.3)					
Age	Tezepelumab	n<10	all levels					NE
< 65 years	Tezepelumab	57	2 (3.5)					
< 65 years	Placebo	55	6 (10.9)					
>= 65 years	Tezepelumab	9	1 (11.1)					
>= 65 years	Placebo	10	2 (20.0)					
Exacerbations in the year before study	Tezepelumab	n<10	all levels					NE
<= 2	Tezepelumab	44	1 (2.3)					
<= 2	Placebo	45	4 (8.9)					
> 2	Tezepelumab	22	2 (9.1)					
> 2	Placebo	20	4 (20.0)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_ILSTK: Time to first severe asthma exacerbation by key subgroups
DITTL

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Race	Tezepelumab	N<10	any level					NE
White	Tezepelumab	60	3 (5.0)					
White	Placebo	58	5 (8.6)					
Black or African American	Tezepelumab	2	0 (0.0)					
Black or African American	Placebo	2	1 (50.0)					
Asian	Tezepelumab	3	0 (0.0)					
Asian	Placebo	3	0 (0.0)					
Other	Tezepelumab	1	0 (0.0)					
Other	Placebo	2	2 (100.0)					
Region	Tezepelumab	N<10	any level					NE
Europe	Tezepelumab	40	3 (7.5)					
Europe	Placebo	36	1 (2.8)					
America	Tezepelumab	6	0 (0.0)					
America	Placebo	4	1 (25.0)					
Asia/Pacific	Tezepelumab	3	0 (0.0)					
Asia/Pacific	Placebo	3	0 (0.0)					
Rest of the world	Tezepelumab	17	0 (0.0)					
Rest of the world	Placebo	22	6 (27.3)					
BMI	Tezepelumab	n<10	all levels					NE
18.5 - < 25.0 kg/m**2	Tezepelumab	15	1 (6.7)					
18.5 - < 25.0 kg/m**2	Placebo	21	2 (9.5)					
25.0 - < 30.0 kg/m**2	Tezepelumab	24	1 (4.2)					
25.0 - < 30.0 kg/m**2	Placebo	20	2 (10.0)					
>= 30.0 kg/m**2	Tezepelumab	27	1 (3.7)					
>= 30.0 kg/m**2	Placebo	24	4 (16.7)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_ILSTK: Time to first severe asthma exacerbation by key subgroups
DITTL

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eosinophils - Low	Tezepelumab	n<10	all levels					NE
< 150 cells/uL	Tezepelumab	11	1 (9.1)					
< 150 cells/uL	Placebo	14	2 (14.3)					
>= 150 cells/uL	Tezepelumab	54	2 (3.7)					
>= 150 cells/uL	Placebo	51	6 (11.8)					
Baseline eosinophils - High	Tezepelumab	n<10	all levels					NE
< 300 cells/uL	Tezepelumab	33	1 (3.0)					
< 300 cells/uL	Placebo	34	5 (14.7)					
>= 300 cells/uL	Tezepelumab	32	2 (6.3)					
>= 300 cells/uL	Placebo	31	3 (9.7)					
Baseline FENO	Tezepelumab	n<10	all levels					NE
< 25 ppb	Tezepelumab	39	2 (5.1)					
< 25 ppb	Placebo	30	3 (10.0)					
>= 25 ppb	Tezepelumab	27	1 (3.7)					
>= 25 ppb	Placebo	34	5 (14.7)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_ILSTK: Time to first severe asthma exacerbation by key subgroups
DITTL

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline specific perennial FEIA status	Tezepelumab	n<10	all levels					NE
All negative	Tezepelumab	27	3 (11.1)					
All negative	Placebo	29	4 (13.8)					
Any positive	Tezepelumab	34	0 (0.0)					
Any positive	Placebo	33	3 (9.1)					
Total serum IgE	Tezepelumab	n<10	all levels					NE
Low	Tezepelumab	23	1 (4.3)					
Low	Placebo	14	4 (28.6)					
Normal	Tezepelumab	40	2 (5.0)					
Normal	Placebo	44	4 (9.1)					
High	Tezepelumab	3	0 (0.0)					
High	Placebo	7	0 (0.0)					
OCS at baseline	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	9	0 (0.0)					
Yes	Placebo	13	2 (15.4)					
No	Tezepelumab	57	3 (5.3)					
No	Placebo	52	6 (11.5)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_ILSTK: Time to first severe asthma exacerbation by key subgroups
DITTL

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
LAMA use at baseline	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	7	3 (42.9)					
Yes	Placebo	3	0 (0.0)					
No	Tezepelumab	59	0 (0.0)					
No	Placebo	62	8 (12.9)					
Tiotropium use at baseline	Tezepelumab	N<10	any level					NE
Yes	Tezepelumab	6	3 (50.0)					
Yes	Placebo	2	0 (0.0)					
No	Tezepelumab	60	0 (0.0)					
No	Placebo	63	8 (12.7)					
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	17	1 (5.9)					
Yes	Placebo	21	2 (9.5)					
No	Tezepelumab	49	2 (4.1)					
No	Placebo	44	6 (13.6)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_ILSTP: Time to first severe asthma exacerbation by study specific subgroups
DITTL

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Race (cat. P)	Tezepelumab	n<10	all levels					NE
White	Tezepelumab	60	3 (5.0)					
White	Placebo	58	5 (8.6)					
Non-white	Tezepelumab	6	0 (0.0)					
Non-white	Placebo	7	3 (42.9)					
Region (cat. P)	Tezepelumab							NE
North America/Western EU	Tezepelumab	6	0 (0.0)	NE		NE		NE
North America/Western EU	Placebo	4	1 (25.0)	NE				
Rest of world	Tezepelumab	60	3 (5.0)	NE				
Rest of world	Placebo	61	7 (11.5)	NE				
Baseline eosinophils (cat. P)	Tezepelumab	n<10	all levels					NE
< 250 cells/uL	Tezepelumab	30	1 (3.3)					
< 250 cells/uL	Placebo	29	5 (17.2)					
>= 250 cells/uL	Tezepelumab	36	2 (5.6)					
>= 250 cells/uL	Placebo	36	3 (8.3)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_ILSTP: Time to first severe asthma exacerbation by study specific subgroups
DITTL

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline FENO (cat. P)	Tezepelumab	n<10	all levels					NE
< 24 ppb	Tezepelumab	38	2 (5.3)					
< 24 ppb	Placebo	30	3 (10.0)					
>= 24 ppb	Tezepelumab	28	1 (3.6)					
>= 24 ppb	Placebo	34	5 (14.7)					
Baseline FENO (cat. M)	Tezepelumab	n<10	all levels					NE
< 22.0 ppb	Tezepelumab	32	2 (6.3)					
< 22.0 ppb	Placebo	27	3 (11.1)					
>= 22.0 ppb	Tezepelumab	34	1 (2.9)					
>= 22.0 ppb	Placebo	37	5 (13.5)					
Baseline all FEIA status	Tezepelumab	n<10	all levels					NE
All negative	Tezepelumab	25	3 (12.0)					
All negative	Placebo	22	4 (18.2)					
Any positive	Tezepelumab	35	0 (0.0)					
Any positive	Placebo	41	3 (7.3)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_ILSTP: Time to first severe asthma exacerbation by study specific subgroups
DITTL

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Th2 status	Tezepelumab							NE
Low	Tezepelumab	41	2 (4.9)	NE				
Low	Placebo	30	8 (26.7)	NE				
High	Tezepelumab	25	1 (4.0)	NE		NE		NE
High	Placebo	34	0 (0.0)	NE				
Baseline Periostin	Tezepelumab	n<10	all levels					NE
Low (< 20.9 ng/ml)	Tezepelumab	26	1 (3.8)					
Low (< 20.9 ng/ml)	Placebo	31	3 (9.7)					
High (>= 20.9 ng/ml)	Tezepelumab	40	2 (5.0)					
High (>= 20.9 ng/ml)	Placebo	34	5 (14.7)					
Current post-BD FEV1 reversibility	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	57	3 (5.3)					
Yes	Placebo	60	5 (8.3)					
No	Tezepelumab	9	0 (0.0)					
No	Placebo	5	3 (60.0)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2EST_ILSTP: Time to first severe asthma exacerbation by study specific subgroups
DITTL

Time to first severe asthma exacerbation				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Maintenance OCS use at baseline	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	9	0 (0.0)					
Yes	Placebo	14	3 (21.4)					
No	Tezepelumab	57	3 (5.3)					
No	Placebo	51	5 (9.8)					
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab	n<10	all levels					NE
Yes	Tezepelumab	51	3 (5.9)					
Yes	Placebo	49	4 (8.2)					
No	Tezepelumab	15	0 (0.0)					
No	Placebo	16	4 (25.0)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_ILMT0: Time to first non-severe asthma exacerbation
DITTL

Time to first non-severe asthma exacerbation			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Tezepelumab	66	10 (15.2)	NE		0.299	(0.141, 0.632)	0.002 *
Placebo	65	23 (35.4)	NE				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least on event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year.
Source Data: atte, created on: 11AUG2022

Figure PF2ENT_ILMK0: Time to first non-severe asthma exacerbation - Kaplan-Meier plot
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
Reference table: PT2ENT_ILMT0
Source Data: atte, created on: 11AUG2022

Table PT2ENT_ILSTK: Time to first non-severe asthma exacerbation by key subgroups
DITTL

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Tezepelumab							0.879	
Male	Tezepelumab	19	2 (10.5)	NE		0.336	(0.059, 1.920)	0.220	
Male	Placebo	20	4 (20.0)	NE					
Female	Tezepelumab	47	8 (17.0)	NE		0.288	(0.125, 0.663)	0.003	*
Female	Placebo	45	19 (42.2)	NE					
Age	Tezepelumab							0.613	
< 65 years	Tezepelumab	57	8 (14.0)	NE		0.274	(0.120, 0.627)	0.002	*
< 65 years	Placebo	55	20 (36.4)	NE					
>= 65 years	Tezepelumab	9	2 (22.2)	NE		0.263	(0.025, 2.768)	0.266	
>= 65 years	Placebo	10	3 (30.0)	NE					
Exacerbations in the year before study	Tezepelumab							0.075	
<= 2	Tezepelumab	44	5 (11.4)	NE		0.687	(0.218, 2.165)	0.521	
<= 2	Placebo	45	7 (15.6)	NE					
> 2	Tezepelumab	22	5 (22.7)	NE		0.168	(0.061, 0.466)	<0.001	*
> 2	Placebo	20	16 (80.0)	24.6	(4.3, 38.6)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_ILSTK: Time to first non-severe asthma exacerbation by key subgroups
DITTL

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Race	Tezepelumab	N<10	any level					NE	
White	Tezepelumab	60	9 (15.0)						
White	Placebo	58	18 (31.0)						
Black or African American	Tezepelumab	2	0 (0.0)						
Black or African American	Placebo	2	2 (100.0)						
Asian	Tezepelumab	3	1 (33.3)						
Asian	Placebo	3	1 (33.3)						
Other	Tezepelumab	1	0 (0.0)						
Other	Placebo	2	2 (100.0)						
Region	Tezepelumab	N<10	any level					NE	
Europe	Tezepelumab	40	7 (17.5)						
Europe	Placebo	36	10 (27.8)						
America	Tezepelumab	6	1 (16.7)						
America	Placebo	4	3 (75.0)						
Asia/Pacific	Tezepelumab	3	1 (33.3)						
Asia/Pacific	Placebo	3	1 (33.3)						
Rest of the world	Tezepelumab	17	1 (5.9)						
Rest of the world	Placebo	22	9 (40.9)						
BMI	Tezepelumab							0.427	
18.5 - < 25.0 kg/m**2	Tezepelumab	15	2 (13.3)	NE		0.112	(0.023, 0.558)	0.008	*
18.5 - < 25.0 kg/m**2	Placebo	21	10 (47.6)	NE					
25.0 - < 30.0 kg/m**2	Tezepelumab	24	3 (12.5)	NE		0.432	(0.107, 1.740)	0.238	
25.0 - < 30.0 kg/m**2	Placebo	20	6 (30.0)	NE					
>= 30.0 kg/m**2	Tezepelumab	27	5 (18.5)	NE		0.443	(0.138, 1.420)	0.171	
>= 30.0 kg/m**2	Placebo	24	7 (29.2)	NE					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_ILSTK: Time to first non-severe asthma exacerbation by key subgroups
DITTL

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eosinophils - Low	Tezepelumab							0.095	
< 150 cells/uL	Tezepelumab	11	1 (9.1)	NE		0.083	(0.010, 0.697)	0.022	*
< 150 cells/uL	Placebo	14	7 (50.0)	NE					
>= 150 cells/uL	Tezepelumab	54	9 (16.7)	NE		0.400	(0.176, 0.912)	0.029	*
>= 150 cells/uL	Placebo	51	16 (31.4)	NE					
Baseline eosinophils - High	Tezepelumab							0.765	
< 300 cells/uL	Tezepelumab	33	5 (15.2)	NE		0.352	(0.122, 1.020)	0.054	
< 300 cells/uL	Placebo	34	11 (32.4)	NE					
>= 300 cells/uL	Tezepelumab	32	5 (15.6)	NE		0.262	(0.090, 0.758)	0.014	*
>= 300 cells/uL	Placebo	31	12 (38.7)	NE					
Baseline FENO	Tezepelumab							0.134	
< 25 ppb	Tezepelumab	39	7 (17.9)	NE		0.486	(0.165, 1.429)	0.190	
< 25 ppb	Placebo	30	7 (23.3)	NE					
>= 25 ppb	Tezepelumab	27	3 (11.1)	NE		0.157	(0.045, 0.544)	0.003	*
>= 25 ppb	Placebo	34	16 (47.1)	NE					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_ILSTK: Time to first non-severe asthma exacerbation by key subgroups
DITTL

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline specific perennial FEIA status	Tezepelumab							0.925	
All negative	Tezepelumab	27	3 (11.1)	NE		0.268	(0.076, 0.953)	0.042	*
All negative	Placebo	29	12 (41.4)	NE					
Any positive	Tezepelumab	34	6 (17.6)	NE		0.344	(0.115, 1.028)	0.056	
Any positive	Placebo	33	10 (30.3)	NE					
Total serum IgE	Tezepelumab							NE	
Low	Tezepelumab	23	4 (17.4)	NE		0.389	(0.111, 1.363)	0.140	
Low	Placebo	14	7 (50.0)	NE					
Normal	Tezepelumab	40	6 (15.0)	NE		0.218	(0.079, 0.602)	0.003	*
Normal	Placebo	44	14 (31.8)	NE					
High	Tezepelumab	3	0 (0.0)	NE		NE		NE	
High	Placebo	7	2 (28.6)	NE					
OCS at baseline	Tezepelumab							0.802	
Yes	Tezepelumab	9	3 (33.3)	NE		0.436	(0.111, 1.716)	0.235	
Yes	Placebo	13	7 (53.8)	55.7	(3.1, NE)				
No	Tezepelumab	57	7 (12.3)	NE		0.286	(0.116, 0.701)	0.006	*
No	Placebo	52	16 (30.8)	NE					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_ILSTK: Time to first non-severe asthma exacerbation by key subgroups
DITTL

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
LAMA use at baseline	Tezepelumab							0.126	
Yes	Tezepelumab	7	1 (14.3)	NE		0.000	(0.000,)	0.998	
Yes	Placebo	3	2 (66.7)	7.9	(2.6, NE)				
No	Tezepelumab	59	9 (15.3)	NE		0.353	(0.161, 0.774)	0.009	*
No	Placebo	62	21 (33.9)	NE					
Tiotropium use at baseline	Tezepelumab	N<10	any level					NE	
Yes	Tezepelumab	6	1 (16.7)						
Yes	Placebo	2	1 (50.0)						
No	Tezepelumab	60	9 (15.0)						
No	Placebo	63	22 (34.9)						
Montelukast/ Cromoglicic acid use at baseline	Tezepelumab							0.632	
Yes	Tezepelumab	17	5 (29.4)	NE		0.428	(0.148, 1.238)	0.117	
Yes	Placebo	21	11 (52.4)	38.6	(4.0, NE)				
No	Tezepelumab	49	5 (10.2)	NE		0.242	(0.084, 0.698)	0.009	*
No	Placebo	44	12 (27.3)	NE					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year (not used for subgroup number of exacerbations) for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_ILSTP: Time to first non-severe asthma exacerbation by study specific subgroups
DITTL

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Race (cat. P)	Tezepelumab							0.457	
White	Tezepelumab	60	9 (15.0)	NE		0.354	(0.158, 0.795)	0.012	*
White	Placebo	58	18 (31.0)	NE					
Non-white	Tezepelumab	6	1 (16.7)	NE		0.000	(0.000,)	0.998	
Non-white	Placebo	7	5 (71.4)	26.1	(4.3, NE)				
Region (cat. P)	Tezepelumab							0.498	
North America/Western EU	Tezepelumab	6	1 (16.7)	NE		0.107	(0.008, 1.377)	0.086	
North America/Western EU	Placebo	4	3 (75.0)	19.6	(7.1, NE)				
Rest of world	Tezepelumab	60	9 (15.0)	NE		0.325	(0.147, 0.719)	0.006	*
Rest of world	Placebo	61	20 (32.8)	NE					
Baseline eosinophils (cat. P)	Tezepelumab							0.295	
< 250 cells/uL	Tezepelumab	30	3 (10.0)	NE		0.193	(0.052, 0.711)	0.013	*
< 250 cells/uL	Placebo	29	10 (34.5)	NE					
>= 250 cells/uL	Tezepelumab	36	7 (19.4)	NE		0.416	(0.164, 1.052)	0.064	
>= 250 cells/uL	Placebo	36	13 (36.1)	NE					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_ILSTP: Time to first non-severe asthma exacerbation by study specific subgroups
DITTL

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline FENO (cat. P)	Tezepelumab							0.125	
< 24 ppb	Tezepelumab	38	7 (18.4)	NE		0.493	(0.167, 1.454)	0.200	
< 24 ppb	Placebo	30	7 (23.3)	NE					
>= 24 ppb	Tezepelumab	28	3 (10.7)	NE		0.154	(0.045, 0.534)	0.003	*
>= 24 ppb	Placebo	34	16 (47.1)	NE					
Baseline FENO (cat. M)	Tezepelumab							0.159	
< 22.0 ppb	Tezepelumab	32	6 (18.8)	NE		0.480	(0.158, 1.460)	0.196	
< 22.0 ppb	Placebo	27	7 (25.9)	NE					
>= 22.0 ppb	Tezepelumab	34	4 (11.8)	NE		0.177	(0.059, 0.536)	0.002	*
>= 22.0 ppb	Placebo	37	16 (43.2)	NE					
Baseline all FEIA status	Tezepelumab							0.937	
All negative	Tezepelumab	25	3 (12.0)	NE		0.298	(0.081, 1.105)	0.070	
All negative	Placebo	22	9 (40.9)	NE					
Any positive	Tezepelumab	35	6 (17.1)	NE		0.281	(0.100, 0.788)	0.016	*
Any positive	Placebo	41	13 (31.7)	NE					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_ILSTP: Time to first non-severe asthma exacerbation by study specific subgroups
DITTL

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Th2 status	Tezepelumab							0.683	
Low	Tezepelumab	41	5 (12.2)	NE		0.249	(0.088, 0.703)	0.009	*
Low	Placebo	30	13 (43.3)	NE					
High	Tezepelumab	25	5 (20.0)	NE		0.319	(0.102, 0.998)	0.050	*
High	Placebo	34	10 (29.4)	NE					
Baseline Periostin	Tezepelumab							0.809	
Low (< 20.9 ng/ml)	Tezepelumab	26	4 (15.4)	NE		0.338	(0.105, 1.084)	0.068	
Low (< 20.9 ng/ml)	Placebo	31	10 (32.3)	NE					
High (>= 20.9 ng/ml)	Tezepelumab	40	6 (15.0)	NE		0.292	(0.109, 0.777)	0.014	*
High (>= 20.9 ng/ml)	Placebo	34	13 (38.2)	NE					
Current post-BD FEV1 reversibility	Tezepelumab							0.377	
Yes	Tezepelumab	57	7 (12.3)	NE		0.257	(0.106, 0.621)	0.003	*
Yes	Placebo	60	19 (31.7)	NE					
No	Tezepelumab	9	3 (33.3)	NE		0.807	(0.145, 4.489)	0.807	
No	Placebo	5	4 (80.0)	4.3	(1.3, NE)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2ENT_ILSTP: Time to first non-severe asthma exacerbation by study specific subgroups
DITTL

Time to first non-severe asthma exacerbation				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Maintenance OCS use at baseline	Tezepelumab							0.792	
Yes	Tezepelumab	9	3 (33.3)	NE		0.413	(0.109, 1.575)	0.196	
Yes	Placebo	14	8 (57.1)	29.7	(3.1, NE)				
No	Tezepelumab	57	7 (12.3)	NE		0.292	(0.118, 0.724)	0.008	*
No	Placebo	51	15 (29.4)	NE					
No chronic OCS use and current post-BD FEV1 reversibility	Tezepelumab							0.989	
Yes	Tezepelumab	51	6 (11.8)	NE		0.311	(0.116, 0.832)	0.020	*
Yes	Placebo	49	13 (26.5)	NE					
No	Tezepelumab	15	4 (26.7)	NE		0.323	(0.100, 1.046)	0.059	
No	Placebo	16	10 (62.5)	21.8	(3.1, NE)				

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year for each subgroup. * = significant treatment effect.
Interaction of subgroup with treatment is investigated with similar model by adding subgroup and interaction to the model.
i = significant interaction.
Source Data: atte, created on: 11AUG2022

Table PT2E_IBMN0: AAER during planned treatment period
DITTB

AAER during planned treatment period					Adjusted rates		Rate ratio		
Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Tezepelumab	12	4	10.5	0.38	0.40	(0.12, 1.33)	0.411	(0.084, 2.002)	0.271
Placebo	9	8	8.6	0.93	0.98	(0.35, 2.75)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model.
A negative binomial model was applied with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
Source Data: aaer, created on: 16AUG2022

Table PT2ES_IBMN0: Severe AAER during planned treatment period
DITTB

Severe AAER during planned treatment period					Adjusted rates		Rate ratio		
Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Tezepelumab	12	0	10.7	0.00	0.00	(0.00, NE)	NE		0.979
Placebo	9	2	8.9	0.22	0.22	(0.06, 0.90)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model.
A negative binomial model was applied with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
Source Data: aaer, created on: 16AUG2022

Table PT2EN_IBMN0: Non-severe AAER during planned treatment period
DITTB

Non-severe AAER during planned treatment period					Adjusted rates		Rate ratio		
Treatment	N	nev	Time at risk (years)	Crude rate	Estimate	95% CI	Estimate	95% CI	p-value
Tezepelumab	12	4	10.5	0.38	0.39	(0.13, 1.13)	0.556	(0.136, 2.272)	0.414
Placebo	9	6	8.7	0.69	0.70	(0.28, 1.76)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of events. NE = not evaluable.
95% CI = 95% confidence interval coming from a negative binomial model.
A negative binomial model was applied with factors treatment. The logarithm of time at risk (excluding time of exacerbations) was used as offset. No additional factors were considered to achieve robust results across all analyses.
Source Data: aaer, created on: 16AUG2022

Table PT2ER_IBMI0: Patients without exacerbations during planned treatment period
DITTB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Patients without exacerbations during planned treatment period	12	8 (66.7) [34.9, 90.1]	9	5 (55.6) [21.2, 86.3]	1.200 [0.591, 2.436]	1.600 [0.270, 9.490]	11.1 [-40.6, 62.8]	0.673

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with events. A patient will be considered as without exacerbation, if no exacerbations was observed in considered timeframe and the patient has completed the planned treatment period.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: atte, created on: 11AUG2022

Table PT2ET_IBMT0: Time to first asthma exacerbation
DITTB

Time to first asthma exacerbation			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Tezepelumab	12	3 (25.0)	NE		0.680	(0.150, 3.076)	0.616
Placebo	9	4 (44.4)	NE				

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least on event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year.
Source Data: atte, created on: 11AUG2022

Figure PF2ET_IBMK0: Time to first asthma exacerbation - Kaplan-Meier plot
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
Reference table: PT2ET_IBMT0
Source Data: atte, created on: 11AUG2022

Table PT2EST_IBMT0: Time to first severe asthma exacerbation
DITTB

Time to first severe asthma exacerbation			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Tezepelumab	12	0 (0.0)	NE		NE		NE
Placebo	9	2 (22.2)	NE				

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least on event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year.
Source Data: atte, created on: 11AUG2022

Figure PF2EST_IBMK0: Time to first severe asthma exacerbation - Kaplan-Meier plot
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
Reference table: PT2EST_IBMT0
Source Data: atte, created on: 11AUG2022

Table PT2ENT_IBMT0: Time to first non-severe asthma exacerbation
DITTB

Time to first non-severe asthma exacerbation			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Tezepelumab	12	3 (25.0)	NE		0.680	(0.150, 3.076)	0.616
Placebo	9	4 (44.4)	NE				

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. nev = number of patients with at least on event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with a factor for treatment group and number of exacerbations in the previous year.
Source Data: atte, created on: 11AUG2022

Figure PF2ENT_IBMK0: Time to first non-severe asthma exacerbation - Kaplan-Meier plot
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
Reference table: PT2ENT_IBMT0
Source Data: atte, created on: 11AUG2022

Table PT2FAC_IOMH0: Course of FEV1 Pre-BD
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	137	137 (100.0)	1.83 (0.58)	0.7	1.38	1.75	2.20	3.9	
		Placebo	138	138 (100.0)	1.82 (0.59)	0.7	1.43	1.72	2.19	3.3	
	Week 4	Tezepelumab	137	131 (95.6)	2.04 (0.74)	0.9	1.50	1.96	2.45	4.9	
		Placebo	138	136 (98.6)	1.87 (0.61)	0.7	1.48	1.82	2.32	3.2	
	Week 8	Tezepelumab	137	124 (90.5)	2.03 (0.66)	0.7	1.52	1.98	2.42	5.1	
		Placebo	138	132 (95.7)	1.92 (0.62)	0.7	1.50	1.90	2.36	3.6	
	Week 12	Tezepelumab	137	128 (93.4)	2.08 (0.72)	0.9	1.51	1.98	2.55	5.1	
		Placebo	138	135 (97.8)	1.90 (0.65)	0.5	1.44	1.83	2.40	4.1	
	Week 20	Tezepelumab	137	119 (86.9)	2.03 (0.73)	1.0	1.47	1.91	2.49	5.5	
		Placebo	138	131 (94.9)	1.90 (0.64)	0.5	1.44	1.87	2.33	3.4	
	Week 28	Tezepelumab	137	124 (90.5)	2.03 (0.75)	0.8	1.42	1.96	2.47	5.4	
		Placebo	138	131 (94.9)	1.87 (0.66)	0.7	1.42	1.84	2.27	3.6	
	Week 40	Tezepelumab	137	122 (89.1)	2.04 (0.70)	0.7	1.44	2.00	2.52	4.7	
		Placebo	138	130 (94.2)	1.92 (0.68)	0.6	1.43	1.80	2.38	4.0	
	Week 52	Tezepelumab	137	119 (86.9)	2.01 (0.66)	0.9	1.45	1.94	2.38	4.7	
		Placebo	138	129 (93.5)	1.90 (0.70)	0.6	1.37	1.80	2.38	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOMH0: Course of FEV1 Pre-BD
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 4	Tezepelumab	137	131 (95.6)	0.22 (0.44)	-0.6	-0.02	0.12	0.38	2.4	0.43 [0.18, 0.67]
		Placebo	138	136 (98.6)	0.05 (0.36)	-1.1	-0.12	0.04	0.18	1.2	
	Week 8	Tezepelumab	137	124 (90.5)	0.22 (0.40)	-0.7	-0.03	0.16	0.40	2.2	0.32 [0.08, 0.57]
		Placebo	138	132 (95.7)	0.09 (0.38)	-1.5	-0.09	0.11	0.25	1.3	
	Week 12	Tezepelumab	137	128 (93.4)	0.25 (0.45)	-0.6	-0.05	0.16	0.43	2.1	0.37 [0.12, 0.61]
		Placebo	138	135 (97.8)	0.09 (0.40)	-1.2	-0.10	0.08	0.29	1.3	
	Week 20	Tezepelumab	137	119 (86.9)	0.22 (0.46)	-0.6	-0.07	0.14	0.43	2.2	0.33 [0.08, 0.58]
		Placebo	138	131 (94.9)	0.09 (0.37)	-1.0	-0.06	0.07	0.26	1.8	
	Week 28	Tezepelumab	137	124 (90.5)	0.22 (0.49)	-1.0	-0.10	0.11	0.50	2.2	0.42 [0.17, 0.67]
		Placebo	138	131 (94.9)	0.04 (0.36)	-1.1	-0.14	0.05	0.25	1.5	
	Week 40	Tezepelumab	137	122 (89.1)	0.24 (0.46)	-0.7	-0.05	0.21	0.47	2.3	0.33 [0.08, 0.58]
		Placebo	138	130 (94.2)	0.10 (0.37)	-1.3	-0.10	0.07	0.30	1.1	
	Week 52	Tezepelumab	137	119 (86.9)	0.21 (0.44)	-0.8	-0.04	0.14	0.43	2.3	0.31 [0.06, 0.56]
		Placebo	138	129 (93.5)	0.08 (0.40)	-1.0	-0.15	0.05	0.24	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITT

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	137	131 (95.6)	0.22 (0.03)	(0.15, 0.29)	0.17 (0.05)	(0.08, 0.27)	<0.001 *
	Placebo	138	136 (98.6)	0.05 (0.03)	(-0.02, 0.12)			
Week 8	Tezepelumab	137	124 (90.5)	0.22 (0.03)	(0.16, 0.29)	0.13 (0.05)	(0.04, 0.23)	0.006 *
	Placebo	138	132 (95.7)	0.09 (0.03)	(0.03, 0.16)			
Week 12	Tezepelumab	137	128 (93.4)	0.24 (0.04)	(0.16, 0.31)	0.15 (0.05)	(0.05, 0.25)	0.004 *
	Placebo	138	135 (97.8)	0.09 (0.04)	(0.02, 0.16)			
Week 20	Tezepelumab	137	119 (86.9)	0.22 (0.04)	(0.15, 0.30)	0.14 (0.05)	(0.04, 0.24)	0.006 *
	Placebo	138	131 (94.9)	0.08 (0.04)	(0.01, 0.15)			
Week 28	Tezepelumab	137	124 (90.5)	0.21 (0.04)	(0.14, 0.29)	0.18 (0.05)	(0.07, 0.28)	0.001 *
	Placebo	138	131 (94.9)	0.04 (0.04)	(-0.03, 0.11)			
Week 40	Tezepelumab	137	122 (89.1)	0.24 (0.04)	(0.16, 0.31)	0.14 (0.05)	(0.04, 0.24)	0.007 *
	Placebo	138	130 (94.2)	0.09 (0.04)	(0.02, 0.17)			
Week 52	Tezepelumab	137	119 (86.9)	0.21 (0.04)	(0.13, 0.28)	0.14 (0.05)	(0.04, 0.25)	0.007 *
	Placebo	138	129 (93.5)	0.06 (0.04)	(-0.01, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Figure PF2FAC_IOMG0: Course of FEV1 Pre-BD
DITT



Note: DITT = Dossier Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source table: PT2FAC_IOMH0
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	50	50 (100.0)	2.16 (0.57)	1.2	1.78	2.15	2.50	3.9	
			Placebo	44	44 (100.0)	2.21 (0.55)	1.3	1.73	2.17	2.66	3.3	
		Week 4	Tezepelumab	50	49 (98.0)	2.45 (0.79)	1.3	1.82	2.36	2.80	4.9	
			Placebo	44	43 (97.7)	2.20 (0.55)	0.7	1.82	2.26	2.65	3.2	
		Week 8	Tezepelumab	50	44 (88.0)	2.39 (0.71)	1.1	1.97	2.32	2.71	5.1	
			Placebo	44	42 (95.5)	2.23 (0.58)	0.8	1.88	2.26	2.64	3.4	
		Week 12	Tezepelumab	50	48 (96.0)	2.49 (0.74)	1.0	2.02	2.50	2.82	5.1	
			Placebo	44	42 (95.5)	2.28 (0.67)	0.5	1.89	2.23	2.71	4.1	
		Week 20	Tezepelumab	50	44 (88.0)	2.49 (0.80)	1.2	1.92	2.46	2.86	5.5	
			Placebo	44	41 (93.2)	2.22 (0.59)	0.7	1.90	2.18	2.73	3.4	
		Week 28	Tezepelumab	50	46 (92.0)	2.42 (0.82)	1.2	1.90	2.31	2.86	5.4	
			Placebo	44	42 (95.5)	2.25 (0.68)	0.8	1.87	2.10	2.69	3.6	
		Week 40	Tezepelumab	50	46 (92.0)	2.39 (0.70)	1.1	1.96	2.37	2.79	4.7	
			Placebo	44	42 (95.5)	2.28 (0.73)	0.6	1.69	2.35	2.82	4.0	
		Week 52	Tezepelumab	50	44 (88.0)	2.30 (0.71)	1.1	1.83	2.31	2.72	4.7	
			Placebo	44	41 (93.2)	2.30 (0.73)	1.0	1.85	2.27	2.76	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	50	49 (98.0)	0.30 (0.49)	-0.6	0.03	0.18	0.45	2.1	0.62 [0.20, 1.04]
			Placebo	44	43 (97.7)	0.00 (0.47)	-1.1	-0.19	-0.04	0.25	1.1	
		Week 8	Tezepelumab	50	44 (88.0)	0.24 (0.47)	-0.7	-0.07	0.18	0.45	2.2	0.47 [0.05, 0.90]
			Placebo	44	42 (95.5)	0.00 (0.53)	-1.5	-0.24	0.01	0.29	1.3	
		Week 12	Tezepelumab	50	48 (96.0)	0.33 (0.53)	-0.6	-0.02	0.26	0.65	1.9	0.46 [0.04, 0.88]
			Placebo	44	42 (95.5)	0.08 (0.53)	-1.2	-0.16	0.09	0.33	1.2	
		Week 20	Tezepelumab	50	44 (88.0)	0.29 (0.55)	-0.6	-0.11	0.24	0.63	1.9	0.51 [0.08, 0.95]
			Placebo	44	41 (93.2)	0.04 (0.43)	-1.0	-0.11	0.08	0.23	1.5	
		Week 28	Tezepelumab	50	46 (92.0)	0.27 (0.54)	-0.7	-0.12	0.07	0.57	1.9	0.44 [0.01, 0.86]
			Placebo	44	42 (95.5)	0.04 (0.50)	-1.1	-0.21	0.08	0.29	1.5	
		Week 40	Tezepelumab	50	46 (92.0)	0.26 (0.48)	-0.5	-0.11	0.27	0.49	1.9	0.37 [-0.05, 0.79]
			Placebo	44	42 (95.5)	0.07 (0.53)	-1.3	-0.20	0.08	0.31	1.1	
		Week 52	Tezepelumab	50	44 (88.0)	0.16 (0.48)	-0.8	-0.15	0.14	0.39	2.0	0.10 [-0.33, 0.52]
			Placebo	44	41 (93.2)	0.11 (0.53)	-0.9	-0.16	0.07	0.35	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	87	87 (100.0)	1.64 (0.50)	0.7	1.32	1.54	1.99	3.1	
			Placebo	94	94 (100.0)	1.64 (0.52)	0.7	1.33	1.54	1.93	3.2	
		Week 4	Tezepelumab	87	82 (94.3)	1.80 (0.59)	0.9	1.33	1.70	2.17	3.6	
			Placebo	94	93 (98.9)	1.71 (0.57)	0.7	1.34	1.66	2.09	3.2	
		Week 8	Tezepelumab	87	80 (92.0)	1.84 (0.54)	0.7	1.41	1.73	2.24	3.4	
			Placebo	94	90 (95.7)	1.77 (0.59)	0.7	1.43	1.69	2.20	3.6	
		Week 12	Tezepelumab	87	80 (92.0)	1.83 (0.58)	0.9	1.39	1.71	2.25	3.5	
			Placebo	94	93 (98.9)	1.73 (0.58)	0.6	1.37	1.64	2.21	2.9	
		Week 20	Tezepelumab	87	75 (86.2)	1.76 (0.53)	1.0	1.39	1.66	2.05	3.4	
			Placebo	94	90 (95.7)	1.75 (0.60)	0.5	1.29	1.72	2.18	3.3	
		Week 28	Tezepelumab	87	78 (89.7)	1.80 (0.59)	0.8	1.35	1.62	2.23	3.4	
			Placebo	94	89 (94.7)	1.69 (0.56)	0.7	1.25	1.66	2.05	3.3	
		Week 40	Tezepelumab	87	76 (87.4)	1.83 (0.62)	0.7	1.34	1.71	2.24	3.5	
			Placebo	94	88 (93.6)	1.75 (0.58)	0.7	1.37	1.67	2.17	3.4	
		Week 52	Tezepelumab	87	75 (86.2)	1.84 (0.58)	0.9	1.36	1.76	2.19	3.4	
			Placebo	94	88 (93.6)	1.71 (0.59)	0.6	1.25	1.68	2.10	3.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	87	82 (94.3)	0.17 (0.40)	-0.6	-0.03	0.09	0.32	2.4	0.29 [-0.01, 0.59]
			Placebo	94	93 (98.9)	0.07 (0.30)	-0.7	-0.08	0.05	0.17	1.2	
		Week 8	Tezepelumab	87	80 (92.0)	0.21 (0.36)	-0.5	-0.02	0.15	0.37	2.2	0.23 [-0.07, 0.53]
			Placebo	94	90 (95.7)	0.13 (0.29)	-0.6	-0.04	0.13	0.24	1.1	
		Week 12	Tezepelumab	87	80 (92.0)	0.20 (0.39)	-0.6	-0.07	0.11	0.38	2.1	0.29 [-0.01, 0.59]
			Placebo	94	93 (98.9)	0.10 (0.33)	-0.7	-0.06	0.08	0.26	1.3	
		Week 20	Tezepelumab	87	75 (86.2)	0.19 (0.40)	-0.6	-0.06	0.09	0.38	2.2	0.20 [-0.11, 0.50]
			Placebo	94	90 (95.7)	0.11 (0.33)	-0.7	-0.04	0.06	0.26	1.8	
		Week 28	Tezepelumab	87	78 (89.7)	0.20 (0.46)	-1.0	-0.06	0.12	0.47	2.2	0.40 [0.10, 0.71]
			Placebo	94	89 (94.7)	0.05 (0.28)	-1.1	-0.10	0.03	0.23	0.8	
		Week 40	Tezepelumab	87	76 (87.4)	0.23 (0.45)	-0.7	-0.03	0.15	0.45	2.3	0.31 [0.00, 0.62]
			Placebo	94	88 (93.6)	0.11 (0.27)	-0.5	-0.07	0.07	0.28	0.9	
		Week 52	Tezepelumab	87	75 (86.2)	0.23 (0.40)	-0.5	-0.01	0.14	0.44	2.3	0.47 [0.16, 0.79]
			Placebo	94	88 (93.6)	0.06 (0.33)	-1.0	-0.12	0.05	0.19	1.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	114	114 (100.0)	1.89 (0.58)	0.7	1.44	1.85	2.24	3.9	
			Placebo	118	118 (100.0)	1.90 (0.57)	0.7	1.46	1.80	2.24	3.3	
		Week 4	Tezepelumab	114	110 (96.5)	2.12 (0.74)	0.9	1.58	2.04	2.64	4.9	
			Placebo	118	116 (98.3)	1.95 (0.59)	0.7	1.55	1.91	2.38	3.2	
		Week 8	Tezepelumab	114	104 (91.2)	2.10 (0.66)	0.7	1.57	2.07	2.51	5.1	
			Placebo	118	112 (94.9)	2.01 (0.60)	0.7	1.57	2.00	2.41	3.6	
		Week 12	Tezepelumab	114	109 (95.6)	2.15 (0.72)	0.9	1.59	2.05	2.58	5.1	
			Placebo	118	115 (97.5)	2.00 (0.64)	0.5	1.52	1.90	2.48	4.1	
		Week 20	Tezepelumab	114	99 (86.8)	2.10 (0.74)	1.0	1.51	1.93	2.63	5.5	
			Placebo	118	111 (94.1)	1.99 (0.60)	0.6	1.57	1.94	2.39	3.4	
		Week 28	Tezepelumab	114	104 (91.2)	2.11 (0.75)	0.9	1.50	2.03	2.57	5.4	
			Placebo	118	111 (94.1)	1.96 (0.64)	0.8	1.58	1.93	2.37	3.6	
		Week 40	Tezepelumab	114	102 (89.5)	2.12 (0.69)	1.0	1.56	2.12	2.65	4.7	
			Placebo	118	110 (93.2)	2.02 (0.65)	0.6	1.56	1.90	2.46	4.0	
		Week 52	Tezepelumab	114	100 (87.7)	2.08 (0.67)	0.9	1.58	1.99	2.44	4.7	
			Placebo	118	110 (93.2)	2.00 (0.67)	0.7	1.46	1.94	2.45	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	114	110 (96.5)	0.24 (0.46)	-0.6	-0.02	0.13	0.39	2.4	0.46 [0.19, 0.72]
			Placebo	118	116 (98.3)	0.05 (0.37)	-1.1	-0.10	0.05	0.20	1.2	
		Week 8	Tezepelumab	114	104 (91.2)	0.23 (0.42)	-0.7	-0.03	0.18	0.41	2.2	0.32 [0.05, 0.59]
			Placebo	118	112 (94.9)	0.10 (0.40)	-1.5	-0.08	0.13	0.28	1.3	
		Week 12	Tezepelumab	114	109 (95.6)	0.27 (0.47)	-0.6	-0.04	0.18	0.45	2.1	0.36 [0.10, 0.62]
			Placebo	118	115 (97.5)	0.11 (0.41)	-1.2	-0.09	0.12	0.31	1.3	
		Week 20	Tezepelumab	114	99 (86.8)	0.24 (0.48)	-0.6	-0.07	0.14	0.43	2.2	0.32 [0.04, 0.59]
			Placebo	118	111 (94.1)	0.11 (0.38)	-1.0	-0.04	0.10	0.26	1.8	
		Week 28	Tezepelumab	114	104 (91.2)	0.24 (0.50)	-1.0	-0.10	0.14	0.50	2.2	0.42 [0.15, 0.69]
			Placebo	118	111 (94.1)	0.06 (0.39)	-1.1	-0.14	0.10	0.28	1.5	
		Week 40	Tezepelumab	114	102 (89.5)	0.27 (0.47)	-0.7	-0.02	0.24	0.49	2.3	0.36 [0.09, 0.63]
			Placebo	118	110 (93.2)	0.12 (0.39)	-1.3	-0.11	0.10	0.31	1.1	
		Week 52	Tezepelumab	114	100 (87.7)	0.23 (0.45)	-0.8	-0.03	0.17	0.47	2.3	0.30 [0.03, 0.57]
			Placebo	118	110 (93.2)	0.10 (0.42)	-1.0	-0.11	0.08	0.26	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	1.50 (0.47)	0.7	1.20	1.34	1.93	2.4	
			Placebo	20	20 (100.0)	1.36 (0.49)	0.8	0.97	1.38	1.54	2.7	
		Week 4	Tezepelumab	23	21 (91.3)	1.62 (0.61)	0.9	1.27	1.42	1.80	3.4	
			Placebo	20	20 (100.0)	1.40 (0.53)	0.7	0.97	1.32	1.69	2.5	
		Week 8	Tezepelumab	23	20 (87.0)	1.69 (0.55)	1.0	1.32	1.60	1.98	3.2	
			Placebo	20	20 (100.0)	1.40 (0.50)	0.7	0.92	1.39	1.77	2.3	
		Week 12	Tezepelumab	23	19 (82.6)	1.67 (0.58)	0.9	1.15	1.52	1.96	3.2	
			Placebo	20	20 (100.0)	1.35 (0.46)	0.7	0.97	1.22	1.69	2.2	
		Week 20	Tezepelumab	23	20 (87.0)	1.67 (0.56)	1.0	1.34	1.53	1.96	3.3	
			Placebo	20	20 (100.0)	1.37 (0.55)	0.5	0.94	1.24	1.76	2.6	
		Week 28	Tezepelumab	23	20 (87.0)	1.65 (0.57)	0.8	1.31	1.49	1.98	3.1	
			Placebo	20	20 (100.0)	1.34 (0.51)	0.7	0.95	1.27	1.49	2.6	
		Week 40	Tezepelumab	23	20 (87.0)	1.60 (0.61)	0.7	1.16	1.44	2.00	3.3	
			Placebo	20	20 (100.0)	1.38 (0.55)	0.7	0.96	1.23	1.62	2.6	
		Week 52	Tezepelumab	23	19 (82.6)	1.65 (0.46)	1.0	1.33	1.58	2.02	2.4	
			Placebo	20	19 (95.0)	1.33 (0.56)	0.6	0.96	1.19	1.72	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	23	21 (91.3)	0.12 (0.32)	-0.6	0.00	0.09	0.19	1.0	0.26 [-0.36, 0.87]
			Placebo	20	20 (100.0)	0.04 (0.33)	-0.3	-0.16	-0.09	0.16	1.1	
		Week 8	Tezepelumab	23	20 (87.0)	0.15 (0.30)	-0.5	-0.01	0.10	0.28	0.8	0.42 [-0.21, 1.04]
			Placebo	20	20 (100.0)	0.03 (0.26)	-0.4	-0.09	0.01	0.15	0.9	
		Week 12	Tezepelumab	23	19 (82.6)	0.13 (0.33)	-0.4	-0.13	0.03	0.35	0.8	0.45 [-0.19, 1.09]
			Placebo	20	20 (100.0)	-0.02 (0.30)	-0.8	-0.12	-0.03	0.06	0.9	
		Week 20	Tezepelumab	23	20 (87.0)	0.14 (0.31)	-0.4	-0.07	0.05	0.30	0.9	0.47 [-0.16, 1.10]
			Placebo	20	20 (100.0)	0.01 (0.26)	-0.4	-0.13	-0.02	0.03	0.8	
		Week 28	Tezepelumab	23	20 (87.0)	0.11 (0.38)	-0.6	-0.11	0.02	0.41	0.8	0.46 [-0.17, 1.08]
			Placebo	20	20 (100.0)	-0.02 (0.17)	-0.3	-0.15	-0.02	0.02	0.4	
		Week 40	Tezepelumab	23	20 (87.0)	0.07 (0.39)	-0.6	-0.12	0.02	0.21	0.9	0.18 [-0.45, 0.80]
			Placebo	20	20 (100.0)	0.02 (0.19)	-0.3	-0.09	-0.02	0.13	0.4	
		Week 52	Tezepelumab	23	19 (82.6)	0.07 (0.29)	-0.5	-0.05	0.03	0.16	0.7	0.52 [-0.13, 1.17]
			Placebo	20	19 (95.0)	-0.06 (0.20)	-0.3	-0.22	-0.12	0.04	0.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	105	105 (100.0)	1.84 (0.58)	0.7	1.38	1.78	2.20	3.9	
			Placebo	110	110 (100.0)	1.81 (0.59)	0.7	1.43	1.71	2.19	3.3	
		Week 4	Tezepelumab	105	101 (96.2)	2.05 (0.76)	0.9	1.52	1.95	2.45	4.9	
			Placebo	110	108 (98.2)	1.88 (0.60)	0.7	1.51	1.88	2.32	3.2	
		Week 8	Tezepelumab	105	95 (90.5)	2.03 (0.67)	0.7	1.55	1.97	2.36	5.1	
			Placebo	110	108 (98.2)	1.92 (0.63)	0.7	1.50	1.92	2.36	3.6	
		Week 12	Tezepelumab	105	98 (93.3)	2.09 (0.74)	0.9	1.51	1.96	2.55	5.1	
			Placebo	110	108 (98.2)	1.90 (0.64)	0.6	1.44	1.85	2.36	3.6	
		Week 20	Tezepelumab	105	95 (90.5)	2.08 (0.76)	1.0	1.51	1.92	2.64	5.5	
			Placebo	110	105 (95.5)	1.89 (0.64)	0.5	1.40	1.87	2.28	3.4	
		Week 28	Tezepelumab	105	97 (92.4)	2.05 (0.78)	0.8	1.42	1.95	2.48	5.4	
			Placebo	110	105 (95.5)	1.89 (0.68)	0.7	1.43	1.87	2.33	3.6	
		Week 40	Tezepelumab	105	96 (91.4)	2.06 (0.73)	0.7	1.45	2.00	2.56	4.7	
			Placebo	110	105 (95.5)	1.94 (0.66)	0.7	1.50	1.82	2.43	3.5	
		Week 52	Tezepelumab	105	93 (88.6)	2.03 (0.68)	0.9	1.50	1.95	2.41	4.7	
			Placebo	110	106 (96.4)	1.92 (0.69)	0.6	1.40	1.89	2.44	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	105	101 (96.2)	0.21 (0.46)	-0.6	-0.02	0.12	0.37	2.4	0.34 [0.06, 0.61]
			Placebo	110	108 (98.2)	0.08 (0.36)	-1.1	-0.11	0.05	0.20	1.2	
		Week 8	Tezepelumab	105	95 (90.5)	0.20 (0.42)	-0.7	-0.03	0.15	0.36	2.2	0.23 [-0.04, 0.51]
			Placebo	110	108 (98.2)	0.11 (0.38)	-1.5	-0.08	0.11	0.24	1.3	
		Week 12	Tezepelumab	105	98 (93.3)	0.24 (0.49)	-0.6	-0.09	0.14	0.41	2.1	0.32 [0.04, 0.59]
			Placebo	110	108 (98.2)	0.10 (0.38)	-0.9	-0.09	0.08	0.28	1.3	
		Week 20	Tezepelumab	105	95 (90.5)	0.24 (0.47)	-0.6	-0.06	0.15	0.43	2.2	0.38 [0.10, 0.66]
			Placebo	110	105 (95.5)	0.09 (0.31)	-0.8	-0.04	0.08	0.23	1.5	
		Week 28	Tezepelumab	105	97 (92.4)	0.19 (0.52)	-1.0	-0.12	0.08	0.44	2.2	0.25 [-0.02, 0.53]
			Placebo	110	105 (95.5)	0.08 (0.33)	-0.9	-0.13	0.08	0.25	1.5	
		Week 40	Tezepelumab	105	96 (91.4)	0.21 (0.49)	-0.7	-0.07	0.16	0.44	2.3	0.21 [-0.07, 0.49]
			Placebo	110	105 (95.5)	0.12 (0.33)	-0.8	-0.08	0.09	0.30	1.1	
		Week 52	Tezepelumab	105	93 (88.6)	0.18 (0.46)	-0.8	-0.05	0.11	0.36	2.3	0.17 [-0.11, 0.44]
			Placebo	110	106 (96.4)	0.11 (0.39)	-0.9	-0.11	0.06	0.25	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	1.80 (0.59)	0.7	1.35	1.73	2.25	3.1	
			Placebo	28	28 (100.0)	1.86 (0.59)	0.9	1.43	1.75	2.30	3.1	
		Week 4	Tezepelumab	32	30 (93.8)	2.01 (0.67)	0.9	1.50	2.03	2.40	3.3	
			Placebo	28	28 (100.0)	1.81 (0.64)	0.7	1.33	1.69	2.35	3.1	
		Week 8	Tezepelumab	32	29 (90.6)	2.04 (0.62)	1.3	1.47	2.11	2.49	3.4	
			Placebo	28	24 (85.7)	1.89 (0.62)	0.8	1.49	1.72	2.35	3.1	
		Week 12	Tezepelumab	32	30 (93.8)	2.03 (0.66)	0.9	1.48	2.03	2.44	3.5	
			Placebo	28	27 (96.4)	1.91 (0.72)	0.5	1.46	1.76	2.46	4.1	
		Week 20	Tezepelumab	32	24 (75.0)	1.83 (0.56)	1.0	1.40	1.69	2.36	2.8	
			Placebo	28	26 (92.9)	1.96 (0.62)	0.7	1.53	1.90	2.46	3.2	
		Week 28	Tezepelumab	32	27 (84.4)	1.99 (0.60)	1.1	1.38	2.06	2.45	3.0	
			Placebo	28	26 (92.9)	1.75 (0.55)	0.8	1.41	1.76	2.05	3.0	
		Week 40	Tezepelumab	32	26 (81.3)	1.98 (0.58)	1.1	1.43	2.02	2.43	3.0	
			Placebo	28	25 (89.3)	1.84 (0.77)	0.6	1.28	1.62	2.24	4.0	
		Week 52	Tezepelumab	32	26 (81.3)	1.96 (0.59)	1.2	1.41	1.87	2.35	3.2	
			Placebo	28	23 (82.1)	1.78 (0.71)	0.7	1.25	1.69	2.28	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	32	30 (93.8)	0.25 (0.37)	-0.3	-0.03	0.11	0.62	1.1	0.80 [0.26, 1.34]
			Placebo	28	28 (100.0)	-0.05 (0.37)	-1.1	-0.24	0.03	0.16	0.6	
		Week 8	Tezepelumab	32	29 (90.6)	0.27 (0.32)	-0.4	0.00	0.32	0.48	0.9	0.74 [0.18, 1.30]
			Placebo	28	24 (85.7)	0.01 (0.38)	-0.9	-0.10	0.06	0.30	0.6	
		Week 12	Tezepelumab	32	30 (93.8)	0.28 (0.30)	-0.1	-0.01	0.24	0.51	0.9	0.55 [0.02, 1.08]
			Placebo	28	27 (96.4)	0.06 (0.48)	-1.2	-0.11	0.08	0.31	1.1	
		Week 20	Tezepelumab	32	24 (75.0)	0.16 (0.41)	-0.6	-0.11	0.09	0.42	0.9	0.14 [-0.42, 0.69]
			Placebo	28	26 (92.9)	0.10 (0.54)	-1.0	-0.13	0.05	0.33	1.8	
		Week 28	Tezepelumab	32	27 (84.4)	0.33 (0.35)	-0.2	0.01	0.27	0.64	0.9	1.11 [0.53, 1.69]
			Placebo	28	26 (92.9)	-0.12 (0.44)	-1.1	-0.34	0.00	0.23	0.4	
		Week 40	Tezepelumab	32	26 (81.3)	0.33 (0.33)	-0.1	0.05	0.31	0.58	1.0	0.79 [0.22, 1.36]
			Placebo	28	25 (89.3)	-0.01 (0.51)	-1.3	-0.20	-0.04	0.22	0.9	
		Week 52	Tezepelumab	32	26 (81.3)	0.31 (0.33)	-0.2	0.03	0.27	0.64	0.8	1.01 [0.41, 1.60]
			Placebo	28	23 (82.1)	-0.07 (0.42)	-1.0	-0.39	-0.04	0.24	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	1.84 (0.57)	0.7	1.39	1.77	2.21	3.9	
			Placebo	123	123 (100.0)	1.83 (0.60)	0.7	1.41	1.72	2.19	3.3	
		Week 4	Tezepelumab	128	122 (95.3)	2.05 (0.74)	0.9	1.53	1.98	2.45	4.9	
			Placebo	123	121 (98.4)	1.88 (0.63)	0.7	1.47	1.86	2.34	3.2	
		Week 8	Tezepelumab	128	115 (89.8)	2.05 (0.66)	0.7	1.55	1.98	2.39	5.1	
			Placebo	123	117 (95.1)	1.93 (0.65)	0.7	1.49	1.93	2.39	3.6	
		Week 12	Tezepelumab	128	119 (93.0)	2.09 (0.71)	0.9	1.52	1.99	2.55	5.1	
			Placebo	123	120 (97.6)	1.90 (0.68)	0.5	1.44	1.84	2.45	4.1	
		Week 20	Tezepelumab	128	111 (86.7)	2.05 (0.73)	1.0	1.49	1.92	2.52	5.5	
			Placebo	123	117 (95.1)	1.90 (0.66)	0.5	1.39	1.90	2.34	3.4	
		Week 28	Tezepelumab	128	115 (89.8)	2.04 (0.74)	0.8	1.45	1.97	2.48	5.4	
			Placebo	123	117 (95.1)	1.86 (0.67)	0.7	1.42	1.85	2.24	3.6	
		Week 40	Tezepelumab	128	114 (89.1)	2.04 (0.70)	0.7	1.44	2.00	2.52	4.7	
			Placebo	123	117 (95.1)	1.94 (0.70)	0.6	1.43	1.82	2.43	4.0	
		Week 52	Tezepelumab	128	111 (86.7)	2.03 (0.66)	0.9	1.50	1.94	2.41	4.7	
			Placebo	123	116 (94.3)	1.91 (0.72)	0.6	1.34	1.83	2.44	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	128	122 (95.3)	0.22 (0.45)	-0.6	-0.02	0.12	0.38	2.4	0.41 [0.16, 0.66]
			Placebo	123	121 (98.4)	0.05 (0.38)	-1.1	-0.12	0.03	0.18	1.2	
		Week 8	Tezepelumab	128	115 (89.8)	0.22 (0.41)	-0.7	-0.02	0.16	0.40	2.2	0.32 [0.06, 0.58]
			Placebo	123	117 (95.1)	0.09 (0.40)	-1.5	-0.09	0.11	0.26	1.3	
		Week 12	Tezepelumab	128	119 (93.0)	0.25 (0.46)	-0.6	-0.05	0.16	0.43	2.1	0.38 [0.13, 0.64]
			Placebo	123	120 (97.6)	0.09 (0.40)	-1.2	-0.11	0.07	0.28	1.3	
		Week 20	Tezepelumab	128	111 (86.7)	0.23 (0.47)	-0.6	-0.07	0.14	0.47	2.2	0.34 [0.08, 0.60]
			Placebo	123	117 (95.1)	0.09 (0.37)	-1.0	-0.06	0.07	0.24	1.8	
		Week 28	Tezepelumab	128	115 (89.8)	0.22 (0.50)	-1.0	-0.11	0.09	0.51	2.2	0.41 [0.15, 0.67]
			Placebo	123	117 (95.1)	0.04 (0.38)	-1.1	-0.14	0.03	0.25	1.5	
		Week 40	Tezepelumab	128	114 (89.1)	0.23 (0.47)	-0.7	-0.07	0.19	0.47	2.3	0.30 [0.05, 0.56]
			Placebo	123	117 (95.1)	0.10 (0.38)	-1.3	-0.11	0.06	0.31	1.1	
		Week 52	Tezepelumab	128	111 (86.7)	0.21 (0.44)	-0.8	-0.04	0.15	0.44	2.3	0.30 [0.04, 0.56]
			Placebo	123	116 (94.3)	0.08 (0.41)	-1.0	-0.15	0.05	0.25	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	1.46 (0.43)	1.1	1.06	1.40	1.92	1.9	
			Placebo	6	6 (100.0)	1.70 (0.37)	1.4	1.45	1.56	1.93	2.3	
		Week 4	Tezepelumab	3	3 (100.0)	1.64 (0.60)	1.1	1.12	1.51	2.30	2.3	
			Placebo	6	6 (100.0)	1.84 (0.38)	1.3	1.64	1.83	1.94	2.5	
		Week 8	Tezepelumab	3	3 (100.0)	1.61 (0.43)	1.4	1.35	1.37	2.11	2.1	
			Placebo	6	6 (100.0)	1.82 (0.23)	1.5	1.69	1.80	2.05	2.1	
		Week 12	Tezepelumab	3	3 (100.0)	1.66 (0.90)	1.0	0.97	1.32	2.68	2.7	
			Placebo	6	6 (100.0)	1.94 (0.30)	1.6	1.76	1.87	2.10	2.5	
		Week 20	Tezepelumab	3	2 (66.7)	1.27 (0.37)	1.0	1.00	1.27	1.53	1.5	
			Placebo	6	6 (100.0)	1.68 (0.28)	1.2	1.50	1.72	1.90	2.0	
		Week 28	Tezepelumab	3	3 (100.0)	1.94 (0.82)	1.3	1.27	1.70	2.86	2.9	
			Placebo	6	5 (83.3)	1.86 (0.44)	1.4	1.63	1.79	1.91	2.6	
		Week 40	Tezepelumab	3	3 (100.0)	1.88 (0.73)	1.3	1.31	1.63	2.71	2.7	
			Placebo	6	6 (100.0)	1.77 (0.30)	1.4	1.48	1.76	2.02	2.2	
		Week 52	Tezepelumab	3	2 (66.7)	1.41 (0.36)	1.2	1.15	1.41	1.66	1.7	
			Placebo	6	5 (83.3)	1.83 (0.20)	1.6	1.69	1.75	2.00	2.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	0.18 (0.17)	0.1	0.06	0.11	0.38	0.4	0.32 [-1.08, 1.72]
			Placebo	6	6 (100.0)	0.14 (0.13)	-0.0	0.01	0.16	0.26	0.3	
		Week 8	Tezepelumab	3	3 (100.0)	0.15 (0.18)	-0.0	-0.05	0.19	0.31	0.3	0.15 [-1.24, 1.54]
			Placebo	6	6 (100.0)	0.12 (0.21)	-0.3	0.14	0.18	0.24	0.3	
		Week 12	Tezepelumab	3	3 (100.0)	0.20 (0.49)	-0.1	-0.09	-0.08	0.76	0.8	-0.09 [-1.47, 1.30]
			Placebo	6	6 (100.0)	0.24 (0.54)	-0.5	0.00	0.22	0.46	1.1	
		Week 20	Tezepelumab	3	2 (66.7)	0.04 (0.13)	-0.1	-0.06	0.04	0.13	0.1	0.17 [-1.43, 1.78]
			Placebo	6	6 (100.0)	-0.02 (0.37)	-0.7	-0.12	0.04	0.26	0.3	
		Week 28	Tezepelumab	3	3 (100.0)	0.48 (0.40)	0.2	0.21	0.30	0.94	0.9	1.56 [-0.12, 3.24]
			Placebo	6	5 (83.3)	0.09 (0.12)	-0.0	-0.02	0.15	0.15	0.2	
		Week 40	Tezepelumab	3	3 (100.0)	0.42 (0.32)	0.2	0.23	0.25	0.79	0.8	1.44 [-0.14, 3.01]
			Placebo	6	6 (100.0)	0.07 (0.21)	-0.3	0.00	0.13	0.22	0.3	
		Week 52	Tezepelumab	3	2 (66.7)	0.17 (0.12)	0.1	0.09	0.17	0.26	0.3	0.31 [-1.34, 1.96]
			Placebo	6	5 (83.3)	0.06 (0.39)	-0.6	0.07	0.15	0.24	0.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	1.95 (0.98)	0.7	1.29	1.99	2.70	3.1	
			Placebo	6	6 (100.0)	1.85 (0.49)	1.4	1.48	1.67	2.23	2.6	
		Week 4	Tezepelumab	5	5 (100.0)	2.18 (1.03)	1.1	1.25	2.30	2.74	3.5	
			Placebo	6	6 (100.0)	1.91 (0.52)	1.4	1.58	1.69	2.39	2.7	
		Week 8	Tezepelumab	5	5 (100.0)	2.15 (0.86)	1.3	1.26	2.49	2.52	3.2	
			Placebo	6	6 (100.0)	1.90 (0.49)	1.4	1.48	1.82	2.29	2.6	
		Week 12	Tezepelumab	5	5 (100.0)	2.15 (0.89)	1.2	1.28	2.42	2.53	3.3	
			Placebo	6	6 (100.0)	1.85 (0.60)	1.1	1.43	1.73	2.38	2.7	
		Week 20	Tezepelumab	5	5 (100.0)	2.05 (0.79)	1.1	1.37	2.39	2.42	3.0	
			Placebo	6	6 (100.0)	1.97 (0.45)	1.6	1.68	1.75	2.26	2.8	
		Week 28	Tezepelumab	5	5 (100.0)	2.17 (0.96)	1.2	1.26	2.38	2.44	3.5	
			Placebo	6	6 (100.0)	2.01 (0.59)	1.2	1.70	1.87	2.44	2.9	
		Week 40	Tezepelumab	5	5 (100.0)	2.15 (0.78)	1.3	1.36	2.43	2.53	3.1	
			Placebo	6	6 (100.0)	1.88 (0.54)	1.4	1.36	1.75	2.41	2.7	
		Week 52	Tezepelumab	5	5 (100.0)	2.07 (0.74)	1.3	1.36	2.28	2.34	3.1	
			Placebo	6	6 (100.0)	1.89 (0.47)	1.4	1.44	1.81	2.31	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	5	5 (100.0)	0.23 (0.22)	-0.0	0.04	0.31	0.39	0.5	0.90 [-0.36, 2.16]
			Placebo	6	6 (100.0)	0.06 (0.16)	-0.2	-0.01	0.08	0.16	0.3	
		Week 8	Tezepelumab	5	5 (100.0)	0.20 (0.32)	-0.2	-0.03	0.14	0.50	0.6	0.60 [-0.62, 1.82]
			Placebo	6	6 (100.0)	0.05 (0.16)	-0.1	-0.06	0.00	0.06	0.4	
		Week 12	Tezepelumab	5	5 (100.0)	0.20 (0.29)	-0.2	-0.01	0.23	0.43	0.5	0.61 [-0.61, 1.83]
			Placebo	6	6 (100.0)	-0.00 (0.36)	-0.7	0.00	0.11	0.15	0.3	
		Week 20	Tezepelumab	5	5 (100.0)	0.10 (0.32)	-0.3	-0.09	0.08	0.40	0.4	-0.06 [-1.25, 1.13]
			Placebo	6	6 (100.0)	0.12 (0.15)	-0.1	0.03	0.13	0.26	0.3	
		Week 28	Tezepelumab	5	5 (100.0)	0.22 (0.35)	-0.3	-0.03	0.39	0.47	0.5	0.22 [-0.97, 1.41]
			Placebo	6	6 (100.0)	0.16 (0.22)	-0.2	-0.01	0.22	0.29	0.4	
		Week 40	Tezepelumab	5	5 (100.0)	0.20 (0.34)	-0.2	0.04	0.05	0.44	0.7	0.58 [-0.63, 1.80]
			Placebo	6	6 (100.0)	0.03 (0.27)	-0.5	-0.08	0.10	0.23	0.3	
		Week 52	Tezepelumab	5	5 (100.0)	0.12 (0.39)	-0.4	0.01	0.07	0.35	0.6	0.26 [-0.93, 1.45]
			Placebo	6	6 (100.0)	0.04 (0.28)	-0.4	-0.08	0.05	0.16	0.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	1.24	1.2	1.24	1.24	1.24	1.2	
			Placebo	3	3 (100.0)	1.69 (0.58)	1.2	1.18	1.58	2.32	2.3	
		Week 4	Tezepelumab	1	1 (100.0)	1.37	1.4	1.37	1.37	1.37	1.4	
			Placebo	3	3 (100.0)	1.45 (0.48)	0.9	0.91	1.66	1.79	1.8	
		Week 8	Tezepelumab	1	1 (100.0)	1.48	1.5	1.48	1.48	1.48	1.5	
			Placebo	3	3 (100.0)	1.77 (0.45)	1.5	1.48	1.54	2.29	2.3	
		Week 12	Tezepelumab	1	1 (100.0)	1.45	1.5	1.45	1.45	1.45	1.5	
			Placebo	3	3 (100.0)	1.86 (0.48)	1.5	1.52	1.65	2.40	2.4	
		Week 20	Tezepelumab	1	1 (100.0)	1.46	1.5	1.46	1.46	1.46	1.5	
			Placebo	3	2 (66.7)	2.20 (0.48)	1.9	1.86	2.20	2.54	2.5	
		Week 28	Tezepelumab	1	1 (100.0)	1.39	1.4	1.39	1.39	1.39	1.4	
			Placebo	3	3 (100.0)	1.71 (0.59)	1.2	1.24	1.53	2.37	2.4	
		Week 40	Placebo	3	1 (33.3)	1.42	1.4	1.42	1.42	1.42	1.4	
		Week 52	Tezepelumab	1	1 (100.0)	1.25	1.3	1.25	1.25	1.25	1.3	
			Placebo	3	2 (66.7)	1.47 (1.15)	0.7	0.66	1.47	2.28	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	0.13	0.1	0.13	0.13	0.13	0.1	NE
			Placebo	3	3 (100.0)	-0.24 (0.31)	-0.5	-0.53	-0.27	0.08	0.1	
		Week 8	Tezepelumab	1	1 (100.0)	0.24	0.2	0.24	0.24	0.24	0.2	NE
			Placebo	3	3 (100.0)	0.08 (0.19)	-0.0	-0.04	-0.03	0.30	0.3	
		Week 12	Tezepelumab	1	1 (100.0)	0.21	0.2	0.21	0.21	0.21	0.2	NE
			Placebo	3	3 (100.0)	0.16 (0.27)	-0.1	-0.06	0.08	0.47	0.5	
		Week 20	Tezepelumab	1	1 (100.0)	0.22	0.2	0.22	0.22	0.22	0.2	NE
			Placebo	3	2 (66.7)	0.45 (0.33)	0.2	0.22	0.45	0.68	0.7	
		Week 28	Tezepelumab	1	1 (100.0)	0.15	0.1	0.15	0.15	0.15	0.1	NE
			Placebo	3	3 (100.0)	0.02 (0.35)	-0.3	-0.34	0.05	0.35	0.4	
		Week 40	Placebo	3	1 (33.3)	0.24	0.2	0.24	0.24	0.24	0.2	
		Week 52	Tezepelumab	1	1 (100.0)	0.01	0.0	0.01	0.01	0.01	0.0	NE
			Placebo	3	2 (66.7)	-0.28 (0.34)	-0.5	-0.52	-0.28	-0.04	-0.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	78	78 (100.0)	1.89 (0.57)	0.7	1.45	1.79	2.22	3.9	
			Placebo	80	80 (100.0)	1.87 (0.61)	0.8	1.45	1.73	2.20	3.3	
		Week 4	Tezepelumab	78	75 (96.2)	2.09 (0.68)	0.9	1.58	2.04	2.46	4.9	
			Placebo	80	80 (100.0)	1.90 (0.63)	0.7	1.48	1.89	2.38	3.2	
		Week 8	Tezepelumab	78	74 (94.9)	2.08 (0.67)	0.7	1.62	2.04	2.38	5.1	
			Placebo	80	76 (95.0)	1.94 (0.65)	0.7	1.49	1.93	2.37	3.6	
		Week 12	Tezepelumab	78	75 (96.2)	2.11 (0.68)	1.0	1.59	2.01	2.55	5.1	
			Placebo	80	79 (98.8)	1.93 (0.70)	0.5	1.44	1.89	2.36	4.1	
		Week 20	Tezepelumab	78	71 (91.0)	2.09 (0.73)	1.0	1.51	1.93	2.52	5.5	
			Placebo	80	79 (98.8)	1.91 (0.65)	0.6	1.39	1.96	2.35	3.4	
		Week 28	Tezepelumab	78	72 (92.3)	2.03 (0.74)	0.9	1.44	1.96	2.41	5.4	
			Placebo	80	79 (98.8)	1.92 (0.68)	0.7	1.44	1.90	2.33	3.6	
		Week 40	Tezepelumab	78	71 (91.0)	2.08 (0.69)	1.0	1.53	2.01	2.45	4.7	
			Placebo	80	79 (98.8)	1.96 (0.71)	0.6	1.39	1.88	2.44	4.0	
		Week 52	Tezepelumab	78	71 (91.0)	2.03 (0.66)	0.9	1.58	1.94	2.37	4.7	
			Placebo	80	79 (98.8)	1.94 (0.71)	0.7	1.37	1.86	2.51	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	78	75 (96.2)	0.21 (0.43)	-0.6	-0.02	0.13	0.40	2.4	0.46 [0.14, 0.78]
			Placebo	80	80 (100.0)	0.03 (0.35)	-1.1	-0.12	0.02	0.17	1.1	
		Week 8	Tezepelumab	78	74 (94.9)	0.21 (0.40)	-0.7	-0.04	0.11	0.38	2.2	0.40 [0.07, 0.72]
			Placebo	80	76 (95.0)	0.06 (0.37)	-0.9	-0.11	0.10	0.21	1.3	
		Week 12	Tezepelumab	78	75 (96.2)	0.24 (0.47)	-0.6	-0.08	0.16	0.45	2.1	0.36 [0.04, 0.68]
			Placebo	80	79 (98.8)	0.08 (0.38)	-1.2	-0.07	0.08	0.28	1.1	
		Week 20	Tezepelumab	78	71 (91.0)	0.23 (0.48)	-0.6	-0.08	0.15	0.48	2.2	0.39 [0.07, 0.71]
			Placebo	80	79 (98.8)	0.06 (0.39)	-1.0	-0.11	0.01	0.22	1.8	
		Week 28	Tezepelumab	78	72 (92.3)	0.17 (0.51)	-1.0	-0.12	0.04	0.42	2.2	0.29 [-0.03, 0.61]
			Placebo	80	79 (98.8)	0.05 (0.36)	-1.1	-0.10	0.03	0.22	1.5	
		Week 40	Tezepelumab	78	71 (91.0)	0.22 (0.47)	-0.7	-0.07	0.15	0.44	2.3	0.33 [0.01, 0.66]
			Placebo	80	79 (98.8)	0.08 (0.36)	-1.1	-0.11	0.04	0.29	1.0	
		Week 52	Tezepelumab	78	71 (91.0)	0.19 (0.45)	-0.8	-0.06	0.11	0.40	2.3	0.29 [-0.03, 0.61]
			Placebo	80	79 (98.8)	0.07 (0.37)	-0.7	-0.13	0.05	0.24	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	10	10 (100.0)	1.73 (0.66)	0.9	1.13	1.62	2.18	2.8	
			Placebo	9	9 (100.0)	1.68 (0.55)	1.0	1.36	1.48	1.93	2.7	
		Week 4	Tezepelumab	10	9 (90.0)	1.80 (0.74)	0.9	1.26	1.70	2.30	3.2	
			Placebo	9	9 (100.0)	1.75 (0.72)	0.8	1.33	1.75	1.94	3.1	
		Week 8	Tezepelumab	10	9 (90.0)	1.86 (0.74)	1.3	1.35	1.47	2.11	3.4	
			Placebo	9	9 (100.0)	1.85 (0.54)	1.4	1.50	1.69	2.05	3.1	
		Week 12	Tezepelumab	10	10 (100.0)	1.89 (0.81)	0.9	1.19	1.76	2.68	3.1	
			Placebo	9	9 (100.0)	1.94 (0.49)	1.2	1.65	1.81	2.23	2.8	
		Week 20	Tezepelumab	10	7 (70.0)	1.79 (0.88)	1.0	1.03	1.53	2.42	3.5	
			Placebo	9	9 (100.0)	1.79 (0.60)	1.2	1.50	1.69	1.86	3.2	
		Week 28	Tezepelumab	10	8 (80.0)	1.93 (0.70)	1.1	1.34	1.77	2.64	2.9	
			Placebo	9	8 (88.9)	1.90 (0.61)	1.2	1.47	1.77	2.27	3.0	
		Week 40	Tezepelumab	10	7 (70.0)	1.92 (0.88)	1.1	1.31	1.63	2.71	3.5	
			Placebo	9	9 (100.0)	1.83 (0.57)	1.4	1.45	1.62	2.02	3.2	
		Week 52	Tezepelumab	10	7 (70.0)	1.89 (0.86)	1.2	1.16	1.66	2.67	3.5	
			Placebo	9	8 (88.9)	1.68 (0.68)	0.7	1.34	1.66	1.88	3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	10	9 (90.0)	0.12 (0.20)	-0.1	-0.06	0.11	0.34	0.4	0.23 [-0.70, 1.16]
			Placebo	9	9 (100.0)	0.07 (0.22)	-0.3	-0.03	0.13	0.20	0.4	
		Week 8	Tezepelumab	10	9 (90.0)	0.24 (0.29)	-0.4	0.17	0.31	0.48	0.6	0.26 [-0.67, 1.19]
			Placebo	9	9 (100.0)	0.17 (0.22)	-0.3	0.14	0.21	0.30	0.4	
		Week 12	Tezepelumab	10	10 (100.0)	0.16 (0.28)	-0.1	-0.08	0.11	0.29	0.8	-0.29 [-1.19, 0.62]
			Placebo	9	9 (100.0)	0.27 (0.45)	-0.5	0.12	0.19	0.47	1.1	
		Week 20	Tezepelumab	10	7 (70.0)	0.17 (0.27)	-0.2	-0.06	0.13	0.38	0.6	0.17 [-0.82, 1.16]
			Placebo	9	9 (100.0)	0.11 (0.39)	-0.7	0.02	0.07	0.33	0.7	
		Week 28	Tezepelumab	10	8 (80.0)	0.33 (0.28)	0.0	0.19	0.27	0.39	0.9	0.65 [-0.36, 1.66]
			Placebo	9	8 (88.9)	0.18 (0.15)	-0.0	0.06	0.19	0.32	0.4	
		Week 40	Tezepelumab	10	7 (70.0)	0.40 (0.26)	0.2	0.20	0.25	0.70	0.8	0.90 [-0.15, 1.94]
			Placebo	9	9 (100.0)	0.15 (0.30)	-0.3	0.00	0.17	0.24	0.7	
		Week 52	Tezepelumab	10	7 (70.0)	0.33 (0.22)	0.0	0.09	0.40	0.49	0.6	1.27 [0.14, 2.39]
			Placebo	9	8 (88.9)	-0.04 (0.35)	-0.6	-0.34	0.11	0.21	0.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	1.95 (0.98)	0.7	1.29	1.99	2.70	3.1	
			Placebo	6	6 (100.0)	1.85 (0.49)	1.4	1.48	1.67	2.23	2.6	
		Week 4	Tezepelumab	5	5 (100.0)	2.18 (1.03)	1.1	1.25	2.30	2.74	3.5	
			Placebo	6	6 (100.0)	1.91 (0.52)	1.4	1.58	1.69	2.39	2.7	
		Week 8	Tezepelumab	5	5 (100.0)	2.15 (0.86)	1.3	1.26	2.49	2.52	3.2	
			Placebo	6	6 (100.0)	1.90 (0.49)	1.4	1.48	1.82	2.29	2.6	
		Week 12	Tezepelumab	5	5 (100.0)	2.15 (0.89)	1.2	1.28	2.42	2.53	3.3	
			Placebo	6	6 (100.0)	1.85 (0.60)	1.1	1.43	1.73	2.38	2.7	
		Week 20	Tezepelumab	5	5 (100.0)	2.05 (0.79)	1.1	1.37	2.39	2.42	3.0	
			Placebo	6	6 (100.0)	1.97 (0.45)	1.6	1.68	1.75	2.26	2.8	
		Week 28	Tezepelumab	5	5 (100.0)	2.17 (0.96)	1.2	1.26	2.38	2.44	3.5	
			Placebo	6	6 (100.0)	2.01 (0.59)	1.2	1.70	1.87	2.44	2.9	
		Week 40	Tezepelumab	5	5 (100.0)	2.15 (0.78)	1.3	1.36	2.43	2.53	3.1	
			Placebo	6	6 (100.0)	1.88 (0.54)	1.4	1.36	1.75	2.41	2.7	
		Week 52	Tezepelumab	5	5 (100.0)	2.07 (0.74)	1.3	1.36	2.28	2.34	3.1	
			Placebo	6	6 (100.0)	1.89 (0.47)	1.4	1.44	1.81	2.31	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	5	5 (100.0)	0.23 (0.22)	-0.0	0.04	0.31	0.39	0.5	0.90 [-0.36, 2.16]
			Placebo	6	6 (100.0)	0.06 (0.16)	-0.2	-0.01	0.08	0.16	0.3	
		Week 8	Tezepelumab	5	5 (100.0)	0.20 (0.32)	-0.2	-0.03	0.14	0.50	0.6	0.60 [-0.62, 1.82]
			Placebo	6	6 (100.0)	0.05 (0.16)	-0.1	-0.06	0.00	0.06	0.4	
		Week 12	Tezepelumab	5	5 (100.0)	0.20 (0.29)	-0.2	-0.01	0.23	0.43	0.5	0.61 [-0.61, 1.83]
			Placebo	6	6 (100.0)	-0.00 (0.36)	-0.7	0.00	0.11	0.15	0.3	
		Week 20	Tezepelumab	5	5 (100.0)	0.10 (0.32)	-0.3	-0.09	0.08	0.40	0.4	-0.06 [-1.25, 1.13]
			Placebo	6	6 (100.0)	0.12 (0.15)	-0.1	0.03	0.13	0.26	0.3	
		Week 28	Tezepelumab	5	5 (100.0)	0.22 (0.35)	-0.3	-0.03	0.39	0.47	0.5	0.22 [-0.97, 1.41]
			Placebo	6	6 (100.0)	0.16 (0.22)	-0.2	-0.01	0.22	0.29	0.4	
		Week 40	Tezepelumab	5	5 (100.0)	0.20 (0.34)	-0.2	0.04	0.05	0.44	0.7	0.58 [-0.63, 1.80]
			Placebo	6	6 (100.0)	0.03 (0.27)	-0.5	-0.08	0.10	0.23	0.3	
		Week 52	Tezepelumab	5	5 (100.0)	0.12 (0.39)	-0.4	0.01	0.07	0.35	0.6	0.26 [-0.93, 1.45]
			Placebo	6	6 (100.0)	0.04 (0.28)	-0.4	-0.08	0.05	0.16	0.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	44	44 (100.0)	1.73 (0.54)	0.7	1.32	1.63	2.14	3.0	
			Placebo	43	43 (100.0)	1.77 (0.58)	0.7	1.33	1.71	2.19	2.9	
		Week 4	Tezepelumab	44	42 (95.5)	1.99 (0.82)	0.9	1.41	1.79	2.28	4.5	
			Placebo	43	41 (95.3)	1.82 (0.58)	0.7	1.49	1.83	2.27	2.9	
		Week 8	Tezepelumab	44	36 (81.8)	1.97 (0.60)	1.0	1.54	1.92	2.42	3.5	
			Placebo	43	41 (95.3)	1.90 (0.62)	0.7	1.54	1.93	2.39	2.9	
		Week 12	Tezepelumab	44	38 (86.4)	2.05 (0.77)	0.9	1.51	1.94	2.58	4.6	
			Placebo	43	41 (95.3)	1.84 (0.61)	0.9	1.44	1.76	2.46	2.9	
		Week 20	Tezepelumab	44	36 (81.8)	1.97 (0.71)	1.0	1.47	1.78	2.54	4.1	
			Placebo	43	37 (86.0)	1.89 (0.66)	0.5	1.40	1.87	2.33	3.0	
		Week 28	Tezepelumab	44	39 (88.6)	2.05 (0.76)	0.8	1.49	2.02	2.66	4.6	
			Placebo	43	38 (88.4)	1.73 (0.62)	0.7	1.24	1.77	2.10	3.1	
		Week 40	Tezepelumab	44	39 (88.6)	1.98 (0.70)	0.7	1.41	2.00	2.65	3.2	
			Placebo	43	36 (83.7)	1.88 (0.66)	0.8	1.48	1.82	2.34	3.3	
		Week 52	Tezepelumab	44	36 (81.8)	1.99 (0.64)	1.0	1.38	1.95	2.43	3.3	
			Placebo	43	36 (83.7)	1.85 (0.70)	0.6	1.31	1.82	2.33	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	44	42 (95.5)	0.26 (0.51)	-0.6	-0.02	0.11	0.38	2.1	0.38 [-0.05, 0.82]
			Placebo	43	41 (95.3)	0.08 (0.43)	-1.0	-0.16	0.06	0.20	1.2	
		Week 8	Tezepelumab	44	36 (81.8)	0.23 (0.45)	-0.5	0.02	0.18	0.38	2.2	0.20 [-0.25, 0.65]
			Placebo	43	41 (95.3)	0.14 (0.45)	-1.5	-0.09	0.15	0.35	1.0	
		Week 12	Tezepelumab	44	38 (86.4)	0.30 (0.47)	-0.2	-0.03	0.20	0.42	1.9	0.48 [0.03, 0.93]
			Placebo	43	41 (95.3)	0.08 (0.44)	-0.9	-0.16	0.04	0.26	1.3	
		Week 20	Tezepelumab	44	36 (81.8)	0.24 (0.47)	-0.6	-0.07	0.11	0.41	1.9	0.24 [-0.22, 0.70]
			Placebo	43	37 (86.0)	0.14 (0.32)	-0.9	-0.02	0.15	0.32	1.0	
		Week 28	Tezepelumab	44	39 (88.6)	0.29 (0.50)	-0.6	-0.06	0.16	0.58	1.9	0.66 [0.20, 1.12]
			Placebo	43	38 (88.4)	-0.01 (0.42)	-1.1	-0.30	0.03	0.30	0.8	
		Week 40	Tezepelumab	44	39 (88.6)	0.25 (0.49)	-0.6	-0.02	0.22	0.47	1.9	0.22 [-0.23, 0.68]
			Placebo	43	36 (83.7)	0.15 (0.43)	-1.3	-0.09	0.13	0.43	1.1	
		Week 52	Tezepelumab	44	36 (81.8)	0.23 (0.45)	-0.5	-0.02	0.16	0.40	2.0	0.22 [-0.24, 0.69]
			Placebo	43	36 (83.7)	0.13 (0.49)	-1.0	-0.15	0.10	0.39	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Placebo	1	1 (100.0)	2.36	2.4	2.36	2.36	2.36	2.4	
		Week 4	Placebo	1	1 (100.0)	2.30	2.3	2.30	2.30	2.30	2.3	
		Week 8	Placebo	1	1 (100.0)	2.41	2.4	2.41	2.41	2.41	2.4	
		Week 12	Placebo	1	1 (100.0)	2.49	2.5	2.49	2.49	2.49	2.5	
		Week 20	Placebo	1	1 (100.0)	2.66	2.7	2.66	2.66	2.66	2.7	
		Week 28	Placebo	1	1 (100.0)	2.58	2.6	2.58	2.58	2.58	2.6	
		Week 40	Placebo	1	1 (100.0)	2.59	2.6	2.59	2.59	2.59	2.6	
		Week 52	Placebo	1	1 (100.0)	2.55	2.6	2.55	2.55	2.55	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 4	Placebo	1	1 (100.0)	-0.06	-0.1	-0.06	-0.06	-0.06	-0.1	
		Week 8	Placebo	1	1 (100.0)	0.05	0.1	0.05	0.05	0.05	0.1	
		Week 12	Placebo	1	1 (100.0)	0.13	0.1	0.13	0.13	0.13	0.1	
		Week 20	Placebo	1	1 (100.0)	0.30	0.3	0.30	0.30	0.30	0.3	
		Week 28	Placebo	1	1 (100.0)	0.22	0.2	0.22	0.22	0.22	0.2	
		Week 40	Placebo	1	1 (100.0)	0.23	0.2	0.23	0.23	0.23	0.2	
		Week 52	Placebo	1	1 (100.0)	0.19	0.2	0.19	0.19	0.19	0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	39	39 (100.0)	1.86 (0.59)	0.7	1.36	1.99	2.36	3.0	
			Placebo	43	43 (100.0)	1.91 (0.67)	0.7	1.45	1.91	2.44	3.2	
		Week 4	Tezepelumab	39	38 (97.4)	2.19 (0.81)	0.9	1.58	2.10	2.74	4.5	
			Placebo	43	42 (97.7)	1.92 (0.67)	0.7	1.58	1.91	2.40	3.2	
		Week 8	Tezepelumab	39	36 (92.3)	2.12 (0.60)	1.2	1.56	2.11	2.50	3.3	
			Placebo	43	41 (95.3)	2.00 (0.75)	0.7	1.48	2.15	2.56	3.6	
		Week 12	Tezepelumab	39	39 (100.0)	2.17 (0.76)	0.9	1.54	2.04	2.55	4.6	
			Placebo	43	42 (97.7)	1.96 (0.68)	0.7	1.55	1.89	2.50	3.3	
		Week 20	Tezepelumab	39	35 (89.7)	2.17 (0.74)	1.0	1.62	1.93	2.64	4.1	
			Placebo	43	42 (97.7)	2.04 (0.68)	0.5	1.54	2.14	2.62	3.3	
		Week 28	Tezepelumab	39	38 (97.4)	2.21 (0.78)	0.8	1.57	2.22	2.72	4.6	
			Placebo	43	42 (97.7)	1.93 (0.74)	0.7	1.43	1.94	2.42	3.6	
		Week 40	Tezepelumab	39	37 (94.9)	2.18 (0.67)	1.0	1.53	2.17	2.72	3.5	
			Placebo	43	41 (95.3)	2.05 (0.74)	0.7	1.57	2.16	2.62	3.5	
		Week 52	Tezepelumab	39	37 (94.9)	2.11 (0.62)	1.1	1.58	2.25	2.45	3.4	
			Placebo	43	42 (97.7)	2.02 (0.77)	0.6	1.34	2.09	2.54	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	39	38 (97.4)	0.34 (0.56)	-0.6	0.02	0.15	0.45	2.4	0.67 [0.22, 1.12]
			Placebo	43	42 (97.7)	0.03 (0.34)	-1.0	-0.14	0.00	0.11	1.2	
		Week 8	Tezepelumab	39	36 (92.3)	0.29 (0.45)	-0.5	0.01	0.20	0.48	2.2	0.49 [0.03, 0.94]
			Placebo	43	41 (95.3)	0.08 (0.43)	-1.5	-0.09	0.08	0.29	1.1	
		Week 12	Tezepelumab	39	39 (100.0)	0.31 (0.50)	-0.6	-0.01	0.18	0.45	2.1	0.50 [0.06, 0.94]
			Placebo	43	42 (97.7)	0.09 (0.38)	-0.9	-0.14	0.12	0.32	0.8	
		Week 20	Tezepelumab	39	35 (89.7)	0.31 (0.53)	-0.6	0.01	0.23	0.48	2.2	0.35 [-0.11, 0.80]
			Placebo	43	42 (97.7)	0.15 (0.38)	-0.5	-0.04	0.10	0.26	1.8	
		Week 28	Tezepelumab	39	38 (97.4)	0.34 (0.54)	-0.9	0.00	0.26	0.64	2.2	0.64 [0.19, 1.09]
			Placebo	43	42 (97.7)	0.05 (0.37)	-1.1	-0.10	0.07	0.29	0.9	
		Week 40	Tezepelumab	39	37 (94.9)	0.36 (0.49)	-0.7	0.06	0.31	0.54	2.3	0.49 [0.04, 0.94]
			Placebo	43	41 (95.3)	0.14 (0.39)	-0.8	-0.09	0.06	0.37	1.1	
		Week 52	Tezepelumab	39	37 (94.9)	0.30 (0.46)	-0.4	0.03	0.20	0.49	2.3	0.36 [-0.09, 0.80]
			Placebo	43	42 (97.7)	0.13 (0.46)	-1.0	-0.16	0.14	0.35	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	45	45 (100.0)	1.79 (0.58)	0.7	1.32	1.78	2.16	3.1	
			Placebo	47	47 (100.0)	1.95 (0.59)	1.0	1.48	1.80	2.34	3.3	
		Week 4	Tezepelumab	45	43 (95.6)	1.95 (0.66)	0.9	1.41	1.95	2.30	3.5	
			Placebo	47	46 (97.9)	1.98 (0.60)	0.7	1.55	1.94	2.42	3.1	
		Week 8	Tezepelumab	45	40 (88.9)	1.99 (0.62)	0.7	1.55	1.95	2.41	3.5	
			Placebo	47	45 (95.7)	1.99 (0.60)	0.8	1.56	2.00	2.35	3.3	
		Week 12	Tezepelumab	45	39 (86.7)	1.98 (0.66)	0.9	1.33	1.96	2.55	3.3	
			Placebo	47	46 (97.9)	2.03 (0.73)	0.5	1.48	1.89	2.48	4.1	
		Week 20	Tezepelumab	45	40 (88.9)	1.96 (0.60)	1.0	1.46	1.84	2.42	3.2	
			Placebo	47	43 (91.5)	1.97 (0.66)	0.7	1.39	1.98	2.33	3.4	
		Week 28	Tezepelumab	45	40 (88.9)	1.91 (0.63)	1.0	1.39	1.81	2.29	3.5	
			Placebo	47	46 (97.9)	1.95 (0.69)	0.8	1.54	1.92	2.33	3.4	
		Week 40	Tezepelumab	45	40 (88.9)	1.93 (0.65)	0.7	1.39	1.89	2.37	3.2	
			Placebo	47	45 (95.7)	2.02 (0.72)	0.6	1.52	1.89	2.44	4.0	
		Week 52	Tezepelumab	45	37 (82.2)	2.00 (0.59)	1.1	1.58	1.95	2.34	3.3	
			Placebo	47	45 (95.7)	1.94 (0.70)	0.8	1.42	1.75	2.31	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	45	43 (95.6)	0.18 (0.42)	-0.6	-0.02	0.13	0.38	2.1	0.37 [-0.05, 0.79]
			Placebo	47	46 (97.9)	0.02 (0.42)	-1.1	-0.13	0.03	0.22	1.1	
		Week 8	Tezepelumab	45	40 (88.9)	0.20 (0.44)	-0.7	-0.03	0.17	0.35	2.2	0.41 [-0.02, 0.84]
			Placebo	47	45 (95.7)	0.02 (0.42)	-0.9	-0.17	-0.01	0.22	1.3	
		Week 12	Tezepelumab	45	39 (86.7)	0.20 (0.44)	-0.6	-0.08	0.06	0.41	1.9	0.30 [-0.13, 0.73]
			Placebo	47	46 (97.9)	0.07 (0.48)	-1.2	-0.18	0.03	0.30	1.3	
		Week 20	Tezepelumab	45	40 (88.9)	0.19 (0.42)	-0.5	-0.08	0.15	0.37	1.9	0.41 [-0.03, 0.84]
			Placebo	47	43 (91.5)	0.02 (0.42)	-1.0	-0.21	0.03	0.23	1.5	
		Week 28	Tezepelumab	45	40 (88.9)	0.15 (0.47)	-1.0	-0.11	0.08	0.34	1.9	0.34 [-0.08, 0.77]
			Placebo	47	46 (97.9)	-0.01 (0.44)	-1.1	-0.21	0.02	0.21	1.5	
		Week 40	Tezepelumab	45	40 (88.9)	0.17 (0.47)	-0.7	-0.07	0.13	0.44	1.9	0.29 [-0.14, 0.71]
			Placebo	47	45 (95.7)	0.04 (0.43)	-1.3	-0.17	0.04	0.30	0.9	
		Week 52	Tezepelumab	45	37 (82.2)	0.21 (0.44)	-0.7	-0.03	0.11	0.40	2.0	0.49 [0.05, 0.93]
			Placebo	47	45 (95.7)	0.00 (0.41)	-0.9	-0.20	0.01	0.24	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	53	53 (100.0)	1.84 (0.59)	1.1	1.40	1.69	2.08	3.9	
			Placebo	47	47 (100.0)	1.60 (0.44)	0.8	1.31	1.50	1.93	2.7	
		Week 4	Tezepelumab	53	50 (94.3)	2.00 (0.75)	0.9	1.46	1.80	2.39	4.9	
			Placebo	47	47 (100.0)	1.70 (0.54)	0.8	1.33	1.63	2.09	3.0	
		Week 8	Tezepelumab	53	48 (90.6)	2.00 (0.74)	1.0	1.48	1.83	2.31	5.1	
			Placebo	47	45 (95.7)	1.76 (0.50)	0.8	1.48	1.69	2.18	2.8	
		Week 12	Tezepelumab	53	50 (94.3)	2.09 (0.74)	1.1	1.51	1.95	2.55	5.1	
			Placebo	47	46 (97.9)	1.71 (0.51)	0.6	1.37	1.69	2.11	2.8	
		Week 20	Tezepelumab	53	44 (83.0)	1.99 (0.82)	1.0	1.47	1.77	2.46	5.5	
			Placebo	47	45 (95.7)	1.69 (0.52)	0.6	1.27	1.68	1.96	2.9	
		Week 28	Tezepelumab	53	46 (86.8)	2.00 (0.80)	0.9	1.42	1.80	2.42	5.4	
			Placebo	47	42 (89.4)	1.69 (0.49)	0.8	1.41	1.64	2.05	2.8	
		Week 40	Tezepelumab	53	45 (84.9)	2.02 (0.77)	0.9	1.45	1.90	2.44	4.7	
			Placebo	47	43 (91.5)	1.68 (0.50)	0.8	1.37	1.62	2.02	2.8	
		Week 52	Tezepelumab	53	45 (84.9)	1.94 (0.75)	0.9	1.36	1.80	2.25	4.7	
			Placebo	47	41 (87.2)	1.71 (0.58)	0.7	1.38	1.64	2.09	3.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	53	50 (94.3)	0.17 (0.32)	-0.6	-0.04	0.10	0.32	1.1	0.23 [-0.17, 0.63]
			Placebo	47	47 (100.0)	0.10 (0.33)	-0.7	-0.10	0.06	0.19	1.0	
		Week 8	Tezepelumab	53	48 (90.6)	0.17 (0.33)	-0.5	-0.04	0.10	0.33	1.2	0.03 [-0.38, 0.44]
			Placebo	47	45 (95.7)	0.16 (0.29)	-0.5	-0.01	0.15	0.27	1.0	
		Week 12	Tezepelumab	53	50 (94.3)	0.23 (0.42)	-0.5	-0.08	0.14	0.42	1.3	0.30 [-0.11, 0.70]
			Placebo	47	46 (97.9)	0.12 (0.33)	-0.8	-0.03	0.08	0.23	1.2	
		Week 20	Tezepelumab	53	44 (83.0)	0.19 (0.44)	-0.6	-0.09	0.07	0.50	1.5	0.25 [-0.16, 0.67]
			Placebo	47	45 (95.7)	0.10 (0.28)	-0.6	-0.03	0.09	0.24	1.0	
		Week 28	Tezepelumab	53	46 (86.8)	0.19 (0.44)	-0.6	-0.12	0.04	0.37	1.5	0.26 [-0.16, 0.68]
			Placebo	47	42 (89.4)	0.10 (0.25)	-0.4	-0.04	0.04	0.27	0.8	
		Week 40	Tezepelumab	53	45 (84.9)	0.20 (0.42)	-0.5	-0.08	0.12	0.40	1.1	0.23 [-0.19, 0.65]
			Placebo	47	43 (91.5)	0.12 (0.28)	-0.5	-0.07	0.08	0.26	1.0	
		Week 52	Tezepelumab	53	45 (84.9)	0.13 (0.40)	-0.8	-0.15	0.11	0.28	1.1	0.09 [-0.34, 0.51]
			Placebo	47	41 (87.2)	0.10 (0.32)	-0.5	-0.07	0.05	0.20	1.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	1.96 (0.57)	1.0	1.45	2.08	2.36	3.1	
			Placebo	33	33 (100.0)	1.83 (0.63)	0.8	1.45	1.64	2.38	3.2	
		Week 4	Tezepelumab	27	27 (100.0)	2.04 (0.59)	1.1	1.50	2.10	2.40	3.3	
			Placebo	33	31 (93.9)	1.92 (0.64)	0.7	1.48	1.81	2.39	3.2	
		Week 8	Tezepelumab	27	26 (96.3)	2.06 (0.59)	1.3	1.55	2.04	2.32	3.4	
			Placebo	33	32 (97.0)	1.97 (0.71)	0.7	1.56	1.89	2.44	3.6	
		Week 12	Tezepelumab	27	26 (96.3)	1.95 (0.62)	1.0	1.48	1.90	2.22	3.5	
			Placebo	33	33 (100.0)	1.87 (0.65)	0.7	1.46	1.76	2.40	3.1	
		Week 20	Tezepelumab	27	24 (88.9)	1.92 (0.59)	1.0	1.47	1.82	2.36	3.5	
			Placebo	33	32 (97.0)	1.94 (0.72)	0.8	1.44	1.82	2.56	3.4	
		Week 28	Tezepelumab	27	25 (92.6)	1.87 (0.60)	0.9	1.40	1.87	2.15	3.4	
			Placebo	33	31 (93.9)	1.91 (0.75)	0.7	1.41	1.74	2.37	3.4	
		Week 40	Tezepelumab	27	25 (92.6)	1.92 (0.65)	1.1	1.43	1.90	2.13	3.5	
			Placebo	33	31 (93.9)	1.95 (0.72)	0.7	1.43	1.71	2.69	3.4	
		Week 52	Tezepelumab	27	24 (88.9)	1.85 (0.64)	1.2	1.35	1.82	2.05	3.5	
			Placebo	33	31 (93.9)	1.92 (0.69)	0.7	1.50	1.74	2.63	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	27	27 (100.0)	0.07 (0.27)	-0.6	-0.08	0.07	0.23	0.6	-0.12 [-0.63, 0.40]
			Placebo	33	31 (93.9)	0.11 (0.35)	-0.5	-0.08	0.07	0.17	1.2	
		Week 8	Tezepelumab	27	26 (96.3)	0.06 (0.24)	-0.5	-0.10	-0.01	0.31	0.6	-0.19 [-0.71, 0.33]
			Placebo	33	32 (97.0)	0.12 (0.35)	-0.4	-0.08	0.00	0.26	1.3	
		Week 12	Tezepelumab	27	26 (96.3)	0.02 (0.27)	-0.6	-0.16	0.02	0.18	0.5	-0.07 [-0.58, 0.45]
			Placebo	33	33 (100.0)	0.04 (0.37)	-0.9	-0.11	0.04	0.16	1.1	
		Week 20	Tezepelumab	27	24 (88.9)	0.00 (0.28)	-0.6	-0.12	-0.05	0.15	0.6	-0.30 [-0.84, 0.23]
			Placebo	33	32 (97.0)	0.10 (0.36)	-0.8	-0.03	0.08	0.25	1.5	
		Week 28	Tezepelumab	27	25 (92.6)	-0.02 (0.35)	-0.9	-0.16	-0.10	0.01	1.1	-0.26 [-0.79, 0.27]
			Placebo	33	31 (93.9)	0.07 (0.34)	-0.5	-0.14	0.01	0.22	1.5	
		Week 40	Tezepelumab	27	25 (92.6)	0.03 (0.38)	-0.7	-0.21	0.05	0.22	0.8	-0.34 [-0.87, 0.20]
			Placebo	33	31 (93.9)	0.14 (0.24)	-0.3	-0.07	0.09	0.26	0.9	
		Week 52	Tezepelumab	27	24 (88.9)	-0.03 (0.37)	-0.8	-0.26	-0.07	0.13	1.1	-0.32 [-0.86, 0.21]
			Placebo	33	31 (93.9)	0.08 (0.32)	-0.4	-0.13	0.04	0.24	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	109	109 (100.0)	1.80 (0.58)	0.7	1.37	1.73	2.17	3.9	
			Placebo	105	105 (100.0)	1.82 (0.58)	0.7	1.41	1.72	2.18	3.3	
		Week 4	Tezepelumab	109	103 (94.5)	2.05 (0.78)	0.9	1.51	1.95	2.47	4.9	
			Placebo	105	105 (100.0)	1.85 (0.60)	0.7	1.47	1.82	2.27	3.2	
		Week 8	Tezepelumab	109	97 (89.0)	2.03 (0.68)	0.7	1.51	1.97	2.44	5.1	
			Placebo	105	100 (95.2)	1.90 (0.59)	0.7	1.48	1.90	2.32	3.4	
		Week 12	Tezepelumab	109	101 (92.7)	2.12 (0.74)	0.9	1.52	2.03	2.55	5.1	
			Placebo	105	102 (97.1)	1.91 (0.66)	0.5	1.44	1.86	2.38	4.1	
		Week 20	Tezepelumab	109	94 (86.2)	2.07 (0.76)	1.0	1.51	1.92	2.58	5.5	
			Placebo	105	99 (94.3)	1.89 (0.61)	0.5	1.44	1.90	2.30	3.1	
		Week 28	Tezepelumab	109	98 (89.9)	2.08 (0.78)	0.8	1.49	2.01	2.54	5.4	
			Placebo	105	100 (95.2)	1.85 (0.63)	0.7	1.43	1.86	2.20	3.6	
		Week 40	Tezepelumab	109	96 (88.1)	2.08 (0.71)	0.7	1.47	2.12	2.56	4.7	
			Placebo	105	99 (94.3)	1.91 (0.67)	0.6	1.43	1.82	2.33	4.0	
		Week 52	Tezepelumab	109	94 (86.2)	2.06 (0.66)	0.9	1.58	2.04	2.41	4.7	
			Placebo	105	98 (93.3)	1.89 (0.70)	0.6	1.34	1.83	2.37	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	109	103 (94.5)	0.26 (0.47)	-0.6	-0.02	0.13	0.41	2.4	0.55 [0.27, 0.82]
			Placebo	105	105 (100.0)	0.03 (0.37)	-1.1	-0.12	0.03	0.20	1.1	
		Week 8	Tezepelumab	109	97 (89.0)	0.26 (0.43)	-0.7	0.02	0.19	0.43	2.2	0.43 [0.15, 0.72]
			Placebo	105	100 (95.2)	0.08 (0.39)	-1.5	-0.09	0.12	0.25	1.1	
		Week 12	Tezepelumab	109	101 (92.7)	0.31 (0.47)	-0.6	-0.03	0.21	0.51	2.1	0.46 [0.18, 0.74]
			Placebo	105	102 (97.1)	0.11 (0.41)	-1.2	-0.09	0.11	0.31	1.3	
		Week 20	Tezepelumab	109	94 (86.2)	0.28 (0.48)	-0.6	-0.03	0.20	0.49	2.2	0.46 [0.17, 0.74]
			Placebo	105	99 (94.3)	0.09 (0.37)	-1.0	-0.07	0.07	0.26	1.8	
		Week 28	Tezepelumab	109	98 (89.9)	0.29 (0.50)	-1.0	-0.05	0.21	0.54	2.2	0.57 [0.29, 0.85]
			Placebo	105	100 (95.2)	0.04 (0.37)	-1.1	-0.15	0.07	0.28	0.9	
		Week 40	Tezepelumab	109	96 (88.1)	0.29 (0.47)	-0.7	-0.01	0.26	0.50	2.3	0.47 [0.19, 0.76]
			Placebo	105	99 (94.3)	0.09 (0.40)	-1.3	-0.13	0.06	0.30	1.1	
		Week 52	Tezepelumab	109	94 (86.2)	0.27 (0.43)	-0.7	0.01	0.20	0.49	2.3	0.45 [0.17, 0.74]
			Placebo	105	98 (93.3)	0.08 (0.42)	-1.0	-0.16	0.06	0.25	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	69	69 (100.0)	1.93 (0.59)	0.7	1.45	1.98	2.37	3.3	
			Placebo	72	72 (100.0)	1.86 (0.62)	0.8	1.44	1.79	2.37	3.2	
		Week 4	Tezepelumab	69	66 (95.7)	2.09 (0.70)	0.9	1.53	2.03	2.45	4.5	
			Placebo	72	70 (97.2)	1.93 (0.63)	0.7	1.48	1.92	2.40	3.2	
		Week 8	Tezepelumab	69	62 (89.9)	2.04 (0.59)	0.7	1.55	2.01	2.44	3.4	
			Placebo	72	68 (94.4)	1.96 (0.67)	0.7	1.54	1.96	2.43	3.6	
		Week 12	Tezepelumab	69	64 (92.8)	2.08 (0.67)	1.0	1.54	2.03	2.49	4.6	
			Placebo	72	70 (97.2)	1.92 (0.63)	0.7	1.44	1.85	2.48	3.3	
		Week 20	Tezepelumab	69	59 (85.5)	2.03 (0.66)	1.0	1.47	1.93	2.52	4.1	
			Placebo	72	68 (94.4)	1.97 (0.69)	0.5	1.46	1.98	2.50	3.4	
		Week 28	Tezepelumab	69	61 (88.4)	2.00 (0.69)	0.9	1.42	1.95	2.38	4.6	
			Placebo	72	67 (93.1)	1.91 (0.69)	0.7	1.44	1.94	2.38	3.4	
		Week 40	Tezepelumab	69	59 (85.5)	2.05 (0.66)	1.0	1.45	1.98	2.53	3.6	
			Placebo	72	66 (91.7)	1.99 (0.69)	0.7	1.50	1.90	2.59	3.5	
		Week 52	Tezepelumab	69	58 (84.1)	1.97 (0.61)	1.1	1.44	1.91	2.34	3.5	
			Placebo	72	67 (93.1)	1.92 (0.67)	0.6	1.40	1.93	2.51	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	69	66 (95.7)	0.14 (0.31)	-0.6	-0.03	0.10	0.31	1.4	0.18 [-0.16, 0.52]
			Placebo	72	70 (97.2)	0.09 (0.34)	-1.0	-0.10	0.03	0.18	1.2	
		Week 8	Tezepelumab	69	62 (89.9)	0.11 (0.25)	-0.5	-0.05	0.08	0.31	0.8	0.02 [-0.33, 0.36]
			Placebo	72	68 (94.4)	0.10 (0.42)	-1.5	-0.08	0.12	0.25	1.3	
		Week 12	Tezepelumab	69	64 (92.8)	0.15 (0.37)	-0.6	-0.11	0.09	0.34	1.5	0.23 [-0.11, 0.57]
			Placebo	72	70 (97.2)	0.07 (0.36)	-0.9	-0.10	0.05	0.26	1.2	
		Week 20	Tezepelumab	69	59 (85.5)	0.10 (0.33)	-0.6	-0.09	0.06	0.31	1.1	-0.08 [-0.43, 0.27]
			Placebo	72	68 (94.4)	0.13 (0.37)	-0.8	-0.03	0.07	0.23	1.8	
		Week 28	Tezepelumab	69	61 (88.4)	0.08 (0.38)	-0.9	-0.13	0.01	0.21	1.5	0.04 [-0.30, 0.39]
			Placebo	72	67 (93.1)	0.06 (0.34)	-1.1	-0.14	0.03	0.22	1.5	
		Week 40	Tezepelumab	69	59 (85.5)	0.14 (0.35)	-0.7	-0.07	0.13	0.35	1.1	0.00 [-0.35, 0.35]
			Placebo	72	66 (91.7)	0.14 (0.30)	-0.5	-0.08	0.07	0.30	1.0	
		Week 52	Tezepelumab	69	58 (84.1)	0.05 (0.32)	-0.8	-0.14	0.03	0.18	1.1	-0.07 [-0.42, 0.28]
			Placebo	72	67 (93.1)	0.07 (0.37)	-1.0	-0.12	0.05	0.19	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	67	67 (100.0)	1.73 (0.56)	0.7	1.32	1.67	2.12	3.9	
			Placebo	66	66 (100.0)	1.78 (0.54)	0.7	1.41	1.70	2.18	3.3	
		Week 4	Tezepelumab	67	64 (95.5)	2.00 (0.79)	0.9	1.37	1.92	2.41	4.9	
			Placebo	66	66 (100.0)	1.80 (0.59)	0.7	1.47	1.77	2.20	3.2	
		Week 8	Tezepelumab	67	61 (91.0)	2.04 (0.73)	1.0	1.49	1.96	2.38	5.1	
			Placebo	66	64 (97.0)	1.87 (0.57)	0.7	1.48	1.83	2.25	3.1	
		Week 12	Tezepelumab	67	63 (94.0)	2.09 (0.77)	0.9	1.51	1.96	2.58	5.1	
			Placebo	66	65 (98.5)	1.88 (0.68)	0.5	1.48	1.81	2.34	4.1	
		Week 20	Tezepelumab	67	59 (88.1)	2.04 (0.80)	1.0	1.48	1.91	2.49	5.5	
			Placebo	66	63 (95.5)	1.82 (0.57)	0.6	1.39	1.72	2.19	3.1	
		Week 28	Tezepelumab	67	62 (92.5)	2.08 (0.80)	0.8	1.49	1.99	2.61	5.4	
			Placebo	66	64 (97.0)	1.82 (0.62)	0.8	1.39	1.77	2.15	3.6	
		Week 40	Tezepelumab	67	62 (92.5)	2.04 (0.75)	0.7	1.41	2.04	2.52	4.7	
			Placebo	66	64 (97.0)	1.86 (0.67)	0.6	1.39	1.70	2.21	4.0	
		Week 52	Tezepelumab	67	60 (89.6)	2.07 (0.71)	0.9	1.53	2.13	2.43	4.7	
			Placebo	66	62 (93.9)	1.87 (0.72)	0.7	1.34	1.70	2.29	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	67	64 (95.5)	0.30 (0.53)	-0.6	-0.01	0.16	0.52	2.4	0.63 [0.27, 0.98]
			Placebo	66	66 (100.0)	0.01 (0.39)	-1.1	-0.20	0.06	0.20	1.1	
		Week 8	Tezepelumab	67	61 (91.0)	0.33 (0.49)	-0.7	0.04	0.22	0.48	2.2	0.59 [0.23, 0.95]
			Placebo	66	64 (97.0)	0.08 (0.34)	-0.9	-0.09	0.08	0.26	0.9	
		Week 12	Tezepelumab	67	63 (94.0)	0.35 (0.50)	-0.6	-0.01	0.21	0.69	2.1	0.50 [0.14, 0.85]
			Placebo	66	65 (98.5)	0.12 (0.44)	-1.2	-0.09	0.13	0.32	1.3	
		Week 20	Tezepelumab	67	59 (88.1)	0.35 (0.54)	-0.5	-0.03	0.23	0.75	2.2	0.67 [0.30, 1.03]
			Placebo	66	63 (95.5)	0.05 (0.36)	-1.0	-0.13	0.07	0.26	1.0	
		Week 28	Tezepelumab	67	62 (92.5)	0.37 (0.54)	-1.0	0.00	0.27	0.73	2.2	0.74 [0.37, 1.10]
			Placebo	66	64 (97.0)	0.03 (0.39)	-1.1	-0.16	0.07	0.29	0.9	
		Week 40	Tezepelumab	67	62 (92.5)	0.34 (0.53)	-0.7	-0.02	0.30	0.66	2.3	0.57 [0.22, 0.93]
			Placebo	66	64 (97.0)	0.06 (0.43)	-1.3	-0.15	0.05	0.30	1.1	
		Week 52	Tezepelumab	67	60 (89.6)	0.37 (0.48)	-0.5	0.04	0.28	0.63	2.3	0.62 [0.25, 0.98]
			Placebo	66	62 (93.9)	0.08 (0.44)	-0.9	-0.16	0.06	0.35	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	78	78 (100.0)	1.80 (0.55)	0.7	1.37	1.79	2.20	3.3	
			Placebo	74	74 (100.0)	1.75 (0.58)	0.7	1.39	1.68	2.15	3.0	
		Week 4	Tezepelumab	78	75 (96.2)	1.96 (0.66)	0.9	1.41	1.89	2.29	3.8	
			Placebo	74	72 (97.3)	1.83 (0.62)	0.7	1.41	1.82	2.34	3.1	
		Week 8	Tezepelumab	78	71 (91.0)	1.96 (0.59)	0.7	1.41	1.98	2.37	3.5	
			Placebo	74	71 (95.9)	1.86 (0.66)	0.7	1.46	1.83	2.33	3.4	
		Week 12	Tezepelumab	78	73 (93.6)	2.00 (0.60)	0.9	1.49	1.96	2.40	3.5	
			Placebo	74	73 (98.6)	1.83 (0.64)	0.6	1.41	1.76	2.34	3.3	
		Week 20	Tezepelumab	78	68 (87.2)	1.93 (0.60)	1.0	1.44	1.87	2.45	3.3	
			Placebo	74	71 (95.9)	1.86 (0.65)	0.5	1.39	1.90	2.30	3.4	
		Week 28	Tezepelumab	78	71 (91.0)	1.94 (0.60)	0.9	1.42	1.90	2.38	3.4	
			Placebo	74	71 (95.9)	1.80 (0.63)	0.7	1.35	1.75	2.17	3.4	
		Week 40	Tezepelumab	78	70 (89.7)	1.97 (0.66)	0.7	1.41	1.97	2.44	3.6	
			Placebo	74	71 (95.9)	1.84 (0.66)	0.7	1.35	1.73	2.41	3.5	
		Week 52	Tezepelumab	78	69 (88.5)	1.93 (0.59)	0.9	1.42	1.88	2.35	3.3	
			Placebo	74	70 (94.6)	1.82 (0.66)	0.6	1.34	1.72	2.27	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	78	75 (96.2)	0.17 (0.40)	-0.6	-0.04	0.10	0.31	2.1	0.19 [-0.13, 0.52]
			Placebo	74	72 (97.3)	0.09 (0.33)	-0.7	-0.08	0.05	0.21	1.1	
		Week 8	Tezepelumab	78	71 (91.0)	0.15 (0.36)	-0.7	-0.04	0.10	0.31	2.2	0.09 [-0.24, 0.42]
			Placebo	74	71 (95.9)	0.12 (0.38)	-0.8	-0.09	0.07	0.21	1.3	
		Week 12	Tezepelumab	78	73 (93.6)	0.18 (0.42)	-0.6	-0.08	0.09	0.33	1.9	0.24 [-0.09, 0.56]
			Placebo	74	73 (98.6)	0.09 (0.37)	-0.9	-0.06	0.06	0.23	1.3	
		Week 20	Tezepelumab	78	68 (87.2)	0.15 (0.41)	-0.6	-0.10	0.12	0.37	1.9	0.10 [-0.23, 0.43]
			Placebo	74	71 (95.9)	0.11 (0.41)	-0.9	-0.04	0.04	0.26	1.8	
		Week 28	Tezepelumab	78	71 (91.0)	0.16 (0.43)	-0.9	-0.12	0.06	0.37	1.9	0.27 [-0.06, 0.60]
			Placebo	74	71 (95.9)	0.05 (0.38)	-1.1	-0.14	0.03	0.22	1.5	
		Week 40	Tezepelumab	78	70 (89.7)	0.19 (0.44)	-0.7	-0.05	0.16	0.38	1.9	0.29 [-0.04, 0.62]
			Placebo	74	71 (95.9)	0.08 (0.35)	-1.3	-0.10	0.09	0.28	1.0	
		Week 52	Tezepelumab	78	69 (88.5)	0.13 (0.40)	-0.8	-0.05	0.11	0.28	2.0	0.15 [-0.19, 0.48]
			Placebo	74	70 (94.6)	0.08 (0.38)	-1.0	-0.11	0.05	0.19	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	1.87 (0.64)	0.7	1.38	1.75	2.31	3.9	
			Placebo	63	63 (100.0)	1.90 (0.60)	1.0	1.45	1.74	2.26	3.3	
		Week 4	Tezepelumab	57	54 (94.7)	2.17 (0.84)	0.9	1.62	2.01	2.71	4.9	
			Placebo	63	63 (100.0)	1.90 (0.60)	0.7	1.55	1.81	2.26	3.2	
		Week 8	Tezepelumab	57	51 (89.5)	2.15 (0.75)	1.1	1.58	2.07	2.57	5.1	
			Placebo	63	60 (95.2)	1.97 (0.58)	0.8	1.55	1.95	2.36	3.6	
		Week 12	Tezepelumab	57	53 (93.0)	2.20 (0.85)	0.9	1.61	2.00	2.68	5.1	
			Placebo	63	61 (96.8)	1.97 (0.67)	0.5	1.53	1.85	2.45	4.1	
		Week 20	Tezepelumab	57	49 (86.0)	2.19 (0.87)	1.0	1.55	1.92	2.79	5.5	
			Placebo	63	59 (93.7)	1.94 (0.62)	0.7	1.50	1.86	2.33	3.3	
		Week 28	Tezepelumab	57	51 (89.5)	2.19 (0.90)	0.8	1.49	2.06	2.77	5.4	
			Placebo	63	59 (93.7)	1.94 (0.68)	0.8	1.53	1.90	2.38	3.6	
		Week 40	Tezepelumab	57	50 (87.7)	2.16 (0.75)	1.0	1.59	2.16	2.65	4.7	
			Placebo	63	58 (92.1)	2.02 (0.70)	0.6	1.52	1.96	2.35	4.0	
		Week 52	Tezepelumab	57	48 (84.2)	2.15 (0.75)	1.1	1.61	2.11	2.48	4.7	
			Placebo	63	58 (92.1)	1.98 (0.73)	0.7	1.38	2.01	2.51	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	57	54 (94.7)	0.30 (0.48)	-0.5	0.00	0.19	0.47	2.4	0.72 [0.34, 1.09]
			Placebo	63	63 (100.0)	-0.01 (0.39)	-1.1	-0.19	0.01	0.17	1.2	
		Week 8	Tezepelumab	57	51 (89.5)	0.31 (0.44)	-0.5	0.04	0.26	0.48	2.2	0.63 [0.24, 1.01]
			Placebo	63	60 (95.2)	0.05 (0.39)	-1.5	-0.13	0.14	0.27	0.9	
		Week 12	Tezepelumab	57	53 (93.0)	0.35 (0.48)	-0.3	-0.03	0.23	0.62	2.1	0.56 [0.18, 0.93]
			Placebo	63	61 (96.8)	0.09 (0.44)	-1.2	-0.14	0.11	0.31	1.2	
		Week 20	Tezepelumab	57	49 (86.0)	0.34 (0.51)	-0.4	-0.01	0.22	0.62	2.2	0.67 [0.28, 1.06]
			Placebo	63	59 (93.7)	0.06 (0.31)	-1.0	-0.08	0.10	0.24	0.7	
		Week 28	Tezepelumab	57	51 (89.5)	0.33 (0.55)	-1.0	0.00	0.21	0.73	2.2	0.65 [0.27, 1.04]
			Placebo	63	59 (93.7)	0.04 (0.35)	-1.1	-0.18	0.08	0.27	0.9	
		Week 40	Tezepelumab	57	50 (87.7)	0.32 (0.49)	-0.7	-0.02	0.30	0.66	2.3	0.43 [0.05, 0.81]
			Placebo	63	58 (92.1)	0.13 (0.40)	-1.1	-0.11	0.05	0.31	1.1	
		Week 52	Tezepelumab	57	48 (84.2)	0.32 (0.46)	-0.4	0.01	0.18	0.64	2.3	0.55 [0.16, 0.94]
			Placebo	63	58 (92.1)	0.07 (0.43)	-0.9	-0.20	0.04	0.32	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	1.75 (0.54)	0.7	1.33	1.66	2.15	3.1	
			Placebo	66	66 (100.0)	1.83 (0.63)	0.7	1.41	1.69	2.27	3.2	
		Week 4	Tezepelumab	57	56 (98.2)	1.96 (0.65)	0.9	1.46	1.89	2.30	3.8	
			Placebo	66	65 (98.5)	1.86 (0.68)	0.7	1.42	1.72	2.39	3.2	
		Week 8	Tezepelumab	57	53 (93.0)	1.98 (0.57)	0.7	1.49	1.98	2.37	3.4	
			Placebo	66	63 (95.5)	1.89 (0.68)	0.7	1.28	1.87	2.41	3.6	
		Week 12	Tezepelumab	57	53 (93.0)	2.02 (0.63)	1.1	1.51	1.96	2.54	3.5	
			Placebo	66	66 (100.0)	1.88 (0.70)	0.5	1.41	1.81	2.48	4.1	
		Week 20	Tezepelumab	57	49 (86.0)	1.94 (0.55)	1.0	1.47	1.92	2.46	2.9	
			Placebo	66	65 (98.5)	1.90 (0.68)	0.5	1.48	1.86	2.39	3.3	
		Week 28	Tezepelumab	57	52 (91.2)	1.93 (0.65)	0.9	1.39	1.90	2.46	3.4	
			Placebo	66	64 (97.0)	1.84 (0.64)	0.7	1.33	1.90	2.26	3.3	
		Week 40	Tezepelumab	57	52 (91.2)	1.92 (0.63)	0.7	1.41	1.96	2.45	3.0	
			Placebo	66	65 (98.5)	1.92 (0.75)	0.6	1.33	1.82	2.46	4.0	
		Week 52	Tezepelumab	57	48 (84.2)	1.95 (0.63)	1.0	1.37	1.92	2.37	3.3	
			Placebo	66	62 (93.9)	1.90 (0.71)	0.6	1.35	1.88	2.44	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	57	56 (98.2)	0.20 (0.38)	-0.6	0.01	0.16	0.37	1.7	0.42 [0.06, 0.78]
			Placebo	66	65 (98.5)	0.04 (0.38)	-1.1	-0.13	0.01	0.18	1.0	
		Week 8	Tezepelumab	57	53 (93.0)	0.22 (0.31)	-0.5	0.02	0.17	0.40	1.1	0.46 [0.09, 0.83]
			Placebo	66	63 (95.5)	0.05 (0.42)	-1.5	-0.09	0.05	0.26	1.1	
		Week 12	Tezepelumab	57	53 (93.0)	0.26 (0.40)	-0.6	-0.03	0.21	0.49	1.2	0.52 [0.15, 0.88]
			Placebo	66	66 (100.0)	0.05 (0.40)	-1.2	-0.09	0.05	0.28	1.2	
		Week 20	Tezepelumab	57	49 (86.0)	0.23 (0.36)	-0.4	-0.06	0.19	0.48	1.0	0.44 [0.07, 0.82]
			Placebo	66	65 (98.5)	0.08 (0.33)	-1.0	-0.07	0.04	0.29	1.0	
		Week 28	Tezepelumab	57	52 (91.2)	0.20 (0.44)	-0.9	-0.08	0.08	0.53	1.2	0.43 [0.06, 0.80]
			Placebo	66	64 (97.0)	0.02 (0.38)	-1.1	-0.14	0.04	0.27	0.8	
		Week 40	Tezepelumab	57	52 (91.2)	0.19 (0.41)	-0.7	-0.04	0.15	0.39	1.1	0.21 [-0.16, 0.58]
			Placebo	66	65 (98.5)	0.10 (0.42)	-1.3	-0.11	0.10	0.35	1.1	
		Week 52	Tezepelumab	57	48 (84.2)	0.21 (0.39)	-0.8	-0.04	0.17	0.38	1.1	0.30 [-0.08, 0.68]
			Placebo	66	62 (93.9)	0.08 (0.43)	-1.0	-0.15	0.03	0.29	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	71	71 (100.0)	1.89 (0.61)	0.7	1.40	1.79	2.31	3.9	
			Placebo	63	63 (100.0)	1.82 (0.58)	0.8	1.41	1.72	2.18	3.3	
		Week 4	Tezepelumab	71	66 (93.0)	2.11 (0.82)	0.9	1.53	1.92	2.67	4.9	
			Placebo	63	63 (100.0)	1.87 (0.56)	0.8	1.52	1.86	2.26	3.2	
		Week 8	Tezepelumab	71	64 (90.1)	2.10 (0.74)	1.1	1.55	2.00	2.49	5.1	
			Placebo	63	60 (95.2)	1.93 (0.57)	0.8	1.56	1.90	2.29	3.4	
		Week 12	Tezepelumab	71	66 (93.0)	2.10 (0.79)	0.9	1.51	1.95	2.44	5.1	
			Placebo	63	60 (95.2)	1.93 (0.61)	0.6	1.52	1.85	2.35	3.6	
		Week 20	Tezepelumab	71	62 (87.3)	2.11 (0.85)	1.0	1.51	1.87	2.75	5.5	
			Placebo	63	58 (92.1)	1.89 (0.59)	0.6	1.40	1.87	2.26	3.1	
		Week 28	Tezepelumab	71	64 (90.1)	2.12 (0.83)	0.8	1.51	2.03	2.61	5.4	
			Placebo	63	58 (92.1)	1.89 (0.69)	0.8	1.41	1.74	2.37	3.6	
		Week 40	Tezepelumab	71	62 (87.3)	2.13 (0.76)	1.0	1.59	2.04	2.65	4.7	
			Placebo	63	56 (88.9)	1.93 (0.63)	0.8	1.49	1.79	2.34	3.5	
		Week 52	Tezepelumab	71	63 (88.7)	2.07 (0.70)	0.9	1.62	1.94	2.44	4.7	
			Placebo	63	58 (92.1)	1.88 (0.69)	0.7	1.38	1.78	2.31	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	71	66 (93.0)	0.23 (0.49)	-0.6	-0.02	0.10	0.37	2.4	0.44 [0.09, 0.79]
			Placebo	63	63 (100.0)	0.04 (0.35)	-1.1	-0.12	0.05	0.19	1.2	
		Week 8	Tezepelumab	71	64 (90.1)	0.22 (0.48)	-0.7	-0.04	0.16	0.42	2.2	0.28 [-0.07, 0.63]
			Placebo	63	60 (95.2)	0.11 (0.33)	-0.5	-0.08	0.12	0.24	1.0	
		Week 12	Tezepelumab	71	66 (93.0)	0.21 (0.49)	-0.6	-0.08	0.09	0.32	2.1	0.18 [-0.17, 0.53]
			Placebo	63	60 (95.2)	0.13 (0.40)	-0.9	-0.09	0.11	0.31	1.3	
		Week 20	Tezepelumab	71	62 (87.3)	0.22 (0.54)	-0.6	-0.09	0.11	0.38	2.2	0.28 [-0.08, 0.64]
			Placebo	63	58 (92.1)	0.08 (0.39)	-0.8	-0.06	0.09	0.23	1.8	
		Week 28	Tezepelumab	71	64 (90.1)	0.23 (0.55)	-1.0	-0.12	0.14	0.47	2.2	0.40 [0.04, 0.76]
			Placebo	63	58 (92.1)	0.05 (0.31)	-0.9	-0.13	0.07	0.23	0.9	
		Week 40	Tezepelumab	71	62 (87.3)	0.26 (0.51)	-0.7	-0.07	0.21	0.50	2.3	0.40 [0.04, 0.77]
			Placebo	63	56 (88.9)	0.09 (0.32)	-0.8	-0.10	0.06	0.25	1.0	
		Week 52	Tezepelumab	71	63 (88.7)	0.21 (0.49)	-0.7	-0.04	0.10	0.44	2.3	0.38 [0.02, 0.74]
			Placebo	63	58 (92.1)	0.04 (0.35)	-0.9	-0.15	0.06	0.18	1.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	35	35 (100.0)	1.73 (0.56)	0.7	1.37	1.60	2.15	3.1	
			Placebo	32	32 (100.0)	1.68 (0.53)	0.8	1.34	1.64	1.98	2.9	
		Week 4	Tezepelumab	35	35 (100.0)	1.85 (0.58)	0.9	1.42	1.70	2.26	3.3	
			Placebo	32	31 (96.9)	1.75 (0.70)	0.7	1.17	1.73	2.30	3.1	
		Week 8	Tezepelumab	35	34 (97.1)	1.93 (0.56)	1.0	1.44	1.89	2.36	3.4	
			Placebo	32	31 (96.9)	1.76 (0.68)	0.7	1.20	1.69	2.31	3.3	
		Week 12	Tezepelumab	35	33 (94.3)	1.92 (0.62)	1.0	1.47	1.76	2.37	3.5	
			Placebo	32	32 (100.0)	1.74 (0.65)	0.5	1.26	1.67	2.27	3.1	
		Week 20	Tezepelumab	35	31 (88.6)	1.84 (0.56)	1.0	1.39	1.75	2.30	2.9	
			Placebo	32	31 (96.9)	1.76 (0.69)	0.5	1.24	1.72	2.12	3.4	
		Week 28	Tezepelumab	35	31 (88.6)	1.80 (0.57)	0.9	1.33	1.70	2.29	3.0	
			Placebo	32	31 (96.9)	1.67 (0.65)	0.7	1.16	1.66	2.01	3.4	
		Week 40	Tezepelumab	35	31 (88.6)	1.89 (0.60)	0.9	1.41	1.84	2.36	3.0	
			Placebo	32	30 (93.8)	1.75 (0.66)	0.6	1.25	1.67	2.18	3.2	
		Week 52	Tezepelumab	35	29 (82.9)	1.85 (0.54)	1.0	1.36	1.80	2.25	2.9	
			Placebo	32	30 (93.8)	1.72 (0.67)	0.6	1.19	1.69	2.06	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	35	35 (100.0)	0.12 (0.30)	-0.6	0.02	0.07	0.26	0.8	0.12 [-0.36, 0.61]
			Placebo	32	31 (96.9)	0.08 (0.35)	-1.1	-0.08	0.09	0.27	0.8	
		Week 8	Tezepelumab	35	34 (97.1)	0.17 (0.27)	-0.5	-0.01	0.21	0.36	0.8	0.31 [-0.18, 0.80]
			Placebo	32	31 (96.9)	0.07 (0.38)	-0.9	-0.11	0.11	0.27	1.3	
		Week 12	Tezepelumab	35	33 (94.3)	0.19 (0.38)	-0.6	-0.04	0.09	0.41	1.3	0.33 [-0.16, 0.82]
			Placebo	32	32 (100.0)	0.06 (0.37)	-1.2	-0.08	0.10	0.29	1.1	
		Week 20	Tezepelumab	35	31 (88.6)	0.15 (0.36)	-0.6	-0.09	0.06	0.43	0.9	0.18 [-0.31, 0.68]
			Placebo	32	31 (96.9)	0.08 (0.42)	-1.0	-0.15	0.06	0.29	1.5	
		Week 28	Tezepelumab	35	31 (88.6)	0.12 (0.39)	-0.9	-0.06	0.04	0.30	0.9	0.29 [-0.21, 0.79]
			Placebo	32	31 (96.9)	-0.01 (0.46)	-1.1	-0.19	-0.01	0.28	1.5	
		Week 40	Tezepelumab	35	31 (88.6)	0.21 (0.41)	-0.7	-0.08	0.22	0.47	1.1	0.38 [-0.13, 0.89]
			Placebo	32	30 (93.8)	0.05 (0.41)	-1.1	-0.17	0.09	0.30	0.9	
		Week 52	Tezepelumab	35	29 (82.9)	0.14 (0.32)	-0.5	-0.05	0.09	0.30	0.9	0.32 [-0.19, 0.84]
			Placebo	32	30 (93.8)	0.02 (0.44)	-1.0	-0.23	0.04	0.29	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	95	95 (100.0)	1.86 (0.59)	0.7	1.38	1.79	2.21	3.9	
			Placebo	98	98 (100.0)	1.85 (0.60)	0.7	1.45	1.72	2.21	3.3	
		Week 4	Tezepelumab	95	90 (94.7)	2.13 (0.79)	0.9	1.58	2.04	2.68	4.9	
			Placebo	98	97 (99.0)	1.88 (0.57)	0.8	1.55	1.82	2.27	3.2	
		Week 8	Tezepelumab	95	84 (88.4)	2.09 (0.71)	0.7	1.57	2.01	2.56	5.1	
			Placebo	98	93 (94.9)	1.94 (0.59)	0.7	1.54	1.94	2.35	3.6	
		Week 12	Tezepelumab	95	88 (92.6)	2.16 (0.76)	0.9	1.62	2.04	2.62	5.1	
			Placebo	98	95 (96.9)	1.93 (0.63)	0.6	1.51	1.85	2.44	4.1	
		Week 20	Tezepelumab	95	82 (86.3)	2.12 (0.79)	1.0	1.52	1.93	2.66	5.5	
			Placebo	98	92 (93.9)	1.92 (0.60)	0.6	1.51	1.92	2.31	3.3	
		Week 28	Tezepelumab	95	88 (92.6)	2.13 (0.79)	0.8	1.51	2.02	2.64	5.4	
			Placebo	98	92 (93.9)	1.90 (0.63)	0.8	1.49	1.92	2.30	3.6	
		Week 40	Tezepelumab	95	86 (90.5)	2.10 (0.74)	0.7	1.50	2.04	2.65	4.7	
			Placebo	98	92 (93.9)	1.95 (0.65)	0.8	1.47	1.83	2.40	4.0	
		Week 52	Tezepelumab	95	84 (88.4)	2.08 (0.71)	0.9	1.57	1.96	2.44	4.7	
			Placebo	98	91 (92.9)	1.93 (0.66)	0.7	1.42	1.93	2.44	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	95	90 (94.7)	0.28 (0.48)	-0.5	-0.02	0.16	0.41	2.4	0.55 [0.26, 0.84]
			Placebo	98	97 (99.0)	0.04 (0.38)	-1.1	-0.12	0.03	0.17	1.2	
		Week 8	Tezepelumab	95	84 (88.4)	0.25 (0.44)	-0.5	-0.01	0.16	0.45	2.2	0.38 [0.09, 0.68]
			Placebo	98	93 (94.9)	0.09 (0.39)	-1.5	-0.06	0.10	0.24	1.1	
		Week 12	Tezepelumab	95	88 (92.6)	0.30 (0.47)	-0.5	-0.04	0.21	0.45	2.1	0.46 [0.16, 0.75]
			Placebo	98	95 (96.9)	0.10 (0.41)	-0.9	-0.11	0.07	0.31	1.3	
		Week 20	Tezepelumab	95	82 (86.3)	0.27 (0.49)	-0.6	-0.05	0.15	0.43	2.2	0.43 [0.13, 0.73]
			Placebo	98	92 (93.9)	0.08 (0.36)	-0.9	-0.06	0.05	0.23	1.8	
		Week 28	Tezepelumab	95	88 (92.6)	0.28 (0.52)	-1.0	-0.10	0.17	0.54	2.2	0.55 [0.25, 0.85]
			Placebo	98	92 (93.9)	0.04 (0.31)	-1.1	-0.10	0.03	0.22	0.8	
		Week 40	Tezepelumab	95	86 (90.5)	0.26 (0.47)	-0.7	-0.01	0.21	0.44	2.3	0.39 [0.09, 0.68]
			Placebo	98	92 (93.9)	0.10 (0.34)	-1.3	-0.08	0.06	0.28	1.1	
		Week 52	Tezepelumab	95	84 (88.4)	0.24 (0.46)	-0.8	-0.01	0.15	0.45	2.3	0.37 [0.07, 0.67]
			Placebo	98	91 (92.9)	0.09 (0.36)	-0.7	-0.12	0.05	0.23	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	1.97 (0.65)	1.2	1.24	1.93	2.70	2.7	
			Placebo	8	8 (100.0)	2.05 (0.65)	1.2	1.38	2.21	2.50	3.0	
		Week 4	Tezepelumab	7	6 (85.7)	1.84 (0.61)	1.3	1.37	1.58	2.45	2.7	
			Placebo	8	8 (100.0)	2.11 (0.68)	1.3	1.43	2.14	2.75	2.9	
		Week 8	Tezepelumab	7	6 (85.7)	1.87 (0.51)	1.3	1.48	1.82	2.32	2.5	
			Placebo	8	8 (100.0)	2.22 (0.73)	1.2	1.65	2.15	2.78	3.4	
		Week 12	Tezepelumab	7	7 (100.0)	1.87 (0.53)	1.3	1.33	1.93	2.53	2.5	
			Placebo	8	8 (100.0)	2.19 (0.84)	1.2	1.51	1.97	3.00	3.3	
		Week 20	Tezepelumab	7	6 (85.7)	1.84 (0.42)	1.4	1.46	1.78	2.26	2.4	
			Placebo	8	8 (100.0)	2.26 (0.70)	1.3	1.58	2.30	2.94	3.1	
		Week 28	Tezepelumab	7	5 (71.4)	1.80 (0.48)	1.3	1.39	1.69	2.15	2.4	
			Placebo	8	8 (100.0)	2.28 (0.82)	1.5	1.59	2.02	3.09	3.4	
		Week 40	Tezepelumab	7	5 (71.4)	1.93 (0.44)	1.4	1.66	1.90	2.16	2.5	
			Placebo	8	8 (100.0)	2.28 (0.90)	1.3	1.52	2.06	3.13	3.5	
		Week 52	Tezepelumab	7	6 (85.7)	1.90 (0.47)	1.3	1.45	1.97	2.28	2.5	
			Placebo	8	8 (100.0)	2.22 (1.01)	1.3	1.34	1.89	3.21	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	-0.01 (0.34)	-0.6	-0.05	0.07	0.13	0.4	-0.27 [-1.33, 0.80]
			Placebo	8	8 (100.0)	0.06 (0.21)	-0.3	-0.06	0.05	0.21	0.4	
		Week 8	Tezepelumab	7	6 (85.7)	0.03 (0.41)	-0.7	-0.18	0.10	0.35	0.5	-0.39 [-1.46, 0.68]
			Placebo	8	8 (100.0)	0.18 (0.34)	-0.2	-0.07	0.13	0.29	0.9	
		Week 12	Tezepelumab	7	7 (100.0)	-0.10 (0.33)	-0.6	-0.35	-0.17	0.21	0.3	-0.59 [-1.63, 0.45]
			Placebo	8	8 (100.0)	0.14 (0.47)	-0.7	-0.08	0.13	0.43	0.8	
		Week 20	Tezepelumab	7	6 (85.7)	0.00 (0.39)	-0.5	-0.31	0.06	0.24	0.5	-0.76 [-1.86, 0.34]
			Placebo	8	8 (100.0)	0.21 (0.15)	0.0	0.12	0.15	0.34	0.4	
		Week 28	Tezepelumab	7	5 (71.4)	-0.08 (0.22)	-0.3	-0.24	-0.21	0.15	0.2	-0.75 [-1.92, 0.41]
			Placebo	8	8 (100.0)	0.24 (0.50)	-0.6	-0.03	0.24	0.57	0.9	
		Week 40	Tezepelumab	7	5 (71.4)	-0.03 (0.50)	-0.5	-0.46	-0.17	0.49	0.5	-0.52 [-1.66, 0.62]
			Placebo	8	8 (100.0)	0.23 (0.51)	-0.5	-0.08	0.13	0.60	1.0	
		Week 52	Tezepelumab	7	6 (85.7)	0.05 (0.58)	-0.5	-0.42	-0.16	0.76	0.8	-0.20 [-1.26, 0.86]
			Placebo	8	8 (100.0)	0.17 (0.65)	-0.9	-0.06	0.06	0.55	1.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.54 (0.72)	0.7	1.17	1.37	1.87	3.0	
			Placebo	13	13 (100.0)	1.71 (0.41)	1.0	1.50	1.74	1.85	2.5	
		Week 4	Tezepelumab	9	9 (100.0)	1.84 (1.09)	0.9	1.19	1.44	2.04	4.5	
			Placebo	13	13 (100.0)	1.60 (0.59)	0.7	1.30	1.65	1.89	2.9	
		Week 8	Tezepelumab	9	7 (77.8)	1.63 (0.42)	1.3	1.26	1.46	2.03	2.2	
			Placebo	13	12 (92.3)	1.77 (0.61)	0.8	1.34	1.94	2.14	2.7	
		Week 12	Tezepelumab	9	8 (88.9)	1.95 (1.12)	1.1	1.25	1.70	1.99	4.6	
			Placebo	13	12 (92.3)	1.71 (0.72)	0.5	1.29	1.65	2.14	3.2	
		Week 20	Tezepelumab	9	8 (88.9)	1.76 (0.99)	1.0	1.24	1.48	1.75	4.1	
			Placebo	13	12 (92.3)	1.79 (0.63)	0.7	1.38	1.80	2.30	2.9	
		Week 28	Tezepelumab	9	8 (88.9)	1.83 (1.17)	1.0	1.17	1.42	1.94	4.6	
			Placebo	13	11 (84.6)	1.69 (0.79)	0.8	0.84	1.58	2.10	3.4	
		Week 40	Tezepelumab	9	7 (77.8)	1.49 (0.33)	1.1	1.30	1.36	1.88	2.0	
			Placebo	13	11 (84.6)	1.79 (0.90)	0.6	1.08	1.71	2.24	3.4	
		Week 52	Tezepelumab	9	7 (77.8)	1.57 (0.29)	1.3	1.33	1.36	1.86	1.9	
			Placebo	13	11 (84.6)	1.84 (1.02)	0.8	1.10	1.38	2.54	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	0.30 (0.46)	-0.0	0.02	0.13	0.38	1.4	1.03 [0.12, 1.94]
			Placebo	13	13 (100.0)	-0.11 (0.35)	-1.1	-0.22	-0.06	0.02	0.4	
		Week 8	Tezepelumab	9	7 (77.8)	0.19 (0.22)	-0.0	-0.03	0.10	0.36	0.6	0.39 [-0.55, 1.33]
			Placebo	13	12 (92.3)	0.05 (0.41)	-0.9	-0.18	0.12	0.31	0.6	
		Week 12	Tezepelumab	9	8 (88.9)	0.31 (0.53)	-0.1	-0.02	0.16	0.36	1.5	0.58 [-0.33, 1.50]
			Placebo	13	12 (92.3)	-0.00 (0.53)	-1.2	-0.12	-0.02	0.30	0.7	
		Week 20	Tezepelumab	9	8 (88.9)	0.12 (0.46)	-0.4	-0.17	0.05	0.25	1.1	0.11 [-0.79, 1.00]
			Placebo	13	12 (92.3)	0.07 (0.39)	-1.0	-0.01	0.12	0.24	0.6	
		Week 28	Tezepelumab	9	8 (88.9)	0.18 (0.70)	-1.0	-0.04	0.11	0.41	1.5	0.32 [-0.60, 1.24]
			Placebo	13	11 (84.6)	-0.01 (0.51)	-0.9	-0.49	0.03	0.30	0.9	
		Week 40	Tezepelumab	9	7 (77.8)	0.05 (0.39)	-0.7	-0.08	0.07	0.16	0.7	-0.09 [-1.03, 0.86]
			Placebo	13	11 (84.6)	0.09 (0.63)	-1.1	-0.32	0.00	0.52	1.1	
		Week 52	Tezepelumab	9	7 (77.8)	0.13 (0.22)	-0.0	-0.01	0.07	0.16	0.6	-0.02 [-0.97, 0.92]
			Placebo	13	11 (84.6)	0.14 (0.74)	-0.9	-0.15	-0.10	0.78	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	1.85 (0.57)	0.7	1.40	1.79	2.21	3.9	
			Placebo	125	125 (100.0)	1.83 (0.60)	0.7	1.43	1.70	2.21	3.3	
		Week 4	Tezepelumab	128	122 (95.3)	2.06 (0.71)	0.9	1.53	2.00	2.46	4.9	
			Placebo	125	123 (98.4)	1.90 (0.61)	0.7	1.49	1.86	2.37	3.2	
		Week 8	Tezepelumab	128	117 (91.4)	2.06 (0.67)	0.7	1.55	2.05	2.44	5.1	
			Placebo	125	120 (96.0)	1.93 (0.63)	0.7	1.50	1.88	2.37	3.6	
		Week 12	Tezepelumab	128	120 (93.8)	2.09 (0.69)	0.9	1.52	2.01	2.55	5.1	
			Placebo	125	123 (98.4)	1.92 (0.65)	0.6	1.46	1.84	2.44	4.1	
		Week 20	Tezepelumab	128	111 (86.7)	2.05 (0.71)	1.0	1.49	1.93	2.52	5.5	
			Placebo	125	119 (95.2)	1.91 (0.64)	0.5	1.44	1.90	2.35	3.4	
		Week 28	Tezepelumab	128	116 (90.6)	2.05 (0.71)	0.8	1.47	2.00	2.49	5.4	
			Placebo	125	120 (96.0)	1.88 (0.64)	0.7	1.43	1.86	2.28	3.6	
		Week 40	Tezepelumab	128	115 (89.8)	2.07 (0.71)	0.7	1.45	2.07	2.59	4.7	
			Placebo	125	119 (95.2)	1.93 (0.66)	0.7	1.45	1.81	2.41	4.0	
		Week 52	Tezepelumab	128	112 (87.5)	2.04 (0.67)	0.9	1.54	1.99	2.41	4.7	
			Placebo	125	118 (94.4)	1.90 (0.66)	0.6	1.42	1.86	2.38	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	122 (95.3)	0.22 (0.44)	-0.6	-0.02	0.12	0.38	2.4	0.37 [0.12, 0.62]
			Placebo	125	123 (98.4)	0.07 (0.36)	-1.1	-0.12	0.06	0.20	1.2	
		Week 8	Tezepelumab	128	117 (91.4)	0.22 (0.41)	-0.7	-0.02	0.16	0.40	2.2	0.32 [0.06, 0.57]
			Placebo	125	120 (96.0)	0.09 (0.38)	-1.5	-0.08	0.11	0.24	1.3	
		Week 12	Tezepelumab	128	120 (93.8)	0.24 (0.45)	-0.6	-0.06	0.16	0.43	2.1	0.34 [0.09, 0.60]
			Placebo	125	123 (98.4)	0.10 (0.39)	-0.9	-0.09	0.09	0.29	1.3	
		Week 20	Tezepelumab	128	111 (86.7)	0.23 (0.46)	-0.6	-0.07	0.15	0.43	2.2	0.34 [0.08, 0.60]
			Placebo	125	119 (95.2)	0.09 (0.37)	-0.9	-0.07	0.07	0.26	1.8	
		Week 28	Tezepelumab	128	116 (90.6)	0.23 (0.47)	-0.9	-0.11	0.11	0.50	2.2	0.43 [0.17, 0.68]
			Placebo	125	120 (96.0)	0.05 (0.35)	-1.1	-0.13	0.05	0.23	1.5	
		Week 40	Tezepelumab	128	115 (89.8)	0.25 (0.46)	-0.7	-0.05	0.23	0.48	2.3	0.37 [0.11, 0.63]
			Placebo	125	119 (95.2)	0.10 (0.34)	-1.3	-0.09	0.08	0.29	1.0	
		Week 52	Tezepelumab	128	112 (87.5)	0.21 (0.45)	-0.8	-0.05	0.15	0.44	2.3	0.35 [0.09, 0.61]
			Placebo	125	118 (94.4)	0.07 (0.36)	-1.0	-0.12	0.06	0.24	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	70	70 (100.0)	1.90 (0.58)	0.8	1.43	1.91	2.22	3.9	
			Placebo	73	73 (100.0)	1.82 (0.61)	0.7	1.43	1.72	2.15	3.3	
		Week 4	Tezepelumab	70	66 (94.3)	2.09 (0.71)	0.9	1.58	2.07	2.64	4.9	
			Placebo	73	71 (97.3)	1.88 (0.62)	0.7	1.47	1.90	2.30	3.2	
		Week 8	Tezepelumab	70	63 (90.0)	2.12 (0.70)	1.1	1.63	2.08	2.52	5.1	
			Placebo	73	71 (97.3)	1.93 (0.61)	0.7	1.49	1.88	2.41	3.3	
		Week 12	Tezepelumab	70	65 (92.9)	2.11 (0.70)	0.9	1.63	2.01	2.55	5.1	
			Placebo	73	72 (98.6)	1.92 (0.62)	0.7	1.47	1.85	2.41	3.6	
		Week 20	Tezepelumab	70	61 (87.1)	2.15 (0.76)	1.0	1.52	1.93	2.63	5.5	
			Placebo	73	71 (97.3)	1.93 (0.62)	0.7	1.44	1.90	2.34	3.4	
		Week 28	Tezepelumab	70	64 (91.4)	2.13 (0.77)	0.8	1.46	2.07	2.66	5.4	
			Placebo	73	72 (98.6)	1.90 (0.66)	0.7	1.42	1.90	2.31	3.6	
		Week 40	Tezepelumab	70	63 (90.0)	2.14 (0.75)	0.7	1.50	2.11	2.71	4.7	
			Placebo	73	73 (100.0)	1.93 (0.63)	0.7	1.44	1.83	2.46	3.2	
		Week 52	Tezepelumab	70	59 (84.3)	2.16 (0.69)	1.1	1.58	2.07	2.61	4.7	
			Placebo	73	69 (94.5)	1.94 (0.66)	0.7	1.42	1.94	2.44	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 4	Tezepelumab	70	66 (94.3)	0.18 (0.39)	-0.6	-0.02	0.12	0.32	2.1	0.30 [-0.04, 0.64]
			Placebo	73	71 (97.3)	0.07 (0.36)	-1.1	-0.10	0.05	0.24	1.2	
		Week 8	Tezepelumab	70	63 (90.0)	0.22 (0.42)	-0.7	-0.04	0.15	0.41	2.2	0.29 [-0.05, 0.63]
			Placebo	73	71 (97.3)	0.11 (0.36)	-0.8	-0.09	0.10	0.26	1.3	
		Week 12	Tezepelumab	70	65 (92.9)	0.19 (0.45)	-0.6	-0.09	0.05	0.35	1.9	0.16 [-0.17, 0.50]
			Placebo	73	72 (98.6)	0.12 (0.38)	-0.9	-0.06	0.13	0.31	1.2	
		Week 20	Tezepelumab	70	61 (87.1)	0.24 (0.47)	-0.6	-0.05	0.14	0.47	1.9	0.26 [-0.08, 0.61]
			Placebo	73	71 (97.3)	0.12 (0.41)	-0.9	-0.06	0.08	0.29	1.8	
		Week 28	Tezepelumab	70	64 (91.4)	0.22 (0.50)	-0.9	-0.12	0.03	0.51	1.9	0.34 [-0.00, 0.68]
			Placebo	73	72 (98.6)	0.07 (0.36)	-0.9	-0.14	0.04	0.30	1.5	
		Week 40	Tezepelumab	70	63 (90.0)	0.24 (0.47)	-0.7	-0.07	0.16	0.47	1.9	0.31 [-0.02, 0.65]
			Placebo	73	73 (100.0)	0.11 (0.35)	-1.3	-0.09	0.09	0.31	1.0	
		Week 52	Tezepelumab	70	59 (84.3)	0.22 (0.43)	-0.5	-0.08	0.15	0.43	2.0	0.30 [-0.05, 0.65]
			Placebo	73	69 (94.5)	0.10 (0.37)	-0.7	-0.11	0.08	0.25	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	67	67 (100.0)	1.75 (0.58)	0.7	1.34	1.67	2.12	3.1	
			Placebo	65	65 (100.0)	1.82 (0.56)	0.9	1.43	1.71	2.21	3.2	
		Week 4	Tezepelumab	67	65 (97.0)	1.99 (0.78)	0.9	1.46	1.81	2.29	4.5	
			Placebo	65	65 (100.0)	1.85 (0.61)	0.7	1.52	1.76	2.34	3.2	
		Week 8	Tezepelumab	67	61 (91.0)	1.94 (0.61)	0.7	1.47	1.90	2.36	3.4	
			Placebo	65	61 (93.8)	1.90 (0.64)	0.8	1.54	1.93	2.29	3.6	
		Week 12	Tezepelumab	67	63 (94.0)	2.04 (0.74)	0.9	1.48	1.90	2.55	4.6	
			Placebo	65	63 (96.9)	1.88 (0.70)	0.5	1.41	1.79	2.40	4.1	
		Week 20	Tezepelumab	67	58 (86.6)	1.91 (0.69)	1.0	1.39	1.73	2.37	4.1	
			Placebo	65	60 (92.3)	1.87 (0.65)	0.5	1.45	1.74	2.33	3.3	
		Week 28	Tezepelumab	67	60 (89.6)	1.93 (0.71)	0.9	1.41	1.76	2.29	4.6	
			Placebo	65	59 (90.8)	1.82 (0.65)	0.7	1.42	1.72	2.24	3.4	
		Week 40	Tezepelumab	67	59 (88.1)	1.93 (0.64)	0.9	1.34	1.93	2.33	3.5	
			Placebo	65	57 (87.7)	1.91 (0.74)	0.6	1.43	1.71	2.29	4.0	
		Week 52	Tezepelumab	67	60 (89.6)	1.87 (0.60)	0.9	1.35	1.80	2.31	3.4	
			Placebo	65	60 (92.3)	1.85 (0.73)	0.6	1.35	1.71	2.31	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 4	Tezepelumab	67	65 (97.0)	0.26 (0.48)	-0.6	-0.02	0.11	0.41	2.4	0.54 [0.19, 0.89]
			Placebo	65	65 (100.0)	0.03 (0.36)	-1.1	-0.15	0.03	0.16	1.1	
		Week 8	Tezepelumab	67	61 (91.0)	0.22 (0.38)	-0.5	-0.01	0.17	0.36	2.2	0.36 [0.00, 0.72]
			Placebo	65	61 (93.8)	0.07 (0.41)	-1.5	-0.06	0.13	0.24	1.0	
		Week 12	Tezepelumab	67	63 (94.0)	0.31 (0.44)	-0.5	-0.01	0.21	0.47	2.1	0.58 [0.22, 0.93]
			Placebo	65	63 (96.9)	0.06 (0.43)	-1.2	-0.12	0.04	0.28	1.3	
		Week 20	Tezepelumab	67	58 (86.6)	0.21 (0.45)	-0.6	-0.07	0.13	0.39	2.2	0.41 [0.05, 0.78]
			Placebo	65	60 (92.3)	0.05 (0.31)	-1.0	-0.04	0.07	0.23	0.8	
		Week 28	Tezepelumab	67	60 (89.6)	0.23 (0.48)	-1.0	-0.04	0.19	0.50	2.2	0.51 [0.14, 0.87]
			Placebo	65	59 (90.8)	0.01 (0.36)	-1.1	-0.17	0.05	0.23	0.9	
		Week 40	Tezepelumab	67	59 (88.1)	0.24 (0.46)	-0.7	-0.05	0.25	0.48	2.3	0.35 [-0.02, 0.72]
			Placebo	65	57 (87.7)	0.09 (0.39)	-1.1	-0.12	0.06	0.23	1.1	
		Week 52	Tezepelumab	67	60 (89.6)	0.19 (0.44)	-0.8	-0.03	0.11	0.42	2.3	0.33 [-0.03, 0.69]
			Placebo	65	60 (92.3)	0.04 (0.43)	-1.0	-0.16	0.04	0.18	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	1.63 (0.44)	0.9	1.29	1.62	2.01	2.2	
			Placebo	6	6 (100.0)	1.28 (0.33)	0.9	1.01	1.29	1.52	1.7	
		Week 4	Tezepelumab	11	11 (100.0)	1.91 (0.49)	1.2	1.41	2.01	2.26	2.7	
			Placebo	6	6 (100.0)	1.04 (0.25)	0.7	0.91	1.05	1.25	1.3	
		Week 8	Tezepelumab	11	11 (100.0)	1.98 (0.50)	1.3	1.40	2.13	2.39	2.6	
			Placebo	6	6 (100.0)	1.16 (0.34)	0.8	0.88	1.09	1.48	1.6	
		Week 12	Tezepelumab	11	11 (100.0)	2.07 (0.61)	1.3	1.40	2.33	2.55	3.0	
			Placebo	6	6 (100.0)	1.17 (0.39)	0.5	0.95	1.25	1.41	1.7	
		Week 20	Tezepelumab	11	11 (100.0)	2.00 (0.50)	1.4	1.39	2.05	2.45	2.9	
			Placebo	6	6 (100.0)	1.49 (0.70)	0.7	0.91	1.39	1.86	2.7	
		Week 28	Tezepelumab	11	10 (90.9)	1.99 (0.71)	0.9	1.29	2.05	2.48	3.3	
			Placebo	6	6 (100.0)	1.18 (0.30)	0.8	0.88	1.14	1.53	1.5	
		Week 40	Tezepelumab	11	11 (100.0)	1.92 (0.58)	1.1	1.21	2.16	2.36	2.7	
			Placebo	6	6 (100.0)	1.08 (0.29)	0.6	0.85	1.15	1.28	1.4	
		Week 52	Tezepelumab	11	11 (100.0)	2.00 (0.61)	1.2	1.36	2.16	2.37	3.1	
			Placebo	6	6 (100.0)	1.04 (0.23)	0.7	0.96	1.03	1.16	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	11	11 (100.0)	0.28 (0.33)	-0.0	-0.04	0.18	0.63	0.9	1.42 [0.30, 2.54]
			Placebo	6	6 (100.0)	-0.25 (0.45)	-1.1	-0.27	-0.18	0.08	0.2	
		Week 8	Tezepelumab	11	11 (100.0)	0.35 (0.31)	-0.1	0.06	0.41	0.56	0.8	1.35 [0.24, 2.45]
			Placebo	6	6 (100.0)	-0.12 (0.43)	-0.9	-0.11	-0.04	0.08	0.3	
		Week 12	Tezepelumab	11	11 (100.0)	0.44 (0.35)	-0.2	0.26	0.41	0.77	0.9	1.25 [0.16, 2.34]
			Placebo	6	6 (100.0)	-0.11 (0.57)	-1.2	-0.11	0.02	0.16	0.5	
		Week 20	Tezepelumab	11	11 (100.0)	0.37 (0.36)	-0.1	0.06	0.24	0.76	0.9	0.26 [-0.74, 1.26]
			Placebo	6	6 (100.0)	0.21 (0.95)	-1.0	-0.15	-0.04	0.68	1.8	
		Week 28	Tezepelumab	11	10 (90.9)	0.37 (0.47)	-0.2	-0.05	0.22	0.76	1.1	1.03 [-0.06, 2.11]
			Placebo	6	6 (100.0)	-0.10 (0.43)	-0.9	-0.23	0.03	0.11	0.4	
		Week 40	Tezepelumab	11	11 (100.0)	0.29 (0.35)	-0.3	0.12	0.24	0.49	1.0	1.23 [0.14, 2.31]
			Placebo	6	6 (100.0)	-0.20 (0.48)	-1.1	-0.32	-0.05	0.09	0.2	
		Week 52	Tezepelumab	11	11 (100.0)	0.38 (0.41)	-0.2	0.07	0.20	0.75	1.0	1.64 [0.48, 2.79]
			Placebo	6	6 (100.0)	-0.25 (0.32)	-0.7	-0.52	-0.19	-0.05	0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	126	126 (100.0)	1.85 (0.59)	0.7	1.38	1.79	2.22	3.9	
			Placebo	132	132 (100.0)	1.85 (0.58)	0.7	1.44	1.74	2.21	3.3	
		Week 4	Tezepelumab	126	120 (95.2)	2.05 (0.76)	0.9	1.51	1.96	2.47	4.9	
			Placebo	132	130 (98.5)	1.91 (0.59)	0.7	1.55	1.88	2.34	3.2	
		Week 8	Tezepelumab	126	113 (89.7)	2.04 (0.68)	0.7	1.55	1.97	2.44	5.1	
			Placebo	132	126 (95.5)	1.95 (0.61)	0.7	1.54	1.94	2.37	3.6	
		Week 12	Tezepelumab	126	117 (92.9)	2.08 (0.73)	0.9	1.51	1.96	2.55	5.1	
			Placebo	132	129 (97.7)	1.94 (0.65)	0.6	1.48	1.85	2.44	4.1	
		Week 20	Tezepelumab	126	108 (85.7)	2.04 (0.75)	1.0	1.48	1.87	2.55	5.5	
			Placebo	132	125 (94.7)	1.92 (0.63)	0.5	1.50	1.90	2.33	3.4	
		Week 28	Tezepelumab	126	114 (90.5)	2.04 (0.75)	0.8	1.42	1.94	2.45	5.4	
			Placebo	132	125 (94.7)	1.90 (0.65)	0.7	1.44	1.90	2.28	3.6	
		Week 40	Tezepelumab	126	111 (88.1)	2.05 (0.71)	0.7	1.44	1.98	2.59	4.7	
			Placebo	132	124 (93.9)	1.96 (0.66)	0.7	1.49	1.86	2.42	4.0	
		Week 52	Tezepelumab	126	108 (85.7)	2.01 (0.67)	0.9	1.47	1.94	2.40	4.7	
			Placebo	132	123 (93.2)	1.94 (0.68)	0.6	1.42	1.90	2.44	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	126	120 (95.2)	0.22 (0.45)	-0.6	-0.02	0.12	0.37	2.4	0.38 [0.13, 0.63]
			Placebo	132	130 (98.5)	0.06 (0.35)	-1.1	-0.12	0.05	0.20	1.2	
		Week 8	Tezepelumab	126	113 (89.7)	0.20 (0.41)	-0.7	-0.03	0.16	0.35	2.2	0.26 [0.01, 0.52]
			Placebo	132	126 (95.5)	0.10 (0.38)	-1.5	-0.08	0.12	0.26	1.3	
		Week 12	Tezepelumab	126	117 (92.9)	0.23 (0.46)	-0.6	-0.07	0.14	0.41	2.1	0.30 [0.05, 0.56]
			Placebo	132	129 (97.7)	0.10 (0.39)	-0.9	-0.09	0.08	0.29	1.3	
		Week 20	Tezepelumab	126	108 (85.7)	0.21 (0.47)	-0.6	-0.08	0.13	0.41	2.2	0.32 [0.06, 0.58]
			Placebo	132	125 (94.7)	0.08 (0.32)	-0.9	-0.04	0.08	0.24	1.5	
		Week 28	Tezepelumab	126	114 (90.5)	0.21 (0.49)	-1.0	-0.11	0.09	0.48	2.2	0.37 [0.12, 0.63]
			Placebo	132	125 (94.7)	0.05 (0.36)	-1.1	-0.14	0.05	0.25	1.5	
		Week 40	Tezepelumab	126	111 (88.1)	0.23 (0.47)	-0.7	-0.07	0.17	0.47	2.3	0.28 [0.03, 0.54]
			Placebo	132	124 (93.9)	0.11 (0.36)	-1.3	-0.09	0.08	0.30	1.1	
		Week 52	Tezepelumab	126	108 (85.7)	0.19 (0.44)	-0.8	-0.04	0.11	0.39	2.3	0.23 [-0.03, 0.49]
			Placebo	132	123 (93.2)	0.09 (0.40)	-1.0	-0.12	0.06	0.25	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.53 (0.42)	0.9	1.29	1.61	1.67	2.2	
			Placebo	3	3 (100.0)	1.24 (0.26)	1.0	1.01	1.18	1.52	1.5	
		Week 4	Tezepelumab	9	9 (100.0)	1.80 (0.45)	1.2	1.41	1.82	2.24	2.4	
			Placebo	3	3 (100.0)	1.13 (0.20)	0.9	0.91	1.17	1.30	1.3	
		Week 8	Tezepelumab	9	9 (100.0)	1.90 (0.51)	1.3	1.40	2.13	2.38	2.4	
			Placebo	3	3 (100.0)	1.33 (0.37)	0.9	0.90	1.48	1.60	1.6	
		Week 12	Tezepelumab	9	9 (100.0)	1.93 (0.56)	1.3	1.40	1.93	2.44	2.6	
			Placebo	3	3 (100.0)	1.41 (0.24)	1.2	1.17	1.41	1.65	1.7	
		Week 20	Tezepelumab	9	9 (100.0)	1.89 (0.44)	1.4	1.39	1.91	2.14	2.5	
			Placebo	3	3 (100.0)	1.43 (0.48)	0.9	0.91	1.53	1.86	1.9	
		Week 28	Tezepelumab	9	8 (88.9)	1.84 (0.63)	0.9	1.28	1.91	2.43	2.5	
			Placebo	3	3 (100.0)	1.40 (0.24)	1.1	1.12	1.53	1.54	1.5	
		Week 40	Tezepelumab	9	9 (100.0)	1.84 (0.61)	1.1	1.21	2.16	2.33	2.7	
			Placebo	3	3 (100.0)	1.24 (0.16)	1.1	1.10	1.20	1.42	1.4	
		Week 52	Tezepelumab	9	9 (100.0)	1.86 (0.53)	1.2	1.36	1.93	2.37	2.5	
			Placebo	3	3 (100.0)	1.00 (0.36)	0.7	0.66	0.96	1.37	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	0.27 (0.36)	-0.0	-0.04	0.18	0.63	0.9	1.14 [-0.26, 2.54]
			Placebo	3	3 (100.0)	-0.11 (0.24)	-0.3	-0.27	-0.22	0.16	0.2	
		Week 8	Tezepelumab	9	9 (100.0)	0.37 (0.33)	-0.1	0.08	0.41	0.56	0.8	0.92 [-0.45, 2.29]
			Placebo	3	3 (100.0)	0.09 (0.21)	-0.1	-0.11	0.08	0.30	0.3	
		Week 12	Tezepelumab	9	9 (100.0)	0.40 (0.35)	-0.2	0.26	0.41	0.61	0.9	0.67 [-0.67, 2.00]
			Placebo	3	3 (100.0)	0.17 (0.29)	-0.1	-0.11	0.16	0.47	0.5	
		Week 20	Tezepelumab	9	9 (100.0)	0.36 (0.36)	-0.1	0.08	0.24	0.53	0.9	0.44 [-0.88, 1.76]
			Placebo	3	3 (100.0)	0.20 (0.42)	-0.1	-0.10	0.01	0.68	0.7	
		Week 28	Tezepelumab	9	8 (88.9)	0.33 (0.42)	-0.2	-0.04	0.22	0.75	0.9	0.43 [-0.91, 1.78]
			Placebo	3	3 (100.0)	0.16 (0.17)	0.0	0.02	0.11	0.35	0.4	
		Week 40	Tezepelumab	9	9 (100.0)	0.31 (0.38)	-0.3	0.12	0.26	0.49	1.0	0.83 [-0.53, 2.19]
			Placebo	3	3 (100.0)	0.00 (0.29)	-0.3	-0.32	0.09	0.24	0.2	
		Week 52	Tezepelumab	9	9 (100.0)	0.33 (0.39)	-0.2	0.07	0.20	0.69	0.8	1.58 [0.10, 3.05]
			Placebo	3	3 (100.0)	-0.24 (0.25)	-0.5	-0.52	-0.15	-0.05	-0.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	1.85 (0.59)	0.7	1.38	1.79	2.22	3.9	
			Placebo	135	135 (100.0)	1.84 (0.59)	0.7	1.43	1.72	2.21	3.3	
		Week 4	Tezepelumab	128	122 (95.3)	2.06 (0.76)	0.9	1.51	1.98	2.47	4.9	
			Placebo	135	133 (98.5)	1.88 (0.61)	0.7	1.52	1.83	2.34	3.2	
		Week 8	Tezepelumab	128	115 (89.8)	2.05 (0.67)	0.7	1.55	1.97	2.48	5.1	
			Placebo	135	129 (95.6)	1.93 (0.62)	0.7	1.50	1.92	2.36	3.6	
		Week 12	Tezepelumab	128	119 (93.0)	2.09 (0.73)	0.9	1.51	1.99	2.55	5.1	
			Placebo	135	132 (97.8)	1.91 (0.66)	0.5	1.46	1.85	2.42	4.1	
		Week 20	Tezepelumab	128	110 (85.9)	2.04 (0.75)	1.0	1.48	1.91	2.58	5.5	
			Placebo	135	128 (94.8)	1.91 (0.64)	0.5	1.46	1.90	2.34	3.4	
		Week 28	Tezepelumab	128	116 (90.6)	2.05 (0.75)	0.8	1.44	1.96	2.48	5.4	
			Placebo	135	128 (94.8)	1.88 (0.66)	0.7	1.43	1.86	2.28	3.6	
		Week 40	Tezepelumab	128	113 (88.3)	2.06 (0.71)	0.7	1.45	1.99	2.53	4.7	
			Placebo	135	127 (94.1)	1.94 (0.68)	0.6	1.45	1.82	2.41	4.0	
		Week 52	Tezepelumab	128	110 (85.9)	2.03 (0.67)	0.9	1.48	1.94	2.41	4.7	
			Placebo	135	126 (93.3)	1.92 (0.69)	0.6	1.40	1.86	2.42	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	122 (95.3)	0.22 (0.44)	-0.6	-0.02	0.12	0.38	2.4	0.40 [0.16, 0.65]
			Placebo	135	133 (98.5)	0.05 (0.36)	-1.1	-0.12	0.05	0.19	1.2	
		Week 8	Tezepelumab	128	115 (89.8)	0.21 (0.41)	-0.7	-0.03	0.16	0.36	2.2	0.29 [0.04, 0.54]
			Placebo	135	129 (95.6)	0.09 (0.39)	-1.5	-0.09	0.11	0.24	1.3	
		Week 12	Tezepelumab	128	119 (93.0)	0.24 (0.46)	-0.6	-0.07	0.15	0.42	2.1	0.34 [0.09, 0.59]
			Placebo	135	132 (97.8)	0.09 (0.40)	-1.2	-0.10	0.08	0.29	1.3	
		Week 20	Tezepelumab	128	110 (85.9)	0.21 (0.47)	-0.6	-0.08	0.13	0.41	2.2	0.30 [0.05, 0.56]
			Placebo	135	128 (94.8)	0.09 (0.37)	-1.0	-0.05	0.07	0.25	1.8	
		Week 28	Tezepelumab	128	116 (90.6)	0.22 (0.49)	-1.0	-0.11	0.09	0.48	2.2	0.40 [0.15, 0.66]
			Placebo	135	128 (94.8)	0.04 (0.37)	-1.1	-0.14	0.04	0.24	1.5	
		Week 40	Tezepelumab	128	113 (88.3)	0.23 (0.47)	-0.7	-0.07	0.17	0.44	2.3	0.31 [0.05, 0.56]
			Placebo	135	127 (94.1)	0.10 (0.37)	-1.3	-0.10	0.06	0.30	1.1	
		Week 52	Tezepelumab	128	110 (85.9)	0.20 (0.44)	-0.8	-0.04	0.12	0.40	2.3	0.27 [0.01, 0.52]
			Placebo	135	126 (93.3)	0.08 (0.40)	-1.0	-0.13	0.06	0.25	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	29	29 (100.0)	1.84 (0.56)	0.7	1.50	1.70	2.31	3.0	
			Placebo	37	37 (100.0)	1.91 (0.55)	0.9	1.48	1.81	2.26	3.3	
		Week 4	Tezepelumab	29	26 (89.7)	2.11 (0.79)	1.1	1.62	1.89	2.45	4.5	
			Placebo	37	37 (100.0)	1.88 (0.62)	0.7	1.54	1.79	2.39	3.0	
		Week 8	Tezepelumab	29	24 (82.8)	2.03 (0.66)	1.1	1.53	1.83	2.41	3.4	
			Placebo	37	35 (94.6)	2.02 (0.58)	0.8	1.54	2.00	2.48	3.3	
		Week 12	Tezepelumab	29	27 (93.1)	2.12 (0.80)	1.2	1.51	1.92	2.55	4.6	
			Placebo	37	36 (97.3)	2.08 (0.75)	0.5	1.52	2.11	2.51	4.1	
		Week 20	Tezepelumab	29	23 (79.3)	2.04 (0.84)	1.0	1.49	1.71	2.49	4.1	
			Placebo	37	35 (94.6)	2.03 (0.63)	0.7	1.53	2.12	2.46	3.4	
		Week 28	Tezepelumab	29	24 (82.8)	2.05 (0.83)	1.0	1.42	1.81	2.46	4.6	
			Placebo	37	35 (94.6)	1.99 (0.64)	0.8	1.54	2.03	2.28	3.4	
		Week 40	Tezepelumab	29	23 (79.3)	2.02 (0.71)	1.1	1.44	1.77	2.65	3.5	
			Placebo	37	35 (94.6)	1.97 (0.73)	0.6	1.43	1.88	2.41	4.0	
		Week 52	Tezepelumab	29	22 (75.9)	2.00 (0.63)	0.9	1.62	1.98	2.30	3.5	
			Placebo	37	35 (94.6)	2.01 (0.74)	0.7	1.42	2.04	2.62	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	29	26 (89.7)	0.32 (0.36)	-0.1	0.07	0.24	0.57	1.4	0.83 [0.31, 1.36]
			Placebo	37	37 (100.0)	-0.02 (0.45)	-1.1	-0.21	-0.04	0.18	1.0	
		Week 8	Tezepelumab	29	24 (82.8)	0.28 (0.39)	-0.4	-0.04	0.16	0.63	1.0	0.45 [-0.07, 0.98]
			Placebo	37	35 (94.6)	0.10 (0.41)	-0.9	-0.03	0.13	0.26	1.3	
		Week 12	Tezepelumab	29	27 (93.1)	0.30 (0.45)	-0.4	-0.04	0.21	0.61	1.5	0.31 [-0.19, 0.81]
			Placebo	37	36 (97.3)	0.16 (0.46)	-1.2	0.01	0.13	0.32	1.1	
		Week 20	Tezepelumab	29	23 (79.3)	0.29 (0.47)	-0.6	-0.04	0.19	0.62	1.2	0.27 [-0.26, 0.80]
			Placebo	37	35 (94.6)	0.16 (0.50)	-1.0	-0.03	0.09	0.29	1.8	
		Week 28	Tezepelumab	29	24 (82.8)	0.27 (0.55)	-1.0	-0.05	0.24	0.67	1.5	0.43 [-0.09, 0.96]
			Placebo	37	35 (94.6)	0.06 (0.44)	-1.1	-0.07	0.03	0.21	1.5	
		Week 40	Tezepelumab	29	23 (79.3)	0.29 (0.42)	-0.7	0.02	0.25	0.66	1.0	0.52 [-0.01, 1.06]
			Placebo	37	35 (94.6)	0.07 (0.41)	-1.1	-0.13	0.06	0.24	0.9	
		Week 52	Tezepelumab	29	22 (75.9)	0.26 (0.41)	-0.7	-0.01	0.19	0.69	0.8	0.38 [-0.16, 0.92]
			Placebo	37	35 (94.6)	0.08 (0.48)	-0.9	-0.15	0.05	0.25	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	108	108 (100.0)	1.83 (0.59)	0.7	1.37	1.77	2.19	3.9	
			Placebo	101	101 (100.0)	1.79 (0.60)	0.7	1.40	1.69	2.15	3.2	
		Week 4	Tezepelumab	108	105 (97.2)	2.02 (0.73)	0.9	1.48	2.00	2.40	4.9	
			Placebo	101	99 (98.0)	1.86 (0.61)	0.7	1.47	1.82	2.27	3.2	
		Week 8	Tezepelumab	108	100 (92.6)	2.04 (0.66)	0.7	1.51	2.01	2.42	5.1	
			Placebo	101	97 (96.0)	1.88 (0.64)	0.7	1.48	1.87	2.31	3.6	
		Week 12	Tezepelumab	108	101 (93.5)	2.07 (0.70)	0.9	1.51	2.03	2.55	5.1	
			Placebo	101	99 (98.0)	1.84 (0.61)	0.6	1.44	1.79	2.32	3.3	
		Week 20	Tezepelumab	108	96 (88.9)	2.03 (0.70)	1.0	1.47	1.92	2.50	5.5	
			Placebo	101	96 (95.0)	1.85 (0.63)	0.5	1.40	1.78	2.23	3.3	
		Week 28	Tezepelumab	108	100 (92.6)	2.03 (0.73)	0.8	1.44	1.98	2.47	5.4	
			Placebo	101	96 (95.0)	1.82 (0.66)	0.7	1.38	1.77	2.22	3.6	
		Week 40	Tezepelumab	108	99 (91.7)	2.04 (0.70)	0.7	1.43	2.01	2.52	4.7	
			Placebo	101	95 (94.1)	1.90 (0.66)	0.7	1.43	1.79	2.36	3.5	
		Week 52	Tezepelumab	108	97 (89.8)	2.02 (0.67)	1.0	1.45	1.93	2.41	4.7	
			Placebo	101	94 (93.1)	1.85 (0.68)	0.6	1.34	1.74	2.29	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	108	105 (97.2)	0.20 (0.45)	-0.6	-0.03	0.10	0.35	2.4	0.30 [0.02, 0.58]
			Placebo	101	99 (98.0)	0.08 (0.32)	-1.0	-0.10	0.05	0.20	1.2	
		Week 8	Tezepelumab	108	100 (92.6)	0.20 (0.41)	-0.7	-0.01	0.16	0.36	2.2	0.30 [0.02, 0.58]
			Placebo	101	97 (96.0)	0.09 (0.38)	-1.5	-0.09	0.09	0.24	1.0	
		Week 12	Tezepelumab	108	101 (93.5)	0.23 (0.45)	-0.6	-0.05	0.15	0.41	2.1	0.40 [0.12, 0.68]
			Placebo	101	99 (98.0)	0.07 (0.38)	-0.9	-0.14	0.06	0.26	1.3	
		Week 20	Tezepelumab	108	96 (88.9)	0.21 (0.46)	-0.6	-0.08	0.13	0.39	2.2	0.37 [0.08, 0.65]
			Placebo	101	96 (95.0)	0.07 (0.31)	-0.9	-0.07	0.06	0.24	1.0	
		Week 28	Tezepelumab	108	100 (92.6)	0.21 (0.47)	-0.9	-0.11	0.09	0.46	2.2	0.42 [0.14, 0.70]
			Placebo	101	96 (95.0)	0.04 (0.33)	-1.1	-0.15	0.06	0.27	0.9	
		Week 40	Tezepelumab	108	99 (91.7)	0.23 (0.47)	-0.7	-0.07	0.17	0.43	2.3	0.28 [-0.01, 0.56]
			Placebo	101	95 (94.1)	0.11 (0.35)	-1.3	-0.09	0.08	0.30	1.1	
		Week 52	Tezepelumab	108	97 (89.8)	0.19 (0.44)	-0.8	-0.05	0.13	0.37	2.3	0.30 [0.01, 0.58]
			Placebo	101	94 (93.1)	0.07 (0.37)	-1.0	-0.15	0.06	0.24	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Sex									0.100
Male	Week 4	Tezepelumab	50	49 (98.0)	0.29 (0.07)	(0.16, 0.43)	0.29 (0.10)	(0.09, 0.49)	0.005 *
		Placebo	44	43 (97.7)	0.00 (0.07)	(-0.14, 0.15)			
	Week 8	Tezepelumab	50	44 (88.0)	0.25 (0.07)	(0.11, 0.39)	0.24 (0.10)	(0.04, 0.45)	0.021 *
		Placebo	44	42 (95.5)	0.01 (0.08)	(-0.14, 0.16)			
	Week 12	Tezepelumab	50	48 (96.0)	0.31 (0.07)	(0.16, 0.45)	0.23 (0.11)	(0.01, 0.44)	0.041 *
		Placebo	44	42 (95.5)	0.08 (0.08)	(-0.08, 0.24)			
	Week 20	Tezepelumab	50	44 (88.0)	0.30 (0.07)	(0.16, 0.44)	0.28 (0.10)	(0.08, 0.49)	0.008 *
		Placebo	44	41 (93.2)	0.02 (0.08)	(-0.13, 0.17)			
	Week 28	Tezepelumab	50	46 (92.0)	0.25 (0.08)	(0.09, 0.40)	0.23 (0.11)	(0.01, 0.46)	0.039 *
		Placebo	44	42 (95.5)	0.01 (0.08)	(-0.15, 0.17)			
	Week 40	Tezepelumab	50	46 (92.0)	0.26 (0.07)	(0.11, 0.41)	0.20 (0.11)	(-0.01, 0.42)	0.065
		Placebo	44	42 (95.5)	0.05 (0.08)	(-0.10, 0.21)			
	Week 52	Tezepelumab	50	44 (88.0)	0.18 (0.08)	(0.02, 0.33)	0.11 (0.11)	(-0.11, 0.34)	0.319
		Placebo	44	41 (93.2)	0.06 (0.08)	(-0.10, 0.22)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Female	Week 4	Tezepelumab	87	82 (94.3)	0.18 (0.04)	(0.10, 0.25)	0.10 (0.05)	(-0.00, 0.20)	0.052
		Placebo	94	93 (98.9)	0.07 (0.04)	(0.00, 0.14)			
	Week 8	Tezepelumab	87	80 (92.0)	0.21 (0.04)	(0.14, 0.27)	0.07 (0.05)	(-0.03, 0.16)	0.151
		Placebo	94	90 (95.7)	0.14 (0.03)	(0.07, 0.20)			
	Week 12	Tezepelumab	87	80 (92.0)	0.19 (0.04)	(0.12, 0.27)	0.10 (0.05)	(-0.01, 0.20)	0.072
		Placebo	94	93 (98.9)	0.10 (0.04)	(0.02, 0.17)			
	Week 20	Tezepelumab	87	75 (86.2)	0.18 (0.04)	(0.10, 0.26)	0.06 (0.06)	(-0.05, 0.17)	0.264
		Placebo	94	90 (95.7)	0.12 (0.04)	(0.04, 0.19)			
	Week 28	Tezepelumab	87	78 (89.7)	0.19 (0.04)	(0.11, 0.27)	0.14 (0.06)	(0.03, 0.25)	0.014 *
		Placebo	94	89 (94.7)	0.05 (0.04)	(-0.02, 0.13)			
	Week 40	Tezepelumab	87	76 (87.4)	0.22 (0.04)	(0.14, 0.30)	0.10 (0.05)	(-0.01, 0.21)	0.067
		Placebo	94	88 (93.6)	0.12 (0.04)	(0.04, 0.19)			
	Week 52	Tezepelumab	87	75 (86.2)	0.22 (0.04)	(0.14, 0.30)	0.16 (0.06)	(0.05, 0.27)	0.005 *
		Placebo	94	88 (93.6)	0.06 (0.04)	(-0.01, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Age									0.766
< 65 years	Week 4	Tezepelumab	114	110 (96.5)	0.24 (0.04)	(0.16, 0.32)	0.19 (0.05)	(0.08, 0.29)	<0.001 *
		Placebo	118	116 (98.3)	0.05 (0.04)	(-0.02, 0.13)			
	Week 8	Tezepelumab	114	104 (91.2)	0.24 (0.04)	(0.16, 0.31)	0.13 (0.05)	(0.03, 0.24)	0.014 *
		Placebo	118	112 (94.9)	0.10 (0.04)	(0.03, 0.18)			
	Week 12	Tezepelumab	114	109 (95.6)	0.26 (0.04)	(0.18, 0.34)	0.15 (0.06)	(0.04, 0.26)	0.010 *
		Placebo	118	115 (97.5)	0.11 (0.04)	(0.03, 0.19)			
	Week 20	Tezepelumab	114	99 (86.8)	0.24 (0.04)	(0.16, 0.32)	0.14 (0.06)	(0.03, 0.26)	0.016 *
		Placebo	118	111 (94.1)	0.10 (0.04)	(0.02, 0.18)			
	Week 28	Tezepelumab	114	104 (91.2)	0.23 (0.04)	(0.15, 0.32)	0.18 (0.06)	(0.06, 0.30)	0.003 *
		Placebo	118	111 (94.1)	0.05 (0.04)	(-0.03, 0.13)			
	Week 40	Tezepelumab	114	102 (89.5)	0.27 (0.04)	(0.19, 0.35)	0.16 (0.06)	(0.04, 0.27)	0.007 *
		Placebo	118	110 (93.2)	0.11 (0.04)	(0.03, 0.19)			
	Week 52	Tezepelumab	114	100 (87.7)	0.23 (0.04)	(0.14, 0.31)	0.15 (0.06)	(0.03, 0.27)	0.016 *
		Placebo	118	110 (93.2)	0.08 (0.04)	(-0.00, 0.16)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 65 years	Week 4	Tezepelumab	23	21 (91.3)	0.12 (0.07)	(-0.02, 0.27)	0.09 (0.10)	(-0.12, 0.30)	0.377
		Placebo	20	20 (100.0)	0.03 (0.07)	(-0.11, 0.18)			
	Week 8	Tezepelumab	23	20 (87.0)	0.16 (0.06)	(0.03, 0.28)	0.13 (0.09)	(-0.05, 0.31)	0.161
		Placebo	20	20 (100.0)	0.03 (0.06)	(-0.10, 0.16)			
	Week 12	Tezepelumab	23	19 (82.6)	0.13 (0.07)	(-0.01, 0.27)	0.15 (0.10)	(-0.05, 0.35)	0.143
		Placebo	20	20 (100.0)	-0.02 (0.07)	(-0.16, 0.12)			
	Week 20	Tezepelumab	23	20 (87.0)	0.14 (0.06)	(0.02, 0.27)	0.14 (0.09)	(-0.04, 0.33)	0.125
		Placebo	20	20 (100.0)	0.00 (0.06)	(-0.13, 0.13)			
	Week 28	Tezepelumab	23	20 (87.0)	0.12 (0.07)	(-0.01, 0.25)	0.14 (0.09)	(-0.05, 0.33)	0.133
		Placebo	20	20 (100.0)	-0.03 (0.07)	(-0.16, 0.11)			
	Week 40	Tezepelumab	23	20 (87.0)	0.07 (0.07)	(-0.07, 0.22)	0.06 (0.10)	(-0.14, 0.27)	0.527
		Placebo	20	20 (100.0)	0.01 (0.07)	(-0.13, 0.15)			
	Week 52	Tezepelumab	23	19 (82.6)	0.09 (0.06)	(-0.03, 0.21)	0.14 (0.08)	(-0.03, 0.30)	0.097
		Placebo	20	19 (95.0)	-0.05 (0.06)	(-0.17, 0.07)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Exacerbations in the year before study									0.184
<= 2	Week 4	Tezepelumab	105	101 (96.2)	0.21 (0.04)	(0.13, 0.29)	0.14 (0.06)	(0.03, 0.25)	0.015 *
		Placebo	110	108 (98.2)	0.07 (0.04)	(-0.00, 0.15)			
	Week 8	Tezepelumab	105	95 (90.5)	0.21 (0.04)	(0.13, 0.29)	0.11 (0.06)	(-0.00, 0.22)	0.059
		Placebo	110	108 (98.2)	0.11 (0.04)	(0.03, 0.18)			
	Week 12	Tezepelumab	105	98 (93.3)	0.23 (0.04)	(0.14, 0.31)	0.14 (0.06)	(0.02, 0.25)	0.024 *
		Placebo	110	108 (98.2)	0.09 (0.04)	(0.01, 0.18)			
	Week 20	Tezepelumab	105	95 (90.5)	0.24 (0.04)	(0.16, 0.32)	0.16 (0.06)	(0.05, 0.27)	0.005 *
		Placebo	110	105 (95.5)	0.08 (0.04)	(0.00, 0.15)			
	Week 28	Tezepelumab	105	97 (92.4)	0.19 (0.04)	(0.11, 0.28)	0.12 (0.06)	(-0.00, 0.24)	0.052
		Placebo	110	105 (95.5)	0.07 (0.04)	(-0.01, 0.16)			
	Week 40	Tezepelumab	105	96 (91.4)	0.22 (0.04)	(0.14, 0.30)	0.10 (0.06)	(-0.01, 0.22)	0.083
		Placebo	110	105 (95.5)	0.12 (0.04)	(0.04, 0.20)			
	Week 52	Tezepelumab	105	93 (88.6)	0.18 (0.04)	(0.10, 0.27)	0.08 (0.06)	(-0.03, 0.20)	0.164
		Placebo	110	106 (96.4)	0.10 (0.04)	(0.02, 0.18)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
> 2	Week 4	Tezepelumab	32	30 (93.8)	0.25 (0.07)	(0.12, 0.38)	0.29 (0.10)	(0.10, 0.49)	0.004 *
		Placebo	28	28 (100.0)	-0.04 (0.07)	(-0.18, 0.10)			
	Week 8	Tezepelumab	32	29 (90.6)	0.26 (0.06)	(0.14, 0.38)	0.23 (0.09)	(0.05, 0.41)	0.013 *
		Placebo	28	24 (85.7)	0.03 (0.07)	(-0.10, 0.16)			
	Week 12	Tezepelumab	32	30 (93.8)	0.27 (0.07)	(0.13, 0.42)	0.20 (0.11)	(-0.02, 0.41)	0.068
		Placebo	28	27 (96.4)	0.07 (0.08)	(-0.08, 0.23)			
	Week 20	Tezepelumab	32	24 (75.0)	0.17 (0.09)	(-0.01, 0.35)	0.06 (0.13)	(-0.19, 0.32)	0.624
		Placebo	28	26 (92.9)	0.11 (0.09)	(-0.08, 0.29)			
	Week 28	Tezepelumab	32	27 (84.4)	0.29 (0.07)	(0.14, 0.43)	0.40 (0.10)	(0.19, 0.61)	<0.001 *
		Placebo	28	26 (92.9)	-0.11 (0.08)	(-0.26, 0.04)			
	Week 40	Tezepelumab	32	26 (81.3)	0.30 (0.08)	(0.14, 0.45)	0.30 (0.11)	(0.07, 0.52)	0.010 *
		Placebo	28	25 (89.3)	0.00 (0.08)	(-0.16, 0.16)			
	Week 52	Tezepelumab	32	26 (81.3)	0.29 (0.07)	(0.15, 0.43)	0.35 (0.10)	(0.15, 0.56)	0.001 *
		Placebo	28	23 (82.1)	-0.06 (0.08)	(-0.22, 0.09)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race				N<10 any level					NE

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region									0.983
Europe	Week 4	Tezepelumab	78	75 (96.2)	0.21 (0.04)	(0.12, 0.30)	0.18 (0.06)	(0.05, 0.30)	0.005 *
		Placebo	80	80 (100.0)	0.03 (0.04)	(-0.05, 0.12)			
	Week 8	Tezepelumab	78	74 (94.9)	0.21 (0.04)	(0.12, 0.30)	0.15 (0.06)	(0.03, 0.27)	0.017 *
		Placebo	80	76 (95.0)	0.06 (0.04)	(-0.02, 0.15)			
	Week 12	Tezepelumab	78	75 (96.2)	0.23 (0.05)	(0.14, 0.33)	0.15 (0.07)	(0.02, 0.29)	0.027 *
		Placebo	80	79 (98.8)	0.08 (0.05)	(-0.01, 0.17)			
	Week 20	Tezepelumab	78	71 (91.0)	0.23 (0.05)	(0.13, 0.33)	0.17 (0.07)	(0.03, 0.31)	0.017 *
		Placebo	80	79 (98.8)	0.06 (0.05)	(-0.03, 0.16)			
	Week 28	Tezepelumab	78	72 (92.3)	0.17 (0.05)	(0.07, 0.27)	0.12 (0.07)	(-0.02, 0.26)	0.086
		Placebo	80	79 (98.8)	0.05 (0.05)	(-0.05, 0.14)			
	Week 40	Tezepelumab	78	71 (91.0)	0.21 (0.05)	(0.11, 0.30)	0.13 (0.07)	(-0.00, 0.26)	0.056
		Placebo	80	79 (98.8)	0.08 (0.05)	(-0.01, 0.17)			
	Week 52	Tezepelumab	78	71 (91.0)	0.17 (0.05)	(0.07, 0.26)	0.10 (0.07)	(-0.03, 0.23)	0.128
		Placebo	80	79 (98.8)	0.07 (0.05)	(-0.02, 0.16)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
America	Week 4	Tezepelumab	10	9 (90.0)	0.13 (0.07)	(-0.02, 0.28)	0.05 (0.10)	(-0.15, 0.26)	0.581
		Placebo	9	9 (100.0)	0.07 (0.07)	(-0.07, 0.22)			
	Week 8	Tezepelumab	10	9 (90.0)	0.21 (0.09)	(0.03, 0.39)	0.04 (0.12)	(-0.21, 0.30)	0.719
		Placebo	9	9 (100.0)	0.17 (0.09)	(-0.02, 0.35)			
	Week 12	Tezepelumab	10	10 (100.0)	0.16 (0.12)	(-0.09, 0.41)	-0.11 (0.17)	(-0.47, 0.25)	0.537
		Placebo	9	9 (100.0)	0.27 (0.12)	(0.00, 0.53)			
	Week 20	Tezepelumab	10	7 (70.0)	0.13 (0.13)	(-0.15, 0.42)	0.03 (0.18)	(-0.36, 0.42)	0.885
		Placebo	9	9 (100.0)	0.11 (0.12)	(-0.16, 0.38)			
	Week 28	Tezepelumab	10	8 (80.0)	0.36 (0.09)	(0.17, 0.55)	0.12 (0.12)	(-0.16, 0.40)	0.355
		Placebo	9	8 (88.9)	0.24 (0.09)	(0.04, 0.44)			
	Week 40	Tezepelumab	10	7 (70.0)	0.33 (0.11)	(0.09, 0.57)	0.18 (0.15)	(-0.15, 0.51)	0.255
		Placebo	9	9 (100.0)	0.15 (0.10)	(-0.08, 0.38)			
	Week 52	Tezepelumab	10	7 (70.0)	0.21 (0.12)	(-0.05, 0.47)	0.27 (0.17)	(-0.10, 0.64)	0.133
		Placebo	9	8 (88.9)	-0.06 (0.12)	(-0.32, 0.20)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Asia/Pacific	Week 4	Tezepelumab	5	5 (100.0)	0.26 (0.17)	(-0.20, 0.71)	0.21 (0.22)	(-0.40, 0.82)	0.396
		Placebo	6	6 (100.0)	0.04 (0.15)	(-0.37, 0.46)			
	Week 8	Tezepelumab	5	5 (100.0)	0.22 (0.13)	(-0.14, 0.58)	0.19 (0.18)	(-0.30, 0.67)	0.354
		Placebo	6	6 (100.0)	0.03 (0.12)	(-0.30, 0.36)			
	Week 12	Tezepelumab	5	5 (100.0)	0.22 (0.18)	(-0.21, 0.65)	0.24 (0.24)	(-0.34, 0.82)	0.348
		Placebo	6	6 (100.0)	-0.02 (0.16)	(-0.41, 0.37)			
	Week 20	Tezepelumab	5	5 (100.0)	0.12 (0.11)	(-0.18, 0.43)	0.02 (0.14)	(-0.39, 0.44)	0.873
		Placebo	6	6 (100.0)	0.10 (0.10)	(-0.18, 0.38)			
	Week 28	Tezepelumab	5	5 (100.0)	0.24 (0.18)	(-0.21, 0.69)	0.10 (0.24)	(-0.51, 0.71)	0.687
		Placebo	6	6 (100.0)	0.14 (0.16)	(-0.27, 0.55)			
	Week 40	Tezepelumab	5	5 (100.0)	0.23 (0.14)	(-0.12, 0.57)	0.22 (0.19)	(-0.25, 0.68)	0.296
		Placebo	6	6 (100.0)	0.01 (0.13)	(-0.30, 0.32)			
	Week 52	Tezepelumab	5	5 (100.0)	0.15 (0.13)	(-0.16, 0.45)	0.13 (0.17)	(-0.29, 0.54)	0.492
		Placebo	6	6 (100.0)	0.02 (0.12)	(-0.26, 0.30)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of the world	Week 4	Tezepelumab	44	42 (95.5)	0.26 (0.07)	(0.11, 0.40)	0.18 (0.10)	(-0.02, 0.39)	0.081
		Placebo	43	41 (95.3)	0.08 (0.07)	(-0.07, 0.22)			
	Week 8	Tezepelumab	44	36 (81.8)	0.26 (0.07)	(0.12, 0.40)	0.12 (0.10)	(-0.08, 0.32)	0.222
		Placebo	43	41 (95.3)	0.14 (0.07)	(-0.00, 0.27)			
	Week 12	Tezepelumab	44	38 (86.4)	0.28 (0.07)	(0.14, 0.42)	0.20 (0.10)	(-0.00, 0.39)	0.050
		Placebo	43	41 (95.3)	0.08 (0.07)	(-0.06, 0.22)			
	Week 20	Tezepelumab	44	36 (81.8)	0.23 (0.07)	(0.10, 0.36)	0.12 (0.09)	(-0.07, 0.30)	0.220
		Placebo	43	37 (86.0)	0.12 (0.07)	(-0.02, 0.25)			
	Week 28	Tezepelumab	44	39 (88.6)	0.29 (0.07)	(0.15, 0.44)	0.32 (0.10)	(0.12, 0.53)	0.003 *
		Placebo	43	38 (88.4)	-0.03 (0.07)	(-0.18, 0.12)			
	Week 40	Tezepelumab	44	39 (88.6)	0.27 (0.08)	(0.12, 0.43)	0.16 (0.11)	(-0.06, 0.37)	0.152
		Placebo	43	36 (83.7)	0.12 (0.08)	(-0.04, 0.27)			
	Week 52	Tezepelumab	44	36 (81.8)	0.26 (0.08)	(0.10, 0.42)	0.20 (0.11)	(-0.03, 0.42)	0.084
		Placebo	43	36 (83.7)	0.06 (0.08)	(-0.10, 0.22)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
BMI				N<10 any level					NE

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - Low									0.014 i
< 150 cells/uL	Week 4	Tezepelumab	27	27 (100.0)	0.08 (0.06)	(-0.04, 0.20)	-0.02 (0.08)	(-0.18, 0.14)	0.769
		Placebo	33	31 (93.9)	0.10 (0.05)	(-0.01, 0.21)			
	Week 8	Tezepelumab	27	26 (96.3)	0.08 (0.06)	(-0.04, 0.20)	-0.04 (0.08)	(-0.20, 0.12)	0.638
		Placebo	33	32 (97.0)	0.12 (0.05)	(0.01, 0.22)			
	Week 12	Tezepelumab	27	26 (96.3)	0.01 (0.06)	(-0.11, 0.14)	-0.02 (0.09)	(-0.20, 0.15)	0.776
		Placebo	33	33 (100.0)	0.04 (0.06)	(-0.08, 0.15)			
	Week 20	Tezepelumab	27	24 (88.9)	0.04 (0.07)	(-0.10, 0.17)	-0.05 (0.09)	(-0.23, 0.12)	0.539
		Placebo	33	32 (97.0)	0.09 (0.06)	(-0.03, 0.21)			
	Week 28	Tezepelumab	27	25 (92.6)	-0.02 (0.07)	(-0.15, 0.12)	-0.10 (0.09)	(-0.28, 0.09)	0.308
		Placebo	33	31 (93.9)	0.08 (0.06)	(-0.04, 0.20)			
	Week 40	Tezepelumab	27	25 (92.6)	0.04 (0.06)	(-0.09, 0.16)	-0.09 (0.08)	(-0.26, 0.07)	0.269
		Placebo	33	31 (93.9)	0.13 (0.06)	(0.02, 0.24)			
	Week 52	Tezepelumab	27	24 (88.9)	-0.05 (0.07)	(-0.20, 0.09)	-0.13 (0.09)	(-0.32, 0.06)	0.177
		Placebo	33	31 (93.9)	0.07 (0.06)	(-0.05, 0.20)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 150 cells/uL	Week 4	Tezepelumab	109	103 (94.5)	0.26 (0.04)	(0.18, 0.34)	0.23 (0.06)	(0.11, 0.34)	<0.001 *
		Placebo	105	105 (100.0)	0.03 (0.04)	(-0.05, 0.11)			
	Week 8	Tezepelumab	109	97 (89.0)	0.26 (0.04)	(0.18, 0.34)	0.18 (0.06)	(0.06, 0.29)	0.002 *
		Placebo	105	100 (95.2)	0.09 (0.04)	(0.01, 0.16)			
	Week 12	Tezepelumab	109	101 (92.7)	0.30 (0.04)	(0.21, 0.38)	0.19 (0.06)	(0.07, 0.31)	0.002 *
		Placebo	105	102 (97.1)	0.11 (0.04)	(0.02, 0.19)			
	Week 20	Tezepelumab	109	94 (86.2)	0.28 (0.04)	(0.19, 0.36)	0.20 (0.06)	(0.08, 0.32)	0.001 *
		Placebo	105	99 (94.3)	0.08 (0.04)	(-0.01, 0.16)			
	Week 28	Tezepelumab	109	98 (89.9)	0.28 (0.04)	(0.19, 0.36)	0.25 (0.06)	(0.13, 0.37)	<0.001 *
		Placebo	105	100 (95.2)	0.03 (0.04)	(-0.06, 0.11)			
	Week 40	Tezepelumab	109	96 (88.1)	0.29 (0.04)	(0.20, 0.38)	0.21 (0.06)	(0.09, 0.33)	<0.001 *
		Placebo	105	99 (94.3)	0.08 (0.04)	(-0.00, 0.17)			
	Week 52	Tezepelumab	109	94 (86.2)	0.27 (0.04)	(0.19, 0.36)	0.22 (0.06)	(0.10, 0.34)	<0.001 *
		Placebo	105	98 (93.3)	0.06 (0.04)	(-0.03, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - High									0.008 i
< 300 cells/uL	Week 4	Tezepelumab	69	66 (95.7)	0.15 (0.04)	(0.07, 0.22)	0.06 (0.05)	(-0.05, 0.17)	0.250
		Placebo	72	70 (97.2)	0.08 (0.04)	(0.01, 0.16)			
	Week 8	Tezepelumab	69	62 (89.9)	0.13 (0.04)	(0.05, 0.22)	0.04 (0.06)	(-0.09, 0.16)	0.557
		Placebo	72	68 (94.4)	0.10 (0.04)	(0.01, 0.18)			
	Week 12	Tezepelumab	69	64 (92.8)	0.15 (0.04)	(0.06, 0.24)	0.08 (0.06)	(-0.04, 0.21)	0.171
		Placebo	72	70 (97.2)	0.06 (0.04)	(-0.02, 0.15)			
	Week 20	Tezepelumab	69	59 (85.5)	0.10 (0.05)	(0.00, 0.19)	-0.01 (0.06)	(-0.14, 0.11)	0.841
		Placebo	72	68 (94.4)	0.11 (0.04)	(0.02, 0.19)			
	Week 28	Tezepelumab	69	61 (88.4)	0.07 (0.05)	(-0.02, 0.17)	0.02 (0.06)	(-0.10, 0.15)	0.709
		Placebo	72	67 (93.1)	0.05 (0.04)	(-0.04, 0.14)			
	Week 40	Tezepelumab	69	59 (85.5)	0.15 (0.04)	(0.07, 0.24)	0.03 (0.06)	(-0.09, 0.15)	0.579
		Placebo	72	66 (91.7)	0.12 (0.04)	(0.04, 0.20)			
	Week 52	Tezepelumab	69	58 (84.1)	0.06 (0.05)	(-0.04, 0.15)	0.01 (0.07)	(-0.12, 0.14)	0.891
		Placebo	72	67 (93.1)	0.05 (0.05)	(-0.04, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 300 cells/uL	Week 4	Tezepelumab	67	64 (95.5)	0.30 (0.06)	(0.18, 0.41)	0.28 (0.08)	(0.12, 0.44)	<0.001 *
		Placebo	66	66 (100.0)	0.01 (0.06)	(-0.10, 0.13)			
	Week 8	Tezepelumab	67	61 (91.0)	0.32 (0.05)	(0.21, 0.42)	0.23 (0.07)	(0.09, 0.38)	0.002 *
		Placebo	66	64 (97.0)	0.08 (0.05)	(-0.02, 0.19)			
	Week 12	Tezepelumab	67	63 (94.0)	0.33 (0.06)	(0.22, 0.45)	0.22 (0.08)	(0.06, 0.39)	0.009 *
		Placebo	66	65 (98.5)	0.11 (0.06)	(-0.00, 0.23)			
	Week 20	Tezepelumab	67	59 (88.1)	0.35 (0.06)	(0.24, 0.47)	0.30 (0.08)	(0.14, 0.46)	<0.001 *
		Placebo	66	63 (95.5)	0.06 (0.06)	(-0.05, 0.17)			
	Week 28	Tezepelumab	67	62 (92.5)	0.36 (0.06)	(0.24, 0.47)	0.33 (0.08)	(0.17, 0.49)	<0.001 *
		Placebo	66	64 (97.0)	0.02 (0.06)	(-0.09, 0.14)			
	Week 40	Tezepelumab	67	62 (92.5)	0.32 (0.06)	(0.21, 0.44)	0.26 (0.08)	(0.09, 0.42)	0.003 *
		Placebo	66	64 (97.0)	0.07 (0.06)	(-0.05, 0.18)			
	Week 52	Tezepelumab	67	60 (89.6)	0.36 (0.06)	(0.24, 0.47)	0.29 (0.08)	(0.13, 0.45)	<0.001 *
		Placebo	66	62 (93.9)	0.07 (0.06)	(-0.04, 0.18)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO									0.023 i
< 25 ppb	Week 4	Tezepelumab	78	75 (96.2)	0.17 (0.04)	(0.08, 0.25)	0.08 (0.06)	(-0.04, 0.20)	0.209
		Placebo	74	72 (97.3)	0.09 (0.04)	(0.01, 0.18)			
	Week 8	Tezepelumab	78	71 (91.0)	0.16 (0.04)	(0.08, 0.24)	0.04 (0.06)	(-0.07, 0.16)	0.465
		Placebo	74	71 (95.9)	0.12 (0.04)	(0.03, 0.20)			
	Week 12	Tezepelumab	78	73 (93.6)	0.18 (0.04)	(0.09, 0.27)	0.09 (0.06)	(-0.03, 0.22)	0.140
		Placebo	74	73 (98.6)	0.09 (0.05)	(-0.00, 0.18)			
	Week 20	Tezepelumab	78	68 (87.2)	0.16 (0.05)	(0.07, 0.25)	0.04 (0.07)	(-0.09, 0.18)	0.512
		Placebo	74	71 (95.9)	0.12 (0.05)	(0.02, 0.21)			
	Week 28	Tezepelumab	78	71 (91.0)	0.15 (0.05)	(0.06, 0.24)	0.10 (0.07)	(-0.03, 0.23)	0.115
		Placebo	74	71 (95.9)	0.05 (0.05)	(-0.04, 0.14)			
	Week 40	Tezepelumab	78	70 (89.7)	0.19 (0.05)	(0.10, 0.28)	0.11 (0.07)	(-0.02, 0.24)	0.091
		Placebo	74	71 (95.9)	0.08 (0.05)	(-0.01, 0.17)			
	Week 52	Tezepelumab	78	69 (88.5)	0.13 (0.05)	(0.03, 0.22)	0.06 (0.07)	(-0.07, 0.19)	0.339
		Placebo	74	70 (94.6)	0.06 (0.05)	(-0.03, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 25 ppb	Week 4	Tezepelumab	57	54 (94.7)	0.30 (0.06)	(0.19, 0.42)	0.31 (0.08)	(0.15, 0.47)	<0.001 *
		Placebo	63	63 (100.0)	-0.00 (0.05)	(-0.11, 0.10)			
	Week 8	Tezepelumab	57	51 (89.5)	0.32 (0.06)	(0.21, 0.43)	0.26 (0.08)	(0.10, 0.41)	0.001 *
		Placebo	63	60 (95.2)	0.06 (0.05)	(-0.04, 0.17)			
	Week 12	Tezepelumab	57	53 (93.0)	0.33 (0.06)	(0.21, 0.46)	0.24 (0.09)	(0.07, 0.41)	0.005 *
		Placebo	63	61 (96.8)	0.09 (0.06)	(-0.03, 0.20)			
	Week 20	Tezepelumab	57	49 (86.0)	0.33 (0.06)	(0.21, 0.44)	0.29 (0.08)	(0.13, 0.45)	<0.001 *
		Placebo	63	59 (93.7)	0.04 (0.05)	(-0.07, 0.15)			
	Week 28	Tezepelumab	57	51 (89.5)	0.31 (0.06)	(0.19, 0.44)	0.30 (0.09)	(0.12, 0.47)	<0.001 *
		Placebo	63	59 (93.7)	0.02 (0.06)	(-0.10, 0.14)			
	Week 40	Tezepelumab	57	50 (87.7)	0.31 (0.06)	(0.19, 0.44)	0.21 (0.09)	(0.04, 0.38)	0.017 *
		Placebo	63	58 (92.1)	0.11 (0.06)	(-0.01, 0.22)			
	Week 52	Tezepelumab	57	48 (84.2)	0.33 (0.06)	(0.21, 0.46)	0.27 (0.09)	(0.10, 0.44)	0.002 *
		Placebo	63	58 (92.1)	0.06 (0.06)	(-0.05, 0.18)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline specific perennial FEIA status									0.999
All negative	Week 4	Tezepelumab	57	56 (98.2)	0.20 (0.05)	(0.10, 0.30)	0.15 (0.07)	(0.02, 0.29)	0.028 *
		Placebo	66	65 (98.5)	0.05 (0.05)	(-0.05, 0.14)			
	Week 8	Tezepelumab	57	53 (93.0)	0.21 (0.05)	(0.11, 0.31)	0.16 (0.07)	(0.03, 0.29)	0.019 *
		Placebo	66	63 (95.5)	0.05 (0.05)	(-0.04, 0.14)			
	Week 12	Tezepelumab	57	53 (93.0)	0.24 (0.05)	(0.14, 0.35)	0.19 (0.07)	(0.04, 0.33)	0.012 *
		Placebo	66	66 (100.0)	0.06 (0.05)	(-0.04, 0.15)			
	Week 20	Tezepelumab	57	49 (86.0)	0.23 (0.05)	(0.13, 0.32)	0.16 (0.06)	(0.03, 0.29)	0.015 *
		Placebo	66	65 (98.5)	0.07 (0.04)	(-0.02, 0.15)			
	Week 28	Tezepelumab	57	52 (91.2)	0.19 (0.06)	(0.08, 0.30)	0.18 (0.08)	(0.03, 0.33)	0.016 *
		Placebo	66	64 (97.0)	0.01 (0.05)	(-0.09, 0.11)			
	Week 40	Tezepelumab	57	52 (91.2)	0.18 (0.06)	(0.06, 0.29)	0.09 (0.08)	(-0.07, 0.24)	0.266
		Placebo	66	65 (98.5)	0.09 (0.05)	(-0.01, 0.19)			
	Week 52	Tezepelumab	57	48 (84.2)	0.20 (0.06)	(0.08, 0.31)	0.14 (0.08)	(-0.02, 0.30)	0.086
		Placebo	66	62 (93.9)	0.06 (0.05)	(-0.05, 0.16)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Any positive	Week 4	Tezepelumab	71	66 (93.0)	0.23 (0.05)	(0.13, 0.34)	0.19 (0.07)	(0.04, 0.34)	0.011 *
		Placebo	63	63 (100.0)	0.04 (0.05)	(-0.06, 0.15)			
	Week 8	Tezepelumab	71	64 (90.1)	0.24 (0.05)	(0.14, 0.34)	0.13 (0.07)	(-0.01, 0.28)	0.075
		Placebo	63	60 (95.2)	0.11 (0.05)	(0.00, 0.21)			
	Week 12	Tezepelumab	71	66 (93.0)	0.20 (0.05)	(0.10, 0.31)	0.08 (0.08)	(-0.08, 0.23)	0.329
		Placebo	63	60 (95.2)	0.13 (0.06)	(0.02, 0.24)			
	Week 20	Tezepelumab	71	62 (87.3)	0.21 (0.06)	(0.10, 0.33)	0.13 (0.08)	(-0.04, 0.30)	0.123
		Placebo	63	58 (92.1)	0.08 (0.06)	(-0.03, 0.20)			
	Week 28	Tezepelumab	71	64 (90.1)	0.23 (0.06)	(0.12, 0.34)	0.17 (0.08)	(0.01, 0.33)	0.035 *
		Placebo	63	58 (92.1)	0.06 (0.06)	(-0.05, 0.17)			
	Week 40	Tezepelumab	71	62 (87.3)	0.27 (0.05)	(0.17, 0.38)	0.18 (0.08)	(0.03, 0.34)	0.019 *
		Placebo	63	56 (88.9)	0.09 (0.06)	(-0.02, 0.20)			
	Week 52	Tezepelumab	71	63 (88.7)	0.22 (0.05)	(0.11, 0.32)	0.18 (0.08)	(0.02, 0.33)	0.023 *
		Placebo	63	58 (92.1)	0.04 (0.06)	(-0.07, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE									0.106
Low	Week 4	Tezepelumab	35	35 (100.0)	0.12 (0.06)	(0.01, 0.23)	0.04 (0.08)	(-0.12, 0.20)	0.626
		Placebo	32	31 (96.9)	0.08 (0.06)	(-0.04, 0.20)			
	Week 8	Tezepelumab	35	34 (97.1)	0.17 (0.06)	(0.06, 0.28)	0.10 (0.08)	(-0.06, 0.26)	0.212
		Placebo	32	31 (96.9)	0.07 (0.06)	(-0.04, 0.19)			
	Week 12	Tezepelumab	35	33 (94.3)	0.18 (0.07)	(0.05, 0.31)	0.11 (0.09)	(-0.07, 0.30)	0.225
		Placebo	32	32 (100.0)	0.06 (0.07)	(-0.07, 0.20)			
	Week 20	Tezepelumab	35	31 (88.6)	0.15 (0.07)	(0.02, 0.29)	0.07 (0.10)	(-0.12, 0.27)	0.438
		Placebo	32	31 (96.9)	0.08 (0.07)	(-0.06, 0.21)			
	Week 28	Tezepelumab	35	31 (88.6)	0.12 (0.07)	(-0.03, 0.27)	0.12 (0.11)	(-0.09, 0.33)	0.264
		Placebo	32	31 (96.9)	-0.00 (0.08)	(-0.15, 0.15)			
	Week 40	Tezepelumab	35	31 (88.6)	0.20 (0.07)	(0.06, 0.34)	0.15 (0.10)	(-0.05, 0.35)	0.150
		Placebo	32	30 (93.8)	0.06 (0.07)	(-0.09, 0.20)			
	Week 52	Tezepelumab	35	29 (82.9)	0.13 (0.07)	(-0.00, 0.27)	0.10 (0.10)	(-0.09, 0.29)	0.301
		Placebo	32	30 (93.8)	0.03 (0.07)	(-0.11, 0.17)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Normal	Week 4	Tezepelumab	95	90 (94.7)	0.28 (0.04)	(0.19, 0.37)	0.24 (0.06)	(0.12, 0.36)	<0.001 *
		Placebo	98	97 (99.0)	0.04 (0.04)	(-0.05, 0.12)			
	Week 8	Tezepelumab	95	84 (88.4)	0.26 (0.04)	(0.17, 0.35)	0.17 (0.06)	(0.05, 0.29)	0.006 *
		Placebo	98	93 (94.9)	0.09 (0.04)	(0.01, 0.17)			
	Week 12	Tezepelumab	95	88 (92.6)	0.29 (0.05)	(0.20, 0.38)	0.19 (0.06)	(0.07, 0.32)	0.003 *
		Placebo	98	95 (96.9)	0.09 (0.04)	(0.01, 0.18)			
	Week 20	Tezepelumab	95	82 (86.3)	0.27 (0.05)	(0.18, 0.36)	0.20 (0.06)	(0.07, 0.32)	0.003 *
		Placebo	98	92 (93.9)	0.07 (0.04)	(-0.01, 0.16)			
	Week 28	Tezepelumab	95	88 (92.6)	0.27 (0.05)	(0.18, 0.36)	0.23 (0.06)	(0.11, 0.35)	<0.001 *
		Placebo	98	92 (93.9)	0.04 (0.04)	(-0.05, 0.13)			
	Week 40	Tezepelumab	95	86 (90.5)	0.27 (0.04)	(0.18, 0.36)	0.17 (0.06)	(0.05, 0.29)	0.006 *
		Placebo	98	92 (93.9)	0.10 (0.04)	(0.01, 0.18)			
	Week 52	Tezepelumab	95	84 (88.4)	0.25 (0.05)	(0.16, 0.34)	0.18 (0.06)	(0.06, 0.31)	0.004 *
		Placebo	98	91 (92.9)	0.06 (0.04)	(-0.02, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 4	Tezepelumab	7	6 (85.7)	-0.03 (0.11)	(-0.26, 0.21)	-0.10 (0.15)	(-0.42, 0.21)	0.495
		Placebo	8	8 (100.0)	0.08 (0.10)	(-0.13, 0.29)			
	Week 8	Tezepelumab	7	6 (85.7)	0.01 (0.14)	(-0.28, 0.31)	-0.17 (0.18)	(-0.57, 0.22)	0.364
		Placebo	8	8 (100.0)	0.19 (0.12)	(-0.08, 0.46)			
	Week 12	Tezepelumab	7	7 (100.0)	-0.10 (0.15)	(-0.44, 0.23)	-0.25 (0.21)	(-0.71, 0.20)	0.251
		Placebo	8	8 (100.0)	0.15 (0.15)	(-0.16, 0.47)			
	Week 20	Tezepelumab	7	6 (85.7)	-0.02 (0.10)	(-0.24, 0.20)	-0.24 (0.14)	(-0.53, 0.05)	0.102
		Placebo	8	8 (100.0)	0.22 (0.09)	(0.02, 0.42)			
	Week 28	Tezepelumab	7	5 (71.4)	-0.01 (0.15)	(-0.34, 0.32)	-0.26 (0.21)	(-0.71, 0.20)	0.242
		Placebo	8	8 (100.0)	0.25 (0.14)	(-0.06, 0.55)			
	Week 40	Tezepelumab	7	5 (71.4)	-0.02 (0.18)	(-0.41, 0.37)	-0.26 (0.25)	(-0.79, 0.27)	0.305
		Placebo	8	8 (100.0)	0.24 (0.17)	(-0.12, 0.60)			
	Week 52	Tezepelumab	7	6 (85.7)	0.04 (0.23)	(-0.45, 0.53)	-0.15 (0.31)	(-0.82, 0.53)	0.648
		Placebo	8	8 (100.0)	0.18 (0.21)	(-0.27, 0.64)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
OCS at baseline									0.594
Yes	Week 4	Tezepelumab	9	9 (100.0)	0.33 (0.12)	(0.09, 0.57)	0.46 (0.15)	(0.15, 0.78)	0.007 *
		Placebo	13	13 (100.0)	-0.13 (0.10)	(-0.34, 0.07)			
	Week 8	Tezepelumab	9	7 (77.8)	0.35 (0.14)	(0.07, 0.64)	0.32 (0.18)	(-0.05, 0.68)	0.084
		Placebo	13	12 (92.3)	0.04 (0.11)	(-0.19, 0.27)			
	Week 12	Tezepelumab	9	8 (88.9)	0.32 (0.16)	(-0.02, 0.66)	0.34 (0.21)	(-0.10, 0.78)	0.120
		Placebo	13	12 (92.3)	-0.02 (0.13)	(-0.30, 0.26)			
	Week 20	Tezepelumab	9	8 (88.9)	0.13 (0.13)	(-0.14, 0.40)	0.07 (0.17)	(-0.28, 0.43)	0.672
		Placebo	13	12 (92.3)	0.06 (0.11)	(-0.17, 0.28)			
	Week 28	Tezepelumab	9	8 (88.9)	0.20 (0.18)	(-0.18, 0.57)	0.21 (0.24)	(-0.29, 0.70)	0.394
		Placebo	13	11 (84.6)	-0.01 (0.15)	(-0.32, 0.31)			
	Week 40	Tezepelumab	9	7 (77.8)	0.26 (0.20)	(-0.16, 0.67)	0.16 (0.26)	(-0.38, 0.70)	0.532
		Placebo	13	11 (84.6)	0.09 (0.16)	(-0.25, 0.44)			
	Week 52	Tezepelumab	9	7 (77.8)	0.30 (0.21)	(-0.14, 0.75)	0.16 (0.28)	(-0.41, 0.74)	0.563
		Placebo	13	11 (84.6)	0.14 (0.17)	(-0.22, 0.50)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	128	122 (95.3)	0.22 (0.04)	(0.15, 0.29)	0.15 (0.05)	(0.05, 0.25)	0.003 *
		Placebo	125	123 (98.4)	0.07 (0.04)	(-0.00, 0.14)			
	Week 8	Tezepelumab	128	117 (91.4)	0.22 (0.03)	(0.15, 0.29)	0.12 (0.05)	(0.03, 0.22)	0.014 *
		Placebo	125	120 (96.0)	0.10 (0.03)	(0.03, 0.17)			
	Week 12	Tezepelumab	128	120 (93.8)	0.23 (0.04)	(0.16, 0.31)	0.14 (0.05)	(0.03, 0.24)	0.010 *
		Placebo	125	123 (98.4)	0.10 (0.04)	(0.03, 0.17)			
	Week 20	Tezepelumab	128	111 (86.7)	0.23 (0.04)	(0.16, 0.31)	0.15 (0.05)	(0.05, 0.26)	0.005 *
		Placebo	125	119 (95.2)	0.08 (0.04)	(0.01, 0.16)			
	Week 28	Tezepelumab	128	116 (90.6)	0.22 (0.04)	(0.14, 0.29)	0.18 (0.05)	(0.07, 0.28)	0.001 *
		Placebo	125	120 (96.0)	0.04 (0.04)	(-0.03, 0.12)			
	Week 40	Tezepelumab	128	115 (89.8)	0.24 (0.04)	(0.17, 0.31)	0.15 (0.05)	(0.04, 0.25)	0.006 *
		Placebo	125	119 (95.2)	0.09 (0.04)	(0.02, 0.17)			
	Week 52	Tezepelumab	128	112 (87.5)	0.20 (0.04)	(0.13, 0.28)	0.15 (0.05)	(0.05, 0.25)	0.005 *
		Placebo	125	118 (94.4)	0.05 (0.04)	(-0.02, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
ICS dose level (at study entry)									0.480
Medium/Low	Week 4	Tezepelumab	70	66 (94.3)	0.19 (0.05)	(0.10, 0.28)	0.13 (0.06)	(0.00, 0.25)	0.047 *
		Placebo	73	71 (97.3)	0.07 (0.04)	(-0.02, 0.15)			
	Week 8	Tezepelumab	70	63 (90.0)	0.22 (0.05)	(0.13, 0.31)	0.12 (0.06)	(-0.01, 0.24)	0.074
		Placebo	73	71 (97.3)	0.10 (0.04)	(0.01, 0.19)			
	Week 12	Tezepelumab	70	65 (92.9)	0.19 (0.05)	(0.09, 0.29)	0.08 (0.07)	(-0.06, 0.22)	0.257
		Placebo	73	72 (98.6)	0.11 (0.05)	(0.02, 0.21)			
	Week 20	Tezepelumab	70	61 (87.1)	0.25 (0.05)	(0.14, 0.35)	0.13 (0.07)	(-0.01, 0.28)	0.075
		Placebo	73	71 (97.3)	0.12 (0.05)	(0.02, 0.22)			
	Week 28	Tezepelumab	70	64 (91.4)	0.22 (0.05)	(0.11, 0.32)	0.15 (0.07)	(0.00, 0.29)	0.044 *
		Placebo	73	72 (98.6)	0.07 (0.05)	(-0.03, 0.17)			
	Week 40	Tezepelumab	70	63 (90.0)	0.24 (0.05)	(0.14, 0.34)	0.13 (0.07)	(-0.00, 0.27)	0.054
		Placebo	73	73 (100.0)	0.10 (0.05)	(0.01, 0.20)			
	Week 52	Tezepelumab	70	59 (84.3)	0.22 (0.05)	(0.12, 0.32)	0.14 (0.07)	(-0.00, 0.27)	0.052
		Placebo	73	69 (94.5)	0.09 (0.05)	(-0.01, 0.18)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 4	Tezepelumab	67	65 (97.0)	0.25 (0.05)	(0.15, 0.36)	0.22 (0.08)	(0.07, 0.37)	0.004 *
		Placebo	65	65 (100.0)	0.03 (0.05)	(-0.08, 0.13)			
	Week 8	Tezepelumab	67	61 (91.0)	0.23 (0.05)	(0.14, 0.33)	0.15 (0.07)	(0.01, 0.29)	0.033 *
		Placebo	65	61 (93.8)	0.08 (0.05)	(-0.02, 0.18)			
	Week 12	Tezepelumab	67	63 (94.0)	0.29 (0.05)	(0.18, 0.40)	0.23 (0.08)	(0.08, 0.38)	0.004 *
		Placebo	65	63 (96.9)	0.06 (0.05)	(-0.05, 0.17)			
	Week 20	Tezepelumab	67	58 (86.6)	0.20 (0.05)	(0.10, 0.30)	0.16 (0.07)	(0.02, 0.30)	0.029 *
		Placebo	65	60 (92.3)	0.04 (0.05)	(-0.06, 0.14)			
	Week 28	Tezepelumab	67	60 (89.6)	0.21 (0.06)	(0.10, 0.32)	0.21 (0.08)	(0.05, 0.36)	0.010 *
		Placebo	65	59 (90.8)	0.01 (0.06)	(-0.10, 0.12)			
	Week 40	Tezepelumab	67	59 (88.1)	0.24 (0.06)	(0.13, 0.35)	0.15 (0.08)	(-0.01, 0.31)	0.065
		Placebo	65	57 (87.7)	0.09 (0.06)	(-0.02, 0.20)			
	Week 52	Tezepelumab	67	60 (89.6)	0.19 (0.06)	(0.07, 0.30)	0.16 (0.08)	(0.00, 0.32)	0.050 *
		Placebo	65	60 (92.3)	0.03 (0.06)	(-0.09, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
LAMA use at baseline									0.038 i
Yes	Week 4	Tezepelumab	11	11 (100.0)	0.35 (0.11)	(0.11, 0.58)	0.71 (0.19)	(0.30, 1.12)	0.002 *
		Placebo	6	6 (100.0)	-0.36 (0.15)	(-0.68, -0.04)			
	Week 8	Tezepelumab	11	11 (100.0)	0.42 (0.11)	(0.17, 0.66)	0.65 (0.20)	(0.23, 1.08)	0.005 *
		Placebo	6	6 (100.0)	-0.24 (0.16)	(-0.58, 0.10)			
	Week 12	Tezepelumab	11	11 (100.0)	0.50 (0.14)	(0.20, 0.80)	0.72 (0.24)	(0.20, 1.25)	0.010 *
		Placebo	6	6 (100.0)	-0.22 (0.19)	(-0.64, 0.19)			
	Week 20	Tezepelumab	11	11 (100.0)	0.43 (0.17)	(0.06, 0.80)	0.34 (0.30)	(-0.30, 0.97)	0.274
		Placebo	6	6 (100.0)	0.09 (0.24)	(-0.41, 0.60)			
	Week 28	Tezepelumab	11	10 (90.9)	0.43 (0.15)	(0.11, 0.75)	0.65 (0.26)	(0.10, 1.20)	0.024 *
		Placebo	6	6 (100.0)	-0.22 (0.20)	(-0.65, 0.22)			
	Week 40	Tezepelumab	11	11 (100.0)	0.35 (0.13)	(0.08, 0.62)	0.67 (0.22)	(0.19, 1.14)	0.010 *
		Placebo	6	6 (100.0)	-0.32 (0.18)	(-0.69, 0.06)			
	Week 52	Tezepelumab	11	11 (100.0)	0.44 (0.13)	(0.16, 0.72)	0.80 (0.22)	(0.32, 1.28)	0.003 *
		Placebo	6	6 (100.0)	-0.36 (0.18)	(-0.74, 0.02)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	126	120 (95.2)	0.21 (0.04)	(0.14, 0.29)	0.15 (0.05)	(0.05, 0.25)	0.003 *
		Placebo	132	130 (98.5)	0.06 (0.03)	(-0.00, 0.13)			
	Week 8	Tezepelumab	126	113 (89.7)	0.21 (0.04)	(0.14, 0.28)	0.11 (0.05)	(0.01, 0.21)	0.027 *
		Placebo	132	126 (95.5)	0.10 (0.03)	(0.04, 0.17)			
	Week 12	Tezepelumab	126	117 (92.9)	0.22 (0.04)	(0.14, 0.30)	0.12 (0.05)	(0.02, 0.23)	0.024 *
		Placebo	132	129 (97.7)	0.10 (0.04)	(0.03, 0.17)			
	Week 20	Tezepelumab	126	108 (85.7)	0.21 (0.04)	(0.14, 0.28)	0.13 (0.05)	(0.03, 0.24)	0.009 *
		Placebo	132	125 (94.7)	0.08 (0.04)	(0.01, 0.15)			
	Week 28	Tezepelumab	126	114 (90.5)	0.20 (0.04)	(0.12, 0.28)	0.15 (0.05)	(0.05, 0.26)	0.005 *
		Placebo	132	125 (94.7)	0.05 (0.04)	(-0.03, 0.12)			
	Week 40	Tezepelumab	126	111 (88.1)	0.23 (0.04)	(0.16, 0.31)	0.12 (0.05)	(0.02, 0.23)	0.023 *
		Placebo	132	124 (93.9)	0.11 (0.04)	(0.04, 0.18)			
	Week 52	Tezepelumab	126	108 (85.7)	0.19 (0.04)	(0.11, 0.27)	0.11 (0.05)	(0.01, 0.22)	0.040 *
		Placebo	132	123 (93.2)	0.08 (0.04)	(0.00, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Tiotropium use at baseline									0.403
Yes	Week 4	Tezepelumab	9	9 (100.0)	0.34 (0.13)	(0.03, 0.65)	0.64 (0.27)	(0.00, 1.28)	0.050 *
		Placebo	3	3 (100.0)	-0.30 (0.23)	(-0.85, 0.25)			
	Week 8	Tezepelumab	9	9 (100.0)	0.44 (0.15)	(0.07, 0.81)	0.54 (0.31)	(-0.21, 1.29)	0.131
		Placebo	3	3 (100.0)	-0.10 (0.27)	(-0.75, 0.55)			
	Week 12	Tezepelumab	9	9 (100.0)	0.47 (0.16)	(0.08, 0.85)	0.48 (0.33)	(-0.30, 1.27)	0.190
		Placebo	3	3 (100.0)	-0.02 (0.29)	(-0.69, 0.66)			
	Week 20	Tezepelumab	9	9 (100.0)	0.43 (0.14)	(0.09, 0.76)	0.42 (0.30)	(-0.27, 1.11)	0.195
		Placebo	3	3 (100.0)	0.01 (0.25)	(-0.58, 0.60)			
	Week 28	Tezepelumab	9	8 (88.9)	0.37 (0.17)	(-0.03, 0.77)	0.40 (0.35)	(-0.42, 1.21)	0.287
		Placebo	3	3 (100.0)	-0.03 (0.30)	(-0.73, 0.67)			
	Week 40	Tezepelumab	9	9 (100.0)	0.37 (0.18)	(-0.04, 0.79)	0.56 (0.36)	(-0.28, 1.40)	0.158
		Placebo	3	3 (100.0)	-0.19 (0.31)	(-0.91, 0.53)			
	Week 52	Tezepelumab	9	9 (100.0)	0.40 (0.16)	(0.02, 0.77)	0.83 (0.33)	(0.07, 1.59)	0.037 *
		Placebo	3	3 (100.0)	-0.43 (0.28)	(-1.09, 0.23)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	128	122 (95.3)	0.22 (0.04)	(0.15, 0.29)	0.16 (0.05)	(0.07, 0.26)	0.001 *
		Placebo	135	133 (98.5)	0.05 (0.03)	(-0.02, 0.12)			
	Week 8	Tezepelumab	128	115 (89.8)	0.21 (0.04)	(0.14, 0.28)	0.12 (0.05)	(0.02, 0.22)	0.014 *
		Placebo	135	129 (95.6)	0.09 (0.03)	(0.03, 0.16)			
	Week 12	Tezepelumab	128	119 (93.0)	0.23 (0.04)	(0.15, 0.30)	0.14 (0.05)	(0.03, 0.24)	0.010 *
		Placebo	135	132 (97.8)	0.09 (0.04)	(0.01, 0.16)			
	Week 20	Tezepelumab	128	110 (85.9)	0.21 (0.04)	(0.14, 0.29)	0.14 (0.05)	(0.03, 0.24)	0.011 *
		Placebo	135	128 (94.8)	0.08 (0.04)	(0.01, 0.15)			
	Week 28	Tezepelumab	128	116 (90.6)	0.21 (0.04)	(0.13, 0.28)	0.17 (0.05)	(0.06, 0.28)	0.002 *
		Placebo	135	128 (94.8)	0.04 (0.04)	(-0.04, 0.11)			
	Week 40	Tezepelumab	128	113 (88.3)	0.23 (0.04)	(0.16, 0.31)	0.14 (0.05)	(0.03, 0.24)	0.012 *
		Placebo	135	127 (94.1)	0.10 (0.04)	(0.02, 0.17)			
	Week 52	Tezepelumab	128	110 (85.9)	0.20 (0.04)	(0.12, 0.27)	0.13 (0.05)	(0.02, 0.24)	0.019 *
		Placebo	135	126 (93.3)	0.07 (0.04)	(-0.01, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Montelukast/ Cromoglicic acid use at baseline									0.443
Yes	Week 4	Tezepelumab	29	26 (89.7)	0.32 (0.08)	(0.15, 0.48)	0.34 (0.11)	(0.13, 0.56)	0.002 *
		Placebo	37	37 (100.0)	-0.03 (0.07)	(-0.16, 0.11)			
	Week 8	Tezepelumab	29	24 (82.8)	0.31 (0.08)	(0.15, 0.48)	0.21 (0.11)	(-0.01, 0.43)	0.056
		Placebo	37	35 (94.6)	0.10 (0.07)	(-0.04, 0.24)			
	Week 12	Tezepelumab	29	27 (93.1)	0.30 (0.09)	(0.13, 0.48)	0.14 (0.12)	(-0.09, 0.37)	0.218
		Placebo	37	36 (97.3)	0.16 (0.08)	(0.01, 0.31)			
	Week 20	Tezepelumab	29	23 (79.3)	0.26 (0.10)	(0.06, 0.45)	0.10 (0.13)	(-0.15, 0.36)	0.425
		Placebo	37	35 (94.6)	0.15 (0.08)	(-0.01, 0.32)			
	Week 28	Tezepelumab	29	24 (82.8)	0.23 (0.10)	(0.04, 0.43)	0.18 (0.13)	(-0.08, 0.43)	0.170
		Placebo	37	35 (94.6)	0.05 (0.08)	(-0.11, 0.22)			
	Week 40	Tezepelumab	29	23 (79.3)	0.29 (0.09)	(0.12, 0.47)	0.23 (0.11)	(0.00, 0.45)	0.050 *
		Placebo	37	35 (94.6)	0.07 (0.07)	(-0.08, 0.21)			
	Week 52	Tezepelumab	29	22 (75.9)	0.26 (0.10)	(0.07, 0.46)	0.17 (0.13)	(-0.08, 0.42)	0.184
		Placebo	37	35 (94.6)	0.09 (0.08)	(-0.07, 0.25)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	108	105 (97.2)	0.20 (0.04)	(0.12, 0.27)	0.12 (0.05)	(0.02, 0.23)	0.024 *
		Placebo	101	99 (98.0)	0.08 (0.04)	(-0.00, 0.15)			
	Week 8	Tezepelumab	108	100 (92.6)	0.21 (0.04)	(0.13, 0.28)	0.12 (0.05)	(0.01, 0.22)	0.026 *
		Placebo	101	97 (96.0)	0.09 (0.04)	(0.01, 0.16)			
	Week 12	Tezepelumab	108	101 (93.5)	0.23 (0.04)	(0.15, 0.30)	0.16 (0.06)	(0.05, 0.28)	0.005 *
		Placebo	101	99 (98.0)	0.06 (0.04)	(-0.02, 0.14)			
	Week 20	Tezepelumab	108	96 (88.9)	0.22 (0.04)	(0.14, 0.29)	0.16 (0.06)	(0.05, 0.27)	0.004 *
		Placebo	101	96 (95.0)	0.05 (0.04)	(-0.02, 0.13)			
	Week 28	Tezepelumab	108	100 (92.6)	0.21 (0.04)	(0.13, 0.29)	0.18 (0.06)	(0.06, 0.29)	0.003 *
		Placebo	101	96 (95.0)	0.03 (0.04)	(-0.05, 0.11)			
	Week 40	Tezepelumab	108	99 (91.7)	0.22 (0.04)	(0.14, 0.30)	0.12 (0.06)	(0.01, 0.24)	0.038 *
		Placebo	101	95 (94.1)	0.10 (0.04)	(0.02, 0.18)			
	Week 52	Tezepelumab	108	97 (89.8)	0.19 (0.04)	(0.11, 0.27)	0.14 (0.06)	(0.03, 0.26)	0.016 *
		Placebo	101	94 (93.1)	0.05 (0.04)	(-0.03, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	1.84 (0.57)	0.7	1.39	1.77	2.21	3.9	
			Placebo	123	123 (100.0)	1.83 (0.60)	0.7	1.41	1.72	2.19	3.3	
		Week 4	Tezepelumab	128	122 (95.3)	2.05 (0.74)	0.9	1.53	1.98	2.45	4.9	
			Placebo	123	121 (98.4)	1.88 (0.63)	0.7	1.47	1.86	2.34	3.2	
		Week 8	Tezepelumab	128	115 (89.8)	2.05 (0.66)	0.7	1.55	1.98	2.39	5.1	
			Placebo	123	117 (95.1)	1.93 (0.65)	0.7	1.49	1.93	2.39	3.6	
		Week 12	Tezepelumab	128	119 (93.0)	2.09 (0.71)	0.9	1.52	1.99	2.55	5.1	
			Placebo	123	120 (97.6)	1.90 (0.68)	0.5	1.44	1.84	2.45	4.1	
		Week 20	Tezepelumab	128	111 (86.7)	2.05 (0.73)	1.0	1.49	1.92	2.52	5.5	
			Placebo	123	117 (95.1)	1.90 (0.66)	0.5	1.39	1.90	2.34	3.4	
		Week 28	Tezepelumab	128	115 (89.8)	2.04 (0.74)	0.8	1.45	1.97	2.48	5.4	
			Placebo	123	117 (95.1)	1.86 (0.67)	0.7	1.42	1.85	2.24	3.6	
		Week 40	Tezepelumab	128	114 (89.1)	2.04 (0.70)	0.7	1.44	2.00	2.52	4.7	
			Placebo	123	117 (95.1)	1.94 (0.70)	0.6	1.43	1.82	2.43	4.0	
		Week 52	Tezepelumab	128	111 (86.7)	2.03 (0.66)	0.9	1.50	1.94	2.41	4.7	
			Placebo	123	116 (94.3)	1.91 (0.72)	0.6	1.34	1.83	2.44	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	128	122 (95.3)	0.22 (0.45)	-0.6	-0.02	0.12	0.38	2.4	0.41 [0.16, 0.66]
			Placebo	123	121 (98.4)	0.05 (0.38)	-1.1	-0.12	0.03	0.18	1.2	
		Week 8	Tezepelumab	128	115 (89.8)	0.22 (0.41)	-0.7	-0.02	0.16	0.40	2.2	0.32 [0.06, 0.58]
			Placebo	123	117 (95.1)	0.09 (0.40)	-1.5	-0.09	0.11	0.26	1.3	
		Week 12	Tezepelumab	128	119 (93.0)	0.25 (0.46)	-0.6	-0.05	0.16	0.43	2.1	0.38 [0.13, 0.64]
			Placebo	123	120 (97.6)	0.09 (0.40)	-1.2	-0.11	0.07	0.28	1.3	
		Week 20	Tezepelumab	128	111 (86.7)	0.23 (0.47)	-0.6	-0.07	0.14	0.47	2.2	0.34 [0.08, 0.60]
			Placebo	123	117 (95.1)	0.09 (0.37)	-1.0	-0.06	0.07	0.24	1.8	
		Week 28	Tezepelumab	128	115 (89.8)	0.22 (0.50)	-1.0	-0.11	0.09	0.51	2.2	0.41 [0.15, 0.67]
			Placebo	123	117 (95.1)	0.04 (0.38)	-1.1	-0.14	0.03	0.25	1.5	
		Week 40	Tezepelumab	128	114 (89.1)	0.23 (0.47)	-0.7	-0.07	0.19	0.47	2.3	0.30 [0.05, 0.56]
			Placebo	123	117 (95.1)	0.10 (0.38)	-1.3	-0.11	0.06	0.31	1.1	
		Week 52	Tezepelumab	128	111 (86.7)	0.21 (0.44)	-0.8	-0.04	0.15	0.44	2.3	0.30 [0.04, 0.56]
			Placebo	123	116 (94.3)	0.08 (0.41)	-1.0	-0.15	0.05	0.25	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.71 (0.78)	0.7	1.24	1.40	1.99	3.1	
			Placebo	15	15 (100.0)	1.76 (0.43)	1.2	1.45	1.58	2.23	2.6	
		Week 4	Tezepelumab	9	9 (100.0)	1.91 (0.85)	1.1	1.25	1.51	2.30	3.5	
			Placebo	15	15 (100.0)	1.79 (0.46)	0.9	1.58	1.75	1.94	2.7	
		Week 8	Tezepelumab	9	9 (100.0)	1.89 (0.71)	1.3	1.35	1.48	2.49	3.2	
			Placebo	15	15 (100.0)	1.84 (0.37)	1.4	1.50	1.75	2.08	2.6	
		Week 12	Tezepelumab	9	9 (100.0)	1.91 (0.83)	1.0	1.28	1.45	2.53	3.3	
			Placebo	15	15 (100.0)	1.89 (0.44)	1.1	1.60	1.81	2.38	2.7	
		Week 20	Tezepelumab	9	8 (88.9)	1.78 (0.72)	1.0	1.24	1.50	2.41	3.0	
			Placebo	15	14 (93.3)	1.88 (0.40)	1.2	1.65	1.78	1.99	2.8	
		Week 28	Tezepelumab	9	9 (100.0)	2.01 (0.84)	1.2	1.27	1.70	2.44	3.5	
			Placebo	15	14 (93.3)	1.89 (0.51)	1.2	1.53	1.80	2.37	2.9	
		Week 40	Tezepelumab	9	8 (88.9)	2.05 (0.72)	1.3	1.35	2.03	2.62	3.1	
			Placebo	15	13 (86.7)	1.79 (0.42)	1.4	1.44	1.71	2.02	2.7	
		Week 52	Tezepelumab	9	8 (88.9)	1.80 (0.69)	1.2	1.28	1.51	2.31	3.1	
			Placebo	15	13 (86.7)	1.80 (0.49)	0.7	1.63	1.75	2.09	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	0.21 (0.18)	-0.0	0.06	0.13	0.38	0.5	0.83 [-0.03, 1.69]
			Placebo	15	15 (100.0)	0.03 (0.22)	-0.5	-0.03	0.08	0.19	0.3	
		Week 8	Tezepelumab	9	9 (100.0)	0.19 (0.25)	-0.2	-0.03	0.19	0.31	0.6	0.50 [-0.34, 1.34]
			Placebo	15	15 (100.0)	0.08 (0.18)	-0.3	-0.04	0.06	0.24	0.4	
		Week 12	Tezepelumab	9	9 (100.0)	0.20 (0.32)	-0.2	-0.08	0.21	0.43	0.8	0.19 [-0.64, 1.01]
			Placebo	15	15 (100.0)	0.13 (0.42)	-0.7	0.00	0.12	0.32	1.1	
		Week 20	Tezepelumab	9	8 (88.9)	0.10 (0.25)	-0.3	-0.07	0.11	0.31	0.4	-0.01 [-0.88, 0.85]
			Placebo	15	14 (93.3)	0.10 (0.31)	-0.7	0.02	0.13	0.26	0.7	
		Week 28	Tezepelumab	9	9 (100.0)	0.30 (0.35)	-0.3	0.15	0.30	0.47	0.9	0.72 [-0.14, 1.59]
			Placebo	15	14 (93.3)	0.11 (0.21)	-0.3	-0.02	0.15	0.23	0.4	
		Week 40	Tezepelumab	9	8 (88.9)	0.29 (0.33)	-0.2	0.05	0.24	0.55	0.8	0.83 [-0.09, 1.75]
			Placebo	15	13 (86.7)	0.06 (0.23)	-0.5	0.00	0.17	0.23	0.3	
		Week 52	Tezepelumab	9	8 (88.9)	0.12 (0.30)	-0.4	0.01	0.08	0.30	0.6	0.39 [-0.50, 1.28]
			Placebo	15	13 (86.7)	-0.00 (0.33)	-0.6	-0.08	0.07	0.16	0.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	10	10 (100.0)	1.73 (0.66)	0.9	1.13	1.62	2.18	2.8	
			Placebo	9	9 (100.0)	1.68 (0.55)	1.0	1.36	1.48	1.93	2.7	
		Week 4	Tezepelumab	10	9 (90.0)	1.80 (0.74)	0.9	1.26	1.70	2.30	3.2	
			Placebo	9	9 (100.0)	1.75 (0.72)	0.8	1.33	1.75	1.94	3.1	
		Week 8	Tezepelumab	10	9 (90.0)	1.86 (0.74)	1.3	1.35	1.47	2.11	3.4	
			Placebo	9	9 (100.0)	1.85 (0.54)	1.4	1.50	1.69	2.05	3.1	
		Week 12	Tezepelumab	10	10 (100.0)	1.89 (0.81)	0.9	1.19	1.76	2.68	3.1	
			Placebo	9	9 (100.0)	1.94 (0.49)	1.2	1.65	1.81	2.23	2.8	
		Week 20	Tezepelumab	10	7 (70.0)	1.79 (0.88)	1.0	1.03	1.53	2.42	3.5	
			Placebo	9	9 (100.0)	1.79 (0.60)	1.2	1.50	1.69	1.86	3.2	
		Week 28	Tezepelumab	10	8 (80.0)	1.93 (0.70)	1.1	1.34	1.77	2.64	2.9	
			Placebo	9	8 (88.9)	1.90 (0.61)	1.2	1.47	1.77	2.27	3.0	
		Week 40	Tezepelumab	10	7 (70.0)	1.92 (0.88)	1.1	1.31	1.63	2.71	3.5	
			Placebo	9	9 (100.0)	1.83 (0.57)	1.4	1.45	1.62	2.02	3.2	
		Week 52	Tezepelumab	10	7 (70.0)	1.89 (0.86)	1.2	1.16	1.66	2.67	3.5	
			Placebo	9	8 (88.9)	1.68 (0.68)	0.7	1.34	1.66	1.88	3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	10	9 (90.0)	0.12 (0.20)	-0.1	-0.06	0.11	0.34	0.4	0.23 [-0.70, 1.16]
			Placebo	9	9 (100.0)	0.07 (0.22)	-0.3	-0.03	0.13	0.20	0.4	
		Week 8	Tezepelumab	10	9 (90.0)	0.24 (0.29)	-0.4	0.17	0.31	0.48	0.6	0.26 [-0.67, 1.19]
			Placebo	9	9 (100.0)	0.17 (0.22)	-0.3	0.14	0.21	0.30	0.4	
		Week 12	Tezepelumab	10	10 (100.0)	0.16 (0.28)	-0.1	-0.08	0.11	0.29	0.8	-0.29 [-1.19, 0.62]
			Placebo	9	9 (100.0)	0.27 (0.45)	-0.5	0.12	0.19	0.47	1.1	
		Week 20	Tezepelumab	10	7 (70.0)	0.17 (0.27)	-0.2	-0.06	0.13	0.38	0.6	0.17 [-0.82, 1.16]
			Placebo	9	9 (100.0)	0.11 (0.39)	-0.7	0.02	0.07	0.33	0.7	
		Week 28	Tezepelumab	10	8 (80.0)	0.33 (0.28)	0.0	0.19	0.27	0.39	0.9	0.65 [-0.36, 1.66]
			Placebo	9	8 (88.9)	0.18 (0.15)	-0.0	0.06	0.19	0.32	0.4	
		Week 40	Tezepelumab	10	7 (70.0)	0.40 (0.26)	0.2	0.20	0.25	0.70	0.8	0.90 [-0.15, 1.94]
			Placebo	9	9 (100.0)	0.15 (0.30)	-0.3	0.00	0.17	0.24	0.7	
		Week 52	Tezepelumab	10	7 (70.0)	0.33 (0.22)	0.0	0.09	0.40	0.49	0.6	1.27 [0.14, 2.39]
			Placebo	9	8 (88.9)	-0.04 (0.35)	-0.6	-0.34	0.11	0.21	0.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	127	127 (100.0)	1.84 (0.58)	0.7	1.38	1.75	2.21	3.9	
			Placebo	129	129 (100.0)	1.83 (0.59)	0.7	1.43	1.72	2.19	3.3	
		Week 4	Tezepelumab	127	122 (96.1)	2.06 (0.74)	0.9	1.52	2.00	2.45	4.9	
			Placebo	129	127 (98.4)	1.88 (0.60)	0.7	1.48	1.83	2.34	3.2	
		Week 8	Tezepelumab	127	115 (90.6)	2.05 (0.66)	0.7	1.55	2.03	2.44	5.1	
			Placebo	129	123 (95.3)	1.92 (0.63)	0.7	1.49	1.92	2.37	3.6	
		Week 12	Tezepelumab	127	118 (92.9)	2.09 (0.71)	0.9	1.51	2.00	2.55	5.1	
			Placebo	129	126 (97.7)	1.90 (0.67)	0.5	1.44	1.84	2.40	4.1	
		Week 20	Tezepelumab	127	112 (88.2)	2.05 (0.72)	1.0	1.49	1.92	2.51	5.5	
			Placebo	129	122 (94.6)	1.91 (0.64)	0.5	1.44	1.90	2.34	3.4	
		Week 28	Tezepelumab	127	116 (91.3)	2.04 (0.75)	0.8	1.44	1.98	2.46	5.4	
			Placebo	129	123 (95.3)	1.86 (0.66)	0.7	1.42	1.84	2.27	3.6	
		Week 40	Tezepelumab	127	115 (90.6)	2.05 (0.69)	0.7	1.44	2.01	2.52	4.7	
			Placebo	129	121 (93.8)	1.93 (0.69)	0.6	1.43	1.82	2.41	4.0	
		Week 52	Tezepelumab	127	112 (88.2)	2.02 (0.65)	0.9	1.49	1.95	2.38	4.7	
			Placebo	129	121 (93.8)	1.91 (0.70)	0.6	1.37	1.86	2.42	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	127	122 (96.1)	0.23 (0.45)	-0.6	-0.02	0.12	0.39	2.4	0.44 [0.19, 0.69]
			Placebo	129	127 (98.4)	0.05 (0.37)	-1.1	-0.12	0.03	0.18	1.2	
		Week 8	Tezepelumab	127	115 (90.6)	0.22 (0.41)	-0.7	-0.03	0.15	0.40	2.2	0.33 [0.07, 0.58]
			Placebo	129	123 (95.3)	0.08 (0.39)	-1.5	-0.09	0.08	0.24	1.3	
		Week 12	Tezepelumab	127	118 (92.9)	0.25 (0.46)	-0.6	-0.04	0.17	0.43	2.1	0.41 [0.16, 0.66]
			Placebo	129	126 (97.7)	0.08 (0.40)	-1.2	-0.11	0.06	0.28	1.3	
		Week 20	Tezepelumab	127	112 (88.2)	0.23 (0.47)	-0.6	-0.08	0.14	0.43	2.2	0.33 [0.07, 0.59]
			Placebo	129	122 (94.6)	0.09 (0.37)	-1.0	-0.06	0.07	0.24	1.8	
		Week 28	Tezepelumab	127	116 (91.3)	0.22 (0.50)	-1.0	-0.11	0.08	0.52	2.2	0.41 [0.16, 0.67]
			Placebo	129	123 (95.3)	0.04 (0.37)	-1.1	-0.15	0.03	0.23	1.5	
		Week 40	Tezepelumab	127	115 (90.6)	0.23 (0.47)	-0.7	-0.07	0.16	0.44	2.3	0.31 [0.05, 0.57]
			Placebo	129	121 (93.8)	0.10 (0.38)	-1.3	-0.10	0.06	0.30	1.1	
		Week 52	Tezepelumab	127	112 (88.2)	0.20 (0.44)	-0.8	-0.05	0.12	0.39	2.3	0.27 [0.01, 0.53]
			Placebo	129	121 (93.8)	0.08 (0.40)	-1.0	-0.13	0.05	0.25	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	61	61 (100.0)	1.84 (0.59)	0.7	1.37	1.92	2.21	3.3	
			Placebo	60	60 (100.0)	1.86 (0.63)	0.8	1.42	1.80	2.28	3.3	
		Week 4	Tezepelumab	61	61 (100.0)	2.03 (0.74)	0.9	1.48	1.96	2.39	4.5	
			Placebo	60	58 (96.7)	1.87 (0.62)	0.7	1.45	1.85	2.38	3.2	
		Week 8	Tezepelumab	61	57 (93.4)	1.99 (0.58)	1.0	1.48	1.97	2.37	3.4	
			Placebo	60	58 (96.7)	1.96 (0.71)	0.7	1.48	1.96	2.47	3.6	
		Week 12	Tezepelumab	61	59 (96.7)	2.00 (0.70)	0.9	1.47	1.95	2.53	4.6	
			Placebo	60	59 (98.3)	1.92 (0.68)	0.7	1.44	1.82	2.46	3.6	
		Week 20	Tezepelumab	61	57 (93.4)	1.98 (0.69)	1.0	1.47	1.92	2.44	4.1	
			Placebo	60	55 (91.7)	1.93 (0.69)	0.8	1.33	1.98	2.46	3.4	
		Week 28	Tezepelumab	61	59 (96.7)	1.98 (0.72)	0.8	1.39	1.90	2.42	4.6	
			Placebo	60	55 (91.7)	1.87 (0.71)	0.7	1.28	1.84	2.34	3.4	
		Week 40	Tezepelumab	61	57 (93.4)	1.99 (0.70)	0.7	1.43	1.98	2.50	3.6	
			Placebo	60	56 (93.3)	1.94 (0.70)	0.7	1.49	1.75	2.53	3.5	
		Week 52	Tezepelumab	61	54 (88.5)	1.93 (0.64)	1.0	1.36	1.91	2.29	3.5	
			Placebo	60	54 (90.0)	1.89 (0.68)	0.7	1.30	1.80	2.51	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	61	61 (100.0)	0.19 (0.48)	-0.6	-0.02	0.07	0.32	2.4	0.39 [0.03, 0.75]
			Placebo	60	58 (96.7)	0.03 (0.36)	-1.1	-0.12	0.04	0.14	1.1	
		Week 8	Tezepelumab	61	57 (93.4)	0.16 (0.36)	-0.5	-0.04	0.14	0.31	2.2	0.14 [-0.22, 0.51]
			Placebo	60	58 (96.7)	0.11 (0.40)	-1.5	-0.09	0.07	0.22	1.3	
		Week 12	Tezepelumab	61	59 (96.7)	0.17 (0.47)	-0.6	-0.13	0.05	0.33	2.1	0.24 [-0.13, 0.60]
			Placebo	60	59 (98.3)	0.06 (0.38)	-0.9	-0.12	0.05	0.24	1.1	
		Week 20	Tezepelumab	61	57 (93.4)	0.14 (0.44)	-0.6	-0.10	0.04	0.35	2.2	0.07 [-0.30, 0.44]
			Placebo	60	55 (91.7)	0.11 (0.42)	-0.9	-0.07	0.05	0.23	1.8	
		Week 28	Tezepelumab	61	59 (96.7)	0.15 (0.49)	-0.9	-0.13	0.01	0.30	2.2	0.30 [-0.07, 0.67]
			Placebo	60	55 (91.7)	0.02 (0.38)	-1.1	-0.15	-0.01	0.22	1.5	
		Week 40	Tezepelumab	61	57 (93.4)	0.18 (0.48)	-0.7	-0.08	0.12	0.38	2.3	0.21 [-0.16, 0.58]
			Placebo	60	56 (93.3)	0.09 (0.35)	-1.3	-0.08	0.08	0.28	1.0	
		Week 52	Tezepelumab	61	54 (88.5)	0.11 (0.44)	-0.8	-0.11	0.05	0.25	2.3	0.13 [-0.25, 0.51]
			Placebo	60	54 (90.0)	0.06 (0.38)	-1.0	-0.13	0.05	0.23	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	76	76 (100.0)	1.82 (0.58)	0.7	1.38	1.73	2.18	3.9	
			Placebo	78	78 (100.0)	1.79 (0.56)	0.7	1.43	1.70	2.19	3.2	
		Week 4	Tezepelumab	76	70 (92.1)	2.05 (0.75)	0.9	1.53	1.98	2.47	4.9	
			Placebo	78	78 (100.0)	1.86 (0.61)	0.7	1.48	1.80	2.27	3.2	
		Week 8	Tezepelumab	76	67 (88.2)	2.07 (0.72)	0.7	1.53	2.03	2.55	5.1	
			Placebo	78	74 (94.9)	1.88 (0.55)	0.7	1.54	1.88	2.28	3.0	
		Week 12	Tezepelumab	76	69 (90.8)	2.14 (0.74)	0.9	1.61	2.04	2.55	5.1	
			Placebo	78	76 (97.4)	1.89 (0.64)	0.5	1.46	1.84	2.35	4.1	
		Week 20	Tezepelumab	76	62 (81.6)	2.08 (0.77)	1.0	1.51	1.86	2.58	5.5	
			Placebo	78	76 (97.4)	1.88 (0.60)	0.5	1.51	1.82	2.27	3.1	
		Week 28	Tezepelumab	76	65 (85.5)	2.09 (0.77)	1.0	1.49	2.01	2.54	5.4	
			Placebo	78	76 (97.4)	1.86 (0.62)	0.7	1.53	1.84	2.23	3.6	
		Week 40	Tezepelumab	76	65 (85.5)	2.08 (0.71)	1.0	1.50	2.01	2.59	4.7	
			Placebo	78	74 (94.9)	1.91 (0.67)	0.6	1.39	1.86	2.32	4.0	
		Week 52	Tezepelumab	76	65 (85.5)	2.08 (0.68)	0.9	1.58	1.96	2.44	4.7	
			Placebo	78	75 (96.2)	1.90 (0.71)	0.6	1.37	1.80	2.31	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	76	70 (92.1)	0.25 (0.40)	-0.6	-0.02	0.15	0.41	2.1	0.47 [0.14, 0.80]
			Placebo	78	78 (100.0)	0.07 (0.36)	-1.1	-0.12	0.05	0.24	1.2	
		Week 8	Tezepelumab	76	67 (88.2)	0.27 (0.43)	-0.7	0.02	0.18	0.47	2.2	0.47 [0.14, 0.81]
			Placebo	78	74 (94.9)	0.08 (0.37)	-0.9	-0.09	0.13	0.27	1.1	
		Week 12	Tezepelumab	76	69 (90.8)	0.32 (0.42)	-0.6	0.02	0.22	0.47	1.9	0.49 [0.16, 0.82]
			Placebo	78	76 (97.4)	0.11 (0.41)	-1.2	-0.09	0.11	0.32	1.3	
		Week 20	Tezepelumab	76	62 (81.6)	0.30 (0.47)	-0.6	0.02	0.21	0.52	1.9	0.57 [0.23, 0.91]
			Placebo	78	76 (97.4)	0.07 (0.33)	-1.0	-0.05	0.08	0.26	1.0	
		Week 28	Tezepelumab	76	65 (85.5)	0.29 (0.48)	-1.0	0.00	0.25	0.52	1.9	0.54 [0.21, 0.88]
			Placebo	78	76 (97.4)	0.07 (0.35)	-1.1	-0.07	0.13	0.27	0.9	
		Week 40	Tezepelumab	76	65 (85.5)	0.29 (0.44)	-0.7	0.04	0.24	0.50	1.9	0.44 [0.11, 0.78]
			Placebo	78	74 (94.9)	0.11 (0.38)	-1.1	-0.12	0.06	0.31	1.1	
		Week 52	Tezepelumab	76	65 (85.5)	0.29 (0.42)	-0.7	0.02	0.23	0.57	2.0	0.47 [0.13, 0.81]
			Placebo	78	75 (96.2)	0.09 (0.42)	-0.7	-0.15	0.06	0.29	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	75	75 (100.0)	1.79 (0.55)	0.7	1.37	1.78	2.18	3.3	
			Placebo	72	72 (100.0)	1.74 (0.56)	0.7	1.40	1.68	2.15	3.0	
		Week 4	Tezepelumab	75	72 (96.0)	1.95 (0.66)	0.9	1.42	1.89	2.26	3.8	
			Placebo	72	70 (97.2)	1.84 (0.63)	0.7	1.41	1.82	2.34	3.1	
		Week 8	Tezepelumab	75	69 (92.0)	1.97 (0.59)	0.7	1.41	1.98	2.37	3.5	
			Placebo	72	69 (95.8)	1.85 (0.65)	0.7	1.46	1.83	2.31	3.4	
		Week 12	Tezepelumab	75	70 (93.3)	2.00 (0.60)	0.9	1.49	1.95	2.40	3.5	
			Placebo	72	71 (98.6)	1.83 (0.64)	0.6	1.41	1.76	2.34	3.3	
		Week 20	Tezepelumab	75	65 (86.7)	1.93 (0.60)	1.0	1.47	1.85	2.44	3.3	
			Placebo	72	69 (95.8)	1.86 (0.66)	0.5	1.39	1.90	2.30	3.4	
		Week 28	Tezepelumab	75	68 (90.7)	1.94 (0.61)	0.9	1.44	1.90	2.38	3.4	
			Placebo	72	69 (95.8)	1.80 (0.64)	0.7	1.35	1.71	2.17	3.4	
		Week 40	Tezepelumab	75	67 (89.3)	1.97 (0.67)	0.7	1.41	1.98	2.44	3.6	
			Placebo	72	69 (95.8)	1.85 (0.67)	0.7	1.35	1.76	2.41	3.5	
		Week 52	Tezepelumab	75	66 (88.0)	1.92 (0.58)	0.9	1.42	1.87	2.35	3.3	
			Placebo	72	69 (95.8)	1.82 (0.66)	0.6	1.34	1.72	2.27	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	75	72 (96.0)	0.17 (0.41)	-0.6	-0.04	0.09	0.31	2.1	0.16 [-0.17, 0.49]
			Placebo	72	70 (97.2)	0.11 (0.32)	-0.7	-0.08	0.06	0.22	1.1	
		Week 8	Tezepelumab	75	69 (92.0)	0.15 (0.37)	-0.7	-0.04	0.10	0.31	2.2	0.10 [-0.23, 0.43]
			Placebo	72	69 (95.8)	0.12 (0.38)	-0.8	-0.08	0.07	0.20	1.3	
		Week 12	Tezepelumab	75	70 (93.3)	0.19 (0.42)	-0.6	-0.08	0.11	0.33	1.9	0.23 [-0.10, 0.57]
			Placebo	72	71 (98.6)	0.10 (0.37)	-0.9	-0.06	0.06	0.24	1.3	
		Week 20	Tezepelumab	75	65 (86.7)	0.16 (0.42)	-0.6	-0.09	0.10	0.39	1.9	0.08 [-0.26, 0.41]
			Placebo	72	69 (95.8)	0.12 (0.39)	-0.8	-0.04	0.04	0.23	1.8	
		Week 28	Tezepelumab	75	68 (90.7)	0.16 (0.44)	-0.9	-0.11	0.06	0.38	1.9	0.26 [-0.07, 0.60]
			Placebo	72	69 (95.8)	0.05 (0.36)	-1.1	-0.12	0.03	0.22	1.5	
		Week 40	Tezepelumab	75	67 (89.3)	0.20 (0.44)	-0.7	-0.05	0.16	0.40	1.9	0.28 [-0.06, 0.61]
			Placebo	72	69 (95.8)	0.10 (0.31)	-0.8	-0.09	0.09	0.26	1.0	
		Week 52	Tezepelumab	75	66 (88.0)	0.14 (0.41)	-0.8	-0.05	0.12	0.28	2.0	0.17 [-0.17, 0.51]
			Placebo	72	69 (95.8)	0.07 (0.38)	-1.0	-0.11	0.05	0.18	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	1.88 (0.63)	0.7	1.38	1.78	2.37	3.9	
			Placebo	65	65 (100.0)	1.91 (0.61)	1.0	1.45	1.74	2.26	3.3	
		Week 4	Tezepelumab	60	57 (95.0)	2.17 (0.83)	0.9	1.62	2.01	2.68	4.9	
			Placebo	65	65 (100.0)	1.89 (0.60)	0.7	1.55	1.81	2.24	3.2	
		Week 8	Tezepelumab	60	53 (88.3)	2.14 (0.74)	1.1	1.58	2.07	2.56	5.1	
			Placebo	65	62 (95.4)	1.98 (0.59)	0.8	1.55	1.95	2.37	3.6	
		Week 12	Tezepelumab	60	56 (93.3)	2.19 (0.84)	0.9	1.58	2.01	2.69	5.1	
			Placebo	65	63 (96.9)	1.97 (0.67)	0.5	1.52	1.85	2.46	4.1	
		Week 20	Tezepelumab	60	52 (86.7)	2.18 (0.86)	1.0	1.53	1.95	2.77	5.5	
			Placebo	65	61 (93.8)	1.93 (0.61)	0.7	1.51	1.86	2.32	3.3	
		Week 28	Tezepelumab	60	54 (90.0)	2.18 (0.88)	0.8	1.49	2.11	2.73	5.4	
			Placebo	65	61 (93.8)	1.94 (0.67)	0.8	1.58	1.90	2.37	3.6	
		Week 40	Tezepelumab	60	53 (88.3)	2.14 (0.74)	1.0	1.59	2.16	2.65	4.7	
			Placebo	65	60 (92.3)	2.00 (0.69)	0.6	1.53	1.87	2.34	4.0	
		Week 52	Tezepelumab	60	51 (85.0)	2.14 (0.75)	1.1	1.58	2.06	2.50	4.7	
			Placebo	65	59 (90.8)	1.98 (0.73)	0.7	1.38	1.97	2.51	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	60	57 (95.0)	0.30 (0.47)	-0.5	0.01	0.18	0.45	2.4	0.73 [0.36, 1.09]
			Placebo	65	65 (100.0)	-0.02 (0.40)	-1.1	-0.19	0.00	0.17	1.2	
		Week 8	Tezepelumab	60	53 (88.3)	0.30 (0.44)	-0.5	0.04	0.24	0.47	2.2	0.60 [0.23, 0.98]
			Placebo	65	62 (95.4)	0.06 (0.39)	-1.5	-0.11	0.14	0.28	0.9	
		Week 12	Tezepelumab	60	56 (93.3)	0.33 (0.48)	-0.4	-0.03	0.22	0.62	2.1	0.54 [0.17, 0.91]
			Placebo	65	63 (96.9)	0.08 (0.44)	-1.2	-0.16	0.11	0.31	1.2	
		Week 20	Tezepelumab	60	52 (86.7)	0.32 (0.49)	-0.4	-0.02	0.21	0.56	2.2	0.67 [0.29, 1.05]
			Placebo	65	61 (93.8)	0.05 (0.33)	-1.0	-0.08	0.10	0.24	0.7	
		Week 28	Tezepelumab	60	54 (90.0)	0.32 (0.54)	-1.0	0.00	0.19	0.54	2.2	0.63 [0.26, 1.01]
			Placebo	65	61 (93.8)	0.03 (0.37)	-1.1	-0.18	0.08	0.27	0.9	
		Week 40	Tezepelumab	60	53 (88.3)	0.30 (0.49)	-0.7	-0.02	0.26	0.54	2.3	0.42 [0.05, 0.79]
			Placebo	65	60 (92.3)	0.10 (0.44)	-1.3	-0.11	0.05	0.31	1.1	
		Week 52	Tezepelumab	60	51 (85.0)	0.30 (0.46)	-0.4	0.01	0.16	0.64	2.3	0.50 [0.12, 0.88]
			Placebo	65	59 (90.8)	0.08 (0.42)	-0.9	-0.20	0.06	0.35	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	65	65 (100.0)	1.83 (0.53)	0.7	1.40	1.79	2.17	3.3	
			Placebo	62	62 (100.0)	1.69 (0.55)	0.7	1.33	1.65	2.12	2.9	
		Week 4	Tezepelumab	65	63 (96.9)	1.98 (0.65)	0.9	1.42	2.00	2.26	3.8	
			Placebo	62	60 (96.8)	1.77 (0.62)	0.7	1.32	1.67	2.29	3.1	
		Week 8	Tezepelumab	65	60 (92.3)	2.00 (0.57)	1.0	1.43	2.04	2.37	3.5	
			Placebo	62	60 (96.8)	1.78 (0.62)	0.7	1.31	1.77	2.30	3.1	
		Week 12	Tezepelumab	65	60 (92.3)	2.03 (0.58)	1.0	1.52	2.00	2.40	3.5	
			Placebo	62	61 (98.4)	1.77 (0.63)	0.6	1.37	1.73	2.32	2.9	
		Week 20	Tezepelumab	65	57 (87.7)	1.94 (0.56)	1.0	1.47	1.85	2.44	3.3	
			Placebo	62	59 (95.2)	1.79 (0.62)	0.5	1.30	1.74	2.26	3.2	
		Week 28	Tezepelumab	65	58 (89.2)	1.93 (0.59)	0.9	1.45	1.90	2.37	3.4	
			Placebo	62	59 (95.2)	1.72 (0.60)	0.7	1.25	1.70	2.17	3.1	
		Week 40	Tezepelumab	65	58 (89.2)	1.98 (0.65)	0.7	1.41	2.00	2.43	3.6	
			Placebo	62	59 (95.2)	1.78 (0.64)	0.7	1.22	1.71	2.33	3.2	
		Week 52	Tezepelumab	65	56 (86.2)	1.94 (0.56)	1.0	1.45	1.91	2.35	3.3	
			Placebo	62	60 (96.8)	1.74 (0.62)	0.6	1.29	1.70	2.10	3.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	65	63 (96.9)	0.16 (0.43)	-0.6	-0.04	0.09	0.31	2.1	0.13 [-0.22, 0.48]
			Placebo	62	60 (96.8)	0.11 (0.33)	-0.7	-0.08	0.06	0.20	1.1	
		Week 8	Tezepelumab	65	60 (92.3)	0.15 (0.39)	-0.7	-0.04	0.11	0.31	2.2	0.13 [-0.23, 0.49]
			Placebo	62	60 (96.8)	0.11 (0.33)	-0.6	-0.07	0.07	0.20	1.1	
		Week 12	Tezepelumab	65	60 (92.3)	0.17 (0.42)	-0.6	-0.09	0.09	0.33	1.9	0.20 [-0.15, 0.56]
			Placebo	62	61 (98.4)	0.10 (0.33)	-0.9	-0.05	0.06	0.23	1.3	
		Week 20	Tezepelumab	65	57 (87.7)	0.14 (0.43)	-0.6	-0.10	0.08	0.35	1.9	0.06 [-0.30, 0.43]
			Placebo	62	59 (95.2)	0.11 (0.37)	-0.8	-0.03	0.03	0.23	1.8	
		Week 28	Tezepelumab	65	58 (89.2)	0.12 (0.44)	-0.9	-0.12	0.02	0.27	1.9	0.20 [-0.16, 0.57]
			Placebo	62	59 (95.2)	0.04 (0.31)	-1.1	-0.10	0.03	0.22	0.8	
		Week 40	Tezepelumab	65	58 (89.2)	0.17 (0.44)	-0.7	-0.05	0.14	0.38	1.9	0.23 [-0.14, 0.59]
			Placebo	62	59 (95.2)	0.08 (0.26)	-0.8	-0.09	0.09	0.25	0.8	
		Week 52	Tezepelumab	65	56 (86.2)	0.12 (0.43)	-0.8	-0.08	0.10	0.26	2.0	0.17 [-0.19, 0.54]
			Placebo	62	60 (96.8)	0.05 (0.34)	-1.0	-0.11	0.05	0.18	1.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	70	70 (100.0)	1.83 (0.64)	0.7	1.36	1.73	2.36	3.9	
			Placebo	75	75 (100.0)	1.93 (0.60)	1.0	1.46	1.76	2.27	3.3	
		Week 4	Tezepelumab	70	66 (94.3)	2.11 (0.82)	0.9	1.53	1.98	2.68	4.9	
			Placebo	75	75 (100.0)	1.93 (0.60)	0.7	1.55	1.90	2.37	3.2	
		Week 8	Tezepelumab	70	62 (88.6)	2.08 (0.75)	0.7	1.55	1.97	2.56	5.1	
			Placebo	75	71 (94.7)	2.02 (0.61)	0.8	1.58	1.97	2.39	3.6	
		Week 12	Tezepelumab	70	66 (94.3)	2.14 (0.83)	0.9	1.51	2.00	2.68	5.1	
			Placebo	75	73 (97.3)	2.00 (0.67)	0.5	1.53	1.87	2.46	4.1	
		Week 20	Tezepelumab	70	60 (85.7)	2.14 (0.86)	1.0	1.50	1.93	2.77	5.5	
			Placebo	75	71 (94.7)	1.98 (0.64)	0.7	1.51	1.87	2.42	3.4	
		Week 28	Tezepelumab	70	64 (91.4)	2.15 (0.86)	0.8	1.46	2.04	2.70	5.4	
			Placebo	75	71 (94.7)	1.98 (0.68)	0.8	1.58	1.90	2.40	3.6	
		Week 40	Tezepelumab	70	62 (88.6)	2.11 (0.75)	1.0	1.53	2.06	2.65	4.7	
			Placebo	75	70 (93.3)	2.04 (0.69)	0.6	1.53	1.96	2.46	4.0	
		Week 52	Tezepelumab	70	61 (87.1)	2.09 (0.75)	0.9	1.57	2.02	2.50	4.7	
			Placebo	75	68 (90.7)	2.03 (0.73)	0.7	1.41	2.04	2.53	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	70	66 (94.3)	0.29 (0.44)	-0.5	0.01	0.18	0.42	2.4	0.69 [0.35, 1.03]
			Placebo	75	75 (100.0)	0.00 (0.39)	-1.1	-0.16	0.02	0.18	1.2	
		Week 8	Tezepelumab	70	62 (88.6)	0.28 (0.42)	-0.5	0.02	0.23	0.46	2.2	0.50 [0.15, 0.84]
			Placebo	75	71 (94.7)	0.07 (0.43)	-1.5	-0.12	0.13	0.30	1.3	
		Week 12	Tezepelumab	70	66 (94.3)	0.32 (0.47)	-0.4	-0.03	0.22	0.56	2.1	0.52 [0.18, 0.86]
			Placebo	75	73 (97.3)	0.08 (0.46)	-1.2	-0.16	0.09	0.31	1.2	
		Week 20	Tezepelumab	70	60 (85.7)	0.32 (0.48)	-0.4	-0.02	0.21	0.58	2.2	0.59 [0.24, 0.94]
			Placebo	75	71 (94.7)	0.07 (0.37)	-1.0	-0.11	0.09	0.26	1.5	
		Week 28	Tezepelumab	70	64 (91.4)	0.33 (0.51)	-1.0	0.00	0.26	0.60	2.2	0.63 [0.28, 0.97]
			Placebo	75	71 (94.7)	0.04 (0.41)	-1.1	-0.18	0.05	0.29	1.5	
		Week 40	Tezepelumab	70	62 (88.6)	0.32 (0.48)	-0.7	-0.02	0.27	0.66	2.3	0.44 [0.10, 0.79]
			Placebo	75	70 (93.3)	0.11 (0.45)	-1.3	-0.11	0.05	0.38	1.1	
		Week 52	Tezepelumab	70	61 (87.1)	0.30 (0.43)	-0.4	0.02	0.23	0.58	2.3	0.45 [0.10, 0.80]
			Placebo	75	68 (90.7)	0.10 (0.45)	-0.9	-0.16	0.06	0.34	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	50	50 (100.0)	1.74 (0.55)	0.7	1.37	1.66	2.15	3.1	
			Placebo	50	50 (100.0)	1.75 (0.61)	0.7	1.39	1.65	2.17	3.2	
		Week 4	Tezepelumab	50	49 (98.0)	1.97 (0.66)	0.9	1.52	1.82	2.29	3.8	
			Placebo	50	49 (98.0)	1.79 (0.71)	0.7	1.30	1.67	2.30	3.2	
		Week 8	Tezepelumab	50	46 (92.0)	1.99 (0.58)	0.7	1.49	2.02	2.38	3.4	
			Placebo	50	47 (94.0)	1.81 (0.72)	0.7	1.20	1.82	2.41	3.6	
		Week 12	Tezepelumab	50	46 (92.0)	2.05 (0.62)	1.1	1.52	1.98	2.55	3.5	
			Placebo	50	50 (100.0)	1.77 (0.65)	0.5	1.32	1.75	2.21	3.0	
		Week 20	Tezepelumab	50	42 (84.0)	1.93 (0.54)	1.0	1.47	1.89	2.45	2.9	
			Placebo	50	49 (98.0)	1.82 (0.70)	0.5	1.26	1.72	2.35	3.3	
		Week 28	Tezepelumab	50	45 (90.0)	1.94 (0.66)	0.9	1.41	1.90	2.48	3.4	
			Placebo	50	48 (96.0)	1.77 (0.66)	0.7	1.25	1.77	2.18	3.3	
		Week 40	Tezepelumab	50	45 (90.0)	1.91 (0.62)	0.7	1.41	1.94	2.44	3.0	
			Placebo	50	49 (98.0)	1.84 (0.74)	0.6	1.22	1.70	2.38	3.4	
		Week 52	Tezepelumab	50	41 (82.0)	1.96 (0.64)	1.0	1.37	1.95	2.37	3.3	
			Placebo	50	47 (94.0)	1.84 (0.73)	0.6	1.20	1.73	2.55	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	50	49 (98.0)	0.22 (0.40)	-0.6	0.01	0.18	0.38	1.7	0.44 [0.04, 0.84]
			Placebo	50	49 (98.0)	0.05 (0.39)	-1.1	-0.14	0.01	0.18	1.0	
		Week 8	Tezepelumab	50	46 (92.0)	0.23 (0.32)	-0.5	0.02	0.19	0.41	1.1	0.49 [0.08, 0.90]
			Placebo	50	47 (94.0)	0.05 (0.42)	-1.5	-0.11	0.08	0.26	1.1	
		Week 12	Tezepelumab	50	46 (92.0)	0.29 (0.41)	-0.6	-0.01	0.25	0.61	1.2	0.72 [0.31, 1.13]
			Placebo	50	50 (100.0)	0.02 (0.35)	-1.2	-0.09	0.04	0.19	0.9	
		Week 20	Tezepelumab	50	42 (84.0)	0.24 (0.38)	-0.4	-0.08	0.21	0.48	1.0	0.46 [0.04, 0.88]
			Placebo	50	49 (98.0)	0.08 (0.32)	-1.0	-0.10	0.02	0.27	1.0	
		Week 28	Tezepelumab	50	45 (90.0)	0.22 (0.46)	-0.9	-0.06	0.09	0.54	1.2	0.46 [0.04, 0.87]
			Placebo	50	48 (96.0)	0.04 (0.34)	-1.1	-0.14	0.08	0.27	0.8	
		Week 40	Tezepelumab	50	45 (90.0)	0.19 (0.43)	-0.7	-0.08	0.16	0.40	1.1	0.21 [-0.20, 0.61]
			Placebo	50	49 (98.0)	0.11 (0.37)	-1.1	-0.11	0.04	0.35	1.1	
		Week 52	Tezepelumab	50	41 (82.0)	0.23 (0.40)	-0.8	-0.02	0.20	0.38	1.1	0.35 [-0.07, 0.77]
			Placebo	50	47 (94.0)	0.08 (0.44)	-1.0	-0.15	0.02	0.29	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	77	77 (100.0)	1.89 (0.61)	0.7	1.40	1.79	2.31	3.9	
			Placebo	80	80 (100.0)	1.87 (0.59)	0.8	1.44	1.78	2.24	3.3	
		Week 4	Tezepelumab	77	72 (93.5)	2.09 (0.81)	0.9	1.52	1.98	2.57	4.9	
			Placebo	80	80 (100.0)	1.91 (0.55)	0.8	1.55	1.91	2.34	3.2	
		Week 8	Tezepelumab	77	70 (90.9)	2.09 (0.72)	1.1	1.55	2.00	2.48	5.1	
			Placebo	80	77 (96.3)	1.97 (0.56)	0.8	1.56	2.00	2.35	3.4	
		Week 12	Tezepelumab	77	72 (93.5)	2.09 (0.78)	0.9	1.50	1.95	2.46	5.1	
			Placebo	80	77 (96.3)	2.00 (0.66)	0.6	1.52	2.02	2.46	4.1	
		Week 20	Tezepelumab	77	68 (88.3)	2.11 (0.83)	1.0	1.51	1.90	2.70	5.5	
			Placebo	80	75 (93.8)	1.95 (0.58)	0.6	1.54	1.90	2.33	3.1	
		Week 28	Tezepelumab	77	70 (90.9)	2.11 (0.81)	0.8	1.50	2.03	2.60	5.4	
			Placebo	80	75 (93.8)	1.92 (0.66)	0.8	1.48	1.93	2.37	3.6	
		Week 40	Tezepelumab	77	68 (88.3)	2.13 (0.75)	1.0	1.58	2.04	2.69	4.7	
			Placebo	80	73 (91.3)	1.98 (0.65)	0.8	1.53	1.82	2.41	4.0	
		Week 52	Tezepelumab	77	69 (89.6)	2.06 (0.69)	0.9	1.62	1.94	2.41	4.7	
			Placebo	80	74 (92.5)	1.93 (0.68)	0.7	1.42	1.93	2.38	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	77	72 (93.5)	0.22 (0.47)	-0.6	-0.02	0.10	0.36	2.4	0.44 [0.12, 0.76]
			Placebo	80	80 (100.0)	0.04 (0.35)	-1.1	-0.12	0.05	0.18	1.2	
		Week 8	Tezepelumab	77	70 (90.9)	0.21 (0.46)	-0.7	-0.04	0.15	0.40	2.2	0.29 [-0.03, 0.62]
			Placebo	80	77 (96.3)	0.09 (0.35)	-0.9	-0.07	0.10	0.24	1.0	
		Week 12	Tezepelumab	77	72 (93.5)	0.20 (0.47)	-0.6	-0.08	0.08	0.30	2.1	0.13 [-0.20, 0.45]
			Placebo	80	77 (96.3)	0.15 (0.42)	-0.9	-0.06	0.11	0.32	1.3	
		Week 20	Tezepelumab	77	68 (88.3)	0.21 (0.52)	-0.6	-0.08	0.11	0.36	2.2	0.29 [-0.04, 0.62]
			Placebo	80	75 (93.8)	0.08 (0.38)	-0.9	-0.05	0.09	0.24	1.8	
		Week 28	Tezepelumab	77	70 (90.9)	0.22 (0.53)	-1.0	-0.12	0.12	0.47	2.2	0.42 [0.09, 0.75]
			Placebo	80	75 (93.8)	0.03 (0.36)	-1.1	-0.15	0.03	0.23	0.9	
		Week 40	Tezepelumab	77	68 (88.3)	0.26 (0.49)	-0.7	-0.04	0.19	0.50	2.3	0.39 [0.05, 0.72]
			Placebo	80	73 (91.3)	0.09 (0.38)	-1.3	-0.08	0.08	0.26	1.0	
		Week 52	Tezepelumab	77	69 (89.6)	0.20 (0.47)	-0.7	-0.04	0.11	0.43	2.3	0.32 [-0.01, 0.65]
			Placebo	80	74 (92.5)	0.06 (0.36)	-0.9	-0.12	0.06	0.20	1.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	70	70 (100.0)	1.82 (0.58)	0.7	1.40	1.77	2.17	3.3	
			Placebo	62	62 (100.0)	1.76 (0.58)	0.8	1.39	1.64	2.17	3.2	
		Week 4	Tezepelumab	70	68 (97.1)	2.03 (0.75)	0.9	1.43	2.03	2.40	4.5	
			Placebo	62	60 (96.8)	1.79 (0.64)	0.7	1.37	1.73	2.27	3.2	
		Week 8	Tezepelumab	70	65 (92.9)	1.99 (0.63)	0.7	1.46	2.03	2.37	3.4	
			Placebo	62	58 (93.5)	1.82 (0.70)	0.7	1.28	1.69	2.29	3.6	
		Week 12	Tezepelumab	70	66 (94.3)	2.04 (0.74)	0.9	1.45	1.96	2.57	4.6	
			Placebo	62	61 (98.4)	1.80 (0.66)	0.5	1.37	1.75	2.26	3.3	
		Week 20	Tezepelumab	70	62 (88.6)	1.96 (0.70)	1.0	1.43	1.82	2.45	4.1	
			Placebo	62	58 (93.5)	1.82 (0.68)	0.5	1.27	1.73	2.34	3.4	
		Week 28	Tezepelumab	70	64 (91.4)	1.98 (0.73)	0.8	1.39	1.90	2.46	4.6	
			Placebo	62	59 (95.2)	1.74 (0.70)	0.7	1.24	1.69	2.08	3.4	
		Week 40	Tezepelumab	70	62 (88.6)	1.97 (0.69)	0.9	1.41	1.92	2.50	3.6	
			Placebo	62	56 (90.3)	1.83 (0.70)	0.6	1.31	1.67	2.41	3.5	
		Week 52	Tezepelumab	70	61 (87.1)	1.97 (0.67)	0.9	1.37	1.88	2.35	3.5	
			Placebo	62	56 (90.3)	1.78 (0.67)	0.6	1.21	1.70	2.13	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	70	68 (97.1)	0.21 (0.47)	-0.6	0.02	0.12	0.31	2.4	0.39 [0.04, 0.74]
			Placebo	62	60 (96.8)	0.04 (0.35)	-1.1	-0.11	0.08	0.18	1.2	
		Week 8	Tezepelumab	70	65 (92.9)	0.18 (0.37)	-0.7	-0.04	0.15	0.35	2.2	0.29 [-0.06, 0.65]
			Placebo	62	58 (93.5)	0.07 (0.39)	-1.5	-0.09	0.12	0.26	1.3	
		Week 12	Tezepelumab	70	66 (94.3)	0.22 (0.46)	-0.6	-0.08	0.11	0.41	2.1	0.40 [0.05, 0.75]
			Placebo	62	61 (98.4)	0.05 (0.37)	-1.2	-0.09	0.06	0.28	1.1	
		Week 20	Tezepelumab	70	62 (88.6)	0.17 (0.43)	-0.6	-0.09	0.05	0.39	2.2	0.23 [-0.13, 0.59]
			Placebo	62	58 (93.5)	0.08 (0.32)	-1.0	-0.04	0.06	0.26	1.5	
		Week 28	Tezepelumab	70	64 (91.4)	0.17 (0.48)	-0.9	-0.12	0.02	0.34	2.2	0.36 [0.00, 0.72]
			Placebo	62	59 (95.2)	0.01 (0.39)	-1.1	-0.17	0.02	0.22	1.5	
		Week 40	Tezepelumab	70	62 (88.6)	0.17 (0.46)	-0.7	-0.08	0.10	0.36	2.3	0.20 [-0.16, 0.56]
			Placebo	62	56 (90.3)	0.09 (0.36)	-1.1	-0.09	0.04	0.29	1.0	
		Week 52	Tezepelumab	70	61 (87.1)	0.17 (0.43)	-0.5	-0.06	0.11	0.35	2.3	0.36 [-0.00, 0.73]
			Placebo	62	56 (90.3)	0.03 (0.37)	-1.0	-0.16	0.03	0.22	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	65	65 (100.0)	1.85 (0.59)	0.7	1.36	1.78	2.22	3.9	
			Placebo	75	75 (100.0)	1.88 (0.60)	0.7	1.45	1.76	2.21	3.3	
		Week 4	Tezepelumab	65	61 (93.8)	2.07 (0.75)	0.9	1.54	1.88	2.71	4.9	
			Placebo	75	75 (100.0)	1.93 (0.59)	0.8	1.55	1.91	2.39	3.2	
		Week 8	Tezepelumab	65	57 (87.7)	2.10 (0.71)	1.1	1.56	1.98	2.52	5.1	
			Placebo	75	73 (97.3)	1.99 (0.56)	0.7	1.58	2.05	2.39	3.1	
		Week 12	Tezepelumab	65	60 (92.3)	2.13 (0.71)	0.9	1.60	2.05	2.55	5.1	
			Placebo	75	73 (97.3)	1.99 (0.65)	0.6	1.53	1.90	2.46	4.1	
		Week 20	Tezepelumab	65	55 (84.6)	2.12 (0.77)	1.0	1.55	1.93	2.58	5.5	
			Placebo	75	72 (96.0)	1.97 (0.60)	0.6	1.56	1.98	2.33	3.1	
		Week 28	Tezepelumab	65	58 (89.2)	2.10 (0.78)	1.0	1.50	2.00	2.50	5.4	
			Placebo	75	71 (94.7)	1.97 (0.61)	0.8	1.58	1.94	2.38	3.6	
		Week 40	Tezepelumab	65	58 (89.2)	2.12 (0.73)	0.7	1.59	2.09	2.65	4.7	
			Placebo	75	73 (97.3)	2.00 (0.66)	0.8	1.53	1.94	2.36	4.0	
		Week 52	Tezepelumab	65	56 (86.2)	2.06 (0.67)	1.1	1.58	1.99	2.44	4.7	
			Placebo	75	72 (96.0)	1.99 (0.71)	0.7	1.42	1.94	2.45	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	65	61 (93.8)	0.24 (0.41)	-0.5	-0.03	0.12	0.41	2.1	0.47 [0.12, 0.81]
			Placebo	75	75 (100.0)	0.05 (0.38)	-1.1	-0.12	0.02	0.20	1.1	
		Week 8	Tezepelumab	65	57 (87.7)	0.26 (0.44)	-0.5	0.00	0.16	0.46	2.2	0.38 [0.03, 0.73]
			Placebo	75	73 (97.3)	0.11 (0.38)	-0.9	-0.07	0.07	0.24	1.1	
		Week 12	Tezepelumab	65	60 (92.3)	0.28 (0.44)	-0.5	-0.02	0.20	0.48	1.9	0.36 [0.01, 0.70]
			Placebo	75	73 (97.3)	0.12 (0.43)	-0.9	-0.11	0.11	0.31	1.3	
		Week 20	Tezepelumab	65	55 (84.6)	0.28 (0.49)	-0.6	-0.03	0.21	0.49	1.9	0.42 [0.07, 0.78]
			Placebo	75	72 (96.0)	0.10 (0.40)	-0.9	-0.07	0.08	0.24	1.8	
		Week 28	Tezepelumab	65	58 (89.2)	0.28 (0.50)	-1.0	-0.08	0.23	0.57	1.9	0.49 [0.14, 0.84]
			Placebo	75	71 (94.7)	0.07 (0.35)	-1.1	-0.05	0.07	0.29	0.9	
		Week 40	Tezepelumab	65	58 (89.2)	0.30 (0.45)	-0.7	0.04	0.27	0.54	1.9	0.47 [0.12, 0.82]
			Placebo	75	73 (97.3)	0.10 (0.38)	-1.3	-0.12	0.08	0.30	1.1	
		Week 52	Tezepelumab	65	56 (86.2)	0.24 (0.45)	-0.8	0.01	0.17	0.49	2.0	0.29 [-0.06, 0.64]
			Placebo	75	72 (96.0)	0.11 (0.42)	-0.9	-0.10	0.07	0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	62	62 (100.0)	1.94 (0.59)	0.9	1.49	1.91	2.24	3.9	
			Placebo	67	67 (100.0)	1.94 (0.56)	0.8	1.51	1.81	2.32	3.3	
		Week 4	Tezepelumab	62	60 (96.8)	2.02 (0.67)	0.9	1.56	1.95	2.34	4.9	
			Placebo	67	66 (98.5)	1.95 (0.60)	0.7	1.55	1.93	2.38	3.2	
		Week 8	Tezepelumab	62	58 (93.5)	2.05 (0.65)	1.1	1.57	2.05	2.35	5.1	
			Placebo	67	63 (94.0)	2.00 (0.62)	0.7	1.59	2.00	2.41	3.6	
		Week 12	Tezepelumab	62	57 (91.9)	2.08 (0.70)	0.9	1.56	2.01	2.44	5.1	
			Placebo	67	64 (95.5)	1.94 (0.62)	0.5	1.51	1.88	2.46	3.6	
		Week 20	Tezepelumab	62	56 (90.3)	2.03 (0.72)	1.0	1.49	1.92	2.44	5.5	
			Placebo	67	62 (92.5)	2.00 (0.62)	0.6	1.60	1.98	2.42	3.4	
		Week 28	Tezepelumab	62	54 (87.1)	1.99 (0.75)	0.9	1.42	1.96	2.36	5.4	
			Placebo	67	63 (94.0)	1.99 (0.62)	0.7	1.59	1.94	2.38	3.6	
		Week 40	Tezepelumab	62	54 (87.1)	2.05 (0.70)	1.1	1.45	2.00	2.50	4.7	
			Placebo	67	62 (92.5)	2.01 (0.61)	0.6	1.62	1.98	2.46	3.4	
		Week 52	Tezepelumab	62	53 (85.5)	2.00 (0.67)	1.1	1.45	1.93	2.29	4.7	
			Placebo	67	62 (92.5)	2.00 (0.62)	0.7	1.62	1.94	2.44	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	62	60 (96.8)	0.07 (0.29)	-0.6	-0.07	0.06	0.19	1.0	0.18 [-0.17, 0.53]
			Placebo	67	66 (98.5)	0.01 (0.39)	-1.1	-0.13	0.00	0.17	1.0	
		Week 8	Tezepelumab	62	58 (93.5)	0.10 (0.30)	-0.7	-0.08	0.08	0.32	1.2	0.13 [-0.23, 0.49]
			Placebo	67	63 (94.0)	0.06 (0.44)	-1.5	-0.12	0.11	0.21	1.3	
		Week 12	Tezepelumab	62	57 (91.9)	0.14 (0.41)	-0.6	-0.08	0.06	0.32	1.3	0.28 [-0.07, 0.64]
			Placebo	67	64 (95.5)	0.03 (0.41)	-1.2	-0.16	0.04	0.23	1.2	
		Week 20	Tezepelumab	62	56 (90.3)	0.09 (0.39)	-0.6	-0.11	0.05	0.23	1.5	-0.00 [-0.36, 0.36]
			Placebo	67	62 (92.5)	0.10 (0.44)	-1.0	-0.05	0.05	0.23	1.8	
		Week 28	Tezepelumab	62	54 (87.1)	0.07 (0.39)	-0.9	-0.14	-0.04	0.17	1.5	0.00 [-0.36, 0.37]
			Placebo	67	63 (94.0)	0.06 (0.36)	-1.1	-0.10	0.05	0.23	1.5	
		Week 40	Tezepelumab	62	54 (87.1)	0.12 (0.38)	-0.7	-0.09	0.10	0.35	1.1	0.08 [-0.29, 0.44]
			Placebo	67	62 (92.5)	0.09 (0.34)	-1.1	-0.12	0.08	0.26	1.0	
		Week 52	Tezepelumab	62	53 (85.5)	0.08 (0.35)	-0.8	-0.12	0.05	0.24	1.1	0.06 [-0.31, 0.42]
			Placebo	67	62 (92.5)	0.06 (0.41)	-1.0	-0.12	0.06	0.24	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	74	74 (100.0)	1.73 (0.56)	0.7	1.32	1.65	2.16	3.1	
			Placebo	71	71 (100.0)	1.71 (0.59)	0.7	1.33	1.58	2.19	3.1	
		Week 4	Tezepelumab	74	70 (94.6)	2.04 (0.80)	0.9	1.42	1.96	2.64	4.5	
			Placebo	71	70 (98.6)	1.79 (0.61)	0.7	1.33	1.77	2.26	2.9	
		Week 8	Tezepelumab	74	65 (87.8)	2.01 (0.67)	0.7	1.47	1.94	2.49	3.5	
			Placebo	71	69 (97.2)	1.84 (0.62)	0.7	1.42	1.82	2.28	3.4	
		Week 12	Tezepelumab	74	70 (94.6)	2.07 (0.74)	0.9	1.49	1.96	2.55	4.6	
			Placebo	71	71 (100.0)	1.86 (0.69)	0.7	1.32	1.76	2.35	4.1	
		Week 20	Tezepelumab	74	63 (85.1)	2.04 (0.74)	1.0	1.43	1.86	2.60	4.1	
			Placebo	71	69 (97.2)	1.81 (0.64)	0.5	1.29	1.74	2.26	3.1	
		Week 28	Tezepelumab	74	69 (93.2)	2.06 (0.74)	0.8	1.49	1.90	2.54	4.6	
			Placebo	71	68 (95.8)	1.75 (0.67)	0.7	1.24	1.70	2.16	3.4	
		Week 40	Tezepelumab	74	67 (90.5)	2.02 (0.71)	0.7	1.36	1.98	2.53	3.5	
			Placebo	71	68 (95.8)	1.84 (0.72)	0.8	1.36	1.64	2.26	4.0	
		Week 52	Tezepelumab	74	65 (87.8)	2.01 (0.66)	0.9	1.48	1.94	2.41	3.5	
			Placebo	71	67 (94.4)	1.80 (0.75)	0.6	1.22	1.64	2.31	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	74	70 (94.6)	0.35 (0.50)	-0.6	0.03	0.22	0.47	2.4	0.61 [0.27, 0.95]
			Placebo	71	70 (98.6)	0.09 (0.33)	-0.7	-0.10	0.07	0.20	1.2	
		Week 8	Tezepelumab	74	65 (87.8)	0.32 (0.46)	-0.5	0.04	0.22	0.48	2.2	0.50 [0.15, 0.84]
			Placebo	71	69 (97.2)	0.12 (0.32)	-0.9	-0.06	0.10	0.27	1.0	
		Week 12	Tezepelumab	74	70 (94.6)	0.33 (0.47)	-0.2	-0.01	0.22	0.51	2.1	0.42 [0.08, 0.75]
			Placebo	71	71 (100.0)	0.15 (0.39)	-0.8	-0.06	0.13	0.32	1.3	
		Week 20	Tezepelumab	74	63 (85.1)	0.34 (0.49)	-0.4	0.01	0.27	0.53	2.2	0.65 [0.30, 1.00]
			Placebo	71	69 (97.2)	0.09 (0.28)	-0.9	-0.07	0.08	0.26	0.8	
		Week 28	Tezepelumab	74	69 (93.2)	0.34 (0.52)	-1.0	0.01	0.27	0.59	2.2	0.69 [0.35, 1.04]
			Placebo	71	68 (95.8)	0.03 (0.37)	-1.1	-0.18	0.04	0.30	0.9	
		Week 40	Tezepelumab	74	67 (90.5)	0.33 (0.50)	-0.7	0.04	0.25	0.56	2.3	0.49 [0.15, 0.83]
			Placebo	71	68 (95.8)	0.11 (0.40)	-1.3	-0.08	0.04	0.30	1.1	
		Week 52	Tezepelumab	74	65 (87.8)	0.30 (0.48)	-0.7	0.03	0.20	0.57	2.3	0.49 [0.15, 0.84]
			Placebo	71	67 (94.4)	0.09 (0.39)	-0.9	-0.16	0.04	0.30	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	114	114 (100.0)	1.83 (0.59)	0.7	1.38	1.79	2.21	3.9	
			Placebo	126	126 (100.0)	1.85 (0.58)	0.7	1.44	1.77	2.21	3.3	
		Week 4	Tezepelumab	114	111 (97.4)	2.05 (0.75)	0.9	1.52	1.96	2.45	4.9	
			Placebo	126	124 (98.4)	1.91 (0.60)	0.7	1.54	1.90	2.36	3.2	
		Week 8	Tezepelumab	114	104 (91.2)	2.04 (0.67)	0.7	1.55	1.98	2.42	5.1	
			Placebo	126	120 (95.2)	1.96 (0.62)	0.7	1.54	1.95	2.40	3.6	
		Week 12	Tezepelumab	114	107 (93.9)	2.11 (0.74)	0.9	1.54	2.00	2.57	5.1	
			Placebo	126	123 (97.6)	1.94 (0.65)	0.5	1.48	1.87	2.45	4.1	
		Week 20	Tezepelumab	114	101 (88.6)	2.06 (0.75)	1.0	1.51	1.92	2.52	5.5	
			Placebo	126	120 (95.2)	1.94 (0.62)	0.5	1.51	1.92	2.34	3.4	
		Week 28	Tezepelumab	114	104 (91.2)	2.06 (0.76)	0.8	1.49	1.98	2.54	5.4	
			Placebo	126	119 (94.4)	1.91 (0.64)	0.7	1.53	1.90	2.28	3.6	
		Week 40	Tezepelumab	114	103 (90.4)	2.07 (0.72)	0.7	1.45	2.00	2.64	4.7	
			Placebo	126	120 (95.2)	1.98 (0.66)	0.6	1.49	1.89	2.42	4.0	
		Week 52	Tezepelumab	114	100 (87.7)	2.02 (0.68)	0.9	1.54	1.93	2.38	4.7	
			Placebo	126	118 (93.7)	1.94 (0.69)	0.6	1.42	1.92	2.44	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	114	111 (97.4)	0.23 (0.46)	-0.6	-0.02	0.13	0.38	2.4	0.41 [0.15, 0.67]
			Placebo	126	124 (98.4)	0.06 (0.37)	-1.1	-0.12	0.05	0.21	1.2	
		Week 8	Tezepelumab	114	104 (91.2)	0.23 (0.42)	-0.7	0.00	0.17	0.40	2.2	0.32 [0.05, 0.58]
			Placebo	126	120 (95.2)	0.10 (0.39)	-1.5	-0.08	0.13	0.27	1.3	
		Week 12	Tezepelumab	114	107 (93.9)	0.28 (0.47)	-0.6	-0.03	0.18	0.45	2.1	0.40 [0.13, 0.66]
			Placebo	126	123 (97.6)	0.10 (0.41)	-1.2	-0.10	0.11	0.31	1.3	
		Week 20	Tezepelumab	114	101 (88.6)	0.26 (0.48)	-0.6	-0.06	0.17	0.48	2.2	0.37 [0.10, 0.64]
			Placebo	126	120 (95.2)	0.10 (0.38)	-1.0	-0.05	0.08	0.26	1.8	
		Week 28	Tezepelumab	114	104 (91.2)	0.25 (0.50)	-0.9	-0.09	0.13	0.54	2.2	0.44 [0.18, 0.71]
			Placebo	126	119 (94.4)	0.06 (0.37)	-1.1	-0.14	0.09	0.28	1.5	
		Week 40	Tezepelumab	114	103 (90.4)	0.27 (0.48)	-0.7	-0.03	0.24	0.50	2.3	0.35 [0.09, 0.62]
			Placebo	126	120 (95.2)	0.12 (0.37)	-1.3	-0.08	0.09	0.30	1.1	
		Week 52	Tezepelumab	114	100 (87.7)	0.22 (0.45)	-0.8	-0.03	0.16	0.44	2.3	0.30 [0.03, 0.57]
			Placebo	126	118 (93.7)	0.09 (0.41)	-1.0	-0.12	0.07	0.26	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	1.81 (0.57)	1.0	1.37	1.68	2.17	3.1	
			Placebo	12	12 (100.0)	1.50 (0.62)	0.8	1.12	1.45	1.55	3.0	
		Week 4	Tezepelumab	23	20 (87.0)	1.98 (0.69)	1.0	1.42	1.98	2.38	3.5	
			Placebo	12	12 (100.0)	1.44 (0.61)	0.7	0.94	1.42	1.65	3.0	
		Week 8	Tezepelumab	23	20 (87.0)	1.99 (0.59)	1.2	1.39	2.02	2.45	3.2	
			Placebo	12	12 (100.0)	1.46 (0.48)	0.7	1.10	1.50	1.65	2.3	
		Week 12	Tezepelumab	23	21 (91.3)	1.92 (0.61)	1.1	1.40	1.88	2.37	3.3	
			Placebo	12	12 (100.0)	1.48 (0.55)	0.7	1.09	1.46	1.69	2.5	
		Week 20	Tezepelumab	23	18 (78.3)	1.88 (0.59)	1.2	1.39	1.54	2.38	3.0	
			Placebo	12	11 (91.7)	1.50 (0.64)	0.8	0.91	1.30	1.78	2.7	
		Week 28	Tezepelumab	23	20 (87.0)	1.90 (0.69)	0.9	1.33	1.84	2.44	3.5	
			Placebo	12	12 (100.0)	1.40 (0.62)	0.7	0.90	1.31	1.62	2.7	
		Week 40	Tezepelumab	23	19 (82.6)	1.89 (0.62)	1.1	1.34	1.73	2.45	3.1	
			Placebo	12	10 (83.3)	1.30 (0.52)	0.7	0.92	1.21	1.62	2.5	
		Week 52	Tezepelumab	23	19 (82.6)	1.97 (0.60)	1.2	1.36	2.01	2.41	3.1	
			Placebo	12	11 (91.7)	1.39 (0.52)	0.7	1.00	1.34	1.69	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	0.16 (0.32)	-0.2	-0.03	0.06	0.27	1.1	0.81 [0.06, 1.55]
			Placebo	12	12 (100.0)	-0.06 (0.20)	-0.5	-0.18	-0.03	0.08	0.2	
		Week 8	Tezepelumab	23	20 (87.0)	0.14 (0.30)	-0.3	-0.07	0.09	0.40	0.9	0.67 [-0.07, 1.41]
			Placebo	12	12 (100.0)	-0.05 (0.27)	-0.8	-0.10	-0.01	0.11	0.2	
		Week 12	Tezepelumab	23	21 (91.3)	0.10 (0.30)	-0.3	-0.09	-0.01	0.22	0.9	0.44 [-0.28, 1.16]
			Placebo	12	12 (100.0)	-0.02 (0.20)	-0.5	-0.10	-0.01	0.07	0.3	
		Week 20	Tezepelumab	23	18 (78.3)	0.05 (0.30)	-0.4	-0.10	0.00	0.08	0.9	0.16 [-0.59, 0.91]
			Placebo	12	11 (91.7)	0.01 (0.18)	-0.3	-0.15	-0.02	0.22	0.3	
		Week 28	Tezepelumab	23	20 (87.0)	0.06 (0.39)	-1.0	-0.14	0.00	0.27	0.8	0.52 [-0.21, 1.24]
			Placebo	12	12 (100.0)	-0.11 (0.20)	-0.5	-0.27	-0.06	0.01	0.2	
		Week 40	Tezepelumab	23	19 (82.6)	0.07 (0.33)	-0.7	-0.14	0.06	0.23	0.8	0.64 [-0.15, 1.42]
			Placebo	12	10 (83.3)	-0.12 (0.22)	-0.5	-0.24	-0.11	-0.04	0.2	
		Week 52	Tezepelumab	23	19 (82.6)	0.11 (0.31)	-0.4	-0.06	0.03	0.24	0.8	0.79 [0.02, 1.56]
			Placebo	12	11 (91.7)	-0.11 (0.24)	-0.7	-0.15	-0.11	0.02	0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.54 (0.72)	0.7	1.17	1.37	1.87	3.0	
			Placebo	14	14 (100.0)	1.76 (0.43)	1.0	1.50	1.75	2.18	2.5	
		Week 4	Tezepelumab	9	9 (100.0)	1.84 (1.09)	0.9	1.19	1.44	2.04	4.5	
			Placebo	14	14 (100.0)	1.61 (0.57)	0.7	1.30	1.66	1.89	2.9	
		Week 8	Tezepelumab	9	7 (77.8)	1.63 (0.42)	1.3	1.26	1.46	2.03	2.2	
			Placebo	14	13 (92.9)	1.81 (0.60)	0.8	1.60	1.94	2.15	2.7	
		Week 12	Tezepelumab	9	8 (88.9)	1.95 (1.12)	1.1	1.25	1.70	1.99	4.6	
			Placebo	14	13 (92.9)	1.76 (0.71)	0.5	1.41	1.76	2.16	3.2	
		Week 20	Tezepelumab	9	8 (88.9)	1.76 (0.99)	1.0	1.24	1.48	1.75	4.1	
			Placebo	14	13 (92.9)	1.84 (0.64)	0.7	1.53	1.86	2.32	2.9	
		Week 28	Tezepelumab	9	8 (88.9)	1.83 (1.17)	1.0	1.17	1.42	1.94	4.6	
			Placebo	14	12 (85.7)	1.75 (0.78)	0.8	1.19	1.59	2.24	3.4	
		Week 40	Tezepelumab	9	7 (77.8)	1.49 (0.33)	1.1	1.30	1.36	1.88	2.0	
			Placebo	14	11 (78.6)	1.79 (0.90)	0.6	1.08	1.71	2.24	3.4	
		Week 52	Tezepelumab	9	7 (77.8)	1.57 (0.29)	1.3	1.33	1.36	1.86	1.9	
			Placebo	14	12 (85.7)	1.88 (0.98)	0.8	1.20	1.39	2.41	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	0.30 (0.46)	-0.0	0.02	0.13	0.38	1.4	1.11 [0.21, 2.01]
			Placebo	14	14 (100.0)	-0.14 (0.35)	-1.1	-0.25	-0.08	0.02	0.4	
		Week 8	Tezepelumab	9	7 (77.8)	0.19 (0.22)	-0.0	-0.03	0.10	0.36	0.6	0.42 [-0.51, 1.35]
			Placebo	14	13 (92.9)	0.05 (0.39)	-0.9	-0.17	0.08	0.28	0.6	
		Week 12	Tezepelumab	9	8 (88.9)	0.31 (0.53)	-0.1	-0.02	0.16	0.36	1.5	0.59 [-0.31, 1.49]
			Placebo	14	13 (92.9)	0.00 (0.51)	-1.2	-0.11	-0.02	0.26	0.7	
		Week 20	Tezepelumab	9	8 (88.9)	0.12 (0.46)	-0.4	-0.17	0.05	0.25	1.1	0.08 [-0.80, 0.96]
			Placebo	14	13 (92.9)	0.09 (0.37)	-1.0	0.01	0.15	0.23	0.6	
		Week 28	Tezepelumab	9	8 (88.9)	0.18 (0.70)	-1.0	-0.04	0.11	0.41	1.5	0.32 [-0.58, 1.22]
			Placebo	14	12 (85.7)	-0.00 (0.48)	-0.9	-0.34	0.04	0.29	0.9	
		Week 40	Tezepelumab	9	7 (77.8)	0.05 (0.39)	-0.7	-0.08	0.07	0.16	0.7	-0.09 [-1.03, 0.86]
			Placebo	14	11 (78.6)	0.09 (0.63)	-1.1	-0.32	0.00	0.52	1.1	
		Week 52	Tezepelumab	9	7 (77.8)	0.13 (0.22)	-0.0	-0.01	0.07	0.16	0.6	0.00 [-0.93, 0.93]
			Placebo	14	12 (85.7)	0.13 (0.71)	-0.9	-0.15	-0.07	0.47	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	1.85 (0.57)	0.7	1.40	1.79	2.21	3.9	
			Placebo	124	124 (100.0)	1.83 (0.60)	0.7	1.42	1.70	2.21	3.3	
		Week 4	Tezepelumab	128	122 (95.3)	2.06 (0.71)	0.9	1.53	2.00	2.46	4.9	
			Placebo	124	122 (98.4)	1.90 (0.61)	0.7	1.49	1.88	2.37	3.2	
		Week 8	Tezepelumab	128	117 (91.4)	2.06 (0.67)	0.7	1.55	2.05	2.44	5.1	
			Placebo	124	119 (96.0)	1.93 (0.63)	0.7	1.49	1.88	2.37	3.6	
		Week 12	Tezepelumab	128	120 (93.8)	2.09 (0.69)	0.9	1.52	2.01	2.55	5.1	
			Placebo	124	122 (98.4)	1.92 (0.65)	0.6	1.46	1.84	2.44	4.1	
		Week 20	Tezepelumab	128	111 (86.7)	2.05 (0.71)	1.0	1.49	1.93	2.52	5.5	
			Placebo	124	118 (95.2)	1.91 (0.64)	0.5	1.44	1.89	2.34	3.4	
		Week 28	Tezepelumab	128	116 (90.6)	2.05 (0.71)	0.8	1.47	2.00	2.49	5.4	
			Placebo	124	119 (96.0)	1.88 (0.64)	0.7	1.42	1.85	2.27	3.6	
		Week 40	Tezepelumab	128	115 (89.8)	2.07 (0.71)	0.7	1.45	2.07	2.59	4.7	
			Placebo	124	119 (96.0)	1.93 (0.66)	0.7	1.45	1.81	2.41	4.0	
		Week 52	Tezepelumab	128	112 (87.5)	2.04 (0.67)	0.9	1.54	1.99	2.41	4.7	
			Placebo	124	117 (94.4)	1.90 (0.66)	0.6	1.42	1.85	2.38	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	122 (95.3)	0.22 (0.44)	-0.6	-0.02	0.12	0.38	2.4	0.36 [0.11, 0.61]
			Placebo	124	122 (98.4)	0.07 (0.36)	-1.1	-0.12	0.06	0.20	1.2	
		Week 8	Tezepelumab	128	117 (91.4)	0.22 (0.41)	-0.7	-0.02	0.16	0.40	2.2	0.31 [0.06, 0.57]
			Placebo	124	119 (96.0)	0.09 (0.38)	-1.5	-0.09	0.11	0.24	1.3	
		Week 12	Tezepelumab	128	120 (93.8)	0.24 (0.45)	-0.6	-0.06	0.16	0.43	2.1	0.34 [0.09, 0.59]
			Placebo	124	122 (98.4)	0.10 (0.39)	-0.9	-0.09	0.09	0.29	1.3	
		Week 20	Tezepelumab	128	111 (86.7)	0.23 (0.46)	-0.6	-0.07	0.15	0.43	2.2	0.34 [0.08, 0.60]
			Placebo	124	118 (95.2)	0.09 (0.37)	-0.9	-0.07	0.06	0.26	1.8	
		Week 28	Tezepelumab	128	116 (90.6)	0.23 (0.47)	-0.9	-0.11	0.11	0.50	2.2	0.42 [0.17, 0.68]
			Placebo	124	119 (96.0)	0.05 (0.35)	-1.1	-0.14	0.05	0.23	1.5	
		Week 40	Tezepelumab	128	115 (89.8)	0.25 (0.46)	-0.7	-0.05	0.23	0.48	2.3	0.37 [0.11, 0.63]
			Placebo	124	119 (96.0)	0.10 (0.34)	-1.3	-0.09	0.08	0.29	1.0	
		Week 52	Tezepelumab	128	112 (87.5)	0.21 (0.45)	-0.8	-0.05	0.15	0.44	2.3	0.35 [0.09, 0.61]
			Placebo	124	117 (94.4)	0.07 (0.36)	-1.0	-0.12	0.06	0.24	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	108	108 (100.0)	1.85 (0.57)	0.7	1.40	1.79	2.22	3.9	
			Placebo	115	115 (100.0)	1.86 (0.59)	0.7	1.43	1.78	2.23	3.3	
		Week 4	Tezepelumab	108	105 (97.2)	2.06 (0.72)	0.9	1.53	1.96	2.45	4.9	
			Placebo	115	113 (98.3)	1.93 (0.59)	0.7	1.55	1.91	2.38	3.2	
		Week 8	Tezepelumab	108	100 (92.6)	2.06 (0.68)	0.7	1.56	1.98	2.44	5.1	
			Placebo	115	110 (95.7)	1.97 (0.62)	0.7	1.53	1.94	2.41	3.6	
		Week 12	Tezepelumab	108	102 (94.4)	2.10 (0.70)	0.9	1.56	2.01	2.57	5.1	
			Placebo	115	113 (98.3)	1.96 (0.64)	0.6	1.48	1.89	2.45	4.1	
		Week 20	Tezepelumab	108	96 (88.9)	2.07 (0.73)	1.0	1.52	1.93	2.56	5.5	
			Placebo	115	110 (95.7)	1.94 (0.62)	0.5	1.51	1.92	2.35	3.4	
		Week 28	Tezepelumab	108	99 (91.7)	2.06 (0.72)	0.8	1.49	1.98	2.54	5.4	
			Placebo	115	110 (95.7)	1.92 (0.63)	0.7	1.53	1.91	2.28	3.6	
		Week 40	Tezepelumab	108	99 (91.7)	2.09 (0.72)	0.7	1.50	2.07	2.65	4.7	
			Placebo	115	111 (96.5)	1.98 (0.64)	0.8	1.50	1.88	2.43	4.0	
		Week 52	Tezepelumab	108	96 (88.9)	2.04 (0.68)	0.9	1.57	1.95	2.40	4.7	
			Placebo	115	109 (94.8)	1.94 (0.66)	0.6	1.46	1.93	2.44	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	108	105 (97.2)	0.22 (0.45)	-0.6	-0.02	0.12	0.38	2.4	0.35 [0.08, 0.62]
			Placebo	115	113 (98.3)	0.08 (0.37)	-1.1	-0.12	0.06	0.24	1.2	
		Week 8	Tezepelumab	108	100 (92.6)	0.23 (0.43)	-0.7	-0.01	0.17	0.40	2.2	0.30 [0.03, 0.57]
			Placebo	115	110 (95.7)	0.11 (0.39)	-1.5	-0.08	0.12	0.27	1.3	
		Week 12	Tezepelumab	108	102 (94.4)	0.27 (0.46)	-0.6	-0.04	0.18	0.45	2.1	0.37 [0.10, 0.63]
			Placebo	115	113 (98.3)	0.11 (0.40)	-0.9	-0.09	0.11	0.30	1.3	
		Week 20	Tezepelumab	108	96 (88.9)	0.26 (0.48)	-0.6	-0.06	0.18	0.48	2.2	0.37 [0.09, 0.65]
			Placebo	115	110 (95.7)	0.10 (0.38)	-0.9	-0.06	0.07	0.26	1.8	
		Week 28	Tezepelumab	108	99 (91.7)	0.24 (0.49)	-0.9	-0.10	0.12	0.54	2.2	0.43 [0.15, 0.70]
			Placebo	115	110 (95.7)	0.06 (0.36)	-1.1	-0.13	0.08	0.26	1.5	
		Week 40	Tezepelumab	108	99 (91.7)	0.27 (0.48)	-0.7	-0.03	0.25	0.50	2.3	0.38 [0.10, 0.65]
			Placebo	115	111 (96.5)	0.11 (0.34)	-1.3	-0.08	0.09	0.30	1.0	
		Week 52	Tezepelumab	108	96 (88.9)	0.22 (0.46)	-0.8	-0.04	0.16	0.44	2.3	0.34 [0.06, 0.62]
			Placebo	115	109 (94.8)	0.08 (0.36)	-1.0	-0.12	0.07	0.25	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	29	29 (100.0)	1.75 (0.64)	0.7	1.37	1.68	2.15	3.1	
			Placebo	23	23 (100.0)	1.63 (0.54)	0.8	1.31	1.52	1.85	3.0	
		Week 4	Tezepelumab	29	26 (89.7)	1.98 (0.85)	0.9	1.25	1.98	2.29	4.5	
			Placebo	23	23 (100.0)	1.56 (0.61)	0.7	1.00	1.64	1.79	3.0	
		Week 8	Tezepelumab	29	24 (82.8)	1.94 (0.58)	1.2	1.36	2.00	2.37	3.2	
			Placebo	23	22 (95.7)	1.63 (0.57)	0.7	1.12	1.63	2.13	2.7	
		Week 12	Tezepelumab	29	26 (89.7)	1.97 (0.79)	1.1	1.38	1.89	2.37	4.6	
			Placebo	23	22 (95.7)	1.62 (0.66)	0.5	1.16	1.53	2.11	3.2	
		Week 20	Tezepelumab	29	23 (79.3)	1.89 (0.75)	1.0	1.39	1.56	2.38	4.1	
			Placebo	23	21 (91.3)	1.68 (0.66)	0.7	1.23	1.68	2.27	2.9	
		Week 28	Tezepelumab	29	25 (86.2)	1.95 (0.85)	0.9	1.29	1.77	2.44	4.6	
			Placebo	23	21 (91.3)	1.57 (0.72)	0.7	0.98	1.53	1.98	3.4	
		Week 40	Tezepelumab	29	23 (79.3)	1.83 (0.59)	1.1	1.34	1.73	2.30	3.1	
			Placebo	23	19 (82.6)	1.60 (0.80)	0.6	0.99	1.28	2.02	3.4	
		Week 52	Tezepelumab	29	23 (79.3)	1.90 (0.58)	1.2	1.34	1.86	2.35	3.1	
			Placebo	23	20 (87.0)	1.65 (0.86)	0.7	1.07	1.38	2.11	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITT

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	29	26 (89.7)	0.23 (0.38)	-0.2	-0.02	0.11	0.38	1.4	0.89 [0.31, 1.48]
			Placebo	23	23 (100.0)	-0.08 (0.29)	-1.1	-0.14	-0.04	0.09	0.4	
		Week 8	Tezepelumab	29	24 (82.8)	0.17 (0.29)	-0.3	-0.04	0.12	0.40	0.9	0.52 [-0.07, 1.11]
			Placebo	23	22 (95.7)	0.01 (0.35)	-0.9	-0.11	0.03	0.24	0.6	
		Week 12	Tezepelumab	29	26 (89.7)	0.17 (0.40)	-0.3	-0.08	0.06	0.23	1.5	0.43 [-0.14, 1.01]
			Placebo	23	22 (95.7)	-0.01 (0.41)	-1.2	-0.11	0.01	0.17	0.7	
		Week 20	Tezepelumab	29	23 (79.3)	0.09 (0.36)	-0.4	-0.11	0.02	0.21	1.1	0.14 [-0.45, 0.73]
			Placebo	23	21 (91.3)	0.05 (0.32)	-1.0	-0.02	0.01	0.22	0.6	
		Week 28	Tezepelumab	29	25 (86.2)	0.14 (0.46)	-1.0	-0.12	0.01	0.28	1.5	0.43 [-0.15, 1.02]
			Placebo	23	21 (91.3)	-0.04 (0.38)	-0.9	-0.23	-0.02	0.20	0.9	
		Week 40	Tezepelumab	29	23 (79.3)	0.10 (0.32)	-0.7	-0.11	0.07	0.23	0.8	0.19 [-0.42, 0.80]
			Placebo	23	19 (82.6)	0.02 (0.50)	-1.1	-0.24	-0.04	0.22	1.1	
		Week 52	Tezepelumab	29	23 (79.3)	0.13 (0.30)	-0.4	-0.03	0.07	0.24	0.8	0.22 [-0.38, 0.82]
			Placebo	23	20 (87.0)	0.03 (0.58)	-0.9	-0.15	-0.07	0.11	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race (cat. P)									0.948
White	Week 4	Tezepelumab	128	122 (95.3)	0.22 (0.04)	(0.15, 0.30)	0.17 (0.05)	(0.07, 0.27)	0.001 *
		Placebo	123	121 (98.4)	0.05 (0.04)	(-0.02, 0.13)			
	Week 8	Tezepelumab	128	115 (89.8)	0.23 (0.04)	(0.16, 0.30)	0.13 (0.05)	(0.03, 0.24)	0.010 *
		Placebo	123	117 (95.1)	0.09 (0.04)	(0.02, 0.17)			
	Week 12	Tezepelumab	128	119 (93.0)	0.24 (0.04)	(0.16, 0.32)	0.16 (0.05)	(0.05, 0.26)	0.005 *
		Placebo	123	120 (97.6)	0.08 (0.04)	(0.01, 0.16)			
	Week 20	Tezepelumab	128	111 (86.7)	0.23 (0.04)	(0.15, 0.31)	0.15 (0.06)	(0.04, 0.26)	0.007 *
		Placebo	123	117 (95.1)	0.08 (0.04)	(0.00, 0.16)			
	Week 28	Tezepelumab	128	115 (89.8)	0.21 (0.04)	(0.13, 0.29)	0.18 (0.06)	(0.06, 0.29)	0.002 *
		Placebo	123	117 (95.1)	0.03 (0.04)	(-0.05, 0.11)			
	Week 40	Tezepelumab	128	114 (89.1)	0.23 (0.04)	(0.16, 0.31)	0.13 (0.06)	(0.02, 0.24)	0.018 *
		Placebo	123	117 (95.1)	0.10 (0.04)	(0.02, 0.18)			
	Week 52	Tezepelumab	128	111 (86.7)	0.21 (0.04)	(0.13, 0.29)	0.14 (0.06)	(0.03, 0.25)	0.016 *
		Placebo	123	116 (94.3)	0.07 (0.04)	(-0.01, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Non-white	Week 4	Tezepelumab	9	9 (100.0)	0.20 (0.07)	(0.05, 0.35)	0.17 (0.09)	(-0.02, 0.36)	0.076
		Placebo	15	15 (100.0)	0.03 (0.06)	(-0.08, 0.15)			
	Week 8	Tezepelumab	9	9 (100.0)	0.18 (0.06)	(0.05, 0.32)	0.10 (0.08)	(-0.07, 0.27)	0.233
		Placebo	15	15 (100.0)	0.08 (0.05)	(-0.02, 0.19)			
	Week 12	Tezepelumab	9	9 (100.0)	0.20 (0.13)	(-0.06, 0.46)	0.07 (0.16)	(-0.26, 0.40)	0.674
		Placebo	15	15 (100.0)	0.13 (0.10)	(-0.07, 0.33)			
	Week 20	Tezepelumab	9	8 (88.9)	0.12 (0.10)	(-0.08, 0.32)	0.03 (0.12)	(-0.22, 0.28)	0.814
		Placebo	15	14 (93.3)	0.09 (0.07)	(-0.06, 0.24)			
	Week 28	Tezepelumab	9	9 (100.0)	0.30 (0.09)	(0.10, 0.49)	0.20 (0.12)	(-0.04, 0.45)	0.101
		Placebo	15	14 (93.3)	0.09 (0.07)	(-0.06, 0.25)			
	Week 40	Tezepelumab	9	8 (88.9)	0.27 (0.09)	(0.09, 0.46)	0.21 (0.11)	(-0.02, 0.45)	0.068
		Placebo	15	13 (86.7)	0.06 (0.07)	(-0.08, 0.20)			
	Week 52	Tezepelumab	9	8 (88.9)	0.15 (0.12)	(-0.12, 0.43)	0.23 (0.16)	(-0.13, 0.58)	0.184
		Placebo	15	13 (86.7)	-0.07 (0.10)	(-0.29, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region (cat. P)									0.700
North America/Western EU	Week 4	Tezepelumab	10	9 (90.0)	0.13 (0.07)	(-0.02, 0.28)	0.05 (0.10)	(-0.15, 0.26)	0.581
		Placebo	9	9 (100.0)	0.07 (0.07)	(-0.07, 0.22)			
	Week 8	Tezepelumab	10	9 (90.0)	0.21 (0.09)	(0.03, 0.39)	0.04 (0.12)	(-0.21, 0.30)	0.719
		Placebo	9	9 (100.0)	0.17 (0.09)	(-0.02, 0.35)			
	Week 12	Tezepelumab	10	10 (100.0)	0.16 (0.12)	(-0.09, 0.41)	-0.11 (0.17)	(-0.47, 0.25)	0.537
		Placebo	9	9 (100.0)	0.27 (0.12)	(0.00, 0.53)			
	Week 20	Tezepelumab	10	7 (70.0)	0.13 (0.13)	(-0.15, 0.42)	0.03 (0.18)	(-0.36, 0.42)	0.885
		Placebo	9	9 (100.0)	0.11 (0.12)	(-0.16, 0.38)			
	Week 28	Tezepelumab	10	8 (80.0)	0.36 (0.09)	(0.17, 0.55)	0.12 (0.12)	(-0.16, 0.40)	0.355
		Placebo	9	8 (88.9)	0.24 (0.09)	(0.04, 0.44)			
	Week 40	Tezepelumab	10	7 (70.0)	0.33 (0.11)	(0.09, 0.57)	0.18 (0.15)	(-0.15, 0.51)	0.255
		Placebo	9	9 (100.0)	0.15 (0.10)	(-0.08, 0.38)			
	Week 52	Tezepelumab	10	7 (70.0)	0.21 (0.12)	(-0.05, 0.47)	0.27 (0.17)	(-0.10, 0.64)	0.133
		Placebo	9	8 (88.9)	-0.06 (0.12)	(-0.32, 0.20)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of world	Week 4	Tezepelumab	127	122 (96.1)	0.23 (0.04)	(0.15, 0.30)	0.18 (0.05)	(0.08, 0.28)	<0.001 *
		Placebo	129	127 (98.4)	0.05 (0.04)	(-0.02, 0.12)			
	Week 8	Tezepelumab	127	115 (90.6)	0.23 (0.04)	(0.15, 0.30)	0.14 (0.05)	(0.04, 0.24)	0.006 *
		Placebo	129	123 (95.3)	0.09 (0.04)	(0.02, 0.16)			
	Week 12	Tezepelumab	127	118 (92.9)	0.24 (0.04)	(0.17, 0.32)	0.17 (0.05)	(0.06, 0.27)	0.002 *
		Placebo	129	126 (97.7)	0.08 (0.04)	(0.00, 0.15)			
	Week 20	Tezepelumab	127	112 (88.2)	0.23 (0.04)	(0.15, 0.30)	0.15 (0.05)	(0.04, 0.25)	0.007 *
		Placebo	129	122 (94.6)	0.08 (0.04)	(0.01, 0.15)			
	Week 28	Tezepelumab	127	116 (91.3)	0.21 (0.04)	(0.13, 0.29)	0.18 (0.06)	(0.07, 0.29)	0.001 *
		Placebo	129	123 (95.3)	0.03 (0.04)	(-0.05, 0.11)			
	Week 40	Tezepelumab	127	115 (90.6)	0.23 (0.04)	(0.15, 0.31)	0.14 (0.05)	(0.03, 0.25)	0.012 *
		Placebo	129	121 (93.8)	0.09 (0.04)	(0.02, 0.17)			
	Week 52	Tezepelumab	127	112 (88.2)	0.20 (0.04)	(0.12, 0.28)	0.13 (0.06)	(0.02, 0.24)	0.019 *
		Placebo	129	121 (93.8)	0.07 (0.04)	(-0.01, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. P)									0.424
< 250 cells/uL	Week 4	Tezepelumab	61	61 (100.0)	0.19 (0.05)	(0.09, 0.30)	0.16 (0.08)	(0.01, 0.32)	0.033 *
		Placebo	60	58 (96.7)	0.03 (0.05)	(-0.08, 0.14)			
	Week 8	Tezepelumab	61	57 (93.4)	0.19 (0.05)	(0.09, 0.29)	0.08 (0.07)	(-0.06, 0.22)	0.289
		Placebo	60	58 (96.7)	0.11 (0.05)	(0.01, 0.21)			
	Week 12	Tezepelumab	61	59 (96.7)	0.16 (0.05)	(0.05, 0.27)	0.09 (0.08)	(-0.06, 0.25)	0.223
		Placebo	60	59 (98.3)	0.07 (0.06)	(-0.04, 0.18)			
	Week 20	Tezepelumab	61	57 (93.4)	0.15 (0.06)	(0.04, 0.26)	0.06 (0.08)	(-0.10, 0.22)	0.439
		Placebo	60	55 (91.7)	0.09 (0.06)	(-0.03, 0.20)			
	Week 28	Tezepelumab	61	59 (96.7)	0.14 (0.06)	(0.03, 0.26)	0.13 (0.08)	(-0.03, 0.30)	0.111
		Placebo	60	55 (91.7)	0.01 (0.06)	(-0.10, 0.13)			
	Week 40	Tezepelumab	61	57 (93.4)	0.19 (0.06)	(0.08, 0.31)	0.12 (0.08)	(-0.04, 0.28)	0.137
		Placebo	60	56 (93.3)	0.07 (0.06)	(-0.04, 0.19)			
	Week 52	Tezepelumab	61	54 (88.5)	0.13 (0.06)	(0.01, 0.24)	0.11 (0.08)	(-0.05, 0.27)	0.192
		Placebo	60	54 (90.0)	0.02 (0.06)	(-0.09, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 250 cells/uL	Week 4	Tezepelumab	76	70 (92.1)	0.24 (0.05)	(0.15, 0.33)	0.18 (0.06)	(0.05, 0.30)	0.005 *
		Placebo	78	78 (100.0)	0.07 (0.04)	(-0.02, 0.15)			
	Week 8	Tezepelumab	76	67 (88.2)	0.25 (0.05)	(0.16, 0.34)	0.17 (0.06)	(0.04, 0.30)	0.009 *
		Placebo	78	74 (94.9)	0.08 (0.04)	(-0.01, 0.17)			
	Week 12	Tezepelumab	76	69 (90.8)	0.30 (0.05)	(0.21, 0.40)	0.20 (0.07)	(0.06, 0.34)	0.005 *
		Placebo	78	76 (97.4)	0.10 (0.05)	(0.01, 0.20)			
	Week 20	Tezepelumab	76	62 (81.6)	0.29 (0.05)	(0.19, 0.38)	0.21 (0.07)	(0.08, 0.34)	0.002 *
		Placebo	78	76 (97.4)	0.08 (0.05)	(-0.01, 0.17)			
	Week 28	Tezepelumab	76	65 (85.5)	0.27 (0.05)	(0.17, 0.37)	0.21 (0.07)	(0.08, 0.35)	0.003 *
		Placebo	78	76 (97.4)	0.06 (0.05)	(-0.03, 0.16)			
	Week 40	Tezepelumab	76	65 (85.5)	0.27 (0.05)	(0.18, 0.37)	0.16 (0.07)	(0.03, 0.30)	0.019 *
		Placebo	78	74 (94.9)	0.11 (0.05)	(0.02, 0.20)			
	Week 52	Tezepelumab	76	65 (85.5)	0.27 (0.05)	(0.17, 0.37)	0.18 (0.07)	(0.05, 0.32)	0.010 *
		Placebo	78	75 (96.2)	0.09 (0.05)	(-0.00, 0.19)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. P)									0.021 i
< 24 ppb	Week 4	Tezepelumab	75	72 (96.0)	0.17 (0.04)	(0.08, 0.25)	0.06 (0.06)	(-0.06, 0.18)	0.308
		Placebo	72	70 (97.2)	0.11 (0.04)	(0.02, 0.19)			
	Week 8	Tezepelumab	75	69 (92.0)	0.16 (0.04)	(0.07, 0.25)	0.04 (0.06)	(-0.08, 0.17)	0.469
		Placebo	72	69 (95.8)	0.12 (0.04)	(0.03, 0.20)			
	Week 12	Tezepelumab	75	70 (93.3)	0.19 (0.05)	(0.09, 0.28)	0.09 (0.07)	(-0.04, 0.22)	0.164
		Placebo	72	71 (98.6)	0.09 (0.05)	(0.00, 0.19)			
	Week 20	Tezepelumab	75	65 (86.7)	0.16 (0.05)	(0.06, 0.26)	0.03 (0.07)	(-0.10, 0.17)	0.644
		Placebo	72	69 (95.8)	0.13 (0.05)	(0.03, 0.22)			
	Week 28	Tezepelumab	75	68 (90.7)	0.16 (0.05)	(0.06, 0.25)	0.10 (0.07)	(-0.03, 0.23)	0.136
		Placebo	72	69 (95.8)	0.06 (0.05)	(-0.04, 0.15)			
	Week 40	Tezepelumab	75	67 (89.3)	0.20 (0.05)	(0.11, 0.29)	0.10 (0.06)	(-0.03, 0.23)	0.116
		Placebo	72	69 (95.8)	0.10 (0.04)	(0.01, 0.19)			
	Week 52	Tezepelumab	75	66 (88.0)	0.13 (0.05)	(0.04, 0.22)	0.06 (0.07)	(-0.07, 0.19)	0.381
		Placebo	72	69 (95.8)	0.07 (0.05)	(-0.02, 0.16)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 24 ppb	Week 4	Tezepelumab	60	57 (95.0)	0.29 (0.06)	(0.18, 0.41)	0.31 (0.08)	(0.16, 0.46)	<0.001 *
		Placebo	65	65 (100.0)	-0.01 (0.05)	(-0.12, 0.09)			
	Week 8	Tezepelumab	60	53 (88.3)	0.31 (0.05)	(0.20, 0.42)	0.24 (0.07)	(0.09, 0.39)	0.002 *
		Placebo	65	62 (95.4)	0.07 (0.05)	(-0.03, 0.17)			
	Week 12	Tezepelumab	60	56 (93.3)	0.32 (0.06)	(0.20, 0.44)	0.24 (0.08)	(0.07, 0.40)	0.006 *
		Placebo	65	63 (96.9)	0.08 (0.06)	(-0.03, 0.20)			
	Week 20	Tezepelumab	60	52 (86.7)	0.32 (0.06)	(0.20, 0.43)	0.29 (0.08)	(0.13, 0.44)	<0.001 *
		Placebo	65	61 (93.8)	0.03 (0.05)	(-0.08, 0.13)			
	Week 28	Tezepelumab	60	54 (90.0)	0.30 (0.06)	(0.18, 0.42)	0.29 (0.09)	(0.12, 0.46)	0.001 *
		Placebo	65	61 (93.8)	0.01 (0.06)	(-0.11, 0.13)			
	Week 40	Tezepelumab	60	53 (88.3)	0.30 (0.06)	(0.17, 0.42)	0.21 (0.09)	(0.04, 0.38)	0.016 *
		Placebo	65	60 (92.3)	0.09 (0.06)	(-0.03, 0.20)			
	Week 52	Tezepelumab	60	51 (85.0)	0.32 (0.06)	(0.19, 0.44)	0.26 (0.09)	(0.09, 0.43)	0.003 *
		Placebo	65	59 (90.8)	0.06 (0.06)	(-0.06, 0.17)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. M)									0.040 i
< 22.0 ppb	Week 4	Tezepelumab	65	63 (96.9)	0.16 (0.05)	(0.06, 0.25)	0.06 (0.07)	(-0.08, 0.19)	0.391
		Placebo	62	60 (96.8)	0.10 (0.05)	(0.00, 0.19)			
	Week 8	Tezepelumab	65	60 (92.3)	0.16 (0.04)	(0.08, 0.25)	0.06 (0.06)	(-0.06, 0.19)	0.337
		Placebo	62	60 (96.8)	0.10 (0.05)	(0.01, 0.19)			
	Week 12	Tezepelumab	65	60 (92.3)	0.17 (0.05)	(0.08, 0.27)	0.08 (0.07)	(-0.05, 0.21)	0.236
		Placebo	62	61 (98.4)	0.09 (0.05)	(-0.00, 0.19)			
	Week 20	Tezepelumab	65	57 (87.7)	0.14 (0.05)	(0.04, 0.24)	0.03 (0.07)	(-0.12, 0.17)	0.719
		Placebo	62	59 (95.2)	0.11 (0.05)	(0.01, 0.21)			
	Week 28	Tezepelumab	65	58 (89.2)	0.12 (0.05)	(0.02, 0.22)	0.08 (0.07)	(-0.06, 0.21)	0.271
		Placebo	62	59 (95.2)	0.04 (0.05)	(-0.05, 0.14)			
	Week 40	Tezepelumab	65	58 (89.2)	0.17 (0.05)	(0.07, 0.26)	0.08 (0.07)	(-0.05, 0.21)	0.228
		Placebo	62	59 (95.2)	0.09 (0.05)	(-0.01, 0.18)			
	Week 52	Tezepelumab	65	56 (86.2)	0.11 (0.05)	(0.01, 0.21)	0.06 (0.07)	(-0.08, 0.20)	0.406
		Placebo	62	60 (96.8)	0.05 (0.05)	(-0.05, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 22.0 ppb	Week 4	Tezepelumab	70	66 (94.3)	0.29 (0.05)	(0.19, 0.39)	0.28 (0.07)	(0.14, 0.42)	<0.001 *
		Placebo	75	75 (100.0)	0.01 (0.05)	(-0.09, 0.10)			
	Week 8	Tezepelumab	70	62 (88.6)	0.29 (0.05)	(0.18, 0.39)	0.20 (0.07)	(0.06, 0.34)	0.005 *
		Placebo	75	71 (94.7)	0.08 (0.05)	(-0.02, 0.18)			
	Week 12	Tezepelumab	70	66 (94.3)	0.31 (0.06)	(0.20, 0.42)	0.23 (0.08)	(0.07, 0.38)	0.005 *
		Placebo	75	73 (97.3)	0.08 (0.05)	(-0.02, 0.19)			
	Week 20	Tezepelumab	70	60 (85.7)	0.31 (0.05)	(0.21, 0.42)	0.26 (0.07)	(0.12, 0.41)	<0.001 *
		Placebo	75	71 (94.7)	0.05 (0.05)	(-0.05, 0.15)			
	Week 28	Tezepelumab	70	64 (91.4)	0.31 (0.06)	(0.20, 0.43)	0.28 (0.08)	(0.12, 0.44)	<0.001 *
		Placebo	75	71 (94.7)	0.03 (0.05)	(-0.08, 0.14)			
	Week 40	Tezepelumab	70	62 (88.6)	0.31 (0.06)	(0.20, 0.43)	0.21 (0.08)	(0.06, 0.37)	0.008 *
		Placebo	75	70 (93.3)	0.10 (0.05)	(-0.01, 0.21)			
	Week 52	Tezepelumab	70	61 (87.1)	0.30 (0.06)	(0.19, 0.42)	0.23 (0.08)	(0.07, 0.38)	0.004 *
		Placebo	75	68 (90.7)	0.07 (0.05)	(-0.03, 0.18)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline all FEIA status									0.723
All negative	Week 4	Tezepelumab	50	49 (98.0)	0.22 (0.06)	(0.11, 0.33)	0.17 (0.08)	(0.01, 0.33)	0.033 *
		Placebo	50	49 (98.0)	0.05 (0.06)	(-0.06, 0.16)			
	Week 8	Tezepelumab	50	46 (92.0)	0.23 (0.05)	(0.12, 0.33)	0.17 (0.07)	(0.02, 0.32)	0.024 *
		Placebo	50	47 (94.0)	0.06 (0.05)	(-0.05, 0.16)			
	Week 12	Tezepelumab	50	46 (92.0)	0.28 (0.05)	(0.17, 0.39)	0.26 (0.08)	(0.11, 0.41)	<0.001 *
		Placebo	50	50 (100.0)	0.02 (0.05)	(-0.09, 0.13)			
	Week 20	Tezepelumab	50	42 (84.0)	0.24 (0.05)	(0.13, 0.35)	0.18 (0.07)	(0.03, 0.33)	0.018 *
		Placebo	50	49 (98.0)	0.06 (0.05)	(-0.04, 0.16)			
	Week 28	Tezepelumab	50	45 (90.0)	0.21 (0.06)	(0.09, 0.33)	0.20 (0.08)	(0.03, 0.37)	0.019 *
		Placebo	50	48 (96.0)	0.01 (0.06)	(-0.11, 0.13)			
	Week 40	Tezepelumab	50	45 (90.0)	0.18 (0.06)	(0.06, 0.30)	0.09 (0.08)	(-0.07, 0.26)	0.271
		Placebo	50	49 (98.0)	0.09 (0.06)	(-0.03, 0.20)			
	Week 52	Tezepelumab	50	41 (82.0)	0.22 (0.07)	(0.09, 0.35)	0.15 (0.09)	(-0.03, 0.34)	0.097
		Placebo	50	47 (94.0)	0.06 (0.06)	(-0.06, 0.19)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Any positive	Week 4	Tezepelumab	77	72 (93.5)	0.22 (0.05)	(0.12, 0.31)	0.18 (0.07)	(0.05, 0.31)	0.007 *
		Placebo	80	80 (100.0)	0.04 (0.05)	(-0.05, 0.13)			
	Week 8	Tezepelumab	77	70 (90.9)	0.23 (0.05)	(0.13, 0.32)	0.13 (0.07)	(0.00, 0.26)	0.048 *
		Placebo	80	77 (96.3)	0.09 (0.05)	(0.00, 0.18)			
	Week 12	Tezepelumab	77	72 (93.5)	0.19 (0.05)	(0.09, 0.30)	0.05 (0.07)	(-0.09, 0.19)	0.487
		Placebo	80	77 (96.3)	0.14 (0.05)	(0.04, 0.24)			
	Week 20	Tezepelumab	77	68 (88.3)	0.21 (0.05)	(0.11, 0.32)	0.13 (0.07)	(-0.02, 0.27)	0.082
		Placebo	80	75 (93.8)	0.08 (0.05)	(-0.01, 0.18)			
	Week 28	Tezepelumab	77	70 (90.9)	0.22 (0.05)	(0.11, 0.32)	0.17 (0.07)	(0.03, 0.32)	0.018 *
		Placebo	80	75 (93.8)	0.04 (0.05)	(-0.06, 0.14)			
	Week 40	Tezepelumab	77	68 (88.3)	0.27 (0.05)	(0.17, 0.37)	0.18 (0.07)	(0.03, 0.32)	0.016 *
		Placebo	80	73 (91.3)	0.09 (0.05)	(-0.01, 0.19)			
	Week 52	Tezepelumab	77	69 (89.6)	0.21 (0.05)	(0.11, 0.31)	0.16 (0.07)	(0.02, 0.30)	0.024 *
		Placebo	80	74 (92.5)	0.05 (0.05)	(-0.05, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Th2 status									0.870
Low	Week 4	Tezepelumab	70	68 (97.1)	0.21 (0.05)	(0.11, 0.31)	0.16 (0.07)	(0.02, 0.31)	0.026 *
		Placebo	62	60 (96.8)	0.04 (0.05)	(-0.06, 0.15)			
	Week 8	Tezepelumab	70	65 (92.9)	0.19 (0.05)	(0.10, 0.29)	0.12 (0.07)	(-0.01, 0.26)	0.080
		Placebo	62	58 (93.5)	0.07 (0.05)	(-0.03, 0.17)			
	Week 12	Tezepelumab	70	66 (94.3)	0.21 (0.05)	(0.11, 0.31)	0.16 (0.07)	(0.01, 0.31)	0.032 *
		Placebo	62	61 (98.4)	0.05 (0.05)	(-0.06, 0.16)			
	Week 20	Tezepelumab	70	62 (88.6)	0.17 (0.05)	(0.07, 0.26)	0.11 (0.07)	(-0.03, 0.25)	0.119
		Placebo	62	58 (93.5)	0.06 (0.05)	(-0.04, 0.16)			
	Week 28	Tezepelumab	70	64 (91.4)	0.17 (0.06)	(0.06, 0.27)	0.18 (0.08)	(0.02, 0.33)	0.029 *
		Placebo	62	59 (95.2)	-0.01 (0.06)	(-0.12, 0.10)			
	Week 40	Tezepelumab	70	62 (88.6)	0.19 (0.05)	(0.08, 0.30)	0.12 (0.08)	(-0.03, 0.27)	0.126
		Placebo	62	56 (90.3)	0.07 (0.06)	(-0.04, 0.18)			
	Week 52	Tezepelumab	70	61 (87.1)	0.18 (0.05)	(0.08, 0.28)	0.18 (0.08)	(0.03, 0.33)	0.021 *
		Placebo	62	56 (90.3)	0.00 (0.05)	(-0.10, 0.11)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 4	Tezepelumab	65	61 (93.8)	0.23 (0.05)	(0.14, 0.33)	0.18 (0.07)	(0.05, 0.31)	0.009 *
		Placebo	75	75 (100.0)	0.06 (0.05)	(-0.03, 0.15)			
	Week 8	Tezepelumab	65	57 (87.7)	0.25 (0.05)	(0.15, 0.35)	0.14 (0.07)	(0.01, 0.28)	0.037 *
		Placebo	75	73 (97.3)	0.11 (0.05)	(0.02, 0.20)			
	Week 12	Tezepelumab	65	60 (92.3)	0.26 (0.06)	(0.15, 0.37)	0.14 (0.07)	(-0.01, 0.29)	0.063
		Placebo	75	73 (97.3)	0.12 (0.05)	(0.02, 0.22)			
	Week 20	Tezepelumab	65	55 (84.6)	0.28 (0.06)	(0.17, 0.39)	0.17 (0.08)	(0.02, 0.32)	0.023 *
		Placebo	75	72 (96.0)	0.11 (0.05)	(0.01, 0.21)			
	Week 28	Tezepelumab	65	58 (89.2)	0.26 (0.05)	(0.15, 0.37)	0.18 (0.07)	(0.04, 0.33)	0.013 *
		Placebo	75	71 (94.7)	0.08 (0.05)	(-0.02, 0.18)			
	Week 40	Tezepelumab	65	58 (89.2)	0.28 (0.05)	(0.18, 0.39)	0.17 (0.07)	(0.03, 0.31)	0.017 *
		Placebo	75	73 (97.3)	0.11 (0.05)	(0.02, 0.21)			
	Week 52	Tezepelumab	65	56 (86.2)	0.23 (0.06)	(0.12, 0.34)	0.13 (0.08)	(-0.02, 0.28)	0.099
		Placebo	75	72 (96.0)	0.10 (0.05)	(0.00, 0.20)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline Periostin									0.037 i
Low (< 20.9 ng/ml)	Week 4	Tezepelumab	62	60 (96.8)	0.07 (0.04)	(-0.02, 0.16)	0.06 (0.06)	(-0.06, 0.18)	0.321
		Placebo	67	66 (98.5)	0.01 (0.04)	(-0.08, 0.09)			
	Week 8	Tezepelumab	62	58 (93.5)	0.10 (0.05)	(0.01, 0.20)	0.04 (0.07)	(-0.09, 0.17)	0.504
		Placebo	67	63 (94.0)	0.06 (0.05)	(-0.03, 0.15)			
	Week 12	Tezepelumab	62	57 (91.9)	0.13 (0.05)	(0.03, 0.24)	0.11 (0.07)	(-0.04, 0.25)	0.139
		Placebo	67	64 (95.5)	0.02 (0.05)	(-0.08, 0.12)			
	Week 20	Tezepelumab	62	56 (90.3)	0.10 (0.06)	(-0.01, 0.21)	0.02 (0.08)	(-0.13, 0.17)	0.781
		Placebo	67	62 (92.5)	0.08 (0.05)	(-0.03, 0.18)			
	Week 28	Tezepelumab	62	54 (87.1)	0.07 (0.05)	(-0.03, 0.17)	0.02 (0.07)	(-0.12, 0.16)	0.775
		Placebo	67	63 (94.0)	0.05 (0.05)	(-0.04, 0.15)			
	Week 40	Tezepelumab	62	54 (87.1)	0.12 (0.05)	(0.03, 0.21)	0.04 (0.07)	(-0.09, 0.17)	0.533
		Placebo	67	62 (92.5)	0.08 (0.04)	(-0.01, 0.17)			
	Week 52	Tezepelumab	62	53 (85.5)	0.07 (0.05)	(-0.03, 0.18)	0.02 (0.07)	(-0.12, 0.17)	0.728
		Placebo	67	62 (92.5)	0.05 (0.05)	(-0.05, 0.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High (>= 20.9 ng/ml)	Week 4	Tezepelumab	74	70 (94.6)	0.34 (0.05)	(0.24, 0.44)	0.25 (0.07)	(0.11, 0.39)	<0.001 *
		Placebo	71	70 (98.6)	0.09 (0.05)	(-0.01, 0.19)			
	Week 8	Tezepelumab	74	65 (87.8)	0.33 (0.05)	(0.23, 0.42)	0.20 (0.07)	(0.07, 0.33)	0.003 *
		Placebo	71	69 (97.2)	0.12 (0.05)	(0.03, 0.22)			
	Week 12	Tezepelumab	74	70 (94.6)	0.32 (0.05)	(0.22, 0.42)	0.17 (0.07)	(0.03, 0.32)	0.019 *
		Placebo	71	71 (100.0)	0.15 (0.05)	(0.05, 0.25)			
	Week 20	Tezepelumab	74	63 (85.1)	0.33 (0.05)	(0.24, 0.42)	0.24 (0.07)	(0.11, 0.37)	<0.001 *
		Placebo	71	69 (97.2)	0.09 (0.05)	(-0.00, 0.18)			
	Week 28	Tezepelumab	74	69 (93.2)	0.33 (0.05)	(0.22, 0.43)	0.30 (0.08)	(0.14, 0.45)	<0.001 *
		Placebo	71	68 (95.8)	0.03 (0.05)	(-0.08, 0.14)			
	Week 40	Tezepelumab	74	67 (90.5)	0.33 (0.06)	(0.22, 0.44)	0.22 (0.08)	(0.07, 0.38)	0.005 *
		Placebo	71	68 (95.8)	0.11 (0.05)	(-0.00, 0.22)			
	Week 52	Tezepelumab	74	65 (87.8)	0.31 (0.05)	(0.20, 0.41)	0.23 (0.08)	(0.08, 0.38)	0.002 *
		Placebo	71	67 (94.4)	0.07 (0.05)	(-0.03, 0.18)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Current post-BD FEV1 reversibility									0.646
Yes	Week 4	Tezepelumab	114	111 (97.4)	0.23 (0.04)	(0.15, 0.30)	0.17 (0.05)	(0.06, 0.27)	0.002 *
		Placebo	126	124 (98.4)	0.06 (0.04)	(-0.01, 0.13)			
	Week 8	Tezepelumab	114	104 (91.2)	0.24 (0.04)	(0.16, 0.31)	0.13 (0.05)	(0.03, 0.23)	0.013 *
		Placebo	126	120 (95.2)	0.11 (0.04)	(0.04, 0.18)			
	Week 12	Tezepelumab	114	107 (93.9)	0.26 (0.04)	(0.18, 0.35)	0.16 (0.06)	(0.05, 0.28)	0.005 *
		Placebo	126	123 (97.6)	0.10 (0.04)	(0.02, 0.18)			
	Week 20	Tezepelumab	114	101 (88.6)	0.25 (0.04)	(0.17, 0.33)	0.16 (0.06)	(0.05, 0.27)	0.006 *
		Placebo	126	120 (95.2)	0.09 (0.04)	(0.02, 0.17)			
	Week 28	Tezepelumab	114	104 (91.2)	0.24 (0.04)	(0.16, 0.32)	0.19 (0.06)	(0.07, 0.30)	0.001 *
		Placebo	126	119 (94.4)	0.06 (0.04)	(-0.02, 0.13)			
	Week 40	Tezepelumab	114	103 (90.4)	0.26 (0.04)	(0.18, 0.35)	0.15 (0.06)	(0.04, 0.26)	0.010 *
		Placebo	126	120 (95.2)	0.12 (0.04)	(0.04, 0.19)			
	Week 52	Tezepelumab	114	100 (87.7)	0.22 (0.04)	(0.13, 0.30)	0.14 (0.06)	(0.02, 0.26)	0.018 *
		Placebo	126	118 (93.7)	0.08 (0.04)	(-0.00, 0.16)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	23	20 (87.0)	0.19 (0.07)	(0.05, 0.32)	0.27 (0.11)	(0.05, 0.49)	0.020 *
		Placebo	12	12 (100.0)	-0.08 (0.09)	(-0.26, 0.09)			
	Week 8	Tezepelumab	23	20 (87.0)	0.15 (0.06)	(0.03, 0.28)	0.22 (0.10)	(0.02, 0.43)	0.036 *
		Placebo	12	12 (100.0)	-0.07 (0.08)	(-0.23, 0.09)			
	Week 12	Tezepelumab	23	21 (91.3)	0.11 (0.06)	(-0.01, 0.23)	0.15 (0.10)	(-0.05, 0.35)	0.136
		Placebo	12	12 (100.0)	-0.04 (0.08)	(-0.20, 0.12)			
	Week 20	Tezepelumab	23	18 (78.3)	0.10 (0.06)	(-0.02, 0.22)	0.12 (0.10)	(-0.08, 0.33)	0.222
		Placebo	12	11 (91.7)	-0.02 (0.08)	(-0.18, 0.14)			
	Week 28	Tezepelumab	23	20 (87.0)	0.08 (0.07)	(-0.07, 0.23)	0.21 (0.12)	(-0.04, 0.46)	0.102
		Placebo	12	12 (100.0)	-0.13 (0.10)	(-0.33, 0.07)			
	Week 40	Tezepelumab	23	19 (82.6)	0.10 (0.06)	(-0.03, 0.23)	0.23 (0.11)	(0.01, 0.45)	0.038 *
		Placebo	12	10 (83.3)	-0.13 (0.09)	(-0.31, 0.04)			
	Week 52	Tezepelumab	23	19 (82.6)	0.13 (0.06)	(0.01, 0.25)	0.27 (0.10)	(0.06, 0.47)	0.012 *
		Placebo	12	11 (91.7)	-0.13 (0.08)	(-0.29, 0.03)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Maintenance OCS use at baseline									0.556
Yes	Week 4	Tezepelumab	9	9 (100.0)	0.33 (0.12)	(0.07, 0.59)	0.49 (0.16)	(0.16, 0.82)	0.006 *
		Placebo	14	14 (100.0)	-0.16 (0.10)	(-0.37, 0.04)			
	Week 8	Tezepelumab	9	7 (77.8)	0.35 (0.13)	(0.07, 0.63)	0.32 (0.17)	(-0.04, 0.68)	0.076
		Placebo	14	13 (92.9)	0.03 (0.11)	(-0.19, 0.25)			
	Week 12	Tezepelumab	9	8 (88.9)	0.32 (0.16)	(-0.02, 0.65)	0.33 (0.21)	(-0.10, 0.75)	0.128
		Placebo	14	13 (92.9)	-0.01 (0.13)	(-0.27, 0.26)			
	Week 20	Tezepelumab	9	8 (88.9)	0.13 (0.13)	(-0.14, 0.40)	0.06 (0.17)	(-0.29, 0.40)	0.729
		Placebo	14	13 (92.9)	0.07 (0.10)	(-0.14, 0.28)			
	Week 28	Tezepelumab	9	8 (88.9)	0.19 (0.18)	(-0.18, 0.57)	0.20 (0.23)	(-0.28, 0.68)	0.405
		Placebo	14	12 (85.7)	-0.00 (0.14)	(-0.30, 0.30)			
	Week 40	Tezepelumab	9	7 (77.8)	0.27 (0.21)	(-0.16, 0.70)	0.20 (0.26)	(-0.35, 0.75)	0.453
		Placebo	14	11 (78.6)	0.07 (0.16)	(-0.28, 0.41)			
	Week 52	Tezepelumab	9	7 (77.8)	0.31 (0.22)	(-0.14, 0.76)	0.18 (0.27)	(-0.40, 0.75)	0.524
		Placebo	14	12 (85.7)	0.13 (0.17)	(-0.22, 0.48)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	128	122 (95.3)	0.22 (0.04)	(0.15, 0.29)	0.15 (0.05)	(0.05, 0.24)	0.004 *
		Placebo	124	122 (98.4)	0.07 (0.04)	(0.00, 0.14)			
	Week 8	Tezepelumab	128	117 (91.4)	0.22 (0.03)	(0.15, 0.29)	0.12 (0.05)	(0.02, 0.22)	0.015 *
		Placebo	124	119 (96.0)	0.10 (0.03)	(0.03, 0.17)			
	Week 12	Tezepelumab	128	120 (93.8)	0.24 (0.04)	(0.16, 0.31)	0.14 (0.05)	(0.03, 0.24)	0.011 *
		Placebo	124	122 (98.4)	0.10 (0.04)	(0.02, 0.17)			
	Week 20	Tezepelumab	128	111 (86.7)	0.23 (0.04)	(0.16, 0.31)	0.15 (0.05)	(0.05, 0.26)	0.005 *
		Placebo	124	118 (95.2)	0.08 (0.04)	(0.01, 0.16)			
	Week 28	Tezepelumab	128	116 (90.6)	0.22 (0.04)	(0.14, 0.29)	0.18 (0.05)	(0.07, 0.28)	0.001 *
		Placebo	124	119 (96.0)	0.04 (0.04)	(-0.03, 0.12)			
	Week 40	Tezepelumab	128	115 (89.8)	0.24 (0.04)	(0.17, 0.31)	0.15 (0.05)	(0.04, 0.25)	0.006 *
		Placebo	124	119 (96.0)	0.09 (0.04)	(0.02, 0.17)			
	Week 52	Tezepelumab	128	112 (87.5)	0.20 (0.04)	(0.13, 0.28)	0.15 (0.05)	(0.04, 0.25)	0.005 *
		Placebo	124	117 (94.4)	0.05 (0.04)	(-0.02, 0.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No chronic OCS use and current post-BD FEV1 reversibility									0.528
Yes	Week 4	Tezepelumab	108	105 (97.2)	0.22 (0.04)	(0.14, 0.29)	0.14 (0.05)	(0.03, 0.25)	0.011 *
		Placebo	115	113 (98.3)	0.08 (0.04)	(0.00, 0.15)			
	Week 8	Tezepelumab	108	100 (92.6)	0.23 (0.04)	(0.15, 0.30)	0.11 (0.05)	(0.01, 0.22)	0.034 *
		Placebo	115	110 (95.7)	0.11 (0.04)	(0.04, 0.18)			
	Week 12	Tezepelumab	108	102 (94.4)	0.26 (0.04)	(0.17, 0.34)	0.15 (0.06)	(0.03, 0.26)	0.013 *
		Placebo	115	113 (98.3)	0.11 (0.04)	(0.03, 0.19)			
	Week 20	Tezepelumab	108	96 (88.9)	0.25 (0.04)	(0.17, 0.33)	0.16 (0.06)	(0.04, 0.27)	0.007 *
		Placebo	115	110 (95.7)	0.09 (0.04)	(0.01, 0.17)			
	Week 28	Tezepelumab	108	99 (91.7)	0.23 (0.04)	(0.15, 0.32)	0.18 (0.06)	(0.06, 0.29)	0.003 *
		Placebo	115	110 (95.7)	0.06 (0.04)	(-0.02, 0.14)			
	Week 40	Tezepelumab	108	99 (91.7)	0.26 (0.04)	(0.18, 0.34)	0.15 (0.06)	(0.03, 0.26)	0.011 *
		Placebo	115	111 (96.5)	0.11 (0.04)	(0.03, 0.19)			
	Week 52	Tezepelumab	108	96 (88.9)	0.21 (0.04)	(0.13, 0.29)	0.14 (0.06)	(0.03, 0.25)	0.015 *
		Placebo	115	109 (94.8)	0.07 (0.04)	(-0.01, 0.15)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IOSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITT

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	29	26 (89.7)	0.23 (0.07)	(0.10, 0.36)	0.30 (0.10)	(0.11, 0.50)	0.003 *
		Placebo	23	23 (100.0)	-0.07 (0.07)	(-0.22, 0.07)			
	Week 8	Tezepelumab	29	24 (82.8)	0.21 (0.07)	(0.07, 0.35)	0.20 (0.10)	(-0.01, 0.41)	0.060
		Placebo	23	22 (95.7)	0.01 (0.08)	(-0.14, 0.16)			
	Week 12	Tezepelumab	29	26 (89.7)	0.16 (0.08)	(0.01, 0.32)	0.16 (0.11)	(-0.07, 0.39)	0.156
		Placebo	23	22 (95.7)	-0.00 (0.08)	(-0.17, 0.17)			
	Week 20	Tezepelumab	29	23 (79.3)	0.10 (0.06)	(-0.03, 0.24)	0.06 (0.10)	(-0.13, 0.25)	0.539
		Placebo	23	21 (91.3)	0.05 (0.07)	(-0.09, 0.19)			
	Week 28	Tezepelumab	29	25 (86.2)	0.13 (0.08)	(-0.03, 0.30)	0.17 (0.12)	(-0.08, 0.41)	0.174
		Placebo	23	21 (91.3)	-0.03 (0.09)	(-0.21, 0.14)			
	Week 40	Tezepelumab	29	23 (79.3)	0.16 (0.09)	(-0.02, 0.33)	0.14 (0.13)	(-0.12, 0.40)	0.284
		Placebo	23	19 (82.6)	0.02 (0.10)	(-0.18, 0.21)			
	Week 52	Tezepelumab	29	23 (79.3)	0.18 (0.10)	(-0.01, 0.37)	0.15 (0.14)	(-0.14, 0.43)	0.303
		Placebo	23	20 (87.0)	0.03 (0.10)	(-0.18, 0.24)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILMH0: Course of FEV1 Pre-BD
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	66	66 (100.0)	1.75 (0.59)	0.7	1.34	1.66	2.12	3.1	
		Placebo	65	65 (100.0)	1.82 (0.56)	0.9	1.43	1.71	2.21	3.2	
	Week 4	Tezepelumab	66	64 (97.0)	1.99 (0.78)	0.9	1.45	1.82	2.34	4.5	
		Placebo	65	65 (100.0)	1.85 (0.61)	0.7	1.52	1.76	2.34	3.2	
	Week 8	Tezepelumab	66	60 (90.9)	1.94 (0.62)	0.7	1.47	1.88	2.37	3.4	
		Placebo	65	61 (93.8)	1.90 (0.64)	0.8	1.54	1.93	2.29	3.6	
	Week 12	Tezepelumab	66	62 (93.9)	2.04 (0.75)	0.9	1.48	1.89	2.55	4.6	
		Placebo	65	63 (96.9)	1.88 (0.70)	0.5	1.41	1.79	2.40	4.1	
	Week 20	Tezepelumab	66	57 (86.4)	1.91 (0.69)	1.0	1.39	1.71	2.37	4.1	
		Placebo	65	60 (92.3)	1.87 (0.65)	0.5	1.45	1.74	2.33	3.3	
	Week 28	Tezepelumab	66	60 (90.9)	1.93 (0.71)	0.9	1.41	1.76	2.29	4.6	
		Placebo	65	59 (90.8)	1.82 (0.65)	0.7	1.42	1.72	2.24	3.4	
	Week 40	Tezepelumab	66	58 (87.9)	1.93 (0.64)	0.9	1.34	1.91	2.33	3.5	
		Placebo	65	57 (87.7)	1.91 (0.74)	0.6	1.43	1.71	2.29	4.0	
	Week 52	Tezepelumab	66	59 (89.4)	1.86 (0.60)	0.9	1.34	1.80	2.27	3.4	
		Placebo	65	60 (92.3)	1.85 (0.73)	0.6	1.35	1.71	2.31	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILMH0: Course of FEV1 Pre-BD
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 4	Tezepelumab	66	64 (97.0)	0.26 (0.49)	-0.6	-0.01	0.12	0.42	2.4	0.55 [0.20, 0.90]
		Placebo	65	65 (100.0)	0.03 (0.36)	-1.1	-0.15	0.03	0.16	1.1	
	Week 8	Tezepelumab	66	60 (90.9)	0.21 (0.38)	-0.5	-0.02	0.17	0.36	2.2	0.35 [-0.01, 0.71]
		Placebo	65	61 (93.8)	0.07 (0.41)	-1.5	-0.06	0.13	0.24	1.0	
	Week 12	Tezepelumab	66	62 (93.9)	0.31 (0.45)	-0.5	-0.01	0.21	0.47	2.1	0.58 [0.22, 0.93]
		Placebo	65	63 (96.9)	0.06 (0.43)	-1.2	-0.12	0.04	0.28	1.3	
	Week 20	Tezepelumab	66	57 (86.4)	0.21 (0.45)	-0.6	-0.07	0.12	0.39	2.2	0.41 [0.04, 0.77]
		Placebo	65	60 (92.3)	0.05 (0.31)	-1.0	-0.04	0.07	0.23	0.8	
	Week 28	Tezepelumab	66	60 (90.9)	0.23 (0.48)	-1.0	-0.04	0.19	0.50	2.2	0.51 [0.14, 0.87]
		Placebo	65	59 (90.8)	0.01 (0.36)	-1.1	-0.17	0.05	0.23	0.9	
	Week 40	Tezepelumab	66	58 (87.9)	0.24 (0.46)	-0.7	-0.05	0.24	0.44	2.3	0.34 [-0.03, 0.71]
		Placebo	65	57 (87.7)	0.09 (0.39)	-1.1	-0.12	0.06	0.23	1.1	
	Week 52	Tezepelumab	66	59 (89.4)	0.18 (0.44)	-0.8	-0.04	0.11	0.40	2.3	0.31 [-0.05, 0.67]
		Placebo	65	60 (92.3)	0.04 (0.43)	-1.0	-0.16	0.04	0.18	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	64 (97.0)	0.26 (0.05)	(0.15, 0.36)	0.23 (0.08)	(0.08, 0.38)	0.003 *
	Placebo	65	65 (100.0)	0.03 (0.05)	(-0.08, 0.14)			
Week 8	Tezepelumab	66	60 (90.9)	0.23 (0.05)	(0.13, 0.33)	0.15 (0.07)	(0.01, 0.29)	0.038 *
	Placebo	65	61 (93.8)	0.08 (0.05)	(-0.02, 0.18)			
Week 12	Tezepelumab	66	62 (93.9)	0.29 (0.06)	(0.18, 0.40)	0.23 (0.08)	(0.08, 0.38)	0.004 *
	Placebo	65	63 (96.9)	0.06 (0.06)	(-0.05, 0.17)			
Week 20	Tezepelumab	66	57 (86.4)	0.20 (0.05)	(0.10, 0.30)	0.16 (0.07)	(0.02, 0.30)	0.030 *
	Placebo	65	60 (92.3)	0.04 (0.05)	(-0.06, 0.14)			
Week 28	Tezepelumab	66	60 (90.9)	0.21 (0.06)	(0.10, 0.32)	0.20 (0.08)	(0.05, 0.36)	0.012 *
	Placebo	65	59 (90.8)	0.01 (0.06)	(-0.10, 0.12)			
Week 40	Tezepelumab	66	58 (87.9)	0.23 (0.06)	(0.12, 0.35)	0.14 (0.08)	(-0.01, 0.30)	0.075
	Placebo	65	57 (87.7)	0.09 (0.06)	(-0.02, 0.20)			
Week 52	Tezepelumab	66	59 (89.4)	0.18 (0.06)	(0.06, 0.29)	0.15 (0.08)	(-0.01, 0.31)	0.066
	Placebo	65	60 (92.3)	0.03 (0.06)	(-0.09, 0.14)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Figure PF2FAC_ILMG0: Course of FEV1 Pre-BD
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source table: PT2FAC_ILMH0
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	19	19 (100.0)	2.15 (0.51)	1.2	1.78	2.08	2.51	3.1	
			Placebo	20	20 (100.0)	2.07 (0.51)	1.3	1.65	2.17	2.45	3.1	
		Week 4	Tezepelumab	19	18 (94.7)	2.55 (0.85)	1.5	1.82	2.30	3.31	4.5	
			Placebo	20	20 (100.0)	2.00 (0.62)	0.7	1.60	2.02	2.46	2.9	
		Week 8	Tezepelumab	19	15 (78.9)	2.31 (0.53)	1.6	1.94	2.29	2.72	3.2	
			Placebo	20	19 (95.0)	2.05 (0.62)	0.8	1.59	2.15	2.48	3.4	
		Week 12	Tezepelumab	19	18 (94.7)	2.52 (0.76)	1.5	2.04	2.45	2.92	4.6	
			Placebo	20	19 (95.0)	2.18 (0.82)	0.5	1.62	2.16	2.54	4.1	
		Week 20	Tezepelumab	19	16 (84.2)	2.43 (0.75)	1.2	1.82	2.53	2.82	4.1	
			Placebo	20	18 (90.0)	2.11 (0.65)	0.7	1.64	2.19	2.52	3.1	
		Week 28	Tezepelumab	19	18 (94.7)	2.41 (0.77)	1.4	1.98	2.22	2.72	4.6	
			Placebo	20	18 (90.0)	2.09 (0.72)	0.8	1.54	2.05	2.45	3.4	
		Week 40	Tezepelumab	19	17 (89.5)	2.29 (0.54)	1.2	2.01	2.20	2.52	3.3	
			Placebo	20	18 (90.0)	2.18 (0.93)	0.6	1.62	1.92	2.78	4.0	
		Week 52	Tezepelumab	19	17 (89.5)	2.11 (0.55)	1.2	1.80	2.20	2.38	3.2	
			Placebo	20	18 (90.0)	2.23 (0.90)	1.0	1.46	2.13	2.63	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	19	18 (94.7)	0.44 (0.54)	-0.5	0.10	0.38	0.76	1.7	0.96 [0.28, 1.63]
			Placebo	20	20 (100.0)	-0.07 (0.51)	-1.1	-0.24	-0.09	0.18	1.1	
		Week 8	Tezepelumab	19	15 (78.9)	0.18 (0.35)	-0.5	-0.13	0.16	0.44	0.8	0.44 [-0.25, 1.12]
			Placebo	20	19 (95.0)	-0.04 (0.60)	-1.5	-0.18	0.06	0.24	0.9	
		Week 12	Tezepelumab	19	18 (94.7)	0.39 (0.48)	-0.5	0.09	0.33	0.72	1.5	0.56 [-0.10, 1.22]
			Placebo	20	19 (95.0)	0.09 (0.58)	-1.2	-0.11	0.06	0.61	1.0	
		Week 20	Tezepelumab	19	16 (84.2)	0.22 (0.48)	-0.6	-0.10	0.26	0.56	1.1	0.38 [-0.30, 1.06]
			Placebo	20	18 (90.0)	0.06 (0.38)	-1.0	-0.01	0.07	0.23	0.8	
		Week 28	Tezepelumab	19	18 (94.7)	0.30 (0.49)	-0.7	-0.10	0.36	0.57	1.5	0.51 [-0.15, 1.18]
			Placebo	20	18 (90.0)	0.04 (0.52)	-1.1	-0.12	0.11	0.30	0.9	
		Week 40	Tezepelumab	19	17 (89.5)	0.23 (0.40)	-0.5	0.06	0.34	0.43	0.9	0.23 [-0.44, 0.89]
			Placebo	20	18 (90.0)	0.12 (0.58)	-1.1	-0.32	0.13	0.29	1.1	
		Week 52	Tezepelumab	19	17 (89.5)	0.05 (0.41)	-0.8	-0.25	0.11	0.28	0.6	-0.23 [-0.90, 0.43]
			Placebo	20	18 (90.0)	0.17 (0.61)	-0.9	-0.16	0.12	0.39	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	47	47 (100.0)	1.59 (0.55)	0.7	1.24	1.45	1.97	3.1	
			Placebo	45	45 (100.0)	1.71 (0.56)	0.9	1.33	1.56	2.15	3.2	
		Week 4	Tezepelumab	47	46 (97.9)	1.77 (0.64)	0.9	1.26	1.67	2.20	3.6	
			Placebo	45	45 (100.0)	1.78 (0.60)	0.7	1.48	1.68	2.09	3.2	
		Week 8	Tezepelumab	47	45 (95.7)	1.82 (0.60)	0.7	1.40	1.62	2.23	3.4	
			Placebo	45	42 (93.3)	1.83 (0.64)	0.8	1.48	1.79	2.28	3.6	
		Week 12	Tezepelumab	47	44 (93.6)	1.85 (0.65)	0.9	1.33	1.67	2.34	3.5	
			Placebo	45	44 (97.8)	1.74 (0.60)	0.6	1.24	1.69	2.23	2.8	
		Week 20	Tezepelumab	47	41 (87.2)	1.71 (0.56)	1.0	1.37	1.56	2.05	3.4	
			Placebo	45	42 (93.3)	1.76 (0.63)	0.5	1.29	1.70	2.18	3.3	
		Week 28	Tezepelumab	47	42 (89.4)	1.73 (0.58)	0.9	1.33	1.58	2.15	3.4	
			Placebo	45	41 (91.1)	1.71 (0.59)	0.7	1.40	1.69	2.05	3.3	
		Week 40	Tezepelumab	47	41 (87.2)	1.77 (0.63)	0.9	1.30	1.66	2.17	3.5	
			Placebo	45	39 (86.7)	1.79 (0.61)	0.8	1.38	1.68	2.21	3.4	
		Week 52	Tezepelumab	47	42 (89.4)	1.76 (0.60)	0.9	1.31	1.68	1.95	3.4	
			Placebo	45	42 (93.3)	1.69 (0.59)	0.6	1.26	1.61	2.04	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	47	46 (97.9)	0.20 (0.45)	-0.6	-0.04	0.09	0.37	2.4	0.34 [-0.07, 0.76]
			Placebo	45	45 (100.0)	0.07 (0.27)	-0.5	-0.05	0.08	0.16	0.9	
		Week 8	Tezepelumab	47	45 (95.7)	0.22 (0.40)	-0.5	-0.01	0.17	0.35	2.2	0.29 [-0.14, 0.71]
			Placebo	45	42 (93.3)	0.12 (0.30)	-0.6	-0.06	0.14	0.27	1.0	
		Week 12	Tezepelumab	47	44 (93.6)	0.28 (0.43)	-0.2	-0.02	0.18	0.46	2.1	0.59 [0.17, 1.02]
			Placebo	45	44 (97.8)	0.04 (0.35)	-0.7	-0.14	0.04	0.25	1.3	
		Week 20	Tezepelumab	47	41 (87.2)	0.20 (0.45)	-0.4	-0.06	0.09	0.38	2.2	0.42 [-0.02, 0.85]
			Placebo	45	42 (93.3)	0.05 (0.28)	-0.7	-0.08	0.06	0.22	0.6	
		Week 28	Tezepelumab	47	42 (89.4)	0.20 (0.48)	-1.0	-0.03	0.17	0.37	2.2	0.51 [0.07, 0.94]
			Placebo	45	41 (91.1)	0.00 (0.28)	-1.1	-0.17	0.05	0.22	0.3	
		Week 40	Tezepelumab	47	41 (87.2)	0.24 (0.49)	-0.7	-0.07	0.16	0.48	2.3	0.40 [-0.05, 0.84]
			Placebo	45	39 (86.7)	0.08 (0.28)	-0.5	-0.08	0.03	0.23	0.9	
		Week 52	Tezepelumab	47	42 (89.4)	0.23 (0.44)	-0.5	-0.03	0.11	0.40	2.3	0.62 [0.18, 1.06]
			Placebo	45	42 (93.3)	-0.01 (0.33)	-1.0	-0.16	0.00	0.16	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	1.78 (0.60)	0.7	1.37	1.72	2.12	3.1	
			Placebo	55	55 (100.0)	1.92 (0.55)	0.9	1.48	1.81	2.27	3.2	
		Week 4	Tezepelumab	57	55 (96.5)	2.05 (0.77)	0.9	1.51	1.89	2.40	4.5	
			Placebo	55	55 (100.0)	1.94 (0.59)	0.7	1.58	1.86	2.39	3.2	
		Week 8	Tezepelumab	57	52 (91.2)	1.96 (0.61)	0.7	1.48	1.92	2.37	3.4	
			Placebo	55	51 (92.7)	2.00 (0.61)	0.8	1.60	2.05	2.37	3.6	
		Week 12	Tezepelumab	57	54 (94.7)	2.08 (0.75)	0.9	1.51	2.02	2.55	4.6	
			Placebo	55	53 (96.4)	1.98 (0.69)	0.5	1.52	1.90	2.46	4.1	
		Week 20	Tezepelumab	57	49 (86.0)	1.93 (0.69)	1.0	1.46	1.74	2.37	4.1	
			Placebo	55	50 (90.9)	1.98 (0.62)	0.6	1.62	1.92	2.35	3.3	
		Week 28	Tezepelumab	57	52 (91.2)	1.97 (0.70)	1.0	1.47	1.84	2.29	4.6	
			Placebo	55	49 (89.1)	1.94 (0.64)	0.8	1.58	1.91	2.37	3.4	
		Week 40	Tezepelumab	57	50 (87.7)	1.96 (0.62)	1.0	1.43	1.94	2.36	3.5	
			Placebo	55	47 (85.5)	2.05 (0.72)	0.6	1.53	2.02	2.38	4.0	
		Week 52	Tezepelumab	57	51 (89.5)	1.89 (0.61)	0.9	1.36	1.80	2.27	3.4	
			Placebo	55	50 (90.9)	1.97 (0.72)	0.7	1.42	1.80	2.44	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	57	55 (96.5)	0.30 (0.49)	-0.5	0.02	0.13	0.45	2.4	0.64 [0.26, 1.03]
			Placebo	55	55 (100.0)	0.02 (0.36)	-1.1	-0.12	0.05	0.17	0.9	
		Week 8	Tezepelumab	57	52 (91.2)	0.23 (0.39)	-0.5	-0.02	0.20	0.38	2.2	0.37 [-0.02, 0.76]
			Placebo	55	51 (92.7)	0.07 (0.43)	-1.5	-0.06	0.15	0.28	1.0	
		Week 12	Tezepelumab	57	54 (94.7)	0.33 (0.46)	-0.5	0.04	0.23	0.49	2.1	0.61 [0.22, 0.99]
			Placebo	55	53 (96.4)	0.06 (0.45)	-1.2	-0.09	0.08	0.29	1.3	
		Week 20	Tezepelumab	57	49 (86.0)	0.23 (0.47)	-0.6	-0.07	0.13	0.40	2.2	0.42 [0.02, 0.82]
			Placebo	55	50 (90.9)	0.06 (0.31)	-1.0	-0.02	0.10	0.23	0.6	
		Week 28	Tezepelumab	57	52 (91.2)	0.26 (0.49)	-1.0	-0.01	0.21	0.52	2.2	0.54 [0.14, 0.93]
			Placebo	55	49 (89.1)	0.02 (0.39)	-1.1	-0.09	0.11	0.26	0.9	
		Week 40	Tezepelumab	57	50 (87.7)	0.26 (0.47)	-0.7	0.04	0.26	0.48	2.3	0.33 [-0.07, 0.73]
			Placebo	55	47 (85.5)	0.12 (0.42)	-1.1	-0.12	0.08	0.25	1.1	
		Week 52	Tezepelumab	57	51 (89.5)	0.21 (0.46)	-0.8	-0.03	0.11	0.46	2.3	0.32 [-0.08, 0.71]
			Placebo	55	50 (90.9)	0.06 (0.47)	-1.0	-0.16	0.06	0.25	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.57 (0.53)	0.7	1.32	1.45	2.00	2.4	
			Placebo	10	10 (100.0)	1.29 (0.31)	0.9	0.99	1.38	1.52	1.8	
		Week 4	Tezepelumab	9	9 (100.0)	1.62 (0.80)	0.9	1.19	1.41	1.80	3.4	
			Placebo	10	10 (100.0)	1.35 (0.48)	0.7	1.09	1.24	1.63	2.5	
		Week 8	Tezepelumab	9	8 (88.9)	1.79 (0.70)	1.0	1.36	1.60	2.14	3.2	
			Placebo	10	10 (100.0)	1.36 (0.49)	0.8	0.90	1.39	1.60	2.2	
		Week 12	Tezepelumab	9	8 (88.9)	1.81 (0.73)	1.1	1.24	1.60	2.22	3.2	
			Placebo	10	10 (100.0)	1.33 (0.44)	0.9	0.91	1.22	1.62	2.2	
		Week 20	Tezepelumab	9	8 (88.9)	1.77 (0.76)	1.0	1.21	1.55	2.20	3.3	
			Placebo	10	10 (100.0)	1.29 (0.49)	0.5	0.97	1.19	1.53	2.1	
		Week 28	Tezepelumab	9	8 (88.9)	1.68 (0.75)	0.9	1.22	1.45	2.05	3.1	
			Placebo	10	10 (100.0)	1.24 (0.38)	0.7	0.92	1.24	1.44	2.0	
		Week 40	Tezepelumab	9	8 (88.9)	1.73 (0.78)	0.9	1.16	1.51	2.16	3.3	
			Placebo	10	10 (100.0)	1.27 (0.37)	0.8	0.99	1.16	1.62	1.9	
		Week 52	Tezepelumab	9	8 (88.9)	1.66 (0.53)	1.0	1.30	1.49	2.16	2.4	
			Placebo	10	10 (100.0)	1.24 (0.42)	0.6	0.96	1.16	1.63	1.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	0.05 (0.41)	-0.6	-0.14	0.02	0.13	1.0	-0.01 [-0.91, 0.89]
			Placebo	10	10 (100.0)	0.05 (0.41)	-0.3	-0.17	-0.12	0.16	1.1	
		Week 8	Tezepelumab	9	8 (88.9)	0.12 (0.36)	-0.5	0.03	0.10	0.18	0.8	0.17 [-0.76, 1.10]
			Placebo	10	10 (100.0)	0.07 (0.31)	-0.2	-0.09	-0.03	0.08	0.9	
		Week 12	Tezepelumab	9	8 (88.9)	0.13 (0.33)	-0.2	-0.13	0.06	0.27	0.8	0.30 [-0.63, 1.24]
			Placebo	10	10 (100.0)	0.03 (0.33)	-0.2	-0.12	-0.04	0.06	0.9	
		Week 20	Tezepelumab	9	8 (88.9)	0.10 (0.38)	-0.4	-0.09	0.04	0.22	0.9	0.27 [-0.66, 1.21]
			Placebo	10	10 (100.0)	0.00 (0.32)	-0.4	-0.22	-0.04	0.05	0.8	
		Week 28	Tezepelumab	9	8 (88.9)	0.01 (0.40)	-0.6	-0.22	-0.01	0.16	0.8	0.20 [-0.73, 1.14]
			Placebo	10	10 (100.0)	-0.05 (0.15)	-0.3	-0.17	-0.03	0.02	0.2	
		Week 40	Tezepelumab	9	8 (88.9)	0.06 (0.40)	-0.5	-0.10	-0.04	0.19	0.9	0.28 [-0.66, 1.21]
			Placebo	10	10 (100.0)	-0.03 (0.20)	-0.3	-0.14	-0.01	0.09	0.3	
		Week 52	Tezepelumab	9	8 (88.9)	-0.01 (0.21)	-0.5	-0.05	0.03	0.13	0.2	0.18 [-0.76, 1.11]
			Placebo	10	10 (100.0)	-0.05 (0.22)	-0.3	-0.22	-0.10	0.07	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	44	44 (100.0)	1.75 (0.57)	0.7	1.35	1.61	2.10	3.1	
			Placebo	45	45 (100.0)	1.74 (0.56)	0.9	1.40	1.62	2.18	3.2	
		Week 4	Tezepelumab	44	43 (97.7)	2.00 (0.83)	0.9	1.41	1.80	2.39	4.5	
			Placebo	45	45 (100.0)	1.79 (0.59)	0.7	1.48	1.67	2.21	3.2	
		Week 8	Tezepelumab	44	40 (90.9)	1.92 (0.61)	0.7	1.47	1.88	2.30	3.3	
			Placebo	45	44 (97.8)	1.85 (0.65)	0.8	1.45	1.86	2.26	3.6	
		Week 12	Tezepelumab	44	42 (95.5)	2.09 (0.77)	1.0	1.49	1.96	2.69	4.6	
			Placebo	45	44 (97.8)	1.82 (0.66)	0.6	1.31	1.76	2.23	3.3	
		Week 20	Tezepelumab	44	41 (93.2)	1.99 (0.73)	1.0	1.46	1.74	2.45	4.1	
			Placebo	45	42 (93.3)	1.78 (0.64)	0.5	1.29	1.72	2.26	3.3	
		Week 28	Tezepelumab	44	42 (95.5)	1.95 (0.76)	0.9	1.42	1.73	2.29	4.6	
			Placebo	45	40 (88.9)	1.80 (0.70)	0.7	1.38	1.66	2.23	3.4	
		Week 40	Tezepelumab	44	40 (90.9)	1.94 (0.67)	0.9	1.32	1.90	2.37	3.5	
			Placebo	45	40 (88.9)	1.85 (0.70)	0.8	1.44	1.67	2.23	3.5	
		Week 52	Tezepelumab	44	41 (93.2)	1.86 (0.61)	0.9	1.36	1.80	2.27	3.4	
			Placebo	45	42 (93.3)	1.81 (0.75)	0.6	1.30	1.64	2.31	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	44	43 (97.7)	0.27 (0.54)	-0.6	0.03	0.13	0.41	2.4	0.48 [0.06, 0.91]
			Placebo	45	45 (100.0)	0.05 (0.34)	-1.0	-0.12	0.03	0.16	1.1	
		Week 8	Tezepelumab	44	40 (90.9)	0.21 (0.41)	-0.5	0.01	0.16	0.35	2.2	0.24 [-0.18, 0.67]
			Placebo	45	44 (97.8)	0.11 (0.40)	-1.5	-0.05	0.13	0.21	1.0	
		Week 12	Tezepelumab	44	42 (95.5)	0.33 (0.50)	-0.5	0.04	0.21	0.45	2.1	0.56 [0.13, 0.99]
			Placebo	45	44 (97.8)	0.08 (0.40)	-0.9	-0.10	0.04	0.25	1.3	
		Week 20	Tezepelumab	44	41 (93.2)	0.24 (0.46)	-0.4	-0.06	0.19	0.39	2.2	0.51 [0.07, 0.95]
			Placebo	45	42 (93.3)	0.05 (0.27)	-0.6	-0.05	0.07	0.21	0.8	
		Week 28	Tezepelumab	44	42 (95.5)	0.20 (0.53)	-1.0	-0.06	0.19	0.44	2.2	0.30 [-0.13, 0.74]
			Placebo	45	40 (88.9)	0.07 (0.29)	-0.6	-0.11	0.09	0.21	0.9	
		Week 40	Tezepelumab	44	40 (90.9)	0.21 (0.51)	-0.7	-0.07	0.23	0.44	2.3	0.24 [-0.20, 0.68]
			Placebo	45	40 (88.9)	0.10 (0.34)	-0.5	-0.07	0.06	0.23	1.1	
		Week 52	Tezepelumab	44	41 (93.2)	0.14 (0.47)	-0.8	-0.03	0.09	0.36	2.3	0.11 [-0.32, 0.54]
			Placebo	45	42 (93.3)	0.09 (0.42)	-0.9	-0.16	0.05	0.17	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	22	22 (100.0)	1.76 (0.63)	0.7	1.29	1.73	2.31	3.1	
			Placebo	20	20 (100.0)	2.00 (0.53)	1.3	1.55	1.92	2.33	3.1	
		Week 4	Tezepelumab	22	21 (95.5)	1.98 (0.69)	0.9	1.51	1.89	2.29	3.3	
			Placebo	20	20 (100.0)	1.97 (0.65)	0.7	1.60	1.87	2.47	3.1	
		Week 8	Tezepelumab	22	20 (90.9)	1.99 (0.65)	1.3	1.41	1.88	2.42	3.4	
			Placebo	20	17 (85.0)	2.02 (0.60)	0.8	1.61	2.08	2.39	3.1	
		Week 12	Tezepelumab	22	20 (90.9)	1.95 (0.71)	0.9	1.40	1.86	2.41	3.5	
			Placebo	20	19 (95.0)	2.00 (0.79)	0.5	1.48	1.93	2.48	4.1	
		Week 20	Tezepelumab	22	16 (72.7)	1.71 (0.54)	1.0	1.30	1.53	2.12	2.8	
			Placebo	20	18 (90.0)	2.08 (0.65)	0.7	1.65	2.01	2.54	3.2	
		Week 28	Tezepelumab	22	18 (81.8)	1.90 (0.60)	1.1	1.35	1.76	2.29	3.0	
			Placebo	20	19 (95.0)	1.88 (0.56)	0.8	1.58	1.91	2.27	3.0	
		Week 40	Tezepelumab	22	18 (81.8)	1.91 (0.60)	1.1	1.36	1.91	2.30	3.0	
			Placebo	20	17 (85.0)	2.07 (0.83)	0.6	1.36	2.18	2.38	4.0	
		Week 52	Tezepelumab	22	18 (81.8)	1.87 (0.60)	1.2	1.34	1.75	2.15	3.2	
			Placebo	20	18 (90.0)	1.95 (0.69)	1.0	1.38	1.88	2.42	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	22	21 (95.5)	0.25 (0.35)	-0.3	-0.03	0.11	0.62	0.9	0.74 [0.11, 1.37]
			Placebo	20	20 (100.0)	-0.03 (0.41)	-1.1	-0.24	0.05	0.24	0.6	
		Week 8	Tezepelumab	22	20 (90.9)	0.22 (0.32)	-0.4	-0.04	0.32	0.44	0.8	0.63 [-0.03, 1.29]
			Placebo	20	17 (85.0)	-0.02 (0.45)	-0.9	-0.17	0.08	0.31	0.6	
		Week 12	Tezepelumab	22	20 (90.9)	0.26 (0.30)	-0.1	-0.02	0.22	0.49	0.9	0.63 [-0.01, 1.28]
			Placebo	20	19 (95.0)	0.01 (0.49)	-1.2	-0.17	0.05	0.31	1.0	
		Week 20	Tezepelumab	22	16 (72.7)	0.13 (0.44)	-0.6	-0.12	0.09	0.36	0.9	0.17 [-0.50, 0.85]
			Placebo	20	18 (90.0)	0.06 (0.40)	-1.0	-0.03	0.09	0.29	0.6	
		Week 28	Tezepelumab	22	18 (81.8)	0.30 (0.36)	-0.2	-0.03	0.24	0.57	0.9	0.97 [0.29, 1.66]
			Placebo	20	19 (95.0)	-0.11 (0.47)	-1.1	-0.37	0.02	0.27	0.3	
		Week 40	Tezepelumab	22	18 (81.8)	0.30 (0.34)	-0.1	0.05	0.25	0.54	1.0	0.55 [-0.13, 1.23]
			Placebo	20	17 (85.0)	0.07 (0.51)	-1.1	-0.20	-0.04	0.47	0.9	
		Week 52	Tezepelumab	22	18 (81.8)	0.27 (0.34)	-0.2	-0.04	0.21	0.64	0.8	0.83 [0.15, 1.51]
			Placebo	20	18 (90.0)	-0.07 (0.45)	-1.0	-0.39	0.00	0.25	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	1.78 (0.56)	0.7	1.39	1.73	2.15	3.1	
			Placebo	58	58 (100.0)	1.81 (0.58)	0.9	1.41	1.68	2.19	3.2	
		Week 4	Tezepelumab	60	58 (96.7)	2.03 (0.76)	0.9	1.50	1.86	2.39	4.5	
			Placebo	58	58 (100.0)	1.84 (0.63)	0.7	1.45	1.74	2.34	3.2	
		Week 8	Tezepelumab	60	54 (90.0)	1.97 (0.60)	0.7	1.51	1.94	2.37	3.4	
			Placebo	58	54 (93.1)	1.89 (0.67)	0.8	1.48	1.91	2.35	3.6	
		Week 12	Tezepelumab	60	56 (93.3)	2.09 (0.73)	0.9	1.51	2.02	2.56	4.6	
			Placebo	58	56 (96.6)	1.88 (0.73)	0.5	1.39	1.78	2.45	4.1	
		Week 20	Tezepelumab	60	51 (85.0)	1.95 (0.69)	1.0	1.45	1.75	2.38	4.1	
			Placebo	58	54 (93.1)	1.86 (0.68)	0.5	1.33	1.74	2.33	3.3	
		Week 28	Tezepelumab	60	54 (90.0)	1.96 (0.69)	0.9	1.49	1.84	2.29	4.6	
			Placebo	58	52 (89.7)	1.80 (0.68)	0.7	1.41	1.69	2.16	3.4	
		Week 40	Tezepelumab	60	53 (88.3)	1.94 (0.64)	0.9	1.43	1.94	2.33	3.5	
			Placebo	58	52 (89.7)	1.91 (0.76)	0.6	1.41	1.70	2.32	4.0	
		Week 52	Tezepelumab	60	53 (88.3)	1.89 (0.59)	0.9	1.36	1.83	2.27	3.4	
			Placebo	58	54 (93.1)	1.85 (0.76)	0.6	1.30	1.67	2.42	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	60	58 (96.7)	0.27 (0.51)	-0.6	-0.02	0.12	0.42	2.4	0.53 [0.16, 0.90]
			Placebo	58	58 (100.0)	0.03 (0.37)	-1.1	-0.15	0.02	0.17	1.1	
		Week 8	Tezepelumab	60	54 (90.0)	0.21 (0.40)	-0.5	-0.01	0.17	0.36	2.2	0.31 [-0.07, 0.69]
			Placebo	58	54 (93.1)	0.09 (0.44)	-1.5	-0.07	0.14	0.28	1.0	
		Week 12	Tezepelumab	60	56 (93.3)	0.33 (0.46)	-0.5	0.04	0.22	0.48	2.1	0.55 [0.18, 0.93]
			Placebo	58	56 (96.6)	0.08 (0.43)	-1.2	-0.12	0.05	0.30	1.3	
		Week 20	Tezepelumab	60	51 (85.0)	0.22 (0.48)	-0.6	-0.08	0.12	0.43	2.2	0.39 [0.01, 0.78]
			Placebo	58	54 (93.1)	0.06 (0.31)	-1.0	-0.03	0.07	0.23	0.8	
		Week 28	Tezepelumab	60	54 (90.0)	0.22 (0.50)	-1.0	-0.06	0.17	0.51	2.2	0.49 [0.10, 0.87]
			Placebo	58	52 (89.7)	0.01 (0.38)	-1.1	-0.18	0.05	0.25	0.9	
		Week 40	Tezepelumab	60	53 (88.3)	0.24 (0.48)	-0.7	-0.07	0.25	0.44	2.3	0.30 [-0.08, 0.68]
			Placebo	58	52 (89.7)	0.10 (0.40)	-1.1	-0.12	0.05	0.25	1.1	
		Week 52	Tezepelumab	60	53 (88.3)	0.18 (0.46)	-0.8	-0.04	0.11	0.40	2.3	0.26 [-0.12, 0.64]
			Placebo	58	54 (93.1)	0.06 (0.45)	-1.0	-0.16	0.04	0.25	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	1.23 (0.24)	1.1	1.06	1.23	1.40	1.4	
			Placebo	2	2 (100.0)	2.14 (0.29)	1.9	1.93	2.14	2.34	2.3	
		Week 4	Tezepelumab	2	2 (100.0)	1.32 (0.28)	1.1	1.12	1.32	1.51	1.5	
			Placebo	2	2 (100.0)	2.21 (0.37)	1.9	1.94	2.21	2.47	2.5	
		Week 8	Tezepelumab	2	2 (100.0)	1.36 (0.01)	1.4	1.35	1.36	1.37	1.4	
			Placebo	2	2 (100.0)	2.07 (0.02)	2.1	2.05	2.07	2.08	2.1	
		Week 12	Tezepelumab	2	2 (100.0)	1.15 (0.25)	1.0	0.97	1.15	1.32	1.3	
			Placebo	2	2 (100.0)	1.87 (0.08)	1.8	1.81	1.87	1.93	1.9	
		Week 20	Tezepelumab	2	2 (100.0)	1.27 (0.37)	1.0	1.00	1.27	1.53	1.5	
			Placebo	2	2 (100.0)	1.82 (0.24)	1.7	1.65	1.82	1.99	2.0	
		Week 28	Tezepelumab	2	2 (100.0)	1.49 (0.30)	1.3	1.27	1.49	1.70	1.7	
			Placebo	2	2 (100.0)	2.24 (0.47)	1.9	1.91	2.24	2.57	2.6	
		Week 40	Tezepelumab	2	2 (100.0)	1.47 (0.23)	1.3	1.31	1.47	1.63	1.6	
			Placebo	2	2 (100.0)	2.09 (0.09)	2.0	2.02	2.09	2.15	2.2	
		Week 52	Tezepelumab	2	2 (100.0)	1.41 (0.36)	1.2	1.15	1.41	1.66	1.7	
			Placebo	2	2 (100.0)	1.88 (0.18)	1.8	1.75	1.88	2.00	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	2	2 (100.0)	0.09 (0.04)	0.1	0.06	0.09	0.11	0.1	0.23 [-1.74, 2.20]
			Placebo	2	2 (100.0)	0.07 (0.08)	0.0	0.01	0.07	0.13	0.1	
		Week 8	Tezepelumab	2	2 (100.0)	0.13 (0.25)	-0.0	-0.05	0.13	0.31	0.3	0.70 [-1.37, 2.78]
			Placebo	2	2 (100.0)	-0.07 (0.31)	-0.3	-0.29	-0.07	0.15	0.2	
		Week 12	Tezepelumab	2	2 (100.0)	-0.08 (0.01)	-0.1	-0.09	-0.08	-0.08	-0.1	0.68 [-1.39, 2.75]
			Placebo	2	2 (100.0)	-0.26 (0.37)	-0.5	-0.53	-0.26	0.00	0.0	
		Week 20	Tezepelumab	2	2 (100.0)	0.04 (0.13)	-0.1	-0.06	0.04	0.13	0.1	0.90 [-1.25, 3.06]
			Placebo	2	2 (100.0)	-0.32 (0.53)	-0.7	-0.69	-0.32	0.06	0.1	
		Week 28	Tezepelumab	2	2 (100.0)	0.26 (0.06)	0.2	0.21	0.26	0.30	0.3	1.13 [-1.12, 3.38]
			Placebo	2	2 (100.0)	0.11 (0.18)	-0.0	-0.02	0.11	0.23	0.2	
		Week 40	Tezepelumab	2	2 (100.0)	0.24 (0.01)	0.2	0.23	0.24	0.25	0.3	1.07 [-1.15, 3.30]
			Placebo	2	2 (100.0)	-0.05 (0.38)	-0.3	-0.32	-0.05	0.22	0.2	
		Week 52	Tezepelumab	2	2 (100.0)	0.17 (0.12)	0.1	0.09	0.17	0.26	0.3	1.28 [-1.05, 3.60]
			Placebo	2	2 (100.0)	-0.26 (0.47)	-0.6	-0.59	-0.26	0.07	0.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	1.69 (1.23)	0.7	0.70	1.29	3.07	3.1	
			Placebo	3	3 (100.0)	1.84 (0.38)	1.5	1.48	1.81	2.23	2.2	
		Week 4	Tezepelumab	3	3 (100.0)	1.96 (1.37)	1.1	1.09	1.25	3.54	3.5	
			Placebo	3	3 (100.0)	1.86 (0.46)	1.6	1.58	1.60	2.39	2.4	
		Week 8	Tezepelumab	3	3 (100.0)	1.91 (1.13)	1.3	1.25	1.26	3.21	3.2	
			Placebo	3	3 (100.0)	1.84 (0.41)	1.5	1.48	1.75	2.29	2.3	
		Week 12	Tezepelumab	3	3 (100.0)	1.93 (1.19)	1.2	1.21	1.28	3.30	3.3	
			Placebo	3	3 (100.0)	1.70 (0.64)	1.1	1.11	1.62	2.38	2.4	
		Week 20	Tezepelumab	3	3 (100.0)	1.82 (1.02)	1.1	1.10	1.37	2.98	3.0	
			Placebo	3	3 (100.0)	1.85 (0.35)	1.6	1.62	1.68	2.26	2.3	
		Week 28	Tezepelumab	3	3 (100.0)	2.01 (1.33)	1.2	1.23	1.26	3.54	3.5	
			Placebo	3	3 (100.0)	1.98 (0.40)	1.7	1.70	1.80	2.44	2.4	
		Week 40	Tezepelumab	3	3 (100.0)	1.94 (1.02)	1.3	1.34	1.36	3.11	3.1	
			Placebo	3	3 (100.0)	1.83 (0.53)	1.4	1.36	1.71	2.41	2.4	
		Week 52	Tezepelumab	3	3 (100.0)	1.92 (1.01)	1.3	1.31	1.36	3.08	3.1	
			Placebo	3	3 (100.0)	1.79 (0.46)	1.4	1.42	1.64	2.31	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	0.27 (0.27)	-0.0	-0.04	0.39	0.47	0.5	1.07 [-0.69, 2.84]
			Placebo	3	3 (100.0)	0.02 (0.20)	-0.2	-0.21	0.10	0.16	0.2	
		Week 8	Tezepelumab	3	3 (100.0)	0.22 (0.30)	-0.0	-0.03	0.14	0.55	0.6	1.02 [-0.73, 2.77]
			Placebo	3	3 (100.0)	0.00 (0.06)	-0.1	-0.06	0.00	0.06	0.1	
		Week 12	Tezepelumab	3	3 (100.0)	0.24 (0.26)	-0.0	-0.01	0.23	0.51	0.5	0.97 [-0.76, 2.71]
			Placebo	3	3 (100.0)	-0.14 (0.49)	-0.7	-0.70	0.14	0.15	0.1	
		Week 20	Tezepelumab	3	3 (100.0)	0.13 (0.25)	-0.1	-0.09	0.08	0.40	0.4	0.58 [-1.07, 2.23]
			Placebo	3	3 (100.0)	0.01 (0.14)	-0.1	-0.13	0.03	0.14	0.1	
		Week 28	Tezepelumab	3	3 (100.0)	0.32 (0.31)	-0.0	-0.03	0.47	0.53	0.5	0.78 [-0.91, 2.47]
			Placebo	3	3 (100.0)	0.14 (0.13)	-0.0	-0.01	0.21	0.22	0.2	
		Week 40	Tezepelumab	3	3 (100.0)	0.25 (0.36)	0.0	0.04	0.05	0.66	0.7	0.72 [-0.96, 2.39]
			Placebo	3	3 (100.0)	-0.01 (0.38)	-0.5	-0.45	0.18	0.23	0.2	
		Week 52	Tezepelumab	3	3 (100.0)	0.23 (0.33)	0.0	0.01	0.07	0.61	0.6	0.89 [-0.82, 2.61]
			Placebo	3	3 (100.0)	-0.05 (0.30)	-0.4	-0.39	0.08	0.16	0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	1.24	1.2	1.24	1.24	1.24	1.2	
			Placebo	2	2 (100.0)	1.95 (0.52)	1.6	1.58	1.95	2.32	2.3	
		Week 4	Tezepelumab	1	1 (100.0)	1.37	1.4	1.37	1.37	1.37	1.4	
			Placebo	2	2 (100.0)	1.73 (0.09)	1.7	1.66	1.73	1.79	1.8	
		Week 8	Tezepelumab	1	1 (100.0)	1.48	1.5	1.48	1.48	1.48	1.5	
			Placebo	2	2 (100.0)	1.92 (0.53)	1.5	1.54	1.92	2.29	2.3	
		Week 12	Tezepelumab	1	1 (100.0)	1.45	1.5	1.45	1.45	1.45	1.5	
			Placebo	2	2 (100.0)	1.96 (0.62)	1.5	1.52	1.96	2.40	2.4	
		Week 20	Tezepelumab	1	1 (100.0)	1.46	1.5	1.46	1.46	1.46	1.5	
			Placebo	2	1 (50.0)	2.54	2.5	2.54	2.54	2.54	2.5	
		Week 28	Tezepelumab	1	1 (100.0)	1.39	1.4	1.39	1.39	1.39	1.4	
			Placebo	2	2 (100.0)	1.81 (0.80)	1.2	1.24	1.81	2.37	2.4	
		Week 52	Tezepelumab	1	1 (100.0)	1.25	1.3	1.25	1.25	1.25	1.3	
			Placebo	2	1 (50.0)	2.28	2.3	2.28	2.28	2.28	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	0.13	0.1	0.13	0.13	0.13	0.1	NE
			Placebo	2	2 (100.0)	-0.23 (0.43)	-0.5	-0.53	-0.23	0.08	0.1	
		Week 8	Tezepelumab	1	1 (100.0)	0.24	0.2	0.24	0.24	0.24	0.2	NE
			Placebo	2	2 (100.0)	-0.03 (0.01)	-0.0	-0.04	-0.03	-0.03	-0.0	
		Week 12	Tezepelumab	1	1 (100.0)	0.21	0.2	0.21	0.21	0.21	0.2	NE
			Placebo	2	2 (100.0)	0.01 (0.10)	-0.1	-0.06	0.01	0.08	0.1	
		Week 20	Tezepelumab	1	1 (100.0)	0.22	0.2	0.22	0.22	0.22	0.2	NE
			Placebo	2	1 (50.0)	0.22	0.2	0.22	0.22	0.22	0.2	
		Week 28	Tezepelumab	1	1 (100.0)	0.15	0.1	0.15	0.15	0.15	0.1	NE
			Placebo	2	2 (100.0)	-0.14 (0.28)	-0.3	-0.34	-0.14	0.05	0.1	
		Week 52	Tezepelumab	1	1 (100.0)	0.01	0.0	0.01	0.01	0.01	0.0	NE
			Placebo	2	1 (50.0)	-0.04	-0.0	-0.04	-0.04	-0.04	-0.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	1.81 (0.54)	0.7	1.41	1.76	2.19	3.1	
			Placebo	36	36 (100.0)	1.83 (0.60)	0.9	1.43	1.68	2.22	3.2	
		Week 4	Tezepelumab	40	38 (95.0)	2.04 (0.62)	0.9	1.54	2.00	2.39	3.6	
			Placebo	36	36 (100.0)	1.86 (0.66)	0.7	1.43	1.70	2.44	3.2	
		Week 8	Tezepelumab	40	38 (95.0)	2.03 (0.59)	0.7	1.57	1.98	2.37	3.4	
			Placebo	36	34 (94.4)	1.93 (0.69)	0.8	1.59	1.86	2.37	3.6	
		Week 12	Tezepelumab	40	38 (95.0)	2.12 (0.60)	1.2	1.56	2.05	2.55	3.5	
			Placebo	36	36 (100.0)	1.92 (0.78)	0.5	1.44	1.75	2.46	4.1	
		Week 20	Tezepelumab	40	35 (87.5)	1.98 (0.61)	1.0	1.47	1.86	2.38	3.4	
			Placebo	36	36 (100.0)	1.88 (0.68)	0.6	1.42	1.81	2.35	3.3	
		Week 28	Tezepelumab	40	36 (90.0)	1.93 (0.58)	1.0	1.51	1.90	2.29	3.4	
			Placebo	36	35 (97.2)	1.88 (0.67)	0.8	1.48	1.72	2.21	3.4	
		Week 40	Tezepelumab	40	35 (87.5)	2.03 (0.62)	1.0	1.66	2.11	2.33	3.5	
			Placebo	36	35 (97.2)	1.96 (0.77)	0.6	1.50	1.69	2.35	4.0	
		Week 52	Tezepelumab	40	36 (90.0)	1.93 (0.55)	0.9	1.58	1.89	2.31	3.4	
			Placebo	36	36 (100.0)	1.89 (0.74)	0.7	1.38	1.71	2.43	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	40	38 (95.0)	0.27 (0.49)	-0.3	-0.02	0.13	0.42	2.4	0.54 [0.07, 1.00]
			Placebo	36	36 (100.0)	0.03 (0.37)	-1.1	-0.15	0.02	0.17	1.1	
		Week 8	Tezepelumab	40	38 (95.0)	0.25 (0.41)	-0.2	-0.01	0.17	0.35	2.2	0.40 [-0.07, 0.86]
			Placebo	36	34 (94.4)	0.09 (0.37)	-0.9	-0.04	0.16	0.24	0.9	
		Week 12	Tezepelumab	40	38 (95.0)	0.34 (0.47)	-0.5	0.09	0.22	0.49	2.1	0.56 [0.10, 1.03]
			Placebo	36	36 (100.0)	0.09 (0.41)	-1.2	-0.07	0.07	0.30	1.0	
		Week 20	Tezepelumab	40	35 (87.5)	0.26 (0.51)	-0.6	-0.06	0.19	0.49	2.2	0.49 [0.01, 0.96]
			Placebo	36	36 (100.0)	0.05 (0.34)	-1.0	-0.06	0.13	0.23	0.8	
		Week 28	Tezepelumab	40	36 (90.0)	0.21 (0.53)	-1.0	-0.08	0.12	0.51	2.2	0.34 [-0.12, 0.81]
			Placebo	36	35 (97.2)	0.05 (0.38)	-1.1	-0.09	0.13	0.26	0.9	
		Week 40	Tezepelumab	40	35 (87.5)	0.30 (0.51)	-0.7	-0.01	0.26	0.50	2.3	0.42 [-0.05, 0.90]
			Placebo	36	35 (97.2)	0.11 (0.41)	-1.1	-0.08	0.06	0.22	1.0	
		Week 52	Tezepelumab	40	36 (90.0)	0.21 (0.50)	-0.8	-0.03	0.13	0.45	2.3	0.33 [-0.13, 0.80]
			Placebo	36	36 (100.0)	0.07 (0.37)	-0.7	-0.16	0.05	0.22	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	1.29 (0.32)	0.9	1.06	1.25	1.40	1.8	
			Placebo	4	4 (100.0)	2.15 (0.48)	1.6	1.78	2.14	2.53	2.7	
		Week 4	Tezepelumab	6	6 (100.0)	1.37 (0.34)	0.9	1.12	1.39	1.70	1.7	
			Placebo	4	4 (100.0)	2.33 (0.58)	1.8	1.88	2.21	2.78	3.1	
		Week 8	Tezepelumab	6	6 (100.0)	1.44 (0.21)	1.3	1.30	1.36	1.47	1.9	
			Placebo	4	4 (100.0)	2.21 (0.65)	1.6	1.82	2.07	2.61	3.1	
		Week 12	Tezepelumab	6	6 (100.0)	1.32 (0.38)	0.9	0.97	1.26	1.71	1.8	
			Placebo	4	4 (100.0)	2.20 (0.46)	1.8	1.87	2.08	2.54	2.8	
		Week 20	Tezepelumab	6	5 (83.3)	1.33 (0.32)	1.0	1.03	1.34	1.53	1.7	
			Placebo	4	4 (100.0)	2.13 (0.73)	1.7	1.67	1.84	2.60	3.2	
		Week 28	Tezepelumab	6	5 (83.3)	1.46 (0.30)	1.1	1.27	1.40	1.70	1.8	
			Placebo	4	4 (100.0)	2.36 (0.52)	1.9	1.94	2.27	2.79	3.0	
		Week 40	Tezepelumab	6	5 (83.3)	1.45 (0.30)	1.1	1.31	1.33	1.63	1.9	
			Placebo	4	4 (100.0)	2.20 (0.72)	1.5	1.74	2.09	2.67	3.2	
		Week 52	Tezepelumab	6	5 (83.3)	1.42 (0.30)	1.2	1.16	1.34	1.66	1.8	
			Placebo	4	4 (100.0)	2.06 (0.68)	1.5	1.61	1.88	2.51	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	6	6 (100.0)	0.08 (0.17)	-0.1	-0.06	0.09	0.13	0.4	-0.60 [-1.90, 0.70]
			Placebo	4	4 (100.0)	0.18 (0.15)	0.0	0.07	0.17	0.29	0.4	
		Week 8	Tezepelumab	6	6 (100.0)	0.15 (0.31)	-0.4	-0.05	0.24	0.33	0.5	0.29 [-0.98, 1.56]
			Placebo	4	4 (100.0)	0.06 (0.30)	-0.3	-0.17	0.06	0.29	0.4	
		Week 12	Tezepelumab	6	6 (100.0)	0.03 (0.22)	-0.1	-0.09	-0.06	0.06	0.5	-0.07 [-1.34, 1.19]
			Placebo	4	4 (100.0)	0.05 (0.47)	-0.5	-0.26	0.06	0.37	0.6	
		Week 20	Tezepelumab	6	5 (83.3)	0.15 (0.16)	-0.1	0.09	0.13	0.21	0.4	0.49 [-0.85, 1.83]
			Placebo	4	4 (100.0)	-0.02 (0.49)	-0.7	-0.32	0.06	0.28	0.5	
		Week 28	Tezepelumab	6	5 (83.3)	0.29 (0.12)	0.2	0.21	0.27	0.30	0.5	0.53 [-0.82, 1.87]
			Placebo	4	4 (100.0)	0.21 (0.16)	-0.0	0.11	0.26	0.32	0.3	
		Week 40	Tezepelumab	6	5 (83.3)	0.27 (0.13)	0.2	0.20	0.23	0.25	0.5	0.85 [-0.54, 2.24]
			Placebo	4	4 (100.0)	0.05 (0.36)	-0.3	-0.25	0.02	0.35	0.5	
		Week 52	Tezepelumab	6	5 (83.3)	0.24 (0.18)	0.0	0.09	0.26	0.40	0.4	1.18 [-0.28, 2.63]
			Placebo	4	4 (100.0)	-0.09 (0.38)	-0.6	-0.38	-0.05	0.19	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	1.69 (1.23)	0.7	0.70	1.29	3.07	3.1	
			Placebo	3	3 (100.0)	1.84 (0.38)	1.5	1.48	1.81	2.23	2.2	
		Week 4	Tezepelumab	3	3 (100.0)	1.96 (1.37)	1.1	1.09	1.25	3.54	3.5	
			Placebo	3	3 (100.0)	1.86 (0.46)	1.6	1.58	1.60	2.39	2.4	
		Week 8	Tezepelumab	3	3 (100.0)	1.91 (1.13)	1.3	1.25	1.26	3.21	3.2	
			Placebo	3	3 (100.0)	1.84 (0.41)	1.5	1.48	1.75	2.29	2.3	
		Week 12	Tezepelumab	3	3 (100.0)	1.93 (1.19)	1.2	1.21	1.28	3.30	3.3	
			Placebo	3	3 (100.0)	1.70 (0.64)	1.1	1.11	1.62	2.38	2.4	
		Week 20	Tezepelumab	3	3 (100.0)	1.82 (1.02)	1.1	1.10	1.37	2.98	3.0	
			Placebo	3	3 (100.0)	1.85 (0.35)	1.6	1.62	1.68	2.26	2.3	
		Week 28	Tezepelumab	3	3 (100.0)	2.01 (1.33)	1.2	1.23	1.26	3.54	3.5	
			Placebo	3	3 (100.0)	1.98 (0.40)	1.7	1.70	1.80	2.44	2.4	
		Week 40	Tezepelumab	3	3 (100.0)	1.94 (1.02)	1.3	1.34	1.36	3.11	3.1	
			Placebo	3	3 (100.0)	1.83 (0.53)	1.4	1.36	1.71	2.41	2.4	
		Week 52	Tezepelumab	3	3 (100.0)	1.92 (1.01)	1.3	1.31	1.36	3.08	3.1	
			Placebo	3	3 (100.0)	1.79 (0.46)	1.4	1.42	1.64	2.31	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	0.27 (0.27)	-0.0	-0.04	0.39	0.47	0.5	1.07 [-0.69, 2.84]
			Placebo	3	3 (100.0)	0.02 (0.20)	-0.2	-0.21	0.10	0.16	0.2	
		Week 8	Tezepelumab	3	3 (100.0)	0.22 (0.30)	-0.0	-0.03	0.14	0.55	0.6	1.02 [-0.73, 2.77]
			Placebo	3	3 (100.0)	0.00 (0.06)	-0.1	-0.06	0.00	0.06	0.1	
		Week 12	Tezepelumab	3	3 (100.0)	0.24 (0.26)	-0.0	-0.01	0.23	0.51	0.5	0.97 [-0.76, 2.71]
			Placebo	3	3 (100.0)	-0.14 (0.49)	-0.7	-0.70	0.14	0.15	0.1	
		Week 20	Tezepelumab	3	3 (100.0)	0.13 (0.25)	-0.1	-0.09	0.08	0.40	0.4	0.58 [-1.07, 2.23]
			Placebo	3	3 (100.0)	0.01 (0.14)	-0.1	-0.13	0.03	0.14	0.1	
		Week 28	Tezepelumab	3	3 (100.0)	0.32 (0.31)	-0.0	-0.03	0.47	0.53	0.5	0.78 [-0.91, 2.47]
			Placebo	3	3 (100.0)	0.14 (0.13)	-0.0	-0.01	0.21	0.22	0.2	
		Week 40	Tezepelumab	3	3 (100.0)	0.25 (0.36)	0.0	0.04	0.05	0.66	0.7	0.72 [-0.96, 2.39]
			Placebo	3	3 (100.0)	-0.01 (0.38)	-0.5	-0.45	0.18	0.23	0.2	
		Week 52	Tezepelumab	3	3 (100.0)	0.23 (0.33)	0.0	0.01	0.07	0.61	0.6	0.89 [-0.82, 2.61]
			Placebo	3	3 (100.0)	-0.05 (0.30)	-0.4	-0.39	0.08	0.16	0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	17	17 (100.0)	1.79 (0.61)	0.7	1.32	1.68	2.12	3.0	
			Placebo	22	22 (100.0)	1.75 (0.55)	0.9	1.40	1.65	2.19	2.9	
		Week 4	Tezepelumab	17	17 (100.0)	2.10 (1.04)	0.9	1.41	1.78	2.74	4.5	
			Placebo	22	22 (100.0)	1.74 (0.53)	0.7	1.52	1.72	2.15	2.7	
		Week 8	Tezepelumab	17	13 (76.5)	1.93 (0.64)	1.0	1.55	1.61	2.39	2.9	
			Placebo	22	20 (90.9)	1.78 (0.59)	0.8	1.25	1.97	2.29	2.6	
		Week 12	Tezepelumab	17	15 (88.2)	2.16 (0.98)	1.1	1.48	1.64	2.92	4.6	
			Placebo	22	20 (90.9)	1.75 (0.60)	0.9	1.23	1.77	2.28	2.6	
		Week 20	Tezepelumab	17	14 (82.4)	1.97 (0.87)	1.0	1.38	1.62	2.60	4.1	
			Placebo	22	17 (77.3)	1.78 (0.66)	0.5	1.23	1.74	2.32	2.7	
		Week 28	Tezepelumab	17	16 (94.1)	2.08 (0.93)	0.9	1.42	1.97	2.57	4.6	
			Placebo	22	17 (77.3)	1.55 (0.59)	0.7	1.12	1.53	2.10	2.5	
		Week 40	Tezepelumab	17	15 (88.2)	1.84 (0.68)	0.9	1.18	1.93	2.41	3.0	
			Placebo	22	15 (68.2)	1.75 (0.72)	0.8	1.08	1.71	2.24	3.3	
		Week 52	Tezepelumab	17	15 (88.2)	1.84 (0.70)	1.0	1.30	1.69	2.38	3.2	
			Placebo	22	17 (77.3)	1.73 (0.80)	0.6	1.10	1.53	2.28	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	17	17 (100.0)	0.32 (0.59)	-0.6	0.02	0.10	0.62	1.7	0.67 [0.02, 1.32]
			Placebo	22	22 (100.0)	-0.01 (0.39)	-1.0	-0.25	0.00	0.14	0.9	
		Week 8	Tezepelumab	17	13 (76.5)	0.13 (0.35)	-0.5	0.02	0.12	0.36	0.6	0.17 [-0.53, 0.86]
			Placebo	22	20 (90.9)	0.05 (0.53)	-1.5	-0.13	-0.02	0.32	1.0	
		Week 12	Tezepelumab	17	15 (88.2)	0.35 (0.48)	-0.2	-0.03	0.22	0.65	1.5	0.70 [0.01, 1.39]
			Placebo	22	20 (90.9)	0.02 (0.46)	-0.9	-0.14	-0.04	0.25	1.3	
		Week 20	Tezepelumab	17	14 (82.4)	0.11 (0.41)	-0.4	-0.13	-0.05	0.31	1.1	0.13 [-0.58, 0.84]
			Placebo	22	17 (77.3)	0.07 (0.23)	-0.4	-0.02	0.05	0.22	0.6	
		Week 28	Tezepelumab	17	16 (94.1)	0.23 (0.49)	-0.6	-0.11	0.18	0.52	1.5	0.89 [0.17, 1.61]
			Placebo	22	17 (77.3)	-0.14 (0.34)	-1.1	-0.31	-0.03	0.05	0.3	
		Week 40	Tezepelumab	17	15 (88.2)	0.07 (0.40)	-0.5	-0.22	-0.02	0.40	0.8	-0.06 [-0.77, 0.66]
			Placebo	22	15 (68.2)	0.09 (0.39)	-0.5	-0.17	0.00	0.25	1.1	
		Week 52	Tezepelumab	17	15 (88.2)	0.07 (0.35)	-0.5	-0.21	0.01	0.26	0.8	0.04 [-0.65, 0.74]
			Placebo	22	17 (77.3)	0.05 (0.59)	-1.0	-0.15	-0.01	0.17	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	1.66 (0.67)	0.7	1.15	1.44	2.17	3.0	
			Placebo	21	21 (100.0)	2.00 (0.63)	0.9	1.52	2.03	2.43	3.2	
		Week 4	Tezepelumab	15	15 (100.0)	2.36 (1.05)	1.1	1.50	2.08	3.36	4.5	
			Placebo	21	21 (100.0)	1.90 (0.64)	0.7	1.60	1.91	2.37	3.2	
		Week 8	Tezepelumab	15	13 (86.7)	2.18 (0.72)	1.3	1.49	2.13	2.72	3.3	
			Placebo	21	19 (90.5)	2.05 (0.78)	0.8	1.48	2.19	2.52	3.6	
		Week 12	Tezepelumab	15	15 (100.0)	2.30 (1.00)	1.0	1.48	2.04	3.20	4.6	
			Placebo	21	21 (100.0)	2.01 (0.70)	0.7	1.62	2.16	2.50	3.3	
		Week 20	Tezepelumab	15	12 (80.0)	2.26 (0.96)	1.0	1.56	2.12	2.93	4.1	
			Placebo	21	20 (95.2)	2.07 (0.66)	0.5	1.65	2.18	2.47	3.3	
		Week 28	Tezepelumab	15	15 (100.0)	2.32 (0.92)	1.2	1.66	2.17	2.97	4.6	
			Placebo	21	20 (95.2)	1.99 (0.69)	0.7	1.64	2.02	2.40	3.4	
		Week 40	Tezepelumab	15	14 (93.3)	2.18 (0.73)	1.2	1.36	2.17	2.52	3.5	
			Placebo	21	19 (90.5)	2.19 (0.75)	0.8	1.71	2.24	2.53	3.5	
		Week 52	Tezepelumab	15	14 (93.3)	2.04 (0.71)	1.2	1.36	2.04	2.41	3.4	
			Placebo	21	20 (95.2)	2.09 (0.81)	0.6	1.40	2.06	2.65	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	15	15 (100.0)	0.70 (0.70)	-0.0	0.09	0.45	0.98	2.4	1.59 [0.82, 2.35]
			Placebo	21	21 (100.0)	-0.09 (0.29)	-1.0	-0.21	-0.06	0.09	0.4	
		Week 8	Tezepelumab	15	13 (86.7)	0.59 (0.52)	-0.0	0.40	0.49	0.60	2.2	1.11 [0.35, 1.87]
			Placebo	21	19 (90.5)	0.02 (0.50)	-1.5	-0.09	0.08	0.20	0.9	
		Week 12	Tezepelumab	15	15 (100.0)	0.64 (0.58)	-0.1	0.33	0.51	0.82	2.1	1.23 [0.51, 1.96]
			Placebo	21	21 (100.0)	0.01 (0.45)	-0.9	-0.36	-0.02	0.31	0.8	
		Week 20	Tezepelumab	15	12 (80.0)	0.62 (0.63)	-0.1	0.15	0.44	0.90	2.2	1.19 [0.41, 1.96]
			Placebo	21	20 (95.2)	0.11 (0.25)	-0.4	-0.04	0.13	0.22	0.6	
		Week 28	Tezepelumab	15	15 (100.0)	0.66 (0.56)	-0.0	0.27	0.54	0.76	2.2	1.36 [0.62, 2.11]
			Placebo	21	20 (95.2)	0.03 (0.38)	-1.1	-0.11	0.06	0.21	0.9	
		Week 40	Tezepelumab	15	14 (93.3)	0.62 (0.54)	0.1	0.35	0.52	0.73	2.3	0.90 [0.17, 1.62]
			Placebo	21	19 (90.5)	0.18 (0.45)	-0.5	-0.14	0.10	0.48	1.1	
		Week 52	Tezepelumab	15	14 (93.3)	0.48 (0.59)	-0.1	0.07	0.35	0.64	2.3	0.60 [-0.10, 1.30]
			Placebo	21	20 (95.2)	0.13 (0.56)	-1.0	-0.19	0.09	0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	24	24 (100.0)	1.86 (0.67)	0.7	1.36	1.84	2.46	3.1	
			Placebo	20	20 (100.0)	1.89 (0.60)	1.0	1.42	1.73	2.29	3.1	
		Week 4	Tezepelumab	24	23 (95.8)	2.00 (0.73)	0.9	1.52	1.95	2.46	3.5	
			Placebo	20	20 (100.0)	1.94 (0.67)	0.7	1.50	1.92	2.46	3.1	
		Week 8	Tezepelumab	24	22 (91.7)	2.06 (0.61)	0.7	1.60	1.97	2.56	3.2	
			Placebo	20	19 (95.0)	1.92 (0.61)	0.8	1.56	2.05	2.29	3.1	
		Week 12	Tezepelumab	24	20 (83.3)	2.07 (0.71)	0.9	1.47	2.06	2.72	3.3	
			Placebo	20	19 (95.0)	2.02 (0.88)	0.5	1.25	1.93	2.62	4.1	
		Week 20	Tezepelumab	24	21 (87.5)	2.03 (0.63)	1.0	1.56	1.94	2.49	3.0	
			Placebo	20	18 (90.0)	1.96 (0.76)	0.7	1.29	1.85	2.46	3.2	
		Week 28	Tezepelumab	24	21 (87.5)	1.95 (0.71)	1.0	1.40	1.84	2.29	3.5	
			Placebo	20	19 (95.0)	1.87 (0.78)	0.8	1.23	1.74	2.45	3.4	
		Week 40	Tezepelumab	24	21 (87.5)	2.04 (0.65)	1.0	1.56	2.00	2.64	3.1	
			Placebo	20	18 (90.0)	1.97 (0.91)	0.6	1.43	1.67	2.41	4.0	
		Week 52	Tezepelumab	24	21 (87.5)	2.05 (0.62)	1.1	1.69	1.94	2.35	3.2	
			Placebo	20	19 (95.0)	1.89 (0.82)	1.0	1.30	1.72	2.42	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	24	23 (95.8)	0.16 (0.33)	-0.5	-0.06	0.13	0.41	0.8	0.30 [-0.30, 0.90]
			Placebo	20	20 (100.0)	0.04 (0.47)	-1.1	-0.22	0.09	0.25	1.1	
		Week 8	Tezepelumab	24	22 (91.7)	0.17 (0.28)	-0.5	-0.02	0.17	0.35	0.8	0.39 [-0.23, 1.01]
			Placebo	20	19 (95.0)	0.02 (0.48)	-0.9	-0.18	0.06	0.27	0.9	
		Week 12	Tezepelumab	24	20 (83.3)	0.25 (0.32)	-0.2	-0.01	0.22	0.43	0.9	0.27 [-0.36, 0.90]
			Placebo	20	19 (95.0)	0.12 (0.59)	-1.2	-0.16	0.02	0.61	1.3	
		Week 20	Tezepelumab	24	21 (87.5)	0.17 (0.30)	-0.4	-0.07	0.19	0.35	0.9	0.43 [-0.21, 1.07]
			Placebo	20	18 (90.0)	0.02 (0.41)	-1.0	-0.03	0.04	0.23	0.8	
		Week 28	Tezepelumab	24	21 (87.5)	0.10 (0.44)	-1.0	-0.10	0.17	0.29	0.9	0.30 [-0.33, 0.92]
			Placebo	20	19 (95.0)	-0.04 (0.47)	-1.1	-0.31	0.07	0.26	0.9	
		Week 40	Tezepelumab	24	21 (87.5)	0.19 (0.38)	-0.7	-0.02	0.20	0.44	1.0	0.37 [-0.26, 1.01]
			Placebo	20	18 (90.0)	0.03 (0.47)	-1.1	-0.17	0.03	0.22	0.9	
		Week 52	Tezepelumab	24	21 (87.5)	0.20 (0.36)	-0.7	-0.03	0.11	0.49	0.8	0.51 [-0.12, 1.14]
			Placebo	20	19 (95.0)	-0.01 (0.46)	-0.9	-0.26	0.03	0.26	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	1.71 (0.46)	1.2	1.40	1.52	2.01	3.1	
			Placebo	24	24 (100.0)	1.61 (0.41)	1.0	1.36	1.56	1.83	2.4	
		Week 4	Tezepelumab	27	26 (96.3)	1.77 (0.56)	0.9	1.41	1.66	2.15	3.3	
			Placebo	24	24 (100.0)	1.73 (0.53)	0.8	1.43	1.65	1.93	3.0	
		Week 8	Tezepelumab	27	25 (92.6)	1.71 (0.51)	1.0	1.41	1.57	1.97	3.4	
			Placebo	24	23 (95.8)	1.74 (0.52)	0.8	1.48	1.65	2.13	2.7	
		Week 12	Tezepelumab	27	27 (100.0)	1.88 (0.57)	1.1	1.47	1.71	2.33	3.5	
			Placebo	24	23 (95.8)	1.63 (0.45)	0.6	1.37	1.62	2.09	2.4	
		Week 20	Tezepelumab	27	24 (88.9)	1.64 (0.49)	1.0	1.36	1.50	1.91	2.7	
			Placebo	24	22 (91.7)	1.61 (0.47)	0.6	1.33	1.66	1.86	2.5	
		Week 28	Tezepelumab	27	24 (88.9)	1.68 (0.41)	0.9	1.41	1.57	2.00	2.5	
			Placebo	24	20 (83.3)	1.62 (0.43)	0.8	1.43	1.59	2.02	2.4	
		Week 40	Tezepelumab	27	23 (85.2)	1.67 (0.50)	0.9	1.18	1.66	2.15	2.5	
			Placebo	24	20 (83.3)	1.60 (0.36)	1.0	1.39	1.63	1.79	2.4	
		Week 52	Tezepelumab	27	24 (88.9)	1.60 (0.42)	0.9	1.31	1.52	1.82	2.4	
			Placebo	24	21 (87.5)	1.59 (0.47)	0.7	1.38	1.58	1.85	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	27	26 (96.3)	0.10 (0.28)	-0.6	-0.04	0.08	0.14	0.8	-0.05 [-0.61, 0.50]
			Placebo	24	24 (100.0)	0.12 (0.30)	-0.5	-0.03	0.09	0.17	0.9	
		Week 8	Tezepelumab	27	25 (92.6)	0.05 (0.22)	-0.5	-0.07	0.09	0.23	0.5	-0.43 [-1.01, 0.14]
			Placebo	24	23 (95.8)	0.16 (0.25)	-0.2	-0.04	0.15	0.28	1.0	
		Week 12	Tezepelumab	27	27 (100.0)	0.17 (0.36)	-0.5	-0.04	0.14	0.26	1.3	0.43 [-0.13, 0.99]
			Placebo	24	23 (95.8)	0.05 (0.18)	-0.4	-0.06	0.05	0.17	0.4	
		Week 20	Tezepelumab	27	24 (88.9)	0.03 (0.34)	-0.6	-0.12	0.02	0.16	0.8	0.04 [-0.54, 0.62]
			Placebo	24	22 (91.7)	0.02 (0.27)	-0.6	-0.05	0.04	0.22	0.4	
		Week 28	Tezepelumab	27	24 (88.9)	0.07 (0.27)	-0.6	-0.10	0.03	0.24	0.6	0.13 [-0.47, 0.72]
			Placebo	24	20 (83.3)	0.04 (0.21)	-0.4	-0.11	0.04	0.22	0.4	
		Week 40	Tezepelumab	27	23 (85.2)	0.05 (0.35)	-0.5	-0.12	0.06	0.25	1.1	-0.05 [-0.65, 0.55]
			Placebo	24	20 (83.3)	0.06 (0.23)	-0.5	-0.06	0.07	0.23	0.5	
		Week 52	Tezepelumab	27	24 (88.9)	-0.01 (0.29)	-0.8	-0.23	0.02	0.16	0.5	-0.08 [-0.66, 0.51]
			Placebo	24	21 (87.5)	0.01 (0.24)	-0.5	-0.10	0.01	0.08	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	1.87 (0.63)	1.1	1.41	1.72	2.21	3.1	
			Placebo	14	14 (100.0)	1.67 (0.65)	1.0	1.40	1.48	1.85	3.2	
		Week 4	Tezepelumab	11	11 (100.0)	1.99 (0.65)	1.1	1.48	1.81	2.40	3.3	
			Placebo	14	14 (100.0)	1.77 (0.69)	0.9	1.30	1.59	1.99	3.2	
		Week 8	Tezepelumab	11	10 (90.9)	2.02 (0.65)	1.4	1.40	1.97	2.37	3.4	
			Placebo	14	14 (100.0)	1.84 (0.82)	0.8	1.48	1.61	2.29	3.6	
		Week 12	Tezepelumab	11	10 (90.9)	1.85 (0.74)	1.0	1.47	1.60	2.14	3.5	
			Placebo	14	14 (100.0)	1.68 (0.64)	0.9	1.25	1.49	2.11	2.8	
		Week 20	Tezepelumab	11	8 (72.7)	1.64 (0.44)	1.0	1.41	1.52	1.91	2.5	
			Placebo	14	14 (100.0)	1.75 (0.77)	0.9	1.07	1.65	1.86	3.3	
		Week 28	Tezepelumab	11	9 (81.8)	1.73 (0.40)	1.3	1.45	1.73	1.98	2.5	
			Placebo	14	12 (85.7)	1.75 (0.78)	0.8	1.18	1.67	2.06	3.3	
		Week 40	Tezepelumab	11	9 (81.8)	1.66 (0.43)	1.1	1.31	1.66	1.93	2.3	
			Placebo	14	12 (85.7)	1.70 (0.79)	0.9	1.15	1.55	1.70	3.4	
		Week 52	Tezepelumab	11	9 (81.8)	1.51 (0.41)	1.2	1.21	1.37	1.80	2.4	
			Placebo	14	13 (92.9)	1.70 (0.66)	0.8	1.37	1.56	1.93	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	11	11 (100.0)	0.12 (0.27)	-0.3	-0.04	0.10	0.32	0.6	0.08 [-0.71, 0.87]
			Placebo	14	14 (100.0)	0.10 (0.32)	-0.5	0.00	0.11	0.14	0.9	
		Week 8	Tezepelumab	11	10 (90.9)	0.08 (0.22)	-0.2	-0.13	0.04	0.31	0.3	-0.31 [-1.13, 0.50]
			Placebo	14	14 (100.0)	0.16 (0.31)	-0.2	-0.03	0.11	0.28	1.0	
		Week 12	Tezepelumab	11	10 (90.9)	0.07 (0.29)	-0.5	-0.09	0.08	0.33	0.5	0.27 [-0.55, 1.08]
			Placebo	14	14 (100.0)	0.01 (0.16)	-0.4	-0.11	0.04	0.13	0.3	
		Week 20	Tezepelumab	11	8 (72.7)	-0.07 (0.24)	-0.6	-0.11	-0.07	0.08	0.2	-0.60 [-1.48, 0.29]
			Placebo	14	14 (100.0)	0.08 (0.25)	-0.6	-0.02	0.10	0.22	0.5	
		Week 28	Tezepelumab	11	9 (81.8)	0.08 (0.26)	-0.2	-0.10	0.01	0.21	0.6	0.04 [-0.83, 0.90]
			Placebo	14	12 (85.7)	0.07 (0.16)	-0.2	-0.02	0.08	0.23	0.3	
		Week 40	Tezepelumab	11	9 (81.8)	0.02 (0.40)	-0.5	-0.35	0.06	0.16	0.8	-0.26 [-1.12, 0.61]
			Placebo	14	12 (85.7)	0.09 (0.20)	-0.3	-0.01	0.07	0.23	0.5	
		Week 52	Tezepelumab	11	9 (81.8)	-0.14 (0.31)	-0.8	-0.25	-0.04	0.09	0.2	-0.67 [-1.55, 0.20]
			Placebo	14	13 (92.9)	0.04 (0.24)	-0.4	-0.10	0.03	0.16	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	54	54 (100.0)	1.74 (0.58)	0.7	1.34	1.63	2.12	3.1	
			Placebo	51	51 (100.0)	1.86 (0.54)	0.9	1.45	1.78	2.23	3.1	
		Week 4	Tezepelumab	54	52 (96.3)	2.00 (0.82)	0.9	1.45	1.82	2.28	4.5	
			Placebo	51	51 (100.0)	1.87 (0.59)	0.7	1.55	1.82	2.39	3.0	
		Week 8	Tezepelumab	54	49 (90.7)	1.93 (0.62)	0.7	1.47	1.85	2.36	3.3	
			Placebo	51	47 (92.2)	1.91 (0.58)	0.8	1.54	2.00	2.31	3.4	
		Week 12	Tezepelumab	54	51 (94.4)	2.10 (0.74)	0.9	1.51	2.03	2.69	4.6	
			Placebo	51	49 (96.1)	1.93 (0.71)	0.5	1.52	1.87	2.44	4.1	
		Week 20	Tezepelumab	54	48 (88.9)	1.97 (0.72)	1.0	1.42	1.75	2.44	4.1	
			Placebo	51	46 (90.2)	1.90 (0.62)	0.5	1.55	1.96	2.33	3.1	
		Week 28	Tezepelumab	54	50 (92.6)	1.98 (0.75)	0.9	1.42	1.84	2.36	4.6	
			Placebo	51	47 (92.2)	1.84 (0.63)	0.7	1.44	1.85	2.24	3.4	
		Week 40	Tezepelumab	54	48 (88.9)	1.99 (0.66)	0.9	1.40	2.00	2.46	3.5	
			Placebo	51	45 (88.2)	1.97 (0.72)	0.6	1.50	1.94	2.35	4.0	
		Week 52	Tezepelumab	54	49 (90.7)	1.94 (0.61)	0.9	1.36	1.86	2.34	3.4	
			Placebo	51	47 (92.2)	1.89 (0.75)	0.6	1.32	1.72	2.42	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	54	52 (96.3)	0.30 (0.52)	-0.6	-0.01	0.13	0.46	2.4	0.64 [0.24, 1.03]
			Placebo	51	51 (100.0)	0.01 (0.37)	-1.1	-0.17	0.01	0.17	1.1	
		Week 8	Tezepelumab	54	49 (90.7)	0.24 (0.41)	-0.5	0.02	0.17	0.41	2.2	0.46 [0.05, 0.86]
			Placebo	51	47 (92.2)	0.04 (0.44)	-1.5	-0.09	0.13	0.24	0.9	
		Week 12	Tezepelumab	54	51 (94.4)	0.37 (0.46)	-0.2	0.04	0.23	0.56	2.1	0.63 [0.23, 1.03]
			Placebo	51	49 (96.1)	0.07 (0.48)	-1.2	-0.17	0.06	0.31	1.3	
		Week 20	Tezepelumab	54	48 (88.9)	0.26 (0.47)	-0.6	-0.07	0.19	0.46	2.2	0.53 [0.12, 0.94]
			Placebo	51	46 (90.2)	0.04 (0.33)	-1.0	-0.08	0.07	0.23	0.8	
		Week 28	Tezepelumab	54	50 (92.6)	0.26 (0.51)	-1.0	-0.03	0.24	0.52	2.2	0.57 [0.17, 0.98]
			Placebo	51	47 (92.2)	-0.00 (0.40)	-1.1	-0.18	0.03	0.23	0.9	
		Week 40	Tezepelumab	54	48 (88.9)	0.28 (0.47)	-0.7	-0.02	0.27	0.49	2.3	0.43 [0.02, 0.84]
			Placebo	51	45 (88.2)	0.09 (0.43)	-1.1	-0.17	0.06	0.24	1.1	
		Week 52	Tezepelumab	54	49 (90.7)	0.24 (0.44)	-0.7	0.01	0.16	0.46	2.3	0.43 [0.03, 0.84]
			Placebo	51	47 (92.2)	0.04 (0.48)	-1.0	-0.22	0.06	0.18	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	33	33 (100.0)	1.87 (0.60)	0.7	1.41	1.79	2.21	3.1	
			Placebo	34	34 (100.0)	1.84 (0.63)	0.9	1.46	1.69	2.32	3.2	
		Week 4	Tezepelumab	33	33 (100.0)	2.05 (0.79)	0.9	1.50	1.81	2.39	4.5	
			Placebo	34	34 (100.0)	1.87 (0.63)	0.7	1.48	1.67	2.34	3.2	
		Week 8	Tezepelumab	33	31 (93.9)	1.97 (0.61)	0.7	1.47	1.90	2.37	3.4	
			Placebo	34	31 (91.2)	1.91 (0.73)	0.8	1.48	1.88	2.37	3.6	
		Week 12	Tezepelumab	33	32 (97.0)	2.12 (0.78)	1.0	1.50	1.98	2.51	4.6	
			Placebo	34	32 (94.1)	1.87 (0.64)	0.9	1.43	1.78	2.42	3.3	
		Week 20	Tezepelumab	33	29 (87.9)	1.95 (0.71)	1.0	1.47	1.71	2.30	4.1	
			Placebo	34	31 (91.2)	1.88 (0.70)	0.5	1.38	1.74	2.42	3.3	
		Week 28	Tezepelumab	33	30 (90.9)	1.97 (0.75)	1.0	1.49	1.76	2.15	4.6	
			Placebo	34	29 (85.3)	1.88 (0.71)	0.7	1.48	1.74	2.37	3.4	
		Week 40	Tezepelumab	33	28 (84.8)	1.95 (0.60)	1.0	1.54	1.91	2.33	3.1	
			Placebo	34	28 (82.4)	1.96 (0.72)	0.8	1.51	1.84	2.37	3.5	
		Week 52	Tezepelumab	33	29 (87.9)	1.80 (0.57)	1.1	1.36	1.69	2.07	3.2	
			Placebo	34	30 (88.2)	1.83 (0.66)	0.6	1.40	1.80	2.28	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	33	33 (100.0)	0.18 (0.35)	-0.3	-0.04	0.10	0.32	1.4	0.45 [-0.04, 0.93]
			Placebo	34	34 (100.0)	0.03 (0.32)	-1.0	-0.14	0.06	0.14	0.9	
		Week 8	Tezepelumab	33	31 (93.9)	0.11 (0.21)	-0.4	-0.04	0.10	0.31	0.5	0.11 [-0.39, 0.60]
			Placebo	34	31 (91.2)	0.08 (0.44)	-1.5	-0.06	0.15	0.28	1.0	
		Week 12	Tezepelumab	33	32 (97.0)	0.27 (0.41)	-0.5	0.01	0.22	0.43	1.5	0.64 [0.14, 1.14]
			Placebo	34	32 (94.1)	0.04 (0.29)	-0.9	-0.08	0.04	0.24	0.8	
		Week 20	Tezepelumab	33	29 (87.9)	0.12 (0.35)	-0.6	-0.08	0.06	0.24	1.1	0.15 [-0.36, 0.65]
			Placebo	34	31 (91.2)	0.07 (0.23)	-0.6	-0.03	0.12	0.23	0.5	
		Week 28	Tezepelumab	33	30 (90.9)	0.16 (0.40)	-0.7	-0.10	0.07	0.30	1.5	0.27 [-0.24, 0.79]
			Placebo	34	29 (85.3)	0.06 (0.32)	-1.1	-0.03	0.11	0.22	0.9	
		Week 40	Tezepelumab	33	28 (84.8)	0.17 (0.34)	-0.5	-0.03	0.19	0.35	1.1	0.10 [-0.42, 0.63]
			Placebo	34	28 (82.4)	0.14 (0.29)	-0.3	-0.05	0.13	0.24	1.0	
		Week 52	Tezepelumab	33	29 (87.9)	0.04 (0.30)	-0.8	-0.05	0.03	0.16	0.6	0.04 [-0.47, 0.55]
			Placebo	34	30 (88.2)	0.02 (0.34)	-1.0	-0.15	0.06	0.17	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	1.64 (0.56)	0.7	1.17	1.55	2.05	2.7	
			Placebo	31	31 (100.0)	1.80 (0.49)	1.0	1.41	1.74	2.21	3.1	
		Week 4	Tezepelumab	32	30 (93.8)	1.95 (0.79)	0.9	1.26	1.82	2.26	3.8	
			Placebo	31	31 (100.0)	1.83 (0.59)	0.7	1.55	1.82	2.37	2.9	
		Week 8	Tezepelumab	32	28 (87.5)	1.92 (0.64)	1.0	1.38	1.89	2.36	3.3	
			Placebo	31	30 (96.8)	1.88 (0.54)	0.8	1.54	2.01	2.25	2.7	
		Week 12	Tezepelumab	32	29 (90.6)	1.99 (0.71)	0.9	1.36	1.88	2.55	3.3	
			Placebo	31	31 (100.0)	1.88 (0.77)	0.5	1.37	1.81	2.38	4.1	
		Week 20	Tezepelumab	32	27 (84.4)	1.89 (0.69)	1.0	1.37	1.74	2.38	3.4	
			Placebo	31	29 (93.5)	1.85 (0.61)	0.6	1.55	1.72	2.27	3.1	
		Week 28	Tezepelumab	32	29 (90.6)	1.92 (0.68)	0.9	1.35	1.84	2.42	3.4	
			Placebo	31	30 (96.8)	1.77 (0.61)	0.8	1.40	1.71	2.21	3.4	
		Week 40	Tezepelumab	32	29 (90.6)	1.92 (0.69)	0.9	1.34	1.94	2.41	3.5	
			Placebo	31	29 (93.5)	1.87 (0.76)	0.6	1.38	1.69	2.24	4.0	
		Week 52	Tezepelumab	32	29 (90.6)	1.94 (0.64)	0.9	1.36	1.92	2.37	3.4	
			Placebo	31	30 (96.8)	1.87 (0.81)	0.7	1.30	1.61	2.44	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	32	30 (93.8)	0.36 (0.60)	-0.6	0.02	0.20	0.64	2.4	0.66 [0.14, 1.18]
			Placebo	31	31 (100.0)	0.02 (0.41)	-1.1	-0.21	0.02	0.20	1.1	
		Week 8	Tezepelumab	32	28 (87.5)	0.32 (0.50)	-0.5	0.05	0.28	0.55	2.2	0.57 [0.04, 1.09]
			Placebo	31	30 (96.8)	0.07 (0.39)	-0.9	-0.07	0.06	0.24	0.9	
		Week 12	Tezepelumab	32	29 (90.6)	0.37 (0.49)	-0.2	0.03	0.21	0.61	2.1	0.58 [0.06, 1.10]
			Placebo	31	31 (100.0)	0.07 (0.54)	-1.2	-0.23	0.08	0.33	1.3	
		Week 20	Tezepelumab	32	27 (84.4)	0.31 (0.54)	-0.4	-0.07	0.21	0.49	2.2	0.62 [0.08, 1.15]
			Placebo	31	29 (93.5)	0.03 (0.38)	-1.0	-0.13	0.07	0.22	0.8	
		Week 28	Tezepelumab	32	29 (90.6)	0.31 (0.55)	-1.0	0.02	0.27	0.53	2.2	0.71 [0.18, 1.24]
			Placebo	31	30 (96.8)	-0.03 (0.40)	-1.1	-0.31	0.01	0.23	0.9	
		Week 40	Tezepelumab	32	29 (90.6)	0.31 (0.55)	-0.7	-0.02	0.34	0.54	2.3	0.51 [-0.01, 1.03]
			Placebo	31	29 (93.5)	0.05 (0.47)	-1.1	-0.17	-0.02	0.18	1.1	
		Week 52	Tezepelumab	32	29 (90.6)	0.33 (0.51)	-0.5	0.03	0.28	0.57	2.3	0.52 [-0.00, 1.04]
			Placebo	31	30 (96.8)	0.07 (0.52)	-0.9	-0.22	-0.00	0.35	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	39	39 (100.0)	1.73 (0.56)	0.7	1.34	1.72	2.08	3.1	
			Placebo	30	30 (100.0)	1.63 (0.55)	0.9	1.29	1.54	1.93	2.9	
		Week 4	Tezepelumab	39	38 (97.4)	1.87 (0.70)	0.9	1.26	1.81	2.26	3.8	
			Placebo	30	30 (100.0)	1.76 (0.63)	0.7	1.30	1.62	2.27	3.1	
		Week 8	Tezepelumab	39	35 (89.7)	1.87 (0.60)	0.7	1.37	1.80	2.35	3.4	
			Placebo	30	29 (96.7)	1.78 (0.67)	0.8	1.36	1.71	2.22	3.4	
		Week 12	Tezepelumab	39	37 (94.9)	1.96 (0.65)	0.9	1.47	1.90	2.37	3.5	
			Placebo	30	29 (96.7)	1.74 (0.65)	0.6	1.22	1.68	2.21	3.3	
		Week 20	Tezepelumab	39	34 (87.2)	1.80 (0.59)	1.0	1.35	1.68	2.30	2.9	
			Placebo	30	28 (93.3)	1.72 (0.65)	0.5	1.27	1.69	2.08	3.2	
		Week 28	Tezepelumab	39	35 (89.7)	1.81 (0.51)	0.9	1.45	1.73	2.15	3.0	
			Placebo	30	27 (90.0)	1.68 (0.64)	0.7	1.12	1.66	2.01	3.4	
		Week 40	Tezepelumab	39	35 (89.7)	1.84 (0.59)	0.9	1.31	1.88	2.33	3.0	
			Placebo	30	27 (90.0)	1.75 (0.67)	0.8	1.20	1.65	2.15	3.5	
		Week 52	Tezepelumab	39	35 (89.7)	1.73 (0.51)	0.9	1.30	1.69	2.25	2.9	
			Placebo	30	29 (96.7)	1.63 (0.64)	0.6	1.26	1.64	1.90	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	39	38 (97.4)	0.16 (0.38)	-0.6	-0.04	0.10	0.32	1.7	0.10 [-0.38, 0.58]
			Placebo	30	30 (100.0)	0.13 (0.34)	-0.3	-0.12	0.09	0.20	1.1	
		Week 8	Tezepelumab	39	35 (89.7)	0.12 (0.25)	-0.5	-0.04	0.10	0.31	0.8	-0.16 [-0.65, 0.34]
			Placebo	30	29 (96.7)	0.17 (0.35)	-0.6	-0.01	0.13	0.20	1.0	
		Week 12	Tezepelumab	39	37 (94.9)	0.22 (0.37)	-0.5	-0.04	0.18	0.33	1.3	0.25 [-0.24, 0.73]
			Placebo	30	29 (96.7)	0.13 (0.37)	-0.4	-0.05	0.05	0.23	1.3	
		Week 20	Tezepelumab	39	34 (87.2)	0.11 (0.35)	-0.6	-0.10	0.09	0.27	0.9	0.05 [-0.45, 0.55]
			Placebo	30	28 (93.3)	0.10 (0.25)	-0.4	-0.02	0.06	0.22	0.8	
		Week 28	Tezepelumab	39	35 (89.7)	0.14 (0.34)	-0.7	-0.06	0.17	0.30	0.9	0.25 [-0.25, 0.75]
			Placebo	30	27 (90.0)	0.06 (0.34)	-1.1	-0.12	0.11	0.23	0.9	
		Week 40	Tezepelumab	39	35 (89.7)	0.18 (0.37)	-0.5	-0.05	0.16	0.35	1.1	0.22 [-0.28, 0.72]
			Placebo	30	27 (90.0)	0.10 (0.29)	-0.3	-0.14	0.15	0.24	1.0	
		Week 52	Tezepelumab	39	35 (89.7)	0.06 (0.33)	-0.8	-0.05	0.09	0.26	0.8	0.12 [-0.37, 0.62]
			Placebo	30	29 (96.7)	0.02 (0.35)	-1.0	-0.15	0.06	0.17	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	1.78 (0.64)	0.7	1.32	1.58	2.38	3.1	
			Placebo	34	34 (100.0)	1.98 (0.54)	1.1	1.50	1.88	2.32	3.2	
		Week 4	Tezepelumab	27	26 (96.3)	2.17 (0.87)	1.1	1.54	1.89	2.47	4.5	
			Placebo	34	34 (100.0)	1.91 (0.58)	0.7	1.63	1.78	2.37	3.2	
		Week 8	Tezepelumab	27	25 (92.6)	2.04 (0.64)	1.3	1.51	1.93	2.39	3.3	
			Placebo	34	31 (91.2)	1.98 (0.61)	0.8	1.60	2.05	2.37	3.6	
		Week 12	Tezepelumab	27	25 (92.6)	2.17 (0.87)	1.1	1.51	1.88	2.75	4.6	
			Placebo	34	33 (97.1)	1.97 (0.74)	0.5	1.52	1.85	2.46	4.1	
		Week 20	Tezepelumab	27	23 (85.2)	2.08 (0.81)	1.0	1.46	1.75	2.82	4.1	
			Placebo	34	31 (91.2)	1.98 (0.65)	0.7	1.55	1.94	2.42	3.3	
		Week 28	Tezepelumab	27	25 (92.6)	2.11 (0.91)	1.0	1.39	1.84	2.61	4.6	
			Placebo	34	31 (91.2)	1.93 (0.66)	0.8	1.58	1.80	2.38	3.4	
		Week 40	Tezepelumab	27	23 (85.2)	2.05 (0.72)	1.1	1.43	1.94	2.64	3.5	
			Placebo	34	29 (85.3)	2.05 (0.78)	0.6	1.52	2.02	2.35	4.0	
		Week 52	Tezepelumab	27	24 (88.9)	2.05 (0.68)	1.3	1.47	1.93	2.38	3.4	
			Placebo	34	30 (88.2)	2.04 (0.78)	1.0	1.40	1.90	2.59	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	27	26 (96.3)	0.41 (0.59)	-0.5	0.02	0.32	0.66	2.4	1.01 [0.46, 1.55]
			Placebo	34	34 (100.0)	-0.07 (0.36)	-1.1	-0.21	0.00	0.13	0.7	
		Week 8	Tezepelumab	27	25 (92.6)	0.33 (0.49)	-0.5	0.09	0.35	0.49	2.2	0.77 [0.22, 1.31]
			Placebo	34	31 (91.2)	-0.03 (0.45)	-1.5	-0.17	-0.02	0.27	0.6	
		Week 12	Tezepelumab	27	25 (92.6)	0.44 (0.53)	-0.2	0.04	0.41	0.61	2.1	0.91 [0.37, 1.46]
			Placebo	34	33 (97.1)	-0.02 (0.47)	-1.2	-0.23	0.02	0.31	1.0	
		Week 20	Tezepelumab	27	23 (85.2)	0.35 (0.56)	-0.4	-0.07	0.22	0.49	2.2	0.77 [0.21, 1.33]
			Placebo	34	31 (91.2)	0.00 (0.35)	-1.0	-0.13	0.08	0.23	0.6	
		Week 28	Tezepelumab	27	25 (92.6)	0.35 (0.61)	-1.0	0.01	0.21	0.53	2.2	0.77 [0.22, 1.32]
			Placebo	34	31 (91.2)	-0.04 (0.39)	-1.1	-0.25	0.00	0.20	0.9	
		Week 40	Tezepelumab	27	23 (85.2)	0.33 (0.58)	-0.7	-0.07	0.36	0.54	2.3	0.48 [-0.08, 1.03]
			Placebo	34	29 (85.3)	0.08 (0.48)	-1.1	-0.12	0.02	0.21	1.1	
		Week 52	Tezepelumab	27	24 (88.9)	0.35 (0.52)	-0.3	0.00	0.22	0.63	2.3	0.56 [0.01, 1.10]
			Placebo	34	30 (88.2)	0.06 (0.51)	-0.9	-0.22	-0.02	0.26	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	1.80 (0.60)	0.7	1.40	1.87	2.21	3.1	
			Placebo	29	29 (100.0)	1.89 (0.64)	0.9	1.48	1.76	2.27	3.2	
		Week 4	Tezepelumab	27	27 (100.0)	2.01 (0.77)	0.9	1.44	1.82	2.39	3.8	
			Placebo	29	29 (100.0)	1.87 (0.72)	0.7	1.48	1.68	2.42	3.2	
		Week 8	Tezepelumab	27	26 (96.3)	2.02 (0.66)	0.7	1.49	2.03	2.44	3.4	
			Placebo	29	27 (93.1)	1.89 (0.76)	0.8	1.13	1.82	2.48	3.6	
		Week 12	Tezepelumab	27	25 (92.6)	2.05 (0.71)	1.1	1.51	2.08	2.55	3.5	
			Placebo	29	29 (100.0)	1.87 (0.78)	0.5	1.37	1.79	2.46	4.1	
		Week 20	Tezepelumab	27	23 (85.2)	1.90 (0.59)	1.0	1.39	1.86	2.45	2.9	
			Placebo	29	28 (96.6)	1.91 (0.73)	0.5	1.54	1.73	2.41	3.3	
		Week 28	Tezepelumab	27	24 (88.9)	1.92 (0.65)	0.9	1.40	1.81	2.46	3.0	
			Placebo	29	27 (93.1)	1.81 (0.66)	0.7	1.53	1.80	2.24	3.3	
		Week 40	Tezepelumab	27	24 (88.9)	1.91 (0.65)	0.9	1.34	1.97	2.43	3.0	
			Placebo	29	28 (96.6)	1.97 (0.85)	0.6	1.28	1.91	2.46	4.0	
		Week 52	Tezepelumab	27	24 (88.9)	1.89 (0.66)	1.0	1.32	1.81	2.37	3.2	
			Placebo	29	28 (96.6)	1.91 (0.79)	0.6	1.31	1.73	2.49	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	27	27 (100.0)	0.21 (0.44)	-0.6	0.01	0.13	0.38	1.7	0.55 [0.02, 1.08]
			Placebo	29	29 (100.0)	-0.02 (0.41)	-1.1	-0.21	0.00	0.18	0.7	
		Week 8	Tezepelumab	27	26 (96.3)	0.18 (0.28)	-0.5	-0.01	0.14	0.35	0.8	0.49 [-0.06, 1.04]
			Placebo	29	27 (93.1)	-0.02 (0.49)	-1.5	-0.11	0.08	0.31	0.6	
		Week 12	Tezepelumab	27	25 (92.6)	0.25 (0.38)	-0.5	-0.03	0.21	0.47	1.1	0.64 [0.09, 1.19]
			Placebo	29	29 (100.0)	-0.02 (0.44)	-1.2	-0.11	-0.02	0.24	1.0	
		Week 20	Tezepelumab	27	23 (85.2)	0.18 (0.34)	-0.4	-0.08	0.06	0.39	0.9	0.39 [-0.17, 0.94]
			Placebo	29	28 (96.6)	0.05 (0.32)	-1.0	-0.02	0.06	0.23	0.6	
		Week 28	Tezepelumab	27	24 (88.9)	0.16 (0.36)	-0.6	-0.08	0.09	0.40	0.9	0.58 [0.02, 1.15]
			Placebo	29	27 (93.1)	-0.06 (0.40)	-1.1	-0.17	0.03	0.26	0.3	
		Week 40	Tezepelumab	27	24 (88.9)	0.16 (0.35)	-0.5	-0.07	0.14	0.36	1.0	0.12 [-0.43, 0.66]
			Placebo	29	28 (96.6)	0.11 (0.47)	-1.1	-0.18	0.09	0.41	1.1	
		Week 52	Tezepelumab	27	24 (88.9)	0.14 (0.38)	-0.8	-0.05	0.16	0.37	0.8	0.20 [-0.35, 0.75]
			Placebo	29	28 (96.6)	0.05 (0.48)	-1.0	-0.15	0.05	0.28	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	34	34 (100.0)	1.75 (0.61)	0.7	1.29	1.66	2.05	3.1	
			Placebo	33	33 (100.0)	1.76 (0.51)	0.9	1.41	1.66	2.18	2.9	
		Week 4	Tezepelumab	34	32 (94.1)	1.99 (0.82)	0.9	1.48	1.76	2.14	4.5	
			Placebo	33	33 (100.0)	1.83 (0.53)	0.8	1.52	1.79	2.27	2.9	
		Week 8	Tezepelumab	34	30 (88.2)	1.90 (0.61)	1.1	1.47	1.79	2.13	3.3	
			Placebo	33	31 (93.9)	1.90 (0.55)	0.8	1.58	1.94	2.29	3.4	
		Week 12	Tezepelumab	34	32 (94.1)	2.02 (0.78)	0.9	1.47	1.85	2.41	4.6	
			Placebo	33	31 (93.9)	1.87 (0.64)	0.6	1.48	1.76	2.38	3.3	
		Week 20	Tezepelumab	34	29 (85.3)	1.92 (0.79)	1.0	1.46	1.64	2.19	4.1	
			Placebo	33	29 (87.9)	1.83 (0.60)	0.6	1.38	1.74	2.26	3.0	
		Week 28	Tezepelumab	34	31 (91.2)	1.96 (0.79)	1.0	1.42	1.73	2.22	4.6	
			Placebo	33	29 (87.9)	1.86 (0.69)	0.8	1.40	1.69	2.37	3.4	
		Week 40	Tezepelumab	34	29 (85.3)	1.93 (0.66)	1.1	1.36	1.86	2.17	3.5	
			Placebo	33	26 (78.8)	1.85 (0.64)	1.0	1.50	1.67	2.14	3.5	
		Week 52	Tezepelumab	34	30 (88.2)	1.85 (0.58)	0.9	1.36	1.80	2.15	3.4	
			Placebo	33	29 (87.9)	1.78 (0.69)	0.7	1.38	1.63	2.04	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	34	32 (94.1)	0.28 (0.54)	-0.5	-0.03	0.11	0.40	2.4	0.48 [-0.01, 0.97]
			Placebo	33	33 (100.0)	0.07 (0.33)	-0.5	-0.14	0.08	0.13	1.1	
		Week 8	Tezepelumab	34	30 (88.2)	0.23 (0.47)	-0.5	-0.04	0.16	0.40	2.2	0.19 [-0.31, 0.69]
			Placebo	33	31 (93.9)	0.15 (0.35)	-0.5	-0.06	0.15	0.24	1.0	
		Week 12	Tezepelumab	34	32 (94.1)	0.31 (0.48)	-0.2	0.04	0.21	0.43	2.1	0.43 [-0.07, 0.93]
			Placebo	33	31 (93.9)	0.12 (0.42)	-0.7	-0.12	0.06	0.28	1.3	
		Week 20	Tezepelumab	34	29 (85.3)	0.20 (0.54)	-0.6	-0.09	0.12	0.35	2.2	0.32 [-0.19, 0.84]
			Placebo	33	29 (87.9)	0.06 (0.31)	-0.7	-0.05	0.13	0.22	0.8	
		Week 28	Tezepelumab	34	31 (91.2)	0.26 (0.59)	-1.0	-0.03	0.17	0.53	2.2	0.34 [-0.17, 0.85]
			Placebo	33	29 (87.9)	0.10 (0.32)	-0.6	-0.12	0.15	0.23	0.9	
		Week 40	Tezepelumab	34	29 (85.3)	0.27 (0.54)	-0.7	-0.02	0.23	0.50	2.3	0.43 [-0.10, 0.97]
			Placebo	33	26 (78.8)	0.07 (0.33)	-0.5	-0.11	0.03	0.22	1.0	
		Week 52	Tezepelumab	34	30 (88.2)	0.19 (0.51)	-0.7	-0.03	0.09	0.40	2.3	0.37 [-0.14, 0.89]
			Placebo	33	29 (87.9)	0.02 (0.40)	-0.9	-0.16	0.01	0.13	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	1.71 (0.56)	0.7	1.37	1.49	2.07	3.1	
			Placebo	14	14 (100.0)	1.76 (0.66)	0.9	1.25	1.80	2.17	2.9	
		Week 4	Tezepelumab	23	23 (100.0)	1.86 (0.65)	0.9	1.41	1.66	2.29	3.3	
			Placebo	14	14 (100.0)	1.84 (0.86)	0.7	1.02	1.83	2.59	3.1	
		Week 8	Tezepelumab	23	22 (95.7)	1.95 (0.61)	1.0	1.44	1.77	2.37	3.4	
			Placebo	14	13 (92.9)	1.82 (0.82)	0.8	1.08	2.08	2.48	3.1	
		Week 12	Tezepelumab	23	21 (91.3)	1.98 (0.69)	1.0	1.47	2.13	2.44	3.5	
			Placebo	14	14 (100.0)	1.73 (0.69)	0.5	1.17	1.84	2.21	2.8	
		Week 20	Tezepelumab	23	20 (87.0)	1.79 (0.58)	1.0	1.39	1.61	2.27	2.9	
			Placebo	14	14 (100.0)	1.74 (0.78)	0.5	1.12	1.79	2.35	3.2	
		Week 28	Tezepelumab	23	20 (87.0)	1.80 (0.55)	0.9	1.34	1.64	2.22	3.0	
			Placebo	14	13 (92.9)	1.62 (0.70)	0.7	1.06	1.72	2.01	3.0	
		Week 40	Tezepelumab	23	20 (87.0)	1.87 (0.59)	0.9	1.37	1.86	2.35	3.0	
			Placebo	14	12 (85.7)	1.82 (0.80)	0.6	1.09	1.92	2.34	3.2	
		Week 52	Tezepelumab	23	20 (87.0)	1.76 (0.52)	1.0	1.35	1.71	2.30	2.9	
			Placebo	14	13 (92.9)	1.65 (0.72)	0.6	1.08	1.58	2.00	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	23	23 (100.0)	0.14 (0.31)	-0.6	0.02	0.09	0.26	0.8	0.17 [-0.50, 0.83]
			Placebo	14	14 (100.0)	0.08 (0.45)	-1.1	-0.17	0.15	0.31	0.7	
		Week 8	Tezepelumab	23	22 (95.7)	0.20 (0.26)	-0.5	0.09	0.23	0.32	0.8	0.51 [-0.19, 1.21]
			Placebo	14	13 (92.9)	0.03 (0.41)	-0.9	-0.11	0.19	0.29	0.5	
		Week 12	Tezepelumab	23	21 (91.3)	0.27 (0.40)	-0.2	-0.03	0.14	0.47	1.3	0.74 [0.04, 1.43]
			Placebo	14	14 (100.0)	-0.03 (0.40)	-1.2	-0.09	0.04	0.26	0.3	
		Week 20	Tezepelumab	23	20 (87.0)	0.15 (0.37)	-0.6	-0.07	0.06	0.39	0.9	0.42 [-0.27, 1.11]
			Placebo	14	14 (100.0)	-0.02 (0.42)	-1.0	-0.21	-0.01	0.29	0.5	
		Week 28	Tezepelumab	23	20 (87.0)	0.16 (0.32)	-0.6	-0.01	0.09	0.29	0.9	0.75 [0.03, 1.47]
			Placebo	14	13 (92.9)	-0.13 (0.46)	-1.1	-0.37	-0.02	0.28	0.3	
		Week 40	Tezepelumab	23	20 (87.0)	0.23 (0.39)	-0.5	-0.07	0.24	0.43	1.1	0.55 [-0.18, 1.28]
			Placebo	14	12 (85.7)	-0.01 (0.50)	-1.1	-0.19	-0.02	0.28	0.9	
		Week 52	Tezepelumab	23	20 (87.0)	0.12 (0.30)	-0.5	-0.06	0.09	0.31	0.8	0.64 [-0.08, 1.35]
			Placebo	14	13 (92.9)	-0.10 (0.43)	-1.0	-0.26	-0.05	0.25	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	1.78 (0.60)	0.7	1.33	1.76	2.17	3.1	
			Placebo	44	44 (100.0)	1.83 (0.54)	1.0	1.47	1.68	2.20	3.2	
		Week 4	Tezepelumab	40	39 (97.5)	2.10 (0.85)	0.9	1.50	1.82	2.46	4.5	
			Placebo	44	44 (100.0)	1.83 (0.52)	0.8	1.57	1.72	2.24	3.2	
		Week 8	Tezepelumab	40	36 (90.0)	1.96 (0.64)	0.7	1.48	1.94	2.26	3.3	
			Placebo	44	41 (93.2)	1.88 (0.56)	0.8	1.58	1.88	2.25	3.6	
		Week 12	Tezepelumab	40	38 (95.0)	2.10 (0.79)	0.9	1.54	1.89	2.70	4.6	
			Placebo	44	42 (95.5)	1.89 (0.68)	0.6	1.46	1.80	2.40	4.1	
		Week 20	Tezepelumab	40	35 (87.5)	2.00 (0.76)	1.0	1.37	1.82	2.60	4.1	
			Placebo	44	39 (88.6)	1.86 (0.61)	0.6	1.51	1.73	2.28	3.3	
		Week 28	Tezepelumab	40	38 (95.0)	2.04 (0.78)	1.0	1.49	1.84	2.42	4.6	
			Placebo	44	39 (88.6)	1.82 (0.59)	0.8	1.42	1.74	2.24	3.3	
		Week 40	Tezepelumab	40	37 (92.5)	1.96 (0.68)	1.0	1.34	1.93	2.33	3.5	
			Placebo	44	38 (86.4)	1.89 (0.69)	0.9	1.43	1.75	2.24	4.0	
		Week 52	Tezepelumab	40	37 (92.5)	1.93 (0.65)	0.9	1.36	1.86	2.27	3.4	
			Placebo	44	40 (90.9)	1.87 (0.67)	0.7	1.41	1.72	2.30	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	40	39 (97.5)	0.33 (0.57)	-0.5	-0.04	0.14	0.47	2.4	0.72 [0.27, 1.16]
			Placebo	44	44 (100.0)	-0.00 (0.35)	-1.0	-0.16	0.00	0.13	1.1	
		Week 8	Tezepelumab	40	36 (90.0)	0.22 (0.45)	-0.5	-0.04	0.13	0.45	2.2	0.36 [-0.09, 0.81]
			Placebo	44	41 (93.2)	0.06 (0.43)	-1.5	-0.06	0.07	0.19	1.0	
		Week 12	Tezepelumab	40	38 (95.0)	0.35 (0.48)	-0.5	0.04	0.25	0.51	2.1	0.63 [0.18, 1.08]
			Placebo	44	42 (95.5)	0.06 (0.43)	-0.9	-0.16	0.03	0.28	1.3	
		Week 20	Tezepelumab	40	35 (87.5)	0.23 (0.51)	-0.6	-0.09	0.12	0.39	2.2	0.47 [0.01, 0.94]
			Placebo	44	39 (88.6)	0.04 (0.28)	-0.7	-0.05	0.07	0.22	0.8	
		Week 28	Tezepelumab	40	38 (95.0)	0.27 (0.56)	-1.0	-0.10	0.27	0.53	2.2	0.60 [0.15, 1.06]
			Placebo	44	39 (88.6)	0.01 (0.27)	-1.1	-0.12	0.03	0.20	0.4	
		Week 40	Tezepelumab	40	37 (92.5)	0.23 (0.51)	-0.7	-0.02	0.20	0.43	2.3	0.34 [-0.11, 0.80]
			Placebo	44	38 (86.4)	0.09 (0.32)	-0.5	-0.08	0.04	0.22	1.1	
		Week 52	Tezepelumab	40	37 (92.5)	0.20 (0.50)	-0.8	-0.01	0.11	0.44	2.3	0.31 [-0.14, 0.76]
			Placebo	44	40 (90.9)	0.06 (0.38)	-0.6	-0.16	0.02	0.16	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	1.70 (0.87)	1.2	1.16	1.24	2.71	2.7	
			Placebo	7	7 (100.0)	1.91 (0.57)	1.2	1.31	2.18	2.47	2.5	
		Week 4	Tezepelumab	3	2 (66.7)	1.46 (0.12)	1.4	1.37	1.46	1.54	1.5	
			Placebo	7	7 (100.0)	1.99 (0.64)	1.3	1.40	1.89	2.61	2.9	
		Week 8	Tezepelumab	3	2 (66.7)	1.50 (0.02)	1.5	1.48	1.50	1.51	1.5	
			Placebo	7	7 (100.0)	2.13 (0.74)	1.2	1.65	2.00	2.71	3.4	
		Week 12	Tezepelumab	3	3 (100.0)	1.77 (0.66)	1.3	1.33	1.45	2.53	2.5	
			Placebo	7	7 (100.0)	2.10 (0.87)	1.2	1.48	1.56	3.17	3.3	
		Week 20	Tezepelumab	3	2 (66.7)	1.56 (0.13)	1.5	1.46	1.56	1.65	1.7	
			Placebo	7	7 (100.0)	2.13 (0.66)	1.3	1.55	2.26	2.92	3.0	
		Week 28	Tezepelumab	3	2 (66.7)	1.36 (0.04)	1.3	1.33	1.36	1.39	1.4	
			Placebo	7	7 (100.0)	2.21 (0.86)	1.5	1.58	1.60	3.38	3.4	
		Week 40	Tezepelumab	3	1 (33.3)	1.66	1.7	1.66	1.66	1.66	1.7	
			Placebo	7	7 (100.0)	2.19 (0.94)	1.3	1.50	1.71	3.38	3.5	
		Week 52	Tezepelumab	3	2 (66.7)	1.59 (0.47)	1.3	1.25	1.59	1.92	1.9	
			Placebo	7	7 (100.0)	2.12 (1.06)	1.3	1.30	1.46	3.53	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	3	2 (66.7)	0.26 (0.18)	0.1	0.13	0.26	0.38	0.4	0.78 [-0.84, 2.41]
			Placebo	7	7 (100.0)	0.08 (0.22)	-0.3	-0.05	0.09	0.25	0.4	
		Week 8	Tezepelumab	3	2 (66.7)	0.30 (0.08)	0.2	0.24	0.30	0.35	0.4	0.22 [-1.35, 1.80]
			Placebo	7	7 (100.0)	0.22 (0.34)	-0.2	0.02	0.20	0.34	0.9	
		Week 12	Tezepelumab	3	3 (100.0)	0.07 (0.21)	-0.2	-0.18	0.17	0.21	0.2	-0.28 [-1.64, 1.08]
			Placebo	7	7 (100.0)	0.19 (0.48)	-0.7	0.02	0.15	0.70	0.8	
		Week 20	Tezepelumab	3	2 (66.7)	0.36 (0.19)	0.2	0.22	0.36	0.49	0.5	0.79 [-0.84, 2.41]
			Placebo	7	7 (100.0)	0.23 (0.16)	0.0	0.13	0.15	0.43	0.4	
		Week 28	Tezepelumab	3	2 (66.7)	0.16 (0.01)	0.1	0.15	0.16	0.17	0.2	-0.30 [-1.88, 1.28]
			Placebo	7	7 (100.0)	0.30 (0.50)	-0.6	0.15	0.27	0.86	0.9	
		Week 40	Tezepelumab	3	1 (33.3)	0.50	0.5	0.50	0.50	0.50	0.5	NE
			Placebo	7	7 (100.0)	0.28 (0.53)	-0.5	-0.04	0.18	0.91	1.0	
		Week 52	Tezepelumab	3	2 (66.7)	0.39 (0.53)	0.0	0.01	0.39	0.76	0.8	0.25 [-1.32, 1.83]
			Placebo	7	7 (100.0)	0.22 (0.69)	-0.9	0.01	0.07	1.01	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.54 (0.72)	0.7	1.17	1.37	1.87	3.0	
			Placebo	13	13 (100.0)	1.71 (0.41)	1.0	1.50	1.74	1.85	2.5	
		Week 4	Tezepelumab	9	9 (100.0)	1.84 (1.09)	0.9	1.19	1.44	2.04	4.5	
			Placebo	13	13 (100.0)	1.60 (0.59)	0.7	1.30	1.65	1.89	2.9	
		Week 8	Tezepelumab	9	7 (77.8)	1.63 (0.42)	1.3	1.26	1.46	2.03	2.2	
			Placebo	13	12 (92.3)	1.77 (0.61)	0.8	1.34	1.94	2.14	2.7	
		Week 12	Tezepelumab	9	8 (88.9)	1.95 (1.12)	1.1	1.25	1.70	1.99	4.6	
			Placebo	13	12 (92.3)	1.71 (0.72)	0.5	1.29	1.65	2.14	3.2	
		Week 20	Tezepelumab	9	8 (88.9)	1.76 (0.99)	1.0	1.24	1.48	1.75	4.1	
			Placebo	13	12 (92.3)	1.79 (0.63)	0.7	1.38	1.80	2.30	2.9	
		Week 28	Tezepelumab	9	8 (88.9)	1.83 (1.17)	1.0	1.17	1.42	1.94	4.6	
			Placebo	13	11 (84.6)	1.69 (0.79)	0.8	0.84	1.58	2.10	3.4	
		Week 40	Tezepelumab	9	7 (77.8)	1.49 (0.33)	1.1	1.30	1.36	1.88	2.0	
			Placebo	13	11 (84.6)	1.79 (0.90)	0.6	1.08	1.71	2.24	3.4	
		Week 52	Tezepelumab	9	7 (77.8)	1.57 (0.29)	1.3	1.33	1.36	1.86	1.9	
			Placebo	13	11 (84.6)	1.84 (1.02)	0.8	1.10	1.38	2.54	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	0.30 (0.46)	-0.0	0.02	0.13	0.38	1.4	1.03 [0.12, 1.94]
			Placebo	13	13 (100.0)	-0.11 (0.35)	-1.1	-0.22	-0.06	0.02	0.4	
		Week 8	Tezepelumab	9	7 (77.8)	0.19 (0.22)	-0.0	-0.03	0.10	0.36	0.6	0.39 [-0.55, 1.33]
			Placebo	13	12 (92.3)	0.05 (0.41)	-0.9	-0.18	0.12	0.31	0.6	
		Week 12	Tezepelumab	9	8 (88.9)	0.31 (0.53)	-0.1	-0.02	0.16	0.36	1.5	0.58 [-0.33, 1.50]
			Placebo	13	12 (92.3)	-0.00 (0.53)	-1.2	-0.12	-0.02	0.30	0.7	
		Week 20	Tezepelumab	9	8 (88.9)	0.12 (0.46)	-0.4	-0.17	0.05	0.25	1.1	0.11 [-0.79, 1.00]
			Placebo	13	12 (92.3)	0.07 (0.39)	-1.0	-0.01	0.12	0.24	0.6	
		Week 28	Tezepelumab	9	8 (88.9)	0.18 (0.70)	-1.0	-0.04	0.11	0.41	1.5	0.32 [-0.60, 1.24]
			Placebo	13	11 (84.6)	-0.01 (0.51)	-0.9	-0.49	0.03	0.30	0.9	
		Week 40	Tezepelumab	9	7 (77.8)	0.05 (0.39)	-0.7	-0.08	0.07	0.16	0.7	-0.09 [-1.03, 0.86]
			Placebo	13	11 (84.6)	0.09 (0.63)	-1.1	-0.32	0.00	0.52	1.1	
		Week 52	Tezepelumab	9	7 (77.8)	0.13 (0.22)	-0.0	-0.01	0.07	0.16	0.6	-0.02 [-0.97, 0.92]
			Placebo	13	11 (84.6)	0.14 (0.74)	-0.9	-0.15	-0.10	0.78	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	1.79 (0.56)	0.7	1.40	1.68	2.17	3.1	
			Placebo	52	52 (100.0)	1.85 (0.60)	0.9	1.42	1.68	2.27	3.2	
		Week 4	Tezepelumab	57	55 (96.5)	2.02 (0.73)	0.9	1.50	1.82	2.40	3.8	
			Placebo	52	52 (100.0)	1.91 (0.60)	0.7	1.55	1.81	2.41	3.2	
		Week 8	Tezepelumab	57	53 (93.0)	1.98 (0.63)	0.7	1.49	1.90	2.37	3.4	
			Placebo	52	49 (94.2)	1.93 (0.65)	0.8	1.54	1.88	2.31	3.6	
		Week 12	Tezepelumab	57	54 (94.7)	2.06 (0.69)	0.9	1.49	2.02	2.57	3.5	
			Placebo	52	51 (98.1)	1.91 (0.70)	0.6	1.44	1.81	2.44	4.1	
		Week 20	Tezepelumab	57	49 (86.0)	1.94 (0.64)	1.0	1.46	1.75	2.38	3.4	
			Placebo	52	48 (92.3)	1.89 (0.67)	0.5	1.45	1.73	2.35	3.3	
		Week 28	Tezepelumab	57	52 (91.2)	1.95 (0.63)	0.9	1.47	1.84	2.33	3.5	
			Placebo	52	48 (92.3)	1.86 (0.63)	0.7	1.43	1.77	2.26	3.4	
		Week 40	Tezepelumab	57	51 (89.5)	1.99 (0.65)	0.9	1.43	1.99	2.41	3.5	
			Placebo	52	46 (88.5)	1.94 (0.70)	0.8	1.50	1.75	2.35	4.0	
		Week 52	Tezepelumab	57	52 (91.2)	1.90 (0.63)	0.9	1.35	1.80	2.35	3.4	
			Placebo	52	49 (94.2)	1.85 (0.66)	0.6	1.42	1.72	2.31	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	55 (96.5)	0.26 (0.49)	-0.6	-0.03	0.11	0.45	2.4	0.45 [0.07, 0.84]
			Placebo	52	52 (100.0)	0.06 (0.36)	-1.0	-0.14	0.08	0.17	1.1	
		Week 8	Tezepelumab	57	53 (93.0)	0.21 (0.40)	-0.5	-0.01	0.17	0.35	2.2	0.34 [-0.05, 0.73]
			Placebo	52	49 (94.2)	0.08 (0.42)	-1.5	-0.06	0.13	0.20	1.0	
		Week 12	Tezepelumab	57	54 (94.7)	0.31 (0.44)	-0.5	0.03	0.23	0.47	2.1	0.56 [0.17, 0.95]
			Placebo	52	51 (98.1)	0.07 (0.40)	-0.9	-0.16	0.05	0.28	1.3	
		Week 20	Tezepelumab	57	49 (86.0)	0.22 (0.46)	-0.6	-0.07	0.17	0.39	2.2	0.46 [0.06, 0.87]
			Placebo	52	48 (92.3)	0.04 (0.29)	-0.7	-0.09	0.06	0.22	0.8	
		Week 28	Tezepelumab	57	52 (91.2)	0.24 (0.45)	-0.7	-0.04	0.19	0.50	2.2	0.56 [0.16, 0.96]
			Placebo	52	48 (92.3)	0.02 (0.33)	-1.1	-0.11	0.06	0.22	0.9	
		Week 40	Tezepelumab	57	51 (89.5)	0.26 (0.47)	-0.5	-0.05	0.26	0.48	2.3	0.42 [0.02, 0.83]
			Placebo	52	46 (88.5)	0.09 (0.32)	-0.5	-0.11	0.06	0.22	1.0	
		Week 52	Tezepelumab	57	52 (91.2)	0.19 (0.46)	-0.8	-0.05	0.11	0.42	2.3	0.40 [0.01, 0.80]
			Placebo	52	49 (94.2)	0.02 (0.34)	-1.0	-0.16	0.04	0.17	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	1.64 (0.46)	0.9	1.29	1.62	2.01	2.2	
			Placebo	3	3 (100.0)	1.42 (0.37)	1.0	1.01	1.52	1.74	1.7	
		Week 4	Tezepelumab	7	7 (100.0)	1.90 (0.43)	1.3	1.41	2.01	2.26	2.4	
			Placebo	3	3 (100.0)	1.04 (0.34)	0.7	0.65	1.17	1.30	1.3	
		Week 8	Tezepelumab	7	7 (100.0)	1.90 (0.52)	1.3	1.35	2.07	2.39	2.4	
			Placebo	3	3 (100.0)	1.10 (0.44)	0.8	0.80	0.90	1.60	1.6	
		Week 12	Tezepelumab	7	7 (100.0)	2.00 (0.60)	1.3	1.28	2.33	2.55	2.6	
			Placebo	3	3 (100.0)	1.04 (0.45)	0.5	0.54	1.17	1.41	1.4	
		Week 20	Tezepelumab	7	7 (100.0)	1.95 (0.46)	1.4	1.37	2.05	2.45	2.5	
			Placebo	3	3 (100.0)	1.06 (0.42)	0.7	0.74	0.91	1.53	1.5	
		Week 28	Tezepelumab	7	7 (100.0)	1.90 (0.52)	1.3	1.29	1.95	2.48	2.5	
			Placebo	3	3 (100.0)	1.17 (0.35)	0.8	0.84	1.12	1.54	1.5	
		Week 40	Tezepelumab	7	7 (100.0)	1.87 (0.64)	1.1	1.19	2.15	2.36	2.7	
			Placebo	3	3 (100.0)	0.98 (0.30)	0.6	0.63	1.10	1.20	1.2	
		Week 52	Tezepelumab	7	7 (100.0)	1.85 (0.48)	1.2	1.36	1.93	2.37	2.4	
			Placebo	3	3 (100.0)	1.12 (0.22)	1.0	0.96	1.03	1.37	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	7	7 (100.0)	0.26 (0.37)	-0.0	-0.04	0.14	0.64	0.9	1.42 [-0.10, 2.94]
			Placebo	3	3 (100.0)	-0.38 (0.64)	-1.1	-1.09	-0.22	0.16	0.2	
		Week 8	Tezepelumab	7	7 (100.0)	0.26 (0.34)	-0.1	-0.03	0.08	0.56	0.8	1.44 [-0.09, 2.96]
			Placebo	3	3 (100.0)	-0.32 (0.54)	-0.9	-0.94	-0.11	0.08	0.1	
		Week 12	Tezepelumab	7	7 (100.0)	0.35 (0.37)	-0.2	-0.01	0.36	0.61	0.9	1.53 [-0.02, 3.07]
			Placebo	3	3 (100.0)	-0.38 (0.72)	-1.2	-1.20	-0.11	0.16	0.2	
		Week 20	Tezepelumab	7	7 (100.0)	0.30 (0.42)	-0.1	0.04	0.08	0.87	0.9	1.46 [-0.07, 2.99]
			Placebo	3	3 (100.0)	-0.36 (0.55)	-1.0	-1.00	-0.10	0.01	0.0	
		Week 28	Tezepelumab	7	7 (100.0)	0.26 (0.41)	-0.2	-0.06	0.16	0.73	0.9	1.14 [-0.32, 2.60]
			Placebo	3	3 (100.0)	-0.26 (0.56)	-0.9	-0.90	0.02	0.11	0.1	
		Week 40	Tezepelumab	7	7 (100.0)	0.23 (0.42)	-0.3	0.05	0.14	0.37	1.0	1.43 [-0.09, 2.96]
			Placebo	3	3 (100.0)	-0.45 (0.61)	-1.1	-1.11	-0.32	0.09	0.1	
		Week 52	Tezepelumab	7	7 (100.0)	0.21 (0.36)	-0.2	-0.06	0.15	0.64	0.8	1.43 [-0.09, 2.95]
			Placebo	3	3 (100.0)	-0.30 (0.36)	-0.7	-0.71	-0.15	-0.05	-0.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	59	59 (100.0)	1.77 (0.60)	0.7	1.34	1.68	2.17	3.1	
			Placebo	62	62 (100.0)	1.84 (0.57)	0.9	1.43	1.74	2.23	3.2	
		Week 4	Tezepelumab	59	57 (96.6)	2.00 (0.82)	0.9	1.46	1.80	2.40	4.5	
			Placebo	62	62 (100.0)	1.89 (0.59)	0.7	1.55	1.78	2.37	3.2	
		Week 8	Tezepelumab	59	53 (89.8)	1.95 (0.63)	0.7	1.47	1.85	2.36	3.4	
			Placebo	62	58 (93.5)	1.94 (0.62)	0.8	1.56	1.97	2.31	3.6	
		Week 12	Tezepelumab	59	55 (93.2)	2.05 (0.77)	0.9	1.48	1.88	2.69	4.6	
			Placebo	62	60 (96.8)	1.92 (0.69)	0.6	1.47	1.83	2.42	4.1	
		Week 20	Tezepelumab	59	50 (84.7)	1.91 (0.72)	1.0	1.39	1.68	2.37	4.1	
			Placebo	62	57 (91.9)	1.91 (0.64)	0.5	1.55	1.86	2.33	3.3	
		Week 28	Tezepelumab	59	53 (89.8)	1.94 (0.74)	0.9	1.42	1.73	2.29	4.6	
			Placebo	62	56 (90.3)	1.86 (0.65)	0.7	1.46	1.77	2.26	3.4	
		Week 40	Tezepelumab	59	51 (86.4)	1.93 (0.65)	0.9	1.36	1.88	2.33	3.5	
			Placebo	62	54 (87.1)	1.97 (0.72)	0.8	1.50	1.79	2.35	4.0	
		Week 52	Tezepelumab	59	52 (88.1)	1.86 (0.62)	0.9	1.34	1.80	2.26	3.4	
			Placebo	62	57 (91.9)	1.89 (0.73)	0.6	1.40	1.72	2.31	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	59	57 (96.6)	0.26 (0.50)	-0.6	0.01	0.11	0.41	2.4	0.51 [0.15, 0.88]
			Placebo	62	62 (100.0)	0.05 (0.34)	-1.0	-0.14	0.04	0.17	1.1	
		Week 8	Tezepelumab	59	53 (89.8)	0.21 (0.39)	-0.5	-0.01	0.17	0.35	2.2	0.29 [-0.09, 0.66]
			Placebo	62	58 (93.5)	0.09 (0.40)	-1.5	-0.06	0.13	0.27	1.0	
		Week 12	Tezepelumab	59	55 (93.2)	0.30 (0.46)	-0.5	-0.01	0.21	0.47	2.1	0.52 [0.15, 0.89]
			Placebo	62	60 (96.8)	0.08 (0.41)	-0.9	-0.11	0.05	0.28	1.3	
		Week 20	Tezepelumab	59	50 (84.7)	0.19 (0.46)	-0.6	-0.08	0.13	0.39	2.2	0.33 [-0.06, 0.71]
			Placebo	62	57 (91.9)	0.07 (0.28)	-0.7	-0.03	0.08	0.23	0.8	
		Week 28	Tezepelumab	59	53 (89.8)	0.22 (0.49)	-1.0	-0.02	0.20	0.48	2.2	0.47 [0.09, 0.85]
			Placebo	62	56 (90.3)	0.03 (0.35)	-1.1	-0.15	0.06	0.23	0.9	
		Week 40	Tezepelumab	59	51 (86.4)	0.24 (0.47)	-0.7	-0.07	0.25	0.48	2.3	0.28 [-0.11, 0.66]
			Placebo	62	54 (87.1)	0.12 (0.36)	-0.5	-0.11	0.06	0.24	1.1	
		Week 52	Tezepelumab	59	52 (88.1)	0.17 (0.45)	-0.8	-0.03	0.11	0.40	2.3	0.26 [-0.12, 0.63]
			Placebo	62	57 (91.9)	0.06 (0.43)	-1.0	-0.16	0.06	0.18	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	1.58 (0.47)	0.9	1.29	1.54	1.99	2.2	
			Placebo	2	2 (100.0)	1.27 (0.36)	1.0	1.01	1.27	1.52	1.5	
		Week 4	Tezepelumab	6	6 (100.0)	1.86 (0.46)	1.3	1.41	1.92	2.26	2.4	
			Placebo	2	2 (100.0)	1.24 (0.09)	1.2	1.17	1.24	1.30	1.3	
		Week 8	Tezepelumab	6	6 (100.0)	1.87 (0.56)	1.3	1.35	1.89	2.39	2.4	
			Placebo	2	2 (100.0)	1.25 (0.49)	0.9	0.90	1.25	1.60	1.6	
		Week 12	Tezepelumab	6	6 (100.0)	1.94 (0.64)	1.3	1.28	1.99	2.55	2.6	
			Placebo	2	2 (100.0)	1.29 (0.17)	1.2	1.17	1.29	1.41	1.4	
		Week 20	Tezepelumab	6	6 (100.0)	1.93 (0.50)	1.4	1.37	1.96	2.45	2.5	
			Placebo	2	2 (100.0)	1.22 (0.44)	0.9	0.91	1.22	1.53	1.5	
		Week 28	Tezepelumab	6	6 (100.0)	1.90 (0.57)	1.3	1.29	1.91	2.48	2.5	
			Placebo	2	2 (100.0)	1.33 (0.30)	1.1	1.12	1.33	1.54	1.5	
		Week 40	Tezepelumab	6	6 (100.0)	1.83 (0.69)	1.1	1.19	1.84	2.36	2.7	
			Placebo	2	2 (100.0)	1.15 (0.07)	1.1	1.10	1.15	1.20	1.2	
		Week 52	Tezepelumab	6	6 (100.0)	1.80 (0.50)	1.2	1.36	1.75	2.37	2.4	
			Placebo	2	2 (100.0)	1.17 (0.29)	1.0	0.96	1.17	1.37	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	6	6 (100.0)	0.27 (0.40)	-0.0	-0.04	0.10	0.64	0.9	0.81 [-0.86, 2.47]
			Placebo	2	2 (100.0)	-0.03 (0.27)	-0.2	-0.22	-0.03	0.16	0.2	
		Week 8	Tezepelumab	6	6 (100.0)	0.29 (0.36)	-0.1	-0.03	0.24	0.56	0.8	0.90 [-0.78, 2.58]
			Placebo	2	2 (100.0)	-0.01 (0.13)	-0.1	-0.11	-0.01	0.08	0.1	
		Week 12	Tezepelumab	6	6 (100.0)	0.36 (0.41)	-0.2	-0.01	0.41	0.61	0.9	0.88 [-0.79, 2.56]
			Placebo	2	2 (100.0)	0.02 (0.19)	-0.1	-0.11	0.02	0.16	0.2	
		Week 20	Tezepelumab	6	6 (100.0)	0.35 (0.44)	-0.1	0.06	0.16	0.87	0.9	0.97 [-0.72, 2.66]
			Placebo	2	2 (100.0)	-0.04 (0.08)	-0.1	-0.10	-0.04	0.01	0.0	
		Week 28	Tezepelumab	6	6 (100.0)	0.32 (0.43)	-0.2	-0.03	0.22	0.73	0.9	0.64 [-1.00, 2.28]
			Placebo	2	2 (100.0)	0.07 (0.06)	0.0	0.02	0.07	0.11	0.1	
		Week 40	Tezepelumab	6	6 (100.0)	0.25 (0.46)	-0.3	0.05	0.19	0.37	1.0	0.84 [-0.83, 2.50]
			Placebo	2	2 (100.0)	-0.12 (0.29)	-0.3	-0.32	-0.12	0.09	0.1	
		Week 52	Tezepelumab	6	6 (100.0)	0.22 (0.39)	-0.2	-0.06	0.12	0.64	0.8	0.89 [-0.79, 2.57]
			Placebo	2	2 (100.0)	-0.10 (0.07)	-0.1	-0.15	-0.10	-0.05	-0.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	1.77 (0.60)	0.7	1.35	1.70	2.15	3.1	
			Placebo	63	63 (100.0)	1.84 (0.56)	0.9	1.43	1.74	2.23	3.2	
		Week 4	Tezepelumab	60	58 (96.7)	2.01 (0.81)	0.9	1.46	1.81	2.40	4.5	
			Placebo	63	63 (100.0)	1.87 (0.61)	0.7	1.55	1.76	2.37	3.2	
		Week 8	Tezepelumab	60	54 (90.0)	1.95 (0.63)	0.7	1.47	1.88	2.36	3.4	
			Placebo	63	59 (93.7)	1.92 (0.63)	0.8	1.54	1.94	2.31	3.6	
		Week 12	Tezepelumab	60	56 (93.3)	2.05 (0.76)	0.9	1.49	1.89	2.61	4.6	
			Placebo	63	61 (96.8)	1.89 (0.70)	0.5	1.46	1.81	2.40	4.1	
		Week 20	Tezepelumab	60	51 (85.0)	1.91 (0.72)	1.0	1.39	1.68	2.37	4.1	
			Placebo	63	58 (92.1)	1.89 (0.65)	0.5	1.51	1.80	2.33	3.3	
		Week 28	Tezepelumab	60	54 (90.0)	1.94 (0.73)	0.9	1.42	1.76	2.29	4.6	
			Placebo	63	57 (90.5)	1.84 (0.66)	0.7	1.44	1.74	2.24	3.4	
		Week 40	Tezepelumab	60	52 (86.7)	1.94 (0.64)	0.9	1.40	1.91	2.32	3.5	
			Placebo	63	55 (87.3)	1.94 (0.74)	0.6	1.45	1.79	2.35	4.0	
		Week 52	Tezepelumab	60	53 (88.3)	1.87 (0.62)	0.9	1.34	1.80	2.25	3.4	
			Placebo	63	58 (92.1)	1.88 (0.73)	0.6	1.38	1.72	2.31	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	60	58 (96.7)	0.26 (0.50)	-0.6	0.01	0.12	0.41	2.4	0.54 [0.18, 0.90]
			Placebo	63	63 (100.0)	0.03 (0.37)	-1.1	-0.15	0.03	0.17	1.1	
		Week 8	Tezepelumab	60	54 (90.0)	0.20 (0.39)	-0.5	-0.01	0.17	0.35	2.2	0.32 [-0.05, 0.69]
			Placebo	63	59 (93.7)	0.07 (0.42)	-1.5	-0.06	0.13	0.27	1.0	
		Week 12	Tezepelumab	60	56 (93.3)	0.30 (0.45)	-0.5	0.01	0.21	0.46	2.1	0.55 [0.18, 0.92]
			Placebo	63	61 (96.8)	0.06 (0.43)	-1.2	-0.12	0.04	0.28	1.3	
		Week 20	Tezepelumab	60	51 (85.0)	0.19 (0.46)	-0.6	-0.08	0.12	0.39	2.2	0.36 [-0.02, 0.74]
			Placebo	63	58 (92.1)	0.05 (0.31)	-1.0	-0.03	0.07	0.23	0.8	
		Week 28	Tezepelumab	60	54 (90.0)	0.22 (0.49)	-1.0	-0.06	0.19	0.48	2.2	0.48 [0.11, 0.86]
			Placebo	63	57 (90.5)	0.01 (0.37)	-1.1	-0.17	0.05	0.23	0.9	
		Week 40	Tezepelumab	60	52 (86.7)	0.23 (0.47)	-0.7	-0.06	0.24	0.46	2.3	0.31 [-0.07, 0.70]
			Placebo	63	55 (87.3)	0.10 (0.40)	-1.1	-0.12	0.06	0.24	1.1	
		Week 52	Tezepelumab	60	53 (88.3)	0.17 (0.45)	-0.8	-0.03	0.11	0.40	2.3	0.28 [-0.09, 0.66]
			Placebo	63	58 (92.1)	0.05 (0.44)	-1.0	-0.16	0.05	0.18	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	17	17 (100.0)	1.84 (0.65)	0.7	1.37	1.79	2.38	3.0	
			Placebo	21	21 (100.0)	2.11 (0.43)	1.5	1.74	2.17	2.32	3.1	
		Week 4	Tezepelumab	17	15 (88.2)	2.12 (0.96)	1.1	1.44	1.89	2.95	4.5	
			Placebo	21	21 (100.0)	2.07 (0.60)	0.7	1.65	1.91	2.46	3.0	
		Week 8	Tezepelumab	17	14 (82.4)	1.90 (0.68)	1.1	1.46	1.60	2.44	3.2	
			Placebo	21	19 (90.5)	2.13 (0.49)	0.8	1.75	2.25	2.56	2.7	
		Week 12	Tezepelumab	17	16 (94.1)	2.18 (0.92)	1.2	1.44	1.94	2.71	4.6	
			Placebo	21	20 (95.2)	2.17 (0.78)	0.5	1.62	2.23	2.56	4.1	
		Week 20	Tezepelumab	17	13 (76.5)	1.99 (0.94)	1.0	1.37	1.65	2.49	4.1	
			Placebo	21	20 (95.2)	2.13 (0.61)	0.7	1.68	2.22	2.53	3.1	
		Week 28	Tezepelumab	17	14 (82.4)	2.08 (0.98)	1.0	1.33	1.71	2.54	4.6	
			Placebo	21	20 (95.2)	2.08 (0.56)	0.8	1.67	2.06	2.40	3.4	
		Week 40	Tezepelumab	17	13 (76.5)	2.01 (0.75)	1.1	1.36	1.77	2.65	3.3	
			Placebo	21	19 (90.5)	2.13 (0.77)	0.6	1.68	2.18	2.53	4.0	
		Week 52	Tezepelumab	17	13 (76.5)	1.88 (0.60)	0.9	1.36	1.92	2.15	3.2	
			Placebo	21	20 (95.2)	2.16 (0.70)	1.0	1.53	2.18	2.61	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	17	15 (88.2)	0.37 (0.45)	-0.1	-0.02	0.38	0.64	1.4	0.96 [0.26, 1.66]
			Placebo	21	21 (100.0)	-0.05 (0.43)	-1.1	-0.22	-0.06	0.18	0.7	
		Week 8	Tezepelumab	17	14 (82.4)	0.24 (0.38)	-0.4	-0.04	0.13	0.55	0.8	0.66 [-0.05, 1.36]
			Placebo	21	19 (90.5)	-0.01 (0.39)	-0.9	-0.06	0.08	0.24	0.5	
		Week 12	Tezepelumab	17	16 (94.1)	0.37 (0.45)	-0.2	0.06	0.24	0.61	1.5	0.70 [0.02, 1.38]
			Placebo	21	20 (95.2)	0.03 (0.50)	-1.2	-0.14	0.07	0.31	1.0	
		Week 20	Tezepelumab	17	13 (76.5)	0.30 (0.51)	-0.6	0.02	0.27	0.75	1.1	0.72 [-0.00, 1.44]
			Placebo	21	20 (95.2)	-0.00 (0.35)	-1.0	-0.05	0.06	0.22	0.4	
		Week 28	Tezepelumab	17	14 (82.4)	0.33 (0.64)	-1.0	0.04	0.44	0.76	1.5	0.72 [0.02, 1.43]
			Placebo	21	20 (95.2)	-0.06 (0.45)	-1.1	-0.23	0.00	0.20	0.9	
		Week 40	Tezepelumab	17	13 (76.5)	0.37 (0.45)	-0.7	0.07	0.44	0.66	1.0	0.76 [0.03, 1.50]
			Placebo	21	19 (90.5)	0.01 (0.49)	-1.1	-0.32	-0.06	0.22	0.9	
		Week 52	Tezepelumab	17	13 (76.5)	0.24 (0.45)	-0.7	-0.01	0.10	0.71	0.8	0.44 [-0.26, 1.15]
			Placebo	21	20 (95.2)	0.03 (0.48)	-0.9	-0.24	0.02	0.30	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	49	49 (100.0)	1.72 (0.57)	0.7	1.34	1.63	2.07	3.1	
			Placebo	44	44 (100.0)	1.68 (0.57)	0.9	1.32	1.53	2.04	3.2	
		Week 4	Tezepelumab	49	49 (100.0)	1.95 (0.73)	0.9	1.48	1.81	2.29	3.8	
			Placebo	44	44 (100.0)	1.74 (0.59)	0.7	1.41	1.67	2.18	3.2	
		Week 8	Tezepelumab	49	46 (93.9)	1.95 (0.61)	0.7	1.48	1.92	2.36	3.4	
			Placebo	44	42 (95.5)	1.79 (0.67)	0.8	1.36	1.68	2.17	3.6	
		Week 12	Tezepelumab	49	46 (93.9)	1.99 (0.68)	0.9	1.48	1.89	2.44	3.5	
			Placebo	44	43 (97.7)	1.74 (0.62)	0.6	1.23	1.68	2.16	3.3	
		Week 20	Tezepelumab	49	44 (89.8)	1.89 (0.61)	1.0	1.46	1.75	2.34	3.4	
			Placebo	44	40 (90.9)	1.73 (0.64)	0.5	1.26	1.69	2.08	3.3	
		Week 28	Tezepelumab	49	46 (93.9)	1.89 (0.61)	0.9	1.42	1.76	2.26	3.5	
			Placebo	44	39 (88.6)	1.69 (0.67)	0.7	1.23	1.60	2.03	3.4	
		Week 40	Tezepelumab	49	45 (91.8)	1.90 (0.62)	0.9	1.33	1.93	2.33	3.5	
			Placebo	44	38 (86.4)	1.81 (0.70)	0.8	1.38	1.63	2.24	3.5	
		Week 52	Tezepelumab	49	46 (93.9)	1.86 (0.61)	1.0	1.33	1.78	2.27	3.4	
			Placebo	44	40 (90.9)	1.70 (0.70)	0.6	1.25	1.61	1.94	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHK: Change from baseline in FEV1 Pre-BD by key subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	49	49 (100.0)	0.23 (0.50)	-0.6	0.01	0.11	0.37	2.4	0.40 [-0.01, 0.81]
			Placebo	44	44 (100.0)	0.06 (0.33)	-1.0	-0.08	0.06	0.15	1.1	
		Week 8	Tezepelumab	49	46 (93.9)	0.20 (0.39)	-0.5	0.00	0.18	0.34	2.2	0.23 [-0.19, 0.65]
			Placebo	44	42 (95.5)	0.11 (0.43)	-1.5	-0.07	0.13	0.27	1.0	
		Week 12	Tezepelumab	49	46 (93.9)	0.29 (0.45)	-0.5	-0.01	0.21	0.45	2.1	0.52 [0.10, 0.94]
			Placebo	44	43 (97.7)	0.07 (0.40)	-0.9	-0.12	0.02	0.26	1.3	
		Week 20	Tezepelumab	49	44 (89.8)	0.18 (0.44)	-0.6	-0.08	0.10	0.35	2.2	0.28 [-0.15, 0.71]
			Placebo	44	40 (90.9)	0.08 (0.29)	-0.7	-0.04	0.07	0.23	0.8	
		Week 28	Tezepelumab	49	46 (93.9)	0.20 (0.42)	-0.6	-0.06	0.15	0.44	2.2	0.40 [-0.03, 0.83]
			Placebo	44	39 (88.6)	0.05 (0.31)	-1.1	-0.17	0.11	0.26	0.9	
		Week 40	Tezepelumab	49	45 (91.8)	0.20 (0.46)	-0.5	-0.07	0.16	0.36	2.3	0.16 [-0.28, 0.59]
			Placebo	44	38 (86.4)	0.13 (0.34)	-0.3	-0.05	0.06	0.25	1.1	
		Week 52	Tezepelumab	49	46 (93.9)	0.16 (0.44)	-0.8	-0.04	0.11	0.37	2.3	0.26 [-0.17, 0.69]
			Placebo	44	40 (90.9)	0.05 (0.42)	-1.0	-0.16	0.05	0.16	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Sex									0.332
Male	Week 4	Tezepelumab	19	18 (94.7)	0.41 (0.12)	(0.16, 0.66)	0.48 (0.17)	(0.13, 0.83)	0.008 *
		Placebo	20	20 (100.0)	-0.07 (0.12)	(-0.31, 0.17)			
	Week 8	Tezepelumab	19	15 (78.9)	0.26 (0.13)	(-0.00, 0.52)	0.30 (0.18)	(-0.06, 0.65)	0.098
		Placebo	20	19 (95.0)	-0.04 (0.12)	(-0.28, 0.21)			
	Week 12	Tezepelumab	19	18 (94.7)	0.34 (0.13)	(0.09, 0.60)	0.25 (0.18)	(-0.11, 0.61)	0.163
		Placebo	20	19 (95.0)	0.09 (0.12)	(-0.16, 0.34)			
	Week 20	Tezepelumab	19	16 (84.2)	0.22 (0.11)	(-0.00, 0.45)	0.22 (0.15)	(-0.09, 0.53)	0.162
		Placebo	20	18 (90.0)	0.00 (0.11)	(-0.21, 0.22)			
	Week 28	Tezepelumab	19	18 (94.7)	0.28 (0.13)	(0.02, 0.53)	0.30 (0.18)	(-0.06, 0.66)	0.101
		Placebo	20	18 (90.0)	-0.02 (0.12)	(-0.28, 0.23)			
	Week 40	Tezepelumab	19	17 (89.5)	0.27 (0.13)	(0.00, 0.53)	0.21 (0.18)	(-0.17, 0.58)	0.269
		Placebo	20	18 (90.0)	0.06 (0.13)	(-0.20, 0.33)			
	Week 52	Tezepelumab	19	17 (89.5)	0.09 (0.14)	(-0.19, 0.37)	-0.03 (0.19)	(-0.42, 0.36)	0.886
		Placebo	20	18 (90.0)	0.12 (0.13)	(-0.15, 0.39)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Female	Week 4	Tezepelumab	47	46 (97.9)	0.19 (0.05)	(0.08, 0.30)	0.11 (0.08)	(-0.04, 0.27)	0.145
		Placebo	45	45 (100.0)	0.08 (0.06)	(-0.03, 0.19)			
	Week 8	Tezepelumab	47	45 (95.7)	0.22 (0.05)	(0.12, 0.32)	0.08 (0.07)	(-0.07, 0.22)	0.293
		Placebo	45	42 (93.3)	0.14 (0.05)	(0.04, 0.24)			
	Week 12	Tezepelumab	47	44 (93.6)	0.26 (0.06)	(0.15, 0.38)	0.21 (0.08)	(0.05, 0.38)	0.013 *
		Placebo	45	44 (97.8)	0.05 (0.06)	(-0.07, 0.17)			
	Week 20	Tezepelumab	47	41 (87.2)	0.19 (0.06)	(0.08, 0.30)	0.13 (0.08)	(-0.03, 0.29)	0.117
		Placebo	45	42 (93.3)	0.06 (0.06)	(-0.05, 0.18)			
	Week 28	Tezepelumab	47	42 (89.4)	0.18 (0.06)	(0.06, 0.29)	0.16 (0.08)	(-0.01, 0.32)	0.065
		Placebo	45	41 (91.1)	0.02 (0.06)	(-0.10, 0.14)			
	Week 40	Tezepelumab	47	41 (87.2)	0.22 (0.06)	(0.10, 0.33)	0.11 (0.08)	(-0.06, 0.28)	0.203
		Placebo	45	39 (86.7)	0.11 (0.06)	(-0.01, 0.23)			
	Week 52	Tezepelumab	47	42 (89.4)	0.21 (0.06)	(0.09, 0.32)	0.22 (0.08)	(0.05, 0.38)	0.010 *
		Placebo	45	42 (93.3)	-0.01 (0.06)	(-0.12, 0.11)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Age									0.588
< 65 years	Week 4	Tezepelumab	57	55 (96.5)	0.29 (0.06)	(0.17, 0.40)	0.26 (0.08)	(0.09, 0.42)	0.002 *
		Placebo	55	55 (100.0)	0.03 (0.06)	(-0.08, 0.15)			
	Week 8	Tezepelumab	57	52 (91.2)	0.25 (0.06)	(0.13, 0.36)	0.15 (0.08)	(-0.00, 0.31)	0.056
		Placebo	55	51 (92.7)	0.09 (0.06)	(-0.02, 0.20)			
	Week 12	Tezepelumab	57	54 (94.7)	0.31 (0.06)	(0.19, 0.43)	0.24 (0.09)	(0.06, 0.41)	0.008 *
		Placebo	55	53 (96.4)	0.07 (0.06)	(-0.05, 0.20)			
	Week 20	Tezepelumab	57	49 (86.0)	0.21 (0.06)	(0.10, 0.32)	0.16 (0.08)	(-0.00, 0.31)	0.054
		Placebo	55	50 (90.9)	0.06 (0.06)	(-0.05, 0.17)			
	Week 28	Tezepelumab	57	52 (91.2)	0.24 (0.06)	(0.11, 0.36)	0.21 (0.09)	(0.03, 0.39)	0.020 *
		Placebo	55	49 (89.1)	0.02 (0.06)	(-0.10, 0.15)			
	Week 40	Tezepelumab	57	50 (87.7)	0.26 (0.06)	(0.13, 0.38)	0.14 (0.09)	(-0.04, 0.32)	0.132
		Placebo	55	47 (85.5)	0.12 (0.06)	(-0.01, 0.25)			
	Week 52	Tezepelumab	57	51 (89.5)	0.20 (0.07)	(0.07, 0.34)	0.16 (0.09)	(-0.03, 0.34)	0.099
		Placebo	55	50 (90.9)	0.05 (0.07)	(-0.08, 0.18)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 65 years	Week 4	Tezepelumab	9	9 (100.0)	0.03 (0.14)	(-0.25, 0.32)	-0.04 (0.19)	(-0.45, 0.36)	0.816
		Placebo	10	10 (100.0)	0.08 (0.13)	(-0.20, 0.35)			
	Week 8	Tezepelumab	9	8 (88.9)	0.11 (0.11)	(-0.12, 0.33)	0.02 (0.15)	(-0.30, 0.33)	0.911
		Placebo	10	10 (100.0)	0.09 (0.10)	(-0.12, 0.30)			
	Week 12	Tezepelumab	9	8 (88.9)	0.12 (0.11)	(-0.11, 0.35)	0.06 (0.15)	(-0.26, 0.38)	0.689
		Placebo	10	10 (100.0)	0.06 (0.10)	(-0.16, 0.27)			
	Week 20	Tezepelumab	9	8 (88.9)	0.08 (0.11)	(-0.15, 0.32)	0.06 (0.16)	(-0.27, 0.39)	0.720
		Placebo	10	10 (100.0)	0.02 (0.10)	(-0.20, 0.25)			
	Week 28	Tezepelumab	9	8 (88.9)	-0.01 (0.10)	(-0.22, 0.19)	0.01 (0.13)	(-0.27, 0.30)	0.916
		Placebo	10	10 (100.0)	-0.03 (0.09)	(-0.21, 0.16)			
	Week 40	Tezepelumab	9	8 (88.9)	0.04 (0.10)	(-0.17, 0.25)	0.04 (0.14)	(-0.25, 0.34)	0.768
		Placebo	10	10 (100.0)	-0.00 (0.09)	(-0.20, 0.19)			
	Week 52	Tezepelumab	9	8 (88.9)	-0.04 (0.08)	(-0.21, 0.13)	-0.01 (0.11)	(-0.25, 0.23)	0.936
		Placebo	10	10 (100.0)	-0.03 (0.07)	(-0.18, 0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Exacerbations in the year before study									0.878
<= 2	Week 4	Tezepelumab	44	43 (97.7)	0.26 (0.07)	(0.12, 0.40)	0.21 (0.10)	(0.02, 0.40)	0.033 *
		Placebo	45	45 (100.0)	0.05 (0.07)	(-0.08, 0.19)			
	Week 8	Tezepelumab	44	40 (90.9)	0.23 (0.06)	(0.10, 0.36)	0.13 (0.09)	(-0.05, 0.31)	0.162
		Placebo	45	44 (97.8)	0.10 (0.06)	(-0.02, 0.23)			
	Week 12	Tezepelumab	44	42 (95.5)	0.31 (0.07)	(0.18, 0.45)	0.24 (0.10)	(0.04, 0.43)	0.016 *
		Placebo	45	44 (97.8)	0.08 (0.07)	(-0.06, 0.21)			
	Week 20	Tezepelumab	44	41 (93.2)	0.23 (0.06)	(0.11, 0.35)	0.20 (0.08)	(0.03, 0.37)	0.019 *
		Placebo	45	42 (93.3)	0.03 (0.06)	(-0.09, 0.15)			
	Week 28	Tezepelumab	44	42 (95.5)	0.19 (0.07)	(0.06, 0.32)	0.14 (0.09)	(-0.05, 0.33)	0.140
		Placebo	45	40 (88.9)	0.05 (0.07)	(-0.08, 0.18)			
	Week 40	Tezepelumab	44	40 (90.9)	0.22 (0.07)	(0.08, 0.36)	0.14 (0.10)	(-0.06, 0.33)	0.174
		Placebo	45	40 (88.9)	0.08 (0.07)	(-0.05, 0.22)			
	Week 52	Tezepelumab	44	41 (93.2)	0.16 (0.07)	(0.01, 0.30)	0.09 (0.10)	(-0.11, 0.30)	0.372
		Placebo	45	42 (93.3)	0.06 (0.07)	(-0.08, 0.21)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
> 2	Week 4	Tezepelumab	22	21 (95.5)	0.24 (0.08)	(0.07, 0.41)	0.27 (0.12)	(0.02, 0.51)	0.036 *
		Placebo	20	20 (100.0)	-0.02 (0.09)	(-0.20, 0.15)			
	Week 8	Tezepelumab	22	20 (90.9)	0.22 (0.08)	(0.06, 0.39)	0.20 (0.12)	(-0.04, 0.44)	0.102
		Placebo	20	17 (85.0)	0.02 (0.09)	(-0.15, 0.20)			
	Week 12	Tezepelumab	22	20 (90.9)	0.24 (0.09)	(0.05, 0.43)	0.22 (0.13)	(-0.05, 0.49)	0.108
		Placebo	20	19 (95.0)	0.02 (0.10)	(-0.17, 0.21)			
	Week 20	Tezepelumab	22	16 (72.7)	0.11 (0.10)	(-0.08, 0.30)	0.04 (0.14)	(-0.23, 0.32)	0.761
		Placebo	20	18 (90.0)	0.07 (0.10)	(-0.13, 0.26)			
	Week 28	Tezepelumab	22	18 (81.8)	0.25 (0.09)	(0.05, 0.44)	0.34 (0.14)	(0.07, 0.62)	0.016 *
		Placebo	20	19 (95.0)	-0.10 (0.10)	(-0.29, 0.10)			
	Week 40	Tezepelumab	22	18 (81.8)	0.28 (0.10)	(0.08, 0.47)	0.19 (0.14)	(-0.09, 0.48)	0.184
		Placebo	20	17 (85.0)	0.09 (0.10)	(-0.12, 0.29)			
	Week 52	Tezepelumab	22	18 (81.8)	0.23 (0.09)	(0.05, 0.42)	0.30 (0.13)	(0.03, 0.57)	0.030 *
		Placebo	20	18 (90.0)	-0.06 (0.09)	(-0.25, 0.13)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race				N<10 any level					NE

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region				N<10 any level					NE

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
BMI									<0.001 i
18.5 - < 25.0 kg/m**2	Week 4	Tezepelumab	15	15 (100.0)	0.69 (0.13)	(0.42, 0.96)	0.78 (0.18)	(0.42, 1.15)	<0.001 *
		Placebo	21	21 (100.0)	-0.09 (0.11)	(-0.32, 0.14)			
	Week 8	Tezepelumab	15	13 (86.7)	0.65 (0.14)	(0.37, 0.92)	0.58 (0.18)	(0.21, 0.95)	0.003 *
		Placebo	21	19 (90.5)	0.07 (0.12)	(-0.17, 0.30)			
	Week 12	Tezepelumab	15	15 (100.0)	0.64 (0.14)	(0.36, 0.91)	0.62 (0.18)	(0.25, 0.99)	0.002 *
		Placebo	21	21 (100.0)	0.02 (0.11)	(-0.22, 0.25)			
	Week 20	Tezepelumab	15	12 (80.0)	0.58 (0.13)	(0.33, 0.84)	0.53 (0.17)	(0.19, 0.87)	0.003 *
		Placebo	21	20 (95.2)	0.05 (0.10)	(-0.16, 0.27)			
	Week 28	Tezepelumab	15	15 (100.0)	0.66 (0.14)	(0.37, 0.95)	0.71 (0.19)	(0.32, 1.09)	<0.001 *
		Placebo	21	20 (95.2)	-0.05 (0.12)	(-0.29, 0.20)			
	Week 40	Tezepelumab	15	14 (93.3)	0.67 (0.15)	(0.37, 0.97)	0.55 (0.19)	(0.15, 0.95)	0.009 *
		Placebo	21	19 (90.5)	0.12 (0.12)	(-0.14, 0.37)			
	Week 52	Tezepelumab	15	14 (93.3)	0.53 (0.16)	(0.20, 0.87)	0.45 (0.22)	(0.01, 0.89)	0.047 *
		Placebo	21	20 (95.2)	0.08 (0.14)	(-0.20, 0.37)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
25.0 - < 30.0 kg/m**2	Week 4	Tezepelumab	24	23 (95.8)	0.16 (0.08)	(-0.01, 0.32)	0.11 (0.12)	(-0.13, 0.36)	0.365
		Placebo	20	20 (100.0)	0.04 (0.09)	(-0.14, 0.22)			
	Week 8	Tezepelumab	24	22 (91.7)	0.16 (0.07)	(0.01, 0.31)	0.15 (0.11)	(-0.07, 0.37)	0.188
		Placebo	20	19 (95.0)	0.02 (0.08)	(-0.15, 0.18)			
	Week 12	Tezepelumab	24	20 (83.3)	0.19 (0.11)	(-0.03, 0.40)	0.07 (0.15)	(-0.24, 0.38)	0.647
		Placebo	20	19 (95.0)	0.12 (0.11)	(-0.11, 0.34)			
	Week 20	Tezepelumab	24	21 (87.5)	0.15 (0.08)	(-0.00, 0.31)	0.10 (0.11)	(-0.13, 0.33)	0.402
		Placebo	20	18 (90.0)	0.06 (0.08)	(-0.11, 0.23)			
	Week 28	Tezepelumab	24	21 (87.5)	0.08 (0.10)	(-0.12, 0.27)	0.11 (0.14)	(-0.18, 0.40)	0.434
		Placebo	20	19 (95.0)	-0.04 (0.10)	(-0.25, 0.17)			
	Week 40	Tezepelumab	24	21 (87.5)	0.17 (0.10)	(-0.03, 0.36)	0.10 (0.14)	(-0.19, 0.38)	0.488
		Placebo	20	18 (90.0)	0.07 (0.10)	(-0.14, 0.28)			
	Week 52	Tezepelumab	24	21 (87.5)	0.18 (0.09)	(-0.00, 0.36)	0.19 (0.13)	(-0.07, 0.46)	0.147
		Placebo	20	19 (95.0)	-0.01 (0.09)	(-0.20, 0.18)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 30.0 kg/m**2	Week 4	Tezepelumab	27	26 (96.3)	0.09 (0.06)	(-0.02, 0.21)	-0.02 (0.08)	(-0.19, 0.14)	0.778
		Placebo	24	24 (100.0)	0.12 (0.06)	(-0.00, 0.24)			
	Week 8	Tezepelumab	27	25 (92.6)	0.07 (0.05)	(-0.03, 0.17)	-0.09 (0.07)	(-0.23, 0.06)	0.234
		Placebo	24	23 (95.8)	0.16 (0.05)	(0.05, 0.26)			
	Week 12	Tezepelumab	27	27 (100.0)	0.17 (0.06)	(0.05, 0.28)	0.12 (0.08)	(-0.04, 0.29)	0.148
		Placebo	24	23 (95.8)	0.05 (0.06)	(-0.08, 0.17)			
	Week 20	Tezepelumab	27	24 (88.9)	0.02 (0.06)	(-0.11, 0.15)	0.01 (0.09)	(-0.18, 0.19)	0.919
		Placebo	24	22 (91.7)	0.01 (0.07)	(-0.12, 0.14)			
	Week 28	Tezepelumab	27	24 (88.9)	0.06 (0.05)	(-0.04, 0.16)	0.02 (0.07)	(-0.13, 0.16)	0.806
		Placebo	24	20 (83.3)	0.05 (0.05)	(-0.06, 0.15)			
	Week 40	Tezepelumab	27	23 (85.2)	0.04 (0.06)	(-0.08, 0.16)	-0.02 (0.09)	(-0.20, 0.16)	0.833
		Placebo	24	20 (83.3)	0.06 (0.06)	(-0.07, 0.19)			
	Week 52	Tezepelumab	27	24 (88.9)	-0.02 (0.05)	(-0.13, 0.09)	-0.03 (0.08)	(-0.18, 0.13)	0.735
		Placebo	24	21 (87.5)	0.01 (0.06)	(-0.11, 0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - Low									0.109
< 150 cells/uL	Week 4	Tezepelumab	11	11 (100.0)	0.10 (0.10)	(-0.11, 0.30)	-0.00 (0.13)	(-0.28, 0.27)	0.982
		Placebo	14	14 (100.0)	0.10 (0.09)	(-0.08, 0.28)			
	Week 8	Tezepelumab	11	10 (90.9)	0.07 (0.08)	(-0.11, 0.24)	-0.10 (0.11)	(-0.33, 0.13)	0.376
		Placebo	14	14 (100.0)	0.17 (0.07)	(0.02, 0.32)			
	Week 12	Tezepelumab	11	10 (90.9)	0.04 (0.08)	(-0.12, 0.19)	0.02 (0.10)	(-0.18, 0.23)	0.804
		Placebo	14	14 (100.0)	0.01 (0.06)	(-0.12, 0.14)			
	Week 20	Tezepelumab	11	8 (72.7)	-0.04 (0.09)	(-0.22, 0.13)	-0.13 (0.11)	(-0.35, 0.09)	0.246
		Placebo	14	14 (100.0)	0.08 (0.06)	(-0.05, 0.22)			
	Week 28	Tezepelumab	11	9 (81.8)	0.10 (0.07)	(-0.05, 0.25)	0.01 (0.10)	(-0.19, 0.21)	0.914
		Placebo	14	12 (85.7)	0.09 (0.06)	(-0.04, 0.22)			
	Week 40	Tezepelumab	11	9 (81.8)	0.01 (0.10)	(-0.20, 0.23)	-0.08 (0.14)	(-0.36, 0.20)	0.562
		Placebo	14	12 (85.7)	0.09 (0.09)	(-0.09, 0.28)			
	Week 52	Tezepelumab	11	9 (81.8)	-0.14 (0.10)	(-0.34, 0.07)	-0.20 (0.13)	(-0.46, 0.07)	0.132
		Placebo	14	13 (92.9)	0.06 (0.08)	(-0.11, 0.23)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 150 cells/uL	Week 4	Tezepelumab	54	52 (96.3)	0.28 (0.06)	(0.16, 0.41)	0.27 (0.09)	(0.09, 0.45)	0.003 *
		Placebo	51	51 (100.0)	0.01 (0.06)	(-0.11, 0.14)			
	Week 8	Tezepelumab	54	49 (90.7)	0.25 (0.06)	(0.14, 0.37)	0.19 (0.08)	(0.03, 0.36)	0.024 *
		Placebo	51	47 (92.2)	0.06 (0.06)	(-0.06, 0.18)			
	Week 12	Tezepelumab	54	51 (94.4)	0.34 (0.07)	(0.21, 0.47)	0.27 (0.09)	(0.08, 0.45)	0.005 *
		Placebo	51	49 (96.1)	0.08 (0.07)	(-0.05, 0.21)			
	Week 20	Tezepelumab	54	48 (88.9)	0.24 (0.06)	(0.12, 0.36)	0.20 (0.08)	(0.04, 0.37)	0.017 *
		Placebo	51	46 (90.2)	0.04 (0.06)	(-0.08, 0.16)			
	Week 28	Tezepelumab	54	50 (92.6)	0.24 (0.07)	(0.11, 0.37)	0.26 (0.09)	(0.07, 0.45)	0.007 *
		Placebo	51	47 (92.2)	-0.02 (0.07)	(-0.16, 0.11)			
	Week 40	Tezepelumab	54	48 (88.9)	0.28 (0.07)	(0.15, 0.41)	0.19 (0.09)	(0.00, 0.38)	0.048 *
		Placebo	51	45 (88.2)	0.09 (0.07)	(-0.05, 0.22)			
	Week 52	Tezepelumab	54	49 (90.7)	0.24 (0.07)	(0.10, 0.37)	0.22 (0.10)	(0.02, 0.41)	0.028 *
		Placebo	51	47 (92.2)	0.02 (0.07)	(-0.11, 0.16)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils - High									0.224
< 300 cells/uL	Week 4	Tezepelumab	33	33 (100.0)	0.18 (0.06)	(0.06, 0.29)	0.15 (0.08)	(-0.01, 0.31)	0.073
		Placebo	34	34 (100.0)	0.03 (0.06)	(-0.09, 0.14)			
	Week 8	Tezepelumab	33	31 (93.9)	0.16 (0.07)	(0.03, 0.30)	0.08 (0.09)	(-0.11, 0.27)	0.403
		Placebo	34	31 (91.2)	0.08 (0.07)	(-0.05, 0.22)			
	Week 12	Tezepelumab	33	32 (97.0)	0.26 (0.06)	(0.13, 0.38)	0.22 (0.09)	(0.04, 0.39)	0.016 *
		Placebo	34	32 (94.1)	0.04 (0.06)	(-0.08, 0.16)			
	Week 20	Tezepelumab	33	29 (87.9)	0.11 (0.06)	(-0.00, 0.22)	0.07 (0.08)	(-0.09, 0.22)	0.407
		Placebo	34	31 (91.2)	0.04 (0.06)	(-0.07, 0.16)			
	Week 28	Tezepelumab	33	30 (90.9)	0.14 (0.07)	(-0.00, 0.28)	0.10 (0.10)	(-0.10, 0.30)	0.335
		Placebo	34	29 (85.3)	0.04 (0.07)	(-0.10, 0.18)			
	Week 40	Tezepelumab	33	28 (84.8)	0.20 (0.07)	(0.06, 0.34)	0.09 (0.10)	(-0.10, 0.29)	0.353
		Placebo	34	28 (82.4)	0.11 (0.07)	(-0.03, 0.24)			
	Week 52	Tezepelumab	33	29 (87.9)	0.06 (0.07)	(-0.08, 0.21)	0.08 (0.10)	(-0.13, 0.28)	0.457
		Placebo	34	30 (88.2)	-0.01 (0.07)	(-0.15, 0.13)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 300 cells/uL	Week 4	Tezepelumab	32	30 (93.8)	0.33 (0.09)	(0.15, 0.52)	0.29 (0.13)	(0.03, 0.56)	0.031 *
		Placebo	31	31 (100.0)	0.04 (0.09)	(-0.15, 0.23)			
	Week 8	Tezepelumab	32	28 (87.5)	0.30 (0.08)	(0.14, 0.46)	0.21 (0.11)	(-0.01, 0.44)	0.067
		Placebo	31	30 (96.8)	0.09 (0.08)	(-0.07, 0.24)			
	Week 12	Tezepelumab	32	29 (90.6)	0.33 (0.10)	(0.13, 0.52)	0.24 (0.14)	(-0.04, 0.51)	0.088
		Placebo	31	31 (100.0)	0.09 (0.10)	(-0.10, 0.28)			
	Week 20	Tezepelumab	32	27 (84.4)	0.29 (0.09)	(0.12, 0.46)	0.23 (0.12)	(-0.01, 0.47)	0.061
		Placebo	31	29 (93.5)	0.06 (0.08)	(-0.11, 0.23)			
	Week 28	Tezepelumab	32	29 (90.6)	0.28 (0.09)	(0.10, 0.45)	0.30 (0.12)	(0.05, 0.55)	0.018 *
		Placebo	31	30 (96.8)	-0.02 (0.09)	(-0.20, 0.15)			
	Week 40	Tezepelumab	32	29 (90.6)	0.28 (0.10)	(0.09, 0.47)	0.21 (0.14)	(-0.06, 0.48)	0.123
		Placebo	31	29 (93.5)	0.07 (0.09)	(-0.12, 0.26)			
	Week 52	Tezepelumab	32	29 (90.6)	0.30 (0.10)	(0.11, 0.49)	0.23 (0.14)	(-0.04, 0.50)	0.100
		Placebo	31	30 (96.8)	0.07 (0.09)	(-0.12, 0.26)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO									0.007 i
< 25 ppb	Week 4	Tezepelumab	39	38 (97.4)	0.16 (0.06)	(0.04, 0.27)	0.03 (0.09)	(-0.15, 0.20)	0.752
		Placebo	30	30 (100.0)	0.13 (0.07)	(-0.00, 0.26)			
	Week 8	Tezepelumab	39	35 (89.7)	0.13 (0.05)	(0.03, 0.23)	-0.04 (0.07)	(-0.19, 0.11)	0.617
		Placebo	30	29 (96.7)	0.17 (0.06)	(0.06, 0.28)			
	Week 12	Tezepelumab	39	37 (94.9)	0.21 (0.06)	(0.09, 0.33)	0.08 (0.09)	(-0.10, 0.26)	0.372
		Placebo	30	29 (96.7)	0.13 (0.07)	(-0.00, 0.27)			
	Week 20	Tezepelumab	39	34 (87.2)	0.11 (0.05)	(0.00, 0.21)	-0.01 (0.08)	(-0.17, 0.15)	0.897
		Placebo	30	28 (93.3)	0.12 (0.06)	(0.00, 0.24)			
	Week 28	Tezepelumab	39	35 (89.7)	0.14 (0.06)	(0.02, 0.25)	0.07 (0.09)	(-0.10, 0.24)	0.428
		Placebo	30	27 (90.0)	0.07 (0.06)	(-0.06, 0.20)			
	Week 40	Tezepelumab	39	35 (89.7)	0.17 (0.06)	(0.06, 0.28)	0.05 (0.08)	(-0.12, 0.21)	0.594
		Placebo	30	27 (90.0)	0.12 (0.06)	(-0.00, 0.25)			
	Week 52	Tezepelumab	39	35 (89.7)	0.06 (0.06)	(-0.05, 0.17)	0.04 (0.08)	(-0.13, 0.21)	0.669
		Placebo	30	29 (96.7)	0.02 (0.06)	(-0.10, 0.15)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 25 ppb	Week 4	Tezepelumab	27	26 (96.3)	0.40 (0.09)	(0.21, 0.59)	0.46 (0.13)	(0.21, 0.71)	<0.001 *
		Placebo	34	34 (100.0)	-0.06 (0.08)	(-0.23, 0.10)			
	Week 8	Tezepelumab	27	25 (92.6)	0.36 (0.09)	(0.17, 0.55)	0.36 (0.13)	(0.10, 0.61)	0.007 *
		Placebo	34	31 (91.2)	0.00 (0.08)	(-0.16, 0.17)			
	Week 12	Tezepelumab	27	25 (92.6)	0.39 (0.10)	(0.19, 0.60)	0.40 (0.14)	(0.13, 0.67)	0.005 *
		Placebo	34	33 (97.1)	-0.01 (0.09)	(-0.19, 0.17)			
	Week 20	Tezepelumab	27	23 (85.2)	0.32 (0.09)	(0.14, 0.51)	0.35 (0.13)	(0.10, 0.60)	0.007 *
		Placebo	34	31 (91.2)	-0.03 (0.08)	(-0.19, 0.13)			
	Week 28	Tezepelumab	27	25 (92.6)	0.31 (0.10)	(0.11, 0.52)	0.37 (0.14)	(0.09, 0.65)	0.010 *
		Placebo	34	31 (91.2)	-0.06 (0.09)	(-0.24, 0.12)			
	Week 40	Tezepelumab	27	23 (85.2)	0.33 (0.11)	(0.11, 0.55)	0.27 (0.15)	(-0.02, 0.57)	0.070
		Placebo	34	29 (85.3)	0.06 (0.10)	(-0.13, 0.26)			
	Week 52	Tezepelumab	27	24 (88.9)	0.36 (0.11)	(0.14, 0.57)	0.31 (0.15)	(0.02, 0.60)	0.037 *
		Placebo	34	30 (88.2)	0.05 (0.10)	(-0.14, 0.24)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline specific perennial FEIA status									0.671
All negative	Week 4	Tezepelumab	27	27 (100.0)	0.21 (0.08)	(0.04, 0.37)	0.23 (0.11)	(0.00, 0.46)	0.047 *
		Placebo	29	29 (100.0)	-0.02 (0.08)	(-0.18, 0.13)			
	Week 8	Tezepelumab	27	26 (96.3)	0.17 (0.08)	(0.02, 0.33)	0.17 (0.11)	(-0.04, 0.39)	0.116
		Placebo	29	27 (93.1)	0.00 (0.07)	(-0.15, 0.15)			
	Week 12	Tezepelumab	27	25 (92.6)	0.23 (0.08)	(0.07, 0.40)	0.25 (0.11)	(0.03, 0.48)	0.030 *
		Placebo	29	29 (100.0)	-0.02 (0.08)	(-0.17, 0.14)			
	Week 20	Tezepelumab	27	23 (85.2)	0.19 (0.07)	(0.04, 0.33)	0.17 (0.10)	(-0.03, 0.37)	0.089
		Placebo	29	28 (96.6)	0.01 (0.07)	(-0.12, 0.15)			
	Week 28	Tezepelumab	27	24 (88.9)	0.15 (0.08)	(-0.02, 0.32)	0.26 (0.11)	(0.03, 0.49)	0.027 *
		Placebo	29	27 (93.1)	-0.11 (0.08)	(-0.27, 0.05)			
	Week 40	Tezepelumab	27	24 (88.9)	0.16 (0.09)	(-0.02, 0.33)	0.08 (0.12)	(-0.16, 0.32)	0.501
		Placebo	29	28 (96.6)	0.08 (0.08)	(-0.09, 0.24)			
	Week 52	Tezepelumab	27	24 (88.9)	0.13 (0.09)	(-0.05, 0.31)	0.12 (0.12)	(-0.13, 0.37)	0.356
		Placebo	29	28 (96.6)	0.02 (0.09)	(-0.16, 0.19)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Any positive	Week 4	Tezepelumab	34	32 (94.1)	0.27 (0.08)	(0.12, 0.43)	0.20 (0.11)	(-0.02, 0.42)	0.076
		Placebo	33	33 (100.0)	0.07 (0.08)	(-0.08, 0.23)			
	Week 8	Tezepelumab	34	30 (88.2)	0.25 (0.07)	(0.10, 0.40)	0.10 (0.11)	(-0.11, 0.31)	0.338
		Placebo	33	31 (93.9)	0.15 (0.07)	(0.00, 0.30)			
	Week 12	Tezepelumab	34	32 (94.1)	0.29 (0.08)	(0.14, 0.45)	0.17 (0.11)	(-0.05, 0.40)	0.128
		Placebo	33	31 (93.9)	0.12 (0.08)	(-0.04, 0.28)			
	Week 20	Tezepelumab	34	29 (85.3)	0.18 (0.08)	(0.03, 0.34)	0.11 (0.11)	(-0.11, 0.33)	0.319
		Placebo	33	29 (87.9)	0.07 (0.08)	(-0.08, 0.23)			
	Week 28	Tezepelumab	34	31 (91.2)	0.24 (0.08)	(0.07, 0.41)	0.13 (0.12)	(-0.11, 0.37)	0.277
		Placebo	33	29 (87.9)	0.11 (0.08)	(-0.06, 0.28)			
	Week 40	Tezepelumab	34	29 (85.3)	0.28 (0.08)	(0.11, 0.44)	0.20 (0.12)	(-0.04, 0.43)	0.097
		Placebo	33	26 (78.8)	0.08 (0.08)	(-0.09, 0.25)			
	Week 52	Tezepelumab	34	30 (88.2)	0.20 (0.08)	(0.03, 0.37)	0.19 (0.12)	(-0.05, 0.43)	0.122
		Placebo	33	29 (87.9)	0.01 (0.09)	(-0.16, 0.18)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Total serum IgE									0.540
Low	Week 4	Tezepelumab	23	23 (100.0)	0.14 (0.08)	(-0.01, 0.30)	0.06 (0.13)	(-0.19, 0.32)	0.614
		Placebo	14	14 (100.0)	0.08 (0.10)	(-0.12, 0.28)			
	Week 8	Tezepelumab	23	22 (95.7)	0.20 (0.07)	(0.06, 0.33)	0.15 (0.11)	(-0.07, 0.38)	0.171
		Placebo	14	13 (92.9)	0.04 (0.09)	(-0.14, 0.22)			
	Week 12	Tezepelumab	23	21 (91.3)	0.25 (0.09)	(0.07, 0.42)	0.28 (0.14)	(-0.00, 0.56)	0.052
		Placebo	14	14 (100.0)	-0.03 (0.11)	(-0.25, 0.19)			
	Week 20	Tezepelumab	23	20 (87.0)	0.14 (0.08)	(-0.03, 0.31)	0.16 (0.13)	(-0.11, 0.43)	0.241
		Placebo	14	14 (100.0)	-0.02 (0.10)	(-0.23, 0.19)			
	Week 28	Tezepelumab	23	20 (87.0)	0.15 (0.08)	(-0.02, 0.31)	0.26 (0.13)	(-0.00, 0.53)	0.053
		Placebo	14	13 (92.9)	-0.12 (0.10)	(-0.32, 0.09)			
	Week 40	Tezepelumab	23	20 (87.0)	0.22 (0.09)	(0.04, 0.41)	0.20 (0.15)	(-0.10, 0.50)	0.183
		Placebo	14	12 (85.7)	0.02 (0.12)	(-0.21, 0.26)			
	Week 52	Tezepelumab	23	20 (87.0)	0.11 (0.08)	(-0.04, 0.27)	0.20 (0.12)	(-0.05, 0.45)	0.107
		Placebo	14	13 (92.9)	-0.09 (0.10)	(-0.29, 0.11)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Normal	Week 4	Tezepelumab	40	39 (97.5)	0.33 (0.07)	(0.18, 0.48)	0.33 (0.10)	(0.12, 0.53)	0.002 *
		Placebo	44	44 (100.0)	0.00 (0.07)	(-0.14, 0.14)			
	Week 8	Tezepelumab	40	36 (90.0)	0.26 (0.07)	(0.12, 0.40)	0.19 (0.10)	(-0.00, 0.38)	0.055
		Placebo	44	41 (93.2)	0.07 (0.07)	(-0.07, 0.20)			
	Week 12	Tezepelumab	40	38 (95.0)	0.33 (0.07)	(0.19, 0.48)	0.27 (0.10)	(0.06, 0.47)	0.011 *
		Placebo	44	42 (95.5)	0.07 (0.07)	(-0.07, 0.21)			
	Week 20	Tezepelumab	40	35 (87.5)	0.23 (0.07)	(0.10, 0.37)	0.20 (0.10)	(0.02, 0.39)	0.035 *
		Placebo	44	39 (88.6)	0.03 (0.07)	(-0.10, 0.16)			
	Week 28	Tezepelumab	40	38 (95.0)	0.26 (0.07)	(0.11, 0.40)	0.25 (0.10)	(0.05, 0.46)	0.014 *
		Placebo	44	39 (88.6)	0.00 (0.07)	(-0.14, 0.14)			
	Week 40	Tezepelumab	40	37 (92.5)	0.25 (0.07)	(0.10, 0.39)	0.17 (0.10)	(-0.03, 0.38)	0.096
		Placebo	44	38 (86.4)	0.07 (0.07)	(-0.07, 0.22)			
	Week 52	Tezepelumab	40	37 (92.5)	0.21 (0.08)	(0.06, 0.36)	0.18 (0.10)	(-0.03, 0.39)	0.094
		Placebo	44	40 (90.9)	0.04 (0.07)	(-0.11, 0.18)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 4	Tezepelumab	3	2 (66.7)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 8	Tezepelumab	3	2 (66.7)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 12	Tezepelumab	3	3 (100.0)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 20	Tezepelumab	3	2 (66.7)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 28	Tezepelumab	3	2 (66.7)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 40	Tezepelumab	3	1 (33.3)	NE		NE		
		Placebo	7	7 (100.0)					
	Week 52	Tezepelumab	3	2 (66.7)	NE		NE		
		Placebo	7	7 (100.0)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
OCS at baseline									0.983
Yes	Week 4	Tezepelumab	9	9 (100.0)	0.33 (0.12)	(0.09, 0.57)	0.46 (0.15)	(0.15, 0.78)	0.007 *
		Placebo	13	13 (100.0)	-0.13 (0.10)	(-0.34, 0.07)			
	Week 8	Tezepelumab	9	7 (77.8)	0.35 (0.14)	(0.07, 0.64)	0.32 (0.18)	(-0.05, 0.68)	0.084
		Placebo	13	12 (92.3)	0.04 (0.11)	(-0.19, 0.27)			
	Week 12	Tezepelumab	9	8 (88.9)	0.32 (0.16)	(-0.02, 0.66)	0.34 (0.21)	(-0.10, 0.78)	0.120
		Placebo	13	12 (92.3)	-0.02 (0.13)	(-0.30, 0.26)			
	Week 20	Tezepelumab	9	8 (88.9)	0.13 (0.13)	(-0.14, 0.40)	0.07 (0.17)	(-0.28, 0.43)	0.672
		Placebo	13	12 (92.3)	0.06 (0.11)	(-0.17, 0.28)			
	Week 28	Tezepelumab	9	8 (88.9)	0.20 (0.18)	(-0.18, 0.57)	0.21 (0.24)	(-0.29, 0.70)	0.394
		Placebo	13	11 (84.6)	-0.01 (0.15)	(-0.32, 0.31)			
	Week 40	Tezepelumab	9	7 (77.8)	0.26 (0.20)	(-0.16, 0.67)	0.16 (0.26)	(-0.38, 0.70)	0.532
		Placebo	13	11 (84.6)	0.09 (0.16)	(-0.25, 0.44)			
	Week 52	Tezepelumab	9	7 (77.8)	0.30 (0.21)	(-0.14, 0.75)	0.16 (0.28)	(-0.41, 0.74)	0.563
		Placebo	13	11 (84.6)	0.14 (0.17)	(-0.22, 0.50)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	57	55 (96.5)	0.25 (0.06)	(0.13, 0.36)	0.18 (0.08)	(0.02, 0.35)	0.032 *
		Placebo	52	52 (100.0)	0.07 (0.06)	(-0.05, 0.19)			
	Week 8	Tezepelumab	57	53 (93.0)	0.22 (0.05)	(0.11, 0.32)	0.12 (0.08)	(-0.03, 0.28)	0.111
		Placebo	52	49 (94.2)	0.09 (0.06)	(-0.02, 0.20)			
	Week 12	Tezepelumab	57	54 (94.7)	0.29 (0.06)	(0.18, 0.40)	0.21 (0.08)	(0.05, 0.37)	0.013 *
		Placebo	52	51 (98.1)	0.08 (0.06)	(-0.04, 0.20)			
	Week 20	Tezepelumab	57	49 (86.0)	0.22 (0.05)	(0.11, 0.33)	0.18 (0.08)	(0.02, 0.33)	0.026 *
		Placebo	52	48 (92.3)	0.04 (0.06)	(-0.07, 0.15)			
	Week 28	Tezepelumab	57	52 (91.2)	0.21 (0.06)	(0.11, 0.32)	0.20 (0.08)	(0.04, 0.36)	0.013 *
		Placebo	52	48 (92.3)	0.01 (0.06)	(-0.10, 0.13)			
	Week 40	Tezepelumab	57	51 (89.5)	0.24 (0.06)	(0.13, 0.35)	0.15 (0.08)	(-0.02, 0.31)	0.079
		Placebo	52	46 (88.5)	0.09 (0.06)	(-0.03, 0.21)			
	Week 52	Tezepelumab	57	52 (91.2)	0.17 (0.06)	(0.05, 0.28)	0.16 (0.08)	(0.00, 0.33)	0.047 *
		Placebo	52	49 (94.2)	0.00 (0.06)	(-0.11, 0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
LAMA use at baseline									0.083
Yes	Week 4	Tezepelumab	7	7 (100.0)	0.31 (0.15)	(-0.10, 0.72)	0.82 (0.28)	(0.05, 1.60)	0.042 *
		Placebo	3	3 (100.0)	-0.51 (0.23)	(-1.15, 0.13)			
	Week 8	Tezepelumab	7	7 (100.0)	0.31 (0.18)	(-0.34, 0.96)	0.76 (0.33)	(-0.44, 1.97)	0.124
		Placebo	3	3 (100.0)	-0.45 (0.27)	(-1.46, 0.55)			
	Week 12	Tezepelumab	7	7 (100.0)	0.41 (0.20)	(-0.20, 1.02)	0.92 (0.38)	(-0.21, 2.06)	0.083
		Placebo	3	3 (100.0)	-0.51 (0.32)	(-1.45, 0.43)			
	Week 20	Tezepelumab	7	7 (100.0)	0.36 (0.16)	(-0.10, 0.82)	0.85 (0.31)	(-0.01, 1.71)	0.051
		Placebo	3	3 (100.0)	-0.49 (0.25)	(-1.20, 0.22)			
	Week 28	Tezepelumab	7	7 (100.0)	0.32 (0.18)	(-0.20, 0.84)	0.70 (0.33)	(-0.27, 1.68)	0.110
		Placebo	3	3 (100.0)	-0.39 (0.27)	(-1.19, 0.42)			
	Week 40	Tezepelumab	7	7 (100.0)	0.29 (0.21)	(-0.35, 0.92)	0.86 (0.38)	(-0.31, 2.04)	0.104
		Placebo	3	3 (100.0)	-0.58 (0.32)	(-1.56, 0.40)			
	Week 52	Tezepelumab	7	7 (100.0)	0.27 (0.15)	(-0.43, 0.97)	0.70 (0.28)	(-0.61, 2.01)	0.142
		Placebo	3	3 (100.0)	-0.43 (0.23)	(-1.52, 0.65)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	59	57 (96.6)	0.26 (0.06)	(0.15, 0.37)	0.21 (0.08)	(0.05, 0.36)	0.009 *
		Placebo	62	62 (100.0)	0.05 (0.05)	(-0.06, 0.16)			
	Week 8	Tezepelumab	59	53 (89.8)	0.23 (0.05)	(0.12, 0.33)	0.13 (0.07)	(-0.02, 0.28)	0.086
		Placebo	62	58 (93.5)	0.10 (0.05)	(-0.00, 0.20)			
	Week 12	Tezepelumab	59	55 (93.2)	0.28 (0.06)	(0.17, 0.40)	0.20 (0.08)	(0.04, 0.36)	0.014 *
		Placebo	62	60 (96.8)	0.08 (0.06)	(-0.03, 0.19)			
	Week 20	Tezepelumab	59	50 (84.7)	0.19 (0.05)	(0.08, 0.29)	0.12 (0.07)	(-0.02, 0.27)	0.096
		Placebo	62	57 (91.9)	0.06 (0.05)	(-0.04, 0.16)			
	Week 28	Tezepelumab	59	53 (89.8)	0.20 (0.06)	(0.08, 0.32)	0.18 (0.08)	(0.02, 0.35)	0.028 *
		Placebo	62	56 (90.3)	0.02 (0.06)	(-0.09, 0.13)			
	Week 40	Tezepelumab	59	51 (86.4)	0.24 (0.06)	(0.12, 0.35)	0.12 (0.08)	(-0.04, 0.28)	0.148
		Placebo	62	54 (87.1)	0.12 (0.06)	(0.00, 0.23)			
	Week 52	Tezepelumab	59	52 (88.1)	0.18 (0.06)	(0.05, 0.30)	0.13 (0.09)	(-0.04, 0.31)	0.128
		Placebo	62	57 (91.9)	0.04 (0.06)	(-0.08, 0.16)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Tiotropium use at baseline				N<10 any level					NE

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Montelukast/ Cromoglicic acid use at baseline									0.392
Yes	Week 4	Tezepelumab	17	15 (88.2)	0.39 (0.11)	(0.16, 0.62)	0.47 (0.15)	(0.17, 0.78)	0.004 *
		Placebo	21	21 (100.0)	-0.08 (0.10)	(-0.28, 0.11)			
	Week 8	Tezepelumab	17	14 (82.4)	0.33 (0.11)	(0.10, 0.56)	0.38 (0.15)	(0.07, 0.68)	0.018 *
		Placebo	21	19 (90.5)	-0.05 (0.10)	(-0.24, 0.15)			
	Week 12	Tezepelumab	17	16 (94.1)	0.40 (0.11)	(0.17, 0.63)	0.40 (0.16)	(0.08, 0.72)	0.015 *
		Placebo	21	20 (95.2)	-0.00 (0.10)	(-0.21, 0.21)			
	Week 20	Tezepelumab	17	13 (76.5)	0.27 (0.11)	(0.05, 0.50)	0.31 (0.15)	(0.01, 0.62)	0.045 *
		Placebo	21	20 (95.2)	-0.04 (0.09)	(-0.23, 0.15)			
	Week 28	Tezepelumab	17	14 (82.4)	0.30 (0.15)	(-0.01, 0.60)	0.39 (0.20)	(-0.01, 0.79)	0.058
		Placebo	21	20 (95.2)	-0.09 (0.13)	(-0.35, 0.17)			
	Week 40	Tezepelumab	17	13 (76.5)	0.41 (0.13)	(0.15, 0.67)	0.44 (0.17)	(0.09, 0.79)	0.016 *
		Placebo	21	19 (90.5)	-0.02 (0.11)	(-0.25, 0.20)			
	Week 52	Tezepelumab	17	13 (76.5)	0.28 (0.14)	(-0.00, 0.56)	0.29 (0.18)	(-0.09, 0.66)	0.129
		Placebo	21	20 (95.2)	-0.01 (0.12)	(-0.25, 0.23)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCK: Change from baseline in FEV1 Pre-BD by key subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	49	49 (100.0)	0.23 (0.06)	(0.11, 0.35)	0.17 (0.09)	(-0.00, 0.35)	0.052
		Placebo	44	44 (100.0)	0.06 (0.06)	(-0.07, 0.19)			
	Week 8	Tezepelumab	49	46 (93.9)	0.22 (0.06)	(0.11, 0.33)	0.10 (0.08)	(-0.06, 0.27)	0.226
		Placebo	44	42 (95.5)	0.12 (0.06)	(-0.00, 0.24)			
	Week 12	Tezepelumab	49	46 (93.9)	0.27 (0.06)	(0.15, 0.39)	0.20 (0.09)	(0.03, 0.38)	0.025 *
		Placebo	44	43 (97.7)	0.07 (0.06)	(-0.06, 0.19)			
	Week 20	Tezepelumab	49	44 (89.8)	0.19 (0.06)	(0.08, 0.30)	0.13 (0.08)	(-0.03, 0.29)	0.113
		Placebo	44	40 (90.9)	0.06 (0.06)	(-0.06, 0.18)			
	Week 28	Tezepelumab	49	46 (93.9)	0.19 (0.06)	(0.08, 0.31)	0.16 (0.08)	(-0.00, 0.33)	0.054
		Placebo	44	39 (88.6)	0.03 (0.06)	(-0.09, 0.15)			
	Week 40	Tezepelumab	49	45 (91.8)	0.19 (0.06)	(0.07, 0.32)	0.08 (0.09)	(-0.09, 0.26)	0.346
		Placebo	44	38 (86.4)	0.11 (0.06)	(-0.02, 0.24)			
	Week 52	Tezepelumab	49	46 (93.9)	0.16 (0.06)	(0.03, 0.29)	0.15 (0.09)	(-0.04, 0.33)	0.119
		Placebo	44	40 (90.9)	0.01 (0.07)	(-0.12, 0.15)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	1.78 (0.56)	0.7	1.39	1.73	2.15	3.1	
			Placebo	58	58 (100.0)	1.81 (0.58)	0.9	1.41	1.68	2.19	3.2	
		Week 4	Tezepelumab	60	58 (96.7)	2.03 (0.76)	0.9	1.50	1.86	2.39	4.5	
			Placebo	58	58 (100.0)	1.84 (0.63)	0.7	1.45	1.74	2.34	3.2	
		Week 8	Tezepelumab	60	54 (90.0)	1.97 (0.60)	0.7	1.51	1.94	2.37	3.4	
			Placebo	58	54 (93.1)	1.89 (0.67)	0.8	1.48	1.91	2.35	3.6	
		Week 12	Tezepelumab	60	56 (93.3)	2.09 (0.73)	0.9	1.51	2.02	2.56	4.6	
			Placebo	58	56 (96.6)	1.88 (0.73)	0.5	1.39	1.78	2.45	4.1	
		Week 20	Tezepelumab	60	51 (85.0)	1.95 (0.69)	1.0	1.45	1.75	2.38	4.1	
			Placebo	58	54 (93.1)	1.86 (0.68)	0.5	1.33	1.74	2.33	3.3	
		Week 28	Tezepelumab	60	54 (90.0)	1.96 (0.69)	0.9	1.49	1.84	2.29	4.6	
			Placebo	58	52 (89.7)	1.80 (0.68)	0.7	1.41	1.69	2.16	3.4	
		Week 40	Tezepelumab	60	53 (88.3)	1.94 (0.64)	0.9	1.43	1.94	2.33	3.5	
			Placebo	58	52 (89.7)	1.91 (0.76)	0.6	1.41	1.70	2.32	4.0	
		Week 52	Tezepelumab	60	53 (88.3)	1.89 (0.59)	0.9	1.36	1.83	2.27	3.4	
			Placebo	58	54 (93.1)	1.85 (0.76)	0.6	1.30	1.67	2.42	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	60	58 (96.7)	0.27 (0.51)	-0.6	-0.02	0.12	0.42	2.4	0.53 [0.16, 0.90]
			Placebo	58	58 (100.0)	0.03 (0.37)	-1.1	-0.15	0.02	0.17	1.1	
		Week 8	Tezepelumab	60	54 (90.0)	0.21 (0.40)	-0.5	-0.01	0.17	0.36	2.2	0.31 [-0.07, 0.69]
			Placebo	58	54 (93.1)	0.09 (0.44)	-1.5	-0.07	0.14	0.28	1.0	
		Week 12	Tezepelumab	60	56 (93.3)	0.33 (0.46)	-0.5	0.04	0.22	0.48	2.1	0.55 [0.18, 0.93]
			Placebo	58	56 (96.6)	0.08 (0.43)	-1.2	-0.12	0.05	0.30	1.3	
		Week 20	Tezepelumab	60	51 (85.0)	0.22 (0.48)	-0.6	-0.08	0.12	0.43	2.2	0.39 [0.01, 0.78]
			Placebo	58	54 (93.1)	0.06 (0.31)	-1.0	-0.03	0.07	0.23	0.8	
		Week 28	Tezepelumab	60	54 (90.0)	0.22 (0.50)	-1.0	-0.06	0.17	0.51	2.2	0.49 [0.10, 0.87]
			Placebo	58	52 (89.7)	0.01 (0.38)	-1.1	-0.18	0.05	0.25	0.9	
		Week 40	Tezepelumab	60	53 (88.3)	0.24 (0.48)	-0.7	-0.07	0.25	0.44	2.3	0.30 [-0.08, 0.68]
			Placebo	58	52 (89.7)	0.10 (0.40)	-1.1	-0.12	0.05	0.25	1.1	
		Week 52	Tezepelumab	60	53 (88.3)	0.18 (0.46)	-0.8	-0.04	0.11	0.40	2.3	0.26 [-0.12, 0.64]
			Placebo	58	54 (93.1)	0.06 (0.45)	-1.0	-0.16	0.04	0.25	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	1.46 (0.83)	0.7	1.06	1.27	1.40	3.1	
			Placebo	7	7 (100.0)	1.96 (0.35)	1.5	1.58	1.93	2.32	2.3	
		Week 4	Tezepelumab	6	6 (100.0)	1.65 (0.94)	1.1	1.12	1.31	1.51	3.5	
			Placebo	7	7 (100.0)	1.92 (0.37)	1.6	1.60	1.79	2.39	2.5	
		Week 8	Tezepelumab	6	6 (100.0)	1.65 (0.77)	1.3	1.26	1.36	1.48	3.2	
			Placebo	7	7 (100.0)	1.93 (0.34)	1.5	1.54	2.05	2.29	2.3	
		Week 12	Tezepelumab	6	6 (100.0)	1.59 (0.85)	1.0	1.21	1.30	1.45	3.3	
			Placebo	7	7 (100.0)	1.82 (0.46)	1.1	1.52	1.81	2.38	2.4	
		Week 20	Tezepelumab	6	6 (100.0)	1.57 (0.72)	1.0	1.10	1.42	1.53	3.0	
			Placebo	7	6 (85.7)	1.96 (0.38)	1.6	1.65	1.84	2.26	2.5	
		Week 28	Tezepelumab	6	6 (100.0)	1.73 (0.90)	1.2	1.26	1.33	1.70	3.5	
			Placebo	7	7 (100.0)	2.00 (0.48)	1.2	1.70	1.91	2.44	2.6	
		Week 40	Tezepelumab	6	5 (83.3)	1.75 (0.77)	1.3	1.34	1.36	1.63	3.1	
			Placebo	7	5 (71.4)	1.93 (0.41)	1.4	1.71	2.02	2.15	2.4	
		Week 52	Tezepelumab	6	6 (100.0)	1.64 (0.73)	1.2	1.25	1.34	1.66	3.1	
			Placebo	7	6 (85.7)	1.90 (0.36)	1.4	1.64	1.88	2.28	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	6	6 (100.0)	0.19 (0.20)	-0.0	0.06	0.12	0.39	0.5	0.98 [-0.18, 2.15]
			Placebo	7	7 (100.0)	-0.04 (0.25)	-0.5	-0.21	0.08	0.13	0.2	
		Week 8	Tezepelumab	6	6 (100.0)	0.19 (0.23)	-0.0	-0.03	0.19	0.31	0.6	1.23 [0.02, 2.43]
			Placebo	7	7 (100.0)	-0.03 (0.14)	-0.3	-0.06	-0.03	0.06	0.2	
		Week 12	Tezepelumab	6	6 (100.0)	0.13 (0.23)	-0.1	-0.08	0.10	0.23	0.5	0.87 [-0.28, 2.02]
			Placebo	7	7 (100.0)	-0.13 (0.34)	-0.7	-0.53	0.00	0.14	0.1	
		Week 20	Tezepelumab	6	6 (100.0)	0.11 (0.18)	-0.1	-0.06	0.11	0.22	0.4	0.66 [-0.51, 1.82]
			Placebo	7	6 (85.7)	-0.06 (0.33)	-0.7	-0.13	0.04	0.14	0.2	
		Week 28	Tezepelumab	6	6 (100.0)	0.27 (0.21)	-0.0	0.15	0.26	0.47	0.5	1.09 [-0.09, 2.27]
			Placebo	7	7 (100.0)	0.05 (0.20)	-0.3	-0.02	0.05	0.22	0.2	
		Week 40	Tezepelumab	6	5 (83.3)	0.25 (0.25)	0.0	0.05	0.23	0.25	0.7	0.93 [-0.39, 2.26]
			Placebo	7	5 (71.4)	-0.03 (0.33)	-0.5	-0.32	0.18	0.22	0.2	
		Week 52	Tezepelumab	6	6 (100.0)	0.18 (0.23)	0.0	0.01	0.08	0.26	0.6	1.09 [-0.14, 2.32]
			Placebo	7	6 (85.7)	-0.12 (0.30)	-0.6	-0.39	0.02	0.08	0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	1.29 (0.32)	0.9	1.06	1.25	1.40	1.8	
			Placebo	4	4 (100.0)	2.15 (0.48)	1.6	1.78	2.14	2.53	2.7	
		Week 4	Tezepelumab	6	6 (100.0)	1.37 (0.34)	0.9	1.12	1.39	1.70	1.7	
			Placebo	4	4 (100.0)	2.33 (0.58)	1.8	1.88	2.21	2.78	3.1	
		Week 8	Tezepelumab	6	6 (100.0)	1.44 (0.21)	1.3	1.30	1.36	1.47	1.9	
			Placebo	4	4 (100.0)	2.21 (0.65)	1.6	1.82	2.07	2.61	3.1	
		Week 12	Tezepelumab	6	6 (100.0)	1.32 (0.38)	0.9	0.97	1.26	1.71	1.8	
			Placebo	4	4 (100.0)	2.20 (0.46)	1.8	1.87	2.08	2.54	2.8	
		Week 20	Tezepelumab	6	5 (83.3)	1.33 (0.32)	1.0	1.03	1.34	1.53	1.7	
			Placebo	4	4 (100.0)	2.13 (0.73)	1.7	1.67	1.84	2.60	3.2	
		Week 28	Tezepelumab	6	5 (83.3)	1.46 (0.30)	1.1	1.27	1.40	1.70	1.8	
			Placebo	4	4 (100.0)	2.36 (0.52)	1.9	1.94	2.27	2.79	3.0	
		Week 40	Tezepelumab	6	5 (83.3)	1.45 (0.30)	1.1	1.31	1.33	1.63	1.9	
			Placebo	4	4 (100.0)	2.20 (0.72)	1.5	1.74	2.09	2.67	3.2	
		Week 52	Tezepelumab	6	5 (83.3)	1.42 (0.30)	1.2	1.16	1.34	1.66	1.8	
			Placebo	4	4 (100.0)	2.06 (0.68)	1.5	1.61	1.88	2.51	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	6	6 (100.0)	0.08 (0.17)	-0.1	-0.06	0.09	0.13	0.4	-0.60 [-1.90, 0.70]
			Placebo	4	4 (100.0)	0.18 (0.15)	0.0	0.07	0.17	0.29	0.4	
		Week 8	Tezepelumab	6	6 (100.0)	0.15 (0.31)	-0.4	-0.05	0.24	0.33	0.5	0.29 [-0.98, 1.56]
			Placebo	4	4 (100.0)	0.06 (0.30)	-0.3	-0.17	0.06	0.29	0.4	
		Week 12	Tezepelumab	6	6 (100.0)	0.03 (0.22)	-0.1	-0.09	-0.06	0.06	0.5	-0.07 [-1.34, 1.19]
			Placebo	4	4 (100.0)	0.05 (0.47)	-0.5	-0.26	0.06	0.37	0.6	
		Week 20	Tezepelumab	6	5 (83.3)	0.15 (0.16)	-0.1	0.09	0.13	0.21	0.4	0.49 [-0.85, 1.83]
			Placebo	4	4 (100.0)	-0.02 (0.49)	-0.7	-0.32	0.06	0.28	0.5	
		Week 28	Tezepelumab	6	5 (83.3)	0.29 (0.12)	0.2	0.21	0.27	0.30	0.5	0.53 [-0.82, 1.87]
			Placebo	4	4 (100.0)	0.21 (0.16)	-0.0	0.11	0.26	0.32	0.3	
		Week 40	Tezepelumab	6	5 (83.3)	0.27 (0.13)	0.2	0.20	0.23	0.25	0.5	0.85 [-0.54, 2.24]
			Placebo	4	4 (100.0)	0.05 (0.36)	-0.3	-0.25	0.02	0.35	0.5	
		Week 52	Tezepelumab	6	5 (83.3)	0.24 (0.18)	0.0	0.09	0.26	0.40	0.4	1.18 [-0.28, 2.63]
			Placebo	4	4 (100.0)	-0.09 (0.38)	-0.6	-0.38	-0.05	0.19	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	1.80 (0.59)	0.7	1.39	1.73	2.19	3.1	
			Placebo	61	61 (100.0)	1.80 (0.57)	0.9	1.41	1.69	2.19	3.2	
		Week 4	Tezepelumab	60	58 (96.7)	2.06 (0.79)	0.9	1.48	1.92	2.40	4.5	
			Placebo	61	61 (100.0)	1.82 (0.60)	0.7	1.48	1.68	2.27	3.2	
		Week 8	Tezepelumab	60	54 (90.0)	2.00 (0.62)	0.7	1.51	1.95	2.37	3.4	
			Placebo	61	57 (93.4)	1.87 (0.64)	0.8	1.48	1.88	2.29	3.6	
		Week 12	Tezepelumab	60	56 (93.3)	2.12 (0.74)	1.1	1.51	2.04	2.63	4.6	
			Placebo	61	59 (96.7)	1.85 (0.71)	0.5	1.37	1.75	2.40	4.1	
		Week 20	Tezepelumab	60	52 (86.7)	1.97 (0.69)	1.0	1.46	1.79	2.42	4.1	
			Placebo	61	56 (91.8)	1.85 (0.65)	0.5	1.36	1.74	2.33	3.3	
		Week 28	Tezepelumab	60	55 (91.7)	1.98 (0.72)	0.9	1.45	1.84	2.36	4.6	
			Placebo	61	55 (90.2)	1.79 (0.65)	0.7	1.40	1.69	2.21	3.4	
		Week 40	Tezepelumab	60	53 (88.3)	1.97 (0.65)	0.9	1.43	1.99	2.36	3.5	
			Placebo	61	53 (86.9)	1.89 (0.74)	0.6	1.39	1.71	2.29	4.0	
		Week 52	Tezepelumab	60	54 (90.0)	1.90 (0.61)	0.9	1.36	1.85	2.34	3.4	
			Placebo	61	56 (91.8)	1.84 (0.74)	0.6	1.31	1.67	2.31	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	60	58 (96.7)	0.28 (0.50)	-0.6	0.01	0.13	0.45	2.4	0.60 [0.24, 0.97]
			Placebo	61	61 (100.0)	0.02 (0.37)	-1.1	-0.16	0.02	0.16	1.1	
		Week 8	Tezepelumab	60	54 (90.0)	0.22 (0.39)	-0.5	-0.01	0.16	0.36	2.2	0.36 [-0.02, 0.73]
			Placebo	61	57 (93.4)	0.07 (0.42)	-1.5	-0.06	0.13	0.24	1.0	
		Week 12	Tezepelumab	60	56 (93.3)	0.34 (0.46)	-0.5	0.05	0.23	0.50	2.1	0.64 [0.26, 1.01]
			Placebo	61	59 (96.7)	0.06 (0.43)	-1.2	-0.12	0.04	0.28	1.3	
		Week 20	Tezepelumab	60	52 (86.7)	0.21 (0.47)	-0.6	-0.08	0.11	0.42	2.2	0.40 [0.02, 0.78]
			Placebo	61	56 (91.8)	0.06 (0.30)	-1.0	-0.04	0.07	0.23	0.8	
		Week 28	Tezepelumab	60	55 (91.7)	0.22 (0.50)	-1.0	-0.06	0.16	0.52	2.2	0.51 [0.13, 0.89]
			Placebo	61	55 (90.2)	-0.00 (0.37)	-1.1	-0.18	0.03	0.22	0.9	
		Week 40	Tezepelumab	60	53 (88.3)	0.23 (0.48)	-0.7	-0.07	0.25	0.44	2.3	0.31 [-0.07, 0.70]
			Placebo	61	53 (86.9)	0.09 (0.40)	-1.1	-0.11	0.06	0.23	1.1	
		Week 52	Tezepelumab	60	54 (90.0)	0.17 (0.45)	-0.8	-0.04	0.11	0.40	2.3	0.27 [-0.11, 0.64]
			Placebo	61	56 (91.8)	0.05 (0.44)	-1.0	-0.16	0.04	0.18	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	30	30 (100.0)	1.72 (0.53)	0.7	1.34	1.60	2.07	3.0	
			Placebo	29	29 (100.0)	1.84 (0.60)	1.0	1.43	1.67	2.17	3.2	
		Week 4	Tezepelumab	30	30 (100.0)	1.99 (0.84)	0.9	1.41	1.79	2.39	4.5	
			Placebo	29	29 (100.0)	1.93 (0.60)	0.9	1.55	1.76	2.45	3.2	
		Week 8	Tezepelumab	30	27 (90.0)	1.88 (0.57)	1.0	1.40	1.74	2.37	3.3	
			Placebo	29	28 (96.6)	1.95 (0.72)	0.8	1.51	1.94	2.40	3.6	
		Week 12	Tezepelumab	30	29 (96.7)	2.00 (0.81)	1.0	1.45	1.82	2.44	4.6	
			Placebo	29	28 (96.6)	1.87 (0.61)	0.9	1.48	1.77	2.34	3.3	
		Week 20	Tezepelumab	30	28 (93.3)	1.94 (0.76)	1.0	1.42	1.70	2.38	4.1	
			Placebo	29	26 (89.7)	1.89 (0.67)	0.9	1.38	1.80	2.33	3.3	
		Week 28	Tezepelumab	30	29 (96.7)	1.93 (0.77)	0.9	1.39	1.70	2.15	4.6	
			Placebo	29	25 (86.2)	1.82 (0.68)	0.8	1.35	1.69	2.08	3.4	
		Week 40	Tezepelumab	30	27 (90.0)	1.88 (0.62)	0.9	1.31	1.78	2.33	3.5	
			Placebo	29	25 (86.2)	1.91 (0.70)	0.9	1.58	1.71	2.24	3.5	
		Week 52	Tezepelumab	30	28 (93.3)	1.77 (0.59)	1.0	1.29	1.64	2.26	3.4	
			Placebo	29	25 (86.2)	1.86 (0.68)	0.8	1.50	1.72	2.42	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	30	30 (100.0)	0.27 (0.62)	-0.6	-0.04	0.08	0.39	2.4	0.35 [-0.16, 0.87]
			Placebo	29	29 (100.0)	0.09 (0.39)	-1.0	-0.10	0.09	0.14	1.1	
		Week 8	Tezepelumab	30	27 (90.0)	0.20 (0.46)	-0.5	-0.04	0.10	0.32	2.2	0.17 [-0.36, 0.70]
			Placebo	29	28 (96.6)	0.12 (0.49)	-1.5	-0.06	0.15	0.37	1.0	
		Week 12	Tezepelumab	30	29 (96.7)	0.32 (0.58)	-0.5	-0.04	0.15	0.49	2.1	0.57 [0.04, 1.10]
			Placebo	29	28 (96.6)	0.04 (0.39)	-0.9	-0.14	0.04	0.24	0.9	
		Week 20	Tezepelumab	30	28 (93.3)	0.23 (0.54)	-0.6	-0.09	0.10	0.44	2.2	0.34 [-0.20, 0.87]
			Placebo	29	26 (89.7)	0.08 (0.31)	-0.6	-0.05	0.10	0.23	0.8	
		Week 28	Tezepelumab	30	29 (96.7)	0.24 (0.55)	-0.6	-0.06	0.09	0.44	2.2	0.49 [-0.06, 1.03]
			Placebo	29	25 (86.2)	0.01 (0.37)	-1.1	-0.18	0.02	0.23	0.9	
		Week 40	Tezepelumab	30	27 (90.0)	0.23 (0.56)	-0.5	-0.08	0.23	0.40	2.3	0.27 [-0.28, 0.82]
			Placebo	29	25 (86.2)	0.11 (0.32)	-0.5	-0.02	0.21	0.24	1.0	
		Week 52	Tezepelumab	30	28 (93.3)	0.13 (0.52)	-0.8	-0.06	0.06	0.26	2.3	0.16 [-0.38, 0.70]
			Placebo	29	25 (86.2)	0.06 (0.44)	-1.0	-0.11	0.07	0.25	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	36	36 (100.0)	1.78 (0.64)	0.7	1.33	1.68	2.35	3.1	
			Placebo	36	36 (100.0)	1.81 (0.54)	0.9	1.43	1.73	2.25	3.1	
		Week 4	Tezepelumab	36	34 (94.4)	2.00 (0.74)	0.9	1.53	1.92	2.26	3.5	
			Placebo	36	36 (100.0)	1.79 (0.61)	0.7	1.44	1.70	2.24	3.0	
		Week 8	Tezepelumab	36	33 (91.7)	1.99 (0.66)	0.7	1.49	1.96	2.36	3.4	
			Placebo	36	33 (91.7)	1.85 (0.56)	0.8	1.58	1.93	2.28	2.7	
		Week 12	Tezepelumab	36	33 (91.7)	2.08 (0.70)	0.9	1.51	2.00	2.55	3.5	
			Placebo	36	35 (97.2)	1.88 (0.77)	0.5	1.37	1.81	2.40	4.1	
		Week 20	Tezepelumab	36	29 (80.6)	1.89 (0.64)	1.0	1.39	1.74	2.37	3.3	
			Placebo	36	34 (94.4)	1.85 (0.65)	0.5	1.53	1.73	2.28	3.1	
		Week 28	Tezepelumab	36	31 (86.1)	1.94 (0.66)	1.0	1.42	1.84	2.36	3.5	
			Placebo	36	34 (94.4)	1.83 (0.65)	0.7	1.53	1.77	2.27	3.4	
		Week 40	Tezepelumab	36	31 (86.1)	1.97 (0.67)	1.0	1.34	1.94	2.52	3.3	
			Placebo	36	32 (88.9)	1.92 (0.78)	0.6	1.37	1.98	2.33	4.0	
		Week 52	Tezepelumab	36	31 (86.1)	1.95 (0.61)	0.9	1.36	1.86	2.34	3.2	
			Placebo	36	35 (97.2)	1.85 (0.78)	0.6	1.32	1.64	2.31	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	36	34 (94.4)	0.26 (0.33)	-0.5	0.03	0.18	0.45	1.0	0.83 [0.34, 1.32]
			Placebo	36	36 (100.0)	-0.02 (0.34)	-1.1	-0.20	-0.01	0.17	0.7	
		Week 8	Tezepelumab	36	33 (91.7)	0.22 (0.31)	-0.5	0.04	0.18	0.44	0.8	0.58 [0.09, 1.07]
			Placebo	36	33 (91.7)	0.03 (0.34)	-0.9	-0.06	0.08	0.20	0.8	
		Week 12	Tezepelumab	36	33 (91.7)	0.30 (0.30)	-0.2	0.06	0.23	0.45	0.9	0.59 [0.10, 1.07]
			Placebo	36	35 (97.2)	0.07 (0.46)	-1.2	-0.11	0.08	0.31	1.3	
		Week 20	Tezepelumab	36	29 (80.6)	0.18 (0.36)	-0.6	-0.07	0.12	0.38	0.9	0.47 [-0.03, 0.98]
			Placebo	36	34 (94.4)	0.02 (0.31)	-1.0	-0.03	0.07	0.22	0.5	
		Week 28	Tezepelumab	36	31 (86.1)	0.22 (0.41)	-1.0	-0.03	0.27	0.51	0.9	0.52 [0.03, 1.02]
			Placebo	36	34 (94.4)	0.01 (0.37)	-1.1	-0.05	0.06	0.21	0.9	
		Week 40	Tezepelumab	36	31 (86.1)	0.24 (0.36)	-0.7	0.04	0.26	0.50	1.0	0.40 [-0.10, 0.89]
			Placebo	36	32 (88.9)	0.08 (0.44)	-1.1	-0.16	0.01	0.18	1.1	
		Week 52	Tezepelumab	36	31 (86.1)	0.22 (0.35)	-0.7	0.01	0.15	0.53	0.8	0.46 [-0.03, 0.95]
			Placebo	36	35 (97.2)	0.04 (0.44)	-0.7	-0.22	-0.01	0.16	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	38	38 (100.0)	1.75 (0.55)	0.7	1.40	1.73	2.08	3.1	
			Placebo	30	30 (100.0)	1.63 (0.55)	0.9	1.29	1.54	1.93	2.9	
		Week 4	Tezepelumab	38	37 (97.4)	1.89 (0.70)	0.9	1.41	1.81	2.26	3.8	
			Placebo	30	30 (100.0)	1.76 (0.63)	0.7	1.30	1.62	2.27	3.1	
		Week 8	Tezepelumab	38	34 (89.5)	1.89 (0.60)	0.7	1.40	1.85	2.35	3.4	
			Placebo	30	29 (96.7)	1.78 (0.67)	0.8	1.36	1.71	2.22	3.4	
		Week 12	Tezepelumab	38	36 (94.7)	1.98 (0.65)	0.9	1.48	1.97	2.45	3.5	
			Placebo	30	29 (96.7)	1.74 (0.65)	0.6	1.22	1.68	2.21	3.3	
		Week 20	Tezepelumab	38	33 (86.8)	1.81 (0.59)	1.0	1.37	1.68	2.30	2.9	
			Placebo	30	28 (93.3)	1.72 (0.65)	0.5	1.27	1.69	2.08	3.2	
		Week 28	Tezepelumab	38	34 (89.5)	1.82 (0.51)	0.9	1.49	1.76	2.15	3.0	
			Placebo	30	27 (90.0)	1.68 (0.64)	0.7	1.12	1.66	2.01	3.4	
		Week 40	Tezepelumab	38	34 (89.5)	1.86 (0.59)	0.9	1.31	1.91	2.33	3.0	
			Placebo	30	27 (90.0)	1.75 (0.67)	0.8	1.20	1.65	2.15	3.5	
		Week 52	Tezepelumab	38	34 (89.5)	1.75 (0.51)	0.9	1.34	1.75	2.25	2.9	
			Placebo	30	29 (96.7)	1.63 (0.64)	0.6	1.26	1.64	1.90	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	38	37 (97.4)	0.17 (0.38)	-0.6	-0.04	0.10	0.32	1.7	0.10 [-0.38, 0.58]
			Placebo	30	30 (100.0)	0.13 (0.34)	-0.3	-0.12	0.09	0.20	1.1	
		Week 8	Tezepelumab	38	34 (89.5)	0.12 (0.25)	-0.5	-0.04	0.10	0.31	0.8	-0.16 [-0.65, 0.34]
			Placebo	30	29 (96.7)	0.17 (0.35)	-0.6	-0.01	0.13	0.20	1.0	
		Week 12	Tezepelumab	38	36 (94.7)	0.23 (0.37)	-0.5	-0.04	0.19	0.35	1.3	0.26 [-0.23, 0.75]
			Placebo	30	29 (96.7)	0.13 (0.37)	-0.4	-0.05	0.05	0.23	1.3	
		Week 20	Tezepelumab	38	33 (86.8)	0.11 (0.35)	-0.6	-0.10	0.08	0.27	0.9	0.04 [-0.46, 0.55]
			Placebo	30	28 (93.3)	0.10 (0.25)	-0.4	-0.02	0.06	0.22	0.8	
		Week 28	Tezepelumab	38	34 (89.5)	0.14 (0.35)	-0.7	-0.06	0.13	0.30	0.9	0.24 [-0.27, 0.74]
			Placebo	30	27 (90.0)	0.06 (0.34)	-1.1	-0.12	0.11	0.23	0.9	
		Week 40	Tezepelumab	38	34 (89.5)	0.17 (0.37)	-0.5	-0.05	0.16	0.35	1.1	0.22 [-0.29, 0.72]
			Placebo	30	27 (90.0)	0.10 (0.29)	-0.3	-0.14	0.15	0.24	1.0	
		Week 52	Tezepelumab	38	34 (89.5)	0.07 (0.33)	-0.8	-0.05	0.09	0.26	0.8	0.13 [-0.37, 0.62]
			Placebo	30	29 (96.7)	0.02 (0.35)	-1.0	-0.15	0.06	0.17	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	28	28 (100.0)	1.76 (0.64)	0.7	1.28	1.55	2.35	3.1	
			Placebo	34	34 (100.0)	1.98 (0.54)	1.1	1.50	1.88	2.32	3.2	
		Week 4	Tezepelumab	28	27 (96.4)	2.13 (0.87)	1.1	1.53	1.82	2.47	4.5	
			Placebo	34	34 (100.0)	1.91 (0.58)	0.7	1.63	1.78	2.37	3.2	
		Week 8	Tezepelumab	28	26 (92.9)	2.02 (0.65)	1.3	1.49	1.89	2.39	3.3	
			Placebo	34	31 (91.2)	1.98 (0.61)	0.8	1.60	2.05	2.37	3.6	
		Week 12	Tezepelumab	28	26 (92.9)	2.13 (0.87)	1.1	1.51	1.85	2.75	4.6	
			Placebo	34	33 (97.1)	1.97 (0.74)	0.5	1.52	1.85	2.46	4.1	
		Week 20	Tezepelumab	28	24 (85.7)	2.05 (0.81)	1.0	1.46	1.75	2.60	4.1	
			Placebo	34	31 (91.2)	1.98 (0.65)	0.7	1.55	1.94	2.42	3.3	
		Week 28	Tezepelumab	28	26 (92.9)	2.08 (0.90)	1.0	1.39	1.75	2.61	4.6	
			Placebo	34	31 (91.2)	1.93 (0.66)	0.8	1.58	1.80	2.38	3.4	
		Week 40	Tezepelumab	28	24 (85.7)	2.02 (0.72)	1.1	1.40	1.90	2.50	3.5	
			Placebo	34	29 (85.3)	2.05 (0.78)	0.6	1.52	2.02	2.35	4.0	
		Week 52	Tezepelumab	28	25 (89.3)	2.01 (0.69)	1.2	1.36	1.92	2.34	3.4	
			Placebo	34	30 (88.2)	2.04 (0.78)	1.0	1.40	1.90	2.59	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	28	27 (96.4)	0.40 (0.58)	-0.5	0.02	0.26	0.66	2.4	0.99 [0.46, 1.53]
			Placebo	34	34 (100.0)	-0.07 (0.36)	-1.1	-0.21	0.00	0.13	0.7	
		Week 8	Tezepelumab	28	26 (92.9)	0.33 (0.49)	-0.5	0.09	0.31	0.49	2.2	0.76 [0.22, 1.30]
			Placebo	34	31 (91.2)	-0.03 (0.45)	-1.5	-0.17	-0.02	0.27	0.6	
		Week 12	Tezepelumab	28	26 (92.9)	0.42 (0.52)	-0.2	0.04	0.32	0.61	2.1	0.89 [0.35, 1.43]
			Placebo	34	33 (97.1)	-0.02 (0.47)	-1.2	-0.23	0.02	0.31	1.0	
		Week 20	Tezepelumab	28	24 (85.7)	0.34 (0.55)	-0.4	-0.03	0.22	0.46	2.2	0.76 [0.21, 1.32]
			Placebo	34	31 (91.2)	0.00 (0.35)	-1.0	-0.13	0.08	0.23	0.6	
		Week 28	Tezepelumab	28	26 (92.9)	0.35 (0.60)	-1.0	0.01	0.24	0.53	2.2	0.77 [0.23, 1.31]
			Placebo	34	31 (91.2)	-0.04 (0.39)	-1.1	-0.25	0.00	0.20	0.9	
		Week 40	Tezepelumab	28	24 (85.7)	0.32 (0.56)	-0.7	-0.04	0.32	0.54	2.3	0.47 [-0.08, 1.02]
			Placebo	34	29 (85.3)	0.08 (0.48)	-1.1	-0.12	0.02	0.21	1.1	
		Week 52	Tezepelumab	28	25 (89.3)	0.33 (0.52)	-0.3	0.01	0.16	0.61	2.3	0.53 [-0.01, 1.08]
			Placebo	34	30 (88.2)	0.06 (0.51)	-0.9	-0.22	-0.02	0.26	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	1.84 (0.51)	0.7	1.45	1.79	2.10	3.1	
			Placebo	27	27 (100.0)	1.60 (0.55)	0.9	1.20	1.48	1.93	2.9	
		Week 4	Tezepelumab	32	31 (96.9)	1.95 (0.69)	0.9	1.46	1.82	2.29	3.8	
			Placebo	27	27 (100.0)	1.74 (0.65)	0.7	1.17	1.59	2.27	3.1	
		Week 8	Tezepelumab	32	29 (90.6)	1.95 (0.55)	1.0	1.44	1.94	2.35	3.4	
			Placebo	27	26 (96.3)	1.74 (0.62)	0.8	1.22	1.77	2.22	3.1	
		Week 12	Tezepelumab	32	30 (93.8)	2.03 (0.61)	1.0	1.51	2.04	2.37	3.5	
			Placebo	27	26 (96.3)	1.67 (0.59)	0.6	1.20	1.65	2.12	2.8	
		Week 20	Tezepelumab	32	28 (87.5)	1.84 (0.54)	1.0	1.42	1.70	2.34	2.8	
			Placebo	27	25 (92.6)	1.68 (0.64)	0.5	1.21	1.68	2.03	3.2	
		Week 28	Tezepelumab	32	28 (87.5)	1.84 (0.47)	0.9	1.49	1.79	2.22	2.7	
			Placebo	27	24 (88.9)	1.60 (0.56)	0.7	1.12	1.62	2.00	3.0	
		Week 40	Tezepelumab	32	28 (87.5)	1.88 (0.54)	0.9	1.40	1.94	2.32	3.0	
			Placebo	27	24 (88.9)	1.69 (0.60)	0.8	1.16	1.67	2.05	3.2	
		Week 52	Tezepelumab	32	28 (87.5)	1.80 (0.45)	1.0	1.37	1.82	2.26	2.4	
			Placebo	27	26 (96.3)	1.57 (0.55)	0.6	1.08	1.64	1.90	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	32	31 (96.9)	0.14 (0.39)	-0.6	-0.06	0.09	0.25	1.7	0.01 [-0.51, 0.53]
			Placebo	27	27 (100.0)	0.14 (0.35)	-0.3	-0.12	0.10	0.25	1.1	
		Week 8	Tezepelumab	32	29 (90.6)	0.11 (0.26)	-0.5	-0.04	0.10	0.31	0.8	-0.16 [-0.69, 0.37]
			Placebo	27	26 (96.3)	0.16 (0.34)	-0.6	-0.01	0.14	0.20	1.0	
		Week 12	Tezepelumab	32	30 (93.8)	0.18 (0.34)	-0.5	-0.04	0.16	0.32	1.1	0.27 [-0.26, 0.79]
			Placebo	27	26 (96.3)	0.09 (0.35)	-0.4	-0.09	0.03	0.16	1.3	
		Week 20	Tezepelumab	32	28 (87.5)	0.07 (0.34)	-0.6	-0.11	0.05	0.23	0.9	-0.06 [-0.59, 0.48]
			Placebo	27	25 (92.6)	0.09 (0.26)	-0.4	-0.02	0.06	0.22	0.8	
		Week 28	Tezepelumab	32	28 (87.5)	0.08 (0.34)	-0.7	-0.11	0.04	0.27	0.9	0.17 [-0.38, 0.71]
			Placebo	27	24 (88.9)	0.02 (0.30)	-1.1	-0.10	0.09	0.22	0.4	
		Week 40	Tezepelumab	32	28 (87.5)	0.11 (0.33)	-0.5	-0.08	0.14	0.32	1.0	0.12 [-0.43, 0.66]
			Placebo	27	24 (88.9)	0.08 (0.23)	-0.3	-0.08	0.15	0.24	0.5	
		Week 52	Tezepelumab	32	28 (87.5)	0.03 (0.33)	-0.8	-0.06	0.08	0.21	0.8	0.12 [-0.42, 0.65]
			Placebo	27	26 (96.3)	-0.01 (0.31)	-1.0	-0.15	0.05	0.17	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	34	34 (100.0)	1.67 (0.65)	0.7	1.16	1.48	2.31	3.1	
			Placebo	37	37 (100.0)	1.97 (0.53)	1.1	1.56	1.85	2.32	3.2	
		Week 4	Tezepelumab	34	33 (97.1)	2.03 (0.87)	0.9	1.44	1.73	2.46	4.5	
			Placebo	37	37 (100.0)	1.91 (0.58)	0.7	1.63	1.79	2.37	3.2	
		Week 8	Tezepelumab	34	31 (91.2)	1.94 (0.68)	0.7	1.47	1.74	2.39	3.3	
			Placebo	37	34 (91.9)	2.00 (0.64)	0.8	1.59	2.03	2.37	3.6	
		Week 12	Tezepelumab	34	32 (94.1)	2.06 (0.87)	0.9	1.41	1.76	2.73	4.6	
			Placebo	37	36 (97.3)	2.01 (0.74)	0.5	1.53	1.86	2.48	4.1	
		Week 20	Tezepelumab	34	29 (85.3)	1.98 (0.82)	1.0	1.39	1.74	2.37	4.1	
			Placebo	37	34 (91.9)	1.99 (0.65)	0.7	1.55	1.90	2.42	3.3	
		Week 28	Tezepelumab	34	32 (94.1)	2.01 (0.87)	1.0	1.37	1.73	2.45	4.6	
			Placebo	37	34 (91.9)	1.96 (0.68)	0.8	1.58	1.89	2.38	3.4	
		Week 40	Tezepelumab	34	30 (88.2)	1.97 (0.73)	1.0	1.33	1.90	2.50	3.5	
			Placebo	37	32 (86.5)	2.07 (0.80)	0.6	1.49	2.02	2.44	4.0	
		Week 52	Tezepelumab	34	31 (91.2)	1.92 (0.71)	0.9	1.31	1.80	2.34	3.4	
			Placebo	37	33 (89.2)	2.06 (0.79)	1.0	1.40	1.75	2.59	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	34	33 (97.1)	0.38 (0.54)	-0.5	0.03	0.26	0.62	2.4	0.97 [0.48, 1.47]
			Placebo	37	37 (100.0)	-0.06 (0.35)	-1.1	-0.19	0.00	0.13	0.7	
		Week 8	Tezepelumab	34	31 (91.2)	0.31 (0.45)	-0.5	0.09	0.33	0.48	2.2	0.68 [0.18, 1.18]
			Placebo	37	34 (91.9)	0.00 (0.46)	-1.5	-0.15	0.01	0.27	0.9	
		Week 12	Tezepelumab	34	32 (94.1)	0.43 (0.50)	-0.2	0.05	0.37	0.59	2.1	0.82 [0.32, 1.31]
			Placebo	37	36 (97.3)	0.03 (0.48)	-1.2	-0.23	0.05	0.32	1.0	
		Week 20	Tezepelumab	34	29 (85.3)	0.34 (0.52)	-0.4	0.02	0.22	0.49	2.2	0.75 [0.24, 1.27]
			Placebo	37	34 (91.9)	0.01 (0.34)	-1.0	-0.08	0.07	0.23	0.6	
		Week 28	Tezepelumab	34	32 (94.1)	0.36 (0.55)	-1.0	0.06	0.33	0.57	2.2	0.76 [0.26, 1.26]
			Placebo	37	34 (91.9)	-0.00 (0.41)	-1.1	-0.18	0.02	0.23	0.9	
		Week 40	Tezepelumab	34	30 (88.2)	0.35 (0.54)	-0.7	-0.02	0.35	0.54	2.3	0.50 [-0.01, 1.00]
			Placebo	37	32 (86.5)	0.10 (0.49)	-1.1	-0.14	0.03	0.35	1.1	
		Week 52	Tezepelumab	34	31 (91.2)	0.32 (0.48)	-0.3	0.01	0.28	0.57	2.3	0.47 [-0.03, 0.97]
			Placebo	37	33 (89.2)	0.08 (0.52)	-0.9	-0.16	0.01	0.26	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	25	25 (100.0)	1.80 (0.61)	0.7	1.41	1.87	2.17	3.1	
			Placebo	22	22 (100.0)	1.87 (0.64)	0.9	1.41	1.72	2.27	3.2	
		Week 4	Tezepelumab	25	25 (100.0)	2.00 (0.77)	0.9	1.48	1.82	2.29	3.8	
			Placebo	22	22 (100.0)	1.86 (0.79)	0.7	1.30	1.68	2.59	3.2	
		Week 8	Tezepelumab	25	24 (96.0)	2.00 (0.66)	0.7	1.48	2.03	2.41	3.4	
			Placebo	22	20 (90.9)	1.87 (0.83)	0.8	1.11	1.77	2.55	3.6	
		Week 12	Tezepelumab	25	23 (92.0)	2.06 (0.70)	1.1	1.51	2.08	2.55	3.5	
			Placebo	22	22 (100.0)	1.79 (0.67)	0.5	1.37	1.77	2.24	2.8	
		Week 20	Tezepelumab	25	21 (84.0)	1.88 (0.56)	1.0	1.45	1.86	2.38	2.8	
			Placebo	22	21 (95.5)	1.86 (0.75)	0.5	1.53	1.72	2.35	3.3	
		Week 28	Tezepelumab	25	22 (88.0)	1.89 (0.63)	0.9	1.45	1.81	2.44	3.0	
			Placebo	22	20 (90.9)	1.78 (0.72)	0.7	1.33	1.73	2.18	3.3	
		Week 40	Tezepelumab	25	22 (88.0)	1.90 (0.63)	0.9	1.43	1.97	2.33	3.0	
			Placebo	22	21 (95.5)	1.91 (0.81)	0.6	1.20	1.79	2.38	3.4	
		Week 52	Tezepelumab	25	22 (88.0)	1.87 (0.64)	1.0	1.33	1.81	2.37	3.2	
			Placebo	22	21 (95.5)	1.84 (0.79)	0.6	1.25	1.72	2.42	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	25	25 (100.0)	0.20 (0.45)	-0.6	0.01	0.13	0.26	1.7	0.46 [-0.12, 1.04]
			Placebo	22	22 (100.0)	-0.00 (0.44)	-1.1	-0.22	0.00	0.29	0.7	
		Week 8	Tezepelumab	25	24 (96.0)	0.16 (0.28)	-0.5	-0.02	0.10	0.34	0.8	0.45 [-0.15, 1.06]
			Placebo	22	20 (90.9)	-0.02 (0.51)	-1.5	-0.14	0.13	0.33	0.5	
		Week 12	Tezepelumab	25	23 (92.0)	0.25 (0.38)	-0.5	-0.03	0.21	0.47	1.1	0.84 [0.23, 1.45]
			Placebo	22	22 (100.0)	-0.07 (0.40)	-1.2	-0.17	-0.02	0.24	0.4	
		Week 20	Tezepelumab	25	21 (84.0)	0.17 (0.35)	-0.4	-0.08	0.06	0.35	0.9	0.39 [-0.22, 1.00]
			Placebo	22	21 (95.5)	0.03 (0.35)	-1.0	-0.03	0.01	0.23	0.5	
		Week 28	Tezepelumab	25	22 (88.0)	0.15 (0.36)	-0.6	-0.10	0.09	0.29	0.9	0.55 [-0.07, 1.17]
			Placebo	22	20 (90.9)	-0.06 (0.39)	-1.1	-0.24	0.07	0.27	0.3	
		Week 40	Tezepelumab	25	22 (88.0)	0.15 (0.35)	-0.5	-0.08	0.14	0.35	1.0	0.17 [-0.43, 0.77]
			Placebo	22	21 (95.5)	0.08 (0.49)	-1.1	-0.19	0.04	0.35	1.1	
		Week 52	Tezepelumab	25	22 (88.0)	0.13 (0.39)	-0.8	-0.05	0.16	0.36	0.8	0.24 [-0.36, 0.84]
			Placebo	22	21 (95.5)	0.02 (0.51)	-1.0	-0.16	-0.05	0.26	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	35	35 (100.0)	1.77 (0.61)	0.7	1.29	1.68	2.31	3.1	
			Placebo	41	41 (100.0)	1.81 (0.54)	0.9	1.43	1.71	2.21	3.1	
		Week 4	Tezepelumab	35	33 (94.3)	2.01 (0.82)	0.9	1.50	1.78	2.20	4.5	
			Placebo	41	41 (100.0)	1.84 (0.51)	0.8	1.55	1.79	2.27	2.9	
		Week 8	Tezepelumab	35	31 (88.6)	1.93 (0.62)	1.1	1.47	1.85	2.37	3.3	
			Placebo	41	39 (95.1)	1.92 (0.54)	0.8	1.58	2.00	2.29	3.4	
		Week 12	Tezepelumab	35	33 (94.3)	2.05 (0.79)	0.9	1.48	1.88	2.44	4.6	
			Placebo	41	39 (95.1)	1.94 (0.73)	0.6	1.48	1.81	2.44	4.1	
		Week 20	Tezepelumab	35	30 (85.7)	1.95 (0.79)	1.0	1.46	1.65	2.37	4.1	
			Placebo	41	37 (90.2)	1.89 (0.61)	0.6	1.51	1.86	2.32	3.1	
		Week 28	Tezepelumab	35	32 (91.4)	1.99 (0.80)	1.0	1.46	1.76	2.24	4.6	
			Placebo	41	37 (90.2)	1.86 (0.64)	0.8	1.44	1.70	2.24	3.4	
		Week 40	Tezepelumab	35	30 (85.7)	1.97 (0.67)	1.1	1.36	1.87	2.20	3.5	
			Placebo	41	34 (82.9)	1.93 (0.71)	0.9	1.50	1.71	2.24	4.0	
		Week 52	Tezepelumab	35	31 (88.6)	1.88 (0.60)	0.9	1.36	1.80	2.17	3.4	
			Placebo	41	37 (90.2)	1.87 (0.72)	0.7	1.40	1.70	2.31	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	35	33 (94.3)	0.29 (0.53)	-0.5	-0.02	0.11	0.41	2.4	0.59 [0.12, 1.05]
			Placebo	41	41 (100.0)	0.04 (0.33)	-0.7	-0.14	0.05	0.13	1.1	
		Week 8	Tezepelumab	35	31 (88.6)	0.23 (0.47)	-0.5	-0.04	0.16	0.41	2.2	0.28 [-0.20, 0.75]
			Placebo	41	39 (95.1)	0.12 (0.36)	-0.9	-0.06	0.07	0.21	1.0	
		Week 12	Tezepelumab	35	33 (94.3)	0.32 (0.47)	-0.2	0.04	0.21	0.45	2.1	0.40 [-0.07, 0.87]
			Placebo	41	39 (95.1)	0.14 (0.44)	-0.7	-0.09	0.08	0.29	1.3	
		Week 20	Tezepelumab	35	30 (85.7)	0.21 (0.54)	-0.6	-0.09	0.13	0.38	2.2	0.34 [-0.15, 0.82]
			Placebo	41	37 (90.2)	0.07 (0.29)	-0.7	-0.03	0.09	0.22	0.8	
		Week 28	Tezepelumab	35	32 (91.4)	0.27 (0.58)	-1.0	-0.01	0.19	0.54	2.2	0.47 [-0.01, 0.95]
			Placebo	41	37 (90.2)	0.05 (0.36)	-1.1	-0.12	0.07	0.22	0.9	
		Week 40	Tezepelumab	35	30 (85.7)	0.28 (0.54)	-0.7	-0.02	0.24	0.50	2.3	0.40 [-0.09, 0.90]
			Placebo	41	34 (82.9)	0.10 (0.34)	-0.5	-0.08	0.06	0.22	1.0	
		Week 52	Tezepelumab	35	31 (88.6)	0.20 (0.50)	-0.7	-0.03	0.10	0.44	2.3	0.31 [-0.17, 0.79]
			Placebo	41	37 (90.2)	0.06 (0.40)	-0.9	-0.16	0.04	0.16	1.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	41	41 (100.0)	1.77 (0.58)	0.7	1.40	1.62	2.17	3.1	
			Placebo	30	30 (100.0)	1.78 (0.63)	0.9	1.29	1.66	2.17	3.2	
		Week 4	Tezepelumab	41	40 (97.6)	2.07 (0.84)	0.9	1.43	2.10	2.43	4.5	
			Placebo	30	30 (100.0)	1.79 (0.72)	0.7	1.17	1.67	2.27	3.2	
		Week 8	Tezepelumab	41	38 (92.7)	2.00 (0.65)	0.7	1.46	2.05	2.39	3.4	
			Placebo	30	27 (90.0)	1.80 (0.82)	0.8	1.08	1.61	2.31	3.6	
		Week 12	Tezepelumab	41	38 (92.7)	2.12 (0.81)	1.0	1.47	2.11	2.69	4.6	
			Placebo	30	29 (96.7)	1.74 (0.70)	0.5	1.20	1.74	2.21	3.3	
		Week 20	Tezepelumab	41	36 (87.8)	1.94 (0.73)	1.0	1.42	1.72	2.42	4.1	
			Placebo	30	27 (90.0)	1.78 (0.75)	0.5	1.13	1.72	2.35	3.3	
		Week 28	Tezepelumab	41	37 (90.2)	2.00 (0.76)	0.9	1.45	1.95	2.44	4.6	
			Placebo	30	27 (90.0)	1.70 (0.75)	0.7	1.06	1.69	2.05	3.4	
		Week 40	Tezepelumab	41	35 (85.4)	1.96 (0.67)	0.9	1.31	2.00	2.50	3.5	
			Placebo	30	24 (80.0)	1.85 (0.82)	0.6	1.09	1.69	2.34	3.5	
		Week 52	Tezepelumab	41	36 (87.8)	1.90 (0.67)	0.9	1.35	1.80	2.36	3.4	
			Placebo	30	26 (86.7)	1.71 (0.72)	0.6	1.10	1.56	2.07	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	41	40 (97.6)	0.31 (0.55)	-0.6	0.03	0.13	0.52	2.4	0.62 [0.13, 1.10]
			Placebo	30	30 (100.0)	0.01 (0.38)	-1.1	-0.10	0.10	0.17	0.7	
		Week 8	Tezepelumab	41	38 (92.7)	0.24 (0.41)	-0.5	0.02	0.23	0.35	2.2	0.48 [-0.02, 0.98]
			Placebo	30	27 (90.0)	0.03 (0.48)	-1.5	-0.11	0.15	0.29	0.9	
		Week 12	Tezepelumab	41	38 (92.7)	0.36 (0.50)	-0.2	0.03	0.21	0.49	2.1	0.83 [0.33, 1.33]
			Placebo	30	29 (96.7)	-0.02 (0.39)	-1.2	-0.12	0.00	0.26	0.8	
		Week 20	Tezepelumab	41	36 (87.8)	0.23 (0.49)	-0.6	-0.07	0.12	0.41	2.2	0.42 [-0.08, 0.93]
			Placebo	30	27 (90.0)	0.05 (0.33)	-1.0	-0.03	0.06	0.23	0.5	
		Week 28	Tezepelumab	41	37 (90.2)	0.28 (0.50)	-0.6	0.01	0.16	0.48	2.2	0.66 [0.15, 1.17]
			Placebo	30	27 (90.0)	-0.03 (0.39)	-1.1	-0.19	0.05	0.23	0.9	
		Week 40	Tezepelumab	41	35 (85.4)	0.25 (0.51)	-0.5	-0.07	0.16	0.40	2.3	0.31 [-0.21, 0.83]
			Placebo	30	24 (80.0)	0.11 (0.43)	-1.1	-0.09	0.04	0.28	1.0	
		Week 52	Tezepelumab	41	36 (87.8)	0.21 (0.47)	-0.5	-0.04	0.13	0.37	2.3	0.53 [0.02, 1.05]
			Placebo	30	26 (86.7)	-0.02 (0.39)	-1.0	-0.16	-0.01	0.17	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	25	25 (100.0)	1.72 (0.60)	0.7	1.29	1.73	2.00	3.1	
			Placebo	34	34 (100.0)	1.87 (0.51)	1.0	1.46	1.74	2.23	3.1	
		Week 4	Tezepelumab	25	24 (96.0)	1.87 (0.67)	0.9	1.48	1.77	2.00	3.5	
			Placebo	34	34 (100.0)	1.91 (0.50)	0.8	1.58	1.86	2.37	2.9	
		Week 8	Tezepelumab	25	22 (88.0)	1.85 (0.56)	1.3	1.47	1.79	1.97	3.2	
			Placebo	34	33 (97.1)	1.98 (0.44)	0.9	1.60	2.05	2.29	2.7	
		Week 12	Tezepelumab	25	24 (96.0)	1.91 (0.63)	0.9	1.50	1.82	2.21	3.3	
			Placebo	34	33 (97.1)	1.99 (0.70)	0.6	1.53	1.87	2.46	4.1	
		Week 20	Tezepelumab	25	21 (84.0)	1.87 (0.64)	1.0	1.37	1.71	2.13	3.3	
			Placebo	34	32 (94.1)	1.95 (0.58)	0.6	1.58	1.94	2.33	3.1	
		Week 28	Tezepelumab	25	23 (92.0)	1.83 (0.62)	1.0	1.40	1.66	2.17	3.5	
			Placebo	34	31 (91.2)	1.94 (0.56)	0.8	1.54	1.97	2.38	3.4	
		Week 40	Tezepelumab	25	23 (92.0)	1.88 (0.61)	1.1	1.34	1.80	2.17	3.3	
			Placebo	34	32 (94.1)	1.97 (0.69)	1.0	1.48	1.80	2.30	4.0	
		Week 52	Tezepelumab	25	23 (92.0)	1.81 (0.49)	1.2	1.34	1.80	2.17	3.1	
			Placebo	34	33 (97.1)	1.97 (0.74)	0.7	1.42	1.75	2.44	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	25	24 (96.0)	0.19 (0.36)	-0.5	-0.06	0.10	0.40	1.0	0.41 [-0.12, 0.94]
			Placebo	34	34 (100.0)	0.04 (0.35)	-0.7	-0.16	-0.03	0.16	1.1	
		Week 8	Tezepelumab	25	22 (88.0)	0.16 (0.33)	-0.5	-0.03	0.15	0.44	0.8	0.16 [-0.38, 0.70]
			Placebo	34	33 (97.1)	0.10 (0.37)	-0.9	-0.06	0.06	0.20	1.0	
		Week 12	Tezepelumab	25	24 (96.0)	0.22 (0.33)	-0.5	-0.03	0.23	0.43	0.9	0.26 [-0.27, 0.79]
			Placebo	34	33 (97.1)	0.12 (0.46)	-0.7	-0.11	0.04	0.31	1.3	
		Week 20	Tezepelumab	25	21 (84.0)	0.17 (0.39)	-0.6	-0.08	0.12	0.38	0.9	0.34 [-0.21, 0.90]
			Placebo	34	32 (94.1)	0.05 (0.30)	-0.7	-0.06	0.07	0.22	0.8	
		Week 28	Tezepelumab	25	23 (92.0)	0.16 (0.45)	-1.0	-0.10	0.20	0.53	0.8	0.29 [-0.26, 0.83]
			Placebo	34	31 (91.2)	0.04 (0.35)	-1.1	-0.05	0.03	0.23	0.9	
		Week 40	Tezepelumab	25	23 (92.0)	0.21 (0.40)	-0.7	-0.01	0.26	0.50	0.9	0.35 [-0.19, 0.89]
			Placebo	34	32 (94.1)	0.08 (0.37)	-0.5	-0.14	0.06	0.23	1.1	
		Week 52	Tezepelumab	25	23 (92.0)	0.13 (0.40)	-0.8	-0.03	0.07	0.46	0.8	0.09 [-0.44, 0.62]
			Placebo	34	33 (97.1)	0.09 (0.48)	-0.9	-0.16	0.06	0.18	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	26	26 (100.0)	1.87 (0.53)	0.9	1.41	1.89	2.17	3.1	
			Placebo	31	31 (100.0)	1.96 (0.57)	1.0	1.50	1.78	2.38	3.2	
		Week 4	Tezepelumab	26	26 (100.0)	1.91 (0.53)	0.9	1.52	1.85	2.26	3.3	
			Placebo	31	31 (100.0)	1.91 (0.63)	0.7	1.55	1.67	2.46	3.2	
		Week 8	Tezepelumab	26	26 (100.0)	1.95 (0.50)	1.3	1.55	1.93	2.35	3.4	
			Placebo	31	29 (93.5)	1.96 (0.63)	0.8	1.60	1.93	2.35	3.6	
		Week 12	Tezepelumab	26	24 (92.3)	2.02 (0.59)	0.9	1.51	2.09	2.37	3.5	
			Placebo	31	29 (93.5)	1.90 (0.60)	0.5	1.56	1.81	2.44	2.9	
		Week 20	Tezepelumab	26	24 (92.3)	1.83 (0.50)	1.0	1.47	1.66	2.24	2.9	
			Placebo	31	28 (90.3)	1.95 (0.66)	0.6	1.58	1.80	2.44	3.3	
		Week 28	Tezepelumab	26	24 (92.3)	1.84 (0.43)	1.1	1.47	1.83	2.21	2.6	
			Placebo	31	27 (87.1)	1.97 (0.61)	0.8	1.57	1.85	2.42	3.3	
		Week 40	Tezepelumab	26	23 (88.5)	1.89 (0.49)	1.1	1.45	1.99	2.33	2.6	
			Placebo	31	26 (83.9)	1.97 (0.63)	0.6	1.58	1.92	2.35	3.4	
		Week 52	Tezepelumab	26	24 (92.3)	1.81 (0.46)	1.3	1.37	1.75	2.17	3.0	
			Placebo	31	27 (87.1)	1.86 (0.55)	0.7	1.50	1.75	2.31	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	26	26 (100.0)	0.04 (0.26)	-0.5	-0.12	0.05	0.13	0.8	0.28 [-0.24, 0.80]
			Placebo	31	31 (100.0)	-0.05 (0.35)	-1.1	-0.16	0.00	0.13	0.6	
		Week 8	Tezepelumab	26	26 (100.0)	0.08 (0.23)	-0.5	-0.05	0.09	0.31	0.5	0.25 [-0.28, 0.78]
			Placebo	31	29 (93.5)	-0.01 (0.43)	-1.5	-0.06	0.13	0.20	0.5	
		Week 12	Tezepelumab	26	24 (92.3)	0.21 (0.37)	-0.5	-0.03	0.12	0.34	1.3	0.75 [0.19, 1.31]
			Placebo	31	29 (93.5)	-0.06 (0.36)	-1.2	-0.17	0.04	0.13	0.4	
		Week 20	Tezepelumab	26	24 (92.3)	0.04 (0.29)	-0.6	-0.10	0.05	0.18	0.8	0.11 [-0.44, 0.65]
			Placebo	31	28 (90.3)	0.01 (0.34)	-1.0	-0.04	0.11	0.23	0.5	
		Week 28	Tezepelumab	26	24 (92.3)	0.05 (0.24)	-0.4	-0.11	0.03	0.19	0.6	0.10 [-0.45, 0.65]
			Placebo	31	27 (87.1)	0.02 (0.34)	-1.1	-0.02	0.11	0.23	0.4	
		Week 40	Tezepelumab	26	23 (88.5)	0.08 (0.34)	-0.5	-0.11	0.06	0.28	1.1	0.11 [-0.46, 0.67]
			Placebo	31	26 (83.9)	0.04 (0.33)	-1.1	-0.11	0.09	0.22	0.5	
		Week 52	Tezepelumab	26	24 (92.3)	0.02 (0.27)	-0.8	-0.06	0.02	0.21	0.4	0.33 [-0.22, 0.89]
			Placebo	31	27 (87.1)	-0.08 (0.33)	-1.0	-0.26	0.01	0.16	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	1.67 (0.62)	0.7	1.17	1.55	2.05	3.1	
			Placebo	34	34 (100.0)	1.69 (0.54)	0.9	1.33	1.60	2.18	3.1	
		Week 4	Tezepelumab	40	38 (95.0)	2.05 (0.92)	0.9	1.41	1.78	2.74	4.5	
			Placebo	34	34 (100.0)	1.79 (0.59)	0.7	1.33	1.79	2.27	2.9	
		Week 8	Tezepelumab	40	34 (85.0)	1.93 (0.70)	0.7	1.37	1.74	2.44	3.3	
			Placebo	34	32 (94.1)	1.84 (0.65)	0.8	1.39	1.92	2.27	3.4	
		Week 12	Tezepelumab	40	38 (95.0)	2.06 (0.84)	1.0	1.33	1.85	2.70	4.6	
			Placebo	34	34 (100.0)	1.85 (0.78)	0.7	1.20	1.71	2.24	4.1	
		Week 20	Tezepelumab	40	33 (82.5)	1.97 (0.81)	1.0	1.37	1.74	2.60	4.1	
			Placebo	34	32 (94.1)	1.80 (0.65)	0.5	1.22	1.72	2.27	3.1	
		Week 28	Tezepelumab	40	36 (90.0)	2.00 (0.85)	0.9	1.33	1.76	2.48	4.6	
			Placebo	34	32 (94.1)	1.71 (0.68)	0.7	1.18	1.65	2.09	3.4	
		Week 40	Tezepelumab	40	35 (87.5)	1.95 (0.73)	0.9	1.31	1.88	2.52	3.5	
			Placebo	34	31 (91.2)	1.87 (0.82)	0.8	1.27	1.65	2.29	4.0	
		Week 52	Tezepelumab	40	35 (87.5)	1.90 (0.69)	0.9	1.31	1.83	2.37	3.4	
			Placebo	34	33 (97.1)	1.84 (0.86)	0.6	1.24	1.53	2.31	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	40	38 (95.0)	0.42 (0.54)	-0.6	0.06	0.36	0.64	2.4	0.69 [0.21, 1.16]
			Placebo	34	34 (100.0)	0.10 (0.37)	-0.7	-0.12	0.08	0.18	1.1	
		Week 8	Tezepelumab	40	34 (85.0)	0.31 (0.44)	-0.5	0.09	0.28	0.49	2.2	0.40 [-0.09, 0.89]
			Placebo	34	32 (94.1)	0.14 (0.39)	-0.9	-0.06	0.06	0.30	1.0	
		Week 12	Tezepelumab	40	38 (95.0)	0.37 (0.48)	-0.2	0.03	0.24	0.56	2.1	0.45 [-0.02, 0.92]
			Placebo	34	34 (100.0)	0.16 (0.46)	-0.7	-0.09	0.06	0.33	1.3	
		Week 20	Tezepelumab	40	33 (82.5)	0.33 (0.51)	-0.4	-0.06	0.31	0.49	2.2	0.58 [0.08, 1.08]
			Placebo	34	32 (94.1)	0.09 (0.28)	-0.5	-0.05	0.06	0.23	0.8	
		Week 28	Tezepelumab	40	36 (90.0)	0.35 (0.56)	-1.0	0.03	0.33	0.57	2.2	0.71 [0.21, 1.20]
			Placebo	34	32 (94.1)	0.00 (0.39)	-1.1	-0.18	0.01	0.21	0.9	
		Week 40	Tezepelumab	40	35 (87.5)	0.34 (0.50)	-0.7	0.05	0.34	0.54	2.3	0.44 [-0.05, 0.93]
			Placebo	34	31 (91.2)	0.13 (0.44)	-0.5	-0.14	0.00	0.29	1.1	
		Week 52	Tezepelumab	40	35 (87.5)	0.29 (0.50)	-0.7	0.01	0.16	0.57	2.3	0.29 [-0.19, 0.77]
			Placebo	34	33 (97.1)	0.15 (0.49)	-0.9	-0.16	0.06	0.39	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	1.73 (0.59)	0.7	1.32	1.62	2.08	3.1	
			Placebo	60	60 (100.0)	1.84 (0.57)	0.9	1.42	1.75	2.22	3.2	
		Week 4	Tezepelumab	57	55 (96.5)	1.98 (0.80)	0.9	1.46	1.80	2.39	4.5	
			Placebo	60	60 (100.0)	1.88 (0.62)	0.7	1.54	1.79	2.38	3.2	
		Week 8	Tezepelumab	57	51 (89.5)	1.92 (0.62)	0.7	1.47	1.80	2.37	3.4	
			Placebo	60	56 (93.3)	1.92 (0.65)	0.8	1.52	1.97	2.33	3.6	
		Week 12	Tezepelumab	57	53 (93.0)	2.04 (0.76)	0.9	1.48	1.87	2.55	4.6	
			Placebo	60	58 (96.7)	1.90 (0.71)	0.5	1.44	1.83	2.44	4.1	
		Week 20	Tezepelumab	57	49 (86.0)	1.91 (0.71)	1.0	1.45	1.71	2.37	4.1	
			Placebo	60	56 (93.3)	1.88 (0.66)	0.5	1.45	1.80	2.33	3.3	
		Week 28	Tezepelumab	57	51 (89.5)	1.93 (0.70)	0.9	1.42	1.73	2.26	4.6	
			Placebo	60	54 (90.0)	1.85 (0.66)	0.7	1.44	1.77	2.24	3.4	
		Week 40	Tezepelumab	57	49 (86.0)	1.92 (0.64)	0.9	1.36	1.88	2.33	3.5	
			Placebo	60	54 (90.0)	1.95 (0.74)	0.6	1.45	1.79	2.35	4.0	
		Week 52	Tezepelumab	57	50 (87.7)	1.83 (0.60)	0.9	1.33	1.78	2.17	3.4	
			Placebo	60	56 (93.3)	1.87 (0.74)	0.6	1.35	1.72	2.37	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	57	55 (96.5)	0.28 (0.51)	-0.6	0.02	0.13	0.41	2.4	0.54 [0.16, 0.91]
			Placebo	60	60 (100.0)	0.04 (0.37)	-1.1	-0.13	0.04	0.17	1.1	
		Week 8	Tezepelumab	57	51 (89.5)	0.23 (0.40)	-0.5	0.00	0.22	0.36	2.2	0.35 [-0.03, 0.74]
			Placebo	60	56 (93.3)	0.08 (0.43)	-1.5	-0.06	0.13	0.27	1.0	
		Week 12	Tezepelumab	57	53 (93.0)	0.33 (0.46)	-0.5	0.04	0.22	0.49	2.1	0.59 [0.21, 0.97]
			Placebo	60	58 (96.7)	0.06 (0.44)	-1.2	-0.16	0.05	0.29	1.3	
		Week 20	Tezepelumab	57	49 (86.0)	0.24 (0.47)	-0.6	-0.06	0.17	0.40	2.2	0.49 [0.10, 0.88]
			Placebo	60	56 (93.3)	0.05 (0.32)	-1.0	-0.06	0.07	0.23	0.8	
		Week 28	Tezepelumab	57	51 (89.5)	0.26 (0.48)	-0.7	-0.02	0.17	0.52	2.2	0.55 [0.16, 0.94]
			Placebo	60	54 (90.0)	0.02 (0.37)	-1.1	-0.12	0.09	0.23	0.9	
		Week 40	Tezepelumab	57	49 (86.0)	0.27 (0.47)	-0.5	-0.02	0.25	0.44	2.3	0.39 [0.00, 0.78]
			Placebo	60	54 (90.0)	0.10 (0.40)	-1.1	-0.11	0.06	0.24	1.1	
		Week 52	Tezepelumab	57	50 (87.7)	0.19 (0.46)	-0.8	-0.04	0.11	0.40	2.3	0.30 [-0.08, 0.69]
			Placebo	60	56 (93.3)	0.05 (0.45)	-1.0	-0.16	0.06	0.22	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.91 (0.57)	1.3	1.45	1.81	2.17	3.1	
			Placebo	5	5 (100.0)	1.63 (0.41)	1.3	1.46	1.52	1.58	2.3	
		Week 4	Tezepelumab	9	9 (100.0)	2.08 (0.70)	1.3	1.44	2.08	2.29	3.5	
			Placebo	5	5 (100.0)	1.47 (0.32)	1.0	1.30	1.59	1.66	1.8	
		Week 8	Tezepelumab	9	9 (100.0)	2.04 (0.62)	1.3	1.46	2.07	2.36	3.2	
			Placebo	5	5 (100.0)	1.62 (0.43)	1.1	1.54	1.60	1.61	2.3	
		Week 12	Tezepelumab	9	9 (100.0)	2.08 (0.68)	1.3	1.51	2.04	2.37	3.3	
			Placebo	5	5 (100.0)	1.60 (0.47)	1.2	1.41	1.51	1.52	2.4	
		Week 20	Tezepelumab	9	8 (88.9)	1.95 (0.61)	1.4	1.38	1.90	2.34	3.0	
			Placebo	5	4 (80.0)	1.75 (0.56)	1.2	1.38	1.61	2.11	2.5	
		Week 28	Tezepelumab	9	9 (100.0)	1.98 (0.79)	1.0	1.29	2.17	2.29	3.5	
			Placebo	5	5 (100.0)	1.52 (0.59)	0.8	1.24	1.54	1.69	2.4	
		Week 40	Tezepelumab	9	9 (100.0)	1.95 (0.68)	1.1	1.34	2.17	2.30	3.1	
			Placebo	5	3 (60.0)	1.32 (0.32)	1.1	1.08	1.20	1.68	1.7	
		Week 52	Tezepelumab	9	9 (100.0)	2.03 (0.62)	1.2	1.36	2.20	2.35	3.1	
			Placebo	5	4 (80.0)	1.56 (0.51)	1.1	1.24	1.44	1.89	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	0.17 (0.28)	-0.1	-0.04	0.07	0.45	0.7	1.18 [-0.01, 2.37]
			Placebo	5	5 (100.0)	-0.16 (0.27)	-0.5	-0.25	-0.22	0.08	0.1	
		Week 8	Tezepelumab	9	9 (100.0)	0.13 (0.23)	-0.1	-0.04	0.09	0.18	0.5	0.68 [-0.45, 1.80]
			Placebo	5	5 (100.0)	-0.00 (0.12)	-0.2	-0.04	-0.03	0.08	0.2	
		Week 12	Tezepelumab	9	9 (100.0)	0.17 (0.32)	-0.2	-0.04	0.14	0.23	0.9	0.73 [-0.40, 1.86]
			Placebo	5	5 (100.0)	-0.03 (0.09)	-0.1	-0.09	-0.06	0.05	0.1	
		Week 20	Tezepelumab	9	8 (88.9)	0.00 (0.25)	-0.4	-0.11	-0.04	0.15	0.4	-0.47 [-1.69, 0.75]
			Placebo	5	4 (80.0)	0.11 (0.13)	-0.0	-0.01	0.12	0.22	0.2	
		Week 28	Tezepelumab	9	9 (100.0)	0.07 (0.48)	-1.0	-0.12	0.21	0.47	0.5	0.42 [-0.69, 1.52]
			Placebo	5	5 (100.0)	-0.11 (0.30)	-0.5	-0.34	0.02	0.05	0.2	
		Week 40	Tezepelumab	9	9 (100.0)	0.04 (0.39)	-0.7	-0.11	0.05	0.35	0.5	0.36 [-0.95, 1.68]
			Placebo	5	3 (60.0)	-0.09 (0.28)	-0.3	-0.32	-0.17	0.22	0.2	
		Week 52	Tezepelumab	9	9 (100.0)	0.12 (0.27)	-0.2	-0.03	0.01	0.24	0.6	0.82 [-0.41, 2.04]
			Placebo	5	4 (80.0)	-0.07 (0.09)	-0.1	-0.15	-0.09	0.00	0.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	1.54 (0.72)	0.7	1.17	1.37	1.87	3.0	
			Placebo	14	14 (100.0)	1.76 (0.43)	1.0	1.50	1.75	2.18	2.5	
		Week 4	Tezepelumab	9	9 (100.0)	1.84 (1.09)	0.9	1.19	1.44	2.04	4.5	
			Placebo	14	14 (100.0)	1.61 (0.57)	0.7	1.30	1.66	1.89	2.9	
		Week 8	Tezepelumab	9	7 (77.8)	1.63 (0.42)	1.3	1.26	1.46	2.03	2.2	
			Placebo	14	13 (92.9)	1.81 (0.60)	0.8	1.60	1.94	2.15	2.7	
		Week 12	Tezepelumab	9	8 (88.9)	1.95 (1.12)	1.1	1.25	1.70	1.99	4.6	
			Placebo	14	13 (92.9)	1.76 (0.71)	0.5	1.41	1.76	2.16	3.2	
		Week 20	Tezepelumab	9	8 (88.9)	1.76 (0.99)	1.0	1.24	1.48	1.75	4.1	
			Placebo	14	13 (92.9)	1.84 (0.64)	0.7	1.53	1.86	2.32	2.9	
		Week 28	Tezepelumab	9	8 (88.9)	1.83 (1.17)	1.0	1.17	1.42	1.94	4.6	
			Placebo	14	12 (85.7)	1.75 (0.78)	0.8	1.19	1.59	2.24	3.4	
		Week 40	Tezepelumab	9	7 (77.8)	1.49 (0.33)	1.1	1.30	1.36	1.88	2.0	
			Placebo	14	11 (78.6)	1.79 (0.90)	0.6	1.08	1.71	2.24	3.4	
		Week 52	Tezepelumab	9	7 (77.8)	1.57 (0.29)	1.3	1.33	1.36	1.86	1.9	
			Placebo	14	12 (85.7)	1.88 (0.98)	0.8	1.20	1.39	2.41	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	0.30 (0.46)	-0.0	0.02	0.13	0.38	1.4	1.11 [0.21, 2.01]
			Placebo	14	14 (100.0)	-0.14 (0.35)	-1.1	-0.25	-0.08	0.02	0.4	
		Week 8	Tezepelumab	9	7 (77.8)	0.19 (0.22)	-0.0	-0.03	0.10	0.36	0.6	0.42 [-0.51, 1.35]
			Placebo	14	13 (92.9)	0.05 (0.39)	-0.9	-0.17	0.08	0.28	0.6	
		Week 12	Tezepelumab	9	8 (88.9)	0.31 (0.53)	-0.1	-0.02	0.16	0.36	1.5	0.59 [-0.31, 1.49]
			Placebo	14	13 (92.9)	0.00 (0.51)	-1.2	-0.11	-0.02	0.26	0.7	
		Week 20	Tezepelumab	9	8 (88.9)	0.12 (0.46)	-0.4	-0.17	0.05	0.25	1.1	0.08 [-0.80, 0.96]
			Placebo	14	13 (92.9)	0.09 (0.37)	-1.0	0.01	0.15	0.23	0.6	
		Week 28	Tezepelumab	9	8 (88.9)	0.18 (0.70)	-1.0	-0.04	0.11	0.41	1.5	0.32 [-0.58, 1.22]
			Placebo	14	12 (85.7)	-0.00 (0.48)	-0.9	-0.34	0.04	0.29	0.9	
		Week 40	Tezepelumab	9	7 (77.8)	0.05 (0.39)	-0.7	-0.08	0.07	0.16	0.7	-0.09 [-1.03, 0.86]
			Placebo	14	11 (78.6)	0.09 (0.63)	-1.1	-0.32	0.00	0.52	1.1	
		Week 52	Tezepelumab	9	7 (77.8)	0.13 (0.22)	-0.0	-0.01	0.07	0.16	0.6	0.00 [-0.93, 0.93]
			Placebo	14	12 (85.7)	0.13 (0.71)	-0.9	-0.15	-0.07	0.47	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	1.79 (0.56)	0.7	1.40	1.68	2.17	3.1	
			Placebo	51	51 (100.0)	1.84 (0.60)	0.9	1.41	1.67	2.26	3.2	
		Week 4	Tezepelumab	57	55 (96.5)	2.02 (0.73)	0.9	1.50	1.82	2.40	3.8	
			Placebo	51	51 (100.0)	1.91 (0.61)	0.7	1.55	1.82	2.42	3.2	
		Week 8	Tezepelumab	57	53 (93.0)	1.98 (0.63)	0.7	1.49	1.90	2.37	3.4	
			Placebo	51	48 (94.1)	1.92 (0.65)	0.8	1.51	1.86	2.33	3.6	
		Week 12	Tezepelumab	57	54 (94.7)	2.06 (0.69)	0.9	1.49	2.02	2.57	3.5	
			Placebo	51	50 (98.0)	1.90 (0.70)	0.6	1.44	1.80	2.44	4.1	
		Week 20	Tezepelumab	57	49 (86.0)	1.94 (0.64)	1.0	1.46	1.75	2.38	3.4	
			Placebo	51	47 (92.2)	1.87 (0.67)	0.5	1.38	1.72	2.35	3.3	
		Week 28	Tezepelumab	57	52 (91.2)	1.95 (0.63)	0.9	1.47	1.84	2.33	3.5	
			Placebo	51	47 (92.2)	1.84 (0.63)	0.7	1.42	1.74	2.24	3.4	
		Week 40	Tezepelumab	57	51 (89.5)	1.99 (0.65)	0.9	1.43	1.99	2.41	3.5	
			Placebo	51	46 (90.2)	1.94 (0.70)	0.8	1.50	1.75	2.35	4.0	
		Week 52	Tezepelumab	57	52 (91.2)	1.90 (0.63)	0.9	1.35	1.80	2.35	3.4	
			Placebo	51	48 (94.1)	1.85 (0.67)	0.6	1.41	1.72	2.31	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	55 (96.5)	0.26 (0.49)	-0.6	-0.03	0.11	0.45	2.4	0.43 [0.04, 0.81]
			Placebo	51	51 (100.0)	0.07 (0.35)	-1.0	-0.12	0.08	0.18	1.1	
		Week 8	Tezepelumab	57	53 (93.0)	0.21 (0.40)	-0.5	-0.01	0.17	0.35	2.2	0.33 [-0.06, 0.72]
			Placebo	51	48 (94.1)	0.08 (0.42)	-1.5	-0.06	0.13	0.21	1.0	
		Week 12	Tezepelumab	57	54 (94.7)	0.31 (0.44)	-0.5	0.03	0.23	0.47	2.1	0.56 [0.17, 0.95]
			Placebo	51	50 (98.0)	0.07 (0.41)	-0.9	-0.16	0.05	0.28	1.3	
		Week 20	Tezepelumab	57	49 (86.0)	0.22 (0.46)	-0.6	-0.07	0.17	0.39	2.2	0.47 [0.07, 0.88]
			Placebo	51	47 (92.2)	0.04 (0.29)	-0.7	-0.10	0.06	0.22	0.8	
		Week 28	Tezepelumab	57	52 (91.2)	0.24 (0.45)	-0.7	-0.04	0.19	0.50	2.2	0.56 [0.15, 0.96]
			Placebo	51	47 (92.2)	0.02 (0.33)	-1.1	-0.12	0.07	0.22	0.9	
		Week 40	Tezepelumab	57	51 (89.5)	0.26 (0.47)	-0.5	-0.05	0.26	0.48	2.3	0.42 [0.02, 0.83]
			Placebo	51	46 (90.2)	0.09 (0.32)	-0.5	-0.11	0.06	0.22	1.0	
		Week 52	Tezepelumab	57	52 (91.2)	0.19 (0.46)	-0.8	-0.05	0.11	0.42	2.3	0.40 [0.00, 0.80]
			Placebo	51	48 (94.1)	0.02 (0.34)	-1.0	-0.16	0.05	0.18	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	51	51 (100.0)	1.75 (0.56)	0.7	1.34	1.62	2.12	3.1	
			Placebo	49	49 (100.0)	1.85 (0.61)	0.9	1.41	1.69	2.26	3.2	
		Week 4	Tezepelumab	51	49 (96.1)	1.98 (0.73)	0.9	1.50	1.80	2.39	3.8	
			Placebo	49	49 (100.0)	1.92 (0.62)	0.7	1.55	1.86	2.42	3.2	
		Week 8	Tezepelumab	51	47 (92.2)	1.94 (0.63)	0.7	1.48	1.80	2.39	3.4	
			Placebo	49	46 (93.9)	1.94 (0.66)	0.8	1.48	1.95	2.35	3.6	
		Week 12	Tezepelumab	51	48 (94.1)	2.02 (0.69)	0.9	1.49	1.85	2.56	3.5	
			Placebo	49	48 (98.0)	1.92 (0.71)	0.6	1.41	1.84	2.46	4.1	
		Week 20	Tezepelumab	51	44 (86.3)	1.90 (0.64)	1.0	1.46	1.73	2.41	3.4	
			Placebo	49	46 (93.9)	1.88 (0.67)	0.5	1.38	1.73	2.35	3.3	
		Week 28	Tezepelumab	51	46 (90.2)	1.90 (0.61)	0.9	1.45	1.75	2.26	3.4	
			Placebo	49	45 (91.8)	1.86 (0.64)	0.7	1.44	1.80	2.24	3.4	
		Week 40	Tezepelumab	51	45 (88.2)	1.95 (0.65)	0.9	1.43	1.93	2.36	3.5	
			Placebo	49	45 (91.8)	1.95 (0.71)	0.8	1.50	1.79	2.35	4.0	
		Week 52	Tezepelumab	51	46 (90.2)	1.85 (0.62)	0.9	1.34	1.78	2.25	3.4	
			Placebo	49	47 (95.9)	1.85 (0.67)	0.6	1.40	1.72	2.31	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	51	49 (96.1)	0.26 (0.51)	-0.6	0.01	0.11	0.41	2.4	0.42 [0.02, 0.82]
			Placebo	49	49 (100.0)	0.07 (0.36)	-1.0	-0.12	0.08	0.18	1.1	
		Week 8	Tezepelumab	51	47 (92.2)	0.22 (0.42)	-0.5	-0.01	0.17	0.35	2.2	0.32 [-0.09, 0.73]
			Placebo	49	46 (93.9)	0.08 (0.43)	-1.5	-0.06	0.13	0.21	1.0	
		Week 12	Tezepelumab	51	48 (94.1)	0.32 (0.45)	-0.5	0.04	0.23	0.48	2.1	0.56 [0.15, 0.97]
			Placebo	49	48 (98.0)	0.07 (0.42)	-0.9	-0.16	0.05	0.28	1.3	
		Week 20	Tezepelumab	51	44 (86.3)	0.24 (0.47)	-0.6	-0.06	0.18	0.44	2.2	0.52 [0.10, 0.94]
			Placebo	49	46 (93.9)	0.04 (0.30)	-0.7	-0.10	0.06	0.22	0.8	
		Week 28	Tezepelumab	51	46 (90.2)	0.23 (0.46)	-0.7	-0.02	0.17	0.51	2.2	0.53 [0.11, 0.95]
			Placebo	49	45 (91.8)	0.02 (0.33)	-1.1	-0.09	0.07	0.22	0.9	
		Week 40	Tezepelumab	51	45 (88.2)	0.28 (0.48)	-0.5	-0.02	0.26	0.44	2.3	0.46 [0.04, 0.88]
			Placebo	49	45 (91.8)	0.09 (0.33)	-0.5	-0.11	0.06	0.22	1.0	
		Week 52	Tezepelumab	51	46 (90.2)	0.19 (0.48)	-0.8	-0.04	0.11	0.40	2.3	0.40 [-0.02, 0.81]
			Placebo	49	47 (95.9)	0.02 (0.35)	-1.0	-0.16	0.06	0.18	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	1.76 (0.71)	0.7	1.29	1.72	2.17	3.1	
			Placebo	16	16 (100.0)	1.73 (0.41)	1.0	1.48	1.73	2.02	2.5	
		Week 4	Tezepelumab	15	15 (100.0)	2.04 (0.96)	0.9	1.25	2.04	2.29	4.5	
			Placebo	16	16 (100.0)	1.61 (0.53)	0.7	1.32	1.66	1.84	2.9	
		Week 8	Tezepelumab	15	13 (86.7)	1.93 (0.59)	1.3	1.35	2.03	2.35	3.2	
			Placebo	16	15 (93.8)	1.77 (0.56)	0.8	1.54	1.93	2.15	2.7	
		Week 12	Tezepelumab	15	14 (93.3)	2.11 (0.94)	1.1	1.28	1.97	2.37	4.6	
			Placebo	16	15 (93.8)	1.73 (0.66)	0.5	1.41	1.53	2.16	3.2	
		Week 20	Tezepelumab	15	13 (86.7)	1.95 (0.87)	1.0	1.37	1.67	2.30	4.1	
			Placebo	16	14 (87.5)	1.83 (0.61)	0.7	1.53	1.80	2.32	2.9	
		Week 28	Tezepelumab	15	14 (93.3)	2.04 (1.00)	1.0	1.26	1.94	2.29	4.6	
			Placebo	16	14 (87.5)	1.71 (0.73)	0.8	1.24	1.59	2.10	3.4	
		Week 40	Tezepelumab	15	13 (86.7)	1.84 (0.62)	1.1	1.34	1.88	2.29	3.1	
			Placebo	16	12 (75.0)	1.78 (0.86)	0.6	1.14	1.70	2.13	3.4	
		Week 52	Tezepelumab	15	13 (86.7)	1.89 (0.57)	1.2	1.36	1.86	2.34	3.1	
			Placebo	16	13 (81.3)	1.85 (0.94)	0.8	1.30	1.40	2.28	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSHP: Change from baseline in FEV1 Pre-BD by study specific subgroups
DITTL

Subgroup	FEV1 Pre-BD		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	15	15 (100.0)	0.28 (0.39)	-0.1	-0.02	0.13	0.45	1.4	1.06 [0.30, 1.82]
			Placebo	16	16 (100.0)	-0.11 (0.34)	-1.1	-0.24	-0.05	0.11	0.4	
		Week 8	Tezepelumab	15	13 (86.7)	0.19 (0.23)	-0.1	-0.03	0.14	0.36	0.6	0.47 [-0.28, 1.23]
			Placebo	16	15 (93.8)	0.05 (0.36)	-0.9	-0.17	0.08	0.28	0.6	
		Week 12	Tezepelumab	15	14 (93.3)	0.28 (0.46)	-0.2	-0.03	0.18	0.41	1.5	0.60 [-0.14, 1.35]
			Placebo	16	15 (93.8)	0.00 (0.47)	-1.2	-0.11	-0.02	0.26	0.7	
		Week 20	Tezepelumab	15	13 (86.7)	0.10 (0.38)	-0.4	-0.11	0.02	0.21	1.1	0.01 [-0.74, 0.77]
			Placebo	16	14 (87.5)	0.09 (0.36)	-1.0	0.01	0.17	0.23	0.6	
		Week 28	Tezepelumab	15	14 (93.3)	0.21 (0.55)	-1.0	-0.06	0.24	0.48	1.5	0.44 [-0.31, 1.19]
			Placebo	16	14 (87.5)	-0.01 (0.46)	-0.9	-0.34	0.04	0.27	0.9	
		Week 40	Tezepelumab	15	13 (86.7)	0.10 (0.36)	-0.7	-0.08	0.07	0.35	0.7	-0.01 [-0.80, 0.77]
			Placebo	16	12 (75.0)	0.10 (0.60)	-1.1	-0.25	0.08	0.50	1.1	
		Week 52	Tezepelumab	15	13 (86.7)	0.15 (0.27)	-0.2	-0.01	0.07	0.24	0.6	0.06 [-0.71, 0.83]
			Placebo	16	13 (81.3)	0.12 (0.68)	-0.9	-0.15	-0.04	0.16	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Race (cat. P)									0.924
White	Week 4	Tezepelumab	60	58 (96.7)	0.26 (0.06)	(0.15, 0.38)	0.23 (0.08)	(0.06, 0.39)	0.007 *
		Placebo	58	58 (100.0)	0.04 (0.06)	(-0.08, 0.15)			
	Week 8	Tezepelumab	60	54 (90.0)	0.24 (0.06)	(0.13, 0.35)	0.14 (0.08)	(-0.01, 0.30)	0.072
		Placebo	58	54 (93.1)	0.09 (0.06)	(-0.02, 0.20)			
	Week 12	Tezepelumab	60	56 (93.3)	0.31 (0.06)	(0.19, 0.43)	0.23 (0.08)	(0.06, 0.39)	0.008 *
		Placebo	58	56 (96.6)	0.08 (0.06)	(-0.04, 0.20)			
	Week 20	Tezepelumab	60	51 (85.0)	0.21 (0.06)	(0.10, 0.32)	0.16 (0.08)	(0.00, 0.31)	0.047 *
		Placebo	58	54 (93.1)	0.06 (0.05)	(-0.05, 0.16)			
	Week 28	Tezepelumab	60	54 (90.0)	0.20 (0.06)	(0.08, 0.32)	0.20 (0.09)	(0.03, 0.38)	0.020 *
		Placebo	58	52 (89.7)	-0.00 (0.06)	(-0.12, 0.12)			
	Week 40	Tezepelumab	60	53 (88.3)	0.23 (0.06)	(0.11, 0.36)	0.13 (0.09)	(-0.04, 0.31)	0.127
		Placebo	58	52 (89.7)	0.10 (0.06)	(-0.02, 0.22)			
	Week 52	Tezepelumab	60	53 (88.3)	0.18 (0.06)	(0.05, 0.31)	0.13 (0.09)	(-0.04, 0.31)	0.135
		Placebo	58	54 (93.1)	0.04 (0.06)	(-0.08, 0.17)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Non-white	Week 4	Tezepelumab	6	6 (100.0)	0.17 (0.10)	(-0.04, 0.39)	0.20 (0.13)	(-0.10, 0.50)	0.163
		Placebo	7	7 (100.0)	-0.03 (0.09)	(-0.23, 0.17)			
	Week 8	Tezepelumab	6	6 (100.0)	0.18 (0.07)	(0.02, 0.34)	0.20 (0.10)	(-0.02, 0.43)	0.076
		Placebo	7	7 (100.0)	-0.02 (0.07)	(-0.17, 0.13)			
	Week 12	Tezepelumab	6	6 (100.0)	0.12 (0.12)	(-0.15, 0.39)	0.24 (0.17)	(-0.13, 0.61)	0.187
		Placebo	7	7 (100.0)	-0.12 (0.11)	(-0.37, 0.13)			
	Week 20	Tezepelumab	6	6 (100.0)	0.10 (0.10)	(-0.13, 0.33)	0.14 (0.14)	(-0.17, 0.46)	0.339
		Placebo	7	6 (85.7)	-0.04 (0.10)	(-0.26, 0.17)			
	Week 28	Tezepelumab	6	6 (100.0)	0.26 (0.09)	(0.06, 0.46)	0.20 (0.12)	(-0.07, 0.48)	0.136
		Placebo	7	7 (100.0)	0.06 (0.08)	(-0.12, 0.24)			
	Week 40	Tezepelumab	6	5 (83.3)	0.17 (0.11)	(-0.08, 0.42)	0.20 (0.16)	(-0.15, 0.55)	0.236
		Placebo	7	5 (71.4)	-0.03 (0.11)	(-0.28, 0.21)			
	Week 52	Tezepelumab	6	6 (100.0)	0.16 (0.10)	(-0.07, 0.39)	0.27 (0.15)	(-0.05, 0.60)	0.092
		Placebo	7	6 (85.7)	-0.11 (0.10)	(-0.33, 0.11)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Region (cat. P)									0.460
North America/Western EU	Week 4	Tezepelumab	6	6 (100.0)	NE		NE		
		Placebo	4	4 (100.0)					
	Week 8	Tezepelumab	6	6 (100.0)	NE		NE		
		Placebo	4	4 (100.0)					
	Week 12	Tezepelumab	6	6 (100.0)	NE		NE		
		Placebo	4	4 (100.0)					
	Week 20	Tezepelumab	6	5 (83.3)	NE		NE		
		Placebo	4	4 (100.0)					
	Week 28	Tezepelumab	6	5 (83.3)	NE		NE		
		Placebo	4	4 (100.0)					
	Week 40	Tezepelumab	6	5 (83.3)	NE		NE		
		Placebo	4	4 (100.0)					
	Week 52	Tezepelumab	6	5 (83.3)	NE		NE		
		Placebo	4	4 (100.0)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Rest of world	Week 4	Tezepelumab	60	58 (96.7)	0.28 (0.06)	(0.16, 0.39)	0.26 (0.08)	(0.10, 0.42)	0.002 *
		Placebo	61	61 (100.0)	0.02 (0.06)	(-0.09, 0.13)			
	Week 8	Tezepelumab	60	54 (90.0)	0.24 (0.05)	(0.13, 0.35)	0.16 (0.08)	(0.01, 0.31)	0.037 *
		Placebo	61	57 (93.4)	0.08 (0.05)	(-0.02, 0.19)			
	Week 12	Tezepelumab	60	56 (93.3)	0.32 (0.06)	(0.20, 0.43)	0.26 (0.08)	(0.10, 0.42)	0.002 *
		Placebo	61	59 (96.7)	0.06 (0.06)	(-0.06, 0.17)			
	Week 20	Tezepelumab	60	52 (86.7)	0.21 (0.05)	(0.11, 0.32)	0.17 (0.08)	(0.02, 0.32)	0.027 *
		Placebo	61	56 (91.8)	0.05 (0.05)	(-0.06, 0.15)			
	Week 28	Tezepelumab	60	55 (91.7)	0.21 (0.06)	(0.09, 0.33)	0.22 (0.08)	(0.05, 0.39)	0.010 *
		Placebo	61	55 (90.2)	-0.01 (0.06)	(-0.13, 0.11)			
	Week 40	Tezepelumab	60	53 (88.3)	0.24 (0.06)	(0.12, 0.36)	0.15 (0.09)	(-0.02, 0.32)	0.090
		Placebo	61	53 (86.9)	0.09 (0.06)	(-0.03, 0.21)			
	Week 52	Tezepelumab	60	54 (90.0)	0.18 (0.06)	(0.06, 0.30)	0.15 (0.09)	(-0.02, 0.32)	0.093
		Placebo	61	56 (91.8)	0.03 (0.06)	(-0.09, 0.16)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline eosinophils (cat. P)									0.996
< 250 cells/uL	Week 4	Tezepelumab	30	30 (100.0)	0.27 (0.10)	(0.08, 0.46)	0.18 (0.14)	(-0.10, 0.45)	0.201
		Placebo	29	29 (100.0)	0.09 (0.10)	(-0.10, 0.29)			
	Week 8	Tezepelumab	30	27 (90.0)	0.26 (0.09)	(0.08, 0.44)	0.13 (0.13)	(-0.13, 0.39)	0.311
		Placebo	29	28 (96.6)	0.13 (0.09)	(-0.05, 0.31)			
	Week 12	Tezepelumab	30	29 (96.7)	0.30 (0.09)	(0.12, 0.49)	0.26 (0.13)	(-0.00, 0.52)	0.053
		Placebo	29	28 (96.6)	0.05 (0.09)	(-0.14, 0.23)			
	Week 20	Tezepelumab	30	28 (93.3)	0.23 (0.09)	(0.06, 0.40)	0.19 (0.12)	(-0.06, 0.44)	0.127
		Placebo	29	26 (89.7)	0.04 (0.09)	(-0.14, 0.22)			
	Week 28	Tezepelumab	30	29 (96.7)	0.23 (0.09)	(0.04, 0.41)	0.24 (0.13)	(-0.03, 0.51)	0.078
		Placebo	29	25 (86.2)	-0.01 (0.10)	(-0.20, 0.18)			
	Week 40	Tezepelumab	30	27 (90.0)	0.26 (0.09)	(0.07, 0.44)	0.20 (0.13)	(-0.07, 0.47)	0.140
		Placebo	29	25 (86.2)	0.05 (0.10)	(-0.14, 0.25)			
	Week 52	Tezepelumab	30	28 (93.3)	0.16 (0.10)	(-0.04, 0.36)	0.16 (0.14)	(-0.12, 0.45)	0.256
		Placebo	29	25 (86.2)	-0.00 (0.10)	(-0.21, 0.21)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 250 cells/uL	Week 4	Tezepelumab	36	34 (94.4)	0.25 (0.06)	(0.13, 0.36)	0.27 (0.08)	(0.11, 0.43)	0.001 *
		Placebo	36	36 (100.0)	-0.02 (0.06)	(-0.13, 0.09)			
	Week 8	Tezepelumab	36	33 (91.7)	0.21 (0.06)	(0.10, 0.32)	0.17 (0.08)	(0.01, 0.32)	0.036 *
		Placebo	36	33 (91.7)	0.04 (0.05)	(-0.07, 0.15)			
	Week 12	Tezepelumab	36	33 (91.7)	0.28 (0.07)	(0.14, 0.41)	0.21 (0.10)	(0.02, 0.40)	0.033 *
		Placebo	36	35 (97.2)	0.07 (0.07)	(-0.07, 0.20)			
	Week 20	Tezepelumab	36	29 (80.6)	0.18 (0.06)	(0.06, 0.30)	0.13 (0.08)	(-0.04, 0.30)	0.123
		Placebo	36	34 (94.4)	0.05 (0.06)	(-0.07, 0.16)			
	Week 28	Tezepelumab	36	31 (86.1)	0.20 (0.07)	(0.06, 0.33)	0.19 (0.09)	(-0.00, 0.37)	0.054
		Placebo	36	34 (94.4)	0.01 (0.07)	(-0.12, 0.14)			
	Week 40	Tezepelumab	36	31 (86.1)	0.22 (0.07)	(0.08, 0.36)	0.11 (0.10)	(-0.09, 0.31)	0.266
		Placebo	36	32 (88.9)	0.11 (0.07)	(-0.03, 0.25)			
	Week 52	Tezepelumab	36	31 (86.1)	0.21 (0.07)	(0.06, 0.35)	0.17 (0.10)	(-0.03, 0.37)	0.093
		Placebo	36	35 (97.2)	0.04 (0.07)	(-0.10, 0.17)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. P)									0.008 i
< 24 ppb	Week 4	Tezepelumab	38	37 (97.4)	0.16 (0.06)	(0.04, 0.28)	0.03 (0.09)	(-0.15, 0.21)	0.754
		Placebo	30	30 (100.0)	0.13 (0.07)	(-0.00, 0.26)			
	Week 8	Tezepelumab	38	34 (89.5)	0.13 (0.05)	(0.03, 0.23)	-0.04 (0.08)	(-0.19, 0.11)	0.605
		Placebo	30	29 (96.7)	0.17 (0.06)	(0.06, 0.28)			
	Week 12	Tezepelumab	38	36 (94.7)	0.22 (0.06)	(0.09, 0.34)	0.09 (0.09)	(-0.10, 0.27)	0.357
		Placebo	30	29 (96.7)	0.13 (0.07)	(-0.00, 0.27)			
	Week 20	Tezepelumab	38	33 (86.8)	0.10 (0.05)	(-0.00, 0.21)	-0.01 (0.08)	(-0.17, 0.15)	0.856
		Placebo	30	28 (93.3)	0.12 (0.06)	(0.00, 0.24)			
	Week 28	Tezepelumab	38	34 (89.5)	0.13 (0.06)	(0.02, 0.25)	0.06 (0.09)	(-0.11, 0.24)	0.464
		Placebo	30	27 (90.0)	0.07 (0.06)	(-0.06, 0.20)			
	Week 40	Tezepelumab	38	34 (89.5)	0.16 (0.06)	(0.05, 0.28)	0.04 (0.09)	(-0.13, 0.21)	0.612
		Placebo	30	27 (90.0)	0.12 (0.06)	(-0.01, 0.25)			
	Week 52	Tezepelumab	38	34 (89.5)	0.06 (0.06)	(-0.06, 0.17)	0.04 (0.09)	(-0.13, 0.21)	0.671
		Placebo	30	29 (96.7)	0.02 (0.06)	(-0.10, 0.15)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 24 ppb	Week 4	Tezepelumab	28	27 (96.4)	0.39 (0.09)	(0.20, 0.57)	0.45 (0.13)	(0.20, 0.70)	<0.001 *
		Placebo	34	34 (100.0)	-0.06 (0.08)	(-0.23, 0.10)			
	Week 8	Tezepelumab	28	26 (92.9)	0.35 (0.09)	(0.17, 0.54)	0.35 (0.13)	(0.10, 0.60)	0.007 *
		Placebo	34	31 (91.2)	0.00 (0.08)	(-0.16, 0.17)			
	Week 12	Tezepelumab	28	26 (92.9)	0.38 (0.10)	(0.18, 0.58)	0.39 (0.13)	(0.12, 0.66)	0.006 *
		Placebo	34	33 (97.1)	-0.01 (0.09)	(-0.18, 0.17)			
	Week 20	Tezepelumab	28	24 (85.7)	0.32 (0.09)	(0.14, 0.50)	0.35 (0.12)	(0.10, 0.60)	0.007 *
		Placebo	34	31 (91.2)	-0.03 (0.08)	(-0.19, 0.13)			
	Week 28	Tezepelumab	28	26 (92.9)	0.31 (0.10)	(0.11, 0.51)	0.37 (0.14)	(0.10, 0.64)	0.009 *
		Placebo	34	31 (91.2)	-0.06 (0.09)	(-0.24, 0.12)			
	Week 40	Tezepelumab	28	24 (85.7)	0.33 (0.11)	(0.12, 0.54)	0.27 (0.15)	(-0.02, 0.56)	0.070
		Placebo	34	29 (85.3)	0.06 (0.10)	(-0.13, 0.25)			
	Week 52	Tezepelumab	28	25 (89.3)	0.35 (0.11)	(0.13, 0.56)	0.30 (0.14)	(0.01, 0.59)	0.042 *
		Placebo	34	30 (88.2)	0.05 (0.10)	(-0.14, 0.24)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline FENO (cat. M)									0.011 i
< 22.0 ppb	Week 4	Tezepelumab	32	31 (96.9)	0.14 (0.07)	(-0.00, 0.27)	-0.00 (0.10)	(-0.20, 0.20)	0.983
		Placebo	27	27 (100.0)	0.14 (0.07)	(-0.01, 0.28)			
	Week 8	Tezepelumab	32	29 (90.6)	0.12 (0.06)	(0.01, 0.23)	-0.03 (0.08)	(-0.20, 0.13)	0.685
		Placebo	27	26 (96.3)	0.15 (0.06)	(0.04, 0.27)			
	Week 12	Tezepelumab	32	30 (93.8)	0.17 (0.06)	(0.05, 0.30)	0.09 (0.09)	(-0.10, 0.27)	0.358
		Placebo	27	26 (96.3)	0.09 (0.07)	(-0.05, 0.22)			
	Week 20	Tezepelumab	32	28 (87.5)	0.07 (0.06)	(-0.05, 0.19)	-0.05 (0.09)	(-0.22, 0.13)	0.594
		Placebo	27	25 (92.6)	0.12 (0.06)	(-0.01, 0.24)			
	Week 28	Tezepelumab	32	28 (87.5)	0.07 (0.06)	(-0.05, 0.19)	0.03 (0.09)	(-0.15, 0.21)	0.763
		Placebo	27	24 (88.9)	0.04 (0.07)	(-0.09, 0.17)			
	Week 40	Tezepelumab	32	28 (87.5)	0.10 (0.05)	(-0.00, 0.21)	0.01 (0.08)	(-0.15, 0.17)	0.907
		Placebo	27	24 (88.9)	0.09 (0.06)	(-0.02, 0.21)			
	Week 52	Tezepelumab	32	28 (87.5)	0.02 (0.06)	(-0.10, 0.14)	0.04 (0.09)	(-0.14, 0.21)	0.687
		Placebo	27	26 (96.3)	-0.01 (0.06)	(-0.14, 0.11)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
>= 22.0 ppb	Week 4	Tezepelumab	34	33 (97.1)	0.37 (0.08)	(0.21, 0.53)	0.43 (0.11)	(0.20, 0.65)	<0.001 *
		Placebo	37	37 (100.0)	-0.06 (0.08)	(-0.21, 0.10)			
	Week 8	Tezepelumab	34	31 (91.2)	0.34 (0.08)	(0.17, 0.50)	0.31 (0.12)	(0.08, 0.54)	0.009 *
		Placebo	37	34 (91.9)	0.02 (0.08)	(-0.13, 0.18)			
	Week 12	Tezepelumab	34	32 (94.1)	0.40 (0.09)	(0.22, 0.57)	0.36 (0.12)	(0.12, 0.61)	0.005 *
		Placebo	37	36 (97.3)	0.03 (0.08)	(-0.14, 0.20)			
	Week 20	Tezepelumab	34	29 (85.3)	0.33 (0.08)	(0.17, 0.49)	0.34 (0.11)	(0.12, 0.57)	0.003 *
		Placebo	37	34 (91.9)	-0.01 (0.08)	(-0.17, 0.14)			
	Week 28	Tezepelumab	34	32 (94.1)	0.34 (0.09)	(0.16, 0.52)	0.36 (0.12)	(0.12, 0.61)	0.005 *
		Placebo	37	34 (91.9)	-0.02 (0.08)	(-0.19, 0.14)			
	Week 40	Tezepelumab	34	30 (88.2)	0.36 (0.10)	(0.17, 0.55)	0.28 (0.13)	(0.01, 0.55)	0.039 *
		Placebo	37	32 (86.5)	0.07 (0.09)	(-0.11, 0.26)			
	Week 52	Tezepelumab	34	31 (91.2)	0.32 (0.09)	(0.14, 0.51)	0.26 (0.13)	(0.00, 0.53)	0.049 *
		Placebo	37	33 (89.2)	0.06 (0.09)	(-0.12, 0.24)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline all FEIA status									0.654
All negative	Week 4	Tezepelumab	25	25 (100.0)	0.20 (0.09)	(0.02, 0.39)	0.20 (0.13)	(-0.07, 0.47)	0.138
		Placebo	22	22 (100.0)	0.00 (0.10)	(-0.19, 0.20)			
	Week 8	Tezepelumab	25	24 (96.0)	0.16 (0.08)	(-0.00, 0.33)	0.14 (0.12)	(-0.10, 0.38)	0.248
		Placebo	22	20 (90.9)	0.02 (0.09)	(-0.16, 0.20)			
	Week 12	Tezepelumab	25	23 (92.0)	0.24 (0.08)	(0.08, 0.39)	0.31 (0.11)	(0.08, 0.54)	0.010 *
		Placebo	22	22 (100.0)	-0.07 (0.08)	(-0.24, 0.10)			
	Week 20	Tezepelumab	25	21 (84.0)	0.18 (0.08)	(0.01, 0.34)	0.19 (0.12)	(-0.04, 0.42)	0.106
		Placebo	22	21 (95.5)	-0.02 (0.08)	(-0.18, 0.15)			
	Week 28	Tezepelumab	25	22 (88.0)	0.14 (0.08)	(-0.03, 0.31)	0.25 (0.12)	(0.01, 0.50)	0.044 *
		Placebo	22	20 (90.9)	-0.11 (0.09)	(-0.29, 0.07)			
	Week 40	Tezepelumab	25	22 (88.0)	0.15 (0.09)	(-0.04, 0.34)	0.12 (0.14)	(-0.16, 0.39)	0.389
		Placebo	22	21 (95.5)	0.03 (0.10)	(-0.17, 0.23)			
	Week 52	Tezepelumab	25	22 (88.0)	0.12 (0.10)	(-0.08, 0.32)	0.14 (0.14)	(-0.15, 0.43)	0.327
		Placebo	22	21 (95.5)	-0.02 (0.10)	(-0.23, 0.19)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Any positive	Week 4	Tezepelumab	35	33 (94.3)	0.28 (0.07)	(0.13, 0.43)	0.24 (0.10)	(0.04, 0.44)	0.020 *
		Placebo	41	41 (100.0)	0.04 (0.07)	(-0.09, 0.17)			
	Week 8	Tezepelumab	35	31 (88.6)	0.26 (0.07)	(0.11, 0.40)	0.14 (0.10)	(-0.06, 0.33)	0.174
		Placebo	41	39 (95.1)	0.12 (0.07)	(-0.01, 0.25)			
	Week 12	Tezepelumab	35	33 (94.3)	0.30 (0.08)	(0.14, 0.45)	0.15 (0.11)	(-0.06, 0.37)	0.156
		Placebo	41	39 (95.1)	0.14 (0.07)	(-0.00, 0.29)			
	Week 20	Tezepelumab	35	30 (85.7)	0.20 (0.07)	(0.05, 0.34)	0.11 (0.10)	(-0.09, 0.31)	0.266
		Placebo	41	37 (90.2)	0.08 (0.07)	(-0.05, 0.22)			
	Week 28	Tezepelumab	35	32 (91.4)	0.25 (0.08)	(0.08, 0.42)	0.17 (0.11)	(-0.06, 0.40)	0.137
		Placebo	41	37 (90.2)	0.08 (0.08)	(-0.07, 0.23)			
	Week 40	Tezepelumab	35	30 (85.7)	0.28 (0.08)	(0.13, 0.44)	0.17 (0.11)	(-0.05, 0.39)	0.125
		Placebo	41	34 (82.9)	0.12 (0.07)	(-0.03, 0.26)			
	Week 52	Tezepelumab	35	31 (88.6)	0.21 (0.08)	(0.05, 0.37)	0.15 (0.11)	(-0.07, 0.37)	0.180
		Placebo	41	37 (90.2)	0.06 (0.07)	(-0.09, 0.21)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Th2 status									0.147
Low	Week 4	Tezepelumab	41	40 (97.6)	0.31 (0.08)	(0.15, 0.46)	0.30 (0.12)	(0.06, 0.53)	0.013 *
		Placebo	30	30 (100.0)	0.01 (0.09)	(-0.17, 0.19)			
	Week 8	Tezepelumab	41	38 (92.7)	0.27 (0.07)	(0.12, 0.41)	0.21 (0.11)	(-0.02, 0.43)	0.068
		Placebo	30	27 (90.0)	0.06 (0.08)	(-0.10, 0.23)			
	Week 12	Tezepelumab	41	38 (92.7)	0.35 (0.07)	(0.20, 0.49)	0.36 (0.11)	(0.14, 0.58)	0.002 *
		Placebo	30	29 (96.7)	-0.02 (0.08)	(-0.18, 0.15)			
	Week 20	Tezepelumab	41	36 (87.8)	0.23 (0.07)	(0.08, 0.37)	0.22 (0.11)	(0.00, 0.44)	0.047 *
		Placebo	30	27 (90.0)	0.01 (0.08)	(-0.16, 0.17)			
	Week 28	Tezepelumab	41	37 (90.2)	0.26 (0.08)	(0.11, 0.41)	0.33 (0.12)	(0.10, 0.56)	0.006 *
		Placebo	30	27 (90.0)	-0.07 (0.09)	(-0.24, 0.11)			
	Week 40	Tezepelumab	41	35 (85.4)	0.27 (0.08)	(0.11, 0.43)	0.20 (0.12)	(-0.05, 0.45)	0.112
		Placebo	30	24 (80.0)	0.07 (0.09)	(-0.12, 0.26)			
	Week 52	Tezepelumab	41	36 (87.8)	0.23 (0.08)	(0.07, 0.38)	0.30 (0.12)	(0.07, 0.53)	0.013 *
		Placebo	30	26 (86.7)	-0.07 (0.09)	(-0.25, 0.10)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High	Week 4	Tezepelumab	25	24 (96.0)	0.16 (0.07)	(0.02, 0.30)	0.11 (0.09)	(-0.08, 0.29)	0.268
		Placebo	34	34 (100.0)	0.05 (0.06)	(-0.07, 0.18)			
	Week 8	Tezepelumab	25	22 (88.0)	0.16 (0.07)	(0.02, 0.29)	0.04 (0.09)	(-0.13, 0.22)	0.617
		Placebo	34	33 (97.1)	0.11 (0.06)	(-0.00, 0.22)			
	Week 12	Tezepelumab	25	24 (96.0)	0.18 (0.09)	(0.01, 0.36)	0.06 (0.11)	(-0.17, 0.28)	0.624
		Placebo	34	33 (97.1)	0.13 (0.07)	(-0.02, 0.28)			
	Week 20	Tezepelumab	25	21 (84.0)	0.14 (0.07)	(-0.00, 0.29)	0.05 (0.10)	(-0.14, 0.25)	0.578
		Placebo	34	32 (94.1)	0.09 (0.06)	(-0.03, 0.21)			
	Week 28	Tezepelumab	25	23 (92.0)	0.12 (0.08)	(-0.04, 0.28)	0.04 (0.11)	(-0.17, 0.26)	0.688
		Placebo	34	31 (91.2)	0.08 (0.07)	(-0.06, 0.22)			
	Week 40	Tezepelumab	25	23 (92.0)	0.17 (0.08)	(0.01, 0.34)	0.07 (0.11)	(-0.14, 0.29)	0.489
		Placebo	34	32 (94.1)	0.10 (0.07)	(-0.04, 0.24)			
	Week 52	Tezepelumab	25	23 (92.0)	0.09 (0.09)	(-0.09, 0.28)	-0.01 (0.12)	(-0.25, 0.23)	0.908
		Placebo	34	33 (97.1)	0.11 (0.08)	(-0.05, 0.26)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Baseline Periostin									0.329
Low (< 20.9 ng/ml)	Week 4	Tezepelumab	26	26 (100.0)	0.03 (0.06)	(-0.09, 0.15)	0.07 (0.08)	(-0.09, 0.24)	0.365
		Placebo	31	31 (100.0)	-0.04 (0.06)	(-0.15, 0.07)			
	Week 8	Tezepelumab	26	26 (100.0)	0.08 (0.07)	(-0.05, 0.21)	0.07 (0.09)	(-0.11, 0.25)	0.425
		Placebo	31	29 (93.5)	0.01 (0.06)	(-0.12, 0.13)			
	Week 12	Tezepelumab	26	24 (92.3)	0.17 (0.07)	(0.03, 0.32)	0.22 (0.10)	(0.03, 0.42)	0.025 *
		Placebo	31	29 (93.5)	-0.05 (0.07)	(-0.18, 0.08)			
	Week 20	Tezepelumab	26	24 (92.3)	0.04 (0.07)	(-0.10, 0.18)	0.05 (0.09)	(-0.14, 0.24)	0.570
		Placebo	31	28 (90.3)	-0.01 (0.06)	(-0.14, 0.11)			
	Week 28	Tezepelumab	26	24 (92.3)	0.05 (0.06)	(-0.08, 0.17)	0.03 (0.08)	(-0.14, 0.20)	0.709
		Placebo	31	27 (87.1)	0.01 (0.06)	(-0.10, 0.13)			
	Week 40	Tezepelumab	26	23 (88.5)	0.08 (0.07)	(-0.06, 0.22)	0.05 (0.10)	(-0.14, 0.25)	0.573
		Placebo	31	26 (83.9)	0.02 (0.06)	(-0.11, 0.15)			
	Week 52	Tezepelumab	26	24 (92.3)	0.01 (0.06)	(-0.11, 0.14)	0.10 (0.08)	(-0.06, 0.27)	0.214
		Placebo	31	27 (87.1)	-0.09 (0.06)	(-0.20, 0.02)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
High (>= 20.9 ng/ml)	Week 4	Tezepelumab	40	38 (95.0)	0.41 (0.08)	(0.26, 0.56)	0.31 (0.11)	(0.09, 0.54)	0.006 *
		Placebo	34	34 (100.0)	0.09 (0.08)	(-0.07, 0.26)			
	Week 8	Tezepelumab	40	34 (85.0)	0.33 (0.07)	(0.20, 0.47)	0.18 (0.10)	(-0.02, 0.39)	0.073
		Placebo	34	32 (94.1)	0.15 (0.07)	(0.00, 0.30)			
	Week 12	Tezepelumab	40	38 (95.0)	0.37 (0.08)	(0.22, 0.52)	0.21 (0.11)	(-0.01, 0.43)	0.061
		Placebo	34	34 (100.0)	0.16 (0.08)	(-0.00, 0.32)			
	Week 20	Tezepelumab	40	33 (82.5)	0.31 (0.07)	(0.17, 0.45)	0.21 (0.10)	(0.01, 0.41)	0.040 *
		Placebo	34	32 (94.1)	0.10 (0.07)	(-0.05, 0.24)			
	Week 28	Tezepelumab	40	36 (90.0)	0.31 (0.08)	(0.15, 0.48)	0.29 (0.12)	(0.06, 0.53)	0.015 *
		Placebo	34	32 (94.1)	0.02 (0.09)	(-0.15, 0.19)			
	Week 40	Tezepelumab	40	35 (87.5)	0.34 (0.08)	(0.18, 0.50)	0.20 (0.12)	(-0.03, 0.43)	0.094
		Placebo	34	31 (91.2)	0.14 (0.08)	(-0.03, 0.31)			
	Week 52	Tezepelumab	40	35 (87.5)	0.29 (0.08)	(0.12, 0.45)	0.15 (0.12)	(-0.09, 0.39)	0.215
		Placebo	34	33 (97.1)	0.14 (0.09)	(-0.04, 0.31)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Current post-BD FEV1 reversibility									0.870
Yes	Week 4	Tezepelumab	57	55 (96.5)	0.27 (0.06)	(0.15, 0.39)	0.22 (0.08)	(0.06, 0.39)	0.008 *
		Placebo	60	60 (100.0)	0.05 (0.06)	(-0.07, 0.16)			
	Week 8	Tezepelumab	57	51 (89.5)	0.25 (0.06)	(0.13, 0.36)	0.16 (0.08)	(-0.00, 0.31)	0.051
		Placebo	60	56 (93.3)	0.09 (0.06)	(-0.02, 0.20)			
	Week 12	Tezepelumab	57	53 (93.0)	0.31 (0.06)	(0.19, 0.43)	0.24 (0.09)	(0.07, 0.41)	0.006 *
		Placebo	60	58 (96.7)	0.07 (0.06)	(-0.05, 0.19)			
	Week 20	Tezepelumab	57	49 (86.0)	0.23 (0.06)	(0.11, 0.34)	0.18 (0.08)	(0.03, 0.34)	0.022 *
		Placebo	60	56 (93.3)	0.04 (0.05)	(-0.07, 0.15)			
	Week 28	Tezepelumab	57	51 (89.5)	0.23 (0.06)	(0.11, 0.35)	0.21 (0.08)	(0.05, 0.38)	0.013 *
		Placebo	60	54 (90.0)	0.02 (0.06)	(-0.10, 0.13)			
	Week 40	Tezepelumab	57	49 (86.0)	0.27 (0.06)	(0.14, 0.39)	0.16 (0.09)	(-0.01, 0.34)	0.063
		Placebo	60	54 (90.0)	0.10 (0.06)	(-0.02, 0.22)			
	Week 52	Tezepelumab	57	50 (87.7)	0.19 (0.07)	(0.06, 0.32)	0.15 (0.09)	(-0.03, 0.33)	0.107
		Placebo	60	56 (93.3)	0.04 (0.06)	(-0.09, 0.16)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	9	9 (100.0)	NE		NE		
		Placebo	5	5 (100.0)					
	Week 8	Tezepelumab	9	9 (100.0)	NE		NE		
		Placebo	5	5 (100.0)					
	Week 12	Tezepelumab	9	9 (100.0)	NE		NE		
		Placebo	5	5 (100.0)					
	Week 20	Tezepelumab	9	8 (88.9)	NE		NE		
		Placebo	5	4 (80.0)					
	Week 28	Tezepelumab	9	9 (100.0)	NE		NE		
		Placebo	5	5 (100.0)					
	Week 40	Tezepelumab	9	9 (100.0)	NE		NE		
		Placebo	5	3 (60.0)					
	Week 52	Tezepelumab	9	9 (100.0)	NE		NE		
		Placebo	5	4 (80.0)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Maintenance OCS use at baseline									0.977
Yes	Week 4	Tezepelumab	9	9 (100.0)	0.33 (0.12)	(0.07, 0.59)	0.49 (0.16)	(0.16, 0.82)	0.006 *
		Placebo	14	14 (100.0)	-0.16 (0.10)	(-0.37, 0.04)			
	Week 8	Tezepelumab	9	7 (77.8)	0.35 (0.13)	(0.07, 0.63)	0.32 (0.17)	(-0.04, 0.68)	0.076
		Placebo	14	13 (92.9)	0.03 (0.11)	(-0.19, 0.25)			
	Week 12	Tezepelumab	9	8 (88.9)	0.32 (0.16)	(-0.02, 0.65)	0.33 (0.21)	(-0.10, 0.75)	0.128
		Placebo	14	13 (92.9)	-0.01 (0.13)	(-0.27, 0.26)			
	Week 20	Tezepelumab	9	8 (88.9)	0.13 (0.13)	(-0.14, 0.40)	0.06 (0.17)	(-0.29, 0.40)	0.729
		Placebo	14	13 (92.9)	0.07 (0.10)	(-0.14, 0.28)			
	Week 28	Tezepelumab	9	8 (88.9)	0.19 (0.18)	(-0.18, 0.57)	0.20 (0.23)	(-0.28, 0.68)	0.405
		Placebo	14	12 (85.7)	-0.00 (0.14)	(-0.30, 0.30)			
	Week 40	Tezepelumab	9	7 (77.8)	0.27 (0.21)	(-0.16, 0.70)	0.20 (0.26)	(-0.35, 0.75)	0.453
		Placebo	14	11 (78.6)	0.07 (0.16)	(-0.28, 0.41)			
	Week 52	Tezepelumab	9	7 (77.8)	0.31 (0.22)	(-0.14, 0.76)	0.18 (0.27)	(-0.40, 0.75)	0.524
		Placebo	14	12 (85.7)	0.13 (0.17)	(-0.22, 0.48)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	57	55 (96.5)	0.25 (0.06)	(0.14, 0.36)	0.17 (0.08)	(0.00, 0.34)	0.044 *
		Placebo	51	51 (100.0)	0.08 (0.06)	(-0.04, 0.20)			
	Week 8	Tezepelumab	57	53 (93.0)	0.22 (0.05)	(0.11, 0.33)	0.12 (0.08)	(-0.03, 0.28)	0.117
		Placebo	51	48 (94.1)	0.09 (0.06)	(-0.02, 0.21)			
	Week 12	Tezepelumab	57	54 (94.7)	0.29 (0.06)	(0.17, 0.40)	0.21 (0.08)	(0.05, 0.38)	0.013 *
		Placebo	51	50 (98.0)	0.08 (0.06)	(-0.04, 0.20)			
	Week 20	Tezepelumab	57	49 (86.0)	0.22 (0.05)	(0.11, 0.33)	0.18 (0.08)	(0.03, 0.34)	0.023 *
		Placebo	51	47 (92.2)	0.03 (0.06)	(-0.08, 0.15)			
	Week 28	Tezepelumab	57	52 (91.2)	0.22 (0.06)	(0.11, 0.33)	0.20 (0.08)	(0.04, 0.36)	0.013 *
		Placebo	51	47 (92.2)	0.01 (0.06)	(-0.10, 0.13)			
	Week 40	Tezepelumab	57	51 (89.5)	0.24 (0.06)	(0.13, 0.35)	0.15 (0.08)	(-0.01, 0.32)	0.073
		Placebo	51	46 (90.2)	0.09 (0.06)	(-0.03, 0.21)			
	Week 52	Tezepelumab	57	52 (91.2)	0.17 (0.06)	(0.05, 0.28)	0.16 (0.08)	(0.00, 0.33)	0.049 *
		Placebo	51	48 (94.1)	0.00 (0.06)	(-0.12, 0.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No chronic OCS use and current post-BD FEV1 reversibility									0.966
Yes	Week 4	Tezepelumab	51	49 (96.1)	0.25 (0.06)	(0.12, 0.37)	0.16 (0.09)	(-0.01, 0.34)	0.069
		Placebo	49	49 (100.0)	0.08 (0.06)	(-0.04, 0.21)			
	Week 8	Tezepelumab	51	47 (92.2)	0.22 (0.06)	(0.10, 0.34)	0.12 (0.08)	(-0.05, 0.29)	0.164
		Placebo	49	46 (93.9)	0.10 (0.06)	(-0.02, 0.22)			
	Week 12	Tezepelumab	51	48 (94.1)	0.29 (0.06)	(0.17, 0.42)	0.21 (0.09)	(0.03, 0.38)	0.022 *
		Placebo	49	48 (98.0)	0.09 (0.06)	(-0.04, 0.21)			
	Week 20	Tezepelumab	51	44 (86.3)	0.22 (0.06)	(0.11, 0.34)	0.19 (0.08)	(0.02, 0.36)	0.029 *
		Placebo	49	46 (93.9)	0.04 (0.06)	(-0.08, 0.16)			
	Week 28	Tezepelumab	51	46 (90.2)	0.21 (0.06)	(0.09, 0.33)	0.19 (0.09)	(0.02, 0.36)	0.029 *
		Placebo	49	45 (91.8)	0.02 (0.06)	(-0.10, 0.14)			
	Week 40	Tezepelumab	51	45 (88.2)	0.25 (0.06)	(0.12, 0.37)	0.15 (0.09)	(-0.02, 0.33)	0.087
		Placebo	49	45 (91.8)	0.10 (0.06)	(-0.03, 0.22)			
	Week 52	Tezepelumab	51	46 (90.2)	0.16 (0.06)	(0.04, 0.28)	0.15 (0.09)	(-0.02, 0.33)	0.087
		Placebo	49	47 (95.9)	0.01 (0.06)	(-0.11, 0.13)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_ILSCP: Change from baseline in FEV1 Pre-BD by study specific subgroups - MMRM results
DITTL

Change from baseline in FEV1 Pre-BD					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
No	Week 4	Tezepelumab	15	15 (100.0)	0.28 (0.09)	(0.09, 0.47)	0.39 (0.13)	(0.12, 0.65)	0.006 *
		Placebo	16	16 (100.0)	-0.11 (0.09)	(-0.29, 0.08)			
	Week 8	Tezepelumab	15	13 (86.7)	0.26 (0.09)	(0.07, 0.45)	0.21 (0.13)	(-0.06, 0.47)	0.117
		Placebo	16	15 (93.8)	0.05 (0.09)	(-0.13, 0.24)			
	Week 12	Tezepelumab	15	14 (93.3)	0.27 (0.12)	(0.03, 0.51)	0.26 (0.16)	(-0.07, 0.59)	0.116
		Placebo	16	15 (93.8)	0.01 (0.11)	(-0.22, 0.24)			
	Week 20	Tezepelumab	15	13 (86.7)	0.10 (0.09)	(-0.09, 0.29)	0.01 (0.13)	(-0.25, 0.27)	0.944
		Placebo	16	14 (87.5)	0.09 (0.09)	(-0.09, 0.27)			
	Week 28	Tezepelumab	15	14 (93.3)	0.20 (0.13)	(-0.06, 0.46)	0.19 (0.18)	(-0.17, 0.55)	0.279
		Placebo	16	14 (87.5)	0.01 (0.12)	(-0.25, 0.26)			
	Week 40	Tezepelumab	15	13 (86.7)	0.20 (0.14)	(-0.09, 0.48)	0.10 (0.20)	(-0.30, 0.51)	0.598
		Placebo	16	12 (75.0)	0.09 (0.14)	(-0.19, 0.37)			
	Week 52	Tezepelumab	15	13 (86.7)	0.23 (0.14)	(-0.07, 0.52)	0.10 (0.20)	(-0.32, 0.51)	0.632
		Placebo	16	13 (81.3)	0.13 (0.14)	(-0.16, 0.42)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
i = significant interaction effect. NE = not evaluable.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L. For investigation of heterogeneity, factors subgroup and interaction subgroup * treatment were added.
Source Data: afev, created on: 11AUG2022

Figure PF2FAC_ILSHK11: Course of FEV1 Pre-BD by BMI
DITTL

BMI: 18.5 - < 25.0 kg/m**2



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: PT2FAC_ILSHK

Figure PF2FAC_ILSHK11: Course of FEV1 Pre-BD by BMI
DITTL

BMI: 25.0 - < 30.0 kg/m**2



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: PT2FAC_ILSHK

Figure PF2FAC_ILSHK11: Course of FEV1 Pre-BD by BMI
DITTL

BMI: >= 30.0 kg/m**2



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: PT2FAC_ILSHK

Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: PT2FAC_ILSHK

Figure PF2FAC_ILSHK20: Course of FEV1 Pre-BD by baseline FENO
DITTL

Baseline FENO: < 25 ppb



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: PT2FAC_ILSHK

Figure PF2FAC_ILSHK20: Course of FEV1 Pre-BD by baseline FENO
DITTL

Baseline FENO: >= 25 ppb



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: PT2FAC_ILSHK

Figure PF2FAC_ILSHP23: Course of FEV1 Pre-BD by baseline FENO (cat. P)
DITTL

Baseline FENO (cat. P): < 24 ppb



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: PT2FAC_ILSHP

Figure PF2FAC_ILSHP23: Course of FEV1 Pre-BD by baseline FENO (cat. P)
DITTL

Baseline FENO (cat. P): >= 24 ppb



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: PT2FAC_ILSHP

Figure PF2FAC_ILSHP24: Course of FEV1 Pre-BD by baseline FENO (cat. M)
DITTL

Baseline FENO (cat. M): < 22.0 ppb



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: PT2FAC_ILSHP

Figure PF2FAC_ILSHP24: Course of FEV1 Pre-BD by baseline FENO (cat. M)
DITTL

Baseline FENO (cat. M): >= 22.0 ppb



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source tables: PT2FAC_ILSHP

Table PT2FAC_IBMH0: Course of FEV1 Pre-BD
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
FEV1 Pre-BD	Baseline	Tezepelumab	12	12 (100.0)	1.90 (0.64)	1.1	1.40	1.77	2.40	3.1	
		Placebo	9	9 (100.0)	1.83 (0.83)	0.9	1.01	1.93	2.52	2.9	
	Week 4	Tezepelumab	12	12 (100.0)	2.06 (0.69)	1.1	1.50	2.18	2.54	3.3	
		Placebo	9	9 (100.0)	1.96 (0.90)	0.7	1.17	1.94	2.61	3.1	
	Week 8	Tezepelumab	12	12 (100.0)	2.07 (0.66)	1.4	1.42	2.05	2.47	3.4	
		Placebo	9	9 (100.0)	1.96 (0.99)	0.8	1.11	2.08	2.67	3.4	
	Week 12	Tezepelumab	12	11 (91.7)	2.11 (0.76)	1.0	1.47	2.14	2.71	3.5	
		Placebo	9	9 (100.0)	1.92 (0.87)	0.9	1.20	1.93	2.50	3.3	
	Week 20	Tezepelumab	12	10 (83.3)	1.86 (0.63)	1.0	1.47	1.61	2.30	2.9	
		Placebo	9	9 (100.0)	1.90 (0.96)	0.5	1.12	1.99	2.70	3.2	
	Week 28	Tezepelumab	12	10 (83.3)	1.88 (0.52)	1.3	1.45	1.86	2.12	3.0	
		Placebo	9	9 (100.0)	1.84 (0.88)	0.7	1.12	1.85	2.01	3.4	
	Week 40	Tezepelumab	12	10 (83.3)	1.96 (0.57)	1.2	1.45	1.95	2.33	3.0	
		Placebo	9	8 (88.9)	2.14 (0.98)	0.8	1.30	2.17	2.95	3.5	
	Week 52	Tezepelumab	12	10 (83.3)	1.82 (0.54)	1.2	1.37	1.73	2.25	2.9	
		Placebo	9	9 (100.0)	1.81 (0.96)	0.6	1.08	1.86	2.00	3.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IBMH0: Course of FEV1 Pre-BD
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in FEV1 Pre-BD	Week 4	Tezepelumab	12	12 (100.0)	0.16 (0.31)	-0.3	-0.05	0.09	0.34	0.8	0.10 [-0.76, 0.96]
		Placebo	9	9 (100.0)	0.13 (0.28)	-0.3	0.01	0.11	0.25	0.6	
	Week 8	Tezepelumab	12	12 (100.0)	0.17 (0.19)	-0.1	-0.03	0.27	0.32	0.4	0.15 [-0.72, 1.01]
		Placebo	9	9 (100.0)	0.13 (0.41)	-0.6	-0.09	0.15	0.29	0.9	
	Week 12	Tezepelumab	12	11 (91.7)	0.28 (0.43)	-0.1	-0.04	0.09	0.49	1.3	0.50 [-0.40, 1.40]
		Placebo	9	9 (100.0)	0.09 (0.34)	-0.4	-0.05	0.02	0.16	0.8	
	Week 20	Tezepelumab	12	10 (83.3)	0.16 (0.40)	-0.6	-0.06	0.10	0.53	0.8	0.26 [-0.65, 1.16]
		Placebo	9	9 (100.0)	0.07 (0.28)	-0.4	-0.10	0.06	0.21	0.5	
	Week 28	Tezepelumab	12	10 (83.3)	0.18 (0.25)	-0.1	0.01	0.07	0.30	0.6	0.41 [-0.50, 1.33]
		Placebo	9	9 (100.0)	0.01 (0.53)	-1.1	-0.17	0.11	0.28	0.9	
	Week 40	Tezepelumab	12	10 (83.3)	0.26 (0.36)	-0.1	0.04	0.24	0.29	1.1	0.16 [-0.78, 1.09]
		Placebo	9	8 (88.9)	0.20 (0.41)	-0.2	-0.17	0.16	0.39	1.0	
	Week 52	Tezepelumab	12	10 (83.3)	0.12 (0.23)	-0.2	-0.04	0.09	0.26	0.5	0.35 [-0.56, 1.25]
		Placebo	9	9 (100.0)	-0.02 (0.56)	-1.0	-0.26	0.06	0.17	1.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Table PT2FAC_IBMC0: Change from baseline in FEV1 Pre-BD - MMRM results
DITTB

Change from baseline in FEV1 Pre-BD				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	12 (100.0)	0.14 (0.09)	(-0.06, 0.34)	0.02 (0.14)	(-0.29, 0.33)	0.897
	Placebo	9	9 (100.0)	0.12 (0.11)	(-0.11, 0.35)			
Week 8	Tezepelumab	12	12 (100.0)	0.16 (0.09)	(-0.03, 0.36)	0.03 (0.14)	(-0.26, 0.33)	0.816
	Placebo	9	9 (100.0)	0.13 (0.11)	(-0.10, 0.35)			
Week 12	Tezepelumab	12	11 (91.7)	0.24 (0.13)	(-0.03, 0.51)	0.15 (0.19)	(-0.26, 0.56)	0.440
	Placebo	9	9 (100.0)	0.08 (0.14)	(-0.22, 0.39)			
Week 20	Tezepelumab	12	10 (83.3)	0.15 (0.11)	(-0.08, 0.38)	0.08 (0.16)	(-0.26, 0.42)	0.612
	Placebo	9	9 (100.0)	0.07 (0.12)	(-0.18, 0.31)			
Week 28	Tezepelumab	12	10 (83.3)	0.13 (0.13)	(-0.15, 0.42)	0.13 (0.20)	(-0.30, 0.56)	0.528
	Placebo	9	9 (100.0)	0.00 (0.15)	(-0.31, 0.32)			
Week 40	Tezepelumab	12	10 (83.3)	0.23 (0.12)	(-0.02, 0.48)	0.01 (0.18)	(-0.36, 0.39)	0.940
	Placebo	9	8 (88.9)	0.21 (0.13)	(-0.07, 0.50)			
Week 52	Tezepelumab	12	10 (83.3)	0.10 (0.13)	(-0.18, 0.37)	0.12 (0.20)	(-0.29, 0.54)	0.537
	Placebo	9	9 (100.0)	-0.03 (0.15)	(-0.34, 0.28)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source Data: afev, created on: 11AUG2022

Figure PF2FAC_IBMG0: Course of FEV1 Pre-BD
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
FEV1 Pre-BD = Forced expiratory volume in one second pre-bronchodilator measured in L.
Source table: PT2FAC_IBMH0
Source Data: afev, created on: 11AUG2022

Table PT2H5D_IOMP0: Decrease of at least 0.9 points in ACQ-5 score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in ACQ-5 score	Week 28	137	134 (97.8)	75 (54.7) [46.0, 63.3]	138	129 (93.5)	60 (43.5) [35.1, 52.2]	1.259 [0.987, 1.607]	1.573 [0.977, 2.531]	11.3 [-1.2, 23.7]	0.062
	Week 52	137	135 (98.5)	86 (62.8) [54.1, 70.9]	138	131 (94.9)	65 (47.1) [38.6, 55.8]	1.333 [1.071, 1.659]	1.894 [1.170, 3.065]	15.7 [3.3, 28.0]	0.009 *

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_IOSPK: Decrease of at least 0.9 points in ACQ-5 score by key subgroups
DITT

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.939	
Male	50	49 (98.0)	30 (60.0) [45.2, 73.6]	44	43 (97.7)	20 (45.5) [30.4, 61.2]	1.320 [0.889, 1.959]	1.800 [0.793, 4.087]	14.5 [-7.6, 36.7]	0.161	
Female	87	86 (98.9)	56 (64.4) [53.4, 74.4]	94	88 (93.6)	45 (47.9) [37.5, 58.4]	1.345 [1.034, 1.748]	1.967 [1.083, 3.573]	16.5 [1.1, 31.9]	0.026	*
Age										0.657	
< 65 years	114	113 (99.1)	72 (63.2) [53.6, 72.0]	118	113 (95.8)	57 (48.3) [39.0, 57.7]	1.307 [1.035, 1.651]	1.835 [1.086, 3.100]	14.9 [1.4, 28.4]	0.023	*
>= 65 years	23	22 (95.7)	14 (60.9) [38.5, 80.3]	20	18 (90.0)	8 (40.0) [19.1, 63.9]	1.522 [0.811, 2.854]	2.333 [0.685, 7.946]	20.9 [-13.1, 54.8]	0.177	
Exacerbations in the year before study										0.394	
<= 2	105	103 (98.1)	64 (61.0) [50.9, 70.3]	110	105 (95.5)	53 (48.2) [38.6, 57.9]	1.265 [0.988, 1.619]	1.679 [0.977, 2.886]	12.8 [-1.4, 26.9]	0.061	
> 2	32	32 (100.0)	22 (68.8) [50.0, 83.9]	28	26 (92.9)	12 (42.9) [24.5, 62.8]	1.604 [0.985, 2.612]	2.933 [1.018, 8.448]	25.9 [-1.8, 53.6]	0.045	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_IOSPK: Decrease of at least 0.9 points in ACQ-5 score by key subgroups
DITT

	Tezepelumab			Placebo							
Decrease of at least 0.9 points in ACQ-5 score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race		N<10	any level							NE	
White	128	126 (98.4)	79 (61.7) [52.7, 70.2]	123	116 (94.3)	56 (45.5) [36.5, 54.8]					
Black or African American	3	3 (100.0)	3 (100.0) [29.2, 100.0]	6	6 (100.0)	3 (50.0) [11.8, 88.2]					
Asian	5	5 (100.0)	4 (80.0) [28.4, 99.5]	6	6 (100.0)	3 (50.0) [11.8, 88.2]					
Other	1	1 (100.0)	0 (0.0) [0.0, 97.5]	3	3 (100.0)	3 (100.0) [29.2, 100.0]					
Region										0.774	
Europe	78	78 (100.0)	49 (62.8) [51.1, 73.5]	80	75 (93.8)	35 (43.8) [32.7, 55.3]	1.436 [1.062, 1.941]	2.172 [1.149, 4.108]	19.1 [2.5, 35.6]	0.017	*
America	10	10 (100.0)	9 (90.0) [55.5, 99.7]	9	8 (88.9)	6 (66.7) [29.9, 92.5]	1.350 [0.814, 2.239]	4.500 [0.374, 54.155]	23.3 [-23.2, 69.9]	0.303	#
Asia/Pacific	5	5 (100.0)	4 (80.0) [28.4, 99.5]	6	6 (100.0)	3 (50.0) [11.8, 88.2]	1.600 [0.643, 3.984]	4.000 [0.265, 60.325]	30.0 [-41.5, 100.0]	0.545	#
Rest of the world	44	42 (95.5)	24 (54.5) [38.8, 69.6]	43	42 (97.7)	21 (48.8) [33.3, 64.5]	1.117 [0.743, 1.679]	1.257 [0.541, 2.919]	5.7 [-17.6, 29.0]	0.596	
BMI		N<10	any level							NE	
< 18.5 kg/m**2	0			1	1 (100.0)	0 (0.0) [0.0, 97.5]					
18.5 - < 25.0 kg/m**2	39	39 (100.0)	30 (76.9) [60.7, 88.9]	43	42 (97.7)	23 (53.5) [37.7, 68.8]					
25.0 - < 30.0 kg/m**2	45	45 (100.0)	26 (57.8) [42.2, 72.3]	47	45 (95.7)	17 (36.2) [22.7, 51.5]					
>= 30.0 kg/m**2	53	51 (96.2)	30 (56.6) [42.3, 70.2]	47	43 (91.5)	25 (53.2) [38.1, 67.9]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_IOSPK: Decrease of at least 0.9 points in ACQ-5 score by key subgroups
DITT

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.353	
< 150 cells/uL	27	27 (100.0)	14 (51.9) [31.9, 71.3]	33	31 (93.9)	16 (48.5) [30.8, 66.5]	1.069 [0.645, 1.773]	1.144 [0.414, 3.166]	3.4 [-25.4, 32.1]	0.797	
>= 150 cells/uL	109	107 (98.2)	71 (65.1) [55.4, 74.0]	105	100 (95.2)	49 (46.7) [36.9, 56.7]	1.396 [1.091, 1.786]	2.135 [1.232, 3.700]	18.5 [4.5, 32.5]	0.007	*
Baseline eosinophils - High										0.049	i
< 300 cells/uL	69	67 (97.1)	39 (56.5) [44.0, 68.4]	72	66 (91.7)	38 (52.8) [40.7, 64.7]	1.071 [0.793, 1.447]	1.163 [0.599, 2.259]	3.7 [-14.1, 21.6]	0.656	
>= 300 cells/uL	67	67 (100.0)	46 (68.7) [56.2, 79.4]	66	65 (98.5)	27 (40.9) [29.0, 53.7]	1.678 [1.204, 2.339]	3.164 [1.552, 6.450]	27.7 [10.0, 45.5]	0.001	*
Baseline FENO										0.002	i
< 25 ppb	78	77 (98.7)	39 (50.0) [38.5, 61.5]	74	70 (94.6)	39 (52.7) [40.7, 64.4]	0.949 [0.696, 1.293]	0.897 [0.475, 1.696]	-2.7 [-19.9, 14.5]	0.740	
>= 25 ppb	57	56 (98.2)	45 (78.9) [66.1, 88.6]	63	60 (95.2)	26 (41.3) [29.0, 54.4]	1.913 [1.384, 2.644]	5.337 [2.373, 12.003]	37.7 [19.9, 55.5]	<0.001	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_IOSPK: Decrease of at least 0.9 points in ACQ-5 score by key subgroups
DITT

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.004	i
All negative	57	57 (100.0)	38 (66.7) [52.9, 78.6]	66	62 (93.9)	22 (33.3) [22.2, 46.0]	2.000 [1.358, 2.946]	4.000 [1.886, 8.483]	33.3 [15.0, 51.7]	<0.001	*
Any positive	71	69 (97.2)	41 (57.7) [45.4, 69.4]	63	60 (95.2)	37 (58.7) [45.6, 71.0]	0.983 [0.738, 1.310]	0.960 [0.483, 1.911]	-1.0 [-19.2, 17.2]	0.909	
Total serum IgE										0.167	
Low	35	35 (100.0)	21 (60.0) [42.1, 76.1]	32	28 (87.5)	12 (37.5) [21.1, 56.3]	1.600 [0.949, 2.699]	2.500 [0.934, 6.692]	22.5 [-3.8, 48.8]	0.068	
Normal	95	93 (97.9)	62 (65.3) [54.8, 74.7]	98	95 (96.9)	47 (48.0) [37.8, 58.3]	1.361 [1.057, 1.753]	2.039 [1.142, 3.638]	17.3 [2.5, 32.1]	0.016	*
High	7	7 (100.0)	3 (42.9) [9.9, 81.6]	8	8 (100.0)	6 (75.0) [34.9, 96.8]	0.571 [0.222, 1.469]	0.250 [0.028, 2.237]	-32.1 [-92.9, 28.6]	0.315	#
OCS at baseline										0.270	
Yes	9	9 (100.0)	7 (77.8) [40.0, 97.2]	13	13 (100.0)	5 (38.5) [13.9, 68.4]	2.022 [0.935, 4.373]	5.600 [0.814, 38.512]	39.3 [-8.0, 86.6]	0.099	#
No	128	126 (98.4)	79 (61.7) [52.7, 70.2]	125	118 (94.4)	60 (48.0) [39.0, 57.1]	1.286 [1.024, 1.615]	1.747 [1.059, 2.880]	13.7 [0.8, 26.7]	0.029	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_IOSPK: Decrease of at least 0.9 points in ACQ-5 score by key subgroups
DITT

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
ICS dose level (at study entry)										0.875	
Medium/Low	70	68 (97.1)	44 (62.9) [50.5, 74.1]	73	71 (97.3)	35 (47.9) [36.1, 60.0]	1.311 [0.972, 1.768]	1.837 [0.942, 3.583]	14.9 [-2.6, 32.4]	0.074	
High	67	67 (100.0)	42 (62.7) [50.0, 74.2]	65	60 (92.3)	30 (46.2) [33.7, 59.0]	1.358 [0.985, 1.872]	1.960 [0.978, 3.927]	16.5 [-1.7, 34.8]	0.057	
LAMA use at baseline										0.399	
Yes	11	11 (100.0)	8 (72.7) [39.0, 94.0]	6	5 (83.3)	2 (33.3) [4.3, 77.7]	2.182 [0.665, 7.158]	5.333 [0.618, 45.991]	39.4 [-19.5, 98.3]	0.162	#
No	126	124 (98.4)	78 (61.9) [52.8, 70.4]	132	126 (95.5)	63 (47.7) [39.0, 56.6]	1.297 [1.036, 1.624]	1.780 [1.084, 2.922]	14.2 [1.4, 27.0]	0.022	*
Tiotropium use at baseline										0.627	
Yes	9	9 (100.0)	6 (66.7) [29.9, 92.5]	3	3 (100.0)	1 (33.3) [0.8, 90.6]	2.000 [0.378, 10.578]	4.000 [0.250, 63.950]	33.3 [-50.5, 100.0]	0.523	#
No	128	126 (98.4)	80 (62.5) [53.5, 70.9]	135	128 (94.8)	64 (47.4) [38.8, 56.2]	1.318 [1.055, 1.647]	1.849 [1.130, 3.024]	15.1 [2.4, 27.7]	0.014	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_IOSPK: Decrease of at least 0.9 points in ACQ-5 score by key subgroups
DITT

	Tezepelumab			Placebo						
Decrease of at least 0.9 points in ACQ-5 score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline										0.509
Yes	29	28 (96.6)	21 (72.4) [52.8, 87.3]	37	37 (100.0)	22 (59.5) [42.1, 75.2]	1.218 [0.860, 1.725]	1.790 [0.629, 5.093]	13.0 [-12.8, 38.7]	0.277
No	108	107 (99.1)	65 (60.2) [50.3, 69.5]	101	94 (93.1)	43 (42.6) [32.8, 52.8]	1.414 [1.075, 1.858]	2.039 [1.175, 3.539]	17.6 [3.3, 31.9]	0.011 *

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_IOSPP: Decrease of at least 0.9 points in ACQ-5 score by study specific subgroups
DITT

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.882	
White	128	126 (98.4)	79 (61.7) [52.7, 70.2]	123	116 (94.3)	56 (45.5) [36.5, 54.8]	1.356 [1.070, 1.717]	1.929 [1.167, 3.190]	16.2 [3.2, 29.2]	0.010	*
Non-white	9	9 (100.0)	7 (77.8) [40.0, 97.2]	15	15 (100.0)	9 (60.0) [32.3, 83.7]	1.296 [0.755, 2.227]	2.333 [0.356, 15.300]	17.8 [-27.9, 63.4]	0.657	#
Region (cat. P)										0.949	
North America/Western EU	10	10 (100.0)	9 (90.0) [55.5, 99.7]	9	8 (88.9)	6 (66.7) [29.9, 92.5]	1.350 [0.814, 2.239]	4.500 [0.374, 54.155]	23.3 [-23.2, 69.9]	0.303	#
Rest of world	127	125 (98.4)	77 (60.6) [51.6, 69.2]	129	123 (95.3)	59 (45.7) [36.9, 54.7]	1.326 [1.049, 1.676]	1.827 [1.112, 3.002]	14.9 [2.0, 27.8]	0.017	*
Baseline eosinophils (cat. P)										0.190	
< 250 cells/uL	61	61 (100.0)	37 (60.7) [47.3, 72.9]	60	55 (91.7)	32 (53.3) [40.0, 66.3]	1.137 [0.833, 1.553]	1.349 [0.655, 2.777]	7.3 [-11.9, 26.6]	0.418	
>= 250 cells/uL	76	74 (97.4)	49 (64.5) [52.7, 75.1]	78	76 (97.4)	33 (42.3) [31.2, 54.0]	1.524 [1.120, 2.074]	2.475 [1.292, 4.740]	22.2 [5.5, 38.8]	0.006	*
Baseline FENO (cat. P)										0.009	i
< 24 ppb	75	74 (98.7)	38 (50.7) [38.9, 62.4]	72	68 (94.4)	37 (51.4) [39.3, 63.3]	0.986 [0.718, 1.353]	0.972 [0.509, 1.855]	-0.7 [-18.2, 16.8]	0.930	
>= 24 ppb	60	59 (98.3)	46 (76.7) [64.0, 86.6]	65	62 (95.4)	28 (43.1) [30.8, 56.0]	1.780 [1.302, 2.432]	4.342 [2.003, 9.414]	33.6 [15.9, 51.3]	<0.001	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_IOSPP: Decrease of at least 0.9 points in ACQ-5 score by study specific subgroups
DITT

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. M)										0.002	i
< 22.0 ppb	65	64 (98.5)	29 (44.6) [32.3, 57.5]	62	59 (95.2)	32 (51.6) [38.6, 64.5]	0.864 [0.602, 1.242]	0.755 [0.376, 1.518]	-7.0 [-25.9, 11.9]	0.432	
>= 22.0 ppb	70	69 (98.6)	55 (78.6) [67.1, 87.5]	75	71 (94.7)	33 (44.0) [32.5, 55.9]	1.786 [1.345, 2.370]	4.667 [2.248, 9.690]	34.6 [18.4, 50.7]	<0.001	*
Baseline all FEIA status										0.046	i
All negative	50	50 (100.0)	32 (64.0) [49.2, 77.1]	50	46 (92.0)	17 (34.0) [21.2, 48.8]	1.882 [1.214, 2.919]	3.451 [1.517, 7.852]	30.0 [9.3, 50.7]	0.003	*
Any positive	77	75 (97.4)	46 (59.7) [47.9, 70.8]	80	77 (96.3)	43 (53.8) [42.2, 65.0]	1.111 [0.845, 1.461]	1.277 [0.678, 2.404]	6.0 [-10.8, 22.7]	0.450	
Th2 status										0.790	
Low	70	70 (100.0)	41 (58.6) [46.2, 70.2]	62	57 (91.9)	28 (45.2) [32.5, 58.3]	1.297 [0.925, 1.818]	1.717 [0.861, 3.423]	13.4 [-5.0, 31.9]	0.125	
High	65	63 (96.9)	43 (66.2) [53.4, 77.4]	75	73 (97.3)	36 (48.0) [36.3, 59.8]	1.378 [1.028, 1.847]	2.117 [1.067, 4.200]	18.2 [0.6, 35.7]	0.031	*
Baseline Periostin										0.058	
Low (< 20.9 ng/ml)	62	61 (98.4)	32 (51.6) [38.6, 64.5]	67	64 (95.5)	33 (49.3) [36.8, 61.8]	1.048 [0.744, 1.476]	1.099 [0.551, 2.193]	2.4 [-16.5, 21.2]	0.790	
High (>= 20.9 ng/ml)	74	73 (98.6)	54 (73.0) [61.4, 82.6]	71	67 (94.4)	32 (45.1) [33.2, 57.3]	1.619 [1.209, 2.168]	3.291 [1.644, 6.587]	27.9 [11.1, 44.7]	<0.001	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_IOSPP: Decrease of at least 0.9 points in ACQ-5 score by study specific subgroups
DITT

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility										0.206	
Yes	114	113 (99.1)	67 (58.8) [49.2, 67.9]	126	121 (96.0)	60 (47.6) [38.7, 56.7]	1.234 [0.972, 1.568]	1.568 [0.941, 2.614]	11.2 [-2.2, 24.5]	0.085	
No	23	22 (95.7)	19 (82.6) [61.2, 95.0]	12	10 (83.3)	5 (41.7) [15.2, 72.3]	1.983 [0.989, 3.973]	6.650 [1.377, 32.114]	40.9 [2.7, 79.2]	0.022	*
Maintenance OCS use at baseline										0.371	
Yes	9	9 (100.0)	7 (77.8) [40.0, 97.2]	14	14 (100.0)	6 (42.9) [17.7, 71.1]	1.815 [0.903, 3.649]	4.667 [0.702, 31.036]	34.9 [-11.8, 81.6]	0.197	#
No	128	126 (98.4)	79 (61.7) [52.7, 70.2]	124	117 (94.4)	59 (47.6) [38.5, 56.7]	1.297 [1.031, 1.632]	1.776 [1.076, 2.932]	14.1 [1.2, 27.1]	0.024	*
No chronic OCS use and current post-BD FEV1 reversibility										0.159	
Yes	108	107 (99.1)	63 (58.3) [48.5, 67.7]	115	110 (95.7)	55 (47.8) [38.4, 57.3]	1.220 [0.951, 1.564]	1.527 [0.900, 2.593]	10.5 [-3.4, 24.4]	0.117	
No	29	28 (96.6)	23 (79.3) [60.3, 92.0]	23	21 (91.3)	10 (43.5) [23.2, 65.5]	1.824 [1.105, 3.013]	4.983 [1.472, 16.869]	35.8 [6.9, 64.8]	0.008	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5I_IOMP0: Increase of at least 0.9 points in ACQ-5 score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in ACQ-5 score	Week 28	137	134 (97.8)	4 (2.9) [0.8, 7.3]	138	129 (93.5)	5 (3.6) [1.2, 8.3]	0.806 [0.221, 2.937]	0.800 [0.210, 3.045]	-0.7 [-5.6, 4.2]	1.000 #
	Week 52	137	135 (98.5)	3 (2.2) [0.5, 6.3]	138	131 (94.9)	5 (3.6) [1.2, 8.3]	0.604 [0.147, 2.480]	0.596 [0.140, 2.542]	-1.4 [-6.1, 3.3]	0.723 #

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOMH0: Course of ACQ-5 score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	137	137 (100.0)	2.84 (0.84)	0.0	2.40	2.80	3.20	5.2	
		Placebo	138	138 (100.0)	2.82 (0.72)	0.4	2.40	2.80	3.20	5.0	
	Week 2	Tezepelumab	137	131 (95.6)	2.27 (0.97)	0.0	1.60	2.40	3.00	4.4	
		Placebo	138	125 (90.6)	2.42 (0.84)	0.0	2.00	2.40	3.00	5.0	
	Week 4	Tezepelumab	137	131 (95.6)	1.96 (1.01)	0.0	1.20	2.20	2.80	4.2	
		Placebo	138	125 (90.6)	2.30 (0.88)	0.2	1.80	2.40	2.80	4.4	
	Week 6	Tezepelumab	137	131 (95.6)	1.87 (1.00)	0.0	1.20	1.80	2.60	4.2	
		Placebo	138	126 (91.3)	2.20 (1.02)	0.2	1.40	2.20	2.80	6.0	
	Week 8	Tezepelumab	137	131 (95.6)	1.79 (1.08)	0.0	1.00	1.80	2.80	5.2	
		Placebo	138	127 (92.0)	2.14 (1.00)	0.0	1.60	2.20	2.80	5.0	
	Week 10	Tezepelumab	137	131 (95.6)	1.72 (1.05)	0.0	1.00	1.80	2.60	4.8	
		Placebo	138	128 (92.8)	2.07 (0.96)	0.0	1.40	2.00	2.80	5.2	
	Week 12	Tezepelumab	137	131 (95.6)	1.64 (1.08)	0.0	0.80	1.60	2.60	4.8	
		Placebo	138	128 (92.8)	1.99 (1.00)	0.0	1.20	2.00	2.80	4.4	
	Week 14	Tezepelumab	137	131 (95.6)	1.51 (1.06)	0.0	0.60	1.40	2.20	4.8	
		Placebo	138	128 (92.8)	1.94 (0.95)	0.0	1.20	2.00	2.60	5.0	
	Week 16	Tezepelumab	137	131 (95.6)	1.67 (1.11)	0.0	0.80	1.60	2.60	4.8	
		Placebo	138	128 (92.8)	2.06 (1.08)	0.0	1.20	2.00	3.00	5.0	
	Week 18	Tezepelumab	137	132 (96.4)	1.55 (1.01)	0.0	0.80	1.40	2.20	4.8	
		Placebo	138	128 (92.8)	1.95 (1.03)	0.0	1.40	2.00	2.60	5.0	
	Week 20	Tezepelumab	137	132 (96.4)	1.64 (1.08)	0.0	0.80	1.60	2.40	5.0	
		Placebo	138	128 (92.8)	2.01 (1.04)	0.0	1.30	2.20	2.80	5.0	
	Week 22	Tezepelumab	137	132 (96.4)	1.67 (1.02)	0.0	1.00	1.80	2.40	4.8	
		Placebo	138	128 (92.8)	1.96 (1.05)	0.0	1.20	2.00	2.70	5.0	
	Week 24	Tezepelumab	137	132 (96.4)	1.66 (1.09)	0.0	0.80	1.60	2.50	4.8	
		Placebo	138	128 (92.8)	1.95 (1.03)	0.0	1.00	2.00	2.80	4.4	
	Week 26	Tezepelumab	137	133 (97.1)	1.61 (1.05)	0.0	1.00	1.60	2.40	4.8	
		Placebo	138	128 (92.8)	1.90 (1.01)	0.0	1.00	1.80	2.80	4.4	
	Week 28	Tezepelumab	137	134 (97.8)	1.68 (1.10)	0.0	1.00	1.60	2.40	4.8	
		Placebo	138	129 (93.5)	1.96 (1.09)	0.0	1.00	2.20	2.80	4.4	
	Week 30	Tezepelumab	137	135 (98.5)	1.61 (1.05)	0.0	0.80	1.60	2.40	4.8	
		Placebo	138	130 (94.2)	1.94 (1.07)	0.0	1.00	2.00	2.80	4.4	
	Week 32	Tezepelumab	137	135 (98.5)	1.57 (1.07)	0.0	0.80	1.40	2.40	4.8	
		Placebo	138	130 (94.2)	1.89 (1.08)	0.0	1.00	1.80	2.80	4.8	
	Week 34	Tezepelumab	137	135 (98.5)	1.58 (1.12)	0.0	0.80	1.40	2.40	4.8	
		Placebo	138	130 (94.2)	1.85 (1.08)	0.0	1.00	1.80	2.60	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOMH0: Course of ACQ-5 score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Week 36	Tezepelumab	137	135 (98.5)	1.66 (1.11)	0.0	0.80	1.60	2.40	5.0	
		Placebo	138	130 (94.2)	1.94 (1.10)	0.0	1.00	2.00	2.80	4.8	
	Week 38	Tezepelumab	137	135 (98.5)	1.56 (1.10)	0.0	0.80	1.40	2.40	4.8	
		Placebo	138	130 (94.2)	1.86 (1.07)	0.0	1.00	1.80	2.80	4.8	
	Week 40	Tezepelumab	137	135 (98.5)	1.59 (1.11)	0.0	0.60	1.60	2.40	4.8	
		Placebo	138	130 (94.2)	1.94 (1.10)	0.0	1.00	2.00	2.80	4.4	
	Week 42	Tezepelumab	137	135 (98.5)	1.55 (1.10)	0.0	0.80	1.40	2.20	4.8	
		Placebo	138	130 (94.2)	1.90 (1.05)	0.0	1.00	2.00	2.60	4.6	
	Week 44	Tezepelumab	137	135 (98.5)	1.58 (1.09)	0.0	0.60	1.60	2.40	4.8	
		Placebo	138	131 (94.9)	1.95 (1.07)	0.0	1.00	2.00	2.80	4.4	
	Week 46	Tezepelumab	137	135 (98.5)	1.55 (1.10)	0.0	0.80	1.40	2.40	4.8	
		Placebo	138	131 (94.9)	1.83 (1.02)	0.0	1.00	2.00	2.60	4.4	
	Week 48	Tezepelumab	137	135 (98.5)	1.61 (1.11)	0.0	0.80	1.60	2.40	4.8	
		Placebo	138	131 (94.9)	1.87 (1.07)	0.0	1.00	2.00	2.60	4.6	
	Week 50	Tezepelumab	137	135 (98.5)	1.52 (1.09)	0.0	0.80	1.40	2.20	4.8	
		Placebo	138	131 (94.9)	1.84 (1.01)	0.0	1.00	2.00	2.60	4.4	
	Week 52	Tezepelumab	137	135 (98.5)	1.55 (1.09)	0.0	0.60	1.40	2.20	4.8	
		Placebo	138	131 (94.9)	1.89 (1.04)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOMH0: Course of ACQ-5 score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 score	Week 2	Tezepelumab	137	131 (95.6)	-0.57 (0.75)	-3.2	-1.00	-0.40	0.00	0.8	-0.21 [-0.45, 0.04]
		Placebo	138	125 (90.6)	-0.41 (0.77)	-3.0	-0.80	-0.40	0.00	1.4	
	Week 4	Tezepelumab	137	131 (95.6)	-0.88 (0.97)	-3.8	-1.40	-0.80	-0.20	2.6	-0.37 [-0.62, -0.13]
		Placebo	138	125 (90.6)	-0.53 (0.91)	-3.0	-1.20	-0.40	0.00	1.6	
	Week 6	Tezepelumab	137	131 (95.6)	-0.97 (1.04)	-4.0	-1.60	-1.00	-0.20	2.6	-0.34 [-0.59, -0.09]
		Placebo	138	126 (91.3)	-0.63 (0.97)	-3.4	-1.40	-0.60	0.00	1.6	
	Week 8	Tezepelumab	137	131 (95.6)	-1.05 (1.09)	-4.0	-1.80	-1.00	-0.40	2.6	-0.35 [-0.59, -0.10]
		Placebo	138	127 (92.0)	-0.69 (0.97)	-3.6	-1.20	-0.60	0.00	1.0	
	Week 10	Tezepelumab	137	131 (95.6)	-1.12 (1.06)	-4.0	-1.80	-1.20	-0.40	2.6	-0.34 [-0.59, -0.09]
		Placebo	138	128 (92.8)	-0.77 (1.02)	-3.8	-1.40	-0.60	-0.10	2.6	
	Week 12	Tezepelumab	137	131 (95.6)	-1.20 (1.07)	-4.0	-2.00	-1.20	-0.60	2.6	-0.34 [-0.58, -0.09]
		Placebo	138	128 (92.8)	-0.84 (1.05)	-3.8	-1.40	-0.70	-0.20	1.6	
	Week 14	Tezepelumab	137	131 (95.6)	-1.33 (1.08)	-4.2	-2.00	-1.40	-0.60	2.6	-0.42 [-0.66, -0.17]
		Placebo	138	128 (92.8)	-0.90 (1.01)	-3.4	-1.40	-0.80	-0.30	2.4	
	Week 16	Tezepelumab	137	131 (95.6)	-1.17 (1.12)	-4.4	-2.00	-1.00	-0.40	2.6	-0.36 [-0.60, -0.11]
		Placebo	138	128 (92.8)	-0.78 (1.10)	-3.6	-1.40	-0.80	0.00	2.6	
	Week 18	Tezepelumab	137	132 (96.4)	-1.28 (1.08)	-4.4	-2.00	-1.20	-0.60	2.6	-0.37 [-0.61, -0.12]
		Placebo	138	128 (92.8)	-0.88 (1.08)	-3.6	-1.50	-0.80	-0.20	2.6	
	Week 20	Tezepelumab	137	132 (96.4)	-1.19 (1.10)	-4.4	-2.00	-1.10	-0.40	2.6	-0.33 [-0.57, -0.08]
		Placebo	138	128 (92.8)	-0.83 (1.12)	-3.6	-1.40	-0.60	-0.20	2.6	
	Week 22	Tezepelumab	137	132 (96.4)	-1.17 (1.12)	-4.4	-1.80	-1.00	-0.50	2.6	-0.26 [-0.50, -0.02]
		Placebo	138	128 (92.8)	-0.88 (1.09)	-3.8	-1.60	-0.80	-0.20	2.6	
	Week 24	Tezepelumab	137	132 (96.4)	-1.18 (1.07)	-4.8	-1.90	-1.10	-0.40	2.6	-0.27 [-0.51, -0.03]
		Placebo	138	128 (92.8)	-0.88 (1.10)	-3.8	-1.60	-0.80	-0.20	2.6	
	Week 26	Tezepelumab	137	133 (97.1)	-1.21 (1.11)	-4.4	-2.00	-1.20	-0.40	2.6	-0.25 [-0.49, -0.01]
		Placebo	138	128 (92.8)	-0.94 (1.10)	-4.2	-1.70	-1.00	0.00	2.6	
	Week 28	Tezepelumab	137	134 (97.8)	-1.15 (1.13)	-4.4	-2.00	-1.10	-0.40	2.6	-0.25 [-0.50, -0.01]
		Placebo	138	129 (93.5)	-0.86 (1.15)	-4.2	-1.60	-0.80	-0.20	2.6	
	Week 30	Tezepelumab	137	135 (98.5)	-1.22 (1.14)	-4.4	-2.20	-1.20	-0.60	2.6	-0.30 [-0.54, -0.06]
		Placebo	138	130 (94.2)	-0.88 (1.15)	-3.4	-1.60	-1.00	-0.20	2.6	
	Week 32	Tezepelumab	137	135 (98.5)	-1.27 (1.13)	-4.4	-2.20	-1.20	-0.60	2.6	-0.30 [-0.54, -0.06]
		Placebo	138	130 (94.2)	-0.93 (1.13)	-3.6	-1.60	-1.00	-0.20	2.6	
	Week 34	Tezepelumab	137	135 (98.5)	-1.25 (1.16)	-4.4	-2.20	-1.20	-0.40	2.6	-0.25 [-0.49, -0.01]
		Placebo	138	130 (94.2)	-0.96 (1.12)	-4.2	-1.60	-1.00	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOMH0: Course of ACQ-5 score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 score	Week 36	Tezepelumab	137	135 (98.5)	-1.17 (1.20)	-4.4	-2.00	-1.20	-0.20	2.6	-0.25 [-0.49, -0.01]
		Placebo	138	130 (94.2)	-0.88 (1.16)	-3.6	-1.60	-1.00	0.00	2.6	
	Week 38	Tezepelumab	137	135 (98.5)	-1.27 (1.19)	-4.4	-2.20	-1.20	-0.40	2.6	-0.26 [-0.51, -0.02]
		Placebo	138	130 (94.2)	-0.96 (1.15)	-4.2	-1.60	-1.00	-0.20	2.6	
	Week 40	Tezepelumab	137	135 (98.5)	-1.24 (1.20)	-4.4	-2.20	-1.00	-0.40	2.6	-0.31 [-0.55, -0.06]
		Placebo	138	130 (94.2)	-0.88 (1.13)	-4.2	-1.60	-0.80	-0.20	2.6	
	Week 42	Tezepelumab	137	135 (98.5)	-1.28 (1.19)	-4.4	-2.20	-1.20	-0.40	2.6	-0.32 [-0.56, -0.08]
		Placebo	138	130 (94.2)	-0.91 (1.11)	-4.2	-1.60	-1.00	-0.20	2.6	
	Week 44	Tezepelumab	137	135 (98.5)	-1.25 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.33 [-0.57, -0.09]
		Placebo	138	131 (94.9)	-0.86 (1.14)	-4.2	-1.60	-0.80	0.00	2.6	
	Week 46	Tezepelumab	137	135 (98.5)	-1.28 (1.19)	-4.4	-2.20	-1.20	-0.40	2.6	-0.26 [-0.50, -0.02]
		Placebo	138	131 (94.9)	-0.99 (1.10)	-4.2	-1.60	-1.00	-0.20	2.6	
	Week 48	Tezepelumab	137	135 (98.5)	-1.22 (1.19)	-4.4	-2.00	-1.00	-0.40	2.6	-0.23 [-0.48, 0.01]
		Placebo	138	131 (94.9)	-0.95 (1.13)	-3.8	-1.60	-1.00	-0.20	2.6	
	Week 50	Tezepelumab	137	135 (98.5)	-1.31 (1.19)	-4.4	-2.20	-1.40	-0.60	2.6	-0.30 [-0.54, -0.05]
		Placebo	138	131 (94.9)	-0.97 (1.08)	-4.2	-1.60	-1.00	-0.20	2.6	
	Week 52	Tezepelumab	137	135 (98.5)	-1.28 (1.20)	-4.4	-2.20	-1.20	-0.40	2.6	-0.31 [-0.55, -0.07]
		Placebo	138	131 (94.9)	-0.93 (1.11)	-4.2	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOMC0: Change from baseline in ACQ-5 score - MMRM results
DITT

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	137	130 (94.9)	-0.56 (0.06)	(-0.68, -0.43)	-0.16 (0.09)	(-0.34, 0.02)	0.074
	Placebo	138	124 (89.9)	-0.39 (0.07)	(-0.52, -0.26)			
Week 4	Tezepelumab	137	125 (91.2)	-0.88 (0.08)	(-1.03, -0.73)	-0.37 (0.11)	(-0.58, -0.15)	<0.001 *
	Placebo	138	123 (89.1)	-0.51 (0.08)	(-0.66, -0.36)			
Week 6	Tezepelumab	137	125 (91.2)	-0.98 (0.08)	(-1.14, -0.82)	-0.37 (0.12)	(-0.60, -0.14)	0.002 *
	Placebo	138	123 (89.1)	-0.61 (0.08)	(-0.77, -0.45)			
Week 8	Tezepelumab	137	125 (91.2)	-1.06 (0.08)	(-1.22, -0.89)	-0.38 (0.12)	(-0.62, -0.15)	0.002 *
	Placebo	138	124 (89.9)	-0.67 (0.09)	(-0.84, -0.50)			
Week 10	Tezepelumab	137	124 (90.5)	-1.12 (0.08)	(-1.28, -0.95)	-0.38 (0.12)	(-0.62, -0.14)	0.002 *
	Placebo	138	123 (89.1)	-0.74 (0.09)	(-0.91, -0.57)			
Week 12	Tezepelumab	137	124 (90.5)	-1.22 (0.09)	(-1.38, -1.05)	-0.39 (0.12)	(-0.63, -0.15)	0.001 *
	Placebo	138	122 (88.4)	-0.82 (0.09)	(-0.99, -0.65)			
Week 14	Tezepelumab	137	121 (88.3)	-1.36 (0.08)	(-1.53, -1.20)	-0.48 (0.12)	(-0.72, -0.25)	<0.001 *
	Placebo	138	121 (87.7)	-0.88 (0.08)	(-1.05, -0.71)			
Week 16	Tezepelumab	137	116 (84.7)	-1.18 (0.09)	(-1.36, -1.01)	-0.43 (0.13)	(-0.69, -0.18)	<0.001 *
	Placebo	138	117 (84.8)	-0.75 (0.09)	(-0.93, -0.57)			
Week 18	Tezepelumab	137	116 (84.7)	-1.32 (0.08)	(-1.49, -1.15)	-0.44 (0.12)	(-0.68, -0.20)	<0.001 *
	Placebo	138	115 (83.3)	-0.88 (0.09)	(-1.05, -0.71)			
Week 20	Tezepelumab	137	114 (83.2)	-1.22 (0.09)	(-1.39, -1.04)	-0.40 (0.13)	(-0.66, -0.15)	0.002 *
	Placebo	138	112 (81.2)	-0.81 (0.09)	(-0.99, -0.64)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOMC0: Change from baseline in ACQ-5 score - MMRM results
DITT

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	137	113 (82.5)	-1.20 (0.09)	(-1.37, -1.02)	-0.31 (0.12)	(-0.56, -0.07)	0.013 *
	Placebo	138	114 (82.6)	-0.88 (0.09)	(-1.06, -0.71)			
Week 24	Tezepelumab	137	113 (82.5)	-1.20 (0.09)	(-1.38, -1.03)	-0.33 (0.13)	(-0.58, -0.08)	0.009 *
	Placebo	138	111 (80.4)	-0.87 (0.09)	(-1.05, -0.69)			
Week 26	Tezepelumab	137	115 (83.9)	-1.27 (0.09)	(-1.44, -1.10)	-0.32 (0.12)	(-0.57, -0.08)	0.010 *
	Placebo	138	110 (79.7)	-0.95 (0.09)	(-1.12, -0.77)			
Week 28	Tezepelumab	137	112 (81.8)	-1.18 (0.09)	(-1.36, -0.99)	-0.32 (0.13)	(-0.58, -0.06)	0.018 *
	Placebo	138	111 (80.4)	-0.86 (0.10)	(-1.04, -0.67)			
Week 30	Tezepelumab	137	116 (84.7)	-1.25 (0.09)	(-1.43, -1.07)	-0.35 (0.13)	(-0.60, -0.09)	0.008 *
	Placebo	138	111 (80.4)	-0.91 (0.09)	(-1.09, -0.72)			
Week 32	Tezepelumab	137	117 (85.4)	-1.30 (0.09)	(-1.48, -1.12)	-0.35 (0.13)	(-0.60, -0.10)	0.007 *
	Placebo	138	112 (81.2)	-0.95 (0.09)	(-1.13, -0.77)			
Week 34	Tezepelumab	137	116 (84.7)	-1.29 (0.09)	(-1.47, -1.11)	-0.29 (0.13)	(-0.55, -0.04)	0.025 *
	Placebo	138	110 (79.7)	-0.99 (0.09)	(-1.18, -0.81)			
Week 36	Tezepelumab	137	116 (84.7)	-1.19 (0.10)	(-1.38, -1.00)	-0.27 (0.14)	(-0.53, -0.00)	0.049 *
	Placebo	138	110 (79.7)	-0.92 (0.10)	(-1.11, -0.73)			
Week 38	Tezepelumab	137	115 (83.9)	-1.30 (0.09)	(-1.48, -1.12)	-0.29 (0.13)	(-0.54, -0.03)	0.028 *
	Placebo	138	111 (80.4)	-1.01 (0.09)	(-1.19, -0.83)			
Week 40	Tezepelumab	137	114 (83.2)	-1.28 (0.09)	(-1.46, -1.09)	-0.37 (0.13)	(-0.64, -0.11)	0.005 *
	Placebo	138	113 (81.9)	-0.90 (0.09)	(-1.09, -0.72)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOMC0: Change from baseline in ACQ-5 score - MMRM results
DITT

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	137	113 (82.5)	-1.32 (0.09)	(-1.50, -1.13)	-0.40 (0.13)	(-0.66, -0.14)	0.003 *
	Placebo	138	108 (78.3)	-0.92 (0.09)	(-1.10, -0.73)			
Week 44	Tezepelumab	137	113 (82.5)	-1.29 (0.10)	(-1.48, -1.10)	-0.41 (0.14)	(-0.68, -0.14)	0.003 *
	Placebo	138	111 (80.4)	-0.88 (0.10)	(-1.07, -0.69)			
Week 46	Tezepelumab	137	112 (81.8)	-1.32 (0.09)	(-1.50, -1.14)	-0.31 (0.13)	(-0.57, -0.06)	0.017 *
	Placebo	138	110 (79.7)	-1.01 (0.09)	(-1.19, -0.83)			
Week 48	Tezepelumab	137	109 (79.6)	-1.24 (0.09)	(-1.43, -1.06)	-0.28 (0.13)	(-0.54, -0.02)	0.035 *
	Placebo	138	113 (81.9)	-0.96 (0.09)	(-1.15, -0.78)			
Week 50	Tezepelumab	137	110 (80.3)	-1.36 (0.09)	(-1.54, -1.18)	-0.35 (0.13)	(-0.61, -0.10)	0.006 *
	Placebo	138	112 (81.2)	-1.01 (0.09)	(-1.19, -0.83)			
Week 52	Tezepelumab	137	44 (32.1)	-1.28 (0.11)	(-1.49, -1.08)	-0.46 (0.15)	(-0.75, -0.17)	0.002 *
	Placebo	138	53 (38.4)	-0.83 (0.10)	(-1.03, -0.63)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Figure PF2H5C_IOMG0: Course of ACQ-5 score
DITT



Note: DITT = Dossier Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
ACQ = asthma control questionnaire.
Source table: PT2H5C_IOMH0
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	50	50 (100.0)	2.83 (0.86)	0.8	2.40	2.80	3.20	5.0	
			Placebo	44	44 (100.0)	2.80 (0.80)	0.4	2.40	2.90	3.20	4.8	
		Week 2	Tezepelumab	50	47 (94.0)	2.20 (0.99)	0.0	1.60	2.20	3.00	4.0	
			Placebo	44	42 (95.5)	2.43 (0.94)	0.0	1.80	2.80	3.00	4.8	
		Week 4	Tezepelumab	50	47 (94.0)	1.86 (1.10)	0.0	1.00	2.20	2.80	3.6	
			Placebo	44	42 (95.5)	2.26 (0.92)	0.4	1.60	2.40	2.80	4.2	
		Week 6	Tezepelumab	50	47 (94.0)	1.84 (1.09)	0.0	1.00	1.80	2.60	4.0	
			Placebo	44	42 (95.5)	2.26 (1.01)	0.6	1.40	2.20	3.00	4.6	
		Week 8	Tezepelumab	50	47 (94.0)	1.76 (1.07)	0.0	1.00	1.80	2.60	4.2	
			Placebo	44	42 (95.5)	2.19 (0.97)	0.2	1.40	2.40	3.00	4.6	
		Week 10	Tezepelumab	50	47 (94.0)	1.72 (1.08)	0.0	1.00	1.60	2.60	3.4	
			Placebo	44	42 (95.5)	2.09 (0.98)	0.0	1.20	2.30	2.80	4.4	
		Week 12	Tezepelumab	50	47 (94.0)	1.57 (1.02)	0.0	0.80	1.40	2.40	3.6	
			Placebo	44	42 (95.5)	1.96 (1.11)	0.0	1.00	2.10	3.00	4.4	
		Week 14	Tezepelumab	50	47 (94.0)	1.42 (1.02)	0.0	0.60	1.20	2.20	4.2	
			Placebo	44	42 (95.5)	1.86 (0.95)	0.4	1.00	1.80	2.60	5.0	
		Week 16	Tezepelumab	50	47 (94.0)	1.69 (1.20)	0.0	0.60	1.80	2.80	4.6	
			Placebo	44	42 (95.5)	2.00 (1.03)	0.2	1.00	2.00	2.80	4.4	
		Week 18	Tezepelumab	50	47 (94.0)	1.54 (1.05)	0.0	0.80	1.60	2.40	4.2	
			Placebo	44	42 (95.5)	1.91 (0.97)	0.2	1.00	1.90	2.60	4.4	
		Week 20	Tezepelumab	50	47 (94.0)	1.61 (1.10)	0.0	0.80	1.40	2.40	5.0	
			Placebo	44	42 (95.5)	1.99 (1.04)	0.2	1.20	1.90	2.80	4.4	
		Week 22	Tezepelumab	50	47 (94.0)	1.54 (1.00)	0.0	1.00	1.60	2.40	3.8	
			Placebo	44	42 (95.5)	1.87 (1.06)	0.0	1.00	1.80	2.60	4.4	
		Week 24	Tezepelumab	50	47 (94.0)	1.55 (1.09)	0.0	0.80	1.60	2.40	3.8	
			Placebo	44	42 (95.5)	1.86 (1.07)	0.0	1.00	1.80	2.60	4.4	
		Week 26	Tezepelumab	50	48 (96.0)	1.52 (1.10)	0.0	0.80	1.20	2.30	4.0	
			Placebo	44	42 (95.5)	1.86 (0.97)	0.4	1.00	1.60	2.80	4.4	
		Week 28	Tezepelumab	50	48 (96.0)	1.53 (1.10)	0.0	0.40	1.40	2.40	3.8	
			Placebo	44	43 (97.7)	2.05 (1.19)	0.0	1.00	2.20	2.80	4.4	
		Week 30	Tezepelumab	50	49 (98.0)	1.52 (1.05)	0.0	0.60	1.60	2.40	3.8	
			Placebo	44	43 (97.7)	1.84 (1.09)	0.0	1.00	2.00	2.60	4.4	
		Week 32	Tezepelumab	50	49 (98.0)	1.52 (1.09)	0.0	0.60	1.40	2.40	4.2	
			Placebo	44	43 (97.7)	1.81 (1.11)	0.0	0.80	1.60	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Male	Absolute values	Week 34	Tezepelumab	50	49 (98.0)	1.51 (1.15)	0.0	0.60	1.20	2.40	4.2	
			Placebo	44	43 (97.7)	1.80 (1.11)	0.0	1.00	1.60	2.60	4.4	
		Week 36	Tezepelumab	50	49 (98.0)	1.59 (1.11)	0.0	0.60	1.60	2.40	3.8	
			Placebo	44	43 (97.7)	1.89 (1.13)	0.0	1.00	2.00	2.80	4.4	
		Week 38	Tezepelumab	50	49 (98.0)	1.51 (1.15)	0.0	0.80	1.40	2.20	4.6	
			Placebo	44	43 (97.7)	1.70 (1.04)	0.0	1.00	1.40	2.60	4.4	
		Week 40	Tezepelumab	50	49 (98.0)	1.54 (1.15)	0.0	0.40	1.40	2.60	3.6	
			Placebo	44	43 (97.7)	1.87 (1.14)	0.0	1.00	1.80	2.60	4.4	
		Week 42	Tezepelumab	50	49 (98.0)	1.50 (1.15)	0.0	0.60	1.40	2.40	4.0	
			Placebo	44	43 (97.7)	1.81 (1.15)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	50	49 (98.0)	1.51 (1.12)	0.0	0.60	1.40	2.40	3.8	
			Placebo	44	43 (97.7)	1.87 (1.10)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	50	49 (98.0)	1.52 (1.16)	0.0	0.60	1.20	2.40	3.8	
			Placebo	44	43 (97.7)	1.73 (1.07)	0.0	1.00	2.00	2.60	4.4	
		Week 48	Tezepelumab	50	49 (98.0)	1.60 (1.16)	0.0	0.40	1.60	2.40	3.8	
			Placebo	44	43 (97.7)	1.77 (1.16)	0.0	0.80	2.00	2.80	4.4	
		Week 50	Tezepelumab	50	49 (98.0)	1.49 (1.13)	0.0	0.60	1.40	2.20	4.2	
			Placebo	44	43 (97.7)	1.86 (1.02)	0.0	1.00	2.00	2.60	4.4	
		Week 52	Tezepelumab	50	49 (98.0)	1.53 (1.13)	0.0	0.60	1.40	2.20	4.4	
			Placebo	44	43 (97.7)	1.88 (1.07)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	50	47 (94.0)	-0.60 (0.74)	-2.6	-1.20	-0.60	-0.20	0.4	-0.20 [-0.61, 0.22]
			Placebo	44	42 (95.5)	-0.44 (0.86)	-3.0	-0.80	-0.20	0.00	1.4	
		Week 4	Tezepelumab	50	47 (94.0)	-0.94 (1.06)	-3.8	-1.80	-0.80	-0.20	1.2	-0.32 [-0.74, 0.10]
			Placebo	44	42 (95.5)	-0.61 (0.99)	-3.0	-1.40	-0.60	0.00	1.6	
		Week 6	Tezepelumab	50	47 (94.0)	-0.97 (1.14)	-4.0	-1.60	-1.00	-0.20	1.2	-0.33 [-0.75, 0.09]
			Placebo	44	42 (95.5)	-0.61 (1.00)	-3.2	-1.40	-0.60	0.20	1.4	
		Week 8	Tezepelumab	50	47 (94.0)	-1.04 (1.07)	-4.0	-1.80	-1.00	-0.20	1.0	-0.36 [-0.78, 0.06]
			Placebo	44	42 (95.5)	-0.69 (0.88)	-3.6	-1.20	-0.60	0.00	0.6	
		Week 10	Tezepelumab	50	47 (94.0)	-1.08 (1.11)	-4.0	-1.60	-1.20	0.00	1.0	-0.28 [-0.70, 0.14]
			Placebo	44	42 (95.5)	-0.78 (1.04)	-3.8	-1.40	-0.60	0.00	1.6	
		Week 12	Tezepelumab	50	47 (94.0)	-1.24 (1.09)	-4.0	-2.00	-1.20	-0.60	1.2	-0.30 [-0.72, 0.12]
			Placebo	44	42 (95.5)	-0.91 (1.12)	-3.8	-1.60	-0.60	0.00	1.4	
		Week 14	Tezepelumab	50	47 (94.0)	-1.38 (1.09)	-4.2	-2.00	-1.40	-0.80	1.2	-0.37 [-0.79, 0.05]
			Placebo	44	42 (95.5)	-1.01 (0.89)	-3.4	-1.40	-1.00	-0.40	0.4	
		Week 16	Tezepelumab	50	47 (94.0)	-1.11 (1.24)	-4.4	-1.80	-1.00	-0.40	1.8	-0.21 [-0.62, 0.21]
			Placebo	44	42 (95.5)	-0.88 (1.02)	-3.6	-1.40	-1.00	0.00	1.0	
		Week 18	Tezepelumab	50	47 (94.0)	-1.26 (1.10)	-4.4	-2.00	-1.00	-0.60	1.2	-0.29 [-0.71, 0.12]
			Placebo	44	42 (95.5)	-0.96 (0.93)	-3.6	-1.60	-1.00	-0.20	0.4	
		Week 20	Tezepelumab	50	47 (94.0)	-1.19 (1.13)	-4.4	-1.80	-1.00	-0.40	1.0	-0.29 [-0.70, 0.13]
			Placebo	44	42 (95.5)	-0.89 (1.01)	-3.6	-1.60	-0.60	-0.20	1.0	
		Week 22	Tezepelumab	50	47 (94.0)	-1.26 (1.08)	-4.4	-1.80	-1.20	-0.60	1.2	-0.25 [-0.67, 0.17]
			Placebo	44	42 (95.5)	-1.00 (1.00)	-3.8	-1.60	-1.00	-0.40	0.8	
		Week 24	Tezepelumab	50	47 (94.0)	-1.26 (1.14)	-4.8	-2.00	-1.20	-0.60	1.4	-0.22 [-0.64, 0.20]
			Placebo	44	42 (95.5)	-1.01 (1.04)	-3.6	-1.60	-0.90	-0.40	0.6	
		Week 26	Tezepelumab	50	48 (96.0)	-1.27 (1.15)	-4.4	-2.00	-1.30	-0.40	1.2	-0.24 [-0.65, 0.18]
			Placebo	44	42 (95.5)	-1.01 (0.93)	-3.4	-1.60	-1.10	-0.40	0.8	
		Week 28	Tezepelumab	50	48 (96.0)	-1.26 (1.17)	-4.4	-1.90	-1.20	-0.60	1.0	-0.43 [-0.85, -0.01]
			Placebo	44	43 (97.7)	-0.77 (1.12)	-3.4	-1.60	-0.40	0.00	1.2	
		Week 30	Tezepelumab	50	49 (98.0)	-1.28 (1.20)	-4.4	-2.00	-1.20	-0.60	2.0	-0.27 [-0.68, 0.15]
			Placebo	44	43 (97.7)	-0.98 (1.07)	-3.4	-1.80	-1.00	-0.20	1.2	
		Week 32	Tezepelumab	50	49 (98.0)	-1.29 (1.21)	-4.4	-2.20	-1.00	-0.60	1.8	-0.25 [-0.66, 0.16]
			Placebo	44	43 (97.7)	-1.00 (1.04)	-3.2	-1.80	-1.00	0.00	0.8	
		Week 34	Tezepelumab	50	49 (98.0)	-1.29 (1.25)	-4.4	-2.00	-1.20	-0.60	2.2	-0.24 [-0.65, 0.17]
			Placebo	44	43 (97.7)	-1.02 (1.02)	-3.4	-2.00	-1.00	-0.20	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Male	Change from baseline	Week 36	Tezepelumab	50	49 (98.0)	-1.22 (1.28)	-4.4	-2.00	-1.20	-0.60	1.6	-0.25 [-0.66, 0.16]
			Placebo	44	43 (97.7)	-0.92 (1.06)	-3.2	-1.40	-1.00	0.00	1.4	
		Week 38	Tezepelumab	50	49 (98.0)	-1.29 (1.28)	-4.4	-2.20	-1.40	-0.60	2.6	-0.15 [-0.56, 0.26]
			Placebo	44	43 (97.7)	-1.11 (1.10)	-3.4	-2.00	-1.20	-0.40	1.2	
		Week 40	Tezepelumab	50	49 (98.0)	-1.26 (1.25)	-4.4	-2.00	-1.00	-0.60	1.8	-0.27 [-0.68, 0.14]
			Placebo	44	43 (97.7)	-0.94 (1.06)	-3.6	-1.80	-1.00	-0.20	1.4	
		Week 42	Tezepelumab	50	49 (98.0)	-1.31 (1.28)	-4.4	-2.00	-1.20	-0.40	2.2	-0.25 [-0.67, 0.16]
			Placebo	44	43 (97.7)	-1.00 (1.12)	-3.6	-2.00	-0.80	-0.20	1.6	
		Week 44	Tezepelumab	50	49 (98.0)	-1.30 (1.20)	-4.4	-2.00	-1.20	-0.60	1.6	-0.32 [-0.73, 0.10]
			Placebo	44	43 (97.7)	-0.94 (1.02)	-3.2	-1.80	-0.80	-0.40	1.2	
		Week 46	Tezepelumab	50	49 (98.0)	-1.29 (1.24)	-4.4	-1.80	-1.20	-0.60	1.8	-0.17 [-0.58, 0.24]
			Placebo	44	43 (97.7)	-1.09 (1.00)	-3.2	-1.80	-1.00	-0.40	0.6	
		Week 48	Tezepelumab	50	49 (98.0)	-1.21 (1.27)	-4.4	-2.00	-1.00	-0.40	2.0	-0.14 [-0.55, 0.27]
			Placebo	44	43 (97.7)	-1.05 (1.07)	-3.2	-1.80	-1.00	-0.40	1.0	
		Week 50	Tezepelumab	50	49 (98.0)	-1.31 (1.29)	-4.4	-2.00	-1.40	-0.40	2.0	-0.31 [-0.72, 0.10]
			Placebo	44	43 (97.7)	-0.95 (0.96)	-3.2	-1.60	-0.80	-0.40	0.6	
		Week 52	Tezepelumab	50	49 (98.0)	-1.27 (1.28)	-4.4	-2.00	-1.20	-0.40	2.0	-0.30 [-0.71, 0.12]
			Placebo	44	43 (97.7)	-0.93 (1.01)	-3.2	-1.60	-0.80	-0.20	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	87	87 (100.0)	2.85 (0.84)	0.0	2.40	2.80	3.20	5.2	
			Placebo	94	94 (100.0)	2.82 (0.69)	1.0	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	87	84 (96.6)	2.30 (0.96)	0.0	1.70	2.40	3.00	4.4	
			Placebo	94	83 (88.3)	2.41 (0.79)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	87	84 (96.6)	2.01 (0.96)	0.0	1.20	2.10	2.80	4.2	
			Placebo	94	83 (88.3)	2.32 (0.86)	0.2	1.80	2.40	3.00	4.4	
		Week 6	Tezepelumab	87	84 (96.6)	1.89 (0.95)	0.0	1.40	1.80	2.60	4.2	
			Placebo	94	84 (89.4)	2.17 (1.03)	0.2	1.60	2.20	2.80	6.0	
		Week 8	Tezepelumab	87	84 (96.6)	1.81 (1.10)	0.0	1.00	1.60	2.80	5.2	
			Placebo	94	85 (90.4)	2.12 (1.02)	0.0	1.60	2.20	2.60	5.0	
		Week 10	Tezepelumab	87	84 (96.6)	1.72 (1.04)	0.0	0.90	1.80	2.40	4.8	
			Placebo	94	86 (91.5)	2.06 (0.96)	0.0	1.40	2.00	2.60	5.2	
		Week 12	Tezepelumab	87	84 (96.6)	1.68 (1.13)	0.0	0.70	1.60	2.60	4.8	
			Placebo	94	86 (91.5)	2.01 (0.94)	0.0	1.40	2.00	2.60	4.4	
		Week 14	Tezepelumab	87	84 (96.6)	1.55 (1.08)	0.0	0.80	1.40	2.40	4.8	
			Placebo	94	86 (91.5)	1.97 (0.95)	0.0	1.20	2.10	2.60	5.0	
		Week 16	Tezepelumab	87	84 (96.6)	1.66 (1.06)	0.0	0.80	1.60	2.50	4.8	
			Placebo	94	86 (91.5)	2.09 (1.10)	0.0	1.40	2.20	3.00	5.0	
		Week 18	Tezepelumab	87	85 (97.7)	1.56 (0.99)	0.0	0.80	1.40	2.20	4.8	
			Placebo	94	86 (91.5)	1.97 (1.06)	0.0	1.40	2.00	2.60	5.0	
		Week 20	Tezepelumab	87	85 (97.7)	1.66 (1.07)	0.0	0.80	1.60	2.40	4.8	
			Placebo	94	86 (91.5)	2.02 (1.05)	0.0	1.40	2.20	2.80	5.0	
		Week 22	Tezepelumab	87	85 (97.7)	1.74 (1.04)	0.0	1.00	1.80	2.40	4.8	
			Placebo	94	86 (91.5)	2.00 (1.04)	0.0	1.20	2.00	2.80	5.0	
		Week 24	Tezepelumab	87	85 (97.7)	1.72 (1.09)	0.0	0.80	1.80	2.60	4.8	
			Placebo	94	86 (91.5)	2.00 (1.01)	0.0	1.20	2.20	2.80	4.0	
		Week 26	Tezepelumab	87	85 (97.7)	1.67 (1.02)	0.0	1.00	1.60	2.40	4.8	
			Placebo	94	86 (91.5)	1.92 (1.04)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	87	86 (98.9)	1.76 (1.10)	0.0	1.00	1.80	2.80	4.8	
			Placebo	94	86 (91.5)	1.91 (1.04)	0.0	1.00	2.10	2.80	4.4	
		Week 30	Tezepelumab	87	86 (98.9)	1.66 (1.05)	0.0	0.80	1.60	2.40	4.8	
			Placebo	94	87 (92.6)	1.99 (1.06)	0.0	1.20	2.00	2.80	4.2	
		Week 32	Tezepelumab	87	86 (98.9)	1.59 (1.07)	0.0	0.80	1.40	2.40	4.8	
			Placebo	94	87 (92.6)	1.93 (1.07)	0.0	1.00	2.00	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	Absolute values	Week 34	Tezepelumab	87	86 (98.9)	1.62 (1.11)	0.0	0.80	1.50	2.40	4.8	
			Placebo	94	87 (92.6)	1.88 (1.07)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	87	86 (98.9)	1.70 (1.11)	0.0	1.00	1.60	2.40	5.0	
			Placebo	94	87 (92.6)	1.96 (1.09)	0.0	1.00	2.20	2.80	4.8	
		Week 38	Tezepelumab	87	86 (98.9)	1.60 (1.08)	0.0	0.80	1.60	2.40	4.8	
			Placebo	94	87 (92.6)	1.94 (1.08)	0.0	1.00	2.00	2.80	4.8	
		Week 40	Tezepelumab	87	86 (98.9)	1.62 (1.09)	0.0	0.80	1.80	2.40	4.8	
			Placebo	94	87 (92.6)	1.97 (1.09)	0.0	1.00	2.20	2.80	4.2	
		Week 42	Tezepelumab	87	86 (98.9)	1.58 (1.07)	0.0	1.00	1.50	2.20	4.8	
			Placebo	94	87 (92.6)	1.95 (1.00)	0.0	1.20	2.00	2.60	4.6	
		Week 44	Tezepelumab	87	86 (98.9)	1.62 (1.08)	0.0	0.80	1.60	2.40	4.8	
			Placebo	94	88 (93.6)	1.99 (1.06)	0.0	1.00	2.00	2.80	4.2	
		Week 46	Tezepelumab	87	86 (98.9)	1.57 (1.08)	0.0	0.80	1.50	2.20	4.8	
			Placebo	94	88 (93.6)	1.88 (1.00)	0.0	1.20	2.00	2.70	4.4	
		Week 48	Tezepelumab	87	86 (98.9)	1.62 (1.09)	0.0	0.80	1.60	2.40	4.8	
			Placebo	94	88 (93.6)	1.92 (1.02)	0.0	1.10	2.00	2.60	4.6	
		Week 50	Tezepelumab	87	86 (98.9)	1.53 (1.08)	0.0	0.80	1.40	2.20	4.8	
			Placebo	94	88 (93.6)	1.83 (1.01)	0.0	1.00	1.90	2.60	4.0	
		Week 52	Tezepelumab	87	86 (98.9)	1.56 (1.08)	0.0	0.80	1.60	2.20	4.8	
			Placebo	94	88 (93.6)	1.90 (1.04)	0.0	1.00	2.00	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	87	84 (96.6)	-0.55 (0.75)	-3.2	-1.00	-0.40	0.00	0.8	-0.21 [-0.52, 0.09]
			Placebo	94	83 (88.3)	-0.40 (0.72)	-2.8	-0.80	-0.40	0.00	1.2	
		Week 4	Tezepelumab	87	84 (96.6)	-0.85 (0.92)	-3.6	-1.40	-0.80	-0.20	2.6	-0.40 [-0.70, -0.09]
			Placebo	94	83 (88.3)	-0.49 (0.87)	-3.0	-1.00	-0.40	0.20	1.0	
		Week 6	Tezepelumab	87	84 (96.6)	-0.97 (0.98)	-3.4	-1.60	-1.00	-0.40	2.6	-0.35 [-0.65, -0.04]
			Placebo	94	84 (89.4)	-0.64 (0.95)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	87	84 (96.6)	-1.05 (1.10)	-3.2	-1.60	-1.10	-0.40	2.6	-0.34 [-0.64, -0.03]
			Placebo	94	85 (90.4)	-0.69 (1.01)	-3.0	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	87	84 (96.6)	-1.14 (1.03)	-3.4	-1.80	-1.20	-0.60	2.6	-0.37 [-0.68, -0.07]
			Placebo	94	86 (91.5)	-0.76 (1.02)	-3.2	-1.40	-0.80	-0.20	2.6	
		Week 12	Tezepelumab	87	84 (96.6)	-1.18 (1.06)	-3.2	-1.90	-1.20	-0.50	2.6	-0.36 [-0.66, -0.05]
			Placebo	94	86 (91.5)	-0.81 (1.01)	-3.2	-1.40	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	87	84 (96.6)	-1.30 (1.08)	-4.0	-2.00	-1.30	-0.60	2.6	-0.43 [-0.73, -0.13]
			Placebo	94	86 (91.5)	-0.84 (1.06)	-3.2	-1.40	-0.80	-0.20	2.4	
		Week 16	Tezepelumab	87	84 (96.6)	-1.20 (1.06)	-3.4	-2.00	-1.20	-0.60	2.6	-0.43 [-0.74, -0.13]
			Placebo	94	86 (91.5)	-0.73 (1.14)	-3.6	-1.40	-0.60	0.00	2.6	
		Week 18	Tezepelumab	87	85 (97.7)	-1.29 (1.08)	-3.8	-2.00	-1.20	-0.80	2.6	-0.40 [-0.70, -0.10]
			Placebo	94	86 (91.5)	-0.85 (1.15)	-3.4	-1.40	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	87	85 (97.7)	-1.19 (1.09)	-3.4	-2.00	-1.20	-0.40	2.6	-0.34 [-0.64, -0.04]
			Placebo	94	86 (91.5)	-0.80 (1.17)	-3.6	-1.40	-0.70	-0.20	2.6	
		Week 22	Tezepelumab	87	85 (97.7)	-1.11 (1.15)	-3.4	-2.00	-1.00	-0.40	2.6	-0.26 [-0.56, 0.04]
			Placebo	94	86 (91.5)	-0.82 (1.13)	-3.4	-1.60	-0.80	0.00	2.6	
		Week 24	Tezepelumab	87	85 (97.7)	-1.13 (1.03)	-3.4	-1.80	-1.00	-0.40	2.6	-0.29 [-0.59, 0.01]
			Placebo	94	86 (91.5)	-0.82 (1.14)	-3.8	-1.40	-0.80	0.00	2.6	
		Week 26	Tezepelumab	87	85 (97.7)	-1.18 (1.09)	-3.4	-2.20	-1.00	-0.40	2.6	-0.25 [-0.55, 0.05]
			Placebo	94	86 (91.5)	-0.90 (1.18)	-4.2	-1.80	-0.90	0.00	2.6	
		Week 28	Tezepelumab	87	86 (98.9)	-1.09 (1.11)	-3.4	-2.00	-1.00	-0.20	2.6	-0.16 [-0.46, 0.14]
			Placebo	94	86 (91.5)	-0.90 (1.16)	-4.2	-1.60	-0.90	-0.20	2.6	
		Week 30	Tezepelumab	87	86 (98.9)	-1.19 (1.11)	-3.8	-2.20	-1.00	-0.40	2.6	-0.31 [-0.61, -0.01]
			Placebo	94	87 (92.6)	-0.83 (1.19)	-3.4	-1.60	-0.80	0.00	2.6	
		Week 32	Tezepelumab	87	86 (98.9)	-1.25 (1.10)	-3.6	-2.20	-1.20	-0.60	2.6	-0.32 [-0.62, -0.02]
			Placebo	94	87 (92.6)	-0.89 (1.17)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 34	Tezepelumab	87	86 (98.9)	-1.23 (1.11)	-3.2	-2.20	-1.20	-0.40	2.6	-0.25 [-0.55, 0.05]
			Placebo	94	87 (92.6)	-0.94 (1.17)	-4.2	-1.60	-1.00	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	Change from baseline	Week 36	Tezepelumab	87	86 (98.9)	-1.14 (1.16)	-3.2	-2.00	-1.20	-0.20	2.6	-0.24 [-0.54, 0.06]
			Placebo	94	87 (92.6)	-0.86 (1.22)	-3.6	-1.60	-0.80	0.00	2.6	
		Week 38	Tezepelumab	87	86 (98.9)	-1.25 (1.14)	-3.8	-2.20	-1.20	-0.40	2.6	-0.32 [-0.62, -0.02]
			Placebo	94	87 (92.6)	-0.88 (1.18)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 40	Tezepelumab	87	86 (98.9)	-1.23 (1.18)	-4.2	-2.20	-1.10	-0.40	2.6	-0.32 [-0.62, -0.02]
			Placebo	94	87 (92.6)	-0.85 (1.17)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 42	Tezepelumab	87	86 (98.9)	-1.27 (1.15)	-3.6	-2.20	-1.30	-0.60	2.6	-0.35 [-0.65, -0.05]
			Placebo	94	87 (92.6)	-0.87 (1.12)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	87	86 (98.9)	-1.23 (1.22)	-4.4	-2.20	-1.20	-0.40	2.6	-0.33 [-0.63, -0.03]
			Placebo	94	88 (93.6)	-0.83 (1.20)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 46	Tezepelumab	87	86 (98.9)	-1.28 (1.17)	-4.0	-2.20	-1.30	-0.40	2.6	-0.30 [-0.59, 0.00]
			Placebo	94	88 (93.6)	-0.94 (1.15)	-4.2	-1.60	-1.00	-0.10	2.6	
		Week 48	Tezepelumab	87	86 (98.9)	-1.23 (1.15)	-4.0	-2.20	-1.10	-0.40	2.6	-0.28 [-0.58, 0.02]
			Placebo	94	88 (93.6)	-0.90 (1.16)	-3.8	-1.60	-0.90	-0.20	2.6	
		Week 50	Tezepelumab	87	86 (98.9)	-1.31 (1.14)	-3.8	-2.20	-1.30	-0.60	2.6	-0.29 [-0.59, 0.01]
			Placebo	94	88 (93.6)	-0.98 (1.14)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 52	Tezepelumab	87	86 (98.9)	-1.29 (1.16)	-4.0	-2.20	-1.20	-0.40	2.6	-0.32 [-0.61, -0.02]
			Placebo	94	88 (93.6)	-0.92 (1.16)	-4.2	-1.60	-1.00	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	114	114 (100.0)	2.88 (0.86)	0.0	2.40	2.80	3.20	5.2	
			Placebo	118	118 (100.0)	2.86 (0.73)	1.0	2.40	3.00	3.20	5.0	
		Week 2	Tezepelumab	114	110 (96.5)	2.26 (0.98)	0.0	1.60	2.40	3.00	4.4	
			Placebo	118	108 (91.5)	2.43 (0.86)	0.0	2.00	2.40	3.00	5.0	
		Week 4	Tezepelumab	114	110 (96.5)	1.99 (1.03)	0.0	1.20	2.20	2.80	4.2	
			Placebo	118	108 (91.5)	2.30 (0.86)	0.2	1.80	2.40	3.00	4.4	
		Week 6	Tezepelumab	114	110 (96.5)	1.89 (1.04)	0.0	1.20	1.80	2.80	4.2	
			Placebo	118	109 (92.4)	2.17 (1.04)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	114	110 (96.5)	1.80 (1.13)	0.0	1.00	1.80	2.80	5.2	
			Placebo	118	110 (93.2)	2.14 (1.02)	0.0	1.40	2.30	2.80	5.0	
		Week 10	Tezepelumab	114	110 (96.5)	1.71 (1.10)	0.0	0.80	1.80	2.60	4.8	
			Placebo	118	111 (94.1)	2.04 (0.98)	0.0	1.40	2.00	2.60	5.2	
		Week 12	Tezepelumab	114	110 (96.5)	1.63 (1.12)	0.0	0.60	1.60	2.60	4.8	
			Placebo	118	111 (94.1)	1.96 (1.03)	0.0	1.20	2.00	2.80	4.4	
		Week 14	Tezepelumab	114	110 (96.5)	1.48 (1.12)	0.0	0.60	1.30	2.20	4.8	
			Placebo	118	111 (94.1)	1.91 (0.97)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	114	110 (96.5)	1.69 (1.16)	0.0	0.80	1.60	2.60	4.8	
			Placebo	118	111 (94.1)	2.06 (1.10)	0.0	1.00	2.00	3.00	5.0	
		Week 18	Tezepelumab	114	110 (96.5)	1.53 (1.07)	0.0	0.80	1.20	2.40	4.8	
			Placebo	118	111 (94.1)	1.92 (1.05)	0.0	1.20	1.80	2.60	5.0	
		Week 20	Tezepelumab	114	110 (96.5)	1.64 (1.12)	0.0	0.80	1.80	2.40	5.0	
			Placebo	118	111 (94.1)	1.99 (1.05)	0.0	1.20	2.00	2.80	5.0	
		Week 22	Tezepelumab	114	110 (96.5)	1.66 (1.06)	0.0	0.80	1.80	2.40	4.8	
			Placebo	118	111 (94.1)	1.95 (1.06)	0.0	1.20	2.00	2.80	5.0	
		Week 24	Tezepelumab	114	110 (96.5)	1.66 (1.14)	0.0	0.80	1.80	2.60	4.8	
			Placebo	118	111 (94.1)	1.94 (1.02)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	114	111 (97.4)	1.61 (1.10)	0.0	0.80	1.60	2.40	4.8	
			Placebo	118	111 (94.1)	1.88 (1.00)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	114	112 (98.2)	1.68 (1.14)	0.0	0.90	1.80	2.50	4.8	
			Placebo	118	111 (94.1)	1.97 (1.09)	0.0	1.00	2.20	2.80	4.4	
		Week 30	Tezepelumab	114	113 (99.1)	1.60 (1.10)	0.0	0.80	1.60	2.40	4.8	
			Placebo	118	112 (94.9)	1.97 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	114	113 (99.1)	1.59 (1.13)	0.0	0.80	1.40	2.40	4.8	
			Placebo	118	112 (94.9)	1.91 (1.10)	0.0	0.90	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 65 years	Absolute values	Week 34	Tezepelumab	114	113 (99.1)	1.58 (1.17)	0.0	0.80	1.40	2.40	4.8	
			Placebo	118	112 (94.9)	1.85 (1.10)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	114	113 (99.1)	1.69 (1.16)	0.0	0.80	1.60	2.40	5.0	
			Placebo	118	112 (94.9)	1.95 (1.11)	0.0	1.00	2.00	2.80	4.8	
		Week 38	Tezepelumab	114	113 (99.1)	1.58 (1.16)	0.0	0.60	1.60	2.40	4.8	
			Placebo	118	112 (94.9)	1.87 (1.09)	0.0	1.00	1.80	2.80	4.8	
		Week 40	Tezepelumab	114	113 (99.1)	1.62 (1.16)	0.0	0.60	1.80	2.60	4.8	
			Placebo	118	112 (94.9)	1.94 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	114	113 (99.1)	1.58 (1.15)	0.0	0.80	1.40	2.40	4.8	
			Placebo	118	112 (94.9)	1.94 (1.05)	0.0	1.10	2.00	2.70	4.6	
		Week 44	Tezepelumab	114	113 (99.1)	1.61 (1.14)	0.0	0.60	1.60	2.60	4.8	
			Placebo	118	113 (95.8)	1.97 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	114	113 (99.1)	1.57 (1.16)	0.0	0.80	1.20	2.40	4.8	
			Placebo	118	113 (95.8)	1.84 (1.02)	0.0	1.20	2.00	2.60	4.4	
		Week 48	Tezepelumab	114	113 (99.1)	1.66 (1.16)	0.0	0.80	1.60	2.60	4.8	
			Placebo	118	113 (95.8)	1.88 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 50	Tezepelumab	114	113 (99.1)	1.55 (1.16)	0.0	0.60	1.40	2.20	4.8	
			Placebo	118	113 (95.8)	1.86 (1.02)	0.0	1.00	1.80	2.60	4.4	
		Week 52	Tezepelumab	114	113 (99.1)	1.59 (1.14)	0.0	0.80	1.60	2.20	4.8	
			Placebo	118	113 (95.8)	1.91 (1.05)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 2	Tezepelumab	114	110 (96.5)	-0.61 (0.75)	-3.2	-1.20	-0.60	-0.20	0.8	-0.24 [-0.51, 0.02]
			Placebo	118	108 (91.5)	-0.42 (0.80)	-3.0	-0.80	-0.20	0.00	1.4	
		Week 4	Tezepelumab	114	110 (96.5)	-0.88 (0.97)	-3.8	-1.40	-0.80	-0.20	2.6	-0.35 [-0.61, -0.08]
			Placebo	118	108 (91.5)	-0.55 (0.93)	-3.0	-1.20	-0.40	0.10	1.6	
		Week 6	Tezepelumab	114	110 (96.5)	-0.99 (1.06)	-4.0	-1.60	-1.00	-0.40	2.6	-0.30 [-0.57, -0.04]
			Placebo	118	109 (92.4)	-0.68 (0.99)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	114	110 (96.5)	-1.07 (1.11)	-4.0	-1.80	-1.00	-0.40	2.6	-0.34 [-0.61, -0.07]
			Placebo	118	110 (93.2)	-0.71 (1.00)	-3.6	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	114	110 (96.5)	-1.16 (1.09)	-4.0	-1.80	-1.20	-0.40	2.6	-0.32 [-0.59, -0.06]
			Placebo	118	111 (94.1)	-0.81 (1.07)	-3.8	-1.40	-0.60	-0.20	2.6	
		Week 12	Tezepelumab	114	110 (96.5)	-1.24 (1.10)	-4.0	-2.00	-1.30	-0.60	2.6	-0.32 [-0.58, -0.05]
			Placebo	118	111 (94.1)	-0.89 (1.10)	-3.8	-1.60	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	114	110 (96.5)	-1.39 (1.12)	-4.2	-2.20	-1.40	-0.80	2.6	-0.41 [-0.68, -0.14]
			Placebo	118	111 (94.1)	-0.95 (1.05)	-3.4	-1.40	-1.00	-0.40	2.4	
		Week 16	Tezepelumab	114	110 (96.5)	-1.19 (1.17)	-4.4	-2.00	-1.10	-0.40	2.6	-0.34 [-0.60, -0.07]
			Placebo	118	111 (94.1)	-0.80 (1.15)	-3.6	-1.40	-0.80	0.00	2.6	
		Week 18	Tezepelumab	114	110 (96.5)	-1.35 (1.12)	-4.4	-2.00	-1.20	-0.60	2.6	-0.37 [-0.64, -0.10]
			Placebo	118	111 (94.1)	-0.93 (1.13)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	114	110 (96.5)	-1.23 (1.13)	-4.4	-2.00	-1.20	-0.60	2.6	-0.32 [-0.58, -0.05]
			Placebo	118	111 (94.1)	-0.87 (1.16)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	114	110 (96.5)	-1.21 (1.17)	-4.4	-2.00	-1.20	-0.60	2.6	-0.27 [-0.53, -0.00]
			Placebo	118	111 (94.1)	-0.90 (1.13)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 24	Tezepelumab	114	110 (96.5)	-1.22 (1.10)	-4.8	-2.00	-1.20	-0.60	2.6	-0.27 [-0.53, -0.00]
			Placebo	118	111 (94.1)	-0.92 (1.14)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 26	Tezepelumab	114	111 (97.4)	-1.25 (1.13)	-4.4	-2.20	-1.20	-0.40	2.6	-0.24 [-0.51, 0.02]
			Placebo	118	111 (94.1)	-0.98 (1.13)	-4.2	-1.80	-1.00	0.00	2.6	
		Week 28	Tezepelumab	114	112 (98.2)	-1.18 (1.15)	-4.4	-2.10	-1.20	-0.30	2.6	-0.25 [-0.51, 0.01]
			Placebo	118	111 (94.1)	-0.89 (1.19)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 30	Tezepelumab	114	113 (99.1)	-1.27 (1.19)	-4.4	-2.20	-1.20	-0.60	2.6	-0.32 [-0.58, -0.06]
			Placebo	118	112 (94.9)	-0.89 (1.21)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 32	Tezepelumab	114	113 (99.1)	-1.28 (1.17)	-4.4	-2.20	-1.20	-0.60	2.6	-0.29 [-0.55, -0.02]
			Placebo	118	112 (94.9)	-0.94 (1.18)	-3.6	-1.80	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	114	113 (99.1)	-1.29 (1.20)	-4.4	-2.20	-1.40	-0.40	2.6	-0.24 [-0.50, 0.02]
			Placebo	118	112 (94.9)	-1.00 (1.17)	-4.2	-1.80	-1.00	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 65 years	Change from baseline	Week 36	Tezepelumab	114	113 (99.1)	-1.18 (1.25)	-4.4	-2.20	-1.20	-0.20	2.6	-0.22 [-0.49, 0.04]
			Placebo	118	112 (94.9)	-0.90 (1.22)	-3.6	-1.60	-1.00	0.00	2.6	
		Week 38	Tezepelumab	114	113 (99.1)	-1.29 (1.23)	-4.4	-2.20	-1.40	-0.40	2.6	-0.25 [-0.51, 0.01]
			Placebo	118	112 (94.9)	-0.99 (1.22)	-4.2	-2.00	-1.00	-0.20	2.6	
		Week 40	Tezepelumab	114	113 (99.1)	-1.25 (1.24)	-4.4	-2.20	-1.00	-0.40	2.6	-0.28 [-0.54, -0.02]
			Placebo	118	112 (94.9)	-0.91 (1.16)	-4.2	-1.60	-0.80	-0.20	2.6	
		Week 42	Tezepelumab	114	113 (99.1)	-1.29 (1.24)	-4.4	-2.20	-1.40	-0.40	2.6	-0.32 [-0.58, -0.05]
			Placebo	118	112 (94.9)	-0.91 (1.16)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	114	113 (99.1)	-1.26 (1.24)	-4.4	-2.20	-1.20	-0.40	2.6	-0.31 [-0.57, -0.04]
			Placebo	118	113 (95.8)	-0.89 (1.19)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 46	Tezepelumab	114	113 (99.1)	-1.30 (1.23)	-4.4	-2.20	-1.40	-0.40	2.6	-0.25 [-0.51, 0.01]
			Placebo	118	113 (95.8)	-1.01 (1.13)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	114	113 (99.1)	-1.21 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.20 [-0.46, 0.06]
			Placebo	118	113 (95.8)	-0.97 (1.17)	-3.8	-1.60	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	114	113 (99.1)	-1.32 (1.23)	-4.4	-2.20	-1.40	-0.40	2.6	-0.27 [-0.54, -0.01]
			Placebo	118	113 (95.8)	-1.00 (1.13)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 52	Tezepelumab	114	113 (99.1)	-1.28 (1.23)	-4.4	-2.20	-1.20	-0.40	2.6	-0.28 [-0.54, -0.02]
			Placebo	118	113 (95.8)	-0.95 (1.16)	-4.2	-1.60	-1.00	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	2.63 (0.72)	1.0	2.20	2.80	3.00	4.6	
			Placebo	20	20 (100.0)	2.58 (0.66)	0.4	2.30	2.80	2.80	3.4	
		Week 2	Tezepelumab	23	21 (91.3)	2.30 (0.92)	0.0	1.60	2.60	3.00	4.0	
			Placebo	20	17 (85.0)	2.36 (0.68)	1.0	1.80	2.40	3.00	3.2	
		Week 4	Tezepelumab	23	21 (91.3)	1.78 (0.93)	0.0	1.00	1.60	2.60	3.2	
			Placebo	20	17 (85.0)	2.31 (0.98)	0.4	1.80	2.60	2.80	4.2	
		Week 6	Tezepelumab	23	21 (91.3)	1.77 (0.79)	0.0	1.40	1.60	2.40	3.2	
			Placebo	20	17 (85.0)	2.36 (0.90)	0.8	1.80	2.40	3.00	4.2	
		Week 8	Tezepelumab	23	21 (91.3)	1.74 (0.79)	0.0	1.40	1.60	2.20	3.0	
			Placebo	20	17 (85.0)	2.16 (0.88)	0.4	1.60	2.00	2.80	3.8	
		Week 10	Tezepelumab	23	21 (91.3)	1.77 (0.79)	0.0	1.40	1.60	2.20	3.4	
			Placebo	20	17 (85.0)	2.26 (0.84)	0.6	1.60	2.40	2.80	3.6	
		Week 12	Tezepelumab	23	21 (91.3)	1.67 (0.89)	0.0	1.00	1.60	2.20	3.6	
			Placebo	20	17 (85.0)	2.19 (0.77)	0.2	2.00	2.00	3.00	3.2	
		Week 14	Tezepelumab	23	21 (91.3)	1.64 (0.66)	0.0	1.20	1.60	1.80	2.8	
			Placebo	20	17 (85.0)	2.13 (0.82)	0.8	1.40	2.40	2.80	3.2	
		Week 16	Tezepelumab	23	21 (91.3)	1.59 (0.78)	0.0	1.00	1.60	2.00	2.8	
			Placebo	20	17 (85.0)	2.09 (0.94)	0.0	1.40	2.40	2.80	3.2	
		Week 18	Tezepelumab	23	22 (95.7)	1.66 (0.69)	0.0	1.20	1.60	2.20	2.8	
			Placebo	20	17 (85.0)	2.13 (0.87)	0.6	1.40	2.40	2.80	3.2	
		Week 20	Tezepelumab	23	22 (95.7)	1.66 (0.86)	0.0	1.20	1.50	2.80	3.0	
			Placebo	20	17 (85.0)	2.13 (1.00)	0.0	1.60	2.20	2.80	3.8	
		Week 22	Tezepelumab	23	22 (95.7)	1.69 (0.82)	0.0	1.20	1.70	2.40	2.8	
			Placebo	20	17 (85.0)	2.00 (0.98)	0.2	1.60	2.00	2.60	4.0	
		Week 24	Tezepelumab	23	22 (95.7)	1.65 (0.82)	0.0	1.00	1.60	2.40	3.0	
			Placebo	20	17 (85.0)	2.05 (1.06)	0.2	1.20	2.20	2.80	3.8	
		Week 26	Tezepelumab	23	22 (95.7)	1.61 (0.72)	0.0	1.20	1.60	2.20	2.8	
			Placebo	20	17 (85.0)	2.05 (1.09)	0.4	1.20	1.80	3.00	4.4	
		Week 28	Tezepelumab	23	22 (95.7)	1.64 (0.92)	0.0	1.20	1.60	2.40	3.0	
			Placebo	20	18 (90.0)	1.89 (1.16)	0.0	1.00	2.10	2.80	4.4	
		Week 30	Tezepelumab	23	22 (95.7)	1.66 (0.74)	0.0	1.20	1.70	2.20	2.8	
			Placebo	20	18 (90.0)	1.79 (1.01)	0.0	1.00	2.00	2.40	3.4	
		Week 32	Tezepelumab	23	22 (95.7)	1.44 (0.76)	0.0	1.00	1.40	2.20	2.8	
			Placebo	20	18 (90.0)	1.76 (1.00)	0.0	1.20	1.70	2.80	3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 65 years	Absolute values	Week 34	Tezepelumab	23	22 (95.7)	1.56 (0.89)	0.0	1.00	1.40	2.40	3.0	
			Placebo	20	18 (90.0)	1.86 (1.01)	0.0	1.40	2.00	2.60	3.6	
		Week 36	Tezepelumab	23	22 (95.7)	1.51 (0.80)	0.0	0.80	1.60	2.00	3.0	
			Placebo	20	18 (90.0)	1.86 (1.06)	0.0	1.00	2.20	2.80	3.6	
		Week 38	Tezepelumab	23	22 (95.7)	1.49 (0.76)	0.0	1.00	1.40	2.40	3.0	
			Placebo	20	18 (90.0)	1.79 (0.93)	0.0	1.00	1.90	2.60	3.0	
		Week 40	Tezepelumab	23	22 (95.7)	1.45 (0.80)	0.0	0.80	1.50	2.00	2.8	
			Placebo	20	18 (90.0)	1.90 (1.22)	0.0	1.00	1.90	3.00	4.2	
		Week 42	Tezepelumab	23	22 (95.7)	1.39 (0.72)	0.0	0.80	1.40	1.80	2.8	
			Placebo	20	18 (90.0)	1.67 (1.03)	0.0	0.60	1.90	2.20	3.8	
		Week 44	Tezepelumab	23	22 (95.7)	1.39 (0.81)	0.0	0.80	1.50	2.00	2.8	
			Placebo	20	18 (90.0)	1.86 (1.01)	0.0	1.00	2.10	2.80	3.4	
		Week 46	Tezepelumab	23	22 (95.7)	1.46 (0.72)	0.0	1.00	1.50	2.00	2.8	
			Placebo	20	18 (90.0)	1.76 (1.09)	0.0	1.00	1.90	2.20	4.4	
		Week 48	Tezepelumab	23	22 (95.7)	1.35 (0.80)	0.0	0.80	1.20	2.00	2.6	
			Placebo	20	18 (90.0)	1.77 (1.13)	0.0	1.00	1.60	2.40	4.6	
		Week 50	Tezepelumab	23	22 (95.7)	1.36 (0.70)	0.0	0.80	1.30	1.80	2.6	
			Placebo	20	18 (90.0)	1.74 (0.95)	0.0	0.80	2.10	2.40	3.0	
		Week 52	Tezepelumab	23	22 (95.7)	1.32 (0.74)	0.0	0.60	1.40	1.80	2.8	
			Placebo	20	18 (90.0)	1.78 (1.03)	0.0	0.80	2.10	2.60	3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 2	Tezepelumab	23	21 (91.3)	-0.35 (0.69)	-3.0	-0.60	-0.20	0.00	0.4	-0.02 [-0.66, 0.62]
			Placebo	20	17 (85.0)	-0.34 (0.49)	-1.0	-0.60	-0.40	0.00	0.8	
		Week 4	Tezepelumab	23	21 (91.3)	-0.88 (0.95)	-3.0	-1.40	-0.80	-0.40	0.6	-0.55 [-1.20, 0.11]
			Placebo	20	17 (85.0)	-0.40 (0.76)	-1.6	-1.00	-0.60	0.00	1.4	
		Week 6	Tezepelumab	23	21 (91.3)	-0.89 (0.95)	-3.0	-1.60	-0.80	0.00	0.6	-0.63 [-1.29, 0.02]
			Placebo	20	17 (85.0)	-0.34 (0.74)	-1.6	-0.80	-0.60	0.20	1.4	
		Week 8	Tezepelumab	23	21 (91.3)	-0.91 (0.97)	-3.0	-1.60	-0.80	-0.40	0.4	-0.43 [-1.08, 0.22]
			Placebo	20	17 (85.0)	-0.54 (0.71)	-1.8	-1.00	-0.80	0.00	1.0	
		Week 10	Tezepelumab	23	21 (91.3)	-0.89 (0.83)	-3.0	-1.40	-0.80	-0.20	0.2	-0.61 [-1.27, 0.04]
			Placebo	20	17 (85.0)	-0.45 (0.55)	-1.4	-0.80	-0.40	0.00	0.2	
		Week 12	Tezepelumab	23	21 (91.3)	-0.99 (0.86)	-3.0	-1.20	-0.80	-0.40	0.2	-0.65 [-1.31, 0.01]
			Placebo	20	17 (85.0)	-0.52 (0.51)	-1.4	-0.80	-0.60	-0.20	0.2	
		Week 14	Tezepelumab	23	21 (91.3)	-1.02 (0.78)	-3.0	-1.40	-0.80	-0.40	0.2	-0.61 [-1.27, 0.04]
			Placebo	20	17 (85.0)	-0.58 (0.64)	-1.6	-1.00	-0.60	0.00	0.4	
		Week 16	Tezepelumab	23	21 (91.3)	-1.07 (0.82)	-3.0	-1.40	-1.00	-0.60	0.4	-0.60 [-1.25, 0.06]
			Placebo	20	17 (85.0)	-0.61 (0.68)	-2.2	-1.00	-0.60	0.00	0.2	
		Week 18	Tezepelumab	23	22 (95.7)	-0.96 (0.82)	-3.0	-1.40	-0.80	-0.60	0.4	-0.51 [-1.15, 0.14]
			Placebo	20	17 (85.0)	-0.58 (0.68)	-1.6	-1.00	-0.40	0.00	0.4	
		Week 20	Tezepelumab	23	22 (95.7)	-0.96 (0.89)	-3.0	-1.40	-0.90	-0.40	0.4	-0.47 [-1.11, 0.17]
			Placebo	20	17 (85.0)	-0.58 (0.74)	-2.2	-1.00	-0.60	-0.20	1.0	
		Week 22	Tezepelumab	23	22 (95.7)	-0.94 (0.87)	-3.0	-1.60	-0.70	-0.40	0.2	-0.28 [-0.91, 0.36]
			Placebo	20	17 (85.0)	-0.71 (0.77)	-2.0	-1.20	-0.80	-0.40	1.2	
		Week 24	Tezepelumab	23	22 (95.7)	-0.98 (0.89)	-3.0	-1.40	-0.80	-0.20	0.2	-0.37 [-1.01, 0.26]
			Placebo	20	17 (85.0)	-0.66 (0.82)	-1.8	-1.20	-0.80	0.00	1.0	
		Week 26	Tezepelumab	23	22 (95.7)	-1.02 (1.01)	-3.4	-1.40	-0.80	-0.20	0.4	-0.37 [-1.01, 0.27]
			Placebo	20	17 (85.0)	-0.66 (0.91)	-1.8	-1.40	-1.20	0.00	1.6	
		Week 28	Tezepelumab	23	22 (95.7)	-0.99 (1.02)	-3.0	-1.40	-0.90	-0.60	1.0	-0.32 [-0.94, 0.31]
			Placebo	20	18 (90.0)	-0.69 (0.88)	-2.0	-1.60	-0.60	-0.20	1.6	
		Week 30	Tezepelumab	23	22 (95.7)	-0.96 (0.84)	-3.0	-1.20	-0.80	-0.40	0.4	-0.23 [-0.85, 0.40]
			Placebo	20	18 (90.0)	-0.79 (0.69)	-1.8	-1.40	-0.80	-0.40	0.6	
		Week 32	Tezepelumab	23	22 (95.7)	-1.19 (0.93)	-3.2	-1.60	-1.00	-0.60	0.4	-0.44 [-1.07, 0.19]
			Placebo	20	18 (90.0)	-0.82 (0.68)	-1.8	-1.40	-0.90	-0.20	0.2	
		Week 34	Tezepelumab	23	22 (95.7)	-1.06 (0.93)	-3.0	-1.80	-0.80	-0.60	0.6	-0.41 [-1.04, 0.22]
			Placebo	20	18 (90.0)	-0.72 (0.72)	-1.8	-1.20	-0.90	-0.20	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 65 years	Change from baseline	Week 36	Tezepelumab	23	22 (95.7)	-1.12 (0.95)	-3.0	-1.80	-1.00	-0.60	0.6	-0.46 [-1.09, 0.18]
			Placebo	20	18 (90.0)	-0.72 (0.76)	-2.2	-1.20	-0.70	-0.20	0.8	
		Week 38	Tezepelumab	23	22 (95.7)	-1.14 (0.97)	-3.6	-1.40	-0.90	-0.60	0.6	-0.42 [-1.05, 0.21]
			Placebo	20	18 (90.0)	-0.79 (0.62)	-1.6	-1.20	-1.00	-0.20	0.2	
		Week 40	Tezepelumab	23	22 (95.7)	-1.18 (1.01)	-3.8	-1.60	-1.20	-0.60	0.4	-0.52 [-1.15, 0.12]
			Placebo	20	18 (90.0)	-0.68 (0.93)	-2.0	-1.40	-0.50	0.00	1.4	
		Week 42	Tezepelumab	23	22 (95.7)	-1.24 (0.95)	-3.0	-1.80	-1.20	-0.60	0.4	-0.37 [-0.99, 0.26]
			Placebo	20	18 (90.0)	-0.91 (0.81)	-2.2	-1.60	-1.10	-0.20	1.0	
		Week 44	Tezepelumab	23	22 (95.7)	-1.24 (1.10)	-4.4	-1.60	-1.20	-0.60	0.4	-0.53 [-1.17, 0.10]
			Placebo	20	18 (90.0)	-0.72 (0.77)	-2.0	-1.40	-0.70	0.00	0.6	
		Week 46	Tezepelumab	23	22 (95.7)	-1.16 (1.00)	-4.0	-1.60	-1.00	-0.80	0.4	-0.36 [-0.99, 0.27]
			Placebo	20	18 (90.0)	-0.82 (0.89)	-2.2	-1.40	-1.00	-0.40	1.6	
		Week 48	Tezepelumab	23	22 (95.7)	-1.27 (1.08)	-4.0	-2.00	-1.00	-0.60	0.4	-0.46 [-1.09, 0.17]
			Placebo	20	18 (90.0)	-0.81 (0.89)	-1.8	-1.40	-1.10	-0.40	1.8	
		Week 50	Tezepelumab	23	22 (95.7)	-1.26 (0.95)	-3.6	-1.60	-1.20	-0.80	0.4	-0.51 [-1.15, 0.12]
			Placebo	20	18 (90.0)	-0.83 (0.67)	-2.2	-1.40	-0.80	-0.40	0.2	
		Week 52	Tezepelumab	23	22 (95.7)	-1.31 (1.06)	-4.0	-1.80	-1.20	-0.80	0.4	-0.56 [-1.20, 0.07]
			Placebo	20	18 (90.0)	-0.80 (0.68)	-2.0	-1.40	-0.70	-0.40	0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	105	105 (100.0)	2.79 (0.79)	0.0	2.40	2.80	3.20	5.0	
			Placebo	110	110 (100.0)	2.78 (0.70)	0.4	2.40	2.80	3.20	4.8	
		Week 2	Tezepelumab	105	100 (95.2)	2.24 (0.92)	0.0	1.60	2.40	2.80	4.4	
			Placebo	110	100 (90.9)	2.41 (0.84)	0.0	1.90	2.50	3.00	4.8	
		Week 4	Tezepelumab	105	100 (95.2)	1.99 (1.01)	0.0	1.20	2.20	2.80	4.2	
			Placebo	110	100 (90.9)	2.23 (0.88)	0.2	1.70	2.40	2.80	4.4	
		Week 6	Tezepelumab	105	100 (95.2)	1.87 (0.98)	0.0	1.20	1.80	2.60	4.2	
			Placebo	110	101 (91.8)	2.13 (0.97)	0.2	1.40	2.20	2.80	4.8	
		Week 8	Tezepelumab	105	100 (95.2)	1.76 (0.99)	0.0	1.00	1.60	2.60	4.2	
			Placebo	110	102 (92.7)	2.12 (0.96)	0.0	1.60	2.10	2.80	4.6	
		Week 10	Tezepelumab	105	100 (95.2)	1.72 (0.99)	0.0	1.00	1.80	2.50	4.2	
			Placebo	110	103 (93.6)	2.00 (0.91)	0.0	1.40	2.00	2.60	4.4	
		Week 12	Tezepelumab	105	100 (95.2)	1.67 (1.07)	0.0	0.80	1.60	2.60	4.2	
			Placebo	110	103 (93.6)	1.96 (0.98)	0.0	1.20	2.00	2.80	4.4	
		Week 14	Tezepelumab	105	100 (95.2)	1.55 (1.04)	0.0	0.80	1.40	2.40	4.2	
			Placebo	110	103 (93.6)	1.93 (0.92)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	105	100 (95.2)	1.68 (1.06)	0.0	0.80	1.70	2.60	4.6	
			Placebo	110	103 (93.6)	2.03 (0.99)	0.0	1.20	2.00	2.80	4.4	
		Week 18	Tezepelumab	105	101 (96.2)	1.60 (0.95)	0.0	1.00	1.60	2.20	4.2	
			Placebo	110	103 (93.6)	1.92 (0.94)	0.0	1.40	2.00	2.60	4.4	
		Week 20	Tezepelumab	105	101 (96.2)	1.63 (1.01)	0.0	0.80	1.80	2.40	4.2	
			Placebo	110	103 (93.6)	1.99 (0.98)	0.0	1.40	2.20	2.80	4.4	
		Week 22	Tezepelumab	105	101 (96.2)	1.66 (0.98)	0.0	1.00	1.80	2.40	4.2	
			Placebo	110	103 (93.6)	1.89 (0.97)	0.0	1.20	2.00	2.60	4.4	
		Week 24	Tezepelumab	105	101 (96.2)	1.67 (1.07)	0.0	0.80	1.80	2.40	4.8	
			Placebo	110	103 (93.6)	1.90 (0.98)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	105	102 (97.1)	1.61 (0.98)	0.0	1.00	1.60	2.40	4.2	
			Placebo	110	103 (93.6)	1.83 (0.95)	0.0	1.00	1.60	2.80	4.4	
		Week 28	Tezepelumab	105	102 (97.1)	1.69 (1.05)	0.0	1.00	1.80	2.40	4.2	
			Placebo	110	104 (94.5)	1.93 (1.04)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	105	103 (98.1)	1.65 (1.01)	0.0	1.00	1.60	2.40	4.2	
			Placebo	110	104 (94.5)	1.87 (1.04)	0.0	1.00	2.00	2.70	4.4	
		Week 32	Tezepelumab	105	103 (98.1)	1.57 (1.04)	0.0	0.80	1.40	2.40	4.2	
			Placebo	110	104 (94.5)	1.85 (1.03)	0.0	1.00	1.80	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
<= 2	Absolute values	Week 34	Tezepelumab	105	103 (98.1)	1.58 (1.11)	0.0	0.80	1.40	2.40	4.2	
			Placebo	110	104 (94.5)	1.81 (1.00)	0.0	1.00	1.80	2.60	4.4	
		Week 36	Tezepelumab	105	103 (98.1)	1.66 (1.10)	0.0	0.80	1.80	2.40	5.0	
			Placebo	110	104 (94.5)	1.81 (1.03)	0.0	1.00	2.00	2.60	4.4	
		Week 38	Tezepelumab	105	103 (98.1)	1.55 (1.07)	0.0	0.80	1.40	2.40	4.4	
			Placebo	110	104 (94.5)	1.75 (1.00)	0.0	1.00	1.80	2.60	4.4	
		Week 40	Tezepelumab	105	103 (98.1)	1.59 (1.10)	0.0	0.60	1.60	2.40	4.2	
			Placebo	110	104 (94.5)	1.83 (1.06)	0.0	1.00	1.80	2.80	4.4	
		Week 42	Tezepelumab	105	103 (98.1)	1.54 (1.05)	0.0	0.60	1.60	2.20	4.2	
			Placebo	110	104 (94.5)	1.85 (1.05)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	105	103 (98.1)	1.62 (1.06)	0.0	0.80	1.60	2.60	4.2	
			Placebo	110	105 (95.5)	1.84 (1.04)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	105	103 (98.1)	1.58 (1.09)	0.0	0.80	1.60	2.40	4.2	
			Placebo	110	105 (95.5)	1.78 (1.04)	0.0	1.00	2.00	2.60	4.4	
		Week 48	Tezepelumab	105	103 (98.1)	1.64 (1.10)	0.0	0.80	1.80	2.40	4.2	
			Placebo	110	105 (95.5)	1.79 (1.07)	0.0	1.00	1.80	2.60	4.6	
		Week 50	Tezepelumab	105	103 (98.1)	1.53 (1.05)	0.0	0.80	1.40	2.20	4.2	
			Placebo	110	105 (95.5)	1.77 (1.00)	0.0	1.00	1.80	2.60	4.4	
		Week 52	Tezepelumab	105	103 (98.1)	1.53 (1.06)	0.0	0.60	1.40	2.20	4.2	
			Placebo	110	105 (95.5)	1.82 (1.01)	0.0	1.00	2.00	2.60	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	105	100 (95.2)	-0.54 (0.70)	-3.0	-0.80	-0.40	0.00	0.8	-0.20 [-0.48, 0.08]
			Placebo	110	100 (90.9)	-0.40 (0.74)	-3.0	-0.80	-0.20	0.10	1.4	
		Week 4	Tezepelumab	105	100 (95.2)	-0.80 (0.92)	-3.8	-1.30	-0.70	-0.20	1.2	-0.25 [-0.52, 0.03]
			Placebo	110	100 (90.9)	-0.57 (0.91)	-3.0	-1.20	-0.40	0.00	1.6	
		Week 6	Tezepelumab	105	100 (95.2)	-0.92 (0.94)	-4.0	-1.40	-1.00	-0.20	1.2	-0.27 [-0.55, 0.01]
			Placebo	110	101 (91.8)	-0.67 (0.95)	-3.4	-1.40	-0.60	0.00	1.4	
		Week 8	Tezepelumab	105	100 (95.2)	-1.03 (0.92)	-4.0	-1.60	-1.00	-0.40	1.0	-0.36 [-0.64, -0.08]
			Placebo	110	102 (92.7)	-0.69 (0.95)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	105	100 (95.2)	-1.06 (0.93)	-4.0	-1.60	-1.10	-0.40	1.0	-0.27 [-0.55, 0.00]
			Placebo	110	103 (93.6)	-0.81 (0.93)	-3.8	-1.40	-0.60	-0.20	0.8	
		Week 12	Tezepelumab	105	100 (95.2)	-1.12 (0.95)	-4.0	-1.80	-1.10	-0.40	1.2	-0.26 [-0.54, 0.01]
			Placebo	110	103 (93.6)	-0.86 (1.01)	-3.8	-1.40	-0.60	-0.20	1.4	
		Week 14	Tezepelumab	105	100 (95.2)	-1.23 (0.95)	-4.0	-1.80	-1.20	-0.50	1.2	-0.36 [-0.64, -0.09]
			Placebo	110	103 (93.6)	-0.88 (0.97)	-3.4	-1.40	-0.80	-0.20	1.4	
		Week 16	Tezepelumab	105	100 (95.2)	-1.11 (0.98)	-4.0	-1.80	-1.00	-0.50	1.8	-0.33 [-0.60, -0.05]
			Placebo	110	103 (93.6)	-0.78 (1.03)	-3.6	-1.40	-0.60	0.00	1.4	
		Week 18	Tezepelumab	105	101 (96.2)	-1.18 (0.94)	-4.0	-1.80	-1.00	-0.60	1.2	-0.30 [-0.57, -0.02]
			Placebo	110	103 (93.6)	-0.90 (0.98)	-3.6	-1.40	-0.60	-0.20	1.0	
		Week 20	Tezepelumab	105	101 (96.2)	-1.15 (0.96)	-4.0	-1.80	-1.00	-0.40	1.0	-0.32 [-0.60, -0.05]
			Placebo	110	103 (93.6)	-0.83 (1.03)	-3.6	-1.40	-0.60	-0.20	1.2	
		Week 22	Tezepelumab	105	101 (96.2)	-1.12 (0.99)	-4.0	-1.80	-1.00	-0.60	2.0	-0.20 [-0.47, 0.08]
			Placebo	110	103 (93.6)	-0.92 (1.00)	-3.8	-1.60	-0.80	-0.20	1.4	
		Week 24	Tezepelumab	105	101 (96.2)	-1.11 (0.95)	-4.0	-1.80	-1.00	-0.40	1.4	-0.20 [-0.47, 0.08]
			Placebo	110	103 (93.6)	-0.91 (1.06)	-3.8	-1.40	-0.80	-0.20	1.8	
		Week 26	Tezepelumab	105	102 (97.1)	-1.16 (0.99)	-4.0	-1.80	-1.00	-0.40	1.2	-0.18 [-0.45, 0.10]
			Placebo	110	103 (93.6)	-0.99 (1.02)	-4.2	-1.80	-1.00	-0.20	1.6	
		Week 28	Tezepelumab	105	102 (97.1)	-1.08 (1.00)	-4.0	-1.80	-1.00	-0.40	1.0	-0.20 [-0.48, 0.07]
			Placebo	110	104 (94.5)	-0.87 (1.10)	-4.2	-1.60	-0.80	-0.20	1.6	
		Week 30	Tezepelumab	105	103 (98.1)	-1.13 (1.03)	-3.8	-1.80	-1.00	-0.40	2.0	-0.19 [-0.47, 0.08]
			Placebo	110	104 (94.5)	-0.92 (1.13)	-3.4	-1.60	-0.90	-0.20	2.0	
		Week 32	Tezepelumab	105	103 (98.1)	-1.21 (1.06)	-4.0	-2.00	-1.00	-0.60	1.8	-0.25 [-0.52, 0.02]
			Placebo	110	104 (94.5)	-0.94 (1.07)	-3.6	-1.70	-0.80	-0.20	1.4	
		Week 34	Tezepelumab	105	103 (98.1)	-1.20 (1.07)	-4.0	-2.00	-1.20	-0.40	2.2	-0.20 [-0.48, 0.07]
			Placebo	110	104 (94.5)	-0.98 (1.05)	-4.2	-1.60	-1.00	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
<= 2	Change from baseline	Week 36	Tezepelumab	105	103 (98.1)	-1.12 (1.10)	-4.0	-1.80	-1.20	-0.20	2.0	-0.13 [-0.40, 0.15]
			Placebo	110	104 (94.5)	-0.98 (1.09)	-3.6	-1.60	-1.00	-0.20	1.4	
		Week 38	Tezepelumab	105	103 (98.1)	-1.23 (1.11)	-4.0	-2.00	-1.20	-0.40	2.6	-0.17 [-0.44, 0.10]
			Placebo	110	104 (94.5)	-1.04 (1.06)	-4.2	-1.60	-1.00	-0.40	1.6	
		Week 40	Tezepelumab	105	103 (98.1)	-1.19 (1.12)	-4.2	-2.00	-1.00	-0.40	1.8	-0.20 [-0.48, 0.07]
			Placebo	110	104 (94.5)	-0.97 (1.06)	-4.2	-1.60	-0.90	-0.20	1.4	
		Week 42	Tezepelumab	105	103 (98.1)	-1.24 (1.08)	-4.0	-2.00	-1.20	-0.40	2.2	-0.28 [-0.55, -0.01]
			Placebo	110	104 (94.5)	-0.94 (1.09)	-4.2	-1.60	-0.90	-0.20	1.4	
		Week 44	Tezepelumab	105	103 (98.1)	-1.16 (1.12)	-4.4	-2.00	-1.00	-0.40	1.6	-0.19 [-0.46, 0.08]
			Placebo	110	105 (95.5)	-0.95 (1.09)	-4.2	-1.60	-0.80	-0.20	1.4	
		Week 46	Tezepelumab	105	103 (98.1)	-1.20 (1.12)	-4.0	-2.00	-1.00	-0.40	1.8	-0.17 [-0.44, 0.10]
			Placebo	110	105 (95.5)	-1.01 (1.07)	-4.2	-1.60	-1.00	-0.20	1.6	
		Week 48	Tezepelumab	105	103 (98.1)	-1.14 (1.11)	-4.0	-2.00	-1.00	-0.40	2.0	-0.13 [-0.40, 0.14]
			Placebo	110	105 (95.5)	-1.00 (1.11)	-3.8	-1.60	-1.00	-0.40	1.8	
		Week 50	Tezepelumab	105	103 (98.1)	-1.25 (1.10)	-4.0	-2.00	-1.20	-0.60	2.0	-0.22 [-0.49, 0.05]
			Placebo	110	105 (95.5)	-1.02 (1.04)	-4.2	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	105	103 (98.1)	-1.25 (1.12)	-4.0	-2.00	-1.20	-0.40	2.0	-0.26 [-0.53, 0.01]
			Placebo	110	105 (95.5)	-0.97 (1.04)	-4.2	-1.60	-1.00	-0.40	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	3.00 (0.99)	0.2	2.40	2.90	3.40	5.2	
			Placebo	28	28 (100.0)	2.95 (0.79)	1.0	2.60	3.00	3.40	5.0	
		Week 2	Tezepelumab	32	31 (96.9)	2.35 (1.12)	0.0	1.60	2.40	3.40	4.0	
			Placebo	28	25 (89.3)	2.46 (0.82)	0.4	2.20	2.40	2.80	5.0	
		Week 4	Tezepelumab	32	31 (96.9)	1.86 (1.04)	0.2	1.00	2.00	2.80	3.4	
			Placebo	28	25 (89.3)	2.57 (0.83)	0.8	2.20	2.60	3.00	4.2	
		Week 6	Tezepelumab	32	31 (96.9)	1.88 (1.08)	0.0	1.20	1.80	2.80	4.0	
			Placebo	28	25 (89.3)	2.45 (1.19)	1.0	1.80	2.20	2.80	6.0	
		Week 8	Tezepelumab	32	31 (96.9)	1.90 (1.34)	0.0	0.60	1.80	3.00	5.2	
			Placebo	28	25 (89.3)	2.22 (1.16)	0.2	1.60	2.40	3.20	5.0	
		Week 10	Tezepelumab	32	31 (96.9)	1.72 (1.24)	0.0	0.60	1.60	2.80	4.8	
			Placebo	28	25 (89.3)	2.34 (1.12)	0.4	1.80	2.40	3.00	5.2	
		Week 12	Tezepelumab	32	31 (96.9)	1.54 (1.14)	0.0	0.60	1.60	2.20	4.8	
			Placebo	28	25 (89.3)	2.14 (1.08)	0.0	1.20	2.40	3.00	4.4	
		Week 14	Tezepelumab	32	31 (96.9)	1.35 (1.13)	0.0	0.60	1.20	1.80	4.8	
			Placebo	28	25 (89.3)	1.97 (1.08)	0.0	1.40	1.80	2.60	5.0	
		Week 16	Tezepelumab	32	31 (96.9)	1.64 (1.26)	0.0	0.80	1.20	2.80	4.8	
			Placebo	28	25 (89.3)	2.17 (1.41)	0.0	1.40	2.00	3.20	5.0	
		Week 18	Tezepelumab	32	31 (96.9)	1.40 (1.19)	0.0	0.60	1.00	2.20	4.8	
			Placebo	28	25 (89.3)	2.09 (1.34)	0.0	1.00	2.00	2.60	5.0	
		Week 20	Tezepelumab	32	31 (96.9)	1.70 (1.28)	0.0	0.60	1.40	2.60	5.0	
			Placebo	28	25 (89.3)	2.09 (1.29)	0.0	1.20	2.00	2.80	5.0	
		Week 22	Tezepelumab	32	31 (96.9)	1.70 (1.18)	0.0	0.60	1.60	2.40	4.8	
			Placebo	28	25 (89.3)	2.22 (1.29)	0.0	1.20	2.60	3.00	5.0	
		Week 24	Tezepelumab	32	31 (96.9)	1.63 (1.16)	0.0	0.80	1.60	2.60	4.8	
			Placebo	28	25 (89.3)	2.16 (1.18)	0.0	1.20	2.40	3.00	4.0	
		Week 26	Tezepelumab	32	31 (96.9)	1.64 (1.25)	0.0	0.80	1.40	2.40	4.8	
			Placebo	28	25 (89.3)	2.20 (1.22)	0.0	1.00	2.20	3.20	4.0	
		Week 28	Tezepelumab	32	32 (100.0)	1.63 (1.27)	0.0	0.50	1.30	2.60	4.8	
			Placebo	28	25 (89.3)	2.10 (1.29)	0.0	0.80	2.20	3.40	4.0	
		Week 30	Tezepelumab	32	32 (100.0)	1.49 (1.16)	0.0	0.80	1.10	2.20	4.8	
			Placebo	28	26 (92.9)	2.24 (1.15)	0.0	1.60	2.20	3.20	4.0	
		Week 32	Tezepelumab	32	32 (100.0)	1.56 (1.19)	0.0	0.80	1.30	2.40	4.8	
			Placebo	28	26 (92.9)	2.08 (1.28)	0.4	0.80	1.80	3.40	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 2	Absolute values	Week 34	Tezepelumab	32	32 (100.0)	1.57 (1.17)	0.0	0.80	1.30	2.40	4.8	
			Placebo	28	26 (92.9)	2.03 (1.37)	0.0	0.80	2.00	3.40	4.8	
		Week 36	Tezepelumab	32	32 (100.0)	1.66 (1.16)	0.0	0.90	1.60	2.50	4.8	
			Placebo	28	26 (92.9)	2.46 (1.24)	0.0	1.60	2.60	3.40	4.8	
		Week 38	Tezepelumab	32	32 (100.0)	1.60 (1.22)	0.0	0.60	1.50	2.40	4.8	
			Placebo	28	26 (92.9)	2.31 (1.23)	0.0	1.40	2.60	3.20	4.8	
		Week 40	Tezepelumab	32	32 (100.0)	1.60 (1.16)	0.0	0.80	1.70	2.30	4.8	
			Placebo	28	26 (92.9)	2.39 (1.17)	0.0	1.80	2.40	3.00	4.4	
		Week 42	Tezepelumab	32	32 (100.0)	1.58 (1.25)	0.0	0.90	1.40	2.10	4.8	
			Placebo	28	26 (92.9)	2.11 (1.03)	0.0	1.60	2.20	2.60	4.6	
		Week 44	Tezepelumab	32	32 (100.0)	1.45 (1.18)	0.0	0.60	1.00	2.20	4.8	
			Placebo	28	26 (92.9)	2.41 (1.10)	0.6	1.20	2.60	3.20	4.2	
		Week 46	Tezepelumab	32	32 (100.0)	1.45 (1.16)	0.0	0.80	1.00	2.20	4.8	
			Placebo	28	26 (92.9)	2.05 (0.95)	0.0	1.40	2.00	2.80	4.0	
		Week 48	Tezepelumab	32	32 (100.0)	1.51 (1.16)	0.0	0.80	1.20	2.20	4.8	
			Placebo	28	26 (92.9)	2.18 (1.02)	0.0	1.60	2.40	2.80	4.0	
		Week 50	Tezepelumab	32	32 (100.0)	1.50 (1.23)	0.0	0.80	1.10	2.30	4.8	
			Placebo	28	26 (92.9)	2.12 (1.01)	0.2	1.20	2.30	2.80	4.0	
		Week 52	Tezepelumab	32	32 (100.0)	1.61 (1.20)	0.0	0.80	1.60	2.30	4.8	
			Placebo	28	26 (92.9)	2.18 (1.15)	0.0	1.20	2.40	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	32	31 (96.9)	-0.66 (0.89)	-3.2	-1.20	-0.40	0.00	0.8	-0.22 [-0.75, 0.31]
			Placebo	28	25 (89.3)	-0.46 (0.88)	-2.8	-1.00	-0.60	0.00	1.2	
		Week 4	Tezepelumab	32	31 (96.9)	-1.15 (1.08)	-2.6	-2.00	-1.20	-0.60	2.6	-0.78 [-1.33, -0.23]
			Placebo	28	25 (89.3)	-0.36 (0.91)	-2.2	-1.20	-0.20	0.40	1.2	
		Week 6	Tezepelumab	32	31 (96.9)	-1.14 (1.30)	-3.6	-2.00	-1.40	-0.20	2.6	-0.55 [-1.09, -0.01]
			Placebo	28	25 (89.3)	-0.48 (1.05)	-1.8	-1.20	-0.60	0.20	1.6	
		Week 8	Tezepelumab	32	31 (96.9)	-1.11 (1.52)	-3.2	-2.40	-1.40	-0.40	2.6	-0.31 [-0.84, 0.22]
			Placebo	28	25 (89.3)	-0.70 (1.04)	-3.0	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	32	31 (96.9)	-1.30 (1.39)	-3.6	-2.40	-1.20	-0.40	2.6	-0.52 [-1.06, 0.01]
			Placebo	28	25 (89.3)	-0.58 (1.33)	-2.2	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	32	31 (96.9)	-1.47 (1.37)	-4.0	-2.60	-1.40	-0.60	2.6	-0.53 [-1.06, 0.01]
			Placebo	28	25 (89.3)	-0.78 (1.20)	-3.0	-1.60	-0.80	0.20	1.6	
		Week 14	Tezepelumab	32	31 (96.9)	-1.66 (1.40)	-4.2	-2.80	-1.60	-1.00	2.6	-0.53 [-1.07, 0.00]
			Placebo	28	25 (89.3)	-0.96 (1.18)	-3.0	-1.40	-1.40	-0.60	2.4	
		Week 16	Tezepelumab	32	31 (96.9)	-1.37 (1.50)	-4.4	-2.40	-1.40	-0.40	2.6	-0.43 [-0.96, 0.11]
			Placebo	28	25 (89.3)	-0.76 (1.37)	-3.0	-1.40	-1.00	-0.20	2.6	
		Week 18	Tezepelumab	32	31 (96.9)	-1.61 (1.44)	-4.4	-2.60	-1.80	-0.60	2.6	-0.54 [-1.07, -0.00]
			Placebo	28	25 (89.3)	-0.84 (1.44)	-3.2	-1.60	-1.00	-0.40	2.6	
		Week 20	Tezepelumab	32	31 (96.9)	-1.32 (1.46)	-4.4	-2.40	-1.40	-0.40	2.6	-0.33 [-0.86, 0.20]
			Placebo	28	25 (89.3)	-0.84 (1.43)	-3.6	-1.60	-0.80	-0.60	2.6	
		Week 22	Tezepelumab	32	31 (96.9)	-1.32 (1.49)	-4.4	-2.60	-1.40	0.20	2.6	-0.42 [-0.96, 0.11]
			Placebo	28	25 (89.3)	-0.70 (1.40)	-3.2	-1.60	-1.00	0.00	2.6	
		Week 24	Tezepelumab	32	31 (96.9)	-1.39 (1.40)	-4.8	-2.40	-1.40	-0.60	2.6	-0.46 [-0.99, 0.08]
			Placebo	28	25 (89.3)	-0.77 (1.29)	-3.0	-1.60	-1.00	0.00	2.6	
		Week 26	Tezepelumab	32	31 (96.9)	-1.37 (1.44)	-4.4	-2.60	-1.40	-0.40	2.6	-0.45 [-0.99, 0.08]
			Placebo	28	25 (89.3)	-0.73 (1.41)	-3.0	-1.60	-1.20	0.40	2.6	
		Week 28	Tezepelumab	32	32 (100.0)	-1.37 (1.47)	-4.4	-2.50	-1.40	-0.40	2.6	-0.38 [-0.90, 0.15]
			Placebo	28	25 (89.3)	-0.83 (1.36)	-3.0	-1.80	-0.80	0.00	2.6	
		Week 30	Tezepelumab	32	32 (100.0)	-1.51 (1.43)	-4.4	-2.60	-1.40	-0.80	2.6	-0.61 [-1.14, -0.08]
			Placebo	28	26 (92.9)	-0.69 (1.24)	-2.6	-1.40	-1.00	0.20	2.6	
		Week 32	Tezepelumab	32	32 (100.0)	-1.44 (1.35)	-4.4	-2.40	-1.60	-0.80	2.6	-0.43 [-0.96, 0.09]
			Placebo	28	26 (92.9)	-0.85 (1.34)	-2.8	-1.60	-1.40	-0.20	2.6	
		Week 34	Tezepelumab	32	32 (100.0)	-1.43 (1.40)	-4.4	-2.50	-1.40	-0.70	2.6	-0.38 [-0.90, 0.14]
			Placebo	28	26 (92.9)	-0.90 (1.40)	-3.2	-1.80	-1.30	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 2	Change from baseline	Week 36	Tezepelumab	32	32 (100.0)	-1.34 (1.47)	-4.4	-2.40	-1.40	-0.30	2.6	-0.61 [-1.14, -0.08]
			Placebo	28	26 (92.9)	-0.47 (1.38)	-3.2	-1.40	-0.70	0.40	2.6	
		Week 38	Tezepelumab	32	32 (100.0)	-1.40 (1.42)	-4.4	-2.40	-1.50	-0.50	2.6	-0.54 [-1.07, -0.02]
			Placebo	28	26 (92.9)	-0.62 (1.45)	-3.2	-1.60	-0.80	0.20	2.6	
		Week 40	Tezepelumab	32	32 (100.0)	-1.40 (1.43)	-4.4	-2.60	-1.40	-0.60	2.6	-0.62 [-1.15, -0.09]
			Placebo	28	26 (92.9)	-0.54 (1.35)	-2.8	-1.60	-0.60	0.20	2.6	
		Week 42	Tezepelumab	32	32 (100.0)	-1.42 (1.50)	-4.4	-2.40	-1.60	-0.70	2.6	-0.43 [-0.95, 0.09]
			Placebo	28	26 (92.9)	-0.82 (1.24)	-2.8	-1.40	-1.10	-0.20	2.6	
		Week 44	Tezepelumab	32	32 (100.0)	-1.55 (1.45)	-4.4	-2.70	-1.40	-0.80	2.6	-0.75 [-1.28, -0.21]
			Placebo	28	26 (92.9)	-0.52 (1.28)	-2.4	-1.40	-0.90	0.20	2.6	
		Week 46	Tezepelumab	32	32 (100.0)	-1.55 (1.38)	-4.4	-2.40	-1.50	-0.90	2.6	-0.51 [-1.04, 0.01]
			Placebo	28	26 (92.9)	-0.88 (1.21)	-3.2	-1.60	-1.10	0.00	2.6	
		Week 48	Tezepelumab	32	32 (100.0)	-1.49 (1.41)	-4.4	-2.50	-1.60	-0.80	2.6	-0.55 [-1.08, -0.03]
			Placebo	28	26 (92.9)	-0.75 (1.21)	-3.2	-1.60	-0.80	0.00	2.6	
		Week 50	Tezepelumab	32	32 (100.0)	-1.50 (1.43)	-4.4	-2.60	-1.60	-0.70	2.6	-0.51 [-1.04, 0.01]
			Placebo	28	26 (92.9)	-0.81 (1.24)	-2.8	-1.60	-0.80	-0.20	2.6	
		Week 52	Tezepelumab	32	32 (100.0)	-1.39 (1.44)	-4.4	-2.60	-1.40	-0.40	2.6	-0.46 [-0.98, 0.07]
			Placebo	28	26 (92.9)	-0.75 (1.36)	-2.8	-1.60	-0.70	0.00	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	2.85 (0.86)	0.0	2.40	2.80	3.20	5.2	
			Placebo	123	123 (100.0)	2.80 (0.69)	0.4	2.40	2.80	3.20	4.8	
		Week 2	Tezepelumab	128	122 (95.3)	2.29 (0.97)	0.0	1.60	2.40	3.00	4.4	
			Placebo	123	110 (89.4)	2.38 (0.81)	0.0	2.00	2.40	3.00	4.8	
		Week 4	Tezepelumab	128	122 (95.3)	1.96 (1.03)	0.0	1.20	2.20	2.80	4.2	
			Placebo	123	110 (89.4)	2.27 (0.87)	0.2	1.80	2.40	2.80	4.2	
		Week 6	Tezepelumab	128	122 (95.3)	1.89 (1.02)	0.0	1.20	1.80	2.60	4.2	
			Placebo	123	111 (90.2)	2.16 (0.96)	0.2	1.40	2.20	2.80	5.0	
		Week 8	Tezepelumab	128	122 (95.3)	1.82 (1.10)	0.0	1.00	1.80	2.80	5.2	
			Placebo	123	112 (91.1)	2.12 (0.96)	0.0	1.60	2.20	2.80	4.6	
		Week 10	Tezepelumab	128	122 (95.3)	1.76 (1.07)	0.0	1.00	1.80	2.60	4.8	
			Placebo	123	113 (91.9)	2.06 (0.94)	0.0	1.40	2.20	2.80	4.4	
		Week 12	Tezepelumab	128	122 (95.3)	1.67 (1.09)	0.0	0.80	1.60	2.60	4.8	
			Placebo	123	113 (91.9)	2.00 (1.00)	0.0	1.20	2.20	2.80	4.4	
		Week 14	Tezepelumab	128	122 (95.3)	1.54 (1.08)	0.0	0.60	1.40	2.40	4.8	
			Placebo	123	113 (91.9)	1.94 (0.91)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	128	122 (95.3)	1.70 (1.12)	0.0	0.80	1.70	2.60	4.8	
			Placebo	123	113 (91.9)	2.04 (1.02)	0.0	1.20	2.00	2.80	4.4	
		Week 18	Tezepelumab	128	123 (96.1)	1.58 (1.03)	0.0	0.80	1.60	2.40	4.8	
			Placebo	123	113 (91.9)	1.93 (1.01)	0.0	1.40	1.80	2.60	4.8	
		Week 20	Tezepelumab	128	123 (96.1)	1.68 (1.10)	0.0	0.80	1.80	2.60	5.0	
			Placebo	123	113 (91.9)	1.99 (1.01)	0.0	1.40	2.00	2.80	4.4	
		Week 22	Tezepelumab	128	123 (96.1)	1.70 (1.03)	0.0	1.00	1.80	2.40	4.8	
			Placebo	123	113 (91.9)	1.94 (1.02)	0.0	1.20	2.00	2.80	4.4	
		Week 24	Tezepelumab	128	123 (96.1)	1.69 (1.11)	0.0	0.80	1.80	2.60	4.8	
			Placebo	123	113 (91.9)	1.94 (1.02)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	128	124 (96.9)	1.66 (1.06)	0.0	1.00	1.60	2.40	4.8	
			Placebo	123	113 (91.9)	1.91 (0.99)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	128	125 (97.7)	1.72 (1.11)	0.0	1.00	1.80	2.60	4.8	
			Placebo	123	114 (92.7)	1.99 (1.06)	0.0	1.00	2.20	2.80	4.4	
		Week 30	Tezepelumab	128	126 (98.4)	1.65 (1.06)	0.0	0.80	1.60	2.40	4.8	
			Placebo	123	115 (93.5)	1.97 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	128	126 (98.4)	1.60 (1.09)	0.0	0.80	1.40	2.40	4.8	
			Placebo	123	115 (93.5)	1.92 (1.08)	0.0	1.00	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Absolute values	Week 34	Tezepelumab	128	126 (98.4)	1.62 (1.14)	0.0	0.80	1.50	2.40	4.8	
			Placebo	123	115 (93.5)	1.90 (1.05)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	128	126 (98.4)	1.68 (1.12)	0.0	0.80	1.60	2.40	5.0	
			Placebo	123	115 (93.5)	1.93 (1.09)	0.0	1.00	2.00	2.80	4.8	
		Week 38	Tezepelumab	128	126 (98.4)	1.60 (1.12)	0.0	0.80	1.50	2.40	4.8	
			Placebo	123	115 (93.5)	1.88 (1.05)	0.0	1.00	2.00	2.80	4.8	
		Week 40	Tezepelumab	128	126 (98.4)	1.63 (1.13)	0.0	0.60	1.80	2.40	4.8	
			Placebo	123	115 (93.5)	1.95 (1.09)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	128	126 (98.4)	1.58 (1.12)	0.0	0.80	1.60	2.40	4.8	
			Placebo	123	115 (93.5)	1.93 (1.06)	0.0	1.00	2.00	2.80	4.6	
		Week 44	Tezepelumab	128	126 (98.4)	1.61 (1.11)	0.0	0.80	1.60	2.60	4.8	
			Placebo	123	116 (94.3)	1.95 (1.05)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	128	126 (98.4)	1.59 (1.12)	0.0	0.80	1.60	2.40	4.8	
			Placebo	123	116 (94.3)	1.86 (1.02)	0.0	1.20	2.00	2.60	4.4	
		Week 48	Tezepelumab	128	126 (98.4)	1.63 (1.13)	0.0	0.80	1.60	2.40	4.8	
			Placebo	123	116 (94.3)	1.87 (1.07)	0.0	1.00	2.00	2.80	4.6	
		Week 50	Tezepelumab	128	126 (98.4)	1.55 (1.11)	0.0	0.80	1.40	2.20	4.8	
			Placebo	123	116 (94.3)	1.85 (1.01)	0.0	1.00	2.00	2.60	4.4	
		Week 52	Tezepelumab	128	126 (98.4)	1.59 (1.10)	0.0	0.80	1.60	2.20	4.8	
			Placebo	123	116 (94.3)	1.90 (1.03)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	128	122 (95.3)	-0.56 (0.72)	-3.0	-1.00	-0.40	0.00	0.8	-0.16 [-0.42, 0.09]
			Placebo	123	110 (89.4)	-0.44 (0.77)	-3.0	-0.80	-0.40	0.00	1.4	
		Week 4	Tezepelumab	128	122 (95.3)	-0.89 (0.97)	-3.8	-1.40	-0.80	-0.20	2.6	-0.36 [-0.62, -0.10]
			Placebo	123	110 (89.4)	-0.54 (0.90)	-3.0	-1.00	-0.40	0.00	1.6	
		Week 6	Tezepelumab	128	122 (95.3)	-0.96 (1.05)	-4.0	-1.60	-1.00	-0.20	2.6	-0.31 [-0.57, -0.05]
			Placebo	123	111 (90.2)	-0.65 (0.96)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	128	122 (95.3)	-1.02 (1.09)	-4.0	-1.60	-1.00	-0.40	2.6	-0.32 [-0.58, -0.06]
			Placebo	123	112 (91.1)	-0.70 (0.91)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	128	122 (95.3)	-1.09 (1.06)	-4.0	-1.80	-1.20	-0.40	2.6	-0.33 [-0.58, -0.07]
			Placebo	123	113 (91.9)	-0.76 (0.99)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	128	122 (95.3)	-1.17 (1.07)	-4.0	-1.80	-1.20	-0.40	2.6	-0.33 [-0.59, -0.08]
			Placebo	123	113 (91.9)	-0.82 (1.03)	-3.8	-1.40	-0.60	-0.20	1.6	
		Week 14	Tezepelumab	128	122 (95.3)	-1.31 (1.10)	-4.2	-2.00	-1.20	-0.60	2.6	-0.41 [-0.67, -0.15]
			Placebo	123	113 (91.9)	-0.88 (0.95)	-3.4	-1.40	-0.80	-0.40	1.4	
		Week 16	Tezepelumab	128	122 (95.3)	-1.15 (1.13)	-4.4	-1.80	-1.00	-0.40	2.6	-0.34 [-0.60, -0.08]
			Placebo	123	113 (91.9)	-0.78 (1.02)	-3.6	-1.40	-0.80	0.00	2.6	
		Week 18	Tezepelumab	128	123 (96.1)	-1.26 (1.10)	-4.4	-1.80	-1.00	-0.60	2.6	-0.34 [-0.60, -0.08]
			Placebo	123	113 (91.9)	-0.90 (1.03)	-3.6	-1.40	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	128	123 (96.1)	-1.16 (1.10)	-4.4	-1.80	-1.00	-0.40	2.6	-0.31 [-0.56, -0.05]
			Placebo	123	113 (91.9)	-0.83 (1.04)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	128	123 (96.1)	-1.14 (1.13)	-4.4	-1.80	-1.00	-0.40	2.6	-0.24 [-0.49, 0.02]
			Placebo	123	113 (91.9)	-0.88 (1.05)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 24	Tezepelumab	128	123 (96.1)	-1.15 (1.08)	-4.8	-1.80	-1.00	-0.40	2.6	-0.25 [-0.51, 0.01]
			Placebo	123	113 (91.9)	-0.88 (1.07)	-3.6	-1.40	-0.80	-0.20	2.6	
		Week 26	Tezepelumab	128	124 (96.9)	-1.17 (1.12)	-4.4	-2.00	-1.00	-0.40	2.6	-0.24 [-0.50, 0.01]
			Placebo	123	113 (91.9)	-0.91 (1.04)	-3.4	-1.60	-1.00	0.00	2.6	
		Week 28	Tezepelumab	128	125 (97.7)	-1.11 (1.14)	-4.4	-1.80	-1.00	-0.20	2.6	-0.27 [-0.53, -0.02]
			Placebo	123	114 (92.7)	-0.81 (1.08)	-3.4	-1.60	-0.80	0.00	2.6	
		Week 30	Tezepelumab	128	126 (98.4)	-1.19 (1.16)	-4.4	-2.20	-1.00	-0.40	2.6	-0.31 [-0.57, -0.06]
			Placebo	123	115 (93.5)	-0.83 (1.14)	-3.4	-1.60	-0.80	-0.20	2.6	
		Week 32	Tezepelumab	128	126 (98.4)	-1.24 (1.15)	-4.4	-2.20	-1.00	-0.60	2.6	-0.31 [-0.57, -0.06]
			Placebo	123	115 (93.5)	-0.89 (1.11)	-3.4	-1.60	-0.80	-0.20	2.6	
		Week 34	Tezepelumab	128	126 (98.4)	-1.22 (1.17)	-4.4	-2.00	-1.20	-0.40	2.6	-0.28 [-0.53, -0.02]
			Placebo	123	115 (93.5)	-0.91 (1.09)	-3.4	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Change from baseline	Week 36	Tezepelumab	128	126 (98.4)	-1.16 (1.20)	-4.4	-2.00	-1.20	-0.40	2.6	-0.24 [-0.49, 0.01]
			Placebo	123	115 (93.5)	-0.87 (1.15)	-3.6	-1.40	-1.00	0.00	2.6	
		Week 38	Tezepelumab	128	126 (98.4)	-1.24 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.27 [-0.53, -0.02]
			Placebo	123	115 (93.5)	-0.92 (1.12)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 40	Tezepelumab	128	126 (98.4)	-1.21 (1.22)	-4.4	-2.20	-1.00	-0.40	2.6	-0.31 [-0.57, -0.06]
			Placebo	123	115 (93.5)	-0.85 (1.10)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 42	Tezepelumab	128	126 (98.4)	-1.26 (1.22)	-4.4	-2.00	-1.20	-0.40	2.6	-0.33 [-0.59, -0.08]
			Placebo	123	115 (93.5)	-0.87 (1.11)	-3.6	-1.40	-0.80	-0.20	2.6	
		Week 44	Tezepelumab	128	126 (98.4)	-1.22 (1.23)	-4.4	-2.00	-1.20	-0.40	2.6	-0.32 [-0.57, -0.07]
			Placebo	123	116 (94.3)	-0.85 (1.10)	-3.4	-1.50	-0.80	0.00	2.6	
		Week 46	Tezepelumab	128	126 (98.4)	-1.25 (1.21)	-4.4	-2.00	-1.20	-0.40	2.6	-0.27 [-0.52, -0.01]
			Placebo	123	116 (94.3)	-0.94 (1.09)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	128	126 (98.4)	-1.20 (1.21)	-4.4	-2.00	-1.00	-0.40	2.6	-0.24 [-0.49, 0.02]
			Placebo	123	116 (94.3)	-0.93 (1.12)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	128	126 (98.4)	-1.29 (1.20)	-4.4	-2.20	-1.20	-0.60	2.6	-0.30 [-0.55, -0.05]
			Placebo	123	116 (94.3)	-0.95 (1.04)	-3.6	-1.60	-1.00	-0.30	2.6	
		Week 52	Tezepelumab	128	126 (98.4)	-1.25 (1.20)	-4.4	-2.00	-1.20	-0.40	2.6	-0.31 [-0.56, -0.05]
			Placebo	123	116 (94.3)	-0.90 (1.05)	-3.6	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.93 (0.46)	2.4	2.40	3.20	3.20	3.2	
			Placebo	6	6 (100.0)	2.70 (0.83)	2.0	2.00	2.40	3.40	4.0	
		Week 2	Tezepelumab	3	3 (100.0)	1.53 (1.33)	0.0	0.00	2.20	2.40	2.4	
			Placebo	6	6 (100.0)	2.63 (0.85)	1.4	2.00	2.70	3.20	3.8	
		Week 4	Tezepelumab	3	3 (100.0)	1.60 (0.72)	0.8	0.80	1.80	2.20	2.2	
			Placebo	6	6 (100.0)	2.67 (1.16)	0.8	2.40	2.70	3.00	4.4	
		Week 6	Tezepelumab	3	3 (100.0)	1.33 (0.83)	0.4	0.40	1.60	2.00	2.0	
			Placebo	6	6 (100.0)	2.60 (1.25)	1.0	2.00	2.50	2.80	4.8	
		Week 8	Tezepelumab	3	3 (100.0)	1.13 (0.90)	0.2	0.20	1.20	2.00	2.0	
			Placebo	6	6 (100.0)	2.80 (1.10)	1.0	2.60	2.80	3.20	4.4	
		Week 10	Tezepelumab	3	3 (100.0)	0.93 (0.95)	0.2	0.20	0.60	2.00	2.0	
			Placebo	6	6 (100.0)	2.70 (1.42)	1.0	1.80	2.60	3.00	5.2	
		Week 12	Tezepelumab	3	3 (100.0)	1.13 (0.61)	0.6	0.60	1.00	1.80	1.8	
			Placebo	6	6 (100.0)	2.50 (1.09)	1.0	1.60	2.50	3.60	3.8	
		Week 14	Tezepelumab	3	3 (100.0)	0.73 (0.31)	0.4	0.40	0.80	1.00	1.0	
			Placebo	6	6 (100.0)	2.63 (1.52)	1.0	1.00	2.70	3.40	5.0	
		Week 16	Tezepelumab	3	3 (100.0)	1.73 (1.45)	0.8	0.80	1.00	3.40	3.4	
			Placebo	6	6 (100.0)	3.03 (1.29)	1.0	2.60	3.10	3.40	5.0	
		Week 18	Tezepelumab	3	3 (100.0)	1.00 (0.60)	0.4	0.40	1.00	1.60	1.6	
			Placebo	6	6 (100.0)	2.87 (1.28)	1.0	2.60	2.80	3.00	5.0	
		Week 20	Tezepelumab	3	3 (100.0)	0.93 (0.31)	0.6	0.60	1.00	1.20	1.2	
			Placebo	6	6 (100.0)	2.67 (1.47)	0.4	2.40	2.60	3.00	5.0	
		Week 22	Tezepelumab	3	3 (100.0)	1.20 (0.35)	1.0	1.00	1.00	1.60	1.6	
			Placebo	6	6 (100.0)	2.53 (1.48)	0.4	2.00	2.60	2.60	5.0	
		Week 24	Tezepelumab	3	3 (100.0)	0.93 (0.12)	0.8	0.80	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	2.47 (1.16)	0.4	2.40	2.60	2.80	4.0	
		Week 26	Tezepelumab	3	3 (100.0)	0.80 (0.20)	0.6	0.60	0.80	1.00	1.0	
			Placebo	6	6 (100.0)	2.33 (1.22)	0.4	1.60	2.60	2.80	4.0	
		Week 28	Tezepelumab	3	3 (100.0)	0.80 (0.35)	0.4	0.40	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	2.43 (1.21)	0.4	2.20	2.40	3.20	4.0	
		Week 30	Tezepelumab	3	3 (100.0)	0.87 (0.23)	0.6	0.60	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	2.13 (1.18)	0.4	1.60	2.10	2.60	4.0	
		Week 32	Tezepelumab	3	3 (100.0)	1.33 (0.31)	1.0	1.00	1.40	1.60	1.6	
			Placebo	6	6 (100.0)	2.13 (1.22)	0.4	1.60	2.10	2.60	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Black or African American	Absolute values	Week 34	Tezepelumab	3	3 (100.0)	1.07 (0.31)	0.8	0.80	1.00	1.40	1.4	
			Placebo	6	6 (100.0)	1.90 (1.44)	0.0	0.60	2.10	2.60	4.0	
		Week 36	Tezepelumab	3	3 (100.0)	1.53 (0.92)	1.0	1.00	1.00	2.60	2.6	
			Placebo	6	6 (100.0)	2.20 (1.29)	0.0	2.00	2.30	2.60	4.0	
		Week 38	Tezepelumab	3	3 (100.0)	0.80 (0.20)	0.6	0.60	0.80	1.00	1.0	
			Placebo	6	6 (100.0)	2.17 (1.42)	0.0	1.40	2.20	3.20	4.0	
		Week 40	Tezepelumab	3	3 (100.0)	1.20 (0.35)	1.0	1.00	1.00	1.60	1.6	
			Placebo	6	6 (100.0)	2.30 (1.29)	0.0	2.20	2.50	2.60	4.0	
		Week 42	Tezepelumab	3	3 (100.0)	1.20 (0.53)	0.8	0.80	1.00	1.80	1.8	
			Placebo	6	6 (100.0)	1.80 (0.97)	0.0	1.60	2.00	2.60	2.6	
		Week 44	Tezepelumab	3	3 (100.0)	1.27 (0.46)	1.0	1.00	1.00	1.80	1.8	
			Placebo	6	6 (100.0)	1.87 (0.90)	0.8	1.00	2.00	2.60	2.8	
		Week 46	Tezepelumab	3	3 (100.0)	0.93 (0.12)	0.8	0.80	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	1.83 (0.92)	0.6	1.00	1.90	2.60	3.0	
		Week 48	Tezepelumab	3	3 (100.0)	1.07 (0.31)	0.8	0.80	1.00	1.40	1.4	
			Placebo	6	6 (100.0)	1.83 (1.07)	0.4	1.00	1.90	2.60	3.2	
		Week 50	Tezepelumab	3	3 (100.0)	0.60 (0.53)	0.0	0.00	0.80	1.00	1.0	
			Placebo	6	6 (100.0)	2.27 (0.96)	1.0	1.80	2.20	2.60	3.8	
		Week 52	Tezepelumab	3	3 (100.0)	0.60 (0.53)	0.0	0.00	0.80	1.00	1.0	
			Placebo	6	6 (100.0)	2.30 (1.29)	0.0	1.80	2.70	2.80	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-1.40 (1.59)	-3.2	-3.20	-0.80	-0.20	-0.2	-1.08 [-2.58, 0.42]
			Placebo	6	6 (100.0)	-0.07 (1.06)	-1.4	-1.20	0.10	0.80	1.2	
		Week 4	Tezepelumab	3	3 (100.0)	-1.33 (1.10)	-2.4	-2.40	-1.40	-0.20	-0.2	-1.19 [-2.71, 0.33]
			Placebo	6	6 (100.0)	-0.03 (1.08)	-1.4	-1.40	0.40	0.80	1.0	
		Week 6	Tezepelumab	3	3 (100.0)	-1.60 (1.20)	-2.8	-2.80	-1.60	-0.40	-0.4	-1.30 [-2.84, 0.25]
			Placebo	6	6 (100.0)	-0.10 (1.14)	-1.4	-1.20	-0.10	0.80	1.4	
		Week 8	Tezepelumab	3	3 (100.0)	-1.80 (1.31)	-3.0	-3.00	-2.00	-0.40	-0.4	-1.63 [-3.26, -0.00]
			Placebo	6	6 (100.0)	0.10 (1.10)	-1.4	-1.20	0.60	1.00	1.0	
		Week 10	Tezepelumab	3	3 (100.0)	-2.00 (1.40)	-3.0	-3.00	-2.60	-0.40	-0.4	-1.38 [-2.95, 0.18]
			Placebo	6	6 (100.0)	0.00 (1.46)	-1.4	-1.20	-0.30	0.60	2.6	
		Week 12	Tezepelumab	3	3 (100.0)	-1.80 (1.06)	-2.6	-2.60	-2.20	-0.60	-0.6	-1.58 [-3.19, 0.04]
			Placebo	6	6 (100.0)	-0.20 (1.00)	-1.4	-1.20	-0.10	0.40	1.2	
		Week 14	Tezepelumab	3	3 (100.0)	-2.20 (0.60)	-2.8	-2.80	-2.20	-1.60	-1.6	-1.66 [-3.30, -0.03]
			Placebo	6	6 (100.0)	-0.07 (1.47)	-1.4	-1.20	-0.50	0.80	2.4	
		Week 16	Tezepelumab	3	3 (100.0)	-1.20 (1.91)	-2.4	-2.40	-2.20	1.00	1.0	-0.94 [-2.41, 0.53]
			Placebo	6	6 (100.0)	0.33 (1.52)	-1.4	-1.20	0.40	1.40	2.4	
		Week 18	Tezepelumab	3	3 (100.0)	-1.93 (1.03)	-2.8	-2.80	-2.20	-0.80	-0.8	-1.56 [-3.17, 0.05]
			Placebo	6	6 (100.0)	0.17 (1.45)	-1.4	-1.20	0.10	1.00	2.4	
		Week 20	Tezepelumab	3	3 (100.0)	-2.00 (0.72)	-2.6	-2.60	-2.20	-1.20	-1.2	-1.46 [-3.04, 0.12]
			Placebo	6	6 (100.0)	-0.03 (1.53)	-1.8	-1.40	0.00	0.60	2.4	
		Week 22	Tezepelumab	3	3 (100.0)	-1.73 (0.81)	-2.2	-2.20	-2.20	-0.80	-0.8	-1.15 [-2.66, 0.36]
			Placebo	6	6 (100.0)	-0.17 (1.54)	-1.8	-1.40	-0.40	0.60	2.4	
		Week 24	Tezepelumab	3	3 (100.0)	-2.00 (0.53)	-2.4	-2.40	-2.20	-1.40	-1.4	-1.57 [-3.18, 0.04]
			Placebo	6	6 (100.0)	-0.23 (1.29)	-1.8	-1.40	-0.20	0.80	1.4	
		Week 26	Tezepelumab	3	3 (100.0)	-2.13 (0.50)	-2.6	-2.60	-2.20	-1.60	-1.6	-1.40 [-2.97, 0.17]
			Placebo	6	6 (100.0)	-0.37 (1.46)	-1.8	-1.80	-0.40	0.80	1.4	
		Week 28	Tezepelumab	3	3 (100.0)	-2.13 (0.70)	-2.8	-2.80	-2.20	-1.40	-1.4	-1.51 [-3.11, 0.08]
			Placebo	6	6 (100.0)	-0.27 (1.39)	-1.8	-1.40	-0.50	1.20	1.4	
		Week 30	Tezepelumab	3	3 (100.0)	-2.07 (0.61)	-2.6	-2.60	-2.20	-1.40	-1.4	-1.39 [-2.96, 0.17]
			Placebo	6	6 (100.0)	-0.57 (1.22)	-1.8	-1.40	-0.90	0.20	1.4	
		Week 32	Tezepelumab	3	3 (100.0)	-1.60 (0.60)	-2.2	-2.20	-1.60	-1.00	-1.0	-0.88 [-2.34, 0.58]
			Placebo	6	6 (100.0)	-0.57 (1.34)	-1.8	-1.80	-0.90	0.60	1.4	
		Week 34	Tezepelumab	3	3 (100.0)	-1.87 (0.76)	-2.4	-2.40	-2.20	-1.00	-1.0	-0.92 [-2.38, 0.55]
			Placebo	6	6 (100.0)	-0.80 (1.29)	-2.2	-1.40	-1.30	0.00	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Black or African American	Change from baseline	Week 36	Tezepelumab	3	3 (100.0)	-1.40 (1.39)	-2.2	-2.20	-2.20	0.20	0.2	-0.65 [-2.08, 0.77]
			Placebo	6	6 (100.0)	-0.50 (1.37)	-2.2	-1.40	-0.60	0.40	1.4	
		Week 38	Tezepelumab	3	3 (100.0)	-2.13 (0.50)	-2.6	-2.60	-2.20	-1.60	-1.6	-1.23 [-2.75, 0.30]
			Placebo	6	6 (100.0)	-0.53 (1.51)	-2.2	-1.60	-1.00	1.20	1.4	
		Week 40	Tezepelumab	3	3 (100.0)	-1.73 (0.42)	-2.2	-2.20	-1.60	-1.40	-1.4	-1.14 [-2.65, 0.37]
			Placebo	6	6 (100.0)	-0.40 (1.36)	-2.2	-1.40	-0.40	0.60	1.4	
		Week 42	Tezepelumab	3	3 (100.0)	-1.73 (0.42)	-2.2	-2.20	-1.60	-1.40	-1.4	-0.88 [-2.34, 0.58]
			Placebo	6	6 (100.0)	-0.90 (1.09)	-2.2	-1.60	-1.20	0.20	0.6	
		Week 44	Tezepelumab	3	3 (100.0)	-1.67 (0.46)	-2.2	-2.20	-1.40	-1.40	-1.4	-0.79 [-2.24, 0.65]
			Placebo	6	6 (100.0)	-0.83 (1.21)	-2.0	-1.60	-1.40	0.60	0.8	
		Week 46	Tezepelumab	3	3 (100.0)	-2.00 (0.35)	-2.2	-2.20	-2.20	-1.60	-1.6	-1.19 [-2.71, 0.33]
			Placebo	6	6 (100.0)	-0.87 (1.11)	-1.6	-1.60	-1.50	0.00	1.0	
		Week 48	Tezepelumab	3	3 (100.0)	-1.87 (0.31)	-2.2	-2.20	-1.80	-1.60	-1.6	-0.88 [-2.34, 0.58]
			Placebo	6	6 (100.0)	-0.87 (1.33)	-2.0	-1.80	-1.50	0.40	1.2	
		Week 50	Tezepelumab	3	3 (100.0)	-2.33 (0.81)	-3.2	-3.20	-2.20	-1.60	-1.6	-1.57 [-3.18, 0.04]
			Placebo	6	6 (100.0)	-0.43 (1.34)	-1.6	-1.60	-0.80	0.60	1.6	
		Week 52	Tezepelumab	3	3 (100.0)	-2.33 (0.81)	-3.2	-3.20	-2.20	-1.60	-1.6	-1.30 [-2.84, 0.24]
			Placebo	6	6 (100.0)	-0.40 (1.68)	-2.6	-1.60	-0.30	0.80	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.64 (0.55)	2.0	2.40	2.40	3.00	3.4	
			Placebo	6	6 (100.0)	2.73 (0.87)	1.8	2.00	2.60	3.20	4.2	
		Week 2	Tezepelumab	5	5 (100.0)	2.16 (0.86)	1.0	1.60	2.40	2.60	3.2	
			Placebo	6	6 (100.0)	2.50 (0.92)	1.6	1.80	2.40	2.60	4.2	
		Week 4	Tezepelumab	5	5 (100.0)	1.80 (0.75)	0.8	1.20	2.20	2.40	2.4	
			Placebo	6	6 (100.0)	2.00 (0.47)	1.4	1.60	2.00	2.40	2.6	
		Week 6	Tezepelumab	5	5 (100.0)	1.48 (0.44)	1.0	1.00	1.80	1.80	1.8	
			Placebo	6	6 (100.0)	1.87 (0.63)	1.0	1.40	1.90	2.40	2.6	
		Week 8	Tezepelumab	5	5 (100.0)	1.28 (0.52)	0.6	1.00	1.20	1.80	1.8	
			Placebo	6	6 (100.0)	2.03 (0.46)	1.4	1.60	2.10	2.40	2.6	
		Week 10	Tezepelumab	5	5 (100.0)	1.20 (0.37)	0.8	0.80	1.40	1.40	1.6	
			Placebo	6	6 (100.0)	1.73 (0.45)	1.0	1.60	1.80	1.80	2.4	
		Week 12	Tezepelumab	5	5 (100.0)	0.84 (0.71)	0.0	0.20	1.00	1.40	1.6	
			Placebo	6	6 (100.0)	1.70 (0.37)	1.2	1.40	1.70	2.00	2.2	
		Week 14	Tezepelumab	5	5 (100.0)	0.96 (0.30)	0.6	0.80	1.00	1.00	1.4	
			Placebo	6	6 (100.0)	1.43 (0.43)	1.0	1.00	1.40	1.80	2.0	
		Week 16	Tezepelumab	5	5 (100.0)	0.92 (0.41)	0.2	1.00	1.00	1.20	1.2	
			Placebo	6	6 (100.0)	1.40 (0.68)	0.6	0.60	1.50	2.00	2.2	
		Week 18	Tezepelumab	5	5 (100.0)	1.00 (0.49)	0.6	0.60	1.00	1.00	1.8	
			Placebo	6	6 (100.0)	1.77 (0.54)	1.0	1.20	2.00	2.20	2.2	
		Week 20	Tezepelumab	5	5 (100.0)	1.16 (0.75)	0.4	0.80	1.00	1.20	2.4	
			Placebo	6	6 (100.0)	1.80 (1.00)	0.6	1.00	1.70	2.40	3.4	
		Week 22	Tezepelumab	5	5 (100.0)	1.04 (0.86)	0.0	0.80	1.00	1.00	2.4	
			Placebo	6	6 (100.0)	1.60 (0.87)	0.4	1.20	1.40	2.60	2.6	
		Week 24	Tezepelumab	5	5 (100.0)	1.04 (0.52)	0.4	0.80	1.00	1.20	1.8	
			Placebo	6	6 (100.0)	1.73 (0.98)	0.4	0.80	1.90	2.60	2.8	
		Week 26	Tezepelumab	5	5 (100.0)	0.80 (0.35)	0.2	0.80	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	1.43 (0.88)	0.0	1.00	1.60	1.80	2.6	
		Week 28	Tezepelumab	5	5 (100.0)	0.88 (0.39)	0.2	1.00	1.00	1.00	1.2	
			Placebo	6	6 (100.0)	1.07 (1.06)	0.0	0.00	1.00	2.00	2.4	
		Week 30	Tezepelumab	5	5 (100.0)	0.88 (0.23)	0.6	0.80	0.80	1.00	1.2	
			Placebo	6	6 (100.0)	1.07 (0.94)	0.0	0.00	1.10	2.00	2.2	
		Week 32	Tezepelumab	5	5 (100.0)	0.68 (0.36)	0.2	0.40	0.80	1.00	1.0	
			Placebo	6	6 (100.0)	1.17 (0.73)	0.2	0.60	1.20	1.80	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asian	Absolute values	Week 34	Tezepelumab	5	5 (100.0)	0.72 (0.33)	0.4	0.40	0.80	0.80	1.2	
			Placebo	6	6 (100.0)	1.10 (1.03)	0.0	0.00	1.20	1.60	2.6	
		Week 36	Tezepelumab	5	5 (100.0)	1.08 (0.91)	0.2	0.60	1.00	1.00	2.6	
			Placebo	6	6 (100.0)	1.73 (1.27)	0.0	0.60	1.90	2.60	3.4	
		Week 38	Tezepelumab	5	5 (100.0)	1.08 (0.89)	0.0	0.60	0.80	2.00	2.0	
			Placebo	6	6 (100.0)	1.00 (0.91)	0.0	0.00	1.10	1.80	2.0	
		Week 40	Tezepelumab	5	5 (100.0)	0.88 (0.54)	0.4	0.60	0.80	0.80	1.8	
			Placebo	6	6 (100.0)	1.33 (1.09)	0.0	0.00	1.70	2.00	2.6	
		Week 42	Tezepelumab	5	5 (100.0)	0.80 (0.28)	0.4	0.60	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	1.20 (0.95)	0.0	0.00	1.60	2.00	2.0	
		Week 44	Tezepelumab	5	5 (100.0)	0.68 (0.33)	0.2	0.60	0.60	1.00	1.0	
			Placebo	6	6 (100.0)	1.97 (1.56)	0.0	0.20	2.40	3.00	3.8	
		Week 46	Tezepelumab	5	5 (100.0)	0.80 (0.35)	0.2	0.80	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	1.03 (1.02)	0.0	0.00	1.00	2.00	2.2	
		Week 48	Tezepelumab	5	5 (100.0)	1.16 (0.84)	0.4	0.80	1.00	1.00	2.6	
			Placebo	6	6 (100.0)	1.50 (1.07)	0.0	0.40	1.80	2.40	2.6	
		Week 50	Tezepelumab	5	5 (100.0)	1.20 (0.76)	0.4	0.80	1.00	1.40	2.4	
			Placebo	6	6 (100.0)	1.30 (0.72)	0.0	1.00	1.50	1.80	2.0	
		Week 52	Tezepelumab	5	5 (100.0)	1.00 (0.82)	0.4	0.40	0.80	1.00	2.4	
			Placebo	6	6 (100.0)	1.37 (0.71)	0.0	1.40	1.50	1.80	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	-0.48 (0.67)	-1.4	-0.80	-0.40	-0.20	0.4	-0.49 [-1.70, 0.71]
			Placebo	6	6 (100.0)	-0.23 (0.29)	-0.8	-0.20	-0.20	0.00	0.0	
		Week 4	Tezepelumab	5	5 (100.0)	-0.84 (0.75)	-1.6	-1.20	-1.00	-0.80	0.4	-0.13 [-1.32, 1.06]
			Placebo	6	6 (100.0)	-0.73 (0.84)	-1.8	-1.80	-0.30	-0.20	0.0	
		Week 6	Tezepelumab	5	5 (100.0)	-1.16 (0.55)	-1.6	-1.40	-1.40	-1.20	-0.2	-0.47 [-1.68, 0.73]
			Placebo	6	6 (100.0)	-0.87 (0.67)	-1.8	-1.60	-0.60	-0.40	-0.2	
		Week 8	Tezepelumab	5	5 (100.0)	-1.36 (0.67)	-1.8	-1.80	-1.60	-1.40	-0.2	-0.76 [-2.00, 0.48]
			Placebo	6	6 (100.0)	-0.70 (1.00)	-2.6	-0.80	-0.50	0.00	0.2	
		Week 10	Tezepelumab	5	5 (100.0)	-1.44 (0.61)	-2.0	-1.60	-1.60	-1.60	-0.4	-0.60 [-1.82, 0.62]
			Placebo	6	6 (100.0)	-1.00 (0.82)	-2.6	-0.80	-0.80	-0.80	-0.2	
		Week 12	Tezepelumab	5	5 (100.0)	-1.80 (0.71)	-2.4	-2.20	-2.00	-1.80	-0.6	-0.87 [-2.12, 0.38]
			Placebo	6	6 (100.0)	-1.03 (1.00)	-3.0	-1.00	-0.70	-0.60	-0.2	
		Week 14	Tezepelumab	5	5 (100.0)	-1.68 (0.41)	-2.0	-2.00	-1.80	-1.60	-1.0	-0.46 [-1.67, 0.74]
			Placebo	6	6 (100.0)	-1.30 (1.04)	-3.2	-1.40	-1.20	-0.60	-0.2	
		Week 16	Tezepelumab	5	5 (100.0)	-1.72 (0.52)	-2.2	-2.20	-1.80	-1.40	-1.0	-0.38 [-1.58, 0.82]
			Placebo	6	6 (100.0)	-1.33 (1.29)	-3.6	-2.00	-0.90	-0.40	-0.2	
		Week 18	Tezepelumab	5	5 (100.0)	-1.64 (0.84)	-2.4	-2.00	-1.80	-1.80	-0.2	-0.69 [-1.92, 0.54]
			Placebo	6	6 (100.0)	-0.97 (1.07)	-3.0	-1.00	-0.70	-0.40	0.0	
		Week 20	Tezepelumab	5	5 (100.0)	-1.48 (1.07)	-2.2	-2.00	-2.00	-1.60	0.4	-0.41 [-1.61, 0.79]
			Placebo	6	6 (100.0)	-0.93 (1.51)	-3.6	-1.40	-0.60	-0.20	0.8	
		Week 22	Tezepelumab	5	5 (100.0)	-1.60 (1.17)	-2.4	-2.40	-2.00	-1.60	0.4	-0.41 [-1.61, 0.79]
			Placebo	6	6 (100.0)	-1.13 (1.11)	-3.0	-1.60	-1.00	-0.20	0.0	
		Week 24	Tezepelumab	5	5 (100.0)	-1.60 (0.84)	-2.4	-2.00	-1.80	-1.60	-0.2	-0.49 [-1.69, 0.72]
			Placebo	6	6 (100.0)	-1.00 (1.48)	-3.8	-1.20	-0.60	0.00	0.2	
		Week 26	Tezepelumab	5	5 (100.0)	-1.84 (0.52)	-2.4	-2.20	-2.00	-1.40	-1.2	-0.46 [-1.67, 0.74]
			Placebo	6	6 (100.0)	-1.30 (1.50)	-4.2	-1.40	-0.90	-0.40	0.0	
		Week 28	Tezepelumab	5	5 (100.0)	-1.76 (0.57)	-2.4	-2.20	-1.80	-1.40	-1.0	-0.08 [-1.27, 1.11]
			Placebo	6	6 (100.0)	-1.67 (1.47)	-4.2	-2.20	-1.40	-0.60	-0.2	
		Week 30	Tezepelumab	5	5 (100.0)	-1.76 (0.65)	-2.6	-2.00	-1.80	-1.60	-0.8	-0.09 [-1.28, 1.10]
			Placebo	6	6 (100.0)	-1.67 (1.26)	-3.2	-2.60	-1.70	-1.20	0.4	
		Week 32	Tezepelumab	5	5 (100.0)	-1.96 (0.65)	-2.6	-2.40	-2.20	-1.60	-1.0	-0.39 [-1.59, 0.81]
			Placebo	6	6 (100.0)	-1.57 (1.24)	-3.6	-1.80	-1.70	-0.60	0.0	
		Week 34	Tezepelumab	5	5 (100.0)	-1.92 (0.76)	-2.6	-2.60	-2.00	-1.60	-0.8	-0.24 [-1.43, 0.95]
			Placebo	6	6 (100.0)	-1.63 (1.43)	-4.2	-2.00	-1.40	-0.60	-0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asian	Change from baseline	Week 36	Tezepelumab	5	5 (100.0)	-1.56 (1.28)	-2.4	-2.40	-2.20	-1.40	0.6	-0.39 [-1.59, 0.81]
			Placebo	6	6 (100.0)	-1.00 (1.56)	-3.6	-2.00	-0.50	-0.20	0.8	
		Week 38	Tezepelumab	5	5 (100.0)	-1.56 (0.95)	-2.4	-2.20	-1.80	-1.40	0.0	0.14 [-1.05, 1.33]
			Placebo	6	6 (100.0)	-1.73 (1.42)	-4.2	-2.00	-1.60	-1.00	0.0	
		Week 40	Tezepelumab	5	5 (100.0)	-1.76 (0.95)	-2.6	-2.40	-2.00	-1.60	-0.2	-0.27 [-1.46, 0.92]
			Placebo	6	6 (100.0)	-1.40 (1.57)	-4.2	-2.00	-1.10	0.00	0.0	
		Week 42	Tezepelumab	5	5 (100.0)	-1.84 (0.62)	-2.4	-2.40	-2.00	-1.40	-1.0	-0.26 [-1.45, 0.93]
			Placebo	6	6 (100.0)	-1.53 (1.49)	-4.2	-2.00	-1.20	-0.80	0.2	
		Week 44	Tezepelumab	5	5 (100.0)	-1.96 (0.74)	-2.8	-2.40	-2.20	-1.40	-1.0	-0.77 [-2.01, 0.46]
			Placebo	6	6 (100.0)	-0.77 (1.96)	-4.2	-1.80	-0.10	0.40	1.2	
		Week 46	Tezepelumab	5	5 (100.0)	-1.84 (0.61)	-2.4	-2.20	-2.20	-1.40	-1.0	-0.12 [-1.31, 1.07]
			Placebo	6	6 (100.0)	-1.70 (1.50)	-4.2	-2.20	-1.50	-1.00	0.2	
		Week 48	Tezepelumab	5	5 (100.0)	-1.48 (1.20)	-2.4	-2.00	-2.00	-1.60	0.6	-0.18 [-1.37, 1.01]
			Placebo	6	6 (100.0)	-1.23 (1.44)	-3.8	-2.00	-0.70	-0.20	0.0	
		Week 50	Tezepelumab	5	5 (100.0)	-1.44 (1.13)	-2.6	-2.00	-1.60	-1.40	0.4	-0.01 [-1.19, 1.18]
			Placebo	6	6 (100.0)	-1.43 (1.42)	-4.2	-1.40	-1.10	-0.60	-0.2	
		Week 52	Tezepelumab	5	5 (100.0)	-1.64 (1.24)	-2.6	-2.60	-2.00	-1.40	0.4	-0.20 [-1.39, 0.99]
			Placebo	6	6 (100.0)	-1.37 (1.46)	-4.2	-1.40	-0.90	-0.60	-0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.60	2.6	2.60	2.60	2.60	2.6	
			Placebo	3	3 (100.0)	3.87 (1.03)	3.0	3.00	3.60	5.00	5.0	
		Week 2	Tezepelumab	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
			Placebo	3	3 (100.0)	3.33 (1.53)	2.0	2.00	3.00	5.00	5.0	
		Week 4	Tezepelumab	1	1 (100.0)	3.40	3.4	3.40	3.40	3.40	3.4	
			Placebo	3	3 (100.0)	3.20 (0.69)	2.4	2.40	3.60	3.60	3.6	
		Week 6	Tezepelumab	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	
			Placebo	3	3 (100.0)	3.33 (2.44)	1.2	1.20	2.80	6.00	6.0	
		Week 8	Tezepelumab	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
			Placebo	3	3 (100.0)	1.93 (2.66)	0.2	0.20	0.60	5.00	5.0	
		Week 10	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	3	3 (100.0)	1.73 (1.14)	0.8	0.80	1.40	3.00	3.0	
		Week 12	Tezepelumab	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	
			Placebo	3	3 (100.0)	1.40 (1.51)	0.0	0.00	1.20	3.00	3.0	
		Week 14	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	3	3 (100.0)	1.53 (1.50)	0.0	0.00	1.60	3.00	3.0	
		Week 16	Tezepelumab	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
			Placebo	3	3 (100.0)	2.20 (2.55)	0.0	0.00	1.60	5.00	5.0	
		Week 18	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	3	3 (100.0)	1.47 (1.50)	0.0	0.00	1.40	3.00	3.0	
		Week 20	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	3	3 (100.0)	1.73 (1.55)	0.0	0.00	2.20	3.00	3.0	
		Week 22	Tezepelumab	1	1 (100.0)	2.60	2.6	2.60	2.60	2.60	2.6	
			Placebo	3	3 (100.0)	2.33 (1.36)	0.8	0.80	2.80	3.40	3.4	
		Week 24	Tezepelumab	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
			Placebo	3	3 (100.0)	1.80 (1.40)	0.8	0.80	1.20	3.40	3.4	
		Week 26	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	3	3 (100.0)	1.47 (1.75)	0.0	0.00	1.00	3.40	3.4	
		Week 28	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	3	3 (100.0)	1.40 (1.78)	0.0	0.00	0.80	3.40	3.4	
		Week 30	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	3	3 (100.0)	2.07 (1.17)	1.2	1.20	1.60	3.40	3.4	
		Week 32	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	3	3 (100.0)	1.93 (1.33)	0.8	0.80	1.60	3.40	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Other	Absolute values	Week 34	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	3	3 (100.0)	1.67 (1.62)	0.2	0.20	1.40	3.40	3.4	
		Week 36	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	3	3 (100.0)	2.27 (0.99)	1.6	1.60	1.80	3.40	3.4	
		Week 38	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	3	3 (100.0)	2.20 (1.06)	1.4	1.40	1.80	3.40	3.4	
		Week 40	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	3	3 (100.0)	1.93 (1.33)	0.8	0.80	1.60	3.40	3.4	
		Week 42	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	3	3 (100.0)	2.47 (0.81)	2.0	2.00	2.00	3.40	3.4	
		Week 44	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	3	3 (100.0)	2.20 (1.44)	0.6	0.60	2.60	3.40	3.4	
		Week 46	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	3	3 (100.0)	2.40 (0.87)	1.8	1.80	2.00	3.40	3.4	
		Week 48	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	3	3 (100.0)	2.53 (0.90)	1.6	1.60	2.60	3.40	3.4	
		Week 50	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	3	3 (100.0)	1.87 (1.60)	0.2	0.20	2.00	3.40	3.4	
		Week 52	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	3	3 (100.0)	1.87 (1.60)	0.2	0.20	2.00	3.40	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.20	0.2	0.20	0.20	0.20	0.2	NE
			Placebo	3	3 (100.0)	-0.53 (0.50)	-1.0	-1.00	-0.60	0.00	0.0	
		Week 4	Tezepelumab	1	1 (100.0)	0.80	0.8	0.80	0.80	0.80	0.8	NE
			Placebo	3	3 (100.0)	-0.67 (1.10)	-1.4	-1.40	-1.20	0.60	0.6	
		Week 6	Tezepelumab	1	1 (100.0)	0.40	0.4	0.40	0.40	0.40	0.4	NE
			Placebo	3	3 (100.0)	-0.53 (1.42)	-1.8	-1.80	-0.80	1.00	1.0	
		Week 8	Tezepelumab	1	1 (100.0)	0.20	0.2	0.20	0.20	0.20	0.2	NE
			Placebo	3	3 (100.0)	-1.93 (1.68)	-3.0	-3.00	-2.80	0.00	0.0	
		Week 10	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	3	3 (100.0)	-2.13 (0.12)	-2.2	-2.20	-2.20	-2.00	-2.0	
		Week 12	Tezepelumab	1	1 (100.0)	0.40	0.4	0.40	0.40	0.40	0.4	NE
			Placebo	3	3 (100.0)	-2.47 (0.50)	-3.0	-3.00	-2.40	-2.00	-2.0	
		Week 14	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	3	3 (100.0)	-2.33 (0.58)	-3.0	-3.00	-2.00	-2.00	-2.0	
		Week 16	Tezepelumab	1	1 (100.0)	-1.20	-1.2	-1.20	-1.20	-1.20	-1.2	NE
			Placebo	3	3 (100.0)	-1.67 (1.53)	-3.0	-3.00	-2.00	0.00	0.0	
		Week 18	Tezepelumab	1	1 (100.0)	-0.60	-0.6	-0.60	-0.60	-0.60	-0.6	NE
			Placebo	3	3 (100.0)	-2.40 (0.53)	-3.0	-3.00	-2.20	-2.00	-2.0	
		Week 20	Tezepelumab	1	1 (100.0)	-0.60	-0.6	-0.60	-0.60	-0.60	-0.6	NE
			Placebo	3	3 (100.0)	-2.13 (1.40)	-3.6	-3.60	-2.00	-0.80	-0.8	
		Week 22	Tezepelumab	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	NE
			Placebo	3	3 (100.0)	-1.53 (1.30)	-2.8	-2.80	-1.60	-0.20	-0.2	
		Week 24	Tezepelumab	1	1 (100.0)	0.20	0.2	0.20	0.20	0.20	0.2	NE
			Placebo	3	3 (100.0)	-2.07 (0.42)	-2.4	-2.40	-2.20	-1.60	-1.6	
		Week 26	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	3	3 (100.0)	-2.40 (0.72)	-3.0	-3.00	-2.60	-1.60	-1.6	
		Week 28	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	3	3 (100.0)	-2.47 (0.76)	-3.0	-3.00	-2.80	-1.60	-1.6	
		Week 30	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	3	3 (100.0)	-1.80 (0.53)	-2.4	-2.40	-1.60	-1.40	-1.4	
		Week 32	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	3	3 (100.0)	-1.93 (0.76)	-2.8	-2.80	-1.60	-1.40	-1.4	
		Week 34	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	3	3 (100.0)	-2.20 (0.60)	-2.8	-2.80	-2.20	-1.60	-1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Other	Change from baseline	Week 36	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	3	3 (100.0)	-1.60 (0.20)	-1.8	-1.80	-1.60	-1.40	-1.4	
		Week 38	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	3	3 (100.0)	-1.67 (0.50)	-2.2	-2.20	-1.60	-1.20	-1.2	
		Week 40	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	3	3 (100.0)	-1.93 (0.31)	-2.2	-2.20	-2.00	-1.60	-1.6	
		Week 42	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	3	3 (100.0)	-1.40 (0.35)	-1.6	-1.60	-1.60	-1.00	-1.0	
		Week 44	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	3	3 (100.0)	-1.67 (0.70)	-2.4	-2.40	-1.60	-1.00	-1.0	
		Week 46	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	3	3 (100.0)	-1.47 (0.23)	-1.6	-1.60	-1.60	-1.20	-1.2	
		Week 48	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	3	3 (100.0)	-1.33 (0.83)	-2.0	-2.00	-1.60	-0.40	-0.4	
		Week 50	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	3	3 (100.0)	-2.00 (0.69)	-2.8	-2.80	-1.60	-1.60	-1.6	
		Week 52	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	3	3 (100.0)	-2.00 (0.69)	-2.8	-2.80	-1.60	-1.60	-1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	78	78 (100.0)	2.87 (0.87)	0.0	2.40	2.80	3.20	5.0	
			Placebo	80	80 (100.0)	2.65 (0.64)	0.4	2.40	2.80	3.00	3.6	
		Week 2	Tezepelumab	78	76 (97.4)	2.37 (0.97)	0.0	1.70	2.60	3.00	4.4	
			Placebo	80	70 (87.5)	2.25 (0.75)	0.0	1.80	2.40	2.80	3.4	
		Week 4	Tezepelumab	78	76 (97.4)	2.04 (1.03)	0.0	1.10	2.20	2.80	4.2	
			Placebo	80	70 (87.5)	2.17 (0.90)	0.2	1.40	2.40	2.80	4.2	
		Week 6	Tezepelumab	78	76 (97.4)	1.93 (1.03)	0.0	1.30	1.80	2.70	4.2	
			Placebo	80	71 (88.8)	2.04 (0.97)	0.2	1.20	2.00	2.80	5.0	
		Week 8	Tezepelumab	78	76 (97.4)	1.93 (1.14)	0.0	1.00	1.90	2.80	5.2	
			Placebo	80	71 (88.8)	1.97 (0.92)	0.0	1.40	2.00	2.80	4.0	
		Week 10	Tezepelumab	78	76 (97.4)	1.86 (1.09)	0.0	1.00	1.90	2.70	4.8	
			Placebo	80	72 (90.0)	2.01 (0.92)	0.0	1.30	2.10	2.80	4.0	
		Week 12	Tezepelumab	78	76 (97.4)	1.80 (1.14)	0.0	1.00	1.80	2.70	4.8	
			Placebo	80	72 (90.0)	1.87 (1.02)	0.0	1.10	2.00	2.60	4.4	
		Week 14	Tezepelumab	78	76 (97.4)	1.64 (1.17)	0.0	0.60	1.60	2.60	4.8	
			Placebo	80	72 (90.0)	1.83 (0.85)	0.0	1.10	1.80	2.60	3.2	
		Week 16	Tezepelumab	78	76 (97.4)	1.79 (1.14)	0.0	0.90	1.80	2.80	4.8	
			Placebo	80	72 (90.0)	1.96 (1.02)	0.0	1.10	2.00	2.80	4.0	
		Week 18	Tezepelumab	78	77 (98.7)	1.69 (1.09)	0.0	1.00	1.80	2.40	4.8	
			Placebo	80	72 (90.0)	1.80 (0.95)	0.0	1.10	1.80	2.50	4.8	
		Week 20	Tezepelumab	78	77 (98.7)	1.76 (1.17)	0.0	0.80	1.80	2.60	5.0	
			Placebo	80	72 (90.0)	1.79 (0.91)	0.0	1.20	1.80	2.60	3.6	
		Week 22	Tezepelumab	78	77 (98.7)	1.80 (1.08)	0.0	1.00	1.80	2.60	4.8	
			Placebo	80	72 (90.0)	1.77 (0.92)	0.0	1.00	1.80	2.60	3.6	
		Week 24	Tezepelumab	78	77 (98.7)	1.74 (1.12)	0.0	1.00	1.80	2.60	4.8	
			Placebo	80	72 (90.0)	1.79 (0.95)	0.0	1.00	1.80	2.60	3.4	
		Week 26	Tezepelumab	78	78 (100.0)	1.77 (1.09)	0.0	1.00	1.80	2.60	4.8	
			Placebo	80	72 (90.0)	1.75 (0.89)	0.0	1.00	1.60	2.40	3.8	
		Week 28	Tezepelumab	78	78 (100.0)	1.83 (1.15)	0.0	1.00	1.90	2.80	4.8	
			Placebo	80	73 (91.3)	1.82 (1.03)	0.0	1.00	2.00	2.80	4.0	
		Week 30	Tezepelumab	78	78 (100.0)	1.77 (1.13)	0.0	1.00	1.80	2.60	4.8	
			Placebo	80	74 (92.5)	1.82 (1.04)	0.0	1.00	2.00	2.60	4.2	
		Week 32	Tezepelumab	78	78 (100.0)	1.73 (1.13)	0.0	1.00	1.70	2.60	4.8	
			Placebo	80	74 (92.5)	1.72 (0.98)	0.0	0.80	1.80	2.60	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	Absolute values	Week 34	Tezepelumab	78	78 (100.0)	1.73 (1.20)	0.0	1.00	1.60	2.80	4.8	
			Placebo	80	74 (92.5)	1.76 (0.96)	0.0	1.00	1.80	2.60	3.8	
		Week 36	Tezepelumab	78	78 (100.0)	1.82 (1.19)	0.0	0.80	1.90	2.80	5.0	
			Placebo	80	74 (92.5)	1.77 (1.04)	0.0	1.00	1.70	2.80	4.4	
		Week 38	Tezepelumab	78	78 (100.0)	1.69 (1.19)	0.0	0.80	1.60	2.40	4.8	
			Placebo	80	74 (92.5)	1.76 (0.96)	0.0	1.00	1.80	2.60	3.4	
		Week 40	Tezepelumab	78	78 (100.0)	1.71 (1.17)	0.0	0.80	1.80	2.60	4.8	
			Placebo	80	74 (92.5)	1.82 (1.06)	0.0	1.00	1.80	2.80	4.4	
		Week 42	Tezepelumab	78	78 (100.0)	1.72 (1.21)	0.0	0.80	1.60	2.60	4.8	
			Placebo	80	74 (92.5)	1.78 (1.02)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	78	78 (100.0)	1.71 (1.16)	0.0	0.80	1.80	2.80	4.8	
			Placebo	80	75 (93.8)	1.81 (1.02)	0.0	1.00	2.00	2.60	4.2	
		Week 46	Tezepelumab	78	78 (100.0)	1.69 (1.20)	0.0	0.80	1.60	2.60	4.8	
			Placebo	80	75 (93.8)	1.69 (0.94)	0.0	1.00	1.80	2.40	3.6	
		Week 48	Tezepelumab	78	78 (100.0)	1.73 (1.21)	0.0	0.80	1.80	2.80	4.8	
			Placebo	80	75 (93.8)	1.70 (0.99)	0.0	0.80	1.80	2.60	4.0	
		Week 50	Tezepelumab	78	78 (100.0)	1.65 (1.18)	0.0	0.80	1.40	2.60	4.8	
			Placebo	80	75 (93.8)	1.68 (0.96)	0.0	1.00	1.80	2.60	3.4	
		Week 52	Tezepelumab	78	78 (100.0)	1.71 (1.17)	0.0	0.80	1.80	2.60	4.8	
			Placebo	80	75 (93.8)	1.74 (1.01)	0.0	1.00	1.80	2.60	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	78	76 (97.4)	-0.53 (0.70)	-2.2	-0.90	-0.40	0.00	0.8	-0.11 [-0.43, 0.22]
			Placebo	80	70 (87.5)	-0.45 (0.78)	-3.0	-0.80	-0.40	0.00	1.4	
		Week 4	Tezepelumab	78	76 (97.4)	-0.86 (1.00)	-3.8	-1.40	-0.80	-0.20	2.6	-0.35 [-0.67, -0.02]
			Placebo	80	70 (87.5)	-0.52 (0.94)	-3.0	-1.20	-0.40	0.00	1.6	
		Week 6	Tezepelumab	78	76 (97.4)	-0.97 (1.02)	-4.0	-1.60	-1.00	-0.30	2.6	-0.32 [-0.65, 0.01]
			Placebo	80	71 (88.8)	-0.65 (0.99)	-3.4	-1.40	-0.60	0.20	1.6	
		Week 8	Tezepelumab	78	76 (97.4)	-0.97 (1.13)	-4.0	-1.60	-1.00	-0.40	2.6	-0.25 [-0.57, 0.08]
			Placebo	80	71 (88.8)	-0.72 (0.86)	-3.0	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	78	76 (97.4)	-1.04 (1.06)	-4.0	-1.80	-1.20	-0.20	2.6	-0.35 [-0.67, -0.02]
			Placebo	80	72 (90.0)	-0.69 (0.93)	-3.2	-1.20	-0.60	0.00	1.6	
		Week 12	Tezepelumab	78	76 (97.4)	-1.10 (1.09)	-4.0	-1.80	-1.10	-0.40	2.6	-0.25 [-0.57, 0.07]
			Placebo	80	72 (90.0)	-0.83 (1.04)	-3.2	-1.40	-0.80	0.00	1.4	
		Week 14	Tezepelumab	78	76 (97.4)	-1.26 (1.14)	-4.0	-2.10	-1.30	-0.40	2.6	-0.38 [-0.70, -0.05]
			Placebo	80	72 (90.0)	-0.86 (0.94)	-3.2	-1.40	-0.80	-0.30	1.4	
		Week 16	Tezepelumab	78	76 (97.4)	-1.11 (1.11)	-4.0	-1.80	-1.00	-0.40	2.6	-0.35 [-0.68, -0.03]
			Placebo	80	72 (90.0)	-0.74 (1.00)	-3.0	-1.40	-0.80	0.00	1.4	
		Week 18	Tezepelumab	78	77 (98.7)	-1.20 (1.10)	-4.0	-2.00	-1.00	-0.60	2.6	-0.29 [-0.61, 0.03]
			Placebo	80	72 (90.0)	-0.90 (0.96)	-3.0	-1.60	-0.80	-0.20	1.4	
		Week 20	Tezepelumab	78	77 (98.7)	-1.13 (1.11)	-4.0	-1.80	-1.00	-0.20	2.6	-0.22 [-0.54, 0.10]
			Placebo	80	72 (90.0)	-0.91 (0.93)	-3.0	-1.50	-0.70	-0.40	1.0	
		Week 22	Tezepelumab	78	77 (98.7)	-1.09 (1.14)	-4.0	-1.80	-1.00	-0.40	2.6	-0.15 [-0.47, 0.17]
			Placebo	80	72 (90.0)	-0.93 (0.95)	-2.8	-1.60	-0.90	-0.40	1.4	
		Week 24	Tezepelumab	78	77 (98.7)	-1.15 (1.05)	-4.0	-1.80	-1.20	-0.40	2.6	-0.24 [-0.56, 0.08]
			Placebo	80	72 (90.0)	-0.90 (0.98)	-3.2	-1.60	-0.80	-0.20	1.8	
		Week 26	Tezepelumab	78	78 (100.0)	-1.11 (1.12)	-4.0	-2.00	-1.00	-0.20	2.6	-0.16 [-0.48, 0.16]
			Placebo	80	72 (90.0)	-0.94 (0.94)	-3.0	-1.60	-1.10	-0.30	0.8	
		Week 28	Tezepelumab	78	78 (100.0)	-1.05 (1.15)	-4.0	-2.00	-1.00	-0.20	2.6	-0.19 [-0.51, 0.13]
			Placebo	80	73 (91.3)	-0.84 (1.03)	-3.0	-1.60	-0.80	-0.20	1.2	
		Week 30	Tezepelumab	78	78 (100.0)	-1.11 (1.17)	-3.8	-2.20	-1.00	-0.40	2.6	-0.22 [-0.54, 0.09]
			Placebo	80	74 (92.5)	-0.85 (1.12)	-3.2	-1.60	-0.80	-0.20	2.0	
		Week 32	Tezepelumab	78	78 (100.0)	-1.14 (1.12)	-4.0	-1.80	-1.10	-0.40	2.6	-0.18 [-0.50, 0.14]
			Placebo	80	74 (92.5)	-0.95 (0.97)	-3.2	-1.60	-1.00	-0.20	1.4	
		Week 34	Tezepelumab	78	78 (100.0)	-1.14 (1.17)	-4.0	-2.00	-1.30	-0.40	2.6	-0.21 [-0.53, 0.10]
			Placebo	80	74 (92.5)	-0.91 (0.96)	-2.8	-1.60	-1.00	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	Change from baseline	Week 36	Tezepelumab	78	78 (100.0)	-1.05 (1.22)	-4.0	-1.80	-1.10	-0.20	2.6	-0.13 [-0.45, 0.19]
			Placebo	80	74 (92.5)	-0.90 (1.06)	-3.6	-1.60	-1.00	-0.20	1.4	
		Week 38	Tezepelumab	78	78 (100.0)	-1.18 (1.22)	-4.0	-2.20	-1.20	-0.40	2.6	-0.24 [-0.56, 0.08]
			Placebo	80	74 (92.5)	-0.91 (1.01)	-3.0	-1.60	-0.90	-0.20	1.6	
		Week 40	Tezepelumab	78	78 (100.0)	-1.17 (1.20)	-4.0	-2.20	-1.10	-0.40	2.6	-0.29 [-0.61, 0.03]
			Placebo	80	74 (92.5)	-0.85 (1.04)	-3.2	-1.60	-0.80	-0.20	1.4	
		Week 42	Tezepelumab	78	78 (100.0)	-1.16 (1.25)	-4.0	-2.20	-1.20	-0.40	2.6	-0.23 [-0.55, 0.09]
			Placebo	80	74 (92.5)	-0.89 (1.04)	-3.0	-1.60	-0.80	-0.20	1.6	
		Week 44	Tezepelumab	78	78 (100.0)	-1.16 (1.25)	-4.4	-2.00	-1.00	-0.40	2.6	-0.26 [-0.58, 0.06]
			Placebo	80	75 (93.8)	-0.86 (1.05)	-3.4	-1.60	-0.80	-0.20	1.6	
		Week 46	Tezepelumab	78	78 (100.0)	-1.18 (1.24)	-4.0	-2.20	-1.10	-0.20	2.6	-0.18 [-0.50, 0.14]
			Placebo	80	75 (93.8)	-0.98 (0.99)	-3.2	-1.60	-1.00	-0.20	1.2	
		Week 48	Tezepelumab	78	78 (100.0)	-1.14 (1.23)	-4.0	-2.00	-1.00	-0.20	2.6	-0.15 [-0.47, 0.16]
			Placebo	80	75 (93.8)	-0.97 (1.01)	-3.4	-1.60	-1.00	-0.20	1.4	
		Week 50	Tezepelumab	78	78 (100.0)	-1.22 (1.20)	-4.0	-2.00	-1.40	-0.40	2.6	-0.21 [-0.53, 0.11]
			Placebo	80	75 (93.8)	-0.99 (0.99)	-3.6	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	78	78 (100.0)	-1.17 (1.21)	-4.0	-2.00	-1.20	-0.20	2.6	-0.22 [-0.53, 0.10]
			Placebo	80	75 (93.8)	-0.93 (1.01)	-3.6	-1.60	-0.80	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	10	10 (100.0)	3.06 (1.14)	1.8	2.20	2.90	3.20	5.2	
			Placebo	9	9 (100.0)	3.02 (0.77)	2.0	2.20	3.40	3.60	4.0	
		Week 2	Tezepelumab	10	9 (90.0)	1.89 (1.21)	0.0	1.00	2.20	2.40	3.6	
			Placebo	9	8 (88.9)	2.40 (0.89)	1.4	1.60	2.30	3.10	3.8	
		Week 4	Tezepelumab	10	9 (90.0)	1.73 (0.98)	0.2	1.20	1.80	2.20	3.4	
			Placebo	9	8 (88.9)	2.40 (1.18)	0.8	1.60	2.50	2.90	4.4	
		Week 6	Tezepelumab	10	9 (90.0)	1.69 (1.05)	0.0	1.20	1.80	2.20	3.4	
			Placebo	9	8 (88.9)	2.25 (1.33)	0.6	1.20	2.30	2.80	4.8	
		Week 8	Tezepelumab	10	9 (90.0)	1.22 (0.97)	0.0	0.60	1.20	2.00	3.0	
			Placebo	9	8 (88.9)	2.00 (1.44)	0.2	0.80	2.00	2.90	4.4	
		Week 10	Tezepelumab	10	9 (90.0)	1.04 (0.97)	0.0	0.40	0.60	1.40	3.0	
			Placebo	9	8 (88.9)	2.10 (1.61)	0.0	1.00	2.00	2.80	5.2	
		Week 12	Tezepelumab	10	9 (90.0)	1.04 (0.53)	0.6	0.60	0.80	1.20	2.0	
			Placebo	9	8 (88.9)	2.03 (1.32)	0.0	1.10	2.00	3.10	3.8	
		Week 14	Tezepelumab	10	9 (90.0)	0.82 (0.60)	0.0	0.60	0.80	0.80	2.2	
			Placebo	9	8 (88.9)	2.30 (1.47)	0.4	1.30	2.10	3.10	5.0	
		Week 16	Tezepelumab	10	9 (90.0)	1.27 (0.97)	0.4	0.80	1.00	1.40	3.4	
			Placebo	9	8 (88.9)	2.23 (1.53)	0.2	1.10	2.10	3.10	5.0	
		Week 18	Tezepelumab	10	9 (90.0)	0.96 (0.67)	0.0	0.40	1.00	1.20	2.2	
			Placebo	9	8 (88.9)	2.18 (1.48)	0.2	1.20	2.10	2.80	5.0	
		Week 20	Tezepelumab	10	9 (90.0)	1.00 (0.57)	0.4	0.60	1.00	1.20	2.2	
			Placebo	9	8 (88.9)	1.90 (1.72)	0.0	0.30	2.00	2.80	5.0	
		Week 22	Tezepelumab	10	9 (90.0)	0.93 (0.65)	0.0	0.60	0.80	1.00	2.2	
			Placebo	9	8 (88.9)	2.00 (1.61)	0.0	0.60	2.30	2.60	5.0	
		Week 24	Tezepelumab	10	9 (90.0)	1.00 (0.75)	0.0	0.80	1.00	1.20	2.2	
			Placebo	9	8 (88.9)	1.85 (1.34)	0.2	0.70	1.90	2.70	4.0	
		Week 26	Tezepelumab	10	9 (90.0)	0.96 (0.65)	0.0	0.60	0.80	1.40	2.2	
			Placebo	9	8 (88.9)	1.73 (1.29)	0.4	0.70	1.30	2.70	4.0	
		Week 28	Tezepelumab	10	10 (100.0)	0.88 (0.63)	0.0	0.40	0.90	1.20	2.2	
			Placebo	9	8 (88.9)	1.75 (1.25)	0.4	0.60	1.80	2.40	4.0	
		Week 30	Tezepelumab	10	10 (100.0)	0.90 (0.66)	0.0	0.40	0.90	1.20	2.2	
			Placebo	9	8 (88.9)	1.75 (1.21)	0.4	0.80	1.60	2.40	4.0	
		Week 32	Tezepelumab	10	10 (100.0)	1.04 (0.62)	0.2	0.40	1.00	1.40	2.2	
			Placebo	9	8 (88.9)	1.60 (1.20)	0.4	0.70	1.40	2.10	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
America	Absolute values	Week 34	Tezepelumab	10	10 (100.0)	1.06 (0.64)	0.0	0.80	1.00	1.40	2.2	
			Placebo	9	8 (88.9)	1.60 (1.30)	0.0	0.60	1.40	2.40	4.0	
		Week 36	Tezepelumab	10	10 (100.0)	1.40 (0.80)	0.4	0.80	1.20	2.20	2.6	
			Placebo	9	8 (88.9)	1.90 (1.18)	0.0	1.20	1.90	2.50	4.0	
		Week 38	Tezepelumab	10	10 (100.0)	0.98 (0.58)	0.4	0.60	0.80	1.00	2.2	
			Placebo	9	8 (88.9)	1.93 (1.28)	0.0	1.20	1.60	2.90	4.0	
		Week 40	Tezepelumab	10	10 (100.0)	1.04 (0.76)	0.0	0.40	1.00	1.60	2.2	
			Placebo	9	8 (88.9)	1.85 (1.23)	0.0	1.00	1.90	2.50	4.0	
		Week 42	Tezepelumab	10	10 (100.0)	0.98 (0.70)	0.0	0.40	0.90	1.40	2.2	
			Placebo	9	8 (88.9)	1.58 (0.80)	0.0	1.20	1.70	2.10	2.6	
		Week 44	Tezepelumab	10	10 (100.0)	1.10 (0.67)	0.4	0.40	1.00	1.80	2.2	
			Placebo	9	8 (88.9)	1.68 (0.84)	0.8	1.00	1.30	2.60	2.8	
		Week 46	Tezepelumab	10	10 (100.0)	0.90 (0.67)	0.0	0.40	0.80	1.00	2.2	
			Placebo	9	8 (88.9)	1.63 (0.87)	0.6	0.90	1.50	2.30	3.0	
		Week 48	Tezepelumab	10	10 (100.0)	0.96 (0.62)	0.2	0.40	0.80	1.40	2.2	
			Placebo	9	8 (88.9)	1.55 (0.92)	0.4	1.00	1.30	2.10	3.2	
		Week 50	Tezepelumab	10	10 (100.0)	0.70 (0.68)	0.0	0.00	0.70	1.00	2.2	
			Placebo	9	8 (88.9)	1.90 (0.96)	0.8	1.20	1.80	2.30	3.8	
		Week 52	Tezepelumab	10	10 (100.0)	0.86 (0.69)	0.0	0.40	0.80	1.20	2.2	
			Placebo	9	8 (88.9)	1.90 (1.20)	0.0	1.10	1.90	2.70	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	10	9 (90.0)	-1.22 (1.14)	-3.2	-1.80	-1.20	-0.20	0.2	-0.57 [-1.55, 0.40]
			Placebo	9	8 (88.9)	-0.58 (1.11)	-2.4	-1.30	-0.50	0.10	1.2	
		Week 4	Tezepelumab	10	9 (90.0)	-1.38 (1.07)	-3.0	-2.20	-1.40	-0.60	0.2	-0.65 [-1.63, 0.33]
			Placebo	9	8 (88.9)	-0.58 (1.39)	-3.0	-1.40	-0.50	0.60	1.0	
		Week 6	Tezepelumab	10	9 (90.0)	-1.42 (1.55)	-3.6	-2.80	-1.60	-0.20	0.4	-0.47 [-1.44, 0.50]
			Placebo	9	8 (88.9)	-0.73 (1.40)	-3.2	-1.30	-0.80	0.10	1.4	
		Week 8	Tezepelumab	10	9 (90.0)	-1.89 (1.01)	-3.2	-2.80	-2.00	-1.00	-0.4	-0.67 [-1.65, 0.32]
			Placebo	9	8 (88.9)	-0.98 (1.70)	-3.6	-2.20	-1.00	0.60	1.0	
		Week 10	Tezepelumab	10	9 (90.0)	-2.07 (1.14)	-3.6	-3.00	-2.20	-1.40	-0.4	-0.77 [-1.76, 0.22]
			Placebo	9	8 (88.9)	-0.88 (1.90)	-3.8	-1.80	-1.20	0.10	2.6	
		Week 12	Tezepelumab	10	9 (90.0)	-2.07 (1.15)	-4.0	-2.60	-2.20	-1.20	-0.6	-0.80 [-1.80, 0.19]
			Placebo	9	8 (88.9)	-0.95 (1.62)	-3.8	-1.90	-0.90	0.30	1.2	
		Week 14	Tezepelumab	10	9 (90.0)	-2.29 (1.08)	-4.2	-3.00	-2.20	-1.40	-1.0	-1.11 [-2.15, -0.08]
			Placebo	9	8 (88.9)	-0.68 (1.78)	-3.4	-1.70	-0.90	0.40	2.4	
		Week 16	Tezepelumab	10	9 (90.0)	-1.84 (1.59)	-4.4	-2.80	-2.20	-0.80	1.0	-0.64 [-1.62, 0.34]
			Placebo	9	8 (88.9)	-0.75 (1.84)	-3.6	-1.70	-1.10	0.40	2.4	
		Week 18	Tezepelumab	10	9 (90.0)	-2.16 (1.29)	-4.4	-3.00	-2.20	-0.80	-0.8	-0.87 [-1.88, 0.13]
			Placebo	9	8 (88.9)	-0.80 (1.80)	-3.6	-1.80	-0.90	0.10	2.4	
		Week 20	Tezepelumab	10	9 (90.0)	-2.11 (1.23)	-4.4	-2.80	-2.20	-1.20	-0.6	-0.63 [-1.61, 0.35]
			Placebo	9	8 (88.9)	-1.08 (2.03)	-3.6	-2.70	-1.10	0.10	2.4	
		Week 22	Tezepelumab	10	9 (90.0)	-2.18 (1.18)	-4.4	-3.00	-2.20	-1.20	-0.8	-0.76 [-1.75, 0.23]
			Placebo	9	8 (88.9)	-0.97 (1.95)	-3.8	-2.30	-1.10	0.20	2.4	
		Week 24	Tezepelumab	10	9 (90.0)	-2.11 (1.47)	-4.8	-3.00	-2.20	-1.40	0.2	-0.64 [-1.62, 0.34]
			Placebo	9	8 (88.9)	-1.13 (1.62)	-3.6	-2.10	-1.30	0.00	1.4	
		Week 26	Tezepelumab	10	9 (90.0)	-2.16 (1.30)	-4.4	-3.00	-2.20	-1.40	-0.4	-0.62 [-1.60, 0.36]
			Placebo	9	8 (88.9)	-1.25 (1.62)	-3.4	-2.20	-1.60	-0.20	1.4	
		Week 28	Tezepelumab	10	10 (100.0)	-2.18 (1.21)	-4.4	-3.00	-2.20	-1.40	-0.6	-0.70 [-1.66, 0.26]
			Placebo	9	8 (88.9)	-1.23 (1.54)	-3.4	-2.30	-1.30	-0.30	1.4	
		Week 30	Tezepelumab	10	10 (100.0)	-2.16 (1.24)	-4.4	-3.00	-2.30	-1.40	-0.4	-0.69 [-1.65, 0.27]
			Placebo	9	8 (88.9)	-1.23 (1.49)	-3.4	-2.10	-1.40	-0.40	1.4	
		Week 32	Tezepelumab	10	10 (100.0)	-2.02 (1.19)	-4.4	-2.80	-1.90	-1.00	-0.4	-0.49 [-1.44, 0.45]
			Placebo	9	8 (88.9)	-1.38 (1.44)	-3.2	-2.30	-1.60	-0.70	1.4	
		Week 34	Tezepelumab	10	10 (100.0)	-2.00 (1.22)	-4.4	-2.60	-2.10	-1.00	-0.2	-0.49 [-1.43, 0.46]
			Placebo	9	8 (88.9)	-1.38 (1.35)	-3.2	-2.20	-1.40	-1.00	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
America	Change from baseline	Week 36	Tezepelumab	10	10 (100.0)	-1.66 (1.56)	-4.4	-2.80	-1.80	0.00	0.4	-0.40 [-1.34, 0.54]
			Placebo	9	8 (88.9)	-1.08 (1.34)	-2.6	-2.00	-1.40	-0.30	1.4	
		Week 38	Tezepelumab	10	10 (100.0)	-2.08 (1.18)	-4.4	-2.60	-2.20	-1.40	-0.2	-0.76 [-1.72, 0.21]
			Placebo	9	8 (88.9)	-1.05 (1.57)	-2.8	-2.20	-1.50	0.20	1.4	
		Week 40	Tezepelumab	10	10 (100.0)	-2.02 (1.31)	-4.4	-3.00	-1.90	-1.40	0.2	-0.68 [-1.64, 0.28]
			Placebo	9	8 (88.9)	-1.13 (1.33)	-2.6	-2.10	-1.40	-0.40	1.4	
		Week 42	Tezepelumab	10	10 (100.0)	-2.08 (1.21)	-4.4	-3.00	-1.90	-1.40	-0.6	-0.64 [-1.59, 0.32]
			Placebo	9	8 (88.9)	-1.40 (0.85)	-2.6	-1.90	-1.50	-1.00	0.2	
		Week 44	Tezepelumab	10	10 (100.0)	-1.96 (1.25)	-4.4	-2.80	-1.80	-1.40	0.0	-0.58 [-1.53, 0.37]
			Placebo	9	8 (88.9)	-1.30 (0.99)	-2.6	-1.80	-1.40	-1.10	0.8	
		Week 46	Tezepelumab	10	10 (100.0)	-2.16 (1.20)	-4.4	-3.00	-2.20	-1.40	-0.2	-0.72 [-1.68, 0.24]
			Placebo	9	8 (88.9)	-1.35 (1.02)	-2.6	-1.60	-1.60	-1.40	1.0	
		Week 48	Tezepelumab	10	10 (100.0)	-2.10 (1.14)	-4.4	-2.80	-2.00	-1.40	-0.4	-0.58 [-1.53, 0.37]
			Placebo	9	8 (88.9)	-1.43 (1.18)	-2.8	-2.00	-1.70	-1.20	1.2	
		Week 50	Tezepelumab	10	10 (100.0)	-2.36 (1.12)	-4.4	-3.20	-2.40	-1.40	-0.8	-1.09 [-2.10, -0.09]
			Placebo	9	8 (88.9)	-1.08 (1.24)	-2.4	-1.60	-1.50	-0.80	1.6	
		Week 52	Tezepelumab	10	10 (100.0)	-2.20 (1.20)	-4.4	-3.20	-1.90	-1.20	-0.8	-0.84 [-1.82, 0.13]
			Placebo	9	8 (88.9)	-1.08 (1.49)	-2.6	-2.00	-1.50	-0.30	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.64 (0.55)	2.0	2.40	2.40	3.00	3.4	
			Placebo	6	6 (100.0)	2.73 (0.87)	1.8	2.00	2.60	3.20	4.2	
		Week 2	Tezepelumab	5	5 (100.0)	2.16 (0.86)	1.0	1.60	2.40	2.60	3.2	
			Placebo	6	6 (100.0)	2.50 (0.92)	1.6	1.80	2.40	2.60	4.2	
		Week 4	Tezepelumab	5	5 (100.0)	1.80 (0.75)	0.8	1.20	2.20	2.40	2.4	
			Placebo	6	6 (100.0)	2.00 (0.47)	1.4	1.60	2.00	2.40	2.6	
		Week 6	Tezepelumab	5	5 (100.0)	1.48 (0.44)	1.0	1.00	1.80	1.80	1.8	
			Placebo	6	6 (100.0)	1.87 (0.63)	1.0	1.40	1.90	2.40	2.6	
		Week 8	Tezepelumab	5	5 (100.0)	1.28 (0.52)	0.6	1.00	1.20	1.80	1.8	
			Placebo	6	6 (100.0)	2.03 (0.46)	1.4	1.60	2.10	2.40	2.6	
		Week 10	Tezepelumab	5	5 (100.0)	1.20 (0.37)	0.8	0.80	1.40	1.40	1.6	
			Placebo	6	6 (100.0)	1.73 (0.45)	1.0	1.60	1.80	1.80	2.4	
		Week 12	Tezepelumab	5	5 (100.0)	0.84 (0.71)	0.0	0.20	1.00	1.40	1.6	
			Placebo	6	6 (100.0)	1.70 (0.37)	1.2	1.40	1.70	2.00	2.2	
		Week 14	Tezepelumab	5	5 (100.0)	0.96 (0.30)	0.6	0.80	1.00	1.00	1.4	
			Placebo	6	6 (100.0)	1.43 (0.43)	1.0	1.00	1.40	1.80	2.0	
		Week 16	Tezepelumab	5	5 (100.0)	0.92 (0.41)	0.2	1.00	1.00	1.20	1.2	
			Placebo	6	6 (100.0)	1.40 (0.68)	0.6	0.60	1.50	2.00	2.2	
		Week 18	Tezepelumab	5	5 (100.0)	1.00 (0.49)	0.6	0.60	1.00	1.00	1.8	
			Placebo	6	6 (100.0)	1.77 (0.54)	1.0	1.20	2.00	2.20	2.2	
		Week 20	Tezepelumab	5	5 (100.0)	1.16 (0.75)	0.4	0.80	1.00	1.20	2.4	
			Placebo	6	6 (100.0)	1.80 (1.00)	0.6	1.00	1.70	2.40	3.4	
		Week 22	Tezepelumab	5	5 (100.0)	1.04 (0.86)	0.0	0.80	1.00	1.00	2.4	
			Placebo	6	6 (100.0)	1.60 (0.87)	0.4	1.20	1.40	2.60	2.6	
		Week 24	Tezepelumab	5	5 (100.0)	1.04 (0.52)	0.4	0.80	1.00	1.20	1.8	
			Placebo	6	6 (100.0)	1.73 (0.98)	0.4	0.80	1.90	2.60	2.8	
		Week 26	Tezepelumab	5	5 (100.0)	0.80 (0.35)	0.2	0.80	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	1.43 (0.88)	0.0	1.00	1.60	1.80	2.6	
		Week 28	Tezepelumab	5	5 (100.0)	0.88 (0.39)	0.2	1.00	1.00	1.00	1.2	
			Placebo	6	6 (100.0)	1.07 (1.06)	0.0	0.00	1.00	2.00	2.4	
		Week 30	Tezepelumab	5	5 (100.0)	0.88 (0.23)	0.6	0.80	0.80	1.00	1.2	
			Placebo	6	6 (100.0)	1.07 (0.94)	0.0	0.00	1.10	2.00	2.2	
		Week 32	Tezepelumab	5	5 (100.0)	0.68 (0.36)	0.2	0.40	0.80	1.00	1.0	
			Placebo	6	6 (100.0)	1.17 (0.73)	0.2	0.60	1.20	1.80	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia/Pacific	Absolute values	Week 34	Tezepelumab	5	5 (100.0)	0.72 (0.33)	0.4	0.40	0.80	0.80	1.2	
			Placebo	6	6 (100.0)	1.10 (1.03)	0.0	0.00	1.20	1.60	2.6	
		Week 36	Tezepelumab	5	5 (100.0)	1.08 (0.91)	0.2	0.60	1.00	1.00	2.6	
			Placebo	6	6 (100.0)	1.73 (1.27)	0.0	0.60	1.90	2.60	3.4	
		Week 38	Tezepelumab	5	5 (100.0)	1.08 (0.89)	0.0	0.60	0.80	2.00	2.0	
			Placebo	6	6 (100.0)	1.00 (0.91)	0.0	0.00	1.10	1.80	2.0	
		Week 40	Tezepelumab	5	5 (100.0)	0.88 (0.54)	0.4	0.60	0.80	0.80	1.8	
			Placebo	6	6 (100.0)	1.33 (1.09)	0.0	0.00	1.70	2.00	2.6	
		Week 42	Tezepelumab	5	5 (100.0)	0.80 (0.28)	0.4	0.60	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	1.20 (0.95)	0.0	0.00	1.60	2.00	2.0	
		Week 44	Tezepelumab	5	5 (100.0)	0.68 (0.33)	0.2	0.60	0.60	1.00	1.0	
			Placebo	6	6 (100.0)	1.97 (1.56)	0.0	0.20	2.40	3.00	3.8	
		Week 46	Tezepelumab	5	5 (100.0)	0.80 (0.35)	0.2	0.80	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	1.03 (1.02)	0.0	0.00	1.00	2.00	2.2	
		Week 48	Tezepelumab	5	5 (100.0)	1.16 (0.84)	0.4	0.80	1.00	1.00	2.6	
			Placebo	6	6 (100.0)	1.50 (1.07)	0.0	0.40	1.80	2.40	2.6	
		Week 50	Tezepelumab	5	5 (100.0)	1.20 (0.76)	0.4	0.80	1.00	1.40	2.4	
			Placebo	6	6 (100.0)	1.30 (0.72)	0.0	1.00	1.50	1.80	2.0	
		Week 52	Tezepelumab	5	5 (100.0)	1.00 (0.82)	0.4	0.40	0.80	1.00	2.4	
			Placebo	6	6 (100.0)	1.37 (0.71)	0.0	1.40	1.50	1.80	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	-0.48 (0.67)	-1.4	-0.80	-0.40	-0.20	0.4	-0.49 [-1.70, 0.71]
			Placebo	6	6 (100.0)	-0.23 (0.29)	-0.8	-0.20	-0.20	0.00	0.0	
		Week 4	Tezepelumab	5	5 (100.0)	-0.84 (0.75)	-1.6	-1.20	-1.00	-0.80	0.4	-0.13 [-1.32, 1.06]
			Placebo	6	6 (100.0)	-0.73 (0.84)	-1.8	-1.80	-0.30	-0.20	0.0	
		Week 6	Tezepelumab	5	5 (100.0)	-1.16 (0.55)	-1.6	-1.40	-1.40	-1.20	-0.2	-0.47 [-1.68, 0.73]
			Placebo	6	6 (100.0)	-0.87 (0.67)	-1.8	-1.60	-0.60	-0.40	-0.2	
		Week 8	Tezepelumab	5	5 (100.0)	-1.36 (0.67)	-1.8	-1.80	-1.60	-1.40	-0.2	-0.76 [-2.00, 0.48]
			Placebo	6	6 (100.0)	-0.70 (1.00)	-2.6	-0.80	-0.50	0.00	0.2	
		Week 10	Tezepelumab	5	5 (100.0)	-1.44 (0.61)	-2.0	-1.60	-1.60	-1.60	-0.4	-0.60 [-1.82, 0.62]
			Placebo	6	6 (100.0)	-1.00 (0.82)	-2.6	-0.80	-0.80	-0.80	-0.2	
		Week 12	Tezepelumab	5	5 (100.0)	-1.80 (0.71)	-2.4	-2.20	-2.00	-1.80	-0.6	-0.87 [-2.12, 0.38]
			Placebo	6	6 (100.0)	-1.03 (1.00)	-3.0	-1.00	-0.70	-0.60	-0.2	
		Week 14	Tezepelumab	5	5 (100.0)	-1.68 (0.41)	-2.0	-2.00	-1.80	-1.60	-1.0	-0.46 [-1.67, 0.74]
			Placebo	6	6 (100.0)	-1.30 (1.04)	-3.2	-1.40	-1.20	-0.60	-0.2	
		Week 16	Tezepelumab	5	5 (100.0)	-1.72 (0.52)	-2.2	-2.20	-1.80	-1.40	-1.0	-0.38 [-1.58, 0.82]
			Placebo	6	6 (100.0)	-1.33 (1.29)	-3.6	-2.00	-0.90	-0.40	-0.2	
		Week 18	Tezepelumab	5	5 (100.0)	-1.64 (0.84)	-2.4	-2.00	-1.80	-1.80	-0.2	-0.69 [-1.92, 0.54]
			Placebo	6	6 (100.0)	-0.97 (1.07)	-3.0	-1.00	-0.70	-0.40	0.0	
		Week 20	Tezepelumab	5	5 (100.0)	-1.48 (1.07)	-2.2	-2.00	-2.00	-1.60	0.4	-0.41 [-1.61, 0.79]
			Placebo	6	6 (100.0)	-0.93 (1.51)	-3.6	-1.40	-0.60	-0.20	0.8	
		Week 22	Tezepelumab	5	5 (100.0)	-1.60 (1.17)	-2.4	-2.40	-2.00	-1.60	0.4	-0.41 [-1.61, 0.79]
			Placebo	6	6 (100.0)	-1.13 (1.11)	-3.0	-1.60	-1.00	-0.20	0.0	
		Week 24	Tezepelumab	5	5 (100.0)	-1.60 (0.84)	-2.4	-2.00	-1.80	-1.60	-0.2	-0.49 [-1.69, 0.72]
			Placebo	6	6 (100.0)	-1.00 (1.48)	-3.8	-1.20	-0.60	0.00	0.2	
		Week 26	Tezepelumab	5	5 (100.0)	-1.84 (0.52)	-2.4	-2.20	-2.00	-1.40	-1.2	-0.46 [-1.67, 0.74]
			Placebo	6	6 (100.0)	-1.30 (1.50)	-4.2	-1.40	-0.90	-0.40	0.0	
		Week 28	Tezepelumab	5	5 (100.0)	-1.76 (0.57)	-2.4	-2.20	-1.80	-1.40	-1.0	-0.08 [-1.27, 1.11]
			Placebo	6	6 (100.0)	-1.67 (1.47)	-4.2	-2.20	-1.40	-0.60	-0.2	
		Week 30	Tezepelumab	5	5 (100.0)	-1.76 (0.65)	-2.6	-2.00	-1.80	-1.60	-0.8	-0.09 [-1.28, 1.10]
			Placebo	6	6 (100.0)	-1.67 (1.26)	-3.2	-2.60	-1.70	-1.20	0.4	
		Week 32	Tezepelumab	5	5 (100.0)	-1.96 (0.65)	-2.6	-2.40	-2.20	-1.60	-1.0	-0.39 [-1.59, 0.81]
			Placebo	6	6 (100.0)	-1.57 (1.24)	-3.6	-1.80	-1.70	-0.60	0.0	
		Week 34	Tezepelumab	5	5 (100.0)	-1.92 (0.76)	-2.6	-2.60	-2.00	-1.60	-0.8	-0.24 [-1.43, 0.95]
			Placebo	6	6 (100.0)	-1.63 (1.43)	-4.2	-2.00	-1.40	-0.60	-0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia/Pacific	Change from baseline	Week 36	Tezepelumab	5	5 (100.0)	-1.56 (1.28)	-2.4	-2.40	-2.20	-1.40	0.6	-0.39 [-1.59, 0.81]
			Placebo	6	6 (100.0)	-1.00 (1.56)	-3.6	-2.00	-0.50	-0.20	0.8	
		Week 38	Tezepelumab	5	5 (100.0)	-1.56 (0.95)	-2.4	-2.20	-1.80	-1.40	0.0	0.14 [-1.05, 1.33]
			Placebo	6	6 (100.0)	-1.73 (1.42)	-4.2	-2.00	-1.60	-1.00	0.0	
		Week 40	Tezepelumab	5	5 (100.0)	-1.76 (0.95)	-2.6	-2.40	-2.00	-1.60	-0.2	-0.27 [-1.46, 0.92]
			Placebo	6	6 (100.0)	-1.40 (1.57)	-4.2	-2.00	-1.10	0.00	0.0	
		Week 42	Tezepelumab	5	5 (100.0)	-1.84 (0.62)	-2.4	-2.40	-2.00	-1.40	-1.0	-0.26 [-1.45, 0.93]
			Placebo	6	6 (100.0)	-1.53 (1.49)	-4.2	-2.00	-1.20	-0.80	0.2	
		Week 44	Tezepelumab	5	5 (100.0)	-1.96 (0.74)	-2.8	-2.40	-2.20	-1.40	-1.0	-0.77 [-2.01, 0.46]
			Placebo	6	6 (100.0)	-0.77 (1.96)	-4.2	-1.80	-0.10	0.40	1.2	
		Week 46	Tezepelumab	5	5 (100.0)	-1.84 (0.61)	-2.4	-2.20	-2.20	-1.40	-1.0	-0.12 [-1.31, 1.07]
			Placebo	6	6 (100.0)	-1.70 (1.50)	-4.2	-2.20	-1.50	-1.00	0.2	
		Week 48	Tezepelumab	5	5 (100.0)	-1.48 (1.20)	-2.4	-2.00	-2.00	-1.60	0.6	-0.18 [-1.37, 1.01]
			Placebo	6	6 (100.0)	-1.23 (1.44)	-3.8	-2.00	-0.70	-0.20	0.0	
		Week 50	Tezepelumab	5	5 (100.0)	-1.44 (1.13)	-2.6	-2.00	-1.60	-1.40	0.4	-0.01 [-1.19, 1.18]
			Placebo	6	6 (100.0)	-1.43 (1.42)	-4.2	-1.40	-1.10	-0.60	-0.2	
		Week 52	Tezepelumab	5	5 (100.0)	-1.64 (1.24)	-2.6	-2.60	-2.00	-1.40	0.4	-0.20 [-1.39, 0.99]
			Placebo	6	6 (100.0)	-1.37 (1.46)	-4.2	-1.40	-0.90	-0.60	-0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	44	44 (100.0)	2.75 (0.75)	0.4	2.40	2.80	3.20	4.8	
			Placebo	43	43 (100.0)	3.10 (0.76)	1.4	2.80	3.00	3.40	5.0	
		Week 2	Tezepelumab	44	41 (93.2)	2.17 (0.92)	0.0	1.60	2.40	2.80	3.8	
			Placebo	43	41 (95.3)	2.70 (0.90)	0.4	2.20	2.80	3.20	5.0	
		Week 4	Tezepelumab	44	41 (93.2)	1.87 (1.03)	0.0	1.20	1.80	2.80	3.6	
			Placebo	43	41 (95.3)	2.55 (0.79)	0.2	2.00	2.60	3.00	4.2	
		Week 6	Tezepelumab	44	41 (93.2)	1.84 (1.01)	0.0	1.20	1.80	2.60	3.8	
			Placebo	43	41 (95.3)	2.51 (1.04)	0.2	2.00	2.40	3.00	6.0	
		Week 8	Tezepelumab	44	41 (93.2)	1.73 (1.00)	0.0	1.00	1.60	2.60	3.4	
			Placebo	43	42 (97.7)	2.48 (1.04)	0.0	2.00	2.40	3.00	5.0	
		Week 10	Tezepelumab	44	41 (93.2)	1.67 (0.99)	0.0	1.20	1.80	2.40	3.4	
			Placebo	43	42 (97.7)	2.22 (0.93)	0.2	1.80	2.40	3.00	4.4	
		Week 12	Tezepelumab	44	41 (93.2)	1.57 (1.04)	0.0	0.60	1.60	2.40	3.6	
			Placebo	43	42 (97.7)	2.25 (0.93)	0.0	2.00	2.30	3.00	4.4	
		Week 14	Tezepelumab	44	41 (93.2)	1.47 (0.91)	0.0	1.00	1.40	2.00	3.6	
			Placebo	43	42 (97.7)	2.12 (1.01)	0.0	1.40	2.10	2.80	5.0	
		Week 16	Tezepelumab	44	41 (93.2)	1.62 (1.09)	0.0	0.80	1.60	2.60	4.6	
			Placebo	43	42 (97.7)	2.30 (1.10)	0.0	1.60	2.40	3.00	5.0	
		Week 18	Tezepelumab	44	41 (93.2)	1.49 (0.92)	0.0	1.00	1.40	2.20	3.6	
			Placebo	43	42 (97.7)	2.20 (1.08)	0.0	1.60	2.40	3.00	4.4	
		Week 20	Tezepelumab	44	41 (93.2)	1.63 (0.97)	0.0	1.00	1.80	2.40	3.4	
			Placebo	43	42 (97.7)	2.42 (1.02)	0.0	2.00	2.60	3.00	4.4	
		Week 22	Tezepelumab	44	41 (93.2)	1.66 (0.92)	0.0	1.20	1.80	2.20	3.6	
			Placebo	43	42 (97.7)	2.33 (1.08)	0.0	1.80	2.50	3.00	4.4	
		Week 24	Tezepelumab	44	41 (93.2)	1.71 (1.09)	0.0	1.20	1.60	2.60	4.8	
			Placebo	43	42 (97.7)	2.27 (1.05)	0.0	1.60	2.40	3.00	4.4	
		Week 26	Tezepelumab	44	41 (93.2)	1.57 (1.00)	0.0	1.00	1.60	2.20	3.6	
			Placebo	43	42 (97.7)	2.25 (1.10)	0.0	1.20	2.50	3.00	4.4	
		Week 28	Tezepelumab	44	41 (93.2)	1.68 (1.05)	0.0	1.00	1.80	2.40	3.6	
			Placebo	43	42 (97.7)	2.36 (1.06)	0.0	1.60	2.40	3.00	4.4	
		Week 30	Tezepelumab	44	42 (95.5)	1.57 (0.92)	0.0	1.00	1.60	2.20	3.8	
			Placebo	43	42 (97.7)	2.31 (1.01)	0.0	1.60	2.50	3.00	4.4	
		Week 32	Tezepelumab	44	42 (95.5)	1.49 (1.02)	0.0	0.60	1.40	2.20	4.2	
			Placebo	43	42 (97.7)	2.36 (1.13)	0.0	1.60	2.60	3.00	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of the world	Absolute values	Week 34	Tezepelumab	44	42 (95.5)	1.52 (1.05)	0.0	0.80	1.60	2.20	4.2	
			Placebo	43	42 (97.7)	2.18 (1.19)	0.0	1.40	2.40	3.00	4.8	
		Week 36	Tezepelumab	44	42 (95.5)	1.49 (1.00)	0.0	0.80	1.60	2.20	3.8	
			Placebo	43	42 (97.7)	2.28 (1.13)	0.0	1.80	2.40	3.00	4.8	
		Week 38	Tezepelumab	44	42 (95.5)	1.52 (1.01)	0.0	0.80	1.60	2.20	3.6	
			Placebo	43	42 (97.7)	2.15 (1.16)	0.0	1.40	2.00	3.00	4.8	
		Week 40	Tezepelumab	44	42 (95.5)	1.60 (1.05)	0.0	0.60	1.70	2.40	3.8	
			Placebo	43	42 (97.7)	2.24 (1.10)	0.0	1.40	2.40	3.00	4.4	
		Week 42	Tezepelumab	44	42 (95.5)	1.46 (0.92)	0.0	0.80	1.60	2.00	3.4	
			Placebo	43	42 (97.7)	2.29 (1.06)	0.0	1.80	2.50	3.00	4.4	
		Week 44	Tezepelumab	44	42 (95.5)	1.55 (1.04)	0.0	0.60	1.60	2.40	3.8	
			Placebo	43	42 (97.7)	2.27 (1.08)	0.0	1.60	2.50	3.00	4.4	
		Week 46	Tezepelumab	44	42 (95.5)	1.53 (0.98)	0.0	1.00	1.60	2.20	3.6	
			Placebo	43	42 (97.7)	2.24 (1.08)	0.0	1.60	2.30	3.00	4.4	
		Week 48	Tezepelumab	44	42 (95.5)	1.59 (0.99)	0.0	0.80	1.60	2.40	3.6	
			Placebo	43	42 (97.7)	2.28 (1.13)	0.0	1.60	2.40	3.00	4.6	
		Week 50	Tezepelumab	44	42 (95.5)	1.51 (0.96)	0.0	0.80	1.60	2.20	3.6	
			Placebo	43	42 (97.7)	2.20 (1.06)	0.0	1.60	2.40	3.00	4.4	
		Week 52	Tezepelumab	44	42 (95.5)	1.48 (0.97)	0.0	0.80	1.60	2.00	3.6	
			Placebo	43	42 (97.7)	2.23 (1.05)	0.2	1.60	2.40	3.00	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	44	41 (93.2)	-0.52 (0.69)	-3.0	-0.80	-0.40	0.00	0.4	-0.24 [-0.67, 0.19]
			Placebo	43	41 (95.3)	-0.35 (0.73)	-2.8	-0.80	-0.20	0.20	1.0	
		Week 4	Tezepelumab	44	41 (93.2)	-0.82 (0.90)	-3.0	-1.40	-0.80	-0.40	1.2	-0.37 [-0.81, 0.07]
			Placebo	43	41 (95.3)	-0.51 (0.78)	-2.6	-1.00	-0.60	0.00	0.8	
		Week 6	Tezepelumab	44	41 (93.2)	-0.85 (0.97)	-3.0	-1.40	-0.80	-0.20	1.2	-0.33 [-0.76, 0.11]
			Placebo	43	41 (95.3)	-0.55 (0.88)	-2.6	-1.00	-0.40	0.00	1.6	
		Week 8	Tezepelumab	44	41 (93.2)	-0.96 (1.01)	-3.0	-1.60	-1.00	-0.40	1.0	-0.38 [-0.82, 0.05]
			Placebo	43	42 (97.7)	-0.58 (0.98)	-2.8	-1.00	-0.60	0.20	1.0	
		Week 10	Tezepelumab	44	41 (93.2)	-1.02 (0.99)	-3.0	-1.60	-0.80	-0.40	1.0	-0.18 [-0.61, 0.25]
			Placebo	43	42 (97.7)	-0.84 (1.01)	-3.0	-1.60	-0.70	-0.40	2.6	
		Week 12	Tezepelumab	44	41 (93.2)	-1.13 (0.95)	-3.0	-1.60	-1.00	-0.80	1.2	-0.33 [-0.76, 0.11]
			Placebo	43	42 (97.7)	-0.81 (0.97)	-3.0	-1.20	-0.60	-0.20	1.6	
		Week 14	Tezepelumab	44	41 (93.2)	-1.22 (0.93)	-3.0	-1.80	-1.20	-0.80	1.2	-0.29 [-0.73, 0.14]
			Placebo	43	42 (97.7)	-0.94 (0.95)	-3.0	-1.40	-0.90	-0.40	1.4	
		Week 16	Tezepelumab	44	41 (93.2)	-1.07 (1.05)	-3.0	-1.60	-1.00	-0.80	1.8	-0.28 [-0.71, 0.15]
			Placebo	43	42 (97.7)	-0.77 (1.09)	-3.0	-1.40	-0.60	-0.20	2.6	
		Week 18	Tezepelumab	44	41 (93.2)	-1.20 (0.96)	-3.4	-1.80	-1.20	-0.60	1.2	-0.32 [-0.76, 0.11]
			Placebo	43	42 (97.7)	-0.86 (1.15)	-3.4	-1.40	-0.60	-0.20	2.6	
		Week 20	Tezepelumab	44	41 (93.2)	-1.06 (0.97)	-3.0	-1.60	-1.00	-0.40	1.0	-0.39 [-0.83, 0.04]
			Placebo	43	42 (97.7)	-0.64 (1.15)	-3.4	-1.40	-0.60	0.00	2.6	
		Week 22	Tezepelumab	44	41 (93.2)	-1.03 (0.97)	-3.4	-1.60	-0.80	-0.40	1.2	-0.28 [-0.71, 0.15]
			Placebo	43	42 (97.7)	-0.73 (1.13)	-3.4	-1.40	-0.60	0.00	2.6	
		Week 24	Tezepelumab	44	41 (93.2)	-0.98 (0.96)	-3.0	-1.60	-0.80	-0.20	1.4	-0.18 [-0.61, 0.25]
			Placebo	43	42 (97.7)	-0.79 (1.17)	-3.4	-1.40	-0.80	0.00	2.6	
		Week 26	Tezepelumab	44	41 (93.2)	-1.13 (1.00)	-3.2	-1.80	-1.00	-0.60	1.2	-0.29 [-0.72, 0.15]
			Placebo	43	42 (97.7)	-0.81 (1.20)	-3.0	-1.80	-0.80	0.00	2.6	
		Week 28	Tezepelumab	44	41 (93.2)	-1.01 (0.98)	-3.0	-1.60	-0.80	-0.20	1.0	-0.28 [-0.72, 0.15]
			Placebo	43	42 (97.7)	-0.70 (1.19)	-3.0	-1.60	-0.70	0.00	2.6	
		Week 30	Tezepelumab	44	42 (95.5)	-1.15 (1.02)	-3.2	-1.60	-1.20	-0.40	1.4	-0.38 [-0.81, 0.05]
			Placebo	43	42 (97.7)	-0.75 (1.11)	-3.4	-1.40	-0.80	0.00	2.6	
		Week 32	Tezepelumab	44	42 (95.5)	-1.23 (1.12)	-3.6	-2.20	-1.00	-0.60	1.8	-0.44 [-0.87, -0.01]
			Placebo	43	42 (97.7)	-0.70 (1.27)	-3.4	-1.40	-0.60	0.20	2.6	
		Week 34	Tezepelumab	44	42 (95.5)	-1.20 (1.11)	-3.8	-1.80	-1.10	-0.60	1.8	-0.26 [-0.69, 0.17]
			Placebo	43	42 (97.7)	-0.89 (1.28)	-3.4	-1.80	-0.80	0.00	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of the world	Change from baseline	Week 36	Tezepelumab	44	42 (95.5)	-1.23 (1.06)	-3.6	-2.00	-1.00	-0.60	1.4	-0.38 [-0.81, 0.05]
			Placebo	43	42 (97.7)	-0.79 (1.28)	-3.4	-1.40	-0.80	0.20	2.6	
		Week 38	Tezepelumab	44	42 (95.5)	-1.20 (1.12)	-3.8	-1.80	-1.00	-0.60	1.0	-0.24 [-0.67, 0.19]
			Placebo	43	42 (97.7)	-0.91 (1.26)	-3.4	-1.60	-1.00	0.20	2.6	
		Week 40	Tezepelumab	44	42 (95.5)	-1.12 (1.15)	-4.2	-1.60	-1.00	-0.60	1.2	-0.25 [-0.68, 0.18]
			Placebo	43	42 (97.7)	-0.82 (1.21)	-3.6	-1.60	-0.70	0.00	2.6	
		Week 42	Tezepelumab	44	42 (95.5)	-1.26 (1.07)	-3.6	-2.00	-1.10	-0.40	1.0	-0.43 [-0.86, 0.01]
			Placebo	43	42 (97.7)	-0.77 (1.20)	-3.6	-1.40	-0.80	0.20	2.6	
		Week 44	Tezepelumab	44	42 (95.5)	-1.17 (1.13)	-3.8	-1.60	-1.10	-0.60	1.2	-0.32 [-0.75, 0.11]
			Placebo	43	42 (97.7)	-0.80 (1.19)	-3.4	-1.60	-0.80	0.20	2.6	
		Week 46	Tezepelumab	44	42 (95.5)	-1.19 (1.06)	-3.6	-1.60	-1.10	-0.40	1.2	-0.32 [-0.75, 0.11]
			Placebo	43	42 (97.7)	-0.82 (1.22)	-3.2	-1.40	-1.00	0.00	2.6	
		Week 48	Tezepelumab	44	42 (95.5)	-1.13 (1.08)	-3.6	-2.00	-0.80	-0.40	1.2	-0.29 [-0.73, 0.14]
			Placebo	43	42 (97.7)	-0.78 (1.27)	-3.2	-1.60	-0.80	0.20	2.6	
		Week 50	Tezepelumab	44	42 (95.5)	-1.21 (1.09)	-3.8	-1.80	-1.00	-0.60	1.2	-0.31 [-0.74, 0.12]
			Placebo	43	42 (97.7)	-0.86 (1.17)	-3.2	-1.60	-0.90	-0.20	2.6	
		Week 52	Tezepelumab	44	42 (95.5)	-1.24 (1.12)	-3.8	-2.00	-1.00	-0.40	1.2	-0.35 [-0.78, 0.08]
			Placebo	43	42 (97.7)	-0.83 (1.18)	-3.2	-1.60	-0.90	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 2	Placebo	1	1 (100.0)	1.60	1.6	1.60	1.60	1.60	1.6	
		Week 4	Placebo	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
		Week 6	Placebo	1	1 (100.0)	1.80	1.8	1.80	1.80	1.80	1.8	
		Week 8	Placebo	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
		Week 10	Placebo	1	1 (100.0)	1.80	1.8	1.80	1.80	1.80	1.8	
		Week 12	Placebo	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
		Week 14	Placebo	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
		Week 16	Placebo	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
		Week 18	Placebo	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
		Week 20	Placebo	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
		Week 22	Placebo	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
		Week 24	Placebo	1	1 (100.0)	3.20	3.2	3.20	3.20	3.20	3.2	
		Week 26	Placebo	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
		Week 28	Placebo	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
		Week 30	Placebo	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
		Week 32	Placebo	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
		Week 34	Placebo	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	
		Week 36	Placebo	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
		Week 38	Placebo	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	
		Week 40	Placebo	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
		Week 42	Placebo	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
		Week 44	Placebo	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
		Week 46	Placebo	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
		Week 48	Placebo	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
		Week 50	Placebo	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	
		Week 52	Placebo	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 2	Placebo	1	1 (100.0)	0.20	0.2	0.20	0.20	0.20	0.2	
		Week 4	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 6	Placebo	1	1 (100.0)	0.40	0.4	0.40	0.40	0.40	0.4	
		Week 8	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 10	Placebo	1	1 (100.0)	0.40	0.4	0.40	0.40	0.40	0.4	
		Week 12	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 14	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 16	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 18	Placebo	1	1 (100.0)	0.60	0.6	0.60	0.60	0.60	0.6	
		Week 20	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 22	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 24	Placebo	1	1 (100.0)	1.80	1.8	1.80	1.80	1.80	1.8	
		Week 26	Placebo	1	1 (100.0)	0.80	0.8	0.80	0.80	0.80	0.8	
		Week 28	Placebo	1	1 (100.0)	0.80	0.8	0.80	0.80	0.80	0.8	
		Week 30	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 32	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 34	Placebo	1	1 (100.0)	1.60	1.6	1.60	1.60	1.60	1.6	
		Week 36	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 38	Placebo	1	1 (100.0)	1.60	1.6	1.60	1.60	1.60	1.6	
		Week 40	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 42	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 44	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 46	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 48	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 50	Placebo	1	1 (100.0)	1.60	1.6	1.60	1.60	1.60	1.6	
		Week 52	Placebo	1	1 (100.0)	1.60	1.6	1.60	1.60	1.60	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	39	39 (100.0)	2.63 (0.87)	0.0	2.20	2.60	3.20	4.6	
			Placebo	43	43 (100.0)	2.73 (0.78)	0.4	2.20	2.80	3.00	4.8	
		Week 2	Tezepelumab	39	38 (97.4)	1.84 (0.91)	0.0	1.20	1.90	2.40	3.8	
			Placebo	43	40 (93.0)	2.32 (1.00)	0.0	1.80	2.30	2.90	4.8	
		Week 4	Tezepelumab	39	38 (97.4)	1.47 (0.96)	0.0	0.40	1.50	2.20	3.0	
			Placebo	43	40 (93.0)	2.22 (0.90)	0.6	1.40	2.40	2.80	4.2	
		Week 6	Tezepelumab	39	38 (97.4)	1.40 (0.93)	0.0	0.60	1.60	2.20	3.2	
			Placebo	43	40 (93.0)	2.01 (0.98)	0.2	1.40	2.00	2.70	4.6	
		Week 8	Tezepelumab	39	38 (97.4)	1.31 (0.95)	0.0	0.60	1.20	2.00	3.0	
			Placebo	43	40 (93.0)	2.02 (1.00)	0.0	1.30	2.00	2.60	4.6	
		Week 10	Tezepelumab	39	38 (97.4)	1.24 (0.94)	0.0	0.60	1.10	2.00	3.4	
			Placebo	43	40 (93.0)	2.00 (1.01)	0.0	1.30	2.00	2.60	4.4	
		Week 12	Tezepelumab	39	38 (97.4)	0.96 (0.85)	0.0	0.20	0.80	1.60	2.8	
			Placebo	43	40 (93.0)	1.93 (1.01)	0.0	1.20	1.90	2.60	4.4	
		Week 14	Tezepelumab	39	38 (97.4)	0.85 (0.76)	0.0	0.20	0.80	1.20	3.0	
			Placebo	43	40 (93.0)	1.92 (1.07)	0.0	1.20	1.90	2.60	5.0	
		Week 16	Tezepelumab	39	38 (97.4)	1.18 (0.96)	0.0	0.60	1.00	1.80	3.0	
			Placebo	43	40 (93.0)	1.79 (1.16)	0.0	0.70	1.70	2.80	4.4	
		Week 18	Tezepelumab	39	38 (97.4)	0.96 (0.79)	0.0	0.20	1.00	1.60	3.0	
			Placebo	43	40 (93.0)	1.72 (1.06)	0.0	1.00	1.60	2.40	4.4	
		Week 20	Tezepelumab	39	38 (97.4)	1.06 (0.86)	0.0	0.40	1.00	1.40	3.0	
			Placebo	43	40 (93.0)	1.80 (1.18)	0.0	1.00	1.50	2.80	4.4	
		Week 22	Tezepelumab	39	38 (97.4)	1.11 (0.87)	0.0	0.40	1.00	2.00	3.0	
			Placebo	43	40 (93.0)	1.75 (1.22)	0.0	0.80	1.60	2.80	4.4	
		Week 24	Tezepelumab	39	38 (97.4)	1.09 (0.87)	0.0	0.20	1.00	1.80	2.8	
			Placebo	43	40 (93.0)	1.77 (1.15)	0.0	0.90	1.60	2.80	4.4	
		Week 26	Tezepelumab	39	38 (97.4)	1.05 (0.84)	0.0	0.20	1.00	1.60	3.6	
			Placebo	43	40 (93.0)	1.75 (1.12)	0.0	1.00	1.60	2.70	4.4	
		Week 28	Tezepelumab	39	38 (97.4)	1.13 (0.98)	0.0	0.20	1.00	2.00	3.6	
			Placebo	43	41 (95.3)	1.79 (1.23)	0.0	0.80	1.60	2.80	4.4	
		Week 30	Tezepelumab	39	39 (100.0)	1.09 (0.84)	0.0	0.60	1.00	1.60	3.0	
			Placebo	43	41 (95.3)	1.89 (1.22)	0.0	1.00	2.00	3.00	4.4	
		Week 32	Tezepelumab	39	39 (100.0)	1.05 (0.84)	0.0	0.40	1.00	1.40	2.8	
			Placebo	43	41 (95.3)	1.68 (1.24)	0.0	0.80	1.20	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
18.5 - < 25.0 kg/m**2	Absolute values	Week 34	Tezepelumab	39	39 (100.0)	0.96 (0.86)	0.0	0.00	1.00	1.20	3.6	
			Placebo	43	41 (95.3)	1.59 (1.21)	0.0	0.80	1.40	2.40	4.8	
		Week 36	Tezepelumab	39	39 (100.0)	1.06 (1.00)	0.0	0.00	1.00	1.60	5.0	
			Placebo	43	41 (95.3)	1.76 (1.27)	0.0	0.80	1.60	2.80	4.8	
		Week 38	Tezepelumab	39	39 (100.0)	1.03 (0.87)	0.0	0.20	1.00	1.60	3.0	
			Placebo	43	41 (95.3)	1.68 (1.33)	0.0	0.60	1.40	2.80	4.8	
		Week 40	Tezepelumab	39	39 (100.0)	1.03 (0.91)	0.0	0.00	0.80	2.00	2.6	
			Placebo	43	41 (95.3)	1.70 (1.20)	0.0	0.80	1.80	2.60	4.4	
		Week 42	Tezepelumab	39	39 (100.0)	0.97 (0.77)	0.0	0.20	1.00	1.60	2.4	
			Placebo	43	41 (95.3)	1.65 (1.26)	0.0	0.60	1.40	2.60	4.6	
		Week 44	Tezepelumab	39	39 (100.0)	0.97 (0.92)	0.0	0.00	0.80	1.60	3.8	
			Placebo	43	42 (97.7)	1.83 (1.19)	0.0	1.00	1.80	2.80	4.4	
		Week 46	Tezepelumab	39	39 (100.0)	0.90 (0.74)	0.0	0.00	0.80	1.40	2.2	
			Placebo	43	42 (97.7)	1.65 (1.18)	0.0	0.80	1.60	2.40	4.4	
		Week 48	Tezepelumab	39	39 (100.0)	1.05 (0.86)	0.0	0.20	1.00	1.80	2.8	
			Placebo	43	42 (97.7)	1.75 (1.21)	0.0	0.80	2.00	2.60	4.6	
		Week 50	Tezepelumab	39	39 (100.0)	1.00 (0.81)	0.0	0.20	1.00	1.80	2.8	
			Placebo	43	42 (97.7)	1.59 (1.09)	0.0	0.80	1.30	2.40	4.4	
		Week 52	Tezepelumab	39	39 (100.0)	1.02 (0.80)	0.0	0.20	1.00	1.80	2.8	
			Placebo	43	42 (97.7)	1.64 (1.09)	0.0	0.80	1.40	2.60	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	39	38 (97.4)	-0.76 (0.67)	-2.2	-1.20	-0.60	-0.20	0.4	-0.36 [-0.80, 0.09]
			Placebo	43	40 (93.0)	-0.49 (0.87)	-3.0	-0.90	-0.30	0.00	1.2	
		Week 4	Tezepelumab	39	38 (97.4)	-1.13 (1.06)	-3.8	-1.80	-0.90	-0.60	1.0	-0.57 [-1.03, -0.12]
			Placebo	43	40 (93.0)	-0.59 (0.80)	-2.2	-1.10	-0.40	0.00	0.8	
		Week 6	Tezepelumab	39	38 (97.4)	-1.20 (1.06)	-4.0	-1.60	-1.10	-0.40	0.4	-0.44 [-0.89, 0.01]
			Placebo	43	40 (93.0)	-0.80 (0.78)	-2.4	-1.40	-0.60	-0.20	0.4	
		Week 8	Tezepelumab	39	38 (97.4)	-1.29 (1.10)	-4.0	-2.00	-1.10	-0.40	0.8	-0.52 [-0.98, -0.07]
			Placebo	43	40 (93.0)	-0.79 (0.81)	-2.6	-1.20	-0.70	-0.20	1.0	
		Week 10	Tezepelumab	39	38 (97.4)	-1.36 (1.10)	-4.0	-2.00	-1.50	-0.60	1.0	-0.56 [-1.01, -0.10]
			Placebo	43	40 (93.0)	-0.81 (0.90)	-2.6	-1.40	-0.70	0.00	0.8	
		Week 12	Tezepelumab	39	38 (97.4)	-1.64 (1.00)	-4.0	-2.20	-1.80	-1.00	0.8	-0.81 [-1.27, -0.35]
			Placebo	43	40 (93.0)	-0.88 (0.89)	-3.0	-1.30	-0.70	-0.30	0.8	
		Week 14	Tezepelumab	39	38 (97.4)	-1.75 (1.07)	-4.0	-2.20	-2.00	-1.20	1.0	-0.86 [-1.32, -0.39]
			Placebo	43	40 (93.0)	-0.89 (0.92)	-3.2	-1.40	-1.00	-0.30	1.0	
		Week 16	Tezepelumab	39	38 (97.4)	-1.42 (1.12)	-4.0	-2.20	-1.40	-0.40	1.0	-0.38 [-0.83, 0.07]
			Placebo	43	40 (93.0)	-1.02 (1.00)	-3.6	-1.40	-1.00	-0.40	0.8	
		Week 18	Tezepelumab	39	38 (97.4)	-1.64 (1.06)	-4.0	-2.40	-1.50	-0.80	0.6	-0.56 [-1.01, -0.10]
			Placebo	43	40 (93.0)	-1.09 (0.92)	-3.2	-1.50	-0.90	-0.40	0.4	
		Week 20	Tezepelumab	39	38 (97.4)	-1.54 (1.02)	-4.0	-2.20	-1.60	-0.80	0.8	-0.51 [-0.97, -0.06]
			Placebo	43	40 (93.0)	-1.01 (1.07)	-3.6	-1.60	-0.80	-0.30	1.2	
		Week 22	Tezepelumab	39	38 (97.4)	-1.49 (1.17)	-4.0	-2.40	-1.60	-0.60	2.0	-0.39 [-0.84, 0.05]
			Placebo	43	40 (93.0)	-1.06 (1.06)	-3.2	-2.00	-1.00	-0.40	1.2	
		Week 24	Tezepelumab	39	38 (97.4)	-1.51 (0.97)	-4.0	-2.20	-1.80	-0.80	0.2	-0.47 [-0.92, -0.02]
			Placebo	43	40 (93.0)	-1.04 (1.04)	-3.8	-1.60	-1.00	-0.20	1.0	
		Week 26	Tezepelumab	39	38 (97.4)	-1.55 (0.99)	-4.0	-2.20	-1.50	-0.80	0.2	-0.47 [-0.92, -0.02]
			Placebo	43	40 (93.0)	-1.06 (1.07)	-4.2	-1.80	-1.10	-0.40	1.6	
		Week 28	Tezepelumab	39	38 (97.4)	-1.47 (1.00)	-4.0	-2.20	-1.40	-0.60	0.2	-0.48 [-0.93, -0.03]
			Placebo	43	41 (95.3)	-0.96 (1.13)	-4.2	-1.60	-1.00	-0.20	1.6	
		Week 30	Tezepelumab	39	39 (100.0)	-1.54 (1.03)	-3.8	-2.20	-1.40	-0.80	0.8	-0.64 [-1.09, -0.19]
			Placebo	43	41 (95.3)	-0.86 (1.10)	-3.2	-1.60	-1.00	-0.20	2.0	
		Week 32	Tezepelumab	39	39 (100.0)	-1.58 (0.98)	-4.0	-2.20	-1.60	-1.00	0.8	-0.49 [-0.94, -0.05]
			Placebo	43	41 (95.3)	-1.07 (1.10)	-3.6	-1.80	-1.00	-0.40	1.8	
		Week 34	Tezepelumab	39	39 (100.0)	-1.67 (0.97)	-4.0	-2.20	-1.80	-1.00	0.4	-0.48 [-0.93, -0.04]
			Placebo	43	41 (95.3)	-1.16 (1.13)	-4.2	-2.00	-1.20	-0.40	1.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
18.5 - < 25.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	39	39 (100.0)	-1.57 (1.15)	-4.0	-2.40	-1.60	-1.00	2.0	-0.50 [-0.94, -0.05]
			Placebo	43	41 (95.3)	-0.99 (1.19)	-3.6	-1.80	-1.00	-0.20	1.8	
		Week 38	Tezepelumab	39	39 (100.0)	-1.61 (1.04)	-4.0	-2.20	-1.60	-1.00	0.4	-0.47 [-0.92, -0.03]
			Placebo	43	41 (95.3)	-1.06 (1.23)	-4.2	-2.00	-1.00	-0.20	1.8	
		Week 40	Tezepelumab	39	39 (100.0)	-1.61 (1.07)	-4.0	-2.40	-1.60	-0.80	0.8	-0.52 [-0.97, -0.07]
			Placebo	43	41 (95.3)	-1.04 (1.09)	-4.2	-1.60	-1.00	-0.40	1.4	
		Week 42	Tezepelumab	39	39 (100.0)	-1.66 (1.07)	-4.0	-2.40	-1.60	-0.80	0.4	-0.50 [-0.94, -0.05]
			Placebo	43	41 (95.3)	-1.10 (1.17)	-4.2	-1.80	-1.20	-0.40	1.4	
		Week 44	Tezepelumab	39	39 (100.0)	-1.66 (1.16)	-4.0	-2.40	-1.60	-1.00	1.2	-0.66 [-1.11, -0.21]
			Placebo	43	42 (97.7)	-0.91 (1.12)	-4.2	-1.60	-0.90	-0.20	1.6	
		Week 46	Tezepelumab	39	39 (100.0)	-1.73 (1.01)	-4.0	-2.40	-1.60	-1.00	0.2	-0.58 [-1.02, -0.13]
			Placebo	43	42 (97.7)	-1.10 (1.16)	-4.2	-1.80	-1.10	-0.40	1.6	
		Week 48	Tezepelumab	39	39 (100.0)	-1.58 (1.02)	-4.0	-2.20	-1.60	-0.80	0.2	-0.55 [-0.99, -0.10]
			Placebo	43	42 (97.7)	-0.99 (1.14)	-3.8	-1.60	-1.00	-0.40	1.8	
		Week 50	Tezepelumab	39	39 (100.0)	-1.63 (0.99)	-4.0	-2.40	-1.60	-1.00	0.6	-0.48 [-0.92, -0.04]
			Placebo	43	42 (97.7)	-1.15 (1.01)	-4.2	-2.00	-1.00	-0.40	0.6	
		Week 52	Tezepelumab	39	39 (100.0)	-1.62 (0.99)	-4.0	-2.40	-1.60	-1.00	0.4	-0.51 [-0.96, -0.07]
			Placebo	43	42 (97.7)	-1.10 (1.00)	-4.2	-1.80	-1.00	-0.40	0.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	45	45 (100.0)	2.86 (0.95)	0.2	2.20	2.80	3.20	4.8	
			Placebo	47	47 (100.0)	2.80 (0.72)	1.4	2.40	3.00	3.20	4.6	
		Week 2	Tezepelumab	45	44 (97.8)	2.30 (1.04)	0.0	1.60	2.40	3.00	4.2	
			Placebo	47	44 (93.6)	2.38 (0.71)	0.6	2.00	2.60	3.00	3.4	
		Week 4	Tezepelumab	45	44 (97.8)	2.05 (1.08)	0.0	1.10	2.20	2.90	4.2	
			Placebo	47	44 (93.6)	2.36 (0.89)	0.4	1.80	2.60	3.00	4.2	
		Week 6	Tezepelumab	45	44 (97.8)	1.98 (0.99)	0.0	1.20	1.80	2.80	4.2	
			Placebo	47	45 (95.7)	2.30 (0.88)	0.4	1.80	2.40	3.00	4.2	
		Week 8	Tezepelumab	45	44 (97.8)	1.90 (1.13)	0.0	1.00	1.80	2.80	4.2	
			Placebo	47	45 (95.7)	2.13 (0.94)	0.2	1.60	2.40	2.80	4.0	
		Week 10	Tezepelumab	45	44 (97.8)	1.82 (1.17)	0.0	1.10	1.70	2.60	4.8	
			Placebo	47	45 (95.7)	2.17 (1.00)	0.0	1.40	2.40	2.80	5.2	
		Week 12	Tezepelumab	45	44 (97.8)	1.78 (1.24)	0.0	0.70	1.60	2.80	4.8	
			Placebo	47	45 (95.7)	2.18 (1.05)	0.0	1.40	2.20	3.00	4.4	
		Week 14	Tezepelumab	45	44 (97.8)	1.75 (1.25)	0.0	0.60	1.60	2.70	4.8	
			Placebo	47	45 (95.7)	2.06 (0.95)	0.0	1.40	2.00	2.80	5.0	
		Week 16	Tezepelumab	45	44 (97.8)	1.68 (1.25)	0.0	0.60	1.50	2.70	4.8	
			Placebo	47	45 (95.7)	2.23 (1.07)	0.0	1.60	2.40	3.00	5.0	
		Week 18	Tezepelumab	45	44 (97.8)	1.71 (1.18)	0.0	0.80	1.40	2.60	4.8	
			Placebo	47	45 (95.7)	2.18 (0.96)	0.0	1.80	2.20	2.80	5.0	
		Week 20	Tezepelumab	45	44 (97.8)	1.75 (1.23)	0.0	0.50	2.00	2.70	4.8	
			Placebo	47	45 (95.7)	2.20 (1.08)	0.0	1.40	2.40	3.00	5.0	
		Week 22	Tezepelumab	45	44 (97.8)	1.82 (1.20)	0.0	0.80	2.00	2.60	4.8	
			Placebo	47	45 (95.7)	2.20 (1.08)	0.0	1.40	2.40	3.00	5.0	
		Week 24	Tezepelumab	45	44 (97.8)	1.80 (1.32)	0.0	0.50	1.80	2.80	4.8	
			Placebo	47	45 (95.7)	2.15 (1.05)	0.0	1.60	2.40	3.00	4.0	
		Week 26	Tezepelumab	45	44 (97.8)	1.71 (1.19)	0.0	0.80	1.70	2.50	4.8	
			Placebo	47	45 (95.7)	2.15 (1.04)	0.0	1.40	2.40	3.00	4.0	
		Week 28	Tezepelumab	45	45 (100.0)	1.68 (1.25)	0.0	0.40	1.60	2.80	4.8	
			Placebo	47	45 (95.7)	2.19 (1.07)	0.0	1.40	2.40	2.80	4.0	
		Week 30	Tezepelumab	45	45 (100.0)	1.69 (1.21)	0.0	0.60	1.60	2.40	4.8	
			Placebo	47	45 (95.7)	2.14 (1.07)	0.0	1.20	2.20	3.00	4.2	
		Week 32	Tezepelumab	45	45 (100.0)	1.54 (1.29)	0.0	0.40	1.20	2.40	4.8	
			Placebo	47	45 (95.7)	2.10 (1.04)	0.0	1.60	2.40	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
25.0 - < 30.0 kg/m**2	Absolute values	Week 34	Tezepelumab	45	45 (100.0)	1.64 (1.30)	0.0	0.40	1.60	2.80	4.8	
			Placebo	47	45 (95.7)	2.13 (1.06)	0.0	1.20	2.40	3.00	4.0	
		Week 36	Tezepelumab	45	45 (100.0)	1.77 (1.24)	0.0	0.60	2.00	2.60	4.8	
			Placebo	47	45 (95.7)	2.23 (1.04)	0.0	1.40	2.60	3.00	4.4	
		Week 38	Tezepelumab	45	45 (100.0)	1.56 (1.23)	0.0	0.60	1.40	2.40	4.8	
			Placebo	47	45 (95.7)	2.06 (0.96)	0.0	1.40	2.00	2.80	4.0	
		Week 40	Tezepelumab	45	45 (100.0)	1.61 (1.26)	0.0	0.40	1.60	2.60	4.8	
			Placebo	47	45 (95.7)	2.13 (1.05)	0.0	1.40	2.00	3.00	4.4	
		Week 42	Tezepelumab	45	45 (100.0)	1.61 (1.29)	0.0	0.60	1.40	2.40	4.8	
			Placebo	47	45 (95.7)	2.14 (0.98)	0.0	1.60	2.20	2.80	4.6	
		Week 44	Tezepelumab	45	45 (100.0)	1.57 (1.20)	0.0	0.40	1.40	2.60	4.8	
			Placebo	47	45 (95.7)	2.08 (0.99)	0.0	1.20	2.20	2.80	4.2	
		Week 46	Tezepelumab	45	45 (100.0)	1.56 (1.24)	0.0	0.60	1.20	2.60	4.8	
			Placebo	47	45 (95.7)	2.00 (0.98)	0.0	1.40	2.00	2.80	4.0	
		Week 48	Tezepelumab	45	45 (100.0)	1.61 (1.27)	0.0	0.40	1.40	2.80	4.8	
			Placebo	47	45 (95.7)	1.98 (1.04)	0.0	1.20	2.00	2.80	4.0	
		Week 50	Tezepelumab	45	45 (100.0)	1.52 (1.22)	0.0	0.60	1.20	2.40	4.8	
			Placebo	47	45 (95.7)	2.16 (0.95)	0.0	1.40	2.40	2.80	4.0	
		Week 52	Tezepelumab	45	45 (100.0)	1.58 (1.21)	0.0	0.60	1.40	2.60	4.8	
			Placebo	47	45 (95.7)	2.16 (1.02)	0.0	1.60	2.40	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	45	44 (97.8)	-0.56 (0.77)	-3.0	-1.10	-0.40	0.00	0.8	-0.24 [-0.66, 0.18]
			Placebo	47	44 (93.6)	-0.38 (0.76)	-2.4	-0.80	-0.30	0.20	1.4	
		Week 4	Tezepelumab	45	44 (97.8)	-0.82 (1.04)	-3.0	-1.50	-0.80	-0.20	2.6	-0.43 [-0.85, -0.01]
			Placebo	47	44 (93.6)	-0.39 (0.95)	-3.0	-1.00	-0.20	0.20	1.6	
		Week 6	Tezepelumab	45	44 (97.8)	-0.89 (1.14)	-3.6	-1.40	-1.00	-0.20	2.6	-0.42 [-0.84, 0.00]
			Placebo	47	45 (95.7)	-0.44 (0.97)	-3.2	-0.80	-0.40	0.20	1.6	
		Week 8	Tezepelumab	45	44 (97.8)	-0.96 (1.15)	-3.2	-1.60	-1.00	-0.20	2.6	-0.33 [-0.75, 0.09]
			Placebo	47	45 (95.7)	-0.61 (0.98)	-3.6	-1.00	-0.60	0.20	1.0	
		Week 10	Tezepelumab	45	44 (97.8)	-1.04 (1.18)	-3.6	-1.50	-1.00	-0.60	2.6	-0.40 [-0.82, 0.02]
			Placebo	47	45 (95.7)	-0.58 (1.13)	-3.8	-1.00	-0.60	-0.20	2.6	
		Week 12	Tezepelumab	45	44 (97.8)	-1.08 (1.21)	-4.0	-1.70	-1.20	-0.40	2.6	-0.44 [-0.86, -0.02]
			Placebo	47	45 (95.7)	-0.57 (1.11)	-3.8	-1.00	-0.60	0.00	1.6	
		Week 14	Tezepelumab	45	44 (97.8)	-1.11 (1.24)	-4.2	-1.80	-1.20	-0.40	2.6	-0.37 [-0.79, 0.05]
			Placebo	47	45 (95.7)	-0.68 (1.03)	-3.4	-1.40	-0.60	0.00	2.4	
		Week 16	Tezepelumab	45	44 (97.8)	-1.18 (1.23)	-4.4	-2.00	-1.00	-0.50	2.6	-0.55 [-0.98, -0.13]
			Placebo	47	45 (95.7)	-0.52 (1.16)	-3.6	-1.20	-0.40	0.20	2.6	
		Week 18	Tezepelumab	45	44 (97.8)	-1.15 (1.30)	-4.4	-2.00	-1.20	-0.40	2.6	-0.49 [-0.91, -0.07]
			Placebo	47	45 (95.7)	-0.56 (1.09)	-3.6	-1.20	-0.60	0.00	2.6	
		Week 20	Tezepelumab	45	44 (97.8)	-1.11 (1.31)	-4.4	-1.80	-1.00	-0.30	2.6	-0.46 [-0.88, -0.04]
			Placebo	47	45 (95.7)	-0.54 (1.17)	-3.6	-1.20	-0.40	0.00	2.6	
		Week 22	Tezepelumab	45	44 (97.8)	-1.05 (1.32)	-4.4	-1.80	-0.90	-0.30	2.6	-0.40 [-0.82, 0.02]
			Placebo	47	45 (95.7)	-0.55 (1.16)	-3.8	-1.40	-0.60	0.20	2.6	
		Week 24	Tezepelumab	45	44 (97.8)	-1.07 (1.32)	-4.8	-2.00	-0.80	-0.20	2.6	-0.38 [-0.80, 0.04]
			Placebo	47	45 (95.7)	-0.60 (1.12)	-3.6	-1.20	-0.40	0.00	2.6	
		Week 26	Tezepelumab	45	44 (97.8)	-1.15 (1.35)	-4.4	-2.10	-1.00	-0.30	2.6	-0.45 [-0.87, -0.03]
			Placebo	47	45 (95.7)	-0.60 (1.13)	-3.4	-1.40	-0.40	0.20	2.6	
		Week 28	Tezepelumab	45	45 (100.0)	-1.17 (1.32)	-4.4	-2.20	-1.00	-0.20	2.6	-0.50 [-0.92, -0.08]
			Placebo	47	45 (95.7)	-0.56 (1.14)	-3.4	-1.20	-0.40	0.00	2.6	
		Week 30	Tezepelumab	45	45 (100.0)	-1.16 (1.34)	-4.4	-2.20	-1.00	-0.40	2.6	-0.44 [-0.86, -0.02]
			Placebo	47	45 (95.7)	-0.60 (1.20)	-3.4	-1.40	-0.80	0.20	2.6	
		Week 32	Tezepelumab	45	45 (100.0)	-1.32 (1.43)	-4.4	-2.40	-1.60	-0.40	2.6	-0.52 [-0.94, -0.10]
			Placebo	47	45 (95.7)	-0.64 (1.11)	-3.2	-1.40	-0.40	0.00	2.6	
		Week 34	Tezepelumab	45	45 (100.0)	-1.21 (1.39)	-4.4	-2.20	-1.40	-0.20	2.6	-0.47 [-0.89, -0.05]
			Placebo	47	45 (95.7)	-0.62 (1.12)	-3.2	-1.40	-0.60	0.00	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
25.0 - < 30.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	45	45 (100.0)	-1.08 (1.43)	-4.4	-2.40	-1.00	0.00	2.6	-0.44 [-0.86, -0.02]
			Placebo	47	45 (95.7)	-0.52 (1.10)	-3.0	-1.20	-0.40	0.00	2.6	
		Week 38	Tezepelumab	45	45 (100.0)	-1.29 (1.43)	-4.4	-2.20	-1.40	-0.20	2.6	-0.47 [-0.89, -0.05]
			Placebo	47	45 (95.7)	-0.68 (1.14)	-3.0	-1.40	-0.60	0.00	2.6	
		Week 40	Tezepelumab	45	45 (100.0)	-1.25 (1.48)	-4.4	-2.40	-1.20	-0.20	2.6	-0.48 [-0.90, -0.06]
			Placebo	47	45 (95.7)	-0.62 (1.12)	-3.0	-1.20	-0.60	0.00	2.6	
		Week 42	Tezepelumab	45	45 (100.0)	-1.25 (1.44)	-4.4	-2.20	-1.60	-0.40	2.6	-0.50 [-0.92, -0.08]
			Placebo	47	45 (95.7)	-0.60 (1.09)	-3.0	-1.20	-0.60	0.00	2.6	
		Week 44	Tezepelumab	45	45 (100.0)	-1.28 (1.42)	-4.4	-2.20	-1.40	-0.20	2.6	-0.49 [-0.91, -0.07]
			Placebo	47	45 (95.7)	-0.67 (1.07)	-3.0	-1.40	-0.60	0.00	2.6	
		Week 46	Tezepelumab	45	45 (100.0)	-1.29 (1.40)	-4.4	-2.20	-1.40	-0.20	2.6	-0.44 [-0.86, -0.02]
			Placebo	47	45 (95.7)	-0.75 (1.05)	-3.0	-1.40	-0.80	0.00	2.6	
		Week 48	Tezepelumab	45	45 (100.0)	-1.25 (1.45)	-4.4	-2.40	-1.20	-0.20	2.6	-0.38 [-0.79, 0.04]
			Placebo	47	45 (95.7)	-0.76 (1.10)	-3.0	-1.40	-0.80	-0.20	2.6	
		Week 50	Tezepelumab	45	45 (100.0)	-1.33 (1.42)	-4.4	-2.20	-1.60	-0.20	2.6	-0.59 [-1.01, -0.17]
			Placebo	47	45 (95.7)	-0.59 (1.06)	-3.0	-1.20	-0.40	0.00	2.6	
		Week 52	Tezepelumab	45	45 (100.0)	-1.28 (1.45)	-4.4	-2.20	-1.20	-0.20	2.6	-0.54 [-0.96, -0.12]
			Placebo	47	45 (95.7)	-0.58 (1.10)	-3.0	-1.40	-0.60	0.00	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	53	53 (100.0)	2.98 (0.69)	1.6	2.60	2.80	3.20	5.2	
			Placebo	47	47 (100.0)	2.95 (0.63)	1.6	2.60	3.00	3.40	5.0	
		Week 2	Tezepelumab	53	49 (92.5)	2.57 (0.82)	0.0	2.20	2.80	3.00	4.4	
			Placebo	47	40 (85.1)	2.58 (0.79)	0.4	2.20	2.70	3.00	5.0	
		Week 4	Tezepelumab	53	49 (92.5)	2.26 (0.86)	0.2	1.80	2.60	2.80	3.6	
			Placebo	47	40 (85.1)	2.31 (0.87)	0.2	1.80	2.40	2.80	4.4	
		Week 6	Tezepelumab	53	49 (92.5)	2.13 (0.96)	0.0	1.40	2.20	3.00	4.0	
			Placebo	47	40 (85.1)	2.28 (1.20)	0.2	1.50	2.20	2.80	6.0	
		Week 8	Tezepelumab	53	49 (92.5)	2.07 (1.03)	0.0	1.40	2.00	2.80	5.2	
			Placebo	47	41 (87.2)	2.26 (1.08)	0.0	1.80	2.40	3.00	5.0	
		Week 10	Tezepelumab	53	49 (92.5)	2.00 (0.90)	0.0	1.40	2.00	2.80	3.6	
			Placebo	47	42 (89.4)	2.04 (0.89)	0.2	1.40	2.10	3.00	3.6	
		Week 12	Tezepelumab	53	49 (92.5)	2.04 (0.83)	0.0	1.40	2.00	2.80	3.6	
			Placebo	47	42 (89.4)	1.85 (0.92)	0.0	1.00	2.00	2.40	3.6	
		Week 14	Tezepelumab	53	49 (92.5)	1.79 (0.85)	0.0	1.20	1.80	2.20	4.2	
			Placebo	47	42 (89.4)	1.80 (0.82)	0.0	1.00	1.80	2.60	3.4	
		Week 16	Tezepelumab	53	49 (92.5)	2.04 (0.93)	0.0	1.40	2.00	2.80	4.6	
			Placebo	47	42 (89.4)	2.12 (0.99)	0.0	1.40	2.00	3.00	5.0	
		Week 18	Tezepelumab	53	50 (94.3)	1.86 (0.82)	0.0	1.20	2.00	2.40	4.2	
			Placebo	47	42 (89.4)	1.93 (1.05)	0.0	1.40	1.90	2.60	4.8	
		Week 20	Tezepelumab	53	50 (94.3)	1.99 (0.91)	0.0	1.20	2.00	2.60	5.0	
			Placebo	47	42 (89.4)	1.98 (0.84)	0.0	1.60	2.10	2.60	3.2	
		Week 22	Tezepelumab	53	50 (94.3)	1.96 (0.78)	0.0	1.40	2.10	2.60	3.8	
			Placebo	47	42 (89.4)	1.88 (0.78)	0.0	1.40	2.00	2.60	3.4	
		Week 24	Tezepelumab	53	50 (94.3)	1.96 (0.83)	0.0	1.40	1.90	2.60	3.8	
			Placebo	47	42 (89.4)	1.89 (0.84)	0.0	1.20	2.00	2.60	3.4	
		Week 26	Tezepelumab	53	51 (96.2)	1.95 (0.89)	0.0	1.20	2.00	2.60	4.0	
			Placebo	47	42 (89.4)	1.78 (0.85)	0.0	1.00	1.80	2.40	3.8	
		Week 28	Tezepelumab	53	51 (96.2)	2.07 (0.86)	0.0	1.40	2.20	2.80	3.8	
			Placebo	47	42 (89.4)	1.87 (0.96)	0.0	1.00	2.00	2.60	4.0	
		Week 30	Tezepelumab	53	51 (96.2)	1.93 (0.89)	0.0	1.40	2.00	2.60	3.8	
			Placebo	47	43 (91.5)	1.76 (0.90)	0.0	1.00	1.80	2.40	3.4	
		Week 32	Tezepelumab	53	51 (96.2)	1.98 (0.84)	0.0	1.40	2.00	2.60	4.0	
			Placebo	47	43 (91.5)	1.86 (0.95)	0.0	1.20	1.80	2.60	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 30.0 kg/m**2	Absolute values	Week 34	Tezepelumab	53	51 (96.2)	2.00 (0.92)	0.0	1.20	2.00	2.80	4.2	
			Placebo	47	43 (91.5)	1.80 (0.91)	0.0	1.40	1.80	2.40	3.8	
		Week 36	Tezepelumab	53	51 (96.2)	2.02 (0.86)	0.0	1.20	2.20	2.60	3.6	
			Placebo	47	43 (91.5)	1.79 (0.95)	0.0	1.00	1.80	2.60	3.6	
		Week 38	Tezepelumab	53	51 (96.2)	1.98 (0.98)	0.0	1.20	2.00	2.60	4.6	
			Placebo	47	43 (91.5)	1.79 (0.87)	0.2	1.20	1.80	2.40	3.4	
		Week 40	Tezepelumab	53	51 (96.2)	2.01 (0.91)	0.0	1.40	2.00	2.80	3.8	
			Placebo	47	43 (91.5)	1.94 (1.04)	0.2	1.00	2.20	2.80	4.2	
		Week 42	Tezepelumab	53	51 (96.2)	1.93 (0.94)	0.0	1.40	1.80	2.60	4.0	
			Placebo	47	43 (91.5)	1.88 (0.85)	0.2	1.40	2.00	2.60	3.4	
		Week 44	Tezepelumab	53	51 (96.2)	2.05 (0.87)	0.0	1.20	2.20	2.80	3.8	
			Placebo	47	43 (91.5)	1.92 (1.04)	0.0	1.00	2.00	2.80	4.2	
		Week 46	Tezepelumab	53	51 (96.2)	2.03 (0.96)	0.0	1.20	2.00	2.80	3.8	
			Placebo	47	43 (91.5)	1.82 (0.91)	0.2	1.20	1.80	2.60	3.6	
		Week 48	Tezepelumab	53	51 (96.2)	2.04 (0.96)	0.0	1.40	2.00	2.80	4.2	
			Placebo	47	43 (91.5)	1.84 (0.95)	0.2	1.00	1.80	2.60	3.4	
		Week 50	Tezepelumab	53	51 (96.2)	1.91 (1.02)	0.0	1.00	1.80	2.60	4.2	
			Placebo	47	43 (91.5)	1.73 (0.90)	0.0	1.00	1.80	2.60	3.4	
		Week 52	Tezepelumab	53	51 (96.2)	1.93 (1.03)	0.0	1.20	1.80	2.60	4.4	
			Placebo	47	43 (91.5)	1.83 (0.97)	0.0	1.00	2.00	2.60	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	53	49 (92.5)	-0.43 (0.76)	-3.2	-0.60	-0.20	0.00	0.8	-0.05 [-0.47, 0.37]
			Placebo	47	40 (85.1)	-0.40 (0.67)	-1.8	-0.80	-0.40	0.00	1.2	
		Week 4	Tezepelumab	53	49 (92.5)	-0.75 (0.79)	-3.0	-1.20	-0.60	-0.20	0.8	-0.10 [-0.51, 0.32]
			Placebo	47	40 (85.1)	-0.67 (0.94)	-3.0	-1.40	-0.80	0.00	1.0	
		Week 6	Tezepelumab	53	49 (92.5)	-0.87 (0.90)	-3.2	-1.60	-1.00	0.00	1.2	-0.17 [-0.59, 0.25]
			Placebo	47	40 (85.1)	-0.70 (1.11)	-3.4	-1.50	-0.80	0.00	1.6	
		Week 8	Tezepelumab	53	49 (92.5)	-0.93 (1.00)	-3.2	-1.60	-1.00	-0.40	2.6	-0.20 [-0.62, 0.21]
			Placebo	47	41 (87.2)	-0.72 (1.08)	-3.0	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	53	49 (92.5)	-1.00 (0.88)	-3.2	-1.60	-1.00	-0.20	0.4	-0.05 [-0.46, 0.37]
			Placebo	47	42 (89.4)	-0.96 (0.99)	-3.2	-1.60	-1.00	-0.20	0.8	
		Week 12	Tezepelumab	53	49 (92.5)	-0.96 (0.89)	-3.2	-1.60	-1.00	-0.40	0.6	0.19 [-0.22, 0.61]
			Placebo	47	42 (89.4)	-1.15 (1.03)	-3.2	-2.00	-1.00	-0.40	0.8	
		Week 14	Tezepelumab	53	49 (92.5)	-1.21 (0.84)	-3.2	-1.60	-1.20	-0.80	0.4	-0.02 [-0.44, 0.39]
			Placebo	47	42 (89.4)	-1.19 (0.96)	-3.2	-1.80	-1.00	-0.40	0.8	
		Week 16	Tezepelumab	53	49 (92.5)	-0.96 (0.99)	-3.0	-1.40	-1.00	-0.40	1.8	-0.09 [-0.50, 0.32]
			Placebo	47	42 (89.4)	-0.87 (1.05)	-3.0	-1.40	-0.80	0.00	1.4	
		Week 18	Tezepelumab	53	50 (94.3)	-1.12 (0.82)	-3.2	-1.80	-1.00	-0.60	0.2	-0.06 [-0.47, 0.35]
			Placebo	47	42 (89.4)	-1.07 (1.14)	-3.4	-2.00	-1.20	-0.20	1.4	
		Week 20	Tezepelumab	53	50 (94.3)	-0.99 (0.89)	-3.0	-1.60	-1.00	-0.40	0.6	0.02 [-0.39, 0.43]
			Placebo	47	42 (89.4)	-1.01 (1.03)	-3.6	-1.40	-0.80	-0.40	1.0	
		Week 22	Tezepelumab	53	50 (94.3)	-1.02 (0.83)	-3.2	-1.40	-0.90	-0.60	0.6	0.11 [-0.30, 0.52]
			Placebo	47	42 (89.4)	-1.11 (0.89)	-3.4	-1.60	-1.10	-0.60	0.6	
		Week 24	Tezepelumab	53	50 (94.3)	-1.02 (0.84)	-3.2	-1.40	-1.00	-0.40	0.6	0.09 [-0.32, 0.50]
			Placebo	47	42 (89.4)	-1.10 (1.03)	-3.4	-1.60	-1.00	-0.40	0.8	
		Week 26	Tezepelumab	53	51 (96.2)	-1.01 (0.92)	-3.2	-1.60	-1.00	-0.40	0.6	0.22 [-0.19, 0.63]
			Placebo	47	42 (89.4)	-1.22 (1.01)	-3.0	-2.00	-1.20	-0.40	0.8	
		Week 28	Tezepelumab	53	51 (96.2)	-0.89 (0.98)	-3.2	-1.40	-0.80	-0.20	1.0	0.23 [-0.18, 0.64]
			Placebo	47	42 (89.4)	-1.13 (1.10)	-3.0	-1.80	-1.20	-0.20	1.2	
		Week 30	Tezepelumab	53	51 (96.2)	-1.03 (0.99)	-3.2	-1.40	-1.00	-0.40	2.0	0.20 [-0.20, 0.61]
			Placebo	47	43 (91.5)	-1.23 (1.03)	-3.4	-1.80	-1.20	-0.40	0.6	
		Week 32	Tezepelumab	53	51 (96.2)	-0.98 (0.86)	-3.0	-1.40	-1.00	-0.60	1.0	0.17 [-0.24, 0.57]
			Placebo	47	43 (91.5)	-1.14 (1.08)	-3.4	-1.80	-1.20	-0.40	0.8	
		Week 34	Tezepelumab	53	51 (96.2)	-0.96 (0.97)	-3.0	-1.60	-1.00	-0.40	2.2	0.24 [-0.17, 0.65]
			Placebo	47	43 (91.5)	-1.20 (0.98)	-3.4	-1.60	-1.20	-0.60	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 30.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	53	51 (96.2)	-0.94 (0.93)	-3.0	-1.60	-1.00	-0.20	1.6	0.26 [-0.15, 0.67]
			Placebo	47	43 (91.5)	-1.20 (1.09)	-3.6	-1.80	-1.20	-0.40	0.6	
		Week 38	Tezepelumab	53	51 (96.2)	-0.98 (1.00)	-3.0	-1.80	-1.00	-0.40	2.6	0.22 [-0.18, 0.63]
			Placebo	47	43 (91.5)	-1.20 (0.97)	-3.4	-1.60	-1.20	-0.60	1.2	
		Week 40	Tezepelumab	53	51 (96.2)	-0.95 (0.94)	-3.2	-1.40	-1.00	-0.40	1.8	0.10 [-0.31, 0.51]
			Placebo	47	43 (91.5)	-1.05 (1.12)	-3.6	-2.00	-1.00	-0.20	0.8	
		Week 42	Tezepelumab	53	51 (96.2)	-1.03 (0.96)	-3.2	-1.60	-1.00	-0.40	2.2	0.09 [-0.31, 0.50]
			Placebo	47	43 (91.5)	-1.12 (0.98)	-3.6	-1.60	-1.00	-0.20	0.6	
		Week 44	Tezepelumab	53	51 (96.2)	-0.91 (0.94)	-3.0	-1.40	-1.00	-0.20	1.6	0.15 [-0.25, 0.56]
			Placebo	47	43 (91.5)	-1.07 (1.18)	-3.4	-2.00	-1.00	0.00	0.8	
		Week 46	Tezepelumab	53	51 (96.2)	-0.93 (1.00)	-3.2	-1.40	-1.00	-0.20	1.8	0.24 [-0.16, 0.65]
			Placebo	47	43 (91.5)	-1.18 (1.03)	-3.2	-1.80	-1.20	-0.40	1.0	
		Week 48	Tezepelumab	53	51 (96.2)	-0.92 (0.98)	-3.0	-1.40	-1.00	-0.40	2.0	0.23 [-0.18, 0.64]
			Placebo	47	43 (91.5)	-1.16 (1.10)	-3.4	-1.60	-1.20	-0.40	1.2	
		Week 50	Tezepelumab	53	51 (96.2)	-1.05 (1.05)	-3.2	-1.80	-1.00	-0.40	2.0	0.21 [-0.20, 0.61]
			Placebo	47	43 (91.5)	-1.26 (1.00)	-3.6	-1.80	-1.40	-0.40	0.6	
		Week 52	Tezepelumab	53	51 (96.2)	-1.03 (1.05)	-3.2	-1.60	-1.00	-0.40	2.0	0.13 [-0.28, 0.53]
			Placebo	47	43 (91.5)	-1.17 (1.09)	-3.6	-1.80	-1.00	-0.40	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	2.82 (0.76)	1.0	2.40	2.80	3.20	5.0	
			Placebo	33	33 (100.0)	2.84 (0.60)	1.8	2.60	2.80	3.00	4.6	
		Week 2	Tezepelumab	27	27 (100.0)	2.39 (0.82)	0.6	1.60	2.40	2.80	3.8	
			Placebo	33	30 (90.9)	2.13 (0.80)	0.4	1.80	2.10	2.80	3.4	
		Week 4	Tezepelumab	27	27 (100.0)	2.04 (0.97)	0.2	1.00	2.20	2.80	3.6	
			Placebo	33	30 (90.9)	2.20 (0.93)	0.2	1.80	2.10	3.00	4.2	
		Week 6	Tezepelumab	27	27 (100.0)	1.86 (0.91)	0.0	1.40	1.80	2.60	3.6	
			Placebo	33	30 (90.9)	1.97 (0.99)	0.2	1.20	2.10	2.80	4.2	
		Week 8	Tezepelumab	27	27 (100.0)	2.04 (1.15)	0.0	1.20	2.00	2.80	5.2	
			Placebo	33	30 (90.9)	1.95 (1.01)	0.2	1.20	2.00	2.80	4.0	
		Week 10	Tezepelumab	27	27 (100.0)	1.90 (1.18)	0.0	1.20	1.80	2.80	4.8	
			Placebo	33	30 (90.9)	1.87 (0.86)	0.2	1.20	1.90	2.60	3.2	
		Week 12	Tezepelumab	27	27 (100.0)	1.76 (1.10)	0.0	1.00	1.60	2.60	4.8	
			Placebo	33	30 (90.9)	1.70 (0.97)	0.0	1.00	2.00	2.20	3.2	
		Week 14	Tezepelumab	27	27 (100.0)	1.56 (1.01)	0.0	1.00	1.20	2.20	4.8	
			Placebo	33	30 (90.9)	1.66 (0.91)	0.0	1.00	1.70	2.20	3.2	
		Week 16	Tezepelumab	27	27 (100.0)	1.85 (1.11)	0.0	1.00	1.80	2.60	4.8	
			Placebo	33	30 (90.9)	1.86 (1.02)	0.0	1.00	1.90	2.80	3.4	
		Week 18	Tezepelumab	27	27 (100.0)	1.70 (1.05)	0.0	1.00	1.60	2.40	4.8	
			Placebo	33	30 (90.9)	1.83 (1.14)	0.0	1.00	1.70	2.80	4.8	
		Week 20	Tezepelumab	27	27 (100.0)	1.81 (1.07)	0.0	1.00	1.80	2.60	4.8	
			Placebo	33	30 (90.9)	1.95 (0.92)	0.0	1.40	2.20	2.60	3.0	
		Week 22	Tezepelumab	27	27 (100.0)	1.76 (1.08)	0.0	1.00	1.80	2.60	4.8	
			Placebo	33	30 (90.9)	1.86 (0.95)	0.0	1.20	1.90	2.60	3.2	
		Week 24	Tezepelumab	27	27 (100.0)	1.79 (1.09)	0.0	1.00	1.80	2.60	4.8	
			Placebo	33	30 (90.9)	1.94 (1.04)	0.0	1.00	2.20	2.80	3.4	
		Week 26	Tezepelumab	27	27 (100.0)	1.78 (1.11)	0.0	1.00	1.60	2.80	4.8	
			Placebo	33	30 (90.9)	1.83 (1.16)	0.0	1.00	1.70	3.00	3.8	
		Week 28	Tezepelumab	27	27 (100.0)	1.80 (1.16)	0.0	1.00	1.80	2.60	4.8	
			Placebo	33	30 (90.9)	1.75 (1.18)	0.0	0.80	2.10	2.80	3.2	
		Week 30	Tezepelumab	27	27 (100.0)	1.79 (1.16)	0.0	1.00	1.80	2.60	4.8	
			Placebo	33	31 (93.9)	1.74 (1.06)	0.0	1.00	1.60	2.40	3.4	
		Week 32	Tezepelumab	27	27 (100.0)	1.80 (1.08)	0.0	1.00	1.40	2.60	4.8	
			Placebo	33	31 (93.9)	1.83 (1.07)	0.0	1.00	1.80	2.80	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 150 cells/uL	Absolute values	Week 34	Tezepelumab	27	27 (100.0)	1.74 (1.10)	0.0	1.00	1.20	2.80	4.8	
			Placebo	33	31 (93.9)	1.77 (1.10)	0.0	1.00	1.60	3.00	3.6	
		Week 36	Tezepelumab	27	27 (100.0)	1.78 (1.07)	0.0	1.00	1.60	2.40	4.8	
			Placebo	33	31 (93.9)	1.87 (1.06)	0.0	1.00	2.20	2.80	3.2	
		Week 38	Tezepelumab	27	27 (100.0)	1.73 (1.05)	0.0	1.00	1.40	2.40	4.8	
			Placebo	33	31 (93.9)	1.80 (1.05)	0.0	1.00	1.80	2.80	3.4	
		Week 40	Tezepelumab	27	27 (100.0)	1.90 (1.17)	0.0	1.00	1.80	2.80	4.8	
			Placebo	33	31 (93.9)	1.87 (1.17)	0.0	1.00	1.80	3.00	4.2	
		Week 42	Tezepelumab	27	27 (100.0)	1.75 (1.10)	0.0	1.00	1.80	2.20	4.8	
			Placebo	33	31 (93.9)	1.82 (1.02)	0.0	1.00	2.20	2.60	3.2	
		Week 44	Tezepelumab	27	27 (100.0)	1.96 (1.10)	0.0	1.20	2.00	2.80	4.8	
			Placebo	33	31 (93.9)	1.91 (1.24)	0.0	0.60	2.60	3.00	4.2	
		Week 46	Tezepelumab	27	27 (100.0)	1.82 (1.13)	0.0	1.00	2.00	2.40	4.8	
			Placebo	33	31 (93.9)	1.75 (1.11)	0.0	0.60	2.00	2.80	3.4	
		Week 48	Tezepelumab	27	27 (100.0)	1.81 (1.12)	0.0	1.00	1.80	2.40	4.8	
			Placebo	33	31 (93.9)	1.81 (1.17)	0.0	0.60	2.20	2.80	3.4	
		Week 50	Tezepelumab	27	27 (100.0)	1.74 (1.10)	0.0	0.80	1.80	2.20	4.8	
			Placebo	33	31 (93.9)	1.81 (1.10)	0.0	1.00	1.80	2.80	3.8	
		Week 52	Tezepelumab	27	27 (100.0)	1.77 (1.10)	0.0	0.80	1.80	2.60	4.8	
			Placebo	33	31 (93.9)	1.92 (1.11)	0.0	1.00	2.20	2.80	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	27	27 (100.0)	-0.43 (0.73)	-2.6	-0.80	-0.20	0.20	0.4	0.26 [-0.26, 0.79]
			Placebo	33	30 (90.9)	-0.63 (0.76)	-2.4	-1.00	-0.80	-0.20	1.2	
		Week 4	Tezepelumab	27	27 (100.0)	-0.79 (0.88)	-3.0	-1.40	-0.60	-0.20	0.6	-0.26 [-0.78, 0.27]
			Placebo	33	30 (90.9)	-0.56 (0.88)	-2.4	-1.00	-0.60	0.00	1.4	
		Week 6	Tezepelumab	27	27 (100.0)	-0.96 (0.85)	-3.2	-1.60	-1.00	-0.20	0.6	-0.20 [-0.72, 0.33]
			Placebo	33	30 (90.9)	-0.79 (0.95)	-2.6	-1.40	-0.80	-0.20	1.4	
		Week 8	Tezepelumab	27	27 (100.0)	-0.78 (1.13)	-3.2	-1.20	-0.60	-0.40	2.6	0.03 [-0.49, 0.55]
			Placebo	33	30 (90.9)	-0.81 (1.04)	-2.8	-1.40	-0.80	0.00	1.0	
		Week 10	Tezepelumab	27	27 (100.0)	-0.93 (1.03)	-3.2	-1.60	-1.00	0.20	0.6	-0.04 [-0.56, 0.48]
			Placebo	33	30 (90.9)	-0.89 (0.82)	-2.6	-1.60	-0.70	-0.20	0.6	
		Week 12	Tezepelumab	27	27 (100.0)	-1.06 (0.90)	-2.6	-1.80	-1.00	-0.20	0.6	0.00 [-0.52, 0.52]
			Placebo	33	30 (90.9)	-1.06 (0.99)	-3.0	-1.40	-0.80	-0.60	0.8	
		Week 14	Tezepelumab	27	27 (100.0)	-1.26 (0.89)	-3.2	-2.20	-1.20	-0.80	0.6	-0.17 [-0.69, 0.35]
			Placebo	33	30 (90.9)	-1.10 (0.94)	-3.0	-1.60	-1.00	-0.60	0.8	
		Week 16	Tezepelumab	27	27 (100.0)	-0.97 (0.99)	-2.8	-1.80	-1.00	-0.20	0.6	-0.07 [-0.59, 0.45]
			Placebo	33	30 (90.9)	-0.90 (1.07)	-3.0	-1.40	-1.00	-0.20	1.4	
		Week 18	Tezepelumab	27	27 (100.0)	-1.13 (0.92)	-3.2	-1.80	-1.00	-0.60	0.6	-0.19 [-0.71, 0.33]
			Placebo	33	30 (90.9)	-0.93 (1.11)	-3.0	-1.60	-0.90	-0.20	1.4	
		Week 20	Tezepelumab	27	27 (100.0)	-1.01 (0.97)	-2.8	-1.80	-1.00	-0.20	0.6	-0.21 [-0.74, 0.31]
			Placebo	33	30 (90.9)	-0.81 (0.92)	-3.0	-1.00	-0.80	-0.20	0.8	
		Week 22	Tezepelumab	27	27 (100.0)	-1.07 (1.00)	-3.2	-2.00	-1.00	-0.40	0.6	-0.18 [-0.70, 0.34]
			Placebo	33	30 (90.9)	-0.90 (0.88)	-2.8	-1.60	-0.90	-0.20	0.6	
		Week 24	Tezepelumab	27	27 (100.0)	-1.04 (0.93)	-3.2	-1.80	-1.00	-0.20	0.6	-0.21 [-0.74, 0.31]
			Placebo	33	30 (90.9)	-0.82 (1.09)	-3.0	-1.40	-0.90	0.00	0.8	
		Week 26	Tezepelumab	27	27 (100.0)	-1.04 (1.00)	-3.2	-2.00	-1.00	-0.40	0.6	-0.11 [-0.63, 0.41]
			Placebo	33	30 (90.9)	-0.93 (1.12)	-3.0	-1.80	-0.90	0.20	0.8	
		Week 28	Tezepelumab	27	27 (100.0)	-1.02 (1.03)	-3.2	-1.80	-1.00	0.00	0.6	-0.01 [-0.53, 0.51]
			Placebo	33	30 (90.9)	-1.01 (1.15)	-3.0	-2.00	-0.90	-0.20	1.2	
		Week 30	Tezepelumab	27	27 (100.0)	-1.03 (1.07)	-3.2	-2.20	-1.00	-0.40	1.0	-0.00 [-0.52, 0.51]
			Placebo	33	31 (93.9)	-1.03 (0.93)	-3.0	-1.60	-1.00	-0.40	0.4	
		Week 32	Tezepelumab	27	27 (100.0)	-1.02 (0.98)	-2.8	-1.80	-1.00	-0.40	1.2	-0.08 [-0.60, 0.43]
			Placebo	33	31 (93.9)	-0.94 (0.98)	-3.0	-1.60	-1.00	-0.20	0.6	
		Week 34	Tezepelumab	27	27 (100.0)	-1.08 (0.93)	-2.4	-2.00	-1.00	-0.40	0.6	-0.09 [-0.60, 0.43]
			Placebo	33	31 (93.9)	-1.00 (0.98)	-2.8	-1.60	-1.00	-0.20	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 150 cells/uL	Change from baseline	Week 36	Tezepelumab	27	27 (100.0)	-1.04 (0.96)	-2.8	-1.80	-1.00	-0.40	0.6	-0.15 [-0.67, 0.37]
			Placebo	33	31 (93.9)	-0.90 (1.01)	-3.2	-1.40	-0.80	-0.20	0.8	
		Week 38	Tezepelumab	27	27 (100.0)	-1.09 (0.90)	-2.4	-1.80	-1.00	-0.40	0.6	-0.13 [-0.64, 0.39]
			Placebo	33	31 (93.9)	-0.97 (1.01)	-3.0	-1.60	-1.00	-0.20	1.2	
		Week 40	Tezepelumab	27	27 (100.0)	-0.93 (1.03)	-3.2	-1.80	-0.80	-0.20	0.6	-0.03 [-0.54, 0.49]
			Placebo	33	31 (93.9)	-0.90 (1.08)	-3.0	-1.60	-1.00	0.20	0.8	
		Week 42	Tezepelumab	27	27 (100.0)	-1.07 (0.96)	-3.2	-1.80	-1.00	-0.40	0.6	-0.13 [-0.65, 0.38]
			Placebo	33	31 (93.9)	-0.95 (0.92)	-3.0	-1.60	-0.80	-0.20	0.8	
		Week 44	Tezepelumab	27	27 (100.0)	-0.87 (0.98)	-2.8	-1.80	-0.80	-0.20	0.6	-0.01 [-0.52, 0.51]
			Placebo	33	31 (93.9)	-0.86 (1.18)	-3.0	-1.80	-0.80	0.20	0.8	
		Week 46	Tezepelumab	27	27 (100.0)	-1.00 (0.98)	-3.2	-1.80	-1.00	-0.20	0.6	0.02 [-0.50, 0.53]
			Placebo	33	31 (93.9)	-1.02 (1.05)	-3.0	-1.80	-1.00	-0.40	1.0	
		Week 48	Tezepelumab	27	27 (100.0)	-1.01 (0.96)	-2.8	-1.80	-1.00	-0.40	0.6	-0.04 [-0.56, 0.47]
			Placebo	33	31 (93.9)	-0.96 (1.11)	-3.0	-1.80	-0.80	-0.20	1.2	
		Week 50	Tezepelumab	27	27 (100.0)	-1.08 (0.98)	-3.2	-1.80	-1.00	-0.40	0.6	-0.12 [-0.64, 0.40]
			Placebo	33	31 (93.9)	-0.96 (1.04)	-3.0	-1.80	-1.00	-0.20	1.2	
		Week 52	Tezepelumab	27	27 (100.0)	-1.05 (0.99)	-3.2	-1.80	-1.00	-0.40	0.6	-0.20 [-0.72, 0.32]
			Placebo	33	31 (93.9)	-0.85 (1.08)	-3.0	-1.80	-1.00	0.00	1.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	109	109 (100.0)	2.85 (0.87)	0.0	2.40	2.80	3.20	5.2	
			Placebo	105	105 (100.0)	2.81 (0.76)	0.4	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	109	103 (94.5)	2.23 (1.01)	0.0	1.60	2.40	3.00	4.4	
			Placebo	105	95 (90.5)	2.51 (0.83)	0.0	2.00	2.60	3.00	5.0	
		Week 4	Tezepelumab	109	103 (94.5)	1.95 (1.03)	0.0	1.20	2.20	2.80	4.2	
			Placebo	105	95 (90.5)	2.33 (0.86)	0.2	1.80	2.40	2.80	4.4	
		Week 6	Tezepelumab	109	103 (94.5)	1.86 (1.03)	0.0	1.20	1.80	2.60	4.2	
			Placebo	105	96 (91.4)	2.27 (1.02)	0.2	1.60	2.20	2.80	6.0	
		Week 8	Tezepelumab	109	103 (94.5)	1.72 (1.06)	0.0	1.00	1.60	2.60	4.2	
			Placebo	105	97 (92.4)	2.20 (1.00)	0.0	1.60	2.40	2.80	5.0	
		Week 10	Tezepelumab	109	103 (94.5)	1.67 (1.02)	0.0	0.80	1.60	2.40	4.2	
			Placebo	105	98 (93.3)	2.13 (0.98)	0.0	1.40	2.20	2.80	5.2	
		Week 12	Tezepelumab	109	103 (94.5)	1.61 (1.09)	0.0	0.60	1.60	2.60	4.2	
			Placebo	105	98 (93.3)	2.08 (0.99)	0.0	1.20	2.20	2.80	4.4	
		Week 14	Tezepelumab	109	103 (94.5)	1.49 (1.08)	0.0	0.60	1.40	2.40	4.2	
			Placebo	105	98 (93.3)	2.02 (0.95)	0.0	1.40	2.00	2.60	5.0	
		Week 16	Tezepelumab	109	103 (94.5)	1.62 (1.11)	0.0	0.80	1.40	2.60	4.6	
			Placebo	105	98 (93.3)	2.12 (1.09)	0.0	1.40	2.10	3.00	5.0	
		Week 18	Tezepelumab	109	104 (95.4)	1.52 (1.01)	0.0	0.80	1.40	2.20	4.2	
			Placebo	105	98 (93.3)	1.99 (0.99)	0.0	1.40	2.00	2.60	5.0	
		Week 20	Tezepelumab	109	104 (95.4)	1.60 (1.09)	0.0	0.80	1.60	2.40	5.0	
			Placebo	105	98 (93.3)	2.02 (1.08)	0.0	1.20	2.10	2.80	5.0	
		Week 22	Tezepelumab	109	104 (95.4)	1.65 (1.02)	0.0	0.80	1.60	2.40	4.2	
			Placebo	105	98 (93.3)	1.99 (1.08)	0.0	1.20	2.00	2.80	5.0	
		Week 24	Tezepelumab	109	104 (95.4)	1.63 (1.10)	0.0	0.80	1.60	2.40	4.8	
			Placebo	105	98 (93.3)	1.96 (1.03)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	109	105 (96.3)	1.57 (1.04)	0.0	0.80	1.60	2.40	4.2	
			Placebo	105	98 (93.3)	1.92 (0.97)	0.0	1.20	1.80	2.80	4.4	
		Week 28	Tezepelumab	109	106 (97.2)	1.65 (1.09)	0.0	0.80	1.60	2.40	4.2	
			Placebo	105	99 (94.3)	2.02 (1.06)	0.0	1.00	2.20	2.80	4.4	
		Week 30	Tezepelumab	109	107 (98.2)	1.57 (1.02)	0.0	0.80	1.60	2.20	4.2	
			Placebo	105	99 (94.3)	2.00 (1.07)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	109	107 (98.2)	1.52 (1.07)	0.0	0.60	1.40	2.40	4.2	
			Placebo	105	99 (94.3)	1.91 (1.09)	0.0	1.00	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 150 cells/uL	Absolute values	Week 34	Tezepelumab	109	107 (98.2)	1.55 (1.13)	0.0	0.60	1.40	2.40	4.2	
			Placebo	105	99 (94.3)	1.88 (1.08)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	109	107 (98.2)	1.63 (1.12)	0.0	0.80	1.60	2.40	5.0	
			Placebo	105	99 (94.3)	1.96 (1.12)	0.0	1.00	2.00	2.80	4.8	
		Week 38	Tezepelumab	109	107 (98.2)	1.53 (1.12)	0.0	0.60	1.40	2.40	4.6	
			Placebo	105	99 (94.3)	1.88 (1.08)	0.0	1.00	2.00	2.60	4.8	
		Week 40	Tezepelumab	109	107 (98.2)	1.52 (1.09)	0.0	0.60	1.60	2.40	4.2	
			Placebo	105	99 (94.3)	1.96 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	109	107 (98.2)	1.51 (1.09)	0.0	0.60	1.40	2.20	4.6	
			Placebo	105	99 (94.3)	1.93 (1.06)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	109	107 (98.2)	1.49 (1.08)	0.0	0.60	1.40	2.40	4.2	
			Placebo	105	100 (95.2)	1.97 (1.02)	0.0	1.10	2.00	2.70	4.4	
		Week 46	Tezepelumab	109	107 (98.2)	1.49 (1.09)	0.0	0.80	1.20	2.40	4.2	
			Placebo	105	100 (95.2)	1.86 (1.00)	0.0	1.20	2.00	2.60	4.4	
		Week 48	Tezepelumab	109	107 (98.2)	1.56 (1.11)	0.0	0.60	1.40	2.40	4.2	
			Placebo	105	100 (95.2)	1.89 (1.04)	0.0	1.00	2.00	2.60	4.6	
		Week 50	Tezepelumab	109	107 (98.2)	1.47 (1.09)	0.0	0.80	1.20	2.20	4.2	
			Placebo	105	100 (95.2)	1.85 (0.98)	0.0	1.00	2.00	2.60	4.4	
		Week 52	Tezepelumab	109	107 (98.2)	1.50 (1.09)	0.0	0.60	1.40	2.20	4.4	
			Placebo	105	100 (95.2)	1.88 (1.03)	0.0	1.00	2.00	2.60	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	109	103 (94.5)	-0.61 (0.75)	-3.2	-1.00	-0.40	-0.20	0.8	-0.36 [-0.64, -0.07]
			Placebo	105	95 (90.5)	-0.35 (0.76)	-3.0	-0.80	-0.20	0.20	1.4	
		Week 4	Tezepelumab	109	103 (94.5)	-0.90 (0.99)	-3.8	-1.40	-0.80	-0.20	2.6	-0.39 [-0.67, -0.11]
			Placebo	105	95 (90.5)	-0.52 (0.92)	-3.0	-1.20	-0.40	0.20	1.6	
		Week 6	Tezepelumab	109	103 (94.5)	-0.98 (1.08)	-4.0	-1.60	-1.00	-0.20	2.6	-0.39 [-0.67, -0.11]
			Placebo	105	96 (91.4)	-0.58 (0.97)	-3.4	-1.20	-0.60	0.00	1.6	
		Week 8	Tezepelumab	109	103 (94.5)	-1.12 (1.07)	-4.0	-1.80	-1.20	-0.40	2.6	-0.46 [-0.74, -0.18]
			Placebo	105	97 (92.4)	-0.65 (0.95)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	109	103 (94.5)	-1.17 (1.07)	-4.0	-1.80	-1.20	-0.60	2.6	-0.42 [-0.70, -0.14]
			Placebo	105	98 (93.3)	-0.73 (1.08)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	109	103 (94.5)	-1.24 (1.11)	-4.0	-2.00	-1.20	-0.60	2.6	-0.42 [-0.70, -0.14]
			Placebo	105	98 (93.3)	-0.78 (1.06)	-3.8	-1.40	-0.60	0.00	1.6	
		Week 14	Tezepelumab	109	103 (94.5)	-1.35 (1.13)	-4.2	-2.00	-1.40	-0.60	2.6	-0.48 [-0.76, -0.20]
			Placebo	105	98 (93.3)	-0.84 (1.02)	-3.4	-1.40	-0.80	-0.20	2.4	
		Week 16	Tezepelumab	109	103 (94.5)	-1.22 (1.16)	-4.4	-2.00	-1.20	-0.60	2.6	-0.43 [-0.71, -0.15]
			Placebo	105	98 (93.3)	-0.74 (1.11)	-3.6	-1.40	-0.60	0.00	2.6	
		Week 18	Tezepelumab	109	104 (95.4)	-1.32 (1.13)	-4.4	-2.00	-1.20	-0.70	2.6	-0.41 [-0.69, -0.13]
			Placebo	105	98 (93.3)	-0.87 (1.08)	-3.6	-1.40	-0.70	-0.20	2.6	
		Week 20	Tezepelumab	109	104 (95.4)	-1.23 (1.13)	-4.4	-2.00	-1.20	-0.60	2.6	-0.35 [-0.63, -0.07]
			Placebo	105	98 (93.3)	-0.83 (1.17)	-3.6	-1.60	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	109	104 (95.4)	-1.19 (1.16)	-4.4	-1.80	-1.10	-0.50	2.6	-0.28 [-0.55, 0.00]
			Placebo	105	98 (93.3)	-0.87 (1.15)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 24	Tezepelumab	109	104 (95.4)	-1.21 (1.11)	-4.8	-2.00	-1.20	-0.40	2.6	-0.28 [-0.55, 0.00]
			Placebo	105	98 (93.3)	-0.90 (1.11)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 26	Tezepelumab	109	105 (96.3)	-1.26 (1.14)	-4.4	-2.00	-1.20	-0.40	2.6	-0.28 [-0.56, -0.01]
			Placebo	105	98 (93.3)	-0.94 (1.10)	-4.2	-1.60	-1.20	0.00	2.6	
		Week 28	Tezepelumab	109	106 (97.2)	-1.18 (1.16)	-4.4	-2.00	-1.20	-0.40	2.6	-0.32 [-0.59, -0.04]
			Placebo	105	99 (94.3)	-0.81 (1.15)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 30	Tezepelumab	109	107 (98.2)	-1.27 (1.16)	-4.4	-2.20	-1.20	-0.60	2.6	-0.37 [-0.65, -0.09]
			Placebo	105	99 (94.3)	-0.83 (1.21)	-3.4	-1.60	-0.80	-0.20	2.6	
		Week 32	Tezepelumab	109	107 (98.2)	-1.32 (1.17)	-4.4	-2.20	-1.20	-0.60	2.6	-0.34 [-0.61, -0.06]
			Placebo	105	99 (94.3)	-0.92 (1.17)	-3.6	-1.80	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	109	107 (98.2)	-1.29 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.28 [-0.56, -0.01]
			Placebo	105	99 (94.3)	-0.95 (1.17)	-4.2	-1.60	-1.00	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 150 cells/uL	Change from baseline	Week 36	Tezepelumab	109	107 (98.2)	-1.20 (1.26)	-4.4	-2.20	-1.20	-0.20	2.6	-0.27 [-0.54, 0.01]
			Placebo	105	99 (94.3)	-0.87 (1.22)	-3.6	-1.60	-1.00	0.00	2.6	
		Week 38	Tezepelumab	109	107 (98.2)	-1.31 (1.26)	-4.4	-2.20	-1.20	-0.40	2.6	-0.29 [-0.56, -0.01]
			Placebo	105	99 (94.3)	-0.96 (1.20)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 40	Tezepelumab	109	107 (98.2)	-1.31 (1.23)	-4.4	-2.20	-1.20	-0.60	2.6	-0.37 [-0.64, -0.09]
			Placebo	105	99 (94.3)	-0.87 (1.16)	-4.2	-1.60	-0.80	-0.20	2.6	
		Week 42	Tezepelumab	109	107 (98.2)	-1.33 (1.24)	-4.4	-2.20	-1.40	-0.60	2.6	-0.35 [-0.63, -0.08]
			Placebo	105	99 (94.3)	-0.90 (1.17)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	109	107 (98.2)	-1.35 (1.25)	-4.4	-2.20	-1.20	-0.60	2.6	-0.40 [-0.68, -0.13]
			Placebo	105	100 (95.2)	-0.87 (1.13)	-4.2	-1.50	-0.90	-0.20	2.6	
		Week 46	Tezepelumab	109	107 (98.2)	-1.35 (1.24)	-4.4	-2.20	-1.40	-0.60	2.6	-0.32 [-0.59, -0.04]
			Placebo	105	100 (95.2)	-0.98 (1.12)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	109	107 (98.2)	-1.27 (1.24)	-4.4	-2.20	-1.20	-0.40	2.6	-0.27 [-0.55, 0.00]
			Placebo	105	100 (95.2)	-0.95 (1.14)	-3.8	-1.60	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	109	107 (98.2)	-1.36 (1.24)	-4.4	-2.20	-1.40	-0.60	2.6	-0.33 [-0.60, -0.06]
			Placebo	105	100 (95.2)	-0.98 (1.10)	-4.2	-1.60	-1.00	-0.30	2.6	
		Week 52	Tezepelumab	109	107 (98.2)	-1.33 (1.25)	-4.4	-2.20	-1.20	-0.40	2.6	-0.32 [-0.60, -0.05]
			Placebo	105	100 (95.2)	-0.95 (1.12)	-4.2	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	69	69 (100.0)	2.88 (0.78)	0.4	2.40	2.80	3.20	5.2	
			Placebo	72	72 (100.0)	2.76 (0.72)	0.4	2.20	2.80	3.20	4.8	
		Week 2	Tezepelumab	69	64 (92.8)	2.37 (0.93)	0.0	1.70	2.60	2.90	4.2	
			Placebo	72	62 (86.1)	2.30 (0.78)	0.4	2.00	2.40	2.80	4.8	
		Week 4	Tezepelumab	69	64 (92.8)	2.09 (1.01)	0.0	1.30	2.30	2.80	4.2	
			Placebo	72	62 (86.1)	2.11 (0.88)	0.2	1.60	2.20	2.80	4.2	
		Week 6	Tezepelumab	69	64 (92.8)	1.97 (1.00)	0.0	1.40	2.00	2.80	4.2	
			Placebo	72	62 (86.1)	1.99 (1.00)	0.2	1.40	2.00	2.60	5.0	
		Week 8	Tezepelumab	69	64 (92.8)	1.96 (1.12)	0.0	1.20	2.00	2.80	5.2	
			Placebo	72	63 (87.5)	1.94 (0.97)	0.0	1.40	2.00	2.60	4.6	
		Week 10	Tezepelumab	69	64 (92.8)	1.83 (1.09)	0.0	1.20	1.70	2.60	4.8	
			Placebo	72	63 (87.5)	1.92 (0.91)	0.2	1.20	1.80	2.40	4.4	
		Week 12	Tezepelumab	69	64 (92.8)	1.72 (1.14)	0.0	0.70	1.60	2.60	4.8	
			Placebo	72	63 (87.5)	1.77 (0.95)	0.0	1.00	2.00	2.40	4.4	
		Week 14	Tezepelumab	69	64 (92.8)	1.58 (1.07)	0.0	1.00	1.50	2.20	4.8	
			Placebo	72	63 (87.5)	1.76 (0.91)	0.0	1.00	1.80	2.40	5.0	
		Week 16	Tezepelumab	69	64 (92.8)	1.77 (1.11)	0.0	0.90	1.80	2.60	4.8	
			Placebo	72	63 (87.5)	1.89 (0.98)	0.0	1.00	1.80	2.80	4.4	
		Week 18	Tezepelumab	69	65 (94.2)	1.70 (1.04)	0.0	1.00	1.80	2.40	4.8	
			Placebo	72	63 (87.5)	1.81 (1.04)	0.0	1.00	1.80	2.60	4.8	
		Week 20	Tezepelumab	69	65 (94.2)	1.76 (1.13)	0.0	1.00	1.80	2.40	5.0	
			Placebo	72	63 (87.5)	1.86 (1.01)	0.0	1.20	2.00	2.60	4.4	
		Week 22	Tezepelumab	69	65 (94.2)	1.75 (1.07)	0.0	1.00	1.80	2.60	4.8	
			Placebo	72	63 (87.5)	1.81 (1.00)	0.0	1.00	1.80	2.60	4.4	
		Week 24	Tezepelumab	69	65 (94.2)	1.73 (1.07)	0.0	1.00	1.80	2.60	4.8	
			Placebo	72	63 (87.5)	1.79 (1.04)	0.0	0.80	1.80	2.60	4.4	
		Week 26	Tezepelumab	69	66 (95.7)	1.71 (1.10)	0.0	1.00	1.60	2.60	4.8	
			Placebo	72	63 (87.5)	1.74 (1.05)	0.0	1.00	1.60	2.60	4.4	
		Week 28	Tezepelumab	69	66 (95.7)	1.77 (1.11)	0.0	1.00	1.80	2.60	4.8	
			Placebo	72	64 (88.9)	1.75 (1.13)	0.0	0.80	1.80	2.60	4.4	
		Week 30	Tezepelumab	69	67 (97.1)	1.71 (1.11)	0.0	0.80	1.80	2.60	4.8	
			Placebo	72	65 (90.3)	1.75 (1.10)	0.0	0.80	1.60	2.60	4.4	
		Week 32	Tezepelumab	69	67 (97.1)	1.67 (1.10)	0.0	1.00	1.40	2.60	4.8	
			Placebo	72	65 (90.3)	1.69 (1.06)	0.0	0.80	1.60	2.60	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 300 cells/uL	Absolute values	Week 34	Tezepelumab	69	67 (97.1)	1.66 (1.15)	0.0	1.00	1.40	2.60	4.8	
			Placebo	72	65 (90.3)	1.62 (1.06)	0.0	0.80	1.60	2.40	4.4	
		Week 36	Tezepelumab	69	67 (97.1)	1.72 (1.18)	0.0	0.80	1.60	2.60	5.0	
			Placebo	72	65 (90.3)	1.70 (1.10)	0.0	0.80	1.60	2.60	4.4	
		Week 38	Tezepelumab	69	67 (97.1)	1.69 (1.18)	0.0	0.80	1.40	2.40	4.8	
			Placebo	72	65 (90.3)	1.68 (1.06)	0.0	1.00	1.60	2.60	4.4	
		Week 40	Tezepelumab	69	67 (97.1)	1.76 (1.16)	0.0	0.80	1.80	2.60	4.8	
			Placebo	72	65 (90.3)	1.71 (1.15)	0.0	0.80	1.60	2.60	4.4	
		Week 42	Tezepelumab	69	67 (97.1)	1.65 (1.14)	0.0	0.80	1.60	2.20	4.8	
			Placebo	72	65 (90.3)	1.70 (1.06)	0.0	0.80	2.00	2.60	4.4	
		Week 44	Tezepelumab	69	67 (97.1)	1.75 (1.13)	0.0	1.00	1.80	2.60	4.8	
			Placebo	72	66 (91.7)	1.76 (1.13)	0.0	0.80	1.70	2.80	4.4	
		Week 46	Tezepelumab	69	67 (97.1)	1.68 (1.16)	0.0	0.80	1.60	2.40	4.8	
			Placebo	72	66 (91.7)	1.69 (1.07)	0.0	0.80	1.80	2.40	4.4	
		Week 48	Tezepelumab	69	67 (97.1)	1.74 (1.14)	0.0	1.00	1.80	2.60	4.8	
			Placebo	72	66 (91.7)	1.67 (1.15)	0.0	0.80	1.60	2.60	4.6	
		Week 50	Tezepelumab	69	67 (97.1)	1.70 (1.17)	0.0	0.80	1.80	2.40	4.8	
			Placebo	72	66 (91.7)	1.72 (1.07)	0.0	0.80	1.80	2.60	4.4	
		Week 52	Tezepelumab	69	67 (97.1)	1.70 (1.18)	0.0	0.80	1.80	2.40	4.8	
			Placebo	72	66 (91.7)	1.74 (1.10)	0.0	0.80	1.80	2.60	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 2	Tezepelumab	69	64 (92.8)	-0.50 (0.75)	-3.2	-0.80	-0.40	0.00	0.4	-0.05 [-0.40, 0.30]
			Placebo	72	62 (86.1)	-0.46 (0.76)	-2.8	-1.00	-0.40	0.00	1.4	
		Week 4	Tezepelumab	69	64 (92.8)	-0.78 (0.83)	-3.0	-1.20	-0.60	-0.20	0.8	-0.15 [-0.50, 0.20]
			Placebo	72	62 (86.1)	-0.65 (0.92)	-3.0	-1.20	-0.70	-0.20	1.6	
		Week 6	Tezepelumab	69	64 (92.8)	-0.91 (0.83)	-3.2	-1.40	-0.80	-0.20	0.6	-0.15 [-0.50, 0.20]
			Placebo	72	62 (86.1)	-0.78 (0.97)	-3.4	-1.40	-0.70	-0.20	1.6	
		Week 8	Tezepelumab	69	64 (92.8)	-0.91 (1.01)	-3.2	-1.60	-0.80	-0.40	2.6	-0.08 [-0.42, 0.27]
			Placebo	72	63 (87.5)	-0.84 (0.95)	-3.0	-1.40	-0.80	-0.20	1.0	
		Week 10	Tezepelumab	69	64 (92.8)	-1.05 (0.93)	-3.2	-1.60	-1.10	-0.30	0.6	-0.21 [-0.56, 0.14]
			Placebo	72	63 (87.5)	-0.85 (0.94)	-3.2	-1.40	-0.80	-0.20	1.6	
		Week 12	Tezepelumab	69	64 (92.8)	-1.16 (0.99)	-3.2	-2.00	-1.10	-0.40	0.6	-0.16 [-0.51, 0.19]
			Placebo	72	63 (87.5)	-1.00 (0.96)	-3.2	-1.40	-0.80	-0.40	1.0	
		Week 14	Tezepelumab	69	64 (92.8)	-1.30 (0.91)	-3.2	-2.00	-1.30	-0.60	0.6	-0.30 [-0.65, 0.05]
			Placebo	72	63 (87.5)	-1.01 (0.98)	-3.2	-1.60	-1.00	-0.40	1.4	
		Week 16	Tezepelumab	69	64 (92.8)	-1.10 (0.96)	-3.0	-1.80	-1.00	-0.40	0.6	-0.22 [-0.57, 0.13]
			Placebo	72	63 (87.5)	-0.89 (1.02)	-3.0	-1.40	-1.00	-0.20	1.4	
		Week 18	Tezepelumab	69	65 (94.2)	-1.17 (0.90)	-3.2	-1.80	-1.00	-0.60	0.6	-0.21 [-0.55, 0.14]
			Placebo	72	63 (87.5)	-0.97 (1.04)	-3.2	-1.60	-1.00	-0.20	1.4	
		Week 20	Tezepelumab	69	65 (94.2)	-1.10 (1.01)	-3.0	-2.00	-1.00	-0.40	0.6	-0.18 [-0.53, 0.16]
			Placebo	72	63 (87.5)	-0.92 (1.02)	-3.0	-1.40	-0.80	-0.40	1.2	
		Week 22	Tezepelumab	69	65 (94.2)	-1.11 (1.00)	-3.2	-1.80	-1.00	-0.40	0.6	-0.14 [-0.49, 0.21]
			Placebo	72	63 (87.5)	-0.97 (0.99)	-3.2	-1.60	-1.00	-0.40	1.4	
		Week 24	Tezepelumab	69	65 (94.2)	-1.14 (0.94)	-3.2	-2.00	-1.00	-0.40	0.6	-0.15 [-0.50, 0.19]
			Placebo	72	63 (87.5)	-0.98 (1.08)	-3.2	-1.60	-1.00	-0.20	1.8	
		Week 26	Tezepelumab	69	66 (95.7)	-1.13 (0.99)	-3.2	-2.00	-1.00	-0.40	0.6	-0.10 [-0.45, 0.24]
			Placebo	72	63 (87.5)	-1.03 (1.03)	-3.0	-1.80	-1.20	-0.40	1.6	
		Week 28	Tezepelumab	69	66 (95.7)	-1.08 (1.06)	-3.2	-2.00	-1.00	-0.20	1.0	-0.08 [-0.43, 0.26]
			Placebo	72	64 (88.9)	-0.99 (1.10)	-3.0	-1.70	-1.00	-0.30	1.6	
		Week 30	Tezepelumab	69	67 (97.1)	-1.15 (1.09)	-3.2	-2.20	-1.00	-0.40	2.0	-0.14 [-0.49, 0.20]
			Placebo	72	65 (90.3)	-0.99 (1.10)	-3.2	-1.60	-1.00	-0.40	2.0	
		Week 32	Tezepelumab	69	67 (97.1)	-1.19 (1.03)	-3.6	-2.20	-1.00	-0.60	1.2	-0.13 [-0.47, 0.21]
			Placebo	72	65 (90.3)	-1.05 (1.02)	-3.2	-1.60	-1.00	-0.40	1.4	
		Week 34	Tezepelumab	69	67 (97.1)	-1.20 (1.10)	-3.8	-2.00	-1.00	-0.40	2.2	-0.08 [-0.42, 0.26]
			Placebo	72	65 (90.3)	-1.12 (1.03)	-3.4	-1.60	-1.20	-0.40	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 300 cells/uL	Change from baseline	Week 36	Tezepelumab	69	67 (97.1)	-1.14 (1.14)	-3.6	-2.20	-1.00	-0.40	2.0	-0.09 [-0.43, 0.25]
			Placebo	72	65 (90.3)	-1.04 (1.10)	-3.6	-1.60	-1.00	-0.40	1.4	
		Week 38	Tezepelumab	69	67 (97.1)	-1.17 (1.13)	-3.6	-2.20	-1.00	-0.40	2.6	-0.10 [-0.45, 0.24]
			Placebo	72	65 (90.3)	-1.06 (1.06)	-3.4	-1.60	-1.20	-0.40	1.6	
		Week 40	Tezepelumab	69	67 (97.1)	-1.10 (1.12)	-3.6	-2.00	-1.00	-0.20	1.8	-0.07 [-0.41, 0.28]
			Placebo	72	65 (90.3)	-1.03 (1.11)	-3.6	-1.60	-1.20	-0.20	1.4	
		Week 42	Tezepelumab	69	67 (97.1)	-1.21 (1.09)	-3.6	-2.00	-1.00	-0.40	2.2	-0.16 [-0.51, 0.18]
			Placebo	72	65 (90.3)	-1.04 (1.04)	-3.6	-1.60	-1.00	-0.40	1.4	
		Week 44	Tezepelumab	69	67 (97.1)	-1.11 (1.07)	-3.8	-2.00	-1.00	-0.40	1.6	-0.12 [-0.46, 0.22]
			Placebo	72	66 (91.7)	-0.98 (1.13)	-3.4	-1.80	-1.00	0.00	1.4	
		Week 46	Tezepelumab	69	67 (97.1)	-1.18 (1.10)	-3.6	-2.20	-1.00	-0.40	1.8	-0.11 [-0.46, 0.23]
			Placebo	72	66 (91.7)	-1.05 (1.07)	-3.2	-1.60	-1.00	-0.40	1.6	
		Week 48	Tezepelumab	69	67 (97.1)	-1.12 (1.08)	-3.6	-2.00	-1.00	-0.40	2.0	-0.05 [-0.39, 0.29]
			Placebo	72	66 (91.7)	-1.07 (1.15)	-3.4	-1.80	-1.10	-0.40	1.8	
		Week 50	Tezepelumab	69	67 (97.1)	-1.16 (1.12)	-3.6	-2.00	-1.20	-0.40	2.0	-0.13 [-0.47, 0.21]
			Placebo	72	66 (91.7)	-1.02 (1.11)	-3.6	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	69	67 (97.1)	-1.16 (1.14)	-3.6	-2.00	-1.00	-0.40	2.0	-0.14 [-0.48, 0.20]
			Placebo	72	66 (91.7)	-1.00 (1.15)	-3.6	-1.80	-1.00	-0.40	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	67	67 (100.0)	2.81 (0.91)	0.0	2.20	2.80	3.20	4.8	
			Placebo	66	66 (100.0)	2.88 (0.72)	1.0	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	67	66 (98.5)	2.16 (1.00)	0.0	1.40	2.20	3.00	4.4	
			Placebo	66	63 (95.5)	2.53 (0.88)	0.0	2.00	2.60	3.00	5.0	
		Week 4	Tezepelumab	67	66 (98.5)	1.84 (1.01)	0.0	1.00	1.90	2.60	3.6	
			Placebo	66	63 (95.5)	2.48 (0.84)	0.8	2.00	2.60	3.00	4.4	
		Week 6	Tezepelumab	67	66 (98.5)	1.76 (1.01)	0.0	1.00	1.80	2.40	3.8	
			Placebo	66	64 (97.0)	2.40 (1.00)	0.2	1.80	2.40	2.90	6.0	
		Week 8	Tezepelumab	67	66 (98.5)	1.62 (1.03)	0.0	1.00	1.60	2.60	3.8	
			Placebo	66	64 (97.0)	2.34 (1.00)	0.0	1.60	2.50	3.00	5.0	
		Week 10	Tezepelumab	67	66 (98.5)	1.62 (1.02)	0.0	0.80	1.70	2.40	3.6	
			Placebo	66	65 (98.5)	2.22 (0.99)	0.0	1.60	2.40	3.00	5.2	
		Week 12	Tezepelumab	67	66 (98.5)	1.57 (1.04)	0.0	0.80	1.60	2.40	3.6	
			Placebo	66	65 (98.5)	2.21 (1.00)	0.0	1.40	2.40	3.00	4.4	
		Week 14	Tezepelumab	67	66 (98.5)	1.44 (1.07)	0.0	0.60	1.40	2.40	3.8	
			Placebo	66	65 (98.5)	2.11 (0.96)	0.0	1.40	2.20	2.60	5.0	
		Week 16	Tezepelumab	67	66 (98.5)	1.57 (1.11)	0.0	0.80	1.40	2.60	4.6	
			Placebo	66	65 (98.5)	2.23 (1.15)	0.0	1.40	2.40	3.00	5.0	
		Week 18	Tezepelumab	67	66 (98.5)	1.41 (0.98)	0.0	0.80	1.20	2.20	3.6	
			Placebo	66	65 (98.5)	2.09 (1.01)	0.0	1.60	2.20	2.60	5.0	
		Week 20	Tezepelumab	67	66 (98.5)	1.54 (1.02)	0.0	0.80	1.40	2.40	3.6	
			Placebo	66	65 (98.5)	2.15 (1.06)	0.0	1.40	2.40	2.80	5.0	
		Week 22	Tezepelumab	67	66 (98.5)	1.59 (0.98)	0.0	0.80	1.60	2.40	3.6	
			Placebo	66	65 (98.5)	2.10 (1.08)	0.0	1.60	2.20	2.80	5.0	
		Week 24	Tezepelumab	67	66 (98.5)	1.59 (1.12)	0.0	0.80	1.60	2.40	4.8	
			Placebo	66	65 (98.5)	2.10 (0.99)	0.0	1.40	2.40	2.80	4.0	
		Week 26	Tezepelumab	67	66 (98.5)	1.52 (1.00)	0.0	0.80	1.40	2.40	3.6	
			Placebo	66	65 (98.5)	2.05 (0.96)	0.0	1.20	2.00	2.80	4.0	
		Week 28	Tezepelumab	67	67 (100.0)	1.59 (1.10)	0.0	0.40	1.40	2.40	3.6	
			Placebo	66	65 (98.5)	2.16 (1.02)	0.0	1.20	2.40	2.80	4.0	
		Week 30	Tezepelumab	67	67 (100.0)	1.51 (0.99)	0.0	0.80	1.60	2.20	3.8	
			Placebo	66	65 (98.5)	2.13 (1.02)	0.0	1.40	2.20	2.80	4.2	
		Week 32	Tezepelumab	67	67 (100.0)	1.48 (1.04)	0.0	0.60	1.40	2.40	4.2	
			Placebo	66	65 (98.5)	2.10 (1.07)	0.0	1.00	2.00	3.00	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 300 cells/uL	Absolute values	Week 34	Tezepelumab	67	67 (100.0)	1.51 (1.10)	0.0	0.60	1.40	2.40	4.2	
			Placebo	66	65 (98.5)	2.08 (1.06)	0.0	1.20	2.20	2.80	4.8	
		Week 36	Tezepelumab	67	67 (100.0)	1.61 (1.05)	0.0	0.80	1.60	2.40	3.8	
			Placebo	66	65 (98.5)	2.18 (1.05)	0.0	1.40	2.40	2.80	4.8	
		Week 38	Tezepelumab	67	67 (100.0)	1.45 (1.02)	0.0	0.60	1.40	2.20	3.6	
			Placebo	66	65 (98.5)	2.04 (1.06)	0.0	1.00	2.00	2.80	4.8	
		Week 40	Tezepelumab	67	67 (100.0)	1.44 (1.04)	0.0	0.40	1.40	2.20	3.6	
			Placebo	66	65 (98.5)	2.17 (1.01)	0.0	1.20	2.20	3.00	4.4	
		Week 42	Tezepelumab	67	67 (100.0)	1.46 (1.05)	0.0	0.60	1.40	2.40	4.6	
			Placebo	66	65 (98.5)	2.10 (1.01)	0.0	1.60	2.00	2.80	4.6	
		Week 44	Tezepelumab	67	67 (100.0)	1.42 (1.04)	0.0	0.60	1.20	2.40	3.8	
			Placebo	66	65 (98.5)	2.15 (0.97)	0.0	1.40	2.20	3.00	4.2	
		Week 46	Tezepelumab	67	67 (100.0)	1.42 (1.04)	0.0	0.80	1.20	2.40	3.6	
			Placebo	66	65 (98.5)	1.98 (0.96)	0.0	1.20	2.00	2.80	4.0	
		Week 48	Tezepelumab	67	67 (100.0)	1.49 (1.09)	0.0	0.60	1.40	2.40	4.2	
			Placebo	66	65 (98.5)	2.06 (0.94)	0.0	1.40	2.20	2.80	4.0	
		Week 50	Tezepelumab	67	67 (100.0)	1.36 (1.00)	0.0	0.60	1.20	2.00	4.2	
			Placebo	66	65 (98.5)	1.97 (0.93)	0.0	1.00	2.00	2.80	4.0	
		Week 52	Tezepelumab	67	67 (100.0)	1.41 (0.98)	0.0	0.60	1.20	2.00	4.2	
			Placebo	66	65 (98.5)	2.04 (0.97)	0.0	1.40	2.20	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 2	Tezepelumab	67	66 (98.5)	-0.65 (0.74)	-3.0	-1.20	-0.60	-0.20	0.8	-0.38 [-0.73, -0.03]
			Placebo	66	63 (95.5)	-0.36 (0.77)	-3.0	-0.80	-0.20	0.20	1.2	
		Week 4	Tezepelumab	67	66 (98.5)	-0.97 (1.08)	-3.8	-1.60	-1.00	-0.20	2.6	-0.56 [-0.91, -0.20]
			Placebo	66	63 (95.5)	-0.41 (0.89)	-3.0	-1.00	-0.20	0.20	1.2	
		Week 6	Tezepelumab	67	66 (98.5)	-1.05 (1.21)	-4.0	-1.80	-1.00	-0.20	2.6	-0.51 [-0.86, -0.16]
			Placebo	66	64 (97.0)	-0.49 (0.95)	-3.2	-1.10	-0.30	0.20	1.6	
		Week 8	Tezepelumab	67	66 (98.5)	-1.18 (1.16)	-4.0	-1.80	-1.20	-0.40	2.6	-0.60 [-0.95, -0.25]
			Placebo	66	64 (97.0)	-0.54 (0.97)	-3.6	-1.00	-0.40	0.20	1.0	
		Week 10	Tezepelumab	67	66 (98.5)	-1.19 (1.18)	-4.0	-1.80	-1.20	-0.60	2.6	-0.45 [-0.80, -0.10]
			Placebo	66	65 (98.5)	-0.68 (1.09)	-3.8	-1.20	-0.60	0.00	2.6	
		Week 12	Tezepelumab	67	66 (98.5)	-1.24 (1.16)	-4.0	-1.80	-1.20	-0.80	2.6	-0.49 [-0.84, -0.14]
			Placebo	66	65 (98.5)	-0.69 (1.11)	-3.8	-1.20	-0.60	0.00	1.6	
		Week 14	Tezepelumab	67	66 (98.5)	-1.37 (1.23)	-4.2	-2.00	-1.40	-0.80	2.6	-0.51 [-0.86, -0.16]
			Placebo	66	65 (98.5)	-0.79 (1.03)	-3.4	-1.40	-0.60	-0.20	2.4	
		Week 16	Tezepelumab	67	66 (98.5)	-1.24 (1.27)	-4.4	-2.00	-1.20	-0.60	2.6	-0.46 [-0.81, -0.12]
			Placebo	66	65 (98.5)	-0.67 (1.17)	-3.6	-1.40	-0.40	0.00	2.6	
		Week 18	Tezepelumab	67	66 (98.5)	-1.40 (1.24)	-4.4	-2.00	-1.40	-0.80	2.6	-0.50 [-0.85, -0.15]
			Placebo	66	65 (98.5)	-0.81 (1.13)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 20	Tezepelumab	67	66 (98.5)	-1.27 (1.18)	-4.4	-2.00	-1.30	-0.60	2.6	-0.44 [-0.79, -0.10]
			Placebo	66	65 (98.5)	-0.74 (1.20)	-3.6	-1.40	-0.60	0.00	2.6	
		Week 22	Tezepelumab	67	66 (98.5)	-1.22 (1.25)	-4.4	-1.80	-1.20	-0.60	2.6	-0.36 [-0.70, -0.01]
			Placebo	66	65 (98.5)	-0.79 (1.17)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 24	Tezepelumab	67	66 (98.5)	-1.22 (1.20)	-4.8	-1.80	-1.20	-0.40	2.6	-0.36 [-0.71, -0.02]
			Placebo	66	65 (98.5)	-0.79 (1.12)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 26	Tezepelumab	67	66 (98.5)	-1.29 (1.23)	-4.4	-2.20	-1.30	-0.60	2.6	-0.38 [-0.72, -0.03]
			Placebo	66	65 (98.5)	-0.84 (1.16)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 28	Tezepelumab	67	67 (100.0)	-1.22 (1.20)	-4.4	-2.00	-1.20	-0.60	2.6	-0.41 [-0.75, -0.06]
			Placebo	66	65 (98.5)	-0.73 (1.18)	-4.2	-1.60	-0.60	0.00	2.6	
		Week 30	Tezepelumab	67	67 (100.0)	-1.29 (1.21)	-4.4	-2.20	-1.20	-0.60	2.6	-0.44 [-0.79, -0.10]
			Placebo	66	65 (98.5)	-0.76 (1.19)	-3.4	-1.40	-0.80	0.00	2.6	
		Week 32	Tezepelumab	67	67 (100.0)	-1.33 (1.24)	-4.4	-2.20	-1.40	-0.60	2.6	-0.43 [-0.78, -0.08]
			Placebo	66	65 (98.5)	-0.80 (1.22)	-3.6	-1.80	-0.60	0.00	2.6	
		Week 34	Tezepelumab	67	67 (100.0)	-1.29 (1.23)	-4.4	-2.20	-1.20	-0.60	2.6	-0.40 [-0.74, -0.05]
			Placebo	66	65 (98.5)	-0.81 (1.19)	-4.2	-1.60	-0.60	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 300 cells/uL	Change from baseline	Week 36	Tezepelumab	67	67 (100.0)	-1.20 (1.27)	-4.4	-2.00	-1.20	-0.20	2.6	-0.39 [-0.73, -0.04]
			Placebo	66	65 (98.5)	-0.72 (1.22)	-3.6	-1.40	-0.60	0.00	2.6	
		Week 38	Tezepelumab	67	67 (100.0)	-1.36 (1.25)	-4.4	-2.20	-1.20	-0.60	2.6	-0.40 [-0.75, -0.06]
			Placebo	66	65 (98.5)	-0.86 (1.23)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 40	Tezepelumab	67	67 (100.0)	-1.37 (1.28)	-4.4	-2.20	-1.20	-0.60	2.6	-0.53 [-0.87, -0.18]
			Placebo	66	65 (98.5)	-0.73 (1.15)	-4.2	-1.40	-0.60	0.00	2.6	
		Week 42	Tezepelumab	67	67 (100.0)	-1.34 (1.30)	-4.4	-2.20	-1.40	-0.40	2.6	-0.45 [-0.79, -0.10]
			Placebo	66	65 (98.5)	-0.79 (1.18)	-4.2	-1.40	-0.80	0.00	2.6	
		Week 44	Tezepelumab	67	67 (100.0)	-1.39 (1.34)	-4.4	-2.20	-1.40	-0.60	2.6	-0.51 [-0.86, -0.17]
			Placebo	66	65 (98.5)	-0.75 (1.14)	-4.2	-1.40	-0.60	0.00	2.6	
		Week 46	Tezepelumab	67	67 (100.0)	-1.38 (1.28)	-4.4	-2.20	-1.40	-0.60	2.6	-0.38 [-0.73, -0.04]
			Placebo	66	65 (98.5)	-0.92 (1.13)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 48	Tezepelumab	67	67 (100.0)	-1.32 (1.29)	-4.4	-2.20	-1.20	-0.40	2.6	-0.40 [-0.75, -0.06]
			Placebo	66	65 (98.5)	-0.83 (1.11)	-3.8	-1.40	-0.80	0.00	2.6	
		Week 50	Tezepelumab	67	67 (100.0)	-1.45 (1.25)	-4.4	-2.40	-1.40	-0.80	2.6	-0.46 [-0.80, -0.11]
			Placebo	66	65 (98.5)	-0.92 (1.05)	-4.2	-1.60	-0.80	-0.20	2.6	
		Week 52	Tezepelumab	67	67 (100.0)	-1.39 (1.25)	-4.4	-2.20	-1.40	-0.80	2.6	-0.46 [-0.81, -0.12]
			Placebo	66	65 (98.5)	-0.85 (1.07)	-4.2	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	78	78 (100.0)	2.78 (0.70)	0.8	2.40	2.80	3.20	5.0	
			Placebo	74	74 (100.0)	2.80 (0.67)	0.4	2.40	2.80	3.20	4.2	
		Week 2	Tezepelumab	78	73 (93.6)	2.27 (0.97)	0.0	1.60	2.40	2.80	4.4	
			Placebo	74	66 (89.2)	2.35 (0.75)	0.4	2.00	2.40	3.00	4.4	
		Week 4	Tezepelumab	78	73 (93.6)	2.01 (0.91)	0.0	1.40	2.20	2.80	3.6	
			Placebo	74	66 (89.2)	2.17 (0.82)	0.2	1.60	2.20	2.80	4.2	
		Week 6	Tezepelumab	78	73 (93.6)	1.95 (0.91)	0.0	1.40	1.80	2.60	4.0	
			Placebo	74	66 (89.2)	2.10 (0.91)	0.2	1.60	2.20	2.60	5.0	
		Week 8	Tezepelumab	78	73 (93.6)	1.87 (1.04)	0.0	1.20	1.60	2.80	5.2	
			Placebo	74	66 (89.2)	2.18 (0.89)	0.0	1.60	2.20	3.00	4.0	
		Week 10	Tezepelumab	78	73 (93.6)	1.81 (1.03)	0.0	1.20	1.80	2.60	4.8	
			Placebo	74	67 (90.5)	2.00 (0.86)	0.0	1.40	2.00	2.40	4.2	
		Week 12	Tezepelumab	78	73 (93.6)	1.73 (1.10)	0.0	0.80	1.60	2.60	4.8	
			Placebo	74	67 (90.5)	1.97 (0.92)	0.0	1.40	2.00	2.60	4.4	
		Week 14	Tezepelumab	78	73 (93.6)	1.55 (1.05)	0.0	0.80	1.40	2.20	4.8	
			Placebo	74	67 (90.5)	1.90 (0.88)	0.0	1.20	1.80	2.60	4.2	
		Week 16	Tezepelumab	78	73 (93.6)	1.82 (1.11)	0.0	1.00	1.80	2.60	4.8	
			Placebo	74	67 (90.5)	2.01 (0.92)	0.0	1.40	2.00	2.80	3.8	
		Week 18	Tezepelumab	78	74 (94.9)	1.70 (1.00)	0.0	1.00	1.80	2.40	4.8	
			Placebo	74	67 (90.5)	1.93 (0.99)	0.0	1.40	1.80	2.60	4.8	
		Week 20	Tezepelumab	78	74 (94.9)	1.78 (1.10)	0.0	1.00	1.80	2.60	5.0	
			Placebo	74	67 (90.5)	1.95 (0.99)	0.0	1.40	2.00	2.80	3.8	
		Week 22	Tezepelumab	78	74 (94.9)	1.74 (1.03)	0.0	1.00	1.80	2.60	4.8	
			Placebo	74	67 (90.5)	1.88 (0.98)	0.0	1.20	2.00	2.60	4.0	
		Week 24	Tezepelumab	78	74 (94.9)	1.73 (1.06)	0.0	1.00	1.80	2.60	4.8	
			Placebo	74	67 (90.5)	1.84 (0.99)	0.0	1.00	2.00	2.60	3.8	
		Week 26	Tezepelumab	78	75 (96.2)	1.74 (1.07)	0.0	1.00	1.80	2.60	4.8	
			Placebo	74	67 (90.5)	1.81 (0.91)	0.0	1.00	1.80	2.40	4.4	
		Week 28	Tezepelumab	78	76 (97.4)	1.75 (1.10)	0.0	1.00	1.70	2.70	4.8	
			Placebo	74	68 (91.9)	1.95 (1.00)	0.0	1.00	2.20	2.70	4.4	
		Week 30	Tezepelumab	78	77 (98.7)	1.73 (1.06)	0.0	1.00	1.60	2.60	4.8	
			Placebo	74	69 (93.2)	1.94 (1.00)	0.0	1.00	2.00	2.80	4.2	
		Week 32	Tezepelumab	78	77 (98.7)	1.69 (1.09)	0.0	1.00	1.60	2.60	4.8	
			Placebo	74	69 (93.2)	1.82 (1.00)	0.0	1.00	1.80	2.80	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 25 ppb	Absolute values	Week 34	Tezepelumab	78	77 (98.7)	1.66 (1.16)	0.0	0.80	1.40	2.60	4.8	
			Placebo	74	69 (93.2)	1.83 (0.96)	0.0	1.00	1.80	2.60	3.6	
		Week 36	Tezepelumab	78	77 (98.7)	1.77 (1.13)	0.0	1.00	1.60	2.60	5.0	
			Placebo	74	69 (93.2)	1.77 (1.03)	0.0	0.80	2.00	2.80	3.6	
		Week 38	Tezepelumab	78	77 (98.7)	1.70 (1.16)	0.0	0.80	1.60	2.40	4.8	
			Placebo	74	69 (93.2)	1.80 (0.98)	0.0	1.00	1.80	2.60	4.0	
		Week 40	Tezepelumab	78	77 (98.7)	1.75 (1.13)	0.0	0.80	1.80	2.60	4.8	
			Placebo	74	69 (93.2)	1.85 (1.04)	0.0	1.00	1.80	2.80	4.2	
		Week 42	Tezepelumab	78	77 (98.7)	1.69 (1.11)	0.0	1.00	1.60	2.40	4.8	
			Placebo	74	69 (93.2)	1.86 (1.02)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	78	77 (98.7)	1.78 (1.12)	0.0	1.00	1.80	2.80	4.8	
			Placebo	74	70 (94.6)	1.90 (1.04)	0.0	1.00	2.00	2.80	4.2	
		Week 46	Tezepelumab	78	77 (98.7)	1.77 (1.12)	0.0	1.00	1.80	2.60	4.8	
			Placebo	74	70 (94.6)	1.74 (1.01)	0.0	1.00	1.80	2.40	4.4	
		Week 48	Tezepelumab	78	77 (98.7)	1.79 (1.14)	0.0	1.00	1.80	2.60	4.8	
			Placebo	74	70 (94.6)	1.71 (1.06)	0.0	0.80	1.60	2.60	4.6	
		Week 50	Tezepelumab	78	77 (98.7)	1.70 (1.14)	0.0	1.00	1.80	2.60	4.8	
			Placebo	74	70 (94.6)	1.77 (0.97)	0.0	1.00	1.80	2.60	3.8	
		Week 52	Tezepelumab	78	77 (98.7)	1.75 (1.13)	0.0	1.00	1.80	2.60	4.8	
			Placebo	74	70 (94.6)	1.82 (1.01)	0.0	1.00	1.80	2.60	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	78	73 (93.6)	-0.51 (0.75)	-3.2	-0.80	-0.40	0.00	0.8	-0.01 [-0.34, 0.32]
			Placebo	74	66 (89.2)	-0.50 (0.73)	-2.8	-0.80	-0.40	0.00	1.4	
		Week 4	Tezepelumab	78	73 (93.6)	-0.77 (0.74)	-3.0	-1.20	-0.80	-0.20	0.6	-0.11 [-0.44, 0.23]
			Placebo	74	66 (89.2)	-0.68 (0.89)	-3.0	-1.20	-0.60	-0.20	1.6	
		Week 6	Tezepelumab	78	73 (93.6)	-0.83 (0.82)	-3.0	-1.40	-0.80	-0.20	0.8	-0.08 [-0.42, 0.25]
			Placebo	74	66 (89.2)	-0.76 (0.95)	-3.4	-1.40	-0.60	-0.20	1.6	
		Week 8	Tezepelumab	78	73 (93.6)	-0.91 (0.96)	-3.2	-1.40	-1.00	-0.40	2.6	-0.24 [-0.58, 0.09]
			Placebo	74	66 (89.2)	-0.68 (0.93)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	78	73 (93.6)	-0.97 (0.90)	-3.4	-1.60	-1.00	-0.20	0.6	-0.13 [-0.46, 0.21]
			Placebo	74	67 (90.5)	-0.86 (0.88)	-3.8	-1.40	-0.80	-0.20	0.8	
		Week 12	Tezepelumab	78	73 (93.6)	-1.05 (0.93)	-3.0	-1.60	-1.00	-0.40	0.6	-0.16 [-0.49, 0.17]
			Placebo	74	67 (90.5)	-0.90 (1.01)	-3.8	-1.20	-0.80	-0.20	1.4	
		Week 14	Tezepelumab	78	73 (93.6)	-1.23 (0.89)	-3.4	-1.80	-1.20	-0.60	0.6	-0.29 [-0.63, 0.04]
			Placebo	74	67 (90.5)	-0.96 (0.97)	-3.4	-1.60	-0.80	-0.40	1.4	
		Week 16	Tezepelumab	78	73 (93.6)	-0.96 (0.95)	-3.2	-1.40	-1.00	-0.40	1.8	-0.11 [-0.44, 0.22]
			Placebo	74	67 (90.5)	-0.85 (0.99)	-3.6	-1.40	-0.80	0.00	1.4	
		Week 18	Tezepelumab	78	74 (94.9)	-1.07 (0.86)	-3.4	-1.80	-1.00	-0.60	0.6	-0.15 [-0.48, 0.18]
			Placebo	74	67 (90.5)	-0.93 (1.06)	-3.6	-1.60	-0.80	-0.20	1.4	
		Week 20	Tezepelumab	78	74 (94.9)	-0.99 (0.97)	-3.4	-1.60	-0.90	-0.20	0.6	-0.08 [-0.41, 0.26]
			Placebo	74	67 (90.5)	-0.92 (1.10)	-3.6	-1.40	-0.80	-0.20	1.2	
		Week 22	Tezepelumab	78	74 (94.9)	-1.04 (0.91)	-3.2	-1.60	-0.90	-0.40	0.6	-0.06 [-0.39, 0.27]
			Placebo	74	67 (90.5)	-0.98 (1.09)	-3.8	-1.60	-1.00	-0.40	1.4	
		Week 24	Tezepelumab	78	74 (94.9)	-1.04 (0.91)	-3.4	-1.80	-0.80	-0.40	0.6	-0.02 [-0.35, 0.31]
			Placebo	74	67 (90.5)	-1.02 (1.10)	-3.6	-1.60	-1.00	-0.20	1.8	
		Week 26	Tezepelumab	78	75 (96.2)	-1.01 (0.93)	-3.0	-1.80	-0.80	-0.40	0.6	0.04 [-0.29, 0.37]
			Placebo	74	67 (90.5)	-1.05 (1.01)	-3.4	-1.80	-1.20	-0.40	1.6	
		Week 28	Tezepelumab	78	76 (97.4)	-1.01 (1.01)	-3.4	-1.70	-0.90	-0.20	1.0	-0.13 [-0.46, 0.20]
			Placebo	74	68 (91.9)	-0.87 (1.07)	-3.4	-1.60	-0.80	-0.20	1.6	
		Week 30	Tezepelumab	78	77 (98.7)	-1.04 (1.00)	-3.2	-1.80	-1.00	-0.40	2.0	-0.14 [-0.47, 0.18]
			Placebo	74	69 (93.2)	-0.89 (1.12)	-3.4	-1.60	-0.80	-0.20	1.4	
		Week 32	Tezepelumab	78	77 (98.7)	-1.08 (0.98)	-3.6	-1.60	-1.00	-0.60	1.2	-0.07 [-0.40, 0.25]
			Placebo	74	69 (93.2)	-1.01 (1.07)	-3.4	-1.80	-1.00	-0.40	1.4	
		Week 34	Tezepelumab	78	77 (98.7)	-1.11 (1.07)	-3.8	-2.00	-1.00	-0.40	2.2	-0.10 [-0.43, 0.22]
			Placebo	74	69 (93.2)	-1.00 (1.03)	-3.4	-1.60	-1.00	-0.40	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 25 ppb	Change from baseline	Week 36	Tezepelumab	78	77 (98.7)	-1.00 (1.06)	-3.6	-1.80	-1.00	-0.20	2.0	0.05 [-0.27, 0.38]
			Placebo	74	69 (93.2)	-1.06 (1.13)	-3.6	-1.80	-1.00	-0.40	1.4	
		Week 38	Tezepelumab	78	77 (98.7)	-1.07 (1.07)	-3.6	-1.80	-1.00	-0.40	2.6	-0.03 [-0.36, 0.29]
			Placebo	74	69 (93.2)	-1.03 (1.08)	-3.2	-1.60	-1.00	-0.20	1.6	
		Week 40	Tezepelumab	78	77 (98.7)	-1.02 (1.05)	-3.6	-1.60	-1.00	-0.20	1.8	-0.04 [-0.36, 0.29]
			Placebo	74	69 (93.2)	-0.98 (1.05)	-3.2	-1.60	-1.00	-0.40	1.4	
		Week 42	Tezepelumab	78	77 (98.7)	-1.08 (1.02)	-3.6	-1.80	-1.00	-0.40	2.2	-0.10 [-0.43, 0.22]
			Placebo	74	69 (93.2)	-0.97 (1.05)	-3.2	-1.60	-1.00	-0.40	1.4	
		Week 44	Tezepelumab	78	77 (98.7)	-0.98 (1.05)	-3.8	-1.60	-0.80	-0.20	1.6	-0.05 [-0.38, 0.27]
			Placebo	74	70 (94.6)	-0.93 (1.09)	-3.4	-1.60	-0.80	0.00	1.4	
		Week 46	Tezepelumab	78	77 (98.7)	-1.00 (1.01)	-3.6	-1.80	-1.00	-0.20	1.8	0.08 [-0.24, 0.41]
			Placebo	74	70 (94.6)	-1.09 (1.07)	-3.2	-1.80	-1.00	-0.40	1.6	
		Week 48	Tezepelumab	78	77 (98.7)	-0.97 (1.05)	-3.6	-1.80	-0.80	-0.20	2.0	0.14 [-0.19, 0.46]
			Placebo	74	70 (94.6)	-1.12 (1.11)	-3.4	-1.80	-1.00	-0.40	1.8	
		Week 50	Tezepelumab	78	77 (98.7)	-1.06 (1.05)	-3.6	-1.80	-1.00	-0.40	2.0	-0.01 [-0.33, 0.31]
			Placebo	74	70 (94.6)	-1.05 (1.06)	-3.6	-1.60	-1.10	-0.40	1.6	
		Week 52	Tezepelumab	78	77 (98.7)	-1.02 (1.05)	-3.6	-1.80	-1.00	-0.20	2.0	-0.01 [-0.33, 0.32]
			Placebo	74	70 (94.6)	-1.01 (1.10)	-3.6	-1.60	-1.00	-0.40	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.91 (1.02)	0.0	2.40	2.80	3.40	5.2	
			Placebo	63	63 (100.0)	2.84 (0.78)	1.0	2.40	3.00	3.20	5.0	
		Week 2	Tezepelumab	57	56 (98.2)	2.25 (0.98)	0.0	1.60	2.40	3.00	4.2	
			Placebo	63	58 (92.1)	2.49 (0.94)	0.0	2.00	2.60	3.00	5.0	
		Week 4	Tezepelumab	57	56 (98.2)	1.86 (1.15)	0.0	0.90	2.10	2.80	4.2	
			Placebo	63	58 (92.1)	2.44 (0.93)	0.2	2.00	2.60	3.00	4.4	
		Week 6	Tezepelumab	57	56 (98.2)	1.78 (1.13)	0.0	1.00	1.80	2.70	4.2	
			Placebo	63	59 (93.7)	2.32 (1.14)	0.2	1.40	2.40	2.80	6.0	
		Week 8	Tezepelumab	57	56 (98.2)	1.67 (1.15)	0.0	0.70	1.80	2.60	4.2	
			Placebo	63	60 (95.2)	2.13 (1.11)	0.0	1.40	2.40	2.80	5.0	
		Week 10	Tezepelumab	57	56 (98.2)	1.61 (1.10)	0.0	0.80	1.70	2.40	4.2	
			Placebo	63	60 (95.2)	2.11 (1.05)	0.0	1.30	2.20	2.80	5.2	
		Week 12	Tezepelumab	57	56 (98.2)	1.53 (1.09)	0.0	0.60	1.50	2.40	4.2	
			Placebo	63	60 (95.2)	2.04 (1.08)	0.0	1.20	2.30	2.80	4.4	
		Week 14	Tezepelumab	57	56 (98.2)	1.46 (1.09)	0.0	0.60	1.40	2.40	4.2	
			Placebo	63	60 (95.2)	1.99 (1.02)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	57	56 (98.2)	1.48 (1.10)	0.0	0.60	1.20	2.20	4.2	
			Placebo	63	60 (95.2)	2.14 (1.23)	0.0	1.00	2.40	3.00	5.0	
		Week 18	Tezepelumab	57	56 (98.2)	1.37 (1.02)	0.0	0.80	1.20	2.00	4.2	
			Placebo	63	60 (95.2)	1.99 (1.08)	0.0	1.30	2.10	2.60	5.0	
		Week 20	Tezepelumab	57	56 (98.2)	1.48 (1.05)	0.0	0.70	1.20	2.20	4.2	
			Placebo	63	60 (95.2)	2.09 (1.10)	0.0	1.30	2.30	2.80	5.0	
		Week 22	Tezepelumab	57	56 (98.2)	1.60 (1.03)	0.0	0.80	1.60	2.20	4.2	
			Placebo	63	60 (95.2)	2.06 (1.11)	0.0	1.20	2.30	2.80	5.0	
		Week 24	Tezepelumab	57	56 (98.2)	1.55 (1.15)	0.0	0.70	1.30	2.30	4.8	
			Placebo	63	60 (95.2)	2.09 (1.05)	0.0	1.30	2.30	2.80	4.4	
		Week 26	Tezepelumab	57	56 (98.2)	1.45 (1.01)	0.0	0.70	1.40	2.20	4.2	
			Placebo	63	60 (95.2)	2.02 (1.11)	0.0	1.00	1.90	3.00	4.4	
		Week 28	Tezepelumab	57	56 (98.2)	1.57 (1.12)	0.0	0.50	1.60	2.40	4.2	
			Placebo	63	60 (95.2)	1.98 (1.20)	0.0	1.00	2.10	2.80	4.4	
		Week 30	Tezepelumab	57	56 (98.2)	1.46 (1.03)	0.0	0.70	1.40	2.20	4.2	
			Placebo	63	60 (95.2)	1.96 (1.16)	0.0	1.10	2.00	2.80	4.4	
		Week 32	Tezepelumab	57	56 (98.2)	1.40 (1.06)	0.0	0.40	1.20	2.20	4.2	
			Placebo	63	60 (95.2)	1.99 (1.17)	0.0	1.10	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 25 ppb	Absolute values	Week 34	Tezepelumab	57	56 (98.2)	1.47 (1.09)	0.0	0.50	1.30	2.20	4.2	
			Placebo	63	60 (95.2)	1.90 (1.21)	0.0	1.00	1.90	2.70	4.8	
		Week 36	Tezepelumab	57	56 (98.2)	1.51 (1.09)	0.0	0.60	1.60	2.20	4.2	
			Placebo	63	60 (95.2)	2.14 (1.16)	0.0	1.20	2.30	2.90	4.8	
		Week 38	Tezepelumab	57	56 (98.2)	1.40 (1.01)	0.0	0.70	1.20	2.20	4.2	
			Placebo	63	60 (95.2)	1.93 (1.17)	0.0	1.00	1.90	2.80	4.8	
		Week 40	Tezepelumab	57	56 (98.2)	1.38 (1.06)	0.0	0.40	1.20	2.20	4.2	
			Placebo	63	60 (95.2)	2.03 (1.17)	0.0	1.00	2.20	2.90	4.4	
		Week 42	Tezepelumab	57	56 (98.2)	1.36 (1.07)	0.0	0.60	1.20	2.10	4.6	
			Placebo	63	60 (95.2)	1.95 (1.10)	0.0	1.10	2.00	2.60	4.6	
		Week 44	Tezepelumab	57	56 (98.2)	1.28 (0.99)	0.0	0.50	1.00	2.10	4.2	
			Placebo	63	60 (95.2)	2.01 (1.12)	0.0	1.10	2.20	2.80	4.4	
		Week 46	Tezepelumab	57	56 (98.2)	1.27 (1.03)	0.0	0.60	1.00	2.00	4.2	
			Placebo	63	60 (95.2)	1.93 (1.05)	0.0	1.20	2.00	2.70	4.4	
		Week 48	Tezepelumab	57	56 (98.2)	1.37 (1.05)	0.0	0.50	1.20	2.10	4.2	
			Placebo	63	60 (95.2)	2.05 (1.06)	0.0	1.30	2.20	2.80	4.4	
		Week 50	Tezepelumab	57	56 (98.2)	1.29 (1.00)	0.0	0.60	1.00	2.10	4.2	
			Placebo	63	60 (95.2)	1.92 (1.06)	0.0	1.00	2.00	2.70	4.4	
		Week 52	Tezepelumab	57	56 (98.2)	1.29 (1.00)	0.0	0.50	1.00	2.00	4.2	
			Placebo	63	60 (95.2)	1.97 (1.09)	0.0	1.00	2.10	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 2	Tezepelumab	57	56 (98.2)	-0.66 (0.75)	-2.6	-1.20	-0.50	-0.20	0.8	-0.44 [-0.81, -0.06]
			Placebo	63	58 (92.1)	-0.32 (0.81)	-3.0	-1.00	-0.20	0.20	1.2	
		Week 4	Tezepelumab	57	56 (98.2)	-1.05 (1.19)	-3.8	-1.80	-1.10	-0.20	2.6	-0.64 [-1.01, -0.26]
			Placebo	63	58 (92.1)	-0.37 (0.92)	-2.2	-1.20	-0.20	0.40	1.4	
		Week 6	Tezepelumab	57	56 (98.2)	-1.14 (1.26)	-4.0	-1.80	-1.10	-0.30	2.6	-0.57 [-0.95, -0.20]
			Placebo	63	59 (93.7)	-0.49 (0.98)	-2.4	-1.40	-0.40	0.20	1.6	
		Week 8	Tezepelumab	57	56 (98.2)	-1.24 (1.23)	-4.0	-2.00	-1.30	-0.40	2.6	-0.50 [-0.87, -0.13]
			Placebo	63	60 (95.2)	-0.68 (1.01)	-3.0	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	57	56 (98.2)	-1.30 (1.23)	-4.0	-2.10	-1.40	-0.60	2.6	-0.51 [-0.88, -0.14]
			Placebo	63	60 (95.2)	-0.70 (1.12)	-3.0	-1.60	-0.60	0.00	2.6	
		Week 12	Tezepelumab	57	56 (98.2)	-1.39 (1.22)	-4.0	-2.10	-1.40	-0.80	2.6	-0.53 [-0.90, -0.16]
			Placebo	63	60 (95.2)	-0.77 (1.09)	-3.0	-1.50	-0.60	0.00	1.6	
		Week 14	Tezepelumab	57	56 (98.2)	-1.45 (1.30)	-4.2	-2.20	-1.40	-0.80	2.6	-0.54 [-0.91, -0.17]
			Placebo	63	60 (95.2)	-0.82 (1.06)	-3.2	-1.40	-0.90	-0.20	2.4	
		Week 16	Tezepelumab	57	56 (98.2)	-1.43 (1.29)	-4.4	-2.20	-1.40	-0.80	2.6	-0.61 [-0.98, -0.24]
			Placebo	63	60 (95.2)	-0.67 (1.21)	-3.6	-1.40	-0.60	0.00	2.6	
		Week 18	Tezepelumab	57	56 (98.2)	-1.54 (1.29)	-4.4	-2.30	-1.60	-0.80	2.6	-0.60 [-0.97, -0.23]
			Placebo	63	60 (95.2)	-0.82 (1.12)	-3.0	-1.40	-0.70	-0.20	2.6	
		Week 20	Tezepelumab	57	56 (98.2)	-1.43 (1.22)	-4.4	-2.10	-1.50	-0.80	2.6	-0.60 [-0.98, -0.23]
			Placebo	63	60 (95.2)	-0.72 (1.14)	-3.6	-1.40	-0.60	-0.10	2.6	
		Week 22	Tezepelumab	57	56 (98.2)	-1.31 (1.35)	-4.4	-2.10	-1.40	-0.60	2.6	-0.45 [-0.82, -0.08]
			Placebo	63	60 (95.2)	-0.75 (1.09)	-3.0	-1.40	-0.80	0.00	2.6	
		Week 24	Tezepelumab	57	56 (98.2)	-1.36 (1.26)	-4.8	-2.00	-1.50	-0.60	2.6	-0.54 [-0.91, -0.17]
			Placebo	63	60 (95.2)	-0.72 (1.11)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 26	Tezepelumab	57	56 (98.2)	-1.46 (1.29)	-4.4	-2.30	-1.50	-0.60	2.6	-0.54 [-0.91, -0.17]
			Placebo	63	60 (95.2)	-0.79 (1.19)	-4.2	-1.60	-0.80	0.10	2.6	
		Week 28	Tezepelumab	57	56 (98.2)	-1.34 (1.28)	-4.4	-2.20	-1.40	-0.50	2.6	-0.40 [-0.77, -0.04]
			Placebo	63	60 (95.2)	-0.83 (1.24)	-4.2	-1.60	-0.70	0.00	2.6	
		Week 30	Tezepelumab	57	56 (98.2)	-1.45 (1.30)	-4.4	-2.40	-1.40	-0.80	2.6	-0.48 [-0.85, -0.11]
			Placebo	63	60 (95.2)	-0.85 (1.20)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 32	Tezepelumab	57	56 (98.2)	-1.51 (1.30)	-4.4	-2.40	-1.60	-0.90	2.6	-0.55 [-0.92, -0.18]
			Placebo	63	60 (95.2)	-0.82 (1.20)	-3.6	-1.60	-0.80	0.00	2.6	
		Week 34	Tezepelumab	57	56 (98.2)	-1.44 (1.27)	-4.4	-2.30	-1.60	-0.70	2.6	-0.43 [-0.80, -0.06]
			Placebo	63	60 (95.2)	-0.91 (1.23)	-4.2	-1.70	-0.90	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 25 ppb	Change from baseline	Week 36	Tezepelumab	57	56 (98.2)	-1.40 (1.36)	-4.4	-2.40	-1.60	-0.60	2.6	-0.57 [-0.94, -0.20]
			Placebo	63	60 (95.2)	-0.67 (1.19)	-3.6	-1.40	-0.50	0.00	2.6	
		Week 38	Tezepelumab	57	56 (98.2)	-1.51 (1.31)	-4.4	-2.40	-1.50	-0.80	2.6	-0.49 [-0.86, -0.12]
			Placebo	63	60 (95.2)	-0.88 (1.24)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 40	Tezepelumab	57	56 (98.2)	-1.54 (1.34)	-4.4	-2.50	-1.60	-0.90	2.6	-0.59 [-0.96, -0.22]
			Placebo	63	60 (95.2)	-0.78 (1.23)	-4.2	-1.50	-0.80	0.00	2.6	
		Week 42	Tezepelumab	57	56 (98.2)	-1.55 (1.37)	-4.4	-2.40	-1.60	-0.70	2.6	-0.54 [-0.91, -0.17]
			Placebo	63	60 (95.2)	-0.86 (1.20)	-4.2	-1.60	-0.90	-0.20	2.6	
		Week 44	Tezepelumab	57	56 (98.2)	-1.63 (1.33)	-4.4	-2.60	-1.60	-0.90	2.6	-0.65 [-1.03, -0.28]
			Placebo	63	60 (95.2)	-0.81 (1.20)	-4.2	-1.60	-0.90	0.00	2.6	
		Week 46	Tezepelumab	57	56 (98.2)	-1.64 (1.33)	-4.4	-2.50	-1.60	-1.00	2.6	-0.62 [-0.99, -0.25]
			Placebo	63	60 (95.2)	-0.88 (1.13)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 48	Tezepelumab	57	56 (98.2)	-1.54 (1.30)	-4.4	-2.40	-1.60	-0.70	2.6	-0.64 [-1.01, -0.26]
			Placebo	63	60 (95.2)	-0.77 (1.13)	-3.8	-1.40	-0.70	0.00	2.6	
		Week 50	Tezepelumab	57	56 (98.2)	-1.62 (1.30)	-4.4	-2.50	-1.60	-1.00	2.6	-0.61 [-0.98, -0.23]
			Placebo	63	60 (95.2)	-0.90 (1.10)	-4.2	-1.60	-0.90	-0.20	2.6	
		Week 52	Tezepelumab	57	56 (98.2)	-1.62 (1.32)	-4.4	-2.60	-1.60	-1.00	2.6	-0.64 [-1.01, -0.27]
			Placebo	63	60 (95.2)	-0.84 (1.13)	-4.2	-1.60	-0.70	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.95 (0.75)	1.0	2.60	3.00	3.20	5.0	
			Placebo	66	66 (100.0)	2.79 (0.71)	1.0	2.60	2.90	3.20	4.8	
		Week 2	Tezepelumab	57	56 (98.2)	2.34 (0.92)	0.0	1.60	2.60	3.00	4.0	
			Placebo	66	58 (87.9)	2.44 (0.80)	0.4	2.00	2.60	3.00	4.8	
		Week 4	Tezepelumab	57	56 (98.2)	1.99 (0.91)	0.0	1.30	2.20	2.80	3.6	
			Placebo	66	58 (87.9)	2.44 (0.90)	0.2	2.00	2.60	3.00	4.2	
		Week 6	Tezepelumab	57	56 (98.2)	1.80 (0.93)	0.0	1.30	1.80	2.40	3.8	
			Placebo	66	59 (89.4)	2.22 (0.99)	0.2	1.60	2.20	2.80	5.0	
		Week 8	Tezepelumab	57	56 (98.2)	1.83 (1.02)	0.0	1.40	1.90	2.60	5.2	
			Placebo	66	60 (90.9)	2.23 (0.96)	0.0	1.70	2.40	3.00	4.6	
		Week 10	Tezepelumab	57	56 (98.2)	1.71 (0.99)	0.0	1.20	1.80	2.30	4.8	
			Placebo	66	60 (90.9)	2.10 (0.95)	0.2	1.40	2.20	2.70	4.4	
		Week 12	Tezepelumab	57	56 (98.2)	1.65 (1.10)	0.0	0.80	1.60	2.60	4.8	
			Placebo	66	60 (90.9)	2.13 (0.98)	0.0	1.50	2.20	2.80	4.4	
		Week 14	Tezepelumab	57	56 (98.2)	1.51 (1.00)	0.0	0.90	1.40	2.20	4.8	
			Placebo	66	60 (90.9)	2.00 (0.96)	0.0	1.40	2.00	2.60	5.0	
		Week 16	Tezepelumab	57	56 (98.2)	1.69 (1.09)	0.0	0.80	1.70	2.50	4.8	
			Placebo	66	60 (90.9)	2.16 (1.04)	0.0	1.60	2.30	3.00	4.4	
		Week 18	Tezepelumab	57	56 (98.2)	1.54 (0.93)	0.0	1.00	1.50	2.10	4.8	
			Placebo	66	60 (90.9)	2.00 (0.97)	0.0	1.40	2.00	2.60	4.4	
		Week 20	Tezepelumab	57	56 (98.2)	1.58 (1.05)	0.0	0.80	1.60	2.40	4.8	
			Placebo	66	60 (90.9)	2.21 (1.03)	0.0	1.50	2.40	2.90	4.4	
		Week 22	Tezepelumab	57	56 (98.2)	1.71 (0.99)	0.0	1.20	1.70	2.40	4.8	
			Placebo	66	60 (90.9)	2.13 (1.03)	0.0	1.50	2.20	2.80	4.4	
		Week 24	Tezepelumab	57	56 (98.2)	1.73 (1.08)	0.0	1.10	1.60	2.60	4.8	
			Placebo	66	60 (90.9)	2.15 (1.06)	0.0	1.40	2.40	3.00	4.4	
		Week 26	Tezepelumab	57	57 (100.0)	1.59 (0.99)	0.0	1.00	1.60	2.40	4.8	
			Placebo	66	60 (90.9)	2.09 (1.05)	0.0	1.00	2.10	3.00	4.4	
		Week 28	Tezepelumab	57	57 (100.0)	1.67 (1.03)	0.0	1.00	1.80	2.40	4.8	
			Placebo	66	60 (90.9)	2.17 (1.10)	0.0	1.20	2.30	2.90	4.4	
		Week 30	Tezepelumab	57	57 (100.0)	1.69 (1.04)	0.0	1.00	1.60	2.40	4.8	
			Placebo	66	61 (92.4)	2.14 (1.07)	0.0	1.60	2.40	3.00	4.4	
		Week 32	Tezepelumab	57	57 (100.0)	1.65 (1.04)	0.0	1.00	1.60	2.40	4.8	
			Placebo	66	61 (92.4)	2.18 (1.10)	0.0	1.20	2.40	3.00	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Absolute values	Week 34	Tezepelumab	57	57 (100.0)	1.66 (1.11)	0.0	1.00	1.40	2.60	4.8	
			Placebo	66	61 (92.4)	2.10 (1.14)	0.0	1.40	2.20	3.00	4.8	
		Week 36	Tezepelumab	57	57 (100.0)	1.75 (1.15)	0.0	1.00	1.60	2.40	5.0	
			Placebo	66	61 (92.4)	2.26 (1.10)	0.0	1.40	2.40	3.00	4.8	
		Week 38	Tezepelumab	57	57 (100.0)	1.67 (1.10)	0.0	1.00	1.60	2.40	4.8	
			Placebo	66	61 (92.4)	2.07 (1.10)	0.0	1.00	2.00	2.80	4.8	
		Week 40	Tezepelumab	57	57 (100.0)	1.66 (1.11)	0.0	0.80	1.80	2.40	4.8	
			Placebo	66	61 (92.4)	2.24 (1.06)	0.0	1.60	2.40	3.00	4.4	
		Week 42	Tezepelumab	57	57 (100.0)	1.65 (1.07)	0.0	1.00	1.60	2.40	4.8	
			Placebo	66	61 (92.4)	2.13 (1.09)	0.0	1.40	2.20	2.80	4.6	
		Week 44	Tezepelumab	57	57 (100.0)	1.66 (1.11)	0.0	0.80	1.60	2.40	4.8	
			Placebo	66	62 (93.9)	2.33 (1.00)	0.0	1.60	2.60	3.00	4.4	
		Week 46	Tezepelumab	57	57 (100.0)	1.68 (1.12)	0.0	1.00	1.60	2.40	4.8	
			Placebo	66	62 (93.9)	2.08 (1.05)	0.0	1.40	2.00	2.80	4.4	
		Week 48	Tezepelumab	57	57 (100.0)	1.70 (1.10)	0.0	0.80	1.80	2.40	4.8	
			Placebo	66	62 (93.9)	2.16 (1.06)	0.0	1.40	2.40	2.80	4.6	
		Week 50	Tezepelumab	57	57 (100.0)	1.62 (1.06)	0.0	0.80	1.40	2.40	4.8	
			Placebo	66	62 (93.9)	2.09 (0.99)	0.0	1.20	2.20	2.80	4.4	
		Week 52	Tezepelumab	57	57 (100.0)	1.63 (1.08)	0.0	0.80	1.60	2.40	4.8	
			Placebo	66	62 (93.9)	2.15 (1.03)	0.0	1.20	2.40	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	57	56 (98.2)	-0.64 (0.69)	-3.0	-1.00	-0.60	-0.20	0.4	-0.40 [-0.77, -0.03]
			Placebo	66	58 (87.9)	-0.35 (0.74)	-2.8	-0.80	-0.30	0.00	1.4	
		Week 4	Tezepelumab	57	56 (98.2)	-0.98 (0.79)	-3.0	-1.40	-0.80	-0.40	0.6	-0.73 [-1.11, -0.35]
			Placebo	66	58 (87.9)	-0.36 (0.91)	-2.6	-1.00	-0.20	0.20	1.6	
		Week 6	Tezepelumab	57	56 (98.2)	-1.17 (0.86)	-3.0	-1.70	-1.20	-0.60	1.2	-0.66 [-1.03, -0.28]
			Placebo	66	59 (89.4)	-0.56 (0.99)	-2.6	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	57	56 (98.2)	-1.14 (1.03)	-3.2	-1.80	-1.20	-0.50	2.6	-0.61 [-0.98, -0.23]
			Placebo	66	60 (90.9)	-0.57 (0.87)	-2.8	-1.00	-0.60	0.00	1.0	
		Week 10	Tezepelumab	57	56 (98.2)	-1.27 (0.92)	-3.4	-1.80	-1.20	-0.80	0.6	-0.60 [-0.97, -0.23]
			Placebo	66	60 (90.9)	-0.70 (0.99)	-3.0	-1.10	-0.60	-0.20	2.6	
		Week 12	Tezepelumab	57	56 (98.2)	-1.32 (0.95)	-3.2	-2.00	-1.20	-0.60	0.6	-0.67 [-1.05, -0.30]
			Placebo	66	60 (90.9)	-0.67 (0.98)	-3.0	-1.00	-0.60	0.00	1.6	
		Week 14	Tezepelumab	57	56 (98.2)	-1.46 (0.97)	-4.0	-2.10	-1.40	-0.90	0.6	-0.69 [-1.07, -0.32]
			Placebo	66	60 (90.9)	-0.79 (0.96)	-3.0	-1.40	-0.80	-0.20	1.4	
		Week 16	Tezepelumab	57	56 (98.2)	-1.29 (1.06)	-3.2	-2.20	-1.20	-0.80	1.0	-0.64 [-1.01, -0.27]
			Placebo	66	60 (90.9)	-0.63 (0.99)	-3.0	-1.20	-0.60	0.00	2.6	
		Week 18	Tezepelumab	57	56 (98.2)	-1.43 (0.99)	-3.8	-2.00	-1.40	-0.80	0.6	-0.64 [-1.01, -0.26]
			Placebo	66	60 (90.9)	-0.80 (1.00)	-3.2	-1.40	-0.60	-0.30	2.6	
		Week 20	Tezepelumab	57	56 (98.2)	-1.40 (0.97)	-3.4	-2.20	-1.30	-0.80	0.6	-0.80 [-1.18, -0.42]
			Placebo	66	60 (90.9)	-0.59 (1.04)	-3.0	-1.20	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	57	56 (98.2)	-1.26 (0.99)	-3.4	-1.90	-1.20	-0.60	0.6	-0.59 [-0.96, -0.22]
			Placebo	66	60 (90.9)	-0.67 (1.02)	-3.2	-1.40	-0.60	0.00	2.6	
		Week 24	Tezepelumab	57	56 (98.2)	-1.24 (0.92)	-3.4	-1.90	-1.20	-0.50	0.6	-0.58 [-0.95, -0.21]
			Placebo	66	60 (90.9)	-0.65 (1.11)	-3.0	-1.30	-0.50	0.00	2.6	
		Week 26	Tezepelumab	57	57 (100.0)	-1.37 (1.04)	-3.4	-2.20	-1.40	-0.60	0.6	-0.61 [-0.99, -0.24]
			Placebo	66	60 (90.9)	-0.71 (1.11)	-3.0	-1.50	-0.80	0.20	2.6	
		Week 28	Tezepelumab	57	57 (100.0)	-1.28 (1.00)	-3.4	-2.20	-1.20	-0.80	1.0	-0.62 [-0.99, -0.25]
			Placebo	66	60 (90.9)	-0.63 (1.12)	-3.0	-1.20	-0.50	0.00	2.6	
		Week 30	Tezepelumab	57	57 (100.0)	-1.27 (1.14)	-3.8	-2.20	-1.20	-0.60	2.0	-0.54 [-0.90, -0.17]
			Placebo	66	61 (92.4)	-0.66 (1.13)	-3.2	-1.40	-0.60	0.00	2.6	
		Week 32	Tezepelumab	57	57 (100.0)	-1.31 (1.09)	-3.6	-2.20	-1.00	-0.80	1.2	-0.62 [-0.99, -0.25]
			Placebo	66	61 (92.4)	-0.62 (1.13)	-3.2	-1.40	-0.40	0.00	2.6	
		Week 34	Tezepelumab	57	57 (100.0)	-1.29 (1.14)	-3.2	-2.20	-1.40	-0.60	2.2	-0.52 [-0.88, -0.15]
			Placebo	66	61 (92.4)	-0.70 (1.17)	-3.4	-1.40	-0.60	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Change from baseline	Week 36	Tezepelumab	57	57 (100.0)	-1.20 (1.20)	-3.2	-2.20	-1.20	-0.60	2.0	-0.55 [-0.92, -0.18]
			Placebo	66	61 (92.4)	-0.54 (1.19)	-3.2	-1.20	-0.40	0.00	2.6	
		Week 38	Tezepelumab	57	57 (100.0)	-1.28 (1.19)	-3.8	-2.20	-1.20	-0.80	2.6	-0.46 [-0.83, -0.09]
			Placebo	66	61 (92.4)	-0.73 (1.22)	-3.4	-1.40	-0.60	0.00	2.6	
		Week 40	Tezepelumab	57	57 (100.0)	-1.29 (1.20)	-4.2	-2.20	-1.20	-0.80	1.8	-0.62 [-0.99, -0.25]
			Placebo	66	61 (92.4)	-0.56 (1.16)	-3.6	-1.20	-0.60	0.00	2.6	
		Week 42	Tezepelumab	57	57 (100.0)	-1.31 (1.14)	-3.6	-2.00	-1.20	-0.60	2.2	-0.54 [-0.91, -0.17]
			Placebo	66	61 (92.4)	-0.67 (1.21)	-3.6	-1.40	-0.60	0.00	2.6	
		Week 44	Tezepelumab	57	57 (100.0)	-1.29 (1.24)	-4.4	-2.00	-1.20	-0.60	1.6	-0.70 [-1.07, -0.33]
			Placebo	66	62 (93.9)	-0.47 (1.12)	-3.2	-1.20	-0.40	0.20	2.6	
		Week 46	Tezepelumab	57	57 (100.0)	-1.27 (1.19)	-4.0	-2.00	-1.20	-0.80	1.8	-0.47 [-0.83, -0.10]
			Placebo	66	62 (93.9)	-0.72 (1.19)	-3.2	-1.40	-0.80	0.20	2.6	
		Week 48	Tezepelumab	57	57 (100.0)	-1.25 (1.18)	-4.0	-2.20	-1.00	-0.40	2.0	-0.53 [-0.90, -0.16]
			Placebo	66	62 (93.9)	-0.64 (1.15)	-3.2	-1.20	-0.60	0.00	2.6	
		Week 50	Tezepelumab	57	57 (100.0)	-1.33 (1.11)	-3.8	-2.00	-1.40	-0.80	2.0	-0.57 [-0.94, -0.20]
			Placebo	66	62 (93.9)	-0.70 (1.09)	-3.2	-1.20	-0.60	0.00	2.6	
		Week 52	Tezepelumab	57	57 (100.0)	-1.32 (1.16)	-4.0	-2.20	-1.20	-0.60	2.0	-0.60 [-0.97, -0.23]
			Placebo	66	62 (93.9)	-0.64 (1.11)	-3.2	-1.20	-0.60	0.00	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	71	71 (100.0)	2.74 (0.91)	0.0	2.20	2.80	3.20	5.2	
			Placebo	63	63 (100.0)	2.84 (0.76)	0.4	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	71	67 (94.4)	2.19 (1.03)	0.0	1.60	2.20	3.00	4.4	
			Placebo	63	58 (92.1)	2.40 (0.87)	0.0	2.00	2.40	3.00	5.0	
		Week 4	Tezepelumab	71	67 (94.4)	1.89 (1.12)	0.0	1.00	2.00	2.80	4.2	
			Placebo	63	58 (92.1)	2.25 (0.82)	0.2	1.80	2.30	2.80	4.4	
		Week 6	Tezepelumab	71	67 (94.4)	1.91 (1.08)	0.0	1.00	1.80	2.80	4.2	
			Placebo	63	58 (92.1)	2.19 (1.04)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	71	67 (94.4)	1.75 (1.16)	0.0	1.00	1.60	2.80	4.2	
			Placebo	63	58 (92.1)	2.11 (1.01)	0.2	1.40	2.00	2.80	5.0	
		Week 10	Tezepelumab	71	67 (94.4)	1.73 (1.12)	0.0	0.80	1.60	2.60	4.2	
			Placebo	63	59 (93.7)	2.11 (0.94)	0.0	1.60	2.20	3.00	5.2	
		Week 12	Tezepelumab	71	67 (94.4)	1.64 (1.10)	0.0	0.60	1.60	2.60	4.2	
			Placebo	63	59 (93.7)	1.92 (0.98)	0.0	1.20	2.00	2.60	4.4	
		Week 14	Tezepelumab	71	67 (94.4)	1.51 (1.13)	0.0	0.60	1.20	2.40	4.2	
			Placebo	63	59 (93.7)	1.96 (0.92)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	71	67 (94.4)	1.64 (1.09)	0.0	0.80	1.40	2.80	4.2	
			Placebo	63	59 (93.7)	2.05 (1.07)	0.0	1.20	2.00	2.80	5.0	
		Week 18	Tezepelumab	71	67 (94.4)	1.56 (1.10)	0.0	0.80	1.20	2.40	4.2	
			Placebo	63	59 (93.7)	2.00 (1.06)	0.0	1.40	2.00	2.80	5.0	
		Week 20	Tezepelumab	71	67 (94.4)	1.68 (1.12)	0.0	0.80	1.40	2.60	5.0	
			Placebo	63	59 (93.7)	1.91 (0.95)	0.0	1.20	1.80	2.60	5.0	
		Week 22	Tezepelumab	71	67 (94.4)	1.62 (1.08)	0.0	0.80	1.60	2.40	4.2	
			Placebo	63	59 (93.7)	1.92 (0.98)	0.0	1.20	2.00	2.60	5.0	
		Week 24	Tezepelumab	71	67 (94.4)	1.58 (1.10)	0.0	0.80	1.60	2.40	4.2	
			Placebo	63	59 (93.7)	1.85 (0.88)	0.2	1.00	1.80	2.60	4.0	
		Week 26	Tezepelumab	71	67 (94.4)	1.63 (1.11)	0.0	0.80	1.60	2.40	4.2	
			Placebo	63	59 (93.7)	1.78 (0.93)	0.0	1.00	1.60	2.60	4.0	
		Week 28	Tezepelumab	71	68 (95.8)	1.69 (1.16)	0.0	0.70	1.60	2.80	4.2	
			Placebo	63	60 (95.2)	1.81 (1.04)	0.0	1.00	1.90	2.60	4.0	
		Week 30	Tezepelumab	71	69 (97.2)	1.57 (1.08)	0.0	0.60	1.40	2.20	4.2	
			Placebo	63	60 (95.2)	1.83 (1.02)	0.0	1.00	1.90	2.50	4.2	
		Week 32	Tezepelumab	71	69 (97.2)	1.50 (1.11)	0.0	0.80	1.20	2.40	4.2	
			Placebo	63	60 (95.2)	1.68 (0.96)	0.0	0.80	1.60	2.60	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Absolute values	Week 34	Tezepelumab	71	69 (97.2)	1.52 (1.17)	0.0	0.60	1.20	2.40	4.2	
			Placebo	63	60 (95.2)	1.70 (0.95)	0.0	1.00	1.80	2.50	4.0	
		Week 36	Tezepelumab	71	69 (97.2)	1.61 (1.11)	0.0	0.80	1.40	2.40	4.2	
			Placebo	63	60 (95.2)	1.73 (0.99)	0.0	1.00	1.80	2.60	4.0	
		Week 38	Tezepelumab	71	69 (97.2)	1.52 (1.14)	0.0	0.60	1.40	2.20	4.6	
			Placebo	63	60 (95.2)	1.74 (0.99)	0.0	1.00	1.50	2.60	4.0	
		Week 40	Tezepelumab	71	69 (97.2)	1.53 (1.14)	0.0	0.60	1.40	2.40	4.2	
			Placebo	63	60 (95.2)	1.72 (1.02)	0.0	0.90	1.70	2.60	4.2	
		Week 42	Tezepelumab	71	69 (97.2)	1.48 (1.14)	0.0	0.60	1.20	2.20	4.6	
			Placebo	63	60 (95.2)	1.77 (0.95)	0.0	1.00	2.00	2.60	3.4	
		Week 44	Tezepelumab	71	69 (97.2)	1.50 (1.10)	0.0	0.60	1.20	2.40	4.2	
			Placebo	63	60 (95.2)	1.67 (1.01)	0.0	0.90	1.80	2.60	4.2	
		Week 46	Tezepelumab	71	69 (97.2)	1.43 (1.11)	0.0	0.60	1.00	2.20	4.2	
			Placebo	63	60 (95.2)	1.65 (0.92)	0.0	1.00	1.60	2.30	3.4	
		Week 48	Tezepelumab	71	69 (97.2)	1.54 (1.15)	0.0	0.60	1.40	2.40	4.2	
			Placebo	63	60 (95.2)	1.65 (0.97)	0.0	1.00	1.60	2.50	3.4	
		Week 50	Tezepelumab	71	69 (97.2)	1.46 (1.16)	0.0	0.60	1.20	2.20	4.2	
			Placebo	63	60 (95.2)	1.60 (0.93)	0.0	1.00	1.60	2.40	3.4	
		Week 52	Tezepelumab	71	69 (97.2)	1.51 (1.14)	0.0	0.60	1.20	2.20	4.4	
			Placebo	63	60 (95.2)	1.63 (0.96)	0.0	1.00	1.60	2.40	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status											
Any positive	Change from baseline	Week 2	Tezepelumab	71	67 (94.4)	-0.51 (0.81)	-3.2	-0.80	-0.40	0.00	0.8	-0.07 [-0.42, 0.28]
			Placebo	63	58 (92.1)	-0.46 (0.79)	-3.0	-1.00	-0.30	0.00	1.2	
		Week 4	Tezepelumab	71	67 (94.4)	-0.81 (1.10)	-3.8	-1.40	-0.60	-0.20	2.6	-0.20 [-0.55, 0.15]
			Placebo	63	58 (92.1)	-0.61 (0.90)	-3.0	-1.40	-0.40	0.00	1.0	
		Week 6	Tezepelumab	71	67 (94.4)	-0.80 (1.12)	-4.0	-1.40	-0.80	0.00	2.6	-0.12 [-0.47, 0.23]
			Placebo	63	58 (92.1)	-0.67 (0.95)	-3.4	-1.40	-0.60	0.00	1.4	
		Week 8	Tezepelumab	71	67 (94.4)	-0.96 (1.12)	-4.0	-1.60	-1.00	-0.20	2.6	-0.19 [-0.55, 0.16]
			Placebo	63	58 (92.1)	-0.75 (1.04)	-3.6	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	71	67 (94.4)	-0.98 (1.11)	-4.0	-1.60	-1.00	-0.20	2.6	-0.19 [-0.54, 0.16]
			Placebo	63	59 (93.7)	-0.77 (1.07)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	71	67 (94.4)	-1.07 (1.12)	-4.0	-1.80	-1.00	-0.40	2.6	-0.10 [-0.45, 0.25]
			Placebo	63	59 (93.7)	-0.96 (1.09)	-3.8	-1.80	-0.80	-0.20	1.4	
		Week 14	Tezepelumab	71	67 (94.4)	-1.19 (1.13)	-4.0	-2.00	-1.20	-0.40	2.6	-0.26 [-0.61, 0.09]
			Placebo	63	59 (93.7)	-0.91 (1.06)	-3.4	-1.60	-0.80	-0.20	2.4	
		Week 16	Tezepelumab	71	67 (94.4)	-1.07 (1.08)	-4.0	-1.80	-1.00	-0.40	2.6	-0.23 [-0.58, 0.13]
			Placebo	63	59 (93.7)	-0.82 (1.19)	-3.6	-1.40	-1.00	0.00	2.4	
		Week 18	Tezepelumab	71	67 (94.4)	-1.15 (1.12)	-4.0	-1.80	-1.00	-0.40	2.6	-0.25 [-0.60, 0.10]
			Placebo	63	59 (93.7)	-0.87 (1.16)	-3.6	-1.60	-0.80	0.00	2.4	
		Week 20	Tezepelumab	71	67 (94.4)	-1.03 (1.11)	-4.0	-1.80	-1.00	-0.40	2.6	-0.06 [-0.41, 0.29]
			Placebo	63	59 (93.7)	-0.96 (1.12)	-3.6	-1.60	-0.80	-0.20	2.4	
		Week 22	Tezepelumab	71	67 (94.4)	-1.09 (1.19)	-4.0	-1.80	-1.00	-0.40	2.6	-0.12 [-0.47, 0.23]
			Placebo	63	59 (93.7)	-0.95 (1.10)	-3.8	-1.60	-1.00	0.00	2.4	
		Week 24	Tezepelumab	71	67 (94.4)	-1.13 (1.11)	-4.0	-2.00	-1.00	-0.40	2.6	-0.10 [-0.45, 0.25]
			Placebo	63	59 (93.7)	-1.02 (1.01)	-3.8	-1.60	-1.00	-0.20	1.4	
		Week 26	Tezepelumab	71	67 (94.4)	-1.08 (1.12)	-4.0	-1.80	-1.00	-0.40	2.6	0.01 [-0.34, 0.36]
			Placebo	63	59 (93.7)	-1.09 (1.08)	-4.2	-1.80	-1.20	0.00	1.4	
		Week 28	Tezepelumab	71	68 (95.8)	-1.02 (1.15)	-4.0	-1.80	-0.80	-0.20	2.6	0.00 [-0.34, 0.35]
			Placebo	63	60 (95.2)	-1.02 (1.15)	-4.2	-1.70	-1.00	-0.20	1.4	
		Week 30	Tezepelumab	71	69 (97.2)	-1.15 (1.13)	-3.8	-1.80	-1.00	-0.40	2.6	-0.13 [-0.48, 0.21]
			Placebo	63	60 (95.2)	-1.00 (1.14)	-3.4	-1.80	-1.20	-0.20	2.0	
		Week 32	Tezepelumab	71	69 (97.2)	-1.23 (1.15)	-4.0	-2.00	-1.20	-0.60	2.6	-0.07 [-0.41, 0.28]
			Placebo	63	60 (95.2)	-1.15 (1.04)	-3.6	-1.80	-1.30	-0.40	1.4	
		Week 34	Tezepelumab	71	69 (97.2)	-1.20 (1.17)	-4.0	-2.00	-1.20	-0.40	2.6	-0.06 [-0.41, 0.29]
			Placebo	63	60 (95.2)	-1.13 (1.02)	-4.2	-1.70	-1.20	-0.30	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Change from baseline	Week 36	Tezepelumab	71	69 (97.2)	-1.11 (1.20)	-4.0	-1.80	-1.20	-0.20	2.6	-0.01 [-0.36, 0.33]
			Placebo	63	60 (95.2)	-1.10 (1.06)	-3.6	-1.70	-1.20	-0.20	1.4	
		Week 38	Tezepelumab	71	69 (97.2)	-1.21 (1.20)	-4.0	-2.20	-1.20	-0.40	2.6	-0.10 [-0.45, 0.25]
			Placebo	63	60 (95.2)	-1.09 (1.05)	-4.2	-1.60	-1.20	-0.40	1.4	
		Week 40	Tezepelumab	71	69 (97.2)	-1.19 (1.19)	-4.0	-2.00	-1.00	-0.40	2.6	-0.07 [-0.42, 0.27]
			Placebo	63	60 (95.2)	-1.11 (1.02)	-4.2	-1.70	-1.20	-0.40	1.4	
		Week 42	Tezepelumab	71	69 (97.2)	-1.24 (1.22)	-4.0	-2.00	-1.40	-0.40	2.6	-0.17 [-0.51, 0.18]
			Placebo	63	60 (95.2)	-1.06 (0.96)	-4.2	-1.60	-1.00	-0.30	0.6	
		Week 44	Tezepelumab	71	69 (97.2)	-1.22 (1.18)	-4.0	-2.20	-1.20	-0.40	2.6	-0.05 [-0.40, 0.29]
			Placebo	63	60 (95.2)	-1.16 (1.03)	-4.2	-1.80	-1.20	-0.40	0.8	
		Week 46	Tezepelumab	71	69 (97.2)	-1.29 (1.17)	-4.0	-2.20	-1.20	-0.40	2.6	-0.10 [-0.45, 0.24]
			Placebo	63	60 (95.2)	-1.18 (0.92)	-4.2	-1.60	-1.30	-0.50	1.0	
		Week 48	Tezepelumab	71	69 (97.2)	-1.18 (1.19)	-4.0	-2.00	-1.20	-0.40	2.6	0.01 [-0.34, 0.35]
			Placebo	63	60 (95.2)	-1.18 (1.01)	-3.8	-1.80	-1.20	-0.40	1.2	
		Week 50	Tezepelumab	71	69 (97.2)	-1.27 (1.26)	-4.0	-2.20	-1.40	-0.40	2.6	-0.03 [-0.38, 0.32]
			Placebo	63	60 (95.2)	-1.23 (0.96)	-4.2	-1.70	-1.40	-0.40	0.6	
		Week 52	Tezepelumab	71	69 (97.2)	-1.21 (1.23)	-4.0	-2.00	-1.20	-0.20	2.6	-0.01 [-0.36, 0.34]
			Placebo	63	60 (95.2)	-1.20 (1.00)	-4.2	-1.70	-1.30	-0.50	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	35	35 (100.0)	2.70 (0.64)	1.0	2.20	2.60	3.20	4.2	
			Placebo	32	32 (100.0)	2.61 (0.67)	1.0	2.20	2.80	3.00	3.8	
		Week 2	Tezepelumab	35	33 (94.3)	2.20 (0.94)	0.0	1.60	2.20	2.80	4.0	
			Placebo	32	27 (84.4)	2.10 (0.85)	0.4	1.60	2.00	2.80	3.8	
		Week 4	Tezepelumab	35	33 (94.3)	1.90 (0.93)	0.2	1.00	1.80	2.80	3.4	
			Placebo	32	27 (84.4)	2.07 (0.93)	0.6	1.20	2.20	2.80	4.2	
		Week 6	Tezepelumab	35	33 (94.3)	1.68 (0.95)	0.0	1.20	1.60	2.40	3.8	
			Placebo	32	28 (87.5)	2.13 (1.06)	0.4	1.30	2.10	2.80	5.0	
		Week 8	Tezepelumab	35	33 (94.3)	1.79 (1.16)	0.0	1.00	1.60	2.60	5.2	
			Placebo	32	28 (87.5)	2.21 (1.10)	0.4	1.20	2.40	3.00	4.0	
		Week 10	Tezepelumab	35	33 (94.3)	1.61 (1.10)	0.0	0.80	1.60	2.20	4.8	
			Placebo	32	28 (87.5)	1.94 (1.01)	0.2	1.20	1.90	2.40	4.0	
		Week 12	Tezepelumab	35	33 (94.3)	1.50 (1.12)	0.0	0.60	1.40	2.20	4.8	
			Placebo	32	28 (87.5)	1.77 (0.99)	0.0	1.00	2.00	2.30	4.4	
		Week 14	Tezepelumab	35	33 (94.3)	1.43 (1.04)	0.0	1.00	1.40	1.80	4.8	
			Placebo	32	28 (87.5)	1.57 (0.88)	0.0	1.00	1.50	2.40	3.0	
		Week 16	Tezepelumab	35	33 (94.3)	1.56 (1.13)	0.0	0.80	1.40	2.40	4.8	
			Placebo	32	28 (87.5)	1.97 (1.20)	0.0	0.90	2.00	2.90	4.0	
		Week 18	Tezepelumab	35	34 (97.1)	1.48 (1.05)	0.0	1.00	1.20	2.20	4.8	
			Placebo	32	28 (87.5)	1.69 (1.16)	0.0	0.80	1.70	2.70	4.0	
		Week 20	Tezepelumab	35	34 (97.1)	1.56 (1.13)	0.0	0.60	1.40	2.40	4.8	
			Placebo	32	28 (87.5)	1.81 (1.27)	0.0	0.40	2.10	2.80	4.0	
		Week 22	Tezepelumab	35	34 (97.1)	1.67 (1.10)	0.0	1.00	1.70	2.40	4.8	
			Placebo	32	28 (87.5)	1.76 (1.25)	0.0	0.60	1.70	2.90	4.0	
		Week 24	Tezepelumab	35	34 (97.1)	1.52 (1.09)	0.0	0.80	1.40	2.20	4.8	
			Placebo	32	28 (87.5)	1.86 (1.31)	0.0	0.40	2.20	3.00	4.0	
		Week 26	Tezepelumab	35	35 (100.0)	1.57 (1.05)	0.0	1.00	1.40	2.20	4.8	
			Placebo	32	28 (87.5)	1.90 (1.15)	0.0	1.00	1.70	2.80	4.4	
		Week 28	Tezepelumab	35	35 (100.0)	1.62 (1.18)	0.0	0.40	1.60	2.80	4.8	
			Placebo	32	28 (87.5)	2.20 (1.26)	0.0	1.10	2.30	3.20	4.4	
		Week 30	Tezepelumab	35	35 (100.0)	1.69 (1.13)	0.0	1.00	1.60	2.40	4.8	
			Placebo	32	28 (87.5)	1.91 (1.23)	0.0	0.70	2.20	3.00	4.0	
		Week 32	Tezepelumab	35	35 (100.0)	1.63 (1.15)	0.0	1.00	1.40	2.80	4.8	
			Placebo	32	28 (87.5)	1.97 (1.18)	0.0	0.80	2.20	3.00	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Absolute values	Week 34	Tezepelumab	35	35 (100.0)	1.65 (1.22)	0.0	0.80	1.40	2.80	4.8	
			Placebo	32	28 (87.5)	1.86 (1.25)	0.0	0.80	1.90	3.00	4.0	
		Week 36	Tezepelumab	35	35 (100.0)	1.61 (1.15)	0.0	0.80	1.40	2.60	4.8	
			Placebo	32	28 (87.5)	1.91 (1.29)	0.0	0.90	2.00	3.00	4.4	
		Week 38	Tezepelumab	35	35 (100.0)	1.68 (1.23)	0.0	0.60	1.40	2.60	4.8	
			Placebo	32	28 (87.5)	1.85 (1.14)	0.0	1.00	1.90	2.90	4.0	
		Week 40	Tezepelumab	35	35 (100.0)	1.72 (1.18)	0.0	0.80	1.80	2.60	4.8	
			Placebo	32	28 (87.5)	2.16 (1.29)	0.0	1.00	2.30	3.00	4.4	
		Week 42	Tezepelumab	35	35 (100.0)	1.67 (1.20)	0.0	0.80	1.60	2.60	4.8	
			Placebo	32	28 (87.5)	2.06 (1.27)	0.0	0.80	2.30	2.90	4.6	
		Week 44	Tezepelumab	35	35 (100.0)	1.67 (1.22)	0.0	0.80	1.60	2.80	4.8	
			Placebo	32	28 (87.5)	2.15 (1.16)	0.0	1.30	2.50	3.00	4.2	
		Week 46	Tezepelumab	35	35 (100.0)	1.69 (1.18)	0.0	1.00	1.80	2.60	4.8	
			Placebo	32	28 (87.5)	1.92 (1.26)	0.0	0.80	2.00	3.00	4.4	
		Week 48	Tezepelumab	35	35 (100.0)	1.68 (1.19)	0.0	0.80	1.60	2.60	4.8	
			Placebo	32	28 (87.5)	1.99 (1.30)	0.0	0.80	2.10	2.80	4.6	
		Week 50	Tezepelumab	35	35 (100.0)	1.59 (1.20)	0.0	0.80	1.40	2.60	4.8	
			Placebo	32	28 (87.5)	2.04 (1.16)	0.0	1.00	2.30	3.00	4.0	
		Week 52	Tezepelumab	35	35 (100.0)	1.55 (1.20)	0.0	0.40	1.60	2.00	4.8	
			Placebo	32	28 (87.5)	2.06 (1.20)	0.0	1.00	2.20	3.00	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	35	33 (94.3)	-0.55 (0.71)	-3.2	-0.80	-0.40	0.00	0.4	-0.01 [-0.52, 0.49]
			Placebo	32	27 (84.4)	-0.53 (0.97)	-2.8	-1.00	-0.40	0.20	1.2	
		Week 4	Tezepelumab	35	33 (94.3)	-0.85 (0.81)	-2.4	-1.40	-0.80	-0.20	0.6	-0.33 [-0.85, 0.18]
			Placebo	32	27 (84.4)	-0.56 (0.96)	-2.4	-1.00	-0.80	0.20	1.2	
		Week 6	Tezepelumab	35	33 (94.3)	-1.06 (0.94)	-2.8	-1.60	-1.20	-0.40	1.2	-0.57 [-1.08, -0.05]
			Placebo	32	28 (87.5)	-0.49 (1.07)	-2.6	-1.20	-0.50	0.20	1.6	
		Week 8	Tezepelumab	35	33 (94.3)	-0.96 (1.16)	-3.2	-1.60	-1.00	-0.40	2.6	-0.50 [-1.01, 0.01]
			Placebo	32	28 (87.5)	-0.41 (1.04)	-2.6	-1.00	-0.40	0.40	1.0	
		Week 10	Tezepelumab	35	33 (94.3)	-1.13 (1.01)	-3.4	-1.80	-1.20	-0.60	0.6	-0.43 [-0.94, 0.08]
			Placebo	32	28 (87.5)	-0.69 (1.09)	-2.6	-1.20	-0.60	-0.30	2.6	
		Week 12	Tezepelumab	35	33 (94.3)	-1.24 (0.93)	-3.0	-2.00	-1.20	-0.60	0.6	-0.39 [-0.90, 0.12]
			Placebo	32	28 (87.5)	-0.85 (1.08)	-3.0	-1.20	-0.80	-0.50	1.6	
		Week 14	Tezepelumab	35	33 (94.3)	-1.32 (0.92)	-3.4	-2.00	-1.40	-0.80	0.6	-0.27 [-0.78, 0.23]
			Placebo	32	28 (87.5)	-1.05 (1.03)	-3.0	-1.50	-1.00	-0.60	1.4	
		Week 16	Tezepelumab	35	33 (94.3)	-1.19 (1.03)	-3.2	-2.00	-1.20	-0.40	0.6	-0.46 [-0.98, 0.05]
			Placebo	32	28 (87.5)	-0.65 (1.30)	-3.0	-1.40	-0.80	0.00	2.6	
		Week 18	Tezepelumab	35	34 (97.1)	-1.25 (0.99)	-3.4	-2.00	-1.20	-0.60	0.6	-0.27 [-0.77, 0.24]
			Placebo	32	28 (87.5)	-0.94 (1.35)	-3.4	-1.80	-0.90	-0.20	2.6	
		Week 20	Tezepelumab	35	34 (97.1)	-1.16 (1.03)	-3.4	-2.20	-1.00	-0.40	0.6	-0.29 [-0.80, 0.21]
			Placebo	32	28 (87.5)	-0.81 (1.41)	-3.4	-2.00	-0.70	0.10	2.6	
		Week 22	Tezepelumab	35	34 (97.1)	-1.05 (1.01)	-3.2	-1.80	-1.00	-0.40	0.6	-0.16 [-0.66, 0.34]
			Placebo	32	28 (87.5)	-0.86 (1.42)	-3.4	-1.80	-0.90	0.10	2.6	
		Week 24	Tezepelumab	35	34 (97.1)	-1.20 (0.98)	-3.4	-2.20	-1.20	-0.40	0.6	-0.36 [-0.87, 0.14]
			Placebo	32	28 (87.5)	-0.76 (1.47)	-3.4	-1.80	-0.60	0.30	2.6	
		Week 26	Tezepelumab	35	35 (100.0)	-1.13 (1.00)	-3.0	-2.20	-1.00	-0.40	0.6	-0.34 [-0.84, 0.16]
			Placebo	32	28 (87.5)	-0.72 (1.37)	-3.0	-1.70	-1.00	0.40	2.6	
		Week 28	Tezepelumab	35	35 (100.0)	-1.07 (1.17)	-3.4	-2.20	-1.20	0.00	1.0	-0.52 [-1.03, -0.02]
			Placebo	32	28 (87.5)	-0.42 (1.35)	-3.0	-1.40	-0.20	0.50	2.6	
		Week 30	Tezepelumab	35	35 (100.0)	-1.01 (1.09)	-2.8	-2.20	-1.00	-0.40	2.0	-0.24 [-0.74, 0.26]
			Placebo	32	28 (87.5)	-0.71 (1.37)	-3.4	-1.60	-0.60	0.30	2.6	
		Week 32	Tezepelumab	35	35 (100.0)	-1.06 (1.03)	-3.2	-2.00	-1.00	-0.40	1.0	-0.35 [-0.85, 0.15]
			Placebo	32	28 (87.5)	-0.65 (1.35)	-3.4	-1.70	-0.60	0.30	2.6	
		Week 34	Tezepelumab	35	35 (100.0)	-1.05 (1.17)	-3.0	-2.20	-1.20	-0.40	2.2	-0.23 [-0.73, 0.27]
			Placebo	32	28 (87.5)	-0.76 (1.41)	-3.4	-1.70	-0.70	0.30	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Change from baseline	Week 36	Tezepelumab	35	35 (100.0)	-1.09 (1.11)	-3.2	-2.00	-1.20	-0.40	1.6	-0.30 [-0.80, 0.20]
			Placebo	32	28 (87.5)	-0.71 (1.46)	-3.4	-1.60	-0.70	0.30	2.6	
		Week 38	Tezepelumab	35	35 (100.0)	-1.02 (1.20)	-3.2	-2.20	-1.20	-0.40	2.6	-0.19 [-0.69, 0.31]
			Placebo	32	28 (87.5)	-0.77 (1.39)	-3.2	-1.60	-0.80	0.20	2.6	
		Week 40	Tezepelumab	35	35 (100.0)	-0.98 (1.14)	-3.4	-1.80	-1.00	0.00	1.8	-0.39 [-0.89, 0.11]
			Placebo	32	28 (87.5)	-0.46 (1.49)	-3.2	-1.50	-0.30	0.50	2.6	
		Week 42	Tezepelumab	35	35 (100.0)	-1.03 (1.15)	-2.8	-2.20	-1.00	-0.20	2.2	-0.35 [-0.85, 0.15]
			Placebo	32	28 (87.5)	-0.56 (1.50)	-3.2	-1.60	-0.60	0.40	2.6	
		Week 44	Tezepelumab	35	35 (100.0)	-1.02 (1.16)	-3.4	-1.80	-1.20	-0.20	1.6	-0.43 [-0.93, 0.07]
			Placebo	32	28 (87.5)	-0.47 (1.42)	-3.4	-1.30	-0.20	0.40	2.6	
		Week 46	Tezepelumab	35	35 (100.0)	-1.01 (1.09)	-2.6	-2.00	-1.00	0.00	1.8	-0.24 [-0.74, 0.26]
			Placebo	32	28 (87.5)	-0.70 (1.52)	-3.2	-1.80	-0.70	0.30	2.6	
		Week 48	Tezepelumab	35	35 (100.0)	-1.02 (1.12)	-2.6	-2.20	-0.80	-0.40	2.0	-0.30 [-0.80, 0.20]
			Placebo	32	28 (87.5)	-0.63 (1.51)	-3.2	-1.60	-0.50	0.40	2.6	
		Week 50	Tezepelumab	35	35 (100.0)	-1.11 (1.17)	-3.2	-2.20	-1.00	-0.40	2.0	-0.41 [-0.91, 0.09]
			Placebo	32	28 (87.5)	-0.58 (1.42)	-3.0	-1.50	-0.50	0.30	2.6	
		Week 52	Tezepelumab	35	35 (100.0)	-1.14 (1.19)	-3.2	-2.20	-1.00	-0.40	2.0	-0.45 [-0.95, 0.06]
			Placebo	32	28 (87.5)	-0.56 (1.46)	-3.0	-1.60	-0.50	0.30	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	95	95 (100.0)	2.91 (0.90)	0.0	2.40	2.80	3.20	5.2	
			Placebo	98	98 (100.0)	2.86 (0.75)	0.4	2.40	2.90	3.20	5.0	
		Week 2	Tezepelumab	95	91 (95.8)	2.27 (1.00)	0.0	1.60	2.40	3.00	4.4	
			Placebo	98	90 (91.8)	2.48 (0.84)	0.0	2.00	2.60	3.00	5.0	
		Week 4	Tezepelumab	95	91 (95.8)	1.95 (1.05)	0.0	1.20	2.20	2.80	4.2	
			Placebo	98	90 (91.8)	2.38 (0.86)	0.2	1.80	2.40	3.00	4.4	
		Week 6	Tezepelumab	95	91 (95.8)	1.89 (1.02)	0.0	1.20	2.00	2.60	4.2	
			Placebo	98	90 (91.8)	2.21 (1.02)	0.2	1.60	2.20	2.80	6.0	
		Week 8	Tezepelumab	95	91 (95.8)	1.76 (1.07)	0.0	1.00	1.80	2.60	4.2	
			Placebo	98	91 (92.9)	2.12 (0.99)	0.0	1.60	2.20	2.60	5.0	
		Week 10	Tezepelumab	95	91 (95.8)	1.72 (1.04)	0.0	1.00	1.80	2.60	4.2	
			Placebo	98	92 (93.9)	2.10 (0.95)	0.0	1.40	2.10	2.80	5.2	
		Week 12	Tezepelumab	95	91 (95.8)	1.65 (1.08)	0.0	0.60	1.80	2.60	4.2	
			Placebo	98	92 (93.9)	2.06 (1.01)	0.0	1.20	2.20	2.80	4.4	
		Week 14	Tezepelumab	95	91 (95.8)	1.49 (1.05)	0.0	0.60	1.40	2.20	4.2	
			Placebo	98	92 (93.9)	2.07 (0.96)	0.0	1.40	2.10	2.70	5.0	
		Week 16	Tezepelumab	95	91 (95.8)	1.69 (1.11)	0.0	0.80	1.80	2.60	4.6	
			Placebo	98	92 (93.9)	2.10 (1.07)	0.0	1.40	2.20	3.00	5.0	
		Week 18	Tezepelumab	95	91 (95.8)	1.54 (1.00)	0.0	0.80	1.60	2.20	4.2	
			Placebo	98	92 (93.9)	2.01 (1.01)	0.0	1.40	2.00	2.60	5.0	
		Week 20	Tezepelumab	95	91 (95.8)	1.64 (1.07)	0.0	0.80	1.80	2.40	5.0	
			Placebo	98	92 (93.9)	2.09 (0.99)	0.0	1.40	2.30	2.80	5.0	
		Week 22	Tezepelumab	95	91 (95.8)	1.64 (1.01)	0.0	0.80	1.80	2.40	4.2	
			Placebo	98	92 (93.9)	2.02 (1.01)	0.0	1.20	2.00	2.80	5.0	
		Week 24	Tezepelumab	95	91 (95.8)	1.67 (1.10)	0.0	0.80	1.80	2.40	4.8	
			Placebo	98	92 (93.9)	1.99 (0.96)	0.0	1.10	2.00	2.80	4.4	
		Week 26	Tezepelumab	95	91 (95.8)	1.60 (1.06)	0.0	0.80	1.60	2.40	4.2	
			Placebo	98	92 (93.9)	1.91 (1.01)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	95	92 (96.8)	1.67 (1.08)	0.0	0.90	1.80	2.40	4.2	
			Placebo	98	93 (94.9)	1.88 (1.05)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	95	93 (97.9)	1.55 (1.03)	0.0	0.80	1.60	2.20	4.2	
			Placebo	98	94 (95.9)	1.98 (1.05)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	95	93 (97.9)	1.52 (1.06)	0.0	0.80	1.40	2.20	4.2	
			Placebo	98	94 (95.9)	1.89 (1.09)	0.0	1.00	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Normal	Absolute values	Week 34	Tezepelumab	95	93 (97.9)	1.54 (1.10)	0.0	0.80	1.40	2.40	4.2	
			Placebo	98	94 (95.9)	1.86 (1.07)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	95	93 (97.9)	1.67 (1.12)	0.0	0.80	1.80	2.40	5.0	
			Placebo	98	94 (95.9)	1.97 (1.07)	0.0	1.00	2.10	2.80	4.8	
		Week 38	Tezepelumab	95	93 (97.9)	1.50 (1.07)	0.0	0.80	1.40	2.20	4.6	
			Placebo	98	94 (95.9)	1.87 (1.08)	0.0	1.00	1.80	2.60	4.8	
		Week 40	Tezepelumab	95	93 (97.9)	1.52 (1.10)	0.0	0.60	1.60	2.20	4.2	
			Placebo	98	94 (95.9)	1.89 (1.06)	0.0	1.00	1.90	2.80	4.4	
		Week 42	Tezepelumab	95	93 (97.9)	1.48 (1.07)	0.0	0.80	1.40	2.20	4.6	
			Placebo	98	94 (95.9)	1.85 (1.00)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	95	93 (97.9)	1.52 (1.05)	0.0	0.60	1.60	2.40	4.2	
			Placebo	98	95 (96.9)	1.91 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	95	93 (97.9)	1.48 (1.09)	0.0	0.80	1.20	2.20	4.2	
			Placebo	98	95 (96.9)	1.80 (0.98)	0.0	1.20	2.00	2.60	4.4	
		Week 48	Tezepelumab	95	93 (97.9)	1.56 (1.10)	0.0	0.60	1.60	2.40	4.2	
			Placebo	98	95 (96.9)	1.84 (1.02)	0.0	1.00	2.00	2.60	4.4	
		Week 50	Tezepelumab	95	93 (97.9)	1.47 (1.08)	0.0	0.60	1.20	2.20	4.2	
			Placebo	98	95 (96.9)	1.79 (0.98)	0.0	1.00	1.80	2.60	4.4	
		Week 52	Tezepelumab	95	93 (97.9)	1.54 (1.07)	0.0	0.60	1.40	2.20	4.4	
			Placebo	98	95 (96.9)	1.85 (1.02)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 2	Tezepelumab	95	91 (95.8)	-0.61 (0.77)	-3.0	-1.20	-0.40	-0.20	0.8	-0.31 [-0.60, -0.02]
			Placebo	98	90 (91.8)	-0.38 (0.72)	-3.0	-0.80	-0.30	0.00	1.4	
		Week 4	Tezepelumab	95	91 (95.8)	-0.94 (1.02)	-3.8	-1.60	-0.80	-0.20	2.6	-0.48 [-0.78, -0.18]
			Placebo	98	90 (91.8)	-0.48 (0.88)	-3.0	-1.20	-0.40	0.20	1.6	
		Week 6	Tezepelumab	95	91 (95.8)	-1.00 (1.07)	-4.0	-1.60	-1.00	-0.20	2.6	-0.34 [-0.64, -0.05]
			Placebo	98	90 (91.8)	-0.66 (0.92)	-3.2	-1.40	-0.60	0.00	1.4	
		Week 8	Tezepelumab	95	91 (95.8)	-1.12 (1.07)	-4.0	-1.80	-1.00	-0.40	2.6	-0.37 [-0.66, -0.08]
			Placebo	98	91 (92.9)	-0.75 (0.93)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	95	91 (95.8)	-1.17 (1.07)	-4.0	-1.80	-1.20	-0.40	2.6	-0.37 [-0.67, -0.08]
			Placebo	98	92 (93.9)	-0.78 (1.00)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	95	91 (95.8)	-1.24 (1.11)	-4.0	-2.00	-1.20	-0.60	2.6	-0.39 [-0.69, -0.10]
			Placebo	98	92 (93.9)	-0.81 (1.04)	-3.8	-1.40	-0.60	0.00	1.4	
		Week 14	Tezepelumab	95	91 (95.8)	-1.40 (1.12)	-4.2	-2.20	-1.40	-0.80	2.6	-0.56 [-0.86, -0.27]
			Placebo	98	92 (93.9)	-0.80 (1.00)	-3.4	-1.40	-0.70	-0.10	2.4	
		Week 16	Tezepelumab	95	91 (95.8)	-1.20 (1.17)	-4.4	-2.00	-1.00	-0.40	2.6	-0.38 [-0.67, -0.09]
			Placebo	98	92 (93.9)	-0.77 (1.05)	-3.6	-1.40	-0.60	0.00	2.4	
		Week 18	Tezepelumab	95	91 (95.8)	-1.35 (1.13)	-4.4	-2.00	-1.20	-0.80	2.6	-0.44 [-0.74, -0.15]
			Placebo	98	92 (93.9)	-0.87 (1.02)	-3.6	-1.50	-0.60	-0.20	2.4	
		Week 20	Tezepelumab	95	91 (95.8)	-1.24 (1.13)	-4.4	-2.00	-1.20	-0.40	2.6	-0.42 [-0.72, -0.13]
			Placebo	98	92 (93.9)	-0.79 (1.03)	-3.6	-1.40	-0.60	-0.20	2.4	
		Week 22	Tezepelumab	95	91 (95.8)	-1.24 (1.18)	-4.4	-2.00	-1.20	-0.60	2.6	-0.35 [-0.65, -0.06]
			Placebo	98	92 (93.9)	-0.86 (1.00)	-3.8	-1.60	-0.80	-0.10	2.4	
		Week 24	Tezepelumab	95	91 (95.8)	-1.22 (1.12)	-4.8	-2.00	-1.20	-0.40	2.6	-0.31 [-0.60, -0.02]
			Placebo	98	92 (93.9)	-0.89 (0.99)	-3.8	-1.40	-0.80	-0.20	1.4	
		Week 26	Tezepelumab	95	91 (95.8)	-1.28 (1.17)	-4.4	-2.20	-1.20	-0.60	2.6	-0.29 [-0.58, 0.01]
			Placebo	98	92 (93.9)	-0.97 (1.04)	-4.2	-1.70	-1.00	0.00	1.4	
		Week 28	Tezepelumab	95	92 (96.8)	-1.22 (1.14)	-4.4	-2.00	-1.20	-0.60	2.6	-0.23 [-0.52, 0.06]
			Placebo	98	93 (94.9)	-0.97 (1.06)	-4.2	-1.60	-0.80	-0.20	1.4	
		Week 30	Tezepelumab	95	93 (97.9)	-1.35 (1.16)	-4.4	-2.20	-1.20	-0.60	2.6	-0.42 [-0.71, -0.13]
			Placebo	98	94 (95.9)	-0.87 (1.09)	-3.4	-1.60	-1.00	-0.20	2.0	
		Week 32	Tezepelumab	95	93 (97.9)	-1.38 (1.17)	-4.4	-2.20	-1.20	-0.80	2.6	-0.37 [-0.66, -0.08]
			Placebo	98	94 (95.9)	-0.96 (1.07)	-3.6	-1.60	-0.90	-0.20	1.8	
		Week 34	Tezepelumab	95	93 (97.9)	-1.36 (1.16)	-4.4	-2.20	-1.40	-0.80	2.6	-0.33 [-0.62, -0.04]
			Placebo	98	94 (95.9)	-0.99 (1.04)	-4.2	-1.60	-1.00	-0.20	1.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Normal	Change from baseline	Week 36	Tezepelumab	95	93 (97.9)	-1.23 (1.25)	-4.4	-2.00	-1.20	-0.20	2.6	-0.29 [-0.58, -0.01]
			Placebo	98	94 (95.9)	-0.88 (1.07)	-3.6	-1.60	-1.00	0.00	1.8	
		Week 38	Tezepelumab	95	93 (97.9)	-1.40 (1.19)	-4.4	-2.20	-1.40	-0.60	2.6	-0.36 [-0.65, -0.07]
			Placebo	98	94 (95.9)	-0.99 (1.08)	-4.2	-1.60	-1.00	-0.40	1.8	
		Week 40	Tezepelumab	95	93 (97.9)	-1.37 (1.22)	-4.4	-2.20	-1.20	-0.60	2.6	-0.37 [-0.66, -0.08]
			Placebo	98	94 (95.9)	-0.96 (0.99)	-4.2	-1.60	-0.80	-0.20	1.4	
		Week 42	Tezepelumab	95	93 (97.9)	-1.41 (1.21)	-4.4	-2.20	-1.40	-0.60	2.6	-0.37 [-0.66, -0.09]
			Placebo	98	94 (95.9)	-1.00 (0.97)	-4.2	-1.60	-1.00	-0.40	1.0	
		Week 44	Tezepelumab	95	93 (97.9)	-1.38 (1.23)	-4.4	-2.20	-1.20	-0.60	2.6	-0.38 [-0.67, -0.10]
			Placebo	98	95 (96.9)	-0.94 (1.03)	-4.2	-1.60	-1.00	-0.20	1.2	
		Week 46	Tezepelumab	95	93 (97.9)	-1.42 (1.23)	-4.4	-2.20	-1.40	-0.80	2.6	-0.34 [-0.63, -0.05]
			Placebo	98	95 (96.9)	-1.04 (0.96)	-4.2	-1.60	-1.00	-0.40	1.0	
		Week 48	Tezepelumab	95	93 (97.9)	-1.33 (1.23)	-4.4	-2.20	-1.20	-0.40	2.6	-0.29 [-0.58, -0.00]
			Placebo	98	95 (96.9)	-1.01 (1.00)	-3.8	-1.60	-1.00	-0.40	1.2	
		Week 50	Tezepelumab	95	93 (97.9)	-1.43 (1.20)	-4.4	-2.20	-1.40	-0.60	2.6	-0.34 [-0.63, -0.05]
			Placebo	98	95 (96.9)	-1.06 (0.94)	-4.2	-1.60	-1.00	-0.40	0.8	
		Week 52	Tezepelumab	95	93 (97.9)	-1.36 (1.21)	-4.4	-2.00	-1.20	-0.60	2.6	-0.33 [-0.62, -0.04]
			Placebo	98	95 (96.9)	-1.00 (0.98)	-4.2	-1.60	-0.80	-0.40	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	2.66 (0.87)	1.6	1.80	2.60	3.00	4.2	
			Placebo	8	8 (100.0)	3.13 (0.30)	2.6	3.00	3.10	3.30	3.6	
		Week 2	Tezepelumab	7	7 (100.0)	2.51 (0.61)	1.6	2.00	2.60	3.20	3.2	
			Placebo	8	8 (100.0)	2.78 (0.31)	2.4	2.50	2.80	3.00	3.2	
		Week 4	Tezepelumab	7	7 (100.0)	2.40 (0.97)	1.0	1.20	2.80	3.20	3.4	
			Placebo	8	8 (100.0)	2.15 (0.87)	0.6	1.60	2.30	2.80	3.2	
		Week 6	Tezepelumab	7	7 (100.0)	2.49 (0.83)	1.8	1.80	2.00	3.20	3.8	
			Placebo	8	8 (100.0)	2.33 (1.01)	0.2	1.90	2.60	3.00	3.4	
		Week 8	Tezepelumab	7	7 (100.0)	2.20 (0.95)	1.2	1.20	2.20	3.20	3.4	
			Placebo	8	8 (100.0)	2.18 (0.90)	0.6	1.60	2.30	2.90	3.2	
		Week 10	Tezepelumab	7	7 (100.0)	2.23 (0.92)	1.0	1.40	2.40	3.20	3.4	
			Placebo	8	8 (100.0)	2.23 (0.95)	0.4	1.70	2.50	3.00	3.0	
		Week 12	Tezepelumab	7	7 (100.0)	2.14 (0.97)	1.0	1.00	2.60	3.00	3.2	
			Placebo	8	8 (100.0)	1.98 (0.81)	0.4	1.50	2.30	2.50	2.8	
		Week 14	Tezepelumab	7	7 (100.0)	2.11 (1.19)	0.6	1.00	2.40	3.00	3.8	
			Placebo	8	8 (100.0)	1.65 (0.67)	0.4	1.30	1.70	2.10	2.6	
		Week 16	Tezepelumab	7	7 (100.0)	1.91 (1.04)	0.8	1.00	1.40	3.00	3.2	
			Placebo	8	8 (100.0)	1.88 (0.71)	0.8	1.40	2.00	2.20	3.0	
		Week 18	Tezepelumab	7	7 (100.0)	2.00 (0.98)	1.0	1.00	2.00	3.00	3.4	
			Placebo	8	8 (100.0)	2.23 (0.59)	1.2	1.90	2.30	2.50	3.2	
		Week 20	Tezepelumab	7	7 (100.0)	2.06 (0.98)	1.0	1.20	2.00	2.80	3.6	
			Placebo	8	8 (100.0)	1.73 (0.64)	0.8	1.20	1.90	2.00	2.8	
		Week 22	Tezepelumab	7	7 (100.0)	1.97 (0.94)	1.0	1.00	2.00	2.60	3.4	
			Placebo	8	8 (100.0)	1.95 (0.65)	0.8	1.50	2.20	2.40	2.6	
		Week 24	Tezepelumab	7	7 (100.0)	2.09 (1.01)	1.0	1.20	2.00	2.80	3.6	
			Placebo	8	8 (100.0)	1.83 (0.63)	0.4	1.70	2.00	2.20	2.4	
		Week 26	Tezepelumab	7	7 (100.0)	1.94 (0.82)	1.0	1.20	2.00	2.80	3.0	
			Placebo	8	8 (100.0)	1.80 (0.39)	1.2	1.60	1.70	2.10	2.4	
		Week 28	Tezepelumab	7	7 (100.0)	2.03 (0.97)	1.0	1.20	2.00	2.80	3.6	
			Placebo	8	8 (100.0)	1.98 (0.95)	0.8	1.30	1.80	2.50	3.8	
		Week 30	Tezepelumab	7	7 (100.0)	2.03 (0.93)	1.0	1.00	2.40	2.80	3.2	
			Placebo	8	8 (100.0)	1.60 (0.61)	0.4	1.30	1.70	2.00	2.4	
		Week 32	Tezepelumab	7	7 (100.0)	1.86 (0.96)	0.4	1.00	2.40	2.60	2.8	
			Placebo	8	8 (100.0)	1.68 (0.49)	0.6	1.60	1.70	2.00	2.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Absolute values	Week 34	Tezepelumab	7	7 (100.0)	1.83 (0.96)	0.4	1.00	2.20	2.80	2.8	
			Placebo	8	8 (100.0)	1.78 (0.66)	0.8	1.20	1.90	2.30	2.6	
		Week 36	Tezepelumab	7	7 (100.0)	1.80 (0.85)	0.6	1.00	2.20	2.40	2.8	
			Placebo	8	8 (100.0)	1.70 (0.81)	0.0	1.40	1.90	2.20	2.6	
		Week 38	Tezepelumab	7	7 (100.0)	1.86 (0.85)	0.8	1.00	2.20	2.60	3.0	
			Placebo	8	8 (100.0)	1.83 (0.82)	0.6	1.30	1.80	2.30	3.2	
		Week 40	Tezepelumab	7	7 (100.0)	1.86 (0.90)	0.6	1.00	2.20	2.60	2.8	
			Placebo	8	8 (100.0)	1.73 (0.74)	0.4	1.40	1.80	2.00	3.0	
		Week 42	Tezepelumab	7	7 (100.0)	1.83 (0.90)	0.6	1.00	2.20	2.60	3.0	
			Placebo	8	8 (100.0)	2.03 (0.73)	0.8	1.60	2.00	2.70	2.8	
		Week 44	Tezepelumab	7	7 (100.0)	1.89 (0.92)	0.6	1.00	2.40	2.80	2.8	
			Placebo	8	8 (100.0)	1.80 (0.86)	0.2	1.30	1.90	2.50	2.8	
		Week 46	Tezepelumab	7	7 (100.0)	1.86 (0.86)	0.8	1.00	2.00	2.60	3.0	
			Placebo	8	8 (100.0)	1.83 (0.59)	0.8	1.40	2.00	2.20	2.6	
		Week 48	Tezepelumab	7	7 (100.0)	1.86 (0.88)	0.8	1.00	2.00	2.80	3.0	
			Placebo	8	8 (100.0)	1.75 (0.72)	0.2	1.50	2.00	2.20	2.4	
		Week 50	Tezepelumab	7	7 (100.0)	1.86 (0.73)	0.8	1.20	2.20	2.40	2.8	
			Placebo	8	8 (100.0)	1.78 (0.77)	0.0	1.70	2.00	2.20	2.4	
		Week 52	Tezepelumab	7	7 (100.0)	1.69 (0.89)	0.4	0.80	2.20	2.20	2.8	
			Placebo	8	8 (100.0)	1.78 (0.77)	0.0	1.70	2.00	2.20	2.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	7	7 (100.0)	-0.14 (0.44)	-1.0	-0.40	0.00	0.20	0.2	0.46 [-0.57, 1.49]
			Placebo	8	8 (100.0)	-0.35 (0.45)	-1.0	-0.80	-0.20	0.00	0.2	
		Week 4	Tezepelumab	7	7 (100.0)	-0.26 (0.88)	-1.2	-1.00	-0.60	0.80	1.0	0.72 [-0.33, 1.77]
			Placebo	8	8 (100.0)	-0.98 (1.09)	-3.0	-1.70	-0.70	0.00	0.0	
		Week 6	Tezepelumab	7	7 (100.0)	-0.17 (0.76)	-1.2	-1.00	0.20	0.40	0.8	0.62 [-0.42, 1.67]
			Placebo	8	8 (100.0)	-0.80 (1.18)	-3.4	-1.10	-0.50	-0.10	0.4	
		Week 8	Tezepelumab	7	7 (100.0)	-0.46 (0.80)	-1.8	-1.00	-0.40	0.20	0.4	0.52 [-0.52, 1.55]
			Placebo	8	8 (100.0)	-0.95 (1.07)	-3.0	-1.60	-0.60	-0.20	0.2	
		Week 10	Tezepelumab	7	7 (100.0)	-0.43 (0.92)	-1.6	-1.40	-0.20	0.40	0.8	0.44 [-0.58, 1.47]
			Placebo	8	8 (100.0)	-0.90 (1.17)	-3.2	-1.50	-0.40	-0.10	0.0	
		Week 12	Tezepelumab	7	7 (100.0)	-0.51 (1.03)	-2.0	-1.40	-0.60	0.40	0.8	0.61 [-0.43, 1.65]
			Placebo	8	8 (100.0)	-1.15 (1.05)	-3.2	-1.70	-0.80	-0.40	-0.2	
		Week 14	Tezepelumab	7	7 (100.0)	-0.54 (1.04)	-2.0	-1.80	-0.40	0.00	1.0	0.95 [-0.13, 2.03]
			Placebo	8	8 (100.0)	-1.48 (0.92)	-3.2	-1.90	-1.40	-0.80	-0.4	
		Week 16	Tezepelumab	7	7 (100.0)	-0.74 (0.98)	-1.8	-1.60	-1.00	0.00	1.0	0.54 [-0.50, 1.57]
			Placebo	8	8 (100.0)	-1.25 (0.91)	-2.8	-1.80	-1.20	-0.60	0.0	
		Week 18	Tezepelumab	7	7 (100.0)	-0.66 (0.83)	-2.0	-1.20	-0.60	0.00	0.6	0.30 [-0.72, 1.32]
			Placebo	8	8 (100.0)	-0.90 (0.79)	-2.4	-1.20	-1.00	-0.30	0.2	
		Week 20	Tezepelumab	7	7 (100.0)	-0.60 (0.86)	-2.0	-1.20	-0.60	-0.20	0.8	0.94 [-0.14, 2.02]
			Placebo	8	8 (100.0)	-1.40 (0.84)	-2.8	-2.00	-1.30	-0.80	-0.2	
		Week 22	Tezepelumab	7	7 (100.0)	-0.69 (0.75)	-2.0	-1.20	-0.60	0.00	0.2	0.62 [-0.42, 1.67]
			Placebo	8	8 (100.0)	-1.18 (0.82)	-2.8	-1.50	-1.10	-0.60	-0.2	
		Week 24	Tezepelumab	7	7 (100.0)	-0.57 (0.73)	-1.8	-1.20	-0.60	0.20	0.2	0.89 [-0.18, 1.96]
			Placebo	8	8 (100.0)	-1.30 (0.89)	-3.2	-1.50	-1.10	-0.90	-0.2	
		Week 26	Tezepelumab	7	7 (100.0)	-0.71 (0.82)	-2.0	-1.40	-0.40	0.00	0.2	0.84 [-0.22, 1.91]
			Placebo	8	8 (100.0)	-1.33 (0.63)	-2.4	-1.60	-1.40	-0.90	-0.4	
		Week 28	Tezepelumab	7	7 (100.0)	-0.63 (0.68)	-1.8	-1.20	-0.60	-0.20	0.2	0.55 [-0.49, 1.58]
			Placebo	8	8 (100.0)	-1.15 (1.14)	-2.8	-1.80	-1.40	-0.40	0.8	
		Week 30	Tezepelumab	7	7 (100.0)	-0.63 (0.89)	-2.0	-1.20	-0.60	-0.20	0.8	1.06 [-0.03, 2.15]
			Placebo	8	8 (100.0)	-1.53 (0.81)	-3.2	-1.80	-1.40	-1.00	-0.6	
		Week 32	Tezepelumab	7	7 (100.0)	-0.80 (1.11)	-2.6	-1.60	-0.60	-0.20	0.8	0.70 [-0.35, 1.75]
			Placebo	8	8 (100.0)	-1.45 (0.75)	-3.0	-1.70	-1.30	-1.10	-0.4	
		Week 34	Tezepelumab	7	7 (100.0)	-0.83 (1.00)	-2.6	-1.40	-0.60	-0.20	0.4	0.55 [-0.48, 1.59]
			Placebo	8	8 (100.0)	-1.35 (0.89)	-2.8	-2.00	-1.20	-0.80	0.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Change from baseline	Week 36	Tezepelumab	7	7 (100.0)	-0.86 (0.99)	-2.4	-1.80	-0.60	-0.20	0.4	0.55 [-0.48, 1.59]
			Placebo	8	8 (100.0)	-1.43 (1.06)	-3.6	-1.80	-1.20	-0.80	-0.2	
		Week 38	Tezepelumab	7	7 (100.0)	-0.80 (0.92)	-2.2	-1.60	-0.60	0.00	0.4	0.50 [-0.53, 1.54]
			Placebo	8	8 (100.0)	-1.30 (1.05)	-3.0	-1.90	-1.30	-0.60	0.2	
		Week 40	Tezepelumab	7	7 (100.0)	-0.80 (1.04)	-2.4	-1.60	-0.60	-0.20	0.8	0.58 [-0.46, 1.62]
			Placebo	8	8 (100.0)	-1.40 (1.02)	-3.2	-1.80	-1.20	-1.20	0.4	
		Week 42	Tezepelumab	7	7 (100.0)	-0.83 (0.97)	-2.4	-1.60	-0.60	0.00	0.4	0.28 [-0.74, 1.30]
			Placebo	8	8 (100.0)	-1.10 (1.00)	-2.8	-1.70	-1.10	-0.20	0.0	
		Week 44	Tezepelumab	7	7 (100.0)	-0.77 (0.98)	-2.4	-1.40	-0.60	-0.20	0.6	0.53 [-0.50, 1.57]
			Placebo	8	8 (100.0)	-1.33 (1.09)	-3.4	-1.90	-1.20	-0.50	0.0	
		Week 46	Tezepelumab	7	7 (100.0)	-0.80 (0.80)	-2.2	-1.20	-0.60	-0.20	0.2	0.60 [-0.44, 1.64]
			Placebo	8	8 (100.0)	-1.30 (0.86)	-2.8	-1.80	-1.10	-0.90	0.0	
		Week 48	Tezepelumab	7	7 (100.0)	-0.80 (0.74)	-2.0	-1.20	-0.80	-0.20	0.2	0.66 [-0.38, 1.71]
			Placebo	8	8 (100.0)	-1.38 (0.96)	-3.4	-1.70	-1.10	-0.90	-0.2	
		Week 50	Tezepelumab	7	7 (100.0)	-0.80 (0.89)	-2.0	-1.60	-0.80	-0.20	0.6	0.57 [-0.47, 1.61]
			Placebo	8	8 (100.0)	-1.35 (1.03)	-3.6	-1.60	-1.10	-0.80	-0.2	
		Week 52	Tezepelumab	7	7 (100.0)	-0.97 (1.05)	-2.6	-2.00	-0.80	-0.20	0.4	0.36 [-0.66, 1.39]
			Placebo	8	8 (100.0)	-1.35 (1.03)	-3.6	-1.60	-1.10	-0.80	-0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.73 (0.45)	2.2	2.40	2.80	3.00	3.4	
			Placebo	13	13 (100.0)	2.75 (0.91)	0.4	2.80	3.00	3.00	4.0	
		Week 2	Tezepelumab	9	9 (100.0)	2.31 (0.69)	1.0	2.00	2.60	2.80	3.2	
			Placebo	13	11 (84.6)	2.56 (0.54)	1.4	2.20	2.60	3.00	3.2	
		Week 4	Tezepelumab	9	9 (100.0)	1.76 (0.89)	0.2	1.20	1.80	2.40	3.0	
			Placebo	13	11 (84.6)	2.80 (0.72)	2.0	2.20	2.60	3.40	4.2	
		Week 6	Tezepelumab	9	9 (100.0)	1.40 (0.63)	0.6	1.00	1.40	1.80	2.6	
			Placebo	13	11 (84.6)	2.91 (0.61)	1.8	2.80	3.00	3.20	4.0	
		Week 8	Tezepelumab	9	9 (100.0)	1.29 (0.84)	0.0	1.00	1.60	1.60	2.6	
			Placebo	13	12 (92.3)	2.62 (0.74)	1.2	2.30	2.40	3.00	4.0	
		Week 10	Tezepelumab	9	9 (100.0)	1.00 (0.78)	0.0	0.60	0.80	1.40	2.4	
			Placebo	13	12 (92.3)	2.52 (0.73)	1.0	2.10	2.50	3.00	4.0	
		Week 12	Tezepelumab	9	9 (100.0)	0.93 (0.82)	0.0	0.00	1.00	1.60	2.2	
			Placebo	13	12 (92.3)	2.73 (0.66)	2.0	2.30	2.70	3.00	4.4	
		Week 14	Tezepelumab	9	9 (100.0)	0.96 (0.63)	0.0	0.60	1.40	1.40	1.6	
			Placebo	13	12 (92.3)	2.23 (0.50)	1.4	2.00	2.20	2.50	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	0.96 (0.51)	0.0	0.60	1.20	1.40	1.4	
			Placebo	13	12 (92.3)	2.60 (0.90)	1.0	2.10	2.70	3.00	4.0	
		Week 18	Tezepelumab	9	9 (100.0)	1.18 (0.60)	0.0	1.00	1.20	1.60	2.0	
			Placebo	13	12 (92.3)	2.58 (0.54)	1.8	2.40	2.60	2.70	4.0	
		Week 20	Tezepelumab	9	9 (100.0)	1.18 (0.76)	0.0	0.80	1.20	1.40	2.8	
			Placebo	13	12 (92.3)	2.50 (0.84)	1.0	2.00	2.60	2.80	4.0	
		Week 22	Tezepelumab	9	9 (100.0)	1.31 (0.94)	0.0	1.00	1.40	1.60	2.8	
			Placebo	13	12 (92.3)	2.53 (0.96)	0.8	1.90	2.60	3.30	4.0	
		Week 24	Tezepelumab	9	9 (100.0)	1.18 (0.77)	0.0	0.80	1.20	1.40	2.8	
			Placebo	13	12 (92.3)	2.62 (0.78)	1.4	2.00	2.50	3.30	4.0	
		Week 26	Tezepelumab	9	9 (100.0)	1.36 (0.69)	0.0	1.00	1.40	1.80	2.4	
			Placebo	13	12 (92.3)	2.57 (0.95)	1.2	1.80	2.40	3.30	4.0	
		Week 28	Tezepelumab	9	9 (100.0)	1.62 (0.94)	0.0	1.00	1.40	2.40	3.0	
			Placebo	13	13 (100.0)	2.35 (1.16)	0.0	1.80	2.60	3.20	4.0	
		Week 30	Tezepelumab	9	9 (100.0)	1.31 (0.74)	0.0	0.80	1.40	1.60	2.4	
			Placebo	13	13 (100.0)	2.31 (1.17)	0.0	1.80	2.40	3.20	4.0	
		Week 32	Tezepelumab	9	9 (100.0)	1.22 (0.76)	0.0	0.80	1.20	1.80	2.2	
			Placebo	13	13 (100.0)	2.43 (1.33)	0.0	1.60	2.40	3.20	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.36 (1.10)	0.0	0.80	1.20	2.40	3.0	
			Placebo	13	13 (100.0)	2.32 (1.33)	0.2	1.40	2.20	3.20	4.8	
		Week 36	Tezepelumab	9	9 (100.0)	1.44 (0.84)	0.0	1.00	1.20	2.20	2.8	
			Placebo	13	13 (100.0)	2.49 (1.38)	0.0	1.80	2.40	3.20	4.8	
		Week 38	Tezepelumab	9	9 (100.0)	1.47 (1.06)	0.0	0.60	1.40	2.20	3.0	
			Placebo	13	13 (100.0)	2.34 (1.34)	0.0	1.60	2.60	3.20	4.8	
		Week 40	Tezepelumab	9	9 (100.0)	1.22 (0.94)	0.0	0.80	1.20	1.80	2.6	
			Placebo	13	13 (100.0)	2.43 (1.20)	0.0	1.80	2.60	3.00	4.4	
		Week 42	Tezepelumab	9	9 (100.0)	1.29 (0.81)	0.0	1.00	1.20	1.40	2.6	
			Placebo	13	13 (100.0)	2.34 (1.24)	0.0	2.00	2.40	2.80	4.6	
		Week 44	Tezepelumab	9	9 (100.0)	1.42 (0.92)	0.0	1.00	1.40	1.60	3.0	
			Placebo	13	13 (100.0)	2.29 (1.13)	0.0	1.60	2.40	2.60	4.2	
		Week 46	Tezepelumab	9	9 (100.0)	1.49 (1.03)	0.0	1.00	1.20	1.80	3.2	
			Placebo	13	13 (100.0)	2.23 (0.98)	0.0	2.00	2.40	2.60	4.0	
		Week 48	Tezepelumab	9	9 (100.0)	1.42 (0.95)	0.0	0.80	1.20	2.00	3.0	
			Placebo	13	13 (100.0)	2.28 (1.11)	0.0	2.00	2.40	2.60	4.0	
		Week 50	Tezepelumab	9	9 (100.0)	1.13 (0.75)	0.0	0.80	1.00	1.40	2.6	
			Placebo	13	13 (100.0)	2.22 (1.05)	0.0	2.00	2.40	2.60	4.0	
		Week 52	Tezepelumab	9	9 (100.0)	1.13 (0.75)	0.0	0.80	1.00	1.40	2.6	
			Placebo	13	13 (100.0)	2.32 (1.13)	0.0	2.00	2.40	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.42 (0.39)	-1.4	-0.40	-0.20	-0.20	-0.2	-0.13 [-1.01, 0.75]
			Placebo	13	11 (84.6)	-0.35 (0.69)	-1.6	-0.80	-0.40	0.00	1.0	
		Week 4	Tezepelumab	9	9 (100.0)	-0.98 (0.70)	-2.2	-1.20	-1.00	-0.40	0.0	-1.13 [-2.08, -0.17]
			Placebo	13	11 (84.6)	-0.11 (0.83)	-1.4	-1.00	0.00	0.60	1.2	
		Week 6	Tezepelumab	9	9 (100.0)	-1.33 (0.66)	-2.4	-1.80	-1.40	-0.80	-0.2	-1.85 [-2.92, -0.78]
			Placebo	13	11 (84.6)	0.00 (0.76)	-0.8	-0.80	-0.20	0.40	1.6	
		Week 8	Tezepelumab	9	9 (100.0)	-1.44 (0.66)	-2.4	-1.60	-1.40	-1.40	-0.2	-1.34 [-2.30, -0.38]
			Placebo	13	12 (92.3)	-0.33 (0.93)	-1.8	-1.00	-0.40	0.40	1.0	
		Week 10	Tezepelumab	9	9 (100.0)	-1.73 (0.62)	-2.4	-2.20	-2.00	-1.40	-0.8	-1.36 [-2.33, -0.40]
			Placebo	13	12 (92.3)	-0.43 (1.14)	-2.0	-1.00	-0.40	-0.10	2.6	
		Week 12	Tezepelumab	9	9 (100.0)	-1.80 (0.60)	-2.4	-2.20	-2.00	-1.40	-0.8	-1.95 [-3.01, -0.89]
			Placebo	13	12 (92.3)	-0.22 (0.94)	-1.6	-0.80	-0.40	0.10	1.6	
		Week 14	Tezepelumab	9	9 (100.0)	-1.78 (0.49)	-2.4	-2.20	-1.80	-1.60	-0.8	-1.48 [-2.46, -0.49]
			Placebo	13	12 (92.3)	-0.72 (0.85)	-1.6	-1.30	-0.90	-0.50	1.4	
		Week 16	Tezepelumab	9	9 (100.0)	-1.78 (0.48)	-2.4	-2.20	-1.80	-1.60	-0.8	-1.44 [-2.42, -0.46]
			Placebo	13	12 (92.3)	-0.35 (1.24)	-2.0	-1.30	-0.40	0.00	2.6	
		Week 18	Tezepelumab	9	9 (100.0)	-1.56 (0.71)	-2.4	-1.80	-1.60	-1.40	-0.2	-1.31 [-2.27, -0.35]
			Placebo	13	12 (92.3)	-0.37 (1.03)	-1.4	-1.00	-0.50	-0.20	2.6	
		Week 20	Tezepelumab	9	9 (100.0)	-1.56 (0.66)	-2.4	-2.20	-1.60	-1.40	-0.4	-1.10 [-2.04, -0.17]
			Placebo	13	12 (92.3)	-0.45 (1.19)	-2.0	-1.30	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	9	9 (100.0)	-1.42 (0.86)	-2.4	-2.40	-1.60	-0.80	-0.2	-0.89 [-1.80, 0.02]
			Placebo	13	12 (92.3)	-0.42 (1.29)	-2.2	-1.30	-0.50	0.30	2.6	
		Week 24	Tezepelumab	9	9 (100.0)	-1.56 (0.70)	-2.4	-1.80	-1.60	-1.60	-0.2	-1.22 [-2.16, -0.27]
			Placebo	13	12 (92.3)	-0.33 (1.18)	-1.6	-1.20	-0.50	0.30	2.6	
		Week 26	Tezepelumab	9	9 (100.0)	-1.38 (0.75)	-2.4	-1.60	-1.40	-0.80	-0.2	-0.91 [-1.82, -0.00]
			Placebo	13	12 (92.3)	-0.38 (1.28)	-1.8	-1.40	-0.80	0.30	2.6	
		Week 28	Tezepelumab	9	9 (100.0)	-1.11 (0.93)	-2.4	-1.60	-0.80	-0.80	0.2	-0.63 [-1.50, 0.24]
			Placebo	13	13 (100.0)	-0.40 (1.24)	-2.0	-1.20	-0.40	0.20	2.6	
		Week 30	Tezepelumab	9	9 (100.0)	-1.42 (0.71)	-2.6	-1.60	-1.40	-0.80	-0.6	-0.92 [-1.82, -0.02]
			Placebo	13	13 (100.0)	-0.45 (1.24)	-1.8	-1.20	-0.80	0.20	2.6	
		Week 32	Tezepelumab	9	9 (100.0)	-1.51 (0.62)	-2.4	-1.80	-1.60	-1.00	-0.8	-1.05 [-1.96, -0.14]
			Placebo	13	13 (100.0)	-0.32 (1.37)	-1.8	-1.40	-0.40	0.20	2.6	
		Week 34	Tezepelumab	9	9 (100.0)	-1.38 (0.92)	-2.6	-2.20	-1.60	-0.60	0.0	-0.74 [-1.63, 0.14]
			Placebo	13	13 (100.0)	-0.43 (1.46)	-2.2	-1.40	-0.80	0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.29 (0.90)	-2.4	-2.00	-1.40	-0.80	0.0	-0.83 [-1.71, 0.06]
			Placebo	13	13 (100.0)	-0.26 (1.43)	-2.2	-1.20	-0.40	0.20	2.6	
		Week 38	Tezepelumab	9	9 (100.0)	-1.27 (0.77)	-2.4	-1.80	-1.40	-0.80	0.0	-0.71 [-1.58, 0.17]
			Placebo	13	13 (100.0)	-0.42 (1.42)	-2.6	-1.40	-0.40	0.20	2.6	
		Week 40	Tezepelumab	9	9 (100.0)	-1.51 (0.79)	-2.6	-2.20	-1.60	-0.80	-0.4	-1.08 [-1.99, -0.16]
			Placebo	13	13 (100.0)	-0.32 (1.27)	-2.0	-1.20	-0.60	0.20	2.6	
		Week 42	Tezepelumab	9	9 (100.0)	-1.44 (0.73)	-2.4	-1.80	-1.60	-0.80	-0.4	-0.91 [-1.80, -0.01]
			Placebo	13	13 (100.0)	-0.42 (1.34)	-2.4	-1.40	-0.60	0.00	2.6	
		Week 44	Tezepelumab	9	9 (100.0)	-1.31 (0.91)	-2.8	-1.60	-1.40	-0.80	0.0	-0.76 [-1.64, 0.12]
			Placebo	13	13 (100.0)	-0.46 (1.23)	-1.8	-1.20	-0.80	0.00	2.6	
		Week 46	Tezepelumab	9	9 (100.0)	-1.24 (0.92)	-2.4	-1.60	-1.40	-0.80	0.2	-0.70 [-1.57, 0.18]
			Placebo	13	13 (100.0)	-0.52 (1.11)	-1.8	-1.20	-1.00	0.00	2.6	
		Week 48	Tezepelumab	9	9 (100.0)	-1.31 (0.99)	-2.4	-2.40	-1.60	-0.40	0.0	-0.74 [-1.62, 0.14]
			Placebo	13	13 (100.0)	-0.48 (1.21)	-2.0	-1.20	-0.60	-0.20	2.6	
		Week 50	Tezepelumab	9	9 (100.0)	-1.60 (0.75)	-2.6	-2.40	-1.60	-1.20	-0.4	-1.03 [-1.94, -0.12]
			Placebo	13	13 (100.0)	-0.54 (1.18)	-2.0	-1.40	-0.60	-0.20	2.6	
		Week 52	Tezepelumab	9	9 (100.0)	-1.60 (0.75)	-2.6	-2.40	-1.60	-1.20	-0.4	-1.11 [-2.02, -0.19]
			Placebo	13	13 (100.0)	-0.43 (1.22)	-2.0	-1.20	-0.60	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	2.85 (0.86)	0.0	2.40	2.80	3.20	5.2	
			Placebo	125	125 (100.0)	2.82 (0.70)	1.0	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	128	122 (95.3)	2.27 (0.99)	0.0	1.60	2.40	3.00	4.4	
			Placebo	125	114 (91.2)	2.40 (0.86)	0.0	2.00	2.40	3.00	5.0	
		Week 4	Tezepelumab	128	122 (95.3)	1.97 (1.02)	0.0	1.20	2.20	2.80	4.2	
			Placebo	125	114 (91.2)	2.25 (0.88)	0.2	1.80	2.40	2.80	4.4	
		Week 6	Tezepelumab	128	122 (95.3)	1.90 (1.02)	0.0	1.20	1.80	2.60	4.2	
			Placebo	125	115 (92.0)	2.13 (1.03)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	128	122 (95.3)	1.83 (1.09)	0.0	1.00	1.80	2.80	5.2	
			Placebo	125	115 (92.0)	2.09 (1.01)	0.0	1.40	2.00	2.80	5.0	
		Week 10	Tezepelumab	128	122 (95.3)	1.77 (1.05)	0.0	1.00	1.80	2.60	4.8	
			Placebo	125	116 (92.8)	2.02 (0.97)	0.0	1.40	2.00	2.80	5.2	
		Week 12	Tezepelumab	128	122 (95.3)	1.69 (1.09)	0.0	0.80	1.70	2.60	4.8	
			Placebo	125	116 (92.8)	1.92 (1.00)	0.0	1.20	2.00	2.60	4.4	
		Week 14	Tezepelumab	128	122 (95.3)	1.55 (1.07)	0.0	0.80	1.40	2.40	4.8	
			Placebo	125	116 (92.8)	1.91 (0.98)	0.0	1.10	1.80	2.60	5.0	
		Week 16	Tezepelumab	128	122 (95.3)	1.72 (1.12)	0.0	0.80	1.80	2.60	4.8	
			Placebo	125	116 (92.8)	2.01 (1.08)	0.0	1.10	2.00	3.00	5.0	
		Week 18	Tezepelumab	128	123 (96.1)	1.58 (1.03)	0.0	0.80	1.60	2.40	4.8	
			Placebo	125	116 (92.8)	1.89 (1.05)	0.0	1.20	1.80	2.60	5.0	
		Week 20	Tezepelumab	128	123 (96.1)	1.68 (1.09)	0.0	0.80	1.80	2.40	5.0	
			Placebo	125	116 (92.8)	1.96 (1.05)	0.0	1.20	2.00	2.80	5.0	
		Week 22	Tezepelumab	128	123 (96.1)	1.69 (1.03)	0.0	1.00	1.80	2.40	4.8	
			Placebo	125	116 (92.8)	1.90 (1.04)	0.0	1.10	2.00	2.60	5.0	
		Week 24	Tezepelumab	128	123 (96.1)	1.69 (1.10)	0.0	0.80	1.80	2.60	4.8	
			Placebo	125	116 (92.8)	1.88 (1.03)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	128	124 (96.9)	1.63 (1.07)	0.0	0.80	1.60	2.40	4.8	
			Placebo	125	116 (92.8)	1.83 (1.00)	0.0	1.00	1.70	2.80	4.4	
		Week 28	Tezepelumab	128	125 (97.7)	1.68 (1.11)	0.0	1.00	1.60	2.60	4.8	
			Placebo	125	116 (92.8)	1.91 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	128	126 (98.4)	1.63 (1.07)	0.0	0.80	1.60	2.40	4.8	
			Placebo	125	117 (93.6)	1.90 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	128	126 (98.4)	1.59 (1.09)	0.0	0.80	1.40	2.40	4.8	
			Placebo	125	117 (93.6)	1.83 (1.04)	0.0	0.80	1.80	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	128	126 (98.4)	1.60 (1.13)	0.0	0.80	1.40	2.40	4.8	
			Placebo	125	117 (93.6)	1.80 (1.05)	0.0	1.00	1.80	2.60	4.4	
		Week 36	Tezepelumab	128	126 (98.4)	1.68 (1.13)	0.0	0.80	1.60	2.40	5.0	
			Placebo	125	117 (93.6)	1.88 (1.05)	0.0	1.00	2.00	2.80	4.4	
		Week 38	Tezepelumab	128	126 (98.4)	1.57 (1.11)	0.0	0.80	1.40	2.40	4.8	
			Placebo	125	117 (93.6)	1.81 (1.03)	0.0	1.00	1.80	2.60	4.4	
		Week 40	Tezepelumab	128	126 (98.4)	1.62 (1.12)	0.0	0.60	1.80	2.40	4.8	
			Placebo	125	117 (93.6)	1.88 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	128	126 (98.4)	1.57 (1.11)	0.0	0.80	1.60	2.20	4.8	
			Placebo	125	117 (93.6)	1.86 (1.02)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	128	126 (98.4)	1.59 (1.10)	0.0	0.60	1.60	2.40	4.8	
			Placebo	125	118 (94.4)	1.92 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	128	126 (98.4)	1.55 (1.11)	0.0	0.80	1.40	2.40	4.8	
			Placebo	125	118 (94.4)	1.79 (1.02)	0.0	1.00	2.00	2.60	4.4	
		Week 48	Tezepelumab	128	126 (98.4)	1.62 (1.13)	0.0	0.80	1.60	2.40	4.8	
			Placebo	125	118 (94.4)	1.82 (1.06)	0.0	1.00	1.90	2.60	4.6	
		Week 50	Tezepelumab	128	126 (98.4)	1.55 (1.11)	0.0	0.80	1.40	2.20	4.8	
			Placebo	125	118 (94.4)	1.80 (1.00)	0.0	1.00	1.80	2.60	4.4	
		Week 52	Tezepelumab	128	126 (98.4)	1.58 (1.11)	0.0	0.60	1.60	2.20	4.8	
			Placebo	125	118 (94.4)	1.84 (1.03)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	128	122 (95.3)	-0.58 (0.77)	-3.2	-1.00	-0.40	0.00	0.8	-0.21 [-0.47, 0.04]
			Placebo	125	114 (91.2)	-0.42 (0.78)	-3.0	-0.80	-0.40	0.00	1.4	
		Week 4	Tezepelumab	128	122 (95.3)	-0.87 (0.99)	-3.8	-1.40	-0.80	-0.20	2.6	-0.32 [-0.57, -0.06]
			Placebo	125	114 (91.2)	-0.57 (0.91)	-3.0	-1.20	-0.40	0.00	1.6	
		Week 6	Tezepelumab	128	122 (95.3)	-0.94 (1.06)	-4.0	-1.60	-1.00	-0.20	2.6	-0.25 [-0.51, 0.00]
			Placebo	125	115 (92.0)	-0.69 (0.96)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	128	122 (95.3)	-1.02 (1.11)	-4.0	-1.80	-1.00	-0.40	2.6	-0.28 [-0.53, -0.02]
			Placebo	125	115 (92.0)	-0.73 (0.97)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	128	122 (95.3)	-1.07 (1.07)	-4.0	-1.60	-1.10	-0.40	2.6	-0.26 [-0.52, -0.01]
			Placebo	125	116 (92.8)	-0.80 (1.01)	-3.8	-1.40	-0.60	-0.10	2.6	
		Week 12	Tezepelumab	128	122 (95.3)	-1.16 (1.08)	-4.0	-1.80	-1.20	-0.40	2.6	-0.23 [-0.49, 0.02]
			Placebo	125	116 (92.8)	-0.91 (1.04)	-3.8	-1.40	-0.80	-0.20	1.4	
		Week 14	Tezepelumab	128	122 (95.3)	-1.30 (1.11)	-4.2	-2.00	-1.20	-0.60	2.6	-0.36 [-0.62, -0.10]
			Placebo	125	116 (92.8)	-0.92 (1.02)	-3.4	-1.40	-0.80	-0.20	2.4	
		Week 16	Tezepelumab	128	122 (95.3)	-1.12 (1.14)	-4.4	-1.80	-1.00	-0.40	2.6	-0.27 [-0.53, -0.02]
			Placebo	125	116 (92.8)	-0.82 (1.08)	-3.6	-1.40	-0.80	0.00	2.4	
		Week 18	Tezepelumab	128	123 (96.1)	-1.26 (1.11)	-4.4	-2.00	-1.00	-0.60	2.6	-0.30 [-0.55, -0.04]
			Placebo	125	116 (92.8)	-0.94 (1.08)	-3.6	-1.60	-0.80	-0.20	2.4	
		Week 20	Tezepelumab	128	123 (96.1)	-1.16 (1.12)	-4.4	-2.00	-1.00	-0.40	2.6	-0.26 [-0.52, -0.01]
			Placebo	125	116 (92.8)	-0.87 (1.11)	-3.6	-1.50	-0.70	-0.20	2.4	
		Week 22	Tezepelumab	128	123 (96.1)	-1.15 (1.14)	-4.4	-1.80	-1.00	-0.40	2.6	-0.20 [-0.45, 0.05]
			Placebo	125	116 (92.8)	-0.93 (1.06)	-3.8	-1.60	-0.80	-0.20	2.4	
		Week 24	Tezepelumab	128	123 (96.1)	-1.15 (1.09)	-4.8	-2.00	-1.00	-0.40	2.6	-0.19 [-0.45, 0.06]
			Placebo	125	116 (92.8)	-0.94 (1.09)	-3.8	-1.60	-0.90	-0.20	1.8	
		Week 26	Tezepelumab	128	124 (96.9)	-1.20 (1.13)	-4.4	-2.00	-1.10	-0.40	2.6	-0.19 [-0.44, 0.07]
			Placebo	125	116 (92.8)	-0.99 (1.07)	-4.2	-1.80	-1.00	-0.10	1.6	
		Week 28	Tezepelumab	128	125 (97.7)	-1.15 (1.14)	-4.4	-2.00	-1.20	-0.40	2.6	-0.21 [-0.46, 0.04]
			Placebo	125	116 (92.8)	-0.91 (1.13)	-4.2	-1.60	-0.80	-0.20	1.6	
		Week 30	Tezepelumab	128	126 (98.4)	-1.21 (1.17)	-4.4	-2.20	-1.10	-0.40	2.6	-0.25 [-0.50, 0.01]
			Placebo	125	117 (93.6)	-0.92 (1.13)	-3.4	-1.60	-1.00	-0.20	2.0	
		Week 32	Tezepelumab	128	126 (98.4)	-1.25 (1.16)	-4.4	-2.20	-1.00	-0.60	2.6	-0.23 [-0.48, 0.03]
			Placebo	125	117 (93.6)	-0.99 (1.08)	-3.6	-1.80	-1.00	-0.20	1.4	
		Week 34	Tezepelumab	128	126 (98.4)	-1.24 (1.17)	-4.4	-2.20	-1.20	-0.40	2.6	-0.19 [-0.45, 0.06]
			Placebo	125	117 (93.6)	-1.02 (1.07)	-4.2	-1.60	-1.00	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	128	126 (98.4)	-1.16 (1.22)	-4.4	-2.00	-1.20	-0.20	2.6	-0.18 [-0.44, 0.07]
			Placebo	125	117 (93.6)	-0.95 (1.12)	-3.6	-1.60	-1.00	0.00	1.4	
		Week 38	Tezepelumab	128	126 (98.4)	-1.27 (1.22)	-4.4	-2.20	-1.20	-0.40	2.6	-0.21 [-0.47, 0.04]
			Placebo	125	117 (93.6)	-1.02 (1.11)	-4.2	-1.60	-1.00	-0.20	1.6	
		Week 40	Tezepelumab	128	126 (98.4)	-1.22 (1.22)	-4.4	-2.20	-1.00	-0.40	2.6	-0.24 [-0.49, 0.02]
			Placebo	125	117 (93.6)	-0.94 (1.11)	-4.2	-1.60	-0.80	-0.20	1.4	
		Week 42	Tezepelumab	128	126 (98.4)	-1.27 (1.22)	-4.4	-2.20	-1.20	-0.40	2.6	-0.26 [-0.51, -0.01]
			Placebo	125	117 (93.6)	-0.97 (1.08)	-4.2	-1.60	-1.00	-0.20	1.4	
		Week 44	Tezepelumab	128	126 (98.4)	-1.25 (1.23)	-4.4	-2.20	-1.20	-0.40	2.6	-0.29 [-0.54, -0.04]
			Placebo	125	118 (94.4)	-0.91 (1.12)	-4.2	-1.60	-0.80	0.00	1.6	
		Week 46	Tezepelumab	128	126 (98.4)	-1.28 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.21 [-0.47, 0.04]
			Placebo	125	118 (94.4)	-1.04 (1.09)	-4.2	-1.60	-1.00	-0.20	1.6	
		Week 48	Tezepelumab	128	126 (98.4)	-1.22 (1.21)	-4.4	-2.00	-1.00	-0.40	2.6	-0.18 [-0.44, 0.07]
			Placebo	125	118 (94.4)	-1.00 (1.11)	-3.8	-1.60	-1.00	-0.20	1.8	
		Week 50	Tezepelumab	128	126 (98.4)	-1.29 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.23 [-0.49, 0.02]
			Placebo	125	118 (94.4)	-1.02 (1.06)	-4.2	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	128	126 (98.4)	-1.26 (1.22)	-4.4	-2.00	-1.20	-0.40	2.6	-0.24 [-0.49, 0.01]
			Placebo	125	118 (94.4)	-0.98 (1.09)	-4.2	-1.60	-1.00	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	70	70 (100.0)	2.83 (0.80)	0.4	2.40	2.80	3.20	4.8	
			Placebo	73	73 (100.0)	2.78 (0.68)	1.4	2.40	2.80	3.20	4.2	
		Week 2	Tezepelumab	70	67 (95.7)	2.20 (0.92)	0.0	1.80	2.40	2.80	4.2	
			Placebo	73	67 (91.8)	2.44 (0.87)	0.0	1.80	2.60	3.00	4.4	
		Week 4	Tezepelumab	70	67 (95.7)	1.83 (1.02)	0.0	1.00	2.00	2.60	4.2	
			Placebo	73	67 (91.8)	2.34 (0.84)	0.4	1.80	2.40	3.00	4.4	
		Week 6	Tezepelumab	70	67 (95.7)	1.77 (0.97)	0.0	1.20	1.80	2.40	4.2	
			Placebo	73	68 (93.2)	2.18 (0.89)	0.2	1.60	2.30	2.80	4.8	
		Week 8	Tezepelumab	70	67 (95.7)	1.77 (1.00)	0.0	1.00	1.60	2.60	4.2	
			Placebo	73	68 (93.2)	2.15 (0.87)	0.4	1.60	2.20	2.70	4.4	
		Week 10	Tezepelumab	70	67 (95.7)	1.71 (0.98)	0.0	1.20	1.80	2.40	4.2	
			Placebo	73	69 (94.5)	2.00 (0.84)	0.2	1.40	2.00	2.60	4.2	
		Week 12	Tezepelumab	70	67 (95.7)	1.65 (1.08)	0.0	0.80	1.60	2.40	4.2	
			Placebo	73	69 (94.5)	2.04 (0.94)	0.0	1.40	2.20	2.80	4.4	
		Week 14	Tezepelumab	70	67 (95.7)	1.44 (1.00)	0.0	0.80	1.20	2.20	4.2	
			Placebo	73	69 (94.5)	1.99 (0.90)	0.0	1.20	2.00	2.80	4.2	
		Week 16	Tezepelumab	70	67 (95.7)	1.62 (1.04)	0.0	0.80	1.60	2.60	4.2	
			Placebo	73	69 (94.5)	2.08 (0.96)	0.0	1.40	2.00	3.00	3.8	
		Week 18	Tezepelumab	70	67 (95.7)	1.42 (0.93)	0.0	0.80	1.20	2.00	4.2	
			Placebo	73	69 (94.5)	1.97 (0.89)	0.0	1.40	1.80	2.60	3.8	
		Week 20	Tezepelumab	70	67 (95.7)	1.60 (1.02)	0.0	0.80	1.60	2.40	4.2	
			Placebo	73	69 (94.5)	1.98 (0.98)	0.0	1.40	2.20	2.80	3.6	
		Week 22	Tezepelumab	70	67 (95.7)	1.56 (1.02)	0.0	0.80	1.60	2.40	4.2	
			Placebo	73	69 (94.5)	1.94 (0.94)	0.0	1.20	2.00	2.80	3.6	
		Week 24	Tezepelumab	70	67 (95.7)	1.57 (1.08)	0.0	0.80	1.60	2.40	4.8	
			Placebo	73	69 (94.5)	1.87 (0.99)	0.0	1.00	1.80	2.80	3.4	
		Week 26	Tezepelumab	70	67 (95.7)	1.44 (0.95)	0.0	0.80	1.20	2.20	4.2	
			Placebo	73	69 (94.5)	1.83 (0.89)	0.0	1.00	1.80	2.80	3.2	
		Week 28	Tezepelumab	70	67 (95.7)	1.61 (1.05)	0.0	1.00	1.60	2.60	4.2	
			Placebo	73	69 (94.5)	1.96 (0.97)	0.0	1.20	2.20	2.80	3.8	
		Week 30	Tezepelumab	70	68 (97.1)	1.51 (0.99)	0.0	0.80	1.40	2.20	4.2	
			Placebo	73	70 (95.9)	1.95 (0.97)	0.0	1.00	2.10	2.80	4.2	
		Week 32	Tezepelumab	70	68 (97.1)	1.49 (1.03)	0.0	0.80	1.40	2.20	4.2	
			Placebo	73	70 (95.9)	1.88 (1.04)	0.0	1.00	1.80	2.80	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Medium/Low	Absolute values	Week 34	Tezepelumab	70	68 (97.1)	1.44 (1.05)	0.0	0.70	1.20	2.20	4.2	
			Placebo	73	70 (95.9)	1.83 (1.04)	0.0	1.00	1.70	2.60	3.8	
		Week 36	Tezepelumab	70	68 (97.1)	1.65 (1.12)	0.0	0.80	1.70	2.40	5.0	
			Placebo	73	70 (95.9)	1.84 (1.01)	0.0	1.00	2.00	2.80	3.6	
		Week 38	Tezepelumab	70	68 (97.1)	1.41 (0.95)	0.0	0.80	1.30	2.10	4.2	
			Placebo	73	70 (95.9)	1.81 (1.02)	0.0	1.00	1.80	2.80	4.0	
		Week 40	Tezepelumab	70	68 (97.1)	1.48 (1.03)	0.0	0.60	1.50	2.20	4.2	
			Placebo	73	70 (95.9)	1.83 (1.01)	0.0	1.00	1.90	2.80	3.6	
		Week 42	Tezepelumab	70	68 (97.1)	1.45 (1.05)	0.0	0.70	1.40	2.10	4.6	
			Placebo	73	70 (95.9)	1.89 (1.05)	0.0	1.00	2.10	2.80	4.6	
		Week 44	Tezepelumab	70	68 (97.1)	1.47 (1.04)	0.0	0.60	1.40	2.20	4.2	
			Placebo	73	71 (97.3)	1.91 (1.03)	0.0	1.00	2.00	2.80	3.8	
		Week 46	Tezepelumab	70	68 (97.1)	1.39 (1.00)	0.0	0.70	1.20	2.10	4.2	
			Placebo	73	71 (97.3)	1.79 (1.04)	0.0	1.00	2.00	2.80	3.6	
		Week 48	Tezepelumab	70	68 (97.1)	1.50 (1.04)	0.0	0.60	1.50	2.30	4.2	
			Placebo	73	71 (97.3)	1.80 (1.04)	0.0	0.80	1.80	2.80	3.6	
		Week 50	Tezepelumab	70	68 (97.1)	1.38 (0.97)	0.0	0.80	1.30	2.10	4.2	
			Placebo	73	71 (97.3)	1.86 (1.00)	0.0	1.00	2.00	2.80	3.8	
		Week 52	Tezepelumab	70	68 (97.1)	1.41 (0.99)	0.0	0.60	1.40	2.00	4.2	
			Placebo	73	71 (97.3)	1.89 (1.01)	0.0	1.00	2.00	2.80	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 2	Tezepelumab	70	67 (95.7)	-0.59 (0.70)	-3.0	-0.80	-0.40	-0.20	0.4	-0.34 [-0.68, 0.00]
			Placebo	73	67 (91.8)	-0.33 (0.80)	-3.0	-0.80	-0.20	0.20	1.4	
		Week 4	Tezepelumab	70	67 (95.7)	-0.96 (0.98)	-3.8	-1.60	-0.80	-0.20	1.2	-0.58 [-0.92, -0.23]
			Placebo	73	67 (91.8)	-0.43 (0.85)	-2.4	-1.00	-0.40	0.20	1.6	
		Week 6	Tezepelumab	70	67 (95.7)	-1.02 (1.05)	-4.0	-1.60	-1.00	-0.40	1.2	-0.45 [-0.80, -0.11]
			Placebo	73	68 (93.2)	-0.58 (0.89)	-2.6	-1.30	-0.60	0.00	1.4	
		Week 8	Tezepelumab	70	67 (95.7)	-1.03 (1.02)	-4.0	-1.60	-1.00	-0.40	1.0	-0.44 [-0.78, -0.09]
			Placebo	73	68 (93.2)	-0.61 (0.88)	-3.0	-1.00	-0.60	0.00	1.0	
		Week 10	Tezepelumab	70	67 (95.7)	-1.09 (0.98)	-4.0	-1.60	-1.00	-0.40	1.0	-0.33 [-0.67, 0.01]
			Placebo	73	69 (94.5)	-0.77 (0.90)	-3.0	-1.40	-0.60	-0.20	0.8	
		Week 12	Tezepelumab	70	67 (95.7)	-1.14 (1.02)	-4.0	-1.80	-1.00	-0.40	1.2	-0.40 [-0.74, -0.06]
			Placebo	73	69 (94.5)	-0.74 (1.02)	-3.0	-1.20	-0.60	0.00	1.4	
		Week 14	Tezepelumab	70	67 (95.7)	-1.35 (1.03)	-4.2	-2.00	-1.40	-0.80	1.2	-0.58 [-0.93, -0.24]
			Placebo	73	69 (94.5)	-0.78 (0.93)	-3.2	-1.40	-0.80	-0.20	1.4	
		Week 16	Tezepelumab	70	67 (95.7)	-1.18 (1.08)	-4.4	-1.80	-1.00	-0.40	1.0	-0.46 [-0.80, -0.12]
			Placebo	73	69 (94.5)	-0.69 (1.03)	-3.6	-1.40	-0.60	0.00	1.4	
		Week 18	Tezepelumab	70	67 (95.7)	-1.37 (1.05)	-4.4	-2.00	-1.20	-0.60	1.2	-0.57 [-0.91, -0.23]
			Placebo	73	69 (94.5)	-0.81 (0.94)	-3.4	-1.40	-0.60	-0.40	1.0	
		Week 20	Tezepelumab	70	67 (95.7)	-1.20 (1.08)	-4.4	-2.00	-1.00	-0.40	1.0	-0.38 [-0.72, -0.04]
			Placebo	73	69 (94.5)	-0.79 (1.07)	-3.6	-1.40	-0.60	-0.20	1.2	
		Week 22	Tezepelumab	70	67 (95.7)	-1.23 (1.12)	-4.4	-1.80	-1.20	-0.40	1.2	-0.37 [-0.71, -0.03]
			Placebo	73	69 (94.5)	-0.84 (1.00)	-3.4	-1.60	-0.80	-0.20	1.4	
		Week 24	Tezepelumab	70	67 (95.7)	-1.22 (1.05)	-4.8	-1.80	-1.00	-0.40	1.4	-0.30 [-0.64, 0.04]
			Placebo	73	69 (94.5)	-0.90 (1.09)	-3.8	-1.40	-0.80	-0.20	1.8	
		Week 26	Tezepelumab	70	67 (95.7)	-1.36 (1.08)	-4.4	-2.00	-1.20	-0.60	1.2	-0.40 [-0.74, -0.06]
			Placebo	73	69 (94.5)	-0.94 (1.02)	-4.2	-1.60	-1.00	-0.20	0.8	
		Week 28	Tezepelumab	70	67 (95.7)	-1.18 (1.05)	-4.4	-1.80	-1.00	-0.40	1.0	-0.34 [-0.68, -0.00]
			Placebo	73	69 (94.5)	-0.82 (1.08)	-4.2	-1.60	-0.80	-0.20	1.2	
		Week 30	Tezepelumab	70	68 (97.1)	-1.30 (1.09)	-4.4	-2.00	-1.10	-0.60	1.4	-0.43 [-0.77, -0.10]
			Placebo	73	70 (95.9)	-0.83 (1.08)	-3.4	-1.60	-0.80	-0.20	1.4	
		Week 32	Tezepelumab	70	68 (97.1)	-1.32 (1.15)	-4.4	-2.10	-1.00	-0.60	1.8	-0.38 [-0.72, -0.04]
			Placebo	73	70 (95.9)	-0.89 (1.09)	-3.6	-1.80	-0.80	-0.20	1.4	
		Week 34	Tezepelumab	70	68 (97.1)	-1.36 (1.10)	-4.4	-2.00	-1.20	-0.70	1.8	-0.38 [-0.72, -0.05]
			Placebo	73	70 (95.9)	-0.94 (1.10)	-4.2	-1.60	-0.80	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Medium/Low	Change from baseline	Week 36	Tezepelumab	70	68 (97.1)	-1.16 (1.22)	-4.4	-1.90	-1.00	-0.40	2.0	-0.19 [-0.53, 0.14]
			Placebo	73	70 (95.9)	-0.93 (1.12)	-3.6	-1.80	-0.90	0.00	1.4	
		Week 38	Tezepelumab	70	68 (97.1)	-1.40 (1.13)	-4.4	-2.20	-1.20	-0.60	1.0	-0.37 [-0.71, -0.04]
			Placebo	73	70 (95.9)	-0.97 (1.16)	-4.2	-1.60	-1.00	-0.20	1.6	
		Week 40	Tezepelumab	70	68 (97.1)	-1.33 (1.18)	-4.4	-2.10	-1.00	-0.60	1.2	-0.35 [-0.68, -0.01]
			Placebo	73	70 (95.9)	-0.95 (1.06)	-4.2	-1.60	-0.80	-0.20	1.4	
		Week 42	Tezepelumab	70	68 (97.1)	-1.36 (1.17)	-4.4	-2.10	-1.30	-0.60	1.8	-0.41 [-0.75, -0.07]
			Placebo	73	70 (95.9)	-0.89 (1.13)	-4.2	-1.60	-0.80	-0.20	1.4	
		Week 44	Tezepelumab	70	68 (97.1)	-1.34 (1.21)	-4.4	-2.00	-1.20	-0.60	1.2	-0.40 [-0.74, -0.07]
			Placebo	73	71 (97.3)	-0.87 (1.13)	-4.2	-1.60	-0.80	0.00	1.4	
		Week 46	Tezepelumab	70	68 (97.1)	-1.42 (1.16)	-4.4	-2.00	-1.30	-0.70	1.2	-0.38 [-0.71, -0.04]
			Placebo	73	71 (97.3)	-0.99 (1.14)	-4.2	-1.60	-1.00	0.00	1.0	
		Week 48	Tezepelumab	70	68 (97.1)	-1.31 (1.19)	-4.4	-2.00	-1.20	-0.40	1.2	-0.29 [-0.62, 0.05]
			Placebo	73	71 (97.3)	-0.97 (1.14)	-3.8	-1.80	-1.00	-0.20	1.4	
		Week 50	Tezepelumab	70	68 (97.1)	-1.43 (1.14)	-4.4	-2.00	-1.40	-0.60	1.2	-0.45 [-0.79, -0.12]
			Placebo	73	71 (97.3)	-0.92 (1.10)	-4.2	-1.60	-1.00	-0.20	1.6	
		Week 52	Tezepelumab	70	68 (97.1)	-1.40 (1.19)	-4.4	-2.00	-1.20	-0.50	1.2	-0.45 [-0.78, -0.11]
			Placebo	73	71 (97.3)	-0.88 (1.11)	-4.2	-1.60	-0.80	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	67	67 (100.0)	2.85 (0.89)	0.0	2.40	2.80	3.20	5.2	
			Placebo	65	65 (100.0)	2.86 (0.77)	0.4	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	67	64 (95.5)	2.34 (1.01)	0.0	1.60	2.60	3.00	4.4	
			Placebo	65	58 (89.2)	2.40 (0.80)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	67	64 (95.5)	2.09 (1.00)	0.2	1.30	2.20	2.90	3.6	
			Placebo	65	58 (89.2)	2.25 (0.92)	0.2	1.80	2.50	2.80	4.2	
		Week 6	Tezepelumab	67	64 (95.5)	1.97 (1.03)	0.0	1.20	1.90	2.80	4.0	
			Placebo	65	58 (89.2)	2.21 (1.16)	0.2	1.40	2.20	3.00	6.0	
		Week 8	Tezepelumab	67	64 (95.5)	1.82 (1.17)	0.0	1.00	1.80	2.80	5.2	
			Placebo	65	59 (90.8)	2.13 (1.14)	0.0	1.20	2.40	3.00	5.0	
		Week 10	Tezepelumab	67	64 (95.5)	1.73 (1.13)	0.0	0.80	1.70	2.60	4.8	
			Placebo	65	59 (90.8)	2.15 (1.08)	0.0	1.60	2.20	3.00	5.2	
		Week 12	Tezepelumab	67	64 (95.5)	1.63 (1.10)	0.0	0.60	1.60	2.60	4.8	
			Placebo	65	59 (90.8)	1.94 (1.06)	0.0	1.00	2.00	2.60	4.4	
		Week 14	Tezepelumab	67	64 (95.5)	1.58 (1.12)	0.0	0.60	1.40	2.30	4.8	
			Placebo	65	59 (90.8)	1.87 (1.00)	0.0	1.20	2.00	2.40	5.0	
		Week 16	Tezepelumab	67	64 (95.5)	1.73 (1.18)	0.0	0.80	1.70	2.70	4.8	
			Placebo	65	59 (90.8)	2.03 (1.21)	0.0	1.00	2.00	2.80	5.0	
		Week 18	Tezepelumab	67	65 (97.0)	1.68 (1.08)	0.0	0.80	1.60	2.40	4.8	
			Placebo	65	59 (90.8)	1.93 (1.18)	0.0	1.00	2.00	2.60	5.0	
		Week 20	Tezepelumab	67	65 (97.0)	1.69 (1.14)	0.0	0.80	1.80	2.60	5.0	
			Placebo	65	59 (90.8)	2.03 (1.11)	0.0	1.20	2.00	2.80	5.0	
		Week 22	Tezepelumab	67	65 (97.0)	1.78 (1.02)	0.0	1.00	2.00	2.40	4.8	
			Placebo	65	59 (90.8)	1.98 (1.16)	0.0	1.00	2.00	2.60	5.0	
		Week 24	Tezepelumab	67	65 (97.0)	1.74 (1.10)	0.0	1.00	1.80	2.60	4.8	
			Placebo	65	59 (90.8)	2.05 (1.07)	0.0	1.40	2.20	2.80	4.4	
		Week 26	Tezepelumab	67	66 (98.5)	1.79 (1.11)	0.0	1.00	1.80	2.60	4.8	
			Placebo	65	59 (90.8)	1.98 (1.14)	0.0	1.00	1.80	3.00	4.4	
		Week 28	Tezepelumab	67	67 (100.0)	1.74 (1.15)	0.0	1.00	1.80	2.40	4.8	
			Placebo	65	60 (92.3)	1.96 (1.23)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	67	67 (100.0)	1.71 (1.10)	0.0	0.80	1.60	2.60	4.8	
			Placebo	65	60 (92.3)	1.94 (1.18)	0.0	1.00	2.00	2.90	4.4	
		Week 32	Tezepelumab	67	67 (100.0)	1.64 (1.12)	0.0	0.80	1.60	2.60	4.8	
			Placebo	65	60 (92.3)	1.90 (1.14)	0.0	1.00	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Absolute values	Week 34	Tezepelumab	67	67 (100.0)	1.72 (1.18)	0.0	0.80	1.60	2.80	4.8	
			Placebo	65	60 (92.3)	1.88 (1.14)	0.0	0.90	1.80	2.60	4.8	
		Week 36	Tezepelumab	67	67 (100.0)	1.67 (1.10)	0.0	1.00	1.60	2.40	4.8	
			Placebo	65	60 (92.3)	2.05 (1.19)	0.0	1.20	2.10	2.80	4.8	
		Week 38	Tezepelumab	67	67 (100.0)	1.72 (1.22)	0.0	0.80	1.80	2.60	4.8	
			Placebo	65	60 (92.3)	1.92 (1.13)	0.0	1.00	1.80	2.70	4.8	
		Week 40	Tezepelumab	67	67 (100.0)	1.71 (1.18)	0.0	0.80	1.80	2.60	4.8	
			Placebo	65	60 (92.3)	2.06 (1.19)	0.0	1.10	2.10	3.00	4.4	
		Week 42	Tezepelumab	67	67 (100.0)	1.65 (1.14)	0.0	0.80	1.60	2.40	4.8	
			Placebo	65	60 (92.3)	1.92 (1.06)	0.0	1.10	2.00	2.60	4.6	
		Week 44	Tezepelumab	67	67 (100.0)	1.69 (1.14)	0.0	0.80	1.80	2.60	4.8	
			Placebo	65	60 (92.3)	2.01 (1.12)	0.0	1.20	2.00	2.80	4.4	
		Week 46	Tezepelumab	67	67 (100.0)	1.71 (1.18)	0.0	0.80	1.80	2.60	4.8	
			Placebo	65	60 (92.3)	1.88 (1.01)	0.0	1.20	2.00	2.40	4.4	
		Week 48	Tezepelumab	67	67 (100.0)	1.72 (1.18)	0.0	0.80	1.80	2.60	4.8	
			Placebo	65	60 (92.3)	1.94 (1.10)	0.0	1.00	2.00	2.60	4.6	
		Week 50	Tezepelumab	67	67 (100.0)	1.66 (1.20)	0.0	0.80	1.40	2.60	4.8	
			Placebo	65	60 (92.3)	1.82 (1.03)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	67	67 (100.0)	1.69 (1.18)	0.0	0.80	1.60	2.60	4.8	
			Placebo	65	60 (92.3)	1.89 (1.09)	0.0	1.00	2.00	2.70	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 2	Tezepelumab	67	64 (95.5)	-0.55 (0.79)	-3.2	-1.10	-0.40	0.20	0.8	-0.06 [-0.42, 0.29]
			Placebo	65	58 (89.2)	-0.50 (0.72)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	67	64 (95.5)	-0.80 (0.95)	-2.6	-1.40	-0.80	-0.20	2.6	-0.16 [-0.51, 0.20]
			Placebo	65	58 (89.2)	-0.65 (0.97)	-3.0	-1.40	-0.40	0.00	1.2	
		Week 6	Tezepelumab	67	64 (95.5)	-0.92 (1.03)	-2.8	-1.60	-1.00	-0.10	2.6	-0.22 [-0.58, 0.14]
			Placebo	65	58 (89.2)	-0.69 (1.05)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	67	64 (95.5)	-1.07 (1.16)	-3.2	-1.80	-1.00	-0.40	2.6	-0.26 [-0.61, 0.10]
			Placebo	65	59 (90.8)	-0.78 (1.06)	-3.6	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	67	64 (95.5)	-1.15 (1.14)	-3.4	-1.90	-1.20	-0.50	2.6	-0.35 [-0.70, 0.01]
			Placebo	65	59 (90.8)	-0.76 (1.16)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	67	64 (95.5)	-1.26 (1.13)	-3.2	-2.20	-1.30	-0.60	2.6	-0.27 [-0.62, 0.09]
			Placebo	65	59 (90.8)	-0.97 (1.08)	-3.8	-1.60	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	67	64 (95.5)	-1.31 (1.14)	-4.0	-2.20	-1.40	-0.60	2.6	-0.25 [-0.60, 0.11]
			Placebo	65	59 (90.8)	-1.04 (1.08)	-3.4	-1.60	-1.20	-0.40	2.4	
		Week 16	Tezepelumab	67	64 (95.5)	-1.16 (1.17)	-3.2	-2.20	-1.20	-0.50	2.6	-0.25 [-0.60, 0.11]
			Placebo	65	59 (90.8)	-0.87 (1.18)	-3.6	-1.40	-1.00	-0.20	2.6	
		Week 18	Tezepelumab	67	65 (97.0)	-1.19 (1.11)	-3.8	-1.80	-1.00	-0.60	2.6	-0.18 [-0.54, 0.17]
			Placebo	65	59 (90.8)	-0.98 (1.23)	-3.6	-2.00	-1.00	-0.20	2.6	
		Week 20	Tezepelumab	67	65 (97.0)	-1.18 (1.12)	-3.4	-2.20	-1.20	-0.40	2.6	-0.27 [-0.62, 0.09]
			Placebo	65	59 (90.8)	-0.87 (1.18)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	67	65 (97.0)	-1.10 (1.13)	-3.2	-1.80	-1.00	-0.60	2.6	-0.15 [-0.50, 0.21]
			Placebo	65	59 (90.8)	-0.93 (1.18)	-3.8	-1.60	-1.00	-0.20	2.6	
		Week 24	Tezepelumab	67	65 (97.0)	-1.13 (1.10)	-3.4	-2.00	-1.20	-0.40	2.6	-0.24 [-0.59, 0.11]
			Placebo	65	59 (90.8)	-0.86 (1.13)	-3.6	-1.60	-0.80	0.00	2.6	
		Week 26	Tezepelumab	67	66 (98.5)	-1.06 (1.13)	-3.0	-2.20	-1.00	-0.20	2.6	-0.12 [-0.47, 0.24]
			Placebo	65	59 (90.8)	-0.93 (1.20)	-3.4	-1.80	-1.20	0.00	2.6	
		Week 28	Tezepelumab	67	67 (100.0)	-1.12 (1.21)	-3.4	-2.20	-1.20	0.00	2.6	-0.17 [-0.52, 0.18]
			Placebo	65	60 (92.3)	-0.91 (1.23)	-3.4	-1.80	-1.10	0.00	2.6	
		Week 30	Tezepelumab	67	67 (100.0)	-1.14 (1.19)	-3.8	-2.20	-1.20	-0.40	2.6	-0.17 [-0.52, 0.18]
			Placebo	65	60 (92.3)	-0.93 (1.23)	-3.4	-1.60	-1.10	-0.20	2.6	
		Week 32	Tezepelumab	67	67 (100.0)	-1.21 (1.13)	-3.2	-2.20	-1.20	-0.60	2.6	-0.21 [-0.56, 0.14]
			Placebo	65	60 (92.3)	-0.96 (1.17)	-3.2	-1.60	-1.20	-0.20	2.6	
		Week 34	Tezepelumab	67	67 (100.0)	-1.14 (1.21)	-3.0	-2.20	-1.40	-0.20	2.6	-0.12 [-0.47, 0.22]
			Placebo	65	60 (92.3)	-0.99 (1.16)	-3.2	-1.70	-1.20	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Change from baseline	Week 36	Tezepelumab	67	67 (100.0)	-1.18 (1.19)	-3.2	-2.20	-1.20	-0.20	2.6	-0.30 [-0.65, 0.05]
			Placebo	65	60 (92.3)	-0.81 (1.22)	-3.6	-1.40	-1.00	-0.10	2.6	
		Week 38	Tezepelumab	67	67 (100.0)	-1.13 (1.23)	-3.2	-2.20	-1.20	-0.20	2.6	-0.16 [-0.51, 0.19]
			Placebo	65	60 (92.3)	-0.94 (1.15)	-3.2	-1.60	-1.00	-0.40	2.6	
		Week 40	Tezepelumab	67	67 (100.0)	-1.14 (1.22)	-3.4	-2.20	-1.20	-0.40	2.6	-0.28 [-0.63, 0.07]
			Placebo	65	60 (92.3)	-0.80 (1.22)	-3.2	-1.60	-0.80	0.00	2.6	
		Week 42	Tezepelumab	67	67 (100.0)	-1.20 (1.21)	-3.6	-2.20	-1.20	-0.40	2.6	-0.22 [-0.57, 0.13]
			Placebo	65	60 (92.3)	-0.94 (1.10)	-2.8	-1.60	-1.00	-0.30	2.6	
		Week 44	Tezepelumab	67	67 (100.0)	-1.16 (1.21)	-3.8	-2.20	-1.20	-0.40	2.6	-0.26 [-0.61, 0.09]
			Placebo	65	60 (92.3)	-0.86 (1.15)	-3.4	-1.60	-1.00	-0.10	2.6	
		Week 46	Tezepelumab	67	67 (100.0)	-1.14 (1.21)	-3.6	-2.20	-1.20	-0.20	2.6	-0.14 [-0.49, 0.21]
			Placebo	65	60 (92.3)	-0.98 (1.06)	-3.2	-1.60	-1.00	-0.50	2.6	
		Week 48	Tezepelumab	67	67 (100.0)	-1.14 (1.20)	-3.0	-2.20	-1.00	-0.40	2.6	-0.18 [-0.53, 0.17]
			Placebo	65	60 (92.3)	-0.92 (1.13)	-3.4	-1.60	-1.00	-0.30	2.6	
		Week 50	Tezepelumab	67	67 (100.0)	-1.19 (1.23)	-3.2	-2.20	-1.20	-0.40	2.6	-0.13 [-0.48, 0.22]
			Placebo	65	60 (92.3)	-1.04 (1.06)	-3.6	-1.60	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	67	67 (100.0)	-1.17 (1.21)	-3.2	-2.20	-1.20	-0.20	2.6	-0.17 [-0.52, 0.18]
			Placebo	65	60 (92.3)	-0.97 (1.11)	-3.6	-1.60	-0.90	-0.40	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	3.00 (0.79)	1.8	2.40	3.00	3.40	4.6	
			Placebo	6	6 (100.0)	2.97 (0.39)	2.4	2.80	3.00	3.00	3.6	
		Week 2	Tezepelumab	11	11 (100.0)	2.65 (0.86)	1.0	2.00	2.60	3.20	4.0	
			Placebo	6	5 (83.3)	2.52 (0.50)	1.8	2.40	2.40	3.00	3.0	
		Week 4	Tezepelumab	11	11 (100.0)	1.84 (0.95)	0.2	0.80	2.20	2.60	2.8	
			Placebo	6	5 (83.3)	2.84 (1.01)	1.8	2.20	2.40	3.60	4.2	
		Week 6	Tezepelumab	11	11 (100.0)	1.78 (0.65)	1.0	1.20	1.60	2.40	3.0	
			Placebo	6	5 (83.3)	2.60 (1.11)	1.2	1.80	2.80	3.20	4.0	
		Week 8	Tezepelumab	11	11 (100.0)	1.65 (0.69)	0.6	1.00	1.60	2.20	2.8	
			Placebo	6	5 (83.3)	2.32 (1.17)	0.6	2.00	2.20	3.20	3.6	
		Week 10	Tezepelumab	11	11 (100.0)	1.62 (0.85)	0.4	0.80	1.60	2.40	3.2	
			Placebo	6	5 (83.3)	2.08 (0.64)	1.4	1.60	2.00	2.40	3.0	
		Week 12	Tezepelumab	11	11 (100.0)	1.53 (0.87)	0.0	0.80	1.40	2.40	2.8	
			Placebo	6	5 (83.3)	2.68 (1.21)	1.2	2.00	2.60	3.20	4.4	
		Week 14	Tezepelumab	11	11 (100.0)	1.47 (0.76)	0.4	0.80	1.40	2.20	2.8	
			Placebo	6	5 (83.3)	1.96 (0.78)	1.2	1.60	1.60	2.20	3.2	
		Week 16	Tezepelumab	11	11 (100.0)	1.67 (0.78)	0.6	0.80	1.80	2.40	2.8	
			Placebo	6	5 (83.3)	2.44 (1.12)	1.4	1.60	2.00	3.20	4.0	
		Week 18	Tezepelumab	11	11 (100.0)	1.38 (0.77)	0.4	0.60	1.20	2.20	2.4	
			Placebo	6	5 (83.3)	1.96 (0.68)	1.4	1.40	1.60	2.60	2.8	
		Week 20	Tezepelumab	11	11 (100.0)	1.47 (0.69)	0.4	1.00	1.20	2.00	2.6	
			Placebo	6	5 (83.3)	2.04 (1.36)	0.0	1.60	2.20	2.80	3.6	
		Week 22	Tezepelumab	11	11 (100.0)	1.58 (0.74)	0.0	1.20	1.80	2.20	2.4	
			Placebo	6	5 (83.3)	2.36 (1.09)	0.8	1.80	2.60	3.00	3.6	
		Week 24	Tezepelumab	11	11 (100.0)	1.60 (0.71)	0.4	1.00	1.60	2.00	2.8	
			Placebo	6	5 (83.3)	2.52 (0.86)	1.2	2.20	2.80	3.00	3.4	
		Week 26	Tezepelumab	11	11 (100.0)	1.62 (0.65)	0.8	1.00	1.60	2.40	2.6	
			Placebo	6	5 (83.3)	2.36 (1.14)	1.0	1.60	2.20	3.20	3.8	
		Week 28	Tezepelumab	11	11 (100.0)	1.60 (0.63)	0.4	1.00	1.80	2.00	2.4	
			Placebo	6	5 (83.3)	2.44 (1.09)	0.8	2.20	2.60	2.80	3.8	
		Week 30	Tezepelumab	11	11 (100.0)	1.58 (0.68)	0.8	0.80	1.80	2.00	2.6	
			Placebo	6	5 (83.3)	2.64 (1.04)	1.2	2.40	2.40	3.20	4.0	
		Week 32	Tezepelumab	11	11 (100.0)	1.62 (0.73)	0.6	1.00	1.40	2.40	2.8	
			Placebo	6	5 (83.3)	2.00 (1.30)	0.8	0.80	1.80	2.80	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	11	11 (100.0)	1.58 (0.66)	0.8	1.00	1.40	2.20	2.4	
			Placebo	6	5 (83.3)	2.28 (0.81)	1.4	2.00	2.20	2.20	3.6	
		Week 36	Tezepelumab	11	11 (100.0)	1.49 (0.56)	0.6	1.00	1.40	2.00	2.4	
			Placebo	6	5 (83.3)	2.52 (1.17)	1.4	1.80	2.20	2.80	4.4	
		Week 38	Tezepelumab	11	11 (100.0)	1.58 (0.70)	0.6	1.00	1.40	2.40	2.4	
			Placebo	6	5 (83.3)	2.00 (0.89)	1.0	1.40	1.80	2.60	3.2	
		Week 40	Tezepelumab	11	11 (100.0)	1.64 (0.76)	0.4	0.80	1.80	2.40	2.6	
			Placebo	6	5 (83.3)	2.56 (1.40)	0.8	1.60	3.00	3.00	4.4	
		Week 42	Tezepelumab	11	11 (100.0)	1.49 (0.55)	1.0	1.00	1.20	2.00	2.4	
			Placebo	6	5 (83.3)	2.36 (1.34)	1.0	2.00	2.00	2.20	4.6	
		Week 44	Tezepelumab	11	11 (100.0)	1.55 (0.71)	0.4	1.00	1.60	2.40	2.4	
			Placebo	6	5 (83.3)	2.56 (1.15)	1.0	2.20	2.60	2.80	4.2	
		Week 46	Tezepelumab	11	11 (100.0)	1.49 (0.60)	0.6	1.00	1.60	2.00	2.4	
			Placebo	6	5 (83.3)	2.12 (0.58)	1.4	2.00	2.00	2.20	3.0	
		Week 48	Tezepelumab	11	11 (100.0)	1.49 (0.52)	0.8	1.00	1.20	2.00	2.4	
			Placebo	6	5 (83.3)	2.24 (1.19)	0.8	1.60	2.40	2.40	4.0	
		Week 50	Tezepelumab	11	11 (100.0)	1.75 (0.64)	0.8	1.20	1.80	2.40	2.8	
			Placebo	6	5 (83.3)	2.24 (0.73)	1.4	2.00	2.20	2.20	3.4	
		Week 52	Tezepelumab	11	11 (100.0)	1.73 (0.62)	0.8	1.20	1.80	2.20	2.8	
			Placebo	6	5 (83.3)	2.48 (1.04)	1.2	2.00	2.40	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	-0.35 (0.56)	-1.4	-0.60	-0.40	0.20	0.2	0.18 [-0.88, 1.24]
			Placebo	6	5 (83.3)	-0.44 (0.43)	-1.0	-0.60	-0.60	0.00	0.0	
		Week 4	Tezepelumab	11	11 (100.0)	-1.16 (0.99)	-2.4	-2.00	-1.00	-0.80	1.0	-1.04 [-2.17, 0.08]
			Placebo	6	5 (83.3)	-0.12 (1.03)	-1.2	-1.00	-0.20	0.60	1.2	
		Week 6	Tezepelumab	11	11 (100.0)	-1.22 (0.85)	-2.6	-1.60	-1.40	-0.80	0.2	-0.96 [-2.08, 0.15]
			Placebo	6	5 (83.3)	-0.36 (0.99)	-1.6	-0.80	-0.60	0.20	1.0	
		Week 8	Tezepelumab	11	11 (100.0)	-1.35 (1.05)	-3.2	-1.80	-1.40	-1.00	0.4	-0.60 [-1.68, 0.48]
			Placebo	6	5 (83.3)	-0.64 (1.42)	-3.0	-0.80	-0.20	0.20	0.6	
		Week 10	Tezepelumab	11	11 (100.0)	-1.38 (1.20)	-3.4	-1.80	-1.60	-1.00	0.8	-0.44 [-1.51, 0.63]
			Placebo	6	5 (83.3)	-0.88 (0.92)	-2.2	-1.20	-1.00	0.00	0.0	
		Week 12	Tezepelumab	11	11 (100.0)	-1.47 (1.19)	-3.2	-2.40	-1.40	-1.00	0.8	-0.95 [-2.06, 0.17]
			Placebo	6	5 (83.3)	-0.28 (1.42)	-2.4	-0.80	0.20	0.20	1.4	
		Week 14	Tezepelumab	11	11 (100.0)	-1.53 (1.36)	-4.0	-2.20	-1.40	-0.60	1.0	-0.42 [-1.49, 0.65]
			Placebo	6	5 (83.3)	-1.00 (0.95)	-2.0	-1.60	-1.40	-0.20	0.2	
		Week 16	Tezepelumab	11	11 (100.0)	-1.33 (1.18)	-3.2	-2.40	-1.20	-0.80	1.0	-0.69 [-1.78, 0.40]
			Placebo	6	5 (83.3)	-0.52 (1.15)	-2.0	-1.00	-0.80	0.20	1.0	
		Week 18	Tezepelumab	11	11 (100.0)	-1.62 (1.27)	-3.8	-2.60	-1.40	-0.80	0.6	-0.54 [-1.61, 0.54]
			Placebo	6	5 (83.3)	-1.00 (0.81)	-2.2	-1.40	-0.80	-0.40	-0.2	
		Week 20	Tezepelumab	11	11 (100.0)	-1.53 (1.07)	-3.4	-2.20	-1.60	-1.00	0.8	-0.49 [-1.56, 0.58]
			Placebo	6	5 (83.3)	-0.92 (1.59)	-3.6	-0.80	-0.60	-0.20	0.6	
		Week 22	Tezepelumab	11	11 (100.0)	-1.42 (1.10)	-3.2	-2.40	-1.40	-0.60	0.2	-0.69 [-1.77, 0.40]
			Placebo	6	5 (83.3)	-0.60 (1.41)	-2.8	-1.00	-0.40	0.60	0.6	
		Week 24	Tezepelumab	11	11 (100.0)	-1.40 (0.91)	-3.4	-1.80	-1.40	-0.80	0.2	-0.98 [-2.10, 0.13]
			Placebo	6	5 (83.3)	-0.44 (1.12)	-2.4	-0.20	0.00	0.00	0.4	
		Week 26	Tezepelumab	11	11 (100.0)	-1.38 (0.94)	-3.0	-2.20	-1.40	-0.40	0.2	-0.73 [-1.82, 0.36]
			Placebo	6	5 (83.3)	-0.60 (1.33)	-2.6	-1.20	-0.20	0.20	0.8	
		Week 28	Tezepelumab	11	11 (100.0)	-1.40 (1.00)	-3.4	-2.20	-1.40	-1.00	0.2	-0.79 [-1.89, 0.31]
			Placebo	6	5 (83.3)	-0.52 (1.35)	-2.8	-0.20	-0.20	-0.20	0.8	
		Week 30	Tezepelumab	11	11 (100.0)	-1.42 (1.27)	-3.8	-2.40	-1.20	-1.00	0.8	-0.85 [-1.95, 0.26]
			Placebo	6	5 (83.3)	-0.32 (1.36)	-2.4	-0.60	-0.40	0.80	1.0	
		Week 32	Tezepelumab	11	11 (100.0)	-1.38 (0.96)	-3.2	-1.80	-1.60	-1.00	0.8	-0.39 [-1.45, 0.68]
			Placebo	6	5 (83.3)	-0.96 (1.37)	-2.8	-1.60	-1.00	-0.20	0.8	
		Week 34	Tezepelumab	11	11 (100.0)	-1.42 (1.08)	-3.0	-2.20	-1.60	-0.60	0.4	-0.70 [-1.78, 0.39]
			Placebo	6	5 (83.3)	-0.68 (1.01)	-2.2	-0.80	-0.60	-0.40	0.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	11	11 (100.0)	-1.51 (1.01)	-3.2	-2.00	-1.40	-1.00	0.4	-1.01 [-2.13, 0.12]
			Placebo	6	5 (83.3)	-0.44 (1.19)	-1.8	-1.00	-0.60	-0.20	1.4	
		Week 38	Tezepelumab	11	11 (100.0)	-1.42 (1.08)	-3.2	-2.00	-1.80	-1.00	0.4	-0.44 [-1.51, 0.63]
			Placebo	6	5 (83.3)	-0.96 (0.92)	-2.2	-1.40	-1.00	-0.40	0.2	
		Week 40	Tezepelumab	11	11 (100.0)	-1.36 (1.25)	-3.4	-2.40	-1.20	-0.80	0.8	-0.75 [-1.84, 0.35]
			Placebo	6	5 (83.3)	-0.40 (1.39)	-2.0	-1.60	0.00	0.20	1.4	
		Week 42	Tezepelumab	11	11 (100.0)	-1.51 (1.16)	-3.6	-2.20	-1.40	-1.00	0.4	-0.76 [-1.86, 0.33]
			Placebo	6	5 (83.3)	-0.60 (1.28)	-1.6	-1.40	-0.80	-0.80	1.6	
		Week 44	Tezepelumab	11	11 (100.0)	-1.45 (1.24)	-3.8	-2.00	-1.20	-0.80	0.6	-0.89 [-2.00, 0.22]
			Placebo	6	5 (83.3)	-0.40 (1.03)	-1.4	-1.00	-0.80	0.00	1.2	
		Week 46	Tezepelumab	11	11 (100.0)	-1.51 (0.96)	-3.6	-2.00	-1.40	-1.00	0.2	-0.77 [-1.86, 0.33]
			Placebo	6	5 (83.3)	-0.84 (0.59)	-1.6	-1.00	-1.00	-0.60	0.0	
		Week 48	Tezepelumab	11	11 (100.0)	-1.51 (0.89)	-2.8	-2.20	-1.60	-1.00	0.2	-0.81 [-1.91, 0.29]
			Placebo	6	5 (83.3)	-0.72 (1.17)	-2.0	-1.60	-0.60	-0.40	1.0	
		Week 50	Tezepelumab	11	11 (100.0)	-1.25 (0.95)	-2.6	-1.80	-1.40	-0.80	0.6	-0.60 [-1.68, 0.48]
			Placebo	6	5 (83.3)	-0.72 (0.73)	-1.6	-1.00	-0.80	-0.60	0.4	
		Week 52	Tezepelumab	11	11 (100.0)	-1.27 (0.91)	-2.6	-1.80	-1.40	-0.80	0.4	-0.85 [-1.95, 0.26]
			Placebo	6	5 (83.3)	-0.48 (1.01)	-1.6	-1.20	-0.40	-0.20	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	126	126 (100.0)	2.83 (0.85)	0.0	2.40	2.80	3.20	5.2	
			Placebo	132	132 (100.0)	2.81 (0.73)	0.4	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	126	120 (95.2)	2.23 (0.97)	0.0	1.60	2.40	2.90	4.4	
			Placebo	132	120 (90.9)	2.41 (0.85)	0.0	2.00	2.40	3.00	5.0	
		Week 4	Tezepelumab	126	120 (95.2)	1.97 (1.02)	0.0	1.20	2.10	2.80	4.2	
			Placebo	132	120 (90.9)	2.28 (0.87)	0.2	1.80	2.40	2.80	4.4	
		Week 6	Tezepelumab	126	120 (95.2)	1.88 (1.03)	0.0	1.20	1.80	2.60	4.2	
			Placebo	132	121 (91.7)	2.18 (1.02)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	126	120 (95.2)	1.81 (1.11)	0.0	1.00	1.80	2.80	5.2	
			Placebo	132	122 (92.4)	2.13 (1.00)	0.0	1.60	2.20	2.80	5.0	
		Week 10	Tezepelumab	126	120 (95.2)	1.73 (1.07)	0.0	1.00	1.80	2.60	4.8	
			Placebo	132	123 (93.2)	2.07 (0.97)	0.0	1.40	2.00	2.80	5.2	
		Week 12	Tezepelumab	126	120 (95.2)	1.65 (1.10)	0.0	0.70	1.60	2.60	4.8	
			Placebo	132	123 (93.2)	1.97 (0.98)	0.0	1.20	2.00	2.80	4.4	
		Week 14	Tezepelumab	126	120 (95.2)	1.51 (1.09)	0.0	0.60	1.40	2.30	4.8	
			Placebo	132	123 (93.2)	1.94 (0.96)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	126	120 (95.2)	1.67 (1.13)	0.0	0.80	1.60	2.60	4.8	
			Placebo	132	123 (93.2)	2.05 (1.08)	0.0	1.20	2.00	3.00	5.0	
		Week 18	Tezepelumab	126	121 (96.0)	1.57 (1.03)	0.0	1.00	1.40	2.20	4.8	
			Placebo	132	123 (93.2)	1.95 (1.04)	0.0	1.20	2.00	2.60	5.0	
		Week 20	Tezepelumab	126	121 (96.0)	1.66 (1.11)	0.0	0.80	1.60	2.40	5.0	
			Placebo	132	123 (93.2)	2.00 (1.03)	0.0	1.20	2.20	2.80	5.0	
		Week 22	Tezepelumab	126	121 (96.0)	1.68 (1.05)	0.0	1.00	1.80	2.40	4.8	
			Placebo	132	123 (93.2)	1.94 (1.05)	0.0	1.20	2.00	2.60	5.0	
		Week 24	Tezepelumab	126	121 (96.0)	1.66 (1.12)	0.0	0.80	1.60	2.60	4.8	
			Placebo	132	123 (93.2)	1.93 (1.03)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	126	122 (96.8)	1.61 (1.08)	0.0	0.80	1.60	2.40	4.8	
			Placebo	132	123 (93.2)	1.88 (1.01)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	126	123 (97.6)	1.68 (1.13)	0.0	0.80	1.60	2.60	4.8	
			Placebo	132	124 (93.9)	1.94 (1.09)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	126	124 (98.4)	1.61 (1.08)	0.0	0.80	1.60	2.40	4.8	
			Placebo	132	125 (94.7)	1.91 (1.07)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	126	124 (98.4)	1.56 (1.10)	0.0	0.80	1.40	2.40	4.8	
			Placebo	132	125 (94.7)	1.89 (1.08)	0.0	1.00	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	126	124 (98.4)	1.58 (1.16)	0.0	0.70	1.40	2.40	4.8	
			Placebo	132	125 (94.7)	1.84 (1.09)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	126	124 (98.4)	1.68 (1.14)	0.0	0.80	1.60	2.50	5.0	
			Placebo	132	125 (94.7)	1.92 (1.09)	0.0	1.00	2.00	2.80	4.8	
		Week 38	Tezepelumab	126	124 (98.4)	1.56 (1.13)	0.0	0.80	1.40	2.40	4.8	
			Placebo	132	125 (94.7)	1.85 (1.08)	0.0	1.00	1.80	2.80	4.8	
		Week 40	Tezepelumab	126	124 (98.4)	1.59 (1.13)	0.0	0.60	1.60	2.40	4.8	
			Placebo	132	125 (94.7)	1.91 (1.09)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	126	124 (98.4)	1.55 (1.13)	0.0	0.60	1.40	2.30	4.8	
			Placebo	132	125 (94.7)	1.89 (1.04)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	126	124 (98.4)	1.58 (1.12)	0.0	0.60	1.60	2.60	4.8	
			Placebo	132	126 (95.5)	1.93 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	126	124 (98.4)	1.55 (1.14)	0.0	0.80	1.30	2.40	4.8	
			Placebo	132	126 (95.5)	1.82 (1.04)	0.0	1.00	2.00	2.60	4.4	
		Week 48	Tezepelumab	126	124 (98.4)	1.62 (1.15)	0.0	0.60	1.60	2.50	4.8	
			Placebo	132	126 (95.5)	1.85 (1.06)	0.0	1.00	2.00	2.60	4.6	
		Week 50	Tezepelumab	126	124 (98.4)	1.50 (1.13)	0.0	0.70	1.30	2.20	4.8	
			Placebo	132	126 (95.5)	1.83 (1.02)	0.0	1.00	1.80	2.60	4.4	
		Week 52	Tezepelumab	126	124 (98.4)	1.53 (1.12)	0.0	0.60	1.40	2.20	4.8	
			Placebo	132	126 (95.5)	1.87 (1.04)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	126	120 (95.2)	-0.59 (0.76)	-3.2	-1.00	-0.40	0.00	0.8	-0.23 [-0.49, 0.02]
			Placebo	132	120 (90.9)	-0.41 (0.78)	-3.0	-0.80	-0.40	0.00	1.4	
		Week 4	Tezepelumab	126	120 (95.2)	-0.86 (0.96)	-3.8	-1.40	-0.80	-0.20	2.6	-0.33 [-0.58, -0.07]
			Placebo	132	120 (90.9)	-0.55 (0.90)	-3.0	-1.20	-0.40	0.00	1.6	
		Week 6	Tezepelumab	126	120 (95.2)	-0.95 (1.05)	-4.0	-1.60	-1.00	-0.20	2.6	-0.30 [-0.56, -0.05]
			Placebo	132	121 (91.7)	-0.64 (0.97)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	126	120 (95.2)	-1.02 (1.09)	-4.0	-1.70	-1.00	-0.40	2.6	-0.32 [-0.57, -0.07]
			Placebo	132	122 (92.4)	-0.69 (0.95)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	126	120 (95.2)	-1.10 (1.05)	-4.0	-1.80	-1.10	-0.40	2.6	-0.32 [-0.58, -0.07]
			Placebo	132	123 (93.2)	-0.76 (1.03)	-3.8	-1.40	-0.60	-0.20	2.6	
		Week 12	Tezepelumab	126	120 (95.2)	-1.17 (1.06)	-4.0	-2.00	-1.20	-0.50	2.6	-0.30 [-0.55, -0.04]
			Placebo	132	123 (93.2)	-0.87 (1.03)	-3.8	-1.40	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	126	120 (95.2)	-1.32 (1.06)	-4.2	-2.00	-1.30	-0.70	2.6	-0.41 [-0.66, -0.15]
			Placebo	132	123 (93.2)	-0.89 (1.01)	-3.4	-1.40	-0.80	-0.40	2.4	
		Week 16	Tezepelumab	126	120 (95.2)	-1.16 (1.12)	-4.4	-1.90	-1.00	-0.40	2.6	-0.33 [-0.59, -0.08]
			Placebo	132	123 (93.2)	-0.79 (1.10)	-3.6	-1.40	-0.80	0.00	2.6	
		Week 18	Tezepelumab	126	121 (96.0)	-1.25 (1.07)	-4.4	-2.00	-1.20	-0.60	2.6	-0.35 [-0.60, -0.09]
			Placebo	132	123 (93.2)	-0.88 (1.09)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	126	121 (96.0)	-1.16 (1.10)	-4.4	-2.00	-1.00	-0.40	2.6	-0.30 [-0.55, -0.05]
			Placebo	132	123 (93.2)	-0.83 (1.10)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	126	121 (96.0)	-1.14 (1.13)	-4.4	-1.80	-1.00	-0.40	2.6	-0.23 [-0.48, 0.02]
			Placebo	132	123 (93.2)	-0.89 (1.08)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 24	Tezepelumab	126	121 (96.0)	-1.16 (1.09)	-4.8	-2.00	-1.00	-0.40	2.6	-0.23 [-0.48, 0.02]
			Placebo	132	123 (93.2)	-0.90 (1.10)	-3.8	-1.60	-1.00	-0.20	2.6	
		Week 26	Tezepelumab	126	122 (96.8)	-1.20 (1.13)	-4.4	-2.00	-1.10	-0.40	2.6	-0.22 [-0.47, 0.03]
			Placebo	132	123 (93.2)	-0.95 (1.10)	-4.2	-1.80	-1.00	0.00	2.6	
		Week 28	Tezepelumab	126	123 (97.6)	-1.13 (1.14)	-4.4	-2.00	-1.00	-0.20	2.6	-0.22 [-0.47, 0.03]
			Placebo	132	124 (93.9)	-0.87 (1.14)	-4.2	-1.60	-0.80	-0.10	2.6	
		Week 30	Tezepelumab	126	124 (98.4)	-1.20 (1.13)	-4.4	-2.20	-1.10	-0.50	2.6	-0.27 [-0.52, -0.02]
			Placebo	132	125 (94.7)	-0.90 (1.14)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 32	Tezepelumab	126	124 (98.4)	-1.25 (1.15)	-4.4	-2.20	-1.00	-0.60	2.6	-0.29 [-0.54, -0.04]
			Placebo	132	125 (94.7)	-0.92 (1.12)	-3.6	-1.60	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	126	124 (98.4)	-1.24 (1.17)	-4.4	-2.20	-1.20	-0.40	2.6	-0.23 [-0.48, 0.02]
			Placebo	132	125 (94.7)	-0.98 (1.13)	-4.2	-1.60	-1.00	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	126	124 (98.4)	-1.14 (1.21)	-4.4	-2.00	-1.20	-0.20	2.6	-0.21 [-0.45, 0.04]
			Placebo	132	125 (94.7)	-0.90 (1.17)	-3.6	-1.60	-1.00	0.00	2.6	
		Week 38	Tezepelumab	126	124 (98.4)	-1.25 (1.20)	-4.4	-2.20	-1.20	-0.40	2.6	-0.25 [-0.50, -0.00]
			Placebo	132	125 (94.7)	-0.96 (1.16)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 40	Tezepelumab	126	124 (98.4)	-1.23 (1.20)	-4.4	-2.20	-1.00	-0.40	2.6	-0.28 [-0.53, -0.03]
			Placebo	132	125 (94.7)	-0.90 (1.12)	-4.2	-1.60	-0.80	-0.20	2.6	
		Week 42	Tezepelumab	126	124 (98.4)	-1.26 (1.20)	-4.4	-2.10	-1.20	-0.40	2.6	-0.29 [-0.54, -0.04]
			Placebo	132	125 (94.7)	-0.93 (1.11)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	126	124 (98.4)	-1.24 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.30 [-0.55, -0.05]
			Placebo	132	126 (95.5)	-0.88 (1.14)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 46	Tezepelumab	126	124 (98.4)	-1.26 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.23 [-0.48, 0.02]
			Placebo	132	126 (95.5)	-0.99 (1.12)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	126	124 (98.4)	-1.20 (1.21)	-4.4	-2.00	-1.00	-0.40	2.6	-0.20 [-0.45, 0.05]
			Placebo	132	126 (95.5)	-0.96 (1.13)	-3.8	-1.60	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	126	124 (98.4)	-1.32 (1.21)	-4.4	-2.20	-1.30	-0.50	2.6	-0.29 [-0.54, -0.04]
			Placebo	132	126 (95.5)	-0.98 (1.09)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 52	Tezepelumab	126	124 (98.4)	-1.28 (1.22)	-4.4	-2.20	-1.20	-0.40	2.6	-0.29 [-0.54, -0.04]
			Placebo	132	126 (95.5)	-0.94 (1.11)	-4.2	-1.60	-0.90	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.96 (0.87)	1.8	2.40	3.00	3.20	4.6	
			Placebo	3	3 (100.0)	3.13 (0.42)	2.8	2.80	3.00	3.60	3.6	
		Week 2	Tezepelumab	9	9 (100.0)	2.60 (0.94)	1.0	2.00	2.60	3.20	4.0	
			Placebo	3	3 (100.0)	2.60 (0.69)	1.8	1.80	3.00	3.00	3.0	
		Week 4	Tezepelumab	9	9 (100.0)	1.71 (1.01)	0.2	0.80	2.20	2.60	2.8	
			Placebo	3	3 (100.0)	2.60 (0.92)	1.8	1.80	2.40	3.60	3.6	
		Week 6	Tezepelumab	9	9 (100.0)	1.76 (0.68)	1.0	1.20	1.60	2.00	3.0	
			Placebo	3	3 (100.0)	2.40 (1.06)	1.2	1.20	2.80	3.20	3.2	
		Week 8	Tezepelumab	9	9 (100.0)	1.60 (0.71)	0.6	1.00	1.60	2.20	2.8	
			Placebo	3	3 (100.0)	1.93 (1.30)	0.6	0.60	2.00	3.20	3.2	
		Week 10	Tezepelumab	9	9 (100.0)	1.58 (0.89)	0.4	0.80	1.60	1.80	3.2	
			Placebo	3	3 (100.0)	2.00 (0.87)	1.4	1.40	1.60	3.00	3.0	
		Week 12	Tezepelumab	9	9 (100.0)	1.40 (0.91)	0.0	0.80	1.40	1.80	2.8	
			Placebo	3	3 (100.0)	2.13 (1.01)	1.2	1.20	2.00	3.20	3.2	
		Week 14	Tezepelumab	9	9 (100.0)	1.38 (0.78)	0.4	0.80	1.40	1.60	2.8	
			Placebo	3	3 (100.0)	2.00 (1.06)	1.2	1.20	1.60	3.20	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	1.53 (0.80)	0.6	0.80	1.60	1.80	2.8	
			Placebo	3	3 (100.0)	2.27 (0.83)	1.6	1.60	2.00	3.20	3.2	
		Week 18	Tezepelumab	9	9 (100.0)	1.18 (0.69)	0.4	0.60	1.00	1.60	2.4	
			Placebo	3	3 (100.0)	1.87 (0.81)	1.4	1.40	1.40	2.80	2.8	
		Week 20	Tezepelumab	9	9 (100.0)	1.33 (0.68)	0.4	1.00	1.20	1.80	2.6	
			Placebo	3	3 (100.0)	1.67 (1.47)	0.0	0.00	2.20	2.80	2.8	
		Week 22	Tezepelumab	9	9 (100.0)	1.49 (0.77)	0.0	1.20	1.80	2.00	2.2	
			Placebo	3	3 (100.0)	1.73 (0.90)	0.8	0.80	1.80	2.60	2.6	
		Week 24	Tezepelumab	9	9 (100.0)	1.51 (0.74)	0.4	1.00	1.60	2.00	2.8	
			Placebo	3	3 (100.0)	2.33 (0.99)	1.2	1.20	2.80	3.00	3.0	
		Week 26	Tezepelumab	9	9 (100.0)	1.42 (0.53)	0.8	1.00	1.40	1.60	2.4	
			Placebo	3	3 (100.0)	1.93 (1.14)	1.0	1.00	1.60	3.20	3.2	
		Week 28	Tezepelumab	9	9 (100.0)	1.49 (0.63)	0.4	1.00	1.60	2.00	2.4	
			Placebo	3	3 (100.0)	2.07 (1.10)	0.8	0.80	2.60	2.80	2.8	
		Week 30	Tezepelumab	9	9 (100.0)	1.44 (0.67)	0.8	0.80	1.20	2.00	2.6	
			Placebo	3	3 (100.0)	2.00 (0.69)	1.2	1.20	2.40	2.40	2.4	
		Week 32	Tezepelumab	9	9 (100.0)	1.51 (0.76)	0.6	1.00	1.40	1.80	2.8	
			Placebo	3	3 (100.0)	1.80 (1.00)	0.8	0.80	1.80	2.80	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.51 (0.67)	0.8	1.00	1.20	2.20	2.4	
			Placebo	3	3 (100.0)	1.93 (0.46)	1.4	1.40	2.20	2.20	2.2	
		Week 36	Tezepelumab	9	9 (100.0)	1.40 (0.53)	0.6	1.00	1.20	1.80	2.2	
			Placebo	3	3 (100.0)	2.27 (0.50)	1.8	1.80	2.20	2.80	2.8	
		Week 38	Tezepelumab	9	9 (100.0)	1.56 (0.70)	0.6	1.20	1.40	2.20	2.4	
			Placebo	3	3 (100.0)	1.93 (0.61)	1.4	1.40	1.80	2.60	2.6	
		Week 40	Tezepelumab	9	9 (100.0)	1.62 (0.77)	0.4	0.80	1.80	2.00	2.6	
			Placebo	3	3 (100.0)	2.53 (0.81)	1.6	1.60	3.00	3.00	3.0	
		Week 42	Tezepelumab	9	9 (100.0)	1.44 (0.50)	1.0	1.00	1.20	1.80	2.2	
			Placebo	3	3 (100.0)	2.07 (0.12)	2.0	2.00	2.00	2.20	2.2	
		Week 44	Tezepelumab	9	9 (100.0)	1.42 (0.72)	0.4	1.00	1.20	2.00	2.4	
			Placebo	3	3 (100.0)	2.53 (0.31)	2.2	2.20	2.60	2.80	2.8	
		Week 46	Tezepelumab	9	9 (100.0)	1.47 (0.53)	0.6	1.00	1.60	2.00	2.0	
			Placebo	3	3 (100.0)	2.07 (0.12)	2.0	2.00	2.00	2.20	2.2	
		Week 48	Tezepelumab	9	9 (100.0)	1.42 (0.47)	0.8	1.00	1.20	1.80	2.0	
			Placebo	3	3 (100.0)	2.13 (0.46)	1.6	1.60	2.40	2.40	2.4	
		Week 50	Tezepelumab	9	9 (100.0)	1.71 (0.66)	0.8	1.20	1.80	2.00	2.8	
			Placebo	3	3 (100.0)	2.13 (0.12)	2.0	2.00	2.20	2.20	2.2	
		Week 52	Tezepelumab	9	9 (100.0)	1.69 (0.64)	0.8	1.20	1.80	2.00	2.8	
			Placebo	3	3 (100.0)	2.40 (0.40)	2.0	2.00	2.40	2.80	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.36 (0.62)	-1.4	-0.60	-0.40	0.20	0.2	0.30 [-1.02, 1.61]
			Placebo	3	3 (100.0)	-0.53 (0.50)	-1.0	-1.00	-0.60	0.00	0.0	
		Week 4	Tezepelumab	9	9 (100.0)	-1.24 (1.09)	-2.4	-2.00	-1.60	-1.00	1.0	-0.66 [-2.00, 0.67]
			Placebo	3	3 (100.0)	-0.53 (0.99)	-1.2	-1.20	-1.00	0.60	0.6	
		Week 6	Tezepelumab	9	9 (100.0)	-1.20 (0.93)	-2.6	-1.60	-1.40	-0.80	0.2	-0.50 [-1.83, 0.82]
			Placebo	3	3 (100.0)	-0.73 (0.90)	-1.6	-1.60	-0.80	0.20	0.2	
		Week 8	Tezepelumab	9	9 (100.0)	-1.36 (1.17)	-3.2	-1.80	-1.40	-1.00	0.4	-0.12 [-1.43, 1.19]
			Placebo	3	3 (100.0)	-1.20 (1.64)	-3.0	-3.00	-0.80	0.20	0.2	
		Week 10	Tezepelumab	9	9 (100.0)	-1.38 (1.33)	-3.4	-1.60	-1.60	-1.20	0.8	-0.19 [-1.50, 1.12]
			Placebo	3	3 (100.0)	-1.13 (1.10)	-2.2	-2.20	-1.20	0.00	0.0	
		Week 12	Tezepelumab	9	9 (100.0)	-1.56 (1.31)	-3.2	-2.40	-1.80	-1.20	0.8	-0.42 [-1.74, 0.90]
			Placebo	3	3 (100.0)	-1.00 (1.31)	-2.4	-2.40	-0.80	0.20	0.2	
		Week 14	Tezepelumab	9	9 (100.0)	-1.58 (1.51)	-4.0	-2.20	-1.40	-0.60	1.0	-0.31 [-1.62, 1.01]
			Placebo	3	3 (100.0)	-1.13 (1.17)	-2.0	-2.00	-1.60	0.20	0.2	
		Week 16	Tezepelumab	9	9 (100.0)	-1.42 (1.30)	-3.2	-2.40	-1.40	-1.20	1.0	-0.44 [-1.76, 0.88]
			Placebo	3	3 (100.0)	-0.87 (1.10)	-2.0	-2.00	-0.80	0.20	0.2	
		Week 18	Tezepelumab	9	9 (100.0)	-1.78 (1.36)	-3.8	-2.60	-1.80	-1.00	0.6	-0.39 [-1.71, 0.92]
			Placebo	3	3 (100.0)	-1.27 (1.01)	-2.2	-2.20	-1.40	-0.20	-0.2	
		Week 20	Tezepelumab	9	9 (100.0)	-1.62 (1.17)	-3.4	-2.20	-1.60	-1.20	0.8	-0.12 [-1.42, 1.19]
			Placebo	3	3 (100.0)	-1.47 (1.86)	-3.6	-3.60	-0.60	-0.20	-0.2	
		Week 22	Tezepelumab	9	9 (100.0)	-1.47 (1.22)	-3.2	-2.40	-1.60	-0.60	0.2	-0.05 [-1.36, 1.25]
			Placebo	3	3 (100.0)	-1.40 (1.25)	-2.8	-2.80	-1.00	-0.40	-0.4	
		Week 24	Tezepelumab	9	9 (100.0)	-1.44 (1.01)	-3.4	-1.80	-1.40	-0.80	0.2	-0.59 [-1.92, 0.74]
			Placebo	3	3 (100.0)	-0.80 (1.39)	-2.4	-2.40	0.00	0.00	0.0	
		Week 26	Tezepelumab	9	9 (100.0)	-1.53 (0.97)	-3.0	-2.20	-1.40	-1.40	0.2	-0.31 [-1.62, 1.00]
			Placebo	3	3 (100.0)	-1.20 (1.40)	-2.6	-2.60	-1.20	0.20	0.2	
		Week 28	Tezepelumab	9	9 (100.0)	-1.47 (1.11)	-3.4	-2.20	-1.40	-1.20	0.2	-0.33 [-1.65, 0.98]
			Placebo	3	3 (100.0)	-1.07 (1.50)	-2.8	-2.80	-0.20	-0.20	-0.2	
		Week 30	Tezepelumab	9	9 (100.0)	-1.51 (1.40)	-3.8	-2.40	-1.60	-1.00	0.8	-0.28 [-1.59, 1.03]
			Placebo	3	3 (100.0)	-1.13 (1.10)	-2.4	-2.40	-0.60	-0.40	-0.4	
		Week 32	Tezepelumab	9	9 (100.0)	-1.44 (1.06)	-3.2	-1.80	-1.60	-1.20	0.8	-0.10 [-1.41, 1.21]
			Placebo	3	3 (100.0)	-1.33 (1.33)	-2.8	-2.80	-1.00	-0.20	-0.2	
		Week 34	Tezepelumab	9	9 (100.0)	-1.44 (1.20)	-3.0	-2.20	-1.60	-0.60	0.4	-0.21 [-1.52, 1.10]
			Placebo	3	3 (100.0)	-1.20 (0.87)	-2.2	-2.20	-0.80	-0.60	-0.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.56 (1.11)	-3.2	-2.00	-1.40	-1.00	0.4	-0.65 [-1.99, 0.69]
			Placebo	3	3 (100.0)	-0.87 (0.83)	-1.8	-1.80	-0.60	-0.20	-0.2	
		Week 38	Tezepelumab	9	9 (100.0)	-1.40 (1.17)	-3.2	-1.80	-1.80	-1.00	0.4	-0.18 [-1.49, 1.13]
			Placebo	3	3 (100.0)	-1.20 (0.92)	-2.2	-2.20	-1.00	-0.40	-0.4	
		Week 40	Tezepelumab	9	9 (100.0)	-1.33 (1.37)	-3.4	-2.40	-1.20	-0.80	0.8	-0.55 [-1.88, 0.78]
			Placebo	3	3 (100.0)	-0.60 (1.22)	-2.0	-2.00	0.00	0.20	0.2	
		Week 42	Tezepelumab	9	9 (100.0)	-1.51 (1.27)	-3.6	-2.20	-1.40	-1.00	0.4	-0.39 [-1.70, 0.93]
			Placebo	3	3 (100.0)	-1.07 (0.46)	-1.6	-1.60	-0.80	-0.80	-0.8	
		Week 44	Tezepelumab	9	9 (100.0)	-1.53 (1.37)	-3.8	-2.00	-1.40	-0.80	0.6	-0.75 [-2.09, 0.60]
			Placebo	3	3 (100.0)	-0.60 (0.53)	-1.0	-1.00	-0.80	0.00	0.0	
		Week 46	Tezepelumab	9	9 (100.0)	-1.49 (1.03)	-3.6	-2.00	-1.40	-1.00	0.2	-0.44 [-1.76, 0.88]
			Placebo	3	3 (100.0)	-1.07 (0.50)	-1.6	-1.60	-1.00	-0.60	-0.6	
		Week 48	Tezepelumab	9	9 (100.0)	-1.53 (0.97)	-2.8	-2.20	-1.60	-1.00	0.2	-0.56 [-1.89, 0.77]
			Placebo	3	3 (100.0)	-1.00 (0.87)	-2.0	-2.00	-0.60	-0.40	-0.4	
		Week 50	Tezepelumab	9	9 (100.0)	-1.24 (1.05)	-2.6	-1.80	-1.40	-0.80	0.6	-0.25 [-1.56, 1.06]
			Placebo	3	3 (100.0)	-1.00 (0.53)	-1.6	-1.60	-0.80	-0.60	-0.6	
		Week 52	Tezepelumab	9	9 (100.0)	-1.27 (1.00)	-2.6	-1.80	-1.40	-0.80	0.4	-0.56 [-1.88, 0.77]
			Placebo	3	3 (100.0)	-0.73 (0.76)	-1.6	-1.60	-0.40	-0.20	-0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	2.83 (0.84)	0.0	2.40	2.80	3.20	5.2	
			Placebo	135	135 (100.0)	2.81 (0.73)	0.4	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	128	122 (95.3)	2.24 (0.97)	0.0	1.60	2.40	3.00	4.4	
			Placebo	135	122 (90.4)	2.41 (0.84)	0.0	2.00	2.40	3.00	5.0	
		Week 4	Tezepelumab	128	122 (95.3)	1.98 (1.02)	0.0	1.20	2.20	2.80	4.2	
			Placebo	135	122 (90.4)	2.29 (0.88)	0.2	1.80	2.40	2.80	4.4	
		Week 6	Tezepelumab	128	122 (95.3)	1.88 (1.02)	0.0	1.20	1.80	2.60	4.2	
			Placebo	135	123 (91.1)	2.19 (1.02)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	128	122 (95.3)	1.81 (1.11)	0.0	1.00	1.80	2.80	5.2	
			Placebo	135	124 (91.9)	2.15 (1.00)	0.0	1.60	2.20	2.80	5.0	
		Week 10	Tezepelumab	128	122 (95.3)	1.73 (1.07)	0.0	1.00	1.80	2.60	4.8	
			Placebo	135	125 (92.6)	2.07 (0.96)	0.0	1.40	2.00	2.80	5.2	
		Week 12	Tezepelumab	128	122 (95.3)	1.66 (1.10)	0.0	0.80	1.60	2.60	4.8	
			Placebo	135	125 (92.6)	1.99 (1.00)	0.0	1.20	2.00	2.80	4.4	
		Week 14	Tezepelumab	128	122 (95.3)	1.52 (1.08)	0.0	0.60	1.40	2.40	4.8	
			Placebo	135	125 (92.6)	1.94 (0.95)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	128	122 (95.3)	1.68 (1.13)	0.0	0.80	1.60	2.60	4.8	
			Placebo	135	125 (92.6)	2.06 (1.09)	0.0	1.20	2.00	3.00	5.0	
		Week 18	Tezepelumab	128	123 (96.1)	1.58 (1.03)	0.0	1.00	1.60	2.40	4.8	
			Placebo	135	125 (92.6)	1.95 (1.04)	0.0	1.40	2.00	2.60	5.0	
		Week 20	Tezepelumab	128	123 (96.1)	1.67 (1.10)	0.0	0.80	1.80	2.40	5.0	
			Placebo	135	125 (92.6)	2.01 (1.04)	0.0	1.40	2.20	2.80	5.0	
		Week 22	Tezepelumab	128	123 (96.1)	1.68 (1.04)	0.0	1.00	1.80	2.40	4.8	
			Placebo	135	125 (92.6)	1.96 (1.05)	0.0	1.20	2.00	2.80	5.0	
		Week 24	Tezepelumab	128	123 (96.1)	1.67 (1.11)	0.0	0.80	1.60	2.60	4.8	
			Placebo	135	125 (92.6)	1.94 (1.03)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	128	124 (96.9)	1.63 (1.07)	0.0	0.80	1.60	2.40	4.8	
			Placebo	135	125 (92.6)	1.90 (1.01)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	128	125 (97.7)	1.69 (1.13)	0.0	1.00	1.60	2.60	4.8	
			Placebo	135	126 (93.3)	1.96 (1.10)	0.0	1.00	2.10	2.80	4.4	
		Week 30	Tezepelumab	128	126 (98.4)	1.62 (1.07)	0.0	0.80	1.60	2.40	4.8	
			Placebo	135	127 (94.1)	1.94 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	128	126 (98.4)	1.57 (1.09)	0.0	0.80	1.40	2.40	4.8	
			Placebo	135	127 (94.1)	1.89 (1.09)	0.0	1.00	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	128	126 (98.4)	1.58 (1.15)	0.0	0.80	1.40	2.40	4.8	
			Placebo	135	127 (94.1)	1.85 (1.09)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	128	126 (98.4)	1.68 (1.14)	0.0	0.80	1.60	2.40	5.0	
			Placebo	135	127 (94.1)	1.93 (1.11)	0.0	1.00	2.00	2.80	4.8	
		Week 38	Tezepelumab	128	126 (98.4)	1.57 (1.13)	0.0	0.80	1.40	2.40	4.8	
			Placebo	135	127 (94.1)	1.86 (1.08)	0.0	1.00	1.80	2.80	4.8	
		Week 40	Tezepelumab	128	126 (98.4)	1.59 (1.13)	0.0	0.60	1.60	2.40	4.8	
			Placebo	135	127 (94.1)	1.92 (1.10)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	128	126 (98.4)	1.56 (1.13)	0.0	0.60	1.40	2.40	4.8	
			Placebo	135	127 (94.1)	1.90 (1.06)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	128	126 (98.4)	1.59 (1.11)	0.0	0.60	1.60	2.60	4.8	
			Placebo	135	128 (94.8)	1.94 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	128	126 (98.4)	1.56 (1.13)	0.0	0.80	1.30	2.40	4.8	
			Placebo	135	128 (94.8)	1.83 (1.04)	0.0	1.00	2.00	2.60	4.4	
		Week 48	Tezepelumab	128	126 (98.4)	1.62 (1.15)	0.0	0.60	1.60	2.40	4.8	
			Placebo	135	128 (94.8)	1.86 (1.08)	0.0	1.00	2.00	2.70	4.6	
		Week 50	Tezepelumab	128	126 (98.4)	1.51 (1.12)	0.0	0.80	1.40	2.20	4.8	
			Placebo	135	128 (94.8)	1.84 (1.02)	0.0	1.00	1.80	2.60	4.4	
		Week 52	Tezepelumab	128	126 (98.4)	1.54 (1.12)	0.0	0.60	1.40	2.20	4.8	
			Placebo	135	128 (94.8)	1.88 (1.05)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	128	122 (95.3)	-0.59 (0.75)	-3.2	-1.00	-0.40	0.00	0.8	-0.23 [-0.48, 0.02]
			Placebo	135	122 (90.4)	-0.41 (0.77)	-3.0	-0.80	-0.40	0.00	1.4	
		Week 4	Tezepelumab	128	122 (95.3)	-0.85 (0.96)	-3.8	-1.40	-0.80	-0.20	2.6	-0.35 [-0.60, -0.09]
			Placebo	135	122 (90.4)	-0.53 (0.91)	-3.0	-1.20	-0.40	0.00	1.6	
		Week 6	Tezepelumab	128	122 (95.3)	-0.95 (1.04)	-4.0	-1.60	-1.00	-0.20	2.6	-0.32 [-0.58, -0.07]
			Placebo	135	123 (91.1)	-0.63 (0.97)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	128	122 (95.3)	-1.02 (1.08)	-4.0	-1.60	-1.00	-0.40	2.6	-0.34 [-0.59, -0.09]
			Placebo	135	124 (91.9)	-0.68 (0.95)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	128	122 (95.3)	-1.10 (1.04)	-4.0	-1.80	-1.10	-0.40	2.6	-0.33 [-0.58, -0.08]
			Placebo	135	125 (92.6)	-0.76 (1.02)	-3.8	-1.40	-0.60	-0.20	2.6	
		Week 12	Tezepelumab	128	122 (95.3)	-1.17 (1.05)	-4.0	-2.00	-1.20	-0.60	2.6	-0.32 [-0.57, -0.07]
			Placebo	135	125 (92.6)	-0.84 (1.05)	-3.8	-1.40	-0.60	-0.20	1.6	
		Week 14	Tezepelumab	128	122 (95.3)	-1.31 (1.05)	-4.2	-2.00	-1.30	-0.80	2.6	-0.41 [-0.66, -0.16]
			Placebo	135	125 (92.6)	-0.89 (1.01)	-3.4	-1.40	-0.80	-0.40	2.4	
		Week 16	Tezepelumab	128	122 (95.3)	-1.15 (1.11)	-4.4	-1.80	-1.00	-0.40	2.6	-0.34 [-0.59, -0.09]
			Placebo	135	125 (92.6)	-0.77 (1.10)	-3.6	-1.40	-0.80	0.00	2.6	
		Week 18	Tezepelumab	128	123 (96.1)	-1.25 (1.06)	-4.4	-2.00	-1.00	-0.60	2.6	-0.35 [-0.60, -0.10]
			Placebo	135	125 (92.6)	-0.88 (1.09)	-3.6	-1.40	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	128	123 (96.1)	-1.16 (1.09)	-4.4	-2.00	-1.00	-0.40	2.6	-0.31 [-0.56, -0.06]
			Placebo	135	125 (92.6)	-0.81 (1.10)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	128	123 (96.1)	-1.14 (1.12)	-4.4	-1.80	-1.00	-0.40	2.6	-0.25 [-0.50, -0.00]
			Placebo	135	125 (92.6)	-0.87 (1.08)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 24	Tezepelumab	128	123 (96.1)	-1.16 (1.08)	-4.8	-2.00	-1.00	-0.40	2.6	-0.25 [-0.50, 0.00]
			Placebo	135	125 (92.6)	-0.89 (1.10)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 26	Tezepelumab	128	124 (96.9)	-1.19 (1.12)	-4.4	-2.00	-1.00	-0.40	2.6	-0.23 [-0.48, 0.02]
			Placebo	135	125 (92.6)	-0.93 (1.10)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 28	Tezepelumab	128	125 (97.7)	-1.12 (1.13)	-4.4	-2.00	-1.00	-0.40	2.6	-0.24 [-0.49, 0.01]
			Placebo	135	126 (93.3)	-0.85 (1.14)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 30	Tezepelumab	128	126 (98.4)	-1.20 (1.13)	-4.4	-2.20	-1.00	-0.60	2.6	-0.29 [-0.54, -0.04]
			Placebo	135	127 (94.1)	-0.87 (1.15)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 32	Tezepelumab	128	126 (98.4)	-1.25 (1.14)	-4.4	-2.20	-1.00	-0.60	2.6	-0.30 [-0.54, -0.05]
			Placebo	135	127 (94.1)	-0.92 (1.13)	-3.6	-1.60	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	128	126 (98.4)	-1.24 (1.16)	-4.4	-2.20	-1.20	-0.40	2.6	-0.24 [-0.49, 0.00]
			Placebo	135	127 (94.1)	-0.96 (1.13)	-4.2	-1.60	-1.00	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	128	126 (98.4)	-1.14 (1.20)	-4.4	-2.00	-1.20	-0.20	2.6	-0.22 [-0.47, 0.03]
			Placebo	135	127 (94.1)	-0.88 (1.17)	-3.6	-1.60	-1.00	0.00	2.6	
		Week 38	Tezepelumab	128	126 (98.4)	-1.26 (1.19)	-4.4	-2.20	-1.20	-0.40	2.6	-0.26 [-0.51, -0.01]
			Placebo	135	127 (94.1)	-0.95 (1.16)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 40	Tezepelumab	128	126 (98.4)	-1.23 (1.19)	-4.4	-2.20	-1.00	-0.40	2.6	-0.30 [-0.54, -0.05]
			Placebo	135	127 (94.1)	-0.89 (1.14)	-4.2	-1.60	-0.80	-0.20	2.6	
		Week 42	Tezepelumab	128	126 (98.4)	-1.27 (1.19)	-4.4	-2.00	-1.20	-0.40	2.6	-0.31 [-0.56, -0.06]
			Placebo	135	127 (94.1)	-0.91 (1.13)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	128	126 (98.4)	-1.23 (1.20)	-4.4	-2.20	-1.20	-0.40	2.6	-0.31 [-0.56, -0.06]
			Placebo	135	128 (94.8)	-0.87 (1.15)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 46	Tezepelumab	128	126 (98.4)	-1.27 (1.20)	-4.4	-2.20	-1.20	-0.40	2.6	-0.24 [-0.49, 0.00]
			Placebo	135	128 (94.8)	-0.98 (1.11)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	128	126 (98.4)	-1.20 (1.20)	-4.4	-2.00	-1.00	-0.40	2.6	-0.21 [-0.46, 0.03]
			Placebo	135	128 (94.8)	-0.95 (1.14)	-3.8	-1.60	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	128	126 (98.4)	-1.32 (1.20)	-4.4	-2.20	-1.30	-0.60	2.6	-0.30 [-0.55, -0.05]
			Placebo	135	128 (94.8)	-0.97 (1.09)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 52	Tezepelumab	128	126 (98.4)	-1.28 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.30 [-0.55, -0.06]
			Placebo	135	128 (94.8)	-0.93 (1.12)	-4.2	-1.60	-0.90	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	29	29 (100.0)	3.12 (0.99)	0.2	2.60	3.00	3.80	5.2	
			Placebo	37	37 (100.0)	2.95 (0.54)	1.8	2.60	3.00	3.40	4.0	
		Week 2	Tezepelumab	29	28 (96.6)	2.51 (0.96)	0.6	1.90	2.60	3.20	4.4	
			Placebo	37	35 (94.6)	2.38 (0.73)	0.4	2.00	2.40	3.00	3.8	
		Week 4	Tezepelumab	29	28 (96.6)	2.18 (1.03)	0.2	1.20	2.60	3.00	3.4	
			Placebo	37	35 (94.6)	2.26 (0.96)	0.2	1.60	2.40	2.80	4.4	
		Week 6	Tezepelumab	29	28 (96.6)	1.96 (1.12)	0.0	1.10	1.80	2.90	4.0	
			Placebo	37	35 (94.6)	2.22 (1.13)	0.2	1.40	2.20	2.80	5.0	
		Week 8	Tezepelumab	29	28 (96.6)	1.91 (1.18)	0.0	1.10	1.90	3.00	4.2	
			Placebo	37	35 (94.6)	2.06 (1.10)	0.0	1.20	2.40	2.80	4.4	
		Week 10	Tezepelumab	29	28 (96.6)	1.66 (1.16)	0.0	0.60	1.60	2.80	3.6	
			Placebo	37	36 (97.3)	2.03 (0.96)	0.0	1.30	2.30	2.80	4.0	
		Week 12	Tezepelumab	29	28 (96.6)	1.63 (1.13)	0.0	0.60	1.70	2.70	3.6	
			Placebo	37	36 (97.3)	1.87 (1.12)	0.0	1.00	1.90	2.70	4.4	
		Week 14	Tezepelumab	29	28 (96.6)	1.54 (1.23)	0.0	0.50	1.60	2.50	4.2	
			Placebo	37	36 (97.3)	1.77 (0.81)	0.0	1.50	1.80	2.20	3.4	
		Week 16	Tezepelumab	29	28 (96.6)	1.74 (1.10)	0.0	0.90	1.60	2.70	4.2	
			Placebo	37	36 (97.3)	1.85 (1.09)	0.0	0.90	2.00	2.80	4.0	
		Week 18	Tezepelumab	29	28 (96.6)	1.56 (1.10)	0.0	0.90	1.20	2.50	4.2	
			Placebo	37	36 (97.3)	1.77 (1.05)	0.0	1.00	1.80	2.60	4.8	
		Week 20	Tezepelumab	29	28 (96.6)	1.68 (1.19)	0.0	0.80	1.20	2.70	5.0	
			Placebo	37	36 (97.3)	1.85 (1.01)	0.0	1.20	1.80	2.70	3.6	
		Week 22	Tezepelumab	29	28 (96.6)	1.56 (1.11)	0.0	0.70	1.40	2.50	3.8	
			Placebo	37	36 (97.3)	1.93 (0.88)	0.0	1.20	2.00	2.60	3.6	
		Week 24	Tezepelumab	29	28 (96.6)	1.69 (1.23)	0.0	0.70	1.30	2.50	4.8	
			Placebo	37	36 (97.3)	1.86 (0.94)	0.0	1.10	2.10	2.60	3.4	
		Week 26	Tezepelumab	29	28 (96.6)	1.66 (1.06)	0.0	1.00	1.60	2.50	4.0	
			Placebo	37	36 (97.3)	1.69 (1.00)	0.0	1.00	1.60	2.60	3.8	
		Week 28	Tezepelumab	29	28 (96.6)	1.74 (1.17)	0.0	1.00	1.50	2.80	3.8	
			Placebo	37	36 (97.3)	1.72 (1.12)	0.0	0.80	1.70	2.60	4.0	
		Week 30	Tezepelumab	29	28 (96.6)	1.64 (1.03)	0.0	0.90	1.50	2.60	3.6	
			Placebo	37	36 (97.3)	1.67 (1.01)	0.0	1.00	1.80	2.40	4.0	
		Week 32	Tezepelumab	29	28 (96.6)	1.51 (1.07)	0.0	0.80	1.20	2.40	4.0	
			Placebo	37	36 (97.3)	1.70 (0.98)	0.0	0.90	1.60	2.60	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	29	28 (96.6)	1.67 (1.12)	0.0	0.90	1.20	2.60	4.2	
			Placebo	37	36 (97.3)	1.71 (0.92)	0.0	1.00	1.80	2.40	3.6	
		Week 36	Tezepelumab	29	28 (96.6)	1.63 (1.09)	0.0	0.80	1.30	2.50	3.6	
			Placebo	37	36 (97.3)	1.99 (1.02)	0.0	1.30	2.00	2.80	4.4	
		Week 38	Tezepelumab	29	28 (96.6)	1.56 (1.15)	0.0	0.80	1.20	2.50	4.6	
			Placebo	37	36 (97.3)	1.82 (0.93)	0.0	1.10	1.90	2.60	3.4	
		Week 40	Tezepelumab	29	28 (96.6)	1.42 (1.14)	0.0	0.50	1.10	2.60	3.6	
			Placebo	37	36 (97.3)	1.98 (1.08)	0.0	1.10	2.00	2.60	4.4	
		Week 42	Tezepelumab	29	28 (96.6)	1.53 (1.13)	0.0	0.80	1.20	2.70	3.8	
			Placebo	37	36 (97.3)	1.88 (0.97)	0.0	1.10	2.00	2.60	4.6	
		Week 44	Tezepelumab	29	28 (96.6)	1.53 (1.07)	0.0	0.70	1.20	2.60	3.8	
			Placebo	37	37 (100.0)	1.88 (1.12)	0.0	1.00	1.80	2.60	4.2	
		Week 46	Tezepelumab	29	28 (96.6)	1.64 (1.20)	0.0	0.80	1.20	2.80	3.8	
			Placebo	37	37 (100.0)	1.77 (0.93)	0.0	1.40	2.00	2.40	3.4	
		Week 48	Tezepelumab	29	28 (96.6)	1.64 (1.20)	0.0	0.80	1.20	2.80	4.2	
			Placebo	37	37 (100.0)	1.83 (1.04)	0.0	1.00	2.00	2.60	4.0	
		Week 50	Tezepelumab	29	28 (96.6)	1.54 (1.16)	0.0	0.80	1.20	2.30	4.2	
			Placebo	37	37 (100.0)	1.76 (0.95)	0.0	1.00	2.00	2.60	3.4	
		Week 52	Tezepelumab	29	28 (96.6)	1.54 (1.23)	0.0	0.70	1.20	2.40	4.4	
			Placebo	37	37 (100.0)	1.79 (0.99)	0.0	1.00	2.00	2.60	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	29	28 (96.6)	-0.62 (0.83)	-2.6	-1.00	-0.40	-0.20	0.8	-0.08 [-0.58, 0.42]
			Placebo	37	35 (94.6)	-0.56 (0.71)	-2.4	-1.00	-0.60	0.00	0.8	
		Week 4	Tezepelumab	29	28 (96.6)	-0.95 (1.18)	-3.8	-1.50	-1.00	-0.20	2.6	-0.25 [-0.75, 0.25]
			Placebo	37	35 (94.6)	-0.69 (0.98)	-2.4	-1.60	-0.80	0.20	1.2	
		Week 6	Tezepelumab	29	28 (96.6)	-1.16 (1.29)	-4.0	-1.80	-1.10	-0.40	2.6	-0.38 [-0.88, 0.12]
			Placebo	37	35 (94.6)	-0.72 (1.04)	-2.6	-1.40	-0.80	0.00	1.6	
		Week 8	Tezepelumab	29	28 (96.6)	-1.22 (1.32)	-4.0	-2.00	-1.10	-0.40	2.6	-0.29 [-0.79, 0.21]
			Placebo	37	35 (94.6)	-0.88 (1.05)	-3.0	-1.60	-0.60	-0.20	1.0	
		Week 10	Tezepelumab	29	28 (96.6)	-1.46 (1.37)	-4.0	-2.20	-1.50	-0.50	2.6	-0.48 [-0.98, 0.02]
			Placebo	37	36 (97.3)	-0.92 (0.92)	-2.6	-1.50	-0.80	-0.40	1.6	
		Week 12	Tezepelumab	29	28 (96.6)	-1.50 (1.30)	-4.0	-2.30	-1.50	-0.60	2.6	-0.34 [-0.84, 0.16]
			Placebo	37	36 (97.3)	-1.09 (1.12)	-3.0	-2.00	-1.00	-0.20	1.4	
		Week 14	Tezepelumab	29	28 (96.6)	-1.59 (1.34)	-4.0	-2.40	-1.70	-0.60	2.6	-0.37 [-0.86, 0.13]
			Placebo	37	36 (97.3)	-1.19 (0.84)	-3.0	-1.60	-1.40	-0.40	0.2	
		Week 16	Tezepelumab	29	28 (96.6)	-1.39 (1.30)	-4.0	-2.20	-1.40	-0.50	2.6	-0.25 [-0.75, 0.25]
			Placebo	37	36 (97.3)	-1.11 (1.02)	-3.0	-1.90	-1.20	-0.20	1.0	
		Week 18	Tezepelumab	29	28 (96.6)	-1.57 (1.37)	-4.0	-2.60	-1.70	-0.70	2.6	-0.32 [-0.82, 0.17]
			Placebo	37	36 (97.3)	-1.18 (1.04)	-3.0	-2.00	-1.20	-0.40	1.4	
		Week 20	Tezepelumab	29	28 (96.6)	-1.45 (1.36)	-4.0	-2.30	-1.60	-0.50	2.6	-0.29 [-0.78, 0.21]
			Placebo	37	36 (97.3)	-1.11 (1.06)	-3.6	-1.70	-1.00	-0.30	0.8	
		Week 22	Tezepelumab	29	28 (96.6)	-1.57 (1.37)	-4.0	-2.60	-1.60	-0.60	2.6	-0.47 [-0.97, 0.03]
			Placebo	37	36 (97.3)	-1.03 (0.95)	-2.8	-1.70	-1.00	-0.30	0.6	
		Week 24	Tezepelumab	29	28 (96.6)	-1.44 (1.29)	-4.0	-2.20	-1.40	-0.60	2.6	-0.30 [-0.79, 0.20]
			Placebo	37	36 (97.3)	-1.10 (0.99)	-3.0	-1.70	-1.00	-0.20	0.4	
		Week 26	Tezepelumab	29	28 (96.6)	-1.46 (1.37)	-4.0	-2.50	-1.40	-0.50	2.6	-0.17 [-0.66, 0.33]
			Placebo	37	36 (97.3)	-1.27 (1.04)	-3.0	-2.00	-1.40	-0.40	0.8	
		Week 28	Tezepelumab	29	28 (96.6)	-1.39 (1.40)	-4.0	-2.40	-1.30	-0.50	2.6	-0.12 [-0.61, 0.38]
			Placebo	37	36 (97.3)	-1.24 (1.13)	-3.0	-2.30	-1.20	-0.30	1.2	
		Week 30	Tezepelumab	29	28 (96.6)	-1.49 (1.31)	-3.8	-2.60	-1.40	-0.80	2.6	-0.18 [-0.67, 0.32]
			Placebo	37	36 (97.3)	-1.28 (1.04)	-3.0	-2.20	-1.40	-0.60	1.0	
		Week 32	Tezepelumab	29	28 (96.6)	-1.62 (1.34)	-4.0	-2.60	-1.60	-0.80	2.6	-0.32 [-0.82, 0.18]
			Placebo	37	36 (97.3)	-1.26 (0.97)	-3.2	-1.80	-1.40	-0.60	0.8	
		Week 34	Tezepelumab	29	28 (96.6)	-1.46 (1.34)	-4.0	-2.30	-1.50	-0.60	2.6	-0.19 [-0.68, 0.31]
			Placebo	37	36 (97.3)	-1.25 (0.89)	-2.8	-1.90	-1.40	-0.60	0.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	29	28 (96.6)	-1.50 (1.37)	-4.0	-2.60	-1.60	-0.70	2.6	-0.45 [-0.95, 0.05]
			Placebo	37	36 (97.3)	-0.97 (1.00)	-3.0	-1.40	-1.00	-0.30	1.4	
		Week 38	Tezepelumab	29	28 (96.6)	-1.56 (1.37)	-4.0	-2.50	-1.60	-0.70	2.6	-0.37 [-0.87, 0.13]
			Placebo	37	36 (97.3)	-1.13 (0.95)	-3.0	-1.80	-1.20	-0.30	0.4	
		Week 40	Tezepelumab	29	28 (96.6)	-1.71 (1.43)	-4.2	-2.60	-1.60	-0.80	2.6	-0.59 [-1.10, -0.09]
			Placebo	37	36 (97.3)	-0.98 (1.06)	-3.0	-1.60	-1.10	-0.10	1.4	
		Week 42	Tezepelumab	29	28 (96.6)	-1.60 (1.39)	-4.0	-2.70	-1.60	-0.70	2.6	-0.44 [-0.94, 0.06]
			Placebo	37	36 (97.3)	-1.08 (1.00)	-3.0	-1.60	-1.20	-0.20	1.6	
		Week 44	Tezepelumab	29	28 (96.6)	-1.60 (1.39)	-4.0	-2.70	-1.40	-0.80	2.6	-0.43 [-0.93, 0.07]
			Placebo	37	37 (100.0)	-1.07 (1.11)	-3.0	-1.80	-1.20	-0.40	1.2	
		Week 46	Tezepelumab	29	28 (96.6)	-1.49 (1.44)	-4.0	-2.60	-1.40	-0.70	2.6	-0.27 [-0.76, 0.22]
			Placebo	37	37 (100.0)	-1.17 (0.94)	-3.2	-1.60	-1.20	-0.80	0.6	
		Week 48	Tezepelumab	29	28 (96.6)	-1.49 (1.46)	-4.0	-2.70	-1.60	-0.50	2.6	-0.30 [-0.79, 0.19]
			Placebo	37	37 (100.0)	-1.12 (1.06)	-3.0	-1.60	-1.20	-0.40	1.0	
		Week 50	Tezepelumab	29	28 (96.6)	-1.59 (1.42)	-4.0	-2.60	-1.60	-0.90	2.6	-0.35 [-0.84, 0.15]
			Placebo	37	37 (100.0)	-1.18 (0.94)	-3.0	-1.80	-1.00	-0.60	0.4	
		Week 52	Tezepelumab	29	28 (96.6)	-1.59 (1.46)	-4.0	-2.60	-1.60	-0.90	2.6	-0.36 [-0.85, 0.14]
			Placebo	37	37 (100.0)	-1.16 (0.99)	-3.0	-1.80	-1.20	-0.40	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	108	108 (100.0)	2.76 (0.79)	0.0	2.40	2.80	3.20	5.0	
			Placebo	101	101 (100.0)	2.77 (0.77)	0.4	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	108	103 (95.4)	2.20 (0.96)	0.0	1.60	2.40	2.80	4.2	
			Placebo	101	90 (89.1)	2.43 (0.88)	0.0	2.00	2.40	3.00	5.0	
		Week 4	Tezepelumab	108	103 (95.4)	1.90 (1.01)	0.0	1.00	2.00	2.60	4.2	
			Placebo	101	90 (89.1)	2.32 (0.85)	0.2	1.80	2.40	3.00	4.2	
		Week 6	Tezepelumab	108	103 (95.4)	1.84 (0.97)	0.0	1.20	1.80	2.60	4.2	
			Placebo	101	91 (90.1)	2.19 (0.98)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	108	103 (95.4)	1.76 (1.06)	0.0	1.00	1.80	2.60	5.2	
			Placebo	101	92 (91.1)	2.17 (0.96)	0.0	1.60	2.20	2.80	5.0	
		Week 10	Tezepelumab	108	103 (95.4)	1.74 (1.02)	0.0	1.00	1.80	2.40	4.8	
			Placebo	101	92 (91.1)	2.08 (0.96)	0.0	1.40	2.00	2.80	5.2	
		Week 12	Tezepelumab	108	103 (95.4)	1.64 (1.08)	0.0	0.80	1.60	2.60	4.8	
			Placebo	101	92 (91.1)	2.04 (0.94)	0.0	1.40	2.10	2.80	4.4	
		Week 14	Tezepelumab	108	103 (95.4)	1.50 (1.01)	0.0	0.80	1.40	2.20	4.8	
			Placebo	101	92 (91.1)	2.00 (0.99)	0.0	1.20	2.00	2.80	5.0	
		Week 16	Tezepelumab	108	103 (95.4)	1.65 (1.11)	0.0	0.80	1.60	2.60	4.8	
			Placebo	101	92 (91.1)	2.14 (1.07)	0.0	1.40	2.20	3.00	5.0	
		Week 18	Tezepelumab	108	104 (96.3)	1.55 (0.99)	0.0	0.80	1.60	2.20	4.8	
			Placebo	101	92 (91.1)	2.02 (1.02)	0.0	1.40	2.10	2.70	5.0	
		Week 20	Tezepelumab	108	104 (96.3)	1.63 (1.05)	0.0	0.80	1.80	2.40	4.8	
			Placebo	101	92 (91.1)	2.07 (1.06)	0.0	1.40	2.40	2.80	5.0	
		Week 22	Tezepelumab	108	104 (96.3)	1.70 (1.00)	0.0	1.00	1.80	2.40	4.8	
			Placebo	101	92 (91.1)	1.97 (1.11)	0.0	1.00	2.00	2.80	5.0	
		Week 24	Tezepelumab	108	104 (96.3)	1.65 (1.06)	0.0	0.80	1.70	2.50	4.8	
			Placebo	101	92 (91.1)	1.99 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	108	105 (97.2)	1.60 (1.05)	0.0	0.80	1.60	2.40	4.8	
			Placebo	101	92 (91.1)	1.98 (1.01)	0.0	1.20	1.80	2.80	4.4	
		Week 28	Tezepelumab	108	106 (98.1)	1.66 (1.08)	0.0	1.00	1.80	2.40	4.8	
			Placebo	101	93 (92.1)	2.05 (1.07)	0.0	1.00	2.20	2.80	4.4	
		Week 30	Tezepelumab	108	107 (99.1)	1.60 (1.06)	0.0	0.80	1.60	2.40	4.8	
			Placebo	101	94 (93.1)	2.04 (1.08)	0.0	1.00	2.20	2.80	4.4	
		Week 32	Tezepelumab	108	107 (99.1)	1.58 (1.08)	0.0	0.80	1.40	2.40	4.8	
			Placebo	101	94 (93.1)	1.97 (1.11)	0.0	1.00	2.00	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	108	107 (99.1)	1.56 (1.13)	0.0	0.60	1.40	2.40	4.8	
			Placebo	101	94 (93.1)	1.91 (1.14)	0.0	1.00	1.80	2.80	4.8	
		Week 36	Tezepelumab	108	107 (99.1)	1.67 (1.12)	0.0	0.80	1.60	2.40	5.0	
			Placebo	101	94 (93.1)	1.92 (1.13)	0.0	1.00	2.10	2.80	4.8	
		Week 38	Tezepelumab	108	107 (99.1)	1.56 (1.09)	0.0	0.80	1.60	2.40	4.8	
			Placebo	101	94 (93.1)	1.87 (1.12)	0.0	1.00	1.80	2.80	4.8	
		Week 40	Tezepelumab	108	107 (99.1)	1.64 (1.10)	0.0	0.60	1.80	2.40	4.8	
			Placebo	101	94 (93.1)	1.92 (1.11)	0.0	1.00	1.90	2.80	4.4	
		Week 42	Tezepelumab	108	107 (99.1)	1.55 (1.09)	0.0	0.80	1.60	2.20	4.8	
			Placebo	101	94 (93.1)	1.91 (1.08)	0.0	1.00	2.00	2.80	4.6	
		Week 44	Tezepelumab	108	107 (99.1)	1.59 (1.10)	0.0	0.60	1.60	2.40	4.8	
			Placebo	101	94 (93.1)	1.98 (1.05)	0.0	1.00	2.10	2.80	4.4	
		Week 46	Tezepelumab	108	107 (99.1)	1.53 (1.08)	0.0	0.80	1.40	2.20	4.8	
			Placebo	101	94 (93.1)	1.85 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 48	Tezepelumab	108	107 (99.1)	1.60 (1.09)	0.0	0.80	1.60	2.40	4.8	
			Placebo	101	94 (93.1)	1.88 (1.08)	0.0	1.00	2.00	2.80	4.6	
		Week 50	Tezepelumab	108	107 (99.1)	1.52 (1.08)	0.0	0.80	1.40	2.20	4.8	
			Placebo	101	94 (93.1)	1.87 (1.03)	0.0	1.00	1.90	2.80	4.4	
		Week 52	Tezepelumab	108	107 (99.1)	1.55 (1.06)	0.0	0.60	1.60	2.20	4.8	
			Placebo	101	94 (93.1)	1.93 (1.06)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	108	103 (95.4)	-0.56 (0.73)	-3.2	-1.00	-0.40	0.00	0.4	-0.27 [-0.55, 0.02]
			Placebo	101	90 (89.1)	-0.36 (0.79)	-3.0	-0.80	-0.20	0.20	1.4	
		Week 4	Tezepelumab	108	103 (95.4)	-0.86 (0.91)	-3.6	-1.40	-0.80	-0.20	1.2	-0.44 [-0.72, -0.15]
			Placebo	101	90 (89.1)	-0.47 (0.88)	-3.0	-1.00	-0.40	0.00	1.6	
		Week 6	Tezepelumab	108	103 (95.4)	-0.92 (0.95)	-3.6	-1.60	-1.00	-0.20	1.2	-0.34 [-0.62, -0.06]
			Placebo	101	91 (90.1)	-0.60 (0.94)	-3.4	-1.40	-0.40	0.00	1.6	
		Week 8	Tezepelumab	108	103 (95.4)	-1.00 (1.02)	-3.0	-1.60	-1.00	-0.40	2.6	-0.39 [-0.67, -0.11]
			Placebo	101	92 (91.1)	-0.62 (0.93)	-3.6	-1.00	-0.60	0.00	1.0	
		Week 10	Tezepelumab	108	103 (95.4)	-1.03 (0.94)	-3.6	-1.60	-1.00	-0.40	1.0	-0.32 [-0.60, -0.04]
			Placebo	101	92 (91.1)	-0.70 (1.06)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	108	103 (95.4)	-1.12 (0.99)	-4.0	-1.80	-1.00	-0.40	1.2	-0.37 [-0.66, -0.09]
			Placebo	101	92 (91.1)	-0.75 (1.01)	-3.8	-1.20	-0.60	-0.10	1.6	
		Week 14	Tezepelumab	108	103 (95.4)	-1.26 (0.99)	-4.2	-1.80	-1.20	-0.60	1.2	-0.47 [-0.75, -0.18]
			Placebo	101	92 (91.1)	-0.78 (1.05)	-3.4	-1.40	-0.80	-0.20	2.4	
		Week 16	Tezepelumab	108	103 (95.4)	-1.11 (1.07)	-4.4	-1.80	-1.00	-0.40	1.8	-0.43 [-0.71, -0.14]
			Placebo	101	92 (91.1)	-0.65 (1.11)	-3.6	-1.20	-0.60	0.00	2.6	
		Week 18	Tezepelumab	108	104 (96.3)	-1.21 (0.99)	-4.4	-1.80	-1.00	-0.60	1.2	-0.43 [-0.71, -0.14]
			Placebo	101	92 (91.1)	-0.77 (1.08)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 20	Tezepelumab	108	104 (96.3)	-1.12 (1.01)	-4.4	-1.80	-1.00	-0.40	1.0	-0.37 [-0.66, -0.09]
			Placebo	101	92 (91.1)	-0.72 (1.12)	-3.6	-1.30	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	108	104 (96.3)	-1.06 (1.03)	-4.4	-1.80	-1.00	-0.40	2.0	-0.22 [-0.50, 0.06]
			Placebo	101	92 (91.1)	-0.82 (1.14)	-3.8	-1.60	-0.80	0.00	2.6	
		Week 24	Tezepelumab	108	104 (96.3)	-1.11 (1.00)	-4.8	-1.80	-1.00	-0.40	1.4	-0.29 [-0.57, -0.01]
			Placebo	101	92 (91.1)	-0.80 (1.14)	-3.8	-1.40	-0.80	0.00	2.6	
		Week 26	Tezepelumab	108	105 (97.2)	-1.14 (1.03)	-4.4	-2.00	-1.00	-0.40	1.2	-0.32 [-0.60, -0.04]
			Placebo	101	92 (91.1)	-0.81 (1.11)	-4.2	-1.40	-0.80	0.00	2.6	
		Week 28	Tezepelumab	108	106 (98.1)	-1.08 (1.04)	-4.4	-1.80	-1.00	-0.20	1.0	-0.34 [-0.63, -0.06]
			Placebo	101	93 (92.1)	-0.71 (1.12)	-4.2	-1.60	-0.60	0.00	2.6	
		Week 30	Tezepelumab	108	107 (99.1)	-1.15 (1.09)	-4.4	-1.80	-1.00	-0.40	2.0	-0.38 [-0.66, -0.10]
			Placebo	101	94 (93.1)	-0.72 (1.16)	-3.4	-1.60	-0.60	0.00	2.6	
		Week 32	Tezepelumab	108	107 (99.1)	-1.17 (1.06)	-4.4	-2.00	-1.00	-0.60	1.8	-0.34 [-0.61, -0.06]
			Placebo	101	94 (93.1)	-0.80 (1.16)	-3.6	-1.60	-0.60	-0.20	2.6	
		Week 34	Tezepelumab	108	107 (99.1)	-1.20 (1.11)	-4.4	-2.00	-1.20	-0.40	2.2	-0.30 [-0.58, -0.02]
			Placebo	101	94 (93.1)	-0.86 (1.18)	-4.2	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHK: Change from baseline in ACQ-5 score by key subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	108	107 (99.1)	-1.08 (1.14)	-4.4	-2.00	-1.00	-0.20	2.0	-0.20 [-0.48, 0.08]
			Placebo	101	94 (93.1)	-0.84 (1.23)	-3.6	-1.60	-0.80	0.00	2.6	
		Week 38	Tezepelumab	108	107 (99.1)	-1.19 (1.13)	-4.4	-2.20	-1.20	-0.40	2.6	-0.25 [-0.53, 0.02]
			Placebo	101	94 (93.1)	-0.89 (1.22)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 40	Tezepelumab	108	107 (99.1)	-1.12 (1.11)	-4.4	-1.80	-1.00	-0.40	1.8	-0.24 [-0.52, 0.04]
			Placebo	101	94 (93.1)	-0.84 (1.16)	-4.2	-1.60	-0.80	-0.20	2.6	
		Week 42	Tezepelumab	108	107 (99.1)	-1.20 (1.12)	-4.4	-2.00	-1.20	-0.40	2.2	-0.31 [-0.59, -0.03]
			Placebo	101	94 (93.1)	-0.85 (1.15)	-4.2	-1.60	-0.80	-0.20	2.6	
		Week 44	Tezepelumab	108	107 (99.1)	-1.16 (1.15)	-4.4	-2.00	-1.00	-0.40	1.6	-0.33 [-0.61, -0.05]
			Placebo	101	94 (93.1)	-0.78 (1.15)	-4.2	-1.40	-0.60	0.00	2.6	
		Week 46	Tezepelumab	108	107 (99.1)	-1.23 (1.12)	-4.4	-2.00	-1.20	-0.40	1.8	-0.28 [-0.56, 0.00]
			Placebo	101	94 (93.1)	-0.91 (1.15)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 48	Tezepelumab	108	107 (99.1)	-1.15 (1.11)	-4.4	-2.00	-1.00	-0.40	2.0	-0.24 [-0.52, 0.04]
			Placebo	101	94 (93.1)	-0.88 (1.15)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 50	Tezepelumab	108	107 (99.1)	-1.24 (1.12)	-4.4	-2.00	-1.20	-0.40	2.0	-0.31 [-0.59, -0.03]
			Placebo	101	94 (93.1)	-0.89 (1.12)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 52	Tezepelumab	108	107 (99.1)	-1.20 (1.11)	-4.4	-2.00	-1.20	-0.40	2.0	-0.33 [-0.60, -0.05]
			Placebo	101	94 (93.1)	-0.83 (1.15)	-4.2	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	2.85 (0.86)	0.0	2.40	2.80	3.20	5.2	
			Placebo	123	123 (100.0)	2.80 (0.69)	0.4	2.40	2.80	3.20	4.8	
		Week 2	Tezepelumab	128	122 (95.3)	2.29 (0.97)	0.0	1.60	2.40	3.00	4.4	
			Placebo	123	110 (89.4)	2.38 (0.81)	0.0	2.00	2.40	3.00	4.8	
		Week 4	Tezepelumab	128	122 (95.3)	1.96 (1.03)	0.0	1.20	2.20	2.80	4.2	
			Placebo	123	110 (89.4)	2.27 (0.87)	0.2	1.80	2.40	2.80	4.2	
		Week 6	Tezepelumab	128	122 (95.3)	1.89 (1.02)	0.0	1.20	1.80	2.60	4.2	
			Placebo	123	111 (90.2)	2.16 (0.96)	0.2	1.40	2.20	2.80	5.0	
		Week 8	Tezepelumab	128	122 (95.3)	1.82 (1.10)	0.0	1.00	1.80	2.80	5.2	
			Placebo	123	112 (91.1)	2.12 (0.96)	0.0	1.60	2.20	2.80	4.6	
		Week 10	Tezepelumab	128	122 (95.3)	1.76 (1.07)	0.0	1.00	1.80	2.60	4.8	
			Placebo	123	113 (91.9)	2.06 (0.94)	0.0	1.40	2.20	2.80	4.4	
		Week 12	Tezepelumab	128	122 (95.3)	1.67 (1.09)	0.0	0.80	1.60	2.60	4.8	
			Placebo	123	113 (91.9)	2.00 (1.00)	0.0	1.20	2.20	2.80	4.4	
		Week 14	Tezepelumab	128	122 (95.3)	1.54 (1.08)	0.0	0.60	1.40	2.40	4.8	
			Placebo	123	113 (91.9)	1.94 (0.91)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	128	122 (95.3)	1.70 (1.12)	0.0	0.80	1.70	2.60	4.8	
			Placebo	123	113 (91.9)	2.04 (1.02)	0.0	1.20	2.00	2.80	4.4	
		Week 18	Tezepelumab	128	123 (96.1)	1.58 (1.03)	0.0	0.80	1.60	2.40	4.8	
			Placebo	123	113 (91.9)	1.93 (1.01)	0.0	1.40	1.80	2.60	4.8	
		Week 20	Tezepelumab	128	123 (96.1)	1.68 (1.10)	0.0	0.80	1.80	2.60	5.0	
			Placebo	123	113 (91.9)	1.99 (1.01)	0.0	1.40	2.00	2.80	4.4	
		Week 22	Tezepelumab	128	123 (96.1)	1.70 (1.03)	0.0	1.00	1.80	2.40	4.8	
			Placebo	123	113 (91.9)	1.94 (1.02)	0.0	1.20	2.00	2.80	4.4	
		Week 24	Tezepelumab	128	123 (96.1)	1.69 (1.11)	0.0	0.80	1.80	2.60	4.8	
			Placebo	123	113 (91.9)	1.94 (1.02)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	128	124 (96.9)	1.66 (1.06)	0.0	1.00	1.60	2.40	4.8	
			Placebo	123	113 (91.9)	1.91 (0.99)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	128	125 (97.7)	1.72 (1.11)	0.0	1.00	1.80	2.60	4.8	
			Placebo	123	114 (92.7)	1.99 (1.06)	0.0	1.00	2.20	2.80	4.4	
		Week 30	Tezepelumab	128	126 (98.4)	1.65 (1.06)	0.0	0.80	1.60	2.40	4.8	
			Placebo	123	115 (93.5)	1.97 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	128	126 (98.4)	1.60 (1.09)	0.0	0.80	1.40	2.40	4.8	
			Placebo	123	115 (93.5)	1.92 (1.08)	0.0	1.00	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Absolute values	Week 34	Tezepelumab	128	126 (98.4)	1.62 (1.14)	0.0	0.80	1.50	2.40	4.8	
			Placebo	123	115 (93.5)	1.90 (1.05)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	128	126 (98.4)	1.68 (1.12)	0.0	0.80	1.60	2.40	5.0	
			Placebo	123	115 (93.5)	1.93 (1.09)	0.0	1.00	2.00	2.80	4.8	
		Week 38	Tezepelumab	128	126 (98.4)	1.60 (1.12)	0.0	0.80	1.50	2.40	4.8	
			Placebo	123	115 (93.5)	1.88 (1.05)	0.0	1.00	2.00	2.80	4.8	
		Week 40	Tezepelumab	128	126 (98.4)	1.63 (1.13)	0.0	0.60	1.80	2.40	4.8	
			Placebo	123	115 (93.5)	1.95 (1.09)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	128	126 (98.4)	1.58 (1.12)	0.0	0.80	1.60	2.40	4.8	
			Placebo	123	115 (93.5)	1.93 (1.06)	0.0	1.00	2.00	2.80	4.6	
		Week 44	Tezepelumab	128	126 (98.4)	1.61 (1.11)	0.0	0.80	1.60	2.60	4.8	
			Placebo	123	116 (94.3)	1.95 (1.05)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	128	126 (98.4)	1.59 (1.12)	0.0	0.80	1.60	2.40	4.8	
			Placebo	123	116 (94.3)	1.86 (1.02)	0.0	1.20	2.00	2.60	4.4	
		Week 48	Tezepelumab	128	126 (98.4)	1.63 (1.13)	0.0	0.80	1.60	2.40	4.8	
			Placebo	123	116 (94.3)	1.87 (1.07)	0.0	1.00	2.00	2.80	4.6	
		Week 50	Tezepelumab	128	126 (98.4)	1.55 (1.11)	0.0	0.80	1.40	2.20	4.8	
			Placebo	123	116 (94.3)	1.85 (1.01)	0.0	1.00	2.00	2.60	4.4	
		Week 52	Tezepelumab	128	126 (98.4)	1.59 (1.10)	0.0	0.80	1.60	2.20	4.8	
			Placebo	123	116 (94.3)	1.90 (1.03)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 2	Tezepelumab	128	122 (95.3)	-0.56 (0.72)	-3.0	-1.00	-0.40	0.00	0.8	-0.16 [-0.42, 0.09]
			Placebo	123	110 (89.4)	-0.44 (0.77)	-3.0	-0.80	-0.40	0.00	1.4	
		Week 4	Tezepelumab	128	122 (95.3)	-0.89 (0.97)	-3.8	-1.40	-0.80	-0.20	2.6	-0.36 [-0.62, -0.10]
			Placebo	123	110 (89.4)	-0.54 (0.90)	-3.0	-1.00	-0.40	0.00	1.6	
		Week 6	Tezepelumab	128	122 (95.3)	-0.96 (1.05)	-4.0	-1.60	-1.00	-0.20	2.6	-0.31 [-0.57, -0.05]
			Placebo	123	111 (90.2)	-0.65 (0.96)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	128	122 (95.3)	-1.02 (1.09)	-4.0	-1.60	-1.00	-0.40	2.6	-0.32 [-0.58, -0.06]
			Placebo	123	112 (91.1)	-0.70 (0.91)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	128	122 (95.3)	-1.09 (1.06)	-4.0	-1.80	-1.20	-0.40	2.6	-0.33 [-0.58, -0.07]
			Placebo	123	113 (91.9)	-0.76 (0.99)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	128	122 (95.3)	-1.17 (1.07)	-4.0	-1.80	-1.20	-0.40	2.6	-0.33 [-0.59, -0.08]
			Placebo	123	113 (91.9)	-0.82 (1.03)	-3.8	-1.40	-0.60	-0.20	1.6	
		Week 14	Tezepelumab	128	122 (95.3)	-1.31 (1.10)	-4.2	-2.00	-1.20	-0.60	2.6	-0.41 [-0.67, -0.15]
			Placebo	123	113 (91.9)	-0.88 (0.95)	-3.4	-1.40	-0.80	-0.40	1.4	
		Week 16	Tezepelumab	128	122 (95.3)	-1.15 (1.13)	-4.4	-1.80	-1.00	-0.40	2.6	-0.34 [-0.60, -0.08]
			Placebo	123	113 (91.9)	-0.78 (1.02)	-3.6	-1.40	-0.80	0.00	2.6	
		Week 18	Tezepelumab	128	123 (96.1)	-1.26 (1.10)	-4.4	-1.80	-1.00	-0.60	2.6	-0.34 [-0.60, -0.08]
			Placebo	123	113 (91.9)	-0.90 (1.03)	-3.6	-1.40	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	128	123 (96.1)	-1.16 (1.10)	-4.4	-1.80	-1.00	-0.40	2.6	-0.31 [-0.56, -0.05]
			Placebo	123	113 (91.9)	-0.83 (1.04)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	128	123 (96.1)	-1.14 (1.13)	-4.4	-1.80	-1.00	-0.40	2.6	-0.24 [-0.49, 0.02]
			Placebo	123	113 (91.9)	-0.88 (1.05)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 24	Tezepelumab	128	123 (96.1)	-1.15 (1.08)	-4.8	-1.80	-1.00	-0.40	2.6	-0.25 [-0.51, 0.01]
			Placebo	123	113 (91.9)	-0.88 (1.07)	-3.6	-1.40	-0.80	-0.20	2.6	
		Week 26	Tezepelumab	128	124 (96.9)	-1.17 (1.12)	-4.4	-2.00	-1.00	-0.40	2.6	-0.24 [-0.50, 0.01]
			Placebo	123	113 (91.9)	-0.91 (1.04)	-3.4	-1.60	-1.00	0.00	2.6	
		Week 28	Tezepelumab	128	125 (97.7)	-1.11 (1.14)	-4.4	-1.80	-1.00	-0.20	2.6	-0.27 [-0.53, -0.02]
			Placebo	123	114 (92.7)	-0.81 (1.08)	-3.4	-1.60	-0.80	0.00	2.6	
		Week 30	Tezepelumab	128	126 (98.4)	-1.19 (1.16)	-4.4	-2.20	-1.00	-0.40	2.6	-0.31 [-0.57, -0.06]
			Placebo	123	115 (93.5)	-0.83 (1.14)	-3.4	-1.60	-0.80	-0.20	2.6	
		Week 32	Tezepelumab	128	126 (98.4)	-1.24 (1.15)	-4.4	-2.20	-1.00	-0.60	2.6	-0.31 [-0.57, -0.06]
			Placebo	123	115 (93.5)	-0.89 (1.11)	-3.4	-1.60	-0.80	-0.20	2.6	
		Week 34	Tezepelumab	128	126 (98.4)	-1.22 (1.17)	-4.4	-2.00	-1.20	-0.40	2.6	-0.28 [-0.53, -0.02]
			Placebo	123	115 (93.5)	-0.91 (1.09)	-3.4	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Change from baseline	Week 36	Tezepelumab	128	126 (98.4)	-1.16 (1.20)	-4.4	-2.00	-1.20	-0.40	2.6	-0.24 [-0.49, 0.01]
			Placebo	123	115 (93.5)	-0.87 (1.15)	-3.6	-1.40	-1.00	0.00	2.6	
		Week 38	Tezepelumab	128	126 (98.4)	-1.24 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.27 [-0.53, -0.02]
			Placebo	123	115 (93.5)	-0.92 (1.12)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 40	Tezepelumab	128	126 (98.4)	-1.21 (1.22)	-4.4	-2.20	-1.00	-0.40	2.6	-0.31 [-0.57, -0.06]
			Placebo	123	115 (93.5)	-0.85 (1.10)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 42	Tezepelumab	128	126 (98.4)	-1.26 (1.22)	-4.4	-2.00	-1.20	-0.40	2.6	-0.33 [-0.59, -0.08]
			Placebo	123	115 (93.5)	-0.87 (1.11)	-3.6	-1.40	-0.80	-0.20	2.6	
		Week 44	Tezepelumab	128	126 (98.4)	-1.22 (1.23)	-4.4	-2.00	-1.20	-0.40	2.6	-0.32 [-0.57, -0.07]
			Placebo	123	116 (94.3)	-0.85 (1.10)	-3.4	-1.50	-0.80	0.00	2.6	
		Week 46	Tezepelumab	128	126 (98.4)	-1.25 (1.21)	-4.4	-2.00	-1.20	-0.40	2.6	-0.27 [-0.52, -0.01]
			Placebo	123	116 (94.3)	-0.94 (1.09)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	128	126 (98.4)	-1.20 (1.21)	-4.4	-2.00	-1.00	-0.40	2.6	-0.24 [-0.49, 0.02]
			Placebo	123	116 (94.3)	-0.93 (1.12)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	128	126 (98.4)	-1.29 (1.20)	-4.4	-2.20	-1.20	-0.60	2.6	-0.30 [-0.55, -0.05]
			Placebo	123	116 (94.3)	-0.95 (1.04)	-3.6	-1.60	-1.00	-0.30	2.6	
		Week 52	Tezepelumab	128	126 (98.4)	-1.25 (1.20)	-4.4	-2.00	-1.20	-0.40	2.6	-0.31 [-0.56, -0.05]
			Placebo	123	116 (94.3)	-0.90 (1.05)	-3.6	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.73 (0.48)	2.0	2.40	2.60	3.20	3.4	
			Placebo	15	15 (100.0)	2.95 (0.95)	1.8	2.00	2.60	3.60	5.0	
		Week 2	Tezepelumab	9	9 (100.0)	2.02 (1.00)	0.0	1.60	2.40	2.60	3.2	
			Placebo	15	15 (100.0)	2.72 (1.00)	1.4	2.00	2.60	3.20	5.0	
		Week 4	Tezepelumab	9	9 (100.0)	1.91 (0.86)	0.8	1.20	2.20	2.40	3.4	
			Placebo	15	15 (100.0)	2.51 (0.92)	0.8	1.80	2.40	3.00	4.4	
		Week 6	Tezepelumab	9	9 (100.0)	1.60 (0.74)	0.4	1.00	1.80	1.80	3.0	
			Placebo	15	15 (100.0)	2.45 (1.37)	1.0	1.40	2.40	2.80	6.0	
		Week 8	Tezepelumab	9	9 (100.0)	1.40 (0.79)	0.2	1.00	1.20	1.80	2.8	
			Placebo	15	15 (100.0)	2.32 (1.30)	0.2	1.40	2.40	3.00	5.0	
		Week 10	Tezepelumab	9	9 (100.0)	1.24 (0.71)	0.2	0.80	1.40	1.60	2.4	
			Placebo	15	15 (100.0)	2.12 (1.10)	0.8	1.40	1.80	2.60	5.2	
		Week 12	Tezepelumab	9	9 (100.0)	1.18 (0.91)	0.0	0.60	1.00	1.60	3.0	
			Placebo	15	15 (100.0)	1.96 (1.01)	0.0	1.20	1.80	2.60	3.8	
		Week 14	Tezepelumab	9	9 (100.0)	1.04 (0.58)	0.4	0.80	1.00	1.00	2.4	
			Placebo	15	15 (100.0)	1.93 (1.25)	0.0	1.00	1.60	2.80	5.0	
		Week 16	Tezepelumab	9	9 (100.0)	1.24 (0.88)	0.2	1.00	1.00	1.20	3.4	
			Placebo	15	15 (100.0)	2.21 (1.51)	0.0	1.00	2.00	3.20	5.0	
		Week 18	Tezepelumab	9	9 (100.0)	1.11 (0.57)	0.4	0.60	1.00	1.60	2.0	
			Placebo	15	15 (100.0)	2.15 (1.18)	0.0	1.20	2.20	3.00	5.0	
		Week 20	Tezepelumab	9	9 (100.0)	1.18 (0.64)	0.4	0.80	1.00	1.20	2.4	
			Placebo	15	15 (100.0)	2.13 (1.30)	0.0	1.00	2.40	3.00	5.0	
		Week 22	Tezepelumab	9	9 (100.0)	1.27 (0.81)	0.0	1.00	1.00	1.60	2.6	
			Placebo	15	15 (100.0)	2.12 (1.23)	0.4	1.20	2.60	2.60	5.0	
		Week 24	Tezepelumab	9	9 (100.0)	1.20 (0.71)	0.4	0.80	1.00	1.20	2.8	
			Placebo	15	15 (100.0)	2.04 (1.11)	0.4	0.80	2.40	2.80	4.0	
		Week 26	Tezepelumab	9	9 (100.0)	0.98 (0.60)	0.2	0.80	1.00	1.00	2.4	
			Placebo	15	15 (100.0)	1.80 (1.20)	0.0	1.00	1.80	2.60	4.0	
		Week 28	Tezepelumab	9	9 (100.0)	1.02 (0.61)	0.2	1.00	1.00	1.00	2.4	
			Placebo	15	15 (100.0)	1.68 (1.34)	0.0	0.40	2.00	2.60	4.0	
		Week 30	Tezepelumab	9	9 (100.0)	1.04 (0.55)	0.6	0.80	1.00	1.00	2.4	
			Placebo	15	15 (100.0)	1.69 (1.14)	0.0	1.00	1.60	2.20	4.0	
		Week 32	Tezepelumab	9	9 (100.0)	1.09 (0.66)	0.2	0.80	1.00	1.40	2.4	
			Placebo	15	15 (100.0)	1.71 (1.09)	0.2	0.80	1.60	2.60	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Non-white	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.02 (0.61)	0.4	0.80	0.80	1.20	2.4	
			Placebo	15	15 (100.0)	1.53 (1.28)	0.0	0.20	1.60	2.60	4.0	
		Week 36	Tezepelumab	9	9 (100.0)	1.38 (0.91)	0.2	1.00	1.00	2.40	2.6	
			Placebo	15	15 (100.0)	2.03 (1.17)	0.0	1.60	2.20	2.60	4.0	
		Week 38	Tezepelumab	9	9 (100.0)	1.11 (0.77)	0.0	0.60	0.80	2.00	2.2	
			Placebo	15	15 (100.0)	1.71 (1.24)	0.0	0.60	1.80	2.60	4.0	
		Week 40	Tezepelumab	9	9 (100.0)	1.13 (0.60)	0.4	0.80	1.00	1.60	2.2	
			Placebo	15	15 (100.0)	1.84 (1.21)	0.0	0.80	2.00	2.60	4.0	
		Week 42	Tezepelumab	9	9 (100.0)	1.09 (0.57)	0.4	0.80	1.00	1.00	2.2	
			Placebo	15	15 (100.0)	1.69 (1.00)	0.0	1.40	2.00	2.20	3.4	
		Week 44	Tezepelumab	9	9 (100.0)	1.07 (0.66)	0.2	0.60	1.00	1.00	2.4	
			Placebo	15	15 (100.0)	1.97 (1.21)	0.0	0.80	2.60	2.80	3.8	
		Week 46	Tezepelumab	9	9 (100.0)	1.02 (0.58)	0.2	0.80	1.00	1.00	2.4	
			Placebo	15	15 (100.0)	1.63 (1.04)	0.0	0.60	1.80	2.20	3.4	
		Week 48	Tezepelumab	9	9 (100.0)	1.24 (0.71)	0.4	0.80	1.00	1.40	2.6	
			Placebo	15	15 (100.0)	1.84 (1.04)	0.0	1.00	2.00	2.60	3.4	
		Week 50	Tezepelumab	9	9 (100.0)	1.11 (0.78)	0.0	0.80	1.00	1.40	2.4	
			Placebo	15	15 (100.0)	1.80 (1.04)	0.0	1.00	1.80	2.60	3.8	
		Week 52	Tezepelumab	9	9 (100.0)	1.00 (0.81)	0.0	0.40	0.80	1.00	2.4	
			Placebo	15	15 (100.0)	1.84 (1.15)	0.0	1.40	1.80	2.80	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.71 (1.08)	-3.2	-0.80	-0.40	-0.20	0.4	-0.56 [-1.40, 0.28]
			Placebo	15	15 (100.0)	-0.23 (0.71)	-1.4	-0.80	-0.20	0.00	1.2	
		Week 4	Tezepelumab	9	9 (100.0)	-0.82 (1.01)	-2.4	-1.40	-1.00	-0.20	0.8	-0.39 [-1.22, 0.45]
			Placebo	15	15 (100.0)	-0.44 (0.98)	-1.8	-1.40	-0.20	0.40	1.0	
		Week 6	Tezepelumab	9	9 (100.0)	-1.13 (0.94)	-2.8	-1.60	-1.40	-0.40	0.4	-0.65 [-1.49, 0.20]
			Placebo	15	15 (100.0)	-0.49 (1.02)	-1.8	-1.40	-0.60	0.40	1.4	
		Week 8	Tezepelumab	9	9 (100.0)	-1.33 (1.01)	-3.0	-1.80	-1.60	-0.40	0.2	-0.57 [-1.42, 0.27]
			Placebo	15	15 (100.0)	-0.63 (1.34)	-3.0	-1.40	-0.40	0.60	1.0	
		Week 10	Tezepelumab	9	9 (100.0)	-1.49 (0.99)	-3.0	-2.00	-1.60	-0.40	-0.2	-0.55 [-1.40, 0.29]
			Placebo	15	15 (100.0)	-0.83 (1.30)	-2.6	-2.00	-0.80	-0.20	2.6	
		Week 12	Tezepelumab	9	9 (100.0)	-1.56 (1.03)	-2.6	-2.20	-2.00	-0.60	0.4	-0.49 [-1.33, 0.35]
			Placebo	15	15 (100.0)	-0.99 (1.22)	-3.0	-2.00	-0.80	-0.20	1.2	
		Week 14	Tezepelumab	9	9 (100.0)	-1.69 (0.74)	-2.8	-2.00	-1.80	-1.60	-0.2	-0.56 [-1.40, 0.29]
			Placebo	15	15 (100.0)	-1.01 (1.41)	-3.2	-2.00	-1.20	-0.20	2.4	
		Week 16	Tezepelumab	9	9 (100.0)	-1.49 (1.06)	-2.4	-2.20	-1.80	-1.20	1.0	-0.53 [-1.37, 0.31]
			Placebo	15	15 (100.0)	-0.73 (1.60)	-3.6	-2.00	-0.60	0.00	2.4	
		Week 18	Tezepelumab	9	9 (100.0)	-1.62 (0.89)	-2.8	-2.20	-1.80	-0.80	-0.2	-0.64 [-1.49, 0.21]
			Placebo	15	15 (100.0)	-0.80 (1.47)	-3.0	-2.00	-1.00	0.00	2.4	
		Week 20	Tezepelumab	9	9 (100.0)	-1.56 (0.95)	-2.6	-2.20	-2.00	-1.20	0.4	-0.53 [-1.37, 0.31]
			Placebo	15	15 (100.0)	-0.81 (1.60)	-3.6	-1.80	-0.80	0.40	2.4	
		Week 22	Tezepelumab	9	9 (100.0)	-1.47 (1.07)	-2.4	-2.20	-2.00	-0.80	0.4	-0.51 [-1.35, 0.33]
			Placebo	15	15 (100.0)	-0.83 (1.36)	-3.0	-1.60	-0.80	0.00	2.4	
		Week 24	Tezepelumab	9	9 (100.0)	-1.53 (0.94)	-2.4	-2.20	-1.80	-1.40	0.2	-0.51 [-1.35, 0.33]
			Placebo	15	15 (100.0)	-0.91 (1.37)	-3.8	-1.80	-1.00	0.20	1.4	
		Week 26	Tezepelumab	9	9 (100.0)	-1.76 (0.75)	-2.6	-2.20	-2.00	-1.40	-0.2	-0.48 [-1.32, 0.36]
			Placebo	15	15 (100.0)	-1.15 (1.50)	-4.2	-1.80	-1.40	0.00	1.4	
		Week 28	Tezepelumab	9	9 (100.0)	-1.71 (0.80)	-2.8	-2.20	-1.80	-1.40	-0.2	-0.34 [-1.17, 0.49]
			Placebo	15	15 (100.0)	-1.27 (1.53)	-4.2	-2.20	-1.40	-0.20	1.4	
		Week 30	Tezepelumab	9	9 (100.0)	-1.69 (0.80)	-2.6	-2.20	-1.80	-1.40	-0.2	-0.40 [-1.24, 0.43]
			Placebo	15	15 (100.0)	-1.25 (1.21)	-3.2	-2.00	-1.40	-0.40	1.4	
		Week 32	Tezepelumab	9	9 (100.0)	-1.64 (0.79)	-2.6	-2.20	-1.60	-1.00	-0.2	-0.36 [-1.19, 0.47]
			Placebo	15	15 (100.0)	-1.24 (1.27)	-3.6	-1.80	-1.60	-0.40	1.4	
		Week 34	Tezepelumab	9	9 (100.0)	-1.71 (0.87)	-2.6	-2.40	-2.00	-1.00	-0.2	-0.26 [-1.09, 0.57]
			Placebo	15	15 (100.0)	-1.41 (1.30)	-4.2	-2.20	-1.40	-0.60	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Non-white	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.36 (1.22)	-2.4	-2.20	-2.20	-0.20	0.6	-0.34 [-1.17, 0.49]
			Placebo	15	15 (100.0)	-0.92 (1.31)	-3.6	-1.80	-1.40	0.20	1.4	
		Week 38	Tezepelumab	9	9 (100.0)	-1.62 (0.90)	-2.6	-2.20	-1.80	-1.40	0.0	-0.31 [-1.14, 0.52]
			Placebo	15	15 (100.0)	-1.24 (1.39)	-4.2	-2.00	-1.40	-0.60	1.4	
		Week 40	Tezepelumab	9	9 (100.0)	-1.60 (0.84)	-2.6	-2.20	-1.60	-1.40	-0.2	-0.40 [-1.24, 0.43]
			Placebo	15	15 (100.0)	-1.11 (1.40)	-4.2	-2.00	-1.20	0.00	1.4	
		Week 42	Tezepelumab	9	9 (100.0)	-1.64 (0.68)	-2.4	-2.20	-1.60	-1.40	-0.4	-0.39 [-1.22, 0.44]
			Placebo	15	15 (100.0)	-1.25 (1.15)	-4.2	-1.60	-1.20	-0.80	0.6	
		Week 44	Tezepelumab	9	9 (100.0)	-1.67 (0.81)	-2.8	-2.20	-1.40	-1.40	-0.2	-0.55 [-1.40, 0.29]
			Placebo	15	15 (100.0)	-0.97 (1.45)	-4.2	-1.80	-1.40	0.40	1.2	
		Week 46	Tezepelumab	9	9 (100.0)	-1.71 (0.74)	-2.4	-2.20	-2.20	-1.40	-0.2	-0.38 [-1.21, 0.46]
			Placebo	15	15 (100.0)	-1.32 (1.18)	-4.2	-1.60	-1.60	-1.00	1.0	
		Week 48	Tezepelumab	9	9 (100.0)	-1.49 (0.97)	-2.4	-2.00	-1.80	-1.60	0.6	-0.33 [-1.17, 0.50]
			Placebo	15	15 (100.0)	-1.11 (1.23)	-3.8	-2.00	-1.40	-0.20	1.2	
		Week 50	Tezepelumab	9	9 (100.0)	-1.62 (1.09)	-3.2	-2.20	-1.60	-1.40	0.4	-0.38 [-1.21, 0.46]
			Placebo	15	15 (100.0)	-1.15 (1.36)	-4.2	-1.60	-1.40	-0.20	1.6	
		Week 52	Tezepelumab	9	9 (100.0)	-1.73 (1.14)	-3.2	-2.60	-2.00	-1.40	0.4	-0.45 [-1.29, 0.38]
			Placebo	15	15 (100.0)	-1.11 (1.50)	-4.2	-1.60	-1.40	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	10	10 (100.0)	3.06 (1.14)	1.8	2.20	2.90	3.20	5.2	
			Placebo	9	9 (100.0)	3.02 (0.77)	2.0	2.20	3.40	3.60	4.0	
		Week 2	Tezepelumab	10	9 (90.0)	1.89 (1.21)	0.0	1.00	2.20	2.40	3.6	
			Placebo	9	8 (88.9)	2.40 (0.89)	1.4	1.60	2.30	3.10	3.8	
		Week 4	Tezepelumab	10	9 (90.0)	1.73 (0.98)	0.2	1.20	1.80	2.20	3.4	
			Placebo	9	8 (88.9)	2.40 (1.18)	0.8	1.60	2.50	2.90	4.4	
		Week 6	Tezepelumab	10	9 (90.0)	1.69 (1.05)	0.0	1.20	1.80	2.20	3.4	
			Placebo	9	8 (88.9)	2.25 (1.33)	0.6	1.20	2.30	2.80	4.8	
		Week 8	Tezepelumab	10	9 (90.0)	1.22 (0.97)	0.0	0.60	1.20	2.00	3.0	
			Placebo	9	8 (88.9)	2.00 (1.44)	0.2	0.80	2.00	2.90	4.4	
		Week 10	Tezepelumab	10	9 (90.0)	1.04 (0.97)	0.0	0.40	0.60	1.40	3.0	
			Placebo	9	8 (88.9)	2.10 (1.61)	0.0	1.00	2.00	2.80	5.2	
		Week 12	Tezepelumab	10	9 (90.0)	1.04 (0.53)	0.6	0.60	0.80	1.20	2.0	
			Placebo	9	8 (88.9)	2.03 (1.32)	0.0	1.10	2.00	3.10	3.8	
		Week 14	Tezepelumab	10	9 (90.0)	0.82 (0.60)	0.0	0.60	0.80	0.80	2.2	
			Placebo	9	8 (88.9)	2.30 (1.47)	0.4	1.30	2.10	3.10	5.0	
		Week 16	Tezepelumab	10	9 (90.0)	1.27 (0.97)	0.4	0.80	1.00	1.40	3.4	
			Placebo	9	8 (88.9)	2.23 (1.53)	0.2	1.10	2.10	3.10	5.0	
		Week 18	Tezepelumab	10	9 (90.0)	0.96 (0.67)	0.0	0.40	1.00	1.20	2.2	
			Placebo	9	8 (88.9)	2.18 (1.48)	0.2	1.20	2.10	2.80	5.0	
		Week 20	Tezepelumab	10	9 (90.0)	1.00 (0.57)	0.4	0.60	1.00	1.20	2.2	
			Placebo	9	8 (88.9)	1.90 (1.72)	0.0	0.30	2.00	2.80	5.0	
		Week 22	Tezepelumab	10	9 (90.0)	0.93 (0.65)	0.0	0.60	0.80	1.00	2.2	
			Placebo	9	8 (88.9)	2.00 (1.61)	0.0	0.60	2.30	2.60	5.0	
		Week 24	Tezepelumab	10	9 (90.0)	1.00 (0.75)	0.0	0.80	1.00	1.20	2.2	
			Placebo	9	8 (88.9)	1.85 (1.34)	0.2	0.70	1.90	2.70	4.0	
		Week 26	Tezepelumab	10	9 (90.0)	0.96 (0.65)	0.0	0.60	0.80	1.40	2.2	
			Placebo	9	8 (88.9)	1.73 (1.29)	0.4	0.70	1.30	2.70	4.0	
		Week 28	Tezepelumab	10	10 (100.0)	0.88 (0.63)	0.0	0.40	0.90	1.20	2.2	
			Placebo	9	8 (88.9)	1.75 (1.25)	0.4	0.60	1.80	2.40	4.0	
		Week 30	Tezepelumab	10	10 (100.0)	0.90 (0.66)	0.0	0.40	0.90	1.20	2.2	
			Placebo	9	8 (88.9)	1.75 (1.21)	0.4	0.80	1.60	2.40	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
North America/Western EU	Absolute values	Week 32	Tezepelumab	10	10 (100.0)	1.04 (0.62)	0.2	0.40	1.00	1.40	2.2	
			Placebo	9	8 (88.9)	1.60 (1.20)	0.4	0.70	1.40	2.10	4.0	
		Week 34	Tezepelumab	10	10 (100.0)	1.06 (0.64)	0.0	0.80	1.00	1.40	2.2	
			Placebo	9	8 (88.9)	1.60 (1.30)	0.0	0.60	1.40	2.40	4.0	
		Week 36	Tezepelumab	10	10 (100.0)	1.40 (0.80)	0.4	0.80	1.20	2.20	2.6	
			Placebo	9	8 (88.9)	1.90 (1.18)	0.0	1.20	1.90	2.50	4.0	
		Week 38	Tezepelumab	10	10 (100.0)	0.98 (0.58)	0.4	0.60	0.80	1.00	2.2	
			Placebo	9	8 (88.9)	1.93 (1.28)	0.0	1.20	1.60	2.90	4.0	
		Week 40	Tezepelumab	10	10 (100.0)	1.04 (0.76)	0.0	0.40	1.00	1.60	2.2	
			Placebo	9	8 (88.9)	1.85 (1.23)	0.0	1.00	1.90	2.50	4.0	
		Week 42	Tezepelumab	10	10 (100.0)	0.98 (0.70)	0.0	0.40	0.90	1.40	2.2	
			Placebo	9	8 (88.9)	1.58 (0.80)	0.0	1.20	1.70	2.10	2.6	
		Week 44	Tezepelumab	10	10 (100.0)	1.10 (0.67)	0.4	0.40	1.00	1.80	2.2	
			Placebo	9	8 (88.9)	1.68 (0.84)	0.8	1.00	1.30	2.60	2.8	
		Week 46	Tezepelumab	10	10 (100.0)	0.90 (0.67)	0.0	0.40	0.80	1.00	2.2	
			Placebo	9	8 (88.9)	1.63 (0.87)	0.6	0.90	1.50	2.30	3.0	
		Week 48	Tezepelumab	10	10 (100.0)	0.96 (0.62)	0.2	0.40	0.80	1.40	2.2	
			Placebo	9	8 (88.9)	1.55 (0.92)	0.4	1.00	1.30	2.10	3.2	
		Week 50	Tezepelumab	10	10 (100.0)	0.70 (0.68)	0.0	0.00	0.70	1.00	2.2	
			Placebo	9	8 (88.9)	1.90 (0.96)	0.8	1.20	1.80	2.30	3.8	
		Week 52	Tezepelumab	10	10 (100.0)	0.86 (0.69)	0.0	0.40	0.80	1.20	2.2	
			Placebo	9	8 (88.9)	1.90 (1.20)	0.0	1.10	1.90	2.70	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 2	Tezepelumab	10	9 (90.0)	-1.22 (1.14)	-3.2	-1.80	-1.20	-0.20	0.2	-0.57 [-1.55, 0.40]
			Placebo	9	8 (88.9)	-0.58 (1.11)	-2.4	-1.30	-0.50	0.10	1.2	
		Week 4	Tezepelumab	10	9 (90.0)	-1.38 (1.07)	-3.0	-2.20	-1.40	-0.60	0.2	-0.65 [-1.63, 0.33]
			Placebo	9	8 (88.9)	-0.58 (1.39)	-3.0	-1.40	-0.50	0.60	1.0	
		Week 6	Tezepelumab	10	9 (90.0)	-1.42 (1.55)	-3.6	-2.80	-1.60	-0.20	0.4	-0.47 [-1.44, 0.50]
			Placebo	9	8 (88.9)	-0.73 (1.40)	-3.2	-1.30	-0.80	0.10	1.4	
		Week 8	Tezepelumab	10	9 (90.0)	-1.89 (1.01)	-3.2	-2.80	-2.00	-1.00	-0.4	-0.67 [-1.65, 0.32]
			Placebo	9	8 (88.9)	-0.98 (1.70)	-3.6	-2.20	-1.00	0.60	1.0	
		Week 10	Tezepelumab	10	9 (90.0)	-2.07 (1.14)	-3.6	-3.00	-2.20	-1.40	-0.4	-0.77 [-1.76, 0.22]
			Placebo	9	8 (88.9)	-0.88 (1.90)	-3.8	-1.80	-1.20	0.10	2.6	
		Week 12	Tezepelumab	10	9 (90.0)	-2.07 (1.15)	-4.0	-2.60	-2.20	-1.20	-0.6	-0.80 [-1.80, 0.19]
			Placebo	9	8 (88.9)	-0.95 (1.62)	-3.8	-1.90	-0.90	0.30	1.2	
		Week 14	Tezepelumab	10	9 (90.0)	-2.29 (1.08)	-4.2	-3.00	-2.20	-1.40	-1.0	-1.11 [-2.15, -0.08]
			Placebo	9	8 (88.9)	-0.68 (1.78)	-3.4	-1.70	-0.90	0.40	2.4	
		Week 16	Tezepelumab	10	9 (90.0)	-1.84 (1.59)	-4.4	-2.80	-2.20	-0.80	1.0	-0.64 [-1.62, 0.34]
			Placebo	9	8 (88.9)	-0.75 (1.84)	-3.6	-1.70	-1.10	0.40	2.4	
		Week 18	Tezepelumab	10	9 (90.0)	-2.16 (1.29)	-4.4	-3.00	-2.20	-0.80	-0.8	-0.87 [-1.88, 0.13]
			Placebo	9	8 (88.9)	-0.80 (1.80)	-3.6	-1.80	-0.90	0.10	2.4	
		Week 20	Tezepelumab	10	9 (90.0)	-2.11 (1.23)	-4.4	-2.80	-2.20	-1.20	-0.6	-0.63 [-1.61, 0.35]
			Placebo	9	8 (88.9)	-1.08 (2.03)	-3.6	-2.70	-1.10	0.10	2.4	
		Week 22	Tezepelumab	10	9 (90.0)	-2.18 (1.18)	-4.4	-3.00	-2.20	-1.20	-0.8	-0.76 [-1.75, 0.23]
			Placebo	9	8 (88.9)	-0.97 (1.95)	-3.8	-2.30	-1.10	0.20	2.4	
		Week 24	Tezepelumab	10	9 (90.0)	-2.11 (1.47)	-4.8	-3.00	-2.20	-1.40	0.2	-0.64 [-1.62, 0.34]
			Placebo	9	8 (88.9)	-1.13 (1.62)	-3.6	-2.10	-1.30	0.00	1.4	
		Week 26	Tezepelumab	10	9 (90.0)	-2.16 (1.30)	-4.4	-3.00	-2.20	-1.40	-0.4	-0.62 [-1.60, 0.36]
			Placebo	9	8 (88.9)	-1.25 (1.62)	-3.4	-2.20	-1.60	-0.20	1.4	
		Week 28	Tezepelumab	10	10 (100.0)	-2.18 (1.21)	-4.4	-3.00	-2.20	-1.40	-0.6	-0.70 [-1.66, 0.26]
			Placebo	9	8 (88.9)	-1.23 (1.54)	-3.4	-2.30	-1.30	-0.30	1.4	
		Week 30	Tezepelumab	10	10 (100.0)	-2.16 (1.24)	-4.4	-3.00	-2.30	-1.40	-0.4	-0.69 [-1.65, 0.27]
			Placebo	9	8 (88.9)	-1.23 (1.49)	-3.4	-2.10	-1.40	-0.40	1.4	
		Week 32	Tezepelumab	10	10 (100.0)	-2.02 (1.19)	-4.4	-2.80	-1.90	-1.00	-0.4	-0.49 [-1.44, 0.45]
			Placebo	9	8 (88.9)	-1.38 (1.44)	-3.2	-2.30	-1.60	-0.70	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
North America/Western EU	Change from baseline	Week 34	Tezepelumab	10	10 (100.0)	-2.00 (1.22)	-4.4	-2.60	-2.10	-1.00	-0.2	-0.49 [-1.43, 0.46]
			Placebo	9	8 (88.9)	-1.38 (1.35)	-3.2	-2.20	-1.40	-1.00	1.4	
		Week 36	Tezepelumab	10	10 (100.0)	-1.66 (1.56)	-4.4	-2.80	-1.80	0.00	0.4	-0.40 [-1.34, 0.54]
			Placebo	9	8 (88.9)	-1.08 (1.34)	-2.6	-2.00	-1.40	-0.30	1.4	
		Week 38	Tezepelumab	10	10 (100.0)	-2.08 (1.18)	-4.4	-2.60	-2.20	-1.40	-0.2	-0.76 [-1.72, 0.21]
			Placebo	9	8 (88.9)	-1.05 (1.57)	-2.8	-2.20	-1.50	0.20	1.4	
		Week 40	Tezepelumab	10	10 (100.0)	-2.02 (1.31)	-4.4	-3.00	-1.90	-1.40	0.2	-0.68 [-1.64, 0.28]
			Placebo	9	8 (88.9)	-1.13 (1.33)	-2.6	-2.10	-1.40	-0.40	1.4	
		Week 42	Tezepelumab	10	10 (100.0)	-2.08 (1.21)	-4.4	-3.00	-1.90	-1.40	-0.6	-0.64 [-1.59, 0.32]
			Placebo	9	8 (88.9)	-1.40 (0.85)	-2.6	-1.90	-1.50	-1.00	0.2	
		Week 44	Tezepelumab	10	10 (100.0)	-1.96 (1.25)	-4.4	-2.80	-1.80	-1.40	0.0	-0.58 [-1.53, 0.37]
			Placebo	9	8 (88.9)	-1.30 (0.99)	-2.6	-1.80	-1.40	-1.10	0.8	
		Week 46	Tezepelumab	10	10 (100.0)	-2.16 (1.20)	-4.4	-3.00	-2.20	-1.40	-0.2	-0.72 [-1.68, 0.24]
			Placebo	9	8 (88.9)	-1.35 (1.02)	-2.6	-1.60	-1.60	-1.40	1.0	
		Week 48	Tezepelumab	10	10 (100.0)	-2.10 (1.14)	-4.4	-2.80	-2.00	-1.40	-0.4	-0.58 [-1.53, 0.37]
			Placebo	9	8 (88.9)	-1.43 (1.18)	-2.8	-2.00	-1.70	-1.20	1.2	
		Week 50	Tezepelumab	10	10 (100.0)	-2.36 (1.12)	-4.4	-3.20	-2.40	-1.40	-0.8	-1.09 [-2.10, -0.09]
			Placebo	9	8 (88.9)	-1.08 (1.24)	-2.4	-1.60	-1.50	-0.80	1.6	
		Week 52	Tezepelumab	10	10 (100.0)	-2.20 (1.20)	-4.4	-3.20	-1.90	-1.20	-0.8	-0.84 [-1.82, 0.13]
			Placebo	9	8 (88.9)	-1.08 (1.49)	-2.6	-2.00	-1.50	-0.30	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	127	127 (100.0)	2.82 (0.82)	0.0	2.40	2.80	3.20	5.0	
			Placebo	129	129 (100.0)	2.80 (0.72)	0.4	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	127	122 (96.1)	2.30 (0.95)	0.0	1.60	2.40	3.00	4.4	
			Placebo	129	117 (90.7)	2.42 (0.84)	0.0	2.00	2.40	3.00	5.0	
		Week 4	Tezepelumab	127	122 (96.1)	1.98 (1.02)	0.0	1.20	2.20	2.80	4.2	
			Placebo	129	117 (90.7)	2.29 (0.86)	0.2	1.80	2.40	2.80	4.2	
		Week 6	Tezepelumab	127	122 (96.1)	1.88 (1.00)	0.0	1.20	1.80	2.60	4.2	
			Placebo	129	118 (91.5)	2.19 (1.00)	0.2	1.60	2.20	2.80	6.0	
		Week 8	Tezepelumab	127	122 (96.1)	1.84 (1.08)	0.0	1.00	1.80	2.80	5.2	
			Placebo	129	119 (92.2)	2.15 (0.97)	0.0	1.60	2.20	2.80	5.0	
		Week 10	Tezepelumab	127	122 (96.1)	1.77 (1.04)	0.0	1.00	1.80	2.60	4.8	
			Placebo	129	120 (93.0)	2.07 (0.91)	0.0	1.40	2.00	2.80	4.4	
		Week 12	Tezepelumab	127	122 (96.1)	1.68 (1.10)	0.0	0.80	1.60	2.60	4.8	
			Placebo	129	120 (93.0)	1.99 (0.98)	0.0	1.20	2.00	2.80	4.4	
		Week 14	Tezepelumab	127	122 (96.1)	1.56 (1.07)	0.0	0.80	1.40	2.40	4.8	
			Placebo	129	120 (93.0)	1.91 (0.91)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	127	122 (96.1)	1.70 (1.11)	0.0	0.80	1.60	2.60	4.8	
			Placebo	129	120 (93.0)	2.05 (1.05)	0.0	1.30	2.00	2.90	5.0	
		Week 18	Tezepelumab	127	123 (96.9)	1.59 (1.02)	0.0	1.00	1.60	2.40	4.8	
			Placebo	129	120 (93.0)	1.94 (1.00)	0.0	1.40	2.00	2.60	4.8	
		Week 20	Tezepelumab	127	123 (96.9)	1.69 (1.09)	0.0	0.80	1.80	2.60	5.0	
			Placebo	129	120 (93.0)	2.01 (0.99)	0.0	1.40	2.20	2.80	4.4	
		Week 22	Tezepelumab	127	123 (96.9)	1.72 (1.03)	0.0	1.00	1.80	2.40	4.8	
			Placebo	129	120 (93.0)	1.95 (1.01)	0.0	1.20	2.00	2.80	4.4	
		Week 24	Tezepelumab	127	123 (96.9)	1.70 (1.10)	0.0	0.80	1.80	2.60	4.8	
			Placebo	129	120 (93.0)	1.96 (1.01)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	127	124 (97.6)	1.66 (1.05)	0.0	1.00	1.60	2.40	4.8	
			Placebo	129	120 (93.0)	1.91 (1.00)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	127	124 (97.6)	1.74 (1.11)	0.0	1.00	1.80	2.60	4.8	
			Placebo	129	121 (93.8)	1.97 (1.09)	0.0	1.00	2.20	2.80	4.4	
		Week 30	Tezepelumab	127	125 (98.4)	1.67 (1.05)	0.0	0.80	1.60	2.40	4.8	
			Placebo	129	122 (94.6)	1.95 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	127	125 (98.4)	1.61 (1.09)	0.0	0.80	1.40	2.40	4.8	
			Placebo	129	122 (94.6)	1.91 (1.08)	0.0	1.00	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of world	Absolute values	Week 34	Tezepelumab	127	125 (98.4)	1.62 (1.14)	0.0	0.80	1.40	2.40	4.8	
			Placebo	129	122 (94.6)	1.87 (1.07)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	127	125 (98.4)	1.68 (1.13)	0.0	0.80	1.60	2.40	5.0	
			Placebo	129	122 (94.6)	1.94 (1.10)	0.0	1.00	2.00	2.80	4.8	
		Week 38	Tezepelumab	127	125 (98.4)	1.61 (1.12)	0.0	0.80	1.60	2.40	4.8	
			Placebo	129	122 (94.6)	1.86 (1.06)	0.0	1.00	1.80	2.80	4.8	
		Week 40	Tezepelumab	127	125 (98.4)	1.64 (1.12)	0.0	0.60	1.80	2.40	4.8	
			Placebo	129	122 (94.6)	1.94 (1.10)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	127	125 (98.4)	1.59 (1.11)	0.0	0.80	1.60	2.40	4.8	
			Placebo	129	122 (94.6)	1.93 (1.06)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	127	125 (98.4)	1.62 (1.11)	0.0	0.80	1.60	2.60	4.8	
			Placebo	129	123 (95.3)	1.97 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	127	125 (98.4)	1.60 (1.12)	0.0	0.80	1.60	2.40	4.8	
			Placebo	129	123 (95.3)	1.84 (1.03)	0.0	1.20	2.00	2.60	4.4	
		Week 48	Tezepelumab	127	125 (98.4)	1.66 (1.13)	0.0	0.80	1.80	2.40	4.8	
			Placebo	129	123 (95.3)	1.89 (1.08)	0.0	1.00	2.00	2.80	4.6	
		Week 50	Tezepelumab	127	125 (98.4)	1.59 (1.10)	0.0	0.80	1.40	2.20	4.8	
			Placebo	129	123 (95.3)	1.84 (1.01)	0.0	1.00	2.00	2.60	4.4	
		Week 52	Tezepelumab	127	125 (98.4)	1.60 (1.10)	0.0	0.80	1.60	2.20	4.8	
			Placebo	129	123 (95.3)	1.89 (1.04)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 2	Tezepelumab	127	122 (96.1)	-0.52 (0.69)	-3.0	-0.80	-0.40	0.00	0.8	-0.17 [-0.42, 0.09]
			Placebo	129	117 (90.7)	-0.40 (0.74)	-3.0	-0.80	-0.40	0.00	1.4	
		Week 4	Tezepelumab	127	122 (96.1)	-0.84 (0.95)	-3.8	-1.40	-0.80	-0.20	2.6	-0.35 [-0.60, -0.09]
			Placebo	129	117 (90.7)	-0.53 (0.88)	-3.0	-1.00	-0.40	0.00	1.6	
		Week 6	Tezepelumab	127	122 (96.1)	-0.94 (0.99)	-4.0	-1.60	-1.00	-0.20	2.6	-0.33 [-0.58, -0.07]
			Placebo	129	118 (91.5)	-0.62 (0.94)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	127	122 (96.1)	-0.98 (1.07)	-4.0	-1.60	-1.00	-0.40	2.6	-0.32 [-0.57, -0.06]
			Placebo	129	119 (92.2)	-0.67 (0.91)	-3.0	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	127	122 (96.1)	-1.05 (1.02)	-4.0	-1.60	-1.10	-0.40	2.6	-0.29 [-0.55, -0.04]
			Placebo	129	120 (93.0)	-0.76 (0.95)	-3.2	-1.40	-0.60	-0.10	2.6	
		Week 12	Tezepelumab	127	122 (96.1)	-1.14 (1.04)	-4.0	-1.80	-1.20	-0.40	2.6	-0.29 [-0.55, -0.04]
			Placebo	129	120 (93.0)	-0.83 (1.01)	-3.2	-1.40	-0.70	-0.20	1.6	
		Week 14	Tezepelumab	127	122 (96.1)	-1.26 (1.05)	-4.0	-2.00	-1.20	-0.60	2.6	-0.35 [-0.60, -0.10]
			Placebo	129	120 (93.0)	-0.91 (0.95)	-3.2	-1.40	-0.80	-0.40	1.4	
		Week 16	Tezepelumab	127	122 (96.1)	-1.12 (1.07)	-4.0	-1.80	-1.00	-0.40	2.6	-0.32 [-0.58, -0.07]
			Placebo	129	120 (93.0)	-0.78 (1.04)	-3.6	-1.40	-0.70	0.00	2.6	
		Week 18	Tezepelumab	127	123 (96.9)	-1.22 (1.04)	-4.0	-1.80	-1.00	-0.60	2.6	-0.32 [-0.57, -0.06]
			Placebo	129	120 (93.0)	-0.89 (1.03)	-3.4	-1.50	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	127	123 (96.9)	-1.12 (1.06)	-4.0	-1.80	-1.00	-0.40	2.6	-0.29 [-0.55, -0.04]
			Placebo	129	120 (93.0)	-0.81 (1.04)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	127	123 (96.9)	-1.09 (1.09)	-4.0	-1.80	-1.00	-0.40	2.6	-0.21 [-0.46, 0.04]
			Placebo	129	120 (93.0)	-0.87 (1.02)	-3.4	-1.60	-0.80	-0.20	2.6	
		Week 24	Tezepelumab	127	123 (96.9)	-1.11 (1.01)	-4.0	-1.80	-1.00	-0.40	2.6	-0.23 [-0.48, 0.02]
			Placebo	129	120 (93.0)	-0.87 (1.07)	-3.8	-1.50	-0.80	-0.20	2.6	
		Week 26	Tezepelumab	127	124 (97.6)	-1.14 (1.07)	-4.0	-2.00	-1.00	-0.40	2.6	-0.21 [-0.47, 0.04]
			Placebo	129	120 (93.0)	-0.92 (1.07)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 28	Tezepelumab	127	124 (97.6)	-1.06 (1.08)	-4.0	-1.80	-1.00	-0.20	2.6	-0.21 [-0.46, 0.04]
			Placebo	129	121 (93.8)	-0.83 (1.12)	-4.2	-1.60	-0.80	-0.20	2.6	
		Week 30	Tezepelumab	127	125 (98.4)	-1.15 (1.11)	-3.8	-1.80	-1.00	-0.40	2.6	-0.26 [-0.51, -0.01]
			Placebo	129	122 (94.6)	-0.85 (1.13)	-3.4	-1.60	-0.80	-0.20	2.6	
		Week 32	Tezepelumab	127	125 (98.4)	-1.20 (1.11)	-4.0	-2.00	-1.00	-0.60	2.6	-0.28 [-0.53, -0.03]
			Placebo	129	122 (94.6)	-0.90 (1.10)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 34	Tezepelumab	127	125 (98.4)	-1.19 (1.14)	-4.0	-2.00	-1.20	-0.40	2.6	-0.23 [-0.48, 0.02]
			Placebo	129	122 (94.6)	-0.94 (1.11)	-4.2	-1.60	-1.00	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of world	Change from baseline	Week 36	Tezepelumab	127	125 (98.4)	-1.13 (1.16)	-4.0	-2.00	-1.20	-0.40	2.6	-0.23 [-0.48, 0.02]
			Placebo	129	122 (94.6)	-0.87 (1.16)	-3.6	-1.40	-0.80	0.00	2.6	
		Week 38	Tezepelumab	127	125 (98.4)	-1.20 (1.17)	-4.0	-2.00	-1.20	-0.40	2.6	-0.22 [-0.47, 0.03]
			Placebo	129	122 (94.6)	-0.95 (1.13)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 40	Tezepelumab	127	125 (98.4)	-1.18 (1.17)	-4.2	-2.00	-1.00	-0.40	2.6	-0.27 [-0.52, -0.02]
			Placebo	129	122 (94.6)	-0.86 (1.12)	-4.2	-1.60	-0.80	-0.20	2.6	
		Week 42	Tezepelumab	127	125 (98.4)	-1.22 (1.17)	-4.0	-2.00	-1.20	-0.40	2.6	-0.29 [-0.54, -0.04]
			Placebo	129	122 (94.6)	-0.88 (1.12)	-4.2	-1.40	-0.80	-0.20	2.6	
		Week 44	Tezepelumab	127	125 (98.4)	-1.20 (1.19)	-4.4	-2.00	-1.20	-0.40	2.6	-0.31 [-0.56, -0.06]
			Placebo	129	123 (95.3)	-0.84 (1.14)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 46	Tezepelumab	127	125 (98.4)	-1.21 (1.17)	-4.0	-2.00	-1.20	-0.40	2.6	-0.22 [-0.47, 0.03]
			Placebo	129	123 (95.3)	-0.96 (1.10)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	127	125 (98.4)	-1.15 (1.17)	-4.0	-2.00	-1.00	-0.40	2.6	-0.20 [-0.45, 0.05]
			Placebo	129	123 (95.3)	-0.92 (1.12)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 50	Tezepelumab	127	125 (98.4)	-1.23 (1.16)	-4.0	-2.00	-1.20	-0.40	2.6	-0.23 [-0.48, 0.02]
			Placebo	129	123 (95.3)	-0.97 (1.08)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 52	Tezepelumab	127	125 (98.4)	-1.21 (1.17)	-4.0	-2.00	-1.20	-0.40	2.6	-0.26 [-0.51, -0.01]
			Placebo	129	123 (95.3)	-0.92 (1.09)	-4.2	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	61	61 (100.0)	2.82 (0.76)	0.0	2.40	2.80	3.20	5.0	
			Placebo	60	60 (100.0)	2.94 (0.66)	1.8	2.60	2.80	3.20	5.0	
		Week 2	Tezepelumab	61	58 (95.1)	2.31 (0.91)	0.0	1.80	2.60	2.80	3.8	
			Placebo	60	55 (91.7)	2.38 (0.88)	0.4	1.80	2.40	3.00	5.0	
		Week 4	Tezepelumab	61	58 (95.1)	2.00 (0.91)	0.0	1.40	2.20	2.60	3.6	
			Placebo	60	55 (91.7)	2.15 (0.92)	0.2	1.40	2.20	2.80	4.2	
		Week 6	Tezepelumab	61	58 (95.1)	1.93 (0.91)	0.0	1.40	1.90	2.60	3.6	
			Placebo	60	55 (91.7)	2.10 (1.11)	0.2	1.40	2.00	2.80	6.0	
		Week 8	Tezepelumab	61	58 (95.1)	1.87 (0.94)	0.0	1.20	1.90	2.80	3.6	
			Placebo	60	55 (91.7)	2.10 (1.03)	0.0	1.40	2.00	2.80	5.0	
		Week 10	Tezepelumab	61	58 (95.1)	1.81 (0.97)	0.0	1.20	1.80	2.40	4.8	
			Placebo	60	55 (91.7)	2.09 (0.94)	0.2	1.40	2.00	3.00	4.4	
		Week 12	Tezepelumab	61	58 (95.1)	1.75 (1.04)	0.0	1.00	1.60	2.60	4.8	
			Placebo	60	55 (91.7)	1.95 (0.94)	0.0	1.20	2.00	2.60	4.4	
		Week 14	Tezepelumab	61	58 (95.1)	1.61 (0.94)	0.0	1.00	1.40	2.20	4.8	
			Placebo	60	55 (91.7)	1.94 (0.95)	0.0	1.20	2.00	2.80	5.0	
		Week 16	Tezepelumab	61	58 (95.1)	1.81 (1.08)	0.0	1.00	1.80	2.60	4.8	
			Placebo	60	55 (91.7)	1.99 (1.06)	0.0	1.20	2.00	2.80	5.0	
		Week 18	Tezepelumab	61	59 (96.7)	1.66 (0.89)	0.0	1.00	1.60	2.20	4.8	
			Placebo	60	55 (91.7)	1.92 (1.11)	0.0	1.00	1.80	2.80	4.8	
		Week 20	Tezepelumab	61	59 (96.7)	1.78 (0.97)	0.0	1.20	1.80	2.60	4.8	
			Placebo	60	55 (91.7)	1.93 (1.03)	0.0	1.00	2.00	2.80	4.4	
		Week 22	Tezepelumab	61	59 (96.7)	1.80 (0.94)	0.0	1.00	1.80	2.60	4.8	
			Placebo	60	55 (91.7)	1.88 (1.05)	0.0	1.00	1.80	2.80	4.4	
		Week 24	Tezepelumab	61	59 (96.7)	1.80 (1.08)	0.0	1.00	1.80	2.60	4.8	
			Placebo	60	55 (91.7)	1.92 (1.07)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	61	60 (98.4)	1.72 (0.99)	0.0	1.00	1.60	2.40	4.8	
			Placebo	60	55 (91.7)	1.87 (1.04)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	61	60 (98.4)	1.82 (1.03)	0.0	1.10	1.80	2.70	4.8	
			Placebo	60	55 (91.7)	1.99 (1.14)	0.0	1.00	2.20	2.80	4.4	
		Week 30	Tezepelumab	61	61 (100.0)	1.72 (1.04)	0.0	1.00	1.80	2.40	4.8	
			Placebo	60	55 (91.7)	1.82 (1.10)	0.0	0.80	1.80	3.00	4.4	
		Week 32	Tezepelumab	61	61 (100.0)	1.69 (1.01)	0.0	1.00	1.40	2.40	4.8	
			Placebo	60	55 (91.7)	1.87 (1.15)	0.0	0.80	1.80	3.00	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 250 cells/uL	Absolute values	Week 34	Tezepelumab	61	61 (100.0)	1.69 (1.07)	0.0	1.00	1.40	2.60	4.8	
			Placebo	60	55 (91.7)	1.85 (1.15)	0.0	1.00	1.60	2.80	4.8	
		Week 36	Tezepelumab	61	61 (100.0)	1.70 (1.00)	0.0	1.00	1.80	2.40	4.8	
			Placebo	60	55 (91.7)	1.87 (1.16)	0.0	0.80	2.00	2.80	4.8	
		Week 38	Tezepelumab	61	61 (100.0)	1.69 (1.03)	0.0	1.00	1.60	2.40	4.8	
			Placebo	60	55 (91.7)	1.84 (1.14)	0.0	1.00	1.80	2.80	4.8	
		Week 40	Tezepelumab	61	61 (100.0)	1.76 (1.06)	0.0	1.00	2.00	2.40	4.8	
			Placebo	60	55 (91.7)	1.86 (1.17)	0.0	0.80	1.80	3.00	4.4	
		Week 42	Tezepelumab	61	61 (100.0)	1.67 (1.05)	0.0	1.00	1.80	2.20	4.8	
			Placebo	60	55 (91.7)	1.84 (1.06)	0.0	0.80	2.00	2.60	4.4	
		Week 44	Tezepelumab	61	61 (100.0)	1.74 (1.04)	0.0	1.00	1.80	2.60	4.8	
			Placebo	60	55 (91.7)	1.93 (1.12)	0.0	0.80	2.00	2.80	4.4	
		Week 46	Tezepelumab	61	61 (100.0)	1.70 (1.03)	0.0	1.00	1.80	2.40	4.8	
			Placebo	60	55 (91.7)	1.83 (1.07)	0.0	1.00	2.00	2.80	4.4	
		Week 48	Tezepelumab	61	61 (100.0)	1.70 (1.02)	0.0	1.00	1.80	2.40	4.8	
			Placebo	60	55 (91.7)	1.83 (1.13)	0.0	0.80	2.00	2.80	4.4	
		Week 50	Tezepelumab	61	61 (100.0)	1.63 (1.05)	0.0	0.80	1.80	2.20	4.8	
			Placebo	60	55 (91.7)	1.91 (1.07)	0.0	1.00	1.80	2.80	4.4	
		Week 52	Tezepelumab	61	61 (100.0)	1.61 (1.06)	0.0	0.80	1.80	2.20	4.8	
			Placebo	60	55 (91.7)	1.92 (1.08)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 2	Tezepelumab	61	58 (95.1)	-0.52 (0.79)	-3.2	-0.80	-0.30	0.00	0.4	0.01 [-0.36, 0.38]
			Placebo	60	55 (91.7)	-0.53 (0.73)	-2.8	-0.80	-0.40	0.00	1.2	
		Week 4	Tezepelumab	61	58 (95.1)	-0.83 (0.82)	-3.0	-1.40	-0.70	-0.20	0.8	-0.08 [-0.45, 0.29]
			Placebo	60	55 (91.7)	-0.76 (0.87)	-3.0	-1.40	-0.80	0.00	1.4	
		Week 6	Tezepelumab	61	58 (95.1)	-0.90 (0.88)	-3.2	-1.60	-0.80	-0.20	0.6	-0.10 [-0.47, 0.27]
			Placebo	60	55 (91.7)	-0.81 (0.93)	-3.4	-1.40	-0.80	-0.20	1.4	
		Week 8	Tezepelumab	61	58 (95.1)	-0.96 (0.91)	-3.2	-1.60	-0.90	-0.40	0.8	-0.17 [-0.54, 0.20]
			Placebo	60	55 (91.7)	-0.81 (0.88)	-3.0	-1.40	-0.80	0.00	1.0	
		Week 10	Tezepelumab	61	58 (95.1)	-1.02 (0.96)	-3.2	-1.60	-1.00	-0.20	1.0	-0.22 [-0.59, 0.15]
			Placebo	60	55 (91.7)	-0.82 (0.91)	-3.2	-1.40	-0.80	-0.20	1.6	
		Week 12	Tezepelumab	61	58 (95.1)	-1.08 (0.93)	-3.0	-1.80	-1.10	-0.20	0.6	-0.12 [-0.49, 0.24]
			Placebo	60	55 (91.7)	-0.96 (0.93)	-3.2	-1.40	-0.80	-0.60	0.8	
		Week 14	Tezepelumab	61	58 (95.1)	-1.22 (0.90)	-3.2	-1.80	-1.30	-0.60	0.6	-0.28 [-0.65, 0.09]
			Placebo	60	55 (91.7)	-0.97 (0.90)	-3.2	-1.60	-1.00	-0.40	0.8	
		Week 16	Tezepelumab	61	58 (95.1)	-1.02 (1.05)	-3.0	-1.80	-1.00	-0.20	1.8	-0.10 [-0.47, 0.27]
			Placebo	60	55 (91.7)	-0.92 (0.94)	-3.0	-1.40	-1.00	0.00	1.0	
		Week 18	Tezepelumab	61	59 (96.7)	-1.16 (0.90)	-3.4	-1.80	-1.00	-0.60	0.6	-0.18 [-0.55, 0.19]
			Placebo	60	55 (91.7)	-0.99 (1.00)	-3.2	-1.60	-1.00	-0.20	1.4	
		Week 20	Tezepelumab	61	59 (96.7)	-1.03 (0.94)	-3.0	-1.80	-1.00	-0.40	0.6	-0.06 [-0.43, 0.31]
			Placebo	60	55 (91.7)	-0.98 (0.99)	-3.0	-1.60	-0.80	-0.40	1.2	
		Week 22	Tezepelumab	61	59 (96.7)	-1.02 (1.05)	-3.4	-1.80	-0.80	-0.40	2.0	0.01 [-0.36, 0.38]
			Placebo	60	55 (91.7)	-1.03 (0.97)	-3.2	-1.60	-1.20	-0.20	0.6	
		Week 24	Tezepelumab	61	59 (96.7)	-1.02 (0.93)	-3.2	-1.80	-1.00	-0.20	0.6	-0.03 [-0.40, 0.34]
			Placebo	60	55 (91.7)	-0.99 (1.02)	-3.2	-1.60	-1.00	-0.20	0.8	
		Week 26	Tezepelumab	61	60 (98.4)	-1.08 (0.99)	-3.2	-1.80	-1.00	-0.20	0.6	-0.03 [-0.40, 0.33]
			Placebo	60	55 (91.7)	-1.04 (0.94)	-3.0	-1.80	-1.20	-0.40	0.8	
		Week 28	Tezepelumab	61	60 (98.4)	-0.98 (1.03)	-3.2	-1.80	-1.00	-0.10	1.0	-0.06 [-0.43, 0.30]
			Placebo	60	55 (91.7)	-0.92 (1.03)	-3.0	-1.60	-0.80	-0.20	1.2	
		Week 30	Tezepelumab	61	61 (100.0)	-1.10 (1.09)	-3.2	-1.80	-1.00	-0.40	2.0	-0.01 [-0.37, 0.36]
			Placebo	60	55 (91.7)	-1.09 (0.97)	-3.2	-1.80	-1.00	-0.40	0.8	
		Week 32	Tezepelumab	61	61 (100.0)	-1.13 (1.04)	-3.6	-1.80	-1.00	-0.60	1.2	-0.09 [-0.46, 0.27]
			Placebo	60	55 (91.7)	-1.04 (1.05)	-3.2	-1.60	-1.20	-0.40	1.8	
		Week 34	Tezepelumab	61	61 (100.0)	-1.13 (1.11)	-3.8	-2.00	-1.00	-0.40	2.2	-0.07 [-0.43, 0.30]
			Placebo	60	55 (91.7)	-1.06 (1.01)	-3.2	-1.60	-1.20	-0.40	1.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 250 cells/uL	Change from baseline	Week 36	Tezepelumab	61	61 (100.0)	-1.11 (1.03)	-3.6	-1.80	-1.00	-0.40	1.6	-0.06 [-0.43, 0.30]
			Placebo	60	55 (91.7)	-1.04 (1.10)	-3.6	-1.60	-1.00	-0.20	1.8	
		Week 38	Tezepelumab	61	61 (100.0)	-1.12 (1.09)	-3.8	-1.80	-1.00	-0.40	2.6	-0.05 [-0.42, 0.31]
			Placebo	60	55 (91.7)	-1.07 (1.08)	-3.2	-1.60	-1.20	-0.40	1.8	
		Week 40	Tezepelumab	61	61 (100.0)	-1.06 (1.12)	-4.2	-1.60	-1.00	-0.20	1.8	-0.01 [-0.37, 0.36]
			Placebo	60	55 (91.7)	-1.05 (1.03)	-3.2	-1.60	-1.20	-0.20	0.8	
		Week 42	Tezepelumab	61	61 (100.0)	-1.15 (1.09)	-3.6	-1.80	-1.00	-0.40	2.2	-0.08 [-0.45, 0.28]
			Placebo	60	55 (91.7)	-1.07 (0.93)	-3.0	-1.60	-1.00	-0.20	0.8	
		Week 44	Tezepelumab	61	61 (100.0)	-1.07 (1.10)	-3.8	-1.80	-1.00	-0.20	1.6	-0.09 [-0.46, 0.27]
			Placebo	60	55 (91.7)	-0.97 (1.04)	-3.4	-1.60	-1.00	0.00	0.8	
		Week 46	Tezepelumab	61	61 (100.0)	-1.11 (1.07)	-3.6	-1.80	-1.00	-0.20	1.8	-0.03 [-0.40, 0.33]
			Placebo	60	55 (91.7)	-1.08 (1.00)	-3.2	-1.60	-1.20	-0.40	1.0	
		Week 48	Tezepelumab	61	61 (100.0)	-1.11 (1.04)	-3.6	-1.80	-1.00	-0.40	2.0	-0.03 [-0.39, 0.33]
			Placebo	60	55 (91.7)	-1.08 (1.08)	-3.4	-1.60	-1.00	-0.40	1.2	
		Week 50	Tezepelumab	61	61 (100.0)	-1.19 (1.11)	-3.8	-1.80	-1.00	-0.40	2.0	-0.17 [-0.54, 0.19]
			Placebo	60	55 (91.7)	-1.00 (1.03)	-3.6	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	61	61 (100.0)	-1.20 (1.14)	-3.8	-2.00	-1.00	-0.40	2.0	-0.20 [-0.56, 0.17]
			Placebo	60	55 (91.7)	-0.99 (1.06)	-3.6	-1.60	-1.00	-0.40	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	76	76 (100.0)	2.86 (0.91)	0.2	2.40	2.80	3.40	5.2	
			Placebo	78	78 (100.0)	2.73 (0.76)	0.4	2.20	3.00	3.20	4.2	
		Week 2	Tezepelumab	76	73 (96.1)	2.23 (1.01)	0.0	1.60	2.20	3.00	4.4	
			Placebo	78	70 (89.7)	2.45 (0.81)	0.0	2.00	2.60	3.00	4.4	
		Week 4	Tezepelumab	76	73 (96.1)	1.92 (1.09)	0.0	1.20	2.00	2.80	4.2	
			Placebo	78	70 (89.7)	2.42 (0.83)	0.4	1.80	2.50	3.00	4.4	
		Week 6	Tezepelumab	76	73 (96.1)	1.82 (1.08)	0.0	1.00	1.80	2.60	4.2	
			Placebo	78	71 (91.0)	2.27 (0.94)	0.2	1.80	2.40	2.80	5.0	
		Week 8	Tezepelumab	76	73 (96.1)	1.73 (1.19)	0.0	0.80	1.60	2.60	5.2	
			Placebo	78	72 (92.3)	2.17 (0.99)	0.0	1.60	2.40	2.90	4.4	
		Week 10	Tezepelumab	76	73 (96.1)	1.65 (1.12)	0.0	0.80	1.60	2.60	4.2	
			Placebo	78	73 (93.6)	2.05 (0.98)	0.0	1.40	2.00	2.60	5.2	
		Week 12	Tezepelumab	76	73 (96.1)	1.55 (1.12)	0.0	0.60	1.60	2.40	4.2	
			Placebo	78	73 (93.6)	2.03 (1.04)	0.0	1.20	2.20	2.80	4.4	
		Week 14	Tezepelumab	76	73 (96.1)	1.42 (1.14)	0.0	0.60	1.40	2.20	4.2	
			Placebo	78	73 (93.6)	1.93 (0.95)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	76	73 (96.1)	1.56 (1.12)	0.0	0.60	1.40	2.40	4.2	
			Placebo	78	73 (93.6)	2.12 (1.10)	0.0	1.60	2.20	3.00	5.0	
		Week 18	Tezepelumab	76	73 (96.1)	1.46 (1.10)	0.0	0.60	1.20	2.40	4.2	
			Placebo	78	73 (93.6)	1.98 (0.97)	0.0	1.40	2.00	2.60	5.0	
		Week 20	Tezepelumab	76	73 (96.1)	1.53 (1.15)	0.0	0.60	1.40	2.40	5.0	
			Placebo	78	73 (93.6)	2.06 (1.05)	0.0	1.40	2.20	2.80	5.0	
		Week 22	Tezepelumab	76	73 (96.1)	1.56 (1.08)	0.0	0.60	1.60	2.40	4.2	
			Placebo	78	73 (93.6)	2.02 (1.04)	0.0	1.40	2.00	2.60	5.0	
		Week 24	Tezepelumab	76	73 (96.1)	1.54 (1.09)	0.0	0.60	1.60	2.40	4.2	
			Placebo	78	73 (93.6)	1.97 (1.00)	0.0	1.20	2.20	2.80	4.0	
		Week 26	Tezepelumab	76	73 (96.1)	1.52 (1.09)	0.0	0.80	1.40	2.40	4.2	
			Placebo	78	73 (93.6)	1.93 (1.00)	0.0	1.20	1.80	2.60	4.4	
		Week 28	Tezepelumab	76	74 (97.4)	1.56 (1.15)	0.0	0.40	1.50	2.40	4.2	
			Placebo	78	74 (94.9)	1.93 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	76	74 (97.4)	1.52 (1.05)	0.0	0.60	1.40	2.20	4.2	
			Placebo	78	75 (96.2)	2.03 (1.05)	0.0	1.20	2.20	2.80	4.2	
		Week 32	Tezepelumab	76	74 (97.4)	1.47 (1.12)	0.0	0.60	1.40	2.40	4.2	
			Placebo	78	75 (96.2)	1.91 (1.03)	0.0	1.00	1.80	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 250 cells/uL	Absolute values	Week 34	Tezepelumab	76	74 (97.4)	1.49 (1.16)	0.0	0.60	1.30	2.20	4.2	
			Placebo	78	75 (96.2)	1.86 (1.04)	0.0	1.00	2.00	2.60	4.0	
		Week 36	Tezepelumab	76	74 (97.4)	1.62 (1.20)	0.0	0.60	1.60	2.40	5.0	
			Placebo	78	75 (96.2)	1.99 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 38	Tezepelumab	76	74 (97.4)	1.46 (1.15)	0.0	0.60	1.20	2.20	4.6	
			Placebo	78	75 (96.2)	1.87 (1.02)	0.0	1.00	2.00	2.60	4.0	
		Week 40	Tezepelumab	76	74 (97.4)	1.45 (1.13)	0.0	0.40	1.40	2.20	4.2	
			Placebo	78	75 (96.2)	1.99 (1.05)	0.0	1.20	2.20	2.80	4.4	
		Week 42	Tezepelumab	76	74 (97.4)	1.45 (1.13)	0.0	0.60	1.20	2.20	4.6	
			Placebo	78	75 (96.2)	1.95 (1.05)	0.0	1.20	2.00	2.60	4.6	
		Week 44	Tezepelumab	76	74 (97.4)	1.44 (1.12)	0.0	0.40	1.20	2.40	4.2	
			Placebo	78	76 (97.4)	1.97 (1.04)	0.0	1.20	2.00	2.70	4.2	
		Week 46	Tezepelumab	76	74 (97.4)	1.42 (1.15)	0.0	0.60	1.00	2.20	4.2	
			Placebo	78	76 (97.4)	1.83 (0.99)	0.0	1.20	2.00	2.60	4.4	
		Week 48	Tezepelumab	76	74 (97.4)	1.53 (1.19)	0.0	0.40	1.40	2.60	4.2	
			Placebo	78	76 (97.4)	1.89 (1.03)	0.0	1.00	2.00	2.60	4.6	
		Week 50	Tezepelumab	76	74 (97.4)	1.43 (1.13)	0.0	0.60	1.20	2.20	4.2	
			Placebo	78	76 (97.4)	1.80 (0.97)	0.0	1.00	2.00	2.60	4.0	
		Week 52	Tezepelumab	76	74 (97.4)	1.49 (1.12)	0.0	0.60	1.30	2.20	4.4	
			Placebo	78	76 (97.4)	1.87 (1.02)	0.0	1.00	2.00	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 2	Tezepelumab	76	73 (96.1)	-0.61 (0.71)	-2.2	-1.20	-0.60	-0.20	0.8	-0.39 [-0.72, -0.06]
			Placebo	78	70 (89.7)	-0.32 (0.79)	-3.0	-0.80	-0.20	0.20	1.4	
		Week 4	Tezepelumab	76	73 (96.1)	-0.92 (1.07)	-3.8	-1.60	-0.80	-0.20	2.6	-0.58 [-0.91, -0.24]
			Placebo	78	70 (89.7)	-0.35 (0.90)	-3.0	-1.00	-0.20	0.40	1.6	
		Week 6	Tezepelumab	76	73 (96.1)	-1.02 (1.15)	-4.0	-1.60	-1.00	-0.40	2.6	-0.50 [-0.83, -0.17]
			Placebo	78	71 (91.0)	-0.49 (0.97)	-3.2	-1.20	-0.40	0.20	1.6	
		Week 8	Tezepelumab	76	73 (96.1)	-1.12 (1.21)	-4.0	-1.80	-1.20	-0.40	2.6	-0.46 [-0.79, -0.13]
			Placebo	78	72 (92.3)	-0.60 (1.03)	-3.6	-1.10	-0.50	0.20	1.0	
		Week 10	Tezepelumab	76	73 (96.1)	-1.19 (1.13)	-4.0	-1.80	-1.20	-0.60	2.6	-0.42 [-0.75, -0.09]
			Placebo	78	73 (93.6)	-0.73 (1.10)	-3.8	-1.20	-0.60	0.00	2.6	
		Week 12	Tezepelumab	76	73 (96.1)	-1.30 (1.16)	-4.0	-2.00	-1.20	-0.60	2.6	-0.48 [-0.81, -0.15]
			Placebo	78	73 (93.6)	-0.75 (1.13)	-3.8	-1.40	-0.60	0.00	1.6	
		Week 14	Tezepelumab	76	73 (96.1)	-1.42 (1.20)	-4.2	-2.20	-1.40	-0.80	2.6	-0.50 [-0.83, -0.17]
			Placebo	78	73 (93.6)	-0.85 (1.08)	-3.4	-1.40	-0.80	-0.20	2.4	
		Week 16	Tezepelumab	76	73 (96.1)	-1.29 (1.17)	-4.4	-2.00	-1.20	-0.60	2.6	-0.53 [-0.86, -0.20]
			Placebo	78	73 (93.6)	-0.67 (1.20)	-3.6	-1.40	-0.40	0.00	2.6	
		Week 18	Tezepelumab	76	73 (96.1)	-1.38 (1.21)	-4.4	-2.20	-1.40	-0.80	2.6	-0.49 [-0.82, -0.16]
			Placebo	78	73 (93.6)	-0.81 (1.14)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 20	Tezepelumab	76	73 (96.1)	-1.32 (1.20)	-4.4	-2.00	-1.40	-0.60	2.6	-0.50 [-0.83, -0.17]
			Placebo	78	73 (93.6)	-0.72 (1.20)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	76	73 (96.1)	-1.28 (1.17)	-4.4	-2.00	-1.20	-0.60	2.6	-0.45 [-0.78, -0.12]
			Placebo	78	73 (93.6)	-0.76 (1.16)	-3.8	-1.40	-0.60	-0.20	2.6	
		Week 24	Tezepelumab	76	73 (96.1)	-1.31 (1.16)	-4.8	-2.00	-1.40	-0.60	2.6	-0.43 [-0.76, -0.10]
			Placebo	78	73 (93.6)	-0.81 (1.17)	-3.8	-1.40	-0.80	0.00	2.6	
		Week 26	Tezepelumab	76	73 (96.1)	-1.32 (1.19)	-4.4	-2.20	-1.40	-0.60	2.6	-0.39 [-0.72, -0.06]
			Placebo	78	73 (93.6)	-0.85 (1.21)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 28	Tezepelumab	76	74 (97.4)	-1.28 (1.19)	-4.4	-2.20	-1.20	-0.60	2.6	-0.39 [-0.71, -0.06]
			Placebo	78	74 (94.9)	-0.82 (1.23)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 30	Tezepelumab	76	74 (97.4)	-1.33 (1.18)	-4.4	-2.20	-1.20	-0.60	2.6	-0.50 [-0.82, -0.17]
			Placebo	78	75 (96.2)	-0.72 (1.25)	-3.4	-1.40	-0.60	0.00	2.6	
		Week 32	Tezepelumab	76	74 (97.4)	-1.38 (1.20)	-4.4	-2.20	-1.40	-0.80	2.6	-0.45 [-0.77, -0.12]
			Placebo	78	75 (96.2)	-0.85 (1.18)	-3.6	-1.80	-0.80	-0.20	2.6	
		Week 34	Tezepelumab	76	74 (97.4)	-1.35 (1.19)	-4.4	-2.20	-1.40	-0.80	2.6	-0.38 [-0.71, -0.06]
			Placebo	78	75 (96.2)	-0.90 (1.20)	-4.2	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 250 cells/uL	Change from baseline	Week 36	Tezepelumab	76	74 (97.4)	-1.22 (1.33)	-4.4	-2.20	-1.20	-0.20	2.6	-0.36 [-0.69, -0.04]
			Placebo	78	75 (96.2)	-0.76 (1.21)	-3.6	-1.40	-0.60	0.00	2.6	
		Week 38	Tezepelumab	76	74 (97.4)	-1.38 (1.26)	-4.4	-2.20	-1.30	-0.60	2.6	-0.41 [-0.73, -0.08]
			Placebo	78	75 (96.2)	-0.88 (1.20)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 40	Tezepelumab	76	74 (97.4)	-1.39 (1.24)	-4.4	-2.20	-1.40	-0.60	2.6	-0.52 [-0.84, -0.19]
			Placebo	78	75 (96.2)	-0.76 (1.19)	-4.2	-1.40	-0.80	0.00	2.6	
		Week 42	Tezepelumab	76	74 (97.4)	-1.39 (1.26)	-4.4	-2.20	-1.60	-0.60	2.6	-0.48 [-0.80, -0.15]
			Placebo	78	75 (96.2)	-0.80 (1.23)	-4.2	-1.40	-0.80	0.00	2.6	
		Week 44	Tezepelumab	76	74 (97.4)	-1.40 (1.28)	-4.4	-2.20	-1.30	-0.60	2.6	-0.50 [-0.82, -0.17]
			Placebo	78	76 (97.4)	-0.78 (1.20)	-4.2	-1.50	-0.60	0.00	2.6	
		Week 46	Tezepelumab	76	74 (97.4)	-1.42 (1.27)	-4.4	-2.20	-1.40	-0.80	2.6	-0.41 [-0.73, -0.09]
			Placebo	78	76 (97.4)	-0.92 (1.17)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 48	Tezepelumab	76	74 (97.4)	-1.31 (1.30)	-4.4	-2.20	-1.30	-0.40	2.6	-0.37 [-0.70, -0.05]
			Placebo	78	76 (97.4)	-0.86 (1.16)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 50	Tezepelumab	76	74 (97.4)	-1.41 (1.25)	-4.4	-2.20	-1.60	-0.60	2.6	-0.39 [-0.71, -0.07]
			Placebo	78	76 (97.4)	-0.95 (1.12)	-4.2	-1.60	-0.90	-0.20	2.6	
		Week 52	Tezepelumab	76	74 (97.4)	-1.35 (1.25)	-4.4	-2.20	-1.40	-0.60	2.6	-0.39 [-0.71, -0.07]
			Placebo	78	76 (97.4)	-0.88 (1.15)	-4.2	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	75	75 (100.0)	2.81 (0.70)	0.8	2.40	2.80	3.20	5.0	
			Placebo	72	72 (100.0)	2.77 (0.66)	0.4	2.40	2.80	3.20	4.2	
		Week 2	Tezepelumab	75	70 (93.3)	2.29 (0.99)	0.0	1.60	2.40	3.00	4.4	
			Placebo	72	64 (88.9)	2.32 (0.72)	0.4	1.90	2.40	2.90	4.4	
		Week 4	Tezepelumab	75	70 (93.3)	2.01 (0.91)	0.0	1.40	2.10	2.80	3.6	
			Placebo	72	64 (88.9)	2.15 (0.82)	0.2	1.60	2.20	2.80	4.2	
		Week 6	Tezepelumab	75	70 (93.3)	1.95 (0.93)	0.0	1.40	1.80	2.60	4.0	
			Placebo	72	64 (88.9)	2.07 (0.90)	0.2	1.50	2.20	2.60	5.0	
		Week 8	Tezepelumab	75	70 (93.3)	1.88 (1.05)	0.0	1.20	1.70	2.80	5.2	
			Placebo	72	64 (88.9)	2.14 (0.88)	0.0	1.60	2.10	2.80	4.0	
		Week 10	Tezepelumab	75	70 (93.3)	1.81 (1.05)	0.0	1.20	1.80	2.60	4.8	
			Placebo	72	65 (90.3)	2.00 (0.86)	0.0	1.40	2.00	2.40	4.2	
		Week 12	Tezepelumab	75	70 (93.3)	1.77 (1.09)	0.0	0.80	1.70	2.60	4.8	
			Placebo	72	65 (90.3)	1.96 (0.91)	0.0	1.40	2.00	2.60	4.4	
		Week 14	Tezepelumab	75	70 (93.3)	1.59 (1.05)	0.0	0.80	1.50	2.20	4.8	
			Placebo	72	65 (90.3)	1.90 (0.86)	0.0	1.20	1.80	2.60	4.2	
		Week 16	Tezepelumab	75	70 (93.3)	1.82 (1.12)	0.0	1.00	1.80	2.60	4.8	
			Placebo	72	65 (90.3)	2.01 (0.91)	0.0	1.40	2.00	2.80	3.8	
		Week 18	Tezepelumab	75	71 (94.7)	1.71 (1.01)	0.0	1.00	1.80	2.40	4.8	
			Placebo	72	65 (90.3)	1.94 (0.95)	0.0	1.40	1.80	2.40	4.8	
		Week 20	Tezepelumab	75	71 (94.7)	1.81 (1.10)	0.0	1.00	1.80	2.60	5.0	
			Placebo	72	65 (90.3)	1.95 (0.95)	0.0	1.40	2.00	2.80	3.8	
		Week 22	Tezepelumab	75	71 (94.7)	1.76 (1.04)	0.0	1.00	2.00	2.60	4.8	
			Placebo	72	65 (90.3)	1.89 (0.94)	0.0	1.20	2.00	2.60	4.0	
		Week 24	Tezepelumab	75	71 (94.7)	1.75 (1.07)	0.0	0.80	1.80	2.60	4.8	
			Placebo	72	65 (90.3)	1.85 (0.96)	0.0	1.00	2.00	2.60	3.8	
		Week 26	Tezepelumab	75	72 (96.0)	1.77 (1.09)	0.0	1.00	1.80	2.60	4.8	
			Placebo	72	65 (90.3)	1.81 (0.90)	0.0	1.00	1.80	2.40	4.4	
		Week 28	Tezepelumab	75	73 (97.3)	1.76 (1.12)	0.0	1.00	1.80	2.80	4.8	
			Placebo	72	66 (91.7)	1.93 (0.99)	0.0	1.00	2.20	2.60	4.4	
		Week 30	Tezepelumab	75	74 (98.7)	1.74 (1.08)	0.0	0.80	1.70	2.60	4.8	
			Placebo	72	67 (93.1)	1.95 (0.97)	0.0	1.00	2.00	2.80	4.2	
		Week 32	Tezepelumab	75	74 (98.7)	1.70 (1.10)	0.0	1.00	1.60	2.60	4.8	
			Placebo	72	67 (93.1)	1.82 (0.97)	0.0	1.00	1.80	2.80	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 24 ppb	Absolute values	Week 34	Tezepelumab	75	74 (98.7)	1.68 (1.18)	0.0	0.80	1.40	2.80	4.8	
			Placebo	72	67 (93.1)	1.83 (0.93)	0.0	1.00	1.80	2.60	3.6	
		Week 36	Tezepelumab	75	74 (98.7)	1.73 (1.08)	0.0	0.80	1.60	2.60	4.8	
			Placebo	72	67 (93.1)	1.78 (1.01)	0.0	0.80	2.00	2.80	3.6	
		Week 38	Tezepelumab	75	74 (98.7)	1.69 (1.17)	0.0	0.80	1.50	2.40	4.8	
			Placebo	72	67 (93.1)	1.81 (0.97)	0.0	1.00	1.80	2.60	4.0	
		Week 40	Tezepelumab	75	74 (98.7)	1.75 (1.15)	0.0	0.80	1.80	2.80	4.8	
			Placebo	72	67 (93.1)	1.85 (1.02)	0.0	1.00	1.80	2.80	4.2	
		Week 42	Tezepelumab	75	74 (98.7)	1.70 (1.13)	0.0	1.00	1.70	2.60	4.8	
			Placebo	72	67 (93.1)	1.87 (1.00)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	75	74 (98.7)	1.79 (1.14)	0.0	0.80	1.80	2.80	4.8	
			Placebo	72	68 (94.4)	1.91 (1.02)	0.0	1.00	2.00	2.80	4.2	
		Week 46	Tezepelumab	75	74 (98.7)	1.79 (1.14)	0.0	1.00	1.90	2.60	4.8	
			Placebo	72	68 (94.4)	1.74 (1.00)	0.0	1.00	1.80	2.40	4.4	
		Week 48	Tezepelumab	75	74 (98.7)	1.80 (1.15)	0.0	1.00	1.80	2.60	4.8	
			Placebo	72	68 (94.4)	1.71 (1.05)	0.0	0.80	1.60	2.60	4.6	
		Week 50	Tezepelumab	75	74 (98.7)	1.73 (1.16)	0.0	1.00	1.80	2.60	4.8	
			Placebo	72	68 (94.4)	1.77 (0.96)	0.0	1.00	1.80	2.60	3.8	
		Week 52	Tezepelumab	75	74 (98.7)	1.78 (1.14)	0.0	1.00	1.80	2.60	4.8	
			Placebo	72	68 (94.4)	1.81 (1.01)	0.0	1.00	1.80	2.60	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 2	Tezepelumab	75	70 (93.3)	-0.52 (0.75)	-3.2	-0.80	-0.40	0.00	0.8	-0.01 [-0.35, 0.33]
			Placebo	72	64 (88.9)	-0.51 (0.73)	-2.8	-0.80	-0.40	0.00	1.4	
		Week 4	Tezepelumab	75	70 (93.3)	-0.80 (0.75)	-3.0	-1.20	-0.80	-0.20	0.6	-0.15 [-0.49, 0.19]
			Placebo	72	64 (88.9)	-0.68 (0.90)	-3.0	-1.20	-0.60	-0.10	1.6	
		Week 6	Tezepelumab	75	70 (93.3)	-0.85 (0.82)	-3.0	-1.40	-0.80	-0.20	0.8	-0.10 [-0.44, 0.24]
			Placebo	72	64 (88.9)	-0.76 (0.95)	-3.4	-1.40	-0.60	-0.20	1.6	
		Week 8	Tezepelumab	75	70 (93.3)	-0.93 (0.98)	-3.2	-1.60	-1.00	-0.20	2.6	-0.25 [-0.59, 0.09]
			Placebo	72	64 (88.9)	-0.69 (0.94)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	75	70 (93.3)	-0.99 (0.91)	-3.4	-1.60	-1.00	-0.20	0.6	-0.17 [-0.51, 0.17]
			Placebo	72	65 (90.3)	-0.84 (0.88)	-3.8	-1.20	-0.80	-0.20	0.8	
		Week 12	Tezepelumab	75	70 (93.3)	-1.03 (0.92)	-3.0	-1.60	-1.00	-0.40	0.6	-0.17 [-0.50, 0.17]
			Placebo	72	65 (90.3)	-0.87 (1.01)	-3.8	-1.20	-0.80	-0.20	1.4	
		Week 14	Tezepelumab	75	70 (93.3)	-1.22 (0.88)	-3.4	-1.80	-1.20	-0.60	0.6	-0.31 [-0.65, 0.03]
			Placebo	72	65 (90.3)	-0.94 (0.96)	-3.4	-1.40	-0.80	-0.40	1.4	
		Week 16	Tezepelumab	75	70 (93.3)	-0.99 (0.97)	-3.2	-1.40	-1.00	-0.40	1.8	-0.17 [-0.50, 0.17]
			Placebo	72	65 (90.3)	-0.82 (0.98)	-3.6	-1.40	-0.80	0.00	1.4	
		Week 18	Tezepelumab	75	71 (94.7)	-1.08 (0.88)	-3.4	-1.80	-1.00	-0.60	0.6	-0.20 [-0.53, 0.14]
			Placebo	72	65 (90.3)	-0.90 (1.03)	-3.6	-1.40	-0.80	-0.20	1.4	
		Week 20	Tezepelumab	75	71 (94.7)	-0.98 (0.96)	-3.4	-1.60	-1.00	-0.20	0.6	-0.10 [-0.43, 0.24]
			Placebo	72	65 (90.3)	-0.88 (1.07)	-3.6	-1.40	-0.80	-0.20	1.2	
		Week 22	Tezepelumab	75	71 (94.7)	-1.03 (0.93)	-3.2	-1.80	-0.80	-0.40	0.6	-0.09 [-0.42, 0.25]
			Placebo	72	65 (90.3)	-0.95 (1.06)	-3.8	-1.60	-1.00	-0.40	1.4	
		Week 24	Tezepelumab	75	71 (94.7)	-1.05 (0.92)	-3.4	-1.80	-0.80	-0.40	0.6	-0.06 [-0.40, 0.28]
			Placebo	72	65 (90.3)	-0.99 (1.07)	-3.6	-1.60	-1.00	-0.20	1.8	
		Week 26	Tezepelumab	75	72 (96.0)	-1.01 (0.94)	-3.0	-1.60	-0.90	-0.30	0.6	0.01 [-0.32, 0.35]
			Placebo	72	65 (90.3)	-1.02 (1.01)	-3.4	-1.80	-1.20	-0.40	1.6	
		Week 28	Tezepelumab	75	73 (97.3)	-1.02 (1.02)	-3.4	-1.80	-1.00	-0.20	1.0	-0.15 [-0.48, 0.19]
			Placebo	72	66 (91.7)	-0.87 (1.08)	-3.4	-1.60	-0.80	-0.20	1.6	
		Week 30	Tezepelumab	75	74 (98.7)	-1.06 (1.01)	-3.2	-2.00	-1.00	-0.40	2.0	-0.20 [-0.53, 0.14]
			Placebo	72	67 (93.1)	-0.85 (1.09)	-3.4	-1.60	-0.80	-0.20	1.4	
		Week 32	Tezepelumab	75	74 (98.7)	-1.09 (1.00)	-3.6	-1.60	-1.00	-0.40	1.2	-0.11 [-0.44, 0.22]
			Placebo	72	67 (93.1)	-0.98 (1.04)	-3.2	-1.80	-1.00	-0.40	1.4	
		Week 34	Tezepelumab	75	74 (98.7)	-1.12 (1.08)	-3.8	-2.00	-1.00	-0.40	2.2	-0.14 [-0.47, 0.19]
			Placebo	72	67 (93.1)	-0.97 (1.00)	-3.2	-1.60	-1.00	-0.40	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 24 ppb	Change from baseline	Week 36	Tezepelumab	75	74 (98.7)	-1.06 (1.01)	-3.6	-1.80	-1.00	-0.20	1.6	-0.04 [-0.37, 0.29]
			Placebo	72	67 (93.1)	-1.02 (1.11)	-3.6	-1.80	-1.00	-0.20	1.4	
		Week 38	Tezepelumab	75	74 (98.7)	-1.10 (1.08)	-3.6	-2.00	-1.00	-0.40	2.6	-0.10 [-0.43, 0.23]
			Placebo	72	67 (93.1)	-0.99 (1.06)	-3.2	-1.60	-1.00	-0.20	1.6	
		Week 40	Tezepelumab	75	74 (98.7)	-1.04 (1.06)	-3.6	-1.80	-1.00	-0.20	1.8	-0.08 [-0.42, 0.25]
			Placebo	72	67 (93.1)	-0.95 (1.03)	-3.2	-1.60	-1.00	-0.20	1.4	
		Week 42	Tezepelumab	75	74 (98.7)	-1.09 (1.04)	-3.6	-1.80	-1.00	-0.40	2.2	-0.15 [-0.48, 0.18]
			Placebo	72	67 (93.1)	-0.93 (1.02)	-3.0	-1.60	-1.00	-0.20	1.4	
		Week 44	Tezepelumab	75	74 (98.7)	-1.00 (1.07)	-3.8	-1.80	-0.90	-0.20	1.6	-0.11 [-0.44, 0.22]
			Placebo	72	68 (94.4)	-0.89 (1.06)	-3.4	-1.60	-0.80	0.00	1.4	
		Week 46	Tezepelumab	75	74 (98.7)	-1.01 (1.02)	-3.6	-1.80	-1.00	-0.20	1.8	0.05 [-0.28, 0.38]
			Placebo	72	68 (94.4)	-1.06 (1.06)	-3.2	-1.70	-1.00	-0.40	1.6	
		Week 48	Tezepelumab	75	74 (98.7)	-0.99 (1.07)	-3.6	-1.80	-0.90	-0.20	2.0	0.09 [-0.24, 0.42]
			Placebo	72	68 (94.4)	-1.09 (1.10)	-3.4	-1.70	-1.00	-0.40	1.8	
		Week 50	Tezepelumab	75	74 (98.7)	-1.06 (1.07)	-3.6	-1.80	-1.00	-0.40	2.0	-0.03 [-0.36, 0.30]
			Placebo	72	68 (94.4)	-1.03 (1.06)	-3.6	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	75	74 (98.7)	-1.01 (1.06)	-3.6	-1.80	-1.00	-0.20	2.0	-0.02 [-0.35, 0.31]
			Placebo	72	68 (94.4)	-0.99 (1.10)	-3.6	-1.60	-1.00	-0.40	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	2.87 (1.01)	0.0	2.40	2.80	3.40	5.2	
			Placebo	65	65 (100.0)	2.87 (0.79)	1.0	2.40	3.00	3.20	5.0	
		Week 2	Tezepelumab	60	59 (98.3)	2.23 (0.96)	0.0	1.60	2.20	3.00	4.2	
			Placebo	65	60 (92.3)	2.52 (0.94)	0.0	2.00	2.60	3.00	5.0	
		Week 4	Tezepelumab	60	59 (98.3)	1.87 (1.13)	0.0	1.00	2.20	2.80	4.2	
			Placebo	65	60 (92.3)	2.46 (0.92)	0.2	2.00	2.60	3.00	4.4	
		Week 6	Tezepelumab	60	59 (98.3)	1.78 (1.10)	0.0	1.00	1.80	2.60	4.2	
			Placebo	65	61 (93.8)	2.34 (1.13)	0.2	1.40	2.40	2.80	6.0	
		Week 8	Tezepelumab	60	59 (98.3)	1.67 (1.13)	0.0	0.80	1.80	2.60	4.2	
			Placebo	65	62 (95.4)	2.17 (1.11)	0.0	1.40	2.40	2.80	5.0	
		Week 10	Tezepelumab	60	59 (98.3)	1.61 (1.07)	0.0	0.80	1.60	2.40	4.2	
			Placebo	65	62 (95.4)	2.12 (1.04)	0.0	1.40	2.20	2.80	5.2	
		Week 12	Tezepelumab	60	59 (98.3)	1.48 (1.08)	0.0	0.60	1.40	2.40	4.2	
			Placebo	65	62 (95.4)	2.04 (1.08)	0.0	1.20	2.30	2.80	4.4	
		Week 14	Tezepelumab	60	59 (98.3)	1.42 (1.09)	0.0	0.60	1.20	2.40	4.2	
			Placebo	65	62 (95.4)	1.99 (1.04)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	60	59 (98.3)	1.49 (1.09)	0.0	0.60	1.20	2.20	4.2	
			Placebo	65	62 (95.4)	2.14 (1.23)	0.0	1.00	2.40	3.00	5.0	
		Week 18	Tezepelumab	60	59 (98.3)	1.37 (1.00)	0.0	0.80	1.20	2.00	4.2	
			Placebo	65	62 (95.4)	1.99 (1.11)	0.0	1.20	2.10	2.60	5.0	
		Week 20	Tezepelumab	60	59 (98.3)	1.45 (1.04)	0.0	0.60	1.20	2.20	4.2	
			Placebo	65	62 (95.4)	2.08 (1.13)	0.0	1.20	2.30	2.80	5.0	
		Week 22	Tezepelumab	60	59 (98.3)	1.58 (1.01)	0.0	0.80	1.60	2.20	4.2	
			Placebo	65	62 (95.4)	2.05 (1.14)	0.0	1.20	2.30	2.80	5.0	
		Week 24	Tezepelumab	60	59 (98.3)	1.54 (1.13)	0.0	0.80	1.20	2.20	4.8	
			Placebo	65	62 (95.4)	2.08 (1.08)	0.0	1.20	2.30	2.80	4.4	
		Week 26	Tezepelumab	60	59 (98.3)	1.43 (0.99)	0.0	0.80	1.40	2.20	4.2	
			Placebo	65	62 (95.4)	2.01 (1.11)	0.0	1.00	1.90	3.00	4.4	
		Week 28	Tezepelumab	60	59 (98.3)	1.57 (1.10)	0.0	0.60	1.60	2.40	4.2	
			Placebo	65	62 (95.4)	2.01 (1.20)	0.0	1.00	2.10	2.80	4.4	
		Week 30	Tezepelumab	60	59 (98.3)	1.47 (1.00)	0.0	0.80	1.40	2.20	4.2	
			Placebo	65	62 (95.4)	1.95 (1.18)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	60	59 (98.3)	1.40 (1.03)	0.0	0.40	1.20	2.20	4.2	
			Placebo	65	62 (95.4)	1.98 (1.19)	0.0	1.00	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 24 ppb	Absolute values	Week 34	Tezepelumab	60	59 (98.3)	1.46 (1.06)	0.0	0.60	1.20	2.20	4.2	
			Placebo	65	62 (95.4)	1.90 (1.23)	0.0	1.00	1.90	2.80	4.8	
		Week 36	Tezepelumab	60	59 (98.3)	1.57 (1.16)	0.0	0.60	1.60	2.20	5.0	
			Placebo	65	62 (95.4)	2.12 (1.17)	0.0	1.20	2.30	3.00	4.8	
		Week 38	Tezepelumab	60	59 (98.3)	1.42 (1.01)	0.0	0.80	1.20	2.20	4.2	
			Placebo	65	62 (95.4)	1.92 (1.18)	0.0	1.00	1.90	2.80	4.8	
		Week 40	Tezepelumab	60	59 (98.3)	1.39 (1.04)	0.0	0.40	1.20	2.20	4.2	
			Placebo	65	62 (95.4)	2.03 (1.19)	0.0	1.00	2.20	3.00	4.4	
		Week 42	Tezepelumab	60	59 (98.3)	1.37 (1.05)	0.0	0.60	1.20	2.00	4.6	
			Placebo	65	62 (95.4)	1.94 (1.11)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	60	59 (98.3)	1.30 (0.97)	0.0	0.60	1.00	2.00	4.2	
			Placebo	65	62 (95.4)	1.99 (1.14)	0.0	1.00	2.20	2.80	4.4	
		Week 46	Tezepelumab	60	59 (98.3)	1.27 (1.01)	0.0	0.60	1.00	2.00	4.2	
			Placebo	65	62 (95.4)	1.92 (1.05)	0.0	1.20	2.00	2.80	4.4	
		Week 48	Tezepelumab	60	59 (98.3)	1.39 (1.04)	0.0	0.60	1.20	2.20	4.2	
			Placebo	65	62 (95.4)	2.04 (1.07)	0.0	1.20	2.20	2.80	4.4	
		Week 50	Tezepelumab	60	59 (98.3)	1.27 (0.97)	0.0	0.60	1.00	2.00	4.2	
			Placebo	65	62 (95.4)	1.92 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 52	Tezepelumab	60	59 (98.3)	1.27 (0.97)	0.0	0.60	1.00	2.00	4.2	
			Placebo	65	62 (95.4)	1.97 (1.09)	0.0	1.00	2.10	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 2	Tezepelumab	60	59 (98.3)	-0.64 (0.75)	-2.6	-1.20	-0.40	0.00	0.8	-0.42 [-0.78, -0.05]
			Placebo	65	60 (92.3)	-0.32 (0.80)	-3.0	-0.90	-0.20	0.20	1.2	
		Week 4	Tezepelumab	60	59 (98.3)	-1.00 (1.18)	-3.8	-1.80	-1.00	-0.20	2.6	-0.58 [-0.95, -0.22]
			Placebo	65	60 (92.3)	-0.39 (0.91)	-2.2	-1.20	-0.20	0.30	1.4	
		Week 6	Tezepelumab	60	59 (98.3)	-1.09 (1.25)	-4.0	-1.80	-1.00	-0.20	2.6	-0.54 [-0.90, -0.17]
			Placebo	65	61 (93.8)	-0.50 (0.98)	-2.4	-1.40	-0.40	0.20	1.6	
		Week 8	Tezepelumab	60	59 (98.3)	-1.20 (1.21)	-4.0	-2.00	-1.20	-0.40	2.6	-0.48 [-0.84, -0.12]
			Placebo	65	62 (95.4)	-0.67 (1.00)	-3.0	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	60	59 (98.3)	-1.26 (1.22)	-4.0	-2.00	-1.20	-0.60	2.6	-0.46 [-0.82, -0.09]
			Placebo	65	62 (95.4)	-0.73 (1.12)	-3.0	-1.60	-0.60	0.00	2.6	
		Week 12	Tezepelumab	60	59 (98.3)	-1.39 (1.21)	-4.0	-2.20	-1.40	-0.80	2.6	-0.51 [-0.87, -0.15]
			Placebo	65	62 (95.4)	-0.80 (1.10)	-3.0	-1.60	-0.60	0.00	1.6	
		Week 14	Tezepelumab	60	59 (98.3)	-1.46 (1.29)	-4.2	-2.20	-1.40	-0.80	2.6	-0.51 [-0.87, -0.15]
			Placebo	65	62 (95.4)	-0.85 (1.07)	-3.2	-1.40	-0.90	-0.20	2.4	
		Week 16	Tezepelumab	60	59 (98.3)	-1.38 (1.27)	-4.4	-2.20	-1.40	-0.60	2.6	-0.54 [-0.90, -0.18]
			Placebo	65	62 (95.4)	-0.71 (1.22)	-3.6	-1.40	-0.60	0.00	2.6	
		Week 18	Tezepelumab	60	59 (98.3)	-1.51 (1.27)	-4.4	-2.20	-1.60	-0.80	2.6	-0.53 [-0.90, -0.17]
			Placebo	65	62 (95.4)	-0.86 (1.15)	-3.4	-1.40	-0.70	-0.20	2.6	
		Week 20	Tezepelumab	60	59 (98.3)	-1.43 (1.22)	-4.4	-2.20	-1.40	-0.60	2.6	-0.56 [-0.92, -0.19]
			Placebo	65	62 (95.4)	-0.76 (1.17)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	60	59 (98.3)	-1.29 (1.32)	-4.4	-2.00	-1.40	-0.60	2.6	-0.41 [-0.77, -0.05]
			Placebo	65	62 (95.4)	-0.79 (1.12)	-3.4	-1.40	-0.80	0.00	2.6	
		Week 24	Tezepelumab	60	59 (98.3)	-1.33 (1.23)	-4.8	-2.00	-1.40	-0.60	2.6	-0.48 [-0.84, -0.12]
			Placebo	65	62 (95.4)	-0.76 (1.14)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 26	Tezepelumab	60	59 (98.3)	-1.44 (1.27)	-4.4	-2.20	-1.40	-0.60	2.6	-0.49 [-0.85, -0.13]
			Placebo	65	62 (95.4)	-0.83 (1.20)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 28	Tezepelumab	60	59 (98.3)	-1.31 (1.25)	-4.4	-2.20	-1.20	-0.60	2.6	-0.38 [-0.74, -0.02]
			Placebo	65	62 (95.4)	-0.84 (1.23)	-4.2	-1.60	-0.70	0.00	2.6	
		Week 30	Tezepelumab	60	59 (98.3)	-1.41 (1.27)	-4.4	-2.40	-1.40	-0.60	2.6	-0.41 [-0.77, -0.05]
			Placebo	65	62 (95.4)	-0.89 (1.22)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 32	Tezepelumab	60	59 (98.3)	-1.48 (1.27)	-4.4	-2.40	-1.60	-0.80	2.6	-0.49 [-0.86, -0.13]
			Placebo	65	62 (95.4)	-0.86 (1.22)	-3.6	-1.60	-0.80	0.00	2.6	
		Week 34	Tezepelumab	60	59 (98.3)	-1.42 (1.25)	-4.4	-2.20	-1.60	-0.60	2.6	-0.38 [-0.74, -0.02]
			Placebo	65	62 (95.4)	-0.95 (1.25)	-4.2	-1.80	-0.90	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 24 ppb	Change from baseline	Week 36	Tezepelumab	60	59 (98.3)	-1.31 (1.41)	-4.4	-2.40	-1.40	-0.40	2.6	-0.44 [-0.80, -0.08]
			Placebo	65	62 (95.4)	-0.73 (1.22)	-3.6	-1.40	-0.80	0.00	2.6	
		Week 38	Tezepelumab	60	59 (98.3)	-1.45 (1.31)	-4.4	-2.40	-1.40	-0.60	2.6	-0.41 [-0.77, -0.05]
			Placebo	65	62 (95.4)	-0.93 (1.26)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 40	Tezepelumab	60	59 (98.3)	-1.48 (1.33)	-4.4	-2.40	-1.60	-0.80	2.6	-0.52 [-0.88, -0.15]
			Placebo	65	62 (95.4)	-0.82 (1.25)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 42	Tezepelumab	60	59 (98.3)	-1.51 (1.34)	-4.4	-2.40	-1.60	-0.60	2.6	-0.47 [-0.83, -0.11]
			Placebo	65	62 (95.4)	-0.91 (1.21)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	60	59 (98.3)	-1.58 (1.32)	-4.4	-2.60	-1.40	-0.80	2.6	-0.57 [-0.93, -0.21]
			Placebo	65	62 (95.4)	-0.85 (1.23)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 46	Tezepelumab	60	59 (98.3)	-1.61 (1.31)	-4.4	-2.40	-1.60	-1.00	2.6	-0.55 [-0.92, -0.19]
			Placebo	65	62 (95.4)	-0.93 (1.14)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 48	Tezepelumab	60	59 (98.3)	-1.49 (1.29)	-4.4	-2.40	-1.60	-0.60	2.6	-0.56 [-0.92, -0.19]
			Placebo	65	62 (95.4)	-0.81 (1.15)	-3.8	-1.40	-0.90	0.00	2.6	
		Week 50	Tezepelumab	60	59 (98.3)	-1.60 (1.28)	-4.4	-2.40	-1.60	-1.00	2.6	-0.56 [-0.93, -0.20]
			Placebo	65	62 (95.4)	-0.93 (1.11)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 52	Tezepelumab	60	59 (98.3)	-1.60 (1.29)	-4.4	-2.60	-1.60	-1.00	2.6	-0.61 [-0.97, -0.24]
			Placebo	65	62 (95.4)	-0.87 (1.12)	-4.2	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	65	65 (100.0)	2.81 (0.72)	0.8	2.40	2.80	3.20	5.0	
			Placebo	62	62 (100.0)	2.78 (0.66)	0.4	2.40	2.80	3.20	4.2	
		Week 2	Tezepelumab	65	61 (93.8)	2.32 (0.94)	0.0	1.60	2.40	3.00	4.0	
			Placebo	62	56 (90.3)	2.37 (0.71)	0.4	2.00	2.40	3.00	4.4	
		Week 4	Tezepelumab	65	61 (93.8)	2.02 (0.91)	0.0	1.40	2.20	2.80	3.6	
			Placebo	62	56 (90.3)	2.17 (0.83)	0.2	1.70	2.20	2.80	4.2	
		Week 6	Tezepelumab	65	61 (93.8)	1.91 (0.93)	0.0	1.40	1.80	2.60	4.0	
			Placebo	62	56 (90.3)	2.11 (0.92)	0.2	1.50	2.20	2.70	5.0	
		Week 8	Tezepelumab	65	61 (93.8)	1.92 (1.08)	0.0	1.20	1.80	2.80	5.2	
			Placebo	62	56 (90.3)	2.19 (0.81)	0.0	1.80	2.20	2.80	4.0	
		Week 10	Tezepelumab	65	61 (93.8)	1.83 (1.05)	0.0	1.20	1.80	2.60	4.8	
			Placebo	62	57 (91.9)	2.04 (0.84)	0.2	1.40	2.00	2.40	4.2	
		Week 12	Tezepelumab	65	61 (93.8)	1.83 (1.10)	0.0	1.00	1.80	2.80	4.8	
			Placebo	62	57 (91.9)	2.01 (0.84)	0.0	1.60	2.20	2.60	3.6	
		Week 14	Tezepelumab	65	61 (93.8)	1.67 (1.02)	0.0	1.00	1.60	2.40	4.8	
			Placebo	62	57 (91.9)	1.96 (0.87)	0.0	1.40	2.00	2.60	4.2	
		Week 16	Tezepelumab	65	61 (93.8)	1.86 (1.13)	0.0	1.00	1.80	2.60	4.8	
			Placebo	62	57 (91.9)	2.09 (0.91)	0.0	1.60	2.00	2.80	3.8	
		Week 18	Tezepelumab	65	62 (95.4)	1.77 (0.99)	0.0	1.00	1.80	2.40	4.8	
			Placebo	62	57 (91.9)	1.98 (0.96)	0.0	1.40	2.00	2.60	4.8	
		Week 20	Tezepelumab	65	62 (95.4)	1.89 (1.09)	0.0	1.20	2.00	2.60	5.0	
			Placebo	62	57 (91.9)	1.97 (0.95)	0.0	1.40	2.00	2.80	3.8	
		Week 22	Tezepelumab	65	62 (95.4)	1.84 (1.02)	0.0	1.20	2.00	2.60	4.8	
			Placebo	62	57 (91.9)	1.94 (0.91)	0.0	1.20	2.00	2.60	4.0	
		Week 24	Tezepelumab	65	62 (95.4)	1.84 (1.03)	0.0	1.20	1.80	2.60	4.8	
			Placebo	62	57 (91.9)	1.93 (0.96)	0.0	1.00	2.00	2.80	3.8	
		Week 26	Tezepelumab	65	63 (96.9)	1.83 (1.03)	0.0	1.00	1.80	2.60	4.8	
			Placebo	62	57 (91.9)	1.88 (0.92)	0.0	1.00	1.80	2.60	4.4	
		Week 28	Tezepelumab	65	63 (96.9)	1.84 (1.07)	0.0	1.00	1.80	2.80	4.8	
			Placebo	62	58 (93.5)	1.98 (0.96)	0.0	1.00	2.20	2.80	4.4	
		Week 30	Tezepelumab	65	64 (98.5)	1.82 (1.03)	0.0	1.00	1.80	2.60	4.8	
			Placebo	62	58 (93.5)	1.93 (0.94)	0.0	1.00	2.10	2.80	3.4	
		Week 32	Tezepelumab	65	64 (98.5)	1.80 (1.05)	0.0	1.00	1.80	2.60	4.8	
			Placebo	62	58 (93.5)	1.84 (0.97)	0.0	1.00	1.90	2.80	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 22.0 ppb	Absolute values	Week 34	Tezepelumab	65	64 (98.5)	1.77 (1.13)	0.0	1.00	1.60	2.80	4.8	
			Placebo	62	58 (93.5)	1.86 (0.94)	0.0	1.00	1.90	2.60	3.6	
		Week 36	Tezepelumab	65	64 (98.5)	1.82 (1.06)	0.0	1.00	1.80	2.70	4.8	
			Placebo	62	58 (93.5)	1.83 (1.04)	0.0	1.00	2.10	2.80	3.6	
		Week 38	Tezepelumab	65	64 (98.5)	1.80 (1.15)	0.0	0.90	1.70	2.60	4.8	
			Placebo	62	58 (93.5)	1.84 (0.97)	0.0	1.00	1.80	2.60	4.0	
		Week 40	Tezepelumab	65	64 (98.5)	1.87 (1.11)	0.0	1.00	1.90	2.80	4.8	
			Placebo	62	58 (93.5)	1.89 (1.06)	0.0	1.00	2.00	2.80	4.2	
		Week 42	Tezepelumab	65	64 (98.5)	1.82 (1.11)	0.0	1.00	1.80	2.70	4.8	
			Placebo	62	58 (93.5)	1.86 (1.04)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	65	64 (98.5)	1.91 (1.12)	0.0	1.10	1.90	2.80	4.8	
			Placebo	62	59 (95.2)	1.92 (1.03)	0.0	1.00	2.00	2.80	4.2	
		Week 46	Tezepelumab	65	64 (98.5)	1.89 (1.10)	0.0	1.00	2.00	2.70	4.8	
			Placebo	62	59 (95.2)	1.74 (1.03)	0.0	1.00	1.60	2.60	4.4	
		Week 48	Tezepelumab	65	64 (98.5)	1.90 (1.09)	0.0	1.00	2.00	2.80	4.8	
			Placebo	62	59 (95.2)	1.73 (1.07)	0.0	0.80	1.80	2.60	4.6	
		Week 50	Tezepelumab	65	64 (98.5)	1.82 (1.11)	0.0	1.00	1.80	2.60	4.8	
			Placebo	62	59 (95.2)	1.75 (1.00)	0.0	1.00	1.80	2.60	3.8	
		Week 52	Tezepelumab	65	64 (98.5)	1.85 (1.12)	0.0	1.00	1.80	2.60	4.8	
			Placebo	62	59 (95.2)	1.80 (1.03)	0.0	1.00	1.80	2.80	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 2	Tezepelumab	65	61 (93.8)	-0.49 (0.74)	-3.2	-0.80	-0.40	0.00	0.4	-0.02 [-0.38, 0.34]
			Placebo	62	56 (90.3)	-0.48 (0.63)	-2.8	-0.80	-0.40	0.00	0.8	
		Week 4	Tezepelumab	65	61 (93.8)	-0.79 (0.78)	-3.0	-1.20	-0.80	-0.20	0.6	-0.15 [-0.51, 0.22]
			Placebo	62	56 (90.3)	-0.67 (0.83)	-3.0	-1.20	-0.60	0.00	1.0	
		Week 6	Tezepelumab	65	61 (93.8)	-0.90 (0.84)	-3.0	-1.40	-1.00	-0.20	0.8	-0.19 [-0.56, 0.17]
			Placebo	62	56 (90.3)	-0.73 (0.91)	-3.4	-1.30	-0.60	-0.10	1.6	
		Week 8	Tezepelumab	65	61 (93.8)	-0.89 (1.03)	-3.2	-1.40	-1.00	-0.20	2.6	-0.25 [-0.61, 0.12]
			Placebo	62	56 (90.3)	-0.66 (0.82)	-3.0	-1.10	-0.60	-0.10	1.0	
		Week 10	Tezepelumab	65	61 (93.8)	-0.97 (0.94)	-3.4	-1.60	-0.80	-0.20	0.6	-0.18 [-0.55, 0.18]
			Placebo	62	57 (91.9)	-0.81 (0.79)	-3.2	-1.20	-0.80	-0.40	0.8	
		Week 12	Tezepelumab	65	61 (93.8)	-0.98 (0.94)	-3.0	-1.60	-0.80	-0.20	0.6	-0.15 [-0.51, 0.22]
			Placebo	62	57 (91.9)	-0.84 (0.91)	-3.2	-1.00	-0.80	-0.40	1.0	
		Week 14	Tezepelumab	65	61 (93.8)	-1.13 (0.86)	-3.4	-1.60	-1.20	-0.60	0.6	-0.27 [-0.63, 0.09]
			Placebo	62	57 (91.9)	-0.89 (0.92)	-3.2	-1.40	-0.80	-0.40	1.4	
		Week 16	Tezepelumab	65	61 (93.8)	-0.95 (0.99)	-3.2	-1.40	-1.00	-0.20	1.8	-0.19 [-0.55, 0.17]
			Placebo	62	57 (91.9)	-0.76 (0.92)	-3.0	-1.40	-0.60	0.00	1.4	
		Week 18	Tezepelumab	65	62 (95.4)	-1.02 (0.88)	-3.4	-1.80	-0.80	-0.40	0.6	-0.16 [-0.52, 0.20]
			Placebo	62	57 (91.9)	-0.87 (0.99)	-3.2	-1.40	-0.80	-0.20	1.4	
		Week 20	Tezepelumab	65	62 (95.4)	-0.90 (0.97)	-3.4	-1.60	-0.80	-0.20	0.6	-0.02 [-0.38, 0.34]
			Placebo	62	57 (91.9)	-0.88 (0.98)	-3.0	-1.40	-0.80	-0.40	1.0	
		Week 22	Tezepelumab	65	62 (95.4)	-0.96 (0.93)	-3.2	-1.60	-0.80	-0.40	0.6	-0.05 [-0.41, 0.31]
			Placebo	62	57 (91.9)	-0.91 (0.97)	-3.2	-1.60	-0.80	-0.40	1.4	
		Week 24	Tezepelumab	65	62 (95.4)	-0.95 (0.92)	-3.4	-1.40	-0.80	-0.20	0.6	-0.03 [-0.39, 0.33]
			Placebo	62	57 (91.9)	-0.93 (1.03)	-3.2	-1.60	-1.00	-0.20	1.8	
		Week 26	Tezepelumab	65	63 (96.9)	-0.95 (0.92)	-3.0	-1.40	-0.80	-0.20	0.6	0.02 [-0.34, 0.38]
			Placebo	62	57 (91.9)	-0.97 (0.98)	-3.0	-1.60	-1.20	-0.40	1.6	
		Week 28	Tezepelumab	65	63 (96.9)	-0.94 (1.02)	-3.4	-1.40	-0.80	-0.20	1.0	-0.10 [-0.46, 0.26]
			Placebo	62	58 (93.5)	-0.83 (0.99)	-3.0	-1.60	-0.80	-0.20	1.6	
		Week 30	Tezepelumab	65	64 (98.5)	-0.97 (1.01)	-3.2	-1.60	-0.80	-0.30	2.0	-0.09 [-0.44, 0.27]
			Placebo	62	58 (93.5)	-0.88 (1.02)	-3.2	-1.60	-0.80	-0.20	1.4	
		Week 32	Tezepelumab	65	64 (98.5)	-1.00 (0.99)	-3.6	-1.60	-0.90	-0.40	1.2	-0.02 [-0.38, 0.33]
			Placebo	62	58 (93.5)	-0.97 (0.98)	-3.2	-1.60	-0.90	-0.40	1.4	
		Week 34	Tezepelumab	65	64 (98.5)	-1.03 (1.07)	-3.8	-1.80	-0.90	-0.30	2.2	-0.07 [-0.43, 0.28]
			Placebo	62	58 (93.5)	-0.96 (0.97)	-3.2	-1.40	-1.00	-0.40	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 22.0 ppb	Change from baseline	Week 36	Tezepelumab	65	64 (98.5)	-0.97 (1.02)	-3.6	-1.70	-0.90	-0.20	1.6	0.01 [-0.35, 0.37]
			Placebo	62	58 (93.5)	-0.98 (1.09)	-3.6	-1.60	-0.80	-0.40	1.4	
		Week 38	Tezepelumab	65	64 (98.5)	-1.00 (1.08)	-3.6	-1.80	-0.90	-0.30	2.6	-0.03 [-0.38, 0.33]
			Placebo	62	58 (93.5)	-0.97 (1.03)	-3.2	-1.60	-1.00	-0.40	1.6	
		Week 40	Tezepelumab	65	64 (98.5)	-0.93 (1.06)	-3.6	-1.60	-0.80	-0.20	1.8	-0.01 [-0.36, 0.35]
			Placebo	62	58 (93.5)	-0.92 (1.03)	-3.2	-1.60	-1.00	-0.40	1.4	
		Week 42	Tezepelumab	65	64 (98.5)	-0.98 (1.05)	-3.6	-1.60	-0.80	-0.30	2.2	-0.03 [-0.38, 0.33]
			Placebo	62	58 (93.5)	-0.95 (1.01)	-3.0	-1.40	-1.00	-0.40	1.4	
		Week 44	Tezepelumab	65	64 (98.5)	-0.88 (1.08)	-3.8	-1.50	-0.80	-0.10	1.6	0.00 [-0.35, 0.36]
			Placebo	62	59 (95.2)	-0.89 (1.02)	-3.4	-1.60	-0.80	-0.20	1.4	
		Week 46	Tezepelumab	65	64 (98.5)	-0.90 (1.02)	-3.6	-1.40	-0.80	-0.20	1.8	0.16 [-0.19, 0.52]
			Placebo	62	59 (95.2)	-1.07 (1.04)	-3.2	-1.80	-1.00	-0.40	1.6	
		Week 48	Tezepelumab	65	64 (98.5)	-0.89 (1.05)	-3.6	-1.70	-0.80	-0.20	2.0	0.17 [-0.18, 0.53]
			Placebo	62	59 (95.2)	-1.07 (1.09)	-3.4	-1.60	-1.00	-0.40	1.8	
		Week 50	Tezepelumab	65	64 (98.5)	-0.97 (1.06)	-3.6	-1.70	-0.80	-0.30	2.0	0.08 [-0.28, 0.43]
			Placebo	62	59 (95.2)	-1.05 (1.05)	-3.6	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	65	64 (98.5)	-0.95 (1.08)	-3.6	-1.70	-0.80	-0.20	2.0	0.06 [-0.30, 0.41]
			Placebo	62	59 (95.2)	-1.01 (1.08)	-3.6	-1.60	-1.00	-0.40	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	70	70 (100.0)	2.86 (0.96)	0.0	2.40	2.80	3.40	5.2	
			Placebo	75	75 (100.0)	2.85 (0.78)	1.0	2.40	3.00	3.20	5.0	
		Week 2	Tezepelumab	70	68 (97.1)	2.21 (1.00)	0.0	1.60	2.20	3.00	4.4	
			Placebo	75	68 (90.7)	2.46 (0.93)	0.0	2.00	2.60	3.00	5.0	
		Week 4	Tezepelumab	70	68 (97.1)	1.88 (1.11)	0.0	1.00	2.10	2.80	4.2	
			Placebo	75	68 (90.7)	2.40 (0.91)	0.2	1.80	2.60	3.00	4.4	
		Week 6	Tezepelumab	70	68 (97.1)	1.84 (1.08)	0.0	1.00	1.80	2.70	4.2	
			Placebo	75	69 (92.0)	2.27 (1.10)	0.2	1.40	2.40	2.80	6.0	
		Week 8	Tezepelumab	70	68 (97.1)	1.66 (1.09)	0.0	0.90	1.70	2.60	4.2	
			Placebo	75	70 (93.3)	2.13 (1.13)	0.0	1.40	2.30	2.80	5.0	
		Week 10	Tezepelumab	70	68 (97.1)	1.62 (1.07)	0.0	0.80	1.60	2.40	4.2	
			Placebo	75	70 (93.3)	2.07 (1.03)	0.0	1.40	2.00	2.80	5.2	
		Week 12	Tezepelumab	70	68 (97.1)	1.47 (1.06)	0.0	0.60	1.40	2.30	4.2	
			Placebo	75	70 (93.3)	1.99 (1.11)	0.0	1.20	2.00	2.80	4.4	
		Week 14	Tezepelumab	70	68 (97.1)	1.36 (1.10)	0.0	0.60	1.20	2.10	4.2	
			Placebo	75	70 (93.3)	1.93 (1.02)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	70	68 (97.1)	1.50 (1.08)	0.0	0.60	1.20	2.20	4.2	
			Placebo	75	70 (93.3)	2.06 (1.20)	0.0	1.00	2.10	3.00	5.0	
		Week 18	Tezepelumab	70	68 (97.1)	1.36 (1.01)	0.0	0.80	1.20	2.00	4.2	
			Placebo	75	70 (93.3)	1.94 (1.09)	0.0	1.20	1.90	2.60	5.0	
		Week 20	Tezepelumab	70	68 (97.1)	1.43 (1.04)	0.0	0.60	1.20	2.20	4.2	
			Placebo	75	70 (93.3)	2.05 (1.12)	0.0	1.20	2.30	2.80	5.0	
		Week 22	Tezepelumab	70	68 (97.1)	1.54 (1.02)	0.0	0.80	1.50	2.20	4.2	
			Placebo	75	70 (93.3)	1.99 (1.15)	0.0	1.00	2.00	2.80	5.0	
		Week 24	Tezepelumab	70	68 (97.1)	1.49 (1.13)	0.0	0.60	1.20	2.20	4.8	
			Placebo	75	70 (93.3)	1.99 (1.08)	0.0	1.00	2.10	2.80	4.4	
		Week 26	Tezepelumab	70	68 (97.1)	1.42 (1.04)	0.0	0.70	1.30	2.20	4.2	
			Placebo	75	70 (93.3)	1.93 (1.08)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	70	69 (98.6)	1.52 (1.13)	0.0	0.40	1.40	2.40	4.2	
			Placebo	75	70 (93.3)	1.96 (1.20)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	70	69 (98.6)	1.43 (1.04)	0.0	0.60	1.40	2.00	4.2	
			Placebo	75	71 (94.7)	1.97 (1.17)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	70	69 (98.6)	1.35 (1.07)	0.0	0.40	1.20	2.20	4.2	
			Placebo	75	71 (94.7)	1.95 (1.17)	0.0	1.00	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 22.0 ppb	Absolute values	Week 34	Tezepelumab	70	69 (98.6)	1.41 (1.11)	0.0	0.40	1.20	2.20	4.2	
			Placebo	75	71 (94.7)	1.87 (1.19)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	70	69 (98.6)	1.51 (1.15)	0.0	0.60	1.40	2.20	5.0	
			Placebo	75	71 (94.7)	2.04 (1.15)	0.0	1.00	2.00	2.80	4.8	
		Week 38	Tezepelumab	70	69 (98.6)	1.37 (1.03)	0.0	0.60	1.20	2.20	4.2	
			Placebo	75	71 (94.7)	1.87 (1.15)	0.0	1.00	1.80	2.80	4.8	
		Week 40	Tezepelumab	70	69 (98.6)	1.34 (1.06)	0.0	0.40	1.20	2.20	4.2	
			Placebo	75	71 (94.7)	1.97 (1.14)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	70	69 (98.6)	1.31 (1.05)	0.0	0.60	1.20	2.00	4.6	
			Placebo	75	71 (94.7)	1.94 (1.07)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	70	69 (98.6)	1.26 (0.98)	0.0	0.40	1.00	2.00	4.2	
			Placebo	75	71 (94.7)	1.97 (1.11)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	70	69 (98.6)	1.24 (1.03)	0.0	0.60	1.00	2.00	4.2	
			Placebo	75	71 (94.7)	1.90 (1.02)	0.0	1.20	2.00	2.60	4.4	
		Week 48	Tezepelumab	70	69 (98.6)	1.35 (1.08)	0.0	0.40	1.20	2.00	4.2	
			Placebo	75	71 (94.7)	1.97 (1.06)	0.0	1.20	2.00	2.80	4.4	
		Week 50	Tezepelumab	70	69 (98.6)	1.26 (1.03)	0.0	0.60	1.00	2.00	4.2	
			Placebo	75	71 (94.7)	1.91 (1.02)	0.0	1.00	2.00	2.60	4.4	
		Week 52	Tezepelumab	70	69 (98.6)	1.29 (1.01)	0.0	0.60	1.00	2.00	4.2	
			Placebo	75	71 (94.7)	1.96 (1.06)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 2	Tezepelumab	70	68 (97.1)	-0.65 (0.76)	-2.6	-1.20	-0.60	-0.10	0.8	-0.35 [-0.68, -0.01]
			Placebo	75	68 (90.7)	-0.37 (0.87)	-3.0	-0.90	-0.20	0.20	1.4	
		Week 4	Tezepelumab	70	68 (97.1)	-0.98 (1.11)	-3.8	-1.70	-1.00	-0.20	2.6	-0.53 [-0.88, -0.19]
			Placebo	75	68 (90.7)	-0.43 (0.96)	-3.0	-1.20	-0.20	0.20	1.6	
		Week 6	Tezepelumab	70	68 (97.1)	-1.02 (1.20)	-4.0	-1.80	-1.00	-0.20	2.6	-0.42 [-0.76, -0.09]
			Placebo	75	69 (92.0)	-0.55 (1.01)	-3.2	-1.40	-0.40	0.00	1.6	
		Week 8	Tezepelumab	70	68 (97.1)	-1.20 (1.13)	-4.0	-1.80	-1.20	-0.40	2.6	-0.45 [-0.79, -0.12]
			Placebo	75	70 (93.3)	-0.70 (1.07)	-3.6	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	70	68 (97.1)	-1.24 (1.16)	-4.0	-2.00	-1.30	-0.60	2.6	-0.42 [-0.75, -0.08]
			Placebo	75	70 (93.3)	-0.76 (1.15)	-3.8	-1.60	-0.60	0.00	2.6	
		Week 12	Tezepelumab	70	68 (97.1)	-1.39 (1.15)	-4.0	-2.10	-1.40	-0.80	2.6	-0.48 [-0.82, -0.14]
			Placebo	75	70 (93.3)	-0.83 (1.16)	-3.8	-1.60	-0.60	0.00	1.6	
		Week 14	Tezepelumab	70	68 (97.1)	-1.50 (1.24)	-4.2	-2.20	-1.50	-0.90	2.6	-0.52 [-0.86, -0.18]
			Placebo	75	70 (93.3)	-0.89 (1.08)	-3.4	-1.40	-0.90	-0.20	2.4	
		Week 16	Tezepelumab	70	68 (97.1)	-1.36 (1.21)	-4.4	-2.20	-1.30	-0.60	2.6	-0.48 [-0.82, -0.15]
			Placebo	75	70 (93.3)	-0.77 (1.23)	-3.6	-1.40	-0.80	0.00	2.6	
		Week 18	Tezepelumab	70	68 (97.1)	-1.51 (1.21)	-4.4	-2.20	-1.40	-0.80	2.6	-0.53 [-0.86, -0.19]
			Placebo	75	70 (93.3)	-0.89 (1.17)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	70	68 (97.1)	-1.44 (1.16)	-4.4	-2.20	-1.40	-0.80	2.6	-0.56 [-0.90, -0.22]
			Placebo	75	70 (93.3)	-0.77 (1.22)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	70	68 (97.1)	-1.33 (1.26)	-4.4	-2.10	-1.40	-0.60	2.6	-0.40 [-0.74, -0.06]
			Placebo	75	70 (93.3)	-0.84 (1.18)	-3.8	-1.60	-0.80	0.00	2.6	
		Week 24	Tezepelumab	70	68 (97.1)	-1.38 (1.18)	-4.8	-2.00	-1.40	-0.60	2.6	-0.46 [-0.80, -0.12]
			Placebo	75	70 (93.3)	-0.84 (1.17)	-3.8	-1.40	-0.80	0.00	2.6	
		Week 26	Tezepelumab	70	68 (97.1)	-1.44 (1.23)	-4.4	-2.20	-1.40	-0.60	2.6	-0.45 [-0.79, -0.11]
			Placebo	75	70 (93.3)	-0.90 (1.20)	-4.2	-1.80	-0.90	0.00	2.6	
		Week 28	Tezepelumab	70	69 (98.6)	-1.34 (1.21)	-4.4	-2.20	-1.40	-0.60	2.6	-0.38 [-0.72, -0.05]
			Placebo	75	70 (93.3)	-0.87 (1.27)	-4.2	-1.80	-0.90	0.00	2.6	
		Week 30	Tezepelumab	70	69 (98.6)	-1.43 (1.22)	-4.4	-2.40	-1.40	-0.80	2.6	-0.46 [-0.80, -0.13]
			Placebo	75	71 (94.7)	-0.86 (1.26)	-3.4	-1.60	-1.00	0.00	2.6	
		Week 32	Tezepelumab	70	69 (98.6)	-1.51 (1.22)	-4.4	-2.40	-1.60	-1.00	2.6	-0.51 [-0.85, -0.17]
			Placebo	75	71 (94.7)	-0.88 (1.24)	-3.6	-1.80	-1.00	0.00	2.6	
		Week 34	Tezepelumab	70	69 (98.6)	-1.46 (1.22)	-4.4	-2.40	-1.60	-0.80	2.6	-0.40 [-0.73, -0.06]
			Placebo	75	71 (94.7)	-0.96 (1.24)	-4.2	-1.80	-1.00	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 22.0 ppb	Change from baseline	Week 36	Tezepelumab	70	69 (98.6)	-1.35 (1.34)	-4.4	-2.40	-1.40	-0.60	2.6	-0.44 [-0.77, -0.10]
			Placebo	75	71 (94.7)	-0.79 (1.23)	-3.6	-1.60	-1.00	0.00	2.6	
		Week 38	Tezepelumab	70	69 (98.6)	-1.50 (1.25)	-4.4	-2.20	-1.40	-0.80	2.6	-0.43 [-0.77, -0.09]
			Placebo	75	71 (94.7)	-0.96 (1.26)	-4.2	-2.00	-1.00	0.00	2.6	
		Week 40	Tezepelumab	70	69 (98.6)	-1.52 (1.27)	-4.4	-2.40	-1.60	-0.80	2.6	-0.53 [-0.87, -0.20]
			Placebo	75	71 (94.7)	-0.86 (1.22)	-4.2	-1.60	-0.80	0.00	2.6	
		Week 42	Tezepelumab	70	69 (98.6)	-1.55 (1.27)	-4.4	-2.40	-1.60	-0.80	2.6	-0.53 [-0.87, -0.19]
			Placebo	75	71 (94.7)	-0.90 (1.20)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	70	69 (98.6)	-1.60 (1.24)	-4.4	-2.40	-1.40	-1.00	2.6	-0.60 [-0.94, -0.26]
			Placebo	75	71 (94.7)	-0.86 (1.24)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 46	Tezepelumab	70	69 (98.6)	-1.62 (1.25)	-4.4	-2.40	-1.60	-1.00	2.6	-0.57 [-0.91, -0.23]
			Placebo	75	71 (94.7)	-0.93 (1.15)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 48	Tezepelumab	70	69 (98.6)	-1.51 (1.25)	-4.4	-2.40	-1.60	-0.80	2.6	-0.54 [-0.88, -0.21]
			Placebo	75	71 (94.7)	-0.86 (1.16)	-3.8	-1.60	-1.00	0.00	2.6	
		Week 50	Tezepelumab	70	69 (98.6)	-1.61 (1.23)	-4.4	-2.40	-1.60	-1.00	2.6	-0.58 [-0.92, -0.25]
			Placebo	75	71 (94.7)	-0.92 (1.11)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 52	Tezepelumab	70	69 (98.6)	-1.57 (1.24)	-4.4	-2.40	-1.60	-1.00	2.6	-0.59 [-0.93, -0.25]
			Placebo	75	71 (94.7)	-0.87 (1.14)	-4.2	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	50	50 (100.0)	3.00 (0.78)	1.0	2.60	3.00	3.20	5.0	
			Placebo	50	50 (100.0)	2.79 (0.70)	1.0	2.60	2.90	3.20	4.8	
		Week 2	Tezepelumab	50	49 (98.0)	2.41 (0.91)	0.0	1.80	2.60	3.00	4.0	
			Placebo	50	42 (84.0)	2.39 (0.85)	0.4	2.00	2.40	3.00	4.8	
		Week 4	Tezepelumab	50	49 (98.0)	2.08 (0.90)	0.0	1.60	2.20	2.80	3.6	
			Placebo	50	42 (84.0)	2.40 (0.97)	0.2	1.80	2.60	3.00	4.2	
		Week 6	Tezepelumab	50	49 (98.0)	1.82 (0.95)	0.0	1.20	1.80	2.40	3.8	
			Placebo	50	43 (86.0)	2.22 (1.08)	0.2	1.40	2.00	2.80	5.0	
		Week 8	Tezepelumab	50	49 (98.0)	1.89 (1.04)	0.0	1.40	2.00	2.60	5.2	
			Placebo	50	44 (88.0)	2.20 (1.03)	0.0	1.60	2.40	3.00	4.6	
		Week 10	Tezepelumab	50	49 (98.0)	1.76 (1.02)	0.0	1.20	1.80	2.40	4.8	
			Placebo	50	44 (88.0)	2.13 (0.98)	0.2	1.40	2.20	2.60	4.4	
		Week 12	Tezepelumab	50	49 (98.0)	1.68 (1.11)	0.0	0.80	1.60	2.60	4.8	
			Placebo	50	44 (88.0)	2.15 (1.01)	0.2	1.50	2.20	2.80	4.4	
		Week 14	Tezepelumab	50	49 (98.0)	1.55 (1.03)	0.0	1.00	1.40	2.40	4.8	
			Placebo	50	44 (88.0)	2.00 (1.00)	0.0	1.30	1.90	2.60	5.0	
		Week 16	Tezepelumab	50	49 (98.0)	1.75 (1.11)	0.0	0.80	1.80	2.60	4.8	
			Placebo	50	44 (88.0)	2.15 (1.10)	0.0	1.40	2.40	3.00	4.4	
		Week 18	Tezepelumab	50	49 (98.0)	1.59 (0.96)	0.0	1.00	1.60	2.20	4.8	
			Placebo	50	44 (88.0)	1.92 (1.01)	0.0	1.20	1.80	2.60	4.4	
		Week 20	Tezepelumab	50	49 (98.0)	1.64 (1.07)	0.0	0.80	1.60	2.40	4.8	
			Placebo	50	44 (88.0)	2.10 (1.08)	0.2	1.30	2.40	2.80	4.4	
		Week 22	Tezepelumab	50	49 (98.0)	1.76 (1.00)	0.0	1.20	1.80	2.40	4.8	
			Placebo	50	44 (88.0)	2.04 (1.11)	0.0	1.10	2.10	2.80	4.4	
		Week 24	Tezepelumab	50	49 (98.0)	1.80 (1.11)	0.0	1.20	1.60	2.60	4.8	
			Placebo	50	44 (88.0)	2.09 (1.11)	0.0	1.10	2.20	3.00	4.4	
		Week 26	Tezepelumab	50	50 (100.0)	1.64 (1.00)	0.0	1.00	1.50	2.40	4.8	
			Placebo	50	44 (88.0)	2.04 (1.10)	0.4	1.00	2.00	3.00	4.4	
		Week 28	Tezepelumab	50	50 (100.0)	1.72 (1.05)	0.0	1.00	1.80	2.40	4.8	
			Placebo	50	44 (88.0)	2.16 (1.10)	0.0	1.10	2.20	2.80	4.4	
		Week 30	Tezepelumab	50	50 (100.0)	1.76 (1.05)	0.0	1.00	1.80	2.40	4.8	
			Placebo	50	45 (90.0)	2.17 (1.07)	0.0	1.60	2.40	3.00	4.4	
		Week 32	Tezepelumab	50	50 (100.0)	1.73 (1.04)	0.0	1.00	1.70	2.60	4.8	
			Placebo	50	45 (90.0)	2.17 (1.09)	0.0	1.20	2.40	3.00	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Absolute values	Week 34	Tezepelumab	50	50 (100.0)	1.74 (1.13)	0.0	1.00	1.50	2.80	4.8	
			Placebo	50	45 (90.0)	2.08 (1.12)	0.0	1.20	2.20	3.00	4.4	
		Week 36	Tezepelumab	50	50 (100.0)	1.82 (1.17)	0.0	1.00	1.70	2.60	5.0	
			Placebo	50	45 (90.0)	2.18 (1.09)	0.0	1.40	2.40	3.00	4.4	
		Week 38	Tezepelumab	50	50 (100.0)	1.74 (1.12)	0.0	1.00	1.60	2.40	4.8	
			Placebo	50	45 (90.0)	2.13 (1.07)	0.0	1.20	2.20	3.00	4.4	
		Week 40	Tezepelumab	50	50 (100.0)	1.73 (1.13)	0.0	0.80	1.80	2.40	4.8	
			Placebo	50	45 (90.0)	2.31 (1.08)	0.2	1.60	2.40	3.00	4.4	
		Week 42	Tezepelumab	50	50 (100.0)	1.74 (1.07)	0.0	1.00	1.60	2.40	4.8	
			Placebo	50	45 (90.0)	2.17 (1.13)	0.2	1.40	2.20	2.80	4.6	
		Week 44	Tezepelumab	50	50 (100.0)	1.72 (1.12)	0.0	1.00	1.60	2.80	4.8	
			Placebo	50	46 (92.0)	2.31 (1.00)	0.2	1.60	2.50	3.00	4.4	
		Week 46	Tezepelumab	50	50 (100.0)	1.76 (1.14)	0.0	1.00	1.60	2.60	4.8	
			Placebo	50	46 (92.0)	2.10 (1.08)	0.0	1.40	2.00	3.00	4.4	
		Week 48	Tezepelumab	50	50 (100.0)	1.79 (1.11)	0.0	1.00	1.80	2.60	4.8	
			Placebo	50	46 (92.0)	2.19 (1.12)	0.0	1.40	2.40	2.80	4.6	
		Week 50	Tezepelumab	50	50 (100.0)	1.72 (1.06)	0.0	1.00	1.50	2.60	4.8	
			Placebo	50	46 (92.0)	2.09 (1.03)	0.4	1.00	2.20	2.80	4.4	
		Week 52	Tezepelumab	50	50 (100.0)	1.71 (1.09)	0.0	1.00	1.60	2.60	4.8	
			Placebo	50	46 (92.0)	2.15 (1.07)	0.0	1.00	2.40	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	50	49 (98.0)	-0.61 (0.67)	-3.0	-0.80	-0.60	-0.20	0.4	-0.30 [-0.71, 0.12]
			Placebo	50	42 (84.0)	-0.40 (0.73)	-2.8	-0.80	-0.40	0.00	1.2	
		Week 4	Tezepelumab	50	49 (98.0)	-0.95 (0.81)	-3.0	-1.40	-0.80	-0.40	0.6	-0.65 [-1.07, -0.23]
			Placebo	50	42 (84.0)	-0.39 (0.92)	-2.6	-1.00	-0.20	0.20	1.4	
		Week 6	Tezepelumab	50	49 (98.0)	-1.20 (0.87)	-3.0	-1.80	-1.20	-0.80	1.2	-0.69 [-1.11, -0.27]
			Placebo	50	43 (86.0)	-0.56 (1.01)	-2.6	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	50	49 (98.0)	-1.14 (1.07)	-3.2	-1.80	-1.20	-0.60	2.6	-0.55 [-0.97, -0.14]
			Placebo	50	44 (88.0)	-0.60 (0.87)	-2.8	-1.00	-0.60	-0.10	1.0	
		Week 10	Tezepelumab	50	49 (98.0)	-1.27 (0.96)	-3.4	-1.80	-1.20	-0.80	0.6	-0.62 [-1.04, -0.20]
			Placebo	50	44 (88.0)	-0.67 (0.98)	-2.6	-1.10	-0.60	-0.20	2.6	
		Week 12	Tezepelumab	50	49 (98.0)	-1.34 (0.98)	-3.2	-2.00	-1.20	-0.60	0.6	-0.72 [-1.15, -0.30]
			Placebo	50	44 (88.0)	-0.65 (0.94)	-3.0	-1.00	-0.60	0.00	1.6	
		Week 14	Tezepelumab	50	49 (98.0)	-1.47 (1.02)	-4.0	-2.20	-1.40	-0.80	0.6	-0.69 [-1.11, -0.27]
			Placebo	50	44 (88.0)	-0.80 (0.93)	-2.6	-1.40	-0.90	-0.40	1.4	
		Week 16	Tezepelumab	50	49 (98.0)	-1.27 (1.11)	-3.2	-2.20	-1.40	-0.60	1.0	-0.60 [-1.01, -0.18]
			Placebo	50	44 (88.0)	-0.65 (0.98)	-2.6	-1.20	-0.70	-0.10	2.6	
		Week 18	Tezepelumab	50	49 (98.0)	-1.44 (1.04)	-3.8	-2.00	-1.40	-0.80	0.6	-0.55 [-0.97, -0.14]
			Placebo	50	44 (88.0)	-0.88 (0.98)	-3.2	-1.40	-0.80	-0.40	2.6	
		Week 20	Tezepelumab	50	49 (98.0)	-1.38 (1.01)	-3.4	-2.20	-1.40	-0.80	0.6	-0.67 [-1.09, -0.26]
			Placebo	50	44 (88.0)	-0.70 (1.02)	-3.0	-1.30	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	50	49 (98.0)	-1.26 (1.02)	-3.4	-1.80	-1.20	-0.60	0.6	-0.48 [-0.90, -0.07]
			Placebo	50	44 (88.0)	-0.76 (1.07)	-3.2	-1.40	-0.80	-0.40	2.6	
		Week 24	Tezepelumab	50	49 (98.0)	-1.22 (0.95)	-3.4	-1.80	-1.20	-0.40	0.6	-0.50 [-0.91, -0.09]
			Placebo	50	44 (88.0)	-0.71 (1.12)	-3.0	-1.40	-0.60	-0.20	2.6	
		Week 26	Tezepelumab	50	50 (100.0)	-1.36 (1.07)	-3.4	-2.20	-1.40	-0.60	0.6	-0.56 [-0.97, -0.14]
			Placebo	50	44 (88.0)	-0.75 (1.13)	-2.6	-1.60	-1.00	0.00	2.6	
		Week 28	Tezepelumab	50	50 (100.0)	-1.28 (1.04)	-3.4	-2.20	-1.30	-0.80	1.0	-0.60 [-1.02, -0.19]
			Placebo	50	44 (88.0)	-0.64 (1.09)	-2.6	-1.20	-0.60	-0.20	2.6	
		Week 30	Tezepelumab	50	50 (100.0)	-1.24 (1.19)	-3.8	-2.20	-1.10	-0.60	2.0	-0.54 [-0.95, -0.13]
			Placebo	50	45 (90.0)	-0.63 (1.06)	-2.8	-1.20	-0.60	-0.20	2.6	
		Week 32	Tezepelumab	50	50 (100.0)	-1.27 (1.13)	-3.6	-2.20	-1.10	-0.80	1.2	-0.59 [-1.00, -0.18]
			Placebo	50	45 (90.0)	-0.63 (1.06)	-2.6	-1.40	-0.40	0.00	2.6	
		Week 34	Tezepelumab	50	50 (100.0)	-1.26 (1.19)	-3.2	-2.20	-1.40	-0.40	2.2	-0.46 [-0.87, -0.05]
			Placebo	50	45 (90.0)	-0.72 (1.14)	-3.2	-1.40	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Change from baseline	Week 36	Tezepelumab	50	50 (100.0)	-1.18 (1.26)	-3.2	-2.20	-1.20	-0.20	2.0	-0.47 [-0.87, -0.06]
			Placebo	50	45 (90.0)	-0.62 (1.15)	-3.2	-1.20	-0.60	0.00	2.6	
		Week 38	Tezepelumab	50	50 (100.0)	-1.26 (1.24)	-3.8	-2.20	-1.20	-0.40	2.6	-0.50 [-0.91, -0.09]
			Placebo	50	45 (90.0)	-0.67 (1.11)	-3.2	-1.20	-0.40	-0.20	2.6	
		Week 40	Tezepelumab	50	50 (100.0)	-1.27 (1.25)	-4.2	-2.20	-1.10	-0.60	1.8	-0.66 [-1.07, -0.25]
			Placebo	50	45 (90.0)	-0.49 (1.12)	-2.8	-1.20	-0.60	0.00	2.6	
		Week 42	Tezepelumab	50	50 (100.0)	-1.26 (1.18)	-3.6	-2.00	-1.20	-0.40	2.2	-0.54 [-0.95, -0.13]
			Placebo	50	45 (90.0)	-0.63 (1.18)	-2.8	-1.40	-0.80	-0.20	2.6	
		Week 44	Tezepelumab	50	50 (100.0)	-1.28 (1.29)	-4.4	-2.00	-1.20	-0.40	1.6	-0.67 [-1.08, -0.26]
			Placebo	50	46 (92.0)	-0.49 (1.06)	-2.6	-1.20	-0.40	0.00	2.6	
		Week 46	Tezepelumab	50	50 (100.0)	-1.24 (1.25)	-4.0	-2.00	-1.10	-0.20	1.8	-0.44 [-0.85, -0.04]
			Placebo	50	46 (92.0)	-0.70 (1.18)	-3.2	-1.40	-0.80	0.00	2.6	
		Week 48	Tezepelumab	50	50 (100.0)	-1.21 (1.24)	-4.0	-2.20	-1.00	-0.40	2.0	-0.50 [-0.90, -0.09]
			Placebo	50	46 (92.0)	-0.61 (1.17)	-3.2	-1.20	-0.60	0.00	2.6	
		Week 50	Tezepelumab	50	50 (100.0)	-1.28 (1.16)	-3.8	-2.00	-1.20	-0.60	2.0	-0.51 [-0.91, -0.10]
			Placebo	50	46 (92.0)	-0.71 (1.10)	-2.8	-1.40	-0.80	0.00	2.6	
		Week 52	Tezepelumab	50	50 (100.0)	-1.29 (1.21)	-4.0	-2.00	-1.20	-0.60	2.0	-0.56 [-0.97, -0.15]
			Placebo	50	46 (92.0)	-0.64 (1.11)	-2.8	-1.20	-0.50	0.00	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	77	77 (100.0)	2.73 (0.88)	0.0	2.40	2.80	3.20	5.2	
			Placebo	80	80 (100.0)	2.83 (0.75)	0.4	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	77	73 (94.8)	2.15 (1.02)	0.0	1.60	2.20	2.80	4.4	
			Placebo	80	75 (93.8)	2.44 (0.82)	0.0	2.00	2.60	3.00	5.0	
		Week 4	Tezepelumab	77	73 (94.8)	1.86 (1.10)	0.0	1.00	2.00	2.80	4.2	
			Placebo	80	75 (93.8)	2.29 (0.81)	0.2	1.80	2.40	2.80	4.4	
		Week 6	Tezepelumab	77	73 (94.8)	1.88 (1.06)	0.0	1.20	1.80	2.60	4.2	
			Placebo	80	75 (93.8)	2.17 (1.00)	0.2	1.60	2.20	2.80	6.0	
		Week 8	Tezepelumab	77	73 (94.8)	1.71 (1.14)	0.0	1.00	1.60	2.80	4.2	
			Placebo	80	75 (93.8)	2.13 (0.98)	0.0	1.60	2.20	2.80	5.0	
		Week 10	Tezepelumab	77	73 (94.8)	1.69 (1.10)	0.0	0.80	1.60	2.60	4.2	
			Placebo	80	76 (95.0)	2.06 (0.95)	0.0	1.50	2.10	2.80	5.2	
		Week 12	Tezepelumab	77	73 (94.8)	1.62 (1.10)	0.0	0.60	1.60	2.60	4.2	
			Placebo	80	76 (95.0)	1.92 (0.98)	0.0	1.20	2.00	2.60	4.4	
		Week 14	Tezepelumab	77	73 (94.8)	1.49 (1.11)	0.0	0.60	1.40	2.20	4.2	
			Placebo	80	76 (95.0)	1.95 (0.92)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	77	73 (94.8)	1.60 (1.08)	0.0	0.80	1.40	2.40	4.2	
			Placebo	80	76 (95.0)	2.06 (1.05)	0.0	1.40	2.00	2.80	5.0	
		Week 18	Tezepelumab	77	73 (94.8)	1.53 (1.07)	0.0	0.80	1.20	2.40	4.2	
			Placebo	80	76 (95.0)	2.02 (1.04)	0.0	1.40	2.00	2.80	5.0	
		Week 20	Tezepelumab	77	73 (94.8)	1.63 (1.11)	0.0	0.80	1.40	2.40	5.0	
			Placebo	80	76 (95.0)	2.02 (0.98)	0.0	1.40	2.10	2.80	5.0	
		Week 22	Tezepelumab	77	73 (94.8)	1.60 (1.07)	0.0	0.80	1.60	2.40	4.2	
			Placebo	80	76 (95.0)	1.99 (0.97)	0.0	1.20	2.00	2.60	5.0	
		Week 24	Tezepelumab	77	73 (94.8)	1.55 (1.08)	0.0	0.80	1.60	2.40	4.2	
			Placebo	80	76 (95.0)	1.93 (0.93)	0.0	1.10	2.00	2.60	4.0	
		Week 26	Tezepelumab	77	73 (94.8)	1.59 (1.10)	0.0	0.80	1.60	2.40	4.2	
			Placebo	80	76 (95.0)	1.85 (0.96)	0.0	1.20	1.80	2.70	4.0	
		Week 28	Tezepelumab	77	74 (96.1)	1.65 (1.15)	0.0	0.60	1.60	2.40	4.2	
			Placebo	80	77 (96.3)	1.86 (1.08)	0.0	1.00	2.00	2.80	4.0	
		Week 30	Tezepelumab	77	75 (97.4)	1.54 (1.07)	0.0	0.60	1.40	2.20	4.2	
			Placebo	80	77 (96.3)	1.85 (1.05)	0.0	1.00	2.00	2.60	4.2	
		Week 32	Tezepelumab	77	75 (97.4)	1.47 (1.10)	0.0	0.60	1.20	2.20	4.2	
			Placebo	80	77 (96.3)	1.76 (1.04)	0.0	0.80	1.80	2.60	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Absolute values	Week 34	Tezepelumab	77	75 (97.4)	1.50 (1.16)	0.0	0.60	1.20	2.20	4.2	
			Placebo	80	77 (96.3)	1.78 (1.03)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	77	75 (97.4)	1.58 (1.10)	0.0	0.80	1.60	2.40	4.2	
			Placebo	80	77 (96.3)	1.86 (1.07)	0.0	1.00	2.00	2.60	4.8	
		Week 38	Tezepelumab	77	75 (97.4)	1.49 (1.12)	0.0	0.60	1.40	2.20	4.6	
			Placebo	80	77 (96.3)	1.75 (1.04)	0.0	1.00	1.60	2.60	4.8	
		Week 40	Tezepelumab	77	75 (97.4)	1.51 (1.13)	0.0	0.40	1.40	2.40	4.2	
			Placebo	80	77 (96.3)	1.77 (1.04)	0.0	1.00	1.80	2.60	4.2	
		Week 42	Tezepelumab	77	75 (97.4)	1.45 (1.13)	0.0	0.60	1.20	2.20	4.6	
			Placebo	80	77 (96.3)	1.79 (0.97)	0.0	1.00	2.00	2.60	3.4	
		Week 44	Tezepelumab	77	75 (97.4)	1.49 (1.09)	0.0	0.60	1.20	2.40	4.2	
			Placebo	80	77 (96.3)	1.80 (1.06)	0.0	1.00	2.00	2.60	4.2	
		Week 46	Tezepelumab	77	75 (97.4)	1.41 (1.09)	0.0	0.60	1.00	2.20	4.2	
			Placebo	80	77 (96.3)	1.71 (0.95)	0.0	1.00	1.80	2.60	3.4	
		Week 48	Tezepelumab	77	75 (97.4)	1.51 (1.13)	0.0	0.40	1.40	2.20	4.2	
			Placebo	80	77 (96.3)	1.72 (0.99)	0.0	1.00	1.60	2.60	3.4	
		Week 50	Tezepelumab	77	75 (97.4)	1.42 (1.15)	0.0	0.60	1.00	2.20	4.2	
			Placebo	80	77 (96.3)	1.68 (0.96)	0.0	1.00	1.80	2.60	3.4	
		Week 52	Tezepelumab	77	75 (97.4)	1.48 (1.12)	0.0	0.60	1.20	2.20	4.4	
			Placebo	80	77 (96.3)	1.72 (0.99)	0.0	1.00	1.80	2.60	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	77	73 (94.8)	-0.55 (0.81)	-3.2	-1.00	-0.40	0.00	0.8	-0.18 [-0.50, 0.14]
			Placebo	80	75 (93.8)	-0.41 (0.78)	-3.0	-0.80	-0.20	0.00	1.4	
		Week 4	Tezepelumab	77	73 (94.8)	-0.84 (1.07)	-3.8	-1.40	-0.80	-0.20	2.6	-0.29 [-0.61, 0.04]
			Placebo	80	75 (93.8)	-0.56 (0.92)	-3.0	-1.20	-0.40	0.00	1.6	
		Week 6	Tezepelumab	77	73 (94.8)	-0.82 (1.09)	-4.0	-1.40	-0.80	0.00	2.6	-0.15 [-0.47, 0.18]
			Placebo	80	75 (93.8)	-0.67 (0.96)	-3.4	-1.40	-0.60	0.00	1.4	
		Week 8	Tezepelumab	77	73 (94.8)	-0.99 (1.09)	-4.0	-1.60	-1.00	-0.40	2.6	-0.25 [-0.58, 0.07]
			Placebo	80	75 (93.8)	-0.72 (1.02)	-3.6	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	77	73 (94.8)	-1.01 (1.08)	-4.0	-1.60	-1.00	-0.40	2.6	-0.20 [-0.52, 0.12]
			Placebo	80	76 (95.0)	-0.79 (1.07)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	77	73 (94.8)	-1.08 (1.10)	-4.0	-1.80	-1.00	-0.40	2.6	-0.13 [-0.46, 0.19]
			Placebo	80	76 (95.0)	-0.93 (1.10)	-3.8	-1.70	-0.80	-0.20	1.4	
		Week 14	Tezepelumab	77	73 (94.8)	-1.21 (1.10)	-4.0	-2.00	-1.20	-0.40	2.6	-0.28 [-0.61, 0.04]
			Placebo	80	76 (95.0)	-0.90 (1.07)	-3.4	-1.50	-0.60	-0.20	2.4	
		Week 16	Tezepelumab	77	73 (94.8)	-1.10 (1.06)	-4.0	-1.80	-1.00	-0.40	2.6	-0.28 [-0.60, 0.04]
			Placebo	80	76 (95.0)	-0.79 (1.17)	-3.6	-1.40	-0.70	0.00	2.4	
		Week 18	Tezepelumab	77	73 (94.8)	-1.17 (1.08)	-4.0	-1.80	-1.00	-0.60	2.6	-0.31 [-0.63, 0.02]
			Placebo	80	76 (95.0)	-0.83 (1.15)	-3.6	-1.60	-0.60	0.00	2.4	
		Week 20	Tezepelumab	77	73 (94.8)	-1.07 (1.09)	-4.0	-1.80	-1.00	-0.40	2.6	-0.21 [-0.53, 0.11]
			Placebo	80	76 (95.0)	-0.84 (1.15)	-3.6	-1.40	-0.60	-0.20	2.4	
		Week 22	Tezepelumab	77	73 (94.8)	-1.10 (1.17)	-4.0	-1.80	-1.00	-0.40	2.6	-0.22 [-0.54, 0.11]
			Placebo	80	76 (95.0)	-0.86 (1.08)	-3.8	-1.60	-0.80	0.00	2.4	
		Week 24	Tezepelumab	77	73 (94.8)	-1.15 (1.08)	-4.0	-2.00	-1.00	-0.60	2.6	-0.21 [-0.53, 0.12]
			Placebo	80	76 (95.0)	-0.93 (1.07)	-3.8	-1.50	-0.80	-0.10	1.4	
		Week 26	Tezepelumab	77	73 (94.8)	-1.11 (1.10)	-4.0	-1.80	-1.00	-0.40	2.6	-0.10 [-0.42, 0.22]
			Placebo	80	76 (95.0)	-1.00 (1.11)	-4.2	-1.80	-1.10	0.00	1.4	
		Week 28	Tezepelumab	77	74 (96.1)	-1.05 (1.13)	-4.0	-1.80	-0.80	-0.20	2.6	-0.08 [-0.40, 0.24]
			Placebo	80	77 (96.3)	-0.96 (1.18)	-4.2	-1.80	-0.80	0.00	1.4	
		Week 30	Tezepelumab	77	75 (97.4)	-1.18 (1.11)	-3.8	-2.00	-1.00	-0.40	2.6	-0.18 [-0.50, 0.14]
			Placebo	80	77 (96.3)	-0.97 (1.19)	-3.4	-1.80	-1.00	0.00	2.0	
		Week 32	Tezepelumab	77	75 (97.4)	-1.24 (1.12)	-4.0	-2.20	-1.20	-0.60	2.6	-0.16 [-0.48, 0.15]
			Placebo	80	77 (96.3)	-1.06 (1.13)	-3.6	-1.80	-1.20	-0.40	1.8	
		Week 34	Tezepelumab	77	75 (97.4)	-1.22 (1.14)	-4.0	-2.00	-1.20	-0.40	2.6	-0.16 [-0.47, 0.16]
			Placebo	80	77 (96.3)	-1.04 (1.10)	-4.2	-1.60	-1.20	-0.20	1.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Change from baseline	Week 36	Tezepelumab	77	75 (97.4)	-1.13 (1.17)	-4.0	-2.00	-1.20	-0.20	2.6	-0.15 [-0.47, 0.17]
			Placebo	80	77 (96.3)	-0.96 (1.16)	-3.6	-1.60	-1.00	0.00	1.8	
		Week 38	Tezepelumab	77	75 (97.4)	-1.23 (1.16)	-4.0	-2.20	-1.20	-0.40	2.6	-0.13 [-0.45, 0.19]
			Placebo	80	77 (96.3)	-1.07 (1.16)	-4.2	-2.00	-1.20	-0.40	1.8	
		Week 40	Tezepelumab	77	75 (97.4)	-1.21 (1.16)	-4.0	-2.20	-1.00	-0.40	2.6	-0.14 [-0.45, 0.18]
			Placebo	80	77 (96.3)	-1.05 (1.09)	-4.2	-1.60	-1.00	-0.20	1.4	
		Week 42	Tezepelumab	77	75 (97.4)	-1.27 (1.19)	-4.0	-2.20	-1.40	-0.60	2.6	-0.22 [-0.54, 0.10]
			Placebo	80	77 (96.3)	-1.03 (1.05)	-4.2	-1.60	-1.00	-0.20	0.8	
		Week 44	Tezepelumab	77	75 (97.4)	-1.22 (1.15)	-4.0	-2.20	-1.20	-0.40	2.6	-0.18 [-0.49, 0.14]
			Placebo	80	77 (96.3)	-1.02 (1.13)	-4.2	-1.80	-1.00	-0.40	1.2	
		Week 46	Tezepelumab	77	75 (97.4)	-1.31 (1.14)	-4.0	-2.20	-1.20	-0.60	2.6	-0.18 [-0.50, 0.14]
			Placebo	80	77 (96.3)	-1.11 (1.02)	-4.2	-1.60	-1.20	-0.40	1.0	
		Week 48	Tezepelumab	77	75 (97.4)	-1.21 (1.15)	-4.0	-2.00	-1.20	-0.40	2.6	-0.09 [-0.41, 0.23]
			Placebo	80	77 (96.3)	-1.10 (1.06)	-3.8	-1.80	-1.00	-0.40	1.2	
		Week 50	Tezepelumab	77	75 (97.4)	-1.30 (1.22)	-4.0	-2.20	-1.40	-0.40	2.6	-0.14 [-0.46, 0.18]
			Placebo	80	77 (96.3)	-1.14 (1.02)	-4.2	-1.60	-1.20	-0.40	0.8	
		Week 52	Tezepelumab	77	75 (97.4)	-1.23 (1.20)	-4.0	-2.00	-1.20	-0.40	2.6	-0.11 [-0.43, 0.21]
			Placebo	80	77 (96.3)	-1.10 (1.06)	-4.2	-1.60	-1.00	-0.40	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	70	70 (100.0)	2.70 (0.72)	0.0	2.40	2.80	3.20	4.2	
			Placebo	62	62 (100.0)	2.82 (0.73)	1.0	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	70	68 (97.1)	2.22 (0.88)	0.0	1.60	2.40	2.80	4.4	
			Placebo	62	54 (87.1)	2.34 (0.93)	0.4	1.80	2.20	3.00	5.0	
		Week 4	Tezepelumab	70	68 (97.1)	1.94 (0.92)	0.2	1.10	2.00	2.70	3.4	
			Placebo	62	54 (87.1)	2.32 (0.93)	0.6	1.80	2.50	3.00	4.4	
		Week 6	Tezepelumab	70	68 (97.1)	1.80 (0.95)	0.0	1.20	1.70	2.60	3.8	
			Placebo	62	55 (88.7)	2.26 (1.20)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	70	68 (97.1)	1.81 (1.09)	0.0	1.00	1.70	2.70	5.2	
			Placebo	62	56 (90.3)	2.24 (1.12)	0.2	1.50	2.40	3.00	5.0	
		Week 10	Tezepelumab	70	68 (97.1)	1.70 (1.03)	0.0	1.00	1.70	2.40	4.8	
			Placebo	62	56 (90.3)	2.10 (0.97)	0.2	1.40	2.10	3.00	4.4	
		Week 12	Tezepelumab	70	68 (97.1)	1.55 (1.07)	0.0	0.60	1.40	2.40	4.8	
			Placebo	62	56 (90.3)	1.98 (1.02)	0.0	1.50	2.00	2.70	4.4	
		Week 14	Tezepelumab	70	68 (97.1)	1.44 (1.01)	0.0	0.60	1.40	2.10	4.8	
			Placebo	62	56 (90.3)	1.89 (1.01)	0.0	1.20	1.80	2.70	5.0	
		Week 16	Tezepelumab	70	68 (97.1)	1.62 (1.06)	0.0	0.80	1.60	2.50	4.8	
			Placebo	62	56 (90.3)	2.08 (1.17)	0.0	1.40	2.00	3.00	5.0	
		Week 18	Tezepelumab	70	69 (98.6)	1.49 (0.94)	0.0	1.00	1.40	2.00	4.8	
			Placebo	62	56 (90.3)	1.88 (1.18)	0.0	1.00	1.80	2.80	4.8	
		Week 20	Tezepelumab	70	69 (98.6)	1.59 (1.05)	0.0	0.60	1.60	2.40	4.8	
			Placebo	62	56 (90.3)	1.95 (1.13)	0.0	1.10	2.10	2.80	4.4	
		Week 22	Tezepelumab	70	69 (98.6)	1.68 (0.99)	0.0	1.00	1.80	2.40	4.8	
			Placebo	62	56 (90.3)	1.90 (1.16)	0.0	1.00	1.80	2.80	4.4	
		Week 24	Tezepelumab	70	69 (98.6)	1.58 (1.00)	0.0	1.00	1.60	2.40	4.8	
			Placebo	62	56 (90.3)	1.96 (1.16)	0.0	1.00	2.20	2.90	4.4	
		Week 26	Tezepelumab	70	70 (100.0)	1.58 (1.01)	0.0	1.00	1.60	2.40	4.8	
			Placebo	62	56 (90.3)	1.93 (1.16)	0.0	1.00	1.80	3.00	4.4	
		Week 28	Tezepelumab	70	70 (100.0)	1.66 (1.11)	0.0	1.00	1.60	2.80	4.8	
			Placebo	62	56 (90.3)	2.10 (1.18)	0.0	1.10	2.20	3.00	4.4	
		Week 30	Tezepelumab	70	70 (100.0)	1.61 (1.06)	0.0	1.00	1.60	2.40	4.8	
			Placebo	62	57 (91.9)	2.00 (1.11)	0.0	1.00	2.20	3.00	4.4	
		Week 32	Tezepelumab	70	70 (100.0)	1.57 (1.06)	0.0	1.00	1.40	2.40	4.8	
			Placebo	62	57 (91.9)	2.02 (1.09)	0.0	1.20	2.00	3.00	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Absolute values	Week 34	Tezepelumab	70	70 (100.0)	1.57 (1.10)	0.0	0.80	1.30	2.40	4.8	
			Placebo	62	57 (91.9)	1.91 (1.14)	0.0	1.00	1.80	3.00	4.4	
		Week 36	Tezepelumab	70	70 (100.0)	1.65 (1.17)	0.0	0.80	1.50	2.40	5.0	
			Placebo	62	57 (91.9)	2.00 (1.15)	0.0	1.40	2.00	3.00	4.4	
		Week 38	Tezepelumab	70	70 (100.0)	1.63 (1.12)	0.0	0.80	1.60	2.40	4.8	
			Placebo	62	57 (91.9)	1.96 (1.11)	0.0	1.00	2.00	3.00	4.4	
		Week 40	Tezepelumab	70	70 (100.0)	1.64 (1.07)	0.0	0.80	1.80	2.40	4.8	
			Placebo	62	57 (91.9)	2.09 (1.20)	0.0	1.00	2.20	3.00	4.4	
		Week 42	Tezepelumab	70	70 (100.0)	1.63 (1.15)	0.0	1.00	1.60	2.40	4.8	
			Placebo	62	57 (91.9)	2.03 (1.11)	0.0	1.40	2.20	2.80	4.6	
		Week 44	Tezepelumab	70	70 (100.0)	1.66 (1.10)	0.0	0.80	1.60	2.60	4.8	
			Placebo	62	57 (91.9)	2.11 (1.13)	0.0	1.20	2.20	3.00	4.4	
		Week 46	Tezepelumab	70	70 (100.0)	1.58 (1.09)	0.0	0.80	1.60	2.40	4.8	
			Placebo	62	57 (91.9)	1.99 (1.11)	0.0	1.20	2.00	2.80	4.4	
		Week 48	Tezepelumab	70	70 (100.0)	1.63 (1.13)	0.0	0.80	1.60	2.40	4.8	
			Placebo	62	57 (91.9)	2.05 (1.16)	0.0	1.20	2.20	2.80	4.6	
		Week 50	Tezepelumab	70	70 (100.0)	1.57 (1.10)	0.0	0.80	1.50	2.40	4.8	
			Placebo	62	57 (91.9)	2.01 (1.09)	0.0	1.20	2.00	2.80	4.4	
		Week 52	Tezepelumab	70	70 (100.0)	1.57 (1.11)	0.0	0.80	1.70	2.40	4.8	
			Placebo	62	57 (91.9)	2.06 (1.12)	0.0	1.00	2.20	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 2	Tezepelumab	70	68 (97.1)	-0.51 (0.75)	-3.2	-0.80	-0.40	0.00	0.8	-0.05 [-0.41, 0.30]
			Placebo	62	54 (87.1)	-0.46 (0.84)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	70	68 (97.1)	-0.78 (0.94)	-3.0	-1.40	-0.80	-0.20	2.6	-0.32 [-0.68, 0.04]
			Placebo	62	54 (87.1)	-0.49 (0.92)	-2.4	-1.00	-0.60	0.20	1.4	
		Week 6	Tezepelumab	70	68 (97.1)	-0.93 (1.03)	-3.2	-1.60	-1.00	-0.20	2.6	-0.37 [-0.73, -0.01]
			Placebo	62	55 (88.7)	-0.54 (1.05)	-2.6	-1.40	-0.60	0.20	1.6	
		Week 8	Tezepelumab	70	68 (97.1)	-0.92 (1.15)	-3.2	-1.60	-1.00	-0.30	2.6	-0.33 [-0.68, 0.03]
			Placebo	62	56 (90.3)	-0.57 (0.98)	-2.8	-1.10	-0.60	0.10	1.0	
		Week 10	Tezepelumab	70	68 (97.1)	-1.03 (1.10)	-3.4	-1.70	-1.00	-0.30	2.6	-0.30 [-0.66, 0.05]
			Placebo	62	56 (90.3)	-0.71 (0.99)	-2.6	-1.40	-0.60	-0.20	2.6	
		Week 12	Tezepelumab	70	68 (97.1)	-1.17 (1.06)	-3.0	-2.00	-1.20	-0.60	2.6	-0.33 [-0.68, 0.03]
			Placebo	62	56 (90.3)	-0.83 (1.01)	-3.0	-1.30	-0.80	-0.30	1.6	
		Week 14	Tezepelumab	70	68 (97.1)	-1.28 (1.04)	-3.4	-2.00	-1.20	-0.80	2.6	-0.35 [-0.70, 0.01]
			Placebo	62	56 (90.3)	-0.93 (1.02)	-3.0	-1.50	-1.00	-0.40	1.4	
		Week 16	Tezepelumab	70	68 (97.1)	-1.10 (1.06)	-3.2	-2.00	-1.00	-0.40	2.6	-0.35 [-0.70, 0.01]
			Placebo	62	56 (90.3)	-0.73 (1.10)	-3.0	-1.40	-0.80	-0.10	2.6	
		Week 18	Tezepelumab	70	69 (98.6)	-1.23 (1.02)	-3.4	-2.00	-1.20	-0.80	2.6	-0.27 [-0.63, 0.08]
			Placebo	62	56 (90.3)	-0.93 (1.18)	-3.4	-1.60	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	70	69 (98.6)	-1.13 (1.09)	-3.4	-2.00	-1.00	-0.40	2.6	-0.24 [-0.60, 0.11]
			Placebo	62	56 (90.3)	-0.86 (1.12)	-3.4	-1.40	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	70	69 (98.6)	-1.03 (1.12)	-3.2	-1.80	-1.00	-0.40	2.6	-0.11 [-0.46, 0.25]
			Placebo	62	56 (90.3)	-0.91 (1.14)	-3.4	-1.60	-0.90	-0.20	2.6	
		Week 24	Tezepelumab	70	69 (98.6)	-1.14 (1.03)	-3.4	-1.80	-1.00	-0.40	2.6	-0.26 [-0.61, 0.09]
			Placebo	62	56 (90.3)	-0.85 (1.18)	-3.4	-1.60	-0.90	-0.20	2.6	
		Week 26	Tezepelumab	70	70 (100.0)	-1.13 (1.04)	-3.2	-1.80	-1.10	-0.40	2.6	-0.22 [-0.57, 0.13]
			Placebo	62	56 (90.3)	-0.88 (1.19)	-3.0	-1.70	-1.20	0.10	2.6	
		Week 28	Tezepelumab	70	70 (100.0)	-1.05 (1.16)	-3.4	-1.80	-1.00	-0.20	2.6	-0.29 [-0.64, 0.07]
			Placebo	62	56 (90.3)	-0.71 (1.17)	-3.0	-1.60	-0.70	0.00	2.6	
		Week 30	Tezepelumab	70	70 (100.0)	-1.09 (1.12)	-3.2	-2.20	-1.00	-0.40	2.6	-0.25 [-0.60, 0.11]
			Placebo	62	57 (91.9)	-0.81 (1.12)	-3.4	-1.60	-0.80	-0.20	2.6	
		Week 32	Tezepelumab	70	70 (100.0)	-1.13 (1.08)	-3.2	-2.00	-1.00	-0.60	2.6	-0.31 [-0.67, 0.04]
			Placebo	62	57 (91.9)	-0.79 (1.10)	-3.4	-1.40	-0.80	-0.20	2.6	
		Week 34	Tezepelumab	70	70 (100.0)	-1.13 (1.14)	-3.0	-2.00	-1.30	-0.40	2.6	-0.19 [-0.54, 0.16]
			Placebo	62	57 (91.9)	-0.91 (1.14)	-3.4	-1.60	-1.20	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Change from baseline	Week 36	Tezepelumab	70	70 (100.0)	-1.06 (1.21)	-3.2	-2.00	-1.10	-0.20	2.6	-0.21 [-0.56, 0.14]
			Placebo	62	57 (91.9)	-0.81 (1.17)	-3.4	-1.40	-0.80	-0.20	2.6	
		Week 38	Tezepelumab	70	70 (100.0)	-1.07 (1.18)	-3.2	-2.20	-1.10	-0.20	2.6	-0.19 [-0.54, 0.16]
			Placebo	62	57 (91.9)	-0.85 (1.19)	-3.2	-1.60	-1.00	0.00	2.6	
		Week 40	Tezepelumab	70	70 (100.0)	-1.07 (1.14)	-3.4	-2.00	-1.00	-0.40	2.6	-0.29 [-0.64, 0.06]
			Placebo	62	57 (91.9)	-0.72 (1.23)	-3.2	-1.60	-0.80	0.20	2.6	
		Week 42	Tezepelumab	70	70 (100.0)	-1.07 (1.19)	-3.2	-2.00	-1.00	-0.40	2.6	-0.24 [-0.59, 0.11]
			Placebo	62	57 (91.9)	-0.79 (1.18)	-3.2	-1.60	-0.80	-0.20	2.6	
		Week 44	Tezepelumab	70	70 (100.0)	-1.04 (1.14)	-3.4	-1.80	-1.00	-0.20	2.6	-0.28 [-0.64, 0.07]
			Placebo	62	57 (91.9)	-0.71 (1.22)	-3.4	-1.40	-0.80	0.20	2.6	
		Week 46	Tezepelumab	70	70 (100.0)	-1.12 (1.13)	-3.2	-2.00	-1.00	-0.20	2.6	-0.25 [-0.60, 0.10]
			Placebo	62	57 (91.9)	-0.83 (1.20)	-3.2	-1.60	-0.80	0.00	2.6	
		Week 48	Tezepelumab	70	70 (100.0)	-1.07 (1.17)	-2.8	-2.00	-1.00	-0.20	2.6	-0.25 [-0.61, 0.10]
			Placebo	62	57 (91.9)	-0.76 (1.22)	-3.2	-1.60	-0.80	0.00	2.6	
		Week 50	Tezepelumab	70	70 (100.0)	-1.13 (1.16)	-3.2	-2.20	-1.00	-0.40	2.6	-0.29 [-0.64, 0.06]
			Placebo	62	57 (91.9)	-0.80 (1.16)	-3.0	-1.60	-0.80	-0.20	2.6	
		Week 52	Tezepelumab	70	70 (100.0)	-1.13 (1.18)	-3.2	-2.20	-1.00	-0.40	2.6	-0.31 [-0.66, 0.04]
			Placebo	62	57 (91.9)	-0.76 (1.21)	-3.0	-1.60	-0.80	0.00	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	65	65 (100.0)	2.95 (0.93)	0.4	2.40	2.80	3.40	5.2	
			Placebo	75	75 (100.0)	2.81 (0.72)	0.4	2.40	3.00	3.20	4.2	
		Week 2	Tezepelumab	65	61 (93.8)	2.28 (1.05)	0.0	1.60	2.40	3.00	4.2	
			Placebo	75	70 (93.3)	2.47 (0.77)	0.0	2.20	2.60	3.00	4.4	
		Week 4	Tezepelumab	65	61 (93.8)	1.94 (1.11)	0.0	1.20	2.20	2.80	4.2	
			Placebo	75	70 (93.3)	2.31 (0.81)	0.2	1.80	2.40	2.80	4.2	
		Week 6	Tezepelumab	65	61 (93.8)	1.93 (1.07)	0.0	1.20	2.00	2.80	4.2	
			Placebo	75	70 (93.3)	2.18 (0.83)	0.2	1.80	2.20	2.80	4.2	
		Week 8	Tezepelumab	65	61 (93.8)	1.76 (1.09)	0.0	1.00	1.80	2.80	4.2	
			Placebo	75	70 (93.3)	2.09 (0.87)	0.0	1.60	2.20	2.60	4.0	
		Week 10	Tezepelumab	65	61 (93.8)	1.72 (1.08)	0.0	0.80	1.80	2.60	4.2	
			Placebo	75	71 (94.7)	2.07 (0.94)	0.0	1.40	2.00	2.60	5.2	
		Week 12	Tezepelumab	65	61 (93.8)	1.70 (1.10)	0.0	0.80	1.80	2.60	4.2	
			Placebo	75	71 (94.7)	2.03 (0.98)	0.0	1.20	2.20	2.80	4.4	
		Week 14	Tezepelumab	65	61 (93.8)	1.55 (1.12)	0.0	0.80	1.40	2.40	4.2	
			Placebo	75	71 (94.7)	2.00 (0.89)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	65	61 (93.8)	1.70 (1.17)	0.0	0.80	1.80	2.60	4.6	
			Placebo	75	71 (94.7)	2.07 (1.00)	0.0	1.20	2.20	2.80	5.0	
		Week 18	Tezepelumab	65	61 (93.8)	1.59 (1.09)	0.0	0.80	1.40	2.40	4.2	
			Placebo	75	71 (94.7)	2.03 (0.89)	0.0	1.40	2.00	2.60	5.0	
		Week 20	Tezepelumab	65	61 (93.8)	1.69 (1.13)	0.0	0.80	1.60	2.40	5.0	
			Placebo	75	71 (94.7)	2.08 (0.96)	0.0	1.40	2.20	2.80	5.0	
		Week 22	Tezepelumab	65	61 (93.8)	1.62 (1.06)	0.0	0.80	1.60	2.20	4.2	
			Placebo	75	71 (94.7)	2.03 (0.95)	0.0	1.20	2.00	2.60	5.0	
		Week 24	Tezepelumab	65	61 (93.8)	1.70 (1.18)	0.0	0.80	1.80	2.60	4.8	
			Placebo	75	71 (94.7)	1.96 (0.91)	0.0	1.20	2.00	2.60	4.0	
		Week 26	Tezepelumab	65	61 (93.8)	1.65 (1.10)	0.0	0.80	1.60	2.40	4.2	
			Placebo	75	71 (94.7)	1.89 (0.88)	0.0	1.20	1.80	2.80	4.0	
		Week 28	Tezepelumab	65	62 (95.4)	1.68 (1.11)	0.0	1.00	1.70	2.40	4.2	
			Placebo	75	72 (96.0)	1.86 (1.02)	0.0	1.00	2.00	2.80	4.0	
		Week 30	Tezepelumab	65	63 (96.9)	1.58 (1.05)	0.0	0.80	1.60	2.40	4.2	
			Placebo	75	72 (96.0)	1.91 (1.04)	0.0	1.00	2.00	2.70	4.2	
		Week 32	Tezepelumab	65	63 (96.9)	1.55 (1.11)	0.0	0.60	1.40	2.40	4.2	
			Placebo	75	72 (96.0)	1.81 (1.07)	0.0	0.90	1.80	2.70	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Absolute values	Week 34	Tezepelumab	65	63 (96.9)	1.56 (1.16)	0.0	0.60	1.60	2.40	4.2	
			Placebo	75	72 (96.0)	1.83 (1.04)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	65	63 (96.9)	1.66 (1.06)	0.0	0.80	2.00	2.40	4.2	
			Placebo	75	72 (96.0)	1.91 (1.06)	0.0	1.00	2.00	2.60	4.8	
		Week 38	Tezepelumab	65	63 (96.9)	1.49 (1.10)	0.0	0.60	1.20	2.20	4.6	
			Placebo	75	72 (96.0)	1.79 (1.04)	0.0	1.00	1.70	2.60	4.8	
		Week 40	Tezepelumab	65	63 (96.9)	1.54 (1.16)	0.0	0.60	1.40	2.40	4.2	
			Placebo	75	72 (96.0)	1.83 (1.00)	0.0	1.00	2.00	2.60	4.0	
		Week 42	Tezepelumab	65	63 (96.9)	1.45 (1.05)	0.0	0.60	1.20	2.20	4.2	
			Placebo	75	72 (96.0)	1.83 (1.00)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	65	63 (96.9)	1.50 (1.09)	0.0	0.60	1.40	2.40	4.2	
			Placebo	75	73 (97.3)	1.85 (1.00)	0.0	1.00	2.00	2.60	3.8	
		Week 46	Tezepelumab	65	63 (96.9)	1.52 (1.13)	0.0	0.80	1.20	2.40	4.2	
			Placebo	75	73 (97.3)	1.73 (0.94)	0.0	1.20	2.00	2.60	3.4	
		Week 48	Tezepelumab	65	63 (96.9)	1.58 (1.11)	0.0	0.80	1.40	2.40	4.2	
			Placebo	75	73 (97.3)	1.75 (0.97)	0.0	1.00	2.00	2.60	3.6	
		Week 50	Tezepelumab	65	63 (96.9)	1.46 (1.11)	0.0	0.60	1.20	2.20	4.2	
			Placebo	75	73 (97.3)	1.73 (0.92)	0.0	1.00	1.80	2.40	3.4	
		Week 52	Tezepelumab	65	63 (96.9)	1.53 (1.09)	0.0	0.60	1.20	2.20	4.4	
			Placebo	75	73 (97.3)	1.78 (0.96)	0.0	1.00	2.00	2.60	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 2	Tezepelumab	65	61 (93.8)	-0.65 (0.75)	-3.0	-1.20	-0.60	-0.20	0.4	-0.37 [-0.72, -0.03]
			Placebo	75	70 (93.3)	-0.38 (0.72)	-3.0	-0.80	-0.20	0.00	1.4	
		Week 4	Tezepelumab	65	61 (93.8)	-0.99 (1.00)	-3.8	-1.60	-0.80	-0.40	1.2	-0.49 [-0.83, -0.14]
			Placebo	75	70 (93.3)	-0.53 (0.88)	-3.0	-1.20	-0.20	0.00	1.6	
		Week 6	Tezepelumab	65	61 (93.8)	-1.00 (1.06)	-4.0	-1.60	-1.00	-0.20	1.2	-0.34 [-0.69, 0.00]
			Placebo	75	70 (93.3)	-0.67 (0.87)	-3.4	-1.20	-0.60	0.00	1.0	
		Week 8	Tezepelumab	65	61 (93.8)	-1.17 (1.02)	-4.0	-1.80	-1.20	-0.40	1.0	-0.42 [-0.77, -0.08]
			Placebo	75	70 (93.3)	-0.76 (0.93)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	65	61 (93.8)	-1.21 (1.03)	-4.0	-1.80	-1.20	-0.40	1.0	-0.41 [-0.76, -0.07]
			Placebo	75	71 (94.7)	-0.78 (1.04)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	65	61 (93.8)	-1.23 (1.10)	-4.0	-1.80	-1.20	-0.40	1.2	-0.37 [-0.71, -0.02]
			Placebo	75	71 (94.7)	-0.83 (1.07)	-3.8	-1.40	-0.60	0.00	1.4	
		Week 14	Tezepelumab	65	61 (93.8)	-1.38 (1.15)	-4.2	-2.20	-1.40	-0.60	1.2	-0.49 [-0.84, -0.14]
			Placebo	75	71 (94.7)	-0.86 (0.99)	-3.4	-1.40	-0.60	-0.20	2.4	
		Week 16	Tezepelumab	65	61 (93.8)	-1.23 (1.20)	-4.4	-1.80	-1.20	-0.60	1.8	-0.38 [-0.73, -0.04]
			Placebo	75	71 (94.7)	-0.79 (1.09)	-3.6	-1.40	-0.60	0.00	2.4	
		Week 18	Tezepelumab	65	61 (93.8)	-1.34 (1.17)	-4.4	-2.00	-1.20	-0.60	1.2	-0.48 [-0.82, -0.13]
			Placebo	75	71 (94.7)	-0.83 (1.00)	-3.6	-1.40	-0.60	-0.20	2.4	
		Week 20	Tezepelumab	65	61 (93.8)	-1.25 (1.13)	-4.4	-2.00	-1.20	-0.60	1.0	-0.42 [-0.76, -0.07]
			Placebo	75	71 (94.7)	-0.78 (1.11)	-3.6	-1.40	-0.60	-0.20	2.4	
		Week 22	Tezepelumab	65	61 (93.8)	-1.31 (1.13)	-4.4	-2.00	-1.20	-0.60	1.2	-0.44 [-0.79, -0.10]
			Placebo	75	71 (94.7)	-0.83 (1.05)	-3.8	-1.40	-0.80	0.00	2.4	
		Week 24	Tezepelumab	65	61 (93.8)	-1.23 (1.13)	-4.8	-2.00	-1.20	-0.40	1.4	-0.31 [-0.66, 0.03]
			Placebo	75	71 (94.7)	-0.89 (1.04)	-3.8	-1.40	-0.80	-0.20	1.4	
		Week 26	Tezepelumab	65	61 (93.8)	-1.28 (1.17)	-4.4	-2.20	-1.40	-0.40	1.2	-0.29 [-0.63, 0.05]
			Placebo	75	71 (94.7)	-0.96 (1.04)	-4.2	-1.60	-1.00	0.00	1.4	
		Week 28	Tezepelumab	65	62 (95.4)	-1.24 (1.10)	-4.4	-2.00	-1.20	-0.60	1.0	-0.25 [-0.60, 0.09]
			Placebo	75	72 (96.0)	-0.96 (1.12)	-4.2	-1.70	-0.80	-0.20	1.4	
		Week 30	Tezepelumab	65	63 (96.9)	-1.36 (1.16)	-4.4	-2.20	-1.20	-0.60	1.4	-0.38 [-0.72, -0.04]
			Placebo	75	72 (96.0)	-0.91 (1.18)	-3.4	-1.60	-1.00	-0.10	2.0	
		Week 32	Tezepelumab	65	63 (96.9)	-1.39 (1.17)	-4.4	-2.20	-1.40	-0.60	1.8	-0.33 [-0.67, 0.02]
			Placebo	75	72 (96.0)	-1.01 (1.14)	-3.6	-1.80	-1.00	-0.20	1.8	
		Week 34	Tezepelumab	65	63 (96.9)	-1.38 (1.17)	-4.4	-2.20	-1.20	-0.60	1.8	-0.34 [-0.68, -0.00]
			Placebo	75	72 (96.0)	-0.99 (1.11)	-4.2	-1.80	-1.00	-0.20	1.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Change from baseline	Week 36	Tezepelumab	65	63 (96.9)	-1.28 (1.18)	-4.4	-2.00	-1.20	-0.40	1.4	-0.31 [-0.65, 0.03]
			Placebo	75	72 (96.0)	-0.92 (1.16)	-3.6	-1.70	-1.00	0.00	1.8	
		Week 38	Tezepelumab	65	63 (96.9)	-1.45 (1.16)	-4.4	-2.20	-1.40	-0.60	1.0	-0.37 [-0.71, -0.03]
			Placebo	75	72 (96.0)	-1.03 (1.13)	-4.2	-1.80	-1.00	-0.40	1.8	
		Week 40	Tezepelumab	65	63 (96.9)	-1.40 (1.22)	-4.4	-2.20	-1.40	-0.60	1.2	-0.36 [-0.70, -0.02]
			Placebo	75	72 (96.0)	-0.99 (1.04)	-4.2	-1.60	-0.90	-0.30	1.4	
		Week 42	Tezepelumab	65	63 (96.9)	-1.49 (1.16)	-4.4	-2.20	-1.60	-0.60	1.0	-0.44 [-0.79, -0.10]
			Placebo	75	72 (96.0)	-1.00 (1.06)	-4.2	-1.40	-1.00	-0.20	1.0	
		Week 44	Tezepelumab	65	63 (96.9)	-1.44 (1.21)	-4.4	-2.20	-1.40	-0.60	0.6	-0.42 [-0.76, -0.07]
			Placebo	75	73 (97.3)	-0.97 (1.06)	-4.2	-1.60	-0.80	-0.40	1.2	
		Week 46	Tezepelumab	65	63 (96.9)	-1.42 (1.21)	-4.4	-2.20	-1.40	-0.60	1.2	-0.30 [-0.63, 0.04]
			Placebo	75	73 (97.3)	-1.09 (1.01)	-4.2	-1.60	-1.20	-0.40	0.8	
		Week 48	Tezepelumab	65	63 (96.9)	-1.36 (1.17)	-4.4	-2.00	-1.20	-0.40	1.2	-0.26 [-0.60, 0.08]
			Placebo	75	73 (97.3)	-1.07 (1.03)	-3.8	-1.60	-1.00	-0.40	0.8	
		Week 50	Tezepelumab	65	63 (96.9)	-1.48 (1.18)	-4.4	-2.20	-1.60	-0.60	1.2	-0.36 [-0.70, -0.02]
			Placebo	75	73 (97.3)	-1.09 (1.00)	-4.2	-1.60	-1.00	-0.40	0.8	
		Week 52	Tezepelumab	65	63 (96.9)	-1.41 (1.18)	-4.4	-2.00	-1.40	-0.60	1.2	-0.34 [-0.68, -0.00]
			Placebo	75	73 (97.3)	-1.04 (1.01)	-4.2	-1.60	-0.80	-0.40	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	62	62 (100.0)	2.90 (0.72)	1.6	2.40	2.90	3.20	5.0	
			Placebo	67	67 (100.0)	2.76 (0.70)	0.4	2.40	3.00	3.20	4.8	
		Week 2	Tezepelumab	62	58 (93.5)	2.45 (0.85)	0.0	1.80	2.60	3.00	4.2	
			Placebo	67	59 (88.1)	2.32 (0.82)	0.0	2.00	2.40	2.80	4.8	
		Week 4	Tezepelumab	62	58 (93.5)	2.23 (0.92)	0.2	1.60	2.40	2.80	4.2	
			Placebo	67	59 (88.1)	2.25 (0.91)	0.2	1.60	2.40	3.00	4.2	
		Week 6	Tezepelumab	62	58 (93.5)	2.12 (0.99)	0.0	1.40	2.10	3.00	4.2	
			Placebo	67	59 (88.1)	2.09 (1.03)	0.2	1.40	2.00	2.80	5.0	
		Week 8	Tezepelumab	62	58 (93.5)	2.16 (1.04)	0.0	1.40	2.20	3.00	5.2	
			Placebo	67	60 (89.6)	2.11 (1.01)	0.0	1.40	2.30	2.90	4.6	
		Week 10	Tezepelumab	62	58 (93.5)	2.04 (1.02)	0.0	1.20	2.10	2.80	4.8	
			Placebo	67	61 (91.0)	2.06 (0.98)	0.2	1.40	2.00	2.80	5.2	
		Week 12	Tezepelumab	62	58 (93.5)	2.01 (1.06)	0.0	1.00	2.20	2.60	4.8	
			Placebo	67	61 (91.0)	1.99 (1.09)	0.0	1.20	2.00	2.80	4.4	
		Week 14	Tezepelumab	62	58 (93.5)	1.90 (1.07)	0.0	1.20	1.80	2.60	4.8	
			Placebo	67	61 (91.0)	1.99 (1.03)	0.0	1.00	2.00	2.60	5.0	
		Week 16	Tezepelumab	62	58 (93.5)	2.04 (1.06)	0.0	1.20	2.20	2.80	4.8	
			Placebo	67	61 (91.0)	2.16 (1.08)	0.0	1.40	2.20	3.00	5.0	
		Week 18	Tezepelumab	62	59 (95.2)	1.87 (1.06)	0.0	1.00	2.00	2.60	4.8	
			Placebo	67	61 (91.0)	2.01 (1.07)	0.0	1.40	2.00	2.60	5.0	
		Week 20	Tezepelumab	62	59 (95.2)	2.01 (1.06)	0.0	1.20	2.00	2.60	5.0	
			Placebo	67	61 (91.0)	2.05 (1.02)	0.0	1.40	2.20	2.80	5.0	
		Week 22	Tezepelumab	62	59 (95.2)	1.97 (1.04)	0.0	1.20	2.20	2.60	4.8	
			Placebo	67	61 (91.0)	2.02 (1.03)	0.0	1.20	2.00	2.80	5.0	
		Week 24	Tezepelumab	62	59 (95.2)	1.93 (1.05)	0.0	1.20	2.00	2.60	4.8	
			Placebo	67	61 (91.0)	1.94 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	62	60 (96.8)	1.97 (1.03)	0.0	1.10	2.00	2.70	4.8	
			Placebo	67	61 (91.0)	1.93 (1.04)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	62	61 (98.4)	1.99 (1.07)	0.0	1.40	2.20	2.80	4.8	
			Placebo	67	62 (92.5)	1.91 (1.08)	0.0	1.00	2.20	2.80	4.4	
		Week 30	Tezepelumab	62	61 (98.4)	1.95 (1.09)	0.0	1.00	2.00	2.60	4.8	
			Placebo	67	63 (94.0)	1.97 (1.13)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	62	61 (98.4)	1.96 (1.09)	0.0	1.00	2.00	2.80	4.8	
			Placebo	67	63 (94.0)	1.93 (1.11)	0.0	0.80	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low (< 20.9 ng/ml)	Absolute values	Week 34	Tezepelumab	62	61 (98.4)	1.91 (1.16)	0.0	1.00	2.00	2.80	4.8	
			Placebo	67	63 (94.0)	1.85 (1.10)	0.0	1.00	1.80	2.80	4.4	
		Week 36	Tezepelumab	62	61 (98.4)	1.97 (1.08)	0.0	1.20	2.20	2.80	4.8	
			Placebo	67	63 (94.0)	1.91 (1.13)	0.0	1.00	2.00	2.80	4.4	
		Week 38	Tezepelumab	62	61 (98.4)	1.93 (1.15)	0.0	1.00	2.00	2.60	4.8	
			Placebo	67	63 (94.0)	1.84 (1.07)	0.0	1.00	1.80	2.80	4.4	
		Week 40	Tezepelumab	62	61 (98.4)	1.99 (1.13)	0.0	1.00	2.00	2.80	4.8	
			Placebo	67	63 (94.0)	1.95 (1.16)	0.0	0.80	2.00	3.00	4.4	
		Week 42	Tezepelumab	62	61 (98.4)	1.90 (1.13)	0.0	1.00	2.00	2.80	4.8	
			Placebo	67	63 (94.0)	1.89 (1.07)	0.0	0.80	2.00	2.60	4.6	
		Week 44	Tezepelumab	62	61 (98.4)	1.94 (1.08)	0.0	1.20	2.00	2.80	4.8	
			Placebo	67	64 (95.5)	1.94 (1.13)	0.0	1.00	2.10	2.80	4.4	
		Week 46	Tezepelumab	62	61 (98.4)	1.94 (1.15)	0.0	1.00	2.00	2.80	4.8	
			Placebo	67	64 (95.5)	1.80 (1.08)	0.0	0.90	1.90	2.80	4.4	
		Week 48	Tezepelumab	62	61 (98.4)	1.95 (1.12)	0.0	1.20	2.00	2.80	4.8	
			Placebo	67	64 (95.5)	1.78 (1.13)	0.0	0.80	1.90	2.80	4.4	
		Week 50	Tezepelumab	62	61 (98.4)	1.87 (1.17)	0.0	1.00	1.80	2.80	4.8	
			Placebo	67	64 (95.5)	1.81 (1.09)	0.0	1.00	1.90	2.80	4.4	
		Week 52	Tezepelumab	62	61 (98.4)	1.93 (1.15)	0.0	1.00	2.00	2.80	4.8	
			Placebo	67	64 (95.5)	1.83 (1.14)	0.0	0.90	1.90	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 2	Tezepelumab	62	58 (93.5)	-0.47 (0.66)	-3.2	-0.80	-0.40	0.00	0.4	0.01 [-0.35, 0.37]
			Placebo	67	59 (88.1)	-0.48 (0.82)	-3.0	-1.00	-0.40	0.00	1.4	
		Week 4	Tezepelumab	62	58 (93.5)	-0.69 (0.79)	-2.4	-1.20	-0.60	-0.20	1.2	-0.16 [-0.52, 0.20]
			Placebo	67	59 (88.1)	-0.54 (0.98)	-3.0	-1.20	-0.20	0.20	1.6	
		Week 6	Tezepelumab	62	58 (93.5)	-0.80 (0.90)	-3.6	-1.40	-0.80	0.00	1.2	-0.10 [-0.46, 0.26]
			Placebo	67	59 (88.1)	-0.71 (1.03)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	62	58 (93.5)	-0.76 (0.94)	-3.0	-1.20	-0.80	-0.20	2.6	-0.07 [-0.43, 0.29]
			Placebo	67	60 (89.6)	-0.69 (1.01)	-3.0	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	62	58 (93.5)	-0.88 (0.91)	-3.6	-1.60	-1.00	-0.20	1.0	-0.13 [-0.49, 0.23]
			Placebo	67	61 (91.0)	-0.76 (1.03)	-3.2	-1.40	-0.60	-0.20	2.6	
		Week 12	Tezepelumab	62	58 (93.5)	-0.91 (0.96)	-4.0	-1.60	-0.80	-0.40	1.2	-0.08 [-0.44, 0.28]
			Placebo	67	61 (91.0)	-0.82 (1.12)	-3.2	-1.40	-0.80	-0.20	1.4	
		Week 14	Tezepelumab	62	58 (93.5)	-1.02 (0.96)	-4.2	-1.60	-1.00	-0.40	1.2	-0.20 [-0.56, 0.16]
			Placebo	67	61 (91.0)	-0.82 (1.08)	-3.2	-1.40	-0.80	-0.20	2.4	
		Week 16	Tezepelumab	62	58 (93.5)	-0.88 (0.95)	-4.4	-1.20	-1.00	-0.20	1.0	-0.21 [-0.57, 0.15]
			Placebo	67	61 (91.0)	-0.65 (1.15)	-3.0	-1.40	-0.60	0.20	2.4	
		Week 18	Tezepelumab	62	59 (95.2)	-1.03 (0.95)	-4.4	-1.80	-1.00	-0.60	1.2	-0.22 [-0.58, 0.14]
			Placebo	67	61 (91.0)	-0.81 (1.11)	-3.2	-1.60	-0.60	-0.20	2.4	
		Week 20	Tezepelumab	62	59 (95.2)	-0.89 (0.98)	-4.4	-1.60	-0.80	-0.20	1.0	-0.13 [-0.49, 0.23]
			Placebo	67	61 (91.0)	-0.76 (1.10)	-3.0	-1.40	-0.60	-0.20	2.4	
		Week 22	Tezepelumab	62	59 (95.2)	-0.94 (0.99)	-4.4	-1.60	-0.80	-0.20	1.2	-0.14 [-0.50, 0.22]
			Placebo	67	61 (91.0)	-0.79 (1.10)	-3.2	-1.60	-0.60	0.00	2.4	
		Week 24	Tezepelumab	62	59 (95.2)	-0.98 (0.97)	-4.8	-1.40	-0.80	-0.40	1.4	-0.10 [-0.46, 0.26]
			Placebo	67	61 (91.0)	-0.87 (1.13)	-3.2	-1.60	-0.80	-0.20	1.8	
		Week 26	Tezepelumab	62	60 (96.8)	-0.91 (0.96)	-4.4	-1.40	-0.80	-0.30	1.2	-0.03 [-0.39, 0.32]
			Placebo	67	61 (91.0)	-0.88 (1.08)	-3.0	-1.80	-0.80	0.00	1.4	
		Week 28	Tezepelumab	62	61 (98.4)	-0.90 (1.06)	-4.4	-1.40	-0.80	-0.20	1.0	-0.03 [-0.38, 0.32]
			Placebo	67	62 (92.5)	-0.86 (1.12)	-3.0	-1.60	-0.70	-0.20	1.4	
		Week 30	Tezepelumab	62	61 (98.4)	-0.93 (1.10)	-4.4	-1.60	-1.00	-0.20	2.0	-0.11 [-0.47, 0.24]
			Placebo	67	63 (94.0)	-0.80 (1.19)	-3.2	-1.60	-0.60	-0.20	2.0	
		Week 32	Tezepelumab	62	61 (98.4)	-0.92 (1.04)	-4.4	-1.60	-1.00	-0.40	1.8	-0.07 [-0.42, 0.29]
			Placebo	67	63 (94.0)	-0.85 (1.12)	-3.2	-1.60	-0.80	-0.20	1.4	
		Week 34	Tezepelumab	62	61 (98.4)	-0.97 (1.11)	-4.4	-1.80	-1.00	-0.20	2.2	-0.04 [-0.39, 0.31]
			Placebo	67	63 (94.0)	-0.93 (1.14)	-3.4	-1.60	-0.80	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low (< 20.9 ng/ml)	Change from baseline	Week 36	Tezepelumab	62	61 (98.4)	-0.91 (1.03)	-4.4	-1.60	-1.00	-0.20	1.6	-0.04 [-0.39, 0.31]
			Placebo	67	63 (94.0)	-0.87 (1.16)	-3.6	-1.60	-0.80	0.00	1.4	
		Week 38	Tezepelumab	62	61 (98.4)	-0.95 (1.11)	-4.4	-1.80	-1.00	-0.20	2.6	-0.01 [-0.36, 0.34]
			Placebo	67	63 (94.0)	-0.94 (1.13)	-3.4	-1.60	-1.00	-0.20	1.6	
		Week 40	Tezepelumab	62	61 (98.4)	-0.89 (1.09)	-4.4	-1.60	-1.00	-0.20	1.8	-0.05 [-0.40, 0.30]
			Placebo	67	63 (94.0)	-0.83 (1.14)	-3.6	-1.60	-0.80	0.00	1.4	
		Week 42	Tezepelumab	62	61 (98.4)	-0.98 (1.08)	-4.4	-1.60	-1.00	-0.20	2.2	-0.09 [-0.44, 0.27]
			Placebo	67	63 (94.0)	-0.89 (1.09)	-3.6	-1.40	-0.80	-0.20	1.6	
		Week 44	Tezepelumab	62	61 (98.4)	-0.94 (1.02)	-4.4	-1.60	-1.00	-0.20	1.6	-0.10 [-0.45, 0.25]
			Placebo	67	64 (95.5)	-0.83 (1.12)	-3.4	-1.60	-0.70	0.00	1.4	
		Week 46	Tezepelumab	62	61 (98.4)	-0.94 (1.09)	-4.4	-1.60	-1.00	-0.20	1.8	0.03 [-0.32, 0.38]
			Placebo	67	64 (95.5)	-0.98 (1.08)	-3.2	-1.60	-1.00	0.00	1.0	
		Week 48	Tezepelumab	62	61 (98.4)	-0.93 (1.05)	-4.4	-1.40	-1.00	-0.40	2.0	0.05 [-0.30, 0.40]
			Placebo	67	64 (95.5)	-0.99 (1.13)	-3.4	-1.60	-0.90	-0.20	1.4	
		Week 50	Tezepelumab	62	61 (98.4)	-1.02 (1.16)	-4.4	-1.80	-1.00	-0.20	2.0	-0.04 [-0.39, 0.31]
			Placebo	67	64 (95.5)	-0.97 (1.15)	-3.6	-1.60	-1.00	-0.10	1.6	
		Week 52	Tezepelumab	62	61 (98.4)	-0.95 (1.15)	-4.4	-1.60	-1.00	-0.20	2.0	-0.01 [-0.36, 0.34]
			Placebo	67	64 (95.5)	-0.94 (1.20)	-3.6	-1.70	-1.00	-0.10	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	74	74 (100.0)	2.79 (0.94)	0.0	2.40	2.80	3.20	5.2	
			Placebo	71	71 (100.0)	2.87 (0.74)	1.0	2.40	2.80	3.40	5.0	
		Week 2	Tezepelumab	74	72 (97.3)	2.11 (1.03)	0.0	1.40	2.20	2.80	4.4	
			Placebo	71	66 (93.0)	2.51 (0.85)	0.6	2.00	2.50	3.00	5.0	
		Week 4	Tezepelumab	74	72 (97.3)	1.73 (1.04)	0.0	0.90	1.80	2.60	3.4	
			Placebo	71	66 (93.0)	2.34 (0.85)	0.4	1.80	2.40	2.80	4.4	
		Week 6	Tezepelumab	74	72 (97.3)	1.65 (0.96)	0.0	1.00	1.70	2.30	3.8	
			Placebo	71	67 (94.4)	2.29 (1.01)	0.2	1.60	2.40	2.80	6.0	
		Week 8	Tezepelumab	74	72 (97.3)	1.48 (1.03)	0.0	0.60	1.40	2.30	3.8	
			Placebo	71	67 (94.4)	2.17 (1.00)	0.0	1.60	2.20	2.80	5.0	
		Week 10	Tezepelumab	74	72 (97.3)	1.45 (1.01)	0.0	0.60	1.50	2.00	3.6	
			Placebo	71	67 (94.4)	2.08 (0.94)	0.0	1.40	2.20	2.80	4.2	
		Week 12	Tezepelumab	74	72 (97.3)	1.32 (1.00)	0.0	0.60	1.40	2.00	3.6	
			Placebo	71	67 (94.4)	2.00 (0.91)	0.0	1.40	2.20	2.80	3.6	
		Week 14	Tezepelumab	74	72 (97.3)	1.18 (0.93)	0.0	0.50	1.10	1.60	3.8	
			Placebo	71	67 (94.4)	1.89 (0.87)	0.0	1.20	1.80	2.60	4.2	
		Week 16	Tezepelumab	74	72 (97.3)	1.36 (1.06)	0.0	0.60	1.20	1.90	4.6	
			Placebo	71	67 (94.4)	1.97 (1.08)	0.0	1.00	2.00	2.80	5.0	
		Week 18	Tezepelumab	74	72 (97.3)	1.27 (0.89)	0.0	0.60	1.20	2.00	3.4	
			Placebo	71	67 (94.4)	1.90 (1.00)	0.0	1.20	1.80	2.60	4.0	
		Week 20	Tezepelumab	74	72 (97.3)	1.33 (0.99)	0.0	0.50	1.20	2.00	3.6	
			Placebo	71	67 (94.4)	1.96 (1.07)	0.0	1.20	2.00	2.80	4.0	
		Week 22	Tezepelumab	74	72 (97.3)	1.41 (0.95)	0.0	0.70	1.40	2.20	3.4	
			Placebo	71	67 (94.4)	1.90 (1.06)	0.0	1.20	2.00	2.60	4.0	
		Week 24	Tezepelumab	74	72 (97.3)	1.42 (1.08)	0.0	0.50	1.20	2.10	4.8	
			Placebo	71	67 (94.4)	1.96 (1.00)	0.0	1.20	2.20	2.80	4.0	
		Week 26	Tezepelumab	74	72 (97.3)	1.30 (0.97)	0.0	0.60	1.20	1.90	3.6	
			Placebo	71	67 (94.4)	1.87 (0.99)	0.0	1.00	1.60	2.80	4.4	
		Week 28	Tezepelumab	74	72 (97.3)	1.39 (1.06)	0.0	0.40	1.20	2.20	3.6	
			Placebo	71	67 (94.4)	2.00 (1.12)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	74	73 (98.6)	1.32 (0.93)	0.0	0.60	1.20	2.00	3.6	
			Placebo	71	67 (94.4)	1.91 (1.02)	0.0	1.20	2.00	2.80	4.0	
		Week 32	Tezepelumab	74	73 (98.6)	1.21 (0.93)	0.0	0.40	1.00	2.00	3.6	
			Placebo	71	67 (94.4)	1.86 (1.06)	0.0	1.00	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High (>= 20.9 ng/ml)	Absolute values	Week 34	Tezepelumab	74	73 (98.6)	1.29 (1.02)	0.0	0.40	1.20	2.00	4.2	
			Placebo	71	67 (94.4)	1.86 (1.07)	0.0	1.20	1.80	2.60	4.8	
		Week 36	Tezepelumab	74	73 (98.6)	1.39 (1.07)	0.0	0.60	1.40	2.20	5.0	
			Placebo	71	67 (94.4)	1.97 (1.08)	0.0	1.20	2.00	2.80	4.8	
		Week 38	Tezepelumab	74	73 (98.6)	1.25 (0.96)	0.0	0.60	1.20	2.00	3.6	
			Placebo	71	67 (94.4)	1.88 (1.07)	0.0	1.00	1.80	2.60	4.8	
		Week 40	Tezepelumab	74	73 (98.6)	1.24 (0.97)	0.0	0.40	1.20	2.00	3.2	
			Placebo	71	67 (94.4)	1.93 (1.05)	0.0	1.00	2.00	2.60	4.2	
		Week 42	Tezepelumab	74	73 (98.6)	1.24 (0.98)	0.0	0.40	1.20	1.80	4.6	
			Placebo	71	67 (94.4)	1.92 (1.04)	0.0	1.20	2.00	2.60	4.6	
		Week 44	Tezepelumab	74	73 (98.6)	1.26 (1.01)	0.0	0.40	1.00	2.00	3.8	
			Placebo	71	67 (94.4)	1.96 (1.02)	0.0	1.20	2.00	2.80	4.0	
		Week 46	Tezepelumab	74	73 (98.6)	1.21 (0.95)	0.0	0.60	1.00	1.80	3.6	
			Placebo	71	67 (94.4)	1.86 (0.97)	0.0	1.20	2.00	2.60	4.4	
		Week 48	Tezepelumab	74	73 (98.6)	1.31 (1.02)	0.0	0.40	1.20	2.20	4.2	
			Placebo	71	67 (94.4)	1.95 (1.01)	0.0	1.20	2.00	2.60	4.6	
		Week 50	Tezepelumab	74	73 (98.6)	1.22 (0.94)	0.0	0.60	1.00	2.00	4.2	
			Placebo	71	67 (94.4)	1.88 (0.93)	0.0	1.00	2.00	2.60	4.0	
		Week 52	Tezepelumab	74	73 (98.6)	1.22 (0.94)	0.0	0.40	1.00	1.80	4.2	
			Placebo	71	67 (94.4)	1.95 (0.94)	0.0	1.20	2.00	2.60	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 2	Tezepelumab	74	72 (97.3)	-0.67 (0.80)	-3.0	-1.20	-0.50	-0.20	0.8	-0.41 [-0.75, -0.07]
			Placebo	71	66 (93.0)	-0.35 (0.72)	-2.4	-0.80	-0.40	0.00	1.2	
		Week 4	Tezepelumab	74	72 (97.3)	-1.05 (1.06)	-3.8	-1.70	-1.00	-0.40	2.6	-0.55 [-0.89, -0.21]
			Placebo	71	66 (93.0)	-0.52 (0.85)	-3.0	-1.00	-0.40	0.00	1.0	
		Week 6	Tezepelumab	74	72 (97.3)	-1.13 (1.11)	-4.0	-1.80	-1.00	-0.30	2.6	-0.56 [-0.90, -0.22]
			Placebo	71	67 (94.4)	-0.56 (0.91)	-3.2	-1.20	-0.60	0.00	1.6	
		Week 8	Tezepelumab	74	72 (97.3)	-1.29 (1.14)	-4.0	-2.00	-1.40	-0.40	2.6	-0.58 [-0.92, -0.24]
			Placebo	71	67 (94.4)	-0.69 (0.93)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	74	72 (97.3)	-1.33 (1.12)	-4.0	-2.10	-1.40	-0.60	2.6	-0.52 [-0.86, -0.18]
			Placebo	71	67 (94.4)	-0.77 (1.02)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	74	72 (97.3)	-1.46 (1.09)	-4.0	-2.20	-1.40	-0.80	2.6	-0.58 [-0.92, -0.24]
			Placebo	71	67 (94.4)	-0.86 (0.99)	-3.8	-1.40	-0.60	-0.20	1.6	
		Week 14	Tezepelumab	74	72 (97.3)	-1.60 (1.10)	-4.0	-2.20	-1.70	-1.00	2.6	-0.62 [-0.96, -0.28]
			Placebo	71	67 (94.4)	-0.97 (0.94)	-3.4	-1.40	-1.00	-0.40	1.4	
		Week 16	Tezepelumab	74	72 (97.3)	-1.42 (1.19)	-4.0	-2.20	-1.40	-0.80	2.6	-0.47 [-0.81, -0.14]
			Placebo	71	67 (94.4)	-0.89 (1.05)	-3.6	-1.40	-1.00	-0.20	2.6	
		Week 18	Tezepelumab	74	72 (97.3)	-1.51 (1.14)	-4.0	-2.20	-1.50	-0.80	2.6	-0.50 [-0.84, -0.16]
			Placebo	71	67 (94.4)	-0.96 (1.06)	-3.6	-1.40	-1.00	-0.40	2.6	
		Week 20	Tezepelumab	74	72 (97.3)	-1.45 (1.12)	-4.0	-2.30	-1.40	-0.80	2.6	-0.50 [-0.83, -0.16]
			Placebo	71	67 (94.4)	-0.89 (1.14)	-3.6	-1.40	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	74	72 (97.3)	-1.37 (1.19)	-4.0	-2.40	-1.20	-0.60	2.6	-0.36 [-0.69, -0.02]
			Placebo	71	67 (94.4)	-0.96 (1.07)	-3.8	-1.60	-1.00	-0.20	2.6	
		Week 24	Tezepelumab	74	72 (97.3)	-1.36 (1.12)	-4.0	-2.20	-1.40	-0.50	2.6	-0.42 [-0.76, -0.08]
			Placebo	71	67 (94.4)	-0.90 (1.08)	-3.8	-1.60	-1.00	-0.20	2.6	
		Week 26	Tezepelumab	74	72 (97.3)	-1.48 (1.17)	-4.0	-2.30	-1.40	-0.70	2.6	-0.42 [-0.76, -0.09]
			Placebo	71	67 (94.4)	-0.99 (1.13)	-4.2	-1.60	-1.20	-0.20	2.6	
		Week 28	Tezepelumab	74	72 (97.3)	-1.38 (1.14)	-4.0	-2.20	-1.40	-0.70	2.6	-0.45 [-0.79, -0.12]
			Placebo	71	67 (94.4)	-0.86 (1.18)	-4.2	-1.60	-1.00	0.00	2.6	
		Week 30	Tezepelumab	74	73 (98.6)	-1.48 (1.13)	-3.8	-2.40	-1.40	-0.80	2.6	-0.47 [-0.81, -0.14]
			Placebo	71	67 (94.4)	-0.95 (1.11)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 32	Tezepelumab	74	73 (98.6)	-1.58 (1.12)	-4.0	-2.40	-1.60	-0.80	2.6	-0.51 [-0.85, -0.18]
			Placebo	71	67 (94.4)	-1.00 (1.14)	-3.6	-1.80	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	74	73 (98.6)	-1.50 (1.15)	-4.0	-2.40	-1.60	-0.80	2.6	-0.44 [-0.78, -0.11]
			Placebo	71	67 (94.4)	-1.00 (1.11)	-4.2	-1.60	-1.20	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High (>= 20.9 ng/ml)	Change from baseline	Week 36	Tezepelumab	74	73 (98.6)	-1.40 (1.29)	-4.0	-2.40	-1.40	-0.60	2.6	-0.41 [-0.75, -0.08]
			Placebo	71	67 (94.4)	-0.89 (1.18)	-3.6	-1.60	-1.00	0.00	2.6	
		Week 38	Tezepelumab	74	73 (98.6)	-1.54 (1.19)	-4.0	-2.40	-1.60	-0.80	2.6	-0.47 [-0.81, -0.14]
			Placebo	71	67 (94.4)	-0.98 (1.18)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 40	Tezepelumab	74	73 (98.6)	-1.55 (1.21)	-4.2	-2.40	-1.60	-0.80	2.6	-0.53 [-0.87, -0.19]
			Placebo	71	67 (94.4)	-0.93 (1.13)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 42	Tezepelumab	74	73 (98.6)	-1.55 (1.22)	-4.0	-2.40	-1.60	-0.80	2.6	-0.52 [-0.85, -0.18]
			Placebo	71	67 (94.4)	-0.94 (1.14)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	74	73 (98.6)	-1.53 (1.29)	-4.4	-2.40	-1.40	-0.80	2.6	-0.52 [-0.86, -0.18]
			Placebo	71	67 (94.4)	-0.90 (1.16)	-4.2	-1.60	-1.00	-0.20	2.6	
		Week 46	Tezepelumab	74	73 (98.6)	-1.58 (1.19)	-4.0	-2.40	-1.60	-0.80	2.6	-0.50 [-0.84, -0.17]
			Placebo	71	67 (94.4)	-1.00 (1.13)	-4.2	-1.60	-1.00	-0.60	2.6	
		Week 48	Tezepelumab	74	73 (98.6)	-1.48 (1.24)	-4.0	-2.40	-1.60	-0.40	2.6	-0.48 [-0.82, -0.15]
			Placebo	71	67 (94.4)	-0.91 (1.13)	-3.8	-1.60	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	74	73 (98.6)	-1.57 (1.17)	-4.0	-2.40	-1.60	-0.80	2.6	-0.54 [-0.88, -0.20]
			Placebo	71	67 (94.4)	-0.98 (1.01)	-4.2	-1.60	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	74	73 (98.6)	-1.57 (1.18)	-4.0	-2.40	-1.60	-0.80	2.6	-0.60 [-0.94, -0.26]
			Placebo	71	67 (94.4)	-0.91 (1.03)	-4.2	-1.60	-0.80	-0.40	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	114	114 (100.0)	2.86 (0.87)	0.0	2.40	2.80	3.20	5.2	
			Placebo	126	126 (100.0)	2.82 (0.70)	0.4	2.40	2.80	3.20	4.8	
		Week 2	Tezepelumab	114	109 (95.6)	2.32 (0.98)	0.0	1.80	2.40	3.00	4.4	
			Placebo	126	115 (91.3)	2.40 (0.82)	0.0	2.00	2.40	3.00	4.8	
		Week 4	Tezepelumab	114	109 (95.6)	2.01 (1.02)	0.0	1.20	2.20	2.80	4.2	
			Placebo	126	115 (91.3)	2.26 (0.88)	0.2	1.80	2.40	2.80	4.4	
		Week 6	Tezepelumab	114	109 (95.6)	1.93 (1.01)	0.0	1.20	2.00	2.60	4.2	
			Placebo	126	116 (92.1)	2.16 (0.98)	0.2	1.40	2.20	2.80	5.0	
		Week 8	Tezepelumab	114	109 (95.6)	1.85 (1.07)	0.0	1.00	1.80	2.80	5.2	
			Placebo	126	117 (92.9)	2.13 (0.98)	0.0	1.60	2.20	2.80	4.6	
		Week 10	Tezepelumab	114	109 (95.6)	1.81 (1.05)	0.0	1.00	1.80	2.60	4.8	
			Placebo	126	118 (93.7)	2.03 (0.96)	0.0	1.40	2.00	2.60	5.2	
		Week 12	Tezepelumab	114	109 (95.6)	1.71 (1.07)	0.0	0.80	1.80	2.60	4.8	
			Placebo	126	118 (93.7)	2.00 (1.00)	0.0	1.20	2.00	2.80	4.4	
		Week 14	Tezepelumab	114	109 (95.6)	1.58 (1.09)	0.0	0.80	1.40	2.40	4.8	
			Placebo	126	118 (93.7)	1.93 (0.94)	0.0	1.20	2.00	2.60	5.0	
		Week 16	Tezepelumab	114	109 (95.6)	1.78 (1.12)	0.0	1.00	1.80	2.80	4.8	
			Placebo	126	118 (93.7)	2.02 (1.04)	0.0	1.20	2.00	2.80	5.0	
		Week 18	Tezepelumab	114	110 (96.5)	1.65 (1.03)	0.0	1.00	1.60	2.40	4.8	
			Placebo	126	118 (93.7)	1.90 (0.99)	0.0	1.20	1.90	2.60	5.0	
		Week 20	Tezepelumab	114	110 (96.5)	1.74 (1.09)	0.0	1.00	1.80	2.60	5.0	
			Placebo	126	118 (93.7)	1.97 (1.06)	0.0	1.20	2.00	2.80	5.0	
		Week 22	Tezepelumab	114	110 (96.5)	1.76 (1.04)	0.0	1.00	2.00	2.40	4.8	
			Placebo	126	118 (93.7)	1.92 (1.06)	0.0	1.00	2.00	2.60	5.0	
		Week 24	Tezepelumab	114	110 (96.5)	1.72 (1.07)	0.0	1.00	1.80	2.60	4.8	
			Placebo	126	118 (93.7)	1.93 (1.02)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	114	111 (97.4)	1.70 (1.07)	0.0	1.00	1.80	2.40	4.8	
			Placebo	126	118 (93.7)	1.87 (0.98)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	114	112 (98.2)	1.73 (1.11)	0.0	1.00	1.80	2.50	4.8	
			Placebo	126	119 (94.4)	1.95 (1.09)	0.0	1.00	2.20	2.80	4.4	
		Week 30	Tezepelumab	114	113 (99.1)	1.72 (1.06)	0.0	1.00	1.80	2.40	4.8	
			Placebo	126	120 (95.2)	1.91 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	114	113 (99.1)	1.67 (1.09)	0.0	1.00	1.60	2.60	4.8	
			Placebo	126	120 (95.2)	1.88 (1.09)	0.0	0.80	1.80	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	114	113 (99.1)	1.69 (1.15)	0.0	0.80	1.60	2.60	4.8	
			Placebo	126	120 (95.2)	1.86 (1.07)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	114	113 (99.1)	1.73 (1.13)	0.0	0.80	1.80	2.60	5.0	
			Placebo	126	120 (95.2)	1.92 (1.10)	0.0	1.00	2.00	2.80	4.8	
		Week 38	Tezepelumab	114	113 (99.1)	1.66 (1.12)	0.0	0.80	1.60	2.40	4.8	
			Placebo	126	120 (95.2)	1.80 (1.06)	0.0	1.00	1.80	2.60	4.8	
		Week 40	Tezepelumab	114	113 (99.1)	1.69 (1.12)	0.0	0.80	1.80	2.40	4.8	
			Placebo	126	120 (95.2)	1.91 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	114	113 (99.1)	1.61 (1.09)	0.0	0.80	1.60	2.40	4.8	
			Placebo	126	120 (95.2)	1.89 (1.05)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	114	113 (99.1)	1.64 (1.12)	0.0	0.80	1.60	2.60	4.8	
			Placebo	126	121 (96.0)	1.93 (1.05)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	114	113 (99.1)	1.64 (1.12)	0.0	0.80	1.60	2.40	4.8	
			Placebo	126	121 (96.0)	1.80 (1.01)	0.0	1.00	2.00	2.60	4.4	
		Week 48	Tezepelumab	114	113 (99.1)	1.69 (1.14)	0.0	0.80	1.80	2.60	4.8	
			Placebo	126	121 (96.0)	1.84 (1.06)	0.0	1.00	2.00	2.60	4.6	
		Week 50	Tezepelumab	114	113 (99.1)	1.62 (1.13)	0.0	0.80	1.40	2.40	4.8	
			Placebo	126	121 (96.0)	1.84 (0.99)	0.0	1.00	2.00	2.60	4.4	
		Week 52	Tezepelumab	114	113 (99.1)	1.64 (1.13)	0.0	0.80	1.80	2.40	4.8	
			Placebo	126	121 (96.0)	1.88 (1.03)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 2	Tezepelumab	114	109 (95.6)	-0.54 (0.76)	-3.2	-1.00	-0.40	0.00	0.8	-0.13 [-0.39, 0.13]
			Placebo	126	115 (91.3)	-0.44 (0.75)	-3.0	-0.80	-0.40	0.00	1.2	
		Week 4	Tezepelumab	114	109 (95.6)	-0.85 (1.00)	-3.8	-1.40	-0.80	-0.20	2.6	-0.28 [-0.55, -0.02]
			Placebo	126	115 (91.3)	-0.58 (0.89)	-3.0	-1.20	-0.40	0.00	1.4	
		Week 6	Tezepelumab	114	109 (95.6)	-0.92 (1.06)	-4.0	-1.60	-1.00	-0.20	2.6	-0.24 [-0.51, 0.02]
			Placebo	126	116 (92.1)	-0.68 (0.94)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	114	109 (95.6)	-1.01 (1.11)	-4.0	-1.60	-1.00	-0.40	2.6	-0.29 [-0.55, -0.02]
			Placebo	126	117 (92.9)	-0.71 (0.96)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	114	109 (95.6)	-1.05 (1.08)	-4.0	-1.60	-1.00	-0.40	2.6	-0.23 [-0.49, 0.03]
			Placebo	126	118 (93.7)	-0.81 (0.98)	-3.8	-1.40	-0.60	-0.20	2.6	
		Week 12	Tezepelumab	114	109 (95.6)	-1.14 (1.10)	-4.0	-1.80	-1.00	-0.40	2.6	-0.28 [-0.54, -0.02]
			Placebo	126	118 (93.7)	-0.85 (1.02)	-3.8	-1.40	-0.70	-0.20	1.4	
		Week 14	Tezepelumab	114	109 (95.6)	-1.28 (1.13)	-4.2	-2.00	-1.20	-0.60	2.6	-0.34 [-0.60, -0.08]
			Placebo	126	118 (93.7)	-0.92 (0.97)	-3.4	-1.40	-0.80	-0.40	2.4	
		Week 16	Tezepelumab	114	109 (95.6)	-1.08 (1.16)	-4.4	-1.80	-1.00	-0.40	2.6	-0.23 [-0.49, 0.03]
			Placebo	126	118 (93.7)	-0.82 (1.05)	-3.6	-1.40	-0.80	-0.20	2.4	
		Week 18	Tezepelumab	114	110 (96.5)	-1.20 (1.10)	-4.4	-1.80	-1.00	-0.60	2.6	-0.25 [-0.51, 0.01]
			Placebo	126	118 (93.7)	-0.94 (1.01)	-3.6	-1.60	-0.80	-0.20	2.4	
		Week 20	Tezepelumab	114	110 (96.5)	-1.11 (1.13)	-4.4	-1.80	-1.00	-0.40	2.6	-0.22 [-0.48, 0.04]
			Placebo	126	118 (93.7)	-0.87 (1.09)	-3.6	-1.40	-0.60	-0.20	2.4	
		Week 22	Tezepelumab	114	110 (96.5)	-1.09 (1.15)	-4.4	-1.80	-1.00	-0.40	2.6	-0.15 [-0.41, 0.11]
			Placebo	126	118 (93.7)	-0.93 (1.06)	-3.8	-1.60	-0.80	-0.20	2.4	
		Week 24	Tezepelumab	114	110 (96.5)	-1.13 (1.11)	-4.8	-1.80	-1.00	-0.40	2.6	-0.20 [-0.46, 0.06]
			Placebo	126	118 (93.7)	-0.91 (1.07)	-3.8	-1.40	-0.80	-0.20	1.8	
		Week 26	Tezepelumab	114	111 (97.4)	-1.14 (1.14)	-4.4	-2.00	-1.00	-0.40	2.6	-0.15 [-0.41, 0.11]
			Placebo	126	118 (93.7)	-0.98 (1.05)	-4.2	-1.80	-1.00	-0.20	1.6	
		Week 28	Tezepelumab	114	112 (98.2)	-1.11 (1.16)	-4.4	-1.80	-1.00	-0.30	2.6	-0.20 [-0.46, 0.06]
			Placebo	126	119 (94.4)	-0.88 (1.11)	-4.2	-1.60	-0.80	-0.20	1.6	
		Week 30	Tezepelumab	114	113 (99.1)	-1.13 (1.18)	-4.4	-1.80	-1.00	-0.40	2.6	-0.19 [-0.44, 0.07]
			Placebo	126	120 (95.2)	-0.91 (1.13)	-3.4	-1.60	-1.00	-0.20	2.0	
		Week 32	Tezepelumab	114	113 (99.1)	-1.17 (1.16)	-4.4	-2.20	-1.00	-0.60	2.6	-0.20 [-0.45, 0.06]
			Placebo	126	120 (95.2)	-0.95 (1.11)	-3.6	-1.80	-0.90	-0.20	1.8	
		Week 34	Tezepelumab	114	113 (99.1)	-1.16 (1.19)	-4.4	-2.00	-1.00	-0.40	2.6	-0.17 [-0.43, 0.09]
			Placebo	126	120 (95.2)	-0.96 (1.09)	-4.2	-1.60	-1.00	-0.20	1.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	114	113 (99.1)	-1.12 (1.24)	-4.4	-2.00	-1.00	-0.20	2.6	-0.18 [-0.44, 0.08]
			Placebo	126	120 (95.2)	-0.90 (1.14)	-3.6	-1.50	-1.00	0.00	1.8	
		Week 38	Tezepelumab	114	113 (99.1)	-1.18 (1.22)	-4.4	-2.00	-1.20	-0.40	2.6	-0.13 [-0.39, 0.12]
			Placebo	126	120 (95.2)	-1.03 (1.12)	-4.2	-1.60	-1.00	-0.30	1.8	
		Week 40	Tezepelumab	114	113 (99.1)	-1.15 (1.22)	-4.4	-2.00	-1.00	-0.40	2.6	-0.20 [-0.46, 0.06]
			Placebo	126	120 (95.2)	-0.92 (1.10)	-4.2	-1.60	-0.80	-0.20	1.4	
		Week 42	Tezepelumab	114	113 (99.1)	-1.23 (1.20)	-4.4	-2.00	-1.20	-0.40	2.6	-0.25 [-0.51, 0.00]
			Placebo	126	120 (95.2)	-0.94 (1.09)	-4.2	-1.60	-1.00	-0.20	1.6	
		Week 44	Tezepelumab	114	113 (99.1)	-1.20 (1.24)	-4.4	-2.00	-1.20	-0.40	2.6	-0.26 [-0.52, -0.01]
			Placebo	126	121 (96.0)	-0.90 (1.09)	-4.2	-1.60	-0.80	0.00	1.6	
		Week 46	Tezepelumab	114	113 (99.1)	-1.21 (1.22)	-4.4	-2.00	-1.00	-0.40	2.6	-0.16 [-0.42, 0.10]
			Placebo	126	121 (96.0)	-1.02 (1.06)	-4.2	-1.60	-1.00	-0.20	1.6	
		Week 48	Tezepelumab	114	113 (99.1)	-1.15 (1.22)	-4.4	-2.00	-1.00	-0.40	2.6	-0.14 [-0.40, 0.11]
			Placebo	126	121 (96.0)	-0.99 (1.10)	-3.8	-1.60	-1.00	-0.20	1.8	
		Week 50	Tezepelumab	114	113 (99.1)	-1.22 (1.22)	-4.4	-2.00	-1.20	-0.40	2.6	-0.21 [-0.47, 0.05]
			Placebo	126	121 (96.0)	-0.98 (1.04)	-4.2	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	114	113 (99.1)	-1.21 (1.24)	-4.4	-2.00	-1.20	-0.40	2.6	-0.23 [-0.48, 0.03]
			Placebo	126	121 (96.0)	-0.95 (1.06)	-4.2	-1.60	-0.80	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	2.76 (0.73)	1.0	2.20	2.80	3.00	4.8	
			Placebo	12	12 (100.0)	2.75 (0.97)	1.4	2.10	2.90	3.00	5.0	
		Week 2	Tezepelumab	23	22 (95.7)	2.04 (0.89)	0.2	1.40	2.20	2.80	3.2	
			Placebo	12	10 (83.3)	2.66 (0.99)	1.2	2.20	2.40	3.00	5.0	
		Week 4	Tezepelumab	23	22 (95.7)	1.70 (0.94)	0.2	1.00	1.50	2.60	3.2	
			Placebo	12	10 (83.3)	2.72 (0.79)	1.2	2.20	2.80	3.60	3.6	
		Week 6	Tezepelumab	23	22 (95.7)	1.55 (0.91)	0.0	1.00	1.50	2.20	3.0	
			Placebo	12	10 (83.3)	2.68 (1.37)	1.0	2.20	2.60	3.00	6.0	
		Week 8	Tezepelumab	23	22 (95.7)	1.51 (1.13)	0.0	0.60	1.30	2.40	3.8	
			Placebo	12	10 (83.3)	2.26 (1.30)	0.2	1.60	2.20	2.80	5.0	
		Week 10	Tezepelumab	23	22 (95.7)	1.29 (0.95)	0.0	0.60	1.20	2.00	3.2	
			Placebo	12	10 (83.3)	2.50 (0.93)	0.8	1.80	2.80	3.00	4.0	
		Week 12	Tezepelumab	23	22 (95.7)	1.27 (1.09)	0.0	0.20	1.00	2.00	3.6	
			Placebo	12	10 (83.3)	1.96 (1.01)	0.0	1.40	2.00	3.00	3.2	
		Week 14	Tezepelumab	23	22 (95.7)	1.15 (0.82)	0.0	0.60	1.00	1.60	2.8	
			Placebo	12	10 (83.3)	2.08 (1.05)	0.0	1.80	2.30	2.80	3.2	
		Week 16	Tezepelumab	23	22 (95.7)	1.14 (0.89)	0.0	0.40	1.00	1.60	2.8	
			Placebo	12	10 (83.3)	2.50 (1.43)	0.0	1.60	2.50	3.20	5.0	
		Week 18	Tezepelumab	23	22 (95.7)	1.07 (0.74)	0.0	0.60	1.00	1.40	2.8	
			Placebo	12	10 (83.3)	2.54 (1.37)	0.0	1.80	2.70	3.20	4.8	
		Week 20	Tezepelumab	23	22 (95.7)	1.17 (0.89)	0.0	0.80	1.00	1.60	3.0	
			Placebo	12	10 (83.3)	2.38 (0.80)	1.2	2.00	2.30	2.80	4.0	
		Week 22	Tezepelumab	23	22 (95.7)	1.22 (0.81)	0.0	0.80	1.20	1.60	3.0	
			Placebo	12	10 (83.3)	2.44 (0.82)	1.4	1.80	2.40	2.80	4.0	
		Week 24	Tezepelumab	23	22 (95.7)	1.33 (1.13)	0.0	0.60	1.10	1.80	4.8	
			Placebo	12	10 (83.3)	2.18 (1.10)	0.8	1.20	2.10	3.00	4.0	
		Week 26	Tezepelumab	23	22 (95.7)	1.18 (0.77)	0.0	0.80	1.00	1.60	2.8	
			Placebo	12	10 (83.3)	2.26 (1.36)	0.0	1.40	2.20	3.40	4.0	
		Week 28	Tezepelumab	23	22 (95.7)	1.39 (1.04)	0.0	0.80	1.20	2.40	3.0	
			Placebo	12	10 (83.3)	2.10 (1.24)	0.0	1.20	2.10	2.80	4.0	
		Week 30	Tezepelumab	23	22 (95.7)	1.05 (0.75)	0.0	0.60	1.00	1.60	2.8	
			Placebo	12	10 (83.3)	2.28 (0.95)	0.6	1.60	2.30	2.60	4.0	
		Week 32	Tezepelumab	23	22 (95.7)	1.01 (0.78)	0.0	0.40	1.00	1.40	2.8	
			Placebo	12	10 (83.3)	2.08 (0.99)	1.0	1.40	1.70	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	23	22 (95.7)	1.01 (0.79)	0.0	0.40	1.00	1.60	2.8	
			Placebo	12	10 (83.3)	1.74 (1.23)	0.2	0.80	1.50	2.20	4.0	
		Week 36	Tezepelumab	23	22 (95.7)	1.30 (0.91)	0.0	0.60	1.20	2.00	3.4	
			Placebo	12	10 (83.3)	2.12 (1.17)	0.6	1.00	2.20	2.80	4.0	
		Week 38	Tezepelumab	23	22 (95.7)	1.05 (0.83)	0.0	0.20	1.00	1.60	2.8	
			Placebo	12	10 (83.3)	2.56 (1.00)	1.0	1.80	2.80	3.40	4.0	
		Week 40	Tezepelumab	23	22 (95.7)	1.08 (0.86)	0.0	0.60	0.80	1.60	2.8	
			Placebo	12	10 (83.3)	2.32 (1.29)	0.8	1.00	2.20	3.40	4.2	
		Week 42	Tezepelumab	23	22 (95.7)	1.21 (1.09)	0.0	0.60	1.00	1.60	4.6	
			Placebo	12	10 (83.3)	2.14 (1.07)	0.6	1.60	2.20	2.60	4.0	
		Week 44	Tezepelumab	23	22 (95.7)	1.25 (0.88)	0.0	0.60	1.10	2.00	2.8	
			Placebo	12	10 (83.3)	2.24 (1.33)	0.6	1.00	2.20	3.40	4.2	
		Week 46	Tezepelumab	23	22 (95.7)	1.08 (0.86)	0.0	0.60	1.00	1.40	3.2	
			Placebo	12	10 (83.3)	2.16 (1.14)	0.6	1.40	2.00	3.00	4.0	
		Week 48	Tezepelumab	23	22 (95.7)	1.18 (0.86)	0.0	0.40	1.10	1.60	3.0	
			Placebo	12	10 (83.3)	2.22 (1.18)	0.8	1.00	2.50	3.20	4.0	
		Week 50	Tezepelumab	23	22 (95.7)	0.99 (0.72)	0.0	0.60	1.00	1.40	2.8	
			Placebo	12	10 (83.3)	1.86 (1.24)	0.2	0.80	1.90	2.60	4.0	
		Week 52	Tezepelumab	23	22 (95.7)	1.08 (0.73)	0.0	0.60	1.00	1.60	2.8	
			Placebo	12	10 (83.3)	2.04 (1.28)	0.2	0.80	2.30	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 2	Tezepelumab	23	22 (95.7)	-0.72 (0.65)	-2.0	-1.20	-0.70	-0.20	0.4	-0.88 [-1.66, -0.10]
			Placebo	12	10 (83.3)	-0.06 (0.95)	-1.0	-1.00	-0.20	1.00	1.4	
		Week 4	Tezepelumab	23	22 (95.7)	-1.05 (0.78)	-2.6	-1.60	-1.10	-0.80	0.6	-1.22 [-2.02, -0.41]
			Placebo	12	10 (83.3)	0.00 (1.05)	-1.4	-1.00	0.30	0.80	1.6	
		Week 6	Tezepelumab	23	22 (95.7)	-1.20 (0.86)	-2.8	-1.60	-1.40	-0.80	0.6	-1.22 [-2.03, -0.41]
			Placebo	12	10 (83.3)	-0.04 (1.12)	-1.8	-1.20	0.10	0.80	1.6	
		Week 8	Tezepelumab	23	22 (95.7)	-1.25 (0.95)	-2.8	-1.80	-1.60	-0.80	1.0	-0.78 [-1.56, -0.01]
			Placebo	12	10 (83.3)	-0.46 (1.11)	-2.8	-1.00	-0.30	0.20	1.0	
		Week 10	Tezepelumab	23	22 (95.7)	-1.46 (0.88)	-2.8	-2.00	-1.60	-1.00	0.4	-1.18 [-1.99, -0.38]
			Placebo	12	10 (83.3)	-0.22 (1.37)	-2.2	-0.80	-0.20	0.40	2.6	
		Week 12	Tezepelumab	23	22 (95.7)	-1.48 (0.84)	-2.8	-2.20	-1.80	-1.00	0.0	-0.70 [-1.47, 0.07]
			Placebo	12	10 (83.3)	-0.76 (1.37)	-3.0	-1.80	-0.70	0.20	1.6	
		Week 14	Tezepelumab	23	22 (95.7)	-1.60 (0.75)	-2.8	-2.20	-1.70	-1.20	0.2	-0.97 [-1.75, -0.18]
			Placebo	12	10 (83.3)	-0.64 (1.40)	-3.0	-1.60	-0.60	0.40	1.4	
		Week 16	Tezepelumab	23	22 (95.7)	-1.62 (0.81)	-3.0	-2.20	-1.80	-1.00	0.0	-1.28 [-2.09, -0.47]
			Placebo	12	10 (83.3)	-0.22 (1.56)	-3.0	-1.40	0.00	0.80	2.6	
		Week 18	Tezepelumab	23	22 (95.7)	-1.68 (0.89)	-3.4	-2.20	-1.80	-1.00	0.4	-1.29 [-2.10, -0.47]
			Placebo	12	10 (83.3)	-0.18 (1.64)	-3.0	-1.20	0.10	0.60	2.6	
		Week 20	Tezepelumab	23	22 (95.7)	-1.58 (0.85)	-2.8	-2.20	-1.80	-1.40	0.2	-1.19 [-2.00, -0.39]
			Placebo	12	10 (83.3)	-0.34 (1.40)	-2.0	-1.40	-0.70	0.60	2.6	
		Week 22	Tezepelumab	23	22 (95.7)	-1.54 (0.92)	-3.4	-2.20	-1.60	-0.80	0.2	-1.19 [-1.99, -0.38]
			Placebo	12	10 (83.3)	-0.28 (1.31)	-1.6	-1.40	-0.60	0.60	2.6	
		Week 24	Tezepelumab	23	22 (95.7)	-1.43 (0.82)	-2.8	-2.00	-1.60	-0.80	0.0	-0.84 [-1.61, -0.06]
			Placebo	12	10 (83.3)	-0.54 (1.48)	-2.2	-1.60	-1.10	0.40	2.6	
		Week 26	Tezepelumab	23	22 (95.7)	-1.57 (0.89)	-3.2	-2.20	-1.60	-1.00	0.4	-0.97 [-1.75, -0.18]
			Placebo	12	10 (83.3)	-0.46 (1.60)	-3.0	-1.40	-0.60	0.40	2.6	
		Week 28	Tezepelumab	23	22 (95.7)	-1.36 (0.97)	-2.8	-2.20	-1.50	-0.80	0.2	-0.63 [-1.39, 0.14]
			Placebo	12	10 (83.3)	-0.62 (1.59)	-3.0	-1.60	-0.70	0.20	2.6	
		Week 30	Tezepelumab	23	22 (95.7)	-1.71 (0.82)	-3.0	-2.20	-1.70	-1.20	0.0	-1.24 [-2.05, -0.43]
			Placebo	12	10 (83.3)	-0.44 (1.39)	-1.6	-1.40	-0.90	0.20	2.6	
		Week 32	Tezepelumab	23	22 (95.7)	-1.75 (0.85)	-3.6	-2.20	-1.80	-1.20	0.0	-1.08 [-1.87, -0.28]
			Placebo	12	10 (83.3)	-0.64 (1.35)	-2.0	-1.40	-1.20	-0.20	2.6	
		Week 34	Tezepelumab	23	22 (95.7)	-1.75 (0.83)	-3.2	-2.20	-1.90	-1.20	0.2	-0.72 [-1.49, 0.05]
			Placebo	12	10 (83.3)	-0.98 (1.49)	-2.8	-1.60	-1.30	-0.80	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	23	22 (95.7)	-1.45 (0.96)	-2.8	-2.20	-1.70	-0.80	0.6	-0.74 [-1.51, 0.03]
			Placebo	12	10 (83.3)	-0.60 (1.51)	-2.4	-1.60	-0.90	0.40	2.6	
		Week 38	Tezepelumab	23	22 (95.7)	-1.70 (0.91)	-3.8	-2.20	-1.80	-1.00	0.4	-1.46 [-2.30, -0.63]
			Placebo	12	10 (83.3)	-0.16 (1.32)	-1.6	-1.20	-0.20	0.40	2.6	
		Week 40	Tezepelumab	23	22 (95.7)	-1.67 (1.01)	-4.2	-2.20	-1.70	-1.00	0.4	-1.09 [-1.89, -0.29]
			Placebo	12	10 (83.3)	-0.40 (1.47)	-2.2	-1.60	-0.40	0.20	2.6	
		Week 42	Tezepelumab	23	22 (95.7)	-1.55 (1.14)	-3.4	-2.20	-1.90	-1.00	1.8	-0.78 [-1.56, -0.01]
			Placebo	12	10 (83.3)	-0.58 (1.43)	-2.2	-1.60	-0.90	0.20	2.6	
		Week 44	Tezepelumab	23	22 (95.7)	-1.51 (1.02)	-3.8	-2.20	-1.60	-0.80	0.4	-0.83 [-1.61, -0.06]
			Placebo	12	10 (83.3)	-0.48 (1.63)	-2.4	-1.80	-1.00	0.80	2.6	
		Week 46	Tezepelumab	23	22 (95.7)	-1.67 (0.94)	-3.6	-2.20	-1.80	-1.00	0.2	-0.98 [-1.77, -0.19]
			Placebo	12	10 (83.3)	-0.56 (1.50)	-2.2	-1.60	-1.10	0.60	2.6	
		Week 48	Tezepelumab	23	22 (95.7)	-1.57 (0.98)	-3.4	-2.20	-1.60	-1.00	0.4	-0.94 [-1.72, -0.15]
			Placebo	12	10 (83.3)	-0.50 (1.46)	-2.2	-1.60	-0.60	-0.20	2.6	
		Week 50	Tezepelumab	23	22 (95.7)	-1.76 (0.88)	-3.8	-2.20	-1.80	-1.20	0.4	-0.80 [-1.57, -0.02]
			Placebo	12	10 (83.3)	-0.86 (1.57)	-2.8	-2.00	-1.10	-0.20	2.6	
		Week 52	Tezepelumab	23	22 (95.7)	-1.67 (0.89)	-3.8	-2.20	-1.50	-1.00	0.4	-0.85 [-1.63, -0.07]
			Placebo	12	10 (83.3)	-0.68 (1.64)	-2.8	-2.00	-1.10	0.60	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.73 (0.45)	2.2	2.40	2.80	3.00	3.4	
			Placebo	14	14 (100.0)	2.77 (0.88)	0.4	2.80	3.00	3.00	4.0	
		Week 2	Tezepelumab	9	9 (100.0)	2.31 (0.69)	1.0	2.00	2.60	2.80	3.2	
			Placebo	14	12 (85.7)	2.52 (0.54)	1.4	2.20	2.50	3.00	3.2	
		Week 4	Tezepelumab	9	9 (100.0)	1.76 (0.89)	0.2	1.20	1.80	2.40	3.0	
			Placebo	14	12 (85.7)	2.87 (0.73)	2.0	2.20	2.70	3.50	4.2	
		Week 6	Tezepelumab	9	9 (100.0)	1.40 (0.63)	0.6	1.00	1.40	1.80	2.6	
			Placebo	14	12 (85.7)	2.77 (0.76)	1.2	2.40	2.90	3.20	4.0	
		Week 8	Tezepelumab	9	9 (100.0)	1.29 (0.84)	0.0	1.00	1.60	1.60	2.6	
			Placebo	14	13 (92.9)	2.43 (0.98)	0.2	2.20	2.40	2.80	4.0	
		Week 10	Tezepelumab	9	9 (100.0)	1.00 (0.78)	0.0	0.60	0.80	1.40	2.4	
			Placebo	14	13 (92.9)	2.38 (0.85)	0.8	2.00	2.40	3.00	4.0	
		Week 12	Tezepelumab	9	9 (100.0)	0.93 (0.82)	0.0	0.00	1.00	1.60	2.2	
			Placebo	14	13 (92.9)	2.52 (0.99)	0.0	2.20	2.60	3.00	4.4	
		Week 14	Tezepelumab	9	9 (100.0)	0.96 (0.63)	0.0	0.60	1.40	1.40	1.6	
			Placebo	14	13 (92.9)	2.06 (0.78)	0.0	2.00	2.20	2.40	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	0.96 (0.51)	0.0	0.60	1.20	1.40	1.4	
			Placebo	14	13 (92.9)	2.40 (1.13)	0.0	2.00	2.60	2.80	4.0	
		Week 18	Tezepelumab	9	9 (100.0)	1.18 (0.60)	0.0	1.00	1.20	1.60	2.0	
			Placebo	14	13 (92.9)	2.38 (0.88)	0.0	2.40	2.60	2.60	4.0	
		Week 20	Tezepelumab	9	9 (100.0)	1.18 (0.76)	0.0	0.80	1.20	1.40	2.8	
			Placebo	14	13 (92.9)	2.48 (0.81)	1.0	2.00	2.60	2.80	4.0	
		Week 22	Tezepelumab	9	9 (100.0)	1.31 (0.94)	0.0	1.00	1.40	1.60	2.8	
			Placebo	14	13 (92.9)	2.55 (0.92)	0.8	2.00	2.60	3.20	4.0	
		Week 24	Tezepelumab	9	9 (100.0)	1.18 (0.77)	0.0	0.80	1.20	1.40	2.8	
			Placebo	14	13 (92.9)	2.48 (0.90)	0.8	2.00	2.40	3.20	4.0	
		Week 26	Tezepelumab	9	9 (100.0)	1.36 (0.69)	0.0	1.00	1.40	1.80	2.4	
			Placebo	14	13 (92.9)	2.37 (1.15)	0.0	1.60	2.20	3.20	4.0	
		Week 28	Tezepelumab	9	9 (100.0)	1.62 (0.94)	0.0	1.00	1.40	2.40	3.0	
			Placebo	14	14 (100.0)	2.19 (1.28)	0.0	1.40	2.40	3.20	4.0	
		Week 30	Tezepelumab	9	9 (100.0)	1.31 (0.74)	0.0	0.80	1.40	1.60	2.4	
			Placebo	14	14 (100.0)	2.26 (1.14)	0.0	1.60	2.20	3.20	4.0	
		Week 32	Tezepelumab	9	9 (100.0)	1.22 (0.76)	0.0	0.80	1.20	1.80	2.2	
			Placebo	14	14 (100.0)	2.37 (1.29)	0.0	1.60	2.30	3.20	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.36 (1.10)	0.0	0.80	1.20	2.40	3.0	
			Placebo	14	14 (100.0)	2.17 (1.39)	0.2	1.20	2.10	3.20	4.8	
		Week 36	Tezepelumab	9	9 (100.0)	1.44 (0.84)	0.0	1.00	1.20	2.20	2.8	
			Placebo	14	14 (100.0)	2.43 (1.34)	0.0	1.60	2.20	3.20	4.8	
		Week 38	Tezepelumab	9	9 (100.0)	1.47 (1.06)	0.0	0.60	1.40	2.20	3.0	
			Placebo	14	14 (100.0)	2.30 (1.29)	0.0	1.60	2.30	3.20	4.8	
		Week 40	Tezepelumab	9	9 (100.0)	1.22 (0.94)	0.0	0.80	1.20	1.80	2.6	
			Placebo	14	14 (100.0)	2.31 (1.23)	0.0	1.40	2.50	3.00	4.4	
		Week 42	Tezepelumab	9	9 (100.0)	1.29 (0.81)	0.0	1.00	1.20	1.40	2.6	
			Placebo	14	14 (100.0)	2.31 (1.20)	0.0	2.00	2.30	2.80	4.6	
		Week 44	Tezepelumab	9	9 (100.0)	1.42 (0.92)	0.0	1.00	1.40	1.60	3.0	
			Placebo	14	14 (100.0)	2.17 (1.18)	0.0	1.40	2.30	2.60	4.2	
		Week 46	Tezepelumab	9	9 (100.0)	1.49 (1.03)	0.0	1.00	1.20	1.80	3.2	
			Placebo	14	14 (100.0)	2.20 (0.95)	0.0	1.80	2.20	2.60	4.0	
		Week 48	Tezepelumab	9	9 (100.0)	1.42 (0.95)	0.0	0.80	1.20	2.00	3.0	
			Placebo	14	14 (100.0)	2.30 (1.07)	0.0	2.00	2.40	2.60	4.0	
		Week 50	Tezepelumab	9	9 (100.0)	1.13 (0.75)	0.0	0.80	1.00	1.40	2.6	
			Placebo	14	14 (100.0)	2.07 (1.15)	0.0	1.20	2.30	2.60	4.0	
		Week 52	Tezepelumab	9	9 (100.0)	1.13 (0.75)	0.0	0.80	1.00	1.40	2.6	
			Placebo	14	14 (100.0)	2.17 (1.22)	0.0	1.20	2.40	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.42 (0.39)	-1.4	-0.40	-0.20	-0.20	-0.2	-0.04 [-0.90, 0.83]
			Placebo	14	12 (85.7)	-0.40 (0.69)	-1.6	-0.90	-0.50	0.00	1.0	
		Week 4	Tezepelumab	9	9 (100.0)	-0.98 (0.70)	-2.2	-1.20	-1.00	-0.40	0.0	-1.21 [-2.16, -0.26]
			Placebo	14	12 (85.7)	-0.05 (0.81)	-1.4	-0.80	0.00	0.60	1.2	
		Week 6	Tezepelumab	9	9 (100.0)	-1.33 (0.66)	-2.4	-1.80	-1.40	-0.80	-0.2	-1.47 [-2.45, -0.49]
			Placebo	14	12 (85.7)	-0.15 (0.89)	-1.8	-0.80	-0.20	0.30	1.6	
		Week 8	Tezepelumab	9	9 (100.0)	-1.44 (0.66)	-2.4	-1.60	-1.40	-1.40	-0.2	-0.95 [-1.85, -0.05]
			Placebo	14	13 (92.9)	-0.52 (1.12)	-2.8	-1.00	-0.40	0.20	1.0	
		Week 10	Tezepelumab	9	9 (100.0)	-1.73 (0.62)	-2.4	-2.20	-2.00	-1.40	-0.8	-1.16 [-2.08, -0.24]
			Placebo	14	13 (92.9)	-0.57 (1.19)	-2.2	-1.00	-0.40	-0.20	2.6	
		Week 12	Tezepelumab	9	9 (100.0)	-1.80 (0.60)	-2.4	-2.20	-2.00	-1.40	-0.8	-1.38 [-2.33, -0.43]
			Placebo	14	13 (92.9)	-0.43 (1.18)	-3.0	-0.80	-0.60	0.00	1.6	
		Week 14	Tezepelumab	9	9 (100.0)	-1.78 (0.49)	-2.4	-2.20	-1.80	-1.60	-0.8	-1.03 [-1.94, -0.13]
			Placebo	14	13 (92.9)	-0.89 (1.03)	-3.0	-1.40	-1.00	-0.60	1.4	
		Week 16	Tezepelumab	9	9 (100.0)	-1.78 (0.48)	-2.4	-2.20	-1.80	-1.60	-0.8	-1.09 [-2.01, -0.18]
			Placebo	14	13 (92.9)	-0.55 (1.39)	-3.0	-1.40	-0.60	-0.20	2.6	
		Week 18	Tezepelumab	9	9 (100.0)	-1.56 (0.71)	-2.4	-1.80	-1.60	-1.40	-0.2	-0.94 [-1.84, -0.04]
			Placebo	14	13 (92.9)	-0.57 (1.23)	-3.0	-1.20	-0.60	-0.20	2.6	
		Week 20	Tezepelumab	9	9 (100.0)	-1.56 (0.66)	-2.4	-2.20	-1.60	-1.40	-0.4	-1.10 [-2.02, -0.19]
			Placebo	14	13 (92.9)	-0.48 (1.14)	-2.0	-1.20	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	9	9 (100.0)	-1.42 (0.86)	-2.4	-2.40	-1.60	-0.80	-0.2	-0.93 [-1.83, -0.03]
			Placebo	14	13 (92.9)	-0.40 (1.24)	-2.2	-1.20	-0.40	0.20	2.6	
		Week 24	Tezepelumab	9	9 (100.0)	-1.56 (0.70)	-2.4	-1.80	-1.60	-1.60	-0.2	-1.02 [-1.93, -0.11]
			Placebo	14	13 (92.9)	-0.48 (1.24)	-2.2	-1.20	-0.80	0.20	2.6	
		Week 26	Tezepelumab	9	9 (100.0)	-1.38 (0.75)	-2.4	-1.60	-1.40	-0.80	-0.2	-0.66 [-1.53, 0.21]
			Placebo	14	13 (92.9)	-0.58 (1.42)	-3.0	-1.40	-1.20	0.20	2.6	
		Week 28	Tezepelumab	9	9 (100.0)	-1.11 (0.93)	-2.4	-1.60	-0.80	-0.80	0.2	-0.43 [-1.27, 0.42]
			Placebo	14	14 (100.0)	-0.59 (1.38)	-3.0	-1.40	-0.80	0.20	2.6	
		Week 30	Tezepelumab	9	9 (100.0)	-1.42 (0.71)	-2.6	-1.60	-1.40	-0.80	-0.6	-0.86 [-1.74, 0.01]
			Placebo	14	14 (100.0)	-0.51 (1.22)	-1.8	-1.40	-0.90	0.20	2.6	
		Week 32	Tezepelumab	9	9 (100.0)	-1.51 (0.62)	-2.4	-1.80	-1.60	-1.00	-0.8	-0.99 [-1.88, -0.10]
			Placebo	14	14 (100.0)	-0.40 (1.35)	-1.8	-1.40	-0.70	0.20	2.6	
		Week 34	Tezepelumab	9	9 (100.0)	-1.38 (0.92)	-2.6	-2.20	-1.60	-0.60	0.0	-0.58 [-1.44, 0.27]
			Placebo	14	14 (100.0)	-0.60 (1.54)	-2.8	-1.80	-1.00	0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.29 (0.90)	-2.4	-2.00	-1.40	-0.80	0.0	-0.76 [-1.63, 0.10]
			Placebo	14	14 (100.0)	-0.34 (1.41)	-2.2	-1.40	-0.70	0.20	2.6	
		Week 38	Tezepelumab	9	9 (100.0)	-1.27 (0.77)	-2.4	-1.80	-1.40	-0.80	0.0	-0.67 [-1.53, 0.19]
			Placebo	14	14 (100.0)	-0.47 (1.38)	-2.6	-1.40	-0.80	0.20	2.6	
		Week 40	Tezepelumab	9	9 (100.0)	-1.51 (0.79)	-2.6	-2.20	-1.60	-0.80	-0.4	-0.92 [-1.80, -0.04]
			Placebo	14	14 (100.0)	-0.46 (1.32)	-2.2	-1.40	-0.60	0.20	2.6	
		Week 42	Tezepelumab	9	9 (100.0)	-1.44 (0.73)	-2.4	-1.80	-1.60	-0.80	-0.4	-0.89 [-1.77, -0.01]
			Placebo	14	14 (100.0)	-0.46 (1.29)	-2.4	-1.40	-0.70	0.00	2.6	
		Week 44	Tezepelumab	9	9 (100.0)	-1.31 (0.91)	-2.8	-1.60	-1.40	-0.80	0.0	-0.61 [-1.47, 0.25]
			Placebo	14	14 (100.0)	-0.60 (1.29)	-2.4	-1.40	-0.90	0.00	2.6	
		Week 46	Tezepelumab	9	9 (100.0)	-1.24 (0.92)	-2.4	-1.60	-1.40	-0.80	0.2	-0.66 [-1.52, 0.20]
			Placebo	14	14 (100.0)	-0.57 (1.08)	-1.8	-1.20	-1.00	0.00	2.6	
		Week 48	Tezepelumab	9	9 (100.0)	-1.31 (0.99)	-2.4	-2.40	-1.60	-0.40	0.0	-0.76 [-1.63, 0.10]
			Placebo	14	14 (100.0)	-0.47 (1.16)	-2.0	-1.20	-0.60	-0.20	2.6	
		Week 50	Tezepelumab	9	9 (100.0)	-1.60 (0.75)	-2.6	-2.40	-1.60	-1.20	-0.4	-0.81 [-1.68, 0.06]
			Placebo	14	14 (100.0)	-0.70 (1.28)	-2.8	-1.40	-0.70	-0.20	2.6	
		Week 52	Tezepelumab	9	9 (100.0)	-1.60 (0.75)	-2.6	-2.40	-1.60	-1.20	-0.4	-0.87 [-1.75, 0.00]
			Placebo	14	14 (100.0)	-0.60 (1.33)	-2.8	-1.40	-0.60	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	2.85 (0.86)	0.0	2.40	2.80	3.20	5.2	
			Placebo	124	124 (100.0)	2.82 (0.71)	1.0	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	128	122 (95.3)	2.27 (0.99)	0.0	1.60	2.40	3.00	4.4	
			Placebo	124	113 (91.1)	2.41 (0.86)	0.0	2.00	2.40	3.00	5.0	
		Week 4	Tezepelumab	128	122 (95.3)	1.97 (1.02)	0.0	1.20	2.20	2.80	4.2	
			Placebo	124	113 (91.1)	2.24 (0.87)	0.2	1.80	2.40	2.80	4.4	
		Week 6	Tezepelumab	128	122 (95.3)	1.90 (1.02)	0.0	1.20	1.80	2.60	4.2	
			Placebo	124	114 (91.9)	2.14 (1.03)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	128	122 (95.3)	1.83 (1.09)	0.0	1.00	1.80	2.80	5.2	
			Placebo	124	114 (91.9)	2.11 (1.00)	0.0	1.40	2.10	2.80	5.0	
		Week 10	Tezepelumab	128	122 (95.3)	1.77 (1.05)	0.0	1.00	1.80	2.60	4.8	
			Placebo	124	115 (92.7)	2.03 (0.97)	0.0	1.40	2.00	2.80	5.2	
		Week 12	Tezepelumab	128	122 (95.3)	1.69 (1.09)	0.0	0.80	1.70	2.60	4.8	
			Placebo	124	115 (92.7)	1.93 (0.98)	0.0	1.20	2.00	2.60	4.4	
		Week 14	Tezepelumab	128	122 (95.3)	1.55 (1.07)	0.0	0.80	1.40	2.40	4.8	
			Placebo	124	115 (92.7)	1.92 (0.97)	0.0	1.20	1.80	2.60	5.0	
		Week 16	Tezepelumab	128	122 (95.3)	1.72 (1.12)	0.0	0.80	1.80	2.60	4.8	
			Placebo	124	115 (92.7)	2.02 (1.07)	0.0	1.20	2.00	3.00	5.0	
		Week 18	Tezepelumab	128	123 (96.1)	1.58 (1.03)	0.0	0.80	1.60	2.40	4.8	
			Placebo	124	115 (92.7)	1.90 (1.04)	0.0	1.20	1.80	2.60	5.0	
		Week 20	Tezepelumab	128	123 (96.1)	1.68 (1.09)	0.0	0.80	1.80	2.40	5.0	
			Placebo	124	115 (92.7)	1.95 (1.06)	0.0	1.20	2.00	2.80	5.0	
		Week 22	Tezepelumab	128	123 (96.1)	1.69 (1.03)	0.0	1.00	1.80	2.40	4.8	
			Placebo	124	115 (92.7)	1.89 (1.04)	0.0	1.00	2.00	2.60	5.0	
		Week 24	Tezepelumab	128	123 (96.1)	1.69 (1.10)	0.0	0.80	1.80	2.60	4.8	
			Placebo	124	115 (92.7)	1.89 (1.02)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	128	124 (96.9)	1.63 (1.07)	0.0	0.80	1.60	2.40	4.8	
			Placebo	124	115 (92.7)	1.85 (0.99)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	128	125 (97.7)	1.68 (1.11)	0.0	1.00	1.60	2.60	4.8	
			Placebo	124	115 (92.7)	1.93 (1.07)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	128	126 (98.4)	1.63 (1.07)	0.0	0.80	1.60	2.40	4.8	
			Placebo	124	116 (93.5)	1.90 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	128	126 (98.4)	1.59 (1.09)	0.0	0.80	1.40	2.40	4.8	
			Placebo	124	116 (93.5)	1.83 (1.04)	0.0	0.80	1.80	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	128	126 (98.4)	1.60 (1.13)	0.0	0.80	1.40	2.40	4.8	
			Placebo	124	116 (93.5)	1.82 (1.04)	0.0	1.00	1.80	2.60	4.4	
		Week 36	Tezepelumab	128	126 (98.4)	1.68 (1.13)	0.0	0.80	1.60	2.40	5.0	
			Placebo	124	116 (93.5)	1.88 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 38	Tezepelumab	128	126 (98.4)	1.57 (1.11)	0.0	0.80	1.40	2.40	4.8	
			Placebo	124	116 (93.5)	1.81 (1.03)	0.0	1.00	1.80	2.70	4.4	
		Week 40	Tezepelumab	128	126 (98.4)	1.62 (1.12)	0.0	0.60	1.80	2.40	4.8	
			Placebo	124	116 (93.5)	1.89 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	128	126 (98.4)	1.57 (1.11)	0.0	0.80	1.60	2.20	4.8	
			Placebo	124	116 (93.5)	1.86 (1.02)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	128	126 (98.4)	1.59 (1.10)	0.0	0.60	1.60	2.40	4.8	
			Placebo	124	117 (94.4)	1.93 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	128	126 (98.4)	1.55 (1.11)	0.0	0.80	1.40	2.40	4.8	
			Placebo	124	117 (94.4)	1.79 (1.03)	0.0	1.00	2.00	2.60	4.4	
		Week 48	Tezepelumab	128	126 (98.4)	1.62 (1.13)	0.0	0.80	1.60	2.40	4.8	
			Placebo	124	117 (94.4)	1.82 (1.06)	0.0	1.00	1.80	2.60	4.6	
		Week 50	Tezepelumab	128	126 (98.4)	1.55 (1.11)	0.0	0.80	1.40	2.20	4.8	
			Placebo	124	117 (94.4)	1.82 (0.99)	0.0	1.00	1.80	2.60	4.4	
		Week 52	Tezepelumab	128	126 (98.4)	1.58 (1.11)	0.0	0.60	1.60	2.20	4.8	
			Placebo	124	117 (94.4)	1.86 (1.02)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 2	Tezepelumab	128	122 (95.3)	-0.58 (0.77)	-3.2	-1.00	-0.40	0.00	0.8	-0.22 [-0.47, 0.04]
			Placebo	124	113 (91.1)	-0.41 (0.78)	-3.0	-0.80	-0.40	0.00	1.4	
		Week 4	Tezepelumab	128	122 (95.3)	-0.87 (0.99)	-3.8	-1.40	-0.80	-0.20	2.6	-0.31 [-0.56, -0.05]
			Placebo	124	113 (91.1)	-0.58 (0.91)	-3.0	-1.20	-0.40	0.00	1.6	
		Week 6	Tezepelumab	128	122 (95.3)	-0.94 (1.06)	-4.0	-1.60	-1.00	-0.20	2.6	-0.26 [-0.52, -0.00]
			Placebo	124	114 (91.9)	-0.68 (0.96)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	128	122 (95.3)	-1.02 (1.11)	-4.0	-1.80	-1.00	-0.40	2.6	-0.30 [-0.55, -0.04]
			Placebo	124	114 (91.9)	-0.71 (0.95)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	128	122 (95.3)	-1.07 (1.07)	-4.0	-1.60	-1.10	-0.40	2.6	-0.28 [-0.53, -0.02]
			Placebo	124	115 (92.7)	-0.79 (1.00)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	128	122 (95.3)	-1.16 (1.08)	-4.0	-1.80	-1.20	-0.40	2.6	-0.25 [-0.51, 0.00]
			Placebo	124	115 (92.7)	-0.89 (1.03)	-3.8	-1.40	-0.80	-0.20	1.4	
		Week 14	Tezepelumab	128	122 (95.3)	-1.30 (1.11)	-4.2	-2.00	-1.20	-0.60	2.6	-0.38 [-0.64, -0.12]
			Placebo	124	115 (92.7)	-0.90 (1.01)	-3.4	-1.40	-0.80	-0.20	2.4	
		Week 16	Tezepelumab	128	122 (95.3)	-1.12 (1.14)	-4.4	-1.80	-1.00	-0.40	2.6	-0.29 [-0.55, -0.04]
			Placebo	124	115 (92.7)	-0.80 (1.07)	-3.6	-1.40	-0.80	0.00	2.4	
		Week 18	Tezepelumab	128	123 (96.1)	-1.26 (1.11)	-4.4	-2.00	-1.00	-0.60	2.6	-0.32 [-0.57, -0.06]
			Placebo	124	115 (92.7)	-0.92 (1.06)	-3.6	-1.60	-0.80	-0.20	2.4	
		Week 20	Tezepelumab	128	123 (96.1)	-1.16 (1.12)	-4.4	-2.00	-1.00	-0.40	2.6	-0.26 [-0.52, -0.01]
			Placebo	124	115 (92.7)	-0.87 (1.11)	-3.6	-1.60	-0.60	-0.20	2.4	
		Week 22	Tezepelumab	128	123 (96.1)	-1.15 (1.14)	-4.4	-1.80	-1.00	-0.40	2.6	-0.19 [-0.45, 0.06]
			Placebo	124	115 (92.7)	-0.93 (1.06)	-3.8	-1.60	-0.80	-0.20	2.4	
		Week 24	Tezepelumab	128	123 (96.1)	-1.15 (1.09)	-4.8	-2.00	-1.00	-0.40	2.6	-0.20 [-0.46, 0.05]
			Placebo	124	115 (92.7)	-0.93 (1.08)	-3.8	-1.60	-0.80	-0.20	1.8	
		Week 26	Tezepelumab	128	124 (96.9)	-1.20 (1.13)	-4.4	-2.00	-1.10	-0.40	2.6	-0.20 [-0.46, 0.05]
			Placebo	124	115 (92.7)	-0.98 (1.06)	-4.2	-1.80	-1.00	0.00	1.6	
		Week 28	Tezepelumab	128	125 (97.7)	-1.15 (1.14)	-4.4	-2.00	-1.20	-0.40	2.6	-0.23 [-0.48, 0.03]
			Placebo	124	115 (92.7)	-0.89 (1.12)	-4.2	-1.60	-0.80	-0.20	1.6	
		Week 30	Tezepelumab	128	126 (98.4)	-1.21 (1.17)	-4.4	-2.20	-1.10	-0.40	2.6	-0.25 [-0.50, 0.00]
			Placebo	124	116 (93.5)	-0.92 (1.14)	-3.4	-1.60	-1.00	-0.20	2.0	
		Week 32	Tezepelumab	128	126 (98.4)	-1.25 (1.16)	-4.4	-2.20	-1.00	-0.60	2.6	-0.23 [-0.48, 0.02]
			Placebo	124	116 (93.5)	-0.99 (1.09)	-3.6	-1.80	-1.00	-0.20	1.4	
		Week 34	Tezepelumab	128	126 (98.4)	-1.24 (1.17)	-4.4	-2.20	-1.20	-0.40	2.6	-0.21 [-0.46, 0.04]
			Placebo	124	116 (93.5)	-1.01 (1.06)	-4.2	-1.60	-1.00	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	128	126 (98.4)	-1.16 (1.22)	-4.4	-2.00	-1.20	-0.20	2.6	-0.19 [-0.44, 0.07]
			Placebo	124	116 (93.5)	-0.94 (1.12)	-3.6	-1.60	-1.00	0.00	1.4	
		Week 38	Tezepelumab	128	126 (98.4)	-1.27 (1.22)	-4.4	-2.20	-1.20	-0.40	2.6	-0.21 [-0.47, 0.04]
			Placebo	124	116 (93.5)	-1.02 (1.11)	-4.2	-1.60	-1.00	-0.20	1.6	
		Week 40	Tezepelumab	128	126 (98.4)	-1.22 (1.22)	-4.4	-2.20	-1.00	-0.40	2.6	-0.25 [-0.50, 0.01]
			Placebo	124	116 (93.5)	-0.93 (1.11)	-4.2	-1.60	-0.80	-0.20	1.4	
		Week 42	Tezepelumab	128	126 (98.4)	-1.27 (1.22)	-4.4	-2.20	-1.20	-0.40	2.6	-0.26 [-0.51, -0.01]
			Placebo	124	116 (93.5)	-0.97 (1.08)	-4.2	-1.60	-1.00	-0.20	1.4	
		Week 44	Tezepelumab	128	126 (98.4)	-1.25 (1.23)	-4.4	-2.20	-1.20	-0.40	2.6	-0.30 [-0.55, -0.05]
			Placebo	124	117 (94.4)	-0.90 (1.12)	-4.2	-1.60	-0.80	0.00	1.6	
		Week 46	Tezepelumab	128	126 (98.4)	-1.28 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.21 [-0.47, 0.04]
			Placebo	124	117 (94.4)	-1.04 (1.09)	-4.2	-1.60	-1.00	-0.20	1.6	
		Week 48	Tezepelumab	128	126 (98.4)	-1.22 (1.21)	-4.4	-2.00	-1.00	-0.40	2.6	-0.18 [-0.43, 0.07]
			Placebo	124	117 (94.4)	-1.01 (1.12)	-3.8	-1.60	-1.00	-0.20	1.8	
		Week 50	Tezepelumab	128	126 (98.4)	-1.29 (1.21)	-4.4	-2.20	-1.20	-0.40	2.6	-0.25 [-0.50, 0.00]
			Placebo	124	117 (94.4)	-1.01 (1.06)	-4.2	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	128	126 (98.4)	-1.26 (1.22)	-4.4	-2.00	-1.20	-0.40	2.6	-0.26 [-0.51, -0.00]
			Placebo	124	117 (94.4)	-0.96 (1.08)	-4.2	-1.60	-1.00	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	108	108 (100.0)	2.86 (0.88)	0.0	2.40	2.80	3.20	5.2	
			Placebo	115	115 (100.0)	2.82 (0.68)	1.0	2.40	2.80	3.20	4.8	
		Week 2	Tezepelumab	108	103 (95.4)	2.30 (1.00)	0.0	1.60	2.40	3.00	4.4	
			Placebo	115	106 (92.2)	2.38 (0.84)	0.0	2.00	2.40	3.00	4.8	
		Week 4	Tezepelumab	108	103 (95.4)	2.02 (1.04)	0.0	1.20	2.20	2.80	4.2	
			Placebo	115	106 (92.2)	2.22 (0.88)	0.2	1.60	2.40	2.80	4.4	
		Week 6	Tezepelumab	108	103 (95.4)	1.95 (1.03)	0.0	1.20	2.00	2.80	4.2	
			Placebo	115	107 (93.0)	2.10 (0.98)	0.2	1.40	2.20	2.80	5.0	
		Week 8	Tezepelumab	108	103 (95.4)	1.87 (1.08)	0.0	1.00	1.80	2.80	5.2	
			Placebo	115	107 (93.0)	2.09 (0.99)	0.0	1.40	2.20	2.80	4.6	
		Week 10	Tezepelumab	108	103 (95.4)	1.84 (1.06)	0.0	1.00	1.80	2.60	4.8	
			Placebo	115	108 (93.9)	2.01 (0.98)	0.0	1.30	2.00	2.70	5.2	
		Week 12	Tezepelumab	108	103 (95.4)	1.74 (1.08)	0.0	0.80	1.80	2.60	4.8	
			Placebo	115	108 (93.9)	1.94 (1.00)	0.0	1.20	2.00	2.70	4.4	
		Week 14	Tezepelumab	108	103 (95.4)	1.61 (1.11)	0.0	0.80	1.60	2.40	4.8	
			Placebo	115	108 (93.9)	1.91 (0.98)	0.0	1.10	1.80	2.60	5.0	
		Week 16	Tezepelumab	108	103 (95.4)	1.82 (1.13)	0.0	1.00	1.80	2.80	4.8	
			Placebo	115	108 (93.9)	1.99 (1.06)	0.0	1.00	2.00	3.00	5.0	
		Week 18	Tezepelumab	108	104 (96.3)	1.68 (1.05)	0.0	1.00	1.70	2.40	4.8	
			Placebo	115	108 (93.9)	1.85 (1.01)	0.0	1.10	1.80	2.60	5.0	
		Week 20	Tezepelumab	108	104 (96.3)	1.76 (1.10)	0.0	0.90	2.00	2.60	5.0	
			Placebo	115	108 (93.9)	1.94 (1.08)	0.0	1.20	2.00	2.80	5.0	
		Week 22	Tezepelumab	108	104 (96.3)	1.77 (1.04)	0.0	1.00	2.00	2.50	4.8	
			Placebo	115	108 (93.9)	1.87 (1.06)	0.0	1.00	2.00	2.60	5.0	
		Week 24	Tezepelumab	108	104 (96.3)	1.74 (1.08)	0.0	0.90	1.80	2.60	4.8	
			Placebo	115	108 (93.9)	1.89 (1.04)	0.0	1.00	2.00	2.80	4.4	
		Week 26	Tezepelumab	108	105 (97.2)	1.72 (1.09)	0.0	1.00	1.80	2.40	4.8	
			Placebo	115	108 (93.9)	1.82 (0.98)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	108	106 (98.1)	1.75 (1.12)	0.0	1.00	1.80	2.60	4.8	
			Placebo	115	108 (93.9)	1.92 (1.08)	0.0	1.00	2.10	2.80	4.4	
		Week 30	Tezepelumab	108	107 (99.1)	1.74 (1.07)	0.0	1.00	1.80	2.60	4.8	
			Placebo	115	109 (94.8)	1.89 (1.07)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	108	107 (99.1)	1.69 (1.10)	0.0	1.00	1.60	2.60	4.8	
			Placebo	115	109 (94.8)	1.84 (1.06)	0.0	0.80	1.80	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	108	107 (99.1)	1.70 (1.15)	0.0	0.80	1.60	2.60	4.8	
			Placebo	115	109 (94.8)	1.83 (1.05)	0.0	1.00	1.80	2.60	4.4	
		Week 36	Tezepelumab	108	107 (99.1)	1.76 (1.14)	0.0	0.80	1.80	2.60	5.0	
			Placebo	115	109 (94.8)	1.88 (1.06)	0.0	1.00	2.00	2.80	4.4	
		Week 38	Tezepelumab	108	107 (99.1)	1.66 (1.13)	0.0	0.80	1.60	2.40	4.8	
			Placebo	115	109 (94.8)	1.77 (1.02)	0.0	1.00	1.80	2.60	4.4	
		Week 40	Tezepelumab	108	107 (99.1)	1.72 (1.14)	0.0	0.80	2.00	2.60	4.8	
			Placebo	115	109 (94.8)	1.87 (1.07)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	108	107 (99.1)	1.64 (1.10)	0.0	0.80	1.60	2.40	4.8	
			Placebo	115	109 (94.8)	1.85 (1.03)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	108	107 (99.1)	1.66 (1.13)	0.0	0.80	1.80	2.60	4.8	
			Placebo	115	110 (95.7)	1.91 (1.04)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	108	107 (99.1)	1.65 (1.13)	0.0	0.80	1.60	2.40	4.8	
			Placebo	115	110 (95.7)	1.77 (1.02)	0.0	1.00	2.00	2.60	4.4	
		Week 48	Tezepelumab	108	107 (99.1)	1.72 (1.15)	0.0	0.80	1.80	2.60	4.8	
			Placebo	115	110 (95.7)	1.81 (1.06)	0.0	1.00	1.90	2.60	4.6	
		Week 50	Tezepelumab	108	107 (99.1)	1.65 (1.14)	0.0	0.80	1.60	2.40	4.8	
			Placebo	115	110 (95.7)	1.82 (0.99)	0.0	1.00	1.80	2.60	4.4	
		Week 52	Tezepelumab	108	107 (99.1)	1.67 (1.14)	0.0	0.80	1.80	2.40	4.8	
			Placebo	115	110 (95.7)	1.85 (1.02)	0.0	1.00	2.00	2.80	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 2	Tezepelumab	108	103 (95.4)	-0.56 (0.78)	-3.2	-1.00	-0.40	0.00	0.8	-0.15 [-0.43, 0.12]
			Placebo	115	106 (92.2)	-0.44 (0.76)	-3.0	-0.80	-0.30	0.00	1.2	
		Week 4	Tezepelumab	108	103 (95.4)	-0.83 (1.02)	-3.8	-1.40	-0.80	-0.20	2.6	-0.24 [-0.52, 0.03]
			Placebo	115	106 (92.2)	-0.60 (0.89)	-3.0	-1.20	-0.40	0.00	1.4	
		Week 6	Tezepelumab	108	103 (95.4)	-0.91 (1.08)	-4.0	-1.60	-1.00	0.00	2.6	-0.18 [-0.45, 0.09]
			Placebo	115	107 (93.0)	-0.72 (0.95)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	108	103 (95.4)	-0.99 (1.13)	-4.0	-1.60	-1.00	-0.40	2.6	-0.25 [-0.52, 0.02]
			Placebo	115	107 (93.0)	-0.73 (0.96)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	108	103 (95.4)	-1.02 (1.09)	-4.0	-1.60	-1.00	-0.20	2.6	-0.19 [-0.46, 0.08]
			Placebo	115	108 (93.9)	-0.81 (1.01)	-3.8	-1.40	-0.60	-0.20	2.6	
		Week 12	Tezepelumab	108	103 (95.4)	-1.12 (1.12)	-4.0	-1.80	-1.00	-0.40	2.6	-0.21 [-0.48, 0.06]
			Placebo	115	108 (93.9)	-0.89 (1.04)	-3.8	-1.40	-0.80	-0.20	1.4	
		Week 14	Tezepelumab	108	103 (95.4)	-1.25 (1.15)	-4.2	-1.80	-1.20	-0.40	2.6	-0.31 [-0.58, -0.04]
			Placebo	115	108 (93.9)	-0.91 (1.01)	-3.4	-1.40	-0.80	-0.30	2.4	
		Week 16	Tezepelumab	108	103 (95.4)	-1.03 (1.17)	-4.4	-1.60	-1.00	-0.40	2.6	-0.18 [-0.45, 0.09]
			Placebo	115	108 (93.9)	-0.83 (1.07)	-3.6	-1.40	-0.80	0.00	2.4	
		Week 18	Tezepelumab	108	104 (96.3)	-1.17 (1.12)	-4.4	-1.80	-1.00	-0.60	2.6	-0.19 [-0.46, 0.08]
			Placebo	115	108 (93.9)	-0.97 (1.04)	-3.6	-1.60	-0.80	-0.30	2.4	
		Week 20	Tezepelumab	108	104 (96.3)	-1.09 (1.14)	-4.4	-1.80	-1.00	-0.40	2.6	-0.19 [-0.46, 0.08]
			Placebo	115	108 (93.9)	-0.88 (1.11)	-3.6	-1.50	-0.60	-0.20	2.4	
		Week 22	Tezepelumab	108	104 (96.3)	-1.08 (1.16)	-4.4	-1.80	-1.00	-0.40	2.6	-0.11 [-0.38, 0.16]
			Placebo	115	108 (93.9)	-0.95 (1.07)	-3.8	-1.60	-0.80	-0.20	2.4	
		Week 24	Tezepelumab	108	104 (96.3)	-1.11 (1.12)	-4.8	-1.80	-1.00	-0.40	2.6	-0.15 [-0.42, 0.12]
			Placebo	115	108 (93.9)	-0.94 (1.09)	-3.8	-1.60	-0.80	-0.20	1.8	
		Week 26	Tezepelumab	108	105 (97.2)	-1.12 (1.15)	-4.4	-2.00	-1.00	-0.40	2.6	-0.11 [-0.38, 0.16]
			Placebo	115	108 (93.9)	-1.00 (1.06)	-4.2	-1.80	-1.00	-0.20	1.6	
		Week 28	Tezepelumab	108	106 (98.1)	-1.08 (1.17)	-4.4	-1.80	-1.00	-0.20	2.6	-0.16 [-0.43, 0.11]
			Placebo	115	108 (93.9)	-0.90 (1.13)	-4.2	-1.60	-0.80	-0.20	1.6	
		Week 30	Tezepelumab	108	107 (99.1)	-1.11 (1.19)	-4.4	-1.80	-1.00	-0.40	2.6	-0.15 [-0.41, 0.12]
			Placebo	115	109 (94.8)	-0.93 (1.15)	-3.4	-1.60	-1.00	-0.20	2.0	
		Week 32	Tezepelumab	108	107 (99.1)	-1.15 (1.18)	-4.4	-2.20	-1.00	-0.40	2.6	-0.15 [-0.41, 0.12]
			Placebo	115	109 (94.8)	-0.99 (1.10)	-3.6	-1.80	-0.80	-0.20	1.4	
		Week 34	Tezepelumab	108	107 (99.1)	-1.15 (1.20)	-4.4	-2.00	-1.00	-0.40	2.6	-0.13 [-0.40, 0.13]
			Placebo	115	109 (94.8)	-0.99 (1.08)	-4.2	-1.60	-1.00	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	108	107 (99.1)	-1.09 (1.25)	-4.4	-2.00	-1.00	-0.20	2.6	-0.13 [-0.39, 0.14]
			Placebo	115	109 (94.8)	-0.94 (1.12)	-3.6	-1.60	-1.00	0.00	1.4	
		Week 38	Tezepelumab	108	107 (99.1)	-1.19 (1.24)	-4.4	-2.20	-1.20	-0.40	2.6	-0.11 [-0.37, 0.16]
			Placebo	115	109 (94.8)	-1.06 (1.11)	-4.2	-2.00	-1.00	-0.40	1.6	
		Week 40	Tezepelumab	108	107 (99.1)	-1.13 (1.24)	-4.4	-2.00	-1.00	-0.40	2.6	-0.15 [-0.42, 0.11]
			Placebo	115	109 (94.8)	-0.95 (1.11)	-4.2	-1.60	-0.80	-0.20	1.4	
		Week 42	Tezepelumab	108	107 (99.1)	-1.21 (1.22)	-4.4	-2.00	-1.20	-0.40	2.6	-0.21 [-0.48, 0.06]
			Placebo	115	109 (94.8)	-0.97 (1.09)	-4.2	-1.60	-1.00	-0.20	1.4	
		Week 44	Tezepelumab	108	107 (99.1)	-1.19 (1.25)	-4.4	-2.00	-1.20	-0.40	2.6	-0.23 [-0.50, 0.04]
			Placebo	115	110 (95.7)	-0.91 (1.11)	-4.2	-1.60	-0.80	0.00	1.6	
		Week 46	Tezepelumab	108	107 (99.1)	-1.19 (1.24)	-4.4	-2.00	-1.00	-0.20	2.6	-0.12 [-0.39, 0.14]
			Placebo	115	110 (95.7)	-1.05 (1.09)	-4.2	-1.60	-1.00	-0.20	1.6	
		Week 48	Tezepelumab	108	107 (99.1)	-1.13 (1.23)	-4.4	-2.00	-1.00	-0.40	2.6	-0.10 [-0.36, 0.17]
			Placebo	115	110 (95.7)	-1.01 (1.12)	-3.8	-1.60	-1.00	-0.20	1.8	
		Week 50	Tezepelumab	108	107 (99.1)	-1.20 (1.24)	-4.4	-2.00	-1.20	-0.40	2.6	-0.17 [-0.44, 0.10]
			Placebo	115	110 (95.7)	-1.00 (1.06)	-4.2	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	108	107 (99.1)	-1.18 (1.25)	-4.4	-2.00	-1.20	-0.20	2.6	-0.18 [-0.45, 0.08]
			Placebo	115	110 (95.7)	-0.97 (1.08)	-4.2	-1.60	-0.90	-0.20	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	29	29 (100.0)	2.77 (0.68)	1.0	2.40	2.80	3.00	4.8	
			Placebo	23	23 (100.0)	2.80 (0.91)	0.4	2.60	3.00	3.00	5.0	
		Week 2	Tezepelumab	29	28 (96.6)	2.14 (0.84)	0.2	1.50	2.50	2.80	3.2	
			Placebo	23	19 (82.6)	2.60 (0.80)	1.2	2.20	2.40	3.00	5.0	
		Week 4	Tezepelumab	29	28 (96.6)	1.72 (0.90)	0.2	1.10	1.70	2.60	3.2	
			Placebo	23	19 (82.6)	2.75 (0.74)	1.2	2.20	2.80	3.40	4.2	
		Week 6	Tezepelumab	29	28 (96.6)	1.56 (0.85)	0.0	1.00	1.50	2.00	3.0	
			Placebo	23	19 (82.6)	2.77 (1.07)	1.0	2.20	2.80	3.20	6.0	
		Week 8	Tezepelumab	29	28 (96.6)	1.51 (1.06)	0.0	0.60	1.50	2.30	3.8	
			Placebo	23	20 (87.0)	2.42 (1.06)	0.2	1.80	2.40	2.80	5.0	
		Week 10	Tezepelumab	29	28 (96.6)	1.28 (0.91)	0.0	0.60	1.30	1.80	3.2	
			Placebo	23	20 (87.0)	2.41 (0.76)	0.8	2.00	2.50	3.00	4.0	
		Week 12	Tezepelumab	29	28 (96.6)	1.26 (1.02)	0.0	0.40	1.20	1.90	3.6	
			Placebo	23	20 (87.0)	2.31 (0.92)	0.0	1.80	2.40	2.90	4.4	
		Week 14	Tezepelumab	29	28 (96.6)	1.13 (0.77)	0.0	0.60	1.10	1.60	2.8	
			Placebo	23	20 (87.0)	2.08 (0.76)	0.0	1.80	2.10	2.70	3.2	
		Week 16	Tezepelumab	29	28 (96.6)	1.11 (0.83)	0.0	0.50	1.00	1.50	2.8	
			Placebo	23	20 (87.0)	2.45 (1.14)	0.0	1.80	2.50	2.90	5.0	
		Week 18	Tezepelumab	29	28 (96.6)	1.09 (0.70)	0.0	0.60	1.10	1.50	2.8	
			Placebo	23	20 (87.0)	2.48 (0.97)	0.0	1.90	2.60	2.80	4.8	
		Week 20	Tezepelumab	29	28 (96.6)	1.21 (0.88)	0.0	0.80	1.00	1.60	3.0	
			Placebo	23	20 (87.0)	2.35 (0.76)	1.0	2.00	2.40	2.80	4.0	
		Week 22	Tezepelumab	29	28 (96.6)	1.27 (0.85)	0.0	0.80	1.20	1.60	3.0	
			Placebo	23	20 (87.0)	2.41 (0.85)	0.8	1.80	2.50	3.00	4.0	
		Week 24	Tezepelumab	29	28 (96.6)	1.33 (1.07)	0.0	0.70	1.20	1.70	4.8	
			Placebo	23	20 (87.0)	2.31 (0.91)	0.8	1.60	2.30	3.10	4.0	
		Week 26	Tezepelumab	29	28 (96.6)	1.21 (0.76)	0.0	0.90	1.10	1.60	2.8	
			Placebo	23	20 (87.0)	2.31 (1.12)	0.0	1.50	2.20	3.30	4.0	
		Week 28	Tezepelumab	29	28 (96.6)	1.39 (0.99)	0.0	0.90	1.20	2.30	3.0	
			Placebo	23	21 (91.3)	2.13 (1.16)	0.0	1.40	2.20	2.80	4.0	
		Week 30	Tezepelumab	29	28 (96.6)	1.11 (0.78)	0.0	0.70	1.00	1.60	2.8	
			Placebo	23	21 (91.3)	2.21 (1.04)	0.0	1.60	2.20	2.60	4.0	
		Week 32	Tezepelumab	29	28 (96.6)	1.08 (0.79)	0.0	0.40	1.00	1.50	2.8	
			Placebo	23	21 (91.3)	2.17 (1.17)	0.0	1.40	2.00	2.80	4.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	29	28 (96.6)	1.11 (0.87)	0.0	0.40	1.00	1.60	3.0	
			Placebo	23	21 (91.3)	1.97 (1.28)	0.2	1.00	1.60	2.60	4.8	
		Week 36	Tezepelumab	29	28 (96.6)	1.29 (0.89)	0.0	0.70	1.20	1.80	3.4	
			Placebo	23	21 (91.3)	2.23 (1.28)	0.0	1.60	2.00	2.80	4.8	
		Week 38	Tezepelumab	29	28 (96.6)	1.19 (0.91)	0.0	0.40	1.20	1.70	3.0	
			Placebo	23	21 (91.3)	2.35 (1.18)	0.0	1.60	2.60	3.20	4.8	
		Week 40	Tezepelumab	29	28 (96.6)	1.12 (0.84)	0.0	0.60	0.90	1.70	2.8	
			Placebo	23	21 (91.3)	2.28 (1.21)	0.0	1.40	2.20	3.00	4.4	
		Week 42	Tezepelumab	29	28 (96.6)	1.21 (1.02)	0.0	0.60	1.00	1.50	4.6	
			Placebo	23	21 (91.3)	2.17 (1.14)	0.0	1.60	2.20	2.60	4.6	
		Week 44	Tezepelumab	29	28 (96.6)	1.26 (0.89)	0.0	0.60	1.20	1.80	3.0	
			Placebo	23	21 (91.3)	2.19 (1.19)	0.0	1.20	2.20	2.80	4.2	
		Week 46	Tezepelumab	29	28 (96.6)	1.15 (0.88)	0.0	0.70	1.00	1.50	3.2	
			Placebo	23	21 (91.3)	2.12 (1.00)	0.0	1.60	2.00	2.80	4.0	
		Week 48	Tezepelumab	29	28 (96.6)	1.18 (0.84)	0.0	0.60	1.10	1.50	3.0	
			Placebo	23	21 (91.3)	2.16 (1.10)	0.0	1.20	2.40	2.80	4.0	
		Week 50	Tezepelumab	29	28 (96.6)	1.02 (0.74)	0.0	0.60	1.00	1.40	2.8	
			Placebo	23	21 (91.3)	1.96 (1.09)	0.0	1.00	2.00	2.60	4.0	
		Week 52	Tezepelumab	29	28 (96.6)	1.09 (0.74)	0.0	0.60	1.00	1.60	2.8	
			Placebo	23	21 (91.3)	2.09 (1.15)	0.0	1.00	2.40	2.80	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 2	Tezepelumab	29	28 (96.6)	-0.63 (0.60)	-2.0	-0.80	-0.50	-0.20	0.4	-0.50 [-1.09, 0.09]
			Placebo	23	19 (82.6)	-0.28 (0.81)	-1.6	-1.00	-0.40	0.00	1.4	
		Week 4	Tezepelumab	29	28 (96.6)	-1.05 (0.75)	-2.6	-1.60	-1.10	-0.60	0.6	-1.11 [-1.73, -0.48]
			Placebo	23	19 (82.6)	-0.14 (0.93)	-1.4	-1.00	0.00	0.60	1.6	
		Week 6	Tezepelumab	29	28 (96.6)	-1.21 (0.81)	-2.8	-1.70	-1.40	-0.80	0.6	-1.29 [-1.93, -0.65]
			Placebo	23	19 (82.6)	-0.12 (0.89)	-1.8	-0.80	-0.20	0.80	1.6	
		Week 8	Tezepelumab	29	28 (96.6)	-1.26 (0.90)	-2.8	-1.80	-1.60	-0.80	1.0	-0.83 [-1.43, -0.23]
			Placebo	23	20 (87.0)	-0.49 (0.98)	-2.8	-1.00	-0.50	0.20	1.0	
		Week 10	Tezepelumab	29	28 (96.6)	-1.49 (0.84)	-2.8	-2.10	-1.60	-0.90	0.4	-1.05 [-1.67, -0.44]
			Placebo	23	20 (87.0)	-0.50 (1.08)	-2.2	-1.00	-0.40	0.00	2.6	
		Week 12	Tezepelumab	29	28 (96.6)	-1.51 (0.79)	-2.8	-2.20	-1.80	-1.00	0.0	-0.97 [-1.58, -0.37]
			Placebo	23	20 (87.0)	-0.60 (1.10)	-3.0	-1.30	-0.60	0.00	1.6	
		Week 14	Tezepelumab	29	28 (96.6)	-1.64 (0.71)	-2.8	-2.20	-1.80	-1.30	0.2	-0.95 [-1.55, -0.34]
			Placebo	23	20 (87.0)	-0.83 (1.03)	-3.0	-1.50	-1.00	-0.20	1.4	
		Week 16	Tezepelumab	29	28 (96.6)	-1.66 (0.77)	-3.0	-2.20	-1.80	-1.20	0.0	-1.21 [-1.84, -0.59]
			Placebo	23	20 (87.0)	-0.46 (1.25)	-3.0	-1.40	-0.40	0.10	2.6	
		Week 18	Tezepelumab	29	28 (96.6)	-1.69 (0.83)	-3.4	-2.20	-1.80	-1.20	0.4	-1.26 [-1.89, -0.63]
			Placebo	23	20 (87.0)	-0.43 (1.20)	-3.0	-1.20	-0.50	0.10	2.6	
		Week 20	Tezepelumab	29	28 (96.6)	-1.56 (0.82)	-2.8	-2.20	-1.70	-1.20	0.2	-1.05 [-1.66, -0.44]
			Placebo	23	20 (87.0)	-0.56 (1.11)	-2.0	-1.40	-0.70	-0.20	2.6	
		Week 22	Tezepelumab	29	28 (96.6)	-1.50 (0.91)	-3.4	-2.20	-1.60	-0.80	0.2	-0.99 [-1.60, -0.38]
			Placebo	23	20 (87.0)	-0.50 (1.14)	-2.2	-1.40	-0.70	0.30	2.6	
		Week 24	Tezepelumab	29	28 (96.6)	-1.44 (0.82)	-2.8	-2.10	-1.60	-0.80	0.0	-0.87 [-1.47, -0.27]
			Placebo	23	20 (87.0)	-0.60 (1.15)	-2.2	-1.50	-1.10	0.30	2.6	
		Week 26	Tezepelumab	29	28 (96.6)	-1.56 (0.85)	-3.2	-2.20	-1.60	-0.90	0.4	-0.92 [-1.52, -0.32]
			Placebo	23	20 (87.0)	-0.60 (1.27)	-3.0	-1.40	-1.20	0.30	2.6	
		Week 28	Tezepelumab	29	28 (96.6)	-1.39 (0.92)	-2.8	-2.20	-1.50	-0.80	0.2	-0.68 [-1.26, -0.10]
			Placebo	23	21 (91.3)	-0.66 (1.25)	-3.0	-1.40	-0.80	0.20	2.6	
		Week 30	Tezepelumab	29	28 (96.6)	-1.66 (0.81)	-3.0	-2.30	-1.60	-1.00	0.0	-1.12 [-1.73, -0.51]
			Placebo	23	21 (91.3)	-0.58 (1.14)	-1.8	-1.40	-1.00	0.20	2.6	
		Week 32	Tezepelumab	29	28 (96.6)	-1.69 (0.82)	-3.6	-2.20	-1.80	-1.00	0.0	-1.06 [-1.67, -0.46]
			Placebo	23	21 (91.3)	-0.62 (1.22)	-2.0	-1.40	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	29	28 (96.6)	-1.66 (0.87)	-3.2	-2.20	-1.80	-0.90	0.2	-0.76 [-1.35, -0.18]
			Placebo	23	21 (91.3)	-0.82 (1.34)	-2.8	-1.60	-1.20	0.00	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IOSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITT

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	29	28 (96.6)	-1.48 (0.94)	-2.8	-2.20	-1.70	-0.80	0.6	-0.81 [-1.40, -0.22]
			Placebo	23	21 (91.3)	-0.56 (1.35)	-2.4	-1.40	-1.00	0.20	2.6	
		Week 38	Tezepelumab	29	28 (96.6)	-1.58 (0.92)	-3.8	-2.20	-1.70	-0.90	0.4	-1.06 [-1.67, -0.46]
			Placebo	23	21 (91.3)	-0.44 (1.25)	-2.6	-1.40	-0.40	0.20	2.6	
		Week 40	Tezepelumab	29	28 (96.6)	-1.65 (0.96)	-4.2	-2.30	-1.60	-0.90	0.4	-1.06 [-1.66, -0.45]
			Placebo	23	21 (91.3)	-0.51 (1.21)	-2.2	-1.40	-0.60	0.20	2.6	
		Week 42	Tezepelumab	29	28 (96.6)	-1.56 (1.06)	-3.4	-2.20	-1.80	-0.90	1.8	-0.83 [-1.42, -0.24]
			Placebo	23	21 (91.3)	-0.62 (1.22)	-2.4	-1.40	-0.80	0.00	2.6	
		Week 44	Tezepelumab	29	28 (96.6)	-1.51 (1.00)	-3.8	-2.20	-1.60	-0.80	0.4	-0.81 [-1.40, -0.22]
			Placebo	23	21 (91.3)	-0.60 (1.27)	-2.4	-1.60	-1.00	0.20	2.6	
		Week 46	Tezepelumab	29	28 (96.6)	-1.62 (0.92)	-3.6	-2.20	-1.70	-0.90	0.2	-0.95 [-1.54, -0.35]
			Placebo	23	21 (91.3)	-0.67 (1.11)	-2.2	-1.40	-1.00	0.00	2.6	
		Week 48	Tezepelumab	29	28 (96.6)	-1.59 (0.95)	-3.4	-2.30	-1.60	-0.90	0.4	-0.93 [-1.52, -0.33]
			Placebo	23	21 (91.3)	-0.63 (1.16)	-2.2	-1.40	-0.60	-0.20	2.6	
		Week 50	Tezepelumab	29	28 (96.6)	-1.75 (0.87)	-3.8	-2.40	-1.80	-1.10	0.4	-0.91 [-1.50, -0.31]
			Placebo	23	21 (91.3)	-0.83 (1.19)	-2.8	-1.60	-0.80	-0.20	2.6	
		Week 52	Tezepelumab	29	28 (96.6)	-1.68 (0.88)	-3.8	-2.40	-1.60	-1.00	0.4	-0.92 [-1.52, -0.33]
			Placebo	23	21 (91.3)	-0.70 (1.26)	-2.8	-1.60	-0.80	-0.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_IOMP0: Decrease of at least 0.9 points in ACQ-6 score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in ACQ-6 score	Week 28	137	134 (97.8)	74 (54.0) [45.3, 62.6]	138	129 (93.5)	55 (39.9) [31.6, 48.5]	1.355 [1.048, 1.752]	1.773 [1.098, 2.860]	14.2 [1.8, 26.6]	0.019 *
	Week 52	137	135 (98.5)	80 (58.4) [49.7, 66.7]	138	131 (94.9)	60 (43.5) [35.1, 52.2]	1.343 [1.060, 1.702]	1.825 [1.131, 2.943]	14.9 [2.5, 27.3]	0.014 *

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_IOSPK: Decrease of at least 0.9 points in ACQ-6 score by key subgroups
DITT

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.672	
Male	50	49 (98.0)	27 (54.0) [39.3, 68.2]	44	43 (97.7)	19 (43.2) [28.3, 59.0]	1.251 [0.818, 1.912]	1.545 [0.683, 3.492]	10.8 [-11.4, 33.1]	0.298	
Female	87	86 (98.9)	53 (60.9) [49.9, 71.2]	94	88 (93.6)	41 (43.6) [33.4, 54.2]	1.397 [1.050, 1.857]	2.015 [1.114, 3.646]	17.3 [1.9, 32.7]	0.020	*
Age										0.660	
< 65 years	114	113 (99.1)	69 (60.5) [50.9, 69.6]	118	113 (95.8)	54 (45.8) [36.6, 55.2]	1.323 [1.034, 1.692]	1.817 [1.079, 3.062]	14.8 [1.2, 28.3]	0.025	*
>= 65 years	23	22 (95.7)	11 (47.8) [26.8, 69.4]	20	18 (90.0)	6 (30.0) [11.9, 54.3]	1.594 [0.721, 3.527]	2.139 [0.608, 7.530]	17.8 [-15.5, 51.1]	0.239	
Exacerbations in the year before study										0.548	
<= 2	105	103 (98.1)	59 (56.2) [46.2, 65.9]	110	105 (95.5)	48 (43.6) [34.2, 53.4]	1.288 [0.982, 1.689]	1.657 [0.966, 2.840]	12.6 [-1.6, 26.7]	0.066	
> 2	32	32 (100.0)	21 (65.6) [46.8, 81.4]	28	26 (92.9)	12 (42.9) [24.5, 62.8]	1.531 [0.933, 2.514]	2.545 [0.895, 7.239]	22.8 [-5.2, 50.7]	0.079	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_IOSPK: Decrease of at least 0.9 points in ACQ-6 score by key subgroups
DITT

	Tezepelumab			Placebo						
Decrease of at least 0.9 points in ACQ-6 score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10	any level							NE
White	128	126 (98.4)	73 (57.0) [48.0, 65.7]	123	116 (94.3)	52 (42.3) [33.4, 51.5]				
Black or African American	3	3 (100.0)	3 (100.0) [29.2, 100.0]	6	6 (100.0)	3 (50.0) [11.8, 88.2]				
Asian	5	5 (100.0)	4 (80.0) [28.4, 99.5]	6	6 (100.0)	2 (33.3) [4.3, 77.7]				
Other	1	1 (100.0)	0 (0.0) [0.0, 97.5]	3	3 (100.0)	3 (100.0) [29.2, 100.0]				
Region										0.210
Europe	78	78 (100.0)	46 (59.0) [47.3, 70.0]	80	75 (93.8)	30 (37.5) [26.9, 49.0]	1.573 [1.122, 2.205]	2.396 [1.264, 4.540]	21.5 [5.0, 38.0]	0.007 *
America	10	10 (100.0)	9 (90.0) [55.5, 99.7]	9	8 (88.9)	6 (66.7) [29.9, 92.5]	1.350 [0.814, 2.239]	4.500 [0.374, 54.155]	23.3 [-23.2, 69.9]	0.303 #
Asia/Pacific	5	5 (100.0)	4 (80.0) [28.4, 99.5]	6	6 (100.0)	2 (33.3) [4.3, 77.7]	2.400 [0.713, 8.077]	8.000 [0.500, 127.900]	46.7 [-23.2, 100.0]	0.242 #
Rest of the world	44	42 (95.5)	21 (47.7) [32.5, 63.3]	43	42 (97.7)	22 (51.2) [35.5, 66.7]	0.933 [0.610, 1.427]	0.872 [0.376, 2.021]	-3.4 [-26.7, 19.9]	0.750
BMI		N<10	any level							NE
< 18.5 kg/m**2	0			1	1 (100.0)	0 (0.0) [0.0, 97.5]				
18.5 - < 25.0 kg/m**2	39	39 (100.0)	28 (71.8) [55.1, 85.0]	43	42 (97.7)	19 (44.2) [29.1, 60.1]				
25.0 - < 30.0 kg/m**2	45	45 (100.0)	26 (57.8) [42.2, 72.3]	47	45 (95.7)	18 (38.3) [24.5, 53.6]				
>= 30.0 kg/m**2	53	51 (96.2)	26 (49.1) [35.1, 63.2]	47	43 (91.5)	23 (48.9) [34.1, 63.9]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_IOSPK: Decrease of at least 0.9 points in ACQ-6 score by key subgroups
DITT

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.532	
< 150 cells/uL	27	27 (100.0)	13 (48.1) [28.7, 68.1]	33	31 (93.9)	14 (42.4) [25.5, 60.8]	1.135 [0.650, 1.983]	1.260 [0.453, 3.505]	5.7 [-22.9, 34.4]	0.660	
>= 150 cells/uL	109	107 (98.2)	66 (60.6) [50.7, 69.8]	105	100 (95.2)	46 (43.8) [34.1, 53.8]	1.382 [1.061, 1.800]	1.969 [1.142, 3.392]	16.7 [2.6, 30.9]	0.014	*
Baseline eosinophils - High										0.190	
< 300 cells/uL	69	67 (97.1)	36 (52.2) [39.8, 64.4]	72	66 (91.7)	33 (45.8) [34.0, 58.0]	1.138 [0.812, 1.596]	1.289 [0.665, 2.499]	6.3 [-11.6, 24.2]	0.453	
>= 300 cells/uL	67	67 (100.0)	43 (64.2) [51.5, 75.5]	66	65 (98.5)	27 (40.9) [29.0, 53.7]	1.569 [1.116, 2.206]	2.588 [1.285, 5.212]	23.3 [5.3, 41.3]	0.007	*
Baseline FENO										0.016	i
< 25 ppb	78	77 (98.7)	37 (47.4) [36.0, 59.1]	74	70 (94.6)	35 (47.3) [35.6, 59.3]	1.003 [0.717, 1.402]	1.006 [0.532, 1.901]	0.1 [-17.1, 17.3]	0.986	
>= 25 ppb	57	56 (98.2)	41 (71.9) [58.5, 83.0]	63	60 (95.2)	25 (39.7) [27.6, 52.8]	1.813 [1.284, 2.559]	3.895 [1.809, 8.388]	32.2 [13.8, 50.7]	<0.001	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_IOSPK: Decrease of at least 0.9 points in ACQ-6 score by key subgroups
DITT

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										<0.001	i
All negative	57	57 (100.0)	36 (63.2) [49.3, 75.6]	66	62 (93.9)	17 (25.8) [15.8, 38.0]	2.452 [1.556, 3.865]	4.941 [2.286, 10.679]	37.4 [19.4, 55.4]	<0.001	*
Any positive	71	69 (97.2)	39 (54.9) [42.7, 66.8]	63	60 (95.2)	37 (58.7) [45.6, 71.0]	0.935 [0.696, 1.257]	0.856 [0.431, 1.700]	-3.8 [-22.1, 14.5]	0.659	
Total serum IgE										0.181	
Low	35	35 (100.0)	18 (51.4) [34.0, 68.6]	32	28 (87.5)	11 (34.4) [18.6, 53.2]	1.496 [0.840, 2.664]	2.021 [0.754, 5.416]	17.1 [-9.3, 43.4]	0.163	
Normal	95	93 (97.9)	59 (62.1) [51.6, 71.9]	98	95 (96.9)	43 (43.9) [33.9, 54.3]	1.415 [1.077, 1.861]	2.096 [1.179, 3.727]	18.2 [3.3, 33.1]	0.011	*
High	7	7 (100.0)	3 (42.9) [9.9, 81.6]	8	8 (100.0)	6 (75.0) [34.9, 96.8]	0.571 [0.222, 1.469]	0.250 [0.028, 2.237]	-32.1 [-92.9, 28.6]	0.315	#
OCS at baseline										0.511	
Yes	9	9 (100.0)	7 (77.8) [40.0, 97.2]	13	13 (100.0)	6 (46.2) [19.2, 74.9]	1.685 [0.851, 3.337]	4.083 [0.603, 27.650]	31.6 [-16.1, 79.4]	0.203	#
No	128	126 (98.4)	73 (57.0) [48.0, 65.7]	125	118 (94.4)	54 (43.2) [34.4, 52.4]	1.320 [1.027, 1.697]	1.745 [1.061, 2.871]	13.8 [0.8, 26.8]	0.028	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_IOSPK: Decrease of at least 0.9 points in ACQ-6 score by key subgroups
DITT

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
ICS dose level (at study entry)										0.747	
Medium/Low	70	68 (97.1)	41 (58.6) [46.2, 70.2]	73	71 (97.3)	33 (45.2) [33.5, 57.3]	1.296 [0.941, 1.785]	1.714 [0.884, 3.323]	13.4 [-4.3, 31.0]	0.111	
High	67	67 (100.0)	39 (58.2) [45.5, 70.2]	65	60 (92.3)	27 (41.5) [29.4, 54.4]	1.401 [0.985, 1.994]	1.960 [0.981, 3.917]	16.7 [-1.7, 35.0]	0.056	
LAMA use at baseline										0.559	
Yes	11	11 (100.0)	7 (63.6) [30.8, 89.1]	6	5 (83.3)	2 (33.3) [4.3, 77.7]	1.909 [0.566, 6.444]	3.500 [0.431, 28.447]	30.3 [-29.8, 90.4]	0.335	#
No	126	124 (98.4)	73 (57.9) [48.8, 66.7]	132	126 (95.5)	58 (43.9) [35.3, 52.8]	1.319 [1.034, 1.682]	1.757 [1.073, 2.878]	14.0 [1.1, 26.9]	0.025	*
Tiotropium use at baseline										0.630	
Yes	9	9 (100.0)	6 (66.7) [29.9, 92.5]	3	3 (100.0)	1 (33.3) [0.8, 90.6]	2.000 [0.378, 10.578]	4.000 [0.250, 63.950]	33.3 [-50.5, 100.0]	0.523	#
No	128	126 (98.4)	74 (57.8) [48.8, 66.5]	135	128 (94.8)	59 (43.7) [35.2, 52.5]	1.323 [1.039, 1.685]	1.765 [1.083, 2.877]	14.1 [1.4, 26.8]	0.022	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_IOSPK: Decrease of at least 0.9 points in ACQ-6 score by key subgroups
DITT

	Tezepelumab			Placebo						
Decrease of at least 0.9 points in ACQ-6 score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline										0.666
Yes	29	28 (96.6)	21 (72.4) [52.8, 87.3]	37	37 (100.0)	21 (56.8) [39.5, 72.9]	1.276 [0.890, 1.829]	2.000 [0.705, 5.671]	15.7 [-10.2, 41.5]	0.193
No	108	107 (99.1)	59 (54.6) [44.8, 64.2]	101	94 (93.1)	39 (38.6) [29.1, 48.8]	1.415 [1.048, 1.910]	1.914 [1.103, 3.322]	16.0 [1.7, 30.3]	0.021 *

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_IOSPP: Decrease of at least 0.9 points in ACQ-6 score by study specific subgroups
DITT

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.812	
White	128	126 (98.4)	73 (57.0) [48.0, 65.7]	123	116 (94.3)	52 (42.3) [33.4, 51.5]	1.349 [1.045, 1.742]	1.812 [1.099, 2.989]	14.8 [1.7, 27.8]	0.020	*
Non-white	9	9 (100.0)	7 (77.8) [40.0, 97.2]	15	15 (100.0)	8 (53.3) [26.6, 78.7]	1.458 [0.810, 2.626]	3.063 [0.472, 19.879]	24.4 [-21.5, 70.4]	0.389	#
Region (cat. P)										0.970	
North America/Western EU	10	10 (100.0)	9 (90.0) [55.5, 99.7]	9	8 (88.9)	6 (66.7) [29.9, 92.5]	1.350 [0.814, 2.239]	4.500 [0.374, 54.155]	23.3 [-23.2, 69.9]	0.303	#
Rest of world	127	125 (98.4)	71 (55.9) [46.8, 64.7]	129	123 (95.3)	54 (41.9) [33.2, 50.9]	1.336 [1.035, 1.724]	1.761 [1.073, 2.889]	14.0 [1.1, 27.0]	0.025	*
Baseline eosinophils (cat. P)										0.252	
< 250 cells/uL	61	61 (100.0)	34 (55.7) [42.4, 68.5]	60	55 (91.7)	29 (48.3) [35.2, 61.6]	1.153 [0.817, 1.627]	1.346 [0.658, 2.752]	7.4 [-12.0, 26.8]	0.417	
>= 250 cells/uL	76	74 (97.4)	46 (60.5) [48.6, 71.6]	78	76 (97.4)	31 (39.7) [28.8, 51.5]	1.523 [1.097, 2.114]	2.325 [1.219, 4.435]	20.8 [4.0, 37.5]	0.010	*
Baseline FENO (cat. P)										0.051	
< 24 ppb	75	74 (98.7)	36 (48.0) [36.3, 59.8]	72	68 (94.4)	33 (45.8) [34.0, 58.0]	1.047 [0.742, 1.478]	1.091 [0.571, 2.086]	2.2 [-15.3, 19.7]	0.793	
>= 24 ppb	60	59 (98.3)	42 (70.0) [56.8, 81.2]	65	62 (95.4)	27 (41.5) [29.4, 54.4]	1.685 [1.208, 2.350]	3.284 [1.566, 6.886]	28.5 [10.2, 46.7]	0.001	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_IOSPP: Decrease of at least 0.9 points in ACQ-6 score by study specific subgroups
DITT

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. M)										0.007	i
< 22.0 ppb	65	64 (98.5)	27 (41.5) [29.4, 54.4]	62	59 (95.2)	29 (46.8) [34.0, 59.9]	0.888 [0.600, 1.314]	0.809 [0.401, 1.631]	-5.2 [-24.1, 13.6]	0.554	
>= 22.0 ppb	70	69 (98.6)	51 (72.9) [60.9, 82.8]	75	71 (94.7)	31 (41.3) [30.1, 53.3]	1.763 [1.299, 2.392]	3.810 [1.894, 7.665]	31.5 [14.9, 48.2]	<0.001	*
Baseline all FEIA status										0.026	i
All negative	50	50 (100.0)	30 (60.0) [45.2, 73.6]	50	46 (92.0)	14 (28.0) [16.2, 42.5]	2.143 [1.301, 3.529]	3.857 [1.670, 8.911]	32.0 [11.6, 52.4]	0.001	*
Any positive	77	75 (97.4)	44 (57.1) [45.4, 68.4]	80	77 (96.3)	41 (51.3) [39.8, 62.6]	1.115 [0.836, 1.487]	1.268 [0.676, 2.379]	5.9 [-10.9, 22.7]	0.460	
Th2 status										0.869	
Low	70	70 (100.0)	36 (51.4) [39.2, 63.6]	62	57 (91.9)	24 (38.7) [26.6, 51.9]	1.329 [0.902, 1.957]	1.676 [0.838, 3.354]	12.7 [-5.7, 31.1]	0.145	
High	65	63 (96.9)	42 (64.6) [51.8, 76.1]	75	73 (97.3)	35 (46.7) [35.1, 58.6]	1.385 [1.024, 1.872]	2.087 [1.056, 4.125]	17.9 [0.3, 35.6]	0.034	*
Baseline Periostin										0.016	i
Low (< 20.9 ng/ml)	62	61 (98.4)	26 (41.9) [29.5, 55.2]	67	64 (95.5)	30 (44.8) [32.6, 57.4]	0.937 [0.631, 1.391]	0.891 [0.443, 1.789]	-2.8 [-21.5, 15.8]	0.746	
High (>= 20.9 ng/ml)	74	73 (98.6)	54 (73.0) [61.4, 82.6]	71	67 (94.4)	30 (42.3) [30.6, 54.6]	1.727 [1.273, 2.343]	3.690 [1.839, 7.404]	30.7 [14.0, 47.4]	<0.001	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_IOSPP: Decrease of at least 0.9 points in ACQ-6 score by study specific subgroups
DITT

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility										0.205	
Yes	114	113 (99.1)	61 (53.5) [43.9, 62.9]	126	121 (96.0)	55 (43.7) [34.8, 52.8]	1.226 [0.943, 1.593]	1.486 [0.893, 2.473]	9.9 [-3.6, 23.3]	0.128	
No	23	22 (95.7)	19 (82.6) [61.2, 95.0]	12	10 (83.3)	5 (41.7) [15.2, 72.3]	1.983 [0.989, 3.973]	6.650 [1.377, 32.114]	40.9 [2.7, 79.2]	0.022	*
Maintenance OCS use at baseline										0.658	
Yes	9	9 (100.0)	7 (77.8) [40.0, 97.2]	14	14 (100.0)	7 (50.0) [23.0, 77.0]	1.556 [0.829, 2.919]	3.500 [0.529, 23.137]	27.8 [-19.1, 74.6]	0.228	#
No	128	126 (98.4)	73 (57.0) [48.0, 65.7]	124	117 (94.4)	53 (42.7) [33.9, 51.9]	1.334 [1.036, 1.719]	1.778 [1.079, 2.929]	14.3 [1.3, 27.3]	0.024	*
No chronic OCS use and current post-BD FEV1 reversibility										0.291	
Yes	108	107 (99.1)	57 (52.8) [42.9, 62.5]	115	110 (95.7)	49 (42.6) [33.4, 52.2]	1.239 [0.939, 1.634]	1.505 [0.887, 2.554]	10.2 [-3.8, 24.1]	0.129	
No	29	28 (96.6)	23 (79.3) [60.3, 92.0]	23	21 (91.3)	11 (47.8) [26.8, 69.4]	1.658 [1.041, 2.642]	4.182 [1.241, 14.096]	31.5 [2.4, 60.6]	0.019	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6I_IOMP0: Increase of at least 0.9 points in ACQ-6 score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in ACQ-6 score	Week 28	137	134 (97.8)	2 (1.5) [0.2, 5.2]	138	129 (93.5)	7 (5.1) [2.1, 10.2]	0.288 [0.061, 1.361]	0.277 [0.057, 1.359]	-3.6 [-8.5, 1.3]	0.172 #
	Week 52	137	135 (98.5)	3 (2.2) [0.5, 6.3]	138	131 (94.9)	6 (4.3) [1.6, 9.2]	0.504 [0.129, 1.973]	0.493 [0.121, 2.011]	-2.2 [-7.1, 2.8]	0.501 #

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOMH0: Course of ACQ-6 score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	137	137 (100.0)	2.70 (0.80)	0.0	2.33	2.67	3.00	4.8	
		Placebo	138	138 (100.0)	2.66 (0.69)	0.3	2.33	2.67	3.00	4.7	
	Week 2	Tezepelumab	137	131 (95.6)	2.17 (0.91)	0.0	1.67	2.17	2.83	4.3	
		Placebo	138	125 (90.6)	2.30 (0.79)	0.2	2.00	2.33	2.83	4.8	
	Week 4	Tezepelumab	137	131 (95.6)	1.89 (0.96)	0.0	1.17	2.00	2.67	4.3	
		Placebo	138	125 (90.6)	2.18 (0.84)	0.2	1.50	2.33	2.67	4.2	
	Week 6	Tezepelumab	137	131 (95.6)	1.80 (0.97)	0.0	1.17	1.83	2.50	4.3	
		Placebo	138	126 (91.3)	2.08 (0.96)	0.2	1.50	2.17	2.67	5.5	
	Week 8	Tezepelumab	137	131 (95.6)	1.73 (1.02)	0.0	1.00	1.67	2.67	4.8	
		Placebo	138	127 (92.0)	2.06 (0.95)	0.0	1.33	2.00	2.67	4.7	
	Week 10	Tezepelumab	137	131 (95.6)	1.66 (1.01)	0.0	0.83	1.67	2.33	4.3	
		Placebo	138	128 (92.8)	1.98 (0.91)	0.0	1.33	2.00	2.58	5.3	
	Week 12	Tezepelumab	137	131 (95.6)	1.59 (1.03)	0.0	0.83	1.50	2.50	4.3	
		Placebo	138	128 (92.8)	1.90 (0.93)	0.0	1.17	2.00	2.67	4.3	
	Week 14	Tezepelumab	137	131 (95.6)	1.46 (1.00)	0.0	0.67	1.33	2.17	4.3	
		Placebo	138	128 (92.8)	1.84 (0.91)	0.0	1.17	1.83	2.50	5.0	
	Week 16	Tezepelumab	137	131 (95.6)	1.61 (1.05)	0.0	0.83	1.50	2.50	4.3	
		Placebo	138	128 (92.8)	1.97 (1.03)	0.0	1.17	2.00	2.67	5.0	
	Week 18	Tezepelumab	137	132 (96.4)	1.50 (0.97)	0.0	0.83	1.42	2.17	4.3	
		Placebo	138	128 (92.8)	1.86 (0.98)	0.0	1.17	1.83	2.50	5.0	
	Week 20	Tezepelumab	137	132 (96.4)	1.58 (1.02)	0.0	0.83	1.50	2.25	5.0	
		Placebo	138	128 (92.8)	1.92 (1.00)	0.0	1.17	2.17	2.67	5.0	
	Week 22	Tezepelumab	137	132 (96.4)	1.60 (0.97)	0.0	0.92	1.67	2.33	4.3	
		Placebo	138	128 (92.8)	1.87 (1.00)	0.0	1.17	2.00	2.67	5.0	
	Week 24	Tezepelumab	137	132 (96.4)	1.59 (1.03)	0.0	0.83	1.67	2.33	4.3	
		Placebo	138	128 (92.8)	1.87 (0.98)	0.0	1.00	2.00	2.50	4.5	
	Week 26	Tezepelumab	137	133 (97.1)	1.56 (1.01)	0.0	0.83	1.50	2.17	4.3	
		Placebo	138	128 (92.8)	1.82 (0.98)	0.0	1.00	1.67	2.50	4.5	
	Week 28	Tezepelumab	137	134 (97.8)	1.60 (1.03)	0.0	0.83	1.50	2.50	4.3	
		Placebo	138	129 (93.5)	1.87 (1.04)	0.0	1.00	2.00	2.50	4.5	
	Week 30	Tezepelumab	137	135 (98.5)	1.55 (1.00)	0.0	0.83	1.50	2.17	4.3	
		Placebo	138	130 (94.2)	1.87 (1.02)	0.0	1.17	1.83	2.50	4.5	
	Week 32	Tezepelumab	137	135 (98.5)	1.51 (1.02)	0.0	0.83	1.50	2.33	4.3	
		Placebo	138	130 (94.2)	1.82 (1.02)	0.0	1.00	1.83	2.50	4.5	
	Week 34	Tezepelumab	137	135 (98.5)	1.52 (1.06)	0.0	0.67	1.33	2.33	4.3	
		Placebo	138	130 (94.2)	1.78 (1.03)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOMH0: Course of ACQ-6 score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Week 36	Tezepelumab	137	135 (98.5)	1.60 (1.04)	0.0	0.83	1.67	2.33	4.5	
		Placebo	138	130 (94.2)	1.86 (1.03)	0.0	1.00	1.83	2.67	4.5	
	Week 38	Tezepelumab	137	135 (98.5)	1.50 (1.04)	0.0	0.83	1.50	2.17	4.5	
		Placebo	138	130 (94.2)	1.78 (1.02)	0.0	1.00	1.83	2.50	4.5	
	Week 40	Tezepelumab	137	135 (98.5)	1.53 (1.04)	0.0	0.67	1.67	2.17	4.3	
		Placebo	138	130 (94.2)	1.86 (1.04)	0.0	1.00	1.83	2.67	4.5	
	Week 42	Tezepelumab	137	135 (98.5)	1.50 (1.04)	0.0	0.83	1.50	2.17	4.7	
		Placebo	138	130 (94.2)	1.82 (1.01)	0.0	1.00	1.92	2.50	4.7	
	Week 44	Tezepelumab	137	135 (98.5)	1.52 (1.02)	0.0	0.67	1.50	2.33	4.3	
		Placebo	138	131 (94.9)	1.87 (1.01)	0.0	1.00	2.00	2.67	4.5	
	Week 46	Tezepelumab	137	135 (98.5)	1.49 (1.03)	0.0	0.83	1.33	2.17	4.3	
		Placebo	138	131 (94.9)	1.76 (0.98)	0.0	1.00	1.83	2.50	4.5	
	Week 48	Tezepelumab	137	135 (98.5)	1.55 (1.04)	0.0	0.67	1.50	2.33	4.3	
		Placebo	138	131 (94.9)	1.79 (1.01)	0.0	1.00	2.00	2.50	4.5	
	Week 50	Tezepelumab	137	135 (98.5)	1.46 (1.03)	0.0	0.83	1.33	2.17	4.3	
		Placebo	138	131 (94.9)	1.77 (0.96)	0.0	1.00	1.83	2.50	4.5	
	Week 52	Tezepelumab	137	135 (98.5)	1.49 (1.03)	0.0	0.67	1.50	2.17	4.3	
		Placebo	138	131 (94.9)	1.82 (1.00)	0.0	1.00	2.00	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOMH0: Course of ACQ-6 score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 score	Week 2	Tezepelumab	137	131 (95.6)	-0.54 (0.67)	-2.8	-0.83	-0.33	0.00	0.7	-0.25 [-0.49, -0.00]
		Placebo	138	125 (90.6)	-0.37 (0.71)	-2.8	-0.83	-0.33	0.00	1.2	
	Week 4	Tezepelumab	137	131 (95.6)	-0.82 (0.88)	-3.5	-1.33	-0.83	-0.17	2.3	-0.39 [-0.63, -0.14]
		Placebo	138	125 (90.6)	-0.49 (0.83)	-3.0	-1.00	-0.33	0.17	1.2	
	Week 6	Tezepelumab	137	131 (95.6)	-0.91 (0.96)	-3.8	-1.50	-0.83	-0.33	2.3	-0.36 [-0.60, -0.11]
		Placebo	138	126 (91.3)	-0.58 (0.90)	-3.3	-1.17	-0.50	0.00	1.5	
	Week 8	Tezepelumab	137	131 (95.6)	-0.97 (1.00)	-3.8	-1.67	-1.00	-0.33	2.3	-0.38 [-0.63, -0.13]
		Placebo	138	127 (92.0)	-0.61 (0.90)	-3.2	-1.00	-0.67	0.00	1.0	
	Week 10	Tezepelumab	137	131 (95.6)	-1.05 (0.98)	-3.8	-1.67	-1.00	-0.33	2.3	-0.37 [-0.61, -0.12]
		Placebo	138	128 (92.8)	-0.69 (0.96)	-3.3	-1.33	-0.67	-0.17	2.7	
	Week 12	Tezepelumab	137	131 (95.6)	-1.12 (0.98)	-3.7	-1.83	-1.17	-0.50	2.3	-0.35 [-0.60, -0.11]
		Placebo	138	128 (92.8)	-0.77 (0.96)	-3.3	-1.33	-0.67	-0.17	1.3	
	Week 14	Tezepelumab	137	131 (95.6)	-1.25 (0.99)	-3.8	-2.00	-1.17	-0.67	2.3	-0.43 [-0.68, -0.18]
		Placebo	138	128 (92.8)	-0.83 (0.95)	-3.2	-1.33	-0.83	-0.33	2.3	
	Week 16	Tezepelumab	137	131 (95.6)	-1.10 (1.04)	-4.2	-1.83	-1.00	-0.50	2.3	-0.39 [-0.63, -0.14]
		Placebo	138	128 (92.8)	-0.70 (1.03)	-3.5	-1.33	-0.67	0.00	2.3	
	Week 18	Tezepelumab	137	132 (96.4)	-1.20 (1.00)	-4.2	-1.83	-1.00	-0.67	2.3	-0.39 [-0.64, -0.14]
		Placebo	138	128 (92.8)	-0.81 (1.01)	-3.2	-1.42	-0.67	-0.17	2.3	
	Week 20	Tezepelumab	137	132 (96.4)	-1.12 (1.01)	-4.2	-1.83	-1.00	-0.33	2.3	-0.36 [-0.60, -0.11]
		Placebo	138	128 (92.8)	-0.75 (1.04)	-3.5	-1.33	-0.67	-0.17	2.3	
	Week 22	Tezepelumab	137	132 (96.4)	-1.10 (1.03)	-4.3	-1.83	-1.00	-0.50	2.3	-0.30 [-0.54, -0.05]
		Placebo	138	128 (92.8)	-0.80 (1.01)	-3.3	-1.50	-0.83	-0.17	2.3	
	Week 24	Tezepelumab	137	132 (96.4)	-1.11 (0.98)	-4.5	-1.75	-1.00	-0.50	2.3	-0.31 [-0.55, -0.06]
		Placebo	138	128 (92.8)	-0.80 (1.04)	-3.5	-1.50	-0.75	-0.08	2.3	
	Week 26	Tezepelumab	137	133 (97.1)	-1.14 (1.03)	-4.2	-1.83	-1.00	-0.33	2.3	-0.28 [-0.52, -0.03]
		Placebo	138	128 (92.8)	-0.85 (1.04)	-4.0	-1.50	-1.00	-0.17	2.3	
	Week 28	Tezepelumab	137	134 (97.8)	-1.08 (1.04)	-4.2	-1.83	-1.00	-0.33	2.3	-0.29 [-0.53, -0.05]
		Placebo	138	129 (93.5)	-0.78 (1.07)	-4.0	-1.50	-0.83	-0.17	2.3	
	Week 30	Tezepelumab	137	135 (98.5)	-1.14 (1.05)	-4.2	-2.00	-1.00	-0.50	2.3	-0.34 [-0.58, -0.09]
		Placebo	138	130 (94.2)	-0.79 (1.06)	-3.2	-1.50	-0.83	-0.17	2.3	
	Week 32	Tezepelumab	137	135 (98.5)	-1.18 (1.05)	-4.2	-2.00	-1.00	-0.67	2.3	-0.33 [-0.57, -0.09]
		Placebo	138	130 (94.2)	-0.84 (1.04)	-3.5	-1.50	-0.75	-0.17	2.3	
	Week 34	Tezepelumab	137	135 (98.5)	-1.17 (1.06)	-4.2	-2.00	-1.17	-0.50	2.3	-0.28 [-0.52, -0.04]
		Placebo	138	130 (94.2)	-0.87 (1.05)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOMH0: Course of ACQ-6 score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 score	Week 36	Tezepelumab	137	135 (98.5)	-1.09 (1.09)	-4.2	-1.83	-1.00	-0.33	2.3	-0.28 [-0.52, -0.03]
		Placebo	138	130 (94.2)	-0.79 (1.07)	-3.5	-1.33	-0.83	0.00	2.3	
	Week 38	Tezepelumab	137	135 (98.5)	-1.19 (1.09)	-4.2	-2.00	-1.17	-0.50	2.3	-0.30 [-0.54, -0.05]
		Placebo	138	130 (94.2)	-0.87 (1.06)	-4.0	-1.50	-0.83	-0.17	2.3	
	Week 40	Tezepelumab	137	135 (98.5)	-1.17 (1.09)	-4.2	-2.00	-1.00	-0.50	2.3	-0.34 [-0.58, -0.10]
		Placebo	138	130 (94.2)	-0.80 (1.06)	-4.0	-1.50	-0.83	-0.17	2.3	
	Week 42	Tezepelumab	137	135 (98.5)	-1.19 (1.09)	-4.2	-2.00	-1.17	-0.50	2.3	-0.34 [-0.58, -0.10]
		Placebo	138	130 (94.2)	-0.83 (1.04)	-4.0	-1.50	-0.83	-0.17	2.3	
	Week 44	Tezepelumab	137	135 (98.5)	-1.17 (1.10)	-4.3	-1.83	-1.00	-0.50	2.3	-0.36 [-0.60, -0.11]
		Placebo	138	131 (94.9)	-0.79 (1.06)	-4.0	-1.50	-0.83	0.00	2.3	
	Week 46	Tezepelumab	137	135 (98.5)	-1.21 (1.09)	-4.2	-2.00	-1.17	-0.50	2.3	-0.30 [-0.54, -0.05]
		Placebo	138	131 (94.9)	-0.89 (1.03)	-4.0	-1.50	-1.00	-0.17	2.3	
	Week 48	Tezepelumab	137	135 (98.5)	-1.15 (1.09)	-4.2	-2.00	-1.00	-0.33	2.3	-0.26 [-0.51, -0.02]
		Placebo	138	131 (94.9)	-0.86 (1.06)	-3.7	-1.50	-0.83	-0.33	2.3	
	Week 50	Tezepelumab	137	135 (98.5)	-1.23 (1.09)	-4.2	-2.00	-1.17	-0.50	2.3	-0.33 [-0.57, -0.09]
		Placebo	138	131 (94.9)	-0.88 (1.02)	-4.0	-1.50	-1.00	-0.33	2.3	
	Week 52	Tezepelumab	137	135 (98.5)	-1.20 (1.09)	-4.2	-2.00	-1.17	-0.50	2.3	-0.35 [-0.59, -0.11]
		Placebo	138	131 (94.9)	-0.83 (1.05)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOMC0: Change from baseline in ACQ-6 score - MMRM results
DITT

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	137	130 (94.9)	NE		NE		
	Placebo	138	124 (89.9)					
Week 4	Tezepelumab	137	125 (91.2)	NE		NE		
	Placebo	138	123 (89.1)					
Week 6	Tezepelumab	137	125 (91.2)	NE		NE		
	Placebo	138	123 (89.1)					
Week 8	Tezepelumab	137	125 (91.2)	NE		NE		
	Placebo	138	124 (89.9)					
Week 10	Tezepelumab	137	124 (90.5)	NE		NE		
	Placebo	138	123 (89.1)					
Week 12	Tezepelumab	137	124 (90.5)	NE		NE		
	Placebo	138	122 (88.4)					
Week 14	Tezepelumab	137	121 (88.3)	NE		NE		
	Placebo	138	121 (87.7)					
Week 16	Tezepelumab	137	116 (84.7)	NE		NE		
	Placebo	138	117 (84.8)					
Week 18	Tezepelumab	137	116 (84.7)	NE		NE		
	Placebo	138	115 (83.3)					
Week 20	Tezepelumab	137	114 (83.2)	NE		NE		
	Placebo	138	112 (81.2)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOMC0: Change from baseline in ACQ-6 score - MMRM results
DITT

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	137	113 (82.5)	NE		NE		
	Placebo	138	114 (82.6)					
Week 24	Tezepelumab	137	113 (82.5)	NE		NE		
	Placebo	138	111 (80.4)					
Week 26	Tezepelumab	137	115 (83.9)	NE		NE		
	Placebo	138	110 (79.7)					
Week 28	Tezepelumab	137	112 (81.8)	NE		NE		
	Placebo	138	111 (80.4)					
Week 30	Tezepelumab	137	116 (84.7)	NE		NE		
	Placebo	138	111 (80.4)					
Week 32	Tezepelumab	137	117 (85.4)	NE		NE		
	Placebo	138	112 (81.2)					
Week 34	Tezepelumab	137	116 (84.7)	NE		NE		
	Placebo	138	110 (79.7)					
Week 36	Tezepelumab	137	116 (84.7)	NE		NE		
	Placebo	138	110 (79.7)					
Week 38	Tezepelumab	137	115 (83.9)	NE		NE		
	Placebo	138	111 (80.4)					
Week 40	Tezepelumab	137	114 (83.2)	NE		NE		
	Placebo	138	113 (81.9)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOMC0: Change from baseline in ACQ-6 score - MMRM results
DITT

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	137	113 (82.5)	NE		NE		
	Placebo	138	108 (78.3)					
Week 44	Tezepelumab	137	113 (82.5)	NE		NE		
	Placebo	138	111 (80.4)					
Week 46	Tezepelumab	137	112 (81.8)	NE		NE		
	Placebo	138	110 (79.7)					
Week 48	Tezepelumab	137	109 (79.6)	NE		NE		
	Placebo	138	113 (81.9)					
Week 50	Tezepelumab	137	110 (80.3)	NE		NE		
	Placebo	138	112 (81.2)					
Week 52	Tezepelumab	137	44 (32.1)	NE		NE		
	Placebo	138	53 (38.4)					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Figure PF2H6C_IOMG0: Course of ACQ-6 score
DITT



Note: DITT = Dossier Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
ACQ = asthma control questionnaire.
Source table: PT2H6C_IOMH0
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	50	50 (100.0)	2.71 (0.82)	0.8	2.33	2.67	3.17	4.8	
			Placebo	44	44 (100.0)	2.64 (0.75)	0.3	2.33	2.75	3.00	4.3	
		Week 2	Tezepelumab	50	47 (94.0)	2.14 (0.95)	0.0	1.50	2.17	2.83	3.8	
			Placebo	44	42 (95.5)	2.33 (0.90)	0.2	1.67	2.42	2.83	4.8	
		Week 4	Tezepelumab	50	47 (94.0)	1.84 (1.03)	0.0	1.17	2.00	2.83	3.5	
			Placebo	44	42 (95.5)	2.15 (0.89)	0.5	1.50	2.25	2.67	4.2	
		Week 6	Tezepelumab	50	47 (94.0)	1.81 (1.06)	0.0	1.17	1.83	2.50	4.0	
			Placebo	44	42 (95.5)	2.15 (0.98)	0.5	1.17	2.25	2.83	4.7	
		Week 8	Tezepelumab	50	47 (94.0)	1.73 (1.02)	0.0	1.00	1.67	2.50	4.2	
			Placebo	44	42 (95.5)	2.12 (0.95)	0.2	1.33	2.17	2.83	4.7	
		Week 10	Tezepelumab	50	47 (94.0)	1.68 (1.03)	0.0	1.00	1.67	2.50	3.5	
			Placebo	44	42 (95.5)	2.01 (0.93)	0.0	1.33	2.00	2.67	4.2	
		Week 12	Tezepelumab	50	47 (94.0)	1.56 (0.97)	0.0	0.83	1.50	2.50	3.5	
			Placebo	44	42 (95.5)	1.88 (1.04)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	50	47 (94.0)	1.42 (0.97)	0.0	0.83	1.33	2.00	4.2	
			Placebo	44	42 (95.5)	1.79 (0.94)	0.3	1.00	1.67	2.33	5.0	
		Week 16	Tezepelumab	50	47 (94.0)	1.67 (1.14)	0.0	0.83	1.67	2.50	4.3	
			Placebo	44	42 (95.5)	1.94 (1.00)	0.2	1.00	1.92	2.67	4.5	
		Week 18	Tezepelumab	50	47 (94.0)	1.52 (1.00)	0.0	0.83	1.67	2.17	4.2	
			Placebo	44	42 (95.5)	1.82 (0.96)	0.2	1.00	1.83	2.50	4.5	
		Week 20	Tezepelumab	50	47 (94.0)	1.58 (1.04)	0.0	0.83	1.50	2.17	5.0	
			Placebo	44	42 (95.5)	1.92 (1.04)	0.2	1.17	2.00	2.83	4.5	
		Week 22	Tezepelumab	50	47 (94.0)	1.51 (0.95)	0.0	0.83	1.50	2.17	3.8	
			Placebo	44	42 (95.5)	1.81 (1.03)	0.0	1.00	1.83	2.67	4.5	
		Week 24	Tezepelumab	50	47 (94.0)	1.53 (1.04)	0.0	0.83	1.67	2.33	3.8	
			Placebo	44	42 (95.5)	1.79 (1.05)	0.2	0.83	1.67	2.50	4.5	
		Week 26	Tezepelumab	50	48 (96.0)	1.48 (1.07)	0.0	0.75	1.25	2.08	4.0	
			Placebo	44	42 (95.5)	1.80 (0.97)	0.3	1.00	1.50	2.50	4.5	
		Week 28	Tezepelumab	50	48 (96.0)	1.50 (1.04)	0.0	0.67	1.50	2.17	3.8	
			Placebo	44	43 (97.7)	1.96 (1.15)	0.0	1.00	2.17	2.83	4.5	
		Week 30	Tezepelumab	50	49 (98.0)	1.51 (1.03)	0.0	0.67	1.33	2.17	3.8	
			Placebo	44	43 (97.7)	1.76 (1.07)	0.0	1.00	1.83	2.50	4.5	
		Week 32	Tezepelumab	50	49 (98.0)	1.49 (1.05)	0.0	0.67	1.33	2.17	4.2	
			Placebo	44	43 (97.7)	1.75 (1.09)	0.0	0.83	1.50	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Male	Absolute values	Week 34	Tezepelumab	50	49 (98.0)	1.49 (1.10)	0.0	0.67	1.17	2.17	4.2	
			Placebo	44	43 (97.7)	1.74 (1.10)	0.0	0.83	1.50	2.50	4.5	
		Week 36	Tezepelumab	50	49 (98.0)	1.57 (1.06)	0.0	0.67	1.67	2.33	3.8	
			Placebo	44	43 (97.7)	1.83 (1.08)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	50	49 (98.0)	1.48 (1.09)	0.0	0.67	1.50	2.00	4.5	
			Placebo	44	43 (97.7)	1.64 (1.02)	0.0	1.00	1.50	2.33	4.5	
		Week 40	Tezepelumab	50	49 (98.0)	1.51 (1.09)	0.0	0.50	1.33	2.33	3.7	
			Placebo	44	43 (97.7)	1.81 (1.10)	0.0	1.00	1.67	2.67	4.5	
		Week 42	Tezepelumab	50	49 (98.0)	1.48 (1.09)	0.0	0.50	1.33	2.17	3.8	
			Placebo	44	43 (97.7)	1.76 (1.11)	0.0	1.00	1.83	2.50	4.5	
		Week 44	Tezepelumab	50	49 (98.0)	1.48 (1.06)	0.0	0.50	1.33	2.33	3.8	
			Placebo	44	43 (97.7)	1.81 (1.08)	0.0	1.00	2.00	2.50	4.5	
		Week 46	Tezepelumab	50	49 (98.0)	1.49 (1.09)	0.0	0.67	1.17	2.33	3.8	
			Placebo	44	43 (97.7)	1.69 (1.06)	0.0	1.00	1.83	2.33	4.5	
		Week 48	Tezepelumab	50	49 (98.0)	1.57 (1.09)	0.0	0.67	1.50	2.33	3.8	
			Placebo	44	43 (97.7)	1.72 (1.13)	0.0	0.83	2.00	2.50	4.5	
		Week 50	Tezepelumab	50	49 (98.0)	1.48 (1.08)	0.0	0.67	1.33	2.17	4.2	
			Placebo	44	43 (97.7)	1.80 (1.02)	0.0	1.00	1.67	2.50	4.5	
		Week 52	Tezepelumab	50	49 (98.0)	1.52 (1.07)	0.0	0.67	1.33	2.17	4.3	
			Placebo	44	43 (97.7)	1.83 (1.06)	0.0	1.00	1.67	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	50	47 (94.0)	-0.55 (0.66)	-2.3	-1.00	-0.50	-0.17	0.5	-0.26 [-0.67, 0.16]
			Placebo	44	42 (95.5)	-0.37 (0.78)	-2.7	-0.67	-0.33	0.17	1.2	
		Week 4	Tezepelumab	50	47 (94.0)	-0.85 (0.97)	-3.5	-1.50	-0.83	-0.17	1.7	-0.33 [-0.75, 0.09]
			Placebo	44	42 (95.5)	-0.55 (0.88)	-2.7	-1.33	-0.50	0.00	1.2	
		Week 6	Tezepelumab	50	47 (94.0)	-0.88 (1.04)	-3.8	-1.50	-0.83	-0.17	1.3	-0.34 [-0.76, 0.08]
			Placebo	44	42 (95.5)	-0.55 (0.90)	-2.8	-1.17	-0.50	0.17	1.0	
		Week 8	Tezepelumab	50	47 (94.0)	-0.96 (0.99)	-3.8	-1.67	-1.00	-0.33	1.0	-0.41 [-0.83, 0.01]
			Placebo	44	42 (95.5)	-0.58 (0.82)	-3.2	-1.00	-0.50	0.00	0.8	
		Week 10	Tezepelumab	50	47 (94.0)	-1.01 (1.03)	-3.8	-1.50	-1.00	0.00	1.0	-0.32 [-0.74, 0.09]
			Placebo	44	42 (95.5)	-0.69 (0.94)	-3.3	-1.17	-0.58	-0.17	2.0	
		Week 12	Tezepelumab	50	47 (94.0)	-1.13 (1.00)	-3.7	-1.83	-1.00	-0.50	1.2	-0.32 [-0.74, 0.10]
			Placebo	44	42 (95.5)	-0.81 (1.00)	-3.3	-1.33	-0.75	0.00	1.2	
		Week 14	Tezepelumab	50	47 (94.0)	-1.27 (1.00)	-3.8	-1.83	-1.33	-0.83	1.2	-0.39 [-0.81, 0.03]
			Placebo	44	42 (95.5)	-0.91 (0.84)	-3.0	-1.33	-0.83	-0.33	0.7	
		Week 16	Tezepelumab	50	47 (94.0)	-1.02 (1.15)	-4.2	-1.67	-1.00	-0.33	1.5	-0.25 [-0.67, 0.16]
			Placebo	44	42 (95.5)	-0.76 (0.93)	-3.2	-1.33	-0.67	0.17	0.8	
		Week 18	Tezepelumab	50	47 (94.0)	-1.17 (1.02)	-4.2	-1.83	-1.00	-0.50	1.2	-0.30 [-0.72, 0.11]
			Placebo	44	42 (95.5)	-0.88 (0.85)	-3.2	-1.50	-0.92	-0.17	0.3	
		Week 20	Tezepelumab	50	47 (94.0)	-1.11 (1.04)	-4.2	-1.67	-1.00	-0.67	1.0	-0.34 [-0.76, 0.08]
			Placebo	44	42 (95.5)	-0.78 (0.95)	-3.2	-1.50	-0.67	-0.17	0.8	
		Week 22	Tezepelumab	50	47 (94.0)	-1.18 (1.00)	-4.3	-1.67	-1.00	-0.67	1.2	-0.31 [-0.72, 0.11]
			Placebo	44	42 (95.5)	-0.89 (0.93)	-3.3	-1.50	-0.92	-0.33	0.7	
		Week 24	Tezepelumab	50	47 (94.0)	-1.16 (1.05)	-4.5	-1.67	-1.00	-0.67	1.5	-0.26 [-0.67, 0.16]
			Placebo	44	42 (95.5)	-0.90 (0.97)	-3.2	-1.50	-0.75	-0.17	0.5	
		Week 26	Tezepelumab	50	48 (96.0)	-1.19 (1.07)	-4.2	-1.83	-1.17	-0.50	1.3	-0.29 [-0.71, 0.13]
			Placebo	44	42 (95.5)	-0.90 (0.88)	-2.8	-1.50	-1.00	-0.33	0.7	
		Week 28	Tezepelumab	50	48 (96.0)	-1.17 (1.08)	-4.2	-1.75	-1.08	-0.67	1.0	-0.45 [-0.87, -0.04]
			Placebo	44	43 (97.7)	-0.68 (1.05)	-2.8	-1.50	-0.50	0.17	1.2	
		Week 30	Tezepelumab	50	49 (98.0)	-1.18 (1.11)	-4.2	-1.83	-1.00	-0.67	1.8	-0.28 [-0.69, 0.13]
			Placebo	44	43 (97.7)	-0.88 (0.99)	-2.8	-1.67	-0.83	-0.17	1.0	
		Week 32	Tezepelumab	50	49 (98.0)	-1.19 (1.12)	-4.2	-2.00	-1.00	-0.67	1.8	-0.28 [-0.70, 0.13]
			Placebo	44	43 (97.7)	-0.89 (0.98)	-3.0	-1.50	-0.83	-0.17	0.7	
		Week 34	Tezepelumab	50	49 (98.0)	-1.19 (1.15)	-4.2	-1.83	-1.17	-0.67	2.0	-0.27 [-0.68, 0.14]
			Placebo	44	43 (97.7)	-0.91 (0.96)	-3.2	-1.83	-0.83	-0.17	0.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Male	Change from baseline	Week 36	Tezepelumab	50	49 (98.0)	-1.11 (1.18)	-4.2	-1.67	-1.00	-0.67	1.5	-0.27 [-0.69, 0.14]
			Placebo	44	43 (97.7)	-0.81 (0.96)	-2.8	-1.33	-1.00	0.00	1.2	
		Week 38	Tezepelumab	50	49 (98.0)	-1.20 (1.17)	-4.2	-1.83	-1.17	-0.50	2.3	-0.18 [-0.59, 0.23]
			Placebo	44	43 (97.7)	-1.00 (1.03)	-3.0	-1.83	-1.00	-0.17	1.0	
		Week 40	Tezepelumab	50	49 (98.0)	-1.17 (1.14)	-4.2	-1.83	-1.00	-0.67	1.7	-0.32 [-0.73, 0.09]
			Placebo	44	43 (97.7)	-0.83 (0.98)	-3.2	-1.67	-0.83	0.00	1.2	
		Week 42	Tezepelumab	50	49 (98.0)	-1.21 (1.15)	-4.2	-1.83	-1.17	-0.67	2.0	-0.30 [-0.71, 0.11]
			Placebo	44	43 (97.7)	-0.88 (1.02)	-3.2	-1.83	-0.83	-0.17	1.5	
		Week 44	Tezepelumab	50	49 (98.0)	-1.20 (1.09)	-4.2	-1.83	-1.00	-0.50	1.5	-0.35 [-0.76, 0.06]
			Placebo	44	43 (97.7)	-0.84 (0.96)	-2.8	-1.67	-0.83	-0.17	1.2	
		Week 46	Tezepelumab	50	49 (98.0)	-1.19 (1.12)	-4.2	-1.67	-1.00	-0.67	1.7	-0.22 [-0.63, 0.19]
			Placebo	44	43 (97.7)	-0.96 (0.97)	-3.0	-1.83	-1.00	-0.33	1.0	
		Week 48	Tezepelumab	50	49 (98.0)	-1.11 (1.15)	-4.2	-1.67	-1.00	-0.50	1.8	-0.17 [-0.58, 0.24]
			Placebo	44	43 (97.7)	-0.92 (1.02)	-3.0	-1.67	-0.83	-0.33	1.0	
		Week 50	Tezepelumab	50	49 (98.0)	-1.20 (1.17)	-4.2	-1.83	-1.33	-0.50	1.8	-0.34 [-0.75, 0.08]
			Placebo	44	43 (97.7)	-0.84 (0.92)	-3.0	-1.67	-0.83	-0.17	1.0	
		Week 52	Tezepelumab	50	49 (98.0)	-1.16 (1.17)	-4.2	-1.67	-1.00	-0.50	1.8	-0.32 [-0.73, 0.09]
			Placebo	44	43 (97.7)	-0.82 (0.94)	-2.8	-1.50	-0.83	-0.17	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	87	87 (100.0)	2.70 (0.79)	0.0	2.33	2.67	3.00	4.8	
			Placebo	94	94 (100.0)	2.66 (0.66)	1.3	2.17	2.67	3.00	4.7	
		Week 2	Tezepelumab	87	84 (96.6)	2.18 (0.90)	0.0	1.67	2.33	2.67	4.3	
			Placebo	94	83 (88.3)	2.29 (0.74)	0.3	2.00	2.17	2.67	4.7	
		Week 4	Tezepelumab	87	84 (96.6)	1.91 (0.91)	0.0	1.25	2.00	2.67	4.3	
			Placebo	94	83 (88.3)	2.19 (0.82)	0.2	1.67	2.33	2.67	4.2	
		Week 6	Tezepelumab	87	84 (96.6)	1.79 (0.92)	0.0	1.25	1.75	2.50	4.3	
			Placebo	94	84 (89.4)	2.05 (0.96)	0.2	1.50	2.17	2.50	5.5	
		Week 8	Tezepelumab	87	84 (96.6)	1.73 (1.03)	0.0	1.00	1.67	2.67	4.8	
			Placebo	94	85 (90.4)	2.03 (0.95)	0.0	1.50	2.00	2.67	4.7	
		Week 10	Tezepelumab	87	84 (96.6)	1.64 (1.00)	0.0	0.83	1.67	2.25	4.3	
			Placebo	94	86 (91.5)	1.96 (0.91)	0.0	1.33	2.00	2.50	5.3	
		Week 12	Tezepelumab	87	84 (96.6)	1.61 (1.06)	0.0	0.67	1.50	2.50	4.3	
			Placebo	94	86 (91.5)	1.91 (0.88)	0.0	1.33	2.00	2.50	4.3	
		Week 14	Tezepelumab	87	84 (96.6)	1.48 (1.02)	0.0	0.67	1.33	2.17	4.3	
			Placebo	94	86 (91.5)	1.87 (0.90)	0.0	1.33	2.00	2.50	5.0	
		Week 16	Tezepelumab	87	84 (96.6)	1.58 (1.00)	0.0	0.83	1.50	2.25	4.3	
			Placebo	94	86 (91.5)	1.99 (1.04)	0.0	1.33	2.00	2.67	5.0	
		Week 18	Tezepelumab	87	85 (97.7)	1.49 (0.95)	0.0	0.83	1.33	2.00	4.3	
			Placebo	94	86 (91.5)	1.89 (1.00)	0.0	1.33	1.83	2.50	5.0	
		Week 20	Tezepelumab	87	85 (97.7)	1.58 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	94	86 (91.5)	1.92 (0.99)	0.0	1.17	2.17	2.50	5.0	
		Week 22	Tezepelumab	87	85 (97.7)	1.65 (0.98)	0.0	1.00	1.67	2.33	4.3	
			Placebo	94	86 (91.5)	1.90 (0.99)	0.0	1.17	2.00	2.67	5.0	
		Week 24	Tezepelumab	87	85 (97.7)	1.63 (1.03)	0.0	0.83	1.67	2.33	4.3	
			Placebo	94	86 (91.5)	1.91 (0.94)	0.0	1.17	2.00	2.50	4.2	
		Week 26	Tezepelumab	87	85 (97.7)	1.60 (0.97)	0.0	0.83	1.50	2.17	4.3	
			Placebo	94	86 (91.5)	1.83 (0.99)	0.0	1.17	1.83	2.50	4.2	
		Week 28	Tezepelumab	87	86 (98.9)	1.66 (1.03)	0.0	1.00	1.67	2.50	4.3	
			Placebo	94	86 (91.5)	1.83 (0.98)	0.0	1.00	2.00	2.50	4.2	
		Week 30	Tezepelumab	87	86 (98.9)	1.58 (0.98)	0.0	0.83	1.50	2.17	4.3	
			Placebo	94	87 (92.6)	1.92 (0.99)	0.0	1.17	2.00	2.67	4.2	
		Week 32	Tezepelumab	87	86 (98.9)	1.52 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	94	87 (92.6)	1.85 (1.00)	0.0	1.17	1.83	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	Absolute values	Week 34	Tezepelumab	87	86 (98.9)	1.54 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	94	87 (92.6)	1.80 (1.01)	0.0	1.17	1.83	2.50	4.5	
		Week 36	Tezepelumab	87	86 (98.9)	1.62 (1.03)	0.0	0.83	1.58	2.33	4.5	
			Placebo	94	87 (92.6)	1.88 (1.02)	0.0	1.00	2.00	2.67	4.5	
		Week 38	Tezepelumab	87	86 (98.9)	1.51 (1.01)	0.0	0.83	1.50	2.17	4.3	
			Placebo	94	87 (92.6)	1.85 (1.01)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	87	86 (98.9)	1.53 (1.02)	0.0	0.67	1.67	2.17	4.3	
			Placebo	94	87 (92.6)	1.88 (1.01)	0.0	1.17	2.00	2.67	4.2	
		Week 42	Tezepelumab	87	86 (98.9)	1.51 (1.02)	0.0	0.83	1.50	2.00	4.7	
			Placebo	94	87 (92.6)	1.85 (0.96)	0.0	1.33	2.00	2.50	4.7	
		Week 44	Tezepelumab	87	86 (98.9)	1.54 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	94	88 (93.6)	1.89 (0.98)	0.0	1.08	2.00	2.67	4.0	
		Week 46	Tezepelumab	87	86 (98.9)	1.48 (1.01)	0.0	0.83	1.33	2.17	4.3	
			Placebo	94	88 (93.6)	1.80 (0.94)	0.0	1.17	1.92	2.50	3.8	
		Week 48	Tezepelumab	87	86 (98.9)	1.53 (1.02)	0.0	0.83	1.50	2.33	4.3	
			Placebo	94	88 (93.6)	1.83 (0.95)	0.0	1.17	2.00	2.50	4.2	
		Week 50	Tezepelumab	87	86 (98.9)	1.45 (1.01)	0.0	0.83	1.33	2.17	4.3	
			Placebo	94	88 (93.6)	1.76 (0.94)	0.0	1.00	1.83	2.50	3.8	
		Week 52	Tezepelumab	87	86 (98.9)	1.47 (1.01)	0.0	0.83	1.50	2.17	4.3	
			Placebo	94	88 (93.6)	1.82 (0.97)	0.0	1.00	2.00	2.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	87	84 (96.6)	-0.53 (0.68)	-2.8	-0.83	-0.33	0.00	0.7	-0.24 [-0.55, 0.06]
			Placebo	94	83 (88.3)	-0.36 (0.67)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	87	84 (96.6)	-0.80 (0.84)	-3.3	-1.33	-0.83	-0.25	2.3	-0.42 [-0.72, -0.11]
			Placebo	94	83 (88.3)	-0.46 (0.81)	-3.0	-1.00	-0.33	0.17	1.0	
		Week 6	Tezepelumab	87	84 (96.6)	-0.92 (0.91)	-3.2	-1.50	-1.00	-0.33	2.3	-0.37 [-0.67, -0.06]
			Placebo	94	84 (89.4)	-0.59 (0.90)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	87	84 (96.6)	-0.98 (1.01)	-3.0	-1.58	-1.00	-0.42	2.3	-0.36 [-0.67, -0.06]
			Placebo	94	85 (90.4)	-0.62 (0.94)	-3.0	-1.00	-0.67	0.00	1.0	
		Week 10	Tezepelumab	87	84 (96.6)	-1.07 (0.95)	-3.2	-1.67	-1.08	-0.50	2.3	-0.39 [-0.69, -0.09]
			Placebo	94	86 (91.5)	-0.69 (0.97)	-3.2	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	87	84 (96.6)	-1.11 (0.97)	-3.0	-1.83	-1.17	-0.42	2.3	-0.37 [-0.67, -0.06]
			Placebo	94	86 (91.5)	-0.75 (0.95)	-3.2	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	87	84 (96.6)	-1.23 (1.00)	-3.7	-2.00	-1.17	-0.67	2.3	-0.44 [-0.75, -0.14]
			Placebo	94	86 (91.5)	-0.79 (0.99)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 16	Tezepelumab	87	84 (96.6)	-1.14 (0.97)	-3.2	-1.83	-1.00	-0.50	2.3	-0.46 [-0.76, -0.15]
			Placebo	94	86 (91.5)	-0.67 (1.08)	-3.5	-1.33	-0.67	0.00	2.3	
		Week 18	Tezepelumab	87	85 (97.7)	-1.22 (0.99)	-3.5	-1.83	-1.17	-0.67	2.3	-0.43 [-0.73, -0.13]
			Placebo	94	86 (91.5)	-0.77 (1.09)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	87	85 (97.7)	-1.12 (0.99)	-3.2	-2.00	-1.17	-0.33	2.3	-0.36 [-0.67, -0.06]
			Placebo	94	86 (91.5)	-0.74 (1.09)	-3.5	-1.33	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	87	85 (97.7)	-1.06 (1.05)	-3.2	-1.83	-1.00	-0.33	2.3	-0.29 [-0.59, 0.01]
			Placebo	94	86 (91.5)	-0.75 (1.05)	-3.2	-1.33	-0.75	-0.17	2.3	
		Week 24	Tezepelumab	87	85 (97.7)	-1.07 (0.95)	-3.2	-1.83	-1.00	-0.50	2.3	-0.32 [-0.63, -0.02]
			Placebo	94	86 (91.5)	-0.75 (1.07)	-3.5	-1.33	-0.75	0.00	2.3	
		Week 26	Tezepelumab	87	85 (97.7)	-1.11 (1.02)	-3.5	-2.00	-1.00	-0.33	2.3	-0.26 [-0.57, 0.04]
			Placebo	94	86 (91.5)	-0.82 (1.12)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 28	Tezepelumab	87	86 (98.9)	-1.04 (1.02)	-3.2	-2.00	-1.00	-0.17	2.3	-0.20 [-0.50, 0.10]
			Placebo	94	86 (91.5)	-0.83 (1.09)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 30	Tezepelumab	87	86 (98.9)	-1.12 (1.01)	-3.5	-2.00	-1.00	-0.50	2.3	-0.36 [-0.66, -0.06]
			Placebo	94	87 (92.6)	-0.74 (1.09)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 32	Tezepelumab	87	86 (98.9)	-1.18 (1.01)	-3.5	-2.00	-1.08	-0.50	2.3	-0.35 [-0.65, -0.05]
			Placebo	94	87 (92.6)	-0.81 (1.08)	-3.5	-1.50	-0.67	-0.33	2.3	
		Week 34	Tezepelumab	87	86 (98.9)	-1.16 (1.02)	-3.0	-2.00	-1.17	-0.33	2.3	-0.28 [-0.58, 0.01]
			Placebo	94	87 (92.6)	-0.86 (1.09)	-4.0	-1.33	-0.83	-0.33	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	Change from baseline	Week 36	Tezepelumab	87	86 (98.9)	-1.08 (1.05)	-3.0	-1.83	-1.08	-0.33	2.3	-0.27 [-0.57, 0.03]
			Placebo	94	87 (92.6)	-0.78 (1.13)	-3.5	-1.33	-0.83	0.00	2.3	
		Week 38	Tezepelumab	87	86 (98.9)	-1.18 (1.04)	-3.7	-2.00	-1.17	-0.33	2.3	-0.35 [-0.65, -0.05]
			Placebo	94	87 (92.6)	-0.81 (1.08)	-4.0	-1.33	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	87	86 (98.9)	-1.16 (1.07)	-3.8	-2.00	-1.17	-0.33	2.3	-0.35 [-0.65, -0.05]
			Placebo	94	87 (92.6)	-0.78 (1.10)	-4.0	-1.33	-0.83	-0.17	2.3	
		Week 42	Tezepelumab	87	86 (98.9)	-1.19 (1.06)	-3.3	-2.00	-1.17	-0.50	2.3	-0.36 [-0.66, -0.06]
			Placebo	94	87 (92.6)	-0.80 (1.05)	-4.0	-1.33	-0.83	-0.17	2.3	
		Week 44	Tezepelumab	87	86 (98.9)	-1.16 (1.11)	-4.3	-2.00	-1.00	-0.50	2.3	-0.35 [-0.65, -0.05]
			Placebo	94	88 (93.6)	-0.76 (1.11)	-4.0	-1.50	-0.83	0.00	2.3	
		Week 46	Tezepelumab	87	86 (98.9)	-1.22 (1.07)	-4.2	-2.00	-1.17	-0.33	2.3	-0.33 [-0.63, -0.03]
			Placebo	94	88 (93.6)	-0.86 (1.07)	-4.0	-1.50	-1.00	-0.17	2.3	
		Week 48	Tezepelumab	87	86 (98.9)	-1.17 (1.06)	-4.2	-2.00	-1.00	-0.33	2.3	-0.31 [-0.61, -0.01]
			Placebo	94	88 (93.6)	-0.83 (1.09)	-3.7	-1.50	-0.83	-0.25	2.3	
		Week 50	Tezepelumab	87	86 (98.9)	-1.24 (1.04)	-3.8	-2.00	-1.17	-0.50	2.3	-0.32 [-0.62, -0.03]
			Placebo	94	88 (93.6)	-0.90 (1.07)	-4.0	-1.50	-1.00	-0.33	2.3	
		Week 52	Tezepelumab	87	86 (98.9)	-1.23 (1.05)	-4.2	-2.00	-1.17	-0.50	2.3	-0.36 [-0.66, -0.06]
			Placebo	94	88 (93.6)	-0.84 (1.10)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	114	114 (100.0)	2.74 (0.81)	0.0	2.33	2.67	3.17	4.8	
			Placebo	118	118 (100.0)	2.70 (0.69)	1.2	2.33	2.67	3.17	4.7	
		Week 2	Tezepelumab	114	110 (96.5)	2.17 (0.93)	0.0	1.67	2.17	2.83	4.3	
			Placebo	118	108 (91.5)	2.31 (0.82)	0.2	2.00	2.33	2.83	4.8	
		Week 4	Tezepelumab	114	110 (96.5)	1.92 (0.98)	0.0	1.17	2.00	2.67	4.3	
			Placebo	118	108 (91.5)	2.19 (0.84)	0.2	1.58	2.33	2.67	4.2	
		Week 6	Tezepelumab	114	110 (96.5)	1.82 (1.01)	0.0	1.17	1.83	2.50	4.3	
			Placebo	118	109 (92.4)	2.07 (0.99)	0.2	1.33	2.17	2.67	5.5	
		Week 8	Tezepelumab	114	110 (96.5)	1.74 (1.08)	0.0	0.83	1.67	2.67	4.8	
			Placebo	118	110 (93.2)	2.05 (0.97)	0.0	1.33	2.17	2.67	4.7	
		Week 10	Tezepelumab	114	110 (96.5)	1.65 (1.06)	0.0	0.83	1.67	2.50	4.3	
			Placebo	118	111 (94.1)	1.96 (0.94)	0.0	1.33	2.00	2.50	5.3	
		Week 12	Tezepelumab	114	110 (96.5)	1.59 (1.07)	0.0	0.67	1.67	2.50	4.3	
			Placebo	118	111 (94.1)	1.88 (0.96)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	114	110 (96.5)	1.44 (1.06)	0.0	0.67	1.33	2.17	4.3	
			Placebo	118	111 (94.1)	1.83 (0.93)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	114	110 (96.5)	1.62 (1.11)	0.0	0.67	1.58	2.50	4.3	
			Placebo	118	111 (94.1)	1.98 (1.05)	0.0	1.17	2.00	2.67	5.0	
		Week 18	Tezepelumab	114	110 (96.5)	1.48 (1.02)	0.0	0.67	1.33	2.17	4.3	
			Placebo	118	111 (94.1)	1.85 (1.01)	0.0	1.17	1.83	2.33	5.0	
		Week 20	Tezepelumab	114	110 (96.5)	1.58 (1.07)	0.0	0.83	1.67	2.17	5.0	
			Placebo	118	111 (94.1)	1.92 (1.02)	0.0	1.17	2.17	2.67	5.0	
		Week 22	Tezepelumab	114	110 (96.5)	1.59 (1.01)	0.0	0.83	1.67	2.33	4.3	
			Placebo	118	111 (94.1)	1.88 (1.01)	0.0	1.17	2.00	2.67	5.0	
		Week 24	Tezepelumab	114	110 (96.5)	1.60 (1.08)	0.0	0.67	1.67	2.33	4.3	
			Placebo	118	111 (94.1)	1.87 (0.98)	0.0	1.00	2.00	2.50	4.5	
		Week 26	Tezepelumab	114	111 (97.4)	1.56 (1.07)	0.0	0.83	1.50	2.33	4.3	
			Placebo	118	111 (94.1)	1.81 (0.97)	0.0	1.00	1.67	2.50	4.5	
		Week 28	Tezepelumab	114	112 (98.2)	1.61 (1.08)	0.0	0.83	1.67	2.50	4.3	
			Placebo	118	111 (94.1)	1.90 (1.04)	0.0	1.00	2.00	2.67	4.5	
		Week 30	Tezepelumab	114	113 (99.1)	1.55 (1.06)	0.0	0.67	1.50	2.33	4.3	
			Placebo	118	112 (94.9)	1.90 (1.03)	0.0	1.08	1.92	2.67	4.5	
		Week 32	Tezepelumab	114	113 (99.1)	1.53 (1.07)	0.0	0.67	1.50	2.33	4.3	
			Placebo	118	112 (94.9)	1.85 (1.04)	0.0	1.00	1.83	2.58	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 65 years	Absolute values	Week 34	Tezepelumab	114	113 (99.1)	1.52 (1.11)	0.0	0.67	1.33	2.33	4.3	
			Placebo	118	112 (94.9)	1.79 (1.05)	0.0	1.00	1.75	2.50	4.5	
		Week 36	Tezepelumab	114	113 (99.1)	1.62 (1.10)	0.0	0.83	1.67	2.33	4.5	
			Placebo	118	112 (94.9)	1.89 (1.04)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	114	113 (99.1)	1.51 (1.09)	0.0	0.67	1.50	2.17	4.5	
			Placebo	118	112 (94.9)	1.80 (1.04)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	114	113 (99.1)	1.55 (1.09)	0.0	0.50	1.67	2.33	4.3	
			Placebo	118	112 (94.9)	1.87 (1.03)	0.0	1.00	1.83	2.58	4.5	
		Week 42	Tezepelumab	114	113 (99.1)	1.53 (1.10)	0.0	0.83	1.50	2.17	4.7	
			Placebo	118	112 (94.9)	1.87 (1.02)	0.0	1.17	2.00	2.58	4.7	
		Week 44	Tezepelumab	114	113 (99.1)	1.55 (1.07)	0.0	0.67	1.50	2.33	4.3	
			Placebo	118	113 (95.8)	1.89 (1.03)	0.0	1.00	2.00	2.67	4.5	
		Week 46	Tezepelumab	114	113 (99.1)	1.50 (1.10)	0.0	0.67	1.17	2.33	4.3	
			Placebo	118	113 (95.8)	1.78 (0.98)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	114	113 (99.1)	1.59 (1.09)	0.0	0.67	1.67	2.33	4.3	
			Placebo	118	113 (95.8)	1.82 (1.01)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	114	113 (99.1)	1.49 (1.09)	0.0	0.67	1.33	2.17	4.3	
			Placebo	118	113 (95.8)	1.79 (0.98)	0.0	1.00	1.83	2.50	4.5	
		Week 52	Tezepelumab	114	113 (99.1)	1.53 (1.08)	0.0	0.67	1.50	2.33	4.3	
			Placebo	118	113 (95.8)	1.84 (1.00)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 2	Tezepelumab	114	110 (96.5)	-0.57 (0.68)	-2.8	-1.00	-0.50	-0.17	0.7	-0.28 [-0.54, -0.01]
			Placebo	118	108 (91.5)	-0.38 (0.74)	-2.8	-0.83	-0.33	0.17	1.2	
		Week 4	Tezepelumab	114	110 (96.5)	-0.82 (0.89)	-3.5	-1.33	-0.83	-0.17	2.3	-0.36 [-0.63, -0.09]
			Placebo	118	108 (91.5)	-0.50 (0.86)	-3.0	-1.17	-0.33	0.17	1.2	
		Week 6	Tezepelumab	114	110 (96.5)	-0.92 (0.97)	-3.8	-1.50	-1.00	-0.33	2.3	-0.32 [-0.59, -0.06]
			Placebo	118	109 (92.4)	-0.61 (0.93)	-3.3	-1.33	-0.50	0.00	1.5	
		Week 8	Tezepelumab	114	110 (96.5)	-1.00 (1.01)	-3.8	-1.67	-1.00	-0.33	2.3	-0.37 [-0.63, -0.10]
			Placebo	118	110 (93.2)	-0.64 (0.94)	-3.2	-1.17	-0.58	0.00	1.0	
		Week 10	Tezepelumab	114	110 (96.5)	-1.09 (1.01)	-3.8	-1.67	-1.17	-0.50	2.3	-0.36 [-0.63, -0.09]
			Placebo	118	111 (94.1)	-0.73 (1.00)	-3.3	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	114	110 (96.5)	-1.15 (1.01)	-3.7	-1.83	-1.17	-0.50	2.3	-0.33 [-0.60, -0.07]
			Placebo	118	111 (94.1)	-0.82 (1.01)	-3.3	-1.33	-0.83	-0.17	1.3	
		Week 14	Tezepelumab	114	110 (96.5)	-1.30 (1.03)	-3.8	-2.00	-1.33	-0.83	2.3	-0.43 [-0.70, -0.17]
			Placebo	118	111 (94.1)	-0.87 (0.98)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 16	Tezepelumab	114	110 (96.5)	-1.12 (1.08)	-4.2	-2.00	-1.00	-0.50	2.3	-0.37 [-0.64, -0.11]
			Placebo	118	111 (94.1)	-0.71 (1.08)	-3.5	-1.33	-0.67	0.00	2.3	
		Week 18	Tezepelumab	114	110 (96.5)	-1.26 (1.03)	-4.2	-1.83	-1.08	-0.67	2.3	-0.40 [-0.67, -0.14]
			Placebo	118	111 (94.1)	-0.84 (1.06)	-3.2	-1.50	-0.83	-0.33	2.3	
		Week 20	Tezepelumab	114	110 (96.5)	-1.16 (1.03)	-4.2	-1.83	-1.17	-0.50	2.3	-0.37 [-0.63, -0.10]
			Placebo	118	111 (94.1)	-0.77 (1.09)	-3.5	-1.50	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	114	110 (96.5)	-1.15 (1.06)	-4.3	-1.83	-1.08	-0.50	2.3	-0.32 [-0.58, -0.05]
			Placebo	118	111 (94.1)	-0.82 (1.04)	-3.3	-1.50	-0.83	-0.17	2.3	
		Week 24	Tezepelumab	114	110 (96.5)	-1.15 (1.00)	-4.5	-1.83	-1.00	-0.50	2.3	-0.31 [-0.57, -0.04]
			Placebo	118	111 (94.1)	-0.83 (1.07)	-3.5	-1.50	-0.67	-0.17	2.3	
		Week 26	Tezepelumab	114	111 (97.4)	-1.17 (1.05)	-4.2	-2.00	-1.17	-0.50	2.3	-0.27 [-0.54, -0.01]
			Placebo	118	111 (94.1)	-0.88 (1.07)	-4.0	-1.67	-1.00	-0.17	2.3	
		Week 28	Tezepelumab	114	112 (98.2)	-1.11 (1.05)	-4.2	-2.00	-1.00	-0.33	2.3	-0.29 [-0.56, -0.03]
			Placebo	118	111 (94.1)	-0.80 (1.11)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 30	Tezepelumab	114	113 (99.1)	-1.19 (1.08)	-4.2	-2.00	-1.17	-0.50	2.3	-0.36 [-0.62, -0.10]
			Placebo	118	112 (94.9)	-0.79 (1.11)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	114	113 (99.1)	-1.20 (1.07)	-4.2	-2.00	-1.17	-0.67	2.3	-0.33 [-0.59, -0.07]
			Placebo	118	112 (94.9)	-0.84 (1.10)	-3.5	-1.58	-0.75	-0.17	2.3	
		Week 34	Tezepelumab	114	113 (99.1)	-1.21 (1.09)	-4.2	-2.00	-1.17	-0.67	2.3	-0.28 [-0.54, -0.02]
			Placebo	118	112 (94.9)	-0.90 (1.10)	-4.0	-1.58	-0.92	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 65 years	Change from baseline	Week 36	Tezepelumab	114	113 (99.1)	-1.11 (1.13)	-4.2	-1.83	-1.17	-0.33	2.3	-0.27 [-0.53, -0.00]
			Placebo	118	112 (94.9)	-0.81 (1.12)	-3.5	-1.33	-0.83	0.00	2.3	
		Week 38	Tezepelumab	114	113 (99.1)	-1.22 (1.11)	-4.2	-2.00	-1.33	-0.33	2.3	-0.29 [-0.56, -0.03]
			Placebo	118	112 (94.9)	-0.89 (1.12)	-4.0	-1.67	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	114	113 (99.1)	-1.18 (1.12)	-4.2	-2.00	-1.00	-0.50	2.3	-0.33 [-0.59, -0.07]
			Placebo	118	112 (94.9)	-0.82 (1.09)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 42	Tezepelumab	114	113 (99.1)	-1.21 (1.12)	-4.2	-2.00	-1.17	-0.50	2.3	-0.35 [-0.61, -0.08]
			Placebo	118	112 (94.9)	-0.82 (1.08)	-4.0	-1.50	-0.83	-0.08	2.3	
		Week 44	Tezepelumab	114	113 (99.1)	-1.18 (1.11)	-4.2	-2.00	-1.00	-0.50	2.3	-0.34 [-0.60, -0.08]
			Placebo	118	113 (95.8)	-0.80 (1.11)	-4.0	-1.50	-0.83	0.00	2.3	
		Week 46	Tezepelumab	114	113 (99.1)	-1.23 (1.11)	-4.2	-2.00	-1.17	-0.50	2.3	-0.29 [-0.55, -0.03]
			Placebo	118	113 (95.8)	-0.91 (1.07)	-4.0	-1.50	-1.00	-0.17	2.3	
		Week 48	Tezepelumab	114	113 (99.1)	-1.14 (1.10)	-4.2	-2.00	-1.00	-0.33	2.3	-0.24 [-0.50, 0.02]
			Placebo	118	113 (95.8)	-0.88 (1.10)	-3.7	-1.50	-0.83	-0.17	2.3	
		Week 50	Tezepelumab	114	113 (99.1)	-1.24 (1.12)	-4.2	-2.00	-1.33	-0.50	2.3	-0.31 [-0.58, -0.05]
			Placebo	118	113 (95.8)	-0.90 (1.07)	-4.0	-1.67	-1.00	-0.17	2.3	
		Week 52	Tezepelumab	114	113 (99.1)	-1.20 (1.11)	-4.2	-2.00	-1.17	-0.50	2.3	-0.32 [-0.58, -0.06]
			Placebo	118	113 (95.8)	-0.85 (1.09)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	2.49 (0.72)	1.0	2.17	2.50	2.83	4.8	
			Placebo	20	20 (100.0)	2.41 (0.64)	0.3	2.25	2.50	2.75	3.3	
		Week 2	Tezepelumab	23	21 (91.3)	2.17 (0.82)	0.2	1.67	2.33	2.67	4.0	
			Placebo	20	17 (85.0)	2.23 (0.66)	1.0	1.67	2.33	2.83	3.2	
		Week 4	Tezepelumab	23	21 (91.3)	1.69 (0.81)	0.2	1.17	1.50	2.33	3.3	
			Placebo	20	17 (85.0)	2.12 (0.88)	0.5	1.50	2.33	2.67	3.7	
		Week 6	Tezepelumab	23	21 (91.3)	1.67 (0.68)	0.0	1.33	1.50	2.17	2.7	
			Placebo	20	17 (85.0)	2.18 (0.80)	0.7	1.67	2.17	2.67	3.5	
		Week 8	Tezepelumab	23	21 (91.3)	1.68 (0.69)	0.0	1.33	1.50	2.17	2.7	
			Placebo	20	17 (85.0)	2.10 (0.85)	0.3	1.67	2.00	2.83	3.5	
		Week 10	Tezepelumab	23	21 (91.3)	1.71 (0.72)	0.0	1.33	1.67	2.00	3.5	
			Placebo	20	17 (85.0)	2.08 (0.78)	0.7	1.33	2.17	2.67	3.2	
		Week 12	Tezepelumab	23	21 (91.3)	1.60 (0.81)	0.0	1.17	1.50	2.17	3.7	
			Placebo	20	17 (85.0)	2.03 (0.74)	0.2	1.83	2.00	2.67	3.2	
		Week 14	Tezepelumab	23	21 (91.3)	1.57 (0.59)	0.0	1.33	1.50	1.67	2.8	
			Placebo	20	17 (85.0)	1.95 (0.79)	0.7	1.33	2.17	2.50	3.2	
		Week 16	Tezepelumab	23	21 (91.3)	1.52 (0.69)	0.0	1.17	1.50	1.83	2.8	
			Placebo	20	17 (85.0)	1.92 (0.87)	0.0	1.50	2.00	2.67	3.2	
		Week 18	Tezepelumab	23	22 (95.7)	1.59 (0.63)	0.0	1.17	1.50	2.00	2.8	
			Placebo	20	17 (85.0)	1.93 (0.82)	0.5	1.17	2.17	2.67	2.8	
		Week 20	Tezepelumab	23	22 (95.7)	1.60 (0.78)	0.0	1.17	1.50	2.50	2.8	
			Placebo	20	17 (85.0)	1.92 (0.91)	0.0	1.50	2.00	2.50	3.3	
		Week 22	Tezepelumab	23	22 (95.7)	1.64 (0.74)	0.0	1.17	1.58	2.17	2.8	
			Placebo	20	17 (85.0)	1.85 (0.94)	0.2	1.50	1.83	2.50	3.7	
		Week 24	Tezepelumab	23	22 (95.7)	1.58 (0.74)	0.0	1.00	1.58	2.17	2.8	
			Placebo	20	17 (85.0)	1.90 (0.99)	0.2	1.00	2.00	2.50	3.5	
		Week 26	Tezepelumab	23	22 (95.7)	1.54 (0.61)	0.0	1.33	1.50	2.00	2.5	
			Placebo	20	17 (85.0)	1.90 (1.02)	0.3	1.17	1.83	2.67	4.0	
		Week 28	Tezepelumab	23	22 (95.7)	1.55 (0.79)	0.0	1.00	1.50	2.17	2.7	
			Placebo	20	18 (90.0)	1.73 (1.05)	0.0	1.00	1.92	2.50	4.0	
		Week 30	Tezepelumab	23	22 (95.7)	1.58 (0.64)	0.0	1.00	1.58	2.17	2.5	
			Placebo	20	18 (90.0)	1.64 (0.91)	0.0	1.17	1.75	2.17	3.0	
		Week 32	Tezepelumab	23	22 (95.7)	1.39 (0.70)	0.0	1.00	1.25	2.00	2.5	
			Placebo	20	18 (90.0)	1.60 (0.91)	0.0	1.00	1.50	2.33	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 65 years	Absolute values	Week 34	Tezepelumab	23	22 (95.7)	1.52 (0.78)	0.0	1.00	1.50	2.17	2.7	
			Placebo	20	18 (90.0)	1.70 (0.91)	0.0	1.33	1.83	2.33	3.2	
		Week 36	Tezepelumab	23	22 (95.7)	1.48 (0.67)	0.0	1.00	1.58	2.00	2.7	
			Placebo	20	18 (90.0)	1.69 (0.98)	0.0	0.83	1.83	2.50	3.2	
		Week 38	Tezepelumab	23	22 (95.7)	1.44 (0.68)	0.0	1.00	1.33	2.00	2.7	
			Placebo	20	18 (90.0)	1.64 (0.85)	0.0	1.00	1.75	2.33	2.7	
		Week 40	Tezepelumab	23	22 (95.7)	1.41 (0.71)	0.0	0.83	1.50	2.00	2.5	
			Placebo	20	18 (90.0)	1.74 (1.10)	0.0	0.83	1.75	2.67	3.7	
		Week 42	Tezepelumab	23	22 (95.7)	1.36 (0.65)	0.0	1.00	1.50	1.67	2.5	
			Placebo	20	18 (90.0)	1.54 (0.93)	0.0	0.50	1.75	2.17	3.3	
		Week 44	Tezepelumab	23	22 (95.7)	1.37 (0.72)	0.0	0.83	1.33	1.83	2.5	
			Placebo	20	18 (90.0)	1.71 (0.93)	0.0	0.83	1.83	2.33	3.0	
		Week 46	Tezepelumab	23	22 (95.7)	1.40 (0.64)	0.0	1.00	1.42	2.00	2.5	
			Placebo	20	18 (90.0)	1.63 (0.98)	0.0	0.83	1.83	2.17	3.8	
		Week 48	Tezepelumab	23	22 (95.7)	1.32 (0.70)	0.0	0.67	1.17	2.00	2.3	
			Placebo	20	18 (90.0)	1.64 (1.03)	0.0	0.83	1.50	2.33	4.2	
		Week 50	Tezepelumab	23	22 (95.7)	1.32 (0.60)	0.0	0.83	1.25	1.67	2.3	
			Placebo	20	18 (90.0)	1.61 (0.87)	0.0	0.67	1.83	2.33	2.8	
		Week 52	Tezepelumab	23	22 (95.7)	1.28 (0.65)	0.0	0.83	1.33	1.67	2.5	
			Placebo	20	18 (90.0)	1.68 (0.96)	0.0	0.67	2.08	2.50	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 2	Tezepelumab	23	21 (91.3)	-0.35 (0.60)	-2.5	-0.50	-0.33	0.00	0.5	-0.10 [-0.74, 0.54]
			Placebo	20	17 (85.0)	-0.29 (0.41)	-1.0	-0.50	-0.33	-0.17	0.7	
		Week 4	Tezepelumab	23	21 (91.3)	-0.83 (0.84)	-2.5	-1.33	-0.67	-0.33	0.5	-0.56 [-1.21, 0.10]
			Placebo	20	17 (85.0)	-0.40 (0.65)	-1.3	-1.00	-0.50	0.00	1.2	
		Week 6	Tezepelumab	23	21 (91.3)	-0.84 (0.90)	-2.7	-1.33	-0.67	0.00	0.5	-0.63 [-1.28, 0.03]
			Placebo	20	17 (85.0)	-0.34 (0.64)	-1.3	-0.83	-0.33	0.00	1.0	
		Week 8	Tezepelumab	23	21 (91.3)	-0.83 (0.91)	-2.7	-1.33	-0.67	-0.33	0.5	-0.53 [-1.18, 0.12]
			Placebo	20	17 (85.0)	-0.42 (0.58)	-1.2	-0.83	-0.67	0.00	1.0	
		Week 10	Tezepelumab	23	21 (91.3)	-0.81 (0.77)	-2.7	-1.33	-0.67	-0.17	0.3	-0.55 [-1.20, 0.10]
			Placebo	20	17 (85.0)	-0.44 (0.52)	-1.3	-0.83	-0.50	0.00	0.3	
		Week 12	Tezepelumab	23	21 (91.3)	-0.92 (0.78)	-2.7	-1.17	-0.67	-0.50	0.2	-0.64 [-1.30, 0.02]
			Placebo	20	17 (85.0)	-0.49 (0.50)	-1.5	-0.67	-0.50	-0.17	0.3	
		Week 14	Tezepelumab	23	21 (91.3)	-0.94 (0.76)	-2.7	-1.33	-0.67	-0.33	0.2	-0.55 [-1.20, 0.10]
			Placebo	20	17 (85.0)	-0.57 (0.59)	-1.5	-1.00	-0.50	-0.17	0.3	
		Week 16	Tezepelumab	23	21 (91.3)	-0.99 (0.78)	-2.7	-1.33	-1.00	-0.67	0.3	-0.55 [-1.20, 0.10]
			Placebo	20	17 (85.0)	-0.60 (0.63)	-2.0	-1.00	-0.50	0.00	0.3	
		Week 18	Tezepelumab	23	22 (95.7)	-0.89 (0.79)	-2.7	-1.33	-0.83	-0.50	0.3	-0.42 [-1.06, 0.22]
			Placebo	20	17 (85.0)	-0.59 (0.63)	-1.5	-1.33	-0.33	-0.17	0.3	
		Week 20	Tezepelumab	23	22 (95.7)	-0.89 (0.85)	-2.7	-1.17	-0.75	-0.33	0.3	-0.37 [-1.01, 0.27]
			Placebo	20	17 (85.0)	-0.60 (0.67)	-2.0	-1.00	-0.50	-0.33	0.8	
		Week 22	Tezepelumab	23	22 (95.7)	-0.85 (0.84)	-2.7	-1.50	-0.67	-0.17	0.2	-0.23 [-0.86, 0.41]
			Placebo	20	17 (85.0)	-0.67 (0.76)	-1.8	-1.17	-0.83	-0.33	1.2	
		Week 24	Tezepelumab	23	22 (95.7)	-0.91 (0.85)	-2.7	-1.33	-0.67	-0.17	0.2	-0.35 [-0.99, 0.29]
			Placebo	20	17 (85.0)	-0.62 (0.80)	-1.5	-1.33	-0.83	0.00	1.0	
		Week 26	Tezepelumab	23	22 (95.7)	-0.95 (0.96)	-3.5	-1.33	-0.67	-0.33	0.3	-0.36 [-1.00, 0.28]
			Placebo	20	17 (85.0)	-0.62 (0.86)	-1.5	-1.33	-1.17	-0.33	1.5	
		Week 28	Tezepelumab	23	22 (95.7)	-0.93 (0.96)	-2.7	-1.33	-0.83	-0.67	0.8	-0.30 [-0.92, 0.33]
			Placebo	20	18 (90.0)	-0.67 (0.81)	-1.8	-1.50	-0.50	-0.33	1.5	
		Week 30	Tezepelumab	23	22 (95.7)	-0.91 (0.83)	-3.0	-1.33	-0.75	-0.33	0.3	-0.20 [-0.83, 0.42]
			Placebo	20	18 (90.0)	-0.76 (0.62)	-1.7	-1.50	-0.75	-0.33	0.5	
		Week 32	Tezepelumab	23	22 (95.7)	-1.10 (0.94)	-3.5	-1.50	-0.83	-0.67	0.3	-0.37 [-1.00, 0.26]
			Placebo	20	18 (90.0)	-0.80 (0.63)	-1.8	-1.17	-0.83	-0.33	0.2	
		Week 34	Tezepelumab	23	22 (95.7)	-0.97 (0.90)	-2.8	-1.50	-0.67	-0.33	0.5	-0.35 [-0.97, 0.28]
			Placebo	20	18 (90.0)	-0.69 (0.64)	-1.7	-1.17	-0.75	-0.33	0.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 65 years	Change from baseline	Week 36	Tezepelumab	23	22 (95.7)	-1.01 (0.90)	-3.0	-1.50	-0.83	-0.50	0.7	-0.37 [-1.00, 0.26]
			Placebo	20	18 (90.0)	-0.70 (0.70)	-2.0	-1.17	-0.67	-0.33	0.7	
		Week 38	Tezepelumab	23	22 (95.7)	-1.05 (0.94)	-3.7	-1.33	-0.83	-0.67	0.5	-0.36 [-0.99, 0.27]
			Placebo	20	18 (90.0)	-0.76 (0.57)	-1.5	-1.17	-0.92	-0.17	0.2	
		Week 40	Tezepelumab	23	22 (95.7)	-1.08 (0.96)	-3.8	-1.50	-1.00	-0.67	0.3	-0.46 [-1.09, 0.17]
			Placebo	20	18 (90.0)	-0.66 (0.84)	-1.8	-1.33	-0.50	0.00	1.2	
		Week 42	Tezepelumab	23	22 (95.7)	-1.12 (0.91)	-3.2	-1.67	-1.00	-0.67	0.3	-0.31 [-0.94, 0.32]
			Placebo	20	18 (90.0)	-0.86 (0.74)	-2.0	-1.33	-1.17	-0.33	0.8	
		Week 44	Tezepelumab	23	22 (95.7)	-1.11 (1.05)	-4.3	-1.50	-1.00	-0.50	0.3	-0.46 [-1.10, 0.17]
			Placebo	20	18 (90.0)	-0.69 (0.74)	-1.8	-1.33	-0.75	-0.17	0.5	
		Week 46	Tezepelumab	23	22 (95.7)	-1.08 (1.00)	-4.2	-1.33	-0.83	-0.67	0.3	-0.34 [-0.97, 0.29]
			Placebo	20	18 (90.0)	-0.77 (0.82)	-2.2	-1.17	-0.83	-0.33	1.3	
		Week 48	Tezepelumab	23	22 (95.7)	-1.17 (1.05)	-4.2	-1.67	-0.83	-0.50	0.3	-0.42 [-1.05, 0.21]
			Placebo	20	18 (90.0)	-0.76 (0.83)	-1.8	-1.33	-0.83	-0.50	1.7	
		Week 50	Tezepelumab	23	22 (95.7)	-1.17 (0.94)	-3.8	-1.50	-1.00	-0.67	0.3	-0.47 [-1.10, 0.16]
			Placebo	20	18 (90.0)	-0.79 (0.63)	-2.0	-1.17	-0.75	-0.33	0.3	
		Week 52	Tezepelumab	23	22 (95.7)	-1.20 (1.02)	-4.2	-1.67	-0.92	-0.67	0.3	-0.55 [-1.18, 0.09]
			Placebo	20	18 (90.0)	-0.72 (0.67)	-1.8	-1.33	-0.67	-0.17	0.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	105	105 (100.0)	2.65 (0.75)	0.0	2.33	2.67	3.00	4.8	
			Placebo	110	110 (100.0)	2.61 (0.67)	0.3	2.33	2.67	3.00	4.5	
		Week 2	Tezepelumab	105	100 (95.2)	2.14 (0.87)	0.0	1.67	2.17	2.67	4.3	
			Placebo	110	100 (90.9)	2.29 (0.80)	0.2	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	105	100 (95.2)	1.91 (0.94)	0.0	1.17	2.00	2.67	4.3	
			Placebo	110	100 (90.9)	2.11 (0.83)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	105	100 (95.2)	1.79 (0.94)	0.0	1.17	1.83	2.50	4.3	
			Placebo	110	101 (91.8)	2.02 (0.91)	0.2	1.33	2.17	2.67	4.7	
		Week 8	Tezepelumab	105	100 (95.2)	1.71 (0.93)	0.0	1.08	1.67	2.50	4.3	
			Placebo	110	102 (92.7)	2.03 (0.92)	0.0	1.50	2.00	2.67	4.7	
		Week 10	Tezepelumab	105	100 (95.2)	1.66 (0.95)	0.0	1.00	1.67	2.33	4.3	
			Placebo	110	103 (93.6)	1.90 (0.85)	0.0	1.33	2.00	2.50	4.2	
		Week 12	Tezepelumab	105	100 (95.2)	1.62 (1.01)	0.0	0.83	1.67	2.50	4.3	
			Placebo	110	103 (93.6)	1.86 (0.92)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	105	100 (95.2)	1.50 (0.98)	0.0	0.83	1.50	2.25	4.3	
			Placebo	110	103 (93.6)	1.83 (0.88)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	105	100 (95.2)	1.62 (1.00)	0.0	0.83	1.67	2.50	4.3	
			Placebo	110	103 (93.6)	1.94 (0.94)	0.0	1.17	2.17	2.67	4.5	
		Week 18	Tezepelumab	105	101 (96.2)	1.54 (0.91)	0.0	1.00	1.50	2.17	4.3	
			Placebo	110	103 (93.6)	1.83 (0.89)	0.0	1.17	1.83	2.50	4.5	
		Week 20	Tezepelumab	105	101 (96.2)	1.57 (0.96)	0.0	0.83	1.67	2.17	4.3	
			Placebo	110	103 (93.6)	1.89 (0.93)	0.0	1.33	2.17	2.50	4.5	
		Week 22	Tezepelumab	105	101 (96.2)	1.59 (0.92)	0.0	1.00	1.67	2.17	4.3	
			Placebo	110	103 (93.6)	1.81 (0.93)	0.0	1.17	2.00	2.50	4.5	
		Week 24	Tezepelumab	105	101 (96.2)	1.60 (1.01)	0.0	1.00	1.67	2.33	4.3	
			Placebo	110	103 (93.6)	1.82 (0.92)	0.0	1.00	2.00	2.50	4.5	
		Week 26	Tezepelumab	105	102 (97.1)	1.55 (0.95)	0.0	1.00	1.50	2.17	4.3	
			Placebo	110	103 (93.6)	1.75 (0.90)	0.0	1.00	1.67	2.50	4.5	
		Week 28	Tezepelumab	105	102 (97.1)	1.62 (0.98)	0.0	1.00	1.67	2.50	4.3	
			Placebo	110	104 (94.5)	1.83 (0.97)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	105	103 (98.1)	1.59 (0.96)	0.0	0.83	1.67	2.17	4.3	
			Placebo	110	104 (94.5)	1.78 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 32	Tezepelumab	105	103 (98.1)	1.51 (0.99)	0.0	0.83	1.50	2.17	4.3	
			Placebo	110	104 (94.5)	1.76 (0.96)	0.0	1.00	1.75	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
<= 2	Absolute values	Week 34	Tezepelumab	105	103 (98.1)	1.53 (1.05)	0.0	0.83	1.50	2.33	4.3	
			Placebo	110	104 (94.5)	1.72 (0.94)	0.0	1.00	1.67	2.50	4.5	
		Week 36	Tezepelumab	105	103 (98.1)	1.60 (1.03)	0.0	0.83	1.67	2.33	4.5	
			Placebo	110	104 (94.5)	1.73 (0.95)	0.0	1.00	1.83	2.50	4.5	
		Week 38	Tezepelumab	105	103 (98.1)	1.50 (1.01)	0.0	0.83	1.50	2.17	4.3	
			Placebo	110	104 (94.5)	1.67 (0.95)	0.0	1.00	1.67	2.33	4.5	
		Week 40	Tezepelumab	105	103 (98.1)	1.53 (1.03)	0.0	0.67	1.50	2.17	4.3	
			Placebo	110	104 (94.5)	1.73 (0.98)	0.0	1.00	1.83	2.50	4.5	
		Week 42	Tezepelumab	105	103 (98.1)	1.49 (0.99)	0.0	0.83	1.50	2.17	4.3	
			Placebo	110	104 (94.5)	1.77 (1.00)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	105	103 (98.1)	1.56 (0.99)	0.0	0.83	1.50	2.33	4.3	
			Placebo	110	105 (95.5)	1.75 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 46	Tezepelumab	105	103 (98.1)	1.51 (1.02)	0.0	0.83	1.50	2.17	4.3	
			Placebo	110	105 (95.5)	1.69 (0.98)	0.0	1.00	1.83	2.33	4.5	
		Week 48	Tezepelumab	105	103 (98.1)	1.58 (1.03)	0.0	0.67	1.67	2.33	4.3	
			Placebo	110	105 (95.5)	1.71 (1.01)	0.0	1.00	1.83	2.50	4.5	
		Week 50	Tezepelumab	105	103 (98.1)	1.47 (1.00)	0.0	0.83	1.33	2.17	4.3	
			Placebo	110	105 (95.5)	1.69 (0.94)	0.0	1.00	1.67	2.50	4.5	
		Week 52	Tezepelumab	105	103 (98.1)	1.48 (1.00)	0.0	0.67	1.50	2.00	4.3	
			Placebo	110	105 (95.5)	1.75 (0.95)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	105	100 (95.2)	-0.51 (0.63)	-2.5	-0.83	-0.33	0.00	0.7	-0.26 [-0.54, 0.02]
			Placebo	110	100 (90.9)	-0.34 (0.67)	-2.7	-0.67	-0.33	0.17	1.2	
		Week 4	Tezepelumab	105	100 (95.2)	-0.74 (0.84)	-3.5	-1.17	-0.67	-0.17	1.7	-0.26 [-0.54, 0.01]
			Placebo	110	100 (90.9)	-0.52 (0.83)	-3.0	-1.00	-0.42	0.00	1.2	
		Week 6	Tezepelumab	105	100 (95.2)	-0.86 (0.88)	-3.8	-1.33	-0.83	-0.33	1.3	-0.29 [-0.57, -0.01]
			Placebo	110	101 (91.8)	-0.60 (0.87)	-3.3	-1.17	-0.50	0.00	1.3	
		Week 8	Tezepelumab	105	100 (95.2)	-0.94 (0.85)	-3.8	-1.50	-1.00	-0.42	1.0	-0.40 [-0.68, -0.12]
			Placebo	110	102 (92.7)	-0.59 (0.88)	-3.2	-1.00	-0.67	0.00	1.0	
		Week 10	Tezepelumab	105	100 (95.2)	-0.98 (0.86)	-3.8	-1.50	-1.00	-0.33	1.0	-0.30 [-0.57, -0.02]
			Placebo	110	103 (93.6)	-0.73 (0.85)	-3.3	-1.33	-0.67	-0.17	0.8	
		Week 12	Tezepelumab	105	100 (95.2)	-1.03 (0.87)	-3.7	-1.67	-1.00	-0.33	1.2	-0.29 [-0.57, -0.01]
			Placebo	110	103 (93.6)	-0.77 (0.93)	-3.3	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	105	100 (95.2)	-1.15 (0.88)	-3.8	-1.83	-1.17	-0.58	1.2	-0.39 [-0.67, -0.11]
			Placebo	110	103 (93.6)	-0.80 (0.90)	-3.2	-1.33	-0.67	-0.17	1.3	
		Week 16	Tezepelumab	105	100 (95.2)	-1.02 (0.89)	-3.8	-1.67	-1.00	-0.50	1.5	-0.36 [-0.64, -0.08]
			Placebo	110	103 (93.6)	-0.69 (0.96)	-3.5	-1.17	-0.67	0.00	1.3	
		Week 18	Tezepelumab	105	101 (96.2)	-1.10 (0.86)	-3.8	-1.67	-1.00	-0.67	1.2	-0.32 [-0.60, -0.05]
			Placebo	110	103 (93.6)	-0.81 (0.91)	-3.2	-1.33	-0.67	-0.17	1.3	
		Week 20	Tezepelumab	105	101 (96.2)	-1.07 (0.89)	-3.8	-1.67	-1.00	-0.33	1.0	-0.36 [-0.63, -0.08]
			Placebo	110	103 (93.6)	-0.74 (0.97)	-3.5	-1.33	-0.67	-0.17	1.2	
		Week 22	Tezepelumab	105	101 (96.2)	-1.05 (0.91)	-3.8	-1.50	-1.00	-0.50	1.8	-0.24 [-0.51, 0.04]
			Placebo	110	103 (93.6)	-0.83 (0.93)	-3.3	-1.50	-0.83	-0.17	1.3	
		Week 24	Tezepelumab	105	101 (96.2)	-1.04 (0.87)	-3.8	-1.67	-1.00	-0.33	1.5	-0.24 [-0.51, 0.04]
			Placebo	110	103 (93.6)	-0.82 (0.99)	-3.5	-1.50	-0.83	-0.17	1.7	
		Week 26	Tezepelumab	105	102 (97.1)	-1.08 (0.93)	-3.8	-1.67	-1.00	-0.33	1.3	-0.20 [-0.48, 0.07]
			Placebo	110	103 (93.6)	-0.89 (0.96)	-4.0	-1.50	-1.00	-0.17	1.5	
		Week 28	Tezepelumab	105	102 (97.1)	-1.01 (0.92)	-3.8	-1.67	-1.00	-0.33	1.0	-0.24 [-0.51, 0.04]
			Placebo	110	104 (94.5)	-0.78 (1.02)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	105	103 (98.1)	-1.05 (0.94)	-3.7	-1.67	-1.00	-0.33	1.8	-0.22 [-0.49, 0.05]
			Placebo	110	104 (94.5)	-0.83 (1.04)	-3.2	-1.50	-0.83	-0.17	2.0	
		Week 32	Tezepelumab	105	103 (98.1)	-1.13 (0.98)	-3.8	-1.83	-1.00	-0.67	1.8	-0.28 [-0.55, -0.00]
			Placebo	110	104 (94.5)	-0.86 (1.01)	-3.5	-1.50	-0.67	-0.17	1.3	
		Week 34	Tezepelumab	105	103 (98.1)	-1.11 (0.99)	-3.8	-1.83	-1.00	-0.33	2.0	-0.23 [-0.50, 0.05]
			Placebo	110	104 (94.5)	-0.89 (0.98)	-4.0	-1.50	-0.83	-0.25	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
<= 2	Change from baseline	Week 36	Tezepelumab	105	103 (98.1)	-1.04 (1.02)	-3.8	-1.67	-1.00	-0.33	1.7	-0.15 [-0.42, 0.12]
			Placebo	110	104 (94.5)	-0.88 (1.00)	-3.5	-1.50	-0.83	-0.17	1.3	
		Week 38	Tezepelumab	105	103 (98.1)	-1.14 (1.02)	-3.8	-1.83	-1.17	-0.33	2.3	-0.19 [-0.47, 0.08]
			Placebo	110	104 (94.5)	-0.95 (0.99)	-4.0	-1.50	-0.83	-0.33	1.3	
		Week 40	Tezepelumab	105	103 (98.1)	-1.11 (1.02)	-3.8	-1.83	-1.00	-0.33	1.7	-0.23 [-0.51, 0.04]
			Placebo	110	104 (94.5)	-0.88 (0.99)	-4.0	-1.50	-0.83	-0.25	1.3	
		Week 42	Tezepelumab	105	103 (98.1)	-1.15 (0.98)	-3.8	-1.83	-1.00	-0.50	2.0	-0.30 [-0.58, -0.03]
			Placebo	110	104 (94.5)	-0.85 (1.01)	-4.0	-1.50	-0.83	-0.17	1.3	
		Week 44	Tezepelumab	105	103 (98.1)	-1.08 (1.01)	-4.3	-1.67	-1.00	-0.33	1.5	-0.22 [-0.49, 0.05]
			Placebo	110	105 (95.5)	-0.86 (1.01)	-4.0	-1.50	-0.83	-0.17	1.3	
		Week 46	Tezepelumab	105	103 (98.1)	-1.12 (1.02)	-4.2	-1.83	-1.00	-0.33	1.7	-0.20 [-0.47, 0.07]
			Placebo	110	105 (95.5)	-0.92 (1.01)	-4.0	-1.50	-1.00	-0.17	1.3	
		Week 48	Tezepelumab	105	103 (98.1)	-1.06 (1.02)	-4.2	-1.83	-1.00	-0.33	1.8	-0.15 [-0.43, 0.12]
			Placebo	110	105 (95.5)	-0.90 (1.05)	-3.7	-1.50	-0.83	-0.33	1.7	
		Week 50	Tezepelumab	105	103 (98.1)	-1.16 (1.01)	-3.8	-1.83	-1.17	-0.50	1.8	-0.25 [-0.52, 0.03]
			Placebo	110	105 (95.5)	-0.92 (0.97)	-4.0	-1.50	-1.00	-0.33	1.5	
		Week 52	Tezepelumab	105	103 (98.1)	-1.16 (1.03)	-4.2	-1.83	-1.00	-0.50	1.8	-0.30 [-0.57, -0.02]
			Placebo	110	105 (95.5)	-0.87 (0.97)	-4.0	-1.50	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	2.87 (0.93)	0.3	2.33	2.75	3.25	4.8	
			Placebo	28	28 (100.0)	2.84 (0.74)	1.3	2.25	2.92	3.17	4.7	
		Week 2	Tezepelumab	32	31 (96.9)	2.26 (1.06)	0.0	1.33	2.17	3.00	3.8	
			Placebo	28	25 (89.3)	2.35 (0.77)	0.3	2.00	2.33	2.67	4.7	
		Week 4	Tezepelumab	32	31 (96.9)	1.82 (1.02)	0.2	0.83	1.83	2.83	3.5	
			Placebo	28	25 (89.3)	2.46 (0.84)	0.7	2.17	2.33	3.17	4.2	
		Week 6	Tezepelumab	32	31 (96.9)	1.81 (1.06)	0.0	1.00	1.67	2.67	4.0	
			Placebo	28	25 (89.3)	2.35 (1.12)	0.8	1.67	2.33	2.67	5.5	
		Week 8	Tezepelumab	32	31 (96.9)	1.81 (1.30)	0.0	0.67	1.67	2.83	4.8	
			Placebo	28	25 (89.3)	2.14 (1.09)	0.2	1.33	2.17	2.83	4.7	
		Week 10	Tezepelumab	32	31 (96.9)	1.63 (1.19)	0.0	0.67	1.50	2.67	4.3	
			Placebo	28	25 (89.3)	2.29 (1.11)	0.8	1.67	2.33	2.83	5.3	
		Week 12	Tezepelumab	32	31 (96.9)	1.50 (1.09)	0.0	0.50	1.50	2.17	4.3	
			Placebo	28	25 (89.3)	2.05 (1.01)	0.0	1.33	2.00	2.67	4.2	
		Week 14	Tezepelumab	32	31 (96.9)	1.33 (1.07)	0.0	0.67	1.17	1.83	4.3	
			Placebo	28	25 (89.3)	1.89 (1.05)	0.0	1.33	1.67	2.50	5.0	
		Week 16	Tezepelumab	32	31 (96.9)	1.56 (1.22)	0.0	0.67	1.17	2.67	4.3	
			Placebo	28	25 (89.3)	2.09 (1.35)	0.0	1.17	1.83	3.17	5.0	
		Week 18	Tezepelumab	32	31 (96.9)	1.35 (1.13)	0.0	0.67	1.00	2.33	4.3	
			Placebo	28	25 (89.3)	2.02 (1.31)	0.0	1.00	1.83	2.50	5.0	
		Week 20	Tezepelumab	32	31 (96.9)	1.63 (1.22)	0.0	0.67	1.33	2.50	5.0	
			Placebo	28	25 (89.3)	2.03 (1.26)	0.2	1.17	2.17	2.83	5.0	
		Week 22	Tezepelumab	32	31 (96.9)	1.61 (1.12)	0.0	0.50	1.50	2.50	4.3	
			Placebo	28	25 (89.3)	2.15 (1.24)	0.0	1.17	2.17	2.83	5.0	
		Week 24	Tezepelumab	32	31 (96.9)	1.57 (1.10)	0.0	0.83	1.50	2.33	4.3	
			Placebo	28	25 (89.3)	2.11 (1.16)	0.2	1.17	2.33	3.00	4.2	
		Week 26	Tezepelumab	32	31 (96.9)	1.57 (1.19)	0.0	0.67	1.33	2.33	4.3	
			Placebo	28	25 (89.3)	2.13 (1.21)	0.0	1.00	2.00	3.17	4.2	
		Week 28	Tezepelumab	32	32 (100.0)	1.56 (1.20)	0.0	0.58	1.25	2.50	4.3	
			Placebo	28	25 (89.3)	2.04 (1.28)	0.0	1.00	2.00	3.33	4.2	
		Week 30	Tezepelumab	32	32 (100.0)	1.43 (1.11)	0.0	0.67	1.08	2.25	4.3	
			Placebo	28	26 (92.9)	2.21 (1.12)	0.0	1.33	2.17	3.17	4.2	
		Week 32	Tezepelumab	32	32 (100.0)	1.52 (1.12)	0.0	0.67	1.25	2.42	4.3	
			Placebo	28	26 (92.9)	2.06 (1.23)	0.3	1.00	1.92	3.17	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 2	Absolute values	Week 34	Tezepelumab	32	32 (100.0)	1.51 (1.10)	0.0	0.67	1.17	2.42	4.3	
			Placebo	28	26 (92.9)	2.01 (1.34)	0.0	0.67	1.83	3.33	4.5	
		Week 36	Tezepelumab	32	32 (100.0)	1.59 (1.07)	0.0	0.83	1.50	2.33	4.3	
			Placebo	28	26 (92.9)	2.39 (1.20)	0.0	1.83	2.42	3.17	4.5	
		Week 38	Tezepelumab	32	32 (100.0)	1.52 (1.14)	0.0	0.67	1.50	2.25	4.5	
			Placebo	28	26 (92.9)	2.24 (1.16)	0.0	1.67	2.50	2.83	4.5	
		Week 40	Tezepelumab	32	32 (100.0)	1.53 (1.10)	0.0	0.67	1.67	2.17	4.3	
			Placebo	28	26 (92.9)	2.34 (1.13)	0.0	1.83	2.33	3.17	4.2	
		Week 42	Tezepelumab	32	32 (100.0)	1.53 (1.21)	0.0	0.83	1.33	2.08	4.7	
			Placebo	28	26 (92.9)	2.06 (1.01)	0.0	1.33	2.00	2.50	4.5	
		Week 44	Tezepelumab	32	32 (100.0)	1.40 (1.12)	0.0	0.67	1.00	2.33	4.3	
			Placebo	28	26 (92.9)	2.32 (1.08)	0.5	1.17	2.50	3.00	4.2	
		Week 46	Tezepelumab	32	32 (100.0)	1.40 (1.10)	0.0	0.67	1.00	2.25	4.3	
			Placebo	28	26 (92.9)	2.03 (0.95)	0.0	1.17	2.17	2.67	3.8	
		Week 48	Tezepelumab	32	32 (100.0)	1.44 (1.09)	0.0	0.67	1.00	2.33	4.3	
			Placebo	28	26 (92.9)	2.12 (0.98)	0.0	1.67	2.17	2.67	3.8	
		Week 50	Tezepelumab	32	32 (100.0)	1.43 (1.15)	0.0	0.67	1.00	2.33	4.3	
			Placebo	28	26 (92.9)	2.08 (0.99)	0.2	1.33	2.17	2.83	3.8	
		Week 52	Tezepelumab	32	32 (100.0)	1.53 (1.12)	0.0	0.67	1.50	2.33	4.3	
			Placebo	28	26 (92.9)	2.12 (1.12)	0.0	1.00	2.17	2.83	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	32	31 (96.9)	-0.63 (0.80)	-2.8	-1.17	-0.50	0.17	0.7	-0.20 [-0.73, 0.33]
			Placebo	28	25 (89.3)	-0.47 (0.84)	-2.8	-0.83	-0.50	0.00	1.0	
		Week 4	Tezepelumab	32	31 (96.9)	-1.07 (0.98)	-2.5	-1.83	-1.33	-0.50	2.3	-0.77 [-1.32, -0.22]
			Placebo	28	25 (89.3)	-0.36 (0.84)	-2.0	-1.00	-0.33	0.33	1.2	
		Week 6	Tezepelumab	32	31 (96.9)	-1.08 (1.17)	-3.0	-1.83	-1.33	-0.33	2.3	-0.55 [-1.08, -0.01]
			Placebo	28	25 (89.3)	-0.47 (1.01)	-2.0	-1.17	-0.67	0.33	1.5	
		Week 8	Tezepelumab	32	31 (96.9)	-1.08 (1.38)	-3.0	-2.17	-1.33	-0.33	2.3	-0.32 [-0.85, 0.21]
			Placebo	28	25 (89.3)	-0.68 (0.98)	-3.0	-1.17	-0.50	0.00	0.8	
		Week 10	Tezepelumab	32	31 (96.9)	-1.25 (1.27)	-3.5	-2.17	-1.33	-0.50	2.3	-0.56 [-1.09, -0.02]
			Placebo	28	25 (89.3)	-0.53 (1.32)	-2.2	-1.33	-0.50	0.00	2.7	
		Week 12	Tezepelumab	32	31 (96.9)	-1.39 (1.25)	-3.7	-2.33	-1.50	-0.67	2.3	-0.51 [-1.05, 0.02]
			Placebo	28	25 (89.3)	-0.77 (1.13)	-3.2	-1.50	-1.00	0.17	1.3	
		Week 14	Tezepelumab	32	31 (96.9)	-1.56 (1.27)	-3.8	-2.50	-1.50	-0.83	2.3	-0.52 [-1.06, 0.01]
			Placebo	28	25 (89.3)	-0.93 (1.11)	-3.2	-1.50	-1.17	-0.67	2.3	
		Week 16	Tezepelumab	32	31 (96.9)	-1.33 (1.39)	-4.2	-2.17	-1.33	-0.33	2.3	-0.44 [-0.98, 0.09]
			Placebo	28	25 (89.3)	-0.73 (1.28)	-3.2	-1.50	-1.00	-0.17	2.3	
		Week 18	Tezepelumab	32	31 (96.9)	-1.53 (1.31)	-4.2	-2.50	-1.67	-0.67	2.3	-0.55 [-1.08, -0.01]
			Placebo	28	25 (89.3)	-0.80 (1.37)	-3.2	-1.50	-0.83	-0.33	2.3	
		Week 20	Tezepelumab	32	31 (96.9)	-1.26 (1.33)	-4.2	-2.17	-1.50	-0.33	2.3	-0.35 [-0.89, 0.18]
			Placebo	28	25 (89.3)	-0.79 (1.33)	-3.2	-1.67	-0.83	-0.50	2.3	
		Week 22	Tezepelumab	32	31 (96.9)	-1.28 (1.35)	-4.3	-2.33	-1.33	-0.17	2.3	-0.46 [-0.99, 0.07]
			Placebo	28	25 (89.3)	-0.67 (1.29)	-3.2	-1.33	-0.83	0.00	2.3	
		Week 24	Tezepelumab	32	31 (96.9)	-1.32 (1.27)	-4.5	-2.17	-1.33	-0.67	2.3	-0.48 [-1.01, 0.06]
			Placebo	28	25 (89.3)	-0.71 (1.25)	-3.0	-1.67	-0.67	0.00	2.3	
		Week 26	Tezepelumab	32	31 (96.9)	-1.32 (1.32)	-4.2	-2.33	-1.33	-0.50	2.3	-0.47 [-1.00, 0.06]
			Placebo	28	25 (89.3)	-0.69 (1.34)	-3.2	-1.50	-1.17	0.33	2.3	
		Week 28	Tezepelumab	32	32 (100.0)	-1.31 (1.33)	-4.2	-2.25	-1.33	-0.42	2.3	-0.41 [-0.93, 0.12]
			Placebo	28	25 (89.3)	-0.78 (1.28)	-3.2	-1.83	-1.00	-0.17	2.3	
		Week 30	Tezepelumab	32	32 (100.0)	-1.44 (1.31)	-4.2	-2.42	-1.50	-0.83	2.3	-0.67 [-1.20, -0.14]
			Placebo	28	26 (92.9)	-0.62 (1.12)	-2.2	-1.33	-0.83	0.17	2.3	
		Week 32	Tezepelumab	32	32 (100.0)	-1.35 (1.24)	-4.2	-2.17	-1.33	-0.67	2.3	-0.48 [-1.01, 0.04]
			Placebo	28	26 (92.9)	-0.76 (1.19)	-2.3	-1.50	-1.17	-0.17	2.3	
		Week 34	Tezepelumab	32	32 (100.0)	-1.36 (1.27)	-4.2	-2.33	-1.50	-0.67	2.3	-0.43 [-0.95, 0.09]
			Placebo	28	26 (92.9)	-0.81 (1.31)	-3.2	-1.50	-1.08	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 2	Change from baseline	Week 36	Tezepelumab	32	32 (100.0)	-1.28 (1.32)	-4.2	-2.25	-1.33	-0.42	2.3	-0.65 [-1.18, -0.12]
			Placebo	28	26 (92.9)	-0.43 (1.29)	-3.2	-1.33	-0.58	0.33	2.3	
		Week 38	Tezepelumab	32	32 (100.0)	-1.35 (1.27)	-4.2	-2.17	-1.67	-0.50	2.3	-0.59 [-1.12, -0.06]
			Placebo	28	26 (92.9)	-0.58 (1.31)	-3.2	-1.33	-0.75	0.17	2.3	
		Week 40	Tezepelumab	32	32 (100.0)	-1.34 (1.30)	-4.2	-2.42	-1.17	-0.58	2.3	-0.67 [-1.20, -0.14]
			Placebo	28	26 (92.9)	-0.48 (1.29)	-2.8	-1.33	-0.75	0.33	2.3	
		Week 42	Tezepelumab	32	32 (100.0)	-1.34 (1.38)	-4.2	-2.17	-1.50	-0.67	2.3	-0.45 [-0.97, 0.08]
			Placebo	28	26 (92.9)	-0.76 (1.17)	-2.8	-1.33	-1.17	-0.17	2.3	
		Week 44	Tezepelumab	32	32 (100.0)	-1.47 (1.31)	-4.2	-2.50	-1.42	-0.75	2.3	-0.76 [-1.30, -0.22]
			Placebo	28	26 (92.9)	-0.50 (1.23)	-2.7	-1.33	-0.75	0.33	2.3	
		Week 46	Tezepelumab	32	32 (100.0)	-1.47 (1.25)	-4.2	-2.17	-1.67	-0.83	2.3	-0.57 [-1.09, -0.04]
			Placebo	28	26 (92.9)	-0.79 (1.13)	-3.2	-1.33	-1.08	-0.17	2.3	
		Week 48	Tezepelumab	32	32 (100.0)	-1.43 (1.27)	-4.2	-2.33	-1.67	-0.67	2.3	-0.60 [-1.13, -0.07]
			Placebo	28	26 (92.9)	-0.71 (1.13)	-3.2	-1.50	-0.83	0.00	2.3	
		Week 50	Tezepelumab	32	32 (100.0)	-1.44 (1.28)	-4.2	-2.42	-1.75	-0.67	2.3	-0.56 [-1.08, -0.03]
			Placebo	28	26 (92.9)	-0.74 (1.20)	-3.0	-1.33	-0.75	-0.17	2.3	
		Week 52	Tezepelumab	32	32 (100.0)	-1.34 (1.29)	-4.2	-2.50	-1.42	-0.50	2.3	-0.49 [-1.02, 0.03]
			Placebo	28	26 (92.9)	-0.70 (1.31)	-3.0	-1.33	-0.75	0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	2.71 (0.82)	0.0	2.33	2.67	3.08	4.8	
			Placebo	123	123 (100.0)	2.64 (0.66)	0.3	2.33	2.67	3.00	4.5	
		Week 2	Tezepelumab	128	122 (95.3)	2.19 (0.91)	0.0	1.67	2.17	2.83	4.3	
			Placebo	123	110 (89.4)	2.26 (0.77)	0.2	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	128	122 (95.3)	1.89 (0.97)	0.0	1.17	2.00	2.67	4.3	
			Placebo	123	110 (89.4)	2.15 (0.83)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	128	122 (95.3)	1.82 (0.98)	0.0	1.17	1.83	2.50	4.3	
			Placebo	123	111 (90.2)	2.05 (0.92)	0.2	1.50	2.17	2.67	4.7	
		Week 8	Tezepelumab	128	122 (95.3)	1.76 (1.04)	0.0	1.00	1.67	2.67	4.8	
			Placebo	123	112 (91.1)	2.04 (0.92)	0.0	1.42	2.00	2.67	4.7	
		Week 10	Tezepelumab	128	122 (95.3)	1.69 (1.02)	0.0	1.00	1.67	2.33	4.3	
			Placebo	123	113 (91.9)	1.97 (0.89)	0.0	1.33	2.00	2.67	4.2	
		Week 12	Tezepelumab	128	122 (95.3)	1.62 (1.04)	0.0	0.83	1.67	2.50	4.3	
			Placebo	123	113 (91.9)	1.90 (0.93)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	128	122 (95.3)	1.49 (1.02)	0.0	0.83	1.50	2.17	4.3	
			Placebo	123	113 (91.9)	1.84 (0.87)	0.0	1.33	1.83	2.50	5.0	
		Week 16	Tezepelumab	128	122 (95.3)	1.64 (1.06)	0.0	0.83	1.67	2.50	4.3	
			Placebo	123	113 (91.9)	1.95 (0.96)	0.0	1.17	2.00	2.67	4.5	
		Week 18	Tezepelumab	128	123 (96.1)	1.53 (0.99)	0.0	0.83	1.50	2.17	4.3	
			Placebo	123	113 (91.9)	1.84 (0.96)	0.0	1.17	1.83	2.33	4.7	
		Week 20	Tezepelumab	128	123 (96.1)	1.61 (1.04)	0.0	0.83	1.67	2.33	5.0	
			Placebo	123	113 (91.9)	1.90 (0.96)	0.0	1.17	2.00	2.67	4.5	
		Week 22	Tezepelumab	128	123 (96.1)	1.63 (0.98)	0.0	1.00	1.67	2.33	4.3	
			Placebo	123	113 (91.9)	1.85 (0.97)	0.0	1.17	2.00	2.67	4.5	
		Week 24	Tezepelumab	128	123 (96.1)	1.63 (1.05)	0.0	0.83	1.67	2.33	4.3	
			Placebo	123	113 (91.9)	1.86 (0.96)	0.0	1.00	2.00	2.50	4.5	
		Week 26	Tezepelumab	128	124 (96.9)	1.60 (1.02)	0.0	1.00	1.50	2.25	4.3	
			Placebo	123	113 (91.9)	1.83 (0.95)	0.0	1.00	1.67	2.67	4.5	
		Week 28	Tezepelumab	128	125 (97.7)	1.65 (1.05)	0.0	1.00	1.67	2.50	4.3	
			Placebo	123	114 (92.7)	1.91 (1.00)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	128	126 (98.4)	1.59 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	123	115 (93.5)	1.89 (1.00)	0.0	1.17	2.00	2.67	4.5	
		Week 32	Tezepelumab	128	126 (98.4)	1.54 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	123	115 (93.5)	1.83 (1.02)	0.0	1.00	1.83	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Absolute values	Week 34	Tezepelumab	128	126 (98.4)	1.56 (1.08)	0.0	0.83	1.50	2.50	4.3	
			Placebo	123	115 (93.5)	1.81 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	128	126 (98.4)	1.62 (1.05)	0.0	0.83	1.67	2.33	4.5	
			Placebo	123	115 (93.5)	1.84 (1.02)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	128	126 (98.4)	1.53 (1.05)	0.0	0.83	1.50	2.17	4.5	
			Placebo	123	115 (93.5)	1.79 (0.99)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	128	126 (98.4)	1.56 (1.06)	0.0	0.67	1.67	2.33	4.3	
			Placebo	123	115 (93.5)	1.86 (1.02)	0.0	1.00	1.83	2.67	4.5	
		Week 42	Tezepelumab	128	126 (98.4)	1.53 (1.06)	0.0	0.83	1.50	2.17	4.7	
			Placebo	123	115 (93.5)	1.85 (1.02)	0.0	1.00	2.00	2.67	4.7	
		Week 44	Tezepelumab	128	126 (98.4)	1.56 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	123	116 (94.3)	1.87 (1.00)	0.0	1.00	2.00	2.58	4.5	
		Week 46	Tezepelumab	128	126 (98.4)	1.52 (1.05)	0.0	0.83	1.42	2.33	4.3	
			Placebo	123	116 (94.3)	1.78 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	128	126 (98.4)	1.57 (1.06)	0.0	0.67	1.58	2.33	4.3	
			Placebo	123	116 (94.3)	1.79 (1.02)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	128	126 (98.4)	1.49 (1.05)	0.0	0.83	1.33	2.17	4.3	
			Placebo	123	116 (94.3)	1.77 (0.96)	0.0	1.00	1.83	2.50	4.5	
		Week 52	Tezepelumab	128	126 (98.4)	1.53 (1.04)	0.0	0.83	1.50	2.17	4.3	
			Placebo	123	116 (94.3)	1.83 (0.99)	0.0	1.00	2.00	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	128	122 (95.3)	-0.53 (0.65)	-2.5	-0.83	-0.42	0.00	0.7	-0.21 [-0.47, 0.05]
			Placebo	123	110 (89.4)	-0.38 (0.72)	-2.8	-0.83	-0.33	0.17	1.2	
		Week 4	Tezepelumab	128	122 (95.3)	-0.82 (0.89)	-3.5	-1.33	-0.83	-0.17	2.3	-0.38 [-0.64, -0.12]
			Placebo	123	110 (89.4)	-0.49 (0.82)	-3.0	-1.00	-0.42	0.00	1.2	
		Week 6	Tezepelumab	128	122 (95.3)	-0.90 (0.97)	-3.8	-1.50	-0.83	-0.33	2.3	-0.33 [-0.59, -0.07]
			Placebo	123	111 (90.2)	-0.59 (0.89)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	128	122 (95.3)	-0.95 (1.00)	-3.8	-1.50	-1.00	-0.33	2.3	-0.37 [-0.63, -0.11]
			Placebo	123	112 (91.1)	-0.61 (0.85)	-3.2	-1.00	-0.67	0.00	1.0	
		Week 10	Tezepelumab	128	122 (95.3)	-1.02 (0.98)	-3.8	-1.67	-1.00	-0.33	2.3	-0.35 [-0.61, -0.10]
			Placebo	123	113 (91.9)	-0.68 (0.91)	-3.3	-1.33	-0.67	-0.17	2.5	
		Week 12	Tezepelumab	128	122 (95.3)	-1.09 (0.98)	-3.7	-1.67	-1.00	-0.50	2.3	-0.36 [-0.61, -0.10]
			Placebo	123	113 (91.9)	-0.75 (0.93)	-3.3	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	128	122 (95.3)	-1.22 (1.01)	-3.8	-2.00	-1.17	-0.67	2.3	-0.42 [-0.68, -0.17]
			Placebo	123	113 (91.9)	-0.82 (0.88)	-3.2	-1.33	-0.83	-0.33	1.3	
		Week 16	Tezepelumab	128	122 (95.3)	-1.08 (1.04)	-4.2	-1.83	-1.00	-0.33	2.3	-0.38 [-0.64, -0.12]
			Placebo	123	113 (91.9)	-0.70 (0.95)	-3.2	-1.17	-0.67	0.00	2.3	
		Week 18	Tezepelumab	128	123 (96.1)	-1.18 (1.01)	-4.2	-1.83	-1.00	-0.67	2.3	-0.37 [-0.63, -0.12]
			Placebo	123	113 (91.9)	-0.81 (0.96)	-3.2	-1.33	-0.67	-0.33	2.3	
		Week 20	Tezepelumab	128	123 (96.1)	-1.09 (1.02)	-4.2	-1.83	-1.00	-0.33	2.3	-0.34 [-0.60, -0.08]
			Placebo	123	113 (91.9)	-0.75 (0.97)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	128	123 (96.1)	-1.08 (1.04)	-4.3	-1.67	-1.00	-0.50	2.3	-0.28 [-0.54, -0.02]
			Placebo	123	113 (91.9)	-0.80 (0.97)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	128	123 (96.1)	-1.08 (0.99)	-4.5	-1.67	-1.00	-0.50	2.3	-0.29 [-0.55, -0.03]
			Placebo	123	113 (91.9)	-0.79 (0.99)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 26	Tezepelumab	128	124 (96.9)	-1.10 (1.04)	-4.2	-1.83	-1.00	-0.33	2.3	-0.27 [-0.53, -0.02]
			Placebo	123	113 (91.9)	-0.82 (0.98)	-2.8	-1.50	-1.00	-0.17	2.3	
		Week 28	Tezepelumab	128	125 (97.7)	-1.05 (1.05)	-4.2	-1.83	-1.00	-0.33	2.3	-0.31 [-0.57, -0.05]
			Placebo	123	114 (92.7)	-0.73 (1.00)	-2.8	-1.50	-0.67	-0.17	2.3	
		Week 30	Tezepelumab	128	126 (98.4)	-1.11 (1.06)	-4.2	-1.83	-1.00	-0.50	2.3	-0.35 [-0.60, -0.09]
			Placebo	123	115 (93.5)	-0.75 (1.04)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 32	Tezepelumab	128	126 (98.4)	-1.16 (1.06)	-4.2	-1.83	-1.00	-0.67	2.3	-0.34 [-0.59, -0.09]
			Placebo	123	115 (93.5)	-0.80 (1.02)	-3.0	-1.50	-0.67	-0.17	2.3	
		Week 34	Tezepelumab	128	126 (98.4)	-1.14 (1.08)	-4.2	-2.00	-1.00	-0.50	2.3	-0.30 [-0.56, -0.05]
			Placebo	123	115 (93.5)	-0.82 (1.01)	-3.2	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Change from baseline	Week 36	Tezepelumab	128	126 (98.4)	-1.08 (1.10)	-4.2	-1.83	-1.00	-0.33	2.3	-0.27 [-0.52, -0.01]
			Placebo	123	115 (93.5)	-0.79 (1.05)	-3.5	-1.33	-0.83	0.00	2.3	
		Week 38	Tezepelumab	128	126 (98.4)	-1.17 (1.10)	-4.2	-2.00	-1.17	-0.50	2.3	-0.30 [-0.56, -0.05]
			Placebo	123	115 (93.5)	-0.84 (1.03)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	128	126 (98.4)	-1.14 (1.11)	-4.2	-2.00	-1.00	-0.50	2.3	-0.34 [-0.60, -0.09]
			Placebo	123	115 (93.5)	-0.78 (1.02)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 42	Tezepelumab	128	126 (98.4)	-1.17 (1.11)	-4.2	-1.83	-1.17	-0.50	2.3	-0.36 [-0.61, -0.10]
			Placebo	123	115 (93.5)	-0.79 (1.03)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 44	Tezepelumab	128	126 (98.4)	-1.14 (1.11)	-4.3	-1.83	-1.00	-0.50	2.3	-0.35 [-0.60, -0.10]
			Placebo	123	116 (94.3)	-0.77 (1.01)	-3.3	-1.50	-0.83	-0.17	2.3	
		Week 46	Tezepelumab	128	126 (98.4)	-1.18 (1.11)	-4.2	-2.00	-1.00	-0.50	2.3	-0.30 [-0.56, -0.05]
			Placebo	123	116 (94.3)	-0.85 (1.02)	-3.2	-1.50	-0.92	-0.17	2.3	
		Week 48	Tezepelumab	128	126 (98.4)	-1.13 (1.11)	-4.2	-1.83	-1.00	-0.33	2.3	-0.26 [-0.52, -0.01]
			Placebo	123	116 (94.3)	-0.84 (1.05)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	128	126 (98.4)	-1.21 (1.10)	-4.2	-2.00	-1.17	-0.50	2.3	-0.33 [-0.58, -0.08]
			Placebo	123	116 (94.3)	-0.86 (0.98)	-3.5	-1.50	-0.83	-0.33	2.3	
		Week 52	Tezepelumab	128	126 (98.4)	-1.17 (1.10)	-4.2	-1.83	-1.00	-0.50	2.3	-0.35 [-0.60, -0.09]
			Placebo	123	116 (94.3)	-0.81 (0.99)	-3.5	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.78 (0.42)	2.3	2.33	2.83	3.17	3.2	
			Placebo	6	6 (100.0)	2.61 (0.77)	1.8	2.00	2.42	3.17	3.8	
		Week 2	Tezepelumab	3	3 (100.0)	1.56 (1.36)	0.0	0.00	2.17	2.50	2.5	
			Placebo	6	6 (100.0)	2.50 (0.69)	1.5	2.00	2.58	2.83	3.5	
		Week 4	Tezepelumab	3	3 (100.0)	1.67 (0.73)	0.8	0.83	2.00	2.17	2.2	
			Placebo	6	6 (100.0)	2.53 (1.10)	0.7	2.33	2.50	3.17	4.0	
		Week 6	Tezepelumab	3	3 (100.0)	1.44 (0.82)	0.5	0.50	1.83	2.00	2.0	
			Placebo	6	6 (100.0)	2.53 (1.12)	1.0	2.33	2.42	2.50	4.5	
		Week 8	Tezepelumab	3	3 (100.0)	1.22 (0.95)	0.2	0.17	1.50	2.00	2.0	
			Placebo	6	6 (100.0)	2.64 (1.00)	1.0	2.33	2.67	3.17	4.0	
		Week 10	Tezepelumab	3	3 (100.0)	0.94 (0.84)	0.2	0.17	0.83	1.83	1.8	
			Placebo	6	6 (100.0)	2.61 (1.50)	0.8	1.83	2.42	2.83	5.3	
		Week 12	Tezepelumab	3	3 (100.0)	1.22 (0.67)	0.5	0.50	1.33	1.83	1.8	
			Placebo	6	6 (100.0)	2.42 (1.14)	0.8	1.67	2.33	3.33	4.0	
		Week 14	Tezepelumab	3	3 (100.0)	0.78 (0.25)	0.5	0.50	0.83	1.00	1.0	
			Placebo	6	6 (100.0)	2.53 (1.50)	0.8	1.17	2.50	3.17	5.0	
		Week 16	Tezepelumab	3	3 (100.0)	1.89 (1.46)	0.7	0.67	1.50	3.50	3.5	
			Placebo	6	6 (100.0)	2.86 (1.34)	0.8	2.50	2.83	3.17	5.0	
		Week 18	Tezepelumab	3	3 (100.0)	1.17 (0.60)	0.5	0.50	1.33	1.67	1.7	
			Placebo	6	6 (100.0)	2.72 (1.34)	0.8	2.33	2.67	2.83	5.0	
		Week 20	Tezepelumab	3	3 (100.0)	1.06 (0.10)	1.0	1.00	1.00	1.17	1.2	
			Placebo	6	6 (100.0)	2.56 (1.49)	0.3	2.33	2.42	2.83	5.0	
		Week 22	Tezepelumab	3	3 (100.0)	1.17 (0.17)	1.0	1.00	1.17	1.33	1.3	
			Placebo	6	6 (100.0)	2.39 (1.50)	0.3	2.00	2.25	2.50	5.0	
		Week 24	Tezepelumab	3	3 (100.0)	0.94 (0.19)	0.8	0.83	0.83	1.17	1.2	
			Placebo	6	6 (100.0)	2.36 (1.22)	0.3	2.33	2.42	2.50	4.2	
		Week 26	Tezepelumab	3	3 (100.0)	0.83 (0.29)	0.7	0.67	0.67	1.17	1.2	
			Placebo	6	6 (100.0)	2.22 (1.27)	0.3	1.50	2.42	2.50	4.2	
		Week 28	Tezepelumab	3	3 (100.0)	0.83 (0.33)	0.5	0.50	0.83	1.17	1.2	
			Placebo	6	6 (100.0)	2.33 (1.27)	0.3	2.00	2.25	3.00	4.2	
		Week 30	Tezepelumab	3	3 (100.0)	0.89 (0.25)	0.7	0.67	0.83	1.17	1.2	
			Placebo	6	6 (100.0)	2.08 (1.25)	0.3	1.67	1.92	2.50	4.2	
		Week 32	Tezepelumab	3	3 (100.0)	1.39 (0.25)	1.2	1.17	1.33	1.67	1.7	
			Placebo	6	6 (100.0)	2.08 (1.30)	0.3	1.50	2.00	2.50	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Black or African American	Absolute values	Week 34	Tezepelumab	3	3 (100.0)	1.11 (0.10)	1.0	1.00	1.17	1.17	1.2	
			Placebo	6	6 (100.0)	1.89 (1.46)	0.0	0.67	2.00	2.50	4.2	
		Week 36	Tezepelumab	3	3 (100.0)	1.56 (0.67)	1.2	1.17	1.17	2.33	2.3	
			Placebo	6	6 (100.0)	2.14 (1.34)	0.0	1.83	2.17	2.50	4.2	
		Week 38	Tezepelumab	3	3 (100.0)	0.89 (0.25)	0.7	0.67	0.83	1.17	1.2	
			Placebo	6	6 (100.0)	2.08 (1.39)	0.0	1.50	2.08	2.67	4.2	
		Week 40	Tezepelumab	3	3 (100.0)	1.22 (0.42)	0.8	0.83	1.17	1.67	1.7	
			Placebo	6	6 (100.0)	2.22 (1.34)	0.0	2.00	2.33	2.50	4.2	
		Week 42	Tezepelumab	3	3 (100.0)	1.17 (0.50)	0.7	0.67	1.17	1.67	1.7	
			Placebo	6	6 (100.0)	1.69 (0.93)	0.0	1.50	1.83	2.50	2.5	
		Week 44	Tezepelumab	3	3 (100.0)	1.22 (0.42)	0.8	0.83	1.17	1.67	1.7	
			Placebo	6	6 (100.0)	1.75 (0.85)	0.7	1.00	1.92	2.50	2.5	
		Week 46	Tezepelumab	3	3 (100.0)	0.94 (0.25)	0.7	0.67	1.00	1.17	1.2	
			Placebo	6	6 (100.0)	1.72 (0.85)	0.5	1.00	1.83	2.50	2.7	
		Week 48	Tezepelumab	3	3 (100.0)	1.06 (0.35)	0.7	0.67	1.17	1.33	1.3	
			Placebo	6	6 (100.0)	1.72 (0.98)	0.3	1.00	1.83	2.50	2.8	
		Week 50	Tezepelumab	3	3 (100.0)	0.67 (0.50)	0.2	0.17	0.67	1.17	1.2	
			Placebo	6	6 (100.0)	2.14 (0.95)	1.0	1.50	2.08	2.50	3.7	
		Week 52	Tezepelumab	3	3 (100.0)	0.67 (0.50)	0.2	0.17	0.67	1.17	1.2	
			Placebo	6	6 (100.0)	2.17 (1.24)	0.0	1.67	2.50	2.67	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-1.22 (1.42)	-2.8	-2.83	-0.67	-0.17	-0.2	-1.00 [-2.48, 0.48]
			Placebo	6	6 (100.0)	-0.11 (0.96)	-1.3	-1.17	0.08	0.67	1.0	
		Week 4	Tezepelumab	3	3 (100.0)	-1.11 (0.92)	-2.0	-2.00	-1.17	-0.17	-0.2	-1.02 [-2.50, 0.47]
			Placebo	6	6 (100.0)	-0.08 (1.05)	-1.5	-1.33	0.42	0.67	0.8	
		Week 6	Tezepelumab	3	3 (100.0)	-1.33 (1.00)	-2.3	-2.33	-1.33	-0.33	-0.3	-1.20 [-2.73, 0.32]
			Placebo	6	6 (100.0)	-0.08 (1.05)	-1.3	-1.17	-0.00	0.67	1.3	
		Week 8	Tezepelumab	3	3 (100.0)	-1.56 (1.17)	-2.7	-2.67	-1.67	-0.33	-0.3	-1.50 [-3.10, 0.09]
			Placebo	6	6 (100.0)	0.03 (1.00)	-1.3	-1.17	0.50	0.83	0.8	
		Week 10	Tezepelumab	3	3 (100.0)	-1.83 (1.17)	-2.7	-2.67	-2.33	-0.50	-0.5	-1.31 [-2.85, 0.24]
			Placebo	6	6 (100.0)	-0.00 (1.49)	-1.3	-1.33	-0.25	0.50	2.7	
		Week 12	Tezepelumab	3	3 (100.0)	-1.56 (0.95)	-2.3	-2.33	-1.83	-0.50	-0.5	-1.35 [-2.90, 0.21]
			Placebo	6	6 (100.0)	-0.19 (1.04)	-1.3	-1.33	-0.08	0.33	1.3	
		Week 14	Tezepelumab	3	3 (100.0)	-2.00 (0.44)	-2.3	-2.33	-2.17	-1.50	-1.5	-1.57 [-3.18, 0.04]
			Placebo	6	6 (100.0)	-0.08 (1.42)	-1.3	-1.33	-0.42	0.67	2.3	
		Week 16	Tezepelumab	3	3 (100.0)	-0.89 (1.80)	-2.2	-2.17	-1.67	1.17	1.2	-0.73 [-2.16, 0.71]
			Placebo	6	6 (100.0)	0.25 (1.46)	-1.3	-1.33	0.33	1.17	2.3	
		Week 18	Tezepelumab	3	3 (100.0)	-1.61 (0.86)	-2.3	-2.33	-1.83	-0.67	-0.7	-1.35 [-2.90, 0.21]
			Placebo	6	6 (100.0)	0.11 (1.41)	-1.3	-1.33	0.08	0.83	2.3	
		Week 20	Tezepelumab	3	3 (100.0)	-1.72 (0.35)	-2.0	-2.00	-1.83	-1.33	-1.3	-1.31 [-2.86, 0.23]
			Placebo	6	6 (100.0)	-0.06 (1.49)	-1.8	-1.33	-0.00	0.50	2.3	
		Week 22	Tezepelumab	3	3 (100.0)	-1.61 (0.54)	-2.0	-2.00	-1.83	-1.00	-1.0	-1.08 [-2.57, 0.42]
			Placebo	6	6 (100.0)	-0.22 (1.49)	-1.8	-1.33	-0.42	0.33	2.3	
		Week 24	Tezepelumab	3	3 (100.0)	-1.83 (0.29)	-2.0	-2.00	-2.00	-1.50	-1.5	-1.44 [-3.02, 0.14]
			Placebo	6	6 (100.0)	-0.25 (1.29)	-1.8	-1.33	-0.25	0.67	1.5	
		Week 26	Tezepelumab	3	3 (100.0)	-1.94 (0.25)	-2.2	-2.17	-2.00	-1.67	-1.7	-1.31 [-2.85, 0.24]
			Placebo	6	6 (100.0)	-0.39 (1.40)	-1.8	-1.67	-0.42	0.50	1.5	
		Week 28	Tezepelumab	3	3 (100.0)	-1.94 (0.42)	-2.3	-2.33	-2.00	-1.50	-1.5	-1.42 [-2.99, 0.15]
			Placebo	6	6 (100.0)	-0.28 (1.36)	-1.8	-1.33	-0.50	1.00	1.5	
		Week 30	Tezepelumab	3	3 (100.0)	-1.89 (0.35)	-2.2	-2.17	-2.00	-1.50	-1.5	-1.28 [-2.82, 0.26]
			Placebo	6	6 (100.0)	-0.53 (1.24)	-1.8	-1.33	-0.83	0.17	1.5	
		Week 32	Tezepelumab	3	3 (100.0)	-1.39 (0.54)	-2.0	-2.00	-1.17	-1.00	-1.0	-0.74 [-2.18, 0.70]
			Placebo	6	6 (100.0)	-0.53 (1.33)	-1.8	-1.67	-0.83	0.50	1.5	
		Week 34	Tezepelumab	3	3 (100.0)	-1.67 (0.44)	-2.0	-2.00	-1.83	-1.17	-1.2	-0.85 [-2.30, 0.61]
			Placebo	6	6 (100.0)	-0.72 (1.29)	-2.2	-1.33	-1.17	0.00	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Black or African American	Change from baseline	Week 36	Tezepelumab	3	3 (100.0)	-1.22 (1.07)	-2.0	-2.00	-1.67	0.00	0.0	-0.58 [-2.00, 0.84]
			Placebo	6	6 (100.0)	-0.47 (1.36)	-2.2	-1.33	-0.58	0.33	1.5	
		Week 38	Tezepelumab	3	3 (100.0)	-1.89 (0.19)	-2.0	-2.00	-2.00	-1.67	-1.7	-1.12 [-2.63, 0.38]
			Placebo	6	6 (100.0)	-0.53 (1.43)	-2.2	-1.50	-0.92	0.83	1.5	
		Week 40	Tezepelumab	3	3 (100.0)	-1.56 (0.42)	-2.0	-2.00	-1.50	-1.17	-1.2	-1.00 [-2.49, 0.48]
			Placebo	6	6 (100.0)	-0.39 (1.35)	-2.2	-1.33	-0.42	0.50	1.5	
		Week 42	Tezepelumab	3	3 (100.0)	-1.61 (0.42)	-2.0	-2.00	-1.67	-1.17	-1.2	-0.77 [-2.22, 0.67]
			Placebo	6	6 (100.0)	-0.92 (1.03)	-2.2	-1.50	-1.25	0.17	0.5	
		Week 44	Tezepelumab	3	3 (100.0)	-1.56 (0.42)	-2.0	-2.00	-1.50	-1.17	-1.2	-0.71 [-2.14, 0.73]
			Placebo	6	6 (100.0)	-0.86 (1.13)	-1.8	-1.67	-1.42	0.50	0.7	
		Week 46	Tezepelumab	3	3 (100.0)	-1.83 (0.17)	-2.0	-2.00	-1.83	-1.67	-1.7	-1.06 [-2.55, 0.44]
			Placebo	6	6 (100.0)	-0.89 (1.05)	-1.7	-1.67	-1.42	0.00	0.8	
		Week 48	Tezepelumab	3	3 (100.0)	-1.72 (0.25)	-2.0	-2.00	-1.67	-1.50	-1.5	-0.79 [-2.24, 0.66]
			Placebo	6	6 (100.0)	-0.89 (1.24)	-1.8	-1.83	-1.50	0.33	1.0	
		Week 50	Tezepelumab	3	3 (100.0)	-2.11 (0.51)	-2.7	-2.67	-2.00	-1.67	-1.7	-1.48 [-3.07, 0.11]
			Placebo	6	6 (100.0)	-0.47 (1.27)	-1.7	-1.50	-0.83	0.50	1.5	
		Week 52	Tezepelumab	3	3 (100.0)	-2.11 (0.51)	-2.7	-2.67	-2.00	-1.67	-1.7	-1.20 [-2.72, 0.33]
			Placebo	6	6 (100.0)	-0.44 (1.62)	-2.7	-1.50	-0.33	0.67	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.50 (0.46)	2.0	2.17	2.50	2.67	3.2	
			Placebo	6	6 (100.0)	2.50 (0.90)	1.5	1.83	2.33	3.00	4.0	
		Week 2	Tezepelumab	5	5 (100.0)	2.00 (0.81)	0.8	1.67	2.17	2.33	3.0	
			Placebo	6	6 (100.0)	2.31 (0.95)	1.3	1.50	2.25	2.50	4.0	
		Week 4	Tezepelumab	5	5 (100.0)	1.63 (0.70)	0.7	1.17	1.83	2.17	2.3	
			Placebo	6	6 (100.0)	1.78 (0.51)	1.3	1.33	1.67	2.00	2.7	
		Week 6	Tezepelumab	5	5 (100.0)	1.33 (0.39)	0.8	1.00	1.50	1.67	1.7	
			Placebo	6	6 (100.0)	1.69 (0.66)	0.8	1.17	1.75	2.33	2.3	
		Week 8	Tezepelumab	5	5 (100.0)	1.17 (0.47)	0.7	0.83	1.00	1.67	1.7	
			Placebo	6	6 (100.0)	1.83 (0.53)	1.2	1.50	1.75	2.17	2.7	
		Week 10	Tezepelumab	5	5 (100.0)	1.10 (0.35)	0.7	0.83	1.17	1.33	1.5	
			Placebo	6	6 (100.0)	1.58 (0.48)	0.8	1.33	1.58	2.00	2.2	
		Week 12	Tezepelumab	5	5 (100.0)	0.80 (0.64)	0.0	0.33	0.83	1.33	1.5	
			Placebo	6	6 (100.0)	1.56 (0.43)	1.2	1.17	1.42	2.00	2.2	
		Week 14	Tezepelumab	5	5 (100.0)	0.90 (0.28)	0.7	0.67	0.83	1.00	1.3	
			Placebo	6	6 (100.0)	1.39 (0.49)	0.8	1.00	1.33	1.67	2.2	
		Week 16	Tezepelumab	5	5 (100.0)	0.83 (0.29)	0.3	0.83	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	1.28 (0.73)	0.5	0.50	1.25	1.83	2.3	
		Week 18	Tezepelumab	5	5 (100.0)	0.97 (0.52)	0.5	0.67	0.83	1.00	1.8	
			Placebo	6	6 (100.0)	1.61 (0.55)	0.8	1.17	1.67	2.00	2.3	
		Week 20	Tezepelumab	5	5 (100.0)	1.07 (0.66)	0.5	0.67	0.83	1.17	2.2	
			Placebo	6	6 (100.0)	1.64 (0.96)	0.5	0.83	1.50	2.50	3.0	
		Week 22	Tezepelumab	5	5 (100.0)	0.97 (0.78)	0.0	0.83	0.83	1.00	2.2	
			Placebo	6	6 (100.0)	1.50 (0.87)	0.3	1.00	1.33	2.33	2.7	
		Week 24	Tezepelumab	5	5 (100.0)	0.93 (0.45)	0.5	0.67	0.83	1.00	1.7	
			Placebo	6	6 (100.0)	1.67 (0.95)	0.5	0.67	1.75	2.67	2.7	
		Week 26	Tezepelumab	5	5 (100.0)	0.70 (0.30)	0.2	0.83	0.83	0.83	0.8	
			Placebo	6	6 (100.0)	1.36 (0.85)	0.0	0.83	1.50	2.00	2.3	
		Week 28	Tezepelumab	5	5 (100.0)	0.83 (0.29)	0.3	0.83	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	1.03 (1.04)	0.0	0.00	0.92	2.17	2.2	
		Week 30	Tezepelumab	5	5 (100.0)	0.80 (0.22)	0.7	0.67	0.67	0.83	1.2	
			Placebo	6	6 (100.0)	1.03 (0.89)	0.0	0.00	1.17	1.83	2.0	
		Week 32	Tezepelumab	5	5 (100.0)	0.63 (0.38)	0.2	0.33	0.67	1.00	1.0	
			Placebo	6	6 (100.0)	1.11 (0.78)	0.2	0.50	1.08	1.67	2.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asian	Absolute values	Week 34	Tezepelumab	5	5 (100.0)	0.67 (0.31)	0.3	0.50	0.67	0.67	1.2	
			Placebo	6	6 (100.0)	1.03 (0.97)	0.0	0.00	1.00	1.83	2.3	
		Week 36	Tezepelumab	5	5 (100.0)	0.97 (0.79)	0.3	0.50	0.83	0.83	2.3	
			Placebo	6	6 (100.0)	1.64 (1.24)	0.0	0.50	1.83	2.50	3.2	
		Week 38	Tezepelumab	5	5 (100.0)	0.93 (0.79)	0.0	0.50	0.67	1.67	1.8	
			Placebo	6	6 (100.0)	0.94 (0.88)	0.0	0.00	1.00	1.83	1.8	
		Week 40	Tezepelumab	5	5 (100.0)	0.77 (0.52)	0.3	0.50	0.67	0.67	1.7	
			Placebo	6	6 (100.0)	1.31 (1.05)	0.0	0.00	1.75	1.83	2.5	
		Week 42	Tezepelumab	5	5 (100.0)	0.73 (0.22)	0.5	0.50	0.83	0.83	1.0	
			Placebo	6	6 (100.0)	1.17 (0.91)	0.0	0.00	1.67	1.83	1.8	
		Week 44	Tezepelumab	5	5 (100.0)	0.63 (0.27)	0.3	0.50	0.50	0.83	1.0	
			Placebo	6	6 (100.0)	1.81 (1.43)	0.0	0.17	2.17	3.00	3.3	
		Week 46	Tezepelumab	5	5 (100.0)	0.77 (0.28)	0.3	0.67	0.83	1.00	1.0	
			Placebo	6	6 (100.0)	1.00 (0.98)	0.0	0.00	1.08	1.83	2.0	
		Week 48	Tezepelumab	5	5 (100.0)	1.07 (0.73)	0.5	0.67	0.83	1.00	2.3	
			Placebo	6	6 (100.0)	1.42 (1.02)	0.0	0.33	1.83	2.17	2.3	
		Week 50	Tezepelumab	5	5 (100.0)	1.07 (0.66)	0.5	0.67	0.83	1.17	2.2	
			Placebo	6	6 (100.0)	1.28 (0.74)	0.0	0.83	1.58	1.67	2.0	
		Week 52	Tezepelumab	5	5 (100.0)	0.90 (0.73)	0.3	0.50	0.67	0.83	2.2	
			Placebo	6	6 (100.0)	1.33 (0.71)	0.0	1.17	1.58	1.67	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	-0.50 (0.59)	-1.3	-0.83	-0.33	-0.17	0.2	-0.69 [-1.92, 0.54]
			Placebo	6	6 (100.0)	-0.19 (0.27)	-0.7	-0.33	-0.08	0.00	0.0	
		Week 4	Tezepelumab	5	5 (100.0)	-0.87 (0.72)	-1.5	-1.33	-1.00	-0.83	0.3	-0.18 [-1.37, 1.01]
			Placebo	6	6 (100.0)	-0.72 (0.89)	-2.0	-1.67	-0.33	-0.17	0.2	
		Week 6	Tezepelumab	5	5 (100.0)	-1.17 (0.49)	-1.5	-1.50	-1.33	-1.17	-0.3	-0.61 [-1.83, 0.61]
			Placebo	6	6 (100.0)	-0.81 (0.66)	-1.8	-1.33	-0.67	-0.17	-0.2	
		Week 8	Tezepelumab	5	5 (100.0)	-1.33 (0.59)	-1.8	-1.67	-1.50	-1.33	-0.3	-0.80 [-2.04, 0.44]
			Placebo	6	6 (100.0)	-0.67 (0.99)	-2.5	-0.83	-0.50	0.17	0.2	
		Week 10	Tezepelumab	5	5 (100.0)	-1.40 (0.52)	-1.8	-1.67	-1.50	-1.50	-0.5	-0.65 [-1.88, 0.57]
			Placebo	6	6 (100.0)	-0.92 (0.87)	-2.7	-0.83	-0.58	-0.50	-0.3	
		Week 12	Tezepelumab	5	5 (100.0)	-1.70 (0.62)	-2.2	-2.17	-1.83	-1.67	-0.7	-0.91 [-2.17, 0.35]
			Placebo	6	6 (100.0)	-0.94 (0.97)	-2.8	-1.00	-0.67	-0.33	-0.2	
		Week 14	Tezepelumab	5	5 (100.0)	-1.60 (0.37)	-1.8	-1.83	-1.83	-1.50	-1.0	-0.60 [-1.82, 0.62]
			Placebo	6	6 (100.0)	-1.11 (1.05)	-3.0	-1.33	-1.00	-0.33	0.0	
		Week 16	Tezepelumab	5	5 (100.0)	-1.67 (0.51)	-2.2	-2.17	-1.67	-1.33	-1.0	-0.44 [-1.65, 0.76]
			Placebo	6	6 (100.0)	-1.22 (1.26)	-3.5	-1.67	-0.92	-0.17	-0.2	
		Week 18	Tezepelumab	5	5 (100.0)	-1.53 (0.79)	-2.2	-1.83	-1.83	-1.67	-0.2	-0.69 [-1.92, 0.54]
			Placebo	6	6 (100.0)	-0.89 (1.04)	-2.8	-1.00	-0.67	-0.17	0.0	
		Week 20	Tezepelumab	5	5 (100.0)	-1.43 (0.92)	-2.0	-2.00	-1.83	-1.50	0.2	-0.45 [-1.65, 0.76]
			Placebo	6	6 (100.0)	-0.86 (1.50)	-3.5	-1.33	-0.58	0.00	0.8	
		Week 22	Tezepelumab	5	5 (100.0)	-1.53 (0.97)	-2.2	-2.17	-1.83	-1.67	0.2	-0.49 [-1.70, 0.72]
			Placebo	6	6 (100.0)	-1.00 (1.16)	-3.0	-1.50	-0.83	0.00	0.2	
		Week 24	Tezepelumab	5	5 (100.0)	-1.57 (0.76)	-2.3	-2.00	-1.67	-1.50	-0.3	-0.61 [-1.83, 0.61]
			Placebo	6	6 (100.0)	-0.83 (1.46)	-3.5	-1.17	-0.50	0.17	0.5	
		Week 26	Tezepelumab	5	5 (100.0)	-1.80 (0.55)	-2.3	-2.33	-1.83	-1.33	-1.2	-0.56 [-1.78, 0.65]
			Placebo	6	6 (100.0)	-1.14 (1.50)	-4.0	-1.33	-0.75	-0.17	0.2	
		Week 28	Tezepelumab	5	5 (100.0)	-1.67 (0.51)	-2.2	-2.17	-1.67	-1.33	-1.0	-0.17 [-1.36, 1.02]
			Placebo	6	6 (100.0)	-1.47 (1.45)	-4.0	-1.83	-1.33	-0.33	0.0	
		Week 30	Tezepelumab	5	5 (100.0)	-1.70 (0.61)	-2.5	-1.83	-1.83	-1.50	-0.8	-0.23 [-1.42, 0.97]
			Placebo	6	6 (100.0)	-1.47 (1.24)	-3.2	-2.17	-1.50	-1.00	0.5	
		Week 32	Tezepelumab	5	5 (100.0)	-1.87 (0.59)	-2.3	-2.33	-2.17	-1.50	-1.0	-0.46 [-1.67, 0.74]
			Placebo	6	6 (100.0)	-1.39 (1.27)	-3.5	-1.67	-1.50	-0.33	0.2	
		Week 34	Tezepelumab	5	5 (100.0)	-1.83 (0.68)	-2.5	-2.33	-2.00	-1.50	-0.8	-0.32 [-1.52, 0.87]
			Placebo	6	6 (100.0)	-1.47 (1.38)	-4.0	-1.83	-1.08	-0.67	-0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asian	Change from baseline	Week 36	Tezepelumab	5	5 (100.0)	-1.53 (1.11)	-2.3	-2.17	-2.17	-1.33	0.3	-0.48 [-1.69, 0.72]
			Placebo	6	6 (100.0)	-0.86 (1.58)	-3.5	-1.83	-0.33	-0.17	1.0	
		Week 38	Tezepelumab	5	5 (100.0)	-1.57 (0.81)	-2.5	-2.00	-1.67	-1.33	-0.3	-0.01 [-1.20, 1.18]
			Placebo	6	6 (100.0)	-1.56 (1.37)	-4.0	-1.83	-1.42	-0.67	0.0	
		Week 40	Tezepelumab	5	5 (100.0)	-1.73 (0.86)	-2.5	-2.17	-2.17	-1.50	-0.3	-0.41 [-1.61, 0.79]
			Placebo	6	6 (100.0)	-1.19 (1.60)	-4.0	-1.83	-0.92	0.17	0.3	
		Week 42	Tezepelumab	5	5 (100.0)	-1.77 (0.48)	-2.2	-2.17	-2.00	-1.33	-1.2	-0.37 [-1.57, 0.82]
			Placebo	6	6 (100.0)	-1.33 (1.49)	-4.0	-1.83	-1.00	-0.50	0.3	
		Week 44	Tezepelumab	5	5 (100.0)	-1.87 (0.68)	-2.7	-2.17	-2.17	-1.33	-1.0	-0.79 [-2.03, 0.45]
			Placebo	6	6 (100.0)	-0.69 (1.89)	-4.0	-1.67	-0.08	0.50	1.2	
		Week 46	Tezepelumab	5	5 (100.0)	-1.73 (0.53)	-2.2	-2.17	-2.00	-1.33	-1.0	-0.20 [-1.39, 0.99]
			Placebo	6	6 (100.0)	-1.50 (1.47)	-4.0	-1.83	-1.42	-0.67	0.3	
		Week 48	Tezepelumab	5	5 (100.0)	-1.43 (1.02)	-2.2	-2.00	-1.83	-1.50	0.3	-0.27 [-1.47, 0.92]
			Placebo	6	6 (100.0)	-1.08 (1.46)	-3.7	-1.83	-0.58	0.00	0.2	
		Week 50	Tezepelumab	5	5 (100.0)	-1.43 (1.00)	-2.5	-2.00	-1.50	-1.33	0.2	-0.17 [-1.36, 1.02]
			Placebo	6	6 (100.0)	-1.22 (1.45)	-4.0	-1.33	-0.92	-0.17	0.0	
		Week 52	Tezepelumab	5	5 (100.0)	-1.60 (1.08)	-2.5	-2.33	-2.00	-1.33	0.2	-0.33 [-1.53, 0.87]
			Placebo	6	6 (100.0)	-1.17 (1.47)	-4.0	-1.33	-0.75	-0.17	0.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.33	2.3	2.33	2.33	2.33	2.3	
			Placebo	3	3 (100.0)	3.72 (0.82)	3.2	3.17	3.33	4.67	4.7	
		Week 2	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	
			Placebo	3	3 (100.0)	3.22 (1.29)	2.2	2.17	2.83	4.67	4.7	
		Week 4	Tezepelumab	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	
			Placebo	3	3 (100.0)	3.11 (0.67)	2.3	2.33	3.50	3.50	3.5	
		Week 6	Tezepelumab	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
			Placebo	3	3 (100.0)	3.11 (2.20)	1.2	1.17	2.67	5.50	5.5	
		Week 8	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	
			Placebo	3	3 (100.0)	1.83 (2.47)	0.2	0.17	0.67	4.67	4.7	
		Week 10	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	3	3 (100.0)	1.83 (1.04)	1.0	1.00	1.50	3.00	3.0	
		Week 12	Tezepelumab	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
			Placebo	3	3 (100.0)	1.39 (1.42)	0.0	0.00	1.33	2.83	2.8	
		Week 14	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	3	3 (100.0)	1.56 (1.50)	0.0	0.00	1.67	3.00	3.0	
		Week 16	Tezepelumab	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
			Placebo	3	3 (100.0)	2.22 (2.44)	0.0	0.00	1.83	4.83	4.8	
		Week 18	Tezepelumab	1	1 (100.0)	1.83	1.8	1.83	1.83	1.83	1.8	
			Placebo	3	3 (100.0)	1.50 (1.50)	0.0	0.00	1.50	3.00	3.0	
		Week 20	Tezepelumab	1	1 (100.0)	1.83	1.8	1.83	1.83	1.83	1.8	
			Placebo	3	3 (100.0)	1.83 (1.48)	0.2	0.17	2.33	3.00	3.0	
		Week 22	Tezepelumab	1	1 (100.0)	2.33	2.3	2.33	2.33	2.33	2.3	
			Placebo	3	3 (100.0)	2.28 (1.29)	0.8	0.83	2.67	3.33	3.3	
		Week 24	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	
			Placebo	3	3 (100.0)	1.72 (1.42)	0.7	0.67	1.17	3.33	3.3	
		Week 26	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	3	3 (100.0)	1.44 (1.71)	0.0	0.00	1.00	3.33	3.3	
		Week 28	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	3	3 (100.0)	1.39 (1.73)	0.0	0.00	0.83	3.33	3.3	
		Week 30	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	3	3 (100.0)	2.17 (1.04)	1.3	1.33	1.83	3.33	3.3	
		Week 32	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	3	3 (100.0)	2.11 (1.11)	1.2	1.17	1.83	3.33	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Other	Absolute values	Week 34	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	3	3 (100.0)	1.78 (1.50)	0.3	0.33	1.67	3.33	3.3	
		Week 36	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	3	3 (100.0)	2.39 (0.82)	1.8	1.83	2.00	3.33	3.3	
		Week 38	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	3	3 (100.0)	2.28 (0.92)	1.7	1.67	1.83	3.33	3.3	
		Week 40	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	3	3 (100.0)	2.00 (1.26)	0.8	0.83	1.83	3.33	3.3	
		Week 42	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	3	3 (100.0)	2.44 (0.77)	2.0	2.00	2.00	3.33	3.3	
		Week 44	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	3	3 (100.0)	2.17 (1.48)	0.5	0.50	2.67	3.33	3.3	
		Week 46	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	3	3 (100.0)	2.50 (0.73)	2.0	2.00	2.17	3.33	3.3	
		Week 48	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	3	3 (100.0)	2.61 (0.75)	1.8	1.83	2.67	3.33	3.3	
		Week 50	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	3	3 (100.0)	1.89 (1.60)	0.2	0.17	2.17	3.33	3.3	
		Week 52	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	3	3 (100.0)	1.89 (1.60)	0.2	0.17	2.17	3.33	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.17	0.2	0.17	0.17	0.17	0.2	NE
			Placebo	3	3 (100.0)	-0.50 (0.50)	-1.0	-1.00	-0.50	0.00	0.0	
		Week 4	Tezepelumab	1	1 (100.0)	0.67	0.7	0.67	0.67	0.67	0.7	NE
			Placebo	3	3 (100.0)	-0.61 (0.82)	-1.2	-1.17	-1.00	0.33	0.3	
		Week 6	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	3	3 (100.0)	-0.61 (1.42)	-2.0	-2.00	-0.67	0.83	0.8	
		Week 8	Tezepelumab	1	1 (100.0)	0.17	0.2	0.17	0.17	0.17	0.2	NE
			Placebo	3	3 (100.0)	-1.89 (1.64)	-3.0	-3.00	-2.67	0.00	0.0	
		Week 10	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	3	3 (100.0)	-1.89 (0.25)	-2.2	-2.17	-1.83	-1.67	-1.7	
		Week 12	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	3	3 (100.0)	-2.33 (0.73)	-3.2	-3.17	-2.00	-1.83	-1.8	
		Week 14	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	3	3 (100.0)	-2.17 (0.87)	-3.2	-3.17	-1.67	-1.67	-1.7	
		Week 16	Tezepelumab	1	1 (100.0)	-1.00	-1.0	-1.00	-1.00	-1.00	-1.0	NE
			Placebo	3	3 (100.0)	-1.50 (1.67)	-3.2	-3.17	-1.50	0.17	0.2	
		Week 18	Tezepelumab	1	1 (100.0)	-0.50	-0.5	-0.50	-0.50	-0.50	-0.5	NE
			Placebo	3	3 (100.0)	-2.22 (0.82)	-3.2	-3.17	-1.83	-1.67	-1.7	
		Week 20	Tezepelumab	1	1 (100.0)	-0.50	-0.5	-0.50	-0.50	-0.50	-0.5	NE
			Placebo	3	3 (100.0)	-1.89 (1.18)	-3.2	-3.17	-1.67	-0.83	-0.8	
		Week 22	Tezepelumab	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	NE
			Placebo	3	3 (100.0)	-1.44 (1.00)	-2.5	-2.50	-1.33	-0.50	-0.5	
		Week 24	Tezepelumab	1	1 (100.0)	0.17	0.2	0.17	0.17	0.17	0.2	NE
			Placebo	3	3 (100.0)	-2.00 (0.60)	-2.5	-2.50	-2.17	-1.33	-1.3	
		Week 26	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	3	3 (100.0)	-2.28 (0.92)	-3.2	-3.17	-2.33	-1.33	-1.3	
		Week 28	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	3	3 (100.0)	-2.33 (0.93)	-3.2	-3.17	-2.50	-1.33	-1.3	
		Week 30	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	3	3 (100.0)	-1.56 (0.38)	-2.0	-2.00	-1.33	-1.33	-1.3	
		Week 32	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	3	3 (100.0)	-1.61 (0.48)	-2.2	-2.17	-1.33	-1.33	-1.3	
		Week 34	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	3	3 (100.0)	-1.94 (0.79)	-2.8	-2.83	-1.67	-1.33	-1.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Other	Change from baseline	Week 36	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	3	3 (100.0)	-1.33 (0.00)	-1.3	-1.33	-1.33	-1.33	-1.3	
		Week 38	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	3	3 (100.0)	-1.44 (0.19)	-1.7	-1.67	-1.33	-1.33	-1.3	
		Week 40	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	3	3 (100.0)	-1.72 (0.54)	-2.3	-2.33	-1.50	-1.33	-1.3	
		Week 42	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	3	3 (100.0)	-1.28 (0.10)	-1.3	-1.33	-1.33	-1.17	-1.2	
		Week 44	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	3	3 (100.0)	-1.56 (1.02)	-2.7	-2.67	-1.33	-0.67	-0.7	
		Week 46	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	3	3 (100.0)	-1.22 (0.10)	-1.3	-1.33	-1.17	-1.17	-1.2	
		Week 48	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	3	3 (100.0)	-1.11 (0.54)	-1.5	-1.50	-1.33	-0.50	-0.5	
		Week 50	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	3	3 (100.0)	-1.83 (1.01)	-3.0	-3.00	-1.33	-1.17	-1.2	
		Week 52	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	3	3 (100.0)	-1.83 (1.01)	-3.0	-3.00	-1.33	-1.17	-1.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	78	78 (100.0)	2.74 (0.83)	0.0	2.33	2.67	3.17	4.8	
			Placebo	80	80 (100.0)	2.48 (0.60)	0.3	2.17	2.50	3.00	3.5	
		Week 2	Tezepelumab	78	76 (97.4)	2.26 (0.92)	0.2	1.67	2.33	2.83	4.3	
			Placebo	80	70 (87.5)	2.12 (0.69)	0.2	1.67	2.17	2.67	3.3	
		Week 4	Tezepelumab	78	76 (97.4)	1.95 (0.98)	0.2	1.17	2.17	2.67	4.3	
			Placebo	80	70 (87.5)	2.05 (0.83)	0.3	1.50	2.17	2.67	4.2	
		Week 6	Tezepelumab	78	76 (97.4)	1.85 (0.99)	0.0	1.33	1.83	2.58	4.3	
			Placebo	80	71 (88.8)	1.93 (0.91)	0.2	1.17	2.00	2.50	4.7	
		Week 8	Tezepelumab	78	76 (97.4)	1.84 (1.07)	0.0	1.17	1.67	2.67	4.8	
			Placebo	80	71 (88.8)	1.88 (0.87)	0.0	1.33	1.83	2.50	4.0	
		Week 10	Tezepelumab	78	76 (97.4)	1.79 (1.05)	0.0	1.08	1.75	2.67	4.3	
			Placebo	80	72 (90.0)	1.90 (0.87)	0.0	1.25	2.00	2.67	4.2	
		Week 12	Tezepelumab	78	76 (97.4)	1.74 (1.08)	0.0	0.92	1.75	2.50	4.3	
			Placebo	80	72 (90.0)	1.77 (0.95)	0.0	1.08	1.83	2.50	4.3	
		Week 14	Tezepelumab	78	76 (97.4)	1.58 (1.10)	0.0	0.67	1.50	2.33	4.3	
			Placebo	80	72 (90.0)	1.72 (0.81)	0.0	1.00	1.83	2.42	3.2	
		Week 16	Tezepelumab	78	76 (97.4)	1.71 (1.08)	0.0	0.92	1.67	2.50	4.3	
			Placebo	80	72 (90.0)	1.85 (0.95)	0.0	1.00	1.83	2.67	3.8	
		Week 18	Tezepelumab	78	77 (98.7)	1.62 (1.04)	0.0	0.83	1.67	2.33	4.3	
			Placebo	80	72 (90.0)	1.70 (0.90)	0.0	1.00	1.67	2.33	4.7	
		Week 20	Tezepelumab	78	77 (98.7)	1.68 (1.10)	0.0	0.83	1.83	2.50	5.0	
			Placebo	80	72 (90.0)	1.70 (0.87)	0.0	1.17	1.67	2.50	3.5	
		Week 22	Tezepelumab	78	77 (98.7)	1.71 (1.01)	0.0	1.00	1.83	2.33	4.3	
			Placebo	80	72 (90.0)	1.67 (0.87)	0.0	1.00	1.58	2.33	3.5	
		Week 24	Tezepelumab	78	77 (98.7)	1.67 (1.06)	0.0	1.00	1.67	2.33	4.3	
			Placebo	80	72 (90.0)	1.71 (0.89)	0.0	1.00	1.75	2.50	3.2	
		Week 26	Tezepelumab	78	78 (100.0)	1.69 (1.04)	0.0	1.00	1.67	2.50	4.3	
			Placebo	80	72 (90.0)	1.66 (0.86)	0.0	1.00	1.50	2.17	3.7	
		Week 28	Tezepelumab	78	78 (100.0)	1.74 (1.07)	0.0	1.00	1.83	2.50	4.3	
			Placebo	80	73 (91.3)	1.73 (0.98)	0.0	1.00	1.83	2.50	3.8	
		Week 30	Tezepelumab	78	78 (100.0)	1.70 (1.06)	0.0	0.83	1.67	2.50	4.3	
			Placebo	80	74 (92.5)	1.73 (0.99)	0.0	1.00	1.75	2.50	4.0	
		Week 32	Tezepelumab	78	78 (100.0)	1.64 (1.06)	0.0	1.00	1.58	2.50	4.3	
			Placebo	80	74 (92.5)	1.63 (0.91)	0.0	1.00	1.50	2.33	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	Absolute values	Week 34	Tezepelumab	78	78 (100.0)	1.65 (1.12)	0.0	0.83	1.50	2.50	4.3	
			Placebo	80	74 (92.5)	1.67 (0.90)	0.0	1.00	1.67	2.33	3.5	
		Week 36	Tezepelumab	78	78 (100.0)	1.74 (1.11)	0.0	0.83	1.75	2.67	4.5	
			Placebo	80	74 (92.5)	1.68 (0.96)	0.0	1.00	1.67	2.50	4.2	
		Week 38	Tezepelumab	78	78 (100.0)	1.62 (1.11)	0.0	1.00	1.50	2.50	4.5	
			Placebo	80	74 (92.5)	1.66 (0.90)	0.0	1.00	1.58	2.50	3.2	
		Week 40	Tezepelumab	78	78 (100.0)	1.62 (1.09)	0.0	0.83	1.67	2.50	4.3	
			Placebo	80	74 (92.5)	1.72 (1.00)	0.0	0.83	1.67	2.50	4.2	
		Week 42	Tezepelumab	78	78 (100.0)	1.65 (1.14)	0.0	1.00	1.50	2.50	4.7	
			Placebo	80	74 (92.5)	1.69 (1.00)	0.0	0.83	1.83	2.33	4.7	
		Week 44	Tezepelumab	78	78 (100.0)	1.65 (1.08)	0.0	0.83	1.58	2.50	4.3	
			Placebo	80	75 (93.8)	1.72 (0.98)	0.0	0.83	1.83	2.50	4.2	
		Week 46	Tezepelumab	78	78 (100.0)	1.61 (1.11)	0.0	0.83	1.42	2.50	4.3	
			Placebo	80	75 (93.8)	1.60 (0.90)	0.0	0.83	1.67	2.33	3.3	
		Week 48	Tezepelumab	78	78 (100.0)	1.66 (1.12)	0.0	0.67	1.67	2.67	4.3	
			Placebo	80	75 (93.8)	1.61 (0.94)	0.0	0.83	1.67	2.50	3.8	
		Week 50	Tezepelumab	78	78 (100.0)	1.58 (1.10)	0.0	0.83	1.33	2.33	4.3	
			Placebo	80	75 (93.8)	1.60 (0.91)	0.0	1.00	1.67	2.33	3.3	
		Week 52	Tezepelumab	78	78 (100.0)	1.63 (1.09)	0.0	0.83	1.67	2.33	4.3	
			Placebo	80	75 (93.8)	1.67 (0.97)	0.0	1.00	1.67	2.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	78	76 (97.4)	-0.50 (0.64)	-2.0	-0.83	-0.33	0.00	0.7	-0.15 [-0.48, 0.17]
			Placebo	80	70 (87.5)	-0.40 (0.69)	-2.7	-0.83	-0.33	0.00	1.2	
		Week 4	Tezepelumab	78	76 (97.4)	-0.81 (0.91)	-3.5	-1.25	-0.83	-0.17	2.3	-0.39 [-0.72, -0.06]
			Placebo	80	70 (87.5)	-0.47 (0.84)	-3.0	-1.00	-0.33	0.00	1.2	
		Week 6	Tezepelumab	78	76 (97.4)	-0.91 (0.95)	-3.8	-1.33	-1.00	-0.33	2.3	-0.36 [-0.68, -0.03]
			Placebo	80	71 (88.8)	-0.58 (0.91)	-3.3	-1.17	-0.50	0.17	1.5	
		Week 8	Tezepelumab	78	76 (97.4)	-0.92 (1.03)	-3.8	-1.50	-1.00	-0.42	2.3	-0.31 [-0.64, 0.01]
			Placebo	80	71 (88.8)	-0.63 (0.79)	-3.0	-1.00	-0.67	-0.17	1.0	
		Week 10	Tezepelumab	78	76 (97.4)	-0.97 (0.97)	-3.8	-1.50	-1.00	-0.25	2.3	-0.38 [-0.70, -0.05]
			Placebo	80	72 (90.0)	-0.62 (0.87)	-3.2	-1.17	-0.50	0.00	2.0	
		Week 12	Tezepelumab	78	76 (97.4)	-1.02 (0.99)	-3.7	-1.67	-1.08	-0.33	2.3	-0.28 [-0.61, 0.04]
			Placebo	80	72 (90.0)	-0.75 (0.95)	-3.2	-1.33	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	78	76 (97.4)	-1.18 (1.04)	-3.8	-2.00	-1.17	-0.33	2.3	-0.39 [-0.72, -0.07]
			Placebo	80	72 (90.0)	-0.80 (0.88)	-3.2	-1.33	-0.67	-0.25	1.3	
		Week 16	Tezepelumab	78	76 (97.4)	-1.05 (1.01)	-3.8	-1.83	-1.00	-0.33	2.3	-0.39 [-0.72, -0.06]
			Placebo	80	72 (90.0)	-0.67 (0.93)	-2.8	-1.33	-0.67	0.00	1.3	
		Week 18	Tezepelumab	78	77 (98.7)	-1.13 (1.01)	-3.8	-1.83	-1.00	-0.50	2.3	-0.32 [-0.64, 0.00]
			Placebo	80	72 (90.0)	-0.82 (0.90)	-2.7	-1.42	-0.75	-0.25	1.5	
		Week 20	Tezepelumab	78	77 (98.7)	-1.07 (1.02)	-3.8	-1.67	-1.00	-0.33	2.3	-0.26 [-0.58, 0.06]
			Placebo	80	72 (90.0)	-0.82 (0.86)	-2.8	-1.42	-0.67	-0.33	1.2	
		Week 22	Tezepelumab	78	77 (98.7)	-1.03 (1.04)	-3.8	-1.67	-1.00	-0.50	2.3	-0.19 [-0.52, 0.13]
			Placebo	80	72 (90.0)	-0.85 (0.87)	-2.8	-1.50	-0.83	-0.33	1.3	
		Week 24	Tezepelumab	78	77 (98.7)	-1.08 (0.95)	-3.8	-1.67	-1.00	-0.50	2.3	-0.29 [-0.61, 0.03]
			Placebo	80	72 (90.0)	-0.81 (0.91)	-3.2	-1.50	-0.67	-0.25	1.7	
		Week 26	Tezepelumab	78	78 (100.0)	-1.04 (1.04)	-3.8	-1.83	-1.00	-0.33	2.3	-0.20 [-0.52, 0.13]
			Placebo	80	72 (90.0)	-0.86 (0.88)	-2.7	-1.42	-1.00	-0.33	1.0	
		Week 28	Tezepelumab	78	78 (100.0)	-1.00 (1.05)	-3.8	-1.67	-1.00	-0.17	2.3	-0.23 [-0.55, 0.09]
			Placebo	80	73 (91.3)	-0.76 (0.97)	-2.8	-1.50	-0.67	-0.17	1.2	
		Week 30	Tezepelumab	78	78 (100.0)	-1.04 (1.06)	-3.7	-1.83	-1.00	-0.33	2.3	-0.26 [-0.58, 0.06]
			Placebo	80	74 (92.5)	-0.77 (1.03)	-3.2	-1.50	-0.67	-0.17	2.0	
		Week 32	Tezepelumab	78	78 (100.0)	-1.09 (1.03)	-3.8	-1.83	-1.00	-0.50	2.3	-0.24 [-0.56, 0.08]
			Placebo	80	74 (92.5)	-0.86 (0.90)	-3.0	-1.50	-0.75	-0.33	1.3	
		Week 34	Tezepelumab	78	78 (100.0)	-1.09 (1.07)	-3.8	-2.00	-1.08	-0.33	2.3	-0.27 [-0.58, 0.05]
			Placebo	80	74 (92.5)	-0.82 (0.89)	-2.8	-1.33	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	Change from baseline	Week 36	Tezepelumab	78	78 (100.0)	-0.99 (1.11)	-3.8	-1.67	-1.00	-0.17	2.3	-0.17 [-0.49, 0.15]
			Placebo	80	74 (92.5)	-0.81 (0.97)	-3.5	-1.33	-0.83	-0.33	1.3	
		Week 38	Tezepelumab	78	78 (100.0)	-1.12 (1.12)	-3.8	-2.00	-1.17	-0.33	2.3	-0.28 [-0.60, 0.04]
			Placebo	80	74 (92.5)	-0.83 (0.93)	-3.0	-1.33	-0.83	-0.33	1.3	
		Week 40	Tezepelumab	78	78 (100.0)	-1.12 (1.08)	-3.8	-2.00	-1.00	-0.33	2.3	-0.34 [-0.66, -0.01]
			Placebo	80	74 (92.5)	-0.77 (0.97)	-3.2	-1.33	-0.83	-0.17	1.3	
		Week 42	Tezepelumab	78	78 (100.0)	-1.08 (1.14)	-3.8	-2.00	-1.00	-0.50	2.3	-0.26 [-0.58, 0.06]
			Placebo	80	74 (92.5)	-0.80 (0.99)	-2.8	-1.50	-0.83	-0.17	1.5	
		Week 44	Tezepelumab	78	78 (100.0)	-1.09 (1.14)	-4.3	-1.83	-1.00	-0.33	2.3	-0.29 [-0.61, 0.03]
			Placebo	80	75 (93.8)	-0.78 (0.98)	-3.3	-1.50	-0.67	-0.17	1.5	
		Week 46	Tezepelumab	78	78 (100.0)	-1.13 (1.14)	-4.2	-2.00	-1.00	-0.33	2.3	-0.23 [-0.55, 0.09]
			Placebo	80	75 (93.8)	-0.89 (0.92)	-2.8	-1.50	-0.83	-0.33	1.2	
		Week 48	Tezepelumab	78	78 (100.0)	-1.08 (1.13)	-4.2	-1.83	-1.00	-0.17	2.3	-0.18 [-0.50, 0.13]
			Placebo	80	75 (93.8)	-0.88 (0.95)	-3.3	-1.50	-0.83	-0.33	1.3	
		Week 50	Tezepelumab	78	78 (100.0)	-1.15 (1.10)	-3.8	-2.00	-1.25	-0.33	2.3	-0.26 [-0.57, 0.06]
			Placebo	80	75 (93.8)	-0.89 (0.92)	-3.5	-1.50	-0.83	-0.33	1.5	
		Week 52	Tezepelumab	78	78 (100.0)	-1.10 (1.10)	-4.2	-1.83	-1.17	-0.33	2.3	-0.27 [-0.59, 0.05]
			Placebo	80	75 (93.8)	-0.83 (0.94)	-3.5	-1.50	-0.67	-0.17	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	10	10 (100.0)	3.00 (1.04)	2.0	2.33	2.75	3.17	4.8	
			Placebo	9	9 (100.0)	2.91 (0.68)	1.8	2.33	3.17	3.33	3.8	
		Week 2	Tezepelumab	10	9 (90.0)	1.96 (1.22)	0.0	1.17	2.17	2.50	3.8	
			Placebo	9	8 (88.9)	2.27 (0.78)	1.2	1.67	2.25	2.83	3.5	
		Week 4	Tezepelumab	10	9 (90.0)	1.87 (0.96)	0.3	1.50	2.00	2.17	3.3	
			Placebo	9	8 (88.9)	2.27 (1.14)	0.7	1.50	2.42	2.83	4.0	
		Week 6	Tezepelumab	10	9 (90.0)	1.83 (1.01)	0.2	1.67	1.83	2.33	3.3	
			Placebo	9	8 (88.9)	2.19 (1.23)	0.5	1.25	2.42	2.58	4.5	
		Week 8	Tezepelumab	10	9 (90.0)	1.37 (0.96)	0.2	0.67	1.33	2.00	3.0	
			Placebo	9	8 (88.9)	1.88 (1.33)	0.2	0.83	1.75	2.83	4.0	
		Week 10	Tezepelumab	10	9 (90.0)	1.13 (0.90)	0.2	0.67	0.83	1.50	3.0	
			Placebo	9	8 (88.9)	2.02 (1.65)	0.0	0.83	1.92	2.67	5.3	
		Week 12	Tezepelumab	10	9 (90.0)	1.20 (0.54)	0.5	0.83	1.17	1.33	2.2	
			Placebo	9	8 (88.9)	1.94 (1.32)	0.0	1.08	1.75	2.92	4.0	
		Week 14	Tezepelumab	10	9 (90.0)	0.94 (0.59)	0.2	0.83	0.83	1.00	2.3	
			Placebo	9	8 (88.9)	2.17 (1.48)	0.3	1.08	2.08	2.83	5.0	
		Week 16	Tezepelumab	10	9 (90.0)	1.43 (0.97)	0.5	0.67	1.33	1.50	3.5	
			Placebo	9	8 (88.9)	2.15 (1.51)	0.2	1.00	2.17	2.83	5.0	
		Week 18	Tezepelumab	10	9 (90.0)	1.13 (0.66)	0.2	0.67	1.33	1.33	2.3	
			Placebo	9	8 (88.9)	2.10 (1.47)	0.2	1.17	2.00	2.67	5.0	
		Week 20	Tezepelumab	10	9 (90.0)	1.15 (0.54)	0.5	0.83	1.00	1.33	2.3	
			Placebo	9	8 (88.9)	1.88 (1.67)	0.2	0.25	2.00	2.67	5.0	
		Week 22	Tezepelumab	10	9 (90.0)	1.00 (0.61)	0.2	0.83	0.83	1.17	2.3	
			Placebo	9	8 (88.9)	1.92 (1.58)	0.0	0.58	2.17	2.42	5.0	
		Week 24	Tezepelumab	10	9 (90.0)	1.11 (0.74)	0.2	0.83	0.83	1.33	2.3	
			Placebo	9	8 (88.9)	1.79 (1.34)	0.2	0.75	1.75	2.50	4.2	
		Week 26	Tezepelumab	10	9 (90.0)	1.06 (0.69)	0.0	0.67	0.83	1.50	2.3	
			Placebo	9	8 (88.9)	1.69 (1.27)	0.3	0.75	1.33	2.42	4.2	
		Week 28	Tezepelumab	10	10 (100.0)	0.97 (0.68)	0.0	0.50	0.83	1.50	2.3	
			Placebo	9	8 (88.9)	1.73 (1.25)	0.3	0.67	1.75	2.25	4.2	
		Week 30	Tezepelumab	10	10 (100.0)	1.00 (0.68)	0.2	0.67	0.83	1.50	2.3	
			Placebo	9	8 (88.9)	1.75 (1.22)	0.3	0.92	1.58	2.25	4.2	
		Week 32	Tezepelumab	10	10 (100.0)	1.15 (0.64)	0.2	0.67	1.17	1.67	2.3	
			Placebo	9	8 (88.9)	1.63 (1.22)	0.3	0.83	1.42	2.00	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
America	Absolute values	Week 34	Tezepelumab	10	10 (100.0)	1.15 (0.63)	0.0	0.83	1.17	1.33	2.3	
			Placebo	9	8 (88.9)	1.63 (1.32)	0.0	0.58	1.58	2.25	4.2	
		Week 36	Tezepelumab	10	10 (100.0)	1.45 (0.73)	0.5	0.83	1.17	2.33	2.3	
			Placebo	9	8 (88.9)	1.92 (1.19)	0.0	1.33	1.92	2.33	4.2	
		Week 38	Tezepelumab	10	10 (100.0)	1.08 (0.60)	0.3	0.67	0.83	1.33	2.3	
			Placebo	9	8 (88.9)	1.88 (1.26)	0.0	1.17	1.67	2.58	4.2	
		Week 40	Tezepelumab	10	10 (100.0)	1.13 (0.75)	0.2	0.67	1.00	1.67	2.3	
			Placebo	9	8 (88.9)	1.85 (1.23)	0.0	1.08	1.92	2.33	4.2	
		Week 42	Tezepelumab	10	10 (100.0)	1.07 (0.69)	0.2	0.67	1.00	1.50	2.3	
			Placebo	9	8 (88.9)	1.52 (0.75)	0.0	1.25	1.58	2.00	2.5	
		Week 44	Tezepelumab	10	10 (100.0)	1.17 (0.66)	0.3	0.67	1.00	1.67	2.3	
			Placebo	9	8 (88.9)	1.63 (0.80)	0.7	1.08	1.25	2.50	2.7	
		Week 46	Tezepelumab	10	10 (100.0)	1.00 (0.68)	0.2	0.67	0.92	1.17	2.3	
			Placebo	9	8 (88.9)	1.58 (0.79)	0.5	1.00	1.42	2.33	2.7	
		Week 48	Tezepelumab	10	10 (100.0)	1.05 (0.63)	0.2	0.67	1.00	1.33	2.3	
			Placebo	9	8 (88.9)	1.52 (0.84)	0.3	0.92	1.42	2.17	2.8	
		Week 50	Tezepelumab	10	10 (100.0)	0.83 (0.69)	0.0	0.17	0.75	1.17	2.3	
			Placebo	9	8 (88.9)	1.85 (0.90)	1.0	1.17	1.58	2.33	3.7	
		Week 52	Tezepelumab	10	10 (100.0)	0.97 (0.64)	0.2	0.67	0.92	1.33	2.3	
			Placebo	9	8 (88.9)	1.85 (1.11)	0.0	1.17	1.92	2.50	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	10	9 (90.0)	-1.11 (1.02)	-2.8	-1.50	-1.00	-0.17	0.2	-0.54 [-1.51, 0.43]
			Placebo	9	8 (88.9)	-0.56 (1.00)	-2.2	-1.25	-0.50	0.08	1.0	
		Week 4	Tezepelumab	10	9 (90.0)	-1.20 (0.92)	-2.7	-1.83	-1.17	-0.50	0.2	-0.59 [-1.57, 0.39]
			Placebo	9	8 (88.9)	-0.56 (1.25)	-2.7	-1.42	-0.50	0.58	0.8	
		Week 6	Tezepelumab	10	9 (90.0)	-1.24 (1.28)	-3.0	-2.33	-1.33	-0.33	0.3	-0.47 [-1.43, 0.50]
			Placebo	9	8 (88.9)	-0.65 (1.27)	-2.8	-1.25	-0.75	0.17	1.3	
		Week 8	Tezepelumab	10	9 (90.0)	-1.70 (0.91)	-2.8	-2.50	-1.83	-0.83	-0.3	-0.61 [-1.59, 0.36]
			Placebo	9	8 (88.9)	-0.96 (1.49)	-3.2	-2.00	-1.17	0.50	0.8	
		Week 10	Tezepelumab	10	9 (90.0)	-1.94 (1.03)	-3.5	-2.67	-2.00	-1.33	-0.5	-0.79 [-1.78, 0.20]
			Placebo	9	8 (88.9)	-0.81 (1.79)	-3.3	-1.67	-1.33	0.08	2.7	
		Week 12	Tezepelumab	10	9 (90.0)	-1.87 (1.02)	-3.7	-2.33	-1.83	-1.00	-0.5	-0.78 [-1.77, 0.21]
			Placebo	9	8 (88.9)	-0.90 (1.47)	-3.3	-1.67	-1.17	0.25	1.3	
		Week 14	Tezepelumab	10	9 (90.0)	-2.13 (0.88)	-3.8	-2.50	-2.17	-1.50	-1.0	-1.13 [-2.17, -0.10]
			Placebo	9	8 (88.9)	-0.67 (1.63)	-3.0	-1.50	-1.17	0.33	2.3	
		Week 16	Tezepelumab	10	9 (90.0)	-1.65 (1.51)	-4.2	-2.50	-1.83	-0.67	1.2	-0.60 [-1.58, 0.37]
			Placebo	9	8 (88.9)	-0.69 (1.67)	-3.2	-1.42	-1.25	0.33	2.3	
		Week 18	Tezepelumab	10	9 (90.0)	-1.94 (1.18)	-4.2	-2.50	-1.83	-0.67	-0.7	-0.86 [-1.86, 0.14]
			Placebo	9	8 (88.9)	-0.73 (1.64)	-3.2	-1.58	-1.00	0.08	2.3	
		Week 20	Tezepelumab	10	9 (90.0)	-1.93 (1.10)	-4.2	-2.50	-1.83	-1.33	-0.5	-0.64 [-1.62, 0.34]
			Placebo	9	8 (88.9)	-0.96 (1.86)	-3.2	-2.50	-1.00	0.08	2.3	
		Week 22	Tezepelumab	10	9 (90.0)	-2.07 (1.05)	-4.3	-2.50	-1.83	-1.17	-1.0	-0.81 [-1.80, 0.19]
			Placebo	9	8 (88.9)	-0.92 (1.78)	-3.3	-2.17	-1.08	0.08	2.3	
		Week 24	Tezepelumab	10	9 (90.0)	-1.96 (1.32)	-4.5	-2.50	-2.00	-1.50	0.2	-0.65 [-1.63, 0.33]
			Placebo	9	8 (88.9)	-1.04 (1.51)	-3.2	-2.00	-1.25	-0.08	1.5	
		Week 26	Tezepelumab	10	9 (90.0)	-2.02 (1.18)	-4.2	-2.50	-2.00	-1.67	-0.3	-0.66 [-1.65, 0.32]
			Placebo	9	8 (88.9)	-1.15 (1.45)	-2.8	-2.08	-1.50	-0.33	1.5	
		Week 28	Tezepelumab	10	10 (100.0)	-2.03 (1.10)	-4.2	-2.50	-2.00	-1.50	-0.5	-0.75 [-1.71, 0.22]
			Placebo	9	8 (88.9)	-1.10 (1.41)	-2.8	-2.17	-1.25	-0.33	1.5	
		Week 30	Tezepelumab	10	10 (100.0)	-2.00 (1.11)	-4.2	-2.50	-2.08	-1.50	-0.3	-0.75 [-1.72, 0.21]
			Placebo	9	8 (88.9)	-1.08 (1.35)	-2.8	-1.92	-1.33	-0.42	1.5	
		Week 32	Tezepelumab	10	10 (100.0)	-1.85 (1.10)	-4.2	-2.50	-1.92	-1.00	-0.3	-0.53 [-1.48, 0.41]
			Placebo	9	8 (88.9)	-1.21 (1.33)	-2.8	-2.00	-1.50	-0.67	1.5	
		Week 34	Tezepelumab	10	10 (100.0)	-1.85 (1.09)	-4.2	-2.33	-1.83	-1.17	-0.2	-0.55 [-1.50, 0.40]
			Placebo	9	8 (88.9)	-1.21 (1.27)	-2.8	-1.92	-1.25	-1.00	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
America	Change from baseline	Week 36	Tezepelumab	10	10 (100.0)	-1.55 (1.39)	-4.2	-2.50	-1.75	0.00	0.3	-0.47 [-1.42, 0.47]
			Placebo	9	8 (88.9)	-0.92 (1.26)	-2.2	-1.75	-1.33	-0.25	1.5	
		Week 38	Tezepelumab	10	10 (100.0)	-1.92 (1.06)	-4.2	-2.17	-2.00	-1.67	-0.2	-0.78 [-1.75, 0.19]
			Placebo	9	8 (88.9)	-0.96 (1.42)	-2.5	-1.92	-1.42	0.00	1.5	
		Week 40	Tezepelumab	10	10 (100.0)	-1.87 (1.20)	-4.2	-2.50	-1.92	-1.17	0.2	-0.73 [-1.69, 0.23]
			Placebo	9	8 (88.9)	-0.98 (1.24)	-2.2	-1.83	-1.33	-0.42	1.5	
		Week 42	Tezepelumab	10	10 (100.0)	-1.93 (1.10)	-4.2	-2.50	-1.92	-1.17	-0.5	-0.65 [-1.60, 0.31]
			Placebo	9	8 (88.9)	-1.31 (0.74)	-2.2	-1.83	-1.33	-1.08	0.2	
		Week 44	Tezepelumab	10	10 (100.0)	-1.83 (1.14)	-4.2	-2.50	-1.92	-1.17	0.0	-0.60 [-1.56, 0.35]
			Placebo	9	8 (88.9)	-1.21 (0.88)	-2.2	-1.75	-1.42	-0.92	0.7	
		Week 46	Tezepelumab	10	10 (100.0)	-2.00 (1.08)	-4.2	-2.50	-1.92	-1.67	-0.2	-0.75 [-1.71, 0.22]
			Placebo	9	8 (88.9)	-1.25 (0.90)	-2.2	-1.67	-1.42	-1.25	0.8	
		Week 48	Tezepelumab	10	10 (100.0)	-1.95 (1.04)	-4.2	-2.50	-1.92	-1.50	-0.3	-0.61 [-1.56, 0.34]
			Placebo	9	8 (88.9)	-1.31 (1.05)	-2.5	-1.83	-1.58	-1.08	1.0	
		Week 50	Tezepelumab	10	10 (100.0)	-2.17 (0.99)	-4.2	-2.67	-2.17	-1.67	-0.7	-1.14 [-2.15, -0.13]
			Placebo	9	8 (88.9)	-0.98 (1.11)	-2.0	-1.58	-1.33	-0.75	1.5	
		Week 52	Tezepelumab	10	10 (100.0)	-2.03 (1.05)	-4.2	-2.67	-1.92	-1.00	-0.7	-0.87 [-1.85, 0.10]
			Placebo	9	8 (88.9)	-0.98 (1.38)	-2.7	-1.75	-1.33	-0.25	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	5	5 (100.0)	2.50 (0.46)	2.0	2.17	2.50	2.67	3.2	
			Placebo	6	6 (100.0)	2.50 (0.90)	1.5	1.83	2.33	3.00	4.0	
		Week 2	Tezepelumab	5	5 (100.0)	2.00 (0.81)	0.8	1.67	2.17	2.33	3.0	
			Placebo	6	6 (100.0)	2.31 (0.95)	1.3	1.50	2.25	2.50	4.0	
		Week 4	Tezepelumab	5	5 (100.0)	1.63 (0.70)	0.7	1.17	1.83	2.17	2.3	
			Placebo	6	6 (100.0)	1.78 (0.51)	1.3	1.33	1.67	2.00	2.7	
		Week 6	Tezepelumab	5	5 (100.0)	1.33 (0.39)	0.8	1.00	1.50	1.67	1.7	
			Placebo	6	6 (100.0)	1.69 (0.66)	0.8	1.17	1.75	2.33	2.3	
		Week 8	Tezepelumab	5	5 (100.0)	1.17 (0.47)	0.7	0.83	1.00	1.67	1.7	
			Placebo	6	6 (100.0)	1.83 (0.53)	1.2	1.50	1.75	2.17	2.7	
		Week 10	Tezepelumab	5	5 (100.0)	1.10 (0.35)	0.7	0.83	1.17	1.33	1.5	
			Placebo	6	6 (100.0)	1.58 (0.48)	0.8	1.33	1.58	2.00	2.2	
		Week 12	Tezepelumab	5	5 (100.0)	0.80 (0.64)	0.0	0.33	0.83	1.33	1.5	
			Placebo	6	6 (100.0)	1.56 (0.43)	1.2	1.17	1.42	2.00	2.2	
		Week 14	Tezepelumab	5	5 (100.0)	0.90 (0.28)	0.7	0.67	0.83	1.00	1.3	
			Placebo	6	6 (100.0)	1.39 (0.49)	0.8	1.00	1.33	1.67	2.2	
		Week 16	Tezepelumab	5	5 (100.0)	0.83 (0.29)	0.3	0.83	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	1.28 (0.73)	0.5	0.50	1.25	1.83	2.3	
		Week 18	Tezepelumab	5	5 (100.0)	0.97 (0.52)	0.5	0.67	0.83	1.00	1.8	
			Placebo	6	6 (100.0)	1.61 (0.55)	0.8	1.17	1.67	2.00	2.3	
		Week 20	Tezepelumab	5	5 (100.0)	1.07 (0.66)	0.5	0.67	0.83	1.17	2.2	
			Placebo	6	6 (100.0)	1.64 (0.96)	0.5	0.83	1.50	2.50	3.0	
		Week 22	Tezepelumab	5	5 (100.0)	0.97 (0.78)	0.0	0.83	0.83	1.00	2.2	
			Placebo	6	6 (100.0)	1.50 (0.87)	0.3	1.00	1.33	2.33	2.7	
		Week 24	Tezepelumab	5	5 (100.0)	0.93 (0.45)	0.5	0.67	0.83	1.00	1.7	
			Placebo	6	6 (100.0)	1.67 (0.95)	0.5	0.67	1.75	2.67	2.7	
		Week 26	Tezepelumab	5	5 (100.0)	0.70 (0.30)	0.2	0.83	0.83	0.83	0.8	
			Placebo	6	6 (100.0)	1.36 (0.85)	0.0	0.83	1.50	2.00	2.3	
		Week 28	Tezepelumab	5	5 (100.0)	0.83 (0.29)	0.3	0.83	1.00	1.00	1.0	
			Placebo	6	6 (100.0)	1.03 (1.04)	0.0	0.00	0.92	2.17	2.2	
		Week 30	Tezepelumab	5	5 (100.0)	0.80 (0.22)	0.7	0.67	0.67	0.83	1.2	
			Placebo	6	6 (100.0)	1.03 (0.89)	0.0	0.00	1.17	1.83	2.0	
		Week 32	Tezepelumab	5	5 (100.0)	0.63 (0.38)	0.2	0.33	0.67	1.00	1.0	
			Placebo	6	6 (100.0)	1.11 (0.78)	0.2	0.50	1.08	1.67	2.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia/Pacific	Absolute values	Week 34	Tezepelumab	5	5 (100.0)	0.67 (0.31)	0.3	0.50	0.67	0.67	1.2	
			Placebo	6	6 (100.0)	1.03 (0.97)	0.0	0.00	1.00	1.83	2.3	
		Week 36	Tezepelumab	5	5 (100.0)	0.97 (0.79)	0.3	0.50	0.83	0.83	2.3	
			Placebo	6	6 (100.0)	1.64 (1.24)	0.0	0.50	1.83	2.50	3.2	
		Week 38	Tezepelumab	5	5 (100.0)	0.93 (0.79)	0.0	0.50	0.67	1.67	1.8	
			Placebo	6	6 (100.0)	0.94 (0.88)	0.0	0.00	1.00	1.83	1.8	
		Week 40	Tezepelumab	5	5 (100.0)	0.77 (0.52)	0.3	0.50	0.67	0.67	1.7	
			Placebo	6	6 (100.0)	1.31 (1.05)	0.0	0.00	1.75	1.83	2.5	
		Week 42	Tezepelumab	5	5 (100.0)	0.73 (0.22)	0.5	0.50	0.83	0.83	1.0	
			Placebo	6	6 (100.0)	1.17 (0.91)	0.0	0.00	1.67	1.83	1.8	
		Week 44	Tezepelumab	5	5 (100.0)	0.63 (0.27)	0.3	0.50	0.50	0.83	1.0	
			Placebo	6	6 (100.0)	1.81 (1.43)	0.0	0.17	2.17	3.00	3.3	
		Week 46	Tezepelumab	5	5 (100.0)	0.77 (0.28)	0.3	0.67	0.83	1.00	1.0	
			Placebo	6	6 (100.0)	1.00 (0.98)	0.0	0.00	1.08	1.83	2.0	
		Week 48	Tezepelumab	5	5 (100.0)	1.07 (0.73)	0.5	0.67	0.83	1.00	2.3	
			Placebo	6	6 (100.0)	1.42 (1.02)	0.0	0.33	1.83	2.17	2.3	
		Week 50	Tezepelumab	5	5 (100.0)	1.07 (0.66)	0.5	0.67	0.83	1.17	2.2	
			Placebo	6	6 (100.0)	1.28 (0.74)	0.0	0.83	1.58	1.67	2.0	
		Week 52	Tezepelumab	5	5 (100.0)	0.90 (0.73)	0.3	0.50	0.67	0.83	2.2	
			Placebo	6	6 (100.0)	1.33 (0.71)	0.0	1.17	1.58	1.67	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	5	5 (100.0)	-0.50 (0.59)	-1.3	-0.83	-0.33	-0.17	0.2	-0.69 [-1.92, 0.54]
			Placebo	6	6 (100.0)	-0.19 (0.27)	-0.7	-0.33	-0.08	0.00	0.0	
		Week 4	Tezepelumab	5	5 (100.0)	-0.87 (0.72)	-1.5	-1.33	-1.00	-0.83	0.3	-0.18 [-1.37, 1.01]
			Placebo	6	6 (100.0)	-0.72 (0.89)	-2.0	-1.67	-0.33	-0.17	0.2	
		Week 6	Tezepelumab	5	5 (100.0)	-1.17 (0.49)	-1.5	-1.50	-1.33	-1.17	-0.3	-0.61 [-1.83, 0.61]
			Placebo	6	6 (100.0)	-0.81 (0.66)	-1.8	-1.33	-0.67	-0.17	-0.2	
		Week 8	Tezepelumab	5	5 (100.0)	-1.33 (0.59)	-1.8	-1.67	-1.50	-1.33	-0.3	-0.80 [-2.04, 0.44]
			Placebo	6	6 (100.0)	-0.67 (0.99)	-2.5	-0.83	-0.50	0.17	0.2	
		Week 10	Tezepelumab	5	5 (100.0)	-1.40 (0.52)	-1.8	-1.67	-1.50	-1.50	-0.5	-0.65 [-1.88, 0.57]
			Placebo	6	6 (100.0)	-0.92 (0.87)	-2.7	-0.83	-0.58	-0.50	-0.3	
		Week 12	Tezepelumab	5	5 (100.0)	-1.70 (0.62)	-2.2	-2.17	-1.83	-1.67	-0.7	-0.91 [-2.17, 0.35]
			Placebo	6	6 (100.0)	-0.94 (0.97)	-2.8	-1.00	-0.67	-0.33	-0.2	
		Week 14	Tezepelumab	5	5 (100.0)	-1.60 (0.37)	-1.8	-1.83	-1.83	-1.50	-1.0	-0.60 [-1.82, 0.62]
			Placebo	6	6 (100.0)	-1.11 (1.05)	-3.0	-1.33	-1.00	-0.33	0.0	
		Week 16	Tezepelumab	5	5 (100.0)	-1.67 (0.51)	-2.2	-2.17	-1.67	-1.33	-1.0	-0.44 [-1.65, 0.76]
			Placebo	6	6 (100.0)	-1.22 (1.26)	-3.5	-1.67	-0.92	-0.17	-0.2	
		Week 18	Tezepelumab	5	5 (100.0)	-1.53 (0.79)	-2.2	-1.83	-1.83	-1.67	-0.2	-0.69 [-1.92, 0.54]
			Placebo	6	6 (100.0)	-0.89 (1.04)	-2.8	-1.00	-0.67	-0.17	0.0	
		Week 20	Tezepelumab	5	5 (100.0)	-1.43 (0.92)	-2.0	-2.00	-1.83	-1.50	0.2	-0.45 [-1.65, 0.76]
			Placebo	6	6 (100.0)	-0.86 (1.50)	-3.5	-1.33	-0.58	0.00	0.8	
		Week 22	Tezepelumab	5	5 (100.0)	-1.53 (0.97)	-2.2	-2.17	-1.83	-1.67	0.2	-0.49 [-1.70, 0.72]
			Placebo	6	6 (100.0)	-1.00 (1.16)	-3.0	-1.50	-0.83	0.00	0.2	
		Week 24	Tezepelumab	5	5 (100.0)	-1.57 (0.76)	-2.3	-2.00	-1.67	-1.50	-0.3	-0.61 [-1.83, 0.61]
			Placebo	6	6 (100.0)	-0.83 (1.46)	-3.5	-1.17	-0.50	0.17	0.5	
		Week 26	Tezepelumab	5	5 (100.0)	-1.80 (0.55)	-2.3	-2.33	-1.83	-1.33	-1.2	-0.56 [-1.78, 0.65]
			Placebo	6	6 (100.0)	-1.14 (1.50)	-4.0	-1.33	-0.75	-0.17	0.2	
		Week 28	Tezepelumab	5	5 (100.0)	-1.67 (0.51)	-2.2	-2.17	-1.67	-1.33	-1.0	-0.17 [-1.36, 1.02]
			Placebo	6	6 (100.0)	-1.47 (1.45)	-4.0	-1.83	-1.33	-0.33	0.0	
		Week 30	Tezepelumab	5	5 (100.0)	-1.70 (0.61)	-2.5	-1.83	-1.83	-1.50	-0.8	-0.23 [-1.42, 0.97]
			Placebo	6	6 (100.0)	-1.47 (1.24)	-3.2	-2.17	-1.50	-1.00	0.5	
		Week 32	Tezepelumab	5	5 (100.0)	-1.87 (0.59)	-2.3	-2.33	-2.17	-1.50	-1.0	-0.46 [-1.67, 0.74]
			Placebo	6	6 (100.0)	-1.39 (1.27)	-3.5	-1.67	-1.50	-0.33	0.2	
		Week 34	Tezepelumab	5	5 (100.0)	-1.83 (0.68)	-2.5	-2.33	-2.00	-1.50	-0.8	-0.32 [-1.52, 0.87]
			Placebo	6	6 (100.0)	-1.47 (1.38)	-4.0	-1.83	-1.08	-0.67	-0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia/Pacific	Change from baseline	Week 36	Tezepelumab	5	5 (100.0)	-1.53 (1.11)	-2.3	-2.17	-2.17	-1.33	0.3	-0.48 [-1.69, 0.72]
			Placebo	6	6 (100.0)	-0.86 (1.58)	-3.5	-1.83	-0.33	-0.17	1.0	
		Week 38	Tezepelumab	5	5 (100.0)	-1.57 (0.81)	-2.5	-2.00	-1.67	-1.33	-0.3	-0.01 [-1.20, 1.18]
			Placebo	6	6 (100.0)	-1.56 (1.37)	-4.0	-1.83	-1.42	-0.67	0.0	
		Week 40	Tezepelumab	5	5 (100.0)	-1.73 (0.86)	-2.5	-2.17	-2.17	-1.50	-0.3	-0.41 [-1.61, 0.79]
			Placebo	6	6 (100.0)	-1.19 (1.60)	-4.0	-1.83	-0.92	0.17	0.3	
		Week 42	Tezepelumab	5	5 (100.0)	-1.77 (0.48)	-2.2	-2.17	-2.00	-1.33	-1.2	-0.37 [-1.57, 0.82]
			Placebo	6	6 (100.0)	-1.33 (1.49)	-4.0	-1.83	-1.00	-0.50	0.3	
		Week 44	Tezepelumab	5	5 (100.0)	-1.87 (0.68)	-2.7	-2.17	-2.17	-1.33	-1.0	-0.79 [-2.03, 0.45]
			Placebo	6	6 (100.0)	-0.69 (1.89)	-4.0	-1.67	-0.08	0.50	1.2	
		Week 46	Tezepelumab	5	5 (100.0)	-1.73 (0.53)	-2.2	-2.17	-2.00	-1.33	-1.0	-0.20 [-1.39, 0.99]
			Placebo	6	6 (100.0)	-1.50 (1.47)	-4.0	-1.83	-1.42	-0.67	0.3	
		Week 48	Tezepelumab	5	5 (100.0)	-1.43 (1.02)	-2.2	-2.00	-1.83	-1.50	0.3	-0.27 [-1.47, 0.92]
			Placebo	6	6 (100.0)	-1.08 (1.46)	-3.7	-1.83	-0.58	0.00	0.2	
		Week 50	Tezepelumab	5	5 (100.0)	-1.43 (1.00)	-2.5	-2.00	-1.50	-1.33	0.2	-0.17 [-1.36, 1.02]
			Placebo	6	6 (100.0)	-1.22 (1.45)	-4.0	-1.33	-0.92	-0.17	0.0	
		Week 52	Tezepelumab	5	5 (100.0)	-1.60 (1.08)	-2.5	-2.33	-2.00	-1.33	0.2	-0.33 [-1.53, 0.87]
			Placebo	6	6 (100.0)	-1.17 (1.47)	-4.0	-1.33	-0.75	-0.17	0.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	44	44 (100.0)	2.59 (0.71)	0.3	2.25	2.58	2.92	4.3	
			Placebo	43	43 (100.0)	2.96 (0.71)	1.5	2.50	2.83	3.33	4.7	
		Week 2	Tezepelumab	44	41 (93.2)	2.06 (0.85)	0.0	1.67	2.17	2.67	3.7	
			Placebo	43	41 (95.3)	2.61 (0.87)	0.3	2.17	2.67	3.00	4.8	
		Week 4	Tezepelumab	44	41 (93.2)	1.81 (0.97)	0.0	1.17	1.83	2.50	3.3	
			Placebo	43	41 (95.3)	2.44 (0.78)	0.2	2.00	2.33	2.83	4.2	
		Week 6	Tezepelumab	44	41 (93.2)	1.75 (0.97)	0.0	1.17	1.67	2.50	3.7	
			Placebo	43	41 (95.3)	2.39 (0.98)	0.2	2.00	2.33	2.83	5.5	
		Week 8	Tezepelumab	44	41 (93.2)	1.69 (0.97)	0.0	0.83	1.83	2.50	3.3	
			Placebo	43	42 (97.7)	2.42 (0.97)	0.0	2.00	2.33	2.83	4.7	
		Week 10	Tezepelumab	44	41 (93.2)	1.59 (0.96)	0.0	1.00	1.83	2.33	3.3	
			Placebo	43	42 (97.7)	2.16 (0.85)	0.2	1.83	2.17	2.67	4.2	
		Week 12	Tezepelumab	44	41 (93.2)	1.50 (0.99)	0.0	0.67	1.50	2.33	3.5	
			Placebo	43	42 (97.7)	2.16 (0.84)	0.0	1.83	2.25	2.67	4.3	
		Week 14	Tezepelumab	44	41 (93.2)	1.42 (0.87)	0.0	1.00	1.33	2.00	3.5	
			Placebo	43	42 (97.7)	2.06 (0.95)	0.0	1.33	2.00	2.67	5.0	
		Week 16	Tezepelumab	44	41 (93.2)	1.56 (1.04)	0.0	0.67	1.67	2.50	4.3	
			Placebo	43	42 (97.7)	2.25 (1.04)	0.0	1.50	2.25	2.83	4.8	
		Week 18	Tezepelumab	44	41 (93.2)	1.42 (0.90)	0.0	0.83	1.50	2.00	3.5	
			Placebo	43	42 (97.7)	2.14 (1.02)	0.0	1.67	2.33	2.67	4.5	
		Week 20	Tezepelumab	44	41 (93.2)	1.56 (0.95)	0.0	1.00	1.67	2.17	3.3	
			Placebo	43	42 (97.7)	2.35 (0.96)	0.2	1.83	2.50	2.83	4.5	
		Week 22	Tezepelumab	44	41 (93.2)	1.58 (0.90)	0.0	1.17	1.67	2.17	3.5	
			Placebo	43	42 (97.7)	2.26 (1.01)	0.0	1.83	2.33	2.83	4.5	
		Week 24	Tezepelumab	44	41 (93.2)	1.64 (1.04)	0.0	1.00	1.67	2.50	4.2	
			Placebo	43	42 (97.7)	2.19 (1.01)	0.2	1.67	2.33	2.83	4.5	
		Week 26	Tezepelumab	44	41 (93.2)	1.51 (0.99)	0.0	1.00	1.50	2.17	3.7	
			Placebo	43	42 (97.7)	2.18 (1.05)	0.0	1.50	2.42	2.83	4.5	
		Week 28	Tezepelumab	44	41 (93.2)	1.60 (1.02)	0.0	1.00	1.50	2.33	3.5	
			Placebo	43	42 (97.7)	2.27 (0.99)	0.0	1.50	2.33	2.83	4.5	
		Week 30	Tezepelumab	44	42 (95.5)	1.50 (0.92)	0.0	0.83	1.50	2.17	3.8	
			Placebo	43	42 (97.7)	2.25 (0.93)	0.2	1.67	2.33	2.83	4.5	
		Week 32	Tezepelumab	44	42 (95.5)	1.46 (1.01)	0.0	0.50	1.50	2.33	4.2	
			Placebo	43	42 (97.7)	2.28 (1.06)	0.2	1.50	2.50	2.83	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of the world	Absolute values	Week 34	Tezepelumab	44	42 (95.5)	1.48 (1.02)	0.0	0.67	1.50	2.17	4.2	
			Placebo	43	42 (97.7)	2.11 (1.14)	0.0	1.50	2.33	2.83	4.5	
		Week 36	Tezepelumab	44	42 (95.5)	1.44 (0.96)	0.0	0.83	1.50	2.00	3.8	
			Placebo	43	42 (97.7)	2.19 (1.05)	0.0	1.83	2.33	2.83	4.5	
		Week 38	Tezepelumab	44	42 (95.5)	1.45 (0.97)	0.0	0.83	1.50	2.17	3.5	
			Placebo	43	42 (97.7)	2.09 (1.10)	0.0	1.50	2.00	2.83	4.5	
		Week 40	Tezepelumab	44	42 (95.5)	1.54 (1.02)	0.0	0.67	1.67	2.17	3.7	
			Placebo	43	42 (97.7)	2.17 (1.02)	0.3	1.67	2.25	2.83	4.5	
		Week 42	Tezepelumab	44	42 (95.5)	1.41 (0.91)	0.0	0.83	1.50	2.00	3.5	
			Placebo	43	42 (97.7)	2.21 (0.99)	0.3	1.83	2.50	2.83	4.5	
		Week 44	Tezepelumab	44	42 (95.5)	1.48 (0.98)	0.0	0.83	1.50	2.33	3.5	
			Placebo	43	42 (97.7)	2.19 (1.00)	0.2	1.50	2.33	2.83	4.5	
		Week 46	Tezepelumab	44	42 (95.5)	1.46 (0.95)	0.0	0.83	1.58	2.00	3.3	
			Placebo	43	42 (97.7)	2.18 (1.01)	0.0	1.50	2.17	2.83	4.5	
		Week 48	Tezepelumab	44	42 (95.5)	1.51 (0.97)	0.0	0.67	1.58	2.33	3.5	
			Placebo	43	42 (97.7)	2.22 (1.06)	0.0	1.50	2.25	3.00	4.5	
		Week 50	Tezepelumab	44	42 (95.5)	1.44 (0.95)	0.0	0.83	1.58	2.17	3.7	
			Placebo	43	42 (97.7)	2.12 (1.01)	0.2	1.50	2.17	2.83	4.5	
		Week 52	Tezepelumab	44	42 (95.5)	1.42 (0.96)	0.0	0.67	1.58	2.00	3.7	
			Placebo	43	42 (97.7)	2.15 (1.00)	0.2	1.50	2.17	2.83	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	44	41 (93.2)	-0.49 (0.61)	-2.5	-0.67	-0.33	0.00	0.5	-0.28 [-0.71, 0.16]
			Placebo	43	41 (95.3)	-0.30 (0.73)	-2.8	-0.67	-0.33	0.17	1.0	
		Week 4	Tezepelumab	44	41 (93.2)	-0.74 (0.84)	-2.5	-1.33	-0.67	-0.33	1.7	-0.33 [-0.77, 0.10]
			Placebo	43	41 (95.3)	-0.47 (0.73)	-2.3	-0.83	-0.67	0.17	0.8	
		Week 6	Tezepelumab	44	41 (93.2)	-0.79 (0.95)	-2.7	-1.50	-0.67	-0.17	1.3	-0.30 [-0.74, 0.14]
			Placebo	43	41 (95.3)	-0.52 (0.84)	-2.3	-1.00	-0.50	0.00	1.5	
		Week 8	Tezepelumab	44	41 (93.2)	-0.86 (0.95)	-2.8	-1.33	-0.83	-0.33	1.0	-0.38 [-0.82, 0.05]
			Placebo	43	42 (97.7)	-0.50 (0.94)	-3.0	-1.00	-0.50	0.33	1.0	
		Week 10	Tezepelumab	44	41 (93.2)	-0.95 (0.94)	-2.8	-1.33	-0.83	-0.33	1.0	-0.21 [-0.64, 0.22]
			Placebo	43	42 (97.7)	-0.76 (0.92)	-2.3	-1.33	-0.67	-0.33	2.5	
		Week 12	Tezepelumab	44	41 (93.2)	-1.05 (0.91)	-2.8	-1.67	-1.00	-0.67	1.2	-0.32 [-0.75, 0.12]
			Placebo	43	42 (97.7)	-0.76 (0.90)	-3.2	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	44	41 (93.2)	-1.13 (0.89)	-2.8	-1.83	-1.17	-0.67	1.2	-0.30 [-0.73, 0.14]
			Placebo	43	42 (97.7)	-0.86 (0.90)	-3.2	-1.33	-0.83	-0.33	1.2	
		Week 16	Tezepelumab	44	41 (93.2)	-0.99 (0.98)	-2.8	-1.67	-1.00	-0.67	1.5	-0.31 [-0.75, 0.12]
			Placebo	43	42 (97.7)	-0.67 (1.04)	-3.2	-1.17	-0.67	0.00	2.3	
		Week 18	Tezepelumab	44	41 (93.2)	-1.13 (0.90)	-3.2	-1.67	-1.00	-0.67	1.2	-0.34 [-0.78, 0.09]
			Placebo	43	42 (97.7)	-0.78 (1.09)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	44	41 (93.2)	-0.99 (0.91)	-2.7	-1.50	-0.83	-0.50	1.0	-0.42 [-0.85, 0.02]
			Placebo	43	42 (97.7)	-0.57 (1.07)	-3.0	-1.00	-0.67	0.00	2.3	
		Week 22	Tezepelumab	44	41 (93.2)	-0.96 (0.92)	-3.2	-1.33	-0.83	-0.33	1.2	-0.31 [-0.74, 0.13]
			Placebo	43	42 (97.7)	-0.66 (1.04)	-3.2	-1.33	-0.50	0.00	2.3	
		Week 24	Tezepelumab	44	41 (93.2)	-0.91 (0.89)	-2.7	-1.50	-0.83	-0.33	1.5	-0.18 [-0.61, 0.25]
			Placebo	43	42 (97.7)	-0.73 (1.11)	-3.0	-1.50	-0.75	0.17	2.3	
		Week 26	Tezepelumab	44	41 (93.2)	-1.03 (0.94)	-3.0	-1.67	-0.83	-0.50	1.3	-0.28 [-0.71, 0.15]
			Placebo	43	42 (97.7)	-0.74 (1.16)	-3.2	-1.50	-0.83	0.17	2.3	
		Week 28	Tezepelumab	44	41 (93.2)	-0.95 (0.92)	-2.8	-1.50	-0.83	-0.17	1.0	-0.29 [-0.73, 0.14]
			Placebo	43	42 (97.7)	-0.65 (1.12)	-3.2	-1.50	-0.75	0.17	2.3	
		Week 30	Tezepelumab	44	42 (95.5)	-1.07 (0.96)	-2.8	-1.50	-1.00	-0.33	1.5	-0.40 [-0.83, 0.03]
			Placebo	43	42 (97.7)	-0.67 (1.01)	-3.0	-1.33	-0.67	0.17	2.3	
		Week 32	Tezepelumab	44	42 (95.5)	-1.11 (1.05)	-3.3	-2.00	-0.92	-0.67	1.8	-0.42 [-0.85, 0.01]
			Placebo	43	42 (97.7)	-0.64 (1.17)	-3.0	-1.50	-0.58	0.17	2.3	
		Week 34	Tezepelumab	44	42 (95.5)	-1.09 (1.03)	-3.3	-1.67	-1.00	-0.50	1.8	-0.25 [-0.68, 0.18]
			Placebo	43	42 (97.7)	-0.81 (1.20)	-3.2	-1.50	-0.83	0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of the world	Change from baseline	Week 36	Tezepelumab	44	42 (95.5)	-1.12 (0.98)	-3.2	-1.67	-1.00	-0.50	1.5	-0.36 [-0.79, 0.07]
			Placebo	43	42 (97.7)	-0.73 (1.18)	-3.2	-1.33	-0.92	0.17	2.3	
		Week 38	Tezepelumab	44	42 (95.5)	-1.11 (1.02)	-3.5	-1.67	-1.00	-0.50	0.8	-0.25 [-0.68, 0.18]
			Placebo	43	42 (97.7)	-0.83 (1.18)	-3.2	-1.50	-1.00	0.17	2.3	
		Week 40	Tezepelumab	44	42 (95.5)	-1.02 (1.05)	-3.8	-1.50	-0.83	-0.67	1.2	-0.25 [-0.68, 0.18]
			Placebo	43	42 (97.7)	-0.75 (1.12)	-3.2	-1.50	-0.83	0.17	2.3	
		Week 42	Tezepelumab	44	42 (95.5)	-1.15 (0.97)	-3.2	-1.67	-1.17	-0.50	0.8	-0.43 [-0.86, 0.01]
			Placebo	43	42 (97.7)	-0.71 (1.10)	-3.2	-1.33	-0.83	0.17	2.3	
		Week 44	Tezepelumab	44	42 (95.5)	-1.09 (1.00)	-3.5	-1.50	-1.00	-0.50	1.0	-0.34 [-0.77, 0.10]
			Placebo	43	42 (97.7)	-0.73 (1.10)	-3.0	-1.50	-0.83	0.17	2.3	
		Week 46	Tezepelumab	44	42 (95.5)	-1.10 (0.96)	-3.3	-1.50	-0.92	-0.50	1.0	-0.34 [-0.77, 0.10]
			Placebo	43	42 (97.7)	-0.74 (1.16)	-3.2	-1.33	-0.92	0.17	2.3	
		Week 48	Tezepelumab	44	42 (95.5)	-1.05 (0.99)	-3.2	-1.83	-0.83	-0.50	1.2	-0.32 [-0.75, 0.11]
			Placebo	43	42 (97.7)	-0.70 (1.20)	-3.2	-1.33	-0.83	0.33	2.3	
		Week 50	Tezepelumab	44	42 (95.5)	-1.12 (1.01)	-3.5	-1.83	-0.92	-0.50	1.2	-0.30 [-0.73, 0.13]
			Placebo	43	42 (97.7)	-0.80 (1.12)	-3.0	-1.50	-1.00	-0.17	2.3	
		Week 52	Tezepelumab	44	42 (95.5)	-1.14 (1.02)	-3.5	-1.83	-0.92	-0.50	1.2	-0.35 [-0.78, 0.08]
			Placebo	43	42 (97.7)	-0.77 (1.12)	-3.0	-1.50	-1.00	0.00	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 2	Placebo	1	1 (100.0)	1.50	1.5	1.50	1.50	1.50	1.5	
		Week 4	Placebo	1	1 (100.0)	2.33	2.3	2.33	2.33	2.33	2.3	
		Week 6	Placebo	1	1 (100.0)	1.83	1.8	1.83	1.83	1.83	1.8	
		Week 8	Placebo	1	1 (100.0)	2.33	2.3	2.33	2.33	2.33	2.3	
		Week 10	Placebo	1	1 (100.0)	1.83	1.8	1.83	1.83	1.83	1.8	
		Week 12	Placebo	1	1 (100.0)	2.33	2.3	2.33	2.33	2.33	2.3	
		Week 14	Placebo	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
		Week 16	Placebo	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
		Week 18	Placebo	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
		Week 20	Placebo	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	
		Week 22	Placebo	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
		Week 24	Placebo	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	
		Week 26	Placebo	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
		Week 28	Placebo	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
		Week 30	Placebo	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
		Week 32	Placebo	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
		Week 34	Placebo	1	1 (100.0)	2.83	2.8	2.83	2.83	2.83	2.8	
		Week 36	Placebo	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
		Week 38	Placebo	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
		Week 40	Placebo	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
		Week 42	Placebo	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
		Week 44	Placebo	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
		Week 46	Placebo	1	1 (100.0)	2.33	2.3	2.33	2.33	2.33	2.3	
		Week 48	Placebo	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
		Week 50	Placebo	1	1 (100.0)	2.83	2.8	2.83	2.83	2.83	2.8	
		Week 52	Placebo	1	1 (100.0)	2.83	2.8	2.83	2.83	2.83	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 2	Placebo	1	1 (100.0)	0.17	0.2	0.17	0.17	0.17	0.2	
		Week 4	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 6	Placebo	1	1 (100.0)	0.50	0.5	0.50	0.50	0.50	0.5	
		Week 8	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 10	Placebo	1	1 (100.0)	0.50	0.5	0.50	0.50	0.50	0.5	
		Week 12	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 14	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 16	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 18	Placebo	1	1 (100.0)	0.83	0.8	0.83	0.83	0.83	0.8	
		Week 20	Placebo	1	1 (100.0)	1.17	1.2	1.17	1.17	1.17	1.2	
		Week 22	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 24	Placebo	1	1 (100.0)	1.67	1.7	1.67	1.67	1.67	1.7	
		Week 26	Placebo	1	1 (100.0)	0.67	0.7	0.67	0.67	0.67	0.7	
		Week 28	Placebo	1	1 (100.0)	0.83	0.8	0.83	0.83	0.83	0.8	
		Week 30	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 32	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 34	Placebo	1	1 (100.0)	1.50	1.5	1.50	1.50	1.50	1.5	
		Week 36	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 38	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 40	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 42	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 44	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 46	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 48	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 50	Placebo	1	1 (100.0)	1.50	1.5	1.50	1.50	1.50	1.5	
		Week 52	Placebo	1	1 (100.0)	1.50	1.5	1.50	1.50	1.50	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	39	39 (100.0)	2.50 (0.83)	0.0	2.00	2.50	3.00	4.3	
			Placebo	43	43 (100.0)	2.57 (0.74)	0.3	2.17	2.50	3.00	4.3	
		Week 2	Tezepelumab	39	38 (97.4)	1.76 (0.84)	0.0	1.17	1.83	2.33	3.7	
			Placebo	43	40 (93.0)	2.23 (0.98)	0.2	1.67	2.17	2.83	4.8	
		Week 4	Tezepelumab	39	38 (97.4)	1.44 (0.93)	0.0	0.50	1.50	2.17	3.3	
			Placebo	43	40 (93.0)	2.12 (0.87)	0.7	1.50	2.08	2.67	4.2	
		Week 6	Tezepelumab	39	38 (97.4)	1.34 (0.91)	0.0	0.50	1.50	2.00	3.2	
			Placebo	43	40 (93.0)	1.95 (0.98)	0.2	1.17	2.00	2.58	4.7	
		Week 8	Tezepelumab	39	38 (97.4)	1.28 (0.90)	0.0	0.50	1.17	2.00	2.8	
			Placebo	43	40 (93.0)	1.96 (0.98)	0.0	1.17	1.92	2.58	4.7	
		Week 10	Tezepelumab	39	38 (97.4)	1.18 (0.88)	0.0	0.50	1.08	1.83	3.3	
			Placebo	43	40 (93.0)	1.90 (0.96)	0.0	1.08	2.00	2.42	4.2	
		Week 12	Tezepelumab	39	38 (97.4)	0.95 (0.80)	0.0	0.17	0.83	1.50	2.7	
			Placebo	43	40 (93.0)	1.86 (0.96)	0.0	1.17	1.92	2.50	4.3	
		Week 14	Tezepelumab	39	38 (97.4)	0.84 (0.72)	0.0	0.17	0.83	1.17	2.8	
			Placebo	43	40 (93.0)	1.85 (1.04)	0.0	1.25	1.83	2.50	5.0	
		Week 16	Tezepelumab	39	38 (97.4)	1.15 (0.92)	0.0	0.50	1.00	1.67	3.0	
			Placebo	43	40 (93.0)	1.73 (1.11)	0.0	0.92	1.50	2.50	4.5	
		Week 18	Tezepelumab	39	38 (97.4)	0.94 (0.77)	0.0	0.17	0.83	1.50	3.0	
			Placebo	43	40 (93.0)	1.65 (1.02)	0.0	1.00	1.67	2.33	4.5	
		Week 20	Tezepelumab	39	38 (97.4)	1.03 (0.82)	0.0	0.33	1.00	1.33	2.7	
			Placebo	43	40 (93.0)	1.74 (1.12)	0.0	0.83	1.58	2.75	4.5	
		Week 22	Tezepelumab	39	38 (97.4)	1.06 (0.82)	0.0	0.33	1.00	1.67	2.8	
			Placebo	43	40 (93.0)	1.70 (1.16)	0.0	0.83	1.50	2.67	4.5	
		Week 24	Tezepelumab	39	38 (97.4)	1.04 (0.85)	0.0	0.17	1.00	1.67	2.7	
			Placebo	43	40 (93.0)	1.74 (1.09)	0.0	0.83	1.67	2.58	4.5	
		Week 26	Tezepelumab	39	38 (97.4)	1.01 (0.81)	0.0	0.33	1.00	1.67	3.5	
			Placebo	43	40 (93.0)	1.70 (1.09)	0.0	1.00	1.50	2.42	4.5	
		Week 28	Tezepelumab	39	38 (97.4)	1.08 (0.91)	0.0	0.33	1.00	1.67	3.5	
			Placebo	43	41 (95.3)	1.75 (1.19)	0.0	1.00	1.50	2.50	4.5	
		Week 30	Tezepelumab	39	39 (100.0)	1.05 (0.82)	0.0	0.50	0.83	1.50	3.2	
			Placebo	43	41 (95.3)	1.83 (1.16)	0.0	0.83	1.83	2.83	4.5	
		Week 32	Tezepelumab	39	39 (100.0)	1.01 (0.80)	0.0	0.33	1.00	1.67	2.5	
			Placebo	43	41 (95.3)	1.64 (1.19)	0.0	0.67	1.17	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
18.5 - < 25.0 kg/m**2	Absolute values	Week 34	Tezepelumab	39	39 (100.0)	0.94 (0.83)	0.0	0.00	1.00	1.33	3.3	
			Placebo	43	41 (95.3)	1.56 (1.18)	0.0	0.67	1.33	2.33	4.5	
		Week 36	Tezepelumab	39	39 (100.0)	1.03 (0.94)	0.0	0.17	0.83	1.67	4.5	
			Placebo	43	41 (95.3)	1.72 (1.22)	0.0	0.83	1.83	2.67	4.5	
		Week 38	Tezepelumab	39	39 (100.0)	1.00 (0.82)	0.0	0.17	1.00	1.67	3.0	
			Placebo	43	41 (95.3)	1.63 (1.28)	0.0	0.50	1.50	2.67	4.5	
		Week 40	Tezepelumab	39	39 (100.0)	1.00 (0.87)	0.0	0.00	0.83	1.83	2.7	
			Placebo	43	41 (95.3)	1.66 (1.15)	0.0	0.83	1.67	2.50	4.5	
		Week 42	Tezepelumab	39	39 (100.0)	0.96 (0.75)	0.0	0.17	1.00	1.67	2.3	
			Placebo	43	41 (95.3)	1.62 (1.24)	0.0	0.67	1.33	2.67	4.7	
		Week 44	Tezepelumab	39	39 (100.0)	0.95 (0.87)	0.0	0.00	0.83	1.50	3.5	
			Placebo	43	42 (97.7)	1.78 (1.14)	0.0	0.83	1.83	2.67	4.5	
		Week 46	Tezepelumab	39	39 (100.0)	0.90 (0.73)	0.0	0.17	0.83	1.33	2.3	
			Placebo	43	42 (97.7)	1.60 (1.13)	0.0	0.83	1.67	2.33	4.5	
		Week 48	Tezepelumab	39	39 (100.0)	1.03 (0.84)	0.0	0.17	1.00	1.67	2.8	
			Placebo	43	42 (97.7)	1.70 (1.16)	0.0	0.67	1.92	2.50	4.5	
		Week 50	Tezepelumab	39	39 (100.0)	0.97 (0.75)	0.0	0.17	1.00	1.67	2.5	
			Placebo	43	42 (97.7)	1.57 (1.05)	0.0	0.83	1.33	2.33	4.5	
		Week 52	Tezepelumab	39	39 (100.0)	0.98 (0.75)	0.0	0.33	1.00	1.67	2.5	
			Placebo	43	42 (97.7)	1.62 (1.07)	0.0	0.83	1.42	2.33	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	39	38 (97.4)	-0.71 (0.61)	-2.0	-1.17	-0.67	-0.17	0.3	-0.40 [-0.85, 0.05]
			Placebo	43	40 (93.0)	-0.42 (0.85)	-2.8	-0.83	-0.33	0.17	1.0	
		Week 4	Tezepelumab	39	38 (97.4)	-1.04 (1.02)	-3.5	-1.50	-0.92	-0.50	1.7	-0.57 [-1.02, -0.11]
			Placebo	43	40 (93.0)	-0.53 (0.75)	-2.0	-1.00	-0.42	0.00	0.8	
		Week 6	Tezepelumab	39	38 (97.4)	-1.13 (0.99)	-3.8	-1.83	-1.08	-0.33	0.3	-0.48 [-0.93, -0.03]
			Placebo	43	40 (93.0)	-0.70 (0.79)	-2.2	-1.33	-0.58	-0.17	0.8	
		Week 8	Tezepelumab	39	38 (97.4)	-1.20 (1.03)	-3.8	-1.83	-1.00	-0.50	0.7	-0.55 [-1.00, -0.10]
			Placebo	43	40 (93.0)	-0.69 (0.81)	-2.5	-1.08	-0.67	-0.08	1.0	
		Week 10	Tezepelumab	39	38 (97.4)	-1.29 (1.02)	-3.8	-2.00	-1.42	-0.67	0.8	-0.56 [-1.01, -0.11]
			Placebo	43	40 (93.0)	-0.75 (0.89)	-2.7	-1.33	-0.58	0.00	0.7	
		Week 12	Tezepelumab	39	38 (97.4)	-1.52 (0.93)	-3.7	-2.00	-1.67	-0.83	0.7	-0.83 [-1.29, -0.36]
			Placebo	43	40 (93.0)	-0.79 (0.85)	-2.8	-1.08	-0.75	-0.08	0.8	
		Week 14	Tezepelumab	39	38 (97.4)	-1.63 (1.01)	-3.8	-2.17	-1.83	-1.00	0.8	-0.88 [-1.35, -0.42]
			Placebo	43	40 (93.0)	-0.80 (0.89)	-3.0	-1.33	-0.83	-0.25	1.0	
		Week 16	Tezepelumab	39	38 (97.4)	-1.32 (1.04)	-3.8	-2.00	-1.42	-0.50	0.8	-0.40 [-0.85, 0.05]
			Placebo	43	40 (93.0)	-0.92 (0.95)	-3.5	-1.58	-0.83	-0.25	0.8	
		Week 18	Tezepelumab	39	38 (97.4)	-1.53 (1.00)	-3.8	-2.17	-1.58	-0.83	0.5	-0.57 [-1.02, -0.11]
			Placebo	43	40 (93.0)	-1.00 (0.89)	-3.2	-1.58	-0.83	-0.33	0.3	
		Week 20	Tezepelumab	39	38 (97.4)	-1.44 (0.97)	-3.8	-2.00	-1.50	-0.67	0.7	-0.53 [-0.98, -0.08]
			Placebo	43	40 (93.0)	-0.91 (1.04)	-3.5	-1.67	-0.83	-0.17	1.0	
		Week 22	Tezepelumab	39	38 (97.4)	-1.41 (1.10)	-3.8	-2.17	-1.67	-0.50	1.8	-0.44 [-0.89, 0.01]
			Placebo	43	40 (93.0)	-0.95 (1.01)	-3.2	-1.67	-0.83	-0.25	1.2	
		Week 24	Tezepelumab	39	38 (97.4)	-1.43 (0.92)	-3.8	-2.00	-1.67	-0.67	0.2	-0.54 [-0.99, -0.08]
			Placebo	43	40 (93.0)	-0.91 (1.01)	-3.5	-1.50	-0.83	0.00	1.0	
		Week 26	Tezepelumab	39	38 (97.4)	-1.46 (0.94)	-3.8	-2.00	-1.50	-0.67	0.2	-0.51 [-0.96, -0.06]
			Placebo	43	40 (93.0)	-0.95 (1.05)	-4.0	-1.50	-1.00	-0.33	1.5	
		Week 28	Tezepelumab	39	38 (97.4)	-1.39 (0.94)	-3.8	-2.00	-1.42	-0.67	0.2	-0.54 [-0.99, -0.09]
			Placebo	43	41 (95.3)	-0.85 (1.08)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	39	39 (100.0)	-1.44 (0.97)	-3.7	-2.00	-1.50	-0.67	0.5	-0.67 [-1.12, -0.22]
			Placebo	43	41 (95.3)	-0.76 (1.05)	-3.2	-1.50	-0.83	-0.33	2.0	
		Week 32	Tezepelumab	39	39 (100.0)	-1.49 (0.92)	-3.8	-2.17	-1.50	-0.83	0.7	-0.54 [-0.99, -0.09]
			Placebo	43	41 (95.3)	-0.96 (1.04)	-3.5	-1.67	-1.00	-0.33	1.5	
		Week 34	Tezepelumab	39	39 (100.0)	-1.56 (0.93)	-3.8	-2.17	-1.67	-0.83	0.3	-0.52 [-0.96, -0.07]
			Placebo	43	41 (95.3)	-1.03 (1.09)	-4.0	-1.83	-1.00	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
18.5 - < 25.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	39	39 (100.0)	-1.47 (1.07)	-3.8	-2.17	-1.50	-0.83	1.7	-0.54 [-0.98, -0.09]
			Placebo	43	41 (95.3)	-0.88 (1.13)	-3.5	-1.67	-1.00	0.00	1.5	
		Week 38	Tezepelumab	39	39 (100.0)	-1.49 (0.98)	-3.8	-2.00	-1.50	-0.83	0.3	-0.49 [-0.93, -0.04]
			Placebo	43	41 (95.3)	-0.96 (1.17)	-4.0	-1.83	-0.83	-0.17	1.5	
		Week 40	Tezepelumab	39	39 (100.0)	-1.50 (1.00)	-3.8	-2.17	-1.50	-0.83	0.7	-0.55 [-0.99, -0.10]
			Placebo	43	41 (95.3)	-0.93 (1.06)	-4.0	-1.67	-0.83	-0.33	1.2	
		Week 42	Tezepelumab	39	39 (100.0)	-1.54 (0.99)	-3.8	-2.17	-1.50	-0.50	0.2	-0.53 [-0.97, -0.08]
			Placebo	43	41 (95.3)	-0.97 (1.15)	-4.0	-1.67	-1.00	-0.17	1.3	
		Week 44	Tezepelumab	39	39 (100.0)	-1.54 (1.06)	-3.8	-2.17	-1.50	-0.83	1.0	-0.68 [-1.13, -0.24]
			Placebo	43	42 (97.7)	-0.81 (1.07)	-4.0	-1.50	-0.83	0.00	1.5	
		Week 46	Tezepelumab	39	39 (100.0)	-1.59 (0.95)	-3.8	-2.17	-1.50	-0.83	0.2	-0.58 [-1.03, -0.14]
			Placebo	43	42 (97.7)	-0.99 (1.12)	-4.0	-1.67	-1.17	-0.33	1.3	
		Week 48	Tezepelumab	39	39 (100.0)	-1.47 (0.96)	-3.8	-2.00	-1.50	-0.67	0.2	-0.56 [-1.00, -0.11]
			Placebo	43	42 (97.7)	-0.89 (1.10)	-3.7	-1.67	-0.83	-0.33	1.7	
		Week 50	Tezepelumab	39	39 (100.0)	-1.53 (0.92)	-3.8	-2.17	-1.50	-0.83	0.5	-0.53 [-0.97, -0.09]
			Placebo	43	42 (97.7)	-1.02 (0.98)	-4.0	-1.67	-0.92	-0.33	1.0	
		Week 52	Tezepelumab	39	39 (100.0)	-1.51 (0.92)	-3.8	-2.17	-1.50	-0.83	0.3	-0.57 [-1.01, -0.12]
			Placebo	43	42 (97.7)	-0.97 (0.98)	-4.0	-1.67	-0.83	-0.33	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	45	45 (100.0)	2.73 (0.89)	0.3	2.33	2.67	3.00	4.8	
			Placebo	47	47 (100.0)	2.66 (0.70)	1.2	2.17	2.67	3.00	4.5	
		Week 2	Tezepelumab	45	44 (97.8)	2.21 (0.99)	0.0	1.67	2.17	2.83	4.3	
			Placebo	47	44 (93.6)	2.26 (0.65)	1.0	1.92	2.33	2.83	3.3	
		Week 4	Tezepelumab	45	44 (97.8)	1.96 (1.01)	0.0	1.17	2.08	2.75	4.3	
			Placebo	47	44 (93.6)	2.25 (0.85)	0.5	1.58	2.33	2.83	4.2	
		Week 6	Tezepelumab	45	44 (97.8)	1.88 (0.94)	0.0	1.33	1.67	2.58	4.3	
			Placebo	47	45 (95.7)	2.17 (0.81)	0.3	1.67	2.33	2.67	3.8	
		Week 8	Tezepelumab	45	44 (97.8)	1.83 (1.08)	0.0	1.08	1.75	2.67	4.3	
			Placebo	47	45 (95.7)	2.04 (0.92)	0.2	1.33	2.17	2.67	4.0	
		Week 10	Tezepelumab	45	44 (97.8)	1.74 (1.12)	0.0	1.17	1.50	2.50	4.3	
			Placebo	47	45 (95.7)	2.08 (1.00)	0.0	1.33	2.17	2.67	5.3	
		Week 12	Tezepelumab	45	44 (97.8)	1.69 (1.18)	0.0	0.67	1.50	2.50	4.3	
			Placebo	47	45 (95.7)	2.07 (1.01)	0.0	1.33	2.17	2.67	4.3	
		Week 14	Tezepelumab	45	44 (97.8)	1.66 (1.17)	0.0	0.75	1.50	2.42	4.3	
			Placebo	47	45 (95.7)	1.96 (0.93)	0.0	1.33	2.17	2.67	5.0	
		Week 16	Tezepelumab	45	44 (97.8)	1.60 (1.18)	0.0	0.58	1.42	2.50	4.3	
			Placebo	47	45 (95.7)	2.13 (1.05)	0.0	1.50	2.17	2.83	5.0	
		Week 18	Tezepelumab	45	44 (97.8)	1.62 (1.11)	0.0	0.83	1.42	2.33	4.3	
			Placebo	47	45 (95.7)	2.06 (0.94)	0.0	1.50	2.17	2.50	5.0	
		Week 20	Tezepelumab	45	44 (97.8)	1.66 (1.15)	0.0	0.58	1.75	2.50	4.3	
			Placebo	47	45 (95.7)	2.09 (1.06)	0.0	1.33	2.33	2.67	5.0	
		Week 22	Tezepelumab	45	44 (97.8)	1.71 (1.12)	0.0	0.83	1.83	2.42	4.3	
			Placebo	47	45 (95.7)	2.10 (1.04)	0.0	1.50	2.33	2.83	5.0	
		Week 24	Tezepelumab	45	44 (97.8)	1.71 (1.23)	0.0	0.50	1.67	2.42	4.3	
			Placebo	47	45 (95.7)	2.05 (1.01)	0.0	1.50	2.33	2.67	4.2	
		Week 26	Tezepelumab	45	44 (97.8)	1.63 (1.13)	0.0	0.75	1.50	2.33	4.3	
			Placebo	47	45 (95.7)	2.06 (1.01)	0.0	1.33	2.17	2.83	4.2	
		Week 28	Tezepelumab	45	45 (100.0)	1.60 (1.16)	0.0	0.50	1.50	2.50	4.3	
			Placebo	47	45 (95.7)	2.09 (1.02)	0.0	1.33	2.33	2.67	4.2	
		Week 30	Tezepelumab	45	45 (100.0)	1.60 (1.13)	0.0	0.67	1.50	2.17	4.3	
			Placebo	47	45 (95.7)	2.04 (1.03)	0.0	1.33	2.17	2.67	4.2	
		Week 32	Tezepelumab	45	45 (100.0)	1.47 (1.21)	0.0	0.33	1.17	2.00	4.3	
			Placebo	47	45 (95.7)	2.00 (1.01)	0.0	1.33	2.17	2.67	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
25.0 - < 30.0 kg/m**2	Absolute values	Week 34	Tezepelumab	45	45 (100.0)	1.56 (1.21)	0.0	0.67	1.33	2.50	4.3	
			Placebo	47	45 (95.7)	2.01 (1.03)	0.0	1.17	2.33	2.67	4.2	
		Week 36	Tezepelumab	45	45 (100.0)	1.68 (1.15)	0.0	0.67	1.67	2.50	4.3	
			Placebo	47	45 (95.7)	2.11 (0.99)	0.0	1.33	2.33	2.67	4.2	
		Week 38	Tezepelumab	45	45 (100.0)	1.47 (1.15)	0.0	0.50	1.33	2.17	4.3	
			Placebo	47	45 (95.7)	1.96 (0.93)	0.0	1.33	2.17	2.50	4.2	
		Week 40	Tezepelumab	45	45 (100.0)	1.52 (1.17)	0.0	0.50	1.50	2.50	4.3	
			Placebo	47	45 (95.7)	2.03 (0.99)	0.0	1.33	2.00	2.67	4.2	
		Week 42	Tezepelumab	45	45 (100.0)	1.53 (1.23)	0.0	0.67	1.50	2.17	4.7	
			Placebo	47	45 (95.7)	2.03 (0.92)	0.0	1.50	2.17	2.50	4.5	
		Week 44	Tezepelumab	45	45 (100.0)	1.50 (1.11)	0.0	0.50	1.33	2.33	4.3	
			Placebo	47	45 (95.7)	1.97 (0.94)	0.0	1.17	2.17	2.50	4.2	
		Week 46	Tezepelumab	45	45 (100.0)	1.47 (1.15)	0.0	0.67	1.17	2.33	4.3	
			Placebo	47	45 (95.7)	1.92 (0.92)	0.0	1.50	2.00	2.50	3.8	
		Week 48	Tezepelumab	45	45 (100.0)	1.53 (1.17)	0.0	0.67	1.33	2.50	4.3	
			Placebo	47	45 (95.7)	1.89 (0.99)	0.0	1.17	2.17	2.67	3.8	
		Week 50	Tezepelumab	45	45 (100.0)	1.45 (1.13)	0.0	0.67	1.17	2.33	4.3	
			Placebo	47	45 (95.7)	2.04 (0.92)	0.0	1.33	2.17	2.67	3.8	
		Week 52	Tezepelumab	45	45 (100.0)	1.50 (1.13)	0.0	0.67	1.33	2.33	4.3	
			Placebo	47	45 (95.7)	2.05 (0.98)	0.0	1.50	2.17	2.67	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	45	44 (97.8)	-0.53 (0.68)	-2.5	-0.92	-0.42	0.00	0.7	-0.25 [-0.67, 0.17]
			Placebo	47	44 (93.6)	-0.36 (0.67)	-2.2	-0.83	-0.25	0.00	1.2	
		Week 4	Tezepelumab	45	44 (97.8)	-0.78 (0.92)	-2.5	-1.42	-0.83	-0.25	2.3	-0.47 [-0.89, -0.04]
			Placebo	47	44 (93.6)	-0.36 (0.87)	-2.7	-1.00	-0.17	0.17	1.2	
		Week 6	Tezepelumab	45	44 (97.8)	-0.86 (1.05)	-3.0	-1.33	-1.00	-0.33	2.3	-0.45 [-0.87, -0.03]
			Placebo	47	45 (95.7)	-0.43 (0.85)	-2.8	-0.83	-0.33	0.00	1.5	
		Week 8	Tezepelumab	45	44 (97.8)	-0.91 (1.07)	-3.0	-1.50	-1.00	-0.33	2.3	-0.36 [-0.77, 0.06]
			Placebo	47	45 (95.7)	-0.56 (0.89)	-3.2	-1.00	-0.50	0.17	1.0	
		Week 10	Tezepelumab	45	44 (97.8)	-1.00 (1.12)	-3.5	-1.50	-0.83	-0.50	2.3	-0.43 [-0.86, -0.01]
			Placebo	47	45 (95.7)	-0.52 (1.07)	-3.3	-0.83	-0.50	-0.17	2.7	
		Week 12	Tezepelumab	45	44 (97.8)	-1.05 (1.12)	-3.7	-1.67	-1.17	-0.42	2.3	-0.48 [-0.90, -0.06]
			Placebo	47	45 (95.7)	-0.54 (1.01)	-3.3	-1.00	-0.50	0.00	1.3	
		Week 14	Tezepelumab	45	44 (97.8)	-1.08 (1.15)	-3.8	-1.83	-1.08	-0.33	2.3	-0.40 [-0.82, 0.01]
			Placebo	47	45 (95.7)	-0.65 (0.96)	-3.0	-1.17	-0.67	-0.17	2.3	
		Week 16	Tezepelumab	45	44 (97.8)	-1.14 (1.16)	-4.2	-2.00	-1.00	-0.42	2.3	-0.59 [-1.02, -0.17]
			Placebo	47	45 (95.7)	-0.47 (1.09)	-3.2	-1.00	-0.50	0.17	2.3	
		Week 18	Tezepelumab	45	44 (97.8)	-1.11 (1.20)	-4.2	-1.83	-1.17	-0.42	2.3	-0.51 [-0.94, -0.09]
			Placebo	47	45 (95.7)	-0.55 (1.00)	-3.2	-1.00	-0.50	0.00	2.3	
		Week 20	Tezepelumab	45	44 (97.8)	-1.08 (1.20)	-4.2	-1.83	-1.00	-0.33	2.3	-0.50 [-0.92, -0.07]
			Placebo	47	45 (95.7)	-0.51 (1.08)	-3.2	-1.00	-0.33	-0.17	2.3	
		Week 22	Tezepelumab	45	44 (97.8)	-1.03 (1.22)	-4.3	-1.67	-0.92	-0.33	2.3	-0.46 [-0.88, -0.04]
			Placebo	47	45 (95.7)	-0.50 (1.07)	-3.3	-1.17	-0.50	0.33	2.3	
		Week 24	Tezepelumab	45	44 (97.8)	-1.03 (1.21)	-4.5	-1.75	-0.83	-0.33	2.3	-0.42 [-0.84, 0.00]
			Placebo	47	45 (95.7)	-0.56 (1.05)	-3.2	-1.17	-0.50	0.00	2.3	
		Week 26	Tezepelumab	45	44 (97.8)	-1.11 (1.28)	-4.2	-1.92	-1.08	-0.33	2.3	-0.48 [-0.91, -0.06]
			Placebo	47	45 (95.7)	-0.54 (1.05)	-2.8	-1.17	-0.33	0.17	2.3	
		Week 28	Tezepelumab	45	45 (100.0)	-1.13 (1.22)	-4.2	-2.00	-1.00	-0.17	2.3	-0.54 [-0.96, -0.12]
			Placebo	47	45 (95.7)	-0.51 (1.05)	-2.8	-1.00	-0.33	0.00	2.3	
		Week 30	Tezepelumab	45	45 (100.0)	-1.13 (1.24)	-4.2	-2.17	-1.00	-0.33	2.3	-0.49 [-0.90, -0.07]
			Placebo	47	45 (95.7)	-0.56 (1.09)	-2.8	-1.17	-0.67	0.17	2.3	
		Week 32	Tezepelumab	45	45 (100.0)	-1.26 (1.33)	-4.2	-2.17	-1.33	-0.67	2.3	-0.55 [-0.97, -0.13]
			Placebo	47	45 (95.7)	-0.60 (1.04)	-2.8	-1.17	-0.33	-0.17	2.3	
		Week 34	Tezepelumab	45	45 (100.0)	-1.17 (1.29)	-4.2	-2.17	-1.17	-0.33	2.3	-0.50 [-0.92, -0.08]
			Placebo	47	45 (95.7)	-0.59 (1.04)	-2.8	-1.17	-0.50	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
25.0 - < 30.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	45	45 (100.0)	-1.05 (1.31)	-4.2	-2.17	-1.00	-0.17	2.3	-0.47 [-0.89, -0.05]
			Placebo	47	45 (95.7)	-0.50 (1.02)	-2.7	-1.17	-0.33	0.00	2.3	
		Week 38	Tezepelumab	45	45 (100.0)	-1.26 (1.31)	-4.2	-2.17	-1.33	-0.17	2.3	-0.52 [-0.94, -0.10]
			Placebo	47	45 (95.7)	-0.64 (1.07)	-2.7	-1.17	-0.67	0.00	2.3	
		Week 40	Tezepelumab	45	45 (100.0)	-1.21 (1.35)	-4.2	-2.17	-1.17	-0.33	2.3	-0.52 [-0.94, -0.10]
			Placebo	47	45 (95.7)	-0.58 (1.03)	-2.7	-1.17	-0.50	0.00	2.3	
		Week 42	Tezepelumab	45	45 (100.0)	-1.20 (1.33)	-4.2	-2.17	-1.33	-0.50	2.3	-0.53 [-0.95, -0.11]
			Placebo	47	45 (95.7)	-0.57 (0.99)	-2.7	-1.17	-0.67	0.00	2.3	
		Week 44	Tezepelumab	45	45 (100.0)	-1.23 (1.30)	-4.3	-2.17	-1.17	-0.17	2.3	-0.51 [-0.93, -0.09]
			Placebo	47	45 (95.7)	-0.63 (0.99)	-2.7	-1.33	-0.50	-0.17	2.3	
		Week 46	Tezepelumab	45	45 (100.0)	-1.26 (1.30)	-4.2	-2.17	-1.33	-0.33	2.3	-0.49 [-0.91, -0.08]
			Placebo	47	45 (95.7)	-0.69 (0.99)	-2.8	-1.33	-0.67	0.00	2.3	
		Week 48	Tezepelumab	45	45 (100.0)	-1.20 (1.34)	-4.2	-2.17	-1.17	-0.17	2.3	-0.41 [-0.83, 0.01]
			Placebo	47	45 (95.7)	-0.71 (1.03)	-2.8	-1.33	-0.67	-0.17	2.3	
		Week 50	Tezepelumab	45	45 (100.0)	-1.28 (1.31)	-4.2	-2.17	-1.50	-0.50	2.3	-0.61 [-1.04, -0.19]
			Placebo	47	45 (95.7)	-0.56 (1.00)	-2.7	-1.17	-0.50	0.00	2.3	
		Week 52	Tezepelumab	45	45 (100.0)	-1.23 (1.33)	-4.2	-2.17	-1.17	-0.33	2.3	-0.57 [-0.99, -0.15]
			Placebo	47	45 (95.7)	-0.55 (1.04)	-2.7	-1.17	-0.50	0.00	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	53	53 (100.0)	2.83 (0.66)	1.7	2.50	2.83	3.17	4.8	
			Placebo	47	47 (100.0)	2.75 (0.61)	1.5	2.33	2.67	3.17	4.7	
		Week 2	Tezepelumab	53	49 (92.5)	2.45 (0.79)	0.0	2.17	2.67	2.83	4.2	
			Placebo	47	40 (85.1)	2.43 (0.74)	0.5	2.08	2.42	2.83	4.7	
		Week 4	Tezepelumab	53	49 (92.5)	2.17 (0.81)	0.2	1.67	2.33	2.67	3.5	
			Placebo	47	40 (85.1)	2.15 (0.82)	0.2	1.83	2.25	2.50	4.0	
		Week 6	Tezepelumab	53	49 (92.5)	2.07 (0.92)	0.2	1.50	2.00	2.83	4.0	
			Placebo	47	40 (85.1)	2.13 (1.11)	0.2	1.33	2.17	2.67	5.5	
		Week 8	Tezepelumab	53	49 (92.5)	2.00 (0.97)	0.0	1.50	1.83	2.67	4.8	
			Placebo	47	41 (87.2)	2.15 (0.99)	0.0	1.67	2.33	2.83	4.7	
		Week 10	Tezepelumab	53	49 (92.5)	1.95 (0.87)	0.0	1.33	1.83	2.67	3.7	
			Placebo	47	42 (89.4)	1.95 (0.80)	0.2	1.33	2.08	2.67	3.2	
		Week 12	Tezepelumab	53	49 (92.5)	1.99 (0.80)	0.0	1.50	2.17	2.67	3.3	
			Placebo	47	42 (89.4)	1.74 (0.82)	0.0	1.17	1.83	2.17	3.3	
		Week 14	Tezepelumab	53	49 (92.5)	1.76 (0.81)	0.0	1.33	1.67	2.17	4.2	
			Placebo	47	42 (89.4)	1.69 (0.76)	0.0	1.00	1.75	2.17	3.2	
		Week 16	Tezepelumab	53	49 (92.5)	1.97 (0.89)	0.0	1.33	2.00	2.50	4.3	
			Placebo	47	42 (89.4)	2.01 (0.90)	0.0	1.50	1.92	2.67	4.8	
		Week 18	Tezepelumab	53	50 (94.3)	1.81 (0.79)	0.0	1.33	1.83	2.33	4.2	
			Placebo	47	42 (89.4)	1.85 (0.99)	0.0	1.17	1.83	2.50	4.7	
		Week 20	Tezepelumab	53	50 (94.3)	1.93 (0.87)	0.0	1.33	1.83	2.50	5.0	
			Placebo	47	42 (89.4)	1.89 (0.79)	0.2	1.50	2.00	2.50	3.2	
		Week 22	Tezepelumab	53	50 (94.3)	1.90 (0.74)	0.0	1.33	1.83	2.50	3.8	
			Placebo	47	42 (89.4)	1.77 (0.74)	0.2	1.33	1.83	2.33	3.3	
		Week 24	Tezepelumab	53	50 (94.3)	1.91 (0.80)	0.0	1.33	1.83	2.50	3.8	
			Placebo	47	42 (89.4)	1.79 (0.80)	0.2	1.17	1.92	2.50	3.3	
		Week 26	Tezepelumab	53	51 (96.2)	1.89 (0.86)	0.0	1.17	1.83	2.50	4.0	
			Placebo	47	42 (89.4)	1.68 (0.80)	0.0	1.00	1.58	2.17	3.7	
		Week 28	Tezepelumab	53	51 (96.2)	2.00 (0.82)	0.0	1.50	2.00	2.50	3.8	
			Placebo	47	42 (89.4)	1.76 (0.88)	0.0	1.00	1.83	2.33	3.7	
		Week 30	Tezepelumab	53	51 (96.2)	1.89 (0.85)	0.0	1.50	2.00	2.50	3.7	
			Placebo	47	43 (91.5)	1.69 (0.83)	0.0	1.17	1.83	2.33	3.3	
		Week 32	Tezepelumab	53	51 (96.2)	1.93 (0.80)	0.0	1.33	2.00	2.50	4.0	
			Placebo	47	43 (91.5)	1.78 (0.85)	0.2	1.17	1.83	2.50	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 30.0 kg/m**2	Absolute values	Week 34	Tezepelumab	53	51 (96.2)	1.93 (0.87)	0.0	1.17	2.00	2.50	4.2	
			Placebo	47	43 (91.5)	1.72 (0.83)	0.0	1.33	1.67	2.17	3.3	
		Week 36	Tezepelumab	53	51 (96.2)	1.97 (0.81)	0.0	1.50	2.00	2.67	3.7	
			Placebo	47	43 (91.5)	1.72 (0.85)	0.0	1.00	1.83	2.33	3.3	
		Week 38	Tezepelumab	53	51 (96.2)	1.91 (0.91)	0.0	1.17	1.83	2.50	4.5	
			Placebo	47	43 (91.5)	1.71 (0.79)	0.3	1.17	1.83	2.17	3.3	
		Week 40	Tezepelumab	53	51 (96.2)	1.93 (0.86)	0.0	1.33	2.00	2.67	3.7	
			Placebo	47	43 (91.5)	1.84 (0.96)	0.3	1.00	1.83	2.67	4.0	
		Week 42	Tezepelumab	53	51 (96.2)	1.88 (0.89)	0.0	1.33	1.67	2.50	3.8	
			Placebo	47	43 (91.5)	1.78 (0.82)	0.2	1.33	1.83	2.50	3.3	
		Week 44	Tezepelumab	53	51 (96.2)	1.97 (0.82)	0.0	1.33	2.00	2.67	3.8	
			Placebo	47	43 (91.5)	1.82 (0.97)	0.2	0.83	1.83	2.50	4.0	
		Week 46	Tezepelumab	53	51 (96.2)	1.94 (0.91)	0.0	1.17	1.83	2.67	3.8	
			Placebo	47	43 (91.5)	1.73 (0.86)	0.2	1.17	1.83	2.50	3.3	
		Week 48	Tezepelumab	53	51 (96.2)	1.96 (0.89)	0.0	1.33	2.00	2.67	4.0	
			Placebo	47	43 (91.5)	1.75 (0.89)	0.2	1.17	1.83	2.50	3.3	
		Week 50	Tezepelumab	53	51 (96.2)	1.86 (0.97)	0.0	1.17	1.67	2.33	4.2	
			Placebo	47	43 (91.5)	1.66 (0.85)	0.0	1.00	1.83	2.17	3.3	
		Week 52	Tezepelumab	53	51 (96.2)	1.87 (0.97)	0.0	1.17	1.67	2.50	4.3	
			Placebo	47	43 (91.5)	1.75 (0.91)	0.0	1.00	1.83	2.50	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	53	49 (92.5)	-0.41 (0.69)	-2.8	-0.67	-0.33	0.17	0.7	-0.11 [-0.53, 0.31]
			Placebo	47	40 (85.1)	-0.34 (0.59)	-1.5	-0.75	-0.42	0.00	1.0	
		Week 4	Tezepelumab	53	49 (92.5)	-0.68 (0.70)	-2.7	-1.17	-0.67	-0.17	0.7	-0.08 [-0.50, 0.34]
			Placebo	47	40 (85.1)	-0.62 (0.85)	-3.0	-1.17	-0.67	0.00	0.8	
		Week 6	Tezepelumab	53	49 (92.5)	-0.78 (0.82)	-2.8	-1.33	-0.83	0.00	1.2	-0.15 [-0.56, 0.27]
			Placebo	47	40 (85.1)	-0.65 (1.03)	-3.3	-1.33	-0.75	0.08	1.5	
		Week 8	Tezepelumab	53	49 (92.5)	-0.85 (0.89)	-2.8	-1.50	-0.83	-0.33	2.2	-0.24 [-0.66, 0.18]
			Placebo	47	41 (87.2)	-0.63 (0.98)	-3.0	-1.17	-0.50	0.00	1.0	
		Week 10	Tezepelumab	53	49 (92.5)	-0.90 (0.78)	-2.8	-1.33	-1.00	-0.17	0.5	-0.08 [-0.49, 0.34]
			Placebo	47	42 (89.4)	-0.84 (0.88)	-3.2	-1.33	-0.83	-0.17	0.8	
		Week 12	Tezepelumab	53	49 (92.5)	-0.86 (0.78)	-2.7	-1.33	-0.83	-0.33	0.5	0.22 [-0.19, 0.63]
			Placebo	47	42 (89.4)	-1.05 (0.93)	-3.2	-1.83	-0.83	-0.33	0.8	
		Week 14	Tezepelumab	53	49 (92.5)	-1.10 (0.74)	-2.8	-1.50	-1.00	-0.67	0.3	0.01 [-0.41, 0.42]
			Placebo	47	42 (89.4)	-1.10 (0.90)	-3.2	-1.67	-0.83	-0.50	0.7	
		Week 16	Tezepelumab	53	49 (92.5)	-0.88 (0.88)	-2.8	-1.17	-1.00	-0.50	1.5	-0.11 [-0.52, 0.30]
			Placebo	47	42 (89.4)	-0.78 (0.96)	-3.2	-1.33	-0.67	0.00	1.2	
		Week 18	Tezepelumab	53	50 (94.3)	-1.02 (0.72)	-2.8	-1.50	-0.92	-0.67	0.3	-0.09 [-0.50, 0.32]
			Placebo	47	42 (89.4)	-0.94 (1.07)	-3.2	-1.67	-1.17	-0.33	1.5	
		Week 20	Tezepelumab	53	50 (94.3)	-0.90 (0.77)	-2.5	-1.50	-0.92	-0.33	0.7	0.01 [-0.40, 0.42]
			Placebo	47	42 (89.4)	-0.90 (0.93)	-3.2	-1.33	-0.83	-0.50	1.0	
		Week 22	Tezepelumab	53	50 (94.3)	-0.93 (0.70)	-2.8	-1.33	-0.83	-0.50	0.5	0.12 [-0.29, 0.54]
			Placebo	47	42 (89.4)	-1.02 (0.81)	-3.0	-1.50	-1.00	-0.50	0.3	
		Week 24	Tezepelumab	53	50 (94.3)	-0.93 (0.73)	-2.8	-1.33	-0.92	-0.33	0.7	0.10 [-0.31, 0.51]
			Placebo	47	42 (89.4)	-1.01 (0.96)	-3.2	-1.50	-0.83	-0.33	0.7	
		Week 26	Tezepelumab	53	51 (96.2)	-0.92 (0.80)	-3.0	-1.50	-0.83	-0.33	0.7	0.23 [-0.18, 0.64]
			Placebo	47	42 (89.4)	-1.12 (0.95)	-3.2	-1.83	-1.17	-0.50	0.8	
		Week 28	Tezepelumab	53	51 (96.2)	-0.81 (0.86)	-3.0	-1.17	-0.83	-0.17	0.8	0.24 [-0.17, 0.65]
			Placebo	47	42 (89.4)	-1.04 (1.03)	-3.2	-1.67	-1.08	-0.33	1.2	
		Week 30	Tezepelumab	53	51 (96.2)	-0.92 (0.86)	-2.8	-1.50	-1.00	-0.33	1.8	0.20 [-0.21, 0.60]
			Placebo	47	43 (91.5)	-1.10 (0.94)	-3.2	-1.67	-1.17	-0.33	0.5	
		Week 32	Tezepelumab	53	51 (96.2)	-0.88 (0.74)	-2.5	-1.17	-0.83	-0.50	0.8	0.16 [-0.24, 0.57]
			Placebo	47	43 (91.5)	-1.02 (0.98)	-3.0	-1.50	-1.17	-0.33	0.7	
		Week 34	Tezepelumab	53	51 (96.2)	-0.88 (0.84)	-2.5	-1.50	-0.83	-0.50	2.0	0.23 [-0.18, 0.63]
			Placebo	47	43 (91.5)	-1.07 (0.91)	-3.2	-1.50	-1.17	-0.50	0.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 30.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	53	51 (96.2)	-0.84 (0.81)	-2.5	-1.50	-0.83	-0.50	1.5	0.26 [-0.15, 0.67]
			Placebo	47	43 (91.5)	-1.07 (0.97)	-3.5	-1.50	-1.17	-0.33	0.5	
		Week 38	Tezepelumab	53	51 (96.2)	-0.90 (0.87)	-2.5	-1.50	-1.00	-0.33	2.3	0.21 [-0.20, 0.61]
			Placebo	47	43 (91.5)	-1.08 (0.86)	-3.0	-1.50	-1.17	-0.50	0.8	
		Week 40	Tezepelumab	53	51 (96.2)	-0.88 (0.80)	-2.8	-1.33	-0.83	-0.50	1.7	0.08 [-0.33, 0.49]
			Placebo	47	43 (91.5)	-0.95 (1.03)	-3.2	-1.50	-1.00	-0.17	0.8	
		Week 42	Tezepelumab	53	51 (96.2)	-0.93 (0.83)	-2.8	-1.50	-0.83	-0.50	2.0	0.10 [-0.31, 0.50]
			Placebo	47	43 (91.5)	-1.01 (0.90)	-3.2	-1.50	-1.17	-0.33	0.7	
		Week 44	Tezepelumab	53	51 (96.2)	-0.84 (0.81)	-2.5	-1.33	-0.83	-0.33	1.5	0.14 [-0.27, 0.55]
			Placebo	47	43 (91.5)	-0.97 (1.09)	-3.3	-1.83	-0.83	0.00	0.8	
		Week 46	Tezepelumab	53	51 (96.2)	-0.87 (0.87)	-2.8	-1.50	-0.83	-0.17	1.7	0.22 [-0.19, 0.62]
			Placebo	47	43 (91.5)	-1.06 (0.95)	-3.0	-1.67	-1.17	-0.33	0.8	
		Week 48	Tezepelumab	53	51 (96.2)	-0.85 (0.86)	-2.5	-1.50	-0.83	-0.33	1.8	0.21 [-0.20, 0.61]
			Placebo	47	43 (91.5)	-1.04 (1.01)	-3.3	-1.50	-1.00	-0.50	1.0	
		Week 50	Tezepelumab	53	51 (96.2)	-0.95 (0.92)	-2.8	-1.67	-1.00	-0.33	1.8	0.19 [-0.21, 0.60]
			Placebo	47	43 (91.5)	-1.14 (0.95)	-3.5	-1.67	-1.17	-0.50	0.7	
		Week 52	Tezepelumab	53	51 (96.2)	-0.94 (0.92)	-2.8	-1.50	-1.00	-0.33	1.8	0.11 [-0.30, 0.51]
			Placebo	47	43 (91.5)	-1.04 (1.02)	-3.5	-1.67	-1.00	-0.33	0.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	2.71 (0.70)	1.0	2.33	2.67	3.17	4.5	
			Placebo	33	33 (100.0)	2.72 (0.62)	1.7	2.33	2.67	3.00	4.5	
		Week 2	Tezepelumab	27	27 (100.0)	2.31 (0.78)	0.7	1.67	2.33	2.83	3.7	
			Placebo	33	30 (90.9)	2.04 (0.74)	0.5	1.50	2.08	2.50	3.2	
		Week 4	Tezepelumab	27	27 (100.0)	1.99 (0.92)	0.2	1.17	2.17	2.67	3.5	
			Placebo	33	30 (90.9)	2.11 (0.86)	0.3	1.50	2.08	2.83	3.7	
		Week 6	Tezepelumab	27	27 (100.0)	1.86 (0.89)	0.2	1.50	1.83	2.50	3.7	
			Placebo	33	30 (90.9)	1.88 (0.89)	0.3	1.17	2.00	2.50	3.5	
		Week 8	Tezepelumab	27	27 (100.0)	1.98 (1.05)	0.0	1.33	2.00	2.83	4.8	
			Placebo	33	30 (90.9)	1.87 (0.94)	0.2	1.00	2.00	2.67	3.7	
		Week 10	Tezepelumab	27	27 (100.0)	1.86 (1.09)	0.0	1.17	1.67	2.83	4.3	
			Placebo	33	30 (90.9)	1.80 (0.78)	0.3	1.17	1.92	2.33	3.0	
		Week 12	Tezepelumab	27	27 (100.0)	1.75 (1.02)	0.0	1.00	1.67	2.67	4.3	
			Placebo	33	30 (90.9)	1.65 (0.88)	0.0	1.00	1.83	2.17	3.2	
		Week 14	Tezepelumab	27	27 (100.0)	1.54 (0.95)	0.0	1.00	1.50	2.00	4.3	
			Placebo	33	30 (90.9)	1.60 (0.85)	0.0	1.00	1.67	2.17	3.2	
		Week 16	Tezepelumab	27	27 (100.0)	1.80 (1.01)	0.0	1.00	1.67	2.50	4.3	
			Placebo	33	30 (90.9)	1.80 (0.96)	0.0	1.00	1.75	2.67	3.5	
		Week 18	Tezepelumab	27	27 (100.0)	1.65 (0.97)	0.0	1.17	1.33	2.33	4.3	
			Placebo	33	30 (90.9)	1.74 (1.07)	0.0	1.00	1.75	2.67	4.7	
		Week 20	Tezepelumab	27	27 (100.0)	1.73 (0.97)	0.0	1.17	1.67	2.33	4.3	
			Placebo	33	30 (90.9)	1.86 (0.86)	0.0	1.33	2.25	2.50	2.8	
		Week 22	Tezepelumab	27	27 (100.0)	1.70 (0.99)	0.0	1.17	1.83	2.50	4.3	
			Placebo	33	30 (90.9)	1.79 (0.87)	0.3	1.17	2.00	2.67	3.0	
		Week 24	Tezepelumab	27	27 (100.0)	1.72 (1.01)	0.0	1.00	1.67	2.33	4.3	
			Placebo	33	30 (90.9)	1.84 (0.96)	0.0	0.83	2.08	2.50	3.0	
		Week 26	Tezepelumab	27	27 (100.0)	1.72 (1.04)	0.0	1.17	1.33	2.50	4.3	
			Placebo	33	30 (90.9)	1.74 (1.07)	0.0	1.00	1.75	2.83	3.7	
		Week 28	Tezepelumab	27	27 (100.0)	1.74 (1.08)	0.0	1.17	1.67	2.50	4.3	
			Placebo	33	30 (90.9)	1.67 (1.08)	0.0	0.83	2.00	2.83	3.0	
		Week 30	Tezepelumab	27	27 (100.0)	1.75 (1.06)	0.0	1.00	1.67	2.50	4.3	
			Placebo	33	31 (93.9)	1.69 (0.96)	0.0	1.00	1.67	2.67	3.2	
		Week 32	Tezepelumab	27	27 (100.0)	1.73 (0.98)	0.0	1.00	1.50	2.33	4.3	
			Placebo	33	31 (93.9)	1.75 (0.96)	0.0	1.00	1.83	2.67	3.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 150 cells/uL	Absolute values	Week 34	Tezepelumab	27	27 (100.0)	1.69 (1.01)	0.0	1.00	1.33	2.50	4.3	
			Placebo	33	31 (93.9)	1.70 (1.00)	0.0	0.83	1.83	2.67	3.3	
		Week 36	Tezepelumab	27	27 (100.0)	1.73 (0.98)	0.0	1.17	1.67	2.17	4.3	
			Placebo	33	31 (93.9)	1.80 (0.95)	0.0	1.00	2.00	2.67	3.0	
		Week 38	Tezepelumab	27	27 (100.0)	1.68 (0.96)	0.0	1.00	1.67	2.17	4.3	
			Placebo	33	31 (93.9)	1.70 (0.96)	0.0	1.00	1.67	2.67	3.2	
		Week 40	Tezepelumab	27	27 (100.0)	1.81 (1.06)	0.0	1.00	1.83	2.67	4.3	
			Placebo	33	31 (93.9)	1.79 (1.05)	0.0	0.83	1.83	2.67	4.0	
		Week 42	Tezepelumab	27	27 (100.0)	1.70 (1.02)	0.0	1.00	1.67	2.00	4.3	
			Placebo	33	31 (93.9)	1.75 (0.94)	0.0	1.17	2.00	2.50	3.0	
		Week 44	Tezepelumab	27	27 (100.0)	1.87 (1.01)	0.0	1.17	1.83	2.50	4.3	
			Placebo	33	31 (93.9)	1.82 (1.12)	0.0	0.50	2.33	2.67	4.0	
		Week 46	Tezepelumab	27	27 (100.0)	1.77 (1.04)	0.0	1.17	1.83	2.33	4.3	
			Placebo	33	31 (93.9)	1.69 (1.00)	0.0	0.50	2.00	2.50	3.3	
		Week 48	Tezepelumab	27	27 (100.0)	1.75 (1.02)	0.0	1.00	1.67	2.33	4.3	
			Placebo	33	31 (93.9)	1.74 (1.07)	0.0	0.67	2.00	2.67	3.3	
		Week 50	Tezepelumab	27	27 (100.0)	1.69 (1.03)	0.0	0.83	1.67	2.33	4.3	
			Placebo	33	31 (93.9)	1.73 (1.02)	0.0	0.83	1.83	2.50	3.5	
		Week 52	Tezepelumab	27	27 (100.0)	1.72 (1.02)	0.0	0.83	1.67	2.33	4.3	
			Placebo	33	31 (93.9)	1.84 (1.03)	0.0	1.00	2.17	2.67	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	27	27 (100.0)	-0.40 (0.67)	-2.3	-0.67	-0.17	0.17	0.5	0.27 [-0.25, 0.79]
			Placebo	33	30 (90.9)	-0.58 (0.68)	-2.0	-1.00	-0.67	-0.33	1.0	
		Week 4	Tezepelumab	27	27 (100.0)	-0.72 (0.76)	-2.7	-1.00	-0.67	-0.17	0.5	-0.27 [-0.79, 0.25]
			Placebo	33	30 (90.9)	-0.52 (0.76)	-2.2	-1.00	-0.67	0.00	1.2	
		Week 6	Tezepelumab	27	27 (100.0)	-0.85 (0.74)	-2.8	-1.33	-0.83	-0.17	0.5	-0.13 [-0.65, 0.39]
			Placebo	33	30 (90.9)	-0.74 (0.85)	-2.3	-1.33	-0.75	-0.17	1.0	
		Week 8	Tezepelumab	27	27 (100.0)	-0.73 (0.97)	-2.8	-1.33	-0.50	-0.50	2.2	0.03 [-0.49, 0.55]
			Placebo	33	30 (90.9)	-0.76 (0.97)	-3.0	-1.33	-0.67	0.00	1.0	
		Week 10	Tezepelumab	27	27 (100.0)	-0.85 (0.89)	-2.8	-1.50	-0.83	0.00	0.5	-0.03 [-0.55, 0.49]
			Placebo	33	30 (90.9)	-0.83 (0.77)	-2.3	-1.33	-0.67	-0.33	0.5	
		Week 12	Tezepelumab	27	27 (100.0)	-0.96 (0.78)	-2.3	-1.67	-0.83	-0.33	0.5	0.02 [-0.50, 0.54]
			Placebo	33	30 (90.9)	-0.98 (0.92)	-3.2	-1.17	-0.83	-0.50	0.7	
		Week 14	Tezepelumab	27	27 (100.0)	-1.17 (0.79)	-2.8	-1.83	-1.17	-0.83	0.5	-0.16 [-0.68, 0.36]
			Placebo	33	30 (90.9)	-1.03 (0.89)	-3.2	-1.50	-0.83	-0.50	0.7	
		Week 16	Tezepelumab	27	27 (100.0)	-0.91 (0.81)	-2.5	-1.67	-1.00	-0.33	0.5	-0.09 [-0.61, 0.43]
			Placebo	33	30 (90.9)	-0.83 (1.03)	-3.2	-1.33	-0.92	0.00	1.2	
		Week 18	Tezepelumab	27	27 (100.0)	-1.06 (0.79)	-2.8	-1.50	-1.00	-0.50	0.5	-0.18 [-0.70, 0.34]
			Placebo	33	30 (90.9)	-0.88 (1.05)	-3.2	-1.50	-0.83	-0.17	1.5	
		Week 20	Tezepelumab	27	27 (100.0)	-0.98 (0.82)	-2.5	-1.67	-1.00	-0.33	0.5	-0.25 [-0.77, 0.27]
			Placebo	33	30 (90.9)	-0.77 (0.84)	-2.7	-1.00	-0.83	-0.17	0.7	
		Week 22	Tezepelumab	27	27 (100.0)	-1.01 (0.85)	-2.8	-1.83	-0.83	-0.33	0.5	-0.20 [-0.73, 0.32]
			Placebo	33	30 (90.9)	-0.84 (0.79)	-2.5	-1.50	-0.83	-0.33	0.3	
		Week 24	Tezepelumab	27	27 (100.0)	-0.99 (0.80)	-2.8	-1.67	-1.00	-0.33	0.5	-0.22 [-0.74, 0.30]
			Placebo	33	30 (90.9)	-0.79 (1.02)	-2.8	-1.50	-0.75	0.17	0.7	
		Week 26	Tezepelumab	27	27 (100.0)	-0.99 (0.86)	-3.0	-1.67	-1.00	-0.33	0.5	-0.11 [-0.63, 0.41]
			Placebo	33	30 (90.9)	-0.88 (1.07)	-3.2	-1.50	-1.00	0.17	1.0	
		Week 28	Tezepelumab	27	27 (100.0)	-0.97 (0.90)	-3.0	-1.67	-0.83	0.00	0.5	-0.01 [-0.53, 0.51]
			Placebo	33	30 (90.9)	-0.96 (1.07)	-3.2	-1.83	-0.92	-0.33	1.0	
		Week 30	Tezepelumab	27	27 (100.0)	-0.96 (0.90)	-2.8	-2.00	-0.83	-0.17	0.7	-0.03 [-0.54, 0.49]
			Placebo	33	31 (93.9)	-0.94 (0.84)	-2.7	-1.50	-0.83	-0.33	0.3	
		Week 32	Tezepelumab	27	27 (100.0)	-0.98 (0.83)	-2.5	-1.67	-1.00	-0.50	0.8	-0.11 [-0.62, 0.41]
			Placebo	33	31 (93.9)	-0.88 (0.89)	-2.7	-1.33	-1.00	-0.33	0.5	
		Week 34	Tezepelumab	27	27 (100.0)	-1.02 (0.78)	-2.0	-1.67	-1.00	-0.50	0.5	-0.10 [-0.62, 0.41]
			Placebo	33	31 (93.9)	-0.94 (0.91)	-2.8	-1.50	-1.00	-0.33	0.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 150 cells/uL	Change from baseline	Week 36	Tezepelumab	27	27 (100.0)	-0.98 (0.81)	-2.5	-1.83	-1.00	-0.50	0.7	-0.16 [-0.68, 0.35]
			Placebo	33	31 (93.9)	-0.84 (0.92)	-2.7	-1.33	-0.67	-0.17	0.7	
		Week 38	Tezepelumab	27	27 (100.0)	-1.03 (0.75)	-2.2	-1.67	-1.00	-0.50	0.5	-0.12 [-0.63, 0.40]
			Placebo	33	31 (93.9)	-0.93 (0.94)	-2.8	-1.33	-1.00	-0.33	0.8	
		Week 40	Tezepelumab	27	27 (100.0)	-0.90 (0.86)	-2.8	-1.67	-0.83	-0.17	0.5	-0.05 [-0.57, 0.46]
			Placebo	33	31 (93.9)	-0.84 (0.99)	-2.7	-1.67	-0.83	0.17	0.8	
		Week 42	Tezepelumab	27	27 (100.0)	-1.01 (0.80)	-2.8	-1.67	-1.00	-0.50	0.5	-0.15 [-0.66, 0.37]
			Placebo	33	31 (93.9)	-0.89 (0.83)	-2.7	-1.50	-0.83	-0.33	0.7	
		Week 44	Tezepelumab	27	27 (100.0)	-0.84 (0.84)	-2.5	-1.67	-0.83	-0.17	0.5	-0.02 [-0.54, 0.49]
			Placebo	33	31 (93.9)	-0.82 (1.10)	-2.7	-1.67	-0.83	0.33	0.8	
		Week 46	Tezepelumab	27	27 (100.0)	-0.94 (0.82)	-2.8	-1.67	-1.00	-0.33	0.5	-0.00 [-0.52, 0.51]
			Placebo	33	31 (93.9)	-0.94 (0.97)	-2.8	-1.83	-0.83	-0.33	0.8	
		Week 48	Tezepelumab	27	27 (100.0)	-0.96 (0.83)	-2.5	-1.67	-1.00	-0.17	0.5	-0.07 [-0.58, 0.45]
			Placebo	33	31 (93.9)	-0.89 (1.02)	-2.8	-1.67	-0.83	-0.33	1.0	
		Week 50	Tezepelumab	27	27 (100.0)	-1.02 (0.81)	-2.8	-1.67	-1.00	-0.50	0.5	-0.12 [-0.64, 0.40]
			Placebo	33	31 (93.9)	-0.91 (1.00)	-3.0	-1.67	-1.00	-0.33	1.0	
		Week 52	Tezepelumab	27	27 (100.0)	-0.99 (0.81)	-2.8	-1.67	-0.83	-0.50	0.5	-0.22 [-0.73, 0.30]
			Placebo	33	31 (93.9)	-0.79 (1.04)	-3.0	-1.67	-0.83	0.00	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	109	109 (100.0)	2.70 (0.83)	0.0	2.33	2.67	3.00	4.8	
			Placebo	105	105 (100.0)	2.64 (0.71)	0.3	2.33	2.67	3.00	4.7	
		Week 2	Tezepelumab	109	103 (94.5)	2.13 (0.95)	0.0	1.50	2.17	2.83	4.3	
			Placebo	105	95 (90.5)	2.38 (0.80)	0.2	2.00	2.33	2.83	4.8	
		Week 4	Tezepelumab	109	103 (94.5)	1.87 (0.97)	0.0	1.17	2.00	2.67	4.3	
			Placebo	105	95 (90.5)	2.20 (0.84)	0.2	1.67	2.33	2.67	4.2	
		Week 6	Tezepelumab	109	103 (94.5)	1.78 (0.99)	0.0	1.00	1.67	2.50	4.3	
			Placebo	105	96 (91.4)	2.15 (0.98)	0.2	1.58	2.17	2.67	5.5	
		Week 8	Tezepelumab	109	103 (94.5)	1.67 (1.02)	0.0	0.83	1.67	2.50	4.3	
			Placebo	105	97 (92.4)	2.11 (0.95)	0.0	1.50	2.17	2.67	4.7	
		Week 10	Tezepelumab	109	103 (94.5)	1.60 (0.99)	0.0	0.83	1.50	2.33	4.3	
			Placebo	105	98 (93.3)	2.03 (0.95)	0.0	1.33	2.00	2.67	5.3	
		Week 12	Tezepelumab	109	103 (94.5)	1.55 (1.04)	0.0	0.67	1.50	2.33	4.3	
			Placebo	105	98 (93.3)	1.97 (0.94)	0.0	1.33	2.00	2.67	4.3	
		Week 14	Tezepelumab	109	103 (94.5)	1.44 (1.02)	0.0	0.67	1.33	2.17	4.3	
			Placebo	105	98 (93.3)	1.92 (0.92)	0.0	1.33	2.00	2.50	5.0	
		Week 16	Tezepelumab	109	103 (94.5)	1.56 (1.06)	0.0	0.67	1.50	2.50	4.3	
			Placebo	105	98 (93.3)	2.02 (1.05)	0.0	1.33	2.08	2.67	5.0	
		Week 18	Tezepelumab	109	104 (95.4)	1.46 (0.97)	0.0	0.83	1.50	2.17	4.3	
			Placebo	105	98 (93.3)	1.90 (0.96)	0.0	1.33	1.92	2.50	5.0	
		Week 20	Tezepelumab	109	104 (95.4)	1.55 (1.04)	0.0	0.83	1.50	2.17	5.0	
			Placebo	105	98 (93.3)	1.94 (1.04)	0.0	1.17	2.08	2.67	5.0	
		Week 22	Tezepelumab	109	104 (95.4)	1.57 (0.97)	0.0	0.83	1.67	2.33	4.3	
			Placebo	105	98 (93.3)	1.90 (1.04)	0.0	1.17	2.00	2.67	5.0	
		Week 24	Tezepelumab	109	104 (95.4)	1.57 (1.04)	0.0	0.75	1.67	2.33	4.3	
			Placebo	105	98 (93.3)	1.88 (0.99)	0.0	1.17	1.92	2.50	4.5	
		Week 26	Tezepelumab	109	105 (96.3)	1.52 (1.00)	0.0	0.83	1.50	2.17	4.3	
			Placebo	105	98 (93.3)	1.85 (0.95)	0.0	1.17	1.67	2.50	4.5	
		Week 28	Tezepelumab	109	106 (97.2)	1.57 (1.03)	0.0	0.83	1.50	2.50	4.3	
			Placebo	105	99 (94.3)	1.93 (1.03)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	109	107 (98.2)	1.51 (0.98)	0.0	0.67	1.50	2.17	4.3	
			Placebo	105	99 (94.3)	1.92 (1.03)	0.0	1.17	2.00	2.50	4.5	
		Week 32	Tezepelumab	109	107 (98.2)	1.46 (1.02)	0.0	0.67	1.50	2.33	4.3	
			Placebo	105	99 (94.3)	1.84 (1.05)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 150 cells/uL	Absolute values	Week 34	Tezepelumab	109	107 (98.2)	1.49 (1.07)	0.0	0.67	1.50	2.33	4.3	
			Placebo	105	99 (94.3)	1.81 (1.05)	0.0	1.00	1.67	2.50	4.5	
		Week 36	Tezepelumab	109	107 (98.2)	1.57 (1.06)	0.0	0.67	1.67	2.33	4.5	
			Placebo	105	99 (94.3)	1.88 (1.06)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	109	107 (98.2)	1.46 (1.06)	0.0	0.67	1.50	2.17	4.5	
			Placebo	105	99 (94.3)	1.80 (1.04)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	109	107 (98.2)	1.46 (1.03)	0.0	0.50	1.50	2.17	4.3	
			Placebo	105	99 (94.3)	1.88 (1.04)	0.0	1.00	1.83	2.50	4.5	
		Week 42	Tezepelumab	109	107 (98.2)	1.46 (1.05)	0.0	0.67	1.50	2.17	4.7	
			Placebo	105	99 (94.3)	1.85 (1.03)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	109	107 (98.2)	1.44 (1.01)	0.0	0.67	1.33	2.17	4.3	
			Placebo	105	100 (95.2)	1.88 (0.98)	0.0	1.00	2.00	2.58	4.5	
		Week 46	Tezepelumab	109	107 (98.2)	1.42 (1.03)	0.0	0.67	1.17	2.17	4.3	
			Placebo	105	100 (95.2)	1.78 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	109	107 (98.2)	1.50 (1.05)	0.0	0.67	1.50	2.33	4.3	
			Placebo	105	100 (95.2)	1.81 (1.00)	0.0	1.00	1.92	2.50	4.5	
		Week 50	Tezepelumab	109	107 (98.2)	1.41 (1.03)	0.0	0.67	1.17	2.17	4.3	
			Placebo	105	100 (95.2)	1.78 (0.95)	0.0	1.00	1.83	2.50	4.5	
		Week 52	Tezepelumab	109	107 (98.2)	1.44 (1.02)	0.0	0.67	1.33	2.17	4.3	
			Placebo	105	100 (95.2)	1.81 (0.99)	0.0	1.00	1.92	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	109	103 (94.5)	-0.58 (0.67)	-2.8	-1.00	-0.50	-0.17	0.7	-0.41 [-0.69, -0.13]
			Placebo	105	95 (90.5)	-0.30 (0.71)	-2.8	-0.67	-0.17	0.17	1.2	
		Week 4	Tezepelumab	109	103 (94.5)	-0.84 (0.92)	-3.5	-1.50	-0.83	-0.17	2.3	-0.40 [-0.69, -0.12]
			Placebo	105	95 (90.5)	-0.48 (0.86)	-3.0	-1.17	-0.33	0.17	1.2	
		Week 6	Tezepelumab	109	103 (94.5)	-0.93 (1.01)	-3.8	-1.50	-0.83	-0.33	2.3	-0.42 [-0.70, -0.14]
			Placebo	105	96 (91.4)	-0.53 (0.91)	-3.3	-1.17	-0.33	0.00	1.5	
		Week 8	Tezepelumab	109	103 (94.5)	-1.04 (1.00)	-3.8	-1.67	-1.00	-0.33	2.3	-0.51 [-0.79, -0.22]
			Placebo	105	97 (92.4)	-0.57 (0.88)	-3.2	-1.00	-0.50	0.00	1.0	
		Week 10	Tezepelumab	109	103 (94.5)	-1.10 (1.00)	-3.8	-1.67	-1.17	-0.50	2.3	-0.45 [-0.73, -0.17]
			Placebo	105	98 (93.3)	-0.65 (1.01)	-3.3	-1.33	-0.58	0.00	2.7	
		Week 12	Tezepelumab	109	103 (94.5)	-1.16 (1.03)	-3.7	-1.83	-1.17	-0.50	2.3	-0.45 [-0.73, -0.17]
			Placebo	105	98 (93.3)	-0.71 (0.97)	-3.3	-1.33	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	109	103 (94.5)	-1.27 (1.05)	-3.8	-2.00	-1.33	-0.67	2.3	-0.50 [-0.78, -0.22]
			Placebo	105	98 (93.3)	-0.77 (0.96)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 16	Tezepelumab	109	103 (94.5)	-1.15 (1.09)	-4.2	-2.00	-1.00	-0.50	2.3	-0.46 [-0.74, -0.18]
			Placebo	105	98 (93.3)	-0.66 (1.03)	-3.5	-1.33	-0.50	0.00	2.3	
		Week 18	Tezepelumab	109	104 (95.4)	-1.23 (1.05)	-4.2	-1.83	-1.17	-0.67	2.3	-0.44 [-0.72, -0.16]
			Placebo	105	98 (93.3)	-0.78 (1.00)	-3.2	-1.33	-0.67	-0.33	2.3	
		Week 20	Tezepelumab	109	104 (95.4)	-1.15 (1.05)	-4.2	-1.83	-1.08	-0.50	2.3	-0.38 [-0.66, -0.10]
			Placebo	105	98 (93.3)	-0.75 (1.10)	-3.5	-1.50	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	109	104 (95.4)	-1.13 (1.08)	-4.3	-1.83	-1.00	-0.50	2.3	-0.32 [-0.60, -0.04]
			Placebo	105	98 (93.3)	-0.79 (1.07)	-3.3	-1.50	-0.67	-0.17	2.3	
		Week 24	Tezepelumab	109	104 (95.4)	-1.13 (1.03)	-4.5	-1.83	-1.08	-0.50	2.3	-0.32 [-0.60, -0.04]
			Placebo	105	98 (93.3)	-0.80 (1.05)	-3.5	-1.50	-0.75	-0.17	2.3	
		Week 26	Tezepelumab	109	105 (96.3)	-1.17 (1.08)	-4.2	-1.83	-1.17	-0.50	2.3	-0.32 [-0.59, -0.04]
			Placebo	105	98 (93.3)	-0.84 (1.04)	-4.0	-1.50	-1.00	-0.17	2.3	
		Week 28	Tezepelumab	109	106 (97.2)	-1.11 (1.08)	-4.2	-1.83	-1.08	-0.33	2.3	-0.36 [-0.64, -0.08]
			Placebo	105	99 (94.3)	-0.73 (1.07)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 30	Tezepelumab	109	107 (98.2)	-1.19 (1.08)	-4.2	-2.00	-1.00	-0.50	2.3	-0.40 [-0.68, -0.13]
			Placebo	105	99 (94.3)	-0.74 (1.11)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 32	Tezepelumab	109	107 (98.2)	-1.23 (1.09)	-4.2	-2.00	-1.00	-0.67	2.3	-0.37 [-0.65, -0.09]
			Placebo	105	99 (94.3)	-0.82 (1.09)	-3.5	-1.50	-0.67	-0.17	2.3	
		Week 34	Tezepelumab	109	107 (98.2)	-1.20 (1.13)	-4.2	-2.00	-1.17	-0.50	2.3	-0.31 [-0.59, -0.04]
			Placebo	105	99 (94.3)	-0.85 (1.09)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 150 cells/uL	Change from baseline	Week 36	Tezepelumab	109	107 (98.2)	-1.12 (1.16)	-4.2	-2.00	-1.17	-0.33	2.3	-0.30 [-0.57, -0.02]
			Placebo	105	99 (94.3)	-0.78 (1.12)	-3.5	-1.33	-0.83	0.00	2.3	
		Week 38	Tezepelumab	109	107 (98.2)	-1.23 (1.16)	-4.2	-2.00	-1.17	-0.33	2.3	-0.33 [-0.61, -0.05]
			Placebo	105	99 (94.3)	-0.86 (1.10)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	109	107 (98.2)	-1.23 (1.14)	-4.2	-2.17	-1.17	-0.67	2.3	-0.40 [-0.68, -0.13]
			Placebo	105	99 (94.3)	-0.78 (1.08)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 42	Tezepelumab	109	107 (98.2)	-1.24 (1.15)	-4.2	-2.00	-1.33	-0.50	2.3	-0.38 [-0.65, -0.10]
			Placebo	105	99 (94.3)	-0.81 (1.10)	-4.0	-1.50	-0.83	0.00	2.3	
		Week 44	Tezepelumab	109	107 (98.2)	-1.25 (1.15)	-4.3	-2.00	-1.17	-0.50	2.3	-0.43 [-0.70, -0.15]
			Placebo	105	100 (95.2)	-0.78 (1.05)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 46	Tezepelumab	109	107 (98.2)	-1.27 (1.14)	-4.2	-2.00	-1.33	-0.67	2.3	-0.35 [-0.63, -0.08]
			Placebo	105	100 (95.2)	-0.88 (1.06)	-4.0	-1.50	-1.00	-0.17	2.3	
		Week 48	Tezepelumab	109	107 (98.2)	-1.19 (1.15)	-4.2	-2.00	-1.17	-0.33	2.3	-0.30 [-0.58, -0.03]
			Placebo	105	100 (95.2)	-0.85 (1.08)	-3.7	-1.50	-0.83	-0.25	2.3	
		Week 50	Tezepelumab	109	107 (98.2)	-1.28 (1.15)	-4.2	-2.00	-1.33	-0.50	2.3	-0.37 [-0.64, -0.09]
			Placebo	105	100 (95.2)	-0.87 (1.03)	-4.0	-1.42	-0.92	-0.25	2.3	
		Week 52	Tezepelumab	109	107 (98.2)	-1.25 (1.15)	-4.2	-2.00	-1.17	-0.50	2.3	-0.37 [-0.64, -0.09]
			Placebo	105	100 (95.2)	-0.84 (1.05)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	69	69 (100.0)	2.72 (0.74)	0.3	2.33	2.67	3.00	4.8	
			Placebo	72	72 (100.0)	2.61 (0.68)	0.3	2.17	2.58	3.00	4.5	
		Week 2	Tezepelumab	69	64 (92.8)	2.27 (0.88)	0.0	1.67	2.33	2.75	4.3	
			Placebo	72	62 (86.1)	2.19 (0.74)	0.3	1.83	2.17	2.67	4.8	
		Week 4	Tezepelumab	69	64 (92.8)	2.01 (0.96)	0.0	1.17	2.17	2.67	4.3	
			Placebo	72	62 (86.1)	2.00 (0.83)	0.2	1.50	2.08	2.50	3.7	
		Week 6	Tezepelumab	69	64 (92.8)	1.90 (0.96)	0.0	1.42	1.83	2.58	4.3	
			Placebo	72	62 (86.1)	1.90 (0.95)	0.2	1.17	2.00	2.50	4.7	
		Week 8	Tezepelumab	69	64 (92.8)	1.89 (1.06)	0.0	1.17	1.83	2.67	4.8	
			Placebo	72	63 (87.5)	1.87 (0.92)	0.0	1.17	1.83	2.33	4.7	
		Week 10	Tezepelumab	69	64 (92.8)	1.76 (1.03)	0.0	1.17	1.67	2.67	4.3	
			Placebo	72	63 (87.5)	1.85 (0.85)	0.2	1.33	1.83	2.33	4.2	
		Week 12	Tezepelumab	69	64 (92.8)	1.67 (1.08)	0.0	0.75	1.58	2.50	4.3	
			Placebo	72	63 (87.5)	1.72 (0.89)	0.0	1.00	1.83	2.33	4.3	
		Week 14	Tezepelumab	69	64 (92.8)	1.53 (1.01)	0.0	0.83	1.50	2.17	4.3	
			Placebo	72	63 (87.5)	1.68 (0.87)	0.0	1.00	1.67	2.17	5.0	
		Week 16	Tezepelumab	69	64 (92.8)	1.71 (1.06)	0.0	0.92	1.75	2.50	4.3	
			Placebo	72	63 (87.5)	1.82 (0.95)	0.0	1.00	1.83	2.50	4.5	
		Week 18	Tezepelumab	69	65 (94.2)	1.64 (1.00)	0.0	0.83	1.67	2.17	4.3	
			Placebo	72	63 (87.5)	1.73 (0.99)	0.0	1.00	1.67	2.33	4.7	
		Week 20	Tezepelumab	69	65 (94.2)	1.69 (1.08)	0.0	1.00	1.83	2.33	5.0	
			Placebo	72	63 (87.5)	1.78 (0.96)	0.0	1.17	1.83	2.50	4.5	
		Week 22	Tezepelumab	69	65 (94.2)	1.69 (1.01)	0.0	1.00	1.83	2.33	4.3	
			Placebo	72	63 (87.5)	1.72 (0.94)	0.0	1.00	1.83	2.50	4.5	
		Week 24	Tezepelumab	69	65 (94.2)	1.66 (1.02)	0.0	1.00	1.67	2.33	4.3	
			Placebo	72	63 (87.5)	1.72 (0.99)	0.0	0.83	1.67	2.50	4.5	
		Week 26	Tezepelumab	69	66 (95.7)	1.64 (1.05)	0.0	1.00	1.58	2.33	4.3	
			Placebo	72	63 (87.5)	1.67 (1.00)	0.0	1.00	1.50	2.50	4.5	
		Week 28	Tezepelumab	69	66 (95.7)	1.69 (1.06)	0.0	1.00	1.67	2.50	4.3	
			Placebo	72	64 (88.9)	1.68 (1.07)	0.0	0.83	1.83	2.42	4.5	
		Week 30	Tezepelumab	69	67 (97.1)	1.65 (1.05)	0.0	0.83	1.67	2.33	4.3	
			Placebo	72	65 (90.3)	1.70 (1.02)	0.0	1.00	1.67	2.50	4.5	
		Week 32	Tezepelumab	69	67 (97.1)	1.61 (1.04)	0.0	1.00	1.50	2.33	4.3	
			Placebo	72	65 (90.3)	1.62 (0.99)	0.0	0.83	1.50	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 300 cells/uL	Absolute values	Week 34	Tezepelumab	69	67 (97.1)	1.61 (1.07)	0.0	1.00	1.50	2.50	4.3	
			Placebo	72	65 (90.3)	1.57 (1.00)	0.0	0.83	1.50	2.33	4.5	
		Week 36	Tezepelumab	69	67 (97.1)	1.67 (1.10)	0.0	1.00	1.67	2.33	4.5	
			Placebo	72	65 (90.3)	1.64 (1.03)	0.0	0.83	1.83	2.50	4.5	
		Week 38	Tezepelumab	69	67 (97.1)	1.62 (1.11)	0.0	0.83	1.50	2.17	4.5	
			Placebo	72	65 (90.3)	1.61 (1.00)	0.0	0.83	1.67	2.50	4.5	
		Week 40	Tezepelumab	69	67 (97.1)	1.67 (1.09)	0.0	0.83	1.67	2.50	4.3	
			Placebo	72	65 (90.3)	1.64 (1.07)	0.0	0.67	1.67	2.50	4.5	
		Week 42	Tezepelumab	69	67 (97.1)	1.59 (1.08)	0.0	1.00	1.50	2.00	4.3	
			Placebo	72	65 (90.3)	1.64 (1.01)	0.0	0.67	1.83	2.50	4.5	
		Week 44	Tezepelumab	69	67 (97.1)	1.68 (1.07)	0.0	1.00	1.67	2.50	4.3	
			Placebo	72	66 (91.7)	1.69 (1.06)	0.0	0.67	1.75	2.50	4.5	
		Week 46	Tezepelumab	69	67 (97.1)	1.61 (1.10)	0.0	0.83	1.50	2.17	4.3	
			Placebo	72	66 (91.7)	1.62 (1.00)	0.0	0.83	1.75	2.33	4.5	
		Week 48	Tezepelumab	69	67 (97.1)	1.67 (1.07)	0.0	0.83	1.67	2.33	4.3	
			Placebo	72	66 (91.7)	1.61 (1.08)	0.0	0.67	1.58	2.50	4.5	
		Week 50	Tezepelumab	69	67 (97.1)	1.63 (1.11)	0.0	0.83	1.67	2.33	4.3	
			Placebo	72	66 (91.7)	1.65 (1.02)	0.0	0.83	1.67	2.50	4.5	
		Week 52	Tezepelumab	69	67 (97.1)	1.64 (1.12)	0.0	0.83	1.67	2.33	4.3	
			Placebo	72	66 (91.7)	1.68 (1.05)	0.0	0.83	1.75	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High											
< 300 cells/uL	Change from baseline	Week 2	Tezepelumab	69	64 (92.8)	-0.46 (0.68)	-2.8	-0.75	-0.33	0.00	0.5	-0.06 [-0.41, 0.28]
			Placebo	72	62 (86.1)	-0.42 (0.70)	-2.8	-0.83	-0.33	0.17	1.2	
		Week 4	Tezepelumab	69	64 (92.8)	-0.72 (0.74)	-2.7	-1.17	-0.67	-0.17	0.7	-0.15 [-0.50, 0.20]
			Placebo	72	62 (86.1)	-0.60 (0.82)	-3.0	-1.00	-0.67	-0.17	1.2	
		Week 6	Tezepelumab	69	64 (92.8)	-0.83 (0.75)	-2.8	-1.33	-0.83	-0.25	0.5	-0.15 [-0.50, 0.20]
			Placebo	72	62 (86.1)	-0.70 (0.92)	-3.3	-1.33	-0.67	-0.17	1.5	
		Week 8	Tezepelumab	69	64 (92.8)	-0.84 (0.90)	-2.8	-1.50	-0.75	-0.33	2.2	-0.11 [-0.46, 0.24]
			Placebo	72	63 (87.5)	-0.74 (0.89)	-3.0	-1.17	-0.67	-0.17	1.0	
		Week 10	Tezepelumab	69	64 (92.8)	-0.97 (0.83)	-2.8	-1.50	-1.00	-0.33	0.5	-0.24 [-0.59, 0.11]
			Placebo	72	63 (87.5)	-0.76 (0.88)	-3.2	-1.33	-0.67	-0.17	2.0	
		Week 12	Tezepelumab	69	64 (92.8)	-1.06 (0.89)	-2.7	-1.83	-1.00	-0.33	0.5	-0.18 [-0.53, 0.17]
			Placebo	72	63 (87.5)	-0.89 (0.90)	-3.2	-1.33	-0.83	-0.33	1.0	
		Week 14	Tezepelumab	69	64 (92.8)	-1.20 (0.82)	-2.8	-1.83	-1.17	-0.67	0.5	-0.30 [-0.65, 0.05]
			Placebo	72	63 (87.5)	-0.93 (0.93)	-3.2	-1.33	-0.83	-0.33	1.3	
		Week 16	Tezepelumab	69	64 (92.8)	-1.02 (0.84)	-2.7	-1.67	-1.00	-0.33	0.5	-0.25 [-0.60, 0.10]
			Placebo	72	63 (87.5)	-0.79 (0.96)	-3.2	-1.33	-0.83	-0.17	1.3	
		Week 18	Tezepelumab	69	65 (94.2)	-1.07 (0.82)	-2.8	-1.67	-1.00	-0.50	0.5	-0.21 [-0.56, 0.14]
			Placebo	72	63 (87.5)	-0.88 (0.99)	-3.2	-1.50	-0.83	-0.17	1.5	
		Week 20	Tezepelumab	69	65 (94.2)	-1.02 (0.91)	-2.8	-1.83	-1.00	-0.33	0.7	-0.20 [-0.55, 0.14]
			Placebo	72	63 (87.5)	-0.83 (0.94)	-3.0	-1.33	-0.83	-0.33	1.2	
		Week 22	Tezepelumab	69	65 (94.2)	-1.03 (0.89)	-2.8	-1.83	-0.83	-0.33	0.5	-0.15 [-0.50, 0.19]
			Placebo	72	63 (87.5)	-0.89 (0.92)	-3.2	-1.50	-0.83	-0.33	1.3	
		Week 24	Tezepelumab	69	65 (94.2)	-1.05 (0.85)	-2.8	-1.67	-1.00	-0.33	0.7	-0.16 [-0.51, 0.18]
			Placebo	72	63 (87.5)	-0.89 (1.03)	-3.2	-1.50	-0.83	-0.17	1.7	
		Week 26	Tezepelumab	69	66 (95.7)	-1.06 (0.90)	-3.0	-1.83	-1.00	-0.33	0.7	-0.12 [-0.46, 0.23]
			Placebo	72	63 (87.5)	-0.94 (0.99)	-3.2	-1.50	-1.00	-0.33	1.5	
		Week 28	Tezepelumab	69	66 (95.7)	-1.01 (0.96)	-3.0	-1.67	-1.00	-0.33	0.8	-0.11 [-0.45, 0.23]
			Placebo	72	64 (88.9)	-0.90 (1.04)	-3.2	-1.50	-0.83	-0.33	1.5	
		Week 30	Tezepelumab	69	67 (97.1)	-1.05 (0.96)	-2.8	-2.00	-0.83	-0.33	1.8	-0.17 [-0.51, 0.17]
			Placebo	72	65 (90.3)	-0.88 (1.01)	-3.2	-1.50	-0.83	-0.33	2.0	
		Week 32	Tezepelumab	69	67 (97.1)	-1.10 (0.92)	-3.2	-2.00	-1.00	-0.50	0.8	-0.15 [-0.49, 0.19]
			Placebo	72	65 (90.3)	-0.96 (0.94)	-3.0	-1.50	-1.00	-0.33	1.3	
		Week 34	Tezepelumab	69	67 (97.1)	-1.10 (0.98)	-3.3	-1.83	-1.00	-0.33	2.0	-0.09 [-0.43, 0.25]
			Placebo	72	65 (90.3)	-1.01 (0.97)	-3.2	-1.50	-1.00	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 300 cells/uL	Change from baseline	Week 36	Tezepelumab	69	67 (97.1)	-1.04 (1.01)	-3.2	-1.83	-1.00	-0.33	1.7	-0.10 [-0.44, 0.25]
			Placebo	72	65 (90.3)	-0.94 (1.02)	-3.5	-1.50	-0.83	-0.33	1.3	
		Week 38	Tezepelumab	69	67 (97.1)	-1.09 (1.01)	-3.2	-2.00	-1.00	-0.33	2.3	-0.12 [-0.46, 0.22]
			Placebo	72	65 (90.3)	-0.97 (0.99)	-3.2	-1.50	-1.00	-0.33	1.3	
		Week 40	Tezepelumab	69	67 (97.1)	-1.03 (0.99)	-3.2	-2.00	-1.00	-0.33	1.7	-0.10 [-0.44, 0.25]
			Placebo	72	65 (90.3)	-0.94 (1.04)	-3.2	-1.67	-1.00	-0.17	1.3	
		Week 42	Tezepelumab	69	67 (97.1)	-1.11 (0.97)	-3.2	-2.00	-1.17	-0.50	2.0	-0.18 [-0.52, 0.16]
			Placebo	72	65 (90.3)	-0.94 (0.97)	-3.2	-1.50	-0.83	-0.33	1.3	
		Week 44	Tezepelumab	69	67 (97.1)	-1.03 (0.96)	-3.3	-1.83	-1.00	-0.33	1.5	-0.14 [-0.48, 0.20]
			Placebo	72	66 (91.7)	-0.89 (1.05)	-3.3	-1.50	-0.83	0.00	1.3	
		Week 46	Tezepelumab	69	67 (97.1)	-1.09 (0.98)	-3.2	-2.00	-1.00	-0.33	1.7	-0.14 [-0.48, 0.20]
			Placebo	72	66 (91.7)	-0.96 (1.01)	-3.2	-1.67	-1.00	-0.33	1.3	
		Week 48	Tezepelumab	69	67 (97.1)	-1.04 (0.97)	-3.2	-1.83	-1.00	-0.33	1.8	-0.07 [-0.41, 0.27]
			Placebo	72	66 (91.7)	-0.97 (1.08)	-3.3	-1.67	-0.92	-0.33	1.7	
		Week 50	Tezepelumab	69	67 (97.1)	-1.08 (0.99)	-3.2	-1.83	-1.00	-0.33	1.8	-0.14 [-0.48, 0.20]
			Placebo	72	66 (91.7)	-0.93 (1.06)	-3.5	-1.50	-1.00	-0.33	1.5	
		Week 52	Tezepelumab	69	67 (97.1)	-1.07 (1.01)	-3.2	-2.00	-1.00	-0.33	1.8	-0.17 [-0.51, 0.17]
			Placebo	72	66 (91.7)	-0.89 (1.09)	-3.5	-1.67	-0.92	-0.17	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	67	67 (100.0)	2.68 (0.87)	0.0	2.17	2.67	3.17	4.8	
			Placebo	66	66 (100.0)	2.71 (0.70)	1.2	2.33	2.75	3.00	4.7	
		Week 2	Tezepelumab	67	66 (98.5)	2.07 (0.95)	0.0	1.33	2.17	2.83	4.2	
			Placebo	66	63 (95.5)	2.41 (0.83)	0.2	2.00	2.50	2.83	4.7	
		Week 4	Tezepelumab	67	66 (98.5)	1.78 (0.94)	0.0	1.17	1.83	2.67	3.3	
			Placebo	66	63 (95.5)	2.35 (0.82)	0.7	1.83	2.50	2.83	4.2	
		Week 6	Tezepelumab	67	66 (98.5)	1.69 (0.98)	0.0	1.00	1.67	2.50	3.7	
			Placebo	66	64 (97.0)	2.26 (0.95)	0.2	1.67	2.33	2.67	5.5	
		Week 8	Tezepelumab	67	66 (98.5)	1.58 (0.98)	0.0	0.83	1.50	2.50	3.5	
			Placebo	66	64 (97.0)	2.24 (0.95)	0.0	1.58	2.33	2.83	4.7	
		Week 10	Tezepelumab	67	66 (98.5)	1.56 (0.99)	0.0	0.67	1.50	2.33	3.7	
			Placebo	66	65 (98.5)	2.11 (0.97)	0.0	1.50	2.17	2.67	5.3	
		Week 12	Tezepelumab	67	66 (98.5)	1.52 (0.98)	0.0	0.83	1.50	2.17	3.7	
			Placebo	66	65 (98.5)	2.07 (0.95)	0.0	1.33	2.17	2.67	4.3	
		Week 14	Tezepelumab	67	66 (98.5)	1.39 (1.00)	0.0	0.67	1.33	2.17	3.7	
			Placebo	66	65 (98.5)	2.00 (0.92)	0.0	1.33	2.17	2.67	5.0	
		Week 16	Tezepelumab	67	66 (98.5)	1.52 (1.05)	0.0	0.67	1.33	2.50	4.3	
			Placebo	66	65 (98.5)	2.12 (1.09)	0.0	1.33	2.17	2.83	5.0	
		Week 18	Tezepelumab	67	66 (98.5)	1.37 (0.93)	0.0	0.67	1.33	2.00	3.5	
			Placebo	66	65 (98.5)	2.00 (0.97)	0.0	1.50	2.17	2.50	5.0	
		Week 20	Tezepelumab	67	66 (98.5)	1.48 (0.97)	0.0	0.83	1.42	2.17	3.5	
			Placebo	66	65 (98.5)	2.06 (1.02)	0.0	1.33	2.33	2.83	5.0	
		Week 22	Tezepelumab	67	66 (98.5)	1.51 (0.92)	0.0	0.83	1.50	2.17	3.5	
			Placebo	66	65 (98.5)	2.02 (1.04)	0.0	1.33	2.00	2.67	5.0	
		Week 24	Tezepelumab	67	66 (98.5)	1.53 (1.05)	0.0	0.67	1.50	2.33	4.2	
			Placebo	66	65 (98.5)	2.02 (0.95)	0.0	1.33	2.17	2.67	4.2	
		Week 26	Tezepelumab	67	66 (98.5)	1.47 (0.96)	0.0	0.67	1.50	2.17	3.7	
			Placebo	66	65 (98.5)	1.97 (0.94)	0.0	1.33	1.83	2.67	4.2	
		Week 28	Tezepelumab	67	67 (100.0)	1.52 (1.02)	0.0	0.67	1.50	2.50	3.5	
			Placebo	66	65 (98.5)	2.06 (0.98)	0.0	1.33	2.17	2.67	4.2	
		Week 30	Tezepelumab	67	67 (100.0)	1.46 (0.95)	0.0	0.83	1.50	2.17	3.8	
			Placebo	66	65 (98.5)	2.03 (0.99)	0.0	1.33	2.17	2.67	4.2	
		Week 32	Tezepelumab	67	67 (100.0)	1.43 (0.99)	0.0	0.67	1.33	2.17	4.2	
			Placebo	66	65 (98.5)	2.01 (1.02)	0.0	1.17	2.00	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 300 cells/uL	Absolute values	Week 34	Tezepelumab	67	67 (100.0)	1.45 (1.04)	0.0	0.67	1.33	2.17	4.2	
			Placebo	66	65 (98.5)	1.99 (1.03)	0.0	1.17	2.00	2.50	4.5	
		Week 36	Tezepelumab	67	67 (100.0)	1.54 (0.99)	0.0	0.67	1.67	2.33	3.8	
			Placebo	66	65 (98.5)	2.08 (1.00)	0.0	1.50	2.17	2.67	4.5	
		Week 38	Tezepelumab	67	67 (100.0)	1.39 (0.95)	0.0	0.67	1.50	2.17	3.5	
			Placebo	66	65 (98.5)	1.95 (1.01)	0.0	1.17	2.00	2.50	4.5	
		Week 40	Tezepelumab	67	67 (100.0)	1.39 (0.98)	0.0	0.50	1.50	2.17	3.5	
			Placebo	66	65 (98.5)	2.07 (0.96)	0.0	1.33	2.17	2.67	4.2	
		Week 42	Tezepelumab	67	67 (100.0)	1.42 (1.01)	0.0	0.67	1.33	2.17	4.7	
			Placebo	66	65 (98.5)	2.01 (0.98)	0.0	1.50	2.00	2.67	4.7	
		Week 44	Tezepelumab	67	67 (100.0)	1.38 (0.96)	0.0	0.50	1.33	2.17	3.5	
			Placebo	66	65 (98.5)	2.04 (0.94)	0.0	1.33	2.00	2.67	4.2	
		Week 46	Tezepelumab	67	67 (100.0)	1.37 (0.97)	0.0	0.67	1.17	2.00	3.7	
			Placebo	66	65 (98.5)	1.90 (0.93)	0.0	1.17	2.00	2.50	3.8	
		Week 48	Tezepelumab	67	67 (100.0)	1.44 (1.01)	0.0	0.67	1.33	2.17	4.0	
			Placebo	66	65 (98.5)	1.98 (0.91)	0.0	1.33	2.17	2.67	3.8	
		Week 50	Tezepelumab	67	67 (100.0)	1.31 (0.93)	0.0	0.67	1.00	2.00	4.0	
			Placebo	66	65 (98.5)	1.89 (0.89)	0.0	1.17	1.83	2.50	3.8	
		Week 52	Tezepelumab	67	67 (100.0)	1.36 (0.91)	0.0	0.67	1.33	2.00	4.0	
			Placebo	66	65 (98.5)	1.96 (0.93)	0.0	1.33	2.17	2.67	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 2	Tezepelumab	67	66 (98.5)	-0.62 (0.67)	-2.5	-1.00	-0.67	-0.17	0.7	-0.44 [-0.79, -0.09]
			Placebo	66	63 (95.5)	-0.31 (0.72)	-2.7	-0.67	-0.17	0.00	1.0	
		Week 4	Tezepelumab	67	66 (98.5)	-0.91 (1.00)	-3.5	-1.50	-0.83	-0.17	2.3	-0.58 [-0.93, -0.23]
			Placebo	66	63 (95.5)	-0.37 (0.83)	-2.7	-1.00	-0.17	0.17	1.2	
		Week 6	Tezepelumab	67	66 (98.5)	-1.00 (1.12)	-3.8	-1.67	-1.00	-0.33	2.3	-0.54 [-0.89, -0.19]
			Placebo	66	64 (97.0)	-0.46 (0.87)	-2.8	-1.08	-0.33	0.17	1.5	
		Week 8	Tezepelumab	67	66 (98.5)	-1.11 (1.08)	-3.8	-1.83	-1.00	-0.33	2.3	-0.63 [-0.99, -0.28]
			Placebo	66	64 (97.0)	-0.48 (0.90)	-3.2	-0.92	-0.50	0.17	1.0	
		Week 10	Tezepelumab	67	66 (98.5)	-1.13 (1.11)	-3.8	-1.83	-1.17	-0.50	2.3	-0.48 [-0.82, -0.13]
			Placebo	66	65 (98.5)	-0.62 (1.03)	-3.3	-1.33	-0.50	-0.17	2.7	
		Week 12	Tezepelumab	67	66 (98.5)	-1.17 (1.07)	-3.7	-1.83	-1.17	-0.67	2.3	-0.50 [-0.84, -0.15]
			Placebo	66	65 (98.5)	-0.65 (1.01)	-3.3	-1.33	-0.50	0.00	1.3	
		Week 14	Tezepelumab	67	66 (98.5)	-1.30 (1.15)	-3.8	-2.00	-1.33	-0.67	2.3	-0.54 [-0.88, -0.19]
			Placebo	66	65 (98.5)	-0.73 (0.95)	-3.0	-1.33	-0.67	0.00	2.3	
		Week 16	Tezepelumab	67	66 (98.5)	-1.17 (1.20)	-4.2	-2.00	-1.08	-0.50	2.3	-0.49 [-0.84, -0.14]
			Placebo	66	65 (98.5)	-0.61 (1.09)	-3.5	-1.17	-0.50	0.17	2.3	
		Week 18	Tezepelumab	67	66 (98.5)	-1.32 (1.15)	-4.2	-2.00	-1.17	-0.67	2.3	-0.54 [-0.88, -0.19]
			Placebo	66	65 (98.5)	-0.73 (1.04)	-3.2	-1.33	-0.50	-0.33	2.3	
		Week 20	Tezepelumab	67	66 (98.5)	-1.21 (1.10)	-4.2	-1.83	-1.17	-0.50	2.3	-0.48 [-0.83, -0.13]
			Placebo	66	65 (98.5)	-0.67 (1.13)	-3.5	-1.33	-0.50	-0.17	2.3	
		Week 22	Tezepelumab	67	66 (98.5)	-1.18 (1.16)	-4.3	-1.83	-1.08	-0.50	2.3	-0.41 [-0.76, -0.07]
			Placebo	66	65 (98.5)	-0.71 (1.09)	-3.3	-1.33	-0.50	-0.17	2.3	
		Week 24	Tezepelumab	67	66 (98.5)	-1.16 (1.11)	-4.5	-1.83	-1.17	-0.50	2.3	-0.42 [-0.77, -0.07]
			Placebo	66	65 (98.5)	-0.71 (1.04)	-3.5	-1.33	-0.50	0.00	2.3	
		Week 26	Tezepelumab	67	66 (98.5)	-1.22 (1.16)	-4.2	-2.00	-1.17	-0.50	2.3	-0.41 [-0.76, -0.06]
			Placebo	66	65 (98.5)	-0.76 (1.09)	-4.0	-1.50	-0.67	0.00	2.3	
		Week 28	Tezepelumab	67	67 (100.0)	-1.16 (1.12)	-4.2	-1.83	-1.17	-0.33	2.3	-0.45 [-0.79, -0.10]
			Placebo	66	65 (98.5)	-0.66 (1.10)	-4.0	-1.33	-0.50	0.00	2.3	
		Week 30	Tezepelumab	67	67 (100.0)	-1.23 (1.13)	-4.2	-2.00	-1.33	-0.50	2.3	-0.48 [-0.82, -0.13]
			Placebo	66	65 (98.5)	-0.69 (1.10)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 32	Tezepelumab	67	67 (100.0)	-1.25 (1.17)	-4.2	-2.00	-1.17	-0.67	2.3	-0.47 [-0.82, -0.12]
			Placebo	66	65 (98.5)	-0.72 (1.13)	-3.5	-1.50	-0.50	0.00	2.3	
		Week 34	Tezepelumab	67	67 (100.0)	-1.23 (1.15)	-4.2	-2.00	-1.17	-0.67	2.3	-0.44 [-0.79, -0.10]
			Placebo	66	65 (98.5)	-0.73 (1.11)	-4.0	-1.33	-0.50	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 300 cells/uL	Change from baseline	Week 36	Tezepelumab	67	67 (100.0)	-1.15 (1.19)	-4.2	-1.83	-1.17	-0.17	2.3	-0.43 [-0.78, -0.09]
			Placebo	66	65 (98.5)	-0.65 (1.12)	-3.5	-1.33	-0.50	0.17	2.3	
		Week 38	Tezepelumab	67	67 (100.0)	-1.29 (1.16)	-4.2	-2.00	-1.33	-0.67	2.3	-0.45 [-0.79, -0.10]
			Placebo	66	65 (98.5)	-0.78 (1.13)	-4.0	-1.50	-0.83	0.00	2.3	
		Week 40	Tezepelumab	67	67 (100.0)	-1.29 (1.18)	-4.2	-2.00	-1.17	-0.67	2.3	-0.56 [-0.91, -0.21]
			Placebo	66	65 (98.5)	-0.66 (1.07)	-4.0	-1.33	-0.67	-0.17	2.3	
		Week 42	Tezepelumab	67	67 (100.0)	-1.26 (1.20)	-4.2	-2.00	-1.33	-0.50	2.3	-0.47 [-0.82, -0.13]
			Placebo	66	65 (98.5)	-0.72 (1.10)	-4.0	-1.33	-0.83	0.00	2.3	
		Week 44	Tezepelumab	67	67 (100.0)	-1.31 (1.22)	-4.3	-2.00	-1.17	-0.50	2.3	-0.54 [-0.89, -0.19]
			Placebo	66	65 (98.5)	-0.68 (1.07)	-4.0	-1.33	-0.67	-0.17	2.3	
		Week 46	Tezepelumab	67	67 (100.0)	-1.31 (1.19)	-4.2	-2.00	-1.33	-0.67	2.3	-0.43 [-0.77, -0.08]
			Placebo	66	65 (98.5)	-0.83 (1.06)	-4.0	-1.33	-1.00	0.00	2.3	
		Week 48	Tezepelumab	67	67 (100.0)	-1.25 (1.20)	-4.2	-2.00	-1.17	-0.33	2.3	-0.44 [-0.79, -0.10]
			Placebo	66	65 (98.5)	-0.75 (1.05)	-3.7	-1.33	-0.83	0.00	2.3	
		Week 50	Tezepelumab	67	67 (100.0)	-1.37 (1.17)	-4.2	-2.17	-1.33	-0.67	2.3	-0.50 [-0.85, -0.15]
			Placebo	66	65 (98.5)	-0.83 (0.99)	-4.0	-1.33	-0.83	-0.17	2.3	
		Week 52	Tezepelumab	67	67 (100.0)	-1.33 (1.17)	-4.2	-2.00	-1.33	-0.67	2.3	-0.51 [-0.86, -0.16]
			Placebo	66	65 (98.5)	-0.77 (1.01)	-4.0	-1.33	-0.67	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	78	78 (100.0)	2.66 (0.66)	0.8	2.17	2.67	3.00	4.5	
			Placebo	74	74 (100.0)	2.65 (0.67)	0.3	2.33	2.67	3.00	4.2	
		Week 2	Tezepelumab	78	73 (93.6)	2.18 (0.91)	0.0	1.50	2.17	2.83	4.2	
			Placebo	74	66 (89.2)	2.25 (0.73)	0.3	1.83	2.33	2.83	4.3	
		Week 4	Tezepelumab	78	73 (93.6)	1.94 (0.87)	0.0	1.33	2.00	2.67	3.5	
			Placebo	74	66 (89.2)	2.06 (0.80)	0.2	1.50	2.17	2.67	4.2	
		Week 6	Tezepelumab	78	73 (93.6)	1.88 (0.89)	0.0	1.33	1.83	2.50	4.0	
			Placebo	74	66 (89.2)	1.99 (0.88)	0.2	1.33	2.00	2.50	4.7	
		Week 8	Tezepelumab	78	73 (93.6)	1.81 (0.98)	0.0	1.17	1.67	2.67	4.8	
			Placebo	74	66 (89.2)	2.09 (0.87)	0.0	1.67	2.00	2.83	4.0	
		Week 10	Tezepelumab	78	73 (93.6)	1.75 (0.99)	0.0	1.17	1.67	2.67	4.3	
			Placebo	74	67 (90.5)	1.91 (0.83)	0.0	1.33	2.00	2.33	4.2	
		Week 12	Tezepelumab	78	73 (93.6)	1.68 (1.03)	0.0	0.83	1.67	2.50	4.3	
			Placebo	74	67 (90.5)	1.88 (0.89)	0.0	1.33	2.00	2.50	4.3	
		Week 14	Tezepelumab	78	73 (93.6)	1.50 (0.99)	0.0	0.83	1.50	2.17	4.3	
			Placebo	74	67 (90.5)	1.81 (0.85)	0.0	1.17	1.83	2.50	4.2	
		Week 16	Tezepelumab	78	73 (93.6)	1.76 (1.04)	0.0	1.00	1.67	2.50	4.3	
			Placebo	74	67 (90.5)	1.91 (0.89)	0.0	1.33	1.83	2.67	3.8	
		Week 18	Tezepelumab	78	74 (94.9)	1.64 (0.95)	0.0	1.00	1.67	2.33	4.3	
			Placebo	74	67 (90.5)	1.84 (0.96)	0.0	1.17	1.83	2.50	4.7	
		Week 20	Tezepelumab	78	74 (94.9)	1.71 (1.04)	0.0	1.00	1.83	2.50	5.0	
			Placebo	74	67 (90.5)	1.85 (0.96)	0.0	1.17	2.00	2.67	3.7	
		Week 22	Tezepelumab	78	74 (94.9)	1.67 (0.97)	0.0	1.00	1.83	2.33	4.3	
			Placebo	74	67 (90.5)	1.80 (0.94)	0.0	1.17	1.83	2.67	3.7	
		Week 24	Tezepelumab	78	74 (94.9)	1.67 (1.00)	0.0	1.00	1.67	2.33	4.3	
			Placebo	74	67 (90.5)	1.77 (0.95)	0.0	0.83	1.83	2.50	3.5	
		Week 26	Tezepelumab	78	75 (96.2)	1.68 (1.02)	0.0	1.00	1.67	2.50	4.3	
			Placebo	74	67 (90.5)	1.74 (0.87)	0.0	1.00	1.67	2.33	4.0	
		Week 28	Tezepelumab	78	76 (97.4)	1.68 (1.03)	0.0	1.00	1.67	2.50	4.3	
			Placebo	74	68 (91.9)	1.86 (0.94)	0.0	1.00	2.00	2.50	4.0	
		Week 30	Tezepelumab	78	77 (98.7)	1.66 (1.01)	0.0	0.83	1.67	2.33	4.3	
			Placebo	74	69 (93.2)	1.85 (0.93)	0.0	1.17	1.83	2.67	4.0	
		Week 32	Tezepelumab	78	77 (98.7)	1.62 (1.02)	0.0	1.00	1.50	2.50	4.3	
			Placebo	74	69 (93.2)	1.73 (0.95)	0.0	1.00	1.67	2.67	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 25 ppb	Absolute values	Week 34	Tezepelumab	78	77 (98.7)	1.60 (1.08)	0.0	1.00	1.50	2.50	4.3	
			Placebo	74	69 (93.2)	1.74 (0.92)	0.0	1.00	1.83	2.50	3.7	
		Week 36	Tezepelumab	78	77 (98.7)	1.70 (1.05)	0.0	1.00	1.67	2.50	4.5	
			Placebo	74	69 (93.2)	1.70 (0.96)	0.0	0.83	1.83	2.50	3.2	
		Week 38	Tezepelumab	78	77 (98.7)	1.63 (1.08)	0.0	0.83	1.67	2.33	4.5	
			Placebo	74	69 (93.2)	1.71 (0.93)	0.0	1.00	1.83	2.50	4.0	
		Week 40	Tezepelumab	78	77 (98.7)	1.67 (1.06)	0.0	0.83	1.67	2.50	4.3	
			Placebo	74	69 (93.2)	1.76 (0.98)	0.0	1.00	1.83	2.50	4.0	
		Week 42	Tezepelumab	78	77 (98.7)	1.63 (1.05)	0.0	1.00	1.50	2.33	4.3	
			Placebo	74	69 (93.2)	1.77 (0.98)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	78	77 (98.7)	1.71 (1.05)	0.0	1.00	1.67	2.67	4.3	
			Placebo	74	70 (94.6)	1.81 (0.98)	0.0	0.83	1.83	2.50	4.0	
		Week 46	Tezepelumab	78	77 (98.7)	1.69 (1.05)	0.0	1.00	1.83	2.50	4.3	
			Placebo	74	70 (94.6)	1.66 (0.95)	0.0	0.83	1.83	2.33	3.8	
		Week 48	Tezepelumab	78	77 (98.7)	1.72 (1.06)	0.0	1.00	1.67	2.50	4.3	
			Placebo	74	70 (94.6)	1.63 (1.00)	0.0	0.83	1.50	2.50	4.2	
		Week 50	Tezepelumab	78	77 (98.7)	1.63 (1.07)	0.0	0.83	1.67	2.33	4.3	
			Placebo	74	70 (94.6)	1.70 (0.93)	0.0	1.00	1.67	2.33	3.7	
		Week 52	Tezepelumab	78	77 (98.7)	1.67 (1.06)	0.0	1.00	1.67	2.33	4.3	
			Placebo	74	70 (94.6)	1.75 (0.98)	0.0	1.00	1.83	2.50	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	78	73 (93.6)	-0.49 (0.67)	-2.8	-0.67	-0.33	0.00	0.7	-0.07 [-0.40, 0.26]
			Placebo	74	66 (89.2)	-0.44 (0.67)	-2.8	-0.83	-0.33	0.00	1.2	
		Week 4	Tezepelumab	78	73 (93.6)	-0.73 (0.66)	-2.5	-1.17	-0.67	-0.33	0.5	-0.12 [-0.46, 0.21]
			Placebo	74	66 (89.2)	-0.64 (0.80)	-3.0	-1.00	-0.67	-0.17	1.2	
		Week 6	Tezepelumab	78	73 (93.6)	-0.79 (0.75)	-2.7	-1.33	-0.83	-0.33	0.7	-0.11 [-0.44, 0.22]
			Placebo	74	66 (89.2)	-0.70 (0.89)	-3.3	-1.17	-0.67	-0.17	1.5	
		Week 8	Tezepelumab	78	73 (93.6)	-0.86 (0.87)	-3.0	-1.33	-0.83	-0.33	2.2	-0.29 [-0.63, 0.04]
			Placebo	74	66 (89.2)	-0.61 (0.86)	-3.2	-1.00	-0.67	0.00	1.0	
		Week 10	Tezepelumab	78	73 (93.6)	-0.92 (0.82)	-3.2	-1.33	-0.83	-0.33	0.5	-0.14 [-0.47, 0.19]
			Placebo	74	67 (90.5)	-0.80 (0.82)	-3.3	-1.33	-0.83	-0.33	0.7	
		Week 12	Tezepelumab	78	73 (93.6)	-0.99 (0.85)	-2.8	-1.67	-0.83	-0.33	0.5	-0.19 [-0.52, 0.15]
			Placebo	74	67 (90.5)	-0.82 (0.94)	-3.3	-1.33	-0.67	-0.33	1.3	
		Week 14	Tezepelumab	78	73 (93.6)	-1.16 (0.81)	-3.2	-1.83	-1.17	-0.67	0.5	-0.32 [-0.65, 0.01]
			Placebo	74	67 (90.5)	-0.89 (0.90)	-3.2	-1.33	-0.83	-0.33	1.3	
		Week 16	Tezepelumab	78	73 (93.6)	-0.91 (0.85)	-3.0	-1.33	-1.00	-0.33	1.5	-0.13 [-0.47, 0.20]
			Placebo	74	67 (90.5)	-0.79 (0.93)	-3.2	-1.33	-0.67	-0.17	1.3	
		Week 18	Tezepelumab	78	74 (94.9)	-1.02 (0.79)	-3.2	-1.67	-0.92	-0.50	0.5	-0.18 [-0.51, 0.16]
			Placebo	74	67 (90.5)	-0.86 (0.98)	-3.2	-1.33	-0.83	-0.17	1.5	
		Week 20	Tezepelumab	78	74 (94.9)	-0.95 (0.89)	-3.2	-1.67	-0.83	-0.33	0.7	-0.10 [-0.43, 0.23]
			Placebo	74	67 (90.5)	-0.86 (1.02)	-3.2	-1.50	-0.67	-0.33	1.2	
		Week 22	Tezepelumab	78	74 (94.9)	-0.99 (0.83)	-3.0	-1.67	-0.83	-0.33	0.5	-0.09 [-0.42, 0.24]
			Placebo	74	67 (90.5)	-0.90 (1.01)	-3.3	-1.50	-0.83	-0.33	1.3	
		Week 24	Tezepelumab	78	74 (94.9)	-0.99 (0.82)	-3.2	-1.67	-0.83	-0.33	0.7	-0.06 [-0.39, 0.27]
			Placebo	74	67 (90.5)	-0.94 (1.02)	-3.2	-1.50	-0.83	-0.33	1.7	
		Week 26	Tezepelumab	78	75 (96.2)	-0.96 (0.85)	-2.8	-1.67	-0.83	-0.33	0.7	0.00 [-0.33, 0.33]
			Placebo	74	67 (90.5)	-0.96 (0.95)	-2.8	-1.67	-1.17	-0.33	1.5	
		Week 28	Tezepelumab	78	76 (97.4)	-0.96 (0.91)	-3.2	-1.67	-0.92	-0.25	0.8	-0.16 [-0.49, 0.16]
			Placebo	74	68 (91.9)	-0.81 (0.99)	-2.8	-1.50	-0.83	-0.33	1.5	
		Week 30	Tezepelumab	78	77 (98.7)	-0.98 (0.90)	-2.8	-1.83	-0.83	-0.33	1.8	-0.17 [-0.50, 0.15]
			Placebo	74	69 (93.2)	-0.82 (1.01)	-3.2	-1.50	-0.67	-0.17	1.3	
		Week 32	Tezepelumab	78	77 (98.7)	-1.03 (0.88)	-3.2	-1.50	-1.00	-0.50	0.8	-0.10 [-0.43, 0.22]
			Placebo	74	69 (93.2)	-0.94 (0.98)	-3.0	-1.50	-0.83	-0.33	1.3	
		Week 34	Tezepelumab	78	77 (98.7)	-1.05 (0.96)	-3.3	-1.83	-1.00	-0.33	2.0	-0.12 [-0.45, 0.20]
			Placebo	74	69 (93.2)	-0.93 (0.96)	-3.2	-1.50	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 25 ppb	Change from baseline	Week 36	Tezepelumab	78	77 (98.7)	-0.95 (0.95)	-3.2	-1.50	-1.00	-0.33	1.7	0.02 [-0.30, 0.35]
			Placebo	74	69 (93.2)	-0.97 (1.03)	-3.5	-1.50	-1.00	-0.33	1.3	
		Week 38	Tezepelumab	78	77 (98.7)	-1.02 (0.96)	-3.2	-1.83	-1.00	-0.33	2.3	-0.05 [-0.38, 0.27]
			Placebo	74	69 (93.2)	-0.97 (0.99)	-3.2	-1.50	-1.00	-0.33	1.3	
		Week 40	Tezepelumab	78	77 (98.7)	-0.98 (0.94)	-3.2	-1.50	-0.83	-0.33	1.7	-0.07 [-0.39, 0.26]
			Placebo	74	69 (93.2)	-0.92 (0.98)	-3.2	-1.50	-0.83	-0.33	1.3	
		Week 42	Tezepelumab	78	77 (98.7)	-1.02 (0.92)	-3.2	-1.67	-0.83	-0.50	2.0	-0.12 [-0.45, 0.20]
			Placebo	74	69 (93.2)	-0.90 (0.98)	-2.8	-1.50	-0.83	-0.33	1.3	
		Week 44	Tezepelumab	78	77 (98.7)	-0.94 (0.94)	-3.3	-1.67	-0.83	-0.17	1.5	-0.08 [-0.41, 0.24]
			Placebo	74	70 (94.6)	-0.86 (1.00)	-3.3	-1.50	-0.83	-0.17	1.3	
		Week 46	Tezepelumab	78	77 (98.7)	-0.96 (0.91)	-3.2	-1.83	-0.83	-0.33	1.7	0.05 [-0.27, 0.37]
			Placebo	74	70 (94.6)	-1.01 (1.00)	-3.2	-1.67	-1.00	-0.33	1.3	
		Week 48	Tezepelumab	78	77 (98.7)	-0.93 (0.95)	-3.2	-1.67	-0.83	-0.17	1.8	0.11 [-0.22, 0.43]
			Placebo	74	70 (94.6)	-1.04 (1.04)	-3.3	-1.67	-0.83	-0.50	1.7	
		Week 50	Tezepelumab	78	77 (98.7)	-1.02 (0.94)	-3.2	-1.67	-1.00	-0.50	1.8	-0.05 [-0.37, 0.28]
			Placebo	74	70 (94.6)	-0.97 (0.99)	-3.5	-1.50	-1.00	-0.33	1.5	
		Week 52	Tezepelumab	78	77 (98.7)	-0.98 (0.93)	-3.2	-1.67	-0.83	-0.33	1.8	-0.06 [-0.38, 0.27]
			Placebo	74	70 (94.6)	-0.92 (1.03)	-3.5	-1.67	-0.92	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.75 (0.98)	0.0	2.33	2.67	3.17	4.8	
			Placebo	63	63 (100.0)	2.67 (0.72)	1.3	2.17	2.67	3.00	4.7	
		Week 2	Tezepelumab	57	56 (98.2)	2.14 (0.94)	0.0	1.67	2.17	2.83	4.3	
			Placebo	63	58 (92.1)	2.36 (0.88)	0.2	2.00	2.42	2.83	4.8	
		Week 4	Tezepelumab	57	56 (98.2)	1.79 (1.06)	0.0	1.00	1.83	2.67	4.3	
			Placebo	63	58 (92.1)	2.31 (0.87)	0.3	1.83	2.33	2.83	4.2	
		Week 6	Tezepelumab	57	56 (98.2)	1.70 (1.07)	0.0	0.92	1.75	2.50	4.3	
			Placebo	63	59 (93.7)	2.19 (1.05)	0.2	1.50	2.33	2.67	5.5	
		Week 8	Tezepelumab	57	56 (98.2)	1.62 (1.09)	0.0	0.75	1.67	2.50	4.3	
			Placebo	63	60 (95.2)	2.04 (1.03)	0.0	1.25	2.17	2.50	4.7	
		Week 10	Tezepelumab	57	56 (98.2)	1.54 (1.05)	0.0	0.67	1.58	2.33	4.3	
			Placebo	63	60 (95.2)	2.02 (0.97)	0.0	1.33	2.00	2.67	5.3	
		Week 12	Tezepelumab	57	56 (98.2)	1.47 (1.04)	0.0	0.50	1.42	2.17	4.3	
			Placebo	63	60 (95.2)	1.93 (0.99)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	57	56 (98.2)	1.40 (1.04)	0.0	0.58	1.25	2.25	4.3	
			Placebo	63	60 (95.2)	1.89 (0.98)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	57	56 (98.2)	1.42 (1.06)	0.0	0.58	1.33	2.17	4.3	
			Placebo	63	60 (95.2)	2.06 (1.16)	0.0	1.00	2.17	2.67	5.0	
		Week 18	Tezepelumab	57	56 (98.2)	1.32 (0.98)	0.0	0.67	1.08	2.00	4.3	
			Placebo	63	60 (95.2)	1.91 (1.01)	0.0	1.17	2.17	2.50	5.0	
		Week 20	Tezepelumab	57	56 (98.2)	1.42 (1.00)	0.0	0.67	1.17	2.00	4.3	
			Placebo	63	60 (95.2)	2.02 (1.04)	0.0	1.25	2.33	2.67	5.0	
		Week 22	Tezepelumab	57	56 (98.2)	1.51 (0.98)	0.0	0.83	1.50	2.08	4.3	
			Placebo	63	60 (95.2)	1.97 (1.05)	0.0	1.17	2.08	2.67	5.0	
		Week 24	Tezepelumab	57	56 (98.2)	1.49 (1.09)	0.0	0.58	1.17	2.33	4.3	
			Placebo	63	60 (95.2)	2.01 (0.99)	0.0	1.25	2.17	2.58	4.5	
		Week 26	Tezepelumab	57	56 (98.2)	1.39 (0.98)	0.0	0.67	1.33	2.17	4.3	
			Placebo	63	60 (95.2)	1.93 (1.08)	0.0	1.08	1.75	2.83	4.5	
		Week 28	Tezepelumab	57	56 (98.2)	1.49 (1.06)	0.0	0.58	1.50	2.33	4.3	
			Placebo	63	60 (95.2)	1.91 (1.15)	0.0	1.00	2.00	2.67	4.5	
		Week 30	Tezepelumab	57	56 (98.2)	1.41 (0.99)	0.0	0.75	1.42	2.00	4.3	
			Placebo	63	60 (95.2)	1.90 (1.11)	0.0	1.17	1.92	2.50	4.5	
		Week 32	Tezepelumab	57	56 (98.2)	1.36 (1.03)	0.0	0.50	1.17	2.17	4.3	
			Placebo	63	60 (95.2)	1.93 (1.10)	0.0	1.17	1.92	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 25 ppb	Absolute values	Week 34	Tezepelumab	57	56 (98.2)	1.41 (1.04)	0.0	0.58	1.25	2.08	4.3	
			Placebo	63	60 (95.2)	1.85 (1.15)	0.0	1.00	1.67	2.50	4.5	
		Week 36	Tezepelumab	57	56 (98.2)	1.46 (1.04)	0.0	0.58	1.50	2.25	4.3	
			Placebo	63	60 (95.2)	2.06 (1.09)	0.0	1.25	2.17	2.67	4.5	
		Week 38	Tezepelumab	57	56 (98.2)	1.34 (0.97)	0.0	0.67	1.25	2.00	4.3	
			Placebo	63	60 (95.2)	1.86 (1.12)	0.0	1.00	1.92	2.50	4.5	
		Week 40	Tezepelumab	57	56 (98.2)	1.32 (1.00)	0.0	0.50	1.17	2.00	4.3	
			Placebo	63	60 (95.2)	1.96 (1.10)	0.0	1.00	2.17	2.67	4.5	
		Week 42	Tezepelumab	57	56 (98.2)	1.32 (1.03)	0.0	0.58	1.17	1.83	4.7	
			Placebo	63	60 (95.2)	1.88 (1.05)	0.0	1.08	2.00	2.50	4.5	
		Week 44	Tezepelumab	57	56 (98.2)	1.24 (0.93)	0.0	0.50	1.08	2.00	4.3	
			Placebo	63	60 (95.2)	1.92 (1.06)	0.0	1.08	2.00	2.67	4.5	
		Week 46	Tezepelumab	57	56 (98.2)	1.22 (0.97)	0.0	0.67	1.00	1.83	4.3	
			Placebo	63	60 (95.2)	1.86 (1.00)	0.0	1.17	2.00	2.50	4.5	
		Week 48	Tezepelumab	57	56 (98.2)	1.32 (0.99)	0.0	0.67	1.17	2.00	4.3	
			Placebo	63	60 (95.2)	1.97 (1.01)	0.0	1.25	2.17	2.67	4.5	
		Week 50	Tezepelumab	57	56 (98.2)	1.24 (0.95)	0.0	0.67	1.00	1.92	4.3	
			Placebo	63	60 (95.2)	1.84 (1.01)	0.0	1.00	1.92	2.50	4.5	
		Week 52	Tezepelumab	57	56 (98.2)	1.25 (0.95)	0.0	0.50	1.00	1.92	4.3	
			Placebo	63	60 (95.2)	1.89 (1.03)	0.0	1.08	2.17	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 2	Tezepelumab	57	56 (98.2)	-0.61 (0.68)	-2.3	-1.00	-0.50	-0.17	0.7	-0.45 [-0.82, -0.08]
			Placebo	63	58 (92.1)	-0.28 (0.74)	-2.7	-0.67	-0.25	0.17	1.0	
		Week 4	Tezepelumab	57	56 (98.2)	-0.96 (1.10)	-3.5	-1.50	-1.08	-0.17	2.3	-0.65 [-1.02, -0.27]
			Placebo	63	58 (92.1)	-0.33 (0.84)	-2.0	-1.00	-0.17	0.33	1.2	
		Week 6	Tezepelumab	57	56 (98.2)	-1.05 (1.18)	-3.8	-1.83	-1.08	-0.33	2.3	-0.58 [-0.95, -0.21]
			Placebo	63	59 (93.7)	-0.44 (0.90)	-2.2	-1.17	-0.33	0.17	1.5	
		Week 8	Tezepelumab	57	56 (98.2)	-1.13 (1.14)	-3.8	-1.83	-1.00	-0.33	2.3	-0.51 [-0.88, -0.14]
			Placebo	63	60 (95.2)	-0.60 (0.95)	-3.0	-1.17	-0.50	0.00	1.0	
		Week 10	Tezepelumab	57	56 (98.2)	-1.21 (1.15)	-3.8	-1.92	-1.33	-0.50	2.3	-0.55 [-0.92, -0.18]
			Placebo	63	60 (95.2)	-0.62 (1.04)	-2.7	-1.33	-0.50	0.00	2.7	
		Week 12	Tezepelumab	57	56 (98.2)	-1.28 (1.12)	-3.7	-1.92	-1.33	-0.67	2.3	-0.54 [-0.91, -0.17]
			Placebo	63	60 (95.2)	-0.71 (1.00)	-3.2	-1.33	-0.67	0.00	1.3	
		Week 14	Tezepelumab	57	56 (98.2)	-1.35 (1.21)	-3.8	-2.08	-1.33	-0.67	2.3	-0.54 [-0.91, -0.17]
			Placebo	63	60 (95.2)	-0.75 (1.01)	-3.2	-1.33	-0.83	-0.08	2.3	
		Week 16	Tezepelumab	57	56 (98.2)	-1.33 (1.22)	-4.2	-2.17	-1.42	-0.75	2.3	-0.64 [-1.02, -0.27]
			Placebo	63	60 (95.2)	-0.58 (1.13)	-3.5	-1.17	-0.58	0.17	2.3	
		Week 18	Tezepelumab	57	56 (98.2)	-1.43 (1.20)	-4.2	-2.08	-1.50	-0.67	2.3	-0.62 [-0.99, -0.24]
			Placebo	63	60 (95.2)	-0.73 (1.06)	-3.2	-1.50	-0.67	-0.25	2.3	
		Week 20	Tezepelumab	57	56 (98.2)	-1.33 (1.13)	-4.2	-2.00	-1.42	-0.67	2.3	-0.64 [-1.02, -0.27]
			Placebo	63	60 (95.2)	-0.62 (1.07)	-3.5	-1.17	-0.67	-0.08	2.3	
		Week 22	Tezepelumab	57	56 (98.2)	-1.24 (1.25)	-4.3	-2.00	-1.17	-0.67	2.3	-0.50 [-0.87, -0.13]
			Placebo	63	60 (95.2)	-0.67 (1.00)	-3.0	-1.33	-0.58	0.00	2.3	
		Week 24	Tezepelumab	57	56 (98.2)	-1.26 (1.17)	-4.5	-1.92	-1.42	-0.50	2.3	-0.57 [-0.94, -0.20]
			Placebo	63	60 (95.2)	-0.63 (1.04)	-3.5	-1.33	-0.50	0.08	2.3	
		Week 26	Tezepelumab	57	56 (98.2)	-1.36 (1.22)	-4.2	-2.25	-1.42	-0.58	2.3	-0.55 [-0.92, -0.18]
			Placebo	63	60 (95.2)	-0.71 (1.13)	-4.0	-1.42	-0.67	0.17	2.3	
		Week 28	Tezepelumab	57	56 (98.2)	-1.26 (1.19)	-4.2	-2.08	-1.42	-0.33	2.3	-0.44 [-0.81, -0.07]
			Placebo	63	60 (95.2)	-0.74 (1.17)	-4.0	-1.50	-0.67	0.00	2.3	
		Week 30	Tezepelumab	57	56 (98.2)	-1.34 (1.21)	-4.2	-2.25	-1.33	-0.67	2.3	-0.52 [-0.89, -0.15]
			Placebo	63	60 (95.2)	-0.74 (1.12)	-3.2	-1.42	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	57	56 (98.2)	-1.39 (1.23)	-4.2	-2.17	-1.50	-0.67	2.3	-0.58 [-0.95, -0.21]
			Placebo	63	60 (95.2)	-0.71 (1.11)	-3.5	-1.50	-0.67	-0.08	2.3	
		Week 34	Tezepelumab	57	56 (98.2)	-1.34 (1.19)	-4.2	-2.17	-1.50	-0.67	2.3	-0.46 [-0.83, -0.09]
			Placebo	63	60 (95.2)	-0.79 (1.15)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 25 ppb	Change from baseline	Week 36	Tezepelumab	57	56 (98.2)	-1.29 (1.27)	-4.2	-2.17	-1.50	-0.50	2.3	-0.60 [-0.97, -0.22]
			Placebo	63	60 (95.2)	-0.59 (1.10)	-3.5	-1.33	-0.42	0.17	2.3	
		Week 38	Tezepelumab	57	56 (98.2)	-1.41 (1.23)	-4.2	-2.17	-1.33	-0.75	2.3	-0.53 [-0.90, -0.16]
			Placebo	63	60 (95.2)	-0.78 (1.15)	-4.0	-1.42	-0.83	0.00	2.3	
		Week 40	Tezepelumab	57	56 (98.2)	-1.43 (1.25)	-4.2	-2.25	-1.50	-0.75	2.3	-0.62 [-0.99, -0.25]
			Placebo	63	60 (95.2)	-0.68 (1.14)	-4.0	-1.33	-0.75	0.17	2.3	
		Week 42	Tezepelumab	57	56 (98.2)	-1.43 (1.27)	-4.2	-2.17	-1.50	-0.75	2.3	-0.55 [-0.93, -0.18]
			Placebo	63	60 (95.2)	-0.77 (1.11)	-4.0	-1.33	-0.83	-0.08	2.3	
		Week 44	Tezepelumab	57	56 (98.2)	-1.51 (1.22)	-4.3	-2.33	-1.50	-0.75	2.3	-0.66 [-1.04, -0.29]
			Placebo	63	60 (95.2)	-0.72 (1.13)	-4.0	-1.42	-0.75	-0.08	2.3	
		Week 46	Tezepelumab	57	56 (98.2)	-1.53 (1.24)	-4.2	-2.33	-1.50	-0.83	2.3	-0.65 [-1.03, -0.28]
			Placebo	63	60 (95.2)	-0.78 (1.06)	-4.0	-1.33	-0.83	0.00	2.3	
		Week 48	Tezepelumab	57	56 (98.2)	-1.43 (1.23)	-4.2	-2.17	-1.50	-0.67	2.3	-0.66 [-1.03, -0.28]
			Placebo	63	60 (95.2)	-0.67 (1.06)	-3.7	-1.33	-0.75	0.17	2.3	
		Week 50	Tezepelumab	57	56 (98.2)	-1.51 (1.22)	-4.2	-2.42	-1.50	-0.83	2.3	-0.62 [-0.99, -0.25]
			Placebo	63	60 (95.2)	-0.80 (1.05)	-4.0	-1.33	-0.83	-0.17	2.3	
		Week 52	Tezepelumab	57	56 (98.2)	-1.50 (1.24)	-4.2	-2.42	-1.50	-0.83	2.3	-0.65 [-1.03, -0.28]
			Placebo	63	60 (95.2)	-0.75 (1.06)	-4.0	-1.33	-0.67	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.80 (0.70)	1.0	2.33	2.83	3.00	4.8	
			Placebo	66	66 (100.0)	2.62 (0.67)	1.3	2.17	2.67	3.00	4.3	
		Week 2	Tezepelumab	57	56 (98.2)	2.21 (0.83)	0.2	1.58	2.33	2.83	4.0	
			Placebo	66	58 (87.9)	2.31 (0.78)	0.3	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	57	56 (98.2)	1.89 (0.84)	0.2	1.17	2.08	2.50	3.5	
			Placebo	66	58 (87.9)	2.30 (0.87)	0.2	1.83	2.33	2.83	4.2	
		Week 6	Tezepelumab	57	56 (98.2)	1.71 (0.88)	0.0	1.17	1.67	2.42	3.7	
			Placebo	66	59 (89.4)	2.12 (0.96)	0.2	1.50	2.17	2.67	4.7	
		Week 8	Tezepelumab	57	56 (98.2)	1.73 (0.95)	0.0	1.33	1.83	2.33	4.8	
			Placebo	66	60 (90.9)	2.14 (0.92)	0.0	1.67	2.25	2.75	4.7	
		Week 10	Tezepelumab	57	56 (98.2)	1.62 (0.94)	0.0	1.08	1.67	2.08	4.3	
			Placebo	66	60 (90.9)	2.00 (0.90)	0.2	1.33	2.00	2.50	4.2	
		Week 12	Tezepelumab	57	56 (98.2)	1.57 (1.02)	0.0	0.83	1.50	2.42	4.3	
			Placebo	66	60 (90.9)	2.00 (0.92)	0.0	1.42	2.00	2.67	4.3	
		Week 14	Tezepelumab	57	56 (98.2)	1.43 (0.93)	0.0	0.83	1.50	2.00	4.3	
			Placebo	66	60 (90.9)	1.90 (0.93)	0.0	1.33	1.83	2.50	5.0	
		Week 16	Tezepelumab	57	56 (98.2)	1.57 (1.01)	0.0	0.83	1.58	2.25	4.3	
			Placebo	66	60 (90.9)	2.06 (1.00)	0.0	1.33	2.17	2.75	4.5	
		Week 18	Tezepelumab	57	56 (98.2)	1.44 (0.88)	0.0	0.83	1.42	2.00	4.3	
			Placebo	66	60 (90.9)	1.90 (0.95)	0.0	1.25	1.83	2.33	4.5	
		Week 20	Tezepelumab	57	56 (98.2)	1.47 (0.96)	0.0	0.92	1.50	2.17	4.3	
			Placebo	66	60 (90.9)	2.09 (1.00)	0.0	1.33	2.33	2.75	4.5	
		Week 22	Tezepelumab	57	56 (98.2)	1.60 (0.92)	0.0	1.17	1.67	2.33	4.3	
			Placebo	66	60 (90.9)	2.03 (1.00)	0.0	1.33	2.00	2.67	4.5	
		Week 24	Tezepelumab	57	56 (98.2)	1.62 (0.98)	0.0	1.00	1.67	2.33	4.3	
			Placebo	66	60 (90.9)	2.05 (1.02)	0.0	1.33	2.25	2.67	4.5	
		Week 26	Tezepelumab	57	57 (100.0)	1.49 (0.91)	0.0	1.00	1.33	2.17	4.3	
			Placebo	66	60 (90.9)	2.00 (1.03)	0.0	1.00	2.00	2.83	4.5	
		Week 28	Tezepelumab	57	57 (100.0)	1.55 (0.93)	0.0	1.00	1.50	2.17	4.3	
			Placebo	66	60 (90.9)	2.06 (1.06)	0.0	1.08	2.17	2.75	4.5	
		Week 30	Tezepelumab	57	57 (100.0)	1.57 (0.95)	0.0	0.83	1.50	2.17	4.3	
			Placebo	66	61 (92.4)	2.04 (1.03)	0.0	1.50	2.17	2.83	4.5	
		Week 32	Tezepelumab	57	57 (100.0)	1.55 (0.94)	0.0	1.00	1.67	2.33	4.3	
			Placebo	66	61 (92.4)	2.08 (1.06)	0.0	1.17	2.17	2.83	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Absolute values	Week 34	Tezepelumab	57	57 (100.0)	1.55 (1.00)	0.0	1.00	1.50	2.50	4.3	
			Placebo	66	61 (92.4)	2.01 (1.09)	0.0	1.33	1.83	2.83	4.5	
		Week 36	Tezepelumab	57	57 (100.0)	1.63 (1.03)	0.0	1.00	1.67	2.33	4.5	
			Placebo	66	61 (92.4)	2.13 (1.05)	0.0	1.50	2.33	2.83	4.5	
		Week 38	Tezepelumab	57	57 (100.0)	1.56 (1.01)	0.0	0.83	1.50	2.17	4.3	
			Placebo	66	61 (92.4)	1.96 (1.05)	0.0	1.17	2.00	2.67	4.5	
		Week 40	Tezepelumab	57	57 (100.0)	1.55 (1.00)	0.0	0.83	1.67	2.17	4.3	
			Placebo	66	61 (92.4)	2.12 (1.01)	0.0	1.50	2.17	2.67	4.5	
		Week 42	Tezepelumab	57	57 (100.0)	1.54 (0.98)	0.0	1.00	1.50	2.17	4.3	
			Placebo	66	61 (92.4)	2.04 (1.05)	0.0	1.33	2.00	2.67	4.7	
		Week 44	Tezepelumab	57	57 (100.0)	1.54 (0.99)	0.0	0.83	1.50	2.50	4.3	
			Placebo	66	62 (93.9)	2.20 (0.97)	0.0	1.67	2.42	2.83	4.5	
		Week 46	Tezepelumab	57	57 (100.0)	1.55 (1.01)	0.0	0.83	1.50	2.17	4.3	
			Placebo	66	62 (93.9)	1.98 (1.00)	0.0	1.33	2.00	2.67	4.5	
		Week 48	Tezepelumab	57	57 (100.0)	1.58 (1.00)	0.0	0.83	1.50	2.33	4.3	
			Placebo	66	62 (93.9)	2.06 (1.02)	0.0	1.50	2.17	2.67	4.5	
		Week 50	Tezepelumab	57	57 (100.0)	1.51 (0.97)	0.0	0.83	1.33	2.17	4.3	
			Placebo	66	62 (93.9)	2.00 (0.96)	0.0	1.33	2.17	2.67	4.5	
		Week 52	Tezepelumab	57	57 (100.0)	1.52 (0.99)	0.0	0.83	1.50	2.17	4.3	
			Placebo	66	62 (93.9)	2.06 (0.99)	0.0	1.33	2.17	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	57	56 (98.2)	-0.61 (0.61)	-2.5	-0.92	-0.58	-0.17	0.5	-0.47 [-0.84, -0.10]
			Placebo	66	58 (87.9)	-0.30 (0.70)	-2.8	-0.67	-0.25	0.17	1.2	
		Week 4	Tezepelumab	57	56 (98.2)	-0.93 (0.70)	-2.5	-1.42	-0.83	-0.50	0.5	-0.80 [-1.18, -0.42]
			Placebo	66	58 (87.9)	-0.31 (0.83)	-2.3	-0.83	-0.17	0.17	1.2	
		Week 6	Tezepelumab	57	56 (98.2)	-1.11 (0.80)	-2.7	-1.67	-1.08	-0.67	1.2	-0.72 [-1.10, -0.34]
			Placebo	66	59 (89.4)	-0.49 (0.91)	-2.3	-1.17	-0.50	0.17	1.5	
		Week 8	Tezepelumab	57	56 (98.2)	-1.09 (0.95)	-3.0	-1.67	-1.00	-0.50	2.2	-0.69 [-1.06, -0.31]
			Placebo	66	60 (90.9)	-0.48 (0.81)	-2.5	-0.92	-0.50	0.00	1.0	
		Week 10	Tezepelumab	57	56 (98.2)	-1.20 (0.85)	-3.2	-1.67	-1.25	-0.67	0.5	-0.65 [-1.02, -0.27]
			Placebo	66	60 (90.9)	-0.62 (0.93)	-2.3	-1.17	-0.50	-0.17	2.5	
		Week 12	Tezepelumab	57	56 (98.2)	-1.25 (0.87)	-3.0	-1.83	-1.17	-0.67	0.5	-0.72 [-1.10, -0.35]
			Placebo	66	60 (90.9)	-0.61 (0.89)	-2.7	-1.00	-0.50	0.00	1.3	
		Week 14	Tezepelumab	57	56 (98.2)	-1.39 (0.88)	-3.7	-2.00	-1.42	-0.83	0.5	-0.75 [-1.12, -0.37]
			Placebo	66	60 (90.9)	-0.72 (0.91)	-2.7	-1.33	-0.75	0.00	1.3	
		Week 16	Tezepelumab	57	56 (98.2)	-1.24 (0.97)	-3.0	-2.08	-1.08	-0.67	1.2	-0.73 [-1.11, -0.35]
			Placebo	66	60 (90.9)	-0.56 (0.92)	-2.7	-1.00	-0.50	0.08	2.3	
		Week 18	Tezepelumab	57	56 (98.2)	-1.38 (0.90)	-3.5	-1.92	-1.33	-0.83	0.5	-0.71 [-1.09, -0.34]
			Placebo	66	60 (90.9)	-0.72 (0.95)	-3.2	-1.33	-0.67	-0.25	2.3	
		Week 20	Tezepelumab	57	56 (98.2)	-1.35 (0.87)	-3.2	-2.00	-1.33	-0.75	0.5	-0.88 [-1.26, -0.50]
			Placebo	66	60 (90.9)	-0.53 (0.97)	-3.0	-1.00	-0.50	0.00	2.3	
		Week 22	Tezepelumab	57	56 (98.2)	-1.22 (0.89)	-3.2	-1.92	-1.08	-0.67	0.5	-0.68 [-1.06, -0.31]
			Placebo	66	60 (90.9)	-0.59 (0.95)	-3.2	-1.17	-0.50	0.00	2.3	
		Week 24	Tezepelumab	57	56 (98.2)	-1.20 (0.81)	-3.2	-1.83	-1.17	-0.67	0.5	-0.67 [-1.04, -0.29]
			Placebo	66	60 (90.9)	-0.57 (1.05)	-3.0	-1.33	-0.50	0.17	2.3	
		Week 26	Tezepelumab	57	57 (100.0)	-1.31 (0.94)	-3.5	-2.00	-1.33	-0.67	0.5	-0.69 [-1.07, -0.32]
			Placebo	66	60 (90.9)	-0.62 (1.05)	-2.7	-1.33	-0.67	0.17	2.3	
		Week 28	Tezepelumab	57	57 (100.0)	-1.25 (0.91)	-3.2	-2.00	-1.17	-0.67	0.8	-0.71 [-1.09, -0.34]
			Placebo	66	60 (90.9)	-0.56 (1.04)	-2.8	-1.17	-0.42	0.17	2.3	
		Week 30	Tezepelumab	57	57 (100.0)	-1.23 (1.03)	-3.5	-2.17	-1.00	-0.67	1.8	-0.62 [-0.99, -0.25]
			Placebo	66	61 (92.4)	-0.58 (1.03)	-2.8	-1.17	-0.50	0.17	2.3	
		Week 32	Tezepelumab	57	57 (100.0)	-1.25 (0.99)	-3.5	-2.00	-1.00	-0.83	0.8	-0.70 [-1.07, -0.32]
			Placebo	66	61 (92.4)	-0.54 (1.04)	-3.0	-1.17	-0.33	0.17	2.3	
		Week 34	Tezepelumab	57	57 (100.0)	-1.25 (1.03)	-3.0	-2.00	-1.33	-0.67	2.0	-0.61 [-0.97, -0.24]
			Placebo	66	61 (92.4)	-0.61 (1.07)	-3.2	-1.33	-0.50	0.00	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Change from baseline	Week 36	Tezepelumab	57	57 (100.0)	-1.17 (1.08)	-3.0	-2.00	-1.17	-0.50	1.7	-0.62 [-0.99, -0.25]
			Placebo	66	61 (92.4)	-0.49 (1.09)	-3.2	-1.00	-0.33	0.17	2.3	
		Week 38	Tezepelumab	57	57 (100.0)	-1.24 (1.08)	-3.7	-2.00	-1.17	-0.67	2.3	-0.53 [-0.90, -0.16]
			Placebo	66	61 (92.4)	-0.66 (1.12)	-3.2	-1.33	-0.50	0.17	2.3	
		Week 40	Tezepelumab	57	57 (100.0)	-1.25 (1.07)	-3.8	-2.00	-1.00	-0.67	1.7	-0.70 [-1.07, -0.33]
			Placebo	66	61 (92.4)	-0.50 (1.07)	-3.2	-1.17	-0.50	0.17	2.3	
		Week 42	Tezepelumab	57	57 (100.0)	-1.26 (1.03)	-3.3	-2.00	-1.17	-0.67	2.0	-0.62 [-0.99, -0.25]
			Placebo	66	61 (92.4)	-0.58 (1.13)	-3.2	-1.33	-0.67	0.17	2.3	
		Week 44	Tezepelumab	57	57 (100.0)	-1.25 (1.11)	-4.3	-1.83	-1.00	-0.50	1.5	-0.78 [-1.15, -0.41]
			Placebo	66	62 (93.9)	-0.41 (1.04)	-2.8	-1.17	-0.33	0.33	2.3	
		Week 46	Tezepelumab	57	57 (100.0)	-1.25 (1.09)	-4.2	-2.00	-1.17	-0.67	1.7	-0.55 [-0.92, -0.19]
			Placebo	66	62 (93.9)	-0.63 (1.12)	-3.2	-1.33	-0.67	0.17	2.3	
		Week 48	Tezepelumab	57	57 (100.0)	-1.22 (1.09)	-4.2	-2.00	-1.17	-0.50	1.8	-0.61 [-0.97, -0.24]
			Placebo	66	62 (93.9)	-0.56 (1.09)	-3.2	-1.17	-0.50	0.17	2.3	
		Week 50	Tezepelumab	57	57 (100.0)	-1.28 (1.02)	-3.8	-2.00	-1.33	-0.67	1.8	-0.65 [-1.02, -0.28]
			Placebo	66	62 (93.9)	-0.62 (1.03)	-3.0	-1.17	-0.67	0.00	2.3	
		Week 52	Tezepelumab	57	57 (100.0)	-1.27 (1.06)	-4.2	-2.00	-1.17	-0.67	1.8	-0.69 [-1.06, -0.32]
			Placebo	66	62 (93.9)	-0.55 (1.03)	-2.8	-1.00	-0.42	0.00	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	71	71 (100.0)	2.62 (0.86)	0.0	2.17	2.67	3.17	4.8	
			Placebo	63	63 (100.0)	2.69 (0.73)	0.3	2.33	2.67	3.17	4.7	
		Week 2	Tezepelumab	71	67 (94.4)	2.11 (0.99)	0.0	1.67	2.17	2.83	4.3	
			Placebo	63	58 (92.1)	2.29 (0.81)	0.2	2.00	2.33	2.83	4.7	
		Week 4	Tezepelumab	71	67 (94.4)	1.84 (1.07)	0.0	1.00	1.83	2.67	4.3	
			Placebo	63	58 (92.1)	2.13 (0.79)	0.3	1.50	2.17	2.67	4.0	
		Week 6	Tezepelumab	71	67 (94.4)	1.85 (1.05)	0.0	1.17	1.67	2.67	4.3	
			Placebo	63	58 (92.1)	2.06 (0.97)	0.2	1.33	2.17	2.67	5.5	
		Week 8	Tezepelumab	71	67 (94.4)	1.71 (1.11)	0.0	0.83	1.67	2.67	4.3	
			Placebo	63	58 (92.1)	2.01 (0.95)	0.2	1.33	2.00	2.67	4.7	
		Week 10	Tezepelumab	71	67 (94.4)	1.69 (1.08)	0.0	0.67	1.67	2.67	4.3	
			Placebo	63	59 (93.7)	2.03 (0.91)	0.0	1.50	2.00	2.67	5.3	
		Week 12	Tezepelumab	71	67 (94.4)	1.61 (1.07)	0.0	0.50	1.67	2.50	4.3	
			Placebo	63	59 (93.7)	1.84 (0.92)	0.0	1.17	1.83	2.50	4.3	
		Week 14	Tezepelumab	71	67 (94.4)	1.49 (1.08)	0.0	0.50	1.33	2.33	4.3	
			Placebo	63	59 (93.7)	1.87 (0.88)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	71	67 (94.4)	1.60 (1.06)	0.0	0.83	1.50	2.50	4.3	
			Placebo	63	59 (93.7)	1.95 (1.01)	0.0	1.17	1.83	2.67	5.0	
		Week 18	Tezepelumab	71	67 (94.4)	1.54 (1.06)	0.0	0.67	1.33	2.33	4.3	
			Placebo	63	59 (93.7)	1.92 (1.00)	0.0	1.33	2.00	2.50	5.0	
		Week 20	Tezepelumab	71	67 (94.4)	1.65 (1.09)	0.0	0.83	1.50	2.50	5.0	
			Placebo	63	59 (93.7)	1.85 (0.92)	0.2	1.17	1.83	2.50	5.0	
		Week 22	Tezepelumab	71	67 (94.4)	1.58 (1.03)	0.0	0.83	1.67	2.33	4.3	
			Placebo	63	59 (93.7)	1.84 (0.94)	0.0	1.17	2.00	2.50	5.0	
		Week 24	Tezepelumab	71	67 (94.4)	1.55 (1.09)	0.0	0.67	1.50	2.33	4.3	
			Placebo	63	59 (93.7)	1.80 (0.85)	0.2	1.00	1.83	2.50	4.2	
		Week 26	Tezepelumab	71	67 (94.4)	1.60 (1.11)	0.0	0.83	1.67	2.33	4.3	
			Placebo	63	59 (93.7)	1.72 (0.88)	0.0	1.17	1.50	2.33	4.2	
		Week 28	Tezepelumab	71	68 (95.8)	1.65 (1.12)	0.0	0.67	1.67	2.50	4.3	
			Placebo	63	60 (95.2)	1.75 (0.97)	0.0	1.00	1.83	2.50	4.2	
		Week 30	Tezepelumab	71	69 (97.2)	1.55 (1.07)	0.0	0.67	1.50	2.33	4.3	
			Placebo	63	60 (95.2)	1.78 (0.96)	0.0	1.17	1.83	2.50	4.2	
		Week 32	Tezepelumab	71	69 (97.2)	1.47 (1.10)	0.0	0.67	1.17	2.33	4.3	
			Placebo	63	60 (95.2)	1.63 (0.90)	0.0	1.00	1.50	2.42	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Absolute values	Week 34	Tezepelumab	71	69 (97.2)	1.50 (1.15)	0.0	0.67	1.33	2.33	4.3	
			Placebo	63	60 (95.2)	1.64 (0.91)	0.0	1.00	1.67	2.33	4.2	
		Week 36	Tezepelumab	71	69 (97.2)	1.59 (1.09)	0.0	0.83	1.67	2.33	4.3	
			Placebo	63	60 (95.2)	1.70 (0.92)	0.0	1.00	1.83	2.42	4.2	
		Week 38	Tezepelumab	71	69 (97.2)	1.48 (1.10)	0.0	0.67	1.50	2.00	4.5	
			Placebo	63	60 (95.2)	1.68 (0.94)	0.0	1.00	1.58	2.42	4.2	
		Week 40	Tezepelumab	71	69 (97.2)	1.50 (1.11)	0.0	0.50	1.50	2.33	4.3	
			Placebo	63	60 (95.2)	1.67 (0.97)	0.0	0.83	1.67	2.50	4.2	
		Week 42	Tezepelumab	71	69 (97.2)	1.46 (1.12)	0.0	0.67	1.33	2.00	4.7	
			Placebo	63	60 (95.2)	1.69 (0.90)	0.0	0.92	1.83	2.50	3.3	
		Week 44	Tezepelumab	71	69 (97.2)	1.49 (1.07)	0.0	0.50	1.33	2.33	4.3	
			Placebo	63	60 (95.2)	1.62 (0.95)	0.0	0.83	1.67	2.42	4.0	
		Week 46	Tezepelumab	71	69 (97.2)	1.42 (1.08)	0.0	0.67	1.00	2.17	4.3	
			Placebo	63	60 (95.2)	1.60 (0.87)	0.0	1.00	1.58	2.25	3.3	
		Week 48	Tezepelumab	71	69 (97.2)	1.52 (1.11)	0.0	0.67	1.50	2.33	4.3	
			Placebo	63	60 (95.2)	1.59 (0.91)	0.0	0.83	1.50	2.42	3.3	
		Week 50	Tezepelumab	71	69 (97.2)	1.44 (1.12)	0.0	0.67	1.17	2.17	4.3	
			Placebo	63	60 (95.2)	1.54 (0.87)	0.0	1.00	1.50	2.25	3.3	
		Week 52	Tezepelumab	71	69 (97.2)	1.48 (1.10)	0.0	0.67	1.33	2.17	4.3	
			Placebo	63	60 (95.2)	1.58 (0.91)	0.0	1.00	1.58	2.25	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	71	67 (94.4)	-0.48 (0.73)	-2.8	-0.83	-0.33	0.17	0.7	-0.07 [-0.43, 0.28]
			Placebo	63	58 (92.1)	-0.42 (0.70)	-2.7	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	71	67 (94.4)	-0.75 (1.01)	-3.5	-1.33	-0.67	-0.17	2.3	-0.17 [-0.52, 0.18]
			Placebo	63	58 (92.1)	-0.59 (0.83)	-3.0	-1.17	-0.42	0.00	0.8	
		Week 6	Tezepelumab	71	67 (94.4)	-0.74 (1.03)	-3.8	-1.33	-0.67	0.00	2.3	-0.10 [-0.45, 0.25]
			Placebo	63	58 (92.1)	-0.65 (0.88)	-3.3	-1.17	-0.50	-0.17	1.3	
		Week 8	Tezepelumab	71	67 (94.4)	-0.88 (1.01)	-3.8	-1.50	-0.83	-0.33	2.3	-0.17 [-0.53, 0.18]
			Placebo	63	58 (92.1)	-0.70 (0.96)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	71	67 (94.4)	-0.90 (1.02)	-3.8	-1.50	-1.00	-0.17	2.3	-0.20 [-0.55, 0.15]
			Placebo	63	59 (93.7)	-0.70 (1.00)	-3.3	-1.33	-0.67	0.00	2.7	
		Week 12	Tezepelumab	71	67 (94.4)	-0.98 (1.03)	-3.7	-1.67	-0.83	-0.33	2.3	-0.10 [-0.45, 0.25]
			Placebo	63	59 (93.7)	-0.88 (1.00)	-3.3	-1.50	-0.83	-0.17	1.3	
		Week 14	Tezepelumab	71	67 (94.4)	-1.10 (1.04)	-3.8	-1.83	-1.17	-0.33	2.3	-0.24 [-0.59, 0.11]
			Placebo	63	59 (93.7)	-0.85 (0.99)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 16	Tezepelumab	71	67 (94.4)	-0.99 (1.00)	-3.8	-1.67	-1.00	-0.33	2.3	-0.21 [-0.56, 0.14]
			Placebo	63	59 (93.7)	-0.77 (1.11)	-3.5	-1.33	-0.67	0.00	2.3	
		Week 18	Tezepelumab	71	67 (94.4)	-1.05 (1.02)	-3.8	-1.67	-0.83	-0.50	2.3	-0.24 [-0.59, 0.11]
			Placebo	63	59 (93.7)	-0.80 (1.08)	-3.2	-1.50	-0.67	0.00	2.3	
		Week 20	Tezepelumab	71	67 (94.4)	-0.94 (1.02)	-3.8	-1.67	-0.83	-0.33	2.3	-0.07 [-0.42, 0.28]
			Placebo	63	59 (93.7)	-0.87 (1.03)	-3.5	-1.50	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	71	67 (94.4)	-1.01 (1.08)	-3.8	-1.67	-0.83	-0.33	2.3	-0.12 [-0.48, 0.23]
			Placebo	63	59 (93.7)	-0.88 (1.01)	-3.3	-1.50	-0.83	-0.17	2.3	
		Week 24	Tezepelumab	71	67 (94.4)	-1.04 (1.03)	-3.8	-1.67	-0.83	-0.50	2.3	-0.11 [-0.46, 0.24]
			Placebo	63	59 (93.7)	-0.93 (0.95)	-3.5	-1.50	-0.83	-0.17	1.5	
		Week 26	Tezepelumab	71	67 (94.4)	-0.99 (1.05)	-3.8	-1.83	-0.83	-0.33	2.3	0.02 [-0.33, 0.36]
			Placebo	63	59 (93.7)	-1.01 (1.02)	-4.0	-1.67	-1.00	-0.17	1.5	
		Week 28	Tezepelumab	71	68 (95.8)	-0.94 (1.06)	-3.8	-1.75	-0.75	-0.17	2.3	-0.00 [-0.35, 0.35]
			Placebo	63	60 (95.2)	-0.94 (1.08)	-4.0	-1.58	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	71	69 (97.2)	-1.05 (1.03)	-3.7	-1.83	-1.00	-0.33	2.3	-0.14 [-0.48, 0.21]
			Placebo	63	60 (95.2)	-0.90 (1.04)	-3.2	-1.50	-1.08	-0.17	2.0	
		Week 32	Tezepelumab	71	69 (97.2)	-1.12 (1.06)	-3.8	-1.83	-1.00	-0.50	2.3	-0.07 [-0.42, 0.28]
			Placebo	63	60 (95.2)	-1.05 (0.96)	-3.5	-1.67	-1.17	-0.33	1.5	
		Week 34	Tezepelumab	71	69 (97.2)	-1.09 (1.08)	-3.8	-1.83	-1.00	-0.50	2.3	-0.05 [-0.40, 0.29]
			Placebo	63	60 (95.2)	-1.04 (0.95)	-4.0	-1.58	-1.00	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Change from baseline	Week 36	Tezepelumab	71	69 (97.2)	-1.01 (1.10)	-3.8	-1.67	-1.00	-0.17	2.3	-0.02 [-0.37, 0.32]
			Placebo	63	60 (95.2)	-0.98 (0.97)	-3.5	-1.42	-1.00	-0.33	1.5	
		Week 38	Tezepelumab	71	69 (97.2)	-1.12 (1.08)	-3.8	-2.00	-1.17	-0.33	2.3	-0.11 [-0.46, 0.23]
			Placebo	63	60 (95.2)	-1.00 (0.97)	-4.0	-1.58	-1.08	-0.50	1.5	
		Week 40	Tezepelumab	71	69 (97.2)	-1.10 (1.08)	-3.8	-1.83	-1.00	-0.33	2.3	-0.09 [-0.43, 0.26]
			Placebo	63	60 (95.2)	-1.01 (0.96)	-4.0	-1.50	-1.17	-0.33	1.5	
		Week 42	Tezepelumab	71	69 (97.2)	-1.13 (1.11)	-3.8	-1.83	-1.17	-0.50	2.3	-0.14 [-0.49, 0.20]
			Placebo	63	60 (95.2)	-0.99 (0.88)	-4.0	-1.42	-1.08	-0.33	0.7	
		Week 44	Tezepelumab	71	69 (97.2)	-1.11 (1.06)	-3.8	-1.83	-1.00	-0.50	2.3	-0.04 [-0.39, 0.31]
			Placebo	63	60 (95.2)	-1.07 (0.96)	-4.0	-1.75	-1.08	-0.50	0.8	
		Week 46	Tezepelumab	71	69 (97.2)	-1.18 (1.07)	-3.8	-2.00	-1.17	-0.67	2.3	-0.10 [-0.45, 0.25]
			Placebo	63	60 (95.2)	-1.08 (0.85)	-4.0	-1.58	-1.17	-0.42	0.8	
		Week 48	Tezepelumab	71	69 (97.2)	-1.07 (1.07)	-3.8	-1.83	-1.00	-0.33	2.3	0.02 [-0.33, 0.36]
			Placebo	63	60 (95.2)	-1.09 (0.93)	-3.7	-1.67	-1.17	-0.50	1.0	
		Week 50	Tezepelumab	71	69 (97.2)	-1.16 (1.14)	-3.8	-2.00	-1.33	-0.33	2.3	-0.02 [-0.36, 0.33]
			Placebo	63	60 (95.2)	-1.14 (0.89)	-4.0	-1.67	-1.17	-0.58	0.5	
		Week 52	Tezepelumab	71	69 (97.2)	-1.11 (1.11)	-3.8	-1.83	-1.00	-0.33	2.3	-0.00 [-0.35, 0.34]
			Placebo	63	60 (95.2)	-1.11 (0.95)	-4.0	-1.67	-1.17	-0.50	0.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	35	35 (100.0)	2.54 (0.61)	1.0	2.17	2.50	2.83	3.8	
			Placebo	32	32 (100.0)	2.45 (0.63)	1.3	2.00	2.50	3.00	3.7	
		Week 2	Tezepelumab	35	33 (94.3)	2.08 (0.86)	0.0	1.50	2.17	2.67	3.7	
			Placebo	32	27 (84.4)	2.00 (0.80)	0.3	1.33	2.00	2.67	3.7	
		Week 4	Tezepelumab	35	33 (94.3)	1.78 (0.85)	0.2	1.00	1.83	2.50	3.2	
			Placebo	32	27 (84.4)	1.97 (0.90)	0.5	1.33	2.33	2.67	4.2	
		Week 6	Tezepelumab	35	33 (94.3)	1.60 (0.88)	0.0	1.00	1.50	2.17	3.7	
			Placebo	32	28 (87.5)	2.00 (0.99)	0.3	1.17	2.00	2.50	4.7	
		Week 8	Tezepelumab	35	33 (94.3)	1.69 (1.06)	0.0	1.00	1.50	2.33	4.8	
			Placebo	32	28 (87.5)	2.12 (1.01)	0.3	1.08	2.33	2.83	3.7	
		Week 10	Tezepelumab	35	33 (94.3)	1.53 (1.02)	0.0	0.83	1.50	2.00	4.3	
			Placebo	32	28 (87.5)	1.84 (0.97)	0.2	1.17	1.83	2.25	4.2	
		Week 12	Tezepelumab	35	33 (94.3)	1.42 (1.03)	0.0	0.50	1.33	2.17	4.3	
			Placebo	32	28 (87.5)	1.67 (0.91)	0.0	1.00	1.83	2.17	4.2	
		Week 14	Tezepelumab	35	33 (94.3)	1.34 (0.95)	0.0	0.83	1.17	1.83	4.3	
			Placebo	32	28 (87.5)	1.48 (0.79)	0.0	0.92	1.33	2.17	2.8	
		Week 16	Tezepelumab	35	33 (94.3)	1.47 (1.03)	0.0	0.67	1.33	2.17	4.3	
			Placebo	32	28 (87.5)	1.88 (1.13)	0.0	0.92	1.83	2.67	3.8	
		Week 18	Tezepelumab	35	34 (97.1)	1.38 (0.96)	0.0	0.83	1.25	2.00	4.3	
			Placebo	32	28 (87.5)	1.58 (1.06)	0.0	0.67	1.58	2.50	3.8	
		Week 20	Tezepelumab	35	34 (97.1)	1.48 (1.04)	0.0	0.83	1.42	2.17	4.3	
			Placebo	32	28 (87.5)	1.70 (1.18)	0.0	0.50	1.83	2.58	3.8	
		Week 22	Tezepelumab	35	34 (97.1)	1.56 (1.01)	0.0	1.00	1.50	2.33	4.3	
			Placebo	32	28 (87.5)	1.67 (1.15)	0.0	0.58	1.50	2.75	3.8	
		Week 24	Tezepelumab	35	34 (97.1)	1.44 (1.00)	0.0	0.83	1.33	2.00	4.3	
			Placebo	32	28 (87.5)	1.75 (1.19)	0.0	0.50	1.92	2.83	3.8	
		Week 26	Tezepelumab	35	35 (100.0)	1.48 (0.96)	0.0	0.83	1.33	2.17	4.3	
			Placebo	32	28 (87.5)	1.78 (1.09)	0.0	0.92	1.67	2.67	4.0	
		Week 28	Tezepelumab	35	35 (100.0)	1.51 (1.06)	0.0	0.50	1.50	2.50	4.3	
			Placebo	32	28 (87.5)	2.04 (1.17)	0.0	1.00	2.17	3.00	4.0	
		Week 30	Tezepelumab	35	35 (100.0)	1.59 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	32	28 (87.5)	1.78 (1.14)	0.0	0.75	1.83	2.83	3.8	
		Week 32	Tezepelumab	35	35 (100.0)	1.55 (1.05)	0.0	0.83	1.50	2.50	4.3	
			Placebo	32	28 (87.5)	1.86 (1.12)	0.0	0.83	1.92	2.75	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Absolute values	Week 34	Tezepelumab	35	35 (100.0)	1.56 (1.11)	0.0	0.67	1.50	2.50	4.3	
			Placebo	32	28 (87.5)	1.74 (1.16)	0.0	0.75	1.75	2.83	3.8	
		Week 36	Tezepelumab	35	35 (100.0)	1.54 (1.03)	0.0	1.00	1.50	2.33	4.3	
			Placebo	32	28 (87.5)	1.77 (1.21)	0.0	0.83	1.75	2.75	4.2	
		Week 38	Tezepelumab	35	35 (100.0)	1.58 (1.11)	0.0	0.83	1.50	2.67	4.3	
			Placebo	32	28 (87.5)	1.73 (1.07)	0.0	0.92	1.75	2.67	3.8	
		Week 40	Tezepelumab	35	35 (100.0)	1.61 (1.07)	0.0	0.67	1.67	2.50	4.3	
			Placebo	32	28 (87.5)	2.02 (1.20)	0.0	0.83	2.33	2.83	4.2	
		Week 42	Tezepelumab	35	35 (100.0)	1.57 (1.08)	0.0	0.83	1.67	2.33	4.3	
			Placebo	32	28 (87.5)	1.94 (1.21)	0.0	0.83	2.08	2.75	4.5	
		Week 44	Tezepelumab	35	35 (100.0)	1.57 (1.11)	0.0	0.67	1.50	2.50	4.3	
			Placebo	32	28 (87.5)	2.02 (1.11)	0.0	1.17	2.33	2.83	4.2	
		Week 46	Tezepelumab	35	35 (100.0)	1.58 (1.07)	0.0	0.83	1.67	2.50	4.3	
			Placebo	32	28 (87.5)	1.83 (1.19)	0.0	0.67	1.83	2.92	3.8	
		Week 48	Tezepelumab	35	35 (100.0)	1.57 (1.08)	0.0	1.00	1.50	2.33	4.3	
			Placebo	32	28 (87.5)	1.89 (1.22)	0.0	0.67	1.92	2.67	4.2	
		Week 50	Tezepelumab	35	35 (100.0)	1.49 (1.07)	0.0	0.83	1.50	2.33	4.3	
			Placebo	32	28 (87.5)	1.93 (1.10)	0.0	1.00	2.00	2.75	3.8	
		Week 52	Tezepelumab	35	35 (100.0)	1.46 (1.07)	0.0	0.50	1.67	2.00	4.3	
			Placebo	32	28 (87.5)	1.97 (1.14)	0.0	1.00	2.08	2.75	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	35	33 (94.3)	-0.52 (0.64)	-2.8	-0.67	-0.50	0.00	0.5	-0.05 [-0.56, 0.46]
			Placebo	32	27 (84.4)	-0.48 (0.89)	-2.8	-0.83	-0.33	0.17	1.0	
		Week 4	Tezepelumab	35	33 (94.3)	-0.81 (0.71)	-2.0	-1.33	-0.83	-0.33	0.5	-0.38 [-0.89, 0.13]
			Placebo	32	27 (84.4)	-0.51 (0.89)	-2.2	-1.00	-0.67	0.33	1.2	
		Week 6	Tezepelumab	35	33 (94.3)	-0.99 (0.89)	-2.5	-1.50	-1.00	-0.33	1.2	-0.56 [-1.08, -0.05]
			Placebo	32	28 (87.5)	-0.46 (1.00)	-2.3	-1.17	-0.33	0.17	1.5	
		Week 8	Tezepelumab	35	33 (94.3)	-0.90 (1.05)	-3.0	-1.50	-0.83	-0.33	2.2	-0.56 [-1.07, -0.04]
			Placebo	32	28 (87.5)	-0.35 (0.95)	-2.3	-0.92	-0.42	0.50	1.0	
		Week 10	Tezepelumab	35	33 (94.3)	-1.06 (0.93)	-3.2	-1.67	-1.00	-0.50	0.5	-0.44 [-0.95, 0.07]
			Placebo	32	28 (87.5)	-0.63 (1.07)	-2.3	-1.25	-0.58	-0.33	2.5	
		Week 12	Tezepelumab	35	33 (94.3)	-1.17 (0.86)	-2.8	-1.83	-1.17	-0.67	0.5	-0.41 [-0.91, 0.10]
			Placebo	32	28 (87.5)	-0.80 (1.00)	-2.7	-1.25	-0.83	-0.50	1.3	
		Week 14	Tezepelumab	35	33 (94.3)	-1.25 (0.86)	-3.2	-1.83	-1.17	-0.67	0.5	-0.29 [-0.80, 0.22]
			Placebo	32	28 (87.5)	-0.99 (0.96)	-2.7	-1.58	-0.92	-0.58	1.3	
		Week 16	Tezepelumab	35	33 (94.3)	-1.12 (0.91)	-3.0	-1.83	-1.00	-0.50	0.5	-0.50 [-1.01, 0.01]
			Placebo	32	28 (87.5)	-0.59 (1.22)	-2.7	-1.42	-0.67	0.08	2.3	
		Week 18	Tezepelumab	35	34 (97.1)	-1.19 (0.92)	-3.2	-1.83	-1.08	-0.67	0.5	-0.29 [-0.79, 0.22]
			Placebo	32	28 (87.5)	-0.88 (1.26)	-3.2	-1.67	-0.83	-0.17	2.3	
		Week 20	Tezepelumab	35	34 (97.1)	-1.09 (0.94)	-3.2	-2.00	-1.00	-0.33	0.5	-0.28 [-0.79, 0.22]
			Placebo	32	28 (87.5)	-0.77 (1.32)	-3.0	-1.92	-0.75	0.17	2.3	
		Week 22	Tezepelumab	35	34 (97.1)	-1.00 (0.94)	-3.0	-1.83	-0.92	-0.17	0.5	-0.19 [-0.69, 0.31]
			Placebo	32	28 (87.5)	-0.79 (1.33)	-3.2	-1.67	-0.92	0.17	2.3	
		Week 24	Tezepelumab	35	34 (97.1)	-1.13 (0.91)	-3.2	-2.00	-1.17	-0.33	0.5	-0.37 [-0.87, 0.14]
			Placebo	32	28 (87.5)	-0.71 (1.37)	-3.0	-1.58	-0.50	0.25	2.3	
		Week 26	Tezepelumab	35	35 (100.0)	-1.06 (0.92)	-2.8	-2.00	-1.00	-0.33	0.5	-0.35 [-0.85, 0.16]
			Placebo	32	28 (87.5)	-0.68 (1.28)	-2.7	-1.50	-1.00	0.42	2.3	
		Week 28	Tezepelumab	35	35 (100.0)	-1.03 (1.05)	-3.2	-2.00	-1.00	0.00	0.8	-0.53 [-1.04, -0.02]
			Placebo	32	28 (87.5)	-0.42 (1.27)	-2.7	-1.50	-0.33	0.58	2.3	
		Week 30	Tezepelumab	35	35 (100.0)	-0.96 (1.00)	-2.7	-2.00	-1.00	-0.17	1.8	-0.24 [-0.74, 0.26]
			Placebo	32	28 (87.5)	-0.68 (1.27)	-3.0	-1.50	-0.67	0.33	2.3	
		Week 32	Tezepelumab	35	35 (100.0)	-0.99 (0.94)	-3.0	-1.83	-0.83	-0.50	0.8	-0.35 [-0.85, 0.15]
			Placebo	32	28 (87.5)	-0.61 (1.28)	-3.0	-1.58	-0.50	0.42	2.3	
		Week 34	Tezepelumab	35	35 (100.0)	-0.99 (1.07)	-2.8	-1.83	-1.00	-0.33	2.0	-0.22 [-0.72, 0.28]
			Placebo	32	28 (87.5)	-0.73 (1.32)	-3.2	-1.58	-0.75	0.33	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Change from baseline	Week 36	Tezepelumab	35	35 (100.0)	-1.00 (1.01)	-3.0	-1.67	-1.00	-0.50	1.5	-0.27 [-0.77, 0.23]
			Placebo	32	28 (87.5)	-0.69 (1.37)	-3.2	-1.58	-0.75	0.25	2.3	
		Week 38	Tezepelumab	35	35 (100.0)	-0.96 (1.09)	-3.0	-2.00	-1.00	-0.17	2.3	-0.19 [-0.69, 0.30]
			Placebo	32	28 (87.5)	-0.73 (1.30)	-3.2	-1.50	-0.75	0.17	2.3	
		Week 40	Tezepelumab	35	35 (100.0)	-0.93 (1.04)	-3.2	-1.67	-1.00	0.00	1.7	-0.40 [-0.90, 0.10]
			Placebo	32	28 (87.5)	-0.45 (1.40)	-2.8	-1.58	-0.33	0.58	2.3	
		Week 42	Tezepelumab	35	35 (100.0)	-0.98 (1.05)	-2.7	-2.00	-0.83	-0.17	2.0	-0.37 [-0.87, 0.13]
			Placebo	32	28 (87.5)	-0.52 (1.41)	-2.8	-1.50	-0.58	0.42	2.3	
		Week 44	Tezepelumab	35	35 (100.0)	-0.97 (1.06)	-3.2	-1.67	-1.00	-0.17	1.5	-0.45 [-0.95, 0.06]
			Placebo	32	28 (87.5)	-0.44 (1.33)	-3.0	-1.42	-0.25	0.42	2.3	
		Week 46	Tezepelumab	35	35 (100.0)	-0.97 (0.99)	-2.7	-1.83	-1.00	-0.17	1.7	-0.27 [-0.77, 0.23]
			Placebo	32	28 (87.5)	-0.64 (1.44)	-3.2	-1.92	-0.67	0.33	2.3	
		Week 48	Tezepelumab	35	35 (100.0)	-0.97 (1.02)	-2.7	-2.00	-0.83	-0.17	1.8	-0.32 [-0.82, 0.18]
			Placebo	32	28 (87.5)	-0.58 (1.43)	-3.2	-1.67	-0.50	0.33	2.3	
		Week 50	Tezepelumab	35	35 (100.0)	-1.06 (1.05)	-2.7	-2.00	-1.00	-0.50	1.8	-0.44 [-0.94, 0.06]
			Placebo	32	28 (87.5)	-0.54 (1.34)	-2.8	-1.42	-0.50	0.33	2.3	
		Week 52	Tezepelumab	35	35 (100.0)	-1.09 (1.06)	-2.7	-2.00	-1.00	-0.50	1.8	-0.49 [-0.99, 0.01]
			Placebo	32	28 (87.5)	-0.49 (1.37)	-2.8	-1.50	-0.33	0.50	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	95	95 (100.0)	2.77 (0.86)	0.0	2.33	2.67	3.17	4.8	
			Placebo	98	98 (100.0)	2.69 (0.71)	0.3	2.33	2.67	3.00	4.7	
		Week 2	Tezepelumab	95	91 (95.8)	2.18 (0.95)	0.0	1.67	2.17	2.83	4.3	
			Placebo	98	90 (91.8)	2.36 (0.80)	0.2	2.00	2.33	2.83	4.8	
		Week 4	Tezepelumab	95	91 (95.8)	1.88 (0.99)	0.0	1.17	2.00	2.67	4.3	
			Placebo	98	90 (91.8)	2.26 (0.81)	0.2	1.83	2.33	2.67	4.2	
		Week 6	Tezepelumab	95	91 (95.8)	1.82 (0.99)	0.0	1.17	1.83	2.50	4.3	
			Placebo	98	90 (91.8)	2.10 (0.96)	0.2	1.50	2.17	2.67	5.5	
		Week 8	Tezepelumab	95	91 (95.8)	1.72 (1.02)	0.0	1.00	1.67	2.67	4.3	
			Placebo	98	91 (92.9)	2.04 (0.95)	0.0	1.50	2.00	2.50	4.7	
		Week 10	Tezepelumab	95	91 (95.8)	1.66 (1.01)	0.0	0.83	1.67	2.33	4.3	
			Placebo	98	92 (93.9)	2.01 (0.90)	0.0	1.33	2.00	2.67	5.3	
		Week 12	Tezepelumab	95	91 (95.8)	1.61 (1.03)	0.0	0.83	1.67	2.50	4.3	
			Placebo	98	92 (93.9)	1.97 (0.95)	0.0	1.33	2.17	2.67	4.3	
		Week 14	Tezepelumab	95	91 (95.8)	1.46 (1.01)	0.0	0.67	1.50	2.17	4.3	
			Placebo	98	92 (93.9)	1.98 (0.93)	0.0	1.33	2.00	2.50	5.0	
		Week 16	Tezepelumab	95	91 (95.8)	1.64 (1.07)	0.0	0.83	1.67	2.50	4.3	
			Placebo	98	92 (93.9)	2.02 (1.02)	0.0	1.25	2.17	2.67	5.0	
		Week 18	Tezepelumab	95	91 (95.8)	1.51 (0.98)	0.0	0.83	1.50	2.17	4.3	
			Placebo	98	92 (93.9)	1.93 (0.98)	0.0	1.33	1.83	2.50	5.0	
		Week 20	Tezepelumab	95	91 (95.8)	1.59 (1.02)	0.0	0.83	1.67	2.17	5.0	
			Placebo	98	92 (93.9)	2.01 (0.96)	0.0	1.33	2.33	2.67	5.0	
		Week 22	Tezepelumab	95	91 (95.8)	1.58 (0.96)	0.0	0.83	1.67	2.33	4.3	
			Placebo	98	92 (93.9)	1.94 (0.98)	0.0	1.17	2.00	2.67	5.0	
		Week 24	Tezepelumab	95	91 (95.8)	1.62 (1.05)	0.0	0.83	1.67	2.33	4.3	
			Placebo	98	92 (93.9)	1.92 (0.93)	0.0	1.17	2.00	2.50	4.5	
		Week 26	Tezepelumab	95	91 (95.8)	1.56 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	98	92 (93.9)	1.85 (0.98)	0.0	1.00	1.67	2.67	4.5	
		Week 28	Tezepelumab	95	92 (96.8)	1.61 (1.03)	0.0	0.83	1.67	2.42	4.3	
			Placebo	98	93 (94.9)	1.82 (1.01)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	95	93 (97.9)	1.51 (1.00)	0.0	0.67	1.50	2.17	4.3	
			Placebo	98	94 (95.9)	1.92 (1.00)	0.0	1.17	2.00	2.50	4.5	
		Week 32	Tezepelumab	95	93 (97.9)	1.47 (1.02)	0.0	0.67	1.33	2.00	4.3	
			Placebo	98	94 (95.9)	1.82 (1.03)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Normal	Absolute values	Week 34	Tezepelumab	95	93 (97.9)	1.49 (1.05)	0.0	0.67	1.33	2.17	4.3	
			Placebo	98	94 (95.9)	1.80 (1.03)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	95	93 (97.9)	1.61 (1.06)	0.0	0.83	1.67	2.33	4.5	
			Placebo	98	94 (95.9)	1.91 (1.00)	0.0	1.00	2.00	2.67	4.5	
		Week 38	Tezepelumab	95	93 (97.9)	1.45 (1.02)	0.0	0.83	1.33	2.17	4.5	
			Placebo	98	94 (95.9)	1.80 (1.02)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	95	93 (97.9)	1.47 (1.04)	0.0	0.67	1.50	2.17	4.3	
			Placebo	98	94 (95.9)	1.82 (1.01)	0.0	1.00	1.83	2.50	4.5	
		Week 42	Tezepelumab	95	93 (97.9)	1.45 (1.05)	0.0	0.83	1.33	2.00	4.7	
			Placebo	98	94 (95.9)	1.78 (0.97)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	95	93 (97.9)	1.48 (1.00)	0.0	0.67	1.33	2.33	4.3	
			Placebo	98	95 (96.9)	1.83 (1.00)	0.0	1.00	2.00	2.50	4.5	
		Week 46	Tezepelumab	95	93 (97.9)	1.43 (1.03)	0.0	0.67	1.17	2.17	4.3	
			Placebo	98	95 (96.9)	1.74 (0.94)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	95	93 (97.9)	1.51 (1.05)	0.0	0.67	1.50	2.33	4.3	
			Placebo	98	95 (96.9)	1.77 (0.97)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	95	93 (97.9)	1.43 (1.04)	0.0	0.67	1.17	2.17	4.3	
			Placebo	98	95 (96.9)	1.73 (0.94)	0.0	1.00	1.83	2.50	4.5	
		Week 52	Tezepelumab	95	93 (97.9)	1.49 (1.03)	0.0	0.67	1.33	2.17	4.3	
			Placebo	98	95 (96.9)	1.79 (0.97)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 2	Tezepelumab	95	91 (95.8)	-0.58 (0.69)	-2.5	-1.00	-0.50	-0.17	0.7	-0.35 [-0.65, -0.06]
			Placebo	98	90 (91.8)	-0.34 (0.67)	-2.7	-0.83	-0.33	0.17	1.2	
		Week 4	Tezepelumab	95	91 (95.8)	-0.87 (0.92)	-3.5	-1.50	-0.83	-0.17	2.3	-0.51 [-0.81, -0.22]
			Placebo	98	90 (91.8)	-0.44 (0.78)	-2.7	-1.00	-0.33	0.17	1.2	
		Week 6	Tezepelumab	95	91 (95.8)	-0.93 (0.98)	-3.8	-1.50	-0.83	-0.33	2.3	-0.38 [-0.67, -0.08]
			Placebo	98	90 (91.8)	-0.59 (0.85)	-2.8	-1.17	-0.50	0.00	1.3	
		Week 8	Tezepelumab	95	91 (95.8)	-1.04 (0.99)	-3.8	-1.67	-1.00	-0.50	2.3	-0.41 [-0.70, -0.12]
			Placebo	98	91 (92.9)	-0.66 (0.86)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	95	91 (95.8)	-1.09 (1.00)	-3.8	-1.67	-1.17	-0.50	2.3	-0.42 [-0.71, -0.12]
			Placebo	98	92 (93.9)	-0.69 (0.92)	-3.3	-1.33	-0.67	0.00	2.7	
		Week 12	Tezepelumab	95	91 (95.8)	-1.15 (1.02)	-3.7	-1.83	-1.17	-0.50	2.3	-0.42 [-0.71, -0.13]
			Placebo	98	92 (93.9)	-0.73 (0.96)	-3.3	-1.33	-0.67	0.00	1.3	
		Week 14	Tezepelumab	95	91 (95.8)	-1.30 (1.03)	-3.8	-2.00	-1.17	-0.83	2.3	-0.59 [-0.89, -0.29]
			Placebo	98	92 (93.9)	-0.72 (0.93)	-3.2	-1.33	-0.67	-0.08	2.3	
		Week 16	Tezepelumab	95	91 (95.8)	-1.12 (1.09)	-4.2	-2.00	-1.00	-0.33	2.3	-0.42 [-0.71, -0.13]
			Placebo	98	92 (93.9)	-0.68 (0.97)	-3.5	-1.17	-0.67	0.00	2.3	
		Week 18	Tezepelumab	95	91 (95.8)	-1.25 (1.04)	-4.2	-1.83	-1.17	-0.67	2.3	-0.47 [-0.77, -0.18]
			Placebo	98	92 (93.9)	-0.78 (0.95)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	95	91 (95.8)	-1.17 (1.04)	-4.2	-1.83	-1.17	-0.50	2.3	-0.48 [-0.77, -0.19]
			Placebo	98	92 (93.9)	-0.69 (0.95)	-3.5	-1.17	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	95	91 (95.8)	-1.18 (1.08)	-4.3	-1.83	-1.17	-0.67	2.3	-0.41 [-0.70, -0.12]
			Placebo	98	92 (93.9)	-0.77 (0.91)	-3.3	-1.33	-0.67	-0.17	2.3	
		Week 24	Tezepelumab	95	91 (95.8)	-1.14 (1.02)	-4.5	-1.83	-1.00	-0.50	2.3	-0.36 [-0.66, -0.07]
			Placebo	98	92 (93.9)	-0.78 (0.93)	-3.5	-1.33	-0.67	-0.17	1.5	
		Week 26	Tezepelumab	95	91 (95.8)	-1.20 (1.09)	-4.2	-2.00	-1.17	-0.50	2.3	-0.33 [-0.62, -0.04]
			Placebo	98	92 (93.9)	-0.86 (0.99)	-4.0	-1.50	-0.92	-0.17	1.5	
		Week 28	Tezepelumab	95	92 (96.8)	-1.14 (1.06)	-4.2	-1.83	-1.08	-0.50	2.3	-0.28 [-0.57, 0.01]
			Placebo	98	93 (94.9)	-0.86 (0.99)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	95	93 (97.9)	-1.25 (1.07)	-4.2	-2.00	-1.33	-0.67	2.3	-0.48 [-0.77, -0.19]
			Placebo	98	94 (95.9)	-0.76 (0.99)	-3.2	-1.50	-0.83	-0.17	2.0	
		Week 32	Tezepelumab	95	93 (97.9)	-1.29 (1.08)	-4.2	-2.00	-1.17	-0.67	2.3	-0.42 [-0.71, -0.13]
			Placebo	98	94 (95.9)	-0.86 (0.97)	-3.5	-1.50	-0.67	-0.33	1.5	
		Week 34	Tezepelumab	95	93 (97.9)	-1.27 (1.06)	-4.2	-2.00	-1.33	-0.67	2.3	-0.39 [-0.68, -0.10]
			Placebo	98	94 (95.9)	-0.88 (0.96)	-4.0	-1.50	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Normal	Change from baseline	Week 36	Tezepelumab	95	93 (97.9)	-1.15 (1.14)	-4.2	-1.83	-1.17	-0.33	2.3	-0.35 [-0.64, -0.06]
			Placebo	98	94 (95.9)	-0.77 (0.97)	-3.5	-1.33	-0.83	-0.17	1.5	
		Week 38	Tezepelumab	95	93 (97.9)	-1.31 (1.09)	-4.2	-2.00	-1.33	-0.67	2.3	-0.41 [-0.70, -0.13]
			Placebo	98	94 (95.9)	-0.88 (0.99)	-4.0	-1.33	-0.83	-0.33	1.5	
		Week 40	Tezepelumab	95	93 (97.9)	-1.29 (1.11)	-4.2	-2.00	-1.17	-0.67	2.3	-0.42 [-0.71, -0.13]
			Placebo	98	94 (95.9)	-0.86 (0.92)	-4.0	-1.33	-0.83	-0.17	1.5	
		Week 42	Tezepelumab	95	93 (97.9)	-1.31 (1.11)	-4.2	-2.00	-1.33	-0.67	2.3	-0.41 [-0.70, -0.12]
			Placebo	98	94 (95.9)	-0.90 (0.90)	-4.0	-1.33	-0.83	-0.33	1.3	
		Week 44	Tezepelumab	95	93 (97.9)	-1.28 (1.12)	-4.3	-2.00	-1.17	-0.50	2.3	-0.42 [-0.71, -0.13]
			Placebo	98	95 (96.9)	-0.85 (0.95)	-4.0	-1.50	-0.83	-0.17	1.2	
		Week 46	Tezepelumab	95	93 (97.9)	-1.33 (1.13)	-4.2	-2.00	-1.33	-0.67	2.3	-0.39 [-0.68, -0.10]
			Placebo	98	95 (96.9)	-0.94 (0.89)	-4.0	-1.50	-1.00	-0.33	1.0	
		Week 48	Tezepelumab	95	93 (97.9)	-1.25 (1.13)	-4.2	-2.00	-1.17	-0.50	2.3	-0.33 [-0.62, -0.04]
			Placebo	98	95 (96.9)	-0.91 (0.93)	-3.7	-1.50	-0.83	-0.33	1.0	
		Week 50	Tezepelumab	95	93 (97.9)	-1.33 (1.11)	-4.2	-2.00	-1.33	-0.67	2.3	-0.38 [-0.67, -0.09]
			Placebo	98	95 (96.9)	-0.95 (0.89)	-4.0	-1.50	-1.00	-0.33	1.0	
		Week 52	Tezepelumab	95	93 (97.9)	-1.27 (1.12)	-4.2	-1.83	-1.33	-0.67	2.3	-0.37 [-0.66, -0.09]
			Placebo	98	95 (96.9)	-0.89 (0.92)	-4.0	-1.50	-0.83	-0.17	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	2.55 (0.81)	1.7	1.67	2.50	3.00	4.0	
			Placebo	8	8 (100.0)	3.00 (0.33)	2.5	2.75	3.00	3.25	3.5	
		Week 2	Tezepelumab	7	7 (100.0)	2.40 (0.59)	1.7	1.83	2.33	3.17	3.2	
			Placebo	8	8 (100.0)	2.67 (0.38)	2.2	2.42	2.58	2.92	3.3	
		Week 4	Tezepelumab	7	7 (100.0)	2.40 (0.93)	1.2	1.33	3.00	3.17	3.3	
			Placebo	8	8 (100.0)	2.00 (0.90)	0.5	1.42	2.00	2.67	3.3	
		Week 6	Tezepelumab	7	7 (100.0)	2.38 (0.80)	1.5	1.83	2.00	3.17	3.7	
			Placebo	8	8 (100.0)	2.15 (0.96)	0.2	1.67	2.50	2.83	3.0	
		Week 8	Tezepelumab	7	7 (100.0)	2.12 (0.92)	1.0	1.17	2.00	3.17	3.3	
			Placebo	8	8 (100.0)	2.02 (0.91)	0.5	1.50	2.00	2.67	3.3	
		Week 10	Tezepelumab	7	7 (100.0)	2.17 (0.85)	1.2	1.33	2.17	3.17	3.3	
			Placebo	8	8 (100.0)	2.10 (0.95)	0.3	1.58	2.33	2.75	3.2	
		Week 12	Tezepelumab	7	7 (100.0)	2.10 (0.89)	0.8	1.17	2.33	2.83	3.2	
			Placebo	8	8 (100.0)	1.83 (0.75)	0.3	1.58	2.00	2.25	2.7	
		Week 14	Tezepelumab	7	7 (100.0)	2.07 (1.07)	0.8	1.00	2.17	3.00	3.7	
			Placebo	8	8 (100.0)	1.54 (0.63)	0.3	1.17	1.75	2.00	2.2	
		Week 16	Tezepelumab	7	7 (100.0)	1.86 (0.94)	1.0	1.00	1.33	2.83	3.2	
			Placebo	8	8 (100.0)	1.75 (0.66)	0.7	1.25	1.92	2.17	2.7	
		Week 18	Tezepelumab	7	7 (100.0)	1.95 (0.90)	0.8	1.17	1.83	2.83	3.3	
			Placebo	8	8 (100.0)	2.10 (0.57)	1.2	1.83	2.17	2.25	3.2	
		Week 20	Tezepelumab	7	7 (100.0)	2.02 (0.93)	0.8	1.33	1.83	2.83	3.5	
			Placebo	8	8 (100.0)	1.65 (0.68)	0.7	1.17	1.67	2.00	2.8	
		Week 22	Tezepelumab	7	7 (100.0)	1.93 (0.89)	0.8	1.17	1.67	2.67	3.3	
			Placebo	8	8 (100.0)	1.81 (0.58)	0.7	1.58	2.00	2.17	2.3	
		Week 24	Tezepelumab	7	7 (100.0)	2.00 (0.96)	1.0	1.00	1.67	2.83	3.5	
			Placebo	8	8 (100.0)	1.75 (0.64)	0.3	1.58	1.92	2.17	2.3	
		Week 26	Tezepelumab	7	7 (100.0)	1.90 (0.86)	0.8	1.17	1.67	2.83	3.2	
			Placebo	8	8 (100.0)	1.69 (0.36)	1.0	1.50	1.75	1.92	2.2	
		Week 28	Tezepelumab	7	7 (100.0)	1.95 (0.94)	1.0	1.00	1.67	2.83	3.5	
			Placebo	8	8 (100.0)	1.88 (0.99)	0.7	1.17	1.83	2.25	3.8	
		Week 30	Tezepelumab	7	7 (100.0)	1.95 (0.89)	0.8	1.00	2.17	2.83	3.2	
			Placebo	8	8 (100.0)	1.52 (0.68)	0.3	1.17	1.50	2.00	2.5	
		Week 32	Tezepelumab	7	7 (100.0)	1.83 (0.92)	0.3	1.00	2.17	2.67	2.8	
			Placebo	8	8 (100.0)	1.58 (0.55)	0.5	1.42	1.50	2.08	2.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Absolute values	Week 34	Tezepelumab	7	7 (100.0)	1.81 (0.93)	0.3	1.00	2.00	2.83	2.8	
			Placebo	8	8 (100.0)	1.67 (0.65)	0.7	1.08	1.83	2.25	2.3	
		Week 36	Tezepelumab	7	7 (100.0)	1.79 (0.83)	0.5	1.00	2.00	2.50	2.8	
			Placebo	8	8 (100.0)	1.63 (0.80)	0.0	1.25	1.83	2.17	2.5	
		Week 38	Tezepelumab	7	7 (100.0)	1.83 (0.84)	0.7	1.00	2.00	2.67	3.0	
			Placebo	8	8 (100.0)	1.73 (0.86)	0.5	1.17	1.58	2.33	3.2	
		Week 40	Tezepelumab	7	7 (100.0)	1.83 (0.87)	0.5	1.00	2.00	2.67	2.8	
			Placebo	8	8 (100.0)	1.65 (0.76)	0.3	1.17	1.75	2.08	2.8	
		Week 42	Tezepelumab	7	7 (100.0)	1.79 (0.88)	0.5	1.00	1.83	2.67	3.0	
			Placebo	8	8 (100.0)	1.90 (0.76)	0.7	1.33	2.00	2.50	2.8	
		Week 44	Tezepelumab	7	7 (100.0)	1.83 (0.89)	0.5	1.00	2.00	2.83	2.8	
			Placebo	8	8 (100.0)	1.71 (0.82)	0.2	1.17	2.00	2.33	2.5	
		Week 46	Tezepelumab	7	7 (100.0)	1.83 (0.85)	0.7	1.00	1.83	2.67	3.0	
			Placebo	8	8 (100.0)	1.73 (0.66)	0.7	1.17	1.92	2.25	2.5	
		Week 48	Tezepelumab	7	7 (100.0)	1.83 (0.87)	0.8	0.83	1.83	2.83	3.0	
			Placebo	8	8 (100.0)	1.67 (0.73)	0.2	1.25	2.08	2.17	2.2	
		Week 50	Tezepelumab	7	7 (100.0)	1.83 (0.70)	0.8	1.17	2.00	2.33	2.8	
			Placebo	8	8 (100.0)	1.67 (0.75)	0.0	1.50	1.92	2.17	2.2	
		Week 52	Tezepelumab	7	7 (100.0)	1.69 (0.87)	0.3	0.83	2.00	2.33	2.8	
			Placebo	8	8 (100.0)	1.69 (0.74)	0.0	1.58	1.92	2.17	2.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	7	7 (100.0)	-0.14 (0.38)	-0.8	-0.33	0.00	0.17	0.2	0.49 [-0.54, 1.52]
			Placebo	8	8 (100.0)	-0.33 (0.40)	-0.8	-0.75	-0.25	0.00	0.2	
		Week 4	Tezepelumab	7	7 (100.0)	-0.14 (1.01)	-1.2	-0.83	-0.50	0.67	1.7	0.83 [-0.24, 1.89]
			Placebo	8	8 (100.0)	-1.00 (1.07)	-3.0	-1.58	-0.83	-0.08	0.0	
		Week 6	Tezepelumab	7	7 (100.0)	-0.17 (0.67)	-1.2	-0.83	0.17	0.33	0.7	0.75 [-0.31, 1.80]
			Placebo	8	8 (100.0)	-0.85 (1.09)	-3.3	-1.08	-0.50	-0.17	0.0	
		Week 8	Tezepelumab	7	7 (100.0)	-0.43 (0.71)	-1.7	-0.83	-0.50	0.17	0.3	0.59 [-0.45, 1.63]
			Placebo	8	8 (100.0)	-0.98 (1.09)	-3.0	-1.58	-0.75	-0.33	0.5	
		Week 10	Tezepelumab	7	7 (100.0)	-0.38 (0.80)	-1.5	-1.17	-0.17	0.33	0.7	0.53 [-0.51, 1.56]
			Placebo	8	8 (100.0)	-0.90 (1.11)	-3.2	-1.33	-0.58	-0.25	0.3	
		Week 12	Tezepelumab	7	7 (100.0)	-0.45 (0.90)	-1.8	-1.17	-0.50	0.33	0.7	0.79 [-0.27, 1.85]
			Placebo	8	8 (100.0)	-1.17 (0.91)	-3.2	-1.42	-0.75	-0.67	-0.5	
		Week 14	Tezepelumab	7	7 (100.0)	-0.48 (0.91)	-1.8	-1.50	-0.33	0.00	0.8	1.11 [0.01, 2.21]
			Placebo	8	8 (100.0)	-1.46 (0.86)	-3.2	-1.92	-1.25	-0.83	-0.5	
		Week 16	Tezepelumab	7	7 (100.0)	-0.69 (0.82)	-1.7	-1.33	-0.83	-0.17	0.8	0.64 [-0.40, 1.68]
			Placebo	8	8 (100.0)	-1.25 (0.92)	-2.8	-1.83	-1.17	-0.58	0.0	
		Week 18	Tezepelumab	7	7 (100.0)	-0.60 (0.72)	-1.8	-1.00	-0.50	-0.17	0.5	0.39 [-0.64, 1.41]
			Placebo	8	8 (100.0)	-0.90 (0.82)	-2.3	-1.33	-0.92	-0.33	0.3	
		Week 20	Tezepelumab	7	7 (100.0)	-0.52 (0.77)	-1.8	-1.00	-0.50	-0.17	0.7	1.00 [-0.08, 2.09]
			Placebo	8	8 (100.0)	-1.35 (0.87)	-2.8	-1.92	-1.25	-0.83	0.0	
		Week 22	Tezepelumab	7	7 (100.0)	-0.62 (0.64)	-1.8	-1.00	-0.50	0.00	0.0	0.76 [-0.29, 1.82]
			Placebo	8	8 (100.0)	-1.19 (0.82)	-2.8	-1.58	-0.92	-0.58	-0.5	
		Week 24	Tezepelumab	7	7 (100.0)	-0.55 (0.64)	-1.7	-1.00	-0.50	0.00	0.2	0.90 [-0.17, 1.97]
			Placebo	8	8 (100.0)	-1.25 (0.88)	-3.2	-1.50	-1.08	-0.67	-0.3	
		Week 26	Tezepelumab	7	7 (100.0)	-0.64 (0.72)	-1.8	-1.17	-0.50	0.00	0.2	1.01 [-0.07, 2.10]
			Placebo	8	8 (100.0)	-1.31 (0.60)	-2.5	-1.58	-1.25	-0.83	-0.7	
		Week 28	Tezepelumab	7	7 (100.0)	-0.60 (0.58)	-1.7	-1.00	-0.50	-0.17	0.0	0.57 [-0.47, 1.60]
			Placebo	8	8 (100.0)	-1.13 (1.16)	-2.8	-1.75	-1.33	-0.50	1.0	
		Week 30	Tezepelumab	7	7 (100.0)	-0.60 (0.74)	-1.8	-1.00	-0.67	-0.17	0.5	1.10 [0.00, 2.20]
			Placebo	8	8 (100.0)	-1.48 (0.85)	-3.2	-1.83	-1.33	-1.00	-0.3	
		Week 32	Tezepelumab	7	7 (100.0)	-0.71 (0.97)	-2.3	-1.33	-0.67	-0.17	0.7	0.81 [-0.25, 1.87]
			Placebo	8	8 (100.0)	-1.42 (0.77)	-3.0	-1.67	-1.33	-0.92	-0.5	
		Week 34	Tezepelumab	7	7 (100.0)	-0.74 (0.88)	-2.3	-1.17	-0.67	-0.17	0.3	0.68 [-0.37, 1.73]
			Placebo	8	8 (100.0)	-1.33 (0.87)	-2.8	-2.00	-1.08	-0.75	-0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Change from baseline	Week 36	Tezepelumab	7	7 (100.0)	-0.76 (0.87)	-2.2	-1.50	-0.67	-0.17	0.3	0.65 [-0.39, 1.70]
			Placebo	8	8 (100.0)	-1.38 (1.00)	-3.5	-1.67	-1.17	-0.75	-0.3	
		Week 38	Tezepelumab	7	7 (100.0)	-0.71 (0.80)	-2.0	-1.33	-0.67	0.00	0.3	0.58 [-0.46, 1.62]
			Placebo	8	8 (100.0)	-1.27 (1.07)	-3.0	-1.92	-1.25	-0.58	0.3	
		Week 40	Tezepelumab	7	7 (100.0)	-0.71 (0.91)	-2.2	-1.33	-0.67	-0.17	0.7	0.67 [-0.38, 1.72]
			Placebo	8	8 (100.0)	-1.35 (0.99)	-3.2	-1.75	-1.25	-1.00	0.3	
		Week 42	Tezepelumab	7	7 (100.0)	-0.76 (0.82)	-2.2	-1.33	-0.67	0.00	0.2	0.38 [-0.64, 1.41]
			Placebo	8	8 (100.0)	-1.10 (0.96)	-2.8	-1.58	-1.08	-0.33	0.0	
		Week 44	Tezepelumab	7	7 (100.0)	-0.71 (0.83)	-2.2	-1.17	-0.67	-0.17	0.3	0.60 [-0.44, 1.64]
			Placebo	8	8 (100.0)	-1.29 (1.06)	-3.3	-1.92	-1.00	-0.58	0.0	
		Week 46	Tezepelumab	7	7 (100.0)	-0.71 (0.71)	-2.0	-1.00	-0.67	-0.17	0.2	0.70 [-0.35, 1.74]
			Placebo	8	8 (100.0)	-1.27 (0.87)	-2.8	-1.67	-1.25	-0.75	0.0	
		Week 48	Tezepelumab	7	7 (100.0)	-0.71 (0.66)	-1.8	-1.00	-0.83	-0.17	0.2	0.76 [-0.30, 1.81]
			Placebo	8	8 (100.0)	-1.33 (0.93)	-3.3	-1.58	-1.17	-0.75	-0.3	
		Week 50	Tezepelumab	7	7 (100.0)	-0.71 (0.77)	-1.7	-1.50	-0.83	-0.17	0.5	0.70 [-0.35, 1.75]
			Placebo	8	8 (100.0)	-1.33 (0.96)	-3.5	-1.50	-1.08	-0.83	-0.3	
		Week 52	Tezepelumab	7	7 (100.0)	-0.86 (0.92)	-2.3	-1.67	-0.83	-0.17	0.3	0.49 [-0.55, 1.52]
			Placebo	8	8 (100.0)	-1.31 (0.96)	-3.5	-1.42	-1.08	-0.83	-0.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.56 (0.46)	2.0	2.17	2.50	2.83	3.2	
			Placebo	13	13 (100.0)	2.67 (0.86)	0.3	2.67	3.00	3.17	3.5	
		Week 2	Tezepelumab	9	9 (100.0)	2.15 (0.68)	0.8	1.83	2.33	2.67	3.0	
			Placebo	13	11 (84.6)	2.52 (0.52)	1.5	2.17	2.50	2.83	3.3	
		Week 4	Tezepelumab	9	9 (100.0)	1.61 (0.79)	0.2	1.33	1.67	2.17	2.7	
			Placebo	13	11 (84.6)	2.70 (0.77)	1.8	2.17	2.33	3.33	4.2	
		Week 6	Tezepelumab	9	9 (100.0)	1.33 (0.58)	0.5	0.83	1.50	1.67	2.3	
			Placebo	13	11 (84.6)	2.76 (0.63)	1.5	2.50	3.00	3.00	3.8	
		Week 8	Tezepelumab	9	9 (100.0)	1.22 (0.75)	0.0	0.83	1.50	1.50	2.3	
			Placebo	13	12 (92.3)	2.54 (0.74)	1.2	2.08	2.42	3.00	3.7	
		Week 10	Tezepelumab	9	9 (100.0)	0.96 (0.77)	0.0	0.50	0.83	1.50	2.3	
			Placebo	13	12 (92.3)	2.46 (0.74)	1.0	2.08	2.42	2.92	4.0	
		Week 12	Tezepelumab	9	9 (100.0)	0.91 (0.81)	0.0	0.00	1.00	1.50	2.2	
			Placebo	13	12 (92.3)	2.58 (0.63)	1.8	2.08	2.58	2.75	4.2	
		Week 14	Tezepelumab	9	9 (100.0)	0.91 (0.62)	0.0	0.50	1.33	1.33	1.5	
			Placebo	13	12 (92.3)	2.11 (0.53)	1.3	1.83	2.17	2.42	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	0.87 (0.50)	0.0	0.50	1.00	1.17	1.5	
			Placebo	13	12 (92.3)	2.50 (0.84)	1.0	2.08	2.50	2.92	3.8	
		Week 18	Tezepelumab	9	9 (100.0)	1.13 (0.60)	0.0	1.00	1.17	1.50	2.0	
			Placebo	13	12 (92.3)	2.49 (0.52)	1.7	2.17	2.42	2.67	3.8	
		Week 20	Tezepelumab	9	9 (100.0)	1.15 (0.78)	0.0	0.83	1.00	1.50	2.8	
			Placebo	13	12 (92.3)	2.40 (0.80)	1.0	1.92	2.50	2.75	3.8	
		Week 22	Tezepelumab	9	9 (100.0)	1.26 (0.90)	0.0	1.00	1.33	1.50	2.5	
			Placebo	13	12 (92.3)	2.47 (0.90)	0.8	2.00	2.58	3.17	3.8	
		Week 24	Tezepelumab	9	9 (100.0)	1.11 (0.75)	0.0	0.67	1.00	1.50	2.5	
			Placebo	13	12 (92.3)	2.54 (0.74)	1.3	2.08	2.42	3.08	3.8	
		Week 26	Tezepelumab	9	9 (100.0)	1.31 (0.73)	0.0	0.83	1.33	2.00	2.2	
			Placebo	13	12 (92.3)	2.50 (0.90)	1.2	1.67	2.42	3.25	3.8	
		Week 28	Tezepelumab	9	9 (100.0)	1.54 (0.90)	0.0	1.00	1.50	2.33	2.7	
			Placebo	13	13 (100.0)	2.32 (1.09)	0.0	1.83	2.33	3.00	3.8	
		Week 30	Tezepelumab	9	9 (100.0)	1.22 (0.72)	0.0	0.67	1.33	1.50	2.2	
			Placebo	13	13 (100.0)	2.27 (1.11)	0.0	1.67	2.50	3.00	3.8	
		Week 32	Tezepelumab	9	9 (100.0)	1.17 (0.77)	0.0	0.67	1.00	1.67	2.3	
			Placebo	13	13 (100.0)	2.36 (1.25)	0.0	1.50	2.50	3.00	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.26 (1.05)	0.0	0.67	1.00	2.17	2.7	
			Placebo	13	13 (100.0)	2.29 (1.22)	0.2	1.67	2.33	3.00	4.5	
		Week 36	Tezepelumab	9	9 (100.0)	1.37 (0.79)	0.0	0.83	1.50	2.00	2.5	
			Placebo	13	13 (100.0)	2.41 (1.28)	0.0	1.83	2.17	3.00	4.5	
		Week 38	Tezepelumab	9	9 (100.0)	1.37 (1.01)	0.0	0.50	1.50	2.00	2.7	
			Placebo	13	13 (100.0)	2.29 (1.25)	0.0	1.67	2.50	3.00	4.5	
		Week 40	Tezepelumab	9	9 (100.0)	1.15 (0.90)	0.0	0.67	1.00	2.00	2.3	
			Placebo	13	13 (100.0)	2.37 (1.14)	0.0	1.67	2.50	3.00	4.2	
		Week 42	Tezepelumab	9	9 (100.0)	1.24 (0.75)	0.0	0.83	1.00	1.67	2.3	
			Placebo	13	13 (100.0)	2.28 (1.17)	0.0	2.00	2.33	2.50	4.5	
		Week 44	Tezepelumab	9	9 (100.0)	1.33 (0.85)	0.0	0.83	1.50	1.67	2.7	
			Placebo	13	13 (100.0)	2.24 (1.09)	0.0	1.67	2.33	2.50	4.2	
		Week 46	Tezepelumab	9	9 (100.0)	1.39 (0.92)	0.0	0.83	1.00	1.83	2.8	
			Placebo	13	13 (100.0)	2.21 (0.94)	0.0	1.83	2.17	2.50	3.8	
		Week 48	Tezepelumab	9	9 (100.0)	1.37 (0.88)	0.0	1.00	1.00	2.00	2.8	
			Placebo	13	13 (100.0)	2.22 (1.04)	0.0	2.00	2.17	2.50	3.8	
		Week 50	Tezepelumab	9	9 (100.0)	1.06 (0.69)	0.0	0.67	1.00	1.50	2.3	
			Placebo	13	13 (100.0)	2.15 (0.99)	0.0	2.00	2.17	2.50	3.8	
		Week 52	Tezepelumab	9	9 (100.0)	1.06 (0.69)	0.0	0.67	1.00	1.50	2.3	
			Placebo	13	13 (100.0)	2.24 (1.06)	0.0	2.17	2.17	2.83	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.41 (0.39)	-1.3	-0.50	-0.17	-0.17	-0.2	-0.16 [-1.05, 0.72]
			Placebo	13	11 (84.6)	-0.32 (0.64)	-1.5	-0.67	-0.33	0.00	1.0	
		Week 4	Tezepelumab	9	9 (100.0)	-0.94 (0.58)	-1.8	-1.33	-1.00	-0.50	-0.2	-1.12 [-2.08, -0.17]
			Placebo	13	11 (84.6)	-0.14 (0.81)	-1.3	-0.83	0.00	0.50	1.2	
		Week 6	Tezepelumab	9	9 (100.0)	-1.22 (0.63)	-2.2	-1.50	-1.33	-0.67	-0.2	-1.68 [-2.71, -0.64]
			Placebo	13	11 (84.6)	-0.08 (0.72)	-1.0	-0.50	-0.17	0.33	1.5	
		Week 8	Tezepelumab	9	9 (100.0)	-1.33 (0.60)	-2.0	-1.67	-1.33	-1.33	-0.2	-1.30 [-2.26, -0.34]
			Placebo	13	12 (92.3)	-0.32 (0.89)	-2.0	-0.83	-0.50	0.42	1.0	
		Week 10	Tezepelumab	9	9 (100.0)	-1.59 (0.55)	-2.2	-2.00	-1.83	-1.33	-0.7	-1.33 [-2.29, -0.37]
			Placebo	13	12 (92.3)	-0.40 (1.08)	-2.0	-0.92	-0.58	-0.17	2.5	
		Week 12	Tezepelumab	9	9 (100.0)	-1.65 (0.54)	-2.2	-2.00	-1.83	-1.33	-0.7	-1.94 [-3.01, -0.88]
			Placebo	13	12 (92.3)	-0.28 (0.81)	-1.2	-0.75	-0.58	0.08	1.3	
		Week 14	Tezepelumab	9	9 (100.0)	-1.65 (0.46)	-2.2	-2.00	-1.83	-1.50	-0.7	-1.33 [-2.30, -0.37]
			Placebo	13	12 (92.3)	-0.75 (0.79)	-1.8	-1.17	-0.83	-0.67	1.2	
		Week 16	Tezepelumab	9	9 (100.0)	-1.69 (0.45)	-2.2	-2.00	-1.83	-1.67	-0.7	-1.43 [-2.41, -0.45]
			Placebo	13	12 (92.3)	-0.36 (1.15)	-2.2	-1.08	-0.50	0.08	2.3	
		Week 18	Tezepelumab	9	9 (100.0)	-1.43 (0.64)	-2.2	-1.67	-1.67	-1.33	-0.2	-1.25 [-2.20, -0.30]
			Placebo	13	12 (92.3)	-0.38 (0.96)	-1.5	-0.92	-0.50	-0.17	2.3	
		Week 20	Tezepelumab	9	9 (100.0)	-1.41 (0.59)	-2.0	-2.00	-1.50	-1.33	-0.3	-1.01 [-1.94, -0.09]
			Placebo	13	12 (92.3)	-0.46 (1.12)	-2.2	-1.08	-0.75	-0.08	2.3	
		Week 22	Tezepelumab	9	9 (100.0)	-1.30 (0.73)	-2.2	-2.00	-1.50	-0.67	-0.3	-0.90 [-1.81, 0.01]
			Placebo	13	12 (92.3)	-0.39 (1.17)	-2.0	-1.08	-0.50	0.33	2.3	
		Week 24	Tezepelumab	9	9 (100.0)	-1.44 (0.62)	-2.3	-1.67	-1.50	-1.33	-0.3	-1.25 [-2.20, -0.30]
			Placebo	13	12 (92.3)	-0.32 (1.06)	-1.5	-1.08	-0.58	0.25	2.3	
		Week 26	Tezepelumab	9	9 (100.0)	-1.24 (0.72)	-2.3	-1.50	-1.33	-0.67	0.0	-0.88 [-1.79, 0.03]
			Placebo	13	12 (92.3)	-0.36 (1.16)	-1.7	-1.25	-0.75	0.33	2.3	
		Week 28	Tezepelumab	9	9 (100.0)	-1.02 (0.82)	-2.2	-1.50	-0.83	-0.67	0.3	-0.66 [-1.54, 0.21]
			Placebo	13	13 (100.0)	-0.35 (1.13)	-1.8	-1.00	-0.33	0.33	2.3	
		Week 30	Tezepelumab	9	9 (100.0)	-1.33 (0.62)	-2.5	-1.50	-1.33	-0.83	-0.7	-0.97 [-1.87, -0.07]
			Placebo	13	13 (100.0)	-0.40 (1.14)	-2.0	-1.00	-0.67	0.33	2.3	
		Week 32	Tezepelumab	9	9 (100.0)	-1.39 (0.55)	-2.2	-1.83	-1.50	-0.83	-0.7	-1.06 [-1.97, -0.14]
			Placebo	13	13 (100.0)	-0.31 (1.25)	-1.8	-1.17	-0.50	0.33	2.3	
		Week 34	Tezepelumab	9	9 (100.0)	-1.30 (0.83)	-2.5	-2.00	-1.50	-0.67	-0.2	-0.82 [-1.71, 0.06]
			Placebo	13	13 (100.0)	-0.37 (1.28)	-2.0	-1.17	-0.67	0.33	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.19 (0.78)	-2.3	-1.67	-1.33	-0.67	0.0	-0.85 [-1.74, 0.04]
			Placebo	13	13 (100.0)	-0.26 (1.26)	-1.8	-1.17	-0.33	0.33	2.3	
		Week 38	Tezepelumab	9	9 (100.0)	-1.19 (0.67)	-2.0	-1.67	-1.33	-0.67	-0.2	-0.76 [-1.64, 0.12]
			Placebo	13	13 (100.0)	-0.37 (1.27)	-2.2	-1.17	-0.33	0.17	2.3	
		Week 40	Tezepelumab	9	9 (100.0)	-1.41 (0.72)	-2.5	-2.00	-1.50	-0.67	-0.5	-1.11 [-2.03, -0.19]
			Placebo	13	13 (100.0)	-0.29 (1.16)	-1.7	-1.17	-0.33	0.33	2.3	
		Week 42	Tezepelumab	9	9 (100.0)	-1.31 (0.59)	-2.2	-1.50	-1.50	-0.67	-0.5	-0.93 [-1.83, -0.04]
			Placebo	13	13 (100.0)	-0.38 (1.19)	-2.0	-1.17	-0.67	0.00	2.3	
		Week 44	Tezepelumab	9	9 (100.0)	-1.22 (0.80)	-2.7	-1.50	-1.33	-0.67	-0.2	-0.78 [-1.66, 0.10]
			Placebo	13	13 (100.0)	-0.42 (1.15)	-1.8	-1.17	-0.83	0.00	2.3	
		Week 46	Tezepelumab	9	9 (100.0)	-1.17 (0.75)	-2.2	-1.50	-1.33	-0.67	0.0	-0.77 [-1.65, 0.12]
			Placebo	13	13 (100.0)	-0.46 (1.02)	-1.5	-1.00	-0.83	0.00	2.3	
		Week 48	Tezepelumab	9	9 (100.0)	-1.19 (0.86)	-2.2	-2.00	-1.50	-0.50	0.0	-0.74 [-1.62, 0.14]
			Placebo	13	13 (100.0)	-0.45 (1.08)	-1.7	-1.17	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	9	9 (100.0)	-1.50 (0.67)	-2.5	-2.00	-1.50	-1.17	-0.5	-1.07 [-1.99, -0.16]
			Placebo	13	13 (100.0)	-0.51 (1.06)	-1.7	-1.17	-0.83	-0.33	2.3	
		Week 52	Tezepelumab	9	9 (100.0)	-1.50 (0.67)	-2.5	-2.00	-1.50	-1.17	-0.5	-1.14 [-2.06, -0.22]
			Placebo	13	13 (100.0)	-0.42 (1.09)	-1.7	-1.00	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	2.71 (0.82)	0.0	2.33	2.67	3.08	4.8	
			Placebo	125	125 (100.0)	2.65 (0.67)	1.2	2.17	2.67	3.00	4.7	
		Week 2	Tezepelumab	128	122 (95.3)	2.17 (0.93)	0.0	1.67	2.17	2.83	4.3	
			Placebo	125	114 (91.2)	2.28 (0.81)	0.2	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	128	122 (95.3)	1.91 (0.97)	0.0	1.17	2.00	2.67	4.3	
			Placebo	125	114 (91.2)	2.13 (0.83)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	128	122 (95.3)	1.83 (0.98)	0.0	1.17	1.83	2.50	4.3	
			Placebo	125	115 (92.0)	2.02 (0.97)	0.2	1.33	2.17	2.50	5.5	
		Week 8	Tezepelumab	128	122 (95.3)	1.77 (1.03)	0.0	1.00	1.75	2.67	4.8	
			Placebo	125	115 (92.0)	2.00 (0.96)	0.0	1.33	2.00	2.67	4.7	
		Week 10	Tezepelumab	128	122 (95.3)	1.71 (1.01)	0.0	1.00	1.67	2.33	4.3	
			Placebo	125	116 (92.8)	1.93 (0.92)	0.0	1.33	2.00	2.50	5.3	
		Week 12	Tezepelumab	128	122 (95.3)	1.64 (1.03)	0.0	0.83	1.67	2.50	4.3	
			Placebo	125	116 (92.8)	1.83 (0.93)	0.0	1.17	1.83	2.50	4.3	
		Week 14	Tezepelumab	128	122 (95.3)	1.50 (1.01)	0.0	0.83	1.50	2.17	4.3	
			Placebo	125	116 (92.8)	1.81 (0.94)	0.0	1.00	1.83	2.50	5.0	
		Week 16	Tezepelumab	128	122 (95.3)	1.66 (1.06)	0.0	0.83	1.67	2.50	4.3	
			Placebo	125	116 (92.8)	1.92 (1.03)	0.0	1.17	1.83	2.67	5.0	
		Week 18	Tezepelumab	128	123 (96.1)	1.53 (0.99)	0.0	0.83	1.50	2.17	4.3	
			Placebo	125	116 (92.8)	1.80 (1.00)	0.0	1.17	1.83	2.33	5.0	
		Week 20	Tezepelumab	128	123 (96.1)	1.61 (1.03)	0.0	0.83	1.67	2.33	5.0	
			Placebo	125	116 (92.8)	1.87 (1.01)	0.0	1.17	1.92	2.58	5.0	
		Week 22	Tezepelumab	128	123 (96.1)	1.62 (0.97)	0.0	0.83	1.67	2.33	4.3	
			Placebo	125	116 (92.8)	1.81 (0.99)	0.0	1.08	1.92	2.50	5.0	
		Week 24	Tezepelumab	128	123 (96.1)	1.63 (1.04)	0.0	0.83	1.67	2.33	4.3	
			Placebo	125	116 (92.8)	1.80 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 26	Tezepelumab	128	124 (96.9)	1.57 (1.02)	0.0	0.83	1.50	2.25	4.3	
			Placebo	125	116 (92.8)	1.75 (0.96)	0.0	1.00	1.67	2.50	4.5	
		Week 28	Tezepelumab	128	125 (97.7)	1.61 (1.04)	0.0	0.83	1.50	2.50	4.3	
			Placebo	125	116 (92.8)	1.82 (1.03)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	128	126 (98.4)	1.57 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	125	117 (93.6)	1.82 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 32	Tezepelumab	128	126 (98.4)	1.53 (1.03)	0.0	0.83	1.50	2.33	4.3	
			Placebo	125	117 (93.6)	1.76 (0.98)	0.0	1.00	1.67	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	128	126 (98.4)	1.54 (1.06)	0.0	0.83	1.42	2.33	4.3	
			Placebo	125	117 (93.6)	1.72 (1.00)	0.0	1.00	1.67	2.50	4.5	
		Week 36	Tezepelumab	128	126 (98.4)	1.62 (1.05)	0.0	0.83	1.67	2.33	4.5	
			Placebo	125	117 (93.6)	1.80 (0.99)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	128	126 (98.4)	1.51 (1.04)	0.0	0.83	1.50	2.17	4.5	
			Placebo	125	117 (93.6)	1.72 (0.98)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	128	126 (98.4)	1.55 (1.05)	0.0	0.67	1.67	2.33	4.3	
			Placebo	125	117 (93.6)	1.80 (1.01)	0.0	1.00	1.83	2.50	4.5	
		Week 42	Tezepelumab	128	126 (98.4)	1.52 (1.06)	0.0	0.83	1.50	2.17	4.7	
			Placebo	125	117 (93.6)	1.77 (0.98)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	128	126 (98.4)	1.53 (1.03)	0.0	0.67	1.50	2.33	4.3	
			Placebo	125	118 (94.4)	1.82 (1.00)	0.0	1.00	1.92	2.67	4.5	
		Week 46	Tezepelumab	128	126 (98.4)	1.49 (1.04)	0.0	0.67	1.33	2.17	4.3	
			Placebo	125	118 (94.4)	1.71 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	128	126 (98.4)	1.56 (1.06)	0.0	0.67	1.50	2.33	4.3	
			Placebo	125	118 (94.4)	1.74 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 50	Tezepelumab	128	126 (98.4)	1.49 (1.05)	0.0	0.83	1.33	2.17	4.3	
			Placebo	125	118 (94.4)	1.73 (0.95)	0.0	1.00	1.67	2.50	4.5	
		Week 52	Tezepelumab	128	126 (98.4)	1.52 (1.04)	0.0	0.67	1.50	2.17	4.3	
			Placebo	125	118 (94.4)	1.77 (0.98)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	128	122 (95.3)	-0.55 (0.69)	-2.8	-0.83	-0.50	0.00	0.7	-0.25 [-0.51, 0.00]
			Placebo	125	114 (91.2)	-0.37 (0.71)	-2.8	-0.83	-0.33	0.17	1.2	
		Week 4	Tezepelumab	128	122 (95.3)	-0.81 (0.90)	-3.5	-1.33	-0.83	-0.17	2.3	-0.33 [-0.59, -0.07]
			Placebo	125	114 (91.2)	-0.52 (0.83)	-3.0	-1.00	-0.42	0.00	1.2	
		Week 6	Tezepelumab	128	122 (95.3)	-0.89 (0.97)	-3.8	-1.50	-0.83	-0.33	2.3	-0.28 [-0.53, -0.02]
			Placebo	125	115 (92.0)	-0.63 (0.90)	-3.3	-1.33	-0.50	0.00	1.5	
		Week 8	Tezepelumab	128	122 (95.3)	-0.95 (1.02)	-3.8	-1.50	-0.92	-0.33	2.3	-0.32 [-0.57, -0.06]
			Placebo	125	115 (92.0)	-0.64 (0.90)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	128	122 (95.3)	-1.01 (0.99)	-3.8	-1.50	-1.00	-0.33	2.3	-0.30 [-0.55, -0.04]
			Placebo	125	116 (92.8)	-0.72 (0.94)	-3.3	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	128	122 (95.3)	-1.08 (0.99)	-3.7	-1.67	-1.00	-0.50	2.3	-0.26 [-0.51, -0.00]
			Placebo	125	116 (92.8)	-0.82 (0.97)	-3.3	-1.33	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	128	122 (95.3)	-1.22 (1.02)	-3.8	-1.83	-1.17	-0.67	2.3	-0.38 [-0.64, -0.13]
			Placebo	125	116 (92.8)	-0.84 (0.96)	-3.2	-1.33	-0.83	-0.25	2.3	
		Week 16	Tezepelumab	128	122 (95.3)	-1.05 (1.05)	-4.2	-1.83	-1.00	-0.33	2.3	-0.31 [-0.56, -0.05]
			Placebo	125	116 (92.8)	-0.73 (1.01)	-3.5	-1.33	-0.67	0.00	2.3	
		Week 18	Tezepelumab	128	123 (96.1)	-1.18 (1.02)	-4.2	-1.83	-1.00	-0.67	2.3	-0.33 [-0.58, -0.07]
			Placebo	125	116 (92.8)	-0.85 (1.01)	-3.2	-1.50	-0.83	-0.25	2.3	
		Week 20	Tezepelumab	128	123 (96.1)	-1.09 (1.03)	-4.2	-1.83	-1.00	-0.33	2.3	-0.30 [-0.56, -0.05]
			Placebo	125	116 (92.8)	-0.78 (1.03)	-3.5	-1.42	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	128	123 (96.1)	-1.09 (1.05)	-4.3	-1.83	-1.00	-0.50	2.3	-0.24 [-0.50, 0.01]
			Placebo	125	116 (92.8)	-0.84 (0.98)	-3.3	-1.50	-0.83	-0.25	2.3	
		Week 24	Tezepelumab	128	123 (96.1)	-1.08 (1.00)	-4.5	-1.83	-1.00	-0.33	2.3	-0.23 [-0.49, 0.02]
			Placebo	125	116 (92.8)	-0.85 (1.03)	-3.5	-1.50	-0.75	-0.17	1.7	
		Week 26	Tezepelumab	128	124 (96.9)	-1.13 (1.05)	-4.2	-1.83	-1.00	-0.33	2.3	-0.22 [-0.47, 0.03]
			Placebo	125	116 (92.8)	-0.90 (1.02)	-4.0	-1.50	-1.00	-0.17	1.5	
		Week 28	Tezepelumab	128	125 (97.7)	-1.09 (1.05)	-4.2	-1.83	-1.00	-0.33	2.3	-0.25 [-0.50, 0.01]
			Placebo	125	116 (92.8)	-0.83 (1.06)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	128	126 (98.4)	-1.13 (1.07)	-4.2	-2.00	-1.00	-0.33	2.3	-0.28 [-0.53, -0.03]
			Placebo	125	117 (93.6)	-0.83 (1.04)	-3.2	-1.50	-0.83	-0.17	2.0	
		Week 32	Tezepelumab	128	126 (98.4)	-1.17 (1.07)	-4.2	-2.00	-1.00	-0.50	2.3	-0.26 [-0.51, -0.01]
			Placebo	125	117 (93.6)	-0.90 (1.01)	-3.5	-1.50	-0.83	-0.33	1.5	
		Week 34	Tezepelumab	128	126 (98.4)	-1.16 (1.08)	-4.2	-2.00	-1.17	-0.50	2.3	-0.22 [-0.47, 0.03]
			Placebo	125	117 (93.6)	-0.93 (1.01)	-4.0	-1.50	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	128	126 (98.4)	-1.09 (1.12)	-4.2	-1.83	-1.00	-0.33	2.3	-0.22 [-0.47, 0.04]
			Placebo	125	117 (93.6)	-0.85 (1.04)	-3.5	-1.33	-0.83	-0.17	1.5	
		Week 38	Tezepelumab	128	126 (98.4)	-1.19 (1.11)	-4.2	-2.00	-1.17	-0.33	2.3	-0.24 [-0.50, 0.01]
			Placebo	125	117 (93.6)	-0.93 (1.03)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 40	Tezepelumab	128	126 (98.4)	-1.15 (1.11)	-4.2	-2.00	-1.00	-0.33	2.3	-0.27 [-0.53, -0.02]
			Placebo	125	117 (93.6)	-0.85 (1.04)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 42	Tezepelumab	128	126 (98.4)	-1.19 (1.12)	-4.2	-2.00	-1.17	-0.50	2.3	-0.29 [-0.54, -0.03]
			Placebo	125	117 (93.6)	-0.88 (1.01)	-4.0	-1.50	-0.83	-0.17	1.3	
		Week 44	Tezepelumab	128	126 (98.4)	-1.17 (1.12)	-4.3	-1.83	-1.00	-0.50	2.3	-0.31 [-0.57, -0.06]
			Placebo	125	118 (94.4)	-0.83 (1.05)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 46	Tezepelumab	128	126 (98.4)	-1.21 (1.11)	-4.2	-2.00	-1.00	-0.50	2.3	-0.25 [-0.50, 0.00]
			Placebo	125	118 (94.4)	-0.94 (1.03)	-4.0	-1.67	-1.00	-0.17	1.3	
		Week 48	Tezepelumab	128	126 (98.4)	-1.14 (1.11)	-4.2	-1.83	-1.00	-0.33	2.3	-0.22 [-0.47, 0.03]
			Placebo	125	118 (94.4)	-0.91 (1.06)	-3.7	-1.50	-0.83	-0.33	1.7	
		Week 50	Tezepelumab	128	126 (98.4)	-1.21 (1.11)	-4.2	-2.00	-1.17	-0.50	2.3	-0.27 [-0.52, -0.02]
			Placebo	125	118 (94.4)	-0.92 (1.01)	-4.0	-1.50	-1.00	-0.33	1.5	
		Week 52	Tezepelumab	128	126 (98.4)	-1.18 (1.12)	-4.2	-2.00	-1.00	-0.50	2.3	-0.28 [-0.54, -0.03]
			Placebo	125	118 (94.4)	-0.88 (1.04)	-4.0	-1.50	-0.83	-0.17	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	70	70 (100.0)	2.70 (0.77)	0.3	2.33	2.67	3.00	4.8	
			Placebo	73	73 (100.0)	2.61 (0.66)	1.2	2.17	2.67	3.00	4.2	
		Week 2	Tezepelumab	70	67 (95.7)	2.12 (0.87)	0.0	1.67	2.17	2.67	4.3	
			Placebo	73	67 (91.8)	2.31 (0.82)	0.2	1.83	2.33	2.83	4.3	
		Week 4	Tezepelumab	70	67 (95.7)	1.78 (0.95)	0.0	1.00	1.83	2.50	4.3	
			Placebo	73	67 (91.8)	2.20 (0.78)	0.5	1.67	2.33	2.67	4.2	
		Week 6	Tezepelumab	70	67 (95.7)	1.71 (0.94)	0.0	1.17	1.67	2.33	4.3	
			Placebo	73	68 (93.2)	2.07 (0.83)	0.3	1.50	2.17	2.50	4.5	
		Week 8	Tezepelumab	70	67 (95.7)	1.72 (0.96)	0.0	1.00	1.67	2.50	4.3	
			Placebo	73	68 (93.2)	2.05 (0.83)	0.3	1.50	2.00	2.50	4.0	
		Week 10	Tezepelumab	70	67 (95.7)	1.65 (0.95)	0.0	1.17	1.67	2.33	4.3	
			Placebo	73	69 (94.5)	1.90 (0.78)	0.2	1.33	2.00	2.50	4.2	
		Week 12	Tezepelumab	70	67 (95.7)	1.61 (1.02)	0.0	0.83	1.50	2.50	4.3	
			Placebo	73	69 (94.5)	1.93 (0.89)	0.0	1.33	2.00	2.67	4.3	
		Week 14	Tezepelumab	70	67 (95.7)	1.42 (0.96)	0.0	0.83	1.33	2.00	4.3	
			Placebo	73	69 (94.5)	1.89 (0.86)	0.0	1.17	1.83	2.50	4.2	
		Week 16	Tezepelumab	70	67 (95.7)	1.57 (0.99)	0.0	0.83	1.50	2.50	4.3	
			Placebo	73	69 (94.5)	1.98 (0.92)	0.0	1.33	2.17	2.67	3.8	
		Week 18	Tezepelumab	70	67 (95.7)	1.40 (0.91)	0.0	0.83	1.33	2.00	4.3	
			Placebo	73	69 (94.5)	1.86 (0.85)	0.0	1.33	1.83	2.33	3.8	
		Week 20	Tezepelumab	70	67 (95.7)	1.54 (0.96)	0.0	0.83	1.50	2.17	4.3	
			Placebo	73	69 (94.5)	1.88 (0.93)	0.0	1.33	2.17	2.50	3.7	
		Week 22	Tezepelumab	70	67 (95.7)	1.51 (0.97)	0.0	0.83	1.33	2.33	4.3	
			Placebo	73	69 (94.5)	1.83 (0.88)	0.2	1.17	1.83	2.50	3.7	
		Week 24	Tezepelumab	70	67 (95.7)	1.52 (1.02)	0.0	0.83	1.50	2.33	4.3	
			Placebo	73	69 (94.5)	1.77 (0.91)	0.0	1.00	1.83	2.50	3.5	
		Week 26	Tezepelumab	70	67 (95.7)	1.41 (0.93)	0.0	0.83	1.17	2.17	4.3	
			Placebo	73	69 (94.5)	1.74 (0.85)	0.0	1.00	1.67	2.50	3.3	
		Week 28	Tezepelumab	70	67 (95.7)	1.55 (0.99)	0.0	0.83	1.50	2.50	4.3	
			Placebo	73	69 (94.5)	1.85 (0.90)	0.0	1.17	2.00	2.50	3.7	
		Week 30	Tezepelumab	70	68 (97.1)	1.46 (0.94)	0.0	0.83	1.33	2.00	4.3	
			Placebo	73	70 (95.9)	1.84 (0.91)	0.0	1.17	1.83	2.50	4.0	
		Week 32	Tezepelumab	70	68 (97.1)	1.43 (0.98)	0.0	0.83	1.17	2.08	4.3	
			Placebo	73	70 (95.9)	1.78 (0.97)	0.0	1.00	1.58	2.67	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Medium/Low	Absolute values	Week 34	Tezepelumab	70	68 (97.1)	1.40 (1.00)	0.0	0.83	1.17	2.00	4.3	
			Placebo	73	70 (95.9)	1.75 (0.98)	0.0	1.00	1.67	2.50	3.7	
		Week 36	Tezepelumab	70	68 (97.1)	1.59 (1.04)	0.0	0.83	1.67	2.25	4.5	
			Placebo	73	70 (95.9)	1.75 (0.94)	0.0	1.00	1.83	2.67	3.0	
		Week 38	Tezepelumab	70	68 (97.1)	1.37 (0.91)	0.0	0.75	1.25	2.00	4.3	
			Placebo	73	70 (95.9)	1.71 (0.95)	0.0	1.00	1.67	2.50	4.0	
		Week 40	Tezepelumab	70	68 (97.1)	1.43 (0.97)	0.0	0.75	1.42	2.17	4.3	
			Placebo	73	70 (95.9)	1.73 (0.94)	0.0	1.00	1.83	2.50	3.5	
		Week 42	Tezepelumab	70	68 (97.1)	1.41 (1.01)	0.0	0.75	1.33	2.00	4.7	
			Placebo	73	70 (95.9)	1.80 (1.00)	0.0	1.00	2.00	2.67	4.7	
		Week 44	Tezepelumab	70	68 (97.1)	1.42 (0.97)	0.0	0.75	1.33	2.00	4.3	
			Placebo	73	71 (97.3)	1.80 (0.97)	0.0	0.83	2.00	2.67	3.8	
		Week 46	Tezepelumab	70	68 (97.1)	1.35 (0.94)	0.0	0.75	1.17	2.00	4.3	
			Placebo	73	71 (97.3)	1.69 (0.98)	0.0	1.00	1.83	2.50	3.3	
		Week 48	Tezepelumab	70	68 (97.1)	1.46 (0.98)	0.0	0.67	1.42	2.17	4.3	
			Placebo	73	71 (97.3)	1.72 (0.98)	0.0	0.83	1.67	2.50	3.5	
		Week 50	Tezepelumab	70	68 (97.1)	1.35 (0.92)	0.0	0.83	1.17	2.00	4.3	
			Placebo	73	71 (97.3)	1.77 (0.94)	0.0	1.00	1.83	2.50	3.5	
		Week 52	Tezepelumab	70	68 (97.1)	1.37 (0.93)	0.0	0.67	1.33	1.92	4.3	
			Placebo	73	71 (97.3)	1.80 (0.97)	0.0	1.00	2.00	2.50	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 2	Tezepelumab	70	67 (95.7)	-0.56 (0.64)	-2.5	-0.83	-0.50	-0.17	0.5	-0.39 [-0.73, -0.04]
			Placebo	73	67 (91.8)	-0.30 (0.72)	-2.7	-0.83	-0.33	0.17	1.2	
		Week 4	Tezepelumab	70	67 (95.7)	-0.90 (0.89)	-3.5	-1.50	-0.83	-0.17	0.8	-0.59 [-0.94, -0.25]
			Placebo	73	67 (91.8)	-0.40 (0.77)	-2.2	-1.00	-0.33	0.17	1.2	
		Week 6	Tezepelumab	70	67 (95.7)	-0.96 (0.98)	-3.8	-1.50	-0.83	-0.33	1.3	-0.48 [-0.82, -0.14]
			Placebo	73	68 (93.2)	-0.53 (0.82)	-2.3	-1.17	-0.50	0.00	1.3	
		Week 8	Tezepelumab	70	67 (95.7)	-0.96 (0.96)	-3.8	-1.50	-1.00	-0.33	1.0	-0.47 [-0.81, -0.12]
			Placebo	73	68 (93.2)	-0.54 (0.81)	-2.7	-1.00	-0.58	0.00	1.0	
		Week 10	Tezepelumab	70	67 (95.7)	-1.03 (0.93)	-3.8	-1.50	-1.00	-0.33	1.0	-0.38 [-0.72, -0.04]
			Placebo	73	69 (94.5)	-0.70 (0.80)	-2.7	-1.33	-0.67	-0.17	0.8	
		Week 12	Tezepelumab	70	67 (95.7)	-1.07 (0.94)	-3.7	-1.67	-1.00	-0.33	1.2	-0.42 [-0.76, -0.08]
			Placebo	73	69 (94.5)	-0.67 (0.93)	-2.8	-1.33	-0.50	-0.17	1.3	
		Week 14	Tezepelumab	70	67 (95.7)	-1.26 (0.96)	-3.8	-1.83	-1.17	-0.67	1.2	-0.59 [-0.93, -0.25]
			Placebo	73	69 (94.5)	-0.72 (0.86)	-3.0	-1.17	-0.67	-0.17	1.3	
		Week 16	Tezepelumab	70	67 (95.7)	-1.10 (1.02)	-4.2	-1.67	-1.00	-0.33	1.2	-0.49 [-0.83, -0.15]
			Placebo	73	69 (94.5)	-0.62 (0.95)	-3.5	-1.17	-0.67	0.00	1.3	
		Week 18	Tezepelumab	70	67 (95.7)	-1.28 (0.99)	-4.2	-1.83	-1.17	-0.67	1.2	-0.57 [-0.91, -0.23]
			Placebo	73	69 (94.5)	-0.75 (0.87)	-3.0	-1.33	-0.67	-0.33	1.3	
		Week 20	Tezepelumab	70	67 (95.7)	-1.14 (1.00)	-4.2	-1.83	-1.00	-0.33	1.0	-0.41 [-0.75, -0.07]
			Placebo	73	69 (94.5)	-0.73 (0.98)	-3.5	-1.33	-0.67	-0.17	1.2	
		Week 22	Tezepelumab	70	67 (95.7)	-1.16 (1.05)	-4.3	-1.83	-1.00	-0.33	1.2	-0.39 [-0.73, -0.05]
			Placebo	73	69 (94.5)	-0.78 (0.91)	-3.0	-1.50	-0.67	-0.17	1.3	
		Week 24	Tezepelumab	70	67 (95.7)	-1.16 (0.99)	-4.5	-1.67	-1.00	-0.50	1.5	-0.33 [-0.66, 0.01]
			Placebo	73	69 (94.5)	-0.83 (1.00)	-3.5	-1.50	-0.83	-0.17	1.7	
		Week 26	Tezepelumab	70	67 (95.7)	-1.27 (1.03)	-4.2	-1.83	-1.17	-0.50	1.3	-0.40 [-0.74, -0.06]
			Placebo	73	69 (94.5)	-0.87 (0.97)	-4.0	-1.33	-1.00	-0.17	1.0	
		Week 28	Tezepelumab	70	67 (95.7)	-1.12 (0.99)	-4.2	-1.67	-1.00	-0.33	1.0	-0.36 [-0.70, -0.03]
			Placebo	73	69 (94.5)	-0.76 (1.00)	-4.0	-1.50	-0.67	-0.17	1.0	
		Week 30	Tezepelumab	70	68 (97.1)	-1.22 (1.01)	-4.2	-1.83	-1.00	-0.50	1.5	-0.46 [-0.80, -0.12]
			Placebo	73	70 (95.9)	-0.77 (0.99)	-3.2	-1.50	-0.67	-0.17	1.3	
		Week 32	Tezepelumab	70	68 (97.1)	-1.25 (1.08)	-4.2	-1.92	-1.00	-0.67	1.8	-0.41 [-0.74, -0.07]
			Placebo	73	70 (95.9)	-0.83 (1.01)	-3.5	-1.50	-0.67	-0.17	1.3	
		Week 34	Tezepelumab	70	68 (97.1)	-1.28 (1.03)	-4.2	-1.92	-1.17	-0.67	1.8	-0.41 [-0.75, -0.07]
			Placebo	73	70 (95.9)	-0.86 (1.02)	-4.0	-1.50	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Medium/Low	Change from baseline	Week 36	Tezepelumab	70	68 (97.1)	-1.10 (1.12)	-4.2	-1.75	-1.00	-0.42	1.7	-0.22 [-0.56, 0.11]
			Placebo	73	70 (95.9)	-0.86 (1.03)	-3.5	-1.50	-0.83	0.00	1.3	
		Week 38	Tezepelumab	70	68 (97.1)	-1.32 (1.05)	-4.2	-1.83	-1.25	-0.67	0.8	-0.40 [-0.74, -0.06]
			Placebo	73	70 (95.9)	-0.90 (1.06)	-4.0	-1.50	-0.83	-0.17	1.3	
		Week 40	Tezepelumab	70	68 (97.1)	-1.25 (1.08)	-4.2	-1.83	-1.00	-0.58	1.2	-0.36 [-0.70, -0.02]
			Placebo	73	70 (95.9)	-0.88 (0.98)	-4.0	-1.50	-0.83	-0.17	1.3	
		Week 42	Tezepelumab	70	68 (97.1)	-1.27 (1.09)	-4.2	-1.83	-1.17	-0.67	1.8	-0.43 [-0.77, -0.09]
			Placebo	73	70 (95.9)	-0.81 (1.05)	-4.0	-1.50	-0.83	0.00	1.3	
		Week 44	Tezepelumab	70	68 (97.1)	-1.26 (1.10)	-4.3	-1.83	-1.00	-0.58	1.0	-0.43 [-0.76, -0.09]
			Placebo	73	71 (97.3)	-0.81 (1.04)	-4.0	-1.50	-0.67	-0.17	1.3	
		Week 46	Tezepelumab	70	68 (97.1)	-1.34 (1.08)	-4.2	-1.83	-1.25	-0.67	1.0	-0.40 [-0.74, -0.06]
			Placebo	73	71 (97.3)	-0.91 (1.06)	-4.0	-1.50	-1.00	0.00	1.0	
		Week 48	Tezepelumab	70	68 (97.1)	-1.23 (1.11)	-4.2	-1.83	-1.08	-0.42	1.2	-0.31 [-0.64, 0.03]
			Placebo	73	71 (97.3)	-0.89 (1.07)	-3.7	-1.67	-0.83	-0.17	1.3	
		Week 50	Tezepelumab	70	68 (97.1)	-1.34 (1.07)	-4.2	-1.92	-1.33	-0.58	1.2	-0.47 [-0.81, -0.13]
			Placebo	73	71 (97.3)	-0.84 (1.03)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 52	Tezepelumab	70	68 (97.1)	-1.32 (1.09)	-4.2	-1.92	-1.17	-0.58	1.2	-0.47 [-0.81, -0.14]
			Placebo	73	71 (97.3)	-0.81 (1.04)	-4.0	-1.50	-0.83	-0.17	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	67	67 (100.0)	2.70 (0.83)	0.0	2.17	2.67	3.17	4.8	
			Placebo	65	65 (100.0)	2.71 (0.72)	0.3	2.33	2.67	3.17	4.7	
		Week 2	Tezepelumab	67	64 (95.5)	2.22 (0.95)	0.0	1.50	2.33	2.92	4.2	
			Placebo	65	58 (89.2)	2.29 (0.77)	0.3	2.00	2.33	2.67	4.8	
		Week 4	Tezepelumab	67	64 (95.5)	2.00 (0.95)	0.2	1.33	2.17	2.75	3.5	
			Placebo	65	58 (89.2)	2.15 (0.91)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	67	64 (95.5)	1.88 (1.00)	0.0	1.08	1.83	2.67	4.0	
			Placebo	65	58 (89.2)	2.10 (1.10)	0.2	1.17	2.17	2.67	5.5	
		Week 8	Tezepelumab	67	64 (95.5)	1.75 (1.10)	0.0	0.83	1.67	2.67	4.8	
			Placebo	65	59 (90.8)	2.06 (1.08)	0.0	1.17	2.17	2.83	4.7	
		Week 10	Tezepelumab	67	64 (95.5)	1.67 (1.08)	0.0	0.83	1.67	2.50	4.3	
			Placebo	65	59 (90.8)	2.07 (1.05)	0.0	1.50	2.17	2.67	5.3	
		Week 12	Tezepelumab	67	64 (95.5)	1.57 (1.05)	0.0	0.50	1.58	2.50	4.3	
			Placebo	65	59 (90.8)	1.86 (0.99)	0.0	1.00	2.00	2.50	4.3	
		Week 14	Tezepelumab	67	64 (95.5)	1.50 (1.05)	0.0	0.67	1.50	2.25	4.3	
			Placebo	65	59 (90.8)	1.79 (0.97)	0.0	1.17	1.83	2.17	5.0	
		Week 16	Tezepelumab	67	64 (95.5)	1.65 (1.11)	0.0	0.67	1.58	2.50	4.3	
			Placebo	65	59 (90.8)	1.96 (1.15)	0.0	1.00	2.00	2.67	5.0	
		Week 18	Tezepelumab	67	65 (97.0)	1.61 (1.02)	0.0	0.83	1.67	2.33	4.3	
			Placebo	65	59 (90.8)	1.87 (1.13)	0.0	1.00	1.83	2.50	5.0	
		Week 20	Tezepelumab	67	65 (97.0)	1.63 (1.08)	0.0	0.83	1.83	2.33	5.0	
			Placebo	65	59 (90.8)	1.97 (1.08)	0.0	1.17	2.17	2.67	5.0	
		Week 22	Tezepelumab	67	65 (97.0)	1.68 (0.96)	0.0	1.00	1.83	2.33	4.3	
			Placebo	65	59 (90.8)	1.93 (1.13)	0.0	1.00	2.00	2.67	5.0	
		Week 24	Tezepelumab	67	65 (97.0)	1.67 (1.04)	0.0	0.83	1.67	2.33	4.3	
			Placebo	65	59 (90.8)	1.99 (1.04)	0.0	1.33	2.00	2.67	4.5	
		Week 26	Tezepelumab	67	66 (98.5)	1.71 (1.06)	0.0	0.83	1.75	2.50	4.3	
			Placebo	65	59 (90.8)	1.92 (1.11)	0.0	1.00	1.83	2.83	4.5	
		Week 28	Tezepelumab	67	67 (100.0)	1.66 (1.08)	0.0	0.83	1.67	2.50	4.3	
			Placebo	65	60 (92.3)	1.91 (1.18)	0.0	1.00	2.00	2.67	4.5	
		Week 30	Tezepelumab	67	67 (100.0)	1.64 (1.05)	0.0	0.83	1.67	2.33	4.3	
			Placebo	65	60 (92.3)	1.89 (1.14)	0.0	1.00	1.83	2.67	4.5	
		Week 32	Tezepelumab	67	67 (100.0)	1.59 (1.06)	0.0	0.67	1.67	2.33	4.3	
			Placebo	65	60 (92.3)	1.86 (1.09)	0.0	1.17	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Absolute values	Week 34	Tezepelumab	67	67 (100.0)	1.64 (1.11)	0.0	0.67	1.50	2.50	4.3	
			Placebo	65	60 (92.3)	1.82 (1.09)	0.0	1.00	1.83	2.42	4.5	
		Week 36	Tezepelumab	67	67 (100.0)	1.61 (1.04)	0.0	0.83	1.67	2.33	4.3	
			Placebo	65	60 (92.3)	1.99 (1.13)	0.0	1.17	1.92	2.75	4.5	
		Week 38	Tezepelumab	67	67 (100.0)	1.64 (1.14)	0.0	0.83	1.67	2.50	4.5	
			Placebo	65	60 (92.3)	1.86 (1.09)	0.0	1.08	1.83	2.50	4.5	
		Week 40	Tezepelumab	67	67 (100.0)	1.62 (1.11)	0.0	0.67	1.83	2.50	4.3	
			Placebo	65	60 (92.3)	2.00 (1.13)	0.0	1.25	2.00	2.67	4.5	
		Week 42	Tezepelumab	67	67 (100.0)	1.59 (1.08)	0.0	0.83	1.67	2.33	4.3	
			Placebo	65	60 (92.3)	1.86 (1.02)	0.0	1.17	1.83	2.50	4.5	
		Week 44	Tezepelumab	67	67 (100.0)	1.62 (1.07)	0.0	0.67	1.67	2.50	4.3	
			Placebo	65	60 (92.3)	1.94 (1.06)	0.0	1.17	2.00	2.58	4.5	
		Week 46	Tezepelumab	67	67 (100.0)	1.63 (1.11)	0.0	0.83	1.83	2.50	4.3	
			Placebo	65	60 (92.3)	1.84 (0.98)	0.0	1.17	1.83	2.33	4.5	
		Week 48	Tezepelumab	67	67 (100.0)	1.63 (1.10)	0.0	0.67	1.67	2.33	4.3	
			Placebo	65	60 (92.3)	1.88 (1.05)	0.0	1.00	2.08	2.50	4.5	
		Week 50	Tezepelumab	67	67 (100.0)	1.58 (1.13)	0.0	0.67	1.50	2.33	4.3	
			Placebo	65	60 (92.3)	1.78 (0.99)	0.0	1.00	1.83	2.33	4.5	
		Week 52	Tezepelumab	67	67 (100.0)	1.61 (1.11)	0.0	0.67	1.50	2.33	4.3	
			Placebo	65	60 (92.3)	1.85 (1.04)	0.0	1.08	1.92	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 2	Tezepelumab	67	64 (95.5)	-0.51 (0.71)	-2.8	-1.00	-0.33	0.08	0.7	-0.10 [-0.45, 0.26]
			Placebo	65	58 (89.2)	-0.45 (0.68)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	67	64 (95.5)	-0.74 (0.88)	-2.5	-1.25	-0.83	-0.17	2.3	-0.17 [-0.53, 0.19]
			Placebo	65	58 (89.2)	-0.59 (0.90)	-3.0	-1.17	-0.33	0.00	1.2	
		Week 6	Tezepelumab	67	64 (95.5)	-0.85 (0.94)	-2.7	-1.50	-0.92	-0.17	2.3	-0.23 [-0.58, 0.13]
			Placebo	65	58 (89.2)	-0.64 (0.98)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	67	64 (95.5)	-0.99 (1.04)	-3.0	-1.67	-1.00	-0.33	2.3	-0.29 [-0.65, 0.06]
			Placebo	65	59 (90.8)	-0.69 (1.00)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	67	64 (95.5)	-1.07 (1.03)	-3.2	-1.75	-1.17	-0.42	2.3	-0.36 [-0.72, -0.00]
			Placebo	65	59 (90.8)	-0.68 (1.11)	-3.3	-1.33	-0.50	-0.17	2.7	
		Week 12	Tezepelumab	67	64 (95.5)	-1.16 (1.02)	-3.0	-2.00	-1.17	-0.67	2.3	-0.28 [-0.63, 0.08]
			Placebo	65	59 (90.8)	-0.89 (0.99)	-3.3	-1.33	-0.83	-0.33	1.3	
		Week 14	Tezepelumab	67	64 (95.5)	-1.23 (1.03)	-3.7	-2.00	-1.17	-0.67	2.3	-0.27 [-0.62, 0.09]
			Placebo	65	59 (90.8)	-0.95 (1.02)	-3.2	-1.50	-1.00	-0.33	2.3	
		Week 16	Tezepelumab	67	64 (95.5)	-1.09 (1.06)	-3.0	-2.00	-1.00	-0.50	2.3	-0.28 [-0.63, 0.08]
			Placebo	65	59 (90.8)	-0.79 (1.11)	-3.2	-1.33	-0.83	0.00	2.3	
		Week 18	Tezepelumab	67	65 (97.0)	-1.11 (1.00)	-3.5	-1.83	-1.00	-0.67	2.3	-0.22 [-0.58, 0.13]
			Placebo	65	59 (90.8)	-0.87 (1.16)	-3.2	-1.67	-0.83	-0.17	2.3	
		Week 20	Tezepelumab	67	65 (97.0)	-1.09 (1.02)	-3.2	-2.00	-1.00	-0.50	2.3	-0.30 [-0.65, 0.06]
			Placebo	65	59 (90.8)	-0.78 (1.11)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	67	65 (97.0)	-1.04 (1.02)	-3.0	-1.83	-1.00	-0.67	2.3	-0.21 [-0.56, 0.15]
			Placebo	65	59 (90.8)	-0.82 (1.12)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	67	65 (97.0)	-1.05 (0.98)	-3.2	-1.83	-1.00	-0.33	2.3	-0.29 [-0.64, 0.07]
			Placebo	65	59 (90.8)	-0.76 (1.09)	-3.2	-1.50	-0.67	0.00	2.3	
		Week 26	Tezepelumab	67	66 (98.5)	-1.00 (1.03)	-2.8	-2.00	-1.00	-0.17	2.3	-0.16 [-0.51, 0.19]
			Placebo	65	59 (90.8)	-0.82 (1.13)	-3.2	-1.50	-1.00	0.17	2.3	
		Week 28	Tezepelumab	67	67 (100.0)	-1.04 (1.09)	-3.2	-2.00	-1.00	-0.17	2.3	-0.22 [-0.57, 0.13]
			Placebo	65	60 (92.3)	-0.80 (1.16)	-3.2	-1.67	-0.83	-0.17	2.3	
		Week 30	Tezepelumab	67	67 (100.0)	-1.06 (1.08)	-3.5	-2.00	-1.00	-0.33	2.3	-0.22 [-0.57, 0.13]
			Placebo	65	60 (92.3)	-0.81 (1.14)	-3.2	-1.50	-0.92	-0.17	2.3	
		Week 32	Tezepelumab	67	67 (100.0)	-1.11 (1.02)	-3.0	-2.00	-1.00	-0.50	2.3	-0.25 [-0.60, 0.10]
			Placebo	65	60 (92.3)	-0.85 (1.09)	-3.0	-1.50	-1.00	-0.33	2.3	
		Week 34	Tezepelumab	67	67 (100.0)	-1.05 (1.09)	-2.8	-2.00	-1.17	-0.33	2.3	-0.16 [-0.51, 0.19]
			Placebo	65	60 (92.3)	-0.88 (1.08)	-3.2	-1.50	-1.00	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Change from baseline	Week 36	Tezepelumab	67	67 (100.0)	-1.08 (1.07)	-3.0	-2.00	-1.17	-0.17	2.3	-0.34 [-0.69, 0.01]
			Placebo	65	60 (92.3)	-0.71 (1.13)	-3.5	-1.33	-0.83	-0.08	2.3	
		Week 38	Tezepelumab	67	67 (100.0)	-1.06 (1.11)	-3.0	-2.00	-1.17	-0.17	2.3	-0.20 [-0.55, 0.15]
			Placebo	65	60 (92.3)	-0.85 (1.08)	-3.2	-1.33	-0.92	-0.08	2.3	
		Week 40	Tezepelumab	67	67 (100.0)	-1.08 (1.10)	-3.2	-2.00	-1.00	-0.33	2.3	-0.33 [-0.69, 0.02]
			Placebo	65	60 (92.3)	-0.70 (1.15)	-3.2	-1.33	-0.75	0.17	2.3	
		Week 42	Tezepelumab	67	67 (100.0)	-1.11 (1.09)	-3.3	-2.00	-1.17	-0.50	2.3	-0.25 [-0.60, 0.10]
			Placebo	65	60 (92.3)	-0.85 (1.03)	-2.8	-1.33	-1.00	-0.17	2.3	
		Week 44	Tezepelumab	67	67 (100.0)	-1.08 (1.09)	-3.5	-2.00	-1.00	-0.33	2.3	-0.29 [-0.64, 0.06]
			Placebo	65	60 (92.3)	-0.77 (1.09)	-3.3	-1.50	-0.83	0.00	2.3	
		Week 46	Tezepelumab	67	67 (100.0)	-1.07 (1.09)	-3.3	-2.00	-1.00	-0.17	2.3	-0.19 [-0.54, 0.16]
			Placebo	65	60 (92.3)	-0.87 (1.00)	-3.2	-1.42	-1.00	-0.33	2.3	
		Week 48	Tezepelumab	67	67 (100.0)	-1.06 (1.08)	-2.7	-2.00	-1.00	-0.33	2.3	-0.22 [-0.57, 0.13]
			Placebo	65	60 (92.3)	-0.82 (1.07)	-3.3	-1.42	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	67	67 (100.0)	-1.12 (1.10)	-2.7	-2.00	-1.17	-0.33	2.3	-0.18 [-0.53, 0.17]
			Placebo	65	60 (92.3)	-0.93 (1.01)	-3.5	-1.42	-1.00	-0.42	2.3	
		Week 52	Tezepelumab	67	67 (100.0)	-1.09 (1.09)	-2.7	-2.00	-1.00	-0.33	2.3	-0.22 [-0.57, 0.13]
			Placebo	65	60 (92.3)	-0.86 (1.06)	-3.5	-1.42	-0.83	-0.25	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	2.82 (0.79)	1.7	2.17	2.83	3.33	4.3	
			Placebo	6	6 (100.0)	2.78 (0.42)	2.2	2.50	2.83	3.00	3.3	
		Week 2	Tezepelumab	11	11 (100.0)	2.47 (0.85)	0.8	1.83	2.67	3.00	3.7	
			Placebo	6	5 (83.3)	2.37 (0.62)	1.7	2.00	2.17	2.83	3.2	
		Week 4	Tezepelumab	11	11 (100.0)	1.80 (1.01)	0.2	0.83	2.17	2.50	3.3	
			Placebo	6	5 (83.3)	2.67 (1.13)	1.5	1.83	2.33	3.50	4.2	
		Week 6	Tezepelumab	11	11 (100.0)	1.70 (0.70)	0.8	1.00	1.50	2.50	3.0	
			Placebo	6	5 (83.3)	2.53 (1.11)	1.2	1.67	2.67	3.33	3.8	
		Week 8	Tezepelumab	11	11 (100.0)	1.56 (0.69)	0.5	0.83	1.50	2.00	2.7	
			Placebo	6	5 (83.3)	2.23 (1.20)	0.7	1.67	2.00	3.17	3.7	
		Week 10	Tezepelumab	11	11 (100.0)	1.56 (0.83)	0.3	0.67	1.50	2.33	3.0	
			Placebo	6	5 (83.3)	2.00 (0.68)	1.3	1.50	1.83	2.33	3.0	
		Week 12	Tezepelumab	11	11 (100.0)	1.47 (0.85)	0.0	0.67	1.50	2.33	2.7	
			Placebo	6	5 (83.3)	2.60 (1.12)	1.3	1.83	2.50	3.17	4.2	
		Week 14	Tezepelumab	11	11 (100.0)	1.39 (0.75)	0.3	0.67	1.33	2.17	2.5	
			Placebo	6	5 (83.3)	1.83 (0.83)	1.0	1.33	1.67	2.00	3.2	
		Week 16	Tezepelumab	11	11 (100.0)	1.58 (0.78)	0.5	0.83	1.67	2.50	2.5	
			Placebo	6	5 (83.3)	2.37 (1.10)	1.2	1.83	1.83	3.17	3.8	
		Week 18	Tezepelumab	11	11 (100.0)	1.30 (0.78)	0.3	0.50	1.00	2.17	2.5	
			Placebo	6	5 (83.3)	1.83 (0.72)	1.2	1.33	1.50	2.33	2.8	
		Week 20	Tezepelumab	11	11 (100.0)	1.39 (0.71)	0.3	0.83	1.17	1.83	2.5	
			Placebo	6	5 (83.3)	1.97 (1.28)	0.2	1.50	1.83	2.83	3.5	
		Week 22	Tezepelumab	11	11 (100.0)	1.48 (0.73)	0.0	1.17	1.67	1.83	2.5	
			Placebo	6	5 (83.3)	2.23 (1.06)	0.8	1.50	2.67	2.67	3.5	
		Week 24	Tezepelumab	11	11 (100.0)	1.50 (0.71)	0.3	1.00	1.67	1.83	2.7	
			Placebo	6	5 (83.3)	2.37 (0.81)	1.2	2.00	2.50	3.00	3.2	
		Week 26	Tezepelumab	11	11 (100.0)	1.52 (0.66)	0.7	1.00	1.33	2.17	2.7	
			Placebo	6	5 (83.3)	2.23 (1.15)	1.0	1.33	2.00	3.17	3.7	
		Week 28	Tezepelumab	11	11 (100.0)	1.50 (0.64)	0.3	1.00	1.67	2.00	2.5	
			Placebo	6	5 (83.3)	2.30 (1.05)	0.8	2.00	2.17	2.83	3.7	
		Week 30	Tezepelumab	11	11 (100.0)	1.48 (0.64)	0.7	0.83	1.67	2.00	2.5	
			Placebo	6	5 (83.3)	2.50 (0.94)	1.3	2.00	2.50	2.83	3.8	
		Week 32	Tezepelumab	11	11 (100.0)	1.53 (0.73)	0.5	1.00	1.33	2.33	2.5	
			Placebo	6	5 (83.3)	1.97 (1.24)	0.7	1.17	1.50	2.83	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	11	11 (100.0)	1.52 (0.60)	0.7	1.00	1.50	2.00	2.5	
			Placebo	6	5 (83.3)	2.23 (0.75)	1.7	1.83	1.83	2.33	3.5	
		Week 36	Tezepelumab	11	11 (100.0)	1.44 (0.58)	0.5	1.00	1.50	2.00	2.5	
			Placebo	6	5 (83.3)	2.43 (1.11)	1.3	1.83	2.00	2.83	4.2	
		Week 38	Tezepelumab	11	11 (100.0)	1.48 (0.67)	0.5	1.00	1.67	2.00	2.5	
			Placebo	6	5 (83.3)	2.00 (0.89)	1.0	1.50	1.67	2.67	3.2	
		Week 40	Tezepelumab	11	11 (100.0)	1.53 (0.72)	0.3	0.83	1.83	2.00	2.5	
			Placebo	6	5 (83.3)	2.47 (1.32)	0.7	1.83	2.50	3.17	4.2	
		Week 42	Tezepelumab	11	11 (100.0)	1.39 (0.56)	0.8	1.00	1.00	1.83	2.5	
			Placebo	6	5 (83.3)	2.27 (1.37)	0.8	1.67	2.00	2.33	4.5	
		Week 44	Tezepelumab	11	11 (100.0)	1.44 (0.72)	0.3	0.83	1.33	2.00	2.5	
			Placebo	6	5 (83.3)	2.50 (1.18)	0.8	2.33	2.50	2.67	4.2	
		Week 46	Tezepelumab	11	11 (100.0)	1.41 (0.62)	0.5	0.83	1.33	1.83	2.5	
			Placebo	6	5 (83.3)	2.10 (0.72)	1.2	1.83	2.17	2.17	3.2	
		Week 48	Tezepelumab	11	11 (100.0)	1.41 (0.59)	0.7	1.00	1.17	1.83	2.5	
			Placebo	6	5 (83.3)	2.17 (1.15)	0.7	1.83	2.00	2.50	3.8	
		Week 50	Tezepelumab	11	11 (100.0)	1.62 (0.63)	0.8	1.00	1.67	2.17	2.5	
			Placebo	6	5 (83.3)	2.20 (0.74)	1.3	1.83	2.17	2.33	3.3	
		Week 52	Tezepelumab	11	11 (100.0)	1.61 (0.62)	0.8	1.00	1.67	2.00	2.5	
			Placebo	6	5 (83.3)	2.43 (1.03)	1.0	2.17	2.33	2.83	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	-0.35 (0.56)	-1.3	-0.67	-0.33	0.17	0.2	0.16 [-0.90, 1.22]
			Placebo	6	5 (83.3)	-0.43 (0.43)	-0.8	-0.83	-0.50	-0.17	0.2	
		Week 4	Tezepelumab	11	11 (100.0)	-1.02 (1.08)	-2.3	-1.83	-0.83	-0.83	1.7	-0.84 [-1.95, 0.26]
			Placebo	6	5 (83.3)	-0.13 (0.95)	-1.0	-1.00	-0.33	0.50	1.2	
		Week 6	Tezepelumab	11	11 (100.0)	-1.12 (0.80)	-2.5	-1.50	-1.33	-0.67	0.2	-1.05 [-2.18, 0.08]
			Placebo	6	5 (83.3)	-0.27 (0.85)	-1.3	-0.67	-0.50	0.33	0.8	
		Week 8	Tezepelumab	11	11 (100.0)	-1.26 (0.96)	-3.0	-1.50	-1.33	-0.83	0.3	-0.65 [-1.73, 0.44]
			Placebo	6	5 (83.3)	-0.57 (1.29)	-2.7	-0.83	-0.17	0.17	0.7	
		Week 10	Tezepelumab	11	11 (100.0)	-1.26 (1.07)	-3.2	-1.67	-1.33	-0.83	0.7	-0.45 [-1.52, 0.62]
			Placebo	6	5 (83.3)	-0.80 (0.85)	-1.8	-1.17	-1.17	0.00	0.2	
		Week 12	Tezepelumab	11	11 (100.0)	-1.35 (1.07)	-3.0	-2.17	-1.17	-0.83	0.7	-1.03 [-2.16, 0.09]
			Placebo	6	5 (83.3)	-0.20 (1.20)	-2.0	-0.67	0.17	0.33	1.2	
		Week 14	Tezepelumab	11	11 (100.0)	-1.42 (1.25)	-3.7	-2.17	-1.33	-0.67	0.8	-0.40 [-1.46, 0.67]
			Placebo	6	5 (83.3)	-0.97 (0.89)	-1.7	-1.67	-1.50	-0.17	0.2	
		Week 16	Tezepelumab	11	11 (100.0)	-1.24 (1.08)	-3.0	-2.17	-1.00	-0.83	0.8	-0.78 [-1.88, 0.32]
			Placebo	6	5 (83.3)	-0.43 (0.93)	-1.5	-1.00	-0.67	0.17	0.8	
		Week 18	Tezepelumab	11	11 (100.0)	-1.52 (1.16)	-3.5	-2.50	-1.17	-0.83	0.5	-0.53 [-1.60, 0.55]
			Placebo	6	5 (83.3)	-0.97 (0.64)	-1.8	-1.33	-0.83	-0.67	-0.2	
		Week 20	Tezepelumab	11	11 (100.0)	-1.42 (1.00)	-3.2	-2.00	-1.50	-0.83	0.7	-0.53 [-1.60, 0.55]
			Placebo	6	5 (83.3)	-0.83 (1.39)	-3.2	-0.67	-0.67	-0.17	0.5	
		Week 22	Tezepelumab	11	11 (100.0)	-1.33 (1.00)	-3.0	-2.17	-1.33	-0.67	0.2	-0.71 [-1.80, 0.38]
			Placebo	6	5 (83.3)	-0.57 (1.25)	-2.5	-1.00	-0.33	0.50	0.5	
		Week 24	Tezepelumab	11	11 (100.0)	-1.32 (0.81)	-3.2	-1.67	-1.17	-0.83	0.0	-1.03 [-2.15, 0.10]
			Placebo	6	5 (83.3)	-0.43 (0.98)	-2.2	-0.17	0.00	0.00	0.2	
		Week 26	Tezepelumab	11	11 (100.0)	-1.30 (0.87)	-2.8	-2.00	-1.33	-0.33	0.0	-0.76 [-1.85, 0.34]
			Placebo	6	5 (83.3)	-0.57 (1.19)	-2.3	-1.17	-0.17	0.17	0.7	
		Week 28	Tezepelumab	11	11 (100.0)	-1.32 (0.93)	-3.2	-2.00	-1.33	-0.83	0.0	-0.81 [-1.91, 0.29]
			Placebo	6	5 (83.3)	-0.50 (1.18)	-2.5	-0.33	-0.17	-0.17	0.7	
		Week 30	Tezepelumab	11	11 (100.0)	-1.33 (1.15)	-3.5	-2.17	-1.00	-0.83	0.5	-0.90 [-2.01, 0.21]
			Placebo	6	5 (83.3)	-0.30 (1.14)	-2.0	-0.50	-0.50	0.67	0.8	
		Week 32	Tezepelumab	11	11 (100.0)	-1.29 (0.92)	-3.0	-1.83	-1.50	-0.83	0.7	-0.47 [-1.54, 0.61]
			Placebo	6	5 (83.3)	-0.83 (1.11)	-2.2	-1.50	-1.00	-0.17	0.7	
		Week 34	Tezepelumab	11	11 (100.0)	-1.30 (1.02)	-2.8	-2.00	-1.50	-0.67	0.3	-0.77 [-1.86, 0.33]
			Placebo	6	5 (83.3)	-0.57 (0.78)	-1.7	-0.67	-0.67	-0.33	0.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	11	11 (100.0)	-1.38 (0.98)	-3.0	-1.83	-1.33	-0.83	0.3	-1.04 [-2.17, 0.08]
			Placebo	6	5 (83.3)	-0.37 (0.95)	-1.3	-0.83	-0.67	-0.17	1.2	
		Week 38	Tezepelumab	11	11 (100.0)	-1.33 (1.01)	-3.0	-2.00	-1.67	-0.83	0.3	-0.57 [-1.65, 0.51]
			Placebo	6	5 (83.3)	-0.80 (0.72)	-1.7	-1.17	-1.00	-0.33	0.2	
		Week 40	Tezepelumab	11	11 (100.0)	-1.29 (1.15)	-3.2	-2.17	-1.17	-0.83	0.7	-0.83 [-1.93, 0.27]
			Placebo	6	5 (83.3)	-0.33 (1.15)	-1.5	-1.50	0.00	0.17	1.2	
		Week 42	Tezepelumab	11	11 (100.0)	-1.42 (1.06)	-3.3	-2.00	-1.33	-0.83	0.2	-0.81 [-1.91, 0.29]
			Placebo	6	5 (83.3)	-0.53 (1.17)	-1.3	-1.33	-0.83	-0.67	1.5	
		Week 44	Tezepelumab	11	11 (100.0)	-1.38 (1.13)	-3.5	-1.83	-1.33	-0.83	0.3	-1.00 [-2.12, 0.12]
			Placebo	6	5 (83.3)	-0.30 (0.95)	-1.3	-0.67	-0.67	0.00	1.2	
		Week 46	Tezepelumab	11	11 (100.0)	-1.41 (0.92)	-3.3	-2.00	-1.33	-0.83	0.2	-0.86 [-1.97, 0.24]
			Placebo	6	5 (83.3)	-0.70 (0.52)	-1.2	-1.00	-0.83	-0.67	0.2	
		Week 48	Tezepelumab	11	11 (100.0)	-1.41 (0.86)	-2.7	-2.00	-1.50	-0.67	0.2	-0.87 [-1.97, 0.24]
			Placebo	6	5 (83.3)	-0.63 (0.96)	-1.5	-1.50	-0.50	-0.50	0.8	
		Week 50	Tezepelumab	11	11 (100.0)	-1.20 (0.89)	-2.5	-1.83	-1.33	-0.83	0.5	-0.73 [-1.83, 0.36]
			Placebo	6	5 (83.3)	-0.60 (0.56)	-1.2	-0.83	-0.67	-0.67	0.3	
		Week 52	Tezepelumab	11	11 (100.0)	-1.21 (0.86)	-2.5	-1.83	-1.33	-0.83	0.3	-0.99 [-2.11, 0.13]
			Placebo	6	5 (83.3)	-0.37 (0.84)	-1.2	-1.17	-0.17	-0.17	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	126	126 (100.0)	2.69 (0.80)	0.0	2.33	2.67	3.00	4.8	
			Placebo	132	132 (100.0)	2.65 (0.70)	0.3	2.25	2.67	3.00	4.7	
		Week 2	Tezepelumab	126	120 (95.2)	2.14 (0.92)	0.0	1.58	2.17	2.67	4.3	
			Placebo	132	120 (90.9)	2.30 (0.80)	0.2	1.92	2.33	2.83	4.8	
		Week 4	Tezepelumab	126	120 (95.2)	1.89 (0.96)	0.0	1.17	2.00	2.67	4.3	
			Placebo	132	120 (90.9)	2.16 (0.83)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	126	120 (95.2)	1.81 (0.99)	0.0	1.17	1.83	2.50	4.3	
			Placebo	132	121 (91.7)	2.06 (0.96)	0.2	1.50	2.17	2.67	5.5	
		Week 8	Tezepelumab	126	120 (95.2)	1.75 (1.05)	0.0	1.00	1.67	2.67	4.8	
			Placebo	132	122 (92.4)	2.05 (0.95)	0.0	1.33	2.08	2.67	4.7	
		Week 10	Tezepelumab	126	120 (95.2)	1.67 (1.03)	0.0	0.92	1.67	2.33	4.3	
			Placebo	132	123 (93.2)	1.98 (0.93)	0.0	1.33	2.00	2.67	5.3	
		Week 12	Tezepelumab	126	120 (95.2)	1.60 (1.05)	0.0	0.83	1.58	2.50	4.3	
			Placebo	132	123 (93.2)	1.87 (0.92)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	126	120 (95.2)	1.47 (1.02)	0.0	0.75	1.33	2.17	4.3	
			Placebo	132	123 (93.2)	1.84 (0.92)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	126	120 (95.2)	1.61 (1.07)	0.0	0.83	1.50	2.50	4.3	
			Placebo	132	123 (93.2)	1.96 (1.03)	0.0	1.17	2.00	2.67	5.0	
		Week 18	Tezepelumab	126	121 (96.0)	1.52 (0.98)	0.0	0.83	1.50	2.17	4.3	
			Placebo	132	123 (93.2)	1.87 (1.00)	0.0	1.17	1.83	2.50	5.0	
		Week 20	Tezepelumab	126	121 (96.0)	1.60 (1.05)	0.0	0.83	1.50	2.33	5.0	
			Placebo	132	123 (93.2)	1.92 (0.99)	0.0	1.17	2.17	2.67	5.0	
		Week 22	Tezepelumab	126	121 (96.0)	1.61 (0.99)	0.0	0.83	1.67	2.33	4.3	
			Placebo	132	123 (93.2)	1.86 (1.00)	0.0	1.17	2.00	2.50	5.0	
		Week 24	Tezepelumab	126	121 (96.0)	1.60 (1.06)	0.0	0.83	1.67	2.33	4.3	
			Placebo	132	123 (93.2)	1.85 (0.98)	0.0	1.00	2.00	2.50	4.5	
		Week 26	Tezepelumab	126	122 (96.8)	1.56 (1.03)	0.0	0.83	1.50	2.17	4.3	
			Placebo	132	123 (93.2)	1.80 (0.97)	0.0	1.00	1.67	2.50	4.5	
		Week 28	Tezepelumab	126	123 (97.6)	1.61 (1.06)	0.0	0.83	1.50	2.50	4.3	
			Placebo	132	124 (93.9)	1.86 (1.04)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	126	124 (98.4)	1.56 (1.03)	0.0	0.83	1.50	2.33	4.3	
			Placebo	132	125 (94.7)	1.84 (1.01)	0.0	1.00	1.83	2.50	4.5	
		Week 32	Tezepelumab	126	124 (98.4)	1.51 (1.04)	0.0	0.75	1.50	2.33	4.3	
			Placebo	132	125 (94.7)	1.81 (1.02)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	126	124 (98.4)	1.52 (1.09)	0.0	0.67	1.33	2.42	4.3	
			Placebo	132	125 (94.7)	1.76 (1.04)	0.0	1.00	1.67	2.50	4.5	
		Week 36	Tezepelumab	126	124 (98.4)	1.61 (1.07)	0.0	0.83	1.67	2.33	4.5	
			Placebo	132	125 (94.7)	1.84 (1.03)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	126	124 (98.4)	1.50 (1.06)	0.0	0.83	1.50	2.17	4.5	
			Placebo	132	125 (94.7)	1.77 (1.02)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	126	124 (98.4)	1.53 (1.07)	0.0	0.67	1.58	2.25	4.3	
			Placebo	132	125 (94.7)	1.83 (1.02)	0.0	1.00	1.83	2.50	4.5	
		Week 42	Tezepelumab	126	124 (98.4)	1.51 (1.08)	0.0	0.67	1.50	2.17	4.7	
			Placebo	132	125 (94.7)	1.81 (0.99)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	126	124 (98.4)	1.53 (1.05)	0.0	0.67	1.50	2.33	4.3	
			Placebo	132	126 (95.5)	1.84 (1.00)	0.0	1.00	2.00	2.50	4.5	
		Week 46	Tezepelumab	126	124 (98.4)	1.49 (1.06)	0.0	0.67	1.25	2.25	4.3	
			Placebo	132	126 (95.5)	1.75 (0.98)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	126	124 (98.4)	1.56 (1.08)	0.0	0.67	1.50	2.33	4.3	
			Placebo	132	126 (95.5)	1.78 (1.01)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	126	124 (98.4)	1.45 (1.06)	0.0	0.67	1.33	2.17	4.3	
			Placebo	132	126 (95.5)	1.75 (0.97)	0.0	1.00	1.75	2.50	4.5	
		Week 52	Tezepelumab	126	124 (98.4)	1.48 (1.06)	0.0	0.67	1.42	2.17	4.3	
			Placebo	132	126 (95.5)	1.80 (0.99)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	126	120 (95.2)	-0.55 (0.68)	-2.8	-0.83	-0.50	-0.08	0.7	-0.27 [-0.53, -0.02]
			Placebo	132	120 (90.9)	-0.36 (0.72)	-2.8	-0.83	-0.33	0.08	1.2	
		Week 4	Tezepelumab	126	120 (95.2)	-0.80 (0.86)	-3.5	-1.33	-0.67	-0.17	2.3	-0.35 [-0.61, -0.10]
			Placebo	132	120 (90.9)	-0.50 (0.83)	-3.0	-1.00	-0.33	0.08	1.2	
		Week 6	Tezepelumab	126	120 (95.2)	-0.89 (0.97)	-3.8	-1.50	-0.83	-0.33	2.3	-0.32 [-0.57, -0.06]
			Placebo	132	121 (91.7)	-0.59 (0.90)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	126	120 (95.2)	-0.95 (1.00)	-3.8	-1.67	-1.00	-0.33	2.3	-0.35 [-0.61, -0.10]
			Placebo	132	122 (92.4)	-0.61 (0.89)	-3.2	-1.00	-0.67	0.00	1.0	
		Week 10	Tezepelumab	126	120 (95.2)	-1.03 (0.97)	-3.8	-1.67	-1.00	-0.33	2.3	-0.35 [-0.61, -0.10]
			Placebo	132	123 (93.2)	-0.69 (0.96)	-3.3	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	126	120 (95.2)	-1.09 (0.97)	-3.7	-1.83	-1.00	-0.50	2.3	-0.31 [-0.56, -0.06]
			Placebo	132	123 (93.2)	-0.80 (0.95)	-3.3	-1.33	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	126	120 (95.2)	-1.23 (0.97)	-3.8	-1.92	-1.17	-0.67	2.3	-0.42 [-0.68, -0.17]
			Placebo	132	123 (93.2)	-0.82 (0.95)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 16	Tezepelumab	126	120 (95.2)	-1.08 (1.03)	-4.2	-1.83	-1.00	-0.42	2.3	-0.36 [-0.61, -0.11]
			Placebo	132	123 (93.2)	-0.71 (1.03)	-3.5	-1.33	-0.67	0.00	2.3	
		Week 18	Tezepelumab	126	121 (96.0)	-1.17 (0.98)	-4.2	-1.83	-1.00	-0.67	2.3	-0.37 [-0.62, -0.12]
			Placebo	132	123 (93.2)	-0.80 (1.03)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	126	121 (96.0)	-1.09 (1.01)	-4.2	-1.83	-1.00	-0.33	2.3	-0.33 [-0.59, -0.08]
			Placebo	132	123 (93.2)	-0.75 (1.03)	-3.5	-1.33	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	126	121 (96.0)	-1.08 (1.03)	-4.3	-1.67	-1.00	-0.50	2.3	-0.27 [-0.52, -0.02]
			Placebo	132	123 (93.2)	-0.81 (1.00)	-3.3	-1.50	-0.83	-0.17	2.3	
		Week 24	Tezepelumab	126	121 (96.0)	-1.09 (1.00)	-4.5	-1.83	-1.00	-0.33	2.3	-0.27 [-0.52, -0.02]
			Placebo	132	123 (93.2)	-0.81 (1.04)	-3.5	-1.50	-0.83	-0.17	2.3	
		Week 26	Tezepelumab	126	122 (96.8)	-1.12 (1.05)	-4.2	-1.83	-1.00	-0.33	2.3	-0.25 [-0.50, 0.00]
			Placebo	132	123 (93.2)	-0.86 (1.04)	-4.0	-1.50	-1.00	-0.17	2.3	
		Week 28	Tezepelumab	126	123 (97.6)	-1.06 (1.05)	-4.2	-1.83	-1.00	-0.33	2.3	-0.26 [-0.51, -0.01]
			Placebo	132	124 (93.9)	-0.79 (1.07)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 30	Tezepelumab	126	124 (98.4)	-1.12 (1.04)	-4.2	-1.92	-1.00	-0.50	2.3	-0.30 [-0.55, -0.05]
			Placebo	132	125 (94.7)	-0.81 (1.05)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	126	124 (98.4)	-1.17 (1.06)	-4.2	-2.00	-1.00	-0.58	2.3	-0.32 [-0.57, -0.07]
			Placebo	132	125 (94.7)	-0.84 (1.04)	-3.5	-1.50	-0.67	-0.17	2.3	
		Week 34	Tezepelumab	126	124 (98.4)	-1.16 (1.07)	-4.2	-2.00	-1.08	-0.50	2.3	-0.26 [-0.51, -0.01]
			Placebo	132	125 (94.7)	-0.89 (1.06)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	126	124 (98.4)	-1.07 (1.10)	-4.2	-1.83	-1.00	-0.33	2.3	-0.24 [-0.48, 0.01]
			Placebo	132	125 (94.7)	-0.81 (1.08)	-3.5	-1.33	-0.83	0.00	2.3	
		Week 38	Tezepelumab	126	124 (98.4)	-1.18 (1.09)	-4.2	-2.00	-1.17	-0.42	2.3	-0.28 [-0.53, -0.03]
			Placebo	132	125 (94.7)	-0.88 (1.08)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	126	124 (98.4)	-1.16 (1.09)	-4.2	-2.00	-1.00	-0.42	2.3	-0.32 [-0.57, -0.07]
			Placebo	132	125 (94.7)	-0.82 (1.06)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 42	Tezepelumab	126	124 (98.4)	-1.17 (1.09)	-4.2	-1.92	-1.17	-0.50	2.3	-0.31 [-0.56, -0.06]
			Placebo	132	125 (94.7)	-0.84 (1.04)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 44	Tezepelumab	126	124 (98.4)	-1.15 (1.10)	-4.3	-1.92	-1.00	-0.50	2.3	-0.32 [-0.57, -0.07]
			Placebo	132	126 (95.5)	-0.81 (1.06)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 46	Tezepelumab	126	124 (98.4)	-1.19 (1.10)	-4.2	-2.00	-1.00	-0.42	2.3	-0.27 [-0.52, -0.02]
			Placebo	132	126 (95.5)	-0.90 (1.05)	-4.0	-1.50	-1.00	-0.17	2.3	
		Week 48	Tezepelumab	126	124 (98.4)	-1.12 (1.11)	-4.2	-1.92	-1.00	-0.33	2.3	-0.23 [-0.48, 0.02]
			Placebo	132	126 (95.5)	-0.87 (1.07)	-3.7	-1.50	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	126	124 (98.4)	-1.23 (1.10)	-4.2	-2.00	-1.17	-0.50	2.3	-0.32 [-0.56, -0.07]
			Placebo	132	126 (95.5)	-0.89 (1.03)	-4.0	-1.50	-1.00	-0.33	2.3	
		Week 52	Tezepelumab	126	124 (98.4)	-1.20 (1.11)	-4.2	-2.00	-1.17	-0.50	2.3	-0.33 [-0.58, -0.08]
			Placebo	132	126 (95.5)	-0.85 (1.05)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.74 (0.85)	1.7	2.17	2.83	3.00	4.3	
			Placebo	3	3 (100.0)	2.94 (0.42)	2.5	2.50	3.00	3.33	3.3	
		Week 2	Tezepelumab	9	9 (100.0)	2.37 (0.91)	0.8	1.83	2.33	3.00	3.7	
			Placebo	3	3 (100.0)	2.56 (0.79)	1.7	1.67	2.83	3.17	3.2	
		Week 4	Tezepelumab	9	9 (100.0)	1.69 (1.09)	0.2	0.83	2.00	2.50	3.3	
			Placebo	3	3 (100.0)	2.44 (1.00)	1.5	1.50	2.33	3.50	3.5	
		Week 6	Tezepelumab	9	9 (100.0)	1.63 (0.73)	0.8	1.00	1.50	1.83	3.0	
			Placebo	3	3 (100.0)	2.39 (1.11)	1.2	1.17	2.67	3.33	3.3	
		Week 8	Tezepelumab	9	9 (100.0)	1.46 (0.69)	0.5	0.83	1.33	2.00	2.7	
			Placebo	3	3 (100.0)	1.83 (1.26)	0.7	0.67	1.67	3.17	3.2	
		Week 10	Tezepelumab	9	9 (100.0)	1.48 (0.86)	0.3	0.67	1.50	1.83	3.0	
			Placebo	3	3 (100.0)	1.94 (0.92)	1.3	1.33	1.50	3.00	3.0	
		Week 12	Tezepelumab	9	9 (100.0)	1.31 (0.85)	0.0	0.67	1.33	1.50	2.7	
			Placebo	3	3 (100.0)	2.11 (0.95)	1.3	1.33	1.83	3.17	3.2	
		Week 14	Tezepelumab	9	9 (100.0)	1.26 (0.73)	0.3	0.67	1.17	1.67	2.5	
			Placebo	3	3 (100.0)	1.94 (1.11)	1.0	1.00	1.67	3.17	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	1.41 (0.76)	0.5	0.83	1.33	1.83	2.5	
			Placebo	3	3 (100.0)	2.28 (0.77)	1.8	1.83	1.83	3.17	3.2	
		Week 18	Tezepelumab	9	9 (100.0)	1.07 (0.66)	0.3	0.50	0.83	1.67	2.2	
			Placebo	3	3 (100.0)	1.83 (0.88)	1.2	1.17	1.50	2.83	2.8	
		Week 20	Tezepelumab	9	9 (100.0)	1.22 (0.65)	0.3	0.83	1.00	1.83	2.3	
			Placebo	3	3 (100.0)	1.61 (1.35)	0.2	0.17	1.83	2.83	2.8	
		Week 22	Tezepelumab	9	9 (100.0)	1.35 (0.71)	0.0	1.17	1.67	1.83	2.2	
			Placebo	3	3 (100.0)	1.67 (0.93)	0.8	0.83	1.50	2.67	2.7	
		Week 24	Tezepelumab	9	9 (100.0)	1.37 (0.70)	0.3	1.00	1.50	1.67	2.7	
			Placebo	3	3 (100.0)	2.22 (0.95)	1.2	1.17	2.50	3.00	3.0	
		Week 26	Tezepelumab	9	9 (100.0)	1.28 (0.45)	0.7	1.00	1.33	1.33	2.2	
			Placebo	3	3 (100.0)	1.83 (1.17)	1.0	1.00	1.33	3.17	3.2	
		Week 28	Tezepelumab	9	9 (100.0)	1.35 (0.59)	0.3	1.00	1.33	1.67	2.2	
			Placebo	3	3 (100.0)	1.94 (1.02)	0.8	0.83	2.17	2.83	2.8	
		Week 30	Tezepelumab	9	9 (100.0)	1.31 (0.57)	0.7	0.83	1.17	1.67	2.2	
			Placebo	3	3 (100.0)	1.94 (0.59)	1.3	1.33	2.00	2.50	2.5	
		Week 32	Tezepelumab	9	9 (100.0)	1.39 (0.72)	0.5	1.00	1.17	2.00	2.5	
			Placebo	3	3 (100.0)	1.83 (0.88)	1.2	1.17	1.50	2.83	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.41 (0.57)	0.7	1.00	1.33	2.00	2.0	
			Placebo	3	3 (100.0)	1.94 (0.35)	1.7	1.67	1.83	2.33	2.3	
		Week 36	Tezepelumab	9	9 (100.0)	1.31 (0.52)	0.5	1.00	1.17	1.67	2.0	
			Placebo	3	3 (100.0)	2.22 (0.54)	1.8	1.83	2.00	2.83	2.8	
		Week 38	Tezepelumab	9	9 (100.0)	1.43 (0.64)	0.5	1.00	1.67	2.00	2.2	
			Placebo	3	3 (100.0)	1.94 (0.63)	1.5	1.50	1.67	2.67	2.7	
		Week 40	Tezepelumab	9	9 (100.0)	1.48 (0.70)	0.3	0.83	1.83	2.00	2.3	
			Placebo	3	3 (100.0)	2.50 (0.67)	1.8	1.83	2.50	3.17	3.2	
		Week 42	Tezepelumab	9	9 (100.0)	1.31 (0.47)	0.8	1.00	1.00	1.67	2.0	
			Placebo	3	3 (100.0)	2.00 (0.33)	1.7	1.67	2.00	2.33	2.3	
		Week 44	Tezepelumab	9	9 (100.0)	1.30 (0.69)	0.3	0.83	1.17	1.83	2.5	
			Placebo	3	3 (100.0)	2.50 (0.17)	2.3	2.33	2.50	2.67	2.7	
		Week 46	Tezepelumab	9	9 (100.0)	1.35 (0.54)	0.5	1.00	1.33	1.83	2.2	
			Placebo	3	3 (100.0)	2.06 (0.19)	1.8	1.83	2.17	2.17	2.2	
		Week 48	Tezepelumab	9	9 (100.0)	1.31 (0.52)	0.7	1.00	1.00	1.67	2.2	
			Placebo	3	3 (100.0)	2.11 (0.35)	1.8	1.83	2.00	2.50	2.5	
		Week 50	Tezepelumab	9	9 (100.0)	1.56 (0.62)	0.8	1.00	1.67	2.00	2.5	
			Placebo	3	3 (100.0)	2.11 (0.25)	1.8	1.83	2.17	2.33	2.3	
		Week 52	Tezepelumab	9	9 (100.0)	1.54 (0.60)	0.8	1.00	1.67	2.00	2.5	
			Placebo	3	3 (100.0)	2.44 (0.35)	2.2	2.17	2.33	2.83	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.37 (0.62)	-1.3	-0.67	-0.33	0.17	0.2	0.03 [-1.28, 1.34]
			Placebo	3	3 (100.0)	-0.39 (0.51)	-0.8	-0.83	-0.50	0.17	0.2	
		Week 4	Tezepelumab	9	9 (100.0)	-1.06 (1.20)	-2.3	-1.83	-1.50	-0.83	1.7	-0.49 [-1.81, 0.84]
			Placebo	3	3 (100.0)	-0.50 (0.87)	-1.0	-1.00	-1.00	0.50	0.5	
		Week 6	Tezepelumab	9	9 (100.0)	-1.11 (0.87)	-2.5	-1.33	-1.33	-0.67	0.2	-0.64 [-1.98, 0.70]
			Placebo	3	3 (100.0)	-0.56 (0.84)	-1.3	-1.33	-0.67	0.33	0.3	
		Week 8	Tezepelumab	9	9 (100.0)	-1.28 (1.06)	-3.0	-1.50	-1.33	-0.83	0.3	-0.15 [-1.45, 1.16]
			Placebo	3	3 (100.0)	-1.11 (1.44)	-2.7	-2.67	-0.83	0.17	0.2	
		Week 10	Tezepelumab	9	9 (100.0)	-1.26 (1.18)	-3.2	-1.50	-1.33	-1.00	0.7	-0.23 [-1.54, 1.08]
			Placebo	3	3 (100.0)	-1.00 (0.93)	-1.8	-1.83	-1.17	0.00	0.0	
		Week 12	Tezepelumab	9	9 (100.0)	-1.43 (1.18)	-3.0	-2.17	-1.33	-1.17	0.7	-0.51 [-1.83, 0.82]
			Placebo	3	3 (100.0)	-0.83 (1.09)	-2.0	-2.00	-0.67	0.17	0.2	
		Week 14	Tezepelumab	9	9 (100.0)	-1.48 (1.38)	-3.7	-2.17	-1.33	-0.67	0.8	-0.37 [-1.68, 0.95]
			Placebo	3	3 (100.0)	-1.00 (1.01)	-1.7	-1.67	-1.50	0.17	0.2	
		Week 16	Tezepelumab	9	9 (100.0)	-1.33 (1.18)	-3.0	-2.17	-1.33	-1.00	0.8	-0.59 [-1.93, 0.74]
			Placebo	3	3 (100.0)	-0.67 (0.83)	-1.5	-1.50	-0.67	0.17	0.2	
		Week 18	Tezepelumab	9	9 (100.0)	-1.67 (1.24)	-3.5	-2.50	-1.67	-1.00	0.5	-0.47 [-1.79, 0.85]
			Placebo	3	3 (100.0)	-1.11 (0.86)	-1.8	-1.83	-1.33	-0.17	-0.2	
		Week 20	Tezepelumab	9	9 (100.0)	-1.52 (1.09)	-3.2	-2.00	-1.67	-1.00	0.7	-0.15 [-1.46, 1.16]
			Placebo	3	3 (100.0)	-1.33 (1.61)	-3.2	-3.17	-0.67	-0.17	-0.2	
		Week 22	Tezepelumab	9	9 (100.0)	-1.39 (1.10)	-3.0	-2.17	-1.50	-0.67	0.2	-0.10 [-1.41, 1.21]
			Placebo	3	3 (100.0)	-1.28 (1.11)	-2.5	-2.50	-1.00	-0.33	-0.3	
		Week 24	Tezepelumab	9	9 (100.0)	-1.37 (0.89)	-3.2	-1.67	-1.17	-1.00	0.0	-0.67 [-2.01, 0.67]
			Placebo	3	3 (100.0)	-0.72 (1.25)	-2.2	-2.17	0.00	0.00	0.0	
		Week 26	Tezepelumab	9	9 (100.0)	-1.46 (0.88)	-2.8	-2.00	-1.50	-1.33	0.0	-0.37 [-1.68, 0.95]
			Placebo	3	3 (100.0)	-1.11 (1.25)	-2.3	-2.33	-1.17	0.17	0.2	
		Week 28	Tezepelumab	9	9 (100.0)	-1.39 (1.02)	-3.2	-2.00	-1.33	-0.83	0.0	-0.36 [-1.67, 0.96]
			Placebo	3	3 (100.0)	-1.00 (1.30)	-2.5	-2.50	-0.33	-0.17	-0.2	
		Week 30	Tezepelumab	9	9 (100.0)	-1.43 (1.26)	-3.5	-2.17	-1.50	-0.83	0.5	-0.36 [-1.67, 0.96]
			Placebo	3	3 (100.0)	-1.00 (0.87)	-2.0	-2.00	-0.50	-0.50	-0.5	
		Week 32	Tezepelumab	9	9 (100.0)	-1.35 (1.01)	-3.0	-1.83	-1.50	-0.83	0.7	-0.24 [-1.55, 1.07]
			Placebo	3	3 (100.0)	-1.11 (1.00)	-2.2	-2.17	-1.00	-0.17	-0.2	
		Week 34	Tezepelumab	9	9 (100.0)	-1.33 (1.13)	-2.8	-2.00	-1.50	-0.67	0.3	-0.32 [-1.63, 0.99]
			Placebo	3	3 (100.0)	-1.00 (0.58)	-1.7	-1.67	-0.67	-0.67	-0.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.43 (1.08)	-3.0	-1.83	-1.33	-0.83	0.3	-0.70 [-2.05, 0.64]
			Placebo	3	3 (100.0)	-0.72 (0.59)	-1.3	-1.33	-0.67	-0.17	-0.2	
		Week 38	Tezepelumab	9	9 (100.0)	-1.31 (1.08)	-3.0	-1.67	-1.67	-1.17	0.3	-0.31 [-1.62, 1.00]
			Placebo	3	3 (100.0)	-1.00 (0.67)	-1.7	-1.67	-1.00	-0.33	-0.3	
		Week 40	Tezepelumab	9	9 (100.0)	-1.26 (1.25)	-3.2	-2.17	-1.17	-0.83	0.7	-0.68 [-2.02, 0.66]
			Placebo	3	3 (100.0)	-0.44 (0.92)	-1.5	-1.50	0.00	0.17	0.2	
		Week 42	Tezepelumab	9	9 (100.0)	-1.43 (1.15)	-3.3	-2.00	-1.33	-0.83	0.2	-0.46 [-1.79, 0.86]
			Placebo	3	3 (100.0)	-0.94 (0.35)	-1.3	-1.33	-0.83	-0.67	-0.7	
		Week 44	Tezepelumab	9	9 (100.0)	-1.44 (1.24)	-3.5	-1.83	-1.33	-0.83	0.3	-0.89 [-2.25, 0.47]
			Placebo	3	3 (100.0)	-0.44 (0.38)	-0.7	-0.67	-0.67	0.00	0.0	
		Week 46	Tezepelumab	9	9 (100.0)	-1.39 (0.97)	-3.3	-1.83	-1.33	-1.00	0.2	-0.57 [-1.90, 0.76]
			Placebo	3	3 (100.0)	-0.89 (0.25)	-1.2	-1.17	-0.83	-0.67	-0.7	
		Week 48	Tezepelumab	9	9 (100.0)	-1.43 (0.93)	-2.7	-2.00	-1.50	-0.67	0.2	-0.68 [-2.02, 0.66]
			Placebo	3	3 (100.0)	-0.83 (0.58)	-1.5	-1.50	-0.50	-0.50	-0.5	
		Week 50	Tezepelumab	9	9 (100.0)	-1.19 (0.98)	-2.5	-1.83	-1.33	-0.83	0.5	-0.40 [-1.72, 0.92]
			Placebo	3	3 (100.0)	-0.83 (0.29)	-1.2	-1.17	-0.67	-0.67	-0.7	
		Week 52	Tezepelumab	9	9 (100.0)	-1.20 (0.94)	-2.5	-1.83	-1.33	-0.83	0.3	-0.80 [-2.15, 0.55]
			Placebo	3	3 (100.0)	-0.50 (0.58)	-1.2	-1.17	-0.17	-0.17	-0.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	2.70 (0.80)	0.0	2.33	2.67	3.08	4.8	
			Placebo	135	135 (100.0)	2.65 (0.69)	0.3	2.17	2.67	3.00	4.7	
		Week 2	Tezepelumab	128	122 (95.3)	2.15 (0.91)	0.0	1.67	2.17	2.67	4.3	
			Placebo	135	122 (90.4)	2.29 (0.80)	0.2	2.00	2.33	2.83	4.8	
		Week 4	Tezepelumab	128	122 (95.3)	1.90 (0.95)	0.0	1.17	2.00	2.67	4.3	
			Placebo	135	122 (90.4)	2.17 (0.84)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	128	122 (95.3)	1.81 (0.98)	0.0	1.17	1.83	2.50	4.3	
			Placebo	135	123 (91.1)	2.08 (0.96)	0.2	1.50	2.17	2.67	5.5	
		Week 8	Tezepelumab	128	122 (95.3)	1.75 (1.04)	0.0	1.00	1.67	2.67	4.8	
			Placebo	135	124 (91.9)	2.06 (0.95)	0.0	1.42	2.08	2.67	4.7	
		Week 10	Tezepelumab	128	122 (95.3)	1.67 (1.02)	0.0	1.00	1.67	2.33	4.3	
			Placebo	135	125 (92.6)	1.98 (0.92)	0.0	1.33	2.00	2.50	5.3	
		Week 12	Tezepelumab	128	122 (95.3)	1.61 (1.04)	0.0	0.83	1.67	2.50	4.3	
			Placebo	135	125 (92.6)	1.89 (0.94)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	128	122 (95.3)	1.47 (1.02)	0.0	0.83	1.42	2.17	4.3	
			Placebo	135	125 (92.6)	1.84 (0.91)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	128	122 (95.3)	1.62 (1.07)	0.0	0.83	1.50	2.50	4.3	
			Placebo	135	125 (92.6)	1.96 (1.03)	0.0	1.17	2.00	2.67	5.0	
		Week 18	Tezepelumab	128	123 (96.1)	1.53 (0.98)	0.0	0.83	1.50	2.17	4.3	
			Placebo	135	125 (92.6)	1.87 (0.99)	0.0	1.17	1.83	2.50	5.0	
		Week 20	Tezepelumab	128	123 (96.1)	1.61 (1.04)	0.0	0.83	1.67	2.33	5.0	
			Placebo	135	125 (92.6)	1.93 (1.00)	0.0	1.17	2.17	2.67	5.0	
		Week 22	Tezepelumab	128	123 (96.1)	1.61 (0.98)	0.0	0.83	1.67	2.33	4.3	
			Placebo	135	125 (92.6)	1.88 (1.00)	0.0	1.17	2.00	2.67	5.0	
		Week 24	Tezepelumab	128	123 (96.1)	1.61 (1.05)	0.0	0.83	1.67	2.33	4.3	
			Placebo	135	125 (92.6)	1.86 (0.98)	0.0	1.00	2.00	2.50	4.5	
		Week 26	Tezepelumab	128	124 (96.9)	1.58 (1.03)	0.0	0.83	1.50	2.25	4.3	
			Placebo	135	125 (92.6)	1.82 (0.98)	0.0	1.00	1.67	2.50	4.5	
		Week 28	Tezepelumab	128	125 (97.7)	1.62 (1.06)	0.0	0.83	1.50	2.50	4.3	
			Placebo	135	126 (93.3)	1.87 (1.04)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	128	126 (98.4)	1.57 (1.02)	0.0	0.83	1.50	2.33	4.3	
			Placebo	135	127 (94.1)	1.86 (1.02)	0.0	1.00	1.83	2.67	4.5	
		Week 32	Tezepelumab	128	126 (98.4)	1.52 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	135	127 (94.1)	1.82 (1.03)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	128	126 (98.4)	1.53 (1.08)	0.0	0.67	1.42	2.50	4.3	
			Placebo	135	127 (94.1)	1.78 (1.04)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	128	126 (98.4)	1.62 (1.06)	0.0	0.83	1.67	2.33	4.5	
			Placebo	135	127 (94.1)	1.85 (1.04)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	128	126 (98.4)	1.51 (1.06)	0.0	0.83	1.50	2.17	4.5	
			Placebo	135	127 (94.1)	1.78 (1.02)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	128	126 (98.4)	1.53 (1.06)	0.0	0.67	1.58	2.33	4.3	
			Placebo	135	127 (94.1)	1.84 (1.04)	0.0	1.00	1.83	2.67	4.5	
		Week 42	Tezepelumab	128	126 (98.4)	1.51 (1.07)	0.0	0.67	1.50	2.17	4.7	
			Placebo	135	127 (94.1)	1.82 (1.02)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	128	126 (98.4)	1.54 (1.04)	0.0	0.67	1.50	2.33	4.3	
			Placebo	135	128 (94.8)	1.85 (1.02)	0.0	1.00	2.00	2.58	4.5	
		Week 46	Tezepelumab	128	126 (98.4)	1.50 (1.06)	0.0	0.67	1.25	2.33	4.3	
			Placebo	135	128 (94.8)	1.75 (0.99)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	128	126 (98.4)	1.56 (1.07)	0.0	0.67	1.50	2.33	4.3	
			Placebo	135	128 (94.8)	1.78 (1.02)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	128	126 (98.4)	1.46 (1.06)	0.0	0.67	1.33	2.17	4.3	
			Placebo	135	128 (94.8)	1.76 (0.97)	0.0	1.00	1.75	2.50	4.5	
		Week 52	Tezepelumab	128	126 (98.4)	1.49 (1.05)	0.0	0.67	1.42	2.17	4.3	
			Placebo	135	128 (94.8)	1.81 (1.00)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	128	122 (95.3)	-0.55 (0.68)	-2.8	-0.83	-0.50	-0.17	0.7	-0.27 [-0.52, -0.01]
			Placebo	135	122 (90.4)	-0.36 (0.71)	-2.8	-0.83	-0.33	0.00	1.2	
		Week 4	Tezepelumab	128	122 (95.3)	-0.80 (0.86)	-3.5	-1.33	-0.75	-0.17	2.3	-0.37 [-0.62, -0.12]
			Placebo	135	122 (90.4)	-0.49 (0.83)	-3.0	-1.00	-0.33	0.17	1.2	
		Week 6	Tezepelumab	128	122 (95.3)	-0.89 (0.96)	-3.8	-1.50	-0.83	-0.33	2.3	-0.34 [-0.59, -0.09]
			Placebo	135	123 (91.1)	-0.58 (0.90)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	128	122 (95.3)	-0.95 (0.99)	-3.8	-1.67	-1.00	-0.33	2.3	-0.37 [-0.63, -0.12]
			Placebo	135	124 (91.9)	-0.60 (0.89)	-3.2	-1.00	-0.58	0.00	1.0	
		Week 10	Tezepelumab	128	122 (95.3)	-1.03 (0.97)	-3.8	-1.67	-1.00	-0.33	2.3	-0.36 [-0.61, -0.11]
			Placebo	135	125 (92.6)	-0.68 (0.96)	-3.3	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	128	122 (95.3)	-1.09 (0.96)	-3.7	-1.83	-1.00	-0.50	2.3	-0.33 [-0.59, -0.08]
			Placebo	135	125 (92.6)	-0.77 (0.96)	-3.3	-1.33	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	128	122 (95.3)	-1.23 (0.97)	-3.8	-1.83	-1.17	-0.67	2.3	-0.42 [-0.67, -0.17]
			Placebo	135	125 (92.6)	-0.82 (0.95)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 16	Tezepelumab	128	122 (95.3)	-1.08 (1.03)	-4.2	-1.83	-1.00	-0.50	2.3	-0.37 [-0.62, -0.12]
			Placebo	135	125 (92.6)	-0.70 (1.04)	-3.5	-1.33	-0.67	0.00	2.3	
		Week 18	Tezepelumab	128	123 (96.1)	-1.16 (0.97)	-4.2	-1.83	-1.00	-0.67	2.3	-0.37 [-0.62, -0.12]
			Placebo	135	125 (92.6)	-0.80 (1.02)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	128	123 (96.1)	-1.09 (1.00)	-4.2	-1.83	-1.00	-0.33	2.3	-0.34 [-0.60, -0.09]
			Placebo	135	125 (92.6)	-0.74 (1.03)	-3.5	-1.33	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	128	123 (96.1)	-1.08 (1.03)	-4.3	-1.67	-1.00	-0.50	2.3	-0.29 [-0.54, -0.04]
			Placebo	135	125 (92.6)	-0.79 (1.01)	-3.3	-1.50	-0.83	-0.17	2.3	
		Week 24	Tezepelumab	128	123 (96.1)	-1.09 (0.99)	-4.5	-1.83	-1.00	-0.33	2.3	-0.28 [-0.53, -0.03]
			Placebo	135	125 (92.6)	-0.80 (1.04)	-3.5	-1.50	-0.83	-0.17	2.3	
		Week 26	Tezepelumab	128	124 (96.9)	-1.11 (1.04)	-4.2	-1.83	-1.00	-0.33	2.3	-0.26 [-0.51, -0.01]
			Placebo	135	125 (92.6)	-0.84 (1.04)	-4.0	-1.50	-1.00	-0.17	2.3	
		Week 28	Tezepelumab	128	125 (97.7)	-1.06 (1.04)	-4.2	-1.83	-1.00	-0.33	2.3	-0.27 [-0.52, -0.02]
			Placebo	135	126 (93.3)	-0.77 (1.07)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 30	Tezepelumab	128	126 (98.4)	-1.12 (1.03)	-4.2	-1.83	-1.00	-0.50	2.3	-0.32 [-0.57, -0.07]
			Placebo	135	127 (94.1)	-0.78 (1.06)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	128	126 (98.4)	-1.17 (1.05)	-4.2	-2.00	-1.00	-0.67	2.3	-0.32 [-0.57, -0.08]
			Placebo	135	127 (94.1)	-0.83 (1.05)	-3.5	-1.50	-0.67	-0.17	2.3	
		Week 34	Tezepelumab	128	126 (98.4)	-1.16 (1.06)	-4.2	-2.00	-1.08	-0.50	2.3	-0.27 [-0.52, -0.03]
			Placebo	135	127 (94.1)	-0.87 (1.06)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	128	126 (98.4)	-1.07 (1.10)	-4.2	-1.83	-1.00	-0.33	2.3	-0.25 [-0.50, -0.00]
			Placebo	135	127 (94.1)	-0.80 (1.08)	-3.5	-1.33	-0.83	0.00	2.3	
		Week 38	Tezepelumab	128	126 (98.4)	-1.18 (1.09)	-4.2	-2.00	-1.17	-0.50	2.3	-0.29 [-0.54, -0.04]
			Placebo	135	127 (94.1)	-0.87 (1.07)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	128	126 (98.4)	-1.16 (1.08)	-4.2	-2.00	-1.00	-0.50	2.3	-0.33 [-0.58, -0.08]
			Placebo	135	127 (94.1)	-0.81 (1.07)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 42	Tezepelumab	128	126 (98.4)	-1.18 (1.09)	-4.2	-2.00	-1.17	-0.50	2.3	-0.33 [-0.58, -0.08]
			Placebo	135	127 (94.1)	-0.83 (1.05)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 44	Tezepelumab	128	126 (98.4)	-1.15 (1.09)	-4.3	-1.83	-1.00	-0.50	2.3	-0.33 [-0.58, -0.08]
			Placebo	135	128 (94.8)	-0.80 (1.07)	-4.0	-1.50	-0.83	-0.08	2.3	
		Week 46	Tezepelumab	128	126 (98.4)	-1.19 (1.10)	-4.2	-2.00	-1.00	-0.50	2.3	-0.28 [-0.53, -0.03]
			Placebo	135	128 (94.8)	-0.89 (1.04)	-4.0	-1.50	-1.00	-0.17	2.3	
		Week 48	Tezepelumab	128	126 (98.4)	-1.13 (1.10)	-4.2	-1.83	-1.00	-0.33	2.3	-0.24 [-0.49, 0.00]
			Placebo	135	128 (94.8)	-0.86 (1.07)	-3.7	-1.50	-0.83	-0.25	2.3	
		Week 50	Tezepelumab	128	126 (98.4)	-1.23 (1.10)	-4.2	-2.00	-1.17	-0.50	2.3	-0.33 [-0.57, -0.08]
			Placebo	135	128 (94.8)	-0.88 (1.03)	-4.0	-1.50	-1.00	-0.25	2.3	
		Week 52	Tezepelumab	128	126 (98.4)	-1.20 (1.11)	-4.2	-2.00	-1.17	-0.50	2.3	-0.34 [-0.58, -0.09]
			Placebo	135	128 (94.8)	-0.84 (1.05)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	29	29 (100.0)	2.95 (0.91)	0.3	2.50	2.83	3.50	4.8	
			Placebo	37	37 (100.0)	2.77 (0.54)	1.5	2.33	2.83	3.17	3.8	
		Week 2	Tezepelumab	29	28 (96.6)	2.39 (0.89)	0.7	1.75	2.42	3.00	4.2	
			Placebo	37	35 (94.6)	2.25 (0.67)	0.5	2.00	2.33	2.83	3.5	
		Week 4	Tezepelumab	29	28 (96.6)	2.07 (0.97)	0.3	1.25	2.42	2.67	3.5	
			Placebo	37	35 (94.6)	2.14 (0.91)	0.3	1.50	2.33	2.50	4.2	
		Week 6	Tezepelumab	29	28 (96.6)	1.87 (1.08)	0.0	0.92	1.83	2.67	4.0	
			Placebo	37	35 (94.6)	2.11 (1.06)	0.2	1.33	2.17	2.67	4.7	
		Week 8	Tezepelumab	29	28 (96.6)	1.82 (1.14)	0.0	0.92	1.67	2.67	4.2	
			Placebo	37	35 (94.6)	1.95 (1.03)	0.0	1.17	2.17	2.67	4.0	
		Week 10	Tezepelumab	29	28 (96.6)	1.63 (1.15)	0.0	0.58	1.58	2.67	3.7	
			Placebo	37	36 (97.3)	1.96 (0.93)	0.0	1.25	2.08	2.67	4.2	
		Week 12	Tezepelumab	29	28 (96.6)	1.58 (1.08)	0.0	0.58	1.58	2.50	3.3	
			Placebo	37	36 (97.3)	1.78 (1.06)	0.0	1.00	1.75	2.58	4.2	
		Week 14	Tezepelumab	29	28 (96.6)	1.50 (1.18)	0.0	0.42	1.42	2.33	4.2	
			Placebo	37	36 (97.3)	1.68 (0.78)	0.0	1.33	1.67	2.17	3.2	
		Week 16	Tezepelumab	29	28 (96.6)	1.67 (1.07)	0.0	0.92	1.50	2.50	4.2	
			Placebo	37	36 (97.3)	1.78 (1.04)	0.0	1.00	1.83	2.58	3.8	
		Week 18	Tezepelumab	29	28 (96.6)	1.54 (1.09)	0.0	0.83	1.25	2.42	4.2	
			Placebo	37	36 (97.3)	1.70 (1.01)	0.0	1.00	1.67	2.42	4.7	
		Week 20	Tezepelumab	29	28 (96.6)	1.62 (1.17)	0.0	0.75	1.25	2.50	5.0	
			Placebo	37	36 (97.3)	1.80 (0.96)	0.0	1.17	1.75	2.67	3.5	
		Week 22	Tezepelumab	29	28 (96.6)	1.51 (1.07)	0.0	0.75	1.25	2.33	3.8	
			Placebo	37	36 (97.3)	1.88 (0.84)	0.0	1.25	2.00	2.58	3.5	
		Week 24	Tezepelumab	29	28 (96.6)	1.62 (1.17)	0.0	0.67	1.33	2.42	4.2	
			Placebo	37	36 (97.3)	1.80 (0.91)	0.0	1.17	2.00	2.50	3.2	
		Week 26	Tezepelumab	29	28 (96.6)	1.60 (1.07)	0.0	0.83	1.42	2.42	4.0	
			Placebo	37	36 (97.3)	1.65 (0.98)	0.0	1.00	1.50	2.42	3.7	
		Week 28	Tezepelumab	29	28 (96.6)	1.68 (1.14)	0.0	0.92	1.58	2.58	3.8	
			Placebo	37	36 (97.3)	1.67 (1.09)	0.0	0.75	1.67	2.50	3.7	
		Week 30	Tezepelumab	29	28 (96.6)	1.58 (1.02)	0.2	0.75	1.42	2.42	3.7	
			Placebo	37	36 (97.3)	1.66 (0.98)	0.0	1.00	1.83	2.42	3.8	
		Week 32	Tezepelumab	29	28 (96.6)	1.47 (1.07)	0.0	0.67	1.17	2.42	4.0	
			Placebo	37	36 (97.3)	1.69 (0.96)	0.0	0.92	1.58	2.42	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	29	28 (96.6)	1.60 (1.11)	0.0	0.75	1.25	2.42	4.2	
			Placebo	37	36 (97.3)	1.67 (0.89)	0.0	1.00	1.75	2.33	3.5	
		Week 36	Tezepelumab	29	28 (96.6)	1.58 (1.07)	0.0	0.75	1.58	2.42	3.7	
			Placebo	37	36 (97.3)	1.95 (0.98)	0.0	1.33	1.92	2.75	4.2	
		Week 38	Tezepelumab	29	28 (96.6)	1.51 (1.13)	0.0	0.83	1.08	2.42	4.5	
			Placebo	37	36 (97.3)	1.78 (0.89)	0.0	1.17	1.83	2.50	3.2	
		Week 40	Tezepelumab	29	28 (96.6)	1.38 (1.11)	0.0	0.42	1.00	2.42	3.7	
			Placebo	37	36 (97.3)	1.93 (1.02)	0.0	1.17	2.00	2.50	4.2	
		Week 42	Tezepelumab	29	28 (96.6)	1.49 (1.10)	0.0	0.83	1.00	2.58	3.8	
			Placebo	37	36 (97.3)	1.83 (0.94)	0.0	1.25	2.00	2.42	4.5	
		Week 44	Tezepelumab	29	28 (96.6)	1.49 (1.06)	0.0	0.58	1.33	2.33	3.8	
			Placebo	37	37 (100.0)	1.83 (1.07)	0.0	1.00	1.83	2.50	4.2	
		Week 46	Tezepelumab	29	28 (96.6)	1.58 (1.15)	0.0	0.83	1.25	2.67	3.8	
			Placebo	37	37 (100.0)	1.76 (0.92)	0.0	1.17	2.00	2.33	3.3	
		Week 48	Tezepelumab	29	28 (96.6)	1.58 (1.16)	0.0	0.67	1.17	2.67	4.0	
			Placebo	37	37 (100.0)	1.80 (0.99)	0.0	1.17	2.00	2.50	3.8	
		Week 50	Tezepelumab	29	28 (96.6)	1.48 (1.13)	0.0	0.75	1.08	2.33	4.2	
			Placebo	37	37 (100.0)	1.72 (0.92)	0.0	1.00	2.00	2.33	3.3	
		Week 52	Tezepelumab	29	28 (96.6)	1.48 (1.18)	0.0	0.67	1.08	2.33	4.3	
			Placebo	37	37 (100.0)	1.74 (0.97)	0.0	1.00	2.00	2.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	29	28 (96.6)	-0.58 (0.74)	-2.3	-0.92	-0.33	-0.17	0.7	-0.09 [-0.59, 0.40]
			Placebo	37	35 (94.6)	-0.51 (0.61)	-2.0	-0.83	-0.50	0.00	0.7	
		Week 4	Tezepelumab	29	28 (96.6)	-0.90 (1.09)	-3.5	-1.50	-0.83	-0.17	2.3	-0.29 [-0.79, 0.21]
			Placebo	37	35 (94.6)	-0.62 (0.86)	-2.2	-1.33	-0.83	0.17	1.2	
		Week 6	Tezepelumab	29	28 (96.6)	-1.10 (1.21)	-3.8	-1.83	-1.00	-0.42	2.3	-0.42 [-0.92, 0.09]
			Placebo	37	35 (94.6)	-0.65 (0.94)	-2.3	-1.33	-0.67	0.00	1.5	
		Week 8	Tezepelumab	29	28 (96.6)	-1.15 (1.23)	-3.8	-1.75	-0.92	-0.50	2.3	-0.31 [-0.81, 0.19]
			Placebo	37	35 (94.6)	-0.81 (1.00)	-3.0	-1.50	-0.50	0.00	0.8	
		Week 10	Tezepelumab	29	28 (96.6)	-1.34 (1.28)	-3.8	-2.08	-1.33	-0.58	2.3	-0.48 [-0.98, 0.02]
			Placebo	37	36 (97.3)	-0.82 (0.89)	-2.3	-1.33	-0.75	-0.33	2.0	
		Week 12	Tezepelumab	29	28 (96.6)	-1.38 (1.20)	-3.7	-2.17	-1.33	-0.50	2.3	-0.35 [-0.85, 0.15]
			Placebo	37	36 (97.3)	-1.00 (1.04)	-3.2	-1.83	-1.00	-0.25	1.2	
		Week 14	Tezepelumab	29	28 (96.6)	-1.46 (1.25)	-3.8	-2.42	-1.50	-0.50	2.3	-0.36 [-0.85, 0.14]
			Placebo	37	36 (97.3)	-1.10 (0.82)	-3.2	-1.42	-1.17	-0.50	0.3	
		Week 16	Tezepelumab	29	28 (96.6)	-1.30 (1.20)	-3.8	-2.17	-1.25	-0.50	2.3	-0.28 [-0.78, 0.22]
			Placebo	37	36 (97.3)	-1.00 (0.98)	-3.2	-1.50	-1.17	-0.17	0.8	
		Week 18	Tezepelumab	29	28 (96.6)	-1.43 (1.28)	-3.8	-2.50	-1.50	-0.58	2.3	-0.31 [-0.81, 0.18]
			Placebo	37	36 (97.3)	-1.07 (1.00)	-3.2	-1.83	-1.08	-0.33	1.5	
		Week 20	Tezepelumab	29	28 (96.6)	-1.35 (1.27)	-3.8	-2.33	-1.42	-0.42	2.3	-0.32 [-0.82, 0.17]
			Placebo	37	36 (97.3)	-0.98 (1.00)	-3.2	-1.67	-0.83	-0.33	0.8	
		Week 22	Tezepelumab	29	28 (96.6)	-1.45 (1.27)	-3.8	-2.50	-1.50	-0.58	2.3	-0.52 [-1.02, -0.02]
			Placebo	37	36 (97.3)	-0.90 (0.89)	-2.5	-1.50	-0.83	-0.33	0.7	
		Week 24	Tezepelumab	29	28 (96.6)	-1.35 (1.20)	-3.8	-2.08	-1.33	-0.58	2.3	-0.34 [-0.84, 0.16]
			Placebo	37	36 (97.3)	-0.98 (0.97)	-2.8	-1.67	-0.92	-0.08	0.7	
		Week 26	Tezepelumab	29	28 (96.6)	-1.36 (1.30)	-3.8	-2.50	-1.33	-0.50	2.3	-0.20 [-0.70, 0.29]
			Placebo	37	36 (97.3)	-1.13 (1.01)	-3.2	-1.92	-1.33	-0.25	0.7	
		Week 28	Tezepelumab	29	28 (96.6)	-1.29 (1.31)	-3.8	-2.33	-1.17	-0.42	2.3	-0.15 [-0.64, 0.35]
			Placebo	37	36 (97.3)	-1.11 (1.09)	-3.2	-1.92	-1.08	-0.25	1.2	
		Week 30	Tezepelumab	29	28 (96.6)	-1.38 (1.21)	-3.7	-2.42	-1.33	-0.83	2.3	-0.24 [-0.74, 0.25]
			Placebo	37	36 (97.3)	-1.12 (0.96)	-2.7	-2.00	-1.25	-0.50	0.8	
		Week 32	Tezepelumab	29	28 (96.6)	-1.49 (1.24)	-3.8	-2.50	-1.50	-0.83	2.3	-0.37 [-0.87, 0.12]
			Placebo	37	36 (97.3)	-1.09 (0.92)	-2.8	-1.58	-1.25	-0.50	0.7	
		Week 34	Tezepelumab	29	28 (96.6)	-1.37 (1.25)	-3.8	-2.25	-1.42	-0.67	2.3	-0.25 [-0.75, 0.25]
			Placebo	37	36 (97.3)	-1.11 (0.85)	-2.8	-1.75	-1.17	-0.50	0.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	29	28 (96.6)	-1.38 (1.28)	-3.8	-2.50	-1.42	-0.75	2.3	-0.50 [-1.00, 0.00]
			Placebo	37	36 (97.3)	-0.83 (0.95)	-2.7	-1.33	-0.83	-0.25	1.2	
		Week 38	Tezepelumab	29	28 (96.6)	-1.46 (1.27)	-3.8	-2.33	-1.42	-0.75	2.3	-0.43 [-0.93, 0.07]
			Placebo	37	36 (97.3)	-1.00 (0.88)	-2.7	-1.67	-1.08	-0.25	0.7	
		Week 40	Tezepelumab	29	28 (96.6)	-1.58 (1.31)	-3.8	-2.50	-1.50	-0.75	2.3	-0.64 [-1.14, -0.13]
			Placebo	37	36 (97.3)	-0.85 (1.02)	-2.7	-1.50	-1.00	0.00	1.2	
		Week 42	Tezepelumab	29	28 (96.6)	-1.48 (1.29)	-3.8	-2.58	-1.50	-0.67	2.3	-0.48 [-0.98, 0.02]
			Placebo	37	36 (97.3)	-0.94 (0.94)	-2.7	-1.50	-1.17	-0.25	1.5	
		Week 44	Tezepelumab	29	28 (96.6)	-1.48 (1.29)	-3.8	-2.50	-1.33	-0.67	2.3	-0.46 [-0.96, 0.04]
			Placebo	37	37 (100.0)	-0.94 (1.07)	-2.7	-1.83	-1.17	-0.33	1.2	
		Week 46	Tezepelumab	29	28 (96.6)	-1.39 (1.32)	-3.8	-2.50	-1.33	-0.67	2.3	-0.34 [-0.83, 0.16]
			Placebo	37	37 (100.0)	-1.01 (0.90)	-2.8	-1.33	-1.17	-0.67	0.8	
		Week 48	Tezepelumab	29	28 (96.6)	-1.38 (1.34)	-3.8	-2.50	-1.50	-0.42	2.3	-0.35 [-0.85, 0.14]
			Placebo	37	37 (100.0)	-0.97 (0.99)	-2.8	-1.50	-1.00	-0.33	0.8	
		Week 50	Tezepelumab	29	28 (96.6)	-1.49 (1.31)	-3.8	-2.50	-1.50	-0.92	2.3	-0.40 [-0.89, 0.10]
			Placebo	37	37 (100.0)	-1.05 (0.92)	-3.0	-1.67	-1.00	-0.50	0.7	
		Week 52	Tezepelumab	29	28 (96.6)	-1.49 (1.34)	-3.8	-2.50	-1.58	-0.92	2.3	-0.41 [-0.90, 0.09]
			Placebo	37	37 (100.0)	-1.03 (0.96)	-3.0	-1.67	-1.00	-0.17	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	108	108 (100.0)	2.63 (0.76)	0.0	2.17	2.67	3.00	4.8	
			Placebo	101	101 (100.0)	2.61 (0.73)	0.3	2.17	2.67	3.00	4.7	
		Week 2	Tezepelumab	108	103 (95.4)	2.11 (0.91)	0.0	1.50	2.17	2.67	4.3	
			Placebo	101	90 (89.1)	2.32 (0.84)	0.2	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	108	103 (95.4)	1.84 (0.95)	0.0	1.17	2.00	2.50	4.3	
			Placebo	101	90 (89.1)	2.19 (0.82)	0.2	1.67	2.33	2.67	4.2	
		Week 6	Tezepelumab	108	103 (95.4)	1.78 (0.94)	0.0	1.17	1.67	2.50	4.3	
			Placebo	101	91 (90.1)	2.07 (0.93)	0.2	1.50	2.17	2.67	5.5	
		Week 8	Tezepelumab	108	103 (95.4)	1.71 (1.00)	0.0	1.00	1.67	2.50	4.8	
			Placebo	101	92 (91.1)	2.09 (0.92)	0.0	1.50	2.00	2.75	4.7	
		Week 10	Tezepelumab	108	103 (95.4)	1.67 (0.97)	0.0	1.00	1.67	2.33	4.3	
			Placebo	101	92 (91.1)	1.99 (0.91)	0.0	1.33	2.00	2.50	5.3	
		Week 12	Tezepelumab	108	103 (95.4)	1.59 (1.02)	0.0	0.83	1.50	2.33	4.3	
			Placebo	101	92 (91.1)	1.94 (0.88)	0.0	1.33	2.00	2.67	4.3	
		Week 14	Tezepelumab	108	103 (95.4)	1.45 (0.95)	0.0	0.83	1.33	2.17	4.3	
			Placebo	101	92 (91.1)	1.91 (0.95)	0.3	1.08	2.00	2.50	5.0	
		Week 16	Tezepelumab	108	103 (95.4)	1.59 (1.05)	0.0	0.83	1.50	2.50	4.3	
			Placebo	101	92 (91.1)	2.05 (1.02)	0.0	1.33	2.17	2.67	5.0	
		Week 18	Tezepelumab	108	104 (96.3)	1.49 (0.94)	0.0	0.83	1.50	2.00	4.3	
			Placebo	101	92 (91.1)	1.93 (0.97)	0.0	1.25	2.08	2.50	5.0	
		Week 20	Tezepelumab	108	104 (96.3)	1.57 (0.98)	0.0	0.83	1.67	2.17	4.3	
			Placebo	101	92 (91.1)	1.97 (1.01)	0.0	1.33	2.17	2.67	5.0	
		Week 22	Tezepelumab	108	104 (96.3)	1.62 (0.94)	0.0	0.92	1.67	2.33	4.3	
			Placebo	101	92 (91.1)	1.87 (1.06)	0.0	1.00	2.00	2.67	5.0	
		Week 24	Tezepelumab	108	104 (96.3)	1.58 (1.00)	0.0	0.83	1.67	2.33	4.3	
			Placebo	101	92 (91.1)	1.90 (1.00)	0.2	1.00	2.00	2.50	4.5	
		Week 26	Tezepelumab	108	105 (97.2)	1.54 (0.99)	0.0	0.83	1.50	2.17	4.3	
			Placebo	101	92 (91.1)	1.89 (0.97)	0.0	1.17	1.83	2.67	4.5	
		Week 28	Tezepelumab	108	106 (98.1)	1.58 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	101	93 (92.1)	1.95 (1.01)	0.0	1.00	2.17	2.50	4.5	
		Week 30	Tezepelumab	108	107 (99.1)	1.54 (1.00)	0.0	0.83	1.50	2.17	4.3	
			Placebo	101	94 (93.1)	1.95 (1.02)	0.0	1.17	2.00	2.67	4.5	
		Week 32	Tezepelumab	108	107 (99.1)	1.52 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	101	94 (93.1)	1.87 (1.05)	0.0	1.00	1.83	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	108	107 (99.1)	1.50 (1.05)	0.0	0.67	1.50	2.17	4.3	
			Placebo	101	94 (93.1)	1.82 (1.08)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	108	107 (99.1)	1.60 (1.03)	0.0	0.83	1.67	2.33	4.5	
			Placebo	101	94 (93.1)	1.83 (1.06)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	108	107 (99.1)	1.50 (1.02)	0.0	0.83	1.50	2.17	4.3	
			Placebo	101	94 (93.1)	1.78 (1.06)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	108	107 (99.1)	1.56 (1.02)	0.0	0.83	1.67	2.17	4.3	
			Placebo	101	94 (93.1)	1.83 (1.05)	0.0	1.00	1.83	2.67	4.5	
		Week 42	Tezepelumab	108	107 (99.1)	1.50 (1.03)	0.0	0.83	1.50	2.00	4.7	
			Placebo	101	94 (93.1)	1.82 (1.04)	0.0	1.00	1.83	2.67	4.7	
		Week 44	Tezepelumab	108	107 (99.1)	1.53 (1.02)	0.0	0.83	1.50	2.33	4.3	
			Placebo	101	94 (93.1)	1.88 (0.99)	0.0	1.00	2.00	2.67	4.5	
		Week 46	Tezepelumab	108	107 (99.1)	1.46 (1.01)	0.0	0.67	1.33	2.17	4.3	
			Placebo	101	94 (93.1)	1.76 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	108	107 (99.1)	1.54 (1.02)	0.0	0.67	1.67	2.33	4.3	
			Placebo	101	94 (93.1)	1.79 (1.03)	0.0	1.00	1.83	2.50	4.5	
		Week 50	Tezepelumab	108	107 (99.1)	1.46 (1.01)	0.0	0.83	1.33	2.17	4.3	
			Placebo	101	94 (93.1)	1.79 (0.98)	0.0	1.00	1.83	2.50	4.5	
		Week 52	Tezepelumab	108	107 (99.1)	1.49 (0.99)	0.0	0.67	1.50	2.00	4.3	
			Placebo	101	94 (93.1)	1.85 (1.01)	0.0	1.17	1.92	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	108	103 (95.4)	-0.53 (0.65)	-2.8	-0.83	-0.50	0.00	0.5	-0.31 [-0.60, -0.03]
			Placebo	101	90 (89.1)	-0.31 (0.74)	-2.8	-0.83	-0.17	0.17	1.2	
		Week 4	Tezepelumab	108	103 (95.4)	-0.80 (0.82)	-3.3	-1.33	-0.67	-0.33	1.7	-0.44 [-0.72, -0.15]
			Placebo	101	90 (89.1)	-0.44 (0.82)	-3.0	-0.83	-0.33	0.17	1.2	
		Week 6	Tezepelumab	108	103 (95.4)	-0.86 (0.88)	-3.2	-1.33	-0.83	-0.33	1.3	-0.35 [-0.63, -0.07]
			Placebo	101	91 (90.1)	-0.55 (0.88)	-3.3	-1.17	-0.33	0.00	1.5	
		Week 8	Tezepelumab	108	103 (95.4)	-0.92 (0.92)	-2.8	-1.50	-1.00	-0.33	2.2	-0.44 [-0.72, -0.15]
			Placebo	101	92 (91.1)	-0.53 (0.86)	-3.2	-1.00	-0.67	0.00	1.0	
		Week 10	Tezepelumab	108	103 (95.4)	-0.97 (0.87)	-3.5	-1.50	-1.00	-0.33	1.0	-0.35 [-0.64, -0.07]
			Placebo	101	92 (91.1)	-0.64 (0.98)	-3.3	-1.25	-0.50	0.00	2.7	
		Week 12	Tezepelumab	108	103 (95.4)	-1.04 (0.90)	-3.7	-1.67	-1.00	-0.50	1.2	-0.39 [-0.68, -0.11]
			Placebo	101	92 (91.1)	-0.68 (0.92)	-3.3	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	108	103 (95.4)	-1.19 (0.91)	-3.8	-1.83	-1.17	-0.67	1.2	-0.49 [-0.78, -0.21]
			Placebo	101	92 (91.1)	-0.72 (0.97)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 16	Tezepelumab	108	103 (95.4)	-1.04 (0.98)	-4.2	-1.83	-1.00	-0.33	1.5	-0.46 [-0.74, -0.17]
			Placebo	101	92 (91.1)	-0.58 (1.03)	-3.5	-1.17	-0.58	0.00	2.3	
		Week 18	Tezepelumab	108	104 (96.3)	-1.14 (0.90)	-4.2	-1.83	-1.00	-0.67	1.2	-0.46 [-0.74, -0.17]
			Placebo	101	92 (91.1)	-0.70 (1.00)	-3.2	-1.33	-0.58	-0.17	2.3	
		Week 20	Tezepelumab	108	104 (96.3)	-1.05 (0.92)	-4.2	-1.75	-1.00	-0.33	1.0	-0.40 [-0.68, -0.12]
			Placebo	101	92 (91.1)	-0.66 (1.05)	-3.5	-1.17	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	108	104 (96.3)	-1.01 (0.94)	-4.3	-1.67	-1.00	-0.33	1.8	-0.25 [-0.53, 0.03]
			Placebo	101	92 (91.1)	-0.76 (1.05)	-3.3	-1.50	-0.67	-0.08	2.3	
		Week 24	Tezepelumab	108	104 (96.3)	-1.04 (0.91)	-4.5	-1.67	-1.00	-0.33	1.5	-0.32 [-0.60, -0.04]
			Placebo	101	92 (91.1)	-0.73 (1.06)	-3.5	-1.33	-0.67	-0.08	2.3	
		Week 26	Tezepelumab	108	105 (97.2)	-1.07 (0.95)	-4.2	-1.83	-1.00	-0.33	1.3	-0.34 [-0.62, -0.06]
			Placebo	101	92 (91.1)	-0.74 (1.04)	-4.0	-1.33	-0.75	-0.08	2.3	
		Week 28	Tezepelumab	108	106 (98.1)	-1.03 (0.95)	-4.2	-1.67	-1.00	-0.33	1.0	-0.38 [-0.66, -0.10]
			Placebo	101	93 (92.1)	-0.65 (1.04)	-4.0	-1.33	-0.50	-0.17	2.3	
		Week 30	Tezepelumab	108	107 (99.1)	-1.08 (1.00)	-4.2	-1.83	-1.00	-0.33	1.8	-0.41 [-0.69, -0.13]
			Placebo	101	94 (93.1)	-0.66 (1.07)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 32	Tezepelumab	108	107 (99.1)	-1.10 (0.98)	-4.2	-1.83	-1.00	-0.67	1.8	-0.35 [-0.63, -0.07]
			Placebo	101	94 (93.1)	-0.74 (1.08)	-3.5	-1.50	-0.50	-0.17	2.3	
		Week 34	Tezepelumab	108	107 (99.1)	-1.12 (1.01)	-4.2	-2.00	-1.00	-0.50	2.0	-0.32 [-0.60, -0.04]
			Placebo	101	94 (93.1)	-0.78 (1.10)	-4.0	-1.50	-0.67	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHK: Change from baseline in ACQ-6 score by key subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	108	107 (99.1)	-1.02 (1.03)	-4.2	-1.83	-1.00	-0.33	1.7	-0.22 [-0.50, 0.06]
			Placebo	101	94 (93.1)	-0.78 (1.12)	-3.5	-1.50	-0.75	0.00	2.3	
		Week 38	Tezepelumab	108	107 (99.1)	-1.12 (1.03)	-4.2	-2.00	-1.17	-0.33	2.3	-0.27 [-0.55, 0.00]
			Placebo	101	94 (93.1)	-0.83 (1.13)	-4.0	-1.33	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	108	107 (99.1)	-1.06 (1.00)	-4.2	-1.83	-1.00	-0.33	1.7	-0.27 [-0.55, 0.01]
			Placebo	101	94 (93.1)	-0.78 (1.08)	-4.0	-1.50	-0.75	-0.17	2.3	
		Week 42	Tezepelumab	108	107 (99.1)	-1.12 (1.02)	-4.2	-1.83	-1.17	-0.50	2.0	-0.32 [-0.60, -0.04]
			Placebo	101	94 (93.1)	-0.79 (1.08)	-4.0	-1.33	-0.83	0.00	2.3	
		Week 44	Tezepelumab	108	107 (99.1)	-1.09 (1.03)	-4.3	-1.83	-1.00	-0.33	1.5	-0.35 [-0.63, -0.07]
			Placebo	101	94 (93.1)	-0.73 (1.06)	-4.0	-1.33	-0.67	0.00	2.3	
		Week 46	Tezepelumab	108	107 (99.1)	-1.16 (1.02)	-4.2	-1.83	-1.00	-0.50	1.7	-0.30 [-0.58, -0.02]
			Placebo	101	94 (93.1)	-0.85 (1.08)	-4.0	-1.50	-0.92	-0.17	2.3	
		Week 48	Tezepelumab	108	107 (99.1)	-1.09 (1.01)	-4.2	-1.83	-1.00	-0.33	1.8	-0.25 [-0.53, 0.02]
			Placebo	101	94 (93.1)	-0.82 (1.09)	-3.7	-1.50	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	108	107 (99.1)	-1.16 (1.02)	-4.2	-1.83	-1.17	-0.50	1.8	-0.33 [-0.61, -0.05]
			Placebo	101	94 (93.1)	-0.82 (1.05)	-4.0	-1.50	-0.83	-0.33	2.3	
		Week 52	Tezepelumab	108	107 (99.1)	-1.13 (1.01)	-4.2	-1.83	-1.00	-0.50	1.8	-0.36 [-0.64, -0.08]
			Placebo	101	94 (93.1)	-0.76 (1.07)	-4.0	-1.50	-0.67	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	2.71 (0.82)	0.0	2.33	2.67	3.08	4.8	
			Placebo	123	123 (100.0)	2.64 (0.66)	0.3	2.33	2.67	3.00	4.5	
		Week 2	Tezepelumab	128	122 (95.3)	2.19 (0.91)	0.0	1.67	2.17	2.83	4.3	
			Placebo	123	110 (89.4)	2.26 (0.77)	0.2	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	128	122 (95.3)	1.89 (0.97)	0.0	1.17	2.00	2.67	4.3	
			Placebo	123	110 (89.4)	2.15 (0.83)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	128	122 (95.3)	1.82 (0.98)	0.0	1.17	1.83	2.50	4.3	
			Placebo	123	111 (90.2)	2.05 (0.92)	0.2	1.50	2.17	2.67	4.7	
		Week 8	Tezepelumab	128	122 (95.3)	1.76 (1.04)	0.0	1.00	1.67	2.67	4.8	
			Placebo	123	112 (91.1)	2.04 (0.92)	0.0	1.42	2.00	2.67	4.7	
		Week 10	Tezepelumab	128	122 (95.3)	1.69 (1.02)	0.0	1.00	1.67	2.33	4.3	
			Placebo	123	113 (91.9)	1.97 (0.89)	0.0	1.33	2.00	2.67	4.2	
		Week 12	Tezepelumab	128	122 (95.3)	1.62 (1.04)	0.0	0.83	1.67	2.50	4.3	
			Placebo	123	113 (91.9)	1.90 (0.93)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	128	122 (95.3)	1.49 (1.02)	0.0	0.83	1.50	2.17	4.3	
			Placebo	123	113 (91.9)	1.84 (0.87)	0.0	1.33	1.83	2.50	5.0	
		Week 16	Tezepelumab	128	122 (95.3)	1.64 (1.06)	0.0	0.83	1.67	2.50	4.3	
			Placebo	123	113 (91.9)	1.95 (0.96)	0.0	1.17	2.00	2.67	4.5	
		Week 18	Tezepelumab	128	123 (96.1)	1.53 (0.99)	0.0	0.83	1.50	2.17	4.3	
			Placebo	123	113 (91.9)	1.84 (0.96)	0.0	1.17	1.83	2.33	4.7	
		Week 20	Tezepelumab	128	123 (96.1)	1.61 (1.04)	0.0	0.83	1.67	2.33	5.0	
			Placebo	123	113 (91.9)	1.90 (0.96)	0.0	1.17	2.00	2.67	4.5	
		Week 22	Tezepelumab	128	123 (96.1)	1.63 (0.98)	0.0	1.00	1.67	2.33	4.3	
			Placebo	123	113 (91.9)	1.85 (0.97)	0.0	1.17	2.00	2.67	4.5	
		Week 24	Tezepelumab	128	123 (96.1)	1.63 (1.05)	0.0	0.83	1.67	2.33	4.3	
			Placebo	123	113 (91.9)	1.86 (0.96)	0.0	1.00	2.00	2.50	4.5	
		Week 26	Tezepelumab	128	124 (96.9)	1.60 (1.02)	0.0	1.00	1.50	2.25	4.3	
			Placebo	123	113 (91.9)	1.83 (0.95)	0.0	1.00	1.67	2.67	4.5	
		Week 28	Tezepelumab	128	125 (97.7)	1.65 (1.05)	0.0	1.00	1.67	2.50	4.3	
			Placebo	123	114 (92.7)	1.91 (1.00)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	128	126 (98.4)	1.59 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	123	115 (93.5)	1.89 (1.00)	0.0	1.17	2.00	2.67	4.5	
		Week 32	Tezepelumab	128	126 (98.4)	1.54 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	123	115 (93.5)	1.83 (1.02)	0.0	1.00	1.83	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Absolute values	Week 34	Tezepelumab	128	126 (98.4)	1.56 (1.08)	0.0	0.83	1.50	2.50	4.3	
			Placebo	123	115 (93.5)	1.81 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	128	126 (98.4)	1.62 (1.05)	0.0	0.83	1.67	2.33	4.5	
			Placebo	123	115 (93.5)	1.84 (1.02)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	128	126 (98.4)	1.53 (1.05)	0.0	0.83	1.50	2.17	4.5	
			Placebo	123	115 (93.5)	1.79 (0.99)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	128	126 (98.4)	1.56 (1.06)	0.0	0.67	1.67	2.33	4.3	
			Placebo	123	115 (93.5)	1.86 (1.02)	0.0	1.00	1.83	2.67	4.5	
		Week 42	Tezepelumab	128	126 (98.4)	1.53 (1.06)	0.0	0.83	1.50	2.17	4.7	
			Placebo	123	115 (93.5)	1.85 (1.02)	0.0	1.00	2.00	2.67	4.7	
		Week 44	Tezepelumab	128	126 (98.4)	1.56 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	123	116 (94.3)	1.87 (1.00)	0.0	1.00	2.00	2.58	4.5	
		Week 46	Tezepelumab	128	126 (98.4)	1.52 (1.05)	0.0	0.83	1.42	2.33	4.3	
			Placebo	123	116 (94.3)	1.78 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	128	126 (98.4)	1.57 (1.06)	0.0	0.67	1.58	2.33	4.3	
			Placebo	123	116 (94.3)	1.79 (1.02)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	128	126 (98.4)	1.49 (1.05)	0.0	0.83	1.33	2.17	4.3	
			Placebo	123	116 (94.3)	1.77 (0.96)	0.0	1.00	1.83	2.50	4.5	
		Week 52	Tezepelumab	128	126 (98.4)	1.53 (1.04)	0.0	0.83	1.50	2.17	4.3	
			Placebo	123	116 (94.3)	1.83 (0.99)	0.0	1.00	2.00	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 2	Tezepelumab	128	122 (95.3)	-0.53 (0.65)	-2.5	-0.83	-0.42	0.00	0.7	-0.21 [-0.47, 0.05]
			Placebo	123	110 (89.4)	-0.38 (0.72)	-2.8	-0.83	-0.33	0.17	1.2	
		Week 4	Tezepelumab	128	122 (95.3)	-0.82 (0.89)	-3.5	-1.33	-0.83	-0.17	2.3	-0.38 [-0.64, -0.12]
			Placebo	123	110 (89.4)	-0.49 (0.82)	-3.0	-1.00	-0.42	0.00	1.2	
		Week 6	Tezepelumab	128	122 (95.3)	-0.90 (0.97)	-3.8	-1.50	-0.83	-0.33	2.3	-0.33 [-0.59, -0.07]
			Placebo	123	111 (90.2)	-0.59 (0.89)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	128	122 (95.3)	-0.95 (1.00)	-3.8	-1.50	-1.00	-0.33	2.3	-0.37 [-0.63, -0.11]
			Placebo	123	112 (91.1)	-0.61 (0.85)	-3.2	-1.00	-0.67	0.00	1.0	
		Week 10	Tezepelumab	128	122 (95.3)	-1.02 (0.98)	-3.8	-1.67	-1.00	-0.33	2.3	-0.35 [-0.61, -0.10]
			Placebo	123	113 (91.9)	-0.68 (0.91)	-3.3	-1.33	-0.67	-0.17	2.5	
		Week 12	Tezepelumab	128	122 (95.3)	-1.09 (0.98)	-3.7	-1.67	-1.00	-0.50	2.3	-0.36 [-0.61, -0.10]
			Placebo	123	113 (91.9)	-0.75 (0.93)	-3.3	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	128	122 (95.3)	-1.22 (1.01)	-3.8	-2.00	-1.17	-0.67	2.3	-0.42 [-0.68, -0.17]
			Placebo	123	113 (91.9)	-0.82 (0.88)	-3.2	-1.33	-0.83	-0.33	1.3	
		Week 16	Tezepelumab	128	122 (95.3)	-1.08 (1.04)	-4.2	-1.83	-1.00	-0.33	2.3	-0.38 [-0.64, -0.12]
			Placebo	123	113 (91.9)	-0.70 (0.95)	-3.2	-1.17	-0.67	0.00	2.3	
		Week 18	Tezepelumab	128	123 (96.1)	-1.18 (1.01)	-4.2	-1.83	-1.00	-0.67	2.3	-0.37 [-0.63, -0.12]
			Placebo	123	113 (91.9)	-0.81 (0.96)	-3.2	-1.33	-0.67	-0.33	2.3	
		Week 20	Tezepelumab	128	123 (96.1)	-1.09 (1.02)	-4.2	-1.83	-1.00	-0.33	2.3	-0.34 [-0.60, -0.08]
			Placebo	123	113 (91.9)	-0.75 (0.97)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	128	123 (96.1)	-1.08 (1.04)	-4.3	-1.67	-1.00	-0.50	2.3	-0.28 [-0.54, -0.02]
			Placebo	123	113 (91.9)	-0.80 (0.97)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	128	123 (96.1)	-1.08 (0.99)	-4.5	-1.67	-1.00	-0.50	2.3	-0.29 [-0.55, -0.03]
			Placebo	123	113 (91.9)	-0.79 (0.99)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 26	Tezepelumab	128	124 (96.9)	-1.10 (1.04)	-4.2	-1.83	-1.00	-0.33	2.3	-0.27 [-0.53, -0.02]
			Placebo	123	113 (91.9)	-0.82 (0.98)	-2.8	-1.50	-1.00	-0.17	2.3	
		Week 28	Tezepelumab	128	125 (97.7)	-1.05 (1.05)	-4.2	-1.83	-1.00	-0.33	2.3	-0.31 [-0.57, -0.05]
			Placebo	123	114 (92.7)	-0.73 (1.00)	-2.8	-1.50	-0.67	-0.17	2.3	
		Week 30	Tezepelumab	128	126 (98.4)	-1.11 (1.06)	-4.2	-1.83	-1.00	-0.50	2.3	-0.35 [-0.60, -0.09]
			Placebo	123	115 (93.5)	-0.75 (1.04)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 32	Tezepelumab	128	126 (98.4)	-1.16 (1.06)	-4.2	-1.83	-1.00	-0.67	2.3	-0.34 [-0.59, -0.09]
			Placebo	123	115 (93.5)	-0.80 (1.02)	-3.0	-1.50	-0.67	-0.17	2.3	
		Week 34	Tezepelumab	128	126 (98.4)	-1.14 (1.08)	-4.2	-2.00	-1.00	-0.50	2.3	-0.30 [-0.56, -0.05]
			Placebo	123	115 (93.5)	-0.82 (1.01)	-3.2	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Change from baseline	Week 36	Tezepelumab	128	126 (98.4)	-1.08 (1.10)	-4.2	-1.83	-1.00	-0.33	2.3	-0.27 [-0.52, -0.01]
			Placebo	123	115 (93.5)	-0.79 (1.05)	-3.5	-1.33	-0.83	0.00	2.3	
		Week 38	Tezepelumab	128	126 (98.4)	-1.17 (1.10)	-4.2	-2.00	-1.17	-0.50	2.3	-0.30 [-0.56, -0.05]
			Placebo	123	115 (93.5)	-0.84 (1.03)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	128	126 (98.4)	-1.14 (1.11)	-4.2	-2.00	-1.00	-0.50	2.3	-0.34 [-0.60, -0.09]
			Placebo	123	115 (93.5)	-0.78 (1.02)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 42	Tezepelumab	128	126 (98.4)	-1.17 (1.11)	-4.2	-1.83	-1.17	-0.50	2.3	-0.36 [-0.61, -0.10]
			Placebo	123	115 (93.5)	-0.79 (1.03)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 44	Tezepelumab	128	126 (98.4)	-1.14 (1.11)	-4.3	-1.83	-1.00	-0.50	2.3	-0.35 [-0.60, -0.10]
			Placebo	123	116 (94.3)	-0.77 (1.01)	-3.3	-1.50	-0.83	-0.17	2.3	
		Week 46	Tezepelumab	128	126 (98.4)	-1.18 (1.11)	-4.2	-2.00	-1.00	-0.50	2.3	-0.30 [-0.56, -0.05]
			Placebo	123	116 (94.3)	-0.85 (1.02)	-3.2	-1.50	-0.92	-0.17	2.3	
		Week 48	Tezepelumab	128	126 (98.4)	-1.13 (1.11)	-4.2	-1.83	-1.00	-0.33	2.3	-0.26 [-0.52, -0.01]
			Placebo	123	116 (94.3)	-0.84 (1.05)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	128	126 (98.4)	-1.21 (1.10)	-4.2	-2.00	-1.17	-0.50	2.3	-0.33 [-0.58, -0.08]
			Placebo	123	116 (94.3)	-0.86 (0.98)	-3.5	-1.50	-0.83	-0.33	2.3	
		Week 52	Tezepelumab	128	126 (98.4)	-1.17 (1.10)	-4.2	-1.83	-1.00	-0.50	2.3	-0.35 [-0.60, -0.09]
			Placebo	123	116 (94.3)	-0.81 (0.99)	-3.5	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.57 (0.42)	2.0	2.33	2.50	2.83	3.2	
			Placebo	15	15 (100.0)	2.79 (0.91)	1.5	2.00	2.67	3.33	4.7	
		Week 2	Tezepelumab	9	9 (100.0)	1.91 (0.94)	0.0	1.67	2.17	2.50	3.0	
			Placebo	15	15 (100.0)	2.57 (0.93)	1.3	2.00	2.50	2.83	4.7	
		Week 4	Tezepelumab	9	9 (100.0)	1.80 (0.76)	0.7	1.17	2.00	2.17	3.0	
			Placebo	15	15 (100.0)	2.34 (0.93)	0.7	1.50	2.33	3.17	4.0	
		Week 6	Tezepelumab	9	9 (100.0)	1.52 (0.66)	0.5	1.00	1.67	1.83	2.7	
			Placebo	15	15 (100.0)	2.31 (1.27)	0.8	1.17	2.33	2.50	5.5	
		Week 8	Tezepelumab	9	9 (100.0)	1.33 (0.73)	0.2	0.83	1.50	1.67	2.5	
			Placebo	15	15 (100.0)	2.16 (1.22)	0.2	1.17	2.17	2.83	4.7	
		Week 10	Tezepelumab	9	9 (100.0)	1.17 (0.62)	0.2	0.83	1.17	1.50	2.2	
			Placebo	15	15 (100.0)	2.04 (1.13)	0.8	1.33	1.83	2.50	5.3	
		Week 12	Tezepelumab	9	9 (100.0)	1.15 (0.83)	0.0	0.50	1.33	1.50	2.7	
			Placebo	15	15 (100.0)	1.87 (1.02)	0.0	1.17	1.67	2.50	4.0	
		Week 14	Tezepelumab	9	9 (100.0)	1.00 (0.50)	0.5	0.67	0.83	1.00	2.2	
			Placebo	15	15 (100.0)	1.88 (1.23)	0.0	1.00	1.67	2.50	5.0	
		Week 16	Tezepelumab	9	9 (100.0)	1.24 (0.91)	0.3	0.83	1.00	1.33	3.5	
			Placebo	15	15 (100.0)	2.10 (1.49)	0.0	0.83	1.83	3.00	5.0	
		Week 18	Tezepelumab	9	9 (100.0)	1.13 (0.55)	0.5	0.67	1.00	1.67	1.8	
			Placebo	15	15 (100.0)	2.03 (1.19)	0.0	1.17	2.00	2.83	5.0	
		Week 20	Tezepelumab	9	9 (100.0)	1.15 (0.54)	0.5	0.83	1.00	1.17	2.2	
			Placebo	15	15 (100.0)	2.04 (1.28)	0.2	0.83	2.33	2.83	5.0	
		Week 22	Tezepelumab	9	9 (100.0)	1.19 (0.71)	0.0	0.83	1.00	1.33	2.3	
			Placebo	15	15 (100.0)	2.01 (1.23)	0.3	1.00	2.17	2.67	5.0	
		Week 24	Tezepelumab	9	9 (100.0)	1.11 (0.62)	0.5	0.83	0.83	1.17	2.5	
			Placebo	15	15 (100.0)	1.96 (1.12)	0.3	0.67	2.33	2.67	4.2	
		Week 26	Tezepelumab	9	9 (100.0)	0.91 (0.54)	0.2	0.67	0.83	0.83	2.2	
			Placebo	15	15 (100.0)	1.72 (1.19)	0.0	0.83	1.67	2.50	4.2	
		Week 28	Tezepelumab	9	9 (100.0)	0.98 (0.52)	0.3	0.83	1.00	1.00	2.2	
			Placebo	15	15 (100.0)	1.62 (1.33)	0.0	0.33	2.00	2.50	4.2	
		Week 30	Tezepelumab	9	9 (100.0)	0.98 (0.49)	0.7	0.67	0.83	1.17	2.2	
			Placebo	15	15 (100.0)	1.68 (1.14)	0.0	0.83	1.83	2.00	4.2	
		Week 32	Tezepelumab	9	9 (100.0)	1.06 (0.63)	0.2	0.67	1.00	1.33	2.2	
			Placebo	15	15 (100.0)	1.70 (1.11)	0.2	0.67	1.50	2.50	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Non-white	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	0.98 (0.54)	0.3	0.67	1.00	1.17	2.2	
			Placebo	15	15 (100.0)	1.52 (1.26)	0.0	0.33	1.67	2.33	4.2	
		Week 36	Tezepelumab	9	9 (100.0)	1.30 (0.79)	0.3	0.83	1.17	2.17	2.3	
			Placebo	15	15 (100.0)	1.99 (1.17)	0.0	1.33	2.17	2.50	4.2	
		Week 38	Tezepelumab	9	9 (100.0)	1.04 (0.68)	0.0	0.67	0.83	1.67	2.0	
			Placebo	15	15 (100.0)	1.67 (1.21)	0.0	0.50	1.67	2.50	4.2	
		Week 40	Tezepelumab	9	9 (100.0)	1.06 (0.60)	0.3	0.67	0.83	1.67	2.0	
			Placebo	15	15 (100.0)	1.81 (1.20)	0.0	0.83	1.83	2.50	4.2	
		Week 42	Tezepelumab	9	9 (100.0)	1.02 (0.52)	0.5	0.67	0.83	1.17	2.0	
			Placebo	15	15 (100.0)	1.63 (0.96)	0.0	1.50	1.83	2.00	3.3	
		Week 44	Tezepelumab	9	9 (100.0)	1.00 (0.60)	0.3	0.50	0.83	1.17	2.2	
			Placebo	15	15 (100.0)	1.86 (1.15)	0.0	0.67	2.50	2.67	3.3	
		Week 46	Tezepelumab	9	9 (100.0)	0.98 (0.51)	0.3	0.67	1.00	1.00	2.2	
			Placebo	15	15 (100.0)	1.59 (1.01)	0.0	0.50	1.83	2.17	3.3	
		Week 48	Tezepelumab	9	9 (100.0)	1.17 (0.63)	0.5	0.67	1.00	1.33	2.3	
			Placebo	15	15 (100.0)	1.78 (1.00)	0.0	1.00	2.17	2.50	3.3	
		Week 50	Tezepelumab	9	9 (100.0)	1.04 (0.67)	0.2	0.67	0.83	1.17	2.2	
			Placebo	15	15 (100.0)	1.74 (1.02)	0.0	1.00	1.67	2.50	3.7	
		Week 52	Tezepelumab	9	9 (100.0)	0.94 (0.71)	0.2	0.50	0.67	1.17	2.2	
			Placebo	15	15 (100.0)	1.78 (1.12)	0.0	1.17	1.67	2.50	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.67 (0.95)	-2.8	-0.83	-0.33	-0.17	0.2	-0.58 [-1.42, 0.27]
			Placebo	15	15 (100.0)	-0.22 (0.64)	-1.3	-0.67	-0.17	0.00	1.0	
		Week 4	Tezepelumab	9	9 (100.0)	-0.78 (0.88)	-2.0	-1.33	-1.00	-0.17	0.7	-0.37 [-1.20, 0.47]
			Placebo	15	15 (100.0)	-0.44 (0.93)	-2.0	-1.33	-0.33	0.33	0.8	
		Week 6	Tezepelumab	9	9 (100.0)	-1.06 (0.80)	-2.3	-1.50	-1.33	-0.33	0.3	-0.63 [-1.48, 0.22]
			Placebo	15	15 (100.0)	-0.48 (0.98)	-2.0	-1.33	-0.67	0.33	1.3	
		Week 8	Tezepelumab	9	9 (100.0)	-1.24 (0.90)	-2.7	-1.67	-1.50	-0.33	0.2	-0.53 [-1.37, 0.31]
			Placebo	15	15 (100.0)	-0.63 (1.27)	-3.0	-1.33	-0.33	0.50	0.8	
		Week 10	Tezepelumab	9	9 (100.0)	-1.41 (0.86)	-2.7	-1.83	-1.50	-0.50	-0.2	-0.58 [-1.43, 0.26]
			Placebo	15	15 (100.0)	-0.74 (1.27)	-2.7	-1.67	-0.67	-0.33	2.7	
		Week 12	Tezepelumab	9	9 (100.0)	-1.43 (0.92)	-2.3	-2.17	-1.83	-0.67	0.3	-0.45 [-1.29, 0.38]
			Placebo	15	15 (100.0)	-0.92 (1.20)	-3.2	-1.83	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	9	9 (100.0)	-1.57 (0.66)	-2.3	-1.83	-1.83	-1.50	-0.2	-0.57 [-1.41, 0.27]
			Placebo	15	15 (100.0)	-0.91 (1.37)	-3.2	-1.67	-1.00	0.00	2.3	
		Week 16	Tezepelumab	9	9 (100.0)	-1.33 (1.05)	-2.2	-2.17	-1.67	-1.00	1.2	-0.47 [-1.30, 0.37]
			Placebo	15	15 (100.0)	-0.69 (1.54)	-3.5	-1.50	-0.67	0.17	2.3	
		Week 18	Tezepelumab	9	9 (100.0)	-1.44 (0.79)	-2.3	-1.83	-1.83	-0.67	-0.2	-0.56 [-1.41, 0.28]
			Placebo	15	15 (100.0)	-0.76 (1.41)	-3.2	-1.67	-1.00	0.00	2.3	
		Week 20	Tezepelumab	9	9 (100.0)	-1.43 (0.77)	-2.0	-2.00	-1.83	-1.33	0.2	-0.53 [-1.37, 0.31]
			Placebo	15	15 (100.0)	-0.74 (1.51)	-3.5	-1.67	-0.83	0.33	2.3	
		Week 22	Tezepelumab	9	9 (100.0)	-1.39 (0.91)	-2.2	-2.00	-1.83	-1.00	0.2	-0.52 [-1.37, 0.32]
			Placebo	15	15 (100.0)	-0.78 (1.29)	-3.0	-1.50	-0.83	0.00	2.3	
		Week 24	Tezepelumab	9	9 (100.0)	-1.46 (0.84)	-2.3	-2.00	-1.67	-1.50	0.2	-0.53 [-1.37, 0.31]
			Placebo	15	15 (100.0)	-0.83 (1.36)	-3.5	-1.83	-1.00	0.33	1.5	
		Week 26	Tezepelumab	9	9 (100.0)	-1.67 (0.70)	-2.3	-2.17	-1.83	-1.33	-0.2	-0.48 [-1.32, 0.35]
			Placebo	15	15 (100.0)	-1.07 (1.46)	-4.0	-1.83	-1.33	0.17	1.5	
		Week 28	Tezepelumab	9	9 (100.0)	-1.59 (0.69)	-2.3	-2.17	-1.67	-1.33	-0.2	-0.34 [-1.17, 0.49]
			Placebo	15	15 (100.0)	-1.17 (1.49)	-4.0	-1.83	-1.33	0.00	1.5	
		Week 30	Tezepelumab	9	9 (100.0)	-1.59 (0.71)	-2.5	-2.00	-1.83	-1.50	-0.2	-0.47 [-1.31, 0.37]
			Placebo	15	15 (100.0)	-1.11 (1.17)	-3.2	-1.83	-1.33	-0.33	1.5	
		Week 32	Tezepelumab	9	9 (100.0)	-1.52 (0.75)	-2.3	-2.17	-1.50	-1.00	-0.2	-0.40 [-1.24, 0.43]
			Placebo	15	15 (100.0)	-1.09 (1.21)	-3.5	-1.67	-1.33	-0.33	1.5	
		Week 34	Tezepelumab	9	9 (100.0)	-1.59 (0.76)	-2.5	-2.00	-1.83	-1.17	-0.2	-0.29 [-1.12, 0.54]
			Placebo	15	15 (100.0)	-1.27 (1.27)	-4.0	-1.83	-1.33	-0.67	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Non-white	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.28 (1.05)	-2.3	-2.17	-1.67	-0.17	0.3	-0.40 [-1.23, 0.44]
			Placebo	15	15 (100.0)	-0.80 (1.29)	-3.5	-1.33	-1.33	0.17	1.5	
		Week 38	Tezepelumab	9	9 (100.0)	-1.54 (0.75)	-2.5	-2.00	-1.67	-1.33	-0.3	-0.37 [-1.20, 0.46]
			Placebo	15	15 (100.0)	-1.12 (1.29)	-4.0	-1.67	-1.33	-0.50	1.5	
		Week 40	Tezepelumab	9	9 (100.0)	-1.52 (0.79)	-2.5	-2.17	-1.50	-1.17	-0.3	-0.45 [-1.29, 0.38]
			Placebo	15	15 (100.0)	-0.98 (1.37)	-4.0	-1.83	-1.17	0.17	1.5	
		Week 42	Tezepelumab	9	9 (100.0)	-1.56 (0.61)	-2.2	-2.00	-1.67	-1.17	-0.3	-0.42 [-1.25, 0.42]
			Placebo	15	15 (100.0)	-1.16 (1.10)	-4.0	-1.50	-1.17	-0.50	0.5	
		Week 44	Tezepelumab	9	9 (100.0)	-1.57 (0.76)	-2.7	-2.17	-1.50	-1.17	-0.2	-0.53 [-1.37, 0.31]
			Placebo	15	15 (100.0)	-0.93 (1.41)	-4.0	-1.67	-1.33	0.50	1.2	
		Week 46	Tezepelumab	9	9 (100.0)	-1.59 (0.66)	-2.2	-2.00	-1.83	-1.33	-0.2	-0.40 [-1.24, 0.43]
			Placebo	15	15 (100.0)	-1.20 (1.12)	-4.0	-1.67	-1.33	-0.67	0.8	
		Week 48	Tezepelumab	9	9 (100.0)	-1.41 (0.85)	-2.2	-2.00	-1.67	-1.50	0.3	-0.37 [-1.21, 0.46]
			Placebo	15	15 (100.0)	-1.01 (1.16)	-3.7	-1.83	-1.33	0.00	1.0	
		Week 50	Tezepelumab	9	9 (100.0)	-1.54 (0.94)	-2.7	-2.00	-1.67	-1.33	0.2	-0.41 [-1.25, 0.43]
			Placebo	15	15 (100.0)	-1.04 (1.33)	-4.0	-1.50	-1.17	-0.17	1.5	
		Week 52	Tezepelumab	9	9 (100.0)	-1.63 (0.97)	-2.7	-2.33	-2.00	-1.33	0.2	-0.47 [-1.31, 0.37]
			Placebo	15	15 (100.0)	-1.01 (1.46)	-4.0	-1.50	-1.17	0.00	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	10	10 (100.0)	3.00 (1.04)	2.0	2.33	2.75	3.17	4.8	
			Placebo	9	9 (100.0)	2.91 (0.68)	1.8	2.33	3.17	3.33	3.8	
		Week 2	Tezepelumab	10	9 (90.0)	1.96 (1.22)	0.0	1.17	2.17	2.50	3.8	
			Placebo	9	8 (88.9)	2.27 (0.78)	1.2	1.67	2.25	2.83	3.5	
		Week 4	Tezepelumab	10	9 (90.0)	1.87 (0.96)	0.3	1.50	2.00	2.17	3.3	
			Placebo	9	8 (88.9)	2.27 (1.14)	0.7	1.50	2.42	2.83	4.0	
		Week 6	Tezepelumab	10	9 (90.0)	1.83 (1.01)	0.2	1.67	1.83	2.33	3.3	
			Placebo	9	8 (88.9)	2.19 (1.23)	0.5	1.25	2.42	2.58	4.5	
		Week 8	Tezepelumab	10	9 (90.0)	1.37 (0.96)	0.2	0.67	1.33	2.00	3.0	
			Placebo	9	8 (88.9)	1.88 (1.33)	0.2	0.83	1.75	2.83	4.0	
		Week 10	Tezepelumab	10	9 (90.0)	1.13 (0.90)	0.2	0.67	0.83	1.50	3.0	
			Placebo	9	8 (88.9)	2.02 (1.65)	0.0	0.83	1.92	2.67	5.3	
		Week 12	Tezepelumab	10	9 (90.0)	1.20 (0.54)	0.5	0.83	1.17	1.33	2.2	
			Placebo	9	8 (88.9)	1.94 (1.32)	0.0	1.08	1.75	2.92	4.0	
		Week 14	Tezepelumab	10	9 (90.0)	0.94 (0.59)	0.2	0.83	0.83	1.00	2.3	
			Placebo	9	8 (88.9)	2.17 (1.48)	0.3	1.08	2.08	2.83	5.0	
		Week 16	Tezepelumab	10	9 (90.0)	1.43 (0.97)	0.5	0.67	1.33	1.50	3.5	
			Placebo	9	8 (88.9)	2.15 (1.51)	0.2	1.00	2.17	2.83	5.0	
		Week 18	Tezepelumab	10	9 (90.0)	1.13 (0.66)	0.2	0.67	1.33	1.33	2.3	
			Placebo	9	8 (88.9)	2.10 (1.47)	0.2	1.17	2.00	2.67	5.0	
		Week 20	Tezepelumab	10	9 (90.0)	1.15 (0.54)	0.5	0.83	1.00	1.33	2.3	
			Placebo	9	8 (88.9)	1.88 (1.67)	0.2	0.25	2.00	2.67	5.0	
		Week 22	Tezepelumab	10	9 (90.0)	1.00 (0.61)	0.2	0.83	0.83	1.17	2.3	
			Placebo	9	8 (88.9)	1.92 (1.58)	0.0	0.58	2.17	2.42	5.0	
		Week 24	Tezepelumab	10	9 (90.0)	1.11 (0.74)	0.2	0.83	0.83	1.33	2.3	
			Placebo	9	8 (88.9)	1.79 (1.34)	0.2	0.75	1.75	2.50	4.2	
		Week 26	Tezepelumab	10	9 (90.0)	1.06 (0.69)	0.0	0.67	0.83	1.50	2.3	
			Placebo	9	8 (88.9)	1.69 (1.27)	0.3	0.75	1.33	2.42	4.2	
		Week 28	Tezepelumab	10	10 (100.0)	0.97 (0.68)	0.0	0.50	0.83	1.50	2.3	
			Placebo	9	8 (88.9)	1.73 (1.25)	0.3	0.67	1.75	2.25	4.2	
		Week 30	Tezepelumab	10	10 (100.0)	1.00 (0.68)	0.2	0.67	0.83	1.50	2.3	
			Placebo	9	8 (88.9)	1.75 (1.22)	0.3	0.92	1.58	2.25	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
North America/Western EU	Absolute values	Week 32	Tezepelumab	10	10 (100.0)	1.15 (0.64)	0.2	0.67	1.17	1.67	2.3	
			Placebo	9	8 (88.9)	1.63 (1.22)	0.3	0.83	1.42	2.00	4.2	
		Week 34	Tezepelumab	10	10 (100.0)	1.15 (0.63)	0.0	0.83	1.17	1.33	2.3	
			Placebo	9	8 (88.9)	1.63 (1.32)	0.0	0.58	1.58	2.25	4.2	
		Week 36	Tezepelumab	10	10 (100.0)	1.45 (0.73)	0.5	0.83	1.17	2.33	2.3	
			Placebo	9	8 (88.9)	1.92 (1.19)	0.0	1.33	1.92	2.33	4.2	
		Week 38	Tezepelumab	10	10 (100.0)	1.08 (0.60)	0.3	0.67	0.83	1.33	2.3	
			Placebo	9	8 (88.9)	1.88 (1.26)	0.0	1.17	1.67	2.58	4.2	
		Week 40	Tezepelumab	10	10 (100.0)	1.13 (0.75)	0.2	0.67	1.00	1.67	2.3	
			Placebo	9	8 (88.9)	1.85 (1.23)	0.0	1.08	1.92	2.33	4.2	
		Week 42	Tezepelumab	10	10 (100.0)	1.07 (0.69)	0.2	0.67	1.00	1.50	2.3	
			Placebo	9	8 (88.9)	1.52 (0.75)	0.0	1.25	1.58	2.00	2.5	
		Week 44	Tezepelumab	10	10 (100.0)	1.17 (0.66)	0.3	0.67	1.00	1.67	2.3	
			Placebo	9	8 (88.9)	1.63 (0.80)	0.7	1.08	1.25	2.50	2.7	
		Week 46	Tezepelumab	10	10 (100.0)	1.00 (0.68)	0.2	0.67	0.92	1.17	2.3	
			Placebo	9	8 (88.9)	1.58 (0.79)	0.5	1.00	1.42	2.33	2.7	
		Week 48	Tezepelumab	10	10 (100.0)	1.05 (0.63)	0.2	0.67	1.00	1.33	2.3	
			Placebo	9	8 (88.9)	1.52 (0.84)	0.3	0.92	1.42	2.17	2.8	
		Week 50	Tezepelumab	10	10 (100.0)	0.83 (0.69)	0.0	0.17	0.75	1.17	2.3	
			Placebo	9	8 (88.9)	1.85 (0.90)	1.0	1.17	1.58	2.33	3.7	
		Week 52	Tezepelumab	10	10 (100.0)	0.97 (0.64)	0.2	0.67	0.92	1.33	2.3	
			Placebo	9	8 (88.9)	1.85 (1.11)	0.0	1.17	1.92	2.50	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 2	Tezepelumab	10	9 (90.0)	-1.11 (1.02)	-2.8	-1.50	-1.00	-0.17	0.2	-0.54 [-1.51, 0.43]
			Placebo	9	8 (88.9)	-0.56 (1.00)	-2.2	-1.25	-0.50	0.08	1.0	
		Week 4	Tezepelumab	10	9 (90.0)	-1.20 (0.92)	-2.7	-1.83	-1.17	-0.50	0.2	-0.59 [-1.57, 0.39]
			Placebo	9	8 (88.9)	-0.56 (1.25)	-2.7	-1.42	-0.50	0.58	0.8	
		Week 6	Tezepelumab	10	9 (90.0)	-1.24 (1.28)	-3.0	-2.33	-1.33	-0.33	0.3	-0.47 [-1.43, 0.50]
			Placebo	9	8 (88.9)	-0.65 (1.27)	-2.8	-1.25	-0.75	0.17	1.3	
		Week 8	Tezepelumab	10	9 (90.0)	-1.70 (0.91)	-2.8	-2.50	-1.83	-0.83	-0.3	-0.61 [-1.59, 0.36]
			Placebo	9	8 (88.9)	-0.96 (1.49)	-3.2	-2.00	-1.17	0.50	0.8	
		Week 10	Tezepelumab	10	9 (90.0)	-1.94 (1.03)	-3.5	-2.67	-2.00	-1.33	-0.5	-0.79 [-1.78, 0.20]
			Placebo	9	8 (88.9)	-0.81 (1.79)	-3.3	-1.67	-1.33	0.08	2.7	
		Week 12	Tezepelumab	10	9 (90.0)	-1.87 (1.02)	-3.7	-2.33	-1.83	-1.00	-0.5	-0.78 [-1.77, 0.21]
			Placebo	9	8 (88.9)	-0.90 (1.47)	-3.3	-1.67	-1.17	0.25	1.3	
		Week 14	Tezepelumab	10	9 (90.0)	-2.13 (0.88)	-3.8	-2.50	-2.17	-1.50	-1.0	-1.13 [-2.17, -0.10]
			Placebo	9	8 (88.9)	-0.67 (1.63)	-3.0	-1.50	-1.17	0.33	2.3	
		Week 16	Tezepelumab	10	9 (90.0)	-1.65 (1.51)	-4.2	-2.50	-1.83	-0.67	1.2	-0.60 [-1.58, 0.37]
			Placebo	9	8 (88.9)	-0.69 (1.67)	-3.2	-1.42	-1.25	0.33	2.3	
		Week 18	Tezepelumab	10	9 (90.0)	-1.94 (1.18)	-4.2	-2.50	-1.83	-0.67	-0.7	-0.86 [-1.86, 0.14]
			Placebo	9	8 (88.9)	-0.73 (1.64)	-3.2	-1.58	-1.00	0.08	2.3	
		Week 20	Tezepelumab	10	9 (90.0)	-1.93 (1.10)	-4.2	-2.50	-1.83	-1.33	-0.5	-0.64 [-1.62, 0.34]
			Placebo	9	8 (88.9)	-0.96 (1.86)	-3.2	-2.50	-1.00	0.08	2.3	
		Week 22	Tezepelumab	10	9 (90.0)	-2.07 (1.05)	-4.3	-2.50	-1.83	-1.17	-1.0	-0.81 [-1.80, 0.19]
			Placebo	9	8 (88.9)	-0.92 (1.78)	-3.3	-2.17	-1.08	0.08	2.3	
		Week 24	Tezepelumab	10	9 (90.0)	-1.96 (1.32)	-4.5	-2.50	-2.00	-1.50	0.2	-0.65 [-1.63, 0.33]
			Placebo	9	8 (88.9)	-1.04 (1.51)	-3.2	-2.00	-1.25	-0.08	1.5	
		Week 26	Tezepelumab	10	9 (90.0)	-2.02 (1.18)	-4.2	-2.50	-2.00	-1.67	-0.3	-0.66 [-1.65, 0.32]
			Placebo	9	8 (88.9)	-1.15 (1.45)	-2.8	-2.08	-1.50	-0.33	1.5	
		Week 28	Tezepelumab	10	10 (100.0)	-2.03 (1.10)	-4.2	-2.50	-2.00	-1.50	-0.5	-0.75 [-1.71, 0.22]
			Placebo	9	8 (88.9)	-1.10 (1.41)	-2.8	-2.17	-1.25	-0.33	1.5	
		Week 30	Tezepelumab	10	10 (100.0)	-2.00 (1.11)	-4.2	-2.50	-2.08	-1.50	-0.3	-0.75 [-1.72, 0.21]
			Placebo	9	8 (88.9)	-1.08 (1.35)	-2.8	-1.92	-1.33	-0.42	1.5	
		Week 32	Tezepelumab	10	10 (100.0)	-1.85 (1.10)	-4.2	-2.50	-1.92	-1.00	-0.3	-0.53 [-1.48, 0.41]
			Placebo	9	8 (88.9)	-1.21 (1.33)	-2.8	-2.00	-1.50	-0.67	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
North America/Western EU	Change from baseline	Week 34	Tezepelumab	10	10 (100.0)	-1.85 (1.09)	-4.2	-2.33	-1.83	-1.17	-0.2	-0.55 [-1.50, 0.40]
			Placebo	9	8 (88.9)	-1.21 (1.27)	-2.8	-1.92	-1.25	-1.00	1.5	
		Week 36	Tezepelumab	10	10 (100.0)	-1.55 (1.39)	-4.2	-2.50	-1.75	0.00	0.3	-0.47 [-1.42, 0.47]
			Placebo	9	8 (88.9)	-0.92 (1.26)	-2.2	-1.75	-1.33	-0.25	1.5	
		Week 38	Tezepelumab	10	10 (100.0)	-1.92 (1.06)	-4.2	-2.17	-2.00	-1.67	-0.2	-0.78 [-1.75, 0.19]
			Placebo	9	8 (88.9)	-0.96 (1.42)	-2.5	-1.92	-1.42	0.00	1.5	
		Week 40	Tezepelumab	10	10 (100.0)	-1.87 (1.20)	-4.2	-2.50	-1.92	-1.17	0.2	-0.73 [-1.69, 0.23]
			Placebo	9	8 (88.9)	-0.98 (1.24)	-2.2	-1.83	-1.33	-0.42	1.5	
		Week 42	Tezepelumab	10	10 (100.0)	-1.93 (1.10)	-4.2	-2.50	-1.92	-1.17	-0.5	-0.65 [-1.60, 0.31]
			Placebo	9	8 (88.9)	-1.31 (0.74)	-2.2	-1.83	-1.33	-1.08	0.2	
		Week 44	Tezepelumab	10	10 (100.0)	-1.83 (1.14)	-4.2	-2.50	-1.92	-1.17	0.0	-0.60 [-1.56, 0.35]
			Placebo	9	8 (88.9)	-1.21 (0.88)	-2.2	-1.75	-1.42	-0.92	0.7	
		Week 46	Tezepelumab	10	10 (100.0)	-2.00 (1.08)	-4.2	-2.50	-1.92	-1.67	-0.2	-0.75 [-1.71, 0.22]
			Placebo	9	8 (88.9)	-1.25 (0.90)	-2.2	-1.67	-1.42	-1.25	0.8	
		Week 48	Tezepelumab	10	10 (100.0)	-1.95 (1.04)	-4.2	-2.50	-1.92	-1.50	-0.3	-0.61 [-1.56, 0.34]
			Placebo	9	8 (88.9)	-1.31 (1.05)	-2.5	-1.83	-1.58	-1.08	1.0	
		Week 50	Tezepelumab	10	10 (100.0)	-2.17 (0.99)	-4.2	-2.67	-2.17	-1.67	-0.7	-1.14 [-2.15, -0.13]
			Placebo	9	8 (88.9)	-0.98 (1.11)	-2.0	-1.58	-1.33	-0.75	1.5	
		Week 52	Tezepelumab	10	10 (100.0)	-2.03 (1.05)	-4.2	-2.67	-1.92	-1.00	-0.7	-0.87 [-1.85, 0.10]
			Placebo	9	8 (88.9)	-0.98 (1.38)	-2.7	-1.75	-1.33	-0.25	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	127	127 (100.0)	2.68 (0.78)	0.0	2.33	2.67	3.00	4.8	
			Placebo	129	129 (100.0)	2.64 (0.69)	0.3	2.33	2.67	3.00	4.7	
		Week 2	Tezepelumab	127	122 (96.1)	2.18 (0.89)	0.0	1.67	2.25	2.83	4.3	
			Placebo	129	117 (90.7)	2.30 (0.80)	0.2	2.00	2.33	2.83	4.8	
		Week 4	Tezepelumab	127	122 (96.1)	1.89 (0.96)	0.0	1.17	2.00	2.67	4.3	
			Placebo	129	117 (90.7)	2.17 (0.82)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	127	122 (96.1)	1.79 (0.97)	0.0	1.17	1.67	2.50	4.3	
			Placebo	129	118 (91.5)	2.08 (0.95)	0.2	1.50	2.17	2.67	5.5	
		Week 8	Tezepelumab	127	122 (96.1)	1.76 (1.03)	0.0	1.00	1.67	2.67	4.8	
			Placebo	129	119 (92.2)	2.07 (0.93)	0.0	1.50	2.00	2.67	4.7	
		Week 10	Tezepelumab	127	122 (96.1)	1.70 (1.01)	0.0	1.00	1.67	2.33	4.3	
			Placebo	129	120 (93.0)	1.98 (0.86)	0.0	1.33	2.00	2.58	4.2	
		Week 12	Tezepelumab	127	122 (96.1)	1.62 (1.05)	0.0	0.83	1.67	2.50	4.3	
			Placebo	129	120 (93.0)	1.90 (0.91)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	127	122 (96.1)	1.50 (1.02)	0.0	0.67	1.50	2.17	4.3	
			Placebo	129	120 (93.0)	1.82 (0.87)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	127	122 (96.1)	1.62 (1.06)	0.0	0.83	1.67	2.50	4.3	
			Placebo	129	120 (93.0)	1.96 (0.99)	0.0	1.17	2.00	2.67	4.8	
		Week 18	Tezepelumab	127	123 (96.9)	1.53 (0.98)	0.0	0.83	1.50	2.17	4.3	
			Placebo	129	120 (93.0)	1.85 (0.95)	0.0	1.17	1.83	2.42	4.7	
		Week 20	Tezepelumab	127	123 (96.9)	1.61 (1.04)	0.0	0.83	1.67	2.33	5.0	
			Placebo	129	120 (93.0)	1.92 (0.95)	0.0	1.17	2.17	2.67	4.5	
		Week 22	Tezepelumab	127	123 (96.9)	1.64 (0.98)	0.0	1.00	1.67	2.33	4.3	
			Placebo	129	120 (93.0)	1.87 (0.96)	0.0	1.17	2.00	2.67	4.5	
		Week 24	Tezepelumab	127	123 (96.9)	1.63 (1.04)	0.0	0.83	1.67	2.33	4.3	
			Placebo	129	120 (93.0)	1.88 (0.95)	0.0	1.00	2.00	2.50	4.5	
		Week 26	Tezepelumab	127	124 (97.6)	1.59 (1.02)	0.0	0.92	1.50	2.17	4.3	
			Placebo	129	120 (93.0)	1.83 (0.96)	0.0	1.00	1.75	2.58	4.5	
		Week 28	Tezepelumab	127	124 (97.6)	1.66 (1.04)	0.0	1.00	1.67	2.50	4.3	
			Placebo	129	121 (93.8)	1.88 (1.03)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	127	125 (98.4)	1.59 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	129	122 (94.6)	1.87 (1.01)	0.0	1.17	1.83	2.67	4.5	
		Week 32	Tezepelumab	127	125 (98.4)	1.54 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	129	122 (94.6)	1.83 (1.01)	0.0	1.00	1.83	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of world	Absolute values	Week 34	Tezepelumab	127	125 (98.4)	1.55 (1.08)	0.0	0.67	1.50	2.50	4.3	
			Placebo	129	122 (94.6)	1.79 (1.02)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	127	125 (98.4)	1.61 (1.06)	0.0	0.83	1.67	2.33	4.5	
			Placebo	129	122 (94.6)	1.86 (1.03)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	127	125 (98.4)	1.53 (1.06)	0.0	0.83	1.50	2.17	4.5	
			Placebo	129	122 (94.6)	1.77 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	127	125 (98.4)	1.56 (1.06)	0.0	0.67	1.67	2.33	4.3	
			Placebo	129	122 (94.6)	1.86 (1.03)	0.0	1.00	1.83	2.67	4.5	
		Week 42	Tezepelumab	127	125 (98.4)	1.53 (1.06)	0.0	0.83	1.50	2.17	4.7	
			Placebo	129	122 (94.6)	1.84 (1.02)	0.0	1.00	2.00	2.50	4.7	
		Week 44	Tezepelumab	127	125 (98.4)	1.55 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	129	123 (95.3)	1.88 (1.03)	0.0	1.00	2.00	2.67	4.5	
		Week 46	Tezepelumab	127	125 (98.4)	1.53 (1.05)	0.0	0.83	1.33	2.17	4.3	
			Placebo	129	123 (95.3)	1.77 (0.99)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	127	125 (98.4)	1.59 (1.06)	0.0	0.67	1.67	2.33	4.3	
			Placebo	129	123 (95.3)	1.81 (1.02)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	127	125 (98.4)	1.51 (1.04)	0.0	0.83	1.33	2.17	4.3	
			Placebo	129	123 (95.3)	1.76 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 52	Tezepelumab	127	125 (98.4)	1.53 (1.04)	0.0	0.67	1.50	2.17	4.3	
			Placebo	129	123 (95.3)	1.82 (0.99)	0.0	1.00	2.00	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 2	Tezepelumab	127	122 (96.1)	-0.49 (0.62)	-2.5	-0.83	-0.33	0.00	0.7	-0.22 [-0.47, 0.04]
			Placebo	129	117 (90.7)	-0.35 (0.69)	-2.8	-0.83	-0.33	0.00	1.2	
		Week 4	Tezepelumab	127	122 (96.1)	-0.79 (0.88)	-3.5	-1.33	-0.83	-0.17	2.3	-0.36 [-0.62, -0.11]
			Placebo	129	117 (90.7)	-0.48 (0.80)	-3.0	-1.00	-0.33	0.00	1.2	
		Week 6	Tezepelumab	127	122 (96.1)	-0.88 (0.93)	-3.8	-1.50	-0.83	-0.33	2.3	-0.34 [-0.60, -0.09]
			Placebo	129	118 (91.5)	-0.57 (0.87)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	127	122 (96.1)	-0.92 (0.98)	-3.8	-1.50	-1.00	-0.33	2.3	-0.36 [-0.61, -0.10]
			Placebo	129	119 (92.2)	-0.59 (0.85)	-3.0	-1.00	-0.50	0.00	1.0	
		Week 10	Tezepelumab	127	122 (96.1)	-0.98 (0.94)	-3.8	-1.50	-1.00	-0.33	2.3	-0.32 [-0.58, -0.07]
			Placebo	129	120 (93.0)	-0.68 (0.89)	-3.2	-1.25	-0.67	-0.17	2.5	
		Week 12	Tezepelumab	127	122 (96.1)	-1.06 (0.96)	-3.7	-1.67	-1.00	-0.50	2.3	-0.31 [-0.57, -0.06]
			Placebo	129	120 (93.0)	-0.76 (0.93)	-3.2	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	127	122 (96.1)	-1.18 (0.97)	-3.8	-1.83	-1.17	-0.67	2.3	-0.37 [-0.62, -0.11]
			Placebo	129	120 (93.0)	-0.84 (0.89)	-3.2	-1.33	-0.83	-0.33	1.3	
		Week 16	Tezepelumab	127	122 (96.1)	-1.06 (0.99)	-3.8	-1.83	-1.00	-0.33	2.3	-0.36 [-0.62, -0.11]
			Placebo	129	120 (93.0)	-0.70 (0.98)	-3.5	-1.25	-0.67	0.00	2.3	
		Week 18	Tezepelumab	127	123 (96.9)	-1.14 (0.97)	-3.8	-1.83	-1.00	-0.50	2.3	-0.34 [-0.60, -0.09]
			Placebo	129	120 (93.0)	-0.81 (0.97)	-3.2	-1.42	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	127	123 (96.9)	-1.06 (0.98)	-3.8	-1.67	-1.00	-0.33	2.3	-0.33 [-0.58, -0.07]
			Placebo	129	120 (93.0)	-0.74 (0.98)	-3.5	-1.33	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	127	123 (96.9)	-1.03 (1.00)	-3.8	-1.67	-1.00	-0.33	2.3	-0.25 [-0.50, 0.00]
			Placebo	129	120 (93.0)	-0.79 (0.95)	-3.2	-1.50	-0.75	-0.25	2.3	
		Week 24	Tezepelumab	127	123 (96.9)	-1.04 (0.93)	-3.8	-1.67	-1.00	-0.33	2.3	-0.27 [-0.52, -0.02]
			Placebo	129	120 (93.0)	-0.78 (1.00)	-3.5	-1.50	-0.67	-0.08	2.3	
		Week 26	Tezepelumab	127	124 (97.6)	-1.07 (1.00)	-3.8	-1.75	-1.00	-0.33	2.3	-0.24 [-0.49, 0.01]
			Placebo	129	120 (93.0)	-0.83 (1.02)	-4.0	-1.50	-0.92	-0.17	2.3	
		Week 28	Tezepelumab	127	124 (97.6)	-1.01 (1.00)	-3.8	-1.67	-1.00	-0.17	2.3	-0.24 [-0.49, 0.01]
			Placebo	129	121 (93.8)	-0.76 (1.05)	-4.0	-1.50	-0.67	-0.17	2.3	
		Week 30	Tezepelumab	127	125 (98.4)	-1.07 (1.01)	-3.7	-1.83	-1.00	-0.50	2.3	-0.30 [-0.55, -0.05]
			Placebo	129	122 (94.6)	-0.77 (1.04)	-3.2	-1.50	-0.75	-0.17	2.3	
		Week 32	Tezepelumab	127	125 (98.4)	-1.13 (1.03)	-3.8	-1.83	-1.00	-0.67	2.3	-0.31 [-0.56, -0.06]
			Placebo	129	122 (94.6)	-0.81 (1.02)	-3.5	-1.50	-0.67	-0.17	2.3	
		Week 34	Tezepelumab	127	125 (98.4)	-1.12 (1.05)	-3.8	-2.00	-1.00	-0.50	2.3	-0.25 [-0.51, -0.00]
			Placebo	129	122 (94.6)	-0.85 (1.03)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of world	Change from baseline	Week 36	Tezepelumab	127	125 (98.4)	-1.06 (1.07)	-3.8	-1.83	-1.00	-0.33	2.3	-0.25 [-0.50, -0.00]
			Placebo	129	122 (94.6)	-0.79 (1.07)	-3.5	-1.33	-0.83	0.00	2.3	
		Week 38	Tezepelumab	127	125 (98.4)	-1.13 (1.07)	-3.8	-1.83	-1.17	-0.33	2.3	-0.25 [-0.50, 0.00]
			Placebo	129	122 (94.6)	-0.87 (1.04)	-4.0	-1.33	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	127	125 (98.4)	-1.11 (1.07)	-3.8	-1.83	-1.00	-0.33	2.3	-0.31 [-0.56, -0.05]
			Placebo	129	122 (94.6)	-0.79 (1.05)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 42	Tezepelumab	127	125 (98.4)	-1.13 (1.07)	-3.8	-1.83	-1.17	-0.50	2.3	-0.32 [-0.57, -0.07]
			Placebo	129	122 (94.6)	-0.80 (1.05)	-4.0	-1.33	-0.83	-0.17	2.3	
		Week 44	Tezepelumab	127	125 (98.4)	-1.12 (1.08)	-4.3	-1.83	-1.00	-0.50	2.3	-0.33 [-0.58, -0.08]
			Placebo	129	123 (95.3)	-0.76 (1.07)	-4.0	-1.50	-0.67	0.00	2.3	
		Week 46	Tezepelumab	127	125 (98.4)	-1.14 (1.07)	-4.2	-1.83	-1.00	-0.50	2.3	-0.26 [-0.51, -0.01]
			Placebo	129	123 (95.3)	-0.87 (1.04)	-4.0	-1.50	-1.00	-0.17	2.3	
		Week 48	Tezepelumab	127	125 (98.4)	-1.08 (1.07)	-4.2	-1.83	-1.00	-0.33	2.3	-0.23 [-0.48, 0.02]
			Placebo	129	123 (95.3)	-0.83 (1.06)	-3.7	-1.50	-0.83	-0.17	2.3	
		Week 50	Tezepelumab	127	125 (98.4)	-1.15 (1.06)	-3.8	-1.83	-1.17	-0.50	2.3	-0.27 [-0.52, -0.02]
			Placebo	129	123 (95.3)	-0.88 (1.02)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 52	Tezepelumab	127	125 (98.4)	-1.14 (1.07)	-4.2	-1.83	-1.00	-0.50	2.3	-0.30 [-0.55, -0.05]
			Placebo	129	123 (95.3)	-0.82 (1.03)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	61	61 (100.0)	2.66 (0.70)	0.0	2.33	2.67	3.00	4.5	
			Placebo	60	60 (100.0)	2.78 (0.65)	1.7	2.33	2.67	3.00	4.7	
		Week 2	Tezepelumab	61	58 (95.1)	2.19 (0.84)	0.0	1.67	2.33	2.67	3.7	
			Placebo	60	55 (91.7)	2.26 (0.83)	0.3	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	61	58 (95.1)	1.90 (0.82)	0.2	1.17	2.00	2.50	3.5	
			Placebo	60	55 (91.7)	2.04 (0.88)	0.2	1.50	2.00	2.67	3.7	
		Week 6	Tezepelumab	61	58 (95.1)	1.83 (0.84)	0.0	1.33	1.92	2.50	3.7	
			Placebo	60	55 (91.7)	1.97 (1.03)	0.2	1.17	2.00	2.50	5.5	
		Week 8	Tezepelumab	61	58 (95.1)	1.79 (0.86)	0.0	1.33	1.83	2.67	3.3	
			Placebo	60	55 (91.7)	2.01 (0.99)	0.0	1.17	2.00	2.67	4.7	
		Week 10	Tezepelumab	61	58 (95.1)	1.71 (0.90)	0.0	1.33	1.67	2.33	4.3	
			Placebo	60	55 (91.7)	1.98 (0.90)	0.2	1.33	2.00	2.67	4.2	
		Week 12	Tezepelumab	61	58 (95.1)	1.67 (0.96)	0.0	1.00	1.50	2.50	4.3	
			Placebo	60	55 (91.7)	1.85 (0.89)	0.0	1.17	2.00	2.50	4.3	
		Week 14	Tezepelumab	61	58 (95.1)	1.53 (0.86)	0.0	1.00	1.42	2.17	4.3	
			Placebo	60	55 (91.7)	1.84 (0.92)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	61	58 (95.1)	1.72 (1.01)	0.0	1.00	1.67	2.50	4.3	
			Placebo	60	55 (91.7)	1.90 (1.03)	0.0	1.17	1.83	2.67	4.8	
		Week 18	Tezepelumab	61	59 (96.7)	1.58 (0.82)	0.0	1.00	1.67	2.00	4.3	
			Placebo	60	55 (91.7)	1.82 (1.07)	0.0	0.83	1.83	2.67	4.7	
		Week 20	Tezepelumab	61	59 (96.7)	1.69 (0.89)	0.0	1.17	1.83	2.33	4.3	
			Placebo	60	55 (91.7)	1.83 (1.01)	0.0	1.00	1.83	2.67	4.5	
		Week 22	Tezepelumab	61	59 (96.7)	1.70 (0.87)	0.0	1.17	1.83	2.33	4.3	
			Placebo	60	55 (91.7)	1.79 (1.03)	0.0	0.83	1.83	2.67	4.5	
		Week 24	Tezepelumab	61	59 (96.7)	1.69 (0.98)	0.0	1.00	1.67	2.33	4.3	
			Placebo	60	55 (91.7)	1.84 (1.03)	0.0	0.83	2.00	2.50	4.5	
		Week 26	Tezepelumab	61	60 (98.4)	1.63 (0.93)	0.0	1.08	1.58	2.17	4.3	
			Placebo	60	55 (91.7)	1.78 (1.01)	0.0	1.00	1.67	2.67	4.5	
		Week 28	Tezepelumab	61	60 (98.4)	1.71 (0.95)	0.0	1.17	1.67	2.42	4.3	
			Placebo	60	55 (91.7)	1.89 (1.09)	0.0	0.83	2.00	2.67	4.5	
		Week 30	Tezepelumab	61	61 (100.0)	1.63 (0.96)	0.0	0.83	1.67	2.33	4.3	
			Placebo	60	55 (91.7)	1.75 (1.06)	0.0	0.83	1.67	2.67	4.5	
		Week 32	Tezepelumab	61	61 (100.0)	1.59 (0.92)	0.0	1.00	1.50	2.33	4.3	
			Placebo	60	55 (91.7)	1.79 (1.10)	0.0	0.83	1.50	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 250 cells/uL	Absolute values	Week 34	Tezepelumab	61	61 (100.0)	1.60 (0.98)	0.0	1.00	1.50	2.50	4.3	
			Placebo	60	55 (91.7)	1.77 (1.09)	0.0	0.83	1.83	2.50	4.5	
		Week 36	Tezepelumab	61	61 (100.0)	1.63 (0.91)	0.0	1.00	1.67	2.17	4.3	
			Placebo	60	55 (91.7)	1.78 (1.09)	0.0	0.83	1.83	2.67	4.5	
		Week 38	Tezepelumab	61	61 (100.0)	1.60 (0.94)	0.0	1.00	1.67	2.17	4.3	
			Placebo	60	55 (91.7)	1.75 (1.08)	0.0	0.83	1.67	2.67	4.5	
		Week 40	Tezepelumab	61	61 (100.0)	1.66 (0.97)	0.0	0.83	1.83	2.17	4.3	
			Placebo	60	55 (91.7)	1.77 (1.10)	0.0	0.83	1.83	2.67	4.5	
		Week 42	Tezepelumab	61	61 (100.0)	1.59 (0.97)	0.0	1.00	1.67	2.00	4.3	
			Placebo	60	55 (91.7)	1.75 (1.02)	0.0	0.83	1.83	2.50	4.5	
		Week 44	Tezepelumab	61	61 (100.0)	1.65 (0.97)	0.0	1.00	1.67	2.50	4.3	
			Placebo	60	55 (91.7)	1.84 (1.06)	0.0	0.83	2.00	2.50	4.5	
		Week 46	Tezepelumab	61	61 (100.0)	1.61 (0.95)	0.0	1.00	1.83	2.17	4.3	
			Placebo	60	55 (91.7)	1.75 (1.03)	0.0	0.83	1.83	2.50	4.5	
		Week 48	Tezepelumab	61	61 (100.0)	1.61 (0.94)	0.0	1.00	1.67	2.17	4.3	
			Placebo	60	55 (91.7)	1.75 (1.08)	0.0	0.83	2.00	2.67	4.5	
		Week 50	Tezepelumab	61	61 (100.0)	1.54 (0.96)	0.0	0.83	1.67	2.17	4.3	
			Placebo	60	55 (91.7)	1.82 (1.03)	0.0	1.00	1.83	2.50	4.5	
		Week 52	Tezepelumab	61	61 (100.0)	1.53 (0.97)	0.0	0.83	1.67	2.17	4.3	
			Placebo	60	55 (91.7)	1.85 (1.04)	0.0	1.00	2.17	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 2	Tezepelumab	61	58 (95.1)	-0.49 (0.72)	-2.8	-0.67	-0.33	0.00	0.5	-0.01 [-0.38, 0.36]
			Placebo	60	55 (91.7)	-0.48 (0.68)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	61	58 (95.1)	-0.78 (0.71)	-2.7	-1.17	-0.67	-0.33	0.7	-0.09 [-0.46, 0.28]
			Placebo	60	55 (91.7)	-0.71 (0.80)	-3.0	-1.33	-0.67	-0.17	1.2	
		Week 6	Tezepelumab	61	58 (95.1)	-0.85 (0.79)	-2.8	-1.33	-0.75	-0.17	0.5	-0.09 [-0.46, 0.27]
			Placebo	60	55 (91.7)	-0.78 (0.85)	-3.3	-1.33	-0.67	-0.17	1.0	
		Week 8	Tezepelumab	61	58 (95.1)	-0.89 (0.81)	-2.8	-1.50	-0.83	-0.33	0.7	-0.18 [-0.55, 0.19]
			Placebo	60	55 (91.7)	-0.74 (0.85)	-3.0	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	61	58 (95.1)	-0.97 (0.86)	-2.8	-1.33	-1.00	-0.33	0.8	-0.23 [-0.60, 0.14]
			Placebo	60	55 (91.7)	-0.77 (0.90)	-3.2	-1.33	-0.67	-0.33	2.0	
		Week 12	Tezepelumab	61	58 (95.1)	-1.01 (0.84)	-2.7	-1.67	-1.00	-0.33	0.5	-0.13 [-0.50, 0.24]
			Placebo	60	55 (91.7)	-0.90 (0.87)	-3.2	-1.33	-0.83	-0.33	0.8	
		Week 14	Tezepelumab	61	58 (95.1)	-1.15 (0.81)	-2.8	-1.83	-1.17	-0.50	0.5	-0.29 [-0.66, 0.08]
			Placebo	60	55 (91.7)	-0.91 (0.86)	-3.2	-1.50	-0.83	-0.33	0.8	
		Week 16	Tezepelumab	61	58 (95.1)	-0.96 (0.95)	-2.7	-1.67	-1.00	-0.33	1.5	-0.13 [-0.50, 0.24]
			Placebo	60	55 (91.7)	-0.84 (0.91)	-2.8	-1.33	-1.00	0.00	0.8	
		Week 18	Tezepelumab	61	59 (96.7)	-1.09 (0.80)	-3.2	-1.50	-1.00	-0.67	0.5	-0.19 [-0.56, 0.18]
			Placebo	60	55 (91.7)	-0.92 (0.95)	-3.2	-1.50	-1.00	-0.17	1.5	
		Week 20	Tezepelumab	61	59 (96.7)	-0.98 (0.84)	-2.7	-1.67	-0.83	-0.33	0.7	-0.08 [-0.44, 0.29]
			Placebo	60	55 (91.7)	-0.91 (0.95)	-3.0	-1.50	-0.83	-0.33	1.0	
		Week 22	Tezepelumab	61	59 (96.7)	-0.97 (0.95)	-3.2	-1.67	-0.83	-0.33	1.8	-0.02 [-0.38, 0.35]
			Placebo	60	55 (91.7)	-0.95 (0.94)	-3.2	-1.50	-1.00	-0.17	0.7	
		Week 24	Tezepelumab	61	59 (96.7)	-0.97 (0.83)	-2.8	-1.50	-1.00	-0.33	0.7	-0.07 [-0.44, 0.30]
			Placebo	60	55 (91.7)	-0.91 (0.98)	-3.2	-1.50	-1.00	-0.17	0.7	
		Week 26	Tezepelumab	61	60 (98.4)	-1.02 (0.90)	-3.0	-1.67	-1.00	-0.33	0.7	-0.06 [-0.43, 0.30]
			Placebo	60	55 (91.7)	-0.96 (0.92)	-2.7	-1.50	-1.17	-0.33	1.0	
		Week 28	Tezepelumab	61	60 (98.4)	-0.94 (0.94)	-3.0	-1.67	-1.00	-0.17	0.8	-0.09 [-0.45, 0.28]
			Placebo	60	55 (91.7)	-0.85 (0.98)	-2.8	-1.50	-0.83	-0.17	1.2	
		Week 30	Tezepelumab	61	61 (100.0)	-1.04 (0.97)	-2.8	-1.67	-1.00	-0.33	1.8	-0.04 [-0.40, 0.33]
			Placebo	60	55 (91.7)	-1.00 (0.92)	-3.2	-1.50	-1.00	-0.33	0.7	
		Week 32	Tezepelumab	61	61 (100.0)	-1.07 (0.92)	-3.3	-1.67	-1.00	-0.50	0.8	-0.12 [-0.48, 0.25]
			Placebo	60	55 (91.7)	-0.96 (0.99)	-3.0	-1.67	-1.00	-0.33	1.5	
		Week 34	Tezepelumab	61	61 (100.0)	-1.06 (0.99)	-3.3	-1.67	-1.00	-0.33	2.0	-0.08 [-0.45, 0.28]
			Placebo	60	55 (91.7)	-0.98 (0.95)	-3.2	-1.50	-1.00	-0.50	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 250 cells/uL	Change from baseline	Week 36	Tezepelumab	61	61 (100.0)	-1.04 (0.92)	-3.2	-1.67	-1.00	-0.50	1.5	-0.07 [-0.44, 0.29]
			Placebo	60	55 (91.7)	-0.96 (1.02)	-3.5	-1.50	-1.00	-0.33	1.5	
		Week 38	Tezepelumab	61	61 (100.0)	-1.06 (0.96)	-3.5	-1.67	-1.00	-0.50	2.3	-0.07 [-0.43, 0.30]
			Placebo	60	55 (91.7)	-0.99 (1.02)	-3.2	-1.67	-1.17	-0.17	1.5	
		Week 40	Tezepelumab	61	61 (100.0)	-1.00 (0.99)	-3.8	-1.50	-1.00	-0.33	1.7	-0.03 [-0.39, 0.34]
			Placebo	60	55 (91.7)	-0.98 (0.99)	-3.2	-1.67	-1.17	-0.17	0.8	
		Week 42	Tezepelumab	61	61 (100.0)	-1.07 (0.96)	-3.2	-1.67	-1.00	-0.50	2.0	-0.08 [-0.44, 0.29]
			Placebo	60	55 (91.7)	-1.00 (0.89)	-2.8	-1.50	-1.17	-0.33	0.7	
		Week 44	Tezepelumab	61	61 (100.0)	-1.01 (0.98)	-3.5	-1.50	-1.00	-0.17	1.5	-0.10 [-0.47, 0.26]
			Placebo	60	55 (91.7)	-0.91 (0.99)	-3.3	-1.50	-1.00	-0.17	0.8	
		Week 46	Tezepelumab	61	61 (100.0)	-1.05 (0.94)	-3.3	-1.67	-1.00	-0.33	1.7	-0.06 [-0.42, 0.31]
			Placebo	60	55 (91.7)	-1.00 (0.97)	-3.2	-1.50	-1.17	-0.33	0.8	
		Week 48	Tezepelumab	61	61 (100.0)	-1.05 (0.93)	-3.2	-1.67	-1.00	-0.50	1.8	-0.06 [-0.42, 0.31]
			Placebo	60	55 (91.7)	-0.99 (1.04)	-3.3	-1.50	-1.00	-0.50	1.0	
		Week 50	Tezepelumab	61	61 (100.0)	-1.12 (0.98)	-3.5	-1.67	-1.17	-0.50	1.8	-0.20 [-0.56, 0.17]
			Placebo	60	55 (91.7)	-0.92 (0.99)	-3.5	-1.50	-1.00	-0.33	1.5	
		Week 52	Tezepelumab	61	61 (100.0)	-1.13 (1.00)	-3.5	-1.67	-1.00	-0.50	1.8	-0.23 [-0.59, 0.14]
			Placebo	60	55 (91.7)	-0.90 (1.02)	-3.5	-1.50	-1.00	-0.17	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	76	76 (100.0)	2.73 (0.87)	0.3	2.17	2.67	3.17	4.8	
			Placebo	78	78 (100.0)	2.56 (0.70)	0.3	2.17	2.67	3.00	4.2	
		Week 2	Tezepelumab	76	73 (96.1)	2.15 (0.97)	0.0	1.50	2.17	2.83	4.3	
			Placebo	78	70 (89.7)	2.33 (0.77)	0.2	2.00	2.33	2.83	4.3	
		Week 4	Tezepelumab	76	73 (96.1)	1.87 (1.06)	0.0	1.17	1.83	2.67	4.3	
			Placebo	78	70 (89.7)	2.29 (0.80)	0.5	1.83	2.33	2.67	4.2	
		Week 6	Tezepelumab	76	73 (96.1)	1.77 (1.06)	0.0	1.00	1.67	2.50	4.3	
			Placebo	78	71 (91.0)	2.17 (0.90)	0.2	1.67	2.17	2.67	4.7	
		Week 8	Tezepelumab	76	73 (96.1)	1.68 (1.14)	0.0	0.83	1.50	2.50	4.8	
			Placebo	78	72 (92.3)	2.09 (0.93)	0.0	1.50	2.17	2.67	4.0	
		Week 10	Tezepelumab	76	73 (96.1)	1.61 (1.09)	0.0	0.67	1.50	2.33	4.3	
			Placebo	78	73 (93.6)	1.98 (0.93)	0.0	1.33	2.00	2.50	5.3	
		Week 12	Tezepelumab	76	73 (96.1)	1.53 (1.08)	0.0	0.50	1.50	2.33	4.3	
			Placebo	78	73 (93.6)	1.94 (0.97)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	76	73 (96.1)	1.40 (1.10)	0.0	0.50	1.33	2.17	4.3	
			Placebo	78	73 (93.6)	1.84 (0.91)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	76	73 (96.1)	1.52 (1.08)	0.0	0.67	1.33	2.50	4.3	
			Placebo	78	73 (93.6)	2.02 (1.03)	0.0	1.33	2.17	2.67	5.0	
		Week 18	Tezepelumab	76	73 (96.1)	1.44 (1.07)	0.0	0.67	1.33	2.17	4.3	
			Placebo	78	73 (93.6)	1.90 (0.92)	0.0	1.33	2.00	2.33	5.0	
		Week 20	Tezepelumab	76	73 (96.1)	1.50 (1.11)	0.0	0.50	1.50	2.17	5.0	
			Placebo	78	73 (93.6)	1.98 (1.00)	0.0	1.33	2.17	2.67	5.0	
		Week 22	Tezepelumab	76	73 (96.1)	1.51 (1.04)	0.0	0.67	1.50	2.33	4.3	
			Placebo	78	73 (93.6)	1.93 (0.98)	0.0	1.33	2.00	2.50	5.0	
		Week 24	Tezepelumab	76	73 (96.1)	1.51 (1.07)	0.0	0.50	1.50	2.33	4.3	
			Placebo	78	73 (93.6)	1.90 (0.94)	0.0	1.17	2.00	2.50	4.2	
		Week 26	Tezepelumab	76	73 (96.1)	1.49 (1.07)	0.0	0.67	1.50	2.33	4.3	
			Placebo	78	73 (93.6)	1.85 (0.96)	0.0	1.17	1.67	2.50	4.2	
		Week 28	Tezepelumab	76	74 (97.4)	1.52 (1.09)	0.0	0.50	1.50	2.50	4.3	
			Placebo	78	74 (94.9)	1.86 (1.01)	0.0	1.00	2.00	2.50	4.2	
		Week 30	Tezepelumab	76	74 (97.4)	1.49 (1.03)	0.0	0.67	1.50	2.17	4.3	
			Placebo	78	75 (96.2)	1.95 (0.98)	0.0	1.33	2.00	2.50	4.2	
		Week 32	Tezepelumab	76	74 (97.4)	1.44 (1.10)	0.0	0.50	1.42	2.33	4.3	
			Placebo	78	75 (96.2)	1.84 (0.97)	0.0	1.17	1.83	2.50	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 250 cells/uL	Absolute values	Week 34	Tezepelumab	76	74 (97.4)	1.45 (1.12)	0.0	0.50	1.33	2.17	4.3	
			Placebo	78	75 (96.2)	1.79 (1.00)	0.0	1.00	1.83	2.50	4.2	
		Week 36	Tezepelumab	76	74 (97.4)	1.58 (1.14)	0.0	0.67	1.50	2.33	4.5	
			Placebo	78	75 (96.2)	1.92 (1.00)	0.0	1.17	2.00	2.67	4.2	
		Week 38	Tezepelumab	76	74 (97.4)	1.42 (1.10)	0.0	0.50	1.33	2.17	4.5	
			Placebo	78	75 (96.2)	1.80 (0.97)	0.0	1.00	1.83	2.50	4.2	
		Week 40	Tezepelumab	76	74 (97.4)	1.42 (1.09)	0.0	0.50	1.42	2.17	4.3	
			Placebo	78	75 (96.2)	1.92 (0.99)	0.0	1.17	2.00	2.67	4.2	
		Week 42	Tezepelumab	76	74 (97.4)	1.42 (1.10)	0.0	0.67	1.33	2.17	4.7	
			Placebo	78	75 (96.2)	1.88 (1.00)	0.0	1.17	2.00	2.50	4.7	
		Week 44	Tezepelumab	76	74 (97.4)	1.41 (1.06)	0.0	0.50	1.33	2.33	4.3	
			Placebo	78	76 (97.4)	1.88 (0.98)	0.0	1.08	2.00	2.67	4.2	
		Week 46	Tezepelumab	76	74 (97.4)	1.39 (1.09)	0.0	0.67	1.17	2.33	4.3	
			Placebo	78	76 (97.4)	1.77 (0.94)	0.0	1.17	1.92	2.42	3.8	
		Week 48	Tezepelumab	76	74 (97.4)	1.49 (1.13)	0.0	0.67	1.33	2.33	4.3	
			Placebo	78	76 (97.4)	1.82 (0.97)	0.0	1.08	2.00	2.50	4.2	
		Week 50	Tezepelumab	76	74 (97.4)	1.40 (1.09)	0.0	0.67	1.17	2.17	4.3	
			Placebo	78	76 (97.4)	1.73 (0.92)	0.0	1.00	1.75	2.42	3.8	
		Week 52	Tezepelumab	76	74 (97.4)	1.45 (1.07)	0.0	0.67	1.33	2.17	4.3	
			Placebo	78	76 (97.4)	1.80 (0.97)	0.0	1.00	1.92	2.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 2	Tezepelumab	76	73 (96.1)	-0.57 (0.64)	-2.0	-1.00	-0.67	-0.17	0.7	-0.44 [-0.77, -0.11]
			Placebo	78	70 (89.7)	-0.27 (0.72)	-2.7	-0.67	-0.17	0.17	1.2	
		Week 4	Tezepelumab	76	73 (96.1)	-0.85 (1.00)	-3.5	-1.50	-0.83	-0.17	2.3	-0.58 [-0.92, -0.25]
			Placebo	78	70 (89.7)	-0.31 (0.82)	-2.7	-0.83	-0.17	0.33	1.2	
		Week 6	Tezepelumab	76	73 (96.1)	-0.95 (1.07)	-3.8	-1.50	-1.00	-0.33	2.3	-0.53 [-0.86, -0.20]
			Placebo	78	71 (91.0)	-0.42 (0.90)	-2.8	-1.00	-0.33	0.17	1.5	
		Week 8	Tezepelumab	76	73 (96.1)	-1.04 (1.12)	-3.8	-1.83	-1.00	-0.33	2.3	-0.51 [-0.84, -0.18]
			Placebo	78	72 (92.3)	-0.51 (0.94)	-3.2	-0.92	-0.50	0.17	1.0	
		Week 10	Tezepelumab	76	73 (96.1)	-1.11 (1.06)	-3.8	-1.83	-1.17	-0.50	2.3	-0.46 [-0.79, -0.13]
			Placebo	78	73 (93.6)	-0.63 (1.00)	-3.3	-1.17	-0.50	0.00	2.7	
		Week 12	Tezepelumab	76	73 (96.1)	-1.20 (1.08)	-3.7	-2.00	-1.17	-0.50	2.3	-0.50 [-0.83, -0.17]
			Placebo	78	73 (93.6)	-0.68 (1.02)	-3.3	-1.33	-0.50	0.00	1.3	
		Week 14	Tezepelumab	76	73 (96.1)	-1.32 (1.12)	-3.8	-2.00	-1.33	-0.67	2.3	-0.52 [-0.85, -0.19]
			Placebo	78	73 (93.6)	-0.77 (1.01)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 16	Tezepelumab	76	73 (96.1)	-1.21 (1.09)	-4.2	-2.00	-1.00	-0.67	2.3	-0.56 [-0.89, -0.23]
			Placebo	78	73 (93.6)	-0.59 (1.10)	-3.5	-1.17	-0.50	0.00	2.3	
		Week 18	Tezepelumab	76	73 (96.1)	-1.29 (1.13)	-4.2	-2.00	-1.17	-0.67	2.3	-0.52 [-0.85, -0.19]
			Placebo	78	73 (93.6)	-0.72 (1.06)	-3.2	-1.33	-0.50	-0.17	2.3	
		Week 20	Tezepelumab	76	73 (96.1)	-1.23 (1.12)	-4.2	-2.00	-1.33	-0.50	2.3	-0.54 [-0.87, -0.21]
			Placebo	78	73 (93.6)	-0.63 (1.10)	-3.5	-1.17	-0.50	-0.17	2.3	
		Week 22	Tezepelumab	76	73 (96.1)	-1.21 (1.09)	-4.3	-2.00	-1.17	-0.67	2.3	-0.50 [-0.83, -0.17]
			Placebo	78	73 (93.6)	-0.68 (1.05)	-3.3	-1.17	-0.50	-0.17	2.3	
		Week 24	Tezepelumab	76	73 (96.1)	-1.21 (1.08)	-4.5	-1.83	-1.17	-0.50	2.3	-0.46 [-0.79, -0.13]
			Placebo	78	73 (93.6)	-0.71 (1.08)	-3.5	-1.33	-0.67	0.00	2.3	
		Week 26	Tezepelumab	76	73 (96.1)	-1.23 (1.13)	-4.2	-2.00	-1.17	-0.50	2.3	-0.41 [-0.74, -0.09]
			Placebo	78	73 (93.6)	-0.76 (1.12)	-4.0	-1.50	-0.67	-0.17	2.3	
		Week 28	Tezepelumab	76	74 (97.4)	-1.20 (1.10)	-4.2	-2.00	-1.17	-0.50	2.3	-0.43 [-0.75, -0.10]
			Placebo	78	74 (94.9)	-0.72 (1.14)	-4.0	-1.50	-0.67	-0.17	2.3	
		Week 30	Tezepelumab	76	74 (97.4)	-1.23 (1.10)	-4.2	-2.00	-1.08	-0.67	2.3	-0.53 [-0.86, -0.21]
			Placebo	78	75 (96.2)	-0.63 (1.13)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 32	Tezepelumab	76	74 (97.4)	-1.28 (1.14)	-4.2	-2.00	-1.25	-0.67	2.3	-0.48 [-0.80, -0.15]
			Placebo	78	75 (96.2)	-0.75 (1.07)	-3.5	-1.50	-0.67	-0.17	2.3	
		Week 34	Tezepelumab	76	74 (97.4)	-1.26 (1.12)	-4.2	-2.00	-1.25	-0.67	2.3	-0.42 [-0.74, -0.10]
			Placebo	78	75 (96.2)	-0.80 (1.11)	-4.0	-1.50	-0.67	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 250 cells/uL	Change from baseline	Week 36	Tezepelumab	76	74 (97.4)	-1.14 (1.23)	-4.2	-2.00	-1.25	-0.33	2.3	-0.40 [-0.73, -0.08]
			Placebo	78	75 (96.2)	-0.67 (1.10)	-3.5	-1.33	-0.50	0.17	2.3	
		Week 38	Tezepelumab	76	74 (97.4)	-1.30 (1.17)	-4.2	-2.00	-1.33	-0.33	2.3	-0.45 [-0.78, -0.13]
			Placebo	78	75 (96.2)	-0.79 (1.09)	-4.0	-1.33	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	76	74 (97.4)	-1.30 (1.16)	-4.2	-2.17	-1.33	-0.67	2.3	-0.56 [-0.89, -0.23]
			Placebo	78	75 (96.2)	-0.67 (1.10)	-4.0	-1.33	-0.67	0.00	2.3	
		Week 42	Tezepelumab	76	74 (97.4)	-1.30 (1.18)	-4.2	-2.00	-1.33	-0.50	2.3	-0.51 [-0.84, -0.18]
			Placebo	78	75 (96.2)	-0.71 (1.13)	-4.0	-1.33	-0.83	0.00	2.3	
		Week 44	Tezepelumab	76	74 (97.4)	-1.31 (1.17)	-4.3	-2.00	-1.17	-0.67	2.3	-0.53 [-0.86, -0.20]
			Placebo	78	76 (97.4)	-0.70 (1.11)	-4.0	-1.50	-0.67	0.00	2.3	
		Week 46	Tezepelumab	76	74 (97.4)	-1.33 (1.18)	-4.2	-2.17	-1.33	-0.67	2.3	-0.46 [-0.78, -0.13]
			Placebo	78	76 (97.4)	-0.82 (1.08)	-4.0	-1.42	-0.92	-0.17	2.3	
		Week 48	Tezepelumab	76	74 (97.4)	-1.23 (1.21)	-4.2	-2.00	-1.25	-0.33	2.3	-0.40 [-0.73, -0.08]
			Placebo	78	76 (97.4)	-0.77 (1.08)	-3.7	-1.50	-0.75	-0.17	2.3	
		Week 50	Tezepelumab	76	74 (97.4)	-1.32 (1.17)	-4.2	-2.00	-1.33	-0.50	2.3	-0.42 [-0.74, -0.10]
			Placebo	78	76 (97.4)	-0.86 (1.04)	-4.0	-1.58	-0.83	-0.17	2.3	
		Week 52	Tezepelumab	76	74 (97.4)	-1.26 (1.17)	-4.2	-2.00	-1.25	-0.67	2.3	-0.43 [-0.75, -0.11]
			Placebo	78	76 (97.4)	-0.78 (1.07)	-4.0	-1.50	-0.67	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	75	75 (100.0)	2.68 (0.65)	0.8	2.33	2.67	3.00	4.5	
			Placebo	72	72 (100.0)	2.62 (0.65)	0.3	2.33	2.67	3.00	4.2	
		Week 2	Tezepelumab	75	70 (93.3)	2.19 (0.93)	0.0	1.50	2.25	2.83	4.2	
			Placebo	72	64 (88.9)	2.21 (0.70)	0.3	1.83	2.25	2.75	4.3	
		Week 4	Tezepelumab	75	70 (93.3)	1.94 (0.88)	0.0	1.33	2.00	2.67	3.5	
			Placebo	72	64 (88.9)	2.03 (0.80)	0.2	1.50	2.17	2.67	4.2	
		Week 6	Tezepelumab	75	70 (93.3)	1.88 (0.91)	0.0	1.33	1.83	2.50	4.0	
			Placebo	72	64 (88.9)	1.96 (0.87)	0.2	1.33	2.00	2.50	4.7	
		Week 8	Tezepelumab	75	70 (93.3)	1.82 (0.99)	0.0	1.17	1.67	2.67	4.8	
			Placebo	72	64 (88.9)	2.05 (0.85)	0.0	1.58	2.00	2.75	4.0	
		Week 10	Tezepelumab	75	70 (93.3)	1.76 (1.01)	0.0	1.17	1.67	2.67	4.3	
			Placebo	72	65 (90.3)	1.90 (0.83)	0.0	1.33	2.00	2.33	4.2	
		Week 12	Tezepelumab	75	70 (93.3)	1.71 (1.03)	0.0	0.83	1.67	2.50	4.3	
			Placebo	72	65 (90.3)	1.88 (0.88)	0.0	1.33	2.00	2.33	4.3	
		Week 14	Tezepelumab	75	70 (93.3)	1.54 (0.99)	0.0	0.83	1.50	2.17	4.3	
			Placebo	72	65 (90.3)	1.81 (0.83)	0.0	1.33	1.83	2.50	4.2	
		Week 16	Tezepelumab	75	70 (93.3)	1.75 (1.05)	0.0	1.00	1.75	2.50	4.3	
			Placebo	72	65 (90.3)	1.91 (0.88)	0.0	1.33	1.83	2.50	3.8	
		Week 18	Tezepelumab	75	71 (94.7)	1.65 (0.97)	0.0	0.83	1.67	2.33	4.3	
			Placebo	72	65 (90.3)	1.84 (0.92)	0.0	1.33	1.83	2.33	4.7	
		Week 20	Tezepelumab	75	71 (94.7)	1.74 (1.04)	0.0	1.00	1.83	2.50	5.0	
			Placebo	72	65 (90.3)	1.85 (0.92)	0.0	1.17	2.00	2.50	3.7	
		Week 22	Tezepelumab	75	71 (94.7)	1.69 (0.98)	0.0	1.00	1.83	2.33	4.3	
			Placebo	72	65 (90.3)	1.80 (0.91)	0.0	1.17	1.83	2.50	3.7	
		Week 24	Tezepelumab	75	71 (94.7)	1.68 (1.01)	0.0	0.83	1.67	2.33	4.3	
			Placebo	72	65 (90.3)	1.76 (0.92)	0.0	1.00	1.83	2.50	3.5	
		Week 26	Tezepelumab	75	72 (96.0)	1.70 (1.04)	0.0	0.92	1.67	2.50	4.3	
			Placebo	72	65 (90.3)	1.74 (0.86)	0.0	1.00	1.67	2.17	4.0	
		Week 28	Tezepelumab	75	73 (97.3)	1.69 (1.05)	0.0	1.00	1.67	2.50	4.3	
			Placebo	72	66 (91.7)	1.84 (0.93)	0.0	1.00	2.00	2.50	4.0	
		Week 30	Tezepelumab	75	74 (98.7)	1.67 (1.02)	0.0	0.83	1.67	2.50	4.3	
			Placebo	72	67 (93.1)	1.86 (0.90)	0.0	1.17	1.83	2.67	4.0	
		Week 32	Tezepelumab	75	74 (98.7)	1.63 (1.04)	0.0	1.00	1.58	2.50	4.3	
			Placebo	72	67 (93.1)	1.73 (0.92)	0.0	1.00	1.67	2.67	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 24 ppb	Absolute values	Week 34	Tezepelumab	75	74 (98.7)	1.61 (1.10)	0.0	0.83	1.50	2.50	4.3	
			Placebo	72	67 (93.1)	1.74 (0.88)	0.0	1.00	1.83	2.50	3.3	
		Week 36	Tezepelumab	75	74 (98.7)	1.67 (1.01)	0.0	1.00	1.67	2.50	4.3	
			Placebo	72	67 (93.1)	1.71 (0.95)	0.0	0.83	1.83	2.50	3.2	
		Week 38	Tezepelumab	75	74 (98.7)	1.62 (1.09)	0.0	0.83	1.58	2.33	4.5	
			Placebo	72	67 (93.1)	1.71 (0.92)	0.0	1.00	1.83	2.50	4.0	
		Week 40	Tezepelumab	75	74 (98.7)	1.67 (1.07)	0.0	0.83	1.67	2.67	4.3	
			Placebo	72	67 (93.1)	1.75 (0.95)	0.0	1.00	1.83	2.50	4.0	
		Week 42	Tezepelumab	75	74 (98.7)	1.64 (1.07)	0.0	0.83	1.58	2.50	4.3	
			Placebo	72	67 (93.1)	1.77 (0.97)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	75	74 (98.7)	1.71 (1.07)	0.0	0.83	1.67	2.67	4.3	
			Placebo	72	68 (94.4)	1.82 (0.96)	0.0	0.83	1.83	2.50	4.0	
		Week 46	Tezepelumab	75	74 (98.7)	1.70 (1.06)	0.0	1.00	1.83	2.50	4.3	
			Placebo	72	68 (94.4)	1.66 (0.94)	0.0	0.92	1.83	2.33	3.8	
		Week 48	Tezepelumab	75	74 (98.7)	1.71 (1.07)	0.0	1.00	1.75	2.50	4.3	
			Placebo	72	68 (94.4)	1.63 (0.99)	0.0	0.83	1.50	2.50	4.2	
		Week 50	Tezepelumab	75	74 (98.7)	1.66 (1.09)	0.0	0.83	1.67	2.33	4.3	
			Placebo	72	68 (94.4)	1.69 (0.92)	0.0	1.00	1.67	2.33	3.7	
		Week 52	Tezepelumab	75	74 (98.7)	1.70 (1.07)	0.0	1.00	1.67	2.33	4.3	
			Placebo	72	68 (94.4)	1.74 (0.97)	0.0	1.00	1.83	2.50	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 2	Tezepelumab	75	70 (93.3)	-0.50 (0.68)	-2.8	-0.67	-0.33	0.00	0.7	-0.07 [-0.41, 0.27]
			Placebo	72	64 (88.9)	-0.45 (0.67)	-2.8	-0.83	-0.33	0.00	1.2	
		Week 4	Tezepelumab	75	70 (93.3)	-0.75 (0.66)	-2.5	-1.17	-0.67	-0.33	0.5	-0.17 [-0.51, 0.17]
			Placebo	72	64 (88.9)	-0.63 (0.82)	-3.0	-1.00	-0.67	-0.17	1.2	
		Week 6	Tezepelumab	75	70 (93.3)	-0.81 (0.75)	-2.7	-1.33	-0.83	-0.33	0.7	-0.13 [-0.47, 0.21]
			Placebo	72	64 (88.9)	-0.70 (0.89)	-3.3	-1.17	-0.67	-0.17	1.5	
		Week 8	Tezepelumab	75	70 (93.3)	-0.87 (0.89)	-3.0	-1.33	-0.92	-0.33	2.2	-0.29 [-0.63, 0.05]
			Placebo	72	64 (88.9)	-0.62 (0.87)	-3.2	-1.00	-0.67	0.00	1.0	
		Week 10	Tezepelumab	75	70 (93.3)	-0.93 (0.83)	-3.2	-1.50	-0.92	-0.33	0.5	-0.19 [-0.53, 0.15]
			Placebo	72	65 (90.3)	-0.77 (0.82)	-3.3	-1.17	-0.67	-0.33	0.7	
		Week 12	Tezepelumab	75	70 (93.3)	-0.98 (0.85)	-2.8	-1.67	-0.83	-0.33	0.5	-0.20 [-0.54, 0.13]
			Placebo	72	65 (90.3)	-0.80 (0.93)	-3.3	-1.17	-0.67	-0.33	1.3	
		Week 14	Tezepelumab	75	70 (93.3)	-1.15 (0.80)	-3.2	-1.83	-1.17	-0.67	0.5	-0.34 [-0.68, -0.00]
			Placebo	72	65 (90.3)	-0.87 (0.89)	-3.2	-1.33	-0.83	-0.33	1.3	
		Week 16	Tezepelumab	75	70 (93.3)	-0.94 (0.86)	-3.0	-1.50	-1.00	-0.33	1.5	-0.19 [-0.53, 0.15]
			Placebo	72	65 (90.3)	-0.77 (0.93)	-3.2	-1.33	-0.67	-0.17	1.3	
		Week 18	Tezepelumab	75	71 (94.7)	-1.03 (0.80)	-3.2	-1.67	-1.00	-0.50	0.5	-0.22 [-0.56, 0.12]
			Placebo	72	65 (90.3)	-0.84 (0.96)	-3.2	-1.33	-0.83	-0.17	1.5	
		Week 20	Tezepelumab	75	71 (94.7)	-0.94 (0.87)	-3.2	-1.67	-0.83	-0.33	0.7	-0.12 [-0.45, 0.22]
			Placebo	72	65 (90.3)	-0.83 (0.99)	-3.2	-1.50	-0.67	-0.33	1.2	
		Week 22	Tezepelumab	75	71 (94.7)	-0.99 (0.84)	-3.0	-1.67	-0.83	-0.33	0.5	-0.12 [-0.46, 0.21]
			Placebo	72	65 (90.3)	-0.87 (0.99)	-3.3	-1.50	-0.83	-0.33	1.3	
		Week 24	Tezepelumab	75	71 (94.7)	-1.00 (0.84)	-3.2	-1.67	-0.83	-0.33	0.7	-0.10 [-0.44, 0.24]
			Placebo	72	65 (90.3)	-0.91 (1.01)	-3.2	-1.50	-0.83	-0.33	1.7	
		Week 26	Tezepelumab	75	72 (96.0)	-0.96 (0.86)	-2.8	-1.67	-0.83	-0.33	0.7	-0.03 [-0.37, 0.31]
			Placebo	72	65 (90.3)	-0.94 (0.95)	-2.8	-1.50	-1.00	-0.33	1.5	
		Week 28	Tezepelumab	75	73 (97.3)	-0.97 (0.93)	-3.2	-1.67	-1.00	-0.17	0.8	-0.18 [-0.52, 0.15]
			Placebo	72	66 (91.7)	-0.80 (1.00)	-2.8	-1.50	-0.83	-0.33	1.5	
		Week 30	Tezepelumab	75	74 (98.7)	-1.00 (0.91)	-2.8	-1.83	-0.92	-0.33	1.8	-0.23 [-0.56, 0.11]
			Placebo	72	67 (93.1)	-0.79 (0.98)	-3.2	-1.50	-0.67	-0.17	1.3	
		Week 32	Tezepelumab	75	74 (98.7)	-1.04 (0.90)	-3.2	-1.67	-1.00	-0.50	0.8	-0.14 [-0.47, 0.19]
			Placebo	72	67 (93.1)	-0.91 (0.97)	-3.0	-1.50	-0.83	-0.33	1.3	
		Week 34	Tezepelumab	75	74 (98.7)	-1.06 (0.97)	-3.3	-1.83	-1.00	-0.33	2.0	-0.16 [-0.49, 0.17]
			Placebo	72	67 (93.1)	-0.91 (0.93)	-3.2	-1.50	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 24 ppb	Change from baseline	Week 36	Tezepelumab	75	74 (98.7)	-1.00 (0.91)	-3.2	-1.67	-1.00	-0.33	1.5	-0.07 [-0.40, 0.26]
			Placebo	72	67 (93.1)	-0.94 (1.01)	-3.5	-1.50	-1.00	-0.33	1.3	
		Week 38	Tezepelumab	75	74 (98.7)	-1.05 (0.96)	-3.2	-1.83	-1.00	-0.33	2.3	-0.12 [-0.45, 0.21]
			Placebo	72	67 (93.1)	-0.93 (0.98)	-3.2	-1.50	-1.00	-0.33	1.3	
		Week 40	Tezepelumab	75	74 (98.7)	-1.00 (0.95)	-3.2	-1.67	-0.92	-0.33	1.7	-0.11 [-0.44, 0.22]
			Placebo	72	67 (93.1)	-0.89 (0.96)	-3.2	-1.50	-0.83	-0.33	1.3	
		Week 42	Tezepelumab	75	74 (98.7)	-1.03 (0.94)	-3.2	-1.67	-1.00	-0.50	2.0	-0.17 [-0.50, 0.16]
			Placebo	72	67 (93.1)	-0.87 (0.96)	-2.8	-1.50	-0.83	-0.17	1.3	
		Week 44	Tezepelumab	75	74 (98.7)	-0.95 (0.96)	-3.3	-1.67	-1.00	-0.17	1.5	-0.14 [-0.47, 0.19]
			Placebo	72	68 (94.4)	-0.82 (0.98)	-3.3	-1.50	-0.83	-0.08	1.3	
		Week 46	Tezepelumab	75	74 (98.7)	-0.96 (0.92)	-3.2	-1.83	-0.92	-0.33	1.7	0.02 [-0.31, 0.35]
			Placebo	72	68 (94.4)	-0.98 (0.99)	-3.2	-1.67	-1.00	-0.33	1.3	
		Week 48	Tezepelumab	75	74 (98.7)	-0.95 (0.96)	-3.2	-1.83	-0.92	-0.17	1.8	0.06 [-0.27, 0.39]
			Placebo	72	68 (94.4)	-1.01 (1.04)	-3.3	-1.67	-0.83	-0.50	1.7	
		Week 50	Tezepelumab	75	74 (98.7)	-1.01 (0.95)	-3.2	-1.67	-1.00	-0.33	1.8	-0.07 [-0.40, 0.26]
			Placebo	72	68 (94.4)	-0.95 (0.99)	-3.5	-1.50	-1.00	-0.33	1.5	
		Week 52	Tezepelumab	75	74 (98.7)	-0.97 (0.95)	-3.2	-1.67	-0.83	-0.33	1.8	-0.07 [-0.40, 0.26]
			Placebo	72	68 (94.4)	-0.90 (1.04)	-3.5	-1.67	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	2.72 (0.97)	0.0	2.25	2.67	3.17	4.8	
			Placebo	65	65 (100.0)	2.70 (0.74)	1.3	2.17	2.67	3.17	4.7	
		Week 2	Tezepelumab	60	59 (98.3)	2.13 (0.91)	0.0	1.67	2.17	2.83	4.3	
			Placebo	65	60 (92.3)	2.39 (0.89)	0.2	2.00	2.50	2.83	4.8	
		Week 4	Tezepelumab	60	59 (98.3)	1.81 (1.05)	0.0	1.00	1.83	2.67	4.3	
			Placebo	65	60 (92.3)	2.33 (0.87)	0.3	1.83	2.42	2.83	4.2	
		Week 6	Tezepelumab	60	59 (98.3)	1.70 (1.04)	0.0	1.00	1.83	2.50	4.3	
			Placebo	65	61 (93.8)	2.22 (1.05)	0.2	1.50	2.33	2.67	5.5	
		Week 8	Tezepelumab	60	59 (98.3)	1.62 (1.07)	0.0	0.83	1.67	2.50	4.3	
			Placebo	65	62 (95.4)	2.09 (1.04)	0.0	1.33	2.17	2.67	4.7	
		Week 10	Tezepelumab	60	59 (98.3)	1.54 (1.02)	0.0	0.67	1.67	2.33	4.3	
			Placebo	65	62 (95.4)	2.03 (0.96)	0.0	1.33	2.00	2.67	5.3	
		Week 12	Tezepelumab	60	59 (98.3)	1.44 (1.02)	0.0	0.50	1.33	2.17	4.3	
			Placebo	65	62 (95.4)	1.94 (0.99)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	60	59 (98.3)	1.37 (1.02)	0.0	0.50	1.17	2.17	4.3	
			Placebo	65	62 (95.4)	1.89 (0.99)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	60	59 (98.3)	1.44 (1.05)	0.0	0.67	1.33	2.17	4.3	
			Placebo	65	62 (95.4)	2.06 (1.16)	0.0	1.00	2.17	2.67	5.0	
		Week 18	Tezepelumab	60	59 (98.3)	1.33 (0.96)	0.0	0.67	1.17	2.00	4.3	
			Placebo	65	62 (95.4)	1.91 (1.05)	0.0	1.17	2.17	2.50	5.0	
		Week 20	Tezepelumab	60	59 (98.3)	1.40 (0.99)	0.0	0.67	1.17	2.00	4.3	
			Placebo	65	62 (95.4)	2.02 (1.07)	0.0	1.17	2.33	2.67	5.0	
		Week 22	Tezepelumab	60	59 (98.3)	1.50 (0.96)	0.0	0.83	1.50	2.00	4.3	
			Placebo	65	62 (95.4)	1.97 (1.08)	0.0	1.17	2.08	2.67	5.0	
		Week 24	Tezepelumab	60	59 (98.3)	1.49 (1.07)	0.0	0.67	1.17	2.33	4.3	
			Placebo	65	62 (95.4)	2.01 (1.02)	0.0	1.17	2.17	2.67	4.5	
		Week 26	Tezepelumab	60	59 (98.3)	1.38 (0.96)	0.0	0.67	1.33	2.17	4.3	
			Placebo	65	62 (95.4)	1.93 (1.08)	0.0	1.00	1.75	2.83	4.5	
		Week 28	Tezepelumab	60	59 (98.3)	1.49 (1.03)	0.0	0.67	1.50	2.33	4.3	
			Placebo	65	62 (95.4)	1.93 (1.15)	0.0	1.00	2.00	2.67	4.5	
		Week 30	Tezepelumab	60	59 (98.3)	1.42 (0.97)	0.0	0.83	1.50	2.00	4.3	
			Placebo	65	62 (95.4)	1.90 (1.13)	0.0	1.17	1.92	2.50	4.5	
		Week 32	Tezepelumab	60	59 (98.3)	1.36 (1.00)	0.0	0.50	1.17	2.17	4.3	
			Placebo	65	62 (95.4)	1.93 (1.13)	0.0	1.17	1.92	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 24 ppb	Absolute values	Week 34	Tezepelumab	60	59 (98.3)	1.41 (1.02)	0.0	0.67	1.17	2.00	4.3	
			Placebo	65	62 (95.4)	1.85 (1.18)	0.0	1.00	1.67	2.50	4.5	
		Week 36	Tezepelumab	60	59 (98.3)	1.51 (1.09)	0.0	0.67	1.50	2.33	4.5	
			Placebo	65	62 (95.4)	2.03 (1.11)	0.0	1.17	2.17	2.67	4.5	
		Week 38	Tezepelumab	60	59 (98.3)	1.37 (0.97)	0.0	0.67	1.33	2.00	4.3	
			Placebo	65	62 (95.4)	1.85 (1.12)	0.0	1.00	1.92	2.50	4.5	
		Week 40	Tezepelumab	60	59 (98.3)	1.34 (0.99)	0.0	0.50	1.17	2.00	4.3	
			Placebo	65	62 (95.4)	1.96 (1.12)	0.0	1.00	2.17	2.67	4.5	
		Week 42	Tezepelumab	60	59 (98.3)	1.33 (1.01)	0.0	0.67	1.17	1.83	4.7	
			Placebo	65	62 (95.4)	1.87 (1.06)	0.0	1.00	2.00	2.50	4.5	
		Week 44	Tezepelumab	60	59 (98.3)	1.27 (0.92)	0.0	0.50	1.17	2.00	4.3	
			Placebo	65	62 (95.4)	1.91 (1.08)	0.0	1.00	2.00	2.67	4.5	
		Week 46	Tezepelumab	60	59 (98.3)	1.22 (0.95)	0.0	0.67	1.00	1.83	4.3	
			Placebo	65	62 (95.4)	1.86 (1.01)	0.0	1.17	2.00	2.50	4.5	
		Week 48	Tezepelumab	60	59 (98.3)	1.34 (0.99)	0.0	0.67	1.17	2.00	4.3	
			Placebo	65	62 (95.4)	1.96 (1.02)	0.0	1.17	2.17	2.67	4.5	
		Week 50	Tezepelumab	60	59 (98.3)	1.23 (0.92)	0.0	0.67	1.00	1.83	4.3	
			Placebo	65	62 (95.4)	1.84 (1.01)	0.0	1.00	1.92	2.50	4.5	
		Week 52	Tezepelumab	60	59 (98.3)	1.24 (0.93)	0.0	0.50	1.00	1.83	4.3	
			Placebo	65	62 (95.4)	1.90 (1.03)	0.0	1.00	2.17	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 2	Tezepelumab	60	59 (98.3)	-0.59 (0.67)	-2.3	-1.00	-0.50	0.00	0.7	-0.43 [-0.80, -0.07]
			Placebo	65	60 (92.3)	-0.28 (0.74)	-2.7	-0.75	-0.25	0.17	1.0	
		Week 4	Tezepelumab	60	59 (98.3)	-0.92 (1.09)	-3.5	-1.50	-1.00	-0.17	2.3	-0.59 [-0.95, -0.22]
			Placebo	65	60 (92.3)	-0.35 (0.83)	-2.0	-1.00	-0.17	0.33	1.2	
		Week 6	Tezepelumab	60	59 (98.3)	-1.02 (1.16)	-3.8	-1.83	-1.00	-0.33	2.3	-0.55 [-0.91, -0.18]
			Placebo	65	61 (93.8)	-0.45 (0.90)	-2.2	-1.17	-0.33	0.17	1.5	
		Week 8	Tezepelumab	60	59 (98.3)	-1.10 (1.12)	-3.8	-1.83	-1.00	-0.33	2.3	-0.50 [-0.86, -0.14]
			Placebo	65	62 (95.4)	-0.59 (0.94)	-3.0	-1.17	-0.50	0.00	1.0	
		Week 10	Tezepelumab	60	59 (98.3)	-1.18 (1.13)	-3.8	-1.83	-1.17	-0.50	2.3	-0.49 [-0.85, -0.13]
			Placebo	65	62 (95.4)	-0.65 (1.04)	-2.7	-1.33	-0.50	0.00	2.7	
		Week 12	Tezepelumab	60	59 (98.3)	-1.28 (1.11)	-3.7	-2.00	-1.33	-0.67	2.3	-0.51 [-0.87, -0.15]
			Placebo	65	62 (95.4)	-0.74 (1.01)	-3.2	-1.33	-0.67	0.00	1.3	
		Week 14	Tezepelumab	60	59 (98.3)	-1.35 (1.19)	-3.8	-2.17	-1.33	-0.67	2.3	-0.51 [-0.88, -0.15]
			Placebo	65	62 (95.4)	-0.78 (1.01)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 16	Tezepelumab	60	59 (98.3)	-1.29 (1.21)	-4.2	-2.17	-1.33	-0.67	2.3	-0.57 [-0.94, -0.21]
			Placebo	65	62 (95.4)	-0.62 (1.13)	-3.5	-1.17	-0.67	0.17	2.3	
		Week 18	Tezepelumab	60	59 (98.3)	-1.39 (1.18)	-4.2	-2.00	-1.50	-0.67	2.3	-0.55 [-0.92, -0.19]
			Placebo	65	62 (95.4)	-0.76 (1.08)	-3.2	-1.50	-0.67	-0.33	2.3	
		Week 20	Tezepelumab	60	59 (98.3)	-1.32 (1.13)	-4.2	-2.00	-1.33	-0.67	2.3	-0.60 [-0.96, -0.23]
			Placebo	65	62 (95.4)	-0.66 (1.09)	-3.5	-1.17	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	60	59 (98.3)	-1.22 (1.23)	-4.3	-2.00	-1.17	-0.67	2.3	-0.45 [-0.82, -0.09]
			Placebo	65	62 (95.4)	-0.71 (1.03)	-3.0	-1.33	-0.67	0.00	2.3	
		Week 24	Tezepelumab	60	59 (98.3)	-1.23 (1.14)	-4.5	-1.83	-1.33	-0.50	2.3	-0.51 [-0.87, -0.15]
			Placebo	65	62 (95.4)	-0.67 (1.07)	-3.5	-1.33	-0.50	0.00	2.3	
		Week 26	Tezepelumab	60	59 (98.3)	-1.34 (1.20)	-4.2	-2.17	-1.33	-0.50	2.3	-0.51 [-0.87, -0.14]
			Placebo	65	62 (95.4)	-0.75 (1.14)	-4.0	-1.50	-0.67	0.17	2.3	
		Week 28	Tezepelumab	60	59 (98.3)	-1.23 (1.17)	-4.2	-2.00	-1.33	-0.33	2.3	-0.41 [-0.77, -0.05]
			Placebo	65	62 (95.4)	-0.75 (1.16)	-4.0	-1.50	-0.67	-0.17	2.3	
		Week 30	Tezepelumab	60	59 (98.3)	-1.31 (1.19)	-4.2	-2.17	-1.33	-0.67	2.3	-0.45 [-0.81, -0.09]
			Placebo	65	62 (95.4)	-0.78 (1.14)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	60	59 (98.3)	-1.36 (1.20)	-4.2	-2.17	-1.33	-0.67	2.3	-0.53 [-0.89, -0.16]
			Placebo	65	62 (95.4)	-0.75 (1.13)	-3.5	-1.50	-0.67	-0.17	2.3	
		Week 34	Tezepelumab	60	59 (98.3)	-1.31 (1.18)	-4.2	-2.17	-1.50	-0.67	2.3	-0.41 [-0.77, -0.05]
			Placebo	65	62 (95.4)	-0.83 (1.17)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 24 ppb	Change from baseline	Week 36	Tezepelumab	60	59 (98.3)	-1.21 (1.30)	-4.2	-2.17	-1.50	-0.33	2.3	-0.47 [-0.83, -0.11]
			Placebo	65	62 (95.4)	-0.64 (1.13)	-3.5	-1.33	-0.58	0.17	2.3	
		Week 38	Tezepelumab	60	59 (98.3)	-1.35 (1.22)	-4.2	-2.17	-1.33	-0.67	2.3	-0.45 [-0.81, -0.08]
			Placebo	65	62 (95.4)	-0.82 (1.16)	-4.0	-1.50	-0.83	0.00	2.3	
		Week 40	Tezepelumab	60	59 (98.3)	-1.38 (1.24)	-4.2	-2.17	-1.33	-0.67	2.3	-0.55 [-0.92, -0.19]
			Placebo	65	62 (95.4)	-0.72 (1.16)	-4.0	-1.33	-0.75	0.17	2.3	
		Week 42	Tezepelumab	60	59 (98.3)	-1.39 (1.25)	-4.2	-2.17	-1.50	-0.67	2.3	-0.49 [-0.85, -0.13]
			Placebo	65	62 (95.4)	-0.81 (1.12)	-4.0	-1.33	-0.83	-0.17	2.3	
		Week 44	Tezepelumab	60	59 (98.3)	-1.45 (1.21)	-4.3	-2.17	-1.50	-0.67	2.3	-0.58 [-0.95, -0.22]
			Placebo	65	62 (95.4)	-0.77 (1.15)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 46	Tezepelumab	60	59 (98.3)	-1.50 (1.22)	-4.2	-2.17	-1.50	-0.83	2.3	-0.59 [-0.96, -0.23]
			Placebo	65	62 (95.4)	-0.82 (1.07)	-4.0	-1.33	-0.92	0.00	2.3	
		Week 48	Tezepelumab	60	59 (98.3)	-1.38 (1.22)	-4.2	-2.17	-1.50	-0.50	2.3	-0.58 [-0.94, -0.21]
			Placebo	65	62 (95.4)	-0.72 (1.08)	-3.7	-1.33	-0.83	0.17	2.3	
		Week 50	Tezepelumab	60	59 (98.3)	-1.49 (1.20)	-4.2	-2.33	-1.50	-0.83	2.3	-0.58 [-0.94, -0.22]
			Placebo	65	62 (95.4)	-0.83 (1.05)	-4.0	-1.33	-0.83	-0.17	2.3	
		Week 52	Tezepelumab	60	59 (98.3)	-1.48 (1.21)	-4.2	-2.33	-1.50	-0.83	2.3	-0.62 [-0.98, -0.25]
			Placebo	65	62 (95.4)	-0.78 (1.06)	-4.0	-1.33	-0.75	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	65	65 (100.0)	2.68 (0.68)	0.8	2.17	2.67	3.00	4.5	
			Placebo	62	62 (100.0)	2.63 (0.66)	0.3	2.33	2.67	3.00	4.2	
		Week 2	Tezepelumab	65	61 (93.8)	2.21 (0.89)	0.0	1.50	2.33	2.83	3.8	
			Placebo	62	56 (90.3)	2.25 (0.70)	0.3	1.92	2.33	2.83	4.3	
		Week 4	Tezepelumab	65	61 (93.8)	1.95 (0.88)	0.0	1.33	2.00	2.67	3.5	
			Placebo	62	56 (90.3)	2.04 (0.82)	0.2	1.50	2.17	2.67	4.2	
		Week 6	Tezepelumab	65	61 (93.8)	1.84 (0.90)	0.0	1.33	1.83	2.50	4.0	
			Placebo	62	56 (90.3)	1.99 (0.88)	0.2	1.33	2.00	2.50	4.7	
		Week 8	Tezepelumab	65	61 (93.8)	1.85 (1.01)	0.0	1.33	1.67	2.67	4.8	
			Placebo	62	56 (90.3)	2.08 (0.79)	0.0	1.67	2.08	2.75	4.0	
		Week 10	Tezepelumab	65	61 (93.8)	1.77 (1.00)	0.0	1.33	1.83	2.67	4.3	
			Placebo	62	57 (91.9)	1.92 (0.82)	0.2	1.33	2.00	2.33	4.2	
		Week 12	Tezepelumab	65	61 (93.8)	1.76 (1.03)	0.0	1.00	1.67	2.50	4.3	
			Placebo	62	57 (91.9)	1.91 (0.82)	0.0	1.33	2.00	2.50	3.7	
		Week 14	Tezepelumab	65	61 (93.8)	1.61 (0.96)	0.0	1.00	1.50	2.17	4.3	
			Placebo	62	57 (91.9)	1.85 (0.84)	0.0	1.33	2.00	2.50	4.2	
		Week 16	Tezepelumab	65	61 (93.8)	1.79 (1.05)	0.0	1.00	1.83	2.50	4.3	
			Placebo	62	57 (91.9)	1.97 (0.89)	0.0	1.50	1.83	2.67	3.8	
		Week 18	Tezepelumab	65	62 (95.4)	1.70 (0.94)	0.0	1.17	1.75	2.33	4.3	
			Placebo	62	57 (91.9)	1.88 (0.93)	0.0	1.33	2.00	2.50	4.7	
		Week 20	Tezepelumab	65	62 (95.4)	1.81 (1.02)	0.0	1.17	1.92	2.50	5.0	
			Placebo	62	57 (91.9)	1.86 (0.92)	0.0	1.17	2.00	2.50	3.7	
		Week 22	Tezepelumab	65	62 (95.4)	1.76 (0.96)	0.0	1.17	1.92	2.33	4.3	
			Placebo	62	57 (91.9)	1.85 (0.89)	0.0	1.17	1.83	2.67	3.7	
		Week 24	Tezepelumab	65	62 (95.4)	1.76 (0.97)	0.0	1.17	1.75	2.33	4.3	
			Placebo	62	57 (91.9)	1.83 (0.92)	0.0	1.00	2.00	2.50	3.5	
		Week 26	Tezepelumab	65	63 (96.9)	1.75 (0.98)	0.0	1.17	1.83	2.50	4.3	
			Placebo	62	57 (91.9)	1.79 (0.89)	0.0	1.00	1.83	2.50	4.0	
		Week 28	Tezepelumab	65	63 (96.9)	1.76 (1.00)	0.0	1.17	1.83	2.50	4.3	
			Placebo	62	58 (93.5)	1.88 (0.90)	0.0	1.00	2.08	2.50	4.0	
		Week 30	Tezepelumab	65	64 (98.5)	1.74 (0.97)	0.0	1.00	1.67	2.50	4.3	
			Placebo	62	58 (93.5)	1.83 (0.87)	0.0	1.17	1.83	2.67	3.2	
		Week 32	Tezepelumab	65	64 (98.5)	1.71 (0.98)	0.0	1.00	1.67	2.50	4.3	
			Placebo	62	58 (93.5)	1.75 (0.92)	0.0	1.00	1.83	2.67	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 22.0 ppb	Absolute values	Week 34	Tezepelumab	65	64 (98.5)	1.69 (1.04)	0.0	1.00	1.50	2.50	4.3	
			Placebo	62	58 (93.5)	1.76 (0.89)	0.0	1.00	1.83	2.50	3.3	
		Week 36	Tezepelumab	65	64 (98.5)	1.75 (0.98)	0.0	1.08	1.67	2.58	4.3	
			Placebo	62	58 (93.5)	1.74 (0.98)	0.0	0.83	1.83	2.67	3.2	
		Week 38	Tezepelumab	65	64 (98.5)	1.71 (1.07)	0.0	1.00	1.67	2.50	4.5	
			Placebo	62	58 (93.5)	1.74 (0.92)	0.0	1.00	1.83	2.50	4.0	
		Week 40	Tezepelumab	65	64 (98.5)	1.77 (1.03)	0.0	1.00	1.75	2.67	4.3	
			Placebo	62	58 (93.5)	1.78 (1.00)	0.0	0.83	1.83	2.50	4.0	
		Week 42	Tezepelumab	65	64 (98.5)	1.73 (1.04)	0.0	1.00	1.67	2.50	4.3	
			Placebo	62	58 (93.5)	1.76 (1.01)	0.0	0.83	1.83	2.50	4.7	
		Week 44	Tezepelumab	65	64 (98.5)	1.82 (1.04)	0.0	1.17	1.75	2.67	4.3	
			Placebo	62	59 (95.2)	1.82 (0.98)	0.0	0.83	1.83	2.50	4.0	
		Week 46	Tezepelumab	65	64 (98.5)	1.80 (1.02)	0.0	1.17	1.83	2.67	4.3	
			Placebo	62	59 (95.2)	1.66 (0.97)	0.0	0.83	1.83	2.33	3.8	
		Week 48	Tezepelumab	65	64 (98.5)	1.81 (1.01)	0.0	1.08	2.00	2.58	4.3	
			Placebo	62	59 (95.2)	1.65 (1.02)	0.0	0.67	1.67	2.50	4.2	
		Week 50	Tezepelumab	65	64 (98.5)	1.74 (1.04)	0.0	1.00	1.67	2.33	4.3	
			Placebo	62	59 (95.2)	1.68 (0.95)	0.0	0.83	1.67	2.33	3.7	
		Week 52	Tezepelumab	65	64 (98.5)	1.76 (1.05)	0.0	1.08	1.67	2.42	4.3	
			Placebo	62	59 (95.2)	1.73 (0.99)	0.0	0.83	1.83	2.50	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 2	Tezepelumab	65	61 (93.8)	-0.48 (0.66)	-2.8	-0.67	-0.33	0.00	0.5	-0.07 [-0.43, 0.29]
			Placebo	62	56 (90.3)	-0.43 (0.59)	-2.8	-0.83	-0.33	0.00	0.7	
		Week 4	Tezepelumab	65	61 (93.8)	-0.74 (0.68)	-2.5	-1.00	-0.67	-0.33	0.5	-0.14 [-0.50, 0.22]
			Placebo	62	56 (90.3)	-0.64 (0.78)	-3.0	-1.00	-0.67	-0.17	1.0	
		Week 6	Tezepelumab	65	61 (93.8)	-0.84 (0.76)	-2.7	-1.33	-0.83	-0.33	0.7	-0.19 [-0.55, 0.18]
			Placebo	62	56 (90.3)	-0.69 (0.85)	-3.3	-1.17	-0.67	-0.17	1.5	
		Week 8	Tezepelumab	65	61 (93.8)	-0.83 (0.92)	-3.0	-1.33	-0.83	-0.17	2.2	-0.27 [-0.64, 0.09]
			Placebo	62	56 (90.3)	-0.60 (0.78)	-3.0	-1.00	-0.67	-0.17	1.0	
		Week 10	Tezepelumab	65	61 (93.8)	-0.91 (0.85)	-3.2	-1.33	-0.83	-0.33	0.5	-0.18 [-0.54, 0.18]
			Placebo	62	57 (91.9)	-0.77 (0.74)	-3.2	-1.17	-0.67	-0.33	0.7	
		Week 12	Tezepelumab	65	61 (93.8)	-0.92 (0.85)	-2.8	-1.50	-0.83	-0.33	0.5	-0.17 [-0.53, 0.20]
			Placebo	62	57 (91.9)	-0.78 (0.84)	-3.2	-1.00	-0.67	-0.33	1.0	
		Week 14	Tezepelumab	65	61 (93.8)	-1.07 (0.78)	-3.2	-1.50	-1.00	-0.67	0.5	-0.29 [-0.65, 0.08]
			Placebo	62	57 (91.9)	-0.84 (0.86)	-3.2	-1.33	-0.83	-0.33	1.3	
		Week 16	Tezepelumab	65	61 (93.8)	-0.90 (0.87)	-3.0	-1.33	-1.00	-0.33	1.5	-0.20 [-0.56, 0.16]
			Placebo	62	57 (91.9)	-0.72 (0.89)	-2.8	-1.33	-0.67	-0.17	1.3	
		Week 18	Tezepelumab	65	62 (95.4)	-0.97 (0.79)	-3.2	-1.50	-0.83	-0.33	0.5	-0.18 [-0.54, 0.18]
			Placebo	62	57 (91.9)	-0.81 (0.93)	-3.2	-1.33	-0.83	-0.17	1.5	
		Week 20	Tezepelumab	65	62 (95.4)	-0.86 (0.86)	-3.2	-1.50	-0.83	-0.17	0.7	-0.04 [-0.40, 0.32]
			Placebo	62	57 (91.9)	-0.83 (0.93)	-3.0	-1.50	-0.67	-0.33	1.2	
		Week 22	Tezepelumab	65	62 (95.4)	-0.91 (0.83)	-3.0	-1.50	-0.83	-0.33	0.5	-0.08 [-0.44, 0.28]
			Placebo	62	57 (91.9)	-0.85 (0.93)	-3.2	-1.50	-0.83	-0.33	1.3	
		Week 24	Tezepelumab	65	62 (95.4)	-0.91 (0.81)	-3.2	-1.33	-0.83	-0.33	0.7	-0.06 [-0.42, 0.30]
			Placebo	62	57 (91.9)	-0.86 (0.98)	-3.2	-1.50	-0.83	-0.33	1.7	
		Week 26	Tezepelumab	65	63 (96.9)	-0.90 (0.82)	-2.8	-1.50	-0.83	-0.33	0.7	-0.00 [-0.36, 0.36]
			Placebo	62	57 (91.9)	-0.90 (0.95)	-2.7	-1.50	-1.00	-0.33	1.5	
		Week 28	Tezepelumab	65	63 (96.9)	-0.89 (0.91)	-3.2	-1.33	-0.83	-0.17	0.8	-0.13 [-0.49, 0.23]
			Placebo	62	58 (93.5)	-0.77 (0.93)	-2.8	-1.50	-0.75	-0.33	1.5	
		Week 30	Tezepelumab	65	64 (98.5)	-0.92 (0.90)	-2.8	-1.58	-0.83	-0.33	1.8	-0.11 [-0.47, 0.25]
			Placebo	62	58 (93.5)	-0.82 (0.93)	-3.2	-1.50	-0.67	-0.33	1.3	
		Week 32	Tezepelumab	65	64 (98.5)	-0.95 (0.87)	-3.2	-1.50	-0.83	-0.50	0.8	-0.05 [-0.41, 0.30]
			Placebo	62	58 (93.5)	-0.90 (0.92)	-3.0	-1.50	-0.83	-0.33	1.3	
		Week 34	Tezepelumab	65	64 (98.5)	-0.97 (0.94)	-3.3	-1.67	-0.83	-0.33	2.0	-0.08 [-0.44, 0.27]
			Placebo	62	58 (93.5)	-0.89 (0.90)	-3.2	-1.50	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 22.0 ppb	Change from baseline	Week 36	Tezepelumab	65	64 (98.5)	-0.92 (0.90)	-3.2	-1.50	-0.83	-0.33	1.5	-0.01 [-0.36, 0.35]
			Placebo	62	58 (93.5)	-0.91 (1.01)	-3.5	-1.50	-0.83	-0.33	1.3	
		Week 38	Tezepelumab	65	64 (98.5)	-0.95 (0.96)	-3.2	-1.67	-0.92	-0.33	2.3	-0.04 [-0.40, 0.31]
			Placebo	62	58 (93.5)	-0.91 (0.96)	-3.2	-1.33	-0.92	-0.33	1.3	
		Week 40	Tezepelumab	65	64 (98.5)	-0.89 (0.93)	-3.2	-1.50	-0.83	-0.25	1.7	-0.03 [-0.38, 0.33]
			Placebo	62	58 (93.5)	-0.86 (0.97)	-3.2	-1.50	-0.83	-0.33	1.3	
		Week 42	Tezepelumab	65	64 (98.5)	-0.93 (0.93)	-3.2	-1.50	-0.83	-0.42	2.0	-0.04 [-0.40, 0.31]
			Placebo	62	58 (93.5)	-0.89 (0.96)	-2.8	-1.50	-0.83	-0.33	1.3	
		Week 44	Tezepelumab	65	64 (98.5)	-0.85 (0.95)	-3.3	-1.42	-0.83	-0.17	1.5	-0.02 [-0.37, 0.33]
			Placebo	62	59 (95.2)	-0.83 (0.95)	-3.3	-1.50	-0.83	-0.17	1.3	
		Week 46	Tezepelumab	65	64 (98.5)	-0.87 (0.90)	-3.2	-1.33	-0.75	-0.25	1.7	0.13 [-0.22, 0.49]
			Placebo	62	59 (95.2)	-0.99 (0.99)	-3.2	-1.67	-1.00	-0.33	1.3	
		Week 48	Tezepelumab	65	64 (98.5)	-0.86 (0.93)	-3.2	-1.50	-0.75	-0.17	1.8	0.15 [-0.21, 0.50]
			Placebo	62	59 (95.2)	-1.00 (1.03)	-3.3	-1.67	-0.83	-0.50	1.7	
		Week 50	Tezepelumab	65	64 (98.5)	-0.93 (0.94)	-3.2	-1.58	-0.83	-0.17	1.8	0.05 [-0.31, 0.40]
			Placebo	62	59 (95.2)	-0.97 (0.99)	-3.5	-1.50	-1.00	-0.33	1.5	
		Week 52	Tezepelumab	65	64 (98.5)	-0.91 (0.95)	-3.2	-1.58	-0.83	-0.17	1.8	0.01 [-0.35, 0.36]
			Placebo	62	59 (95.2)	-0.92 (1.03)	-3.5	-1.50	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	70	70 (100.0)	2.72 (0.91)	0.0	2.33	2.67	3.17	4.8	
			Placebo	75	75 (100.0)	2.68 (0.71)	1.3	2.17	2.67	3.00	4.7	
		Week 2	Tezepelumab	70	68 (97.1)	2.12 (0.94)	0.0	1.67	2.17	2.75	4.3	
			Placebo	75	68 (90.7)	2.34 (0.87)	0.2	1.92	2.33	2.83	4.8	
		Week 4	Tezepelumab	70	68 (97.1)	1.81 (1.03)	0.0	1.00	1.83	2.67	4.3	
			Placebo	75	68 (90.7)	2.29 (0.85)	0.3	1.75	2.33	2.75	4.2	
		Week 6	Tezepelumab	70	68 (97.1)	1.76 (1.04)	0.0	1.00	1.83	2.58	4.3	
			Placebo	75	69 (92.0)	2.16 (1.03)	0.2	1.50	2.33	2.67	5.5	
		Week 8	Tezepelumab	70	68 (97.1)	1.61 (1.04)	0.0	0.83	1.67	2.50	4.3	
			Placebo	75	70 (93.3)	2.06 (1.06)	0.0	1.33	2.08	2.67	4.7	
		Week 10	Tezepelumab	70	68 (97.1)	1.56 (1.03)	0.0	0.75	1.58	2.25	4.3	
			Placebo	75	70 (93.3)	2.00 (0.96)	0.0	1.33	2.00	2.67	5.3	
		Week 12	Tezepelumab	70	68 (97.1)	1.43 (1.01)	0.0	0.50	1.33	2.17	4.3	
			Placebo	75	70 (93.3)	1.90 (1.02)	0.0	1.17	1.92	2.67	4.3	
		Week 14	Tezepelumab	70	68 (97.1)	1.32 (1.03)	0.0	0.50	1.17	2.00	4.3	
			Placebo	75	70 (93.3)	1.85 (0.97)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	70	68 (97.1)	1.45 (1.05)	0.0	0.67	1.33	2.17	4.3	
			Placebo	75	70 (93.3)	1.99 (1.13)	0.0	1.00	2.17	2.67	5.0	
		Week 18	Tezepelumab	70	68 (97.1)	1.32 (0.98)	0.0	0.67	1.08	2.00	4.3	
			Placebo	75	70 (93.3)	1.87 (1.03)	0.0	1.17	1.83	2.50	5.0	
		Week 20	Tezepelumab	70	68 (97.1)	1.38 (1.00)	0.0	0.58	1.17	2.00	4.3	
			Placebo	75	70 (93.3)	1.98 (1.06)	0.0	1.17	2.25	2.67	5.0	
		Week 22	Tezepelumab	70	68 (97.1)	1.47 (0.97)	0.0	0.83	1.33	2.08	4.3	
			Placebo	75	70 (93.3)	1.91 (1.08)	0.0	1.00	2.00	2.67	5.0	
		Week 24	Tezepelumab	70	68 (97.1)	1.44 (1.08)	0.0	0.50	1.17	2.25	4.3	
			Placebo	75	70 (93.3)	1.92 (1.02)	0.0	1.17	2.00	2.50	4.5	
		Week 26	Tezepelumab	70	68 (97.1)	1.38 (1.02)	0.0	0.67	1.25	2.08	4.3	
			Placebo	75	70 (93.3)	1.86 (1.04)	0.0	1.00	1.67	2.67	4.5	
		Week 28	Tezepelumab	70	69 (98.6)	1.45 (1.06)	0.0	0.50	1.50	2.17	4.3	
			Placebo	75	70 (93.3)	1.89 (1.15)	0.0	1.00	1.92	2.67	4.5	
		Week 30	Tezepelumab	70	69 (98.6)	1.38 (1.01)	0.0	0.67	1.33	2.00	4.3	
			Placebo	75	71 (94.7)	1.91 (1.12)	0.0	1.17	2.00	2.50	4.5	
		Week 32	Tezepelumab	70	69 (98.6)	1.32 (1.04)	0.0	0.50	1.17	2.17	4.3	
			Placebo	75	71 (94.7)	1.89 (1.10)	0.0	1.17	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 22.0 ppb	Absolute values	Week 34	Tezepelumab	70	69 (98.6)	1.36 (1.07)	0.0	0.50	1.17	2.00	4.3	
			Placebo	75	71 (94.7)	1.82 (1.14)	0.0	1.00	1.67	2.50	4.5	
		Week 36	Tezepelumab	70	69 (98.6)	1.46 (1.09)	0.0	0.67	1.33	2.17	4.5	
			Placebo	75	71 (94.7)	1.97 (1.08)	0.0	1.17	2.00	2.67	4.5	
		Week 38	Tezepelumab	70	69 (98.6)	1.32 (0.99)	0.0	0.67	1.17	2.00	4.3	
			Placebo	75	71 (94.7)	1.81 (1.10)	0.0	1.00	1.67	2.50	4.5	
		Week 40	Tezepelumab	70	69 (98.6)	1.29 (1.01)	0.0	0.50	1.17	2.00	4.3	
			Placebo	75	71 (94.7)	1.90 (1.08)	0.0	1.00	2.00	2.67	4.5	
		Week 42	Tezepelumab	70	69 (98.6)	1.29 (1.02)	0.0	0.50	1.00	1.83	4.7	
			Placebo	75	71 (94.7)	1.87 (1.01)	0.0	1.17	2.00	2.50	4.5	
		Week 44	Tezepelumab	70	69 (98.6)	1.23 (0.93)	0.0	0.50	1.00	2.00	4.3	
			Placebo	75	71 (94.7)	1.89 (1.05)	0.0	1.00	2.00	2.67	4.5	
		Week 46	Tezepelumab	70	69 (98.6)	1.21 (0.98)	0.0	0.67	1.00	1.83	4.3	
			Placebo	75	71 (94.7)	1.84 (0.98)	0.0	1.17	2.00	2.50	4.5	
		Week 48	Tezepelumab	70	69 (98.6)	1.31 (1.03)	0.0	0.67	1.17	2.00	4.3	
			Placebo	75	71 (94.7)	1.90 (1.01)	0.0	1.17	2.17	2.67	4.5	
		Week 50	Tezepelumab	70	69 (98.6)	1.22 (0.97)	0.0	0.67	1.00	1.83	4.3	
			Placebo	75	71 (94.7)	1.84 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 52	Tezepelumab	70	69 (98.6)	1.25 (0.96)	0.0	0.67	1.00	1.83	4.3	
			Placebo	75	71 (94.7)	1.88 (1.00)	0.0	1.00	2.17	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 2	Tezepelumab	70	68 (97.1)	-0.60 (0.69)	-2.3	-1.00	-0.50	-0.08	0.7	-0.38 [-0.72, -0.04]
			Placebo	75	68 (90.7)	-0.32 (0.79)	-2.7	-0.83	-0.33	0.17	1.2	
		Week 4	Tezepelumab	70	68 (97.1)	-0.91 (1.03)	-3.5	-1.50	-0.92	-0.17	2.3	-0.56 [-0.90, -0.22]
			Placebo	75	68 (90.7)	-0.37 (0.86)	-2.7	-1.00	-0.17	0.25	1.2	
		Week 6	Tezepelumab	70	68 (97.1)	-0.96 (1.11)	-3.8	-1.67	-1.00	-0.25	2.3	-0.46 [-0.80, -0.12]
			Placebo	75	69 (92.0)	-0.49 (0.93)	-2.8	-1.17	-0.33	0.17	1.5	
		Week 8	Tezepelumab	70	68 (97.1)	-1.11 (1.06)	-3.8	-1.75	-1.00	-0.50	2.3	-0.49 [-0.83, -0.15]
			Placebo	75	70 (93.3)	-0.60 (1.00)	-3.2	-1.17	-0.50	0.00	1.0	
		Week 10	Tezepelumab	70	68 (97.1)	-1.16 (1.09)	-3.8	-1.83	-1.25	-0.50	2.3	-0.46 [-0.80, -0.13]
			Placebo	75	70 (93.3)	-0.67 (1.06)	-3.3	-1.33	-0.50	0.00	2.7	
		Week 12	Tezepelumab	70	68 (97.1)	-1.29 (1.07)	-3.7	-2.00	-1.33	-0.67	2.3	-0.50 [-0.84, -0.16]
			Placebo	75	70 (93.3)	-0.76 (1.06)	-3.3	-1.33	-0.67	0.00	1.3	
		Week 14	Tezepelumab	70	68 (97.1)	-1.40 (1.15)	-3.8	-2.08	-1.42	-0.75	2.3	-0.54 [-0.88, -0.20]
			Placebo	75	70 (93.3)	-0.82 (1.02)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 16	Tezepelumab	70	68 (97.1)	-1.27 (1.15)	-4.2	-2.08	-1.17	-0.67	2.3	-0.53 [-0.87, -0.19]
			Placebo	75	70 (93.3)	-0.67 (1.14)	-3.5	-1.33	-0.67	0.17	2.3	
		Week 18	Tezepelumab	70	68 (97.1)	-1.40 (1.13)	-4.2	-2.00	-1.50	-0.67	2.3	-0.55 [-0.89, -0.21]
			Placebo	75	70 (93.3)	-0.79 (1.09)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	70	68 (97.1)	-1.34 (1.09)	-4.2	-2.00	-1.33	-0.67	2.3	-0.60 [-0.94, -0.26]
			Placebo	75	70 (93.3)	-0.68 (1.13)	-3.5	-1.17	-0.67	0.00	2.3	
		Week 22	Tezepelumab	70	68 (97.1)	-1.26 (1.17)	-4.3	-2.00	-1.17	-0.67	2.3	-0.45 [-0.79, -0.11]
			Placebo	75	70 (93.3)	-0.75 (1.07)	-3.3	-1.33	-0.67	0.00	2.3	
		Week 24	Tezepelumab	70	68 (97.1)	-1.29 (1.10)	-4.5	-2.00	-1.42	-0.67	2.3	-0.50 [-0.84, -0.16]
			Placebo	75	70 (93.3)	-0.74 (1.09)	-3.5	-1.33	-0.58	0.00	2.3	
		Week 26	Tezepelumab	70	68 (97.1)	-1.35 (1.17)	-4.2	-2.17	-1.42	-0.50	2.3	-0.48 [-0.82, -0.14]
			Placebo	75	70 (93.3)	-0.80 (1.12)	-4.0	-1.50	-0.83	0.17	2.3	
		Week 28	Tezepelumab	70	69 (98.6)	-1.27 (1.13)	-4.2	-2.00	-1.50	-0.50	2.3	-0.42 [-0.76, -0.09]
			Placebo	75	70 (93.3)	-0.77 (1.19)	-4.0	-1.67	-0.83	0.17	2.3	
		Week 30	Tezepelumab	70	69 (98.6)	-1.33 (1.14)	-4.2	-2.17	-1.33	-0.67	2.3	-0.50 [-0.84, -0.17]
			Placebo	75	71 (94.7)	-0.75 (1.16)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	70	69 (98.6)	-1.40 (1.16)	-4.2	-2.17	-1.50	-0.67	2.3	-0.54 [-0.88, -0.20]
			Placebo	75	71 (94.7)	-0.77 (1.14)	-3.5	-1.50	-0.67	0.00	2.3	
		Week 34	Tezepelumab	70	69 (98.6)	-1.36 (1.15)	-4.2	-2.17	-1.50	-0.67	2.3	-0.44 [-0.77, -0.10]
			Placebo	75	71 (94.7)	-0.85 (1.16)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 22.0 ppb	Change from baseline	Week 36	Tezepelumab	70	69 (98.6)	-1.26 (1.24)	-4.2	-2.17	-1.50	-0.50	2.3	-0.47 [-0.81, -0.14]
			Placebo	75	71 (94.7)	-0.70 (1.13)	-3.5	-1.33	-0.83	0.17	2.3	
		Week 38	Tezepelumab	70	69 (98.6)	-1.40 (1.17)	-4.2	-2.17	-1.33	-0.67	2.3	-0.47 [-0.81, -0.13]
			Placebo	75	71 (94.7)	-0.85 (1.15)	-4.0	-1.67	-0.83	0.00	2.3	
		Week 40	Tezepelumab	70	69 (98.6)	-1.42 (1.18)	-4.2	-2.17	-1.50	-0.67	2.3	-0.57 [-0.91, -0.23]
			Placebo	75	71 (94.7)	-0.76 (1.13)	-4.0	-1.33	-0.83	0.17	2.3	
		Week 42	Tezepelumab	70	69 (98.6)	-1.43 (1.18)	-4.2	-2.17	-1.50	-0.83	2.3	-0.56 [-0.89, -0.22]
			Placebo	75	71 (94.7)	-0.80 (1.10)	-4.0	-1.33	-0.83	0.00	2.3	
		Week 44	Tezepelumab	70	69 (98.6)	-1.48 (1.15)	-4.3	-2.17	-1.50	-0.83	2.3	-0.62 [-0.96, -0.28]
			Placebo	75	71 (94.7)	-0.77 (1.15)	-4.0	-1.50	-0.83	0.00	2.3	
		Week 46	Tezepelumab	70	69 (98.6)	-1.51 (1.17)	-4.2	-2.17	-1.50	-0.83	2.3	-0.61 [-0.95, -0.27]
			Placebo	75	71 (94.7)	-0.83 (1.07)	-4.0	-1.33	-0.83	0.00	2.3	
		Week 48	Tezepelumab	70	69 (98.6)	-1.41 (1.18)	-4.2	-2.17	-1.50	-0.67	2.3	-0.57 [-0.91, -0.23]
			Placebo	75	71 (94.7)	-0.76 (1.09)	-3.7	-1.50	-0.83	0.00	2.3	
		Week 50	Tezepelumab	70	69 (98.6)	-1.50 (1.16)	-4.2	-2.33	-1.50	-0.83	2.3	-0.61 [-0.95, -0.27]
			Placebo	75	71 (94.7)	-0.83 (1.05)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 52	Tezepelumab	70	69 (98.6)	-1.46 (1.16)	-4.2	-2.17	-1.50	-0.83	2.3	-0.61 [-0.95, -0.28]
			Placebo	75	71 (94.7)	-0.78 (1.06)	-4.0	-1.50	-0.67	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	50	50 (100.0)	2.84 (0.73)	1.0	2.50	2.83	3.17	4.8	
			Placebo	50	50 (100.0)	2.62 (0.65)	1.3	2.33	2.67	3.00	4.3	
		Week 2	Tezepelumab	50	49 (98.0)	2.29 (0.81)	0.2	1.83	2.33	2.83	4.0	
			Placebo	50	42 (84.0)	2.26 (0.83)	0.3	1.83	2.33	2.67	4.8	
		Week 4	Tezepelumab	50	49 (98.0)	1.97 (0.83)	0.2	1.33	2.17	2.50	3.5	
			Placebo	50	42 (84.0)	2.28 (0.93)	0.2	1.67	2.33	2.83	4.2	
		Week 6	Tezepelumab	50	49 (98.0)	1.74 (0.89)	0.0	1.17	1.67	2.50	3.7	
			Placebo	50	43 (86.0)	2.10 (1.03)	0.2	1.50	2.00	2.67	4.7	
		Week 8	Tezepelumab	50	49 (98.0)	1.79 (0.97)	0.0	1.33	1.83	2.50	4.8	
			Placebo	50	44 (88.0)	2.11 (0.99)	0.0	1.50	2.25	2.67	4.7	
		Week 10	Tezepelumab	50	49 (98.0)	1.67 (0.97)	0.0	1.17	1.67	2.33	4.3	
			Placebo	50	44 (88.0)	2.01 (0.94)	0.2	1.25	2.00	2.50	4.2	
		Week 12	Tezepelumab	50	49 (98.0)	1.60 (1.03)	0.0	0.83	1.50	2.50	4.3	
			Placebo	50	44 (88.0)	2.02 (0.96)	0.2	1.42	2.00	2.67	4.3	
		Week 14	Tezepelumab	50	49 (98.0)	1.47 (0.95)	0.0	0.83	1.50	2.17	4.3	
			Placebo	50	44 (88.0)	1.88 (0.98)	0.3	1.17	1.75	2.58	5.0	
		Week 16	Tezepelumab	50	49 (98.0)	1.64 (1.03)	0.0	0.83	1.67	2.50	4.3	
			Placebo	50	44 (88.0)	2.03 (1.04)	0.3	1.25	2.08	2.67	4.5	
		Week 18	Tezepelumab	50	49 (98.0)	1.49 (0.91)	0.0	1.00	1.50	2.00	4.3	
			Placebo	50	44 (88.0)	1.82 (0.97)	0.0	1.08	1.75	2.33	4.5	
		Week 20	Tezepelumab	50	49 (98.0)	1.53 (0.98)	0.0	1.00	1.50	2.17	4.3	
			Placebo	50	44 (88.0)	1.96 (1.03)	0.2	1.17	2.25	2.50	4.5	
		Week 22	Tezepelumab	50	49 (98.0)	1.65 (0.93)	0.0	1.17	1.67	2.33	4.3	
			Placebo	50	44 (88.0)	1.92 (1.07)	0.0	1.08	2.00	2.67	4.5	
		Week 24	Tezepelumab	50	49 (98.0)	1.69 (1.00)	0.0	1.00	1.67	2.33	4.3	
			Placebo	50	44 (88.0)	1.97 (1.05)	0.2	1.08	2.08	2.67	4.5	
		Week 26	Tezepelumab	50	50 (100.0)	1.54 (0.92)	0.0	1.00	1.33	2.17	4.3	
			Placebo	50	44 (88.0)	1.93 (1.07)	0.3	1.00	1.83	2.83	4.5	
		Week 28	Tezepelumab	50	50 (100.0)	1.60 (0.94)	0.0	1.00	1.50	2.33	4.3	
			Placebo	50	44 (88.0)	2.04 (1.05)	0.0	1.00	2.17	2.58	4.5	
		Week 30	Tezepelumab	50	50 (100.0)	1.64 (0.95)	0.0	0.83	1.58	2.33	4.3	
			Placebo	50	45 (90.0)	2.04 (1.03)	0.0	1.33	2.17	2.83	4.5	
		Week 32	Tezepelumab	50	50 (100.0)	1.62 (0.93)	0.0	1.00	1.67	2.33	4.3	
			Placebo	50	45 (90.0)	2.06 (1.05)	0.0	1.17	2.17	2.83	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Absolute values	Week 34	Tezepelumab	50	50 (100.0)	1.62 (1.00)	0.0	1.00	1.50	2.50	4.3	
			Placebo	50	45 (90.0)	1.97 (1.07)	0.0	1.17	1.83	2.83	4.5	
		Week 36	Tezepelumab	50	50 (100.0)	1.70 (1.04)	0.0	1.00	1.67	2.50	4.5	
			Placebo	50	45 (90.0)	2.04 (1.04)	0.0	1.33	2.17	2.83	4.5	
		Week 38	Tezepelumab	50	50 (100.0)	1.63 (1.02)	0.0	0.83	1.50	2.50	4.3	
			Placebo	50	45 (90.0)	2.00 (1.02)	0.0	1.17	2.00	2.67	4.5	
		Week 40	Tezepelumab	50	50 (100.0)	1.62 (1.01)	0.0	0.83	1.67	2.33	4.3	
			Placebo	50	45 (90.0)	2.17 (1.04)	0.2	1.67	2.17	2.83	4.5	
		Week 42	Tezepelumab	50	50 (100.0)	1.63 (0.98)	0.0	1.00	1.50	2.33	4.3	
			Placebo	50	45 (90.0)	2.07 (1.11)	0.2	1.33	2.17	2.67	4.7	
		Week 44	Tezepelumab	50	50 (100.0)	1.60 (1.00)	0.0	0.83	1.50	2.50	4.3	
			Placebo	50	46 (92.0)	2.18 (0.99)	0.2	1.50	2.33	2.83	4.5	
		Week 46	Tezepelumab	50	50 (100.0)	1.63 (1.03)	0.0	1.00	1.50	2.50	4.3	
			Placebo	50	46 (92.0)	1.99 (1.04)	0.0	1.17	2.00	2.67	4.5	
		Week 48	Tezepelumab	50	50 (100.0)	1.67 (1.01)	0.0	1.00	1.67	2.33	4.3	
			Placebo	50	46 (92.0)	2.07 (1.07)	0.0	1.50	2.17	2.67	4.5	
		Week 50	Tezepelumab	50	50 (100.0)	1.61 (0.97)	0.0	1.00	1.50	2.33	4.3	
			Placebo	50	46 (92.0)	1.98 (0.99)	0.3	1.00	2.17	2.50	4.5	
		Week 52	Tezepelumab	50	50 (100.0)	1.60 (0.99)	0.0	1.00	1.58	2.33	4.3	
			Placebo	50	46 (92.0)	2.05 (1.04)	0.0	1.00	2.17	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	50	49 (98.0)	-0.58 (0.59)	-2.5	-0.83	-0.67	-0.17	0.5	-0.36 [-0.77, 0.06]
			Placebo	50	42 (84.0)	-0.35 (0.70)	-2.8	-0.83	-0.33	0.17	1.0	
		Week 4	Tezepelumab	50	49 (98.0)	-0.89 (0.73)	-2.5	-1.33	-0.83	-0.33	0.5	-0.71 [-1.14, -0.29]
			Placebo	50	42 (84.0)	-0.34 (0.84)	-2.3	-0.83	-0.25	0.17	1.2	
		Week 6	Tezepelumab	50	49 (98.0)	-1.13 (0.82)	-2.7	-1.67	-1.17	-0.67	1.2	-0.71 [-1.14, -0.29]
			Placebo	50	43 (86.0)	-0.50 (0.93)	-2.3	-1.17	-0.50	0.33	1.5	
		Week 8	Tezepelumab	50	49 (98.0)	-1.08 (0.99)	-3.0	-1.67	-1.00	-0.50	2.2	-0.62 [-1.04, -0.21]
			Placebo	50	44 (88.0)	-0.51 (0.82)	-2.5	-0.92	-0.50	0.00	1.0	
		Week 10	Tezepelumab	50	49 (98.0)	-1.19 (0.89)	-3.2	-1.67	-1.33	-0.67	0.5	-0.64 [-1.05, -0.22]
			Placebo	50	44 (88.0)	-0.61 (0.95)	-2.3	-1.17	-0.50	-0.17	2.5	
		Week 12	Tezepelumab	50	49 (98.0)	-1.27 (0.89)	-3.0	-1.83	-1.17	-0.67	0.5	-0.76 [-1.18, -0.34]
			Placebo	50	44 (88.0)	-0.60 (0.87)	-2.7	-1.00	-0.50	0.00	1.3	
		Week 14	Tezepelumab	50	49 (98.0)	-1.40 (0.93)	-3.7	-2.00	-1.50	-0.83	0.5	-0.72 [-1.14, -0.30]
			Placebo	50	44 (88.0)	-0.74 (0.90)	-2.5	-1.33	-0.83	-0.33	1.3	
		Week 16	Tezepelumab	50	49 (98.0)	-1.23 (1.01)	-3.0	-2.00	-1.17	-0.67	1.2	-0.65 [-1.07, -0.24]
			Placebo	50	44 (88.0)	-0.59 (0.93)	-2.5	-1.08	-0.58	0.00	2.3	
		Week 18	Tezepelumab	50	49 (98.0)	-1.37 (0.94)	-3.5	-2.00	-1.33	-0.83	0.5	-0.61 [-1.03, -0.19]
			Placebo	50	44 (88.0)	-0.80 (0.94)	-3.2	-1.42	-0.75	-0.33	2.3	
		Week 20	Tezepelumab	50	49 (98.0)	-1.33 (0.91)	-3.2	-2.00	-1.33	-0.67	0.5	-0.73 [-1.15, -0.31]
			Placebo	50	44 (88.0)	-0.66 (0.96)	-3.0	-1.17	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	50	49 (98.0)	-1.21 (0.91)	-3.2	-1.83	-1.00	-0.67	0.5	-0.54 [-0.96, -0.13]
			Placebo	50	44 (88.0)	-0.69 (1.01)	-3.2	-1.33	-0.67	-0.33	2.3	
		Week 24	Tezepelumab	50	49 (98.0)	-1.18 (0.84)	-3.2	-1.83	-1.17	-0.67	0.5	-0.57 [-0.98, -0.15]
			Placebo	50	44 (88.0)	-0.64 (1.05)	-3.0	-1.42	-0.50	0.00	2.3	
		Week 26	Tezepelumab	50	50 (100.0)	-1.31 (0.97)	-3.5	-2.00	-1.42	-0.67	0.5	-0.62 [-1.03, -0.20]
			Placebo	50	44 (88.0)	-0.69 (1.05)	-2.5	-1.42	-0.83	0.08	2.3	
		Week 28	Tezepelumab	50	50 (100.0)	-1.24 (0.94)	-3.2	-2.00	-1.25	-0.67	0.8	-0.68 [-1.09, -0.26]
			Placebo	50	44 (88.0)	-0.58 (1.01)	-2.5	-1.17	-0.50	-0.17	2.3	
		Week 30	Tezepelumab	50	50 (100.0)	-1.20 (1.07)	-3.5	-2.17	-1.00	-0.67	1.8	-0.60 [-1.01, -0.19]
			Placebo	50	45 (90.0)	-0.58 (0.99)	-2.5	-1.17	-0.50	-0.17	2.3	
		Week 32	Tezepelumab	50	50 (100.0)	-1.22 (1.03)	-3.5	-2.00	-1.00	-0.67	0.8	-0.65 [-1.06, -0.23]
			Placebo	50	45 (90.0)	-0.57 (0.99)	-2.5	-1.33	-0.50	0.00	2.3	
		Week 34	Tezepelumab	50	50 (100.0)	-1.22 (1.07)	-3.0	-2.00	-1.33	-0.50	2.0	-0.53 [-0.94, -0.12]
			Placebo	50	45 (90.0)	-0.65 (1.06)	-3.2	-1.50	-0.67	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Change from baseline	Week 36	Tezepelumab	50	50 (100.0)	-1.14 (1.13)	-3.0	-2.00	-1.08	-0.50	1.7	-0.52 [-0.93, -0.11]
			Placebo	50	45 (90.0)	-0.58 (1.05)	-3.2	-1.17	-0.50	0.00	2.3	
		Week 38	Tezepelumab	50	50 (100.0)	-1.22 (1.13)	-3.7	-2.00	-1.17	-0.50	2.3	-0.55 [-0.96, -0.14]
			Placebo	50	45 (90.0)	-0.62 (1.02)	-3.2	-1.33	-0.50	-0.17	2.3	
		Week 40	Tezepelumab	50	50 (100.0)	-1.23 (1.12)	-3.8	-2.00	-1.00	-0.67	1.7	-0.71 [-1.13, -0.30]
			Placebo	50	45 (90.0)	-0.45 (1.05)	-2.8	-1.17	-0.50	0.17	2.3	
		Week 42	Tezepelumab	50	50 (100.0)	-1.22 (1.07)	-3.3	-2.00	-1.17	-0.67	2.0	-0.60 [-1.01, -0.19]
			Placebo	50	45 (90.0)	-0.56 (1.13)	-2.8	-1.33	-0.67	0.00	2.3	
		Week 44	Tezepelumab	50	50 (100.0)	-1.24 (1.16)	-4.3	-1.83	-1.08	-0.33	1.5	-0.74 [-1.15, -0.33]
			Placebo	50	46 (92.0)	-0.43 (1.00)	-2.5	-1.17	-0.33	0.17	2.3	
		Week 46	Tezepelumab	50	50 (100.0)	-1.21 (1.14)	-4.2	-2.00	-1.08	-0.50	1.7	-0.52 [-0.93, -0.11]
			Placebo	50	46 (92.0)	-0.63 (1.11)	-3.2	-1.33	-0.67	0.17	2.3	
		Week 48	Tezepelumab	50	50 (100.0)	-1.18 (1.14)	-4.2	-2.00	-1.00	-0.50	1.8	-0.56 [-0.97, -0.15]
			Placebo	50	46 (92.0)	-0.55 (1.10)	-3.2	-1.17	-0.50	0.17	2.3	
		Week 50	Tezepelumab	50	50 (100.0)	-1.24 (1.06)	-3.8	-2.00	-1.17	-0.67	1.8	-0.57 [-0.98, -0.16]
			Placebo	50	46 (92.0)	-0.64 (1.03)	-2.8	-1.17	-0.67	0.00	2.3	
		Week 52	Tezepelumab	50	50 (100.0)	-1.24 (1.10)	-4.2	-2.00	-1.17	-0.67	1.8	-0.63 [-1.04, -0.22]
			Placebo	50	46 (92.0)	-0.57 (1.04)	-2.8	-1.33	-0.42	0.00	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	77	77 (100.0)	2.61 (0.83)	0.0	2.17	2.67	3.00	4.8	
			Placebo	80	80 (100.0)	2.67 (0.73)	0.3	2.25	2.67	3.17	4.7	
		Week 2	Tezepelumab	77	73 (94.8)	2.07 (0.98)	0.0	1.33	2.17	2.67	4.3	
			Placebo	80	75 (93.8)	2.32 (0.77)	0.2	2.00	2.33	2.83	4.7	
		Week 4	Tezepelumab	77	73 (94.8)	1.80 (1.04)	0.0	1.17	1.83	2.67	4.3	
			Placebo	80	75 (93.8)	2.16 (0.79)	0.3	1.50	2.33	2.67	4.0	
		Week 6	Tezepelumab	77	73 (94.8)	1.81 (1.04)	0.0	1.17	1.67	2.50	4.3	
			Placebo	80	75 (93.8)	2.06 (0.94)	0.2	1.33	2.33	2.67	5.5	
		Week 8	Tezepelumab	77	73 (94.8)	1.68 (1.09)	0.0	0.83	1.67	2.67	4.3	
			Placebo	80	75 (93.8)	2.03 (0.93)	0.0	1.50	2.00	2.67	4.7	
		Week 10	Tezepelumab	77	73 (94.8)	1.64 (1.06)	0.0	0.83	1.50	2.33	4.3	
			Placebo	80	76 (95.0)	1.99 (0.91)	0.0	1.50	2.00	2.67	5.3	
		Week 12	Tezepelumab	77	73 (94.8)	1.59 (1.06)	0.0	0.50	1.67	2.50	4.3	
			Placebo	80	76 (95.0)	1.84 (0.92)	0.0	1.17	1.92	2.50	4.3	
		Week 14	Tezepelumab	77	73 (94.8)	1.46 (1.06)	0.0	0.50	1.33	2.17	4.3	
			Placebo	80	76 (95.0)	1.86 (0.89)	0.0	1.25	2.00	2.50	5.0	
		Week 16	Tezepelumab	77	73 (94.8)	1.56 (1.05)	0.0	0.83	1.50	2.50	4.3	
			Placebo	80	76 (95.0)	1.97 (1.00)	0.0	1.25	2.00	2.67	5.0	
		Week 18	Tezepelumab	77	73 (94.8)	1.50 (1.04)	0.0	0.83	1.33	2.17	4.3	
			Placebo	80	76 (95.0)	1.94 (1.00)	0.0	1.33	2.00	2.50	5.0	
		Week 20	Tezepelumab	77	73 (94.8)	1.60 (1.08)	0.0	0.83	1.50	2.33	5.0	
			Placebo	80	76 (95.0)	1.95 (0.95)	0.0	1.33	2.17	2.67	5.0	
		Week 22	Tezepelumab	77	73 (94.8)	1.55 (1.03)	0.0	0.83	1.67	2.33	4.3	
			Placebo	80	76 (95.0)	1.92 (0.93)	0.0	1.17	2.00	2.58	5.0	
		Week 24	Tezepelumab	77	73 (94.8)	1.52 (1.07)	0.0	0.67	1.50	2.33	4.3	
			Placebo	80	76 (95.0)	1.87 (0.91)	0.0	1.17	1.92	2.50	4.2	
		Week 26	Tezepelumab	77	73 (94.8)	1.56 (1.10)	0.0	0.83	1.67	2.33	4.3	
			Placebo	80	76 (95.0)	1.79 (0.93)	0.0	1.17	1.67	2.50	4.2	
		Week 28	Tezepelumab	77	74 (96.1)	1.61 (1.11)	0.0	0.50	1.67	2.50	4.3	
			Placebo	80	77 (96.3)	1.80 (1.03)	0.0	1.00	2.00	2.50	4.2	
		Week 30	Tezepelumab	77	75 (97.4)	1.51 (1.06)	0.0	0.67	1.50	2.17	4.3	
			Placebo	80	77 (96.3)	1.81 (0.99)	0.0	1.17	1.83	2.50	4.2	
		Week 32	Tezepelumab	77	75 (97.4)	1.44 (1.08)	0.0	0.50	1.17	2.17	4.3	
			Placebo	80	77 (96.3)	1.71 (0.99)	0.0	1.00	1.67	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Absolute values	Week 34	Tezepelumab	77	75 (97.4)	1.47 (1.13)	0.0	0.67	1.33	2.17	4.3	
			Placebo	80	77 (96.3)	1.72 (0.99)	0.0	1.00	1.67	2.33	4.5	
		Week 36	Tezepelumab	77	75 (97.4)	1.55 (1.08)	0.0	0.67	1.67	2.33	4.3	
			Placebo	80	77 (96.3)	1.81 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 38	Tezepelumab	77	75 (97.4)	1.44 (1.08)	0.0	0.50	1.33	2.00	4.5	
			Placebo	80	77 (96.3)	1.69 (0.99)	0.0	1.00	1.67	2.50	4.5	
		Week 40	Tezepelumab	77	75 (97.4)	1.47 (1.09)	0.0	0.50	1.50	2.17	4.3	
			Placebo	80	77 (96.3)	1.72 (0.98)	0.0	1.00	1.83	2.50	4.2	
		Week 42	Tezepelumab	77	75 (97.4)	1.43 (1.11)	0.0	0.50	1.33	2.00	4.7	
			Placebo	80	77 (96.3)	1.73 (0.92)	0.0	1.00	1.83	2.50	3.3	
		Week 44	Tezepelumab	77	75 (97.4)	1.47 (1.06)	0.0	0.50	1.50	2.33	4.3	
			Placebo	80	77 (96.3)	1.73 (0.99)	0.0	1.00	1.83	2.50	4.0	
		Week 46	Tezepelumab	77	75 (97.4)	1.38 (1.06)	0.0	0.67	1.17	2.17	4.3	
			Placebo	80	77 (96.3)	1.66 (0.90)	0.0	1.00	1.83	2.33	3.3	
		Week 48	Tezepelumab	77	75 (97.4)	1.48 (1.09)	0.0	0.67	1.33	2.33	4.3	
			Placebo	80	77 (96.3)	1.66 (0.94)	0.0	1.00	1.67	2.50	3.3	
		Week 50	Tezepelumab	77	75 (97.4)	1.40 (1.11)	0.0	0.50	1.17	2.17	4.3	
			Placebo	80	77 (96.3)	1.63 (0.91)	0.0	1.00	1.67	2.33	3.3	
		Week 52	Tezepelumab	77	75 (97.4)	1.45 (1.08)	0.0	0.67	1.33	2.17	4.3	
			Placebo	80	77 (96.3)	1.66 (0.94)	0.0	1.00	1.67	2.50	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	77	73 (94.8)	-0.51 (0.73)	-2.8	-0.83	-0.33	0.00	0.7	-0.20 [-0.52, 0.12]
			Placebo	80	75 (93.8)	-0.37 (0.70)	-2.7	-0.83	-0.33	0.00	1.2	
		Week 4	Tezepelumab	77	73 (94.8)	-0.78 (0.98)	-3.5	-1.33	-0.83	-0.17	2.3	-0.28 [-0.60, 0.05]
			Placebo	80	75 (93.8)	-0.53 (0.84)	-3.0	-1.17	-0.33	0.00	1.2	
		Week 6	Tezepelumab	77	73 (94.8)	-0.78 (1.00)	-3.8	-1.33	-0.67	-0.17	2.3	-0.16 [-0.48, 0.17]
			Placebo	80	75 (93.8)	-0.63 (0.89)	-3.3	-1.17	-0.50	0.00	1.3	
		Week 8	Tezepelumab	77	73 (94.8)	-0.91 (0.99)	-3.8	-1.50	-0.83	-0.33	2.3	-0.25 [-0.58, 0.07]
			Placebo	80	75 (93.8)	-0.66 (0.94)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	77	73 (94.8)	-0.94 (0.99)	-3.8	-1.50	-1.00	-0.33	2.3	-0.23 [-0.56, 0.09]
			Placebo	80	76 (95.0)	-0.71 (0.98)	-3.3	-1.33	-0.67	0.00	2.7	
		Week 12	Tezepelumab	77	73 (94.8)	-1.00 (1.01)	-3.7	-1.67	-1.00	-0.50	2.3	-0.14 [-0.47, 0.18]
			Placebo	80	76 (95.0)	-0.85 (1.00)	-3.3	-1.42	-0.75	-0.17	1.3	
		Week 14	Tezepelumab	77	73 (94.8)	-1.12 (1.01)	-3.8	-1.83	-1.17	-0.33	2.3	-0.29 [-0.61, 0.03]
			Placebo	80	76 (95.0)	-0.83 (0.99)	-3.2	-1.33	-0.75	-0.17	2.3	
		Week 16	Tezepelumab	77	73 (94.8)	-1.02 (0.98)	-3.8	-1.67	-1.00	-0.50	2.3	-0.29 [-0.61, 0.03]
			Placebo	80	76 (95.0)	-0.72 (1.08)	-3.5	-1.33	-0.67	0.00	2.3	
		Week 18	Tezepelumab	77	73 (94.8)	-1.08 (0.99)	-3.8	-1.67	-1.00	-0.50	2.3	-0.31 [-0.64, 0.01]
			Placebo	80	76 (95.0)	-0.75 (1.07)	-3.2	-1.42	-0.67	0.00	2.3	
		Week 20	Tezepelumab	77	73 (94.8)	-0.98 (1.00)	-3.8	-1.67	-0.83	-0.33	2.3	-0.23 [-0.55, 0.09]
			Placebo	80	76 (95.0)	-0.75 (1.06)	-3.5	-1.33	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	77	73 (94.8)	-1.03 (1.06)	-3.8	-1.67	-1.00	-0.50	2.3	-0.25 [-0.57, 0.08]
			Placebo	80	76 (95.0)	-0.78 (0.99)	-3.3	-1.42	-0.75	0.00	2.3	
		Week 24	Tezepelumab	77	73 (94.8)	-1.06 (1.01)	-3.8	-1.67	-1.00	-0.50	2.3	-0.24 [-0.56, 0.09]
			Placebo	80	76 (95.0)	-0.83 (1.01)	-3.5	-1.42	-0.75	-0.17	1.5	
		Week 26	Tezepelumab	77	73 (94.8)	-1.03 (1.04)	-3.8	-1.83	-1.00	-0.33	2.3	-0.12 [-0.44, 0.21]
			Placebo	80	76 (95.0)	-0.90 (1.06)	-4.0	-1.50	-1.00	-0.17	1.5	
		Week 28	Tezepelumab	77	74 (96.1)	-0.97 (1.04)	-3.8	-1.83	-0.92	-0.17	2.3	-0.10 [-0.42, 0.22]
			Placebo	80	77 (96.3)	-0.86 (1.11)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	77	75 (97.4)	-1.08 (1.01)	-3.7	-1.83	-1.00	-0.33	2.3	-0.21 [-0.53, 0.11]
			Placebo	80	77 (96.3)	-0.86 (1.08)	-3.2	-1.50	-1.00	-0.17	2.0	
		Week 32	Tezepelumab	77	75 (97.4)	-1.14 (1.03)	-3.8	-1.83	-1.00	-0.50	2.3	-0.19 [-0.51, 0.13]
			Placebo	80	77 (96.3)	-0.95 (1.04)	-3.5	-1.67	-1.00	-0.33	1.5	
		Week 34	Tezepelumab	77	75 (97.4)	-1.12 (1.05)	-3.8	-1.83	-1.00	-0.67	2.3	-0.17 [-0.49, 0.15]
			Placebo	80	77 (96.3)	-0.95 (1.02)	-4.0	-1.50	-1.00	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Change from baseline	Week 36	Tezepelumab	77	75 (97.4)	-1.04 (1.07)	-3.8	-1.67	-1.00	-0.17	2.3	-0.17 [-0.49, 0.15]
			Placebo	80	77 (96.3)	-0.85 (1.06)	-3.5	-1.33	-0.83	-0.17	1.5	
		Week 38	Tezepelumab	77	75 (97.4)	-1.14 (1.06)	-3.8	-2.00	-1.17	-0.33	2.3	-0.16 [-0.48, 0.16]
			Placebo	80	77 (96.3)	-0.97 (1.07)	-4.0	-1.67	-1.00	-0.33	1.5	
		Week 40	Tezepelumab	77	75 (97.4)	-1.12 (1.06)	-3.8	-2.00	-1.00	-0.33	2.3	-0.17 [-0.48, 0.15]
			Placebo	80	77 (96.3)	-0.95 (1.02)	-4.0	-1.50	-1.00	-0.33	1.5	
		Week 42	Tezepelumab	77	75 (97.4)	-1.16 (1.09)	-3.8	-2.00	-1.17	-0.50	2.3	-0.22 [-0.54, 0.10]
			Placebo	80	77 (96.3)	-0.94 (0.96)	-4.0	-1.33	-1.00	-0.33	0.7	
		Week 44	Tezepelumab	77	75 (97.4)	-1.12 (1.04)	-3.8	-2.00	-1.00	-0.50	2.3	-0.18 [-0.50, 0.14]
			Placebo	80	77 (96.3)	-0.94 (1.05)	-4.0	-1.67	-0.83	-0.33	1.2	
		Week 46	Tezepelumab	77	75 (97.4)	-1.20 (1.04)	-3.8	-2.00	-1.17	-0.67	2.3	-0.20 [-0.52, 0.12]
			Placebo	80	77 (96.3)	-1.01 (0.95)	-4.0	-1.50	-1.17	-0.33	0.8	
		Week 48	Tezepelumab	77	75 (97.4)	-1.11 (1.05)	-3.8	-1.83	-1.00	-0.33	2.3	-0.10 [-0.42, 0.22]
			Placebo	80	77 (96.3)	-1.00 (0.99)	-3.7	-1.50	-1.00	-0.33	1.0	
		Week 50	Tezepelumab	77	75 (97.4)	-1.19 (1.11)	-3.8	-2.00	-1.33	-0.33	2.3	-0.15 [-0.47, 0.17]
			Placebo	80	77 (96.3)	-1.03 (0.96)	-4.0	-1.67	-1.00	-0.33	1.0	
		Week 52	Tezepelumab	77	75 (97.4)	-1.14 (1.09)	-3.8	-2.00	-1.00	-0.33	2.3	-0.13 [-0.45, 0.19]
			Placebo	80	77 (96.3)	-1.00 (1.00)	-4.0	-1.50	-1.00	-0.33	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	70	70 (100.0)	2.56 (0.68)	0.0	2.17	2.67	3.00	3.8	
			Placebo	62	62 (100.0)	2.66 (0.69)	1.3	2.17	2.67	3.00	4.7	
		Week 2	Tezepelumab	70	68 (97.1)	2.12 (0.81)	0.0	1.58	2.17	2.67	4.2	
			Placebo	62	54 (87.1)	2.23 (0.88)	0.3	1.67	2.17	2.83	4.8	
		Week 4	Tezepelumab	70	68 (97.1)	1.85 (0.86)	0.2	1.17	2.00	2.50	3.3	
			Placebo	62	54 (87.1)	2.21 (0.88)	0.5	1.50	2.33	2.83	4.2	
		Week 6	Tezepelumab	70	68 (97.1)	1.72 (0.90)	0.0	1.17	1.67	2.33	3.7	
			Placebo	62	55 (88.7)	2.13 (1.11)	0.3	1.17	2.00	2.67	5.5	
		Week 8	Tezepelumab	70	68 (97.1)	1.74 (1.02)	0.0	1.08	1.67	2.58	4.8	
			Placebo	62	56 (90.3)	2.16 (1.05)	0.2	1.42	2.33	2.83	4.7	
		Week 10	Tezepelumab	70	68 (97.1)	1.63 (0.98)	0.0	0.92	1.67	2.33	4.3	
			Placebo	62	56 (90.3)	2.00 (0.92)	0.2	1.25	2.08	2.67	4.2	
		Week 12	Tezepelumab	70	68 (97.1)	1.50 (1.00)	0.0	0.58	1.42	2.42	4.3	
			Placebo	62	56 (90.3)	1.87 (0.95)	0.0	1.33	1.83	2.58	4.3	
		Week 14	Tezepelumab	70	68 (97.1)	1.39 (0.95)	0.0	0.58	1.33	2.08	4.3	
			Placebo	62	56 (90.3)	1.79 (0.96)	0.0	1.08	1.75	2.50	5.0	
		Week 16	Tezepelumab	70	68 (97.1)	1.55 (0.99)	0.0	0.75	1.50	2.50	4.3	
			Placebo	62	56 (90.3)	1.99 (1.11)	0.0	1.17	1.83	2.67	4.8	
		Week 18	Tezepelumab	70	69 (98.6)	1.43 (0.89)	0.0	0.83	1.33	2.00	4.3	
			Placebo	62	56 (90.3)	1.79 (1.12)	0.0	0.83	1.75	2.67	4.7	
		Week 20	Tezepelumab	70	69 (98.6)	1.52 (0.98)	0.0	0.83	1.50	2.17	4.3	
			Placebo	62	56 (90.3)	1.85 (1.06)	0.0	0.92	2.00	2.58	4.5	
		Week 22	Tezepelumab	70	69 (98.6)	1.60 (0.93)	0.0	1.00	1.67	2.33	4.3	
			Placebo	62	56 (90.3)	1.81 (1.08)	0.0	0.92	1.83	2.67	4.5	
		Week 24	Tezepelumab	70	69 (98.6)	1.52 (0.95)	0.0	1.00	1.67	2.33	4.3	
			Placebo	62	56 (90.3)	1.87 (1.07)	0.0	0.83	2.00	2.58	4.5	
		Week 26	Tezepelumab	70	70 (100.0)	1.52 (0.97)	0.0	0.83	1.42	2.17	4.3	
			Placebo	62	56 (90.3)	1.83 (1.11)	0.0	1.00	1.83	2.83	4.5	
		Week 28	Tezepelumab	70	70 (100.0)	1.57 (1.03)	0.0	1.00	1.50	2.50	4.3	
			Placebo	62	56 (90.3)	1.99 (1.11)	0.0	1.00	2.00	2.83	4.5	
		Week 30	Tezepelumab	70	70 (100.0)	1.55 (0.99)	0.0	0.83	1.50	2.17	4.3	
			Placebo	62	57 (91.9)	1.91 (1.05)	0.0	1.17	1.83	2.83	4.5	
		Week 32	Tezepelumab	70	70 (100.0)	1.51 (1.00)	0.0	1.00	1.50	2.33	4.3	
			Placebo	62	57 (91.9)	1.93 (1.02)	0.0	1.17	1.83	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Absolute values	Week 34	Tezepelumab	70	70 (100.0)	1.52 (1.03)	0.0	1.00	1.33	2.17	4.3	
			Placebo	62	57 (91.9)	1.82 (1.07)	0.0	1.17	1.83	2.67	4.5	
		Week 36	Tezepelumab	70	70 (100.0)	1.59 (1.08)	0.0	0.83	1.50	2.33	4.5	
			Placebo	62	57 (91.9)	1.89 (1.09)	0.0	1.33	1.83	2.67	4.5	
		Week 38	Tezepelumab	70	70 (100.0)	1.56 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	62	57 (91.9)	1.85 (1.05)	0.0	1.00	1.83	2.67	4.5	
		Week 40	Tezepelumab	70	70 (100.0)	1.56 (1.00)	0.0	0.83	1.67	2.17	4.3	
			Placebo	62	57 (91.9)	1.99 (1.12)	0.0	1.17	2.00	2.83	4.5	
		Week 42	Tezepelumab	70	70 (100.0)	1.57 (1.10)	0.0	0.83	1.58	2.17	4.7	
			Placebo	62	57 (91.9)	1.94 (1.05)	0.0	1.33	2.00	2.67	4.5	
		Week 44	Tezepelumab	70	70 (100.0)	1.59 (1.03)	0.0	0.83	1.58	2.50	4.3	
			Placebo	62	57 (91.9)	2.00 (1.08)	0.0	1.17	2.00	2.83	4.5	
		Week 46	Tezepelumab	70	70 (100.0)	1.51 (1.03)	0.0	0.83	1.50	2.17	4.3	
			Placebo	62	57 (91.9)	1.91 (1.04)	0.0	1.17	2.00	2.50	4.5	
		Week 48	Tezepelumab	70	70 (100.0)	1.56 (1.05)	0.0	0.67	1.50	2.33	4.3	
			Placebo	62	57 (91.9)	1.96 (1.09)	0.0	1.17	2.00	2.67	4.5	
		Week 50	Tezepelumab	70	70 (100.0)	1.50 (1.02)	0.0	0.83	1.50	2.17	4.3	
			Placebo	62	57 (91.9)	1.93 (1.03)	0.0	1.33	2.00	2.50	4.5	
		Week 52	Tezepelumab	70	70 (100.0)	1.50 (1.03)	0.0	0.67	1.67	2.17	4.3	
			Placebo	62	57 (91.9)	1.98 (1.06)	0.0	1.17	2.17	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 2	Tezepelumab	70	68 (97.1)	-0.47 (0.66)	-2.8	-0.83	-0.33	0.00	0.7	-0.09 [-0.45, 0.27]
			Placebo	62	54 (87.1)	-0.41 (0.77)	-2.8	-0.83	-0.33	0.17	1.0	
		Week 4	Tezepelumab	70	68 (97.1)	-0.74 (0.85)	-2.7	-1.33	-0.67	-0.17	2.3	-0.37 [-0.73, -0.01]
			Placebo	62	54 (87.1)	-0.44 (0.83)	-2.2	-1.00	-0.67	0.17	1.2	
		Week 6	Tezepelumab	70	68 (97.1)	-0.87 (0.95)	-2.8	-1.33	-0.83	-0.25	2.3	-0.38 [-0.74, -0.02]
			Placebo	62	55 (88.7)	-0.50 (0.98)	-2.3	-1.33	-0.50	0.33	1.5	
		Week 8	Tezepelumab	70	68 (97.1)	-0.85 (1.03)	-3.0	-1.50	-0.83	-0.33	2.3	-0.37 [-0.73, -0.01]
			Placebo	62	56 (90.3)	-0.49 (0.93)	-3.0	-1.00	-0.50	0.25	1.0	
		Week 10	Tezepelumab	70	68 (97.1)	-0.96 (1.00)	-3.2	-1.58	-0.83	-0.25	2.3	-0.32 [-0.67, 0.04]
			Placebo	62	56 (90.3)	-0.65 (0.95)	-2.3	-1.33	-0.58	-0.17	2.5	
		Week 12	Tezepelumab	70	68 (97.1)	-1.09 (0.97)	-2.8	-1.83	-1.00	-0.50	2.3	-0.34 [-0.69, 0.02]
			Placebo	62	56 (90.3)	-0.77 (0.95)	-3.2	-1.25	-0.67	-0.25	1.3	
		Week 14	Tezepelumab	70	68 (97.1)	-1.20 (0.95)	-3.2	-1.92	-1.17	-0.67	2.3	-0.35 [-0.71, 0.01]
			Placebo	62	56 (90.3)	-0.86 (0.98)	-3.2	-1.50	-0.83	-0.42	1.3	
		Week 16	Tezepelumab	70	68 (97.1)	-1.04 (0.96)	-3.0	-1.83	-1.00	-0.42	2.3	-0.38 [-0.74, -0.02]
			Placebo	62	56 (90.3)	-0.66 (1.06)	-3.2	-1.25	-0.75	0.08	2.3	
		Week 18	Tezepelumab	70	69 (98.6)	-1.15 (0.94)	-3.2	-1.83	-1.00	-0.67	2.3	-0.29 [-0.64, 0.07]
			Placebo	62	56 (90.3)	-0.86 (1.13)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 20	Tezepelumab	70	69 (98.6)	-1.06 (0.99)	-3.2	-1.83	-1.00	-0.33	2.3	-0.26 [-0.61, 0.09]
			Placebo	62	56 (90.3)	-0.80 (1.04)	-3.0	-1.50	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	70	69 (98.6)	-0.98 (1.01)	-3.0	-1.67	-1.00	-0.33	2.3	-0.13 [-0.49, 0.22]
			Placebo	62	56 (90.3)	-0.84 (1.06)	-3.2	-1.50	-0.83	0.00	2.3	
		Week 24	Tezepelumab	70	69 (98.6)	-1.06 (0.94)	-3.2	-1.67	-1.00	-0.50	2.3	-0.28 [-0.63, 0.08]
			Placebo	62	56 (90.3)	-0.78 (1.11)	-3.0	-1.50	-0.83	0.00	2.3	
		Week 26	Tezepelumab	70	70 (100.0)	-1.05 (0.96)	-3.0	-1.67	-1.00	-0.33	2.3	-0.22 [-0.57, 0.13]
			Placebo	62	56 (90.3)	-0.82 (1.12)	-3.2	-1.50	-1.00	0.17	2.3	
		Week 28	Tezepelumab	70	70 (100.0)	-1.00 (1.05)	-3.2	-1.67	-1.00	-0.17	2.3	-0.31 [-0.67, 0.04]
			Placebo	62	56 (90.3)	-0.66 (1.11)	-3.2	-1.50	-0.75	0.08	2.3	
		Week 30	Tezepelumab	70	70 (100.0)	-1.02 (1.01)	-2.8	-2.00	-1.00	-0.33	2.3	-0.27 [-0.62, 0.08]
			Placebo	62	57 (91.9)	-0.74 (1.04)	-3.0	-1.50	-0.67	-0.33	2.3	
		Week 32	Tezepelumab	70	70 (100.0)	-1.05 (0.99)	-3.0	-1.83	-1.00	-0.50	2.3	-0.33 [-0.68, 0.02]
			Placebo	62	57 (91.9)	-0.72 (1.03)	-3.0	-1.33	-0.67	-0.17	2.3	
		Week 34	Tezepelumab	70	70 (100.0)	-1.05 (1.04)	-2.8	-1.83	-1.08	-0.33	2.3	-0.20 [-0.55, 0.15]
			Placebo	62	57 (91.9)	-0.83 (1.07)	-3.2	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Change from baseline	Week 36	Tezepelumab	70	70 (100.0)	-0.98 (1.09)	-3.0	-1.83	-1.00	-0.33	2.3	-0.21 [-0.56, 0.14]
			Placebo	62	57 (91.9)	-0.75 (1.09)	-3.2	-1.33	-0.83	0.00	2.3	
		Week 38	Tezepelumab	70	70 (100.0)	-1.01 (1.06)	-3.0	-2.00	-1.00	-0.33	2.3	-0.19 [-0.54, 0.16]
			Placebo	62	57 (91.9)	-0.80 (1.11)	-3.2	-1.33	-0.83	0.00	2.3	
		Week 40	Tezepelumab	70	70 (100.0)	-1.00 (1.03)	-3.2	-1.67	-1.00	-0.33	2.3	-0.31 [-0.66, 0.04]
			Placebo	62	57 (91.9)	-0.66 (1.16)	-2.8	-1.50	-0.67	0.17	2.3	
		Week 42	Tezepelumab	70	70 (100.0)	-1.00 (1.09)	-2.8	-1.83	-0.83	-0.50	2.3	-0.26 [-0.61, 0.09]
			Placebo	62	57 (91.9)	-0.71 (1.11)	-2.8	-1.50	-0.83	0.00	2.3	
		Week 44	Tezepelumab	70	70 (100.0)	-0.97 (1.03)	-3.2	-1.67	-1.00	-0.17	2.3	-0.30 [-0.65, 0.05]
			Placebo	62	57 (91.9)	-0.65 (1.15)	-3.0	-1.50	-0.83	0.33	2.3	
		Week 46	Tezepelumab	70	70 (100.0)	-1.05 (1.04)	-2.8	-2.00	-1.00	-0.33	2.3	-0.29 [-0.64, 0.06]
			Placebo	62	57 (91.9)	-0.74 (1.13)	-3.2	-1.50	-0.67	0.00	2.3	
		Week 48	Tezepelumab	70	70 (100.0)	-1.00 (1.06)	-2.7	-2.00	-0.92	-0.17	2.3	-0.29 [-0.64, 0.06]
			Placebo	62	57 (91.9)	-0.69 (1.15)	-3.2	-1.50	-0.67	0.17	2.3	
		Week 50	Tezepelumab	70	70 (100.0)	-1.07 (1.04)	-2.8	-2.00	-1.00	-0.50	2.3	-0.32 [-0.67, 0.03]
			Placebo	62	57 (91.9)	-0.72 (1.10)	-3.0	-1.33	-0.67	0.00	2.3	
		Week 52	Tezepelumab	70	70 (100.0)	-1.07 (1.06)	-2.8	-2.00	-1.00	-0.33	2.3	-0.36 [-0.72, -0.01]
			Placebo	62	57 (91.9)	-0.67 (1.14)	-3.0	-1.50	-0.67	0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	65	65 (100.0)	2.81 (0.87)	0.3	2.33	2.67	3.33	4.8	
			Placebo	75	75 (100.0)	2.65 (0.69)	0.3	2.33	2.67	3.00	4.2	
		Week 2	Tezepelumab	65	61 (93.8)	2.19 (1.00)	0.0	1.67	2.17	2.83	4.3	
			Placebo	75	70 (93.3)	2.35 (0.73)	0.2	2.00	2.33	2.83	4.3	
		Week 4	Tezepelumab	65	61 (93.8)	1.90 (1.06)	0.0	1.17	2.00	2.67	4.3	
			Placebo	75	70 (93.3)	2.18 (0.79)	0.3	1.67	2.33	2.67	4.2	
		Week 6	Tezepelumab	65	61 (93.8)	1.87 (1.05)	0.0	1.17	1.83	2.50	4.3	
			Placebo	75	70 (93.3)	2.07 (0.81)	0.2	1.67	2.25	2.67	4.2	
		Week 8	Tezepelumab	65	61 (93.8)	1.71 (1.05)	0.0	1.00	1.67	2.67	4.3	
			Placebo	75	70 (93.3)	2.00 (0.84)	0.0	1.50	2.00	2.50	4.0	
		Week 10	Tezepelumab	65	61 (93.8)	1.66 (1.04)	0.0	0.83	1.67	2.33	4.3	
			Placebo	75	71 (94.7)	1.99 (0.90)	0.0	1.50	2.00	2.50	5.3	
		Week 12	Tezepelumab	65	61 (93.8)	1.66 (1.04)	0.0	0.83	1.67	2.50	4.3	
			Placebo	75	71 (94.7)	1.94 (0.92)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	65	61 (93.8)	1.51 (1.06)	0.0	0.83	1.50	2.17	4.3	
			Placebo	75	71 (94.7)	1.91 (0.86)	0.0	1.33	2.00	2.50	5.0	
		Week 16	Tezepelumab	65	61 (93.8)	1.66 (1.12)	0.0	0.83	1.67	2.50	4.3	
			Placebo	75	71 (94.7)	1.98 (0.96)	0.0	1.17	2.17	2.67	5.0	
		Week 18	Tezepelumab	65	61 (93.8)	1.55 (1.05)	0.0	0.83	1.33	2.17	4.3	
			Placebo	75	71 (94.7)	1.94 (0.86)	0.0	1.33	2.00	2.33	5.0	
		Week 20	Tezepelumab	65	61 (93.8)	1.63 (1.07)	0.0	0.83	1.50	2.33	5.0	
			Placebo	75	71 (94.7)	2.00 (0.94)	0.0	1.33	2.17	2.67	5.0	
		Week 22	Tezepelumab	65	61 (93.8)	1.55 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	75	71 (94.7)	1.94 (0.93)	0.0	1.17	2.00	2.50	5.0	
		Week 24	Tezepelumab	65	61 (93.8)	1.64 (1.12)	0.0	0.83	1.67	2.33	4.3	
			Placebo	75	71 (94.7)	1.89 (0.89)	0.0	1.17	2.00	2.50	4.2	
		Week 26	Tezepelumab	65	61 (93.8)	1.59 (1.06)	0.0	0.83	1.50	2.33	4.3	
			Placebo	75	71 (94.7)	1.83 (0.86)	0.0	1.17	1.67	2.50	4.2	
		Week 28	Tezepelumab	65	62 (95.4)	1.63 (1.06)	0.0	0.83	1.58	2.33	4.3	
			Placebo	75	72 (96.0)	1.80 (0.98)	0.0	1.00	2.00	2.50	4.2	
		Week 30	Tezepelumab	65	63 (96.9)	1.53 (1.02)	0.0	0.83	1.50	2.33	4.3	
			Placebo	75	72 (96.0)	1.84 (0.99)	0.0	1.17	1.92	2.50	4.2	
		Week 32	Tezepelumab	65	63 (96.9)	1.49 (1.06)	0.0	0.67	1.33	2.33	4.3	
			Placebo	75	72 (96.0)	1.75 (1.02)	0.0	1.00	1.58	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Absolute values	Week 34	Tezepelumab	65	63 (96.9)	1.50 (1.10)	0.0	0.67	1.33	2.33	4.3	
			Placebo	75	72 (96.0)	1.77 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	65	63 (96.9)	1.60 (1.02)	0.0	0.83	1.67	2.33	4.3	
			Placebo	75	72 (96.0)	1.85 (1.00)	0.0	1.00	2.08	2.50	4.5	
		Week 38	Tezepelumab	65	63 (96.9)	1.43 (1.04)	0.0	0.67	1.33	2.00	4.5	
			Placebo	75	72 (96.0)	1.74 (0.99)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	65	63 (96.9)	1.48 (1.10)	0.0	0.50	1.33	2.33	4.3	
			Placebo	75	72 (96.0)	1.77 (0.96)	0.0	1.00	1.83	2.50	4.2	
		Week 42	Tezepelumab	65	63 (96.9)	1.42 (1.00)	0.0	0.67	1.33	2.00	4.3	
			Placebo	75	72 (96.0)	1.75 (0.97)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	65	63 (96.9)	1.46 (1.03)	0.0	0.67	1.33	2.33	4.3	
			Placebo	75	73 (97.3)	1.78 (0.95)	0.0	1.00	2.00	2.50	3.8	
		Week 46	Tezepelumab	65	63 (96.9)	1.47 (1.06)	0.0	0.67	1.17	2.33	4.3	
			Placebo	75	73 (97.3)	1.66 (0.91)	0.0	1.00	1.83	2.33	3.3	
		Week 48	Tezepelumab	65	63 (96.9)	1.53 (1.05)	0.0	0.67	1.50	2.33	4.3	
			Placebo	75	73 (97.3)	1.68 (0.93)	0.0	1.00	1.83	2.33	3.5	
		Week 50	Tezepelumab	65	63 (96.9)	1.42 (1.06)	0.0	0.67	1.17	2.17	4.3	
			Placebo	75	73 (97.3)	1.66 (0.89)	0.0	1.00	1.67	2.33	3.3	
		Week 52	Tezepelumab	65	63 (96.9)	1.49 (1.04)	0.0	0.67	1.33	2.17	4.3	
			Placebo	75	73 (97.3)	1.72 (0.93)	0.0	1.00	1.83	2.50	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 2	Tezepelumab	65	61 (93.8)	-0.61 (0.69)	-2.5	-1.17	-0.50	-0.17	0.5	-0.41 [-0.76, -0.07]
			Placebo	75	70 (93.3)	-0.33 (0.66)	-2.7	-0.67	-0.33	0.00	1.2	
		Week 4	Tezepelumab	65	61 (93.8)	-0.90 (0.92)	-3.5	-1.50	-0.83	-0.33	1.7	-0.46 [-0.81, -0.11]
			Placebo	75	70 (93.3)	-0.50 (0.81)	-3.0	-1.00	-0.33	0.00	1.2	
		Week 6	Tezepelumab	65	61 (93.8)	-0.93 (0.98)	-3.8	-1.50	-0.83	-0.33	1.3	-0.36 [-0.71, -0.01]
			Placebo	75	70 (93.3)	-0.61 (0.80)	-3.3	-1.17	-0.50	-0.17	1.0	
		Week 8	Tezepelumab	65	61 (93.8)	-1.08 (0.96)	-3.8	-1.67	-1.00	-0.50	1.0	-0.45 [-0.79, -0.10]
			Placebo	75	70 (93.3)	-0.68 (0.85)	-3.2	-1.00	-0.67	-0.17	1.0	
		Week 10	Tezepelumab	65	61 (93.8)	-1.14 (0.97)	-3.8	-1.67	-1.17	-0.50	1.0	-0.45 [-0.80, -0.11]
			Placebo	75	71 (94.7)	-0.70 (0.95)	-3.3	-1.33	-0.67	0.00	2.7	
		Week 12	Tezepelumab	65	61 (93.8)	-1.14 (1.01)	-3.7	-1.83	-1.17	-0.50	1.2	-0.39 [-0.73, -0.04]
			Placebo	75	71 (94.7)	-0.75 (0.97)	-3.3	-1.33	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	65	61 (93.8)	-1.29 (1.05)	-3.8	-1.83	-1.33	-0.67	1.2	-0.51 [-0.86, -0.16]
			Placebo	75	71 (94.7)	-0.79 (0.92)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 16	Tezepelumab	65	61 (93.8)	-1.14 (1.13)	-4.2	-1.83	-1.00	-0.50	1.5	-0.40 [-0.75, -0.06]
			Placebo	75	71 (94.7)	-0.71 (1.01)	-3.5	-1.33	-0.50	0.00	2.3	
		Week 18	Tezepelumab	65	61 (93.8)	-1.25 (1.08)	-4.2	-1.83	-1.00	-0.50	1.2	-0.50 [-0.84, -0.15]
			Placebo	75	71 (94.7)	-0.75 (0.92)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	65	61 (93.8)	-1.17 (1.04)	-4.2	-1.83	-1.00	-0.50	1.0	-0.45 [-0.80, -0.10]
			Placebo	75	71 (94.7)	-0.70 (1.05)	-3.5	-1.33	-0.50	-0.17	2.3	
		Week 22	Tezepelumab	65	61 (93.8)	-1.25 (1.04)	-4.3	-1.83	-1.17	-0.67	1.2	-0.50 [-0.84, -0.15]
			Placebo	75	71 (94.7)	-0.75 (0.97)	-3.3	-1.33	-0.67	-0.17	2.3	
		Week 24	Tezepelumab	65	61 (93.8)	-1.16 (1.03)	-4.5	-1.83	-1.00	-0.50	1.5	-0.36 [-0.70, -0.01]
			Placebo	75	71 (94.7)	-0.80 (0.98)	-3.5	-1.33	-0.67	-0.17	1.5	
		Week 26	Tezepelumab	65	61 (93.8)	-1.21 (1.08)	-4.2	-2.00	-1.17	-0.33	1.3	-0.34 [-0.68, 0.01]
			Placebo	75	71 (94.7)	-0.86 (0.98)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 28	Tezepelumab	65	62 (95.4)	-1.16 (1.02)	-4.2	-1.83	-1.17	-0.50	1.0	-0.29 [-0.63, 0.05]
			Placebo	75	72 (96.0)	-0.86 (1.04)	-4.0	-1.58	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	65	63 (96.9)	-1.26 (1.06)	-4.2	-1.83	-1.17	-0.50	1.5	-0.42 [-0.76, -0.08]
			Placebo	75	72 (96.0)	-0.81 (1.07)	-3.2	-1.50	-0.83	-0.17	2.0	
		Week 32	Tezepelumab	65	63 (96.9)	-1.30 (1.07)	-4.2	-2.00	-1.17	-0.67	1.8	-0.37 [-0.71, -0.03]
			Placebo	75	72 (96.0)	-0.91 (1.05)	-3.5	-1.58	-0.83	-0.33	1.5	
		Week 34	Tezepelumab	65	63 (96.9)	-1.30 (1.07)	-4.2	-2.00	-1.17	-0.67	1.8	-0.39 [-0.73, -0.05]
			Placebo	75	72 (96.0)	-0.89 (1.03)	-4.0	-1.58	-0.83	-0.25	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Change from baseline	Week 36	Tezepelumab	65	63 (96.9)	-1.20 (1.09)	-4.2	-1.83	-1.17	-0.50	1.5	-0.36 [-0.70, -0.02]
			Placebo	75	72 (96.0)	-0.81 (1.07)	-3.5	-1.33	-0.83	-0.08	1.5	
		Week 38	Tezepelumab	65	63 (96.9)	-1.37 (1.06)	-4.2	-2.00	-1.33	-0.83	0.8	-0.42 [-0.77, -0.08]
			Placebo	75	72 (96.0)	-0.92 (1.03)	-4.0	-1.67	-0.83	-0.33	1.5	
		Week 40	Tezepelumab	65	63 (96.9)	-1.31 (1.10)	-4.2	-2.17	-1.33	-0.67	1.2	-0.41 [-0.75, -0.07]
			Placebo	75	72 (96.0)	-0.89 (0.97)	-4.0	-1.42	-0.83	-0.25	1.5	
		Week 42	Tezepelumab	65	63 (96.9)	-1.38 (1.05)	-4.2	-2.00	-1.33	-0.67	0.8	-0.47 [-0.81, -0.12]
			Placebo	75	72 (96.0)	-0.91 (0.98)	-4.0	-1.33	-0.83	-0.25	1.3	
		Week 44	Tezepelumab	65	63 (96.9)	-1.34 (1.09)	-4.2	-2.00	-1.17	-0.67	0.7	-0.45 [-0.79, -0.11]
			Placebo	75	73 (97.3)	-0.88 (0.98)	-4.0	-1.50	-0.83	-0.33	1.2	
		Week 46	Tezepelumab	65	63 (96.9)	-1.33 (1.08)	-4.2	-2.17	-1.33	-0.67	1.0	-0.33 [-0.67, 0.00]
			Placebo	75	73 (97.3)	-1.00 (0.94)	-4.0	-1.50	-1.00	-0.33	1.0	
		Week 48	Tezepelumab	65	63 (96.9)	-1.27 (1.06)	-4.2	-1.83	-1.17	-0.67	1.2	-0.28 [-0.62, 0.06]
			Placebo	75	73 (97.3)	-0.98 (0.98)	-3.7	-1.50	-0.83	-0.33	1.0	
		Week 50	Tezepelumab	65	63 (96.9)	-1.38 (1.08)	-4.2	-2.00	-1.33	-0.67	1.2	-0.38 [-0.72, -0.04]
			Placebo	75	73 (97.3)	-0.99 (0.94)	-4.0	-1.67	-1.00	-0.33	1.0	
		Week 52	Tezepelumab	65	63 (96.9)	-1.31 (1.08)	-4.2	-2.00	-1.33	-0.67	1.2	-0.37 [-0.71, -0.03]
			Placebo	75	73 (97.3)	-0.94 (0.95)	-4.0	-1.50	-0.83	-0.33	1.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	62	62 (100.0)	2.77 (0.70)	1.7	2.33	2.67	3.00	4.8	
			Placebo	67	67 (100.0)	2.60 (0.65)	0.3	2.17	2.67	3.00	4.3	
		Week 2	Tezepelumab	62	58 (93.5)	2.36 (0.84)	0.0	1.83	2.42	2.83	4.3	
			Placebo	67	59 (88.1)	2.19 (0.76)	0.2	2.00	2.33	2.67	4.8	
		Week 4	Tezepelumab	62	58 (93.5)	2.17 (0.89)	0.2	1.67	2.25	2.83	4.3	
			Placebo	67	59 (88.1)	2.13 (0.86)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	62	58 (93.5)	2.07 (0.94)	0.0	1.50	2.00	2.67	4.3	
			Placebo	67	59 (88.1)	1.99 (0.97)	0.2	1.17	2.00	2.67	4.7	
		Week 8	Tezepelumab	62	58 (93.5)	2.08 (0.99)	0.0	1.33	2.08	2.67	4.8	
			Placebo	67	60 (89.6)	2.02 (0.97)	0.0	1.33	2.08	2.58	4.7	
		Week 10	Tezepelumab	62	58 (93.5)	1.98 (0.97)	0.0	1.33	1.92	2.67	4.3	
			Placebo	67	61 (91.0)	1.98 (0.93)	0.2	1.33	1.83	2.50	5.3	
		Week 12	Tezepelumab	62	58 (93.5)	1.95 (1.01)	0.0	1.17	2.17	2.67	4.3	
			Placebo	67	61 (91.0)	1.91 (1.05)	0.0	1.17	1.83	2.67	4.3	
		Week 14	Tezepelumab	62	58 (93.5)	1.84 (1.01)	0.0	1.17	1.83	2.50	4.3	
			Placebo	67	61 (91.0)	1.87 (1.00)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	62	58 (93.5)	1.96 (1.00)	0.0	1.33	2.08	2.67	4.3	
			Placebo	67	61 (91.0)	2.07 (1.04)	0.0	1.33	2.17	2.67	5.0	
		Week 18	Tezepelumab	62	59 (95.2)	1.81 (1.00)	0.0	1.17	1.83	2.50	4.3	
			Placebo	67	61 (91.0)	1.90 (1.04)	0.0	1.33	2.00	2.50	5.0	
		Week 20	Tezepelumab	62	59 (95.2)	1.95 (1.00)	0.0	1.33	2.00	2.50	5.0	
			Placebo	67	61 (91.0)	1.97 (1.00)	0.0	1.17	2.17	2.50	5.0	
		Week 22	Tezepelumab	62	59 (95.2)	1.89 (0.98)	0.0	1.17	2.00	2.50	4.3	
			Placebo	67	61 (91.0)	1.94 (1.00)	0.0	1.17	2.00	2.67	5.0	
		Week 24	Tezepelumab	62	59 (95.2)	1.87 (1.00)	0.0	1.17	1.83	2.50	4.3	
			Placebo	67	61 (91.0)	1.86 (1.02)	0.0	1.00	1.83	2.67	4.5	
		Week 26	Tezepelumab	62	60 (96.8)	1.91 (0.98)	0.0	1.17	1.83	2.58	4.3	
			Placebo	67	61 (91.0)	1.85 (1.02)	0.0	1.00	1.83	2.50	4.5	
		Week 28	Tezepelumab	62	61 (98.4)	1.92 (1.00)	0.0	1.33	2.00	2.50	4.3	
			Placebo	67	62 (92.5)	1.83 (1.04)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	62	61 (98.4)	1.89 (1.01)	0.0	1.00	2.00	2.50	4.3	
			Placebo	67	63 (94.0)	1.90 (1.09)	0.0	1.00	1.83	2.67	4.5	
		Week 32	Tezepelumab	62	61 (98.4)	1.90 (1.02)	0.0	1.17	1.83	2.50	4.3	
			Placebo	67	63 (94.0)	1.84 (1.06)	0.0	0.83	1.83	2.67	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low (< 20.9 ng/ml)	Absolute values	Week 34	Tezepelumab	62	61 (98.4)	1.86 (1.08)	0.0	1.00	2.00	2.50	4.3	
			Placebo	67	63 (94.0)	1.78 (1.06)	0.0	0.83	1.83	2.50	4.5	
		Week 36	Tezepelumab	62	61 (98.4)	1.92 (1.01)	0.0	1.17	2.00	2.67	4.3	
			Placebo	67	63 (94.0)	1.84 (1.07)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	62	61 (98.4)	1.86 (1.07)	0.0	1.00	1.83	2.50	4.5	
			Placebo	67	63 (94.0)	1.77 (1.03)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	62	61 (98.4)	1.91 (1.06)	0.0	1.00	2.00	2.67	4.3	
			Placebo	67	63 (94.0)	1.86 (1.12)	0.0	0.83	1.83	2.67	4.5	
		Week 42	Tezepelumab	62	61 (98.4)	1.83 (1.06)	0.0	1.00	1.67	2.67	4.3	
			Placebo	67	63 (94.0)	1.81 (1.03)	0.0	0.83	2.00	2.50	4.5	
		Week 44	Tezepelumab	62	61 (98.4)	1.87 (1.01)	0.0	1.17	2.00	2.67	4.3	
			Placebo	67	64 (95.5)	1.85 (1.08)	0.0	0.83	2.00	2.67	4.5	
		Week 46	Tezepelumab	62	61 (98.4)	1.86 (1.07)	0.0	1.00	1.83	2.67	4.3	
			Placebo	67	64 (95.5)	1.72 (1.04)	0.0	0.92	1.83	2.50	4.5	
		Week 48	Tezepelumab	62	61 (98.4)	1.87 (1.05)	0.0	1.00	2.00	2.67	4.3	
			Placebo	67	64 (95.5)	1.70 (1.08)	0.0	0.75	1.83	2.58	4.5	
		Week 50	Tezepelumab	62	61 (98.4)	1.81 (1.11)	0.0	1.00	1.67	2.67	4.3	
			Placebo	67	64 (95.5)	1.73 (1.05)	0.0	1.00	1.67	2.50	4.5	
		Week 52	Tezepelumab	62	61 (98.4)	1.87 (1.09)	0.0	1.00	1.67	2.50	4.3	
			Placebo	67	64 (95.5)	1.76 (1.10)	0.0	0.83	1.75	2.58	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 2	Tezepelumab	62	58 (93.5)	-0.43 (0.61)	-2.8	-0.67	-0.33	0.00	0.5	-0.01 [-0.37, 0.36]
			Placebo	67	59 (88.1)	-0.43 (0.75)	-2.8	-0.83	-0.17	0.17	1.2	
		Week 4	Tezepelumab	62	58 (93.5)	-0.62 (0.73)	-2.2	-1.00	-0.67	-0.17	1.7	-0.16 [-0.53, 0.20]
			Placebo	67	59 (88.1)	-0.49 (0.88)	-3.0	-1.17	-0.33	0.17	1.2	
		Week 6	Tezepelumab	62	58 (93.5)	-0.72 (0.81)	-3.0	-1.33	-0.75	-0.17	1.3	-0.10 [-0.46, 0.26]
			Placebo	67	59 (88.1)	-0.63 (0.97)	-3.3	-1.33	-0.50	0.00	1.5	
		Week 8	Tezepelumab	62	58 (93.5)	-0.71 (0.84)	-2.7	-1.17	-0.75	-0.33	2.2	-0.11 [-0.47, 0.25]
			Placebo	67	60 (89.6)	-0.61 (0.95)	-3.0	-1.08	-0.50	0.00	1.0	
		Week 10	Tezepelumab	62	58 (93.5)	-0.81 (0.83)	-3.5	-1.33	-0.83	-0.17	1.0	-0.17 [-0.53, 0.19]
			Placebo	67	61 (91.0)	-0.66 (0.97)	-3.2	-1.17	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	62	58 (93.5)	-0.84 (0.87)	-3.7	-1.50	-0.67	-0.33	1.2	-0.10 [-0.46, 0.25]
			Placebo	67	61 (91.0)	-0.73 (1.05)	-3.2	-1.17	-0.83	0.00	1.3	
		Week 14	Tezepelumab	62	58 (93.5)	-0.95 (0.88)	-3.8	-1.50	-1.00	-0.33	1.2	-0.19 [-0.55, 0.17]
			Placebo	67	61 (91.0)	-0.77 (1.04)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 16	Tezepelumab	62	58 (93.5)	-0.83 (0.86)	-4.2	-1.17	-0.83	-0.33	0.8	-0.26 [-0.62, 0.10]
			Placebo	67	61 (91.0)	-0.57 (1.09)	-3.2	-1.33	-0.50	0.17	2.3	
		Week 18	Tezepelumab	62	59 (95.2)	-0.96 (0.87)	-4.2	-1.50	-0.83	-0.50	1.2	-0.23 [-0.59, 0.13]
			Placebo	67	61 (91.0)	-0.74 (1.07)	-3.2	-1.33	-0.50	-0.17	2.3	
		Week 20	Tezepelumab	62	59 (95.2)	-0.83 (0.89)	-4.2	-1.33	-0.67	-0.33	1.0	-0.16 [-0.52, 0.20]
			Placebo	67	61 (91.0)	-0.67 (1.03)	-3.0	-1.17	-0.50	-0.17	2.3	
		Week 22	Tezepelumab	62	59 (95.2)	-0.88 (0.91)	-4.3	-1.50	-0.83	-0.33	1.2	-0.18 [-0.54, 0.18]
			Placebo	67	61 (91.0)	-0.70 (1.04)	-3.2	-1.50	-0.50	0.00	2.3	
		Week 24	Tezepelumab	62	59 (95.2)	-0.91 (0.90)	-4.5	-1.33	-0.83	-0.33	1.5	-0.12 [-0.48, 0.24]
			Placebo	67	61 (91.0)	-0.79 (1.09)	-3.2	-1.50	-0.67	0.00	1.7	
		Week 26	Tezepelumab	62	60 (96.8)	-0.84 (0.89)	-4.2	-1.42	-0.67	-0.33	1.3	-0.05 [-0.41, 0.31]
			Placebo	67	61 (91.0)	-0.80 (1.06)	-3.2	-1.67	-0.67	0.17	1.5	
		Week 28	Tezepelumab	62	61 (98.4)	-0.83 (0.96)	-4.2	-1.50	-0.67	-0.17	1.0	-0.05 [-0.41, 0.30]
			Placebo	67	62 (92.5)	-0.78 (1.06)	-3.2	-1.50	-0.67	-0.17	1.5	
		Week 30	Tezepelumab	62	61 (98.4)	-0.86 (0.98)	-4.2	-1.50	-0.83	-0.33	1.8	-0.14 [-0.50, 0.21]
			Placebo	67	63 (94.0)	-0.70 (1.10)	-3.2	-1.50	-0.50	-0.17	2.0	
		Week 32	Tezepelumab	62	61 (98.4)	-0.85 (0.94)	-4.2	-1.33	-0.83	-0.33	1.8	-0.08 [-0.43, 0.27]
			Placebo	67	63 (94.0)	-0.77 (1.05)	-3.0	-1.50	-0.67	-0.17	1.5	
		Week 34	Tezepelumab	62	61 (98.4)	-0.89 (1.01)	-4.2	-1.50	-0.83	-0.33	2.0	-0.06 [-0.41, 0.29]
			Placebo	67	63 (94.0)	-0.83 (1.08)	-3.2	-1.50	-0.67	-0.17	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low (< 20.9 ng/ml)	Change from baseline	Week 36	Tezepelumab	62	61 (98.4)	-0.83 (0.95)	-4.2	-1.50	-0.83	-0.33	1.5	-0.06 [-0.42, 0.29]
			Placebo	67	63 (94.0)	-0.77 (1.08)	-3.5	-1.33	-0.67	0.00	1.5	
		Week 38	Tezepelumab	62	61 (98.4)	-0.89 (1.01)	-4.2	-1.67	-0.83	-0.17	2.3	-0.05 [-0.40, 0.30]
			Placebo	67	63 (94.0)	-0.84 (1.05)	-3.2	-1.33	-0.83	-0.17	1.5	
		Week 40	Tezepelumab	62	61 (98.4)	-0.84 (0.99)	-4.2	-1.50	-0.83	-0.17	1.7	-0.09 [-0.44, 0.26]
			Placebo	67	63 (94.0)	-0.75 (1.09)	-3.2	-1.33	-0.67	0.00	1.5	
		Week 42	Tezepelumab	62	61 (98.4)	-0.92 (0.97)	-4.2	-1.50	-0.83	-0.33	2.0	-0.11 [-0.47, 0.24]
			Placebo	67	63 (94.0)	-0.80 (1.02)	-3.2	-1.33	-0.83	-0.17	1.5	
		Week 44	Tezepelumab	62	61 (98.4)	-0.88 (0.92)	-4.2	-1.50	-0.83	-0.17	1.5	-0.13 [-0.48, 0.23]
			Placebo	67	64 (95.5)	-0.76 (1.06)	-3.3	-1.50	-0.67	0.08	1.3	
		Week 46	Tezepelumab	62	61 (98.4)	-0.89 (0.98)	-4.2	-1.33	-0.83	-0.17	1.7	-0.01 [-0.36, 0.35]
			Placebo	67	64 (95.5)	-0.88 (1.02)	-3.2	-1.58	-0.83	0.00	1.0	
		Week 48	Tezepelumab	62	61 (98.4)	-0.87 (0.96)	-4.2	-1.33	-0.83	-0.33	1.8	0.03 [-0.32, 0.38]
			Placebo	67	64 (95.5)	-0.91 (1.07)	-3.3	-1.50	-0.83	-0.25	1.3	
		Week 50	Tezepelumab	62	61 (98.4)	-0.94 (1.05)	-4.2	-1.50	-0.83	-0.17	1.8	-0.06 [-0.41, 0.29]
			Placebo	67	64 (95.5)	-0.87 (1.10)	-3.5	-1.67	-0.83	-0.17	1.5	
		Week 52	Tezepelumab	62	61 (98.4)	-0.88 (1.03)	-4.2	-1.50	-0.83	-0.17	1.8	-0.03 [-0.38, 0.32]
			Placebo	67	64 (95.5)	-0.85 (1.14)	-3.5	-1.67	-0.83	-0.17	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	74	74 (100.0)	2.65 (0.88)	0.0	2.17	2.67	3.17	4.8	
			Placebo	71	71 (100.0)	2.71 (0.72)	1.3	2.33	2.67	3.17	4.7	
		Week 2	Tezepelumab	74	72 (97.3)	2.00 (0.95)	0.0	1.42	2.08	2.67	4.2	
			Placebo	71	66 (93.0)	2.39 (0.82)	0.7	1.83	2.33	2.83	4.7	
		Week 4	Tezepelumab	74	72 (97.3)	1.65 (0.95)	0.0	0.83	1.67	2.33	3.3	
			Placebo	71	66 (93.0)	2.22 (0.82)	0.5	1.67	2.33	2.67	4.2	
		Week 6	Tezepelumab	74	72 (97.3)	1.56 (0.92)	0.0	0.92	1.58	2.25	3.7	
			Placebo	71	67 (94.4)	2.16 (0.95)	0.2	1.67	2.17	2.67	5.5	
		Week 8	Tezepelumab	74	72 (97.3)	1.44 (0.96)	0.0	0.67	1.50	2.17	3.5	
			Placebo	71	67 (94.4)	2.08 (0.94)	0.0	1.50	2.00	2.83	4.7	
		Week 10	Tezepelumab	74	72 (97.3)	1.38 (0.96)	0.0	0.67	1.42	1.92	3.7	
			Placebo	71	67 (94.4)	1.98 (0.91)	0.0	1.33	2.17	2.67	4.2	
		Week 12	Tezepelumab	74	72 (97.3)	1.28 (0.94)	0.0	0.50	1.33	1.92	3.7	
			Placebo	71	67 (94.4)	1.89 (0.83)	0.0	1.33	2.00	2.50	3.7	
		Week 14	Tezepelumab	74	72 (97.3)	1.13 (0.88)	0.0	0.50	1.00	1.67	3.7	
			Placebo	71	67 (94.4)	1.81 (0.83)	0.0	1.17	1.83	2.50	4.2	
		Week 16	Tezepelumab	74	72 (97.3)	1.31 (1.00)	0.0	0.50	1.17	1.83	4.3	
			Placebo	71	67 (94.4)	1.88 (1.01)	0.0	1.17	1.83	2.67	4.8	
		Week 18	Tezepelumab	74	72 (97.3)	1.23 (0.86)	0.0	0.67	1.17	1.83	3.3	
			Placebo	71	67 (94.4)	1.83 (0.94)	0.0	1.17	1.83	2.33	3.8	
		Week 20	Tezepelumab	74	72 (97.3)	1.26 (0.93)	0.0	0.50	1.17	1.83	3.5	
			Placebo	71	67 (94.4)	1.88 (1.00)	0.0	1.17	2.00	2.67	3.8	
		Week 22	Tezepelumab	74	72 (97.3)	1.34 (0.89)	0.0	0.67	1.33	2.00	3.3	
			Placebo	71	67 (94.4)	1.81 (1.00)	0.0	1.00	2.00	2.50	3.8	
		Week 24	Tezepelumab	74	72 (97.3)	1.35 (1.00)	0.0	0.50	1.25	2.08	4.2	
			Placebo	71	67 (94.4)	1.89 (0.94)	0.0	1.17	2.00	2.50	3.8	
		Week 26	Tezepelumab	74	72 (97.3)	1.25 (0.93)	0.0	0.50	1.33	1.83	3.7	
			Placebo	71	67 (94.4)	1.80 (0.94)	0.0	1.00	1.50	2.50	4.0	
		Week 28	Tezepelumab	74	72 (97.3)	1.32 (0.98)	0.0	0.42	1.33	2.00	3.5	
			Placebo	71	67 (94.4)	1.92 (1.05)	0.0	1.17	2.00	2.67	4.0	
		Week 30	Tezepelumab	74	73 (98.6)	1.25 (0.89)	0.0	0.67	1.17	1.83	3.7	
			Placebo	71	67 (94.4)	1.83 (0.95)	0.0	1.17	1.83	2.50	3.8	
		Week 32	Tezepelumab	74	73 (98.6)	1.16 (0.89)	0.0	0.33	1.00	1.83	3.7	
			Placebo	71	67 (94.4)	1.79 (0.99)	0.0	1.17	1.50	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High (>= 20.9 ng/ml)	Absolute values	Week 34	Tezepelumab	74	73 (98.6)	1.23 (0.96)	0.0	0.50	1.17	1.83	4.2	
			Placebo	71	67 (94.4)	1.79 (1.01)	0.0	1.17	1.83	2.50	4.5	
		Week 36	Tezepelumab	74	73 (98.6)	1.32 (0.99)	0.0	0.50	1.50	2.00	4.5	
			Placebo	71	67 (94.4)	1.88 (1.01)	0.0	1.17	1.83	2.67	4.5	
		Week 38	Tezepelumab	74	73 (98.6)	1.19 (0.91)	0.0	0.50	1.17	1.67	3.5	
			Placebo	71	67 (94.4)	1.79 (1.01)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	74	73 (98.6)	1.19 (0.91)	0.0	0.33	1.17	2.00	3.2	
			Placebo	71	67 (94.4)	1.85 (0.96)	0.0	1.17	1.83	2.50	3.8	
		Week 42	Tezepelumab	74	73 (98.6)	1.20 (0.94)	0.0	0.50	1.00	1.83	4.7	
			Placebo	71	67 (94.4)	1.84 (0.99)	0.0	1.17	1.83	2.67	4.7	
		Week 44	Tezepelumab	74	73 (98.6)	1.21 (0.93)	0.0	0.50	1.00	2.00	3.5	
			Placebo	71	67 (94.4)	1.88 (0.95)	0.0	1.17	2.00	2.50	3.8	
		Week 46	Tezepelumab	74	73 (98.6)	1.16 (0.88)	0.0	0.67	1.00	1.83	3.7	
			Placebo	71	67 (94.4)	1.79 (0.92)	0.0	1.17	1.83	2.33	3.8	
		Week 48	Tezepelumab	74	73 (98.6)	1.25 (0.95)	0.0	0.50	1.17	2.00	4.0	
			Placebo	71	67 (94.4)	1.88 (0.94)	0.0	1.17	2.00	2.50	4.2	
		Week 50	Tezepelumab	74	73 (98.6)	1.16 (0.87)	0.0	0.50	1.00	1.67	4.0	
			Placebo	71	67 (94.4)	1.81 (0.88)	0.0	1.17	1.83	2.33	3.8	
		Week 52	Tezepelumab	74	73 (98.6)	1.16 (0.86)	0.0	0.50	1.00	1.67	4.0	
			Placebo	71	67 (94.4)	1.88 (0.89)	0.0	1.33	2.00	2.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 2	Tezepelumab	74	72 (97.3)	-0.63 (0.71)	-2.5	-1.17	-0.50	-0.17	0.7	-0.47 [-0.81, -0.13]
			Placebo	71	66 (93.0)	-0.31 (0.66)	-2.2	-0.67	-0.33	0.00	1.0	
		Week 4	Tezepelumab	74	72 (97.3)	-0.99 (0.96)	-3.5	-1.50	-0.92	-0.33	2.3	-0.57 [-0.92, -0.23]
			Placebo	71	66 (93.0)	-0.48 (0.79)	-2.7	-1.00	-0.33	0.00	0.8	
		Week 6	Tezepelumab	74	72 (97.3)	-1.08 (1.03)	-3.8	-1.75	-1.08	-0.33	2.3	-0.59 [-0.92, -0.25]
			Placebo	71	67 (94.4)	-0.53 (0.83)	-2.8	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	74	72 (97.3)	-1.20 (1.05)	-3.8	-1.92	-1.17	-0.50	2.3	-0.61 [-0.95, -0.27]
			Placebo	71	67 (94.4)	-0.61 (0.86)	-3.2	-1.00	-0.67	0.00	1.0	
		Week 10	Tezepelumab	74	72 (97.3)	-1.26 (1.04)	-3.8	-2.00	-1.33	-0.50	2.3	-0.54 [-0.88, -0.20]
			Placebo	71	67 (94.4)	-0.72 (0.95)	-3.3	-1.33	-0.50	-0.17	2.5	
		Week 12	Tezepelumab	74	72 (97.3)	-1.36 (0.99)	-3.7	-2.08	-1.33	-0.67	2.3	-0.59 [-0.93, -0.25]
			Placebo	71	67 (94.4)	-0.81 (0.89)	-3.3	-1.50	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	74	72 (97.3)	-1.50 (1.01)	-3.8	-2.08	-1.58	-0.92	2.3	-0.66 [-1.00, -0.32]
			Placebo	71	67 (94.4)	-0.88 (0.85)	-3.0	-1.33	-0.83	-0.33	1.2	
		Week 16	Tezepelumab	74	72 (97.3)	-1.33 (1.11)	-3.8	-2.17	-1.33	-0.75	2.3	-0.49 [-0.83, -0.16]
			Placebo	71	67 (94.4)	-0.82 (0.97)	-3.5	-1.33	-0.83	-0.17	2.3	
		Week 18	Tezepelumab	74	72 (97.3)	-1.41 (1.05)	-3.8	-2.00	-1.50	-0.67	2.3	-0.54 [-0.88, -0.20]
			Placebo	71	67 (94.4)	-0.87 (0.96)	-3.2	-1.50	-0.83	-0.33	2.3	
		Week 20	Tezepelumab	74	72 (97.3)	-1.37 (1.02)	-3.8	-2.00	-1.42	-0.75	2.3	-0.53 [-0.87, -0.19]
			Placebo	71	67 (94.4)	-0.82 (1.06)	-3.5	-1.33	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	74	72 (97.3)	-1.30 (1.09)	-3.8	-2.08	-1.17	-0.67	2.3	-0.40 [-0.74, -0.07]
			Placebo	71	67 (94.4)	-0.88 (0.97)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	74	72 (97.3)	-1.29 (1.01)	-3.8	-2.00	-1.33	-0.58	2.3	-0.48 [-0.81, -0.14]
			Placebo	71	67 (94.4)	-0.81 (1.00)	-3.5	-1.50	-0.83	-0.17	2.3	
		Week 26	Tezepelumab	74	72 (97.3)	-1.39 (1.08)	-3.8	-2.17	-1.50	-0.67	2.3	-0.47 [-0.81, -0.13]
			Placebo	71	67 (94.4)	-0.90 (1.03)	-4.0	-1.50	-1.17	-0.17	2.3	
		Week 28	Tezepelumab	74	72 (97.3)	-1.32 (1.04)	-3.8	-2.00	-1.33	-0.67	2.3	-0.51 [-0.84, -0.17]
			Placebo	71	67 (94.4)	-0.78 (1.09)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 30	Tezepelumab	74	73 (98.6)	-1.40 (1.04)	-3.7	-2.17	-1.33	-0.83	2.3	-0.52 [-0.85, -0.18]
			Placebo	71	67 (94.4)	-0.87 (1.01)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	74	73 (98.6)	-1.49 (1.04)	-3.8	-2.17	-1.50	-0.83	2.3	-0.56 [-0.90, -0.23]
			Placebo	71	67 (94.4)	-0.90 (1.03)	-3.5	-1.67	-1.00	-0.33	2.3	
		Week 34	Tezepelumab	74	73 (98.6)	-1.42 (1.05)	-3.8	-2.17	-1.50	-0.67	2.3	-0.49 [-0.83, -0.15]
			Placebo	71	67 (94.4)	-0.91 (1.02)	-4.0	-1.50	-0.83	-0.33	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High (>= 20.9 ng/ml)	Change from baseline	Week 36	Tezepelumab	74	73 (98.6)	-1.32 (1.16)	-3.8	-2.17	-1.50	-0.67	2.3	-0.45 [-0.79, -0.12]
			Placebo	71	67 (94.4)	-0.82 (1.07)	-3.5	-1.33	-1.00	-0.17	2.3	
		Week 38	Tezepelumab	74	73 (98.6)	-1.45 (1.09)	-3.8	-2.17	-1.50	-0.83	2.3	-0.50 [-0.84, -0.17]
			Placebo	71	67 (94.4)	-0.91 (1.08)	-4.0	-1.50	-0.83	-0.33	2.3	
		Week 40	Tezepelumab	74	73 (98.6)	-1.46 (1.10)	-3.8	-2.17	-1.50	-0.67	2.3	-0.57 [-0.91, -0.23]
			Placebo	71	67 (94.4)	-0.85 (1.04)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 42	Tezepelumab	74	73 (98.6)	-1.45 (1.12)	-3.8	-2.17	-1.50	-0.67	2.3	-0.54 [-0.88, -0.20]
			Placebo	71	67 (94.4)	-0.86 (1.06)	-4.0	-1.50	-1.17	-0.17	2.3	
		Week 44	Tezepelumab	74	73 (98.6)	-1.43 (1.17)	-4.3	-2.17	-1.50	-0.67	2.3	-0.55 [-0.89, -0.21]
			Placebo	71	67 (94.4)	-0.82 (1.07)	-4.0	-1.50	-0.83	-0.17	2.3	
		Week 46	Tezepelumab	74	73 (98.6)	-1.49 (1.10)	-4.2	-2.17	-1.50	-0.83	2.3	-0.55 [-0.88, -0.21]
			Placebo	71	67 (94.4)	-0.90 (1.05)	-4.0	-1.50	-1.00	-0.50	2.3	
		Week 48	Tezepelumab	74	73 (98.6)	-1.39 (1.14)	-4.2	-2.17	-1.50	-0.50	2.3	-0.52 [-0.86, -0.19]
			Placebo	71	67 (94.4)	-0.82 (1.06)	-3.7	-1.50	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	74	73 (98.6)	-1.48 (1.06)	-3.8	-2.17	-1.50	-0.83	2.3	-0.59 [-0.93, -0.25]
			Placebo	71	67 (94.4)	-0.89 (0.94)	-4.0	-1.50	-1.00	-0.33	2.3	
		Week 52	Tezepelumab	74	73 (98.6)	-1.49 (1.07)	-4.2	-2.17	-1.50	-0.83	2.3	-0.66 [-1.00, -0.32]
			Placebo	71	67 (94.4)	-0.81 (0.96)	-4.0	-1.50	-0.83	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	114	114 (100.0)	2.72 (0.83)	0.0	2.33	2.67	3.17	4.8	
			Placebo	126	126 (100.0)	2.66 (0.67)	0.3	2.33	2.67	3.00	4.5	
		Week 2	Tezepelumab	114	109 (95.6)	2.22 (0.93)	0.0	1.67	2.17	2.83	4.3	
			Placebo	126	115 (91.3)	2.28 (0.78)	0.2	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	114	109 (95.6)	1.94 (0.97)	0.0	1.17	2.00	2.67	4.3	
			Placebo	126	115 (91.3)	2.14 (0.84)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	114	109 (95.6)	1.86 (0.97)	0.0	1.33	1.83	2.50	4.3	
			Placebo	126	116 (92.1)	2.04 (0.93)	0.2	1.42	2.17	2.67	4.7	
		Week 8	Tezepelumab	114	109 (95.6)	1.80 (1.02)	0.0	1.17	1.83	2.67	4.8	
			Placebo	126	117 (92.9)	2.05 (0.93)	0.0	1.50	2.00	2.67	4.7	
		Week 10	Tezepelumab	114	109 (95.6)	1.75 (1.01)	0.0	1.17	1.83	2.33	4.3	
			Placebo	126	118 (93.7)	1.95 (0.91)	0.0	1.33	2.00	2.50	5.3	
		Week 12	Tezepelumab	114	109 (95.6)	1.67 (1.02)	0.0	0.83	1.67	2.50	4.3	
			Placebo	126	118 (93.7)	1.90 (0.93)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	114	109 (95.6)	1.53 (1.03)	0.0	0.83	1.50	2.33	4.3	
			Placebo	126	118 (93.7)	1.83 (0.90)	0.0	1.17	1.83	2.50	5.0	
		Week 16	Tezepelumab	114	109 (95.6)	1.71 (1.06)	0.0	1.00	1.67	2.50	4.3	
			Placebo	126	118 (93.7)	1.94 (0.99)	0.0	1.17	2.00	2.67	5.0	
		Week 18	Tezepelumab	114	110 (96.5)	1.60 (0.99)	0.0	0.83	1.58	2.17	4.3	
			Placebo	126	118 (93.7)	1.82 (0.94)	0.0	1.17	1.83	2.33	5.0	
		Week 20	Tezepelumab	114	110 (96.5)	1.68 (1.04)	0.0	1.00	1.83	2.33	5.0	
			Placebo	126	118 (93.7)	1.89 (1.01)	0.0	1.17	1.92	2.67	5.0	
		Week 22	Tezepelumab	114	110 (96.5)	1.68 (0.98)	0.0	1.00	1.83	2.33	4.3	
			Placebo	126	118 (93.7)	1.84 (1.01)	0.0	1.00	2.00	2.50	5.0	
		Week 24	Tezepelumab	114	110 (96.5)	1.66 (1.03)	0.0	0.83	1.67	2.33	4.3	
			Placebo	126	118 (93.7)	1.86 (0.97)	0.0	1.00	2.00	2.50	4.5	
		Week 26	Tezepelumab	114	111 (97.4)	1.64 (1.03)	0.0	0.83	1.67	2.33	4.3	
			Placebo	126	118 (93.7)	1.80 (0.94)	0.0	1.00	1.67	2.50	4.5	
		Week 28	Tezepelumab	114	112 (98.2)	1.66 (1.04)	0.0	0.92	1.67	2.50	4.3	
			Placebo	126	119 (94.4)	1.86 (1.03)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	114	113 (99.1)	1.65 (1.02)	0.0	0.83	1.67	2.33	4.3	
			Placebo	126	120 (95.2)	1.83 (1.02)	0.0	1.00	1.83	2.50	4.5	
		Week 32	Tezepelumab	114	113 (99.1)	1.62 (1.03)	0.0	1.00	1.67	2.33	4.3	
			Placebo	126	120 (95.2)	1.80 (1.03)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	114	113 (99.1)	1.63 (1.08)	0.0	0.83	1.50	2.50	4.3	
			Placebo	126	120 (95.2)	1.79 (1.02)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	114	113 (99.1)	1.67 (1.06)	0.0	0.83	1.67	2.33	4.5	
			Placebo	126	120 (95.2)	1.84 (1.03)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	114	113 (99.1)	1.60 (1.05)	0.0	0.83	1.67	2.17	4.5	
			Placebo	126	120 (95.2)	1.73 (1.01)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	114	113 (99.1)	1.62 (1.05)	0.0	0.83	1.67	2.33	4.3	
			Placebo	126	120 (95.2)	1.83 (1.01)	0.0	1.00	1.83	2.50	4.5	
		Week 42	Tezepelumab	114	113 (99.1)	1.56 (1.03)	0.0	0.83	1.50	2.17	4.3	
			Placebo	126	120 (95.2)	1.81 (1.01)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	114	113 (99.1)	1.59 (1.05)	0.0	0.83	1.50	2.50	4.3	
			Placebo	126	121 (96.0)	1.85 (0.99)	0.0	1.00	2.00	2.50	4.5	
		Week 46	Tezepelumab	114	113 (99.1)	1.58 (1.06)	0.0	0.83	1.50	2.33	4.3	
			Placebo	126	121 (96.0)	1.73 (0.96)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	114	113 (99.1)	1.63 (1.07)	0.0	0.67	1.67	2.33	4.3	
			Placebo	126	121 (96.0)	1.76 (1.00)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	114	113 (99.1)	1.56 (1.06)	0.0	0.83	1.50	2.33	4.3	
			Placebo	126	121 (96.0)	1.77 (0.94)	0.0	1.00	1.83	2.50	4.5	
		Week 52	Tezepelumab	114	113 (99.1)	1.58 (1.06)	0.0	0.67	1.67	2.33	4.3	
			Placebo	126	121 (96.0)	1.81 (0.98)	0.0	1.00	2.00	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 2	Tezepelumab	114	109 (95.6)	-0.50 (0.68)	-2.8	-0.83	-0.33	0.00	0.7	-0.17 [-0.43, 0.10]
			Placebo	126	115 (91.3)	-0.39 (0.69)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	114	109 (95.6)	-0.78 (0.91)	-3.5	-1.33	-0.67	-0.17	2.3	-0.29 [-0.55, -0.02]
			Placebo	126	115 (91.3)	-0.53 (0.82)	-3.0	-1.00	-0.33	0.00	1.2	
		Week 6	Tezepelumab	114	109 (95.6)	-0.86 (0.98)	-3.8	-1.33	-0.83	-0.33	2.3	-0.25 [-0.52, 0.01]
			Placebo	126	116 (92.1)	-0.62 (0.87)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	114	109 (95.6)	-0.93 (1.02)	-3.8	-1.50	-0.83	-0.33	2.3	-0.32 [-0.59, -0.06]
			Placebo	126	117 (92.9)	-0.62 (0.89)	-3.2	-1.00	-0.67	0.00	1.0	
		Week 10	Tezepelumab	114	109 (95.6)	-0.97 (0.99)	-3.8	-1.33	-1.00	-0.33	2.3	-0.26 [-0.52, 0.01]
			Placebo	126	118 (93.7)	-0.73 (0.92)	-3.3	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	114	109 (95.6)	-1.06 (1.01)	-3.7	-1.67	-1.00	-0.50	2.3	-0.29 [-0.55, -0.03]
			Placebo	126	118 (93.7)	-0.77 (0.93)	-3.3	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	114	109 (95.6)	-1.19 (1.03)	-3.8	-1.83	-1.17	-0.50	2.3	-0.36 [-0.62, -0.10]
			Placebo	126	118 (93.7)	-0.84 (0.91)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 16	Tezepelumab	114	109 (95.6)	-1.01 (1.06)	-4.2	-1.67	-1.00	-0.33	2.3	-0.27 [-0.53, -0.01]
			Placebo	126	118 (93.7)	-0.73 (0.98)	-3.5	-1.33	-0.67	-0.17	2.3	
		Week 18	Tezepelumab	114	110 (96.5)	-1.12 (1.01)	-4.2	-1.67	-1.00	-0.50	2.3	-0.27 [-0.53, -0.01]
			Placebo	126	118 (93.7)	-0.85 (0.94)	-3.2	-1.50	-0.75	-0.33	2.3	
		Week 20	Tezepelumab	114	110 (96.5)	-1.04 (1.03)	-4.2	-1.67	-0.92	-0.33	2.3	-0.24 [-0.50, 0.02]
			Placebo	126	118 (93.7)	-0.79 (1.02)	-3.5	-1.33	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	114	110 (96.5)	-1.03 (1.06)	-4.3	-1.67	-0.92	-0.33	2.3	-0.19 [-0.45, 0.07]
			Placebo	126	118 (93.7)	-0.84 (0.99)	-3.3	-1.50	-0.83	-0.17	2.3	
		Week 24	Tezepelumab	114	110 (96.5)	-1.05 (1.02)	-4.5	-1.67	-0.92	-0.33	2.3	-0.23 [-0.49, 0.03]
			Placebo	126	118 (93.7)	-0.82 (1.01)	-3.5	-1.50	-0.75	-0.17	1.7	
		Week 26	Tezepelumab	114	111 (97.4)	-1.07 (1.06)	-4.2	-1.83	-1.00	-0.33	2.3	-0.18 [-0.44, 0.08]
			Placebo	126	118 (93.7)	-0.88 (1.00)	-4.0	-1.50	-1.00	-0.17	1.5	
		Week 28	Tezepelumab	114	112 (98.2)	-1.04 (1.06)	-4.2	-1.67	-1.00	-0.33	2.3	-0.23 [-0.49, 0.02]
			Placebo	126	119 (94.4)	-0.79 (1.04)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	114	113 (99.1)	-1.05 (1.07)	-4.2	-1.67	-1.00	-0.33	2.3	-0.22 [-0.47, 0.04]
			Placebo	126	120 (95.2)	-0.82 (1.04)	-3.2	-1.50	-0.83	-0.17	2.0	
		Week 32	Tezepelumab	114	113 (99.1)	-1.09 (1.07)	-4.2	-1.83	-1.00	-0.50	2.3	-0.22 [-0.48, 0.04]
			Placebo	126	120 (95.2)	-0.86 (1.03)	-3.5	-1.50	-0.67	-0.17	1.5	
		Week 34	Tezepelumab	114	113 (99.1)	-1.08 (1.09)	-4.2	-1.83	-1.00	-0.33	2.3	-0.20 [-0.46, 0.06]
			Placebo	126	120 (95.2)	-0.87 (1.02)	-4.0	-1.50	-0.83	-0.17	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	114	113 (99.1)	-1.04 (1.13)	-4.2	-1.67	-1.00	-0.33	2.3	-0.21 [-0.46, 0.05]
			Placebo	126	120 (95.2)	-0.81 (1.05)	-3.5	-1.33	-0.83	-0.08	1.5	
		Week 38	Tezepelumab	114	113 (99.1)	-1.11 (1.11)	-4.2	-1.83	-1.00	-0.33	2.3	-0.17 [-0.42, 0.09]
			Placebo	126	120 (95.2)	-0.93 (1.04)	-4.0	-1.58	-0.83	-0.17	1.5	
		Week 40	Tezepelumab	114	113 (99.1)	-1.08 (1.11)	-4.2	-1.83	-1.00	-0.33	2.3	-0.24 [-0.50, 0.02]
			Placebo	126	120 (95.2)	-0.83 (1.03)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 42	Tezepelumab	114	113 (99.1)	-1.15 (1.09)	-4.2	-1.83	-1.17	-0.50	2.3	-0.28 [-0.54, -0.02]
			Placebo	126	120 (95.2)	-0.85 (1.02)	-4.0	-1.42	-0.83	-0.17	1.5	
		Week 44	Tezepelumab	114	113 (99.1)	-1.12 (1.13)	-4.3	-1.83	-1.00	-0.33	2.3	-0.29 [-0.55, -0.03]
			Placebo	126	121 (96.0)	-0.81 (1.02)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 46	Tezepelumab	114	113 (99.1)	-1.13 (1.12)	-4.2	-1.83	-1.00	-0.33	2.3	-0.20 [-0.45, 0.06]
			Placebo	126	121 (96.0)	-0.92 (1.00)	-4.0	-1.50	-1.00	-0.17	1.3	
		Week 48	Tezepelumab	114	113 (99.1)	-1.08 (1.12)	-4.2	-1.83	-1.00	-0.33	2.3	-0.18 [-0.43, 0.08]
			Placebo	126	121 (96.0)	-0.89 (1.04)	-3.7	-1.50	-0.83	-0.33	1.7	
		Week 50	Tezepelumab	114	113 (99.1)	-1.14 (1.12)	-4.2	-1.83	-1.17	-0.50	2.3	-0.25 [-0.50, 0.01]
			Placebo	126	121 (96.0)	-0.88 (0.98)	-4.0	-1.50	-1.00	-0.33	1.5	
		Week 52	Tezepelumab	114	113 (99.1)	-1.13 (1.13)	-4.2	-1.83	-1.00	-0.33	2.3	-0.27 [-0.53, -0.01]
			Placebo	126	121 (96.0)	-0.84 (1.00)	-4.0	-1.50	-0.83	-0.17	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	2.62 (0.65)	1.0	2.17	2.67	2.83	4.3	
			Placebo	12	12 (100.0)	2.63 (0.88)	1.5	1.92	2.67	3.08	4.7	
		Week 2	Tezepelumab	23	22 (95.7)	1.92 (0.82)	0.3	1.17	2.08	2.50	3.0	
			Placebo	12	10 (83.3)	2.55 (0.94)	1.0	2.17	2.42	2.83	4.7	
		Week 4	Tezepelumab	23	22 (95.7)	1.60 (0.82)	0.2	1.17	1.50	2.50	2.8	
			Placebo	12	10 (83.3)	2.58 (0.78)	1.0	2.17	2.50	3.50	3.5	
		Week 6	Tezepelumab	23	22 (95.7)	1.47 (0.87)	0.0	0.83	1.50	1.83	3.0	
			Placebo	12	10 (83.3)	2.58 (1.27)	0.8	2.17	2.50	3.00	5.5	
		Week 8	Tezepelumab	23	22 (95.7)	1.42 (1.02)	0.0	0.67	1.33	2.33	3.5	
			Placebo	12	10 (83.3)	2.10 (1.25)	0.2	1.33	2.08	2.67	4.7	
		Week 10	Tezepelumab	23	22 (95.7)	1.20 (0.87)	0.0	0.67	1.25	1.67	3.0	
			Placebo	12	10 (83.3)	2.37 (0.93)	1.0	1.67	2.50	3.00	4.0	
		Week 12	Tezepelumab	23	22 (95.7)	1.20 (0.99)	0.0	0.33	1.08	1.83	3.3	
			Placebo	12	10 (83.3)	1.85 (0.98)	0.0	1.17	1.92	2.83	3.2	
		Week 14	Tezepelumab	23	22 (95.7)	1.10 (0.79)	0.0	0.67	1.00	1.67	2.7	
			Placebo	12	10 (83.3)	1.93 (1.03)	0.0	1.50	2.08	2.67	3.2	
		Week 16	Tezepelumab	23	22 (95.7)	1.08 (0.83)	0.0	0.33	0.92	1.67	2.7	
			Placebo	12	10 (83.3)	2.33 (1.41)	0.0	1.33	2.33	3.17	4.8	
		Week 18	Tezepelumab	23	22 (95.7)	1.02 (0.71)	0.0	0.50	0.92	1.33	2.7	
			Placebo	12	10 (83.3)	2.38 (1.36)	0.0	1.50	2.58	3.00	4.7	
		Week 20	Tezepelumab	23	22 (95.7)	1.11 (0.80)	0.0	0.67	1.00	1.50	2.7	
			Placebo	12	10 (83.3)	2.30 (0.83)	1.0	2.00	2.33	2.83	3.8	
		Week 22	Tezepelumab	23	22 (95.7)	1.17 (0.76)	0.0	0.83	1.17	1.50	2.7	
			Placebo	12	10 (83.3)	2.27 (0.85)	1.2	1.67	2.08	2.67	3.8	
		Week 24	Tezepelumab	23	22 (95.7)	1.26 (1.02)	0.0	0.50	1.08	1.83	4.2	
			Placebo	12	10 (83.3)	2.05 (1.13)	0.7	1.00	2.08	3.00	3.8	
		Week 26	Tezepelumab	23	22 (95.7)	1.14 (0.76)	0.0	0.83	1.08	1.50	2.7	
			Placebo	12	10 (83.3)	2.13 (1.33)	0.0	1.33	1.92	3.33	3.8	
		Week 28	Tezepelumab	23	22 (95.7)	1.32 (0.94)	0.0	0.83	1.17	2.33	2.7	
			Placebo	12	10 (83.3)	2.02 (1.24)	0.0	1.00	2.00	2.83	3.8	
		Week 30	Tezepelumab	23	22 (95.7)	1.02 (0.70)	0.0	0.67	0.92	1.50	2.7	
			Placebo	12	10 (83.3)	2.23 (0.96)	0.5	1.83	2.25	2.67	3.8	
		Week 32	Tezepelumab	23	22 (95.7)	0.96 (0.75)	0.0	0.33	1.00	1.33	2.7	
			Placebo	12	10 (83.3)	2.03 (1.00)	0.8	1.33	1.75	2.83	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	23	22 (95.7)	0.98 (0.74)	0.0	0.33	1.00	1.33	2.7	
			Placebo	12	10 (83.3)	1.70 (1.19)	0.3	0.67	1.42	2.33	3.8	
		Week 36	Tezepelumab	23	22 (95.7)	1.24 (0.84)	0.0	0.50	1.25	1.67	3.0	
			Placebo	12	10 (83.3)	2.05 (1.18)	0.5	0.83	2.00	2.83	3.8	
		Week 38	Tezepelumab	23	22 (95.7)	1.00 (0.79)	0.0	0.17	1.08	1.50	2.7	
			Placebo	12	10 (83.3)	2.38 (0.95)	0.8	1.67	2.58	3.17	3.8	
		Week 40	Tezepelumab	23	22 (95.7)	1.03 (0.81)	0.0	0.50	0.92	1.50	2.7	
			Placebo	12	10 (83.3)	2.20 (1.29)	0.7	0.83	1.92	3.33	4.0	
		Week 42	Tezepelumab	23	22 (95.7)	1.18 (1.07)	0.0	0.50	1.00	1.50	4.7	
			Placebo	12	10 (83.3)	2.03 (1.08)	0.5	1.33	2.00	2.50	3.8	
		Week 44	Tezepelumab	23	22 (95.7)	1.19 (0.82)	0.0	0.50	1.17	1.83	2.7	
			Placebo	12	10 (83.3)	2.10 (1.32)	0.5	0.83	2.17	3.33	4.0	
		Week 46	Tezepelumab	23	22 (95.7)	1.02 (0.78)	0.0	0.67	0.92	1.17	2.8	
			Placebo	12	10 (83.3)	2.08 (1.13)	0.5	1.17	2.08	2.83	3.8	
		Week 48	Tezepelumab	23	22 (95.7)	1.14 (0.81)	0.0	0.67	1.08	1.50	2.8	
			Placebo	12	10 (83.3)	2.12 (1.18)	0.7	0.83	2.58	2.83	3.8	
		Week 50	Tezepelumab	23	22 (95.7)	0.95 (0.67)	0.0	0.50	0.83	1.33	2.7	
			Placebo	12	10 (83.3)	1.73 (1.24)	0.2	0.67	1.58	2.50	3.8	
		Week 52	Tezepelumab	23	22 (95.7)	1.03 (0.67)	0.0	0.50	0.92	1.50	2.7	
			Placebo	12	10 (83.3)	1.90 (1.27)	0.2	0.67	2.08	2.83	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility											
No	Change from baseline	Week 2	Tezepelumab	23	22 (95.7)	-0.70 (0.63)	-1.8	-1.17	-0.67	-0.17	0.5	-0.89 [-1.67, -0.10]
			Placebo	12	10 (83.3)	-0.07 (0.87)	-1.0	-0.83	-0.17	1.00	1.2	
		Week 4	Tezepelumab	23	22 (95.7)	-1.02 (0.70)	-2.3	-1.50	-1.17	-0.67	0.5	-1.31 [-2.13, -0.50]
			Placebo	12	10 (83.3)	-0.03 (0.86)	-1.2	-1.00	0.17	0.67	1.2	
		Week 6	Tezepelumab	23	22 (95.7)	-1.15 (0.80)	-2.5	-1.50	-1.33	-0.67	0.5	-1.24 [-2.05, -0.43]
			Placebo	12	10 (83.3)	-0.03 (1.10)	-2.0	-0.83	0.17	0.83	1.5	
		Week 8	Tezepelumab	23	22 (95.7)	-1.20 (0.88)	-2.5	-1.83	-1.50	-0.67	0.7	-0.72 [-1.49, 0.05]
			Placebo	12	10 (83.3)	-0.52 (1.12)	-3.0	-1.00	-0.25	0.17	0.8	
		Week 10	Tezepelumab	23	22 (95.7)	-1.42 (0.82)	-2.7	-2.00	-1.58	-1.00	0.3	-1.18 [-1.99, -0.38]
			Placebo	12	10 (83.3)	-0.25 (1.29)	-2.2	-0.83	-0.17	0.17	2.5	
		Week 12	Tezepelumab	23	22 (95.7)	-1.42 (0.78)	-2.5	-2.00	-1.67	-0.67	0.0	-0.67 [-1.44, 0.10]
			Placebo	12	10 (83.3)	-0.77 (1.32)	-3.2	-1.67	-0.67	0.17	1.3	
		Week 14	Tezepelumab	23	22 (95.7)	-1.52 (0.73)	-2.7	-2.17	-1.67	-1.17	0.2	-0.88 [-1.66, -0.10]
			Placebo	12	10 (83.3)	-0.68 (1.33)	-3.2	-1.50	-0.67	0.17	1.2	
		Week 16	Tezepelumab	23	22 (95.7)	-1.54 (0.77)	-2.8	-2.17	-1.75	-1.00	0.0	-1.19 [-1.99, -0.38]
			Placebo	12	10 (83.3)	-0.28 (1.52)	-3.2	-1.33	0.08	0.67	2.3	
		Week 18	Tezepelumab	23	22 (95.7)	-1.61 (0.83)	-3.2	-2.00	-1.83	-1.00	0.3	-1.23 [-2.04, -0.42]
			Placebo	12	10 (83.3)	-0.23 (1.59)	-3.2	-1.33	0.00	0.50	2.3	
		Week 20	Tezepelumab	23	22 (95.7)	-1.51 (0.76)	-2.7	-2.00	-1.67	-1.33	0.2	-1.29 [-2.11, -0.48]
			Placebo	12	10 (83.3)	-0.32 (1.22)	-1.7	-1.00	-0.67	0.50	2.3	
		Week 22	Tezepelumab	23	22 (95.7)	-1.45 (0.82)	-3.2	-1.83	-1.58	-0.67	0.2	-1.18 [-1.99, -0.38]
			Placebo	12	10 (83.3)	-0.35 (1.16)	-1.5	-1.33	-0.67	0.33	2.3	
		Week 24	Tezepelumab	23	22 (95.7)	-1.36 (0.76)	-2.5	-2.00	-1.58	-1.00	0.2	-0.80 [-1.58, -0.03]
			Placebo	12	10 (83.3)	-0.57 (1.40)	-2.5	-1.50	-0.92	0.17	2.3	
		Week 26	Tezepelumab	23	22 (95.7)	-1.48 (0.85)	-3.0	-2.00	-1.50	-1.00	0.3	-0.91 [-1.70, -0.13]
			Placebo	12	10 (83.3)	-0.48 (1.50)	-3.2	-1.33	-0.58	0.50	2.3	
		Week 28	Tezepelumab	23	22 (95.7)	-1.30 (0.89)	-2.5	-2.00	-1.58	-0.67	0.3	-0.63 [-1.39, 0.13]
			Placebo	12	10 (83.3)	-0.60 (1.51)	-3.2	-1.33	-0.42	0.17	2.3	
		Week 30	Tezepelumab	23	22 (95.7)	-1.61 (0.74)	-2.8	-2.17	-1.75	-1.17	0.0	-1.32 [-2.14, -0.50]
			Placebo	12	10 (83.3)	-0.38 (1.25)	-1.5	-1.33	-0.58	0.17	2.3	
		Week 32	Tezepelumab	23	22 (95.7)	-1.66 (0.80)	-3.3	-2.17	-1.83	-1.17	0.0	-1.15 [-1.95, -0.34]
			Placebo	12	10 (83.3)	-0.58 (1.21)	-2.0	-1.33	-1.00	-0.17	2.3	
		Week 34	Tezepelumab	23	22 (95.7)	-1.64 (0.77)	-3.0	-2.17	-1.75	-1.17	0.2	-0.73 [-1.50, 0.04]
			Placebo	12	10 (83.3)	-0.92 (1.38)	-2.8	-1.33	-1.17	-0.67	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	23	22 (95.7)	-1.38 (0.88)	-2.7	-2.00	-1.50	-0.83	0.7	-0.77 [-1.54, 0.00]
			Placebo	12	10 (83.3)	-0.57 (1.37)	-2.3	-1.33	-0.75	0.33	2.3	
		Week 38	Tezepelumab	23	22 (95.7)	-1.62 (0.84)	-3.5	-2.00	-1.75	-1.17	0.3	-1.47 [-2.30, -0.63]
			Placebo	12	10 (83.3)	-0.23 (1.16)	-1.3	-1.17	-0.33	0.17	2.3	
		Week 40	Tezepelumab	23	22 (95.7)	-1.59 (0.92)	-3.8	-2.17	-1.67	-1.00	0.3	-1.09 [-1.88, -0.29]
			Placebo	12	10 (83.3)	-0.42 (1.39)	-2.3	-1.33	-0.50	0.17	2.3	
		Week 42	Tezepelumab	23	22 (95.7)	-1.44 (1.07)	-3.2	-2.00	-1.83	-1.00	1.8	-0.75 [-1.52, 0.02]
			Placebo	12	10 (83.3)	-0.58 (1.28)	-2.0	-1.50	-0.92	0.17	2.3	
		Week 44	Tezepelumab	23	22 (95.7)	-1.43 (0.92)	-3.5	-2.17	-1.50	-0.67	0.3	-0.80 [-1.57, -0.03]
			Placebo	12	10 (83.3)	-0.52 (1.55)	-2.7	-1.83	-0.92	0.67	2.3	
		Week 46	Tezepelumab	23	22 (95.7)	-1.60 (0.84)	-3.3	-2.00	-1.83	-1.00	0.2	-1.04 [-1.84, -0.25]
			Placebo	12	10 (83.3)	-0.53 (1.35)	-2.0	-1.50	-1.00	0.33	2.3	
		Week 48	Tezepelumab	23	22 (95.7)	-1.48 (0.90)	-3.2	-2.00	-1.75	-1.00	0.3	-0.94 [-1.73, -0.16]
			Placebo	12	10 (83.3)	-0.50 (1.33)	-2.2	-1.33	-0.50	-0.33	2.3	
		Week 50	Tezepelumab	23	22 (95.7)	-1.67 (0.78)	-3.5	-2.00	-1.83	-1.17	0.3	-0.76 [-1.54, 0.01]
			Placebo	12	10 (83.3)	-0.88 (1.46)	-3.0	-2.00	-1.00	-0.33	2.3	
		Week 52	Tezepelumab	23	22 (95.7)	-1.59 (0.79)	-3.5	-2.00	-1.58	-1.00	0.3	-0.82 [-1.59, -0.04]
			Placebo	12	10 (83.3)	-0.72 (1.53)	-3.0	-1.83	-1.00	0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.56 (0.46)	2.0	2.17	2.50	2.83	3.2	
			Placebo	14	14 (100.0)	2.70 (0.84)	0.3	2.67	3.00	3.17	3.5	
		Week 2	Tezepelumab	9	9 (100.0)	2.15 (0.68)	0.8	1.83	2.33	2.67	3.0	
			Placebo	14	12 (85.7)	2.49 (0.51)	1.5	2.17	2.50	2.83	3.3	
		Week 4	Tezepelumab	9	9 (100.0)	1.61 (0.79)	0.2	1.33	1.67	2.17	2.7	
			Placebo	14	12 (85.7)	2.76 (0.77)	1.8	2.17	2.50	3.42	4.2	
		Week 6	Tezepelumab	9	9 (100.0)	1.33 (0.58)	0.5	0.83	1.50	1.67	2.3	
			Placebo	14	12 (85.7)	2.63 (0.76)	1.2	2.25	2.83	3.00	3.8	
		Week 8	Tezepelumab	9	9 (100.0)	1.22 (0.75)	0.0	0.83	1.50	1.50	2.3	
			Placebo	14	13 (92.9)	2.36 (0.97)	0.2	2.00	2.33	2.83	3.7	
		Week 10	Tezepelumab	9	9 (100.0)	0.96 (0.77)	0.0	0.50	0.83	1.50	2.3	
			Placebo	14	13 (92.9)	2.35 (0.81)	1.0	2.00	2.33	2.83	4.0	
		Week 12	Tezepelumab	9	9 (100.0)	0.91 (0.81)	0.0	0.00	1.00	1.50	2.2	
			Placebo	14	13 (92.9)	2.38 (0.94)	0.0	2.00	2.50	2.67	4.2	
		Week 14	Tezepelumab	9	9 (100.0)	0.91 (0.62)	0.0	0.50	1.33	1.33	1.5	
			Placebo	14	13 (92.9)	1.95 (0.77)	0.0	1.83	2.17	2.33	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	0.87 (0.50)	0.0	0.50	1.00	1.17	1.5	
			Placebo	14	13 (92.9)	2.31 (1.06)	0.0	2.00	2.50	2.67	3.8	
		Week 18	Tezepelumab	9	9 (100.0)	1.13 (0.60)	0.0	1.00	1.17	1.50	2.0	
			Placebo	14	13 (92.9)	2.29 (0.85)	0.0	2.17	2.33	2.67	3.8	
		Week 20	Tezepelumab	9	9 (100.0)	1.15 (0.78)	0.0	0.83	1.00	1.50	2.8	
			Placebo	14	13 (92.9)	2.40 (0.76)	1.0	2.17	2.50	2.67	3.8	
		Week 22	Tezepelumab	9	9 (100.0)	1.26 (0.90)	0.0	1.00	1.33	1.50	2.5	
			Placebo	14	13 (92.9)	2.49 (0.86)	0.8	2.00	2.67	3.00	3.8	
		Week 24	Tezepelumab	9	9 (100.0)	1.11 (0.75)	0.0	0.67	1.00	1.50	2.5	
			Placebo	14	13 (92.9)	2.40 (0.88)	0.7	2.00	2.33	3.00	3.8	
		Week 26	Tezepelumab	9	9 (100.0)	1.31 (0.73)	0.0	0.83	1.33	2.00	2.2	
			Placebo	14	13 (92.9)	2.31 (1.11)	0.0	1.50	2.33	3.17	3.8	
		Week 28	Tezepelumab	9	9 (100.0)	1.54 (0.90)	0.0	1.00	1.50	2.33	2.7	
			Placebo	14	14 (100.0)	2.15 (1.22)	0.0	1.33	2.33	3.00	3.8	
		Week 30	Tezepelumab	9	9 (100.0)	1.22 (0.72)	0.0	0.67	1.33	1.50	2.2	
			Placebo	14	14 (100.0)	2.24 (1.08)	0.0	1.67	2.33	3.00	3.8	
		Week 32	Tezepelumab	9	9 (100.0)	1.17 (0.77)	0.0	0.67	1.00	1.67	2.3	
			Placebo	14	14 (100.0)	2.32 (1.21)	0.0	1.50	2.33	3.00	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.26 (1.05)	0.0	0.67	1.00	2.17	2.7	
			Placebo	14	14 (100.0)	2.15 (1.28)	0.2	1.17	2.25	3.00	4.5	
		Week 36	Tezepelumab	9	9 (100.0)	1.37 (0.79)	0.0	0.83	1.50	2.00	2.5	
			Placebo	14	14 (100.0)	2.37 (1.24)	0.0	1.83	2.17	3.00	4.5	
		Week 38	Tezepelumab	9	9 (100.0)	1.37 (1.01)	0.0	0.50	1.50	2.00	2.7	
			Placebo	14	14 (100.0)	2.26 (1.20)	0.0	1.67	2.33	3.00	4.5	
		Week 40	Tezepelumab	9	9 (100.0)	1.15 (0.90)	0.0	0.67	1.00	2.00	2.3	
			Placebo	14	14 (100.0)	2.26 (1.17)	0.0	1.50	2.33	3.00	4.2	
		Week 42	Tezepelumab	9	9 (100.0)	1.24 (0.75)	0.0	0.83	1.00	1.67	2.3	
			Placebo	14	14 (100.0)	2.26 (1.13)	0.0	2.00	2.25	2.50	4.5	
		Week 44	Tezepelumab	9	9 (100.0)	1.33 (0.85)	0.0	0.83	1.50	1.67	2.7	
			Placebo	14	14 (100.0)	2.12 (1.15)	0.0	1.33	2.25	2.50	4.2	
		Week 46	Tezepelumab	9	9 (100.0)	1.39 (0.92)	0.0	0.83	1.00	1.83	2.8	
			Placebo	14	14 (100.0)	2.19 (0.91)	0.0	1.83	2.17	2.50	3.8	
		Week 48	Tezepelumab	9	9 (100.0)	1.37 (0.88)	0.0	1.00	1.00	2.00	2.8	
			Placebo	14	14 (100.0)	2.25 (1.01)	0.0	2.00	2.17	2.67	3.8	
		Week 50	Tezepelumab	9	9 (100.0)	1.06 (0.69)	0.0	0.67	1.00	1.50	2.3	
			Placebo	14	14 (100.0)	2.01 (1.09)	0.0	1.33	2.17	2.50	3.8	
		Week 52	Tezepelumab	9	9 (100.0)	1.06 (0.69)	0.0	0.67	1.00	1.50	2.3	
			Placebo	14	14 (100.0)	2.10 (1.16)	0.0	1.33	2.17	2.83	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.41 (0.39)	-1.3	-0.50	-0.17	-0.17	-0.2	-0.06 [-0.92, 0.81]
			Placebo	14	12 (85.7)	-0.38 (0.64)	-1.5	-0.75	-0.42	0.00	1.0	
		Week 4	Tezepelumab	9	9 (100.0)	-0.94 (0.58)	-1.8	-1.33	-1.00	-0.50	-0.2	-1.20 [-2.14, -0.25]
			Placebo	14	12 (85.7)	-0.10 (0.79)	-1.3	-0.75	0.00	0.42	1.2	
		Week 6	Tezepelumab	9	9 (100.0)	-1.22 (0.63)	-2.2	-1.50	-1.33	-0.67	-0.2	-1.25 [-2.20, -0.30]
			Placebo	14	12 (85.7)	-0.24 (0.89)	-2.0	-0.67	-0.25	0.08	1.5	
		Week 8	Tezepelumab	9	9 (100.0)	-1.33 (0.60)	-2.0	-1.67	-1.33	-1.33	-0.2	-0.85 [-1.74, 0.04]
			Placebo	14	13 (92.9)	-0.53 (1.13)	-3.0	-1.00	-0.50	0.17	1.0	
		Week 10	Tezepelumab	9	9 (100.0)	-1.59 (0.55)	-2.2	-2.00	-1.83	-1.33	-0.7	-1.11 [-2.02, -0.19]
			Placebo	14	13 (92.9)	-0.54 (1.14)	-2.2	-1.17	-0.67	-0.33	2.5	
		Week 12	Tezepelumab	9	9 (100.0)	-1.65 (0.54)	-2.2	-2.00	-1.83	-1.33	-0.7	-1.24 [-2.17, -0.31]
			Placebo	14	13 (92.9)	-0.50 (1.11)	-3.2	-0.83	-0.67	0.00	1.3	
		Week 14	Tezepelumab	9	9 (100.0)	-1.65 (0.46)	-2.2	-2.00	-1.83	-1.50	-0.7	-0.85 [-1.74, 0.04]
			Placebo	14	13 (92.9)	-0.94 (1.01)	-3.2	-1.17	-0.83	-0.67	1.2	
		Week 16	Tezepelumab	9	9 (100.0)	-1.69 (0.45)	-2.2	-2.00	-1.83	-1.67	-0.7	-1.02 [-1.93, -0.11]
			Placebo	14	13 (92.9)	-0.58 (1.35)	-3.2	-1.17	-0.50	0.00	2.3	
		Week 18	Tezepelumab	9	9 (100.0)	-1.43 (0.64)	-2.2	-1.67	-1.67	-1.33	-0.2	-0.82 [-1.71, 0.06]
			Placebo	14	13 (92.9)	-0.59 (1.20)	-3.2	-1.00	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	9	9 (100.0)	-1.41 (0.59)	-2.0	-2.00	-1.50	-1.33	-0.3	-1.00 [-1.91, -0.10]
			Placebo	14	13 (92.9)	-0.49 (1.08)	-2.2	-1.00	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	9	9 (100.0)	-1.30 (0.73)	-2.2	-2.00	-1.50	-0.67	-0.3	-0.91 [-1.81, -0.02]
			Placebo	14	13 (92.9)	-0.40 (1.12)	-2.0	-1.00	-0.50	0.33	2.3	
		Week 24	Tezepelumab	9	9 (100.0)	-1.44 (0.62)	-2.3	-1.67	-1.50	-1.33	-0.3	-0.96 [-1.86, -0.06]
			Placebo	14	13 (92.9)	-0.49 (1.18)	-2.5	-1.17	-0.83	0.17	2.3	
		Week 26	Tezepelumab	9	9 (100.0)	-1.24 (0.72)	-2.3	-1.50	-1.33	-0.67	0.0	-0.58 [-1.45, 0.29]
			Placebo	14	13 (92.9)	-0.58 (1.36)	-3.2	-1.33	-0.83	0.33	2.3	
		Week 28	Tezepelumab	9	9 (100.0)	-1.02 (0.82)	-2.2	-1.50	-0.83	-0.67	0.3	-0.41 [-1.25, 0.44]
			Placebo	14	14 (100.0)	-0.55 (1.32)	-3.2	-1.17	-0.58	0.33	2.3	
		Week 30	Tezepelumab	9	9 (100.0)	-1.33 (0.62)	-2.5	-1.50	-1.33	-0.83	-0.7	-0.90 [-1.78, -0.02]
			Placebo	14	14 (100.0)	-0.46 (1.13)	-2.0	-1.17	-0.75	0.33	2.3	
		Week 32	Tezepelumab	9	9 (100.0)	-1.39 (0.55)	-2.2	-1.83	-1.50	-0.83	-0.7	-0.99 [-1.87, -0.10]
			Placebo	14	14 (100.0)	-0.38 (1.23)	-1.8	-1.33	-0.58	0.33	2.3	
		Week 34	Tezepelumab	9	9 (100.0)	-1.30 (0.83)	-2.5	-2.00	-1.50	-0.67	-0.2	-0.62 [-1.48, 0.24]
			Placebo	14	14 (100.0)	-0.55 (1.40)	-2.8	-1.50	-0.83	0.33	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.19 (0.78)	-2.3	-1.67	-1.33	-0.67	0.0	-0.78 [-1.65, 0.09]
			Placebo	14	14 (100.0)	-0.33 (1.25)	-1.8	-1.33	-0.67	0.33	2.3	
		Week 38	Tezepelumab	9	9 (100.0)	-1.19 (0.67)	-2.0	-1.67	-1.33	-0.67	-0.2	-0.70 [-1.56, 0.16]
			Placebo	14	14 (100.0)	-0.44 (1.25)	-2.2	-1.17	-0.67	0.17	2.3	
		Week 40	Tezepelumab	9	9 (100.0)	-1.41 (0.72)	-2.5	-2.00	-1.50	-0.67	-0.5	-0.90 [-1.79, -0.02]
			Placebo	14	14 (100.0)	-0.44 (1.24)	-2.3	-1.33	-0.58	0.33	2.3	
		Week 42	Tezepelumab	9	9 (100.0)	-1.31 (0.59)	-2.2	-1.50	-1.50	-0.67	-0.5	-0.89 [-1.77, -0.01]
			Placebo	14	14 (100.0)	-0.44 (1.17)	-2.0	-1.17	-0.75	0.00	2.3	
		Week 44	Tezepelumab	9	9 (100.0)	-1.22 (0.80)	-2.7	-1.50	-1.33	-0.67	-0.2	-0.58 [-1.43, 0.28]
			Placebo	14	14 (100.0)	-0.58 (1.26)	-2.7	-1.17	-0.83	0.00	2.3	
		Week 46	Tezepelumab	9	9 (100.0)	-1.17 (0.75)	-2.2	-1.50	-1.33	-0.67	0.0	-0.72 [-1.59, 0.15]
			Placebo	14	14 (100.0)	-0.51 (0.99)	-1.5	-1.17	-0.83	0.00	2.3	
		Week 48	Tezepelumab	9	9 (100.0)	-1.19 (0.86)	-2.2	-2.00	-1.50	-0.50	0.0	-0.75 [-1.62, 0.12]
			Placebo	14	14 (100.0)	-0.45 (1.04)	-1.7	-1.17	-0.67	-0.33	2.3	
		Week 50	Tezepelumab	9	9 (100.0)	-1.50 (0.67)	-2.5	-2.00	-1.50	-1.17	-0.5	-0.78 [-1.65, 0.09]
			Placebo	14	14 (100.0)	-0.69 (1.21)	-3.0	-1.17	-0.92	-0.33	2.3	
		Week 52	Tezepelumab	9	9 (100.0)	-1.50 (0.67)	-2.5	-2.00	-1.50	-1.17	-0.5	-0.84 [-1.71, 0.04]
			Placebo	14	14 (100.0)	-0.61 (1.25)	-3.0	-1.17	-0.92	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	128 (100.0)	2.71 (0.82)	0.0	2.33	2.67	3.08	4.8	
			Placebo	124	124 (100.0)	2.65 (0.67)	1.2	2.17	2.67	3.00	4.7	
		Week 2	Tezepelumab	128	122 (95.3)	2.17 (0.93)	0.0	1.67	2.17	2.83	4.3	
			Placebo	124	113 (91.1)	2.28 (0.82)	0.2	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	128	122 (95.3)	1.91 (0.97)	0.0	1.17	2.00	2.67	4.3	
			Placebo	124	113 (91.1)	2.12 (0.83)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	128	122 (95.3)	1.83 (0.98)	0.0	1.17	1.83	2.50	4.3	
			Placebo	124	114 (91.9)	2.03 (0.97)	0.2	1.33	2.17	2.50	5.5	
		Week 8	Tezepelumab	128	122 (95.3)	1.77 (1.03)	0.0	1.00	1.75	2.67	4.8	
			Placebo	124	114 (91.9)	2.02 (0.95)	0.0	1.33	2.00	2.67	4.7	
		Week 10	Tezepelumab	128	122 (95.3)	1.71 (1.01)	0.0	1.00	1.67	2.33	4.3	
			Placebo	124	115 (92.7)	1.94 (0.92)	0.0	1.33	2.00	2.50	5.3	
		Week 12	Tezepelumab	128	122 (95.3)	1.64 (1.03)	0.0	0.83	1.67	2.50	4.3	
			Placebo	124	115 (92.7)	1.84 (0.92)	0.0	1.17	1.83	2.50	4.3	
		Week 14	Tezepelumab	128	122 (95.3)	1.50 (1.01)	0.0	0.83	1.50	2.17	4.3	
			Placebo	124	115 (92.7)	1.83 (0.93)	0.0	1.00	1.83	2.50	5.0	
		Week 16	Tezepelumab	128	122 (95.3)	1.66 (1.06)	0.0	0.83	1.67	2.50	4.3	
			Placebo	124	115 (92.7)	1.93 (1.02)	0.0	1.17	1.83	2.67	5.0	
		Week 18	Tezepelumab	128	123 (96.1)	1.53 (0.99)	0.0	0.83	1.50	2.17	4.3	
			Placebo	124	115 (92.7)	1.82 (0.99)	0.0	1.17	1.83	2.33	5.0	
		Week 20	Tezepelumab	128	123 (96.1)	1.61 (1.03)	0.0	0.83	1.67	2.33	5.0	
			Placebo	124	115 (92.7)	1.87 (1.01)	0.0	1.17	1.83	2.67	5.0	
		Week 22	Tezepelumab	128	123 (96.1)	1.62 (0.97)	0.0	0.83	1.67	2.33	4.3	
			Placebo	124	115 (92.7)	1.80 (0.99)	0.0	1.00	1.83	2.50	5.0	
		Week 24	Tezepelumab	128	123 (96.1)	1.63 (1.04)	0.0	0.83	1.67	2.33	4.3	
			Placebo	124	115 (92.7)	1.81 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 26	Tezepelumab	128	124 (96.9)	1.57 (1.02)	0.0	0.83	1.50	2.25	4.3	
			Placebo	124	115 (92.7)	1.77 (0.95)	0.0	1.00	1.67	2.50	4.5	
		Week 28	Tezepelumab	128	125 (97.7)	1.61 (1.04)	0.0	0.83	1.50	2.50	4.3	
			Placebo	124	115 (92.7)	1.84 (1.02)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	128	126 (98.4)	1.57 (1.01)	0.0	0.83	1.50	2.33	4.3	
			Placebo	124	116 (93.5)	1.82 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 32	Tezepelumab	128	126 (98.4)	1.53 (1.03)	0.0	0.83	1.50	2.33	4.3	
			Placebo	124	116 (93.5)	1.76 (0.99)	0.0	1.00	1.67	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	128	126 (98.4)	1.54 (1.06)	0.0	0.83	1.42	2.33	4.3	
			Placebo	124	116 (93.5)	1.74 (1.00)	0.0	1.00	1.67	2.50	4.5	
		Week 36	Tezepelumab	128	126 (98.4)	1.62 (1.05)	0.0	0.83	1.67	2.33	4.5	
			Placebo	124	116 (93.5)	1.80 (1.00)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	128	126 (98.4)	1.51 (1.04)	0.0	0.83	1.50	2.17	4.5	
			Placebo	124	116 (93.5)	1.72 (0.98)	0.0	1.00	1.75	2.50	4.5	
		Week 40	Tezepelumab	128	126 (98.4)	1.55 (1.05)	0.0	0.67	1.67	2.33	4.3	
			Placebo	124	116 (93.5)	1.81 (1.01)	0.0	1.00	1.83	2.50	4.5	
		Week 42	Tezepelumab	128	126 (98.4)	1.52 (1.06)	0.0	0.83	1.50	2.17	4.7	
			Placebo	124	116 (93.5)	1.77 (0.99)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	128	126 (98.4)	1.53 (1.03)	0.0	0.67	1.50	2.33	4.3	
			Placebo	124	117 (94.4)	1.83 (1.00)	0.0	1.00	2.00	2.67	4.5	
		Week 46	Tezepelumab	128	126 (98.4)	1.49 (1.04)	0.0	0.67	1.33	2.17	4.3	
			Placebo	124	117 (94.4)	1.71 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 48	Tezepelumab	128	126 (98.4)	1.56 (1.06)	0.0	0.67	1.50	2.33	4.3	
			Placebo	124	117 (94.4)	1.74 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 50	Tezepelumab	128	126 (98.4)	1.49 (1.05)	0.0	0.83	1.33	2.17	4.3	
			Placebo	124	117 (94.4)	1.74 (0.95)	0.0	1.00	1.67	2.50	4.5	
		Week 52	Tezepelumab	128	126 (98.4)	1.52 (1.04)	0.0	0.67	1.50	2.17	4.3	
			Placebo	124	117 (94.4)	1.79 (0.98)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 2	Tezepelumab	128	122 (95.3)	-0.55 (0.69)	-2.8	-0.83	-0.50	0.00	0.7	-0.26 [-0.52, -0.00]
			Placebo	124	113 (91.1)	-0.36 (0.72)	-2.8	-0.83	-0.33	0.17	1.2	
		Week 4	Tezepelumab	128	122 (95.3)	-0.81 (0.90)	-3.5	-1.33	-0.83	-0.17	2.3	-0.32 [-0.58, -0.06]
			Placebo	124	113 (91.1)	-0.53 (0.83)	-3.0	-1.00	-0.50	0.00	1.2	
		Week 6	Tezepelumab	128	122 (95.3)	-0.89 (0.97)	-3.8	-1.50	-0.83	-0.33	2.3	-0.29 [-0.55, -0.03]
			Placebo	124	114 (91.9)	-0.61 (0.89)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	128	122 (95.3)	-0.95 (1.02)	-3.8	-1.50	-0.92	-0.33	2.3	-0.34 [-0.60, -0.08]
			Placebo	124	114 (91.9)	-0.62 (0.88)	-3.2	-1.00	-0.67	0.00	1.0	
		Week 10	Tezepelumab	128	122 (95.3)	-1.01 (0.99)	-3.8	-1.50	-1.00	-0.33	2.3	-0.31 [-0.57, -0.05]
			Placebo	124	115 (92.7)	-0.71 (0.94)	-3.3	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	128	122 (95.3)	-1.08 (0.99)	-3.7	-1.67	-1.00	-0.50	2.3	-0.28 [-0.54, -0.03]
			Placebo	124	115 (92.7)	-0.80 (0.95)	-3.3	-1.33	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	128	122 (95.3)	-1.22 (1.02)	-3.8	-1.83	-1.17	-0.67	2.3	-0.41 [-0.66, -0.15]
			Placebo	124	115 (92.7)	-0.82 (0.94)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 16	Tezepelumab	128	122 (95.3)	-1.05 (1.05)	-4.2	-1.83	-1.00	-0.33	2.3	-0.33 [-0.59, -0.08]
			Placebo	124	115 (92.7)	-0.71 (0.99)	-3.5	-1.33	-0.67	0.00	2.3	
		Week 18	Tezepelumab	128	123 (96.1)	-1.18 (1.02)	-4.2	-1.83	-1.00	-0.67	2.3	-0.35 [-0.61, -0.09]
			Placebo	124	115 (92.7)	-0.83 (0.99)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 20	Tezepelumab	128	123 (96.1)	-1.09 (1.03)	-4.2	-1.83	-1.00	-0.33	2.3	-0.30 [-0.56, -0.05]
			Placebo	124	115 (92.7)	-0.78 (1.04)	-3.5	-1.50	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	128	123 (96.1)	-1.09 (1.05)	-4.3	-1.83	-1.00	-0.50	2.3	-0.24 [-0.49, 0.02]
			Placebo	124	115 (92.7)	-0.84 (0.99)	-3.3	-1.50	-0.83	-0.17	2.3	
		Week 24	Tezepelumab	128	123 (96.1)	-1.08 (1.00)	-4.5	-1.83	-1.00	-0.33	2.3	-0.25 [-0.50, 0.01]
			Placebo	124	115 (92.7)	-0.83 (1.02)	-3.5	-1.50	-0.67	-0.17	1.7	
		Week 26	Tezepelumab	128	124 (96.9)	-1.13 (1.05)	-4.2	-1.83	-1.00	-0.33	2.3	-0.24 [-0.50, 0.01]
			Placebo	124	115 (92.7)	-0.88 (1.00)	-4.0	-1.50	-1.00	-0.17	1.5	
		Week 28	Tezepelumab	128	125 (97.7)	-1.09 (1.05)	-4.2	-1.83	-1.00	-0.33	2.3	-0.27 [-0.52, -0.01]
			Placebo	124	115 (92.7)	-0.81 (1.04)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	128	126 (98.4)	-1.13 (1.07)	-4.2	-2.00	-1.00	-0.33	2.3	-0.28 [-0.54, -0.03]
			Placebo	124	116 (93.5)	-0.83 (1.05)	-3.2	-1.50	-0.83	-0.17	2.0	
		Week 32	Tezepelumab	128	126 (98.4)	-1.17 (1.07)	-4.2	-2.00	-1.00	-0.50	2.3	-0.26 [-0.52, -0.01]
			Placebo	124	116 (93.5)	-0.89 (1.01)	-3.5	-1.50	-0.83	-0.25	1.5	
		Week 34	Tezepelumab	128	126 (98.4)	-1.16 (1.08)	-4.2	-2.00	-1.17	-0.50	2.3	-0.24 [-0.49, 0.01]
			Placebo	124	116 (93.5)	-0.91 (1.00)	-4.0	-1.50	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	128	126 (98.4)	-1.09 (1.12)	-4.2	-1.83	-1.00	-0.33	2.3	-0.22 [-0.47, 0.03]
			Placebo	124	116 (93.5)	-0.85 (1.04)	-3.5	-1.42	-0.83	-0.08	1.5	
		Week 38	Tezepelumab	128	126 (98.4)	-1.19 (1.11)	-4.2	-2.00	-1.17	-0.33	2.3	-0.25 [-0.50, 0.01]
			Placebo	124	116 (93.5)	-0.93 (1.03)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 40	Tezepelumab	128	126 (98.4)	-1.15 (1.11)	-4.2	-2.00	-1.00	-0.33	2.3	-0.29 [-0.54, -0.03]
			Placebo	124	116 (93.5)	-0.84 (1.03)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 42	Tezepelumab	128	126 (98.4)	-1.19 (1.12)	-4.2	-2.00	-1.17	-0.50	2.3	-0.29 [-0.54, -0.03]
			Placebo	124	116 (93.5)	-0.88 (1.02)	-4.0	-1.50	-0.83	-0.17	1.3	
		Week 44	Tezepelumab	128	126 (98.4)	-1.17 (1.12)	-4.3	-1.83	-1.00	-0.50	2.3	-0.33 [-0.58, -0.08]
			Placebo	124	117 (94.4)	-0.81 (1.04)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 46	Tezepelumab	128	126 (98.4)	-1.21 (1.11)	-4.2	-2.00	-1.00	-0.50	2.3	-0.25 [-0.50, 0.00]
			Placebo	124	117 (94.4)	-0.94 (1.03)	-4.0	-1.67	-1.00	-0.17	1.3	
		Week 48	Tezepelumab	128	126 (98.4)	-1.14 (1.11)	-4.2	-1.83	-1.00	-0.33	2.3	-0.22 [-0.47, 0.04]
			Placebo	124	117 (94.4)	-0.91 (1.06)	-3.7	-1.50	-0.83	-0.33	1.7	
		Week 50	Tezepelumab	128	126 (98.4)	-1.21 (1.11)	-4.2	-2.00	-1.17	-0.50	2.3	-0.29 [-0.54, -0.03]
			Placebo	124	117 (94.4)	-0.91 (1.00)	-4.0	-1.50	-1.00	-0.33	1.5	
		Week 52	Tezepelumab	128	126 (98.4)	-1.18 (1.12)	-4.2	-2.00	-1.00	-0.50	2.3	-0.30 [-0.56, -0.05]
			Placebo	124	117 (94.4)	-0.86 (1.02)	-4.0	-1.50	-0.83	-0.17	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	108	108 (100.0)	2.72 (0.84)	0.0	2.33	2.67	3.17	4.8	
			Placebo	115	115 (100.0)	2.65 (0.66)	1.2	2.17	2.67	3.00	4.5	
		Week 2	Tezepelumab	108	103 (95.4)	2.21 (0.94)	0.0	1.67	2.17	2.83	4.3	
			Placebo	115	106 (92.2)	2.26 (0.80)	0.2	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	108	103 (95.4)	1.96 (0.98)	0.0	1.17	2.17	2.67	4.3	
			Placebo	115	106 (92.2)	2.10 (0.83)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	108	103 (95.4)	1.88 (0.99)	0.0	1.17	1.83	2.67	4.3	
			Placebo	115	107 (93.0)	1.99 (0.93)	0.2	1.33	2.00	2.67	4.7	
		Week 8	Tezepelumab	108	103 (95.4)	1.82 (1.03)	0.0	1.17	1.83	2.67	4.8	
			Placebo	115	107 (93.0)	2.01 (0.93)	0.0	1.33	2.00	2.67	4.7	
		Week 10	Tezepelumab	108	103 (95.4)	1.78 (1.02)	0.0	1.17	1.83	2.67	4.3	
			Placebo	115	108 (93.9)	1.92 (0.93)	0.0	1.33	2.00	2.50	5.3	
		Week 12	Tezepelumab	108	103 (95.4)	1.69 (1.03)	0.0	0.83	1.67	2.50	4.3	
			Placebo	115	108 (93.9)	1.85 (0.94)	0.0	1.17	1.83	2.50	4.3	
		Week 14	Tezepelumab	108	103 (95.4)	1.56 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	115	108 (93.9)	1.82 (0.94)	0.0	1.00	1.83	2.50	5.0	
		Week 16	Tezepelumab	108	103 (95.4)	1.76 (1.07)	0.0	1.00	1.67	2.50	4.3	
			Placebo	115	108 (93.9)	1.91 (1.01)	0.0	1.17	1.83	2.67	5.0	
		Week 18	Tezepelumab	108	104 (96.3)	1.63 (1.00)	0.0	0.83	1.67	2.33	4.3	
			Placebo	115	108 (93.9)	1.77 (0.97)	0.0	1.08	1.83	2.33	5.0	
		Week 20	Tezepelumab	108	104 (96.3)	1.70 (1.04)	0.0	1.00	1.83	2.33	5.0	
			Placebo	115	108 (93.9)	1.86 (1.03)	0.0	1.17	1.83	2.67	5.0	
		Week 22	Tezepelumab	108	104 (96.3)	1.70 (0.99)	0.0	1.00	1.83	2.33	4.3	
			Placebo	115	108 (93.9)	1.79 (1.01)	0.0	1.00	1.92	2.50	5.0	
		Week 24	Tezepelumab	108	104 (96.3)	1.68 (1.03)	0.0	0.92	1.67	2.33	4.3	
			Placebo	115	108 (93.9)	1.81 (0.98)	0.0	1.00	1.92	2.50	4.5	
		Week 26	Tezepelumab	108	105 (97.2)	1.66 (1.04)	0.0	1.00	1.67	2.33	4.3	
			Placebo	115	108 (93.9)	1.75 (0.94)	0.0	1.00	1.67	2.50	4.5	
		Week 28	Tezepelumab	108	106 (98.1)	1.68 (1.05)	0.0	0.83	1.67	2.50	4.3	
			Placebo	115	108 (93.9)	1.83 (1.02)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	108	107 (99.1)	1.68 (1.02)	0.0	0.83	1.67	2.33	4.3	
			Placebo	115	109 (94.8)	1.81 (1.01)	0.0	1.00	1.83	2.50	4.5	
		Week 32	Tezepelumab	108	107 (99.1)	1.63 (1.04)	0.0	1.00	1.67	2.33	4.3	
			Placebo	115	109 (94.8)	1.76 (1.00)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	108	107 (99.1)	1.64 (1.08)	0.0	0.83	1.50	2.50	4.3	
			Placebo	115	109 (94.8)	1.75 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	108	107 (99.1)	1.69 (1.07)	0.0	0.83	1.83	2.33	4.5	
			Placebo	115	109 (94.8)	1.80 (0.99)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	108	107 (99.1)	1.60 (1.06)	0.0	0.83	1.67	2.17	4.5	
			Placebo	115	109 (94.8)	1.69 (0.98)	0.0	1.00	1.67	2.50	4.5	
		Week 40	Tezepelumab	108	107 (99.1)	1.64 (1.06)	0.0	0.83	1.83	2.50	4.3	
			Placebo	115	109 (94.8)	1.79 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 42	Tezepelumab	108	107 (99.1)	1.58 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	115	109 (94.8)	1.77 (0.99)	0.0	1.00	1.83	2.50	4.7	
		Week 44	Tezepelumab	108	107 (99.1)	1.61 (1.05)	0.0	0.83	1.67	2.50	4.3	
			Placebo	115	110 (95.7)	1.82 (0.98)	0.0	1.00	1.92	2.67	4.5	
		Week 46	Tezepelumab	108	107 (99.1)	1.59 (1.07)	0.0	0.83	1.50	2.33	4.3	
			Placebo	115	110 (95.7)	1.70 (0.97)	0.0	1.00	1.83	2.33	4.5	
		Week 48	Tezepelumab	108	107 (99.1)	1.65 (1.08)	0.0	0.67	1.67	2.33	4.3	
			Placebo	115	110 (95.7)	1.74 (1.00)	0.0	1.00	1.83	2.50	4.5	
		Week 50	Tezepelumab	108	107 (99.1)	1.59 (1.07)	0.0	0.83	1.67	2.33	4.3	
			Placebo	115	110 (95.7)	1.75 (0.94)	0.0	1.00	1.75	2.50	4.5	
		Week 52	Tezepelumab	108	107 (99.1)	1.61 (1.07)	0.0	0.67	1.67	2.33	4.3	
			Placebo	115	110 (95.7)	1.79 (0.97)	0.0	1.00	1.83	2.50	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 2	Tezepelumab	108	103 (95.4)	-0.52 (0.69)	-2.8	-0.83	-0.33	0.00	0.7	-0.19 [-0.47, 0.08]
			Placebo	115	106 (92.2)	-0.38 (0.70)	-2.8	-0.83	-0.33	0.17	1.0	
		Week 4	Tezepelumab	108	103 (95.4)	-0.76 (0.93)	-3.5	-1.33	-0.67	-0.17	2.3	-0.25 [-0.52, 0.02]
			Placebo	115	106 (92.2)	-0.55 (0.82)	-3.0	-1.00	-0.42	0.00	1.2	
		Week 6	Tezepelumab	108	103 (95.4)	-0.84 (1.00)	-3.8	-1.33	-0.83	-0.17	2.3	-0.20 [-0.47, 0.07]
			Placebo	115	107 (93.0)	-0.65 (0.88)	-3.3	-1.33	-0.50	0.00	1.5	
		Week 8	Tezepelumab	108	103 (95.4)	-0.91 (1.03)	-3.8	-1.50	-0.83	-0.33	2.3	-0.29 [-0.56, -0.02]
			Placebo	115	107 (93.0)	-0.63 (0.89)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	108	103 (95.4)	-0.94 (1.01)	-3.8	-1.33	-0.83	-0.33	2.3	-0.22 [-0.49, 0.05]
			Placebo	115	108 (93.9)	-0.73 (0.95)	-3.3	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	108	103 (95.4)	-1.03 (1.02)	-3.7	-1.67	-1.00	-0.33	2.3	-0.24 [-0.51, 0.04]
			Placebo	115	108 (93.9)	-0.80 (0.95)	-3.3	-1.33	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	108	103 (95.4)	-1.16 (1.05)	-3.8	-1.83	-1.17	-0.33	2.3	-0.34 [-0.61, -0.07]
			Placebo	115	108 (93.9)	-0.82 (0.94)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 16	Tezepelumab	108	103 (95.4)	-0.97 (1.07)	-4.2	-1.50	-1.00	-0.33	2.3	-0.22 [-0.49, 0.05]
			Placebo	115	108 (93.9)	-0.74 (0.99)	-3.5	-1.33	-0.67	-0.17	2.3	
		Week 18	Tezepelumab	108	104 (96.3)	-1.09 (1.03)	-4.2	-1.67	-1.00	-0.50	2.3	-0.22 [-0.49, 0.05]
			Placebo	115	108 (93.9)	-0.87 (0.97)	-3.2	-1.50	-0.83	-0.33	2.3	
		Week 20	Tezepelumab	108	104 (96.3)	-1.02 (1.05)	-4.2	-1.67	-0.83	-0.33	2.3	-0.22 [-0.49, 0.05]
			Placebo	115	108 (93.9)	-0.79 (1.05)	-3.5	-1.42	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	108	104 (96.3)	-1.02 (1.07)	-4.3	-1.58	-0.92	-0.33	2.3	-0.16 [-0.43, 0.11]
			Placebo	115	108 (93.9)	-0.85 (1.00)	-3.3	-1.50	-0.83	-0.25	2.3	
		Week 24	Tezepelumab	108	104 (96.3)	-1.04 (1.03)	-4.5	-1.67	-0.83	-0.33	2.3	-0.19 [-0.46, 0.08]
			Placebo	115	108 (93.9)	-0.84 (1.03)	-3.5	-1.50	-0.67	-0.17	1.7	
		Week 26	Tezepelumab	108	105 (97.2)	-1.05 (1.07)	-4.2	-1.67	-0.83	-0.33	2.3	-0.14 [-0.41, 0.12]
			Placebo	115	108 (93.9)	-0.90 (1.01)	-4.0	-1.50	-1.00	-0.17	1.5	
		Week 28	Tezepelumab	108	106 (98.1)	-1.02 (1.08)	-4.2	-1.67	-1.00	-0.17	2.3	-0.20 [-0.47, 0.07]
			Placebo	115	108 (93.9)	-0.81 (1.05)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	108	107 (99.1)	-1.03 (1.09)	-4.2	-1.67	-1.00	-0.33	2.3	-0.18 [-0.45, 0.09]
			Placebo	115	109 (94.8)	-0.84 (1.05)	-3.2	-1.50	-0.83	-0.17	2.0	
		Week 32	Tezepelumab	108	107 (99.1)	-1.08 (1.08)	-4.2	-1.83	-1.00	-0.50	2.3	-0.18 [-0.45, 0.09]
			Placebo	115	109 (94.8)	-0.89 (1.03)	-3.5	-1.50	-0.67	-0.17	1.5	
		Week 34	Tezepelumab	108	107 (99.1)	-1.07 (1.10)	-4.2	-1.83	-1.00	-0.33	2.3	-0.16 [-0.43, 0.10]
			Placebo	115	109 (94.8)	-0.90 (1.02)	-4.0	-1.50	-0.83	-0.33	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	108	107 (99.1)	-1.02 (1.14)	-4.2	-1.67	-1.00	-0.17	2.3	-0.16 [-0.42, 0.11]
			Placebo	115	109 (94.8)	-0.84 (1.05)	-3.5	-1.33	-0.83	-0.17	1.5	
		Week 38	Tezepelumab	108	107 (99.1)	-1.11 (1.13)	-4.2	-2.00	-1.00	-0.33	2.3	-0.14 [-0.41, 0.13]
			Placebo	115	109 (94.8)	-0.96 (1.04)	-4.0	-1.67	-0.83	-0.33	1.5	
		Week 40	Tezepelumab	108	107 (99.1)	-1.07 (1.12)	-4.2	-1.83	-1.00	-0.33	2.3	-0.19 [-0.46, 0.07]
			Placebo	115	109 (94.8)	-0.86 (1.04)	-4.0	-1.50	-0.83	-0.17	1.5	
		Week 42	Tezepelumab	108	107 (99.1)	-1.13 (1.11)	-4.2	-1.83	-1.00	-0.50	2.3	-0.24 [-0.51, 0.03]
			Placebo	115	109 (94.8)	-0.87 (1.03)	-4.0	-1.50	-0.83	-0.17	1.3	
		Week 44	Tezepelumab	108	107 (99.1)	-1.10 (1.14)	-4.3	-1.83	-1.00	-0.33	2.3	-0.26 [-0.52, 0.01]
			Placebo	115	110 (95.7)	-0.83 (1.03)	-4.0	-1.50	-0.75	-0.17	1.5	
		Week 46	Tezepelumab	108	107 (99.1)	-1.12 (1.13)	-4.2	-1.83	-1.00	-0.33	2.3	-0.16 [-0.43, 0.11]
			Placebo	115	110 (95.7)	-0.95 (1.03)	-4.0	-1.67	-1.00	-0.17	1.3	
		Week 48	Tezepelumab	108	107 (99.1)	-1.06 (1.13)	-4.2	-1.83	-1.00	-0.33	2.3	-0.13 [-0.40, 0.13]
			Placebo	115	110 (95.7)	-0.91 (1.07)	-3.7	-1.50	-0.83	-0.17	1.7	
		Week 50	Tezepelumab	108	107 (99.1)	-1.12 (1.13)	-4.2	-1.83	-1.17	-0.33	2.3	-0.21 [-0.48, 0.06]
			Placebo	115	110 (95.7)	-0.90 (1.01)	-4.0	-1.50	-0.92	-0.17	1.5	
		Week 52	Tezepelumab	108	107 (99.1)	-1.10 (1.14)	-4.2	-1.83	-1.00	-0.33	2.3	-0.23 [-0.50, 0.04]
			Placebo	115	110 (95.7)	-0.86 (1.03)	-4.0	-1.50	-0.83	-0.17	1.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	29	29 (100.0)	2.63 (0.62)	1.0	2.17	2.67	2.83	4.3	
			Placebo	23	23 (100.0)	2.68 (0.85)	0.3	2.50	2.83	3.17	4.7	
		Week 2	Tezepelumab	29	28 (96.6)	2.01 (0.78)	0.3	1.50	2.25	2.67	3.0	
			Placebo	23	19 (82.6)	2.50 (0.76)	1.0	2.17	2.50	2.83	4.7	
		Week 4	Tezepelumab	29	28 (96.6)	1.61 (0.80)	0.2	1.17	1.58	2.25	2.8	
			Placebo	23	19 (82.6)	2.61 (0.77)	1.0	2.17	2.50	3.33	4.2	
		Week 6	Tezepelumab	29	28 (96.6)	1.48 (0.81)	0.0	0.92	1.50	1.75	3.0	
			Placebo	23	19 (82.6)	2.62 (1.00)	0.8	2.17	2.50	3.00	5.5	
		Week 8	Tezepelumab	29	28 (96.6)	1.42 (0.96)	0.0	0.67	1.50	2.17	3.5	
			Placebo	23	20 (87.0)	2.30 (1.04)	0.2	1.67	2.33	2.83	4.7	
		Week 10	Tezepelumab	29	28 (96.6)	1.20 (0.85)	0.0	0.58	1.33	1.58	3.0	
			Placebo	23	20 (87.0)	2.31 (0.75)	1.0	1.92	2.33	2.83	4.0	
		Week 12	Tezepelumab	29	28 (96.6)	1.20 (0.94)	0.0	0.42	1.25	1.75	3.3	
			Placebo	23	20 (87.0)	2.18 (0.88)	0.0	1.75	2.17	2.67	4.2	
		Week 14	Tezepelumab	29	28 (96.6)	1.08 (0.74)	0.0	0.58	1.17	1.50	2.7	
			Placebo	23	20 (87.0)	1.94 (0.76)	0.0	1.58	2.00	2.50	3.2	
		Week 16	Tezepelumab	29	28 (96.6)	1.05 (0.77)	0.0	0.42	1.00	1.50	2.7	
			Placebo	23	20 (87.0)	2.32 (1.10)	0.0	1.67	2.33	2.67	4.8	
		Week 18	Tezepelumab	29	28 (96.6)	1.03 (0.67)	0.0	0.58	1.00	1.50	2.7	
			Placebo	23	20 (87.0)	2.35 (0.96)	0.0	1.92	2.33	2.75	4.7	
		Week 20	Tezepelumab	29	28 (96.6)	1.16 (0.81)	0.0	0.75	1.00	1.50	2.8	
			Placebo	23	20 (87.0)	2.26 (0.75)	1.0	1.83	2.33	2.58	3.8	
		Week 22	Tezepelumab	29	28 (96.6)	1.22 (0.80)	0.0	0.83	1.17	1.50	2.7	
			Placebo	23	20 (87.0)	2.29 (0.84)	0.8	1.67	2.17	2.83	3.8	
		Week 24	Tezepelumab	29	28 (96.6)	1.26 (0.97)	0.0	0.58	1.08	1.83	4.2	
			Placebo	23	20 (87.0)	2.21 (0.91)	0.7	1.50	2.25	3.00	3.8	
		Week 26	Tezepelumab	29	28 (96.6)	1.17 (0.75)	0.0	0.83	1.08	1.58	2.7	
			Placebo	23	20 (87.0)	2.22 (1.08)	0.0	1.50	2.25	3.25	3.8	
		Week 28	Tezepelumab	29	28 (96.6)	1.32 (0.91)	0.0	0.83	1.17	2.17	2.7	
			Placebo	23	21 (91.3)	2.08 (1.12)	0.0	1.33	2.17	2.83	3.8	
		Week 30	Tezepelumab	29	28 (96.6)	1.07 (0.73)	0.0	0.67	1.00	1.50	2.7	
			Placebo	23	21 (91.3)	2.17 (1.01)	0.0	1.67	2.17	2.67	3.8	
		Week 32	Tezepelumab	29	28 (96.6)	1.04 (0.76)	0.0	0.33	1.00	1.50	2.7	
			Placebo	23	21 (91.3)	2.11 (1.12)	0.0	1.33	2.00	2.83	4.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	29	28 (96.6)	1.07 (0.82)	0.0	0.42	1.00	1.50	2.7	
			Placebo	23	21 (91.3)	1.94 (1.20)	0.2	0.83	1.83	2.50	4.5	
		Week 36	Tezepelumab	29	28 (96.6)	1.24 (0.82)	0.0	0.67	1.25	1.67	3.0	
			Placebo	23	21 (91.3)	2.15 (1.22)	0.0	1.67	2.17	2.83	4.5	
		Week 38	Tezepelumab	29	28 (96.6)	1.13 (0.86)	0.0	0.33	1.17	1.58	2.7	
			Placebo	23	21 (91.3)	2.25 (1.10)	0.0	1.67	2.50	3.00	4.5	
		Week 40	Tezepelumab	29	28 (96.6)	1.07 (0.80)	0.0	0.50	1.00	1.58	2.7	
			Placebo	23	21 (91.3)	2.18 (1.17)	0.0	1.50	2.17	3.00	4.2	
		Week 42	Tezepelumab	29	28 (96.6)	1.19 (0.99)	0.0	0.58	1.00	1.58	4.7	
			Placebo	23	21 (91.3)	2.09 (1.10)	0.0	1.50	2.17	2.50	4.5	
		Week 44	Tezepelumab	29	28 (96.6)	1.20 (0.83)	0.0	0.50	1.17	1.75	2.7	
			Placebo	23	21 (91.3)	2.10 (1.17)	0.0	1.17	2.17	2.50	4.2	
		Week 46	Tezepelumab	29	28 (96.6)	1.09 (0.80)	0.0	0.75	1.00	1.50	2.8	
			Placebo	23	21 (91.3)	2.07 (0.98)	0.0	1.83	2.17	2.67	3.8	
		Week 48	Tezepelumab	29	28 (96.6)	1.14 (0.79)	0.0	0.67	1.00	1.50	2.8	
			Placebo	23	21 (91.3)	2.08 (1.06)	0.0	1.17	2.17	2.67	3.8	
		Week 50	Tezepelumab	29	28 (96.6)	0.98 (0.68)	0.0	0.58	0.83	1.42	2.7	
			Placebo	23	21 (91.3)	1.87 (1.07)	0.0	1.00	2.17	2.50	3.8	
		Week 52	Tezepelumab	29	28 (96.6)	1.04 (0.68)	0.0	0.58	1.00	1.50	2.7	
			Placebo	23	21 (91.3)	1.98 (1.12)	0.0	1.00	2.17	2.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility											
No	Change from baseline	Week 2	Tezepelumab	29	28 (96.6)	-0.61 (0.59)	-1.8	-0.83	-0.58	-0.17	0.5	-0.51 [-1.10, 0.08]
			Placebo	23	19 (82.6)	-0.28 (0.73)	-1.5	-0.83	-0.33	0.00	1.2	
		Week 4	Tezepelumab	29	28 (96.6)	-1.02 (0.67)	-2.3	-1.50	-1.17	-0.58	0.5	-1.16 [-1.79, -0.53]
			Placebo	23	19 (82.6)	-0.17 (0.82)	-1.3	-1.00	0.00	0.50	1.2	
		Week 6	Tezepelumab	29	28 (96.6)	-1.15 (0.75)	-2.5	-1.50	-1.33	-0.67	0.5	-1.24 [-1.88, -0.60]
			Placebo	23	19 (82.6)	-0.16 (0.87)	-2.0	-0.83	-0.17	0.67	1.5	
		Week 8	Tezepelumab	29	28 (96.6)	-1.21 (0.83)	-2.5	-1.83	-1.50	-0.67	0.7	-0.79 [-1.39, -0.20]
			Placebo	23	20 (87.0)	-0.50 (0.98)	-3.0	-1.00	-0.50	0.08	1.0	
		Week 10	Tezepelumab	29	28 (96.6)	-1.42 (0.77)	-2.7	-2.00	-1.58	-0.92	0.3	-1.06 [-1.68, -0.45]
			Placebo	23	20 (87.0)	-0.49 (1.01)	-2.2	-1.00	-0.58	0.08	2.5	
		Week 12	Tezepelumab	29	28 (96.6)	-1.42 (0.72)	-2.5	-2.00	-1.67	-0.83	0.0	-0.93 [-1.53, -0.32]
			Placebo	23	20 (87.0)	-0.62 (1.02)	-3.2	-1.08	-0.67	0.00	1.3	
		Week 14	Tezepelumab	29	28 (96.6)	-1.55 (0.68)	-2.7	-2.00	-1.83	-1.17	0.2	-0.84 [-1.44, -0.25]
			Placebo	23	20 (87.0)	-0.86 (0.97)	-3.2	-1.42	-0.83	-0.33	1.2	
		Week 16	Tezepelumab	29	28 (96.6)	-1.58 (0.73)	-2.8	-2.08	-1.83	-1.08	0.0	-1.14 [-1.76, -0.53]
			Placebo	23	20 (87.0)	-0.48 (1.21)	-3.2	-1.25	-0.50	0.17	2.3	
		Week 18	Tezepelumab	29	28 (96.6)	-1.60 (0.77)	-3.2	-2.00	-1.75	-1.17	0.3	-1.20 [-1.83, -0.58]
			Placebo	23	20 (87.0)	-0.45 (1.16)	-3.2	-1.08	-0.50	0.08	2.3	
		Week 20	Tezepelumab	29	28 (96.6)	-1.46 (0.73)	-2.7	-2.00	-1.67	-1.17	0.2	-1.07 [-1.69, -0.46]
			Placebo	23	20 (87.0)	-0.54 (1.01)	-2.2	-1.08	-0.83	-0.08	2.3	
		Week 22	Tezepelumab	29	28 (96.6)	-1.40 (0.80)	-3.2	-1.92	-1.50	-0.67	0.2	-1.00 [-1.61, -0.39]
			Placebo	23	20 (87.0)	-0.51 (1.02)	-2.0	-1.25	-0.67	0.33	2.3	
		Week 24	Tezepelumab	29	28 (96.6)	-1.36 (0.74)	-2.5	-2.00	-1.50	-0.83	0.2	-0.86 [-1.46, -0.26]
			Placebo	23	20 (87.0)	-0.59 (1.07)	-2.5	-1.33	-0.83	0.17	2.3	
		Week 26	Tezepelumab	29	28 (96.6)	-1.46 (0.81)	-3.0	-2.00	-1.50	-0.83	0.3	-0.89 [-1.49, -0.29]
			Placebo	23	20 (87.0)	-0.58 (1.19)	-3.2	-1.33	-0.92	0.33	2.3	
		Week 28	Tezepelumab	29	28 (96.6)	-1.31 (0.83)	-2.5	-2.00	-1.50	-0.75	0.3	-0.71 [-1.29, -0.13]
			Placebo	23	21 (91.3)	-0.60 (1.18)	-3.2	-1.17	-0.50	0.17	2.3	
		Week 30	Tezepelumab	29	28 (96.6)	-1.56 (0.74)	-2.8	-2.08	-1.58	-1.00	0.0	-1.18 [-1.80, -0.57]
			Placebo	23	21 (91.3)	-0.52 (1.05)	-2.0	-1.33	-0.67	0.17	2.3	
		Week 32	Tezepelumab	29	28 (96.6)	-1.59 (0.77)	-3.3	-2.08	-1.75	-1.00	0.0	-1.10 [-1.71, -0.50]
			Placebo	23	21 (91.3)	-0.57 (1.10)	-2.0	-1.33	-1.00	-0.17	2.3	
		Week 34	Tezepelumab	29	28 (96.6)	-1.55 (0.81)	-3.0	-2.08	-1.67	-0.83	0.2	-0.81 [-1.40, -0.22]
			Placebo	23	21 (91.3)	-0.75 (1.21)	-2.8	-1.33	-1.00	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IOSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITT

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	29	28 (96.6)	-1.39 (0.85)	-2.7	-2.00	-1.50	-0.75	0.7	-0.84 [-1.44, -0.25]
			Placebo	23	21 (91.3)	-0.53 (1.20)	-2.3	-1.33	-1.00	0.33	2.3	
		Week 38	Tezepelumab	29	28 (96.6)	-1.49 (0.84)	-3.5	-2.00	-1.58	-0.92	0.3	-1.10 [-1.71, -0.50]
			Placebo	23	21 (91.3)	-0.44 (1.10)	-2.2	-1.17	-0.33	0.17	2.3	
		Week 40	Tezepelumab	29	28 (96.6)	-1.55 (0.87)	-3.8	-2.17	-1.50	-1.00	0.3	-1.06 [-1.67, -0.46]
			Placebo	23	21 (91.3)	-0.50 (1.13)	-2.3	-1.33	-0.83	0.17	2.3	
		Week 42	Tezepelumab	29	28 (96.6)	-1.43 (0.98)	-3.2	-2.00	-1.67	-0.83	1.8	-0.81 [-1.40, -0.23]
			Placebo	23	21 (91.3)	-0.60 (1.09)	-2.0	-1.33	-0.83	0.00	2.3	
		Week 44	Tezepelumab	29	28 (96.6)	-1.43 (0.90)	-3.5	-2.08	-1.50	-0.67	0.3	-0.81 [-1.40, -0.22]
			Placebo	23	21 (91.3)	-0.59 (1.21)	-2.7	-1.33	-0.83	0.33	2.3	
		Week 46	Tezepelumab	29	28 (96.6)	-1.54 (0.82)	-3.3	-2.00	-1.75	-1.00	0.2	-1.02 [-1.62, -0.42]
			Placebo	23	21 (91.3)	-0.61 (1.01)	-2.0	-1.33	-0.83	0.00	2.3	
		Week 48	Tezepelumab	29	28 (96.6)	-1.49 (0.86)	-3.2	-2.00	-1.75	-0.83	0.3	-0.94 [-1.54, -0.34]
			Placebo	23	21 (91.3)	-0.60 (1.04)	-2.2	-1.33	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	29	28 (96.6)	-1.65 (0.78)	-3.5	-2.08	-1.83	-1.08	0.3	-0.90 [-1.49, -0.30]
			Placebo	23	21 (91.3)	-0.82 (1.09)	-3.0	-1.33	-1.00	-0.33	2.3	
		Week 52	Tezepelumab	29	28 (96.6)	-1.58 (0.78)	-3.5	-2.08	-1.58	-1.00	0.3	-0.91 [-1.51, -0.32]
			Placebo	23	21 (91.3)	-0.71 (1.16)	-3.0	-1.33	-1.00	-0.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_ILMP0: Decrease of at least 0.9 points in ACQ-5 score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in ACQ-5 score	Week 28	66	66 (100.0)	35 (53.0) [40.3, 65.4]	65	60 (92.3)	31 (47.7) [35.1, 60.5]	1.112 [0.791, 1.564]	1.238 [0.624, 2.459]	5.3 [-13.3, 24.0]	0.543
	Week 52	66	66 (100.0)	42 (63.6) [50.9, 75.1]	65	60 (92.3)	30 (46.2) [33.7, 59.0]	1.379 [1.002, 1.898]	2.042 [1.014, 4.109]	17.5 [-0.8, 35.8]	0.045 *

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_ILSPK: Decrease of at least 0.9 points in ACQ-5 score by key subgroups
DITTL

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.409	
Male	19	19 (100.0)	13 (68.4) [43.4, 87.4]	20	19 (95.0)	8 (40.0) [19.1, 63.9]	1.711 [0.922, 3.172]	3.250 [0.870, 12.137]	28.4 [-6.7, 63.5]	0.079	
Female	47	47 (100.0)	29 (61.7) [46.4, 75.5]	45	41 (91.1)	22 (48.9) [33.7, 64.2]	1.262 [0.868, 1.835]	1.684 [0.735, 3.860]	12.8 [-9.5, 35.1]	0.219	
Age										0.155	
< 65 years	57	57 (100.0)	36 (63.2) [49.3, 75.6]	55	51 (92.7)	28 (50.9) [37.1, 64.6]	1.241 [0.895, 1.720]	1.653 [0.777, 3.515]	12.2 [-7.7, 32.2]	0.192	
>= 65 years	9	9 (100.0)	6 (66.7) [29.9, 92.5]	10	9 (90.0)	2 (20.0) [2.5, 55.6]	3.333 [0.888, 12.514]	8.000 [1.001, 63.963]	46.7 [-3.4, 96.8]	0.070	#
Exacerbations in the year before study										0.211	
<= 2	44	44 (100.0)	27 (61.4) [45.5, 75.6]	45	41 (91.1)	23 (51.1) [35.8, 66.3]	1.201 [0.830, 1.737]	1.519 [0.654, 3.528]	10.3 [-12.5, 33.0]	0.332	
> 2	22	22 (100.0)	15 (68.2) [45.1, 86.1]	20	19 (95.0)	7 (35.0) [15.4, 59.2]	1.948 [1.005, 3.776]	3.980 [1.102, 14.373]	33.2 [-0.2, 66.5]	0.034	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_ILSPK: Decrease of at least 0.9 points in ACQ-5 score by key subgroups
DITTL

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race		N<10	any level							NE	
White	60	60 (100.0)	37 (61.7) [48.2, 73.9]	58	53 (91.4)	25 (43.1) [30.2, 56.8]					
Black or African American	2	2 (100.0)	2 (100.0) [15.8, 100.0]	2	2 (100.0)	1 (50.0) [1.3, 98.7]					
Asian	3	3 (100.0)	3 (100.0) [29.2, 100.0]	3	3 (100.0)	2 (66.7) [9.4, 99.2]					
Other	1	1 (100.0)	0 (0.0) [0.0, 97.5]	2	2 (100.0)	2 (100.0) [15.8, 100.0]					
Region		N<10	any level							NE	
Europe	40	40 (100.0)	24 (60.0) [43.3, 75.1]	36	33 (91.7)	14 (38.9) [23.1, 56.5]					
America	6	6 (100.0)	5 (83.3) [35.9, 99.6]	4	3 (75.0)	2 (50.0) [6.8, 93.2]					
Asia/Pacific	3	3 (100.0)	3 (100.0) [29.2, 100.0]	3	3 (100.0)	2 (66.7) [9.4, 99.2]					
Rest of the world	17	17 (100.0)	10 (58.8) [32.9, 81.6]	22	21 (95.5)	12 (54.5) [32.2, 75.6]					
BMI										0.074	
18.5 - < 25.0 kg/m**2	15	15 (100.0)	12 (80.0) [51.9, 95.7]	21	20 (95.2)	10 (47.6) [25.7, 70.2]	1.680 [1.004, 2.812]	4.400 [0.955, 20.274]	32.4 [-2.8, 67.5]	0.053	
25.0 - < 30.0 kg/m**2	24	24 (100.0)	16 (66.7) [44.7, 84.4]	20	18 (90.0)	6 (30.0) [11.9, 54.3]	2.222 [1.074, 4.596]	4.667 [1.299, 16.761]	36.7 [4.5, 68.8]	0.017	*
>= 30.0 kg/m**2	27	27 (100.0)	14 (51.9) [31.9, 71.3]	24	22 (91.7)	14 (58.3) [36.6, 77.9]	0.889 [0.541, 1.460]	0.769 [0.254, 2.330]	-6.5 [-37.7, 24.7]	0.646	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_ILSPK: Decrease of at least 0.9 points in ACQ-5 score by key subgroups
DITTL

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.293	
< 150 cells/uL	11	11 (100.0)	5 (45.5) [16.7, 76.6]	14	12 (85.7)	7 (50.0) [23.0, 77.0]	0.909 [0.395, 2.091]	0.833 [0.171, 4.058]	-4.5 [-52.1, 43.0]	0.825	
>= 150 cells/uL	54	54 (100.0)	36 (66.7) [52.5, 78.9]	51	48 (94.1)	23 (45.1) [31.1, 59.7]	1.478 [1.035, 2.112]	2.435 [1.105, 5.366]	21.6 [1.1, 42.0]	0.027	*
Baseline eosinophils - High										0.146	
< 300 cells/uL	33	33 (100.0)	19 (57.6) [39.2, 74.5]	34	30 (88.2)	18 (52.9) [35.1, 70.2]	1.088 [0.706, 1.674]	1.206 [0.460, 3.165]	4.6 [-22.1, 31.4]	0.705	
>= 300 cells/uL	32	32 (100.0)	22 (68.8) [50.0, 83.9]	31	30 (96.8)	12 (38.7) [21.8, 57.8]	1.776 [1.076, 2.930]	3.483 [1.232, 9.853]	30.0 [3.4, 56.7]	0.018	*
Baseline FENO										0.158	
< 25 ppb	39	39 (100.0)	20 (51.3) [34.8, 67.6]	30	26 (86.7)	14 (46.7) [28.3, 65.7]	1.099 [0.673, 1.793]	1.203 [0.464, 3.121]	4.6 [-22.1, 31.3]	0.706	
>= 25 ppb	27	27 (100.0)	22 (81.5) [61.9, 93.7]	34	33 (97.1)	16 (47.1) [29.8, 64.9]	1.731 [1.161, 2.581]	4.950 [1.518, 16.137]	34.4 [8.8, 60.0]	0.006	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_ILSPK: Decrease of at least 0.9 points in ACQ-5 score by key subgroups
DITTL

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.194	
All negative	27	27 (100.0)	16 (59.3) [38.8, 77.6]	29	27 (93.1)	10 (34.5) [17.9, 54.3]	1.719 [0.951, 3.104]	2.764 [0.935, 8.173]	24.8 [-4.2, 53.7]	0.066	
Any positive	34	34 (100.0)	21 (61.8) [43.6, 77.8]	33	30 (90.9)	19 (57.6) [39.2, 74.5]	1.073 [0.723, 1.592]	1.190 [0.448, 3.163]	4.2 [-22.3, 30.7]	0.729	
Total serum IgE										0.347	
Low	23	23 (100.0)	13 (56.5) [34.5, 76.8]	14	11 (78.6)	3 (21.4) [4.7, 50.8]	2.638 [0.909, 7.653]	4.767 [1.043, 21.787]	35.1 [-0.2, 70.4]	0.039	*
Normal	40	40 (100.0)	27 (67.5) [50.9, 81.4]	44	42 (95.5)	22 (50.0) [34.6, 65.4]	1.350 [0.937, 1.946]	2.077 [0.855, 5.043]	17.5 [-5.6, 40.6]	0.106	
High	3	3 (100.0)	2 (66.7) [9.4, 99.2]	7	7 (100.0)	5 (71.4) [29.0, 96.3]	0.933 [0.369, 2.359]	0.800 [0.044, 14.643]	-4.8 [-91.5, 82.0]	1.000	#
OCS at baseline										0.287	
Yes	9	9 (100.0)	7 (77.8) [40.0, 97.2]	13	13 (100.0)	5 (38.5) [13.9, 68.4]	2.022 [0.935, 4.373]	5.600 [0.814, 38.512]	39.3 [-8.0, 86.6]	0.099	#
No	57	57 (100.0)	35 (61.4) [47.6, 74.0]	52	47 (90.4)	25 (48.1) [34.0, 62.4]	1.277 [0.900, 1.812]	1.718 [0.802, 3.680]	13.3 [-7.1, 33.7]	0.164	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_ILSPK: Decrease of at least 0.9 points in ACQ-5 score by key subgroups
DITTL

	Tezepelumab			Placebo						
Decrease of at least 0.9 points in ACQ-5 score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline										0.286
Yes	7	7 (100.0)	5 (71.4) [29.0, 96.3]	3	3 (100.0)	0 (0.0) [0.0, 70.8]	5.500 + [0.395, 76.653]	15.400 + [0.557, 425.527]	71.4 [14.2, 100.0]	0.167 #
No	59	59 (100.0)	37 (62.7) [49.1, 75.0]	62	57 (91.9)	30 (48.4) [35.5, 61.4]	1.296 [0.938, 1.791]	1.794 [0.868, 3.706]	14.3 [-4.9, 33.5]	0.115
Tiotropium use at baseline		N<10	any level							NE
Yes	6	6 (100.0)	4 (66.7) [22.3, 95.7]	2	2 (100.0)	0 (0.0) [0.0, 84.2]				
No	60	60 (100.0)	38 (63.3) [49.9, 75.4]	63	58 (92.1)	30 (47.6) [34.9, 60.6]				
Montelukast/ Cromoglicic acid use at baseline										0.846
Yes	17	17 (100.0)	13 (76.5) [50.1, 93.2]	21	21 (100.0)	11 (52.4) [29.8, 74.3]	1.460 [0.898, 2.373]	2.955 [0.721, 12.107]	24.1 [-10.6, 58.8]	0.131
No	49	49 (100.0)	29 (59.2) [44.2, 73.0]	44	39 (88.6)	19 (43.2) [28.3, 59.0]	1.371 [0.909, 2.067]	1.908 [0.836, 4.353]	16.0 [-6.2, 38.2]	0.125

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_ILSPP: Decrease of at least 0.9 points in ACQ-5 score by study specific subgroups
DITTL

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.562	
White	60	60 (100.0)	37 (61.7) [48.2, 73.9]	58	53 (91.4)	25 (43.1) [30.2, 56.8]	1.431 [1.001, 2.044]	2.123 [1.018, 4.431]	18.6 [-0.8, 38.0]	0.044	*
Non-white	6	6 (100.0)	5 (83.3) [35.9, 99.6]	7	7 (100.0)	5 (71.4) [29.0, 96.3]	1.167 [0.647, 2.104]	2.000 [0.134, 29.808]	11.9 [-48.4, 72.2]	1.000	#
Region (cat. P)										0.700	
North America/Western EU	6	6 (100.0)	5 (83.3) [35.9, 99.6]	4	3 (75.0)	2 (50.0) [6.8, 93.2]	1.667 [0.587, 4.731]	5.000 [0.273, 91.518]	33.3 [-44.9, 100.0]	0.500	#
Rest of world	60	60 (100.0)	37 (61.7) [48.2, 73.9]	61	57 (93.4)	28 (45.9) [33.1, 59.2]	1.343 [0.958, 1.883]	1.896 [0.919, 3.911]	15.8 [-3.4, 35.0]	0.083	
Baseline eosinophils (cat. P)										0.025	i
< 250 cells/uL	30	30 (100.0)	15 (50.0) [31.3, 68.7]	29	26 (89.7)	16 (55.2) [35.7, 73.6]	0.906 [0.558, 1.473]	0.813 [0.292, 2.261]	-5.2 [-34.0, 23.7]	0.693	
>= 250 cells/uL	36	36 (100.0)	27 (75.0) [57.8, 87.9]	36	34 (94.4)	14 (38.9) [23.1, 56.5]	1.929 [1.229, 3.027]	4.714 [1.719, 12.931]	36.1 [12.0, 60.2]	0.002	*
Baseline FENO (cat. P)										0.225	
< 24 ppb	38	38 (100.0)	20 (52.6) [35.8, 69.0]	30	26 (86.7)	14 (46.7) [28.3, 65.7]	1.128 [0.693, 1.836]	1.270 [0.487, 3.314]	6.0 [-20.9, 32.8]	0.628	
>= 24 ppb	28	28 (100.0)	22 (78.6) [59.0, 91.7]	34	33 (97.1)	16 (47.1) [29.8, 64.9]	1.670 [1.113, 2.505]	4.125 [1.338, 12.721]	31.5 [5.6, 57.4]	0.012	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_ILSPP: Decrease of at least 0.9 points in ACQ-5 score by study specific subgroups
DITTL

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. M)										0.203	
< 22.0 ppb	32	32 (100.0)	15 (46.9) [29.1, 65.3]	27	24 (88.9)	12 (44.4) [25.5, 64.7]	1.055 [0.602, 1.847]	1.103 [0.394, 3.085]	2.4 [-26.5, 31.3]	0.853	
>= 22.0 ppb	34	34 (100.0)	27 (79.4) [62.1, 91.3]	37	35 (94.6)	18 (48.6) [31.9, 65.6]	1.632 [1.125, 2.370]	4.071 [1.422, 11.658]	30.8 [6.9, 54.7]	0.008	*
Baseline all FEIA status										0.478	
All negative	25	25 (100.0)	14 (56.0) [34.9, 75.6]	22	20 (90.9)	8 (36.4) [17.2, 59.3]	1.540 [0.802, 2.959]	2.227 [0.689, 7.205]	19.6 [-12.6, 51.9]	0.183	
Any positive	35	35 (100.0)	22 (62.9) [44.9, 78.5]	41	38 (92.7)	22 (53.7) [37.4, 69.3]	1.171 [0.800, 1.716]	1.462 [0.582, 3.668]	9.2 [-15.6, 34.0]	0.421	
Th2 status										0.809	
Low	41	41 (100.0)	23 (56.1) [39.7, 71.5]	30	26 (86.7)	12 (40.0) [22.7, 59.4]	1.402 [0.838, 2.348]	1.917 [0.737, 4.986]	16.1 [-10.0, 42.2]	0.183	
High	25	25 (100.0)	19 (76.0) [54.9, 90.6]	34	33 (97.1)	17 (50.0) [32.4, 67.6]	1.520 [1.017, 2.272]	3.167 [1.015, 9.879]	26.0 [-1.2, 53.2]	0.045	*
Baseline Periostin										0.152	
Low (< 20.9 ng/ml)	26	26 (100.0)	14 (53.8) [33.4, 73.4]	31	28 (90.3)	16 (51.6) [33.1, 69.8]	1.043 [0.637, 1.708]	1.094 [0.385, 3.108]	2.2 [-27.3, 31.8]	0.868	
High (>= 20.9 ng/ml)	40	40 (100.0)	28 (70.0) [53.5, 83.4]	34	32 (94.1)	14 (41.2) [24.6, 59.3]	1.700 [1.084, 2.666]	3.333 [1.275, 8.716]	28.8 [4.3, 53.3]	0.013	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_ILSPP: Decrease of at least 0.9 points in ACQ-5 score by study specific subgroups
DITTL

Decrease of at least 0.9 points in ACQ-5 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility										0.346	
Yes	57	57 (100.0)	34 (59.6) [45.8, 72.4]	60	55 (91.7)	28 (46.7) [33.7, 60.0]	1.278 [0.906, 1.804]	1.689 [0.812, 3.516]	13.0 [-6.7, 32.6]	0.161	
No	9	9 (100.0)	8 (88.9) [51.8, 99.7]	5	5 (100.0)	2 (40.0) [5.3, 85.3]	2.222 [0.741, 6.663]	12.000 [0.773, 186.362]	48.9 [-14.3, 100.0]	0.095	#
Maintenance OCS use at baseline										0.410	
Yes	9	9 (100.0)	7 (77.8) [40.0, 97.2]	14	14 (100.0)	6 (42.9) [17.7, 71.1]	1.815 [0.903, 3.649]	4.667 [0.702, 31.036]	34.9 [-11.8, 81.6]	0.197	#
No	57	57 (100.0)	35 (61.4) [47.6, 74.0]	51	46 (90.2)	24 (47.1) [32.9, 61.5]	1.305 [0.914, 1.864]	1.790 [0.832, 3.850]	14.3 [-6.2, 34.8]	0.137	
No chronic OCS use and current post-BD FEV1 reversibility										0.302	
Yes	51	51 (100.0)	30 (58.8) [44.2, 72.4]	49	44 (89.8)	23 (46.9) [32.5, 61.7]	1.253 [0.860, 1.825]	1.615 [0.732, 3.562]	11.9 [-9.6, 33.3]	0.236	
No	15	15 (100.0)	12 (80.0) [51.9, 95.7]	16	16 (100.0)	7 (43.8) [19.8, 70.1]	1.829 [0.993, 3.367]	5.143 [1.033, 25.602]	36.3 [-1.8, 74.3]	0.042	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H5I_ILMP0: Increase of at least 0.9 points in ACQ-5 score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in ACQ-5 score	Week 28	66	66 (100.0)	3 (4.5) [0.9, 12.7]	65	60 (92.3)	4 (6.2) [1.7, 15.0]	0.739 [0.172, 3.172]	0.726 [0.156, 3.380]	-1.6 [-10.8, 7.6]	0.718 #
	Week 52	66	66 (100.0)	2 (3.0) [0.4, 10.5]	65	60 (92.3)	3 (4.6) [1.0, 12.9]	0.657 [0.113, 3.801]	0.646 [0.104, 3.998]	-1.6 [-9.7, 6.5]	0.680 #

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILMH0: Course of ACQ-5 score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	66	66 (100.0)	2.87 (0.88)	0.0	2.40	2.80	3.20	5.2	
		Placebo	65	65 (100.0)	2.86 (0.77)	0.4	2.60	3.00	3.20	5.0	
	Week 2	Tezepelumab	66	63 (95.5)	2.34 (1.02)	0.0	1.60	2.60	3.00	4.4	
		Placebo	65	58 (89.2)	2.40 (0.80)	0.4	2.00	2.40	2.80	5.0	
	Week 4	Tezepelumab	66	63 (95.5)	2.08 (1.00)	0.2	1.20	2.20	3.00	3.6	
		Placebo	65	58 (89.2)	2.25 (0.92)	0.2	1.80	2.50	2.80	4.2	
	Week 6	Tezepelumab	66	63 (95.5)	1.97 (1.04)	0.0	1.20	1.80	2.80	4.0	
		Placebo	65	58 (89.2)	2.21 (1.16)	0.2	1.40	2.20	3.00	6.0	
	Week 8	Tezepelumab	66	63 (95.5)	1.82 (1.18)	0.0	1.00	1.80	2.80	5.2	
		Placebo	65	59 (90.8)	2.13 (1.14)	0.0	1.20	2.40	3.00	5.0	
	Week 10	Tezepelumab	66	63 (95.5)	1.72 (1.14)	0.0	0.80	1.60	2.60	4.8	
		Placebo	65	59 (90.8)	2.15 (1.08)	0.0	1.60	2.20	3.00	5.2	
	Week 12	Tezepelumab	66	63 (95.5)	1.61 (1.10)	0.0	0.60	1.60	2.60	4.8	
		Placebo	65	59 (90.8)	1.94 (1.06)	0.0	1.00	2.00	2.60	4.4	
	Week 14	Tezepelumab	66	63 (95.5)	1.56 (1.12)	0.0	0.60	1.40	2.20	4.8	
		Placebo	65	59 (90.8)	1.87 (1.00)	0.0	1.20	2.00	2.40	5.0	
	Week 16	Tezepelumab	66	63 (95.5)	1.71 (1.18)	0.0	0.80	1.60	2.60	4.8	
		Placebo	65	59 (90.8)	2.03 (1.21)	0.0	1.00	2.00	2.80	5.0	
	Week 18	Tezepelumab	66	64 (97.0)	1.67 (1.08)	0.0	0.80	1.60	2.40	4.8	
		Placebo	65	59 (90.8)	1.93 (1.18)	0.0	1.00	2.00	2.60	5.0	
	Week 20	Tezepelumab	66	64 (97.0)	1.68 (1.14)	0.0	0.80	1.70	2.60	5.0	
		Placebo	65	59 (90.8)	2.03 (1.11)	0.0	1.20	2.00	2.80	5.0	
	Week 22	Tezepelumab	66	64 (97.0)	1.78 (1.03)	0.0	1.00	2.00	2.50	4.8	
		Placebo	65	59 (90.8)	1.98 (1.16)	0.0	1.00	2.00	2.60	5.0	
	Week 24	Tezepelumab	66	64 (97.0)	1.74 (1.11)	0.0	0.90	1.70	2.60	4.8	
		Placebo	65	59 (90.8)	2.05 (1.07)	0.0	1.40	2.20	2.80	4.4	
	Week 26	Tezepelumab	66	65 (98.5)	1.79 (1.12)	0.0	1.00	1.80	2.60	4.8	
		Placebo	65	59 (90.8)	1.98 (1.14)	0.0	1.00	1.80	3.00	4.4	
	Week 28	Tezepelumab	66	66 (100.0)	1.73 (1.16)	0.0	1.00	1.80	2.40	4.8	
		Placebo	65	60 (92.3)	1.96 (1.23)	0.0	1.00	2.00	2.80	4.4	
	Week 30	Tezepelumab	66	66 (100.0)	1.70 (1.10)	0.0	0.80	1.60	2.40	4.8	
		Placebo	65	60 (92.3)	1.94 (1.18)	0.0	1.00	2.00	2.90	4.4	
	Week 32	Tezepelumab	66	66 (100.0)	1.63 (1.12)	0.0	0.80	1.60	2.40	4.8	
		Placebo	65	60 (92.3)	1.90 (1.14)	0.0	1.00	1.80	2.80	4.8	
	Week 34	Tezepelumab	66	66 (100.0)	1.71 (1.19)	0.0	0.80	1.50	2.80	4.8	
		Placebo	65	60 (92.3)	1.88 (1.14)	0.0	0.90	1.80	2.60	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILMH0: Course of ACQ-5 score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Week 36	Tezepelumab	66	66 (100.0)	1.67 (1.11)	0.0	1.00	1.50	2.40	4.8	
		Placebo	65	60 (92.3)	2.05 (1.19)	0.0	1.20	2.10	2.80	4.8	
	Week 38	Tezepelumab	66	66 (100.0)	1.72 (1.23)	0.0	0.80	1.70	2.60	4.8	
		Placebo	65	60 (92.3)	1.92 (1.13)	0.0	1.00	1.80	2.70	4.8	
	Week 40	Tezepelumab	66	66 (100.0)	1.70 (1.18)	0.0	0.80	1.80	2.60	4.8	
		Placebo	65	60 (92.3)	2.06 (1.19)	0.0	1.10	2.10	3.00	4.4	
	Week 42	Tezepelumab	66	66 (100.0)	1.64 (1.15)	0.0	0.80	1.60	2.40	4.8	
		Placebo	65	60 (92.3)	1.92 (1.06)	0.0	1.10	2.00	2.60	4.6	
	Week 44	Tezepelumab	66	66 (100.0)	1.68 (1.14)	0.0	0.80	1.70	2.60	4.8	
		Placebo	65	60 (92.3)	2.01 (1.12)	0.0	1.20	2.00	2.80	4.4	
	Week 46	Tezepelumab	66	66 (100.0)	1.71 (1.19)	0.0	0.80	1.80	2.60	4.8	
		Placebo	65	60 (92.3)	1.88 (1.01)	0.0	1.20	2.00	2.40	4.4	
	Week 48	Tezepelumab	66	66 (100.0)	1.71 (1.19)	0.0	0.80	1.80	2.60	4.8	
		Placebo	65	60 (92.3)	1.94 (1.10)	0.0	1.00	2.00	2.60	4.6	
	Week 50	Tezepelumab	66	66 (100.0)	1.65 (1.20)	0.0	0.80	1.40	2.60	4.8	
		Placebo	65	60 (92.3)	1.82 (1.03)	0.0	1.00	1.80	2.40	4.4	
	Week 52	Tezepelumab	66	66 (100.0)	1.68 (1.18)	0.0	0.80	1.60	2.60	4.8	
		Placebo	65	60 (92.3)	1.89 (1.09)	0.0	1.00	2.00	2.70	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILMH0: Course of ACQ-5 score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 score	Week 2	Tezepelumab	66	63 (95.5)	-0.56 (0.79)	-3.2	-1.20	-0.40	0.20	0.8	-0.08 [-0.43, 0.28]
		Placebo	65	58 (89.2)	-0.50 (0.72)	-2.8	-1.00	-0.40	0.00	1.2	
	Week 4	Tezepelumab	66	63 (95.5)	-0.83 (0.93)	-2.6	-1.40	-0.80	-0.20	2.6	-0.19 [-0.54, 0.17]
		Placebo	65	58 (89.2)	-0.65 (0.97)	-3.0	-1.40	-0.40	0.00	1.2	
	Week 6	Tezepelumab	66	63 (95.5)	-0.93 (1.02)	-2.8	-1.60	-1.00	-0.20	2.6	-0.24 [-0.60, 0.12]
		Placebo	65	58 (89.2)	-0.69 (1.05)	-3.4	-1.40	-0.60	0.00	1.6	
	Week 8	Tezepelumab	66	63 (95.5)	-1.09 (1.15)	-3.2	-1.80	-1.00	-0.40	2.6	-0.28 [-0.64, 0.08]
		Placebo	65	59 (90.8)	-0.78 (1.06)	-3.6	-1.40	-0.60	0.00	1.0	
	Week 10	Tezepelumab	66	63 (95.5)	-1.18 (1.12)	-3.4	-2.00	-1.20	-0.60	2.6	-0.38 [-0.73, -0.02]
		Placebo	65	59 (90.8)	-0.76 (1.16)	-3.8	-1.40	-0.60	0.00	2.6	
	Week 12	Tezepelumab	66	63 (95.5)	-1.29 (1.10)	-3.2	-2.20	-1.40	-0.60	2.6	-0.30 [-0.66, 0.06]
		Placebo	65	59 (90.8)	-0.97 (1.08)	-3.8	-1.60	-0.80	-0.20	1.6	
	Week 14	Tezepelumab	66	63 (95.5)	-1.35 (1.11)	-4.0	-2.20	-1.40	-0.60	2.6	-0.28 [-0.64, 0.07]
		Placebo	65	59 (90.8)	-1.04 (1.08)	-3.4	-1.60	-1.20	-0.40	2.4	
	Week 16	Tezepelumab	66	63 (95.5)	-1.20 (1.15)	-3.2	-2.20	-1.20	-0.60	2.6	-0.28 [-0.63, 0.08]
		Placebo	65	59 (90.8)	-0.87 (1.18)	-3.6	-1.40	-1.00	-0.20	2.6	
	Week 18	Tezepelumab	66	64 (97.0)	-1.22 (1.10)	-3.8	-1.90	-1.00	-0.60	2.6	-0.21 [-0.56, 0.15]
		Placebo	65	59 (90.8)	-0.98 (1.23)	-3.6	-2.00	-1.00	-0.20	2.6	
	Week 20	Tezepelumab	66	64 (97.0)	-1.21 (1.10)	-3.4	-2.20	-1.20	-0.50	2.6	-0.30 [-0.65, 0.06]
		Placebo	65	59 (90.8)	-0.87 (1.18)	-3.6	-1.60	-0.80	-0.20	2.6	
	Week 22	Tezepelumab	66	64 (97.0)	-1.12 (1.13)	-3.2	-2.00	-1.00	-0.60	2.6	-0.16 [-0.52, 0.19]
		Placebo	65	59 (90.8)	-0.93 (1.18)	-3.8	-1.60	-1.00	-0.20	2.6	
	Week 24	Tezepelumab	66	64 (97.0)	-1.15 (1.09)	-3.4	-2.00	-1.20	-0.40	2.6	-0.26 [-0.62, 0.10]
		Placebo	65	59 (90.8)	-0.86 (1.13)	-3.6	-1.60	-0.80	0.00	2.6	
	Week 26	Tezepelumab	66	65 (98.5)	-1.08 (1.13)	-3.0	-2.20	-1.00	-0.20	2.6	-0.13 [-0.49, 0.22]
		Placebo	65	59 (90.8)	-0.93 (1.20)	-3.4	-1.80	-1.20	0.00	2.6	
	Week 28	Tezepelumab	66	66 (100.0)	-1.14 (1.21)	-3.4	-2.20	-1.20	-0.20	2.6	-0.19 [-0.54, 0.16]
		Placebo	65	60 (92.3)	-0.91 (1.23)	-3.4	-1.80	-1.10	0.00	2.6	
	Week 30	Tezepelumab	66	66 (100.0)	-1.17 (1.18)	-3.8	-2.20	-1.20	-0.40	2.6	-0.20 [-0.55, 0.15]
		Placebo	65	60 (92.3)	-0.93 (1.23)	-3.4	-1.60	-1.10	-0.20	2.6	
	Week 32	Tezepelumab	66	66 (100.0)	-1.24 (1.11)	-3.2	-2.20	-1.20	-0.60	2.6	-0.24 [-0.59, 0.11]
		Placebo	65	60 (92.3)	-0.96 (1.17)	-3.2	-1.60	-1.20	-0.20	2.6	
	Week 34	Tezepelumab	66	66 (100.0)	-1.16 (1.20)	-3.0	-2.20	-1.40	-0.40	2.6	-0.14 [-0.49, 0.21]
		Placebo	65	60 (92.3)	-0.99 (1.16)	-3.2	-1.70	-1.20	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILMH0: Course of ACQ-5 score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 score	Week 36	Tezepelumab	66	66 (100.0)	-1.20 (1.18)	-3.2	-2.20	-1.20	-0.20	2.6	-0.33 [-0.68, 0.03]
		Placebo	65	60 (92.3)	-0.81 (1.22)	-3.6	-1.40	-1.00	-0.10	2.6	
	Week 38	Tezepelumab	66	66 (100.0)	-1.15 (1.23)	-3.2	-2.20	-1.30	-0.40	2.6	-0.18 [-0.53, 0.17]
		Placebo	65	60 (92.3)	-0.94 (1.15)	-3.2	-1.60	-1.00	-0.40	2.6	
	Week 40	Tezepelumab	66	66 (100.0)	-1.17 (1.21)	-3.4	-2.20	-1.20	-0.40	2.6	-0.30 [-0.66, 0.05]
		Placebo	65	60 (92.3)	-0.80 (1.22)	-3.2	-1.60	-0.80	0.00	2.6	
	Week 42	Tezepelumab	66	66 (100.0)	-1.23 (1.21)	-3.6	-2.20	-1.30	-0.40	2.6	-0.25 [-0.60, 0.11]
		Placebo	65	60 (92.3)	-0.94 (1.10)	-2.8	-1.60	-1.00	-0.30	2.6	
	Week 44	Tezepelumab	66	66 (100.0)	-1.19 (1.20)	-3.8	-2.20	-1.20	-0.40	2.6	-0.28 [-0.63, 0.07]
		Placebo	65	60 (92.3)	-0.86 (1.15)	-3.4	-1.60	-1.00	-0.10	2.6	
	Week 46	Tezepelumab	66	66 (100.0)	-1.16 (1.21)	-3.6	-2.20	-1.20	-0.20	2.6	-0.16 [-0.51, 0.19]
		Placebo	65	60 (92.3)	-0.98 (1.06)	-3.2	-1.60	-1.00	-0.50	2.6	
	Week 48	Tezepelumab	66	66 (100.0)	-1.16 (1.19)	-3.0	-2.20	-1.00	-0.40	2.6	-0.20 [-0.55, 0.15]
		Placebo	65	60 (92.3)	-0.92 (1.13)	-3.4	-1.60	-1.00	-0.30	2.6	
	Week 50	Tezepelumab	66	66 (100.0)	-1.22 (1.22)	-3.2	-2.20	-1.30	-0.40	2.6	-0.16 [-0.51, 0.19]
		Placebo	65	60 (92.3)	-1.04 (1.06)	-3.6	-1.60	-1.00	-0.40	2.6	
	Week 52	Tezepelumab	66	66 (100.0)	-1.19 (1.20)	-3.2	-2.20	-1.20	-0.40	2.6	-0.19 [-0.54, 0.16]
		Placebo	65	60 (92.3)	-0.97 (1.11)	-3.6	-1.60	-0.90	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILMC0: Change from baseline in ACQ-5 score - MMRM results
DITTL

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	66	63 (95.5)	NE		NE		
	Placebo	65	58 (89.2)					
Week 4	Tezepelumab	66	60 (90.9)	NE		NE		
	Placebo	65	57 (87.7)					
Week 6	Tezepelumab	66	59 (89.4)	NE		NE		
	Placebo	65	57 (87.7)					
Week 8	Tezepelumab	66	60 (90.9)	NE		NE		
	Placebo	65	58 (89.2)					
Week 10	Tezepelumab	66	59 (89.4)	NE		NE		
	Placebo	65	56 (86.2)					
Week 12	Tezepelumab	66	59 (89.4)	NE		NE		
	Placebo	65	55 (84.6)					
Week 14	Tezepelumab	66	59 (89.4)	NE		NE		
	Placebo	65	54 (83.1)					
Week 16	Tezepelumab	66	57 (86.4)	NE		NE		
	Placebo	65	53 (81.5)					
Week 18	Tezepelumab	66	59 (89.4)	NE		NE		
	Placebo	65	50 (76.9)					
Week 20	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	49 (75.4)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILMC0: Change from baseline in ACQ-5 score - MMRM results
DITTL

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	50 (76.9)					
Week 24	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	48 (73.8)					
Week 26	Tezepelumab	66	56 (84.8)	NE		NE		
	Placebo	65	47 (72.3)					
Week 28	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	48 (73.8)					
Week 30	Tezepelumab	66	56 (84.8)	NE		NE		
	Placebo	65	46 (70.8)					
Week 32	Tezepelumab	66	57 (86.4)	NE		NE		
	Placebo	65	48 (73.8)					
Week 34	Tezepelumab	66	57 (86.4)	NE		NE		
	Placebo	65	46 (70.8)					
Week 36	Tezepelumab	66	57 (86.4)	NE		NE		
	Placebo	65	48 (73.8)					
Week 38	Tezepelumab	66	56 (84.8)	NE		NE		
	Placebo	65	48 (73.8)					
Week 40	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	50 (76.9)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILMC0: Change from baseline in ACQ-5 score - MMRM results
DITTL

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	47 (72.3)					
Week 44	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	48 (73.8)					
Week 46	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	48 (73.8)					
Week 48	Tezepelumab	66	53 (80.3)	NE		NE		
	Placebo	65	48 (73.8)					
Week 50	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	49 (75.4)					
Week 52	Tezepelumab	66	18 (27.3)	NE		NE		
	Placebo	65	20 (30.8)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Figure PF2H5C_ILMG0: Course of ACQ-5 score
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
ACQ = asthma control questionnaire.
Source table: PT2H5C_ILMH0
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	19	19 (100.0)	3.09 (0.77)	1.8	2.80	2.80	3.40	5.0	
			Placebo	20	20 (100.0)	2.96 (0.84)	0.4	2.80	3.00	3.20	4.8	
		Week 2	Tezepelumab	19	18 (94.7)	2.56 (0.95)	0.8	1.60	2.60	3.40	4.0	
			Placebo	20	18 (90.0)	2.78 (0.78)	1.0	2.60	2.90	3.00	4.8	
		Week 4	Tezepelumab	19	18 (94.7)	2.21 (1.08)	0.2	1.20	2.60	3.00	3.6	
			Placebo	20	18 (90.0)	2.49 (0.91)	0.8	2.00	2.60	3.00	4.2	
		Week 6	Tezepelumab	19	18 (94.7)	2.20 (1.11)	0.0	1.40	2.40	3.00	4.0	
			Placebo	20	18 (90.0)	2.68 (0.95)	0.6	2.20	2.80	3.20	4.6	
		Week 8	Tezepelumab	19	18 (94.7)	2.04 (1.16)	0.0	1.20	2.30	2.80	4.2	
			Placebo	20	18 (90.0)	2.51 (1.07)	0.2	2.00	2.70	3.20	4.6	
		Week 10	Tezepelumab	19	18 (94.7)	1.98 (1.15)	0.0	1.00	2.10	3.00	3.4	
			Placebo	20	18 (90.0)	2.58 (0.94)	0.0	2.20	2.70	3.00	4.4	
		Week 12	Tezepelumab	19	18 (94.7)	1.70 (0.99)	0.0	1.20	2.00	2.40	3.2	
			Placebo	20	18 (90.0)	2.26 (1.22)	0.0	1.20	2.50	3.00	4.4	
		Week 14	Tezepelumab	19	18 (94.7)	1.62 (1.04)	0.0	0.60	1.60	2.20	4.2	
			Placebo	20	18 (90.0)	2.14 (1.00)	0.4	1.60	2.00	2.60	5.0	
		Week 16	Tezepelumab	19	18 (94.7)	1.98 (1.31)	0.0	0.80	2.00	2.80	4.6	
			Placebo	20	18 (90.0)	2.36 (1.14)	0.2	2.00	2.70	3.00	4.4	
		Week 18	Tezepelumab	19	18 (94.7)	1.91 (1.07)	0.0	1.20	2.00	2.60	4.2	
			Placebo	20	18 (90.0)	2.14 (1.08)	0.2	1.80	2.30	2.80	4.4	
		Week 20	Tezepelumab	19	18 (94.7)	1.89 (1.16)	0.0	1.20	2.00	2.60	5.0	
			Placebo	20	18 (90.0)	2.27 (1.13)	0.2	1.80	2.70	2.80	4.4	
		Week 22	Tezepelumab	19	18 (94.7)	1.87 (0.94)	0.0	1.20	2.00	2.40	3.8	
			Placebo	20	18 (90.0)	2.16 (1.11)	0.0	1.20	2.40	2.80	4.4	
		Week 24	Tezepelumab	19	18 (94.7)	1.93 (1.10)	0.0	1.20	2.00	2.60	3.8	
			Placebo	20	18 (90.0)	2.21 (1.02)	0.2	1.60	2.20	3.00	4.4	
		Week 26	Tezepelumab	19	19 (100.0)	1.94 (1.16)	0.0	1.20	2.00	2.80	4.0	
			Placebo	20	18 (90.0)	2.13 (1.11)	0.4	1.20	1.90	3.00	4.4	
		Week 28	Tezepelumab	19	19 (100.0)	1.83 (1.10)	0.0	1.20	1.80	2.40	3.8	
			Placebo	20	19 (95.0)	2.33 (1.30)	0.0	1.40	2.60	3.40	4.4	
		Week 30	Tezepelumab	19	19 (100.0)	1.89 (1.06)	0.0	1.20	1.80	2.60	3.8	
			Placebo	20	19 (95.0)	1.95 (1.27)	0.0	0.80	2.00	3.00	4.4	
		Week 32	Tezepelumab	19	19 (100.0)	1.82 (1.04)	0.0	1.20	2.00	2.60	4.0	
			Placebo	20	19 (95.0)	2.05 (1.21)	0.0	1.20	2.00	3.00	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Male	Absolute values	Week 34	Tezepelumab	19	19 (100.0)	1.91 (1.20)	0.0	1.00	2.00	2.80	4.0	
			Placebo	20	19 (95.0)	2.02 (1.12)	0.2	0.80	2.00	2.80	4.4	
		Week 36	Tezepelumab	19	19 (100.0)	1.81 (1.12)	0.0	1.20	1.80	2.80	3.6	
			Placebo	20	19 (95.0)	2.17 (1.20)	0.0	1.20	2.00	2.80	4.4	
		Week 38	Tezepelumab	19	19 (100.0)	1.91 (1.32)	0.0	1.20	1.80	2.80	4.6	
			Placebo	20	19 (95.0)	1.99 (1.10)	0.0	1.20	2.00	3.00	4.4	
		Week 40	Tezepelumab	19	19 (100.0)	1.95 (1.19)	0.0	1.20	2.00	2.80	3.6	
			Placebo	20	19 (95.0)	2.20 (1.21)	0.0	1.20	2.00	3.00	4.4	
		Week 42	Tezepelumab	19	19 (100.0)	1.87 (1.22)	0.0	0.80	1.80	2.80	4.0	
			Placebo	20	19 (95.0)	2.19 (1.19)	0.0	1.20	2.20	2.80	4.6	
		Week 44	Tezepelumab	19	19 (100.0)	1.96 (1.16)	0.0	1.20	2.20	3.00	3.8	
			Placebo	20	19 (95.0)	2.16 (1.12)	0.0	1.20	2.20	3.00	4.4	
		Week 46	Tezepelumab	19	19 (100.0)	1.94 (1.19)	0.0	1.00	2.00	2.60	3.8	
			Placebo	20	19 (95.0)	2.14 (0.94)	0.0	1.40	2.00	2.60	4.4	
		Week 48	Tezepelumab	19	19 (100.0)	1.98 (1.19)	0.0	1.00	2.20	2.80	3.8	
			Placebo	20	19 (95.0)	2.14 (1.14)	0.0	1.00	2.40	2.80	4.4	
		Week 50	Tezepelumab	19	19 (100.0)	1.83 (1.21)	0.0	1.00	1.80	2.80	4.2	
			Placebo	20	19 (95.0)	2.14 (1.02)	0.0	1.40	2.20	2.80	4.4	
		Week 52	Tezepelumab	19	19 (100.0)	1.92 (1.16)	0.0	1.00	1.80	2.60	4.4	
			Placebo	20	19 (95.0)	2.19 (1.08)	0.0	1.40	2.20	2.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	19	18 (94.7)	-0.61 (0.66)	-2.0	-1.20	-0.60	-0.20	0.4	-0.36 [-1.02, 0.30]
			Placebo	20	18 (90.0)	-0.36 (0.75)	-2.4	-0.60	0.00	0.20	0.4	
		Week 4	Tezepelumab	19	18 (94.7)	-0.96 (0.82)	-2.6	-1.20	-0.70	-0.40	0.2	-0.33 [-0.99, 0.33]
			Placebo	20	18 (90.0)	-0.64 (1.05)	-3.0	-1.40	-0.30	0.00	1.2	
		Week 6	Tezepelumab	19	18 (94.7)	-0.97 (0.83)	-2.8	-1.40	-0.80	-0.20	0.0	-0.58 [-1.24, 0.09]
			Placebo	20	18 (90.0)	-0.46 (0.94)	-3.2	-0.80	-0.20	0.20	1.0	
		Week 8	Tezepelumab	19	18 (94.7)	-1.12 (0.88)	-2.8	-1.80	-1.00	-0.40	0.0	-0.52 [-1.18, 0.14]
			Placebo	20	18 (90.0)	-0.62 (1.04)	-3.6	-1.20	-0.30	0.20	0.6	
		Week 10	Tezepelumab	19	18 (94.7)	-1.19 (0.88)	-2.8	-1.60	-1.20	-0.60	0.2	-0.65 [-1.32, 0.02]
			Placebo	20	18 (90.0)	-0.56 (1.06)	-3.8	-0.80	-0.40	0.00	1.6	
		Week 12	Tezepelumab	19	18 (94.7)	-1.47 (0.73)	-2.8	-2.20	-1.40	-0.80	-0.4	-0.59 [-1.26, 0.08]
			Placebo	20	18 (90.0)	-0.88 (1.21)	-3.8	-1.60	-0.80	0.00	1.4	
		Week 14	Tezepelumab	19	18 (94.7)	-1.54 (0.68)	-2.8	-2.20	-1.50	-1.00	-0.4	-0.69 [-1.36, -0.01]
			Placebo	20	18 (90.0)	-0.99 (0.92)	-3.4	-1.40	-1.30	-0.20	0.2	
		Week 16	Tezepelumab	19	18 (94.7)	-1.19 (1.10)	-2.8	-2.20	-1.00	-0.40	1.8	-0.37 [-1.03, 0.29]
			Placebo	20	18 (90.0)	-0.78 (1.15)	-3.6	-1.40	-0.30	0.00	1.0	
		Week 18	Tezepelumab	19	18 (94.7)	-1.26 (0.74)	-2.8	-1.80	-1.00	-0.60	-0.4	-0.29 [-0.95, 0.37]
			Placebo	20	18 (90.0)	-0.99 (1.06)	-3.6	-1.40	-0.80	-0.20	0.2	
		Week 20	Tezepelumab	19	18 (94.7)	-1.28 (0.87)	-2.8	-1.80	-1.10	-0.60	0.4	-0.41 [-1.07, 0.25]
			Placebo	20	18 (90.0)	-0.87 (1.13)	-3.6	-1.40	-0.40	-0.20	0.6	
		Week 22	Tezepelumab	19	18 (94.7)	-1.30 (0.75)	-2.8	-1.60	-1.10	-0.80	-0.4	-0.35 [-1.01, 0.31]
			Placebo	20	18 (90.0)	-0.98 (1.07)	-3.8	-1.60	-0.80	-0.40	0.6	
		Week 24	Tezepelumab	19	18 (94.7)	-1.23 (0.91)	-2.8	-2.00	-1.10	-0.60	0.6	-0.33 [-0.98, 0.33]
			Placebo	20	18 (90.0)	-0.92 (0.99)	-3.6	-1.40	-0.80	-0.20	0.4	
		Week 26	Tezepelumab	19	19 (100.0)	-1.16 (1.04)	-2.8	-2.00	-1.00	-0.20	0.6	-0.15 [-0.80, 0.49]
			Placebo	20	18 (90.0)	-1.00 (1.05)	-3.4	-1.60	-1.30	0.00	0.8	
		Week 28	Tezepelumab	19	19 (100.0)	-1.26 (1.04)	-2.8	-2.20	-1.20	-0.80	1.0	-0.54 [-1.19, 0.11]
			Placebo	20	19 (95.0)	-0.66 (1.18)	-3.4	-1.40	-0.40	0.00	1.2	
		Week 30	Tezepelumab	19	19 (100.0)	-1.20 (1.08)	-2.8	-1.80	-1.20	-0.80	2.0	-0.14 [-0.78, 0.49]
			Placebo	20	19 (95.0)	-1.04 (1.11)	-3.4	-1.60	-1.20	-0.40	1.0	
		Week 32	Tezepelumab	19	19 (100.0)	-1.27 (0.99)	-2.8	-2.20	-1.20	-0.60	1.0	-0.32 [-0.96, 0.32]
			Placebo	20	19 (95.0)	-0.94 (1.12)	-3.2	-1.60	-1.00	0.00	0.8	
		Week 34	Tezepelumab	19	19 (100.0)	-1.19 (1.15)	-2.8	-2.00	-1.20	-0.40	2.2	-0.21 [-0.84, 0.43]
			Placebo	20	19 (95.0)	-0.97 (0.99)	-3.2	-1.60	-0.80	-0.20	0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Male	Change from baseline	Week 36	Tezepelumab	19	19 (100.0)	-1.28 (1.04)	-2.8	-2.00	-1.20	-0.80	1.6	-0.46 [-1.10, 0.19]
			Placebo	20	19 (95.0)	-0.82 (0.99)	-2.6	-1.40	-1.00	0.00	1.4	
		Week 38	Tezepelumab	19	19 (100.0)	-1.19 (1.27)	-2.8	-2.00	-1.20	-0.40	2.6	-0.17 [-0.80, 0.47]
			Placebo	20	19 (95.0)	-1.00 (0.98)	-2.8	-1.60	-0.80	-0.40	0.2	
		Week 40	Tezepelumab	19	19 (100.0)	-1.15 (1.09)	-2.8	-2.00	-1.00	-0.60	1.8	-0.32 [-0.96, 0.32]
			Placebo	20	19 (95.0)	-0.79 (1.13)	-2.6	-1.40	-0.80	0.00	1.4	
		Week 42	Tezepelumab	19	19 (100.0)	-1.22 (1.21)	-3.0	-2.00	-1.20	-0.40	2.2	-0.36 [-1.00, 0.28]
			Placebo	20	19 (95.0)	-0.80 (1.12)	-2.6	-1.40	-0.40	-0.20	1.6	
		Week 44	Tezepelumab	19	19 (100.0)	-1.14 (1.09)	-2.8	-2.00	-1.20	-0.40	1.6	-0.30 [-0.94, 0.34]
			Placebo	20	19 (95.0)	-0.83 (0.95)	-2.6	-1.40	-0.80	-0.40	1.2	
		Week 46	Tezepelumab	19	19 (100.0)	-1.16 (1.09)	-2.8	-1.60	-1.20	-0.60	1.8	-0.32 [-0.96, 0.32]
			Placebo	20	19 (95.0)	-0.85 (0.77)	-2.6	-1.40	-0.80	-0.40	0.6	
		Week 48	Tezepelumab	19	19 (100.0)	-1.12 (1.12)	-2.8	-1.60	-1.00	-0.40	2.0	-0.25 [-0.88, 0.39]
			Placebo	20	19 (95.0)	-0.85 (1.01)	-3.0	-1.40	-0.80	0.00	1.0	
		Week 50	Tezepelumab	19	19 (100.0)	-1.26 (1.19)	-2.8	-2.00	-1.20	-0.40	2.0	-0.40 [-1.04, 0.24]
			Placebo	20	19 (95.0)	-0.85 (0.84)	-2.6	-1.40	-0.80	-0.40	0.4	
		Week 52	Tezepelumab	19	19 (100.0)	-1.18 (1.13)	-2.8	-1.80	-1.20	-0.60	2.0	-0.37 [-1.01, 0.27]
			Placebo	20	19 (95.0)	-0.80 (0.91)	-2.6	-1.40	-0.60	-0.20	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	47	47 (100.0)	2.78 (0.92)	0.0	2.20	2.80	3.20	5.2	
			Placebo	45	45 (100.0)	2.82 (0.74)	1.0	2.60	2.80	3.20	5.0	
		Week 2	Tezepelumab	47	45 (95.7)	2.26 (1.04)	0.0	1.60	2.60	3.00	4.4	
			Placebo	45	40 (88.9)	2.23 (0.76)	0.4	2.00	2.20	2.60	5.0	
		Week 4	Tezepelumab	47	45 (95.7)	2.03 (0.98)	0.2	1.40	2.20	2.80	3.4	
			Placebo	45	40 (88.9)	2.15 (0.91)	0.2	1.60	2.30	2.80	3.6	
		Week 6	Tezepelumab	47	45 (95.7)	1.88 (1.00)	0.0	1.20	1.80	2.80	3.8	
			Placebo	45	40 (88.9)	2.01 (1.19)	0.2	1.20	2.00	2.70	6.0	
		Week 8	Tezepelumab	47	45 (95.7)	1.72 (1.18)	0.0	0.80	1.60	2.80	5.2	
			Placebo	45	41 (91.1)	1.96 (1.14)	0.0	1.00	2.00	2.60	5.0	
		Week 10	Tezepelumab	47	45 (95.7)	1.62 (1.13)	0.0	0.80	1.40	2.40	4.8	
			Placebo	45	41 (91.1)	1.97 (1.10)	0.0	1.00	2.00	2.40	5.2	
		Week 12	Tezepelumab	47	45 (95.7)	1.58 (1.16)	0.0	0.60	1.40	2.60	4.8	
			Placebo	45	41 (91.1)	1.80 (0.97)	0.0	1.00	2.00	2.40	3.8	
		Week 14	Tezepelumab	47	45 (95.7)	1.53 (1.17)	0.0	0.60	1.40	2.40	4.8	
			Placebo	45	41 (91.1)	1.75 (0.99)	0.0	1.00	2.00	2.40	5.0	
		Week 16	Tezepelumab	47	45 (95.7)	1.60 (1.12)	0.0	0.80	1.40	2.40	4.8	
			Placebo	45	41 (91.1)	1.89 (1.22)	0.0	1.00	2.00	2.60	5.0	
		Week 18	Tezepelumab	47	46 (97.9)	1.58 (1.08)	0.0	0.80	1.50	2.40	4.8	
			Placebo	45	41 (91.1)	1.84 (1.22)	0.0	1.00	1.80	2.60	5.0	
		Week 20	Tezepelumab	47	46 (97.9)	1.60 (1.14)	0.0	0.60	1.40	2.60	4.8	
			Placebo	45	41 (91.1)	1.93 (1.11)	0.0	1.20	2.00	2.60	5.0	
		Week 22	Tezepelumab	47	46 (97.9)	1.74 (1.07)	0.0	0.80	1.80	2.60	4.8	
			Placebo	45	41 (91.1)	1.91 (1.19)	0.0	1.00	2.00	2.60	5.0	
		Week 24	Tezepelumab	47	46 (97.9)	1.67 (1.11)	0.0	0.80	1.60	2.60	4.8	
			Placebo	45	41 (91.1)	1.98 (1.09)	0.0	1.00	2.00	2.80	4.0	
		Week 26	Tezepelumab	47	46 (97.9)	1.73 (1.11)	0.0	0.80	1.60	2.60	4.8	
			Placebo	45	41 (91.1)	1.91 (1.15)	0.0	1.00	1.80	2.60	4.4	
		Week 28	Tezepelumab	47	47 (100.0)	1.69 (1.19)	0.0	0.60	1.60	2.60	4.8	
			Placebo	45	41 (91.1)	1.79 (1.17)	0.0	1.00	1.60	2.60	4.4	
		Week 30	Tezepelumab	47	47 (100.0)	1.62 (1.12)	0.0	0.80	1.60	2.40	4.8	
			Placebo	45	41 (91.1)	1.93 (1.15)	0.0	1.00	2.00	2.80	4.0	
		Week 32	Tezepelumab	47	47 (100.0)	1.55 (1.15)	0.0	0.60	1.40	2.40	4.8	
			Placebo	45	41 (91.1)	1.83 (1.11)	0.0	1.00	1.80	2.40	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	Absolute values	Week 34	Tezepelumab	47	47 (100.0)	1.63 (1.19)	0.0	0.80	1.40	2.60	4.8	
			Placebo	45	41 (91.1)	1.81 (1.15)	0.0	1.00	1.80	2.40	4.8	
		Week 36	Tezepelumab	47	47 (100.0)	1.61 (1.11)	0.0	0.80	1.40	2.40	4.8	
			Placebo	45	41 (91.1)	2.00 (1.20)	0.0	1.20	2.20	2.80	4.8	
		Week 38	Tezepelumab	47	47 (100.0)	1.64 (1.20)	0.0	0.60	1.60	2.60	4.8	
			Placebo	45	41 (91.1)	1.89 (1.15)	0.0	1.00	1.80	2.60	4.8	
		Week 40	Tezepelumab	47	47 (100.0)	1.60 (1.18)	0.0	0.60	1.60	2.40	4.8	
			Placebo	45	41 (91.1)	2.00 (1.19)	0.0	1.00	2.20	2.80	4.2	
		Week 42	Tezepelumab	47	47 (100.0)	1.55 (1.12)	0.0	0.80	1.40	2.40	4.8	
			Placebo	45	41 (91.1)	1.80 (0.98)	0.0	1.00	2.00	2.40	4.0	
		Week 44	Tezepelumab	47	47 (100.0)	1.57 (1.12)	0.0	0.80	1.40	2.60	4.8	
			Placebo	45	41 (91.1)	1.94 (1.12)	0.0	1.00	2.00	2.60	4.2	
		Week 46	Tezepelumab	47	47 (100.0)	1.62 (1.19)	0.0	0.80	1.60	2.80	4.8	
			Placebo	45	41 (91.1)	1.77 (1.03)	0.0	1.00	1.80	2.40	4.4	
		Week 48	Tezepelumab	47	47 (100.0)	1.60 (1.18)	0.0	0.80	1.40	2.60	4.8	
			Placebo	45	41 (91.1)	1.85 (1.08)	0.0	1.00	2.00	2.40	4.6	
		Week 50	Tezepelumab	47	47 (100.0)	1.57 (1.20)	0.0	0.60	1.40	2.60	4.8	
			Placebo	45	41 (91.1)	1.68 (1.01)	0.0	1.00	1.80	2.40	4.0	
		Week 52	Tezepelumab	47	47 (100.0)	1.58 (1.19)	0.0	0.60	1.40	2.60	4.8	
			Placebo	45	41 (91.1)	1.76 (1.08)	0.0	1.00	1.80	2.60	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	47	45 (95.7)	-0.54 (0.85)	-3.2	-1.00	-0.40	0.20	0.8	0.04 [-0.39, 0.46]
			Placebo	45	40 (88.9)	-0.57 (0.71)	-2.8	-1.00	-0.50	-0.20	1.2	
		Week 4	Tezepelumab	47	45 (95.7)	-0.77 (0.97)	-2.6	-1.40	-0.80	-0.20	2.6	-0.13 [-0.56, 0.30]
			Placebo	45	40 (88.9)	-0.65 (0.94)	-3.0	-1.40	-0.50	0.00	0.8	
		Week 6	Tezepelumab	47	45 (95.7)	-0.92 (1.10)	-2.8	-1.60	-1.00	0.00	2.6	-0.12 [-0.54, 0.31]
			Placebo	45	40 (88.9)	-0.79 (1.09)	-3.4	-1.60	-0.80	-0.10	1.6	
		Week 8	Tezepelumab	47	45 (95.7)	-1.08 (1.25)	-3.2	-1.60	-1.20	-0.40	2.6	-0.19 [-0.62, 0.23]
			Placebo	45	41 (91.1)	-0.85 (1.07)	-3.0	-1.40	-0.80	-0.20	1.0	
		Week 10	Tezepelumab	47	45 (95.7)	-1.18 (1.21)	-3.4	-2.00	-1.40	-0.60	2.6	-0.28 [-0.71, 0.14]
			Placebo	45	41 (91.1)	-0.84 (1.20)	-3.2	-1.60	-0.80	-0.20	2.6	
		Week 12	Tezepelumab	47	45 (95.7)	-1.22 (1.22)	-3.2	-2.20	-1.20	-0.40	2.6	-0.19 [-0.62, 0.23]
			Placebo	45	41 (91.1)	-1.00 (1.03)	-3.2	-1.40	-0.80	-0.40	1.6	
		Week 14	Tezepelumab	47	45 (95.7)	-1.27 (1.24)	-4.0	-2.20	-1.40	-0.40	2.6	-0.18 [-0.60, 0.25]
			Placebo	45	41 (91.1)	-1.06 (1.15)	-3.2	-1.60	-1.00	-0.40	2.4	
		Week 16	Tezepelumab	47	45 (95.7)	-1.20 (1.18)	-3.2	-2.20	-1.20	-0.60	2.6	-0.24 [-0.66, 0.19]
			Placebo	45	41 (91.1)	-0.92 (1.20)	-3.0	-1.40	-1.00	-0.40	2.6	
		Week 18	Tezepelumab	47	46 (97.9)	-1.20 (1.22)	-3.8	-2.20	-1.10	-0.60	2.6	-0.19 [-0.61, 0.24]
			Placebo	45	41 (91.1)	-0.97 (1.31)	-3.2	-2.00	-1.00	-0.20	2.6	
		Week 20	Tezepelumab	47	46 (97.9)	-1.19 (1.19)	-3.4	-2.20	-1.30	-0.40	2.6	-0.26 [-0.68, 0.17]
			Placebo	45	41 (91.1)	-0.88 (1.22)	-3.0	-1.60	-0.80	-0.60	2.6	
		Week 22	Tezepelumab	47	46 (97.9)	-1.04 (1.25)	-3.2	-2.20	-1.00	-0.20	2.6	-0.11 [-0.53, 0.31]
			Placebo	45	41 (91.1)	-0.90 (1.24)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 24	Tezepelumab	47	46 (97.9)	-1.12 (1.16)	-3.4	-1.80	-1.30	-0.40	2.6	-0.24 [-0.66, 0.18]
			Placebo	45	41 (91.1)	-0.83 (1.20)	-3.2	-1.60	-1.00	0.00	2.6	
		Week 26	Tezepelumab	47	46 (97.9)	-1.05 (1.17)	-3.0	-2.20	-1.00	-0.20	2.6	-0.13 [-0.55, 0.29]
			Placebo	45	41 (91.1)	-0.90 (1.27)	-3.0	-1.80	-1.20	0.00	2.6	
		Week 28	Tezepelumab	47	47 (100.0)	-1.09 (1.28)	-3.4	-2.20	-1.00	0.00	2.6	-0.05 [-0.47, 0.37]
			Placebo	45	41 (91.1)	-1.02 (1.25)	-3.0	-2.00	-1.20	-0.20	2.6	
		Week 30	Tezepelumab	47	47 (100.0)	-1.16 (1.23)	-3.8	-2.20	-1.00	-0.20	2.6	-0.22 [-0.64, 0.20]
			Placebo	45	41 (91.1)	-0.88 (1.29)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 32	Tezepelumab	47	47 (100.0)	-1.23 (1.16)	-3.2	-2.20	-1.20	-0.60	2.6	-0.21 [-0.63, 0.21]
			Placebo	45	41 (91.1)	-0.98 (1.21)	-3.0	-1.80	-1.20	-0.40	2.6	
		Week 34	Tezepelumab	47	47 (100.0)	-1.15 (1.24)	-3.0	-2.20	-1.40	-0.20	2.6	-0.12 [-0.54, 0.30]
			Placebo	45	41 (91.1)	-1.00 (1.24)	-3.2	-1.80	-1.20	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	Change from baseline	Week 36	Tezepelumab	47	47 (100.0)	-1.17 (1.24)	-3.2	-2.20	-1.20	0.00	2.6	-0.28 [-0.70, 0.14]
			Placebo	45	41 (91.1)	-0.81 (1.33)	-3.6	-1.60	-1.00	-0.20	2.6	
		Week 38	Tezepelumab	47	47 (100.0)	-1.14 (1.22)	-3.2	-2.20	-1.40	0.00	2.6	-0.18 [-0.60, 0.24]
			Placebo	45	41 (91.1)	-0.92 (1.23)	-3.2	-1.60	-1.00	-0.40	2.6	
		Week 40	Tezepelumab	47	47 (100.0)	-1.18 (1.26)	-3.4	-2.20	-1.40	-0.40	2.6	-0.30 [-0.72, 0.13]
			Placebo	45	41 (91.1)	-0.81 (1.27)	-3.2	-1.60	-0.80	-0.20	2.6	
		Week 42	Tezepelumab	47	47 (100.0)	-1.23 (1.22)	-3.6	-2.20	-1.40	-0.40	2.6	-0.19 [-0.61, 0.23]
			Placebo	45	41 (91.1)	-1.01 (1.10)	-2.8	-1.60	-1.20	-0.60	2.6	
		Week 44	Tezepelumab	47	47 (100.0)	-1.21 (1.25)	-3.8	-2.20	-1.40	-0.20	2.6	-0.27 [-0.69, 0.15]
			Placebo	45	41 (91.1)	-0.87 (1.25)	-3.4	-1.60	-1.00	0.00	2.6	
		Week 46	Tezepelumab	47	47 (100.0)	-1.16 (1.26)	-3.6	-2.20	-1.40	0.00	2.6	-0.10 [-0.52, 0.32]
			Placebo	45	41 (91.1)	-1.04 (1.17)	-3.2	-1.60	-1.20	-0.60	2.6	
		Week 48	Tezepelumab	47	47 (100.0)	-1.17 (1.23)	-3.0	-2.40	-1.00	-0.20	2.6	-0.18 [-0.60, 0.24]
			Placebo	45	41 (91.1)	-0.96 (1.19)	-3.4	-1.60	-1.00	-0.40	2.6	
		Week 50	Tezepelumab	47	47 (100.0)	-1.20 (1.24)	-3.2	-2.20	-1.40	-0.20	2.6	-0.06 [-0.48, 0.36]
			Placebo	45	41 (91.1)	-1.13 (1.14)	-3.6	-1.60	-1.20	-0.60	2.6	
		Week 52	Tezepelumab	47	47 (100.0)	-1.20 (1.24)	-3.2	-2.20	-1.20	-0.20	2.6	-0.12 [-0.54, 0.30]
			Placebo	45	41 (91.1)	-1.05 (1.19)	-3.6	-1.80	-1.00	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.91 (0.93)	0.0	2.40	2.80	3.40	5.2	
			Placebo	55	55 (100.0)	2.91 (0.76)	1.0	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	57	55 (96.5)	2.31 (1.06)	0.0	1.60	2.60	3.00	4.4	
			Placebo	55	50 (90.9)	2.36 (0.84)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	57	55 (96.5)	2.08 (1.03)	0.2	1.20	2.20	3.00	3.6	
			Placebo	55	50 (90.9)	2.21 (0.96)	0.2	1.40	2.50	2.80	4.2	
		Week 6	Tezepelumab	57	55 (96.5)	1.94 (1.08)	0.0	1.20	1.80	2.80	4.0	
			Placebo	55	50 (90.9)	2.17 (1.21)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	57	55 (96.5)	1.78 (1.24)	0.0	0.80	1.80	2.80	5.2	
			Placebo	55	51 (92.7)	2.04 (1.17)	0.0	1.00	2.20	2.80	5.0	
		Week 10	Tezepelumab	57	55 (96.5)	1.67 (1.20)	0.0	0.60	1.60	2.80	4.8	
			Placebo	55	51 (92.7)	2.08 (1.12)	0.0	1.00	2.20	2.80	5.2	
		Week 12	Tezepelumab	57	55 (96.5)	1.55 (1.15)	0.0	0.60	1.60	2.60	4.8	
			Placebo	55	51 (92.7)	1.84 (1.09)	0.0	1.00	2.00	2.60	4.4	
		Week 14	Tezepelumab	57	55 (96.5)	1.51 (1.18)	0.0	0.60	1.40	2.20	4.8	
			Placebo	55	51 (92.7)	1.80 (1.02)	0.0	1.00	1.80	2.20	5.0	
		Week 16	Tezepelumab	57	55 (96.5)	1.67 (1.24)	0.0	0.60	1.40	2.60	4.8	
			Placebo	55	51 (92.7)	1.97 (1.26)	0.0	0.80	2.00	2.80	5.0	
		Week 18	Tezepelumab	57	55 (96.5)	1.63 (1.14)	0.0	0.80	1.60	2.40	4.8	
			Placebo	55	51 (92.7)	1.85 (1.22)	0.0	1.00	1.80	2.60	5.0	
		Week 20	Tezepelumab	57	55 (96.5)	1.61 (1.19)	0.0	0.60	1.60	2.40	5.0	
			Placebo	55	51 (92.7)	1.95 (1.14)	0.0	1.00	2.00	2.80	5.0	
		Week 22	Tezepelumab	57	55 (96.5)	1.73 (1.09)	0.0	0.80	2.00	2.60	4.8	
			Placebo	55	51 (92.7)	1.90 (1.19)	0.0	0.80	2.00	2.60	5.0	
		Week 24	Tezepelumab	57	55 (96.5)	1.72 (1.17)	0.0	0.60	1.80	2.60	4.8	
			Placebo	55	51 (92.7)	1.94 (1.08)	0.0	1.00	2.00	2.60	4.4	
		Week 26	Tezepelumab	57	56 (98.2)	1.76 (1.19)	0.0	0.80	1.80	2.80	4.8	
			Placebo	55	51 (92.7)	1.89 (1.13)	0.0	1.00	1.80	2.60	4.4	
		Week 28	Tezepelumab	57	57 (100.0)	1.66 (1.20)	0.0	0.60	1.60	2.40	4.8	
			Placebo	55	51 (92.7)	1.91 (1.21)	0.0	1.00	1.80	2.80	4.4	
		Week 30	Tezepelumab	57	57 (100.0)	1.65 (1.16)	0.0	0.80	1.60	2.40	4.8	
			Placebo	55	51 (92.7)	1.90 (1.20)	0.0	0.80	2.00	2.80	4.4	
		Week 32	Tezepelumab	57	57 (100.0)	1.62 (1.17)	0.0	0.60	1.60	2.60	4.8	
			Placebo	55	51 (92.7)	1.87 (1.16)	0.0	0.80	1.80	2.60	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 65 years	Absolute values	Week 34	Tezepelumab	57	57 (100.0)	1.69 (1.24)	0.0	0.80	1.60	2.80	4.8	
			Placebo	55	51 (92.7)	1.83 (1.18)	0.0	0.80	1.80	2.60	4.8	
		Week 36	Tezepelumab	57	57 (100.0)	1.66 (1.15)	0.0	1.00	1.60	2.40	4.8	
			Placebo	55	51 (92.7)	2.01 (1.22)	0.0	1.00	2.00	2.80	4.8	
		Week 38	Tezepelumab	57	57 (100.0)	1.70 (1.29)	0.0	0.60	1.80	2.60	4.8	
			Placebo	55	51 (92.7)	1.90 (1.17)	0.0	1.00	1.80	2.80	4.8	
		Week 40	Tezepelumab	57	57 (100.0)	1.71 (1.24)	0.0	0.60	2.00	2.80	4.8	
			Placebo	55	51 (92.7)	2.00 (1.18)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	57	57 (100.0)	1.65 (1.19)	0.0	1.00	1.60	2.40	4.8	
			Placebo	55	51 (92.7)	1.92 (1.07)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	57	57 (100.0)	1.69 (1.19)	0.0	0.80	1.80	2.80	4.8	
			Placebo	55	51 (92.7)	2.00 (1.14)	0.0	1.00	2.00	2.80	4.4	
		Week 46	Tezepelumab	57	57 (100.0)	1.69 (1.26)	0.0	0.80	1.80	2.80	4.8	
			Placebo	55	51 (92.7)	1.84 (0.99)	0.0	1.20	2.00	2.40	4.4	
		Week 48	Tezepelumab	57	57 (100.0)	1.73 (1.24)	0.0	0.80	1.80	2.80	4.8	
			Placebo	55	51 (92.7)	1.90 (1.07)	0.0	1.00	2.00	2.60	4.4	
		Week 50	Tezepelumab	57	57 (100.0)	1.66 (1.26)	0.0	0.60	1.40	2.60	4.8	
			Placebo	55	51 (92.7)	1.81 (1.06)	0.0	1.00	1.80	2.60	4.4	
		Week 52	Tezepelumab	57	57 (100.0)	1.71 (1.23)	0.0	0.80	1.60	2.60	4.8	
			Placebo	55	51 (92.7)	1.87 (1.12)	0.0	1.00	1.80	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 2	Tezepelumab	57	55 (96.5)	-0.62 (0.83)	-3.2	-1.20	-0.40	0.00	0.8	-0.11 [-0.49, 0.27]
			Placebo	55	50 (90.9)	-0.53 (0.76)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	57	55 (96.5)	-0.85 (0.94)	-2.6	-1.40	-0.80	-0.20	2.6	-0.17 [-0.55, 0.22]
			Placebo	55	50 (90.9)	-0.69 (1.01)	-3.0	-1.40	-0.40	0.00	1.2	
		Week 6	Tezepelumab	57	55 (96.5)	-0.99 (1.05)	-2.8	-1.60	-1.00	-0.20	2.6	-0.24 [-0.63, 0.14]
			Placebo	55	50 (90.9)	-0.73 (1.10)	-3.4	-1.60	-0.60	0.00	1.6	
		Week 8	Tezepelumab	57	55 (96.5)	-1.15 (1.19)	-3.2	-2.00	-1.20	-0.40	2.6	-0.26 [-0.64, 0.13]
			Placebo	55	51 (92.7)	-0.86 (1.07)	-3.6	-1.60	-0.60	-0.20	1.0	
		Week 10	Tezepelumab	57	55 (96.5)	-1.26 (1.17)	-3.4	-2.20	-1.40	-0.60	2.6	-0.37 [-0.75, 0.02]
			Placebo	55	51 (92.7)	-0.82 (1.22)	-3.8	-1.60	-0.80	-0.20	2.6	
		Week 12	Tezepelumab	57	55 (96.5)	-1.38 (1.13)	-3.2	-2.20	-1.40	-0.80	2.6	-0.28 [-0.66, 0.10]
			Placebo	55	51 (92.7)	-1.06 (1.12)	-3.8	-1.80	-1.00	-0.40	1.6	
		Week 14	Tezepelumab	57	55 (96.5)	-1.43 (1.15)	-4.0	-2.20	-1.40	-0.80	2.6	-0.28 [-0.66, 0.10]
			Placebo	55	51 (92.7)	-1.11 (1.11)	-3.4	-1.60	-1.20	-0.40	2.4	
		Week 16	Tezepelumab	57	55 (96.5)	-1.27 (1.19)	-3.2	-2.20	-1.20	-0.60	2.6	-0.27 [-0.65, 0.11]
			Placebo	55	51 (92.7)	-0.94 (1.24)	-3.6	-1.60	-1.00	-0.20	2.6	
		Week 18	Tezepelumab	57	55 (96.5)	-1.30 (1.13)	-3.8	-2.20	-1.20	-0.60	2.6	-0.20 [-0.58, 0.18]
			Placebo	55	51 (92.7)	-1.06 (1.27)	-3.6	-2.00	-1.20	-0.20	2.6	
		Week 20	Tezepelumab	57	55 (96.5)	-1.32 (1.13)	-3.4	-2.20	-1.40	-0.60	2.6	-0.31 [-0.69, 0.07]
			Placebo	55	51 (92.7)	-0.96 (1.22)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	57	55 (96.5)	-1.20 (1.19)	-3.2	-2.20	-1.20	-0.60	2.6	-0.16 [-0.54, 0.22]
			Placebo	55	51 (92.7)	-1.01 (1.21)	-3.8	-1.80	-1.00	-0.20	2.6	
		Week 24	Tezepelumab	57	55 (96.5)	-1.21 (1.14)	-3.4	-2.00	-1.40	-0.60	2.6	-0.21 [-0.60, 0.17]
			Placebo	55	51 (92.7)	-0.96 (1.16)	-3.6	-1.60	-1.00	-0.20	2.6	
		Week 26	Tezepelumab	57	56 (98.2)	-1.15 (1.18)	-3.0	-2.20	-1.20	-0.30	2.6	-0.11 [-0.49, 0.27]
			Placebo	55	51 (92.7)	-1.02 (1.19)	-3.4	-1.80	-1.20	0.00	2.6	
		Week 28	Tezepelumab	57	57 (100.0)	-1.25 (1.23)	-3.4	-2.20	-1.40	-0.60	2.6	-0.20 [-0.58, 0.18]
			Placebo	55	51 (92.7)	-1.00 (1.25)	-3.4	-1.80	-1.20	0.00	2.6	
		Week 30	Tezepelumab	57	57 (100.0)	-1.25 (1.23)	-3.8	-2.20	-1.20	-0.60	2.6	-0.20 [-0.58, 0.18]
			Placebo	55	51 (92.7)	-1.00 (1.28)	-3.4	-1.60	-1.20	-0.20	2.6	
		Week 32	Tezepelumab	57	57 (100.0)	-1.29 (1.16)	-3.2	-2.20	-1.60	-0.60	2.6	-0.22 [-0.59, 0.16]
			Placebo	55	51 (92.7)	-1.03 (1.23)	-3.2	-1.80	-1.40	-0.40	2.6	
		Week 34	Tezepelumab	57	57 (100.0)	-1.22 (1.25)	-3.0	-2.20	-1.40	-0.40	2.6	-0.12 [-0.49, 0.26]
			Placebo	55	51 (92.7)	-1.07 (1.21)	-3.2	-1.80	-1.20	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 65 years	Change from baseline	Week 36	Tezepelumab	57	57 (100.0)	-1.24 (1.23)	-3.2	-2.20	-1.40	-0.20	2.6	-0.28 [-0.66, 0.10]
			Placebo	55	51 (92.7)	-0.89 (1.29)	-3.6	-1.60	-1.00	-0.20	2.6	
		Week 38	Tezepelumab	57	57 (100.0)	-1.21 (1.29)	-3.2	-2.20	-1.40	-0.20	2.6	-0.16 [-0.54, 0.22]
			Placebo	55	51 (92.7)	-1.00 (1.22)	-3.2	-2.00	-1.20	-0.40	2.6	
		Week 40	Tezepelumab	57	57 (100.0)	-1.19 (1.27)	-3.4	-2.20	-1.20	-0.40	2.6	-0.23 [-0.61, 0.15]
			Placebo	55	51 (92.7)	-0.90 (1.24)	-3.2	-2.00	-1.00	-0.20	2.6	
		Week 42	Tezepelumab	57	57 (100.0)	-1.25 (1.26)	-3.6	-2.20	-1.40	-0.40	2.6	-0.22 [-0.60, 0.16]
			Placebo	55	51 (92.7)	-0.99 (1.14)	-2.8	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	57	57 (100.0)	-1.22 (1.26)	-3.8	-2.20	-1.20	-0.40	2.6	-0.25 [-0.63, 0.13]
			Placebo	55	51 (92.7)	-0.91 (1.21)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 46	Tezepelumab	57	57 (100.0)	-1.22 (1.26)	-3.6	-2.20	-1.20	-0.20	2.6	-0.12 [-0.50, 0.25]
			Placebo	55	51 (92.7)	-1.07 (1.07)	-3.2	-1.60	-1.20	-0.60	2.6	
		Week 48	Tezepelumab	57	57 (100.0)	-1.17 (1.25)	-3.0	-2.20	-1.20	-0.40	2.6	-0.14 [-0.52, 0.24]
			Placebo	55	51 (92.7)	-1.01 (1.14)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	57	57 (100.0)	-1.24 (1.28)	-3.2	-2.20	-1.40	-0.40	2.6	-0.12 [-0.50, 0.26]
			Placebo	55	51 (92.7)	-1.10 (1.12)	-3.6	-1.80	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	57	57 (100.0)	-1.20 (1.25)	-3.2	-2.20	-1.20	-0.40	2.6	-0.13 [-0.51, 0.25]
			Placebo	55	51 (92.7)	-1.04 (1.18)	-3.6	-1.80	-1.00	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.64 (0.43)	2.0	2.40	2.60	3.00	3.2	
			Placebo	10	10 (100.0)	2.62 (0.82)	0.4	2.80	2.80	3.00	3.4	
		Week 2	Tezepelumab	9	8 (88.9)	2.55 (0.67)	1.6	1.90	2.70	3.10	3.4	
			Placebo	10	8 (80.0)	2.60 (0.44)	1.8	2.30	2.70	3.00	3.0	
		Week 4	Tezepelumab	9	8 (88.9)	2.08 (0.83)	0.8	1.40	2.30	2.70	3.0	
			Placebo	10	8 (80.0)	2.53 (0.61)	1.8	2.00	2.50	2.90	3.6	
		Week 6	Tezepelumab	9	8 (88.9)	2.18 (0.70)	1.4	1.40	2.30	2.70	3.2	
			Placebo	10	8 (80.0)	2.50 (0.72)	1.2	2.10	2.60	3.10	3.2	
		Week 8	Tezepelumab	9	8 (88.9)	2.08 (0.64)	1.2	1.50	2.10	2.60	3.0	
			Placebo	10	8 (80.0)	2.68 (0.74)	1.6	2.00	2.90	3.10	3.8	
		Week 10	Tezepelumab	9	8 (88.9)	2.08 (0.45)	1.4	1.70	2.20	2.40	2.6	
			Placebo	10	8 (80.0)	2.60 (0.63)	1.6	2.20	2.60	3.00	3.6	
		Week 12	Tezepelumab	9	8 (88.9)	2.03 (0.63)	1.2	1.40	2.10	2.60	2.8	
			Placebo	10	8 (80.0)	2.58 (0.57)	2.0	2.00	2.60	3.10	3.2	
		Week 14	Tezepelumab	9	8 (88.9)	1.90 (0.60)	1.4	1.40	1.60	2.50	2.8	
			Placebo	10	8 (80.0)	2.35 (0.74)	1.2	1.80	2.40	3.00	3.2	
		Week 16	Tezepelumab	9	8 (88.9)	2.00 (0.57)	1.4	1.50	1.90	2.50	2.8	
			Placebo	10	8 (80.0)	2.45 (0.66)	1.4	1.90	2.60	3.00	3.2	
		Week 18	Tezepelumab	9	9 (100.0)	1.93 (0.57)	1.2	1.60	1.60	2.40	2.8	
			Placebo	10	8 (80.0)	2.48 (0.69)	1.4	2.00	2.70	2.90	3.2	
		Week 20	Tezepelumab	9	9 (100.0)	2.11 (0.67)	1.4	1.40	1.80	2.80	2.8	
			Placebo	10	8 (80.0)	2.60 (0.73)	1.4	2.10	2.80	2.90	3.8	
		Week 22	Tezepelumab	9	9 (100.0)	2.04 (0.48)	1.4	1.80	2.00	2.40	2.6	
			Placebo	10	8 (80.0)	2.53 (0.79)	1.6	1.80	2.60	2.90	4.0	
		Week 24	Tezepelumab	9	9 (100.0)	1.87 (0.58)	1.2	1.40	1.60	2.40	2.8	
			Placebo	10	8 (80.0)	2.73 (0.62)	1.8	2.30	2.80	3.00	3.8	
		Week 26	Tezepelumab	9	9 (100.0)	1.96 (0.59)	1.0	1.60	1.80	2.40	2.8	
			Placebo	10	8 (80.0)	2.58 (1.09)	1.2	1.50	2.90	3.10	4.4	
		Week 28	Tezepelumab	9	9 (100.0)	2.20 (0.71)	1.2	1.60	2.40	2.80	3.0	
			Placebo	10	9 (90.0)	2.24 (1.33)	0.0	1.20	2.80	2.80	4.4	
		Week 30	Tezepelumab	9	9 (100.0)	2.00 (0.57)	1.2	1.60	1.80	2.60	2.8	
			Placebo	10	9 (90.0)	2.13 (1.09)	0.0	1.60	2.40	3.00	3.4	
		Week 32	Tezepelumab	9	9 (100.0)	1.71 (0.74)	0.4	1.40	1.80	2.20	2.8	
			Placebo	10	9 (90.0)	2.07 (1.05)	0.0	1.60	2.60	2.80	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 65 years	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.84 (0.89)	0.8	1.00	1.40	2.60	3.0	
			Placebo	10	9 (90.0)	2.13 (0.89)	0.2	1.80	2.20	2.60	3.2	
		Week 36	Tezepelumab	9	9 (100.0)	1.69 (0.83)	0.6	1.20	1.40	2.40	3.0	
			Placebo	10	9 (90.0)	2.29 (1.03)	0.0	2.20	2.40	2.80	3.6	
		Week 38	Tezepelumab	9	9 (100.0)	1.82 (0.78)	0.8	1.20	1.40	2.40	3.0	
			Placebo	10	9 (90.0)	2.04 (0.92)	0.0	1.80	2.20	2.60	3.0	
		Week 40	Tezepelumab	9	9 (100.0)	1.60 (0.77)	0.4	1.00	1.80	2.00	2.8	
			Placebo	10	9 (90.0)	2.40 (1.25)	0.0	1.40	3.00	3.00	4.2	
		Week 42	Tezepelumab	9	9 (100.0)	1.58 (0.85)	0.6	0.80	1.40	2.00	2.8	
			Placebo	10	9 (90.0)	1.96 (1.06)	0.0	1.40	2.00	2.20	3.8	
		Week 44	Tezepelumab	9	9 (100.0)	1.62 (0.82)	0.6	0.80	1.60	2.40	2.8	
			Placebo	10	9 (90.0)	2.04 (1.03)	0.0	1.60	2.20	2.80	3.4	
		Week 46	Tezepelumab	9	9 (100.0)	1.84 (0.67)	0.8	1.40	2.00	2.40	2.8	
			Placebo	10	9 (90.0)	2.16 (1.16)	0.0	2.00	2.00	2.20	4.4	
		Week 48	Tezepelumab	9	9 (100.0)	1.58 (0.77)	0.8	0.80	1.40	2.40	2.6	
			Placebo	10	9 (90.0)	2.20 (1.28)	0.0	1.40	2.40	2.40	4.6	
		Week 50	Tezepelumab	9	9 (100.0)	1.56 (0.73)	0.8	1.00	1.40	2.00	2.6	
			Placebo	10	9 (90.0)	1.91 (0.87)	0.0	1.80	2.20	2.40	3.0	
		Week 52	Tezepelumab	9	9 (100.0)	1.49 (0.87)	0.4	0.80	1.40	2.00	2.8	
			Placebo	10	9 (90.0)	2.04 (0.94)	0.0	2.00	2.20	2.80	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 2	Tezepelumab	9	8 (88.9)	-0.18 (0.36)	-0.6	-0.50	-0.20	0.20	0.2	0.38 [-0.61, 1.37]
			Placebo	10	8 (80.0)	-0.32 (0.43)	-1.0	-0.60	-0.40	0.10	0.2	
		Week 4	Tezepelumab	9	8 (88.9)	-0.65 (0.92)	-2.2	-1.40	-0.40	0.20	0.2	-0.32 [-1.31, 0.67]
			Placebo	10	8 (80.0)	-0.40 (0.61)	-1.0	-1.00	-0.50	0.10	0.6	
		Week 6	Tezepelumab	9	8 (88.9)	-0.55 (0.76)	-1.8	-1.20	-0.10	0.00	0.0	-0.18 [-1.16, 0.81]
			Placebo	10	8 (80.0)	-0.42 (0.65)	-1.6	-0.80	-0.40	0.20	0.2	
		Week 8	Tezepelumab	9	8 (88.9)	-0.65 (0.74)	-1.8	-1.20	-0.50	-0.10	0.2	-0.49 [-1.49, 0.51]
			Placebo	10	8 (80.0)	-0.25 (0.89)	-1.8	-0.90	0.10	0.20	1.0	
		Week 10	Tezepelumab	9	8 (88.9)	-0.65 (0.45)	-1.6	-0.80	-0.60	-0.30	-0.2	-0.67 [-1.69, 0.34]
			Placebo	10	8 (80.0)	-0.32 (0.51)	-1.2	-0.70	-0.20	0.10	0.2	
		Week 12	Tezepelumab	9	8 (88.9)	-0.70 (0.65)	-1.8	-1.10	-0.70	-0.20	0.2	-0.60 [-1.61, 0.40]
			Placebo	10	8 (80.0)	-0.35 (0.50)	-0.8	-0.80	-0.50	0.20	0.2	
		Week 14	Tezepelumab	9	8 (88.9)	-0.83 (0.62)	-1.8	-1.30	-0.80	-0.30	0.0	-0.36 [-1.35, 0.63]
			Placebo	10	8 (80.0)	-0.57 (0.77)	-1.6	-1.30	-0.50	0.20	0.2	
		Week 16	Tezepelumab	9	8 (88.9)	-0.73 (0.70)	-1.8	-1.10	-0.90	-0.20	0.4	-0.38 [-1.37, 0.61]
			Placebo	10	8 (80.0)	-0.48 (0.61)	-1.4	-1.00	-0.40	0.10	0.2	
		Week 18	Tezepelumab	9	9 (100.0)	-0.71 (0.70)	-1.6	-1.40	-0.80	0.00	0.2	-0.36 [-1.32, 0.60]
			Placebo	10	8 (80.0)	-0.45 (0.74)	-1.6	-1.10	-0.20	0.10	0.4	
		Week 20	Tezepelumab	9	9 (100.0)	-0.53 (0.56)	-1.2	-1.00	-0.40	-0.20	0.4	-0.32 [-1.28, 0.64]
			Placebo	10	8 (80.0)	-0.33 (0.75)	-1.4	-0.80	-0.40	0.10	1.0	
		Week 22	Tezepelumab	9	9 (100.0)	-0.60 (0.44)	-1.2	-0.80	-0.60	-0.20	0.0	-0.30 [-1.26, 0.65]
			Placebo	10	8 (80.0)	-0.40 (0.84)	-1.4	-1.00	-0.60	0.10	1.2	
		Week 24	Tezepelumab	9	9 (100.0)	-0.78 (0.62)	-1.6	-1.40	-0.80	-0.40	0.2	-0.89 [-1.90, 0.11]
			Placebo	10	8 (80.0)	-0.20 (0.68)	-1.2	-0.70	-0.10	0.10	1.0	
		Week 26	Tezepelumab	9	9 (100.0)	-0.69 (0.69)	-2.0	-1.00	-0.60	-0.20	0.0	-0.38 [-1.34, 0.59]
			Placebo	10	8 (80.0)	-0.35 (1.10)	-1.8	-1.30	-0.20	0.20	1.6	
		Week 28	Tezepelumab	9	9 (100.0)	-0.44 (0.80)	-1.2	-1.00	-0.80	0.00	1.0	-0.05 [-0.97, 0.88]
			Placebo	10	9 (90.0)	-0.40 (1.06)	-2.0	-0.60	-0.20	0.00	1.6	
		Week 30	Tezepelumab	9	9 (100.0)	-0.64 (0.56)	-1.4	-1.00	-0.80	-0.20	0.4	-0.19 [-1.12, 0.73]
			Placebo	10	9 (90.0)	-0.51 (0.79)	-1.8	-1.00	-0.40	0.20	0.6	
		Week 32	Tezepelumab	9	9 (100.0)	-0.93 (0.67)	-2.2	-1.00	-1.00	-0.80	0.4	-0.51 [-1.45, 0.43]
			Placebo	10	9 (90.0)	-0.58 (0.72)	-1.8	-1.00	-0.40	0.00	0.2	
		Week 34	Tezepelumab	9	9 (100.0)	-0.80 (0.82)	-2.0	-1.40	-0.60	-0.40	0.6	-0.40 [-1.34, 0.53]
			Placebo	10	9 (90.0)	-0.51 (0.59)	-1.2	-1.00	-0.60	-0.20	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 65 years	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-0.96 (0.79)	-2.0	-1.20	-1.20	-0.80	0.6	-0.84 [-1.81, 0.13]
			Placebo	10	9 (90.0)	-0.36 (0.63)	-1.2	-0.80	-0.40	0.00	0.8	
		Week 38	Tezepelumab	9	9 (100.0)	-0.82 (0.66)	-1.6	-1.20	-0.80	-0.60	0.6	-0.37 [-1.30, 0.57]
			Placebo	10	9 (90.0)	-0.60 (0.55)	-1.2	-1.00	-0.60	-0.40	0.2	
		Week 40	Tezepelumab	9	9 (100.0)	-1.04 (0.71)	-2.0	-1.40	-1.20	-0.80	0.4	-0.99 [-1.98, -0.01]
			Placebo	10	9 (90.0)	-0.24 (0.89)	-1.6	-0.40	-0.20	0.20	1.4	
		Week 42	Tezepelumab	9	9 (100.0)	-1.07 (0.82)	-2.0	-1.80	-1.20	-0.80	0.4	-0.45 [-1.39, 0.48]
			Placebo	10	9 (90.0)	-0.69 (0.84)	-1.6	-1.40	-0.80	-0.40	1.0	
		Week 44	Tezepelumab	9	9 (100.0)	-1.02 (0.78)	-1.8	-1.60	-1.20	-0.60	0.4	-0.54 [-1.48, 0.40]
			Placebo	10	9 (90.0)	-0.60 (0.79)	-1.8	-1.20	-0.60	0.00	0.6	
		Week 46	Tezepelumab	9	9 (100.0)	-0.80 (0.70)	-1.6	-1.40	-0.80	-0.40	0.4	-0.38 [-1.31, 0.55]
			Placebo	10	9 (90.0)	-0.49 (0.92)	-1.4	-1.00	-0.60	-0.40	1.6	
		Week 48	Tezepelumab	9	9 (100.0)	-1.07 (0.76)	-2.4	-1.60	-1.00	-0.80	0.0	-0.69 [-1.64, 0.27]
			Placebo	10	9 (90.0)	-0.44 (1.03)	-1.8	-1.00	-0.40	-0.40	1.8	
		Week 50	Tezepelumab	9	9 (100.0)	-1.09 (0.78)	-2.4	-1.40	-1.20	-0.80	0.2	-0.52 [-1.46, 0.42]
			Placebo	10	9 (90.0)	-0.73 (0.57)	-1.6	-1.20	-0.60	-0.40	0.2	
		Week 52	Tezepelumab	9	9 (100.0)	-1.16 (0.90)	-2.4	-1.80	-1.20	-0.80	0.4	-0.76 [-1.72, 0.20]
			Placebo	10	9 (90.0)	-0.60 (0.51)	-1.6	-0.80	-0.60	-0.40	0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	44	44 (100.0)	2.77 (0.77)	0.0	2.40	2.80	3.10	5.0	
			Placebo	45	45 (100.0)	2.86 (0.75)	0.4	2.60	2.80	3.20	4.8	
		Week 2	Tezepelumab	44	42 (95.5)	2.33 (0.88)	0.2	1.60	2.60	3.00	4.4	
			Placebo	45	39 (86.7)	2.42 (0.76)	0.4	2.00	2.40	3.00	4.8	
		Week 4	Tezepelumab	44	42 (95.5)	2.18 (0.91)	0.2	1.40	2.30	3.00	3.6	
			Placebo	45	39 (86.7)	2.10 (0.88)	0.2	1.40	2.40	2.80	3.6	
		Week 6	Tezepelumab	44	42 (95.5)	2.03 (0.91)	0.0	1.40	2.00	2.80	3.8	
			Placebo	45	39 (86.7)	2.11 (1.05)	0.2	1.20	2.20	3.00	4.6	
		Week 8	Tezepelumab	44	42 (95.5)	1.80 (0.97)	0.0	1.20	1.80	2.80	3.4	
			Placebo	45	40 (88.9)	2.07 (1.10)	0.0	1.30	2.20	2.80	4.6	
		Week 10	Tezepelumab	44	42 (95.5)	1.71 (0.96)	0.0	1.00	1.60	2.40	3.6	
			Placebo	45	40 (88.9)	2.07 (0.99)	0.0	1.60	2.30	2.70	4.4	
		Week 12	Tezepelumab	44	42 (95.5)	1.63 (0.98)	0.0	0.60	1.60	2.60	3.0	
			Placebo	45	40 (88.9)	1.86 (1.00)	0.0	1.00	2.00	2.60	4.4	
		Week 14	Tezepelumab	44	42 (95.5)	1.62 (1.01)	0.0	0.60	1.60	2.40	3.8	
			Placebo	45	40 (88.9)	1.89 (0.93)	0.0	1.30	2.00	2.40	5.0	
		Week 16	Tezepelumab	44	42 (95.5)	1.71 (1.09)	0.0	0.80	1.80	2.40	4.6	
			Placebo	45	40 (88.9)	1.98 (1.01)	0.0	1.00	2.10	2.80	4.4	
		Week 18	Tezepelumab	44	43 (97.7)	1.74 (0.89)	0.0	1.20	1.80	2.40	3.4	
			Placebo	45	40 (88.9)	1.89 (1.02)	0.0	1.30	2.00	2.60	4.4	
		Week 20	Tezepelumab	44	43 (97.7)	1.65 (0.96)	0.0	1.00	1.80	2.40	3.6	
			Placebo	45	40 (88.9)	1.99 (1.01)	0.0	1.30	2.10	2.80	4.4	
		Week 22	Tezepelumab	44	43 (97.7)	1.79 (0.86)	0.0	1.20	2.00	2.40	3.4	
			Placebo	45	40 (88.9)	1.89 (1.05)	0.0	1.10	2.00	2.60	4.4	
		Week 24	Tezepelumab	44	43 (97.7)	1.74 (1.00)	0.0	1.20	1.80	2.60	3.6	
			Placebo	45	40 (88.9)	2.01 (0.96)	0.0	1.60	2.00	2.60	4.4	
		Week 26	Tezepelumab	44	44 (100.0)	1.79 (0.97)	0.0	1.20	1.80	2.60	3.6	
			Placebo	45	40 (88.9)	1.88 (1.03)	0.0	1.10	1.70	2.50	4.4	
		Week 28	Tezepelumab	44	44 (100.0)	1.75 (1.01)	0.0	1.20	1.80	2.40	3.6	
			Placebo	45	41 (91.1)	1.89 (1.17)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	44	44 (100.0)	1.73 (0.97)	0.0	1.20	1.70	2.40	3.8	
			Placebo	45	41 (91.1)	1.84 (1.15)	0.0	1.00	2.00	2.60	4.4	
		Week 32	Tezepelumab	44	44 (100.0)	1.60 (0.99)	0.0	1.00	1.70	2.40	3.6	
			Placebo	45	41 (91.1)	1.80 (1.04)	0.0	1.00	1.80	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
<= 2	Absolute values	Week 34	Tezepelumab	44	44 (100.0)	1.70 (1.12)	0.0	1.00	1.50	2.70	4.2	
			Placebo	45	41 (91.1)	1.81 (0.97)	0.0	1.20	1.80	2.40	4.4	
		Week 36	Tezepelumab	44	44 (100.0)	1.73 (1.03)	0.0	1.00	1.90	2.50	3.6	
			Placebo	45	41 (91.1)	1.80 (1.04)	0.0	1.00	1.80	2.60	4.4	
		Week 38	Tezepelumab	44	44 (100.0)	1.70 (1.14)	0.0	1.00	1.70	2.40	4.4	
			Placebo	45	41 (91.1)	1.76 (0.98)	0.0	1.00	1.80	2.40	4.4	
		Week 40	Tezepelumab	44	44 (100.0)	1.70 (1.11)	0.0	0.90	1.90	2.60	3.8	
			Placebo	45	41 (91.1)	1.89 (1.13)	0.0	1.00	1.80	2.80	4.4	
		Week 42	Tezepelumab	44	44 (100.0)	1.65 (1.08)	0.0	0.80	1.80	2.40	4.0	
			Placebo	45	41 (91.1)	1.85 (1.03)	0.0	1.00	2.00	2.60	4.4	
		Week 44	Tezepelumab	44	44 (100.0)	1.74 (1.02)	0.0	0.90	1.90	2.60	3.4	
			Placebo	45	41 (91.1)	1.81 (1.04)	0.0	1.20	1.80	2.60	4.4	
		Week 46	Tezepelumab	44	44 (100.0)	1.76 (1.12)	0.0	0.80	2.00	2.70	3.6	
			Placebo	45	41 (91.1)	1.85 (1.01)	0.0	1.20	2.00	2.40	4.4	
		Week 48	Tezepelumab	44	44 (100.0)	1.75 (1.13)	0.0	0.90	1.90	2.60	4.2	
			Placebo	45	41 (91.1)	1.83 (1.12)	0.0	1.00	2.00	2.40	4.6	
		Week 50	Tezepelumab	44	44 (100.0)	1.64 (1.10)	0.0	1.00	1.40	2.40	4.2	
			Placebo	45	41 (91.1)	1.68 (0.97)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	44	44 (100.0)	1.66 (1.08)	0.0	0.90	1.70	2.40	4.2	
			Placebo	45	41 (91.1)	1.78 (1.00)	0.0	1.00	1.80	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	44	42 (95.5)	-0.48 (0.64)	-2.2	-0.80	-0.40	0.00	0.8	0.05 [-0.39, 0.49]
			Placebo	45	39 (86.7)	-0.51 (0.64)	-2.4	-1.00	-0.40	0.00	0.4	
		Week 4	Tezepelumab	44	42 (95.5)	-0.63 (0.71)	-2.6	-1.00	-0.60	0.00	0.8	0.23 [-0.20, 0.67]
			Placebo	45	39 (86.7)	-0.83 (0.93)	-3.0	-1.40	-0.80	-0.20	0.8	
		Week 6	Tezepelumab	44	42 (95.5)	-0.79 (0.76)	-2.8	-1.40	-0.80	0.00	0.4	0.03 [-0.40, 0.47]
			Placebo	45	39 (86.7)	-0.82 (1.00)	-3.4	-1.60	-0.60	0.00	0.6	
		Week 8	Tezepelumab	44	42 (95.5)	-1.01 (0.76)	-2.8	-1.60	-1.00	-0.40	0.2	-0.15 [-0.58, 0.29]
			Placebo	45	40 (88.9)	-0.87 (1.09)	-3.6	-1.60	-0.70	0.00	1.0	
		Week 10	Tezepelumab	44	42 (95.5)	-1.10 (0.83)	-2.8	-1.60	-1.20	-0.60	1.0	-0.26 [-0.69, 0.18]
			Placebo	45	40 (88.9)	-0.87 (1.00)	-3.8	-1.40	-0.60	0.00	0.6	
		Week 12	Tezepelumab	44	42 (95.5)	-1.19 (0.81)	-2.8	-1.80	-1.20	-0.60	0.4	-0.12 [-0.55, 0.32]
			Placebo	45	40 (88.9)	-1.08 (0.98)	-3.8	-1.50	-0.90	-0.30	0.2	
		Week 14	Tezepelumab	44	42 (95.5)	-1.20 (0.78)	-2.6	-1.80	-1.20	-0.60	0.4	-0.16 [-0.60, 0.27]
			Placebo	45	40 (88.9)	-1.05 (1.00)	-3.4	-1.60	-1.00	-0.40	1.0	
		Week 16	Tezepelumab	44	42 (95.5)	-1.10 (0.92)	-2.8	-1.80	-1.00	-0.60	1.8	-0.14 [-0.58, 0.29]
			Placebo	45	40 (88.9)	-0.96 (1.01)	-3.6	-1.40	-0.80	-0.20	0.6	
		Week 18	Tezepelumab	44	43 (97.7)	-1.05 (0.74)	-2.8	-1.40	-1.00	-0.80	0.4	0.00 [-0.43, 0.43]
			Placebo	45	40 (88.9)	-1.06 (1.03)	-3.6	-1.90	-0.90	-0.20	0.4	
		Week 20	Tezepelumab	44	43 (97.7)	-1.15 (0.81)	-2.8	-1.80	-1.20	-0.60	0.4	-0.21 [-0.65, 0.22]
			Placebo	45	40 (88.9)	-0.95 (1.04)	-3.6	-1.40	-0.70	-0.20	1.0	
		Week 22	Tezepelumab	44	43 (97.7)	-1.00 (0.87)	-2.8	-1.60	-1.00	-0.60	2.0	0.05 [-0.38, 0.48]
			Placebo	45	40 (88.9)	-1.05 (1.02)	-3.8	-1.70	-1.00	-0.40	1.2	
		Week 24	Tezepelumab	44	43 (97.7)	-1.05 (0.87)	-2.8	-1.80	-1.00	-0.40	0.6	-0.13 [-0.56, 0.30]
			Placebo	45	40 (88.9)	-0.93 (1.02)	-3.6	-1.40	-0.80	-0.10	1.0	
		Week 26	Tezepelumab	44	44 (100.0)	-0.98 (0.87)	-2.8	-1.60	-0.90	-0.20	0.6	0.09 [-0.34, 0.52]
			Placebo	45	40 (88.9)	-1.07 (1.02)	-3.4	-1.80	-1.20	-0.40	1.6	
		Week 28	Tezepelumab	44	44 (100.0)	-1.03 (0.99)	-2.8	-1.90	-0.90	-0.40	1.0	-0.03 [-0.46, 0.39]
			Placebo	45	41 (91.1)	-0.99 (1.15)	-3.4	-1.80	-1.20	-0.20	1.6	
		Week 30	Tezepelumab	44	44 (100.0)	-1.05 (0.93)	-2.8	-1.60	-1.00	-0.50	2.0	-0.01 [-0.43, 0.42]
			Placebo	45	41 (91.1)	-1.04 (1.20)	-3.4	-1.60	-1.20	-0.20	2.0	
		Week 32	Tezepelumab	44	44 (100.0)	-1.18 (0.90)	-2.8	-1.90	-1.10	-0.60	1.0	-0.11 [-0.53, 0.32]
			Placebo	45	41 (91.1)	-1.07 (1.04)	-3.2	-1.60	-1.00	-0.40	0.8	
		Week 34	Tezepelumab	44	44 (100.0)	-1.07 (1.03)	-2.8	-1.90	-1.30	-0.30	2.2	-0.00 [-0.43, 0.42]
			Placebo	45	41 (91.1)	-1.07 (0.94)	-3.2	-1.60	-1.00	-0.20	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
<= 2	Change from baseline	Week 36	Tezepelumab	44	44 (100.0)	-1.05 (0.99)	-2.8	-1.80	-1.20	-0.20	1.6	0.03 [-0.40, 0.45]
			Placebo	45	41 (91.1)	-1.07 (1.01)	-3.6	-1.60	-1.00	-0.40	0.8	
		Week 38	Tezepelumab	44	44 (100.0)	-1.07 (1.06)	-2.8	-1.90	-1.20	-0.40	2.6	0.05 [-0.38, 0.47]
			Placebo	45	41 (91.1)	-1.12 (0.86)	-3.0	-1.60	-1.00	-0.60	0.2	
		Week 40	Tezepelumab	44	44 (100.0)	-1.07 (1.01)	-2.8	-1.80	-1.10	-0.40	1.8	-0.08 [-0.51, 0.34]
			Placebo	45	41 (91.1)	-0.99 (1.03)	-3.2	-1.60	-1.00	-0.40	1.4	
		Week 42	Tezepelumab	44	44 (100.0)	-1.13 (1.02)	-3.0	-2.00	-1.20	-0.40	2.2	-0.10 [-0.53, 0.33]
			Placebo	45	41 (91.1)	-1.03 (0.95)	-2.8	-1.60	-1.00	-0.40	1.0	
		Week 44	Tezepelumab	44	44 (100.0)	-1.03 (0.96)	-2.8	-1.80	-0.90	-0.30	1.6	0.03 [-0.39, 0.46]
			Placebo	45	41 (91.1)	-1.06 (0.98)	-3.4	-1.60	-1.00	-0.40	0.6	
		Week 46	Tezepelumab	44	44 (100.0)	-1.01 (1.03)	-3.0	-1.60	-1.00	-0.20	1.8	0.02 [-0.41, 0.44]
			Placebo	45	41 (91.1)	-1.03 (0.94)	-2.8	-1.60	-1.00	-0.60	1.6	
		Week 48	Tezepelumab	44	44 (100.0)	-1.02 (1.02)	-2.8	-1.80	-1.00	-0.40	2.0	0.02 [-0.40, 0.45]
			Placebo	45	41 (91.1)	-1.05 (1.07)	-3.4	-1.60	-1.00	-0.40	1.8	
		Week 50	Tezepelumab	44	44 (100.0)	-1.13 (1.04)	-2.8	-1.80	-1.20	-0.40	2.0	0.07 [-0.36, 0.49]
			Placebo	45	41 (91.1)	-1.20 (0.84)	-3.6	-1.60	-1.20	-0.60	0.2	
		Week 52	Tezepelumab	44	44 (100.0)	-1.11 (1.03)	-3.0	-1.80	-1.20	-0.40	2.0	-0.01 [-0.44, 0.41]
			Placebo	45	41 (91.1)	-1.10 (0.88)	-3.6	-1.60	-1.00	-0.60	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	22	22 (100.0)	3.06 (1.06)	0.2	2.40	3.10	3.40	5.2	
			Placebo	20	20 (100.0)	2.87 (0.81)	1.0	2.60	3.00	3.30	5.0	
		Week 2	Tezepelumab	22	21 (95.5)	2.36 (1.27)	0.0	1.20	2.80	3.40	4.0	
			Placebo	20	19 (95.0)	2.36 (0.89)	0.4	2.00	2.40	2.60	5.0	
		Week 4	Tezepelumab	22	21 (95.5)	1.88 (1.16)	0.2	0.80	2.00	2.80	3.4	
			Placebo	20	19 (95.0)	2.56 (0.94)	0.8	2.00	2.60	3.40	4.2	
		Week 6	Tezepelumab	22	21 (95.5)	1.86 (1.27)	0.0	0.60	1.60	2.80	4.0	
			Placebo	20	19 (95.0)	2.42 (1.35)	1.0	1.40	2.00	3.00	6.0	
		Week 8	Tezepelumab	22	21 (95.5)	1.84 (1.54)	0.0	0.60	1.80	3.00	5.2	
			Placebo	20	19 (95.0)	2.25 (1.25)	0.2	1.00	2.40	3.20	5.0	
		Week 10	Tezepelumab	22	21 (95.5)	1.74 (1.46)	0.0	0.40	1.80	2.80	4.8	
			Placebo	20	19 (95.0)	2.33 (1.27)	0.4	1.00	2.20	3.00	5.2	
		Week 12	Tezepelumab	22	21 (95.5)	1.58 (1.35)	0.0	0.60	1.60	2.60	4.8	
			Placebo	20	19 (95.0)	2.12 (1.17)	0.0	1.00	2.20	3.00	4.4	
		Week 14	Tezepelumab	22	21 (95.5)	1.43 (1.34)	0.0	0.40	1.20	2.00	4.8	
			Placebo	20	19 (95.0)	1.83 (1.16)	0.0	1.00	1.80	2.40	5.0	
		Week 16	Tezepelumab	22	21 (95.5)	1.70 (1.38)	0.0	0.80	1.40	2.80	4.8	
			Placebo	20	19 (95.0)	2.15 (1.57)	0.0	0.60	2.00	3.20	5.0	
		Week 18	Tezepelumab	22	21 (95.5)	1.52 (1.41)	0.0	0.40	1.00	2.60	4.8	
			Placebo	20	19 (95.0)	2.03 (1.49)	0.0	1.00	2.00	2.80	5.0	
		Week 20	Tezepelumab	22	21 (95.5)	1.74 (1.47)	0.0	0.60	1.20	2.60	5.0	
			Placebo	20	19 (95.0)	2.13 (1.33)	0.2	1.20	2.00	3.00	5.0	
		Week 22	Tezepelumab	22	21 (95.5)	1.74 (1.34)	0.0	0.60	2.00	2.60	4.8	
			Placebo	20	19 (95.0)	2.18 (1.38)	0.0	1.00	2.40	3.40	5.0	
		Week 24	Tezepelumab	22	21 (95.5)	1.73 (1.32)	0.0	0.80	1.60	2.60	4.8	
			Placebo	20	19 (95.0)	2.13 (1.29)	0.0	0.80	2.40	3.40	4.0	
		Week 26	Tezepelumab	22	21 (95.5)	1.79 (1.42)	0.0	0.80	1.60	2.80	4.8	
			Placebo	20	19 (95.0)	2.20 (1.35)	0.0	1.00	2.20	3.40	4.0	
		Week 28	Tezepelumab	22	22 (100.0)	1.71 (1.43)	0.0	0.40	1.70	2.80	4.8	
			Placebo	20	19 (95.0)	2.12 (1.36)	0.0	0.80	2.40	3.40	4.0	
		Week 30	Tezepelumab	22	22 (100.0)	1.65 (1.35)	0.0	0.60	1.20	2.80	4.8	
			Placebo	20	19 (95.0)	2.15 (1.25)	0.0	1.00	2.00	3.40	4.0	
		Week 32	Tezepelumab	22	22 (100.0)	1.70 (1.37)	0.0	0.60	1.40	2.80	4.8	
			Placebo	20	19 (95.0)	2.12 (1.33)	0.4	0.80	1.80	3.40	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 2	Absolute values	Week 34	Tezepelumab	22	22 (100.0)	1.73 (1.35)	0.0	0.80	1.70	2.80	4.8	
			Placebo	20	19 (95.0)	2.02 (1.46)	0.0	0.80	2.00	3.40	4.8	
		Week 36	Tezepelumab	22	22 (100.0)	1.55 (1.27)	0.0	0.80	1.20	2.40	4.8	
			Placebo	20	19 (95.0)	2.59 (1.35)	0.0	1.60	2.80	3.40	4.8	
		Week 38	Tezepelumab	22	22 (100.0)	1.75 (1.42)	0.0	0.60	1.80	2.60	4.8	
			Placebo	20	19 (95.0)	2.27 (1.36)	0.0	1.00	2.00	3.40	4.8	
		Week 40	Tezepelumab	22	22 (100.0)	1.68 (1.35)	0.0	0.40	1.70	2.80	4.8	
			Placebo	20	19 (95.0)	2.43 (1.27)	0.0	1.80	2.40	3.40	4.4	
		Week 42	Tezepelumab	22	22 (100.0)	1.64 (1.30)	0.0	1.00	1.50	2.80	4.8	
			Placebo	20	19 (95.0)	2.08 (1.14)	0.0	1.20	2.20	2.60	4.6	
		Week 44	Tezepelumab	22	22 (100.0)	1.55 (1.36)	0.0	0.40	1.10	2.80	4.8	
			Placebo	20	19 (95.0)	2.42 (1.18)	0.6	1.20	2.40	3.40	4.2	
		Week 46	Tezepelumab	22	22 (100.0)	1.61 (1.34)	0.0	0.60	1.40	2.60	4.8	
			Placebo	20	19 (95.0)	1.96 (1.03)	0.0	1.00	2.00	2.60	4.0	
		Week 48	Tezepelumab	22	22 (100.0)	1.64 (1.32)	0.0	0.60	1.30	2.80	4.8	
			Placebo	20	19 (95.0)	2.19 (1.04)	0.0	1.80	2.40	2.60	4.0	
		Week 50	Tezepelumab	22	22 (100.0)	1.66 (1.42)	0.0	0.60	1.40	2.80	4.8	
			Placebo	20	19 (95.0)	2.13 (1.11)	0.2	1.00	2.40	2.80	4.0	
		Week 52	Tezepelumab	22	22 (100.0)	1.71 (1.39)	0.0	0.80	1.60	2.80	4.8	
			Placebo	20	19 (95.0)	2.14 (1.24)	0.0	1.00	2.40	2.80	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	22	21 (95.5)	-0.72 (1.03)	-3.2	-1.40	-0.40	0.20	0.8	-0.25 [-0.87, 0.38]
			Placebo	20	19 (95.0)	-0.48 (0.90)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	22	21 (95.5)	-1.21 (1.18)	-2.6	-2.00	-1.20	-0.80	2.6	-0.86 [-1.51, -0.21]
			Placebo	20	19 (95.0)	-0.28 (0.95)	-2.2	-1.40	0.00	0.40	1.2	
		Week 6	Tezepelumab	22	21 (95.5)	-1.23 (1.39)	-2.8	-2.20	-1.60	-0.60	2.6	-0.63 [-1.27, 0.00]
			Placebo	20	19 (95.0)	-0.42 (1.13)	-1.8	-1.20	-0.60	0.40	1.6	
		Week 8	Tezepelumab	22	21 (95.5)	-1.25 (1.70)	-3.2	-2.80	-1.60	-0.40	2.6	-0.47 [-1.10, 0.16]
			Placebo	20	19 (95.0)	-0.59 (0.98)	-2.8	-1.20	-0.40	0.00	1.0	
		Week 10	Tezepelumab	22	21 (95.5)	-1.34 (1.56)	-3.4	-2.80	-1.60	0.00	2.6	-0.55 [-1.18, 0.08]
			Placebo	20	19 (95.0)	-0.52 (1.43)	-2.2	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	22	21 (95.5)	-1.50 (1.53)	-3.2	-2.80	-1.80	-0.80	2.6	-0.55 [-1.18, 0.08]
			Placebo	20	19 (95.0)	-0.73 (1.26)	-3.0	-1.80	-0.80	0.20	1.6	
		Week 14	Tezepelumab	22	21 (95.5)	-1.66 (1.56)	-4.0	-2.80	-2.00	-0.80	2.6	-0.45 [-1.08, 0.17]
			Placebo	20	19 (95.0)	-1.01 (1.25)	-3.0	-1.60	-1.40	-0.60	2.4	
		Week 16	Tezepelumab	22	21 (95.5)	-1.39 (1.50)	-3.2	-2.40	-1.80	-0.40	2.6	-0.47 [-1.10, 0.16]
			Placebo	20	19 (95.0)	-0.69 (1.48)	-3.0	-1.40	-1.00	0.00	2.6	
		Week 18	Tezepelumab	22	21 (95.5)	-1.56 (1.57)	-3.8	-2.80	-1.80	-0.40	2.6	-0.48 [-1.11, 0.15]
			Placebo	20	19 (95.0)	-0.81 (1.59)	-3.2	-2.00	-1.00	-0.20	2.6	
		Week 20	Tezepelumab	22	21 (95.5)	-1.34 (1.55)	-3.4	-2.60	-1.60	-0.40	2.6	-0.42 [-1.04, 0.21]
			Placebo	20	19 (95.0)	-0.72 (1.46)	-3.0	-1.60	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	22	21 (95.5)	-1.34 (1.54)	-3.2	-2.60	-1.80	-0.60	2.6	-0.45 [-1.08, 0.18]
			Placebo	20	19 (95.0)	-0.66 (1.46)	-3.2	-1.60	-1.00	0.00	2.6	
		Week 24	Tezepelumab	22	21 (95.5)	-1.35 (1.45)	-3.4	-2.40	-1.60	-0.80	2.6	-0.45 [-1.08, 0.18]
			Placebo	20	19 (95.0)	-0.72 (1.36)	-3.0	-1.80	-1.00	0.20	2.6	
		Week 26	Tezepelumab	22	21 (95.5)	-1.30 (1.55)	-3.0	-2.60	-1.40	-0.40	2.6	-0.43 [-1.06, 0.20]
			Placebo	20	19 (95.0)	-0.64 (1.50)	-3.0	-1.80	-0.60	0.40	2.6	
		Week 28	Tezepelumab	22	22 (100.0)	-1.35 (1.57)	-3.4	-2.80	-1.80	0.00	2.6	-0.42 [-1.04, 0.20]
			Placebo	20	19 (95.0)	-0.73 (1.41)	-3.0	-1.80	-0.80	0.00	2.6	
		Week 30	Tezepelumab	22	22 (100.0)	-1.42 (1.56)	-3.8	-2.60	-1.90	-0.40	2.6	-0.50 [-1.12, 0.12]
			Placebo	20	19 (95.0)	-0.69 (1.30)	-2.6	-1.60	-1.00	-0.20	2.6	
		Week 32	Tezepelumab	22	22 (100.0)	-1.36 (1.45)	-3.2	-2.40	-1.60	-0.60	2.6	-0.45 [-1.07, 0.18]
			Placebo	20	19 (95.0)	-0.73 (1.41)	-2.4	-1.60	-1.40	-0.20	2.6	
		Week 34	Tezepelumab	22	22 (100.0)	-1.34 (1.51)	-3.0	-2.60	-1.90	-0.40	2.6	-0.34 [-0.96, 0.28]
			Placebo	20	19 (95.0)	-0.82 (1.54)	-3.2	-1.80	-1.20	0.00	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 2	Change from baseline	Week 36	Tezepelumab	22	22 (100.0)	-1.52 (1.46)	-3.2	-2.60	-1.90	-0.80	2.6	-0.87 [-1.51, -0.22]
			Placebo	20	19 (95.0)	-0.25 (1.46)	-3.2	-1.40	-0.20	0.80	2.6	
		Week 38	Tezepelumab	22	22 (100.0)	-1.32 (1.53)	-3.2	-2.40	-1.90	0.00	2.6	-0.49 [-1.11, 0.14]
			Placebo	20	19 (95.0)	-0.57 (1.57)	-3.2	-2.00	-0.40	0.40	2.6	
		Week 40	Tezepelumab	22	22 (100.0)	-1.38 (1.54)	-3.4	-2.60	-1.60	-0.40	2.6	-0.64 [-1.27, -0.01]
			Placebo	20	19 (95.0)	-0.41 (1.50)	-2.8	-1.60	-0.20	0.80	2.6	
		Week 42	Tezepelumab	22	22 (100.0)	-1.43 (1.52)	-3.6	-2.40	-1.80	-0.40	2.6	-0.46 [-1.08, 0.16]
			Placebo	20	19 (95.0)	-0.76 (1.39)	-2.8	-1.60	-1.00	0.00	2.6	
		Week 44	Tezepelumab	22	22 (100.0)	-1.51 (1.56)	-3.8	-2.80	-1.50	-0.80	2.6	-0.73 [-1.37, -0.10]
			Placebo	20	19 (95.0)	-0.42 (1.39)	-2.4	-1.60	-0.60	0.80	2.6	
		Week 46	Tezepelumab	22	22 (100.0)	-1.45 (1.49)	-3.6	-2.40	-1.70	-0.80	2.6	-0.41 [-1.03, 0.21]
			Placebo	20	19 (95.0)	-0.88 (1.30)	-3.2	-1.60	-1.00	0.00	2.6	
		Week 48	Tezepelumab	22	22 (100.0)	-1.43 (1.47)	-3.0	-2.60	-1.90	-0.40	2.6	-0.57 [-1.19, 0.06]
			Placebo	20	19 (95.0)	-0.65 (1.23)	-3.2	-1.60	-0.60	0.00	2.6	
		Week 50	Tezepelumab	22	22 (100.0)	-1.40 (1.52)	-3.2	-2.60	-2.00	-0.40	2.6	-0.47 [-1.09, 0.15]
			Placebo	20	19 (95.0)	-0.72 (1.39)	-2.8	-1.60	-0.60	0.00	2.6	
		Week 52	Tezepelumab	22	22 (100.0)	-1.35 (1.51)	-3.2	-2.60	-1.60	-0.20	2.6	-0.43 [-1.06, 0.19]
			Placebo	20	19 (95.0)	-0.71 (1.48)	-2.8	-2.00	-0.60	0.00	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	2.87 (0.92)	0.0	2.40	2.80	3.20	5.2	
			Placebo	58	58 (100.0)	2.84 (0.75)	0.4	2.60	3.00	3.20	4.8	
		Week 2	Tezepelumab	60	57 (95.0)	2.40 (0.99)	0.2	1.60	2.60	3.00	4.4	
			Placebo	58	51 (87.9)	2.38 (0.75)	0.4	2.00	2.40	2.80	4.8	
		Week 4	Tezepelumab	60	57 (95.0)	2.12 (1.00)	0.2	1.40	2.20	3.00	3.6	
			Placebo	58	51 (87.9)	2.22 (0.90)	0.2	1.80	2.40	2.80	4.2	
		Week 6	Tezepelumab	60	57 (95.0)	2.02 (1.04)	0.0	1.40	2.00	2.80	4.0	
			Placebo	58	51 (87.9)	2.20 (1.07)	0.2	1.40	2.20	3.00	5.0	
		Week 8	Tezepelumab	60	57 (95.0)	1.87 (1.19)	0.0	1.00	1.80	2.80	5.2	
			Placebo	58	52 (89.7)	2.10 (1.09)	0.0	1.30	2.30	2.90	4.6	
		Week 10	Tezepelumab	60	57 (95.0)	1.79 (1.15)	0.0	1.00	1.80	2.60	4.8	
			Placebo	58	52 (89.7)	2.13 (1.03)	0.0	1.60	2.30	2.90	4.4	
		Week 12	Tezepelumab	60	57 (95.0)	1.67 (1.10)	0.0	0.60	1.80	2.60	4.8	
			Placebo	58	52 (89.7)	1.94 (1.05)	0.0	1.00	2.00	2.60	4.4	
		Week 14	Tezepelumab	60	57 (95.0)	1.60 (1.15)	0.0	0.60	1.60	2.20	4.8	
			Placebo	58	52 (89.7)	1.85 (0.91)	0.0	1.30	2.00	2.40	5.0	
		Week 16	Tezepelumab	60	57 (95.0)	1.79 (1.21)	0.0	0.80	1.80	2.80	4.8	
			Placebo	58	52 (89.7)	2.00 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 18	Tezepelumab	60	58 (96.7)	1.75 (1.10)	0.0	1.00	1.80	2.60	4.8	
			Placebo	58	52 (89.7)	1.89 (1.13)	0.0	1.10	1.90	2.60	4.8	
		Week 20	Tezepelumab	60	58 (96.7)	1.75 (1.17)	0.0	0.80	1.80	2.60	5.0	
			Placebo	58	52 (89.7)	1.96 (1.06)	0.0	1.20	2.00	2.80	4.4	
		Week 22	Tezepelumab	60	58 (96.7)	1.85 (1.03)	0.0	1.20	2.00	2.60	4.8	
			Placebo	58	52 (89.7)	1.90 (1.10)	0.0	1.00	2.00	2.60	4.4	
		Week 24	Tezepelumab	60	58 (96.7)	1.80 (1.12)	0.0	1.20	1.80	2.60	4.8	
			Placebo	58	52 (89.7)	2.01 (1.04)	0.0	1.50	2.00	2.70	4.4	
		Week 26	Tezepelumab	60	59 (98.3)	1.87 (1.13)	0.0	1.20	1.80	2.80	4.8	
			Placebo	58	52 (89.7)	1.98 (1.10)	0.0	1.00	1.80	2.90	4.4	
		Week 28	Tezepelumab	60	60 (100.0)	1.81 (1.17)	0.0	1.20	1.80	2.70	4.8	
			Placebo	58	53 (91.4)	1.98 (1.19)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	60	60 (100.0)	1.77 (1.12)	0.0	1.10	1.80	2.60	4.8	
			Placebo	58	53 (91.4)	1.95 (1.15)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	60	60 (100.0)	1.68 (1.15)	0.0	0.70	1.80	2.60	4.8	
			Placebo	58	53 (91.4)	1.89 (1.13)	0.0	1.00	1.80	2.80	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Absolute values	Week 34	Tezepelumab	60	60 (100.0)	1.78 (1.21)	0.0	0.90	1.80	2.80	4.8	
			Placebo	58	53 (91.4)	1.89 (1.09)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	60	60 (100.0)	1.72 (1.13)	0.0	0.90	1.60	2.60	4.8	
			Placebo	58	53 (91.4)	2.00 (1.17)	0.0	1.20	2.00	2.80	4.8	
		Week 38	Tezepelumab	60	60 (100.0)	1.78 (1.25)	0.0	0.90	1.80	2.60	4.8	
			Placebo	58	53 (91.4)	1.92 (1.10)	0.0	1.00	1.80	2.60	4.8	
		Week 40	Tezepelumab	60	60 (100.0)	1.75 (1.21)	0.0	0.70	2.00	2.80	4.8	
			Placebo	58	53 (91.4)	2.06 (1.18)	0.0	1.20	2.20	3.00	4.4	
		Week 42	Tezepelumab	60	60 (100.0)	1.68 (1.18)	0.0	0.80	1.70	2.60	4.8	
			Placebo	58	53 (91.4)	1.95 (1.07)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	60	60 (100.0)	1.73 (1.16)	0.0	0.80	1.80	2.80	4.8	
			Placebo	58	53 (91.4)	1.98 (1.09)	0.0	1.20	2.00	2.60	4.4	
		Week 46	Tezepelumab	60	60 (100.0)	1.77 (1.22)	0.0	0.80	1.90	2.80	4.8	
			Placebo	58	53 (91.4)	1.92 (1.01)	0.0	1.20	2.00	2.40	4.4	
		Week 48	Tezepelumab	60	60 (100.0)	1.77 (1.22)	0.0	0.80	1.90	2.70	4.8	
			Placebo	58	53 (91.4)	1.93 (1.11)	0.0	1.00	2.00	2.40	4.6	
		Week 50	Tezepelumab	60	60 (100.0)	1.72 (1.22)	0.0	0.80	1.70	2.60	4.8	
			Placebo	58	53 (91.4)	1.81 (1.00)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	60	60 (100.0)	1.76 (1.20)	0.0	0.80	1.80	2.60	4.8	
			Placebo	58	53 (91.4)	1.91 (1.05)	0.0	1.00	2.00	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	60	57 (95.0)	-0.51 (0.74)	-2.2	-1.00	-0.40	0.20	0.8	-0.01 [-0.39, 0.37]
			Placebo	58	51 (87.9)	-0.51 (0.75)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	60	57 (95.0)	-0.79 (0.92)	-2.6	-1.20	-0.80	-0.20	2.6	-0.14 [-0.52, 0.24]
			Placebo	58	51 (87.9)	-0.66 (0.98)	-3.0	-1.40	-0.40	0.00	1.2	
		Week 6	Tezepelumab	60	57 (95.0)	-0.88 (1.02)	-2.8	-1.60	-1.00	-0.20	2.6	-0.20 [-0.58, 0.18]
			Placebo	58	51 (87.9)	-0.68 (1.08)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	60	57 (95.0)	-1.04 (1.16)	-3.2	-1.60	-1.00	-0.40	2.6	-0.21 [-0.59, 0.16]
			Placebo	58	52 (89.7)	-0.80 (1.06)	-3.6	-1.50	-0.60	0.00	1.0	
		Week 10	Tezepelumab	60	57 (95.0)	-1.12 (1.12)	-3.4	-1.80	-1.20	-0.60	2.6	-0.32 [-0.70, 0.06]
			Placebo	58	52 (89.7)	-0.76 (1.11)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	60	57 (95.0)	-1.24 (1.10)	-3.2	-2.20	-1.20	-0.60	2.6	-0.26 [-0.64, 0.11]
			Placebo	58	52 (89.7)	-0.95 (1.06)	-3.8	-1.50	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	60	57 (95.0)	-1.31 (1.13)	-4.0	-2.20	-1.20	-0.60	2.6	-0.25 [-0.63, 0.13]
			Placebo	58	52 (89.7)	-1.04 (0.99)	-3.4	-1.60	-1.00	-0.40	1.4	
		Week 16	Tezepelumab	60	57 (95.0)	-1.12 (1.17)	-3.2	-2.00	-1.00	-0.40	2.6	-0.20 [-0.58, 0.17]
			Placebo	58	52 (89.7)	-0.89 (1.11)	-3.6	-1.40	-0.90	-0.20	2.6	
		Week 18	Tezepelumab	60	58 (96.7)	-1.14 (1.11)	-3.8	-1.80	-1.00	-0.60	2.6	-0.13 [-0.50, 0.25]
			Placebo	58	52 (89.7)	-1.00 (1.17)	-3.6	-1.90	-0.90	-0.20	2.6	
		Week 20	Tezepelumab	60	58 (96.7)	-1.14 (1.12)	-3.4	-1.80	-1.10	-0.40	2.6	-0.19 [-0.56, 0.19]
			Placebo	58	52 (89.7)	-0.93 (1.12)	-3.6	-1.50	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	60	58 (96.7)	-1.04 (1.13)	-3.2	-1.60	-1.00	-0.60	2.6	-0.05 [-0.42, 0.32]
			Placebo	58	52 (89.7)	-0.99 (1.15)	-3.8	-1.60	-1.00	-0.30	2.6	
		Week 24	Tezepelumab	60	58 (96.7)	-1.09 (1.09)	-3.4	-1.80	-1.00	-0.40	2.6	-0.19 [-0.56, 0.19]
			Placebo	58	52 (89.7)	-0.88 (1.12)	-3.6	-1.50	-0.80	-0.10	2.6	
		Week 26	Tezepelumab	60	59 (98.3)	-1.01 (1.13)	-3.0	-2.00	-1.00	-0.20	2.6	-0.08 [-0.45, 0.29]
			Placebo	58	52 (89.7)	-0.92 (1.18)	-3.4	-1.80	-1.20	0.00	2.6	
		Week 28	Tezepelumab	60	60 (100.0)	-1.06 (1.22)	-3.4	-2.20	-0.90	0.00	2.6	-0.16 [-0.53, 0.21]
			Placebo	58	53 (91.4)	-0.86 (1.21)	-3.4	-1.60	-1.00	0.00	2.6	
		Week 30	Tezepelumab	60	60 (100.0)	-1.10 (1.19)	-3.8	-2.20	-1.00	-0.40	2.6	-0.18 [-0.55, 0.19]
			Placebo	58	53 (91.4)	-0.89 (1.23)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 32	Tezepelumab	60	60 (100.0)	-1.19 (1.13)	-3.2	-2.20	-1.20	-0.60	2.6	-0.21 [-0.58, 0.16]
			Placebo	58	53 (91.4)	-0.95 (1.18)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	60	60 (100.0)	-1.09 (1.22)	-3.0	-2.20	-1.20	-0.30	2.6	-0.11 [-0.48, 0.26]
			Placebo	58	53 (91.4)	-0.96 (1.14)	-3.2	-1.60	-1.20	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Change from baseline	Week 36	Tezepelumab	60	60 (100.0)	-1.15 (1.20)	-3.2	-2.00	-1.20	-0.20	2.6	-0.25 [-0.62, 0.12]
			Placebo	58	53 (91.4)	-0.85 (1.22)	-3.6	-1.40	-1.00	-0.20	2.6	
		Week 38	Tezepelumab	60	60 (100.0)	-1.09 (1.25)	-3.2	-2.20	-1.20	-0.10	2.6	-0.14 [-0.51, 0.23]
			Placebo	58	53 (91.4)	-0.92 (1.15)	-3.2	-1.60	-1.00	-0.40	2.6	
		Week 40	Tezepelumab	60	60 (100.0)	-1.12 (1.23)	-3.4	-2.20	-1.10	-0.40	2.6	-0.27 [-0.64, 0.10]
			Placebo	58	53 (91.4)	-0.78 (1.22)	-3.2	-1.40	-0.80	0.00	2.6	
		Week 42	Tezepelumab	60	60 (100.0)	-1.19 (1.24)	-3.6	-2.10	-1.20	-0.40	2.6	-0.24 [-0.61, 0.13]
			Placebo	58	53 (91.4)	-0.90 (1.16)	-2.8	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	60	60 (100.0)	-1.14 (1.22)	-3.8	-2.10	-1.20	-0.40	2.6	-0.23 [-0.60, 0.14]
			Placebo	58	53 (91.4)	-0.86 (1.15)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 46	Tezepelumab	60	60 (100.0)	-1.10 (1.23)	-3.6	-2.20	-1.10	-0.20	2.6	-0.15 [-0.52, 0.22]
			Placebo	58	53 (91.4)	-0.92 (1.11)	-3.2	-1.40	-1.00	-0.40	2.6	
		Week 48	Tezepelumab	60	60 (100.0)	-1.10 (1.22)	-3.0	-2.20	-1.00	-0.40	2.6	-0.15 [-0.52, 0.22]
			Placebo	58	53 (91.4)	-0.92 (1.18)	-3.4	-1.40	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	60	60 (100.0)	-1.15 (1.22)	-3.0	-2.20	-1.20	-0.30	2.6	-0.10 [-0.47, 0.27]
			Placebo	58	53 (91.4)	-1.04 (1.03)	-3.6	-1.60	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	60	60 (100.0)	-1.11 (1.20)	-3.0	-2.10	-1.20	-0.20	2.6	-0.15 [-0.52, 0.22]
			Placebo	58	53 (91.4)	-0.94 (1.07)	-3.6	-1.60	-0.80	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	3.20 (0.00)	3.2	3.20	3.20	3.20	3.2	
			Placebo	2	2 (100.0)	2.40 (0.28)	2.2	2.20	2.40	2.60	2.6	
		Week 2	Tezepelumab	2	2 (100.0)	1.20 (1.70)	0.0	0.00	1.20	2.40	2.4	
			Placebo	2	2 (100.0)	1.70 (0.42)	1.4	1.40	1.70	2.00	2.0	
		Week 4	Tezepelumab	2	2 (100.0)	1.30 (0.71)	0.8	0.80	1.30	1.80	1.8	
			Placebo	2	2 (100.0)	1.90 (1.56)	0.8	0.80	1.90	3.00	3.0	
		Week 6	Tezepelumab	2	2 (100.0)	1.00 (0.85)	0.4	0.40	1.00	1.60	1.6	
			Placebo	2	2 (100.0)	1.50 (0.71)	1.0	1.00	1.50	2.00	2.0	
		Week 8	Tezepelumab	2	2 (100.0)	0.70 (0.71)	0.2	0.20	0.70	1.20	1.2	
			Placebo	2	2 (100.0)	2.10 (1.56)	1.0	1.00	2.10	3.20	3.2	
		Week 10	Tezepelumab	2	2 (100.0)	0.40 (0.28)	0.2	0.20	0.40	0.60	0.6	
			Placebo	2	2 (100.0)	3.10 (2.97)	1.0	1.00	3.10	5.20	5.2	
		Week 12	Tezepelumab	2	2 (100.0)	0.80 (0.28)	0.6	0.60	0.80	1.00	1.0	
			Placebo	2	2 (100.0)	2.40 (1.98)	1.0	1.00	2.40	3.80	3.8	
		Week 14	Tezepelumab	2	2 (100.0)	0.70 (0.42)	0.4	0.40	0.70	1.00	1.0	
			Placebo	2	2 (100.0)	3.00 (2.83)	1.0	1.00	3.00	5.00	5.0	
		Week 16	Tezepelumab	2	2 (100.0)	0.90 (0.14)	0.8	0.80	0.90	1.00	1.0	
			Placebo	2	2 (100.0)	3.00 (2.83)	1.0	1.00	3.00	5.00	5.0	
		Week 18	Tezepelumab	2	2 (100.0)	0.70 (0.42)	0.4	0.40	0.70	1.00	1.0	
			Placebo	2	2 (100.0)	3.00 (2.83)	1.0	1.00	3.00	5.00	5.0	
		Week 20	Tezepelumab	2	2 (100.0)	0.80 (0.28)	0.6	0.60	0.80	1.00	1.0	
			Placebo	2	2 (100.0)	2.70 (3.25)	0.4	0.40	2.70	5.00	5.0	
		Week 22	Tezepelumab	2	2 (100.0)	1.00 (0.00)	1.0	1.00	1.00	1.00	1.0	
			Placebo	2	2 (100.0)	2.70 (3.25)	0.4	0.40	2.70	5.00	5.0	
		Week 24	Tezepelumab	2	2 (100.0)	0.90 (0.14)	0.8	0.80	0.90	1.00	1.0	
			Placebo	2	2 (100.0)	2.20 (2.55)	0.4	0.40	2.20	4.00	4.0	
		Week 26	Tezepelumab	2	2 (100.0)	0.80 (0.28)	0.6	0.60	0.80	1.00	1.0	
			Placebo	2	2 (100.0)	2.20 (2.55)	0.4	0.40	2.20	4.00	4.0	
		Week 28	Tezepelumab	2	2 (100.0)	0.70 (0.42)	0.4	0.40	0.70	1.00	1.0	
			Placebo	2	2 (100.0)	2.20 (2.55)	0.4	0.40	2.20	4.00	4.0	
		Week 30	Tezepelumab	2	2 (100.0)	0.80 (0.28)	0.6	0.60	0.80	1.00	1.0	
			Placebo	2	2 (100.0)	2.20 (2.55)	0.4	0.40	2.20	4.00	4.0	
		Week 32	Tezepelumab	2	2 (100.0)	1.30 (0.42)	1.0	1.00	1.30	1.60	1.6	
			Placebo	2	2 (100.0)	2.20 (2.55)	0.4	0.40	2.20	4.00	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Black or African American	Absolute values	Week 34	Tezepelumab	2	2 (100.0)	0.90 (0.14)	0.8	0.80	0.90	1.00	1.0	
			Placebo	2	2 (100.0)	2.00 (2.83)	0.0	0.00	2.00	4.00	4.0	
		Week 36	Tezepelumab	2	2 (100.0)	1.00 (0.00)	1.0	1.00	1.00	1.00	1.0	
			Placebo	2	2 (100.0)	2.00 (2.83)	0.0	0.00	2.00	4.00	4.0	
		Week 38	Tezepelumab	2	2 (100.0)	0.80 (0.28)	0.6	0.60	0.80	1.00	1.0	
			Placebo	2	2 (100.0)	2.00 (2.83)	0.0	0.00	2.00	4.00	4.0	
		Week 40	Tezepelumab	2	2 (100.0)	1.30 (0.42)	1.0	1.00	1.30	1.60	1.6	
			Placebo	2	2 (100.0)	2.00 (2.83)	0.0	0.00	2.00	4.00	4.0	
		Week 42	Tezepelumab	2	2 (100.0)	1.40 (0.57)	1.0	1.00	1.40	1.80	1.8	
			Placebo	2	2 (100.0)	0.80 (1.13)	0.0	0.00	0.80	1.60	1.6	
		Week 44	Tezepelumab	2	2 (100.0)	1.40 (0.57)	1.0	1.00	1.40	1.80	1.8	
			Placebo	2	2 (100.0)	0.90 (0.14)	0.8	0.80	0.90	1.00	1.0	
		Week 46	Tezepelumab	2	2 (100.0)	1.00 (0.00)	1.0	1.00	1.00	1.00	1.0	
			Placebo	2	2 (100.0)	0.80 (0.28)	0.6	0.60	0.80	1.00	1.0	
		Week 48	Tezepelumab	2	2 (100.0)	1.20 (0.28)	1.0	1.00	1.20	1.40	1.4	
			Placebo	2	2 (100.0)	0.70 (0.42)	0.4	0.40	0.70	1.00	1.0	
		Week 50	Tezepelumab	2	2 (100.0)	0.50 (0.71)	0.0	0.00	0.50	1.00	1.0	
			Placebo	2	2 (100.0)	2.40 (1.98)	1.0	1.00	2.40	3.80	3.8	
		Week 52	Tezepelumab	2	2 (100.0)	0.50 (0.71)	0.0	0.00	0.50	1.00	1.0	
			Placebo	2	2 (100.0)	1.90 (2.69)	0.0	0.00	1.90	3.80	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	-2.00 (1.70)	-3.2	-3.20	-2.00	-0.80	-0.8	-1.00 [-3.19, 1.19]
			Placebo	2	2 (100.0)	-0.70 (0.71)	-1.2	-1.20	-0.70	-0.20	-0.2	
		Week 4	Tezepelumab	2	2 (100.0)	-1.90 (0.71)	-2.4	-2.40	-1.90	-1.40	-1.4	-1.36 [-3.73, 1.01]
			Placebo	2	2 (100.0)	-0.50 (1.27)	-1.4	-1.40	-0.50	0.40	0.4	
		Week 6	Tezepelumab	2	2 (100.0)	-2.20 (0.85)	-2.8	-2.80	-2.20	-1.60	-1.6	-1.94 [-4.67, 0.79]
			Placebo	2	2 (100.0)	-0.90 (0.42)	-1.2	-1.20	-0.90	-0.60	-0.6	
		Week 8	Tezepelumab	2	2 (100.0)	-2.50 (0.71)	-3.0	-3.00	-2.50	-2.00	-2.0	-2.14 [-5.01, 0.73]
			Placebo	2	2 (100.0)	-0.30 (1.27)	-1.2	-1.20	-0.30	0.60	0.6	
		Week 10	Tezepelumab	2	2 (100.0)	-2.80 (0.28)	-3.0	-3.00	-2.80	-2.60	-2.6	-1.83 [-4.49, 0.83]
			Placebo	2	2 (100.0)	0.70 (2.69)	-1.2	-1.20	0.70	2.60	2.6	
		Week 12	Tezepelumab	2	2 (100.0)	-2.40 (0.28)	-2.6	-2.60	-2.40	-2.20	-2.2	-1.97 [-4.73, 0.78]
			Placebo	2	2 (100.0)	0.00 (1.70)	-1.2	-1.20	-0.00	1.20	1.2	
		Week 14	Tezepelumab	2	2 (100.0)	-2.50 (0.42)	-2.8	-2.80	-2.50	-2.20	-2.2	-1.70 [-4.27, 0.87]
			Placebo	2	2 (100.0)	0.60 (2.55)	-1.2	-1.20	0.60	2.40	2.4	
		Week 16	Tezepelumab	2	2 (100.0)	-2.30 (0.14)	-2.4	-2.40	-2.30	-2.20	-2.2	-1.61 [-4.12, 0.91]
			Placebo	2	2 (100.0)	0.60 (2.55)	-1.2	-1.20	0.60	2.40	2.4	
		Week 18	Tezepelumab	2	2 (100.0)	-2.50 (0.42)	-2.8	-2.80	-2.50	-2.20	-2.2	-1.70 [-4.27, 0.87]
			Placebo	2	2 (100.0)	0.60 (2.55)	-1.2	-1.20	0.60	2.40	2.4	
		Week 20	Tezepelumab	2	2 (100.0)	-2.40 (0.28)	-2.6	-2.60	-2.40	-2.20	-2.2	-1.28 [-3.61, 1.05]
			Placebo	2	2 (100.0)	0.30 (2.97)	-1.8	-1.80	0.30	2.40	2.4	
		Week 22	Tezepelumab	2	2 (100.0)	-2.20 (0.00)	-2.2	-2.20	-2.20	-2.20	-2.2	-1.19 [-3.47, 1.09]
			Placebo	2	2 (100.0)	0.30 (2.97)	-1.8	-1.80	0.30	2.40	2.4	
		Week 24	Tezepelumab	2	2 (100.0)	-2.30 (0.14)	-2.4	-2.40	-2.30	-2.20	-2.2	-1.31 [-3.65, 1.03]
			Placebo	2	2 (100.0)	-0.20 (2.26)	-1.8	-1.80	-0.20	1.40	1.4	
		Week 26	Tezepelumab	2	2 (100.0)	-2.40 (0.28)	-2.6	-2.60	-2.40	-2.20	-2.2	-1.36 [-3.74, 1.01]
			Placebo	2	2 (100.0)	-0.20 (2.26)	-1.8	-1.80	-0.20	1.40	1.4	
		Week 28	Tezepelumab	2	2 (100.0)	-2.50 (0.42)	-2.8	-2.80	-2.50	-2.20	-2.2	-1.41 [-3.81, 0.99]
			Placebo	2	2 (100.0)	-0.20 (2.26)	-1.8	-1.80	-0.20	1.40	1.4	
		Week 30	Tezepelumab	2	2 (100.0)	-2.40 (0.28)	-2.6	-2.60	-2.40	-2.20	-2.2	-1.36 [-3.74, 1.01]
			Placebo	2	2 (100.0)	-0.20 (2.26)	-1.8	-1.80	-0.20	1.40	1.4	
		Week 32	Tezepelumab	2	2 (100.0)	-1.90 (0.42)	-2.2	-2.20	-1.90	-1.60	-1.6	-1.04 [-3.26, 1.17]
			Placebo	2	2 (100.0)	-0.20 (2.26)	-1.8	-1.80	-0.20	1.40	1.4	
		Week 34	Tezepelumab	2	2 (100.0)	-2.30 (0.14)	-2.4	-2.40	-2.30	-2.20	-2.2	-1.05 [-3.27, 1.16]
			Placebo	2	2 (100.0)	-0.40 (2.55)	-2.2	-2.20	-0.40	1.40	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Black or African American	Change from baseline	Week 36	Tezepelumab	2	2 (100.0)	-2.20 (0.00)	-2.2	-2.20	-2.20	-2.20	-2.2	-1.00 [-3.19, 1.19]
			Placebo	2	2 (100.0)	-0.40 (2.55)	-2.2	-2.20	-0.40	1.40	1.4	
		Week 38	Tezepelumab	2	2 (100.0)	-2.40 (0.28)	-2.6	-2.60	-2.40	-2.20	-2.2	-1.10 [-3.34, 1.13]
			Placebo	2	2 (100.0)	-0.40 (2.55)	-2.2	-2.20	-0.40	1.40	1.4	
		Week 40	Tezepelumab	2	2 (100.0)	-1.90 (0.42)	-2.2	-2.20	-1.90	-1.60	-1.6	-0.82 [-2.94, 1.30]
			Placebo	2	2 (100.0)	-0.40 (2.55)	-2.2	-2.20	-0.40	1.40	1.4	
		Week 42	Tezepelumab	2	2 (100.0)	-1.80 (0.57)	-2.2	-2.20	-1.80	-1.40	-1.4	-0.28 [-2.26, 1.70]
			Placebo	2	2 (100.0)	-1.60 (0.85)	-2.2	-2.20	-1.60	-1.00	-1.0	
		Week 44	Tezepelumab	2	2 (100.0)	-1.80 (0.57)	-2.2	-2.20	-1.80	-1.40	-1.4	-0.73 [-2.81, 1.36]
			Placebo	2	2 (100.0)	-1.50 (0.14)	-1.6	-1.60	-1.50	-1.40	-1.4	
		Week 46	Tezepelumab	2	2 (100.0)	-2.20 (0.00)	-2.2	-2.20	-2.20	-2.20	-2.2	
			Placebo	2	2 (100.0)	-1.60 (0.00)	-1.6	-1.60	-1.60	-1.60	-1.6	
		Week 48	Tezepelumab	2	2 (100.0)	-2.00 (0.28)	-2.2	-2.20	-2.00	-1.80	-1.8	-1.34 [-3.70, 1.02]
			Placebo	2	2 (100.0)	-1.70 (0.14)	-1.8	-1.80	-1.70	-1.60	-1.6	
		Week 50	Tezepelumab	2	2 (100.0)	-2.70 (0.71)	-3.2	-3.20	-2.70	-2.20	-2.2	-1.61 [-4.13, 0.91]
			Placebo	2	2 (100.0)	0.00 (2.26)	-1.6	-1.60	-0.00	1.60	1.6	
		Week 52	Tezepelumab	2	2 (100.0)	-2.70 (0.71)	-3.2	-3.20	-2.70	-2.20	-2.2	-1.02 [-3.22, 1.18]
			Placebo	2	2 (100.0)	-0.50 (2.97)	-2.6	-2.60	-0.50	1.60	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.73 (0.58)	2.4	2.40	2.40	3.40	3.4	
			Placebo	3	3 (100.0)	2.80 (0.35)	2.6	2.60	2.60	3.20	3.2	
		Week 2	Tezepelumab	3	3 (100.0)	1.93 (1.14)	1.0	1.00	1.60	3.20	3.2	
			Placebo	3	3 (100.0)	2.47 (0.12)	2.4	2.40	2.40	2.60	2.6	
		Week 4	Tezepelumab	3	3 (100.0)	1.47 (0.83)	0.8	0.80	1.20	2.40	2.4	
			Placebo	3	3 (100.0)	2.07 (0.61)	1.4	1.40	2.20	2.60	2.6	
		Week 6	Tezepelumab	3	3 (100.0)	1.27 (0.46)	1.0	1.00	1.00	1.80	1.8	
			Placebo	3	3 (100.0)	1.93 (0.83)	1.0	1.00	2.20	2.60	2.6	
		Week 8	Tezepelumab	3	3 (100.0)	1.13 (0.61)	0.6	0.60	1.00	1.80	1.8	
			Placebo	3	3 (100.0)	2.40 (0.20)	2.2	2.20	2.40	2.60	2.6	
		Week 10	Tezepelumab	3	3 (100.0)	1.00 (0.35)	0.8	0.80	0.80	1.40	1.4	
			Placebo	3	3 (100.0)	2.00 (0.35)	1.8	1.80	1.80	2.40	2.4	
		Week 12	Tezepelumab	3	3 (100.0)	0.60 (0.87)	0.0	0.00	0.20	1.60	1.6	
			Placebo	3	3 (100.0)	2.00 (0.20)	1.8	1.80	2.00	2.20	2.2	
		Week 14	Tezepelumab	3	3 (100.0)	0.93 (0.42)	0.6	0.60	0.80	1.40	1.4	
			Placebo	3	3 (100.0)	1.67 (0.42)	1.2	1.20	1.80	2.00	2.0	
		Week 16	Tezepelumab	3	3 (100.0)	0.80 (0.53)	0.2	0.20	1.00	1.20	1.2	
			Placebo	3	3 (100.0)	1.60 (0.87)	0.6	0.60	2.00	2.20	2.2	
		Week 18	Tezepelumab	3	3 (100.0)	0.73 (0.23)	0.6	0.60	0.60	1.00	1.0	
			Placebo	3	3 (100.0)	2.20 (0.00)	2.2	2.20	2.20	2.20	2.2	
		Week 20	Tezepelumab	3	3 (100.0)	0.80 (0.40)	0.4	0.40	0.80	1.20	1.2	
			Placebo	3	3 (100.0)	2.53 (0.81)	1.8	1.80	2.40	3.40	3.4	
		Week 22	Tezepelumab	3	3 (100.0)	0.60 (0.53)	0.0	0.00	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	2.13 (0.81)	1.2	1.20	2.60	2.60	2.6	
		Week 24	Tezepelumab	3	3 (100.0)	0.73 (0.31)	0.4	0.40	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	2.53 (0.31)	2.2	2.20	2.60	2.80	2.8	
		Week 26	Tezepelumab	3	3 (100.0)	0.73 (0.46)	0.2	0.20	1.00	1.00	1.0	
			Placebo	3	3 (100.0)	2.07 (0.46)	1.8	1.80	1.80	2.60	2.6	
		Week 28	Tezepelumab	3	3 (100.0)	0.73 (0.46)	0.2	0.20	1.00	1.00	1.0	
			Placebo	3	3 (100.0)	1.60 (1.06)	0.4	0.40	2.00	2.40	2.4	
		Week 30	Tezepelumab	3	3 (100.0)	0.73 (0.12)	0.6	0.60	0.80	0.80	0.8	
			Placebo	3	3 (100.0)	1.07 (1.01)	0.0	0.00	1.20	2.00	2.0	
		Week 32	Tezepelumab	3	3 (100.0)	0.67 (0.42)	0.2	0.20	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	1.47 (0.61)	0.8	0.80	1.60	2.00	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asian	Absolute values	Week 34	Tezepelumab	3	3 (100.0)	0.67 (0.23)	0.4	0.40	0.80	0.80	0.8	
			Placebo	3	3 (100.0)	1.67 (0.90)	0.8	0.80	1.60	2.60	2.6	
		Week 36	Tezepelumab	3	3 (100.0)	0.73 (0.46)	0.2	0.20	1.00	1.00	1.0	
			Placebo	3	3 (100.0)	2.73 (0.61)	2.2	2.20	2.60	3.40	3.4	
		Week 38	Tezepelumab	3	3 (100.0)	0.87 (1.03)	0.0	0.00	0.60	2.00	2.0	
			Placebo	3	3 (100.0)	1.40 (0.72)	0.6	0.60	1.60	2.00	2.0	
		Week 40	Tezepelumab	3	3 (100.0)	0.67 (0.23)	0.4	0.40	0.80	0.80	0.8	
			Placebo	3	3 (100.0)	2.07 (0.50)	1.6	1.60	2.00	2.60	2.6	
		Week 42	Tezepelumab	3	3 (100.0)	0.80 (0.35)	0.4	0.40	1.00	1.00	1.0	
			Placebo	3	3 (100.0)	1.73 (0.31)	1.4	1.40	1.80	2.00	2.0	
		Week 44	Tezepelumab	3	3 (100.0)	0.60 (0.40)	0.2	0.20	0.60	1.00	1.0	
			Placebo	3	3 (100.0)	3.20 (0.53)	2.8	2.80	3.00	3.80	3.8	
		Week 46	Tezepelumab	3	3 (100.0)	0.73 (0.46)	0.2	0.20	1.00	1.00	1.0	
			Placebo	3	3 (100.0)	1.40 (0.92)	0.4	0.40	1.60	2.20	2.2	
		Week 48	Tezepelumab	3	3 (100.0)	0.73 (0.31)	0.4	0.40	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	2.33 (0.31)	2.0	2.00	2.40	2.60	2.6	
		Week 50	Tezepelumab	3	3 (100.0)	0.73 (0.31)	0.4	0.40	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	1.73 (0.31)	1.4	1.40	1.80	2.00	2.0	
		Week 52	Tezepelumab	3	3 (100.0)	0.73 (0.31)	0.4	0.40	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	1.73 (0.31)	1.4	1.40	1.80	2.00	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.80 (0.60)	-1.4	-1.40	-0.80	-0.20	-0.2	-0.90 [-2.62, 0.81]
			Placebo	3	3 (100.0)	-0.33 (0.42)	-0.8	-0.80	-0.20	0.00	0.0	
		Week 4	Tezepelumab	3	3 (100.0)	-1.27 (0.31)	-1.6	-1.60	-1.20	-1.00	-1.0	-0.76 [-2.44, 0.93]
			Placebo	3	3 (100.0)	-0.73 (0.95)	-1.8	-1.80	-0.40	0.00	0.0	
		Week 6	Tezepelumab	3	3 (100.0)	-1.47 (0.12)	-1.6	-1.60	-1.40	-1.40	-1.4	-1.30 [-3.14, 0.54]
			Placebo	3	3 (100.0)	-0.87 (0.64)	-1.6	-1.60	-0.60	-0.40	-0.4	
		Week 8	Tezepelumab	3	3 (100.0)	-1.60 (0.20)	-1.8	-1.80	-1.60	-1.40	-1.4	-3.79 [-6.87, -0.72]
			Placebo	3	3 (100.0)	-0.40 (0.40)	-0.8	-0.80	-0.40	0.00	0.0	
		Week 10	Tezepelumab	3	3 (100.0)	-1.73 (0.23)	-2.0	-2.00	-1.60	-1.60	-1.6	-5.72 [-9.99, -1.44]
			Placebo	3	3 (100.0)	-0.80 (0.00)	-0.8	-0.80	-0.80	-0.80	-0.8	
		Week 12	Tezepelumab	3	3 (100.0)	-2.13 (0.31)	-2.4	-2.40	-2.20	-1.80	-1.8	-5.16 [-9.08, -1.24]
			Placebo	3	3 (100.0)	-0.80 (0.20)	-1.0	-1.00	-0.80	-0.60	-0.6	
		Week 14	Tezepelumab	3	3 (100.0)	-1.80 (0.20)	-2.0	-2.00	-1.80	-1.60	-1.6	-1.87 [-3.93, 0.19]
			Placebo	3	3 (100.0)	-1.13 (0.46)	-1.4	-1.40	-1.40	-0.60	-0.6	
		Week 16	Tezepelumab	3	3 (100.0)	-1.93 (0.46)	-2.2	-2.20	-2.20	-1.40	-1.4	-1.12 [-2.90, 0.66]
			Placebo	3	3 (100.0)	-1.20 (0.80)	-2.0	-2.00	-1.20	-0.40	-0.4	
		Week 18	Tezepelumab	3	3 (100.0)	-2.00 (0.35)	-2.4	-2.40	-1.80	-1.80	-1.8	-4.04 [-7.27, -0.82]
			Placebo	3	3 (100.0)	-0.60 (0.35)	-1.0	-1.00	-0.40	-0.40	-0.4	
		Week 20	Tezepelumab	3	3 (100.0)	-1.93 (0.31)	-2.2	-2.20	-2.00	-1.60	-1.6	-2.06 [-4.21, 0.08]
			Placebo	3	3 (100.0)	-0.27 (1.10)	-1.4	-1.40	-0.20	0.80	0.8	
		Week 22	Tezepelumab	3	3 (100.0)	-2.13 (0.46)	-2.4	-2.40	-2.40	-1.60	-1.6	-2.47 [-4.81, -0.13]
			Placebo	3	3 (100.0)	-0.67 (0.70)	-1.4	-1.40	-0.60	0.00	0.0	
		Week 24	Tezepelumab	3	3 (100.0)	-2.00 (0.40)	-2.4	-2.40	-2.00	-1.60	-1.6	-3.24 [-5.99, -0.48]
			Placebo	3	3 (100.0)	-0.27 (0.64)	-1.0	-1.00	0.00	0.20	0.2	
		Week 26	Tezepelumab	3	3 (100.0)	-2.00 (0.53)	-2.4	-2.40	-2.20	-1.40	-1.4	-2.04 [-4.17, 0.10]
			Placebo	3	3 (100.0)	-0.73 (0.70)	-1.4	-1.40	-0.80	0.00	0.0	
		Week 28	Tezepelumab	3	3 (100.0)	-2.00 (0.53)	-2.4	-2.40	-2.20	-1.40	-1.4	-1.11 [-2.88, 0.67]
			Placebo	3	3 (100.0)	-1.20 (0.87)	-2.2	-2.20	-0.80	-0.60	-0.6	
		Week 30	Tezepelumab	3	3 (100.0)	-2.00 (0.53)	-2.6	-2.60	-1.80	-1.60	-1.6	-0.41 [-2.03, 1.22]
			Placebo	3	3 (100.0)	-1.73 (0.76)	-2.6	-2.60	-1.40	-1.20	-1.2	
		Week 32	Tezepelumab	3	3 (100.0)	-2.07 (0.42)	-2.4	-2.40	-2.20	-1.60	-1.6	-1.35 [-3.21, 0.50]
			Placebo	3	3 (100.0)	-1.33 (0.64)	-1.8	-1.80	-1.60	-0.60	-0.6	
		Week 34	Tezepelumab	3	3 (100.0)	-2.07 (0.50)	-2.6	-2.60	-2.00	-1.60	-1.6	-1.67 [-3.64, 0.31]
			Placebo	3	3 (100.0)	-1.13 (0.61)	-1.8	-1.80	-1.00	-0.60	-0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asian	Change from baseline	Week 36	Tezepelumab	3	3 (100.0)	-2.00 (0.53)	-2.4	-2.40	-2.20	-1.40	-1.4	-2.96 [-5.56, -0.36]
			Placebo	3	3 (100.0)	-0.07 (0.76)	-0.6	-0.60	-0.40	0.80	0.8	
		Week 38	Tezepelumab	3	3 (100.0)	-1.87 (0.50)	-2.4	-2.40	-1.80	-1.40	-1.4	-0.90 [-2.62, 0.81]
			Placebo	3	3 (100.0)	-1.40 (0.53)	-2.0	-2.00	-1.20	-1.00	-1.0	
		Week 40	Tezepelumab	3	3 (100.0)	-2.07 (0.50)	-2.6	-2.60	-2.00	-1.60	-1.6	-2.31 [-4.57, -0.05]
			Placebo	3	3 (100.0)	-0.73 (0.64)	-1.2	-1.20	-1.00	0.00	0.0	
		Week 42	Tezepelumab	3	3 (100.0)	-1.93 (0.50)	-2.4	-2.40	-2.00	-1.40	-1.4	-2.21 [-4.43, 0.00]
			Placebo	3	3 (100.0)	-1.07 (0.23)	-1.2	-1.20	-1.20	-0.80	-0.8	
		Week 44	Tezepelumab	3	3 (100.0)	-2.13 (0.70)	-2.8	-2.80	-2.20	-1.40	-1.4	-3.37 [-6.19, -0.54]
			Placebo	3	3 (100.0)	0.40 (0.80)	-0.4	-0.40	0.40	1.20	1.2	
		Week 46	Tezepelumab	3	3 (100.0)	-2.00 (0.53)	-2.4	-2.40	-2.20	-1.40	-1.4	-0.97 [-2.71, 0.76]
			Placebo	3	3 (100.0)	-1.40 (0.69)	-2.2	-2.20	-1.00	-1.00	-1.0	
		Week 48	Tezepelumab	3	3 (100.0)	-2.00 (0.40)	-2.4	-2.40	-2.00	-1.60	-1.6	-3.76 [-6.81, -0.70]
			Placebo	3	3 (100.0)	-0.47 (0.42)	-0.8	-0.80	-0.60	0.00	0.0	
		Week 50	Tezepelumab	3	3 (100.0)	-2.00 (0.60)	-2.6	-2.60	-2.00	-1.40	-1.4	-1.81 [-3.84, 0.22]
			Placebo	3	3 (100.0)	-1.07 (0.42)	-1.4	-1.40	-1.20	-0.60	-0.6	
		Week 52	Tezepelumab	3	3 (100.0)	-2.00 (0.60)	-2.6	-2.60	-2.00	-1.40	-1.4	-1.81 [-3.84, 0.22]
			Placebo	3	3 (100.0)	-1.07 (0.42)	-1.4	-1.40	-1.20	-0.60	-0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.60	2.6	2.60	2.60	2.60	2.6	
			Placebo	2	2 (100.0)	4.00 (1.41)	3.0	3.00	4.00	5.00	5.0	
		Week 2	Tezepelumab	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
			Placebo	2	2 (100.0)	3.50 (2.12)	2.0	2.00	3.50	5.00	5.0	
		Week 4	Tezepelumab	1	1 (100.0)	3.40	3.4	3.40	3.40	3.40	3.4	
			Placebo	2	2 (100.0)	3.60 (0.00)	3.6	3.60	3.60	3.60	3.6	
		Week 6	Tezepelumab	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	
			Placebo	2	2 (100.0)	3.60 (3.39)	1.2	1.20	3.60	6.00	6.0	
		Week 8	Tezepelumab	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
			Placebo	2	2 (100.0)	2.60 (3.39)	0.2	0.20	2.60	5.00	5.0	
		Week 10	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	2	2 (100.0)	1.90 (1.56)	0.8	0.80	1.90	3.00	3.0	
		Week 12	Tezepelumab	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	
			Placebo	2	2 (100.0)	1.50 (2.12)	0.0	0.00	1.50	3.00	3.0	
		Week 14	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	2	2 (100.0)	1.50 (2.12)	0.0	0.00	1.50	3.00	3.0	
		Week 16	Tezepelumab	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
			Placebo	2	2 (100.0)	2.50 (3.54)	0.0	0.00	2.50	5.00	5.0	
		Week 18	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	2	2 (100.0)	1.50 (2.12)	0.0	0.00	1.50	3.00	3.0	
		Week 20	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	2	2 (100.0)	2.60 (0.57)	2.2	2.20	2.60	3.00	3.0	
		Week 22	Tezepelumab	1	1 (100.0)	2.60	2.6	2.60	2.60	2.60	2.6	
			Placebo	2	2 (100.0)	3.10 (0.42)	2.8	2.80	3.10	3.40	3.4	
		Week 24	Tezepelumab	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
			Placebo	2	2 (100.0)	2.10 (1.84)	0.8	0.80	2.10	3.40	3.4	
		Week 26	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	2	2 (100.0)	1.70 (2.40)	0.0	0.00	1.70	3.40	3.4	
		Week 28	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	2	2 (100.0)	1.70 (2.40)	0.0	0.00	1.70	3.40	3.4	
		Week 30	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	2	2 (100.0)	2.50 (1.27)	1.6	1.60	2.50	3.40	3.4	
		Week 32	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	2	2 (100.0)	2.50 (1.27)	1.6	1.60	2.50	3.40	3.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Other	Absolute values	Week 34	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	2	2 (100.0)	1.80 (2.26)	0.2	0.20	1.80	3.40	3.4	
		Week 36	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	2	2 (100.0)	2.50 (1.27)	1.6	1.60	2.50	3.40	3.4	
		Week 38	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	2	2 (100.0)	2.60 (1.13)	1.8	1.80	2.60	3.40	3.4	
		Week 40	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	2	2 (100.0)	2.10 (1.84)	0.8	0.80	2.10	3.40	3.4	
		Week 42	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	2	2 (100.0)	2.70 (0.99)	2.0	2.00	2.70	3.40	3.4	
		Week 44	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	2	2 (100.0)	2.00 (1.98)	0.6	0.60	2.00	3.40	3.4	
		Week 46	Tezepelumab	1	1 (100.0)	2.40	2.4	2.40	2.40	2.40	2.4	
			Placebo	2	2 (100.0)	2.60 (1.13)	1.8	1.80	2.60	3.40	3.4	
		Week 48	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	2	2 (100.0)	3.00 (0.57)	2.6	2.60	3.00	3.40	3.4	
		Week 50	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	2	2 (100.0)	1.80 (2.26)	0.2	0.20	1.80	3.40	3.4	
		Week 52	Tezepelumab	1	1 (100.0)	2.20	2.2	2.20	2.20	2.20	2.2	
			Placebo	2	2 (100.0)	1.80 (2.26)	0.2	0.20	1.80	3.40	3.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.20	0.2	0.20	0.20	0.20	0.2	NE
			Placebo	2	2 (100.0)	-0.50 (0.71)	-1.0	-1.00	-0.50	0.00	0.0	
		Week 4	Tezepelumab	1	1 (100.0)	0.80	0.8	0.80	0.80	0.80	0.8	NE
			Placebo	2	2 (100.0)	-0.40 (1.41)	-1.4	-1.40	-0.40	0.60	0.6	
		Week 6	Tezepelumab	1	1 (100.0)	0.40	0.4	0.40	0.40	0.40	0.4	NE
			Placebo	2	2 (100.0)	-0.40 (1.98)	-1.8	-1.80	-0.40	1.00	1.0	
		Week 8	Tezepelumab	1	1 (100.0)	0.20	0.2	0.20	0.20	0.20	0.2	NE
			Placebo	2	2 (100.0)	-1.40 (1.98)	-2.8	-2.80	-1.40	0.00	0.0	
		Week 10	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	2	2 (100.0)	-2.10 (0.14)	-2.2	-2.20	-2.10	-2.00	-2.0	
		Week 12	Tezepelumab	1	1 (100.0)	0.40	0.4	0.40	0.40	0.40	0.4	NE
			Placebo	2	2 (100.0)	-2.50 (0.71)	-3.0	-3.00	-2.50	-2.00	-2.0	
		Week 14	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	2	2 (100.0)	-2.50 (0.71)	-3.0	-3.00	-2.50	-2.00	-2.0	
		Week 16	Tezepelumab	1	1 (100.0)	-1.20	-1.2	-1.20	-1.20	-1.20	-1.2	NE
			Placebo	2	2 (100.0)	-1.50 (2.12)	-3.0	-3.00	-1.50	0.00	0.0	
		Week 18	Tezepelumab	1	1 (100.0)	-0.60	-0.6	-0.60	-0.60	-0.60	-0.6	NE
			Placebo	2	2 (100.0)	-2.50 (0.71)	-3.0	-3.00	-2.50	-2.00	-2.0	
		Week 20	Tezepelumab	1	1 (100.0)	-0.60	-0.6	-0.60	-0.60	-0.60	-0.6	NE
			Placebo	2	2 (100.0)	-1.40 (0.85)	-2.0	-2.00	-1.40	-0.80	-0.8	
		Week 22	Tezepelumab	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	NE
			Placebo	2	2 (100.0)	-0.90 (0.99)	-1.6	-1.60	-0.90	-0.20	-0.2	
		Week 24	Tezepelumab	1	1 (100.0)	0.20	0.2	0.20	0.20	0.20	0.2	NE
			Placebo	2	2 (100.0)	-1.90 (0.42)	-2.2	-2.20	-1.90	-1.60	-1.6	
		Week 26	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	2	2 (100.0)	-2.30 (0.99)	-3.0	-3.00	-2.30	-1.60	-1.6	
		Week 28	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	2	2 (100.0)	-2.30 (0.99)	-3.0	-3.00	-2.30	-1.60	-1.6	
		Week 30	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	2	2 (100.0)	-1.50 (0.14)	-1.6	-1.60	-1.50	-1.40	-1.4	
		Week 32	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	2	2 (100.0)	-1.50 (0.14)	-1.6	-1.60	-1.50	-1.40	-1.4	
		Week 34	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	2	2 (100.0)	-2.20 (0.85)	-2.8	-2.80	-2.20	-1.60	-1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Other	Change from baseline	Week 36	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	2	2 (100.0)	-1.50 (0.14)	-1.6	-1.60	-1.50	-1.40	-1.4	
		Week 38	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	2	2 (100.0)	-1.40 (0.28)	-1.6	-1.60	-1.40	-1.20	-1.2	
		Week 40	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	2	2 (100.0)	-1.90 (0.42)	-2.2	-2.20	-1.90	-1.60	-1.6	
		Week 42	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	2	2 (100.0)	-1.30 (0.42)	-1.6	-1.60	-1.30	-1.00	-1.0	
		Week 44	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	2	2 (100.0)	-2.00 (0.57)	-2.4	-2.40	-2.00	-1.60	-1.6	
		Week 46	Tezepelumab	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	NE
			Placebo	2	2 (100.0)	-1.40 (0.28)	-1.6	-1.60	-1.40	-1.20	-1.2	
		Week 48	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	2	2 (100.0)	-1.00 (0.85)	-1.6	-1.60	-1.00	-0.40	-0.4	
		Week 50	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	2	2 (100.0)	-2.20 (0.85)	-2.8	-2.80	-2.20	-1.60	-1.6	
		Week 52	Tezepelumab	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	NE
			Placebo	2	2 (100.0)	-2.20 (0.85)	-2.8	-2.80	-2.20	-1.60	-1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	2.89 (0.99)	0.0	2.40	2.80	3.40	5.0	
			Placebo	36	36 (100.0)	2.67 (0.71)	0.4	2.40	2.80	3.20	3.6	
		Week 2	Tezepelumab	40	38 (95.0)	2.44 (1.11)	0.2	1.40	2.80	3.20	4.4	
			Placebo	36	32 (88.9)	2.36 (0.68)	0.4	2.00	2.50	2.80	3.2	
		Week 4	Tezepelumab	40	38 (95.0)	2.20 (1.06)	0.2	1.40	2.60	3.00	3.6	
			Placebo	36	32 (88.9)	2.21 (0.92)	0.2	1.40	2.50	2.80	4.2	
		Week 6	Tezepelumab	40	38 (95.0)	2.04 (1.11)	0.0	1.40	2.10	3.00	4.0	
			Placebo	36	32 (88.9)	2.09 (1.11)	0.2	1.30	2.20	2.90	5.0	
		Week 8	Tezepelumab	40	38 (95.0)	1.99 (1.31)	0.0	0.80	1.90	3.00	5.2	
			Placebo	36	32 (88.9)	2.02 (1.06)	0.0	0.90	2.10	3.00	3.6	
		Week 10	Tezepelumab	40	38 (95.0)	1.89 (1.24)	0.0	1.00	2.00	2.80	4.8	
			Placebo	36	32 (88.9)	2.12 (1.01)	0.0	1.60	2.20	3.00	4.0	
		Week 12	Tezepelumab	40	38 (95.0)	1.79 (1.20)	0.0	0.60	2.00	2.80	4.8	
			Placebo	36	32 (88.9)	1.82 (1.06)	0.0	1.00	1.90	2.60	4.4	
		Week 14	Tezepelumab	40	38 (95.0)	1.76 (1.30)	0.0	0.60	1.90	2.80	4.8	
			Placebo	36	32 (88.9)	1.74 (0.85)	0.0	1.00	1.90	2.30	3.2	
		Week 16	Tezepelumab	40	38 (95.0)	1.85 (1.26)	0.0	0.60	2.00	2.80	4.8	
			Placebo	36	32 (88.9)	1.98 (1.07)	0.0	0.90	2.00	2.90	4.0	
		Week 18	Tezepelumab	40	39 (97.5)	1.83 (1.17)	0.0	0.80	2.00	2.60	4.8	
			Placebo	36	32 (88.9)	1.74 (1.11)	0.0	0.90	1.80	2.60	4.8	
		Week 20	Tezepelumab	40	39 (97.5)	1.79 (1.30)	0.0	0.60	2.00	2.60	5.0	
			Placebo	36	32 (88.9)	1.79 (0.94)	0.0	1.10	2.00	2.70	3.6	
		Week 22	Tezepelumab	40	39 (97.5)	1.95 (1.12)	0.0	1.20	2.00	2.60	4.8	
			Placebo	36	32 (88.9)	1.73 (0.96)	0.0	0.90	1.80	2.50	3.6	
		Week 24	Tezepelumab	40	39 (97.5)	1.82 (1.24)	0.0	0.60	2.00	2.80	4.8	
			Placebo	36	32 (88.9)	1.90 (0.92)	0.0	1.30	2.00	2.60	3.4	
		Week 26	Tezepelumab	40	40 (100.0)	1.92 (1.20)	0.0	0.90	2.00	2.80	4.8	
			Placebo	36	32 (88.9)	1.86 (1.01)	0.0	1.00	1.70	2.80	3.8	
		Week 28	Tezepelumab	40	40 (100.0)	1.89 (1.25)	0.0	1.00	2.00	2.80	4.8	
			Placebo	36	33 (91.7)	1.84 (1.17)	0.0	1.00	1.80	2.80	4.0	
		Week 30	Tezepelumab	40	40 (100.0)	1.85 (1.22)	0.0	1.00	2.00	2.60	4.8	
			Placebo	36	33 (91.7)	1.75 (1.14)	0.0	0.80	2.00	2.40	4.0	
		Week 32	Tezepelumab	40	40 (100.0)	1.79 (1.25)	0.0	0.70	1.80	2.80	4.8	
			Placebo	36	33 (91.7)	1.73 (1.00)	0.0	1.00	1.80	2.20	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	Absolute values	Week 34	Tezepelumab	40	40 (100.0)	1.84 (1.30)	0.0	0.90	1.90	2.80	4.8	
			Placebo	36	33 (91.7)	1.75 (0.90)	0.0	1.00	2.00	2.20	3.6	
		Week 36	Tezepelumab	40	40 (100.0)	1.78 (1.22)	0.0	0.70	1.90	2.70	4.8	
			Placebo	36	33 (91.7)	1.85 (1.07)	0.0	1.00	1.80	2.80	4.4	
		Week 38	Tezepelumab	40	40 (100.0)	1.81 (1.34)	0.0	0.80	1.90	2.70	4.8	
			Placebo	36	33 (91.7)	1.81 (0.97)	0.0	1.00	2.00	2.60	3.4	
		Week 40	Tezepelumab	40	40 (100.0)	1.76 (1.29)	0.0	0.50	2.00	2.80	4.8	
			Placebo	36	33 (91.7)	1.98 (1.20)	0.0	1.00	2.20	3.00	4.4	
		Week 42	Tezepelumab	40	40 (100.0)	1.77 (1.28)	0.0	0.80	1.80	2.80	4.8	
			Placebo	36	33 (91.7)	1.79 (1.00)	0.0	1.00	2.00	2.40	4.6	
		Week 44	Tezepelumab	40	40 (100.0)	1.79 (1.24)	0.0	0.80	1.90	2.80	4.8	
			Placebo	36	33 (91.7)	1.87 (1.09)	0.0	1.20	2.00	2.60	4.2	
		Week 46	Tezepelumab	40	40 (100.0)	1.86 (1.30)	0.0	0.80	2.00	3.00	4.8	
			Placebo	36	33 (91.7)	1.76 (0.86)	0.0	1.20	2.00	2.20	3.4	
		Week 48	Tezepelumab	40	40 (100.0)	1.89 (1.30)	0.0	0.90	2.00	2.90	4.8	
			Placebo	36	33 (91.7)	1.83 (1.01)	0.0	1.00	2.00	2.40	4.0	
		Week 50	Tezepelumab	40	40 (100.0)	1.85 (1.31)	0.0	1.00	1.90	2.80	4.8	
			Placebo	36	33 (91.7)	1.67 (0.96)	0.0	1.00	2.00	2.40	3.4	
		Week 52	Tezepelumab	40	40 (100.0)	1.87 (1.28)	0.0	0.90	2.00	2.80	4.8	
			Placebo	36	33 (91.7)	1.81 (1.03)	0.0	1.00	2.00	2.60	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	40	38 (95.0)	-0.49 (0.81)	-2.2	-1.20	-0.40	0.20	0.8	-0.07 [-0.54, 0.40]
			Placebo	36	32 (88.9)	-0.44 (0.66)	-1.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	40	38 (95.0)	-0.74 (1.03)	-2.6	-1.20	-0.80	0.00	2.6	-0.15 [-0.62, 0.32]
			Placebo	36	32 (88.9)	-0.59 (0.94)	-3.0	-1.30	-0.30	0.00	1.2	
		Week 6	Tezepelumab	40	38 (95.0)	-0.89 (1.08)	-2.8	-1.60	-1.00	0.00	2.6	-0.18 [-0.65, 0.30]
			Placebo	36	32 (88.9)	-0.71 (1.06)	-3.4	-1.50	-0.60	0.10	1.6	
		Week 8	Tezepelumab	40	38 (95.0)	-0.95 (1.30)	-3.2	-1.80	-1.10	0.00	2.6	-0.14 [-0.62, 0.33]
			Placebo	36	32 (88.9)	-0.78 (0.93)	-3.0	-1.30	-0.50	-0.10	0.6	
		Week 10	Tezepelumab	40	38 (95.0)	-1.05 (1.25)	-3.4	-1.80	-1.30	0.00	2.6	-0.32 [-0.80, 0.15]
			Placebo	36	32 (88.9)	-0.68 (0.97)	-3.2	-1.30	-0.50	0.00	1.6	
		Week 12	Tezepelumab	40	38 (95.0)	-1.14 (1.22)	-3.2	-2.20	-1.20	-0.20	2.6	-0.14 [-0.61, 0.33]
			Placebo	36	32 (88.9)	-0.98 (1.00)	-3.2	-1.60	-1.00	-0.20	1.4	
		Week 14	Tezepelumab	40	38 (95.0)	-1.18 (1.26)	-4.0	-2.20	-1.30	-0.40	2.6	-0.11 [-0.58, 0.36]
			Placebo	36	32 (88.9)	-1.06 (0.94)	-3.2	-1.50	-1.10	-0.40	1.0	
		Week 16	Tezepelumab	40	38 (95.0)	-1.08 (1.19)	-3.2	-2.20	-1.00	-0.40	2.6	-0.24 [-0.71, 0.24]
			Placebo	36	32 (88.9)	-0.83 (0.97)	-2.8	-1.40	-0.90	0.00	1.0	
		Week 18	Tezepelumab	40	39 (97.5)	-1.08 (1.20)	-3.8	-2.00	-1.00	-0.40	2.6	-0.02 [-0.49, 0.44]
			Placebo	36	32 (88.9)	-1.06 (1.05)	-2.8	-2.00	-1.10	-0.20	1.4	
		Week 20	Tezepelumab	40	39 (97.5)	-1.12 (1.23)	-3.4	-2.20	-1.20	-0.20	2.6	-0.10 [-0.56, 0.37]
			Placebo	36	32 (88.9)	-1.01 (0.89)	-3.0	-1.50	-0.70	-0.40	0.6	
		Week 22	Tezepelumab	40	39 (97.5)	-0.96 (1.26)	-3.2	-1.80	-0.80	-0.40	2.6	0.10 [-0.37, 0.57]
			Placebo	36	32 (88.9)	-1.08 (0.89)	-2.8	-1.60	-1.00	-0.50	0.6	
		Week 24	Tezepelumab	40	39 (97.5)	-1.09 (1.17)	-3.4	-2.00	-1.20	-0.40	2.6	-0.18 [-0.65, 0.29]
			Placebo	36	32 (88.9)	-0.90 (0.89)	-3.2	-1.30	-0.80	-0.20	0.4	
		Week 26	Tezepelumab	40	40 (100.0)	-0.97 (1.18)	-3.0	-2.10	-1.00	-0.20	2.6	-0.03 [-0.49, 0.44]
			Placebo	36	32 (88.9)	-0.94 (0.98)	-2.6	-1.60	-0.80	-0.20	0.8	
		Week 28	Tezepelumab	40	40 (100.0)	-1.00 (1.31)	-3.4	-2.20	-1.00	0.00	2.6	-0.09 [-0.55, 0.37]
			Placebo	36	33 (91.7)	-0.89 (1.08)	-2.8	-1.60	-0.60	-0.20	1.2	
		Week 30	Tezepelumab	40	40 (100.0)	-1.04 (1.31)	-3.8	-2.20	-1.00	-0.20	2.6	-0.04 [-0.50, 0.42]
			Placebo	36	33 (91.7)	-0.98 (1.17)	-3.2	-1.60	-1.00	-0.40	2.0	
		Week 32	Tezepelumab	40	40 (100.0)	-1.09 (1.23)	-3.2	-2.20	-1.20	-0.30	2.6	-0.09 [-0.55, 0.38]
			Placebo	36	33 (91.7)	-0.99 (0.97)	-3.2	-1.40	-1.00	-0.20	0.8	
		Week 34	Tezepelumab	40	40 (100.0)	-1.05 (1.31)	-3.0	-2.20	-1.40	-0.20	2.6	-0.06 [-0.52, 0.40]
			Placebo	36	33 (91.7)	-0.98 (0.83)	-2.8	-1.40	-1.00	-0.20	0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	Change from baseline	Week 36	Tezepelumab	40	40 (100.0)	-1.11 (1.28)	-3.2	-2.20	-1.20	-0.10	2.6	-0.20 [-0.67, 0.26]
			Placebo	36	33 (91.7)	-0.87 (1.00)	-3.6	-1.20	-1.00	-0.20	1.4	
		Week 38	Tezepelumab	40	40 (100.0)	-1.08 (1.32)	-3.2	-2.20	-1.20	-0.20	2.6	-0.14 [-0.60, 0.32]
			Placebo	36	33 (91.7)	-0.92 (0.93)	-3.0	-1.40	-0.80	-0.40	1.0	
		Week 40	Tezepelumab	40	40 (100.0)	-1.13 (1.31)	-3.4	-2.20	-1.20	-0.40	2.6	-0.31 [-0.77, 0.16]
			Placebo	36	33 (91.7)	-0.75 (1.15)	-3.2	-1.20	-0.80	0.00	1.4	
		Week 42	Tezepelumab	40	40 (100.0)	-1.12 (1.34)	-3.6	-2.20	-1.20	-0.40	2.6	-0.15 [-0.61, 0.31]
			Placebo	36	33 (91.7)	-0.93 (1.04)	-2.8	-1.40	-1.00	-0.40	1.6	
		Week 44	Tezepelumab	40	40 (100.0)	-1.09 (1.32)	-3.8	-2.20	-1.10	-0.30	2.6	-0.19 [-0.66, 0.27]
			Placebo	36	33 (91.7)	-0.85 (1.08)	-3.4	-1.40	-0.80	-0.20	1.6	
		Week 46	Tezepelumab	40	40 (100.0)	-1.03 (1.34)	-3.6	-2.20	-1.00	0.00	2.6	-0.05 [-0.51, 0.41]
			Placebo	36	33 (91.7)	-0.97 (0.92)	-2.8	-1.40	-0.80	-0.40	1.2	
		Week 48	Tezepelumab	40	40 (100.0)	-1.00 (1.33)	-2.8	-2.20	-1.00	-0.10	2.6	-0.09 [-0.55, 0.37]
			Placebo	36	33 (91.7)	-0.90 (0.98)	-3.4	-1.40	-0.60	-0.20	1.0	
		Week 50	Tezepelumab	40	40 (100.0)	-1.04 (1.30)	-2.8	-2.10	-1.20	-0.20	2.6	0.01 [-0.45, 0.47]
			Placebo	36	33 (91.7)	-1.05 (0.92)	-3.6	-1.40	-1.00	-0.40	0.4	
		Week 52	Tezepelumab	40	40 (100.0)	-1.01 (1.27)	-3.0	-1.90	-1.20	-0.20	2.6	-0.08 [-0.54, 0.38]
			Placebo	36	33 (91.7)	-0.92 (0.95)	-3.6	-1.20	-0.80	-0.40	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	3.00 (1.23)	1.8	2.00	2.90	3.20	5.2	
			Placebo	4	4 (100.0)	3.00 (0.73)	2.2	2.40	3.00	3.60	3.8	
		Week 2	Tezepelumab	6	5 (83.3)	1.92 (1.25)	0.0	1.60	2.20	2.40	3.4	
			Placebo	4	3 (75.0)	1.60 (0.35)	1.4	1.40	1.40	2.00	2.0	
		Week 4	Tezepelumab	6	5 (83.3)	1.88 (1.01)	0.8	1.20	1.80	2.20	3.4	
			Placebo	4	3 (75.0)	1.53 (1.27)	0.8	0.80	0.80	3.00	3.0	
		Week 6	Tezepelumab	6	5 (83.3)	1.88 (1.08)	0.4	1.60	1.80	2.20	3.4	
			Placebo	4	3 (75.0)	1.20 (0.72)	0.6	0.60	1.00	2.00	2.0	
		Week 8	Tezepelumab	6	5 (83.3)	1.28 (1.04)	0.2	0.80	1.20	1.20	3.0	
			Placebo	4	3 (75.0)	1.47 (1.55)	0.2	0.20	1.00	3.20	3.2	
		Week 10	Tezepelumab	6	5 (83.3)	1.12 (1.15)	0.2	0.40	0.60	1.40	3.0	
			Placebo	4	3 (75.0)	2.07 (2.76)	0.0	0.00	1.00	5.20	5.2	
		Week 12	Tezepelumab	6	5 (83.3)	1.08 (0.58)	0.6	0.60	1.00	1.20	2.0	
			Placebo	4	3 (75.0)	1.60 (1.97)	0.0	0.00	1.00	3.80	3.8	
		Week 14	Tezepelumab	6	5 (83.3)	1.04 (0.68)	0.4	0.80	0.80	1.00	2.2	
			Placebo	4	3 (75.0)	2.13 (2.50)	0.4	0.40	1.00	5.00	5.0	
		Week 16	Tezepelumab	6	5 (83.3)	1.28 (0.56)	0.8	1.00	1.00	1.40	2.2	
			Placebo	4	3 (75.0)	2.07 (2.57)	0.2	0.20	1.00	5.00	5.0	
		Week 18	Tezepelumab	6	5 (83.3)	1.16 (0.65)	0.4	1.00	1.00	1.20	2.2	
			Placebo	4	3 (75.0)	2.07 (2.57)	0.2	0.20	1.00	5.00	5.0	
		Week 20	Tezepelumab	6	5 (83.3)	1.24 (0.61)	0.6	1.00	1.00	1.40	2.2	
			Placebo	4	3 (75.0)	1.87 (2.72)	0.2	0.20	0.40	5.00	5.0	
		Week 22	Tezepelumab	6	5 (83.3)	1.12 (0.63)	0.6	0.80	1.00	1.00	2.2	
			Placebo	4	3 (75.0)	1.80 (2.78)	0.0	0.00	0.40	5.00	5.0	
		Week 24	Tezepelumab	6	5 (83.3)	1.44 (0.62)	0.8	1.00	1.20	2.00	2.2	
			Placebo	4	3 (75.0)	1.53 (2.14)	0.2	0.20	0.40	4.00	4.0	
		Week 26	Tezepelumab	6	5 (83.3)	1.32 (0.59)	0.6	1.00	1.40	1.40	2.2	
			Placebo	4	3 (75.0)	1.60 (2.08)	0.4	0.40	0.40	4.00	4.0	
		Week 28	Tezepelumab	6	6 (100.0)	1.10 (0.68)	0.4	0.40	1.10	1.40	2.2	
			Placebo	4	3 (75.0)	1.60 (2.08)	0.4	0.40	0.40	4.00	4.0	
		Week 30	Tezepelumab	6	6 (100.0)	1.13 (0.71)	0.2	0.60	1.10	1.60	2.2	
			Placebo	4	3 (75.0)	1.60 (2.08)	0.4	0.40	0.40	4.00	4.0	
		Week 32	Tezepelumab	6	6 (100.0)	1.23 (0.67)	0.2	1.00	1.20	1.60	2.2	
			Placebo	4	3 (75.0)	1.67 (2.02)	0.4	0.40	0.60	4.00	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
America	Absolute values	Week 34	Tezepelumab	6	6 (100.0)	1.13 (0.78)	0.0	0.80	1.00	1.80	2.2	
			Placebo	4	3 (75.0)	1.53 (2.16)	0.0	0.00	0.60	4.00	4.0	
		Week 36	Tezepelumab	6	6 (100.0)	1.63 (0.57)	1.0	1.00	1.70	2.20	2.2	
			Placebo	4	3 (75.0)	1.73 (2.05)	0.0	0.00	1.20	4.00	4.0	
		Week 38	Tezepelumab	6	6 (100.0)	1.17 (0.70)	0.4	0.60	1.00	1.80	2.2	
			Placebo	4	3 (75.0)	1.67 (2.08)	0.0	0.00	1.00	4.00	4.0	
		Week 40	Tezepelumab	6	6 (100.0)	1.37 (0.78)	0.2	1.00	1.30	2.20	2.2	
			Placebo	4	3 (75.0)	1.73 (2.05)	0.0	0.00	1.20	4.00	4.0	
		Week 42	Tezepelumab	6	6 (100.0)	1.30 (0.69)	0.2	1.00	1.30	1.80	2.2	
			Placebo	4	3 (75.0)	0.93 (0.83)	0.0	0.00	1.20	1.60	1.6	
		Week 44	Tezepelumab	6	6 (100.0)	1.40 (0.70)	0.4	1.00	1.40	2.00	2.2	
			Placebo	4	3 (75.0)	1.00 (0.20)	0.8	0.80	1.00	1.20	1.2	
		Week 46	Tezepelumab	6	6 (100.0)	1.17 (0.72)	0.2	0.80	1.00	1.80	2.2	
			Placebo	4	3 (75.0)	0.93 (0.31)	0.6	0.60	1.00	1.20	1.2	
		Week 48	Tezepelumab	6	6 (100.0)	1.20 (0.69)	0.2	0.80	1.20	1.60	2.2	
			Placebo	4	3 (75.0)	0.80 (0.35)	0.4	0.40	1.00	1.00	1.0	
		Week 50	Tezepelumab	6	6 (100.0)	0.83 (0.83)	0.0	0.00	0.80	1.20	2.2	
			Placebo	4	3 (75.0)	2.07 (1.51)	1.0	1.00	1.40	3.80	3.8	
		Week 52	Tezepelumab	6	6 (100.0)	1.10 (0.77)	0.0	0.60	1.10	1.60	2.2	
			Placebo	4	3 (75.0)	1.73 (1.92)	0.0	0.00	1.40	3.80	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	6	5 (83.3)	-1.16 (1.37)	-3.2	-1.80	-0.80	-0.20	0.2	0.08 [-1.35, 1.52]
			Placebo	4	3 (75.0)	-1.27 (1.10)	-2.4	-2.40	-1.20	-0.20	-0.2	
		Week 4	Tezepelumab	6	5 (83.3)	-1.20 (1.02)	-2.4	-1.80	-1.40	-0.60	0.2	0.10 [-1.33, 1.54]
			Placebo	4	3 (75.0)	-1.33 (1.70)	-3.0	-3.00	-1.40	0.40	0.4	
		Week 6	Tezepelumab	6	5 (83.3)	-1.20 (1.29)	-2.8	-1.80	-1.60	-0.20	0.4	0.36 [-1.09, 1.80]
			Placebo	4	3 (75.0)	-1.67 (1.36)	-3.2	-3.20	-1.20	-0.60	-0.6	
		Week 8	Tezepelumab	6	5 (83.3)	-1.80 (0.91)	-3.0	-2.20	-2.00	-1.00	-0.8	-0.28 [-1.72, 1.16]
			Placebo	4	3 (75.0)	-1.40 (2.11)	-3.6	-3.60	-1.20	0.60	0.6	
		Week 10	Tezepelumab	6	5 (83.3)	-1.96 (0.96)	-3.0	-2.60	-2.20	-1.40	-0.6	-0.57 [-2.04, 0.89]
			Placebo	4	3 (75.0)	-0.80 (3.22)	-3.8	-3.80	-1.20	2.60	2.6	
		Week 12	Tezepelumab	6	5 (83.3)	-2.00 (0.99)	-3.2	-2.60	-2.20	-1.20	-0.8	-0.44 [-1.90, 1.01]
			Placebo	4	3 (75.0)	-1.27 (2.50)	-3.8	-3.80	-1.20	1.20	1.2	
		Week 14	Tezepelumab	6	5 (83.3)	-2.04 (0.91)	-3.0	-2.80	-2.20	-1.20	-1.0	-0.71 [-2.19, 0.78]
			Placebo	4	3 (75.0)	-0.73 (2.93)	-3.4	-3.40	-1.20	2.40	2.4	
		Week 16	Tezepelumab	6	5 (83.3)	-1.80 (1.05)	-3.0	-2.40	-2.20	-0.80	-0.6	-0.51 [-1.98, 0.95]
			Placebo	4	3 (75.0)	-0.80 (3.02)	-3.6	-3.60	-1.20	2.40	2.4	
		Week 18	Tezepelumab	6	5 (83.3)	-1.92 (1.06)	-3.0	-2.80	-2.20	-0.80	-0.8	-0.57 [-2.04, 0.89]
			Placebo	4	3 (75.0)	-0.80 (3.02)	-3.6	-3.60	-1.20	2.40	2.4	
		Week 20	Tezepelumab	6	5 (83.3)	-1.84 (1.08)	-3.0	-2.60	-2.20	-0.80	-0.6	-0.42 [-1.87, 1.03]
			Placebo	4	3 (75.0)	-1.00 (3.08)	-3.6	-3.60	-1.80	2.40	2.4	
		Week 22	Tezepelumab	6	5 (83.3)	-1.96 (0.77)	-3.0	-2.20	-2.20	-1.20	-1.2	-0.46 [-1.92, 0.99]
			Placebo	4	3 (75.0)	-1.07 (3.16)	-3.8	-3.80	-1.80	2.40	2.4	
		Week 24	Tezepelumab	6	5 (83.3)	-1.64 (1.31)	-3.0	-2.40	-2.20	-0.80	0.2	-0.17 [-1.60, 1.27]
			Placebo	4	3 (75.0)	-1.33 (2.53)	-3.6	-3.60	-1.80	1.40	1.4	
		Week 26	Tezepelumab	6	5 (83.3)	-1.76 (1.19)	-3.0	-2.60	-2.20	-0.60	-0.4	-0.29 [-1.73, 1.15]
			Placebo	4	3 (75.0)	-1.27 (2.44)	-3.4	-3.40	-1.80	1.40	1.4	
		Week 28	Tezepelumab	6	6 (100.0)	-1.90 (1.06)	-3.0	-2.80	-2.20	-0.60	-0.6	-0.40 [-1.80, 1.00]
			Placebo	4	3 (75.0)	-1.27 (2.44)	-3.4	-3.40	-1.80	1.40	1.4	
		Week 30	Tezepelumab	6	6 (100.0)	-1.87 (1.09)	-3.0	-2.60	-2.30	-0.60	-0.4	-0.38 [-1.77, 1.02]
			Placebo	4	3 (75.0)	-1.27 (2.44)	-3.4	-3.40	-1.80	1.40	1.4	
		Week 32	Tezepelumab	6	6 (100.0)	-1.77 (0.96)	-3.0	-2.40	-1.90	-1.00	-0.4	-0.38 [-1.78, 1.02]
			Placebo	4	3 (75.0)	-1.20 (2.36)	-3.2	-3.20	-1.80	1.40	1.4	
		Week 34	Tezepelumab	6	6 (100.0)	-1.87 (1.11)	-3.0	-2.60	-2.30	-0.80	-0.2	-0.33 [-1.73, 1.06]
			Placebo	4	3 (75.0)	-1.33 (2.42)	-3.2	-3.20	-2.20	1.40	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
America	Change from baseline	Week 36	Tezepelumab	6	6 (100.0)	-1.37 (1.35)	-3.0	-2.20	-1.70	0.00	0.4	-0.14 [-1.53, 1.25]
			Placebo	4	3 (75.0)	-1.13 (2.20)	-2.6	-2.60	-2.20	1.40	1.4	
		Week 38	Tezepelumab	6	6 (100.0)	-1.83 (1.09)	-3.0	-2.60	-2.20	-0.80	-0.2	-0.42 [-1.82, 0.99]
			Placebo	4	3 (75.0)	-1.20 (2.27)	-2.8	-2.80	-2.20	1.40	1.4	
		Week 40	Tezepelumab	6	6 (100.0)	-1.63 (1.17)	-3.0	-2.40	-1.90	-0.80	0.2	-0.33 [-1.72, 1.07]
			Placebo	4	3 (75.0)	-1.13 (2.20)	-2.6	-2.60	-2.20	1.40	1.4	
		Week 42	Tezepelumab	6	6 (100.0)	-1.70 (0.99)	-3.0	-2.40	-1.80	-0.60	-0.6	0.25 [-1.15, 1.64]
			Placebo	4	3 (75.0)	-1.93 (0.83)	-2.6	-2.60	-2.20	-1.00	-1.0	
		Week 44	Tezepelumab	6	6 (100.0)	-1.60 (1.09)	-3.0	-2.20	-1.80	-0.80	0.0	0.27 [-1.12, 1.66]
			Placebo	4	3 (75.0)	-1.87 (0.64)	-2.6	-2.60	-1.60	-1.40	-1.4	
		Week 46	Tezepelumab	6	6 (100.0)	-1.83 (1.03)	-3.0	-2.40	-2.20	-1.00	-0.2	0.11 [-1.28, 1.50]
			Placebo	4	3 (75.0)	-1.93 (0.58)	-2.6	-2.60	-1.60	-1.60	-1.6	
		Week 48	Tezepelumab	6	6 (100.0)	-1.80 (0.95)	-3.0	-2.40	-2.00	-1.00	-0.4	0.30 [-1.09, 1.70]
			Placebo	4	3 (75.0)	-2.07 (0.64)	-2.8	-2.80	-1.80	-1.60	-1.6	
		Week 50	Tezepelumab	6	6 (100.0)	-2.17 (0.98)	-3.2	-3.00	-2.40	-1.20	-0.8	-0.98 [-2.45, 0.50]
			Placebo	4	3 (75.0)	-0.80 (2.12)	-2.4	-2.40	-1.60	1.60	1.6	
		Week 52	Tezepelumab	6	6 (100.0)	-1.90 (1.05)	-3.2	-3.00	-1.70	-1.00	-0.8	-0.50 [-1.91, 0.91]
			Placebo	4	3 (75.0)	-1.13 (2.37)	-2.6	-2.60	-2.40	1.60	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.73 (0.58)	2.4	2.40	2.40	3.40	3.4	
			Placebo	3	3 (100.0)	2.80 (0.35)	2.6	2.60	2.60	3.20	3.2	
		Week 2	Tezepelumab	3	3 (100.0)	1.93 (1.14)	1.0	1.00	1.60	3.20	3.2	
			Placebo	3	3 (100.0)	2.47 (0.12)	2.4	2.40	2.40	2.60	2.6	
		Week 4	Tezepelumab	3	3 (100.0)	1.47 (0.83)	0.8	0.80	1.20	2.40	2.4	
			Placebo	3	3 (100.0)	2.07 (0.61)	1.4	1.40	2.20	2.60	2.6	
		Week 6	Tezepelumab	3	3 (100.0)	1.27 (0.46)	1.0	1.00	1.00	1.80	1.8	
			Placebo	3	3 (100.0)	1.93 (0.83)	1.0	1.00	2.20	2.60	2.6	
		Week 8	Tezepelumab	3	3 (100.0)	1.13 (0.61)	0.6	0.60	1.00	1.80	1.8	
			Placebo	3	3 (100.0)	2.40 (0.20)	2.2	2.20	2.40	2.60	2.6	
		Week 10	Tezepelumab	3	3 (100.0)	1.00 (0.35)	0.8	0.80	0.80	1.40	1.4	
			Placebo	3	3 (100.0)	2.00 (0.35)	1.8	1.80	1.80	2.40	2.4	
		Week 12	Tezepelumab	3	3 (100.0)	0.60 (0.87)	0.0	0.00	0.20	1.60	1.6	
			Placebo	3	3 (100.0)	2.00 (0.20)	1.8	1.80	2.00	2.20	2.2	
		Week 14	Tezepelumab	3	3 (100.0)	0.93 (0.42)	0.6	0.60	0.80	1.40	1.4	
			Placebo	3	3 (100.0)	1.67 (0.42)	1.2	1.20	1.80	2.00	2.0	
		Week 16	Tezepelumab	3	3 (100.0)	0.80 (0.53)	0.2	0.20	1.00	1.20	1.2	
			Placebo	3	3 (100.0)	1.60 (0.87)	0.6	0.60	2.00	2.20	2.2	
		Week 18	Tezepelumab	3	3 (100.0)	0.73 (0.23)	0.6	0.60	0.60	1.00	1.0	
			Placebo	3	3 (100.0)	2.20 (0.00)	2.2	2.20	2.20	2.20	2.2	
		Week 20	Tezepelumab	3	3 (100.0)	0.80 (0.40)	0.4	0.40	0.80	1.20	1.2	
			Placebo	3	3 (100.0)	2.53 (0.81)	1.8	1.80	2.40	3.40	3.4	
		Week 22	Tezepelumab	3	3 (100.0)	0.60 (0.53)	0.0	0.00	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	2.13 (0.81)	1.2	1.20	2.60	2.60	2.6	
		Week 24	Tezepelumab	3	3 (100.0)	0.73 (0.31)	0.4	0.40	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	2.53 (0.31)	2.2	2.20	2.60	2.80	2.8	
		Week 26	Tezepelumab	3	3 (100.0)	0.73 (0.46)	0.2	0.20	1.00	1.00	1.0	
			Placebo	3	3 (100.0)	2.07 (0.46)	1.8	1.80	1.80	2.60	2.6	
		Week 28	Tezepelumab	3	3 (100.0)	0.73 (0.46)	0.2	0.20	1.00	1.00	1.0	
			Placebo	3	3 (100.0)	1.60 (1.06)	0.4	0.40	2.00	2.40	2.4	
		Week 30	Tezepelumab	3	3 (100.0)	0.73 (0.12)	0.6	0.60	0.80	0.80	0.8	
			Placebo	3	3 (100.0)	1.07 (1.01)	0.0	0.00	1.20	2.00	2.0	
		Week 32	Tezepelumab	3	3 (100.0)	0.67 (0.42)	0.2	0.20	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	1.47 (0.61)	0.8	0.80	1.60	2.00	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia/Pacific	Absolute values	Week 34	Tezepelumab	3	3 (100.0)	0.67 (0.23)	0.4	0.40	0.80	0.80	0.8	
			Placebo	3	3 (100.0)	1.67 (0.90)	0.8	0.80	1.60	2.60	2.6	
		Week 36	Tezepelumab	3	3 (100.0)	0.73 (0.46)	0.2	0.20	1.00	1.00	1.0	
			Placebo	3	3 (100.0)	2.73 (0.61)	2.2	2.20	2.60	3.40	3.4	
		Week 38	Tezepelumab	3	3 (100.0)	0.87 (1.03)	0.0	0.00	0.60	2.00	2.0	
			Placebo	3	3 (100.0)	1.40 (0.72)	0.6	0.60	1.60	2.00	2.0	
		Week 40	Tezepelumab	3	3 (100.0)	0.67 (0.23)	0.4	0.40	0.80	0.80	0.8	
			Placebo	3	3 (100.0)	2.07 (0.50)	1.6	1.60	2.00	2.60	2.6	
		Week 42	Tezepelumab	3	3 (100.0)	0.80 (0.35)	0.4	0.40	1.00	1.00	1.0	
			Placebo	3	3 (100.0)	1.73 (0.31)	1.4	1.40	1.80	2.00	2.0	
		Week 44	Tezepelumab	3	3 (100.0)	0.60 (0.40)	0.2	0.20	0.60	1.00	1.0	
			Placebo	3	3 (100.0)	3.20 (0.53)	2.8	2.80	3.00	3.80	3.8	
		Week 46	Tezepelumab	3	3 (100.0)	0.73 (0.46)	0.2	0.20	1.00	1.00	1.0	
			Placebo	3	3 (100.0)	1.40 (0.92)	0.4	0.40	1.60	2.20	2.2	
		Week 48	Tezepelumab	3	3 (100.0)	0.73 (0.31)	0.4	0.40	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	2.33 (0.31)	2.0	2.00	2.40	2.60	2.6	
		Week 50	Tezepelumab	3	3 (100.0)	0.73 (0.31)	0.4	0.40	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	1.73 (0.31)	1.4	1.40	1.80	2.00	2.0	
		Week 52	Tezepelumab	3	3 (100.0)	0.73 (0.31)	0.4	0.40	0.80	1.00	1.0	
			Placebo	3	3 (100.0)	1.73 (0.31)	1.4	1.40	1.80	2.00	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.80 (0.60)	-1.4	-1.40	-0.80	-0.20	-0.2	-0.90 [-2.62, 0.81]
			Placebo	3	3 (100.0)	-0.33 (0.42)	-0.8	-0.80	-0.20	0.00	0.0	
		Week 4	Tezepelumab	3	3 (100.0)	-1.27 (0.31)	-1.6	-1.60	-1.20	-1.00	-1.0	-0.76 [-2.44, 0.93]
			Placebo	3	3 (100.0)	-0.73 (0.95)	-1.8	-1.80	-0.40	0.00	0.0	
		Week 6	Tezepelumab	3	3 (100.0)	-1.47 (0.12)	-1.6	-1.60	-1.40	-1.40	-1.4	-1.30 [-3.14, 0.54]
			Placebo	3	3 (100.0)	-0.87 (0.64)	-1.6	-1.60	-0.60	-0.40	-0.4	
		Week 8	Tezepelumab	3	3 (100.0)	-1.60 (0.20)	-1.8	-1.80	-1.60	-1.40	-1.4	-3.79 [-6.87, -0.72]
			Placebo	3	3 (100.0)	-0.40 (0.40)	-0.8	-0.80	-0.40	0.00	0.0	
		Week 10	Tezepelumab	3	3 (100.0)	-1.73 (0.23)	-2.0	-2.00	-1.60	-1.60	-1.6	-5.72 [-9.99, -1.44]
			Placebo	3	3 (100.0)	-0.80 (0.00)	-0.8	-0.80	-0.80	-0.80	-0.8	
		Week 12	Tezepelumab	3	3 (100.0)	-2.13 (0.31)	-2.4	-2.40	-2.20	-1.80	-1.8	-5.16 [-9.08, -1.24]
			Placebo	3	3 (100.0)	-0.80 (0.20)	-1.0	-1.00	-0.80	-0.60	-0.6	
		Week 14	Tezepelumab	3	3 (100.0)	-1.80 (0.20)	-2.0	-2.00	-1.80	-1.60	-1.6	-1.87 [-3.93, 0.19]
			Placebo	3	3 (100.0)	-1.13 (0.46)	-1.4	-1.40	-1.40	-0.60	-0.6	
		Week 16	Tezepelumab	3	3 (100.0)	-1.93 (0.46)	-2.2	-2.20	-2.20	-1.40	-1.4	-1.12 [-2.90, 0.66]
			Placebo	3	3 (100.0)	-1.20 (0.80)	-2.0	-2.00	-1.20	-0.40	-0.4	
		Week 18	Tezepelumab	3	3 (100.0)	-2.00 (0.35)	-2.4	-2.40	-1.80	-1.80	-1.8	-4.04 [-7.27, -0.82]
			Placebo	3	3 (100.0)	-0.60 (0.35)	-1.0	-1.00	-0.40	-0.40	-0.4	
		Week 20	Tezepelumab	3	3 (100.0)	-1.93 (0.31)	-2.2	-2.20	-2.00	-1.60	-1.6	-2.06 [-4.21, 0.08]
			Placebo	3	3 (100.0)	-0.27 (1.10)	-1.4	-1.40	-0.20	0.80	0.8	
		Week 22	Tezepelumab	3	3 (100.0)	-2.13 (0.46)	-2.4	-2.40	-2.40	-1.60	-1.6	-2.47 [-4.81, -0.13]
			Placebo	3	3 (100.0)	-0.67 (0.70)	-1.4	-1.40	-0.60	0.00	0.0	
		Week 24	Tezepelumab	3	3 (100.0)	-2.00 (0.40)	-2.4	-2.40	-2.00	-1.60	-1.6	-3.24 [-5.99, -0.48]
			Placebo	3	3 (100.0)	-0.27 (0.64)	-1.0	-1.00	0.00	0.20	0.2	
		Week 26	Tezepelumab	3	3 (100.0)	-2.00 (0.53)	-2.4	-2.40	-2.20	-1.40	-1.4	-2.04 [-4.17, 0.10]
			Placebo	3	3 (100.0)	-0.73 (0.70)	-1.4	-1.40	-0.80	0.00	0.0	
		Week 28	Tezepelumab	3	3 (100.0)	-2.00 (0.53)	-2.4	-2.40	-2.20	-1.40	-1.4	-1.11 [-2.88, 0.67]
			Placebo	3	3 (100.0)	-1.20 (0.87)	-2.2	-2.20	-0.80	-0.60	-0.6	
		Week 30	Tezepelumab	3	3 (100.0)	-2.00 (0.53)	-2.6	-2.60	-1.80	-1.60	-1.6	-0.41 [-2.03, 1.22]
			Placebo	3	3 (100.0)	-1.73 (0.76)	-2.6	-2.60	-1.40	-1.20	-1.2	
		Week 32	Tezepelumab	3	3 (100.0)	-2.07 (0.42)	-2.4	-2.40	-2.20	-1.60	-1.6	-1.35 [-3.21, 0.50]
			Placebo	3	3 (100.0)	-1.33 (0.64)	-1.8	-1.80	-1.60	-0.60	-0.6	
		Week 34	Tezepelumab	3	3 (100.0)	-2.07 (0.50)	-2.6	-2.60	-2.00	-1.60	-1.6	-1.67 [-3.64, 0.31]
			Placebo	3	3 (100.0)	-1.13 (0.61)	-1.8	-1.80	-1.00	-0.60	-0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia/Pacific	Change from baseline	Week 36	Tezepelumab	3	3 (100.0)	-2.00 (0.53)	-2.4	-2.40	-2.20	-1.40	-1.4	-2.96 [-5.56, -0.36]
			Placebo	3	3 (100.0)	-0.07 (0.76)	-0.6	-0.60	-0.40	0.80	0.8	
		Week 38	Tezepelumab	3	3 (100.0)	-1.87 (0.50)	-2.4	-2.40	-1.80	-1.40	-1.4	-0.90 [-2.62, 0.81]
			Placebo	3	3 (100.0)	-1.40 (0.53)	-2.0	-2.00	-1.20	-1.00	-1.0	
		Week 40	Tezepelumab	3	3 (100.0)	-2.07 (0.50)	-2.6	-2.60	-2.00	-1.60	-1.6	-2.31 [-4.57, -0.05]
			Placebo	3	3 (100.0)	-0.73 (0.64)	-1.2	-1.20	-1.00	0.00	0.0	
		Week 42	Tezepelumab	3	3 (100.0)	-1.93 (0.50)	-2.4	-2.40	-2.00	-1.40	-1.4	-2.21 [-4.43, 0.00]
			Placebo	3	3 (100.0)	-1.07 (0.23)	-1.2	-1.20	-1.20	-0.80	-0.8	
		Week 44	Tezepelumab	3	3 (100.0)	-2.13 (0.70)	-2.8	-2.80	-2.20	-1.40	-1.4	-3.37 [-6.19, -0.54]
			Placebo	3	3 (100.0)	0.40 (0.80)	-0.4	-0.40	0.40	1.20	1.2	
		Week 46	Tezepelumab	3	3 (100.0)	-2.00 (0.53)	-2.4	-2.40	-2.20	-1.40	-1.4	-0.97 [-2.71, 0.76]
			Placebo	3	3 (100.0)	-1.40 (0.69)	-2.2	-2.20	-1.00	-1.00	-1.0	
		Week 48	Tezepelumab	3	3 (100.0)	-2.00 (0.40)	-2.4	-2.40	-2.00	-1.60	-1.6	-3.76 [-6.81, -0.70]
			Placebo	3	3 (100.0)	-0.47 (0.42)	-0.8	-0.80	-0.60	0.00	0.0	
		Week 50	Tezepelumab	3	3 (100.0)	-2.00 (0.60)	-2.6	-2.60	-2.00	-1.40	-1.4	-1.81 [-3.84, 0.22]
			Placebo	3	3 (100.0)	-1.07 (0.42)	-1.4	-1.40	-1.20	-0.60	-0.6	
		Week 52	Tezepelumab	3	3 (100.0)	-2.00 (0.60)	-2.6	-2.60	-2.00	-1.40	-1.4	-1.81 [-3.84, 0.22]
			Placebo	3	3 (100.0)	-1.07 (0.42)	-1.4	-1.40	-1.20	-0.60	-0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	17	17 (100.0)	2.81 (0.49)	2.0	2.60	2.80	3.20	3.8	
			Placebo	22	22 (100.0)	3.16 (0.84)	1.4	2.80	3.00	3.40	5.0	
		Week 2	Tezepelumab	17	17 (100.0)	2.32 (0.71)	1.2	1.60	2.20	2.80	3.8	
			Placebo	22	20 (90.9)	2.57 (1.01)	0.4	2.10	2.40	3.00	5.0	
		Week 4	Tezepelumab	17	17 (100.0)	1.98 (0.91)	0.2	1.60	2.00	2.60	3.4	
			Placebo	22	20 (90.9)	2.45 (0.91)	0.2	2.00	2.60	3.10	3.6	
		Week 6	Tezepelumab	17	17 (100.0)	1.96 (0.96)	0.2	1.20	2.00	2.60	3.8	
			Placebo	22	20 (90.9)	2.60 (1.23)	0.2	2.00	2.70	3.00	6.0	
		Week 8	Tezepelumab	17	17 (100.0)	1.71 (0.91)	0.0	1.00	1.60	2.60	2.8	
			Placebo	22	21 (95.5)	2.35 (1.28)	0.0	1.80	2.40	2.80	5.0	
		Week 10	Tezepelumab	17	17 (100.0)	1.65 (0.92)	0.0	1.40	1.60	2.20	3.4	
			Placebo	22	21 (95.5)	2.24 (1.01)	0.2	1.80	2.40	2.60	4.4	
		Week 12	Tezepelumab	17	17 (100.0)	1.54 (0.92)	0.0	0.60	1.60	2.40	2.8	
			Placebo	22	21 (95.5)	2.17 (1.00)	0.0	2.00	2.20	2.80	4.4	
		Week 14	Tezepelumab	17	17 (100.0)	1.36 (0.75)	0.0	1.20	1.40	1.80	2.6	
			Placebo	22	21 (95.5)	2.06 (1.03)	0.0	1.40	2.20	2.40	5.0	
		Week 16	Tezepelumab	17	17 (100.0)	1.67 (1.18)	0.0	0.80	1.40	2.20	4.6	
			Placebo	22	21 (95.5)	2.18 (1.29)	0.0	1.40	2.20	2.80	5.0	
		Week 18	Tezepelumab	17	17 (100.0)	1.62 (0.97)	0.0	1.00	1.60	2.40	3.2	
			Placebo	22	21 (95.5)	2.16 (1.15)	0.0	1.40	2.40	2.80	4.4	
		Week 20	Tezepelumab	17	17 (100.0)	1.69 (0.90)	0.0	1.00	1.60	2.60	2.8	
			Placebo	22	21 (95.5)	2.36 (1.08)	0.2	1.80	2.40	3.00	4.4	
		Week 22	Tezepelumab	17	17 (100.0)	1.78 (0.78)	0.0	1.40	2.00	2.40	2.8	
			Placebo	22	21 (95.5)	2.38 (1.17)	0.0	1.80	2.40	3.20	4.4	
		Week 24	Tezepelumab	17	17 (100.0)	1.82 (0.92)	0.0	1.20	1.60	2.60	3.4	
			Placebo	22	21 (95.5)	2.28 (1.16)	0.2	1.60	2.20	3.20	4.4	
		Week 26	Tezepelumab	17	17 (100.0)	1.81 (1.04)	0.0	1.40	1.80	2.40	3.6	
			Placebo	22	21 (95.5)	2.20 (1.27)	0.0	1.20	2.20	3.20	4.4	
		Week 28	Tezepelumab	17	17 (100.0)	1.78 (1.03)	0.0	1.40	1.80	2.40	3.6	
			Placebo	22	21 (95.5)	2.26 (1.24)	0.0	1.20	2.40	3.20	4.4	
		Week 30	Tezepelumab	17	17 (100.0)	1.72 (0.88)	0.0	1.20	1.60	2.20	3.0	
			Placebo	22	21 (95.5)	2.41 (1.04)	0.8	1.60	2.40	3.20	4.4	
		Week 32	Tezepelumab	17	17 (100.0)	1.55 (0.91)	0.0	1.00	1.80	2.20	2.8	
			Placebo	22	21 (95.5)	2.27 (1.24)	0.6	1.20	2.00	3.00	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of the world	Absolute values	Week 34	Tezepelumab	17	17 (100.0)	1.80 (1.01)	0.0	1.00	2.20	2.60	3.2	
			Placebo	22	21 (95.5)	2.16 (1.35)	0.0	1.20	1.80	3.20	4.8	
		Week 36	Tezepelumab	17	17 (100.0)	1.59 (1.03)	0.0	1.20	1.40	2.60	3.2	
			Placebo	22	21 (95.5)	2.31 (1.30)	0.0	1.60	2.20	3.20	4.8	
		Week 38	Tezepelumab	17	17 (100.0)	1.84 (1.09)	0.0	1.20	1.80	2.60	3.6	
			Placebo	22	21 (95.5)	2.21 (1.28)	0.0	1.40	1.80	3.00	4.8	
		Week 40	Tezepelumab	17	17 (100.0)	1.85 (1.08)	0.0	1.20	2.00	2.60	3.8	
			Placebo	22	21 (95.5)	2.24 (1.17)	0.4	1.40	2.00	3.00	4.4	
		Week 42	Tezepelumab	17	17 (100.0)	1.61 (0.97)	0.0	1.20	1.60	2.40	3.2	
			Placebo	22	21 (95.5)	2.30 (1.14)	0.4	1.40	2.40	3.00	4.4	
		Week 44	Tezepelumab	17	17 (100.0)	1.69 (1.05)	0.0	1.00	1.60	2.60	3.0	
			Placebo	22	21 (95.5)	2.19 (1.15)	0.6	1.20	2.20	3.20	4.4	
		Week 46	Tezepelumab	17	17 (100.0)	1.73 (1.05)	0.0	1.00	1.80	2.60	3.0	
			Placebo	22	21 (95.5)	2.29 (1.16)	0.0	1.60	2.00	3.00	4.4	
		Week 48	Tezepelumab	17	17 (100.0)	1.66 (1.02)	0.0	0.80	2.20	2.40	3.0	
			Placebo	22	21 (95.5)	2.23 (1.26)	0.0	1.40	2.20	3.00	4.6	
		Week 50	Tezepelumab	17	17 (100.0)	1.64 (0.99)	0.0	0.80	1.60	2.20	3.6	
			Placebo	22	21 (95.5)	2.04 (1.14)	0.2	1.20	1.80	2.60	4.4	
		Week 52	Tezepelumab	17	17 (100.0)	1.59 (1.05)	0.0	0.80	1.60	2.20	3.6	
			Placebo	22	21 (95.5)	2.08 (1.16)	0.2	1.20	2.00	2.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	17	17 (100.0)	-0.49 (0.51)	-1.4	-0.80	-0.40	-0.20	0.4	0.02 [-0.62, 0.67]
			Placebo	22	20 (90.9)	-0.51 (0.78)	-2.8	-0.90	-0.40	0.00	1.0	
		Week 4	Tezepelumab	17	17 (100.0)	-0.84 (0.73)	-2.6	-1.20	-0.60	-0.40	0.2	-0.24 [-0.89, 0.41]
			Placebo	22	20 (90.9)	-0.63 (0.93)	-2.6	-1.30	-0.50	0.00	0.8	
		Week 6	Tezepelumab	17	17 (100.0)	-0.85 (0.93)	-2.6	-1.20	-0.80	-0.20	1.2	-0.37 [-1.03, 0.28]
			Placebo	22	20 (90.9)	-0.48 (1.02)	-2.6	-0.90	-0.30	0.00	1.6	
		Week 8	Tezepelumab	17	17 (100.0)	-1.11 (0.86)	-3.0	-1.60	-1.00	-0.40	0.2	-0.35 [-0.99, 0.30]
			Placebo	22	21 (95.5)	-0.74 (1.16)	-2.8	-1.60	-0.80	0.00	1.0	
		Week 10	Tezepelumab	17	17 (100.0)	-1.16 (0.83)	-3.0	-1.40	-0.80	-0.60	0.0	-0.30 [-0.94, 0.35]
			Placebo	22	21 (95.5)	-0.86 (1.17)	-2.6	-1.60	-0.80	-0.40	2.6	
		Week 12	Tezepelumab	17	17 (100.0)	-1.27 (0.81)	-3.0	-1.40	-1.20	-0.80	0.2	-0.36 [-1.00, 0.29]
			Placebo	22	21 (95.5)	-0.92 (1.08)	-3.0	-1.60	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	17	17 (100.0)	-1.45 (0.78)	-3.0	-1.80	-1.20	-1.00	0.0	-0.43 [-1.08, 0.21]
			Placebo	22	21 (95.5)	-1.04 (1.06)	-3.0	-1.60	-1.00	-0.40	1.4	
		Week 16	Tezepelumab	17	17 (100.0)	-1.14 (1.11)	-3.0	-1.60	-1.20	-1.00	1.8	-0.19 [-0.83, 0.45]
			Placebo	22	21 (95.5)	-0.91 (1.25)	-3.0	-1.40	-0.80	-0.20	2.6	
		Week 18	Tezepelumab	17	17 (100.0)	-1.19 (0.84)	-3.0	-1.60	-1.00	-0.80	0.2	-0.23 [-0.87, 0.42]
			Placebo	22	21 (95.5)	-0.93 (1.31)	-3.2	-2.00	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	17	17 (100.0)	-1.12 (0.80)	-2.8	-1.60	-1.00	-0.40	0.4	-0.35 [-1.00, 0.29]
			Placebo	22	21 (95.5)	-0.73 (1.28)	-3.0	-1.40	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	17	17 (100.0)	-1.04 (0.79)	-2.8	-1.20	-1.00	-0.80	0.2	-0.29 [-0.93, 0.35]
			Placebo	22	21 (95.5)	-0.71 (1.30)	-3.2	-1.40	-1.00	0.20	2.6	
		Week 24	Tezepelumab	17	17 (100.0)	-0.99 (0.85)	-2.8	-1.60	-0.80	-0.60	0.6	-0.15 [-0.79, 0.49]
			Placebo	22	21 (95.5)	-0.82 (1.31)	-3.0	-1.60	-1.20	0.20	2.6	
		Week 26	Tezepelumab	17	17 (100.0)	-1.00 (0.98)	-3.0	-1.40	-0.80	-0.40	0.6	-0.08 [-0.72, 0.56]
			Placebo	22	21 (95.5)	-0.90 (1.41)	-3.0	-1.80	-1.40	0.20	2.6	
		Week 28	Tezepelumab	17	17 (100.0)	-1.04 (0.98)	-3.0	-1.60	-0.80	-0.60	0.6	-0.16 [-0.80, 0.48]
			Placebo	22	21 (95.5)	-0.84 (1.37)	-3.0	-1.80	-1.20	0.00	2.6	
		Week 30	Tezepelumab	17	17 (100.0)	-1.09 (0.83)	-2.8	-1.40	-1.20	-0.60	0.4	-0.39 [-1.03, 0.26]
			Placebo	22	21 (95.5)	-0.69 (1.20)	-2.6	-1.40	-1.00	0.20	2.6	
		Week 32	Tezepelumab	17	17 (100.0)	-1.26 (0.82)	-2.8	-1.80	-1.00	-0.80	0.4	-0.37 [-1.02, 0.28]
			Placebo	22	21 (95.5)	-0.83 (1.38)	-2.6	-1.80	-1.40	0.20	2.6	
		Week 34	Tezepelumab	17	17 (100.0)	-1.01 (0.93)	-2.8	-1.60	-1.00	-0.40	0.6	-0.06 [-0.70, 0.58]
			Placebo	22	21 (95.5)	-0.93 (1.48)	-3.2	-2.00	-1.40	0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of the world	Change from baseline	Week 36	Tezepelumab	17	17 (100.0)	-1.22 (0.95)	-3.0	-1.80	-1.20	-0.60	0.6	-0.35 [-1.00, 0.29]
			Placebo	22	21 (95.5)	-0.78 (1.46)	-3.2	-1.60	-1.00	0.20	2.6	
		Week 38	Tezepelumab	17	17 (100.0)	-0.98 (1.08)	-3.0	-1.60	-1.00	0.00	0.6	-0.07 [-0.71, 0.57]
			Placebo	22	21 (95.5)	-0.89 (1.39)	-3.2	-1.60	-1.20	0.20	2.6	
		Week 40	Tezepelumab	17	17 (100.0)	-0.96 (1.00)	-3.0	-1.60	-0.80	-0.60	0.6	-0.09 [-0.73, 0.55]
			Placebo	22	21 (95.5)	-0.86 (1.30)	-2.8	-1.60	-1.20	-0.40	2.6	
		Week 42	Tezepelumab	17	17 (100.0)	-1.20 (0.99)	-3.0	-1.80	-1.00	-0.40	0.4	-0.35 [-0.99, 0.30]
			Placebo	22	21 (95.5)	-0.80 (1.28)	-2.8	-1.60	-1.00	0.20	2.6	
		Week 44	Tezepelumab	17	17 (100.0)	-1.12 (0.94)	-3.0	-1.60	-1.20	-0.60	0.4	-0.19 [-0.83, 0.45]
			Placebo	22	21 (95.5)	-0.90 (1.25)	-2.8	-1.80	-1.20	0.00	2.6	
		Week 46	Tezepelumab	17	17 (100.0)	-1.08 (0.92)	-3.0	-1.60	-1.20	-0.20	0.4	-0.24 [-0.88, 0.40]
			Placebo	22	21 (95.5)	-0.81 (1.30)	-3.2	-1.40	-1.00	-0.40	2.6	
		Week 48	Tezepelumab	17	17 (100.0)	-1.15 (0.92)	-2.8	-1.80	-0.80	-0.40	0.0	-0.24 [-0.88, 0.40]
			Placebo	22	21 (95.5)	-0.87 (1.39)	-3.2	-1.60	-1.00	-0.40	2.6	
		Week 50	Tezepelumab	17	17 (100.0)	-1.18 (1.02)	-2.8	-1.80	-1.00	-0.40	0.4	-0.11 [-0.75, 0.53]
			Placebo	22	21 (95.5)	-1.06 (1.21)	-2.8	-1.80	-1.40	-0.40	2.6	
		Week 52	Tezepelumab	17	17 (100.0)	-1.22 (1.09)	-2.8	-2.20	-1.00	-0.40	0.4	-0.17 [-0.81, 0.47]
			Placebo	22	21 (95.5)	-1.02 (1.26)	-2.8	-1.80	-1.20	-0.60	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	2.68 (1.02)	0.0	2.20	2.80	3.40	4.6	
			Placebo	21	21 (100.0)	2.64 (0.89)	0.4	2.60	2.80	3.00	4.8	
		Week 2	Tezepelumab	15	15 (100.0)	1.95 (1.01)	0.2	1.20	1.80	2.60	3.8	
			Placebo	21	19 (90.5)	2.34 (0.87)	0.4	2.00	2.40	2.80	4.8	
		Week 4	Tezepelumab	15	15 (100.0)	1.53 (0.93)	0.2	0.80	1.60	2.40	2.8	
			Placebo	21	19 (90.5)	2.29 (0.90)	0.8	1.40	2.60	2.80	3.6	
		Week 6	Tezepelumab	15	15 (100.0)	1.51 (0.99)	0.0	0.60	1.60	2.20	3.2	
			Placebo	21	19 (90.5)	2.06 (1.03)	0.2	1.40	2.20	2.80	4.6	
		Week 8	Tezepelumab	15	15 (100.0)	1.17 (0.93)	0.0	0.20	1.00	1.80	2.8	
			Placebo	21	19 (90.5)	2.13 (1.20)	0.0	1.00	2.40	3.00	4.6	
		Week 10	Tezepelumab	15	15 (100.0)	1.07 (0.93)	0.0	0.40	0.80	1.80	3.4	
			Placebo	21	19 (90.5)	1.98 (1.05)	0.0	1.00	2.00	2.60	4.4	
		Week 12	Tezepelumab	15	15 (100.0)	0.88 (0.85)	0.0	0.00	0.60	1.60	2.6	
			Placebo	21	19 (90.5)	1.93 (1.12)	0.0	1.00	2.00	2.60	4.4	
		Week 14	Tezepelumab	15	15 (100.0)	0.80 (0.56)	0.0	0.20	0.80	1.40	1.6	
			Placebo	21	19 (90.5)	1.95 (1.15)	0.0	1.40	2.00	2.40	5.0	
		Week 16	Tezepelumab	15	15 (100.0)	1.05 (0.84)	0.0	0.40	1.00	1.80	3.0	
			Placebo	21	19 (90.5)	1.76 (1.22)	0.0	0.60	2.00	2.60	4.4	
		Week 18	Tezepelumab	15	15 (100.0)	0.93 (0.80)	0.0	0.20	1.00	1.20	3.0	
			Placebo	21	19 (90.5)	1.82 (1.21)	0.0	1.00	1.80	2.60	4.4	
		Week 20	Tezepelumab	15	15 (100.0)	1.01 (0.75)	0.0	0.60	1.00	1.40	2.6	
			Placebo	21	19 (90.5)	1.93 (1.29)	0.0	0.60	1.80	2.80	4.4	
		Week 22	Tezepelumab	15	15 (100.0)	1.16 (0.88)	0.0	0.40	1.00	2.00	2.4	
			Placebo	21	19 (90.5)	1.77 (1.37)	0.0	0.40	1.60	2.60	4.4	
		Week 24	Tezepelumab	15	15 (100.0)	1.20 (0.89)	0.0	0.60	1.20	2.00	2.8	
			Placebo	21	19 (90.5)	1.96 (1.30)	0.0	1.00	2.20	3.00	4.4	
		Week 26	Tezepelumab	15	15 (100.0)	1.21 (1.04)	0.0	0.00	1.00	2.00	3.6	
			Placebo	21	19 (90.5)	1.92 (1.26)	0.0	1.00	1.60	3.00	4.4	
		Week 28	Tezepelumab	15	15 (100.0)	1.11 (1.00)	0.0	0.00	1.00	1.40	3.6	
			Placebo	21	20 (95.2)	1.88 (1.37)	0.0	0.90	1.70	2.80	4.4	
		Week 30	Tezepelumab	15	15 (100.0)	1.03 (0.81)	0.0	0.40	1.00	1.60	3.0	
			Placebo	21	20 (95.2)	2.03 (1.35)	0.0	0.90	2.10	3.00	4.4	
		Week 32	Tezepelumab	15	15 (100.0)	1.07 (0.81)	0.0	0.40	1.00	1.40	2.8	
			Placebo	21	20 (95.2)	1.74 (1.32)	0.0	0.80	1.30	2.50	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
18.5 - < 25.0 kg/m**2	Absolute values	Week 34	Tezepelumab	15	15 (100.0)	1.01 (0.74)	0.0	0.60	1.00	1.20	2.4	
			Placebo	21	20 (95.2)	1.62 (1.35)	0.0	0.80	1.40	2.20	4.8	
		Week 36	Tezepelumab	15	15 (100.0)	0.92 (0.69)	0.0	0.00	1.00	1.60	2.2	
			Placebo	21	20 (95.2)	2.03 (1.43)	0.0	0.90	2.10	2.90	4.8	
		Week 38	Tezepelumab	15	15 (100.0)	1.11 (0.89)	0.0	0.00	1.00	2.00	2.4	
			Placebo	21	20 (95.2)	1.79 (1.48)	0.0	0.50	1.40	3.00	4.8	
		Week 40	Tezepelumab	15	15 (100.0)	1.00 (0.89)	0.0	0.00	0.80	2.00	2.6	
			Placebo	21	20 (95.2)	1.89 (1.27)	0.0	0.90	1.90	2.70	4.4	
		Week 42	Tezepelumab	15	15 (100.0)	0.95 (0.73)	0.0	0.00	1.00	1.20	2.4	
			Placebo	21	20 (95.2)	1.66 (1.23)	0.0	0.70	1.40	2.40	4.4	
		Week 44	Tezepelumab	15	15 (100.0)	0.81 (0.67)	0.0	0.00	0.80	1.00	2.2	
			Placebo	21	20 (95.2)	2.02 (1.24)	0.0	1.10	2.00	3.00	4.4	
		Week 46	Tezepelumab	15	15 (100.0)	0.83 (0.67)	0.0	0.00	0.80	1.00	2.2	
			Placebo	21	20 (95.2)	1.78 (1.29)	0.0	0.80	1.90	2.30	4.4	
		Week 48	Tezepelumab	15	15 (100.0)	0.93 (0.75)	0.0	0.20	0.80	1.20	2.4	
			Placebo	21	20 (95.2)	1.89 (1.28)	0.0	1.00	2.00	2.40	4.6	
		Week 50	Tezepelumab	15	15 (100.0)	1.07 (0.85)	0.0	0.60	1.00	2.00	2.8	
			Placebo	21	20 (95.2)	1.60 (1.11)	0.0	1.00	1.30	2.40	4.4	
		Week 52	Tezepelumab	15	15 (100.0)	1.12 (0.84)	0.0	0.60	1.00	2.00	2.8	
			Placebo	21	20 (95.2)	1.63 (1.10)	0.0	1.00	1.30	2.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	15	15 (100.0)	-0.73 (0.74)	-2.2	-1.20	-0.60	-0.20	0.4	-0.35 [-1.03, 0.34]
			Placebo	21	19 (90.5)	-0.45 (0.86)	-2.8	-1.00	-0.20	0.00	1.2	
		Week 4	Tezepelumab	15	15 (100.0)	-1.15 (0.93)	-2.6	-1.80	-1.00	-0.60	0.2	-0.72 [-1.42, -0.02]
			Placebo	21	19 (90.5)	-0.49 (0.88)	-2.2	-1.20	-0.20	0.20	0.8	
		Week 6	Tezepelumab	15	15 (100.0)	-1.17 (1.06)	-2.8	-2.00	-1.40	-0.20	0.4	-0.47 [-1.15, 0.22]
			Placebo	21	19 (90.5)	-0.73 (0.86)	-2.4	-1.60	-0.40	0.00	0.4	
		Week 8	Tezepelumab	15	15 (100.0)	-1.51 (1.02)	-3.0	-2.80	-1.40	-0.60	0.0	-0.88 [-1.59, -0.17]
			Placebo	21	19 (90.5)	-0.66 (0.90)	-2.6	-1.00	-0.60	-0.20	1.0	
		Week 10	Tezepelumab	15	15 (100.0)	-1.61 (1.19)	-3.0	-2.80	-1.80	-0.80	1.0	-0.77 [-1.48, -0.07]
			Placebo	21	19 (90.5)	-0.81 (0.90)	-2.6	-1.40	-0.60	0.00	0.6	
		Week 12	Tezepelumab	15	15 (100.0)	-1.80 (1.03)	-3.2	-2.80	-2.20	-0.80	0.2	-1.00 [-1.72, -0.28]
			Placebo	21	19 (90.5)	-0.86 (0.85)	-2.8	-1.20	-0.80	-0.20	0.2	
		Week 14	Tezepelumab	15	15 (100.0)	-1.88 (1.07)	-4.0	-2.60	-2.20	-1.00	0.2	-1.04 [-1.76, -0.32]
			Placebo	21	19 (90.5)	-0.84 (0.94)	-2.6	-1.40	-0.80	-0.20	1.0	
		Week 16	Tezepelumab	15	15 (100.0)	-1.63 (1.03)	-3.0	-2.20	-2.20	-0.80	0.4	-0.60 [-1.29, 0.09]
			Placebo	21	19 (90.5)	-1.03 (0.96)	-2.6	-1.60	-1.00	-0.40	0.6	
		Week 18	Tezepelumab	15	15 (100.0)	-1.75 (1.10)	-3.8	-2.60	-1.80	-0.80	0.2	-0.72 [-1.42, -0.02]
			Placebo	21	19 (90.5)	-0.97 (1.06)	-3.2	-2.00	-0.60	-0.20	0.4	
		Week 20	Tezepelumab	15	15 (100.0)	-1.67 (0.86)	-2.8	-2.40	-1.60	-1.00	0.0	-0.80 [-1.51, -0.10]
			Placebo	21	19 (90.5)	-0.86 (1.09)	-3.0	-1.60	-0.60	-0.20	1.0	
		Week 22	Tezepelumab	15	15 (100.0)	-1.52 (1.35)	-2.8	-2.60	-2.20	-0.80	2.0	-0.40 [-1.08, 0.29]
			Placebo	21	19 (90.5)	-1.02 (1.18)	-3.2	-2.00	-1.00	0.00	1.2	
		Week 24	Tezepelumab	15	15 (100.0)	-1.48 (0.95)	-2.8	-2.20	-1.60	-0.80	0.2	-0.62 [-1.31, 0.08]
			Placebo	21	19 (90.5)	-0.83 (1.12)	-3.0	-1.60	-0.80	0.00	1.0	
		Week 26	Tezepelumab	15	15 (100.0)	-1.47 (1.11)	-3.0	-2.40	-1.60	-0.40	0.2	-0.51 [-1.20, 0.18]
			Placebo	21	19 (90.5)	-0.87 (1.21)	-2.6	-2.00	-0.80	0.20	1.6	
		Week 28	Tezepelumab	15	15 (100.0)	-1.57 (1.07)	-3.0	-2.40	-1.60	-0.60	0.2	-0.71 [-1.40, -0.01]
			Placebo	21	20 (95.2)	-0.79 (1.14)	-2.6	-1.70	-0.70	-0.10	1.6	
		Week 30	Tezepelumab	15	15 (100.0)	-1.65 (1.13)	-3.8	-2.60	-1.60	-0.60	0.0	-0.86 [-1.56, -0.16]
			Placebo	21	20 (95.2)	-0.64 (1.20)	-2.6	-1.40	-0.60	0.00	2.0	
		Week 32	Tezepelumab	15	15 (100.0)	-1.61 (0.86)	-2.8	-2.40	-1.60	-1.00	0.0	-0.67 [-1.36, 0.02]
			Placebo	21	20 (95.2)	-0.93 (1.12)	-2.6	-1.80	-0.80	-0.20	1.8	
		Week 34	Tezepelumab	15	15 (100.0)	-1.67 (0.92)	-2.8	-2.40	-1.80	-1.00	0.2	-0.57 [-1.25, 0.12]
			Placebo	21	20 (95.2)	-1.05 (1.19)	-3.2	-1.90	-1.10	-0.30	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
18.5 - < 25.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	15	15 (100.0)	-1.76 (1.03)	-3.0	-2.60	-1.80	-1.20	0.4	-0.95 [-1.65, -0.24]
			Placebo	21	20 (95.2)	-0.64 (1.28)	-3.2	-1.30	-0.40	0.20	1.8	
		Week 38	Tezepelumab	15	15 (100.0)	-1.57 (1.01)	-3.0	-2.20	-1.80	-0.80	0.4	-0.58 [-1.26, 0.11]
			Placebo	21	20 (95.2)	-0.88 (1.33)	-3.2	-2.00	-0.90	0.20	1.8	
		Week 40	Tezepelumab	15	15 (100.0)	-1.68 (1.06)	-3.0	-2.60	-2.00	-0.80	0.4	-0.82 [-1.52, -0.12]
			Placebo	21	20 (95.2)	-0.78 (1.13)	-2.8	-1.20	-0.80	-0.10	1.4	
		Week 42	Tezepelumab	15	15 (100.0)	-1.73 (1.09)	-3.6	-2.40	-1.80	-0.60	0.0	-0.64 [-1.33, 0.05]
			Placebo	21	20 (95.2)	-1.01 (1.16)	-2.8	-1.90	-0.90	-0.40	1.4	
		Week 44	Tezepelumab	15	15 (100.0)	-1.87 (1.03)	-3.8	-2.80	-1.80	-1.00	0.0	-1.11 [-1.83, -0.39]
			Placebo	21	20 (95.2)	-0.65 (1.14)	-2.6	-1.30	-0.70	0.10	1.6	
		Week 46	Tezepelumab	15	15 (100.0)	-1.85 (0.95)	-3.6	-2.60	-1.60	-1.20	0.0	-0.86 [-1.56, -0.16]
			Placebo	21	20 (95.2)	-0.89 (1.23)	-3.2	-1.60	-0.90	-0.30	1.6	
		Week 48	Tezepelumab	15	15 (100.0)	-1.75 (0.92)	-2.8	-2.80	-1.60	-1.00	0.0	-0.91 [-1.61, -0.20]
			Placebo	21	20 (95.2)	-0.78 (1.16)	-3.2	-1.10	-0.60	-0.20	1.8	
		Week 50	Tezepelumab	15	15 (100.0)	-1.61 (0.89)	-2.8	-2.40	-1.60	-1.20	0.0	-0.61 [-1.29, 0.08]
			Placebo	21	20 (95.2)	-1.07 (0.90)	-2.8	-1.70	-0.90	-0.40	0.2	
		Week 52	Tezepelumab	15	15 (100.0)	-1.56 (0.87)	-2.8	-2.20	-1.60	-1.20	0.0	-0.60 [-1.28, 0.09]
			Placebo	21	20 (95.2)	-1.04 (0.88)	-2.8	-1.70	-0.90	-0.40	0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	24	24 (100.0)	2.80 (0.89)	0.2	2.20	2.80	3.50	4.2	
			Placebo	20	20 (100.0)	2.98 (0.70)	1.4	2.50	3.00	3.30	4.6	
		Week 2	Tezepelumab	24	23 (95.8)	2.23 (1.04)	0.2	1.40	2.20	3.00	4.0	
			Placebo	20	18 (90.0)	2.51 (0.55)	1.4	2.20	2.60	3.00	3.2	
		Week 4	Tezepelumab	24	23 (95.8)	2.07 (1.00)	0.2	1.20	2.20	3.00	3.4	
			Placebo	20	18 (90.0)	2.42 (0.84)	0.8	2.00	2.60	3.00	4.2	
		Week 6	Tezepelumab	24	23 (95.8)	1.89 (0.91)	0.0	1.20	1.80	2.80	3.2	
			Placebo	20	18 (90.0)	2.46 (0.87)	0.6	2.00	2.40	3.00	4.0	
		Week 8	Tezepelumab	24	23 (95.8)	1.73 (1.14)	0.0	0.60	1.80	2.80	3.6	
			Placebo	20	18 (90.0)	2.12 (1.02)	0.2	1.20	2.40	3.00	3.6	
		Week 10	Tezepelumab	24	23 (95.8)	1.71 (1.21)	0.0	0.80	1.60	2.60	4.8	
			Placebo	20	18 (90.0)	2.51 (1.21)	0.0	2.00	2.50	3.00	5.2	
		Week 12	Tezepelumab	24	23 (95.8)	1.57 (1.25)	0.0	0.60	1.40	2.60	4.8	
			Placebo	20	18 (90.0)	2.26 (1.08)	0.0	1.20	2.30	3.00	4.4	
		Week 14	Tezepelumab	24	23 (95.8)	1.63 (1.37)	0.0	0.40	1.40	2.80	4.8	
			Placebo	20	18 (90.0)	2.08 (1.02)	0.4	1.40	2.00	2.60	5.0	
		Week 16	Tezepelumab	24	23 (95.8)	1.63 (1.35)	0.0	0.40	1.40	2.80	4.8	
			Placebo	20	18 (90.0)	2.34 (1.24)	0.2	1.80	2.20	3.00	5.0	
		Week 18	Tezepelumab	24	23 (95.8)	1.70 (1.22)	0.0	0.60	1.60	2.60	4.8	
			Placebo	20	18 (90.0)	2.28 (1.13)	0.2	1.80	2.20	2.80	5.0	
		Week 20	Tezepelumab	24	23 (95.8)	1.59 (1.29)	0.0	0.40	1.40	2.40	4.8	
			Placebo	20	18 (90.0)	2.31 (1.24)	0.2	1.80	2.50	2.80	5.0	
		Week 22	Tezepelumab	24	23 (95.8)	1.76 (1.22)	0.0	0.80	1.60	2.60	4.8	
			Placebo	20	18 (90.0)	2.30 (1.26)	0.0	1.40	2.50	3.00	5.0	
		Week 24	Tezepelumab	24	23 (95.8)	1.61 (1.31)	0.0	0.40	1.40	2.80	4.8	
			Placebo	20	18 (90.0)	2.29 (1.08)	0.2	1.80	2.50	3.00	4.0	
		Week 26	Tezepelumab	24	23 (95.8)	1.70 (1.24)	0.0	0.60	1.80	2.80	4.8	
			Placebo	20	18 (90.0)	2.30 (1.16)	0.4	1.40	2.50	3.20	4.0	
		Week 28	Tezepelumab	24	24 (100.0)	1.54 (1.28)	0.0	0.40	1.50	2.30	4.8	
			Placebo	20	18 (90.0)	2.33 (1.15)	0.4	1.40	2.50	3.00	4.0	
		Week 30	Tezepelumab	24	24 (100.0)	1.58 (1.24)	0.0	0.60	1.50	2.40	4.8	
			Placebo	20	18 (90.0)	2.26 (1.18)	0.4	1.20	2.30	3.00	4.0	
		Week 32	Tezepelumab	24	24 (100.0)	1.38 (1.29)	0.0	0.20	1.10	2.30	4.8	
			Placebo	20	18 (90.0)	2.23 (1.10)	0.4	1.60	2.00	3.00	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
25.0 - < 30.0 kg/m**2	Absolute values	Week 34	Tezepelumab	24	24 (100.0)	1.56 (1.35)	0.0	0.40	1.50	2.80	4.8	
			Placebo	20	18 (90.0)	2.32 (1.12)	0.0	1.80	2.60	3.00	4.0	
		Week 36	Tezepelumab	24	24 (100.0)	1.63 (1.25)	0.0	0.60	1.40	2.50	4.8	
			Placebo	20	18 (90.0)	2.48 (1.13)	0.0	2.00	2.60	3.00	4.4	
		Week 38	Tezepelumab	24	24 (100.0)	1.48 (1.31)	0.0	0.30	1.30	2.50	4.8	
			Placebo	20	18 (90.0)	2.16 (1.03)	0.0	1.40	2.00	2.80	4.0	
		Week 40	Tezepelumab	24	24 (100.0)	1.49 (1.33)	0.0	0.40	1.20	2.70	4.8	
			Placebo	20	18 (90.0)	2.30 (1.14)	0.0	1.40	2.20	3.00	4.4	
		Week 42	Tezepelumab	24	24 (100.0)	1.39 (1.26)	0.0	0.30	1.00	2.30	4.8	
			Placebo	20	18 (90.0)	2.26 (1.07)	0.0	1.60	2.20	2.80	4.6	
		Week 44	Tezepelumab	24	24 (100.0)	1.54 (1.29)	0.0	0.40	1.40	2.70	4.8	
			Placebo	20	18 (90.0)	2.24 (1.00)	0.8	1.20	2.30	3.00	4.2	
		Week 46	Tezepelumab	24	24 (100.0)	1.56 (1.33)	0.0	0.30	1.20	2.70	4.8	
			Placebo	20	18 (90.0)	2.13 (0.83)	0.6	1.40	2.10	2.60	4.0	
		Week 48	Tezepelumab	24	24 (100.0)	1.56 (1.32)	0.0	0.30	1.30	2.70	4.8	
			Placebo	20	18 (90.0)	2.16 (1.01)	0.4	1.20	2.20	2.80	4.0	
		Week 50	Tezepelumab	24	24 (100.0)	1.39 (1.26)	0.0	0.40	1.10	2.40	4.8	
			Placebo	20	18 (90.0)	2.40 (0.83)	1.0	1.80	2.40	2.80	4.0	
		Week 52	Tezepelumab	24	24 (100.0)	1.43 (1.23)	0.0	0.40	1.20	2.40	4.8	
			Placebo	20	18 (90.0)	2.39 (1.00)	0.0	1.80	2.40	2.80	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	24	23 (95.8)	-0.58 (0.76)	-2.2	-1.20	-0.40	0.00	0.8	-0.30 [-0.92, 0.32]
			Placebo	20	18 (90.0)	-0.36 (0.78)	-2.4	-0.80	-0.20	0.20	1.0	
		Week 4	Tezepelumab	24	23 (95.8)	-0.74 (1.01)	-2.6	-1.20	-1.00	-0.40	2.6	-0.29 [-0.91, 0.33]
			Placebo	20	18 (90.0)	-0.44 (1.01)	-3.0	-1.00	-0.20	0.20	1.2	
		Week 6	Tezepelumab	24	23 (95.8)	-0.92 (1.05)	-2.6	-1.40	-1.00	-0.80	2.6	-0.48 [-1.11, 0.14]
			Placebo	20	18 (90.0)	-0.41 (1.05)	-3.2	-0.80	-0.40	0.20	1.6	
		Week 8	Tezepelumab	24	23 (95.8)	-1.08 (1.14)	-3.2	-1.60	-1.00	-0.60	2.6	-0.29 [-0.91, 0.33]
			Placebo	20	18 (90.0)	-0.74 (1.18)	-3.6	-1.60	-0.50	0.20	1.0	
		Week 10	Tezepelumab	24	23 (95.8)	-1.10 (1.20)	-3.4	-1.80	-1.20	-0.60	2.6	-0.54 [-1.17, 0.08]
			Placebo	20	18 (90.0)	-0.36 (1.54)	-3.8	-1.00	-0.50	0.00	2.6	
		Week 12	Tezepelumab	24	23 (95.8)	-1.24 (1.21)	-3.0	-2.20	-1.40	-0.80	2.6	-0.50 [-1.13, 0.12]
			Placebo	20	18 (90.0)	-0.61 (1.31)	-3.8	-1.20	-0.70	0.20	1.6	
		Week 14	Tezepelumab	24	23 (95.8)	-1.17 (1.29)	-3.4	-2.00	-1.20	-0.40	2.6	-0.30 [-0.92, 0.32]
			Placebo	20	18 (90.0)	-0.79 (1.29)	-3.4	-1.40	-1.20	-0.20	2.4	
		Week 16	Tezepelumab	24	23 (95.8)	-1.17 (1.26)	-3.2	-2.20	-1.00	-0.60	2.6	-0.48 [-1.10, 0.15]
			Placebo	20	18 (90.0)	-0.52 (1.49)	-3.6	-1.20	-0.60	0.00	2.6	
		Week 18	Tezepelumab	24	23 (95.8)	-1.11 (1.23)	-3.4	-1.80	-1.20	-0.80	2.6	-0.39 [-1.02, 0.23]
			Placebo	20	18 (90.0)	-0.59 (1.45)	-3.6	-1.40	-1.10	0.00	2.6	
		Week 20	Tezepelumab	24	23 (95.8)	-1.22 (1.29)	-3.4	-2.00	-1.40	-0.60	2.6	-0.48 [-1.11, 0.15]
			Placebo	20	18 (90.0)	-0.56 (1.48)	-3.6	-1.40	-0.60	0.00	2.6	
		Week 22	Tezepelumab	24	23 (95.8)	-1.05 (1.23)	-3.2	-1.80	-1.20	-0.60	2.6	-0.36 [-0.98, 0.26]
			Placebo	20	18 (90.0)	-0.57 (1.50)	-3.8	-1.40	-0.80	0.00	2.6	
		Week 24	Tezepelumab	24	23 (95.8)	-1.20 (1.31)	-3.4	-2.00	-1.40	-0.40	2.6	-0.47 [-1.10, 0.15]
			Placebo	20	18 (90.0)	-0.58 (1.33)	-3.6	-1.20	-0.70	0.00	2.6	
		Week 26	Tezepelumab	24	23 (95.8)	-1.10 (1.27)	-3.0	-2.20	-1.00	-0.60	2.6	-0.41 [-1.03, 0.22]
			Placebo	20	18 (90.0)	-0.57 (1.38)	-3.4	-1.40	-0.70	0.20	2.6	
		Week 28	Tezepelumab	24	24 (100.0)	-1.26 (1.32)	-3.4	-2.20	-1.50	-0.60	2.6	-0.54 [-1.16, 0.08]
			Placebo	20	18 (90.0)	-0.53 (1.37)	-3.4	-1.60	-0.30	0.00	2.6	
		Week 30	Tezepelumab	24	24 (100.0)	-1.23 (1.25)	-2.8	-2.20	-1.40	-0.60	2.6	-0.47 [-1.09, 0.15]
			Placebo	20	18 (90.0)	-0.61 (1.40)	-3.4	-1.40	-1.20	0.20	2.6	
		Week 32	Tezepelumab	24	24 (100.0)	-1.42 (1.32)	-3.2	-2.30	-1.80	-0.80	2.6	-0.59 [-1.21, 0.04]
			Placebo	20	18 (90.0)	-0.63 (1.35)	-3.2	-1.60	-0.80	0.00	2.6	
		Week 34	Tezepelumab	24	24 (100.0)	-1.24 (1.33)	-3.0	-2.20	-1.70	-0.30	2.6	-0.52 [-1.14, 0.10]
			Placebo	20	18 (90.0)	-0.54 (1.34)	-3.2	-1.40	-0.40	0.00	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
25.0 - < 30.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	24	24 (100.0)	-1.17 (1.34)	-3.2	-2.30	-1.20	-0.10	2.6	-0.59 [-1.22, 0.03]
			Placebo	20	18 (90.0)	-0.39 (1.27)	-2.6	-1.20	-0.40	0.00	2.6	
		Week 38	Tezepelumab	24	24 (100.0)	-1.32 (1.36)	-3.2	-2.20	-1.70	-0.40	2.6	-0.45 [-1.07, 0.16]
			Placebo	20	18 (90.0)	-0.71 (1.30)	-2.8	-1.40	-0.70	-0.40	2.6	
		Week 40	Tezepelumab	24	24 (100.0)	-1.31 (1.40)	-3.4	-2.40	-1.60	-0.30	2.6	-0.53 [-1.16, 0.09]
			Placebo	20	18 (90.0)	-0.57 (1.38)	-2.6	-1.40	-0.70	0.00	2.6	
		Week 42	Tezepelumab	24	24 (100.0)	-1.41 (1.33)	-3.0	-2.30	-1.90	-0.60	2.6	-0.60 [-1.22, 0.03]
			Placebo	20	18 (90.0)	-0.61 (1.33)	-2.6	-1.40	-0.70	0.00	2.6	
		Week 44	Tezepelumab	24	24 (100.0)	-1.26 (1.36)	-3.4	-2.20	-1.60	-0.20	2.6	-0.49 [-1.11, 0.13]
			Placebo	20	18 (90.0)	-0.62 (1.19)	-2.6	-1.40	-0.60	-0.20	2.6	
		Week 46	Tezepelumab	24	24 (100.0)	-1.24 (1.34)	-3.0	-2.20	-1.50	-0.30	2.6	-0.41 [-1.03, 0.21]
			Placebo	20	18 (90.0)	-0.73 (1.08)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	24	24 (100.0)	-1.24 (1.35)	-2.8	-2.40	-1.50	-0.40	2.6	-0.41 [-1.03, 0.21]
			Placebo	20	18 (90.0)	-0.71 (1.21)	-2.8	-1.40	-0.90	-0.20	2.6	
		Week 50	Tezepelumab	24	24 (100.0)	-1.41 (1.36)	-2.8	-2.50	-1.80	-0.60	2.6	-0.73 [-1.37, -0.10]
			Placebo	20	18 (90.0)	-0.47 (1.17)	-2.4	-1.20	-0.60	0.00	2.6	
		Week 52	Tezepelumab	24	24 (100.0)	-1.38 (1.35)	-3.0	-2.30	-1.70	-0.60	2.6	-0.68 [-1.31, -0.05]
			Placebo	20	18 (90.0)	-0.48 (1.28)	-2.6	-1.20	-0.60	0.00	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	3.04 (0.80)	1.8	2.60	3.00	3.20	5.2	
			Placebo	24	24 (100.0)	2.96 (0.68)	1.6	2.60	3.00	3.40	5.0	
		Week 2	Tezepelumab	27	25 (92.6)	2.69 (0.93)	0.0	2.20	2.80	3.20	4.4	
			Placebo	24	21 (87.5)	2.35 (0.93)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	27	25 (92.6)	2.42 (0.93)	0.2	2.00	2.60	3.00	3.6	
			Placebo	24	21 (87.5)	2.07 (1.01)	0.2	1.40	2.20	2.60	3.6	
		Week 6	Tezepelumab	27	25 (92.6)	2.33 (1.09)	0.4	1.40	2.60	3.00	4.0	
			Placebo	24	21 (87.5)	2.14 (1.46)	0.2	1.20	2.00	2.80	6.0	
		Week 8	Tezepelumab	27	25 (92.6)	2.28 (1.18)	0.0	1.40	2.60	3.00	5.2	
			Placebo	24	22 (91.7)	2.14 (1.23)	0.0	1.60	2.10	2.80	5.0	
		Week 10	Tezepelumab	27	25 (92.6)	2.12 (1.02)	0.0	1.40	2.40	3.00	3.6	
			Placebo	24	22 (91.7)	2.01 (0.97)	0.2	1.60	2.20	3.00	3.6	
		Week 12	Tezepelumab	27	25 (92.6)	2.10 (0.84)	0.0	1.40	2.20	2.80	3.2	
			Placebo	24	22 (91.7)	1.70 (0.97)	0.0	0.80	2.00	2.40	3.2	
		Week 14	Tezepelumab	27	25 (92.6)	1.94 (0.92)	0.0	1.40	2.00	2.40	4.2	
			Placebo	24	22 (91.7)	1.64 (0.84)	0.0	1.00	1.80	2.20	3.0	
		Week 16	Tezepelumab	27	25 (92.6)	2.17 (1.02)	0.0	1.40	2.20	2.80	4.6	
			Placebo	24	22 (91.7)	2.02 (1.17)	0.0	1.00	2.00	2.80	5.0	
		Week 18	Tezepelumab	27	26 (96.3)	2.08 (0.89)	0.0	1.60	2.20	2.60	4.2	
			Placebo	24	22 (91.7)	1.75 (1.18)	0.0	0.60	1.80	2.60	4.8	
		Week 20	Tezepelumab	27	26 (96.3)	2.14 (1.02)	0.0	1.60	2.10	2.80	5.0	
			Placebo	24	22 (91.7)	1.90 (0.82)	0.2	1.20	2.00	2.60	3.0	
		Week 22	Tezepelumab	27	26 (96.3)	2.15 (0.75)	0.0	1.80	2.20	2.60	3.8	
			Placebo	24	22 (91.7)	1.91 (0.83)	0.4	1.20	2.00	2.40	3.4	
		Week 24	Tezepelumab	27	26 (96.3)	2.17 (0.87)	0.0	1.60	2.30	2.80	3.8	
			Placebo	24	22 (91.7)	1.93 (0.81)	0.4	1.60	2.00	2.40	3.4	
		Week 26	Tezepelumab	27	27 (100.0)	2.19 (0.93)	0.0	1.40	2.20	2.80	4.0	
			Placebo	24	22 (91.7)	1.77 (0.99)	0.0	1.00	1.70	2.40	3.8	
		Week 28	Tezepelumab	27	27 (100.0)	2.25 (0.91)	0.0	1.80	2.40	3.00	3.8	
			Placebo	24	22 (91.7)	1.73 (1.13)	0.0	0.80	1.50	2.60	4.0	
		Week 30	Tezepelumab	27	27 (100.0)	2.19 (0.89)	0.0	1.60	2.20	2.80	3.8	
			Placebo	24	22 (91.7)	1.59 (0.95)	0.0	0.80	1.70	2.40	3.4	
		Week 32	Tezepelumab	27	27 (100.0)	2.16 (0.88)	0.0	1.60	2.20	2.80	4.0	
			Placebo	24	22 (91.7)	1.78 (0.97)	0.0	1.00	1.90	2.40	3.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 30.0 kg/m**2	Absolute values	Week 34	Tezepelumab	27	27 (100.0)	2.23 (1.02)	0.0	1.40	2.40	3.00	4.2	
			Placebo	24	22 (91.7)	1.75 (0.85)	0.2	1.40	1.80	2.20	3.4	
		Week 36	Tezepelumab	27	27 (100.0)	2.11 (0.95)	0.0	1.20	2.20	3.00	3.6	
			Placebo	24	22 (91.7)	1.73 (0.92)	0.0	1.00	1.70	2.40	3.4	
		Week 38	Tezepelumab	27	27 (100.0)	2.26 (1.12)	0.0	1.40	2.20	3.00	4.6	
			Placebo	24	22 (91.7)	1.85 (0.82)	0.6	1.20	1.80	2.40	3.4	
		Week 40	Tezepelumab	27	27 (100.0)	2.27 (0.92)	0.0	1.80	2.20	3.00	3.8	
			Placebo	24	22 (91.7)	2.03 (1.19)	0.2	0.80	2.20	3.00	4.2	
		Week 42	Tezepelumab	27	27 (100.0)	2.25 (0.93)	0.0	1.80	2.20	2.80	4.0	
			Placebo	24	22 (91.7)	1.89 (0.83)	0.2	1.40	2.00	2.40	3.4	
		Week 44	Tezepelumab	27	27 (100.0)	2.28 (0.84)	0.0	1.80	2.40	3.00	3.8	
			Placebo	24	22 (91.7)	1.80 (1.10)	0.0	0.60	1.90	2.40	4.2	
		Week 46	Tezepelumab	27	27 (100.0)	2.33 (0.93)	0.0	1.80	2.40	3.00	3.8	
			Placebo	24	22 (91.7)	1.77 (0.85)	0.2	1.00	1.80	2.40	3.4	
		Week 48	Tezepelumab	27	27 (100.0)	2.28 (0.98)	0.0	1.80	2.20	3.00	4.2	
			Placebo	24	22 (91.7)	1.82 (1.01)	0.2	1.00	2.00	2.60	3.4	
		Week 50	Tezepelumab	27	27 (100.0)	2.20 (1.11)	0.0	1.40	2.00	3.00	4.2	
			Placebo	24	22 (91.7)	1.55 (0.94)	0.0	1.00	1.80	2.00	3.4	
		Week 52	Tezepelumab	27	27 (100.0)	2.21 (1.12)	0.0	1.60	2.00	3.00	4.4	
			Placebo	24	22 (91.7)	1.73 (1.05)	0.0	1.00	1.80	2.60	3.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	27	25 (92.6)	-0.44 (0.87)	-3.2	-0.60	-0.40	0.20	0.8	0.33 [-0.26, 0.91]
			Placebo	24	21 (87.5)	-0.68 (0.51)	-1.8	-1.00	-0.80	-0.20	0.0	
		Week 4	Tezepelumab	27	25 (92.6)	-0.71 (0.84)	-2.4	-1.20	-0.60	0.00	0.8	0.28 [-0.31, 0.86]
			Placebo	24	21 (87.5)	-0.96 (0.97)	-3.0	-1.40	-1.00	-0.20	0.6	
		Week 6	Tezepelumab	27	25 (92.6)	-0.80 (0.99)	-2.8	-1.60	-0.60	0.00	1.2	0.08 [-0.50, 0.66]
			Placebo	24	21 (87.5)	-0.89 (1.19)	-3.4	-1.60	-1.00	-0.20	1.6	
		Week 8	Tezepelumab	27	25 (92.6)	-0.85 (1.20)	-3.0	-1.60	-1.00	0.00	2.6	0.05 [-0.52, 0.63]
			Placebo	24	22 (91.7)	-0.91 (1.11)	-3.0	-1.60	-0.90	0.00	1.0	
		Week 10	Tezepelumab	27	25 (92.6)	-1.01 (0.96)	-3.0	-1.60	-1.20	-0.20	0.4	0.03 [-0.54, 0.60]
			Placebo	24	22 (91.7)	-1.04 (0.94)	-3.2	-1.60	-1.00	-0.40	0.4	
		Week 12	Tezepelumab	27	25 (92.6)	-1.03 (0.97)	-3.2	-1.60	-1.00	-0.40	0.6	0.32 [-0.25, 0.90]
			Placebo	24	22 (91.7)	-1.35 (0.96)	-3.2	-2.00	-1.20	-0.60	0.0	
		Week 14	Tezepelumab	27	25 (92.6)	-1.19 (0.87)	-3.0	-1.60	-1.20	-0.60	0.4	0.24 [-0.33, 0.82]
			Placebo	24	22 (91.7)	-1.41 (0.93)	-3.2	-2.20	-1.40	-0.80	0.2	
		Week 16	Tezepelumab	27	25 (92.6)	-0.96 (1.07)	-3.0	-1.60	-1.00	-0.40	1.8	0.06 [-0.51, 0.64]
			Placebo	24	22 (91.7)	-1.03 (1.05)	-3.0	-1.40	-1.00	0.00	0.4	
		Week 18	Tezepelumab	27	26 (96.3)	-1.01 (0.89)	-3.0	-1.60	-0.90	-0.40	0.2	0.29 [-0.28, 0.86]
			Placebo	24	22 (91.7)	-1.30 (1.12)	-3.0	-2.20	-1.40	-0.20	1.4	
		Week 20	Tezepelumab	27	26 (96.3)	-0.95 (0.99)	-3.0	-1.60	-0.80	-0.20	0.6	0.21 [-0.36, 0.78]
			Placebo	24	22 (91.7)	-1.15 (0.94)	-3.0	-1.60	-1.00	-0.60	1.0	
		Week 22	Tezepelumab	27	26 (96.3)	-0.94 (0.85)	-3.0	-1.20	-0.80	-0.60	0.6	0.24 [-0.33, 0.80]
			Placebo	24	22 (91.7)	-1.14 (0.83)	-2.8	-1.60	-1.00	-0.60	0.2	
		Week 24	Tezepelumab	27	26 (96.3)	-0.92 (0.93)	-3.0	-1.40	-0.80	-0.20	0.6	0.22 [-0.35, 0.79]
			Placebo	24	22 (91.7)	-1.12 (0.94)	-3.2	-1.80	-1.10	-0.60	0.4	
		Week 26	Tezepelumab	27	27 (100.0)	-0.85 (0.99)	-3.0	-1.40	-0.60	0.00	0.6	0.43 [-0.14, 1.00]
			Placebo	24	22 (91.7)	-1.27 (0.95)	-3.0	-2.00	-1.30	-0.60	0.4	
		Week 28	Tezepelumab	27	27 (100.0)	-0.79 (1.11)	-3.0	-1.20	-0.80	0.00	1.0	0.48 [-0.09, 1.05]
			Placebo	24	22 (91.7)	-1.32 (1.13)	-3.0	-2.00	-1.60	-0.60	1.2	
		Week 30	Tezepelumab	27	27 (100.0)	-0.85 (1.08)	-3.0	-1.40	-1.00	-0.20	2.0	0.59 [0.01, 1.17]
			Placebo	24	22 (91.7)	-1.45 (0.94)	-3.2	-2.00	-1.50	-1.00	0.6	
		Week 32	Tezepelumab	27	27 (100.0)	-0.87 (0.93)	-3.0	-1.20	-1.00	-0.40	1.0	0.40 [-0.17, 0.97]
			Placebo	24	22 (91.7)	-1.26 (1.02)	-3.2	-1.80	-1.30	-0.60	0.8	
		Week 34	Tezepelumab	27	27 (100.0)	-0.81 (1.14)	-3.0	-1.60	-0.80	-0.20	2.2	0.48 [-0.09, 1.05]
			Placebo	24	22 (91.7)	-1.30 (0.87)	-2.8	-1.80	-1.40	-0.80	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 30.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	27	27 (100.0)	-0.93 (1.02)	-3.0	-1.60	-1.00	-0.20	1.6	0.39 [-0.18, 0.96]
			Placebo	24	22 (91.7)	-1.32 (0.97)	-3.6	-1.60	-1.30	-0.80	0.6	
		Week 38	Tezepelumab	27	27 (100.0)	-0.78 (1.16)	-3.0	-1.40	-1.00	0.00	2.6	0.41 [-0.16, 0.98]
			Placebo	24	22 (91.7)	-1.19 (0.79)	-3.0	-1.60	-1.30	-0.80	0.2	
		Week 40	Tezepelumab	27	27 (100.0)	-0.77 (0.99)	-3.0	-1.40	-0.80	-0.40	1.8	0.23 [-0.33, 0.80]
			Placebo	24	22 (91.7)	-1.02 (1.17)	-3.2	-2.00	-1.30	0.20	0.8	
		Week 42	Tezepelumab	27	27 (100.0)	-0.79 (1.02)	-3.0	-1.40	-0.80	-0.40	2.2	0.40 [-0.17, 0.97]
			Placebo	24	22 (91.7)	-1.15 (0.80)	-2.8	-1.60	-1.20	-0.80	0.2	
		Week 44	Tezepelumab	27	27 (100.0)	-0.76 (0.96)	-3.0	-1.40	-0.80	-0.20	1.6	0.48 [-0.09, 1.05]
			Placebo	24	22 (91.7)	-1.25 (1.08)	-3.4	-1.80	-1.30	-0.60	0.8	
		Week 46	Tezepelumab	27	27 (100.0)	-0.70 (1.04)	-3.0	-1.40	-0.80	0.00	1.8	0.60 [0.02, 1.17]
			Placebo	24	22 (91.7)	-1.27 (0.84)	-2.8	-1.80	-1.40	-0.80	0.6	
		Week 48	Tezepelumab	27	27 (100.0)	-0.76 (1.05)	-3.0	-1.40	-0.80	-0.20	2.0	0.46 [-0.12, 1.03]
			Placebo	24	22 (91.7)	-1.23 (1.02)	-3.4	-1.60	-1.30	-0.40	0.4	
		Week 50	Tezepelumab	27	27 (100.0)	-0.84 (1.17)	-3.2	-1.60	-0.80	-0.20	2.0	0.62 [0.04, 1.19]
			Placebo	24	22 (91.7)	-1.49 (0.90)	-3.6	-1.80	-1.50	-1.00	0.2	
		Week 52	Tezepelumab	27	27 (100.0)	-0.82 (1.16)	-3.2	-1.40	-1.00	-0.20	2.0	0.45 [-0.12, 1.02]
			Placebo	24	22 (91.7)	-1.32 (1.05)	-3.6	-1.80	-1.30	-0.60	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	3.24 (0.76)	2.4	2.60	3.20	3.40	5.0	
			Placebo	14	14 (100.0)	3.07 (0.60)	1.8	2.80	3.00	3.40	4.6	
		Week 2	Tezepelumab	11	11 (100.0)	2.96 (0.72)	1.6	2.40	3.00	3.60	3.8	
			Placebo	14	12 (85.7)	2.13 (0.69)	0.4	1.90	2.20	2.50	3.0	
		Week 4	Tezepelumab	11	11 (100.0)	2.31 (1.06)	0.2	1.80	2.60	3.00	3.6	
			Placebo	14	12 (85.7)	2.32 (1.02)	0.2	1.90	2.40	3.10	3.6	
		Week 6	Tezepelumab	11	11 (100.0)	2.29 (0.99)	0.6	1.40	2.80	3.20	3.6	
			Placebo	14	12 (85.7)	1.90 (0.88)	0.4	1.20	2.10	2.50	3.2	
		Week 8	Tezepelumab	11	11 (100.0)	2.47 (1.43)	0.0	1.20	2.80	3.20	5.2	
			Placebo	14	12 (85.7)	1.95 (1.20)	0.2	0.80	2.00	2.80	4.0	
		Week 10	Tezepelumab	11	11 (100.0)	2.42 (1.44)	0.0	1.20	2.80	3.40	4.8	
			Placebo	14	12 (85.7)	1.82 (0.94)	0.2	1.00	1.90	2.70	3.0	
		Week 12	Tezepelumab	11	11 (100.0)	2.20 (1.26)	0.0	1.20	2.60	2.80	4.8	
			Placebo	14	12 (85.7)	1.53 (0.97)	0.0	0.60	2.00	2.00	3.2	
		Week 14	Tezepelumab	11	11 (100.0)	1.89 (1.22)	0.0	1.20	1.80	2.20	4.8	
			Placebo	14	12 (85.7)	1.50 (0.88)	0.0	0.90	1.60	2.00	3.2	
		Week 16	Tezepelumab	11	11 (100.0)	2.29 (1.23)	0.0	1.60	2.60	2.80	4.8	
			Placebo	14	12 (85.7)	1.65 (0.99)	0.0	0.80	1.90	2.30	3.2	
		Week 18	Tezepelumab	11	11 (100.0)	2.24 (1.24)	0.0	1.60	2.40	3.00	4.8	
			Placebo	14	12 (85.7)	1.80 (1.37)	0.0	0.90	1.60	2.70	4.8	
		Week 20	Tezepelumab	11	11 (100.0)	2.15 (1.25)	0.0	1.20	2.60	2.60	4.8	
			Placebo	14	12 (85.7)	2.03 (0.71)	0.4	1.70	2.20	2.50	2.8	
		Week 22	Tezepelumab	11	11 (100.0)	2.24 (1.19)	0.0	1.80	2.40	2.60	4.8	
			Placebo	14	12 (85.7)	1.98 (0.81)	0.4	1.70	1.90	2.60	3.2	
		Week 24	Tezepelumab	11	11 (100.0)	2.24 (1.26)	0.0	1.40	2.60	3.00	4.8	
			Placebo	14	12 (85.7)	2.12 (0.87)	0.4	1.70	2.20	2.80	3.2	
		Week 26	Tezepelumab	11	11 (100.0)	2.27 (1.39)	0.0	1.00	2.80	3.00	4.8	
			Placebo	14	12 (85.7)	1.78 (1.27)	0.0	0.80	1.50	3.20	3.8	
		Week 28	Tezepelumab	11	11 (100.0)	2.29 (1.34)	0.0	1.20	2.40	3.20	4.8	
			Placebo	14	12 (85.7)	1.67 (1.19)	0.0	0.60	1.60	2.80	3.2	
		Week 30	Tezepelumab	11	11 (100.0)	2.29 (1.28)	0.0	1.20	2.60	3.00	4.8	
			Placebo	14	12 (85.7)	1.70 (1.02)	0.2	0.90	1.60	2.40	3.2	
		Week 32	Tezepelumab	11	11 (100.0)	2.13 (1.29)	0.0	1.00	2.20	2.80	4.8	
			Placebo	14	12 (85.7)	1.70 (0.98)	0.2	0.90	1.70	2.40	3.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 150 cells/uL	Absolute values	Week 34	Tezepelumab	11	11 (100.0)	2.13 (1.37)	0.0	1.00	2.40	3.00	4.8	
			Placebo	14	12 (85.7)	1.68 (1.00)	0.2	1.00	1.70	2.20	3.2	
		Week 36	Tezepelumab	11	11 (100.0)	2.15 (1.35)	0.0	1.00	1.80	3.00	4.8	
			Placebo	14	12 (85.7)	1.92 (1.01)	0.2	1.20	2.20	2.80	3.2	
		Week 38	Tezepelumab	11	11 (100.0)	2.16 (1.36)	0.0	1.20	1.80	3.20	4.8	
			Placebo	14	12 (85.7)	1.92 (0.94)	0.4	1.50	1.80	2.70	3.4	
		Week 40	Tezepelumab	11	11 (100.0)	2.38 (1.28)	0.0	1.80	2.60	3.00	4.8	
			Placebo	14	12 (85.7)	1.97 (1.27)	0.2	1.10	1.50	3.00	4.2	
		Week 42	Tezepelumab	11	11 (100.0)	2.29 (1.31)	0.0	1.60	1.80	3.20	4.8	
			Placebo	14	12 (85.7)	1.83 (0.91)	0.2	1.40	2.00	2.50	3.2	
		Week 44	Tezepelumab	11	11 (100.0)	2.36 (1.24)	0.0	1.80	2.40	3.00	4.8	
			Placebo	14	12 (85.7)	1.90 (1.35)	0.0	0.60	1.90	3.00	4.2	
		Week 46	Tezepelumab	11	11 (100.0)	2.35 (1.29)	0.0	1.60	2.20	3.00	4.8	
			Placebo	14	12 (85.7)	1.80 (0.89)	0.2	1.40	1.90	2.40	3.2	
		Week 48	Tezepelumab	11	11 (100.0)	2.35 (1.27)	0.0	1.80	2.20	3.00	4.8	
			Placebo	14	12 (85.7)	1.85 (1.06)	0.2	0.90	2.20	2.70	3.2	
		Week 50	Tezepelumab	11	11 (100.0)	2.35 (1.25)	0.0	1.80	2.20	3.00	4.8	
			Placebo	14	12 (85.7)	1.63 (1.04)	0.0	0.80	1.70	2.40	3.2	
		Week 52	Tezepelumab	11	11 (100.0)	2.33 (1.25)	0.0	1.80	2.20	3.00	4.8	
			Placebo	14	12 (85.7)	1.75 (1.06)	0.0	1.00	1.80	2.70	3.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	-0.27 (0.61)	-1.4	-0.80	-0.20	0.20	0.4	0.94 [0.08, 1.81]
			Placebo	14	12 (85.7)	-0.78 (0.46)	-1.4	-1.10	-0.90	-0.40	0.0	
		Week 4	Tezepelumab	11	11 (100.0)	-0.93 (0.79)	-2.2	-1.40	-0.80	-0.20	0.2	-0.40 [-1.23, 0.42]
			Placebo	14	12 (85.7)	-0.60 (0.83)	-2.0	-1.20	-0.50	-0.10	0.6	
		Week 6	Tezepelumab	11	11 (100.0)	-0.95 (0.72)	-1.8	-1.60	-1.20	-0.20	0.2	0.10 [-0.72, 0.92]
			Placebo	14	12 (85.7)	-1.02 (0.73)	-2.2	-1.60	-1.00	-0.40	0.2	
		Week 8	Tezepelumab	11	11 (100.0)	-0.76 (1.40)	-2.4	-2.00	-0.60	0.00	2.6	0.16 [-0.66, 0.98]
			Placebo	14	12 (85.7)	-0.97 (1.16)	-2.8	-1.90	-0.90	0.00	1.0	
		Week 10	Tezepelumab	11	11 (100.0)	-0.82 (1.18)	-2.6	-1.80	-0.60	0.20	0.6	0.28 [-0.54, 1.11]
			Placebo	14	12 (85.7)	-1.10 (0.79)	-2.2	-1.80	-1.00	-0.50	0.0	
		Week 12	Tezepelumab	11	11 (100.0)	-1.04 (1.02)	-2.4	-2.20	-0.80	0.00	0.6	0.35 [-0.48, 1.17]
			Placebo	14	12 (85.7)	-1.38 (0.98)	-3.0	-2.20	-1.10	-0.80	0.2	
		Week 14	Tezepelumab	11	11 (100.0)	-1.35 (0.90)	-2.4	-2.20	-1.40	-0.80	0.6	0.08 [-0.74, 0.90]
			Placebo	14	12 (85.7)	-1.42 (0.92)	-3.0	-2.00	-1.40	-0.80	0.2	
		Week 16	Tezepelumab	11	11 (100.0)	-0.95 (1.04)	-2.4	-2.20	-1.00	-0.20	0.6	0.32 [-0.50, 1.14]
			Placebo	14	12 (85.7)	-1.27 (0.98)	-3.0	-1.90	-1.20	-0.60	0.2	
		Week 18	Tezepelumab	11	11 (100.0)	-1.00 (0.93)	-2.4	-2.00	-0.80	-0.40	0.6	0.11 [-0.71, 0.92]
			Placebo	14	12 (85.7)	-1.12 (1.23)	-3.0	-1.90	-1.40	-0.20	1.4	
		Week 20	Tezepelumab	11	11 (100.0)	-1.09 (0.99)	-2.4	-2.20	-1.00	-0.40	0.6	-0.25 [-1.07, 0.58]
			Placebo	14	12 (85.7)	-0.88 (0.68)	-2.6	-1.20	-0.70	-0.40	-0.2	
		Week 22	Tezepelumab	11	11 (100.0)	-1.00 (1.00)	-2.4	-2.20	-0.80	-0.60	0.6	-0.08 [-0.89, 0.74]
			Placebo	14	12 (85.7)	-0.93 (0.78)	-2.6	-1.40	-1.00	-0.30	0.2	
		Week 24	Tezepelumab	11	11 (100.0)	-1.00 (0.95)	-2.4	-2.00	-0.80	-0.20	0.6	-0.21 [-1.03, 0.61]
			Placebo	14	12 (85.7)	-0.80 (0.98)	-2.6	-1.50	-0.60	0.00	0.2	
		Week 26	Tezepelumab	11	11 (100.0)	-0.96 (1.14)	-2.4	-2.20	-1.00	0.20	0.6	0.15 [-0.67, 0.97]
			Placebo	14	12 (85.7)	-1.13 (1.17)	-3.0	-2.10	-1.20	0.10	0.4	
		Week 28	Tezepelumab	11	11 (100.0)	-0.95 (1.16)	-2.6	-2.20	-0.80	0.20	0.6	0.27 [-0.55, 1.09]
			Placebo	14	12 (85.7)	-1.25 (1.11)	-3.0	-2.20	-1.10	-0.20	0.2	
		Week 30	Tezepelumab	11	11 (100.0)	-0.95 (1.08)	-2.4	-2.20	-0.60	-0.20	0.6	0.27 [-0.55, 1.10]
			Placebo	14	12 (85.7)	-1.22 (0.90)	-2.6	-1.70	-1.40	-0.50	0.2	
		Week 32	Tezepelumab	11	11 (100.0)	-1.11 (1.06)	-2.4	-2.20	-1.20	-0.40	0.6	0.11 [-0.71, 0.93]
			Placebo	14	12 (85.7)	-1.22 (0.90)	-2.6	-1.70	-1.40	-0.40	0.2	
		Week 34	Tezepelumab	11	11 (100.0)	-1.11 (1.10)	-2.4	-2.20	-1.40	0.00	0.6	0.13 [-0.69, 0.94]
			Placebo	14	12 (85.7)	-1.23 (0.88)	-2.8	-1.70	-1.20	-0.70	0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 150 cells/uL	Change from baseline	Week 36	Tezepelumab	11	11 (100.0)	-1.09 (1.07)	-2.4	-2.00	-1.20	0.00	0.6	-0.09 [-0.91, 0.73]
			Placebo	14	12 (85.7)	-1.00 (1.00)	-3.2	-1.30	-0.70	-0.30	0.2	
		Week 38	Tezepelumab	11	11 (100.0)	-1.07 (1.07)	-2.4	-2.00	-1.40	0.00	0.6	-0.08 [-0.90, 0.74]
			Placebo	14	12 (85.7)	-1.00 (0.79)	-2.6	-1.20	-1.10	-0.40	0.2	
		Week 40	Tezepelumab	11	11 (100.0)	-0.85 (0.96)	-2.4	-1.60	-0.80	-0.20	0.6	0.09 [-0.73, 0.91]
			Placebo	14	12 (85.7)	-0.95 (1.11)	-2.6	-1.80	-1.20	0.10	0.8	
		Week 42	Tezepelumab	11	11 (100.0)	-0.95 (1.02)	-2.4	-1.80	-1.00	0.00	0.6	0.16 [-0.66, 0.98]
			Placebo	14	12 (85.7)	-1.08 (0.70)	-2.6	-1.50	-1.00	-0.80	0.2	
		Week 44	Tezepelumab	11	11 (100.0)	-0.87 (1.00)	-2.4	-2.00	-0.80	-0.20	0.6	0.13 [-0.69, 0.94]
			Placebo	14	12 (85.7)	-1.02 (1.26)	-2.8	-2.10	-1.00	0.10	0.8	
		Week 46	Tezepelumab	11	11 (100.0)	-0.89 (0.94)	-2.4	-1.40	-1.00	-0.20	0.6	0.27 [-0.56, 1.09]
			Placebo	14	12 (85.7)	-1.12 (0.75)	-2.6	-1.40	-1.00	-0.60	0.2	
		Week 48	Tezepelumab	11	11 (100.0)	-0.89 (0.96)	-2.4	-1.60	-1.00	-0.20	0.6	0.18 [-0.64, 1.00]
			Placebo	14	12 (85.7)	-1.07 (0.96)	-2.8	-1.70	-0.60	-0.40	0.2	
		Week 50	Tezepelumab	11	11 (100.0)	-0.89 (0.99)	-2.4	-1.80	-0.80	-0.20	0.6	0.42 [-0.41, 1.25]
			Placebo	14	12 (85.7)	-1.28 (0.88)	-2.8	-1.80	-1.20	-0.70	0.2	
		Week 52	Tezepelumab	11	11 (100.0)	-0.91 (0.98)	-2.4	-1.80	-0.80	-0.20	0.6	0.28 [-0.55, 1.10]
			Placebo	14	12 (85.7)	-1.17 (0.90)	-2.8	-1.80	-1.10	-0.40	0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	54	54 (100.0)	2.80 (0.90)	0.0	2.40	2.80	3.20	5.2	
			Placebo	51	51 (100.0)	2.80 (0.80)	0.4	2.40	2.80	3.20	5.0	
		Week 2	Tezepelumab	54	51 (94.4)	2.20 (1.04)	0.0	1.40	2.20	3.00	4.4	
			Placebo	51	46 (90.2)	2.47 (0.82)	0.4	2.00	2.50	2.80	5.0	
		Week 4	Tezepelumab	54	51 (94.4)	2.05 (0.99)	0.2	1.20	2.20	3.00	3.4	
			Placebo	51	46 (90.2)	2.23 (0.90)	0.2	1.40	2.50	2.80	4.2	
		Week 6	Tezepelumab	54	51 (94.4)	1.89 (1.05)	0.0	1.20	1.80	2.80	4.0	
			Placebo	51	46 (90.2)	2.30 (1.21)	0.2	1.40	2.20	3.00	6.0	
		Week 8	Tezepelumab	54	51 (94.4)	1.67 (1.09)	0.0	0.80	1.60	2.60	4.2	
			Placebo	51	47 (92.2)	2.17 (1.13)	0.0	1.40	2.40	3.00	5.0	
		Week 10	Tezepelumab	54	51 (94.4)	1.56 (1.03)	0.0	0.80	1.60	2.40	3.6	
			Placebo	51	47 (92.2)	2.24 (1.11)	0.0	1.80	2.40	3.00	5.2	
		Week 12	Tezepelumab	54	51 (94.4)	1.49 (1.05)	0.0	0.60	1.60	2.40	3.2	
			Placebo	51	47 (92.2)	2.05 (1.07)	0.0	1.00	2.20	2.80	4.4	
		Week 14	Tezepelumab	54	51 (94.4)	1.49 (1.11)	0.0	0.60	1.40	2.40	4.2	
			Placebo	51	47 (92.2)	1.97 (1.02)	0.0	1.40	2.00	2.60	5.0	
		Week 16	Tezepelumab	54	51 (94.4)	1.58 (1.16)	0.0	0.60	1.40	2.40	4.6	
			Placebo	51	47 (92.2)	2.13 (1.25)	0.0	1.00	2.20	3.00	5.0	
		Week 18	Tezepelumab	54	52 (96.3)	1.56 (1.03)	0.0	0.80	1.60	2.30	4.2	
			Placebo	51	47 (92.2)	1.97 (1.14)	0.0	1.00	2.00	2.60	5.0	
		Week 20	Tezepelumab	54	52 (96.3)	1.58 (1.12)	0.0	0.60	1.50	2.30	5.0	
			Placebo	51	47 (92.2)	2.03 (1.20)	0.0	1.00	2.00	2.80	5.0	
		Week 22	Tezepelumab	54	52 (96.3)	1.68 (0.99)	0.0	0.80	2.00	2.40	3.8	
			Placebo	51	47 (92.2)	1.98 (1.24)	0.0	1.00	2.00	2.80	5.0	
		Week 24	Tezepelumab	54	52 (96.3)	1.65 (1.07)	0.0	0.70	1.60	2.50	3.8	
			Placebo	51	47 (92.2)	2.03 (1.12)	0.0	1.00	2.20	2.80	4.4	
		Week 26	Tezepelumab	54	53 (98.1)	1.69 (1.06)	0.0	0.80	1.80	2.40	4.0	
			Placebo	51	47 (92.2)	2.03 (1.11)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	54	54 (100.0)	1.62 (1.11)	0.0	0.60	1.50	2.40	3.8	
			Placebo	51	48 (94.1)	2.03 (1.24)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	54	54 (100.0)	1.59 (1.04)	0.0	0.80	1.60	2.20	3.8	
			Placebo	51	48 (94.1)	2.00 (1.22)	0.0	1.00	2.00	3.00	4.4	
		Week 32	Tezepelumab	54	54 (100.0)	1.55 (1.07)	0.0	0.60	1.50	2.40	4.0	
			Placebo	51	48 (94.1)	1.95 (1.18)	0.0	1.00	1.90	2.80	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 150 cells/uL	Absolute values	Week 34	Tezepelumab	54	54 (100.0)	1.64 (1.15)	0.0	0.80	1.50	2.60	4.2	
			Placebo	51	48 (94.1)	1.92 (1.18)	0.0	0.90	1.90	2.60	4.8	
		Week 36	Tezepelumab	54	54 (100.0)	1.57 (1.05)	0.0	0.80	1.40	2.40	3.6	
			Placebo	51	48 (94.1)	2.09 (1.24)	0.0	1.20	2.00	2.80	4.8	
		Week 38	Tezepelumab	54	54 (100.0)	1.63 (1.20)	0.0	0.60	1.70	2.40	4.6	
			Placebo	51	48 (94.1)	1.93 (1.18)	0.0	1.00	2.00	2.70	4.8	
		Week 40	Tezepelumab	54	54 (100.0)	1.57 (1.13)	0.0	0.40	1.60	2.40	3.8	
			Placebo	51	48 (94.1)	2.09 (1.18)	0.0	1.10	2.20	2.80	4.4	
		Week 42	Tezepelumab	54	54 (100.0)	1.53 (1.08)	0.0	0.80	1.40	2.40	4.0	
			Placebo	51	48 (94.1)	1.95 (1.10)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	54	54 (100.0)	1.56 (1.09)	0.0	0.60	1.40	2.60	3.8	
			Placebo	51	48 (94.1)	2.03 (1.06)	0.0	1.20	2.00	2.60	4.4	
		Week 46	Tezepelumab	54	54 (100.0)	1.59 (1.15)	0.0	0.80	1.60	2.60	3.8	
			Placebo	51	48 (94.1)	1.90 (1.04)	0.0	1.20	2.00	2.40	4.4	
		Week 48	Tezepelumab	54	54 (100.0)	1.60 (1.14)	0.0	0.80	1.40	2.40	4.2	
			Placebo	51	48 (94.1)	1.97 (1.12)	0.0	1.00	2.00	2.50	4.6	
		Week 50	Tezepelumab	54	54 (100.0)	1.52 (1.16)	0.0	0.60	1.20	2.20	4.2	
			Placebo	51	48 (94.1)	1.87 (1.03)	0.0	1.00	1.90	2.40	4.4	
		Week 52	Tezepelumab	54	54 (100.0)	1.57 (1.14)	0.0	0.80	1.40	2.20	4.4	
			Placebo	51	48 (94.1)	1.93 (1.10)	0.0	1.00	2.00	2.70	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	54	51 (94.4)	-0.64 (0.82)	-3.2	-1.20	-0.40	0.00	0.8	-0.26 [-0.66, 0.14]
			Placebo	51	46 (90.2)	-0.43 (0.77)	-2.8	-0.80	-0.20	0.00	1.2	
		Week 4	Tezepelumab	54	51 (94.4)	-0.79 (0.96)	-2.6	-1.20	-0.80	-0.20	2.6	-0.13 [-0.53, 0.27]
			Placebo	51	46 (90.2)	-0.66 (1.01)	-3.0	-1.40	-0.40	0.00	1.2	
		Week 6	Tezepelumab	54	51 (94.4)	-0.95 (1.09)	-2.8	-1.60	-1.00	-0.20	2.6	-0.32 [-0.72, 0.08]
			Placebo	51	46 (90.2)	-0.60 (1.11)	-3.4	-1.20	-0.50	0.20	1.6	
		Week 8	Tezepelumab	54	51 (94.4)	-1.17 (1.10)	-3.2	-1.80	-1.20	-0.40	2.6	-0.41 [-0.81, -0.01]
			Placebo	51	47 (92.2)	-0.73 (1.04)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	54	51 (94.4)	-1.27 (1.11)	-3.4	-2.00	-1.40	-0.60	2.6	-0.52 [-0.92, -0.12]
			Placebo	51	47 (92.2)	-0.67 (1.23)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	54	51 (94.4)	-1.35 (1.13)	-3.2	-2.20	-1.40	-0.80	2.6	-0.44 [-0.84, -0.04]
			Placebo	51	47 (92.2)	-0.86 (1.09)	-3.8	-1.40	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	54	51 (94.4)	-1.35 (1.17)	-4.0	-2.20	-1.40	-0.60	2.6	-0.36 [-0.76, 0.04]
			Placebo	51	47 (92.2)	-0.94 (1.10)	-3.4	-1.40	-1.00	-0.40	2.4	
		Week 16	Tezepelumab	54	51 (94.4)	-1.25 (1.18)	-3.2	-2.20	-1.20	-0.60	2.6	-0.40 [-0.80, -0.00]
			Placebo	51	47 (92.2)	-0.77 (1.21)	-3.6	-1.40	-0.80	0.00	2.6	
		Week 18	Tezepelumab	54	52 (96.3)	-1.26 (1.14)	-3.8	-1.90	-1.10	-0.70	2.6	-0.27 [-0.67, 0.13]
			Placebo	51	47 (92.2)	-0.94 (1.24)	-3.6	-2.00	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	54	52 (96.3)	-1.24 (1.14)	-3.4	-2.20	-1.30	-0.50	2.6	-0.30 [-0.70, 0.09]
			Placebo	51	47 (92.2)	-0.87 (1.28)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	54	52 (96.3)	-1.14 (1.17)	-3.2	-2.00	-1.00	-0.60	2.6	-0.18 [-0.57, 0.22]
			Placebo	51	47 (92.2)	-0.92 (1.27)	-3.8	-1.80	-1.00	0.00	2.6	
		Week 24	Tezepelumab	54	52 (96.3)	-1.18 (1.14)	-3.4	-2.00	-1.30	-0.40	2.6	-0.26 [-0.66, 0.14]
			Placebo	51	47 (92.2)	-0.88 (1.18)	-3.6	-1.60	-1.00	-0.20	2.6	
		Week 26	Tezepelumab	54	53 (98.1)	-1.11 (1.15)	-3.0	-2.20	-1.00	-0.20	2.6	-0.20 [-0.59, 0.20]
			Placebo	51	47 (92.2)	-0.88 (1.21)	-3.4	-1.80	-1.20	0.00	2.6	
		Week 28	Tezepelumab	54	54 (100.0)	-1.18 (1.24)	-3.4	-2.20	-1.20	-0.60	2.6	-0.29 [-0.68, 0.10]
			Placebo	51	48 (94.1)	-0.82 (1.26)	-3.4	-1.60	-1.10	0.00	2.6	
		Week 30	Tezepelumab	54	54 (100.0)	-1.21 (1.21)	-3.8	-2.20	-1.20	-0.60	2.6	-0.28 [-0.67, 0.11]
			Placebo	51	48 (94.1)	-0.86 (1.30)	-3.4	-1.60	-1.00	-0.10	2.6	
		Week 32	Tezepelumab	54	54 (100.0)	-1.25 (1.13)	-3.2	-2.20	-1.20	-0.60	2.6	-0.30 [-0.69, 0.09]
			Placebo	51	48 (94.1)	-0.90 (1.23)	-3.2	-1.60	-1.10	-0.20	2.6	
		Week 34	Tezepelumab	54	54 (100.0)	-1.16 (1.24)	-3.0	-2.20	-1.30	-0.40	2.6	-0.19 [-0.58, 0.20]
			Placebo	51	48 (94.1)	-0.93 (1.22)	-3.2	-1.70	-1.10	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 150 cells/uL	Change from baseline	Week 36	Tezepelumab	54	54 (100.0)	-1.23 (1.22)	-3.2	-2.20	-1.20	-0.20	2.6	-0.37 [-0.76, 0.02]
			Placebo	51	48 (94.1)	-0.77 (1.28)	-3.6	-1.50	-1.00	0.00	2.6	
		Week 38	Tezepelumab	54	54 (100.0)	-1.17 (1.28)	-3.2	-2.20	-1.20	-0.40	2.6	-0.19 [-0.58, 0.20]
			Placebo	51	48 (94.1)	-0.93 (1.23)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 40	Tezepelumab	54	54 (100.0)	-1.23 (1.26)	-3.4	-2.20	-1.30	-0.40	2.6	-0.37 [-0.76, 0.02]
			Placebo	51	48 (94.1)	-0.77 (1.25)	-3.2	-1.40	-0.80	-0.10	2.6	
		Week 42	Tezepelumab	54	54 (100.0)	-1.27 (1.25)	-3.6	-2.20	-1.40	-0.40	2.6	-0.30 [-0.69, 0.09]
			Placebo	51	48 (94.1)	-0.91 (1.19)	-2.8	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	54	54 (100.0)	-1.24 (1.24)	-3.8	-2.20	-1.30	-0.40	2.6	-0.35 [-0.75, 0.04]
			Placebo	51	48 (94.1)	-0.82 (1.14)	-3.4	-1.50	-1.00	-0.30	2.6	
		Week 46	Tezepelumab	54	54 (100.0)	-1.21 (1.27)	-3.6	-2.20	-1.30	-0.20	2.6	-0.21 [-0.60, 0.18]
			Placebo	51	48 (94.1)	-0.95 (1.13)	-3.2	-1.60	-1.00	-0.30	2.6	
		Week 48	Tezepelumab	54	54 (100.0)	-1.20 (1.24)	-3.0	-2.40	-1.10	-0.40	2.6	-0.26 [-0.65, 0.13]
			Placebo	51	48 (94.1)	-0.89 (1.18)	-3.4	-1.50	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	54	54 (100.0)	-1.28 (1.27)	-3.2	-2.40	-1.40	-0.40	2.6	-0.25 [-0.64, 0.14]
			Placebo	51	48 (94.1)	-0.98 (1.10)	-3.6	-1.60	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	54	54 (100.0)	-1.23 (1.25)	-3.2	-2.20	-1.20	-0.40	2.6	-0.25 [-0.64, 0.14]
			Placebo	51	48 (94.1)	-0.93 (1.16)	-3.6	-1.50	-0.80	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	33	33 (100.0)	3.04 (0.79)	1.8	2.60	3.00	3.20	5.2	
			Placebo	34	34 (100.0)	2.92 (0.79)	0.4	2.60	3.00	3.40	4.8	
		Week 2	Tezepelumab	33	31 (93.9)	2.57 (1.04)	0.0	1.60	2.80	3.40	4.0	
			Placebo	34	28 (82.4)	2.41 (0.82)	0.4	2.10	2.40	2.80	4.8	
		Week 4	Tezepelumab	33	31 (93.9)	2.24 (1.09)	0.2	1.40	2.60	3.00	3.6	
			Placebo	34	28 (82.4)	2.13 (0.97)	0.2	1.60	2.20	2.70	3.6	
		Week 6	Tezepelumab	33	31 (93.9)	2.16 (1.07)	0.0	1.40	2.60	3.00	4.0	
			Placebo	34	28 (82.4)	1.99 (1.17)	0.2	1.20	2.10	2.60	5.0	
		Week 8	Tezepelumab	33	31 (93.9)	2.14 (1.29)	0.0	1.20	2.60	3.00	5.2	
			Placebo	34	29 (85.3)	2.00 (1.19)	0.0	1.00	2.00	2.80	4.6	
		Week 10	Tezepelumab	33	31 (93.9)	1.94 (1.25)	0.0	0.80	2.20	3.00	4.8	
			Placebo	34	29 (85.3)	2.01 (1.03)	0.2	1.60	2.00	2.60	4.4	
		Week 12	Tezepelumab	33	31 (93.9)	1.86 (1.21)	0.0	0.60	2.20	2.80	4.8	
			Placebo	34	29 (85.3)	1.70 (1.02)	0.0	1.00	1.80	2.20	4.4	
		Week 14	Tezepelumab	33	31 (93.9)	1.75 (1.16)	0.0	0.60	2.00	2.40	4.8	
			Placebo	34	29 (85.3)	1.68 (0.98)	0.0	1.00	1.80	2.20	5.0	
		Week 16	Tezepelumab	33	31 (93.9)	1.84 (1.21)	0.0	0.80	2.20	2.60	4.8	
			Placebo	34	29 (85.3)	1.74 (0.98)	0.0	1.00	1.80	2.40	4.4	
		Week 18	Tezepelumab	33	32 (97.0)	1.91 (1.14)	0.0	1.00	2.00	2.50	4.8	
			Placebo	34	29 (85.3)	1.78 (1.23)	0.0	1.00	1.80	2.60	4.8	
		Week 20	Tezepelumab	33	32 (97.0)	1.87 (1.25)	0.0	1.00	2.00	2.60	5.0	
			Placebo	34	29 (85.3)	1.81 (1.06)	0.2	1.20	1.80	2.60	4.4	
		Week 22	Tezepelumab	33	32 (97.0)	1.95 (1.09)	0.0	1.10	2.20	2.60	4.8	
			Placebo	34	29 (85.3)	1.81 (1.07)	0.0	1.00	1.80	2.60	4.4	
		Week 24	Tezepelumab	33	32 (97.0)	1.88 (1.16)	0.0	1.10	2.00	2.60	4.8	
			Placebo	34	29 (85.3)	1.86 (1.07)	0.2	0.80	1.80	2.60	4.4	
		Week 26	Tezepelumab	33	33 (100.0)	1.95 (1.21)	0.0	1.00	2.00	2.80	4.8	
			Placebo	34	29 (85.3)	1.72 (1.19)	0.0	1.00	1.40	2.20	4.4	
		Week 28	Tezepelumab	33	33 (100.0)	1.92 (1.21)	0.0	1.20	2.00	2.80	4.8	
			Placebo	34	30 (88.2)	1.71 (1.26)	0.0	0.80	1.30	2.60	4.4	
		Week 30	Tezepelumab	33	33 (100.0)	1.95 (1.17)	0.0	1.20	2.00	2.60	4.8	
			Placebo	34	30 (88.2)	1.75 (1.19)	0.0	0.80	1.60	2.40	4.4	
		Week 32	Tezepelumab	33	33 (100.0)	1.85 (1.18)	0.0	1.00	2.00	2.80	4.8	
			Placebo	34	30 (88.2)	1.59 (1.07)	0.0	0.80	1.60	2.20	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 300 cells/uL	Absolute values	Week 34	Tezepelumab	33	33 (100.0)	1.91 (1.23)	0.0	1.00	2.00	2.80	4.8	
			Placebo	34	30 (88.2)	1.55 (1.07)	0.0	0.80	1.60	2.20	4.4	
		Week 36	Tezepelumab	33	33 (100.0)	1.82 (1.20)	0.0	1.00	1.80	2.60	4.8	
			Placebo	34	30 (88.2)	1.73 (1.19)	0.0	0.80	1.70	2.60	4.4	
		Week 38	Tezepelumab	33	33 (100.0)	1.92 (1.35)	0.0	1.00	2.00	2.80	4.8	
			Placebo	34	30 (88.2)	1.77 (1.11)	0.0	1.00	1.80	2.60	4.4	
		Week 40	Tezepelumab	33	33 (100.0)	1.96 (1.24)	0.0	1.00	2.00	2.80	4.8	
			Placebo	34	30 (88.2)	1.81 (1.28)	0.0	0.60	1.70	2.80	4.4	
		Week 42	Tezepelumab	33	33 (100.0)	1.92 (1.22)	0.0	1.00	2.00	2.80	4.8	
			Placebo	34	30 (88.2)	1.71 (1.12)	0.0	0.80	1.90	2.40	4.4	
		Week 44	Tezepelumab	33	33 (100.0)	1.93 (1.19)	0.0	1.00	2.00	2.80	4.8	
			Placebo	34	30 (88.2)	1.79 (1.23)	0.0	0.60	1.70	2.80	4.4	
		Week 46	Tezepelumab	33	33 (100.0)	1.92 (1.25)	0.0	1.00	2.00	3.00	4.8	
			Placebo	34	30 (88.2)	1.75 (1.11)	0.0	1.00	1.80	2.40	4.4	
		Week 48	Tezepelumab	33	33 (100.0)	1.92 (1.21)	0.0	1.00	2.00	2.80	4.8	
			Placebo	34	30 (88.2)	1.71 (1.24)	0.0	0.40	1.90	2.40	4.6	
		Week 50	Tezepelumab	33	33 (100.0)	1.94 (1.28)	0.0	1.00	2.00	3.00	4.8	
			Placebo	34	30 (88.2)	1.65 (1.13)	0.0	0.60	1.70	2.40	4.4	
		Week 52	Tezepelumab	33	33 (100.0)	1.95 (1.28)	0.0	1.00	2.00	2.80	4.8	
			Placebo	34	30 (88.2)	1.69 (1.14)	0.0	0.80	1.70	2.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 2	Tezepelumab	33	31 (93.9)	-0.55 (0.87)	-3.2	-1.00	-0.40	0.20	0.4	0.01 [-0.50, 0.52]
			Placebo	34	28 (82.4)	-0.56 (0.67)	-2.8	-1.00	-0.40	-0.10	0.4	
		Week 4	Tezepelumab	33	31 (93.9)	-0.88 (0.86)	-2.6	-1.40	-0.80	-0.20	0.8	-0.05 [-0.56, 0.46]
			Placebo	34	28 (82.4)	-0.84 (0.90)	-3.0	-1.40	-0.90	-0.20	0.6	
		Week 6	Tezepelumab	33	31 (93.9)	-0.95 (0.84)	-2.8	-1.60	-1.00	-0.20	0.4	0.03 [-0.49, 0.54]
			Placebo	34	28 (82.4)	-0.98 (0.99)	-3.4	-1.70	-0.80	-0.40	1.6	
		Week 8	Tezepelumab	33	31 (93.9)	-0.98 (1.17)	-3.0	-1.80	-1.20	0.00	2.6	-0.00 [-0.51, 0.51]
			Placebo	34	29 (85.3)	-0.98 (1.05)	-3.0	-1.60	-1.00	-0.20	1.0	
		Week 10	Tezepelumab	33	31 (93.9)	-1.17 (1.03)	-3.0	-1.80	-1.40	-0.20	0.6	-0.20 [-0.71, 0.31]
			Placebo	34	29 (85.3)	-0.97 (0.97)	-3.2	-1.40	-1.00	-0.40	1.6	
		Week 12	Tezepelumab	33	31 (93.9)	-1.26 (1.06)	-3.2	-2.20	-1.20	-0.40	0.6	0.03 [-0.48, 0.53]
			Placebo	34	29 (85.3)	-1.28 (0.88)	-3.2	-1.60	-1.20	-0.80	0.2	
		Week 14	Tezepelumab	33	31 (93.9)	-1.37 (0.97)	-3.0	-2.20	-1.40	-0.60	0.6	-0.08 [-0.58, 0.43]
			Placebo	34	29 (85.3)	-1.30 (0.91)	-3.2	-1.60	-1.40	-0.60	0.2	
		Week 16	Tezepelumab	33	31 (93.9)	-1.28 (0.99)	-3.0	-2.20	-1.20	-0.40	0.6	-0.04 [-0.54, 0.47]
			Placebo	34	29 (85.3)	-1.24 (0.90)	-3.0	-1.60	-1.20	-0.60	0.6	
		Week 18	Tezepelumab	33	32 (97.0)	-1.17 (0.96)	-3.0	-1.90	-1.00	-0.50	0.6	0.03 [-0.47, 0.53]
			Placebo	34	29 (85.3)	-1.20 (1.13)	-3.2	-2.00	-1.40	-0.20	1.4	
		Week 20	Tezepelumab	33	32 (97.0)	-1.21 (1.04)	-3.0	-2.20	-1.10	-0.40	0.6	-0.05 [-0.55, 0.46]
			Placebo	34	29 (85.3)	-1.17 (0.97)	-3.0	-1.60	-1.00	-0.60	1.0	
		Week 22	Tezepelumab	33	32 (97.0)	-1.13 (1.00)	-3.0	-2.00	-1.00	-0.50	0.6	0.03 [-0.47, 0.54]
			Placebo	34	29 (85.3)	-1.17 (0.98)	-3.2	-1.60	-1.20	-0.40	1.2	
		Week 24	Tezepelumab	33	32 (97.0)	-1.20 (1.00)	-3.0	-2.10	-1.00	-0.50	0.6	-0.08 [-0.58, 0.42]
			Placebo	34	29 (85.3)	-1.12 (1.04)	-3.2	-1.80	-1.00	-0.40	1.0	
		Week 26	Tezepelumab	33	33 (100.0)	-1.10 (1.09)	-3.0	-2.20	-1.00	-0.20	0.6	0.15 [-0.35, 0.65]
			Placebo	34	29 (85.3)	-1.26 (1.05)	-3.0	-2.00	-1.40	-0.80	1.6	
		Week 28	Tezepelumab	33	33 (100.0)	-1.13 (1.21)	-3.0	-2.20	-1.20	0.00	1.0	0.05 [-0.44, 0.55]
			Placebo	34	30 (88.2)	-1.19 (1.10)	-3.0	-2.00	-1.30	-0.40	1.6	
		Week 30	Tezepelumab	33	33 (100.0)	-1.09 (1.17)	-3.0	-2.20	-1.00	-0.20	2.0	0.04 [-0.45, 0.54]
			Placebo	34	30 (88.2)	-1.14 (1.08)	-3.2	-1.80	-1.40	-0.40	2.0	
		Week 32	Tezepelumab	33	33 (100.0)	-1.19 (1.07)	-3.0	-2.20	-1.20	-0.60	1.0	0.12 [-0.37, 0.62]
			Placebo	34	30 (88.2)	-1.31 (0.90)	-3.2	-1.80	-1.40	-0.60	0.2	
		Week 34	Tezepelumab	33	33 (100.0)	-1.13 (1.20)	-3.0	-2.20	-1.40	-0.20	2.2	0.20 [-0.30, 0.69]
			Placebo	34	30 (88.2)	-1.35 (0.92)	-3.2	-2.00	-1.30	-0.60	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 300 cells/uL	Change from baseline	Week 36	Tezepelumab	33	33 (100.0)	-1.22 (1.10)	-3.0	-2.20	-1.20	-0.40	1.6	-0.06 [-0.55, 0.44]
			Placebo	34	30 (88.2)	-1.16 (1.08)	-3.6	-1.60	-1.00	-0.40	0.8	
		Week 38	Tezepelumab	33	33 (100.0)	-1.13 (1.28)	-3.0	-2.20	-1.40	0.00	2.6	-0.01 [-0.50, 0.49]
			Placebo	34	30 (88.2)	-1.12 (0.94)	-3.2	-1.40	-1.20	-0.40	0.4	
		Week 40	Tezepelumab	33	33 (100.0)	-1.08 (1.17)	-3.0	-2.00	-1.20	-0.40	1.8	0.01 [-0.49, 0.50]
			Placebo	34	30 (88.2)	-1.09 (1.11)	-3.2	-2.00	-1.20	-0.20	1.4	
		Week 42	Tezepelumab	33	33 (100.0)	-1.12 (1.17)	-3.0	-2.00	-1.20	-0.40	2.2	0.06 [-0.44, 0.55]
			Placebo	34	30 (88.2)	-1.18 (0.92)	-2.8	-1.60	-1.20	-0.40	1.0	
		Week 44	Tezepelumab	33	33 (100.0)	-1.12 (1.09)	-3.0	-2.20	-1.20	-0.40	1.6	-0.01 [-0.51, 0.48]
			Placebo	34	30 (88.2)	-1.10 (1.07)	-3.4	-1.80	-1.10	-0.20	0.8	
		Week 46	Tezepelumab	33	33 (100.0)	-1.13 (1.16)	-3.0	-2.20	-1.00	-0.20	1.8	0.01 [-0.48, 0.51]
			Placebo	34	30 (88.2)	-1.14 (0.99)	-3.2	-1.60	-1.00	-0.60	1.6	
		Week 48	Tezepelumab	33	33 (100.0)	-1.12 (1.12)	-3.0	-2.00	-1.00	-0.40	2.0	0.05 [-0.44, 0.55]
			Placebo	34	30 (88.2)	-1.18 (1.13)	-3.4	-1.80	-1.10	-0.40	1.8	
		Week 50	Tezepelumab	33	33 (100.0)	-1.10 (1.22)	-3.2	-2.00	-1.20	-0.20	2.0	0.12 [-0.38, 0.61]
			Placebo	34	30 (88.2)	-1.24 (1.08)	-3.6	-1.80	-1.20	-0.40	1.6	
		Week 52	Tezepelumab	33	33 (100.0)	-1.10 (1.21)	-3.2	-2.00	-1.20	-0.20	2.0	0.10 [-0.40, 0.59]
			Placebo	34	30 (88.2)	-1.21 (1.08)	-3.6	-1.80	-1.10	-0.40	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	2.70 (0.96)	0.0	2.20	2.80	3.30	4.6	
			Placebo	31	31 (100.0)	2.80 (0.74)	1.0	2.60	2.80	3.20	5.0	
		Week 2	Tezepelumab	32	31 (96.9)	2.11 (0.98)	0.2	1.40	2.00	2.80	4.4	
			Placebo	31	30 (96.8)	2.39 (0.79)	1.0	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	32	31 (96.9)	1.95 (0.90)	0.2	1.20	2.00	2.60	3.4	
			Placebo	31	30 (96.8)	2.37 (0.87)	0.8	2.00	2.60	3.00	4.2	
		Week 6	Tezepelumab	32	31 (96.9)	1.76 (1.00)	0.0	1.00	1.80	2.40	3.8	
			Placebo	31	30 (96.8)	2.43 (1.12)	0.2	1.80	2.60	3.00	6.0	
		Week 8	Tezepelumab	32	31 (96.9)	1.48 (0.98)	0.0	0.60	1.60	2.20	3.4	
			Placebo	31	30 (96.8)	2.25 (1.09)	0.0	1.60	2.40	3.00	5.0	
		Week 10	Tezepelumab	32	31 (96.9)	1.49 (1.00)	0.0	0.60	1.40	2.20	3.6	
			Placebo	31	30 (96.8)	2.29 (1.12)	0.0	2.00	2.40	3.00	5.2	
		Week 12	Tezepelumab	32	31 (96.9)	1.37 (0.96)	0.0	0.60	1.40	2.20	3.0	
			Placebo	31	30 (96.8)	2.18 (1.06)	0.0	1.80	2.40	3.00	4.4	
		Week 14	Tezepelumab	32	31 (96.9)	1.37 (1.09)	0.0	0.60	1.40	2.20	3.8	
			Placebo	31	30 (96.8)	2.05 (1.00)	0.0	1.60	2.20	2.60	5.0	
		Week 16	Tezepelumab	32	31 (96.9)	1.58 (1.17)	0.0	0.60	1.40	2.80	4.6	
			Placebo	31	30 (96.8)	2.32 (1.34)	0.0	1.40	2.50	3.00	5.0	
		Week 18	Tezepelumab	32	31 (96.9)	1.44 (0.99)	0.0	0.80	1.20	2.20	3.4	
			Placebo	31	30 (96.8)	2.08 (1.13)	0.0	1.60	2.30	2.60	5.0	
		Week 20	Tezepelumab	32	31 (96.9)	1.49 (1.03)	0.0	0.60	1.40	2.20	3.6	
			Placebo	31	30 (96.8)	2.25 (1.15)	0.0	1.80	2.40	2.80	5.0	
		Week 22	Tezepelumab	32	31 (96.9)	1.61 (0.97)	0.0	0.80	1.60	2.40	3.4	
			Placebo	31	30 (96.8)	2.15 (1.24)	0.0	1.20	2.30	3.00	5.0	
		Week 24	Tezepelumab	32	31 (96.9)	1.61 (1.07)	0.0	0.60	1.40	2.60	3.6	
			Placebo	31	30 (96.8)	2.23 (1.05)	0.0	1.80	2.30	3.00	4.0	
		Week 26	Tezepelumab	32	31 (96.9)	1.63 (1.03)	0.0	0.80	1.40	2.40	3.6	
			Placebo	31	30 (96.8)	2.23 (1.05)	0.0	1.60	2.30	3.00	4.0	
		Week 28	Tezepelumab	32	32 (100.0)	1.55 (1.11)	0.0	0.50	1.40	2.40	3.6	
			Placebo	31	30 (96.8)	2.21 (1.15)	0.0	1.20	2.40	2.80	4.0	
		Week 30	Tezepelumab	32	32 (100.0)	1.46 (1.00)	0.0	0.80	1.40	2.10	3.6	
			Placebo	31	30 (96.8)	2.12 (1.17)	0.0	1.40	2.10	3.00	4.0	
		Week 32	Tezepelumab	32	32 (100.0)	1.44 (1.03)	0.0	0.50	1.40	2.20	3.6	
			Placebo	31	30 (96.8)	2.22 (1.13)	0.0	1.60	2.00	3.00	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 300 cells/uL	Absolute values	Week 34	Tezepelumab	32	32 (100.0)	1.53 (1.14)	0.0	0.70	1.30	2.50	4.2	
			Placebo	31	30 (96.8)	2.21 (1.12)	0.0	1.40	2.30	2.80	4.8	
		Week 36	Tezepelumab	32	32 (100.0)	1.52 (1.02)	0.0	0.70	1.40	2.20	3.6	
			Placebo	31	30 (96.8)	2.37 (1.12)	0.0	1.40	2.40	3.00	4.8	
		Week 38	Tezepelumab	32	32 (100.0)	1.53 (1.09)	0.0	0.50	1.60	2.40	3.6	
			Placebo	31	30 (96.8)	2.07 (1.15)	0.0	1.00	2.00	2.80	4.8	
		Week 40	Tezepelumab	32	32 (100.0)	1.44 (1.09)	0.0	0.40	1.30	2.50	3.2	
			Placebo	31	30 (96.8)	2.32 (1.06)	0.0	1.80	2.30	3.00	4.4	
		Week 42	Tezepelumab	32	32 (100.0)	1.39 (1.02)	0.0	0.60	1.20	2.40	3.2	
			Placebo	31	30 (96.8)	2.13 (0.97)	0.0	1.60	2.00	2.60	4.6	
		Week 44	Tezepelumab	32	32 (100.0)	1.45 (1.06)	0.0	0.50	1.20	2.60	3.2	
			Placebo	31	30 (96.8)	2.22 (0.96)	0.0	1.60	2.20	2.80	4.2	
		Week 46	Tezepelumab	32	32 (100.0)	1.52 (1.13)	0.0	0.80	1.30	2.60	3.6	
			Placebo	31	30 (96.8)	2.01 (0.90)	0.0	1.40	2.00	2.60	4.0	
		Week 48	Tezepelumab	32	32 (100.0)	1.53 (1.16)	0.0	0.70	1.30	2.40	4.2	
			Placebo	31	30 (96.8)	2.17 (0.89)	0.0	1.60	2.40	2.60	4.0	
		Week 50	Tezepelumab	32	32 (100.0)	1.38 (1.07)	0.0	0.60	1.10	2.10	4.2	
			Placebo	31	30 (96.8)	1.99 (0.90)	0.0	1.20	2.00	2.60	4.0	
		Week 52	Tezepelumab	32	32 (100.0)	1.44 (1.04)	0.0	0.70	1.20	2.10	4.2	
			Placebo	31	30 (96.8)	2.10 (1.00)	0.0	1.40	2.10	2.80	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 2	Tezepelumab	32	31 (96.9)	-0.59 (0.73)	-2.2	-1.20	-0.60	-0.20	0.8	-0.19 [-0.69, 0.32]
			Placebo	31	30 (96.8)	-0.45 (0.78)	-2.4	-1.00	-0.30	0.00	1.2	
		Week 4	Tezepelumab	32	31 (96.9)	-0.75 (1.01)	-2.6	-1.20	-1.00	-0.20	2.6	-0.27 [-0.78, 0.23]
			Placebo	31	30 (96.8)	-0.47 (1.00)	-3.0	-1.00	-0.20	0.40	1.2	
		Week 6	Tezepelumab	32	31 (96.9)	-0.94 (1.20)	-2.8	-1.60	-1.00	-0.20	2.6	-0.47 [-0.98, 0.04]
			Placebo	31	30 (96.8)	-0.41 (1.05)	-3.2	-1.20	-0.20	0.20	1.6	
		Week 8	Tezepelumab	32	31 (96.9)	-1.22 (1.15)	-3.2	-1.80	-1.00	-0.80	2.6	-0.58 [-1.09, -0.06]
			Placebo	31	30 (96.8)	-0.59 (1.04)	-3.6	-1.00	-0.40	0.00	1.0	
		Week 10	Tezepelumab	32	31 (96.9)	-1.21 (1.24)	-3.4	-2.00	-1.20	-0.60	2.6	-0.53 [-1.04, -0.02]
			Placebo	31	30 (96.8)	-0.55 (1.30)	-3.8	-1.00	-0.40	0.00	2.6	
		Week 12	Tezepelumab	32	31 (96.9)	-1.33 (1.18)	-3.2	-2.20	-1.40	-0.80	2.6	-0.57 [-1.08, -0.06]
			Placebo	31	30 (96.8)	-0.66 (1.17)	-3.8	-1.00	-0.50	0.00	1.6	
		Week 14	Tezepelumab	32	31 (96.9)	-1.34 (1.26)	-4.0	-2.00	-1.40	-0.80	2.6	-0.45 [-0.96, 0.06]
			Placebo	31	30 (96.8)	-0.79 (1.18)	-3.4	-1.40	-1.00	-0.20	2.4	
		Week 16	Tezepelumab	32	31 (96.9)	-1.12 (1.31)	-3.2	-2.00	-1.20	-0.60	2.6	-0.46 [-0.97, 0.05]
			Placebo	31	30 (96.8)	-0.52 (1.31)	-3.6	-1.20	-0.30	0.00	2.6	
		Week 18	Tezepelumab	32	31 (96.9)	-1.26 (1.25)	-3.8	-2.00	-1.20	-0.80	2.6	-0.39 [-0.90, 0.11]
			Placebo	31	30 (96.8)	-0.76 (1.30)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 20	Tezepelumab	32	31 (96.9)	-1.21 (1.19)	-3.4	-2.20	-1.40	-0.60	2.6	-0.50 [-1.01, 0.01]
			Placebo	31	30 (96.8)	-0.59 (1.31)	-3.6	-1.40	-0.60	0.00	2.6	
		Week 22	Tezepelumab	32	31 (96.9)	-1.10 (1.28)	-3.2	-2.20	-1.00	-0.60	2.6	-0.31 [-0.81, 0.20]
			Placebo	31	30 (96.8)	-0.69 (1.33)	-3.8	-1.40	-0.70	0.00	2.6	
		Week 24	Tezepelumab	32	31 (96.9)	-1.09 (1.21)	-3.4	-1.80	-1.20	-0.40	2.6	-0.40 [-0.91, 0.11]
			Placebo	31	30 (96.8)	-0.61 (1.18)	-3.6	-1.20	-0.60	0.20	2.6	
		Week 26	Tezepelumab	32	31 (96.9)	-1.07 (1.20)	-3.0	-2.00	-1.20	-0.20	2.6	-0.37 [-0.88, 0.13]
			Placebo	31	30 (96.8)	-0.61 (1.26)	-3.4	-1.60	-0.60	0.20	2.6	
		Week 28	Tezepelumab	32	32 (100.0)	-1.15 (1.25)	-3.4	-2.20	-1.20	-0.60	2.6	-0.41 [-0.91, 0.09]
			Placebo	31	30 (96.8)	-0.63 (1.31)	-3.4	-1.60	-0.40	0.00	2.6	
		Week 30	Tezepelumab	32	32 (100.0)	-1.24 (1.22)	-3.8	-2.20	-1.20	-0.70	2.6	-0.41 [-0.91, 0.09]
			Placebo	31	30 (96.8)	-0.72 (1.35)	-3.4	-1.60	-1.00	0.20	2.6	
		Week 32	Tezepelumab	32	32 (100.0)	-1.26 (1.17)	-3.2	-2.10	-1.40	-0.70	2.6	-0.52 [-1.02, -0.01]
			Placebo	31	30 (96.8)	-0.62 (1.32)	-3.2	-1.60	-0.60	0.20	2.6	
		Week 34	Tezepelumab	32	32 (100.0)	-1.17 (1.24)	-3.0	-2.20	-1.30	-0.40	2.6	-0.43 [-0.93, 0.08]
			Placebo	31	30 (96.8)	-0.63 (1.27)	-3.2	-1.40	-0.60	0.00	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 300 cells/uL	Change from baseline	Week 36	Tezepelumab	32	32 (100.0)	-1.18 (1.29)	-3.2	-2.10	-1.20	-0.10	2.6	-0.56 [-1.07, -0.05]
			Placebo	31	30 (96.8)	-0.47 (1.27)	-2.6	-1.20	-0.50	0.20	2.6	
		Week 38	Tezepelumab	32	32 (100.0)	-1.18 (1.21)	-3.2	-2.20	-1.20	-0.50	2.6	-0.32 [-0.82, 0.18]
			Placebo	31	30 (96.8)	-0.77 (1.32)	-2.8	-1.60	-0.90	0.20	2.6	
		Week 40	Tezepelumab	32	32 (100.0)	-1.26 (1.27)	-3.4	-2.30	-1.30	-0.50	2.6	-0.58 [-1.09, -0.07]
			Placebo	31	30 (96.8)	-0.52 (1.27)	-2.6	-1.20	-0.60	0.20	2.6	
		Week 42	Tezepelumab	32	32 (100.0)	-1.31 (1.26)	-3.6	-2.20	-1.50	-0.50	2.6	-0.49 [-0.99, 0.02]
			Placebo	31	30 (96.8)	-0.71 (1.23)	-2.6	-1.40	-0.90	0.00	2.6	
		Week 44	Tezepelumab	32	32 (100.0)	-1.25 (1.33)	-3.8	-2.20	-1.30	-0.40	2.6	-0.50 [-1.00, 0.01]
			Placebo	31	30 (96.8)	-0.62 (1.19)	-2.6	-1.60	-0.60	0.00	2.6	
		Week 46	Tezepelumab	32	32 (100.0)	-1.18 (1.29)	-3.6	-2.20	-1.20	-0.20	2.6	-0.29 [-0.79, 0.21]
			Placebo	31	30 (96.8)	-0.83 (1.12)	-2.6	-1.60	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	32	32 (100.0)	-1.18 (1.29)	-2.8	-2.40	-1.10	-0.40	2.6	-0.42 [-0.93, 0.08]
			Placebo	31	30 (96.8)	-0.67 (1.09)	-2.8	-1.40	-0.80	0.00	2.6	
		Week 50	Tezepelumab	32	32 (100.0)	-1.33 (1.23)	-2.8	-2.40	-1.40	-0.80	2.6	-0.42 [-0.93, 0.08]
			Placebo	31	30 (96.8)	-0.85 (1.01)	-2.6	-1.60	-0.90	-0.40	2.6	
		Week 52	Tezepelumab	32	32 (100.0)	-1.26 (1.22)	-3.0	-2.20	-1.20	-0.80	2.6	-0.44 [-0.95, 0.06]
			Placebo	31	30 (96.8)	-0.74 (1.10)	-2.6	-1.40	-0.70	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	39	39 (100.0)	2.94 (0.69)	1.8	2.40	2.80	3.20	5.0	
			Placebo	30	30 (100.0)	2.79 (0.68)	0.4	2.60	2.80	3.20	3.8	
		Week 2	Tezepelumab	39	36 (92.3)	2.49 (1.09)	0.0	1.60	2.70	3.40	4.4	
			Placebo	30	25 (83.3)	2.33 (0.66)	0.4	2.00	2.40	2.80	3.2	
		Week 4	Tezepelumab	39	36 (92.3)	2.21 (0.91)	0.2	1.80	2.30	2.90	3.6	
			Placebo	30	25 (83.3)	2.08 (0.89)	0.2	1.40	2.20	2.60	3.6	
		Week 6	Tezepelumab	39	36 (92.3)	2.04 (0.98)	0.0	1.40	1.80	2.80	4.0	
			Placebo	30	25 (83.3)	2.07 (1.06)	0.2	1.40	2.20	2.60	5.0	
		Week 8	Tezepelumab	39	36 (92.3)	1.97 (1.20)	0.0	1.20	1.80	2.90	5.2	
			Placebo	30	25 (83.3)	2.16 (1.00)	0.0	1.80	2.40	3.00	3.8	
		Week 10	Tezepelumab	39	36 (92.3)	1.88 (1.15)	0.0	1.10	1.70	2.70	4.8	
			Placebo	30	25 (83.3)	1.98 (0.88)	0.0	1.80	2.00	2.40	3.0	
		Week 12	Tezepelumab	39	36 (92.3)	1.83 (1.13)	0.0	1.10	1.90	2.70	4.8	
			Placebo	30	25 (83.3)	1.82 (0.88)	0.0	1.00	2.00	2.20	3.2	
		Week 14	Tezepelumab	39	36 (92.3)	1.71 (1.15)	0.0	0.80	1.60	2.30	4.8	
			Placebo	30	25 (83.3)	1.67 (0.81)	0.4	1.00	1.80	2.20	3.2	
		Week 16	Tezepelumab	39	36 (92.3)	1.96 (1.22)	0.0	1.00	2.10	2.80	4.8	
			Placebo	30	25 (83.3)	1.86 (0.84)	0.2	1.40	2.00	2.20	3.2	
		Week 18	Tezepelumab	39	37 (94.9)	1.89 (1.10)	0.0	1.20	2.00	2.60	4.8	
			Placebo	30	25 (83.3)	1.85 (1.14)	0.0	1.00	1.80	2.60	4.8	
		Week 20	Tezepelumab	39	37 (94.9)	1.90 (1.21)	0.0	1.20	1.80	2.60	5.0	
			Placebo	30	25 (83.3)	1.81 (1.02)	0.2	1.00	2.00	2.40	3.8	
		Week 22	Tezepelumab	39	37 (94.9)	1.88 (1.10)	0.0	1.00	2.00	2.60	4.8	
			Placebo	30	25 (83.3)	1.73 (0.99)	0.0	1.00	1.80	2.40	4.0	
		Week 24	Tezepelumab	39	37 (94.9)	1.94 (1.15)	0.0	1.20	2.00	2.60	4.8	
			Placebo	30	25 (83.3)	1.83 (0.98)	0.2	1.00	2.00	2.40	3.8	
		Week 26	Tezepelumab	39	38 (97.4)	2.00 (1.18)	0.0	1.00	2.00	2.80	4.8	
			Placebo	30	25 (83.3)	1.79 (1.03)	0.4	1.00	1.60	2.40	4.4	
		Week 28	Tezepelumab	39	39 (100.0)	1.88 (1.19)	0.0	1.00	1.80	2.80	4.8	
			Placebo	30	26 (86.7)	1.78 (1.13)	0.0	0.80	1.90	2.60	4.4	
		Week 30	Tezepelumab	39	39 (100.0)	1.90 (1.16)	0.0	1.00	2.00	2.60	4.8	
			Placebo	30	26 (86.7)	1.68 (0.98)	0.0	0.80	1.80	2.40	3.4	
		Week 32	Tezepelumab	39	39 (100.0)	1.85 (1.16)	0.0	1.00	1.80	2.80	4.8	
			Placebo	30	26 (86.7)	1.58 (0.92)	0.0	0.80	1.80	2.00	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 25 ppb	Absolute values	Week 34	Tezepelumab	39	39 (100.0)	1.91 (1.27)	0.0	1.00	1.80	2.80	4.8	
			Placebo	30	26 (86.7)	1.68 (0.89)	0.0	0.80	1.80	2.20	3.2	
		Week 36	Tezepelumab	39	39 (100.0)	1.89 (1.15)	0.0	1.00	1.80	2.80	4.8	
			Placebo	30	26 (86.7)	1.66 (1.07)	0.0	0.80	1.70	2.60	3.6	
		Week 38	Tezepelumab	39	39 (100.0)	1.93 (1.32)	0.0	0.80	1.80	3.00	4.8	
			Placebo	30	26 (86.7)	1.70 (0.95)	0.0	1.00	1.80	2.20	3.4	
		Week 40	Tezepelumab	39	39 (100.0)	1.95 (1.22)	0.0	1.00	2.00	2.80	4.8	
			Placebo	30	26 (86.7)	1.77 (1.16)	0.0	0.60	1.80	2.60	4.2	
		Week 42	Tezepelumab	39	39 (100.0)	1.92 (1.19)	0.0	1.00	1.80	2.80	4.8	
			Placebo	30	26 (86.7)	1.71 (0.95)	0.0	1.00	1.90	2.20	3.8	
		Week 44	Tezepelumab	39	39 (100.0)	1.97 (1.15)	0.0	1.00	2.00	3.00	4.8	
			Placebo	30	26 (86.7)	1.84 (1.06)	0.0	1.00	1.80	2.80	4.2	
		Week 46	Tezepelumab	39	39 (100.0)	2.01 (1.19)	0.0	1.00	2.00	3.00	4.8	
			Placebo	30	26 (86.7)	1.64 (0.97)	0.0	1.00	1.60	2.20	4.4	
		Week 48	Tezepelumab	39	39 (100.0)	1.97 (1.20)	0.0	1.00	2.00	2.80	4.8	
			Placebo	30	26 (86.7)	1.62 (1.11)	0.0	0.60	1.70	2.40	4.6	
		Week 50	Tezepelumab	39	39 (100.0)	1.96 (1.28)	0.0	1.00	2.00	3.00	4.8	
			Placebo	30	26 (86.7)	1.59 (0.90)	0.0	1.00	1.70	2.20	3.8	
		Week 52	Tezepelumab	39	39 (100.0)	1.99 (1.24)	0.0	1.20	2.00	2.80	4.8	
			Placebo	30	26 (86.7)	1.71 (0.97)	0.0	1.00	1.80	2.40	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	39	36 (92.3)	-0.51 (0.84)	-3.2	-0.90	-0.40	0.20	0.8	0.14 [-0.37, 0.65]
			Placebo	30	25 (83.3)	-0.62 (0.72)	-2.8	-0.80	-0.40	-0.20	0.2	
		Week 4	Tezepelumab	39	36 (92.3)	-0.79 (0.70)	-2.4	-1.20	-0.80	-0.30	0.2	0.09 [-0.42, 0.60]
			Placebo	30	25 (83.3)	-0.87 (1.02)	-3.0	-1.40	-0.80	-0.20	0.6	
		Week 6	Tezepelumab	39	36 (92.3)	-0.96 (0.78)	-2.8	-1.50	-1.00	-0.30	0.2	-0.09 [-0.60, 0.43]
			Placebo	30	25 (83.3)	-0.88 (1.16)	-3.4	-1.60	-0.80	-0.20	1.6	
		Week 8	Tezepelumab	39	36 (92.3)	-1.04 (1.08)	-3.2	-1.70	-1.10	-0.50	2.6	-0.22 [-0.73, 0.29]
			Placebo	30	25 (83.3)	-0.79 (1.15)	-3.6	-1.20	-0.80	0.20	1.0	
		Week 10	Tezepelumab	39	36 (92.3)	-1.12 (0.97)	-3.4	-1.70	-1.20	-0.50	0.6	-0.15 [-0.66, 0.36]
			Placebo	30	25 (83.3)	-0.98 (1.02)	-3.8	-1.40	-0.80	-0.40	0.4	
		Week 12	Tezepelumab	39	36 (92.3)	-1.17 (0.95)	-3.0	-2.20	-1.20	-0.60	0.6	-0.04 [-0.55, 0.47]
			Placebo	30	25 (83.3)	-1.13 (1.06)	-3.8	-1.80	-0.80	-0.40	0.2	
		Week 14	Tezepelumab	39	36 (92.3)	-1.30 (0.93)	-3.4	-2.10	-1.40	-0.60	0.6	-0.02 [-0.53, 0.49]
			Placebo	30	25 (83.3)	-1.28 (1.06)	-3.4	-1.80	-1.40	-0.40	0.2	
		Week 16	Tezepelumab	39	36 (92.3)	-1.05 (1.06)	-3.2	-1.90	-1.00	-0.40	1.8	0.04 [-0.47, 0.55]
			Placebo	30	25 (83.3)	-1.10 (1.04)	-3.6	-1.40	-1.20	-0.40	0.4	
		Week 18	Tezepelumab	39	37 (94.9)	-1.09 (0.92)	-3.4	-1.80	-1.00	-0.60	0.6	0.02 [-0.49, 0.52]
			Placebo	30	25 (83.3)	-1.10 (1.28)	-3.6	-2.20	-1.20	0.00	1.4	
		Week 20	Tezepelumab	39	37 (94.9)	-1.08 (1.02)	-3.4	-1.80	-1.00	-0.40	0.6	0.06 [-0.45, 0.57]
			Placebo	30	25 (83.3)	-1.14 (1.23)	-3.6	-1.80	-1.20	-0.20	1.0	
		Week 22	Tezepelumab	39	37 (94.9)	-1.10 (0.93)	-3.2	-1.80	-0.80	-0.60	0.6	0.12 [-0.39, 0.63]
			Placebo	30	25 (83.3)	-1.22 (1.18)	-3.8	-2.00	-1.20	-0.40	1.2	
		Week 24	Tezepelumab	39	37 (94.9)	-1.04 (0.99)	-3.4	-2.00	-0.80	-0.40	0.6	0.07 [-0.44, 0.58]
			Placebo	30	25 (83.3)	-1.12 (1.18)	-3.6	-1.80	-1.00	0.00	1.0	
		Week 26	Tezepelumab	39	38 (97.4)	-0.95 (1.03)	-3.0	-2.00	-0.70	-0.20	0.6	0.19 [-0.31, 0.70]
			Placebo	30	25 (83.3)	-1.16 (1.18)	-3.4	-2.00	-1.40	0.00	1.6	
		Week 28	Tezepelumab	39	39 (100.0)	-1.06 (1.14)	-3.4	-2.20	-0.80	0.00	1.0	0.01 [-0.48, 0.51]
			Placebo	30	26 (86.7)	-1.08 (1.22)	-3.4	-2.00	-1.00	-0.20	1.6	
		Week 30	Tezepelumab	39	39 (100.0)	-1.04 (1.09)	-2.8	-2.20	-1.00	-0.40	2.0	0.12 [-0.38, 0.62]
			Placebo	30	26 (86.7)	-1.17 (1.12)	-3.4	-1.80	-1.30	-0.40	0.6	
		Week 32	Tezepelumab	39	39 (100.0)	-1.09 (1.02)	-3.2	-2.20	-1.00	-0.40	1.0	0.17 [-0.32, 0.67]
			Placebo	30	26 (86.7)	-1.27 (1.10)	-3.2	-2.20	-1.30	-0.40	0.8	
		Week 34	Tezepelumab	39	39 (100.0)	-1.03 (1.17)	-3.0	-2.20	-1.00	-0.20	2.2	0.14 [-0.36, 0.63]
			Placebo	30	26 (86.7)	-1.18 (1.03)	-3.2	-1.80	-1.20	-0.60	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 25 ppb	Change from baseline	Week 36	Tezepelumab	39	39 (100.0)	-1.05 (1.06)	-3.2	-2.00	-1.20	-0.20	1.6	0.13 [-0.37, 0.62]
			Placebo	30	26 (86.7)	-1.19 (1.18)	-3.6	-2.00	-1.00	-0.40	0.8	
		Week 38	Tezepelumab	39	39 (100.0)	-1.01 (1.21)	-3.2	-2.20	-1.00	0.00	2.6	0.13 [-0.37, 0.62]
			Placebo	30	26 (86.7)	-1.15 (0.99)	-3.2	-2.00	-1.10	-0.40	0.2	
		Week 40	Tezepelumab	39	39 (100.0)	-0.99 (1.12)	-3.4	-2.00	-0.80	-0.20	1.8	0.08 [-0.41, 0.58]
			Placebo	30	26 (86.7)	-1.08 (1.20)	-3.2	-2.20	-1.20	-0.20	1.4	
		Week 42	Tezepelumab	39	39 (100.0)	-1.02 (1.09)	-3.0	-2.00	-1.00	-0.40	2.2	0.12 [-0.37, 0.62]
			Placebo	30	26 (86.7)	-1.15 (1.00)	-2.8	-1.60	-1.20	-0.60	1.0	
		Week 44	Tezepelumab	39	39 (100.0)	-0.96 (1.07)	-3.4	-2.00	-0.80	-0.20	1.6	0.05 [-0.45, 0.54]
			Placebo	30	26 (86.7)	-1.02 (1.12)	-3.4	-1.80	-1.00	0.00	0.8	
		Week 46	Tezepelumab	39	39 (100.0)	-0.93 (1.07)	-2.8	-2.20	-0.80	-0.20	1.8	0.27 [-0.23, 0.77]
			Placebo	30	26 (86.7)	-1.22 (1.06)	-3.2	-1.80	-1.10	-0.60	1.6	
		Week 48	Tezepelumab	39	39 (100.0)	-0.96 (1.07)	-2.8	-1.80	-0.80	-0.40	2.0	0.24 [-0.26, 0.73]
			Placebo	30	26 (86.7)	-1.23 (1.22)	-3.4	-1.80	-1.00	-0.60	1.8	
		Week 50	Tezepelumab	39	39 (100.0)	-0.97 (1.15)	-3.2	-1.80	-0.80	-0.20	2.0	0.26 [-0.24, 0.76]
			Placebo	30	26 (86.7)	-1.26 (1.07)	-3.6	-1.80	-1.30	-0.60	1.6	
		Week 52	Tezepelumab	39	39 (100.0)	-0.94 (1.11)	-3.2	-1.80	-1.00	-0.20	2.0	0.18 [-0.32, 0.68]
			Placebo	30	26 (86.7)	-1.15 (1.15)	-3.6	-1.80	-1.00	-0.40	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	2.77 (1.11)	0.0	2.20	2.80	3.40	5.2	
			Placebo	34	34 (100.0)	2.94 (0.85)	1.0	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	27	27 (100.0)	2.14 (0.89)	0.2	1.60	2.00	3.00	3.4	
			Placebo	34	32 (94.1)	2.44 (0.91)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	27	27 (100.0)	1.90 (1.11)	0.2	1.00	2.00	3.00	3.4	
			Placebo	34	32 (94.1)	2.38 (0.95)	0.2	1.90	2.60	3.00	4.2	
		Week 6	Tezepelumab	27	27 (100.0)	1.87 (1.12)	0.0	0.80	2.20	2.80	3.8	
			Placebo	34	32 (94.1)	2.34 (1.24)	0.2	1.40	2.30	3.00	6.0	
		Week 8	Tezepelumab	27	27 (100.0)	1.61 (1.13)	0.0	0.60	1.80	2.80	3.4	
			Placebo	34	33 (97.1)	2.15 (1.24)	0.0	1.20	2.40	2.80	5.0	
		Week 10	Tezepelumab	27	27 (100.0)	1.50 (1.09)	0.0	0.60	1.40	2.40	3.2	
			Placebo	34	33 (97.1)	2.23 (1.18)	0.0	1.60	2.40	3.00	5.2	
		Week 12	Tezepelumab	27	27 (100.0)	1.32 (1.02)	0.0	0.60	1.40	2.20	3.0	
			Placebo	34	33 (97.1)	2.06 (1.18)	0.0	1.20	2.40	2.80	4.4	
		Week 14	Tezepelumab	27	27 (100.0)	1.36 (1.07)	0.0	0.60	1.40	2.20	3.8	
			Placebo	34	33 (97.1)	2.05 (1.11)	0.0	1.60	2.00	2.60	5.0	
		Week 16	Tezepelumab	27	27 (100.0)	1.38 (1.06)	0.0	0.40	1.20	2.00	3.6	
			Placebo	34	33 (97.1)	2.21 (1.41)	0.0	1.00	2.40	3.00	5.0	
		Week 18	Tezepelumab	27	27 (100.0)	1.37 (1.00)	0.0	0.80	1.20	2.00	3.4	
			Placebo	34	33 (97.1)	2.03 (1.22)	0.0	1.40	2.20	2.60	5.0	
		Week 20	Tezepelumab	27	27 (100.0)	1.37 (0.99)	0.0	0.60	1.20	2.00	3.6	
			Placebo	34	33 (97.1)	2.24 (1.16)	0.0	1.40	2.40	2.80	5.0	
		Week 22	Tezepelumab	27	27 (100.0)	1.63 (0.92)	0.0	0.80	1.60	2.20	3.4	
			Placebo	34	33 (97.1)	2.21 (1.25)	0.0	1.20	2.40	3.00	5.0	
		Week 24	Tezepelumab	27	27 (100.0)	1.47 (1.01)	0.0	0.60	1.20	2.20	3.6	
			Placebo	34	33 (97.1)	2.25 (1.10)	0.0	1.60	2.20	3.00	4.4	
		Week 26	Tezepelumab	27	27 (100.0)	1.50 (0.98)	0.0	0.60	1.60	2.20	3.2	
			Placebo	34	33 (97.1)	2.16 (1.20)	0.0	1.20	2.20	3.20	4.4	
		Week 28	Tezepelumab	27	27 (100.0)	1.53 (1.10)	0.0	0.40	1.60	2.40	3.6	
			Placebo	34	33 (97.1)	2.14 (1.29)	0.0	1.20	2.00	3.20	4.4	
		Week 30	Tezepelumab	27	27 (100.0)	1.41 (0.95)	0.0	0.60	1.40	2.20	3.2	
			Placebo	34	33 (97.1)	2.17 (1.29)	0.0	1.20	2.20	3.20	4.4	
		Week 32	Tezepelumab	27	27 (100.0)	1.31 (0.99)	0.0	0.40	1.20	2.20	3.2	
			Placebo	34	33 (97.1)	2.19 (1.23)	0.0	1.20	2.00	3.00	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 25 ppb	Absolute values	Week 34	Tezepelumab	27	27 (100.0)	1.41 (1.02)	0.0	0.40	1.20	2.40	3.2	
			Placebo	34	33 (97.1)	2.07 (1.29)	0.0	1.00	2.00	3.00	4.8	
		Week 36	Tezepelumab	27	27 (100.0)	1.35 (0.98)	0.0	0.60	1.20	2.20	3.2	
			Placebo	34	33 (97.1)	2.38 (1.21)	0.0	1.60	2.40	3.20	4.8	
		Week 38	Tezepelumab	27	27 (100.0)	1.41 (1.03)	0.0	0.20	1.60	2.20	3.2	
			Placebo	34	33 (97.1)	2.10 (1.25)	0.0	1.00	2.00	3.00	4.8	
		Week 40	Tezepelumab	27	27 (100.0)	1.33 (1.03)	0.0	0.40	1.20	2.20	3.2	
			Placebo	34	33 (97.1)	2.28 (1.20)	0.0	1.40	2.40	3.00	4.4	
		Week 42	Tezepelumab	27	27 (100.0)	1.24 (0.97)	0.0	0.40	1.20	2.00	3.2	
			Placebo	34	33 (97.1)	2.08 (1.13)	0.0	1.20	2.00	2.60	4.6	
		Week 44	Tezepelumab	27	27 (100.0)	1.25 (0.99)	0.0	0.40	1.00	2.20	3.2	
			Placebo	34	33 (97.1)	2.13 (1.17)	0.0	1.20	2.40	3.00	4.4	
		Week 46	Tezepelumab	27	27 (100.0)	1.27 (1.07)	0.0	0.40	1.00	2.20	3.2	
			Placebo	34	33 (97.1)	2.06 (1.03)	0.0	1.60	2.00	2.60	4.4	
		Week 48	Tezepelumab	27	27 (100.0)	1.33 (1.07)	0.0	0.40	1.00	2.20	3.2	
			Placebo	34	33 (97.1)	2.18 (1.05)	0.0	1.60	2.20	2.80	4.4	
		Week 50	Tezepelumab	27	27 (100.0)	1.19 (0.92)	0.0	0.60	1.00	2.00	3.2	
			Placebo	34	33 (97.1)	1.99 (1.11)	0.0	1.00	2.00	2.60	4.4	
		Week 52	Tezepelumab	27	27 (100.0)	1.22 (0.94)	0.0	0.40	0.80	2.00	3.2	
			Placebo	34	33 (97.1)	2.02 (1.18)	0.0	1.00	2.20	2.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 2	Tezepelumab	27	27 (100.0)	-0.63 (0.74)	-2.2	-1.20	-0.40	0.00	0.8	-0.27 [-0.79, 0.24]
			Placebo	34	32 (94.1)	-0.43 (0.73)	-1.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	27	27 (100.0)	-0.87 (1.18)	-2.6	-1.60	-1.00	0.00	2.6	-0.35 [-0.87, 0.16]
			Placebo	34	32 (94.1)	-0.50 (0.90)	-2.2	-1.20	-0.20	0.10	1.2	
		Week 6	Tezepelumab	27	27 (100.0)	-0.90 (1.30)	-2.8	-1.80	-1.00	0.00	2.6	-0.32 [-0.83, 0.20]
			Placebo	34	32 (94.1)	-0.54 (0.97)	-2.4	-1.30	-0.20	0.00	1.6	
		Week 8	Tezepelumab	27	27 (100.0)	-1.16 (1.25)	-3.0	-2.20	-1.00	-0.40	2.6	-0.37 [-0.88, 0.14]
			Placebo	34	33 (97.1)	-0.74 (1.00)	-2.8	-1.40	-0.40	-0.20	1.0	
		Week 10	Tezepelumab	27	27 (100.0)	-1.27 (1.31)	-3.0	-2.20	-1.40	-0.60	2.6	-0.49 [-1.00, 0.03]
			Placebo	34	33 (97.1)	-0.66 (1.19)	-2.6	-1.60	-0.60	0.00	2.6	
		Week 12	Tezepelumab	27	27 (100.0)	-1.45 (1.28)	-3.2	-2.20	-1.40	-1.00	2.6	-0.52 [-1.04, -0.01]
			Placebo	34	33 (97.1)	-0.83 (1.10)	-3.0	-1.40	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	27	27 (100.0)	-1.41 (1.32)	-4.0	-2.20	-1.40	-0.80	2.6	-0.48 [-0.99, 0.04]
			Placebo	34	33 (97.1)	-0.84 (1.09)	-3.0	-1.40	-1.00	-0.40	2.4	
		Week 16	Tezepelumab	27	27 (100.0)	-1.39 (1.25)	-3.0	-2.20	-1.40	-1.00	2.6	-0.57 [-1.09, -0.05]
			Placebo	34	33 (97.1)	-0.68 (1.26)	-3.0	-1.40	-0.60	-0.20	2.6	
		Week 18	Tezepelumab	27	27 (100.0)	-1.40 (1.30)	-3.8	-2.40	-1.40	-0.80	2.6	-0.43 [-0.95, 0.08]
			Placebo	34	33 (97.1)	-0.86 (1.21)	-3.0	-1.40	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	27	27 (100.0)	-1.40 (1.20)	-3.0	-2.20	-1.60	-0.80	2.6	-0.65 [-1.17, -0.13]
			Placebo	34	33 (97.1)	-0.65 (1.12)	-2.6	-1.20	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	27	27 (100.0)	-1.14 (1.37)	-3.0	-2.40	-1.20	-0.60	2.6	-0.37 [-0.88, 0.15]
			Placebo	34	33 (97.1)	-0.68 (1.16)	-2.6	-1.40	-0.80	-0.20	2.6	
		Week 24	Tezepelumab	27	27 (100.0)	-1.30 (1.23)	-3.0	-2.00	-1.60	-0.60	2.6	-0.57 [-1.09, -0.05]
			Placebo	34	33 (97.1)	-0.64 (1.08)	-2.6	-1.20	-0.60	0.00	2.6	
		Week 26	Tezepelumab	27	27 (100.0)	-1.27 (1.26)	-3.0	-2.20	-1.40	-0.40	2.6	-0.44 [-0.96, 0.07]
			Placebo	34	33 (97.1)	-0.73 (1.20)	-3.0	-1.60	-0.80	0.00	2.6	
		Week 28	Tezepelumab	27	27 (100.0)	-1.24 (1.32)	-3.0	-2.20	-1.20	-0.20	2.6	-0.38 [-0.90, 0.13]
			Placebo	34	33 (97.1)	-0.75 (1.25)	-3.0	-1.60	-1.00	0.00	2.6	
		Week 30	Tezepelumab	27	27 (100.0)	-1.36 (1.30)	-3.8	-2.40	-1.40	-0.80	2.6	-0.49 [-1.01, 0.02]
			Placebo	34	33 (97.1)	-0.72 (1.31)	-2.8	-1.40	-1.00	0.00	2.6	
		Week 32	Tezepelumab	27	27 (100.0)	-1.46 (1.21)	-3.0	-2.20	-1.80	-1.00	2.6	-0.63 [-1.15, -0.11]
			Placebo	34	33 (97.1)	-0.70 (1.19)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	27	27 (100.0)	-1.36 (1.24)	-3.0	-2.20	-1.60	-0.60	2.6	-0.43 [-0.94, 0.09]
			Placebo	34	33 (97.1)	-0.82 (1.25)	-2.8	-1.60	-1.00	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 25 ppb	Change from baseline	Week 36	Tezepelumab	27	27 (100.0)	-1.42 (1.32)	-3.0	-2.40	-1.60	-0.80	2.6	-0.72 [-1.25, -0.20]
			Placebo	34	33 (97.1)	-0.51 (1.20)	-2.6	-1.20	-1.00	0.00	2.6	
		Week 38	Tezepelumab	27	27 (100.0)	-1.36 (1.25)	-3.0	-2.20	-1.60	-0.80	2.6	-0.45 [-0.97, 0.06]
			Placebo	34	33 (97.1)	-0.79 (1.26)	-2.6	-1.60	-1.00	0.00	2.6	
		Week 40	Tezepelumab	27	27 (100.0)	-1.44 (1.30)	-3.0	-2.60	-1.60	-0.80	2.6	-0.66 [-1.19, -0.14]
			Placebo	34	33 (97.1)	-0.61 (1.21)	-2.6	-1.40	-0.80	0.00	2.6	
		Week 42	Tezepelumab	27	27 (100.0)	-1.53 (1.32)	-3.6	-2.40	-1.80	-0.60	2.6	-0.58 [-1.10, -0.06]
			Placebo	34	33 (97.1)	-0.81 (1.17)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	27	27 (100.0)	-1.52 (1.32)	-3.8	-2.60	-1.60	-0.80	2.6	-0.60 [-1.13, -0.08]
			Placebo	34	33 (97.1)	-0.76 (1.19)	-2.6	-1.60	-1.00	-0.20	2.6	
		Week 46	Tezepelumab	27	27 (100.0)	-1.50 (1.33)	-3.6	-2.60	-1.60	-1.00	2.6	-0.56 [-1.08, -0.04]
			Placebo	34	33 (97.1)	-0.83 (1.05)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	27	27 (100.0)	-1.44 (1.32)	-3.0	-2.80	-1.60	-0.40	2.6	-0.62 [-1.14, -0.10]
			Placebo	34	33 (97.1)	-0.71 (1.02)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	27	27 (100.0)	-1.58 (1.25)	-3.0	-2.60	-1.80	-1.20	2.6	-0.59 [-1.11, -0.07]
			Placebo	34	33 (97.1)	-0.90 (1.04)	-2.8	-1.40	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	27	27 (100.0)	-1.55 (1.26)	-3.0	-2.60	-1.80	-1.00	2.6	-0.58 [-1.10, -0.07]
			Placebo	34	33 (97.1)	-0.87 (1.08)	-2.8	-1.40	-0.80	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	2.96 (0.72)	1.8	2.60	2.80	3.00	5.0	
			Placebo	29	29 (100.0)	2.79 (0.73)	1.0	2.60	3.00	3.20	4.8	
		Week 2	Tezepelumab	27	26 (96.3)	2.39 (0.97)	0.2	1.60	2.60	3.00	4.0	
			Placebo	29	26 (89.7)	2.30 (0.80)	0.4	2.00	2.40	2.60	4.8	
		Week 4	Tezepelumab	27	26 (96.3)	2.09 (0.91)	0.2	1.60	2.20	2.80	3.6	
			Placebo	29	26 (89.7)	2.38 (0.93)	0.2	1.80	2.60	2.80	4.2	
		Week 6	Tezepelumab	27	26 (96.3)	1.85 (1.02)	0.0	1.40	1.70	2.60	3.8	
			Placebo	29	26 (89.7)	2.25 (1.13)	0.2	1.40	2.20	2.80	5.0	
		Week 8	Tezepelumab	27	26 (96.3)	1.82 (1.22)	0.0	1.20	1.70	2.60	5.2	
			Placebo	29	27 (93.1)	2.21 (1.11)	0.0	1.60	2.40	2.80	4.6	
		Week 10	Tezepelumab	27	26 (96.3)	1.72 (1.15)	0.0	1.00	1.70	2.40	4.8	
			Placebo	29	27 (93.1)	2.19 (1.04)	0.2	1.60	2.40	2.80	4.4	
		Week 12	Tezepelumab	27	26 (96.3)	1.64 (1.17)	0.0	0.80	1.50	2.60	4.8	
			Placebo	29	27 (93.1)	2.11 (1.08)	0.2	1.20	2.00	2.80	4.4	
		Week 14	Tezepelumab	27	26 (96.3)	1.53 (1.17)	0.0	0.60	1.40	2.20	4.8	
			Placebo	29	27 (93.1)	1.85 (1.01)	0.0	1.20	2.00	2.40	5.0	
		Week 16	Tezepelumab	27	26 (96.3)	1.62 (1.17)	0.0	0.60	1.60	2.40	4.8	
			Placebo	29	27 (93.1)	2.11 (1.22)	0.0	0.60	2.20	3.00	4.4	
		Week 18	Tezepelumab	27	26 (96.3)	1.55 (1.14)	0.0	0.80	1.60	2.20	4.8	
			Placebo	29	27 (93.1)	1.84 (1.10)	0.0	1.00	1.80	2.60	4.4	
		Week 20	Tezepelumab	27	26 (96.3)	1.61 (1.19)	0.0	0.60	1.60	2.60	4.8	
			Placebo	29	27 (93.1)	2.17 (1.21)	0.2	1.20	2.40	2.80	4.4	
		Week 22	Tezepelumab	27	26 (96.3)	1.75 (1.15)	0.0	0.60	1.80	2.60	4.8	
			Placebo	29	27 (93.1)	2.04 (1.27)	0.0	0.80	2.20	2.80	4.4	
		Week 24	Tezepelumab	27	26 (96.3)	1.72 (1.18)	0.0	1.20	1.60	2.60	4.8	
			Placebo	29	27 (93.1)	2.19 (1.17)	0.0	1.40	2.40	3.00	4.4	
		Week 26	Tezepelumab	27	27 (100.0)	1.71 (1.18)	0.0	0.80	1.60	2.60	4.8	
			Placebo	29	27 (93.1)	2.10 (1.22)	0.4	1.00	1.80	3.20	4.4	
		Week 28	Tezepelumab	27	27 (100.0)	1.74 (1.21)	0.0	0.80	1.80	2.60	4.8	
			Placebo	29	27 (93.1)	2.27 (1.24)	0.4	1.00	2.20	3.40	4.4	
		Week 30	Tezepelumab	27	27 (100.0)	1.74 (1.22)	0.0	0.80	1.60	2.60	4.8	
			Placebo	29	27 (93.1)	2.13 (1.24)	0.0	1.00	2.20	3.00	4.4	
		Week 32	Tezepelumab	27	27 (100.0)	1.69 (1.22)	0.0	0.60	1.80	2.80	4.8	
			Placebo	29	27 (93.1)	2.11 (1.24)	0.4	1.00	1.80	3.00	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Absolute values	Week 34	Tezepelumab	27	27 (100.0)	1.77 (1.31)	0.0	0.80	1.40	2.80	4.8	
			Placebo	29	27 (93.1)	1.99 (1.26)	0.0	0.80	1.80	3.00	4.8	
		Week 36	Tezepelumab	27	27 (100.0)	1.70 (1.27)	0.0	0.60	1.40	3.00	4.8	
			Placebo	29	27 (93.1)	2.39 (1.26)	0.0	1.40	2.20	3.40	4.8	
		Week 38	Tezepelumab	27	27 (100.0)	1.87 (1.35)	0.0	0.80	1.80	3.00	4.8	
			Placebo	29	27 (93.1)	2.03 (1.24)	0.0	1.00	2.00	3.00	4.8	
		Week 40	Tezepelumab	27	27 (100.0)	1.78 (1.29)	0.0	0.40	1.80	2.80	4.8	
			Placebo	29	27 (93.1)	2.36 (1.18)	0.4	1.40	2.40	3.00	4.4	
		Week 42	Tezepelumab	27	27 (100.0)	1.78 (1.30)	0.0	1.00	1.80	2.80	4.8	
			Placebo	29	27 (93.1)	2.08 (1.16)	0.4	1.20	2.00	2.60	4.6	
		Week 44	Tezepelumab	27	27 (100.0)	1.76 (1.29)	0.0	0.80	1.80	3.00	4.8	
			Placebo	29	27 (93.1)	2.39 (1.08)	0.4	1.60	2.40	3.00	4.4	
		Week 46	Tezepelumab	27	27 (100.0)	1.87 (1.31)	0.0	0.80	1.80	3.00	4.8	
			Placebo	29	27 (93.1)	2.10 (1.12)	0.0	1.60	2.00	2.60	4.4	
		Week 48	Tezepelumab	27	27 (100.0)	1.85 (1.28)	0.0	0.80	1.80	3.00	4.8	
			Placebo	29	27 (93.1)	2.28 (1.14)	0.0	1.80	2.40	2.80	4.6	
		Week 50	Tezepelumab	27	27 (100.0)	1.84 (1.24)	0.0	0.80	1.80	2.80	4.8	
			Placebo	29	27 (93.1)	1.99 (1.02)	0.4	1.00	2.00	2.40	4.4	
		Week 52	Tezepelumab	27	27 (100.0)	1.81 (1.27)	0.0	0.80	1.80	2.80	4.8	
			Placebo	29	27 (93.1)	2.12 (1.07)	0.4	1.00	2.20	2.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	27	26 (96.3)	-0.61 (0.69)	-2.2	-1.20	-0.40	0.00	0.2	-0.15 [-0.69, 0.39]
			Placebo	29	26 (89.7)	-0.49 (0.84)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	27	26 (96.3)	-0.91 (0.80)	-2.6	-1.40	-0.80	-0.40	0.4	-0.55 [-1.10, 0.01]
			Placebo	29	26 (89.7)	-0.42 (0.99)	-2.6	-1.00	-0.20	0.40	1.2	
		Week 6	Tezepelumab	27	26 (96.3)	-1.15 (0.98)	-2.6	-1.80	-1.20	-0.60	1.2	-0.57 [-1.13, -0.02]
			Placebo	29	26 (89.7)	-0.55 (1.11)	-2.6	-1.60	-0.50	0.20	1.6	
		Week 8	Tezepelumab	27	26 (96.3)	-1.18 (1.25)	-3.2	-2.00	-1.30	-0.40	2.6	-0.50 [-1.05, 0.04]
			Placebo	29	27 (93.1)	-0.61 (1.00)	-2.8	-1.00	-0.40	0.00	1.0	
		Week 10	Tezepelumab	27	26 (96.3)	-1.28 (1.08)	-3.4	-1.80	-1.40	-0.60	0.6	-0.59 [-1.14, -0.04]
			Placebo	29	27 (93.1)	-0.63 (1.13)	-2.6	-1.20	-0.60	0.00	2.6	
		Week 12	Tezepelumab	27	26 (96.3)	-1.36 (1.10)	-3.2	-2.20	-1.20	-0.60	0.6	-0.62 [-1.17, -0.07]
			Placebo	29	27 (93.1)	-0.70 (1.02)	-2.8	-1.20	-0.60	0.00	1.6	
		Week 14	Tezepelumab	27	26 (96.3)	-1.47 (1.14)	-4.0	-2.20	-1.40	-0.80	0.6	-0.47 [-1.02, 0.07]
			Placebo	29	27 (93.1)	-0.96 (0.99)	-2.6	-1.60	-1.00	-0.40	1.4	
		Week 16	Tezepelumab	27	26 (96.3)	-1.38 (1.11)	-3.2	-2.40	-1.20	-0.80	0.6	-0.60 [-1.15, -0.05]
			Placebo	29	27 (93.1)	-0.70 (1.12)	-2.6	-1.40	-0.80	0.00	2.6	
		Week 18	Tezepelumab	27	26 (96.3)	-1.45 (1.11)	-3.8	-2.20	-1.40	-0.80	0.6	-0.42 [-0.97, 0.12]
			Placebo	29	27 (93.1)	-0.98 (1.15)	-3.2	-1.60	-0.80	-0.40	2.6	
		Week 20	Tezepelumab	27	26 (96.3)	-1.39 (1.09)	-3.4	-2.40	-1.30	-0.60	0.6	-0.64 [-1.20, -0.09]
			Placebo	29	27 (93.1)	-0.64 (1.22)	-3.0	-1.40	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	27	26 (96.3)	-1.25 (1.07)	-3.2	-2.40	-1.10	-0.60	0.6	-0.42 [-0.96, 0.13]
			Placebo	29	27 (93.1)	-0.77 (1.25)	-3.2	-1.40	-0.80	0.00	2.6	
		Week 24	Tezepelumab	27	26 (96.3)	-1.28 (1.02)	-3.4	-2.00	-1.40	-0.60	0.6	-0.59 [-1.14, -0.04]
			Placebo	29	27 (93.1)	-0.62 (1.20)	-3.0	-1.60	-0.40	0.20	2.6	
		Week 26	Tezepelumab	27	27 (100.0)	-1.24 (1.09)	-3.0	-2.20	-1.20	-0.40	0.6	-0.44 [-0.98, 0.10]
			Placebo	29	27 (93.1)	-0.71 (1.31)	-2.6	-1.80	-0.80	0.20	2.6	
		Week 28	Tezepelumab	27	27 (100.0)	-1.21 (1.20)	-3.4	-2.20	-1.20	-0.60	1.0	-0.54 [-1.08, 0.00]
			Placebo	29	27 (93.1)	-0.55 (1.27)	-2.6	-1.60	-0.40	0.20	2.6	
		Week 30	Tezepelumab	27	27 (100.0)	-1.21 (1.29)	-3.8	-2.40	-1.20	-0.60	2.0	-0.41 [-0.95, 0.13]
			Placebo	29	27 (93.1)	-0.68 (1.28)	-2.8	-1.40	-0.60	0.20	2.6	
		Week 32	Tezepelumab	27	27 (100.0)	-1.27 (1.15)	-3.2	-2.20	-1.20	-0.80	1.0	-0.46 [-1.00, 0.08]
			Placebo	29	27 (93.1)	-0.70 (1.30)	-2.6	-1.80	-1.00	0.20	2.6	
		Week 34	Tezepelumab	27	27 (100.0)	-1.19 (1.30)	-3.0	-2.20	-1.60	-0.20	2.2	-0.27 [-0.81, 0.26]
			Placebo	29	27 (93.1)	-0.83 (1.30)	-3.2	-1.80	-1.00	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Change from baseline	Week 36	Tezepelumab	27	27 (100.0)	-1.26 (1.27)	-3.2	-2.20	-1.20	-0.20	1.6	-0.64 [-1.18, -0.09]
			Placebo	29	27 (93.1)	-0.43 (1.33)	-3.2	-1.20	-0.40	0.40	2.6	
		Week 38	Tezepelumab	27	27 (100.0)	-1.08 (1.34)	-3.2	-2.20	-1.00	0.00	2.6	-0.22 [-0.75, 0.32]
			Placebo	29	27 (93.1)	-0.79 (1.36)	-3.2	-2.00	-1.00	0.20	2.6	
		Week 40	Tezepelumab	27	27 (100.0)	-1.18 (1.27)	-3.4	-2.20	-1.20	-0.40	1.8	-0.56 [-1.10, -0.02]
			Placebo	29	27 (93.1)	-0.45 (1.32)	-2.8	-1.20	-0.40	0.20	2.6	
		Week 42	Tezepelumab	27	27 (100.0)	-1.18 (1.33)	-3.6	-2.20	-1.20	-0.40	2.2	-0.33 [-0.87, 0.20]
			Placebo	29	27 (93.1)	-0.73 (1.34)	-2.8	-1.60	-0.80	0.00	2.6	
		Week 44	Tezepelumab	27	27 (100.0)	-1.20 (1.34)	-3.8	-2.20	-1.20	0.00	1.6	-0.60 [-1.15, -0.06]
			Placebo	29	27 (93.1)	-0.42 (1.24)	-2.6	-1.40	-0.40	0.20	2.6	
		Week 46	Tezepelumab	27	27 (100.0)	-1.08 (1.29)	-3.6	-2.20	-1.00	0.00	1.8	-0.28 [-0.82, 0.26]
			Placebo	29	27 (93.1)	-0.72 (1.30)	-3.2	-1.40	-0.80	0.00	2.6	
		Week 48	Tezepelumab	27	27 (100.0)	-1.10 (1.27)	-2.8	-2.40	-1.00	0.00	2.0	-0.45 [-0.99, 0.09]
			Placebo	29	27 (93.1)	-0.53 (1.28)	-3.2	-1.40	-0.40	0.20	2.6	
		Week 50	Tezepelumab	27	27 (100.0)	-1.12 (1.17)	-2.8	-2.20	-1.20	-0.40	2.0	-0.25 [-0.79, 0.28]
			Placebo	29	27 (93.1)	-0.83 (1.12)	-2.8	-1.40	-0.60	-0.20	2.6	
		Week 52	Tezepelumab	27	27 (100.0)	-1.15 (1.21)	-2.8	-2.20	-1.20	-0.40	2.0	-0.38 [-0.92, 0.16]
			Placebo	29	27 (93.1)	-0.70 (1.17)	-2.8	-1.20	-0.60	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	34	34 (100.0)	2.82 (1.03)	0.0	2.40	2.80	3.40	5.2	
			Placebo	33	33 (100.0)	2.93 (0.82)	0.4	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	34	33 (97.1)	2.35 (1.09)	0.0	1.60	2.60	3.20	4.4	
			Placebo	33	29 (87.9)	2.50 (0.83)	0.4	2.20	2.60	3.00	5.0	
		Week 4	Tezepelumab	34	33 (97.1)	2.10 (1.10)	0.2	1.20	2.40	3.00	3.4	
			Placebo	33	29 (87.9)	2.23 (0.88)	0.2	1.80	2.20	3.00	3.6	
		Week 6	Tezepelumab	34	33 (97.1)	2.10 (1.07)	0.0	1.20	2.20	2.80	4.0	
			Placebo	33	29 (87.9)	2.26 (1.16)	0.2	1.40	2.20	3.00	6.0	
		Week 8	Tezepelumab	34	33 (97.1)	1.89 (1.20)	0.0	1.00	2.00	2.80	4.2	
			Placebo	33	29 (87.9)	2.19 (1.15)	0.2	1.40	2.40	3.00	5.0	
		Week 10	Tezepelumab	34	33 (97.1)	1.81 (1.16)	0.0	0.80	1.80	2.80	3.6	
			Placebo	33	29 (87.9)	2.19 (1.06)	0.0	1.80	2.20	3.00	5.2	
		Week 12	Tezepelumab	34	33 (97.1)	1.64 (1.11)	0.0	0.60	2.00	2.60	3.2	
			Placebo	33	29 (87.9)	1.84 (0.99)	0.0	1.00	2.00	2.60	3.8	
		Week 14	Tezepelumab	34	33 (97.1)	1.63 (1.14)	0.0	0.60	1.60	2.40	4.2	
			Placebo	33	29 (87.9)	1.97 (0.98)	0.0	1.60	2.00	2.40	5.0	
		Week 16	Tezepelumab	34	33 (97.1)	1.74 (1.13)	0.0	0.80	1.80	2.80	4.2	
			Placebo	33	29 (87.9)	2.03 (1.19)	0.0	1.00	2.00	2.60	5.0	
		Week 18	Tezepelumab	34	33 (97.1)	1.78 (1.07)	0.0	1.00	2.00	2.60	4.2	
			Placebo	33	29 (87.9)	2.10 (1.24)	0.0	1.40	2.20	2.80	5.0	
		Week 20	Tezepelumab	34	33 (97.1)	1.76 (1.17)	0.0	0.80	2.00	2.60	5.0	
			Placebo	33	29 (87.9)	2.01 (0.96)	0.2	1.40	2.00	2.60	5.0	
		Week 22	Tezepelumab	34	33 (97.1)	1.82 (1.00)	0.0	1.00	2.20	2.60	3.8	
			Placebo	33	29 (87.9)	2.03 (1.03)	0.0	1.40	2.00	2.60	5.0	
		Week 24	Tezepelumab	34	33 (97.1)	1.76 (1.08)	0.0	0.80	1.80	2.60	3.8	
			Placebo	33	29 (87.9)	2.01 (0.88)	0.2	1.60	2.00	2.40	4.0	
		Week 26	Tezepelumab	34	33 (97.1)	1.85 (1.11)	0.0	1.00	1.80	2.80	4.0	
			Placebo	33	29 (87.9)	1.95 (1.00)	0.0	1.40	1.80	2.60	4.0	
		Week 28	Tezepelumab	34	34 (100.0)	1.76 (1.15)	0.0	1.00	1.90	2.40	3.8	
			Placebo	33	30 (90.9)	1.77 (1.14)	0.0	1.00	1.70	2.80	4.0	
		Week 30	Tezepelumab	34	34 (100.0)	1.73 (1.05)	0.0	0.80	1.80	2.60	3.6	
			Placebo	33	30 (90.9)	1.86 (1.10)	0.0	1.00	1.90	2.60	4.0	
		Week 32	Tezepelumab	34	34 (100.0)	1.61 (1.07)	0.0	0.80	1.50	2.40	4.0	
			Placebo	33	30 (90.9)	1.81 (0.99)	0.0	1.20	1.90	2.20	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Absolute values	Week 34	Tezepelumab	34	34 (100.0)	1.70 (1.16)	0.0	0.80	1.80	2.60	4.2	
			Placebo	33	30 (90.9)	1.89 (0.97)	0.2	1.20	2.00	2.60	4.0	
		Week 36	Tezepelumab	34	34 (100.0)	1.69 (1.03)	0.0	1.00	1.80	2.40	3.6	
			Placebo	33	30 (90.9)	1.88 (1.02)	0.0	1.00	1.90	2.60	4.0	
		Week 38	Tezepelumab	34	34 (100.0)	1.68 (1.18)	0.0	0.60	1.70	2.40	4.6	
			Placebo	33	30 (90.9)	1.94 (0.97)	0.0	1.20	1.80	2.60	4.0	
		Week 40	Tezepelumab	34	34 (100.0)	1.69 (1.16)	0.0	0.80	1.80	2.80	3.8	
			Placebo	33	30 (90.9)	1.90 (1.10)	0.0	1.20	1.80	2.80	4.2	
		Week 42	Tezepelumab	34	34 (100.0)	1.59 (1.05)	0.0	0.80	1.50	2.40	3.8	
			Placebo	33	30 (90.9)	1.91 (0.89)	0.0	1.20	2.00	2.60	3.4	
		Week 44	Tezepelumab	34	34 (100.0)	1.65 (1.05)	0.0	0.80	1.60	2.60	3.8	
			Placebo	33	30 (90.9)	1.77 (1.05)	0.0	1.00	1.80	2.60	4.2	
		Week 46	Tezepelumab	34	34 (100.0)	1.61 (1.13)	0.0	0.80	1.20	2.60	3.8	
			Placebo	33	30 (90.9)	1.79 (0.85)	0.0	1.20	1.80	2.40	3.4	
		Week 48	Tezepelumab	34	34 (100.0)	1.66 (1.15)	0.0	0.80	1.50	2.60	4.2	
			Placebo	33	30 (90.9)	1.74 (0.96)	0.0	1.00	1.90	2.40	3.4	
		Week 50	Tezepelumab	34	34 (100.0)	1.56 (1.22)	0.0	0.60	1.20	2.60	4.2	
			Placebo	33	30 (90.9)	1.67 (0.96)	0.0	1.00	1.70	2.40	3.4	
		Week 52	Tezepelumab	34	34 (100.0)	1.65 (1.17)	0.0	0.80	1.40	2.60	4.4	
			Placebo	33	30 (90.9)	1.66 (0.99)	0.0	1.00	1.80	2.40	3.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	34	33 (97.1)	-0.48 (0.90)	-3.2	-0.80	-0.20	0.20	0.8	0.05 [-0.45, 0.55]
			Placebo	33	29 (87.9)	-0.52 (0.66)	-2.4	-1.00	-0.40	0.00	0.4	
		Week 4	Tezepelumab	34	33 (97.1)	-0.73 (1.06)	-2.6	-1.20	-0.60	-0.20	2.6	0.05 [-0.45, 0.55]
			Placebo	33	29 (87.9)	-0.78 (0.94)	-3.0	-1.40	-0.60	0.00	0.6	
		Week 6	Tezepelumab	34	33 (97.1)	-0.73 (1.08)	-2.8	-1.40	-0.80	0.00	2.6	0.02 [-0.48, 0.52]
			Placebo	33	29 (87.9)	-0.75 (1.01)	-3.4	-1.20	-0.60	0.00	1.0	
		Week 8	Tezepelumab	34	33 (97.1)	-0.94 (1.12)	-3.0	-1.60	-1.00	-0.40	2.6	-0.10 [-0.60, 0.40]
			Placebo	33	29 (87.9)	-0.83 (1.09)	-3.6	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	34	33 (97.1)	-1.02 (1.19)	-3.0	-1.60	-1.20	-0.20	2.6	-0.17 [-0.67, 0.33]
			Placebo	33	29 (87.9)	-0.83 (1.19)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	34	33 (97.1)	-1.19 (1.17)	-3.2	-2.20	-1.40	-0.60	2.6	-0.02 [-0.52, 0.48]
			Placebo	33	29 (87.9)	-1.17 (1.10)	-3.8	-1.80	-1.00	-0.40	1.2	
		Week 14	Tezepelumab	34	33 (97.1)	-1.20 (1.14)	-3.0	-2.00	-1.20	-0.60	2.6	-0.13 [-0.63, 0.37]
			Placebo	33	29 (87.9)	-1.05 (1.18)	-3.4	-1.60	-1.20	-0.40	2.4	
		Week 16	Tezepelumab	34	33 (97.1)	-1.09 (1.10)	-3.0	-1.80	-1.00	-0.40	2.6	-0.10 [-0.59, 0.40]
			Placebo	33	29 (87.9)	-0.98 (1.24)	-3.6	-1.40	-1.20	-0.20	2.4	
		Week 18	Tezepelumab	34	33 (97.1)	-1.05 (1.10)	-3.0	-1.80	-1.00	-0.60	2.6	-0.11 [-0.61, 0.39]
			Placebo	33	29 (87.9)	-0.92 (1.34)	-3.6	-2.00	-1.00	0.00	2.4	
		Week 20	Tezepelumab	34	33 (97.1)	-1.07 (1.15)	-3.0	-1.80	-1.00	-0.60	2.6	-0.06 [-0.56, 0.44]
			Placebo	33	29 (87.9)	-1.01 (1.13)	-3.6	-1.40	-1.00	-0.40	2.4	
		Week 22	Tezepelumab	34	33 (97.1)	-1.01 (1.23)	-3.0	-1.60	-1.00	-0.60	2.6	-0.02 [-0.52, 0.48]
			Placebo	33	29 (87.9)	-0.99 (1.14)	-3.8	-1.60	-1.00	-0.20	2.4	
		Week 24	Tezepelumab	34	33 (97.1)	-1.07 (1.16)	-3.0	-2.00	-0.80	-0.40	2.6	-0.07 [-0.56, 0.43]
			Placebo	33	29 (87.9)	-1.00 (1.05)	-3.6	-1.40	-1.00	-0.20	1.4	
		Week 26	Tezepelumab	34	33 (97.1)	-0.98 (1.18)	-3.0	-2.00	-0.80	-0.20	2.6	0.08 [-0.42, 0.58]
			Placebo	33	29 (87.9)	-1.06 (1.08)	-3.4	-1.60	-1.20	-0.40	1.4	
		Week 28	Tezepelumab	34	34 (100.0)	-1.06 (1.23)	-3.0	-2.20	-0.80	0.00	2.6	0.07 [-0.42, 0.57]
			Placebo	33	30 (90.9)	-1.15 (1.15)	-3.4	-1.80	-1.40	-0.20	1.4	
		Week 30	Tezepelumab	34	34 (100.0)	-1.09 (1.15)	-3.0	-1.80	-1.00	-0.40	2.6	-0.02 [-0.51, 0.47]
			Placebo	33	30 (90.9)	-1.07 (1.18)	-3.4	-1.60	-1.30	-0.40	2.0	
		Week 32	Tezepelumab	34	34 (100.0)	-1.21 (1.14)	-3.0	-2.20	-1.20	-0.40	2.6	-0.08 [-0.58, 0.41]
			Placebo	33	30 (90.9)	-1.12 (1.03)	-3.2	-1.60	-1.30	-0.40	1.4	
		Week 34	Tezepelumab	34	34 (100.0)	-1.12 (1.20)	-3.0	-2.20	-1.10	-0.20	2.6	-0.07 [-0.57, 0.42]
			Placebo	33	30 (90.9)	-1.04 (1.02)	-3.2	-1.60	-1.20	-0.20	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Change from baseline	Week 36	Tezepelumab	34	34 (100.0)	-1.13 (1.18)	-3.0	-2.20	-1.20	-0.20	2.6	-0.07 [-0.57, 0.42]
			Placebo	33	30 (90.9)	-1.05 (1.03)	-3.6	-1.40	-1.20	-0.20	1.4	
		Week 38	Tezepelumab	34	34 (100.0)	-1.15 (1.22)	-3.0	-2.20	-1.30	-0.20	2.6	-0.15 [-0.64, 0.34]
			Placebo	33	30 (90.9)	-0.99 (0.92)	-3.0	-1.40	-1.20	-0.40	1.4	
		Week 40	Tezepelumab	34	34 (100.0)	-1.14 (1.24)	-3.0	-2.20	-1.10	-0.40	2.6	-0.09 [-0.59, 0.40]
			Placebo	33	30 (90.9)	-1.03 (1.04)	-3.2	-1.60	-1.20	-0.40	1.4	
		Week 42	Tezepelumab	34	34 (100.0)	-1.23 (1.18)	-3.0	-2.00	-1.40	-0.40	2.6	-0.20 [-0.70, 0.29]
			Placebo	33	30 (90.9)	-1.02 (0.82)	-2.8	-1.40	-1.00	-0.40	0.4	
		Week 44	Tezepelumab	34	34 (100.0)	-1.17 (1.15)	-3.0	-2.20	-1.20	-0.40	2.6	-0.01 [-0.50, 0.48]
			Placebo	33	30 (90.9)	-1.16 (0.96)	-3.4	-1.60	-1.20	-0.60	0.8	
		Week 46	Tezepelumab	34	34 (100.0)	-1.22 (1.19)	-3.0	-2.20	-1.20	-0.40	2.6	-0.08 [-0.57, 0.41]
			Placebo	33	30 (90.9)	-1.13 (0.75)	-2.8	-1.60	-1.20	-0.60	0.2	
		Week 48	Tezepelumab	34	34 (100.0)	-1.16 (1.20)	-3.0	-2.00	-1.10	-0.40	2.6	0.03 [-0.46, 0.52]
			Placebo	33	30 (90.9)	-1.19 (0.89)	-3.4	-1.60	-1.10	-0.60	0.2	
		Week 50	Tezepelumab	34	34 (100.0)	-1.26 (1.33)	-3.2	-2.60	-1.40	-0.20	2.6	0.00 [-0.49, 0.49]
			Placebo	33	30 (90.9)	-1.26 (0.85)	-3.6	-1.60	-1.30	-0.80	0.2	
		Week 52	Tezepelumab	34	34 (100.0)	-1.17 (1.28)	-3.2	-2.00	-1.20	-0.20	2.6	0.09 [-0.40, 0.58]
			Placebo	33	30 (90.9)	-1.27 (0.89)	-3.6	-1.60	-1.10	-0.80	0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	2.73 (0.61)	1.8	2.20	2.60	3.20	4.2	
			Placebo	14	14 (100.0)	2.50 (0.76)	1.0	2.00	2.80	3.00	3.4	
		Week 2	Tezepelumab	23	21 (91.3)	2.14 (1.10)	0.0	1.40	2.40	2.80	4.0	
			Placebo	14	11 (78.6)	2.04 (0.74)	0.4	1.80	2.20	2.40	3.0	
		Week 4	Tezepelumab	23	21 (91.3)	1.95 (1.01)	0.2	1.40	1.80	2.80	3.4	
			Placebo	14	11 (78.6)	2.13 (0.96)	0.8	1.40	2.00	2.60	4.2	
		Week 6	Tezepelumab	23	21 (91.3)	1.73 (1.03)	0.0	1.20	1.60	2.60	3.8	
			Placebo	14	11 (78.6)	2.25 (1.32)	1.0	1.20	1.80	3.00	5.0	
		Week 8	Tezepelumab	23	21 (91.3)	1.78 (1.31)	0.0	0.80	1.60	2.60	5.2	
			Placebo	14	11 (78.6)	2.38 (1.27)	0.4	1.00	2.40	3.60	4.0	
		Week 10	Tezepelumab	23	21 (91.3)	1.59 (1.24)	0.0	0.60	1.40	2.20	4.8	
			Placebo	14	11 (78.6)	2.31 (1.14)	0.4	1.60	2.20	3.00	4.0	
		Week 12	Tezepelumab	23	21 (91.3)	1.59 (1.19)	0.0	0.60	1.40	2.60	4.8	
			Placebo	14	11 (78.6)	2.02 (1.19)	0.4	1.00	2.00	3.00	4.4	
		Week 14	Tezepelumab	23	21 (91.3)	1.51 (1.18)	0.0	0.40	1.40	2.00	4.8	
			Placebo	14	11 (78.6)	1.49 (0.78)	0.0	1.00	1.40	2.00	2.8	
		Week 16	Tezepelumab	23	21 (91.3)	1.57 (1.24)	0.0	0.80	1.40	2.40	4.8	
			Placebo	14	11 (78.6)	2.13 (1.28)	0.0	1.00	2.00	2.80	4.0	
		Week 18	Tezepelumab	23	22 (95.7)	1.55 (1.17)	0.0	0.80	1.30	2.40	4.8	
			Placebo	14	11 (78.6)	1.58 (1.35)	0.0	0.60	1.00	2.80	4.0	
		Week 20	Tezepelumab	23	22 (95.7)	1.57 (1.23)	0.0	0.60	1.40	2.60	4.8	
			Placebo	14	11 (78.6)	1.98 (1.48)	0.2	0.40	2.20	3.60	4.0	
		Week 22	Tezepelumab	23	22 (95.7)	1.75 (1.14)	0.0	1.00	1.70	2.40	4.8	
			Placebo	14	11 (78.6)	1.91 (1.58)	0.0	0.40	1.80	3.60	4.0	
		Week 24	Tezepelumab	23	22 (95.7)	1.55 (1.15)	0.0	0.80	1.40	2.20	4.8	
			Placebo	14	11 (78.6)	2.04 (1.51)	0.0	0.40	2.20	3.40	4.0	
		Week 26	Tezepelumab	23	23 (100.0)	1.69 (1.16)	0.0	0.80	1.60	2.40	4.8	
			Placebo	14	11 (78.6)	2.07 (1.48)	0.4	0.80	1.60	3.80	4.4	
		Week 28	Tezepelumab	23	23 (100.0)	1.77 (1.29)	0.0	0.40	1.60	3.00	4.8	
			Placebo	14	11 (78.6)	2.49 (1.51)	0.4	0.80	2.60	4.00	4.4	
		Week 30	Tezepelumab	23	23 (100.0)	1.78 (1.26)	0.0	1.00	1.80	2.60	4.8	
			Placebo	14	11 (78.6)	2.07 (1.53)	0.0	0.60	2.40	3.40	4.0	
		Week 32	Tezepelumab	23	23 (100.0)	1.70 (1.28)	0.0	0.60	1.40	2.80	4.8	
			Placebo	14	11 (78.6)	2.18 (1.33)	0.4	0.80	2.20	3.20	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Absolute values	Week 34	Tezepelumab	23	23 (100.0)	1.83 (1.31)	0.0	0.80	1.40	2.80	4.8	
			Placebo	14	11 (78.6)	1.93 (1.44)	0.0	0.80	2.00	3.20	4.0	
		Week 36	Tezepelumab	23	23 (100.0)	1.70 (1.27)	0.0	0.80	1.40	3.00	4.8	
			Placebo	14	11 (78.6)	2.22 (1.50)	0.0	1.40	2.20	3.60	4.4	
		Week 38	Tezepelumab	23	23 (100.0)	1.82 (1.39)	0.0	0.60	1.60	3.00	4.8	
			Placebo	14	11 (78.6)	2.04 (1.29)	0.0	1.20	2.00	3.20	4.0	
		Week 40	Tezepelumab	23	23 (100.0)	1.83 (1.27)	0.0	0.80	1.80	2.80	4.8	
			Placebo	14	11 (78.6)	2.69 (1.45)	0.0	2.20	3.00	4.00	4.4	
		Week 42	Tezepelumab	23	23 (100.0)	1.81 (1.32)	0.0	0.80	1.80	2.80	4.8	
			Placebo	14	11 (78.6)	2.51 (1.41)	0.0	2.00	2.40	3.80	4.6	
		Week 44	Tezepelumab	23	23 (100.0)	1.73 (1.29)	0.0	0.80	1.60	2.80	4.8	
			Placebo	14	11 (78.6)	2.73 (1.03)	0.8	1.80	2.80	3.40	4.2	
		Week 46	Tezepelumab	23	23 (100.0)	1.83 (1.30)	0.0	1.00	1.80	3.00	4.8	
			Placebo	14	11 (78.6)	2.27 (1.36)	0.0	1.00	2.20	3.20	4.4	
		Week 48	Tezepelumab	23	23 (100.0)	1.78 (1.30)	0.0	0.80	1.40	3.00	4.8	
			Placebo	14	11 (78.6)	2.45 (1.48)	0.0	1.40	2.40	4.00	4.6	
		Week 50	Tezepelumab	23	23 (100.0)	1.69 (1.34)	0.0	0.80	1.60	2.80	4.8	
			Placebo	14	11 (78.6)	2.35 (1.18)	0.4	1.20	2.40	3.40	4.0	
		Week 52	Tezepelumab	23	23 (100.0)	1.66 (1.34)	0.0	0.40	1.60	2.80	4.8	
			Placebo	14	11 (78.6)	2.38 (1.25)	0.4	1.20	2.40	3.80	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	23	21 (91.3)	-0.67 (0.83)	-3.2	-1.00	-0.40	-0.20	0.4	-0.17 [-0.90, 0.56]
			Placebo	14	11 (78.6)	-0.51 (1.14)	-2.8	-1.00	-0.40	0.20	1.2	
		Week 4	Tezepelumab	23	21 (91.3)	-0.86 (0.78)	-2.4	-1.40	-0.80	-0.20	0.4	-0.52 [-1.26, 0.22]
			Placebo	14	11 (78.6)	-0.42 (0.96)	-1.8	-1.00	-0.80	0.40	1.2	
		Week 6	Tezepelumab	23	21 (91.3)	-1.08 (1.01)	-2.8	-1.60	-1.20	-0.40	1.2	-0.71 [-1.46, 0.05]
			Placebo	14	11 (78.6)	-0.29 (1.29)	-1.8	-1.60	-0.60	1.00	1.6	
		Week 8	Tezepelumab	23	21 (91.3)	-1.03 (1.28)	-3.2	-1.60	-1.20	-0.40	2.6	-0.73 [-1.48, 0.02]
			Placebo	14	11 (78.6)	-0.16 (0.97)	-1.8	-0.80	-0.20	1.00	1.0	
		Week 10	Tezepelumab	23	21 (91.3)	-1.22 (1.10)	-3.4	-2.00	-1.20	-0.60	0.6	-0.85 [-1.61, -0.09]
			Placebo	14	11 (78.6)	-0.24 (1.25)	-1.4	-1.20	-0.60	0.00	2.6	
		Week 12	Tezepelumab	23	21 (91.3)	-1.22 (1.00)	-3.0	-2.20	-1.20	-0.60	0.6	-0.67 [-1.42, 0.08]
			Placebo	14	11 (78.6)	-0.53 (1.10)	-2.0	-1.20	-0.80	-0.40	1.6	
		Week 14	Tezepelumab	23	21 (91.3)	-1.30 (1.04)	-3.4	-2.00	-1.40	-0.80	0.6	-0.24 [-0.97, 0.49]
			Placebo	14	11 (78.6)	-1.05 (0.97)	-2.4	-1.60	-1.20	-0.80	1.4	
		Week 16	Tezepelumab	23	21 (91.3)	-1.24 (1.07)	-3.2	-2.20	-1.20	-0.60	0.6	-0.72 [-1.47, 0.03]
			Placebo	14	11 (78.6)	-0.42 (1.28)	-1.8	-1.40	-0.80	0.00	2.6	
		Week 18	Tezepelumab	23	22 (95.7)	-1.23 (1.06)	-3.4	-2.00	-1.30	-0.60	0.6	-0.21 [-0.94, 0.51]
			Placebo	14	11 (78.6)	-0.96 (1.57)	-3.2	-2.20	-1.20	-0.20	2.6	
		Week 20	Tezepelumab	23	22 (95.7)	-1.20 (1.10)	-3.4	-2.20	-1.10	-0.40	0.6	-0.50 [-1.23, 0.24]
			Placebo	14	11 (78.6)	-0.56 (1.59)	-3.0	-1.80	-0.60	0.60	2.6	
		Week 22	Tezepelumab	23	22 (95.7)	-1.02 (1.02)	-3.2	-1.80	-0.90	-0.20	0.6	-0.30 [-1.03, 0.43]
			Placebo	14	11 (78.6)	-0.64 (1.68)	-3.2	-1.80	-1.00	0.60	2.6	
		Week 24	Tezepelumab	23	22 (95.7)	-1.22 (1.03)	-3.4	-2.20	-1.30	-0.60	0.6	-0.58 [-1.31, 0.16]
			Placebo	14	11 (78.6)	-0.51 (1.57)	-3.0	-1.80	-0.60	0.40	2.6	
		Week 26	Tezepelumab	23	23 (100.0)	-1.04 (1.06)	-3.0	-2.20	-1.00	-0.20	0.6	-0.44 [-1.16, 0.29]
			Placebo	14	11 (78.6)	-0.47 (1.74)	-2.4	-1.80	-1.20	0.80	2.6	
		Week 28	Tezepelumab	23	23 (100.0)	-0.97 (1.30)	-3.4	-2.20	-0.80	0.40	1.0	-0.66 [-1.40, 0.08]
			Placebo	14	11 (78.6)	-0.05 (1.54)	-2.4	-1.60	-0.20	1.20	2.6	
		Week 30	Tezepelumab	23	23 (100.0)	-0.95 (1.24)	-2.8	-2.20	-1.00	0.00	2.0	-0.35 [-1.07, 0.37]
			Placebo	14	11 (78.6)	-0.47 (1.60)	-2.8	-1.80	-0.40	0.60	2.6	
		Week 32	Tezepelumab	23	23 (100.0)	-1.03 (1.14)	-3.2	-2.20	-1.00	0.00	1.0	-0.54 [-1.28, 0.19]
			Placebo	14	11 (78.6)	-0.36 (1.42)	-2.4	-1.60	-0.20	0.40	2.6	
		Week 34	Tezepelumab	23	23 (100.0)	-0.90 (1.28)	-3.0	-2.20	-0.80	0.20	2.2	-0.21 [-0.93, 0.51]
			Placebo	14	11 (78.6)	-0.62 (1.58)	-3.2	-1.60	-0.60	0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Change from baseline	Week 36	Tezepelumab	23	23 (100.0)	-1.03 (1.20)	-3.2	-2.20	-1.20	0.00	1.6	-0.52 [-1.25, 0.21]
			Placebo	14	11 (78.6)	-0.33 (1.64)	-3.2	-1.20	-0.60	0.80	2.6	
		Week 38	Tezepelumab	23	23 (100.0)	-0.91 (1.37)	-3.2	-2.20	-1.00	0.40	2.6	-0.28 [-1.00, 0.44]
			Placebo	14	11 (78.6)	-0.51 (1.61)	-3.2	-1.60	-0.40	0.20	2.6	
		Week 40	Tezepelumab	23	23 (100.0)	-0.90 (1.23)	-3.4	-1.60	-1.00	0.40	1.8	-0.76 [-1.50, -0.02]
			Placebo	14	11 (78.6)	0.15 (1.63)	-2.8	-1.20	0.20	1.40	2.6	
		Week 42	Tezepelumab	23	23 (100.0)	-0.92 (1.25)	-2.8	-2.20	-1.00	0.00	2.2	-0.64 [-1.37, 0.10]
			Placebo	14	11 (78.6)	-0.04 (1.65)	-2.8	-1.20	0.00	1.40	2.6	
		Week 44	Tezepelumab	23	23 (100.0)	-1.00 (1.19)	-3.4	-1.80	-1.20	0.00	1.6	-0.96 [-1.72, -0.21]
			Placebo	14	11 (78.6)	0.18 (1.30)	-1.8	-1.00	0.00	1.20	2.6	
		Week 46	Tezepelumab	23	23 (100.0)	-0.90 (1.18)	-2.4	-2.20	-1.00	0.20	1.8	-0.45 [-1.18, 0.27]
			Placebo	14	11 (78.6)	-0.27 (1.72)	-3.2	-1.60	0.00	1.20	2.6	
		Week 48	Tezepelumab	23	23 (100.0)	-0.95 (1.22)	-2.6	-2.20	-0.80	0.00	2.0	-0.63 [-1.36, 0.11]
			Placebo	14	11 (78.6)	-0.09 (1.65)	-3.2	-1.60	0.00	1.00	2.6	
		Week 50	Tezepelumab	23	23 (100.0)	-1.04 (1.30)	-3.2	-2.20	-1.00	0.00	2.0	-0.61 [-1.34, 0.13]
			Placebo	14	11 (78.6)	-0.20 (1.56)	-2.8	-1.00	0.00	0.40	2.6	
		Week 52	Tezepelumab	23	23 (100.0)	-1.07 (1.32)	-3.2	-2.20	-1.00	0.00	2.0	-0.64 [-1.38, 0.09]
			Placebo	14	11 (78.6)	-0.16 (1.60)	-2.8	-1.00	0.00	1.00	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	2.94 (1.01)	0.0	2.40	2.90	3.40	5.2	
			Placebo	44	44 (100.0)	2.94 (0.79)	0.4	2.60	3.00	3.30	5.0	
		Week 2	Tezepelumab	40	39 (97.5)	2.42 (1.00)	0.2	1.60	2.60	3.20	4.4	
			Placebo	44	40 (90.9)	2.42 (0.84)	0.4	2.00	2.40	2.90	5.0	
		Week 4	Tezepelumab	40	39 (97.5)	2.11 (1.00)	0.2	1.20	2.20	2.80	3.6	
			Placebo	44	40 (90.9)	2.30 (0.92)	0.2	1.80	2.60	2.90	3.6	
		Week 6	Tezepelumab	40	39 (97.5)	2.05 (1.05)	0.0	1.20	2.20	2.80	4.0	
			Placebo	44	40 (90.9)	2.18 (1.15)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	40	39 (97.5)	1.78 (1.12)	0.0	1.00	1.80	2.80	4.2	
			Placebo	44	41 (93.2)	2.05 (1.15)	0.0	1.40	2.00	2.80	5.0	
		Week 10	Tezepelumab	40	39 (97.5)	1.75 (1.10)	0.0	0.80	1.60	2.60	3.6	
			Placebo	44	41 (93.2)	2.07 (1.11)	0.0	1.60	2.20	2.80	5.2	
		Week 12	Tezepelumab	40	39 (97.5)	1.56 (1.07)	0.0	0.60	1.60	2.60	3.2	
			Placebo	44	41 (93.2)	1.90 (1.08)	0.0	1.00	2.00	2.60	4.4	
		Week 14	Tezepelumab	40	39 (97.5)	1.52 (1.07)	0.0	0.60	1.40	2.20	4.2	
			Placebo	44	41 (93.2)	2.00 (1.08)	0.0	1.40	2.00	2.60	5.0	
		Week 16	Tezepelumab	40	39 (97.5)	1.77 (1.17)	0.0	0.60	1.80	2.60	4.6	
			Placebo	44	41 (93.2)	2.03 (1.27)	0.0	1.00	2.20	2.80	5.0	
		Week 18	Tezepelumab	40	39 (97.5)	1.70 (1.04)	0.0	0.80	2.00	2.40	4.2	
			Placebo	44	41 (93.2)	1.98 (1.20)	0.0	1.40	2.00	2.60	5.0	
		Week 20	Tezepelumab	40	39 (97.5)	1.69 (1.10)	0.0	0.80	1.80	2.60	5.0	
			Placebo	44	41 (93.2)	2.09 (1.08)	0.0	1.40	2.20	2.80	5.0	
		Week 22	Tezepelumab	40	39 (97.5)	1.74 (0.98)	0.0	0.80	2.00	2.40	3.8	
			Placebo	44	41 (93.2)	2.02 (1.12)	0.0	1.20	2.00	2.60	5.0	
		Week 24	Tezepelumab	40	39 (97.5)	1.78 (1.07)	0.0	0.80	2.00	2.80	3.8	
			Placebo	44	41 (93.2)	2.08 (1.00)	0.0	1.60	2.20	2.80	4.4	
		Week 26	Tezepelumab	40	39 (97.5)	1.83 (1.14)	0.0	1.00	2.00	2.80	4.0	
			Placebo	44	41 (93.2)	1.98 (1.14)	0.0	1.00	1.80	3.00	4.4	
		Week 28	Tezepelumab	40	40 (100.0)	1.67 (1.09)	0.0	0.90	1.80	2.40	3.8	
			Placebo	44	42 (95.5)	1.81 (1.16)	0.0	1.00	1.80	2.80	4.4	
		Week 30	Tezepelumab	40	40 (100.0)	1.61 (1.01)	0.0	0.80	1.60	2.30	3.6	
			Placebo	44	42 (95.5)	1.96 (1.16)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	40	40 (100.0)	1.56 (1.06)	0.0	0.70	1.70	2.20	4.0	
			Placebo	44	42 (95.5)	1.87 (1.17)	0.0	1.00	1.80	2.80	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Normal	Absolute values	Week 34	Tezepelumab	40	40 (100.0)	1.61 (1.15)	0.0	0.70	1.50	2.50	4.2	
			Placebo	44	42 (95.5)	1.87 (1.14)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	40	40 (100.0)	1.63 (1.05)	0.0	0.90	1.60	2.40	3.6	
			Placebo	44	42 (95.5)	2.06 (1.17)	0.0	1.00	2.20	2.80	4.8	
		Week 38	Tezepelumab	40	40 (100.0)	1.64 (1.17)	0.0	0.70	1.70	2.40	4.6	
			Placebo	44	42 (95.5)	1.90 (1.15)	0.0	1.00	1.80	2.60	4.8	
		Week 40	Tezepelumab	40	40 (100.0)	1.60 (1.16)	0.0	0.40	1.90	2.50	3.8	
			Placebo	44	42 (95.5)	1.94 (1.14)	0.0	1.00	1.90	2.80	4.4	
		Week 42	Tezepelumab	40	40 (100.0)	1.52 (1.07)	0.0	0.70	1.30	2.40	3.8	
			Placebo	44	42 (95.5)	1.73 (0.96)	0.0	1.00	1.80	2.40	4.4	
		Week 44	Tezepelumab	40	40 (100.0)	1.62 (1.08)	0.0	0.70	1.70	2.60	3.8	
			Placebo	44	42 (95.5)	1.84 (1.12)	0.0	1.00	1.80	2.60	4.4	
		Week 46	Tezepelumab	40	40 (100.0)	1.60 (1.15)	0.0	0.80	1.50	2.50	3.8	
			Placebo	44	42 (95.5)	1.78 (0.96)	0.0	1.20	1.80	2.40	4.4	
		Week 48	Tezepelumab	40	40 (100.0)	1.64 (1.15)	0.0	0.70	1.80	2.50	4.2	
			Placebo	44	42 (95.5)	1.83 (1.01)	0.0	1.00	2.00	2.60	4.4	
		Week 50	Tezepelumab	40	40 (100.0)	1.61 (1.17)	0.0	0.70	1.30	2.60	4.2	
			Placebo	44	42 (95.5)	1.69 (0.99)	0.0	1.00	1.70	2.40	4.4	
		Week 52	Tezepelumab	40	40 (100.0)	1.67 (1.14)	0.0	0.80	1.60	2.60	4.4	
			Placebo	44	42 (95.5)	1.78 (1.07)	0.0	1.00	1.80	2.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 2	Tezepelumab	40	39 (97.5)	-0.52 (0.80)	-2.2	-1.20	-0.40	0.20	0.8	0.03 [-0.41, 0.47]
			Placebo	44	40 (90.9)	-0.55 (0.63)	-2.4	-1.00	-0.40	0.00	0.4	
		Week 4	Tezepelumab	40	39 (97.5)	-0.84 (1.01)	-2.6	-1.40	-0.60	-0.20	2.6	-0.17 [-0.61, 0.27]
			Placebo	44	40 (90.9)	-0.67 (0.95)	-3.0	-1.40	-0.40	0.00	0.8	
		Week 6	Tezepelumab	40	39 (97.5)	-0.90 (1.05)	-2.8	-1.60	-1.00	-0.20	2.6	-0.11 [-0.55, 0.33]
			Placebo	44	40 (90.9)	-0.79 (0.95)	-3.2	-1.50	-0.70	0.00	1.0	
		Week 8	Tezepelumab	40	39 (97.5)	-1.16 (1.12)	-3.0	-1.80	-1.20	-0.40	2.6	-0.22 [-0.66, 0.22]
			Placebo	44	41 (93.2)	-0.93 (1.03)	-3.6	-1.60	-0.60	-0.20	0.6	
		Week 10	Tezepelumab	40	39 (97.5)	-1.19 (1.17)	-3.0	-2.00	-1.40	-0.60	2.6	-0.25 [-0.69, 0.19]
			Placebo	44	41 (93.2)	-0.90 (1.13)	-3.8	-1.60	-0.80	0.00	2.6	
		Week 12	Tezepelumab	40	39 (97.5)	-1.38 (1.17)	-3.2	-2.20	-1.40	-0.80	2.6	-0.27 [-0.71, 0.17]
			Placebo	44	41 (93.2)	-1.08 (1.08)	-3.8	-1.80	-1.00	-0.20	1.2	
		Week 14	Tezepelumab	40	39 (97.5)	-1.42 (1.17)	-4.0	-2.20	-1.40	-0.80	2.6	-0.39 [-0.83, 0.06]
			Placebo	44	41 (93.2)	-0.98 (1.14)	-3.4	-1.60	-1.00	-0.20	2.4	
		Week 16	Tezepelumab	40	39 (97.5)	-1.17 (1.24)	-3.0	-2.20	-1.00	-0.40	2.6	-0.19 [-0.63, 0.25]
			Placebo	44	41 (93.2)	-0.94 (1.18)	-3.6	-1.40	-0.80	-0.20	2.4	
		Week 18	Tezepelumab	40	39 (97.5)	-1.24 (1.16)	-3.8	-2.00	-1.00	-0.60	2.6	-0.21 [-0.65, 0.23]
			Placebo	44	41 (93.2)	-1.00 (1.21)	-3.6	-2.00	-0.80	-0.20	2.4	
		Week 20	Tezepelumab	40	39 (97.5)	-1.25 (1.15)	-3.0	-2.20	-1.40	-0.40	2.6	-0.33 [-0.77, 0.11]
			Placebo	44	41 (93.2)	-0.88 (1.10)	-3.6	-1.40	-0.80	-0.20	2.4	
		Week 22	Tezepelumab	40	39 (97.5)	-1.21 (1.22)	-3.0	-2.40	-1.20	-0.60	2.6	-0.22 [-0.66, 0.22]
			Placebo	44	41 (93.2)	-0.96 (1.08)	-3.8	-1.60	-1.00	-0.20	2.4	
		Week 24	Tezepelumab	40	39 (97.5)	-1.16 (1.15)	-3.0	-2.00	-1.40	-0.40	2.6	-0.24 [-0.68, 0.20]
			Placebo	44	41 (93.2)	-0.89 (1.03)	-3.6	-1.60	-0.80	0.00	1.4	
		Week 26	Tezepelumab	40	39 (97.5)	-1.12 (1.21)	-3.0	-2.20	-1.00	-0.20	2.6	-0.11 [-0.55, 0.33]
			Placebo	44	41 (93.2)	-1.00 (1.08)	-3.4	-1.80	-0.80	0.00	1.4	
		Week 28	Tezepelumab	40	40 (100.0)	-1.27 (1.19)	-3.0	-2.20	-1.30	-0.60	2.6	-0.15 [-0.58, 0.29]
			Placebo	44	42 (95.5)	-1.10 (1.07)	-3.4	-2.00	-1.20	-0.20	1.4	
		Week 30	Tezepelumab	40	40 (100.0)	-1.33 (1.17)	-3.8	-2.40	-1.20	-0.60	2.6	-0.32 [-0.75, 0.12]
			Placebo	44	42 (95.5)	-0.96 (1.16)	-3.4	-1.60	-1.10	-0.20	2.0	
		Week 32	Tezepelumab	40	40 (100.0)	-1.38 (1.11)	-3.0	-2.40	-1.40	-0.70	2.6	-0.29 [-0.73, 0.14]
			Placebo	44	42 (95.5)	-1.05 (1.12)	-3.2	-1.80	-1.40	-0.40	1.8	
		Week 34	Tezepelumab	40	40 (100.0)	-1.33 (1.18)	-3.0	-2.20	-1.60	-0.40	2.6	-0.25 [-0.68, 0.19]
			Placebo	44	42 (95.5)	-1.05 (1.07)	-3.2	-1.80	-1.20	-0.20	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Normal	Change from baseline	Week 36	Tezepelumab	40	40 (100.0)	-1.31 (1.20)	-3.0	-2.40	-1.30	-0.40	2.6	-0.39 [-0.83, 0.04]
			Placebo	44	42 (95.5)	-0.86 (1.10)	-3.2	-1.60	-1.00	-0.20	1.8	
		Week 38	Tezepelumab	40	40 (100.0)	-1.30 (1.18)	-3.0	-2.20	-1.60	-0.40	2.6	-0.26 [-0.69, 0.18]
			Placebo	44	42 (95.5)	-1.02 (1.02)	-2.8	-1.60	-1.00	-0.40	1.8	
		Week 40	Tezepelumab	40	40 (100.0)	-1.34 (1.22)	-3.0	-2.50	-1.40	-0.60	2.6	-0.33 [-0.77, 0.10]
			Placebo	44	42 (95.5)	-0.97 (1.00)	-2.6	-1.60	-0.80	-0.20	1.4	
		Week 42	Tezepelumab	40	40 (100.0)	-1.41 (1.20)	-3.6	-2.30	-1.60	-0.60	2.6	-0.23 [-0.66, 0.21]
			Placebo	44	42 (95.5)	-1.18 (0.82)	-2.6	-1.60	-1.20	-0.60	0.4	
		Week 44	Tezepelumab	40	40 (100.0)	-1.32 (1.24)	-3.8	-2.30	-1.20	-0.60	2.6	-0.22 [-0.65, 0.22]
			Placebo	44	42 (95.5)	-1.08 (0.98)	-2.8	-1.80	-1.10	-0.40	1.2	
		Week 46	Tezepelumab	40	40 (100.0)	-1.33 (1.24)	-3.6	-2.40	-1.30	-0.40	2.6	-0.19 [-0.62, 0.24]
			Placebo	44	42 (95.5)	-1.14 (0.79)	-2.6	-1.60	-1.20	-0.60	0.6	
		Week 48	Tezepelumab	40	40 (100.0)	-1.30 (1.22)	-3.0	-2.40	-1.10	-0.40	2.6	-0.20 [-0.64, 0.23]
			Placebo	44	42 (95.5)	-1.08 (0.89)	-3.0	-1.60	-1.00	-0.40	0.4	
		Week 50	Tezepelumab	40	40 (100.0)	-1.33 (1.20)	-3.0	-2.40	-1.50	-0.60	2.6	-0.10 [-0.53, 0.33]
			Placebo	44	42 (95.5)	-1.22 (0.78)	-2.8	-1.60	-1.30	-0.60	0.2	
		Week 52	Tezepelumab	40	40 (100.0)	-1.26 (1.18)	-3.0	-1.90	-1.20	-0.60	2.6	-0.12 [-0.56, 0.31]
			Placebo	44	42 (95.5)	-1.13 (0.87)	-2.8	-1.80	-1.00	-0.60	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.07 (0.99)	2.4	2.40	2.60	4.20	4.2	
			Placebo	7	7 (100.0)	3.09 (0.30)	2.6	3.00	3.00	3.20	3.6	
		Week 2	Tezepelumab	3	3 (100.0)	2.73 (0.50)	2.2	2.20	2.80	3.20	3.2	
			Placebo	7	7 (100.0)	2.83 (0.29)	2.4	2.60	2.80	3.20	3.2	
		Week 4	Tezepelumab	3	3 (100.0)	2.60 (1.22)	1.2	1.20	3.20	3.40	3.4	
			Placebo	7	7 (100.0)	2.20 (0.93)	0.6	1.40	2.60	3.00	3.2	
		Week 6	Tezepelumab	3	3 (100.0)	2.67 (0.76)	1.8	1.80	3.00	3.20	3.2	
			Placebo	7	7 (100.0)	2.37 (1.08)	0.2	1.80	2.60	3.00	3.4	
		Week 8	Tezepelumab	3	3 (100.0)	2.53 (1.03)	1.4	1.40	2.80	3.40	3.4	
			Placebo	7	7 (100.0)	2.20 (0.97)	0.6	1.20	2.40	3.00	3.2	
		Week 10	Tezepelumab	3	3 (100.0)	2.20 (1.11)	1.0	1.00	2.40	3.20	3.2	
			Placebo	7	7 (100.0)	2.37 (0.93)	0.4	2.20	2.60	3.00	3.0	
		Week 12	Tezepelumab	3	3 (100.0)	2.40 (0.87)	1.4	1.40	2.80	3.00	3.0	
			Placebo	7	7 (100.0)	2.09 (0.81)	0.4	1.80	2.40	2.60	2.8	
		Week 14	Tezepelumab	3	3 (100.0)	2.27 (1.60)	0.6	0.60	2.40	3.80	3.8	
			Placebo	7	7 (100.0)	1.71 (0.70)	0.4	1.40	1.80	2.20	2.6	
		Week 16	Tezepelumab	3	3 (100.0)	1.80 (1.25)	0.8	0.80	1.40	3.20	3.2	
			Placebo	7	7 (100.0)	1.89 (0.76)	0.8	1.00	2.00	2.40	3.0	
		Week 18	Tezepelumab	3	3 (100.0)	2.20 (1.11)	1.2	1.20	2.00	3.40	3.4	
			Placebo	7	7 (100.0)	2.20 (0.63)	1.2	1.80	2.20	2.60	3.2	
		Week 20	Tezepelumab	3	3 (100.0)	2.27 (1.22)	1.2	1.20	2.00	3.60	3.6	
			Placebo	7	7 (100.0)	1.77 (0.68)	0.8	1.00	2.00	2.00	2.8	
		Week 22	Tezepelumab	3	3 (100.0)	2.40 (1.11)	1.2	1.20	2.60	3.40	3.4	
			Placebo	7	7 (100.0)	1.89 (0.67)	0.8	1.20	2.00	2.40	2.6	
		Week 24	Tezepelumab	3	3 (100.0)	2.53 (1.22)	1.2	1.20	2.80	3.60	3.6	
			Placebo	7	7 (100.0)	1.86 (0.67)	0.4	1.80	2.00	2.20	2.4	
		Week 26	Tezepelumab	3	3 (100.0)	2.13 (0.83)	1.2	1.20	2.40	2.80	2.8	
			Placebo	7	7 (100.0)	1.83 (0.41)	1.2	1.60	1.80	2.20	2.4	
		Week 28	Tezepelumab	3	3 (100.0)	2.40 (1.20)	1.2	1.20	2.40	3.60	3.6	
			Placebo	7	7 (100.0)	2.03 (1.02)	0.8	1.20	2.00	2.60	3.8	
		Week 30	Tezepelumab	3	3 (100.0)	2.27 (1.01)	1.2	1.20	2.40	3.20	3.2	
			Placebo	7	7 (100.0)	1.60 (0.66)	0.4	1.20	1.80	2.00	2.4	
		Week 32	Tezepelumab	3	3 (100.0)	2.07 (0.76)	1.2	1.20	2.40	2.60	2.6	
			Placebo	7	7 (100.0)	1.69 (0.53)	0.6	1.60	1.80	2.00	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Absolute values	Week 34	Tezepelumab	3	3 (100.0)	2.13 (0.83)	1.2	1.20	2.40	2.80	2.8	
			Placebo	7	7 (100.0)	1.86 (0.67)	0.8	1.20	2.00	2.60	2.6	
		Week 36	Tezepelumab	3	3 (100.0)	2.00 (0.69)	1.2	1.20	2.40	2.40	2.4	
			Placebo	7	7 (100.0)	1.77 (0.85)	0.0	1.60	2.00	2.40	2.6	
		Week 38	Tezepelumab	3	3 (100.0)	2.00 (0.72)	1.2	1.20	2.20	2.60	2.6	
			Placebo	7	7 (100.0)	1.91 (0.84)	0.6	1.40	2.00	2.60	3.2	
		Week 40	Tezepelumab	3	3 (100.0)	2.00 (0.72)	1.2	1.20	2.20	2.60	2.6	
			Placebo	7	7 (100.0)	1.80 (0.77)	0.4	1.60	1.80	2.00	3.0	
		Week 42	Tezepelumab	3	3 (100.0)	2.00 (0.72)	1.2	1.20	2.20	2.60	2.6	
			Placebo	7	7 (100.0)	2.14 (0.70)	0.8	2.00	2.00	2.80	2.8	
		Week 44	Tezepelumab	3	3 (100.0)	2.13 (0.83)	1.2	1.20	2.40	2.80	2.8	
			Placebo	7	7 (100.0)	1.89 (0.89)	0.2	1.40	2.00	2.60	2.8	
		Week 46	Tezepelumab	3	3 (100.0)	2.20 (0.92)	1.2	1.20	2.40	3.00	3.0	
			Placebo	7	7 (100.0)	1.91 (0.58)	0.8	1.60	2.00	2.20	2.6	
		Week 48	Tezepelumab	3	3 (100.0)	2.13 (0.90)	1.2	1.20	2.20	3.00	3.0	
			Placebo	7	7 (100.0)	1.80 (0.76)	0.2	1.60	2.00	2.40	2.4	
		Week 50	Tezepelumab	3	3 (100.0)	1.87 (0.58)	1.2	1.20	2.20	2.20	2.2	
			Placebo	7	7 (100.0)	1.80 (0.82)	0.0	1.80	2.00	2.40	2.4	
		Week 52	Tezepelumab	3	3 (100.0)	1.87 (0.58)	1.2	1.20	2.20	2.20	2.2	
			Placebo	7	7 (100.0)	1.80 (0.82)	0.0	1.80	2.00	2.40	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.33 (0.61)	-1.0	-1.00	-0.20	0.20	0.2	-0.17 [-1.52, 1.19]
			Placebo	7	7 (100.0)	-0.26 (0.40)	-0.8	-0.80	-0.20	0.00	0.2	
		Week 4	Tezepelumab	3	3 (100.0)	-0.47 (1.10)	-1.2	-1.20	-1.00	0.80	0.8	0.37 [-1.00, 1.73]
			Placebo	7	7 (100.0)	-0.89 (1.15)	-3.0	-1.80	-0.40	0.00	0.0	
		Week 6	Tezepelumab	3	3 (100.0)	-0.40 (0.72)	-1.0	-1.00	-0.60	0.40	0.4	0.28 [-1.08, 1.64]
			Placebo	7	7 (100.0)	-0.71 (1.25)	-3.4	-0.80	-0.40	0.00	0.4	
		Week 8	Tezepelumab	3	3 (100.0)	-0.53 (0.64)	-1.0	-1.00	-0.80	0.20	0.2	0.34 [-1.02, 1.70]
			Placebo	7	7 (100.0)	-0.89 (1.14)	-3.0	-1.80	-0.40	0.00	0.2	
		Week 10	Tezepelumab	3	3 (100.0)	-0.87 (0.61)	-1.4	-1.40	-1.00	-0.20	-0.2	-0.15 [-1.50, 1.21]
			Placebo	7	7 (100.0)	-0.71 (1.13)	-3.2	-0.80	-0.40	0.00	0.0	
		Week 12	Tezepelumab	3	3 (100.0)	-0.67 (0.95)	-1.4	-1.40	-1.00	0.40	0.4	0.33 [-1.03, 1.69]
			Placebo	7	7 (100.0)	-1.00 (1.04)	-3.2	-1.20	-0.60	-0.20	-0.2	
		Week 14	Tezepelumab	3	3 (100.0)	-0.80 (0.87)	-1.8	-1.80	-0.40	-0.20	-0.2	0.62 [-0.77, 2.00]
			Placebo	7	7 (100.0)	-1.37 (0.94)	-3.2	-1.60	-1.40	-0.40	-0.4	
		Week 16	Tezepelumab	3	3 (100.0)	-1.27 (0.31)	-1.6	-1.60	-1.20	-1.00	-1.0	-0.08 [-1.43, 1.28]
			Placebo	7	7 (100.0)	-1.20 (0.97)	-2.8	-2.00	-1.20	-0.20	0.0	
		Week 18	Tezepelumab	3	3 (100.0)	-0.87 (0.31)	-1.2	-1.20	-0.80	-0.60	-0.6	0.03 [-1.33, 1.38]
			Placebo	7	7 (100.0)	-0.89 (0.86)	-2.4	-1.20	-1.00	-0.20	0.2	
		Week 20	Tezepelumab	3	3 (100.0)	-0.80 (0.35)	-1.2	-1.20	-0.60	-0.60	-0.6	0.66 [-0.73, 2.06]
			Placebo	7	7 (100.0)	-1.31 (0.87)	-2.8	-2.00	-1.20	-0.60	-0.2	
		Week 22	Tezepelumab	3	3 (100.0)	-0.67 (0.61)	-1.2	-1.20	-0.80	0.00	0.0	0.65 [-0.74, 2.04]
			Placebo	7	7 (100.0)	-1.20 (0.88)	-2.8	-1.80	-1.20	-0.60	-0.2	
		Week 24	Tezepelumab	3	3 (100.0)	-0.53 (0.70)	-1.2	-1.20	-0.60	0.20	0.2	0.79 [-0.62, 2.19]
			Placebo	7	7 (100.0)	-1.23 (0.93)	-3.2	-1.20	-1.00	-0.80	-0.2	
		Week 26	Tezepelumab	3	3 (100.0)	-0.93 (0.64)	-1.4	-1.40	-1.20	-0.20	-0.2	0.50 [-0.88, 1.87]
			Placebo	7	7 (100.0)	-1.26 (0.65)	-2.4	-1.40	-1.40	-0.60	-0.4	
		Week 28	Tezepelumab	3	3 (100.0)	-0.67 (0.50)	-1.2	-1.20	-0.60	-0.20	-0.2	0.37 [-1.00, 1.73]
			Placebo	7	7 (100.0)	-1.06 (1.19)	-2.8	-1.80	-1.20	0.00	0.8	
		Week 30	Tezepelumab	3	3 (100.0)	-0.80 (0.53)	-1.2	-1.20	-1.00	-0.20	-0.2	0.86 [-0.55, 2.28]
			Placebo	7	7 (100.0)	-1.49 (0.86)	-3.2	-1.80	-1.20	-0.80	-0.6	
		Week 32	Tezepelumab	3	3 (100.0)	-1.00 (0.72)	-1.6	-1.60	-1.20	-0.20	-0.2	0.51 [-0.86, 1.89]
			Placebo	7	7 (100.0)	-1.40 (0.80)	-3.0	-1.60	-1.20	-1.00	-0.4	
		Week 34	Tezepelumab	3	3 (100.0)	-0.93 (0.64)	-1.4	-1.40	-1.20	-0.20	-0.2	0.35 [-1.01, 1.72]
			Placebo	7	7 (100.0)	-1.23 (0.89)	-2.8	-1.80	-1.20	-0.60	0.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Change from baseline	Week 36	Tezepelumab	3	3 (100.0)	-1.07 (0.81)	-1.8	-1.80	-1.20	-0.20	-0.2	0.24 [-1.12, 1.60]
			Placebo	7	7 (100.0)	-1.31 (1.09)	-3.6	-1.40	-1.20	-0.60	-0.2	
		Week 38	Tezepelumab	3	3 (100.0)	-1.07 (0.61)	-1.6	-1.60	-1.20	-0.40	-0.4	0.11 [-1.25, 1.46]
			Placebo	7	7 (100.0)	-1.17 (1.07)	-3.0	-1.60	-1.20	0.00	0.2	
		Week 40	Tezepelumab	3	3 (100.0)	-1.07 (0.61)	-1.6	-1.60	-1.20	-0.40	-0.4	0.23 [-1.13, 1.59]
			Placebo	7	7 (100.0)	-1.29 (1.04)	-3.2	-1.40	-1.20	-1.20	0.4	
		Week 42	Tezepelumab	3	3 (100.0)	-1.07 (0.61)	-1.6	-1.60	-1.20	-0.40	-0.4	-0.14 [-1.49, 1.21]
			Placebo	7	7 (100.0)	-0.94 (0.96)	-2.8	-1.20	-1.00	-0.20	0.0	
		Week 44	Tezepelumab	3	3 (100.0)	-0.93 (0.64)	-1.4	-1.40	-1.20	-0.20	-0.2	0.26 [-1.10, 1.62]
			Placebo	7	7 (100.0)	-1.20 (1.11)	-3.4	-1.60	-1.20	-0.40	0.0	
		Week 46	Tezepelumab	3	3 (100.0)	-0.87 (0.58)	-1.2	-1.20	-1.20	-0.20	-0.2	0.39 [-0.98, 1.75]
			Placebo	7	7 (100.0)	-1.17 (0.84)	-2.8	-1.40	-1.00	-0.80	0.0	
		Week 48	Tezepelumab	3	3 (100.0)	-0.93 (0.46)	-1.2	-1.20	-1.20	-0.40	-0.4	0.39 [-0.97, 1.76]
			Placebo	7	7 (100.0)	-1.29 (1.01)	-3.4	-1.40	-1.00	-0.80	-0.2	
		Week 50	Tezepelumab	3	3 (100.0)	-1.20 (0.80)	-2.0	-2.00	-1.20	-0.40	-0.4	0.08 [-1.27, 1.44]
			Placebo	7	7 (100.0)	-1.29 (1.09)	-3.6	-1.40	-1.00	-0.60	-0.2	
		Week 52	Tezepelumab	3	3 (100.0)	-1.20 (0.80)	-2.0	-2.00	-1.20	-0.40	-0.4	0.08 [-1.27, 1.44]
			Placebo	7	7 (100.0)	-1.29 (1.09)	-3.6	-1.40	-1.00	-0.60	-0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.73 (0.45)	2.2	2.40	2.80	3.00	3.4	
			Placebo	13	13 (100.0)	2.75 (0.91)	0.4	2.80	3.00	3.00	4.0	
		Week 2	Tezepelumab	9	9 (100.0)	2.31 (0.69)	1.0	2.00	2.60	2.80	3.2	
			Placebo	13	11 (84.6)	2.56 (0.54)	1.4	2.20	2.60	3.00	3.2	
		Week 4	Tezepelumab	9	9 (100.0)	1.76 (0.89)	0.2	1.20	1.80	2.40	3.0	
			Placebo	13	11 (84.6)	2.80 (0.72)	2.0	2.20	2.60	3.40	4.2	
		Week 6	Tezepelumab	9	9 (100.0)	1.40 (0.63)	0.6	1.00	1.40	1.80	2.6	
			Placebo	13	11 (84.6)	2.91 (0.61)	1.8	2.80	3.00	3.20	4.0	
		Week 8	Tezepelumab	9	9 (100.0)	1.29 (0.84)	0.0	1.00	1.60	1.60	2.6	
			Placebo	13	12 (92.3)	2.62 (0.74)	1.2	2.30	2.40	3.00	4.0	
		Week 10	Tezepelumab	9	9 (100.0)	1.00 (0.78)	0.0	0.60	0.80	1.40	2.4	
			Placebo	13	12 (92.3)	2.52 (0.73)	1.0	2.10	2.50	3.00	4.0	
		Week 12	Tezepelumab	9	9 (100.0)	0.93 (0.82)	0.0	0.00	1.00	1.60	2.2	
			Placebo	13	12 (92.3)	2.73 (0.66)	2.0	2.30	2.70	3.00	4.4	
		Week 14	Tezepelumab	9	9 (100.0)	0.96 (0.63)	0.0	0.60	1.40	1.40	1.6	
			Placebo	13	12 (92.3)	2.23 (0.50)	1.4	2.00	2.20	2.50	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	0.96 (0.51)	0.0	0.60	1.20	1.40	1.4	
			Placebo	13	12 (92.3)	2.60 (0.90)	1.0	2.10	2.70	3.00	4.0	
		Week 18	Tezepelumab	9	9 (100.0)	1.18 (0.60)	0.0	1.00	1.20	1.60	2.0	
			Placebo	13	12 (92.3)	2.58 (0.54)	1.8	2.40	2.60	2.70	4.0	
		Week 20	Tezepelumab	9	9 (100.0)	1.18 (0.76)	0.0	0.80	1.20	1.40	2.8	
			Placebo	13	12 (92.3)	2.50 (0.84)	1.0	2.00	2.60	2.80	4.0	
		Week 22	Tezepelumab	9	9 (100.0)	1.31 (0.94)	0.0	1.00	1.40	1.60	2.8	
			Placebo	13	12 (92.3)	2.53 (0.96)	0.8	1.90	2.60	3.30	4.0	
		Week 24	Tezepelumab	9	9 (100.0)	1.18 (0.77)	0.0	0.80	1.20	1.40	2.8	
			Placebo	13	12 (92.3)	2.62 (0.78)	1.4	2.00	2.50	3.30	4.0	
		Week 26	Tezepelumab	9	9 (100.0)	1.36 (0.69)	0.0	1.00	1.40	1.80	2.4	
			Placebo	13	12 (92.3)	2.57 (0.95)	1.2	1.80	2.40	3.30	4.0	
		Week 28	Tezepelumab	9	9 (100.0)	1.62 (0.94)	0.0	1.00	1.40	2.40	3.0	
			Placebo	13	13 (100.0)	2.35 (1.16)	0.0	1.80	2.60	3.20	4.0	
		Week 30	Tezepelumab	9	9 (100.0)	1.31 (0.74)	0.0	0.80	1.40	1.60	2.4	
			Placebo	13	13 (100.0)	2.31 (1.17)	0.0	1.80	2.40	3.20	4.0	
		Week 32	Tezepelumab	9	9 (100.0)	1.22 (0.76)	0.0	0.80	1.20	1.80	2.2	
			Placebo	13	13 (100.0)	2.43 (1.33)	0.0	1.60	2.40	3.20	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.36 (1.10)	0.0	0.80	1.20	2.40	3.0	
			Placebo	13	13 (100.0)	2.32 (1.33)	0.2	1.40	2.20	3.20	4.8	
		Week 36	Tezepelumab	9	9 (100.0)	1.44 (0.84)	0.0	1.00	1.20	2.20	2.8	
			Placebo	13	13 (100.0)	2.49 (1.38)	0.0	1.80	2.40	3.20	4.8	
		Week 38	Tezepelumab	9	9 (100.0)	1.47 (1.06)	0.0	0.60	1.40	2.20	3.0	
			Placebo	13	13 (100.0)	2.34 (1.34)	0.0	1.60	2.60	3.20	4.8	
		Week 40	Tezepelumab	9	9 (100.0)	1.22 (0.94)	0.0	0.80	1.20	1.80	2.6	
			Placebo	13	13 (100.0)	2.43 (1.20)	0.0	1.80	2.60	3.00	4.4	
		Week 42	Tezepelumab	9	9 (100.0)	1.29 (0.81)	0.0	1.00	1.20	1.40	2.6	
			Placebo	13	13 (100.0)	2.34 (1.24)	0.0	2.00	2.40	2.80	4.6	
		Week 44	Tezepelumab	9	9 (100.0)	1.42 (0.92)	0.0	1.00	1.40	1.60	3.0	
			Placebo	13	13 (100.0)	2.29 (1.13)	0.0	1.60	2.40	2.60	4.2	
		Week 46	Tezepelumab	9	9 (100.0)	1.49 (1.03)	0.0	1.00	1.20	1.80	3.2	
			Placebo	13	13 (100.0)	2.23 (0.98)	0.0	2.00	2.40	2.60	4.0	
		Week 48	Tezepelumab	9	9 (100.0)	1.42 (0.95)	0.0	0.80	1.20	2.00	3.0	
			Placebo	13	13 (100.0)	2.28 (1.11)	0.0	2.00	2.40	2.60	4.0	
		Week 50	Tezepelumab	9	9 (100.0)	1.13 (0.75)	0.0	0.80	1.00	1.40	2.6	
			Placebo	13	13 (100.0)	2.22 (1.05)	0.0	2.00	2.40	2.60	4.0	
		Week 52	Tezepelumab	9	9 (100.0)	1.13 (0.75)	0.0	0.80	1.00	1.40	2.6	
			Placebo	13	13 (100.0)	2.32 (1.13)	0.0	2.00	2.40	2.80	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.42 (0.39)	-1.4	-0.40	-0.20	-0.20	-0.2	-0.13 [-1.01, 0.75]
			Placebo	13	11 (84.6)	-0.35 (0.69)	-1.6	-0.80	-0.40	0.00	1.0	
		Week 4	Tezepelumab	9	9 (100.0)	-0.98 (0.70)	-2.2	-1.20	-1.00	-0.40	0.0	-1.13 [-2.08, -0.17]
			Placebo	13	11 (84.6)	-0.11 (0.83)	-1.4	-1.00	0.00	0.60	1.2	
		Week 6	Tezepelumab	9	9 (100.0)	-1.33 (0.66)	-2.4	-1.80	-1.40	-0.80	-0.2	-1.85 [-2.92, -0.78]
			Placebo	13	11 (84.6)	0.00 (0.76)	-0.8	-0.80	-0.20	0.40	1.6	
		Week 8	Tezepelumab	9	9 (100.0)	-1.44 (0.66)	-2.4	-1.60	-1.40	-1.40	-0.2	-1.34 [-2.30, -0.38]
			Placebo	13	12 (92.3)	-0.33 (0.93)	-1.8	-1.00	-0.40	0.40	1.0	
		Week 10	Tezepelumab	9	9 (100.0)	-1.73 (0.62)	-2.4	-2.20	-2.00	-1.40	-0.8	-1.36 [-2.33, -0.40]
			Placebo	13	12 (92.3)	-0.43 (1.14)	-2.0	-1.00	-0.40	-0.10	2.6	
		Week 12	Tezepelumab	9	9 (100.0)	-1.80 (0.60)	-2.4	-2.20	-2.00	-1.40	-0.8	-1.95 [-3.01, -0.89]
			Placebo	13	12 (92.3)	-0.22 (0.94)	-1.6	-0.80	-0.40	0.10	1.6	
		Week 14	Tezepelumab	9	9 (100.0)	-1.78 (0.49)	-2.4	-2.20	-1.80	-1.60	-0.8	-1.48 [-2.46, -0.49]
			Placebo	13	12 (92.3)	-0.72 (0.85)	-1.6	-1.30	-0.90	-0.50	1.4	
		Week 16	Tezepelumab	9	9 (100.0)	-1.78 (0.48)	-2.4	-2.20	-1.80	-1.60	-0.8	-1.44 [-2.42, -0.46]
			Placebo	13	12 (92.3)	-0.35 (1.24)	-2.0	-1.30	-0.40	0.00	2.6	
		Week 18	Tezepelumab	9	9 (100.0)	-1.56 (0.71)	-2.4	-1.80	-1.60	-1.40	-0.2	-1.31 [-2.27, -0.35]
			Placebo	13	12 (92.3)	-0.37 (1.03)	-1.4	-1.00	-0.50	-0.20	2.6	
		Week 20	Tezepelumab	9	9 (100.0)	-1.56 (0.66)	-2.4	-2.20	-1.60	-1.40	-0.4	-1.10 [-2.04, -0.17]
			Placebo	13	12 (92.3)	-0.45 (1.19)	-2.0	-1.30	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	9	9 (100.0)	-1.42 (0.86)	-2.4	-2.40	-1.60	-0.80	-0.2	-0.89 [-1.80, 0.02]
			Placebo	13	12 (92.3)	-0.42 (1.29)	-2.2	-1.30	-0.50	0.30	2.6	
		Week 24	Tezepelumab	9	9 (100.0)	-1.56 (0.70)	-2.4	-1.80	-1.60	-1.60	-0.2	-1.22 [-2.16, -0.27]
			Placebo	13	12 (92.3)	-0.33 (1.18)	-1.6	-1.20	-0.50	0.30	2.6	
		Week 26	Tezepelumab	9	9 (100.0)	-1.38 (0.75)	-2.4	-1.60	-1.40	-0.80	-0.2	-0.91 [-1.82, -0.00]
			Placebo	13	12 (92.3)	-0.38 (1.28)	-1.8	-1.40	-0.80	0.30	2.6	
		Week 28	Tezepelumab	9	9 (100.0)	-1.11 (0.93)	-2.4	-1.60	-0.80	-0.80	0.2	-0.63 [-1.50, 0.24]
			Placebo	13	13 (100.0)	-0.40 (1.24)	-2.0	-1.20	-0.40	0.20	2.6	
		Week 30	Tezepelumab	9	9 (100.0)	-1.42 (0.71)	-2.6	-1.60	-1.40	-0.80	-0.6	-0.92 [-1.82, -0.02]
			Placebo	13	13 (100.0)	-0.45 (1.24)	-1.8	-1.20	-0.80	0.20	2.6	
		Week 32	Tezepelumab	9	9 (100.0)	-1.51 (0.62)	-2.4	-1.80	-1.60	-1.00	-0.8	-1.05 [-1.96, -0.14]
			Placebo	13	13 (100.0)	-0.32 (1.37)	-1.8	-1.40	-0.40	0.20	2.6	
		Week 34	Tezepelumab	9	9 (100.0)	-1.38 (0.92)	-2.6	-2.20	-1.60	-0.60	0.0	-0.74 [-1.63, 0.14]
			Placebo	13	13 (100.0)	-0.43 (1.46)	-2.2	-1.40	-0.80	0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.29 (0.90)	-2.4	-2.00	-1.40	-0.80	0.0	-0.83 [-1.71, 0.06]
			Placebo	13	13 (100.0)	-0.26 (1.43)	-2.2	-1.20	-0.40	0.20	2.6	
		Week 38	Tezepelumab	9	9 (100.0)	-1.27 (0.77)	-2.4	-1.80	-1.40	-0.80	0.0	-0.71 [-1.58, 0.17]
			Placebo	13	13 (100.0)	-0.42 (1.42)	-2.6	-1.40	-0.40	0.20	2.6	
		Week 40	Tezepelumab	9	9 (100.0)	-1.51 (0.79)	-2.6	-2.20	-1.60	-0.80	-0.4	-1.08 [-1.99, -0.16]
			Placebo	13	13 (100.0)	-0.32 (1.27)	-2.0	-1.20	-0.60	0.20	2.6	
		Week 42	Tezepelumab	9	9 (100.0)	-1.44 (0.73)	-2.4	-1.80	-1.60	-0.80	-0.4	-0.91 [-1.80, -0.01]
			Placebo	13	13 (100.0)	-0.42 (1.34)	-2.4	-1.40	-0.60	0.00	2.6	
		Week 44	Tezepelumab	9	9 (100.0)	-1.31 (0.91)	-2.8	-1.60	-1.40	-0.80	0.0	-0.76 [-1.64, 0.12]
			Placebo	13	13 (100.0)	-0.46 (1.23)	-1.8	-1.20	-0.80	0.00	2.6	
		Week 46	Tezepelumab	9	9 (100.0)	-1.24 (0.92)	-2.4	-1.60	-1.40	-0.80	0.2	-0.70 [-1.57, 0.18]
			Placebo	13	13 (100.0)	-0.52 (1.11)	-1.8	-1.20	-1.00	0.00	2.6	
		Week 48	Tezepelumab	9	9 (100.0)	-1.31 (0.99)	-2.4	-2.40	-1.60	-0.40	0.0	-0.74 [-1.62, 0.14]
			Placebo	13	13 (100.0)	-0.48 (1.21)	-2.0	-1.20	-0.60	-0.20	2.6	
		Week 50	Tezepelumab	9	9 (100.0)	-1.60 (0.75)	-2.6	-2.40	-1.60	-1.20	-0.4	-1.03 [-1.94, -0.12]
			Placebo	13	13 (100.0)	-0.54 (1.18)	-2.0	-1.40	-0.60	-0.20	2.6	
		Week 52	Tezepelumab	9	9 (100.0)	-1.60 (0.75)	-2.6	-2.40	-1.60	-1.20	-0.4	-1.11 [-2.02, -0.19]
			Placebo	13	13 (100.0)	-0.43 (1.22)	-2.0	-1.20	-0.60	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.89 (0.93)	0.0	2.40	2.80	3.20	5.2	
			Placebo	52	52 (100.0)	2.89 (0.73)	1.0	2.60	2.80	3.20	5.0	
		Week 2	Tezepelumab	57	54 (94.7)	2.35 (1.07)	0.0	1.60	2.60	3.20	4.4	
			Placebo	52	47 (90.4)	2.36 (0.85)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	57	54 (94.7)	2.13 (1.02)	0.2	1.40	2.30	3.00	3.6	
			Placebo	52	47 (90.4)	2.12 (0.92)	0.2	1.40	2.40	2.80	3.6	
		Week 6	Tezepelumab	57	54 (94.7)	2.07 (1.07)	0.0	1.20	2.20	3.00	4.0	
			Placebo	52	47 (90.4)	2.05 (1.20)	0.2	1.20	2.20	2.60	6.0	
		Week 8	Tezepelumab	57	54 (94.7)	1.90 (1.21)	0.0	1.00	1.80	2.80	5.2	
			Placebo	52	47 (90.4)	2.00 (1.19)	0.0	0.80	2.00	3.00	5.0	
		Week 10	Tezepelumab	57	54 (94.7)	1.84 (1.15)	0.0	1.00	1.80	2.80	4.8	
			Placebo	52	47 (90.4)	2.06 (1.14)	0.0	1.00	2.20	2.80	5.2	
		Week 12	Tezepelumab	57	54 (94.7)	1.73 (1.11)	0.0	0.60	1.90	2.60	4.8	
			Placebo	52	47 (90.4)	1.74 (1.05)	0.0	1.00	1.80	2.60	4.4	
		Week 14	Tezepelumab	57	54 (94.7)	1.66 (1.16)	0.0	0.60	1.60	2.40	4.8	
			Placebo	52	47 (90.4)	1.78 (1.08)	0.0	1.00	1.80	2.40	5.0	
		Week 16	Tezepelumab	57	54 (94.7)	1.83 (1.22)	0.0	0.80	1.90	2.80	4.8	
			Placebo	52	47 (90.4)	1.89 (1.24)	0.0	0.80	2.00	2.80	5.0	
		Week 18	Tezepelumab	57	55 (96.5)	1.75 (1.13)	0.0	0.80	2.00	2.60	4.8	
			Placebo	52	47 (90.4)	1.77 (1.24)	0.0	0.80	1.80	2.60	5.0	
		Week 20	Tezepelumab	57	55 (96.5)	1.76 (1.18)	0.0	0.60	1.80	2.60	5.0	
			Placebo	52	47 (90.4)	1.91 (1.15)	0.0	1.00	2.00	2.80	5.0	
		Week 22	Tezepelumab	57	55 (96.5)	1.85 (1.03)	0.0	1.00	2.00	2.60	4.8	
			Placebo	52	47 (90.4)	1.84 (1.17)	0.0	0.80	1.80	2.60	5.0	
		Week 24	Tezepelumab	57	55 (96.5)	1.83 (1.13)	0.0	1.00	2.00	2.60	4.8	
			Placebo	52	47 (90.4)	1.90 (1.08)	0.0	1.00	2.00	2.60	4.4	
		Week 26	Tezepelumab	57	56 (98.2)	1.86 (1.17)	0.0	0.90	1.90	2.80	4.8	
			Placebo	52	47 (90.4)	1.83 (1.14)	0.0	1.00	1.60	2.80	4.4	
		Week 28	Tezepelumab	57	57 (100.0)	1.75 (1.20)	0.0	0.80	1.80	2.60	4.8	
			Placebo	52	47 (90.4)	1.85 (1.23)	0.0	0.80	1.80	2.80	4.4	
		Week 30	Tezepelumab	57	57 (100.0)	1.76 (1.14)	0.0	1.00	1.80	2.60	4.8	
			Placebo	52	47 (90.4)	1.83 (1.17)	0.0	0.80	2.00	2.80	4.4	
		Week 32	Tezepelumab	57	57 (100.0)	1.69 (1.16)	0.0	0.80	1.80	2.60	4.8	
			Placebo	52	47 (90.4)	1.76 (1.05)	0.0	0.80	1.80	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	57	57 (100.0)	1.76 (1.20)	0.0	0.80	1.80	2.80	4.8	
			Placebo	52	47 (90.4)	1.75 (1.06)	0.0	0.80	1.80	2.40	4.4	
		Week 36	Tezepelumab	57	57 (100.0)	1.70 (1.15)	0.0	0.80	1.60	2.60	4.8	
			Placebo	52	47 (90.4)	1.93 (1.12)	0.0	1.00	2.00	2.80	4.4	
		Week 38	Tezepelumab	57	57 (100.0)	1.75 (1.26)	0.0	0.80	1.80	2.60	4.8	
			Placebo	52	47 (90.4)	1.81 (1.05)	0.0	1.00	1.80	2.60	4.4	
		Week 40	Tezepelumab	57	57 (100.0)	1.77 (1.21)	0.0	0.80	2.00	2.80	4.8	
			Placebo	52	47 (90.4)	1.96 (1.18)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	57	57 (100.0)	1.70 (1.19)	0.0	0.80	1.80	2.60	4.8	
			Placebo	52	47 (90.4)	1.81 (0.99)	0.0	1.00	2.00	2.40	4.4	
		Week 44	Tezepelumab	57	57 (100.0)	1.72 (1.17)	0.0	0.80	1.80	2.80	4.8	
			Placebo	52	47 (90.4)	1.93 (1.11)	0.0	1.00	1.80	2.80	4.4	
		Week 46	Tezepelumab	57	57 (100.0)	1.74 (1.22)	0.0	0.80	2.00	2.60	4.8	
			Placebo	52	47 (90.4)	1.79 (1.01)	0.0	1.00	1.80	2.20	4.4	
		Week 48	Tezepelumab	57	57 (100.0)	1.76 (1.22)	0.0	0.80	1.80	2.60	4.8	
			Placebo	52	47 (90.4)	1.85 (1.09)	0.0	1.00	2.00	2.60	4.6	
		Week 50	Tezepelumab	57	57 (100.0)	1.73 (1.24)	0.0	0.80	1.80	2.60	4.8	
			Placebo	52	47 (90.4)	1.71 (1.00)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	57	57 (100.0)	1.76 (1.22)	0.0	0.80	1.80	2.60	4.8	
			Placebo	52	47 (90.4)	1.77 (1.06)	0.0	1.00	1.80	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	57	54 (94.7)	-0.59 (0.84)	-3.2	-1.20	-0.50	0.20	0.8	-0.06 [-0.45, 0.33]
			Placebo	52	47 (90.4)	-0.54 (0.73)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	57	54 (94.7)	-0.80 (0.96)	-2.6	-1.40	-0.80	-0.20	2.6	-0.03 [-0.42, 0.36]
			Placebo	52	47 (90.4)	-0.77 (0.96)	-3.0	-1.40	-0.80	0.00	0.8	
		Week 6	Tezepelumab	57	54 (94.7)	-0.87 (1.06)	-2.8	-1.60	-1.00	0.00	2.6	-0.02 [-0.41, 0.37]
			Placebo	52	47 (90.4)	-0.85 (1.05)	-3.4	-1.60	-0.60	0.00	1.6	
		Week 8	Tezepelumab	57	54 (94.7)	-1.03 (1.21)	-3.2	-1.80	-1.00	-0.40	2.6	-0.12 [-0.51, 0.27]
			Placebo	52	47 (90.4)	-0.89 (1.07)	-3.6	-1.60	-0.60	0.00	1.0	
		Week 10	Tezepelumab	57	54 (94.7)	-1.09 (1.16)	-3.4	-1.80	-1.20	-0.20	2.6	-0.22 [-0.61, 0.17]
			Placebo	52	47 (90.4)	-0.84 (1.16)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	57	54 (94.7)	-1.21 (1.15)	-3.2	-2.20	-1.20	-0.60	2.6	-0.05 [-0.44, 0.35]
			Placebo	52	47 (90.4)	-1.16 (1.04)	-3.8	-2.00	-1.00	-0.40	1.2	
		Week 14	Tezepelumab	57	54 (94.7)	-1.28 (1.17)	-4.0	-2.20	-1.20	-0.60	2.6	-0.14 [-0.53, 0.25]
			Placebo	52	47 (90.4)	-1.12 (1.12)	-3.4	-1.60	-1.40	-0.40	2.4	
		Week 16	Tezepelumab	57	54 (94.7)	-1.10 (1.20)	-3.2	-2.20	-1.00	-0.40	2.6	-0.08 [-0.47, 0.31]
			Placebo	52	47 (90.4)	-1.01 (1.14)	-3.6	-1.60	-1.00	-0.20	2.4	
		Week 18	Tezepelumab	57	55 (96.5)	-1.16 (1.14)	-3.8	-2.00	-1.00	-0.60	2.6	-0.03 [-0.42, 0.36]
			Placebo	52	47 (90.4)	-1.13 (1.24)	-3.6	-2.20	-1.20	-0.20	2.4	
		Week 20	Tezepelumab	57	55 (96.5)	-1.16 (1.15)	-3.4	-2.20	-1.00	-0.40	2.6	-0.15 [-0.54, 0.24]
			Placebo	52	47 (90.4)	-0.98 (1.17)	-3.6	-1.60	-0.80	-0.20	2.4	
		Week 22	Tezepelumab	57	55 (96.5)	-1.07 (1.17)	-3.2	-1.80	-1.00	-0.60	2.6	-0.01 [-0.40, 0.38]
			Placebo	52	47 (90.4)	-1.06 (1.13)	-3.8	-1.60	-1.00	-0.40	2.4	
		Week 24	Tezepelumab	57	55 (96.5)	-1.08 (1.13)	-3.4	-2.00	-1.00	-0.40	2.6	-0.08 [-0.47, 0.31]
			Placebo	52	47 (90.4)	-1.00 (1.09)	-3.6	-1.80	-1.00	-0.20	1.4	
		Week 26	Tezepelumab	57	56 (98.2)	-1.04 (1.18)	-3.0	-2.20	-1.00	-0.20	2.6	0.03 [-0.36, 0.42]
			Placebo	52	47 (90.4)	-1.07 (1.15)	-3.4	-2.00	-1.20	0.00	1.6	
		Week 28	Tezepelumab	57	57 (100.0)	-1.14 (1.25)	-3.4	-2.20	-1.20	-0.20	2.6	-0.08 [-0.46, 0.31]
			Placebo	52	47 (90.4)	-1.05 (1.20)	-3.4	-2.00	-1.20	-0.20	1.6	
		Week 30	Tezepelumab	57	57 (100.0)	-1.13 (1.24)	-3.8	-2.20	-1.20	-0.40	2.6	-0.05 [-0.44, 0.33]
			Placebo	52	47 (90.4)	-1.06 (1.21)	-3.4	-1.60	-1.20	-0.20	2.0	
		Week 32	Tezepelumab	57	57 (100.0)	-1.20 (1.16)	-3.2	-2.20	-1.20	-0.40	2.6	-0.05 [-0.44, 0.34]
			Placebo	52	47 (90.4)	-1.14 (1.06)	-3.2	-1.80	-1.40	-0.40	1.4	
		Week 34	Tezepelumab	57	57 (100.0)	-1.13 (1.25)	-3.0	-2.20	-1.40	-0.20	2.6	0.02 [-0.37, 0.40]
			Placebo	52	47 (90.4)	-1.14 (1.02)	-3.2	-1.80	-1.20	-0.40	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	57	57 (100.0)	-1.19 (1.22)	-3.2	-2.20	-1.20	-0.20	2.6	-0.19 [-0.58, 0.20]
			Placebo	52	47 (90.4)	-0.97 (1.13)	-3.6	-1.60	-1.00	-0.20	1.4	
		Week 38	Tezepelumab	57	57 (100.0)	-1.14 (1.29)	-3.2	-2.20	-1.20	-0.20	2.6	-0.04 [-0.43, 0.35]
			Placebo	52	47 (90.4)	-1.09 (1.03)	-3.2	-2.00	-1.00	-0.40	1.4	
		Week 40	Tezepelumab	57	57 (100.0)	-1.12 (1.26)	-3.4	-2.20	-1.20	-0.40	2.6	-0.15 [-0.54, 0.24]
			Placebo	52	47 (90.4)	-0.94 (1.18)	-3.2	-2.00	-1.00	-0.20	1.4	
		Week 42	Tezepelumab	57	57 (100.0)	-1.19 (1.27)	-3.6	-2.20	-1.20	-0.40	2.6	-0.09 [-0.48, 0.30]
			Placebo	52	47 (90.4)	-1.09 (1.00)	-2.8	-1.60	-1.00	-0.40	1.4	
		Week 44	Tezepelumab	57	57 (100.0)	-1.17 (1.25)	-3.8	-2.20	-1.20	-0.40	2.6	-0.17 [-0.56, 0.22]
			Placebo	52	47 (90.4)	-0.97 (1.12)	-3.4	-1.80	-1.00	-0.20	1.6	
		Week 46	Tezepelumab	57	57 (100.0)	-1.15 (1.25)	-3.6	-2.20	-1.20	-0.20	2.6	-0.03 [-0.42, 0.35]
			Placebo	52	47 (90.4)	-1.11 (1.02)	-3.2	-1.60	-1.20	-0.60	1.6	
		Week 48	Tezepelumab	57	57 (100.0)	-1.13 (1.23)	-3.0	-2.20	-1.00	-0.40	2.6	-0.07 [-0.46, 0.31]
			Placebo	52	47 (90.4)	-1.05 (1.09)	-3.4	-1.60	-1.00	-0.40	1.8	
		Week 50	Tezepelumab	57	57 (100.0)	-1.16 (1.27)	-3.2	-2.20	-1.20	-0.20	2.6	0.02 [-0.37, 0.40]
			Placebo	52	47 (90.4)	-1.18 (0.99)	-3.6	-1.80	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	57	57 (100.0)	-1.13 (1.25)	-3.2	-2.20	-1.20	-0.20	2.6	-0.00 [-0.39, 0.38]
			Placebo	52	47 (90.4)	-1.12 (1.04)	-3.6	-1.80	-1.00	-0.40	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	3.09 (0.87)	2.0	2.40	3.00	3.80	4.6	
			Placebo	3	3 (100.0)	2.93 (0.12)	2.8	2.80	3.00	3.00	3.0	
		Week 2	Tezepelumab	7	7 (100.0)	2.69 (1.05)	1.0	1.60	3.00	3.40	4.0	
			Placebo	3	3 (100.0)	2.40 (0.60)	1.8	1.80	2.40	3.00	3.0	
		Week 4	Tezepelumab	7	7 (100.0)	1.66 (1.03)	0.2	0.80	2.20	2.60	2.8	
			Placebo	3	3 (100.0)	3.20 (1.25)	1.8	1.80	3.60	4.20	4.2	
		Week 6	Tezepelumab	7	7 (100.0)	1.69 (0.78)	1.0	1.20	1.40	2.60	3.0	
			Placebo	3	3 (100.0)	2.80 (1.44)	1.2	1.20	3.20	4.00	4.0	
		Week 8	Tezepelumab	7	7 (100.0)	1.40 (0.72)	0.6	1.00	1.20	1.80	2.8	
			Placebo	3	3 (100.0)	2.93 (0.83)	2.0	2.00	3.20	3.60	3.6	
		Week 10	Tezepelumab	7	7 (100.0)	1.37 (0.93)	0.4	0.80	1.20	1.80	3.2	
			Placebo	3	3 (100.0)	2.20 (0.72)	1.6	1.60	2.00	3.00	3.0	
		Week 12	Tezepelumab	7	7 (100.0)	1.23 (0.91)	0.0	0.60	1.20	1.80	2.8	
			Placebo	3	3 (100.0)	3.20 (1.20)	2.0	2.00	3.20	4.40	4.4	
		Week 14	Tezepelumab	7	7 (100.0)	1.20 (0.63)	0.4	0.60	1.40	1.60	2.2	
			Placebo	3	3 (100.0)	2.00 (1.06)	1.2	1.20	1.60	3.20	3.2	
		Week 16	Tezepelumab	7	7 (100.0)	1.54 (0.75)	0.6	0.80	1.80	2.20	2.6	
			Placebo	3	3 (100.0)	3.07 (1.01)	2.0	2.00	3.20	4.00	4.0	
		Week 18	Tezepelumab	7	7 (100.0)	1.23 (0.71)	0.4	0.60	1.00	2.00	2.2	
			Placebo	3	3 (100.0)	2.27 (0.76)	1.4	1.40	2.60	2.80	2.8	
		Week 20	Tezepelumab	7	7 (100.0)	1.29 (0.60)	0.4	0.80	1.20	1.80	2.0	
			Placebo	3	3 (100.0)	2.87 (0.70)	2.2	2.20	2.80	3.60	3.6	
		Week 22	Tezepelumab	7	7 (100.0)	1.49 (0.86)	0.0	0.60	1.80	2.20	2.2	
			Placebo	3	3 (100.0)	2.67 (0.90)	1.8	1.80	2.60	3.60	3.6	
		Week 24	Tezepelumab	7	7 (100.0)	1.49 (0.79)	0.4	0.80	1.60	2.00	2.8	
			Placebo	3	3 (100.0)	3.07 (0.31)	2.8	2.80	3.00	3.40	3.4	
		Week 26	Tezepelumab	7	7 (100.0)	1.54 (0.71)	0.8	1.00	1.40	2.40	2.6	
			Placebo	3	3 (100.0)	2.87 (1.14)	1.6	1.60	3.20	3.80	3.8	
		Week 28	Tezepelumab	7	7 (100.0)	1.51 (0.68)	0.4	1.00	1.80	2.00	2.4	
			Placebo	3	3 (100.0)	3.07 (0.64)	2.6	2.60	2.80	3.80	3.8	
		Week 30	Tezepelumab	7	7 (100.0)	1.37 (0.55)	0.8	0.80	1.20	2.00	2.0	
			Placebo	3	3 (100.0)	2.93 (0.92)	2.4	2.40	2.40	4.00	4.0	
		Week 32	Tezepelumab	7	7 (100.0)	1.43 (0.76)	0.6	0.80	1.20	1.80	2.8	
			Placebo	3	3 (100.0)	2.80 (1.00)	1.8	1.80	2.80	3.80	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	7	7 (100.0)	1.34 (0.56)	0.8	0.80	1.20	2.00	2.2	
			Placebo	3	3 (100.0)	2.67 (0.81)	2.2	2.20	2.20	3.60	3.6	
		Week 36	Tezepelumab	7	7 (100.0)	1.23 (0.41)	0.6	1.00	1.20	1.60	1.8	
			Placebo	3	3 (100.0)	3.13 (1.14)	2.2	2.20	2.80	4.40	4.4	
		Week 38	Tezepelumab	7	7 (100.0)	1.46 (0.77)	0.6	0.60	1.40	2.40	2.4	
			Placebo	3	3 (100.0)	2.53 (0.70)	1.8	1.80	2.60	3.20	3.2	
		Week 40	Tezepelumab	7	7 (100.0)	1.49 (0.75)	0.4	0.80	1.80	2.00	2.4	
			Placebo	3	3 (100.0)	3.47 (0.81)	3.0	3.00	3.00	4.40	4.4	
		Week 42	Tezepelumab	7	7 (100.0)	1.37 (0.47)	1.0	1.00	1.00	1.80	2.0	
			Placebo	3	3 (100.0)	2.93 (1.45)	2.0	2.00	2.20	4.60	4.6	
		Week 44	Tezepelumab	7	7 (100.0)	1.34 (0.73)	0.4	0.80	1.00	2.00	2.4	
			Placebo	3	3 (100.0)	3.07 (1.03)	2.2	2.20	2.80	4.20	4.2	
		Week 46	Tezepelumab	7	7 (100.0)	1.31 (0.60)	0.6	0.80	1.00	2.00	2.0	
			Placebo	3	3 (100.0)	2.40 (0.53)	2.0	2.00	2.20	3.00	3.0	
		Week 48	Tezepelumab	7	7 (100.0)	1.43 (0.44)	0.8	1.20	1.20	1.80	2.0	
			Placebo	3	3 (100.0)	2.93 (0.92)	2.4	2.40	2.40	4.00	4.0	
		Week 50	Tezepelumab	7	7 (100.0)	1.74 (0.61)	1.0	1.20	1.80	2.00	2.8	
			Placebo	3	3 (100.0)	2.60 (0.69)	2.2	2.20	2.20	3.40	3.4	
		Week 52	Tezepelumab	7	7 (100.0)	1.74 (0.61)	1.0	1.20	1.80	2.00	2.8	
			Placebo	3	3 (100.0)	3.07 (0.83)	2.4	2.40	2.80	4.00	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	7	7 (100.0)	-0.40 (0.67)	-1.4	-1.20	-0.40	0.20	0.2	0.21 [-1.15, 1.57]
			Placebo	3	3 (100.0)	-0.53 (0.50)	-1.0	-1.00	-0.60	0.00	0.0	
		Week 4	Tezepelumab	7	7 (100.0)	-1.43 (0.80)	-2.4	-2.20	-1.60	-0.80	-0.2	-1.90 [-3.54, -0.26]
			Placebo	3	3 (100.0)	0.27 (1.14)	-1.0	-1.00	0.60	1.20	1.2	
		Week 6	Tezepelumab	7	7 (100.0)	-1.40 (0.89)	-2.6	-2.00	-1.60	-0.80	0.2	-1.24 [-2.72, 0.24]
			Placebo	3	3 (100.0)	-0.13 (1.33)	-1.6	-1.60	0.20	1.00	1.0	
		Week 8	Tezepelumab	7	7 (100.0)	-1.69 (1.08)	-3.2	-2.80	-1.60	-1.00	0.0	-1.69 [-3.27, -0.10]
			Placebo	3	3 (100.0)	0.00 (0.72)	-0.8	-0.80	0.20	0.60	0.6	
		Week 10	Tezepelumab	7	7 (100.0)	-1.71 (1.21)	-3.4	-2.80	-1.60	-1.20	0.4	-0.89 [-2.32, 0.53]
			Placebo	3	3 (100.0)	-0.73 (0.64)	-1.2	-1.20	-1.00	0.00	0.0	
		Week 12	Tezepelumab	7	7 (100.0)	-1.86 (1.12)	-3.2	-3.00	-1.80	-1.20	0.0	-1.91 [-3.55, -0.26]
			Placebo	3	3 (100.0)	0.27 (1.10)	-0.8	-0.80	0.20	1.40	1.4	
		Week 14	Tezepelumab	7	7 (100.0)	-1.89 (1.32)	-4.0	-3.40	-1.60	-0.60	-0.6	-0.76 [-2.17, 0.64]
			Placebo	3	3 (100.0)	-0.93 (0.99)	-1.6	-1.60	-1.40	0.20	0.2	
		Week 16	Tezepelumab	7	7 (100.0)	-1.54 (1.08)	-3.2	-2.80	-1.20	-0.80	-0.2	-1.62 [-3.19, -0.05]
			Placebo	3	3 (100.0)	0.13 (0.90)	-0.8	-0.80	0.20	1.00	1.0	
		Week 18	Tezepelumab	7	7 (100.0)	-1.86 (1.25)	-3.8	-3.40	-1.40	-0.80	-0.8	-1.06 [-2.50, 0.39]
			Placebo	3	3 (100.0)	-0.67 (0.64)	-1.4	-1.40	-0.40	-0.20	-0.2	
		Week 20	Tezepelumab	7	7 (100.0)	-1.80 (0.88)	-3.4	-2.60	-1.60	-1.20	-1.0	-2.11 [-3.82, -0.41]
			Placebo	3	3 (100.0)	-0.07 (0.61)	-0.6	-0.60	-0.20	0.60	0.6	
		Week 22	Tezepelumab	7	7 (100.0)	-1.60 (1.20)	-3.2	-2.60	-1.40	-0.60	0.2	-1.20 [-2.67, 0.28]
			Placebo	3	3 (100.0)	-0.27 (0.81)	-1.0	-1.00	-0.40	0.60	0.6	
		Week 24	Tezepelumab	7	7 (100.0)	-1.60 (0.88)	-3.4	-1.80	-1.40	-0.80	-0.8	-2.25 [-4.00, -0.51]
			Placebo	3	3 (100.0)	0.13 (0.23)	0.0	0.00	0.00	0.40	0.4	
		Week 26	Tezepelumab	7	7 (100.0)	-1.54 (0.95)	-3.0	-2.20	-1.40	-0.40	-0.4	-1.52 [-3.07, 0.02]
			Placebo	3	3 (100.0)	-0.07 (1.03)	-1.2	-1.20	0.20	0.80	0.8	
		Week 28	Tezepelumab	7	7 (100.0)	-1.57 (1.04)	-3.4	-2.20	-1.40	-1.20	0.0	-1.80 [-3.41, -0.18]
			Placebo	3	3 (100.0)	0.13 (0.58)	-0.2	-0.20	-0.20	0.80	0.8	
		Week 30	Tezepelumab	7	7 (100.0)	-1.71 (1.24)	-3.8	-2.80	-1.60	-1.00	0.0	-1.48 [-3.01, 0.06]
			Placebo	3	3 (100.0)	0.00 (0.87)	-0.6	-0.60	-0.40	1.00	1.0	
		Week 32	Tezepelumab	7	7 (100.0)	-1.66 (0.77)	-3.2	-1.80	-1.60	-1.20	-0.8	-1.89 [-3.53, -0.25]
			Placebo	3	3 (100.0)	-0.13 (0.90)	-1.0	-1.00	-0.20	0.80	0.8	
		Week 34	Tezepelumab	7	7 (100.0)	-1.74 (1.02)	-3.0	-2.60	-1.60	-1.60	0.2	-1.54 [-3.09, 0.01]
			Placebo	3	3 (100.0)	-0.27 (0.76)	-0.8	-0.80	-0.60	0.60	0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	7	7 (100.0)	-1.86 (0.91)	-3.2	-3.00	-1.60	-1.20	-0.8	-2.17 [-3.89, -0.45]
			Placebo	3	3 (100.0)	0.20 (1.06)	-0.6	-0.60	-0.20	1.40	1.4	
		Week 38	Tezepelumab	7	7 (100.0)	-1.63 (1.12)	-3.2	-2.20	-1.80	-1.00	0.4	-1.21 [-2.69, 0.26]
			Placebo	3	3 (100.0)	-0.40 (0.60)	-1.0	-1.00	-0.40	0.20	0.2	
		Week 40	Tezepelumab	7	7 (100.0)	-1.60 (1.24)	-3.4	-2.60	-1.60	-0.80	0.4	-1.88 [-3.51, -0.24]
			Placebo	3	3 (100.0)	0.53 (0.76)	0.0	0.00	0.20	1.40	1.4	
		Week 42	Tezepelumab	7	7 (100.0)	-1.71 (1.20)	-3.6	-2.80	-1.40	-1.00	0.0	-1.37 [-2.88, 0.14]
			Placebo	3	3 (100.0)	0.00 (1.39)	-0.8	-0.80	-0.80	1.60	1.6	
		Week 44	Tezepelumab	7	7 (100.0)	-1.74 (1.30)	-3.8	-3.40	-1.20	-0.80	-0.6	-1.52 [-3.07, 0.02]
			Placebo	3	3 (100.0)	0.13 (1.01)	-0.8	-0.80	0.00	1.20	1.2	
		Week 46	Tezepelumab	7	7 (100.0)	-1.77 (0.95)	-3.6	-2.20	-1.40	-1.00	-0.8	-1.44 [-2.97, 0.08]
			Placebo	3	3 (100.0)	-0.53 (0.50)	-1.0	-1.00	-0.60	0.00	0.0	
		Week 48	Tezepelumab	7	7 (100.0)	-1.66 (0.80)	-2.8	-2.60	-1.60	-1.00	-0.8	-2.03 [-3.71, -0.35]
			Placebo	3	3 (100.0)	0.00 (0.87)	-0.6	-0.60	-0.40	1.00	1.0	
		Week 50	Tezepelumab	7	7 (100.0)	-1.34 (0.81)	-2.6	-1.80	-1.40	-0.80	0.0	-1.30 [-2.80, 0.19]
			Placebo	3	3 (100.0)	-0.33 (0.64)	-0.8	-0.80	-0.60	0.40	0.4	
		Week 52	Tezepelumab	7	7 (100.0)	-1.34 (0.81)	-2.6	-1.80	-1.40	-0.80	0.0	-1.84 [-3.47, -0.22]
			Placebo	3	3 (100.0)	0.13 (0.76)	-0.4	-0.40	-0.20	1.00	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	59	59 (100.0)	2.84 (0.89)	0.0	2.40	2.80	3.20	5.2	
			Placebo	62	62 (100.0)	2.86 (0.78)	0.4	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	59	56 (94.9)	2.30 (1.01)	0.0	1.60	2.50	3.00	4.4	
			Placebo	62	55 (88.7)	2.40 (0.81)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	59	56 (94.9)	2.13 (1.00)	0.2	1.40	2.30	3.00	3.6	
			Placebo	62	55 (88.7)	2.20 (0.88)	0.2	1.40	2.40	2.80	3.6	
		Week 6	Tezepelumab	59	56 (94.9)	2.01 (1.07)	0.0	1.30	2.00	2.80	4.0	
			Placebo	62	55 (88.7)	2.18 (1.15)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	59	56 (94.9)	1.87 (1.22)	0.0	0.90	1.80	2.80	5.2	
			Placebo	62	56 (90.3)	2.09 (1.14)	0.0	1.10	2.30	2.80	5.0	
		Week 10	Tezepelumab	59	56 (94.9)	1.76 (1.16)	0.0	0.80	1.80	2.60	4.8	
			Placebo	62	56 (90.3)	2.15 (1.10)	0.0	1.60	2.30	2.90	5.2	
		Week 12	Tezepelumab	59	56 (94.9)	1.66 (1.12)	0.0	0.60	1.70	2.60	4.8	
			Placebo	62	56 (90.3)	1.88 (1.02)	0.0	1.00	2.00	2.60	4.4	
		Week 14	Tezepelumab	59	56 (94.9)	1.60 (1.17)	0.0	0.60	1.50	2.40	4.8	
			Placebo	62	56 (90.3)	1.86 (1.01)	0.0	1.10	2.00	2.40	5.0	
		Week 16	Tezepelumab	59	56 (94.9)	1.73 (1.23)	0.0	0.70	1.60	2.80	4.8	
			Placebo	62	56 (90.3)	1.98 (1.20)	0.0	1.00	2.00	2.80	5.0	
		Week 18	Tezepelumab	59	57 (96.6)	1.73 (1.11)	0.0	1.00	1.80	2.60	4.8	
			Placebo	62	56 (90.3)	1.91 (1.20)	0.0	1.00	2.00	2.60	5.0	
		Week 20	Tezepelumab	59	57 (96.6)	1.73 (1.19)	0.0	0.80	1.80	2.60	5.0	
			Placebo	62	56 (90.3)	1.99 (1.12)	0.0	1.20	2.00	2.80	5.0	
		Week 22	Tezepelumab	59	57 (96.6)	1.81 (1.05)	0.0	1.00	2.00	2.60	4.8	
			Placebo	62	56 (90.3)	1.95 (1.17)	0.0	1.00	2.00	2.60	5.0	
		Week 24	Tezepelumab	59	57 (96.6)	1.77 (1.14)	0.0	1.00	1.80	2.60	4.8	
			Placebo	62	56 (90.3)	1.99 (1.06)	0.0	1.20	2.00	2.60	4.4	
		Week 26	Tezepelumab	59	58 (98.3)	1.82 (1.16)	0.0	1.00	1.80	2.80	4.8	
			Placebo	62	56 (90.3)	1.93 (1.13)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	59	59 (100.0)	1.76 (1.20)	0.0	0.80	1.80	2.80	4.8	
			Placebo	62	57 (91.9)	1.90 (1.22)	0.0	1.00	1.80	2.80	4.4	
		Week 30	Tezepelumab	59	59 (100.0)	1.74 (1.15)	0.0	0.80	1.60	2.60	4.8	
			Placebo	62	57 (91.9)	1.88 (1.18)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	59	59 (100.0)	1.65 (1.16)	0.0	0.60	1.60	2.60	4.8	
			Placebo	62	57 (91.9)	1.86 (1.13)	0.0	1.00	1.80	2.60	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	59	59 (100.0)	1.75 (1.24)	0.0	0.80	1.80	2.80	4.8	
			Placebo	62	57 (91.9)	1.84 (1.14)	0.0	0.80	1.80	2.60	4.8	
		Week 36	Tezepelumab	59	59 (100.0)	1.72 (1.15)	0.0	0.80	1.60	2.60	4.8	
			Placebo	62	57 (91.9)	2.00 (1.18)	0.0	1.20	2.00	2.80	4.8	
		Week 38	Tezepelumab	59	59 (100.0)	1.75 (1.27)	0.0	0.80	1.80	2.60	4.8	
			Placebo	62	57 (91.9)	1.89 (1.14)	0.0	1.00	1.80	2.60	4.8	
		Week 40	Tezepelumab	59	59 (100.0)	1.72 (1.22)	0.0	0.60	1.80	2.80	4.8	
			Placebo	62	57 (91.9)	1.99 (1.17)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	59	59 (100.0)	1.67 (1.20)	0.0	0.60	1.60	2.60	4.8	
			Placebo	62	57 (91.9)	1.87 (1.02)	0.0	1.00	2.00	2.60	4.4	
		Week 44	Tezepelumab	59	59 (100.0)	1.72 (1.18)	0.0	0.80	1.80	2.80	4.8	
			Placebo	62	57 (91.9)	1.95 (1.10)	0.0	1.20	2.00	2.60	4.4	
		Week 46	Tezepelumab	59	59 (100.0)	1.76 (1.24)	0.0	0.80	1.80	2.80	4.8	
			Placebo	62	57 (91.9)	1.86 (1.02)	0.0	1.20	2.00	2.40	4.4	
		Week 48	Tezepelumab	59	59 (100.0)	1.75 (1.24)	0.0	0.80	2.00	2.80	4.8	
			Placebo	62	57 (91.9)	1.89 (1.09)	0.0	1.00	2.00	2.60	4.6	
		Week 50	Tezepelumab	59	59 (100.0)	1.64 (1.26)	0.0	0.60	1.40	2.60	4.8	
			Placebo	62	57 (91.9)	1.78 (1.03)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	59	59 (100.0)	1.67 (1.24)	0.0	0.60	1.60	2.60	4.8	
			Placebo	62	57 (91.9)	1.83 (1.07)	0.0	1.00	2.00	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	59	56 (94.9)	-0.58 (0.81)	-3.2	-1.10	-0.40	0.00	0.8	-0.10 [-0.48, 0.27]
			Placebo	62	55 (88.7)	-0.50 (0.74)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	59	56 (94.9)	-0.75 (0.92)	-2.6	-1.20	-0.80	-0.20	2.6	-0.06 [-0.43, 0.32]
			Placebo	62	55 (88.7)	-0.70 (0.94)	-3.0	-1.40	-0.40	0.00	0.8	
		Week 6	Tezepelumab	59	56 (94.9)	-0.88 (1.03)	-2.8	-1.50	-1.00	-0.10	2.6	-0.15 [-0.53, 0.22]
			Placebo	62	55 (88.7)	-0.72 (1.04)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	59	56 (94.9)	-1.01 (1.15)	-3.0	-1.70	-1.00	-0.40	2.6	-0.17 [-0.55, 0.20]
			Placebo	62	56 (90.3)	-0.82 (1.06)	-3.6	-1.50	-0.60	0.00	1.0	
		Week 10	Tezepelumab	59	56 (94.9)	-1.12 (1.10)	-3.0	-1.90	-1.20	-0.50	2.6	-0.32 [-0.69, 0.06]
			Placebo	62	56 (90.3)	-0.76 (1.18)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	59	56 (94.9)	-1.22 (1.09)	-3.2	-2.20	-1.20	-0.60	2.6	-0.18 [-0.55, 0.19]
			Placebo	62	56 (90.3)	-1.03 (1.05)	-3.8	-1.70	-0.90	-0.30	1.6	
		Week 14	Tezepelumab	59	56 (94.9)	-1.28 (1.08)	-3.0	-2.20	-1.30	-0.70	2.6	-0.22 [-0.59, 0.15]
			Placebo	62	56 (90.3)	-1.04 (1.09)	-3.4	-1.60	-1.10	-0.40	2.4	
		Week 16	Tezepelumab	59	56 (94.9)	-1.15 (1.16)	-3.0	-2.20	-1.10	-0.50	2.6	-0.19 [-0.56, 0.18]
			Placebo	62	56 (90.3)	-0.93 (1.17)	-3.6	-1.40	-1.00	-0.20	2.6	
		Week 18	Tezepelumab	59	57 (96.6)	-1.14 (1.06)	-3.0	-1.80	-1.00	-0.60	2.6	-0.13 [-0.50, 0.24]
			Placebo	62	56 (90.3)	-0.99 (1.25)	-3.6	-2.00	-1.00	-0.20	2.6	
		Week 20	Tezepelumab	59	57 (96.6)	-1.14 (1.11)	-3.0	-2.20	-1.00	-0.40	2.6	-0.19 [-0.56, 0.18]
			Placebo	62	56 (90.3)	-0.92 (1.19)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	59	57 (96.6)	-1.06 (1.12)	-3.0	-1.80	-1.00	-0.60	2.6	-0.08 [-0.45, 0.29]
			Placebo	62	56 (90.3)	-0.96 (1.20)	-3.8	-1.60	-1.00	-0.20	2.6	
		Week 24	Tezepelumab	59	57 (96.6)	-1.09 (1.11)	-3.0	-2.00	-1.00	-0.40	2.6	-0.16 [-0.53, 0.21]
			Placebo	62	56 (90.3)	-0.91 (1.14)	-3.6	-1.60	-1.00	-0.20	2.6	
		Week 26	Tezepelumab	59	58 (98.3)	-1.03 (1.14)	-3.0	-2.20	-1.00	-0.20	2.6	-0.04 [-0.41, 0.32]
			Placebo	62	56 (90.3)	-0.98 (1.19)	-3.4	-1.80	-1.20	0.00	2.6	
		Week 28	Tezepelumab	59	59 (100.0)	-1.08 (1.23)	-3.0	-2.20	-0.80	0.00	2.6	-0.10 [-0.46, 0.26]
			Placebo	62	57 (91.9)	-0.96 (1.23)	-3.4	-1.80	-1.20	0.00	2.6	
		Week 30	Tezepelumab	59	59 (100.0)	-1.11 (1.17)	-3.0	-2.20	-1.00	-0.40	2.6	-0.11 [-0.47, 0.26]
			Placebo	62	57 (91.9)	-0.98 (1.23)	-3.4	-1.60	-1.20	-0.20	2.6	
		Week 32	Tezepelumab	59	59 (100.0)	-1.19 (1.14)	-3.0	-2.20	-1.20	-0.40	2.6	-0.16 [-0.52, 0.21]
			Placebo	62	57 (91.9)	-1.01 (1.17)	-3.2	-1.60	-1.20	-0.40	2.6	
		Week 34	Tezepelumab	59	59 (100.0)	-1.09 (1.21)	-3.0	-2.20	-1.20	-0.20	2.6	-0.05 [-0.42, 0.31]
			Placebo	62	57 (91.9)	-1.03 (1.17)	-3.2	-1.80	-1.20	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	59	59 (100.0)	-1.13 (1.19)	-3.0	-2.20	-1.20	-0.20	2.6	-0.22 [-0.58, 0.15]
			Placebo	62	57 (91.9)	-0.87 (1.21)	-3.6	-1.40	-1.00	-0.20	2.6	
		Week 38	Tezepelumab	59	59 (100.0)	-1.10 (1.24)	-3.0	-2.20	-1.20	-0.20	2.6	-0.10 [-0.47, 0.26]
			Placebo	62	57 (91.9)	-0.97 (1.17)	-3.2	-1.60	-1.20	-0.40	2.6	
		Week 40	Tezepelumab	59	59 (100.0)	-1.12 (1.20)	-3.0	-2.20	-1.20	-0.40	2.6	-0.21 [-0.57, 0.16]
			Placebo	62	57 (91.9)	-0.87 (1.20)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 42	Tezepelumab	59	59 (100.0)	-1.17 (1.20)	-3.0	-2.20	-1.20	-0.40	2.6	-0.15 [-0.52, 0.21]
			Placebo	62	57 (91.9)	-0.99 (1.08)	-2.8	-1.60	-1.00	-0.40	2.6	
		Week 44	Tezepelumab	59	59 (100.0)	-1.13 (1.18)	-3.0	-2.20	-1.20	-0.20	2.6	-0.18 [-0.55, 0.18]
			Placebo	62	57 (91.9)	-0.91 (1.14)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 46	Tezepelumab	59	59 (100.0)	-1.09 (1.22)	-3.0	-2.20	-1.20	-0.20	2.6	-0.07 [-0.43, 0.29]
			Placebo	62	57 (91.9)	-1.01 (1.08)	-3.2	-1.60	-1.00	-0.60	2.6	
		Week 48	Tezepelumab	59	59 (100.0)	-1.10 (1.22)	-3.0	-2.20	-1.00	-0.40	2.6	-0.11 [-0.47, 0.26]
			Placebo	62	57 (91.9)	-0.97 (1.13)	-3.4	-1.60	-1.00	-0.40	2.6	
		Week 50	Tezepelumab	59	59 (100.0)	-1.21 (1.26)	-3.2	-2.20	-1.20	-0.40	2.6	-0.11 [-0.47, 0.26]
			Placebo	62	57 (91.9)	-1.08 (1.07)	-3.6	-1.60	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	59	59 (100.0)	-1.17 (1.24)	-3.2	-2.20	-1.20	-0.20	2.6	-0.12 [-0.48, 0.24]
			Placebo	62	57 (91.9)	-1.03 (1.10)	-3.6	-1.60	-1.00	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	3.10 (0.95)	2.0	2.40	2.90	3.80	4.6	
			Placebo	2	2 (100.0)	2.90 (0.14)	2.8	2.80	2.90	3.00	3.0	
		Week 2	Tezepelumab	6	6 (100.0)	2.70 (1.15)	1.0	1.60	3.10	3.40	4.0	
			Placebo	2	2 (100.0)	2.40 (0.85)	1.8	1.80	2.40	3.00	3.0	
		Week 4	Tezepelumab	6	6 (100.0)	1.57 (1.10)	0.2	0.80	1.50	2.60	2.8	
			Placebo	2	2 (100.0)	2.70 (1.27)	1.8	1.80	2.70	3.60	3.6	
		Week 6	Tezepelumab	6	6 (100.0)	1.73 (0.85)	1.0	1.20	1.30	2.60	3.0	
			Placebo	2	2 (100.0)	2.20 (1.41)	1.2	1.20	2.20	3.20	3.2	
		Week 8	Tezepelumab	6	6 (100.0)	1.40 (0.79)	0.6	1.00	1.10	1.80	2.8	
			Placebo	2	2 (100.0)	2.60 (0.85)	2.0	2.00	2.60	3.20	3.2	
		Week 10	Tezepelumab	6	6 (100.0)	1.40 (1.01)	0.4	0.80	1.10	1.80	3.2	
			Placebo	2	2 (100.0)	2.30 (0.99)	1.6	1.60	2.30	3.00	3.0	
		Week 12	Tezepelumab	6	6 (100.0)	1.13 (0.95)	0.0	0.60	1.00	1.40	2.8	
			Placebo	2	2 (100.0)	2.60 (0.85)	2.0	2.00	2.60	3.20	3.2	
		Week 14	Tezepelumab	6	6 (100.0)	1.17 (0.69)	0.4	0.60	1.10	1.60	2.2	
			Placebo	2	2 (100.0)	2.20 (1.41)	1.2	1.20	2.20	3.20	3.2	
		Week 16	Tezepelumab	6	6 (100.0)	1.43 (0.76)	0.6	0.80	1.40	1.80	2.6	
			Placebo	2	2 (100.0)	2.60 (0.85)	2.0	2.00	2.60	3.20	3.2	
		Week 18	Tezepelumab	6	6 (100.0)	1.07 (0.62)	0.4	0.60	0.90	1.60	2.0	
			Placebo	2	2 (100.0)	2.10 (0.99)	1.4	1.40	2.10	2.80	2.8	
		Week 20	Tezepelumab	6	6 (100.0)	1.20 (0.61)	0.4	0.80	1.10	1.80	2.0	
			Placebo	2	2 (100.0)	2.50 (0.42)	2.2	2.20	2.50	2.80	2.8	
		Week 22	Tezepelumab	6	6 (100.0)	1.47 (0.94)	0.0	0.60	1.90	2.20	2.2	
			Placebo	2	2 (100.0)	2.20 (0.57)	1.8	1.80	2.20	2.60	2.6	
		Week 24	Tezepelumab	6	6 (100.0)	1.47 (0.86)	0.4	0.80	1.40	2.00	2.8	
			Placebo	2	2 (100.0)	2.90 (0.14)	2.8	2.80	2.90	3.00	3.0	
		Week 26	Tezepelumab	6	6 (100.0)	1.37 (0.59)	0.8	1.00	1.20	1.60	2.4	
			Placebo	2	2 (100.0)	2.40 (1.13)	1.6	1.60	2.40	3.20	3.2	
		Week 28	Tezepelumab	6	6 (100.0)	1.47 (0.73)	0.4	1.00	1.50	2.00	2.4	
			Placebo	2	2 (100.0)	2.70 (0.14)	2.6	2.60	2.70	2.80	2.8	
		Week 30	Tezepelumab	6	6 (100.0)	1.27 (0.52)	0.8	0.80	1.10	1.80	2.0	
			Placebo	2	2 (100.0)	2.40 (0.00)	2.4	2.40	2.40	2.40	2.4	
		Week 32	Tezepelumab	6	6 (100.0)	1.37 (0.81)	0.6	0.80	1.10	1.80	2.8	
			Placebo	2	2 (100.0)	2.30 (0.71)	1.8	1.80	2.30	2.80	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	6	6 (100.0)	1.33 (0.62)	0.8	0.80	1.10	2.00	2.2	
			Placebo	2	2 (100.0)	2.20 (0.00)	2.2	2.20	2.20	2.20	2.2	
		Week 36	Tezepelumab	6	6 (100.0)	1.20 (0.44)	0.6	1.00	1.10	1.60	1.8	
			Placebo	2	2 (100.0)	2.50 (0.42)	2.2	2.20	2.50	2.80	2.8	
		Week 38	Tezepelumab	6	6 (100.0)	1.53 (0.82)	0.6	0.60	1.60	2.40	2.4	
			Placebo	2	2 (100.0)	2.20 (0.57)	1.8	1.80	2.20	2.60	2.6	
		Week 40	Tezepelumab	6	6 (100.0)	1.57 (0.78)	0.4	0.80	1.90	2.00	2.4	
			Placebo	2	2 (100.0)	3.00 (0.00)	3.0	3.00	3.00	3.00	3.0	
		Week 42	Tezepelumab	6	6 (100.0)	1.43 (0.48)	1.0	1.00	1.40	1.80	2.0	
			Placebo	2	2 (100.0)	2.10 (0.14)	2.0	2.00	2.10	2.20	2.2	
		Week 44	Tezepelumab	6	6 (100.0)	1.27 (0.77)	0.4	0.80	1.00	2.00	2.4	
			Placebo	2	2 (100.0)	2.50 (0.42)	2.2	2.20	2.50	2.80	2.8	
		Week 46	Tezepelumab	6	6 (100.0)	1.40 (0.61)	0.6	1.00	1.40	2.00	2.0	
			Placebo	2	2 (100.0)	2.10 (0.14)	2.0	2.00	2.10	2.20	2.2	
		Week 48	Tezepelumab	6	6 (100.0)	1.47 (0.47)	0.8	1.20	1.50	1.80	2.0	
			Placebo	2	2 (100.0)	2.40 (0.00)	2.4	2.40	2.40	2.40	2.4	
		Week 50	Tezepelumab	6	6 (100.0)	1.80 (0.64)	1.0	1.20	1.90	2.00	2.8	
			Placebo	2	2 (100.0)	2.20 (0.00)	2.2	2.20	2.20	2.20	2.2	
		Week 52	Tezepelumab	6	6 (100.0)	1.80 (0.64)	1.0	1.20	1.90	2.00	2.8	
			Placebo	2	2 (100.0)	2.60 (0.28)	2.4	2.40	2.60	2.80	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	6	6 (100.0)	-0.40 (0.74)	-1.4	-1.20	-0.10	0.20	0.2	0.14 [-1.47, 1.74]
			Placebo	2	2 (100.0)	-0.50 (0.71)	-1.0	-1.00	-0.50	0.00	0.0	
		Week 4	Tezepelumab	6	6 (100.0)	-1.53 (0.82)	-2.4	-2.20	-1.70	-1.00	-0.2	-1.52 [-3.34, 0.30]
			Placebo	2	2 (100.0)	-0.20 (1.13)	-1.0	-1.00	-0.20	0.60	0.6	
		Week 6	Tezepelumab	6	6 (100.0)	-1.37 (0.98)	-2.6	-2.00	-1.50	-0.80	0.2	-0.65 [-2.29, 0.99]
			Placebo	2	2 (100.0)	-0.70 (1.27)	-1.6	-1.60	-0.70	0.20	0.2	
		Week 8	Tezepelumab	6	6 (100.0)	-1.70 (1.18)	-3.2	-2.80	-1.60	-1.00	0.0	-1.26 [-3.01, 0.49]
			Placebo	2	2 (100.0)	-0.30 (0.71)	-0.8	-0.80	-0.30	0.20	0.2	
		Week 10	Tezepelumab	6	6 (100.0)	-1.70 (1.33)	-3.4	-2.80	-1.60	-1.20	0.4	-0.87 [-2.55, 0.80]
			Placebo	2	2 (100.0)	-0.60 (0.85)	-1.2	-1.20	-0.60	0.00	0.0	
		Week 12	Tezepelumab	6	6 (100.0)	-1.97 (1.18)	-3.2	-3.00	-2.10	-1.40	0.0	-1.49 [-3.30, 0.32]
			Placebo	2	2 (100.0)	-0.30 (0.71)	-0.8	-0.80	-0.30	0.20	0.2	
		Week 14	Tezepelumab	6	6 (100.0)	-1.93 (1.44)	-4.0	-3.40	-1.50	-0.60	-0.6	-0.87 [-2.55, 0.80]
			Placebo	2	2 (100.0)	-0.70 (1.27)	-1.6	-1.60	-0.70	0.20	0.2	
		Week 16	Tezepelumab	6	6 (100.0)	-1.67 (1.12)	-3.2	-2.80	-1.30	-1.20	-0.2	-1.28 [-3.04, 0.47]
			Placebo	2	2 (100.0)	-0.30 (0.71)	-0.8	-0.80	-0.30	0.20	0.2	
		Week 18	Tezepelumab	6	6 (100.0)	-2.03 (1.27)	-3.8	-3.40	-1.60	-1.00	-0.8	-1.02 [-2.72, 0.68]
			Placebo	2	2 (100.0)	-0.80 (0.85)	-1.4	-1.40	-0.80	-0.20	-0.2	
		Week 20	Tezepelumab	6	6 (100.0)	-1.90 (0.92)	-3.4	-2.60	-1.60	-1.20	-1.0	-1.77 [-3.66, 0.12]
			Placebo	2	2 (100.0)	-0.40 (0.28)	-0.6	-0.60	-0.40	-0.20	-0.2	
		Week 22	Tezepelumab	6	6 (100.0)	-1.63 (1.31)	-3.2	-2.60	-1.80	-0.60	0.2	-0.77 [-2.43, 0.89]
			Placebo	2	2 (100.0)	-0.70 (0.42)	-1.0	-1.00	-0.70	-0.40	-0.4	
		Week 24	Tezepelumab	6	6 (100.0)	-1.63 (0.96)	-3.4	-1.80	-1.50	-0.80	-0.8	-1.87 [-3.78, 0.05]
			Placebo	2	2 (100.0)	0.00 (0.00)	0.0	0.00	0.00	0.00	0.0	
		Week 26	Tezepelumab	6	6 (100.0)	-1.73 (0.88)	-3.0	-2.20	-1.70	-1.40	-0.4	-1.37 [-3.15, 0.41]
			Placebo	2	2 (100.0)	-0.50 (0.99)	-1.2	-1.20	-0.50	0.20	0.2	
		Week 28	Tezepelumab	6	6 (100.0)	-1.63 (1.13)	-3.4	-2.20	-1.50	-1.20	0.0	-1.39 [-3.18, 0.39]
			Placebo	2	2 (100.0)	-0.20 (0.00)	-0.2	-0.20	-0.20	-0.20	-0.2	
		Week 30	Tezepelumab	6	6 (100.0)	-1.83 (1.32)	-3.8	-2.80	-1.60	-1.20	0.0	-1.11 [-2.83, 0.61]
			Placebo	2	2 (100.0)	-0.50 (0.14)	-0.6	-0.60	-0.50	-0.40	-0.4	
		Week 32	Tezepelumab	6	6 (100.0)	-1.73 (0.82)	-3.2	-1.80	-1.70	-1.20	-0.8	-1.45 [-3.25, 0.35]
			Placebo	2	2 (100.0)	-0.60 (0.57)	-1.0	-1.00	-0.60	-0.20	-0.2	
		Week 34	Tezepelumab	6	6 (100.0)	-1.77 (1.11)	-3.0	-2.60	-1.80	-1.60	0.2	-1.05 [-2.75, 0.66]
			Placebo	2	2 (100.0)	-0.70 (0.14)	-0.8	-0.80	-0.70	-0.60	-0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	6	6 (100.0)	-1.90 (0.99)	-3.2	-3.00	-1.60	-1.20	-0.8	-1.65 [-3.51, 0.20]
			Placebo	2	2 (100.0)	-0.40 (0.28)	-0.6	-0.60	-0.40	-0.20	-0.2	
		Week 38	Tezepelumab	6	6 (100.0)	-1.57 (1.21)	-3.2	-2.20	-1.70	-1.00	0.4	-0.78 [-2.43, 0.88]
			Placebo	2	2 (100.0)	-0.70 (0.42)	-1.0	-1.00	-0.70	-0.40	-0.4	
		Week 40	Tezepelumab	6	6 (100.0)	-1.53 (1.34)	-3.4	-2.60	-1.40	-0.80	0.4	-1.33 [-3.10, 0.44]
			Placebo	2	2 (100.0)	0.10 (0.14)	0.0	0.00	0.10	0.20	0.2	
		Week 42	Tezepelumab	6	6 (100.0)	-1.67 (1.31)	-3.6	-2.80	-1.30	-1.00	0.0	-0.73 [-2.38, 0.93]
			Placebo	2	2 (100.0)	-0.80 (0.00)	-0.8	-0.80	-0.80	-0.80	-0.8	
		Week 44	Tezepelumab	6	6 (100.0)	-1.83 (1.40)	-3.8	-3.40	-1.20	-0.80	-0.6	-1.10 [-2.82, 0.61]
			Placebo	2	2 (100.0)	-0.40 (0.57)	-0.8	-0.80	-0.40	0.00	0.0	
		Week 46	Tezepelumab	6	6 (100.0)	-1.70 (1.02)	-3.6	-2.00	-1.40	-1.00	-0.8	-0.96 [-2.65, 0.73]
			Placebo	2	2 (100.0)	-0.80 (0.28)	-1.0	-1.00	-0.80	-0.60	-0.6	
		Week 48	Tezepelumab	6	6 (100.0)	-1.63 (0.87)	-2.8	-2.60	-1.30	-1.00	-0.8	-1.42 [-3.21, 0.37]
			Placebo	2	2 (100.0)	-0.50 (0.14)	-0.6	-0.60	-0.50	-0.40	-0.4	
		Week 50	Tezepelumab	6	6 (100.0)	-1.30 (0.88)	-2.6	-1.80	-1.30	-0.80	0.0	-0.74 [-2.40, 0.91]
			Placebo	2	2 (100.0)	-0.70 (0.14)	-0.8	-0.80	-0.70	-0.60	-0.6	
		Week 52	Tezepelumab	6	6 (100.0)	-1.30 (0.88)	-2.6	-1.80	-1.30	-0.80	0.0	-1.24 [-2.98, 0.51]
			Placebo	2	2 (100.0)	-0.30 (0.14)	-0.4	-0.40	-0.30	-0.20	-0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	2.85 (0.88)	0.0	2.40	2.80	3.20	5.2	
			Placebo	63	63 (100.0)	2.86 (0.78)	0.4	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	60	57 (95.0)	2.31 (1.01)	0.0	1.60	2.60	3.00	4.4	
			Placebo	63	56 (88.9)	2.40 (0.80)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	60	57 (95.0)	2.13 (0.99)	0.2	1.40	2.20	3.00	3.6	
			Placebo	63	56 (88.9)	2.24 (0.92)	0.2	1.60	2.50	2.80	4.2	
		Week 6	Tezepelumab	60	57 (95.0)	2.00 (1.06)	0.0	1.40	2.00	2.80	4.0	
			Placebo	63	56 (88.9)	2.21 (1.16)	0.2	1.40	2.20	2.90	6.0	
		Week 8	Tezepelumab	60	57 (95.0)	1.86 (1.21)	0.0	1.00	1.80	2.80	5.2	
			Placebo	63	57 (90.5)	2.11 (1.15)	0.0	1.20	2.40	2.80	5.0	
		Week 10	Tezepelumab	60	57 (95.0)	1.75 (1.15)	0.0	0.80	1.80	2.60	4.8	
			Placebo	63	57 (90.5)	2.15 (1.09)	0.0	1.60	2.20	2.80	5.2	
		Week 12	Tezepelumab	60	57 (95.0)	1.66 (1.11)	0.0	0.60	1.80	2.60	4.8	
			Placebo	63	57 (90.5)	1.92 (1.06)	0.0	1.00	2.00	2.60	4.4	
		Week 14	Tezepelumab	60	57 (95.0)	1.60 (1.16)	0.0	0.60	1.40	2.40	4.8	
			Placebo	63	57 (90.5)	1.86 (1.00)	0.0	1.20	2.00	2.40	5.0	
		Week 16	Tezepelumab	60	57 (95.0)	1.74 (1.22)	0.0	0.80	1.60	2.80	4.8	
			Placebo	63	57 (90.5)	2.01 (1.22)	0.0	1.00	2.00	2.80	5.0	
		Week 18	Tezepelumab	60	58 (96.7)	1.73 (1.10)	0.0	1.00	1.80	2.60	4.8	
			Placebo	63	57 (90.5)	1.93 (1.19)	0.0	1.00	2.00	2.60	5.0	
		Week 20	Tezepelumab	60	58 (96.7)	1.73 (1.18)	0.0	0.80	1.80	2.60	5.0	
			Placebo	63	57 (90.5)	2.02 (1.13)	0.0	1.20	2.00	2.80	5.0	
		Week 22	Tezepelumab	60	58 (96.7)	1.81 (1.04)	0.0	1.00	2.00	2.60	4.8	
			Placebo	63	57 (90.5)	1.98 (1.18)	0.0	1.00	2.00	2.60	5.0	
		Week 24	Tezepelumab	60	58 (96.7)	1.77 (1.13)	0.0	1.00	1.80	2.60	4.8	
			Placebo	63	57 (90.5)	2.02 (1.07)	0.0	1.40	2.00	2.60	4.4	
		Week 26	Tezepelumab	60	59 (98.3)	1.83 (1.16)	0.0	1.00	1.80	2.80	4.8	
			Placebo	63	57 (90.5)	1.96 (1.14)	0.0	1.00	1.80	2.80	4.4	
		Week 28	Tezepelumab	60	60 (100.0)	1.76 (1.19)	0.0	0.90	1.80	2.70	4.8	
			Placebo	63	58 (92.1)	1.93 (1.24)	0.0	1.00	1.90	2.80	4.4	
		Week 30	Tezepelumab	60	60 (100.0)	1.74 (1.14)	0.0	0.90	1.70	2.60	4.8	
			Placebo	63	58 (92.1)	1.92 (1.20)	0.0	1.00	2.00	3.00	4.4	
		Week 32	Tezepelumab	60	60 (100.0)	1.66 (1.15)	0.0	0.70	1.70	2.50	4.8	
			Placebo	63	58 (92.1)	1.89 (1.15)	0.0	1.00	1.80	2.80	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	60	60 (100.0)	1.75 (1.23)	0.0	0.80	1.70	2.80	4.8	
			Placebo	63	58 (92.1)	1.87 (1.16)	0.0	0.80	1.80	2.60	4.8	
		Week 36	Tezepelumab	60	60 (100.0)	1.71 (1.15)	0.0	0.90	1.60	2.60	4.8	
			Placebo	63	58 (92.1)	2.04 (1.21)	0.0	1.20	2.00	2.80	4.8	
		Week 38	Tezepelumab	60	60 (100.0)	1.73 (1.27)	0.0	0.80	1.70	2.60	4.8	
			Placebo	63	58 (92.1)	1.91 (1.15)	0.0	1.00	1.80	2.80	4.8	
		Week 40	Tezepelumab	60	60 (100.0)	1.71 (1.22)	0.0	0.70	1.80	2.80	4.8	
			Placebo	63	58 (92.1)	2.03 (1.20)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	60	60 (100.0)	1.66 (1.19)	0.0	0.70	1.60	2.60	4.8	
			Placebo	63	58 (92.1)	1.92 (1.08)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	60	60 (100.0)	1.72 (1.17)	0.0	0.80	1.80	2.80	4.8	
			Placebo	63	58 (92.1)	1.99 (1.13)	0.0	1.20	2.00	2.80	4.4	
		Week 46	Tezepelumab	60	60 (100.0)	1.74 (1.23)	0.0	0.80	1.80	2.80	4.8	
			Placebo	63	58 (92.1)	1.88 (1.03)	0.0	1.20	2.00	2.40	4.4	
		Week 48	Tezepelumab	60	60 (100.0)	1.74 (1.23)	0.0	0.80	1.90	2.70	4.8	
			Placebo	63	58 (92.1)	1.93 (1.11)	0.0	1.00	2.00	2.60	4.6	
		Week 50	Tezepelumab	60	60 (100.0)	1.63 (1.25)	0.0	0.70	1.40	2.60	4.8	
			Placebo	63	58 (92.1)	1.81 (1.04)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	60	60 (100.0)	1.67 (1.23)	0.0	0.70	1.60	2.60	4.8	
			Placebo	63	58 (92.1)	1.87 (1.10)	0.0	1.00	2.00	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	60	57 (95.0)	-0.58 (0.80)	-3.2	-1.00	-0.40	0.00	0.8	-0.10 [-0.47, 0.27]
			Placebo	63	56 (88.9)	-0.50 (0.73)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	60	57 (95.0)	-0.75 (0.91)	-2.6	-1.20	-0.80	-0.20	2.6	-0.09 [-0.46, 0.28]
			Placebo	63	56 (88.9)	-0.66 (0.97)	-3.0	-1.40	-0.40	0.00	1.2	
		Week 6	Tezepelumab	60	57 (95.0)	-0.89 (1.03)	-2.8	-1.60	-1.00	-0.20	2.6	-0.19 [-0.56, 0.18]
			Placebo	63	56 (88.9)	-0.69 (1.06)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	60	57 (95.0)	-1.02 (1.14)	-3.0	-1.60	-1.00	-0.40	2.6	-0.21 [-0.57, 0.16]
			Placebo	63	57 (90.5)	-0.80 (1.07)	-3.6	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	60	57 (95.0)	-1.13 (1.10)	-3.0	-1.80	-1.20	-0.60	2.6	-0.32 [-0.69, 0.05]
			Placebo	63	57 (90.5)	-0.76 (1.17)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	60	57 (95.0)	-1.22 (1.08)	-3.2	-2.20	-1.20	-0.60	2.6	-0.21 [-0.58, 0.15]
			Placebo	63	57 (90.5)	-0.99 (1.09)	-3.8	-1.60	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	60	57 (95.0)	-1.29 (1.07)	-3.0	-2.20	-1.40	-0.80	2.6	-0.22 [-0.59, 0.15]
			Placebo	63	57 (90.5)	-1.05 (1.08)	-3.4	-1.60	-1.20	-0.40	2.4	
		Week 16	Tezepelumab	60	57 (95.0)	-1.15 (1.15)	-3.0	-2.20	-1.00	-0.60	2.6	-0.22 [-0.58, 0.15]
			Placebo	63	57 (90.5)	-0.89 (1.19)	-3.6	-1.40	-1.00	-0.20	2.6	
		Week 18	Tezepelumab	60	58 (96.7)	-1.13 (1.06)	-3.0	-1.80	-1.00	-0.60	2.6	-0.13 [-0.50, 0.23]
			Placebo	63	57 (90.5)	-0.98 (1.24)	-3.6	-2.00	-1.00	-0.20	2.6	
		Week 20	Tezepelumab	60	58 (96.7)	-1.14 (1.10)	-3.0	-2.20	-1.10	-0.40	2.6	-0.22 [-0.58, 0.15]
			Placebo	63	57 (90.5)	-0.89 (1.20)	-3.6	-1.60	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	60	58 (96.7)	-1.06 (1.11)	-3.0	-1.80	-1.00	-0.60	2.6	-0.11 [-0.48, 0.25]
			Placebo	63	57 (90.5)	-0.93 (1.20)	-3.8	-1.60	-1.00	-0.20	2.6	
		Week 24	Tezepelumab	60	58 (96.7)	-1.10 (1.10)	-3.0	-2.00	-1.10	-0.40	2.6	-0.19 [-0.55, 0.18]
			Placebo	63	57 (90.5)	-0.89 (1.14)	-3.6	-1.60	-1.00	-0.20	2.6	
		Week 26	Tezepelumab	60	59 (98.3)	-1.02 (1.14)	-3.0	-2.20	-1.00	-0.20	2.6	-0.06 [-0.43, 0.30]
			Placebo	63	57 (90.5)	-0.94 (1.21)	-3.4	-1.80	-1.20	0.00	2.6	
		Week 28	Tezepelumab	60	60 (100.0)	-1.09 (1.21)	-3.0	-2.20	-0.90	-0.10	2.6	-0.13 [-0.49, 0.23]
			Placebo	63	58 (92.1)	-0.93 (1.25)	-3.4	-1.80	-1.20	0.00	2.6	
		Week 30	Tezepelumab	60	60 (100.0)	-1.10 (1.16)	-3.0	-2.20	-1.00	-0.40	2.6	-0.13 [-0.49, 0.23]
			Placebo	63	58 (92.1)	-0.94 (1.25)	-3.4	-1.60	-1.20	-0.20	2.6	
		Week 32	Tezepelumab	60	60 (100.0)	-1.19 (1.13)	-3.0	-2.20	-1.20	-0.50	2.6	-0.19 [-0.55, 0.18]
			Placebo	63	58 (92.1)	-0.98 (1.19)	-3.2	-1.60	-1.20	-0.20	2.6	
		Week 34	Tezepelumab	60	60 (100.0)	-1.10 (1.20)	-3.0	-2.20	-1.20	-0.30	2.6	-0.08 [-0.45, 0.28]
			Placebo	63	58 (92.1)	-1.00 (1.18)	-3.2	-1.80	-1.20	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	60	60 (100.0)	-1.13 (1.18)	-3.0	-2.20	-1.20	-0.20	2.6	-0.25 [-0.62, 0.11]
			Placebo	63	58 (92.1)	-0.83 (1.24)	-3.6	-1.40	-1.00	0.00	2.6	
		Week 38	Tezepelumab	60	60 (100.0)	-1.11 (1.23)	-3.0	-2.20	-1.20	-0.30	2.6	-0.13 [-0.50, 0.23]
			Placebo	63	58 (92.1)	-0.95 (1.17)	-3.2	-1.60	-1.10	-0.40	2.6	
		Week 40	Tezepelumab	60	60 (100.0)	-1.14 (1.20)	-3.0	-2.20	-1.20	-0.40	2.6	-0.25 [-0.61, 0.11]
			Placebo	63	58 (92.1)	-0.83 (1.22)	-3.2	-1.60	-0.90	-0.20	2.6	
		Week 42	Tezepelumab	60	60 (100.0)	-1.18 (1.20)	-3.0	-2.10	-1.30	-0.40	2.6	-0.20 [-0.56, 0.16]
			Placebo	63	58 (92.1)	-0.95 (1.12)	-2.8	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	60	60 (100.0)	-1.13 (1.17)	-3.0	-2.20	-1.20	-0.30	2.6	-0.21 [-0.58, 0.15]
			Placebo	63	58 (92.1)	-0.88 (1.17)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 46	Tezepelumab	60	60 (100.0)	-1.11 (1.22)	-3.0	-2.20	-1.20	-0.20	2.6	-0.10 [-0.46, 0.26]
			Placebo	63	58 (92.1)	-0.99 (1.08)	-3.2	-1.60	-1.00	-0.40	2.6	
		Week 48	Tezepelumab	60	60 (100.0)	-1.11 (1.22)	-3.0	-2.20	-1.00	-0.40	2.6	-0.15 [-0.51, 0.22]
			Placebo	63	58 (92.1)	-0.94 (1.15)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	60	60 (100.0)	-1.21 (1.25)	-3.2	-2.20	-1.30	-0.40	2.6	-0.14 [-0.50, 0.23]
			Placebo	63	58 (92.1)	-1.06 (1.07)	-3.6	-1.60	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	60	60 (100.0)	-1.18 (1.24)	-3.2	-2.20	-1.20	-0.30	2.6	-0.16 [-0.52, 0.21]
			Placebo	63	58 (92.1)	-1.00 (1.12)	-3.6	-1.60	-1.00	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	17	17 (100.0)	3.13 (1.12)	0.2	2.40	3.00	3.80	5.2	
			Placebo	21	21 (100.0)	2.96 (0.50)	1.8	2.60	3.00	3.20	4.0	
		Week 2	Tezepelumab	17	17 (100.0)	2.65 (1.06)	1.0	2.00	2.60	3.40	4.4	
			Placebo	21	21 (100.0)	2.45 (0.71)	0.4	2.20	2.60	3.00	3.2	
		Week 4	Tezepelumab	17	17 (100.0)	2.42 (0.93)	0.8	1.60	2.80	3.00	3.4	
			Placebo	21	21 (100.0)	2.24 (1.02)	0.2	1.40	2.40	2.80	4.2	
		Week 6	Tezepelumab	17	17 (100.0)	2.14 (1.13)	0.6	1.20	2.20	2.80	4.0	
			Placebo	21	21 (100.0)	2.31 (1.16)	0.2	1.80	2.20	3.00	5.0	
		Week 8	Tezepelumab	17	17 (100.0)	1.98 (1.24)	0.0	1.00	2.00	3.00	4.2	
			Placebo	21	21 (100.0)	2.09 (1.12)	0.0	1.20	2.40	2.80	3.6	
		Week 10	Tezepelumab	17	17 (100.0)	1.69 (1.26)	0.0	0.60	1.40	2.80	3.6	
			Placebo	21	21 (100.0)	2.14 (1.01)	0.0	1.80	2.40	2.80	4.0	
		Week 12	Tezepelumab	17	17 (100.0)	1.59 (1.13)	0.0	0.60	1.60	2.80	3.2	
			Placebo	21	21 (100.0)	1.84 (1.16)	0.0	1.00	1.80	2.60	4.4	
		Week 14	Tezepelumab	17	17 (100.0)	1.69 (1.34)	0.0	0.60	1.60	2.60	4.2	
			Placebo	21	21 (100.0)	1.62 (0.77)	0.0	1.20	1.80	2.00	3.2	
		Week 16	Tezepelumab	17	17 (100.0)	1.74 (1.18)	0.0	0.80	1.20	2.80	4.2	
			Placebo	21	21 (100.0)	1.74 (1.15)	0.0	0.60	2.00	2.60	4.0	
		Week 18	Tezepelumab	17	17 (100.0)	1.76 (1.13)	0.0	1.00	1.60	2.60	4.2	
			Placebo	21	21 (100.0)	1.65 (1.18)	0.0	0.80	1.80	2.20	4.8	
		Week 20	Tezepelumab	17	17 (100.0)	1.81 (1.31)	0.4	0.80	1.20	2.80	5.0	
			Placebo	21	21 (100.0)	1.87 (0.97)	0.0	1.20	1.80	2.60	3.6	
		Week 22	Tezepelumab	17	17 (100.0)	1.75 (1.10)	0.0	1.00	1.60	2.60	3.8	
			Placebo	21	21 (100.0)	1.90 (0.91)	0.0	1.20	2.00	2.60	3.6	
		Week 24	Tezepelumab	17	17 (100.0)	1.73 (1.08)	0.4	1.00	1.20	2.40	3.8	
			Placebo	21	21 (100.0)	1.96 (0.88)	0.0	1.60	2.20	2.60	3.4	
		Week 26	Tezepelumab	17	17 (100.0)	1.86 (1.08)	0.0	1.00	1.80	2.80	4.0	
			Placebo	21	21 (100.0)	1.74 (1.14)	0.0	1.00	1.60	2.60	3.8	
		Week 28	Tezepelumab	17	17 (100.0)	1.89 (1.21)	0.0	1.00	1.40	2.80	3.8	
			Placebo	21	21 (100.0)	1.74 (1.24)	0.0	0.80	1.60	2.80	4.0	
		Week 30	Tezepelumab	17	17 (100.0)	1.80 (1.01)	0.4	1.00	1.60	2.60	3.6	
			Placebo	21	21 (100.0)	1.58 (1.08)	0.0	0.80	2.00	2.20	4.0	
		Week 32	Tezepelumab	17	17 (100.0)	1.66 (1.09)	0.4	0.80	1.20	2.20	4.0	
			Placebo	21	21 (100.0)	1.72 (1.04)	0.0	1.00	1.80	2.20	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	17	17 (100.0)	1.78 (1.18)	0.0	0.80	1.20	2.60	4.2	
			Placebo	21	21 (100.0)	1.67 (1.00)	0.0	0.80	2.00	2.20	3.6	
		Week 36	Tezepelumab	17	17 (100.0)	1.73 (1.07)	0.0	1.00	1.40	2.40	3.6	
			Placebo	21	21 (100.0)	2.19 (1.04)	0.0	1.60	2.40	2.80	4.4	
		Week 38	Tezepelumab	17	17 (100.0)	1.74 (1.23)	0.0	1.00	1.20	2.40	4.6	
			Placebo	21	21 (100.0)	1.85 (0.95)	0.0	1.20	2.00	2.60	3.4	
		Week 40	Tezepelumab	17	17 (100.0)	1.54 (1.15)	0.0	0.80	1.20	2.60	3.6	
			Placebo	21	21 (100.0)	2.14 (1.19)	0.0	1.40	2.20	2.80	4.4	
		Week 42	Tezepelumab	17	17 (100.0)	1.68 (1.10)	0.0	1.00	1.20	2.60	3.8	
			Placebo	21	21 (100.0)	1.95 (1.04)	0.0	1.20	2.00	2.60	4.6	
		Week 44	Tezepelumab	17	17 (100.0)	1.66 (1.09)	0.0	0.80	1.40	2.60	3.8	
			Placebo	21	21 (100.0)	2.00 (1.25)	0.0	1.20	2.00	2.80	4.2	
		Week 46	Tezepelumab	17	17 (100.0)	1.80 (1.15)	0.0	1.00	1.20	2.80	3.8	
			Placebo	21	21 (100.0)	1.85 (0.88)	0.0	1.40	2.00	2.40	3.4	
		Week 48	Tezepelumab	17	17 (100.0)	1.86 (1.19)	0.2	1.00	1.20	2.80	4.2	
			Placebo	21	21 (100.0)	2.07 (0.99)	0.0	2.00	2.40	2.60	4.0	
		Week 50	Tezepelumab	17	17 (100.0)	1.73 (1.15)	0.6	1.00	1.20	2.20	4.2	
			Placebo	21	21 (100.0)	1.82 (1.00)	0.0	1.00	2.00	2.60	3.4	
		Week 52	Tezepelumab	17	17 (100.0)	1.69 (1.23)	0.2	0.80	1.20	2.20	4.4	
			Placebo	21	21 (100.0)	1.88 (1.08)	0.0	1.00	2.00	2.60	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	17	17 (100.0)	-0.48 (0.82)	-2.2	-1.00	-0.40	-0.20	0.8	0.05 [-0.59, 0.68]
			Placebo	21	21 (100.0)	-0.51 (0.61)	-1.8	-1.00	-0.60	0.00	0.4	
		Week 4	Tezepelumab	17	17 (100.0)	-0.71 (1.13)	-2.6	-1.20	-1.00	-0.20	2.6	0.02 [-0.62, 0.66]
			Placebo	21	21 (100.0)	-0.72 (0.97)	-2.2	-1.60	-0.80	0.00	1.2	
		Week 6	Tezepelumab	17	17 (100.0)	-0.99 (1.32)	-2.8	-1.80	-1.00	-0.20	2.6	-0.30 [-0.94, 0.35]
			Placebo	21	21 (100.0)	-0.65 (0.99)	-2.4	-1.20	-0.80	0.00	1.6	
		Week 8	Tezepelumab	17	17 (100.0)	-1.15 (1.40)	-3.2	-2.20	-1.20	-0.40	2.6	-0.24 [-0.88, 0.41]
			Placebo	21	21 (100.0)	-0.88 (0.95)	-2.8	-1.60	-0.60	-0.20	0.6	
		Week 10	Tezepelumab	17	17 (100.0)	-1.44 (1.42)	-3.4	-2.20	-1.60	-1.00	2.6	-0.52 [-1.17, 0.13]
			Placebo	21	21 (100.0)	-0.82 (0.94)	-2.6	-1.40	-0.60	-0.40	1.6	
		Week 12	Tezepelumab	17	17 (100.0)	-1.54 (1.43)	-3.2	-2.40	-1.80	-1.00	2.6	-0.34 [-0.98, 0.31]
			Placebo	21	21 (100.0)	-1.12 (1.07)	-3.0	-2.00	-1.00	-0.40	1.4	
		Week 14	Tezepelumab	17	17 (100.0)	-1.44 (1.48)	-3.4	-2.20	-1.80	-0.40	2.6	-0.08 [-0.72, 0.56]
			Placebo	21	21 (100.0)	-1.34 (0.74)	-3.0	-1.60	-1.40	-1.00	0.2	
		Week 16	Tezepelumab	17	17 (100.0)	-1.39 (1.40)	-3.2	-2.20	-1.60	-0.60	2.6	-0.14 [-0.78, 0.50]
			Placebo	21	21 (100.0)	-1.22 (1.06)	-3.0	-2.00	-1.40	-0.20	1.0	
		Week 18	Tezepelumab	17	17 (100.0)	-1.36 (1.44)	-3.4	-2.40	-1.60	-0.80	2.6	-0.04 [-0.68, 0.60]
			Placebo	21	21 (100.0)	-1.31 (1.10)	-3.0	-2.20	-1.40	-0.40	1.4	
		Week 20	Tezepelumab	17	17 (100.0)	-1.32 (1.47)	-3.4	-2.20	-1.60	-0.60	2.6	-0.18 [-0.82, 0.46]
			Placebo	21	21 (100.0)	-1.10 (0.99)	-3.0	-1.60	-1.40	-0.40	0.8	
		Week 22	Tezepelumab	17	17 (100.0)	-1.38 (1.41)	-3.2	-2.40	-1.60	-0.60	2.6	-0.27 [-0.91, 0.37]
			Placebo	21	21 (100.0)	-1.07 (0.87)	-2.6	-1.60	-1.00	-0.60	0.6	
		Week 24	Tezepelumab	17	17 (100.0)	-1.40 (1.36)	-3.4	-2.00	-1.60	-0.80	2.6	-0.35 [-1.00, 0.29]
			Placebo	21	21 (100.0)	-1.00 (0.91)	-2.6	-1.60	-1.00	-0.20	0.4	
		Week 26	Tezepelumab	17	17 (100.0)	-1.27 (1.45)	-3.0	-2.40	-1.40	-0.20	2.6	-0.04 [-0.68, 0.60]
			Placebo	21	21 (100.0)	-1.22 (1.05)	-3.0	-2.00	-1.40	-0.60	0.8	
		Week 28	Tezepelumab	17	17 (100.0)	-1.24 (1.54)	-3.4	-2.40	-1.20	0.00	2.6	-0.01 [-0.65, 0.63]
			Placebo	21	21 (100.0)	-1.22 (1.16)	-3.0	-2.00	-1.40	-0.40	1.2	
		Week 30	Tezepelumab	17	17 (100.0)	-1.33 (1.36)	-3.0	-2.40	-1.40	-0.80	2.6	0.05 [-0.59, 0.68]
			Placebo	21	21 (100.0)	-1.38 (0.94)	-2.8	-1.80	-1.40	-1.00	1.0	
		Week 32	Tezepelumab	17	17 (100.0)	-1.47 (1.39)	-3.2	-2.60	-1.60	-1.00	2.6	-0.20 [-0.84, 0.44]
			Placebo	21	21 (100.0)	-1.24 (0.95)	-3.2	-1.60	-1.40	-1.20	0.8	
		Week 34	Tezepelumab	17	17 (100.0)	-1.35 (1.41)	-3.0	-2.20	-1.60	-0.80	2.6	-0.05 [-0.69, 0.59]
			Placebo	21	21 (100.0)	-1.30 (0.86)	-2.8	-1.80	-1.40	-0.80	0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	17	17 (100.0)	-1.40 (1.46)	-3.2	-2.40	-1.60	-0.80	2.6	-0.52 [-1.17, 0.13]
			Placebo	21	21 (100.0)	-0.77 (0.95)	-2.6	-1.20	-1.00	-0.20	1.4	
		Week 38	Tezepelumab	17	17 (100.0)	-1.39 (1.43)	-3.2	-2.40	-1.60	-0.80	2.6	-0.24 [-0.88, 0.40]
			Placebo	21	21 (100.0)	-1.11 (0.87)	-2.6	-1.60	-1.20	-0.40	0.4	
		Week 40	Tezepelumab	17	17 (100.0)	-1.59 (1.44)	-3.4	-2.60	-1.60	-1.00	2.6	-0.60 [-1.25, 0.05]
			Placebo	21	21 (100.0)	-0.82 (1.14)	-2.6	-1.40	-1.00	0.00	1.4	
		Week 42	Tezepelumab	17	17 (100.0)	-1.45 (1.41)	-3.0	-2.40	-1.60	-0.80	2.6	-0.36 [-1.01, 0.28]
			Placebo	21	21 (100.0)	-1.01 (1.01)	-2.6	-1.40	-1.20	-0.20	1.6	
		Week 44	Tezepelumab	17	17 (100.0)	-1.47 (1.44)	-3.4	-2.60	-1.40	-0.80	2.6	-0.40 [-1.04, 0.25]
			Placebo	21	21 (100.0)	-0.96 (1.14)	-2.6	-1.80	-1.20	-0.40	1.2	
		Week 46	Tezepelumab	17	17 (100.0)	-1.33 (1.41)	-3.0	-2.40	-1.40	-0.80	2.6	-0.20 [-0.84, 0.45]
			Placebo	21	21 (100.0)	-1.11 (0.77)	-2.6	-1.40	-1.00	-0.80	0.6	
		Week 48	Tezepelumab	17	17 (100.0)	-1.27 (1.50)	-3.0	-2.60	-1.60	-0.20	2.6	-0.31 [-0.95, 0.33]
			Placebo	21	21 (100.0)	-0.90 (0.92)	-3.0	-1.40	-1.00	-0.40	1.0	
		Week 50	Tezepelumab	17	17 (100.0)	-1.40 (1.43)	-3.0	-2.60	-1.60	-1.20	2.6	-0.22 [-0.86, 0.42]
			Placebo	21	21 (100.0)	-1.14 (0.94)	-2.8	-1.80	-1.00	-0.60	0.4	
		Week 52	Tezepelumab	17	17 (100.0)	-1.44 (1.46)	-3.0	-2.60	-1.60	-1.20	2.6	-0.28 [-0.93, 0.36]
			Placebo	21	21 (100.0)	-1.09 (1.01)	-2.8	-1.80	-1.00	-0.60	1.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	49	49 (100.0)	2.78 (0.78)	0.0	2.40	2.80	3.20	5.0	
			Placebo	44	44 (100.0)	2.81 (0.87)	0.4	2.50	2.80	3.20	5.0	
		Week 2	Tezepelumab	49	46 (93.9)	2.23 (0.99)	0.0	1.60	2.50	3.00	3.8	
			Placebo	44	37 (84.1)	2.37 (0.85)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	49	46 (93.9)	1.95 (1.01)	0.2	1.20	2.10	2.80	3.6	
			Placebo	44	37 (84.1)	2.26 (0.87)	0.2	1.80	2.60	3.00	3.6	
		Week 6	Tezepelumab	49	46 (93.9)	1.91 (1.01)	0.0	1.20	1.80	2.80	3.8	
			Placebo	44	37 (84.1)	2.16 (1.16)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	49	46 (93.9)	1.76 (1.16)	0.0	1.00	1.70	2.80	5.2	
			Placebo	44	38 (86.4)	2.15 (1.17)	0.0	1.40	2.10	3.00	5.0	
		Week 10	Tezepelumab	49	46 (93.9)	1.73 (1.10)	0.0	1.00	1.70	2.60	4.8	
			Placebo	44	38 (86.4)	2.16 (1.13)	0.0	1.60	2.20	3.00	5.2	
		Week 12	Tezepelumab	49	46 (93.9)	1.62 (1.11)	0.0	0.60	1.60	2.60	4.8	
			Placebo	44	38 (86.4)	2.00 (1.01)	0.0	1.20	2.00	2.60	4.4	
		Week 14	Tezepelumab	49	46 (93.9)	1.50 (1.04)	0.0	0.60	1.40	2.20	4.8	
			Placebo	44	38 (86.4)	2.01 (1.09)	0.0	1.20	2.20	2.60	5.0	
		Week 16	Tezepelumab	49	46 (93.9)	1.70 (1.19)	0.0	0.80	1.70	2.60	4.8	
			Placebo	44	38 (86.4)	2.19 (1.22)	0.0	1.40	2.20	2.80	5.0	
		Week 18	Tezepelumab	49	47 (95.9)	1.64 (1.07)	0.0	0.80	1.60	2.40	4.8	
			Placebo	44	38 (86.4)	2.09 (1.16)	0.0	1.40	2.30	2.80	5.0	
		Week 20	Tezepelumab	49	47 (95.9)	1.63 (1.09)	0.0	0.60	1.80	2.60	4.8	
			Placebo	44	38 (86.4)	2.13 (1.19)	0.2	1.40	2.30	2.80	5.0	
		Week 22	Tezepelumab	49	47 (95.9)	1.78 (1.02)	0.0	1.00	2.00	2.40	4.8	
			Placebo	44	38 (86.4)	2.03 (1.29)	0.0	0.80	2.00	2.80	5.0	
		Week 24	Tezepelumab	49	47 (95.9)	1.74 (1.13)	0.0	0.80	1.80	2.60	4.8	
			Placebo	44	38 (86.4)	2.09 (1.16)	0.0	1.40	2.10	2.80	4.4	
		Week 26	Tezepelumab	49	48 (98.0)	1.77 (1.15)	0.0	0.90	1.80	2.60	4.8	
			Placebo	44	38 (86.4)	2.11 (1.13)	0.4	1.20	1.90	3.00	4.4	
		Week 28	Tezepelumab	49	49 (100.0)	1.68 (1.15)	0.0	0.80	1.80	2.40	4.8	
			Placebo	44	39 (88.6)	2.08 (1.22)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	49	49 (100.0)	1.67 (1.14)	0.0	0.60	1.80	2.40	4.8	
			Placebo	44	39 (88.6)	2.13 (1.20)	0.0	1.00	2.40	3.00	4.4	
		Week 32	Tezepelumab	49	49 (100.0)	1.62 (1.14)	0.0	0.60	1.80	2.40	4.8	
			Placebo	44	39 (88.6)	2.00 (1.19)	0.0	1.00	2.00	2.80	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	49	49 (100.0)	1.69 (1.20)	0.0	0.80	1.60	2.80	4.8	
			Placebo	44	39 (88.6)	1.99 (1.20)	0.0	1.00	1.80	2.80	4.8	
		Week 36	Tezepelumab	49	49 (100.0)	1.64 (1.13)	0.0	1.00	1.60	2.40	4.8	
			Placebo	44	39 (88.6)	1.98 (1.27)	0.0	1.00	1.80	2.80	4.8	
		Week 38	Tezepelumab	49	49 (100.0)	1.71 (1.24)	0.0	0.80	1.80	2.60	4.8	
			Placebo	44	39 (88.6)	1.96 (1.22)	0.0	1.00	1.80	2.80	4.8	
		Week 40	Tezepelumab	49	49 (100.0)	1.75 (1.20)	0.0	0.80	2.00	2.80	4.8	
			Placebo	44	39 (88.6)	2.02 (1.20)	0.0	1.00	1.80	3.00	4.4	
		Week 42	Tezepelumab	49	49 (100.0)	1.63 (1.17)	0.0	0.80	1.80	2.40	4.8	
			Placebo	44	39 (88.6)	1.91 (1.08)	0.0	1.00	2.00	2.60	4.4	
		Week 44	Tezepelumab	49	49 (100.0)	1.69 (1.17)	0.0	0.80	1.80	2.60	4.8	
			Placebo	44	39 (88.6)	2.01 (1.06)	0.0	1.20	2.00	2.80	4.4	
		Week 46	Tezepelumab	49	49 (100.0)	1.68 (1.22)	0.0	0.80	1.80	2.60	4.8	
			Placebo	44	39 (88.6)	1.90 (1.08)	0.0	1.20	2.00	2.60	4.4	
		Week 48	Tezepelumab	49	49 (100.0)	1.66 (1.19)	0.0	0.80	1.80	2.40	4.8	
			Placebo	44	39 (88.6)	1.88 (1.16)	0.0	1.00	2.00	2.40	4.6	
		Week 50	Tezepelumab	49	49 (100.0)	1.62 (1.23)	0.0	0.60	1.60	2.60	4.8	
			Placebo	44	39 (88.6)	1.83 (1.05)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	49	49 (100.0)	1.67 (1.18)	0.0	0.80	1.80	2.60	4.8	
			Placebo	44	39 (88.6)	1.90 (1.10)	0.0	1.00	2.00	2.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	49	46 (93.9)	-0.59 (0.79)	-3.2	-1.20	-0.40	0.20	0.4	-0.12 [-0.55, 0.31]
			Placebo	44	37 (84.1)	-0.50 (0.79)	-2.8	-0.80	-0.40	0.00	1.2	
		Week 4	Tezepelumab	49	46 (93.9)	-0.87 (0.85)	-2.6	-1.40	-0.80	-0.20	0.8	-0.29 [-0.73, 0.14]
			Placebo	44	37 (84.1)	-0.61 (0.97)	-3.0	-1.20	-0.40	0.00	0.8	
		Week 6	Tezepelumab	49	46 (93.9)	-0.91 (0.91)	-2.8	-1.60	-1.00	0.00	1.2	-0.21 [-0.64, 0.23]
			Placebo	44	37 (84.1)	-0.71 (1.10)	-3.4	-1.60	-0.40	0.00	1.6	
		Week 8	Tezepelumab	49	46 (93.9)	-1.07 (1.06)	-3.0	-1.80	-1.00	-0.40	2.6	-0.31 [-0.74, 0.12]
			Placebo	44	38 (86.4)	-0.73 (1.12)	-3.6	-1.20	-0.60	0.00	1.0	
		Week 10	Tezepelumab	49	46 (93.9)	-1.09 (0.99)	-3.0	-1.80	-1.20	-0.60	1.0	-0.33 [-0.76, 0.10]
			Placebo	44	38 (86.4)	-0.72 (1.27)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	49	46 (93.9)	-1.20 (0.96)	-3.2	-2.20	-1.20	-0.60	0.6	-0.31 [-0.75, 0.12]
			Placebo	44	38 (86.4)	-0.88 (1.09)	-3.8	-1.20	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	49	46 (93.9)	-1.32 (0.96)	-4.0	-2.00	-1.20	-0.80	0.6	-0.42 [-0.85, 0.02]
			Placebo	44	38 (86.4)	-0.87 (1.20)	-3.4	-1.60	-0.90	-0.20	2.4	
		Week 16	Tezepelumab	49	46 (93.9)	-1.13 (1.04)	-2.8	-2.20	-1.00	-0.60	1.8	-0.39 [-0.83, 0.04]
			Placebo	44	38 (86.4)	-0.68 (1.21)	-3.6	-1.20	-0.50	0.00	2.6	
		Week 18	Tezepelumab	49	47 (95.9)	-1.17 (0.96)	-3.8	-1.80	-1.00	-0.60	0.6	-0.34 [-0.77, 0.09]
			Placebo	44	38 (86.4)	-0.79 (1.27)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 20	Tezepelumab	49	47 (95.9)	-1.17 (0.95)	-2.8	-2.00	-1.00	-0.40	0.6	-0.38 [-0.81, 0.05]
			Placebo	44	38 (86.4)	-0.75 (1.27)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	49	47 (95.9)	-1.02 (1.01)	-2.8	-1.60	-1.00	-0.60	2.0	-0.15 [-0.58, 0.28]
			Placebo	44	38 (86.4)	-0.85 (1.33)	-3.8	-1.60	-0.90	0.00	2.6	
		Week 24	Tezepelumab	49	47 (95.9)	-1.06 (0.98)	-2.8	-2.00	-0.80	-0.20	0.6	-0.25 [-0.68, 0.18]
			Placebo	44	38 (86.4)	-0.78 (1.24)	-3.6	-1.60	-0.80	0.00	2.6	
		Week 26	Tezepelumab	49	48 (98.0)	-1.02 (1.00)	-2.8	-2.10	-0.90	-0.20	0.6	-0.22 [-0.65, 0.21]
			Placebo	44	38 (86.4)	-0.77 (1.25)	-3.4	-1.60	-0.80	0.00	2.6	
		Week 28	Tezepelumab	49	49 (100.0)	-1.10 (1.09)	-2.8	-2.20	-1.00	-0.60	1.0	-0.31 [-0.74, 0.11]
			Placebo	44	39 (88.6)	-0.74 (1.25)	-3.4	-1.60	-0.60	0.00	2.6	
		Week 30	Tezepelumab	49	49 (100.0)	-1.11 (1.12)	-3.8	-2.20	-1.00	-0.40	2.0	-0.35 [-0.78, 0.07]
			Placebo	44	39 (88.6)	-0.69 (1.31)	-3.4	-1.60	-0.60	0.20	2.6	
		Week 32	Tezepelumab	49	49 (100.0)	-1.16 (1.00)	-2.8	-2.20	-1.00	-0.40	1.0	-0.31 [-0.73, 0.12]
			Placebo	44	39 (88.6)	-0.82 (1.26)	-3.2	-1.80	-0.60	-0.20	2.6	
		Week 34	Tezepelumab	49	49 (100.0)	-1.09 (1.13)	-2.8	-2.20	-1.00	-0.20	2.2	-0.22 [-0.65, 0.20]
			Placebo	44	39 (88.6)	-0.83 (1.27)	-3.2	-1.60	-0.80	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHK: Change from baseline in ACQ-5 score by key subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	49	49 (100.0)	-1.13 (1.07)	-3.0	-2.00	-1.20	-0.20	1.6	-0.25 [-0.67, 0.17]
			Placebo	44	39 (88.6)	-0.84 (1.36)	-3.6	-1.60	-0.80	0.00	2.6	
		Week 38	Tezepelumab	49	49 (100.0)	-1.07 (1.16)	-2.8	-2.20	-1.00	-0.20	2.6	-0.18 [-0.61, 0.24]
			Placebo	44	39 (88.6)	-0.85 (1.28)	-3.2	-1.60	-1.00	0.00	2.6	
		Week 40	Tezepelumab	49	49 (100.0)	-1.03 (1.10)	-2.8	-2.00	-1.00	-0.20	1.8	-0.20 [-0.62, 0.22]
			Placebo	44	39 (88.6)	-0.79 (1.27)	-3.2	-1.60	-0.80	-0.20	2.6	
		Week 42	Tezepelumab	49	49 (100.0)	-1.15 (1.13)	-3.6	-2.00	-1.20	-0.40	2.2	-0.21 [-0.63, 0.21]
			Placebo	44	39 (88.6)	-0.91 (1.16)	-2.8	-1.60	-1.00	-0.40	2.6	
		Week 44	Tezepelumab	49	49 (100.0)	-1.09 (1.11)	-3.8	-2.00	-1.20	-0.20	1.6	-0.25 [-0.68, 0.17]
			Placebo	44	39 (88.6)	-0.81 (1.17)	-3.4	-1.60	-0.60	0.00	2.6	
		Week 46	Tezepelumab	49	49 (100.0)	-1.10 (1.14)	-3.6	-2.20	-1.00	-0.20	1.8	-0.16 [-0.58, 0.26]
			Placebo	44	39 (88.6)	-0.91 (1.19)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	49	49 (100.0)	-1.12 (1.08)	-2.8	-2.00	-1.00	-0.40	2.0	-0.16 [-0.58, 0.27]
			Placebo	44	39 (88.6)	-0.94 (1.24)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	49	49 (100.0)	-1.16 (1.14)	-3.2	-2.20	-1.20	-0.40	2.0	-0.15 [-0.57, 0.27]
			Placebo	44	39 (88.6)	-0.99 (1.13)	-3.6	-1.60	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	49	49 (100.0)	-1.11 (1.10)	-3.2	-2.00	-1.00	-0.40	2.0	-0.17 [-0.59, 0.25]
			Placebo	44	39 (88.6)	-0.91 (1.17)	-3.6	-1.60	-0.80	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	2.87 (0.92)	0.0	2.40	2.80	3.20	5.2	
			Placebo	58	58 (100.0)	2.84 (0.75)	0.4	2.60	3.00	3.20	4.8	
		Week 2	Tezepelumab	60	57 (95.0)	2.40 (0.99)	0.2	1.60	2.60	3.00	4.4	
			Placebo	58	51 (87.9)	2.38 (0.75)	0.4	2.00	2.40	2.80	4.8	
		Week 4	Tezepelumab	60	57 (95.0)	2.12 (1.00)	0.2	1.40	2.20	3.00	3.6	
			Placebo	58	51 (87.9)	2.22 (0.90)	0.2	1.80	2.40	2.80	4.2	
		Week 6	Tezepelumab	60	57 (95.0)	2.02 (1.04)	0.0	1.40	2.00	2.80	4.0	
			Placebo	58	51 (87.9)	2.20 (1.07)	0.2	1.40	2.20	3.00	5.0	
		Week 8	Tezepelumab	60	57 (95.0)	1.87 (1.19)	0.0	1.00	1.80	2.80	5.2	
			Placebo	58	52 (89.7)	2.10 (1.09)	0.0	1.30	2.30	2.90	4.6	
		Week 10	Tezepelumab	60	57 (95.0)	1.79 (1.15)	0.0	1.00	1.80	2.60	4.8	
			Placebo	58	52 (89.7)	2.13 (1.03)	0.0	1.60	2.30	2.90	4.4	
		Week 12	Tezepelumab	60	57 (95.0)	1.67 (1.10)	0.0	0.60	1.80	2.60	4.8	
			Placebo	58	52 (89.7)	1.94 (1.05)	0.0	1.00	2.00	2.60	4.4	
		Week 14	Tezepelumab	60	57 (95.0)	1.60 (1.15)	0.0	0.60	1.60	2.20	4.8	
			Placebo	58	52 (89.7)	1.85 (0.91)	0.0	1.30	2.00	2.40	5.0	
		Week 16	Tezepelumab	60	57 (95.0)	1.79 (1.21)	0.0	0.80	1.80	2.80	4.8	
			Placebo	58	52 (89.7)	2.00 (1.08)	0.0	1.00	2.00	2.80	4.4	
		Week 18	Tezepelumab	60	58 (96.7)	1.75 (1.10)	0.0	1.00	1.80	2.60	4.8	
			Placebo	58	52 (89.7)	1.89 (1.13)	0.0	1.10	1.90	2.60	4.8	
		Week 20	Tezepelumab	60	58 (96.7)	1.75 (1.17)	0.0	0.80	1.80	2.60	5.0	
			Placebo	58	52 (89.7)	1.96 (1.06)	0.0	1.20	2.00	2.80	4.4	
		Week 22	Tezepelumab	60	58 (96.7)	1.85 (1.03)	0.0	1.20	2.00	2.60	4.8	
			Placebo	58	52 (89.7)	1.90 (1.10)	0.0	1.00	2.00	2.60	4.4	
		Week 24	Tezepelumab	60	58 (96.7)	1.80 (1.12)	0.0	1.20	1.80	2.60	4.8	
			Placebo	58	52 (89.7)	2.01 (1.04)	0.0	1.50	2.00	2.70	4.4	
		Week 26	Tezepelumab	60	59 (98.3)	1.87 (1.13)	0.0	1.20	1.80	2.80	4.8	
			Placebo	58	52 (89.7)	1.98 (1.10)	0.0	1.00	1.80	2.90	4.4	
		Week 28	Tezepelumab	60	60 (100.0)	1.81 (1.17)	0.0	1.20	1.80	2.70	4.8	
			Placebo	58	53 (91.4)	1.98 (1.19)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	60	60 (100.0)	1.77 (1.12)	0.0	1.10	1.80	2.60	4.8	
			Placebo	58	53 (91.4)	1.95 (1.15)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	60	60 (100.0)	1.68 (1.15)	0.0	0.70	1.80	2.60	4.8	
			Placebo	58	53 (91.4)	1.89 (1.13)	0.0	1.00	1.80	2.80	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Absolute values	Week 34	Tezepelumab	60	60 (100.0)	1.78 (1.21)	0.0	0.90	1.80	2.80	4.8	
			Placebo	58	53 (91.4)	1.89 (1.09)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	60	60 (100.0)	1.72 (1.13)	0.0	0.90	1.60	2.60	4.8	
			Placebo	58	53 (91.4)	2.00 (1.17)	0.0	1.20	2.00	2.80	4.8	
		Week 38	Tezepelumab	60	60 (100.0)	1.78 (1.25)	0.0	0.90	1.80	2.60	4.8	
			Placebo	58	53 (91.4)	1.92 (1.10)	0.0	1.00	1.80	2.60	4.8	
		Week 40	Tezepelumab	60	60 (100.0)	1.75 (1.21)	0.0	0.70	2.00	2.80	4.8	
			Placebo	58	53 (91.4)	2.06 (1.18)	0.0	1.20	2.20	3.00	4.4	
		Week 42	Tezepelumab	60	60 (100.0)	1.68 (1.18)	0.0	0.80	1.70	2.60	4.8	
			Placebo	58	53 (91.4)	1.95 (1.07)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	60	60 (100.0)	1.73 (1.16)	0.0	0.80	1.80	2.80	4.8	
			Placebo	58	53 (91.4)	1.98 (1.09)	0.0	1.20	2.00	2.60	4.4	
		Week 46	Tezepelumab	60	60 (100.0)	1.77 (1.22)	0.0	0.80	1.90	2.80	4.8	
			Placebo	58	53 (91.4)	1.92 (1.01)	0.0	1.20	2.00	2.40	4.4	
		Week 48	Tezepelumab	60	60 (100.0)	1.77 (1.22)	0.0	0.80	1.90	2.70	4.8	
			Placebo	58	53 (91.4)	1.93 (1.11)	0.0	1.00	2.00	2.40	4.6	
		Week 50	Tezepelumab	60	60 (100.0)	1.72 (1.22)	0.0	0.80	1.70	2.60	4.8	
			Placebo	58	53 (91.4)	1.81 (1.00)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	60	60 (100.0)	1.76 (1.20)	0.0	0.80	1.80	2.60	4.8	
			Placebo	58	53 (91.4)	1.91 (1.05)	0.0	1.00	2.00	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 2	Tezepelumab	60	57 (95.0)	-0.51 (0.74)	-2.2	-1.00	-0.40	0.20	0.8	-0.01 [-0.39, 0.37]
			Placebo	58	51 (87.9)	-0.51 (0.75)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	60	57 (95.0)	-0.79 (0.92)	-2.6	-1.20	-0.80	-0.20	2.6	-0.14 [-0.52, 0.24]
			Placebo	58	51 (87.9)	-0.66 (0.98)	-3.0	-1.40	-0.40	0.00	1.2	
		Week 6	Tezepelumab	60	57 (95.0)	-0.88 (1.02)	-2.8	-1.60	-1.00	-0.20	2.6	-0.20 [-0.58, 0.18]
			Placebo	58	51 (87.9)	-0.68 (1.08)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	60	57 (95.0)	-1.04 (1.16)	-3.2	-1.60	-1.00	-0.40	2.6	-0.21 [-0.59, 0.16]
			Placebo	58	52 (89.7)	-0.80 (1.06)	-3.6	-1.50	-0.60	0.00	1.0	
		Week 10	Tezepelumab	60	57 (95.0)	-1.12 (1.12)	-3.4	-1.80	-1.20	-0.60	2.6	-0.32 [-0.70, 0.06]
			Placebo	58	52 (89.7)	-0.76 (1.11)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	60	57 (95.0)	-1.24 (1.10)	-3.2	-2.20	-1.20	-0.60	2.6	-0.26 [-0.64, 0.11]
			Placebo	58	52 (89.7)	-0.95 (1.06)	-3.8	-1.50	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	60	57 (95.0)	-1.31 (1.13)	-4.0	-2.20	-1.20	-0.60	2.6	-0.25 [-0.63, 0.13]
			Placebo	58	52 (89.7)	-1.04 (0.99)	-3.4	-1.60	-1.00	-0.40	1.4	
		Week 16	Tezepelumab	60	57 (95.0)	-1.12 (1.17)	-3.2	-2.00	-1.00	-0.40	2.6	-0.20 [-0.58, 0.17]
			Placebo	58	52 (89.7)	-0.89 (1.11)	-3.6	-1.40	-0.90	-0.20	2.6	
		Week 18	Tezepelumab	60	58 (96.7)	-1.14 (1.11)	-3.8	-1.80	-1.00	-0.60	2.6	-0.13 [-0.50, 0.25]
			Placebo	58	52 (89.7)	-1.00 (1.17)	-3.6	-1.90	-0.90	-0.20	2.6	
		Week 20	Tezepelumab	60	58 (96.7)	-1.14 (1.12)	-3.4	-1.80	-1.10	-0.40	2.6	-0.19 [-0.56, 0.19]
			Placebo	58	52 (89.7)	-0.93 (1.12)	-3.6	-1.50	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	60	58 (96.7)	-1.04 (1.13)	-3.2	-1.60	-1.00	-0.60	2.6	-0.05 [-0.42, 0.32]
			Placebo	58	52 (89.7)	-0.99 (1.15)	-3.8	-1.60	-1.00	-0.30	2.6	
		Week 24	Tezepelumab	60	58 (96.7)	-1.09 (1.09)	-3.4	-1.80	-1.00	-0.40	2.6	-0.19 [-0.56, 0.19]
			Placebo	58	52 (89.7)	-0.88 (1.12)	-3.6	-1.50	-0.80	-0.10	2.6	
		Week 26	Tezepelumab	60	59 (98.3)	-1.01 (1.13)	-3.0	-2.00	-1.00	-0.20	2.6	-0.08 [-0.45, 0.29]
			Placebo	58	52 (89.7)	-0.92 (1.18)	-3.4	-1.80	-1.20	0.00	2.6	
		Week 28	Tezepelumab	60	60 (100.0)	-1.06 (1.22)	-3.4	-2.20	-0.90	0.00	2.6	-0.16 [-0.53, 0.21]
			Placebo	58	53 (91.4)	-0.86 (1.21)	-3.4	-1.60	-1.00	0.00	2.6	
		Week 30	Tezepelumab	60	60 (100.0)	-1.10 (1.19)	-3.8	-2.20	-1.00	-0.40	2.6	-0.18 [-0.55, 0.19]
			Placebo	58	53 (91.4)	-0.89 (1.23)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 32	Tezepelumab	60	60 (100.0)	-1.19 (1.13)	-3.2	-2.20	-1.20	-0.60	2.6	-0.21 [-0.58, 0.16]
			Placebo	58	53 (91.4)	-0.95 (1.18)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	60	60 (100.0)	-1.09 (1.22)	-3.0	-2.20	-1.20	-0.30	2.6	-0.11 [-0.48, 0.26]
			Placebo	58	53 (91.4)	-0.96 (1.14)	-3.2	-1.60	-1.20	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Change from baseline	Week 36	Tezepelumab	60	60 (100.0)	-1.15 (1.20)	-3.2	-2.00	-1.20	-0.20	2.6	-0.25 [-0.62, 0.12]
			Placebo	58	53 (91.4)	-0.85 (1.22)	-3.6	-1.40	-1.00	-0.20	2.6	
		Week 38	Tezepelumab	60	60 (100.0)	-1.09 (1.25)	-3.2	-2.20	-1.20	-0.10	2.6	-0.14 [-0.51, 0.23]
			Placebo	58	53 (91.4)	-0.92 (1.15)	-3.2	-1.60	-1.00	-0.40	2.6	
		Week 40	Tezepelumab	60	60 (100.0)	-1.12 (1.23)	-3.4	-2.20	-1.10	-0.40	2.6	-0.27 [-0.64, 0.10]
			Placebo	58	53 (91.4)	-0.78 (1.22)	-3.2	-1.40	-0.80	0.00	2.6	
		Week 42	Tezepelumab	60	60 (100.0)	-1.19 (1.24)	-3.6	-2.10	-1.20	-0.40	2.6	-0.24 [-0.61, 0.13]
			Placebo	58	53 (91.4)	-0.90 (1.16)	-2.8	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	60	60 (100.0)	-1.14 (1.22)	-3.8	-2.10	-1.20	-0.40	2.6	-0.23 [-0.60, 0.14]
			Placebo	58	53 (91.4)	-0.86 (1.15)	-3.4	-1.60	-1.00	-0.20	2.6	
		Week 46	Tezepelumab	60	60 (100.0)	-1.10 (1.23)	-3.6	-2.20	-1.10	-0.20	2.6	-0.15 [-0.52, 0.22]
			Placebo	58	53 (91.4)	-0.92 (1.11)	-3.2	-1.40	-1.00	-0.40	2.6	
		Week 48	Tezepelumab	60	60 (100.0)	-1.10 (1.22)	-3.0	-2.20	-1.00	-0.40	2.6	-0.15 [-0.52, 0.22]
			Placebo	58	53 (91.4)	-0.92 (1.18)	-3.4	-1.40	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	60	60 (100.0)	-1.15 (1.22)	-3.0	-2.20	-1.20	-0.30	2.6	-0.10 [-0.47, 0.27]
			Placebo	58	53 (91.4)	-1.04 (1.03)	-3.6	-1.60	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	60	60 (100.0)	-1.11 (1.20)	-3.0	-2.10	-1.20	-0.20	2.6	-0.15 [-0.52, 0.22]
			Placebo	58	53 (91.4)	-0.94 (1.07)	-3.6	-1.60	-0.80	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	2.87 (0.45)	2.4	2.40	2.90	3.20	3.4	
			Placebo	7	7 (100.0)	3.03 (0.93)	2.2	2.60	2.60	3.20	5.0	
		Week 2	Tezepelumab	6	6 (100.0)	1.83 (1.20)	0.0	1.00	2.00	2.80	3.2	
			Placebo	7	7 (100.0)	2.54 (1.15)	1.4	2.00	2.40	2.60	5.0	
		Week 4	Tezepelumab	6	6 (100.0)	1.73 (1.03)	0.8	0.80	1.50	2.40	3.4	
			Placebo	7	7 (100.0)	2.46 (1.07)	0.8	1.40	2.60	3.60	3.6	
		Week 6	Tezepelumab	6	6 (100.0)	1.47 (0.90)	0.4	1.00	1.30	1.80	3.0	
			Placebo	7	7 (100.0)	2.29 (1.75)	1.0	1.00	2.00	2.60	6.0	
		Week 8	Tezepelumab	6	6 (100.0)	1.27 (0.93)	0.2	0.60	1.10	1.80	2.8	
			Placebo	7	7 (100.0)	2.37 (1.54)	0.2	1.00	2.40	3.20	5.0	
		Week 10	Tezepelumab	6	6 (100.0)	1.03 (0.77)	0.2	0.60	0.80	1.40	2.4	
			Placebo	7	7 (100.0)	2.29 (1.49)	0.8	1.00	1.80	3.00	5.2	
		Week 12	Tezepelumab	6	6 (100.0)	1.07 (1.11)	0.0	0.20	0.80	1.60	3.0	
			Placebo	7	7 (100.0)	1.97 (1.25)	0.0	1.00	2.00	3.00	3.8	
		Week 14	Tezepelumab	6	6 (100.0)	1.10 (0.72)	0.4	0.60	0.90	1.40	2.4	
			Placebo	7	7 (100.0)	2.00 (1.62)	0.0	1.00	1.80	3.00	5.0	
		Week 16	Tezepelumab	6	6 (100.0)	0.93 (0.41)	0.2	0.80	1.00	1.20	1.4	
			Placebo	7	7 (100.0)	2.26 (2.02)	0.0	0.60	2.00	5.00	5.0	
		Week 18	Tezepelumab	6	6 (100.0)	0.93 (0.58)	0.4	0.60	0.80	1.00	2.0	
			Placebo	7	7 (100.0)	2.23 (1.57)	0.0	1.00	2.20	3.00	5.0	
		Week 20	Tezepelumab	6	6 (100.0)	1.00 (0.57)	0.4	0.60	0.90	1.20	2.0	
			Placebo	7	7 (100.0)	2.60 (1.43)	0.4	1.80	2.40	3.40	5.0	
		Week 22	Tezepelumab	6	6 (100.0)	1.07 (0.85)	0.0	0.80	1.00	1.00	2.6	
			Placebo	7	7 (100.0)	2.57 (1.49)	0.4	1.20	2.60	3.40	5.0	
		Week 24	Tezepelumab	6	6 (100.0)	1.13 (0.85)	0.4	0.80	0.90	1.00	2.8	
			Placebo	7	7 (100.0)	2.31 (1.31)	0.4	0.80	2.60	3.40	4.0	
		Week 26	Tezepelumab	6	6 (100.0)	1.03 (0.74)	0.2	0.60	1.00	1.00	2.4	
			Placebo	7	7 (100.0)	2.00 (1.47)	0.0	0.40	1.80	3.40	4.0	
		Week 28	Tezepelumab	6	6 (100.0)	1.00 (0.77)	0.2	0.40	1.00	1.00	2.4	
			Placebo	7	7 (100.0)	1.80 (1.58)	0.0	0.40	2.00	3.40	4.0	
		Week 30	Tezepelumab	6	6 (100.0)	1.03 (0.69)	0.6	0.60	0.80	1.00	2.4	
			Placebo	7	7 (100.0)	1.80 (1.47)	0.0	0.40	1.60	3.40	4.0	
		Week 32	Tezepelumab	6	6 (100.0)	1.17 (0.75)	0.2	0.80	1.00	1.60	2.4	
			Placebo	7	7 (100.0)	1.97 (1.31)	0.4	0.80	1.60	3.40	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Non-white	Absolute values	Week 34	Tezepelumab	6	6 (100.0)	1.03 (0.70)	0.4	0.80	0.80	1.00	2.4	
			Placebo	7	7 (100.0)	1.80 (1.57)	0.0	0.20	1.60	3.40	4.0	
		Week 36	Tezepelumab	6	6 (100.0)	1.10 (0.71)	0.2	1.00	1.00	1.00	2.4	
			Placebo	7	7 (100.0)	2.46 (1.36)	0.0	1.60	2.60	3.40	4.0	
		Week 38	Tezepelumab	6	6 (100.0)	1.07 (0.86)	0.0	0.60	0.80	2.00	2.2	
			Placebo	7	7 (100.0)	1.91 (1.42)	0.0	0.60	1.80	3.40	4.0	
		Week 40	Tezepelumab	6	6 (100.0)	1.13 (0.65)	0.4	0.80	0.90	1.60	2.2	
			Placebo	7	7 (100.0)	2.06 (1.41)	0.0	0.80	2.00	3.40	4.0	
		Week 42	Tezepelumab	6	6 (100.0)	1.23 (0.65)	0.4	1.00	1.00	1.80	2.2	
			Placebo	7	7 (100.0)	1.74 (1.00)	0.0	1.40	1.80	2.00	3.4	
		Week 44	Tezepelumab	6	6 (100.0)	1.17 (0.80)	0.2	0.60	1.00	1.80	2.4	
			Placebo	7	7 (100.0)	2.20 (1.35)	0.6	0.80	2.80	3.40	3.8	
		Week 46	Tezepelumab	6	6 (100.0)	1.10 (0.71)	0.2	1.00	1.00	1.00	2.4	
			Placebo	7	7 (100.0)	1.57 (1.04)	0.4	0.60	1.60	2.20	3.4	
		Week 48	Tezepelumab	6	6 (100.0)	1.13 (0.62)	0.4	0.80	1.00	1.40	2.2	
			Placebo	7	7 (100.0)	2.06 (1.03)	0.4	1.00	2.40	2.60	3.4	
		Week 50	Tezepelumab	6	6 (100.0)	0.90 (0.75)	0.0	0.40	0.90	1.00	2.2	
			Placebo	7	7 (100.0)	1.94 (1.28)	0.2	1.00	1.80	3.40	3.8	
		Week 52	Tezepelumab	6	6 (100.0)	0.90 (0.75)	0.0	0.40	0.90	1.00	2.2	
			Placebo	7	7 (100.0)	1.80 (1.45)	0.0	0.20	1.80	3.40	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 2	Tezepelumab	6	6 (100.0)	-1.03 (1.20)	-3.2	-1.40	-0.80	-0.20	0.2	-0.62 [-1.74, 0.50]
			Placebo	7	7 (100.0)	-0.49 (0.50)	-1.2	-1.00	-0.20	0.00	0.0	
		Week 4	Tezepelumab	6	6 (100.0)	-1.13 (1.06)	-2.4	-1.60	-1.30	-1.00	0.8	-0.56 [-1.67, 0.56]
			Placebo	7	7 (100.0)	-0.57 (0.96)	-1.8	-1.40	-0.40	0.40	0.6	
		Week 6	Tezepelumab	6	6 (100.0)	-1.40 (1.03)	-2.8	-1.60	-1.50	-1.40	0.4	-0.67 [-1.80, 0.45]
			Placebo	7	7 (100.0)	-0.74 (0.94)	-1.8	-1.60	-0.60	-0.40	1.0	
		Week 8	Tezepelumab	6	6 (100.0)	-1.60 (1.04)	-3.0	-2.00	-1.70	-1.40	0.2	-0.87 [-2.02, 0.28]
			Placebo	7	7 (100.0)	-0.66 (1.11)	-2.8	-1.20	-0.40	0.00	0.6	
		Week 10	Tezepelumab	6	6 (100.0)	-1.83 (0.98)	-3.0	-2.60	-1.80	-1.60	-0.2	-0.81 [-1.95, 0.33]
			Placebo	7	7 (100.0)	-0.74 (1.59)	-2.2	-2.00	-0.80	-0.80	2.6	
		Week 12	Tezepelumab	6	6 (100.0)	-1.80 (1.11)	-2.6	-2.40	-2.20	-1.80	0.4	-0.61 [-1.73, 0.51]
			Placebo	7	7 (100.0)	-1.06 (1.29)	-3.0	-2.00	-1.00	-0.60	1.2	
		Week 14	Tezepelumab	6	6 (100.0)	-1.77 (0.87)	-2.8	-2.20	-1.90	-1.60	-0.2	-0.54 [-1.65, 0.58]
			Placebo	7	7 (100.0)	-1.03 (1.69)	-3.0	-2.00	-1.40	-0.60	2.4	
		Week 16	Tezepelumab	6	6 (100.0)	-1.93 (0.50)	-2.4	-2.20	-2.20	-1.40	-1.2	-0.89 [-2.04, 0.26]
			Placebo	7	7 (100.0)	-0.77 (1.71)	-3.0	-2.00	-1.20	0.00	2.4	
		Week 18	Tezepelumab	6	6 (100.0)	-1.93 (0.76)	-2.8	-2.40	-2.00	-1.80	-0.6	-0.84 [-1.99, 0.30]
			Placebo	7	7 (100.0)	-0.80 (1.69)	-3.0	-2.00	-1.00	-0.40	2.4	
		Week 20	Tezepelumab	6	6 (100.0)	-1.87 (0.70)	-2.6	-2.20	-2.10	-1.60	-0.6	-1.14 [-2.33, 0.05]
			Placebo	7	7 (100.0)	-0.43 (1.58)	-2.0	-1.80	-0.80	0.80	2.4	
		Week 22	Tezepelumab	6	6 (100.0)	-1.80 (0.93)	-2.4	-2.40	-2.20	-1.60	0.0	-1.09 [-2.27, 0.09]
			Placebo	7	7 (100.0)	-0.46 (1.44)	-1.8	-1.60	-0.60	0.00	2.4	
		Week 24	Tezepelumab	6	6 (100.0)	-1.73 (0.99)	-2.4	-2.40	-2.10	-1.60	0.2	-0.87 [-2.02, 0.28]
			Placebo	7	7 (100.0)	-0.71 (1.30)	-2.2	-1.80	-1.00	0.20	1.4	
		Week 26	Tezepelumab	6	6 (100.0)	-1.83 (0.90)	-2.6	-2.40	-2.20	-1.40	-0.2	-0.67 [-1.79, 0.46]
			Placebo	7	7 (100.0)	-1.03 (1.41)	-3.0	-1.80	-1.40	0.00	1.4	
		Week 28	Tezepelumab	6	6 (100.0)	-1.87 (0.94)	-2.8	-2.40	-2.20	-1.40	-0.2	-0.52 [-1.63, 0.59]
			Placebo	7	7 (100.0)	-1.23 (1.42)	-3.0	-2.20	-1.60	-0.60	1.4	
		Week 30	Tezepelumab	6	6 (100.0)	-1.83 (0.90)	-2.6	-2.60	-2.00	-1.60	-0.2	-0.55 [-1.66, 0.57]
			Placebo	7	7 (100.0)	-1.23 (1.25)	-2.6	-1.80	-1.40	-1.20	1.4	
		Week 32	Tezepelumab	6	6 (100.0)	-1.70 (0.81)	-2.4	-2.20	-1.90	-1.60	-0.2	-0.63 [-1.76, 0.49]
			Placebo	7	7 (100.0)	-1.06 (1.16)	-1.8	-1.80	-1.60	-0.60	1.4	
		Week 34	Tezepelumab	6	6 (100.0)	-1.83 (0.87)	-2.6	-2.40	-2.10	-1.60	-0.2	-0.52 [-1.63, 0.59]
			Placebo	7	7 (100.0)	-1.23 (1.37)	-2.8	-2.20	-1.60	-0.60	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Non-white	Change from baseline	Week 36	Tezepelumab	6	6 (100.0)	-1.77 (0.84)	-2.4	-2.20	-2.20	-1.40	-0.2	-1.07 [-2.25, 0.11]
			Placebo	7	7 (100.0)	-0.57 (1.30)	-2.2	-1.60	-0.60	0.80	1.4	
		Week 38	Tezepelumab	6	6 (100.0)	-1.80 (0.81)	-2.6	-2.40	-2.00	-1.40	-0.4	-0.66 [-1.79, 0.46]
			Placebo	7	7 (100.0)	-1.11 (1.19)	-2.2	-2.00	-1.20	-1.00	1.4	
		Week 40	Tezepelumab	6	6 (100.0)	-1.73 (0.76)	-2.6	-2.20	-1.80	-1.60	-0.4	-0.70 [-1.83, 0.43]
			Placebo	7	7 (100.0)	-0.97 (1.29)	-2.2	-2.20	-1.20	0.00	1.4	
		Week 42	Tezepelumab	6	6 (100.0)	-1.63 (0.73)	-2.4	-2.20	-1.70	-1.40	-0.4	-0.57 [-1.69, 0.54]
			Placebo	7	7 (100.0)	-1.29 (0.47)	-2.2	-1.60	-1.20	-1.00	-0.8	
		Week 44	Tezepelumab	6	6 (100.0)	-1.70 (0.91)	-2.8	-2.20	-1.80	-1.40	-0.2	-0.77 [-1.91, 0.36]
			Placebo	7	7 (100.0)	-0.83 (1.28)	-2.4	-1.60	-1.40	0.40	1.2	
		Week 46	Tezepelumab	6	6 (100.0)	-1.77 (0.84)	-2.4	-2.20	-2.20	-1.40	-0.2	-0.48 [-1.58, 0.63]
			Placebo	7	7 (100.0)	-1.46 (0.43)	-2.2	-1.60	-1.60	-1.00	-1.0	
		Week 48	Tezepelumab	6	6 (100.0)	-1.73 (0.71)	-2.4	-2.20	-1.90	-1.60	-0.4	-1.08 [-2.26, 0.10]
			Placebo	7	7 (100.0)	-0.97 (0.70)	-1.8	-1.60	-0.80	-0.40	0.0	
		Week 50	Tezepelumab	6	6 (100.0)	-1.97 (0.98)	-3.2	-2.60	-2.10	-1.40	-0.4	-0.74 [-1.87, 0.40]
			Placebo	7	7 (100.0)	-1.09 (1.36)	-2.8	-1.60	-1.40	-0.60	1.6	
		Week 52	Tezepelumab	6	6 (100.0)	-1.97 (0.98)	-3.2	-2.60	-2.10	-1.40	-0.4	-0.58 [-1.70, 0.53]
			Placebo	7	7 (100.0)	-1.23 (1.47)	-2.8	-2.60	-1.40	-0.60	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	3.00 (1.23)	1.8	2.00	2.90	3.20	5.2	
			Placebo	4	4 (100.0)	3.00 (0.73)	2.2	2.40	3.00	3.60	3.8	
		Week 2	Tezepelumab	6	5 (83.3)	1.92 (1.25)	0.0	1.60	2.20	2.40	3.4	
			Placebo	4	3 (75.0)	1.60 (0.35)	1.4	1.40	1.40	2.00	2.0	
		Week 4	Tezepelumab	6	5 (83.3)	1.88 (1.01)	0.8	1.20	1.80	2.20	3.4	
			Placebo	4	3 (75.0)	1.53 (1.27)	0.8	0.80	0.80	3.00	3.0	
		Week 6	Tezepelumab	6	5 (83.3)	1.88 (1.08)	0.4	1.60	1.80	2.20	3.4	
			Placebo	4	3 (75.0)	1.20 (0.72)	0.6	0.60	1.00	2.00	2.0	
		Week 8	Tezepelumab	6	5 (83.3)	1.28 (1.04)	0.2	0.80	1.20	1.20	3.0	
			Placebo	4	3 (75.0)	1.47 (1.55)	0.2	0.20	1.00	3.20	3.2	
		Week 10	Tezepelumab	6	5 (83.3)	1.12 (1.15)	0.2	0.40	0.60	1.40	3.0	
			Placebo	4	3 (75.0)	2.07 (2.76)	0.0	0.00	1.00	5.20	5.2	
		Week 12	Tezepelumab	6	5 (83.3)	1.08 (0.58)	0.6	0.60	1.00	1.20	2.0	
			Placebo	4	3 (75.0)	1.60 (1.97)	0.0	0.00	1.00	3.80	3.8	
		Week 14	Tezepelumab	6	5 (83.3)	1.04 (0.68)	0.4	0.80	0.80	1.00	2.2	
			Placebo	4	3 (75.0)	2.13 (2.50)	0.4	0.40	1.00	5.00	5.0	
		Week 16	Tezepelumab	6	5 (83.3)	1.28 (0.56)	0.8	1.00	1.00	1.40	2.2	
			Placebo	4	3 (75.0)	2.07 (2.57)	0.2	0.20	1.00	5.00	5.0	
		Week 18	Tezepelumab	6	5 (83.3)	1.16 (0.65)	0.4	1.00	1.00	1.20	2.2	
			Placebo	4	3 (75.0)	2.07 (2.57)	0.2	0.20	1.00	5.00	5.0	
		Week 20	Tezepelumab	6	5 (83.3)	1.24 (0.61)	0.6	1.00	1.00	1.40	2.2	
			Placebo	4	3 (75.0)	1.87 (2.72)	0.2	0.20	0.40	5.00	5.0	
		Week 22	Tezepelumab	6	5 (83.3)	1.12 (0.63)	0.6	0.80	1.00	1.00	2.2	
			Placebo	4	3 (75.0)	1.80 (2.78)	0.0	0.00	0.40	5.00	5.0	
		Week 24	Tezepelumab	6	5 (83.3)	1.44 (0.62)	0.8	1.00	1.20	2.00	2.2	
			Placebo	4	3 (75.0)	1.53 (2.14)	0.2	0.20	0.40	4.00	4.0	
		Week 26	Tezepelumab	6	5 (83.3)	1.32 (0.59)	0.6	1.00	1.40	1.40	2.2	
			Placebo	4	3 (75.0)	1.60 (2.08)	0.4	0.40	0.40	4.00	4.0	
		Week 28	Tezepelumab	6	6 (100.0)	1.10 (0.68)	0.4	0.40	1.10	1.40	2.2	
			Placebo	4	3 (75.0)	1.60 (2.08)	0.4	0.40	0.40	4.00	4.0	
		Week 30	Tezepelumab	6	6 (100.0)	1.13 (0.71)	0.2	0.60	1.10	1.60	2.2	
			Placebo	4	3 (75.0)	1.60 (2.08)	0.4	0.40	0.40	4.00	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
North America/Western EU	Absolute values	Week 32	Tezepelumab	6	6 (100.0)	1.23 (0.67)	0.2	1.00	1.20	1.60	2.2	
			Placebo	4	3 (75.0)	1.67 (2.02)	0.4	0.40	0.60	4.00	4.0	
		Week 34	Tezepelumab	6	6 (100.0)	1.13 (0.78)	0.0	0.80	1.00	1.80	2.2	
			Placebo	4	3 (75.0)	1.53 (2.16)	0.0	0.00	0.60	4.00	4.0	
		Week 36	Tezepelumab	6	6 (100.0)	1.63 (0.57)	1.0	1.00	1.70	2.20	2.2	
			Placebo	4	3 (75.0)	1.73 (2.05)	0.0	0.00	1.20	4.00	4.0	
		Week 38	Tezepelumab	6	6 (100.0)	1.17 (0.70)	0.4	0.60	1.00	1.80	2.2	
			Placebo	4	3 (75.0)	1.67 (2.08)	0.0	0.00	1.00	4.00	4.0	
		Week 40	Tezepelumab	6	6 (100.0)	1.37 (0.78)	0.2	1.00	1.30	2.20	2.2	
			Placebo	4	3 (75.0)	1.73 (2.05)	0.0	0.00	1.20	4.00	4.0	
		Week 42	Tezepelumab	6	6 (100.0)	1.30 (0.69)	0.2	1.00	1.30	1.80	2.2	
			Placebo	4	3 (75.0)	0.93 (0.83)	0.0	0.00	1.20	1.60	1.6	
		Week 44	Tezepelumab	6	6 (100.0)	1.40 (0.70)	0.4	1.00	1.40	2.00	2.2	
			Placebo	4	3 (75.0)	1.00 (0.20)	0.8	0.80	1.00	1.20	1.2	
		Week 46	Tezepelumab	6	6 (100.0)	1.17 (0.72)	0.2	0.80	1.00	1.80	2.2	
			Placebo	4	3 (75.0)	0.93 (0.31)	0.6	0.60	1.00	1.20	1.2	
		Week 48	Tezepelumab	6	6 (100.0)	1.20 (0.69)	0.2	0.80	1.20	1.60	2.2	
			Placebo	4	3 (75.0)	0.80 (0.35)	0.4	0.40	1.00	1.00	1.0	
		Week 50	Tezepelumab	6	6 (100.0)	0.83 (0.83)	0.0	0.00	0.80	1.20	2.2	
			Placebo	4	3 (75.0)	2.07 (1.51)	1.0	1.00	1.40	3.80	3.8	
		Week 52	Tezepelumab	6	6 (100.0)	1.10 (0.77)	0.0	0.60	1.10	1.60	2.2	
			Placebo	4	3 (75.0)	1.73 (1.92)	0.0	0.00	1.40	3.80	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 2	Tezepelumab	6	5 (83.3)	-1.16 (1.37)	-3.2	-1.80	-0.80	-0.20	0.2	0.08 [-1.35, 1.52]
			Placebo	4	3 (75.0)	-1.27 (1.10)	-2.4	-2.40	-1.20	-0.20	-0.2	
		Week 4	Tezepelumab	6	5 (83.3)	-1.20 (1.02)	-2.4	-1.80	-1.40	-0.60	0.2	0.10 [-1.33, 1.54]
			Placebo	4	3 (75.0)	-1.33 (1.70)	-3.0	-3.00	-1.40	0.40	0.4	
		Week 6	Tezepelumab	6	5 (83.3)	-1.20 (1.29)	-2.8	-1.80	-1.60	-0.20	0.4	0.36 [-1.09, 1.80]
			Placebo	4	3 (75.0)	-1.67 (1.36)	-3.2	-3.20	-1.20	-0.60	-0.6	
		Week 8	Tezepelumab	6	5 (83.3)	-1.80 (0.91)	-3.0	-2.20	-2.00	-1.00	-0.8	-0.28 [-1.72, 1.16]
			Placebo	4	3 (75.0)	-1.40 (2.11)	-3.6	-3.60	-1.20	0.60	0.6	
		Week 10	Tezepelumab	6	5 (83.3)	-1.96 (0.96)	-3.0	-2.60	-2.20	-1.40	-0.6	-0.57 [-2.04, 0.89]
			Placebo	4	3 (75.0)	-0.80 (3.22)	-3.8	-3.80	-1.20	2.60	2.6	
		Week 12	Tezepelumab	6	5 (83.3)	-2.00 (0.99)	-3.2	-2.60	-2.20	-1.20	-0.8	-0.44 [-1.90, 1.01]
			Placebo	4	3 (75.0)	-1.27 (2.50)	-3.8	-3.80	-1.20	1.20	1.2	
		Week 14	Tezepelumab	6	5 (83.3)	-2.04 (0.91)	-3.0	-2.80	-2.20	-1.20	-1.0	-0.71 [-2.19, 0.78]
			Placebo	4	3 (75.0)	-0.73 (2.93)	-3.4	-3.40	-1.20	2.40	2.4	
		Week 16	Tezepelumab	6	5 (83.3)	-1.80 (1.05)	-3.0	-2.40	-2.20	-0.80	-0.6	-0.51 [-1.98, 0.95]
			Placebo	4	3 (75.0)	-0.80 (3.02)	-3.6	-3.60	-1.20	2.40	2.4	
		Week 18	Tezepelumab	6	5 (83.3)	-1.92 (1.06)	-3.0	-2.80	-2.20	-0.80	-0.8	-0.57 [-2.04, 0.89]
			Placebo	4	3 (75.0)	-0.80 (3.02)	-3.6	-3.60	-1.20	2.40	2.4	
		Week 20	Tezepelumab	6	5 (83.3)	-1.84 (1.08)	-3.0	-2.60	-2.20	-0.80	-0.6	-0.42 [-1.87, 1.03]
			Placebo	4	3 (75.0)	-1.00 (3.08)	-3.6	-3.60	-1.80	2.40	2.4	
		Week 22	Tezepelumab	6	5 (83.3)	-1.96 (0.77)	-3.0	-2.20	-2.20	-1.20	-1.2	-0.46 [-1.92, 0.99]
			Placebo	4	3 (75.0)	-1.07 (3.16)	-3.8	-3.80	-1.80	2.40	2.4	
		Week 24	Tezepelumab	6	5 (83.3)	-1.64 (1.31)	-3.0	-2.40	-2.20	-0.80	0.2	-0.17 [-1.60, 1.27]
			Placebo	4	3 (75.0)	-1.33 (2.53)	-3.6	-3.60	-1.80	1.40	1.4	
		Week 26	Tezepelumab	6	5 (83.3)	-1.76 (1.19)	-3.0	-2.60	-2.20	-0.60	-0.4	-0.29 [-1.73, 1.15]
			Placebo	4	3 (75.0)	-1.27 (2.44)	-3.4	-3.40	-1.80	1.40	1.4	
		Week 28	Tezepelumab	6	6 (100.0)	-1.90 (1.06)	-3.0	-2.80	-2.20	-0.60	-0.6	-0.40 [-1.80, 1.00]
			Placebo	4	3 (75.0)	-1.27 (2.44)	-3.4	-3.40	-1.80	1.40	1.4	
		Week 30	Tezepelumab	6	6 (100.0)	-1.87 (1.09)	-3.0	-2.60	-2.30	-0.60	-0.4	-0.38 [-1.77, 1.02]
			Placebo	4	3 (75.0)	-1.27 (2.44)	-3.4	-3.40	-1.80	1.40	1.4	
		Week 32	Tezepelumab	6	6 (100.0)	-1.77 (0.96)	-3.0	-2.40	-1.90	-1.00	-0.4	-0.38 [-1.78, 1.02]
			Placebo	4	3 (75.0)	-1.20 (2.36)	-3.2	-3.20	-1.80	1.40	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
North America/Western EU	Change from baseline	Week 34	Tezepelumab	6	6 (100.0)	-1.87 (1.11)	-3.0	-2.60	-2.30	-0.80	-0.2	-0.33 [-1.73, 1.06]
			Placebo	4	3 (75.0)	-1.33 (2.42)	-3.2	-3.20	-2.20	1.40	1.4	
		Week 36	Tezepelumab	6	6 (100.0)	-1.37 (1.35)	-3.0	-2.20	-1.70	0.00	0.4	-0.14 [-1.53, 1.25]
			Placebo	4	3 (75.0)	-1.13 (2.20)	-2.6	-2.60	-2.20	1.40	1.4	
		Week 38	Tezepelumab	6	6 (100.0)	-1.83 (1.09)	-3.0	-2.60	-2.20	-0.80	-0.2	-0.42 [-1.82, 0.99]
			Placebo	4	3 (75.0)	-1.20 (2.27)	-2.8	-2.80	-2.20	1.40	1.4	
		Week 40	Tezepelumab	6	6 (100.0)	-1.63 (1.17)	-3.0	-2.40	-1.90	-0.80	0.2	-0.33 [-1.72, 1.07]
			Placebo	4	3 (75.0)	-1.13 (2.20)	-2.6	-2.60	-2.20	1.40	1.4	
		Week 42	Tezepelumab	6	6 (100.0)	-1.70 (0.99)	-3.0	-2.40	-1.80	-0.60	-0.6	0.25 [-1.15, 1.64]
			Placebo	4	3 (75.0)	-1.93 (0.83)	-2.6	-2.60	-2.20	-1.00	-1.0	
		Week 44	Tezepelumab	6	6 (100.0)	-1.60 (1.09)	-3.0	-2.20	-1.80	-0.80	0.0	0.27 [-1.12, 1.66]
			Placebo	4	3 (75.0)	-1.87 (0.64)	-2.6	-2.60	-1.60	-1.40	-1.4	
		Week 46	Tezepelumab	6	6 (100.0)	-1.83 (1.03)	-3.0	-2.40	-2.20	-1.00	-0.2	0.11 [-1.28, 1.50]
			Placebo	4	3 (75.0)	-1.93 (0.58)	-2.6	-2.60	-1.60	-1.60	-1.6	
		Week 48	Tezepelumab	6	6 (100.0)	-1.80 (0.95)	-3.0	-2.40	-2.00	-1.00	-0.4	0.30 [-1.09, 1.70]
			Placebo	4	3 (75.0)	-2.07 (0.64)	-2.8	-2.80	-1.80	-1.60	-1.6	
		Week 50	Tezepelumab	6	6 (100.0)	-2.17 (0.98)	-3.2	-3.00	-2.40	-1.20	-0.8	-0.98 [-2.45, 0.50]
			Placebo	4	3 (75.0)	-0.80 (2.12)	-2.4	-2.40	-1.60	1.60	1.6	
		Week 52	Tezepelumab	6	6 (100.0)	-1.90 (1.05)	-3.2	-3.00	-1.70	-1.00	-0.8	-0.50 [-1.91, 0.91]
			Placebo	4	3 (75.0)	-1.13 (2.37)	-2.6	-2.60	-2.40	1.60	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	2.86 (0.85)	0.0	2.40	2.80	3.20	5.0	
			Placebo	61	61 (100.0)	2.85 (0.77)	0.4	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	60	58 (96.7)	2.38 (1.00)	0.2	1.60	2.60	3.00	4.4	
			Placebo	61	55 (90.2)	2.44 (0.79)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	60	58 (96.7)	2.10 (1.01)	0.2	1.40	2.30	3.00	3.6	
			Placebo	61	55 (90.2)	2.29 (0.90)	0.2	1.80	2.60	2.80	4.2	
		Week 6	Tezepelumab	60	58 (96.7)	1.98 (1.04)	0.0	1.20	1.90	2.80	4.0	
			Placebo	61	55 (90.2)	2.27 (1.15)	0.2	1.40	2.20	3.00	6.0	
		Week 8	Tezepelumab	60	58 (96.7)	1.86 (1.18)	0.0	1.00	1.80	2.80	5.2	
			Placebo	61	56 (91.8)	2.16 (1.12)	0.0	1.50	2.40	2.90	5.0	
		Week 10	Tezepelumab	60	58 (96.7)	1.77 (1.13)	0.0	0.80	1.80	2.60	4.8	
			Placebo	61	56 (91.8)	2.16 (0.98)	0.0	1.70	2.30	2.90	4.4	
		Week 12	Tezepelumab	60	58 (96.7)	1.66 (1.13)	0.0	0.60	1.70	2.60	4.8	
			Placebo	61	56 (91.8)	1.96 (1.02)	0.0	1.10	2.00	2.60	4.4	
		Week 14	Tezepelumab	60	58 (96.7)	1.60 (1.15)	0.0	0.60	1.50	2.40	4.8	
			Placebo	61	56 (91.8)	1.86 (0.91)	0.0	1.30	2.00	2.40	5.0	
		Week 16	Tezepelumab	60	58 (96.7)	1.74 (1.22)	0.0	0.60	1.80	2.80	4.8	
			Placebo	61	56 (91.8)	2.03 (1.14)	0.0	1.00	2.00	2.80	5.0	
		Week 18	Tezepelumab	60	59 (98.3)	1.72 (1.10)	0.0	0.80	1.80	2.60	4.8	
			Placebo	61	56 (91.8)	1.93 (1.11)	0.0	1.20	2.00	2.60	4.8	
		Week 20	Tezepelumab	60	59 (98.3)	1.72 (1.17)	0.0	0.80	1.80	2.60	5.0	
			Placebo	61	56 (91.8)	2.04 (1.02)	0.0	1.30	2.10	2.80	4.4	
		Week 22	Tezepelumab	60	59 (98.3)	1.83 (1.04)	0.0	1.00	2.00	2.60	4.8	
			Placebo	61	56 (91.8)	1.99 (1.07)	0.0	1.20	2.00	2.60	4.4	
		Week 24	Tezepelumab	60	59 (98.3)	1.77 (1.14)	0.0	0.80	1.80	2.60	4.8	
			Placebo	61	56 (91.8)	2.08 (1.01)	0.0	1.60	2.20	2.80	4.4	
		Week 26	Tezepelumab	60	60 (100.0)	1.83 (1.15)	0.0	1.00	1.80	2.80	4.8	
			Placebo	61	56 (91.8)	2.00 (1.09)	0.0	1.00	1.80	2.90	4.4	
		Week 28	Tezepelumab	60	60 (100.0)	1.80 (1.18)	0.0	1.00	1.80	2.70	4.8	
			Placebo	61	57 (93.4)	1.98 (1.19)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	60	60 (100.0)	1.76 (1.12)	0.0	0.90	1.80	2.60	4.8	
			Placebo	61	57 (93.4)	1.95 (1.14)	0.0	1.00	2.00	2.80	4.4	
		Week 32	Tezepelumab	60	60 (100.0)	1.67 (1.15)	0.0	0.70	1.80	2.60	4.8	
			Placebo	61	57 (93.4)	1.92 (1.10)	0.0	1.00	1.80	2.80	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of world	Absolute values	Week 34	Tezepelumab	60	60 (100.0)	1.77 (1.21)	0.0	0.80	1.70	2.80	4.8	
			Placebo	61	57 (93.4)	1.89 (1.09)	0.0	1.00	1.80	2.60	4.8	
		Week 36	Tezepelumab	60	60 (100.0)	1.67 (1.15)	0.0	0.80	1.50	2.60	4.8	
			Placebo	61	57 (93.4)	2.07 (1.16)	0.0	1.40	2.20	2.80	4.8	
		Week 38	Tezepelumab	60	60 (100.0)	1.77 (1.26)	0.0	0.80	1.80	2.60	4.8	
			Placebo	61	57 (93.4)	1.94 (1.09)	0.0	1.20	1.80	2.60	4.8	
		Week 40	Tezepelumab	60	60 (100.0)	1.73 (1.21)	0.0	0.70	1.90	2.80	4.8	
			Placebo	61	57 (93.4)	2.08 (1.16)	0.0	1.40	2.20	3.00	4.4	
		Week 42	Tezepelumab	60	60 (100.0)	1.68 (1.18)	0.0	0.80	1.70	2.60	4.8	
			Placebo	61	57 (93.4)	1.98 (1.05)	0.0	1.20	2.00	2.60	4.6	
		Week 44	Tezepelumab	60	60 (100.0)	1.71 (1.18)	0.0	0.80	1.70	2.80	4.8	
			Placebo	61	57 (93.4)	2.06 (1.12)	0.0	1.20	2.00	2.80	4.4	
		Week 46	Tezepelumab	60	60 (100.0)	1.76 (1.22)	0.0	0.80	1.90	2.80	4.8	
			Placebo	61	57 (93.4)	1.93 (1.01)	0.0	1.40	2.00	2.40	4.4	
		Week 48	Tezepelumab	60	60 (100.0)	1.76 (1.22)	0.0	0.80	1.90	2.70	4.8	
			Placebo	61	57 (93.4)	2.00 (1.09)	0.0	1.40	2.00	2.60	4.6	
		Week 50	Tezepelumab	60	60 (100.0)	1.73 (1.21)	0.0	0.80	1.70	2.60	4.8	
			Placebo	61	57 (93.4)	1.81 (1.01)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	60	60 (100.0)	1.74 (1.21)	0.0	0.80	1.80	2.60	4.8	
			Placebo	61	57 (93.4)	1.90 (1.05)	0.0	1.00	2.00	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 2	Tezepelumab	60	58 (96.7)	-0.51 (0.72)	-2.2	-1.00	-0.40	0.20	0.8	-0.07 [-0.44, 0.30]
			Placebo	61	55 (90.2)	-0.46 (0.69)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	60	58 (96.7)	-0.79 (0.92)	-2.6	-1.20	-0.80	-0.20	2.6	-0.20 [-0.57, 0.17]
			Placebo	61	55 (90.2)	-0.61 (0.92)	-3.0	-1.40	-0.40	0.00	1.2	
		Week 6	Tezepelumab	60	58 (96.7)	-0.91 (1.01)	-2.8	-1.60	-1.00	-0.20	2.6	-0.27 [-0.64, 0.10]
			Placebo	61	55 (90.2)	-0.63 (1.02)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	60	58 (96.7)	-1.03 (1.16)	-3.2	-1.60	-1.00	-0.40	2.6	-0.26 [-0.63, 0.11]
			Placebo	61	56 (91.8)	-0.75 (1.00)	-3.0	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	60	58 (96.7)	-1.12 (1.12)	-3.4	-1.80	-1.20	-0.40	2.6	-0.34 [-0.71, 0.03]
			Placebo	61	56 (91.8)	-0.75 (1.02)	-3.2	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	60	58 (96.7)	-1.23 (1.10)	-3.2	-2.20	-1.30	-0.60	2.6	-0.27 [-0.64, 0.10]
			Placebo	61	56 (91.8)	-0.95 (1.00)	-3.2	-1.50	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	60	58 (96.7)	-1.29 (1.11)	-4.0	-2.00	-1.40	-0.60	2.6	-0.23 [-0.60, 0.14]
			Placebo	61	56 (91.8)	-1.05 (0.95)	-3.2	-1.60	-1.10	-0.40	1.4	
		Week 16	Tezepelumab	60	58 (96.7)	-1.14 (1.15)	-3.2	-2.20	-1.20	-0.40	2.6	-0.24 [-0.61, 0.13]
			Placebo	61	56 (91.8)	-0.88 (1.06)	-3.0	-1.40	-0.90	-0.20	2.6	
		Week 18	Tezepelumab	60	59 (98.3)	-1.16 (1.09)	-3.8	-1.80	-1.00	-0.60	2.6	-0.16 [-0.52, 0.21]
			Placebo	61	56 (91.8)	-0.99 (1.12)	-3.2	-1.90	-0.90	-0.20	2.6	
		Week 20	Tezepelumab	60	59 (98.3)	-1.16 (1.09)	-3.4	-2.00	-1.20	-0.40	2.6	-0.27 [-0.64, 0.10]
			Placebo	61	56 (91.8)	-0.87 (1.06)	-3.0	-1.40	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	60	59 (98.3)	-1.04 (1.13)	-3.2	-1.80	-1.00	-0.60	2.6	-0.12 [-0.48, 0.25]
			Placebo	61	56 (91.8)	-0.92 (1.05)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 24	Tezepelumab	60	59 (98.3)	-1.11 (1.07)	-3.4	-1.80	-1.20	-0.40	2.6	-0.26 [-0.62, 0.11]
			Placebo	61	56 (91.8)	-0.84 (1.05)	-3.2	-1.50	-0.80	0.00	2.6	
		Week 26	Tezepelumab	60	60 (100.0)	-1.03 (1.12)	-3.0	-2.00	-1.00	-0.20	2.6	-0.10 [-0.47, 0.26]
			Placebo	61	56 (91.8)	-0.91 (1.13)	-3.0	-1.70	-1.20	0.00	2.6	
		Week 28	Tezepelumab	60	60 (100.0)	-1.06 (1.20)	-3.4	-2.20	-1.10	0.00	2.6	-0.14 [-0.51, 0.22]
			Placebo	61	57 (93.4)	-0.89 (1.17)	-3.0	-1.60	-1.00	0.00	2.6	
		Week 30	Tezepelumab	60	60 (100.0)	-1.10 (1.17)	-3.8	-2.00	-1.10	-0.40	2.6	-0.16 [-0.52, 0.20]
			Placebo	61	57 (93.4)	-0.91 (1.17)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 32	Tezepelumab	60	60 (100.0)	-1.19 (1.11)	-3.2	-2.20	-1.20	-0.60	2.6	-0.21 [-0.58, 0.15]
			Placebo	61	57 (93.4)	-0.95 (1.11)	-3.2	-1.60	-1.20	-0.20	2.6	
		Week 34	Tezepelumab	60	60 (100.0)	-1.09 (1.20)	-3.0	-2.10	-1.30	-0.30	2.6	-0.10 [-0.47, 0.26]
			Placebo	61	57 (93.4)	-0.97 (1.09)	-3.2	-1.60	-1.20	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of world	Change from baseline	Week 36	Tezepelumab	60	60 (100.0)	-1.19 (1.17)	-3.2	-2.10	-1.20	-0.30	2.6	-0.33 [-0.70, 0.03]
			Placebo	61	57 (93.4)	-0.80 (1.18)	-3.6	-1.40	-1.00	-0.20	2.6	
		Week 38	Tezepelumab	60	60 (100.0)	-1.09 (1.23)	-3.2	-2.10	-1.20	-0.20	2.6	-0.13 [-0.50, 0.23]
			Placebo	61	57 (93.4)	-0.93 (1.10)	-3.2	-1.60	-1.00	-0.40	2.6	
		Week 40	Tezepelumab	60	60 (100.0)	-1.13 (1.21)	-3.4	-2.10	-1.20	-0.40	2.6	-0.29 [-0.65, 0.08]
			Placebo	61	57 (93.4)	-0.79 (1.17)	-3.2	-1.40	-0.80	0.00	2.6	
		Week 42	Tezepelumab	60	60 (100.0)	-1.18 (1.22)	-3.6	-2.00	-1.20	-0.40	2.6	-0.25 [-0.61, 0.12]
			Placebo	61	57 (93.4)	-0.89 (1.10)	-2.8	-1.40	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	60	60 (100.0)	-1.15 (1.21)	-3.8	-2.10	-1.20	-0.40	2.6	-0.29 [-0.65, 0.07]
			Placebo	61	57 (93.4)	-0.81 (1.15)	-3.4	-1.60	-0.80	0.00	2.6	
		Week 46	Tezepelumab	60	60 (100.0)	-1.09 (1.21)	-3.6	-2.20	-1.20	-0.20	2.6	-0.14 [-0.50, 0.22]
			Placebo	61	57 (93.4)	-0.93 (1.06)	-3.2	-1.40	-1.00	-0.40	2.6	
		Week 48	Tezepelumab	60	60 (100.0)	-1.09 (1.20)	-2.8	-2.10	-1.00	-0.40	2.6	-0.20 [-0.56, 0.17]
			Placebo	61	57 (93.4)	-0.86 (1.12)	-3.4	-1.40	-0.80	-0.20	2.6	
		Week 50	Tezepelumab	60	60 (100.0)	-1.13 (1.21)	-2.8	-2.10	-1.20	-0.30	2.6	-0.06 [-0.43, 0.30]
			Placebo	61	57 (93.4)	-1.06 (1.01)	-3.6	-1.60	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	60	60 (100.0)	-1.12 (1.20)	-3.0	-2.10	-1.20	-0.20	2.6	-0.14 [-0.50, 0.23]
			Placebo	61	57 (93.4)	-0.96 (1.05)	-3.6	-1.60	-0.80	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	30	30 (100.0)	2.81 (0.83)	0.0	2.40	2.80	3.20	5.0	
			Placebo	29	29 (100.0)	3.08 (0.71)	1.8	2.80	3.00	3.20	5.0	
		Week 2	Tezepelumab	30	28 (93.3)	2.39 (1.07)	0.0	1.60	2.70	3.10	3.8	
			Placebo	29	26 (89.7)	2.42 (1.07)	0.4	1.80	2.50	3.00	5.0	
		Week 4	Tezepelumab	30	28 (93.3)	2.10 (0.99)	0.2	1.60	2.30	2.80	3.6	
			Placebo	29	26 (89.7)	2.02 (1.02)	0.2	1.20	2.00	2.80	3.6	
		Week 6	Tezepelumab	30	28 (93.3)	2.10 (0.97)	0.0	1.40	2.30	2.90	3.6	
			Placebo	29	26 (89.7)	2.05 (1.35)	0.2	1.00	2.10	2.80	6.0	
		Week 8	Tezepelumab	30	28 (93.3)	1.99 (1.02)	0.0	1.20	2.00	2.80	3.6	
			Placebo	29	26 (89.7)	2.10 (1.28)	0.0	1.00	2.00	2.80	5.0	
		Week 10	Tezepelumab	30	28 (93.3)	1.96 (1.10)	0.0	1.10	2.00	2.60	4.8	
			Placebo	29	26 (89.7)	2.02 (1.09)	0.2	1.00	1.90	3.00	4.4	
		Week 12	Tezepelumab	30	28 (93.3)	1.89 (1.11)	0.0	1.10	2.10	2.70	4.8	
			Placebo	29	26 (89.7)	1.71 (1.03)	0.2	0.80	1.80	2.20	4.4	
		Week 14	Tezepelumab	30	28 (93.3)	1.78 (1.03)	0.0	1.20	1.70	2.40	4.8	
			Placebo	29	26 (89.7)	1.74 (1.01)	0.4	1.00	1.70	2.20	5.0	
		Week 16	Tezepelumab	30	28 (93.3)	1.93 (1.17)	0.0	1.10	1.80	2.70	4.8	
			Placebo	29	26 (89.7)	1.81 (1.16)	0.4	1.00	1.80	2.20	5.0	
		Week 18	Tezepelumab	30	29 (96.7)	1.88 (0.98)	0.0	1.20	2.00	2.40	4.8	
			Placebo	29	26 (89.7)	1.76 (1.29)	0.0	0.60	1.40	2.80	4.8	
		Week 20	Tezepelumab	30	29 (96.7)	1.90 (1.06)	0.0	1.20	2.00	2.60	4.8	
			Placebo	29	26 (89.7)	1.78 (1.08)	0.2	0.80	1.90	2.60	4.4	
		Week 22	Tezepelumab	30	29 (96.7)	2.06 (0.90)	0.0	1.80	2.20	2.60	4.8	
			Placebo	29	26 (89.7)	1.74 (1.13)	0.0	0.80	1.80	2.60	4.4	
		Week 24	Tezepelumab	30	29 (96.7)	1.96 (1.08)	0.0	1.20	2.00	2.60	4.8	
			Placebo	29	26 (89.7)	1.91 (1.11)	0.2	0.80	1.90	2.60	4.4	
		Week 26	Tezepelumab	30	30 (100.0)	1.97 (1.12)	0.0	1.20	1.90	2.80	4.8	
			Placebo	29	26 (89.7)	1.76 (1.13)	0.4	1.00	1.50	2.80	4.4	
		Week 28	Tezepelumab	30	30 (100.0)	1.97 (1.12)	0.0	1.20	2.00	2.80	4.8	
			Placebo	29	26 (89.7)	1.92 (1.28)	0.2	0.80	1.60	2.80	4.4	
		Week 30	Tezepelumab	30	30 (100.0)	1.96 (1.10)	0.0	1.20	2.00	2.60	4.8	
			Placebo	29	26 (89.7)	1.69 (1.22)	0.0	0.80	1.20	3.00	4.4	
		Week 32	Tezepelumab	30	30 (100.0)	1.89 (1.08)	0.0	1.00	2.20	2.80	4.8	
			Placebo	29	26 (89.7)	1.78 (1.29)	0.0	0.80	1.70	2.80	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 250 cells/uL	Absolute values	Week 34	Tezepelumab	30	30 (100.0)	1.95 (1.19)	0.0	1.00	2.30	2.80	4.8	
			Placebo	29	26 (89.7)	1.74 (1.25)	0.0	0.80	1.60	2.20	4.8	
		Week 36	Tezepelumab	30	30 (100.0)	1.85 (1.11)	0.0	1.00	1.70	2.60	4.8	
			Placebo	29	26 (89.7)	1.84 (1.31)	0.0	0.80	1.70	2.80	4.8	
		Week 38	Tezepelumab	30	30 (100.0)	2.00 (1.17)	0.0	1.20	2.10	2.60	4.8	
			Placebo	29	26 (89.7)	1.88 (1.27)	0.0	1.20	1.70	3.00	4.8	
		Week 40	Tezepelumab	30	30 (100.0)	2.02 (1.11)	0.0	1.20	2.00	2.80	4.8	
			Placebo	29	26 (89.7)	1.85 (1.29)	0.0	0.60	1.80	3.00	4.4	
		Week 42	Tezepelumab	30	30 (100.0)	1.99 (1.14)	0.0	1.20	2.00	2.80	4.8	
			Placebo	29	26 (89.7)	1.79 (1.15)	0.0	0.80	1.80	2.60	4.4	
		Week 44	Tezepelumab	30	30 (100.0)	1.97 (1.13)	0.0	1.00	2.00	2.80	4.8	
			Placebo	29	26 (89.7)	1.92 (1.23)	0.0	0.80	1.80	3.00	4.4	
		Week 46	Tezepelumab	30	30 (100.0)	2.00 (1.13)	0.0	1.00	2.00	2.60	4.8	
			Placebo	29	26 (89.7)	1.79 (1.06)	0.0	1.00	1.90	2.40	4.4	
		Week 48	Tezepelumab	30	30 (100.0)	1.96 (1.12)	0.0	1.00	2.10	2.60	4.8	
			Placebo	29	26 (89.7)	1.73 (1.19)	0.0	0.40	2.00	2.40	4.4	
		Week 50	Tezepelumab	30	30 (100.0)	1.91 (1.18)	0.0	1.00	2.00	2.60	4.8	
			Placebo	29	26 (89.7)	1.85 (1.16)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	30	30 (100.0)	1.87 (1.18)	0.0	1.00	2.00	2.60	4.8	
			Placebo	29	26 (89.7)	1.86 (1.15)	0.0	1.00	1.90	2.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 2	Tezepelumab	30	28 (93.3)	-0.49 (0.83)	-3.2	-0.90	-0.40	0.20	0.4	0.14 [-0.39, 0.68]
			Placebo	29	26 (89.7)	-0.61 (0.76)	-2.8	-1.00	-0.40	0.00	0.2	
		Week 4	Tezepelumab	30	28 (93.3)	-0.78 (0.78)	-2.4	-1.30	-0.70	-0.20	0.8	0.28 [-0.26, 0.81]
			Placebo	29	26 (89.7)	-1.01 (0.87)	-3.0	-1.40	-1.10	-0.20	0.4	
		Week 6	Tezepelumab	30	28 (93.3)	-0.78 (0.85)	-2.8	-1.50	-0.70	0.00	0.4	0.22 [-0.31, 0.76]
			Placebo	29	26 (89.7)	-0.98 (1.01)	-3.4	-1.80	-0.90	-0.20	1.0	
		Week 8	Tezepelumab	30	28 (93.3)	-0.89 (0.91)	-3.0	-1.60	-0.80	0.00	0.6	0.04 [-0.49, 0.57]
			Placebo	29	26 (89.7)	-0.93 (0.99)	-3.0	-1.60	-1.00	0.00	1.0	
		Week 10	Tezepelumab	30	28 (93.3)	-0.91 (1.00)	-3.0	-1.60	-0.80	-0.20	1.0	0.09 [-0.44, 0.63]
			Placebo	29	26 (89.7)	-1.01 (0.99)	-3.2	-1.60	-1.10	-0.40	1.6	
		Week 12	Tezepelumab	30	28 (93.3)	-0.99 (0.96)	-2.6	-1.80	-1.10	-0.10	0.6	0.36 [-0.18, 0.90]
			Placebo	29	26 (89.7)	-1.32 (0.89)	-3.2	-2.00	-1.30	-0.80	0.2	
		Week 14	Tezepelumab	30	28 (93.3)	-1.10 (0.94)	-2.8	-2.00	-1.20	-0.30	0.6	0.21 [-0.32, 0.75]
			Placebo	29	26 (89.7)	-1.29 (0.86)	-3.2	-1.60	-1.40	-0.60	0.2	
		Week 16	Tezepelumab	30	28 (93.3)	-0.95 (1.07)	-2.4	-2.00	-1.00	-0.30	1.8	0.28 [-0.26, 0.81]
			Placebo	29	26 (89.7)	-1.22 (0.87)	-2.8	-1.80	-1.20	-0.40	0.2	
		Week 18	Tezepelumab	30	29 (96.7)	-0.97 (0.85)	-2.8	-1.40	-1.00	-0.60	0.6	0.30 [-0.23, 0.84]
			Placebo	29	26 (89.7)	-1.27 (1.11)	-3.2	-2.20	-1.40	-0.40	1.4	
		Week 20	Tezepelumab	30	29 (96.7)	-0.94 (0.92)	-2.6	-1.60	-0.80	-0.40	0.6	0.33 [-0.21, 0.86]
			Placebo	29	26 (89.7)	-1.25 (0.98)	-3.0	-2.00	-1.20	-0.40	0.2	
		Week 22	Tezepelumab	30	29 (96.7)	-0.79 (1.01)	-2.4	-1.20	-0.80	-0.20	2.0	0.51 [-0.03, 1.04]
			Placebo	29	26 (89.7)	-1.29 (0.96)	-3.2	-1.80	-1.40	-0.60	0.4	
		Week 24	Tezepelumab	30	29 (96.7)	-0.89 (0.94)	-2.4	-1.60	-0.80	-0.20	0.6	0.24 [-0.29, 0.77]
			Placebo	29	26 (89.7)	-1.12 (1.03)	-3.2	-1.80	-1.10	-0.20	0.4	
		Week 26	Tezepelumab	30	30 (100.0)	-0.85 (1.00)	-2.6	-1.60	-0.70	0.00	0.6	0.44 [-0.09, 0.97]
			Placebo	29	26 (89.7)	-1.27 (0.92)	-2.6	-1.80	-1.40	-0.80	0.4	
		Week 28	Tezepelumab	30	30 (100.0)	-0.85 (1.12)	-2.8	-1.60	-0.80	0.00	1.0	0.24 [-0.29, 0.77]
			Placebo	29	26 (89.7)	-1.12 (1.11)	-2.8	-1.80	-1.50	-0.20	1.2	
		Week 30	Tezepelumab	30	30 (100.0)	-0.85 (1.09)	-2.6	-1.60	-0.70	-0.20	2.0	0.46 [-0.07, 0.99]
			Placebo	29	26 (89.7)	-1.34 (1.01)	-3.2	-1.80	-1.50	-0.40	0.4	
		Week 32	Tezepelumab	30	30 (100.0)	-0.93 (0.96)	-2.4	-1.60	-1.00	-0.40	1.0	0.30 [-0.23, 0.83]
			Placebo	29	26 (89.7)	-1.25 (1.15)	-3.2	-1.80	-1.40	-0.60	1.8	
		Week 34	Tezepelumab	30	30 (100.0)	-0.86 (1.15)	-2.6	-1.80	-0.60	-0.20	2.2	0.39 [-0.14, 0.92]
			Placebo	29	26 (89.7)	-1.29 (1.07)	-3.2	-1.80	-1.40	-0.60	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 250 cells/uL	Change from baseline	Week 36	Tezepelumab	30	30 (100.0)	-0.97 (1.02)	-2.4	-1.80	-1.20	-0.20	1.6	0.20 [-0.32, 0.73]
			Placebo	29	26 (89.7)	-1.19 (1.22)	-3.6	-2.00	-1.10	-0.40	1.8	
		Week 38	Tezepelumab	30	30 (100.0)	-0.81 (1.11)	-2.6	-1.60	-0.90	0.00	2.6	0.31 [-0.22, 0.84]
			Placebo	29	26 (89.7)	-1.15 (1.11)	-3.2	-2.00	-1.20	-0.40	1.8	
		Week 40	Tezepelumab	30	30 (100.0)	-0.79 (1.01)	-2.6	-1.60	-0.80	0.00	1.8	0.36 [-0.17, 0.89]
			Placebo	29	26 (89.7)	-1.18 (1.13)	-3.2	-2.20	-1.30	-0.20	0.8	
		Week 42	Tezepelumab	30	30 (100.0)	-0.83 (1.06)	-2.4	-1.60	-0.90	0.00	2.2	0.41 [-0.12, 0.94]
			Placebo	29	26 (89.7)	-1.24 (0.93)	-2.8	-1.80	-1.30	-0.40	0.2	
		Week 44	Tezepelumab	30	30 (100.0)	-0.85 (1.03)	-2.8	-1.60	-0.80	-0.20	1.6	0.25 [-0.27, 0.78]
			Placebo	29	26 (89.7)	-1.12 (1.09)	-3.4	-1.80	-1.20	0.00	0.8	
		Week 46	Tezepelumab	30	30 (100.0)	-0.81 (1.01)	-2.4	-1.40	-0.80	-0.20	1.8	0.45 [-0.09, 0.98]
			Placebo	29	26 (89.7)	-1.24 (0.88)	-3.2	-1.60	-1.10	-0.60	0.2	
		Week 48	Tezepelumab	30	30 (100.0)	-0.85 (1.01)	-2.4	-1.60	-0.80	-0.20	2.0	0.43 [-0.10, 0.96]
			Placebo	29	26 (89.7)	-1.30 (1.08)	-3.4	-1.80	-1.20	-0.40	0.2	
		Week 50	Tezepelumab	30	30 (100.0)	-0.91 (1.13)	-3.2	-1.80	-0.80	-0.20	2.0	0.25 [-0.28, 0.78]
			Placebo	29	26 (89.7)	-1.18 (1.10)	-3.6	-1.80	-1.20	-0.60	1.6	
		Week 52	Tezepelumab	30	30 (100.0)	-0.94 (1.14)	-3.2	-1.80	-0.90	-0.20	2.0	0.21 [-0.32, 0.73]
			Placebo	29	26 (89.7)	-1.17 (1.09)	-3.6	-1.80	-1.10	-0.60	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	36	36 (100.0)	2.92 (0.93)	0.2	2.40	2.80	3.50	5.2	
			Placebo	36	36 (100.0)	2.69 (0.78)	0.4	2.30	2.90	3.20	4.0	
		Week 2	Tezepelumab	36	35 (97.2)	2.31 (0.99)	0.8	1.60	2.20	3.00	4.4	
			Placebo	36	32 (88.9)	2.38 (0.50)	1.4	2.00	2.40	2.80	3.2	
		Week 4	Tezepelumab	36	35 (97.2)	2.06 (1.02)	0.2	1.20	2.20	3.00	3.4	
			Placebo	36	32 (88.9)	2.44 (0.80)	0.8	2.10	2.60	2.90	4.2	
		Week 6	Tezepelumab	36	35 (97.2)	1.87 (1.09)	0.0	1.00	1.80	2.80	4.0	
			Placebo	36	32 (88.9)	2.35 (0.97)	0.2	1.80	2.30	3.00	5.0	
		Week 8	Tezepelumab	36	35 (97.2)	1.68 (1.28)	0.0	0.60	1.60	2.80	5.2	
			Placebo	36	33 (91.7)	2.15 (1.04)	0.0	1.60	2.40	3.00	3.8	
		Week 10	Tezepelumab	36	35 (97.2)	1.53 (1.14)	0.0	0.40	1.40	2.60	3.6	
			Placebo	36	33 (91.7)	2.25 (1.08)	0.0	2.00	2.40	2.80	5.2	
		Week 12	Tezepelumab	36	35 (97.2)	1.39 (1.06)	0.0	0.60	1.40	2.40	3.2	
			Placebo	36	33 (91.7)	2.13 (1.06)	0.0	1.80	2.40	2.80	4.4	
		Week 14	Tezepelumab	36	35 (97.2)	1.38 (1.18)	0.0	0.60	1.20	2.00	4.2	
			Placebo	36	33 (91.7)	1.98 (1.00)	0.0	1.60	2.20	2.60	5.0	
		Week 16	Tezepelumab	36	35 (97.2)	1.53 (1.17)	0.0	0.60	1.40	2.40	4.2	
			Placebo	36	33 (91.7)	2.21 (1.23)	0.0	2.00	2.40	3.00	5.0	
		Week 18	Tezepelumab	36	35 (97.2)	1.50 (1.14)	0.0	0.60	1.20	2.60	4.2	
			Placebo	36	33 (91.7)	2.07 (1.08)	0.0	1.80	2.20	2.60	5.0	
		Week 20	Tezepelumab	36	35 (97.2)	1.49 (1.19)	0.0	0.60	1.40	2.00	5.0	
			Placebo	36	33 (91.7)	2.24 (1.11)	0.0	1.80	2.20	2.80	5.0	
		Week 22	Tezepelumab	36	35 (97.2)	1.54 (1.09)	0.0	0.60	1.60	2.20	3.8	
			Placebo	36	33 (91.7)	2.18 (1.16)	0.0	1.60	2.40	2.60	5.0	
		Week 24	Tezepelumab	36	35 (97.2)	1.56 (1.11)	0.0	0.60	1.40	2.60	3.8	
			Placebo	36	33 (91.7)	2.16 (1.04)	0.0	1.60	2.20	2.80	4.0	
		Week 26	Tezepelumab	36	35 (97.2)	1.64 (1.12)	0.0	0.80	1.40	2.60	4.0	
			Placebo	36	33 (91.7)	2.15 (1.13)	0.0	1.40	2.20	3.00	4.4	
		Week 28	Tezepelumab	36	36 (100.0)	1.54 (1.17)	0.0	0.40	1.40	2.40	3.8	
			Placebo	36	34 (94.4)	1.99 (1.20)	0.0	1.00	2.00	2.80	4.4	
		Week 30	Tezepelumab	36	36 (100.0)	1.48 (1.07)	0.0	0.60	1.40	2.20	3.6	
			Placebo	36	34 (94.4)	2.12 (1.13)	0.0	1.60	2.10	2.80	4.0	
		Week 32	Tezepelumab	36	36 (100.0)	1.42 (1.12)	0.0	0.40	1.30	2.20	4.0	
			Placebo	36	34 (94.4)	1.99 (1.02)	0.0	1.20	2.00	2.80	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 250 cells/uL	Absolute values	Week 34	Tezepelumab	36	36 (100.0)	1.51 (1.17)	0.0	0.50	1.40	2.30	4.2	
			Placebo	36	34 (94.4)	1.98 (1.05)	0.0	1.40	2.00	2.60	4.0	
		Week 36	Tezepelumab	36	36 (100.0)	1.52 (1.10)	0.0	0.60	1.40	2.30	3.6	
			Placebo	36	34 (94.4)	2.22 (1.09)	0.0	1.40	2.40	2.80	4.4	
		Week 38	Tezepelumab	36	36 (100.0)	1.48 (1.24)	0.0	0.40	1.20	2.30	4.6	
			Placebo	36	34 (94.4)	1.96 (1.03)	0.0	1.00	2.00	2.60	4.0	
		Week 40	Tezepelumab	36	36 (100.0)	1.43 (1.19)	0.0	0.40	1.20	2.50	3.8	
			Placebo	36	34 (94.4)	2.22 (1.11)	0.0	1.40	2.20	3.00	4.4	
		Week 42	Tezepelumab	36	36 (100.0)	1.36 (1.08)	0.0	0.50	1.10	2.30	3.8	
			Placebo	36	34 (94.4)	2.02 (0.99)	0.0	1.40	2.00	2.60	4.6	
		Week 44	Tezepelumab	36	36 (100.0)	1.44 (1.11)	0.0	0.40	1.20	2.60	3.8	
			Placebo	36	34 (94.4)	2.08 (1.04)	0.0	1.20	2.10	2.60	4.2	
		Week 46	Tezepelumab	36	36 (100.0)	1.47 (1.20)	0.0	0.60	1.00	2.70	3.8	
			Placebo	36	34 (94.4)	1.95 (0.98)	0.0	1.40	2.00	2.60	4.4	
		Week 48	Tezepelumab	36	36 (100.0)	1.51 (1.21)	0.0	0.50	1.20	2.60	4.2	
			Placebo	36	34 (94.4)	2.11 (1.01)	0.0	1.60	2.20	2.60	4.6	
		Week 50	Tezepelumab	36	36 (100.0)	1.43 (1.20)	0.0	0.60	1.20	2.20	4.2	
			Placebo	36	34 (94.4)	1.81 (0.93)	0.0	1.00	1.90	2.40	4.0	
		Week 52	Tezepelumab	36	36 (100.0)	1.52 (1.18)	0.0	0.60	1.20	2.20	4.4	
			Placebo	36	34 (94.4)	1.92 (1.05)	0.0	1.00	2.00	2.80	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 2	Tezepelumab	36	35 (97.2)	-0.62 (0.78)	-2.2	-1.20	-0.60	0.00	0.8	-0.27 [-0.75, 0.21]
			Placebo	36	32 (88.9)	-0.42 (0.70)	-2.4	-0.90	-0.40	0.00	1.2	
		Week 4	Tezepelumab	36	35 (97.2)	-0.86 (1.04)	-2.6	-1.40	-1.00	-0.20	2.6	-0.51 [-0.99, -0.02]
			Placebo	36	32 (88.9)	-0.36 (0.95)	-3.0	-0.90	-0.20	0.40	1.2	
		Week 6	Tezepelumab	36	35 (97.2)	-1.06 (1.14)	-2.8	-1.80	-1.20	-0.60	2.6	-0.56 [-1.05, -0.07]
			Placebo	36	32 (88.9)	-0.44 (1.04)	-3.2	-1.10	-0.20	0.20	1.6	
		Week 8	Tezepelumab	36	35 (97.2)	-1.25 (1.30)	-3.2	-2.20	-1.40	-0.80	2.6	-0.48 [-0.97, 0.00]
			Placebo	36	33 (91.7)	-0.66 (1.11)	-3.6	-1.00	-0.40	0.00	1.0	
		Week 10	Tezepelumab	36	35 (97.2)	-1.40 (1.18)	-3.4	-2.20	-1.40	-0.80	2.6	-0.69 [-1.18, -0.20]
			Placebo	36	33 (91.7)	-0.56 (1.25)	-3.8	-1.00	-0.40	0.00	2.6	
		Week 12	Tezepelumab	36	35 (97.2)	-1.53 (1.17)	-3.2	-2.40	-1.40	-0.80	2.6	-0.73 [-1.22, -0.24]
			Placebo	36	33 (91.7)	-0.68 (1.14)	-3.8	-1.00	-0.60	-0.20	1.6	
		Week 14	Tezepelumab	36	35 (97.2)	-1.55 (1.21)	-4.0	-2.40	-1.60	-1.00	2.6	-0.59 [-1.08, -0.11]
			Placebo	36	33 (91.7)	-0.84 (1.20)	-3.4	-1.40	-1.00	-0.20	2.4	
		Week 16	Tezepelumab	36	35 (97.2)	-1.39 (1.18)	-3.2	-2.20	-1.40	-0.80	2.6	-0.64 [-1.12, -0.15]
			Placebo	36	33 (91.7)	-0.60 (1.32)	-3.6	-1.20	-0.40	0.00	2.6	
		Week 18	Tezepelumab	36	35 (97.2)	-1.42 (1.24)	-3.8	-2.40	-1.20	-0.80	2.6	-0.54 [-1.02, -0.05]
			Placebo	36	33 (91.7)	-0.75 (1.29)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 20	Tezepelumab	36	35 (97.2)	-1.43 (1.20)	-3.4	-2.40	-1.60	-0.80	2.6	-0.70 [-1.19, -0.21]
			Placebo	36	33 (91.7)	-0.58 (1.25)	-3.6	-1.20	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	36	35 (97.2)	-1.38 (1.16)	-3.2	-2.40	-1.40	-0.80	2.6	-0.61 [-1.10, -0.13]
			Placebo	36	33 (91.7)	-0.64 (1.28)	-3.8	-1.20	-0.60	0.00	2.6	
		Week 24	Tezepelumab	36	35 (97.2)	-1.37 (1.18)	-3.4	-2.00	-1.60	-0.60	2.6	-0.60 [-1.09, -0.12]
			Placebo	36	33 (91.7)	-0.65 (1.18)	-3.6	-1.20	-0.60	0.00	2.6	
		Week 26	Tezepelumab	36	35 (97.2)	-1.29 (1.21)	-3.0	-2.20	-1.40	-0.60	2.6	-0.49 [-0.98, -0.01]
			Placebo	36	33 (91.7)	-0.66 (1.33)	-3.4	-1.40	-0.60	0.20	2.6	
		Week 28	Tezepelumab	36	36 (100.0)	-1.38 (1.24)	-3.4	-2.20	-1.30	-0.70	2.6	-0.49 [-0.97, -0.02]
			Placebo	36	34 (94.4)	-0.75 (1.31)	-3.4	-1.60	-0.70	0.00	2.6	
		Week 30	Tezepelumab	36	36 (100.0)	-1.43 (1.20)	-3.8	-2.40	-1.40	-0.80	2.6	-0.65 [-1.13, -0.17]
			Placebo	36	34 (94.4)	-0.62 (1.30)	-3.4	-1.40	-0.90	0.00	2.6	
		Week 32	Tezepelumab	36	36 (100.0)	-1.50 (1.16)	-3.2	-2.40	-1.70	-0.90	2.6	-0.65 [-1.13, -0.17]
			Placebo	36	34 (94.4)	-0.75 (1.15)	-3.2	-1.40	-0.70	-0.20	2.6	
		Week 34	Tezepelumab	36	36 (100.0)	-1.41 (1.20)	-3.0	-2.30	-1.60	-0.80	2.6	-0.55 [-1.02, -0.07]
			Placebo	36	34 (94.4)	-0.76 (1.18)	-3.2	-1.40	-0.70	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 250 cells/uL	Change from baseline	Week 36	Tezepelumab	36	36 (100.0)	-1.40 (1.28)	-3.2	-2.40	-1.60	-0.70	2.6	-0.72 [-1.20, -0.23]
			Placebo	36	34 (94.4)	-0.52 (1.16)	-2.6	-1.20	-0.50	0.00	2.6	
		Week 38	Tezepelumab	36	36 (100.0)	-1.44 (1.27)	-3.2	-2.30	-1.80	-0.80	2.6	-0.54 [-1.02, -0.06]
			Placebo	36	34 (94.4)	-0.78 (1.17)	-2.8	-1.40	-0.90	0.00	2.6	
		Week 40	Tezepelumab	36	36 (100.0)	-1.49 (1.28)	-3.4	-2.60	-1.60	-0.80	2.6	-0.78 [-1.26, -0.29]
			Placebo	36	34 (94.4)	-0.52 (1.21)	-2.6	-1.20	-0.60	0.00	2.6	
		Week 42	Tezepelumab	36	36 (100.0)	-1.56 (1.23)	-3.6	-2.40	-1.80	-0.80	2.6	-0.70 [-1.18, -0.22]
			Placebo	36	34 (94.4)	-0.72 (1.18)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	36	36 (100.0)	-1.48 (1.27)	-3.8	-2.40	-1.40	-0.80	2.6	-0.66 [-1.15, -0.18]
			Placebo	36	34 (94.4)	-0.66 (1.18)	-2.6	-1.40	-0.70	-0.20	2.6	
		Week 46	Tezepelumab	36	36 (100.0)	-1.45 (1.30)	-3.6	-2.40	-1.50	-0.80	2.6	-0.54 [-1.02, -0.06]
			Placebo	36	34 (94.4)	-0.79 (1.15)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	36	36 (100.0)	-1.41 (1.28)	-3.0	-2.50	-1.60	-0.50	2.6	-0.65 [-1.13, -0.17]
			Placebo	36	34 (94.4)	-0.64 (1.10)	-2.8	-1.20	-0.80	-0.20	2.6	
		Week 50	Tezepelumab	36	36 (100.0)	-1.48 (1.24)	-3.0	-2.50	-1.60	-0.90	2.6	-0.48 [-0.96, -0.01]
			Placebo	36	34 (94.4)	-0.94 (1.03)	-2.8	-1.40	-0.90	-0.40	2.6	
		Week 52	Tezepelumab	36	36 (100.0)	-1.40 (1.23)	-3.0	-2.30	-1.60	-0.90	2.6	-0.49 [-0.97, -0.01]
			Placebo	36	34 (94.4)	-0.82 (1.11)	-2.8	-1.40	-0.80	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	38	38 (100.0)	2.96 (0.68)	1.8	2.40	2.90	3.20	5.0	
			Placebo	30	30 (100.0)	2.79 (0.68)	0.4	2.60	2.80	3.20	3.8	
		Week 2	Tezepelumab	38	35 (92.1)	2.50 (1.11)	0.0	1.60	2.80	3.40	4.4	
			Placebo	30	25 (83.3)	2.33 (0.66)	0.4	2.00	2.40	2.80	3.2	
		Week 4	Tezepelumab	38	35 (92.1)	2.21 (0.92)	0.2	1.80	2.40	3.00	3.6	
			Placebo	30	25 (83.3)	2.08 (0.89)	0.2	1.40	2.20	2.60	3.6	
		Week 6	Tezepelumab	38	35 (92.1)	2.05 (1.00)	0.0	1.40	1.80	2.80	4.0	
			Placebo	30	25 (83.3)	2.07 (1.06)	0.2	1.40	2.20	2.60	5.0	
		Week 8	Tezepelumab	38	35 (92.1)	1.99 (1.21)	0.0	1.20	1.80	3.00	5.2	
			Placebo	30	25 (83.3)	2.16 (1.00)	0.0	1.80	2.40	3.00	3.8	
		Week 10	Tezepelumab	38	35 (92.1)	1.90 (1.17)	0.0	1.00	1.80	2.80	4.8	
			Placebo	30	25 (83.3)	1.98 (0.88)	0.0	1.80	2.00	2.40	3.0	
		Week 12	Tezepelumab	38	35 (92.1)	1.85 (1.14)	0.0	1.00	2.00	2.80	4.8	
			Placebo	30	25 (83.3)	1.82 (0.88)	0.0	1.00	2.00	2.20	3.2	
		Week 14	Tezepelumab	38	35 (92.1)	1.73 (1.16)	0.0	0.80	1.60	2.40	4.8	
			Placebo	30	25 (83.3)	1.67 (0.81)	0.4	1.00	1.80	2.20	3.2	
		Week 16	Tezepelumab	38	35 (92.1)	1.97 (1.23)	0.0	1.00	2.20	2.80	4.8	
			Placebo	30	25 (83.3)	1.86 (0.84)	0.2	1.40	2.00	2.20	3.2	
		Week 18	Tezepelumab	38	36 (94.7)	1.91 (1.11)	0.0	1.10	2.10	2.60	4.8	
			Placebo	30	25 (83.3)	1.85 (1.14)	0.0	1.00	1.80	2.60	4.8	
		Week 20	Tezepelumab	38	36 (94.7)	1.92 (1.22)	0.0	1.10	1.90	2.70	5.0	
			Placebo	30	25 (83.3)	1.81 (1.02)	0.2	1.00	2.00	2.40	3.8	
		Week 22	Tezepelumab	38	36 (94.7)	1.91 (1.10)	0.0	1.10	2.10	2.60	4.8	
			Placebo	30	25 (83.3)	1.73 (0.99)	0.0	1.00	1.80	2.40	4.0	
		Week 24	Tezepelumab	38	36 (94.7)	1.96 (1.16)	0.0	1.10	2.10	2.70	4.8	
			Placebo	30	25 (83.3)	1.83 (0.98)	0.2	1.00	2.00	2.40	3.8	
		Week 26	Tezepelumab	38	37 (97.4)	2.02 (1.19)	0.0	1.00	2.00	2.80	4.8	
			Placebo	30	25 (83.3)	1.79 (1.03)	0.4	1.00	1.60	2.40	4.4	
		Week 28	Tezepelumab	38	38 (100.0)	1.89 (1.20)	0.0	1.00	1.80	2.80	4.8	
			Placebo	30	26 (86.7)	1.78 (1.13)	0.0	0.80	1.90	2.60	4.4	
		Week 30	Tezepelumab	38	38 (100.0)	1.91 (1.18)	0.0	1.00	2.00	2.60	4.8	
			Placebo	30	26 (86.7)	1.68 (0.98)	0.0	0.80	1.80	2.40	3.4	
		Week 32	Tezepelumab	38	38 (100.0)	1.87 (1.17)	0.0	1.00	2.00	2.80	4.8	
			Placebo	30	26 (86.7)	1.58 (0.92)	0.0	0.80	1.80	2.00	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 24 ppb	Absolute values	Week 34	Tezepelumab	38	38 (100.0)	1.92 (1.28)	0.0	1.00	1.90	2.80	4.8	
			Placebo	30	26 (86.7)	1.68 (0.89)	0.0	0.80	1.80	2.20	3.2	
		Week 36	Tezepelumab	38	38 (100.0)	1.88 (1.17)	0.0	1.00	1.70	2.80	4.8	
			Placebo	30	26 (86.7)	1.66 (1.07)	0.0	0.80	1.70	2.60	3.6	
		Week 38	Tezepelumab	38	38 (100.0)	1.93 (1.34)	0.0	0.80	1.80	3.00	4.8	
			Placebo	30	26 (86.7)	1.70 (0.95)	0.0	1.00	1.80	2.20	3.4	
		Week 40	Tezepelumab	38	38 (100.0)	1.94 (1.24)	0.0	1.00	2.00	2.80	4.8	
			Placebo	30	26 (86.7)	1.77 (1.16)	0.0	0.60	1.80	2.60	4.2	
		Week 42	Tezepelumab	38	38 (100.0)	1.94 (1.20)	0.0	1.00	1.90	2.80	4.8	
			Placebo	30	26 (86.7)	1.71 (0.95)	0.0	1.00	1.90	2.20	3.8	
		Week 44	Tezepelumab	38	38 (100.0)	1.97 (1.17)	0.0	1.00	2.00	3.00	4.8	
			Placebo	30	26 (86.7)	1.84 (1.06)	0.0	1.00	1.80	2.80	4.2	
		Week 46	Tezepelumab	38	38 (100.0)	2.02 (1.21)	0.0	1.00	2.00	3.00	4.8	
			Placebo	30	26 (86.7)	1.64 (0.97)	0.0	1.00	1.60	2.20	4.4	
		Week 48	Tezepelumab	38	38 (100.0)	1.98 (1.22)	0.0	1.00	2.10	2.80	4.8	
			Placebo	30	26 (86.7)	1.62 (1.11)	0.0	0.60	1.70	2.40	4.6	
		Week 50	Tezepelumab	38	38 (100.0)	1.98 (1.29)	0.0	1.00	2.00	3.00	4.8	
			Placebo	30	26 (86.7)	1.59 (0.90)	0.0	1.00	1.70	2.20	3.8	
		Week 52	Tezepelumab	38	38 (100.0)	2.02 (1.25)	0.0	1.20	2.00	2.80	4.8	
			Placebo	30	26 (86.7)	1.71 (0.97)	0.0	1.00	1.80	2.40	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 2	Tezepelumab	38	35 (92.1)	-0.53 (0.84)	-3.2	-1.00	-0.40	0.20	0.8	0.12 [-0.40, 0.63]
			Placebo	30	25 (83.3)	-0.62 (0.72)	-2.8	-0.80	-0.40	-0.20	0.2	
		Week 4	Tezepelumab	38	35 (92.1)	-0.82 (0.68)	-2.4	-1.20	-0.80	-0.40	0.2	0.06 [-0.45, 0.57]
			Placebo	30	25 (83.3)	-0.87 (1.02)	-3.0	-1.40	-0.80	-0.20	0.6	
		Week 6	Tezepelumab	38	35 (92.1)	-0.98 (0.78)	-2.8	-1.60	-1.00	-0.40	0.2	-0.11 [-0.62, 0.41]
			Placebo	30	25 (83.3)	-0.88 (1.16)	-3.4	-1.60	-0.80	-0.20	1.6	
		Week 8	Tezepelumab	38	35 (92.1)	-1.05 (1.10)	-3.2	-1.80	-1.20	-0.40	2.6	-0.23 [-0.74, 0.29]
			Placebo	30	25 (83.3)	-0.79 (1.15)	-3.6	-1.20	-0.80	0.20	1.0	
		Week 10	Tezepelumab	38	35 (92.1)	-1.14 (0.98)	-3.4	-1.80	-1.20	-0.40	0.6	-0.16 [-0.68, 0.35]
			Placebo	30	25 (83.3)	-0.98 (1.02)	-3.8	-1.40	-0.80	-0.40	0.4	
		Week 12	Tezepelumab	38	35 (92.1)	-1.18 (0.96)	-3.0	-2.20	-1.20	-0.60	0.6	-0.05 [-0.57, 0.46]
			Placebo	30	25 (83.3)	-1.13 (1.06)	-3.8	-1.80	-0.80	-0.40	0.2	
		Week 14	Tezepelumab	38	35 (92.1)	-1.30 (0.95)	-3.4	-2.20	-1.40	-0.60	0.6	-0.02 [-0.54, 0.49]
			Placebo	30	25 (83.3)	-1.28 (1.06)	-3.4	-1.80	-1.40	-0.40	0.2	
		Week 16	Tezepelumab	38	35 (92.1)	-1.06 (1.07)	-3.2	-2.20	-1.00	-0.40	1.8	0.03 [-0.48, 0.54]
			Placebo	30	25 (83.3)	-1.10 (1.04)	-3.6	-1.40	-1.20	-0.40	0.4	
		Week 18	Tezepelumab	38	36 (94.7)	-1.09 (0.94)	-3.4	-1.80	-1.00	-0.50	0.6	0.01 [-0.50, 0.52]
			Placebo	30	25 (83.3)	-1.10 (1.28)	-3.6	-2.20	-1.20	0.00	1.4	
		Week 20	Tezepelumab	38	36 (94.7)	-1.09 (1.03)	-3.4	-2.00	-1.00	-0.40	0.6	0.05 [-0.46, 0.56]
			Placebo	30	25 (83.3)	-1.14 (1.23)	-3.6	-1.80	-1.20	-0.20	1.0	
		Week 22	Tezepelumab	38	36 (94.7)	-1.09 (0.94)	-3.2	-2.00	-0.80	-0.60	0.6	0.12 [-0.39, 0.63]
			Placebo	30	25 (83.3)	-1.22 (1.18)	-3.8	-2.00	-1.20	-0.40	1.2	
		Week 24	Tezepelumab	38	36 (94.7)	-1.05 (1.00)	-3.4	-2.00	-0.80	-0.40	0.6	0.06 [-0.45, 0.58]
			Placebo	30	25 (83.3)	-1.12 (1.18)	-3.6	-1.80	-1.00	0.00	1.0	
		Week 26	Tezepelumab	38	37 (97.4)	-0.96 (1.04)	-3.0	-2.00	-0.80	-0.20	0.6	0.19 [-0.32, 0.69]
			Placebo	30	25 (83.3)	-1.16 (1.18)	-3.4	-2.00	-1.40	0.00	1.6	
		Week 28	Tezepelumab	38	38 (100.0)	-1.07 (1.15)	-3.4	-2.20	-1.00	0.00	1.0	0.00 [-0.50, 0.50]
			Placebo	30	26 (86.7)	-1.08 (1.22)	-3.4	-2.00	-1.00	-0.20	1.6	
		Week 30	Tezepelumab	38	38 (100.0)	-1.05 (1.10)	-2.8	-2.20	-1.00	-0.40	2.0	0.11 [-0.39, 0.60]
			Placebo	30	26 (86.7)	-1.17 (1.12)	-3.4	-1.80	-1.30	-0.40	0.6	
		Week 32	Tezepelumab	38	38 (100.0)	-1.09 (1.04)	-3.2	-2.20	-1.00	-0.40	1.0	0.17 [-0.33, 0.67]
			Placebo	30	26 (86.7)	-1.27 (1.10)	-3.2	-2.20	-1.30	-0.40	0.8	
		Week 34	Tezepelumab	38	38 (100.0)	-1.05 (1.18)	-3.0	-2.20	-1.10	-0.20	2.2	0.12 [-0.38, 0.61]
			Placebo	30	26 (86.7)	-1.18 (1.03)	-3.2	-1.80	-1.20	-0.60	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 24 ppb	Change from baseline	Week 36	Tezepelumab	38	38 (100.0)	-1.08 (1.06)	-3.2	-2.00	-1.20	-0.20	1.6	0.10 [-0.40, 0.60]
			Placebo	30	26 (86.7)	-1.19 (1.18)	-3.6	-2.00	-1.00	-0.40	0.8	
		Week 38	Tezepelumab	38	38 (100.0)	-1.03 (1.22)	-3.2	-2.20	-1.10	0.00	2.6	0.11 [-0.39, 0.61]
			Placebo	30	26 (86.7)	-1.15 (0.99)	-3.2	-2.00	-1.10	-0.40	0.2	
		Week 40	Tezepelumab	38	38 (100.0)	-1.02 (1.12)	-3.4	-2.00	-0.90	-0.40	1.8	0.06 [-0.44, 0.55]
			Placebo	30	26 (86.7)	-1.08 (1.20)	-3.2	-2.20	-1.20	-0.20	1.4	
		Week 42	Tezepelumab	38	38 (100.0)	-1.03 (1.10)	-3.0	-2.00	-1.10	-0.40	2.2	0.11 [-0.39, 0.61]
			Placebo	30	26 (86.7)	-1.15 (1.00)	-2.8	-1.60	-1.20	-0.60	1.0	
		Week 44	Tezepelumab	38	38 (100.0)	-0.99 (1.07)	-3.4	-2.00	-0.80	-0.20	1.6	0.02 [-0.48, 0.52]
			Placebo	30	26 (86.7)	-1.02 (1.12)	-3.4	-1.80	-1.00	0.00	0.8	
		Week 46	Tezepelumab	38	38 (100.0)	-0.95 (1.08)	-2.8	-2.20	-0.80	-0.20	1.8	0.25 [-0.25, 0.75]
			Placebo	30	26 (86.7)	-1.22 (1.06)	-3.2	-1.80	-1.10	-0.60	1.6	
		Week 48	Tezepelumab	38	38 (100.0)	-0.98 (1.08)	-2.8	-1.80	-0.90	-0.40	2.0	0.22 [-0.28, 0.72]
			Placebo	30	26 (86.7)	-1.23 (1.22)	-3.4	-1.80	-1.00	-0.60	1.8	
		Week 50	Tezepelumab	38	38 (100.0)	-0.98 (1.16)	-3.2	-1.80	-0.90	-0.20	2.0	0.25 [-0.25, 0.75]
			Placebo	30	26 (86.7)	-1.26 (1.07)	-3.6	-1.80	-1.30	-0.60	1.6	
		Week 52	Tezepelumab	38	38 (100.0)	-0.95 (1.13)	-3.2	-1.80	-1.00	-0.20	2.0	0.18 [-0.32, 0.67]
			Placebo	30	26 (86.7)	-1.15 (1.15)	-3.6	-1.80	-1.00	-0.40	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	28	28 (100.0)	2.74 (1.10)	0.0	2.20	2.80	3.30	5.2	
			Placebo	34	34 (100.0)	2.94 (0.85)	1.0	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	28	28 (100.0)	2.14 (0.87)	0.2	1.60	2.10	2.90	3.4	
			Placebo	34	32 (94.1)	2.44 (0.91)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	28	28 (100.0)	1.91 (1.09)	0.2	1.10	2.10	2.90	3.4	
			Placebo	34	32 (94.1)	2.38 (0.95)	0.2	1.90	2.60	3.00	4.2	
		Week 6	Tezepelumab	28	28 (100.0)	1.87 (1.10)	0.0	0.90	2.00	2.80	3.8	
			Placebo	34	32 (94.1)	2.34 (1.24)	0.2	1.40	2.30	3.00	6.0	
		Week 8	Tezepelumab	28	28 (100.0)	1.60 (1.11)	0.0	0.60	1.70	2.70	3.4	
			Placebo	34	33 (97.1)	2.15 (1.24)	0.0	1.20	2.40	2.80	5.0	
		Week 10	Tezepelumab	28	28 (100.0)	1.50 (1.07)	0.0	0.60	1.40	2.40	3.2	
			Placebo	34	33 (97.1)	2.23 (1.18)	0.0	1.60	2.40	3.00	5.2	
		Week 12	Tezepelumab	28	28 (100.0)	1.31 (1.00)	0.0	0.60	1.30	2.10	3.0	
			Placebo	34	33 (97.1)	2.06 (1.18)	0.0	1.20	2.40	2.80	4.4	
		Week 14	Tezepelumab	28	28 (100.0)	1.34 (1.06)	0.0	0.60	1.40	2.10	3.8	
			Placebo	34	33 (97.1)	2.05 (1.11)	0.0	1.60	2.00	2.60	5.0	
		Week 16	Tezepelumab	28	28 (100.0)	1.38 (1.04)	0.0	0.50	1.30	2.00	3.6	
			Placebo	34	33 (97.1)	2.21 (1.41)	0.0	1.00	2.40	3.00	5.0	
		Week 18	Tezepelumab	28	28 (100.0)	1.36 (0.98)	0.0	0.80	1.20	2.00	3.4	
			Placebo	34	33 (97.1)	2.03 (1.22)	0.0	1.40	2.20	2.60	5.0	
		Week 20	Tezepelumab	28	28 (100.0)	1.37 (0.97)	0.0	0.60	1.20	2.00	3.6	
			Placebo	34	33 (97.1)	2.24 (1.16)	0.0	1.40	2.40	2.80	5.0	
		Week 22	Tezepelumab	28	28 (100.0)	1.60 (0.92)	0.0	0.80	1.60	2.20	3.4	
			Placebo	34	33 (97.1)	2.21 (1.25)	0.0	1.20	2.40	3.00	5.0	
		Week 24	Tezepelumab	28	28 (100.0)	1.46 (0.99)	0.0	0.60	1.20	2.10	3.6	
			Placebo	34	33 (97.1)	2.25 (1.10)	0.0	1.60	2.20	3.00	4.4	
		Week 26	Tezepelumab	28	28 (100.0)	1.49 (0.96)	0.0	0.70	1.50	2.20	3.2	
			Placebo	34	33 (97.1)	2.16 (1.20)	0.0	1.20	2.20	3.20	4.4	
		Week 28	Tezepelumab	28	28 (100.0)	1.52 (1.08)	0.0	0.50	1.50	2.40	3.6	
			Placebo	34	33 (97.1)	2.14 (1.29)	0.0	1.20	2.00	3.20	4.4	
		Week 30	Tezepelumab	28	28 (100.0)	1.41 (0.94)	0.0	0.70	1.40	2.10	3.2	
			Placebo	34	33 (97.1)	2.17 (1.29)	0.0	1.20	2.20	3.20	4.4	
		Week 32	Tezepelumab	28	28 (100.0)	1.30 (0.97)	0.0	0.40	1.20	2.10	3.2	
			Placebo	34	33 (97.1)	2.19 (1.23)	0.0	1.20	2.00	3.00	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 24 ppb	Absolute values	Week 34	Tezepelumab	28	28 (100.0)	1.43 (1.01)	0.0	0.50	1.30	2.30	3.2	
			Placebo	34	33 (97.1)	2.07 (1.29)	0.0	1.00	2.00	3.00	4.8	
		Week 36	Tezepelumab	28	28 (100.0)	1.37 (0.97)	0.0	0.60	1.30	2.20	3.2	
			Placebo	34	33 (97.1)	2.38 (1.21)	0.0	1.60	2.40	3.20	4.8	
		Week 38	Tezepelumab	28	28 (100.0)	1.42 (1.02)	0.0	0.30	1.60	2.20	3.2	
			Placebo	34	33 (97.1)	2.10 (1.25)	0.0	1.00	2.00	3.00	4.8	
		Week 40	Tezepelumab	28	28 (100.0)	1.36 (1.03)	0.0	0.40	1.20	2.20	3.2	
			Placebo	34	33 (97.1)	2.28 (1.20)	0.0	1.40	2.40	3.00	4.4	
		Week 42	Tezepelumab	28	28 (100.0)	1.24 (0.95)	0.0	0.50	1.20	2.00	3.2	
			Placebo	34	33 (97.1)	2.08 (1.13)	0.0	1.20	2.00	2.60	4.6	
		Week 44	Tezepelumab	28	28 (100.0)	1.28 (0.98)	0.0	0.50	1.10	2.10	3.2	
			Placebo	34	33 (97.1)	2.13 (1.17)	0.0	1.20	2.40	3.00	4.4	
		Week 46	Tezepelumab	28	28 (100.0)	1.29 (1.05)	0.0	0.50	1.00	2.10	3.2	
			Placebo	34	33 (97.1)	2.06 (1.03)	0.0	1.60	2.00	2.60	4.4	
		Week 48	Tezepelumab	28	28 (100.0)	1.34 (1.05)	0.0	0.50	1.10	2.20	3.2	
			Placebo	34	33 (97.1)	2.18 (1.05)	0.0	1.60	2.20	2.80	4.4	
		Week 50	Tezepelumab	28	28 (100.0)	1.19 (0.91)	0.0	0.60	1.00	1.90	3.2	
			Placebo	34	33 (97.1)	1.99 (1.11)	0.0	1.00	2.00	2.60	4.4	
		Week 52	Tezepelumab	28	28 (100.0)	1.22 (0.92)	0.0	0.50	0.90	2.00	3.2	
			Placebo	34	33 (97.1)	2.02 (1.18)	0.0	1.00	2.20	2.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 2	Tezepelumab	28	28 (100.0)	-0.60 (0.74)	-2.2	-1.20	-0.40	0.00	0.8	-0.23 [-0.74, 0.28]
			Placebo	34	32 (94.1)	-0.43 (0.73)	-1.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	28	28 (100.0)	-0.83 (1.18)	-2.6	-1.60	-1.00	0.00	2.6	-0.32 [-0.83, 0.19]
			Placebo	34	32 (94.1)	-0.50 (0.90)	-2.2	-1.20	-0.20	0.10	1.2	
		Week 6	Tezepelumab	28	28 (100.0)	-0.87 (1.28)	-2.8	-1.80	-0.90	0.00	2.6	-0.30 [-0.81, 0.21]
			Placebo	34	32 (94.1)	-0.54 (0.97)	-2.4	-1.30	-0.20	0.00	1.6	
		Week 8	Tezepelumab	28	28 (100.0)	-1.14 (1.23)	-3.0	-2.00	-1.00	-0.40	2.6	-0.36 [-0.87, 0.15]
			Placebo	34	33 (97.1)	-0.74 (1.00)	-2.8	-1.40	-0.40	-0.20	1.0	
		Week 10	Tezepelumab	28	28 (100.0)	-1.24 (1.29)	-3.0	-2.20	-1.30	-0.60	2.6	-0.47 [-0.98, 0.04]
			Placebo	34	33 (97.1)	-0.66 (1.19)	-2.6	-1.60	-0.60	0.00	2.6	
		Week 12	Tezepelumab	28	28 (100.0)	-1.43 (1.27)	-3.2	-2.20	-1.40	-0.90	2.6	-0.51 [-1.02, 0.00]
			Placebo	34	33 (97.1)	-0.83 (1.10)	-3.0	-1.40	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	28	28 (100.0)	-1.41 (1.30)	-4.0	-2.20	-1.30	-0.80	2.6	-0.47 [-0.99, 0.04]
			Placebo	34	33 (97.1)	-0.84 (1.09)	-3.0	-1.40	-1.00	-0.40	2.4	
		Week 16	Tezepelumab	28	28 (100.0)	-1.36 (1.23)	-3.0	-2.20	-1.30	-0.90	2.6	-0.55 [-1.06, -0.04]
			Placebo	34	33 (97.1)	-0.68 (1.26)	-3.0	-1.40	-0.60	-0.20	2.6	
		Week 18	Tezepelumab	28	28 (100.0)	-1.38 (1.28)	-3.8	-2.20	-1.30	-0.80	2.6	-0.42 [-0.93, 0.09]
			Placebo	34	33 (97.1)	-0.86 (1.21)	-3.0	-1.40	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	28	28 (100.0)	-1.37 (1.19)	-3.0	-2.20	-1.50	-0.70	2.6	-0.63 [-1.14, -0.11]
			Placebo	34	33 (97.1)	-0.65 (1.12)	-2.6	-1.20	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	28	28 (100.0)	-1.14 (1.35)	-3.0	-2.00	-1.20	-0.70	2.6	-0.37 [-0.88, 0.14]
			Placebo	34	33 (97.1)	-0.68 (1.16)	-2.6	-1.40	-0.80	-0.20	2.6	
		Week 24	Tezepelumab	28	28 (100.0)	-1.28 (1.21)	-3.0	-1.90	-1.60	-0.70	2.6	-0.56 [-1.07, -0.05]
			Placebo	34	33 (97.1)	-0.64 (1.08)	-2.6	-1.20	-0.60	0.00	2.6	
		Week 26	Tezepelumab	28	28 (100.0)	-1.25 (1.24)	-3.0	-2.20	-1.40	-0.40	2.6	-0.42 [-0.93, 0.09]
			Placebo	34	33 (97.1)	-0.73 (1.20)	-3.0	-1.60	-0.80	0.00	2.6	
		Week 28	Tezepelumab	28	28 (100.0)	-1.22 (1.30)	-3.0	-2.20	-1.20	-0.40	2.6	-0.37 [-0.88, 0.14]
			Placebo	34	33 (97.1)	-0.75 (1.25)	-3.0	-1.60	-1.00	0.00	2.6	
		Week 30	Tezepelumab	28	28 (100.0)	-1.33 (1.28)	-3.8	-2.30	-1.40	-0.70	2.6	-0.47 [-0.98, 0.04]
			Placebo	34	33 (97.1)	-0.72 (1.31)	-2.8	-1.40	-1.00	0.00	2.6	
		Week 32	Tezepelumab	28	28 (100.0)	-1.44 (1.19)	-3.0	-2.20	-1.70	-1.00	2.6	-0.62 [-1.14, -0.11]
			Placebo	34	33 (97.1)	-0.70 (1.19)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	28	28 (100.0)	-1.31 (1.24)	-3.0	-2.20	-1.50	-0.60	2.6	-0.39 [-0.90, 0.12]
			Placebo	34	33 (97.1)	-0.82 (1.25)	-2.8	-1.60	-1.00	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 24 ppb	Change from baseline	Week 36	Tezepelumab	28	28 (100.0)	-1.37 (1.33)	-3.0	-2.40	-1.60	-0.50	2.6	-0.68 [-1.20, -0.16]
			Placebo	34	33 (97.1)	-0.51 (1.20)	-2.6	-1.20	-1.00	0.00	2.6	
		Week 38	Tezepelumab	28	28 (100.0)	-1.32 (1.25)	-3.0	-2.20	-1.50	-0.70	2.6	-0.42 [-0.93, 0.09]
			Placebo	34	33 (97.1)	-0.79 (1.26)	-2.6	-1.60	-1.00	0.00	2.6	
		Week 40	Tezepelumab	28	28 (100.0)	-1.38 (1.31)	-3.0	-2.60	-1.60	-0.60	2.6	-0.61 [-1.13, -0.10]
			Placebo	34	33 (97.1)	-0.61 (1.21)	-2.6	-1.40	-0.80	0.00	2.6	
		Week 42	Tezepelumab	28	28 (100.0)	-1.50 (1.31)	-3.6	-2.30	-1.80	-0.60	2.6	-0.56 [-1.07, -0.04]
			Placebo	34	33 (97.1)	-0.81 (1.17)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	28	28 (100.0)	-1.46 (1.33)	-3.8	-2.60	-1.60	-0.80	2.6	-0.56 [-1.07, -0.05]
			Placebo	34	33 (97.1)	-0.76 (1.19)	-2.6	-1.60	-1.00	-0.20	2.6	
		Week 46	Tezepelumab	28	28 (100.0)	-1.45 (1.33)	-3.6	-2.50	-1.50	-0.90	2.6	-0.52 [-1.04, -0.01]
			Placebo	34	33 (97.1)	-0.83 (1.05)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	28	28 (100.0)	-1.40 (1.31)	-3.0	-2.60	-1.60	-0.40	2.6	-0.59 [-1.11, -0.08]
			Placebo	34	33 (97.1)	-0.71 (1.02)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	28	28 (100.0)	-1.55 (1.24)	-3.0	-2.50	-1.70	-1.10	2.6	-0.57 [-1.09, -0.06]
			Placebo	34	33 (97.1)	-0.90 (1.04)	-2.8	-1.40	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	28	28 (100.0)	-1.52 (1.25)	-3.0	-2.50	-1.70	-1.00	2.6	-0.56 [-1.08, -0.05]
			Placebo	34	33 (97.1)	-0.87 (1.08)	-2.8	-1.40	-0.80	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	2.94 (0.72)	1.8	2.40	2.80	3.20	5.0	
			Placebo	27	27 (100.0)	2.76 (0.68)	0.4	2.60	2.80	3.20	3.6	
		Week 2	Tezepelumab	32	30 (93.8)	2.49 (1.04)	0.0	1.60	2.70	3.40	4.0	
			Placebo	27	23 (85.2)	2.35 (0.65)	0.4	2.00	2.40	3.00	3.2	
		Week 4	Tezepelumab	32	30 (93.8)	2.16 (0.95)	0.2	1.80	2.20	3.00	3.6	
			Placebo	27	23 (85.2)	2.11 (0.88)	0.2	1.40	2.20	2.80	3.6	
		Week 6	Tezepelumab	32	30 (93.8)	1.94 (0.98)	0.0	1.40	1.80	2.80	4.0	
			Placebo	27	23 (85.2)	2.11 (1.06)	0.2	1.40	2.20	2.80	5.0	
		Week 8	Tezepelumab	32	30 (93.8)	1.98 (1.27)	0.0	1.20	1.70	3.00	5.2	
			Placebo	27	23 (85.2)	2.20 (0.93)	0.0	1.80	2.40	3.00	3.8	
		Week 10	Tezepelumab	32	30 (93.8)	1.85 (1.17)	0.0	1.00	1.70	2.60	4.8	
			Placebo	27	23 (85.2)	2.02 (0.79)	0.2	1.80	2.00	2.40	3.0	
		Week 12	Tezepelumab	32	30 (93.8)	1.87 (1.14)	0.0	1.20	1.90	2.80	4.8	
			Placebo	27	23 (85.2)	1.90 (0.83)	0.4	1.00	2.00	2.40	3.2	
		Week 14	Tezepelumab	32	30 (93.8)	1.76 (1.16)	0.0	1.00	1.70	2.40	4.8	
			Placebo	27	23 (85.2)	1.73 (0.80)	0.4	1.00	1.80	2.20	3.2	
		Week 16	Tezepelumab	32	30 (93.8)	2.01 (1.23)	0.0	1.00	2.10	2.80	4.8	
			Placebo	27	23 (85.2)	1.92 (0.79)	0.4	1.40	2.00	2.40	3.2	
		Week 18	Tezepelumab	32	31 (96.9)	1.91 (1.14)	0.0	1.20	2.00	2.60	4.8	
			Placebo	27	23 (85.2)	1.86 (1.10)	0.0	1.00	1.80	2.60	4.8	
		Week 20	Tezepelumab	32	31 (96.9)	1.95 (1.20)	0.0	1.20	1.80	2.80	5.0	
			Placebo	27	23 (85.2)	1.83 (0.99)	0.2	1.00	2.00	2.40	3.8	
		Week 22	Tezepelumab	32	31 (96.9)	1.95 (1.09)	0.0	1.20	2.00	2.60	4.8	
			Placebo	27	23 (85.2)	1.80 (0.96)	0.0	1.00	1.80	2.60	4.0	
		Week 24	Tezepelumab	32	31 (96.9)	2.00 (1.15)	0.0	1.20	2.20	2.80	4.8	
			Placebo	27	23 (85.2)	1.89 (0.95)	0.2	1.00	2.00	2.60	3.8	
		Week 26	Tezepelumab	32	32 (100.0)	2.01 (1.15)	0.0	1.10	2.00	2.80	4.8	
			Placebo	27	23 (85.2)	1.86 (1.03)	0.4	1.00	1.80	2.40	4.4	
		Week 28	Tezepelumab	32	32 (100.0)	1.94 (1.14)	0.0	1.20	1.90	2.80	4.8	
			Placebo	27	24 (88.9)	1.75 (1.06)	0.0	0.90	1.90	2.50	4.4	
		Week 30	Tezepelumab	32	32 (100.0)	1.98 (1.12)	0.0	1.20	2.00	2.60	4.8	
			Placebo	27	24 (88.9)	1.71 (0.97)	0.0	0.90	1.80	2.40	3.4	
		Week 32	Tezepelumab	32	32 (100.0)	1.93 (1.12)	0.0	1.10	2.00	2.80	4.8	
			Placebo	27	24 (88.9)	1.61 (0.93)	0.0	0.80	1.80	2.10	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 22.0 ppb	Absolute values	Week 34	Tezepelumab	32	32 (100.0)	1.99 (1.22)	0.0	1.00	2.00	2.90	4.8	
			Placebo	27	24 (88.9)	1.72 (0.89)	0.0	1.20	1.80	2.30	3.2	
		Week 36	Tezepelumab	32	32 (100.0)	1.95 (1.16)	0.0	1.00	1.90	2.90	4.8	
			Placebo	27	24 (88.9)	1.68 (1.12)	0.0	0.80	2.00	2.60	3.6	
		Week 38	Tezepelumab	32	32 (100.0)	2.04 (1.34)	0.0	1.00	2.00	3.00	4.8	
			Placebo	27	24 (88.9)	1.67 (0.93)	0.0	1.10	1.80	2.20	3.4	
		Week 40	Tezepelumab	32	32 (100.0)	2.04 (1.21)	0.0	1.10	2.00	2.90	4.8	
			Placebo	27	24 (88.9)	1.79 (1.21)	0.0	0.60	1.80	2.60	4.2	
		Week 42	Tezepelumab	32	32 (100.0)	2.05 (1.19)	0.0	1.00	2.10	2.80	4.8	
			Placebo	27	24 (88.9)	1.68 (0.96)	0.0	0.90	1.90	2.20	3.8	
		Week 44	Tezepelumab	32	32 (100.0)	2.09 (1.16)	0.0	1.30	2.20	3.00	4.8	
			Placebo	27	24 (88.9)	1.87 (1.10)	0.0	0.90	1.90	2.80	4.2	
		Week 46	Tezepelumab	32	32 (100.0)	2.12 (1.17)	0.0	1.10	2.20	3.00	4.8	
			Placebo	27	24 (88.9)	1.63 (1.00)	0.0	0.90	1.60	2.20	4.4	
		Week 48	Tezepelumab	32	32 (100.0)	2.07 (1.15)	0.0	1.20	2.40	2.80	4.8	
			Placebo	27	24 (88.9)	1.63 (1.15)	0.0	0.50	1.70	2.40	4.6	
		Week 50	Tezepelumab	32	32 (100.0)	2.06 (1.24)	0.0	1.10	2.00	3.00	4.8	
			Placebo	27	24 (88.9)	1.58 (0.93)	0.0	1.00	1.70	2.20	3.8	
		Week 52	Tezepelumab	32	32 (100.0)	2.04 (1.25)	0.0	1.10	2.00	2.80	4.8	
			Placebo	27	24 (88.9)	1.71 (1.00)	0.0	1.00	1.80	2.50	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 2	Tezepelumab	32	30 (93.8)	-0.53 (0.80)	-3.2	-0.80	-0.40	0.20	0.4	0.05 [-0.49, 0.60]
			Placebo	27	23 (85.2)	-0.57 (0.65)	-2.8	-0.80	-0.40	-0.20	0.2	
		Week 4	Tezepelumab	32	30 (93.8)	-0.85 (0.73)	-2.4	-1.20	-0.80	-0.40	0.2	-0.06 [-0.61, 0.48]
			Placebo	27	23 (85.2)	-0.80 (0.96)	-3.0	-1.40	-0.80	0.00	0.6	
		Week 6	Tezepelumab	32	30 (93.8)	-1.07 (0.79)	-2.8	-1.60	-1.20	-0.60	0.2	-0.29 [-0.84, 0.25]
			Placebo	27	23 (85.2)	-0.80 (1.10)	-3.4	-1.60	-0.80	0.20	1.6	
		Week 8	Tezepelumab	32	30 (93.8)	-1.03 (1.18)	-3.2	-1.80	-1.10	-0.40	2.6	-0.29 [-0.84, 0.26]
			Placebo	27	23 (85.2)	-0.71 (1.01)	-3.0	-1.20	-0.80	0.20	1.0	
		Week 10	Tezepelumab	32	30 (93.8)	-1.17 (1.00)	-3.4	-1.80	-1.20	-0.60	0.6	-0.29 [-0.83, 0.26]
			Placebo	27	23 (85.2)	-0.90 (0.85)	-3.2	-1.40	-0.80	-0.40	0.4	
		Week 12	Tezepelumab	32	30 (93.8)	-1.14 (0.99)	-3.0	-2.20	-1.20	-0.40	0.6	-0.14 [-0.68, 0.41]
			Placebo	27	23 (85.2)	-1.01 (0.95)	-3.2	-1.80	-0.80	-0.20	0.2	
		Week 14	Tezepelumab	32	30 (93.8)	-1.25 (0.95)	-3.4	-1.80	-1.30	-0.60	0.6	-0.07 [-0.62, 0.47]
			Placebo	27	23 (85.2)	-1.18 (1.00)	-3.2	-1.80	-1.40	-0.20	0.2	
		Week 16	Tezepelumab	32	30 (93.8)	-1.01 (1.09)	-3.2	-1.60	-1.00	-0.40	1.8	-0.01 [-0.56, 0.53]
			Placebo	27	23 (85.2)	-0.99 (0.94)	-2.8	-1.40	-1.20	0.00	0.4	
		Week 18	Tezepelumab	32	31 (96.9)	-1.07 (0.97)	-3.4	-1.80	-0.80	-0.40	0.6	-0.02 [-0.56, 0.52]
			Placebo	27	23 (85.2)	-1.05 (1.19)	-3.2	-2.20	-1.20	0.00	1.4	
		Week 20	Tezepelumab	32	31 (96.9)	-1.03 (1.03)	-3.4	-1.80	-1.00	-0.40	0.6	0.05 [-0.49, 0.59]
			Placebo	27	23 (85.2)	-1.08 (1.16)	-3.0	-1.80	-1.20	-0.20	1.0	
		Week 22	Tezepelumab	32	31 (96.9)	-1.03 (0.96)	-3.2	-1.80	-0.80	-0.40	0.6	0.08 [-0.46, 0.62]
			Placebo	27	23 (85.2)	-1.11 (1.10)	-3.2	-2.00	-1.20	0.00	1.2	
		Week 24	Tezepelumab	32	31 (96.9)	-0.98 (1.01)	-3.4	-2.00	-0.80	-0.20	0.6	0.04 [-0.50, 0.58]
			Placebo	27	23 (85.2)	-1.03 (1.11)	-3.2	-1.80	-1.00	0.00	1.0	
		Week 26	Tezepelumab	32	32 (100.0)	-0.93 (1.03)	-3.0	-2.00	-0.70	-0.20	0.6	0.11 [-0.42, 0.65]
			Placebo	27	23 (85.2)	-1.05 (1.13)	-2.4	-2.00	-1.40	0.00	1.6	
		Week 28	Tezepelumab	32	32 (100.0)	-1.01 (1.15)	-3.4	-1.90	-0.80	-0.30	1.0	0.05 [-0.48, 0.58]
			Placebo	27	24 (88.9)	-1.06 (1.11)	-2.8	-1.90	-1.00	-0.20	1.6	
		Week 30	Tezepelumab	32	32 (100.0)	-0.97 (1.10)	-2.8	-1.90	-1.00	-0.30	2.0	0.12 [-0.41, 0.65]
			Placebo	27	24 (88.9)	-1.10 (1.06)	-3.2	-1.80	-1.30	-0.30	0.6	
		Week 32	Tezepelumab	32	32 (100.0)	-1.01 (1.03)	-3.2	-1.70	-1.00	-0.40	1.0	0.18 [-0.35, 0.71]
			Placebo	27	24 (88.9)	-1.20 (1.07)	-3.2	-2.00	-1.30	-0.40	0.8	
		Week 34	Tezepelumab	32	32 (100.0)	-0.96 (1.17)	-3.0	-2.00	-0.90	-0.20	2.2	0.12 [-0.41, 0.65]
			Placebo	27	24 (88.9)	-1.09 (0.98)	-3.2	-1.60	-1.10	-0.40	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 22.0 ppb	Change from baseline	Week 36	Tezepelumab	32	32 (100.0)	-0.99 (1.07)	-3.2	-1.90	-1.10	-0.20	1.6	0.12 [-0.41, 0.65]
			Placebo	27	24 (88.9)	-1.13 (1.19)	-3.6	-1.90	-0.80	-0.30	0.8	
		Week 38	Tezepelumab	32	32 (100.0)	-0.91 (1.24)	-3.2	-1.90	-0.90	0.00	2.6	0.21 [-0.32, 0.74]
			Placebo	27	24 (88.9)	-1.14 (0.93)	-3.2	-1.80	-1.10	-0.50	0.2	
		Week 40	Tezepelumab	32	32 (100.0)	-0.90 (1.12)	-3.4	-1.60	-0.80	-0.10	1.8	0.10 [-0.43, 0.63]
			Placebo	27	24 (88.9)	-1.02 (1.21)	-3.2	-2.10	-1.10	-0.10	1.4	
		Week 42	Tezepelumab	32	32 (100.0)	-0.89 (1.11)	-3.0	-1.50	-0.80	-0.20	2.2	0.22 [-0.31, 0.75]
			Placebo	27	24 (88.9)	-1.13 (0.98)	-2.8	-1.60	-1.20	-0.70	1.0	
		Week 44	Tezepelumab	32	32 (100.0)	-0.86 (1.09)	-3.4	-1.50	-0.80	-0.10	1.6	0.08 [-0.45, 0.61]
			Placebo	27	24 (88.9)	-0.94 (1.12)	-3.4	-1.70	-0.70	0.00	0.8	
		Week 46	Tezepelumab	32	32 (100.0)	-0.83 (1.07)	-2.8	-1.70	-0.80	-0.10	1.8	0.33 [-0.21, 0.86]
			Placebo	27	24 (88.9)	-1.18 (1.06)	-3.2	-1.80	-1.10	-0.60	1.6	
		Week 48	Tezepelumab	32	32 (100.0)	-0.88 (1.05)	-2.8	-1.70	-0.80	-0.30	2.0	0.27 [-0.27, 0.80]
			Placebo	27	24 (88.9)	-1.18 (1.22)	-3.4	-1.80	-0.90	-0.50	1.8	
		Week 50	Tezepelumab	32	32 (100.0)	-0.89 (1.16)	-3.2	-1.70	-0.80	-0.20	2.0	0.30 [-0.23, 0.83]
			Placebo	27	24 (88.9)	-1.23 (1.09)	-3.6	-1.70	-1.30	-0.50	1.6	
		Week 52	Tezepelumab	32	32 (100.0)	-0.90 (1.15)	-3.2	-1.70	-0.80	-0.20	2.0	0.17 [-0.36, 0.70]
			Placebo	27	24 (88.9)	-1.10 (1.17)	-3.6	-1.70	-0.90	-0.40	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	34	34 (100.0)	2.80 (1.02)	0.0	2.40	2.80	3.40	5.2	
			Placebo	37	37 (100.0)	2.95 (0.83)	1.0	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	34	33 (97.1)	2.21 (0.99)	0.2	1.60	2.20	3.00	4.4	
			Placebo	37	34 (91.9)	2.42 (0.90)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	34	33 (97.1)	2.01 (1.06)	0.2	1.20	2.20	2.80	3.4	
			Placebo	37	34 (91.9)	2.34 (0.96)	0.2	1.80	2.60	3.00	4.2	
		Week 6	Tezepelumab	34	33 (97.1)	2.00 (1.10)	0.0	1.20	2.20	3.00	3.8	
			Placebo	37	34 (91.9)	2.29 (1.24)	0.2	1.40	2.30	3.00	6.0	
		Week 8	Tezepelumab	34	33 (97.1)	1.67 (1.08)	0.0	0.80	1.80	2.80	3.4	
			Placebo	37	35 (94.6)	2.13 (1.26)	0.0	1.00	2.40	3.00	5.0	
		Week 10	Tezepelumab	34	33 (97.1)	1.61 (1.11)	0.0	0.80	1.40	2.40	3.6	
			Placebo	37	35 (94.6)	2.19 (1.22)	0.0	1.00	2.40	3.00	5.2	
		Week 12	Tezepelumab	34	33 (97.1)	1.38 (1.03)	0.0	0.60	1.40	2.20	3.0	
			Placebo	37	35 (94.6)	1.99 (1.20)	0.0	1.00	2.20	2.80	4.4	
		Week 14	Tezepelumab	34	33 (97.1)	1.37 (1.08)	0.0	0.60	1.40	2.00	3.8	
			Placebo	37	35 (94.6)	1.99 (1.12)	0.0	1.60	2.00	2.60	5.0	
		Week 16	Tezepelumab	34	33 (97.1)	1.44 (1.09)	0.0	0.60	1.40	2.20	3.6	
			Placebo	37	35 (94.6)	2.15 (1.41)	0.0	0.60	2.40	3.00	5.0	
		Week 18	Tezepelumab	34	33 (97.1)	1.45 (0.99)	0.0	0.80	1.20	2.20	3.4	
			Placebo	37	35 (94.6)	2.01 (1.24)	0.0	1.20	2.20	2.60	5.0	
		Week 20	Tezepelumab	34	33 (97.1)	1.42 (1.03)	0.0	0.60	1.20	2.00	3.6	
			Placebo	37	35 (94.6)	2.20 (1.18)	0.0	1.40	2.40	2.80	5.0	
		Week 22	Tezepelumab	34	33 (97.1)	1.61 (0.96)	0.0	0.80	1.60	2.40	3.4	
			Placebo	37	35 (94.6)	2.14 (1.27)	0.0	1.20	2.40	3.00	5.0	
		Week 24	Tezepelumab	34	33 (97.1)	1.50 (1.03)	0.0	0.60	1.20	2.20	3.6	
			Placebo	37	35 (94.6)	2.19 (1.12)	0.0	1.60	2.20	3.00	4.4	
		Week 26	Tezepelumab	34	33 (97.1)	1.58 (1.07)	0.0	0.80	1.60	2.20	3.6	
			Placebo	37	35 (94.6)	2.09 (1.21)	0.0	1.00	2.00	3.20	4.4	
		Week 28	Tezepelumab	34	34 (100.0)	1.54 (1.16)	0.0	0.40	1.40	2.40	3.6	
			Placebo	37	35 (94.6)	2.14 (1.32)	0.0	1.00	2.00	3.40	4.4	
		Week 30	Tezepelumab	34	34 (100.0)	1.44 (1.04)	0.0	0.60	1.40	2.20	3.6	
			Placebo	37	35 (94.6)	2.13 (1.29)	0.0	1.20	2.20	3.20	4.4	
		Week 32	Tezepelumab	34	34 (100.0)	1.35 (1.06)	0.0	0.40	1.20	2.20	3.6	
			Placebo	37	35 (94.6)	2.14 (1.23)	0.0	1.20	2.00	3.00	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 22.0 ppb	Absolute values	Week 34	Tezepelumab	34	34 (100.0)	1.45 (1.12)	0.0	0.40	1.30	2.40	4.2	
			Placebo	37	35 (94.6)	2.02 (1.28)	0.0	1.00	2.00	3.00	4.8	
		Week 36	Tezepelumab	34	34 (100.0)	1.40 (1.00)	0.0	0.60	1.40	2.20	3.6	
			Placebo	37	35 (94.6)	2.33 (1.20)	0.0	1.40	2.40	3.20	4.8	
		Week 38	Tezepelumab	34	34 (100.0)	1.41 (1.05)	0.0	0.40	1.50	2.20	3.6	
			Placebo	37	35 (94.6)	2.10 (1.25)	0.0	1.00	2.00	3.00	4.8	
		Week 40	Tezepelumab	34	34 (100.0)	1.37 (1.07)	0.0	0.40	1.20	2.20	3.2	
			Placebo	37	35 (94.6)	2.24 (1.18)	0.0	1.20	2.40	3.00	4.4	
		Week 42	Tezepelumab	34	34 (100.0)	1.26 (0.98)	0.0	0.40	1.20	2.00	3.2	
			Placebo	37	35 (94.6)	2.07 (1.12)	0.0	1.20	2.00	2.80	4.6	
		Week 44	Tezepelumab	34	34 (100.0)	1.29 (0.99)	0.0	0.40	1.10	2.20	3.2	
			Placebo	37	35 (94.6)	2.09 (1.15)	0.0	1.20	2.00	3.00	4.4	
		Week 46	Tezepelumab	34	34 (100.0)	1.32 (1.09)	0.0	0.40	1.00	2.20	3.6	
			Placebo	37	35 (94.6)	2.04 (1.01)	0.0	1.40	2.00	2.60	4.4	
		Week 48	Tezepelumab	34	34 (100.0)	1.38 (1.14)	0.0	0.40	1.10	2.20	4.2	
			Placebo	37	35 (94.6)	2.14 (1.04)	0.0	1.40	2.20	2.80	4.4	
		Week 50	Tezepelumab	34	34 (100.0)	1.26 (1.04)	0.0	0.60	1.00	2.00	4.2	
			Placebo	37	35 (94.6)	1.97 (1.08)	0.0	1.00	2.00	2.60	4.4	
		Week 52	Tezepelumab	34	34 (100.0)	1.34 (1.03)	0.0	0.60	1.20	2.00	4.2	
			Placebo	37	35 (94.6)	2.01 (1.15)	0.0	1.00	2.00	2.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 2	Tezepelumab	34	33 (97.1)	-0.59 (0.80)	-2.2	-1.20	-0.40	0.00	0.8	-0.14 [-0.62, 0.34]
			Placebo	37	34 (91.9)	-0.48 (0.78)	-2.4	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	34	33 (97.1)	-0.80 (1.09)	-2.6	-1.40	-1.00	-0.20	2.6	-0.22 [-0.70, 0.26]
			Placebo	37	34 (91.9)	-0.57 (0.97)	-3.0	-1.20	-0.30	0.00	1.2	
		Week 6	Tezepelumab	34	33 (97.1)	-0.81 (1.20)	-2.8	-1.60	-0.80	0.00	2.6	-0.17 [-0.65, 0.31]
			Placebo	37	34 (91.9)	-0.61 (1.05)	-3.2	-1.40	-0.30	0.00	1.6	
		Week 8	Tezepelumab	34	33 (97.1)	-1.14 (1.15)	-3.0	-1.60	-1.00	-0.40	2.6	-0.31 [-0.79, 0.17]
			Placebo	37	35 (94.6)	-0.79 (1.10)	-3.6	-1.60	-0.40	0.00	1.0	
		Week 10	Tezepelumab	34	33 (97.1)	-1.20 (1.23)	-3.0	-2.20	-1.40	-0.60	2.6	-0.37 [-0.85, 0.11]
			Placebo	37	35 (94.6)	-0.73 (1.28)	-3.8	-1.60	-0.60	0.00	2.6	
		Week 12	Tezepelumab	34	33 (97.1)	-1.43 (1.20)	-3.2	-2.20	-1.40	-0.80	2.6	-0.42 [-0.91, 0.06]
			Placebo	37	35 (94.6)	-0.93 (1.18)	-3.8	-1.60	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	34	33 (97.1)	-1.44 (1.24)	-4.0	-2.20	-1.40	-0.80	2.6	-0.42 [-0.90, 0.06]
			Placebo	37	35 (94.6)	-0.93 (1.14)	-3.4	-1.40	-1.00	-0.40	2.4	
		Week 16	Tezepelumab	34	33 (97.1)	-1.37 (1.18)	-3.0	-2.20	-1.20	-0.80	2.6	-0.48 [-0.96, 0.01]
			Placebo	37	35 (94.6)	-0.77 (1.32)	-3.6	-1.40	-0.80	-0.20	2.6	
		Week 18	Tezepelumab	34	33 (97.1)	-1.36 (1.20)	-3.8	-2.00	-1.20	-0.80	2.6	-0.36 [-0.84, 0.12]
			Placebo	37	35 (94.6)	-0.91 (1.28)	-3.6	-1.80	-0.80	-0.20	2.6	
		Week 20	Tezepelumab	34	33 (97.1)	-1.39 (1.15)	-3.0	-2.20	-1.40	-0.80	2.6	-0.57 [-1.05, -0.08]
			Placebo	37	35 (94.6)	-0.72 (1.20)	-3.6	-1.40	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	34	33 (97.1)	-1.19 (1.28)	-3.0	-2.40	-1.20	-0.80	2.6	-0.33 [-0.80, 0.15]
			Placebo	37	35 (94.6)	-0.78 (1.25)	-3.8	-1.40	-0.80	-0.20	2.6	
		Week 24	Tezepelumab	34	33 (97.1)	-1.31 (1.16)	-3.0	-2.00	-1.60	-0.80	2.6	-0.50 [-0.98, -0.02]
			Placebo	37	35 (94.6)	-0.73 (1.16)	-3.6	-1.40	-0.80	0.00	2.6	
		Week 26	Tezepelumab	34	33 (97.1)	-1.23 (1.22)	-3.0	-2.20	-1.40	-0.40	2.6	-0.32 [-0.80, 0.15]
			Placebo	37	35 (94.6)	-0.83 (1.26)	-3.4	-1.60	-0.80	0.00	2.6	
		Week 28	Tezepelumab	34	34 (100.0)	-1.26 (1.27)	-3.0	-2.20	-1.40	-0.20	2.6	-0.37 [-0.84, 0.11]
			Placebo	37	35 (94.6)	-0.78 (1.32)	-3.4	-1.60	-1.00	0.00	2.6	
		Week 30	Tezepelumab	34	34 (100.0)	-1.36 (1.24)	-3.8	-2.40	-1.40	-0.60	2.6	-0.44 [-0.91, 0.04]
			Placebo	37	35 (94.6)	-0.79 (1.35)	-3.4	-1.60	-1.00	0.00	2.6	
		Week 32	Tezepelumab	34	34 (100.0)	-1.45 (1.15)	-3.0	-2.40	-1.70	-1.00	2.6	-0.56 [-1.04, -0.08]
			Placebo	37	35 (94.6)	-0.78 (1.23)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	34	34 (100.0)	-1.35 (1.22)	-3.0	-2.40	-1.50	-0.60	2.6	-0.36 [-0.84, 0.12]
			Placebo	37	35 (94.6)	-0.90 (1.28)	-3.2	-1.80	-1.20	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 22.0 ppb	Change from baseline	Week 36	Tezepelumab	34	34 (100.0)	-1.40 (1.25)	-3.0	-2.40	-1.60	-0.80	2.6	-0.65 [-1.13, -0.16]
			Placebo	37	35 (94.6)	-0.59 (1.23)	-2.6	-1.40	-1.00	0.00	2.6	
		Week 38	Tezepelumab	34	34 (100.0)	-1.39 (1.19)	-3.0	-2.20	-1.60	-0.80	2.6	-0.46 [-0.93, 0.02]
			Placebo	37	35 (94.6)	-0.82 (1.28)	-2.8	-1.60	-1.00	0.20	2.6	
		Week 40	Tezepelumab	34	34 (100.0)	-1.43 (1.24)	-3.0	-2.60	-1.60	-0.80	2.6	-0.61 [-1.09, -0.12]
			Placebo	37	35 (94.6)	-0.68 (1.23)	-2.6	-1.40	-0.80	0.00	2.6	
		Week 42	Tezepelumab	34	34 (100.0)	-1.54 (1.22)	-3.6	-2.40	-1.80	-0.60	2.6	-0.58 [-1.06, -0.10]
			Placebo	37	35 (94.6)	-0.85 (1.18)	-2.6	-1.60	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	34	34 (100.0)	-1.51 (1.23)	-3.8	-2.40	-1.60	-0.80	2.6	-0.56 [-1.04, -0.08]
			Placebo	37	35 (94.6)	-0.83 (1.20)	-2.6	-1.60	-1.00	-0.20	2.6	
		Week 46	Tezepelumab	34	34 (100.0)	-1.48 (1.26)	-3.6	-2.40	-1.50	-1.00	2.6	-0.51 [-0.99, -0.03]
			Placebo	37	35 (94.6)	-0.88 (1.06)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	34	34 (100.0)	-1.42 (1.27)	-3.0	-2.40	-1.60	-0.40	2.6	-0.55 [-1.03, -0.07]
			Placebo	37	35 (94.6)	-0.78 (1.06)	-2.8	-1.40	-1.00	-0.20	2.6	
		Week 50	Tezepelumab	34	34 (100.0)	-1.54 (1.20)	-3.0	-2.40	-1.70	-1.20	2.6	-0.52 [-1.00, -0.04]
			Placebo	37	35 (94.6)	-0.95 (1.04)	-2.8	-1.60	-1.00	-0.40	2.6	
		Week 52	Tezepelumab	34	34 (100.0)	-1.46 (1.20)	-3.0	-2.40	-1.60	-1.00	2.6	-0.48 [-0.96, -0.00]
			Placebo	37	35 (94.6)	-0.91 (1.08)	-2.8	-1.60	-1.00	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	25	25 (100.0)	2.99 (0.74)	1.8	2.60	3.00	3.00	5.0	
			Placebo	22	22 (100.0)	2.80 (0.80)	1.0	2.60	3.00	3.20	4.8	
		Week 2	Tezepelumab	25	24 (96.0)	2.43 (0.98)	0.2	1.60	2.70	3.10	4.0	
			Placebo	22	19 (86.4)	2.26 (0.89)	0.4	1.80	2.40	2.60	4.8	
		Week 4	Tezepelumab	25	24 (96.0)	2.17 (0.91)	0.2	1.70	2.20	2.80	3.6	
			Placebo	22	19 (86.4)	2.28 (1.06)	0.2	1.40	2.60	3.00	4.2	
		Week 6	Tezepelumab	25	24 (96.0)	1.83 (1.05)	0.0	1.30	1.70	2.70	3.8	
			Placebo	22	19 (86.4)	2.24 (1.28)	0.2	1.40	2.00	3.00	5.0	
		Week 8	Tezepelumab	25	24 (96.0)	1.85 (1.25)	0.0	1.30	1.70	2.70	5.2	
			Placebo	22	20 (90.9)	2.11 (1.25)	0.0	0.80	2.40	3.00	4.6	
		Week 10	Tezepelumab	25	24 (96.0)	1.73 (1.19)	0.0	1.00	1.70	2.50	4.8	
			Placebo	22	20 (90.9)	2.20 (1.16)	0.2	1.30	2.30	2.80	4.4	
		Week 12	Tezepelumab	25	24 (96.0)	1.71 (1.18)	0.0	0.90	1.70	2.60	4.8	
			Placebo	22	20 (90.9)	2.15 (1.24)	0.2	1.00	2.10	3.00	4.4	
		Week 14	Tezepelumab	25	24 (96.0)	1.58 (1.19)	0.0	0.60	1.50	2.30	4.8	
			Placebo	22	20 (90.9)	1.81 (1.15)	0.0	1.00	1.70	2.50	5.0	
		Week 16	Tezepelumab	25	24 (96.0)	1.69 (1.17)	0.0	0.90	1.70	2.50	4.8	
			Placebo	22	20 (90.9)	2.09 (1.35)	0.0	0.60	2.20	3.00	4.4	
		Week 18	Tezepelumab	25	24 (96.0)	1.58 (1.18)	0.0	0.70	1.60	2.30	4.8	
			Placebo	22	20 (90.9)	1.74 (1.26)	0.0	0.70	1.70	2.60	4.4	
		Week 20	Tezepelumab	25	24 (96.0)	1.68 (1.19)	0.0	0.70	1.70	2.60	4.8	
			Placebo	22	20 (90.9)	1.99 (1.35)	0.2	0.70	2.10	2.80	4.4	
		Week 22	Tezepelumab	25	24 (96.0)	1.83 (1.13)	0.0	1.00	1.90	2.60	4.8	
			Placebo	22	20 (90.9)	1.92 (1.39)	0.0	0.70	2.00	2.70	4.4	
		Week 24	Tezepelumab	25	24 (96.0)	1.81 (1.18)	0.0	1.20	1.60	2.70	4.8	
			Placebo	22	20 (90.9)	2.03 (1.30)	0.0	0.90	2.10	2.90	4.4	
		Week 26	Tezepelumab	25	25 (100.0)	1.78 (1.17)	0.0	1.00	1.80	2.60	4.8	
			Placebo	22	20 (90.9)	1.98 (1.35)	0.4	1.00	1.40	3.20	4.4	
		Week 28	Tezepelumab	25	25 (100.0)	1.82 (1.21)	0.0	1.20	1.80	2.60	4.8	
			Placebo	22	20 (90.9)	2.28 (1.31)	0.4	1.00	2.10	3.40	4.4	
		Week 30	Tezepelumab	25	25 (100.0)	1.83 (1.21)	0.0	1.00	1.80	2.60	4.8	
			Placebo	22	20 (90.9)	2.18 (1.29)	0.0	0.90	2.20	3.10	4.4	
		Week 32	Tezepelumab	25	25 (100.0)	1.81 (1.19)	0.0	1.00	1.80	2.80	4.8	
			Placebo	22	20 (90.9)	2.01 (1.25)	0.4	0.90	1.80	3.00	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Absolute values	Week 34	Tezepelumab	25	25 (100.0)	1.88 (1.29)	0.0	1.00	1.40	2.80	4.8	
			Placebo	22	20 (90.9)	1.82 (1.25)	0.0	0.80	1.40	2.60	4.4	
		Week 36	Tezepelumab	25	25 (100.0)	1.78 (1.27)	0.0	1.00	1.60	3.00	4.8	
			Placebo	22	20 (90.9)	2.15 (1.29)	0.0	1.40	1.90	3.00	4.4	
		Week 38	Tezepelumab	25	25 (100.0)	1.98 (1.34)	0.0	1.00	2.20	3.00	4.8	
			Placebo	22	20 (90.9)	1.99 (1.21)	0.0	0.90	2.00	2.90	4.4	
		Week 40	Tezepelumab	25	25 (100.0)	1.88 (1.28)	0.0	1.00	2.00	2.80	4.8	
			Placebo	22	20 (90.9)	2.46 (1.29)	0.4	1.50	2.40	3.30	4.4	
		Week 42	Tezepelumab	25	25 (100.0)	1.90 (1.28)	0.0	1.00	1.80	2.80	4.8	
			Placebo	22	20 (90.9)	2.15 (1.29)	0.4	1.10	2.10	2.70	4.6	
		Week 44	Tezepelumab	25	25 (100.0)	1.86 (1.27)	0.0	0.80	1.80	3.00	4.8	
			Placebo	22	20 (90.9)	2.30 (1.16)	0.4	1.40	2.30	3.10	4.4	
		Week 46	Tezepelumab	25	25 (100.0)	1.98 (1.29)	0.0	1.00	2.00	3.00	4.8	
			Placebo	22	20 (90.9)	2.11 (1.20)	0.0	1.40	2.00	2.50	4.4	
		Week 48	Tezepelumab	25	25 (100.0)	1.97 (1.26)	0.0	1.20	2.00	3.00	4.8	
			Placebo	22	20 (90.9)	2.30 (1.29)	0.0	1.60	2.30	2.90	4.6	
		Week 50	Tezepelumab	25	25 (100.0)	1.95 (1.21)	0.0	1.20	2.00	2.80	4.8	
			Placebo	22	20 (90.9)	1.92 (1.14)	0.4	1.00	1.90	2.40	4.4	
		Week 52	Tezepelumab	25	25 (100.0)	1.94 (1.23)	0.0	1.20	2.00	2.80	4.8	
			Placebo	22	20 (90.9)	2.04 (1.20)	0.4	1.00	2.10	2.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	25	24 (96.0)	-0.61 (0.70)	-2.2	-1.10	-0.40	-0.00	0.2	-0.09 [-0.69, 0.51]
			Placebo	22	19 (86.4)	-0.54 (0.92)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	25	24 (96.0)	-0.88 (0.83)	-2.6	-1.30	-0.80	-0.30	0.4	-0.38 [-0.98, 0.23]
			Placebo	22	19 (86.4)	-0.52 (1.10)	-2.6	-1.20	-0.20	0.40	1.2	
		Week 6	Tezepelumab	25	24 (96.0)	-1.21 (0.99)	-2.6	-1.90	-1.30	-0.70	1.2	-0.59 [-1.20, 0.03]
			Placebo	22	19 (86.4)	-0.56 (1.23)	-2.6	-1.60	-0.60	0.20	1.6	
		Week 8	Tezepelumab	25	24 (96.0)	-1.19 (1.29)	-3.2	-2.00	-1.30	-0.50	2.6	-0.39 [-0.99, 0.21]
			Placebo	22	20 (90.9)	-0.72 (1.10)	-2.8	-1.50	-0.60	-0.10	1.0	
		Week 10	Tezepelumab	25	24 (96.0)	-1.31 (1.11)	-3.4	-2.00	-1.40	-0.70	0.6	-0.58 [-1.18, 0.03]
			Placebo	22	20 (90.9)	-0.63 (1.26)	-2.6	-1.30	-0.60	-0.20	2.6	
		Week 12	Tezepelumab	25	24 (96.0)	-1.33 (1.13)	-3.2	-2.20	-1.20	-0.40	0.6	-0.58 [-1.18, 0.03]
			Placebo	22	20 (90.9)	-0.68 (1.12)	-2.8	-1.30	-0.60	0.00	1.6	
		Week 14	Tezepelumab	25	24 (96.0)	-1.46 (1.18)	-4.0	-2.20	-1.40	-0.70	0.6	-0.38 [-0.98, 0.22]
			Placebo	22	20 (90.9)	-1.02 (1.09)	-2.6	-1.70	-1.10	-0.60	1.4	
		Week 16	Tezepelumab	25	24 (96.0)	-1.35 (1.14)	-3.2	-2.30	-1.20	-0.70	0.6	-0.52 [-1.12, 0.09]
			Placebo	22	20 (90.9)	-0.74 (1.23)	-2.6	-1.40	-0.80	-0.10	2.6	
		Week 18	Tezepelumab	25	24 (96.0)	-1.46 (1.16)	-3.8	-2.20	-1.40	-0.80	0.6	-0.30 [-0.90, 0.29]
			Placebo	22	20 (90.9)	-1.09 (1.28)	-3.2	-2.10	-1.20	-0.40	2.6	
		Week 20	Tezepelumab	25	24 (96.0)	-1.36 (1.12)	-3.4	-2.30	-1.30	-0.50	0.6	-0.43 [-1.03, 0.17]
			Placebo	22	20 (90.9)	-0.84 (1.31)	-3.0	-1.60	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	25	24 (96.0)	-1.21 (1.09)	-3.2	-2.30	-0.90	-0.50	0.6	-0.25 [-0.84, 0.35]
			Placebo	22	20 (90.9)	-0.91 (1.36)	-3.2	-1.90	-1.00	-0.40	2.6	
		Week 24	Tezepelumab	25	24 (96.0)	-1.23 (1.04)	-3.4	-1.90	-1.30	-0.50	0.6	-0.37 [-0.97, 0.23]
			Placebo	22	20 (90.9)	-0.80 (1.31)	-3.0	-1.70	-0.80	-0.10	2.6	
		Week 26	Tezepelumab	25	25 (100.0)	-1.21 (1.11)	-3.0	-2.20	-1.20	-0.40	0.6	-0.28 [-0.87, 0.31]
			Placebo	22	20 (90.9)	-0.85 (1.44)	-2.6	-1.90	-1.20	0.10	2.6	
		Week 28	Tezepelumab	25	25 (100.0)	-1.18 (1.22)	-3.4	-2.20	-1.20	-0.60	1.0	-0.49 [-1.08, 0.11]
			Placebo	22	20 (90.9)	-0.55 (1.36)	-2.6	-1.40	-0.60	0.00	2.6	
		Week 30	Tezepelumab	25	25 (100.0)	-1.16 (1.32)	-3.8	-2.20	-1.20	-0.60	2.0	-0.38 [-0.98, 0.21]
			Placebo	22	20 (90.9)	-0.65 (1.34)	-2.8	-1.50	-0.60	-0.10	2.6	
		Week 32	Tezepelumab	25	25 (100.0)	-1.18 (1.15)	-3.2	-2.20	-1.20	-0.80	1.0	-0.30 [-0.89, 0.29]
			Placebo	22	20 (90.9)	-0.82 (1.29)	-2.6	-1.90	-1.00	-0.10	2.6	
		Week 34	Tezepelumab	25	25 (100.0)	-1.11 (1.32)	-3.0	-2.20	-1.40	-0.20	2.2	-0.08 [-0.67, 0.51]
			Placebo	22	20 (90.9)	-1.01 (1.31)	-3.2	-2.00	-1.30	-0.30	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Change from baseline	Week 36	Tezepelumab	25	25 (100.0)	-1.22 (1.30)	-3.2	-2.20	-1.20	-0.20	1.6	-0.40 [-0.99, 0.20]
			Placebo	22	20 (90.9)	-0.68 (1.39)	-3.2	-1.70	-0.70	0.10	2.6	
		Week 38	Tezepelumab	25	25 (100.0)	-1.02 (1.36)	-3.2	-2.20	-1.00	0.00	2.6	-0.13 [-0.72, 0.46]
			Placebo	22	20 (90.9)	-0.84 (1.37)	-3.2	-1.80	-0.90	-0.10	2.6	
		Week 40	Tezepelumab	25	25 (100.0)	-1.11 (1.29)	-3.4	-2.20	-1.00	-0.40	1.8	-0.55 [-1.15, 0.05]
			Placebo	22	20 (90.9)	-0.37 (1.42)	-2.8	-1.10	-0.30	0.50	2.6	
		Week 42	Tezepelumab	25	25 (100.0)	-1.10 (1.35)	-3.6	-2.00	-1.00	-0.40	2.2	-0.30 [-0.89, 0.29]
			Placebo	22	20 (90.9)	-0.68 (1.47)	-2.8	-1.70	-0.80	-0.10	2.6	
		Week 44	Tezepelumab	25	25 (100.0)	-1.13 (1.36)	-3.8	-2.20	-0.80	0.00	1.6	-0.44 [-1.04, 0.15]
			Placebo	22	20 (90.9)	-0.53 (1.33)	-2.6	-1.60	-0.60	0.00	2.6	
		Week 46	Tezepelumab	25	25 (100.0)	-1.01 (1.31)	-3.6	-2.20	-0.80	0.00	1.8	-0.21 [-0.80, 0.38]
			Placebo	22	20 (90.9)	-0.72 (1.41)	-3.2	-1.50	-0.80	-0.10	2.6	
		Week 48	Tezepelumab	25	25 (100.0)	-1.02 (1.28)	-2.8	-2.20	-0.80	0.00	2.0	-0.37 [-0.96, 0.23]
			Placebo	22	20 (90.9)	-0.53 (1.43)	-3.2	-1.40	-0.40	0.10	2.6	
		Week 50	Tezepelumab	25	25 (100.0)	-1.04 (1.18)	-2.8	-1.80	-1.20	-0.40	2.0	-0.11 [-0.69, 0.48]
			Placebo	22	20 (90.9)	-0.91 (1.27)	-2.8	-2.00	-0.80	-0.30	2.6	
		Week 52	Tezepelumab	25	25 (100.0)	-1.06 (1.21)	-2.8	-1.80	-1.20	-0.40	2.0	-0.21 [-0.80, 0.38]
			Placebo	22	20 (90.9)	-0.79 (1.30)	-2.8	-2.00	-0.60	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	35	35 (100.0)	2.81 (1.02)	0.0	2.40	2.80	3.40	5.2	
			Placebo	41	41 (100.0)	2.90 (0.76)	0.4	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	35	34 (97.1)	2.32 (1.09)	0.0	1.60	2.40	3.20	4.4	
			Placebo	41	37 (90.2)	2.46 (0.77)	0.4	2.20	2.60	3.00	5.0	
		Week 4	Tezepelumab	35	34 (97.1)	2.08 (1.09)	0.2	1.20	2.40	3.00	3.4	
			Placebo	41	37 (90.2)	2.27 (0.85)	0.2	1.80	2.60	2.80	3.6	
		Week 6	Tezepelumab	35	34 (97.1)	2.09 (1.06)	0.0	1.20	2.20	2.80	4.0	
			Placebo	41	37 (90.2)	2.21 (1.11)	0.2	1.40	2.20	2.80	6.0	
		Week 8	Tezepelumab	35	34 (97.1)	1.86 (1.19)	0.0	0.80	1.90	2.80	4.2	
			Placebo	41	37 (90.2)	2.18 (1.10)	0.0	1.80	2.40	3.00	5.0	
		Week 10	Tezepelumab	35	34 (97.1)	1.78 (1.15)	0.0	0.80	1.70	2.80	3.6	
			Placebo	41	37 (90.2)	2.12 (1.04)	0.0	1.80	2.20	2.80	5.2	
		Week 12	Tezepelumab	35	34 (97.1)	1.59 (1.12)	0.0	0.60	1.80	2.60	3.2	
			Placebo	41	37 (90.2)	1.82 (0.94)	0.0	1.20	2.00	2.40	3.8	
		Week 14	Tezepelumab	35	34 (97.1)	1.59 (1.14)	0.0	0.60	1.50	2.40	4.2	
			Placebo	41	37 (90.2)	1.91 (0.94)	0.0	1.40	2.00	2.40	5.0	
		Week 16	Tezepelumab	35	34 (97.1)	1.69 (1.15)	0.0	0.80	1.60	2.80	4.2	
			Placebo	41	37 (90.2)	2.01 (1.15)	0.0	1.00	2.00	2.60	5.0	
		Week 18	Tezepelumab	35	34 (97.1)	1.76 (1.06)	0.0	1.00	2.00	2.60	4.2	
			Placebo	41	37 (90.2)	2.04 (1.15)	0.0	1.40	2.20	2.60	5.0	
		Week 20	Tezepelumab	35	34 (97.1)	1.71 (1.19)	0.0	0.80	1.70	2.60	5.0	
			Placebo	41	37 (90.2)	2.08 (0.97)	0.0	1.80	2.00	2.80	5.0	
		Week 22	Tezepelumab	35	34 (97.1)	1.77 (1.03)	0.0	1.00	2.10	2.60	3.8	
			Placebo	41	37 (90.2)	2.04 (1.03)	0.0	1.40	2.00	2.60	5.0	
		Week 24	Tezepelumab	35	34 (97.1)	1.71 (1.10)	0.0	0.80	1.80	2.60	3.8	
			Placebo	41	37 (90.2)	2.08 (0.91)	0.0	1.80	2.20	2.60	4.0	
		Week 26	Tezepelumab	35	34 (97.1)	1.80 (1.14)	0.0	1.00	1.80	2.80	4.0	
			Placebo	41	37 (90.2)	1.99 (1.01)	0.0	1.40	1.80	2.80	4.0	
		Week 28	Tezepelumab	35	35 (100.0)	1.71 (1.17)	0.0	0.60	1.80	2.40	3.8	
			Placebo	41	38 (92.7)	1.81 (1.16)	0.0	1.00	1.80	2.80	4.0	
		Week 30	Tezepelumab	35	35 (100.0)	1.68 (1.08)	0.0	0.80	1.60	2.60	3.6	
			Placebo	41	38 (92.7)	1.84 (1.12)	0.0	1.00	1.90	2.60	4.0	
		Week 32	Tezepelumab	35	35 (100.0)	1.57 (1.09)	0.0	0.80	1.40	2.40	4.0	
			Placebo	41	38 (92.7)	1.87 (1.09)	0.0	1.20	1.90	2.60	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Absolute values	Week 34	Tezepelumab	35	35 (100.0)	1.65 (1.18)	0.0	0.80	1.80	2.60	4.2	
			Placebo	41	38 (92.7)	1.94 (1.08)	0.0	1.20	2.00	2.60	4.8	
		Week 36	Tezepelumab	35	35 (100.0)	1.65 (1.06)	0.0	1.00	1.60	2.40	3.6	
			Placebo	41	38 (92.7)	2.05 (1.13)	0.0	1.20	2.20	2.80	4.8	
		Week 38	Tezepelumab	35	35 (100.0)	1.63 (1.19)	0.0	0.60	1.60	2.40	4.6	
			Placebo	41	38 (92.7)	1.93 (1.08)	0.0	1.20	1.80	2.60	4.8	
		Week 40	Tezepelumab	35	35 (100.0)	1.64 (1.18)	0.0	0.40	1.60	2.80	3.8	
			Placebo	41	38 (92.7)	1.88 (1.07)	0.0	1.20	1.80	2.60	4.2	
		Week 42	Tezepelumab	35	35 (100.0)	1.55 (1.07)	0.0	0.60	1.40	2.40	3.8	
			Placebo	41	38 (92.7)	1.85 (0.89)	0.0	1.20	2.00	2.60	3.4	
		Week 44	Tezepelumab	35	35 (100.0)	1.61 (1.07)	0.0	0.60	1.40	2.60	3.8	
			Placebo	41	38 (92.7)	1.88 (1.09)	0.0	1.00	1.90	2.60	4.2	
		Week 46	Tezepelumab	35	35 (100.0)	1.56 (1.14)	0.0	0.80	1.20	2.60	3.8	
			Placebo	41	38 (92.7)	1.79 (0.90)	0.0	1.20	1.90	2.40	3.4	
		Week 48	Tezepelumab	35	35 (100.0)	1.62 (1.16)	0.0	0.80	1.40	2.60	4.2	
			Placebo	41	38 (92.7)	1.78 (0.95)	0.0	1.00	2.00	2.40	3.4	
		Week 50	Tezepelumab	35	35 (100.0)	1.52 (1.23)	0.0	0.60	1.20	2.60	4.2	
			Placebo	41	38 (92.7)	1.72 (0.95)	0.0	1.00	1.80	2.40	3.4	
		Week 52	Tezepelumab	35	35 (100.0)	1.61 (1.19)	0.0	0.60	1.20	2.60	4.4	
			Placebo	41	38 (92.7)	1.74 (0.99)	0.0	1.20	1.90	2.60	3.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	35	34 (97.1)	-0.50 (0.90)	-3.2	-1.00	-0.20	0.20	0.8	-0.01 [-0.48, 0.46]
			Placebo	41	37 (90.2)	-0.49 (0.64)	-2.4	-1.00	-0.40	0.00	0.4	
		Week 4	Tezepelumab	35	34 (97.1)	-0.74 (1.04)	-2.6	-1.20	-0.70	-0.20	2.6	-0.05 [-0.52, 0.42]
			Placebo	41	37 (90.2)	-0.69 (0.91)	-3.0	-1.40	-0.40	0.00	0.6	
		Week 6	Tezepelumab	35	34 (97.1)	-0.73 (1.06)	-2.8	-1.40	-0.80	0.00	2.6	0.02 [-0.44, 0.49]
			Placebo	41	37 (90.2)	-0.75 (0.98)	-3.4	-1.20	-0.60	0.00	1.0	
		Week 8	Tezepelumab	35	34 (97.1)	-0.96 (1.11)	-3.0	-1.60	-1.00	-0.40	2.6	-0.17 [-0.64, 0.30]
			Placebo	41	37 (90.2)	-0.77 (1.06)	-3.6	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	35	34 (97.1)	-1.04 (1.17)	-3.0	-1.60	-1.20	-0.20	2.6	-0.17 [-0.64, 0.29]
			Placebo	41	37 (90.2)	-0.84 (1.13)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	35	34 (97.1)	-1.22 (1.16)	-3.2	-2.20	-1.40	-0.60	2.6	-0.08 [-0.55, 0.39]
			Placebo	41	37 (90.2)	-1.14 (1.06)	-3.8	-1.80	-1.00	-0.40	1.2	
		Week 14	Tezepelumab	35	34 (97.1)	-1.22 (1.13)	-3.0	-2.00	-1.20	-0.60	2.6	-0.16 [-0.63, 0.31]
			Placebo	41	37 (90.2)	-1.04 (1.12)	-3.4	-1.60	-1.20	-0.40	2.4	
		Week 16	Tezepelumab	35	34 (97.1)	-1.13 (1.10)	-3.0	-2.20	-1.10	-0.40	2.6	-0.15 [-0.62, 0.31]
			Placebo	41	37 (90.2)	-0.95 (1.19)	-3.6	-1.40	-1.20	-0.20	2.4	
		Week 18	Tezepelumab	35	34 (97.1)	-1.06 (1.08)	-3.0	-1.80	-1.00	-0.60	2.6	-0.12 [-0.59, 0.34]
			Placebo	41	37 (90.2)	-0.91 (1.25)	-3.6	-1.80	-0.60	-0.20	2.4	
		Week 20	Tezepelumab	35	34 (97.1)	-1.11 (1.15)	-3.0	-1.80	-1.00	-0.60	2.6	-0.21 [-0.67, 0.26]
			Placebo	41	37 (90.2)	-0.88 (1.15)	-3.6	-1.40	-0.80	-0.20	2.4	
		Week 22	Tezepelumab	35	34 (97.1)	-1.05 (1.24)	-3.0	-1.80	-1.00	-0.60	2.6	-0.11 [-0.58, 0.35]
			Placebo	41	37 (90.2)	-0.91 (1.12)	-3.8	-1.60	-1.00	0.00	2.4	
		Week 24	Tezepelumab	35	34 (97.1)	-1.11 (1.16)	-3.0	-2.00	-0.90	-0.40	2.6	-0.21 [-0.67, 0.26]
			Placebo	41	37 (90.2)	-0.88 (1.06)	-3.6	-1.40	-0.80	0.00	1.4	
		Week 26	Tezepelumab	35	34 (97.1)	-1.02 (1.19)	-3.0	-2.00	-0.90	-0.20	2.6	-0.05 [-0.51, 0.42]
			Placebo	41	37 (90.2)	-0.96 (1.09)	-3.4	-1.60	-0.80	0.00	1.4	
		Week 28	Tezepelumab	35	35 (100.0)	-1.10 (1.23)	-3.0	-2.20	-0.80	0.00	2.6	-0.02 [-0.48, 0.44]
			Placebo	41	38 (92.7)	-1.08 (1.16)	-3.4	-1.80	-1.30	0.00	1.4	
		Week 30	Tezepelumab	35	35 (100.0)	-1.13 (1.15)	-3.0	-2.20	-1.00	-0.40	2.6	-0.07 [-0.53, 0.39]
			Placebo	41	38 (92.7)	-1.05 (1.19)	-3.4	-1.60	-1.30	-0.20	2.0	
		Week 32	Tezepelumab	35	35 (100.0)	-1.25 (1.14)	-3.0	-2.20	-1.20	-0.40	2.6	-0.20 [-0.66, 0.26]
			Placebo	41	38 (92.7)	-1.02 (1.14)	-3.2	-1.60	-1.30	-0.40	1.8	
		Week 34	Tezepelumab	35	35 (100.0)	-1.16 (1.20)	-3.0	-2.20	-1.20	-0.20	2.6	-0.18 [-0.65, 0.28]
			Placebo	41	38 (92.7)	-0.95 (1.10)	-3.2	-1.60	-1.10	-0.20	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Change from baseline	Week 36	Tezepelumab	35	35 (100.0)	-1.17 (1.19)	-3.0	-2.20	-1.20	-0.20	2.6	-0.28 [-0.74, 0.18]
			Placebo	41	38 (92.7)	-0.84 (1.15)	-3.6	-1.40	-1.00	0.00	1.8	
		Week 38	Tezepelumab	35	35 (100.0)	-1.18 (1.22)	-3.0	-2.20	-1.40	-0.20	2.6	-0.19 [-0.65, 0.27]
			Placebo	41	38 (92.7)	-0.96 (1.05)	-3.0	-1.60	-1.20	-0.40	1.8	
		Week 40	Tezepelumab	35	35 (100.0)	-1.17 (1.24)	-3.0	-2.40	-1.20	-0.40	2.6	-0.14 [-0.60, 0.32]
			Placebo	41	38 (92.7)	-1.01 (1.06)	-3.2	-1.60	-1.20	-0.20	1.4	
		Week 42	Tezepelumab	35	35 (100.0)	-1.26 (1.18)	-3.0	-2.20	-1.40	-0.40	2.6	-0.22 [-0.68, 0.24]
			Placebo	41	38 (92.7)	-1.04 (0.86)	-2.8	-1.60	-1.00	-0.40	0.4	
		Week 44	Tezepelumab	35	35 (100.0)	-1.21 (1.15)	-3.0	-2.20	-1.20	-0.40	2.6	-0.18 [-0.64, 0.28]
			Placebo	41	38 (92.7)	-1.01 (1.05)	-3.4	-1.60	-1.00	-0.40	1.2	
		Week 46	Tezepelumab	35	35 (100.0)	-1.25 (1.19)	-3.0	-2.40	-1.20	-0.40	2.6	-0.15 [-0.61, 0.31]
			Placebo	41	38 (92.7)	-1.09 (0.84)	-2.8	-1.60	-1.20	-0.60	0.6	
		Week 48	Tezepelumab	35	35 (100.0)	-1.19 (1.21)	-3.0	-2.40	-1.20	-0.40	2.6	-0.08 [-0.54, 0.38]
			Placebo	41	38 (92.7)	-1.11 (0.93)	-3.4	-1.60	-1.00	-0.40	0.4	
		Week 50	Tezepelumab	35	35 (100.0)	-1.29 (1.32)	-3.2	-2.60	-1.40	-0.20	2.6	-0.11 [-0.57, 0.35]
			Placebo	41	38 (92.7)	-1.17 (0.86)	-3.6	-1.60	-1.10	-0.60	0.2	
		Week 52	Tezepelumab	35	35 (100.0)	-1.21 (1.28)	-3.2	-2.40	-1.20	-0.20	2.6	-0.05 [-0.51, 0.41]
			Placebo	41	38 (92.7)	-1.15 (0.93)	-3.6	-1.60	-1.00	-0.60	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	41	41 (100.0)	2.69 (0.80)	0.0	2.40	2.80	3.20	4.2	
			Placebo	30	30 (100.0)	2.91 (0.89)	1.0	2.60	3.00	3.20	5.0	
		Week 2	Tezepelumab	41	39 (95.1)	2.17 (1.04)	0.0	1.40	2.40	2.80	4.4	
			Placebo	30	25 (83.3)	2.34 (0.97)	0.4	2.00	2.20	2.60	5.0	
		Week 4	Tezepelumab	41	39 (95.1)	1.92 (1.01)	0.2	1.00	2.00	2.80	3.4	
			Placebo	30	25 (83.3)	2.35 (0.89)	0.8	1.80	2.60	2.80	4.2	
		Week 6	Tezepelumab	41	39 (95.1)	1.77 (1.04)	0.0	0.80	1.60	2.80	3.8	
			Placebo	30	25 (83.3)	2.33 (1.35)	0.8	1.40	2.00	2.80	6.0	
		Week 8	Tezepelumab	41	39 (95.1)	1.69 (1.21)	0.0	0.60	1.60	2.80	5.2	
			Placebo	30	26 (86.7)	2.31 (1.30)	0.2	1.00	2.40	3.20	5.0	
		Week 10	Tezepelumab	41	39 (95.1)	1.57 (1.16)	0.0	0.60	1.40	2.40	4.8	
			Placebo	30	26 (86.7)	2.28 (1.04)	0.4	1.60	2.40	3.00	4.4	
		Week 12	Tezepelumab	41	39 (95.1)	1.51 (1.15)	0.0	0.60	1.40	2.60	4.8	
			Placebo	30	26 (86.7)	2.00 (1.12)	0.0	1.00	2.00	2.80	4.4	
		Week 14	Tezepelumab	41	39 (95.1)	1.44 (1.13)	0.0	0.40	1.40	2.20	4.8	
			Placebo	30	26 (86.7)	1.78 (1.05)	0.0	1.00	1.80	2.40	5.0	
		Week 16	Tezepelumab	41	39 (95.1)	1.52 (1.17)	0.0	0.60	1.40	2.40	4.8	
			Placebo	30	26 (86.7)	2.06 (1.29)	0.0	1.40	2.00	2.80	5.0	
		Week 18	Tezepelumab	41	40 (97.6)	1.48 (1.08)	0.0	0.70	1.50	2.30	4.8	
			Placebo	30	26 (86.7)	1.94 (1.39)	0.0	0.80	1.80	3.00	4.8	
		Week 20	Tezepelumab	41	40 (97.6)	1.48 (1.14)	0.0	0.60	1.40	2.20	4.8	
			Placebo	30	26 (86.7)	2.02 (1.22)	0.2	1.00	2.10	2.80	4.4	
		Week 22	Tezepelumab	41	40 (97.6)	1.71 (1.07)	0.0	0.90	1.80	2.50	4.8	
			Placebo	30	26 (86.7)	2.02 (1.32)	0.0	0.80	1.80	3.00	4.4	
		Week 24	Tezepelumab	41	40 (97.6)	1.56 (1.12)	0.0	0.60	1.50	2.40	4.8	
			Placebo	30	26 (86.7)	2.10 (1.22)	0.0	1.00	2.20	3.00	4.4	
		Week 26	Tezepelumab	41	41 (100.0)	1.62 (1.17)	0.0	0.80	1.60	2.40	4.8	
			Placebo	30	26 (86.7)	2.02 (1.37)	0.0	1.00	1.60	3.20	4.4	
		Week 28	Tezepelumab	41	41 (100.0)	1.61 (1.23)	0.0	0.40	1.60	2.40	4.8	
			Placebo	30	26 (86.7)	2.25 (1.37)	0.0	1.00	2.30	3.40	4.4	
		Week 30	Tezepelumab	41	41 (100.0)	1.65 (1.19)	0.0	0.60	1.60	2.40	4.8	
			Placebo	30	26 (86.7)	2.16 (1.25)	0.0	1.00	2.40	3.20	4.4	
		Week 32	Tezepelumab	41	41 (100.0)	1.56 (1.20)	0.0	0.60	1.40	2.80	4.8	
			Placebo	30	26 (86.7)	2.13 (1.13)	0.4	1.20	2.00	3.00	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Absolute values	Week 34	Tezepelumab	41	41 (100.0)	1.65 (1.27)	0.0	0.80	1.40	2.80	4.8	
			Placebo	30	26 (86.7)	1.95 (1.22)	0.0	1.40	1.80	3.00	4.4	
		Week 36	Tezepelumab	41	41 (100.0)	1.55 (1.23)	0.0	0.60	1.40	2.80	4.8	
			Placebo	30	26 (86.7)	2.21 (1.22)	0.0	1.40	2.00	3.00	4.4	
		Week 38	Tezepelumab	41	41 (100.0)	1.66 (1.30)	0.0	0.60	1.40	2.80	4.8	
			Placebo	30	26 (86.7)	2.20 (1.15)	0.0	1.80	2.00	3.20	4.4	
		Week 40	Tezepelumab	41	41 (100.0)	1.62 (1.21)	0.0	0.60	1.60	2.60	4.8	
			Placebo	30	26 (86.7)	2.37 (1.36)	0.0	1.40	2.40	3.40	4.4	
		Week 42	Tezepelumab	41	41 (100.0)	1.63 (1.24)	0.0	0.80	1.60	2.60	4.8	
			Placebo	30	26 (86.7)	2.26 (1.20)	0.0	1.40	2.30	2.80	4.6	
		Week 44	Tezepelumab	41	41 (100.0)	1.62 (1.21)	0.0	0.80	1.60	2.80	4.8	
			Placebo	30	26 (86.7)	2.35 (1.17)	0.4	1.60	2.40	3.20	4.4	
		Week 46	Tezepelumab	41	41 (100.0)	1.65 (1.26)	0.0	0.80	1.80	2.80	4.8	
			Placebo	30	26 (86.7)	2.22 (1.13)	0.0	1.60	2.20	2.80	4.4	
		Week 48	Tezepelumab	41	41 (100.0)	1.63 (1.28)	0.0	0.60	1.40	2.60	4.8	
			Placebo	30	26 (86.7)	2.32 (1.21)	0.0	1.40	2.30	3.00	4.6	
		Week 50	Tezepelumab	41	41 (100.0)	1.61 (1.25)	0.0	0.80	1.40	2.60	4.8	
			Placebo	30	26 (86.7)	2.13 (1.14)	0.2	1.20	2.10	2.80	4.4	
		Week 52	Tezepelumab	41	41 (100.0)	1.58 (1.27)	0.0	0.40	1.40	2.60	4.8	
			Placebo	30	26 (86.7)	2.18 (1.15)	0.2	1.20	2.10	2.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 2	Tezepelumab	41	39 (95.1)	-0.55 (0.85)	-3.2	-1.00	-0.40	0.20	0.8	0.01 [-0.49, 0.51]
			Placebo	30	25 (83.3)	-0.56 (0.82)	-2.8	-1.00	-0.40	-0.20	1.2	
		Week 4	Tezepelumab	41	39 (95.1)	-0.81 (1.03)	-2.6	-1.40	-0.80	-0.20	2.6	-0.27 [-0.77, 0.24]
			Placebo	30	25 (83.3)	-0.54 (0.89)	-2.0	-1.40	-0.60	0.20	1.2	
		Week 6	Tezepelumab	41	39 (95.1)	-0.96 (1.15)	-2.8	-1.60	-1.00	0.00	2.6	-0.34 [-0.85, 0.16]
			Placebo	30	25 (83.3)	-0.57 (1.12)	-2.2	-1.60	-0.60	0.20	1.6	
		Week 8	Tezepelumab	41	39 (95.1)	-1.04 (1.30)	-3.2	-1.80	-1.20	-0.20	2.6	-0.36 [-0.86, 0.14]
			Placebo	30	26 (86.7)	-0.61 (1.03)	-2.8	-1.20	-0.50	0.00	1.0	
		Week 10	Tezepelumab	41	39 (95.1)	-1.15 (1.27)	-3.4	-2.20	-1.40	-0.20	2.6	-0.43 [-0.93, 0.07]
			Placebo	30	26 (86.7)	-0.64 (1.10)	-2.2	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	41	39 (95.1)	-1.22 (1.19)	-3.0	-2.20	-1.20	-0.60	2.6	-0.26 [-0.76, 0.23]
			Placebo	30	26 (86.7)	-0.92 (1.05)	-3.0	-1.40	-0.80	-0.40	1.6	
		Week 14	Tezepelumab	41	39 (95.1)	-1.29 (1.18)	-3.4	-2.20	-1.40	-0.60	2.6	-0.14 [-0.64, 0.36]
			Placebo	30	26 (86.7)	-1.13 (0.98)	-3.0	-1.60	-1.30	-0.80	1.4	
		Week 16	Tezepelumab	41	39 (95.1)	-1.21 (1.18)	-3.2	-2.20	-1.20	-0.60	2.6	-0.31 [-0.81, 0.19]
			Placebo	30	26 (86.7)	-0.85 (1.07)	-3.0	-1.40	-1.00	-0.40	2.6	
		Week 18	Tezepelumab	41	40 (97.6)	-1.23 (1.15)	-3.4	-2.10	-1.20	-0.80	2.6	-0.21 [-0.70, 0.29]
			Placebo	30	26 (86.7)	-0.98 (1.34)	-3.2	-2.00	-1.10	-0.20	2.6	
		Week 20	Tezepelumab	41	40 (97.6)	-1.23 (1.17)	-3.4	-2.20	-1.30	-0.50	2.6	-0.29 [-0.79, 0.21]
			Placebo	30	26 (86.7)	-0.89 (1.16)	-3.0	-1.60	-0.90	-0.20	2.6	
		Week 22	Tezepelumab	41	40 (97.6)	-1.01 (1.24)	-3.2	-2.00	-1.00	-0.30	2.6	-0.08 [-0.58, 0.41]
			Placebo	30	26 (86.7)	-0.90 (1.23)	-3.2	-1.60	-1.00	-0.20	2.6	
		Week 24	Tezepelumab	41	40 (97.6)	-1.16 (1.16)	-3.4	-2.00	-1.40	-0.30	2.6	-0.29 [-0.79, 0.21]
			Placebo	30	26 (86.7)	-0.82 (1.17)	-3.0	-1.60	-0.90	-0.20	2.6	
		Week 26	Tezepelumab	41	41 (100.0)	-1.07 (1.19)	-3.0	-2.20	-1.00	-0.20	2.6	-0.13 [-0.63, 0.36]
			Placebo	30	26 (86.7)	-0.90 (1.36)	-3.0	-1.80	-1.40	0.20	2.6	
		Week 28	Tezepelumab	41	41 (100.0)	-1.08 (1.32)	-3.4	-2.20	-1.20	0.00	2.6	-0.31 [-0.80, 0.19]
			Placebo	30	26 (86.7)	-0.67 (1.36)	-3.0	-1.60	-0.70	0.20	2.6	
		Week 30	Tezepelumab	41	41 (100.0)	-1.04 (1.26)	-2.8	-2.20	-1.20	-0.20	2.6	-0.23 [-0.72, 0.27]
			Placebo	30	26 (86.7)	-0.75 (1.24)	-2.8	-1.60	-0.80	-0.20	2.6	
		Week 32	Tezepelumab	41	41 (100.0)	-1.13 (1.22)	-3.2	-2.20	-1.20	-0.40	2.6	-0.29 [-0.79, 0.20]
			Placebo	30	26 (86.7)	-0.78 (1.11)	-2.6	-1.40	-1.00	-0.20	2.6	
		Week 34	Tezepelumab	41	41 (100.0)	-1.03 (1.33)	-3.0	-2.20	-1.40	0.00	2.6	-0.06 [-0.55, 0.43]
			Placebo	30	26 (86.7)	-0.96 (1.21)	-3.2	-1.60	-1.20	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Change from baseline	Week 36	Tezepelumab	41	41 (100.0)	-1.14 (1.29)	-3.2	-2.20	-1.20	-0.20	2.6	-0.34 [-0.83, 0.16]
			Placebo	30	26 (86.7)	-0.71 (1.23)	-3.2	-1.40	-0.80	-0.20	2.6	
		Week 38	Tezepelumab	41	41 (100.0)	-1.02 (1.37)	-3.2	-2.20	-1.20	0.00	2.6	-0.24 [-0.73, 0.26]
			Placebo	30	26 (86.7)	-0.72 (1.19)	-3.2	-1.40	-0.90	0.20	2.6	
		Week 40	Tezepelumab	41	41 (100.0)	-1.06 (1.30)	-3.4	-2.20	-1.20	-0.40	2.6	-0.39 [-0.88, 0.11]
			Placebo	30	26 (86.7)	-0.55 (1.39)	-2.8	-1.60	-0.50	0.20	2.6	
		Week 42	Tezepelumab	41	41 (100.0)	-1.05 (1.30)	-3.0	-2.20	-1.20	-0.40	2.6	-0.31 [-0.80, 0.18]
			Placebo	30	26 (86.7)	-0.65 (1.27)	-2.8	-1.40	-0.80	-0.20	2.6	
		Week 44	Tezepelumab	41	41 (100.0)	-1.07 (1.27)	-3.4	-2.20	-1.20	-0.20	2.6	-0.40 [-0.90, 0.09]
			Placebo	30	26 (86.7)	-0.56 (1.25)	-2.6	-1.40	-0.70	0.00	2.6	
		Week 46	Tezepelumab	41	41 (100.0)	-1.03 (1.30)	-3.0	-2.20	-1.00	0.00	2.6	-0.26 [-0.75, 0.23]
			Placebo	30	26 (86.7)	-0.70 (1.24)	-3.2	-1.40	-0.80	-0.20	2.6	
		Week 48	Tezepelumab	41	41 (100.0)	-1.06 (1.32)	-2.8	-2.20	-1.00	-0.20	2.6	-0.35 [-0.85, 0.14]
			Placebo	30	26 (86.7)	-0.60 (1.27)	-3.2	-1.60	-0.40	0.00	2.6	
		Week 50	Tezepelumab	41	41 (100.0)	-1.08 (1.32)	-3.2	-2.20	-1.20	-0.20	2.6	-0.23 [-0.72, 0.27]
			Placebo	30	26 (86.7)	-0.78 (1.25)	-2.8	-1.60	-0.80	-0.20	2.6	
		Week 52	Tezepelumab	41	41 (100.0)	-1.11 (1.35)	-3.2	-2.20	-1.20	-0.20	2.6	-0.29 [-0.78, 0.21]
			Placebo	30	26 (86.7)	-0.73 (1.25)	-2.8	-1.60	-0.80	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	25	25 (100.0)	3.17 (0.95)	1.8	2.40	2.80	3.80	5.2	
			Placebo	34	34 (100.0)	2.82 (0.67)	0.4	2.60	2.90	3.20	4.0	
		Week 2	Tezepelumab	25	24 (96.0)	2.62 (0.94)	0.8	1.70	3.00	3.40	4.0	
			Placebo	34	32 (94.1)	2.44 (0.66)	0.4	2.10	2.60	3.00	3.2	
		Week 4	Tezepelumab	25	24 (96.0)	2.33 (0.95)	0.2	1.50	2.50	3.10	3.6	
			Placebo	34	32 (94.1)	2.24 (0.89)	0.2	1.60	2.50	2.90	3.6	
		Week 6	Tezepelumab	25	24 (96.0)	2.30 (0.96)	0.0	1.80	2.40	3.10	4.0	
			Placebo	34	32 (94.1)	2.19 (0.94)	0.2	1.80	2.30	3.00	3.4	
		Week 8	Tezepelumab	25	24 (96.0)	2.02 (1.11)	0.0	1.10	1.90	3.00	4.2	
			Placebo	34	32 (94.1)	2.05 (0.94)	0.0	1.50	2.20	2.90	3.4	
		Week 10	Tezepelumab	25	24 (96.0)	1.96 (1.07)	0.0	1.20	2.00	2.90	3.4	
			Placebo	34	32 (94.1)	2.11 (1.08)	0.0	1.70	2.20	2.80	5.2	
		Week 12	Tezepelumab	25	24 (96.0)	1.78 (1.03)	0.0	1.20	2.00	2.70	3.2	
			Placebo	34	32 (94.1)	1.94 (1.00)	0.0	1.10	2.20	2.60	3.8	
		Week 14	Tezepelumab	25	24 (96.0)	1.74 (1.11)	0.0	0.80	1.80	2.60	4.2	
			Placebo	34	32 (94.1)	1.99 (0.95)	0.0	1.50	2.10	2.40	5.0	
		Week 16	Tezepelumab	25	24 (96.0)	2.02 (1.16)	0.0	1.10	2.00	2.80	4.6	
			Placebo	34	32 (94.1)	2.06 (1.14)	0.0	1.00	2.20	3.00	5.0	
		Week 18	Tezepelumab	25	24 (96.0)	1.99 (1.04)	0.0	1.10	2.10	2.80	4.2	
			Placebo	34	32 (94.1)	1.97 (0.99)	0.0	1.40	2.20	2.50	5.0	
		Week 20	Tezepelumab	25	24 (96.0)	2.01 (1.10)	0.0	1.20	2.00	2.70	5.0	
			Placebo	34	32 (94.1)	2.09 (1.02)	0.0	1.60	2.10	2.80	5.0	
		Week 22	Tezepelumab	25	24 (96.0)	1.89 (0.98)	0.0	1.10	2.10	2.50	3.8	
			Placebo	34	32 (94.1)	2.00 (1.03)	0.0	1.20	2.00	2.60	5.0	
		Week 24	Tezepelumab	25	24 (96.0)	2.05 (1.04)	0.0	1.20	2.30	2.80	3.8	
			Placebo	34	32 (94.1)	2.05 (0.92)	0.0	1.60	2.10	2.60	4.0	
		Week 26	Tezepelumab	25	24 (96.0)	2.08 (1.00)	0.0	1.40	2.10	2.80	4.0	
			Placebo	34	32 (94.1)	1.99 (0.93)	0.0	1.30	2.00	2.70	4.0	
		Week 28	Tezepelumab	25	25 (100.0)	1.94 (1.03)	0.0	1.20	2.20	2.40	3.8	
			Placebo	34	33 (97.1)	1.77 (1.07)	0.0	1.00	1.80	2.60	4.0	
		Week 30	Tezepelumab	25	25 (100.0)	1.78 (0.95)	0.0	1.20	1.60	2.60	3.6	
			Placebo	34	33 (97.1)	1.79 (1.12)	0.0	1.00	2.00	2.40	4.0	
		Week 32	Tezepelumab	25	25 (100.0)	1.74 (0.99)	0.0	1.00	2.00	2.40	4.0	
			Placebo	34	33 (97.1)	1.76 (1.13)	0.0	1.00	1.80	2.60	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Absolute values	Week 34	Tezepelumab	25	25 (100.0)	1.80 (1.06)	0.0	1.00	2.00	2.60	3.8	
			Placebo	34	33 (97.1)	1.85 (1.08)	0.0	1.00	2.00	2.60	4.8	
		Week 36	Tezepelumab	25	25 (100.0)	1.86 (0.86)	0.0	1.40	2.00	2.40	3.6	
			Placebo	34	33 (97.1)	1.97 (1.18)	0.0	1.00	2.20	2.60	4.8	
		Week 38	Tezepelumab	25	25 (100.0)	1.80 (1.12)	0.0	1.20	2.00	2.40	4.6	
			Placebo	34	33 (97.1)	1.74 (1.09)	0.0	1.00	1.60	2.40	4.8	
		Week 40	Tezepelumab	25	25 (100.0)	1.82 (1.14)	0.0	0.80	2.00	2.60	3.8	
			Placebo	34	33 (97.1)	1.87 (1.00)	0.0	1.20	2.00	2.60	4.0	
		Week 42	Tezepelumab	25	25 (100.0)	1.66 (1.01)	0.0	1.00	1.60	2.40	3.8	
			Placebo	34	33 (97.1)	1.70 (0.86)	0.0	1.00	2.00	2.20	3.0	
		Week 44	Tezepelumab	25	25 (100.0)	1.78 (1.03)	0.0	1.00	2.00	2.60	3.8	
			Placebo	34	33 (97.1)	1.78 (1.00)	0.0	1.00	2.00	2.40	3.8	
		Week 46	Tezepelumab	25	25 (100.0)	1.80 (1.09)	0.0	1.00	2.00	2.60	3.8	
			Placebo	34	33 (97.1)	1.66 (0.83)	0.0	1.20	2.00	2.20	3.4	
		Week 48	Tezepelumab	25	25 (100.0)	1.85 (1.02)	0.0	1.00	2.00	2.60	3.8	
			Placebo	34	33 (97.1)	1.70 (0.91)	0.0	1.00	2.00	2.40	3.0	
		Week 50	Tezepelumab	25	25 (100.0)	1.71 (1.13)	0.0	1.00	1.40	2.60	4.2	
			Placebo	34	33 (97.1)	1.62 (0.87)	0.0	1.00	1.80	2.40	3.0	
		Week 52	Tezepelumab	25	25 (100.0)	1.84 (1.04)	0.4	1.00	1.80	2.60	4.4	
			Placebo	34	33 (97.1)	1.71 (0.98)	0.0	1.00	1.80	2.60	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 2	Tezepelumab	25	24 (96.0)	-0.58 (0.72)	-2.0	-1.20	-0.50	0.10	0.4	-0.16 [-0.69, 0.37]
			Placebo	34	32 (94.1)	-0.47 (0.66)	-2.4	-0.90	-0.30	0.00	0.4	
		Week 4	Tezepelumab	25	24 (96.0)	-0.86 (0.76)	-2.6	-1.20	-0.90	-0.40	0.2	-0.21 [-0.74, 0.32]
			Placebo	34	32 (94.1)	-0.67 (0.99)	-3.0	-1.30	-0.30	0.00	0.6	
		Week 6	Tezepelumab	25	24 (96.0)	-0.89 (0.80)	-2.8	-1.40	-1.00	-0.20	0.4	-0.19 [-0.72, 0.34]
			Placebo	34	32 (94.1)	-0.72 (0.97)	-3.4	-1.20	-0.50	0.00	0.6	
		Week 8	Tezepelumab	25	24 (96.0)	-1.18 (0.88)	-2.8	-1.80	-1.00	-0.60	0.6	-0.33 [-0.86, 0.21]
			Placebo	34	32 (94.1)	-0.86 (1.04)	-3.6	-1.50	-0.60	0.00	0.6	
		Week 10	Tezepelumab	25	24 (96.0)	-1.23 (0.85)	-2.8	-1.70	-1.20	-0.60	0.4	-0.42 [-0.95, 0.12]
			Placebo	34	32 (94.1)	-0.79 (1.18)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	25	24 (96.0)	-1.42 (0.96)	-3.2	-2.20	-1.40	-0.80	0.6	-0.43 [-0.97, 0.10]
			Placebo	34	32 (94.1)	-0.96 (1.11)	-3.8	-1.50	-0.80	-0.20	1.2	
		Week 14	Tezepelumab	25	24 (96.0)	-1.45 (0.99)	-4.0	-2.10	-1.40	-0.70	0.4	-0.49 [-1.03, 0.05]
			Placebo	34	32 (94.1)	-0.92 (1.15)	-3.4	-1.40	-1.00	-0.20	2.4	
		Week 16	Tezepelumab	25	24 (96.0)	-1.17 (1.10)	-3.0	-2.00	-1.00	-0.50	1.8	-0.28 [-0.81, 0.26]
			Placebo	34	32 (94.1)	-0.84 (1.26)	-3.6	-1.80	-0.40	0.00	2.4	
		Week 18	Tezepelumab	25	24 (96.0)	-1.20 (1.02)	-3.8	-1.80	-0.80	-0.50	0.0	-0.24 [-0.77, 0.29]
			Placebo	34	32 (94.1)	-0.94 (1.15)	-3.6	-1.60	-0.70	-0.20	2.4	
		Week 20	Tezepelumab	25	24 (96.0)	-1.18 (0.99)	-3.0	-1.90	-1.00	-0.50	0.6	-0.33 [-0.87, 0.20]
			Placebo	34	32 (94.1)	-0.81 (1.20)	-3.6	-1.40	-0.60	-0.20	2.4	
		Week 22	Tezepelumab	25	24 (96.0)	-1.30 (0.91)	-3.0	-2.10	-1.10	-0.70	0.6	-0.37 [-0.90, 0.16]
			Placebo	34	32 (94.1)	-0.91 (1.16)	-3.8	-1.50	-0.80	-0.10	2.4	
		Week 24	Tezepelumab	25	24 (96.0)	-1.14 (0.99)	-3.0	-2.00	-0.90	-0.50	0.6	-0.27 [-0.80, 0.26]
			Placebo	34	32 (94.1)	-0.86 (1.11)	-3.6	-1.40	-0.80	0.00	1.4	
		Week 26	Tezepelumab	25	24 (96.0)	-1.11 (1.05)	-3.0	-2.10	-1.00	-0.30	0.6	-0.18 [-0.71, 0.35]
			Placebo	34	32 (94.1)	-0.92 (1.07)	-3.4	-1.60	-0.80	0.00	1.4	
		Week 28	Tezepelumab	25	25 (100.0)	-1.23 (1.03)	-3.0	-2.20	-0.80	-0.60	0.6	-0.16 [-0.68, 0.36]
			Placebo	34	33 (97.1)	-1.06 (1.11)	-3.4	-1.80	-1.20	0.00	1.4	
		Week 30	Tezepelumab	25	25 (100.0)	-1.38 (1.02)	-3.8	-2.20	-1.00	-0.80	0.6	-0.30 [-0.83, 0.22]
			Placebo	34	33 (97.1)	-1.04 (1.23)	-3.4	-1.60	-1.20	-0.40	2.0	
		Week 32	Tezepelumab	25	25 (100.0)	-1.42 (0.89)	-3.0	-2.20	-1.20	-0.80	0.6	-0.33 [-0.85, 0.20]
			Placebo	34	33 (97.1)	-1.07 (1.22)	-3.2	-1.80	-1.20	-0.40	1.8	
		Week 34	Tezepelumab	25	25 (100.0)	-1.37 (0.96)	-3.0	-2.20	-1.20	-0.80	0.6	-0.37 [-0.89, 0.16]
			Placebo	34	33 (97.1)	-0.98 (1.13)	-3.2	-1.80	-1.00	-0.20	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Change from baseline	Week 36	Tezepelumab	25	25 (100.0)	-1.31 (0.99)	-3.0	-2.00	-1.20	-0.60	0.4	-0.40 [-0.92, 0.13]
			Placebo	34	33 (97.1)	-0.86 (1.23)	-3.6	-1.40	-1.00	0.00	1.8	
		Week 38	Tezepelumab	25	25 (100.0)	-1.37 (0.94)	-3.0	-2.00	-1.40	-0.80	0.4	-0.27 [-0.79, 0.26]
			Placebo	34	33 (97.1)	-1.09 (1.11)	-3.0	-2.00	-1.20	-0.60	1.8	
		Week 40	Tezepelumab	25	25 (100.0)	-1.35 (1.04)	-3.0	-2.20	-1.20	-0.80	0.6	-0.37 [-0.90, 0.15]
			Placebo	34	33 (97.1)	-0.96 (1.04)	-3.2	-1.40	-1.00	-0.40	1.4	
		Week 42	Tezepelumab	25	25 (100.0)	-1.51 (1.00)	-3.6	-2.00	-1.60	-0.80	0.4	-0.40 [-0.93, 0.12]
			Placebo	34	33 (97.1)	-1.13 (0.91)	-2.8	-1.60	-1.00	-0.60	0.4	
		Week 44	Tezepelumab	25	25 (100.0)	-1.39 (1.08)	-3.8	-2.20	-1.20	-0.80	0.6	-0.32 [-0.84, 0.20]
			Placebo	34	33 (97.1)	-1.05 (1.03)	-3.4	-1.60	-1.00	-0.40	1.2	
		Week 46	Tezepelumab	25	25 (100.0)	-1.37 (1.03)	-3.6	-2.20	-1.20	-0.80	0.6	-0.21 [-0.73, 0.31]
			Placebo	34	33 (97.1)	-1.17 (0.85)	-2.8	-1.60	-1.20	-0.80	0.6	
		Week 48	Tezepelumab	25	25 (100.0)	-1.32 (0.95)	-3.0	-2.00	-1.20	-0.60	0.4	-0.20 [-0.72, 0.32]
			Placebo	34	33 (97.1)	-1.13 (0.95)	-3.4	-1.40	-1.00	-0.60	0.4	
		Week 50	Tezepelumab	25	25 (100.0)	-1.46 (1.01)	-3.0	-2.00	-1.40	-0.80	0.6	-0.27 [-0.79, 0.26]
			Placebo	34	33 (97.1)	-1.21 (0.85)	-3.6	-1.60	-1.20	-0.60	0.2	
		Week 52	Tezepelumab	25	25 (100.0)	-1.33 (0.93)	-3.0	-1.80	-1.20	-1.00	0.4	-0.22 [-0.74, 0.30]
			Placebo	34	33 (97.1)	-1.12 (0.95)	-3.6	-1.80	-1.00	-0.60	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	26	26 (100.0)	3.02 (0.79)	1.8	2.60	3.00	3.20	5.0	
			Placebo	31	31 (100.0)	2.83 (0.78)	0.4	2.40	3.00	3.20	4.8	
		Week 2	Tezepelumab	26	23 (88.5)	2.56 (1.08)	0.0	1.60	2.80	3.40	4.0	
			Placebo	31	26 (83.9)	2.36 (0.89)	0.4	2.00	2.40	2.80	4.8	
		Week 4	Tezepelumab	26	23 (88.5)	2.33 (1.05)	0.2	1.60	2.60	3.20	3.6	
			Placebo	31	26 (83.9)	2.25 (1.09)	0.2	1.40	2.60	3.00	4.2	
		Week 6	Tezepelumab	26	23 (88.5)	2.26 (1.11)	0.0	1.40	2.60	3.00	4.0	
			Placebo	31	26 (83.9)	2.09 (1.27)	0.2	1.20	2.10	2.80	5.0	
		Week 8	Tezepelumab	26	23 (88.5)	2.29 (1.29)	0.0	1.40	2.60	3.00	5.2	
			Placebo	31	27 (87.1)	2.05 (1.25)	0.0	0.80	2.40	3.00	4.6	
		Week 10	Tezepelumab	26	23 (88.5)	2.11 (1.16)	0.0	1.20	2.40	2.80	4.8	
			Placebo	31	27 (87.1)	2.13 (1.23)	0.2	1.00	2.00	3.00	5.2	
		Week 12	Tezepelumab	26	23 (88.5)	2.13 (1.12)	0.0	1.40	2.40	2.80	4.8	
			Placebo	31	27 (87.1)	1.90 (1.23)	0.0	1.00	2.00	2.60	4.4	
		Week 14	Tezepelumab	26	23 (88.5)	2.08 (1.14)	0.0	1.40	2.00	2.80	4.8	
			Placebo	31	27 (87.1)	1.91 (1.20)	0.0	1.00	1.80	2.60	5.0	
		Week 16	Tezepelumab	26	23 (88.5)	2.15 (1.16)	0.0	1.40	2.20	2.80	4.8	
			Placebo	31	27 (87.1)	2.08 (1.29)	0.0	0.80	2.00	3.00	5.0	
		Week 18	Tezepelumab	26	24 (92.3)	2.12 (1.15)	0.0	1.60	2.30	2.60	4.8	
			Placebo	31	27 (87.1)	1.92 (1.38)	0.0	0.80	1.80	2.60	5.0	
		Week 20	Tezepelumab	26	24 (92.3)	2.12 (1.20)	0.0	1.70	2.00	2.70	5.0	
			Placebo	31	27 (87.1)	1.94 (1.23)	0.2	0.80	2.00	2.60	5.0	
		Week 22	Tezepelumab	26	24 (92.3)	2.23 (0.98)	0.0	1.80	2.30	2.60	4.8	
			Placebo	31	27 (87.1)	1.97 (1.26)	0.0	0.80	1.80	2.80	5.0	
		Week 24	Tezepelumab	26	24 (92.3)	2.14 (1.09)	0.0	1.60	2.10	2.80	4.8	
			Placebo	31	27 (87.1)	1.92 (1.16)	0.2	0.80	2.00	2.80	4.4	
		Week 26	Tezepelumab	26	25 (96.2)	2.22 (1.11)	0.0	1.60	2.40	2.80	4.8	
			Placebo	31	27 (87.1)	1.96 (1.26)	0.0	0.80	1.80	3.20	4.4	
		Week 28	Tezepelumab	26	26 (100.0)	2.09 (1.12)	0.0	1.60	2.10	2.80	4.8	
			Placebo	31	28 (90.3)	1.74 (1.27)	0.0	0.80	1.50	2.80	4.4	
		Week 30	Tezepelumab	26	26 (100.0)	2.16 (1.12)	0.0	1.80	2.20	2.60	4.8	
			Placebo	31	28 (90.3)	1.91 (1.32)	0.0	0.80	1.70	3.00	4.4	
		Week 32	Tezepelumab	26	26 (100.0)	2.08 (1.14)	0.0	1.40	2.10	2.80	4.8	
			Placebo	31	28 (90.3)	1.81 (1.23)	0.0	0.70	1.80	2.70	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low (< 20.9 ng/ml)	Absolute values	Week 34	Tezepelumab	26	26 (100.0)	2.13 (1.23)	0.0	1.40	2.20	2.80	4.8	
			Placebo	31	28 (90.3)	1.69 (1.25)	0.0	0.70	1.70	2.40	4.4	
		Week 36	Tezepelumab	26	26 (100.0)	2.10 (1.13)	0.0	1.40	2.20	3.00	4.8	
			Placebo	31	28 (90.3)	1.84 (1.32)	0.0	0.80	1.80	2.80	4.4	
		Week 38	Tezepelumab	26	26 (100.0)	2.18 (1.33)	0.0	1.20	2.10	3.00	4.8	
			Placebo	31	28 (90.3)	1.79 (1.21)	0.0	0.90	1.70	2.70	4.4	
		Week 40	Tezepelumab	26	26 (100.0)	2.20 (1.22)	0.0	1.60	2.10	3.00	4.8	
			Placebo	31	28 (90.3)	1.92 (1.39)	0.0	0.60	1.80	3.00	4.4	
		Week 42	Tezepelumab	26	26 (100.0)	2.12 (1.21)	0.0	1.60	2.00	3.00	4.8	
			Placebo	31	28 (90.3)	1.77 (1.21)	0.0	0.70	2.00	2.50	4.6	
		Week 44	Tezepelumab	26	26 (100.0)	2.13 (1.16)	0.0	1.20	2.20	3.00	4.8	
			Placebo	31	28 (90.3)	1.92 (1.31)	0.0	0.70	1.90	3.00	4.4	
		Week 46	Tezepelumab	26	26 (100.0)	2.14 (1.25)	0.0	1.00	2.20	3.00	4.8	
			Placebo	31	28 (90.3)	1.68 (1.11)	0.0	0.80	1.60	2.50	4.4	
		Week 48	Tezepelumab	26	26 (100.0)	2.18 (1.19)	0.0	1.20	2.20	3.00	4.8	
			Placebo	31	28 (90.3)	1.72 (1.24)	0.0	0.40	1.80	2.60	4.4	
		Week 50	Tezepelumab	26	26 (100.0)	2.07 (1.33)	0.0	1.00	2.00	3.00	4.8	
			Placebo	31	28 (90.3)	1.66 (1.24)	0.0	0.60	1.40	2.60	4.4	
		Week 52	Tezepelumab	26	26 (100.0)	2.13 (1.27)	0.0	1.40	2.00	3.00	4.8	
			Placebo	31	28 (90.3)	1.71 (1.31)	0.0	0.50	1.60	2.70	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 2	Tezepelumab	26	23 (88.5)	-0.57 (0.86)	-3.2	-1.00	-0.40	0.20	0.4	0.01 [-0.55, 0.57]
			Placebo	31	26 (83.9)	-0.58 (0.72)	-2.8	-1.00	-0.50	0.00	0.4	
		Week 4	Tezepelumab	26	23 (88.5)	-0.80 (0.80)	-2.4	-1.40	-0.80	-0.20	0.8	-0.11 [-0.67, 0.46]
			Placebo	31	26 (83.9)	-0.70 (1.06)	-3.0	-1.40	-0.50	0.00	1.2	
		Week 6	Tezepelumab	26	23 (88.5)	-0.87 (0.91)	-2.8	-1.40	-1.00	0.00	1.2	-0.02 [-0.58, 0.55]
			Placebo	31	26 (83.9)	-0.85 (1.12)	-3.4	-1.80	-0.70	0.00	1.6	
		Week 8	Tezepelumab	26	23 (88.5)	-0.84 (1.17)	-3.0	-1.60	-1.00	0.00	2.6	0.06 [-0.50, 0.62]
			Placebo	31	27 (87.1)	-0.91 (1.11)	-3.0	-1.60	-1.00	0.00	1.0	
		Week 10	Tezepelumab	26	23 (88.5)	-1.02 (0.91)	-3.0	-1.60	-1.20	-0.20	0.6	-0.17 [-0.73, 0.38]
			Placebo	31	27 (87.1)	-0.83 (1.21)	-3.2	-1.60	-1.00	0.00	2.6	
		Week 12	Tezepelumab	26	23 (88.5)	-1.00 (0.90)	-2.6	-1.40	-1.20	-0.40	0.6	0.07 [-0.49, 0.62]
			Placebo	31	27 (87.1)	-1.07 (1.11)	-3.2	-1.60	-1.00	-0.40	1.4	
		Week 14	Tezepelumab	26	23 (88.5)	-1.05 (0.84)	-2.8	-1.40	-1.20	-0.40	0.6	-0.00 [-0.56, 0.56]
			Placebo	31	27 (87.1)	-1.05 (1.18)	-3.2	-1.60	-1.20	-0.40	2.4	
		Week 16	Tezepelumab	26	23 (88.5)	-0.98 (0.81)	-2.4	-1.20	-1.00	-0.40	0.6	-0.09 [-0.65, 0.46]
			Placebo	31	27 (87.1)	-0.88 (1.26)	-3.0	-1.60	-1.20	0.00	2.4	
		Week 18	Tezepelumab	26	24 (92.3)	-0.96 (0.83)	-2.8	-1.30	-1.00	-0.50	0.6	0.08 [-0.47, 0.63]
			Placebo	31	27 (87.1)	-1.04 (1.31)	-3.2	-2.20	-1.20	-0.20	2.4	
		Week 20	Tezepelumab	26	24 (92.3)	-0.96 (0.92)	-2.6	-1.70	-1.00	-0.40	0.6	0.06 [-0.49, 0.61]
			Placebo	31	27 (87.1)	-1.02 (1.20)	-3.0	-1.80	-0.80	-0.40	2.4	
		Week 22	Tezepelumab	26	24 (92.3)	-0.85 (0.84)	-2.4	-1.40	-0.80	-0.30	0.6	0.14 [-0.41, 0.69]
			Placebo	31	27 (87.1)	-0.99 (1.21)	-3.2	-1.80	-0.80	-0.40	2.4	
		Week 24	Tezepelumab	26	24 (92.3)	-0.94 (0.88)	-2.4	-1.60	-0.80	-0.30	0.6	0.10 [-0.45, 0.65]
			Placebo	31	27 (87.1)	-1.04 (1.13)	-3.2	-1.80	-1.00	0.00	1.4	
		Week 26	Tezepelumab	26	25 (96.2)	-0.82 (0.93)	-2.6	-1.20	-0.60	-0.20	0.6	0.18 [-0.37, 0.72]
			Placebo	31	27 (87.1)	-1.00 (1.14)	-3.0	-2.00	-0.80	0.00	1.4	
		Week 28	Tezepelumab	26	26 (100.0)	-0.92 (1.11)	-2.8	-2.00	-0.80	0.00	1.0	0.19 [-0.35, 0.72]
			Placebo	31	28 (90.3)	-1.13 (1.10)	-3.0	-1.80	-1.30	-0.40	1.4	
		Week 30	Tezepelumab	26	26 (100.0)	-0.85 (1.09)	-2.6	-1.60	-1.00	-0.20	2.0	0.10 [-0.44, 0.63]
			Placebo	31	28 (90.3)	-0.96 (1.21)	-3.2	-1.60	-1.30	-0.30	2.0	
		Week 32	Tezepelumab	26	26 (100.0)	-0.93 (0.97)	-2.4	-1.60	-1.00	-0.40	1.0	0.12 [-0.41, 0.66]
			Placebo	31	28 (90.3)	-1.06 (1.08)	-3.2	-1.60	-1.20	-0.40	1.4	
		Week 34	Tezepelumab	26	26 (100.0)	-0.88 (1.16)	-2.6	-2.00	-1.00	-0.20	2.2	0.26 [-0.27, 0.80]
			Placebo	31	28 (90.3)	-1.19 (1.12)	-3.2	-2.10	-1.30	-0.30	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low (< 20.9 ng/ml)	Change from baseline	Week 36	Tezepelumab	26	26 (100.0)	-0.92 (0.97)	-2.4	-1.60	-1.10	-0.20	1.6	0.10 [-0.43, 0.64]
			Placebo	31	28 (90.3)	-1.03 (1.18)	-3.6	-1.60	-1.00	-0.30	1.4	
		Week 38	Tezepelumab	26	26 (100.0)	-0.83 (1.22)	-2.6	-1.80	-1.00	0.00	2.6	0.22 [-0.32, 0.76]
			Placebo	31	28 (90.3)	-1.08 (1.04)	-3.2	-1.50	-1.20	-0.40	1.4	
		Week 40	Tezepelumab	26	26 (100.0)	-0.82 (1.09)	-2.6	-1.60	-1.00	0.00	1.8	0.12 [-0.42, 0.65]
			Placebo	31	28 (90.3)	-0.95 (1.22)	-3.2	-1.90	-0.90	-0.10	1.4	
		Week 42	Tezepelumab	26	26 (100.0)	-0.89 (1.12)	-2.8	-1.60	-1.00	0.00	2.2	0.19 [-0.34, 0.73]
			Placebo	31	28 (90.3)	-1.10 (1.02)	-2.8	-1.70	-1.00	-0.40	1.6	
		Week 44	Tezepelumab	26	26 (100.0)	-0.88 (1.01)	-2.6	-1.40	-1.00	-0.20	1.6	0.06 [-0.47, 0.60]
			Placebo	31	28 (90.3)	-0.95 (1.11)	-3.4	-1.70	-0.90	-0.10	1.2	
		Week 46	Tezepelumab	26	26 (100.0)	-0.88 (1.11)	-3.0	-1.40	-0.90	-0.20	1.8	0.31 [-0.23, 0.84]
			Placebo	31	28 (90.3)	-1.19 (0.95)	-3.2	-1.70	-1.30	-0.50	0.6	
		Week 48	Tezepelumab	26	26 (100.0)	-0.84 (1.04)	-2.8	-1.60	-0.80	-0.40	2.0	0.29 [-0.24, 0.83]
			Placebo	31	28 (90.3)	-1.15 (1.07)	-3.4	-1.60	-1.10	-0.40	1.0	
		Week 50	Tezepelumab	26	26 (100.0)	-0.95 (1.27)	-3.2	-1.80	-1.00	0.00	2.0	0.22 [-0.31, 0.76]
			Placebo	31	28 (90.3)	-1.21 (1.16)	-3.6	-2.00	-1.30	-0.40	1.6	
		Week 52	Tezepelumab	26	26 (100.0)	-0.88 (1.21)	-3.2	-1.60	-1.00	-0.20	2.0	0.23 [-0.31, 0.76]
			Placebo	31	28 (90.3)	-1.16 (1.23)	-3.6	-2.30	-1.10	-0.40	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	2.78 (0.94)	0.0	2.40	2.80	3.20	5.2	
			Placebo	34	34 (100.0)	2.89 (0.76)	1.0	2.60	2.90	3.20	5.0	
		Week 2	Tezepelumab	40	40 (100.0)	2.22 (0.98)	0.2	1.60	2.20	3.00	4.4	
			Placebo	34	32 (94.1)	2.43 (0.73)	1.0	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	40	40 (100.0)	1.94 (0.95)	0.2	1.20	2.10	2.70	3.4	
			Placebo	34	32 (94.1)	2.26 (0.78)	0.8	1.80	2.40	2.80	3.6	
		Week 6	Tezepelumab	40	40 (100.0)	1.81 (0.97)	0.0	1.10	1.80	2.60	3.8	
			Placebo	34	32 (94.1)	2.31 (1.06)	0.2	1.80	2.30	3.00	6.0	
		Week 8	Tezepelumab	40	40 (100.0)	1.55 (1.03)	0.0	0.70	1.60	2.60	3.4	
			Placebo	34	32 (94.1)	2.19 (1.06)	0.0	1.70	2.30	2.80	5.0	
		Week 10	Tezepelumab	40	40 (100.0)	1.50 (1.07)	0.0	0.60	1.40	2.30	3.6	
			Placebo	34	32 (94.1)	2.17 (0.95)	0.0	1.90	2.40	2.80	4.0	
		Week 12	Tezepelumab	40	40 (100.0)	1.32 (0.99)	0.0	0.60	1.30	2.10	3.0	
			Placebo	34	32 (94.1)	1.98 (0.91)	0.0	1.50	2.20	2.70	3.2	
		Week 14	Tezepelumab	40	40 (100.0)	1.26 (1.01)	0.0	0.60	1.10	1.80	3.8	
			Placebo	34	32 (94.1)	1.84 (0.81)	0.0	1.30	2.00	2.40	3.0	
		Week 16	Tezepelumab	40	40 (100.0)	1.46 (1.13)	0.0	0.60	1.30	2.30	4.6	
			Placebo	34	32 (94.1)	1.99 (1.15)	0.0	1.20	2.00	2.80	5.0	
		Week 18	Tezepelumab	40	40 (100.0)	1.40 (0.95)	0.0	0.70	1.20	2.10	3.4	
			Placebo	34	32 (94.1)	1.94 (1.00)	0.0	1.40	2.00	2.60	4.0	
		Week 20	Tezepelumab	40	40 (100.0)	1.41 (1.04)	0.0	0.60	1.20	2.20	3.6	
			Placebo	34	32 (94.1)	2.11 (1.02)	0.0	1.40	2.30	2.80	4.0	
		Week 22	Tezepelumab	40	40 (100.0)	1.50 (0.97)	0.0	0.70	1.40	2.20	3.4	
			Placebo	34	32 (94.1)	1.99 (1.09)	0.0	1.40	2.00	2.60	4.0	
		Week 24	Tezepelumab	40	40 (100.0)	1.50 (1.06)	0.0	0.60	1.20	2.40	3.6	
			Placebo	34	32 (94.1)	2.16 (0.98)	0.0	1.70	2.20	2.80	4.0	
		Week 26	Tezepelumab	40	40 (100.0)	1.53 (1.06)	0.0	0.80	1.40	2.30	3.6	
			Placebo	34	32 (94.1)	1.99 (1.05)	0.0	1.10	1.80	2.80	4.4	
		Week 28	Tezepelumab	40	40 (100.0)	1.50 (1.14)	0.0	0.50	1.30	2.40	3.6	
			Placebo	34	32 (94.1)	2.15 (1.17)	0.0	1.10	2.20	2.80	4.4	
		Week 30	Tezepelumab	40	40 (100.0)	1.40 (0.99)	0.0	0.70	1.20	2.10	3.6	
			Placebo	34	32 (94.1)	1.96 (1.07)	0.0	1.10	2.00	2.70	4.0	
		Week 32	Tezepelumab	40	40 (100.0)	1.34 (1.02)	0.0	0.40	1.20	2.20	3.6	
			Placebo	34	32 (94.1)	1.98 (1.06)	0.0	1.10	1.90	2.80	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High (>= 20.9 ng/ml)	Absolute values	Week 34	Tezepelumab	40	40 (100.0)	1.44 (1.09)	0.0	0.60	1.20	2.40	4.2	
			Placebo	34	32 (94.1)	2.04 (1.02)	0.0	1.40	2.00	2.60	4.8	
		Week 36	Tezepelumab	40	40 (100.0)	1.39 (1.01)	0.0	0.60	1.30	2.20	3.6	
			Placebo	34	32 (94.1)	2.24 (1.06)	0.0	1.50	2.20	2.90	4.8	
		Week 38	Tezepelumab	40	40 (100.0)	1.41 (1.07)	0.0	0.50	1.20	2.30	3.6	
			Placebo	34	32 (94.1)	2.04 (1.06)	0.0	1.30	2.00	2.70	4.8	
		Week 40	Tezepelumab	40	40 (100.0)	1.37 (1.05)	0.0	0.40	1.20	2.30	3.2	
			Placebo	34	32 (94.1)	2.19 (0.99)	0.0	1.40	2.20	2.90	4.2	
		Week 42	Tezepelumab	40	40 (100.0)	1.33 (1.00)	0.0	0.60	1.20	2.30	3.2	
			Placebo	34	32 (94.1)	2.06 (0.90)	0.0	1.40	2.00	2.60	4.0	
		Week 44	Tezepelumab	40	40 (100.0)	1.39 (1.04)	0.0	0.50	1.20	2.30	3.2	
			Placebo	34	32 (94.1)	2.08 (0.93)	0.0	1.30	2.00	2.70	4.0	
		Week 46	Tezepelumab	40	40 (100.0)	1.43 (1.08)	0.0	0.80	1.10	2.30	3.6	
			Placebo	34	32 (94.1)	2.06 (0.89)	0.0	1.60	2.00	2.40	4.4	
		Week 48	Tezepelumab	40	40 (100.0)	1.41 (1.10)	0.0	0.60	1.20	2.40	4.2	
			Placebo	34	32 (94.1)	2.14 (0.93)	0.0	1.50	2.30	2.50	4.6	
		Week 50	Tezepelumab	40	40 (100.0)	1.38 (1.04)	0.0	0.60	1.20	2.20	4.2	
			Placebo	34	32 (94.1)	1.97 (0.79)	0.0	1.50	2.00	2.40	4.0	
		Week 52	Tezepelumab	40	40 (100.0)	1.39 (1.04)	0.0	0.60	1.20	2.20	4.2	
			Placebo	34	32 (94.1)	2.06 (0.83)	0.0	1.50	2.00	2.70	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 2	Tezepelumab	40	40 (100.0)	-0.55 (0.76)	-2.2	-1.20	-0.40	0.00	0.8	-0.16 [-0.62, 0.31]
			Placebo	34	32 (94.1)	-0.44 (0.73)	-2.4	-0.80	-0.40	0.00	1.2	
		Week 4	Tezepelumab	40	40 (100.0)	-0.84 (1.00)	-2.6	-1.40	-1.00	-0.20	2.6	-0.24 [-0.71, 0.22]
			Placebo	34	32 (94.1)	-0.61 (0.90)	-3.0	-1.00	-0.40	0.00	0.8	
		Week 6	Tezepelumab	40	40 (100.0)	-0.97 (1.10)	-2.8	-1.70	-1.00	-0.20	2.6	-0.40 [-0.87, 0.07]
			Placebo	34	32 (94.1)	-0.55 (0.99)	-3.2	-1.20	-0.40	0.20	1.6	
		Week 8	Tezepelumab	40	40 (100.0)	-1.23 (1.13)	-3.2	-1.90	-1.20	-0.60	2.6	-0.52 [-0.99, -0.05]
			Placebo	34	32 (94.1)	-0.67 (1.01)	-3.6	-1.10	-0.50	0.00	1.0	
		Week 10	Tezepelumab	40	40 (100.0)	-1.28 (1.23)	-3.4	-2.20	-1.40	-0.60	2.6	-0.50 [-0.97, -0.02]
			Placebo	34	32 (94.1)	-0.69 (1.12)	-3.8	-1.30	-0.60	0.00	2.6	
		Week 12	Tezepelumab	40	40 (100.0)	-1.46 (1.18)	-3.2	-2.30	-1.40	-0.80	2.6	-0.51 [-0.98, -0.04]
			Placebo	34	32 (94.1)	-0.88 (1.07)	-3.8	-1.50	-0.80	-0.20	1.6	
		Week 14	Tezepelumab	40	40 (100.0)	-1.52 (1.21)	-4.0	-2.20	-1.70	-0.80	2.6	-0.44 [-0.91, 0.03]
			Placebo	34	32 (94.1)	-1.03 (1.01)	-3.4	-1.60	-1.10	-0.40	1.4	
		Week 16	Tezepelumab	40	40 (100.0)	-1.32 (1.29)	-3.2	-2.20	-1.50	-0.60	2.6	-0.37 [-0.84, 0.10]
			Placebo	34	32 (94.1)	-0.87 (1.12)	-3.6	-1.30	-0.90	-0.20	2.6	
		Week 18	Tezepelumab	40	40 (100.0)	-1.37 (1.21)	-3.8	-2.30	-1.40	-0.80	2.6	-0.38 [-0.85, 0.09]
			Placebo	34	32 (94.1)	-0.92 (1.17)	-3.6	-1.80	-0.90	-0.10	2.6	
		Week 20	Tezepelumab	40	40 (100.0)	-1.37 (1.18)	-3.4	-2.30	-1.40	-0.60	2.6	-0.52 [-1.00, -0.05]
			Placebo	34	32 (94.1)	-0.75 (1.17)	-3.6	-1.40	-0.70	-0.20	2.6	
		Week 22	Tezepelumab	40	40 (100.0)	-1.28 (1.25)	-3.2	-2.40	-1.20	-0.60	2.6	-0.33 [-0.80, 0.14]
			Placebo	34	32 (94.1)	-0.87 (1.18)	-3.8	-1.40	-1.00	0.00	2.6	
		Week 24	Tezepelumab	40	40 (100.0)	-1.28 (1.20)	-3.4	-2.10	-1.50	-0.50	2.6	-0.49 [-0.96, -0.02]
			Placebo	34	32 (94.1)	-0.71 (1.13)	-3.6	-1.30	-0.80	0.00	2.6	
		Week 26	Tezepelumab	40	40 (100.0)	-1.25 (1.22)	-3.0	-2.20	-1.40	-0.30	2.6	-0.31 [-0.78, 0.16]
			Placebo	34	32 (94.1)	-0.87 (1.26)	-3.4	-1.70	-1.20	0.00	2.6	
		Week 28	Tezepelumab	40	40 (100.0)	-1.28 (1.26)	-3.4	-2.30	-1.30	-0.60	2.6	-0.44 [-0.91, 0.03]
			Placebo	34	32 (94.1)	-0.71 (1.32)	-3.4	-1.70	-0.70	0.00	2.6	
		Week 30	Tezepelumab	40	40 (100.0)	-1.38 (1.20)	-3.8	-2.40	-1.40	-0.70	2.6	-0.39 [-0.86, 0.08]
			Placebo	34	32 (94.1)	-0.90 (1.26)	-3.4	-1.60	-1.00	-0.10	2.6	
		Week 32	Tezepelumab	40	40 (100.0)	-1.44 (1.16)	-3.2	-2.40	-1.60	-0.80	2.6	-0.47 [-0.94, 0.01]
			Placebo	34	32 (94.1)	-0.88 (1.25)	-3.2	-1.70	-1.10	-0.10	2.6	
		Week 34	Tezepelumab	40	40 (100.0)	-1.34 (1.21)	-3.0	-2.30	-1.60	-0.50	2.6	-0.44 [-0.91, 0.03]
			Placebo	34	32 (94.1)	-0.82 (1.18)	-3.2	-1.50	-1.10	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High (>= 20.9 ng/ml)	Change from baseline	Week 36	Tezepelumab	40	40 (100.0)	-1.39 (1.27)	-3.2	-2.40	-1.70	-0.40	2.6	-0.61 [-1.08, -0.13]
			Placebo	34	32 (94.1)	-0.62 (1.25)	-3.2	-1.30	-0.70	0.10	2.6	
		Week 38	Tezepelumab	40	40 (100.0)	-1.37 (1.20)	-3.2	-2.30	-1.50	-0.60	2.6	-0.44 [-0.91, 0.03]
			Placebo	34	32 (94.1)	-0.83 (1.24)	-2.8	-1.60	-1.00	0.10	2.6	
		Week 40	Tezepelumab	40	40 (100.0)	-1.41 (1.24)	-3.4	-2.50	-1.60	-0.60	2.6	-0.59 [-1.07, -0.12]
			Placebo	34	32 (94.1)	-0.68 (1.22)	-2.6	-1.50	-0.80	0.10	2.6	
		Week 42	Tezepelumab	40	40 (100.0)	-1.45 (1.23)	-3.6	-2.30	-1.70	-0.60	2.6	-0.53 [-1.01, -0.06]
			Placebo	34	32 (94.1)	-0.81 (1.17)	-2.6	-1.50	-1.00	-0.20	2.6	
		Week 44	Tezepelumab	40	40 (100.0)	-1.39 (1.28)	-3.8	-2.40	-1.50	-0.60	2.6	-0.49 [-0.96, -0.02]
			Placebo	34	32 (94.1)	-0.78 (1.20)	-2.8	-1.60	-1.10	-0.10	2.6	
		Week 46	Tezepelumab	40	40 (100.0)	-1.35 (1.24)	-3.6	-2.30	-1.40	-0.40	2.6	-0.46 [-0.93, 0.02]
			Placebo	34	32 (94.1)	-0.80 (1.14)	-2.6	-1.40	-1.00	-0.40	2.6	
		Week 48	Tezepelumab	40	40 (100.0)	-1.37 (1.25)	-3.0	-2.40	-1.60	-0.40	2.6	-0.53 [-1.00, -0.06]
			Placebo	34	32 (94.1)	-0.73 (1.16)	-2.8	-1.40	-0.80	-0.10	2.6	
		Week 50	Tezepelumab	40	40 (100.0)	-1.40 (1.17)	-3.0	-2.40	-1.60	-0.80	2.6	-0.47 [-0.94, 0.00]
			Placebo	34	32 (94.1)	-0.89 (0.95)	-2.6	-1.50	-0.90	-0.40	2.6	
		Week 52	Tezepelumab	40	40 (100.0)	-1.39 (1.17)	-3.0	-2.30	-1.60	-0.80	2.6	-0.54 [-1.01, -0.06]
			Placebo	34	32 (94.1)	-0.81 (0.98)	-2.6	-1.50	-0.80	-0.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.93 (0.93)	0.0	2.40	3.00	3.40	5.2	
			Placebo	60	60 (100.0)	2.84 (0.72)	0.4	2.60	2.90	3.20	4.8	
		Week 2	Tezepelumab	57	54 (94.7)	2.48 (0.98)	0.0	1.60	2.60	3.20	4.4	
			Placebo	60	53 (88.3)	2.34 (0.75)	0.4	2.00	2.40	2.80	4.8	
		Week 4	Tezepelumab	57	54 (94.7)	2.22 (0.94)	0.2	1.80	2.40	3.00	3.6	
			Placebo	60	53 (88.3)	2.18 (0.90)	0.2	1.40	2.40	2.80	4.2	
		Week 6	Tezepelumab	57	54 (94.7)	2.14 (0.96)	0.2	1.40	2.20	2.80	4.0	
			Placebo	60	53 (88.3)	2.13 (1.06)	0.2	1.40	2.20	2.80	5.0	
		Week 8	Tezepelumab	57	54 (94.7)	1.99 (1.12)	0.0	1.20	1.80	2.80	5.2	
			Placebo	60	54 (90.0)	2.07 (1.08)	0.0	1.20	2.20	2.80	4.6	
		Week 10	Tezepelumab	57	54 (94.7)	1.89 (1.07)	0.0	1.20	1.80	2.60	4.8	
			Placebo	60	54 (90.0)	2.10 (1.07)	0.0	1.60	2.20	2.80	5.2	
		Week 12	Tezepelumab	57	54 (94.7)	1.80 (1.03)	0.0	1.00	1.90	2.60	4.8	
			Placebo	60	54 (90.0)	1.92 (1.04)	0.0	1.00	2.00	2.60	4.4	
		Week 14	Tezepelumab	57	54 (94.7)	1.71 (1.10)	0.0	0.80	1.60	2.40	4.8	
			Placebo	60	54 (90.0)	1.84 (0.98)	0.0	1.20	2.00	2.40	5.0	
		Week 16	Tezepelumab	57	54 (94.7)	1.89 (1.13)	0.0	1.00	1.80	2.80	4.8	
			Placebo	60	54 (90.0)	1.96 (1.12)	0.0	1.00	2.00	2.80	5.0	
		Week 18	Tezepelumab	57	55 (96.5)	1.83 (1.05)	0.0	1.00	1.80	2.60	4.8	
			Placebo	60	54 (90.0)	1.84 (1.08)	0.0	1.00	1.90	2.60	5.0	
		Week 20	Tezepelumab	57	55 (96.5)	1.87 (1.11)	0.0	1.00	2.00	2.60	5.0	
			Placebo	60	54 (90.0)	1.96 (1.12)	0.0	1.20	2.00	2.80	5.0	
		Week 22	Tezepelumab	57	55 (96.5)	1.93 (0.98)	0.0	1.20	2.00	2.60	4.8	
			Placebo	60	54 (90.0)	1.90 (1.15)	0.0	1.00	2.00	2.60	5.0	
		Week 24	Tezepelumab	57	55 (96.5)	1.93 (1.06)	0.0	1.20	2.00	2.80	4.8	
			Placebo	60	54 (90.0)	1.99 (1.04)	0.0	1.40	2.00	2.60	4.4	
		Week 26	Tezepelumab	57	56 (98.2)	1.96 (1.08)	0.0	1.20	2.00	2.80	4.8	
			Placebo	60	54 (90.0)	1.90 (1.06)	0.0	1.00	1.80	2.60	4.4	
		Week 28	Tezepelumab	57	57 (100.0)	1.87 (1.11)	0.0	1.20	1.80	2.60	4.8	
			Placebo	60	55 (91.7)	1.90 (1.19)	0.0	1.00	1.80	2.80	4.4	
		Week 30	Tezepelumab	57	57 (100.0)	1.87 (1.06)	0.0	1.20	2.00	2.60	4.8	
			Placebo	60	55 (91.7)	1.86 (1.18)	0.0	0.80	2.00	2.80	4.4	
		Week 32	Tezepelumab	57	57 (100.0)	1.81 (1.08)	0.0	1.00	1.80	2.60	4.8	
			Placebo	60	55 (91.7)	1.83 (1.13)	0.0	0.80	1.80	2.60	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	57	57 (100.0)	1.89 (1.15)	0.0	1.00	2.00	2.80	4.8	
			Placebo	60	55 (91.7)	1.83 (1.11)	0.0	0.80	1.80	2.60	4.8	
		Week 36	Tezepelumab	57	57 (100.0)	1.80 (1.08)	0.0	1.00	1.60	2.60	4.8	
			Placebo	60	55 (91.7)	1.97 (1.19)	0.0	1.00	2.00	2.80	4.8	
		Week 38	Tezepelumab	57	57 (100.0)	1.90 (1.18)	0.0	1.00	2.00	2.60	4.8	
			Placebo	60	55 (91.7)	1.82 (1.10)	0.0	1.00	1.80	2.60	4.8	
		Week 40	Tezepelumab	57	57 (100.0)	1.85 (1.14)	0.0	1.00	2.00	2.80	4.8	
			Placebo	60	55 (91.7)	1.97 (1.14)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	57	57 (100.0)	1.79 (1.11)	0.0	1.00	1.80	2.60	4.8	
			Placebo	60	55 (91.7)	1.84 (1.04)	0.0	1.00	2.00	2.60	4.6	
		Week 44	Tezepelumab	57	57 (100.0)	1.81 (1.12)	0.0	0.80	1.80	2.80	4.8	
			Placebo	60	55 (91.7)	1.93 (1.06)	0.0	1.20	2.00	2.60	4.4	
		Week 46	Tezepelumab	57	57 (100.0)	1.85 (1.14)	0.0	1.00	2.00	2.80	4.8	
			Placebo	60	55 (91.7)	1.80 (0.98)	0.0	1.20	2.00	2.40	4.4	
		Week 48	Tezepelumab	57	57 (100.0)	1.84 (1.16)	0.0	1.00	2.00	2.60	4.8	
			Placebo	60	55 (91.7)	1.84 (1.08)	0.0	1.00	2.00	2.40	4.6	
		Week 50	Tezepelumab	57	57 (100.0)	1.81 (1.18)	0.0	1.00	1.80	2.60	4.8	
			Placebo	60	55 (91.7)	1.76 (0.98)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	57	57 (100.0)	1.81 (1.18)	0.0	1.00	1.80	2.60	4.8	
			Placebo	60	55 (91.7)	1.83 (1.04)	0.0	1.00	2.00	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 2	Tezepelumab	57	54 (94.7)	-0.50 (0.79)	-3.2	-1.00	-0.40	0.20	0.8	0.05 [-0.33, 0.43]
			Placebo	60	53 (88.3)	-0.53 (0.72)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	57	54 (94.7)	-0.76 (0.93)	-2.6	-1.20	-0.80	-0.20	2.6	-0.07 [-0.45, 0.31]
			Placebo	60	53 (88.3)	-0.69 (0.95)	-3.0	-1.40	-0.40	0.00	1.2	
		Week 6	Tezepelumab	57	54 (94.7)	-0.83 (1.02)	-2.8	-1.60	-0.90	0.00	2.6	-0.09 [-0.46, 0.29]
			Placebo	60	53 (88.3)	-0.75 (1.01)	-3.4	-1.40	-0.60	0.00	1.6	
		Week 8	Tezepelumab	57	54 (94.7)	-0.99 (1.18)	-3.2	-1.60	-1.00	-0.40	2.6	-0.16 [-0.54, 0.22]
			Placebo	60	54 (90.0)	-0.81 (1.03)	-3.6	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	57	54 (94.7)	-1.09 (1.13)	-3.4	-1.80	-1.20	-0.40	2.6	-0.27 [-0.65, 0.11]
			Placebo	60	54 (90.0)	-0.79 (1.08)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	57	54 (94.7)	-1.18 (1.11)	-3.2	-1.80	-1.20	-0.60	2.6	-0.21 [-0.58, 0.17]
			Placebo	60	54 (90.0)	-0.96 (1.01)	-3.8	-1.40	-0.80	-0.20	1.4	
		Week 14	Tezepelumab	57	54 (94.7)	-1.27 (1.16)	-4.0	-2.00	-1.20	-0.60	2.6	-0.21 [-0.59, 0.17]
			Placebo	60	54 (90.0)	-1.04 (1.02)	-3.4	-1.60	-1.10	-0.40	2.4	
		Week 16	Tezepelumab	57	54 (94.7)	-1.09 (1.17)	-3.2	-2.20	-1.00	-0.40	2.6	-0.14 [-0.52, 0.23]
			Placebo	60	54 (90.0)	-0.93 (1.08)	-3.6	-1.40	-1.00	-0.20	2.4	
		Week 18	Tezepelumab	57	55 (96.5)	-1.13 (1.12)	-3.8	-1.80	-1.00	-0.60	2.6	-0.08 [-0.46, 0.29]
			Placebo	60	54 (90.0)	-1.04 (1.09)	-3.6	-1.80	-1.00	-0.20	2.4	
		Week 20	Tezepelumab	57	55 (96.5)	-1.09 (1.13)	-3.4	-1.80	-1.00	-0.40	2.6	-0.15 [-0.52, 0.23]
			Placebo	60	54 (90.0)	-0.92 (1.12)	-3.6	-1.60	-0.80	-0.20	2.4	
		Week 22	Tezepelumab	57	55 (96.5)	-1.03 (1.16)	-3.2	-1.80	-1.00	-0.40	2.6	-0.03 [-0.41, 0.34]
			Placebo	60	54 (90.0)	-0.99 (1.12)	-3.8	-1.60	-1.00	-0.20	2.4	
		Week 24	Tezepelumab	57	55 (96.5)	-1.03 (1.12)	-3.4	-1.80	-0.80	-0.40	2.6	-0.12 [-0.50, 0.25]
			Placebo	60	54 (90.0)	-0.90 (1.06)	-3.6	-1.60	-0.80	0.00	1.4	
		Week 26	Tezepelumab	57	56 (98.2)	-0.98 (1.15)	-3.0	-2.00	-0.80	-0.20	2.6	0.01 [-0.36, 0.38]
			Placebo	60	54 (90.0)	-0.99 (1.09)	-3.4	-1.80	-1.20	0.00	1.6	
		Week 28	Tezepelumab	57	57 (100.0)	-1.06 (1.23)	-3.4	-2.20	-0.80	-0.20	2.6	-0.11 [-0.48, 0.27]
			Placebo	60	55 (91.7)	-0.94 (1.15)	-3.4	-1.80	-1.20	0.00	1.6	
		Week 30	Tezepelumab	57	57 (100.0)	-1.06 (1.22)	-3.8	-2.20	-1.00	-0.40	2.6	-0.07 [-0.44, 0.30]
			Placebo	60	55 (91.7)	-0.98 (1.19)	-3.4	-1.60	-1.20	-0.20	2.0	
		Week 32	Tezepelumab	57	57 (100.0)	-1.12 (1.14)	-3.2	-2.20	-1.00	-0.40	2.6	-0.10 [-0.47, 0.27]
			Placebo	60	55 (91.7)	-1.01 (1.11)	-3.2	-1.80	-1.20	-0.20	1.8	
		Week 34	Tezepelumab	57	57 (100.0)	-1.05 (1.24)	-3.0	-2.20	-1.00	-0.20	2.6	-0.03 [-0.40, 0.34]
			Placebo	60	55 (91.7)	-1.01 (1.07)	-3.2	-1.80	-1.20	-0.20	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	57	57 (100.0)	-1.13 (1.21)	-3.2	-2.00	-1.20	-0.20	2.6	-0.22 [-0.59, 0.15]
			Placebo	60	55 (91.7)	-0.87 (1.18)	-3.6	-1.40	-1.00	0.00	1.8	
		Week 38	Tezepelumab	57	57 (100.0)	-1.03 (1.26)	-3.2	-2.00	-1.20	0.00	2.6	-0.01 [-0.38, 0.36]
			Placebo	60	55 (91.7)	-1.02 (1.08)	-3.2	-1.60	-1.00	-0.40	1.8	
		Week 40	Tezepelumab	57	57 (100.0)	-1.08 (1.24)	-3.4	-2.00	-1.00	-0.40	2.6	-0.18 [-0.55, 0.19]
			Placebo	60	55 (91.7)	-0.87 (1.13)	-3.2	-1.60	-0.80	-0.20	1.4	
		Week 42	Tezepelumab	57	57 (100.0)	-1.14 (1.25)	-3.6	-2.00	-1.20	-0.40	2.6	-0.12 [-0.50, 0.25]
			Placebo	60	55 (91.7)	-1.00 (1.04)	-2.8	-1.60	-1.00	-0.20	1.6	
		Week 44	Tezepelumab	57	57 (100.0)	-1.12 (1.24)	-3.8	-2.00	-1.20	-0.20	2.6	-0.18 [-0.55, 0.19]
			Placebo	60	55 (91.7)	-0.91 (1.06)	-3.4	-1.60	-1.00	-0.20	1.6	
		Week 46	Tezepelumab	57	57 (100.0)	-1.08 (1.23)	-3.6	-2.20	-1.00	-0.20	2.6	-0.04 [-0.41, 0.33]
			Placebo	60	55 (91.7)	-1.04 (0.99)	-3.2	-1.60	-1.00	-0.40	1.6	
		Week 48	Tezepelumab	57	57 (100.0)	-1.09 (1.22)	-3.0	-2.20	-1.00	-0.40	2.6	-0.09 [-0.46, 0.29]
			Placebo	60	55 (91.7)	-1.00 (1.07)	-3.4	-1.60	-1.00	-0.20	1.8	
		Week 50	Tezepelumab	57	57 (100.0)	-1.13 (1.26)	-3.2	-2.20	-1.20	-0.20	2.6	-0.04 [-0.41, 0.33]
			Placebo	60	55 (91.7)	-1.08 (0.95)	-3.6	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	57	57 (100.0)	-1.12 (1.27)	-3.2	-2.20	-1.20	-0.20	2.6	-0.09 [-0.47, 0.28]
			Placebo	60	55 (91.7)	-1.01 (1.01)	-3.6	-1.60	-1.00	-0.40	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.47 (0.32)	2.2	2.20	2.40	2.80	3.0	
			Placebo	5	5 (100.0)	3.16 (1.28)	1.4	3.00	3.00	3.40	5.0	
		Week 2	Tezepelumab	9	9 (100.0)	1.51 (0.90)	0.2	1.00	1.40	2.00	3.0	
			Placebo	5	5 (100.0)	2.96 (1.19)	2.0	2.40	2.40	3.00	5.0	
		Week 4	Tezepelumab	9	9 (100.0)	1.24 (0.98)	0.2	0.60	1.20	1.40	3.0	
			Placebo	5	5 (100.0)	3.00 (0.82)	2.0	2.20	3.60	3.60	3.6	
		Week 6	Tezepelumab	9	9 (100.0)	0.93 (0.90)	0.0	0.60	0.80	1.00	3.0	
			Placebo	5	5 (100.0)	3.12 (1.79)	1.2	2.20	3.00	3.20	6.0	
		Week 8	Tezepelumab	9	9 (100.0)	0.76 (0.94)	0.0	0.00	0.60	1.00	2.8	
			Placebo	5	5 (100.0)	2.72 (1.72)	0.2	2.40	2.80	3.20	5.0	
		Week 10	Tezepelumab	9	9 (100.0)	0.69 (1.01)	0.0	0.00	0.40	0.80	3.2	
			Placebo	5	5 (100.0)	2.76 (1.18)	0.8	3.00	3.00	3.00	4.0	
		Week 12	Tezepelumab	9	9 (100.0)	0.51 (0.93)	0.0	0.00	0.00	0.60	2.8	
			Placebo	5	5 (100.0)	2.16 (1.37)	0.0	1.60	3.00	3.00	3.2	
		Week 14	Tezepelumab	9	9 (100.0)	0.62 (0.79)	0.0	0.00	0.20	0.80	2.2	
			Placebo	5	5 (100.0)	2.16 (1.32)	0.0	1.80	2.80	3.00	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	0.62 (0.86)	0.0	0.00	0.20	1.00	2.6	
			Placebo	5	5 (100.0)	2.84 (1.93)	0.0	2.00	3.20	4.00	5.0	
		Week 18	Tezepelumab	9	9 (100.0)	0.73 (0.82)	0.0	0.00	0.60	1.20	2.0	
			Placebo	5	5 (100.0)	2.92 (1.82)	0.0	2.80	3.00	4.00	4.8	
		Week 20	Tezepelumab	9	9 (100.0)	0.49 (0.44)	0.0	0.00	0.40	0.80	1.2	
			Placebo	5	5 (100.0)	2.80 (0.79)	2.0	2.20	2.80	3.00	4.0	
		Week 22	Tezepelumab	9	9 (100.0)	0.80 (0.79)	0.0	0.00	0.80	1.40	2.2	
			Placebo	5	5 (100.0)	2.92 (0.83)	1.8	2.60	2.80	3.40	4.0	
		Week 24	Tezepelumab	9	9 (100.0)	0.60 (0.66)	0.0	0.00	0.40	0.80	2.0	
			Placebo	5	5 (100.0)	2.72 (1.22)	0.8	2.40	3.00	3.40	4.0	
		Week 26	Tezepelumab	9	9 (100.0)	0.73 (0.75)	0.0	0.00	0.60	1.40	2.0	
			Placebo	5	5 (100.0)	2.88 (1.64)	0.0	3.20	3.40	3.80	4.0	
		Week 28	Tezepelumab	9	9 (100.0)	0.87 (1.14)	0.0	0.00	0.20	1.20	3.0	
			Placebo	5	5 (100.0)	2.60 (1.54)	0.0	2.80	2.80	3.40	4.0	
		Week 30	Tezepelumab	9	9 (100.0)	0.62 (0.66)	0.0	0.00	0.60	1.20	1.6	
			Placebo	5	5 (100.0)	2.76 (0.94)	1.6	2.40	2.40	3.40	4.0	
		Week 32	Tezepelumab	9	9 (100.0)	0.49 (0.61)	0.0	0.00	0.20	0.80	1.8	
			Placebo	5	5 (100.0)	2.76 (0.98)	1.6	2.00	2.80	3.40	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	0.58 (0.80)	0.0	0.00	0.40	0.80	2.4	
			Placebo	5	5 (100.0)	2.40 (1.46)	0.2	2.20	2.20	3.40	4.0	
		Week 36	Tezepelumab	9	9 (100.0)	0.80 (0.89)	0.0	0.00	0.60	1.00	2.2	
			Placebo	5	5 (100.0)	2.92 (0.89)	1.6	2.80	2.80	3.40	4.0	
		Week 38	Tezepelumab	9	9 (100.0)	0.53 (0.86)	0.0	0.00	0.00	0.60	2.2	
			Placebo	5	5 (100.0)	3.04 (0.85)	1.8	2.60	3.40	3.40	4.0	
		Week 40	Tezepelumab	9	9 (100.0)	0.71 (0.96)	0.0	0.00	0.40	0.80	2.6	
			Placebo	5	5 (100.0)	3.08 (1.36)	0.8	3.00	3.40	4.00	4.2	
		Week 42	Tezepelumab	9	9 (100.0)	0.71 (0.93)	0.0	0.00	0.40	1.00	2.6	
			Placebo	5	5 (100.0)	2.84 (0.84)	2.0	2.20	2.60	3.40	4.0	
		Week 44	Tezepelumab	9	9 (100.0)	0.84 (0.97)	0.0	0.00	0.40	1.40	2.6	
			Placebo	5	5 (100.0)	2.88 (1.49)	0.6	2.20	3.40	4.00	4.2	
		Week 46	Tezepelumab	9	9 (100.0)	0.80 (1.13)	0.0	0.00	0.20	1.00	3.2	
			Placebo	5	5 (100.0)	2.80 (0.93)	1.8	2.00	2.80	3.40	4.0	
		Week 48	Tezepelumab	9	9 (100.0)	0.91 (1.10)	0.0	0.00	0.40	1.80	3.0	
			Placebo	5	5 (100.0)	3.04 (0.65)	2.4	2.60	2.80	3.40	4.0	
		Week 50	Tezepelumab	9	9 (100.0)	0.64 (0.79)	0.0	0.00	0.40	1.00	2.0	
			Placebo	5	5 (100.0)	2.48 (1.45)	0.2	2.20	2.60	3.40	4.0	
		Week 52	Tezepelumab	9	9 (100.0)	0.82 (0.81)	0.0	0.00	0.60	1.60	2.0	
			Placebo	5	5 (100.0)	2.60 (1.45)	0.2	2.60	2.80	3.40	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.96 (0.77)	-2.0	-1.40	-0.80	-0.40	0.2	-0.96 [-2.11, 0.20]
			Placebo	5	5 (100.0)	-0.20 (0.84)	-1.0	-1.00	0.00	0.00	1.0	
		Week 4	Tezepelumab	9	9 (100.0)	-1.22 (0.83)	-2.6	-1.60	-1.20	-0.80	0.0	-1.12 [-2.31, 0.06]
			Placebo	5	5 (100.0)	-0.16 (1.13)	-1.4	-1.40	0.60	0.60	0.8	
		Week 6	Tezepelumab	9	9 (100.0)	-1.53 (0.89)	-2.8	-2.20	-1.40	-1.40	0.2	-1.35 [-2.57, -0.13]
			Placebo	5	5 (100.0)	-0.04 (1.44)	-1.8	-1.20	0.20	1.00	1.6	
		Week 8	Tezepelumab	9	9 (100.0)	-1.71 (0.78)	-2.8	-2.20	-1.80	-1.40	0.0	-1.21 [-2.41, -0.02]
			Placebo	5	5 (100.0)	-0.44 (1.44)	-2.8	-0.60	0.00	0.20	1.0	
		Week 10	Tezepelumab	9	9 (100.0)	-1.78 (0.90)	-2.8	-2.20	-2.00	-1.60	0.4	-1.03 [-2.20, 0.14]
			Placebo	5	5 (100.0)	-0.40 (1.93)	-2.2	-2.00	-0.40	0.00	2.6	
		Week 12	Tezepelumab	9	9 (100.0)	-1.96 (0.80)	-2.8	-2.20	-2.20	-2.00	0.0	-0.76 [-1.90, 0.37]
			Placebo	5	5 (100.0)	-1.00 (1.86)	-3.0	-2.00	-1.80	0.20	1.6	
		Week 14	Tezepelumab	9	9 (100.0)	-1.84 (0.59)	-2.6	-2.20	-2.00	-1.60	-0.6	-0.75 [-1.88, 0.39]
			Placebo	5	5 (100.0)	-1.00 (1.77)	-3.0	-2.00	-1.60	0.20	1.4	
		Week 16	Tezepelumab	9	9 (100.0)	-1.84 (0.73)	-2.8	-2.20	-2.00	-1.80	-0.2	-1.14 [-2.32, 0.04]
			Placebo	5	5 (100.0)	-0.32 (2.08)	-3.0	-1.40	0.00	0.20	2.6	
		Week 18	Tezepelumab	9	9 (100.0)	-1.73 (0.78)	-2.8	-2.20	-1.80	-1.80	-0.2	-1.01 [-2.17, 0.16]
			Placebo	5	5 (100.0)	-0.24 (2.32)	-3.0	-2.00	-0.20	1.40	2.6	
		Week 20	Tezepelumab	9	9 (100.0)	-1.98 (0.43)	-2.8	-2.20	-2.00	-1.60	-1.4	-1.49 [-2.73, -0.24]
			Placebo	5	5 (100.0)	-0.36 (1.79)	-2.0	-1.40	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	9	9 (100.0)	-1.67 (0.75)	-2.8	-2.20	-1.60	-1.40	-0.6	-1.23 [-2.42, -0.03]
			Placebo	5	5 (100.0)	-0.24 (1.72)	-1.6	-1.60	-0.40	-0.20	2.6	
		Week 24	Tezepelumab	9	9 (100.0)	-1.87 (0.55)	-2.8	-2.20	-1.80	-1.60	-0.8	-1.21 [-2.41, -0.02]
			Placebo	5	5 (100.0)	-0.44 (1.88)	-2.2	-1.60	-1.00	0.00	2.6	
		Week 26	Tezepelumab	9	9 (100.0)	-1.73 (0.74)	-2.8	-2.20	-1.60	-1.40	-0.2	-1.06 [-2.23, 0.11]
			Placebo	5	5 (100.0)	-0.28 (2.13)	-3.0	-1.60	0.20	0.40	2.6	
		Week 28	Tezepelumab	9	9 (100.0)	-1.60 (1.04)	-2.8	-2.20	-2.20	-1.40	0.2	-0.71 [-1.84, 0.42]
			Placebo	5	5 (100.0)	-0.56 (2.07)	-3.0	-1.60	-0.60	-0.20	2.6	
		Week 30	Tezepelumab	9	9 (100.0)	-1.84 (0.58)	-2.8	-2.20	-1.80	-1.60	-0.8	-1.31 [-2.52, -0.10]
			Placebo	5	5 (100.0)	-0.40 (1.72)	-1.6	-1.40	-1.00	-0.60	2.6	
		Week 32	Tezepelumab	9	9 (100.0)	-1.98 (0.45)	-2.8	-2.20	-2.00	-1.80	-1.2	-1.45 [-2.69, -0.22]
			Placebo	5	5 (100.0)	-0.40 (1.77)	-1.6	-1.40	-1.40	-0.20	2.6	
		Week 34	Tezepelumab	9	9 (100.0)	-1.89 (0.61)	-2.8	-2.20	-2.00	-1.60	-0.6	-0.89 [-2.04, 0.26]
			Placebo	5	5 (100.0)	-0.76 (2.02)	-2.8	-1.60	-1.20	-0.80	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.67 (0.85)	-2.8	-2.20	-1.80	-1.40	0.0	-1.19 [-2.39, -0.00]
			Placebo	5	5 (100.0)	-0.24 (1.69)	-1.6	-1.40	-0.60	-0.20	2.6	
		Week 38	Tezepelumab	9	9 (100.0)	-1.93 (0.65)	-2.8	-2.20	-2.20	-1.80	-0.8	-1.67 [-2.95, -0.39]
			Placebo	5	5 (100.0)	-0.12 (1.65)	-1.6	-1.20	-0.40	0.00	2.6	
		Week 40	Tezepelumab	9	9 (100.0)	-1.76 (0.75)	-2.8	-2.20	-2.00	-1.60	-0.4	-1.32 [-2.54, -0.11]
			Placebo	5	5 (100.0)	-0.08 (1.92)	-2.2	-1.60	0.00	0.80	2.6	
		Week 42	Tezepelumab	9	9 (100.0)	-1.76 (0.73)	-2.8	-2.20	-2.00	-1.40	-0.4	-1.27 [-2.47, -0.06]
			Placebo	5	5 (100.0)	-0.32 (1.66)	-1.6	-1.00	-0.80	-0.80	2.6	
		Week 44	Tezepelumab	9	9 (100.0)	-1.62 (0.82)	-2.8	-2.20	-1.80	-0.80	-0.4	-1.01 [-2.17, 0.16]
			Placebo	5	5 (100.0)	-0.28 (2.00)	-2.4	-1.60	-0.80	0.80	2.6	
		Week 46	Tezepelumab	9	9 (100.0)	-1.67 (0.92)	-2.8	-2.20	-2.20	-1.40	0.2	-1.06 [-2.23, 0.11]
			Placebo	5	5 (100.0)	-0.36 (1.69)	-1.6	-1.20	-1.00	-0.60	2.6	
		Week 48	Tezepelumab	9	9 (100.0)	-1.56 (0.96)	-2.8	-2.20	-2.00	-1.00	0.0	-1.19 [-2.38, 0.00]
			Placebo	5	5 (100.0)	-0.12 (1.59)	-1.6	-0.60	-0.60	-0.40	2.6	
		Week 50	Tezepelumab	9	9 (100.0)	-1.82 (0.62)	-2.8	-2.20	-2.00	-1.40	-0.8	-0.90 [-2.05, 0.25]
			Placebo	5	5 (100.0)	-0.68 (2.01)	-2.8	-1.60	-0.80	-0.80	2.6	
		Week 52	Tezepelumab	9	9 (100.0)	-1.64 (0.53)	-2.2	-2.20	-1.60	-1.20	-0.8	-0.87 [-2.02, 0.27]
			Placebo	5	5 (100.0)	-0.56 (2.02)	-2.8	-1.60	-0.80	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.73 (0.45)	2.2	2.40	2.80	3.00	3.4	
			Placebo	14	14 (100.0)	2.77 (0.88)	0.4	2.80	3.00	3.00	4.0	
		Week 2	Tezepelumab	9	9 (100.0)	2.31 (0.69)	1.0	2.00	2.60	2.80	3.2	
			Placebo	14	12 (85.7)	2.52 (0.54)	1.4	2.20	2.50	3.00	3.2	
		Week 4	Tezepelumab	9	9 (100.0)	1.76 (0.89)	0.2	1.20	1.80	2.40	3.0	
			Placebo	14	12 (85.7)	2.87 (0.73)	2.0	2.20	2.70	3.50	4.2	
		Week 6	Tezepelumab	9	9 (100.0)	1.40 (0.63)	0.6	1.00	1.40	1.80	2.6	
			Placebo	14	12 (85.7)	2.77 (0.76)	1.2	2.40	2.90	3.20	4.0	
		Week 8	Tezepelumab	9	9 (100.0)	1.29 (0.84)	0.0	1.00	1.60	1.60	2.6	
			Placebo	14	13 (92.9)	2.43 (0.98)	0.2	2.20	2.40	2.80	4.0	
		Week 10	Tezepelumab	9	9 (100.0)	1.00 (0.78)	0.0	0.60	0.80	1.40	2.4	
			Placebo	14	13 (92.9)	2.38 (0.85)	0.8	2.00	2.40	3.00	4.0	
		Week 12	Tezepelumab	9	9 (100.0)	0.93 (0.82)	0.0	0.00	1.00	1.60	2.2	
			Placebo	14	13 (92.9)	2.52 (0.99)	0.0	2.20	2.60	3.00	4.4	
		Week 14	Tezepelumab	9	9 (100.0)	0.96 (0.63)	0.0	0.60	1.40	1.40	1.6	
			Placebo	14	13 (92.9)	2.06 (0.78)	0.0	2.00	2.20	2.40	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	0.96 (0.51)	0.0	0.60	1.20	1.40	1.4	
			Placebo	14	13 (92.9)	2.40 (1.13)	0.0	2.00	2.60	2.80	4.0	
		Week 18	Tezepelumab	9	9 (100.0)	1.18 (0.60)	0.0	1.00	1.20	1.60	2.0	
			Placebo	14	13 (92.9)	2.38 (0.88)	0.0	2.40	2.60	2.60	4.0	
		Week 20	Tezepelumab	9	9 (100.0)	1.18 (0.76)	0.0	0.80	1.20	1.40	2.8	
			Placebo	14	13 (92.9)	2.48 (0.81)	1.0	2.00	2.60	2.80	4.0	
		Week 22	Tezepelumab	9	9 (100.0)	1.31 (0.94)	0.0	1.00	1.40	1.60	2.8	
			Placebo	14	13 (92.9)	2.55 (0.92)	0.8	2.00	2.60	3.20	4.0	
		Week 24	Tezepelumab	9	9 (100.0)	1.18 (0.77)	0.0	0.80	1.20	1.40	2.8	
			Placebo	14	13 (92.9)	2.48 (0.90)	0.8	2.00	2.40	3.20	4.0	
		Week 26	Tezepelumab	9	9 (100.0)	1.36 (0.69)	0.0	1.00	1.40	1.80	2.4	
			Placebo	14	13 (92.9)	2.37 (1.15)	0.0	1.60	2.20	3.20	4.0	
		Week 28	Tezepelumab	9	9 (100.0)	1.62 (0.94)	0.0	1.00	1.40	2.40	3.0	
			Placebo	14	14 (100.0)	2.19 (1.28)	0.0	1.40	2.40	3.20	4.0	
		Week 30	Tezepelumab	9	9 (100.0)	1.31 (0.74)	0.0	0.80	1.40	1.60	2.4	
			Placebo	14	14 (100.0)	2.26 (1.14)	0.0	1.60	2.20	3.20	4.0	
		Week 32	Tezepelumab	9	9 (100.0)	1.22 (0.76)	0.0	0.80	1.20	1.80	2.2	
			Placebo	14	14 (100.0)	2.37 (1.29)	0.0	1.60	2.30	3.20	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.36 (1.10)	0.0	0.80	1.20	2.40	3.0	
			Placebo	14	14 (100.0)	2.17 (1.39)	0.2	1.20	2.10	3.20	4.8	
		Week 36	Tezepelumab	9	9 (100.0)	1.44 (0.84)	0.0	1.00	1.20	2.20	2.8	
			Placebo	14	14 (100.0)	2.43 (1.34)	0.0	1.60	2.20	3.20	4.8	
		Week 38	Tezepelumab	9	9 (100.0)	1.47 (1.06)	0.0	0.60	1.40	2.20	3.0	
			Placebo	14	14 (100.0)	2.30 (1.29)	0.0	1.60	2.30	3.20	4.8	
		Week 40	Tezepelumab	9	9 (100.0)	1.22 (0.94)	0.0	0.80	1.20	1.80	2.6	
			Placebo	14	14 (100.0)	2.31 (1.23)	0.0	1.40	2.50	3.00	4.4	
		Week 42	Tezepelumab	9	9 (100.0)	1.29 (0.81)	0.0	1.00	1.20	1.40	2.6	
			Placebo	14	14 (100.0)	2.31 (1.20)	0.0	2.00	2.30	2.80	4.6	
		Week 44	Tezepelumab	9	9 (100.0)	1.42 (0.92)	0.0	1.00	1.40	1.60	3.0	
			Placebo	14	14 (100.0)	2.17 (1.18)	0.0	1.40	2.30	2.60	4.2	
		Week 46	Tezepelumab	9	9 (100.0)	1.49 (1.03)	0.0	1.00	1.20	1.80	3.2	
			Placebo	14	14 (100.0)	2.20 (0.95)	0.0	1.80	2.20	2.60	4.0	
		Week 48	Tezepelumab	9	9 (100.0)	1.42 (0.95)	0.0	0.80	1.20	2.00	3.0	
			Placebo	14	14 (100.0)	2.30 (1.07)	0.0	2.00	2.40	2.60	4.0	
		Week 50	Tezepelumab	9	9 (100.0)	1.13 (0.75)	0.0	0.80	1.00	1.40	2.6	
			Placebo	14	14 (100.0)	2.07 (1.15)	0.0	1.20	2.30	2.60	4.0	
		Week 52	Tezepelumab	9	9 (100.0)	1.13 (0.75)	0.0	0.80	1.00	1.40	2.6	
			Placebo	14	14 (100.0)	2.17 (1.22)	0.0	1.20	2.40	2.80	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.42 (0.39)	-1.4	-0.40	-0.20	-0.20	-0.2	-0.04 [-0.90, 0.83]
			Placebo	14	12 (85.7)	-0.40 (0.69)	-1.6	-0.90	-0.50	0.00	1.0	
		Week 4	Tezepelumab	9	9 (100.0)	-0.98 (0.70)	-2.2	-1.20	-1.00	-0.40	0.0	-1.21 [-2.16, -0.26]
			Placebo	14	12 (85.7)	-0.05 (0.81)	-1.4	-0.80	0.00	0.60	1.2	
		Week 6	Tezepelumab	9	9 (100.0)	-1.33 (0.66)	-2.4	-1.80	-1.40	-0.80	-0.2	-1.47 [-2.45, -0.49]
			Placebo	14	12 (85.7)	-0.15 (0.89)	-1.8	-0.80	-0.20	0.30	1.6	
		Week 8	Tezepelumab	9	9 (100.0)	-1.44 (0.66)	-2.4	-1.60	-1.40	-1.40	-0.2	-0.95 [-1.85, -0.05]
			Placebo	14	13 (92.9)	-0.52 (1.12)	-2.8	-1.00	-0.40	0.20	1.0	
		Week 10	Tezepelumab	9	9 (100.0)	-1.73 (0.62)	-2.4	-2.20	-2.00	-1.40	-0.8	-1.16 [-2.08, -0.24]
			Placebo	14	13 (92.9)	-0.57 (1.19)	-2.2	-1.00	-0.40	-0.20	2.6	
		Week 12	Tezepelumab	9	9 (100.0)	-1.80 (0.60)	-2.4	-2.20	-2.00	-1.40	-0.8	-1.38 [-2.33, -0.43]
			Placebo	14	13 (92.9)	-0.43 (1.18)	-3.0	-0.80	-0.60	0.00	1.6	
		Week 14	Tezepelumab	9	9 (100.0)	-1.78 (0.49)	-2.4	-2.20	-1.80	-1.60	-0.8	-1.03 [-1.94, -0.13]
			Placebo	14	13 (92.9)	-0.89 (1.03)	-3.0	-1.40	-1.00	-0.60	1.4	
		Week 16	Tezepelumab	9	9 (100.0)	-1.78 (0.48)	-2.4	-2.20	-1.80	-1.60	-0.8	-1.09 [-2.01, -0.18]
			Placebo	14	13 (92.9)	-0.55 (1.39)	-3.0	-1.40	-0.60	-0.20	2.6	
		Week 18	Tezepelumab	9	9 (100.0)	-1.56 (0.71)	-2.4	-1.80	-1.60	-1.40	-0.2	-0.94 [-1.84, -0.04]
			Placebo	14	13 (92.9)	-0.57 (1.23)	-3.0	-1.20	-0.60	-0.20	2.6	
		Week 20	Tezepelumab	9	9 (100.0)	-1.56 (0.66)	-2.4	-2.20	-1.60	-1.40	-0.4	-1.10 [-2.02, -0.19]
			Placebo	14	13 (92.9)	-0.48 (1.14)	-2.0	-1.20	-0.60	-0.20	2.6	
		Week 22	Tezepelumab	9	9 (100.0)	-1.42 (0.86)	-2.4	-2.40	-1.60	-0.80	-0.2	-0.93 [-1.83, -0.03]
			Placebo	14	13 (92.9)	-0.40 (1.24)	-2.2	-1.20	-0.40	0.20	2.6	
		Week 24	Tezepelumab	9	9 (100.0)	-1.56 (0.70)	-2.4	-1.80	-1.60	-1.60	-0.2	-1.02 [-1.93, -0.11]
			Placebo	14	13 (92.9)	-0.48 (1.24)	-2.2	-1.20	-0.80	0.20	2.6	
		Week 26	Tezepelumab	9	9 (100.0)	-1.38 (0.75)	-2.4	-1.60	-1.40	-0.80	-0.2	-0.66 [-1.53, 0.21]
			Placebo	14	13 (92.9)	-0.58 (1.42)	-3.0	-1.40	-1.20	0.20	2.6	
		Week 28	Tezepelumab	9	9 (100.0)	-1.11 (0.93)	-2.4	-1.60	-0.80	-0.80	0.2	-0.43 [-1.27, 0.42]
			Placebo	14	14 (100.0)	-0.59 (1.38)	-3.0	-1.40	-0.80	0.20	2.6	
		Week 30	Tezepelumab	9	9 (100.0)	-1.42 (0.71)	-2.6	-1.60	-1.40	-0.80	-0.6	-0.86 [-1.74, 0.01]
			Placebo	14	14 (100.0)	-0.51 (1.22)	-1.8	-1.40	-0.90	0.20	2.6	
		Week 32	Tezepelumab	9	9 (100.0)	-1.51 (0.62)	-2.4	-1.80	-1.60	-1.00	-0.8	-0.99 [-1.88, -0.10]
			Placebo	14	14 (100.0)	-0.40 (1.35)	-1.8	-1.40	-0.70	0.20	2.6	
		Week 34	Tezepelumab	9	9 (100.0)	-1.38 (0.92)	-2.6	-2.20	-1.60	-0.60	0.0	-0.58 [-1.44, 0.27]
			Placebo	14	14 (100.0)	-0.60 (1.54)	-2.8	-1.80	-1.00	0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.29 (0.90)	-2.4	-2.00	-1.40	-0.80	0.0	-0.76 [-1.63, 0.10]
			Placebo	14	14 (100.0)	-0.34 (1.41)	-2.2	-1.40	-0.70	0.20	2.6	
		Week 38	Tezepelumab	9	9 (100.0)	-1.27 (0.77)	-2.4	-1.80	-1.40	-0.80	0.0	-0.67 [-1.53, 0.19]
			Placebo	14	14 (100.0)	-0.47 (1.38)	-2.6	-1.40	-0.80	0.20	2.6	
		Week 40	Tezepelumab	9	9 (100.0)	-1.51 (0.79)	-2.6	-2.20	-1.60	-0.80	-0.4	-0.92 [-1.80, -0.04]
			Placebo	14	14 (100.0)	-0.46 (1.32)	-2.2	-1.40	-0.60	0.20	2.6	
		Week 42	Tezepelumab	9	9 (100.0)	-1.44 (0.73)	-2.4	-1.80	-1.60	-0.80	-0.4	-0.89 [-1.77, -0.01]
			Placebo	14	14 (100.0)	-0.46 (1.29)	-2.4	-1.40	-0.70	0.00	2.6	
		Week 44	Tezepelumab	9	9 (100.0)	-1.31 (0.91)	-2.8	-1.60	-1.40	-0.80	0.0	-0.61 [-1.47, 0.25]
			Placebo	14	14 (100.0)	-0.60 (1.29)	-2.4	-1.40	-0.90	0.00	2.6	
		Week 46	Tezepelumab	9	9 (100.0)	-1.24 (0.92)	-2.4	-1.60	-1.40	-0.80	0.2	-0.66 [-1.52, 0.20]
			Placebo	14	14 (100.0)	-0.57 (1.08)	-1.8	-1.20	-1.00	0.00	2.6	
		Week 48	Tezepelumab	9	9 (100.0)	-1.31 (0.99)	-2.4	-2.40	-1.60	-0.40	0.0	-0.76 [-1.63, 0.10]
			Placebo	14	14 (100.0)	-0.47 (1.16)	-2.0	-1.20	-0.60	-0.20	2.6	
		Week 50	Tezepelumab	9	9 (100.0)	-1.60 (0.75)	-2.6	-2.40	-1.60	-1.20	-0.4	-0.81 [-1.68, 0.06]
			Placebo	14	14 (100.0)	-0.70 (1.28)	-2.8	-1.40	-0.70	-0.20	2.6	
		Week 52	Tezepelumab	9	9 (100.0)	-1.60 (0.75)	-2.6	-2.40	-1.60	-1.20	-0.4	-0.87 [-1.75, 0.00]
			Placebo	14	14 (100.0)	-0.60 (1.33)	-2.8	-1.40	-0.60	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.89 (0.93)	0.0	2.40	2.80	3.20	5.2	
			Placebo	51	51 (100.0)	2.89 (0.74)	1.0	2.60	2.80	3.20	5.0	
		Week 2	Tezepelumab	57	54 (94.7)	2.35 (1.07)	0.0	1.60	2.60	3.20	4.4	
			Placebo	51	46 (90.2)	2.37 (0.86)	0.4	2.00	2.40	2.80	5.0	
		Week 4	Tezepelumab	57	54 (94.7)	2.13 (1.02)	0.2	1.40	2.30	3.00	3.6	
			Placebo	51	46 (90.2)	2.09 (0.90)	0.2	1.40	2.40	2.80	3.6	
		Week 6	Tezepelumab	57	54 (94.7)	2.07 (1.07)	0.0	1.20	2.20	3.00	4.0	
			Placebo	51	46 (90.2)	2.07 (1.20)	0.2	1.20	2.20	2.60	6.0	
		Week 8	Tezepelumab	57	54 (94.7)	1.90 (1.21)	0.0	1.00	1.80	2.80	5.2	
			Placebo	51	46 (90.2)	2.04 (1.18)	0.0	1.00	2.00	3.00	5.0	
		Week 10	Tezepelumab	57	54 (94.7)	1.84 (1.15)	0.0	1.00	1.80	2.80	4.8	
			Placebo	51	46 (90.2)	2.09 (1.14)	0.0	1.60	2.20	2.80	5.2	
		Week 12	Tezepelumab	57	54 (94.7)	1.73 (1.11)	0.0	0.60	1.90	2.60	4.8	
			Placebo	51	46 (90.2)	1.78 (1.03)	0.0	1.00	1.90	2.60	4.4	
		Week 14	Tezepelumab	57	54 (94.7)	1.66 (1.16)	0.0	0.60	1.60	2.40	4.8	
			Placebo	51	46 (90.2)	1.82 (1.06)	0.0	1.00	1.80	2.40	5.0	
		Week 16	Tezepelumab	57	54 (94.7)	1.83 (1.22)	0.0	0.80	1.90	2.80	4.8	
			Placebo	51	46 (90.2)	1.93 (1.22)	0.0	0.80	2.00	2.80	5.0	
		Week 18	Tezepelumab	57	55 (96.5)	1.75 (1.13)	0.0	0.80	2.00	2.60	4.8	
			Placebo	51	46 (90.2)	1.80 (1.23)	0.0	1.00	1.80	2.60	5.0	
		Week 20	Tezepelumab	57	55 (96.5)	1.76 (1.18)	0.0	0.60	1.80	2.60	5.0	
			Placebo	51	46 (90.2)	1.91 (1.16)	0.0	1.00	2.00	2.80	5.0	
		Week 22	Tezepelumab	57	55 (96.5)	1.85 (1.03)	0.0	1.00	2.00	2.60	4.8	
			Placebo	51	46 (90.2)	1.82 (1.18)	0.0	0.80	1.80	2.60	5.0	
		Week 24	Tezepelumab	57	55 (96.5)	1.83 (1.13)	0.0	1.00	2.00	2.60	4.8	
			Placebo	51	46 (90.2)	1.93 (1.08)	0.0	1.00	2.00	2.60	4.4	
		Week 26	Tezepelumab	57	56 (98.2)	1.86 (1.17)	0.0	0.90	1.90	2.80	4.8	
			Placebo	51	46 (90.2)	1.87 (1.12)	0.0	1.00	1.70	2.80	4.4	
		Week 28	Tezepelumab	57	57 (100.0)	1.75 (1.20)	0.0	0.80	1.80	2.60	4.8	
			Placebo	51	46 (90.2)	1.89 (1.21)	0.0	1.00	1.80	2.80	4.4	
		Week 30	Tezepelumab	57	57 (100.0)	1.76 (1.14)	0.0	1.00	1.80	2.60	4.8	
			Placebo	51	46 (90.2)	1.84 (1.19)	0.0	0.80	2.00	2.80	4.4	
		Week 32	Tezepelumab	57	57 (100.0)	1.69 (1.16)	0.0	0.80	1.80	2.60	4.8	
			Placebo	51	46 (90.2)	1.76 (1.06)	0.0	0.80	1.80	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	57	57 (100.0)	1.76 (1.20)	0.0	0.80	1.80	2.80	4.8	
			Placebo	51	46 (90.2)	1.79 (1.05)	0.0	0.80	1.80	2.40	4.4	
		Week 36	Tezepelumab	57	57 (100.0)	1.70 (1.15)	0.0	0.80	1.60	2.60	4.8	
			Placebo	51	46 (90.2)	1.94 (1.13)	0.0	1.00	2.10	2.80	4.4	
		Week 38	Tezepelumab	57	57 (100.0)	1.75 (1.26)	0.0	0.80	1.80	2.60	4.8	
			Placebo	51	46 (90.2)	1.81 (1.06)	0.0	1.00	1.80	2.60	4.4	
		Week 40	Tezepelumab	57	57 (100.0)	1.77 (1.21)	0.0	0.80	2.00	2.80	4.8	
			Placebo	51	46 (90.2)	1.99 (1.18)	0.0	1.00	2.00	2.80	4.4	
		Week 42	Tezepelumab	57	57 (100.0)	1.70 (1.19)	0.0	0.80	1.80	2.60	4.8	
			Placebo	51	46 (90.2)	1.80 (1.00)	0.0	1.00	2.00	2.40	4.4	
		Week 44	Tezepelumab	57	57 (100.0)	1.72 (1.17)	0.0	0.80	1.80	2.80	4.8	
			Placebo	51	46 (90.2)	1.96 (1.10)	0.0	1.00	1.90	2.80	4.4	
		Week 46	Tezepelumab	57	57 (100.0)	1.74 (1.22)	0.0	0.80	2.00	2.60	4.8	
			Placebo	51	46 (90.2)	1.79 (1.02)	0.0	1.00	1.90	2.20	4.4	
		Week 48	Tezepelumab	57	57 (100.0)	1.76 (1.22)	0.0	0.80	1.80	2.60	4.8	
			Placebo	51	46 (90.2)	1.83 (1.09)	0.0	1.00	2.00	2.40	4.6	
		Week 50	Tezepelumab	57	57 (100.0)	1.73 (1.24)	0.0	0.80	1.80	2.60	4.8	
			Placebo	51	46 (90.2)	1.75 (0.99)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	57	57 (100.0)	1.76 (1.22)	0.0	0.80	1.80	2.60	4.8	
			Placebo	51	46 (90.2)	1.81 (1.04)	0.0	1.00	1.80	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline											
No	Change from baseline	Week 2	Tezepelumab	57	54 (94.7)	-0.59 (0.84)	-3.2	-1.20	-0.50	0.20	0.8	-0.07 [-0.46, 0.32]
			Placebo	51	46 (90.2)	-0.53 (0.74)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	57	54 (94.7)	-0.80 (0.96)	-2.6	-1.40	-0.80	-0.20	2.6	0.00 [-0.39, 0.40]
			Placebo	51	46 (90.2)	-0.80 (0.95)	-3.0	-1.40	-0.80	0.00	0.8	
		Week 6	Tezepelumab	57	54 (94.7)	-0.87 (1.06)	-2.8	-1.60	-1.00	0.00	2.6	-0.04 [-0.43, 0.35]
			Placebo	51	46 (90.2)	-0.83 (1.05)	-3.4	-1.60	-0.60	0.00	1.6	
		Week 8	Tezepelumab	57	54 (94.7)	-1.03 (1.21)	-3.2	-1.80	-1.00	-0.40	2.6	-0.16 [-0.55, 0.24]
			Placebo	51	46 (90.2)	-0.85 (1.04)	-3.6	-1.40	-0.60	0.00	1.0	
		Week 10	Tezepelumab	57	54 (94.7)	-1.09 (1.16)	-3.4	-1.80	-1.20	-0.20	2.6	-0.24 [-0.64, 0.15]
			Placebo	51	46 (90.2)	-0.81 (1.16)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	57	54 (94.7)	-1.21 (1.15)	-3.2	-2.20	-1.20	-0.60	2.6	-0.08 [-0.48, 0.31]
			Placebo	51	46 (90.2)	-1.12 (1.01)	-3.8	-1.80	-1.00	-0.40	1.2	
		Week 14	Tezepelumab	57	54 (94.7)	-1.28 (1.17)	-4.0	-2.20	-1.20	-0.60	2.6	-0.18 [-0.57, 0.22]
			Placebo	51	46 (90.2)	-1.08 (1.10)	-3.4	-1.60	-1.30	-0.40	2.4	
		Week 16	Tezepelumab	57	54 (94.7)	-1.10 (1.20)	-3.2	-2.20	-1.00	-0.40	2.6	-0.12 [-0.51, 0.28]
			Placebo	51	46 (90.2)	-0.97 (1.11)	-3.6	-1.40	-1.00	-0.20	2.4	
		Week 18	Tezepelumab	57	55 (96.5)	-1.16 (1.14)	-3.8	-2.00	-1.00	-0.60	2.6	-0.06 [-0.45, 0.33]
			Placebo	51	46 (90.2)	-1.09 (1.22)	-3.6	-2.00	-1.20	-0.20	2.4	
		Week 20	Tezepelumab	57	55 (96.5)	-1.16 (1.15)	-3.4	-2.20	-1.00	-0.40	2.6	-0.15 [-0.54, 0.25]
			Placebo	51	46 (90.2)	-0.99 (1.18)	-3.6	-1.60	-0.90	-0.20	2.4	
		Week 22	Tezepelumab	57	55 (96.5)	-1.07 (1.17)	-3.2	-1.80	-1.00	-0.60	2.6	0.01 [-0.38, 0.40]
			Placebo	51	46 (90.2)	-1.07 (1.14)	-3.8	-1.60	-1.00	-0.40	2.4	
		Week 24	Tezepelumab	57	55 (96.5)	-1.08 (1.13)	-3.4	-2.00	-1.00	-0.40	2.6	-0.10 [-0.49, 0.29]
			Placebo	51	46 (90.2)	-0.97 (1.09)	-3.6	-1.60	-0.90	-0.20	1.4	
		Week 26	Tezepelumab	57	56 (98.2)	-1.04 (1.18)	-3.0	-2.20	-1.00	-0.20	2.6	-0.01 [-0.40, 0.38]
			Placebo	51	46 (90.2)	-1.03 (1.12)	-3.4	-1.80	-1.20	0.00	1.6	
		Week 28	Tezepelumab	57	57 (100.0)	-1.14 (1.25)	-3.4	-2.20	-1.20	-0.20	2.6	-0.11 [-0.50, 0.28]
			Placebo	51	46 (90.2)	-1.00 (1.18)	-3.4	-1.80	-1.10	-0.20	1.6	
		Week 30	Tezepelumab	57	57 (100.0)	-1.13 (1.24)	-3.8	-2.20	-1.20	-0.40	2.6	-0.06 [-0.45, 0.33]
			Placebo	51	46 (90.2)	-1.06 (1.22)	-3.4	-1.60	-1.20	-0.20	2.0	
		Week 32	Tezepelumab	57	57 (100.0)	-1.20 (1.16)	-3.2	-2.20	-1.20	-0.40	2.6	-0.05 [-0.44, 0.33]
			Placebo	51	46 (90.2)	-1.13 (1.07)	-3.2	-1.80	-1.30	-0.40	1.4	
		Week 34	Tezepelumab	57	57 (100.0)	-1.13 (1.25)	-3.0	-2.20	-1.40	-0.20	2.6	-0.02 [-0.40, 0.37]
			Placebo	51	46 (90.2)	-1.11 (1.00)	-3.2	-1.60	-1.20	-0.40	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	57	57 (100.0)	-1.19 (1.22)	-3.2	-2.20	-1.20	-0.20	2.6	-0.20 [-0.59, 0.19]
			Placebo	51	46 (90.2)	-0.96 (1.14)	-3.6	-1.60	-1.00	-0.20	1.4	
		Week 38	Tezepelumab	57	57 (100.0)	-1.14 (1.29)	-3.2	-2.20	-1.20	-0.20	2.6	-0.04 [-0.43, 0.35]
			Placebo	51	46 (90.2)	-1.09 (1.04)	-3.2	-2.00	-1.00	-0.40	1.4	
		Week 40	Tezepelumab	57	57 (100.0)	-1.12 (1.26)	-3.4	-2.20	-1.20	-0.40	2.6	-0.17 [-0.56, 0.22]
			Placebo	51	46 (90.2)	-0.91 (1.18)	-3.2	-1.60	-0.90	-0.20	1.4	
		Week 42	Tezepelumab	57	57 (100.0)	-1.19 (1.27)	-3.6	-2.20	-1.20	-0.40	2.6	-0.09 [-0.48, 0.30]
			Placebo	51	46 (90.2)	-1.09 (1.01)	-2.8	-1.60	-1.10	-0.40	1.4	
		Week 44	Tezepelumab	57	57 (100.0)	-1.17 (1.25)	-3.8	-2.20	-1.20	-0.40	2.6	-0.20 [-0.59, 0.19]
			Placebo	51	46 (90.2)	-0.94 (1.11)	-3.4	-1.60	-1.00	-0.20	1.6	
		Week 46	Tezepelumab	57	57 (100.0)	-1.15 (1.25)	-3.6	-2.20	-1.20	-0.20	2.6	-0.03 [-0.42, 0.36]
			Placebo	51	46 (90.2)	-1.11 (1.03)	-3.2	-1.60	-1.10	-0.60	1.6	
		Week 48	Tezepelumab	57	57 (100.0)	-1.13 (1.23)	-3.0	-2.20	-1.00	-0.40	2.6	-0.06 [-0.45, 0.33]
			Placebo	51	46 (90.2)	-1.06 (1.10)	-3.4	-1.60	-1.00	-0.40	1.8	
		Week 50	Tezepelumab	57	57 (100.0)	-1.16 (1.27)	-3.2	-2.20	-1.20	-0.20	2.6	-0.01 [-0.40, 0.38]
			Placebo	51	46 (90.2)	-1.15 (0.97)	-3.6	-1.60	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	57	57 (100.0)	-1.13 (1.25)	-3.2	-2.20	-1.20	-0.20	2.6	-0.03 [-0.42, 0.35]
			Placebo	51	46 (90.2)	-1.09 (1.02)	-3.6	-1.80	-1.00	-0.40	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	51	51 (100.0)	2.95 (0.97)	0.0	2.40	3.00	3.40	5.2	
			Placebo	49	49 (100.0)	2.83 (0.69)	1.0	2.60	2.80	3.20	4.8	
		Week 2	Tezepelumab	51	48 (94.1)	2.48 (1.02)	0.0	1.60	2.60	3.30	4.4	
			Placebo	49	44 (89.8)	2.30 (0.78)	0.4	2.00	2.40	2.80	4.8	
		Week 4	Tezepelumab	51	48 (94.1)	2.27 (0.95)	0.2	1.70	2.50	3.00	3.6	
			Placebo	49	44 (89.8)	2.06 (0.89)	0.2	1.40	2.40	2.80	3.6	
		Week 6	Tezepelumab	51	48 (94.1)	2.21 (0.98)	0.2	1.50	2.30	3.00	4.0	
			Placebo	49	44 (89.8)	1.98 (1.07)	0.2	1.10	2.10	2.60	5.0	
		Week 8	Tezepelumab	51	48 (94.1)	2.05 (1.15)	0.0	1.20	2.10	3.00	5.2	
			Placebo	49	44 (89.8)	1.96 (1.11)	0.0	0.90	2.00	2.90	4.6	
		Week 10	Tezepelumab	51	48 (94.1)	1.98 (1.07)	0.0	1.20	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	2.05 (1.15)	0.0	1.30	2.10	2.80	5.2	
		Week 12	Tezepelumab	51	48 (94.1)	1.87 (1.04)	0.0	1.10	2.00	2.70	4.8	
			Placebo	49	44 (89.8)	1.75 (1.04)	0.0	1.00	1.90	2.50	4.4	
		Week 14	Tezepelumab	51	48 (94.1)	1.80 (1.12)	0.0	0.80	1.80	2.60	4.8	
			Placebo	49	44 (89.8)	1.79 (1.07)	0.0	1.00	1.80	2.30	5.0	
		Week 16	Tezepelumab	51	48 (94.1)	2.00 (1.14)	0.0	1.10	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.86 (1.16)	0.0	0.80	2.00	2.70	5.0	
		Week 18	Tezepelumab	51	49 (96.1)	1.91 (1.06)	0.0	1.00	2.00	2.60	4.8	
			Placebo	49	44 (89.8)	1.71 (1.15)	0.0	0.90	1.80	2.40	5.0	
		Week 20	Tezepelumab	51	49 (96.1)	1.93 (1.12)	0.0	1.00	2.00	2.60	5.0	
			Placebo	49	44 (89.8)	1.88 (1.18)	0.0	0.90	1.90	2.80	5.0	
		Week 22	Tezepelumab	51	49 (96.1)	1.99 (0.97)	0.0	1.40	2.20	2.60	4.8	
			Placebo	49	44 (89.8)	1.79 (1.18)	0.0	0.80	1.80	2.60	5.0	
		Week 24	Tezepelumab	51	49 (96.1)	2.00 (1.06)	0.0	1.20	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.88 (1.08)	0.0	1.00	2.00	2.60	4.4	
		Week 26	Tezepelumab	51	50 (98.0)	2.04 (1.09)	0.0	1.40	2.10	2.80	4.8	
			Placebo	49	44 (89.8)	1.79 (1.08)	0.0	1.00	1.60	2.50	4.4	
		Week 28	Tezepelumab	51	51 (100.0)	1.93 (1.13)	0.0	1.20	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.84 (1.21)	0.0	0.90	1.70	2.80	4.4	
		Week 30	Tezepelumab	51	51 (100.0)	1.93 (1.07)	0.0	1.20	2.00	2.60	4.8	
			Placebo	49	44 (89.8)	1.79 (1.19)	0.0	0.80	1.90	2.70	4.4	
		Week 32	Tezepelumab	51	51 (100.0)	1.87 (1.10)	0.0	1.00	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.72 (1.05)	0.0	0.80	1.80	2.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	51	51 (100.0)	1.93 (1.15)	0.0	1.00	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.74 (1.04)	0.0	0.80	1.80	2.40	4.4	
		Week 36	Tezepelumab	51	51 (100.0)	1.87 (1.09)	0.0	1.00	2.00	2.60	4.8	
			Placebo	49	44 (89.8)	1.89 (1.13)	0.0	1.00	1.90	2.70	4.4	
		Week 38	Tezepelumab	51	51 (100.0)	1.93 (1.20)	0.0	1.00	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.74 (1.03)	0.0	1.00	1.80	2.40	4.4	
		Week 40	Tezepelumab	51	51 (100.0)	1.92 (1.16)	0.0	1.00	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.90 (1.14)	0.0	1.00	1.90	2.70	4.4	
		Week 42	Tezepelumab	51	51 (100.0)	1.85 (1.14)	0.0	1.00	1.80	2.80	4.8	
			Placebo	49	44 (89.8)	1.75 (0.98)	0.0	1.00	1.90	2.40	4.4	
		Week 44	Tezepelumab	51	51 (100.0)	1.87 (1.12)	0.0	0.80	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.87 (1.05)	0.0	1.00	1.80	2.70	4.4	
		Week 46	Tezepelumab	51	51 (100.0)	1.91 (1.16)	0.0	0.80	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.73 (1.00)	0.0	1.00	1.80	2.20	4.4	
		Week 48	Tezepelumab	51	51 (100.0)	1.92 (1.17)	0.0	1.00	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.78 (1.08)	0.0	1.00	2.00	2.40	4.6	
		Week 50	Tezepelumab	51	51 (100.0)	1.89 (1.20)	0.0	1.00	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.69 (0.97)	0.0	1.00	1.80	2.40	4.4	
		Week 52	Tezepelumab	51	51 (100.0)	1.89 (1.20)	0.0	1.00	2.00	2.80	4.8	
			Placebo	49	44 (89.8)	1.75 (1.03)	0.0	1.00	1.80	2.50	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 2	Tezepelumab	51	48 (94.1)	-0.52 (0.83)	-3.2	-1.10	-0.40	0.20	0.8	0.01 [-0.40, 0.42]
			Placebo	49	44 (89.8)	-0.53 (0.75)	-2.8	-1.00	-0.40	0.00	1.2	
		Week 4	Tezepelumab	51	48 (94.1)	-0.72 (0.96)	-2.6	-1.30	-0.70	-0.10	2.6	0.05 [-0.35, 0.46]
			Placebo	49	44 (89.8)	-0.78 (0.96)	-3.0	-1.40	-0.60	0.00	0.8	
		Week 6	Tezepelumab	51	48 (94.1)	-0.78 (1.05)	-2.8	-1.40	-0.80	0.00	2.6	0.07 [-0.34, 0.48]
			Placebo	49	44 (89.8)	-0.86 (1.04)	-3.4	-1.60	-0.60	0.00	1.6	
		Week 8	Tezepelumab	51	48 (94.1)	-0.94 (1.22)	-3.2	-1.60	-1.00	-0.40	2.6	-0.06 [-0.47, 0.35]
			Placebo	49	44 (89.8)	-0.88 (1.05)	-3.6	-1.50	-0.70	-0.10	1.0	
		Week 10	Tezepelumab	51	48 (94.1)	-1.02 (1.16)	-3.4	-1.60	-1.10	-0.20	2.6	-0.20 [-0.61, 0.21]
			Placebo	49	44 (89.8)	-0.79 (1.17)	-3.8	-1.40	-0.60	0.00	2.6	
		Week 12	Tezepelumab	51	48 (94.1)	-1.13 (1.15)	-3.2	-1.70	-1.20	-0.50	2.6	-0.04 [-0.45, 0.37]
			Placebo	49	44 (89.8)	-1.08 (1.02)	-3.8	-1.60	-1.00	-0.40	1.2	
		Week 14	Tezepelumab	51	48 (94.1)	-1.20 (1.20)	-4.0	-1.90	-1.20	-0.40	2.6	-0.13 [-0.54, 0.28]
			Placebo	49	44 (89.8)	-1.05 (1.11)	-3.4	-1.60	-1.20	-0.40	2.4	
		Week 16	Tezepelumab	51	48 (94.1)	-1.00 (1.20)	-3.2	-1.50	-1.00	-0.40	2.6	-0.02 [-0.43, 0.39]
			Placebo	49	44 (89.8)	-0.98 (1.12)	-3.6	-1.50	-1.00	-0.20	2.4	
		Week 18	Tezepelumab	51	49 (96.1)	-1.07 (1.16)	-3.8	-1.40	-1.00	-0.60	2.6	0.05 [-0.35, 0.46]
			Placebo	49	44 (89.8)	-1.13 (1.18)	-3.6	-2.10	-1.20	-0.20	2.4	
		Week 20	Tezepelumab	51	49 (96.1)	-1.04 (1.16)	-3.4	-1.80	-1.00	-0.40	2.6	-0.07 [-0.48, 0.33]
			Placebo	49	44 (89.8)	-0.95 (1.19)	-3.6	-1.60	-0.80	-0.20	2.4	
		Week 22	Tezepelumab	51	49 (96.1)	-0.98 (1.19)	-3.2	-1.60	-1.00	-0.40	2.6	0.06 [-0.35, 0.46]
			Placebo	49	44 (89.8)	-1.05 (1.16)	-3.8	-1.70	-1.00	-0.40	2.4	
		Week 24	Tezepelumab	51	49 (96.1)	-0.98 (1.14)	-3.4	-1.80	-0.80	-0.40	2.6	-0.02 [-0.43, 0.39]
			Placebo	49	44 (89.8)	-0.95 (1.11)	-3.6	-1.70	-0.80	-0.10	1.4	
		Week 26	Tezepelumab	51	50 (98.0)	-0.91 (1.18)	-3.0	-2.00	-0.70	-0.20	2.6	0.12 [-0.29, 0.52]
			Placebo	49	44 (89.8)	-1.05 (1.12)	-3.4	-1.90	-1.20	-0.20	1.6	
		Week 28	Tezepelumab	51	51 (100.0)	-1.02 (1.26)	-3.4	-2.20	-0.80	0.00	2.6	-0.01 [-0.42, 0.39]
			Placebo	49	44 (89.8)	-1.00 (1.20)	-3.4	-1.90	-1.10	-0.10	1.6	
		Week 30	Tezepelumab	51	51 (100.0)	-1.01 (1.25)	-3.8	-2.20	-1.00	-0.20	2.6	0.03 [-0.38, 0.43]
			Placebo	49	44 (89.8)	-1.05 (1.24)	-3.4	-1.70	-1.20	-0.20	2.0	
		Week 32	Tezepelumab	51	51 (100.0)	-1.08 (1.17)	-3.2	-2.20	-1.00	-0.40	2.6	0.04 [-0.37, 0.44]
			Placebo	49	44 (89.8)	-1.12 (1.09)	-3.2	-1.80	-1.20	-0.30	1.4	
		Week 34	Tezepelumab	51	51 (100.0)	-1.01 (1.26)	-3.0	-2.20	-1.00	-0.20	2.6	0.07 [-0.33, 0.48]
			Placebo	49	44 (89.8)	-1.10 (1.02)	-3.2	-1.70	-1.10	-0.30	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	51	51 (100.0)	-1.08 (1.24)	-3.2	-2.00	-1.20	0.00	2.6	-0.11 [-0.51, 0.30]
			Placebo	49	44 (89.8)	-0.95 (1.16)	-3.6	-1.50	-1.00	-0.10	1.4	
		Week 38	Tezepelumab	51	51 (100.0)	-1.02 (1.30)	-3.2	-2.20	-1.20	0.00	2.6	0.07 [-0.34, 0.47]
			Placebo	49	44 (89.8)	-1.10 (1.05)	-3.2	-2.00	-1.00	-0.40	1.4	
		Week 40	Tezepelumab	51	51 (100.0)	-1.02 (1.28)	-3.4	-2.00	-1.00	0.00	2.6	-0.07 [-0.48, 0.33]
			Placebo	49	44 (89.8)	-0.93 (1.17)	-3.2	-1.80	-0.90	-0.20	1.4	
		Week 42	Tezepelumab	51	51 (100.0)	-1.09 (1.29)	-3.6	-2.00	-1.20	-0.40	2.6	-0.00 [-0.41, 0.40]
			Placebo	49	44 (89.8)	-1.09 (1.03)	-2.8	-1.70	-1.10	-0.40	1.4	
		Week 44	Tezepelumab	51	51 (100.0)	-1.07 (1.27)	-3.8	-2.00	-1.20	-0.20	2.6	-0.09 [-0.50, 0.31]
			Placebo	49	44 (89.8)	-0.96 (1.10)	-3.4	-1.70	-1.00	-0.20	1.6	
		Week 46	Tezepelumab	51	51 (100.0)	-1.04 (1.27)	-3.6	-2.20	-1.00	-0.20	2.6	0.06 [-0.34, 0.46]
			Placebo	49	44 (89.8)	-1.11 (1.05)	-3.2	-1.70	-1.10	-0.60	1.6	
		Week 48	Tezepelumab	51	51 (100.0)	-1.03 (1.24)	-3.0	-2.00	-1.00	-0.40	2.6	0.03 [-0.38, 0.43]
			Placebo	49	44 (89.8)	-1.06 (1.12)	-3.4	-1.60	-1.00	-0.30	1.8	
		Week 50	Tezepelumab	51	51 (100.0)	-1.06 (1.29)	-3.2	-2.00	-1.20	-0.20	2.6	0.07 [-0.33, 0.48]
			Placebo	49	44 (89.8)	-1.15 (0.99)	-3.6	-1.70	-1.00	-0.40	1.6	
		Week 52	Tezepelumab	51	51 (100.0)	-1.05 (1.29)	-3.2	-2.00	-1.00	-0.20	2.6	0.03 [-0.38, 0.43]
			Placebo	49	44 (89.8)	-1.08 (1.04)	-3.6	-1.80	-1.00	-0.40	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	2.61 (0.41)	2.2	2.20	2.40	3.00	3.4	
			Placebo	16	16 (100.0)	2.95 (0.99)	0.4	2.90	3.00	3.30	5.0	
		Week 2	Tezepelumab	15	15 (100.0)	1.92 (0.92)	0.2	1.00	2.00	2.80	3.2	
			Placebo	16	14 (87.5)	2.69 (0.83)	1.4	2.20	2.50	3.00	5.0	
		Week 4	Tezepelumab	15	15 (100.0)	1.47 (0.94)	0.2	0.60	1.40	2.40	3.0	
			Placebo	16	14 (87.5)	2.86 (0.74)	2.0	2.20	2.70	3.60	4.2	
		Week 6	Tezepelumab	15	15 (100.0)	1.20 (0.86)	0.0	0.60	1.00	1.80	3.0	
			Placebo	16	14 (87.5)	2.96 (1.13)	1.2	2.20	2.90	3.20	6.0	
		Week 8	Tezepelumab	15	15 (100.0)	1.05 (0.95)	0.0	0.00	1.00	1.60	2.8	
			Placebo	16	15 (93.8)	2.63 (1.12)	0.2	2.20	2.40	3.20	5.0	
		Week 10	Tezepelumab	15	15 (100.0)	0.91 (0.95)	0.0	0.00	0.80	1.40	3.2	
			Placebo	16	15 (93.8)	2.47 (0.81)	0.8	2.00	2.60	3.00	4.0	
		Week 12	Tezepelumab	15	15 (100.0)	0.80 (0.92)	0.0	0.00	0.60	1.60	2.8	
			Placebo	16	15 (93.8)	2.49 (0.95)	0.0	2.00	2.60	3.00	4.4	
		Week 14	Tezepelumab	15	15 (100.0)	0.79 (0.73)	0.0	0.00	0.60	1.40	2.2	
			Placebo	16	15 (93.8)	2.11 (0.77)	0.0	1.80	2.20	2.60	3.2	
		Week 16	Tezepelumab	15	15 (100.0)	0.77 (0.76)	0.0	0.00	0.60	1.40	2.6	
			Placebo	16	15 (93.8)	2.55 (1.25)	0.0	2.00	2.60	3.20	5.0	
		Week 18	Tezepelumab	15	15 (100.0)	0.89 (0.74)	0.0	0.00	1.00	1.60	2.0	
			Placebo	16	15 (93.8)	2.59 (1.03)	0.0	2.40	2.60	2.80	4.8	
		Week 20	Tezepelumab	15	15 (100.0)	0.84 (0.77)	0.0	0.00	0.80	1.20	2.8	
			Placebo	16	15 (93.8)	2.48 (0.77)	1.0	2.00	2.60	2.80	4.0	
		Week 22	Tezepelumab	15	15 (100.0)	1.07 (0.92)	0.0	0.00	1.00	1.60	2.8	
			Placebo	16	15 (93.8)	2.56 (0.91)	0.8	1.80	2.60	3.40	4.0	
		Week 24	Tezepelumab	15	15 (100.0)	0.89 (0.83)	0.0	0.00	0.80	1.40	2.8	
			Placebo	16	15 (93.8)	2.53 (0.87)	0.8	2.00	2.40	3.40	4.0	
		Week 26	Tezepelumab	15	15 (100.0)	0.96 (0.80)	0.0	0.00	1.00	1.40	2.4	
			Placebo	16	15 (93.8)	2.53 (1.15)	0.0	1.60	2.60	3.40	4.0	
		Week 28	Tezepelumab	15	15 (100.0)	1.07 (1.04)	0.0	0.00	1.00	2.20	3.0	
			Placebo	16	16 (100.0)	2.30 (1.24)	0.0	1.60	2.60	3.30	4.0	
		Week 30	Tezepelumab	15	15 (100.0)	0.91 (0.81)	0.0	0.00	0.80	1.40	2.4	
			Placebo	16	16 (100.0)	2.34 (1.10)	0.0	1.70	2.40	3.30	4.0	
		Week 32	Tezepelumab	15	15 (100.0)	0.83 (0.80)	0.0	0.00	0.80	1.40	2.2	
			Placebo	16	16 (100.0)	2.41 (1.24)	0.0	1.60	2.30	3.30	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	15	15 (100.0)	0.95 (1.02)	0.0	0.00	0.80	1.40	3.0	
			Placebo	16	16 (100.0)	2.25 (1.33)	0.2	1.30	2.20	3.30	4.8	
		Week 36	Tezepelumab	15	15 (100.0)	0.99 (0.89)	0.0	0.00	1.00	1.40	2.8	
			Placebo	16	16 (100.0)	2.51 (1.28)	0.0	1.70	2.50	3.30	4.8	
		Week 38	Tezepelumab	15	15 (100.0)	1.00 (1.09)	0.0	0.00	0.60	2.00	3.0	
			Placebo	16	16 (100.0)	2.44 (1.26)	0.0	1.70	2.60	3.30	4.8	
		Week 40	Tezepelumab	15	15 (100.0)	0.93 (0.92)	0.0	0.00	0.80	1.80	2.6	
			Placebo	16	16 (100.0)	2.50 (1.26)	0.0	1.60	2.70	3.30	4.4	
		Week 42	Tezepelumab	15	15 (100.0)	0.92 (0.88)	0.0	0.00	1.00	1.40	2.6	
			Placebo	16	16 (100.0)	2.40 (1.15)	0.0	2.00	2.50	3.00	4.6	
		Week 44	Tezepelumab	15	15 (100.0)	1.03 (0.98)	0.0	0.00	1.00	1.60	3.0	
			Placebo	16	16 (100.0)	2.38 (1.24)	0.0	1.50	2.40	3.30	4.2	
		Week 46	Tezepelumab	15	15 (100.0)	1.04 (1.08)	0.0	0.00	1.00	1.80	3.2	
			Placebo	16	16 (100.0)	2.31 (0.94)	0.0	1.90	2.40	2.90	4.0	
		Week 48	Tezepelumab	15	15 (100.0)	1.01 (0.98)	0.0	0.00	0.80	1.80	3.0	
			Placebo	16	16 (100.0)	2.40 (1.04)	0.0	2.00	2.40	3.00	4.0	
		Week 50	Tezepelumab	15	15 (100.0)	0.84 (0.83)	0.0	0.00	0.80	1.40	2.6	
			Placebo	16	16 (100.0)	2.19 (1.12)	0.0	1.60	2.40	2.90	4.0	
		Week 52	Tezepelumab	15	15 (100.0)	0.95 (0.82)	0.0	0.00	0.80	1.60	2.6	
			Placebo	16	16 (100.0)	2.27 (1.18)	0.0	1.60	2.40	3.00	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 2	Tezepelumab	15	15 (100.0)	-0.69 (0.68)	-2.0	-1.20	-0.40	-0.20	0.2	-0.42 [-1.15, 0.32]
			Placebo	16	14 (87.5)	-0.41 (0.66)	-1.6	-1.00	-0.50	0.00	1.0	
		Week 4	Tezepelumab	15	15 (100.0)	-1.15 (0.77)	-2.6	-1.60	-1.20	-0.40	0.0	-1.09 [-1.87, -0.30]
			Placebo	16	14 (87.5)	-0.24 (0.90)	-1.4	-1.00	-0.10	0.60	1.2	
		Week 6	Tezepelumab	15	15 (100.0)	-1.41 (0.79)	-2.8	-1.80	-1.40	-0.80	0.2	-1.48 [-2.30, -0.65]
			Placebo	16	14 (87.5)	-0.14 (0.93)	-1.8	-0.80	-0.20	0.40	1.6	
		Week 8	Tezepelumab	15	15 (100.0)	-1.56 (0.77)	-2.8	-2.20	-1.60	-1.40	0.0	-1.16 [-1.94, -0.38]
			Placebo	16	15 (93.8)	-0.49 (1.05)	-2.8	-1.00	-0.40	0.20	1.0	
		Week 10	Tezepelumab	15	15 (100.0)	-1.71 (0.80)	-2.8	-2.20	-2.00	-1.40	0.4	-1.05 [-1.82, -0.28]
			Placebo	16	15 (93.8)	-0.65 (1.17)	-2.2	-1.60	-0.40	-0.20	2.6	
		Week 12	Tezepelumab	15	15 (100.0)	-1.81 (0.74)	-2.8	-2.20	-2.20	-1.40	0.0	-1.18 [-1.96, -0.40]
			Placebo	16	15 (93.8)	-0.63 (1.21)	-3.0	-1.60	-0.60	0.00	1.6	
		Week 14	Tezepelumab	15	15 (100.0)	-1.83 (0.56)	-2.6	-2.20	-2.00	-1.60	-0.6	-1.00 [-1.76, -0.24]
			Placebo	16	15 (93.8)	-1.01 (1.01)	-3.0	-1.60	-1.00	-0.60	1.4	
		Week 16	Tezepelumab	15	15 (100.0)	-1.84 (0.65)	-2.8	-2.20	-2.00	-1.60	-0.2	-1.22 [-2.00, -0.44]
			Placebo	16	15 (93.8)	-0.57 (1.32)	-3.0	-1.40	-0.60	0.00	2.6	
		Week 18	Tezepelumab	15	15 (100.0)	-1.72 (0.70)	-2.8	-2.20	-1.80	-1.40	-0.2	-1.13 [-1.91, -0.36]
			Placebo	16	15 (93.8)	-0.53 (1.31)	-3.0	-1.20	-0.60	-0.20	2.6	
		Week 20	Tezepelumab	15	15 (100.0)	-1.77 (0.62)	-2.8	-2.20	-1.80	-1.40	-0.4	-1.23 [-2.01, -0.44]
			Placebo	16	15 (93.8)	-0.64 (1.15)	-2.0	-1.40	-0.80	-0.20	2.6	
		Week 22	Tezepelumab	15	15 (100.0)	-1.55 (0.80)	-2.8	-2.40	-1.60	-0.80	-0.2	-0.96 [-1.71, -0.20]
			Placebo	16	15 (93.8)	-0.56 (1.22)	-2.2	-1.60	-0.60	0.20	2.6	
		Week 24	Tezepelumab	15	15 (100.0)	-1.72 (0.69)	-2.8	-2.20	-1.80	-1.60	-0.2	-1.16 [-1.94, -0.39]
			Placebo	16	15 (93.8)	-0.59 (1.19)	-2.2	-1.40	-1.00	0.20	2.6	
		Week 26	Tezepelumab	15	15 (100.0)	-1.65 (0.73)	-2.8	-2.20	-1.60	-1.40	-0.2	-0.97 [-1.73, -0.21]
			Placebo	16	15 (93.8)	-0.59 (1.37)	-3.0	-1.40	-1.20	0.40	2.6	
		Week 28	Tezepelumab	15	15 (100.0)	-1.55 (0.92)	-2.8	-2.20	-1.60	-0.80	0.2	-0.79 [-1.52, -0.05]
			Placebo	16	16 (100.0)	-0.65 (1.31)	-3.0	-1.50	-0.90	0.10	2.6	
		Week 30	Tezepelumab	15	15 (100.0)	-1.71 (0.69)	-2.8	-2.20	-1.60	-1.00	-0.6	-1.13 [-1.89, -0.37]
			Placebo	16	16 (100.0)	-0.61 (1.17)	-1.8	-1.40	-1.00	-0.10	2.6	
		Week 32	Tezepelumab	15	15 (100.0)	-1.79 (0.62)	-2.8	-2.20	-1.80	-1.20	-0.8	-1.21 [-1.98, -0.44]
			Placebo	16	16 (100.0)	-0.54 (1.31)	-1.8	-1.40	-1.10	0.00	2.6	
		Week 34	Tezepelumab	15	15 (100.0)	-1.67 (0.82)	-2.8	-2.20	-1.80	-0.80	0.0	-0.81 [-1.54, -0.07]
			Placebo	16	16 (100.0)	-0.70 (1.46)	-2.8	-1.70	-1.20	0.10	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_ILSHP: Change from baseline in ACQ-5 score by study specific subgroups
DITTL

Subgroup	ACQ-5 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	15	15 (100.0)	-1.63 (0.84)	-2.8	-2.20	-1.80	-0.80	0.0	-1.05 [-1.81, -0.30]
			Placebo	16	16 (100.0)	-0.44 (1.35)	-2.2	-1.40	-0.80	0.00	2.6	
		Week 38	Tezepelumab	15	15 (100.0)	-1.61 (0.81)	-2.8	-2.20	-1.80	-0.80	0.0	-0.99 [-1.74, -0.24]
			Placebo	16	16 (100.0)	-0.51 (1.32)	-2.6	-1.40	-0.80	0.10	2.6	
		Week 40	Tezepelumab	15	15 (100.0)	-1.68 (0.76)	-2.8	-2.20	-1.60	-0.80	-0.4	-1.15 [-1.91, -0.38]
			Placebo	16	16 (100.0)	-0.45 (1.30)	-2.2	-1.40	-0.60	0.30	2.6	
		Week 42	Tezepelumab	15	15 (100.0)	-1.69 (0.72)	-2.8	-2.20	-1.80	-1.00	-0.4	-1.12 [-1.88, -0.36]
			Placebo	16	16 (100.0)	-0.55 (1.24)	-2.4	-1.40	-0.80	-0.10	2.6	
		Week 44	Tezepelumab	15	15 (100.0)	-1.59 (0.87)	-2.8	-2.20	-1.60	-0.80	0.0	-0.92 [-1.66, -0.17]
			Placebo	16	16 (100.0)	-0.58 (1.28)	-2.4	-1.50	-0.90	0.10	2.6	
		Week 46	Tezepelumab	15	15 (100.0)	-1.57 (0.90)	-2.8	-2.20	-1.60	-0.80	0.2	-0.96 [-1.71, -0.21]
			Placebo	16	16 (100.0)	-0.64 (1.04)	-1.8	-1.20	-1.00	-0.20	2.6	
		Week 48	Tezepelumab	15	15 (100.0)	-1.60 (0.90)	-2.8	-2.40	-2.00	-0.80	0.0	-1.03 [-1.78, -0.28]
			Placebo	16	16 (100.0)	-0.55 (1.12)	-2.0	-1.30	-0.60	-0.30	2.6	
		Week 50	Tezepelumab	15	15 (100.0)	-1.77 (0.73)	-2.8	-2.40	-2.00	-1.20	-0.4	-1.00 [-1.75, -0.25]
			Placebo	16	16 (100.0)	-0.76 (1.22)	-2.8	-1.50	-0.80	-0.30	2.6	
		Week 52	Tezepelumab	15	15 (100.0)	-1.67 (0.68)	-2.6	-2.20	-1.60	-1.20	-0.4	-0.97 [-1.72, -0.22]
			Placebo	16	16 (100.0)	-0.67 (1.26)	-2.8	-1.50	-0.70	-0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_ILMP0: Decrease of at least 0.9 points in ACQ-6 score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in ACQ-6 score	Week 28	66	66 (100.0)	35 (53.0) [40.3, 65.4]	65	60 (92.3)	29 (44.6) [32.3, 57.5]	1.189 [0.835, 1.693]	1.402 [0.705, 2.788]	8.4 [-10.2, 27.0]	0.337
	Week 52	66	66 (100.0)	39 (59.1) [46.3, 71.0]	65	60 (92.3)	27 (41.5) [29.4, 54.4]	1.423 [1.001, 2.022]	2.033 [1.014, 4.077]	17.6 [-0.8, 35.9]	0.045 *

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_ILSPK: Decrease of at least 0.9 points in ACQ-6 score by key subgroups
DITTL

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.613	
Male	19	19 (100.0)	11 (57.9) [33.5, 79.7]	20	19 (95.0)	7 (35.0) [15.4, 59.2]	1.654 [0.813, 3.364]	2.554 [0.700, 9.311]	22.9 [-12.7, 58.5]	0.157	
Female	47	47 (100.0)	28 (59.6) [44.3, 73.6]	45	41 (91.1)	20 (44.4) [29.6, 60.0]	1.340 [0.896, 2.005]	1.842 [0.805, 4.215]	15.1 [-7.2, 37.5]	0.149	
Age										0.234	
< 65 years	57	57 (100.0)	35 (61.4) [47.6, 74.0]	55	51 (92.7)	26 (47.3) [33.7, 61.2]	1.299 [0.918, 1.837]	1.774 [0.837, 3.762]	14.1 [-5.9, 34.2]	0.135	
>= 65 years	9	9 (100.0)	4 (44.4) [13.7, 78.8]	10	9 (90.0)	1 (10.0) [0.3, 44.5]	4.444 [0.603, 32.765]	7.200 [0.622, 83.342]	34.4 [-13.5, 82.4]	0.141	#
Exacerbations in the year before study										0.384	
<= 2	44	44 (100.0)	25 (56.8) [41.0, 71.7]	45	41 (91.1)	20 (44.4) [29.6, 60.0]	1.278 [0.843, 1.938]	1.645 [0.712, 3.801]	12.4 [-10.5, 35.2]	0.246	
> 2	22	22 (100.0)	14 (63.6) [40.7, 82.8]	20	19 (95.0)	7 (35.0) [15.4, 59.2]	1.818 [0.925, 3.573]	3.250 [0.918, 11.509]	28.6 [-5.1, 62.4]	0.067	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_ILSPK: Decrease of at least 0.9 points in ACQ-6 score by key subgroups
DITTL

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race		N<10	any level							NE	
White	60	60 (100.0)	34 (56.7) [43.2, 69.4]	58	53 (91.4)	23 (39.7) [27.0, 53.4]					
Black or African American	2	2 (100.0)	2 (100.0) [15.8, 100.0]	2	2 (100.0)	1 (50.0) [1.3, 98.7]					
Asian	3	3 (100.0)	3 (100.0) [29.2, 100.0]	3	3 (100.0)	1 (33.3) [0.8, 90.6]					
Other	1	1 (100.0)	0 (0.0) [0.0, 97.5]	2	2 (100.0)	2 (100.0) [15.8, 100.0]					
Region		N<10	any level							NE	
Europe	40	40 (100.0)	22 (55.0) [38.5, 70.7]	36	33 (91.7)	11 (30.6) [16.3, 48.1]					
America	6	6 (100.0)	5 (83.3) [35.9, 99.6]	4	3 (75.0)	2 (50.0) [6.8, 93.2]					
Asia/Pacific	3	3 (100.0)	3 (100.0) [29.2, 100.0]	3	3 (100.0)	1 (33.3) [0.8, 90.6]					
Rest of the world	17	17 (100.0)	9 (52.9) [27.8, 77.0]	22	21 (95.5)	13 (59.1) [36.4, 79.3]					
BMI										0.021	i
18.5 - < 25.0 kg/m**2	15	15 (100.0)	12 (80.0) [51.9, 95.7]	21	20 (95.2)	7 (33.3) [14.6, 57.0]	2.400 [1.246, 4.623]	8.000 [1.686, 37.951]	46.7 [12.4, 81.0]	0.006	*
25.0 - < 30.0 kg/m**2	24	24 (100.0)	16 (66.7) [44.7, 84.4]	20	18 (90.0)	7 (35.0) [15.4, 59.2]	1.905 [0.984, 3.688]	3.714 [1.063, 12.975]	31.7 [-1.1, 64.4]	0.038	*
>= 30.0 kg/m**2	27	27 (100.0)	11 (40.7) [22.4, 61.2]	24	22 (91.7)	13 (54.2) [32.8, 74.4]	0.752 [0.419, 1.350]	0.582 [0.192, 1.767]	-13.4 [-44.6, 17.7]	0.342	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_ILSPK: Decrease of at least 0.9 points in ACQ-6 score by key subgroups
DITTL

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.838	
< 150 cells/uL	11	11 (100.0)	5 (45.5) [16.7, 76.6]	14	12 (85.7)	5 (35.7) [12.8, 64.9]	1.273 [0.490, 3.309]	1.500 [0.299, 7.531]	9.7 [-37.1, 56.5]	0.697	#
>= 150 cells/uL	54	54 (100.0)	33 (61.1) [46.9, 74.1]	51	48 (94.1)	22 (43.1) [29.3, 57.8]	1.417 [0.969, 2.072]	2.071 [0.951, 4.513]	18.0 [-2.7, 38.7]	0.067	
Baseline eosinophils - High										0.537	
< 300 cells/uL	33	33 (100.0)	17 (51.5) [33.5, 69.2]	34	30 (88.2)	14 (41.2) [24.6, 59.3]	1.251 [0.743, 2.106]	1.518 [0.578, 3.987]	10.3 [-16.4, 37.1]	0.400	
>= 300 cells/uL	32	32 (100.0)	21 (65.6) [46.8, 81.4]	31	30 (96.8)	13 (41.9) [24.5, 60.9]	1.565 [0.964, 2.540]	2.643 [0.953, 7.333]	23.7 [-3.4, 50.8]	0.061	
Baseline FENO										0.368	
< 25 ppb	39	39 (100.0)	19 (48.7) [32.4, 65.2]	30	26 (86.7)	12 (40.0) [22.7, 59.4]	1.218 [0.707, 2.098]	1.425 [0.544, 3.734]	8.7 [-17.8, 35.2]	0.474	
>= 25 ppb	27	27 (100.0)	20 (74.1) [53.7, 88.9]	34	33 (97.1)	15 (44.1) [27.2, 62.1]	1.679 [1.082, 2.605]	3.619 [1.211, 10.819]	30.0 [3.1, 56.8]	0.020	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_ILSPK: Decrease of at least 0.9 points in ACQ-6 score by key subgroups
DITTL

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.056	
All negative	27	27 (100.0)	15 (55.6) [35.3, 74.5]	29	27 (93.1)	7 (24.1) [10.3, 43.5]	2.302 [1.111, 4.767]	3.929 [1.256, 12.284]	31.4 [3.5, 59.4]	0.017	*
Any positive	34	34 (100.0)	20 (58.8) [40.7, 75.4]	33	30 (90.9)	19 (57.6) [39.2, 74.5]	1.022 [0.681, 1.533]	1.053 [0.399, 2.780]	1.2 [-25.4, 27.9]	0.918	
Total serum IgE										0.311	
Low	23	23 (100.0)	11 (47.8) [26.8, 69.4]	14	11 (78.6)	2 (14.3) [1.8, 42.8]	3.348 [0.866, 12.943]	5.500 [0.999, 30.286]	33.5 [0.4, 66.7]	0.074	#
Normal	40	40 (100.0)	26 (65.0) [48.3, 79.4]	44	42 (95.5)	20 (45.5) [30.4, 61.2]	1.430 [0.963, 2.124]	2.229 [0.924, 5.372]	19.5 [-3.7, 42.8]	0.074	
High	3	3 (100.0)	2 (66.7) [9.4, 99.2]	7	7 (100.0)	5 (71.4) [29.0, 96.3]	0.933 [0.369, 2.359]	0.800 [0.044, 14.643]	-4.8 [-91.5, 82.0]	1.000	#
OCS at baseline										0.634	
Yes	9	9 (100.0)	7 (77.8) [40.0, 97.2]	13	13 (100.0)	6 (46.2) [19.2, 74.9]	1.685 [0.851, 3.337]	4.083 [0.603, 27.650]	31.6 [-16.1, 79.4]	0.203	#
No	57	57 (100.0)	32 (56.1) [42.4, 69.3]	52	47 (90.4)	21 (40.4) [27.0, 54.9]	1.390 [0.930, 2.078]	1.890 [0.882, 4.048]	15.8 [-4.6, 36.1]	0.102	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_ILSPK: Decrease of at least 0.9 points in ACQ-6 score by key subgroups
DITTL

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline										0.294
Yes	7	7 (100.0)	5 (71.4) [29.0, 96.3]	3	3 (100.0)	0 (0.0) [0.0, 70.8]	5.500 + [0.395, 76.653]	15.400 + [0.557, 425.527]	71.4 [14.2, 100.0]	0.167 #
No	59	59 (100.0)	34 (57.6) [44.1, 70.4]	62	57 (91.9)	27 (43.5) [31.0, 56.7]	1.323 [0.925, 1.893]	1.763 [0.858, 3.623]	14.1 [-5.2, 33.4]	0.123
Tiotropium use at baseline		N<10	any level							NE
Yes	6	6 (100.0)	4 (66.7) [22.3, 95.7]	2	2 (100.0)	0 (0.0) [0.0, 84.2]				
No	60	60 (100.0)	35 (58.3) [44.9, 70.9]	63	58 (92.1)	27 (42.9) [30.5, 56.0]				
Montelukast/ Cromoglicic acid use at baseline										0.999
Yes	17	17 (100.0)	13 (76.5) [50.1, 93.2]	21	21 (100.0)	11 (52.4) [29.8, 74.3]	1.460 [0.898, 2.373]	2.955 [0.721, 12.107]	24.1 [-10.6, 58.8]	0.131
No	49	49 (100.0)	26 (53.1) [38.3, 67.5]	44	39 (88.6)	16 (36.4) [22.4, 52.2]	1.459 [0.911, 2.338]	1.978 [0.861, 4.545]	16.7 [-5.4, 38.8]	0.108

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_ILSPP: Decrease of at least 0.9 points in ACQ-6 score by study specific subgroups
DITTL

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.962	
White	60	60 (100.0)	34 (56.7) [43.2, 69.4]	58	53 (91.4)	23 (39.7) [27.0, 53.4]	1.429 [0.970, 2.104]	1.990 [0.956, 4.142]	17.0 [-2.5, 36.5]	0.066	
Non-white	6	6 (100.0)	5 (83.3) [35.9, 99.6]	7	7 (100.0)	4 (57.1) [18.4, 90.1]	1.458 [0.700, 3.040]	3.750 [0.274, 51.373]	26.2 [-36.5, 88.9]	0.559	#
Region (cat. P)										0.741	
North America/Western EU	6	6 (100.0)	5 (83.3) [35.9, 99.6]	4	3 (75.0)	2 (50.0) [6.8, 93.2]	1.667 [0.587, 4.731]	5.000 [0.273, 91.518]	33.3 [-44.9, 100.0]	0.500	#
Rest of world	60	60 (100.0)	34 (56.7) [43.2, 69.4]	61	57 (93.4)	25 (41.0) [28.6, 54.3]	1.383 [0.952, 2.009]	1.883 [0.915, 3.876]	15.7 [-3.6, 34.9]	0.086	
Baseline eosinophils (cat. P)										0.144	
< 250 cells/uL	30	30 (100.0)	14 (46.7) [28.3, 65.7]	29	26 (89.7)	13 (44.8) [26.4, 64.3]	1.041 [0.597, 1.816]	1.077 [0.387, 3.001]	1.8 [-27.0, 30.7]	0.888	
>= 250 cells/uL	36	36 (100.0)	25 (69.4) [51.9, 83.7]	36	34 (94.4)	14 (38.9) [23.1, 56.5]	1.786 [1.124, 2.838]	3.571 [1.346, 9.475]	30.6 [5.9, 55.2]	0.010	*
Baseline FENO (cat. P)										0.469	
< 24 ppb	38	38 (100.0)	19 (50.0) [33.4, 66.6]	30	26 (86.7)	12 (40.0) [22.7, 59.4]	1.250 [0.727, 2.148]	1.500 [0.570, 3.951]	10.0 [-16.6, 36.6]	0.414	
>= 24 ppb	28	28 (100.0)	20 (71.4) [51.3, 86.8]	34	33 (97.1)	15 (44.1) [27.2, 62.1]	1.619 [1.038, 2.526]	3.167 [1.094, 9.170]	27.3 [0.4, 54.2]	0.032	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_ILSPP: Decrease of at least 0.9 points in ACQ-6 score by study specific subgroups
DITTL

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. M)										0.220	
< 22.0 ppb	32	32 (100.0)	14 (43.8) [26.4, 62.3]	27	24 (88.9)	11 (40.7) [22.4, 61.2]	1.074 [0.589, 1.959]	1.131 [0.401, 3.194]	3.0 [-25.7, 31.7]	0.817	
>= 22.0 ppb	34	34 (100.0)	25 (73.5) [55.6, 87.1]	37	35 (94.6)	16 (43.2) [27.1, 60.5]	1.700 [1.117, 2.590]	3.646 [1.339, 9.928]	30.3 [5.7, 54.9]	0.010	*
Baseline all FEIA status										0.502	
All negative	25	25 (100.0)	13 (52.0) [31.3, 72.2]	22	20 (90.9)	7 (31.8) [13.9, 54.9]	1.634 [0.797, 3.352]	2.321 [0.705, 7.645]	20.2 [-11.7, 52.1]	0.167	
Any positive	35	35 (100.0)	21 (60.0) [42.1, 76.1]	41	38 (92.7)	20 (48.8) [32.9, 64.9]	1.230 [0.813, 1.861]	1.575 [0.633, 3.922]	11.2 [-13.7, 36.2]	0.331	
Th2 status										0.656	
Low	41	41 (100.0)	21 (51.2) [35.1, 67.1]	30	26 (86.7)	9 (30.0) [14.7, 49.4]	1.707 [0.916, 3.183]	2.450 [0.908, 6.609]	21.2 [-4.1, 46.5]	0.076	
High	25	25 (100.0)	18 (72.0) [50.6, 87.9]	34	33 (97.1)	17 (50.0) [32.4, 67.6]	1.440 [0.950, 2.182]	2.571 [0.854, 7.740]	22.0 [-5.8, 49.8]	0.092	
Baseline Periostin										0.044	i
Low (< 20.9 ng/ml)	26	26 (100.0)	10 (38.5) [20.2, 59.4]	31	28 (90.3)	14 (45.2) [27.3, 64.0]	0.852 [0.457, 1.586]	0.759 [0.263, 2.192]	-6.7 [-35.9, 22.5]	0.613	
High (>= 20.9 ng/ml)	40	40 (100.0)	29 (72.5) [56.1, 85.4]	34	32 (94.1)	13 (38.2) [22.2, 56.4]	1.896 [1.188, 3.028]	4.259 [1.599, 11.346]	34.3 [10.1, 58.4]	0.003	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_ILSPP: Decrease of at least 0.9 points in ACQ-6 score by study specific subgroups
DITTL

Decrease of at least 0.9 points in ACQ-6 score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility										0.241	
Yes	57	57 (100.0)	30 (52.6) [39.0, 66.0]	60	55 (91.7)	25 (41.7) [29.1, 55.1]	1.263 [0.857, 1.861]	1.556 [0.749, 3.230]	11.0 [-8.7, 30.7]	0.237	
No	9	9 (100.0)	9 (100.0) [66.4, 100.0]	5	5 (100.0)	2 (40.0) [5.3, 85.3]	2.500 [0.855, 7.314]	26.600 + [1.007, 702.939]	60.0 [1.5, 100.0]	0.027	*
Maintenance OCS use at baseline										0.829	
Yes	9	9 (100.0)	7 (77.8) [40.0, 97.2]	14	14 (100.0)	7 (50.0) [23.0, 77.0]	1.556 [0.829, 2.919]	3.500 [0.529, 23.137]	27.8 [-19.1, 74.6]	0.228	#
No	57	57 (100.0)	32 (56.1) [42.4, 69.3]	51	46 (90.2)	20 (39.2) [25.8, 53.9]	1.432 [0.949, 2.161]	1.984 [0.921, 4.276]	16.9 [-3.5, 37.4]	0.080	
No chronic OCS use and current post-BD FEV1 reversibility										0.432	
Yes	51	51 (100.0)	26 (51.0) [36.6, 65.2]	49	44 (89.8)	19 (38.8) [25.2, 53.8]	1.315 [0.844, 2.047]	1.642 [0.742, 3.635]	12.2 [-9.1, 33.6]	0.222	
No	15	15 (100.0)	13 (86.7) [59.5, 98.3]	16	16 (100.0)	8 (50.0) [24.7, 75.3]	1.733 [1.022, 2.941]	6.500 [1.094, 38.633]	36.7 [0.3, 73.1]	0.054	#

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aacq, created on: 11AUG2022

Table PT2H6I_ILMP0: Increase of at least 0.9 points in ACQ-6 score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in ACQ-6 score	Week 28	66	66 (100.0)	1 (1.5) [0.0, 8.2]	65	60 (92.3)	5 (7.7) [2.5, 17.0]	0.197 [0.024, 1.640]	0.185 [0.021, 1.626]	-6.2 [-14.8, 2.5]	0.115 #
	Week 52	66	66 (100.0)	2 (3.0) [0.4, 10.5]	65	60 (92.3)	2 (3.1) [0.4, 10.7]	0.985 [0.143, 6.784]	0.984 [0.134, 7.205]	-0.0 [-7.5, 7.4]	1.000 #

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILMH0: Course of ACQ-6 score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	66	66 (100.0)	2.71 (0.83)	0.0	2.17	2.67	3.17	4.8	
		Placebo	65	65 (100.0)	2.71 (0.72)	0.3	2.33	2.67	3.17	4.7	
	Week 2	Tezepelumab	66	63 (95.5)	2.23 (0.96)	0.0	1.50	2.33	3.00	4.2	
		Placebo	65	58 (89.2)	2.29 (0.77)	0.3	2.00	2.33	2.67	4.8	
	Week 4	Tezepelumab	66	63 (95.5)	1.98 (0.95)	0.2	1.33	2.17	2.67	3.5	
		Placebo	65	58 (89.2)	2.15 (0.91)	0.2	1.50	2.33	2.67	4.2	
	Week 6	Tezepelumab	66	63 (95.5)	1.88 (1.00)	0.0	1.00	1.83	2.67	4.0	
		Placebo	65	58 (89.2)	2.10 (1.10)	0.2	1.17	2.17	2.67	5.5	
	Week 8	Tezepelumab	66	63 (95.5)	1.74 (1.11)	0.0	0.83	1.67	2.67	4.8	
		Placebo	65	59 (90.8)	2.06 (1.08)	0.0	1.17	2.17	2.83	4.7	
	Week 10	Tezepelumab	66	63 (95.5)	1.66 (1.08)	0.0	0.83	1.67	2.67	4.3	
		Placebo	65	59 (90.8)	2.07 (1.05)	0.0	1.50	2.17	2.67	5.3	
	Week 12	Tezepelumab	66	63 (95.5)	1.56 (1.05)	0.0	0.50	1.50	2.50	4.3	
		Placebo	65	59 (90.8)	1.86 (0.99)	0.0	1.00	2.00	2.50	4.3	
	Week 14	Tezepelumab	66	63 (95.5)	1.49 (1.05)	0.0	0.67	1.50	2.17	4.3	
		Placebo	65	59 (90.8)	1.79 (0.97)	0.0	1.17	1.83	2.17	5.0	
	Week 16	Tezepelumab	66	63 (95.5)	1.63 (1.12)	0.0	0.67	1.50	2.50	4.3	
		Placebo	65	59 (90.8)	1.96 (1.15)	0.0	1.00	2.00	2.67	5.0	
	Week 18	Tezepelumab	66	64 (97.0)	1.60 (1.02)	0.0	0.75	1.58	2.33	4.3	
		Placebo	65	59 (90.8)	1.87 (1.13)	0.0	1.00	1.83	2.50	5.0	
	Week 20	Tezepelumab	66	64 (97.0)	1.62 (1.09)	0.0	0.83	1.67	2.33	5.0	
		Placebo	65	59 (90.8)	1.97 (1.08)	0.0	1.17	2.17	2.67	5.0	
	Week 22	Tezepelumab	66	64 (97.0)	1.68 (0.97)	0.0	0.92	1.83	2.33	4.3	
		Placebo	65	59 (90.8)	1.93 (1.13)	0.0	1.00	2.00	2.67	5.0	
	Week 24	Tezepelumab	66	64 (97.0)	1.67 (1.05)	0.0	0.83	1.75	2.42	4.3	
		Placebo	65	59 (90.8)	1.99 (1.04)	0.0	1.33	2.00	2.67	4.5	
	Week 26	Tezepelumab	66	65 (98.5)	1.71 (1.07)	0.0	0.83	1.83	2.50	4.3	
		Placebo	65	59 (90.8)	1.92 (1.11)	0.0	1.00	1.83	2.83	4.5	
	Week 28	Tezepelumab	66	66 (100.0)	1.66 (1.09)	0.0	0.83	1.67	2.50	4.3	
		Placebo	65	60 (92.3)	1.91 (1.18)	0.0	1.00	2.00	2.67	4.5	
	Week 30	Tezepelumab	66	66 (100.0)	1.63 (1.06)	0.0	0.83	1.67	2.33	4.3	
		Placebo	65	60 (92.3)	1.89 (1.14)	0.0	1.00	1.83	2.67	4.5	
	Week 32	Tezepelumab	66	66 (100.0)	1.58 (1.06)	0.0	0.67	1.67	2.33	4.3	
		Placebo	65	60 (92.3)	1.86 (1.09)	0.0	1.17	1.83	2.50	4.5	
	Week 34	Tezepelumab	66	66 (100.0)	1.64 (1.12)	0.0	0.67	1.50	2.50	4.3	
		Placebo	65	60 (92.3)	1.82 (1.09)	0.0	1.00	1.83	2.42	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILMH0: Course of ACQ-6 score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Week 36	Tezepelumab	66	66 (100.0)	1.61 (1.05)	0.0	0.83	1.58	2.33	4.3	
		Placebo	65	60 (92.3)	1.99 (1.13)	0.0	1.17	1.92	2.75	4.5	
	Week 38	Tezepelumab	66	66 (100.0)	1.63 (1.15)	0.0	0.83	1.67	2.50	4.5	
		Placebo	65	60 (92.3)	1.86 (1.09)	0.0	1.08	1.83	2.50	4.5	
	Week 40	Tezepelumab	66	66 (100.0)	1.61 (1.11)	0.0	0.67	1.75	2.50	4.3	
		Placebo	65	60 (92.3)	2.00 (1.13)	0.0	1.25	2.00	2.67	4.5	
	Week 42	Tezepelumab	66	66 (100.0)	1.58 (1.09)	0.0	0.83	1.67	2.33	4.3	
		Placebo	65	60 (92.3)	1.86 (1.02)	0.0	1.17	1.83	2.50	4.5	
	Week 44	Tezepelumab	66	66 (100.0)	1.61 (1.08)	0.0	0.67	1.58	2.50	4.3	
		Placebo	65	60 (92.3)	1.94 (1.06)	0.0	1.17	2.00	2.58	4.5	
	Week 46	Tezepelumab	66	66 (100.0)	1.63 (1.12)	0.0	0.83	1.83	2.50	4.3	
		Placebo	65	60 (92.3)	1.84 (0.98)	0.0	1.17	1.83	2.33	4.5	
	Week 48	Tezepelumab	66	66 (100.0)	1.63 (1.11)	0.0	0.67	1.67	2.33	4.3	
		Placebo	65	60 (92.3)	1.88 (1.05)	0.0	1.00	2.08	2.50	4.5	
	Week 50	Tezepelumab	66	66 (100.0)	1.57 (1.13)	0.0	0.67	1.50	2.33	4.3	
		Placebo	65	60 (92.3)	1.78 (0.99)	0.0	1.00	1.83	2.33	4.5	
	Week 52	Tezepelumab	66	66 (100.0)	1.60 (1.12)	0.0	0.67	1.50	2.33	4.3	
		Placebo	65	60 (92.3)	1.85 (1.04)	0.0	1.08	1.92	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILMH0: Course of ACQ-6 score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 score	Week 2	Tezepelumab	66	63 (95.5)	-0.52 (0.71)	-2.8	-1.00	-0.33	0.00	0.7	-0.11 [-0.47, 0.24]
		Placebo	65	58 (89.2)	-0.45 (0.68)	-2.8	-0.83	-0.33	0.00	1.0	
	Week 4	Tezepelumab	66	63 (95.5)	-0.78 (0.83)	-2.5	-1.33	-0.83	-0.17	2.3	-0.22 [-0.58, 0.14]
		Placebo	65	58 (89.2)	-0.59 (0.90)	-3.0	-1.17	-0.33	0.00	1.2	
	Week 6	Tezepelumab	66	63 (95.5)	-0.87 (0.94)	-2.7	-1.50	-1.00	-0.17	2.3	-0.24 [-0.60, 0.12]
		Placebo	65	58 (89.2)	-0.64 (0.98)	-3.3	-1.17	-0.50	0.00	1.5	
	Week 8	Tezepelumab	66	63 (95.5)	-1.01 (1.04)	-3.0	-1.67	-1.00	-0.33	2.3	-0.32 [-0.67, 0.04]
		Placebo	65	59 (90.8)	-0.69 (1.00)	-3.2	-1.17	-0.67	0.00	1.0	
	Week 10	Tezepelumab	66	63 (95.5)	-1.09 (1.02)	-3.2	-1.83	-1.17	-0.50	2.3	-0.39 [-0.75, -0.03]
		Placebo	65	59 (90.8)	-0.68 (1.11)	-3.3	-1.33	-0.50	-0.17	2.7	
	Week 12	Tezepelumab	66	63 (95.5)	-1.19 (1.00)	-3.0	-2.00	-1.17	-0.67	2.3	-0.31 [-0.66, 0.05]
		Placebo	65	59 (90.8)	-0.89 (0.99)	-3.3	-1.33	-0.83	-0.33	1.3	
	Week 14	Tezepelumab	66	63 (95.5)	-1.26 (1.01)	-3.7	-2.00	-1.17	-0.67	2.3	-0.31 [-0.66, 0.05]
		Placebo	65	59 (90.8)	-0.95 (1.02)	-3.2	-1.50	-1.00	-0.33	2.3	
	Week 16	Tezepelumab	66	63 (95.5)	-1.12 (1.04)	-3.0	-2.00	-1.00	-0.50	2.3	-0.31 [-0.67, 0.05]
		Placebo	65	59 (90.8)	-0.79 (1.11)	-3.2	-1.33	-0.83	0.00	2.3	
	Week 18	Tezepelumab	66	64 (97.0)	-1.14 (0.99)	-3.5	-1.83	-1.00	-0.67	2.3	-0.25 [-0.60, 0.11]
		Placebo	65	59 (90.8)	-0.87 (1.16)	-3.2	-1.67	-0.83	-0.17	2.3	
	Week 20	Tezepelumab	66	64 (97.0)	-1.12 (1.00)	-3.2	-2.00	-1.08	-0.50	2.3	-0.32 [-0.68, 0.03]
		Placebo	65	59 (90.8)	-0.78 (1.11)	-3.2	-1.50	-0.83	-0.17	2.3	
	Week 22	Tezepelumab	66	64 (97.0)	-1.06 (1.02)	-3.0	-1.83	-1.00	-0.67	2.3	-0.22 [-0.58, 0.13]
		Placebo	65	59 (90.8)	-0.82 (1.12)	-3.3	-1.50	-0.83	-0.33	2.3	
	Week 24	Tezepelumab	66	64 (97.0)	-1.07 (0.98)	-3.2	-1.83	-1.08	-0.42	2.3	-0.30 [-0.66, 0.05]
		Placebo	65	59 (90.8)	-0.76 (1.09)	-3.2	-1.50	-0.67	0.00	2.3	
	Week 26	Tezepelumab	66	65 (98.5)	-1.01 (1.03)	-2.8	-2.00	-1.00	-0.33	2.3	-0.17 [-0.53, 0.18]
		Placebo	65	59 (90.8)	-0.82 (1.13)	-3.2	-1.50	-1.00	0.17	2.3	
	Week 28	Tezepelumab	66	66 (100.0)	-1.06 (1.09)	-3.2	-2.00	-1.00	-0.17	2.3	-0.23 [-0.58, 0.12]
		Placebo	65	60 (92.3)	-0.80 (1.16)	-3.2	-1.67	-0.83	-0.17	2.3	
	Week 30	Tezepelumab	66	66 (100.0)	-1.08 (1.07)	-3.5	-2.00	-1.00	-0.33	2.3	-0.24 [-0.59, 0.11]
		Placebo	65	60 (92.3)	-0.81 (1.14)	-3.2	-1.50	-0.92	-0.17	2.3	
	Week 32	Tezepelumab	66	66 (100.0)	-1.14 (1.00)	-3.0	-2.00	-1.00	-0.50	2.3	-0.28 [-0.63, 0.07]
		Placebo	65	60 (92.3)	-0.85 (1.09)	-3.0	-1.50	-1.00	-0.33	2.3	
	Week 34	Tezepelumab	66	66 (100.0)	-1.08 (1.09)	-2.8	-2.00	-1.17	-0.33	2.3	-0.18 [-0.53, 0.17]
		Placebo	65	60 (92.3)	-0.88 (1.08)	-3.2	-1.50	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILMH0: Course of ACQ-6 score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 score	Week 36	Tezepelumab	66	66 (100.0)	-1.11 (1.07)	-3.0	-2.00	-1.17	-0.33	2.3	-0.36 [-0.71, -0.01]
		Placebo	65	60 (92.3)	-0.71 (1.13)	-3.5	-1.33	-0.83	-0.08	2.3	
	Week 38	Tezepelumab	66	66 (100.0)	-1.08 (1.11)	-3.0	-2.00	-1.17	-0.33	2.3	-0.22 [-0.57, 0.13]
		Placebo	65	60 (92.3)	-0.85 (1.08)	-3.2	-1.33	-0.92	-0.08	2.3	
	Week 40	Tezepelumab	66	66 (100.0)	-1.11 (1.09)	-3.2	-2.00	-1.08	-0.33	2.3	-0.36 [-0.71, -0.01]
		Placebo	65	60 (92.3)	-0.70 (1.15)	-3.2	-1.33	-0.75	0.17	2.3	
	Week 42	Tezepelumab	66	66 (100.0)	-1.13 (1.09)	-3.3	-2.00	-1.17	-0.50	2.3	-0.27 [-0.62, 0.09]
		Placebo	65	60 (92.3)	-0.85 (1.03)	-2.8	-1.33	-1.00	-0.17	2.3	
	Week 44	Tezepelumab	66	66 (100.0)	-1.10 (1.09)	-3.5	-2.00	-1.08	-0.50	2.3	-0.31 [-0.66, 0.04]
		Placebo	65	60 (92.3)	-0.77 (1.09)	-3.3	-1.50	-0.83	0.00	2.3	
	Week 46	Tezepelumab	66	66 (100.0)	-1.09 (1.08)	-3.3	-2.00	-1.00	-0.17	2.3	-0.21 [-0.56, 0.14]
		Placebo	65	60 (92.3)	-0.87 (1.00)	-3.2	-1.42	-1.00	-0.33	2.3	
	Week 48	Tezepelumab	66	66 (100.0)	-1.08 (1.07)	-2.7	-2.00	-1.00	-0.50	2.3	-0.24 [-0.59, 0.11]
		Placebo	65	60 (92.3)	-0.82 (1.07)	-3.3	-1.42	-0.83	-0.33	2.3	
	Week 50	Tezepelumab	66	66 (100.0)	-1.14 (1.09)	-2.7	-2.00	-1.17	-0.50	2.3	-0.20 [-0.55, 0.15]
		Placebo	65	60 (92.3)	-0.93 (1.01)	-3.5	-1.42	-1.00	-0.42	2.3	
	Week 52	Tezepelumab	66	66 (100.0)	-1.11 (1.08)	-2.7	-2.00	-1.08	-0.50	2.3	-0.24 [-0.59, 0.11]
		Placebo	65	60 (92.3)	-0.86 (1.06)	-3.5	-1.42	-0.83	-0.25	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILMC0: Change from baseline in ACQ-6 score - MMRM results
DITTL

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	66	63 (95.5)	NE		NE		
	Placebo	65	58 (89.2)					
Week 4	Tezepelumab	66	60 (90.9)	NE		NE		
	Placebo	65	57 (87.7)					
Week 6	Tezepelumab	66	59 (89.4)	NE		NE		
	Placebo	65	57 (87.7)					
Week 8	Tezepelumab	66	60 (90.9)	NE		NE		
	Placebo	65	58 (89.2)					
Week 10	Tezepelumab	66	59 (89.4)	NE		NE		
	Placebo	65	56 (86.2)					
Week 12	Tezepelumab	66	59 (89.4)	NE		NE		
	Placebo	65	55 (84.6)					
Week 14	Tezepelumab	66	59 (89.4)	NE		NE		
	Placebo	65	54 (83.1)					
Week 16	Tezepelumab	66	57 (86.4)	NE		NE		
	Placebo	65	53 (81.5)					
Week 18	Tezepelumab	66	59 (89.4)	NE		NE		
	Placebo	65	50 (76.9)					
Week 20	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	49 (75.4)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILMC0: Change from baseline in ACQ-6 score - MMRM results
DITTL

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	50 (76.9)					
Week 24	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	48 (73.8)					
Week 26	Tezepelumab	66	56 (84.8)	NE		NE		
	Placebo	65	47 (72.3)					
Week 28	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	48 (73.8)					
Week 30	Tezepelumab	66	56 (84.8)	NE		NE		
	Placebo	65	46 (70.8)					
Week 32	Tezepelumab	66	57 (86.4)	NE		NE		
	Placebo	65	48 (73.8)					
Week 34	Tezepelumab	66	57 (86.4)	NE		NE		
	Placebo	65	46 (70.8)					
Week 36	Tezepelumab	66	57 (86.4)	NE		NE		
	Placebo	65	48 (73.8)					
Week 38	Tezepelumab	66	56 (84.8)	NE		NE		
	Placebo	65	48 (73.8)					
Week 40	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	50 (76.9)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILMC0: Change from baseline in ACQ-6 score - MMRM results
DITTL

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	47 (72.3)					
Week 44	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	48 (73.8)					
Week 46	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	48 (73.8)					
Week 48	Tezepelumab	66	53 (80.3)	NE		NE		
	Placebo	65	48 (73.8)					
Week 50	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	49 (75.4)					
Week 52	Tezepelumab	66	18 (27.3)	NE		NE		
	Placebo	65	20 (30.8)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Figure PF2H6C_ILMG0: Course of ACQ-6 score
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
ACQ = asthma control questionnaire.
Source table: PT2H6C_ILMH0
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	19	19 (100.0)	2.97 (0.72)	1.7	2.50	2.83	3.50	4.5	
			Placebo	20	20 (100.0)	2.80 (0.78)	0.3	2.50	3.00	3.25	4.3	
		Week 2	Tezepelumab	19	18 (94.7)	2.46 (0.92)	0.7	1.67	2.50	3.33	3.8	
			Placebo	20	18 (90.0)	2.68 (0.82)	1.0	2.33	2.83	3.00	4.8	
		Week 4	Tezepelumab	19	18 (94.7)	2.14 (1.01)	0.2	1.33	2.33	2.83	3.5	
			Placebo	20	18 (90.0)	2.40 (0.95)	0.7	1.83	2.50	2.67	4.2	
		Week 6	Tezepelumab	19	18 (94.7)	2.14 (1.10)	0.0	1.50	2.25	3.00	4.0	
			Placebo	20	18 (90.0)	2.56 (0.97)	0.5	2.17	2.67	3.00	4.7	
		Week 8	Tezepelumab	19	18 (94.7)	1.98 (1.12)	0.0	1.33	2.08	2.83	4.2	
			Placebo	20	18 (90.0)	2.45 (1.09)	0.2	2.00	2.50	3.17	4.7	
		Week 10	Tezepelumab	19	18 (94.7)	1.93 (1.11)	0.0	1.33	2.00	2.83	3.5	
			Placebo	20	18 (90.0)	2.48 (0.94)	0.0	2.00	2.58	3.00	4.2	
		Week 12	Tezepelumab	19	18 (94.7)	1.69 (0.99)	0.0	1.00	1.83	2.50	3.3	
			Placebo	20	18 (90.0)	2.19 (1.15)	0.0	1.33	2.42	2.83	4.3	
		Week 14	Tezepelumab	19	18 (94.7)	1.60 (0.99)	0.0	1.00	1.67	2.00	4.2	
			Placebo	20	18 (90.0)	2.09 (1.00)	0.3	1.67	1.83	2.50	5.0	
		Week 16	Tezepelumab	19	18 (94.7)	1.94 (1.24)	0.0	1.17	1.83	2.50	4.3	
			Placebo	20	18 (90.0)	2.31 (1.12)	0.2	1.83	2.50	3.00	4.5	
		Week 18	Tezepelumab	19	18 (94.7)	1.86 (1.04)	0.0	1.50	1.83	2.50	4.2	
			Placebo	20	18 (90.0)	2.10 (1.06)	0.2	1.67	2.33	2.67	4.5	
		Week 20	Tezepelumab	19	18 (94.7)	1.83 (1.15)	0.0	1.17	1.83	2.33	5.0	
			Placebo	20	18 (90.0)	2.22 (1.12)	0.2	1.67	2.50	2.83	4.5	
		Week 22	Tezepelumab	19	18 (94.7)	1.80 (0.93)	0.0	1.50	1.92	2.33	3.8	
			Placebo	20	18 (90.0)	2.15 (1.12)	0.0	1.17	2.25	2.83	4.5	
		Week 24	Tezepelumab	19	18 (94.7)	1.90 (1.06)	0.0	1.17	2.00	2.67	3.8	
			Placebo	20	18 (90.0)	2.18 (1.04)	0.2	1.67	2.25	3.00	4.5	
		Week 26	Tezepelumab	19	19 (100.0)	1.86 (1.13)	0.0	1.17	1.83	2.67	4.0	
			Placebo	20	18 (90.0)	2.13 (1.12)	0.5	1.17	2.00	3.00	4.5	
		Week 28	Tezepelumab	19	19 (100.0)	1.80 (1.08)	0.0	1.00	1.67	2.33	3.8	
			Placebo	20	19 (95.0)	2.29 (1.27)	0.0	1.33	2.50	3.50	4.5	
		Week 30	Tezepelumab	19	19 (100.0)	1.87 (1.07)	0.0	1.33	1.83	2.50	3.7	
			Placebo	20	19 (95.0)	1.92 (1.25)	0.0	0.67	2.17	2.67	4.5	
		Week 32	Tezepelumab	19	19 (100.0)	1.78 (1.03)	0.0	1.17	1.83	2.33	4.0	
			Placebo	20	19 (95.0)	2.04 (1.20)	0.0	1.17	2.17	2.83	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Male	Absolute values	Week 34	Tezepelumab	19	19 (100.0)	1.87 (1.13)	0.0	1.00	2.00	2.50	3.8	
			Placebo	20	19 (95.0)	2.00 (1.13)	0.2	0.83	2.17	2.67	4.5	
		Week 36	Tezepelumab	19	19 (100.0)	1.79 (1.09)	0.0	1.00	1.83	2.67	3.7	
			Placebo	20	19 (95.0)	2.16 (1.17)	0.0	1.17	2.17	2.83	4.5	
		Week 38	Tezepelumab	19	19 (100.0)	1.85 (1.26)	0.0	1.00	1.67	2.67	4.5	
			Placebo	20	19 (95.0)	1.96 (1.10)	0.0	1.17	2.00	2.67	4.5	
		Week 40	Tezepelumab	19	19 (100.0)	1.89 (1.15)	0.0	1.00	2.00	2.67	3.7	
			Placebo	20	19 (95.0)	2.20 (1.16)	0.0	1.33	2.17	3.00	4.5	
		Week 42	Tezepelumab	19	19 (100.0)	1.85 (1.18)	0.0	1.00	1.83	2.67	3.8	
			Placebo	20	19 (95.0)	2.18 (1.15)	0.0	1.33	2.33	2.67	4.5	
		Week 44	Tezepelumab	19	19 (100.0)	1.92 (1.12)	0.0	1.00	2.17	2.67	3.8	
			Placebo	20	19 (95.0)	2.15 (1.12)	0.0	1.17	2.17	2.83	4.5	
		Week 46	Tezepelumab	19	19 (100.0)	1.89 (1.13)	0.0	1.00	2.00	2.50	3.8	
			Placebo	20	19 (95.0)	2.14 (0.96)	0.0	1.50	2.17	2.50	4.5	
		Week 48	Tezepelumab	19	19 (100.0)	1.93 (1.14)	0.0	1.00	2.17	2.67	3.8	
			Placebo	20	19 (95.0)	2.13 (1.12)	0.0	1.00	2.17	2.67	4.5	
		Week 50	Tezepelumab	19	19 (100.0)	1.81 (1.18)	0.0	1.00	1.67	2.67	4.2	
			Placebo	20	19 (95.0)	2.13 (1.02)	0.0	1.50	2.17	2.83	4.5	
		Week 52	Tezepelumab	19	19 (100.0)	1.89 (1.13)	0.0	1.00	2.00	2.50	4.3	
			Placebo	20	19 (95.0)	2.18 (1.06)	0.0	1.50	2.17	2.83	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 2	Tezepelumab	19	18 (94.7)	-0.58 (0.59)	-1.8	-1.00	-0.67	-0.17	0.3	-0.46 [-1.12, 0.20]
			Placebo	20	18 (90.0)	-0.29 (0.69)	-2.2	-0.67	-0.08	0.17	0.5	
		Week 4	Tezepelumab	19	18 (94.7)	-0.91 (0.73)	-2.3	-1.17	-0.83	-0.50	0.2	-0.40 [-1.06, 0.26]
			Placebo	20	18 (90.0)	-0.56 (0.96)	-2.7	-1.33	-0.25	0.00	1.2	
		Week 6	Tezepelumab	19	18 (94.7)	-0.91 (0.76)	-2.5	-1.33	-0.75	-0.33	0.2	-0.63 [-1.30, 0.04]
			Placebo	20	18 (90.0)	-0.41 (0.84)	-2.8	-0.67	-0.17	0.17	0.8	
		Week 8	Tezepelumab	19	18 (94.7)	-1.06 (0.80)	-2.7	-1.67	-1.00	-0.50	0.0	-0.62 [-1.29, 0.05]
			Placebo	20	18 (90.0)	-0.51 (0.98)	-3.2	-1.00	-0.33	0.17	0.7	
		Week 10	Tezepelumab	19	18 (94.7)	-1.12 (0.79)	-2.7	-1.50	-1.17	-0.67	0.0	-0.69 [-1.37, -0.02]
			Placebo	20	18 (90.0)	-0.48 (1.04)	-3.3	-0.83	-0.42	0.00	2.0	
		Week 12	Tezepelumab	19	18 (94.7)	-1.35 (0.68)	-2.7	-2.00	-1.17	-0.83	-0.5	-0.64 [-1.32, 0.03]
			Placebo	20	18 (90.0)	-0.78 (1.06)	-3.3	-1.17	-0.75	0.00	1.2	
		Week 14	Tezepelumab	19	18 (94.7)	-1.44 (0.62)	-2.7	-1.83	-1.33	-1.00	-0.3	-0.75 [-1.43, -0.07]
			Placebo	20	18 (90.0)	-0.87 (0.89)	-3.0	-1.33	-1.08	-0.17	0.7	
		Week 16	Tezepelumab	19	18 (94.7)	-1.10 (0.99)	-2.7	-2.00	-1.00	-0.50	1.5	-0.44 [-1.10, 0.22]
			Placebo	20	18 (90.0)	-0.65 (1.07)	-3.2	-1.17	-0.25	0.17	0.8	
		Week 18	Tezepelumab	19	18 (94.7)	-1.19 (0.67)	-2.7	-1.50	-1.00	-0.67	-0.3	-0.39 [-1.05, 0.27]
			Placebo	20	18 (90.0)	-0.86 (0.97)	-3.2	-1.50	-0.83	0.00	0.3	
		Week 20	Tezepelumab	19	18 (94.7)	-1.21 (0.79)	-2.7	-1.67	-1.00	-0.67	0.5	-0.50 [-1.17, 0.16]
			Placebo	20	18 (90.0)	-0.74 (1.07)	-3.2	-1.33	-0.33	0.00	0.5	
		Week 22	Tezepelumab	19	18 (94.7)	-1.25 (0.66)	-2.7	-1.67	-1.00	-0.67	-0.5	-0.51 [-1.17, 0.16]
			Placebo	20	18 (90.0)	-0.81 (1.02)	-3.3	-1.50	-0.67	-0.33	0.7	
		Week 24	Tezepelumab	19	18 (94.7)	-1.15 (0.78)	-2.5	-1.83	-1.00	-0.67	0.2	-0.42 [-1.08, 0.24]
			Placebo	20	18 (90.0)	-0.79 (0.95)	-3.2	-1.33	-0.58	0.00	0.5	
		Week 26	Tezepelumab	19	19 (100.0)	-1.11 (0.93)	-2.7	-1.83	-1.00	-0.33	0.2	-0.30 [-0.94, 0.35]
			Placebo	20	18 (90.0)	-0.83 (0.97)	-2.8	-1.50	-1.00	0.17	0.7	
		Week 28	Tezepelumab	19	19 (100.0)	-1.18 (0.93)	-2.7	-2.00	-1.00	-0.67	0.8	-0.63 [-1.28, 0.02]
			Placebo	20	19 (95.0)	-0.54 (1.09)	-2.8	-1.17	-0.33	0.17	1.2	
		Week 30	Tezepelumab	19	19 (100.0)	-1.11 (0.99)	-2.7	-1.83	-1.00	-0.67	1.8	-0.20 [-0.84, 0.44]
			Placebo	20	19 (95.0)	-0.90 (1.02)	-2.8	-1.50	-1.00	-0.17	0.8	
		Week 32	Tezepelumab	19	19 (100.0)	-1.19 (0.88)	-2.7	-2.17	-1.00	-0.67	0.8	-0.43 [-1.07, 0.22]
			Placebo	20	19 (95.0)	-0.78 (1.05)	-2.8	-1.50	-0.67	0.17	0.7	
		Week 34	Tezepelumab	19	19 (100.0)	-1.11 (1.03)	-2.5	-1.83	-1.00	-0.67	2.0	-0.29 [-0.93, 0.35]
			Placebo	20	19 (95.0)	-0.82 (0.93)	-2.8	-1.50	-0.67	-0.17	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Male	Change from baseline	Week 36	Tezepelumab	19	19 (100.0)	-1.18 (0.95)	-2.7	-1.83	-1.17	-0.83	1.5	-0.56 [-1.21, 0.09]
			Placebo	20	19 (95.0)	-0.67 (0.89)	-2.2	-1.17	-0.83	0.17	1.2	
		Week 38	Tezepelumab	19	19 (100.0)	-1.12 (1.16)	-2.7	-1.67	-1.17	-0.50	2.3	-0.25 [-0.89, 0.39]
			Placebo	20	19 (95.0)	-0.86 (0.94)	-2.5	-1.83	-0.83	0.17	0.5	
		Week 40	Tezepelumab	19	19 (100.0)	-1.09 (1.00)	-2.7	-1.83	-0.83	-0.67	1.7	-0.46 [-1.10, 0.19]
			Placebo	20	19 (95.0)	-0.62 (1.04)	-2.3	-1.50	-0.67	0.33	1.2	
		Week 42	Tezepelumab	19	19 (100.0)	-1.12 (1.08)	-2.7	-1.83	-1.00	-0.67	2.0	-0.45 [-1.09, 0.19]
			Placebo	20	19 (95.0)	-0.65 (1.03)	-2.3	-1.17	-0.67	0.17	1.5	
		Week 44	Tezepelumab	19	19 (100.0)	-1.05 (1.00)	-2.7	-1.83	-1.00	-0.50	1.5	-0.39 [-1.03, 0.25]
			Placebo	20	19 (95.0)	-0.68 (0.92)	-2.3	-1.17	-0.83	0.17	1.2	
		Week 46	Tezepelumab	19	19 (100.0)	-1.09 (0.99)	-2.7	-1.50	-1.00	-0.67	1.7	-0.45 [-1.10, 0.19]
			Placebo	20	19 (95.0)	-0.68 (0.78)	-2.2	-1.17	-0.83	0.17	0.8	
		Week 48	Tezepelumab	19	19 (100.0)	-1.04 (1.02)	-2.7	-1.50	-1.00	-0.67	1.8	-0.35 [-0.99, 0.29]
			Placebo	20	19 (95.0)	-0.69 (0.96)	-2.7	-1.17	-0.67	0.17	0.8	
		Week 50	Tezepelumab	19	19 (100.0)	-1.17 (1.06)	-2.7	-2.00	-1.17	-0.50	1.8	-0.50 [-1.15, 0.14]
			Placebo	20	19 (95.0)	-0.69 (0.81)	-2.3	-1.17	-0.67	0.17	0.5	
		Week 52	Tezepelumab	19	19 (100.0)	-1.08 (1.03)	-2.7	-1.67	-1.00	-0.67	1.8	-0.45 [-1.10, 0.19]
			Placebo	20	19 (95.0)	-0.65 (0.86)	-2.3	-1.17	-0.67	0.17	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	47	47 (100.0)	2.61 (0.85)	0.0	2.17	2.67	3.17	4.8	
			Placebo	45	45 (100.0)	2.67 (0.70)	1.3	2.33	2.67	3.00	4.7	
		Week 2	Tezepelumab	47	45 (95.7)	2.13 (0.97)	0.0	1.33	2.33	2.67	4.2	
			Placebo	45	40 (88.9)	2.12 (0.70)	0.3	1.75	2.17	2.50	4.7	
		Week 4	Tezepelumab	47	45 (95.7)	1.91 (0.92)	0.2	1.33	2.00	2.67	3.3	
			Placebo	45	40 (88.9)	2.04 (0.89)	0.2	1.50	2.17	2.67	3.5	
		Week 6	Tezepelumab	47	45 (95.7)	1.78 (0.96)	0.0	1.00	1.67	2.50	3.7	
			Placebo	45	40 (88.9)	1.90 (1.11)	0.2	1.17	2.00	2.42	5.5	
		Week 8	Tezepelumab	47	45 (95.7)	1.65 (1.10)	0.0	0.83	1.50	2.50	4.8	
			Placebo	45	41 (91.1)	1.89 (1.05)	0.0	1.00	2.00	2.50	4.7	
		Week 10	Tezepelumab	47	45 (95.7)	1.55 (1.07)	0.0	0.67	1.50	2.17	4.3	
			Placebo	45	41 (91.1)	1.89 (1.05)	0.0	1.00	2.00	2.33	5.3	
		Week 12	Tezepelumab	47	45 (95.7)	1.50 (1.08)	0.0	0.50	1.50	2.50	4.3	
			Placebo	45	41 (91.1)	1.72 (0.89)	0.0	1.00	1.83	2.17	4.0	
		Week 14	Tezepelumab	47	45 (95.7)	1.44 (1.08)	0.0	0.50	1.33	2.17	4.3	
			Placebo	45	41 (91.1)	1.66 (0.94)	0.0	1.00	1.83	2.17	5.0	
		Week 16	Tezepelumab	47	45 (95.7)	1.51 (1.05)	0.0	0.67	1.33	2.33	4.3	
			Placebo	45	41 (91.1)	1.80 (1.14)	0.0	0.83	1.83	2.33	5.0	
		Week 18	Tezepelumab	47	46 (97.9)	1.50 (1.01)	0.0	0.67	1.42	2.17	4.3	
			Placebo	45	41 (91.1)	1.77 (1.16)	0.0	1.00	1.83	2.33	5.0	
		Week 20	Tezepelumab	47	46 (97.9)	1.53 (1.06)	0.0	0.67	1.50	2.33	4.3	
			Placebo	45	41 (91.1)	1.86 (1.05)	0.0	1.17	1.83	2.50	5.0	
		Week 22	Tezepelumab	47	46 (97.9)	1.63 (0.99)	0.0	0.83	1.75	2.33	4.3	
			Placebo	45	41 (91.1)	1.83 (1.14)	0.0	1.00	2.00	2.33	5.0	
		Week 24	Tezepelumab	47	46 (97.9)	1.58 (1.05)	0.0	0.67	1.67	2.33	4.3	
			Placebo	45	41 (91.1)	1.91 (1.04)	0.0	1.00	2.00	2.50	4.2	
		Week 26	Tezepelumab	47	46 (97.9)	1.64 (1.05)	0.0	0.83	1.58	2.50	4.3	
			Placebo	45	41 (91.1)	1.83 (1.10)	0.0	1.00	1.83	2.33	4.2	
		Week 28	Tezepelumab	47	47 (100.0)	1.60 (1.10)	0.0	0.50	1.50	2.50	4.3	
			Placebo	45	41 (91.1)	1.73 (1.11)	0.0	1.00	1.50	2.33	4.2	
		Week 30	Tezepelumab	47	47 (100.0)	1.54 (1.05)	0.0	0.67	1.50	2.17	4.3	
			Placebo	45	41 (91.1)	1.88 (1.10)	0.0	1.17	1.83	2.67	4.2	
		Week 32	Tezepelumab	47	47 (100.0)	1.49 (1.08)	0.0	0.50	1.50	2.50	4.3	
			Placebo	45	41 (91.1)	1.77 (1.04)	0.0	1.17	1.83	2.33	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	Absolute values	Week 34	Tezepelumab	47	47 (100.0)	1.55 (1.11)	0.0	0.67	1.50	2.50	4.3	
			Placebo	45	41 (91.1)	1.74 (1.08)	0.0	1.00	1.83	2.17	4.5	
		Week 36	Tezepelumab	47	47 (100.0)	1.54 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	45	41 (91.1)	1.91 (1.11)	0.0	1.00	1.83	2.50	4.5	
		Week 38	Tezepelumab	47	47 (100.0)	1.54 (1.10)	0.0	0.50	1.67	2.50	4.3	
			Placebo	45	41 (91.1)	1.81 (1.10)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	47	47 (100.0)	1.50 (1.09)	0.0	0.50	1.67	2.33	4.3	
			Placebo	45	41 (91.1)	1.91 (1.12)	0.0	1.17	2.00	2.50	4.2	
		Week 42	Tezepelumab	47	47 (100.0)	1.48 (1.04)	0.0	0.83	1.50	2.33	4.3	
			Placebo	45	41 (91.1)	1.71 (0.94)	0.0	1.00	1.83	2.33	3.8	
		Week 44	Tezepelumab	47	47 (100.0)	1.49 (1.05)	0.0	0.67	1.50	2.33	4.3	
			Placebo	45	41 (91.1)	1.84 (1.03)	0.0	1.00	1.83	2.50	4.0	
		Week 46	Tezepelumab	47	47 (100.0)	1.52 (1.10)	0.0	0.67	1.50	2.50	4.3	
			Placebo	45	41 (91.1)	1.70 (0.97)	0.0	1.00	1.83	2.33	3.8	
		Week 48	Tezepelumab	47	47 (100.0)	1.51 (1.09)	0.0	0.67	1.50	2.33	4.3	
			Placebo	45	41 (91.1)	1.76 (1.00)	0.0	1.00	2.00	2.17	4.2	
		Week 50	Tezepelumab	47	47 (100.0)	1.48 (1.11)	0.0	0.67	1.33	2.33	4.3	
			Placebo	45	41 (91.1)	1.61 (0.94)	0.0	1.00	1.67	2.17	3.8	
		Week 52	Tezepelumab	47	47 (100.0)	1.49 (1.10)	0.0	0.67	1.33	2.33	4.3	
			Placebo	45	41 (91.1)	1.70 (1.01)	0.0	1.00	1.83	2.33	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 2	Tezepelumab	47	45 (95.7)	-0.50 (0.75)	-2.8	-1.00	-0.33	0.17	0.7	0.02 [-0.40, 0.45]
			Placebo	45	40 (88.9)	-0.52 (0.68)	-2.8	-0.92	-0.50	0.00	1.0	
		Week 4	Tezepelumab	47	45 (95.7)	-0.72 (0.87)	-2.5	-1.33	-0.83	-0.17	2.3	-0.14 [-0.57, 0.28]
			Placebo	45	40 (88.9)	-0.60 (0.88)	-3.0	-1.17	-0.50	0.08	0.8	
		Week 6	Tezepelumab	47	45 (95.7)	-0.85 (1.01)	-2.7	-1.50	-1.00	0.00	2.3	-0.11 [-0.54, 0.31]
			Placebo	45	40 (88.9)	-0.74 (1.04)	-3.3	-1.42	-0.75	-0.08	1.5	
		Week 8	Tezepelumab	47	45 (95.7)	-0.99 (1.13)	-3.0	-1.67	-1.00	-0.33	2.3	-0.21 [-0.63, 0.22]
			Placebo	45	41 (91.1)	-0.76 (1.01)	-3.0	-1.17	-0.67	-0.17	1.0	
		Week 10	Tezepelumab	47	45 (95.7)	-1.08 (1.10)	-3.2	-1.83	-1.33	-0.50	2.3	-0.28 [-0.71, 0.14]
			Placebo	45	41 (91.1)	-0.76 (1.15)	-3.2	-1.50	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	47	45 (95.7)	-1.13 (1.10)	-3.0	-2.00	-1.17	-0.33	2.3	-0.19 [-0.61, 0.24]
			Placebo	45	41 (91.1)	-0.93 (0.97)	-3.2	-1.33	-0.83	-0.50	1.3	
		Week 14	Tezepelumab	47	45 (95.7)	-1.19 (1.12)	-3.7	-2.00	-1.17	-0.50	2.3	-0.18 [-0.61, 0.24]
			Placebo	45	41 (91.1)	-0.99 (1.09)	-3.2	-1.50	-1.00	-0.50	2.3	
		Week 16	Tezepelumab	47	45 (95.7)	-1.13 (1.07)	-3.0	-2.00	-1.00	-0.50	2.3	-0.25 [-0.68, 0.17]
			Placebo	45	41 (91.1)	-0.85 (1.14)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 18	Tezepelumab	47	46 (97.9)	-1.12 (1.10)	-3.5	-1.83	-1.08	-0.50	2.3	-0.21 [-0.63, 0.22]
			Placebo	45	41 (91.1)	-0.88 (1.25)	-3.2	-1.67	-0.83	-0.17	2.3	
		Week 20	Tezepelumab	47	46 (97.9)	-1.08 (1.07)	-3.2	-2.00	-1.17	-0.33	2.3	-0.26 [-0.68, 0.16]
			Placebo	45	41 (91.1)	-0.79 (1.15)	-3.0	-1.50	-0.83	-0.50	2.3	
		Week 22	Tezepelumab	47	46 (97.9)	-0.98 (1.12)	-3.0	-2.00	-0.92	-0.33	2.3	-0.14 [-0.56, 0.28]
			Placebo	45	41 (91.1)	-0.82 (1.17)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	47	46 (97.9)	-1.04 (1.05)	-3.2	-1.83	-1.17	-0.33	2.3	-0.27 [-0.69, 0.15]
			Placebo	45	41 (91.1)	-0.74 (1.16)	-3.2	-1.50	-0.83	0.00	2.3	
		Week 26	Tezepelumab	47	46 (97.9)	-0.97 (1.08)	-2.8	-2.00	-1.00	-0.17	2.3	-0.13 [-0.55, 0.29]
			Placebo	45	41 (91.1)	-0.82 (1.20)	-3.2	-1.83	-0.83	-0.17	2.3	
		Week 28	Tezepelumab	47	47 (100.0)	-1.01 (1.15)	-3.2	-2.00	-1.00	0.00	2.3	-0.08 [-0.49, 0.34]
			Placebo	45	41 (91.1)	-0.92 (1.18)	-3.2	-1.83	-1.00	-0.33	2.3	
		Week 30	Tezepelumab	47	47 (100.0)	-1.07 (1.12)	-3.5	-2.00	-1.00	-0.17	2.3	-0.26 [-0.68, 0.16]
			Placebo	45	41 (91.1)	-0.77 (1.20)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	47	47 (100.0)	-1.12 (1.05)	-3.0	-2.00	-1.17	-0.50	2.3	-0.22 [-0.64, 0.20]
			Placebo	45	41 (91.1)	-0.88 (1.12)	-3.0	-1.50	-1.17	-0.33	2.3	
		Week 34	Tezepelumab	47	47 (100.0)	-1.06 (1.12)	-2.8	-2.00	-1.17	-0.17	2.3	-0.13 [-0.55, 0.28]
			Placebo	45	41 (91.1)	-0.91 (1.15)	-3.2	-1.50	-1.00	-0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	Change from baseline	Week 36	Tezepelumab	47	47 (100.0)	-1.07 (1.12)	-3.0	-2.00	-1.17	-0.17	2.3	-0.29 [-0.71, 0.13]
			Placebo	45	41 (91.1)	-0.74 (1.23)	-3.5	-1.33	-0.83	-0.17	2.3	
		Week 38	Tezepelumab	47	47 (100.0)	-1.07 (1.10)	-3.0	-2.00	-1.17	-0.17	2.3	-0.20 [-0.62, 0.22]
			Placebo	45	41 (91.1)	-0.84 (1.15)	-3.2	-1.33	-1.00	-0.50	2.3	
		Week 40	Tezepelumab	47	47 (100.0)	-1.11 (1.14)	-3.2	-2.17	-1.17	-0.33	2.3	-0.32 [-0.74, 0.10]
			Placebo	45	41 (91.1)	-0.74 (1.20)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 42	Tezepelumab	47	47 (100.0)	-1.13 (1.10)	-3.3	-2.00	-1.17	-0.33	2.3	-0.18 [-0.60, 0.24]
			Placebo	45	41 (91.1)	-0.94 (1.03)	-2.8	-1.33	-1.17	-0.50	2.3	
		Week 44	Tezepelumab	47	47 (100.0)	-1.12 (1.13)	-3.5	-2.00	-1.17	-0.17	2.3	-0.27 [-0.69, 0.15]
			Placebo	45	41 (91.1)	-0.81 (1.17)	-3.3	-1.50	-0.83	0.00	2.3	
		Week 46	Tezepelumab	47	47 (100.0)	-1.09 (1.13)	-3.3	-2.00	-1.17	-0.17	2.3	-0.12 [-0.54, 0.30]
			Placebo	45	41 (91.1)	-0.96 (1.09)	-3.2	-1.67	-1.00	-0.67	2.3	
		Week 48	Tezepelumab	47	47 (100.0)	-1.10 (1.10)	-2.7	-2.00	-1.00	-0.17	2.3	-0.19 [-0.61, 0.23]
			Placebo	45	41 (91.1)	-0.89 (1.12)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	47	47 (100.0)	-1.13 (1.11)	-2.7	-2.00	-1.17	-0.17	2.3	-0.08 [-0.50, 0.34]
			Placebo	45	41 (91.1)	-1.04 (1.08)	-3.5	-1.67	-1.00	-0.50	2.3	
		Week 52	Tezepelumab	47	47 (100.0)	-1.12 (1.11)	-2.7	-2.00	-1.17	-0.33	2.3	-0.15 [-0.57, 0.27]
			Placebo	45	41 (91.1)	-0.95 (1.14)	-3.5	-1.67	-0.83	-0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.76 (0.87)	0.0	2.33	2.83	3.17	4.8	
			Placebo	55	55 (100.0)	2.75 (0.71)	1.3	2.33	2.83	3.17	4.7	
		Week 2	Tezepelumab	57	55 (96.5)	2.21 (1.00)	0.0	1.33	2.33	3.00	4.2	
			Placebo	55	50 (90.9)	2.26 (0.81)	0.3	1.83	2.33	2.67	4.8	
		Week 4	Tezepelumab	57	55 (96.5)	1.99 (0.98)	0.2	1.33	2.17	2.83	3.5	
			Placebo	55	50 (90.9)	2.13 (0.95)	0.2	1.33	2.33	2.67	4.2	
		Week 6	Tezepelumab	57	55 (96.5)	1.87 (1.06)	0.0	1.00	1.83	2.67	4.0	
			Placebo	55	50 (90.9)	2.06 (1.15)	0.2	1.17	2.17	2.67	5.5	
		Week 8	Tezepelumab	57	55 (96.5)	1.72 (1.17)	0.0	0.83	1.67	2.67	4.8	
			Placebo	55	51 (92.7)	1.97 (1.12)	0.0	1.00	2.17	2.67	4.7	
		Week 10	Tezepelumab	57	55 (96.5)	1.62 (1.15)	0.0	0.67	1.50	2.67	4.3	
			Placebo	55	51 (92.7)	2.01 (1.09)	0.0	1.00	2.00	2.67	5.3	
		Week 12	Tezepelumab	57	55 (96.5)	1.51 (1.10)	0.0	0.50	1.50	2.50	4.3	
			Placebo	55	51 (92.7)	1.77 (1.02)	0.0	1.00	1.83	2.33	4.3	
		Week 14	Tezepelumab	57	55 (96.5)	1.45 (1.11)	0.0	0.50	1.33	2.17	4.3	
			Placebo	55	51 (92.7)	1.73 (0.99)	0.0	1.00	1.83	2.17	5.0	
		Week 16	Tezepelumab	57	55 (96.5)	1.60 (1.18)	0.0	0.50	1.50	2.50	4.3	
			Placebo	55	51 (92.7)	1.91 (1.21)	0.0	0.83	2.00	2.67	5.0	
		Week 18	Tezepelumab	57	55 (96.5)	1.57 (1.09)	0.0	0.67	1.50	2.33	4.3	
			Placebo	55	51 (92.7)	1.80 (1.18)	0.0	0.83	1.83	2.33	5.0	
		Week 20	Tezepelumab	57	55 (96.5)	1.56 (1.14)	0.0	0.50	1.50	2.33	5.0	
			Placebo	55	51 (92.7)	1.90 (1.12)	0.0	1.00	2.00	2.67	5.0	
		Week 22	Tezepelumab	57	55 (96.5)	1.64 (1.03)	0.0	0.83	1.83	2.33	4.3	
			Placebo	55	51 (92.7)	1.85 (1.17)	0.0	0.83	2.00	2.67	5.0	
		Week 24	Tezepelumab	57	55 (96.5)	1.65 (1.12)	0.0	0.50	1.67	2.50	4.3	
			Placebo	55	51 (92.7)	1.90 (1.07)	0.0	1.00	2.00	2.50	4.5	
		Week 26	Tezepelumab	57	56 (98.2)	1.69 (1.14)	0.0	0.75	1.67	2.67	4.3	
			Placebo	55	51 (92.7)	1.84 (1.11)	0.0	1.00	1.83	2.50	4.5	
		Week 28	Tezepelumab	57	57 (100.0)	1.60 (1.14)	0.0	0.50	1.50	2.33	4.3	
			Placebo	55	51 (92.7)	1.87 (1.19)	0.0	1.00	1.83	2.67	4.5	
		Week 30	Tezepelumab	57	57 (100.0)	1.60 (1.12)	0.0	0.67	1.50	2.33	4.3	
			Placebo	55	51 (92.7)	1.88 (1.17)	0.0	0.83	1.83	2.67	4.5	
		Week 32	Tezepelumab	57	57 (100.0)	1.57 (1.12)	0.0	0.67	1.67	2.50	4.3	
			Placebo	55	51 (92.7)	1.85 (1.12)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 65 years	Absolute values	Week 34	Tezepelumab	57	57 (100.0)	1.62 (1.16)	0.0	0.67	1.50	2.50	4.3	
			Placebo	55	51 (92.7)	1.79 (1.14)	0.0	0.83	1.83	2.33	4.5	
		Week 36	Tezepelumab	57	57 (100.0)	1.61 (1.10)	0.0	0.83	1.67	2.50	4.3	
			Placebo	55	51 (92.7)	1.97 (1.16)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	57	57 (100.0)	1.61 (1.21)	0.0	0.50	1.67	2.50	4.5	
			Placebo	55	51 (92.7)	1.85 (1.14)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	57	57 (100.0)	1.62 (1.17)	0.0	0.50	1.83	2.67	4.3	
			Placebo	55	51 (92.7)	1.96 (1.14)	0.0	1.17	2.00	2.50	4.5	
		Week 42	Tezepelumab	57	57 (100.0)	1.59 (1.14)	0.0	0.83	1.67	2.33	4.3	
			Placebo	55	51 (92.7)	1.86 (1.05)	0.0	1.00	2.00	2.50	4.5	
		Week 44	Tezepelumab	57	57 (100.0)	1.62 (1.13)	0.0	0.67	1.67	2.67	4.3	
			Placebo	55	51 (92.7)	1.94 (1.09)	0.0	1.17	2.00	2.67	4.5	
		Week 46	Tezepelumab	57	57 (100.0)	1.61 (1.18)	0.0	0.67	1.50	2.67	4.3	
			Placebo	55	51 (92.7)	1.80 (0.98)	0.0	1.17	1.83	2.33	4.5	
		Week 48	Tezepelumab	57	57 (100.0)	1.65 (1.17)	0.0	0.67	1.67	2.67	4.3	
			Placebo	55	51 (92.7)	1.85 (1.03)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	57	57 (100.0)	1.59 (1.19)	0.0	0.67	1.50	2.33	4.3	
			Placebo	55	51 (92.7)	1.77 (1.02)	0.0	1.00	1.67	2.33	4.5	
		Week 52	Tezepelumab	57	57 (100.0)	1.63 (1.16)	0.0	0.67	1.50	2.33	4.3	
			Placebo	55	51 (92.7)	1.82 (1.07)	0.0	1.00	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 2	Tezepelumab	57	55 (96.5)	-0.57 (0.73)	-2.8	-1.00	-0.33	0.00	0.7	-0.14 [-0.52, 0.25]
			Placebo	55	50 (90.9)	-0.47 (0.72)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	57	55 (96.5)	-0.80 (0.83)	-2.5	-1.17	-0.83	-0.33	2.3	-0.21 [-0.60, 0.17]
			Placebo	55	50 (90.9)	-0.61 (0.94)	-3.0	-1.33	-0.33	0.00	1.2	
		Week 6	Tezepelumab	57	55 (96.5)	-0.92 (0.96)	-2.7	-1.50	-1.00	-0.33	2.3	-0.24 [-0.63, 0.14]
			Placebo	55	50 (90.9)	-0.67 (1.04)	-3.3	-1.33	-0.50	0.00	1.5	
		Week 8	Tezepelumab	57	55 (96.5)	-1.07 (1.07)	-3.0	-1.83	-1.00	-0.50	2.3	-0.28 [-0.67, 0.10]
			Placebo	55	51 (92.7)	-0.77 (1.02)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	57	55 (96.5)	-1.17 (1.06)	-3.2	-1.83	-1.33	-0.50	2.3	-0.39 [-0.78, -0.01]
			Placebo	55	51 (92.7)	-0.73 (1.18)	-3.3	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	57	55 (96.5)	-1.27 (1.03)	-3.0	-2.17	-1.17	-0.67	2.3	-0.29 [-0.67, 0.10]
			Placebo	55	51 (92.7)	-0.98 (1.03)	-3.3	-1.67	-0.83	-0.50	1.3	
		Week 14	Tezepelumab	57	55 (96.5)	-1.34 (1.04)	-3.7	-2.00	-1.50	-0.83	2.3	-0.30 [-0.69, 0.08]
			Placebo	55	51 (92.7)	-1.02 (1.06)	-3.2	-1.67	-1.17	-0.50	2.3	
		Week 16	Tezepelumab	57	55 (96.5)	-1.18 (1.07)	-3.0	-2.17	-1.00	-0.50	2.3	-0.31 [-0.69, 0.08]
			Placebo	55	51 (92.7)	-0.84 (1.17)	-3.2	-1.50	-0.83	0.00	2.3	
		Week 18	Tezepelumab	57	55 (96.5)	-1.22 (1.01)	-3.5	-1.83	-1.00	-0.67	2.3	-0.25 [-0.63, 0.13]
			Placebo	55	51 (92.7)	-0.94 (1.21)	-3.2	-1.83	-1.00	-0.17	2.3	
		Week 20	Tezepelumab	57	55 (96.5)	-1.23 (1.02)	-3.2	-2.00	-1.33	-0.67	2.3	-0.35 [-0.73, 0.03]
			Placebo	55	51 (92.7)	-0.85 (1.16)	-3.2	-1.67	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	57	55 (96.5)	-1.14 (1.06)	-3.0	-2.00	-1.17	-0.67	2.3	-0.22 [-0.61, 0.16]
			Placebo	55	51 (92.7)	-0.90 (1.15)	-3.3	-1.83	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	57	55 (96.5)	-1.13 (1.02)	-3.2	-2.00	-1.17	-0.50	2.3	-0.27 [-0.65, 0.12]
			Placebo	55	51 (92.7)	-0.85 (1.12)	-3.2	-1.50	-0.83	0.00	2.3	
		Week 26	Tezepelumab	57	56 (98.2)	-1.08 (1.07)	-2.8	-2.00	-1.00	-0.33	2.3	-0.16 [-0.54, 0.22]
			Placebo	55	51 (92.7)	-0.91 (1.13)	-3.2	-1.83	-1.00	-0.17	2.3	
		Week 28	Tezepelumab	57	57 (100.0)	-1.16 (1.11)	-3.2	-2.00	-1.33	-0.50	2.3	-0.25 [-0.63, 0.13]
			Placebo	55	51 (92.7)	-0.87 (1.18)	-3.2	-1.83	-1.00	-0.17	2.3	
		Week 30	Tezepelumab	57	57 (100.0)	-1.16 (1.12)	-3.5	-2.00	-1.33	-0.50	2.3	-0.25 [-0.63, 0.13]
			Placebo	55	51 (92.7)	-0.87 (1.20)	-3.2	-1.50	-1.00	-0.17	2.3	
		Week 32	Tezepelumab	57	57 (100.0)	-1.19 (1.04)	-3.0	-2.00	-1.17	-0.50	2.3	-0.27 [-0.65, 0.11]
			Placebo	55	51 (92.7)	-0.90 (1.15)	-3.0	-1.50	-1.17	-0.33	2.3	
		Week 34	Tezepelumab	57	57 (100.0)	-1.14 (1.13)	-2.8	-2.00	-1.33	-0.50	2.3	-0.16 [-0.54, 0.21]
			Placebo	55	51 (92.7)	-0.95 (1.14)	-3.2	-1.67	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 65 years	Change from baseline	Week 36	Tezepelumab	57	57 (100.0)	-1.15 (1.11)	-3.0	-2.00	-1.17	-0.33	2.3	-0.33 [-0.71, 0.05]
			Placebo	55	51 (92.7)	-0.78 (1.19)	-3.5	-1.33	-1.00	0.00	2.3	
		Week 38	Tezepelumab	57	57 (100.0)	-1.14 (1.16)	-3.0	-2.00	-1.33	-0.17	2.3	-0.21 [-0.59, 0.16]
			Placebo	55	51 (92.7)	-0.90 (1.15)	-3.2	-1.67	-1.00	0.00	2.3	
		Week 40	Tezepelumab	57	57 (100.0)	-1.13 (1.15)	-3.2	-2.17	-1.00	-0.33	2.3	-0.30 [-0.68, 0.08]
			Placebo	55	51 (92.7)	-0.78 (1.19)	-3.2	-1.67	-0.83	0.17	2.3	
		Week 42	Tezepelumab	57	57 (100.0)	-1.17 (1.13)	-3.3	-2.00	-1.17	-0.50	2.3	-0.25 [-0.63, 0.13]
			Placebo	55	51 (92.7)	-0.89 (1.08)	-2.8	-1.50	-1.00	-0.17	2.3	
		Week 44	Tezepelumab	57	57 (100.0)	-1.13 (1.13)	-3.5	-2.00	-1.17	-0.50	2.3	-0.29 [-0.67, 0.09]
			Placebo	55	51 (92.7)	-0.81 (1.15)	-3.3	-1.50	-0.83	0.00	2.3	
		Week 46	Tezepelumab	57	57 (100.0)	-1.15 (1.13)	-3.3	-2.00	-1.17	-0.17	2.3	-0.18 [-0.56, 0.20]
			Placebo	55	51 (92.7)	-0.95 (1.02)	-3.2	-1.67	-1.00	-0.33	2.3	
		Week 48	Tezepelumab	57	57 (100.0)	-1.11 (1.12)	-2.7	-2.00	-1.00	-0.50	2.3	-0.19 [-0.57, 0.19]
			Placebo	55	51 (92.7)	-0.90 (1.08)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	57	57 (100.0)	-1.17 (1.14)	-2.7	-2.00	-1.33	-0.50	2.3	-0.17 [-0.55, 0.20]
			Placebo	55	51 (92.7)	-0.98 (1.07)	-3.5	-1.67	-1.00	-0.50	2.3	
		Week 52	Tezepelumab	57	57 (100.0)	-1.13 (1.12)	-2.7	-2.00	-1.17	-0.50	2.3	-0.18 [-0.56, 0.20]
			Placebo	55	51 (92.7)	-0.92 (1.12)	-3.5	-1.67	-1.00	-0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.44 (0.42)	1.8	2.17	2.33	2.83	3.2	
			Placebo	10	10 (100.0)	2.47 (0.79)	0.3	2.50	2.58	3.00	3.0	
		Week 2	Tezepelumab	9	8 (88.9)	2.33 (0.60)	1.5	1.75	2.50	2.83	3.0	
			Placebo	10	8 (80.0)	2.48 (0.47)	1.7	2.25	2.42	2.83	3.2	
		Week 4	Tezepelumab	9	8 (88.9)	1.90 (0.69)	0.8	1.33	2.08	2.42	2.7	
			Placebo	10	8 (80.0)	2.31 (0.66)	1.5	1.83	2.25	2.67	3.5	
		Week 6	Tezepelumab	9	8 (88.9)	1.98 (0.51)	1.3	1.50	2.00	2.42	2.7	
			Placebo	10	8 (80.0)	2.35 (0.69)	1.2	2.00	2.33	2.83	3.3	
		Week 8	Tezepelumab	9	8 (88.9)	1.92 (0.49)	1.3	1.50	1.83	2.33	2.7	
			Placebo	10	8 (80.0)	2.60 (0.64)	1.7	2.00	2.83	3.00	3.5	
		Week 10	Tezepelumab	9	8 (88.9)	1.96 (0.28)	1.5	1.75	2.00	2.17	2.3	
			Placebo	10	8 (80.0)	2.42 (0.61)	1.3	2.08	2.42	2.92	3.2	
		Week 12	Tezepelumab	9	8 (88.9)	1.88 (0.48)	1.2	1.50	1.92	2.25	2.5	
			Placebo	10	8 (80.0)	2.44 (0.53)	1.8	1.92	2.50	2.83	3.2	
		Week 14	Tezepelumab	9	8 (88.9)	1.75 (0.46)	1.2	1.42	1.58	2.25	2.3	
			Placebo	10	8 (80.0)	2.21 (0.75)	1.0	1.75	2.17	2.83	3.2	
		Week 16	Tezepelumab	9	8 (88.9)	1.83 (0.46)	1.3	1.42	1.83	2.17	2.5	
			Placebo	10	8 (80.0)	2.29 (0.62)	1.5	1.75	2.33	2.75	3.2	
		Week 18	Tezepelumab	9	9 (100.0)	1.80 (0.48)	1.0	1.50	1.67	2.17	2.5	
			Placebo	10	8 (80.0)	2.31 (0.68)	1.2	1.83	2.67	2.75	2.8	
		Week 20	Tezepelumab	9	9 (100.0)	1.98 (0.63)	1.2	1.50	1.83	2.50	2.8	
			Placebo	10	8 (80.0)	2.42 (0.63)	1.5	1.83	2.58	2.83	3.3	
		Week 22	Tezepelumab	9	9 (100.0)	1.91 (0.43)	1.2	1.67	1.83	2.17	2.5	
			Placebo	10	8 (80.0)	2.42 (0.75)	1.5	1.75	2.50	2.83	3.7	
		Week 24	Tezepelumab	9	9 (100.0)	1.76 (0.48)	1.0	1.50	1.83	2.17	2.3	
			Placebo	10	8 (80.0)	2.58 (0.58)	1.7	2.25	2.50	3.00	3.5	
		Week 26	Tezepelumab	9	9 (100.0)	1.83 (0.43)	1.2	1.50	1.83	2.17	2.5	
			Placebo	10	8 (80.0)	2.44 (1.01)	1.2	1.42	2.67	3.08	4.0	
		Week 28	Tezepelumab	9	9 (100.0)	2.02 (0.61)	1.0	1.50	2.17	2.50	2.7	
			Placebo	10	9 (90.0)	2.09 (1.19)	0.0	1.17	2.50	2.67	4.0	
		Week 30	Tezepelumab	9	9 (100.0)	1.85 (0.50)	1.0	1.50	2.00	2.17	2.5	
			Placebo	10	9 (90.0)	1.98 (0.96)	0.0	1.50	2.17	2.67	3.0	
		Week 32	Tezepelumab	9	9 (100.0)	1.63 (0.70)	0.3	1.17	1.83	2.00	2.5	
			Placebo	10	9 (90.0)	1.91 (0.97)	0.0	1.50	2.33	2.67	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 65 years	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.78 (0.78)	0.7	1.33	1.50	2.50	2.7	
			Placebo	10	9 (90.0)	2.00 (0.79)	0.2	1.83	2.17	2.50	2.8	
		Week 36	Tezepelumab	9	9 (100.0)	1.63 (0.69)	0.5	1.17	1.50	2.00	2.7	
			Placebo	10	9 (90.0)	2.13 (0.95)	0.0	1.83	2.17	2.83	3.2	
		Week 38	Tezepelumab	9	9 (100.0)	1.74 (0.68)	1.0	1.00	1.67	2.17	2.7	
			Placebo	10	9 (90.0)	1.91 (0.85)	0.0	1.67	2.17	2.67	2.7	
		Week 40	Tezepelumab	9	9 (100.0)	1.52 (0.75)	0.3	0.83	1.67	2.00	2.5	
			Placebo	10	9 (90.0)	2.24 (1.12)	0.0	1.50	2.50	2.83	3.7	
		Week 42	Tezepelumab	9	9 (100.0)	1.54 (0.75)	0.5	1.00	1.67	2.00	2.5	
			Placebo	10	9 (90.0)	1.83 (0.93)	0.0	1.50	1.83	2.33	3.3	
		Week 44	Tezepelumab	9	9 (100.0)	1.56 (0.76)	0.5	1.00	1.50	2.33	2.5	
			Placebo	10	9 (90.0)	1.94 (0.93)	0.0	1.67	2.17	2.50	3.0	
		Week 46	Tezepelumab	9	9 (100.0)	1.72 (0.62)	0.7	1.50	1.83	2.17	2.5	
			Placebo	10	9 (90.0)	2.06 (1.01)	0.0	1.83	2.00	2.17	3.8	
		Week 48	Tezepelumab	9	9 (100.0)	1.50 (0.68)	0.7	1.00	1.50	2.17	2.3	
			Placebo	10	9 (90.0)	2.07 (1.16)	0.0	1.50	2.17	2.50	4.2	
		Week 50	Tezepelumab	9	9 (100.0)	1.48 (0.64)	0.7	1.00	1.50	2.00	2.3	
			Placebo	10	9 (90.0)	1.81 (0.81)	0.0	1.67	1.83	2.33	2.8	
		Week 52	Tezepelumab	9	9 (100.0)	1.43 (0.77)	0.3	1.00	1.50	2.00	2.5	
			Placebo	10	9 (90.0)	2.00 (0.89)	0.0	1.83	2.17	2.50	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 2	Tezepelumab	9	8 (88.9)	-0.19 (0.35)	-0.7	-0.50	-0.17	0.17	0.2	0.23 [-0.75, 1.21]
			Placebo	10	8 (80.0)	-0.27 (0.38)	-0.8	-0.50	-0.33	0.00	0.3	
		Week 4	Tezepelumab	9	8 (88.9)	-0.63 (0.83)	-2.0	-1.33	-0.42	0.17	0.2	-0.27 [-1.25, 0.72]
			Placebo	10	8 (80.0)	-0.44 (0.55)	-1.0	-0.92	-0.50	-0.08	0.5	
		Week 6	Tezepelumab	9	8 (88.9)	-0.54 (0.69)	-1.8	-1.00	-0.25	0.00	0.0	-0.23 [-1.22, 0.75]
			Placebo	10	8 (80.0)	-0.40 (0.55)	-1.3	-0.75	-0.33	0.00	0.3	
		Week 8	Tezepelumab	9	8 (88.9)	-0.60 (0.68)	-1.7	-1.08	-0.50	-0.08	0.2	-0.68 [-1.69, 0.33]
			Placebo	10	8 (80.0)	-0.15 (0.67)	-1.0	-0.75	-0.08	0.25	1.0	
		Week 10	Tezepelumab	9	8 (88.9)	-0.56 (0.34)	-1.2	-0.75	-0.58	-0.25	-0.2	-0.54 [-1.54, 0.46]
			Placebo	10	8 (80.0)	-0.33 (0.49)	-1.2	-0.58	-0.42	0.08	0.3	
		Week 12	Tezepelumab	9	8 (88.9)	-0.65 (0.53)	-1.3	-1.08	-0.67	-0.25	0.2	-0.70 [-1.72, 0.31]
			Placebo	10	8 (80.0)	-0.31 (0.41)	-0.7	-0.67	-0.42	0.00	0.3	
		Week 14	Tezepelumab	9	8 (88.9)	-0.77 (0.60)	-1.8	-1.17	-0.67	-0.33	0.0	-0.36 [-1.35, 0.63]
			Placebo	10	8 (80.0)	-0.54 (0.67)	-1.5	-1.08	-0.50	0.00	0.3	
		Week 16	Tezepelumab	9	8 (88.9)	-0.69 (0.68)	-1.8	-1.00	-0.83	-0.17	0.3	-0.37 [-1.36, 0.62]
			Placebo	10	8 (80.0)	-0.46 (0.55)	-1.3	-0.83	-0.42	-0.08	0.3	
		Week 18	Tezepelumab	9	9 (100.0)	-0.65 (0.69)	-1.7	-1.17	-0.67	0.00	0.3	-0.32 [-1.28, 0.64]
			Placebo	10	8 (80.0)	-0.44 (0.63)	-1.3	-1.00	-0.25	0.00	0.3	
		Week 20	Tezepelumab	9	9 (100.0)	-0.46 (0.53)	-1.2	-1.00	-0.33	0.00	0.3	-0.22 [-1.17, 0.74]
			Placebo	10	8 (80.0)	-0.33 (0.68)	-1.3	-0.75	-0.42	0.08	0.8	
		Week 22	Tezepelumab	9	9 (100.0)	-0.54 (0.41)	-1.2	-0.67	-0.67	-0.17	0.0	-0.33 [-1.29, 0.63]
			Placebo	10	8 (80.0)	-0.33 (0.80)	-1.2	-0.92	-0.50	0.08	1.2	
		Week 24	Tezepelumab	9	9 (100.0)	-0.69 (0.56)	-1.3	-1.17	-0.67	-0.33	0.2	-0.84 [-1.84, 0.16]
			Placebo	10	8 (80.0)	-0.17 (0.68)	-1.0	-0.67	-0.25	0.25	1.0	
		Week 26	Tezepelumab	9	9 (100.0)	-0.61 (0.59)	-1.7	-1.00	-0.67	0.00	0.0	-0.36 [-1.32, 0.60]
			Placebo	10	8 (80.0)	-0.31 (1.03)	-1.5	-1.25	-0.33	0.33	1.5	
		Week 28	Tezepelumab	9	9 (100.0)	-0.43 (0.70)	-1.2	-0.83	-0.67	0.00	0.8	-0.04 [-0.97, 0.88]
			Placebo	10	9 (90.0)	-0.39 (0.94)	-1.8	-0.50	-0.33	-0.17	1.5	
		Week 30	Tezepelumab	9	9 (100.0)	-0.59 (0.51)	-1.3	-0.83	-0.67	-0.17	0.3	-0.16 [-1.08, 0.77]
			Placebo	10	9 (90.0)	-0.50 (0.66)	-1.7	-0.83	-0.50	-0.17	0.5	
		Week 32	Tezepelumab	9	9 (100.0)	-0.81 (0.60)	-2.0	-1.00	-0.83	-0.67	0.3	-0.38 [-1.31, 0.55]
			Placebo	10	9 (90.0)	-0.57 (0.66)	-1.8	-1.00	-0.33	-0.17	0.2	
		Week 34	Tezepelumab	9	9 (100.0)	-0.67 (0.71)	-1.7	-1.33	-0.50	-0.33	0.5	-0.30 [-1.23, 0.63]
			Placebo	10	9 (90.0)	-0.48 (0.49)	-1.0	-0.83	-0.67	-0.17	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 65 years	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-0.81 (0.68)	-1.7	-1.17	-0.83	-0.67	0.5	-0.73 [-1.69, 0.23]
			Placebo	10	9 (90.0)	-0.35 (0.57)	-1.2	-0.67	-0.33	-0.17	0.7	
		Week 38	Tezepelumab	9	9 (100.0)	-0.70 (0.56)	-1.3	-1.17	-0.83	-0.50	0.5	-0.24 [-1.17, 0.68]
			Placebo	10	9 (90.0)	-0.57 (0.51)	-1.2	-1.00	-0.83	-0.33	0.2	
		Week 40	Tezepelumab	9	9 (100.0)	-0.93 (0.65)	-1.8	-1.17	-1.17	-0.67	0.3	-0.95 [-1.93, 0.03]
			Placebo	10	9 (90.0)	-0.24 (0.79)	-1.3	-0.50	-0.33	0.17	1.2	
		Week 42	Tezepelumab	9	9 (100.0)	-0.91 (0.73)	-1.8	-1.50	-0.83	-0.67	0.3	-0.35 [-1.28, 0.58]
			Placebo	10	9 (90.0)	-0.65 (0.75)	-1.3	-1.17	-0.83	-0.33	0.8	
		Week 44	Tezepelumab	9	9 (100.0)	-0.89 (0.74)	-1.7	-1.50	-0.83	-0.33	0.3	-0.49 [-1.43, 0.45]
			Placebo	10	9 (90.0)	-0.54 (0.71)	-1.5	-1.17	-0.67	0.00	0.5	
		Week 46	Tezepelumab	9	9 (100.0)	-0.72 (0.65)	-1.5	-1.33	-0.67	-0.33	0.3	-0.41 [-1.34, 0.53]
			Placebo	10	9 (90.0)	-0.43 (0.79)	-1.2	-0.83	-0.67	-0.33	1.3	
		Week 48	Tezepelumab	9	9 (100.0)	-0.94 (0.71)	-2.2	-1.50	-0.83	-0.67	0.0	-0.64 [-1.59, 0.31]
			Placebo	10	9 (90.0)	-0.41 (0.95)	-1.5	-0.83	-0.50	-0.33	1.7	
		Week 50	Tezepelumab	9	9 (100.0)	-0.96 (0.72)	-2.2	-1.33	-0.83	-0.67	0.2	-0.47 [-1.41, 0.47]
			Placebo	10	9 (90.0)	-0.67 (0.53)	-1.5	-1.00	-0.67	-0.33	0.3	
		Week 52	Tezepelumab	9	9 (100.0)	-1.02 (0.83)	-2.2	-1.67	-0.83	-0.67	0.3	-0.78 [-1.74, 0.19]
			Placebo	10	9 (90.0)	-0.48 (0.52)	-1.5	-0.83	-0.33	-0.17	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	44	44 (100.0)	2.63 (0.72)	0.0	2.17	2.67	2.92	4.5	
			Placebo	45	45 (100.0)	2.67 (0.72)	0.3	2.33	2.67	3.00	4.5	
		Week 2	Tezepelumab	44	42 (95.5)	2.22 (0.84)	0.2	1.67	2.33	2.67	4.2	
			Placebo	45	39 (86.7)	2.30 (0.76)	0.5	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	44	42 (95.5)	2.06 (0.84)	0.2	1.50	2.25	2.67	3.5	
			Placebo	45	39 (86.7)	2.00 (0.87)	0.2	1.33	2.17	2.67	3.7	
		Week 6	Tezepelumab	44	42 (95.5)	1.94 (0.87)	0.0	1.50	1.92	2.67	3.7	
			Placebo	45	39 (86.7)	1.99 (1.01)	0.2	1.17	2.17	2.67	4.7	
		Week 8	Tezepelumab	44	42 (95.5)	1.75 (0.88)	0.0	1.33	1.67	2.50	3.3	
			Placebo	45	40 (88.9)	2.00 (1.05)	0.0	1.25	2.17	2.67	4.7	
		Week 10	Tezepelumab	44	42 (95.5)	1.65 (0.90)	0.0	1.00	1.58	2.17	3.7	
			Placebo	45	40 (88.9)	1.96 (0.93)	0.0	1.50	2.17	2.50	4.0	
		Week 12	Tezepelumab	44	42 (95.5)	1.57 (0.91)	0.0	1.00	1.58	2.50	3.0	
			Placebo	45	40 (88.9)	1.78 (0.94)	0.0	1.08	2.00	2.33	4.3	
		Week 14	Tezepelumab	44	42 (95.5)	1.54 (0.93)	0.0	0.83	1.50	2.17	3.7	
			Placebo	45	40 (88.9)	1.80 (0.90)	0.0	1.33	1.92	2.17	5.0	
		Week 16	Tezepelumab	44	42 (95.5)	1.65 (1.01)	0.0	1.17	1.75	2.50	4.3	
			Placebo	45	40 (88.9)	1.90 (0.95)	0.0	1.08	2.08	2.67	4.5	
		Week 18	Tezepelumab	44	43 (97.7)	1.67 (0.83)	0.0	1.17	1.83	2.17	3.3	
			Placebo	45	40 (88.9)	1.82 (0.98)	0.0	1.17	1.92	2.50	4.5	
		Week 20	Tezepelumab	44	43 (97.7)	1.58 (0.90)	0.0	1.00	1.83	2.00	3.5	
			Placebo	45	40 (88.9)	1.92 (0.97)	0.0	1.25	2.08	2.58	4.5	
		Week 22	Tezepelumab	44	43 (97.7)	1.69 (0.79)	0.0	1.17	1.83	2.17	3.3	
			Placebo	45	40 (88.9)	1.83 (1.02)	0.0	1.08	2.00	2.42	4.5	
		Week 24	Tezepelumab	44	43 (97.7)	1.66 (0.94)	0.0	1.00	1.83	2.33	3.5	
			Placebo	45	40 (88.9)	1.94 (0.93)	0.0	1.67	2.00	2.50	4.5	
		Week 26	Tezepelumab	44	44 (100.0)	1.71 (0.92)	0.0	1.25	1.83	2.33	3.7	
			Placebo	45	40 (88.9)	1.81 (0.97)	0.0	1.08	1.67	2.42	4.5	
		Week 28	Tezepelumab	44	44 (100.0)	1.67 (0.95)	0.0	1.17	1.67	2.33	3.5	
			Placebo	45	41 (91.1)	1.83 (1.11)	0.0	1.00	2.00	2.50	4.5	
		Week 30	Tezepelumab	44	44 (100.0)	1.66 (0.92)	0.0	1.17	1.67	2.17	3.7	
			Placebo	45	41 (91.1)	1.77 (1.09)	0.0	1.00	1.83	2.50	4.5	
		Week 32	Tezepelumab	44	44 (100.0)	1.53 (0.94)	0.0	1.00	1.67	2.08	3.7	
			Placebo	45	41 (91.1)	1.74 (0.99)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
<= 2	Absolute values	Week 34	Tezepelumab	44	44 (100.0)	1.63 (1.04)	0.0	0.92	1.50	2.42	4.2	
			Placebo	45	41 (91.1)	1.74 (0.92)	0.0	1.17	1.83	2.33	4.5	
		Week 36	Tezepelumab	44	44 (100.0)	1.66 (0.97)	0.0	1.00	1.75	2.33	3.7	
			Placebo	45	41 (91.1)	1.74 (0.96)	0.0	1.00	1.83	2.33	4.5	
		Week 38	Tezepelumab	44	44 (100.0)	1.61 (1.06)	0.0	1.00	1.67	2.25	4.0	
			Placebo	45	41 (91.1)	1.68 (0.94)	0.0	1.00	1.67	2.17	4.5	
		Week 40	Tezepelumab	44	44 (100.0)	1.61 (1.03)	0.0	0.75	1.75	2.33	3.7	
			Placebo	45	41 (91.1)	1.82 (1.05)	0.0	1.17	1.83	2.50	4.5	
		Week 42	Tezepelumab	44	44 (100.0)	1.59 (1.02)	0.0	0.92	1.58	2.33	3.7	
			Placebo	45	41 (91.1)	1.76 (0.98)	0.0	1.00	1.83	2.50	4.5	
		Week 44	Tezepelumab	44	44 (100.0)	1.67 (0.96)	0.0	1.00	1.75	2.50	3.3	
			Placebo	45	41 (91.1)	1.75 (0.98)	0.0	1.17	1.83	2.33	4.5	
		Week 46	Tezepelumab	44	44 (100.0)	1.67 (1.04)	0.0	0.83	1.83	2.42	3.7	
			Placebo	45	41 (91.1)	1.77 (0.96)	0.0	1.17	1.83	2.33	4.5	
		Week 48	Tezepelumab	44	44 (100.0)	1.67 (1.04)	0.0	0.92	1.75	2.33	4.0	
			Placebo	45	41 (91.1)	1.76 (1.06)	0.0	1.00	2.00	2.33	4.5	
		Week 50	Tezepelumab	44	44 (100.0)	1.57 (1.03)	0.0	0.92	1.50	2.25	4.0	
			Placebo	45	41 (91.1)	1.63 (0.93)	0.0	1.00	1.67	2.17	4.5	
		Week 52	Tezepelumab	44	44 (100.0)	1.60 (1.02)	0.0	1.00	1.50	2.25	4.0	
			Placebo	45	41 (91.1)	1.74 (0.96)	0.0	1.17	1.83	2.33	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 2	Tezepelumab	44	42 (95.5)	-0.45 (0.57)	-1.8	-0.83	-0.33	0.00	0.7	-0.03 [-0.47, 0.41]
			Placebo	45	39 (86.7)	-0.43 (0.58)	-2.2	-0.83	-0.33	0.00	0.5	
		Week 4	Tezepelumab	44	42 (95.5)	-0.61 (0.63)	-2.3	-1.00	-0.58	-0.17	0.7	0.17 [-0.27, 0.61]
			Placebo	45	39 (86.7)	-0.74 (0.88)	-3.0	-1.33	-0.67	0.00	0.8	
		Week 6	Tezepelumab	44	42 (95.5)	-0.73 (0.69)	-2.5	-1.17	-0.75	-0.17	0.3	0.01 [-0.43, 0.44]
			Placebo	45	39 (86.7)	-0.74 (0.93)	-3.3	-1.33	-0.50	-0.17	0.5	
		Week 8	Tezepelumab	44	42 (95.5)	-0.92 (0.68)	-2.5	-1.50	-1.00	-0.50	0.2	-0.21 [-0.65, 0.22]
			Placebo	45	40 (88.9)	-0.74 (1.03)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	44	42 (95.5)	-1.02 (0.75)	-2.5	-1.50	-1.17	-0.50	0.8	-0.28 [-0.72, 0.15]
			Placebo	45	40 (88.9)	-0.78 (0.93)	-3.3	-1.25	-0.58	-0.17	0.7	
		Week 12	Tezepelumab	44	42 (95.5)	-1.10 (0.73)	-2.5	-1.83	-1.17	-0.67	0.3	-0.17 [-0.60, 0.27]
			Placebo	45	40 (88.9)	-0.96 (0.89)	-3.3	-1.17	-0.75	-0.33	0.3	
		Week 14	Tezepelumab	44	42 (95.5)	-1.13 (0.71)	-2.3	-1.83	-1.17	-0.67	0.2	-0.23 [-0.67, 0.20]
			Placebo	45	40 (88.9)	-0.94 (0.95)	-3.2	-1.42	-0.83	-0.33	1.0	
		Week 16	Tezepelumab	44	42 (95.5)	-1.02 (0.83)	-2.5	-1.67	-1.00	-0.67	1.5	-0.19 [-0.63, 0.24]
			Placebo	45	40 (88.9)	-0.84 (0.96)	-3.2	-1.33	-0.67	-0.08	0.5	
		Week 18	Tezepelumab	44	43 (97.7)	-0.98 (0.67)	-2.5	-1.50	-1.00	-0.67	0.3	-0.07 [-0.50, 0.36]
			Placebo	45	40 (88.9)	-0.92 (0.96)	-3.2	-1.58	-0.83	0.00	0.3	
		Week 20	Tezepelumab	44	43 (97.7)	-1.07 (0.74)	-2.5	-1.67	-1.00	-0.50	0.3	-0.28 [-0.72, 0.15]
			Placebo	45	40 (88.9)	-0.83 (0.99)	-3.2	-1.33	-0.67	-0.17	1.0	
		Week 22	Tezepelumab	44	43 (97.7)	-0.96 (0.78)	-2.5	-1.50	-0.83	-0.67	1.8	-0.05 [-0.49, 0.38]
			Placebo	45	40 (88.9)	-0.91 (0.99)	-3.3	-1.58	-0.83	-0.33	1.2	
		Week 24	Tezepelumab	44	43 (97.7)	-0.99 (0.77)	-2.5	-1.67	-1.00	-0.33	0.2	-0.21 [-0.64, 0.22]
			Placebo	45	40 (88.9)	-0.80 (0.97)	-3.2	-1.33	-0.75	0.00	1.0	
		Week 26	Tezepelumab	44	44 (100.0)	-0.92 (0.79)	-2.5	-1.50	-0.83	-0.25	0.2	0.01 [-0.42, 0.44]
			Placebo	45	40 (88.9)	-0.93 (0.95)	-2.8	-1.50	-1.00	-0.33	1.5	
		Week 28	Tezepelumab	44	44 (100.0)	-0.96 (0.88)	-2.5	-1.67	-0.92	-0.33	0.8	-0.10 [-0.53, 0.32]
			Placebo	45	41 (91.1)	-0.86 (1.08)	-2.8	-1.67	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	44	44 (100.0)	-0.97 (0.85)	-2.5	-1.50	-0.92	-0.42	1.8	-0.06 [-0.49, 0.37]
			Placebo	45	41 (91.1)	-0.91 (1.12)	-3.2	-1.50	-1.00	-0.17	2.0	
		Week 32	Tezepelumab	44	44 (100.0)	-1.09 (0.82)	-2.5	-1.83	-1.00	-0.58	0.8	-0.17 [-0.59, 0.26]
			Placebo	45	41 (91.1)	-0.94 (0.99)	-3.0	-1.50	-0.67	-0.33	0.7	
		Week 34	Tezepelumab	44	44 (100.0)	-1.00 (0.94)	-2.5	-1.75	-1.08	-0.33	2.0	-0.06 [-0.49, 0.36]
			Placebo	45	41 (91.1)	-0.94 (0.88)	-2.8	-1.33	-0.83	-0.33	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
<= 2	Change from baseline	Week 36	Tezepelumab	44	44 (100.0)	-0.97 (0.90)	-2.5	-1.75	-1.00	-0.17	1.5	-0.03 [-0.46, 0.39]
			Placebo	45	41 (91.1)	-0.94 (0.93)	-3.5	-1.33	-1.00	-0.33	0.7	
		Week 38	Tezepelumab	44	44 (100.0)	-1.02 (0.96)	-2.5	-1.83	-1.17	-0.33	2.3	-0.02 [-0.44, 0.41]
			Placebo	45	41 (91.1)	-1.00 (0.83)	-3.0	-1.33	-1.00	-0.67	0.5	
		Week 40	Tezepelumab	44	44 (100.0)	-1.02 (0.91)	-2.5	-1.67	-1.00	-0.33	1.7	-0.16 [-0.59, 0.26]
			Placebo	45	41 (91.1)	-0.87 (0.96)	-3.2	-1.33	-0.83	-0.33	1.2	
		Week 42	Tezepelumab	44	44 (100.0)	-1.04 (0.92)	-2.7	-1.83	-0.92	-0.50	2.0	-0.13 [-0.56, 0.29]
			Placebo	45	41 (91.1)	-0.92 (0.88)	-2.8	-1.33	-1.00	-0.17	0.8	
		Week 44	Tezepelumab	44	44 (100.0)	-0.95 (0.86)	-2.5	-1.67	-0.83	-0.25	1.5	-0.02 [-0.45, 0.40]
			Placebo	45	41 (91.1)	-0.93 (0.93)	-3.3	-1.50	-0.83	-0.33	0.5	
		Week 46	Tezepelumab	44	44 (100.0)	-0.96 (0.93)	-2.7	-1.50	-0.92	-0.17	1.7	-0.05 [-0.48, 0.37]
			Placebo	45	41 (91.1)	-0.91 (0.89)	-2.8	-1.33	-1.00	-0.50	1.3	
		Week 48	Tezepelumab	44	44 (100.0)	-0.96 (0.92)	-2.5	-1.75	-0.83	-0.33	1.8	-0.04 [-0.46, 0.39]
			Placebo	45	41 (91.1)	-0.92 (1.02)	-3.3	-1.50	-0.83	-0.33	1.7	
		Week 50	Tezepelumab	44	44 (100.0)	-1.06 (0.93)	-2.5	-1.67	-1.17	-0.50	1.8	-0.00 [-0.43, 0.42]
			Placebo	45	41 (91.1)	-1.05 (0.80)	-3.5	-1.33	-1.00	-0.67	0.5	
		Week 52	Tezepelumab	44	44 (100.0)	-1.03 (0.93)	-2.7	-1.67	-1.00	-0.50	1.8	-0.10 [-0.52, 0.33]
			Placebo	45	41 (91.1)	-0.94 (0.85)	-3.5	-1.33	-0.83	-0.50	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	22	22 (100.0)	2.89 (1.00)	0.3	2.33	2.83	3.33	4.8	
			Placebo	20	20 (100.0)	2.79 (0.74)	1.3	2.25	3.00	3.17	4.7	
		Week 2	Tezepelumab	22	21 (95.5)	2.24 (1.19)	0.0	1.33	2.67	3.33	3.8	
			Placebo	20	19 (95.0)	2.28 (0.83)	0.3	2.00	2.17	2.50	4.7	
		Week 4	Tezepelumab	22	21 (95.5)	1.80 (1.13)	0.2	0.67	1.83	2.83	3.5	
			Placebo	20	19 (95.0)	2.47 (0.94)	0.7	1.83	2.33	3.33	4.2	
		Week 6	Tezepelumab	22	21 (95.5)	1.78 (1.24)	0.0	0.50	1.67	2.67	4.0	
			Placebo	20	19 (95.0)	2.33 (1.27)	0.8	1.17	2.33	3.00	5.5	
		Week 8	Tezepelumab	22	21 (95.5)	1.74 (1.48)	0.0	0.50	1.67	2.83	4.8	
			Placebo	20	19 (95.0)	2.18 (1.17)	0.2	1.00	2.17	3.17	4.7	
		Week 10	Tezepelumab	22	21 (95.5)	1.67 (1.41)	0.0	0.33	1.83	2.83	4.3	
			Placebo	20	19 (95.0)	2.30 (1.26)	0.8	1.00	2.00	3.00	5.3	
		Week 12	Tezepelumab	22	21 (95.5)	1.53 (1.31)	0.0	0.50	1.50	2.67	4.3	
			Placebo	20	19 (95.0)	2.03 (1.10)	0.0	1.00	2.00	2.83	4.2	
		Week 14	Tezepelumab	22	21 (95.5)	1.39 (1.28)	0.0	0.50	1.17	2.00	4.3	
			Placebo	20	19 (95.0)	1.77 (1.13)	0.0	1.00	1.67	2.17	5.0	
		Week 16	Tezepelumab	22	21 (95.5)	1.59 (1.33)	0.0	0.67	1.33	2.67	4.3	
			Placebo	20	19 (95.0)	2.08 (1.51)	0.0	0.67	1.83	3.17	5.0	
		Week 18	Tezepelumab	22	21 (95.5)	1.45 (1.35)	0.0	0.50	0.83	2.33	4.3	
			Placebo	20	19 (95.0)	1.98 (1.43)	0.0	0.83	1.83	2.83	5.0	
		Week 20	Tezepelumab	22	21 (95.5)	1.69 (1.43)	0.0	0.50	1.17	2.67	5.0	
			Placebo	20	19 (95.0)	2.08 (1.30)	0.2	1.17	2.17	3.00	5.0	
		Week 22	Tezepelumab	22	21 (95.5)	1.66 (1.28)	0.0	0.50	1.83	2.50	4.3	
			Placebo	20	19 (95.0)	2.13 (1.35)	0.0	1.00	2.00	3.33	5.0	
		Week 24	Tezepelumab	22	21 (95.5)	1.67 (1.27)	0.0	0.67	1.67	2.67	4.3	
			Placebo	20	19 (95.0)	2.10 (1.25)	0.2	0.67	2.33	3.17	4.2	
		Week 26	Tezepelumab	22	21 (95.5)	1.71 (1.36)	0.0	0.67	1.50	2.67	4.3	
			Placebo	20	19 (95.0)	2.15 (1.35)	0.0	1.00	2.00	3.33	4.2	
		Week 28	Tezepelumab	22	22 (100.0)	1.63 (1.36)	0.0	0.33	1.58	2.67	4.3	
			Placebo	20	19 (95.0)	2.08 (1.35)	0.0	1.00	2.17	3.33	4.2	
		Week 30	Tezepelumab	22	22 (100.0)	1.58 (1.31)	0.0	0.67	1.17	2.67	4.3	
			Placebo	20	19 (95.0)	2.15 (1.23)	0.0	1.00	2.00	3.33	4.2	
		Week 32	Tezepelumab	22	22 (100.0)	1.66 (1.30)	0.0	0.50	1.75	2.67	4.3	
			Placebo	20	19 (95.0)	2.11 (1.28)	0.3	1.00	2.00	3.33	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 2	Absolute values	Week 34	Tezepelumab	22	22 (100.0)	1.66 (1.28)	0.0	0.67	1.67	2.67	4.3	
			Placebo	20	19 (95.0)	2.00 (1.42)	0.0	0.67	1.83	3.33	4.5	
		Week 36	Tezepelumab	22	22 (100.0)	1.51 (1.21)	0.0	0.67	1.17	2.50	4.3	
			Placebo	20	19 (95.0)	2.53 (1.29)	0.0	1.83	2.83	3.50	4.5	
		Week 38	Tezepelumab	22	22 (100.0)	1.67 (1.34)	0.0	0.50	1.75	2.67	4.5	
			Placebo	20	19 (95.0)	2.24 (1.32)	0.0	1.17	2.17	3.17	4.5	
		Week 40	Tezepelumab	22	22 (100.0)	1.61 (1.29)	0.0	0.33	1.75	2.67	4.3	
			Placebo	20	19 (95.0)	2.40 (1.22)	0.0	1.83	2.50	3.33	4.2	
		Week 42	Tezepelumab	22	22 (100.0)	1.58 (1.24)	0.0	0.83	1.67	2.67	4.3	
			Placebo	20	19 (95.0)	2.06 (1.10)	0.0	1.33	2.00	2.50	4.5	
		Week 44	Tezepelumab	22	22 (100.0)	1.49 (1.31)	0.0	0.33	1.08	2.67	4.3	
			Placebo	20	19 (95.0)	2.35 (1.15)	0.5	1.17	2.50	3.33	4.2	
		Week 46	Tezepelumab	22	22 (100.0)	1.54 (1.28)	0.0	0.50	1.25	2.50	4.3	
			Placebo	20	19 (95.0)	1.97 (1.03)	0.0	1.00	2.17	2.50	3.8	
		Week 48	Tezepelumab	22	22 (100.0)	1.55 (1.26)	0.0	0.50	1.17	2.67	4.3	
			Placebo	20	19 (95.0)	2.14 (0.99)	0.0	1.67	2.17	2.67	3.8	
		Week 50	Tezepelumab	22	22 (100.0)	1.58 (1.34)	0.0	0.50	1.33	2.67	4.3	
			Placebo	20	19 (95.0)	2.09 (1.06)	0.2	1.00	2.17	2.83	3.8	
		Week 52	Tezepelumab	22	22 (100.0)	1.61 (1.31)	0.0	0.67	1.50	2.50	4.3	
			Placebo	20	19 (95.0)	2.09 (1.19)	0.0	1.00	2.17	2.83	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 2	Tezepelumab	22	21 (95.5)	-0.67 (0.92)	-2.8	-1.33	-0.50	0.17	0.7	-0.22 [-0.85, 0.40]
			Placebo	20	19 (95.0)	-0.47 (0.88)	-2.8	-0.83	-0.50	0.00	1.0	
		Week 4	Tezepelumab	22	21 (95.5)	-1.11 (1.06)	-2.5	-1.83	-1.33	-0.67	2.3	-0.85 [-1.50, -0.20]
			Placebo	20	19 (95.0)	-0.28 (0.88)	-2.0	-1.00	-0.17	0.33	1.2	
		Week 6	Tezepelumab	22	21 (95.5)	-1.13 (1.28)	-2.7	-2.17	-1.50	-0.50	2.3	-0.60 [-1.23, 0.04]
			Placebo	20	19 (95.0)	-0.42 (1.09)	-2.0	-1.17	-0.50	0.33	1.5	
		Week 8	Tezepelumab	22	21 (95.5)	-1.17 (1.54)	-3.0	-2.67	-1.50	-0.33	2.3	-0.47 [-1.10, 0.16]
			Placebo	20	19 (95.0)	-0.57 (0.95)	-3.0	-1.17	-0.50	0.17	0.8	
		Week 10	Tezepelumab	22	21 (95.5)	-1.24 (1.42)	-3.2	-2.50	-1.50	0.00	2.3	-0.55 [-1.18, 0.08]
			Placebo	20	19 (95.0)	-0.46 (1.43)	-2.2	-1.50	-0.50	0.00	2.7	
		Week 12	Tezepelumab	22	21 (95.5)	-1.38 (1.40)	-3.0	-2.67	-1.67	-0.67	2.3	-0.50 [-1.13, 0.13]
			Placebo	20	19 (95.0)	-0.73 (1.19)	-3.2	-1.50	-0.83	0.17	1.3	
		Week 14	Tezepelumab	22	21 (95.5)	-1.52 (1.41)	-3.7	-2.50	-1.83	-0.67	2.3	-0.41 [-1.04, 0.22]
			Placebo	20	19 (95.0)	-0.98 (1.19)	-3.2	-1.67	-1.17	-0.67	2.3	
		Week 16	Tezepelumab	22	21 (95.5)	-1.33 (1.36)	-3.0	-2.17	-1.83	-0.33	2.3	-0.47 [-1.10, 0.16]
			Placebo	20	19 (95.0)	-0.68 (1.40)	-3.2	-1.50	-0.83	0.17	2.3	
		Week 18	Tezepelumab	22	21 (95.5)	-1.46 (1.42)	-3.5	-2.50	-1.83	-0.33	2.3	-0.47 [-1.10, 0.16]
			Placebo	20	19 (95.0)	-0.77 (1.52)	-3.2	-1.67	-0.83	-0.33	2.3	
		Week 20	Tezepelumab	22	21 (95.5)	-1.22 (1.41)	-3.2	-2.33	-1.50	-0.33	2.3	-0.39 [-1.02, 0.23]
			Placebo	20	19 (95.0)	-0.68 (1.37)	-3.0	-1.67	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	22	21 (95.5)	-1.25 (1.38)	-3.0	-2.50	-1.83	-0.67	2.3	-0.46 [-1.09, 0.17]
			Placebo	20	19 (95.0)	-0.62 (1.36)	-3.2	-1.50	-0.83	0.00	2.3	
		Week 24	Tezepelumab	22	21 (95.5)	-1.24 (1.31)	-3.2	-2.17	-1.50	-0.67	2.3	-0.44 [-1.07, 0.19]
			Placebo	20	19 (95.0)	-0.66 (1.33)	-3.0	-1.67	-0.67	0.17	2.3	
		Week 26	Tezepelumab	22	21 (95.5)	-1.21 (1.41)	-2.8	-2.33	-1.33	-0.33	2.3	-0.42 [-1.05, 0.21]
			Placebo	20	19 (95.0)	-0.61 (1.44)	-3.2	-1.83	-0.67	0.50	2.3	
		Week 28	Tezepelumab	22	22 (100.0)	-1.26 (1.41)	-3.2	-2.33	-1.67	0.00	2.3	-0.42 [-1.04, 0.20]
			Placebo	20	19 (95.0)	-0.68 (1.34)	-3.2	-1.83	-1.00	0.17	2.3	
		Week 30	Tezepelumab	22	22 (100.0)	-1.31 (1.42)	-3.5	-2.50	-1.75	-0.17	2.3	-0.54 [-1.16, 0.09]
			Placebo	20	19 (95.0)	-0.61 (1.18)	-2.2	-1.33	-0.83	-0.33	2.3	
		Week 32	Tezepelumab	22	22 (100.0)	-1.23 (1.31)	-3.0	-2.17	-1.33	-0.50	2.3	-0.45 [-1.08, 0.17]
			Placebo	20	19 (95.0)	-0.64 (1.28)	-2.3	-1.50	-1.17	-0.17	2.3	
		Week 34	Tezepelumab	22	22 (100.0)	-1.23 (1.35)	-2.8	-2.33	-1.67	-0.50	2.3	-0.34 [-0.96, 0.28]
			Placebo	20	19 (95.0)	-0.75 (1.44)	-3.2	-1.50	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 2	Change from baseline	Week 36	Tezepelumab	22	22 (100.0)	-1.38 (1.32)	-3.0	-2.50	-1.58	-0.50	2.3	-0.86 [-1.50, -0.21]
			Placebo	20	19 (95.0)	-0.23 (1.37)	-3.2	-1.17	-0.33	1.00	2.3	
		Week 38	Tezepelumab	22	22 (100.0)	-1.22 (1.36)	-3.0	-2.17	-1.67	0.00	2.3	-0.50 [-1.12, 0.12]
			Placebo	20	19 (95.0)	-0.52 (1.46)	-3.2	-1.67	-0.33	0.50	2.3	
		Week 40	Tezepelumab	22	22 (100.0)	-1.28 (1.39)	-3.2	-2.50	-1.33	-0.50	2.3	-0.66 [-1.29, -0.03]
			Placebo	20	19 (95.0)	-0.35 (1.44)	-2.8	-1.33	-0.17	0.83	2.3	
		Week 42	Tezepelumab	22	22 (100.0)	-1.31 (1.37)	-3.3	-2.17	-1.50	-0.50	2.3	-0.46 [-1.08, 0.16]
			Placebo	20	19 (95.0)	-0.69 (1.31)	-2.8	-1.33	-1.17	0.00	2.3	
		Week 44	Tezepelumab	22	22 (100.0)	-1.39 (1.42)	-3.5	-2.50	-1.42	-0.67	2.3	-0.72 [-1.35, -0.08]
			Placebo	20	19 (95.0)	-0.40 (1.34)	-2.7	-1.50	-0.67	0.83	2.3	
		Week 46	Tezepelumab	22	22 (100.0)	-1.35 (1.33)	-3.3	-2.17	-1.58	-0.67	2.3	-0.44 [-1.06, 0.18]
			Placebo	20	19 (95.0)	-0.78 (1.24)	-3.2	-1.67	-0.83	0.00	2.3	
		Week 48	Tezepelumab	22	22 (100.0)	-1.33 (1.32)	-2.7	-2.50	-1.75	-0.50	2.3	-0.57 [-1.20, 0.05]
			Placebo	20	19 (95.0)	-0.61 (1.17)	-3.2	-1.33	-0.50	0.17	2.3	
		Week 50	Tezepelumab	22	22 (100.0)	-1.31 (1.36)	-2.7	-2.50	-1.92	-0.33	2.3	-0.48 [-1.10, 0.15]
			Placebo	20	19 (95.0)	-0.67 (1.34)	-3.0	-1.67	-0.67	0.17	2.3	
		Week 52	Tezepelumab	22	22 (100.0)	-1.27 (1.35)	-2.7	-2.50	-1.58	-0.17	2.3	-0.44 [-1.06, 0.18]
			Placebo	20	19 (95.0)	-0.67 (1.43)	-3.0	-1.83	-0.50	0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	2.72 (0.86)	0.0	2.17	2.67	3.17	4.8	
			Placebo	58	58 (100.0)	2.68 (0.71)	0.3	2.33	2.75	3.17	4.5	
		Week 2	Tezepelumab	60	57 (95.0)	2.28 (0.94)	0.2	1.50	2.33	3.00	4.2	
			Placebo	58	51 (87.9)	2.27 (0.74)	0.3	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	60	57 (95.0)	2.01 (0.95)	0.2	1.33	2.17	2.67	3.5	
			Placebo	58	51 (87.9)	2.12 (0.89)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	60	57 (95.0)	1.93 (1.02)	0.0	1.33	2.00	2.67	4.0	
			Placebo	58	51 (87.9)	2.09 (1.04)	0.2	1.33	2.17	2.67	4.7	
		Week 8	Tezepelumab	60	57 (95.0)	1.80 (1.12)	0.0	0.83	1.67	2.67	4.8	
			Placebo	58	52 (89.7)	2.04 (1.04)	0.0	1.25	2.17	2.75	4.7	
		Week 10	Tezepelumab	60	57 (95.0)	1.73 (1.10)	0.0	0.83	1.83	2.67	4.3	
			Placebo	58	52 (89.7)	2.04 (0.98)	0.0	1.50	2.17	2.67	4.2	
		Week 12	Tezepelumab	60	57 (95.0)	1.61 (1.05)	0.0	0.67	1.67	2.50	4.3	
			Placebo	58	52 (89.7)	1.85 (0.96)	0.0	1.08	2.00	2.50	4.3	
		Week 14	Tezepelumab	60	57 (95.0)	1.53 (1.08)	0.0	0.67	1.50	2.33	4.3	
			Placebo	58	52 (89.7)	1.77 (0.87)	0.0	1.33	1.83	2.17	5.0	
		Week 16	Tezepelumab	60	57 (95.0)	1.70 (1.14)	0.0	0.67	1.83	2.50	4.3	
			Placebo	58	52 (89.7)	1.93 (1.00)	0.0	1.08	2.00	2.67	4.5	
		Week 18	Tezepelumab	60	58 (96.7)	1.66 (1.04)	0.0	0.83	1.75	2.33	4.3	
			Placebo	58	52 (89.7)	1.84 (1.07)	0.0	1.00	1.83	2.50	4.7	
		Week 20	Tezepelumab	60	58 (96.7)	1.68 (1.12)	0.0	0.83	1.83	2.50	5.0	
			Placebo	58	52 (89.7)	1.89 (1.01)	0.0	1.17	1.92	2.67	4.5	
		Week 22	Tezepelumab	60	58 (96.7)	1.74 (0.97)	0.0	1.00	1.83	2.33	4.3	
			Placebo	58	52 (89.7)	1.85 (1.07)	0.0	1.00	2.00	2.58	4.5	
		Week 24	Tezepelumab	60	58 (96.7)	1.73 (1.07)	0.0	1.00	1.83	2.50	4.3	
			Placebo	58	52 (89.7)	1.95 (1.00)	0.0	1.42	2.00	2.50	4.5	
		Week 26	Tezepelumab	60	59 (98.3)	1.78 (1.08)	0.0	1.17	1.83	2.67	4.3	
			Placebo	58	52 (89.7)	1.91 (1.06)	0.0	1.00	1.83	2.75	4.5	
		Week 28	Tezepelumab	60	60 (100.0)	1.72 (1.11)	0.0	1.00	1.67	2.50	4.3	
			Placebo	58	53 (91.4)	1.92 (1.13)	0.0	1.00	2.00	2.67	4.5	
		Week 30	Tezepelumab	60	60 (100.0)	1.69 (1.08)	0.0	0.92	1.67	2.33	4.3	
			Placebo	58	53 (91.4)	1.90 (1.10)	0.0	1.00	2.00	2.67	4.5	
		Week 32	Tezepelumab	60	60 (100.0)	1.62 (1.09)	0.0	0.67	1.83	2.50	4.3	
			Placebo	58	53 (91.4)	1.84 (1.06)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Absolute values	Week 34	Tezepelumab	60	60 (100.0)	1.70 (1.14)	0.0	0.75	1.83	2.50	4.3	
			Placebo	58	53 (91.4)	1.82 (1.03)	0.0	1.17	1.83	2.33	4.5	
		Week 36	Tezepelumab	60	60 (100.0)	1.66 (1.07)	0.0	1.00	1.67	2.50	4.3	
			Placebo	58	53 (91.4)	1.93 (1.10)	0.0	1.17	1.83	2.67	4.5	
		Week 38	Tezepelumab	60	60 (100.0)	1.69 (1.17)	0.0	0.92	1.67	2.67	4.5	
			Placebo	58	53 (91.4)	1.85 (1.05)	0.0	1.17	1.83	2.50	4.5	
		Week 40	Tezepelumab	60	60 (100.0)	1.66 (1.14)	0.0	0.58	1.83	2.58	4.3	
			Placebo	58	53 (91.4)	1.99 (1.10)	0.0	1.33	2.00	2.67	4.5	
		Week 42	Tezepelumab	60	60 (100.0)	1.62 (1.12)	0.0	0.83	1.67	2.50	4.3	
			Placebo	58	53 (91.4)	1.87 (1.04)	0.0	1.17	2.00	2.50	4.5	
		Week 44	Tezepelumab	60	60 (100.0)	1.66 (1.10)	0.0	0.75	1.67	2.67	4.3	
			Placebo	58	53 (91.4)	1.92 (1.04)	0.0	1.17	2.00	2.50	4.5	
		Week 46	Tezepelumab	60	60 (100.0)	1.68 (1.14)	0.0	0.75	1.83	2.58	4.3	
			Placebo	58	53 (91.4)	1.87 (0.97)	0.0	1.33	1.83	2.33	4.5	
		Week 48	Tezepelumab	60	60 (100.0)	1.68 (1.14)	0.0	0.75	1.75	2.58	4.3	
			Placebo	58	53 (91.4)	1.86 (1.06)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	60	60 (100.0)	1.64 (1.15)	0.0	0.83	1.67	2.33	4.3	
			Placebo	58	53 (91.4)	1.75 (0.96)	0.0	1.00	1.83	2.33	4.5	
		Week 52	Tezepelumab	60	60 (100.0)	1.68 (1.13)	0.0	1.00	1.67	2.42	4.3	
			Placebo	58	53 (91.4)	1.86 (1.00)	0.0	1.17	2.17	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 2	Tezepelumab	60	57 (95.0)	-0.48 (0.66)	-2.0	-1.00	-0.33	0.00	0.7	-0.05 [-0.42, 0.33]
			Placebo	58	51 (87.9)	-0.45 (0.71)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	60	57 (95.0)	-0.75 (0.82)	-2.5	-1.17	-0.67	-0.17	2.3	-0.18 [-0.55, 0.20]
			Placebo	58	51 (87.9)	-0.59 (0.90)	-3.0	-1.17	-0.33	0.00	1.2	
		Week 6	Tezepelumab	60	57 (95.0)	-0.82 (0.94)	-2.7	-1.33	-0.83	-0.17	2.3	-0.20 [-0.58, 0.18]
			Placebo	58	51 (87.9)	-0.63 (1.00)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	60	57 (95.0)	-0.96 (1.04)	-3.0	-1.50	-1.00	-0.33	2.3	-0.27 [-0.64, 0.11]
			Placebo	58	52 (89.7)	-0.69 (0.98)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	60	57 (95.0)	-1.03 (1.02)	-3.2	-1.67	-1.17	-0.50	2.3	-0.33 [-0.71, 0.05]
			Placebo	58	52 (89.7)	-0.69 (1.06)	-3.3	-1.25	-0.50	-0.08	2.5	
		Week 12	Tezepelumab	60	57 (95.0)	-1.15 (1.00)	-3.0	-2.00	-1.17	-0.67	2.3	-0.28 [-0.66, 0.10]
			Placebo	58	52 (89.7)	-0.87 (0.94)	-3.3	-1.17	-0.75	-0.25	1.3	
		Week 14	Tezepelumab	60	57 (95.0)	-1.23 (1.02)	-3.7	-2.00	-1.17	-0.67	2.3	-0.27 [-0.65, 0.11]
			Placebo	58	52 (89.7)	-0.96 (0.93)	-3.2	-1.50	-0.92	-0.33	1.2	
		Week 16	Tezepelumab	60	57 (95.0)	-1.05 (1.06)	-3.0	-1.83	-1.00	-0.50	2.3	-0.24 [-0.62, 0.13]
			Placebo	58	52 (89.7)	-0.80 (1.03)	-3.2	-1.33	-0.83	-0.08	2.3	
		Week 18	Tezepelumab	60	58 (96.7)	-1.08 (1.00)	-3.5	-1.67	-1.00	-0.67	2.3	-0.18 [-0.56, 0.19]
			Placebo	58	52 (89.7)	-0.89 (1.09)	-3.2	-1.58	-0.83	-0.08	2.3	
		Week 20	Tezepelumab	60	58 (96.7)	-1.07 (1.02)	-3.2	-1.67	-1.00	-0.50	2.3	-0.22 [-0.60, 0.15]
			Placebo	58	52 (89.7)	-0.83 (1.05)	-3.2	-1.42	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	60	58 (96.7)	-1.00 (1.02)	-3.0	-1.50	-0.83	-0.67	2.3	-0.12 [-0.49, 0.26]
			Placebo	58	52 (89.7)	-0.87 (1.08)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	60	58 (96.7)	-1.01 (0.98)	-3.2	-1.67	-1.00	-0.33	2.3	-0.24 [-0.61, 0.14]
			Placebo	58	52 (89.7)	-0.77 (1.06)	-3.2	-1.42	-0.67	0.00	2.3	
		Week 26	Tezepelumab	60	59 (98.3)	-0.94 (1.02)	-2.8	-1.83	-0.83	-0.17	2.3	-0.12 [-0.50, 0.25]
			Placebo	58	52 (89.7)	-0.81 (1.09)	-2.8	-1.50	-0.92	0.00	2.3	
		Week 28	Tezepelumab	60	60 (100.0)	-0.99 (1.10)	-3.2	-2.00	-0.92	-0.08	2.3	-0.21 [-0.58, 0.16]
			Placebo	58	53 (91.4)	-0.76 (1.12)	-2.8	-1.50	-0.83	-0.17	2.3	
		Week 30	Tezepelumab	60	60 (100.0)	-1.02 (1.08)	-3.5	-1.92	-1.00	-0.33	2.3	-0.22 [-0.59, 0.16]
			Placebo	58	53 (91.4)	-0.78 (1.14)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	60	60 (100.0)	-1.10 (1.01)	-3.0	-1.92	-1.00	-0.50	2.3	-0.25 [-0.62, 0.13]
			Placebo	58	53 (91.4)	-0.84 (1.09)	-3.0	-1.50	-1.00	-0.33	2.3	
		Week 34	Tezepelumab	60	60 (100.0)	-1.02 (1.10)	-2.8	-2.00	-1.00	-0.33	2.3	-0.15 [-0.52, 0.22]
			Placebo	58	53 (91.4)	-0.86 (1.05)	-3.2	-1.33	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Change from baseline	Week 36	Tezepelumab	60	60 (100.0)	-1.06 (1.08)	-3.0	-1.83	-1.17	-0.25	2.3	-0.28 [-0.65, 0.09]
			Placebo	58	53 (91.4)	-0.75 (1.11)	-3.5	-1.33	-0.83	-0.17	2.3	
		Week 38	Tezepelumab	60	60 (100.0)	-1.03 (1.12)	-3.0	-2.00	-1.17	-0.17	2.3	-0.18 [-0.55, 0.19]
			Placebo	58	53 (91.4)	-0.83 (1.07)	-3.2	-1.33	-0.83	0.00	2.3	
		Week 40	Tezepelumab	60	60 (100.0)	-1.06 (1.11)	-3.2	-2.00	-1.00	-0.33	2.3	-0.33 [-0.70, 0.04]
			Placebo	58	53 (91.4)	-0.69 (1.13)	-3.2	-1.33	-0.67	0.17	2.3	
		Week 42	Tezepelumab	60	60 (100.0)	-1.09 (1.12)	-3.3	-2.00	-1.08	-0.50	2.3	-0.26 [-0.63, 0.11]
			Placebo	58	53 (91.4)	-0.81 (1.08)	-2.8	-1.33	-0.83	-0.17	2.3	
		Week 44	Tezepelumab	60	60 (100.0)	-1.05 (1.10)	-3.5	-1.92	-1.00	-0.42	2.3	-0.27 [-0.65, 0.10]
			Placebo	58	53 (91.4)	-0.75 (1.07)	-3.3	-1.50	-0.83	0.00	2.3	
		Week 46	Tezepelumab	60	60 (100.0)	-1.04 (1.10)	-3.3	-2.00	-1.00	-0.17	2.3	-0.21 [-0.58, 0.16]
			Placebo	58	53 (91.4)	-0.81 (1.04)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 48	Tezepelumab	60	60 (100.0)	-1.03 (1.10)	-2.7	-2.00	-0.83	-0.42	2.3	-0.20 [-0.57, 0.17]
			Placebo	58	53 (91.4)	-0.81 (1.11)	-3.3	-1.33	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	60	60 (100.0)	-1.07 (1.09)	-2.7	-2.00	-1.17	-0.42	2.3	-0.15 [-0.52, 0.22]
			Placebo	58	53 (91.4)	-0.92 (0.97)	-3.5	-1.33	-1.00	-0.50	2.3	
		Week 52	Tezepelumab	60	60 (100.0)	-1.04 (1.08)	-2.7	-1.92	-1.00	-0.42	2.3	-0.21 [-0.58, 0.16]
			Placebo	58	53 (91.4)	-0.82 (1.00)	-3.5	-1.17	-0.83	-0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	3.00 (0.24)	2.8	2.83	3.00	3.17	3.2	
			Placebo	2	2 (100.0)	2.42 (0.35)	2.2	2.17	2.42	2.67	2.7	
		Week 2	Tezepelumab	2	2 (100.0)	1.25 (1.77)	0.0	0.00	1.25	2.50	2.5	
			Placebo	2	2 (100.0)	1.75 (0.35)	1.5	1.50	1.75	2.00	2.0	
		Week 4	Tezepelumab	2	2 (100.0)	1.42 (0.82)	0.8	0.83	1.42	2.00	2.0	
			Placebo	2	2 (100.0)	1.92 (1.77)	0.7	0.67	1.92	3.17	3.2	
		Week 6	Tezepelumab	2	2 (100.0)	1.17 (0.94)	0.5	0.50	1.17	1.83	1.8	
			Placebo	2	2 (100.0)	1.67 (0.94)	1.0	1.00	1.67	2.33	2.3	
		Week 8	Tezepelumab	2	2 (100.0)	0.83 (0.94)	0.2	0.17	0.83	1.50	1.5	
			Placebo	2	2 (100.0)	2.08 (1.53)	1.0	1.00	2.08	3.17	3.2	
		Week 10	Tezepelumab	2	2 (100.0)	0.50 (0.47)	0.2	0.17	0.50	0.83	0.8	
			Placebo	2	2 (100.0)	3.08 (3.18)	0.8	0.83	3.08	5.33	5.3	
		Week 12	Tezepelumab	2	2 (100.0)	0.92 (0.59)	0.5	0.50	0.92	1.33	1.3	
			Placebo	2	2 (100.0)	2.42 (2.24)	0.8	0.83	2.42	4.00	4.0	
		Week 14	Tezepelumab	2	2 (100.0)	0.75 (0.35)	0.5	0.50	0.75	1.00	1.0	
			Placebo	2	2 (100.0)	2.92 (2.95)	0.8	0.83	2.92	5.00	5.0	
		Week 16	Tezepelumab	2	2 (100.0)	1.08 (0.59)	0.7	0.67	1.08	1.50	1.5	
			Placebo	2	2 (100.0)	2.92 (2.95)	0.8	0.83	2.92	5.00	5.0	
		Week 18	Tezepelumab	2	2 (100.0)	0.92 (0.59)	0.5	0.50	0.92	1.33	1.3	
			Placebo	2	2 (100.0)	2.92 (2.95)	0.8	0.83	2.92	5.00	5.0	
		Week 20	Tezepelumab	2	2 (100.0)	1.08 (0.12)	1.0	1.00	1.08	1.17	1.2	
			Placebo	2	2 (100.0)	2.67 (3.30)	0.3	0.33	2.67	5.00	5.0	
		Week 22	Tezepelumab	2	2 (100.0)	1.08 (0.12)	1.0	1.00	1.08	1.17	1.2	
			Placebo	2	2 (100.0)	2.67 (3.30)	0.3	0.33	2.67	5.00	5.0	
		Week 24	Tezepelumab	2	2 (100.0)	1.00 (0.24)	0.8	0.83	1.00	1.17	1.2	
			Placebo	2	2 (100.0)	2.25 (2.71)	0.3	0.33	2.25	4.17	4.2	
		Week 26	Tezepelumab	2	2 (100.0)	0.92 (0.35)	0.7	0.67	0.92	1.17	1.2	
			Placebo	2	2 (100.0)	2.25 (2.71)	0.3	0.33	2.25	4.17	4.2	
		Week 28	Tezepelumab	2	2 (100.0)	0.83 (0.47)	0.5	0.50	0.83	1.17	1.2	
			Placebo	2	2 (100.0)	2.25 (2.71)	0.3	0.33	2.25	4.17	4.2	
		Week 30	Tezepelumab	2	2 (100.0)	0.92 (0.35)	0.7	0.67	0.92	1.17	1.2	
			Placebo	2	2 (100.0)	2.25 (2.71)	0.3	0.33	2.25	4.17	4.2	
		Week 32	Tezepelumab	2	2 (100.0)	1.42 (0.35)	1.2	1.17	1.42	1.67	1.7	
			Placebo	2	2 (100.0)	2.25 (2.71)	0.3	0.33	2.25	4.17	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Black or African American	Absolute values	Week 34	Tezepelumab	2	2 (100.0)	1.08 (0.12)	1.0	1.00	1.08	1.17	1.2	
			Placebo	2	2 (100.0)	2.08 (2.95)	0.0	0.00	2.08	4.17	4.2	
		Week 36	Tezepelumab	2	2 (100.0)	1.17 (0.00)	1.2	1.17	1.17	1.17	1.2	
			Placebo	2	2 (100.0)	2.08 (2.95)	0.0	0.00	2.08	4.17	4.2	
		Week 38	Tezepelumab	2	2 (100.0)	1.00 (0.24)	0.8	0.83	1.00	1.17	1.2	
			Placebo	2	2 (100.0)	2.08 (2.95)	0.0	0.00	2.08	4.17	4.2	
		Week 40	Tezepelumab	2	2 (100.0)	1.42 (0.35)	1.2	1.17	1.42	1.67	1.7	
			Placebo	2	2 (100.0)	2.08 (2.95)	0.0	0.00	2.08	4.17	4.2	
		Week 42	Tezepelumab	2	2 (100.0)	1.42 (0.35)	1.2	1.17	1.42	1.67	1.7	
			Placebo	2	2 (100.0)	0.75 (1.06)	0.0	0.00	0.75	1.50	1.5	
		Week 44	Tezepelumab	2	2 (100.0)	1.42 (0.35)	1.2	1.17	1.42	1.67	1.7	
			Placebo	2	2 (100.0)	0.83 (0.24)	0.7	0.67	0.83	1.00	1.0	
		Week 46	Tezepelumab	2	2 (100.0)	1.08 (0.12)	1.0	1.00	1.08	1.17	1.2	
			Placebo	2	2 (100.0)	0.75 (0.35)	0.5	0.50	0.75	1.00	1.0	
		Week 48	Tezepelumab	2	2 (100.0)	1.25 (0.12)	1.2	1.17	1.25	1.33	1.3	
			Placebo	2	2 (100.0)	0.67 (0.47)	0.3	0.33	0.67	1.00	1.0	
		Week 50	Tezepelumab	2	2 (100.0)	0.67 (0.71)	0.2	0.17	0.67	1.17	1.2	
			Placebo	2	2 (100.0)	2.33 (1.89)	1.0	1.00	2.33	3.67	3.7	
		Week 52	Tezepelumab	2	2 (100.0)	0.67 (0.71)	0.2	0.17	0.67	1.17	1.2	
			Placebo	2	2 (100.0)	1.83 (2.59)	0.0	0.00	1.83	3.67	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 2	Tezepelumab	2	2 (100.0)	-1.75 (1.53)	-2.8	-2.83	-1.75	-0.67	-0.7	-0.91 [-3.06, 1.24]
			Placebo	2	2 (100.0)	-0.67 (0.71)	-1.2	-1.17	-0.67	-0.17	-0.2	
		Week 4	Tezepelumab	2	2 (100.0)	-1.58 (0.59)	-2.0	-2.00	-1.58	-1.17	-1.2	-1.00 [-3.19, 1.19]
			Placebo	2	2 (100.0)	-0.50 (1.41)	-1.5	-1.50	-0.50	0.50	0.5	
		Week 6	Tezepelumab	2	2 (100.0)	-1.83 (0.71)	-2.3	-2.33	-1.83	-1.33	-1.3	-1.66 [-4.21, 0.89]
			Placebo	2	2 (100.0)	-0.75 (0.59)	-1.2	-1.17	-0.75	-0.33	-0.3	
		Week 8	Tezepelumab	2	2 (100.0)	-2.17 (0.71)	-2.7	-2.67	-2.17	-1.67	-1.7	-1.89 [-4.58, 0.81]
			Placebo	2	2 (100.0)	-0.33 (1.18)	-1.2	-1.17	-0.33	0.50	0.5	
		Week 10	Tezepelumab	2	2 (100.0)	-2.50 (0.24)	-2.7	-2.67	-2.50	-2.33	-2.3	-1.58 [-4.07, 0.92]
			Placebo	2	2 (100.0)	0.67 (2.83)	-1.3	-1.33	0.67	2.67	2.7	
		Week 12	Tezepelumab	2	2 (100.0)	-2.08 (0.35)	-2.3	-2.33	-2.08	-1.83	-1.8	-1.54 [-4.01, 0.94]
			Placebo	2	2 (100.0)	-0.00 (1.89)	-1.3	-1.33	-0.00	1.33	1.3	
		Week 14	Tezepelumab	2	2 (100.0)	-2.25 (0.12)	-2.3	-2.33	-2.25	-2.17	-2.2	-1.50 [-3.95, 0.95]
			Placebo	2	2 (100.0)	0.50 (2.59)	-1.3	-1.33	0.50	2.33	2.3	
		Week 16	Tezepelumab	2	2 (100.0)	-1.92 (0.35)	-2.2	-2.17	-1.92	-1.67	-1.7	-1.31 [-3.65, 1.03]
			Placebo	2	2 (100.0)	0.50 (2.59)	-1.3	-1.33	0.50	2.33	2.3	
		Week 18	Tezepelumab	2	2 (100.0)	-2.08 (0.35)	-2.3	-2.33	-2.08	-1.83	-1.8	-1.40 [-3.79, 0.99]
			Placebo	2	2 (100.0)	0.50 (2.59)	-1.3	-1.33	0.50	2.33	2.3	
		Week 20	Tezepelumab	2	2 (100.0)	-1.92 (0.12)	-2.0	-2.00	-1.92	-1.83	-1.8	-1.04 [-3.25, 1.17]
			Placebo	2	2 (100.0)	0.25 (2.95)	-1.8	-1.83	0.25	2.33	2.3	
		Week 22	Tezepelumab	2	2 (100.0)	-1.92 (0.12)	-2.0	-2.00	-1.92	-1.83	-1.8	-1.04 [-3.25, 1.17]
			Placebo	2	2 (100.0)	0.25 (2.95)	-1.8	-1.83	0.25	2.33	2.3	
		Week 24	Tezepelumab	2	2 (100.0)	-2.00 (0.00)	-2.0	-2.00	-2.00	-2.00	-2.0	-1.10 [-3.34, 1.14]
			Placebo	2	2 (100.0)	-0.17 (2.36)	-1.8	-1.83	-0.17	1.50	1.5	
		Week 26	Tezepelumab	2	2 (100.0)	-2.08 (0.12)	-2.2	-2.17	-2.08	-2.00	-2.0	-1.15 [-3.41, 1.11]
			Placebo	2	2 (100.0)	-0.17 (2.36)	-1.8	-1.83	-0.17	1.50	1.5	
		Week 28	Tezepelumab	2	2 (100.0)	-2.17 (0.24)	-2.3	-2.33	-2.17	-2.00	-2.0	-1.19 [-3.48, 1.09]
			Placebo	2	2 (100.0)	-0.17 (2.36)	-1.8	-1.83	-0.17	1.50	1.5	
		Week 30	Tezepelumab	2	2 (100.0)	-2.08 (0.12)	-2.2	-2.17	-2.08	-2.00	-2.0	-1.15 [-3.41, 1.11]
			Placebo	2	2 (100.0)	-0.17 (2.36)	-1.8	-1.83	-0.17	1.50	1.5	
		Week 32	Tezepelumab	2	2 (100.0)	-1.58 (0.59)	-2.0	-2.00	-1.58	-1.17	-1.2	-0.82 [-2.94, 1.30]
			Placebo	2	2 (100.0)	-0.17 (2.36)	-1.8	-1.83	-0.17	1.50	1.5	
		Week 34	Tezepelumab	2	2 (100.0)	-1.92 (0.12)	-2.0	-2.00	-1.92	-1.83	-1.8	-0.86 [-3.00, 1.27]
			Placebo	2	2 (100.0)	-0.33 (2.59)	-2.2	-2.17	-0.33	1.50	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Black or African American	Change from baseline	Week 36	Tezepelumab	2	2 (100.0)	-1.83 (0.24)	-2.0	-2.00	-1.83	-1.67	-1.7	-0.81 [-2.93, 1.30]
			Placebo	2	2 (100.0)	-0.33 (2.59)	-2.2	-2.17	-0.33	1.50	1.5	
		Week 38	Tezepelumab	2	2 (100.0)	-2.00 (0.00)	-2.0	-2.00	-2.00	-2.00	-2.0	-0.91 [-3.06, 1.24]
			Placebo	2	2 (100.0)	-0.33 (2.59)	-2.2	-2.17	-0.33	1.50	1.5	
		Week 40	Tezepelumab	2	2 (100.0)	-1.58 (0.59)	-2.0	-2.00	-1.58	-1.17	-1.2	-0.66 [-2.73, 1.40]
			Placebo	2	2 (100.0)	-0.33 (2.59)	-2.2	-2.17	-0.33	1.50	1.5	
		Week 42	Tezepelumab	2	2 (100.0)	-1.58 (0.59)	-2.0	-2.00	-1.58	-1.17	-1.2	0.13 [-1.84, 2.09]
			Placebo	2	2 (100.0)	-1.67 (0.71)	-2.2	-2.17	-1.67	-1.17	-1.2	
		Week 44	Tezepelumab	2	2 (100.0)	-1.58 (0.59)	-2.0	-2.00	-1.58	-1.17	-1.2	0.00 [-1.96, 1.96]
			Placebo	2	2 (100.0)	-1.58 (0.12)	-1.7	-1.67	-1.58	-1.50	-1.5	
		Week 46	Tezepelumab	2	2 (100.0)	-1.92 (0.12)	-2.0	-2.00	-1.92	-1.83	-1.8	-3.00 [-6.53, 0.53]
			Placebo	2	2 (100.0)	-1.67 (0.00)	-1.7	-1.67	-1.67	-1.67	-1.7	
		Week 48	Tezepelumab	2	2 (100.0)	-1.75 (0.35)	-2.0	-2.00	-1.75	-1.50	-1.5	0.00 [-1.96, 1.96]
			Placebo	2	2 (100.0)	-1.75 (0.12)	-1.8	-1.83	-1.75	-1.67	-1.7	
		Week 50	Tezepelumab	2	2 (100.0)	-2.33 (0.47)	-2.7	-2.67	-2.33	-2.00	-2.0	-1.39 [-3.78, 1.00]
			Placebo	2	2 (100.0)	-0.08 (2.24)	-1.7	-1.67	-0.08	1.50	1.5	
		Week 52	Tezepelumab	2	2 (100.0)	-2.33 (0.47)	-2.7	-2.67	-2.33	-2.00	-2.0	-0.83 [-2.95, 1.29]
			Placebo	2	2 (100.0)	-0.58 (2.95)	-2.7	-2.67	-0.58	1.50	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.61 (0.51)	2.2	2.17	2.50	3.17	3.2	
			Placebo	3	3 (100.0)	2.56 (0.42)	2.2	2.17	2.50	3.00	3.0	
		Week 2	Tezepelumab	3	3 (100.0)	1.83 (1.09)	0.8	0.83	1.67	3.00	3.0	
			Placebo	3	3 (100.0)	2.33 (0.17)	2.2	2.17	2.33	2.50	2.5	
		Week 4	Tezepelumab	3	3 (100.0)	1.33 (0.76)	0.7	0.67	1.17	2.17	2.2	
			Placebo	3	3 (100.0)	1.94 (0.67)	1.3	1.33	1.83	2.67	2.7	
		Week 6	Tezepelumab	3	3 (100.0)	1.17 (0.44)	0.8	0.83	1.00	1.67	1.7	
			Placebo	3	3 (100.0)	1.83 (0.87)	0.8	0.83	2.33	2.33	2.3	
		Week 8	Tezepelumab	3	3 (100.0)	1.06 (0.54)	0.7	0.67	0.83	1.67	1.7	
			Placebo	3	3 (100.0)	2.22 (0.42)	1.8	1.83	2.17	2.67	2.7	
		Week 10	Tezepelumab	3	3 (100.0)	0.94 (0.35)	0.7	0.67	0.83	1.33	1.3	
			Placebo	3	3 (100.0)	1.94 (0.25)	1.7	1.67	2.00	2.17	2.2	
		Week 12	Tezepelumab	3	3 (100.0)	0.61 (0.79)	0.0	0.00	0.33	1.50	1.5	
			Placebo	3	3 (100.0)	1.89 (0.35)	1.5	1.50	2.00	2.17	2.2	
		Week 14	Tezepelumab	3	3 (100.0)	0.89 (0.38)	0.7	0.67	0.67	1.33	1.3	
			Placebo	3	3 (100.0)	1.67 (0.50)	1.2	1.17	1.67	2.17	2.2	
		Week 16	Tezepelumab	3	3 (100.0)	0.72 (0.35)	0.3	0.33	0.83	1.00	1.0	
			Placebo	3	3 (100.0)	1.56 (0.95)	0.5	0.50	1.83	2.33	2.3	
		Week 18	Tezepelumab	3	3 (100.0)	0.72 (0.25)	0.5	0.50	0.67	1.00	1.0	
			Placebo	3	3 (100.0)	2.06 (0.25)	1.8	1.83	2.00	2.33	2.3	
		Week 20	Tezepelumab	3	3 (100.0)	0.78 (0.35)	0.5	0.50	0.67	1.17	1.2	
			Placebo	3	3 (100.0)	2.39 (0.67)	1.7	1.67	2.50	3.00	3.0	
		Week 22	Tezepelumab	3	3 (100.0)	0.61 (0.54)	0.0	0.00	0.83	1.00	1.0	
			Placebo	3	3 (100.0)	2.06 (0.79)	1.2	1.17	2.33	2.67	2.7	
		Week 24	Tezepelumab	3	3 (100.0)	0.67 (0.17)	0.5	0.50	0.67	0.83	0.8	
			Placebo	3	3 (100.0)	2.44 (0.38)	2.0	2.00	2.67	2.67	2.7	
		Week 26	Tezepelumab	3	3 (100.0)	0.61 (0.38)	0.2	0.17	0.83	0.83	0.8	
			Placebo	3	3 (100.0)	2.00 (0.33)	1.7	1.67	2.00	2.33	2.3	
		Week 28	Tezepelumab	3	3 (100.0)	0.72 (0.35)	0.3	0.33	0.83	1.00	1.0	
			Placebo	3	3 (100.0)	1.56 (1.06)	0.3	0.33	2.17	2.17	2.2	
		Week 30	Tezepelumab	3	3 (100.0)	0.67 (0.00)	0.7	0.67	0.67	0.67	0.7	
			Placebo	3	3 (100.0)	1.11 (0.98)	0.0	0.00	1.50	1.83	1.8	
		Week 32	Tezepelumab	3	3 (100.0)	0.61 (0.42)	0.2	0.17	0.67	1.00	1.0	
			Placebo	3	3 (100.0)	1.44 (0.75)	0.7	0.67	1.50	2.17	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asian	Absolute values	Week 34	Tezepelumab	3	3 (100.0)	0.61 (0.10)	0.5	0.50	0.67	0.67	0.7	
			Placebo	3	3 (100.0)	1.61 (0.86)	0.7	0.67	1.83	2.33	2.3	
		Week 36	Tezepelumab	3	3 (100.0)	0.67 (0.29)	0.3	0.33	0.83	0.83	0.8	
			Placebo	3	3 (100.0)	2.67 (0.44)	2.3	2.33	2.50	3.17	3.2	
		Week 38	Tezepelumab	3	3 (100.0)	0.78 (0.95)	0.0	0.00	0.50	1.83	1.8	
			Placebo	3	3 (100.0)	1.39 (0.77)	0.5	0.50	1.83	1.83	1.8	
		Week 40	Tezepelumab	3	3 (100.0)	0.56 (0.19)	0.3	0.33	0.67	0.67	0.7	
			Placebo	3	3 (100.0)	2.06 (0.38)	1.8	1.83	1.83	2.50	2.5	
		Week 42	Tezepelumab	3	3 (100.0)	0.78 (0.25)	0.5	0.50	0.83	1.00	1.0	
			Placebo	3	3 (100.0)	1.72 (0.10)	1.7	1.67	1.67	1.83	1.8	
		Week 44	Tezepelumab	3	3 (100.0)	0.56 (0.25)	0.3	0.33	0.50	0.83	0.8	
			Placebo	3	3 (100.0)	2.94 (0.42)	2.5	2.50	3.00	3.33	3.3	
		Week 46	Tezepelumab	3	3 (100.0)	0.72 (0.35)	0.3	0.33	0.83	1.00	1.0	
			Placebo	3	3 (100.0)	1.39 (0.92)	0.3	0.33	1.83	2.00	2.0	
		Week 48	Tezepelumab	3	3 (100.0)	0.72 (0.25)	0.5	0.50	0.67	1.00	1.0	
			Placebo	3	3 (100.0)	2.22 (0.10)	2.2	2.17	2.17	2.33	2.3	
		Week 50	Tezepelumab	3	3 (100.0)	0.67 (0.17)	0.5	0.50	0.67	0.83	0.8	
			Placebo	3	3 (100.0)	1.78 (0.19)	1.7	1.67	1.67	2.00	2.0	
		Week 52	Tezepelumab	3	3 (100.0)	0.67 (0.17)	0.5	0.50	0.67	0.83	0.8	
			Placebo	3	3 (100.0)	1.78 (0.19)	1.7	1.67	1.67	2.00	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.78 (0.59)	-1.3	-1.33	-0.83	-0.17	-0.2	-1.12 [-2.90, 0.66]
			Placebo	3	3 (100.0)	-0.22 (0.38)	-0.7	-0.67	0.00	0.00	0.0	
		Week 4	Tezepelumab	3	3 (100.0)	-1.28 (0.25)	-1.5	-1.50	-1.33	-1.00	-1.0	-0.96 [-2.69, 0.77]
			Placebo	3	3 (100.0)	-0.61 (0.95)	-1.7	-1.67	-0.33	0.17	0.2	
		Week 6	Tezepelumab	3	3 (100.0)	-1.44 (0.10)	-1.5	-1.50	-1.50	-1.33	-1.3	-1.72 [-3.72, 0.27]
			Placebo	3	3 (100.0)	-0.72 (0.59)	-1.3	-1.33	-0.67	-0.17	-0.2	
		Week 8	Tezepelumab	3	3 (100.0)	-1.56 (0.25)	-1.8	-1.83	-1.50	-1.33	-1.3	-3.08 [-5.75, -0.41]
			Placebo	3	3 (100.0)	-0.33 (0.50)	-0.8	-0.83	-0.33	0.17	0.2	
		Week 10	Tezepelumab	3	3 (100.0)	-1.67 (0.17)	-1.8	-1.83	-1.67	-1.50	-1.5	-5.86 [-10.23, -1.50]
			Placebo	3	3 (100.0)	-0.61 (0.19)	-0.8	-0.83	-0.50	-0.50	-0.5	
		Week 12	Tezepelumab	3	3 (100.0)	-2.00 (0.29)	-2.2	-2.17	-2.17	-1.67	-1.7	-4.28 [-7.64, -0.91]
			Placebo	3	3 (100.0)	-0.67 (0.33)	-1.0	-1.00	-0.67	-0.33	-0.3	
		Week 14	Tezepelumab	3	3 (100.0)	-1.72 (0.19)	-1.8	-1.83	-1.83	-1.50	-1.5	-2.17 [-4.36, 0.03]
			Placebo	3	3 (100.0)	-0.89 (0.51)	-1.3	-1.33	-1.00	-0.33	-0.3	
		Week 16	Tezepelumab	3	3 (100.0)	-1.89 (0.48)	-2.2	-2.17	-2.17	-1.33	-1.3	-1.39 [-3.26, 0.48]
			Placebo	3	3 (100.0)	-1.00 (0.76)	-1.7	-1.67	-1.17	-0.17	-0.2	
		Week 18	Tezepelumab	3	3 (100.0)	-1.89 (0.25)	-2.2	-2.17	-1.83	-1.67	-1.7	-3.86 [-6.97, -0.74]
			Placebo	3	3 (100.0)	-0.50 (0.44)	-1.0	-1.00	-0.33	-0.17	-0.2	
		Week 20	Tezepelumab	3	3 (100.0)	-1.83 (0.29)	-2.0	-2.00	-2.00	-1.50	-1.5	-2.09 [-4.24, 0.07]
			Placebo	3	3 (100.0)	-0.17 (1.09)	-1.3	-1.33	0.00	0.83	0.8	
		Week 22	Tezepelumab	3	3 (100.0)	-2.00 (0.29)	-2.2	-2.17	-2.17	-1.67	-1.7	-3.18 [-5.91, -0.46]
			Placebo	3	3 (100.0)	-0.50 (0.60)	-1.0	-1.00	-0.67	0.17	0.2	
		Week 24	Tezepelumab	3	3 (100.0)	-1.94 (0.42)	-2.3	-2.33	-2.00	-1.50	-1.5	-2.91 [-5.48, -0.33]
			Placebo	3	3 (100.0)	-0.11 (0.79)	-1.0	-1.00	0.17	0.50	0.5	
		Week 26	Tezepelumab	3	3 (100.0)	-2.00 (0.58)	-2.3	-2.33	-2.33	-1.33	-1.3	-2.16 [-4.34, 0.03]
			Placebo	3	3 (100.0)	-0.56 (0.75)	-1.3	-1.33	-0.50	0.17	0.2	
		Week 28	Tezepelumab	3	3 (100.0)	-1.89 (0.48)	-2.2	-2.17	-2.17	-1.33	-1.3	-1.39 [-3.26, 0.48]
			Placebo	3	3 (100.0)	-1.00 (0.76)	-1.8	-1.83	-0.83	-0.33	-0.3	
		Week 30	Tezepelumab	3	3 (100.0)	-1.94 (0.51)	-2.5	-2.50	-1.83	-1.50	-1.5	-0.87 [-2.58, 0.84]
			Placebo	3	3 (100.0)	-1.44 (0.63)	-2.2	-2.17	-1.17	-1.00	-1.0	
		Week 32	Tezepelumab	3	3 (100.0)	-2.00 (0.44)	-2.3	-2.33	-2.17	-1.50	-1.5	-1.56 [-3.49, 0.37]
			Placebo	3	3 (100.0)	-1.11 (0.67)	-1.5	-1.50	-1.50	-0.33	-0.3	
		Week 34	Tezepelumab	3	3 (100.0)	-2.00 (0.50)	-2.5	-2.50	-2.00	-1.50	-1.5	-2.15 [-4.34, 0.04]
			Placebo	3	3 (100.0)	-0.94 (0.48)	-1.5	-1.50	-0.67	-0.67	-0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asian	Change from baseline	Week 36	Tezepelumab	3	3 (100.0)	-1.94 (0.54)	-2.3	-2.33	-2.17	-1.33	-1.3	-3.05 [-5.70, -0.40]
			Placebo	3	3 (100.0)	0.11 (0.79)	-0.5	-0.50	-0.17	1.00	1.0	
		Week 38	Tezepelumab	3	3 (100.0)	-1.83 (0.60)	-2.5	-2.50	-1.67	-1.33	-1.3	-1.21 [-3.01, 0.60]
			Placebo	3	3 (100.0)	-1.17 (0.50)	-1.7	-1.67	-1.17	-0.67	-0.7	
		Week 40	Tezepelumab	3	3 (100.0)	-2.06 (0.51)	-2.5	-2.50	-2.17	-1.50	-1.5	-2.40 [-4.70, -0.09]
			Placebo	3	3 (100.0)	-0.50 (0.76)	-1.2	-1.17	-0.67	0.33	0.3	
		Week 42	Tezepelumab	3	3 (100.0)	-1.83 (0.44)	-2.2	-2.17	-2.00	-1.33	-1.3	-2.56 [-4.95, -0.17]
			Placebo	3	3 (100.0)	-0.83 (0.33)	-1.2	-1.17	-0.83	-0.50	-0.5	
		Week 44	Tezepelumab	3	3 (100.0)	-2.06 (0.67)	-2.7	-2.67	-2.17	-1.33	-1.3	-3.21 [-5.96, -0.47]
			Placebo	3	3 (100.0)	0.39 (0.84)	-0.5	-0.50	0.50	1.17	1.2	
		Week 46	Tezepelumab	3	3 (100.0)	-1.89 (0.48)	-2.2	-2.17	-2.17	-1.33	-1.3	-1.33 [-3.17, 0.52]
			Placebo	3	3 (100.0)	-1.17 (0.60)	-1.8	-1.83	-1.00	-0.67	-0.7	
		Week 48	Tezepelumab	3	3 (100.0)	-1.89 (0.35)	-2.2	-2.17	-2.00	-1.50	-1.5	-3.61 [-6.59, -0.64]
			Placebo	3	3 (100.0)	-0.33 (0.50)	-0.8	-0.83	-0.33	0.17	0.2	
		Week 50	Tezepelumab	3	3 (100.0)	-1.94 (0.59)	-2.5	-2.50	-2.00	-1.33	-1.3	-1.99 [-4.11, 0.12]
			Placebo	3	3 (100.0)	-0.78 (0.59)	-1.3	-1.33	-0.83	-0.17	-0.2	
		Week 52	Tezepelumab	3	3 (100.0)	-1.94 (0.59)	-2.5	-2.50	-2.00	-1.33	-1.3	-1.99 [-4.11, 0.12]
			Placebo	3	3 (100.0)	-0.78 (0.59)	-1.3	-1.33	-0.83	-0.17	-0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.33	2.3	2.33	2.33	2.33	2.3	
			Placebo	2	2 (100.0)	3.92 (1.06)	3.2	3.17	3.92	4.67	4.7	
		Week 2	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	
			Placebo	2	2 (100.0)	3.42 (1.77)	2.2	2.17	3.42	4.67	4.7	
		Week 4	Tezepelumab	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	
			Placebo	2	2 (100.0)	3.50 (0.00)	3.5	3.50	3.50	3.50	3.5	
		Week 6	Tezepelumab	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
			Placebo	2	2 (100.0)	3.33 (3.06)	1.2	1.17	3.33	5.50	5.5	
		Week 8	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	
			Placebo	2	2 (100.0)	2.42 (3.18)	0.2	0.17	2.42	4.67	4.7	
		Week 10	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	2	2 (100.0)	2.00 (1.41)	1.0	1.00	2.00	3.00	3.0	
		Week 12	Tezepelumab	1	1 (100.0)	2.67	2.7	2.67	2.67	2.67	2.7	
			Placebo	2	2 (100.0)	1.42 (2.00)	0.0	0.00	1.42	2.83	2.8	
		Week 14	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	2	2 (100.0)	1.50 (2.12)	0.0	0.00	1.50	3.00	3.0	
		Week 16	Tezepelumab	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
			Placebo	2	2 (100.0)	2.42 (3.42)	0.0	0.00	2.42	4.83	4.8	
		Week 18	Tezepelumab	1	1 (100.0)	1.83	1.8	1.83	1.83	1.83	1.8	
			Placebo	2	2 (100.0)	1.50 (2.12)	0.0	0.00	1.50	3.00	3.0	
		Week 20	Tezepelumab	1	1 (100.0)	1.83	1.8	1.83	1.83	1.83	1.8	
			Placebo	2	2 (100.0)	2.67 (0.47)	2.3	2.33	2.67	3.00	3.0	
		Week 22	Tezepelumab	1	1 (100.0)	2.33	2.3	2.33	2.33	2.33	2.3	
			Placebo	2	2 (100.0)	3.00 (0.47)	2.7	2.67	3.00	3.33	3.3	
		Week 24	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	
			Placebo	2	2 (100.0)	2.00 (1.89)	0.7	0.67	2.00	3.33	3.3	
		Week 26	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	2	2 (100.0)	1.67 (2.36)	0.0	0.00	1.67	3.33	3.3	
		Week 28	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	2	2 (100.0)	1.67 (2.36)	0.0	0.00	1.67	3.33	3.3	
		Week 30	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	2	2 (100.0)	2.58 (1.06)	1.8	1.83	2.58	3.33	3.3	
		Week 32	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	2	2 (100.0)	2.58 (1.06)	1.8	1.83	2.58	3.33	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Other	Absolute values	Week 34	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	2	2 (100.0)	1.83 (2.12)	0.3	0.33	1.83	3.33	3.3	
		Week 36	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	2	2 (100.0)	2.58 (1.06)	1.8	1.83	2.58	3.33	3.3	
		Week 38	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	2	2 (100.0)	2.58 (1.06)	1.8	1.83	2.58	3.33	3.3	
		Week 40	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	2	2 (100.0)	2.08 (1.77)	0.8	0.83	2.08	3.33	3.3	
		Week 42	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	2	2 (100.0)	2.67 (0.94)	2.0	2.00	2.67	3.33	3.3	
		Week 44	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	2	2 (100.0)	1.92 (2.00)	0.5	0.50	1.92	3.33	3.3	
		Week 46	Tezepelumab	1	1 (100.0)	2.17	2.2	2.17	2.17	2.17	2.2	
			Placebo	2	2 (100.0)	2.67 (0.94)	2.0	2.00	2.67	3.33	3.3	
		Week 48	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	2	2 (100.0)	3.00 (0.47)	2.7	2.67	3.00	3.33	3.3	
		Week 50	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	2	2 (100.0)	1.75 (2.24)	0.2	0.17	1.75	3.33	3.3	
		Week 52	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
			Placebo	2	2 (100.0)	1.75 (2.24)	0.2	0.17	1.75	3.33	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 2	Tezepelumab	1	1 (100.0)	0.17	0.2	0.17	0.17	0.17	0.2	NE
			Placebo	2	2 (100.0)	-0.50 (0.71)	-1.0	-1.00	-0.50	0.00	0.0	
		Week 4	Tezepelumab	1	1 (100.0)	0.67	0.7	0.67	0.67	0.67	0.7	NE
			Placebo	2	2 (100.0)	-0.42 (1.06)	-1.2	-1.17	-0.42	0.33	0.3	
		Week 6	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	2	2 (100.0)	-0.58 (2.00)	-2.0	-2.00	-0.58	0.83	0.8	
		Week 8	Tezepelumab	1	1 (100.0)	0.17	0.2	0.17	0.17	0.17	0.2	NE
			Placebo	2	2 (100.0)	-1.50 (2.12)	-3.0	-3.00	-1.50	0.00	0.0	
		Week 10	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	2	2 (100.0)	-1.92 (0.35)	-2.2	-2.17	-1.92	-1.67	-1.7	
		Week 12	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	2	2 (100.0)	-2.50 (0.94)	-3.2	-3.17	-2.50	-1.83	-1.8	
		Week 14	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	2	2 (100.0)	-2.42 (1.06)	-3.2	-3.17	-2.42	-1.67	-1.7	
		Week 16	Tezepelumab	1	1 (100.0)	-1.00	-1.0	-1.00	-1.00	-1.00	-1.0	NE
			Placebo	2	2 (100.0)	-1.50 (2.36)	-3.2	-3.17	-1.50	0.17	0.2	
		Week 18	Tezepelumab	1	1 (100.0)	-0.50	-0.5	-0.50	-0.50	-0.50	-0.5	NE
			Placebo	2	2 (100.0)	-2.42 (1.06)	-3.2	-3.17	-2.42	-1.67	-1.7	
		Week 20	Tezepelumab	1	1 (100.0)	-0.50	-0.5	-0.50	-0.50	-0.50	-0.5	NE
			Placebo	2	2 (100.0)	-1.25 (0.59)	-1.7	-1.67	-1.25	-0.83	-0.8	
		Week 22	Tezepelumab	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	NE
			Placebo	2	2 (100.0)	-0.92 (0.59)	-1.3	-1.33	-0.92	-0.50	-0.5	
		Week 24	Tezepelumab	1	1 (100.0)	0.17	0.2	0.17	0.17	0.17	0.2	NE
			Placebo	2	2 (100.0)	-1.92 (0.82)	-2.5	-2.50	-1.92	-1.33	-1.3	
		Week 26	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	2	2 (100.0)	-2.25 (1.30)	-3.2	-3.17	-2.25	-1.33	-1.3	
		Week 28	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	2	2 (100.0)	-2.25 (1.30)	-3.2	-3.17	-2.25	-1.33	-1.3	
		Week 30	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	2	2 (100.0)	-1.33 (0.00)	-1.3	-1.33	-1.33	-1.33	-1.3	
		Week 32	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	2	2 (100.0)	-1.33 (0.00)	-1.3	-1.33	-1.33	-1.33	-1.3	
		Week 34	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	2	2 (100.0)	-2.08 (1.06)	-2.8	-2.83	-2.08	-1.33	-1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Other	Change from baseline	Week 36	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	2	2 (100.0)	-1.33 (0.00)	-1.3	-1.33	-1.33	-1.33	-1.3	
		Week 38	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	2	2 (100.0)	-1.33 (0.00)	-1.3	-1.33	-1.33	-1.33	-1.3	
		Week 40	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	2	2 (100.0)	-1.83 (0.71)	-2.3	-2.33	-1.83	-1.33	-1.3	
		Week 42	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	2	2 (100.0)	-1.25 (0.12)	-1.3	-1.33	-1.25	-1.17	-1.2	
		Week 44	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	2	2 (100.0)	-2.00 (0.94)	-2.7	-2.67	-2.00	-1.33	-1.3	
		Week 46	Tezepelumab	1	1 (100.0)	-0.17	-0.2	-0.17	-0.17	-0.17	-0.2	NE
			Placebo	2	2 (100.0)	-1.25 (0.12)	-1.3	-1.33	-1.25	-1.17	-1.2	
		Week 48	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	2	2 (100.0)	-0.92 (0.59)	-1.3	-1.33	-0.92	-0.50	-0.5	
		Week 50	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	2	2 (100.0)	-2.17 (1.18)	-3.0	-3.00	-2.17	-1.33	-1.3	
		Week 52	Tezepelumab	1	1 (100.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	NE
			Placebo	2	2 (100.0)	-2.17 (1.18)	-3.0	-3.00	-2.17	-1.33	-1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	2.71 (0.92)	0.0	2.25	2.67	3.17	4.5	
			Placebo	36	36 (100.0)	2.51 (0.67)	0.3	2.25	2.50	3.00	3.5	
		Week 2	Tezepelumab	40	38 (95.0)	2.30 (1.04)	0.2	1.33	2.58	3.00	4.2	
			Placebo	36	32 (88.9)	2.24 (0.66)	0.5	1.75	2.33	2.75	3.3	
		Week 4	Tezepelumab	40	38 (95.0)	2.06 (1.00)	0.2	1.33	2.33	2.83	3.5	
			Placebo	36	32 (88.9)	2.11 (0.88)	0.3	1.42	2.33	2.67	4.2	
		Week 6	Tezepelumab	40	38 (95.0)	1.93 (1.07)	0.0	1.33	1.92	2.67	4.0	
			Placebo	36	32 (88.9)	2.01 (1.06)	0.2	1.25	2.08	2.67	4.7	
		Week 8	Tezepelumab	40	38 (95.0)	1.89 (1.22)	0.0	0.83	1.75	2.67	4.8	
			Placebo	36	32 (88.9)	1.95 (1.00)	0.0	0.92	2.00	2.75	3.7	
		Week 10	Tezepelumab	40	38 (95.0)	1.80 (1.17)	0.0	0.83	1.92	2.67	4.3	
			Placebo	36	32 (88.9)	2.01 (0.97)	0.0	1.42	2.08	2.75	4.2	
		Week 12	Tezepelumab	40	38 (95.0)	1.70 (1.13)	0.0	0.67	1.92	2.50	4.3	
			Placebo	36	32 (88.9)	1.73 (0.97)	0.0	1.00	1.83	2.42	4.2	
		Week 14	Tezepelumab	40	38 (95.0)	1.65 (1.20)	0.0	0.50	1.75	2.33	4.3	
			Placebo	36	32 (88.9)	1.65 (0.79)	0.0	1.00	1.83	2.17	3.2	
		Week 16	Tezepelumab	40	38 (95.0)	1.74 (1.18)	0.0	0.67	1.83	2.50	4.3	
			Placebo	36	32 (88.9)	1.88 (0.98)	0.0	0.92	2.00	2.67	3.8	
		Week 18	Tezepelumab	40	39 (97.5)	1.73 (1.10)	0.0	0.83	1.83	2.33	4.3	
			Placebo	36	32 (88.9)	1.69 (1.05)	0.0	0.83	1.67	2.33	4.7	
		Week 20	Tezepelumab	40	39 (97.5)	1.70 (1.22)	0.0	0.50	1.83	2.50	5.0	
			Placebo	36	32 (88.9)	1.73 (0.90)	0.0	1.00	1.83	2.42	3.5	
		Week 22	Tezepelumab	40	39 (97.5)	1.82 (1.05)	0.0	1.33	1.83	2.33	4.3	
			Placebo	36	32 (88.9)	1.66 (0.92)	0.0	0.92	1.83	2.25	3.5	
		Week 24	Tezepelumab	40	39 (97.5)	1.71 (1.16)	0.0	0.50	1.83	2.50	4.3	
			Placebo	36	32 (88.9)	1.83 (0.86)	0.0	1.25	2.00	2.50	3.2	
		Week 26	Tezepelumab	40	40 (100.0)	1.80 (1.13)	0.0	1.00	1.83	2.67	4.3	
			Placebo	36	32 (88.9)	1.78 (0.97)	0.0	1.00	1.75	2.67	3.7	
		Week 28	Tezepelumab	40	40 (100.0)	1.77 (1.17)	0.0	0.92	1.92	2.58	4.3	
			Placebo	36	33 (91.7)	1.77 (1.13)	0.0	1.00	1.83	2.67	3.8	
		Week 30	Tezepelumab	40	40 (100.0)	1.75 (1.15)	0.0	0.83	1.83	2.50	4.3	
			Placebo	36	33 (91.7)	1.69 (1.10)	0.0	0.83	1.83	2.50	3.8	
		Week 32	Tezepelumab	40	40 (100.0)	1.69 (1.17)	0.0	0.67	1.83	2.58	4.3	
			Placebo	36	33 (91.7)	1.69 (0.95)	0.0	1.17	1.83	2.17	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	Absolute values	Week 34	Tezepelumab	40	40 (100.0)	1.72 (1.22)	0.0	0.75	1.83	2.58	4.3	
			Placebo	36	33 (91.7)	1.68 (0.86)	0.0	1.17	1.83	2.17	3.5	
		Week 36	Tezepelumab	40	40 (100.0)	1.69 (1.14)	0.0	0.67	1.75	2.58	4.3	
			Placebo	36	33 (91.7)	1.78 (1.01)	0.0	1.00	1.83	2.50	4.2	
		Week 38	Tezepelumab	40	40 (100.0)	1.69 (1.24)	0.0	0.83	1.75	2.67	4.5	
			Placebo	36	33 (91.7)	1.73 (0.92)	0.0	1.17	1.83	2.50	3.2	
		Week 40	Tezepelumab	40	40 (100.0)	1.64 (1.19)	0.0	0.50	1.83	2.67	4.3	
			Placebo	36	33 (91.7)	1.91 (1.12)	0.0	1.17	2.17	2.50	4.2	
		Week 42	Tezepelumab	40	40 (100.0)	1.67 (1.20)	0.0	0.83	1.67	2.67	4.3	
			Placebo	36	33 (91.7)	1.73 (0.98)	0.0	1.00	1.83	2.33	4.5	
		Week 44	Tezepelumab	40	40 (100.0)	1.70 (1.16)	0.0	0.75	1.75	2.67	4.3	
			Placebo	36	33 (91.7)	1.82 (1.05)	0.0	1.17	2.00	2.50	4.2	
		Week 46	Tezepelumab	40	40 (100.0)	1.73 (1.21)	0.0	0.75	1.83	2.67	4.3	
			Placebo	36	33 (91.7)	1.71 (0.87)	0.0	1.17	1.83	2.33	3.3	
		Week 48	Tezepelumab	40	40 (100.0)	1.76 (1.21)	0.0	0.75	1.92	2.67	4.3	
			Placebo	36	33 (91.7)	1.76 (0.97)	0.0	1.00	2.00	2.50	3.8	
		Week 50	Tezepelumab	40	40 (100.0)	1.72 (1.22)	0.0	0.83	1.67	2.67	4.3	
			Placebo	36	33 (91.7)	1.63 (0.92)	0.0	1.00	1.83	2.33	3.3	
		Week 52	Tezepelumab	40	40 (100.0)	1.75 (1.20)	0.0	0.83	1.75	2.50	4.3	
			Placebo	36	33 (91.7)	1.77 (0.98)	0.0	1.00	2.17	2.50	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 2	Tezepelumab	40	38 (95.0)	-0.46 (0.72)	-2.0	-1.00	-0.33	0.17	0.7	-0.09 [-0.56, 0.38]
			Placebo	36	32 (88.9)	-0.40 (0.59)	-1.5	-0.83	-0.42	0.08	1.0	
		Week 4	Tezepelumab	40	38 (95.0)	-0.70 (0.92)	-2.5	-1.17	-0.75	-0.17	2.3	-0.18 [-0.66, 0.29]
			Placebo	36	32 (88.9)	-0.53 (0.88)	-3.0	-1.08	-0.33	0.00	1.2	
		Week 6	Tezepelumab	40	38 (95.0)	-0.82 (0.98)	-2.7	-1.33	-0.92	-0.17	2.3	-0.19 [-0.66, 0.28]
			Placebo	36	32 (88.9)	-0.64 (0.99)	-3.3	-1.25	-0.50	0.08	1.5	
		Week 8	Tezepelumab	40	38 (95.0)	-0.87 (1.16)	-3.0	-1.50	-0.92	-0.17	2.3	-0.17 [-0.64, 0.30]
			Placebo	36	32 (88.9)	-0.69 (0.87)	-3.0	-1.00	-0.50	-0.08	0.7	
		Week 10	Tezepelumab	40	38 (95.0)	-0.96 (1.13)	-3.2	-1.67	-1.17	0.00	2.3	-0.31 [-0.78, 0.16]
			Placebo	36	32 (88.9)	-0.63 (0.97)	-3.2	-1.25	-0.50	0.00	2.0	
		Week 12	Tezepelumab	40	38 (95.0)	-1.06 (1.11)	-3.0	-2.00	-1.17	-0.33	2.3	-0.15 [-0.62, 0.32]
			Placebo	36	32 (88.9)	-0.91 (0.91)	-3.2	-1.33	-0.83	-0.33	1.2	
		Week 14	Tezepelumab	40	38 (95.0)	-1.11 (1.14)	-3.7	-2.00	-1.17	-0.33	2.3	-0.11 [-0.58, 0.36]
			Placebo	36	32 (88.9)	-0.99 (0.88)	-3.2	-1.50	-1.00	-0.42	1.0	
		Week 16	Tezepelumab	40	38 (95.0)	-1.02 (1.08)	-3.0	-2.00	-1.00	-0.33	2.3	-0.26 [-0.73, 0.22]
			Placebo	36	32 (88.9)	-0.76 (0.90)	-2.8	-1.33	-0.75	-0.08	0.8	
		Week 18	Tezepelumab	40	39 (97.5)	-1.01 (1.09)	-3.5	-1.83	-0.83	-0.33	2.3	-0.06 [-0.53, 0.41]
			Placebo	36	32 (88.9)	-0.95 (0.99)	-2.5	-1.67	-0.92	-0.17	1.5	
		Week 20	Tezepelumab	40	39 (97.5)	-1.03 (1.13)	-3.2	-2.00	-1.00	-0.33	2.3	-0.13 [-0.59, 0.34]
			Placebo	36	32 (88.9)	-0.91 (0.84)	-2.8	-1.33	-0.75	-0.33	0.5	
		Week 22	Tezepelumab	40	39 (97.5)	-0.92 (1.14)	-3.0	-1.83	-0.83	-0.50	2.3	0.06 [-0.41, 0.53]
			Placebo	36	32 (88.9)	-0.98 (0.85)	-2.8	-1.50	-0.83	-0.42	0.7	
		Week 24	Tezepelumab	40	39 (97.5)	-1.02 (1.06)	-3.2	-1.67	-1.00	-0.33	2.3	-0.22 [-0.69, 0.25]
			Placebo	36	32 (88.9)	-0.81 (0.85)	-3.2	-1.25	-0.58	-0.17	0.5	
		Week 26	Tezepelumab	40	40 (100.0)	-0.90 (1.09)	-2.8	-1.92	-0.92	0.00	2.3	-0.04 [-0.51, 0.42]
			Placebo	36	32 (88.9)	-0.86 (0.91)	-2.5	-1.50	-0.75	-0.33	0.7	
		Week 28	Tezepelumab	40	40 (100.0)	-0.94 (1.18)	-3.2	-2.00	-0.92	0.00	2.3	-0.12 [-0.58, 0.34]
			Placebo	36	33 (91.7)	-0.80 (1.03)	-2.8	-1.50	-0.50	-0.17	1.2	
		Week 30	Tezepelumab	40	40 (100.0)	-0.95 (1.19)	-3.5	-2.00	-0.83	-0.17	2.3	-0.07 [-0.53, 0.40]
			Placebo	36	33 (91.7)	-0.88 (1.11)	-3.2	-1.50	-0.83	-0.33	2.0	
		Week 32	Tezepelumab	40	40 (100.0)	-1.02 (1.11)	-3.0	-1.92	-1.00	-0.33	2.3	-0.14 [-0.60, 0.32]
			Placebo	36	33 (91.7)	-0.88 (0.91)	-3.0	-1.17	-0.67	-0.33	0.7	
		Week 34	Tezepelumab	40	40 (100.0)	-0.98 (1.19)	-2.8	-2.00	-1.17	-0.25	2.3	-0.09 [-0.55, 0.37]
			Placebo	36	33 (91.7)	-0.89 (0.78)	-2.8	-1.33	-0.83	-0.33	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	Change from baseline	Week 36	Tezepelumab	40	40 (100.0)	-1.02 (1.16)	-3.0	-2.00	-1.00	-0.17	2.3	-0.22 [-0.68, 0.24]
			Placebo	36	33 (91.7)	-0.79 (0.92)	-3.5	-1.17	-0.83	-0.33	1.2	
		Week 38	Tezepelumab	40	40 (100.0)	-1.02 (1.19)	-3.0	-2.00	-1.17	-0.25	2.3	-0.17 [-0.63, 0.29]
			Placebo	36	33 (91.7)	-0.84 (0.88)	-3.0	-1.33	-0.83	-0.33	0.8	
		Week 40	Tezepelumab	40	40 (100.0)	-1.07 (1.18)	-3.2	-2.08	-1.08	-0.33	2.3	-0.36 [-0.83, 0.10]
			Placebo	36	33 (91.7)	-0.66 (1.08)	-3.2	-1.17	-0.50	0.00	1.2	
		Week 42	Tezepelumab	40	40 (100.0)	-1.03 (1.21)	-3.3	-2.00	-1.08	-0.25	2.3	-0.17 [-0.64, 0.29]
			Placebo	36	33 (91.7)	-0.84 (1.00)	-2.8	-1.33	-0.83	-0.17	1.5	
		Week 44	Tezepelumab	40	40 (100.0)	-1.00 (1.20)	-3.5	-2.00	-0.92	-0.25	2.3	-0.22 [-0.69, 0.24]
			Placebo	36	33 (91.7)	-0.75 (1.03)	-3.3	-1.17	-0.83	-0.33	1.5	
		Week 46	Tezepelumab	40	40 (100.0)	-0.98 (1.21)	-3.3	-2.00	-1.00	-0.08	2.3	-0.11 [-0.57, 0.35]
			Placebo	36	33 (91.7)	-0.86 (0.90)	-2.8	-1.33	-0.83	-0.33	1.2	
		Week 48	Tezepelumab	40	40 (100.0)	-0.95 (1.20)	-2.7	-2.00	-0.83	-0.17	2.3	-0.13 [-0.59, 0.33]
			Placebo	36	33 (91.7)	-0.81 (0.94)	-3.3	-1.17	-0.67	-0.33	0.8	
		Week 50	Tezepelumab	40	40 (100.0)	-0.99 (1.16)	-2.5	-1.92	-1.17	-0.25	2.3	-0.05 [-0.51, 0.41]
			Placebo	36	33 (91.7)	-0.94 (0.87)	-3.5	-1.17	-0.67	-0.50	0.5	
		Week 52	Tezepelumab	40	40 (100.0)	-0.95 (1.14)	-2.7	-1.75	-1.00	-0.25	2.3	-0.15 [-0.61, 0.32]
			Placebo	36	33 (91.7)	-0.80 (0.90)	-3.5	-1.17	-0.67	-0.33	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	2.86 (1.07)	2.0	2.00	2.58	3.17	4.8	
			Placebo	4	4 (100.0)	2.92 (0.62)	2.2	2.42	3.00	3.42	3.5	
		Week 2	Tezepelumab	6	5 (83.3)	1.97 (1.23)	0.0	1.83	2.17	2.50	3.3	
			Placebo	4	3 (75.0)	1.56 (0.42)	1.2	1.17	1.50	2.00	2.0	
		Week 4	Tezepelumab	6	5 (83.3)	1.97 (0.92)	0.8	1.50	2.00	2.17	3.3	
			Placebo	4	3 (75.0)	1.50 (1.44)	0.7	0.67	0.67	3.17	3.2	
		Week 6	Tezepelumab	6	5 (83.3)	1.93 (1.03)	0.5	1.67	1.83	2.33	3.3	
			Placebo	4	3 (75.0)	1.28 (0.95)	0.5	0.50	1.00	2.33	2.3	
		Week 8	Tezepelumab	6	5 (83.3)	1.43 (1.02)	0.2	1.17	1.33	1.50	3.0	
			Placebo	4	3 (75.0)	1.44 (1.55)	0.2	0.17	1.00	3.17	3.2	
		Week 10	Tezepelumab	6	5 (83.3)	1.23 (1.10)	0.2	0.67	0.83	1.50	3.0	
			Placebo	4	3 (75.0)	2.06 (2.87)	0.0	0.00	0.83	5.33	5.3	
		Week 12	Tezepelumab	6	5 (83.3)	1.27 (0.61)	0.5	1.00	1.33	1.33	2.2	
			Placebo	4	3 (75.0)	1.61 (2.11)	0.0	0.00	0.83	4.00	4.0	
		Week 14	Tezepelumab	6	5 (83.3)	1.13 (0.70)	0.5	0.83	1.00	1.00	2.3	
			Placebo	4	3 (75.0)	2.06 (2.56)	0.3	0.33	0.83	5.00	5.0	
		Week 16	Tezepelumab	6	5 (83.3)	1.47 (0.59)	0.7	1.33	1.50	1.50	2.3	
			Placebo	4	3 (75.0)	2.00 (2.62)	0.2	0.17	0.83	5.00	5.0	
		Week 18	Tezepelumab	6	5 (83.3)	1.37 (0.65)	0.5	1.33	1.33	1.33	2.3	
			Placebo	4	3 (75.0)	2.00 (2.62)	0.2	0.17	0.83	5.00	5.0	
		Week 20	Tezepelumab	6	5 (83.3)	1.47 (0.52)	1.0	1.17	1.33	1.50	2.3	
			Placebo	4	3 (75.0)	1.83 (2.74)	0.2	0.17	0.33	5.00	5.0	
		Week 22	Tezepelumab	6	5 (83.3)	1.23 (0.63)	0.8	0.83	1.00	1.17	2.3	
			Placebo	4	3 (75.0)	1.78 (2.80)	0.0	0.00	0.33	5.00	5.0	
		Week 24	Tezepelumab	6	5 (83.3)	1.57 (0.65)	0.8	1.17	1.33	2.17	2.3	
			Placebo	4	3 (75.0)	1.56 (2.26)	0.2	0.17	0.33	4.17	4.2	
		Week 26	Tezepelumab	6	5 (83.3)	1.47 (0.62)	0.7	1.17	1.50	1.67	2.3	
			Placebo	4	3 (75.0)	1.67 (2.17)	0.3	0.33	0.50	4.17	4.2	
		Week 28	Tezepelumab	6	6 (100.0)	1.22 (0.74)	0.3	0.50	1.33	1.50	2.3	
			Placebo	4	3 (75.0)	1.67 (2.17)	0.3	0.33	0.50	4.17	4.2	
		Week 30	Tezepelumab	6	6 (100.0)	1.25 (0.77)	0.2	0.67	1.33	1.67	2.3	
			Placebo	4	3 (75.0)	1.67 (2.17)	0.3	0.33	0.50	4.17	4.2	
		Week 32	Tezepelumab	6	6 (100.0)	1.36 (0.73)	0.2	1.17	1.42	1.67	2.3	
			Placebo	4	3 (75.0)	1.67 (2.17)	0.3	0.33	0.50	4.17	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
America	Absolute values	Week 34	Tezepelumab	6	6 (100.0)	1.28 (0.79)	0.0	1.00	1.25	1.83	2.3	
			Placebo	4	3 (75.0)	1.56 (2.28)	0.0	0.00	0.50	4.17	4.2	
		Week 36	Tezepelumab	6	6 (100.0)	1.69 (0.59)	1.2	1.17	1.58	2.33	2.3	
			Placebo	4	3 (75.0)	1.78 (2.15)	0.0	0.00	1.17	4.17	4.2	
		Week 38	Tezepelumab	6	6 (100.0)	1.31 (0.71)	0.3	0.83	1.25	1.83	2.3	
			Placebo	4	3 (75.0)	1.67 (2.20)	0.0	0.00	0.83	4.17	4.2	
		Week 40	Tezepelumab	6	6 (100.0)	1.47 (0.78)	0.2	1.17	1.50	2.17	2.3	
			Placebo	4	3 (75.0)	1.78 (2.15)	0.0	0.00	1.17	4.17	4.2	
		Week 42	Tezepelumab	6	6 (100.0)	1.39 (0.71)	0.2	1.17	1.50	1.67	2.3	
			Placebo	4	3 (75.0)	0.89 (0.79)	0.0	0.00	1.17	1.50	1.5	
		Week 44	Tezepelumab	6	6 (100.0)	1.47 (0.70)	0.3	1.17	1.50	2.00	2.3	
			Placebo	4	3 (75.0)	0.94 (0.25)	0.7	0.67	1.00	1.17	1.2	
		Week 46	Tezepelumab	6	6 (100.0)	1.28 (0.74)	0.2	1.00	1.17	1.83	2.3	
			Placebo	4	3 (75.0)	0.89 (0.35)	0.5	0.50	1.00	1.17	1.2	
		Week 48	Tezepelumab	6	6 (100.0)	1.31 (0.71)	0.2	1.17	1.25	1.67	2.3	
			Placebo	4	3 (75.0)	0.72 (0.35)	0.3	0.33	0.83	1.00	1.0	
		Week 50	Tezepelumab	6	6 (100.0)	1.00 (0.85)	0.0	0.17	1.08	1.33	2.3	
			Placebo	4	3 (75.0)	2.00 (1.45)	1.0	1.00	1.33	3.67	3.7	
		Week 52	Tezepelumab	6	6 (100.0)	1.22 (0.70)	0.2	1.00	1.25	1.33	2.3	
			Placebo	4	3 (75.0)	1.67 (1.86)	0.0	0.00	1.33	3.67	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 2	Tezepelumab	6	5 (83.3)	-1.00 (1.20)	-2.8	-1.50	-0.67	-0.17	0.2	0.15 [-1.29, 1.58]
			Placebo	4	3 (75.0)	-1.17 (1.00)	-2.2	-2.17	-1.17	-0.17	-0.2	
		Week 4	Tezepelumab	6	5 (83.3)	-1.00 (0.85)	-2.0	-1.50	-1.17	-0.50	0.2	0.19 [-1.24, 1.63]
			Placebo	4	3 (75.0)	-1.22 (1.60)	-2.7	-2.67	-1.50	0.50	0.5	
		Week 6	Tezepelumab	6	5 (83.3)	-1.03 (1.04)	-2.3	-1.50	-1.33	-0.33	0.3	0.37 [-1.08, 1.81]
			Placebo	4	3 (75.0)	-1.44 (1.27)	-2.8	-2.83	-1.17	-0.33	-0.3	
		Week 8	Tezepelumab	6	5 (83.3)	-1.53 (0.81)	-2.7	-1.83	-1.67	-0.83	-0.7	-0.20 [-1.64, 1.23]
			Placebo	4	3 (75.0)	-1.28 (1.84)	-3.2	-3.17	-1.17	0.50	0.5	
		Week 10	Tezepelumab	6	5 (83.3)	-1.73 (0.85)	-2.7	-2.33	-1.83	-1.33	-0.5	-0.56 [-2.03, 0.90]
			Placebo	4	3 (75.0)	-0.67 (3.06)	-3.3	-3.33	-1.33	2.67	2.7	
		Week 12	Tezepelumab	6	5 (83.3)	-1.70 (0.85)	-2.7	-2.33	-1.83	-1.00	-0.7	-0.39 [-1.84, 1.06]
			Placebo	4	3 (75.0)	-1.11 (2.34)	-3.3	-3.33	-1.33	1.33	1.3	
		Week 14	Tezepelumab	6	5 (83.3)	-1.83 (0.70)	-2.5	-2.33	-2.17	-1.17	-1.0	-0.70 [-2.18, 0.79]
			Placebo	4	3 (75.0)	-0.67 (2.73)	-3.0	-3.00	-1.33	2.33	2.3	
		Week 16	Tezepelumab	6	5 (83.3)	-1.50 (0.89)	-2.5	-2.17	-1.67	-0.67	-0.5	-0.44 [-1.89, 1.01]
			Placebo	4	3 (75.0)	-0.72 (2.80)	-3.2	-3.17	-1.33	2.33	2.3	
		Week 18	Tezepelumab	6	5 (83.3)	-1.60 (0.89)	-2.5	-2.33	-1.83	-0.67	-0.7	-0.50 [-1.95, 0.96]
			Placebo	4	3 (75.0)	-0.72 (2.80)	-3.2	-3.17	-1.33	2.33	2.3	
		Week 20	Tezepelumab	6	5 (83.3)	-1.50 (0.87)	-2.5	-2.00	-1.83	-0.67	-0.5	-0.34 [-1.78, 1.11]
			Placebo	4	3 (75.0)	-0.89 (2.87)	-3.2	-3.17	-1.83	2.33	2.3	
		Week 22	Tezepelumab	6	5 (83.3)	-1.73 (0.57)	-2.5	-2.00	-1.83	-1.17	-1.2	-0.45 [-1.90, 1.01]
			Placebo	4	3 (75.0)	-0.94 (2.94)	-3.3	-3.33	-1.83	2.33	2.3	
		Week 24	Tezepelumab	6	5 (83.3)	-1.40 (1.11)	-2.5	-2.00	-2.00	-0.67	0.2	-0.14 [-1.57, 1.29]
			Placebo	4	3 (75.0)	-1.17 (2.40)	-3.2	-3.17	-1.83	1.50	1.5	
		Week 26	Tezepelumab	6	5 (83.3)	-1.50 (1.01)	-2.5	-2.17	-2.00	-0.50	-0.3	-0.29 [-1.73, 1.15]
			Placebo	4	3 (75.0)	-1.06 (2.27)	-2.8	-2.83	-1.83	1.50	1.5	
		Week 28	Tezepelumab	6	6 (100.0)	-1.64 (0.90)	-2.5	-2.33	-2.00	-0.50	-0.5	-0.41 [-1.81, 1.00]
			Placebo	4	3 (75.0)	-1.06 (2.27)	-2.8	-2.83	-1.83	1.50	1.5	
		Week 30	Tezepelumab	6	6 (100.0)	-1.61 (0.94)	-2.5	-2.17	-2.08	-0.50	-0.3	-0.38 [-1.78, 1.02]
			Placebo	4	3 (75.0)	-1.06 (2.27)	-2.8	-2.83	-1.83	1.50	1.5	
		Week 32	Tezepelumab	6	6 (100.0)	-1.50 (0.85)	-2.5	-2.17	-1.58	-0.83	-0.3	-0.32 [-1.71, 1.08]
			Placebo	4	3 (75.0)	-1.06 (2.27)	-2.8	-2.83	-1.83	1.50	1.5	
		Week 34	Tezepelumab	6	6 (100.0)	-1.58 (0.95)	-2.5	-2.33	-1.92	-0.67	-0.2	-0.28 [-1.67, 1.11]
			Placebo	4	3 (75.0)	-1.17 (2.33)	-2.8	-2.83	-2.17	1.50	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
America	Change from baseline	Week 36	Tezepelumab	6	6 (100.0)	-1.17 (1.13)	-2.5	-2.00	-1.42	0.00	0.3	-0.15 [-1.54, 1.24]
			Placebo	4	3 (75.0)	-0.94 (2.12)	-2.2	-2.17	-2.17	1.50	1.5	
		Week 38	Tezepelumab	6	6 (100.0)	-1.56 (0.92)	-2.5	-2.00	-2.00	-0.67	-0.2	-0.35 [-1.75, 1.05]
			Placebo	4	3 (75.0)	-1.06 (2.22)	-2.5	-2.50	-2.17	1.50	1.5	
		Week 40	Tezepelumab	6	6 (100.0)	-1.39 (1.02)	-2.5	-2.17	-1.58	-0.67	0.2	-0.31 [-1.71, 1.08]
			Placebo	4	3 (75.0)	-0.94 (2.12)	-2.2	-2.17	-2.17	1.50	1.5	
		Week 42	Tezepelumab	6	6 (100.0)	-1.47 (0.87)	-2.5	-2.17	-1.58	-0.50	-0.5	0.45 [-0.95, 1.86]
			Placebo	4	3 (75.0)	-1.83 (0.58)	-2.2	-2.17	-2.17	-1.17	-1.2	
		Week 44	Tezepelumab	6	6 (100.0)	-1.39 (0.95)	-2.5	-2.00	-1.58	-0.67	0.0	0.47 [-0.93, 1.88]
			Placebo	4	3 (75.0)	-1.78 (0.35)	-2.2	-2.17	-1.67	-1.50	-1.5	
		Week 46	Tezepelumab	6	6 (100.0)	-1.58 (0.89)	-2.5	-2.17	-1.92	-0.83	-0.2	0.32 [-1.07, 1.72]
			Placebo	4	3 (75.0)	-1.83 (0.29)	-2.2	-2.17	-1.67	-1.67	-1.7	
		Week 48	Tezepelumab	6	6 (100.0)	-1.56 (0.83)	-2.5	-2.17	-1.75	-0.83	-0.3	0.60 [-0.82, 2.02]
			Placebo	4	3 (75.0)	-2.00 (0.44)	-2.5	-2.50	-1.83	-1.67	-1.7	
		Week 50	Tezepelumab	6	6 (100.0)	-1.86 (0.83)	-2.7	-2.50	-2.17	-1.00	-0.7	-0.91 [-2.38, 0.55]
			Placebo	4	3 (75.0)	-0.72 (1.93)	-2.0	-2.00	-1.67	1.50	1.5	
		Week 52	Tezepelumab	6	6 (100.0)	-1.64 (0.86)	-2.7	-2.50	-1.50	-1.00	-0.7	-0.42 [-1.82, 0.99]
			Placebo	4	3 (75.0)	-1.06 (2.24)	-2.7	-2.67	-2.00	1.50	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.61 (0.51)	2.2	2.17	2.50	3.17	3.2	
			Placebo	3	3 (100.0)	2.56 (0.42)	2.2	2.17	2.50	3.00	3.0	
		Week 2	Tezepelumab	3	3 (100.0)	1.83 (1.09)	0.8	0.83	1.67	3.00	3.0	
			Placebo	3	3 (100.0)	2.33 (0.17)	2.2	2.17	2.33	2.50	2.5	
		Week 4	Tezepelumab	3	3 (100.0)	1.33 (0.76)	0.7	0.67	1.17	2.17	2.2	
			Placebo	3	3 (100.0)	1.94 (0.67)	1.3	1.33	1.83	2.67	2.7	
		Week 6	Tezepelumab	3	3 (100.0)	1.17 (0.44)	0.8	0.83	1.00	1.67	1.7	
			Placebo	3	3 (100.0)	1.83 (0.87)	0.8	0.83	2.33	2.33	2.3	
		Week 8	Tezepelumab	3	3 (100.0)	1.06 (0.54)	0.7	0.67	0.83	1.67	1.7	
			Placebo	3	3 (100.0)	2.22 (0.42)	1.8	1.83	2.17	2.67	2.7	
		Week 10	Tezepelumab	3	3 (100.0)	0.94 (0.35)	0.7	0.67	0.83	1.33	1.3	
			Placebo	3	3 (100.0)	1.94 (0.25)	1.7	1.67	2.00	2.17	2.2	
		Week 12	Tezepelumab	3	3 (100.0)	0.61 (0.79)	0.0	0.00	0.33	1.50	1.5	
			Placebo	3	3 (100.0)	1.89 (0.35)	1.5	1.50	2.00	2.17	2.2	
		Week 14	Tezepelumab	3	3 (100.0)	0.89 (0.38)	0.7	0.67	0.67	1.33	1.3	
			Placebo	3	3 (100.0)	1.67 (0.50)	1.2	1.17	1.67	2.17	2.2	
		Week 16	Tezepelumab	3	3 (100.0)	0.72 (0.35)	0.3	0.33	0.83	1.00	1.0	
			Placebo	3	3 (100.0)	1.56 (0.95)	0.5	0.50	1.83	2.33	2.3	
		Week 18	Tezepelumab	3	3 (100.0)	0.72 (0.25)	0.5	0.50	0.67	1.00	1.0	
			Placebo	3	3 (100.0)	2.06 (0.25)	1.8	1.83	2.00	2.33	2.3	
		Week 20	Tezepelumab	3	3 (100.0)	0.78 (0.35)	0.5	0.50	0.67	1.17	1.2	
			Placebo	3	3 (100.0)	2.39 (0.67)	1.7	1.67	2.50	3.00	3.0	
		Week 22	Tezepelumab	3	3 (100.0)	0.61 (0.54)	0.0	0.00	0.83	1.00	1.0	
			Placebo	3	3 (100.0)	2.06 (0.79)	1.2	1.17	2.33	2.67	2.7	
		Week 24	Tezepelumab	3	3 (100.0)	0.67 (0.17)	0.5	0.50	0.67	0.83	0.8	
			Placebo	3	3 (100.0)	2.44 (0.38)	2.0	2.00	2.67	2.67	2.7	
		Week 26	Tezepelumab	3	3 (100.0)	0.61 (0.38)	0.2	0.17	0.83	0.83	0.8	
			Placebo	3	3 (100.0)	2.00 (0.33)	1.7	1.67	2.00	2.33	2.3	
		Week 28	Tezepelumab	3	3 (100.0)	0.72 (0.35)	0.3	0.33	0.83	1.00	1.0	
			Placebo	3	3 (100.0)	1.56 (1.06)	0.3	0.33	2.17	2.17	2.2	
		Week 30	Tezepelumab	3	3 (100.0)	0.67 (0.00)	0.7	0.67	0.67	0.67	0.7	
			Placebo	3	3 (100.0)	1.11 (0.98)	0.0	0.00	1.50	1.83	1.8	
		Week 32	Tezepelumab	3	3 (100.0)	0.61 (0.42)	0.2	0.17	0.67	1.00	1.0	
			Placebo	3	3 (100.0)	1.44 (0.75)	0.7	0.67	1.50	2.17	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia/Pacific	Absolute values	Week 34	Tezepelumab	3	3 (100.0)	0.61 (0.10)	0.5	0.50	0.67	0.67	0.7	
			Placebo	3	3 (100.0)	1.61 (0.86)	0.7	0.67	1.83	2.33	2.3	
		Week 36	Tezepelumab	3	3 (100.0)	0.67 (0.29)	0.3	0.33	0.83	0.83	0.8	
			Placebo	3	3 (100.0)	2.67 (0.44)	2.3	2.33	2.50	3.17	3.2	
		Week 38	Tezepelumab	3	3 (100.0)	0.78 (0.95)	0.0	0.00	0.50	1.83	1.8	
			Placebo	3	3 (100.0)	1.39 (0.77)	0.5	0.50	1.83	1.83	1.8	
		Week 40	Tezepelumab	3	3 (100.0)	0.56 (0.19)	0.3	0.33	0.67	0.67	0.7	
			Placebo	3	3 (100.0)	2.06 (0.38)	1.8	1.83	1.83	2.50	2.5	
		Week 42	Tezepelumab	3	3 (100.0)	0.78 (0.25)	0.5	0.50	0.83	1.00	1.0	
			Placebo	3	3 (100.0)	1.72 (0.10)	1.7	1.67	1.67	1.83	1.8	
		Week 44	Tezepelumab	3	3 (100.0)	0.56 (0.25)	0.3	0.33	0.50	0.83	0.8	
			Placebo	3	3 (100.0)	2.94 (0.42)	2.5	2.50	3.00	3.33	3.3	
		Week 46	Tezepelumab	3	3 (100.0)	0.72 (0.35)	0.3	0.33	0.83	1.00	1.0	
			Placebo	3	3 (100.0)	1.39 (0.92)	0.3	0.33	1.83	2.00	2.0	
		Week 48	Tezepelumab	3	3 (100.0)	0.72 (0.25)	0.5	0.50	0.67	1.00	1.0	
			Placebo	3	3 (100.0)	2.22 (0.10)	2.2	2.17	2.17	2.33	2.3	
		Week 50	Tezepelumab	3	3 (100.0)	0.67 (0.17)	0.5	0.50	0.67	0.83	0.8	
			Placebo	3	3 (100.0)	1.78 (0.19)	1.7	1.67	1.67	2.00	2.0	
		Week 52	Tezepelumab	3	3 (100.0)	0.67 (0.17)	0.5	0.50	0.67	0.83	0.8	
			Placebo	3	3 (100.0)	1.78 (0.19)	1.7	1.67	1.67	2.00	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.78 (0.59)	-1.3	-1.33	-0.83	-0.17	-0.2	-1.12 [-2.90, 0.66]
			Placebo	3	3 (100.0)	-0.22 (0.38)	-0.7	-0.67	0.00	0.00	0.0	
		Week 4	Tezepelumab	3	3 (100.0)	-1.28 (0.25)	-1.5	-1.50	-1.33	-1.00	-1.0	-0.96 [-2.69, 0.77]
			Placebo	3	3 (100.0)	-0.61 (0.95)	-1.7	-1.67	-0.33	0.17	0.2	
		Week 6	Tezepelumab	3	3 (100.0)	-1.44 (0.10)	-1.5	-1.50	-1.50	-1.33	-1.3	-1.72 [-3.72, 0.27]
			Placebo	3	3 (100.0)	-0.72 (0.59)	-1.3	-1.33	-0.67	-0.17	-0.2	
		Week 8	Tezepelumab	3	3 (100.0)	-1.56 (0.25)	-1.8	-1.83	-1.50	-1.33	-1.3	-3.08 [-5.75, -0.41]
			Placebo	3	3 (100.0)	-0.33 (0.50)	-0.8	-0.83	-0.33	0.17	0.2	
		Week 10	Tezepelumab	3	3 (100.0)	-1.67 (0.17)	-1.8	-1.83	-1.67	-1.50	-1.5	-5.86 [-10.23, -1.50]
			Placebo	3	3 (100.0)	-0.61 (0.19)	-0.8	-0.83	-0.50	-0.50	-0.5	
		Week 12	Tezepelumab	3	3 (100.0)	-2.00 (0.29)	-2.2	-2.17	-2.17	-1.67	-1.7	-4.28 [-7.64, -0.91]
			Placebo	3	3 (100.0)	-0.67 (0.33)	-1.0	-1.00	-0.67	-0.33	-0.3	
		Week 14	Tezepelumab	3	3 (100.0)	-1.72 (0.19)	-1.8	-1.83	-1.83	-1.50	-1.5	-2.17 [-4.36, 0.03]
			Placebo	3	3 (100.0)	-0.89 (0.51)	-1.3	-1.33	-1.00	-0.33	-0.3	
		Week 16	Tezepelumab	3	3 (100.0)	-1.89 (0.48)	-2.2	-2.17	-2.17	-1.33	-1.3	-1.39 [-3.26, 0.48]
			Placebo	3	3 (100.0)	-1.00 (0.76)	-1.7	-1.67	-1.17	-0.17	-0.2	
		Week 18	Tezepelumab	3	3 (100.0)	-1.89 (0.25)	-2.2	-2.17	-1.83	-1.67	-1.7	-3.86 [-6.97, -0.74]
			Placebo	3	3 (100.0)	-0.50 (0.44)	-1.0	-1.00	-0.33	-0.17	-0.2	
		Week 20	Tezepelumab	3	3 (100.0)	-1.83 (0.29)	-2.0	-2.00	-2.00	-1.50	-1.5	-2.09 [-4.24, 0.07]
			Placebo	3	3 (100.0)	-0.17 (1.09)	-1.3	-1.33	0.00	0.83	0.8	
		Week 22	Tezepelumab	3	3 (100.0)	-2.00 (0.29)	-2.2	-2.17	-2.17	-1.67	-1.7	-3.18 [-5.91, -0.46]
			Placebo	3	3 (100.0)	-0.50 (0.60)	-1.0	-1.00	-0.67	0.17	0.2	
		Week 24	Tezepelumab	3	3 (100.0)	-1.94 (0.42)	-2.3	-2.33	-2.00	-1.50	-1.5	-2.91 [-5.48, -0.33]
			Placebo	3	3 (100.0)	-0.11 (0.79)	-1.0	-1.00	0.17	0.50	0.5	
		Week 26	Tezepelumab	3	3 (100.0)	-2.00 (0.58)	-2.3	-2.33	-2.33	-1.33	-1.3	-2.16 [-4.34, 0.03]
			Placebo	3	3 (100.0)	-0.56 (0.75)	-1.3	-1.33	-0.50	0.17	0.2	
		Week 28	Tezepelumab	3	3 (100.0)	-1.89 (0.48)	-2.2	-2.17	-2.17	-1.33	-1.3	-1.39 [-3.26, 0.48]
			Placebo	3	3 (100.0)	-1.00 (0.76)	-1.8	-1.83	-0.83	-0.33	-0.3	
		Week 30	Tezepelumab	3	3 (100.0)	-1.94 (0.51)	-2.5	-2.50	-1.83	-1.50	-1.5	-0.87 [-2.58, 0.84]
			Placebo	3	3 (100.0)	-1.44 (0.63)	-2.2	-2.17	-1.17	-1.00	-1.0	
		Week 32	Tezepelumab	3	3 (100.0)	-2.00 (0.44)	-2.3	-2.33	-2.17	-1.50	-1.5	-1.56 [-3.49, 0.37]
			Placebo	3	3 (100.0)	-1.11 (0.67)	-1.5	-1.50	-1.50	-0.33	-0.3	
		Week 34	Tezepelumab	3	3 (100.0)	-2.00 (0.50)	-2.5	-2.50	-2.00	-1.50	-1.5	-2.15 [-4.34, 0.04]
			Placebo	3	3 (100.0)	-0.94 (0.48)	-1.5	-1.50	-0.67	-0.67	-0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia/Pacific	Change from baseline	Week 36	Tezepelumab	3	3 (100.0)	-1.94 (0.54)	-2.3	-2.33	-2.17	-1.33	-1.3	-3.05 [-5.70, -0.40]
			Placebo	3	3 (100.0)	0.11 (0.79)	-0.5	-0.50	-0.17	1.00	1.0	
		Week 38	Tezepelumab	3	3 (100.0)	-1.83 (0.60)	-2.5	-2.50	-1.67	-1.33	-1.3	-1.21 [-3.01, 0.60]
			Placebo	3	3 (100.0)	-1.17 (0.50)	-1.7	-1.67	-1.17	-0.67	-0.7	
		Week 40	Tezepelumab	3	3 (100.0)	-2.06 (0.51)	-2.5	-2.50	-2.17	-1.50	-1.5	-2.40 [-4.70, -0.09]
			Placebo	3	3 (100.0)	-0.50 (0.76)	-1.2	-1.17	-0.67	0.33	0.3	
		Week 42	Tezepelumab	3	3 (100.0)	-1.83 (0.44)	-2.2	-2.17	-2.00	-1.33	-1.3	-2.56 [-4.95, -0.17]
			Placebo	3	3 (100.0)	-0.83 (0.33)	-1.2	-1.17	-0.83	-0.50	-0.5	
		Week 44	Tezepelumab	3	3 (100.0)	-2.06 (0.67)	-2.7	-2.67	-2.17	-1.33	-1.3	-3.21 [-5.96, -0.47]
			Placebo	3	3 (100.0)	0.39 (0.84)	-0.5	-0.50	0.50	1.17	1.2	
		Week 46	Tezepelumab	3	3 (100.0)	-1.89 (0.48)	-2.2	-2.17	-2.17	-1.33	-1.3	-1.33 [-3.17, 0.52]
			Placebo	3	3 (100.0)	-1.17 (0.60)	-1.8	-1.83	-1.00	-0.67	-0.7	
		Week 48	Tezepelumab	3	3 (100.0)	-1.89 (0.35)	-2.2	-2.17	-2.00	-1.50	-1.5	-3.61 [-6.59, -0.64]
			Placebo	3	3 (100.0)	-0.33 (0.50)	-0.8	-0.83	-0.33	0.17	0.2	
		Week 50	Tezepelumab	3	3 (100.0)	-1.94 (0.59)	-2.5	-2.50	-2.00	-1.33	-1.3	-1.99 [-4.11, 0.12]
			Placebo	3	3 (100.0)	-0.78 (0.59)	-1.3	-1.33	-0.83	-0.17	-0.2	
		Week 52	Tezepelumab	3	3 (100.0)	-1.94 (0.59)	-2.5	-2.50	-2.00	-1.33	-1.3	-1.99 [-4.11, 0.12]
			Placebo	3	3 (100.0)	-0.78 (0.59)	-1.3	-1.33	-0.83	-0.17	-0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	17	17 (100.0)	2.70 (0.55)	1.7	2.33	2.83	3.17	3.5	
			Placebo	22	22 (100.0)	3.01 (0.77)	1.5	2.50	2.92	3.17	4.7	
		Week 2	Tezepelumab	17	17 (100.0)	2.22 (0.70)	1.3	1.67	2.17	2.67	3.7	
			Placebo	22	20 (90.9)	2.48 (0.97)	0.3	2.08	2.33	2.83	4.8	
		Week 4	Tezepelumab	17	17 (100.0)	1.90 (0.88)	0.2	1.67	1.83	2.33	3.3	
			Placebo	22	20 (90.9)	2.35 (0.92)	0.2	1.83	2.33	3.17	3.7	
		Week 6	Tezepelumab	17	17 (100.0)	1.88 (0.93)	0.3	1.17	2.17	2.33	3.7	
			Placebo	22	20 (90.9)	2.43 (1.19)	0.2	1.92	2.42	3.00	5.5	
		Week 8	Tezepelumab	17	17 (100.0)	1.64 (0.90)	0.0	0.83	1.83	2.33	3.0	
			Placebo	22	21 (95.5)	2.29 (1.21)	0.0	1.83	2.33	2.83	4.7	
		Week 10	Tezepelumab	17	17 (100.0)	1.60 (0.92)	0.0	1.33	1.83	2.00	3.3	
			Placebo	22	21 (95.5)	2.17 (0.94)	0.2	1.83	2.17	2.50	4.0	
		Week 12	Tezepelumab	17	17 (100.0)	1.49 (0.95)	0.0	0.50	1.50	2.17	2.8	
			Placebo	22	21 (95.5)	2.08 (0.93)	0.0	1.83	2.17	2.67	4.3	
		Week 14	Tezepelumab	17	17 (100.0)	1.33 (0.76)	0.0	1.00	1.33	1.83	2.5	
			Placebo	22	21 (95.5)	1.99 (1.01)	0.0	1.50	2.00	2.33	5.0	
		Week 16	Tezepelumab	17	17 (100.0)	1.60 (1.15)	0.0	0.67	1.33	2.50	4.3	
			Placebo	22	21 (95.5)	2.13 (1.22)	0.0	1.50	2.00	2.67	4.8	
		Week 18	Tezepelumab	17	17 (100.0)	1.53 (0.97)	0.0	0.83	1.50	2.33	3.2	
			Placebo	22	21 (95.5)	2.10 (1.11)	0.0	1.67	2.33	2.67	4.5	
		Week 20	Tezepelumab	17	17 (100.0)	1.62 (0.93)	0.0	1.00	1.50	2.50	3.0	
			Placebo	22	21 (95.5)	2.29 (1.04)	0.2	1.83	2.50	2.83	4.5	
		Week 22	Tezepelumab	17	17 (100.0)	1.69 (0.81)	0.0	1.17	1.83	2.33	2.8	
			Placebo	22	21 (95.5)	2.33 (1.13)	0.0	1.83	2.33	3.00	4.5	
		Week 24	Tezepelumab	17	17 (100.0)	1.76 (0.91)	0.2	1.00	1.67	2.50	3.3	
			Placebo	22	21 (95.5)	2.22 (1.14)	0.2	1.67	2.17	3.00	4.5	
		Week 26	Tezepelumab	17	17 (100.0)	1.75 (1.04)	0.0	1.33	1.67	2.17	3.5	
			Placebo	22	21 (95.5)	2.16 (1.22)	0.0	1.17	2.17	3.00	4.5	
		Week 28	Tezepelumab	17	17 (100.0)	1.71 (1.03)	0.0	1.33	1.67	2.33	3.5	
			Placebo	22	21 (95.5)	2.21 (1.16)	0.0	1.33	2.17	3.00	4.5	
		Week 30	Tezepelumab	17	17 (100.0)	1.65 (0.93)	0.0	1.00	1.50	2.17	3.3	
			Placebo	22	21 (95.5)	2.35 (0.97)	0.7	1.83	2.33	3.00	4.5	
		Week 32	Tezepelumab	17	17 (100.0)	1.56 (0.94)	0.0	1.00	1.83	2.33	3.2	
			Placebo	22	21 (95.5)	2.21 (1.16)	0.5	1.17	2.00	2.67	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of the world	Absolute values	Week 34	Tezepelumab	17	17 (100.0)	1.75 (0.99)	0.2	1.00	2.00	2.50	3.5	
			Placebo	22	21 (95.5)	2.11 (1.27)	0.0	1.17	1.83	2.83	4.5	
		Week 36	Tezepelumab	17	17 (100.0)	1.56 (1.00)	0.0	1.17	1.50	2.33	3.5	
			Placebo	22	21 (95.5)	2.25 (1.19)	0.0	1.83	2.00	3.00	4.5	
		Week 38	Tezepelumab	17	17 (100.0)	1.76 (1.07)	0.0	1.00	1.67	2.67	3.5	
			Placebo	22	21 (95.5)	2.15 (1.21)	0.0	1.67	1.83	2.67	4.5	
		Week 40	Tezepelumab	17	17 (100.0)	1.77 (1.07)	0.0	1.00	2.00	2.50	3.7	
			Placebo	22	21 (95.5)	2.17 (1.11)	0.3	1.50	2.00	2.83	4.5	
		Week 42	Tezepelumab	17	17 (100.0)	1.58 (0.98)	0.0	1.00	1.67	2.17	3.5	
			Placebo	22	21 (95.5)	2.21 (1.09)	0.3	1.50	2.17	2.67	4.5	
		Week 44	Tezepelumab	17	17 (100.0)	1.64 (1.03)	0.0	0.83	1.67	2.50	3.3	
			Placebo	22	21 (95.5)	2.13 (1.08)	0.5	1.17	2.00	3.00	4.5	
		Week 46	Tezepelumab	17	17 (100.0)	1.67 (1.05)	0.0	0.83	1.83	2.33	3.3	
			Placebo	22	21 (95.5)	2.23 (1.08)	0.0	1.83	2.00	2.83	4.5	
		Week 48	Tezepelumab	17	17 (100.0)	1.60 (1.02)	0.0	1.00	2.00	2.33	3.3	
			Placebo	22	21 (95.5)	2.18 (1.18)	0.0	1.50	2.17	2.83	4.5	
		Week 50	Tezepelumab	17	17 (100.0)	1.59 (1.01)	0.0	1.00	1.67	2.33	3.7	
			Placebo	22	21 (95.5)	1.97 (1.11)	0.2	1.33	1.83	2.50	4.5	
		Week 52	Tezepelumab	17	17 (100.0)	1.55 (1.07)	0.0	1.00	1.50	2.33	3.7	
			Placebo	22	21 (95.5)	2.02 (1.13)	0.2	1.33	2.17	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 2	Tezepelumab	17	17 (100.0)	-0.48 (0.48)	-1.3	-0.67	-0.50	-0.17	0.3	-0.06 [-0.70, 0.59]
			Placebo	22	20 (90.9)	-0.44 (0.79)	-2.8	-0.75	-0.33	-0.08	1.0	
		Week 4	Tezepelumab	17	17 (100.0)	-0.79 (0.67)	-2.3	-1.33	-0.67	-0.50	0.2	-0.28 [-0.93, 0.37]
			Placebo	22	20 (90.9)	-0.58 (0.85)	-2.3	-1.17	-0.50	0.08	0.8	
		Week 6	Tezepelumab	17	17 (100.0)	-0.81 (0.91)	-2.3	-1.17	-0.67	-0.17	1.2	-0.33 [-0.98, 0.32]
			Placebo	22	20 (90.9)	-0.50 (0.98)	-2.3	-0.92	-0.42	0.00	1.5	
		Week 8	Tezepelumab	17	17 (100.0)	-1.06 (0.84)	-2.8	-1.33	-1.00	-0.50	0.2	-0.41 [-1.06, 0.24]
			Placebo	22	21 (95.5)	-0.64 (1.13)	-3.0	-1.17	-0.67	0.33	1.0	
		Week 10	Tezepelumab	17	17 (100.0)	-1.10 (0.79)	-2.8	-1.33	-0.83	-0.67	0.0	-0.35 [-0.99, 0.30]
			Placebo	22	21 (95.5)	-0.76 (1.09)	-2.3	-1.50	-0.67	-0.33	2.5	
		Week 12	Tezepelumab	17	17 (100.0)	-1.21 (0.78)	-2.8	-1.33	-1.17	-0.67	0.2	-0.38 [-1.03, 0.26]
			Placebo	22	21 (95.5)	-0.86 (1.00)	-3.2	-1.17	-0.67	-0.33	1.3	
		Week 14	Tezepelumab	17	17 (100.0)	-1.36 (0.75)	-2.8	-1.83	-1.17	-1.00	0.0	-0.46 [-1.11, 0.19]
			Placebo	22	21 (95.5)	-0.94 (1.02)	-3.2	-1.67	-0.83	-0.33	1.2	
		Week 16	Tezepelumab	17	17 (100.0)	-1.10 (1.03)	-2.8	-1.67	-1.00	-1.00	1.5	-0.25 [-0.90, 0.39]
			Placebo	22	21 (95.5)	-0.81 (1.21)	-3.2	-1.67	-0.83	0.00	2.3	
		Week 18	Tezepelumab	17	17 (100.0)	-1.17 (0.80)	-2.8	-1.50	-1.00	-0.83	0.2	-0.31 [-0.95, 0.33]
			Placebo	22	21 (95.5)	-0.83 (1.25)	-3.2	-1.67	-0.83	0.00	2.3	
		Week 20	Tezepelumab	17	17 (100.0)	-1.08 (0.74)	-2.7	-1.50	-1.00	-0.67	0.3	-0.42 [-1.06, 0.23]
			Placebo	22	21 (95.5)	-0.65 (1.21)	-3.0	-1.33	-0.83	0.00	2.3	
		Week 22	Tezepelumab	17	17 (100.0)	-1.01 (0.74)	-2.7	-1.17	-0.83	-0.67	0.2	-0.39 [-1.04, 0.25]
			Placebo	22	21 (95.5)	-0.60 (1.22)	-3.2	-1.17	-0.83	0.17	2.3	
		Week 24	Tezepelumab	17	17 (100.0)	-0.93 (0.74)	-2.5	-1.33	-0.67	-0.50	0.2	-0.20 [-0.85, 0.44]
			Placebo	22	21 (95.5)	-0.71 (1.26)	-3.0	-1.50	-1.00	0.33	2.3	
		Week 26	Tezepelumab	17	17 (100.0)	-0.95 (0.89)	-2.8	-1.33	-0.83	-0.33	0.2	-0.15 [-0.79, 0.49]
			Placebo	22	21 (95.5)	-0.78 (1.35)	-3.2	-1.67	-1.17	0.33	2.3	
		Week 28	Tezepelumab	17	17 (100.0)	-0.99 (0.91)	-2.8	-1.50	-0.83	-0.67	0.5	-0.23 [-0.87, 0.41]
			Placebo	22	21 (95.5)	-0.73 (1.29)	-3.2	-1.67	-1.00	0.17	2.3	
		Week 30	Tezepelumab	17	17 (100.0)	-1.05 (0.81)	-2.7	-1.50	-1.00	-0.67	0.3	-0.47 [-1.12, 0.18]
			Placebo	22	21 (95.5)	-0.59 (1.09)	-2.3	-1.33	-0.83	0.17	2.3	
		Week 32	Tezepelumab	17	17 (100.0)	-1.14 (0.77)	-2.7	-1.67	-1.00	-0.67	0.3	-0.38 [-1.03, 0.27]
			Placebo	22	21 (95.5)	-0.73 (1.26)	-2.3	-1.67	-1.17	0.17	2.3	
		Week 34	Tezepelumab	17	17 (100.0)	-0.95 (0.86)	-2.5	-1.50	-0.83	-0.50	0.5	-0.11 [-0.75, 0.53]
			Placebo	22	21 (95.5)	-0.83 (1.37)	-3.2	-1.83	-1.00	0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of the world	Change from baseline	Week 36	Tezepelumab	17	17 (100.0)	-1.14 (0.86)	-2.8	-1.50	-1.17	-0.50	0.5	-0.40 [-1.04, 0.25]
			Placebo	22	21 (95.5)	-0.68 (1.32)	-3.2	-1.33	-1.00	0.33	2.3	
		Week 38	Tezepelumab	17	17 (100.0)	-0.93 (0.99)	-2.8	-1.50	-0.83	-0.17	0.5	-0.13 [-0.77, 0.51]
			Placebo	22	21 (95.5)	-0.79 (1.28)	-3.2	-1.67	-1.17	0.17	2.3	
		Week 40	Tezepelumab	17	17 (100.0)	-0.92 (0.93)	-2.8	-1.50	-0.83	-0.67	0.5	-0.14 [-0.79, 0.50]
			Placebo	22	21 (95.5)	-0.76 (1.23)	-2.8	-1.50	-1.00	0.17	2.3	
		Week 42	Tezepelumab	17	17 (100.0)	-1.12 (0.90)	-2.8	-1.67	-0.83	-0.67	0.3	-0.37 [-1.01, 0.28]
			Placebo	22	21 (95.5)	-0.73 (1.16)	-2.8	-1.33	-1.00	0.17	2.3	
		Week 44	Tezepelumab	17	17 (100.0)	-1.06 (0.85)	-2.8	-1.50	-1.00	-0.50	0.3	-0.24 [-0.88, 0.40]
			Placebo	22	21 (95.5)	-0.81 (1.17)	-2.7	-1.50	-1.00	0.17	2.3	
		Week 46	Tezepelumab	17	17 (100.0)	-1.03 (0.84)	-2.8	-1.50	-1.00	-0.50	0.3	-0.30 [-0.95, 0.34]
			Placebo	22	21 (95.5)	-0.71 (1.21)	-3.2	-1.33	-1.00	0.17	2.3	
		Week 48	Tezepelumab	17	17 (100.0)	-1.10 (0.84)	-2.7	-1.67	-0.67	-0.50	0.0	-0.31 [-0.95, 0.33]
			Placebo	22	21 (95.5)	-0.75 (1.29)	-3.2	-1.33	-1.00	0.17	2.3	
		Week 50	Tezepelumab	17	17 (100.0)	-1.11 (0.96)	-2.7	-1.67	-1.00	-0.50	0.5	-0.13 [-0.77, 0.51]
			Placebo	22	21 (95.5)	-0.97 (1.17)	-3.0	-1.67	-1.00	-0.33	2.3	
		Week 52	Tezepelumab	17	17 (100.0)	-1.15 (1.02)	-2.7	-2.00	-1.00	-0.50	0.5	-0.20 [-0.84, 0.44]
			Placebo	22	21 (95.5)	-0.92 (1.22)	-3.0	-1.67	-1.00	-0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	2.52 (0.97)	0.0	2.00	2.50	3.17	4.3	
			Placebo	21	21 (100.0)	2.46 (0.81)	0.3	2.17	2.50	2.83	4.3	
		Week 2	Tezepelumab	15	15 (100.0)	1.82 (0.97)	0.2	1.17	1.83	2.50	3.7	
			Placebo	21	19 (90.5)	2.25 (0.89)	0.3	1.67	2.17	2.50	4.8	
		Week 4	Tezepelumab	15	15 (100.0)	1.46 (0.91)	0.2	0.67	1.50	2.33	2.8	
			Placebo	21	19 (90.5)	2.21 (0.89)	0.8	1.50	2.50	2.67	3.7	
		Week 6	Tezepelumab	15	15 (100.0)	1.42 (0.98)	0.0	0.50	1.67	2.33	3.2	
			Placebo	21	19 (90.5)	1.99 (1.05)	0.2	1.17	2.00	2.67	4.7	
		Week 8	Tezepelumab	15	15 (100.0)	1.13 (0.89)	0.0	0.17	1.17	1.67	2.8	
			Placebo	21	19 (90.5)	2.07 (1.15)	0.0	1.00	2.17	2.67	4.7	
		Week 10	Tezepelumab	15	15 (100.0)	1.03 (0.91)	0.0	0.50	0.67	1.83	3.3	
			Placebo	21	19 (90.5)	1.89 (0.96)	0.0	1.00	2.00	2.33	4.0	
		Week 12	Tezepelumab	15	15 (100.0)	0.88 (0.84)	0.0	0.00	0.50	1.50	2.7	
			Placebo	21	19 (90.5)	1.86 (1.04)	0.0	1.00	2.00	2.50	4.3	
		Week 14	Tezepelumab	15	15 (100.0)	0.79 (0.57)	0.0	0.17	0.67	1.33	1.7	
			Placebo	21	19 (90.5)	1.89 (1.11)	0.0	1.33	2.00	2.17	5.0	
		Week 16	Tezepelumab	15	15 (100.0)	1.03 (0.85)	0.0	0.33	1.00	1.67	3.0	
			Placebo	21	19 (90.5)	1.72 (1.17)	0.0	0.50	2.00	2.33	4.5	
		Week 18	Tezepelumab	15	15 (100.0)	0.93 (0.81)	0.0	0.17	0.83	1.33	3.0	
			Placebo	21	19 (90.5)	1.77 (1.16)	0.0	1.00	1.67	2.50	4.5	
		Week 20	Tezepelumab	15	15 (100.0)	0.98 (0.76)	0.0	0.50	1.00	1.33	2.7	
			Placebo	21	19 (90.5)	1.86 (1.23)	0.0	0.83	1.67	2.83	4.5	
		Week 22	Tezepelumab	15	15 (100.0)	1.10 (0.82)	0.0	0.33	1.00	1.83	2.5	
			Placebo	21	19 (90.5)	1.75 (1.32)	0.0	0.50	1.50	2.67	4.5	
		Week 24	Tezepelumab	15	15 (100.0)	1.13 (0.90)	0.0	0.50	1.00	2.17	2.7	
			Placebo	21	19 (90.5)	1.95 (1.26)	0.0	1.00	2.00	3.00	4.5	
		Week 26	Tezepelumab	15	15 (100.0)	1.13 (0.99)	0.0	0.00	1.00	1.83	3.5	
			Placebo	21	19 (90.5)	1.89 (1.23)	0.0	1.00	1.67	3.00	4.5	
		Week 28	Tezepelumab	15	15 (100.0)	1.06 (0.96)	0.0	0.00	1.00	1.50	3.5	
			Placebo	21	20 (95.2)	1.86 (1.35)	0.0	1.00	1.67	2.83	4.5	
		Week 30	Tezepelumab	15	15 (100.0)	0.98 (0.82)	0.0	0.33	0.83	1.50	3.2	
			Placebo	21	20 (95.2)	2.00 (1.31)	0.0	1.00	2.00	3.00	4.5	
		Week 32	Tezepelumab	15	15 (100.0)	1.02 (0.80)	0.0	0.33	1.00	1.67	2.5	
			Placebo	21	20 (95.2)	1.73 (1.28)	0.0	0.92	1.25	2.42	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
18.5 - < 25.0 kg/m**2	Absolute values	Week 34	Tezepelumab	15	15 (100.0)	0.97 (0.74)	0.0	0.50	1.00	1.33	2.5	
			Placebo	21	20 (95.2)	1.62 (1.31)	0.0	0.75	1.33	2.17	4.5	
		Week 36	Tezepelumab	15	15 (100.0)	0.90 (0.73)	0.0	0.00	0.83	1.50	2.3	
			Placebo	21	20 (95.2)	1.97 (1.37)	0.0	0.92	2.00	2.83	4.5	
		Week 38	Tezepelumab	15	15 (100.0)	1.06 (0.83)	0.0	0.00	1.00	1.83	2.3	
			Placebo	21	20 (95.2)	1.76 (1.43)	0.0	0.50	1.50	2.75	4.5	
		Week 40	Tezepelumab	15	15 (100.0)	0.96 (0.86)	0.0	0.00	0.67	1.83	2.7	
			Placebo	21	20 (95.2)	1.86 (1.23)	0.0	0.83	2.00	2.50	4.5	
		Week 42	Tezepelumab	15	15 (100.0)	0.92 (0.73)	0.0	0.00	1.00	1.50	2.3	
			Placebo	21	20 (95.2)	1.64 (1.21)	0.0	0.67	1.58	2.50	4.5	
		Week 44	Tezepelumab	15	15 (100.0)	0.80 (0.71)	0.0	0.00	0.83	1.17	2.3	
			Placebo	21	20 (95.2)	1.97 (1.20)	0.0	1.08	2.08	3.00	4.5	
		Week 46	Tezepelumab	15	15 (100.0)	0.82 (0.70)	0.0	0.00	0.83	1.17	2.3	
			Placebo	21	20 (95.2)	1.74 (1.25)	0.0	0.75	1.75	2.25	4.5	
		Week 48	Tezepelumab	15	15 (100.0)	0.91 (0.76)	0.0	0.17	1.00	1.17	2.3	
			Placebo	21	20 (95.2)	1.85 (1.23)	0.0	1.00	2.00	2.25	4.5	
		Week 50	Tezepelumab	15	15 (100.0)	1.01 (0.80)	0.0	0.50	0.83	1.67	2.5	
			Placebo	21	20 (95.2)	1.59 (1.10)	0.0	1.00	1.58	2.17	4.5	
		Week 52	Tezepelumab	15	15 (100.0)	1.07 (0.80)	0.0	0.50	1.00	1.67	2.5	
			Placebo	21	20 (95.2)	1.64 (1.10)	0.0	1.00	1.58	2.17	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	15	15 (100.0)	-0.70 (0.69)	-2.0	-1.33	-0.67	-0.17	0.3	-0.43 [-1.12, 0.25]
			Placebo	21	19 (90.5)	-0.35 (0.88)	-2.8	-0.83	0.00	0.17	1.0	
		Week 4	Tezepelumab	15	15 (100.0)	-1.07 (0.87)	-2.5	-1.50	-1.00	-0.50	0.2	-0.81 [-1.51, -0.10]
			Placebo	21	19 (90.5)	-0.39 (0.80)	-2.0	-1.00	-0.17	0.17	0.8	
		Week 6	Tezepelumab	15	15 (100.0)	-1.10 (0.97)	-2.7	-1.83	-1.33	-0.17	0.3	-0.53 [-1.22, 0.16]
			Placebo	21	19 (90.5)	-0.61 (0.87)	-2.2	-1.33	-0.33	0.17	0.3	
		Week 8	Tezepelumab	15	15 (100.0)	-1.39 (0.95)	-2.8	-2.50	-1.33	-0.50	0.0	-0.93 [-1.64, -0.21]
			Placebo	21	19 (90.5)	-0.54 (0.90)	-2.3	-1.00	-0.50	0.17	1.0	
		Week 10	Tezepelumab	15	15 (100.0)	-1.49 (1.08)	-2.8	-2.50	-1.67	-0.83	0.8	-0.79 [-1.50, -0.09]
			Placebo	21	19 (90.5)	-0.71 (0.89)	-2.3	-1.50	-0.50	0.00	0.7	
		Week 12	Tezepelumab	15	15 (100.0)	-1.64 (0.94)	-3.0	-2.50	-1.83	-0.83	0.2	-1.03 [-1.75, -0.30]
			Placebo	21	19 (90.5)	-0.75 (0.82)	-2.7	-1.00	-0.67	0.00	0.2	
		Week 14	Tezepelumab	15	15 (100.0)	-1.73 (0.99)	-3.7	-2.33	-1.83	-1.00	0.2	-1.06 [-1.79, -0.34]
			Placebo	21	19 (90.5)	-0.72 (0.93)	-2.5	-1.33	-0.83	0.00	1.0	
		Week 16	Tezepelumab	15	15 (100.0)	-1.49 (0.96)	-2.8	-2.17	-1.67	-0.67	0.3	-0.64 [-1.33, 0.06]
			Placebo	21	19 (90.5)	-0.89 (0.93)	-2.5	-1.67	-0.83	-0.17	0.5	
		Week 18	Tezepelumab	15	15 (100.0)	-1.59 (1.03)	-3.5	-2.50	-1.67	-0.67	0.2	-0.72 [-1.42, -0.02]
			Placebo	21	19 (90.5)	-0.83 (1.07)	-3.2	-1.83	-0.33	0.00	0.3	
		Week 20	Tezepelumab	15	15 (100.0)	-1.54 (0.82)	-2.7	-2.33	-1.50	-0.83	0.0	-0.81 [-1.52, -0.11]
			Placebo	21	19 (90.5)	-0.75 (1.09)	-3.0	-1.67	-0.67	0.00	0.8	
		Week 22	Tezepelumab	15	15 (100.0)	-1.42 (1.24)	-2.7	-2.50	-2.00	-0.83	1.8	-0.48 [-1.17, 0.21]
			Placebo	21	19 (90.5)	-0.85 (1.16)	-3.2	-1.83	-0.83	0.17	1.2	
		Week 24	Tezepelumab	15	15 (100.0)	-1.39 (0.88)	-2.7	-2.00	-1.50	-0.67	0.2	-0.71 [-1.41, -0.01]
			Placebo	21	19 (90.5)	-0.66 (1.13)	-3.0	-1.33	-0.50	0.17	1.0	
		Week 26	Tezepelumab	15	15 (100.0)	-1.39 (1.03)	-2.8	-2.33	-1.50	-0.33	0.2	-0.60 [-1.30, 0.09]
			Placebo	21	19 (90.5)	-0.72 (1.16)	-2.5	-1.83	-0.67	0.17	1.5	
		Week 28	Tezepelumab	15	15 (100.0)	-1.47 (1.00)	-2.8	-2.17	-1.50	-0.50	0.2	-0.79 [-1.49, -0.10]
			Placebo	21	20 (95.2)	-0.63 (1.09)	-2.5	-1.50	-0.58	0.25	1.5	
		Week 30	Tezepelumab	15	15 (100.0)	-1.54 (1.07)	-3.5	-2.50	-1.50	-0.50	0.0	-0.95 [-1.66, -0.24]
			Placebo	21	20 (95.2)	-0.49 (1.14)	-2.5	-1.08	-0.50	0.25	2.0	
		Week 32	Tezepelumab	15	15 (100.0)	-1.50 (0.81)	-2.5	-2.17	-1.50	-1.00	0.0	-0.76 [-1.46, -0.07]
			Placebo	21	20 (95.2)	-0.77 (1.06)	-2.5	-1.50	-0.58	0.00	1.5	
		Week 34	Tezepelumab	15	15 (100.0)	-1.56 (0.91)	-2.5	-2.33	-1.83	-0.83	0.3	-0.65 [-1.34, 0.04]
			Placebo	21	20 (95.2)	-0.87 (1.14)	-3.2	-1.67	-0.75	-0.17	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
18.5 - < 25.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	15	15 (100.0)	-1.62 (0.97)	-2.8	-2.50	-1.67	-1.17	0.3	-0.98 [-1.69, -0.27]
			Placebo	21	20 (95.2)	-0.53 (1.21)	-3.2	-1.08	-0.25	0.25	1.5	
		Week 38	Tezepelumab	15	15 (100.0)	-1.47 (0.92)	-2.8	-2.17	-1.67	-0.67	0.3	-0.65 [-1.34, 0.03]
			Placebo	21	20 (95.2)	-0.73 (1.25)	-3.2	-1.75	-0.75	0.25	1.5	
		Week 40	Tezepelumab	15	15 (100.0)	-1.57 (0.99)	-2.8	-2.50	-1.83	-0.67	0.3	-0.88 [-1.59, -0.18]
			Placebo	21	20 (95.2)	-0.63 (1.10)	-2.8	-1.00	-0.67	0.17	1.2	
		Week 42	Tezepelumab	15	15 (100.0)	-1.60 (1.00)	-3.3	-2.17	-1.67	-0.50	0.0	-0.70 [-1.39, -0.01]
			Placebo	21	20 (95.2)	-0.85 (1.13)	-2.8	-1.75	-0.83	-0.08	1.3	
		Week 44	Tezepelumab	15	15 (100.0)	-1.72 (0.96)	-3.5	-2.50	-1.67	-0.83	0.0	-1.16 [-1.89, -0.44]
			Placebo	21	20 (95.2)	-0.52 (1.08)	-2.5	-1.17	-0.67	0.33	1.5	
		Week 46	Tezepelumab	15	15 (100.0)	-1.70 (0.89)	-3.3	-2.50	-1.50	-1.00	0.0	-0.90 [-1.60, -0.19]
			Placebo	21	20 (95.2)	-0.75 (1.17)	-3.2	-1.33	-0.75	-0.08	1.3	
		Week 48	Tezepelumab	15	15 (100.0)	-1.61 (0.87)	-2.7	-2.50	-1.50	-0.83	0.0	-0.94 [-1.65, -0.24]
			Placebo	21	20 (95.2)	-0.64 (1.13)	-3.2	-1.00	-0.50	0.17	1.7	
		Week 50	Tezepelumab	15	15 (100.0)	-1.51 (0.84)	-2.5	-2.33	-1.50	-1.00	0.0	-0.69 [-1.38, -0.00]
			Placebo	21	20 (95.2)	-0.90 (0.92)	-2.8	-1.42	-0.75	-0.25	0.5	
		Week 52	Tezepelumab	15	15 (100.0)	-1.46 (0.83)	-2.7	-2.00	-1.50	-1.00	0.0	-0.70 [-1.39, -0.01]
			Placebo	21	20 (95.2)	-0.85 (0.89)	-2.8	-1.42	-0.75	-0.17	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	24	24 (100.0)	2.64 (0.79)	0.3	2.17	2.67	3.08	4.0	
			Placebo	20	20 (100.0)	2.89 (0.65)	1.5	2.50	3.00	3.33	4.5	
		Week 2	Tezepelumab	24	23 (95.8)	2.12 (0.93)	0.3	1.33	2.17	2.83	3.7	
			Placebo	20	18 (90.0)	2.40 (0.54)	1.2	2.17	2.33	2.83	3.3	
		Week 4	Tezepelumab	24	23 (95.8)	1.94 (0.90)	0.3	1.17	2.17	2.67	3.2	
			Placebo	20	18 (90.0)	2.34 (0.86)	0.7	2.17	2.33	2.67	4.2	
		Week 6	Tezepelumab	24	23 (95.8)	1.75 (0.84)	0.0	1.17	1.67	2.50	3.2	
			Placebo	20	18 (90.0)	2.35 (0.81)	0.5	2.00	2.33	3.00	3.8	
		Week 8	Tezepelumab	24	23 (95.8)	1.64 (1.05)	0.0	0.67	1.67	2.67	3.3	
			Placebo	20	18 (90.0)	2.08 (1.01)	0.2	1.17	2.25	2.83	3.7	
		Week 10	Tezepelumab	24	23 (95.8)	1.61 (1.12)	0.0	0.83	1.50	2.33	4.3	
			Placebo	20	18 (90.0)	2.44 (1.26)	0.0	1.83	2.42	2.83	5.3	
		Week 12	Tezepelumab	24	23 (95.8)	1.46 (1.15)	0.0	0.50	1.50	2.50	4.3	
			Placebo	20	18 (90.0)	2.17 (1.04)	0.0	1.33	2.25	2.83	4.2	
		Week 14	Tezepelumab	24	23 (95.8)	1.50 (1.24)	0.0	0.33	1.33	2.33	4.3	
			Placebo	20	18 (90.0)	1.99 (1.02)	0.3	1.33	2.00	2.33	5.0	
		Week 16	Tezepelumab	24	23 (95.8)	1.52 (1.24)	0.0	0.33	1.50	2.50	4.3	
			Placebo	20	18 (90.0)	2.26 (1.21)	0.2	1.67	2.17	2.83	5.0	
		Week 18	Tezepelumab	24	23 (95.8)	1.57 (1.12)	0.0	0.67	1.50	2.17	4.3	
			Placebo	20	18 (90.0)	2.18 (1.13)	0.2	1.50	2.25	2.67	5.0	
		Week 20	Tezepelumab	24	23 (95.8)	1.49 (1.17)	0.0	0.50	1.50	2.17	4.3	
			Placebo	20	18 (90.0)	2.23 (1.22)	0.2	1.67	2.33	2.83	5.0	
		Week 22	Tezepelumab	24	23 (95.8)	1.61 (1.11)	0.0	0.67	1.50	2.33	4.3	
			Placebo	20	18 (90.0)	2.24 (1.25)	0.0	1.50	2.33	2.83	5.0	
		Week 24	Tezepelumab	24	23 (95.8)	1.50 (1.18)	0.0	0.50	1.50	2.33	4.3	
			Placebo	20	18 (90.0)	2.21 (1.08)	0.2	1.67	2.42	2.83	4.2	
		Week 26	Tezepelumab	24	23 (95.8)	1.58 (1.13)	0.0	0.50	1.50	2.50	4.3	
			Placebo	20	18 (90.0)	2.24 (1.15)	0.3	1.33	2.42	3.00	4.2	
		Week 28	Tezepelumab	24	24 (100.0)	1.45 (1.18)	0.0	0.33	1.50	2.08	4.3	
			Placebo	20	18 (90.0)	2.26 (1.13)	0.3	1.33	2.42	2.67	4.2	
		Week 30	Tezepelumab	24	24 (100.0)	1.47 (1.14)	0.0	0.58	1.58	2.17	4.3	
			Placebo	20	18 (90.0)	2.18 (1.15)	0.3	1.17	2.33	2.83	4.2	
		Week 32	Tezepelumab	24	24 (100.0)	1.29 (1.18)	0.0	0.17	1.33	2.00	4.3	
			Placebo	20	18 (90.0)	2.16 (1.08)	0.3	1.50	2.17	2.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
25.0 - < 30.0 kg/m**2	Absolute values	Week 34	Tezepelumab	24	24 (100.0)	1.44 (1.22)	0.0	0.33	1.42	2.50	4.3	
			Placebo	20	18 (90.0)	2.23 (1.11)	0.0	1.67	2.42	2.67	4.2	
		Week 36	Tezepelumab	24	24 (100.0)	1.51 (1.13)	0.0	0.50	1.58	2.42	4.3	
			Placebo	20	18 (90.0)	2.40 (1.10)	0.0	1.83	2.50	2.83	4.2	
		Week 38	Tezepelumab	24	24 (100.0)	1.36 (1.20)	0.0	0.25	1.33	2.33	4.3	
			Placebo	20	18 (90.0)	2.08 (1.02)	0.0	1.33	2.08	2.50	4.2	
		Week 40	Tezepelumab	24	24 (100.0)	1.37 (1.21)	0.0	0.33	1.17	2.42	4.3	
			Placebo	20	18 (90.0)	2.25 (1.08)	0.0	1.50	2.33	2.67	4.2	
		Week 42	Tezepelumab	24	24 (100.0)	1.30 (1.15)	0.0	0.33	1.00	2.00	4.3	
			Placebo	20	18 (90.0)	2.18 (1.00)	0.0	1.50	2.25	2.50	4.5	
		Week 44	Tezepelumab	24	24 (100.0)	1.44 (1.18)	0.0	0.33	1.42	2.50	4.3	
			Placebo	20	18 (90.0)	2.17 (0.97)	0.7	1.17	2.25	2.67	4.2	
		Week 46	Tezepelumab	24	24 (100.0)	1.44 (1.20)	0.0	0.33	1.33	2.50	4.3	
			Placebo	20	18 (90.0)	2.09 (0.79)	0.5	1.50	2.17	2.50	3.8	
		Week 48	Tezepelumab	24	24 (100.0)	1.44 (1.20)	0.0	0.33	1.33	2.42	4.3	
			Placebo	20	18 (90.0)	2.09 (0.96)	0.3	1.17	2.17	2.67	3.8	
		Week 50	Tezepelumab	24	24 (100.0)	1.29 (1.14)	0.0	0.42	1.08	2.25	4.3	
			Placebo	20	18 (90.0)	2.31 (0.79)	1.0	1.67	2.33	2.83	3.8	
		Week 52	Tezepelumab	24	24 (100.0)	1.32 (1.11)	0.0	0.42	1.17	2.25	4.3	
			Placebo	20	18 (90.0)	2.31 (0.96)	0.0	1.67	2.33	2.83	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	24	23 (95.8)	-0.54 (0.66)	-1.8	-1.00	-0.33	0.00	0.7	-0.24 [-0.86, 0.37]
			Placebo	20	18 (90.0)	-0.37 (0.70)	-2.2	-0.67	-0.25	0.00	1.0	
		Week 4	Tezepelumab	24	23 (95.8)	-0.71 (0.90)	-2.3	-1.17	-0.83	-0.33	2.3	-0.31 [-0.93, 0.31]
			Placebo	20	18 (90.0)	-0.43 (0.95)	-2.7	-1.17	-0.25	0.17	1.2	
		Week 6	Tezepelumab	24	23 (95.8)	-0.90 (0.97)	-2.5	-1.33	-1.00	-0.67	2.3	-0.51 [-1.14, 0.12]
			Placebo	20	18 (90.0)	-0.42 (0.92)	-2.8	-0.67	-0.33	0.00	1.5	
		Week 8	Tezepelumab	24	23 (95.8)	-1.01 (1.06)	-3.0	-1.50	-1.00	-0.50	2.3	-0.31 [-0.93, 0.31]
			Placebo	20	18 (90.0)	-0.69 (1.06)	-3.2	-1.17	-0.58	0.17	0.8	
		Week 10	Tezepelumab	24	23 (95.8)	-1.04 (1.12)	-3.2	-1.67	-1.17	-0.50	2.3	-0.55 [-1.18, 0.07]
			Placebo	20	18 (90.0)	-0.32 (1.49)	-3.3	-1.17	-0.50	0.00	2.7	
		Week 12	Tezepelumab	24	23 (95.8)	-1.19 (1.12)	-2.8	-2.17	-1.17	-0.67	2.3	-0.52 [-1.14, 0.11]
			Placebo	20	18 (90.0)	-0.60 (1.16)	-3.3	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	24	23 (95.8)	-1.15 (1.18)	-3.2	-2.00	-1.17	-0.50	2.3	-0.32 [-0.94, 0.30]
			Placebo	20	18 (90.0)	-0.78 (1.19)	-3.0	-1.33	-1.17	-0.33	2.3	
		Week 16	Tezepelumab	24	23 (95.8)	-1.13 (1.18)	-3.0	-2.17	-1.00	-0.67	2.3	-0.49 [-1.12, 0.13]
			Placebo	20	18 (90.0)	-0.51 (1.37)	-3.2	-1.17	-0.67	-0.17	2.3	
		Week 18	Tezepelumab	24	23 (95.8)	-1.08 (1.13)	-3.2	-1.83	-1.17	-0.67	2.3	-0.40 [-1.02, 0.22]
			Placebo	20	18 (90.0)	-0.59 (1.33)	-3.2	-1.33	-1.00	0.00	2.3	
		Week 20	Tezepelumab	24	23 (95.8)	-1.17 (1.18)	-3.2	-2.00	-1.33	-0.50	2.3	-0.50 [-1.12, 0.13]
			Placebo	20	18 (90.0)	-0.54 (1.38)	-3.2	-1.33	-0.58	-0.17	2.3	
		Week 22	Tezepelumab	24	23 (95.8)	-1.04 (1.12)	-3.0	-1.67	-1.17	-0.67	2.3	-0.41 [-1.04, 0.21]
			Placebo	20	18 (90.0)	-0.53 (1.39)	-3.3	-1.17	-0.67	0.00	2.3	
		Week 24	Tezepelumab	24	23 (95.8)	-1.15 (1.18)	-3.2	-2.00	-1.33	-0.50	2.3	-0.50 [-1.12, 0.13]
			Placebo	20	18 (90.0)	-0.56 (1.23)	-3.2	-1.17	-0.58	0.00	2.3	
		Week 26	Tezepelumab	24	23 (95.8)	-1.07 (1.18)	-2.8	-2.00	-1.17	-0.50	2.3	-0.45 [-1.07, 0.18]
			Placebo	20	18 (90.0)	-0.53 (1.26)	-2.8	-1.50	-0.58	0.17	2.3	
		Week 28	Tezepelumab	24	24 (100.0)	-1.19 (1.21)	-3.2	-2.00	-1.42	-0.58	2.3	-0.55 [-1.18, 0.07]
			Placebo	20	18 (90.0)	-0.51 (1.24)	-2.8	-1.50	-0.33	0.00	2.3	
		Week 30	Tezepelumab	24	24 (100.0)	-1.17 (1.13)	-2.7	-2.08	-1.33	-0.67	2.3	-0.49 [-1.11, 0.13]
			Placebo	20	18 (90.0)	-0.59 (1.27)	-2.8	-1.17	-1.00	-0.17	2.3	
		Week 32	Tezepelumab	24	24 (100.0)	-1.35 (1.19)	-3.0	-2.17	-1.75	-0.75	2.3	-0.61 [-1.23, 0.02]
			Placebo	20	18 (90.0)	-0.61 (1.23)	-2.8	-1.50	-0.75	-0.33	2.3	
		Week 34	Tezepelumab	24	24 (100.0)	-1.19 (1.21)	-2.8	-2.17	-1.58	-0.33	2.3	-0.54 [-1.16, 0.08]
			Placebo	20	18 (90.0)	-0.54 (1.24)	-2.8	-1.17	-0.42	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
25.0 - < 30.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	24	24 (100.0)	-1.12 (1.21)	-3.0	-2.17	-1.17	-0.25	2.3	-0.63 [-1.26, -0.01]
			Placebo	20	18 (90.0)	-0.37 (1.17)	-2.2	-1.00	-0.42	0.17	2.3	
		Week 38	Tezepelumab	24	24 (100.0)	-1.28 (1.23)	-3.0	-2.08	-1.58	-0.42	2.3	-0.48 [-1.10, 0.14]
			Placebo	20	18 (90.0)	-0.69 (1.22)	-2.5	-1.17	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	24	24 (100.0)	-1.27 (1.26)	-3.2	-2.25	-1.50	-0.50	2.3	-0.60 [-1.22, 0.03]
			Placebo	20	18 (90.0)	-0.52 (1.26)	-2.2	-1.33	-0.67	0.33	2.3	
		Week 42	Tezepelumab	24	24 (100.0)	-1.34 (1.20)	-2.7	-2.17	-1.75	-0.67	2.3	-0.62 [-1.25, 0.00]
			Placebo	20	18 (90.0)	-0.59 (1.19)	-2.2	-1.17	-0.83	0.17	2.3	
		Week 44	Tezepelumab	24	24 (100.0)	-1.19 (1.23)	-3.2	-2.17	-1.50	-0.33	2.3	-0.50 [-1.12, 0.12]
			Placebo	20	18 (90.0)	-0.60 (1.11)	-2.2	-1.50	-0.75	-0.33	2.3	
		Week 46	Tezepelumab	24	24 (100.0)	-1.20 (1.20)	-2.7	-2.17	-1.42	-0.42	2.3	-0.47 [-1.09, 0.15]
			Placebo	20	18 (90.0)	-0.68 (1.01)	-2.2	-1.17	-0.92	-0.33	2.3	
		Week 48	Tezepelumab	24	24 (100.0)	-1.19 (1.22)	-2.7	-2.17	-1.33	-0.42	2.3	-0.44 [-1.06, 0.18]
			Placebo	20	18 (90.0)	-0.68 (1.12)	-2.5	-1.17	-0.92	-0.17	2.3	
		Week 50	Tezepelumab	24	24 (100.0)	-1.35 (1.22)	-2.7	-2.33	-1.67	-0.58	2.3	-0.77 [-1.40, -0.14]
			Placebo	20	18 (90.0)	-0.45 (1.08)	-2.0	-1.00	-0.67	0.33	2.3	
		Week 52	Tezepelumab	24	24 (100.0)	-1.32 (1.21)	-2.7	-2.25	-1.67	-0.58	2.3	-0.71 [-1.34, -0.08]
			Placebo	20	18 (90.0)	-0.46 (1.20)	-2.7	-1.00	-0.75	0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	2.89 (0.77)	1.7	2.33	2.83	3.17	4.8	
			Placebo	24	24 (100.0)	2.77 (0.66)	1.5	2.42	2.75	3.17	4.7	
		Week 2	Tezepelumab	27	25 (92.6)	2.57 (0.90)	0.0	2.17	2.67	3.00	4.2	
			Placebo	24	21 (87.5)	2.24 (0.86)	0.5	1.83	2.33	2.50	4.7	
		Week 4	Tezepelumab	27	25 (92.6)	2.32 (0.89)	0.2	1.83	2.50	2.83	3.5	
			Placebo	24	21 (87.5)	1.94 (0.98)	0.2	1.33	2.17	2.33	3.5	
		Week 6	Tezepelumab	27	25 (92.6)	2.28 (1.04)	0.5	1.50	2.50	3.00	4.0	
			Placebo	24	21 (87.5)	1.99 (1.35)	0.2	1.17	2.00	2.67	5.5	
		Week 8	Tezepelumab	27	25 (92.6)	2.21 (1.10)	0.0	1.50	2.33	2.83	4.8	
			Placebo	24	22 (91.7)	2.03 (1.14)	0.0	1.67	2.08	2.67	4.7	
		Week 10	Tezepelumab	27	25 (92.6)	2.08 (0.98)	0.0	1.33	2.17	2.83	3.7	
			Placebo	24	22 (91.7)	1.91 (0.89)	0.2	1.33	2.17	2.50	3.2	
		Week 12	Tezepelumab	27	25 (92.6)	2.05 (0.82)	0.0	1.67	2.17	2.67	3.3	
			Placebo	24	22 (91.7)	1.61 (0.87)	0.0	0.67	1.83	2.17	2.8	
		Week 14	Tezepelumab	27	25 (92.6)	1.89 (0.87)	0.0	1.50	1.83	2.33	4.2	
			Placebo	24	22 (91.7)	1.55 (0.78)	0.0	1.00	1.75	2.17	3.0	
		Week 16	Tezepelumab	27	25 (92.6)	2.09 (0.96)	0.0	1.33	2.17	2.50	4.3	
			Placebo	24	22 (91.7)	1.92 (1.07)	0.0	1.17	1.83	2.67	4.8	
		Week 18	Tezepelumab	27	26 (96.3)	2.01 (0.86)	0.0	1.50	2.17	2.50	4.2	
			Placebo	24	22 (91.7)	1.71 (1.12)	0.0	0.67	1.83	2.33	4.7	
		Week 20	Tezepelumab	27	26 (96.3)	2.10 (0.97)	0.0	1.50	2.00	2.50	5.0	
			Placebo	24	22 (91.7)	1.85 (0.78)	0.3	1.17	1.92	2.50	3.0	
		Week 22	Tezepelumab	27	26 (96.3)	2.08 (0.73)	0.0	1.67	2.17	2.50	3.8	
			Placebo	24	22 (91.7)	1.82 (0.80)	0.3	1.17	2.00	2.33	3.3	
		Week 24	Tezepelumab	27	26 (96.3)	2.12 (0.83)	0.0	1.67	2.25	2.67	3.8	
			Placebo	24	22 (91.7)	1.84 (0.79)	0.3	1.50	2.00	2.33	3.3	
		Week 26	Tezepelumab	27	27 (100.0)	2.14 (0.90)	0.0	1.50	2.17	2.67	4.0	
			Placebo	24	22 (91.7)	1.69 (0.92)	0.0	1.00	1.67	2.17	3.7	
		Week 28	Tezepelumab	27	27 (100.0)	2.17 (0.86)	0.0	1.50	2.33	2.67	3.8	
			Placebo	24	22 (91.7)	1.66 (1.04)	0.0	0.83	1.58	2.33	3.7	
		Week 30	Tezepelumab	27	27 (100.0)	2.14 (0.86)	0.0	1.50	2.17	2.50	3.7	
			Placebo	24	22 (91.7)	1.56 (0.90)	0.0	0.83	1.75	2.17	3.3	
		Week 32	Tezepelumab	27	27 (100.0)	2.14 (0.83)	0.0	1.67	2.17	2.50	4.0	
			Placebo	24	22 (91.7)	1.73 (0.90)	0.2	1.17	1.83	2.33	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 30.0 kg/m**2	Absolute values	Week 34	Tezepelumab	27	27 (100.0)	2.19 (0.95)	0.0	1.50	2.17	2.67	4.2	
			Placebo	24	22 (91.7)	1.67 (0.78)	0.3	1.33	1.83	2.17	3.3	
		Week 36	Tezepelumab	27	27 (100.0)	2.09 (0.89)	0.0	1.50	2.00	2.67	3.7	
			Placebo	24	22 (91.7)	1.68 (0.82)	0.0	1.00	1.75	2.17	3.3	
		Week 38	Tezepelumab	27	27 (100.0)	2.19 (1.04)	0.0	1.67	2.00	2.67	4.5	
			Placebo	24	22 (91.7)	1.77 (0.77)	0.5	1.17	1.83	2.17	3.3	
		Week 40	Tezepelumab	27	27 (100.0)	2.19 (0.88)	0.0	1.67	2.00	2.67	3.7	
			Placebo	24	22 (91.7)	1.93 (1.09)	0.3	0.83	2.00	2.83	4.0	
		Week 42	Tezepelumab	27	27 (100.0)	2.20 (0.89)	0.0	1.67	2.17	2.67	3.8	
			Placebo	24	22 (91.7)	1.79 (0.82)	0.2	1.50	1.83	2.33	3.3	
		Week 44	Tezepelumab	27	27 (100.0)	2.22 (0.80)	0.0	1.67	2.33	2.67	3.8	
			Placebo	24	22 (91.7)	1.73 (1.01)	0.2	0.83	1.83	2.33	4.0	
		Week 46	Tezepelumab	27	27 (100.0)	2.24 (0.88)	0.0	1.83	2.17	2.83	3.8	
			Placebo	24	22 (91.7)	1.71 (0.83)	0.3	1.00	1.83	2.33	3.3	
		Week 48	Tezepelumab	27	27 (100.0)	2.20 (0.92)	0.0	1.50	2.17	2.67	4.0	
			Placebo	24	22 (91.7)	1.73 (0.94)	0.2	1.00	1.92	2.50	3.3	
		Week 50	Tezepelumab	27	27 (100.0)	2.14 (1.06)	0.0	1.50	2.00	2.83	4.2	
			Placebo	24	22 (91.7)	1.50 (0.89)	0.0	1.00	1.67	1.83	3.3	
		Week 52	Tezepelumab	27	27 (100.0)	2.15 (1.06)	0.0	1.50	2.00	2.67	4.3	
			Placebo	24	22 (91.7)	1.67 (0.98)	0.0	1.00	1.83	2.50	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 2	Tezepelumab	27	25 (92.6)	-0.41 (0.75)	-2.8	-0.67	-0.33	0.17	0.7	0.30 [-0.28, 0.88]
			Placebo	24	21 (87.5)	-0.60 (0.43)	-1.5	-0.83	-0.67	-0.17	0.0	
		Week 4	Tezepelumab	27	25 (92.6)	-0.66 (0.72)	-2.0	-1.00	-0.67	-0.17	0.7	0.30 [-0.29, 0.88]
			Placebo	24	21 (87.5)	-0.90 (0.88)	-3.0	-1.33	-0.83	-0.33	0.5	
		Week 6	Tezepelumab	27	25 (92.6)	-0.70 (0.89)	-2.3	-1.50	-0.50	0.00	1.2	0.14 [-0.44, 0.72]
			Placebo	24	21 (87.5)	-0.84 (1.13)	-3.3	-1.50	-1.00	-0.17	1.5	
		Week 8	Tezepelumab	27	25 (92.6)	-0.77 (1.04)	-2.7	-1.50	-0.83	-0.17	2.2	0.04 [-0.53, 0.62]
			Placebo	24	22 (91.7)	-0.82 (1.05)	-3.0	-1.17	-0.75	0.00	1.0	
		Week 10	Tezepelumab	27	25 (92.6)	-0.90 (0.83)	-2.7	-1.50	-1.00	-0.17	0.3	0.05 [-0.53, 0.62]
			Placebo	24	22 (91.7)	-0.94 (0.88)	-3.2	-1.33	-0.75	-0.33	0.3	
		Week 12	Tezepelumab	27	25 (92.6)	-0.93 (0.85)	-2.7	-1.33	-0.83	-0.33	0.5	0.36 [-0.22, 0.94]
			Placebo	24	22 (91.7)	-1.24 (0.91)	-3.2	-1.83	-1.00	-0.50	0.0	
		Week 14	Tezepelumab	27	25 (92.6)	-1.09 (0.77)	-2.5	-1.50	-1.17	-0.67	0.3	0.26 [-0.31, 0.84]
			Placebo	24	22 (91.7)	-1.30 (0.90)	-3.2	-2.00	-1.25	-0.67	0.2	
		Week 16	Tezepelumab	27	25 (92.6)	-0.89 (0.91)	-2.5	-1.33	-1.00	-0.33	1.5	0.05 [-0.53, 0.62]
			Placebo	24	22 (91.7)	-0.93 (1.02)	-3.2	-1.33	-0.83	0.00	0.3	
		Week 18	Tezepelumab	27	26 (96.3)	-0.93 (0.77)	-2.5	-1.67	-0.83	-0.33	0.3	0.22 [-0.35, 0.79]
			Placebo	24	22 (91.7)	-1.14 (1.08)	-3.2	-1.83	-1.25	-0.33	1.5	
		Week 20	Tezepelumab	27	26 (96.3)	-0.83 (0.85)	-2.5	-1.50	-0.75	-0.33	0.7	0.19 [-0.38, 0.76]
			Placebo	24	22 (91.7)	-1.00 (0.88)	-2.8	-1.50	-0.83	-0.50	1.0	
		Week 22	Tezepelumab	27	26 (96.3)	-0.86 (0.72)	-2.5	-1.17	-0.75	-0.50	0.5	0.23 [-0.34, 0.80]
			Placebo	24	22 (91.7)	-1.03 (0.78)	-2.8	-1.50	-0.92	-0.50	0.3	
		Week 24	Tezepelumab	27	26 (96.3)	-0.81 (0.79)	-2.5	-1.33	-0.75	-0.33	0.7	0.23 [-0.34, 0.80]
			Placebo	24	22 (91.7)	-1.01 (0.92)	-3.2	-1.50	-0.83	-0.50	0.3	
		Week 26	Tezepelumab	27	27 (100.0)	-0.75 (0.84)	-2.5	-1.50	-0.50	0.00	0.7	0.46 [-0.11, 1.03]
			Placebo	24	22 (91.7)	-1.16 (0.93)	-3.2	-1.83	-1.17	-0.67	0.5	
		Week 28	Tezepelumab	27	27 (100.0)	-0.72 (0.94)	-2.5	-1.17	-0.83	0.00	0.8	0.47 [-0.10, 1.04]
			Placebo	24	22 (91.7)	-1.19 (1.08)	-3.2	-1.83	-1.33	-0.33	1.2	
		Week 30	Tezepelumab	27	27 (100.0)	-0.75 (0.94)	-2.5	-1.33	-0.83	-0.17	1.8	0.58 [0.01, 1.16]
			Placebo	24	22 (91.7)	-1.29 (0.90)	-3.2	-1.83	-1.33	-0.67	0.5	
		Week 32	Tezepelumab	27	27 (100.0)	-0.75 (0.79)	-2.5	-1.17	-0.67	-0.33	0.8	0.41 [-0.16, 0.98]
			Placebo	24	22 (91.7)	-1.11 (0.98)	-3.0	-1.83	-1.17	-0.50	0.7	
		Week 34	Tezepelumab	27	27 (100.0)	-0.70 (0.98)	-2.5	-1.50	-0.67	-0.17	2.0	0.52 [-0.06, 1.09]
			Placebo	24	22 (91.7)	-1.17 (0.82)	-2.8	-1.50	-1.17	-0.67	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 30.0 kg/m**2	Change from baseline	Week 36	Tezepelumab	27	27 (100.0)	-0.80 (0.88)	-2.5	-1.50	-0.83	-0.17	1.5	0.41 [-0.16, 0.98]
			Placebo	24	22 (91.7)	-1.17 (0.89)	-3.5	-1.33	-1.17	-0.67	0.5	
		Week 38	Tezepelumab	27	27 (100.0)	-0.70 (0.99)	-2.5	-1.17	-0.83	0.00	2.3	0.43 [-0.14, 1.00]
			Placebo	24	22 (91.7)	-1.08 (0.74)	-3.0	-1.33	-1.17	-0.83	0.3	
		Week 40	Tezepelumab	27	27 (100.0)	-0.70 (0.85)	-2.5	-1.17	-0.83	-0.33	1.7	0.22 [-0.35, 0.78]
			Placebo	24	22 (91.7)	-0.92 (1.12)	-3.2	-1.67	-1.17	0.00	0.8	
		Week 42	Tezepelumab	27	27 (100.0)	-0.69 (0.88)	-2.5	-1.17	-0.83	-0.17	2.0	0.45 [-0.12, 1.02]
			Placebo	24	22 (91.7)	-1.06 (0.76)	-2.8	-1.33	-1.17	-0.67	0.3	
		Week 44	Tezepelumab	27	27 (100.0)	-0.67 (0.83)	-2.5	-1.17	-0.67	-0.17	1.5	0.48 [-0.09, 1.05]
			Placebo	24	22 (91.7)	-1.12 (1.04)	-3.3	-1.67	-1.17	-0.33	0.8	
		Week 46	Tezepelumab	27	27 (100.0)	-0.65 (0.90)	-2.5	-1.17	-0.67	0.00	1.7	0.57 [-0.01, 1.14]
			Placebo	24	22 (91.7)	-1.14 (0.80)	-2.8	-1.67	-1.17	-0.67	0.5	
		Week 48	Tezepelumab	27	27 (100.0)	-0.69 (0.91)	-2.5	-1.17	-0.67	-0.17	1.8	0.45 [-0.12, 1.03]
			Placebo	24	22 (91.7)	-1.11 (0.95)	-3.3	-1.50	-1.08	-0.50	0.3	
		Week 50	Tezepelumab	27	27 (100.0)	-0.75 (1.01)	-2.7	-1.33	-0.83	-0.17	1.8	0.62 [0.05, 1.20]
			Placebo	24	22 (91.7)	-1.35 (0.88)	-3.5	-1.67	-1.17	-0.83	0.3	
		Week 52	Tezepelumab	27	27 (100.0)	-0.73 (1.00)	-2.7	-1.33	-0.83	-0.17	1.8	0.44 [-0.13, 1.01]
			Placebo	24	22 (91.7)	-1.18 (1.03)	-3.5	-1.67	-1.08	-0.50	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	3.11 (0.70)	2.0	2.67	3.17	3.50	4.5	
			Placebo	14	14 (100.0)	2.96 (0.64)	1.7	2.67	2.92	3.17	4.5	
		Week 2	Tezepelumab	11	11 (100.0)	2.88 (0.70)	1.5	2.50	3.00	3.50	3.7	
			Placebo	14	12 (85.7)	2.13 (0.73)	0.5	1.75	2.25	2.42	3.2	
		Week 4	Tezepelumab	11	11 (100.0)	2.29 (1.03)	0.2	1.67	2.83	2.83	3.5	
			Placebo	14	12 (85.7)	2.26 (0.99)	0.3	1.67	2.25	3.08	3.5	
		Week 6	Tezepelumab	11	11 (100.0)	2.30 (0.97)	0.5	1.50	2.50	3.00	3.7	
			Placebo	14	12 (85.7)	1.89 (0.87)	0.5	1.17	2.00	2.42	3.3	
		Week 8	Tezepelumab	11	11 (100.0)	2.44 (1.28)	0.0	1.50	2.83	3.00	4.8	
			Placebo	14	12 (85.7)	1.92 (1.15)	0.2	0.75	2.08	2.75	3.7	
		Week 10	Tezepelumab	11	11 (100.0)	2.36 (1.30)	0.0	1.00	2.83	3.17	4.3	
			Placebo	14	12 (85.7)	1.82 (0.89)	0.3	1.00	2.08	2.58	3.0	
		Week 12	Tezepelumab	11	11 (100.0)	2.18 (1.13)	0.0	1.33	2.50	2.67	4.3	
			Placebo	14	12 (85.7)	1.56 (0.92)	0.0	0.92	1.83	2.08	3.2	
		Week 14	Tezepelumab	11	11 (100.0)	1.85 (1.10)	0.0	1.17	1.67	2.50	4.3	
			Placebo	14	12 (85.7)	1.47 (0.86)	0.0	0.92	1.58	2.00	3.2	
		Week 16	Tezepelumab	11	11 (100.0)	2.23 (1.09)	0.0	1.50	2.50	2.67	4.3	
			Placebo	14	12 (85.7)	1.64 (0.93)	0.0	1.08	1.75	2.25	3.2	
		Week 18	Tezepelumab	11	11 (100.0)	2.15 (1.12)	0.0	1.33	2.33	2.67	4.3	
			Placebo	14	12 (85.7)	1.79 (1.34)	0.0	0.75	1.67	2.67	4.7	
		Week 20	Tezepelumab	11	11 (100.0)	2.08 (1.14)	0.0	1.17	2.33	2.67	4.3	
			Placebo	14	12 (85.7)	2.03 (0.73)	0.3	1.67	2.33	2.58	2.8	
		Week 22	Tezepelumab	11	11 (100.0)	2.15 (1.08)	0.0	1.50	2.33	2.50	4.3	
			Placebo	14	12 (85.7)	1.94 (0.81)	0.3	1.50	2.08	2.67	3.0	
		Week 24	Tezepelumab	11	11 (100.0)	2.15 (1.17)	0.0	1.17	2.33	2.67	4.3	
			Placebo	14	12 (85.7)	2.06 (0.84)	0.3	1.75	2.25	2.58	3.0	
		Week 26	Tezepelumab	11	11 (100.0)	2.18 (1.29)	0.0	1.17	2.50	3.33	4.3	
			Placebo	14	12 (85.7)	1.76 (1.18)	0.0	0.92	1.50	2.92	3.7	
		Week 28	Tezepelumab	11	11 (100.0)	2.21 (1.25)	0.0	1.17	2.17	3.50	4.3	
			Placebo	14	12 (85.7)	1.64 (1.11)	0.0	0.67	1.75	2.75	3.0	
		Week 30	Tezepelumab	11	11 (100.0)	2.26 (1.19)	0.0	1.17	2.50	3.17	4.3	
			Placebo	14	12 (85.7)	1.74 (0.91)	0.3	1.17	1.67	2.58	3.0	
		Week 32	Tezepelumab	11	11 (100.0)	2.08 (1.19)	0.0	1.17	2.33	2.67	4.3	
			Placebo	14	12 (85.7)	1.71 (0.90)	0.3	1.08	1.67	2.42	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 150 cells/uL	Absolute values	Week 34	Tezepelumab	11	11 (100.0)	2.08 (1.26)	0.0	1.17	2.50	2.67	4.3	
			Placebo	14	12 (85.7)	1.68 (0.90)	0.3	1.00	1.83	2.25	3.0	
		Week 36	Tezepelumab	11	11 (100.0)	2.09 (1.24)	0.0	1.17	2.00	2.67	4.3	
			Placebo	14	12 (85.7)	1.93 (0.86)	0.3	1.33	1.92	2.75	3.0	
		Week 38	Tezepelumab	11	11 (100.0)	2.11 (1.23)	0.0	1.17	1.67	2.83	4.3	
			Placebo	14	12 (85.7)	1.89 (0.85)	0.3	1.58	1.83	2.58	3.2	
		Week 40	Tezepelumab	11	11 (100.0)	2.29 (1.17)	0.0	1.50	2.67	3.00	4.3	
			Placebo	14	12 (85.7)	1.94 (1.16)	0.3	1.08	1.83	2.83	4.0	
		Week 42	Tezepelumab	11	11 (100.0)	2.24 (1.22)	0.0	1.50	2.00	3.33	4.3	
			Placebo	14	12 (85.7)	1.81 (0.89)	0.2	1.42	1.83	2.50	3.0	
		Week 44	Tezepelumab	11	11 (100.0)	2.27 (1.14)	0.0	1.50	2.50	2.67	4.3	
			Placebo	14	12 (85.7)	1.88 (1.23)	0.2	0.83	2.00	2.83	4.0	
		Week 46	Tezepelumab	11	11 (100.0)	2.26 (1.18)	0.0	1.33	2.33	3.17	4.3	
			Placebo	14	12 (85.7)	1.83 (0.82)	0.3	1.67	1.92	2.25	3.0	
		Week 48	Tezepelumab	11	11 (100.0)	2.26 (1.17)	0.0	1.50	2.33	3.00	4.3	
			Placebo	14	12 (85.7)	1.82 (0.97)	0.2	1.08	2.08	2.67	3.0	
		Week 50	Tezepelumab	11	11 (100.0)	2.29 (1.16)	0.0	1.67	2.33	3.17	4.3	
			Placebo	14	12 (85.7)	1.60 (0.98)	0.0	0.83	1.75	2.42	3.0	
		Week 52	Tezepelumab	11	11 (100.0)	2.27 (1.16)	0.0	1.67	2.33	3.17	4.3	
			Placebo	14	12 (85.7)	1.74 (0.99)	0.0	1.08	1.83	2.50	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 2	Tezepelumab	11	11 (100.0)	-0.23 (0.50)	-1.0	-0.67	-0.17	0.17	0.3	0.90 [0.04, 1.77]
			Placebo	14	12 (85.7)	-0.67 (0.48)	-1.3	-1.08	-0.75	-0.33	0.2	
		Week 4	Tezepelumab	11	11 (100.0)	-0.82 (0.65)	-2.0	-1.17	-0.67	-0.33	0.2	-0.43 [-1.26, 0.40]
			Placebo	14	12 (85.7)	-0.53 (0.71)	-1.8	-1.00	-0.50	0.00	0.5	
		Week 6	Tezepelumab	11	11 (100.0)	-0.80 (0.57)	-1.5	-1.33	-0.83	-0.17	0.2	0.15 [-0.67, 0.97]
			Placebo	14	12 (85.7)	-0.90 (0.73)	-2.0	-1.42	-0.83	-0.33	0.3	
		Week 8	Tezepelumab	11	11 (100.0)	-0.67 (1.15)	-2.0	-1.67	-0.50	-0.17	2.2	0.18 [-0.64, 1.00]
			Placebo	14	12 (85.7)	-0.87 (1.16)	-3.0	-1.75	-0.75	0.08	1.0	
		Week 10	Tezepelumab	11	11 (100.0)	-0.74 (0.98)	-2.3	-1.50	-0.67	0.17	0.5	0.26 [-0.56, 1.08]
			Placebo	14	12 (85.7)	-0.97 (0.79)	-2.2	-1.67	-0.92	-0.42	0.2	
		Week 12	Tezepelumab	11	11 (100.0)	-0.92 (0.83)	-2.0	-1.83	-0.83	-0.17	0.5	0.34 [-0.48, 1.17]
			Placebo	14	12 (85.7)	-1.24 (0.98)	-3.2	-1.83	-1.00	-0.67	0.2	
		Week 14	Tezepelumab	11	11 (100.0)	-1.26 (0.78)	-2.2	-2.00	-1.17	-0.83	0.5	0.07 [-0.75, 0.89]
			Placebo	14	12 (85.7)	-1.32 (0.93)	-3.2	-1.75	-1.33	-0.75	0.2	
		Week 16	Tezepelumab	11	11 (100.0)	-0.88 (0.82)	-2.2	-1.67	-1.00	-0.33	0.5	0.30 [-0.53, 1.12]
			Placebo	14	12 (85.7)	-1.15 (1.00)	-3.2	-1.67	-1.00	-0.42	0.2	
		Week 18	Tezepelumab	11	11 (100.0)	-0.95 (0.75)	-2.0	-1.83	-1.00	-0.33	0.5	0.04 [-0.77, 0.86]
			Placebo	14	12 (85.7)	-1.00 (1.26)	-3.2	-1.58	-1.33	-0.17	1.5	
		Week 20	Tezepelumab	11	11 (100.0)	-1.03 (0.84)	-2.2	-2.00	-0.83	-0.50	0.5	-0.35 [-1.18, 0.47]
			Placebo	14	12 (85.7)	-0.76 (0.67)	-2.5	-0.83	-0.75	-0.33	0.0	
		Week 22	Tezepelumab	11	11 (100.0)	-0.95 (0.82)	-2.2	-2.00	-0.83	-0.67	0.5	-0.14 [-0.96, 0.68]
			Placebo	14	12 (85.7)	-0.85 (0.75)	-2.5	-1.17	-0.83	-0.42	0.3	
		Week 24	Tezepelumab	11	11 (100.0)	-0.95 (0.80)	-2.0	-1.83	-1.00	-0.33	0.5	-0.24 [-1.06, 0.58]
			Placebo	14	12 (85.7)	-0.74 (0.99)	-2.5	-1.25	-0.58	0.08	0.3	
		Week 26	Tezepelumab	11	11 (100.0)	-0.92 (0.96)	-2.0	-2.00	-1.00	0.00	0.5	0.10 [-0.72, 0.92]
			Placebo	14	12 (85.7)	-1.03 (1.15)	-3.2	-1.75	-1.08	0.00	0.5	
		Week 28	Tezepelumab	11	11 (100.0)	-0.89 (0.99)	-2.3	-2.00	-0.83	0.00	0.5	0.25 [-0.58, 1.07]
			Placebo	14	12 (85.7)	-1.15 (1.11)	-3.2	-2.00	-0.92	-0.33	0.3	
		Week 30	Tezepelumab	11	11 (100.0)	-0.85 (0.92)	-2.0	-2.00	-0.67	-0.17	0.5	0.23 [-0.59, 1.06]
			Placebo	14	12 (85.7)	-1.06 (0.85)	-2.5	-1.50	-1.08	-0.50	0.3	
		Week 32	Tezepelumab	11	11 (100.0)	-1.03 (0.90)	-2.2	-2.00	-1.00	-0.33	0.5	0.06 [-0.76, 0.88]
			Placebo	14	12 (85.7)	-1.08 (0.87)	-2.5	-1.58	-1.08	-0.33	0.3	
		Week 34	Tezepelumab	11	11 (100.0)	-1.03 (0.91)	-2.0	-2.00	-1.33	0.00	0.5	0.09 [-0.73, 0.91]
			Placebo	14	12 (85.7)	-1.11 (0.88)	-2.8	-1.50	-1.00	-0.67	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 150 cells/uL	Change from baseline	Week 36	Tezepelumab	11	11 (100.0)	-1.02 (0.91)	-2.0	-1.83	-1.17	0.00	0.5	-0.17 [-0.99, 0.65]
			Placebo	14	12 (85.7)	-0.86 (0.92)	-2.7	-1.25	-0.67	-0.25	0.3	
		Week 38	Tezepelumab	11	11 (100.0)	-1.00 (0.87)	-2.0	-1.67	-1.17	0.00	0.5	-0.12 [-0.94, 0.70]
			Placebo	14	12 (85.7)	-0.90 (0.76)	-2.5	-1.25	-1.00	-0.42	0.3	
		Week 40	Tezepelumab	11	11 (100.0)	-0.82 (0.79)	-2.0	-1.50	-0.83	-0.17	0.5	0.03 [-0.79, 0.85]
			Placebo	14	12 (85.7)	-0.85 (1.07)	-2.5	-1.50	-1.00	0.08	0.8	
		Week 42	Tezepelumab	11	11 (100.0)	-0.86 (0.82)	-2.0	-1.50	-0.83	0.00	0.5	0.16 [-0.66, 0.98]
			Placebo	14	12 (85.7)	-0.99 (0.68)	-2.5	-1.33	-0.83	-0.67	0.3	
		Week 44	Tezepelumab	11	11 (100.0)	-0.83 (0.84)	-2.0	-1.83	-0.83	-0.17	0.5	0.08 [-0.74, 0.90]
			Placebo	14	12 (85.7)	-0.92 (1.21)	-2.7	-1.92	-0.92	0.17	0.8	
		Week 46	Tezepelumab	11	11 (100.0)	-0.85 (0.78)	-2.0	-1.33	-1.00	-0.17	0.5	0.14 [-0.67, 0.96]
			Placebo	14	12 (85.7)	-0.96 (0.74)	-2.5	-1.25	-0.75	-0.67	0.3	
		Week 48	Tezepelumab	11	11 (100.0)	-0.85 (0.80)	-2.0	-1.50	-0.83	-0.17	0.5	0.15 [-0.67, 0.97]
			Placebo	14	12 (85.7)	-0.97 (0.89)	-2.5	-1.50	-0.50	-0.42	0.3	
		Week 50	Tezepelumab	11	11 (100.0)	-0.82 (0.78)	-2.0	-1.33	-0.83	-0.17	0.5	0.44 [-0.39, 1.27]
			Placebo	14	12 (85.7)	-1.19 (0.92)	-3.0	-1.67	-0.92	-0.67	0.3	
		Week 52	Tezepelumab	11	11 (100.0)	-0.83 (0.77)	-2.0	-1.33	-0.83	-0.17	0.5	0.26 [-0.56, 1.08]
			Placebo	14	12 (85.7)	-1.06 (0.94)	-3.0	-1.67	-0.83	-0.33	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	54	54 (100.0)	2.64 (0.84)	0.0	2.17	2.67	3.00	4.8	
			Placebo	51	51 (100.0)	2.64 (0.73)	0.3	2.33	2.67	3.00	4.7	
		Week 2	Tezepelumab	54	51 (94.4)	2.08 (0.96)	0.0	1.33	2.17	2.67	4.2	
			Placebo	51	46 (90.2)	2.34 (0.79)	0.3	2.00	2.33	2.83	4.8	
		Week 4	Tezepelumab	54	51 (94.4)	1.93 (0.93)	0.2	1.33	2.17	2.67	3.5	
			Placebo	51	46 (90.2)	2.12 (0.90)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	54	51 (94.4)	1.78 (1.00)	0.0	1.00	1.67	2.50	4.0	
			Placebo	51	46 (90.2)	2.16 (1.16)	0.2	1.33	2.25	2.67	5.5	
		Week 8	Tezepelumab	54	51 (94.4)	1.59 (1.03)	0.0	0.83	1.67	2.50	4.2	
			Placebo	51	47 (92.2)	2.10 (1.08)	0.0	1.33	2.17	2.83	4.7	
		Week 10	Tezepelumab	54	51 (94.4)	1.50 (0.99)	0.0	0.67	1.50	2.17	3.7	
			Placebo	51	47 (92.2)	2.13 (1.08)	0.0	1.67	2.17	2.67	5.3	
		Week 12	Tezepelumab	54	51 (94.4)	1.43 (1.00)	0.0	0.50	1.50	2.17	3.3	
			Placebo	51	47 (92.2)	1.94 (1.00)	0.0	1.00	2.00	2.67	4.3	
		Week 14	Tezepelumab	54	51 (94.4)	1.42 (1.04)	0.0	0.50	1.33	2.17	4.2	
			Placebo	51	47 (92.2)	1.87 (0.99)	0.0	1.33	1.83	2.33	5.0	
		Week 16	Tezepelumab	54	51 (94.4)	1.51 (1.10)	0.0	0.50	1.33	2.33	4.3	
			Placebo	51	47 (92.2)	2.04 (1.19)	0.0	1.00	2.00	2.67	5.0	
		Week 18	Tezepelumab	54	52 (96.3)	1.49 (0.98)	0.0	0.67	1.50	2.17	4.2	
			Placebo	51	47 (92.2)	1.89 (1.09)	0.0	1.00	2.00	2.50	5.0	
		Week 20	Tezepelumab	54	52 (96.3)	1.53 (1.07)	0.0	0.58	1.50	2.08	5.0	
			Placebo	51	47 (92.2)	1.95 (1.15)	0.0	1.00	2.00	2.83	5.0	
		Week 22	Tezepelumab	54	52 (96.3)	1.59 (0.93)	0.0	0.83	1.75	2.25	3.8	
			Placebo	51	47 (92.2)	1.92 (1.21)	0.0	1.00	2.00	2.67	5.0	
		Week 24	Tezepelumab	54	52 (96.3)	1.58 (1.01)	0.0	0.58	1.67	2.33	3.8	
			Placebo	51	47 (92.2)	1.97 (1.09)	0.0	1.00	2.00	2.67	4.5	
		Week 26	Tezepelumab	54	53 (98.1)	1.62 (1.02)	0.0	0.83	1.83	2.17	4.0	
			Placebo	51	47 (92.2)	1.96 (1.10)	0.0	1.00	1.83	2.67	4.5	
		Week 28	Tezepelumab	54	54 (100.0)	1.55 (1.04)	0.0	0.50	1.58	2.33	3.8	
			Placebo	51	48 (94.1)	1.97 (1.20)	0.0	1.00	2.00	2.67	4.5	
		Week 30	Tezepelumab	54	54 (100.0)	1.52 (1.00)	0.0	0.67	1.50	2.17	3.7	
			Placebo	51	48 (94.1)	1.93 (1.19)	0.0	0.92	1.92	2.75	4.5	
		Week 32	Tezepelumab	54	54 (100.0)	1.50 (1.02)	0.0	0.67	1.67	2.33	4.0	
			Placebo	51	48 (94.1)	1.90 (1.14)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 150 cells/uL	Absolute values	Week 34	Tezepelumab	54	54 (100.0)	1.57 (1.08)	0.0	0.67	1.50	2.33	4.2	
			Placebo	51	48 (94.1)	1.86 (1.14)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	54	54 (100.0)	1.52 (1.00)	0.0	0.67	1.50	2.33	3.7	
			Placebo	51	48 (94.1)	2.01 (1.19)	0.0	1.17	2.00	2.75	4.5	
		Week 38	Tezepelumab	54	54 (100.0)	1.55 (1.13)	0.0	0.50	1.67	2.33	4.5	
			Placebo	51	48 (94.1)	1.85 (1.15)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	54	54 (100.0)	1.48 (1.07)	0.0	0.50	1.67	2.33	3.7	
			Placebo	51	48 (94.1)	2.02 (1.14)	0.0	1.25	2.08	2.58	4.5	
		Week 42	Tezepelumab	54	54 (100.0)	1.47 (1.02)	0.0	0.83	1.50	2.33	3.8	
			Placebo	51	48 (94.1)	1.87 (1.06)	0.0	1.08	1.83	2.50	4.5	
		Week 44	Tezepelumab	54	54 (100.0)	1.50 (1.03)	0.0	0.50	1.50	2.33	3.8	
			Placebo	51	48 (94.1)	1.95 (1.03)	0.0	1.17	2.00	2.50	4.5	
		Week 46	Tezepelumab	54	54 (100.0)	1.51 (1.08)	0.0	0.67	1.50	2.33	3.8	
			Placebo	51	48 (94.1)	1.84 (1.02)	0.0	1.17	1.83	2.42	4.5	
		Week 48	Tezepelumab	54	54 (100.0)	1.52 (1.07)	0.0	0.67	1.50	2.33	4.0	
			Placebo	51	48 (94.1)	1.90 (1.07)	0.0	1.00	2.08	2.42	4.5	
		Week 50	Tezepelumab	54	54 (100.0)	1.44 (1.09)	0.0	0.67	1.33	2.33	4.2	
			Placebo	51	48 (94.1)	1.82 (1.00)	0.0	1.00	1.83	2.33	4.5	
		Week 52	Tezepelumab	54	54 (100.0)	1.49 (1.07)	0.0	0.67	1.42	2.33	4.3	
			Placebo	51	48 (94.1)	1.88 (1.06)	0.0	1.08	2.08	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 2	Tezepelumab	54	51 (94.4)	-0.60 (0.73)	-2.8	-1.17	-0.50	0.00	0.7	-0.29 [-0.69, 0.11]
			Placebo	51	46 (90.2)	-0.39 (0.72)	-2.8	-0.83	-0.17	0.00	1.0	
		Week 4	Tezepelumab	54	51 (94.4)	-0.75 (0.87)	-2.5	-1.33	-0.83	-0.17	2.3	-0.17 [-0.57, 0.23]
			Placebo	51	46 (90.2)	-0.60 (0.95)	-3.0	-1.17	-0.33	0.00	1.2	
		Week 6	Tezepelumab	54	51 (94.4)	-0.90 (1.00)	-2.7	-1.50	-1.00	-0.17	2.3	-0.33 [-0.73, 0.07]
			Placebo	51	46 (90.2)	-0.57 (1.04)	-3.3	-1.17	-0.33	0.17	1.5	
		Week 8	Tezepelumab	54	51 (94.4)	-1.09 (1.02)	-3.0	-1.83	-1.00	-0.50	2.3	-0.46 [-0.86, -0.06]
			Placebo	51	47 (92.2)	-0.64 (0.96)	-3.2	-1.00	-0.50	0.00	1.0	
		Week 10	Tezepelumab	54	51 (94.4)	-1.18 (1.02)	-3.2	-1.83	-1.17	-0.67	2.3	-0.52 [-0.93, -0.12]
			Placebo	51	47 (92.2)	-0.60 (1.18)	-3.3	-1.33	-0.50	0.00	2.7	
		Week 12	Tezepelumab	54	51 (94.4)	-1.25 (1.04)	-3.0	-2.17	-1.17	-0.67	2.3	-0.45 [-0.85, -0.05]
			Placebo	51	47 (92.2)	-0.80 (0.99)	-3.3	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	54	51 (94.4)	-1.27 (1.06)	-3.7	-2.00	-1.33	-0.50	2.3	-0.39 [-0.79, 0.01]
			Placebo	51	47 (92.2)	-0.86 (1.04)	-3.2	-1.33	-1.00	-0.33	2.3	
		Week 16	Tezepelumab	54	51 (94.4)	-1.17 (1.09)	-3.0	-2.17	-1.00	-0.67	2.3	-0.43 [-0.83, -0.03]
			Placebo	51	47 (92.2)	-0.70 (1.13)	-3.2	-1.33	-0.67	0.00	2.3	
		Week 18	Tezepelumab	54	52 (96.3)	-1.17 (1.05)	-3.5	-1.83	-1.00	-0.67	2.3	-0.30 [-0.70, 0.09]
			Placebo	51	47 (92.2)	-0.84 (1.15)	-3.2	-1.67	-0.83	0.00	2.3	
		Week 20	Tezepelumab	54	52 (96.3)	-1.14 (1.05)	-3.2	-2.00	-1.17	-0.50	2.3	-0.32 [-0.72, 0.08]
			Placebo	51	47 (92.2)	-0.78 (1.21)	-3.2	-1.67	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	54	52 (96.3)	-1.08 (1.07)	-3.0	-1.83	-1.00	-0.58	2.3	-0.23 [-0.63, 0.16]
			Placebo	51	47 (92.2)	-0.81 (1.20)	-3.3	-1.83	-0.83	-0.17	2.3	
		Week 24	Tezepelumab	54	52 (96.3)	-1.09 (1.03)	-3.2	-1.83	-1.08	-0.42	2.3	-0.30 [-0.70, 0.09]
			Placebo	51	47 (92.2)	-0.76 (1.12)	-3.2	-1.50	-0.83	0.00	2.3	
		Week 26	Tezepelumab	54	53 (98.1)	-1.03 (1.06)	-2.8	-2.00	-1.00	-0.33	2.3	-0.24 [-0.63, 0.16]
			Placebo	51	47 (92.2)	-0.77 (1.13)	-2.8	-1.50	-0.83	0.17	2.3	
		Week 28	Tezepelumab	54	54 (100.0)	-1.09 (1.12)	-3.2	-2.00	-1.08	-0.50	2.3	-0.33 [-0.73, 0.06]
			Placebo	51	48 (94.1)	-0.71 (1.16)	-2.8	-1.58	-0.83	0.08	2.3	
		Week 30	Tezepelumab	54	54 (100.0)	-1.13 (1.11)	-3.5	-2.00	-1.00	-0.67	2.3	-0.32 [-0.71, 0.07]
			Placebo	51	48 (94.1)	-0.75 (1.20)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	54	54 (100.0)	-1.15 (1.03)	-3.0	-2.00	-1.00	-0.67	2.3	-0.33 [-0.72, 0.06]
			Placebo	51	48 (94.1)	-0.79 (1.14)	-3.0	-1.50	-0.83	-0.25	2.3	
		Week 34	Tezepelumab	54	54 (100.0)	-1.07 (1.14)	-2.8	-2.00	-1.08	-0.33	2.3	-0.22 [-0.61, 0.17]
			Placebo	51	48 (94.1)	-0.83 (1.13)	-3.2	-1.50	-0.92	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 150 cells/uL	Change from baseline	Week 36	Tezepelumab	54	54 (100.0)	-1.12 (1.11)	-3.0	-2.00	-1.17	-0.33	2.3	-0.39 [-0.78, 0.00]
			Placebo	51	48 (94.1)	-0.68 (1.18)	-3.5	-1.33	-0.83	0.17	2.3	
		Week 38	Tezepelumab	54	54 (100.0)	-1.10 (1.16)	-3.0	-2.00	-1.17	-0.33	2.3	-0.23 [-0.62, 0.16]
			Placebo	51	48 (94.1)	-0.83 (1.15)	-3.2	-1.50	-0.83	0.08	2.3	
		Week 40	Tezepelumab	54	54 (100.0)	-1.16 (1.15)	-3.2	-2.17	-1.17	-0.33	2.3	-0.42 [-0.82, -0.03]
			Placebo	51	48 (94.1)	-0.67 (1.18)	-3.2	-1.33	-0.75	0.25	2.3	
		Week 42	Tezepelumab	54	54 (100.0)	-1.17 (1.14)	-3.3	-2.00	-1.17	-0.50	2.3	-0.32 [-0.71, 0.07]
			Placebo	51	48 (94.1)	-0.82 (1.10)	-2.8	-1.42	-1.08	-0.08	2.3	
		Week 44	Tezepelumab	54	54 (100.0)	-1.15 (1.14)	-3.5	-2.00	-1.17	-0.50	2.3	-0.38 [-0.77, 0.02]
			Placebo	51	48 (94.1)	-0.73 (1.07)	-3.3	-1.42	-0.83	-0.08	2.3	
		Week 46	Tezepelumab	54	54 (100.0)	-1.13 (1.15)	-3.3	-2.17	-1.17	-0.17	2.3	-0.25 [-0.65, 0.14]
			Placebo	51	48 (94.1)	-0.85 (1.07)	-3.2	-1.50	-1.00	-0.25	2.3	
		Week 48	Tezepelumab	54	54 (100.0)	-1.12 (1.13)	-2.7	-2.17	-1.00	-0.50	2.3	-0.30 [-0.69, 0.09]
			Placebo	51	48 (94.1)	-0.79 (1.11)	-3.3	-1.33	-0.83	0.00	2.3	
		Week 50	Tezepelumab	54	54 (100.0)	-1.20 (1.15)	-2.7	-2.17	-1.33	-0.50	2.3	-0.30 [-0.70, 0.09]
			Placebo	51	48 (94.1)	-0.86 (1.03)	-3.5	-1.33	-1.00	-0.33	2.3	
		Week 52	Tezepelumab	54	54 (100.0)	-1.15 (1.14)	-2.7	-2.00	-1.17	-0.50	2.3	-0.31 [-0.70, 0.08]
			Placebo	51	48 (94.1)	-0.81 (1.10)	-3.5	-1.25	-0.83	-0.25	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	33	33 (100.0)	2.87 (0.76)	1.7	2.33	2.83	3.17	4.8	
			Placebo	34	34 (100.0)	2.75 (0.77)	0.3	2.33	2.83	3.17	4.5	
		Week 2	Tezepelumab	33	31 (93.9)	2.46 (0.97)	0.0	1.67	2.67	3.33	3.8	
			Placebo	34	28 (82.4)	2.31 (0.82)	0.3	2.00	2.33	2.67	4.8	
		Week 4	Tezepelumab	33	31 (93.9)	2.15 (1.03)	0.2	1.17	2.50	2.83	3.5	
			Placebo	34	28 (82.4)	2.02 (0.97)	0.2	1.42	2.17	2.67	3.7	
		Week 6	Tezepelumab	33	31 (93.9)	2.09 (1.01)	0.0	1.33	2.33	2.83	4.0	
			Placebo	34	28 (82.4)	1.91 (1.15)	0.2	1.17	2.00	2.42	4.7	
		Week 8	Tezepelumab	33	31 (93.9)	2.06 (1.20)	0.0	1.33	2.33	2.83	4.8	
			Placebo	34	29 (85.3)	1.95 (1.16)	0.0	1.00	2.00	2.67	4.7	
		Week 10	Tezepelumab	33	31 (93.9)	1.88 (1.18)	0.0	0.83	2.00	2.83	4.3	
			Placebo	34	29 (85.3)	1.94 (1.01)	0.2	1.33	2.00	2.50	4.2	
		Week 12	Tezepelumab	33	31 (93.9)	1.81 (1.14)	0.0	0.50	2.17	2.67	4.3	
			Placebo	34	29 (85.3)	1.66 (0.97)	0.0	1.00	1.83	2.17	4.3	
		Week 14	Tezepelumab	33	31 (93.9)	1.68 (1.08)	0.0	0.67	1.83	2.33	4.3	
			Placebo	34	29 (85.3)	1.63 (0.98)	0.0	1.00	1.67	2.00	5.0	
		Week 16	Tezepelumab	33	31 (93.9)	1.77 (1.15)	0.0	0.67	2.00	2.50	4.3	
			Placebo	34	29 (85.3)	1.69 (0.96)	0.0	0.83	1.83	2.17	4.5	
		Week 18	Tezepelumab	33	32 (97.0)	1.84 (1.08)	0.0	0.92	2.00	2.42	4.3	
			Placebo	34	29 (85.3)	1.74 (1.21)	0.0	0.83	1.67	2.50	4.7	
		Week 20	Tezepelumab	33	32 (97.0)	1.82 (1.18)	0.0	1.00	1.83	2.50	5.0	
			Placebo	34	29 (85.3)	1.78 (1.04)	0.2	1.17	1.83	2.50	4.5	
		Week 22	Tezepelumab	33	32 (97.0)	1.86 (1.02)	0.0	1.08	2.08	2.33	4.3	
			Placebo	34	29 (85.3)	1.76 (1.06)	0.0	1.00	1.67	2.50	4.5	
		Week 24	Tezepelumab	33	32 (97.0)	1.82 (1.09)	0.0	1.00	1.92	2.50	4.3	
			Placebo	34	29 (85.3)	1.82 (1.07)	0.2	0.83	1.83	2.50	4.5	
		Week 26	Tezepelumab	33	33 (100.0)	1.86 (1.16)	0.0	1.17	1.83	2.67	4.3	
			Placebo	34	29 (85.3)	1.68 (1.15)	0.0	1.00	1.33	2.33	4.5	
		Week 28	Tezepelumab	33	33 (100.0)	1.84 (1.14)	0.0	1.17	2.00	2.50	4.3	
			Placebo	34	30 (88.2)	1.67 (1.22)	0.0	0.67	1.33	2.50	4.5	
		Week 30	Tezepelumab	33	33 (100.0)	1.89 (1.11)	0.0	1.17	2.00	2.50	4.3	
			Placebo	34	30 (88.2)	1.73 (1.14)	0.0	0.67	1.67	2.50	4.5	
		Week 32	Tezepelumab	33	33 (100.0)	1.79 (1.11)	0.0	1.00	2.00	2.50	4.3	
			Placebo	34	30 (88.2)	1.57 (1.04)	0.0	0.67	1.50	2.17	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 300 cells/uL	Absolute values	Week 34	Tezepelumab	33	33 (100.0)	1.86 (1.13)	0.0	1.00	2.00	2.50	4.3	
			Placebo	34	30 (88.2)	1.53 (1.04)	0.0	0.67	1.75	2.00	4.5	
		Week 36	Tezepelumab	33	33 (100.0)	1.78 (1.11)	0.0	1.00	1.83	2.67	4.3	
			Placebo	34	30 (88.2)	1.71 (1.11)	0.0	0.83	1.83	2.50	4.5	
		Week 38	Tezepelumab	33	33 (100.0)	1.83 (1.25)	0.0	1.00	1.83	2.67	4.5	
			Placebo	34	30 (88.2)	1.73 (1.08)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	33	33 (100.0)	1.86 (1.17)	0.0	1.00	1.83	2.67	4.3	
			Placebo	34	30 (88.2)	1.77 (1.22)	0.0	0.67	1.83	2.50	4.5	
		Week 42	Tezepelumab	33	33 (100.0)	1.85 (1.15)	0.0	1.00	1.83	2.67	4.3	
			Placebo	34	30 (88.2)	1.67 (1.10)	0.0	0.67	1.75	2.50	4.5	
		Week 44	Tezepelumab	33	33 (100.0)	1.85 (1.12)	0.0	1.00	1.83	2.67	4.3	
			Placebo	34	30 (88.2)	1.76 (1.17)	0.0	0.67	1.67	2.50	4.5	
		Week 46	Tezepelumab	33	33 (100.0)	1.83 (1.17)	0.0	1.00	1.83	2.67	4.3	
			Placebo	34	30 (88.2)	1.73 (1.06)	0.0	1.00	1.83	2.33	4.5	
		Week 48	Tezepelumab	33	33 (100.0)	1.84 (1.13)	0.0	1.00	2.00	2.67	4.3	
			Placebo	34	30 (88.2)	1.68 (1.19)	0.0	0.33	1.83	2.50	4.5	
		Week 50	Tezepelumab	33	33 (100.0)	1.86 (1.21)	0.0	1.17	1.83	2.67	4.3	
			Placebo	34	30 (88.2)	1.63 (1.11)	0.0	0.67	1.75	2.33	4.5	
		Week 52	Tezepelumab	33	33 (100.0)	1.87 (1.21)	0.0	1.17	1.83	2.50	4.3	
			Placebo	34	30 (88.2)	1.68 (1.12)	0.0	0.83	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 2	Tezepelumab	33	31 (93.9)	-0.48 (0.76)	-2.8	-0.83	-0.33	0.17	0.3	-0.01 [-0.52, 0.50]
			Placebo	34	28 (82.4)	-0.48 (0.67)	-2.8	-0.83	-0.33	0.08	0.5	
		Week 4	Tezepelumab	33	31 (93.9)	-0.80 (0.74)	-2.3	-1.33	-0.67	-0.33	0.7	-0.04 [-0.55, 0.47]
			Placebo	34	28 (82.4)	-0.76 (0.85)	-3.0	-1.25	-0.75	-0.17	0.5	
		Week 6	Tezepelumab	33	31 (93.9)	-0.85 (0.74)	-2.3	-1.33	-1.00	-0.17	0.3	0.02 [-0.49, 0.53]
			Placebo	34	28 (82.4)	-0.87 (0.99)	-3.3	-1.58	-0.75	-0.17	1.5	
		Week 8	Tezepelumab	33	31 (93.9)	-0.88 (1.02)	-2.7	-1.67	-0.83	-0.17	2.2	-0.04 [-0.54, 0.47]
			Placebo	34	29 (85.3)	-0.84 (1.04)	-3.0	-1.17	-0.83	-0.17	1.0	
		Week 10	Tezepelumab	33	31 (93.9)	-1.07 (0.90)	-2.7	-1.67	-1.17	-0.17	0.5	-0.23 [-0.73, 0.28]
			Placebo	34	29 (85.3)	-0.86 (0.99)	-3.2	-1.33	-0.67	-0.33	2.0	
		Week 12	Tezepelumab	33	31 (93.9)	-1.14 (0.94)	-2.7	-2.00	-1.17	-0.33	0.5	-0.00 [-0.51, 0.50]
			Placebo	34	29 (85.3)	-1.14 (0.87)	-3.2	-1.33	-0.83	-0.67	0.2	
		Week 14	Tezepelumab	33	31 (93.9)	-1.26 (0.86)	-2.7	-2.00	-1.17	-0.50	0.5	-0.11 [-0.62, 0.40]
			Placebo	34	29 (85.3)	-1.17 (0.92)	-3.2	-1.50	-1.17	-0.67	0.7	
		Week 16	Tezepelumab	33	31 (93.9)	-1.17 (0.87)	-2.7	-2.17	-1.00	-0.50	0.5	-0.07 [-0.58, 0.44]
			Placebo	34	29 (85.3)	-1.11 (0.90)	-3.2	-1.50	-1.00	-0.50	0.5	
		Week 18	Tezepelumab	33	32 (97.0)	-1.07 (0.85)	-2.7	-1.83	-0.92	-0.42	0.5	-0.02 [-0.52, 0.49]
			Placebo	34	29 (85.3)	-1.06 (1.12)	-3.2	-1.67	-1.17	-0.17	1.5	
		Week 20	Tezepelumab	33	32 (97.0)	-1.09 (0.94)	-2.7	-2.00	-0.92	-0.42	0.7	-0.08 [-0.58, 0.43]
			Placebo	34	29 (85.3)	-1.02 (0.95)	-3.0	-1.50	-0.83	-0.50	0.8	
		Week 22	Tezepelumab	33	32 (97.0)	-1.05 (0.89)	-2.7	-1.83	-0.83	-0.58	0.5	-0.02 [-0.52, 0.48]
			Placebo	34	29 (85.3)	-1.03 (0.97)	-3.2	-1.50	-1.00	-0.50	1.2	
		Week 24	Tezepelumab	33	32 (97.0)	-1.09 (0.89)	-2.5	-2.00	-1.08	-0.42	0.7	-0.11 [-0.61, 0.39]
			Placebo	34	29 (85.3)	-0.98 (1.05)	-3.2	-1.67	-0.83	0.00	1.0	
		Week 26	Tezepelumab	33	33 (100.0)	-1.02 (0.99)	-2.7	-2.00	-0.83	-0.17	0.7	0.10 [-0.40, 0.60]
			Placebo	34	29 (85.3)	-1.11 (1.05)	-3.2	-1.83	-1.17	-0.50	1.5	
		Week 28	Tezepelumab	33	33 (100.0)	-1.04 (1.07)	-2.7	-2.00	-0.83	0.00	0.8	0.01 [-0.49, 0.50]
			Placebo	34	30 (88.2)	-1.04 (1.09)	-3.2	-1.83	-1.00	-0.33	1.5	
		Week 30	Tezepelumab	33	33 (100.0)	-0.98 (1.05)	-2.7	-2.00	-0.83	-0.17	1.8	0.00 [-0.49, 0.50]
			Placebo	34	30 (88.2)	-0.98 (1.05)	-3.2	-1.67	-1.08	-0.33	2.0	
		Week 32	Tezepelumab	33	33 (100.0)	-1.09 (0.95)	-2.7	-2.00	-1.00	-0.50	0.8	0.06 [-0.43, 0.56]
			Placebo	34	30 (88.2)	-1.14 (0.89)	-3.0	-1.83	-1.17	-0.33	0.3	
		Week 34	Tezepelumab	33	33 (100.0)	-1.02 (1.06)	-2.5	-2.00	-1.17	-0.33	2.0	0.17 [-0.32, 0.67]
			Placebo	34	30 (88.2)	-1.19 (0.93)	-3.2	-1.67	-1.00	-0.67	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 300 cells/uL	Change from baseline	Week 36	Tezepelumab	33	33 (100.0)	-1.09 (0.99)	-2.7	-2.00	-1.17	-0.50	1.5	-0.08 [-0.58, 0.41]
			Placebo	34	30 (88.2)	-1.01 (1.05)	-3.5	-1.33	-0.83	-0.33	0.7	
		Week 38	Tezepelumab	33	33 (100.0)	-1.04 (1.14)	-2.7	-2.00	-1.17	-0.17	2.3	-0.05 [-0.54, 0.45]
			Placebo	34	30 (88.2)	-0.99 (0.95)	-3.2	-1.33	-1.00	-0.33	0.5	
		Week 40	Tezepelumab	33	33 (100.0)	-1.01 (1.05)	-2.7	-2.00	-1.00	-0.33	1.7	-0.06 [-0.55, 0.44]
			Placebo	34	30 (88.2)	-0.95 (1.09)	-3.2	-1.67	-0.92	-0.17	1.2	
		Week 42	Tezepelumab	33	33 (100.0)	-1.02 (1.05)	-2.7	-2.00	-1.17	-0.33	2.0	0.02 [-0.47, 0.52]
			Placebo	34	30 (88.2)	-1.04 (0.93)	-2.8	-1.50	-1.08	-0.50	0.8	
		Week 44	Tezepelumab	33	33 (100.0)	-1.02 (0.99)	-2.7	-2.00	-1.00	-0.33	1.5	-0.06 [-0.55, 0.44]
			Placebo	34	30 (88.2)	-0.96 (1.05)	-3.3	-1.50	-0.92	-0.17	0.8	
		Week 46	Tezepelumab	33	33 (100.0)	-1.05 (1.04)	-2.7	-2.00	-1.00	-0.17	1.7	-0.06 [-0.55, 0.44]
			Placebo	34	30 (88.2)	-0.99 (0.98)	-3.2	-1.67	-0.83	-0.50	1.3	
		Week 48	Tezepelumab	33	33 (100.0)	-1.04 (1.01)	-2.7	-2.00	-0.83	-0.50	1.8	0.00 [-0.49, 0.50]
			Placebo	34	30 (88.2)	-1.04 (1.11)	-3.3	-1.50	-0.92	-0.33	1.7	
		Week 50	Tezepelumab	33	33 (100.0)	-1.01 (1.09)	-2.7	-2.00	-1.00	-0.17	1.8	0.07 [-0.42, 0.57]
			Placebo	34	30 (88.2)	-1.09 (1.09)	-3.5	-1.67	-0.92	-0.50	1.5	
		Week 52	Tezepelumab	33	33 (100.0)	-1.00 (1.08)	-2.7	-2.00	-1.00	-0.17	1.8	0.03 [-0.46, 0.53]
			Placebo	34	30 (88.2)	-1.03 (1.10)	-3.5	-1.67	-0.83	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	2.56 (0.88)	0.0	2.17	2.58	3.17	4.3	
			Placebo	31	31 (100.0)	2.66 (0.67)	1.3	2.33	2.67	3.00	4.7	
		Week 2	Tezepelumab	32	31 (96.9)	1.99 (0.92)	0.2	1.33	1.83	2.67	4.2	
			Placebo	31	30 (96.8)	2.28 (0.74)	1.0	1.67	2.33	2.83	4.7	
		Week 4	Tezepelumab	32	31 (96.9)	1.83 (0.84)	0.2	1.33	1.83	2.33	3.3	
			Placebo	31	30 (96.8)	2.27 (0.85)	0.7	1.83	2.42	2.67	4.2	
		Week 6	Tezepelumab	32	31 (96.9)	1.66 (0.97)	0.0	0.83	1.67	2.33	3.7	
			Placebo	31	30 (96.8)	2.28 (1.05)	0.2	1.83	2.33	2.83	5.5	
		Week 8	Tezepelumab	32	31 (96.9)	1.41 (0.93)	0.0	0.50	1.50	2.17	3.3	
			Placebo	31	30 (96.8)	2.16 (1.02)	0.0	1.83	2.25	2.83	4.7	
		Week 10	Tezepelumab	32	31 (96.9)	1.44 (0.96)	0.0	0.67	1.50	2.00	3.7	
			Placebo	31	30 (96.8)	2.19 (1.09)	0.0	1.83	2.17	2.83	5.3	
		Week 12	Tezepelumab	32	31 (96.9)	1.32 (0.92)	0.0	0.50	1.50	2.17	3.0	
			Placebo	31	30 (96.8)	2.05 (0.99)	0.0	1.50	2.17	2.67	4.2	
		Week 14	Tezepelumab	32	31 (96.9)	1.30 (1.01)	0.0	0.50	1.33	1.83	3.7	
			Placebo	31	30 (96.8)	1.94 (0.96)	0.0	1.33	2.08	2.50	5.0	
		Week 16	Tezepelumab	32	31 (96.9)	1.50 (1.10)	0.0	0.50	1.33	2.50	4.3	
			Placebo	31	30 (96.8)	2.22 (1.27)	0.0	1.17	2.25	2.83	5.0	
		Week 18	Tezepelumab	32	31 (96.9)	1.37 (0.93)	0.0	0.67	1.50	2.00	3.3	
			Placebo	31	30 (96.8)	2.00 (1.06)	0.0	1.67	2.17	2.33	5.0	
		Week 20	Tezepelumab	32	31 (96.9)	1.42 (0.97)	0.0	0.50	1.50	1.83	3.5	
			Placebo	31	30 (96.8)	2.15 (1.10)	0.0	1.67	2.25	2.83	5.0	
		Week 22	Tezepelumab	32	31 (96.9)	1.51 (0.91)	0.0	0.83	1.50	2.17	3.3	
			Placebo	31	30 (96.8)	2.08 (1.20)	0.0	1.17	2.08	2.83	5.0	
		Week 24	Tezepelumab	32	31 (96.9)	1.53 (1.01)	0.0	0.50	1.50	2.33	3.5	
			Placebo	31	30 (96.8)	2.16 (1.00)	0.0	1.67	2.17	2.83	4.2	
		Week 26	Tezepelumab	32	31 (96.9)	1.56 (0.98)	0.0	0.67	1.50	2.17	3.7	
			Placebo	31	30 (96.8)	2.15 (1.03)	0.0	1.50	2.08	3.00	4.2	
		Week 28	Tezepelumab	32	32 (100.0)	1.48 (1.05)	0.0	0.42	1.50	2.25	3.5	
			Placebo	31	30 (96.8)	2.14 (1.12)	0.0	1.00	2.17	2.83	4.2	
		Week 30	Tezepelumab	32	32 (100.0)	1.38 (0.96)	0.0	0.67	1.50	1.92	3.7	
			Placebo	31	30 (96.8)	2.05 (1.14)	0.0	1.17	2.08	2.83	4.2	
		Week 32	Tezepelumab	32	32 (100.0)	1.40 (0.99)	0.0	0.42	1.50	2.00	3.7	
			Placebo	31	30 (96.8)	2.14 (1.08)	0.0	1.50	2.00	2.67	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 300 cells/uL	Absolute values	Week 34	Tezepelumab	32	32 (100.0)	1.44 (1.08)	0.0	0.58	1.42	2.33	4.2	
			Placebo	31	30 (96.8)	2.12 (1.08)	0.0	1.33	2.17	2.67	4.5	
		Week 36	Tezepelumab	32	32 (100.0)	1.44 (0.98)	0.0	0.58	1.50	2.25	3.7	
			Placebo	31	30 (96.8)	2.27 (1.09)	0.0	1.50	2.17	2.83	4.5	
		Week 38	Tezepelumab	32	32 (100.0)	1.44 (1.03)	0.0	0.42	1.58	2.25	3.5	
			Placebo	31	30 (96.8)	1.99 (1.11)	0.0	1.17	2.08	2.50	4.5	
		Week 40	Tezepelumab	32	32 (100.0)	1.37 (1.02)	0.0	0.33	1.50	2.25	3.2	
			Placebo	31	30 (96.8)	2.24 (1.00)	0.0	1.67	2.25	2.83	4.2	
		Week 42	Tezepelumab	32	32 (100.0)	1.34 (0.97)	0.0	0.58	1.50	2.17	3.3	
			Placebo	31	30 (96.8)	2.04 (0.92)	0.0	1.50	1.92	2.50	4.5	
		Week 44	Tezepelumab	32	32 (100.0)	1.40 (1.00)	0.0	0.42	1.42	2.33	3.0	
			Placebo	31	30 (96.8)	2.12 (0.92)	0.0	1.67	2.08	2.83	4.2	
		Week 46	Tezepelumab	32	32 (100.0)	1.44 (1.05)	0.0	0.67	1.50	2.33	3.7	
			Placebo	31	30 (96.8)	1.94 (0.89)	0.0	1.33	2.00	2.50	3.8	
		Week 48	Tezepelumab	32	32 (100.0)	1.45 (1.08)	0.0	0.58	1.50	2.25	4.0	
			Placebo	31	30 (96.8)	2.08 (0.86)	0.0	1.67	2.17	2.50	3.8	
		Week 50	Tezepelumab	32	32 (100.0)	1.30 (0.99)	0.0	0.58	1.00	2.08	4.0	
			Placebo	31	30 (96.8)	1.92 (0.85)	0.0	1.33	1.83	2.33	3.8	
		Week 52	Tezepelumab	32	32 (100.0)	1.36 (0.96)	0.0	0.67	1.33	2.08	4.0	
			Placebo	31	30 (96.8)	2.02 (0.94)	0.0	1.50	2.17	2.67	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 2	Tezepelumab	32	31 (96.9)	-0.58 (0.67)	-2.0	-1.17	-0.50	-0.17	0.7	-0.24 [-0.74, 0.26]
			Placebo	31	30 (96.8)	-0.42 (0.70)	-2.2	-0.83	-0.25	0.00	1.0	
		Week 4	Tezepelumab	32	31 (96.9)	-0.74 (0.93)	-2.5	-1.17	-0.83	-0.17	2.3	-0.34 [-0.85, 0.17]
			Placebo	31	30 (96.8)	-0.42 (0.93)	-2.7	-1.17	-0.33	0.33	1.2	
		Week 6	Tezepelumab	32	31 (96.9)	-0.91 (1.12)	-2.7	-1.83	-1.00	-0.33	2.3	-0.48 [-0.99, 0.03]
			Placebo	31	30 (96.8)	-0.41 (0.94)	-2.8	-1.00	-0.25	0.17	1.5	
		Week 8	Tezepelumab	32	31 (96.9)	-1.16 (1.07)	-3.0	-1.83	-1.00	-0.67	2.3	-0.62 [-1.13, -0.10]
			Placebo	31	30 (96.8)	-0.53 (0.94)	-3.2	-1.00	-0.42	0.00	0.8	
		Week 10	Tezepelumab	32	31 (96.9)	-1.13 (1.14)	-3.2	-1.83	-1.17	-0.50	2.3	-0.53 [-1.04, -0.02]
			Placebo	31	30 (96.8)	-0.51 (1.22)	-3.3	-1.17	-0.50	0.00	2.7	
		Week 12	Tezepelumab	32	31 (96.9)	-1.25 (1.09)	-3.0	-2.00	-1.17	-0.67	2.3	-0.56 [-1.07, -0.05]
			Placebo	31	30 (96.8)	-0.64 (1.06)	-3.3	-1.00	-0.58	0.00	1.3	
		Week 14	Tezepelumab	32	31 (96.9)	-1.27 (1.16)	-3.7	-1.83	-1.33	-0.67	2.3	-0.46 [-0.97, 0.05]
			Placebo	31	30 (96.8)	-0.75 (1.09)	-3.0	-1.33	-0.83	-0.17	2.3	
		Week 16	Tezepelumab	32	31 (96.9)	-1.07 (1.21)	-3.0	-1.83	-1.17	-0.50	2.3	-0.49 [-1.00, 0.02]
			Placebo	31	30 (96.8)	-0.48 (1.22)	-3.2	-1.17	-0.42	0.17	2.3	
		Week 18	Tezepelumab	32	31 (96.9)	-1.20 (1.15)	-3.5	-1.83	-1.00	-0.67	2.3	-0.43 [-0.94, 0.08]
			Placebo	31	30 (96.8)	-0.69 (1.19)	-3.2	-1.50	-0.67	0.00	2.3	
		Week 20	Tezepelumab	32	31 (96.9)	-1.15 (1.08)	-3.2	-2.00	-1.33	-0.50	2.3	-0.53 [-1.04, -0.01]
			Placebo	31	30 (96.8)	-0.54 (1.22)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	32	31 (96.9)	-1.06 (1.17)	-3.0	-2.00	-1.00	-0.67	2.3	-0.38 [-0.88, 0.13]
			Placebo	31	30 (96.8)	-0.61 (1.22)	-3.3	-1.17	-0.58	0.00	2.3	
		Week 24	Tezepelumab	32	31 (96.9)	-1.04 (1.09)	-3.2	-1.67	-1.00	-0.33	2.3	-0.46 [-0.97, 0.05]
			Placebo	31	30 (96.8)	-0.54 (1.10)	-3.2	-1.33	-0.50	0.17	2.3	
		Week 26	Tezepelumab	32	31 (96.9)	-1.01 (1.10)	-2.8	-1.83	-1.00	-0.33	2.3	-0.41 [-0.92, 0.09]
			Placebo	31	30 (96.8)	-0.54 (1.15)	-2.8	-1.50	-0.58	0.33	2.3	
		Week 28	Tezepelumab	32	32 (100.0)	-1.08 (1.14)	-3.2	-2.00	-1.00	-0.50	2.3	-0.46 [-0.96, 0.05]
			Placebo	31	30 (96.8)	-0.56 (1.18)	-2.8	-1.50	-0.42	0.33	2.3	
		Week 30	Tezepelumab	32	32 (100.0)	-1.18 (1.12)	-3.5	-2.00	-1.17	-0.67	2.3	-0.46 [-0.96, 0.04]
			Placebo	31	30 (96.8)	-0.64 (1.22)	-2.8	-1.33	-0.83	0.17	2.3	
		Week 32	Tezepelumab	32	32 (100.0)	-1.17 (1.06)	-3.0	-1.83	-1.08	-0.67	2.3	-0.55 [-1.05, -0.04]
			Placebo	31	30 (96.8)	-0.55 (1.20)	-2.8	-1.50	-0.50	0.17	2.3	
		Week 34	Tezepelumab	32	32 (100.0)	-1.12 (1.14)	-2.8	-2.08	-1.08	-0.58	2.3	-0.47 [-0.98, 0.03]
			Placebo	31	30 (96.8)	-0.58 (1.15)	-2.8	-1.33	-0.67	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 300 cells/uL	Change from baseline	Week 36	Tezepelumab	32	32 (100.0)	-1.12 (1.17)	-3.0	-1.92	-1.17	-0.17	2.3	-0.60 [-1.11, -0.09]
			Placebo	31	30 (96.8)	-0.42 (1.14)	-2.3	-1.33	-0.42	0.33	2.3	
		Week 38	Tezepelumab	32	32 (100.0)	-1.12 (1.10)	-3.0	-2.00	-1.17	-0.50	2.3	-0.36 [-0.86, 0.14]
			Placebo	31	30 (96.8)	-0.71 (1.19)	-2.5	-1.33	-0.83	0.17	2.3	
		Week 40	Tezepelumab	32	32 (100.0)	-1.19 (1.15)	-3.2	-2.17	-1.08	-0.58	2.3	-0.64 [-1.15, -0.13]
			Placebo	31	30 (96.8)	-0.46 (1.17)	-2.3	-1.33	-0.58	0.33	2.3	
		Week 42	Tezepelumab	32	32 (100.0)	-1.22 (1.14)	-3.3	-2.08	-1.33	-0.50	2.3	-0.51 [-1.01, -0.00]
			Placebo	31	30 (96.8)	-0.66 (1.10)	-2.3	-1.33	-0.92	0.00	2.3	
		Week 44	Tezepelumab	32	32 (100.0)	-1.17 (1.20)	-3.5	-2.00	-1.17	-0.50	2.3	-0.51 [-1.02, -0.01]
			Placebo	31	30 (96.8)	-0.57 (1.11)	-2.3	-1.33	-0.75	0.00	2.3	
		Week 46	Tezepelumab	32	32 (100.0)	-1.12 (1.16)	-3.3	-2.00	-1.08	-0.33	2.3	-0.34 [-0.84, 0.17]
			Placebo	31	30 (96.8)	-0.75 (1.03)	-2.3	-1.33	-1.00	0.00	2.3	
		Week 48	Tezepelumab	32	32 (100.0)	-1.11 (1.16)	-2.7	-2.17	-1.00	-0.42	2.3	-0.46 [-0.97, 0.04]
			Placebo	31	30 (96.8)	-0.61 (1.00)	-2.5	-1.17	-0.83	0.17	2.3	
		Week 50	Tezepelumab	32	32 (100.0)	-1.26 (1.11)	-2.5	-2.25	-1.33	-0.67	2.3	-0.48 [-0.98, 0.03]
			Placebo	31	30 (96.8)	-0.77 (0.91)	-2.3	-1.33	-1.00	-0.33	2.3	
		Week 52	Tezepelumab	32	32 (100.0)	-1.20 (1.10)	-2.7	-2.00	-1.25	-0.67	2.3	-0.49 [-1.00, 0.01]
			Placebo	31	30 (96.8)	-0.68 (1.01)	-2.7	-1.17	-0.83	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	39	39 (100.0)	2.80 (0.66)	1.7	2.33	2.83	3.17	4.5	
			Placebo	30	30 (100.0)	2.64 (0.67)	0.3	2.33	2.75	3.00	3.5	
		Week 2	Tezepelumab	39	36 (92.3)	2.39 (1.03)	0.0	1.50	2.67	3.17	4.2	
			Placebo	30	25 (83.3)	2.25 (0.68)	0.3	2.00	2.33	2.67	3.2	
		Week 4	Tezepelumab	39	36 (92.3)	2.13 (0.89)	0.2	1.67	2.33	2.83	3.5	
			Placebo	30	25 (83.3)	1.98 (0.90)	0.2	1.33	2.17	2.67	3.5	
		Week 6	Tezepelumab	39	36 (92.3)	1.97 (0.96)	0.0	1.42	1.83	2.67	4.0	
			Placebo	30	25 (83.3)	1.97 (1.04)	0.2	1.17	2.00	2.67	4.7	
		Week 8	Tezepelumab	39	36 (92.3)	1.92 (1.13)	0.0	1.33	1.75	2.75	4.8	
			Placebo	30	25 (83.3)	2.09 (0.97)	0.0	1.83	2.17	2.83	3.5	
		Week 10	Tezepelumab	39	36 (92.3)	1.83 (1.10)	0.0	1.08	1.67	2.75	4.3	
			Placebo	30	25 (83.3)	1.89 (0.87)	0.0	1.67	2.17	2.33	3.2	
		Week 12	Tezepelumab	39	36 (92.3)	1.79 (1.07)	0.0	1.08	1.92	2.58	4.3	
			Placebo	30	25 (83.3)	1.77 (0.83)	0.0	1.33	2.00	2.17	3.2	
		Week 14	Tezepelumab	39	36 (92.3)	1.65 (1.07)	0.0	0.92	1.58	2.25	4.3	
			Placebo	30	25 (83.3)	1.62 (0.79)	0.3	1.00	1.67	2.17	3.2	
		Week 16	Tezepelumab	39	36 (92.3)	1.89 (1.14)	0.0	1.17	1.92	2.50	4.3	
			Placebo	30	25 (83.3)	1.78 (0.78)	0.2	1.50	1.83	2.17	3.2	
		Week 18	Tezepelumab	39	37 (94.9)	1.82 (1.04)	0.0	1.33	1.83	2.33	4.3	
			Placebo	30	25 (83.3)	1.80 (1.10)	0.0	1.00	1.83	2.67	4.7	
		Week 20	Tezepelumab	39	37 (94.9)	1.85 (1.13)	0.0	1.17	1.83	2.50	5.0	
			Placebo	30	25 (83.3)	1.77 (0.99)	0.2	0.83	1.83	2.67	3.3	
		Week 22	Tezepelumab	39	37 (94.9)	1.80 (1.03)	0.0	1.17	2.00	2.33	4.3	
			Placebo	30	25 (83.3)	1.69 (0.98)	0.0	1.00	2.00	2.33	3.7	
		Week 24	Tezepelumab	39	37 (94.9)	1.86 (1.08)	0.0	1.17	2.00	2.50	4.3	
			Placebo	30	25 (83.3)	1.78 (0.96)	0.2	0.83	2.00	2.50	3.5	
		Week 26	Tezepelumab	39	38 (97.4)	1.92 (1.12)	0.0	1.17	1.92	2.67	4.3	
			Placebo	30	25 (83.3)	1.75 (0.98)	0.3	1.00	1.67	2.17	4.0	
		Week 28	Tezepelumab	39	39 (100.0)	1.81 (1.12)	0.0	1.17	1.67	2.50	4.3	
			Placebo	30	26 (86.7)	1.72 (1.05)	0.0	0.83	1.92	2.33	4.0	
		Week 30	Tezepelumab	39	39 (100.0)	1.84 (1.11)	0.0	1.17	1.83	2.50	4.3	
			Placebo	30	26 (86.7)	1.64 (0.90)	0.0	0.83	1.83	2.50	3.0	
		Week 32	Tezepelumab	39	39 (100.0)	1.79 (1.09)	0.0	1.00	1.83	2.50	4.3	
			Placebo	30	26 (86.7)	1.54 (0.86)	0.0	0.83	1.67	2.17	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 25 ppb	Absolute values	Week 34	Tezepelumab	39	39 (100.0)	1.85 (1.18)	0.0	1.00	1.83	2.67	4.3	
			Placebo	30	26 (86.7)	1.61 (0.83)	0.0	0.83	1.83	2.17	2.8	
		Week 36	Tezepelumab	39	39 (100.0)	1.83 (1.08)	0.0	1.17	1.83	2.67	4.3	
			Placebo	30	26 (86.7)	1.62 (0.99)	0.0	0.83	1.83	2.33	3.2	
		Week 38	Tezepelumab	39	39 (100.0)	1.85 (1.21)	0.0	1.00	1.67	2.67	4.5	
			Placebo	30	26 (86.7)	1.62 (0.90)	0.0	1.00	1.83	2.17	3.2	
		Week 40	Tezepelumab	39	39 (100.0)	1.86 (1.15)	0.0	1.00	2.00	2.67	4.3	
			Placebo	30	26 (86.7)	1.71 (1.08)	0.0	0.67	1.83	2.33	4.0	
		Week 42	Tezepelumab	39	39 (100.0)	1.86 (1.12)	0.0	1.00	1.83	2.67	4.3	
			Placebo	30	26 (86.7)	1.63 (0.90)	0.0	0.83	1.83	2.33	3.3	
		Week 44	Tezepelumab	39	39 (100.0)	1.90 (1.09)	0.0	1.17	2.00	2.67	4.3	
			Placebo	30	26 (86.7)	1.78 (0.98)	0.0	1.17	1.83	2.50	4.0	
		Week 46	Tezepelumab	39	39 (100.0)	1.91 (1.11)	0.0	1.17	2.00	2.67	4.3	
			Placebo	30	26 (86.7)	1.60 (0.92)	0.0	0.83	1.83	2.17	3.8	
		Week 48	Tezepelumab	39	39 (100.0)	1.88 (1.12)	0.0	1.17	2.00	2.67	4.3	
			Placebo	30	26 (86.7)	1.57 (1.03)	0.0	0.83	1.67	2.17	4.2	
		Week 50	Tezepelumab	39	39 (100.0)	1.88 (1.20)	0.0	1.17	1.83	2.67	4.3	
			Placebo	30	26 (86.7)	1.57 (0.86)	0.0	1.00	1.67	2.17	3.7	
		Week 52	Tezepelumab	39	39 (100.0)	1.91 (1.17)	0.0	1.17	1.83	2.50	4.3	
			Placebo	30	26 (86.7)	1.70 (0.93)	0.0	1.17	1.83	2.33	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 2	Tezepelumab	39	36 (92.3)	-0.48 (0.75)	-2.8	-0.83	-0.33	0.17	0.7	0.09 [-0.42, 0.60]
			Placebo	30	25 (83.3)	-0.55 (0.71)	-2.8	-0.83	-0.33	-0.17	0.3	
		Week 4	Tezepelumab	39	36 (92.3)	-0.74 (0.60)	-2.0	-1.08	-0.67	-0.33	0.2	0.09 [-0.42, 0.60]
			Placebo	30	25 (83.3)	-0.81 (0.96)	-3.0	-1.50	-0.67	-0.17	0.5	
		Week 6	Tezepelumab	39	36 (92.3)	-0.90 (0.70)	-2.5	-1.33	-1.00	-0.33	0.2	-0.09 [-0.60, 0.42]
			Placebo	30	25 (83.3)	-0.82 (1.09)	-3.3	-1.33	-0.67	-0.17	1.5	
		Week 8	Tezepelumab	39	36 (92.3)	-0.95 (0.95)	-3.0	-1.50	-1.00	-0.50	2.2	-0.24 [-0.75, 0.27]
			Placebo	30	25 (83.3)	-0.71 (1.07)	-3.2	-1.17	-0.67	0.17	1.0	
		Week 10	Tezepelumab	39	36 (92.3)	-1.04 (0.86)	-3.2	-1.50	-1.17	-0.42	0.5	-0.14 [-0.66, 0.37]
			Placebo	30	25 (83.3)	-0.91 (0.95)	-3.3	-1.33	-0.67	-0.33	0.3	
		Week 12	Tezepelumab	39	36 (92.3)	-1.08 (0.85)	-2.8	-1.92	-1.08	-0.58	0.5	-0.06 [-0.57, 0.45]
			Placebo	30	25 (83.3)	-1.03 (0.95)	-3.3	-1.50	-0.83	-0.33	0.3	
		Week 14	Tezepelumab	39	36 (92.3)	-1.22 (0.83)	-3.2	-1.92	-1.17	-0.67	0.5	-0.05 [-0.57, 0.46]
			Placebo	30	25 (83.3)	-1.17 (0.97)	-3.2	-1.83	-1.33	-0.33	0.3	
		Week 16	Tezepelumab	39	36 (92.3)	-0.98 (0.93)	-3.0	-1.67	-1.00	-0.42	1.5	0.03 [-0.48, 0.54]
			Placebo	30	25 (83.3)	-1.01 (0.96)	-3.2	-1.33	-1.17	-0.33	0.3	
		Week 18	Tezepelumab	39	37 (94.9)	-1.02 (0.82)	-3.2	-1.50	-1.00	-0.67	0.5	-0.03 [-0.53, 0.48]
			Placebo	30	25 (83.3)	-0.99 (1.18)	-3.2	-1.83	-1.17	-0.17	1.5	
		Week 20	Tezepelumab	39	37 (94.9)	-1.00 (0.91)	-3.2	-1.67	-0.83	-0.33	0.7	0.03 [-0.48, 0.54]
			Placebo	30	25 (83.3)	-1.03 (1.15)	-3.2	-1.83	-0.83	-0.17	1.0	
		Week 22	Tezepelumab	39	37 (94.9)	-1.04 (0.82)	-3.0	-1.83	-0.83	-0.67	0.5	0.07 [-0.44, 0.58]
			Placebo	30	25 (83.3)	-1.11 (1.12)	-3.3	-1.83	-1.00	-0.33	1.2	
		Week 24	Tezepelumab	39	37 (94.9)	-0.98 (0.87)	-3.2	-1.67	-0.67	-0.33	0.7	0.04 [-0.47, 0.54]
			Placebo	30	25 (83.3)	-1.01 (1.13)	-3.2	-1.67	-1.00	-0.17	1.0	
		Week 26	Tezepelumab	39	38 (97.4)	-0.89 (0.92)	-2.8	-1.83	-0.67	0.00	0.7	0.16 [-0.35, 0.66]
			Placebo	30	25 (83.3)	-1.05 (1.10)	-2.8	-1.83	-1.17	-0.33	1.5	
		Week 28	Tezepelumab	39	39 (100.0)	-0.99 (1.01)	-3.2	-2.00	-0.83	0.00	0.8	-0.02 [-0.51, 0.48]
			Placebo	30	26 (86.7)	-0.97 (1.11)	-2.8	-1.83	-1.00	-0.33	1.5	
		Week 30	Tezepelumab	39	39 (100.0)	-0.96 (0.99)	-2.7	-2.00	-0.83	-0.17	1.8	0.10 [-0.40, 0.60]
			Placebo	30	26 (86.7)	-1.06 (0.99)	-3.2	-1.83	-1.08	-0.33	0.5	
		Week 32	Tezepelumab	39	39 (100.0)	-1.01 (0.91)	-3.0	-2.00	-1.00	-0.50	0.8	0.16 [-0.34, 0.65]
			Placebo	30	26 (86.7)	-1.16 (1.01)	-3.0	-1.83	-1.08	-0.33	0.7	
		Week 34	Tezepelumab	39	39 (100.0)	-0.95 (1.05)	-2.8	-1.83	-0.83	-0.17	2.0	0.14 [-0.36, 0.63]
			Placebo	30	26 (86.7)	-1.09 (0.95)	-3.2	-1.67	-0.92	-0.67	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 25 ppb	Change from baseline	Week 36	Tezepelumab	39	39 (100.0)	-0.97 (0.95)	-3.0	-1.83	-1.00	-0.17	1.5	0.11 [-0.39, 0.60]
			Placebo	30	26 (86.7)	-1.08 (1.08)	-3.5	-1.83	-0.92	-0.33	0.7	
		Week 38	Tezepelumab	39	39 (100.0)	-0.95 (1.07)	-3.0	-2.00	-1.00	-0.17	2.3	0.13 [-0.37, 0.62]
			Placebo	30	26 (86.7)	-1.08 (0.95)	-3.2	-1.67	-1.00	-0.33	0.3	
		Week 40	Tezepelumab	39	39 (100.0)	-0.94 (1.00)	-3.2	-2.00	-0.83	-0.33	1.7	0.04 [-0.45, 0.54]
			Placebo	30	26 (86.7)	-0.99 (1.12)	-3.2	-2.00	-1.08	-0.17	1.2	
		Week 42	Tezepelumab	39	39 (100.0)	-0.94 (0.98)	-2.7	-1.83	-0.83	-0.50	2.0	0.13 [-0.37, 0.63]
			Placebo	30	26 (86.7)	-1.06 (0.94)	-2.8	-1.50	-1.17	-0.50	0.8	
		Week 44	Tezepelumab	39	39 (100.0)	-0.90 (0.96)	-3.2	-1.83	-0.83	-0.17	1.5	0.02 [-0.48, 0.51]
			Placebo	30	26 (86.7)	-0.92 (1.03)	-3.3	-1.50	-0.83	-0.17	0.8	
		Week 46	Tezepelumab	39	39 (100.0)	-0.88 (0.96)	-2.5	-2.00	-0.83	-0.17	1.7	0.22 [-0.27, 0.72]
			Placebo	30	26 (86.7)	-1.10 (1.00)	-3.2	-1.67	-1.00	-0.67	1.3	
		Week 48	Tezepelumab	39	39 (100.0)	-0.92 (0.96)	-2.5	-1.83	-0.83	-0.33	1.8	0.20 [-0.30, 0.70]
			Placebo	30	26 (86.7)	-1.13 (1.15)	-3.3	-1.83	-0.83	-0.50	1.7	
		Week 50	Tezepelumab	39	39 (100.0)	-0.92 (1.02)	-2.7	-1.67	-0.83	-0.17	1.8	0.21 [-0.29, 0.70]
			Placebo	30	26 (86.7)	-1.13 (1.01)	-3.5	-1.67	-1.08	-0.67	1.5	
		Week 52	Tezepelumab	39	39 (100.0)	-0.89 (0.99)	-2.7	-1.67	-0.83	-0.17	1.8	0.10 [-0.39, 0.60]
			Placebo	30	26 (86.7)	-1.00 (1.10)	-3.5	-1.67	-0.83	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	2.59 (1.02)	0.0	2.17	2.50	3.17	4.8	
			Placebo	34	34 (100.0)	2.78 (0.77)	1.3	2.33	2.75	3.17	4.7	
		Week 2	Tezepelumab	27	27 (100.0)	2.01 (0.82)	0.2	1.33	2.00	2.67	3.3	
			Placebo	34	32 (94.1)	2.33 (0.86)	0.5	1.92	2.25	2.67	4.8	
		Week 4	Tezepelumab	27	27 (100.0)	1.77 (1.00)	0.2	1.00	1.83	2.67	3.3	
			Placebo	34	32 (94.1)	2.28 (0.93)	0.3	1.75	2.42	2.75	4.2	
		Week 6	Tezepelumab	27	27 (100.0)	1.77 (1.06)	0.0	0.67	1.83	2.67	3.7	
			Placebo	34	32 (94.1)	2.22 (1.17)	0.2	1.42	2.33	2.92	5.5	
		Week 8	Tezepelumab	27	27 (100.0)	1.51 (1.04)	0.0	0.50	1.67	2.50	3.3	
			Placebo	34	33 (97.1)	2.08 (1.17)	0.0	1.17	2.17	2.50	4.7	
		Week 10	Tezepelumab	27	27 (100.0)	1.43 (1.03)	0.0	0.50	1.33	2.33	3.2	
			Placebo	34	33 (97.1)	2.14 (1.12)	0.0	1.50	2.33	2.83	5.3	
		Week 12	Tezepelumab	27	27 (100.0)	1.25 (0.96)	0.0	0.50	1.17	2.17	2.8	
			Placebo	34	33 (97.1)	1.95 (1.11)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	27	27 (100.0)	1.27 (1.00)	0.0	0.50	1.17	2.17	3.7	
			Placebo	34	33 (97.1)	1.94 (1.09)	0.0	1.50	2.00	2.33	5.0	
		Week 16	Tezepelumab	27	27 (100.0)	1.29 (1.00)	0.0	0.33	1.33	1.83	3.3	
			Placebo	34	33 (97.1)	2.13 (1.35)	0.0	1.00	2.17	2.67	5.0	
		Week 18	Tezepelumab	27	27 (100.0)	1.29 (0.94)	0.0	0.67	1.00	2.00	3.3	
			Placebo	34	33 (97.1)	1.96 (1.17)	0.0	1.33	2.17	2.50	5.0	
		Week 20	Tezepelumab	27	27 (100.0)	1.30 (0.95)	0.0	0.50	1.17	1.83	3.5	
			Placebo	34	33 (97.1)	2.16 (1.12)	0.0	1.33	2.33	2.67	5.0	
		Week 22	Tezepelumab	27	27 (100.0)	1.51 (0.87)	0.0	0.83	1.50	2.17	3.3	
			Placebo	34	33 (97.1)	2.15 (1.21)	0.0	1.17	2.17	2.83	5.0	
		Week 24	Tezepelumab	27	27 (100.0)	1.40 (0.97)	0.0	0.50	1.17	2.33	3.5	
			Placebo	34	33 (97.1)	2.19 (1.07)	0.0	1.67	2.17	2.83	4.5	
		Week 26	Tezepelumab	27	27 (100.0)	1.41 (0.94)	0.0	0.50	1.50	2.17	2.8	
			Placebo	34	33 (97.1)	2.09 (1.18)	0.0	1.17	2.00	3.00	4.5	
		Week 28	Tezepelumab	27	27 (100.0)	1.44 (1.03)	0.0	0.33	1.50	2.33	3.5	
			Placebo	34	33 (97.1)	2.09 (1.27)	0.0	1.00	2.17	3.00	4.5	
		Week 30	Tezepelumab	27	27 (100.0)	1.33 (0.91)	0.0	0.67	1.33	2.00	3.2	
			Placebo	34	33 (97.1)	2.13 (1.26)	0.0	1.17	2.17	3.00	4.5	
		Week 32	Tezepelumab	27	27 (100.0)	1.27 (0.96)	0.0	0.33	1.17	2.17	2.8	
			Placebo	34	33 (97.1)	2.15 (1.19)	0.0	1.17	2.00	3.00	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 25 ppb	Absolute values	Week 34	Tezepelumab	27	27 (100.0)	1.34 (0.97)	0.0	0.50	1.33	2.17	2.8	
			Placebo	34	33 (97.1)	2.03 (1.24)	0.0	1.17	2.00	3.00	4.5	
		Week 36	Tezepelumab	27	27 (100.0)	1.29 (0.94)	0.0	0.50	1.17	2.17	2.8	
			Placebo	34	33 (97.1)	2.30 (1.16)	0.0	1.50	2.17	3.00	4.5	
		Week 38	Tezepelumab	27	27 (100.0)	1.31 (0.98)	0.0	0.17	1.33	2.00	2.8	
			Placebo	34	33 (97.1)	2.04 (1.22)	0.0	1.17	2.17	2.83	4.5	
		Week 40	Tezepelumab	27	27 (100.0)	1.25 (0.98)	0.0	0.33	1.00	2.00	2.8	
			Placebo	34	33 (97.1)	2.22 (1.15)	0.0	1.33	2.50	2.83	4.5	
		Week 42	Tezepelumab	27	27 (100.0)	1.19 (0.92)	0.0	0.50	1.00	1.83	2.8	
			Placebo	34	33 (97.1)	2.01 (1.10)	0.0	1.33	2.00	2.50	4.5	
		Week 44	Tezepelumab	27	27 (100.0)	1.20 (0.94)	0.0	0.33	1.00	2.17	2.8	
			Placebo	34	33 (97.1)	2.05 (1.13)	0.0	1.17	2.17	2.83	4.5	
		Week 46	Tezepelumab	27	27 (100.0)	1.21 (1.00)	0.0	0.33	1.00	2.17	3.0	
			Placebo	34	33 (97.1)	2.01 (1.01)	0.0	1.50	2.00	2.50	4.5	
		Week 48	Tezepelumab	27	27 (100.0)	1.27 (1.01)	0.0	0.50	1.00	2.00	3.0	
			Placebo	34	33 (97.1)	2.11 (1.02)	0.0	1.67	2.17	2.67	4.5	
		Week 50	Tezepelumab	27	27 (100.0)	1.13 (0.87)	0.0	0.50	1.00	1.67	2.8	
			Placebo	34	33 (97.1)	1.91 (1.08)	0.0	1.00	2.00	2.50	4.5	
		Week 52	Tezepelumab	27	27 (100.0)	1.17 (0.89)	0.0	0.50	1.00	2.00	2.8	
			Placebo	34	33 (97.1)	1.95 (1.13)	0.0	1.00	2.17	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 2	Tezepelumab	27	27 (100.0)	-0.58 (0.66)	-2.0	-1.00	-0.50	0.00	0.7	-0.29 [-0.81, 0.22]
			Placebo	34	32 (94.1)	-0.39 (0.67)	-1.5	-0.92	-0.33	0.00	1.0	
		Week 4	Tezepelumab	27	27 (100.0)	-0.82 (1.07)	-2.5	-1.50	-0.83	-0.17	2.3	-0.41 [-0.93, 0.11]
			Placebo	34	32 (94.1)	-0.43 (0.82)	-2.0	-1.17	-0.25	0.08	1.2	
		Week 6	Tezepelumab	27	27 (100.0)	-0.83 (1.20)	-2.7	-1.83	-0.83	0.17	2.3	-0.32 [-0.83, 0.20]
			Placebo	34	32 (94.1)	-0.49 (0.90)	-2.2	-1.17	-0.33	0.08	1.5	
		Week 8	Tezepelumab	27	27 (100.0)	-1.09 (1.16)	-2.8	-1.83	-1.00	-0.33	2.3	-0.42 [-0.93, 0.10]
			Placebo	34	33 (97.1)	-0.65 (0.96)	-3.0	-1.00	-0.50	0.00	1.0	
		Week 10	Tezepelumab	27	27 (100.0)	-1.17 (1.20)	-2.8	-2.00	-1.17	-0.50	2.3	-0.50 [-1.01, 0.02]
			Placebo	34	33 (97.1)	-0.59 (1.14)	-2.3	-1.33	-0.50	0.00	2.7	
		Week 12	Tezepelumab	27	27 (100.0)	-1.34 (1.17)	-3.0	-2.17	-1.33	-0.67	2.3	-0.52 [-1.03, 0.00]
			Placebo	34	33 (97.1)	-0.77 (1.03)	-3.2	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	27	27 (100.0)	-1.32 (1.21)	-3.7	-2.17	-1.33	-0.67	2.3	-0.48 [-0.99, 0.04]
			Placebo	34	33 (97.1)	-0.78 (1.06)	-3.2	-1.33	-0.83	-0.50	2.3	
		Week 16	Tezepelumab	27	27 (100.0)	-1.30 (1.15)	-2.8	-2.17	-1.33	-0.83	2.3	-0.60 [-1.12, -0.08]
			Placebo	34	33 (97.1)	-0.60 (1.21)	-3.2	-1.17	-0.50	0.00	2.3	
		Week 18	Tezepelumab	27	27 (100.0)	-1.30 (1.19)	-3.5	-2.17	-1.33	-0.67	2.3	-0.46 [-0.98, 0.06]
			Placebo	34	33 (97.1)	-0.76 (1.16)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	27	27 (100.0)	-1.29 (1.10)	-2.7	-2.00	-1.50	-0.67	2.3	-0.67 [-1.19, -0.15]
			Placebo	34	33 (97.1)	-0.57 (1.07)	-2.5	-1.00	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	27	27 (100.0)	-1.08 (1.25)	-2.7	-2.17	-1.17	-0.67	2.3	-0.43 [-0.94, 0.08]
			Placebo	34	33 (97.1)	-0.58 (1.08)	-2.5	-1.17	-0.67	0.00	2.3	
		Week 24	Tezepelumab	27	27 (100.0)	-1.20 (1.11)	-2.7	-1.83	-1.50	-0.50	2.3	-0.61 [-1.13, -0.09]
			Placebo	34	33 (97.1)	-0.54 (1.04)	-2.5	-1.17	-0.50	0.17	2.3	
		Week 26	Tezepelumab	27	27 (100.0)	-1.19 (1.16)	-2.8	-2.33	-1.17	-0.33	2.3	-0.48 [-0.99, 0.04]
			Placebo	34	33 (97.1)	-0.64 (1.15)	-3.2	-1.33	-0.67	0.17	2.3	
		Week 28	Tezepelumab	27	27 (100.0)	-1.15 (1.20)	-2.8	-2.17	-1.17	-0.17	2.3	-0.43 [-0.94, 0.09]
			Placebo	34	33 (97.1)	-0.64 (1.20)	-3.2	-1.50	-0.83	0.17	2.3	
		Week 30	Tezepelumab	27	27 (100.0)	-1.27 (1.18)	-3.5	-2.33	-1.33	-0.67	2.3	-0.55 [-1.07, -0.03]
			Placebo	34	33 (97.1)	-0.60 (1.23)	-2.5	-1.33	-0.83	0.17	2.3	
		Week 32	Tezepelumab	27	27 (100.0)	-1.32 (1.11)	-2.7	-2.17	-1.67	-0.67	2.3	-0.67 [-1.19, -0.14]
			Placebo	34	33 (97.1)	-0.58 (1.11)	-2.5	-1.33	-0.67	0.17	2.3	
		Week 34	Tezepelumab	27	27 (100.0)	-1.25 (1.14)	-2.5	-2.17	-1.50	-0.67	2.3	-0.48 [-0.99, 0.04]
			Placebo	34	33 (97.1)	-0.70 (1.17)	-2.8	-1.33	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 25 ppb	Change from baseline	Week 36	Tezepelumab	27	27 (100.0)	-1.30 (1.21)	-2.8	-2.33	-1.50	-0.50	2.3	-0.76 [-1.29, -0.23]
			Placebo	34	33 (97.1)	-0.42 (1.11)	-2.5	-1.17	-0.67	0.17	2.3	
		Week 38	Tezepelumab	27	27 (100.0)	-1.28 (1.15)	-2.8	-2.17	-1.33	-0.67	2.3	-0.51 [-1.03, 0.01]
			Placebo	34	33 (97.1)	-0.69 (1.17)	-2.5	-1.33	-0.83	0.17	2.3	
		Week 40	Tezepelumab	27	27 (100.0)	-1.35 (1.19)	-2.8	-2.50	-1.50	-0.67	2.3	-0.72 [-1.24, -0.19]
			Placebo	34	33 (97.1)	-0.51 (1.15)	-2.5	-1.33	-0.67	0.33	2.3	
		Week 42	Tezepelumab	27	27 (100.0)	-1.41 (1.20)	-3.3	-2.17	-1.67	-0.50	2.3	-0.61 [-1.13, -0.09]
			Placebo	34	33 (97.1)	-0.72 (1.08)	-2.5	-1.33	-1.00	-0.17	2.3	
		Week 44	Tezepelumab	27	27 (100.0)	-1.39 (1.20)	-3.5	-2.50	-1.50	-0.67	2.3	-0.61 [-1.13, -0.08]
			Placebo	34	33 (97.1)	-0.68 (1.14)	-2.7	-1.33	-0.83	0.00	2.3	
		Week 46	Tezepelumab	27	27 (100.0)	-1.38 (1.20)	-3.3	-2.50	-1.50	-0.83	2.3	-0.61 [-1.13, -0.09]
			Placebo	34	33 (97.1)	-0.72 (0.98)	-2.5	-1.33	-0.83	-0.17	2.3	
		Week 48	Tezepelumab	27	27 (100.0)	-1.32 (1.20)	-2.7	-2.50	-1.50	-0.50	2.3	-0.65 [-1.17, -0.13]
			Placebo	34	33 (97.1)	-0.62 (0.96)	-2.5	-1.17	-0.83	0.17	2.3	
		Week 50	Tezepelumab	27	27 (100.0)	-1.46 (1.13)	-2.7	-2.50	-1.67	-1.00	2.3	-0.61 [-1.13, -0.09]
			Placebo	34	33 (97.1)	-0.81 (0.99)	-3.0	-1.17	-0.83	-0.33	2.3	
		Week 52	Tezepelumab	27	27 (100.0)	-1.43 (1.15)	-2.7	-2.50	-1.67	-0.83	2.3	-0.59 [-1.11, -0.07]
			Placebo	34	33 (97.1)	-0.78 (1.04)	-3.0	-1.17	-0.83	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	2.80 (0.65)	1.7	2.33	2.83	2.83	4.5	
			Placebo	29	29 (100.0)	2.63 (0.66)	1.3	2.33	2.67	3.00	4.3	
		Week 2	Tezepelumab	27	26 (96.3)	2.28 (0.87)	0.3	1.50	2.58	3.00	3.7	
			Placebo	29	26 (89.7)	2.21 (0.80)	0.3	1.83	2.25	2.50	4.8	
		Week 4	Tezepelumab	27	26 (96.3)	1.97 (0.83)	0.3	1.33	2.08	2.67	3.5	
			Placebo	29	26 (89.7)	2.28 (0.93)	0.2	1.67	2.33	2.67	4.2	
		Week 6	Tezepelumab	27	26 (96.3)	1.77 (0.97)	0.0	1.33	1.67	2.50	3.7	
			Placebo	29	26 (89.7)	2.16 (1.11)	0.2	1.50	2.00	2.67	4.7	
		Week 8	Tezepelumab	27	26 (96.3)	1.73 (1.12)	0.0	1.33	1.58	2.33	4.8	
			Placebo	29	27 (93.1)	2.14 (1.06)	0.0	1.67	2.17	2.67	4.7	
		Week 10	Tezepelumab	27	26 (96.3)	1.64 (1.07)	0.0	1.00	1.75	2.17	4.3	
			Placebo	29	27 (93.1)	2.09 (1.00)	0.2	1.33	2.17	2.67	4.2	
		Week 12	Tezepelumab	27	26 (96.3)	1.54 (1.07)	0.0	0.67	1.50	2.33	4.3	
			Placebo	29	27 (93.1)	2.01 (1.01)	0.2	1.33	2.00	2.67	4.3	
		Week 14	Tezepelumab	27	26 (96.3)	1.43 (1.04)	0.0	0.67	1.50	2.17	4.3	
			Placebo	29	27 (93.1)	1.77 (0.99)	0.3	1.00	1.67	2.17	5.0	
		Week 16	Tezepelumab	27	26 (96.3)	1.49 (1.06)	0.0	0.67	1.42	2.17	4.3	
			Placebo	29	27 (93.1)	2.04 (1.16)	0.3	0.67	2.17	3.00	4.5	
		Week 18	Tezepelumab	27	26 (96.3)	1.42 (1.03)	0.0	0.67	1.50	2.00	4.3	
			Placebo	29	27 (93.1)	1.78 (1.05)	0.0	1.00	1.83	2.33	4.5	
		Week 20	Tezepelumab	27	26 (96.3)	1.51 (1.08)	0.0	0.50	1.50	2.33	4.3	
			Placebo	29	27 (93.1)	2.07 (1.15)	0.2	1.17	2.33	2.83	4.5	
		Week 22	Tezepelumab	27	26 (96.3)	1.62 (1.04)	0.0	0.67	1.75	2.33	4.3	
			Placebo	29	27 (93.1)	1.99 (1.23)	0.0	0.83	2.00	2.83	4.5	
		Week 24	Tezepelumab	27	26 (96.3)	1.61 (1.05)	0.0	1.00	1.67	2.33	4.3	
			Placebo	29	27 (93.1)	2.13 (1.13)	0.2	1.33	2.33	3.00	4.5	
		Week 26	Tezepelumab	27	27 (100.0)	1.59 (1.06)	0.0	0.83	1.50	2.17	4.3	
			Placebo	29	27 (93.1)	2.04 (1.20)	0.3	1.00	2.00	3.00	4.5	
		Week 28	Tezepelumab	27	27 (100.0)	1.61 (1.08)	0.0	0.83	1.50	2.33	4.3	
			Placebo	29	27 (93.1)	2.20 (1.19)	0.3	1.00	2.17	3.33	4.5	
		Week 30	Tezepelumab	27	27 (100.0)	1.62 (1.10)	0.0	0.83	1.50	2.17	4.3	
			Placebo	29	27 (93.1)	2.07 (1.19)	0.0	1.00	2.00	3.00	4.5	
		Week 32	Tezepelumab	27	27 (100.0)	1.60 (1.10)	0.0	0.50	1.83	2.50	4.3	
			Placebo	29	27 (93.1)	2.06 (1.20)	0.3	1.17	2.00	2.83	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Absolute values	Week 34	Tezepelumab	27	27 (100.0)	1.65 (1.16)	0.0	0.67	1.50	2.67	4.3	
			Placebo	29	27 (93.1)	1.94 (1.22)	0.0	1.00	1.83	2.83	4.5	
		Week 36	Tezepelumab	27	27 (100.0)	1.59 (1.13)	0.0	0.67	1.50	2.67	4.3	
			Placebo	29	27 (93.1)	2.28 (1.21)	0.0	1.50	2.33	3.17	4.5	
		Week 38	Tezepelumab	27	27 (100.0)	1.73 (1.22)	0.0	0.83	1.67	2.67	4.3	
			Placebo	29	27 (93.1)	1.96 (1.20)	0.0	1.00	2.00	2.67	4.5	
		Week 40	Tezepelumab	27	27 (100.0)	1.65 (1.16)	0.0	0.50	1.83	2.50	4.3	
			Placebo	29	27 (93.1)	2.28 (1.11)	0.3	1.33	2.33	3.00	4.5	
		Week 42	Tezepelumab	27	27 (100.0)	1.66 (1.19)	0.0	0.83	1.67	2.50	4.3	
			Placebo	29	27 (93.1)	2.02 (1.12)	0.3	1.33	2.00	2.50	4.5	
		Week 44	Tezepelumab	27	27 (100.0)	1.62 (1.16)	0.0	0.67	1.67	2.67	4.3	
			Placebo	29	27 (93.1)	2.30 (1.06)	0.3	1.50	2.33	3.00	4.5	
		Week 46	Tezepelumab	27	27 (100.0)	1.72 (1.17)	0.0	0.83	1.83	2.67	4.3	
			Placebo	29	27 (93.1)	2.05 (1.09)	0.0	1.67	2.00	2.50	4.5	
		Week 48	Tezepelumab	27	27 (100.0)	1.70 (1.15)	0.0	0.67	1.67	2.67	4.3	
			Placebo	29	27 (93.1)	2.20 (1.09)	0.0	1.67	2.17	2.67	4.5	
		Week 50	Tezepelumab	27	27 (100.0)	1.70 (1.12)	0.0	1.00	1.67	2.50	4.3	
			Placebo	29	27 (93.1)	1.94 (1.00)	0.3	1.00	1.83	2.50	4.5	
		Week 52	Tezepelumab	27	27 (100.0)	1.68 (1.15)	0.0	1.00	1.67	2.50	4.3	
			Placebo	29	27 (93.1)	2.08 (1.04)	0.3	1.00	2.17	2.67	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	27	26 (96.3)	-0.56 (0.60)	-1.8	-1.00	-0.42	0.00	0.2	-0.21 [-0.76, 0.33]
			Placebo	29	26 (89.7)	-0.41 (0.83)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	27	26 (96.3)	-0.87 (0.72)	-2.3	-1.33	-0.83	-0.33	0.2	-0.65 [-1.21, -0.09]
			Placebo	29	26 (89.7)	-0.34 (0.91)	-2.3	-0.83	-0.17	0.33	1.2	
		Week 6	Tezepelumab	27	26 (96.3)	-1.07 (0.92)	-2.5	-1.83	-1.08	-0.67	1.2	-0.63 [-1.19, -0.07]
			Placebo	29	26 (89.7)	-0.46 (1.04)	-2.3	-1.33	-0.42	0.33	1.5	
		Week 8	Tezepelumab	27	26 (96.3)	-1.11 (1.13)	-3.0	-1.67	-1.17	-0.33	2.2	-0.59 [-1.14, -0.04]
			Placebo	29	27 (93.1)	-0.49 (0.94)	-2.5	-1.00	-0.33	0.17	1.0	
		Week 10	Tezepelumab	27	26 (96.3)	-1.20 (0.98)	-3.2	-1.67	-1.25	-0.67	0.5	-0.62 [-1.17, -0.07]
			Placebo	29	27 (93.1)	-0.54 (1.12)	-2.3	-1.17	-0.50	0.00	2.5	
		Week 12	Tezepelumab	27	26 (96.3)	-1.29 (1.00)	-3.0	-2.17	-1.17	-0.67	0.5	-0.69 [-1.24, -0.13]
			Placebo	29	27 (93.1)	-0.63 (0.94)	-2.7	-1.17	-0.67	0.00	1.3	
		Week 14	Tezepelumab	27	26 (96.3)	-1.41 (1.04)	-3.7	-2.00	-1.42	-0.67	0.5	-0.55 [-1.10, 0.00]
			Placebo	29	27 (93.1)	-0.86 (0.96)	-2.5	-1.50	-1.00	-0.33	1.2	
		Week 16	Tezepelumab	27	26 (96.3)	-1.35 (1.00)	-3.0	-2.17	-1.08	-0.67	0.5	-0.74 [-1.29, -0.18]
			Placebo	29	27 (93.1)	-0.59 (1.04)	-2.5	-1.33	-0.67	0.17	2.3	
		Week 18	Tezepelumab	27	26 (96.3)	-1.42 (0.99)	-3.5	-2.00	-1.33	-0.83	0.5	-0.54 [-1.09, 0.01]
			Placebo	29	27 (93.1)	-0.85 (1.08)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 20	Tezepelumab	27	26 (96.3)	-1.33 (0.99)	-3.2	-2.17	-1.25	-0.67	0.5	-0.71 [-1.27, -0.16]
			Placebo	29	27 (93.1)	-0.56 (1.16)	-3.0	-1.17	-0.67	0.17	2.3	
		Week 22	Tezepelumab	27	26 (96.3)	-1.22 (0.96)	-3.0	-2.17	-1.00	-0.67	0.5	-0.54 [-1.08, 0.01]
			Placebo	29	27 (93.1)	-0.65 (1.18)	-3.2	-1.17	-0.83	0.17	2.3	
		Week 24	Tezepelumab	27	26 (96.3)	-1.23 (0.90)	-3.2	-1.83	-1.25	-0.67	0.5	-0.70 [-1.26, -0.15]
			Placebo	29	27 (93.1)	-0.51 (1.14)	-3.0	-1.33	-0.50	0.17	2.3	
		Week 26	Tezepelumab	27	27 (100.0)	-1.20 (0.98)	-2.8	-2.00	-1.00	-0.33	0.5	-0.55 [-1.10, -0.01]
			Placebo	29	27 (93.1)	-0.59 (1.21)	-2.5	-1.50	-0.67	0.33	2.3	
		Week 28	Tezepelumab	27	27 (100.0)	-1.19 (1.08)	-3.2	-2.17	-1.00	-0.67	0.8	-0.67 [-1.22, -0.12]
			Placebo	29	27 (93.1)	-0.44 (1.15)	-2.5	-1.50	-0.33	0.33	2.3	
		Week 30	Tezepelumab	27	27 (100.0)	-1.17 (1.17)	-3.5	-2.17	-1.00	-0.67	1.8	-0.52 [-1.06, 0.03]
			Placebo	29	27 (93.1)	-0.57 (1.17)	-2.5	-1.17	-0.50	0.33	2.3	
		Week 32	Tezepelumab	27	27 (100.0)	-1.20 (1.04)	-3.0	-2.17	-1.17	-0.67	0.8	-0.56 [-1.10, -0.01]
			Placebo	29	27 (93.1)	-0.57 (1.19)	-2.5	-1.50	-0.67	0.17	2.3	
		Week 34	Tezepelumab	27	27 (100.0)	-1.14 (1.17)	-2.8	-2.17	-1.50	-0.33	2.0	-0.38 [-0.91, 0.16]
			Placebo	29	27 (93.1)	-0.70 (1.20)	-3.2	-1.50	-0.67	0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Change from baseline	Week 36	Tezepelumab	27	27 (100.0)	-1.21 (1.15)	-3.0	-2.17	-1.17	-0.33	1.5	-0.71 [-1.27, -0.16]
			Placebo	29	27 (93.1)	-0.36 (1.23)	-3.2	-1.00	-0.33	0.50	2.3	
		Week 38	Tezepelumab	27	27 (100.0)	-1.07 (1.21)	-3.0	-2.00	-1.17	-0.17	2.3	-0.32 [-0.86, 0.22]
			Placebo	29	27 (93.1)	-0.67 (1.26)	-3.2	-1.67	-0.83	0.17	2.3	
		Week 40	Tezepelumab	27	27 (100.0)	-1.15 (1.16)	-3.2	-2.17	-1.00	-0.50	1.7	-0.67 [-1.22, -0.12]
			Placebo	29	27 (93.1)	-0.35 (1.23)	-2.8	-1.17	-0.33	0.50	2.3	
		Week 42	Tezepelumab	27	27 (100.0)	-1.14 (1.20)	-3.3	-2.00	-1.17	-0.50	2.0	-0.43 [-0.97, 0.11]
			Placebo	29	27 (93.1)	-0.61 (1.25)	-2.8	-1.33	-0.83	0.17	2.3	
		Week 44	Tezepelumab	27	27 (100.0)	-1.17 (1.21)	-3.5	-2.00	-1.17	-0.17	1.5	-0.71 [-1.26, -0.16]
			Placebo	29	27 (93.1)	-0.33 (1.16)	-2.5	-1.17	-0.33	0.50	2.3	
		Week 46	Tezepelumab	27	27 (100.0)	-1.07 (1.17)	-3.3	-2.00	-1.00	-0.17	1.7	-0.41 [-0.95, 0.13]
			Placebo	29	27 (93.1)	-0.59 (1.22)	-3.2	-1.17	-0.67	0.17	2.3	
		Week 48	Tezepelumab	27	27 (100.0)	-1.09 (1.15)	-2.7	-2.17	-0.83	-0.17	1.8	-0.56 [-1.10, -0.02]
			Placebo	29	27 (93.1)	-0.43 (1.20)	-3.2	-1.17	-0.33	0.33	2.3	
		Week 50	Tezepelumab	27	27 (100.0)	-1.09 (1.07)	-2.7	-2.00	-1.17	-0.50	1.8	-0.37 [-0.91, 0.17]
			Placebo	29	27 (93.1)	-0.70 (1.07)	-2.8	-1.17	-0.67	-0.17	2.3	
		Week 52	Tezepelumab	27	27 (100.0)	-1.12 (1.09)	-2.7	-2.00	-1.17	-0.50	1.8	-0.51 [-1.06, 0.03]
			Placebo	29	27 (93.1)	-0.56 (1.10)	-2.8	-1.00	-0.50	0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	34	34 (100.0)	2.67 (0.98)	0.0	2.17	2.50	3.33	4.8	
			Placebo	33	33 (100.0)	2.80 (0.79)	0.3	2.33	2.83	3.17	4.7	
		Week 2	Tezepelumab	34	33 (97.1)	2.24 (1.05)	0.0	1.67	2.33	3.00	4.2	
			Placebo	33	29 (87.9)	2.40 (0.78)	0.5	2.17	2.33	2.83	4.7	
		Week 4	Tezepelumab	34	33 (97.1)	2.02 (1.06)	0.2	1.33	2.17	2.83	3.5	
			Placebo	33	29 (87.9)	2.14 (0.88)	0.3	1.50	2.17	2.67	3.5	
		Week 6	Tezepelumab	34	33 (97.1)	2.02 (1.05)	0.0	1.17	2.17	2.67	4.0	
			Placebo	33	29 (87.9)	2.13 (1.09)	0.2	1.33	2.33	2.67	5.5	
		Week 8	Tezepelumab	34	33 (97.1)	1.83 (1.14)	0.0	0.83	1.83	2.67	4.2	
			Placebo	33	29 (87.9)	2.09 (1.09)	0.2	1.33	2.17	2.83	4.7	
		Week 10	Tezepelumab	34	33 (97.1)	1.75 (1.13)	0.0	0.67	1.83	2.67	3.7	
			Placebo	33	29 (87.9)	2.12 (1.05)	0.0	1.67	2.17	2.83	5.3	
		Week 12	Tezepelumab	34	33 (97.1)	1.61 (1.09)	0.0	0.50	1.67	2.67	3.3	
			Placebo	33	29 (87.9)	1.79 (0.93)	0.0	1.17	2.00	2.33	4.0	
		Week 14	Tezepelumab	34	33 (97.1)	1.59 (1.09)	0.0	0.67	1.50	2.33	4.2	
			Placebo	33	29 (87.9)	1.89 (0.95)	0.0	1.67	1.83	2.17	5.0	
		Week 16	Tezepelumab	34	33 (97.1)	1.70 (1.10)	0.0	0.67	1.67	2.50	4.2	
			Placebo	33	29 (87.9)	1.96 (1.13)	0.0	1.17	2.00	2.50	5.0	
		Week 18	Tezepelumab	34	33 (97.1)	1.75 (1.05)	0.0	0.83	1.83	2.50	4.2	
			Placebo	33	29 (87.9)	2.04 (1.20)	0.0	1.33	2.17	2.67	5.0	
		Week 20	Tezepelumab	34	33 (97.1)	1.73 (1.15)	0.0	0.83	1.83	2.50	5.0	
			Placebo	33	29 (87.9)	1.98 (0.96)	0.2	1.50	1.83	2.67	5.0	
		Week 22	Tezepelumab	34	33 (97.1)	1.76 (0.97)	0.0	1.00	1.83	2.33	3.8	
			Placebo	33	29 (87.9)	1.98 (1.01)	0.0	1.33	2.00	2.50	5.0	
		Week 24	Tezepelumab	34	33 (97.1)	1.72 (1.09)	0.0	0.83	1.83	2.50	3.8	
			Placebo	33	29 (87.9)	1.97 (0.89)	0.2	1.67	2.00	2.50	4.2	
		Week 26	Tezepelumab	34	33 (97.1)	1.80 (1.12)	0.0	0.83	1.83	2.67	4.0	
			Placebo	33	29 (87.9)	1.90 (0.97)	0.0	1.33	1.83	2.50	4.2	
		Week 28	Tezepelumab	34	34 (100.0)	1.73 (1.14)	0.0	0.83	1.67	2.50	3.8	
			Placebo	33	30 (90.9)	1.74 (1.11)	0.0	1.00	1.67	2.50	4.2	
		Week 30	Tezepelumab	34	34 (100.0)	1.70 (1.07)	0.0	0.67	1.67	2.33	3.7	
			Placebo	33	30 (90.9)	1.84 (1.06)	0.0	1.17	1.83	2.67	4.2	
		Week 32	Tezepelumab	34	34 (100.0)	1.59 (1.08)	0.0	0.67	1.58	2.33	4.0	
			Placebo	33	30 (90.9)	1.77 (0.94)	0.0	1.17	1.83	2.17	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Absolute values	Week 34	Tezepelumab	34	34 (100.0)	1.66 (1.15)	0.0	0.67	1.83	2.50	4.2	
			Placebo	33	30 (90.9)	1.83 (0.93)	0.2	1.17	1.92	2.33	4.2	
		Week 36	Tezepelumab	34	34 (100.0)	1.68 (1.05)	0.0	0.83	1.75	2.33	3.7	
			Placebo	33	30 (90.9)	1.86 (0.95)	0.0	1.00	1.83	2.50	4.2	
		Week 38	Tezepelumab	34	34 (100.0)	1.63 (1.15)	0.0	0.83	1.75	2.33	4.5	
			Placebo	33	30 (90.9)	1.88 (0.94)	0.0	1.17	1.83	2.50	4.2	
		Week 40	Tezepelumab	34	34 (100.0)	1.63 (1.14)	0.0	0.67	1.75	2.67	3.7	
			Placebo	33	30 (90.9)	1.86 (1.06)	0.0	1.17	1.83	2.50	4.2	
		Week 42	Tezepelumab	34	34 (100.0)	1.57 (1.06)	0.0	0.83	1.58	2.50	3.8	
			Placebo	33	30 (90.9)	1.83 (0.86)	0.0	1.17	1.92	2.50	3.3	
		Week 44	Tezepelumab	34	34 (100.0)	1.64 (1.07)	0.0	0.67	1.58	2.33	3.8	
			Placebo	33	30 (90.9)	1.72 (0.97)	0.0	1.00	1.83	2.33	4.0	
		Week 46	Tezepelumab	34	34 (100.0)	1.58 (1.12)	0.0	0.67	1.33	2.33	3.8	
			Placebo	33	30 (90.9)	1.75 (0.81)	0.0	1.17	1.83	2.33	3.3	
		Week 48	Tezepelumab	34	34 (100.0)	1.63 (1.13)	0.0	0.67	1.58	2.50	4.0	
			Placebo	33	30 (90.9)	1.69 (0.91)	0.0	1.00	1.83	2.33	3.3	
		Week 50	Tezepelumab	34	34 (100.0)	1.53 (1.20)	0.0	0.67	1.25	2.33	4.2	
			Placebo	33	30 (90.9)	1.62 (0.90)	0.0	1.00	1.67	2.33	3.3	
		Week 52	Tezepelumab	34	34 (100.0)	1.62 (1.15)	0.0	0.67	1.42	2.33	4.3	
			Placebo	33	30 (90.9)	1.62 (0.94)	0.0	1.17	1.75	2.17	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	34	33 (97.1)	-0.44 (0.80)	-2.8	-0.83	-0.17	0.17	0.7	0.05 [-0.45, 0.55]
			Placebo	33	29 (87.9)	-0.48 (0.58)	-2.2	-0.83	-0.33	0.00	0.3	
		Week 4	Tezepelumab	34	33 (97.1)	-0.67 (0.94)	-2.5	-1.17	-0.67	-0.17	2.3	0.08 [-0.42, 0.57]
			Placebo	33	29 (87.9)	-0.74 (0.87)	-3.0	-1.17	-0.67	-0.17	0.5	
		Week 6	Tezepelumab	34	33 (97.1)	-0.67 (0.96)	-2.7	-1.17	-0.67	-0.17	2.3	0.08 [-0.42, 0.58]
			Placebo	33	29 (87.9)	-0.74 (0.93)	-3.3	-1.17	-0.50	-0.17	0.8	
		Week 8	Tezepelumab	34	33 (97.1)	-0.85 (1.00)	-2.7	-1.33	-0.83	-0.33	2.3	-0.07 [-0.57, 0.43]
			Placebo	33	29 (87.9)	-0.78 (1.04)	-3.2	-1.17	-0.67	-0.17	1.0	
		Week 10	Tezepelumab	34	33 (97.1)	-0.93 (1.07)	-2.7	-1.67	-1.00	-0.17	2.3	-0.16 [-0.66, 0.34]
			Placebo	33	29 (87.9)	-0.75 (1.12)	-3.3	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	34	33 (97.1)	-1.07 (1.05)	-2.7	-2.00	-1.17	-0.67	2.3	0.02 [-0.48, 0.51]
			Placebo	33	29 (87.9)	-1.09 (1.01)	-3.3	-1.50	-0.83	-0.67	1.3	
		Week 14	Tezepelumab	34	33 (97.1)	-1.09 (1.01)	-2.7	-1.83	-1.17	-0.50	2.3	-0.10 [-0.60, 0.40]
			Placebo	33	29 (87.9)	-0.98 (1.12)	-3.2	-1.50	-1.00	-0.33	2.3	
		Week 16	Tezepelumab	34	33 (97.1)	-0.98 (1.00)	-2.5	-1.83	-1.00	-0.50	2.3	-0.07 [-0.56, 0.43]
			Placebo	33	29 (87.9)	-0.91 (1.18)	-3.2	-1.33	-1.00	-0.17	2.3	
		Week 18	Tezepelumab	34	33 (97.1)	-0.93 (0.98)	-2.5	-1.50	-0.83	-0.50	2.3	-0.09 [-0.59, 0.41]
			Placebo	33	29 (87.9)	-0.83 (1.27)	-3.2	-1.67	-1.00	0.00	2.3	
		Week 20	Tezepelumab	34	33 (97.1)	-0.95 (1.02)	-2.7	-1.67	-0.83	-0.50	2.3	-0.05 [-0.55, 0.45]
			Placebo	33	29 (87.9)	-0.90 (1.07)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 22	Tezepelumab	34	33 (97.1)	-0.92 (1.10)	-2.7	-1.67	-0.83	-0.67	2.3	-0.03 [-0.52, 0.47]
			Placebo	33	29 (87.9)	-0.90 (1.07)	-3.3	-1.33	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	34	33 (97.1)	-0.96 (1.05)	-2.7	-1.67	-0.67	-0.33	2.3	-0.05 [-0.55, 0.44]
			Placebo	33	29 (87.9)	-0.91 (1.02)	-3.2	-1.33	-0.83	-0.50	1.5	
		Week 26	Tezepelumab	34	33 (97.1)	-0.88 (1.08)	-2.5	-1.83	-0.67	-0.17	2.3	0.09 [-0.41, 0.59]
			Placebo	33	29 (87.9)	-0.97 (1.03)	-3.2	-1.50	-1.00	-0.50	1.5	
		Week 28	Tezepelumab	34	34 (100.0)	-0.95 (1.10)	-2.7	-2.00	-0.92	0.00	2.3	0.09 [-0.40, 0.59]
			Placebo	33	30 (90.9)	-1.05 (1.10)	-3.2	-1.83	-1.17	-0.33	1.5	
		Week 30	Tezepelumab	34	34 (100.0)	-0.97 (1.04)	-2.5	-1.83	-0.83	-0.17	2.3	-0.02 [-0.51, 0.47]
			Placebo	33	30 (90.9)	-0.95 (1.11)	-3.2	-1.50	-1.17	-0.33	2.0	
		Week 32	Tezepelumab	34	34 (100.0)	-1.08 (1.03)	-2.5	-1.83	-1.00	-0.50	2.3	-0.06 [-0.55, 0.43]
			Placebo	33	30 (90.9)	-1.02 (0.96)	-3.0	-1.33	-1.08	-0.50	1.5	
		Week 34	Tezepelumab	34	34 (100.0)	-1.01 (1.09)	-2.5	-2.00	-1.00	-0.17	2.3	-0.05 [-0.54, 0.44]
			Placebo	33	30 (90.9)	-0.96 (0.96)	-2.8	-1.33	-1.00	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Change from baseline	Week 36	Tezepelumab	34	34 (100.0)	-1.00 (1.07)	-2.5	-1.83	-1.08	-0.17	2.3	-0.07 [-0.56, 0.42]
			Placebo	33	30 (90.9)	-0.93 (0.95)	-3.5	-1.33	-1.00	-0.33	1.5	
		Week 38	Tezepelumab	34	34 (100.0)	-1.04 (1.09)	-2.5	-2.00	-1.25	-0.17	2.3	-0.13 [-0.62, 0.36]
			Placebo	33	30 (90.9)	-0.91 (0.88)	-3.0	-1.33	-1.00	-0.50	1.5	
		Week 40	Tezepelumab	34	34 (100.0)	-1.04 (1.12)	-2.5	-2.17	-1.00	-0.33	2.3	-0.10 [-0.60, 0.39]
			Placebo	33	30 (90.9)	-0.93 (1.00)	-3.2	-1.33	-1.08	-0.33	1.5	
		Week 42	Tezepelumab	34	34 (100.0)	-1.10 (1.06)	-2.7	-2.00	-1.25	-0.50	2.3	-0.15 [-0.64, 0.34]
			Placebo	33	30 (90.9)	-0.96 (0.75)	-2.8	-1.33	-1.08	-0.50	0.3	
		Week 44	Tezepelumab	34	34 (100.0)	-1.03 (1.05)	-2.7	-2.00	-1.00	-0.50	2.3	0.03 [-0.46, 0.52]
			Placebo	33	30 (90.9)	-1.07 (0.92)	-3.3	-1.50	-1.00	-0.50	0.8	
		Week 46	Tezepelumab	34	34 (100.0)	-1.09 (1.07)	-2.7	-2.00	-1.08	-0.33	2.3	-0.06 [-0.55, 0.43]
			Placebo	33	30 (90.9)	-1.04 (0.71)	-2.8	-1.33	-1.17	-0.50	0.3	
		Week 48	Tezepelumab	34	34 (100.0)	-1.04 (1.08)	-2.7	-2.00	-1.00	-0.33	2.3	0.06 [-0.43, 0.55]
			Placebo	33	30 (90.9)	-1.09 (0.83)	-3.3	-1.33	-1.08	-0.50	0.3	
		Week 50	Tezepelumab	34	34 (100.0)	-1.14 (1.18)	-2.7	-2.33	-1.33	-0.33	2.3	0.03 [-0.46, 0.52]
			Placebo	33	30 (90.9)	-1.17 (0.82)	-3.5	-1.50	-1.08	-0.67	0.3	
		Week 52	Tezepelumab	34	34 (100.0)	-1.05 (1.14)	-2.7	-2.00	-1.00	-0.17	2.3	0.11 [-0.38, 0.60]
			Placebo	33	30 (90.9)	-1.17 (0.88)	-3.5	-1.50	-1.00	-0.67	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	23	23 (100.0)	2.56 (0.58)	1.7	2.17	2.50	3.00	3.8	
			Placebo	14	14 (100.0)	2.39 (0.68)	1.3	1.83	2.50	3.00	3.5	
		Week 2	Tezepelumab	23	21 (91.3)	2.02 (1.03)	0.0	1.33	2.33	2.67	3.7	
			Placebo	14	11 (78.6)	1.92 (0.69)	0.3	1.67	2.17	2.33	2.7	
		Week 4	Tezepelumab	23	21 (91.3)	1.83 (0.92)	0.2	1.17	1.83	2.67	3.2	
			Placebo	14	11 (78.6)	2.02 (0.99)	0.7	1.50	1.83	2.33	4.2	
		Week 6	Tezepelumab	23	21 (91.3)	1.63 (0.96)	0.0	1.00	1.50	2.33	3.7	
			Placebo	14	11 (78.6)	2.14 (1.24)	0.8	1.17	1.67	3.00	4.7	
		Week 8	Tezepelumab	23	21 (91.3)	1.67 (1.20)	0.0	0.83	1.50	2.33	4.8	
			Placebo	14	11 (78.6)	2.27 (1.11)	0.7	1.00	2.33	3.50	3.7	
		Week 10	Tezepelumab	23	21 (91.3)	1.51 (1.15)	0.0	0.67	1.50	2.00	4.3	
			Placebo	14	11 (78.6)	2.20 (1.13)	0.8	1.33	2.00	2.83	4.2	
		Week 12	Tezepelumab	23	21 (91.3)	1.49 (1.10)	0.0	0.50	1.33	2.33	4.3	
			Placebo	14	11 (78.6)	1.89 (1.07)	0.7	0.83	1.83	2.67	4.2	
		Week 14	Tezepelumab	23	21 (91.3)	1.40 (1.06)	0.0	0.50	1.33	1.83	4.3	
			Placebo	14	11 (78.6)	1.39 (0.67)	0.3	1.00	1.33	1.83	2.7	
		Week 16	Tezepelumab	23	21 (91.3)	1.45 (1.12)	0.0	0.67	1.33	2.17	4.3	
			Placebo	14	11 (78.6)	2.02 (1.15)	0.5	0.83	1.83	2.67	3.8	
		Week 18	Tezepelumab	23	22 (95.7)	1.43 (1.06)	0.0	0.67	1.33	2.17	4.3	
			Placebo	14	11 (78.6)	1.50 (1.21)	0.0	0.67	1.00	2.67	3.8	
		Week 20	Tezepelumab	23	22 (95.7)	1.49 (1.11)	0.0	0.83	1.33	2.33	4.3	
			Placebo	14	11 (78.6)	1.85 (1.36)	0.2	0.50	1.83	3.33	3.8	
		Week 22	Tezepelumab	23	22 (95.7)	1.62 (1.03)	0.0	1.00	1.50	2.33	4.3	
			Placebo	14	11 (78.6)	1.80 (1.47)	0.0	0.33	1.50	3.50	3.8	
		Week 24	Tezepelumab	23	22 (95.7)	1.46 (1.05)	0.0	0.83	1.33	2.00	4.3	
			Placebo	14	11 (78.6)	1.92 (1.36)	0.2	0.50	2.00	3.17	3.8	
		Week 26	Tezepelumab	23	23 (100.0)	1.57 (1.04)	0.0	0.67	1.50	2.17	4.3	
			Placebo	14	11 (78.6)	1.95 (1.41)	0.3	0.67	1.33	3.67	4.0	
		Week 28	Tezepelumab	23	23 (100.0)	1.62 (1.15)	0.0	0.50	1.50	2.67	4.3	
			Placebo	14	11 (78.6)	2.32 (1.39)	0.3	1.00	2.17	3.67	4.0	
		Week 30	Tezepelumab	23	23 (100.0)	1.65 (1.14)	0.0	0.83	1.67	2.50	4.3	
			Placebo	14	11 (78.6)	1.94 (1.42)	0.0	0.67	2.00	3.00	3.8	
		Week 32	Tezepelumab	23	23 (100.0)	1.61 (1.15)	0.0	0.50	1.67	2.50	4.3	
			Placebo	14	11 (78.6)	2.08 (1.25)	0.3	0.83	2.00	3.17	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Absolute values	Week 34	Tezepelumab	23	23 (100.0)	1.71 (1.18)	0.0	0.67	1.50	2.67	4.3	
			Placebo	14	11 (78.6)	1.82 (1.34)	0.0	0.67	1.83	3.00	3.8	
		Week 36	Tezepelumab	23	23 (100.0)	1.60 (1.12)	0.0	1.00	1.17	2.67	4.3	
			Placebo	14	11 (78.6)	2.06 (1.39)	0.0	1.33	1.83	3.17	4.2	
		Week 38	Tezepelumab	23	23 (100.0)	1.70 (1.24)	0.0	0.83	1.67	2.67	4.3	
			Placebo	14	11 (78.6)	1.94 (1.23)	0.0	1.17	2.00	3.00	3.8	
		Week 40	Tezepelumab	23	23 (100.0)	1.70 (1.15)	0.0	0.67	1.67	2.67	4.3	
			Placebo	14	11 (78.6)	2.53 (1.34)	0.0	2.00	2.50	3.67	4.2	
		Week 42	Tezepelumab	23	23 (100.0)	1.68 (1.18)	0.0	0.83	1.67	2.67	4.3	
			Placebo	14	11 (78.6)	2.38 (1.36)	0.0	1.67	2.50	3.33	4.5	
		Week 44	Tezepelumab	23	23 (100.0)	1.61 (1.15)	0.0	0.67	1.50	2.67	4.3	
			Placebo	14	11 (78.6)	2.61 (1.02)	0.7	1.67	2.83	3.00	4.2	
		Week 46	Tezepelumab	23	23 (100.0)	1.69 (1.17)	0.0	0.83	1.83	2.67	4.3	
			Placebo	14	11 (78.6)	2.18 (1.29)	0.0	1.00	2.50	3.17	3.8	
		Week 48	Tezepelumab	23	23 (100.0)	1.64 (1.17)	0.0	1.00	1.50	2.67	4.3	
			Placebo	14	11 (78.6)	2.33 (1.37)	0.0	1.67	2.50	3.83	4.2	
		Week 50	Tezepelumab	23	23 (100.0)	1.57 (1.19)	0.0	0.67	1.67	2.67	4.3	
			Placebo	14	11 (78.6)	2.26 (1.12)	0.3	1.50	2.17	3.33	3.8	
		Week 52	Tezepelumab	23	23 (100.0)	1.54 (1.19)	0.0	0.33	1.67	2.50	4.3	
			Placebo	14	11 (78.6)	2.35 (1.17)	0.3	1.50	2.33	3.67	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 2	Tezepelumab	23	21 (91.3)	-0.62 (0.74)	-2.8	-0.83	-0.50	-0.17	0.3	-0.14 [-0.87, 0.59]
			Placebo	14	11 (78.6)	-0.50 (1.09)	-2.8	-0.83	-0.50	0.17	1.0	
		Week 4	Tezepelumab	23	21 (91.3)	-0.81 (0.64)	-2.0	-1.33	-0.83	-0.33	0.2	-0.53 [-1.27, 0.21]
			Placebo	14	11 (78.6)	-0.41 (0.94)	-1.7	-1.00	-0.83	0.33	1.2	
		Week 6	Tezepelumab	23	21 (91.3)	-1.00 (0.94)	-2.5	-1.50	-1.00	-0.33	1.2	-0.69 [-1.44, 0.06]
			Placebo	14	11 (78.6)	-0.29 (1.22)	-2.0	-1.33	-0.50	0.83	1.5	
		Week 8	Tezepelumab	23	21 (91.3)	-0.96 (1.13)	-3.0	-1.67	-0.83	-0.33	2.2	-0.76 [-1.52, -0.01]
			Placebo	14	11 (78.6)	-0.15 (0.91)	-1.5	-0.83	-0.33	0.83	1.0	
		Week 10	Tezepelumab	23	21 (91.3)	-1.13 (1.00)	-3.2	-1.83	-1.00	-0.50	0.5	-0.81 [-1.56, -0.05]
			Placebo	14	11 (78.6)	-0.23 (1.32)	-1.5	-1.17	-0.50	0.17	2.5	
		Week 12	Tezepelumab	23	21 (91.3)	-1.14 (0.90)	-2.8	-1.83	-1.17	-0.67	0.5	-0.66 [-1.41, 0.08]
			Placebo	14	11 (78.6)	-0.53 (0.97)	-1.8	-1.17	-0.67	-0.50	1.3	
		Week 14	Tezepelumab	23	21 (91.3)	-1.24 (0.94)	-3.2	-2.00	-1.17	-0.67	0.5	-0.22 [-0.96, 0.51]
			Placebo	14	11 (78.6)	-1.03 (0.90)	-2.2	-1.67	-1.17	-0.67	1.2	
		Week 16	Tezepelumab	23	21 (91.3)	-1.18 (0.94)	-3.0	-1.83	-1.00	-0.67	0.5	-0.75 [-1.50, 0.00]
			Placebo	14	11 (78.6)	-0.41 (1.20)	-1.7	-1.33	-0.67	0.17	2.3	
		Week 18	Tezepelumab	23	22 (95.7)	-1.17 (0.95)	-3.2	-1.83	-1.25	-0.67	0.5	-0.21 [-0.94, 0.51]
			Placebo	14	11 (78.6)	-0.92 (1.46)	-3.2	-1.83	-1.33	0.00	2.3	
		Week 20	Tezepelumab	23	22 (95.7)	-1.11 (0.97)	-3.2	-2.00	-1.00	-0.33	0.5	-0.45 [-1.19, 0.28]
			Placebo	14	11 (78.6)	-0.58 (1.50)	-3.0	-1.83	-0.67	0.50	2.3	
		Week 22	Tezepelumab	23	22 (95.7)	-0.98 (0.92)	-3.0	-1.83	-0.83	-0.17	0.5	-0.30 [-1.03, 0.43]
			Placebo	14	11 (78.6)	-0.62 (1.60)	-3.2	-1.83	-1.00	0.50	2.3	
		Week 24	Tezepelumab	23	22 (95.7)	-1.14 (0.93)	-3.2	-2.00	-1.17	-0.67	0.5	-0.56 [-1.30, 0.18]
			Placebo	14	11 (78.6)	-0.50 (1.49)	-3.0	-1.67	-0.50	0.33	2.3	
		Week 26	Tezepelumab	23	23 (100.0)	-0.99 (0.94)	-2.8	-2.00	-1.00	0.00	0.5	-0.43 [-1.16, 0.30]
			Placebo	14	11 (78.6)	-0.47 (1.63)	-2.5	-1.83	-1.17	0.67	2.3	
		Week 28	Tezepelumab	23	23 (100.0)	-0.93 (1.14)	-3.2	-2.00	-0.83	0.00	0.8	-0.67 [-1.40, 0.07]
			Placebo	14	11 (78.6)	-0.11 (1.45)	-2.2	-1.50	-0.33	1.17	2.3	
		Week 30	Tezepelumab	23	23 (100.0)	-0.91 (1.11)	-2.7	-2.00	-1.00	0.00	1.8	-0.34 [-1.07, 0.38]
			Placebo	14	11 (78.6)	-0.48 (1.45)	-2.5	-1.83	-0.50	0.50	2.3	
		Week 32	Tezepelumab	23	23 (100.0)	-0.95 (1.00)	-3.0	-2.00	-0.83	-0.17	0.8	-0.53 [-1.26, 0.20]
			Placebo	14	11 (78.6)	-0.35 (1.36)	-2.3	-1.50	-0.17	0.67	2.3	
		Week 34	Tezepelumab	23	23 (100.0)	-0.85 (1.15)	-2.8	-1.83	-0.67	0.00	2.0	-0.19 [-0.91, 0.53]
			Placebo	14	11 (78.6)	-0.61 (1.50)	-3.2	-1.50	-0.67	0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Change from baseline	Week 36	Tezepelumab	23	23 (100.0)	-0.96 (1.06)	-3.0	-1.67	-1.17	-0.17	1.5	-0.48 [-1.21, 0.25]
			Placebo	14	11 (78.6)	-0.36 (1.53)	-3.2	-1.00	-0.67	0.67	2.3	
		Week 38	Tezepelumab	23	23 (100.0)	-0.86 (1.21)	-3.0	-2.00	-0.83	0.00	2.3	-0.29 [-1.01, 0.43]
			Placebo	14	11 (78.6)	-0.48 (1.52)	-3.2	-1.33	-0.17	0.33	2.3	
		Week 40	Tezepelumab	23	23 (100.0)	-0.86 (1.10)	-3.2	-1.50	-0.83	0.00	1.7	-0.77 [-1.51, -0.02]
			Placebo	14	11 (78.6)	0.11 (1.56)	-2.8	-1.17	0.33	1.17	2.3	
		Week 42	Tezepelumab	23	23 (100.0)	-0.88 (1.11)	-2.7	-2.00	-0.83	0.00	2.0	-0.65 [-1.38, 0.09]
			Placebo	14	11 (78.6)	-0.05 (1.59)	-2.8	-1.17	0.33	1.33	2.3	
		Week 44	Tezepelumab	23	23 (100.0)	-0.95 (1.07)	-3.2	-1.67	-0.83	-0.17	1.5	-1.01 [-1.77, -0.25]
			Placebo	14	11 (78.6)	0.18 (1.22)	-1.7	-0.83	0.33	1.17	2.3	
		Week 46	Tezepelumab	23	23 (100.0)	-0.87 (1.05)	-2.3	-2.00	-1.00	0.00	1.7	-0.50 [-1.23, 0.23]
			Placebo	14	11 (78.6)	-0.24 (1.63)	-3.2	-1.67	0.17	1.17	2.3	
		Week 48	Tezepelumab	23	23 (100.0)	-0.91 (1.09)	-2.5	-2.00	-0.83	0.00	1.8	-0.65 [-1.39, 0.09]
			Placebo	14	11 (78.6)	-0.09 (1.58)	-3.2	-1.50	0.33	0.83	2.3	
		Week 50	Tezepelumab	23	23 (100.0)	-0.99 (1.15)	-2.7	-2.00	-0.83	0.00	1.8	-0.65 [-1.39, 0.08]
			Placebo	14	11 (78.6)	-0.17 (1.47)	-2.8	-0.83	0.17	0.33	2.3	
		Week 52	Tezepelumab	23	23 (100.0)	-1.01 (1.16)	-2.7	-2.00	-0.83	0.00	1.8	-0.74 [-1.48, 0.00]
			Placebo	14	11 (78.6)	-0.08 (1.49)	-2.8	-0.83	0.17	0.83	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	2.79 (0.94)	0.0	2.33	2.83	3.25	4.8	
			Placebo	44	44 (100.0)	2.76 (0.75)	0.3	2.33	2.83	3.08	4.7	
		Week 2	Tezepelumab	40	39 (97.5)	2.31 (0.94)	0.2	1.67	2.33	3.00	4.2	
			Placebo	44	40 (90.9)	2.32 (0.81)	0.5	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	40	39 (97.5)	2.02 (0.96)	0.2	1.33	2.17	2.67	3.5	
			Placebo	44	40 (90.9)	2.20 (0.91)	0.2	1.58	2.33	2.67	3.7	
		Week 6	Tezepelumab	40	39 (97.5)	1.96 (1.03)	0.0	1.17	2.17	2.67	4.0	
			Placebo	44	40 (90.9)	2.08 (1.10)	0.2	1.25	2.17	2.67	5.5	
		Week 8	Tezepelumab	40	39 (97.5)	1.72 (1.07)	0.0	0.83	1.67	2.67	4.2	
			Placebo	44	41 (93.2)	2.00 (1.11)	0.0	1.33	2.00	2.67	4.7	
		Week 10	Tezepelumab	40	39 (97.5)	1.70 (1.06)	0.0	0.83	1.67	2.67	3.7	
			Placebo	44	41 (93.2)	2.00 (1.06)	0.0	1.50	2.17	2.67	5.3	
		Week 12	Tezepelumab	40	39 (97.5)	1.53 (1.04)	0.0	0.50	1.50	2.50	3.3	
			Placebo	44	41 (93.2)	1.84 (1.03)	0.0	1.17	2.00	2.50	4.3	
		Week 14	Tezepelumab	40	39 (97.5)	1.47 (1.03)	0.0	0.67	1.50	2.33	4.2	
			Placebo	44	41 (93.2)	1.93 (1.06)	0.0	1.50	2.00	2.33	5.0	
		Week 16	Tezepelumab	40	39 (97.5)	1.71 (1.13)	0.0	0.67	1.83	2.50	4.3	
			Placebo	44	41 (93.2)	1.97 (1.22)	0.0	1.00	2.00	2.67	5.0	
		Week 18	Tezepelumab	40	39 (97.5)	1.65 (1.01)	0.0	0.67	1.83	2.33	4.2	
			Placebo	44	41 (93.2)	1.93 (1.18)	0.0	1.33	1.83	2.50	5.0	
		Week 20	Tezepelumab	40	39 (97.5)	1.64 (1.08)	0.0	0.67	1.83	2.33	5.0	
			Placebo	44	41 (93.2)	2.05 (1.06)	0.0	1.33	2.33	2.67	5.0	
		Week 22	Tezepelumab	40	39 (97.5)	1.66 (0.94)	0.0	0.83	1.83	2.33	3.8	
			Placebo	44	41 (93.2)	1.98 (1.12)	0.0	1.17	2.00	2.67	5.0	
		Week 24	Tezepelumab	40	39 (97.5)	1.72 (1.05)	0.0	0.67	1.83	2.67	3.8	
			Placebo	44	41 (93.2)	2.04 (1.01)	0.0	1.67	2.00	2.67	4.5	
		Week 26	Tezepelumab	40	39 (97.5)	1.75 (1.12)	0.0	0.83	1.83	2.67	4.0	
			Placebo	44	41 (93.2)	1.95 (1.12)	0.0	1.00	1.83	2.83	4.5	
		Week 28	Tezepelumab	40	40 (100.0)	1.62 (1.07)	0.0	0.83	1.67	2.25	3.8	
			Placebo	44	42 (95.5)	1.79 (1.15)	0.0	1.00	1.83	2.67	4.5	
		Week 30	Tezepelumab	40	40 (100.0)	1.57 (1.03)	0.0	0.67	1.58	2.25	3.7	
			Placebo	44	42 (95.5)	1.94 (1.13)	0.0	1.17	1.92	2.67	4.5	
		Week 32	Tezepelumab	40	40 (100.0)	1.52 (1.05)	0.0	0.67	1.75	2.17	4.0	
			Placebo	44	42 (95.5)	1.84 (1.12)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Normal	Absolute values	Week 34	Tezepelumab	40	40 (100.0)	1.56 (1.11)	0.0	0.67	1.42	2.42	4.2	
			Placebo	44	42 (95.5)	1.83 (1.11)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	40	40 (100.0)	1.58 (1.05)	0.0	0.75	1.67	2.33	3.7	
			Placebo	44	42 (95.5)	2.02 (1.11)	0.0	1.00	2.08	2.83	4.5	
		Week 38	Tezepelumab	40	40 (100.0)	1.56 (1.14)	0.0	0.67	1.67	2.25	4.5	
			Placebo	44	42 (95.5)	1.84 (1.11)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	40	40 (100.0)	1.53 (1.13)	0.0	0.42	1.75	2.33	3.7	
			Placebo	44	42 (95.5)	1.91 (1.10)	0.0	1.17	1.92	2.50	4.5	
		Week 42	Tezepelumab	40	40 (100.0)	1.49 (1.07)	0.0	0.75	1.50	2.25	3.8	
			Placebo	44	42 (95.5)	1.69 (0.93)	0.0	1.00	1.83	2.33	4.5	
		Week 44	Tezepelumab	40	40 (100.0)	1.57 (1.07)	0.0	0.58	1.58	2.42	3.8	
			Placebo	44	42 (95.5)	1.79 (1.06)	0.0	1.00	1.83	2.33	4.5	
		Week 46	Tezepelumab	40	40 (100.0)	1.55 (1.11)	0.0	0.67	1.50	2.33	3.8	
			Placebo	44	42 (95.5)	1.75 (0.94)	0.0	1.17	1.83	2.17	4.5	
		Week 48	Tezepelumab	40	40 (100.0)	1.58 (1.11)	0.0	0.67	1.67	2.33	4.0	
			Placebo	44	42 (95.5)	1.79 (0.98)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	40	40 (100.0)	1.55 (1.15)	0.0	0.67	1.33	2.33	4.2	
			Placebo	44	42 (95.5)	1.66 (0.96)	0.0	1.00	1.67	2.33	4.5	
		Week 52	Tezepelumab	40	40 (100.0)	1.61 (1.12)	0.0	0.67	1.42	2.33	4.3	
			Placebo	44	42 (95.5)	1.74 (1.02)	0.0	1.00	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 2	Tezepelumab	40	39 (97.5)	-0.49 (0.71)	-2.0	-1.00	-0.33	0.17	0.7	-0.04 [-0.48, 0.40]
			Placebo	44	40 (90.9)	-0.46 (0.59)	-2.2	-0.92	-0.33	0.00	0.5	
		Week 4	Tezepelumab	40	39 (97.5)	-0.78 (0.92)	-2.5	-1.33	-0.83	-0.17	2.3	-0.23 [-0.68, 0.21]
			Placebo	44	40 (90.9)	-0.57 (0.85)	-2.7	-1.17	-0.33	0.08	0.8	
		Week 6	Tezepelumab	40	39 (97.5)	-0.84 (0.96)	-2.7	-1.50	-1.00	-0.17	2.3	-0.15 [-0.59, 0.29]
			Placebo	44	40 (90.9)	-0.70 (0.89)	-2.8	-1.25	-0.50	0.00	0.8	
		Week 8	Tezepelumab	40	39 (97.5)	-1.08 (1.02)	-2.8	-1.83	-1.00	-0.50	2.3	-0.29 [-0.74, 0.15]
			Placebo	44	41 (93.2)	-0.78 (0.96)	-3.2	-1.17	-0.67	0.00	0.5	
		Week 10	Tezepelumab	40	39 (97.5)	-1.10 (1.07)	-2.8	-1.83	-1.17	-0.50	2.3	-0.30 [-0.74, 0.14]
			Placebo	44	41 (93.2)	-0.78 (1.05)	-3.3	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	40	39 (97.5)	-1.27 (1.07)	-3.0	-2.17	-1.17	-0.67	2.3	-0.31 [-0.75, 0.13]
			Placebo	44	41 (93.2)	-0.95 (1.01)	-3.3	-1.67	-0.83	-0.17	1.3	
		Week 14	Tezepelumab	40	39 (97.5)	-1.32 (1.06)	-3.7	-2.00	-1.33	-0.83	2.3	-0.43 [-0.88, 0.01]
			Placebo	44	41 (93.2)	-0.86 (1.07)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 16	Tezepelumab	40	39 (97.5)	-1.09 (1.13)	-2.8	-2.17	-1.00	-0.33	2.3	-0.24 [-0.68, 0.20]
			Placebo	44	41 (93.2)	-0.82 (1.10)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 18	Tezepelumab	40	39 (97.5)	-1.15 (1.05)	-3.5	-1.83	-1.00	-0.67	2.3	-0.27 [-0.71, 0.17]
			Placebo	44	41 (93.2)	-0.85 (1.14)	-3.2	-1.67	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	40	39 (97.5)	-1.16 (1.05)	-2.7	-2.00	-1.33	-0.50	2.3	-0.41 [-0.85, 0.04]
			Placebo	44	41 (93.2)	-0.74 (1.02)	-3.2	-1.17	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	40	39 (97.5)	-1.14 (1.10)	-2.7	-2.17	-1.17	-0.67	2.3	-0.32 [-0.76, 0.12]
			Placebo	44	41 (93.2)	-0.80 (1.01)	-3.3	-1.33	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	40	39 (97.5)	-1.08 (1.03)	-2.7	-1.83	-1.17	-0.33	2.3	-0.33 [-0.77, 0.11]
			Placebo	44	41 (93.2)	-0.75 (0.99)	-3.2	-1.33	-0.67	0.00	1.5	
		Week 26	Tezepelumab	40	39 (97.5)	-1.05 (1.12)	-2.8	-2.00	-0.83	-0.33	2.3	-0.19 [-0.63, 0.25]
			Placebo	44	41 (93.2)	-0.84 (1.02)	-3.2	-1.50	-0.83	-0.17	1.5	
		Week 28	Tezepelumab	40	40 (100.0)	-1.17 (1.09)	-2.8	-2.00	-1.25	-0.58	2.3	-0.22 [-0.65, 0.22]
			Placebo	44	42 (95.5)	-0.94 (1.01)	-3.2	-1.67	-0.92	-0.17	1.5	
		Week 30	Tezepelumab	40	40 (100.0)	-1.22 (1.08)	-3.5	-2.00	-1.33	-0.67	2.3	-0.39 [-0.83, 0.04]
			Placebo	44	42 (95.5)	-0.79 (1.07)	-2.8	-1.33	-0.92	-0.17	2.0	
		Week 32	Tezepelumab	40	40 (100.0)	-1.27 (1.01)	-2.7	-2.17	-1.33	-0.67	2.3	-0.38 [-0.81, 0.06]
			Placebo	44	42 (95.5)	-0.89 (1.02)	-2.8	-1.50	-1.00	-0.33	1.5	
		Week 34	Tezepelumab	40	40 (100.0)	-1.23 (1.08)	-2.5	-2.08	-1.50	-0.67	2.3	-0.32 [-0.76, 0.11]
			Placebo	44	42 (95.5)	-0.90 (0.99)	-2.8	-1.50	-1.00	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Normal	Change from baseline	Week 36	Tezepelumab	40	40 (100.0)	-1.21 (1.10)	-2.8	-2.08	-1.25	-0.42	2.3	-0.47 [-0.91, -0.03]
			Placebo	44	42 (95.5)	-0.71 (1.00)	-2.7	-1.33	-0.75	-0.17	1.5	
		Week 38	Tezepelumab	40	40 (100.0)	-1.23 (1.07)	-2.8	-2.00	-1.42	-0.42	2.3	-0.33 [-0.77, 0.10]
			Placebo	44	42 (95.5)	-0.89 (0.93)	-2.5	-1.33	-0.83	-0.50	1.5	
		Week 40	Tezepelumab	40	40 (100.0)	-1.26 (1.11)	-2.8	-2.25	-1.33	-0.67	2.3	-0.43 [-0.87, 0.01]
			Placebo	44	42 (95.5)	-0.82 (0.95)	-2.5	-1.33	-0.75	-0.33	1.5	
		Week 42	Tezepelumab	40	40 (100.0)	-1.30 (1.09)	-3.3	-2.08	-1.42	-0.67	2.3	-0.27 [-0.71, 0.16]
			Placebo	44	42 (95.5)	-1.04 (0.75)	-2.5	-1.50	-1.17	-0.50	0.5	
		Week 44	Tezepelumab	40	40 (100.0)	-1.21 (1.13)	-3.5	-2.08	-1.25	-0.50	2.3	-0.26 [-0.69, 0.18]
			Placebo	44	42 (95.5)	-0.94 (0.93)	-2.7	-1.50	-1.00	-0.33	1.2	
		Week 46	Tezepelumab	40	40 (100.0)	-1.24 (1.12)	-3.3	-2.17	-1.25	-0.58	2.3	-0.27 [-0.71, 0.16]
			Placebo	44	42 (95.5)	-0.98 (0.75)	-2.5	-1.50	-1.00	-0.67	0.8	
		Week 48	Tezepelumab	40	40 (100.0)	-1.20 (1.10)	-2.7	-2.17	-1.08	-0.50	2.3	-0.27 [-0.70, 0.17]
			Placebo	44	42 (95.5)	-0.94 (0.84)	-2.7	-1.50	-0.83	-0.33	0.5	
		Week 50	Tezepelumab	40	40 (100.0)	-1.24 (1.09)	-2.7	-2.17	-1.33	-0.58	2.3	-0.18 [-0.61, 0.26]
			Placebo	44	42 (95.5)	-1.07 (0.77)	-3.0	-1.67	-1.00	-0.67	0.5	
		Week 52	Tezepelumab	40	40 (100.0)	-1.17 (1.07)	-2.7	-1.92	-1.25	-0.58	2.3	-0.19 [-0.63, 0.24]
			Placebo	44	42 (95.5)	-0.99 (0.85)	-3.0	-1.67	-0.83	-0.50	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.94 (0.92)	2.3	2.33	2.50	4.00	4.0	
			Placebo	7	7 (100.0)	3.00 (0.36)	2.5	2.67	3.00	3.33	3.5	
		Week 2	Tezepelumab	3	3 (100.0)	2.61 (0.51)	2.2	2.17	2.50	3.17	3.2	
			Placebo	7	7 (100.0)	2.74 (0.35)	2.3	2.50	2.67	3.00	3.3	
		Week 4	Tezepelumab	3	3 (100.0)	2.50 (1.01)	1.3	1.33	3.00	3.17	3.2	
			Placebo	7	7 (100.0)	2.07 (0.95)	0.5	1.33	2.17	2.67	3.3	
		Week 6	Tezepelumab	3	3 (100.0)	2.61 (0.59)	2.0	2.00	2.67	3.17	3.2	
			Placebo	7	7 (100.0)	2.19 (1.03)	0.2	1.50	2.67	3.00	3.0	
		Week 8	Tezepelumab	3	3 (100.0)	2.50 (0.83)	1.7	1.67	2.50	3.33	3.3	
			Placebo	7	7 (100.0)	2.05 (0.98)	0.5	1.17	2.17	2.83	3.3	
		Week 10	Tezepelumab	3	3 (100.0)	2.22 (0.92)	1.3	1.33	2.17	3.17	3.2	
			Placebo	7	7 (100.0)	2.24 (0.94)	0.3	2.00	2.50	3.00	3.2	
		Week 12	Tezepelumab	3	3 (100.0)	2.39 (0.63)	1.7	1.67	2.67	2.83	2.8	
			Placebo	7	7 (100.0)	1.93 (0.76)	0.3	2.00	2.00	2.50	2.7	
		Week 14	Tezepelumab	3	3 (100.0)	2.28 (1.34)	1.0	1.00	2.17	3.67	3.7	
			Placebo	7	7 (100.0)	1.62 (0.64)	0.3	1.33	1.83	2.17	2.2	
		Week 16	Tezepelumab	3	3 (100.0)	1.89 (1.11)	1.2	1.17	1.33	3.17	3.2	
			Placebo	7	7 (100.0)	1.79 (0.71)	0.7	1.00	2.00	2.17	2.7	
		Week 18	Tezepelumab	3	3 (100.0)	2.22 (0.98)	1.5	1.50	1.83	3.33	3.3	
			Placebo	7	7 (100.0)	2.10 (0.62)	1.2	1.67	2.17	2.33	3.2	
		Week 20	Tezepelumab	3	3 (100.0)	2.28 (1.07)	1.5	1.50	1.83	3.50	3.5	
			Placebo	7	7 (100.0)	1.69 (0.72)	0.7	1.00	1.67	2.17	2.8	
		Week 22	Tezepelumab	3	3 (100.0)	2.39 (0.92)	1.5	1.50	2.33	3.33	3.3	
			Placebo	7	7 (100.0)	1.79 (0.62)	0.7	1.17	2.00	2.17	2.3	
		Week 24	Tezepelumab	3	3 (100.0)	2.50 (1.00)	1.5	1.50	2.50	3.50	3.5	
			Placebo	7	7 (100.0)	1.79 (0.68)	0.3	1.67	2.00	2.17	2.3	
		Week 26	Tezepelumab	3	3 (100.0)	2.17 (0.67)	1.5	1.50	2.17	2.83	2.8	
			Placebo	7	7 (100.0)	1.71 (0.38)	1.0	1.50	1.83	2.00	2.2	
		Week 28	Tezepelumab	3	3 (100.0)	2.39 (1.02)	1.5	1.50	2.17	3.50	3.5	
			Placebo	7	7 (100.0)	1.93 (1.06)	0.7	1.00	2.17	2.33	3.8	
		Week 30	Tezepelumab	3	3 (100.0)	2.28 (0.84)	1.5	1.50	2.17	3.17	3.2	
			Placebo	7	7 (100.0)	1.55 (0.72)	0.3	1.17	1.67	2.17	2.5	
		Week 32	Tezepelumab	3	3 (100.0)	2.11 (0.59)	1.5	1.50	2.17	2.67	2.7	
			Placebo	7	7 (100.0)	1.62 (0.58)	0.5	1.50	1.50	2.17	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Absolute values	Week 34	Tezepelumab	3	3 (100.0)	2.17 (0.67)	1.5	1.50	2.17	2.83	2.8	
			Placebo	7	7 (100.0)	1.76 (0.64)	0.7	1.17	2.00	2.33	2.3	
		Week 36	Tezepelumab	3	3 (100.0)	2.06 (0.51)	1.5	1.50	2.17	2.50	2.5	
			Placebo	7	7 (100.0)	1.71 (0.82)	0.0	1.50	1.83	2.17	2.5	
		Week 38	Tezepelumab	3	3 (100.0)	2.06 (0.59)	1.5	1.50	2.00	2.67	2.7	
			Placebo	7	7 (100.0)	1.83 (0.88)	0.5	1.33	1.83	2.50	3.2	
		Week 40	Tezepelumab	3	3 (100.0)	2.06 (0.59)	1.5	1.50	2.00	2.67	2.7	
			Placebo	7	7 (100.0)	1.74 (0.77)	0.3	1.33	1.83	2.17	2.8	
		Week 42	Tezepelumab	3	3 (100.0)	2.06 (0.59)	1.5	1.50	2.00	2.67	2.7	
			Placebo	7	7 (100.0)	2.02 (0.72)	0.7	1.67	2.17	2.50	2.8	
		Week 44	Tezepelumab	3	3 (100.0)	2.17 (0.67)	1.5	1.50	2.17	2.83	2.8	
			Placebo	7	7 (100.0)	1.81 (0.82)	0.2	1.33	2.00	2.50	2.5	
		Week 46	Tezepelumab	3	3 (100.0)	2.22 (0.75)	1.5	1.50	2.17	3.00	3.0	
			Placebo	7	7 (100.0)	1.83 (0.64)	0.7	1.33	2.00	2.33	2.5	
		Week 48	Tezepelumab	3	3 (100.0)	2.17 (0.76)	1.5	1.50	2.00	3.00	3.0	
			Placebo	7	7 (100.0)	1.74 (0.76)	0.2	1.33	2.17	2.17	2.2	
		Week 50	Tezepelumab	3	3 (100.0)	1.94 (0.42)	1.5	1.50	2.00	2.33	2.3	
			Placebo	7	7 (100.0)	1.71 (0.79)	0.0	1.67	2.17	2.17	2.2	
		Week 52	Tezepelumab	3	3 (100.0)	1.94 (0.42)	1.5	1.50	2.00	2.33	2.3	
			Placebo	7	7 (100.0)	1.71 (0.79)	0.0	1.67	2.17	2.17	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 2	Tezepelumab	3	3 (100.0)	-0.33 (0.50)	-0.8	-0.83	-0.33	0.17	0.2	-0.18 [-1.53, 1.18]
			Placebo	7	7 (100.0)	-0.26 (0.37)	-0.8	-0.67	-0.17	0.00	0.2	
		Week 4	Tezepelumab	3	3 (100.0)	-0.44 (0.98)	-1.2	-1.17	-0.83	0.67	0.7	0.44 [-0.93, 1.81]
			Placebo	7	7 (100.0)	-0.93 (1.13)	-3.0	-1.67	-0.33	0.00	0.0	
		Week 6	Tezepelumab	3	3 (100.0)	-0.33 (0.60)	-0.8	-0.83	-0.50	0.33	0.3	0.45 [-0.92, 1.82]
			Placebo	7	7 (100.0)	-0.81 (1.16)	-3.3	-1.00	-0.33	-0.17	0.0	
		Week 8	Tezepelumab	3	3 (100.0)	-0.44 (0.54)	-0.8	-0.83	-0.67	0.17	0.2	0.48 [-0.89, 1.85]
			Placebo	7	7 (100.0)	-0.95 (1.18)	-3.0	-2.00	-0.67	-0.17	0.5	
		Week 10	Tezepelumab	3	3 (100.0)	-0.72 (0.51)	-1.2	-1.17	-0.83	-0.17	-0.2	0.04 [-1.31, 1.39]
			Placebo	7	7 (100.0)	-0.76 (1.13)	-3.2	-0.83	-0.50	-0.17	0.3	
		Week 12	Tezepelumab	3	3 (100.0)	-0.56 (0.79)	-1.2	-1.17	-0.83	0.33	0.3	0.57 [-0.81, 1.95]
			Placebo	7	7 (100.0)	-1.07 (0.94)	-3.2	-1.00	-0.67	-0.67	-0.5	
		Week 14	Tezepelumab	3	3 (100.0)	-0.67 (0.73)	-1.5	-1.50	-0.33	-0.17	-0.2	0.83 [-0.58, 2.24]
			Placebo	7	7 (100.0)	-1.38 (0.90)	-3.2	-1.83	-1.17	-0.67	-0.5	
		Week 16	Tezepelumab	3	3 (100.0)	-1.06 (0.25)	-1.3	-1.33	-1.00	-0.83	-0.8	0.18 [-1.17, 1.54]
			Placebo	7	7 (100.0)	-1.21 (0.98)	-2.8	-2.17	-1.17	-0.50	0.0	
		Week 18	Tezepelumab	3	3 (100.0)	-0.72 (0.25)	-1.0	-1.00	-0.67	-0.50	-0.5	0.24 [-1.12, 1.59]
			Placebo	7	7 (100.0)	-0.90 (0.88)	-2.3	-1.50	-1.00	-0.33	0.3	
		Week 20	Tezepelumab	3	3 (100.0)	-0.67 (0.29)	-1.0	-1.00	-0.50	-0.50	-0.5	0.78 [-0.62, 2.19]
			Placebo	7	7 (100.0)	-1.31 (0.94)	-2.8	-2.17	-1.17	-0.83	0.0	
		Week 22	Tezepelumab	3	3 (100.0)	-0.56 (0.51)	-1.0	-1.00	-0.67	0.00	0.0	0.82 [-0.60, 2.23]
			Placebo	7	7 (100.0)	-1.21 (0.89)	-2.8	-2.00	-0.83	-0.50	-0.5	
		Week 24	Tezepelumab	3	3 (100.0)	-0.44 (0.59)	-1.0	-1.00	-0.50	0.17	0.2	0.88 [-0.54, 2.30]
			Placebo	7	7 (100.0)	-1.21 (0.95)	-3.2	-1.50	-1.00	-0.50	-0.3	
		Week 26	Tezepelumab	3	3 (100.0)	-0.78 (0.54)	-1.2	-1.17	-1.00	-0.17	-0.2	0.82 [-0.59, 2.23]
			Placebo	7	7 (100.0)	-1.29 (0.64)	-2.5	-1.67	-1.17	-0.67	-0.7	
		Week 28	Tezepelumab	3	3 (100.0)	-0.56 (0.42)	-1.0	-1.00	-0.50	-0.17	-0.2	0.47 [-0.90, 1.84]
			Placebo	7	7 (100.0)	-1.07 (1.24)	-2.8	-1.83	-1.17	-0.17	1.0	
		Week 30	Tezepelumab	3	3 (100.0)	-0.67 (0.44)	-1.0	-1.00	-0.83	-0.17	-0.2	0.95 [-0.48, 2.38]
			Placebo	7	7 (100.0)	-1.45 (0.92)	-3.2	-2.00	-1.17	-0.83	-0.3	
		Week 32	Tezepelumab	3	3 (100.0)	-0.83 (0.60)	-1.3	-1.33	-1.00	-0.17	-0.2	0.71 [-0.69, 2.10]
			Placebo	7	7 (100.0)	-1.38 (0.83)	-3.0	-1.67	-1.17	-0.67	-0.5	
		Week 34	Tezepelumab	3	3 (100.0)	-0.78 (0.54)	-1.2	-1.17	-1.00	-0.17	-0.2	0.56 [-0.82, 1.94]
			Placebo	7	7 (100.0)	-1.24 (0.90)	-2.8	-2.00	-1.00	-0.67	-0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Change from baseline	Week 36	Tezepelumab	3	3 (100.0)	-0.89 (0.67)	-1.5	-1.50	-1.00	-0.17	-0.2	0.41 [-0.96, 1.78]
			Placebo	7	7 (100.0)	-1.29 (1.04)	-3.5	-1.33	-1.17	-0.50	-0.3	
		Week 38	Tezepelumab	3	3 (100.0)	-0.89 (0.51)	-1.3	-1.33	-1.00	-0.33	-0.3	0.28 [-1.08, 1.64]
			Placebo	7	7 (100.0)	-1.17 (1.11)	-3.0	-1.83	-1.17	0.00	0.3	
		Week 40	Tezepelumab	3	3 (100.0)	-0.89 (0.51)	-1.3	-1.33	-1.00	-0.33	-0.3	0.40 [-0.97, 1.77]
			Placebo	7	7 (100.0)	-1.26 (1.04)	-3.2	-1.50	-1.17	-0.83	0.3	
		Week 42	Tezepelumab	3	3 (100.0)	-0.89 (0.51)	-1.3	-1.33	-1.00	-0.33	-0.3	0.10 [-1.25, 1.45]
			Placebo	7	7 (100.0)	-0.98 (0.96)	-2.8	-1.17	-1.00	0.00	0.0	
		Week 44	Tezepelumab	3	3 (100.0)	-0.78 (0.54)	-1.2	-1.17	-1.00	-0.17	-0.2	0.42 [-0.95, 1.78]
			Placebo	7	7 (100.0)	-1.19 (1.10)	-3.3	-1.83	-0.83	-0.50	0.0	
		Week 46	Tezepelumab	3	3 (100.0)	-0.72 (0.48)	-1.0	-1.00	-1.00	-0.17	-0.2	0.56 [-0.82, 1.93]
			Placebo	7	7 (100.0)	-1.17 (0.88)	-2.8	-1.33	-1.17	-0.50	0.0	
		Week 48	Tezepelumab	3	3 (100.0)	-0.78 (0.38)	-1.0	-1.00	-1.00	-0.33	-0.3	0.56 [-0.82, 1.94]
			Placebo	7	7 (100.0)	-1.26 (0.98)	-3.3	-1.33	-1.17	-0.67	-0.3	
		Week 50	Tezepelumab	3	3 (100.0)	-1.00 (0.67)	-1.7	-1.67	-1.00	-0.33	-0.3	0.30 [-1.06, 1.66]
			Placebo	7	7 (100.0)	-1.29 (1.03)	-3.5	-1.33	-1.00	-0.67	-0.3	
		Week 52	Tezepelumab	3	3 (100.0)	-1.00 (0.67)	-1.7	-1.67	-1.00	-0.33	-0.3	0.30 [-1.06, 1.66]
			Placebo	7	7 (100.0)	-1.29 (1.03)	-3.5	-1.33	-1.00	-0.67	-0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.56 (0.46)	2.0	2.17	2.50	2.83	3.2	
			Placebo	13	13 (100.0)	2.67 (0.86)	0.3	2.67	3.00	3.17	3.5	
		Week 2	Tezepelumab	9	9 (100.0)	2.15 (0.68)	0.8	1.83	2.33	2.67	3.0	
			Placebo	13	11 (84.6)	2.52 (0.52)	1.5	2.17	2.50	2.83	3.3	
		Week 4	Tezepelumab	9	9 (100.0)	1.61 (0.79)	0.2	1.33	1.67	2.17	2.7	
			Placebo	13	11 (84.6)	2.70 (0.77)	1.8	2.17	2.33	3.33	4.2	
		Week 6	Tezepelumab	9	9 (100.0)	1.33 (0.58)	0.5	0.83	1.50	1.67	2.3	
			Placebo	13	11 (84.6)	2.76 (0.63)	1.5	2.50	3.00	3.00	3.8	
		Week 8	Tezepelumab	9	9 (100.0)	1.22 (0.75)	0.0	0.83	1.50	1.50	2.3	
			Placebo	13	12 (92.3)	2.54 (0.74)	1.2	2.08	2.42	3.00	3.7	
		Week 10	Tezepelumab	9	9 (100.0)	0.96 (0.77)	0.0	0.50	0.83	1.50	2.3	
			Placebo	13	12 (92.3)	2.46 (0.74)	1.0	2.08	2.42	2.92	4.0	
		Week 12	Tezepelumab	9	9 (100.0)	0.91 (0.81)	0.0	0.00	1.00	1.50	2.2	
			Placebo	13	12 (92.3)	2.58 (0.63)	1.8	2.08	2.58	2.75	4.2	
		Week 14	Tezepelumab	9	9 (100.0)	0.91 (0.62)	0.0	0.50	1.33	1.33	1.5	
			Placebo	13	12 (92.3)	2.11 (0.53)	1.3	1.83	2.17	2.42	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	0.87 (0.50)	0.0	0.50	1.00	1.17	1.5	
			Placebo	13	12 (92.3)	2.50 (0.84)	1.0	2.08	2.50	2.92	3.8	
		Week 18	Tezepelumab	9	9 (100.0)	1.13 (0.60)	0.0	1.00	1.17	1.50	2.0	
			Placebo	13	12 (92.3)	2.49 (0.52)	1.7	2.17	2.42	2.67	3.8	
		Week 20	Tezepelumab	9	9 (100.0)	1.15 (0.78)	0.0	0.83	1.00	1.50	2.8	
			Placebo	13	12 (92.3)	2.40 (0.80)	1.0	1.92	2.50	2.75	3.8	
		Week 22	Tezepelumab	9	9 (100.0)	1.26 (0.90)	0.0	1.00	1.33	1.50	2.5	
			Placebo	13	12 (92.3)	2.47 (0.90)	0.8	2.00	2.58	3.17	3.8	
		Week 24	Tezepelumab	9	9 (100.0)	1.11 (0.75)	0.0	0.67	1.00	1.50	2.5	
			Placebo	13	12 (92.3)	2.54 (0.74)	1.3	2.08	2.42	3.08	3.8	
		Week 26	Tezepelumab	9	9 (100.0)	1.31 (0.73)	0.0	0.83	1.33	2.00	2.2	
			Placebo	13	12 (92.3)	2.50 (0.90)	1.2	1.67	2.42	3.25	3.8	
		Week 28	Tezepelumab	9	9 (100.0)	1.54 (0.90)	0.0	1.00	1.50	2.33	2.7	
			Placebo	13	13 (100.0)	2.32 (1.09)	0.0	1.83	2.33	3.00	3.8	
		Week 30	Tezepelumab	9	9 (100.0)	1.22 (0.72)	0.0	0.67	1.33	1.50	2.2	
			Placebo	13	13 (100.0)	2.27 (1.11)	0.0	1.67	2.50	3.00	3.8	
		Week 32	Tezepelumab	9	9 (100.0)	1.17 (0.77)	0.0	0.67	1.00	1.67	2.3	
			Placebo	13	13 (100.0)	2.36 (1.25)	0.0	1.50	2.50	3.00	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.26 (1.05)	0.0	0.67	1.00	2.17	2.7	
			Placebo	13	13 (100.0)	2.29 (1.22)	0.2	1.67	2.33	3.00	4.5	
		Week 36	Tezepelumab	9	9 (100.0)	1.37 (0.79)	0.0	0.83	1.50	2.00	2.5	
			Placebo	13	13 (100.0)	2.41 (1.28)	0.0	1.83	2.17	3.00	4.5	
		Week 38	Tezepelumab	9	9 (100.0)	1.37 (1.01)	0.0	0.50	1.50	2.00	2.7	
			Placebo	13	13 (100.0)	2.29 (1.25)	0.0	1.67	2.50	3.00	4.5	
		Week 40	Tezepelumab	9	9 (100.0)	1.15 (0.90)	0.0	0.67	1.00	2.00	2.3	
			Placebo	13	13 (100.0)	2.37 (1.14)	0.0	1.67	2.50	3.00	4.2	
		Week 42	Tezepelumab	9	9 (100.0)	1.24 (0.75)	0.0	0.83	1.00	1.67	2.3	
			Placebo	13	13 (100.0)	2.28 (1.17)	0.0	2.00	2.33	2.50	4.5	
		Week 44	Tezepelumab	9	9 (100.0)	1.33 (0.85)	0.0	0.83	1.50	1.67	2.7	
			Placebo	13	13 (100.0)	2.24 (1.09)	0.0	1.67	2.33	2.50	4.2	
		Week 46	Tezepelumab	9	9 (100.0)	1.39 (0.92)	0.0	0.83	1.00	1.83	2.8	
			Placebo	13	13 (100.0)	2.21 (0.94)	0.0	1.83	2.17	2.50	3.8	
		Week 48	Tezepelumab	9	9 (100.0)	1.37 (0.88)	0.0	1.00	1.00	2.00	2.8	
			Placebo	13	13 (100.0)	2.22 (1.04)	0.0	2.00	2.17	2.50	3.8	
		Week 50	Tezepelumab	9	9 (100.0)	1.06 (0.69)	0.0	0.67	1.00	1.50	2.3	
			Placebo	13	13 (100.0)	2.15 (0.99)	0.0	2.00	2.17	2.50	3.8	
		Week 52	Tezepelumab	9	9 (100.0)	1.06 (0.69)	0.0	0.67	1.00	1.50	2.3	
			Placebo	13	13 (100.0)	2.24 (1.06)	0.0	2.17	2.17	2.83	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.41 (0.39)	-1.3	-0.50	-0.17	-0.17	-0.2	-0.16 [-1.05, 0.72]
			Placebo	13	11 (84.6)	-0.32 (0.64)	-1.5	-0.67	-0.33	0.00	1.0	
		Week 4	Tezepelumab	9	9 (100.0)	-0.94 (0.58)	-1.8	-1.33	-1.00	-0.50	-0.2	-1.12 [-2.08, -0.17]
			Placebo	13	11 (84.6)	-0.14 (0.81)	-1.3	-0.83	0.00	0.50	1.2	
		Week 6	Tezepelumab	9	9 (100.0)	-1.22 (0.63)	-2.2	-1.50	-1.33	-0.67	-0.2	-1.68 [-2.71, -0.64]
			Placebo	13	11 (84.6)	-0.08 (0.72)	-1.0	-0.50	-0.17	0.33	1.5	
		Week 8	Tezepelumab	9	9 (100.0)	-1.33 (0.60)	-2.0	-1.67	-1.33	-1.33	-0.2	-1.30 [-2.26, -0.34]
			Placebo	13	12 (92.3)	-0.32 (0.89)	-2.0	-0.83	-0.50	0.42	1.0	
		Week 10	Tezepelumab	9	9 (100.0)	-1.59 (0.55)	-2.2	-2.00	-1.83	-1.33	-0.7	-1.33 [-2.29, -0.37]
			Placebo	13	12 (92.3)	-0.40 (1.08)	-2.0	-0.92	-0.58	-0.17	2.5	
		Week 12	Tezepelumab	9	9 (100.0)	-1.65 (0.54)	-2.2	-2.00	-1.83	-1.33	-0.7	-1.94 [-3.01, -0.88]
			Placebo	13	12 (92.3)	-0.28 (0.81)	-1.2	-0.75	-0.58	0.08	1.3	
		Week 14	Tezepelumab	9	9 (100.0)	-1.65 (0.46)	-2.2	-2.00	-1.83	-1.50	-0.7	-1.33 [-2.30, -0.37]
			Placebo	13	12 (92.3)	-0.75 (0.79)	-1.8	-1.17	-0.83	-0.67	1.2	
		Week 16	Tezepelumab	9	9 (100.0)	-1.69 (0.45)	-2.2	-2.00	-1.83	-1.67	-0.7	-1.43 [-2.41, -0.45]
			Placebo	13	12 (92.3)	-0.36 (1.15)	-2.2	-1.08	-0.50	0.08	2.3	
		Week 18	Tezepelumab	9	9 (100.0)	-1.43 (0.64)	-2.2	-1.67	-1.67	-1.33	-0.2	-1.25 [-2.20, -0.30]
			Placebo	13	12 (92.3)	-0.38 (0.96)	-1.5	-0.92	-0.50	-0.17	2.3	
		Week 20	Tezepelumab	9	9 (100.0)	-1.41 (0.59)	-2.0	-2.00	-1.50	-1.33	-0.3	-1.01 [-1.94, -0.09]
			Placebo	13	12 (92.3)	-0.46 (1.12)	-2.2	-1.08	-0.75	-0.08	2.3	
		Week 22	Tezepelumab	9	9 (100.0)	-1.30 (0.73)	-2.2	-2.00	-1.50	-0.67	-0.3	-0.90 [-1.81, 0.01]
			Placebo	13	12 (92.3)	-0.39 (1.17)	-2.0	-1.08	-0.50	0.33	2.3	
		Week 24	Tezepelumab	9	9 (100.0)	-1.44 (0.62)	-2.3	-1.67	-1.50	-1.33	-0.3	-1.25 [-2.20, -0.30]
			Placebo	13	12 (92.3)	-0.32 (1.06)	-1.5	-1.08	-0.58	0.25	2.3	
		Week 26	Tezepelumab	9	9 (100.0)	-1.24 (0.72)	-2.3	-1.50	-1.33	-0.67	0.0	-0.88 [-1.79, 0.03]
			Placebo	13	12 (92.3)	-0.36 (1.16)	-1.7	-1.25	-0.75	0.33	2.3	
		Week 28	Tezepelumab	9	9 (100.0)	-1.02 (0.82)	-2.2	-1.50	-0.83	-0.67	0.3	-0.66 [-1.54, 0.21]
			Placebo	13	13 (100.0)	-0.35 (1.13)	-1.8	-1.00	-0.33	0.33	2.3	
		Week 30	Tezepelumab	9	9 (100.0)	-1.33 (0.62)	-2.5	-1.50	-1.33	-0.83	-0.7	-0.97 [-1.87, -0.07]
			Placebo	13	13 (100.0)	-0.40 (1.14)	-2.0	-1.00	-0.67	0.33	2.3	
		Week 32	Tezepelumab	9	9 (100.0)	-1.39 (0.55)	-2.2	-1.83	-1.50	-0.83	-0.7	-1.06 [-1.97, -0.14]
			Placebo	13	13 (100.0)	-0.31 (1.25)	-1.8	-1.17	-0.50	0.33	2.3	
		Week 34	Tezepelumab	9	9 (100.0)	-1.30 (0.83)	-2.5	-2.00	-1.50	-0.67	-0.2	-0.82 [-1.71, 0.06]
			Placebo	13	13 (100.0)	-0.37 (1.28)	-2.0	-1.17	-0.67	0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.19 (0.78)	-2.3	-1.67	-1.33	-0.67	0.0	-0.85 [-1.74, 0.04]
			Placebo	13	13 (100.0)	-0.26 (1.26)	-1.8	-1.17	-0.33	0.33	2.3	
		Week 38	Tezepelumab	9	9 (100.0)	-1.19 (0.67)	-2.0	-1.67	-1.33	-0.67	-0.2	-0.76 [-1.64, 0.12]
			Placebo	13	13 (100.0)	-0.37 (1.27)	-2.2	-1.17	-0.33	0.17	2.3	
		Week 40	Tezepelumab	9	9 (100.0)	-1.41 (0.72)	-2.5	-2.00	-1.50	-0.67	-0.5	-1.11 [-2.03, -0.19]
			Placebo	13	13 (100.0)	-0.29 (1.16)	-1.7	-1.17	-0.33	0.33	2.3	
		Week 42	Tezepelumab	9	9 (100.0)	-1.31 (0.59)	-2.2	-1.50	-1.50	-0.67	-0.5	-0.93 [-1.83, -0.04]
			Placebo	13	13 (100.0)	-0.38 (1.19)	-2.0	-1.17	-0.67	0.00	2.3	
		Week 44	Tezepelumab	9	9 (100.0)	-1.22 (0.80)	-2.7	-1.50	-1.33	-0.67	-0.2	-0.78 [-1.66, 0.10]
			Placebo	13	13 (100.0)	-0.42 (1.15)	-1.8	-1.17	-0.83	0.00	2.3	
		Week 46	Tezepelumab	9	9 (100.0)	-1.17 (0.75)	-2.2	-1.50	-1.33	-0.67	0.0	-0.77 [-1.65, 0.12]
			Placebo	13	13 (100.0)	-0.46 (1.02)	-1.5	-1.00	-0.83	0.00	2.3	
		Week 48	Tezepelumab	9	9 (100.0)	-1.19 (0.86)	-2.2	-2.00	-1.50	-0.50	0.0	-0.74 [-1.62, 0.14]
			Placebo	13	13 (100.0)	-0.45 (1.08)	-1.7	-1.17	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	9	9 (100.0)	-1.50 (0.67)	-2.5	-2.00	-1.50	-1.17	-0.5	-1.07 [-1.99, -0.16]
			Placebo	13	13 (100.0)	-0.51 (1.06)	-1.7	-1.17	-0.83	-0.33	2.3	
		Week 52	Tezepelumab	9	9 (100.0)	-1.50 (0.67)	-2.5	-2.00	-1.50	-1.17	-0.5	-1.14 [-2.06, -0.22]
			Placebo	13	13 (100.0)	-0.42 (1.09)	-1.7	-1.00	-0.83	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.74 (0.87)	0.0	2.33	2.67	3.17	4.8	
			Placebo	52	52 (100.0)	2.72 (0.69)	1.3	2.33	2.67	3.08	4.7	
		Week 2	Tezepelumab	57	54 (94.7)	2.24 (1.00)	0.0	1.50	2.42	3.00	4.2	
			Placebo	52	47 (90.4)	2.24 (0.82)	0.3	1.83	2.33	2.67	4.8	
		Week 4	Tezepelumab	57	54 (94.7)	2.04 (0.96)	0.2	1.33	2.25	2.83	3.5	
			Placebo	52	47 (90.4)	2.02 (0.90)	0.2	1.33	2.33	2.67	3.7	
		Week 6	Tezepelumab	57	54 (94.7)	1.98 (1.03)	0.0	1.17	2.17	2.67	4.0	
			Placebo	52	47 (90.4)	1.95 (1.14)	0.2	1.17	2.00	2.67	5.5	
		Week 8	Tezepelumab	57	54 (94.7)	1.83 (1.14)	0.0	0.83	1.83	2.67	4.8	
			Placebo	52	47 (90.4)	1.94 (1.13)	0.0	0.83	2.00	2.67	4.7	
		Week 10	Tezepelumab	57	54 (94.7)	1.77 (1.09)	0.0	0.83	1.83	2.67	4.3	
			Placebo	52	47 (90.4)	1.97 (1.10)	0.0	1.00	2.00	2.67	5.3	
		Week 12	Tezepelumab	57	54 (94.7)	1.67 (1.05)	0.0	0.67	1.83	2.50	4.3	
			Placebo	52	47 (90.4)	1.67 (0.98)	0.0	1.00	1.83	2.33	4.3	
		Week 14	Tezepelumab	57	54 (94.7)	1.58 (1.08)	0.0	0.67	1.58	2.33	4.3	
			Placebo	52	47 (90.4)	1.71 (1.05)	0.0	1.00	1.67	2.17	5.0	
		Week 16	Tezepelumab	57	54 (94.7)	1.76 (1.14)	0.0	0.67	1.83	2.50	4.3	
			Placebo	52	47 (90.4)	1.82 (1.18)	0.0	0.67	1.83	2.67	5.0	
		Week 18	Tezepelumab	57	55 (96.5)	1.68 (1.06)	0.0	0.67	1.83	2.33	4.3	
			Placebo	52	47 (90.4)	1.72 (1.20)	0.0	0.67	1.67	2.33	5.0	
		Week 20	Tezepelumab	57	55 (96.5)	1.69 (1.12)	0.0	0.83	1.83	2.50	5.0	
			Placebo	52	47 (90.4)	1.86 (1.12)	0.0	0.83	1.83	2.67	5.0	
		Week 22	Tezepelumab	57	55 (96.5)	1.75 (0.97)	0.0	0.83	1.83	2.33	4.3	
			Placebo	52	47 (90.4)	1.79 (1.15)	0.0	0.83	2.00	2.33	5.0	
		Week 24	Tezepelumab	57	55 (96.5)	1.76 (1.07)	0.0	1.00	1.83	2.50	4.3	
			Placebo	52	47 (90.4)	1.85 (1.06)	0.0	0.83	2.00	2.50	4.5	
		Week 26	Tezepelumab	57	56 (98.2)	1.77 (1.11)	0.0	1.00	1.83	2.67	4.3	
			Placebo	52	47 (90.4)	1.77 (1.11)	0.0	1.00	1.67	2.67	4.5	
		Week 28	Tezepelumab	57	57 (100.0)	1.68 (1.12)	0.0	0.83	1.67	2.50	4.3	
			Placebo	52	47 (90.4)	1.79 (1.19)	0.0	0.83	1.83	2.67	4.5	
		Week 30	Tezepelumab	57	57 (100.0)	1.70 (1.09)	0.0	0.83	1.67	2.33	4.3	
			Placebo	52	47 (90.4)	1.79 (1.13)	0.0	0.83	1.83	2.67	4.5	
		Week 32	Tezepelumab	57	57 (100.0)	1.64 (1.10)	0.0	0.67	1.83	2.50	4.3	
			Placebo	52	47 (90.4)	1.72 (1.01)	0.0	1.00	1.83	2.33	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	57	57 (100.0)	1.70 (1.12)	0.0	0.83	1.83	2.50	4.3	
			Placebo	52	47 (90.4)	1.69 (1.03)	0.0	0.83	1.83	2.33	4.5	
		Week 36	Tezepelumab	57	57 (100.0)	1.65 (1.09)	0.0	1.00	1.67	2.50	4.3	
			Placebo	52	47 (90.4)	1.88 (1.07)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	57	57 (100.0)	1.67 (1.17)	0.0	0.83	1.67	2.50	4.5	
			Placebo	52	47 (90.4)	1.74 (1.03)	0.0	1.00	1.83	2.33	4.5	
		Week 40	Tezepelumab	57	57 (100.0)	1.68 (1.13)	0.0	0.67	1.83	2.67	4.3	
			Placebo	52	47 (90.4)	1.90 (1.12)	0.0	1.17	2.00	2.50	4.5	
		Week 42	Tezepelumab	57	57 (100.0)	1.64 (1.13)	0.0	0.83	1.67	2.50	4.3	
			Placebo	52	47 (90.4)	1.74 (0.96)	0.0	1.00	1.83	2.50	4.5	
		Week 44	Tezepelumab	57	57 (100.0)	1.66 (1.11)	0.0	0.67	1.67	2.67	4.3	
			Placebo	52	47 (90.4)	1.85 (1.05)	0.0	1.00	1.83	2.67	4.5	
		Week 46	Tezepelumab	57	57 (100.0)	1.66 (1.15)	0.0	0.67	1.83	2.50	4.3	
			Placebo	52	47 (90.4)	1.73 (0.97)	0.0	1.00	1.83	2.33	4.5	
		Week 48	Tezepelumab	57	57 (100.0)	1.67 (1.14)	0.0	0.67	1.67	2.50	4.3	
			Placebo	52	47 (90.4)	1.79 (1.04)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	57	57 (100.0)	1.65 (1.17)	0.0	0.83	1.67	2.33	4.3	
			Placebo	52	47 (90.4)	1.67 (0.97)	0.0	1.00	1.67	2.33	4.5	
		Week 52	Tezepelumab	57	57 (100.0)	1.69 (1.15)	0.0	1.00	1.67	2.50	4.3	
			Placebo	52	47 (90.4)	1.74 (1.02)	0.0	1.00	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 2	Tezepelumab	57	54 (94.7)	-0.54 (0.75)	-2.8	-1.00	-0.42	0.17	0.7	-0.09 [-0.49, 0.30]
			Placebo	52	47 (90.4)	-0.48 (0.70)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	57	54 (94.7)	-0.75 (0.86)	-2.5	-1.17	-0.75	-0.17	2.3	-0.06 [-0.45, 0.33]
			Placebo	52	47 (90.4)	-0.69 (0.89)	-3.0	-1.33	-0.67	0.00	0.8	
		Week 6	Tezepelumab	57	54 (94.7)	-0.81 (0.97)	-2.7	-1.33	-0.83	-0.17	2.3	-0.04 [-0.43, 0.35]
			Placebo	52	47 (90.4)	-0.77 (1.00)	-3.3	-1.50	-0.67	0.00	1.5	
		Week 8	Tezepelumab	57	54 (94.7)	-0.95 (1.09)	-3.0	-1.67	-0.92	-0.33	2.3	-0.16 [-0.56, 0.23]
			Placebo	52	47 (90.4)	-0.78 (1.01)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	57	54 (94.7)	-1.01 (1.06)	-3.2	-1.67	-1.08	-0.17	2.3	-0.24 [-0.63, 0.15]
			Placebo	52	47 (90.4)	-0.75 (1.12)	-3.3	-1.33	-0.50	-0.17	2.7	
		Week 12	Tezepelumab	57	54 (94.7)	-1.12 (1.04)	-3.0	-2.00	-1.17	-0.50	2.3	-0.07 [-0.46, 0.32]
			Placebo	52	47 (90.4)	-1.04 (0.98)	-3.3	-1.83	-0.83	-0.33	1.3	
		Week 14	Tezepelumab	57	54 (94.7)	-1.20 (1.06)	-3.7	-2.00	-1.17	-0.50	2.3	-0.18 [-0.57, 0.21]
			Placebo	52	47 (90.4)	-1.01 (1.08)	-3.2	-1.50	-1.17	-0.33	2.3	
		Week 16	Tezepelumab	57	54 (94.7)	-1.02 (1.08)	-3.0	-2.00	-1.00	-0.33	2.3	-0.12 [-0.51, 0.27]
			Placebo	52	47 (90.4)	-0.90 (1.09)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 18	Tezepelumab	57	55 (96.5)	-1.09 (1.03)	-3.5	-1.83	-1.00	-0.67	2.3	-0.08 [-0.47, 0.31]
			Placebo	52	47 (90.4)	-1.00 (1.18)	-3.2	-1.83	-1.00	0.00	2.3	
		Week 20	Tezepelumab	57	55 (96.5)	-1.07 (1.05)	-3.2	-2.00	-1.00	-0.50	2.3	-0.20 [-0.59, 0.19]
			Placebo	52	47 (90.4)	-0.86 (1.11)	-3.2	-1.67	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	57	55 (96.5)	-1.02 (1.06)	-3.0	-1.83	-1.00	-0.50	2.3	-0.08 [-0.47, 0.31]
			Placebo	52	47 (90.4)	-0.93 (1.09)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	57	55 (96.5)	-1.01 (1.02)	-3.2	-1.83	-1.00	-0.33	2.3	-0.13 [-0.52, 0.26]
			Placebo	52	47 (90.4)	-0.87 (1.08)	-3.2	-1.50	-0.67	0.00	1.5	
		Week 26	Tezepelumab	57	56 (98.2)	-0.98 (1.07)	-2.8	-2.00	-0.92	-0.17	2.3	-0.03 [-0.42, 0.36]
			Placebo	52	47 (90.4)	-0.94 (1.10)	-3.2	-1.83	-1.00	-0.17	1.5	
		Week 28	Tezepelumab	57	57 (100.0)	-1.06 (1.13)	-3.2	-2.00	-1.00	-0.17	2.3	-0.12 [-0.51, 0.26]
			Placebo	52	47 (90.4)	-0.93 (1.14)	-3.2	-1.83	-1.00	-0.17	1.5	
		Week 30	Tezepelumab	57	57 (100.0)	-1.04 (1.13)	-3.5	-2.00	-1.00	-0.17	2.3	-0.10 [-0.49, 0.28]
			Placebo	52	47 (90.4)	-0.93 (1.13)	-3.2	-1.50	-1.17	-0.17	2.0	
		Week 32	Tezepelumab	57	57 (100.0)	-1.10 (1.05)	-3.0	-2.00	-1.00	-0.50	2.3	-0.10 [-0.49, 0.29]
			Placebo	52	47 (90.4)	-1.00 (1.00)	-3.0	-1.50	-1.17	-0.33	1.5	
		Week 34	Tezepelumab	57	57 (100.0)	-1.04 (1.13)	-2.8	-2.00	-1.17	-0.33	2.3	-0.02 [-0.40, 0.37]
			Placebo	52	47 (90.4)	-1.02 (0.99)	-3.2	-1.50	-1.00	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	57	57 (100.0)	-1.09 (1.11)	-3.0	-2.00	-1.17	-0.17	2.3	-0.23 [-0.62, 0.16]
			Placebo	52	47 (90.4)	-0.84 (1.07)	-3.5	-1.33	-0.83	-0.17	1.5	
		Week 38	Tezepelumab	57	57 (100.0)	-1.07 (1.16)	-3.0	-2.00	-1.17	-0.17	2.3	-0.08 [-0.47, 0.31]
			Placebo	52	47 (90.4)	-0.98 (0.99)	-3.2	-1.67	-1.00	-0.50	1.5	
		Week 40	Tezepelumab	57	57 (100.0)	-1.06 (1.14)	-3.2	-2.00	-1.00	-0.33	2.3	-0.21 [-0.60, 0.17]
			Placebo	52	47 (90.4)	-0.82 (1.13)	-3.2	-1.67	-0.83	0.00	1.5	
		Week 42	Tezepelumab	57	57 (100.0)	-1.10 (1.15)	-3.3	-2.00	-1.17	-0.50	2.3	-0.12 [-0.50, 0.27]
			Placebo	52	47 (90.4)	-0.98 (0.96)	-2.8	-1.50	-1.17	-0.17	1.3	
		Week 44	Tezepelumab	57	57 (100.0)	-1.08 (1.13)	-3.5	-2.00	-1.00	-0.33	2.3	-0.20 [-0.59, 0.19]
			Placebo	52	47 (90.4)	-0.86 (1.07)	-3.3	-1.50	-0.83	0.00	1.5	
		Week 46	Tezepelumab	57	57 (100.0)	-1.08 (1.13)	-3.3	-2.00	-1.00	-0.17	2.3	-0.09 [-0.47, 0.30]
			Placebo	52	47 (90.4)	-0.98 (0.98)	-3.2	-1.67	-1.00	-0.50	1.3	
		Week 48	Tezepelumab	57	57 (100.0)	-1.07 (1.11)	-2.7	-2.00	-1.00	-0.50	2.3	-0.13 [-0.51, 0.26]
			Placebo	52	47 (90.4)	-0.93 (1.05)	-3.3	-1.50	-0.83	-0.33	1.7	
		Week 50	Tezepelumab	57	57 (100.0)	-1.08 (1.14)	-2.7	-2.00	-1.17	-0.33	2.3	-0.04 [-0.42, 0.35]
			Placebo	52	47 (90.4)	-1.05 (0.98)	-3.5	-1.67	-1.00	-0.50	1.5	
		Week 52	Tezepelumab	57	57 (100.0)	-1.05 (1.13)	-2.7	-2.00	-1.00	-0.33	2.3	-0.07 [-0.45, 0.32]
			Placebo	52	47 (90.4)	-0.98 (1.04)	-3.5	-1.67	-0.83	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	7	7 (100.0)	2.90 (0.87)	1.7	2.17	2.83	3.50	4.3	
			Placebo	3	3 (100.0)	2.83 (0.29)	2.5	2.50	3.00	3.00	3.0	
		Week 2	Tezepelumab	7	7 (100.0)	2.50 (1.02)	0.8	1.33	3.00	3.00	3.7	
			Placebo	3	3 (100.0)	2.33 (0.76)	1.7	1.67	2.17	3.17	3.2	
		Week 4	Tezepelumab	7	7 (100.0)	1.57 (0.99)	0.2	0.67	2.00	2.50	2.7	
			Placebo	3	3 (100.0)	3.06 (1.39)	1.5	1.50	3.50	4.17	4.2	
		Week 6	Tezepelumab	7	7 (100.0)	1.62 (0.83)	0.8	1.00	1.50	2.50	3.0	
			Placebo	3	3 (100.0)	2.78 (1.42)	1.2	1.17	3.33	3.83	3.8	
		Week 8	Tezepelumab	7	7 (100.0)	1.33 (0.72)	0.5	0.83	1.33	1.67	2.7	
			Placebo	3	3 (100.0)	2.83 (1.04)	1.7	1.67	3.17	3.67	3.7	
		Week 10	Tezepelumab	7	7 (100.0)	1.36 (0.92)	0.3	0.67	1.33	1.83	3.0	
			Placebo	3	3 (100.0)	2.06 (0.86)	1.3	1.33	1.83	3.00	3.0	
		Week 12	Tezepelumab	7	7 (100.0)	1.21 (0.90)	0.0	0.50	1.33	1.83	2.7	
			Placebo	3	3 (100.0)	3.06 (1.17)	1.8	1.83	3.17	4.17	4.2	
		Week 14	Tezepelumab	7	7 (100.0)	1.17 (0.65)	0.3	0.67	1.17	1.67	2.2	
			Placebo	3	3 (100.0)	1.83 (1.17)	1.0	1.00	1.33	3.17	3.2	
		Week 16	Tezepelumab	7	7 (100.0)	1.45 (0.79)	0.5	0.67	1.67	2.17	2.5	
			Placebo	3	3 (100.0)	2.94 (1.02)	1.8	1.83	3.17	3.83	3.8	
		Week 18	Tezepelumab	7	7 (100.0)	1.17 (0.71)	0.3	0.50	0.83	1.83	2.2	
			Placebo	3	3 (100.0)	2.11 (0.86)	1.2	1.17	2.33	2.83	2.8	
		Week 20	Tezepelumab	7	7 (100.0)	1.21 (0.63)	0.3	0.67	1.17	1.83	1.8	
			Placebo	3	3 (100.0)	2.72 (0.84)	1.8	1.83	2.83	3.50	3.5	
		Week 22	Tezepelumab	7	7 (100.0)	1.40 (0.82)	0.0	0.50	1.83	1.83	2.2	
			Placebo	3	3 (100.0)	2.56 (1.00)	1.5	1.50	2.67	3.50	3.5	
		Week 24	Tezepelumab	7	7 (100.0)	1.40 (0.79)	0.3	0.67	1.67	1.83	2.7	
			Placebo	3	3 (100.0)	2.89 (0.35)	2.5	2.50	3.00	3.17	3.2	
		Week 26	Tezepelumab	7	7 (100.0)	1.45 (0.72)	0.7	0.83	1.33	2.17	2.7	
			Placebo	3	3 (100.0)	2.72 (1.23)	1.3	1.33	3.17	3.67	3.7	
		Week 28	Tezepelumab	7	7 (100.0)	1.43 (0.67)	0.3	0.83	1.67	2.00	2.2	
			Placebo	3	3 (100.0)	2.89 (0.75)	2.2	2.17	2.83	3.67	3.7	
		Week 30	Tezepelumab	7	7 (100.0)	1.31 (0.57)	0.7	0.83	1.17	2.00	2.0	
			Placebo	3	3 (100.0)	2.78 (0.95)	2.0	2.00	2.50	3.83	3.8	
		Week 32	Tezepelumab	7	7 (100.0)	1.36 (0.75)	0.5	0.67	1.00	2.00	2.5	
			Placebo	3	3 (100.0)	2.67 (1.09)	1.5	1.50	2.83	3.67	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	7	7 (100.0)	1.31 (0.52)	0.7	0.67	1.33	1.83	2.0	
			Placebo	3	3 (100.0)	2.56 (0.86)	1.8	1.83	2.33	3.50	3.5	
		Week 36	Tezepelumab	7	7 (100.0)	1.21 (0.50)	0.5	0.83	1.17	1.50	2.0	
			Placebo	3	3 (100.0)	2.94 (1.17)	1.8	1.83	2.83	4.17	4.2	
		Week 38	Tezepelumab	7	7 (100.0)	1.36 (0.69)	0.5	0.50	1.67	2.00	2.2	
			Placebo	3	3 (100.0)	2.44 (0.86)	1.5	1.50	2.67	3.17	3.2	
		Week 40	Tezepelumab	7	7 (100.0)	1.38 (0.70)	0.3	0.67	1.83	2.00	2.0	
			Placebo	3	3 (100.0)	3.28 (0.84)	2.5	2.50	3.17	4.17	4.2	
		Week 42	Tezepelumab	7	7 (100.0)	1.29 (0.48)	0.8	0.83	1.00	1.67	2.0	
			Placebo	3	3 (100.0)	2.83 (1.48)	1.7	1.67	2.33	4.50	4.5	
		Week 44	Tezepelumab	7	7 (100.0)	1.26 (0.76)	0.3	0.83	0.83	1.83	2.5	
			Placebo	3	3 (100.0)	3.00 (1.01)	2.3	2.33	2.50	4.17	4.2	
		Week 46	Tezepelumab	7	7 (100.0)	1.24 (0.61)	0.5	0.83	1.00	1.83	2.2	
			Placebo	3	3 (100.0)	2.39 (0.69)	1.8	1.83	2.17	3.17	3.2	
		Week 48	Tezepelumab	7	7 (100.0)	1.33 (0.52)	0.7	1.00	1.17	1.67	2.2	
			Placebo	3	3 (100.0)	2.78 (0.95)	2.0	2.00	2.50	3.83	3.8	
		Week 50	Tezepelumab	7	7 (100.0)	1.60 (0.58)	0.8	1.00	1.67	2.00	2.5	
			Placebo	3	3 (100.0)	2.50 (0.76)	1.8	1.83	2.33	3.33	3.3	
		Week 52	Tezepelumab	7	7 (100.0)	1.60 (0.58)	0.8	1.00	1.67	2.00	2.5	
			Placebo	3	3 (100.0)	3.00 (0.76)	2.3	2.33	2.83	3.83	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	7	7 (100.0)	-0.40 (0.67)	-1.3	-1.33	-0.33	0.17	0.2	0.15 [-1.21, 1.50]
			Placebo	3	3 (100.0)	-0.50 (0.58)	-0.8	-0.83	-0.83	0.17	0.2	
		Week 4	Tezepelumab	7	7 (100.0)	-1.33 (0.71)	-2.3	-2.00	-1.50	-0.83	-0.3	-1.88 [-3.52, -0.25]
			Placebo	3	3 (100.0)	0.22 (1.11)	-1.0	-1.00	0.50	1.17	1.2	
		Week 6	Tezepelumab	7	7 (100.0)	-1.29 (0.85)	-2.5	-1.83	-1.33	-0.67	0.2	-1.33 [-2.83, 0.17]
			Placebo	3	3 (100.0)	-0.06 (1.13)	-1.3	-1.33	0.33	0.83	0.8	
		Week 8	Tezepelumab	7	7 (100.0)	-1.57 (0.99)	-3.0	-2.67	-1.50	-0.83	-0.2	-1.68 [-3.26, -0.10]
			Placebo	3	3 (100.0)	0.00 (0.76)	-0.8	-0.83	0.17	0.67	0.7	
		Week 10	Tezepelumab	7	7 (100.0)	-1.55 (1.07)	-3.2	-2.50	-1.50	-1.00	0.2	-0.78 [-2.18, 0.63]
			Placebo	3	3 (100.0)	-0.78 (0.67)	-1.2	-1.17	-1.17	0.00	0.0	
		Week 12	Tezepelumab	7	7 (100.0)	-1.69 (1.02)	-3.0	-2.83	-1.33	-1.17	-0.2	-1.92 [-3.57, -0.27]
			Placebo	3	3 (100.0)	0.22 (0.92)	-0.7	-0.67	0.17	1.17	1.2	
		Week 14	Tezepelumab	7	7 (100.0)	-1.74 (1.22)	-3.7	-3.17	-1.50	-0.67	-0.5	-0.63 [-2.02, 0.76]
			Placebo	3	3 (100.0)	-1.00 (1.01)	-1.7	-1.67	-1.50	0.17	0.2	
		Week 16	Tezepelumab	7	7 (100.0)	-1.45 (0.99)	-3.0	-2.67	-1.00	-0.83	-0.3	-1.66 [-3.24, -0.09]
			Placebo	3	3 (100.0)	0.11 (0.75)	-0.7	-0.67	0.17	0.83	0.8	
		Week 18	Tezepelumab	7	7 (100.0)	-1.74 (1.13)	-3.5	-3.17	-1.17	-0.83	-0.8	-0.99 [-2.43, 0.44]
			Placebo	3	3 (100.0)	-0.72 (0.59)	-1.3	-1.33	-0.67	-0.17	-0.2	
		Week 20	Tezepelumab	7	7 (100.0)	-1.69 (0.85)	-3.2	-2.50	-1.50	-1.00	-0.8	-1.99 [-3.66, -0.32]
			Placebo	3	3 (100.0)	-0.11 (0.59)	-0.7	-0.67	-0.17	0.50	0.5	
		Week 22	Tezepelumab	7	7 (100.0)	-1.50 (1.11)	-3.0	-2.50	-1.33	-0.67	0.2	-1.18 [-2.65, 0.29]
			Placebo	3	3 (100.0)	-0.28 (0.75)	-1.0	-1.00	-0.33	0.50	0.5	
		Week 24	Tezepelumab	7	7 (100.0)	-1.50 (0.81)	-3.2	-1.67	-1.33	-1.00	-0.7	-2.23 [-3.96, -0.49]
			Placebo	3	3 (100.0)	0.06 (0.10)	0.0	0.00	0.00	0.17	0.2	
		Week 26	Tezepelumab	7	7 (100.0)	-1.45 (0.91)	-2.8	-2.17	-1.50	-0.33	-0.3	-1.46 [-2.99, 0.07]
			Placebo	3	3 (100.0)	-0.11 (0.95)	-1.2	-1.17	0.17	0.67	0.7	
		Week 28	Tezepelumab	7	7 (100.0)	-1.48 (1.01)	-3.2	-2.17	-1.33	-0.83	0.0	-1.68 [-3.26, -0.10]
			Placebo	3	3 (100.0)	0.06 (0.54)	-0.3	-0.33	-0.17	0.67	0.7	
		Week 30	Tezepelumab	7	7 (100.0)	-1.60 (1.17)	-3.5	-2.67	-1.50	-0.83	0.0	-1.42 [-2.94, 0.10]
			Placebo	3	3 (100.0)	-0.06 (0.77)	-0.5	-0.50	-0.50	0.83	0.8	
		Week 32	Tezepelumab	7	7 (100.0)	-1.55 (0.79)	-3.0	-1.83	-1.50	-0.83	-0.7	-1.73 [-3.33, -0.13]
			Placebo	3	3 (100.0)	-0.17 (0.83)	-1.0	-1.00	-0.17	0.67	0.7	
		Week 34	Tezepelumab	7	7 (100.0)	-1.60 (1.01)	-2.8	-2.50	-1.50	-1.50	0.3	-1.41 [-2.93, 0.11]
			Placebo	3	3 (100.0)	-0.28 (0.67)	-0.7	-0.67	-0.67	0.50	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	7	7 (100.0)	-1.69 (0.94)	-3.0	-2.83	-1.50	-0.83	-0.5	-1.91 [-3.55, -0.26]
			Placebo	3	3 (100.0)	0.11 (0.95)	-0.7	-0.67	-0.17	1.17	1.2	
		Week 38	Tezepelumab	7	7 (100.0)	-1.55 (1.04)	-3.0	-2.17	-1.67	-1.17	0.3	-1.22 [-2.70, 0.26]
			Placebo	3	3 (100.0)	-0.39 (0.59)	-1.0	-1.00	-0.33	0.17	0.2	
		Week 40	Tezepelumab	7	7 (100.0)	-1.52 (1.16)	-3.2	-2.50	-1.50	-0.83	0.3	-1.87 [-3.50, -0.24]
			Placebo	3	3 (100.0)	0.44 (0.63)	0.0	0.00	0.17	1.17	1.2	
		Week 42	Tezepelumab	7	7 (100.0)	-1.62 (1.13)	-3.3	-2.67	-1.33	-0.83	0.0	-1.37 [-2.89, 0.14]
			Placebo	3	3 (100.0)	0.00 (1.30)	-0.8	-0.83	-0.67	1.50	1.5	
		Week 44	Tezepelumab	7	7 (100.0)	-1.64 (1.21)	-3.5	-3.17	-1.33	-0.83	-0.3	-1.58 [-3.14, -0.02]
			Placebo	3	3 (100.0)	0.17 (0.93)	-0.7	-0.67	0.00	1.17	1.2	
		Week 46	Tezepelumab	7	7 (100.0)	-1.67 (0.91)	-3.3	-2.17	-1.33	-1.00	-0.7	-1.47 [-3.00, 0.06]
			Placebo	3	3 (100.0)	-0.44 (0.54)	-0.8	-0.83	-0.67	0.17	0.2	
		Week 48	Tezepelumab	7	7 (100.0)	-1.57 (0.81)	-2.7	-2.50	-1.50	-0.67	-0.7	-1.89 [-3.53, -0.25]
			Placebo	3	3 (100.0)	-0.06 (0.77)	-0.5	-0.50	-0.50	0.83	0.8	
		Week 50	Tezepelumab	7	7 (100.0)	-1.31 (0.80)	-2.5	-1.83	-1.33	-0.83	0.0	-1.30 [-2.79, 0.20]
			Placebo	3	3 (100.0)	-0.33 (0.58)	-0.7	-0.67	-0.67	0.33	0.3	
		Week 52	Tezepelumab	7	7 (100.0)	-1.31 (0.80)	-2.5	-1.83	-1.33	-0.83	0.0	-1.96 [-3.62, -0.30]
			Placebo	3	3 (100.0)	0.17 (0.58)	-0.2	-0.17	-0.17	0.83	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	59	59 (100.0)	2.69 (0.83)	0.0	2.17	2.67	3.17	4.8	
			Placebo	62	62 (100.0)	2.70 (0.74)	0.3	2.33	2.67	3.17	4.7	
		Week 2	Tezepelumab	59	56 (94.9)	2.19 (0.96)	0.0	1.50	2.33	2.83	4.2	
			Placebo	62	55 (88.7)	2.29 (0.78)	0.3	2.00	2.33	2.67	4.8	
		Week 4	Tezepelumab	59	56 (94.9)	2.03 (0.94)	0.2	1.33	2.17	2.83	3.5	
			Placebo	62	55 (88.7)	2.10 (0.87)	0.2	1.50	2.33	2.67	3.7	
		Week 6	Tezepelumab	59	56 (94.9)	1.92 (1.02)	0.0	1.25	1.92	2.67	4.0	
			Placebo	62	55 (88.7)	2.07 (1.09)	0.2	1.17	2.17	2.67	5.5	
		Week 8	Tezepelumab	59	56 (94.9)	1.79 (1.14)	0.0	0.83	1.75	2.67	4.8	
			Placebo	62	56 (90.3)	2.02 (1.08)	0.0	1.08	2.17	2.67	4.7	
		Week 10	Tezepelumab	59	56 (94.9)	1.70 (1.10)	0.0	0.83	1.75	2.67	4.3	
			Placebo	62	56 (90.3)	2.07 (1.06)	0.0	1.50	2.17	2.67	5.3	
		Week 12	Tezepelumab	59	56 (94.9)	1.60 (1.07)	0.0	0.50	1.67	2.50	4.3	
			Placebo	62	56 (90.3)	1.79 (0.95)	0.0	1.00	2.00	2.42	4.3	
		Week 14	Tezepelumab	59	56 (94.9)	1.53 (1.09)	0.0	0.58	1.50	2.33	4.3	
			Placebo	62	56 (90.3)	1.79 (0.97)	0.0	1.25	1.83	2.17	5.0	
		Week 16	Tezepelumab	59	56 (94.9)	1.65 (1.15)	0.0	0.67	1.50	2.50	4.3	
			Placebo	62	56 (90.3)	1.90 (1.14)	0.0	0.92	2.00	2.67	5.0	
		Week 18	Tezepelumab	59	57 (96.6)	1.65 (1.05)	0.0	0.83	1.67	2.33	4.3	
			Placebo	62	56 (90.3)	1.86 (1.15)	0.0	1.00	1.83	2.50	5.0	
		Week 20	Tezepelumab	59	57 (96.6)	1.67 (1.13)	0.0	0.83	1.83	2.50	5.0	
			Placebo	62	56 (90.3)	1.93 (1.08)	0.0	1.17	2.08	2.67	5.0	
		Week 22	Tezepelumab	59	57 (96.6)	1.71 (0.99)	0.0	1.00	1.83	2.33	4.3	
			Placebo	62	56 (90.3)	1.89 (1.14)	0.0	1.00	2.00	2.67	5.0	
		Week 24	Tezepelumab	59	57 (96.6)	1.70 (1.08)	0.0	0.83	1.83	2.50	4.3	
			Placebo	62	56 (90.3)	1.94 (1.04)	0.0	1.17	2.00	2.50	4.5	
		Week 26	Tezepelumab	59	58 (98.3)	1.74 (1.11)	0.0	0.83	1.83	2.50	4.3	
			Placebo	62	56 (90.3)	1.88 (1.09)	0.0	1.00	1.83	2.67	4.5	
		Week 28	Tezepelumab	59	59 (100.0)	1.68 (1.13)	0.0	0.83	1.67	2.50	4.3	
			Placebo	62	57 (91.9)	1.85 (1.18)	0.0	1.00	1.83	2.67	4.5	
		Week 30	Tezepelumab	59	59 (100.0)	1.67 (1.10)	0.0	0.67	1.67	2.33	4.3	
			Placebo	62	57 (91.9)	1.85 (1.13)	0.0	1.00	1.83	2.67	4.5	
		Week 32	Tezepelumab	59	59 (100.0)	1.60 (1.10)	0.0	0.67	1.67	2.50	4.3	
			Placebo	62	57 (91.9)	1.82 (1.09)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	59	59 (100.0)	1.68 (1.16)	0.0	0.67	1.83	2.50	4.3	
			Placebo	62	57 (91.9)	1.78 (1.10)	0.0	1.00	1.83	2.33	4.5	
		Week 36	Tezepelumab	59	59 (100.0)	1.66 (1.09)	0.0	0.83	1.67	2.50	4.3	
			Placebo	62	57 (91.9)	1.94 (1.11)	0.0	1.17	1.83	2.67	4.5	
		Week 38	Tezepelumab	59	59 (100.0)	1.66 (1.19)	0.0	0.83	1.67	2.67	4.5	
			Placebo	62	57 (91.9)	1.83 (1.10)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	59	59 (100.0)	1.64 (1.16)	0.0	0.50	1.67	2.67	4.3	
			Placebo	62	57 (91.9)	1.94 (1.11)	0.0	1.17	2.00	2.50	4.5	
		Week 42	Tezepelumab	59	59 (100.0)	1.62 (1.14)	0.0	0.67	1.67	2.50	4.3	
			Placebo	62	57 (91.9)	1.80 (0.99)	0.0	1.17	1.83	2.50	4.5	
		Week 44	Tezepelumab	59	59 (100.0)	1.66 (1.11)	0.0	0.67	1.67	2.67	4.3	
			Placebo	62	57 (91.9)	1.88 (1.04)	0.0	1.17	1.83	2.50	4.5	
		Week 46	Tezepelumab	59	59 (100.0)	1.67 (1.16)	0.0	0.67	1.83	2.67	4.3	
			Placebo	62	57 (91.9)	1.81 (0.99)	0.0	1.17	1.83	2.33	4.5	
		Week 48	Tezepelumab	59	59 (100.0)	1.67 (1.16)	0.0	0.67	1.83	2.67	4.3	
			Placebo	62	57 (91.9)	1.83 (1.04)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	59	59 (100.0)	1.57 (1.18)	0.0	0.67	1.50	2.33	4.3	
			Placebo	62	57 (91.9)	1.74 (0.99)	0.0	1.00	1.67	2.33	4.5	
		Week 52	Tezepelumab	59	59 (100.0)	1.60 (1.17)	0.0	0.67	1.50	2.33	4.3	
			Placebo	62	57 (91.9)	1.79 (1.02)	0.0	1.00	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 2	Tezepelumab	59	56 (94.9)	-0.54 (0.71)	-2.8	-1.00	-0.42	0.00	0.7	-0.14 [-0.51, 0.24]
			Placebo	62	55 (88.7)	-0.44 (0.69)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	59	56 (94.9)	-0.71 (0.82)	-2.5	-1.17	-0.67	-0.17	2.3	-0.09 [-0.46, 0.28]
			Placebo	62	55 (88.7)	-0.63 (0.87)	-3.0	-1.17	-0.33	0.00	0.8	
		Week 6	Tezepelumab	59	56 (94.9)	-0.82 (0.94)	-2.7	-1.42	-0.83	-0.17	2.3	-0.16 [-0.53, 0.22]
			Placebo	62	55 (88.7)	-0.67 (0.98)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	59	56 (94.9)	-0.94 (1.03)	-2.8	-1.67	-1.00	-0.33	2.3	-0.21 [-0.58, 0.16]
			Placebo	62	56 (90.3)	-0.72 (1.00)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	59	56 (94.9)	-1.04 (1.00)	-2.8	-1.75	-1.17	-0.42	2.3	-0.34 [-0.71, 0.03]
			Placebo	62	56 (90.3)	-0.67 (1.14)	-3.3	-1.33	-0.50	-0.17	2.7	
		Week 12	Tezepelumab	59	56 (94.9)	-1.13 (0.99)	-2.8	-2.00	-1.17	-0.67	2.3	-0.19 [-0.56, 0.18]
			Placebo	62	56 (90.3)	-0.95 (0.97)	-3.3	-1.42	-0.83	-0.42	1.3	
		Week 14	Tezepelumab	59	56 (94.9)	-1.21 (0.97)	-2.8	-2.00	-1.17	-0.67	2.3	-0.25 [-0.62, 0.12]
			Placebo	62	56 (90.3)	-0.95 (1.03)	-3.2	-1.42	-1.00	-0.33	2.3	
		Week 16	Tezepelumab	59	56 (94.9)	-1.08 (1.04)	-2.8	-2.00	-1.00	-0.50	2.3	-0.22 [-0.60, 0.15]
			Placebo	62	56 (90.3)	-0.84 (1.11)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 18	Tezepelumab	59	57 (96.6)	-1.06 (0.96)	-2.8	-1.83	-1.00	-0.67	2.3	-0.17 [-0.54, 0.20]
			Placebo	62	56 (90.3)	-0.88 (1.19)	-3.2	-1.67	-0.92	-0.08	2.3	
		Week 20	Tezepelumab	59	57 (96.6)	-1.05 (1.00)	-2.7	-2.00	-1.00	-0.50	2.3	-0.22 [-0.59, 0.15]
			Placebo	62	56 (90.3)	-0.81 (1.13)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	59	57 (96.6)	-1.00 (1.00)	-2.7	-1.67	-0.83	-0.67	2.3	-0.15 [-0.51, 0.22]
			Placebo	62	56 (90.3)	-0.85 (1.13)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	59	57 (96.6)	-1.02 (0.99)	-2.7	-1.83	-1.00	-0.33	2.3	-0.21 [-0.58, 0.16]
			Placebo	62	56 (90.3)	-0.80 (1.10)	-3.2	-1.50	-0.83	0.00	2.3	
		Week 26	Tezepelumab	59	58 (98.3)	-0.96 (1.04)	-2.8	-2.00	-0.92	-0.17	2.3	-0.09 [-0.46, 0.28]
			Placebo	62	56 (90.3)	-0.86 (1.13)	-3.2	-1.58	-1.00	-0.17	2.3	
		Week 28	Tezepelumab	59	59 (100.0)	-1.01 (1.09)	-2.8	-2.00	-1.00	-0.17	2.3	-0.14 [-0.51, 0.22]
			Placebo	62	57 (91.9)	-0.85 (1.16)	-3.2	-1.67	-1.00	-0.17	2.3	
		Week 30	Tezepelumab	59	59 (100.0)	-1.02 (1.06)	-2.7	-2.00	-1.00	-0.33	2.3	-0.15 [-0.52, 0.21]
			Placebo	62	57 (91.9)	-0.85 (1.15)	-3.2	-1.50	-1.00	-0.17	2.3	
		Week 32	Tezepelumab	59	59 (100.0)	-1.09 (1.02)	-2.7	-2.00	-1.00	-0.50	2.3	-0.20 [-0.56, 0.17]
			Placebo	62	57 (91.9)	-0.88 (1.09)	-3.0	-1.50	-1.17	-0.33	2.3	
		Week 34	Tezepelumab	59	59 (100.0)	-1.01 (1.09)	-2.5	-2.00	-1.00	-0.33	2.3	-0.09 [-0.45, 0.27]
			Placebo	62	57 (91.9)	-0.92 (1.09)	-3.2	-1.50	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	59	59 (100.0)	-1.04 (1.07)	-2.8	-2.00	-1.17	-0.17	2.3	-0.25 [-0.62, 0.11]
			Placebo	62	57 (91.9)	-0.76 (1.13)	-3.5	-1.33	-0.83	-0.17	2.3	
		Week 38	Tezepelumab	59	59 (100.0)	-1.03 (1.11)	-2.8	-2.00	-1.17	-0.17	2.3	-0.14 [-0.51, 0.22]
			Placebo	62	57 (91.9)	-0.87 (1.10)	-3.2	-1.33	-1.00	-0.17	2.3	
		Week 40	Tezepelumab	59	59 (100.0)	-1.06 (1.08)	-2.8	-2.00	-1.00	-0.33	2.3	-0.26 [-0.63, 0.10]
			Placebo	62	57 (91.9)	-0.76 (1.14)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 42	Tezepelumab	59	59 (100.0)	-1.07 (1.08)	-2.8	-2.00	-1.17	-0.50	2.3	-0.17 [-0.54, 0.19]
			Placebo	62	57 (91.9)	-0.89 (1.01)	-2.8	-1.33	-1.17	-0.17	2.3	
		Week 44	Tezepelumab	59	59 (100.0)	-1.04 (1.06)	-2.8	-2.00	-1.00	-0.17	2.3	-0.21 [-0.57, 0.16]
			Placebo	62	57 (91.9)	-0.82 (1.08)	-3.3	-1.50	-0.83	-0.17	2.3	
		Week 46	Tezepelumab	59	59 (100.0)	-1.02 (1.09)	-2.8	-2.00	-1.00	-0.17	2.3	-0.12 [-0.49, 0.24]
			Placebo	62	57 (91.9)	-0.89 (1.02)	-3.2	-1.50	-1.00	-0.33	2.3	
		Week 48	Tezepelumab	59	59 (100.0)	-1.03 (1.09)	-2.7	-2.00	-0.83	-0.33	2.3	-0.15 [-0.51, 0.22]
			Placebo	62	57 (91.9)	-0.87 (1.07)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	59	59 (100.0)	-1.12 (1.12)	-2.7	-2.00	-1.17	-0.33	2.3	-0.15 [-0.51, 0.22]
			Placebo	62	57 (91.9)	-0.96 (1.02)	-3.5	-1.50	-1.00	-0.50	2.3	
		Week 52	Tezepelumab	59	59 (100.0)	-1.09 (1.11)	-2.7	-2.00	-1.00	-0.33	2.3	-0.16 [-0.53, 0.20]
			Placebo	62	57 (91.9)	-0.91 (1.06)	-3.5	-1.50	-0.83	-0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	2.89 (0.95)	1.7	2.17	2.83	3.50	4.3	
			Placebo	2	2 (100.0)	2.75 (0.35)	2.5	2.50	2.75	3.00	3.0	
		Week 2	Tezepelumab	6	6 (100.0)	2.47 (1.12)	0.8	1.33	3.00	3.00	3.7	
			Placebo	2	2 (100.0)	2.42 (1.06)	1.7	1.67	2.42	3.17	3.2	
		Week 4	Tezepelumab	6	6 (100.0)	1.47 (1.05)	0.2	0.67	1.42	2.50	2.7	
			Placebo	2	2 (100.0)	2.50 (1.41)	1.5	1.50	2.50	3.50	3.5	
		Week 6	Tezepelumab	6	6 (100.0)	1.64 (0.90)	0.8	1.00	1.25	2.50	3.0	
			Placebo	2	2 (100.0)	2.25 (1.53)	1.2	1.17	2.25	3.33	3.3	
		Week 8	Tezepelumab	6	6 (100.0)	1.31 (0.78)	0.5	0.83	1.08	1.67	2.7	
			Placebo	2	2 (100.0)	2.42 (1.06)	1.7	1.67	2.42	3.17	3.2	
		Week 10	Tezepelumab	6	6 (100.0)	1.36 (1.00)	0.3	0.67	1.17	1.83	3.0	
			Placebo	2	2 (100.0)	2.17 (1.18)	1.3	1.33	2.17	3.00	3.0	
		Week 12	Tezepelumab	6	6 (100.0)	1.11 (0.94)	0.0	0.50	1.00	1.50	2.7	
			Placebo	2	2 (100.0)	2.50 (0.94)	1.8	1.83	2.50	3.17	3.2	
		Week 14	Tezepelumab	6	6 (100.0)	1.11 (0.70)	0.3	0.67	0.92	1.67	2.2	
			Placebo	2	2 (100.0)	2.08 (1.53)	1.0	1.00	2.08	3.17	3.2	
		Week 16	Tezepelumab	6	6 (100.0)	1.33 (0.79)	0.5	0.67	1.25	1.83	2.5	
			Placebo	2	2 (100.0)	2.50 (0.94)	1.8	1.83	2.50	3.17	3.2	
		Week 18	Tezepelumab	6	6 (100.0)	1.00 (0.61)	0.3	0.50	0.83	1.67	1.8	
			Placebo	2	2 (100.0)	2.00 (1.18)	1.2	1.17	2.00	2.83	2.8	
		Week 20	Tezepelumab	6	6 (100.0)	1.11 (0.62)	0.3	0.67	1.00	1.83	1.8	
			Placebo	2	2 (100.0)	2.33 (0.71)	1.8	1.83	2.33	2.83	2.8	
		Week 22	Tezepelumab	6	6 (100.0)	1.36 (0.88)	0.0	0.50	1.83	1.83	2.2	
			Placebo	2	2 (100.0)	2.08 (0.82)	1.5	1.50	2.08	2.67	2.7	
		Week 24	Tezepelumab	6	6 (100.0)	1.36 (0.86)	0.3	0.67	1.33	1.83	2.7	
			Placebo	2	2 (100.0)	2.75 (0.35)	2.5	2.50	2.75	3.00	3.0	
		Week 26	Tezepelumab	6	6 (100.0)	1.25 (0.52)	0.7	0.83	1.25	1.33	2.2	
			Placebo	2	2 (100.0)	2.25 (1.30)	1.3	1.33	2.25	3.17	3.2	
		Week 28	Tezepelumab	6	6 (100.0)	1.36 (0.71)	0.3	0.83	1.42	2.00	2.2	
			Placebo	2	2 (100.0)	2.50 (0.47)	2.2	2.17	2.50	2.83	2.8	
		Week 30	Tezepelumab	6	6 (100.0)	1.19 (0.53)	0.7	0.83	1.00	1.67	2.0	
			Placebo	2	2 (100.0)	2.25 (0.35)	2.0	2.00	2.25	2.50	2.5	
		Week 32	Tezepelumab	6	6 (100.0)	1.28 (0.79)	0.5	0.67	1.00	2.00	2.5	
			Placebo	2	2 (100.0)	2.17 (0.94)	1.5	1.50	2.17	2.83	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	6	6 (100.0)	1.28 (0.56)	0.7	0.67	1.25	1.83	2.0	
			Placebo	2	2 (100.0)	2.08 (0.35)	1.8	1.83	2.08	2.33	2.3	
		Week 36	Tezepelumab	6	6 (100.0)	1.17 (0.53)	0.5	0.83	1.08	1.50	2.0	
			Placebo	2	2 (100.0)	2.33 (0.71)	1.8	1.83	2.33	2.83	2.8	
		Week 38	Tezepelumab	6	6 (100.0)	1.42 (0.74)	0.5	0.50	1.67	2.00	2.2	
			Placebo	2	2 (100.0)	2.08 (0.82)	1.5	1.50	2.08	2.67	2.7	
		Week 40	Tezepelumab	6	6 (100.0)	1.44 (0.74)	0.3	0.67	1.83	2.00	2.0	
			Placebo	2	2 (100.0)	2.83 (0.47)	2.5	2.50	2.83	3.17	3.2	
		Week 42	Tezepelumab	6	6 (100.0)	1.33 (0.51)	0.8	0.83	1.33	1.67	2.0	
			Placebo	2	2 (100.0)	2.00 (0.47)	1.7	1.67	2.00	2.33	2.3	
		Week 44	Tezepelumab	6	6 (100.0)	1.19 (0.81)	0.3	0.83	0.83	1.83	2.5	
			Placebo	2	2 (100.0)	2.42 (0.12)	2.3	2.33	2.42	2.50	2.5	
		Week 46	Tezepelumab	6	6 (100.0)	1.31 (0.64)	0.5	0.83	1.25	1.83	2.2	
			Placebo	2	2 (100.0)	2.00 (0.24)	1.8	1.83	2.00	2.17	2.2	
		Week 48	Tezepelumab	6	6 (100.0)	1.36 (0.56)	0.7	1.00	1.33	1.67	2.2	
			Placebo	2	2 (100.0)	2.25 (0.35)	2.0	2.00	2.25	2.50	2.5	
		Week 50	Tezepelumab	6	6 (100.0)	1.64 (0.63)	0.8	1.00	1.75	2.00	2.5	
			Placebo	2	2 (100.0)	2.08 (0.35)	1.8	1.83	2.08	2.33	2.3	
		Week 52	Tezepelumab	6	6 (100.0)	1.64 (0.63)	0.8	1.00	1.75	2.00	2.5	
			Placebo	2	2 (100.0)	2.58 (0.35)	2.3	2.33	2.58	2.83	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	6	6 (100.0)	-0.42 (0.74)	-1.3	-1.33	-0.08	0.17	0.2	-0.11 [-1.72, 1.49]
			Placebo	2	2 (100.0)	-0.33 (0.71)	-0.8	-0.83	-0.33	0.17	0.2	
		Week 4	Tezepelumab	6	6 (100.0)	-1.42 (0.74)	-2.3	-2.00	-1.50	-0.83	-0.3	-1.46 [-3.26, 0.34]
			Placebo	2	2 (100.0)	-0.25 (1.06)	-1.0	-1.00	-0.25	0.50	0.5	
		Week 6	Tezepelumab	6	6 (100.0)	-1.25 (0.92)	-2.5	-1.83	-1.33	-0.67	0.2	-0.77 [-2.43, 0.89]
			Placebo	2	2 (100.0)	-0.50 (1.18)	-1.3	-1.33	-0.50	0.33	0.3	
		Week 8	Tezepelumab	6	6 (100.0)	-1.58 (1.08)	-3.0	-2.67	-1.42	-0.83	-0.2	-1.22 [-2.96, 0.52]
			Placebo	2	2 (100.0)	-0.33 (0.71)	-0.8	-0.83	-0.33	0.17	0.2	
		Week 10	Tezepelumab	6	6 (100.0)	-1.53 (1.18)	-3.2	-2.50	-1.33	-1.00	0.2	-0.84 [-2.51, 0.83]
			Placebo	2	2 (100.0)	-0.58 (0.82)	-1.2	-1.17	-0.58	0.00	0.0	
		Week 12	Tezepelumab	6	6 (100.0)	-1.78 (1.09)	-3.0	-2.83	-1.75	-1.17	-0.2	-1.49 [-3.30, 0.32]
			Placebo	2	2 (100.0)	-0.25 (0.59)	-0.7	-0.67	-0.25	0.17	0.2	
		Week 14	Tezepelumab	6	6 (100.0)	-1.78 (1.33)	-3.7	-3.17	-1.33	-0.67	-0.5	-0.85 [-2.52, 0.82]
			Placebo	2	2 (100.0)	-0.67 (1.18)	-1.5	-1.50	-0.67	0.17	0.2	
		Week 16	Tezepelumab	6	6 (100.0)	-1.56 (1.05)	-3.0	-2.67	-1.17	-1.00	-0.3	-1.32 [-3.09, 0.44]
			Placebo	2	2 (100.0)	-0.25 (0.59)	-0.7	-0.67	-0.25	0.17	0.2	
		Week 18	Tezepelumab	6	6 (100.0)	-1.89 (1.16)	-3.5	-3.17	-1.42	-1.00	-0.8	-1.03 [-2.73, 0.68]
			Placebo	2	2 (100.0)	-0.75 (0.82)	-1.3	-1.33	-0.75	-0.17	-0.2	
		Week 20	Tezepelumab	6	6 (100.0)	-1.78 (0.90)	-3.2	-2.50	-1.58	-1.00	-0.8	-1.63 [-3.48, 0.21]
			Placebo	2	2 (100.0)	-0.42 (0.35)	-0.7	-0.67	-0.42	-0.17	-0.2	
		Week 22	Tezepelumab	6	6 (100.0)	-1.53 (1.22)	-3.0	-2.50	-1.58	-0.67	0.2	-0.76 [-2.42, 0.89]
			Placebo	2	2 (100.0)	-0.67 (0.47)	-1.0	-1.00	-0.67	-0.33	-0.3	
		Week 24	Tezepelumab	6	6 (100.0)	-1.53 (0.88)	-3.2	-1.67	-1.33	-1.00	-0.7	-1.91 [-3.84, 0.02]
			Placebo	2	2 (100.0)	0.00 (0.00)	0.0	0.00	0.00	0.00	0.0	
		Week 26	Tezepelumab	6	6 (100.0)	-1.64 (0.84)	-2.8	-2.17	-1.58	-1.33	-0.3	-1.33 [-3.10, 0.44]
			Placebo	2	2 (100.0)	-0.50 (0.94)	-1.2	-1.17	-0.50	0.17	0.2	
		Week 28	Tezepelumab	6	6 (100.0)	-1.53 (1.09)	-3.2	-2.17	-1.50	-0.83	0.0	-1.28 [-3.04, 0.48]
			Placebo	2	2 (100.0)	-0.25 (0.12)	-0.3	-0.33	-0.25	-0.17	-0.2	
		Week 30	Tezepelumab	6	6 (100.0)	-1.69 (1.25)	-3.5	-2.67	-1.58	-0.83	0.0	-1.04 [-2.75, 0.66]
			Placebo	2	2 (100.0)	-0.50 (0.00)	-0.5	-0.50	-0.50	-0.50	-0.5	
		Week 32	Tezepelumab	6	6 (100.0)	-1.61 (0.84)	-3.0	-1.83	-1.67	-0.83	-0.7	-1.28 [-3.03, 0.48]
			Placebo	2	2 (100.0)	-0.58 (0.59)	-1.0	-1.00	-0.58	-0.17	-0.2	
		Week 34	Tezepelumab	6	6 (100.0)	-1.61 (1.10)	-2.8	-2.50	-1.58	-1.50	0.3	-0.94 [-2.62, 0.75]
			Placebo	2	2 (100.0)	-0.67 (0.00)	-0.7	-0.67	-0.67	-0.67	-0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	6	6 (100.0)	-1.72 (1.03)	-3.0	-2.83	-1.58	-0.83	-0.5	-1.37 [-3.15, 0.41]
			Placebo	2	2 (100.0)	-0.42 (0.35)	-0.7	-0.67	-0.42	-0.17	-0.2	
		Week 38	Tezepelumab	6	6 (100.0)	-1.47 (1.12)	-3.0	-2.17	-1.42	-1.17	0.3	-0.77 [-2.43, 0.89]
			Placebo	2	2 (100.0)	-0.67 (0.47)	-1.0	-1.00	-0.67	-0.33	-0.3	
		Week 40	Tezepelumab	6	6 (100.0)	-1.44 (1.25)	-3.2	-2.50	-1.25	-0.83	0.3	-1.34 [-3.11, 0.43]
			Placebo	2	2 (100.0)	0.08 (0.12)	0.0	0.00	0.08	0.17	0.2	
		Week 42	Tezepelumab	6	6 (100.0)	-1.56 (1.23)	-3.3	-2.67	-1.25	-0.83	0.0	-0.72 [-2.37, 0.93]
			Placebo	2	2 (100.0)	-0.75 (0.12)	-0.8	-0.83	-0.75	-0.67	-0.7	
		Week 44	Tezepelumab	6	6 (100.0)	-1.69 (1.31)	-3.5	-3.17	-1.17	-0.83	-0.3	-1.12 [-2.84, 0.60]
			Placebo	2	2 (100.0)	-0.33 (0.47)	-0.7	-0.67	-0.33	0.00	0.0	
		Week 46	Tezepelumab	6	6 (100.0)	-1.58 (0.96)	-3.3	-2.00	-1.25	-1.00	-0.7	-0.94 [-2.63, 0.74]
			Placebo	2	2 (100.0)	-0.75 (0.12)	-0.8	-0.83	-0.75	-0.67	-0.7	
		Week 48	Tezepelumab	6	6 (100.0)	-1.53 (0.88)	-2.7	-2.50	-1.33	-0.67	-0.7	-1.28 [-3.04, 0.48]
			Placebo	2	2 (100.0)	-0.50 (0.00)	-0.5	-0.50	-0.50	-0.50	-0.5	
		Week 50	Tezepelumab	6	6 (100.0)	-1.25 (0.86)	-2.5	-1.83	-1.17	-0.83	0.0	-0.74 [-2.40, 0.91]
			Placebo	2	2 (100.0)	-0.67 (0.00)	-0.7	-0.67	-0.67	-0.67	-0.7	
		Week 52	Tezepelumab	6	6 (100.0)	-1.25 (0.86)	-2.5	-1.83	-1.17	-0.83	0.0	-1.38 [-3.16, 0.40]
			Placebo	2	2 (100.0)	-0.17 (0.00)	-0.2	-0.17	-0.17	-0.17	-0.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	2.70 (0.82)	0.0	2.25	2.67	3.17	4.8	
			Placebo	63	63 (100.0)	2.71 (0.73)	0.3	2.33	2.67	3.17	4.7	
		Week 2	Tezepelumab	60	57 (95.0)	2.20 (0.95)	0.0	1.50	2.33	2.83	4.2	
			Placebo	63	56 (88.9)	2.29 (0.77)	0.3	2.00	2.33	2.67	4.8	
		Week 4	Tezepelumab	60	57 (95.0)	2.03 (0.93)	0.2	1.33	2.17	2.83	3.5	
			Placebo	63	56 (88.9)	2.14 (0.91)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	60	57 (95.0)	1.91 (1.02)	0.0	1.33	1.83	2.67	4.0	
			Placebo	63	56 (88.9)	2.10 (1.10)	0.2	1.25	2.17	2.67	5.5	
		Week 8	Tezepelumab	60	57 (95.0)	1.79 (1.13)	0.0	0.83	1.67	2.67	4.8	
			Placebo	63	57 (90.5)	2.05 (1.09)	0.0	1.17	2.17	2.67	4.7	
		Week 10	Tezepelumab	60	57 (95.0)	1.69 (1.09)	0.0	0.83	1.67	2.67	4.3	
			Placebo	63	57 (90.5)	2.06 (1.05)	0.0	1.50	2.17	2.67	5.3	
		Week 12	Tezepelumab	60	57 (95.0)	1.61 (1.06)	0.0	0.50	1.67	2.50	4.3	
			Placebo	63	57 (90.5)	1.84 (0.99)	0.0	1.00	2.00	2.50	4.3	
		Week 14	Tezepelumab	60	57 (95.0)	1.53 (1.08)	0.0	0.67	1.50	2.33	4.3	
			Placebo	63	57 (90.5)	1.78 (0.97)	0.0	1.33	1.83	2.17	5.0	
		Week 16	Tezepelumab	60	57 (95.0)	1.66 (1.15)	0.0	0.67	1.50	2.50	4.3	
			Placebo	63	57 (90.5)	1.94 (1.16)	0.0	1.00	2.00	2.67	5.0	
		Week 18	Tezepelumab	60	58 (96.7)	1.66 (1.04)	0.0	0.83	1.75	2.33	4.3	
			Placebo	63	57 (90.5)	1.87 (1.14)	0.0	1.00	1.83	2.50	5.0	
		Week 20	Tezepelumab	60	58 (96.7)	1.67 (1.12)	0.0	0.83	1.83	2.50	5.0	
			Placebo	63	57 (90.5)	1.96 (1.09)	0.0	1.17	2.17	2.67	5.0	
		Week 22	Tezepelumab	60	58 (96.7)	1.71 (0.98)	0.0	1.00	1.83	2.33	4.3	
			Placebo	63	57 (90.5)	1.92 (1.15)	0.0	1.00	2.00	2.67	5.0	
		Week 24	Tezepelumab	60	58 (96.7)	1.70 (1.07)	0.0	0.83	1.83	2.50	4.3	
			Placebo	63	57 (90.5)	1.96 (1.05)	0.0	1.33	2.00	2.50	4.5	
		Week 26	Tezepelumab	60	59 (98.3)	1.75 (1.10)	0.0	0.83	1.83	2.67	4.3	
			Placebo	63	57 (90.5)	1.91 (1.11)	0.0	1.00	1.83	2.67	4.5	
		Week 28	Tezepelumab	60	60 (100.0)	1.69 (1.12)	0.0	0.92	1.67	2.50	4.3	
			Placebo	63	58 (92.1)	1.89 (1.20)	0.0	1.00	1.92	2.67	4.5	
		Week 30	Tezepelumab	60	60 (100.0)	1.68 (1.09)	0.0	0.75	1.67	2.33	4.3	
			Placebo	63	58 (92.1)	1.88 (1.15)	0.0	1.00	1.83	2.67	4.5	
		Week 32	Tezepelumab	60	60 (100.0)	1.61 (1.09)	0.0	0.67	1.75	2.42	4.3	
			Placebo	63	58 (92.1)	1.85 (1.10)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	60	60 (100.0)	1.68 (1.15)	0.0	0.67	1.67	2.50	4.3	
			Placebo	63	58 (92.1)	1.81 (1.11)	0.0	1.00	1.83	2.50	4.5	
		Week 36	Tezepelumab	60	60 (100.0)	1.65 (1.08)	0.0	0.92	1.67	2.50	4.3	
			Placebo	63	58 (92.1)	1.98 (1.14)	0.0	1.17	1.92	2.67	4.5	
		Week 38	Tezepelumab	60	60 (100.0)	1.65 (1.18)	0.0	0.83	1.67	2.67	4.5	
			Placebo	63	58 (92.1)	1.85 (1.10)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	60	60 (100.0)	1.63 (1.15)	0.0	0.58	1.67	2.58	4.3	
			Placebo	63	58 (92.1)	1.97 (1.14)	0.0	1.17	2.00	2.67	4.5	
		Week 42	Tezepelumab	60	60 (100.0)	1.61 (1.13)	0.0	0.75	1.67	2.50	4.3	
			Placebo	63	58 (92.1)	1.85 (1.04)	0.0	1.17	1.83	2.50	4.5	
		Week 44	Tezepelumab	60	60 (100.0)	1.66 (1.10)	0.0	0.67	1.67	2.67	4.3	
			Placebo	63	58 (92.1)	1.92 (1.08)	0.0	1.17	1.92	2.67	4.5	
		Week 46	Tezepelumab	60	60 (100.0)	1.66 (1.15)	0.0	0.75	1.83	2.58	4.3	
			Placebo	63	58 (92.1)	1.83 (0.99)	0.0	1.17	1.83	2.33	4.5	
		Week 48	Tezepelumab	60	60 (100.0)	1.66 (1.15)	0.0	0.67	1.75	2.58	4.3	
			Placebo	63	58 (92.1)	1.87 (1.06)	0.0	1.00	2.08	2.50	4.5	
		Week 50	Tezepelumab	60	60 (100.0)	1.57 (1.17)	0.0	0.67	1.42	2.33	4.3	
			Placebo	63	58 (92.1)	1.76 (1.00)	0.0	1.00	1.75	2.33	4.5	
		Week 52	Tezepelumab	60	60 (100.0)	1.60 (1.16)	0.0	0.67	1.50	2.33	4.3	
			Placebo	63	58 (92.1)	1.82 (1.05)	0.0	1.00	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 2	Tezepelumab	60	57 (95.0)	-0.54 (0.71)	-2.8	-1.00	-0.33	0.00	0.7	-0.12 [-0.49, 0.25]
			Placebo	63	56 (88.9)	-0.45 (0.69)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	60	57 (95.0)	-0.71 (0.81)	-2.5	-1.17	-0.67	-0.17	2.3	-0.13 [-0.50, 0.24]
			Placebo	63	56 (88.9)	-0.60 (0.90)	-3.0	-1.17	-0.33	0.00	1.2	
		Week 6	Tezepelumab	60	57 (95.0)	-0.83 (0.94)	-2.7	-1.50	-0.83	-0.17	2.3	-0.19 [-0.56, 0.17]
			Placebo	63	56 (88.9)	-0.64 (0.99)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	60	57 (95.0)	-0.95 (1.03)	-2.8	-1.67	-1.00	-0.33	2.3	-0.24 [-0.61, 0.12]
			Placebo	63	57 (90.5)	-0.70 (1.01)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	60	57 (95.0)	-1.05 (1.00)	-2.8	-1.67	-1.17	-0.50	2.3	-0.34 [-0.71, 0.03]
			Placebo	63	57 (90.5)	-0.68 (1.13)	-3.3	-1.33	-0.50	-0.17	2.7	
		Week 12	Tezepelumab	60	57 (95.0)	-1.13 (0.98)	-2.8	-2.00	-1.17	-0.67	2.3	-0.22 [-0.59, 0.14]
			Placebo	63	57 (90.5)	-0.91 (1.00)	-3.3	-1.33	-0.83	-0.33	1.3	
		Week 14	Tezepelumab	60	57 (95.0)	-1.21 (0.96)	-2.8	-2.00	-1.17	-0.67	2.3	-0.25 [-0.61, 0.12]
			Placebo	63	57 (90.5)	-0.96 (1.03)	-3.2	-1.50	-1.00	-0.33	2.3	
		Week 16	Tezepelumab	60	57 (95.0)	-1.07 (1.03)	-2.8	-2.00	-1.00	-0.50	2.3	-0.25 [-0.62, 0.12]
			Placebo	63	57 (90.5)	-0.81 (1.12)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 18	Tezepelumab	60	58 (96.7)	-1.06 (0.95)	-2.8	-1.83	-1.00	-0.67	2.3	-0.17 [-0.54, 0.19]
			Placebo	63	57 (90.5)	-0.88 (1.17)	-3.2	-1.67	-0.83	-0.17	2.3	
		Week 20	Tezepelumab	60	58 (96.7)	-1.05 (0.99)	-2.7	-2.00	-1.00	-0.50	2.3	-0.25 [-0.61, 0.12]
			Placebo	63	57 (90.5)	-0.79 (1.13)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	60	58 (96.7)	-1.01 (0.99)	-2.7	-1.67	-0.92	-0.67	2.3	-0.17 [-0.54, 0.19]
			Placebo	63	57 (90.5)	-0.82 (1.13)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	60	58 (96.7)	-1.02 (0.98)	-2.7	-1.83	-1.00	-0.33	2.3	-0.23 [-0.60, 0.14]
			Placebo	63	57 (90.5)	-0.78 (1.10)	-3.2	-1.50	-0.83	0.00	2.3	
		Week 26	Tezepelumab	60	59 (98.3)	-0.95 (1.03)	-2.8	-2.00	-0.83	-0.17	2.3	-0.10 [-0.47, 0.26]
			Placebo	63	57 (90.5)	-0.84 (1.14)	-3.2	-1.50	-1.00	-0.17	2.3	
		Week 28	Tezepelumab	60	60 (100.0)	-1.01 (1.08)	-2.8	-2.00	-1.00	-0.17	2.3	-0.17 [-0.53, 0.19]
			Placebo	63	58 (92.1)	-0.82 (1.17)	-3.2	-1.67	-0.92	-0.17	2.3	
		Week 30	Tezepelumab	60	60 (100.0)	-1.02 (1.05)	-2.7	-2.00	-1.00	-0.33	2.3	-0.18 [-0.54, 0.18]
			Placebo	63	58 (92.1)	-0.82 (1.16)	-3.2	-1.50	-1.00	-0.17	2.3	
		Week 32	Tezepelumab	60	60 (100.0)	-1.09 (1.01)	-2.7	-2.00	-1.00	-0.50	2.3	-0.22 [-0.59, 0.14]
			Placebo	63	58 (92.1)	-0.86 (1.10)	-3.0	-1.50	-1.08	-0.33	2.3	
		Week 34	Tezepelumab	60	60 (100.0)	-1.02 (1.08)	-2.5	-2.00	-1.00	-0.33	2.3	-0.12 [-0.48, 0.24]
			Placebo	63	58 (92.1)	-0.89 (1.10)	-3.2	-1.50	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	60	60 (100.0)	-1.04 (1.06)	-2.8	-1.92	-1.17	-0.17	2.3	-0.29 [-0.65, 0.07]
			Placebo	63	58 (92.1)	-0.72 (1.14)	-3.5	-1.33	-0.83	0.00	2.3	
		Week 38	Tezepelumab	60	60 (100.0)	-1.04 (1.11)	-2.8	-2.00	-1.17	-0.25	2.3	-0.17 [-0.54, 0.19]
			Placebo	63	58 (92.1)	-0.85 (1.09)	-3.2	-1.33	-0.92	0.00	2.3	
		Week 40	Tezepelumab	60	60 (100.0)	-1.07 (1.08)	-2.8	-2.00	-1.08	-0.33	2.3	-0.31 [-0.67, 0.06]
			Placebo	63	58 (92.1)	-0.73 (1.16)	-3.2	-1.33	-0.83	0.17	2.3	
		Week 42	Tezepelumab	60	60 (100.0)	-1.09 (1.07)	-2.8	-2.00	-1.17	-0.50	2.3	-0.22 [-0.58, 0.14]
			Placebo	63	58 (92.1)	-0.85 (1.05)	-2.8	-1.33	-1.08	-0.17	2.3	
		Week 44	Tezepelumab	60	60 (100.0)	-1.04 (1.05)	-2.8	-2.00	-1.08	-0.33	2.3	-0.24 [-0.60, 0.12]
			Placebo	63	58 (92.1)	-0.78 (1.11)	-3.3	-1.50	-0.83	0.00	2.3	
		Week 46	Tezepelumab	60	60 (100.0)	-1.04 (1.09)	-2.8	-2.00	-1.00	-0.17	2.3	-0.16 [-0.52, 0.21]
			Placebo	63	58 (92.1)	-0.87 (1.02)	-3.2	-1.50	-1.00	-0.33	2.3	
		Week 48	Tezepelumab	60	60 (100.0)	-1.04 (1.09)	-2.7	-2.00	-0.92	-0.33	2.3	-0.19 [-0.55, 0.18]
			Placebo	63	58 (92.1)	-0.84 (1.09)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	60	60 (100.0)	-1.13 (1.12)	-2.7	-2.00	-1.17	-0.42	2.3	-0.18 [-0.54, 0.18]
			Placebo	63	58 (92.1)	-0.94 (1.03)	-3.5	-1.50	-1.00	-0.33	2.3	
		Week 52	Tezepelumab	60	60 (100.0)	-1.10 (1.11)	-2.7	-2.00	-1.08	-0.42	2.3	-0.20 [-0.56, 0.16]
			Placebo	63	58 (92.1)	-0.88 (1.07)	-3.5	-1.50	-0.83	-0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	17	17 (100.0)	2.96 (1.05)	0.3	2.50	2.83	3.50	4.8	
			Placebo	21	21 (100.0)	2.80 (0.51)	1.7	2.33	3.00	3.17	3.5	
		Week 2	Tezepelumab	17	17 (100.0)	2.51 (1.01)	0.8	1.83	2.50	3.33	4.2	
			Placebo	21	21 (100.0)	2.32 (0.68)	0.5	2.17	2.33	2.83	3.3	
		Week 4	Tezepelumab	17	17 (100.0)	2.29 (0.91)	0.7	1.33	2.67	2.83	3.5	
			Placebo	21	21 (100.0)	2.14 (0.99)	0.3	1.33	2.33	2.50	4.2	
		Week 6	Tezepelumab	17	17 (100.0)	2.05 (1.12)	0.5	1.00	2.00	2.67	4.0	
			Placebo	21	21 (100.0)	2.20 (1.11)	0.2	1.67	2.33	3.00	4.7	
		Week 8	Tezepelumab	17	17 (100.0)	1.90 (1.21)	0.0	0.83	1.67	2.67	4.2	
			Placebo	21	21 (100.0)	1.99 (1.07)	0.0	1.17	2.17	2.67	3.7	
		Week 10	Tezepelumab	17	17 (100.0)	1.67 (1.27)	0.0	0.50	1.33	2.67	3.7	
			Placebo	21	21 (100.0)	2.06 (0.98)	0.0	1.67	2.17	2.67	4.2	
		Week 12	Tezepelumab	17	17 (100.0)	1.56 (1.14)	0.0	0.50	1.67	2.50	3.3	
			Placebo	21	21 (100.0)	1.75 (1.07)	0.0	1.00	1.67	2.50	4.2	
		Week 14	Tezepelumab	17	17 (100.0)	1.65 (1.31)	0.0	0.50	1.50	2.33	4.2	
			Placebo	21	21 (100.0)	1.56 (0.76)	0.0	1.17	1.67	2.00	3.2	
		Week 16	Tezepelumab	17	17 (100.0)	1.69 (1.19)	0.0	0.83	1.17	2.50	4.2	
			Placebo	21	21 (100.0)	1.70 (1.11)	0.0	0.67	1.83	2.50	3.8	
		Week 18	Tezepelumab	17	17 (100.0)	1.75 (1.14)	0.0	1.00	1.50	2.50	4.2	
			Placebo	21	21 (100.0)	1.60 (1.13)	0.0	0.67	1.67	2.33	4.7	
		Week 20	Tezepelumab	17	17 (100.0)	1.75 (1.30)	0.3	0.83	1.17	2.50	5.0	
			Placebo	21	21 (100.0)	1.83 (0.95)	0.0	1.17	1.83	2.50	3.5	
		Week 22	Tezepelumab	17	17 (100.0)	1.70 (1.11)	0.0	1.00	1.50	2.33	3.8	
			Placebo	21	21 (100.0)	1.84 (0.90)	0.0	1.17	2.00	2.50	3.5	
		Week 24	Tezepelumab	17	17 (100.0)	1.67 (1.11)	0.3	0.83	1.17	2.33	3.8	
			Placebo	21	21 (100.0)	1.90 (0.87)	0.0	1.50	2.00	2.50	3.2	
		Week 26	Tezepelumab	17	17 (100.0)	1.80 (1.11)	0.0	0.83	1.83	2.50	4.0	
			Placebo	21	21 (100.0)	1.71 (1.12)	0.0	1.00	1.50	2.50	3.7	
		Week 28	Tezepelumab	17	17 (100.0)	1.84 (1.19)	0.0	1.00	1.67	2.67	3.8	
			Placebo	21	21 (100.0)	1.71 (1.22)	0.0	0.67	1.50	2.83	3.7	
		Week 30	Tezepelumab	17	17 (100.0)	1.75 (1.06)	0.3	0.83	1.50	2.33	3.7	
			Placebo	21	21 (100.0)	1.59 (1.07)	0.0	0.67	1.83	2.33	3.8	
		Week 32	Tezepelumab	17	17 (100.0)	1.63 (1.12)	0.3	0.67	1.50	2.33	4.0	
			Placebo	21	21 (100.0)	1.73 (1.01)	0.0	1.00	1.83	2.17	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	17	17 (100.0)	1.71 (1.20)	0.0	0.67	1.50	2.33	4.2	
			Placebo	21	21 (100.0)	1.64 (0.98)	0.0	0.83	1.83	2.33	3.5	
		Week 36	Tezepelumab	17	17 (100.0)	1.70 (1.10)	0.0	0.83	1.67	2.33	3.7	
			Placebo	21	21 (100.0)	2.15 (0.98)	0.0	1.50	2.17	2.83	4.2	
		Week 38	Tezepelumab	17	17 (100.0)	1.68 (1.22)	0.0	0.83	1.50	2.33	4.5	
			Placebo	21	21 (100.0)	1.80 (0.91)	0.0	1.17	1.83	2.50	3.2	
		Week 40	Tezepelumab	17	17 (100.0)	1.50 (1.16)	0.0	0.67	1.33	2.33	3.7	
			Placebo	21	21 (100.0)	2.10 (1.10)	0.0	1.50	2.17	2.50	4.2	
		Week 42	Tezepelumab	17	17 (100.0)	1.65 (1.10)	0.0	0.83	1.00	2.50	3.8	
			Placebo	21	21 (100.0)	1.91 (0.99)	0.0	1.33	2.00	2.50	4.5	
		Week 44	Tezepelumab	17	17 (100.0)	1.63 (1.11)	0.0	0.67	1.50	2.33	3.8	
			Placebo	21	21 (100.0)	1.94 (1.18)	0.0	1.17	2.17	2.50	4.2	
		Week 46	Tezepelumab	17	17 (100.0)	1.75 (1.14)	0.0	0.83	1.50	2.67	3.8	
			Placebo	21	21 (100.0)	1.85 (0.88)	0.0	1.50	2.00	2.17	3.3	
		Week 48	Tezepelumab	17	17 (100.0)	1.80 (1.18)	0.2	1.00	1.50	2.67	4.0	
			Placebo	21	21 (100.0)	2.02 (0.95)	0.0	2.00	2.17	2.50	3.8	
		Week 50	Tezepelumab	17	17 (100.0)	1.66 (1.15)	0.5	0.83	1.17	2.33	4.2	
			Placebo	21	21 (100.0)	1.79 (0.98)	0.0	1.00	2.17	2.50	3.3	
		Week 52	Tezepelumab	17	17 (100.0)	1.63 (1.22)	0.2	0.67	1.17	2.33	4.3	
			Placebo	21	21 (100.0)	1.83 (1.04)	0.0	1.00	2.17	2.50	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	17	17 (100.0)	-0.45 (0.72)	-2.0	-0.83	-0.33	-0.17	0.7	0.05 [-0.59, 0.69]
			Placebo	21	21 (100.0)	-0.48 (0.52)	-1.5	-0.83	-0.50	0.00	0.3	
		Week 4	Tezepelumab	17	17 (100.0)	-0.67 (1.04)	-2.5	-1.17	-0.83	-0.17	2.3	-0.01 [-0.65, 0.63]
			Placebo	21	21 (100.0)	-0.66 (0.88)	-2.0	-1.33	-0.83	0.00	1.2	
		Week 6	Tezepelumab	17	17 (100.0)	-0.91 (1.22)	-2.7	-1.50	-0.83	-0.33	2.3	-0.29 [-0.94, 0.35]
			Placebo	21	21 (100.0)	-0.60 (0.90)	-2.2	-1.17	-0.67	0.00	1.5	
		Week 8	Tezepelumab	17	17 (100.0)	-1.06 (1.29)	-3.0	-1.83	-1.00	-0.50	2.3	-0.23 [-0.87, 0.42]
			Placebo	21	21 (100.0)	-0.81 (0.93)	-3.0	-1.17	-0.50	-0.17	0.7	
		Week 10	Tezepelumab	17	17 (100.0)	-1.29 (1.32)	-3.2	-2.00	-1.50	-0.83	2.3	-0.49 [-1.14, 0.16]
			Placebo	21	21 (100.0)	-0.74 (0.94)	-2.3	-1.33	-0.67	-0.33	2.0	
		Week 12	Tezepelumab	17	17 (100.0)	-1.40 (1.30)	-2.8	-2.17	-1.67	-0.83	2.3	-0.31 [-0.96, 0.33]
			Placebo	21	21 (100.0)	-1.05 (0.98)	-3.2	-1.83	-1.00	-0.67	1.2	
		Week 14	Tezepelumab	17	17 (100.0)	-1.31 (1.35)	-3.2	-2.17	-1.50	-0.33	2.3	-0.07 [-0.71, 0.57]
			Placebo	21	21 (100.0)	-1.24 (0.76)	-3.2	-1.50	-1.17	-0.83	0.2	
		Week 16	Tezepelumab	17	17 (100.0)	-1.27 (1.29)	-3.0	-2.17	-1.33	-0.50	2.3	-0.15 [-0.79, 0.49]
			Placebo	21	21 (100.0)	-1.10 (1.04)	-3.2	-1.67	-1.17	-0.17	0.8	
		Week 18	Tezepelumab	17	17 (100.0)	-1.22 (1.33)	-3.2	-2.17	-1.50	-0.67	2.3	-0.01 [-0.65, 0.62]
			Placebo	21	21 (100.0)	-1.20 (1.07)	-3.2	-1.83	-1.17	-0.67	1.5	
		Week 20	Tezepelumab	17	17 (100.0)	-1.21 (1.35)	-3.2	-2.00	-1.50	-0.50	2.3	-0.21 [-0.85, 0.43]
			Placebo	21	21 (100.0)	-0.97 (0.95)	-2.7	-1.67	-1.00	-0.33	0.8	
		Week 22	Tezepelumab	17	17 (100.0)	-1.26 (1.28)	-3.0	-2.17	-1.50	-0.67	2.3	-0.29 [-0.93, 0.35]
			Placebo	21	21 (100.0)	-0.96 (0.83)	-2.3	-1.50	-0.83	-0.50	0.7	
		Week 24	Tezepelumab	17	17 (100.0)	-1.29 (1.25)	-3.2	-1.83	-1.50	-0.67	2.3	-0.36 [-1.01, 0.28]
			Placebo	21	21 (100.0)	-0.90 (0.92)	-2.5	-1.50	-1.00	0.00	0.5	
		Week 26	Tezepelumab	17	17 (100.0)	-1.16 (1.35)	-2.8	-2.33	-1.33	-0.33	2.3	-0.05 [-0.69, 0.59]
			Placebo	21	21 (100.0)	-1.10 (1.04)	-3.2	-1.83	-1.33	-0.33	0.7	
		Week 28	Tezepelumab	17	17 (100.0)	-1.12 (1.40)	-3.2	-2.17	-1.17	-0.17	2.3	-0.02 [-0.66, 0.62]
			Placebo	21	21 (100.0)	-1.10 (1.13)	-3.2	-1.83	-1.17	-0.33	1.2	
		Week 30	Tezepelumab	17	17 (100.0)	-1.22 (1.25)	-2.7	-2.33	-1.33	-0.83	2.3	-0.00 [-0.64, 0.64]
			Placebo	21	21 (100.0)	-1.21 (0.88)	-2.5	-2.00	-1.17	-0.83	0.8	
		Week 32	Tezepelumab	17	17 (100.0)	-1.33 (1.27)	-3.0	-2.17	-1.50	-1.00	2.3	-0.24 [-0.88, 0.40]
			Placebo	21	21 (100.0)	-1.07 (0.90)	-2.8	-1.50	-1.17	-1.00	0.7	
		Week 34	Tezepelumab	17	17 (100.0)	-1.25 (1.31)	-2.8	-2.17	-1.50	-0.67	2.3	-0.09 [-0.73, 0.55]
			Placebo	21	21 (100.0)	-1.16 (0.85)	-2.8	-1.50	-1.17	-0.67	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	17	17 (100.0)	-1.26 (1.34)	-3.0	-2.33	-1.50	-0.83	2.3	-0.55 [-1.20, 0.10]
			Placebo	21	21 (100.0)	-0.65 (0.91)	-2.3	-1.17	-0.83	-0.17	1.2	
		Week 38	Tezepelumab	17	17 (100.0)	-1.28 (1.31)	-3.0	-2.33	-1.33	-0.83	2.3	-0.27 [-0.91, 0.38]
			Placebo	21	21 (100.0)	-1.00 (0.84)	-2.3	-1.67	-1.17	-0.33	0.5	
		Week 40	Tezepelumab	17	17 (100.0)	-1.46 (1.32)	-3.2	-2.50	-1.50	-0.83	2.3	-0.63 [-1.29, 0.02]
			Placebo	21	21 (100.0)	-0.70 (1.10)	-2.3	-1.33	-0.83	0.33	1.2	
		Week 42	Tezepelumab	17	17 (100.0)	-1.31 (1.29)	-2.8	-2.17	-1.50	-0.67	2.3	-0.38 [-1.03, 0.26]
			Placebo	21	21 (100.0)	-0.89 (0.94)	-2.3	-1.33	-1.17	-0.50	1.5	
		Week 44	Tezepelumab	17	17 (100.0)	-1.33 (1.33)	-3.2	-2.50	-1.33	-0.67	2.3	-0.39 [-1.04, 0.26]
			Placebo	21	21 (100.0)	-0.86 (1.13)	-2.7	-1.67	-1.00	-0.33	1.2	
		Week 46	Tezepelumab	17	17 (100.0)	-1.22 (1.29)	-2.8	-2.17	-1.33	-0.67	2.3	-0.26 [-0.90, 0.39]
			Placebo	21	21 (100.0)	-0.95 (0.77)	-2.3	-1.33	-1.00	-0.67	0.8	
		Week 48	Tezepelumab	17	17 (100.0)	-1.16 (1.37)	-2.7	-2.50	-1.50	-0.17	2.3	-0.34 [-0.98, 0.31]
			Placebo	21	21 (100.0)	-0.78 (0.88)	-2.7	-1.17	-0.83	-0.33	0.8	
		Week 50	Tezepelumab	17	17 (100.0)	-1.30 (1.31)	-2.5	-2.50	-1.50	-1.00	2.3	-0.26 [-0.90, 0.39]
			Placebo	21	21 (100.0)	-1.02 (0.95)	-3.0	-1.67	-1.00	-0.50	0.5	
		Week 52	Tezepelumab	17	17 (100.0)	-1.33 (1.34)	-2.7	-2.50	-1.67	-1.00	2.3	-0.31 [-0.96, 0.33]
			Placebo	21	21 (100.0)	-0.97 (1.00)	-3.0	-1.67	-1.00	-0.17	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	49	49 (100.0)	2.63 (0.73)	0.0	2.17	2.67	3.00	4.5	
			Placebo	44	44 (100.0)	2.66 (0.80)	0.3	2.33	2.67	3.00	4.7	
		Week 2	Tezepelumab	49	46 (93.9)	2.12 (0.93)	0.0	1.50	2.33	2.83	3.7	
			Placebo	44	37 (84.1)	2.28 (0.83)	0.3	1.83	2.33	2.50	4.8	
		Week 4	Tezepelumab	49	46 (93.9)	1.86 (0.94)	0.2	1.17	2.00	2.67	3.5	
			Placebo	44	37 (84.1)	2.16 (0.88)	0.2	1.50	2.33	2.67	3.7	
		Week 6	Tezepelumab	49	46 (93.9)	1.82 (0.96)	0.0	1.17	1.83	2.50	3.7	
			Placebo	44	37 (84.1)	2.05 (1.11)	0.2	1.17	2.00	2.67	5.5	
		Week 8	Tezepelumab	49	46 (93.9)	1.68 (1.07)	0.0	0.83	1.67	2.50	4.8	
			Placebo	44	38 (86.4)	2.10 (1.10)	0.0	1.33	2.08	2.83	4.7	
		Week 10	Tezepelumab	49	46 (93.9)	1.66 (1.02)	0.0	0.83	1.67	2.33	4.3	
			Placebo	44	38 (86.4)	2.07 (1.10)	0.0	1.33	2.17	2.67	5.3	
		Week 12	Tezepelumab	49	46 (93.9)	1.56 (1.03)	0.0	0.50	1.50	2.50	4.3	
			Placebo	44	38 (86.4)	1.92 (0.95)	0.0	1.33	2.00	2.33	4.3	
		Week 14	Tezepelumab	49	46 (93.9)	1.43 (0.95)	0.0	0.67	1.50	2.17	4.3	
			Placebo	44	38 (86.4)	1.92 (1.06)	0.3	1.33	2.00	2.33	5.0	
		Week 16	Tezepelumab	49	46 (93.9)	1.61 (1.10)	0.0	0.67	1.58	2.50	4.3	
			Placebo	44	38 (86.4)	2.10 (1.16)	0.2	1.50	2.17	2.67	5.0	
		Week 18	Tezepelumab	49	47 (95.9)	1.55 (0.99)	0.0	0.67	1.67	2.17	4.3	
			Placebo	44	38 (86.4)	2.02 (1.12)	0.0	1.33	2.17	2.67	5.0	
		Week 20	Tezepelumab	49	47 (95.9)	1.57 (1.01)	0.0	0.83	1.83	2.33	4.3	
			Placebo	44	38 (86.4)	2.04 (1.15)	0.2	1.33	2.17	2.67	5.0	
		Week 22	Tezepelumab	49	47 (95.9)	1.67 (0.93)	0.0	0.83	1.83	2.33	4.3	
			Placebo	44	38 (86.4)	1.97 (1.25)	0.0	0.83	2.00	2.67	5.0	
		Week 24	Tezepelumab	49	47 (95.9)	1.67 (1.04)	0.0	0.83	1.83	2.50	4.3	
			Placebo	44	38 (86.4)	2.04 (1.13)	0.2	1.33	2.08	2.67	4.5	
		Week 26	Tezepelumab	49	48 (98.0)	1.67 (1.07)	0.0	1.00	1.75	2.50	4.3	
			Placebo	44	38 (86.4)	2.04 (1.09)	0.3	1.17	1.92	2.83	4.5	
		Week 28	Tezepelumab	49	49 (100.0)	1.59 (1.06)	0.0	0.83	1.67	2.17	4.3	
			Placebo	44	39 (88.6)	2.01 (1.17)	0.0	1.00	2.17	2.67	4.5	
		Week 30	Tezepelumab	49	49 (100.0)	1.59 (1.07)	0.0	0.67	1.67	2.17	4.3	
			Placebo	44	39 (88.6)	2.06 (1.15)	0.0	1.17	2.00	2.83	4.5	
		Week 32	Tezepelumab	49	49 (100.0)	1.56 (1.06)	0.0	0.67	1.83	2.33	4.3	
			Placebo	44	39 (88.6)	1.93 (1.14)	0.0	1.17	1.83	2.67	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	49	49 (100.0)	1.62 (1.10)	0.0	0.67	1.50	2.50	4.3	
			Placebo	44	39 (88.6)	1.92 (1.15)	0.0	1.17	1.83	2.50	4.5	
		Week 36	Tezepelumab	49	49 (100.0)	1.58 (1.04)	0.0	1.00	1.50	2.33	4.3	
			Placebo	44	39 (88.6)	1.91 (1.20)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	49	49 (100.0)	1.62 (1.14)	0.0	0.83	1.67	2.50	4.3	
			Placebo	44	39 (88.6)	1.89 (1.19)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	49	49 (100.0)	1.65 (1.11)	0.0	0.67	1.83	2.50	4.3	
			Placebo	44	39 (88.6)	1.95 (1.16)	0.0	1.17	2.00	2.67	4.5	
		Week 42	Tezepelumab	49	49 (100.0)	1.56 (1.09)	0.0	0.83	1.67	2.17	4.3	
			Placebo	44	39 (88.6)	1.82 (1.05)	0.0	1.00	1.83	2.67	4.5	
		Week 44	Tezepelumab	49	49 (100.0)	1.61 (1.08)	0.0	0.83	1.67	2.50	4.3	
			Placebo	44	39 (88.6)	1.94 (1.01)	0.0	1.17	2.00	2.67	4.5	
		Week 46	Tezepelumab	49	49 (100.0)	1.59 (1.12)	0.0	0.67	1.83	2.33	4.3	
			Placebo	44	39 (88.6)	1.83 (1.04)	0.0	1.17	1.83	2.33	4.5	
		Week 48	Tezepelumab	49	49 (100.0)	1.57 (1.09)	0.0	0.67	1.67	2.33	4.3	
			Placebo	44	39 (88.6)	1.80 (1.10)	0.0	1.00	1.83	2.33	4.5	
		Week 50	Tezepelumab	49	49 (100.0)	1.54 (1.14)	0.0	0.67	1.67	2.33	4.3	
			Placebo	44	39 (88.6)	1.77 (1.01)	0.0	1.00	1.67	2.17	4.5	
		Week 52	Tezepelumab	49	49 (100.0)	1.60 (1.09)	0.0	1.00	1.67	2.33	4.3	
			Placebo	44	39 (88.6)	1.86 (1.05)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 2	Tezepelumab	49	46 (93.9)	-0.55 (0.71)	-2.8	-1.00	-0.42	0.00	0.3	-0.17 [-0.61, 0.26]
			Placebo	44	37 (84.1)	-0.42 (0.77)	-2.8	-0.83	-0.17	0.00	1.0	
		Week 4	Tezepelumab	49	46 (93.9)	-0.82 (0.75)	-2.3	-1.33	-0.67	-0.33	0.7	-0.33 [-0.76, 0.11]
			Placebo	44	37 (84.1)	-0.55 (0.92)	-3.0	-1.00	-0.33	0.00	0.8	
		Week 6	Tezepelumab	49	46 (93.9)	-0.85 (0.82)	-2.5	-1.33	-1.00	-0.17	1.2	-0.21 [-0.65, 0.22]
			Placebo	44	37 (84.1)	-0.65 (1.04)	-3.3	-1.33	-0.33	0.00	1.5	
		Week 8	Tezepelumab	49	46 (93.9)	-0.99 (0.95)	-2.7	-1.67	-1.00	-0.33	2.2	-0.37 [-0.81, 0.06]
			Placebo	44	38 (86.4)	-0.62 (1.04)	-3.2	-1.00	-0.67	0.17	1.0	
		Week 10	Tezepelumab	49	46 (93.9)	-1.02 (0.88)	-2.7	-1.67	-1.17	-0.50	0.8	-0.36 [-0.79, 0.08]
			Placebo	44	38 (86.4)	-0.64 (1.21)	-3.3	-1.33	-0.50	0.00	2.7	
		Week 12	Tezepelumab	49	46 (93.9)	-1.12 (0.87)	-3.0	-1.83	-1.17	-0.67	0.5	-0.34 [-0.77, 0.09]
			Placebo	44	38 (86.4)	-0.80 (1.00)	-3.3	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	49	46 (93.9)	-1.25 (0.86)	-3.7	-1.83	-1.17	-0.67	0.5	-0.45 [-0.89, -0.02]
			Placebo	44	38 (86.4)	-0.80 (1.12)	-3.2	-1.50	-0.83	-0.33	2.3	
		Week 16	Tezepelumab	49	46 (93.9)	-1.06 (0.93)	-2.7	-1.83	-1.00	-0.50	1.5	-0.44 [-0.87, -0.00]
			Placebo	44	38 (86.4)	-0.61 (1.13)	-3.2	-1.17	-0.50	0.00	2.3	
		Week 18	Tezepelumab	49	47 (95.9)	-1.11 (0.86)	-3.5	-1.83	-1.00	-0.67	0.5	-0.41 [-0.84, 0.02]
			Placebo	44	38 (86.4)	-0.69 (1.18)	-3.2	-1.33	-0.50	0.00	2.3	
		Week 20	Tezepelumab	49	47 (95.9)	-1.09 (0.85)	-2.7	-1.83	-1.00	-0.50	0.7	-0.41 [-0.84, 0.02]
			Placebo	44	38 (86.4)	-0.67 (1.19)	-3.2	-1.17	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	49	47 (95.9)	-0.98 (0.91)	-2.7	-1.67	-0.83	-0.67	1.8	-0.22 [-0.65, 0.20]
			Placebo	44	38 (86.4)	-0.74 (1.25)	-3.3	-1.33	-0.83	0.00	2.3	
		Week 24	Tezepelumab	49	47 (95.9)	-0.99 (0.86)	-2.5	-1.83	-0.83	-0.33	0.7	-0.31 [-0.74, 0.12]
			Placebo	44	38 (86.4)	-0.68 (1.18)	-3.2	-1.33	-0.58	0.00	2.3	
		Week 26	Tezepelumab	49	48 (98.0)	-0.96 (0.90)	-2.7	-1.92	-0.83	-0.25	0.7	-0.28 [-0.71, 0.15]
			Placebo	44	38 (86.4)	-0.68 (1.16)	-2.8	-1.50	-0.67	0.17	2.3	
		Week 28	Tezepelumab	49	49 (100.0)	-1.04 (0.97)	-2.7	-2.00	-1.00	-0.50	0.8	-0.38 [-0.80, 0.05]
			Placebo	44	39 (88.6)	-0.64 (1.15)	-2.8	-1.50	-0.50	0.00	2.3	
		Week 30	Tezepelumab	49	49 (100.0)	-1.04 (1.02)	-3.5	-2.00	-1.00	-0.33	1.8	-0.40 [-0.82, 0.03]
			Placebo	44	39 (88.6)	-0.60 (1.21)	-3.2	-1.33	-0.50	0.17	2.3	
		Week 32	Tezepelumab	49	49 (100.0)	-1.07 (0.89)	-2.7	-1.83	-1.00	-0.50	0.8	-0.34 [-0.76, 0.09]
			Placebo	44	39 (88.6)	-0.73 (1.17)	-3.0	-1.50	-0.50	-0.17	2.3	
		Week 34	Tezepelumab	49	49 (100.0)	-1.01 (1.01)	-2.5	-2.00	-1.00	-0.33	2.0	-0.26 [-0.68, 0.17]
			Placebo	44	39 (88.6)	-0.74 (1.17)	-3.2	-1.33	-0.67	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHK: Change from baseline in ACQ-6 score by key subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	49	49 (100.0)	-1.05 (0.96)	-2.8	-1.83	-1.17	-0.33	1.5	-0.28 [-0.70, 0.15]
			Placebo	44	39 (88.6)	-0.75 (1.24)	-3.5	-1.33	-0.67	0.00	2.3	
		Week 38	Tezepelumab	49	49 (100.0)	-1.01 (1.03)	-2.7	-2.00	-1.17	-0.17	2.3	-0.23 [-0.65, 0.20]
			Placebo	44	39 (88.6)	-0.76 (1.19)	-3.2	-1.33	-0.83	0.17	2.3	
		Week 40	Tezepelumab	49	49 (100.0)	-0.98 (0.99)	-2.7	-2.00	-0.83	-0.33	1.7	-0.26 [-0.68, 0.16]
			Placebo	44	39 (88.6)	-0.71 (1.19)	-3.2	-1.33	-0.67	0.00	2.3	
		Week 42	Tezepelumab	49	49 (100.0)	-1.07 (1.02)	-3.3	-2.00	-0.83	-0.50	2.0	-0.23 [-0.65, 0.19]
			Placebo	44	39 (88.6)	-0.83 (1.09)	-2.8	-1.33	-0.83	0.00	2.3	
		Week 44	Tezepelumab	49	49 (100.0)	-1.02 (0.99)	-3.5	-1.83	-1.00	-0.17	1.5	-0.29 [-0.72, 0.13]
			Placebo	44	39 (88.6)	-0.72 (1.08)	-3.3	-1.50	-0.83	0.00	2.3	
		Week 46	Tezepelumab	49	49 (100.0)	-1.04 (1.02)	-3.3	-2.00	-1.00	-0.17	1.7	-0.21 [-0.63, 0.22]
			Placebo	44	39 (88.6)	-0.82 (1.12)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 48	Tezepelumab	49	49 (100.0)	-1.06 (0.97)	-2.7	-2.00	-0.83	-0.50	1.8	-0.20 [-0.62, 0.23]
			Placebo	44	39 (88.6)	-0.85 (1.17)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	49	49 (100.0)	-1.09 (1.01)	-2.7	-2.00	-1.00	-0.50	1.8	-0.19 [-0.62, 0.23]
			Placebo	44	39 (88.6)	-0.88 (1.05)	-3.5	-1.33	-1.00	-0.33	2.3	
		Week 52	Tezepelumab	49	49 (100.0)	-1.03 (0.98)	-2.7	-2.00	-1.00	-0.50	1.8	-0.23 [-0.65, 0.19]
			Placebo	44	39 (88.6)	-0.79 (1.10)	-3.5	-1.33	-0.83	-0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	2.72 (0.86)	0.0	2.17	2.67	3.17	4.8	
			Placebo	58	58 (100.0)	2.68 (0.71)	0.3	2.33	2.75	3.17	4.5	
		Week 2	Tezepelumab	60	57 (95.0)	2.28 (0.94)	0.2	1.50	2.33	3.00	4.2	
			Placebo	58	51 (87.9)	2.27 (0.74)	0.3	1.83	2.33	2.83	4.8	
		Week 4	Tezepelumab	60	57 (95.0)	2.01 (0.95)	0.2	1.33	2.17	2.67	3.5	
			Placebo	58	51 (87.9)	2.12 (0.89)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	60	57 (95.0)	1.93 (1.02)	0.0	1.33	2.00	2.67	4.0	
			Placebo	58	51 (87.9)	2.09 (1.04)	0.2	1.33	2.17	2.67	4.7	
		Week 8	Tezepelumab	60	57 (95.0)	1.80 (1.12)	0.0	0.83	1.67	2.67	4.8	
			Placebo	58	52 (89.7)	2.04 (1.04)	0.0	1.25	2.17	2.75	4.7	
		Week 10	Tezepelumab	60	57 (95.0)	1.73 (1.10)	0.0	0.83	1.83	2.67	4.3	
			Placebo	58	52 (89.7)	2.04 (0.98)	0.0	1.50	2.17	2.67	4.2	
		Week 12	Tezepelumab	60	57 (95.0)	1.61 (1.05)	0.0	0.67	1.67	2.50	4.3	
			Placebo	58	52 (89.7)	1.85 (0.96)	0.0	1.08	2.00	2.50	4.3	
		Week 14	Tezepelumab	60	57 (95.0)	1.53 (1.08)	0.0	0.67	1.50	2.33	4.3	
			Placebo	58	52 (89.7)	1.77 (0.87)	0.0	1.33	1.83	2.17	5.0	
		Week 16	Tezepelumab	60	57 (95.0)	1.70 (1.14)	0.0	0.67	1.83	2.50	4.3	
			Placebo	58	52 (89.7)	1.93 (1.00)	0.0	1.08	2.00	2.67	4.5	
		Week 18	Tezepelumab	60	58 (96.7)	1.66 (1.04)	0.0	0.83	1.75	2.33	4.3	
			Placebo	58	52 (89.7)	1.84 (1.07)	0.0	1.00	1.83	2.50	4.7	
		Week 20	Tezepelumab	60	58 (96.7)	1.68 (1.12)	0.0	0.83	1.83	2.50	5.0	
			Placebo	58	52 (89.7)	1.89 (1.01)	0.0	1.17	1.92	2.67	4.5	
		Week 22	Tezepelumab	60	58 (96.7)	1.74 (0.97)	0.0	1.00	1.83	2.33	4.3	
			Placebo	58	52 (89.7)	1.85 (1.07)	0.0	1.00	2.00	2.58	4.5	
		Week 24	Tezepelumab	60	58 (96.7)	1.73 (1.07)	0.0	1.00	1.83	2.50	4.3	
			Placebo	58	52 (89.7)	1.95 (1.00)	0.0	1.42	2.00	2.50	4.5	
		Week 26	Tezepelumab	60	59 (98.3)	1.78 (1.08)	0.0	1.17	1.83	2.67	4.3	
			Placebo	58	52 (89.7)	1.91 (1.06)	0.0	1.00	1.83	2.75	4.5	
		Week 28	Tezepelumab	60	60 (100.0)	1.72 (1.11)	0.0	1.00	1.67	2.50	4.3	
			Placebo	58	53 (91.4)	1.92 (1.13)	0.0	1.00	2.00	2.67	4.5	
		Week 30	Tezepelumab	60	60 (100.0)	1.69 (1.08)	0.0	0.92	1.67	2.33	4.3	
			Placebo	58	53 (91.4)	1.90 (1.10)	0.0	1.00	2.00	2.67	4.5	
		Week 32	Tezepelumab	60	60 (100.0)	1.62 (1.09)	0.0	0.67	1.83	2.50	4.3	
			Placebo	58	53 (91.4)	1.84 (1.06)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Absolute values	Week 34	Tezepelumab	60	60 (100.0)	1.70 (1.14)	0.0	0.75	1.83	2.50	4.3	
			Placebo	58	53 (91.4)	1.82 (1.03)	0.0	1.17	1.83	2.33	4.5	
		Week 36	Tezepelumab	60	60 (100.0)	1.66 (1.07)	0.0	1.00	1.67	2.50	4.3	
			Placebo	58	53 (91.4)	1.93 (1.10)	0.0	1.17	1.83	2.67	4.5	
		Week 38	Tezepelumab	60	60 (100.0)	1.69 (1.17)	0.0	0.92	1.67	2.67	4.5	
			Placebo	58	53 (91.4)	1.85 (1.05)	0.0	1.17	1.83	2.50	4.5	
		Week 40	Tezepelumab	60	60 (100.0)	1.66 (1.14)	0.0	0.58	1.83	2.58	4.3	
			Placebo	58	53 (91.4)	1.99 (1.10)	0.0	1.33	2.00	2.67	4.5	
		Week 42	Tezepelumab	60	60 (100.0)	1.62 (1.12)	0.0	0.83	1.67	2.50	4.3	
			Placebo	58	53 (91.4)	1.87 (1.04)	0.0	1.17	2.00	2.50	4.5	
		Week 44	Tezepelumab	60	60 (100.0)	1.66 (1.10)	0.0	0.75	1.67	2.67	4.3	
			Placebo	58	53 (91.4)	1.92 (1.04)	0.0	1.17	2.00	2.50	4.5	
		Week 46	Tezepelumab	60	60 (100.0)	1.68 (1.14)	0.0	0.75	1.83	2.58	4.3	
			Placebo	58	53 (91.4)	1.87 (0.97)	0.0	1.33	1.83	2.33	4.5	
		Week 48	Tezepelumab	60	60 (100.0)	1.68 (1.14)	0.0	0.75	1.75	2.58	4.3	
			Placebo	58	53 (91.4)	1.86 (1.06)	0.0	1.00	2.00	2.50	4.5	
		Week 50	Tezepelumab	60	60 (100.0)	1.64 (1.15)	0.0	0.83	1.67	2.33	4.3	
			Placebo	58	53 (91.4)	1.75 (0.96)	0.0	1.00	1.83	2.33	4.5	
		Week 52	Tezepelumab	60	60 (100.0)	1.68 (1.13)	0.0	1.00	1.67	2.42	4.3	
			Placebo	58	53 (91.4)	1.86 (1.00)	0.0	1.17	2.17	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 2	Tezepelumab	60	57 (95.0)	-0.48 (0.66)	-2.0	-1.00	-0.33	0.00	0.7	-0.05 [-0.42, 0.33]
			Placebo	58	51 (87.9)	-0.45 (0.71)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	60	57 (95.0)	-0.75 (0.82)	-2.5	-1.17	-0.67	-0.17	2.3	-0.18 [-0.55, 0.20]
			Placebo	58	51 (87.9)	-0.59 (0.90)	-3.0	-1.17	-0.33	0.00	1.2	
		Week 6	Tezepelumab	60	57 (95.0)	-0.82 (0.94)	-2.7	-1.33	-0.83	-0.17	2.3	-0.20 [-0.58, 0.18]
			Placebo	58	51 (87.9)	-0.63 (1.00)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	60	57 (95.0)	-0.96 (1.04)	-3.0	-1.50	-1.00	-0.33	2.3	-0.27 [-0.64, 0.11]
			Placebo	58	52 (89.7)	-0.69 (0.98)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	60	57 (95.0)	-1.03 (1.02)	-3.2	-1.67	-1.17	-0.50	2.3	-0.33 [-0.71, 0.05]
			Placebo	58	52 (89.7)	-0.69 (1.06)	-3.3	-1.25	-0.50	-0.08	2.5	
		Week 12	Tezepelumab	60	57 (95.0)	-1.15 (1.00)	-3.0	-2.00	-1.17	-0.67	2.3	-0.28 [-0.66, 0.10]
			Placebo	58	52 (89.7)	-0.87 (0.94)	-3.3	-1.17	-0.75	-0.25	1.3	
		Week 14	Tezepelumab	60	57 (95.0)	-1.23 (1.02)	-3.7	-2.00	-1.17	-0.67	2.3	-0.27 [-0.65, 0.11]
			Placebo	58	52 (89.7)	-0.96 (0.93)	-3.2	-1.50	-0.92	-0.33	1.2	
		Week 16	Tezepelumab	60	57 (95.0)	-1.05 (1.06)	-3.0	-1.83	-1.00	-0.50	2.3	-0.24 [-0.62, 0.13]
			Placebo	58	52 (89.7)	-0.80 (1.03)	-3.2	-1.33	-0.83	-0.08	2.3	
		Week 18	Tezepelumab	60	58 (96.7)	-1.08 (1.00)	-3.5	-1.67	-1.00	-0.67	2.3	-0.18 [-0.56, 0.19]
			Placebo	58	52 (89.7)	-0.89 (1.09)	-3.2	-1.58	-0.83	-0.08	2.3	
		Week 20	Tezepelumab	60	58 (96.7)	-1.07 (1.02)	-3.2	-1.67	-1.00	-0.50	2.3	-0.22 [-0.60, 0.15]
			Placebo	58	52 (89.7)	-0.83 (1.05)	-3.2	-1.42	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	60	58 (96.7)	-1.00 (1.02)	-3.0	-1.50	-0.83	-0.67	2.3	-0.12 [-0.49, 0.26]
			Placebo	58	52 (89.7)	-0.87 (1.08)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	60	58 (96.7)	-1.01 (0.98)	-3.2	-1.67	-1.00	-0.33	2.3	-0.24 [-0.61, 0.14]
			Placebo	58	52 (89.7)	-0.77 (1.06)	-3.2	-1.42	-0.67	0.00	2.3	
		Week 26	Tezepelumab	60	59 (98.3)	-0.94 (1.02)	-2.8	-1.83	-0.83	-0.17	2.3	-0.12 [-0.50, 0.25]
			Placebo	58	52 (89.7)	-0.81 (1.09)	-2.8	-1.50	-0.92	0.00	2.3	
		Week 28	Tezepelumab	60	60 (100.0)	-0.99 (1.10)	-3.2	-2.00	-0.92	-0.08	2.3	-0.21 [-0.58, 0.16]
			Placebo	58	53 (91.4)	-0.76 (1.12)	-2.8	-1.50	-0.83	-0.17	2.3	
		Week 30	Tezepelumab	60	60 (100.0)	-1.02 (1.08)	-3.5	-1.92	-1.00	-0.33	2.3	-0.22 [-0.59, 0.16]
			Placebo	58	53 (91.4)	-0.78 (1.14)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	60	60 (100.0)	-1.10 (1.01)	-3.0	-1.92	-1.00	-0.50	2.3	-0.25 [-0.62, 0.13]
			Placebo	58	53 (91.4)	-0.84 (1.09)	-3.0	-1.50	-1.00	-0.33	2.3	
		Week 34	Tezepelumab	60	60 (100.0)	-1.02 (1.10)	-2.8	-2.00	-1.00	-0.33	2.3	-0.15 [-0.52, 0.22]
			Placebo	58	53 (91.4)	-0.86 (1.05)	-3.2	-1.33	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
White	Change from baseline	Week 36	Tezepelumab	60	60 (100.0)	-1.06 (1.08)	-3.0	-1.83	-1.17	-0.25	2.3	-0.28 [-0.65, 0.09]
			Placebo	58	53 (91.4)	-0.75 (1.11)	-3.5	-1.33	-0.83	-0.17	2.3	
		Week 38	Tezepelumab	60	60 (100.0)	-1.03 (1.12)	-3.0	-2.00	-1.17	-0.17	2.3	-0.18 [-0.55, 0.19]
			Placebo	58	53 (91.4)	-0.83 (1.07)	-3.2	-1.33	-0.83	0.00	2.3	
		Week 40	Tezepelumab	60	60 (100.0)	-1.06 (1.11)	-3.2	-2.00	-1.00	-0.33	2.3	-0.33 [-0.70, 0.04]
			Placebo	58	53 (91.4)	-0.69 (1.13)	-3.2	-1.33	-0.67	0.17	2.3	
		Week 42	Tezepelumab	60	60 (100.0)	-1.09 (1.12)	-3.3	-2.00	-1.08	-0.50	2.3	-0.26 [-0.63, 0.11]
			Placebo	58	53 (91.4)	-0.81 (1.08)	-2.8	-1.33	-0.83	-0.17	2.3	
		Week 44	Tezepelumab	60	60 (100.0)	-1.05 (1.10)	-3.5	-1.92	-1.00	-0.42	2.3	-0.27 [-0.65, 0.10]
			Placebo	58	53 (91.4)	-0.75 (1.07)	-3.3	-1.50	-0.83	0.00	2.3	
		Week 46	Tezepelumab	60	60 (100.0)	-1.04 (1.10)	-3.3	-2.00	-1.00	-0.17	2.3	-0.21 [-0.58, 0.16]
			Placebo	58	53 (91.4)	-0.81 (1.04)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 48	Tezepelumab	60	60 (100.0)	-1.03 (1.10)	-2.7	-2.00	-0.83	-0.42	2.3	-0.20 [-0.57, 0.17]
			Placebo	58	53 (91.4)	-0.81 (1.11)	-3.3	-1.33	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	60	60 (100.0)	-1.07 (1.09)	-2.7	-2.00	-1.17	-0.42	2.3	-0.15 [-0.52, 0.22]
			Placebo	58	53 (91.4)	-0.92 (0.97)	-3.5	-1.33	-1.00	-0.50	2.3	
		Week 52	Tezepelumab	60	60 (100.0)	-1.04 (1.08)	-2.7	-1.92	-1.00	-0.42	2.3	-0.21 [-0.58, 0.16]
			Placebo	58	53 (91.4)	-0.82 (1.00)	-3.5	-1.17	-0.83	-0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	2.69 (0.43)	2.2	2.33	2.67	3.17	3.2	
			Placebo	7	7 (100.0)	2.90 (0.87)	2.2	2.17	2.67	3.17	4.7	
		Week 2	Tezepelumab	6	6 (100.0)	1.75 (1.15)	0.0	0.83	2.08	2.50	3.0	
			Placebo	7	7 (100.0)	2.48 (1.02)	1.5	2.00	2.17	2.50	4.7	
		Week 4	Tezepelumab	6	6 (100.0)	1.64 (0.90)	0.7	0.83	1.58	2.17	3.0	
			Placebo	7	7 (100.0)	2.38 (1.12)	0.7	1.33	2.67	3.50	3.5	
		Week 6	Tezepelumab	6	6 (100.0)	1.42 (0.79)	0.5	0.83	1.33	1.83	2.7	
			Placebo	7	7 (100.0)	2.21 (1.60)	0.8	1.00	2.33	2.33	5.5	
		Week 8	Tezepelumab	6	6 (100.0)	1.22 (0.83)	0.2	0.67	1.17	1.67	2.5	
			Placebo	7	7 (100.0)	2.24 (1.47)	0.2	1.00	2.17	3.17	4.7	
		Week 10	Tezepelumab	6	6 (100.0)	1.00 (0.68)	0.2	0.67	0.83	1.33	2.2	
			Placebo	7	7 (100.0)	2.29 (1.53)	0.8	1.00	2.00	3.00	5.3	
		Week 12	Tezepelumab	6	6 (100.0)	1.06 (0.98)	0.0	0.33	0.92	1.50	2.7	
			Placebo	7	7 (100.0)	1.90 (1.31)	0.0	0.83	2.00	2.83	4.0	
		Week 14	Tezepelumab	6	6 (100.0)	1.06 (0.62)	0.5	0.67	0.83	1.33	2.2	
			Placebo	7	7 (100.0)	1.98 (1.64)	0.0	0.83	1.67	3.00	5.0	
		Week 16	Tezepelumab	6	6 (100.0)	0.94 (0.43)	0.3	0.67	0.92	1.33	1.5	
			Placebo	7	7 (100.0)	2.19 (2.02)	0.0	0.50	1.83	4.83	5.0	
		Week 18	Tezepelumab	6	6 (100.0)	0.97 (0.53)	0.5	0.50	0.83	1.33	1.8	
			Placebo	7	7 (100.0)	2.14 (1.60)	0.0	0.83	2.00	3.00	5.0	
		Week 20	Tezepelumab	6	6 (100.0)	1.06 (0.47)	0.5	0.67	1.08	1.17	1.8	
			Placebo	7	7 (100.0)	2.55 (1.42)	0.3	1.67	2.50	3.00	5.0	
		Week 22	Tezepelumab	6	6 (100.0)	1.06 (0.75)	0.0	0.83	1.00	1.17	2.3	
			Placebo	7	7 (100.0)	2.50 (1.50)	0.3	1.17	2.67	3.33	5.0	
		Week 24	Tezepelumab	6	6 (100.0)	1.08 (0.73)	0.5	0.67	0.83	1.17	2.5	
			Placebo	7	7 (100.0)	2.26 (1.38)	0.3	0.67	2.67	3.33	4.2	
		Week 26	Tezepelumab	6	6 (100.0)	0.97 (0.67)	0.2	0.67	0.83	1.17	2.2	
			Placebo	7	7 (100.0)	1.98 (1.50)	0.0	0.33	2.00	3.33	4.2	
		Week 28	Tezepelumab	6	6 (100.0)	1.00 (0.65)	0.3	0.50	0.92	1.17	2.2	
			Placebo	7	7 (100.0)	1.79 (1.62)	0.0	0.33	2.17	3.33	4.2	
		Week 30	Tezepelumab	6	6 (100.0)	1.00 (0.61)	0.7	0.67	0.67	1.17	2.2	
			Placebo	7	7 (100.0)	1.86 (1.50)	0.0	0.33	1.83	3.33	4.2	
		Week 32	Tezepelumab	6	6 (100.0)	1.14 (0.71)	0.2	0.67	1.08	1.67	2.2	
			Placebo	7	7 (100.0)	2.00 (1.37)	0.3	0.67	1.83	3.33	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Non-white	Absolute values	Week 34	Tezepelumab	6	6 (100.0)	1.03 (0.61)	0.5	0.67	0.83	1.17	2.2	
			Placebo	7	7 (100.0)	1.81 (1.58)	0.0	0.33	1.83	3.33	4.2	
		Week 36	Tezepelumab	6	6 (100.0)	1.08 (0.61)	0.3	0.83	1.00	1.17	2.2	
			Placebo	7	7 (100.0)	2.48 (1.33)	0.0	1.83	2.50	3.33	4.2	
		Week 38	Tezepelumab	6	6 (100.0)	1.06 (0.77)	0.0	0.50	1.00	1.83	2.0	
			Placebo	7	7 (100.0)	1.93 (1.46)	0.0	0.50	1.83	3.33	4.2	
		Week 40	Tezepelumab	6	6 (100.0)	1.08 (0.65)	0.3	0.67	0.92	1.67	2.0	
			Placebo	7	7 (100.0)	2.07 (1.42)	0.0	0.83	1.83	3.33	4.2	
		Week 42	Tezepelumab	6	6 (100.0)	1.19 (0.55)	0.5	0.83	1.08	1.67	2.0	
			Placebo	7	7 (100.0)	1.71 (0.98)	0.0	1.50	1.67	2.00	3.3	
		Week 44	Tezepelumab	6	6 (100.0)	1.11 (0.70)	0.3	0.50	1.00	1.67	2.2	
			Placebo	7	7 (100.0)	2.05 (1.28)	0.5	0.67	2.50	3.33	3.3	
		Week 46	Tezepelumab	6	6 (100.0)	1.08 (0.60)	0.3	0.83	1.00	1.17	2.2	
			Placebo	7	7 (100.0)	1.57 (1.04)	0.3	0.50	1.83	2.00	3.3	
		Week 48	Tezepelumab	6	6 (100.0)	1.11 (0.53)	0.5	0.67	1.08	1.33	2.0	
			Placebo	7	7 (100.0)	2.00 (1.01)	0.3	1.00	2.17	2.67	3.3	
		Week 50	Tezepelumab	6	6 (100.0)	0.89 (0.64)	0.2	0.50	0.75	1.17	2.0	
			Placebo	7	7 (100.0)	1.93 (1.23)	0.2	1.00	1.67	3.33	3.7	
		Week 52	Tezepelumab	6	6 (100.0)	0.89 (0.64)	0.2	0.50	0.75	1.17	2.0	
			Placebo	7	7 (100.0)	1.79 (1.40)	0.0	0.17	1.67	3.33	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 2	Tezepelumab	6	6 (100.0)	-0.94 (1.06)	-2.8	-1.33	-0.75	-0.17	0.2	-0.64 [-1.76, 0.48]
			Placebo	7	7 (100.0)	-0.43 (0.51)	-1.2	-1.00	-0.17	0.00	0.0	
		Week 4	Tezepelumab	6	6 (100.0)	-1.06 (0.91)	-2.0	-1.50	-1.25	-1.00	0.7	-0.58 [-1.70, 0.53]
			Placebo	7	7 (100.0)	-0.52 (0.91)	-1.7	-1.50	-0.33	0.33	0.5	
		Week 6	Tezepelumab	6	6 (100.0)	-1.28 (0.87)	-2.3	-1.50	-1.42	-1.33	0.3	-0.65 [-1.78, 0.47]
			Placebo	7	7 (100.0)	-0.69 (0.92)	-2.0	-1.33	-0.67	-0.17	0.8	
		Week 8	Tezepelumab	6	6 (100.0)	-1.47 (0.93)	-2.7	-1.83	-1.58	-1.33	0.2	-0.75 [-1.89, 0.38]
			Placebo	7	7 (100.0)	-0.67 (1.18)	-3.0	-1.17	-0.33	0.17	0.5	
		Week 10	Tezepelumab	6	6 (100.0)	-1.69 (0.87)	-2.7	-2.33	-1.75	-1.50	-0.2	-0.83 [-1.97, 0.32]
			Placebo	7	7 (100.0)	-0.62 (1.57)	-2.2	-1.67	-0.83	-0.50	2.7	
		Week 12	Tezepelumab	6	6 (100.0)	-1.64 (1.00)	-2.3	-2.17	-2.00	-1.67	0.3	-0.52 [-1.63, 0.59]
			Placebo	7	7 (100.0)	-1.00 (1.38)	-3.2	-1.83	-1.00	-0.33	1.3	
		Week 14	Tezepelumab	6	6 (100.0)	-1.64 (0.78)	-2.3	-2.17	-1.83	-1.50	-0.2	-0.53 [-1.64, 0.58]
			Placebo	7	7 (100.0)	-0.93 (1.68)	-3.2	-1.67	-1.33	-0.33	2.3	
		Week 16	Tezepelumab	6	6 (100.0)	-1.75 (0.50)	-2.2	-2.17	-1.92	-1.33	-1.0	-0.79 [-1.92, 0.35]
			Placebo	7	7 (100.0)	-0.71 (1.73)	-3.2	-1.67	-1.17	0.17	2.3	
		Week 18	Tezepelumab	6	6 (100.0)	-1.72 (0.65)	-2.3	-2.17	-1.83	-1.67	-0.5	-0.73 [-1.86, 0.40]
			Placebo	7	7 (100.0)	-0.76 (1.69)	-3.2	-1.67	-1.00	-0.17	2.3	
		Week 20	Tezepelumab	6	6 (100.0)	-1.64 (0.59)	-2.0	-2.00	-1.92	-1.50	-0.5	-1.08 [-2.26, 0.10]
			Placebo	7	7 (100.0)	-0.36 (1.52)	-1.8	-1.67	-0.83	0.83	2.3	
		Week 22	Tezepelumab	6	6 (100.0)	-1.64 (0.83)	-2.2	-2.17	-1.92	-1.67	0.0	-1.07 [-2.25, 0.11]
			Placebo	7	7 (100.0)	-0.40 (1.36)	-1.8	-1.33	-0.67	0.17	2.3	
		Week 24	Tezepelumab	6	6 (100.0)	-1.61 (0.91)	-2.3	-2.00	-2.00	-1.50	0.2	-0.80 [-1.94, 0.34]
			Placebo	7	7 (100.0)	-0.64 (1.42)	-2.5	-1.83	-1.00	0.50	1.5	
		Week 26	Tezepelumab	6	6 (100.0)	-1.72 (0.85)	-2.3	-2.33	-2.08	-1.33	-0.2	-0.64 [-1.76, 0.48]
			Placebo	7	7 (100.0)	-0.93 (1.50)	-3.2	-1.83	-1.33	0.17	1.5	
		Week 28	Tezepelumab	6	6 (100.0)	-1.69 (0.83)	-2.3	-2.17	-2.08	-1.33	-0.2	-0.47 [-1.58, 0.63]
			Placebo	7	7 (100.0)	-1.12 (1.46)	-3.2	-1.83	-1.33	-0.33	1.5	
		Week 30	Tezepelumab	6	6 (100.0)	-1.69 (0.82)	-2.5	-2.17	-1.92	-1.50	-0.2	-0.62 [-1.74, 0.50]
			Placebo	7	7 (100.0)	-1.05 (1.19)	-2.2	-1.83	-1.33	-1.00	1.5	
		Week 32	Tezepelumab	6	6 (100.0)	-1.56 (0.81)	-2.3	-2.17	-1.75	-1.17	-0.2	-0.64 [-1.76, 0.48]
			Placebo	7	7 (100.0)	-0.90 (1.16)	-1.8	-1.50	-1.33	-0.33	1.5	
		Week 34	Tezepelumab	6	6 (100.0)	-1.67 (0.80)	-2.5	-2.00	-1.92	-1.50	-0.2	-0.49 [-1.60, 0.62]
			Placebo	7	7 (100.0)	-1.10 (1.38)	-2.8	-2.17	-1.33	-0.67	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Non-white	Change from baseline	Week 36	Tezepelumab	6	6 (100.0)	-1.61 (0.79)	-2.3	-2.17	-1.83	-1.33	-0.2	-1.06 [-2.24, 0.12]
			Placebo	7	7 (100.0)	-0.43 (1.32)	-2.2	-1.33	-0.50	1.00	1.5	
		Week 38	Tezepelumab	6	6 (100.0)	-1.64 (0.75)	-2.5	-2.00	-1.83	-1.33	-0.3	-0.66 [-1.78, 0.47]
			Placebo	7	7 (100.0)	-0.98 (1.18)	-2.2	-1.67	-1.33	-0.67	1.5	
		Week 40	Tezepelumab	6	6 (100.0)	-1.61 (0.79)	-2.5	-2.17	-1.75	-1.17	-0.3	-0.68 [-1.81, 0.45]
			Placebo	7	7 (100.0)	-0.83 (1.37)	-2.3	-2.17	-1.17	0.33	1.5	
		Week 42	Tezepelumab	6	6 (100.0)	-1.50 (0.70)	-2.2	-2.00	-1.67	-1.17	-0.3	-0.51 [-1.62, 0.60]
			Placebo	7	7 (100.0)	-1.19 (0.51)	-2.2	-1.33	-1.17	-0.83	-0.5	
		Week 44	Tezepelumab	6	6 (100.0)	-1.58 (0.89)	-2.7	-2.17	-1.67	-1.17	-0.2	-0.63 [-1.75, 0.49]
			Placebo	7	7 (100.0)	-0.86 (1.33)	-2.7	-1.67	-1.33	0.50	1.2	
		Week 46	Tezepelumab	6	6 (100.0)	-1.61 (0.77)	-2.2	-2.17	-1.92	-1.33	-0.2	-0.46 [-1.57, 0.65]
			Placebo	7	7 (100.0)	-1.33 (0.42)	-1.8	-1.67	-1.33	-1.00	-0.7	
		Week 48	Tezepelumab	6	6 (100.0)	-1.58 (0.67)	-2.2	-2.00	-1.75	-1.50	-0.3	-0.96 [-2.12, 0.20]
			Placebo	7	7 (100.0)	-0.90 (0.74)	-1.8	-1.67	-0.83	-0.33	0.2	
		Week 50	Tezepelumab	6	6 (100.0)	-1.81 (0.86)	-2.7	-2.50	-2.00	-1.33	-0.3	-0.70 [-1.83, 0.43]
			Placebo	7	7 (100.0)	-0.98 (1.39)	-3.0	-1.67	-1.33	-0.17	1.5	
		Week 52	Tezepelumab	6	6 (100.0)	-1.81 (0.86)	-2.7	-2.50	-2.00	-1.33	-0.3	-0.54 [-1.66, 0.57]
			Placebo	7	7 (100.0)	-1.12 (1.52)	-3.0	-2.67	-1.33	-0.17	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	2.86 (1.07)	2.0	2.00	2.58	3.17	4.8	
			Placebo	4	4 (100.0)	2.92 (0.62)	2.2	2.42	3.00	3.42	3.5	
		Week 2	Tezepelumab	6	5 (83.3)	1.97 (1.23)	0.0	1.83	2.17	2.50	3.3	
			Placebo	4	3 (75.0)	1.56 (0.42)	1.2	1.17	1.50	2.00	2.0	
		Week 4	Tezepelumab	6	5 (83.3)	1.97 (0.92)	0.8	1.50	2.00	2.17	3.3	
			Placebo	4	3 (75.0)	1.50 (1.44)	0.7	0.67	0.67	3.17	3.2	
		Week 6	Tezepelumab	6	5 (83.3)	1.93 (1.03)	0.5	1.67	1.83	2.33	3.3	
			Placebo	4	3 (75.0)	1.28 (0.95)	0.5	0.50	1.00	2.33	2.3	
		Week 8	Tezepelumab	6	5 (83.3)	1.43 (1.02)	0.2	1.17	1.33	1.50	3.0	
			Placebo	4	3 (75.0)	1.44 (1.55)	0.2	0.17	1.00	3.17	3.2	
		Week 10	Tezepelumab	6	5 (83.3)	1.23 (1.10)	0.2	0.67	0.83	1.50	3.0	
			Placebo	4	3 (75.0)	2.06 (2.87)	0.0	0.00	0.83	5.33	5.3	
		Week 12	Tezepelumab	6	5 (83.3)	1.27 (0.61)	0.5	1.00	1.33	1.33	2.2	
			Placebo	4	3 (75.0)	1.61 (2.11)	0.0	0.00	0.83	4.00	4.0	
		Week 14	Tezepelumab	6	5 (83.3)	1.13 (0.70)	0.5	0.83	1.00	1.00	2.3	
			Placebo	4	3 (75.0)	2.06 (2.56)	0.3	0.33	0.83	5.00	5.0	
		Week 16	Tezepelumab	6	5 (83.3)	1.47 (0.59)	0.7	1.33	1.50	1.50	2.3	
			Placebo	4	3 (75.0)	2.00 (2.62)	0.2	0.17	0.83	5.00	5.0	
		Week 18	Tezepelumab	6	5 (83.3)	1.37 (0.65)	0.5	1.33	1.33	1.33	2.3	
			Placebo	4	3 (75.0)	2.00 (2.62)	0.2	0.17	0.83	5.00	5.0	
		Week 20	Tezepelumab	6	5 (83.3)	1.47 (0.52)	1.0	1.17	1.33	1.50	2.3	
			Placebo	4	3 (75.0)	1.83 (2.74)	0.2	0.17	0.33	5.00	5.0	
		Week 22	Tezepelumab	6	5 (83.3)	1.23 (0.63)	0.8	0.83	1.00	1.17	2.3	
			Placebo	4	3 (75.0)	1.78 (2.80)	0.0	0.00	0.33	5.00	5.0	
		Week 24	Tezepelumab	6	5 (83.3)	1.57 (0.65)	0.8	1.17	1.33	2.17	2.3	
			Placebo	4	3 (75.0)	1.56 (2.26)	0.2	0.17	0.33	4.17	4.2	
		Week 26	Tezepelumab	6	5 (83.3)	1.47 (0.62)	0.7	1.17	1.50	1.67	2.3	
			Placebo	4	3 (75.0)	1.67 (2.17)	0.3	0.33	0.50	4.17	4.2	
		Week 28	Tezepelumab	6	6 (100.0)	1.22 (0.74)	0.3	0.50	1.33	1.50	2.3	
			Placebo	4	3 (75.0)	1.67 (2.17)	0.3	0.33	0.50	4.17	4.2	
		Week 30	Tezepelumab	6	6 (100.0)	1.25 (0.77)	0.2	0.67	1.33	1.67	2.3	
			Placebo	4	3 (75.0)	1.67 (2.17)	0.3	0.33	0.50	4.17	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
North America/Western EU	Absolute values	Week 32	Tezepelumab	6	6 (100.0)	1.36 (0.73)	0.2	1.17	1.42	1.67	2.3	
			Placebo	4	3 (75.0)	1.67 (2.17)	0.3	0.33	0.50	4.17	4.2	
		Week 34	Tezepelumab	6	6 (100.0)	1.28 (0.79)	0.0	1.00	1.25	1.83	2.3	
			Placebo	4	3 (75.0)	1.56 (2.28)	0.0	0.00	0.50	4.17	4.2	
		Week 36	Tezepelumab	6	6 (100.0)	1.69 (0.59)	1.2	1.17	1.58	2.33	2.3	
			Placebo	4	3 (75.0)	1.78 (2.15)	0.0	0.00	1.17	4.17	4.2	
		Week 38	Tezepelumab	6	6 (100.0)	1.31 (0.71)	0.3	0.83	1.25	1.83	2.3	
			Placebo	4	3 (75.0)	1.67 (2.20)	0.0	0.00	0.83	4.17	4.2	
		Week 40	Tezepelumab	6	6 (100.0)	1.47 (0.78)	0.2	1.17	1.50	2.17	2.3	
			Placebo	4	3 (75.0)	1.78 (2.15)	0.0	0.00	1.17	4.17	4.2	
		Week 42	Tezepelumab	6	6 (100.0)	1.39 (0.71)	0.2	1.17	1.50	1.67	2.3	
			Placebo	4	3 (75.0)	0.89 (0.79)	0.0	0.00	1.17	1.50	1.5	
		Week 44	Tezepelumab	6	6 (100.0)	1.47 (0.70)	0.3	1.17	1.50	2.00	2.3	
			Placebo	4	3 (75.0)	0.94 (0.25)	0.7	0.67	1.00	1.17	1.2	
		Week 46	Tezepelumab	6	6 (100.0)	1.28 (0.74)	0.2	1.00	1.17	1.83	2.3	
			Placebo	4	3 (75.0)	0.89 (0.35)	0.5	0.50	1.00	1.17	1.2	
		Week 48	Tezepelumab	6	6 (100.0)	1.31 (0.71)	0.2	1.17	1.25	1.67	2.3	
			Placebo	4	3 (75.0)	0.72 (0.35)	0.3	0.33	0.83	1.00	1.0	
		Week 50	Tezepelumab	6	6 (100.0)	1.00 (0.85)	0.0	0.17	1.08	1.33	2.3	
			Placebo	4	3 (75.0)	2.00 (1.45)	1.0	1.00	1.33	3.67	3.7	
		Week 52	Tezepelumab	6	6 (100.0)	1.22 (0.70)	0.2	1.00	1.25	1.33	2.3	
			Placebo	4	3 (75.0)	1.67 (1.86)	0.0	0.00	1.33	3.67	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 2	Tezepelumab	6	5 (83.3)	-1.00 (1.20)	-2.8	-1.50	-0.67	-0.17	0.2	0.15 [-1.29, 1.58]
			Placebo	4	3 (75.0)	-1.17 (1.00)	-2.2	-2.17	-1.17	-0.17	-0.2	
		Week 4	Tezepelumab	6	5 (83.3)	-1.00 (0.85)	-2.0	-1.50	-1.17	-0.50	0.2	0.19 [-1.24, 1.63]
			Placebo	4	3 (75.0)	-1.22 (1.60)	-2.7	-2.67	-1.50	0.50	0.5	
		Week 6	Tezepelumab	6	5 (83.3)	-1.03 (1.04)	-2.3	-1.50	-1.33	-0.33	0.3	0.37 [-1.08, 1.81]
			Placebo	4	3 (75.0)	-1.44 (1.27)	-2.8	-2.83	-1.17	-0.33	-0.3	
		Week 8	Tezepelumab	6	5 (83.3)	-1.53 (0.81)	-2.7	-1.83	-1.67	-0.83	-0.7	-0.20 [-1.64, 1.23]
			Placebo	4	3 (75.0)	-1.28 (1.84)	-3.2	-3.17	-1.17	0.50	0.5	
		Week 10	Tezepelumab	6	5 (83.3)	-1.73 (0.85)	-2.7	-2.33	-1.83	-1.33	-0.5	-0.56 [-2.03, 0.90]
			Placebo	4	3 (75.0)	-0.67 (3.06)	-3.3	-3.33	-1.33	2.67	2.7	
		Week 12	Tezepelumab	6	5 (83.3)	-1.70 (0.85)	-2.7	-2.33	-1.83	-1.00	-0.7	-0.39 [-1.84, 1.06]
			Placebo	4	3 (75.0)	-1.11 (2.34)	-3.3	-3.33	-1.33	1.33	1.3	
		Week 14	Tezepelumab	6	5 (83.3)	-1.83 (0.70)	-2.5	-2.33	-2.17	-1.17	-1.0	-0.70 [-2.18, 0.79]
			Placebo	4	3 (75.0)	-0.67 (2.73)	-3.0	-3.00	-1.33	2.33	2.3	
		Week 16	Tezepelumab	6	5 (83.3)	-1.50 (0.89)	-2.5	-2.17	-1.67	-0.67	-0.5	-0.44 [-1.89, 1.01]
			Placebo	4	3 (75.0)	-0.72 (2.80)	-3.2	-3.17	-1.33	2.33	2.3	
		Week 18	Tezepelumab	6	5 (83.3)	-1.60 (0.89)	-2.5	-2.33	-1.83	-0.67	-0.7	-0.50 [-1.95, 0.96]
			Placebo	4	3 (75.0)	-0.72 (2.80)	-3.2	-3.17	-1.33	2.33	2.3	
		Week 20	Tezepelumab	6	5 (83.3)	-1.50 (0.87)	-2.5	-2.00	-1.83	-0.67	-0.5	-0.34 [-1.78, 1.11]
			Placebo	4	3 (75.0)	-0.89 (2.87)	-3.2	-3.17	-1.83	2.33	2.3	
		Week 22	Tezepelumab	6	5 (83.3)	-1.73 (0.57)	-2.5	-2.00	-1.83	-1.17	-1.2	-0.45 [-1.90, 1.01]
			Placebo	4	3 (75.0)	-0.94 (2.94)	-3.3	-3.33	-1.83	2.33	2.3	
		Week 24	Tezepelumab	6	5 (83.3)	-1.40 (1.11)	-2.5	-2.00	-2.00	-0.67	0.2	-0.14 [-1.57, 1.29]
			Placebo	4	3 (75.0)	-1.17 (2.40)	-3.2	-3.17	-1.83	1.50	1.5	
		Week 26	Tezepelumab	6	5 (83.3)	-1.50 (1.01)	-2.5	-2.17	-2.00	-0.50	-0.3	-0.29 [-1.73, 1.15]
			Placebo	4	3 (75.0)	-1.06 (2.27)	-2.8	-2.83	-1.83	1.50	1.5	
		Week 28	Tezepelumab	6	6 (100.0)	-1.64 (0.90)	-2.5	-2.33	-2.00	-0.50	-0.5	-0.41 [-1.81, 1.00]
			Placebo	4	3 (75.0)	-1.06 (2.27)	-2.8	-2.83	-1.83	1.50	1.5	
		Week 30	Tezepelumab	6	6 (100.0)	-1.61 (0.94)	-2.5	-2.17	-2.08	-0.50	-0.3	-0.38 [-1.78, 1.02]
			Placebo	4	3 (75.0)	-1.06 (2.27)	-2.8	-2.83	-1.83	1.50	1.5	
		Week 32	Tezepelumab	6	6 (100.0)	-1.50 (0.85)	-2.5	-2.17	-1.58	-0.83	-0.3	-0.32 [-1.71, 1.08]
			Placebo	4	3 (75.0)	-1.06 (2.27)	-2.8	-2.83	-1.83	1.50	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
North America/Western EU	Change from baseline	Week 34	Tezepelumab	6	6 (100.0)	-1.58 (0.95)	-2.5	-2.33	-1.92	-0.67	-0.2	-0.28 [-1.67, 1.11]
			Placebo	4	3 (75.0)	-1.17 (2.33)	-2.8	-2.83	-2.17	1.50	1.5	
		Week 36	Tezepelumab	6	6 (100.0)	-1.17 (1.13)	-2.5	-2.00	-1.42	0.00	0.3	-0.15 [-1.54, 1.24]
			Placebo	4	3 (75.0)	-0.94 (2.12)	-2.2	-2.17	-2.17	1.50	1.5	
		Week 38	Tezepelumab	6	6 (100.0)	-1.56 (0.92)	-2.5	-2.00	-2.00	-0.67	-0.2	-0.35 [-1.75, 1.05]
			Placebo	4	3 (75.0)	-1.06 (2.22)	-2.5	-2.50	-2.17	1.50	1.5	
		Week 40	Tezepelumab	6	6 (100.0)	-1.39 (1.02)	-2.5	-2.17	-1.58	-0.67	0.2	-0.31 [-1.71, 1.08]
			Placebo	4	3 (75.0)	-0.94 (2.12)	-2.2	-2.17	-2.17	1.50	1.5	
		Week 42	Tezepelumab	6	6 (100.0)	-1.47 (0.87)	-2.5	-2.17	-1.58	-0.50	-0.5	0.45 [-0.95, 1.86]
			Placebo	4	3 (75.0)	-1.83 (0.58)	-2.2	-2.17	-2.17	-1.17	-1.2	
		Week 44	Tezepelumab	6	6 (100.0)	-1.39 (0.95)	-2.5	-2.00	-1.58	-0.67	0.0	0.47 [-0.93, 1.88]
			Placebo	4	3 (75.0)	-1.78 (0.35)	-2.2	-2.17	-1.67	-1.50	-1.5	
		Week 46	Tezepelumab	6	6 (100.0)	-1.58 (0.89)	-2.5	-2.17	-1.92	-0.83	-0.2	0.32 [-1.07, 1.72]
			Placebo	4	3 (75.0)	-1.83 (0.29)	-2.2	-2.17	-1.67	-1.67	-1.7	
		Week 48	Tezepelumab	6	6 (100.0)	-1.56 (0.83)	-2.5	-2.17	-1.75	-0.83	-0.3	0.60 [-0.82, 2.02]
			Placebo	4	3 (75.0)	-2.00 (0.44)	-2.5	-2.50	-1.83	-1.67	-1.7	
		Week 50	Tezepelumab	6	6 (100.0)	-1.86 (0.83)	-2.7	-2.50	-2.17	-1.00	-0.7	-0.91 [-2.38, 0.55]
			Placebo	4	3 (75.0)	-0.72 (1.93)	-2.0	-2.00	-1.67	1.50	1.5	
		Week 52	Tezepelumab	6	6 (100.0)	-1.64 (0.86)	-2.7	-2.50	-1.50	-1.00	-0.7	-0.42 [-1.82, 0.99]
			Placebo	4	3 (75.0)	-1.06 (2.24)	-2.7	-2.67	-2.00	1.50	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	60	60 (100.0)	2.70 (0.81)	0.0	2.25	2.67	3.17	4.5	
			Placebo	61	61 (100.0)	2.69 (0.73)	0.3	2.33	2.67	3.00	4.7	
		Week 2	Tezepelumab	60	58 (96.7)	2.25 (0.94)	0.2	1.50	2.42	3.00	4.2	
			Placebo	61	55 (90.2)	2.33 (0.77)	0.3	2.00	2.33	2.83	4.8	
		Week 4	Tezepelumab	60	58 (96.7)	1.98 (0.96)	0.2	1.33	2.17	2.67	3.5	
			Placebo	61	55 (90.2)	2.19 (0.88)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	60	58 (96.7)	1.88 (1.01)	0.0	1.00	1.83	2.67	4.0	
			Placebo	61	55 (90.2)	2.15 (1.10)	0.2	1.33	2.17	2.67	5.5	
		Week 8	Tezepelumab	60	58 (96.7)	1.77 (1.12)	0.0	0.83	1.67	2.67	4.8	
			Placebo	61	56 (91.8)	2.09 (1.06)	0.0	1.50	2.17	2.75	4.7	
		Week 10	Tezepelumab	60	58 (96.7)	1.70 (1.08)	0.0	0.83	1.75	2.67	4.3	
			Placebo	61	56 (91.8)	2.07 (0.93)	0.0	1.58	2.17	2.67	4.2	
		Week 12	Tezepelumab	60	58 (96.7)	1.58 (1.08)	0.0	0.50	1.67	2.50	4.3	
			Placebo	61	56 (91.8)	1.87 (0.93)	0.0	1.25	2.00	2.50	4.3	
		Week 14	Tezepelumab	60	58 (96.7)	1.52 (1.07)	0.0	0.67	1.50	2.17	4.3	
			Placebo	61	56 (91.8)	1.78 (0.87)	0.0	1.33	1.83	2.17	5.0	
		Week 16	Tezepelumab	60	58 (96.7)	1.65 (1.15)	0.0	0.67	1.67	2.50	4.3	
			Placebo	61	56 (91.8)	1.96 (1.07)	0.0	1.08	2.00	2.67	4.8	
		Week 18	Tezepelumab	60	59 (98.3)	1.62 (1.05)	0.0	0.67	1.67	2.33	4.3	
			Placebo	61	56 (91.8)	1.87 (1.05)	0.0	1.08	1.92	2.50	4.7	
		Week 20	Tezepelumab	60	59 (98.3)	1.63 (1.12)	0.0	0.67	1.83	2.50	5.0	
			Placebo	61	56 (91.8)	1.98 (0.97)	0.0	1.17	2.17	2.67	4.5	
		Week 22	Tezepelumab	60	59 (98.3)	1.72 (0.99)	0.0	1.00	1.83	2.33	4.3	
			Placebo	61	56 (91.8)	1.93 (1.03)	0.0	1.17	2.00	2.67	4.5	
		Week 24	Tezepelumab	60	59 (98.3)	1.68 (1.08)	0.0	0.67	1.83	2.50	4.3	
			Placebo	61	56 (91.8)	2.01 (0.97)	0.0	1.58	2.00	2.58	4.5	
		Week 26	Tezepelumab	60	60 (100.0)	1.73 (1.10)	0.0	0.83	1.83	2.58	4.3	
			Placebo	61	56 (91.8)	1.93 (1.06)	0.0	1.00	1.83	2.75	4.5	
		Week 28	Tezepelumab	60	60 (100.0)	1.70 (1.12)	0.0	0.92	1.67	2.50	4.3	
			Placebo	61	57 (93.4)	1.92 (1.14)	0.0	1.00	2.00	2.67	4.5	
		Week 30	Tezepelumab	60	60 (100.0)	1.67 (1.08)	0.0	0.83	1.67	2.33	4.3	
			Placebo	61	57 (93.4)	1.90 (1.09)	0.0	1.17	1.83	2.67	4.5	
		Week 32	Tezepelumab	60	60 (100.0)	1.60 (1.09)	0.0	0.67	1.83	2.50	4.3	
			Placebo	61	57 (93.4)	1.87 (1.04)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of world	Absolute values	Week 34	Tezepelumab	60	60 (100.0)	1.68 (1.14)	0.0	0.67	1.67	2.50	4.3	
			Placebo	61	57 (93.4)	1.84 (1.03)	0.0	1.17	1.83	2.33	4.5	
		Week 36	Tezepelumab	60	60 (100.0)	1.60 (1.09)	0.0	0.75	1.58	2.50	4.3	
			Placebo	61	57 (93.4)	2.00 (1.08)	0.0	1.33	2.00	2.67	4.5	
		Week 38	Tezepelumab	60	60 (100.0)	1.66 (1.18)	0.0	0.83	1.67	2.67	4.5	
			Placebo	61	57 (93.4)	1.87 (1.04)	0.0	1.17	1.83	2.50	4.5	
		Week 40	Tezepelumab	60	60 (100.0)	1.62 (1.15)	0.0	0.58	1.83	2.58	4.3	
			Placebo	61	57 (93.4)	2.01 (1.09)	0.0	1.33	2.00	2.67	4.5	
		Week 42	Tezepelumab	60	60 (100.0)	1.60 (1.12)	0.0	0.83	1.67	2.50	4.3	
			Placebo	61	57 (93.4)	1.91 (1.01)	0.0	1.33	2.00	2.50	4.5	
		Week 44	Tezepelumab	60	60 (100.0)	1.63 (1.11)	0.0	0.67	1.58	2.67	4.3	
			Placebo	61	57 (93.4)	1.99 (1.06)	0.0	1.17	2.00	2.67	4.5	
		Week 46	Tezepelumab	60	60 (100.0)	1.66 (1.15)	0.0	0.75	1.83	2.58	4.3	
			Placebo	61	57 (93.4)	1.89 (0.98)	0.0	1.33	2.00	2.33	4.5	
		Week 48	Tezepelumab	60	60 (100.0)	1.66 (1.14)	0.0	0.67	1.75	2.58	4.3	
			Placebo	61	57 (93.4)	1.94 (1.04)	0.0	1.33	2.17	2.50	4.5	
		Week 50	Tezepelumab	60	60 (100.0)	1.63 (1.15)	0.0	0.75	1.67	2.33	4.3	
			Placebo	61	57 (93.4)	1.76 (0.98)	0.0	1.00	1.83	2.33	4.5	
		Week 52	Tezepelumab	60	60 (100.0)	1.64 (1.15)	0.0	0.67	1.67	2.42	4.3	
			Placebo	61	57 (93.4)	1.86 (1.01)	0.0	1.17	2.00	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 2	Tezepelumab	60	58 (96.7)	-0.48 (0.65)	-2.0	-1.00	-0.33	0.00	0.7	-0.12 [-0.49, 0.25]
			Placebo	61	55 (90.2)	-0.41 (0.65)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	60	58 (96.7)	-0.76 (0.83)	-2.5	-1.17	-0.83	-0.17	2.3	-0.24 [-0.61, 0.13]
			Placebo	61	55 (90.2)	-0.55 (0.85)	-3.0	-1.17	-0.33	0.00	1.2	
		Week 6	Tezepelumab	60	58 (96.7)	-0.85 (0.94)	-2.7	-1.50	-0.92	-0.17	2.3	-0.28 [-0.65, 0.09]
			Placebo	61	55 (90.2)	-0.59 (0.96)	-3.3	-1.17	-0.50	0.00	1.5	
		Week 8	Tezepelumab	60	58 (96.7)	-0.96 (1.05)	-3.0	-1.50	-1.00	-0.33	2.3	-0.31 [-0.68, 0.06]
			Placebo	61	56 (91.8)	-0.65 (0.95)	-3.0	-1.08	-0.58	0.00	1.0	
		Week 10	Tezepelumab	60	58 (96.7)	-1.04 (1.02)	-3.2	-1.67	-1.17	-0.33	2.3	-0.36 [-0.73, 0.01]
			Placebo	61	56 (91.8)	-0.68 (0.98)	-3.2	-1.25	-0.50	-0.17	2.5	
		Week 12	Tezepelumab	60	58 (96.7)	-1.15 (1.01)	-3.0	-2.00	-1.17	-0.67	2.3	-0.29 [-0.65, 0.08]
			Placebo	61	56 (91.8)	-0.88 (0.91)	-3.2	-1.17	-0.75	-0.33	1.3	
		Week 14	Tezepelumab	60	58 (96.7)	-1.22 (1.02)	-3.7	-1.83	-1.17	-0.67	2.3	-0.25 [-0.62, 0.12]
			Placebo	61	56 (91.8)	-0.97 (0.91)	-3.2	-1.50	-1.00	-0.33	1.2	
		Week 16	Tezepelumab	60	58 (96.7)	-1.09 (1.05)	-3.0	-2.00	-1.00	-0.50	2.3	-0.29 [-0.66, 0.08]
			Placebo	61	56 (91.8)	-0.79 (1.01)	-3.2	-1.33	-0.83	-0.08	2.3	
		Week 18	Tezepelumab	60	59 (98.3)	-1.10 (1.00)	-3.5	-1.83	-1.00	-0.67	2.3	-0.21 [-0.58, 0.16]
			Placebo	61	56 (91.8)	-0.88 (1.06)	-3.2	-1.58	-0.83	-0.17	2.3	
		Week 20	Tezepelumab	60	59 (98.3)	-1.09 (1.01)	-3.2	-2.00	-1.00	-0.50	2.3	-0.31 [-0.68, 0.05]
			Placebo	61	56 (91.8)	-0.77 (1.00)	-3.0	-1.33	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	60	59 (98.3)	-1.00 (1.03)	-3.0	-1.67	-0.83	-0.50	2.3	-0.18 [-0.55, 0.18]
			Placebo	61	56 (91.8)	-0.81 (1.00)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	60	59 (98.3)	-1.04 (0.97)	-3.2	-1.67	-1.00	-0.33	2.3	-0.31 [-0.68, 0.06]
			Placebo	61	56 (91.8)	-0.74 (1.02)	-3.2	-1.33	-0.67	0.00	2.3	
		Week 26	Tezepelumab	60	60 (100.0)	-0.97 (1.03)	-2.8	-1.83	-1.00	-0.17	2.3	-0.15 [-0.52, 0.21]
			Placebo	61	56 (91.8)	-0.81 (1.07)	-3.2	-1.50	-0.92	-0.00	2.3	
		Week 28	Tezepelumab	60	60 (100.0)	-1.00 (1.09)	-3.2	-2.00	-1.00	-0.08	2.3	-0.19 [-0.56, 0.17]
			Placebo	61	57 (93.4)	-0.79 (1.10)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 30	Tezepelumab	60	60 (100.0)	-1.03 (1.08)	-3.5	-1.83	-1.00	-0.25	2.3	-0.21 [-0.58, 0.15]
			Placebo	61	57 (93.4)	-0.80 (1.09)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	60	60 (100.0)	-1.10 (1.01)	-3.0	-1.92	-1.00	-0.50	2.3	-0.26 [-0.63, 0.10]
			Placebo	61	57 (93.4)	-0.84 (1.03)	-3.0	-1.50	-1.00	-0.33	2.3	
		Week 34	Tezepelumab	60	60 (100.0)	-1.02 (1.10)	-2.8	-2.00	-1.08	-0.33	2.3	-0.15 [-0.51, 0.22]
			Placebo	61	57 (93.4)	-0.87 (1.02)	-3.2	-1.33	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Rest of world	Change from baseline	Week 36	Tezepelumab	60	60 (100.0)	-1.10 (1.07)	-3.0	-1.92	-1.17	-0.42	2.3	-0.37 [-0.74, -0.00]
			Placebo	61	57 (93.4)	-0.70 (1.08)	-3.5	-1.33	-0.83	-0.17	2.3	
		Week 38	Tezepelumab	60	60 (100.0)	-1.04 (1.12)	-3.0	-2.00	-1.17	-0.25	2.3	-0.19 [-0.55, 0.18]
			Placebo	61	57 (93.4)	-0.84 (1.02)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 40	Tezepelumab	60	60 (100.0)	-1.08 (1.10)	-3.2	-2.00	-1.00	-0.33	2.3	-0.35 [-0.72, 0.01]
			Placebo	61	57 (93.4)	-0.69 (1.11)	-3.2	-1.33	-0.67	0.17	2.3	
		Week 42	Tezepelumab	60	60 (100.0)	-1.10 (1.11)	-3.3	-2.00	-1.17	-0.50	2.3	-0.28 [-0.64, 0.08]
			Placebo	61	57 (93.4)	-0.80 (1.03)	-2.8	-1.33	-0.83	-0.17	2.3	
		Week 44	Tezepelumab	60	60 (100.0)	-1.07 (1.10)	-3.5	-1.92	-1.00	-0.42	2.3	-0.33 [-0.69, 0.04]
			Placebo	61	57 (93.4)	-0.71 (1.09)	-3.3	-1.33	-0.83	0.00	2.3	
		Week 46	Tezepelumab	60	60 (100.0)	-1.04 (1.10)	-3.3	-2.00	-1.00	-0.17	2.3	-0.21 [-0.57, 0.15]
			Placebo	61	57 (93.4)	-0.82 (1.00)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 48	Tezepelumab	60	60 (100.0)	-1.04 (1.09)	-2.7	-2.00	-0.92	-0.42	2.3	-0.25 [-0.62, 0.11]
			Placebo	61	57 (93.4)	-0.76 (1.06)	-3.3	-1.33	-0.83	-0.33	2.3	
		Week 50	Tezepelumab	60	60 (100.0)	-1.07 (1.09)	-2.7	-2.00	-1.17	-0.33	2.3	-0.12 [-0.49, 0.24]
			Placebo	61	57 (93.4)	-0.94 (0.97)	-3.5	-1.33	-1.00	-0.50	2.3	
		Week 52	Tezepelumab	60	60 (100.0)	-1.06 (1.09)	-2.7	-2.00	-1.08	-0.33	2.3	-0.20 [-0.57, 0.16]
			Placebo	61	57 (93.4)	-0.85 (1.00)	-3.5	-1.33	-0.83	-0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	30	30 (100.0)	2.65 (0.79)	0.0	2.33	2.83	3.17	4.5	
			Placebo	29	29 (100.0)	2.93 (0.70)	1.7	2.50	2.83	3.17	4.7	
		Week 2	Tezepelumab	30	28 (93.3)	2.26 (1.01)	0.0	1.50	2.50	3.00	3.7	
			Placebo	29	26 (89.7)	2.33 (1.03)	0.3	1.67	2.33	2.83	4.8	
		Week 4	Tezepelumab	30	28 (93.3)	1.98 (0.92)	0.2	1.42	2.25	2.67	3.5	
			Placebo	29	26 (89.7)	1.94 (1.03)	0.2	1.17	2.00	2.67	3.7	
		Week 6	Tezepelumab	30	28 (93.3)	1.97 (0.93)	0.0	1.33	2.17	2.67	3.7	
			Placebo	29	26 (89.7)	1.94 (1.29)	0.2	0.83	2.00	2.67	5.5	
		Week 8	Tezepelumab	30	28 (93.3)	1.88 (0.95)	0.0	1.42	1.92	2.67	3.3	
			Placebo	29	26 (89.7)	2.04 (1.24)	0.0	1.00	2.00	2.83	4.7	
		Week 10	Tezepelumab	30	28 (93.3)	1.84 (1.03)	0.0	1.00	1.92	2.50	4.3	
			Placebo	29	26 (89.7)	1.96 (1.08)	0.2	1.00	2.00	2.83	4.2	
		Week 12	Tezepelumab	30	28 (93.3)	1.77 (1.03)	0.0	1.08	2.00	2.50	4.3	
			Placebo	29	26 (89.7)	1.66 (0.99)	0.2	0.83	1.83	2.17	4.3	
		Week 14	Tezepelumab	30	28 (93.3)	1.65 (0.93)	0.0	1.08	1.67	2.25	4.3	
			Placebo	29	26 (89.7)	1.69 (1.00)	0.3	1.00	1.67	2.17	5.0	
		Week 16	Tezepelumab	30	28 (93.3)	1.81 (1.10)	0.0	1.17	1.83	2.50	4.3	
			Placebo	29	26 (89.7)	1.78 (1.13)	0.3	0.83	1.58	2.33	4.8	
		Week 18	Tezepelumab	30	29 (96.7)	1.75 (0.91)	0.0	1.00	1.83	2.33	4.3	
			Placebo	29	26 (89.7)	1.73 (1.27)	0.0	0.67	1.50	2.67	4.7	
		Week 20	Tezepelumab	30	29 (96.7)	1.80 (0.99)	0.0	1.17	1.83	2.50	4.3	
			Placebo	29	26 (89.7)	1.74 (1.09)	0.2	0.67	1.83	2.67	4.5	
		Week 22	Tezepelumab	30	29 (96.7)	1.91 (0.84)	0.0	1.50	2.00	2.33	4.3	
			Placebo	29	26 (89.7)	1.71 (1.15)	0.0	0.67	1.58	2.67	4.5	
		Week 24	Tezepelumab	30	29 (96.7)	1.83 (1.01)	0.0	1.00	1.83	2.50	4.3	
			Placebo	29	26 (89.7)	1.86 (1.12)	0.2	0.83	1.92	2.50	4.5	
		Week 26	Tezepelumab	30	30 (100.0)	1.84 (1.04)	0.0	1.17	1.92	2.50	4.3	
			Placebo	29	26 (89.7)	1.73 (1.14)	0.3	0.83	1.50	2.67	4.5	
		Week 28	Tezepelumab	30	30 (100.0)	1.84 (1.04)	0.0	1.17	1.83	2.50	4.3	
			Placebo	29	26 (89.7)	1.86 (1.24)	0.2	0.83	1.58	2.83	4.5	
		Week 30	Tezepelumab	30	30 (100.0)	1.84 (1.05)	0.0	1.17	1.92	2.50	4.3	
			Placebo	29	26 (89.7)	1.67 (1.19)	0.0	0.67	1.33	2.67	4.5	
		Week 32	Tezepelumab	30	30 (100.0)	1.77 (1.01)	0.0	1.00	1.92	2.50	4.3	
			Placebo	29	26 (89.7)	1.75 (1.24)	0.2	0.67	1.50	2.67	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 250 cells/uL	Absolute values	Week 34	Tezepelumab	30	30 (100.0)	1.84 (1.09)	0.0	1.00	2.00	2.50	4.3	
			Placebo	29	26 (89.7)	1.69 (1.21)	0.0	0.67	1.75	2.17	4.5	
		Week 36	Tezepelumab	30	30 (100.0)	1.76 (1.01)	0.0	1.17	1.75	2.50	4.3	
			Placebo	29	26 (89.7)	1.80 (1.24)	0.0	0.83	1.83	2.67	4.5	
		Week 38	Tezepelumab	30	30 (100.0)	1.88 (1.06)	0.0	1.00	1.83	2.67	4.3	
			Placebo	29	26 (89.7)	1.82 (1.23)	0.0	1.17	1.67	2.67	4.5	
		Week 40	Tezepelumab	30	30 (100.0)	1.88 (1.03)	0.0	1.17	2.00	2.67	4.3	
			Placebo	29	26 (89.7)	1.81 (1.24)	0.0	0.50	1.83	2.50	4.5	
		Week 42	Tezepelumab	30	30 (100.0)	1.88 (1.07)	0.0	1.17	1.83	2.50	4.3	
			Placebo	29	26 (89.7)	1.73 (1.14)	0.0	0.67	1.75	2.50	4.5	
		Week 44	Tezepelumab	30	30 (100.0)	1.85 (1.06)	0.0	1.00	1.92	2.67	4.3	
			Placebo	29	26 (89.7)	1.88 (1.18)	0.2	0.83	1.75	2.83	4.5	
		Week 46	Tezepelumab	30	30 (100.0)	1.87 (1.04)	0.0	1.00	2.00	2.50	4.3	
			Placebo	29	26 (89.7)	1.76 (1.06)	0.0	0.83	1.83	2.33	4.5	
		Week 48	Tezepelumab	30	30 (100.0)	1.83 (1.03)	0.0	1.00	2.00	2.33	4.3	
			Placebo	29	26 (89.7)	1.70 (1.16)	0.0	0.33	1.92	2.50	4.5	
		Week 50	Tezepelumab	30	30 (100.0)	1.79 (1.09)	0.0	1.00	1.83	2.33	4.3	
			Placebo	29	26 (89.7)	1.81 (1.13)	0.0	1.17	1.83	2.50	4.5	
		Week 52	Tezepelumab	30	30 (100.0)	1.76 (1.10)	0.0	1.00	1.83	2.50	4.3	
			Placebo	29	26 (89.7)	1.85 (1.12)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 2	Tezepelumab	30	28 (93.3)	-0.46 (0.74)	-2.8	-0.75	-0.33	0.17	0.3	0.11 [-0.43, 0.64]
			Placebo	29	26 (89.7)	-0.54 (0.73)	-2.8	-0.83	-0.33	0.00	0.5	
		Week 4	Tezepelumab	30	28 (93.3)	-0.73 (0.67)	-2.0	-1.17	-0.67	-0.33	0.7	0.26 [-0.27, 0.80]
			Placebo	29	26 (89.7)	-0.93 (0.83)	-3.0	-1.50	-1.00	-0.17	0.3	
		Week 6	Tezepelumab	30	28 (93.3)	-0.74 (0.77)	-2.3	-1.33	-0.67	-0.08	0.3	0.22 [-0.32, 0.75]
			Placebo	29	26 (89.7)	-0.93 (0.94)	-3.3	-1.67	-0.83	-0.17	0.8	
		Week 8	Tezepelumab	30	28 (93.3)	-0.83 (0.82)	-2.7	-1.50	-0.67	-0.17	0.5	-0.01 [-0.55, 0.52]
			Placebo	29	26 (89.7)	-0.82 (0.98)	-3.0	-1.33	-0.92	0.00	1.0	
		Week 10	Tezepelumab	30	28 (93.3)	-0.87 (0.89)	-2.7	-1.42	-0.83	-0.17	0.8	0.03 [-0.50, 0.56]
			Placebo	29	26 (89.7)	-0.90 (1.02)	-3.2	-1.50	-1.00	-0.33	2.0	
		Week 12	Tezepelumab	30	28 (93.3)	-0.95 (0.86)	-2.3	-1.75	-1.00	-0.25	0.5	0.31 [-0.23, 0.84]
			Placebo	29	26 (89.7)	-1.21 (0.82)	-3.2	-1.83	-1.17	-0.67	0.3	
		Week 14	Tezepelumab	30	28 (93.3)	-1.06 (0.85)	-2.3	-1.83	-1.17	-0.33	0.5	0.14 [-0.39, 0.68]
			Placebo	29	26 (89.7)	-1.18 (0.85)	-3.2	-1.67	-1.25	-0.67	0.7	
		Week 16	Tezepelumab	30	28 (93.3)	-0.90 (0.97)	-2.3	-1.75	-1.00	-0.33	1.5	0.20 [-0.34, 0.73]
			Placebo	29	26 (89.7)	-1.09 (0.88)	-2.8	-1.67	-1.17	-0.33	0.3	
		Week 18	Tezepelumab	30	29 (96.7)	-0.94 (0.77)	-2.3	-1.50	-1.00	-0.50	0.5	0.21 [-0.32, 0.75]
			Placebo	29	26 (89.7)	-1.13 (1.07)	-3.2	-1.83	-1.33	-0.17	1.5	
		Week 20	Tezepelumab	30	29 (96.7)	-0.88 (0.83)	-2.3	-1.50	-0.83	-0.33	0.7	0.28 [-0.26, 0.81]
			Placebo	29	26 (89.7)	-1.13 (0.98)	-3.0	-1.83	-0.83	-0.33	0.3	
		Week 22	Tezepelumab	30	29 (96.7)	-0.77 (0.93)	-2.3	-1.17	-0.83	-0.17	1.8	0.41 [-0.13, 0.94]
			Placebo	29	26 (89.7)	-1.16 (0.98)	-3.2	-1.83	-1.17	-0.50	0.5	
		Week 24	Tezepelumab	30	29 (96.7)	-0.85 (0.85)	-2.3	-1.33	-0.67	-0.17	0.7	0.17 [-0.37, 0.70]
			Placebo	29	26 (89.7)	-1.01 (1.04)	-3.2	-1.50	-0.92	0.00	0.5	
		Week 26	Tezepelumab	30	30 (100.0)	-0.81 (0.91)	-2.3	-1.50	-0.75	0.00	0.7	0.35 [-0.18, 0.88]
			Placebo	29	26 (89.7)	-1.13 (0.93)	-2.5	-1.83	-1.33	-0.50	0.5	
		Week 28	Tezepelumab	30	30 (100.0)	-0.81 (1.01)	-2.3	-1.67	-0.83	0.00	0.8	0.19 [-0.34, 0.71]
			Placebo	29	26 (89.7)	-1.01 (1.08)	-2.8	-1.83	-1.25	-0.33	1.2	
		Week 30	Tezepelumab	30	30 (100.0)	-0.81 (1.02)	-2.5	-1.50	-0.75	-0.17	1.8	0.39 [-0.14, 0.92]
			Placebo	29	26 (89.7)	-1.20 (0.97)	-3.2	-1.83	-1.25	-0.33	0.3	
		Week 32	Tezepelumab	30	30 (100.0)	-0.88 (0.87)	-2.3	-1.50	-0.83	-0.33	0.8	0.24 [-0.29, 0.77]
			Placebo	29	26 (89.7)	-1.12 (1.11)	-3.0	-1.83	-1.17	-0.33	1.5	
		Week 34	Tezepelumab	30	30 (100.0)	-0.81 (1.05)	-2.5	-1.67	-0.67	-0.17	2.0	0.35 [-0.18, 0.88]
			Placebo	29	26 (89.7)	-1.17 (1.03)	-3.2	-2.00	-1.17	-0.67	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 250 cells/uL	Change from baseline	Week 36	Tezepelumab	30	30 (100.0)	-0.89 (0.93)	-2.3	-1.67	-1.00	-0.17	1.5	0.16 [-0.36, 0.69]
			Placebo	29	26 (89.7)	-1.06 (1.16)	-3.5	-1.83	-1.00	-0.33	1.5	
		Week 38	Tezepelumab	30	30 (100.0)	-0.77 (0.99)	-2.3	-1.33	-0.83	-0.17	2.3	0.27 [-0.26, 0.80]
			Placebo	29	26 (89.7)	-1.04 (1.09)	-3.2	-1.83	-1.08	-0.17	1.5	
		Week 40	Tezepelumab	30	30 (100.0)	-0.77 (0.92)	-2.5	-1.17	-0.83	-0.17	1.7	0.28 [-0.25, 0.81]
			Placebo	29	26 (89.7)	-1.05 (1.12)	-3.2	-2.00	-1.25	0.00	0.8	
		Week 42	Tezepelumab	30	30 (100.0)	-0.77 (0.96)	-2.3	-1.50	-0.83	0.00	2.0	0.39 [-0.14, 0.92]
			Placebo	29	26 (89.7)	-1.13 (0.94)	-2.8	-1.67	-1.17	-0.67	0.3	
		Week 44	Tezepelumab	30	30 (100.0)	-0.80 (0.95)	-2.7	-1.50	-0.83	-0.17	1.5	0.19 [-0.34, 0.71]
			Placebo	29	26 (89.7)	-0.99 (1.06)	-3.3	-1.50	-1.00	0.00	0.8	
		Week 46	Tezepelumab	30	30 (100.0)	-0.78 (0.91)	-2.3	-1.33	-0.83	-0.17	1.7	0.35 [-0.18, 0.88]
			Placebo	29	26 (89.7)	-1.10 (0.93)	-3.2	-1.67	-1.08	-0.67	0.3	
		Week 48	Tezepelumab	30	30 (100.0)	-0.82 (0.92)	-2.3	-1.50	-0.75	-0.17	1.8	0.35 [-0.18, 0.88]
			Placebo	29	26 (89.7)	-1.17 (1.08)	-3.3	-1.83	-1.17	-0.50	0.3	
		Week 50	Tezepelumab	30	30 (100.0)	-0.86 (1.02)	-2.7	-1.50	-0.83	-0.17	1.8	0.18 [-0.34, 0.71]
			Placebo	29	26 (89.7)	-1.05 (1.08)	-3.5	-1.67	-1.00	-0.67	1.5	
		Week 52	Tezepelumab	30	30 (100.0)	-0.89 (1.02)	-2.7	-1.50	-0.83	-0.17	1.8	0.12 [-0.40, 0.65]
			Placebo	29	26 (89.7)	-1.02 (1.08)	-3.5	-1.67	-0.92	-0.67	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	36	36 (100.0)	2.77 (0.86)	0.3	2.17	2.67	3.25	4.8	
			Placebo	36	36 (100.0)	2.53 (0.70)	0.3	2.17	2.67	3.00	3.5	
		Week 2	Tezepelumab	36	35 (97.2)	2.20 (0.93)	0.7	1.50	2.17	2.83	4.2	
			Placebo	36	32 (88.9)	2.27 (0.50)	1.2	2.00	2.33	2.50	3.3	
		Week 4	Tezepelumab	36	35 (97.2)	1.97 (0.98)	0.2	1.33	2.17	2.83	3.5	
			Placebo	36	32 (88.9)	2.33 (0.78)	0.7	2.00	2.33	2.67	4.2	
		Week 6	Tezepelumab	36	35 (97.2)	1.81 (1.07)	0.0	0.83	1.83	2.67	4.0	
			Placebo	36	32 (88.9)	2.24 (0.92)	0.2	1.75	2.33	2.75	4.7	
		Week 8	Tezepelumab	36	35 (97.2)	1.63 (1.22)	0.0	0.50	1.50	2.67	4.8	
			Placebo	36	33 (91.7)	2.07 (0.97)	0.0	1.67	2.17	2.67	3.7	
		Week 10	Tezepelumab	36	35 (97.2)	1.51 (1.12)	0.0	0.50	1.50	2.67	3.7	
			Placebo	36	33 (91.7)	2.15 (1.03)	0.0	1.83	2.17	2.67	5.3	
		Week 12	Tezepelumab	36	35 (97.2)	1.39 (1.05)	0.0	0.50	1.50	2.17	3.3	
			Placebo	36	33 (91.7)	2.02 (0.98)	0.0	1.50	2.17	2.67	4.2	
		Week 14	Tezepelumab	36	35 (97.2)	1.35 (1.13)	0.0	0.50	1.17	2.17	4.2	
			Placebo	36	33 (91.7)	1.87 (0.96)	0.0	1.50	2.00	2.33	5.0	
		Week 16	Tezepelumab	36	35 (97.2)	1.49 (1.12)	0.0	0.50	1.33	2.50	4.2	
			Placebo	36	33 (91.7)	2.10 (1.16)	0.0	1.83	2.17	2.67	5.0	
		Week 18	Tezepelumab	36	35 (97.2)	1.48 (1.11)	0.0	0.67	1.50	2.33	4.2	
			Placebo	36	33 (91.7)	1.98 (1.03)	0.0	1.67	2.17	2.33	5.0	
		Week 20	Tezepelumab	36	35 (97.2)	1.46 (1.16)	0.0	0.50	1.50	2.00	5.0	
			Placebo	36	33 (91.7)	2.15 (1.05)	0.0	1.67	2.33	2.83	5.0	
		Week 22	Tezepelumab	36	35 (97.2)	1.49 (1.04)	0.0	0.67	1.50	2.33	3.8	
			Placebo	36	33 (91.7)	2.10 (1.10)	0.0	1.50	2.17	2.67	5.0	
		Week 24	Tezepelumab	36	35 (97.2)	1.53 (1.08)	0.0	0.50	1.50	2.33	3.8	
			Placebo	36	33 (91.7)	2.09 (0.98)	0.0	1.67	2.17	2.67	4.2	
		Week 26	Tezepelumab	36	35 (97.2)	1.60 (1.09)	0.0	0.67	1.67	2.67	4.0	
			Placebo	36	33 (91.7)	2.07 (1.08)	0.0	1.33	2.00	2.83	4.2	
		Week 28	Tezepelumab	36	36 (100.0)	1.50 (1.13)	0.0	0.33	1.50	2.42	3.8	
			Placebo	36	34 (94.4)	1.94 (1.15)	0.0	1.00	2.08	2.67	4.2	
		Week 30	Tezepelumab	36	36 (100.0)	1.46 (1.05)	0.0	0.67	1.50	2.08	3.7	
			Placebo	36	34 (94.4)	2.06 (1.08)	0.0	1.67	2.08	2.67	4.2	
		Week 32	Tezepelumab	36	36 (100.0)	1.41 (1.10)	0.0	0.33	1.50	2.17	4.0	
			Placebo	36	34 (94.4)	1.94 (0.97)	0.0	1.17	2.00	2.50	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 250 cells/uL	Absolute values	Week 34	Tezepelumab	36	36 (100.0)	1.47 (1.12)	0.0	0.50	1.50	2.33	4.2	
			Placebo	36	34 (94.4)	1.92 (1.00)	0.0	1.33	2.00	2.50	4.2	
		Week 36	Tezepelumab	36	36 (100.0)	1.49 (1.08)	0.0	0.50	1.50	2.33	3.7	
			Placebo	36	34 (94.4)	2.14 (1.03)	0.0	1.50	2.17	2.83	4.2	
		Week 38	Tezepelumab	36	36 (100.0)	1.42 (1.19)	0.0	0.33	1.33	2.25	4.5	
			Placebo	36	34 (94.4)	1.89 (1.00)	0.0	1.00	2.00	2.50	4.2	
		Week 40	Tezepelumab	36	36 (100.0)	1.38 (1.14)	0.0	0.33	1.33	2.33	3.7	
			Placebo	36	34 (94.4)	2.15 (1.04)	0.0	1.33	2.17	2.67	4.2	
		Week 42	Tezepelumab	36	36 (100.0)	1.33 (1.06)	0.0	0.50	1.00	2.25	3.8	
			Placebo	36	34 (94.4)	1.95 (0.93)	0.0	1.50	2.00	2.50	4.5	
		Week 44	Tezepelumab	36	36 (100.0)	1.42 (1.07)	0.0	0.33	1.42	2.33	3.8	
			Placebo	36	34 (94.4)	1.99 (0.98)	0.0	1.17	2.00	2.50	4.2	
		Week 46	Tezepelumab	36	36 (100.0)	1.43 (1.15)	0.0	0.50	1.17	2.50	3.8	
			Placebo	36	34 (94.4)	1.89 (0.92)	0.0	1.33	2.00	2.33	3.8	
		Week 48	Tezepelumab	36	36 (100.0)	1.46 (1.16)	0.0	0.50	1.33	2.42	4.0	
			Placebo	36	34 (94.4)	2.02 (0.94)	0.0	1.50	2.17	2.50	4.2	
		Week 50	Tezepelumab	36	36 (100.0)	1.39 (1.15)	0.0	0.50	1.17	2.33	4.2	
			Placebo	36	34 (94.4)	1.75 (0.88)	0.0	1.00	1.75	2.33	3.8	
		Week 52	Tezepelumab	36	36 (100.0)	1.47 (1.13)	0.0	0.58	1.33	2.33	4.3	
			Placebo	36	34 (94.4)	1.85 (0.99)	0.0	1.00	2.08	2.50	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 2	Tezepelumab	36	35 (97.2)	-0.58 (0.68)	-2.0	-1.00	-0.50	0.00	0.7	-0.31 [-0.79, 0.17]
			Placebo	36	32 (88.9)	-0.37 (0.64)	-2.2	-0.75	-0.33	0.00	1.0	
		Week 4	Tezepelumab	36	35 (97.2)	-0.81 (0.95)	-2.5	-1.50	-0.83	-0.17	2.3	-0.55 [-1.04, -0.06]
			Placebo	36	32 (88.9)	-0.31 (0.86)	-2.7	-0.83	-0.17	0.33	1.2	
		Week 6	Tezepelumab	36	35 (97.2)	-0.97 (1.05)	-2.7	-1.50	-1.00	-0.50	2.3	-0.56 [-1.05, -0.07]
			Placebo	36	32 (88.9)	-0.40 (0.97)	-2.8	-1.00	-0.33	0.25	1.5	
		Week 8	Tezepelumab	36	35 (97.2)	-1.15 (1.18)	-3.0	-1.83	-1.17	-0.67	2.3	-0.51 [-1.00, -0.03]
			Placebo	36	33 (91.7)	-0.58 (1.01)	-3.2	-0.83	-0.50	0.00	1.0	
		Week 10	Tezepelumab	36	35 (97.2)	-1.27 (1.09)	-3.2	-2.00	-1.33	-0.67	2.3	-0.68 [-1.17, -0.19]
			Placebo	36	33 (91.7)	-0.50 (1.17)	-3.3	-0.83	-0.50	0.00	2.7	
		Week 12	Tezepelumab	36	35 (97.2)	-1.39 (1.07)	-3.0	-2.17	-1.33	-0.67	2.3	-0.71 [-1.20, -0.22]
			Placebo	36	33 (91.7)	-0.64 (1.05)	-3.3	-1.00	-0.50	0.00	1.3	
		Week 14	Tezepelumab	36	35 (97.2)	-1.43 (1.10)	-3.7	-2.17	-1.50	-0.83	2.3	-0.58 [-1.07, -0.10]
			Placebo	36	33 (91.7)	-0.78 (1.13)	-3.2	-1.33	-0.83	-0.33	2.3	
		Week 16	Tezepelumab	36	35 (97.2)	-1.29 (1.07)	-3.0	-2.17	-1.33	-0.67	2.3	-0.64 [-1.13, -0.16]
			Placebo	36	33 (91.7)	-0.55 (1.22)	-3.2	-1.17	-0.50	0.00	2.3	
		Week 18	Tezepelumab	36	35 (97.2)	-1.30 (1.13)	-3.5	-2.00	-1.17	-0.67	2.3	-0.55 [-1.03, -0.06]
			Placebo	36	33 (91.7)	-0.67 (1.20)	-3.2	-1.17	-0.67	0.00	2.3	
		Week 20	Tezepelumab	36	35 (97.2)	-1.32 (1.09)	-3.2	-2.00	-1.50	-0.67	2.3	-0.73 [-1.22, -0.24]
			Placebo	36	33 (91.7)	-0.50 (1.15)	-3.2	-1.00	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	36	35 (97.2)	-1.30 (1.04)	-3.0	-2.17	-1.17	-0.67	2.3	-0.68 [-1.17, -0.19]
			Placebo	36	33 (91.7)	-0.55 (1.15)	-3.3	-1.00	-0.50	-0.17	2.3	
		Week 24	Tezepelumab	36	35 (97.2)	-1.25 (1.05)	-3.2	-2.00	-1.50	-0.50	2.3	-0.64 [-1.13, -0.15]
			Placebo	36	33 (91.7)	-0.56 (1.11)	-3.2	-1.00	-0.50	0.00	2.3	
		Week 26	Tezepelumab	36	35 (97.2)	-1.19 (1.11)	-2.8	-2.00	-1.17	-0.50	2.3	-0.52 [-1.00, -0.04]
			Placebo	36	33 (91.7)	-0.58 (1.22)	-3.2	-1.33	-0.67	0.17	2.3	
		Week 28	Tezepelumab	36	36 (100.0)	-1.26 (1.12)	-3.2	-2.00	-1.25	-0.58	2.3	-0.54 [-1.01, -0.06]
			Placebo	36	34 (94.4)	-0.64 (1.20)	-3.2	-1.33	-0.67	-0.17	2.3	
		Week 30	Tezepelumab	36	36 (100.0)	-1.31 (1.08)	-3.5	-2.08	-1.33	-0.75	2.3	-0.70 [-1.18, -0.21]
			Placebo	36	34 (94.4)	-0.52 (1.18)	-2.8	-1.17	-0.75	-0.17	2.3	
		Week 32	Tezepelumab	36	36 (100.0)	-1.36 (1.06)	-3.0	-2.17	-1.58	-0.67	2.3	-0.68 [-1.16, -0.20]
			Placebo	36	34 (94.4)	-0.64 (1.04)	-2.8	-1.33	-0.58	-0.17	2.3	
		Week 34	Tezepelumab	36	36 (100.0)	-1.30 (1.08)	-2.8	-2.17	-1.50	-0.67	2.3	-0.59 [-1.07, -0.11]
			Placebo	36	34 (94.4)	-0.66 (1.08)	-2.8	-1.33	-0.67	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 250 cells/uL	Change from baseline	Week 36	Tezepelumab	36	36 (100.0)	-1.28 (1.15)	-3.0	-2.17	-1.42	-0.58	2.3	-0.76 [-1.25, -0.28]
			Placebo	36	34 (94.4)	-0.45 (1.04)	-2.3	-1.17	-0.42	0.17	2.3	
		Week 38	Tezepelumab	36	36 (100.0)	-1.35 (1.14)	-3.0	-2.08	-1.67	-0.67	2.3	-0.59 [-1.07, -0.11]
			Placebo	36	34 (94.4)	-0.70 (1.06)	-2.5	-1.33	-0.83	0.00	2.3	
		Week 40	Tezepelumab	36	36 (100.0)	-1.39 (1.15)	-3.2	-2.33	-1.50	-0.67	2.3	-0.84 [-1.33, -0.35]
			Placebo	36	34 (94.4)	-0.44 (1.11)	-2.3	-1.17	-0.42	0.33	2.3	
		Week 42	Tezepelumab	36	36 (100.0)	-1.44 (1.11)	-3.3	-2.17	-1.67	-0.67	2.3	-0.74 [-1.23, -0.26]
			Placebo	36	34 (94.4)	-0.63 (1.05)	-2.3	-1.17	-0.92	-0.17	2.3	
		Week 44	Tezepelumab	36	36 (100.0)	-1.35 (1.14)	-3.5	-2.17	-1.33	-0.67	2.3	-0.67 [-1.16, -0.19]
			Placebo	36	34 (94.4)	-0.60 (1.10)	-2.7	-1.17	-0.67	0.00	2.3	
		Week 46	Tezepelumab	36	36 (100.0)	-1.34 (1.16)	-3.3	-2.17	-1.42	-0.67	2.3	-0.59 [-1.07, -0.11]
			Placebo	36	34 (94.4)	-0.69 (1.04)	-2.3	-1.17	-0.92	-0.17	2.3	
		Week 48	Tezepelumab	36	36 (100.0)	-1.31 (1.15)	-2.7	-2.33	-1.50	-0.50	2.3	-0.69 [-1.17, -0.20]
			Placebo	36	34 (94.4)	-0.56 (1.00)	-2.5	-1.17	-0.83	-0.17	2.3	
		Week 50	Tezepelumab	36	36 (100.0)	-1.38 (1.11)	-2.7	-2.33	-1.67	-0.75	2.3	-0.52 [-0.99, -0.04]
			Placebo	36	34 (94.4)	-0.84 (0.96)	-3.0	-1.33	-0.92	-0.33	2.3	
		Week 52	Tezepelumab	36	36 (100.0)	-1.30 (1.11)	-2.7	-2.00	-1.58	-0.67	2.3	-0.52 [-1.00, -0.05]
			Placebo	36	34 (94.4)	-0.73 (1.05)	-3.0	-1.17	-0.58	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	38	38 (100.0)	2.82 (0.66)	1.7	2.33	2.83	3.17	4.5	
			Placebo	30	30 (100.0)	2.64 (0.67)	0.3	2.33	2.75	3.00	3.5	
		Week 2	Tezepelumab	38	35 (92.1)	2.40 (1.05)	0.0	1.50	2.67	3.33	4.2	
			Placebo	30	25 (83.3)	2.25 (0.68)	0.3	2.00	2.33	2.67	3.2	
		Week 4	Tezepelumab	38	35 (92.1)	2.13 (0.90)	0.2	1.67	2.33	2.83	3.5	
			Placebo	30	25 (83.3)	1.98 (0.90)	0.2	1.33	2.17	2.67	3.5	
		Week 6	Tezepelumab	38	35 (92.1)	1.98 (0.98)	0.0	1.33	1.83	2.67	4.0	
			Placebo	30	25 (83.3)	1.97 (1.04)	0.2	1.17	2.00	2.67	4.7	
		Week 8	Tezepelumab	38	35 (92.1)	1.94 (1.15)	0.0	1.33	1.83	2.83	4.8	
			Placebo	30	25 (83.3)	2.09 (0.97)	0.0	1.83	2.17	2.83	3.5	
		Week 10	Tezepelumab	38	35 (92.1)	1.84 (1.11)	0.0	1.00	1.67	2.83	4.3	
			Placebo	30	25 (83.3)	1.89 (0.87)	0.0	1.67	2.17	2.33	3.2	
		Week 12	Tezepelumab	38	35 (92.1)	1.80 (1.08)	0.0	1.00	2.00	2.67	4.3	
			Placebo	30	25 (83.3)	1.77 (0.83)	0.0	1.33	2.00	2.17	3.2	
		Week 14	Tezepelumab	38	35 (92.1)	1.67 (1.07)	0.0	1.00	1.67	2.33	4.3	
			Placebo	30	25 (83.3)	1.62 (0.79)	0.3	1.00	1.67	2.17	3.2	
		Week 16	Tezepelumab	38	35 (92.1)	1.90 (1.16)	0.0	1.17	2.00	2.50	4.3	
			Placebo	30	25 (83.3)	1.78 (0.78)	0.2	1.50	1.83	2.17	3.2	
		Week 18	Tezepelumab	38	36 (94.7)	1.84 (1.05)	0.0	1.33	1.83	2.42	4.3	
			Placebo	30	25 (83.3)	1.80 (1.10)	0.0	1.00	1.83	2.67	4.7	
		Week 20	Tezepelumab	38	36 (94.7)	1.86 (1.15)	0.0	1.17	1.83	2.50	5.0	
			Placebo	30	25 (83.3)	1.77 (0.99)	0.2	0.83	1.83	2.67	3.3	
		Week 22	Tezepelumab	38	36 (94.7)	1.83 (1.03)	0.0	1.33	2.00	2.42	4.3	
			Placebo	30	25 (83.3)	1.69 (0.98)	0.0	1.00	2.00	2.33	3.7	
		Week 24	Tezepelumab	38	36 (94.7)	1.88 (1.09)	0.0	1.17	2.00	2.58	4.3	
			Placebo	30	25 (83.3)	1.78 (0.96)	0.2	0.83	2.00	2.50	3.5	
		Week 26	Tezepelumab	38	37 (97.4)	1.93 (1.13)	0.0	1.17	2.00	2.67	4.3	
			Placebo	30	25 (83.3)	1.75 (0.98)	0.3	1.00	1.67	2.17	4.0	
		Week 28	Tezepelumab	38	38 (100.0)	1.82 (1.13)	0.0	1.17	1.75	2.50	4.3	
			Placebo	30	26 (86.7)	1.72 (1.05)	0.0	0.83	1.92	2.33	4.0	
		Week 30	Tezepelumab	38	38 (100.0)	1.85 (1.13)	0.0	1.17	1.92	2.50	4.3	
			Placebo	30	26 (86.7)	1.64 (0.90)	0.0	0.83	1.83	2.50	3.0	
		Week 32	Tezepelumab	38	38 (100.0)	1.80 (1.10)	0.0	1.00	1.83	2.50	4.3	
			Placebo	30	26 (86.7)	1.54 (0.86)	0.0	0.83	1.67	2.17	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 24 ppb	Absolute values	Week 34	Tezepelumab	38	38 (100.0)	1.85 (1.19)	0.0	1.00	1.83	2.67	4.3	
			Placebo	30	26 (86.7)	1.61 (0.83)	0.0	0.83	1.83	2.17	2.8	
		Week 36	Tezepelumab	38	38 (100.0)	1.82 (1.09)	0.0	1.17	1.75	2.67	4.3	
			Placebo	30	26 (86.7)	1.62 (0.99)	0.0	0.83	1.83	2.33	3.2	
		Week 38	Tezepelumab	38	38 (100.0)	1.85 (1.23)	0.0	1.00	1.67	2.67	4.5	
			Placebo	30	26 (86.7)	1.62 (0.90)	0.0	1.00	1.83	2.17	3.2	
		Week 40	Tezepelumab	38	38 (100.0)	1.85 (1.16)	0.0	1.00	1.92	2.67	4.3	
			Placebo	30	26 (86.7)	1.71 (1.08)	0.0	0.67	1.83	2.33	4.0	
		Week 42	Tezepelumab	38	38 (100.0)	1.87 (1.13)	0.0	1.00	1.83	2.67	4.3	
			Placebo	30	26 (86.7)	1.63 (0.90)	0.0	0.83	1.83	2.33	3.3	
		Week 44	Tezepelumab	38	38 (100.0)	1.89 (1.10)	0.0	1.17	1.92	2.67	4.3	
			Placebo	30	26 (86.7)	1.78 (0.98)	0.0	1.17	1.83	2.50	4.0	
		Week 46	Tezepelumab	38	38 (100.0)	1.92 (1.13)	0.0	1.17	2.00	2.67	4.3	
			Placebo	30	26 (86.7)	1.60 (0.92)	0.0	0.83	1.83	2.17	3.8	
		Week 48	Tezepelumab	38	38 (100.0)	1.89 (1.14)	0.0	1.17	2.00	2.67	4.3	
			Placebo	30	26 (86.7)	1.57 (1.03)	0.0	0.83	1.67	2.17	4.2	
		Week 50	Tezepelumab	38	38 (100.0)	1.89 (1.21)	0.0	1.17	1.83	2.67	4.3	
			Placebo	30	26 (86.7)	1.57 (0.86)	0.0	1.00	1.67	2.17	3.7	
		Week 52	Tezepelumab	38	38 (100.0)	1.92 (1.18)	0.0	1.17	1.83	2.50	4.3	
			Placebo	30	26 (86.7)	1.70 (0.93)	0.0	1.17	1.83	2.33	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 2	Tezepelumab	38	35 (92.1)	-0.50 (0.75)	-2.8	-0.83	-0.33	0.17	0.7	0.06 [-0.45, 0.58]
			Placebo	30	25 (83.3)	-0.55 (0.71)	-2.8	-0.83	-0.33	-0.17	0.3	
		Week 4	Tezepelumab	38	35 (92.1)	-0.77 (0.59)	-2.0	-1.17	-0.67	-0.33	0.2	0.06 [-0.45, 0.57]
			Placebo	30	25 (83.3)	-0.81 (0.96)	-3.0	-1.50	-0.67	-0.17	0.5	
		Week 6	Tezepelumab	38	35 (92.1)	-0.91 (0.70)	-2.5	-1.33	-1.00	-0.33	0.2	-0.11 [-0.62, 0.41]
			Placebo	30	25 (83.3)	-0.82 (1.09)	-3.3	-1.33	-0.67	-0.17	1.5	
		Week 8	Tezepelumab	38	35 (92.1)	-0.96 (0.97)	-3.0	-1.50	-1.00	-0.50	2.2	-0.25 [-0.76, 0.27]
			Placebo	30	25 (83.3)	-0.71 (1.07)	-3.2	-1.17	-0.67	0.17	1.0	
		Week 10	Tezepelumab	38	35 (92.1)	-1.05 (0.87)	-3.2	-1.50	-1.17	-0.33	0.5	-0.16 [-0.67, 0.35]
			Placebo	30	25 (83.3)	-0.91 (0.95)	-3.3	-1.33	-0.67	-0.33	0.3	
		Week 12	Tezepelumab	38	35 (92.1)	-1.10 (0.86)	-2.8	-2.00	-1.17	-0.50	0.5	-0.08 [-0.59, 0.44]
			Placebo	30	25 (83.3)	-1.03 (0.95)	-3.3	-1.50	-0.83	-0.33	0.3	
		Week 14	Tezepelumab	38	35 (92.1)	-1.22 (0.85)	-3.2	-2.00	-1.17	-0.67	0.5	-0.06 [-0.57, 0.46]
			Placebo	30	25 (83.3)	-1.17 (0.97)	-3.2	-1.83	-1.33	-0.33	0.3	
		Week 16	Tezepelumab	38	35 (92.1)	-1.00 (0.94)	-3.0	-1.67	-1.00	-0.33	1.5	0.02 [-0.49, 0.53]
			Placebo	30	25 (83.3)	-1.01 (0.96)	-3.2	-1.33	-1.17	-0.33	0.3	
		Week 18	Tezepelumab	38	36 (94.7)	-1.03 (0.83)	-3.2	-1.58	-1.00	-0.50	0.5	-0.03 [-0.55, 0.48]
			Placebo	30	25 (83.3)	-0.99 (1.18)	-3.2	-1.83	-1.17	-0.17	1.5	
		Week 20	Tezepelumab	38	36 (94.7)	-1.01 (0.92)	-3.2	-1.75	-0.92	-0.33	0.7	0.02 [-0.49, 0.53]
			Placebo	30	25 (83.3)	-1.03 (1.15)	-3.2	-1.83	-0.83	-0.17	1.0	
		Week 22	Tezepelumab	38	36 (94.7)	-1.04 (0.84)	-3.0	-1.83	-0.83	-0.58	0.5	0.07 [-0.44, 0.58]
			Placebo	30	25 (83.3)	-1.11 (1.12)	-3.3	-1.83	-1.00	-0.33	1.2	
		Week 24	Tezepelumab	38	36 (94.7)	-0.99 (0.88)	-3.2	-1.75	-0.75	-0.33	0.7	0.03 [-0.48, 0.54]
			Placebo	30	25 (83.3)	-1.01 (1.13)	-3.2	-1.67	-1.00	-0.17	1.0	
		Week 26	Tezepelumab	38	37 (97.4)	-0.90 (0.93)	-2.8	-1.83	-0.67	0.00	0.7	0.15 [-0.36, 0.65]
			Placebo	30	25 (83.3)	-1.05 (1.10)	-2.8	-1.83	-1.17	-0.33	1.5	
		Week 28	Tezepelumab	38	38 (100.0)	-1.00 (1.02)	-3.2	-2.00	-0.92	0.00	0.8	-0.03 [-0.53, 0.47]
			Placebo	30	26 (86.7)	-0.97 (1.11)	-2.8	-1.83	-1.00	-0.33	1.5	
		Week 30	Tezepelumab	38	38 (100.0)	-0.97 (1.00)	-2.7	-2.00	-0.92	-0.17	1.8	0.08 [-0.41, 0.58]
			Placebo	30	26 (86.7)	-1.06 (0.99)	-3.2	-1.83	-1.08	-0.33	0.5	
		Week 32	Tezepelumab	38	38 (100.0)	-1.02 (0.92)	-3.0	-2.00	-1.00	-0.50	0.8	0.15 [-0.35, 0.65]
			Placebo	30	26 (86.7)	-1.16 (1.01)	-3.0	-1.83	-1.08	-0.33	0.7	
		Week 34	Tezepelumab	38	38 (100.0)	-0.97 (1.05)	-2.8	-1.83	-0.92	-0.33	2.0	0.11 [-0.38, 0.61]
			Placebo	30	26 (86.7)	-1.09 (0.95)	-3.2	-1.67	-0.92	-0.67	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 24 ppb	Change from baseline	Week 36	Tezepelumab	38	38 (100.0)	-1.00 (0.95)	-3.0	-1.83	-1.00	-0.33	1.5	0.08 [-0.42, 0.58]
			Placebo	30	26 (86.7)	-1.08 (1.08)	-3.5	-1.83	-0.92	-0.33	0.7	
		Week 38	Tezepelumab	38	38 (100.0)	-0.97 (1.07)	-3.0	-2.00	-1.08	-0.17	2.3	0.11 [-0.39, 0.60]
			Placebo	30	26 (86.7)	-1.08 (0.95)	-3.2	-1.67	-1.00	-0.33	0.3	
		Week 40	Tezepelumab	38	38 (100.0)	-0.97 (1.00)	-3.2	-2.00	-0.83	-0.33	1.7	0.02 [-0.48, 0.52]
			Placebo	30	26 (86.7)	-0.99 (1.12)	-3.2	-2.00	-1.08	-0.17	1.2	
		Week 42	Tezepelumab	38	38 (100.0)	-0.95 (0.99)	-2.7	-1.83	-0.83	-0.50	2.0	0.12 [-0.38, 0.62]
			Placebo	30	26 (86.7)	-1.06 (0.94)	-2.8	-1.50	-1.17	-0.50	0.8	
		Week 44	Tezepelumab	38	38 (100.0)	-0.93 (0.97)	-3.2	-1.83	-0.83	-0.17	1.5	-0.01 [-0.51, 0.49]
			Placebo	30	26 (86.7)	-0.92 (1.03)	-3.3	-1.50	-0.83	-0.17	0.8	
		Week 46	Tezepelumab	38	38 (100.0)	-0.90 (0.97)	-2.5	-2.00	-0.83	-0.17	1.7	0.20 [-0.30, 0.70]
			Placebo	30	26 (86.7)	-1.10 (1.00)	-3.2	-1.67	-1.00	-0.67	1.3	
		Week 48	Tezepelumab	38	38 (100.0)	-0.93 (0.96)	-2.5	-1.83	-0.83	-0.50	1.8	0.19 [-0.31, 0.69]
			Placebo	30	26 (86.7)	-1.13 (1.15)	-3.3	-1.83	-0.83	-0.50	1.7	
		Week 50	Tezepelumab	38	38 (100.0)	-0.93 (1.03)	-2.7	-1.67	-0.92	-0.17	1.8	0.20 [-0.30, 0.70]
			Placebo	30	26 (86.7)	-1.13 (1.01)	-3.5	-1.67	-1.08	-0.67	1.5	
		Week 52	Tezepelumab	38	38 (100.0)	-0.90 (1.00)	-2.7	-1.67	-0.92	-0.17	1.8	0.10 [-0.40, 0.60]
			Placebo	30	26 (86.7)	-1.00 (1.10)	-3.5	-1.67	-0.83	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	28	28 (100.0)	2.57 (1.01)	0.0	2.08	2.50	3.17	4.8	
			Placebo	34	34 (100.0)	2.78 (0.77)	1.3	2.33	2.75	3.17	4.7	
		Week 2	Tezepelumab	28	28 (100.0)	2.02 (0.81)	0.2	1.50	2.08	2.67	3.3	
			Placebo	34	32 (94.1)	2.33 (0.86)	0.5	1.92	2.25	2.67	4.8	
		Week 4	Tezepelumab	28	28 (100.0)	1.79 (0.98)	0.2	1.08	1.92	2.67	3.3	
			Placebo	34	32 (94.1)	2.28 (0.93)	0.3	1.75	2.42	2.75	4.2	
		Week 6	Tezepelumab	28	28 (100.0)	1.76 (1.04)	0.0	0.83	1.75	2.58	3.7	
			Placebo	34	32 (94.1)	2.22 (1.17)	0.2	1.42	2.33	2.92	5.5	
		Week 8	Tezepelumab	28	28 (100.0)	1.50 (1.02)	0.0	0.58	1.58	2.42	3.3	
			Placebo	34	33 (97.1)	2.08 (1.17)	0.0	1.17	2.17	2.50	4.7	
		Week 10	Tezepelumab	28	28 (100.0)	1.43 (1.01)	0.0	0.58	1.42	2.25	3.2	
			Placebo	34	33 (97.1)	2.14 (1.12)	0.0	1.50	2.33	2.83	5.3	
		Week 12	Tezepelumab	28	28 (100.0)	1.26 (0.94)	0.0	0.50	1.25	2.17	2.8	
			Placebo	34	33 (97.1)	1.95 (1.11)	0.0	1.17	2.00	2.67	4.3	
		Week 14	Tezepelumab	28	28 (100.0)	1.26 (0.99)	0.0	0.50	1.17	2.00	3.7	
			Placebo	34	33 (97.1)	1.94 (1.09)	0.0	1.50	2.00	2.33	5.0	
		Week 16	Tezepelumab	28	28 (100.0)	1.30 (0.98)	0.0	0.42	1.33	1.83	3.3	
			Placebo	34	33 (97.1)	2.13 (1.35)	0.0	1.00	2.17	2.67	5.0	
		Week 18	Tezepelumab	28	28 (100.0)	1.29 (0.92)	0.0	0.67	1.08	2.00	3.3	
			Placebo	34	33 (97.1)	1.96 (1.17)	0.0	1.33	2.17	2.50	5.0	
		Week 20	Tezepelumab	28	28 (100.0)	1.31 (0.93)	0.0	0.50	1.17	1.83	3.5	
			Placebo	34	33 (97.1)	2.16 (1.12)	0.0	1.33	2.33	2.67	5.0	
		Week 22	Tezepelumab	28	28 (100.0)	1.49 (0.86)	0.0	0.83	1.50	2.08	3.3	
			Placebo	34	33 (97.1)	2.15 (1.21)	0.0	1.17	2.17	2.83	5.0	
		Week 24	Tezepelumab	28	28 (100.0)	1.39 (0.95)	0.0	0.50	1.17	2.25	3.5	
			Placebo	34	33 (97.1)	2.19 (1.07)	0.0	1.67	2.17	2.83	4.5	
		Week 26	Tezepelumab	28	28 (100.0)	1.41 (0.92)	0.0	0.58	1.50	2.17	2.8	
			Placebo	34	33 (97.1)	2.09 (1.18)	0.0	1.17	2.00	3.00	4.5	
		Week 28	Tezepelumab	28	28 (100.0)	1.44 (1.02)	0.0	0.42	1.50	2.25	3.5	
			Placebo	34	33 (97.1)	2.09 (1.27)	0.0	1.00	2.17	3.00	4.5	
		Week 30	Tezepelumab	28	28 (100.0)	1.34 (0.90)	0.0	0.67	1.42	2.00	3.2	
			Placebo	34	33 (97.1)	2.13 (1.26)	0.0	1.17	2.17	3.00	4.5	
		Week 32	Tezepelumab	28	28 (100.0)	1.27 (0.95)	0.0	0.33	1.17	2.08	2.8	
			Placebo	34	33 (97.1)	2.15 (1.19)	0.0	1.17	2.00	3.00	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 24 ppb	Absolute values	Week 34	Tezepelumab	28	28 (100.0)	1.36 (0.96)	0.0	0.50	1.33	2.17	2.8	
			Placebo	34	33 (97.1)	2.03 (1.24)	0.0	1.17	2.00	3.00	4.5	
		Week 36	Tezepelumab	28	28 (100.0)	1.32 (0.93)	0.0	0.50	1.17	2.17	2.8	
			Placebo	34	33 (97.1)	2.30 (1.16)	0.0	1.50	2.17	3.00	4.5	
		Week 38	Tezepelumab	28	28 (100.0)	1.33 (0.97)	0.0	0.25	1.50	2.00	2.8	
			Placebo	34	33 (97.1)	2.04 (1.22)	0.0	1.17	2.17	2.83	4.5	
		Week 40	Tezepelumab	28	28 (100.0)	1.28 (0.98)	0.0	0.33	1.17	2.08	2.8	
			Placebo	34	33 (97.1)	2.22 (1.15)	0.0	1.33	2.50	2.83	4.5	
		Week 42	Tezepelumab	28	28 (100.0)	1.20 (0.90)	0.0	0.50	1.00	1.75	2.8	
			Placebo	34	33 (97.1)	2.01 (1.10)	0.0	1.33	2.00	2.50	4.5	
		Week 44	Tezepelumab	28	28 (100.0)	1.23 (0.94)	0.0	0.42	1.08	2.08	2.8	
			Placebo	34	33 (97.1)	2.05 (1.13)	0.0	1.17	2.17	2.83	4.5	
		Week 46	Tezepelumab	28	28 (100.0)	1.23 (0.99)	0.0	0.42	1.00	2.00	3.0	
			Placebo	34	33 (97.1)	2.01 (1.01)	0.0	1.50	2.00	2.50	4.5	
		Week 48	Tezepelumab	28	28 (100.0)	1.29 (0.99)	0.0	0.50	1.00	2.00	3.0	
			Placebo	34	33 (97.1)	2.11 (1.02)	0.0	1.67	2.17	2.67	4.5	
		Week 50	Tezepelumab	28	28 (100.0)	1.14 (0.85)	0.0	0.50	1.00	1.67	2.8	
			Placebo	34	33 (97.1)	1.91 (1.08)	0.0	1.00	2.00	2.50	4.5	
		Week 52	Tezepelumab	28	28 (100.0)	1.17 (0.87)	0.0	0.50	1.00	1.83	2.8	
			Placebo	34	33 (97.1)	1.95 (1.13)	0.0	1.00	2.17	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 2	Tezepelumab	28	28 (100.0)	-0.55 (0.66)	-2.0	-1.00	-0.42	0.00	0.7	-0.25 [-0.76, 0.26]
			Placebo	34	32 (94.1)	-0.39 (0.67)	-1.5	-0.92	-0.33	0.00	1.0	
		Week 4	Tezepelumab	28	28 (100.0)	-0.79 (1.07)	-2.5	-1.50	-0.83	-0.08	2.3	-0.37 [-0.89, 0.14]
			Placebo	34	32 (94.1)	-0.43 (0.82)	-2.0	-1.17	-0.25	0.08	1.2	
		Week 6	Tezepelumab	28	28 (100.0)	-0.81 (1.18)	-2.7	-1.67	-0.75	0.08	2.3	-0.30 [-0.81, 0.21]
			Placebo	34	32 (94.1)	-0.49 (0.90)	-2.2	-1.17	-0.33	0.08	1.5	
		Week 8	Tezepelumab	28	28 (100.0)	-1.07 (1.14)	-2.8	-1.83	-1.00	-0.33	2.3	-0.41 [-0.92, 0.10]
			Placebo	34	33 (97.1)	-0.65 (0.96)	-3.0	-1.00	-0.50	0.00	1.0	
		Week 10	Tezepelumab	28	28 (100.0)	-1.14 (1.19)	-2.8	-2.00	-1.17	-0.50	2.3	-0.48 [-0.99, 0.03]
			Placebo	34	33 (97.1)	-0.59 (1.14)	-2.3	-1.33	-0.50	0.00	2.7	
		Week 12	Tezepelumab	28	28 (100.0)	-1.32 (1.16)	-3.0	-2.17	-1.25	-0.67	2.3	-0.50 [-1.01, 0.01]
			Placebo	34	33 (97.1)	-0.77 (1.03)	-3.2	-1.17	-0.67	-0.17	1.3	
		Week 14	Tezepelumab	28	28 (100.0)	-1.32 (1.19)	-3.7	-2.08	-1.25	-0.67	2.3	-0.47 [-0.99, 0.04]
			Placebo	34	33 (97.1)	-0.78 (1.06)	-3.2	-1.33	-0.83	-0.50	2.3	
		Week 16	Tezepelumab	28	28 (100.0)	-1.27 (1.14)	-2.8	-2.17	-1.25	-0.75	2.3	-0.58 [-1.09, -0.06]
			Placebo	34	33 (97.1)	-0.60 (1.21)	-3.2	-1.17	-0.50	0.00	2.3	
		Week 18	Tezepelumab	28	28 (100.0)	-1.28 (1.17)	-3.5	-2.00	-1.25	-0.67	2.3	-0.44 [-0.95, 0.07]
			Placebo	34	33 (97.1)	-0.76 (1.16)	-3.2	-1.50	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	28	28 (100.0)	-1.26 (1.09)	-2.7	-2.00	-1.42	-0.58	2.3	-0.65 [-1.16, -0.13]
			Placebo	34	33 (97.1)	-0.57 (1.07)	-2.5	-1.00	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	28	28 (100.0)	-1.08 (1.23)	-2.7	-1.92	-1.17	-0.67	2.3	-0.44 [-0.95, 0.07]
			Placebo	34	33 (97.1)	-0.58 (1.08)	-2.5	-1.17	-0.67	0.00	2.3	
		Week 24	Tezepelumab	28	28 (100.0)	-1.18 (1.10)	-2.7	-1.83	-1.42	-0.58	2.3	-0.60 [-1.11, -0.08]
			Placebo	34	33 (97.1)	-0.54 (1.04)	-2.5	-1.17	-0.50	0.17	2.3	
		Week 26	Tezepelumab	28	28 (100.0)	-1.16 (1.15)	-2.8	-2.25	-1.17	-0.33	2.3	-0.46 [-0.97, 0.05]
			Placebo	34	33 (97.1)	-0.64 (1.15)	-3.2	-1.33	-0.67	0.17	2.3	
		Week 28	Tezepelumab	28	28 (100.0)	-1.13 (1.19)	-2.8	-2.17	-1.08	-0.33	2.3	-0.41 [-0.92, 0.10]
			Placebo	34	33 (97.1)	-0.64 (1.20)	-3.2	-1.50	-0.83	0.17	2.3	
		Week 30	Tezepelumab	28	28 (100.0)	-1.23 (1.17)	-3.5	-2.17	-1.33	-0.58	2.3	-0.52 [-1.04, -0.01]
			Placebo	34	33 (97.1)	-0.60 (1.23)	-2.5	-1.33	-0.83	0.17	2.3	
		Week 32	Tezepelumab	28	28 (100.0)	-1.30 (1.10)	-2.7	-2.08	-1.58	-0.67	2.3	-0.66 [-1.17, -0.14]
			Placebo	34	33 (97.1)	-0.58 (1.11)	-2.5	-1.33	-0.67	0.17	2.3	
		Week 34	Tezepelumab	28	28 (100.0)	-1.21 (1.14)	-2.5	-2.17	-1.42	-0.58	2.3	-0.44 [-0.95, 0.07]
			Placebo	34	33 (97.1)	-0.70 (1.17)	-2.8	-1.33	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 24 ppb	Change from baseline	Week 36	Tezepelumab	28	28 (100.0)	-1.26 (1.21)	-2.8	-2.25	-1.50	-0.33	2.3	-0.72 [-1.24, -0.20]
			Placebo	34	33 (97.1)	-0.42 (1.11)	-2.5	-1.17	-0.67	0.17	2.3	
		Week 38	Tezepelumab	28	28 (100.0)	-1.24 (1.15)	-2.8	-2.08	-1.33	-0.58	2.3	-0.48 [-0.99, 0.03]
			Placebo	34	33 (97.1)	-0.69 (1.17)	-2.5	-1.33	-0.83	0.17	2.3	
		Week 40	Tezepelumab	28	28 (100.0)	-1.29 (1.20)	-2.8	-2.42	-1.50	-0.58	2.3	-0.67 [-1.19, -0.15]
			Placebo	34	33 (97.1)	-0.51 (1.15)	-2.5	-1.33	-0.67	0.33	2.3	
		Week 42	Tezepelumab	28	28 (100.0)	-1.37 (1.19)	-3.3	-2.17	-1.58	-0.50	2.3	-0.58 [-1.10, -0.07]
			Placebo	34	33 (97.1)	-0.72 (1.08)	-2.5	-1.33	-1.00	-0.17	2.3	
		Week 44	Tezepelumab	28	28 (100.0)	-1.34 (1.21)	-3.5	-2.33	-1.50	-0.67	2.3	-0.56 [-1.07, -0.05]
			Placebo	34	33 (97.1)	-0.68 (1.14)	-2.7	-1.33	-0.83	0.00	2.3	
		Week 46	Tezepelumab	28	28 (100.0)	-1.34 (1.20)	-3.3	-2.33	-1.42	-0.75	2.3	-0.57 [-1.08, -0.05]
			Placebo	34	33 (97.1)	-0.72 (0.98)	-2.5	-1.33	-0.83	-0.17	2.3	
		Week 48	Tezepelumab	28	28 (100.0)	-1.29 (1.19)	-2.7	-2.33	-1.50	-0.42	2.3	-0.62 [-1.13, -0.10]
			Placebo	34	33 (97.1)	-0.62 (0.96)	-2.5	-1.17	-0.83	0.17	2.3	
		Week 50	Tezepelumab	28	28 (100.0)	-1.43 (1.12)	-2.7	-2.42	-1.67	-0.92	2.3	-0.59 [-1.10, -0.07]
			Placebo	34	33 (97.1)	-0.81 (0.99)	-3.0	-1.17	-0.83	-0.33	2.3	
		Week 52	Tezepelumab	28	28 (100.0)	-1.40 (1.14)	-2.7	-2.33	-1.67	-0.75	2.3	-0.57 [-1.09, -0.06]
			Placebo	34	33 (97.1)	-0.78 (1.04)	-3.0	-1.17	-0.83	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	32	32 (100.0)	2.81 (0.69)	1.7	2.25	2.83	3.17	4.5	
			Placebo	27	27 (100.0)	2.62 (0.69)	0.3	2.33	2.67	3.00	3.5	
		Week 2	Tezepelumab	32	30 (93.8)	2.38 (1.00)	0.0	1.50	2.67	3.00	3.8	
			Placebo	27	23 (85.2)	2.26 (0.65)	0.3	2.00	2.33	2.67	3.2	
		Week 4	Tezepelumab	32	30 (93.8)	2.08 (0.92)	0.2	1.67	2.25	2.83	3.5	
			Placebo	27	23 (85.2)	2.01 (0.89)	0.2	1.33	2.17	2.67	3.5	
		Week 6	Tezepelumab	32	30 (93.8)	1.89 (0.96)	0.0	1.33	1.83	2.50	4.0	
			Placebo	27	23 (85.2)	2.01 (1.03)	0.2	1.17	2.00	2.67	4.7	
		Week 8	Tezepelumab	32	30 (93.8)	1.92 (1.19)	0.0	1.33	1.75	2.67	4.8	
			Placebo	27	23 (85.2)	2.12 (0.88)	0.0	1.83	2.17	2.83	3.5	
		Week 10	Tezepelumab	32	30 (93.8)	1.79 (1.10)	0.0	1.00	1.75	2.67	4.3	
			Placebo	27	23 (85.2)	1.91 (0.77)	0.2	1.67	2.17	2.33	3.0	
		Week 12	Tezepelumab	32	30 (93.8)	1.82 (1.08)	0.0	1.17	1.92	2.50	4.3	
			Placebo	27	23 (85.2)	1.83 (0.77)	0.3	1.33	2.00	2.17	3.2	
		Week 14	Tezepelumab	32	30 (93.8)	1.69 (1.06)	0.0	1.00	1.67	2.33	4.3	
			Placebo	27	23 (85.2)	1.67 (0.78)	0.3	1.00	1.67	2.17	3.2	
		Week 16	Tezepelumab	32	30 (93.8)	1.93 (1.14)	0.0	1.17	2.00	2.50	4.3	
			Placebo	27	23 (85.2)	1.83 (0.74)	0.5	1.50	1.83	2.33	3.2	
		Week 18	Tezepelumab	32	31 (96.9)	1.83 (1.06)	0.0	1.33	1.83	2.33	4.3	
			Placebo	27	23 (85.2)	1.81 (1.05)	0.0	1.00	1.83	2.67	4.7	
		Week 20	Tezepelumab	32	31 (96.9)	1.89 (1.13)	0.0	1.17	1.83	2.50	5.0	
			Placebo	27	23 (85.2)	1.79 (0.95)	0.2	0.83	1.83	2.67	3.3	
		Week 22	Tezepelumab	32	31 (96.9)	1.85 (1.01)	0.0	1.50	2.00	2.33	4.3	
			Placebo	27	23 (85.2)	1.75 (0.95)	0.0	1.00	2.00	2.33	3.7	
		Week 24	Tezepelumab	32	31 (96.9)	1.91 (1.07)	0.0	1.17	2.00	2.50	4.3	
			Placebo	27	23 (85.2)	1.83 (0.93)	0.2	0.83	2.00	2.50	3.5	
		Week 26	Tezepelumab	32	32 (100.0)	1.92 (1.07)	0.0	1.25	1.92	2.67	4.3	
			Placebo	27	23 (85.2)	1.80 (0.98)	0.3	1.00	1.67	2.33	4.0	
		Week 28	Tezepelumab	32	32 (100.0)	1.86 (1.06)	0.0	1.33	1.92	2.50	4.3	
			Placebo	27	24 (88.9)	1.69 (0.97)	0.0	0.92	1.92	2.25	4.0	
		Week 30	Tezepelumab	32	32 (100.0)	1.90 (1.05)	0.0	1.25	2.00	2.50	4.3	
			Placebo	27	24 (88.9)	1.65 (0.89)	0.0	0.92	1.83	2.42	3.0	
		Week 32	Tezepelumab	32	32 (100.0)	1.85 (1.04)	0.0	1.17	1.83	2.50	4.3	
			Placebo	27	24 (88.9)	1.56 (0.86)	0.0	0.92	1.67	2.17	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 22.0 ppb	Absolute values	Week 34	Tezepelumab	32	32 (100.0)	1.91 (1.11)	0.0	1.08	1.92	2.67	4.3	
			Placebo	27	24 (88.9)	1.64 (0.83)	0.0	1.25	1.83	2.25	2.8	
		Week 36	Tezepelumab	32	32 (100.0)	1.88 (1.07)	0.0	1.17	1.75	2.67	4.3	
			Placebo	27	24 (88.9)	1.63 (1.03)	0.0	0.83	1.83	2.42	3.2	
		Week 38	Tezepelumab	32	32 (100.0)	1.94 (1.22)	0.0	1.00	1.75	2.67	4.5	
			Placebo	27	24 (88.9)	1.59 (0.87)	0.0	1.08	1.83	2.08	3.2	
		Week 40	Tezepelumab	32	32 (100.0)	1.94 (1.12)	0.0	1.25	2.00	2.67	4.3	
			Placebo	27	24 (88.9)	1.72 (1.12)	0.0	0.58	1.83	2.42	4.0	
		Week 42	Tezepelumab	32	32 (100.0)	1.96 (1.11)	0.0	1.08	1.92	2.67	4.3	
			Placebo	27	24 (88.9)	1.60 (0.90)	0.0	0.75	1.83	2.17	3.3	
		Week 44	Tezepelumab	32	32 (100.0)	1.99 (1.08)	0.0	1.42	2.08	2.67	4.3	
			Placebo	27	24 (88.9)	1.80 (1.02)	0.0	1.00	1.83	2.50	4.0	
		Week 46	Tezepelumab	32	32 (100.0)	2.00 (1.07)	0.0	1.25	2.00	2.67	4.3	
			Placebo	27	24 (88.9)	1.58 (0.94)	0.0	0.75	1.83	2.08	3.8	
		Week 48	Tezepelumab	32	32 (100.0)	1.96 (1.06)	0.0	1.17	2.08	2.67	4.3	
			Placebo	27	24 (88.9)	1.58 (1.06)	0.0	0.58	1.67	2.25	4.2	
		Week 50	Tezepelumab	32	32 (100.0)	1.96 (1.16)	0.0	1.17	1.92	2.67	4.3	
			Placebo	27	24 (88.9)	1.56 (0.88)	0.0	1.00	1.67	2.00	3.7	
		Week 52	Tezepelumab	32	32 (100.0)	1.95 (1.17)	0.0	1.17	1.92	2.58	4.3	
			Placebo	27	24 (88.9)	1.69 (0.96)	0.0	1.08	1.83	2.42	3.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 2	Tezepelumab	32	30 (93.8)	-0.50 (0.72)	-2.8	-0.83	-0.33	0.17	0.3	0.01 [-0.53, 0.55]
			Placebo	27	23 (85.2)	-0.51 (0.63)	-2.8	-0.83	-0.33	-0.17	0.3	
		Week 4	Tezepelumab	32	30 (93.8)	-0.79 (0.62)	-2.0	-1.17	-0.83	-0.33	0.2	-0.04 [-0.59, 0.50]
			Placebo	27	23 (85.2)	-0.76 (0.91)	-3.0	-1.50	-0.67	-0.17	0.5	
		Week 6	Tezepelumab	32	30 (93.8)	-0.99 (0.71)	-2.5	-1.33	-1.00	-0.50	0.2	-0.26 [-0.81, 0.28]
			Placebo	27	23 (85.2)	-0.76 (1.05)	-3.3	-1.33	-0.67	-0.17	1.5	
		Week 8	Tezepelumab	32	30 (93.8)	-0.96 (1.03)	-3.0	-1.67	-1.00	-0.33	2.2	-0.30 [-0.85, 0.24]
			Placebo	27	23 (85.2)	-0.65 (0.95)	-3.0	-1.17	-0.67	0.17	1.0	
		Week 10	Tezepelumab	32	30 (93.8)	-1.09 (0.88)	-3.2	-1.50	-1.17	-0.67	0.5	-0.27 [-0.82, 0.27]
			Placebo	27	23 (85.2)	-0.86 (0.81)	-3.2	-1.33	-0.67	-0.33	0.3	
		Week 12	Tezepelumab	32	30 (93.8)	-1.06 (0.88)	-2.8	-1.83	-1.17	-0.33	0.5	-0.15 [-0.69, 0.40]
			Placebo	27	23 (85.2)	-0.93 (0.86)	-3.2	-1.50	-0.67	-0.33	0.3	
		Week 14	Tezepelumab	32	30 (93.8)	-1.19 (0.85)	-3.2	-1.83	-1.17	-0.67	0.5	-0.10 [-0.64, 0.44]
			Placebo	27	23 (85.2)	-1.10 (0.93)	-3.2	-1.83	-1.33	-0.33	0.3	
		Week 16	Tezepelumab	32	30 (93.8)	-0.95 (0.95)	-3.0	-1.67	-1.00	-0.33	1.5	-0.02 [-0.56, 0.53]
			Placebo	27	23 (85.2)	-0.93 (0.88)	-2.8	-1.33	-1.17	-0.17	0.3	
		Week 18	Tezepelumab	32	31 (96.9)	-1.02 (0.85)	-3.2	-1.67	-1.00	-0.33	0.5	-0.06 [-0.60, 0.48]
			Placebo	27	23 (85.2)	-0.96 (1.11)	-3.2	-1.83	-1.17	-0.17	1.5	
		Week 20	Tezepelumab	32	31 (96.9)	-0.96 (0.92)	-3.2	-1.67	-0.83	-0.33	0.7	0.02 [-0.52, 0.56]
			Placebo	27	23 (85.2)	-0.98 (1.09)	-3.0	-1.83	-0.83	-0.17	1.0	
		Week 22	Tezepelumab	32	31 (96.9)	-0.99 (0.84)	-3.0	-1.83	-0.83	-0.50	0.5	0.03 [-0.50, 0.57]
			Placebo	27	23 (85.2)	-1.02 (1.07)	-3.2	-1.83	-1.00	-0.33	1.2	
		Week 24	Tezepelumab	32	31 (96.9)	-0.93 (0.88)	-3.2	-1.67	-0.67	-0.33	0.7	0.01 [-0.53, 0.55]
			Placebo	27	23 (85.2)	-0.94 (1.07)	-3.2	-1.67	-1.00	0.00	1.0	
		Week 26	Tezepelumab	32	32 (100.0)	-0.89 (0.91)	-2.8	-1.75	-0.67	-0.08	0.7	0.09 [-0.45, 0.62]
			Placebo	27	23 (85.2)	-0.97 (1.08)	-2.5	-1.83	-1.17	-0.17	1.5	
		Week 28	Tezepelumab	32	32 (100.0)	-0.95 (1.01)	-3.2	-1.83	-0.83	-0.33	0.8	0.03 [-0.50, 0.56]
			Placebo	27	24 (88.9)	-0.98 (1.01)	-2.8	-1.75	-1.00	-0.33	1.5	
		Week 30	Tezepelumab	32	32 (100.0)	-0.91 (0.98)	-2.7	-1.75	-0.83	-0.25	1.8	0.11 [-0.42, 0.64]
			Placebo	27	24 (88.9)	-1.01 (0.95)	-3.2	-1.75	-1.08	-0.33	0.5	
		Week 32	Tezepelumab	32	32 (100.0)	-0.96 (0.90)	-3.0	-1.67	-0.92	-0.50	0.8	0.16 [-0.37, 0.69]
			Placebo	27	24 (88.9)	-1.11 (0.98)	-3.0	-1.83	-1.08	-0.33	0.7	
		Week 34	Tezepelumab	32	32 (100.0)	-0.90 (1.03)	-2.8	-1.83	-0.75	-0.25	2.0	0.13 [-0.40, 0.66]
			Placebo	27	24 (88.9)	-1.03 (0.92)	-3.2	-1.50	-0.83	-0.58	0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
< 22.0 ppb	Change from baseline	Week 36	Tezepelumab	32	32 (100.0)	-0.93 (0.95)	-3.0	-1.75	-0.92	-0.25	1.5	0.11 [-0.42, 0.64]
			Placebo	27	24 (88.9)	-1.03 (1.11)	-3.5	-1.67	-0.75	-0.33	0.7	
		Week 38	Tezepelumab	32	32 (100.0)	-0.86 (1.09)	-3.0	-1.83	-0.83	-0.08	2.3	0.21 [-0.32, 0.74]
			Placebo	27	24 (88.9)	-1.08 (0.89)	-3.2	-1.50	-1.00	-0.50	0.2	
		Week 40	Tezepelumab	32	32 (100.0)	-0.87 (1.00)	-3.2	-1.50	-0.83	-0.25	1.7	0.07 [-0.46, 0.60]
			Placebo	27	24 (88.9)	-0.94 (1.14)	-3.2	-1.83	-1.08	-0.08	1.2	
		Week 42	Tezepelumab	32	32 (100.0)	-0.84 (0.99)	-2.7	-1.25	-0.83	-0.33	2.0	0.23 [-0.30, 0.76]
			Placebo	27	24 (88.9)	-1.06 (0.93)	-2.8	-1.42	-1.17	-0.58	0.8	
		Week 44	Tezepelumab	32	32 (100.0)	-0.82 (0.98)	-3.2	-1.42	-0.75	-0.17	1.5	0.05 [-0.48, 0.58]
			Placebo	27	24 (88.9)	-0.87 (1.04)	-3.3	-1.50	-0.75	-0.08	0.8	
		Week 46	Tezepelumab	32	32 (100.0)	-0.81 (0.95)	-2.5	-1.58	-0.67	-0.17	1.7	0.28 [-0.25, 0.81]
			Placebo	27	24 (88.9)	-1.08 (1.01)	-3.2	-1.67	-1.00	-0.67	1.3	
		Week 48	Tezepelumab	32	32 (100.0)	-0.85 (0.93)	-2.5	-1.50	-0.67	-0.33	1.8	0.23 [-0.30, 0.76]
			Placebo	27	24 (88.9)	-1.09 (1.15)	-3.3	-1.67	-0.83	-0.50	1.7	
		Week 50	Tezepelumab	32	32 (100.0)	-0.85 (1.02)	-2.7	-1.50	-0.83	-0.17	1.8	0.26 [-0.28, 0.79]
			Placebo	27	24 (88.9)	-1.11 (1.03)	-3.5	-1.58	-1.08	-0.67	1.5	
		Week 52	Tezepelumab	32	32 (100.0)	-0.86 (1.02)	-2.7	-1.50	-0.83	-0.17	1.8	0.11 [-0.42, 0.64]
			Placebo	27	24 (88.9)	-0.97 (1.12)	-3.5	-1.58	-0.83	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	34	34 (100.0)	2.63 (0.94)	0.0	2.17	2.58	3.17	4.8	
			Placebo	37	37 (100.0)	2.78 (0.75)	1.3	2.33	2.83	3.17	4.7	
		Week 2	Tezepelumab	34	33 (97.1)	2.09 (0.91)	0.2	1.33	2.17	2.67	4.2	
			Placebo	37	34 (91.9)	2.31 (0.87)	0.5	1.83	2.25	2.83	4.8	
		Week 4	Tezepelumab	34	33 (97.1)	1.88 (0.97)	0.2	1.17	2.17	2.67	3.3	
			Placebo	37	34 (91.9)	2.25 (0.95)	0.3	1.67	2.42	2.67	4.2	
		Week 6	Tezepelumab	34	33 (97.1)	1.88 (1.05)	0.0	1.00	1.83	2.67	3.7	
			Placebo	37	34 (91.9)	2.18 (1.17)	0.2	1.33	2.33	2.83	5.5	
		Week 8	Tezepelumab	34	33 (97.1)	1.58 (1.01)	0.0	0.83	1.67	2.50	3.3	
			Placebo	37	35 (94.6)	2.06 (1.20)	0.0	1.00	2.17	2.67	4.7	
		Week 10	Tezepelumab	34	33 (97.1)	1.54 (1.07)	0.0	0.67	1.50	2.33	3.7	
			Placebo	37	35 (94.6)	2.11 (1.16)	0.0	1.00	2.33	2.83	5.3	
		Week 12	Tezepelumab	34	33 (97.1)	1.32 (0.98)	0.0	0.50	1.33	2.17	3.0	
			Placebo	37	35 (94.6)	1.90 (1.12)	0.0	1.00	2.00	2.67	4.3	
		Week 14	Tezepelumab	34	33 (97.1)	1.30 (1.01)	0.0	0.50	1.17	1.83	3.7	
			Placebo	37	35 (94.6)	1.90 (1.09)	0.0	1.33	1.83	2.33	5.0	
		Week 16	Tezepelumab	34	33 (97.1)	1.36 (1.04)	0.0	0.50	1.33	2.00	3.3	
			Placebo	37	35 (94.6)	2.08 (1.35)	0.0	0.67	2.17	2.67	5.0	
		Week 18	Tezepelumab	34	33 (97.1)	1.38 (0.96)	0.0	0.67	1.17	2.17	3.3	
			Placebo	37	35 (94.6)	1.95 (1.19)	0.0	1.00	2.17	2.50	5.0	
		Week 20	Tezepelumab	34	33 (97.1)	1.36 (1.00)	0.0	0.50	1.17	1.83	3.5	
			Placebo	37	35 (94.6)	2.12 (1.14)	0.0	1.17	2.33	2.83	5.0	
		Week 22	Tezepelumab	34	33 (97.1)	1.52 (0.92)	0.0	0.83	1.50	2.17	3.3	
			Placebo	37	35 (94.6)	2.08 (1.23)	0.0	1.17	2.17	2.83	5.0	
		Week 24	Tezepelumab	34	33 (97.1)	1.43 (1.00)	0.0	0.50	1.17	2.33	3.5	
			Placebo	37	35 (94.6)	2.13 (1.09)	0.0	1.67	2.17	2.83	4.5	
		Week 26	Tezepelumab	34	33 (97.1)	1.50 (1.04)	0.0	0.67	1.50	2.17	3.7	
			Placebo	37	35 (94.6)	2.04 (1.18)	0.0	1.00	2.00	3.00	4.5	
		Week 28	Tezepelumab	34	34 (100.0)	1.47 (1.10)	0.0	0.33	1.50	2.33	3.5	
			Placebo	37	35 (94.6)	2.09 (1.30)	0.0	1.00	2.17	3.33	4.5	
		Week 30	Tezepelumab	34	34 (100.0)	1.38 (1.02)	0.0	0.67	1.42	2.00	3.7	
			Placebo	37	35 (94.6)	2.09 (1.26)	0.0	1.17	2.17	3.00	4.5	
		Week 32	Tezepelumab	34	34 (100.0)	1.32 (1.04)	0.0	0.33	1.17	2.33	3.7	
			Placebo	37	35 (94.6)	2.10 (1.19)	0.0	1.17	2.00	3.00	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 22.0 ppb	Absolute values	Week 34	Tezepelumab	34	34 (100.0)	1.39 (1.08)	0.0	0.50	1.33	2.17	4.2	
			Placebo	37	35 (94.6)	1.98 (1.23)	0.0	1.00	2.00	3.00	4.5	
		Week 36	Tezepelumab	34	34 (100.0)	1.35 (0.98)	0.0	0.50	1.17	2.17	3.7	
			Placebo	37	35 (94.6)	2.26 (1.15)	0.0	1.50	2.17	3.00	4.5	
		Week 38	Tezepelumab	34	34 (100.0)	1.34 (1.01)	0.0	0.33	1.50	2.00	3.5	
			Placebo	37	35 (94.6)	2.04 (1.21)	0.0	1.00	2.17	3.00	4.5	
		Week 40	Tezepelumab	34	34 (100.0)	1.30 (1.03)	0.0	0.33	1.17	2.17	3.2	
			Placebo	37	35 (94.6)	2.18 (1.13)	0.0	1.33	2.17	2.83	4.5	
		Week 42	Tezepelumab	34	34 (100.0)	1.23 (0.95)	0.0	0.50	1.00	1.83	3.3	
			Placebo	37	35 (94.6)	2.01 (1.09)	0.0	1.17	2.00	2.50	4.5	
		Week 44	Tezepelumab	34	34 (100.0)	1.26 (0.97)	0.0	0.33	1.08	2.17	3.0	
			Placebo	37	35 (94.6)	2.02 (1.11)	0.0	1.17	2.00	2.83	4.5	
		Week 46	Tezepelumab	34	34 (100.0)	1.27 (1.05)	0.0	0.33	1.00	2.17	3.7	
			Placebo	37	35 (94.6)	1.99 (0.99)	0.0	1.33	2.00	2.50	4.5	
		Week 48	Tezepelumab	34	34 (100.0)	1.32 (1.08)	0.0	0.50	1.00	2.00	4.0	
			Placebo	37	35 (94.6)	2.07 (1.01)	0.0	1.33	2.17	2.67	4.5	
		Week 50	Tezepelumab	34	34 (100.0)	1.21 (0.99)	0.0	0.50	1.00	1.83	4.0	
			Placebo	37	35 (94.6)	1.90 (1.05)	0.0	1.00	2.00	2.50	4.5	
		Week 52	Tezepelumab	34	34 (100.0)	1.28 (0.97)	0.0	0.50	1.08	2.00	4.0	
			Placebo	37	35 (94.6)	1.94 (1.10)	0.0	1.00	2.17	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 2	Tezepelumab	34	33 (97.1)	-0.55 (0.71)	-2.0	-1.00	-0.50	0.00	0.7	-0.17 [-0.65, 0.31]
			Placebo	37	34 (91.9)	-0.42 (0.73)	-2.2	-1.00	-0.33	0.00	1.0	
		Week 4	Tezepelumab	34	33 (97.1)	-0.76 (0.99)	-2.5	-1.33	-0.83	-0.17	2.3	-0.28 [-0.77, 0.20]
			Placebo	37	34 (91.9)	-0.49 (0.89)	-2.7	-1.17	-0.25	0.00	1.2	
		Week 6	Tezepelumab	34	33 (97.1)	-0.76 (1.11)	-2.7	-1.50	-0.67	0.00	2.3	-0.20 [-0.68, 0.28]
			Placebo	37	34 (91.9)	-0.55 (0.96)	-2.8	-1.17	-0.33	0.00	1.5	
		Week 8	Tezepelumab	34	33 (97.1)	-1.06 (1.06)	-2.8	-1.67	-1.00	-0.50	2.3	-0.35 [-0.83, 0.13]
			Placebo	37	35 (94.6)	-0.69 (1.05)	-3.2	-1.17	-0.50	0.00	1.0	
		Week 10	Tezepelumab	34	33 (97.1)	-1.10 (1.14)	-2.8	-1.83	-1.17	-0.50	2.3	-0.39 [-0.87, 0.09]
			Placebo	37	35 (94.6)	-0.64 (1.21)	-3.3	-1.33	-0.50	0.00	2.7	
		Week 12	Tezepelumab	34	33 (97.1)	-1.31 (1.10)	-3.0	-2.17	-1.17	-0.67	2.3	-0.42 [-0.91, 0.06]
			Placebo	37	35 (94.6)	-0.85 (1.09)	-3.3	-1.17	-0.83	-0.17	1.3	
		Week 14	Tezepelumab	34	33 (97.1)	-1.33 (1.14)	-3.7	-2.00	-1.33	-0.67	2.3	-0.43 [-0.91, 0.05]
			Placebo	37	35 (94.6)	-0.85 (1.10)	-3.2	-1.33	-0.83	-0.50	2.3	
		Week 16	Tezepelumab	34	33 (97.1)	-1.27 (1.10)	-2.8	-2.17	-1.17	-0.67	2.3	-0.51 [-0.99, -0.03]
			Placebo	37	35 (94.6)	-0.67 (1.25)	-3.2	-1.33	-0.67	0.00	2.3	
		Week 18	Tezepelumab	34	33 (97.1)	-1.25 (1.11)	-3.5	-1.83	-1.17	-0.67	2.3	-0.39 [-0.87, 0.09]
			Placebo	37	35 (94.6)	-0.80 (1.21)	-3.2	-1.50	-0.67	0.00	2.3	
		Week 20	Tezepelumab	34	33 (97.1)	-1.27 (1.06)	-2.7	-2.00	-1.33	-0.67	2.3	-0.59 [-1.08, -0.11]
			Placebo	37	35 (94.6)	-0.62 (1.13)	-3.2	-1.17	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	34	33 (97.1)	-1.12 (1.17)	-2.7	-2.17	-1.17	-0.67	2.3	-0.39 [-0.87, 0.09]
			Placebo	37	35 (94.6)	-0.67 (1.15)	-3.3	-1.17	-0.67	0.00	2.3	
		Week 24	Tezepelumab	34	33 (97.1)	-1.20 (1.06)	-2.7	-1.83	-1.33	-0.67	2.3	-0.54 [-1.03, -0.06]
			Placebo	37	35 (94.6)	-0.61 (1.11)	-3.2	-1.33	-0.50	0.17	2.3	
		Week 26	Tezepelumab	34	33 (97.1)	-1.14 (1.13)	-2.8	-2.17	-1.17	-0.33	2.3	-0.37 [-0.85, 0.11]
			Placebo	37	35 (94.6)	-0.71 (1.17)	-3.2	-1.50	-0.67	0.17	2.3	
		Week 28	Tezepelumab	34	34 (100.0)	-1.16 (1.16)	-2.8	-2.17	-1.33	-0.17	2.3	-0.42 [-0.90, 0.06]
			Placebo	37	35 (94.6)	-0.66 (1.25)	-3.2	-1.67	-0.83	0.33	2.3	
		Week 30	Tezepelumab	34	34 (100.0)	-1.25 (1.14)	-3.5	-2.17	-1.33	-0.50	2.3	-0.49 [-0.97, -0.01]
			Placebo	37	35 (94.6)	-0.66 (1.26)	-2.8	-1.33	-0.83	0.17	2.3	
		Week 32	Tezepelumab	34	34 (100.0)	-1.31 (1.07)	-2.7	-2.17	-1.58	-0.67	2.3	-0.60 [-1.08, -0.12]
			Placebo	37	35 (94.6)	-0.65 (1.14)	-2.8	-1.33	-0.67	0.17	2.3	
		Week 34	Tezepelumab	34	34 (100.0)	-1.24 (1.13)	-2.5	-2.17	-1.42	-0.67	2.3	-0.41 [-0.89, 0.07]
			Placebo	37	35 (94.6)	-0.77 (1.19)	-2.8	-1.50	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 22.0 ppb	Change from baseline	Week 36	Tezepelumab	34	34 (100.0)	-1.27 (1.15)	-2.8	-2.17	-1.50	-0.50	2.3	-0.69 [-1.18, -0.20]
			Placebo	37	35 (94.6)	-0.49 (1.12)	-2.5	-1.17	-0.83	0.17	2.3	
		Week 38	Tezepelumab	34	34 (100.0)	-1.29 (1.10)	-2.8	-2.00	-1.42	-0.67	2.3	-0.51 [-0.99, -0.03]
			Placebo	37	35 (94.6)	-0.71 (1.19)	-2.5	-1.33	-0.83	0.17	2.3	
		Week 40	Tezepelumab	34	34 (100.0)	-1.33 (1.14)	-2.8	-2.33	-1.50	-0.67	2.3	-0.67 [-1.15, -0.18]
			Placebo	37	35 (94.6)	-0.57 (1.15)	-2.5	-1.33	-0.67	0.33	2.3	
		Week 42	Tezepelumab	34	34 (100.0)	-1.40 (1.12)	-3.3	-2.17	-1.58	-0.50	2.3	-0.60 [-1.09, -0.12]
			Placebo	37	35 (94.6)	-0.74 (1.08)	-2.5	-1.33	-1.00	-0.17	2.3	
		Week 44	Tezepelumab	34	34 (100.0)	-1.37 (1.13)	-3.5	-2.17	-1.50	-0.67	2.3	-0.56 [-1.05, -0.08]
			Placebo	37	35 (94.6)	-0.73 (1.13)	-2.7	-1.50	-0.83	0.00	2.3	
		Week 46	Tezepelumab	34	34 (100.0)	-1.35 (1.15)	-3.3	-2.17	-1.42	-0.83	2.3	-0.56 [-1.04, -0.08]
			Placebo	37	35 (94.6)	-0.76 (0.98)	-2.5	-1.33	-0.83	-0.17	2.3	
		Week 48	Tezepelumab	34	34 (100.0)	-1.30 (1.16)	-2.7	-2.17	-1.50	-0.50	2.3	-0.58 [-1.07, -0.10]
			Placebo	37	35 (94.6)	-0.68 (0.99)	-2.5	-1.17	-0.83	0.17	2.3	
		Week 50	Tezepelumab	34	34 (100.0)	-1.42 (1.10)	-2.7	-2.33	-1.67	-1.00	2.3	-0.55 [-1.03, -0.07]
			Placebo	37	35 (94.6)	-0.84 (0.99)	-3.0	-1.33	-0.83	-0.33	2.3	
		Week 52	Tezepelumab	34	34 (100.0)	-1.35 (1.10)	-2.7	-2.17	-1.58	-0.83	2.3	-0.51 [-0.99, -0.03]
			Placebo	37	35 (94.6)	-0.81 (1.03)	-3.0	-1.33	-0.83	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	25	25 (100.0)	2.83 (0.66)	1.7	2.50	2.83	2.83	4.5	
			Placebo	22	22 (100.0)	2.64 (0.71)	1.3	2.33	2.75	3.00	4.3	
		Week 2	Tezepelumab	25	24 (96.0)	2.32 (0.87)	0.3	1.58	2.67	3.00	3.7	
			Placebo	22	19 (86.4)	2.18 (0.90)	0.3	1.67	2.17	2.50	4.8	
		Week 4	Tezepelumab	25	24 (96.0)	2.04 (0.83)	0.3	1.67	2.25	2.67	3.5	
			Placebo	22	19 (86.4)	2.19 (1.05)	0.2	1.50	2.33	2.83	4.2	
		Week 6	Tezepelumab	25	24 (96.0)	1.76 (1.00)	0.0	1.17	1.67	2.50	3.7	
			Placebo	22	19 (86.4)	2.16 (1.25)	0.2	1.17	1.83	3.00	4.7	
		Week 8	Tezepelumab	25	24 (96.0)	1.76 (1.15)	0.0	1.42	1.58	2.50	4.8	
			Placebo	22	20 (90.9)	2.05 (1.19)	0.0	0.83	2.17	2.67	4.7	
		Week 10	Tezepelumab	25	24 (96.0)	1.66 (1.10)	0.0	0.92	1.75	2.25	4.3	
			Placebo	22	20 (90.9)	2.10 (1.11)	0.2	1.17	2.08	2.58	4.2	
		Week 12	Tezepelumab	25	24 (96.0)	1.62 (1.07)	0.0	0.83	1.67	2.42	4.3	
			Placebo	22	20 (90.9)	2.04 (1.15)	0.2	1.00	2.00	2.67	4.3	
		Week 14	Tezepelumab	25	24 (96.0)	1.49 (1.06)	0.0	0.67	1.50	2.17	4.3	
			Placebo	22	20 (90.9)	1.72 (1.12)	0.3	1.00	1.58	2.33	5.0	
		Week 16	Tezepelumab	25	24 (96.0)	1.56 (1.06)	0.0	0.92	1.58	2.25	4.3	
			Placebo	22	20 (90.9)	2.01 (1.26)	0.3	0.67	1.92	2.83	4.5	
		Week 18	Tezepelumab	25	24 (96.0)	1.47 (1.06)	0.0	0.67	1.50	2.08	4.3	
			Placebo	22	20 (90.9)	1.69 (1.19)	0.0	0.67	1.58	2.42	4.5	
		Week 20	Tezepelumab	25	24 (96.0)	1.58 (1.08)	0.0	0.67	1.67	2.33	4.3	
			Placebo	22	20 (90.9)	1.90 (1.27)	0.2	0.75	1.92	2.67	4.5	
		Week 22	Tezepelumab	25	24 (96.0)	1.70 (1.02)	0.0	1.00	1.83	2.33	4.3	
			Placebo	22	20 (90.9)	1.85 (1.33)	0.0	0.58	2.00	2.67	4.5	
		Week 24	Tezepelumab	25	24 (96.0)	1.69 (1.04)	0.0	1.08	1.75	2.33	4.3	
			Placebo	22	20 (90.9)	1.97 (1.24)	0.2	0.83	2.00	2.75	4.5	
		Week 26	Tezepelumab	25	25 (100.0)	1.67 (1.05)	0.0	1.17	1.83	2.17	4.3	
			Placebo	22	20 (90.9)	1.91 (1.31)	0.3	1.00	1.25	3.00	4.5	
		Week 28	Tezepelumab	25	25 (100.0)	1.69 (1.07)	0.0	1.17	1.83	2.33	4.3	
			Placebo	22	20 (90.9)	2.19 (1.24)	0.3	1.00	2.08	3.25	4.5	
		Week 30	Tezepelumab	25	25 (100.0)	1.71 (1.09)	0.0	0.83	2.00	2.17	4.3	
			Placebo	22	20 (90.9)	2.09 (1.25)	0.0	0.92	2.00	2.92	4.5	
		Week 32	Tezepelumab	25	25 (100.0)	1.71 (1.06)	0.0	1.00	1.83	2.50	4.3	
			Placebo	22	20 (90.9)	1.96 (1.21)	0.3	1.08	1.67	2.75	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Absolute values	Week 34	Tezepelumab	25	25 (100.0)	1.76 (1.14)	0.0	1.00	1.50	2.67	4.3	
			Placebo	22	20 (90.9)	1.77 (1.20)	0.0	0.92	1.58	2.50	4.5	
		Week 36	Tezepelumab	25	25 (100.0)	1.67 (1.12)	0.0	1.00	1.50	2.67	4.3	
			Placebo	22	20 (90.9)	2.04 (1.24)	0.0	1.33	1.83	2.83	4.5	
		Week 38	Tezepelumab	25	25 (100.0)	1.83 (1.20)	0.0	1.00	2.00	2.67	4.3	
			Placebo	22	20 (90.9)	1.92 (1.19)	0.0	0.92	2.00	2.67	4.5	
		Week 40	Tezepelumab	25	25 (100.0)	1.75 (1.14)	0.0	1.00	1.83	2.50	4.3	
			Placebo	22	20 (90.9)	2.36 (1.24)	0.3	1.58	2.50	3.25	4.5	
		Week 42	Tezepelumab	25	25 (100.0)	1.77 (1.16)	0.0	1.00	1.67	2.50	4.3	
			Placebo	22	20 (90.9)	2.07 (1.26)	0.3	1.08	2.00	2.58	4.5	
		Week 44	Tezepelumab	25	25 (100.0)	1.73 (1.14)	0.0	0.83	1.67	2.67	4.3	
			Placebo	22	20 (90.9)	2.23 (1.15)	0.3	1.33	2.33	2.92	4.5	
		Week 46	Tezepelumab	25	25 (100.0)	1.83 (1.15)	0.0	1.00	1.83	2.67	4.3	
			Placebo	22	20 (90.9)	2.06 (1.17)	0.0	1.42	2.00	2.50	4.5	
		Week 48	Tezepelumab	25	25 (100.0)	1.81 (1.12)	0.0	1.00	2.00	2.67	4.3	
			Placebo	22	20 (90.9)	2.22 (1.24)	0.0	1.67	2.08	2.67	4.5	
		Week 50	Tezepelumab	25	25 (100.0)	1.81 (1.09)	0.0	1.17	1.67	2.50	4.3	
			Placebo	22	20 (90.9)	1.87 (1.12)	0.3	1.00	1.83	2.42	4.5	
		Week 52	Tezepelumab	25	25 (100.0)	1.80 (1.10)	0.0	1.17	1.67	2.50	4.3	
			Placebo	22	20 (90.9)	2.01 (1.17)	0.3	1.00	2.17	2.58	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 2	Tezepelumab	25	24 (96.0)	-0.56 (0.61)	-1.8	-1.00	-0.42	-0.08	0.2	-0.14 [-0.74, 0.46]
			Placebo	22	19 (86.4)	-0.46 (0.91)	-2.8	-0.83	-0.33	0.17	1.0	
		Week 4	Tezepelumab	25	24 (96.0)	-0.84 (0.74)	-2.3	-1.25	-0.75	-0.33	0.2	-0.46 [-1.07, 0.15]
			Placebo	22	19 (86.4)	-0.44 (1.02)	-2.3	-1.00	-0.17	0.33	1.2	
		Week 6	Tezepelumab	25	24 (96.0)	-1.12 (0.93)	-2.5	-1.83	-1.17	-0.67	1.2	-0.62 [-1.24, -0.00]
			Placebo	22	19 (86.4)	-0.47 (1.17)	-2.3	-1.50	-0.50	0.33	1.5	
		Week 8	Tezepelumab	25	24 (96.0)	-1.12 (1.16)	-3.0	-1.75	-1.17	-0.42	2.2	-0.47 [-1.07, 0.13]
			Placebo	22	20 (90.9)	-0.61 (1.03)	-2.5	-1.25	-0.50	0.08	1.0	
		Week 10	Tezepelumab	25	24 (96.0)	-1.22 (1.01)	-3.2	-1.83	-1.25	-0.67	0.5	-0.59 [-1.20, 0.01]
			Placebo	22	20 (90.9)	-0.56 (1.24)	-2.3	-1.33	-0.50	-0.17	2.5	
		Week 12	Tezepelumab	25	24 (96.0)	-1.26 (1.03)	-3.0	-2.08	-1.17	-0.50	0.5	-0.63 [-1.24, -0.02]
			Placebo	22	20 (90.9)	-0.62 (1.02)	-2.7	-1.17	-0.58	0.08	1.3	
		Week 14	Tezepelumab	25	24 (96.0)	-1.40 (1.07)	-3.7	-2.08	-1.42	-0.67	0.5	-0.43 [-1.03, 0.17]
			Placebo	22	20 (90.9)	-0.94 (1.06)	-2.5	-1.75	-1.08	-0.50	1.2	
		Week 16	Tezepelumab	25	24 (96.0)	-1.32 (1.02)	-3.0	-2.17	-1.08	-0.67	0.5	-0.62 [-1.23, -0.02]
			Placebo	22	20 (90.9)	-0.65 (1.13)	-2.5	-1.42	-0.75	0.08	2.3	
		Week 18	Tezepelumab	25	24 (96.0)	-1.42 (1.04)	-3.5	-2.08	-1.25	-0.83	0.5	-0.40 [-1.00, 0.20]
			Placebo	22	20 (90.9)	-0.97 (1.21)	-3.2	-1.83	-1.00	-0.25	2.3	
		Week 20	Tezepelumab	25	24 (96.0)	-1.30 (1.01)	-3.2	-2.17	-1.25	-0.50	0.5	-0.49 [-1.09, 0.12]
			Placebo	22	20 (90.9)	-0.76 (1.22)	-3.0	-1.58	-0.75	-0.17	2.3	
		Week 22	Tezepelumab	25	24 (96.0)	-1.18 (0.97)	-3.0	-2.08	-0.92	-0.58	0.5	-0.33 [-0.93, 0.27]
			Placebo	22	20 (90.9)	-0.81 (1.28)	-3.2	-1.67	-0.92	-0.17	2.3	
		Week 24	Tezepelumab	25	24 (96.0)	-1.19 (0.91)	-3.2	-1.83	-1.17	-0.58	0.5	-0.46 [-1.06, 0.14]
			Placebo	22	20 (90.9)	-0.69 (1.24)	-3.0	-1.58	-0.67	0.00	2.3	
		Week 26	Tezepelumab	25	25 (100.0)	-1.17 (0.99)	-2.8	-2.00	-1.00	-0.33	0.5	-0.36 [-0.95, 0.23]
			Placebo	22	20 (90.9)	-0.75 (1.33)	-2.5	-1.67	-1.08	0.17	2.3	
		Week 28	Tezepelumab	25	25 (100.0)	-1.15 (1.09)	-3.2	-2.00	-1.00	-0.67	0.8	-0.58 [-1.19, 0.02]
			Placebo	22	20 (90.9)	-0.47 (1.24)	-2.5	-1.25	-0.58	0.25	2.3	
		Week 30	Tezepelumab	25	25 (100.0)	-1.12 (1.20)	-3.5	-2.00	-1.00	-0.67	1.8	-0.46 [-1.05, 0.14]
			Placebo	22	20 (90.9)	-0.57 (1.23)	-2.5	-1.33	-0.50	0.00	2.3	
		Week 32	Tezepelumab	25	25 (100.0)	-1.12 (1.04)	-3.0	-2.00	-1.00	-0.67	0.8	-0.38 [-0.97, 0.22]
			Placebo	22	20 (90.9)	-0.70 (1.21)	-2.5	-1.67	-0.83	0.17	2.3	
		Week 34	Tezepelumab	25	25 (100.0)	-1.07 (1.19)	-2.8	-2.00	-1.33	-0.33	2.0	-0.16 [-0.75, 0.43]
			Placebo	22	20 (90.9)	-0.88 (1.22)	-3.2	-1.67	-1.08	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
All negative	Change from baseline	Week 36	Tezepelumab	25	25 (100.0)	-1.17 (1.18)	-3.0	-2.00	-1.17	-0.33	1.5	-0.45 [-1.05, 0.15]
			Placebo	22	20 (90.9)	-0.62 (1.28)	-3.2	-1.42	-0.75	0.17	2.3	
		Week 38	Tezepelumab	25	25 (100.0)	-1.01 (1.23)	-3.0	-2.00	-0.83	-0.17	2.3	-0.21 [-0.80, 0.38]
			Placebo	22	20 (90.9)	-0.74 (1.27)	-3.2	-1.58	-0.83	0.17	2.3	
		Week 40	Tezepelumab	25	25 (100.0)	-1.09 (1.17)	-3.2	-2.00	-0.83	-0.50	1.7	-0.63 [-1.24, -0.03]
			Placebo	22	20 (90.9)	-0.30 (1.32)	-2.8	-1.08	-0.25	0.58	2.3	
		Week 42	Tezepelumab	25	25 (100.0)	-1.06 (1.22)	-3.3	-2.00	-0.83	-0.50	2.0	-0.37 [-0.96, 0.22]
			Placebo	22	20 (90.9)	-0.58 (1.38)	-2.8	-1.50	-0.75	0.25	2.3	
		Week 44	Tezepelumab	25	25 (100.0)	-1.11 (1.23)	-3.5	-2.00	-1.00	-0.17	1.5	-0.55 [-1.15, 0.05]
			Placebo	22	20 (90.9)	-0.43 (1.24)	-2.5	-1.33	-0.50	0.25	2.3	
		Week 46	Tezepelumab	25	25 (100.0)	-1.01 (1.19)	-3.3	-2.00	-0.83	-0.17	1.7	-0.32 [-0.92, 0.27]
			Placebo	22	20 (90.9)	-0.60 (1.33)	-3.2	-1.25	-0.67	0.17	2.3	
		Week 48	Tezepelumab	25	25 (100.0)	-1.02 (1.17)	-2.7	-2.00	-0.83	-0.17	1.8	-0.46 [-1.06, 0.13]
			Placebo	22	20 (90.9)	-0.44 (1.34)	-3.2	-1.25	-0.42	0.33	2.3	
		Week 50	Tezepelumab	25	25 (100.0)	-1.02 (1.07)	-2.7	-1.83	-1.00	-0.50	1.8	-0.20 [-0.79, 0.39]
			Placebo	22	20 (90.9)	-0.79 (1.20)	-2.8	-1.75	-0.67	0.00	2.3	
		Week 52	Tezepelumab	25	25 (100.0)	-1.03 (1.09)	-2.7	-1.83	-1.00	-0.50	1.8	-0.33 [-0.93, 0.26]
			Placebo	22	20 (90.9)	-0.65 (1.22)	-2.8	-1.75	-0.42	0.00	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	35	35 (100.0)	2.66 (0.97)	0.0	2.17	2.50	3.33	4.8	
			Placebo	41	41 (100.0)	2.75 (0.74)	0.3	2.33	2.67	3.17	4.7	
		Week 2	Tezepelumab	35	34 (97.1)	2.21 (1.05)	0.0	1.33	2.25	3.00	4.2	
			Placebo	41	37 (90.2)	2.36 (0.73)	0.5	2.00	2.33	2.83	4.7	
		Week 4	Tezepelumab	35	34 (97.1)	1.99 (1.05)	0.2	1.17	2.17	2.83	3.5	
			Placebo	41	37 (90.2)	2.17 (0.84)	0.3	1.67	2.33	2.67	3.5	
		Week 6	Tezepelumab	35	34 (97.1)	2.00 (1.04)	0.0	1.17	2.17	2.67	4.0	
			Placebo	41	37 (90.2)	2.09 (1.04)	0.2	1.33	2.33	2.67	5.5	
		Week 8	Tezepelumab	35	34 (97.1)	1.80 (1.14)	0.0	0.83	1.75	2.67	4.2	
			Placebo	41	37 (90.2)	2.09 (1.06)	0.0	1.67	2.17	2.83	4.7	
		Week 10	Tezepelumab	35	34 (97.1)	1.73 (1.12)	0.0	0.67	1.67	2.67	3.7	
			Placebo	41	37 (90.2)	2.05 (1.02)	0.0	1.67	2.17	2.67	5.3	
		Week 12	Tezepelumab	35	34 (97.1)	1.57 (1.10)	0.0	0.50	1.67	2.67	3.3	
			Placebo	41	37 (90.2)	1.76 (0.89)	0.0	1.33	2.00	2.33	4.0	
		Week 14	Tezepelumab	35	34 (97.1)	1.55 (1.10)	0.0	0.50	1.50	2.33	4.2	
			Placebo	41	37 (90.2)	1.85 (0.91)	0.0	1.50	2.00	2.17	5.0	
		Week 16	Tezepelumab	35	34 (97.1)	1.65 (1.13)	0.0	0.67	1.58	2.50	4.2	
			Placebo	41	37 (90.2)	1.94 (1.11)	0.0	1.17	2.00	2.50	5.0	
		Week 18	Tezepelumab	35	34 (97.1)	1.72 (1.05)	0.0	0.83	1.83	2.50	4.2	
			Placebo	41	37 (90.2)	1.99 (1.12)	0.0	1.33	2.17	2.50	5.0	
		Week 20	Tezepelumab	35	34 (97.1)	1.68 (1.17)	0.0	0.83	1.67	2.50	5.0	
			Placebo	41	37 (90.2)	2.04 (0.96)	0.0	1.67	2.17	2.67	5.0	
		Week 22	Tezepelumab	35	34 (97.1)	1.71 (1.01)	0.0	0.83	1.83	2.33	3.8	
			Placebo	41	37 (90.2)	2.00 (1.02)	0.0	1.33	2.00	2.67	5.0	
		Week 24	Tezepelumab	35	34 (97.1)	1.67 (1.11)	0.0	0.67	1.75	2.50	3.8	
			Placebo	41	37 (90.2)	2.03 (0.92)	0.0	1.67	2.00	2.67	4.2	
		Week 26	Tezepelumab	35	34 (97.1)	1.75 (1.14)	0.0	0.83	1.75	2.67	4.0	
			Placebo	41	37 (90.2)	1.95 (0.99)	0.0	1.33	1.83	2.67	4.2	
		Week 28	Tezepelumab	35	35 (100.0)	1.68 (1.16)	0.0	0.50	1.67	2.50	3.8	
			Placebo	41	38 (92.7)	1.78 (1.14)	0.0	1.00	1.83	2.67	4.2	
		Week 30	Tezepelumab	35	35 (100.0)	1.65 (1.09)	0.0	0.67	1.67	2.33	3.7	
			Placebo	41	38 (92.7)	1.82 (1.08)	0.0	1.17	1.83	2.67	4.2	
		Week 32	Tezepelumab	35	35 (100.0)	1.55 (1.10)	0.0	0.67	1.50	2.33	4.0	
			Placebo	41	38 (92.7)	1.83 (1.04)	0.0	1.17	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Absolute values	Week 34	Tezepelumab	35	35 (100.0)	1.61 (1.17)	0.0	0.67	1.83	2.50	4.2	
			Placebo	41	38 (92.7)	1.89 (1.03)	0.0	1.17	1.92	2.50	4.5	
		Week 36	Tezepelumab	35	35 (100.0)	1.63 (1.07)	0.0	0.83	1.67	2.33	3.7	
			Placebo	41	38 (92.7)	2.01 (1.06)	0.0	1.17	2.17	2.67	4.5	
		Week 38	Tezepelumab	35	35 (100.0)	1.58 (1.17)	0.0	0.50	1.67	2.33	4.5	
			Placebo	41	38 (92.7)	1.87 (1.04)	0.0	1.17	1.83	2.50	4.5	
		Week 40	Tezepelumab	35	35 (100.0)	1.59 (1.16)	0.0	0.33	1.67	2.67	3.7	
			Placebo	41	38 (92.7)	1.85 (1.02)	0.0	1.33	1.83	2.50	4.2	
		Week 42	Tezepelumab	35	35 (100.0)	1.53 (1.07)	0.0	0.67	1.50	2.50	3.8	
			Placebo	41	38 (92.7)	1.79 (0.85)	0.0	1.33	1.83	2.50	3.3	
		Week 44	Tezepelumab	35	35 (100.0)	1.59 (1.09)	0.0	0.50	1.50	2.33	3.8	
			Placebo	41	38 (92.7)	1.82 (1.01)	0.0	1.17	2.00	2.50	4.0	
		Week 46	Tezepelumab	35	35 (100.0)	1.53 (1.14)	0.0	0.67	1.17	2.33	3.8	
			Placebo	41	38 (92.7)	1.75 (0.86)	0.0	1.17	1.83	2.33	3.3	
		Week 48	Tezepelumab	35	35 (100.0)	1.59 (1.14)	0.0	0.67	1.50	2.50	4.0	
			Placebo	41	38 (92.7)	1.74 (0.90)	0.0	1.00	2.08	2.33	3.3	
		Week 50	Tezepelumab	35	35 (100.0)	1.49 (1.21)	0.0	0.50	1.17	2.33	4.2	
			Placebo	41	38 (92.7)	1.68 (0.90)	0.0	1.17	1.67	2.33	3.3	
		Week 52	Tezepelumab	35	35 (100.0)	1.57 (1.16)	0.0	0.67	1.33	2.33	4.3	
			Placebo	41	38 (92.7)	1.70 (0.94)	0.0	1.17	1.83	2.33	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 2	Tezepelumab	35	34 (97.1)	-0.47 (0.80)	-2.8	-0.83	-0.25	0.17	0.7	-0.03 [-0.49, 0.44]
			Placebo	41	37 (90.2)	-0.45 (0.57)	-2.2	-0.83	-0.33	0.00	0.3	
		Week 4	Tezepelumab	35	34 (97.1)	-0.68 (0.93)	-2.5	-1.17	-0.75	-0.17	2.3	-0.06 [-0.52, 0.41]
			Placebo	41	37 (90.2)	-0.63 (0.84)	-3.0	-1.17	-0.33	0.00	0.5	
		Week 6	Tezepelumab	35	34 (97.1)	-0.68 (0.95)	-2.7	-1.17	-0.67	-0.17	2.3	0.04 [-0.42, 0.51]
			Placebo	41	37 (90.2)	-0.72 (0.91)	-3.3	-1.17	-0.50	-0.17	0.8	
		Week 8	Tezepelumab	35	34 (97.1)	-0.87 (0.99)	-2.7	-1.50	-0.83	-0.33	2.3	-0.16 [-0.63, 0.30]
			Placebo	41	37 (90.2)	-0.71 (1.01)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	35	34 (97.1)	-0.94 (1.05)	-2.7	-1.67	-1.08	-0.17	2.3	-0.18 [-0.65, 0.28]
			Placebo	41	37 (90.2)	-0.75 (1.07)	-3.3	-1.33	-0.50	-0.17	2.7	
		Week 12	Tezepelumab	35	34 (97.1)	-1.10 (1.05)	-2.7	-2.00	-1.17	-0.67	2.3	-0.06 [-0.53, 0.40]
			Placebo	41	37 (90.2)	-1.04 (0.97)	-3.3	-1.50	-0.83	-0.50	1.3	
		Week 14	Tezepelumab	35	34 (97.1)	-1.12 (1.01)	-2.7	-1.83	-1.17	-0.50	2.3	-0.16 [-0.62, 0.31]
			Placebo	41	37 (90.2)	-0.95 (1.05)	-3.2	-1.33	-1.00	-0.33	2.3	
		Week 16	Tezepelumab	35	34 (97.1)	-1.02 (1.01)	-2.5	-2.00	-1.00	-0.50	2.3	-0.15 [-0.62, 0.31]
			Placebo	41	37 (90.2)	-0.86 (1.13)	-3.2	-1.33	-1.00	-0.17	2.3	
		Week 18	Tezepelumab	35	34 (97.1)	-0.95 (0.97)	-2.5	-1.50	-0.83	-0.50	2.3	-0.13 [-0.59, 0.34]
			Placebo	41	37 (90.2)	-0.82 (1.18)	-3.2	-1.50	-0.83	0.00	2.3	
		Week 20	Tezepelumab	35	34 (97.1)	-0.99 (1.04)	-2.7	-1.67	-0.92	-0.50	2.3	-0.21 [-0.68, 0.26]
			Placebo	41	37 (90.2)	-0.77 (1.09)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	35	34 (97.1)	-0.97 (1.11)	-2.7	-1.67	-0.92	-0.67	2.3	-0.15 [-0.62, 0.31]
			Placebo	41	37 (90.2)	-0.80 (1.06)	-3.3	-1.33	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	35	34 (97.1)	-1.00 (1.05)	-2.7	-1.83	-0.83	-0.33	2.3	-0.22 [-0.69, 0.25]
			Placebo	41	37 (90.2)	-0.77 (1.03)	-3.2	-1.33	-0.67	0.00	1.5	
		Week 26	Tezepelumab	35	34 (97.1)	-0.92 (1.10)	-2.5	-1.83	-0.75	-0.17	2.3	-0.07 [-0.53, 0.40]
			Placebo	41	37 (90.2)	-0.85 (1.04)	-3.2	-1.50	-0.83	-0.17	1.5	
		Week 28	Tezepelumab	35	35 (100.0)	-0.99 (1.11)	-2.7	-2.00	-1.00	0.00	2.3	-0.03 [-0.49, 0.43]
			Placebo	41	38 (92.7)	-0.96 (1.10)	-3.2	-1.83	-1.08	-0.17	1.5	
		Week 30	Tezepelumab	35	35 (100.0)	-1.01 (1.05)	-2.5	-1.83	-0.83	-0.17	2.3	-0.09 [-0.55, 0.37]
			Placebo	41	38 (92.7)	-0.92 (1.11)	-3.2	-1.50	-1.17	-0.17	2.0	
		Week 32	Tezepelumab	35	35 (100.0)	-1.11 (1.03)	-2.5	-2.00	-1.00	-0.50	2.3	-0.20 [-0.66, 0.26]
			Placebo	41	38 (92.7)	-0.90 (1.05)	-3.0	-1.33	-1.08	-0.33	1.5	
		Week 34	Tezepelumab	35	35 (100.0)	-1.05 (1.10)	-2.5	-2.00	-1.00	-0.17	2.3	-0.19 [-0.65, 0.27]
			Placebo	41	38 (92.7)	-0.85 (1.03)	-2.8	-1.33	-0.92	-0.17	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Any positive	Change from baseline	Week 36	Tezepelumab	35	35 (100.0)	-1.03 (1.08)	-2.5	-2.00	-1.17	-0.17	2.3	-0.29 [-0.75, 0.17]
			Placebo	41	38 (92.7)	-0.72 (1.06)	-3.5	-1.33	-0.75	-0.17	1.5	
		Week 38	Tezepelumab	35	35 (100.0)	-1.08 (1.10)	-2.5	-2.00	-1.33	-0.17	2.3	-0.20 [-0.66, 0.26]
			Placebo	41	38 (92.7)	-0.87 (0.98)	-3.0	-1.33	-1.00	-0.33	1.5	
		Week 40	Tezepelumab	35	35 (100.0)	-1.08 (1.13)	-2.5	-2.17	-1.00	-0.33	2.3	-0.18 [-0.64, 0.28]
			Placebo	41	38 (92.7)	-0.89 (1.01)	-3.2	-1.33	-0.92	-0.33	1.5	
		Week 42	Tezepelumab	35	35 (100.0)	-1.13 (1.07)	-2.7	-2.00	-1.33	-0.50	2.3	-0.20 [-0.66, 0.26]
			Placebo	41	38 (92.7)	-0.95 (0.79)	-2.8	-1.33	-1.00	-0.50	0.5	
		Week 44	Tezepelumab	35	35 (100.0)	-1.07 (1.05)	-2.7	-2.00	-1.00	-0.50	2.3	-0.15 [-0.61, 0.31]
			Placebo	41	38 (92.7)	-0.91 (1.01)	-3.3	-1.50	-0.83	-0.33	1.2	
		Week 46	Tezepelumab	35	35 (100.0)	-1.13 (1.07)	-2.7	-2.17	-1.17	-0.33	2.3	-0.16 [-0.62, 0.30]
			Placebo	41	38 (92.7)	-0.98 (0.79)	-2.8	-1.33	-1.08	-0.50	0.8	
		Week 48	Tezepelumab	35	35 (100.0)	-1.08 (1.08)	-2.7	-2.00	-1.00	-0.33	2.3	-0.08 [-0.54, 0.38]
			Placebo	41	38 (92.7)	-1.00 (0.87)	-3.3	-1.33	-0.92	-0.50	0.5	
		Week 50	Tezepelumab	35	35 (100.0)	-1.17 (1.18)	-2.7	-2.33	-1.33	-0.33	2.3	-0.11 [-0.57, 0.35]
			Placebo	41	38 (92.7)	-1.06 (0.84)	-3.5	-1.33	-1.00	-0.67	0.5	
		Week 52	Tezepelumab	35	35 (100.0)	-1.09 (1.15)	-2.7	-2.00	-1.00	-0.17	2.3	-0.05 [-0.51, 0.41]
			Placebo	41	38 (92.7)	-1.04 (0.91)	-3.5	-1.33	-1.00	-0.50	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	41	41 (100.0)	2.54 (0.76)	0.0	2.17	2.67	3.00	3.8	
			Placebo	30	30 (100.0)	2.76 (0.81)	1.3	2.33	2.83	3.17	4.7	
		Week 2	Tezepelumab	41	39 (95.1)	2.06 (0.97)	0.0	1.33	2.33	2.67	4.2	
			Placebo	30	25 (83.3)	2.25 (0.94)	0.3	1.83	2.17	2.33	4.8	
		Week 4	Tezepelumab	41	39 (95.1)	1.82 (0.95)	0.2	1.00	2.00	2.67	3.3	
			Placebo	30	25 (83.3)	2.25 (0.91)	0.7	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	41	39 (95.1)	1.68 (0.99)	0.0	0.67	1.67	2.50	3.7	
			Placebo	30	25 (83.3)	2.22 (1.29)	0.8	1.17	2.00	2.67	5.5	
		Week 8	Tezepelumab	41	39 (95.1)	1.61 (1.14)	0.0	0.50	1.50	2.50	4.8	
			Placebo	30	26 (86.7)	2.24 (1.23)	0.2	1.00	2.33	2.83	4.7	
		Week 10	Tezepelumab	41	39 (95.1)	1.51 (1.11)	0.0	0.50	1.50	2.17	4.3	
			Placebo	30	26 (86.7)	2.19 (1.00)	0.8	1.33	2.17	2.83	4.2	
		Week 12	Tezepelumab	41	39 (95.1)	1.44 (1.09)	0.0	0.50	1.50	2.50	4.3	
			Placebo	30	26 (86.7)	1.91 (1.05)	0.0	1.00	1.83	2.50	4.3	
		Week 14	Tezepelumab	41	39 (95.1)	1.36 (1.05)	0.0	0.50	1.33	2.17	4.3	
			Placebo	30	26 (86.7)	1.70 (1.02)	0.0	1.00	1.67	2.17	5.0	
		Week 16	Tezepelumab	41	39 (95.1)	1.43 (1.10)	0.0	0.50	1.33	2.50	4.3	
			Placebo	30	26 (86.7)	1.97 (1.23)	0.0	1.17	1.83	2.67	4.8	
		Week 18	Tezepelumab	41	40 (97.6)	1.40 (1.01)	0.0	0.67	1.42	2.17	4.3	
			Placebo	30	26 (86.7)	1.87 (1.34)	0.0	0.67	1.67	2.83	4.7	
		Week 20	Tezepelumab	41	40 (97.6)	1.42 (1.07)	0.0	0.50	1.33	2.00	4.3	
			Placebo	30	26 (86.7)	1.97 (1.17)	0.2	0.83	2.08	2.67	4.5	
		Week 22	Tezepelumab	41	40 (97.6)	1.60 (1.00)	0.0	0.75	1.75	2.33	4.3	
			Placebo	30	26 (86.7)	1.94 (1.26)	0.0	0.67	2.00	2.83	4.5	
		Week 24	Tezepelumab	41	40 (97.6)	1.48 (1.05)	0.0	0.50	1.58	2.25	4.3	
			Placebo	30	26 (86.7)	2.03 (1.17)	0.2	0.83	2.17	2.83	4.5	
		Week 26	Tezepelumab	41	41 (100.0)	1.54 (1.10)	0.0	0.67	1.33	2.17	4.3	
			Placebo	30	26 (86.7)	1.95 (1.32)	0.0	1.00	1.67	3.00	4.5	
		Week 28	Tezepelumab	41	41 (100.0)	1.52 (1.14)	0.0	0.50	1.50	2.33	4.3	
			Placebo	30	26 (86.7)	2.16 (1.32)	0.0	1.00	2.17	3.33	4.5	
		Week 30	Tezepelumab	41	41 (100.0)	1.56 (1.12)	0.0	0.67	1.50	2.17	4.3	
			Placebo	30	26 (86.7)	2.10 (1.21)	0.0	1.00	2.25	3.00	4.5	
		Week 32	Tezepelumab	41	41 (100.0)	1.50 (1.13)	0.0	0.50	1.50	2.50	4.3	
			Placebo	30	26 (86.7)	2.08 (1.09)	0.3	1.17	1.92	2.67	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Absolute values	Week 34	Tezepelumab	41	41 (100.0)	1.57 (1.19)	0.0	0.67	1.33	2.67	4.3	
			Placebo	30	26 (86.7)	1.90 (1.16)	0.0	1.33	1.83	2.67	4.5	
		Week 36	Tezepelumab	41	41 (100.0)	1.49 (1.15)	0.0	0.67	1.17	2.50	4.3	
			Placebo	30	26 (86.7)	2.12 (1.16)	0.0	1.50	1.83	2.83	4.5	
		Week 38	Tezepelumab	41	41 (100.0)	1.57 (1.21)	0.0	0.83	1.50	2.67	4.3	
			Placebo	30	26 (86.7)	2.11 (1.12)	0.0	1.50	2.00	3.00	4.5	
		Week 40	Tezepelumab	41	41 (100.0)	1.53 (1.14)	0.0	0.50	1.67	2.33	4.3	
			Placebo	30	26 (86.7)	2.28 (1.28)	0.0	1.33	2.50	3.33	4.5	
		Week 42	Tezepelumab	41	41 (100.0)	1.54 (1.16)	0.0	0.83	1.67	2.33	4.3	
			Placebo	30	26 (86.7)	2.18 (1.17)	0.0	1.50	2.17	2.83	4.5	
		Week 44	Tezepelumab	41	41 (100.0)	1.53 (1.13)	0.0	0.67	1.50	2.50	4.3	
			Placebo	30	26 (86.7)	2.27 (1.15)	0.3	1.50	2.33	3.00	4.5	
		Week 46	Tezepelumab	41	41 (100.0)	1.55 (1.18)	0.0	0.67	1.50	2.50	4.3	
			Placebo	30	26 (86.7)	2.17 (1.09)	0.0	1.67	2.17	2.83	4.5	
		Week 48	Tezepelumab	41	41 (100.0)	1.53 (1.20)	0.0	0.67	1.33	2.33	4.3	
			Placebo	30	26 (86.7)	2.24 (1.16)	0.0	1.67	2.17	2.67	4.5	
		Week 50	Tezepelumab	41	41 (100.0)	1.51 (1.17)	0.0	0.67	1.50	2.33	4.3	
			Placebo	30	26 (86.7)	2.07 (1.10)	0.2	1.33	2.08	2.50	4.5	
		Week 52	Tezepelumab	41	41 (100.0)	1.49 (1.18)	0.0	0.33	1.50	2.33	4.3	
			Placebo	30	26 (86.7)	2.15 (1.10)	0.2	1.33	2.17	2.67	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 2	Tezepelumab	41	39 (95.1)	-0.51 (0.74)	-2.8	-1.00	-0.33	0.00	0.7	-0.03 [-0.54, 0.47]
			Placebo	30	25 (83.3)	-0.49 (0.81)	-2.8	-0.83	-0.50	0.00	1.0	
		Week 4	Tezepelumab	41	39 (95.1)	-0.76 (0.91)	-2.5	-1.33	-0.67	-0.17	2.3	-0.32 [-0.83, 0.18]
			Placebo	30	25 (83.3)	-0.48 (0.82)	-1.8	-1.00	-0.67	0.17	1.2	
		Week 6	Tezepelumab	41	39 (95.1)	-0.89 (1.05)	-2.7	-1.50	-1.00	-0.17	2.3	-0.36 [-0.86, 0.15]
			Placebo	30	25 (83.3)	-0.51 (1.08)	-2.0	-1.50	-0.50	0.33	1.5	
		Week 8	Tezepelumab	41	39 (95.1)	-0.97 (1.16)	-3.0	-1.67	-1.00	-0.17	2.3	-0.41 [-0.91, 0.09]
			Placebo	30	26 (86.7)	-0.51 (1.02)	-3.0	-1.17	-0.42	0.00	1.0	
		Week 10	Tezepelumab	41	39 (95.1)	-1.06 (1.15)	-3.2	-2.00	-1.17	-0.17	2.3	-0.45 [-0.95, 0.06]
			Placebo	30	26 (86.7)	-0.56 (1.11)	-2.2	-1.33	-0.50	0.00	2.5	
		Week 12	Tezepelumab	41	39 (95.1)	-1.13 (1.07)	-2.8	-2.00	-1.17	-0.50	2.3	-0.28 [-0.78, 0.22]
			Placebo	30	26 (86.7)	-0.84 (0.99)	-3.2	-1.33	-0.75	-0.50	1.3	
		Week 14	Tezepelumab	41	39 (95.1)	-1.21 (1.08)	-3.2	-2.00	-1.17	-0.67	2.3	-0.16 [-0.65, 0.34]
			Placebo	30	26 (86.7)	-1.05 (0.97)	-3.2	-1.50	-1.17	-0.67	1.2	
		Week 16	Tezepelumab	41	39 (95.1)	-1.15 (1.07)	-3.0	-2.00	-1.00	-0.50	2.3	-0.35 [-0.85, 0.15]
			Placebo	30	26 (86.7)	-0.78 (1.05)	-3.2	-1.33	-0.83	-0.50	2.3	
		Week 18	Tezepelumab	41	40 (97.6)	-1.16 (1.05)	-3.2	-1.83	-1.17	-0.67	2.3	-0.25 [-0.74, 0.25]
			Placebo	30	26 (86.7)	-0.88 (1.30)	-3.2	-1.67	-1.00	0.00	2.3	
		Week 20	Tezepelumab	41	40 (97.6)	-1.14 (1.06)	-3.2	-2.00	-1.17	-0.50	2.3	-0.34 [-0.83, 0.16]
			Placebo	30	26 (86.7)	-0.78 (1.09)	-3.0	-1.50	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	41	40 (97.6)	-0.96 (1.13)	-3.0	-1.83	-0.92	-0.42	2.3	-0.13 [-0.63, 0.36]
			Placebo	30	26 (86.7)	-0.81 (1.16)	-3.2	-1.50	-0.92	0.00	2.3	
		Week 24	Tezepelumab	41	40 (97.6)	-1.08 (1.04)	-3.2	-1.92	-1.17	-0.33	2.3	-0.33 [-0.83, 0.16]
			Placebo	30	26 (86.7)	-0.72 (1.14)	-3.0	-1.50	-0.75	0.00	2.3	
		Week 26	Tezepelumab	41	41 (100.0)	-1.00 (1.08)	-2.8	-2.00	-1.00	-0.17	2.3	-0.17 [-0.66, 0.32]
			Placebo	30	26 (86.7)	-0.80 (1.30)	-3.2	-1.50	-1.17	0.17	2.3	
		Week 28	Tezepelumab	41	41 (100.0)	-1.02 (1.18)	-3.2	-2.00	-1.00	0.00	2.3	-0.35 [-0.85, 0.14]
			Placebo	30	26 (86.7)	-0.59 (1.30)	-3.2	-1.50	-0.58	0.33	2.3	
		Week 30	Tezepelumab	41	41 (100.0)	-0.98 (1.15)	-2.7	-2.00	-1.00	-0.17	2.3	-0.29 [-0.78, 0.20]
			Placebo	30	26 (86.7)	-0.65 (1.15)	-2.5	-1.50	-0.50	-0.17	2.3	
		Week 32	Tezepelumab	41	41 (100.0)	-1.03 (1.10)	-3.0	-2.00	-1.00	-0.33	2.3	-0.33 [-0.83, 0.16]
			Placebo	30	26 (86.7)	-0.67 (1.05)	-2.5	-1.33	-0.83	0.17	2.3	
		Week 34	Tezepelumab	41	41 (100.0)	-0.96 (1.20)	-2.8	-2.00	-1.33	-0.17	2.3	-0.09 [-0.59, 0.40]
			Placebo	30	26 (86.7)	-0.85 (1.14)	-3.2	-1.33	-1.00	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low	Change from baseline	Week 36	Tezepelumab	41	41 (100.0)	-1.05 (1.17)	-3.0	-2.00	-1.17	-0.17	2.3	-0.36 [-0.85, 0.14]
			Placebo	30	26 (86.7)	-0.63 (1.14)	-3.2	-1.33	-0.75	0.17	2.3	
		Week 38	Tezepelumab	41	41 (100.0)	-0.97 (1.23)	-3.0	-2.00	-1.17	-0.17	2.3	-0.27 [-0.77, 0.22]
			Placebo	30	26 (86.7)	-0.64 (1.13)	-3.2	-1.33	-0.83	0.17	2.3	
		Week 40	Tezepelumab	41	41 (100.0)	-1.01 (1.18)	-3.2	-2.00	-1.00	-0.33	2.3	-0.43 [-0.93, 0.06]
			Placebo	30	26 (86.7)	-0.47 (1.31)	-2.8	-1.33	-0.33	0.33	2.3	
		Week 42	Tezepelumab	41	41 (100.0)	-0.99 (1.18)	-2.8	-2.00	-0.83	-0.17	2.3	-0.35 [-0.85, 0.14]
			Placebo	30	26 (86.7)	-0.57 (1.22)	-2.8	-1.33	-0.75	0.17	2.3	
		Week 44	Tezepelumab	41	41 (100.0)	-1.00 (1.14)	-3.2	-2.00	-1.00	-0.17	2.3	-0.45 [-0.95, 0.05]
			Placebo	30	26 (86.7)	-0.48 (1.19)	-2.7	-1.33	-0.67	0.33	2.3	
		Week 46	Tezepelumab	41	41 (100.0)	-0.98 (1.18)	-2.8	-2.00	-1.00	-0.17	2.3	-0.34 [-0.83, 0.16]
			Placebo	30	26 (86.7)	-0.58 (1.18)	-3.2	-1.17	-0.67	0.17	2.3	
		Week 48	Tezepelumab	41	41 (100.0)	-1.01 (1.19)	-2.7	-2.00	-0.83	-0.17	2.3	-0.41 [-0.91, 0.08]
			Placebo	30	26 (86.7)	-0.51 (1.21)	-3.2	-1.33	-0.50	0.33	2.3	
		Week 50	Tezepelumab	41	41 (100.0)	-1.02 (1.19)	-2.7	-2.00	-1.00	-0.17	2.3	-0.29 [-0.78, 0.21]
			Placebo	30	26 (86.7)	-0.68 (1.20)	-3.0	-1.17	-0.67	0.17	2.3	
		Week 52	Tezepelumab	41	41 (100.0)	-1.05 (1.21)	-2.7	-2.00	-1.00	-0.33	2.3	-0.38 [-0.87, 0.12]
			Placebo	30	26 (86.7)	-0.60 (1.20)	-3.0	-1.17	-0.67	0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	25	25 (100.0)	3.01 (0.86)	2.0	2.33	2.67	3.50	4.8	
			Placebo	34	34 (100.0)	2.67 (0.65)	0.3	2.33	2.67	3.00	3.5	
		Week 2	Tezepelumab	25	24 (96.0)	2.49 (0.89)	0.7	1.75	2.67	3.25	3.8	
			Placebo	34	32 (94.1)	2.33 (0.64)	0.5	2.00	2.50	2.83	3.3	
		Week 4	Tezepelumab	25	24 (96.0)	2.24 (0.91)	0.2	1.58	2.25	2.92	3.5	
			Placebo	34	32 (94.1)	2.14 (0.88)	0.3	1.50	2.33	2.67	3.5	
		Week 6	Tezepelumab	25	24 (96.0)	2.21 (0.96)	0.0	1.58	2.42	2.75	4.0	
			Placebo	34	32 (94.1)	2.07 (0.90)	0.2	1.67	2.33	2.67	3.3	
		Week 8	Tezepelumab	25	24 (96.0)	1.96 (1.04)	0.0	1.25	1.75	2.75	4.2	
			Placebo	34	32 (94.1)	1.98 (0.90)	0.0	1.50	2.08	2.67	3.5	
		Week 10	Tezepelumab	25	24 (96.0)	1.90 (1.01)	0.0	1.33	1.92	2.67	3.5	
			Placebo	34	32 (94.1)	2.03 (1.05)	0.0	1.58	2.17	2.58	5.3	
		Week 12	Tezepelumab	25	24 (96.0)	1.74 (0.98)	0.0	1.17	1.83	2.50	3.3	
			Placebo	34	32 (94.1)	1.86 (0.93)	0.0	1.25	2.00	2.50	4.0	
		Week 14	Tezepelumab	25	24 (96.0)	1.69 (1.03)	0.0	0.92	1.67	2.33	4.2	
			Placebo	34	32 (94.1)	1.91 (0.92)	0.0	1.50	2.00	2.17	5.0	
		Week 16	Tezepelumab	25	24 (96.0)	1.96 (1.09)	0.0	1.25	1.83	2.50	4.3	
			Placebo	34	32 (94.1)	1.99 (1.08)	0.0	1.00	2.17	2.67	5.0	
		Week 18	Tezepelumab	25	24 (96.0)	1.94 (0.97)	0.0	1.33	2.00	2.50	4.2	
			Placebo	34	32 (94.1)	1.91 (0.95)	0.0	1.50	2.17	2.33	5.0	
		Week 20	Tezepelumab	25	24 (96.0)	1.95 (1.06)	0.0	1.25	1.92	2.50	5.0	
			Placebo	34	32 (94.1)	2.02 (1.00)	0.0	1.50	2.17	2.67	5.0	
		Week 22	Tezepelumab	25	24 (96.0)	1.81 (0.92)	0.0	1.25	1.92	2.33	3.8	
			Placebo	34	32 (94.1)	1.96 (1.02)	0.0	1.17	2.00	2.58	5.0	
		Week 24	Tezepelumab	25	24 (96.0)	1.98 (1.00)	0.0	1.25	2.17	2.67	3.8	
			Placebo	34	32 (94.1)	2.00 (0.92)	0.0	1.67	2.00	2.58	4.2	
		Week 26	Tezepelumab	25	24 (96.0)	2.00 (0.96)	0.0	1.50	2.00	2.58	4.0	
			Placebo	34	32 (94.1)	1.94 (0.91)	0.0	1.33	1.92	2.58	4.2	
		Week 28	Tezepelumab	25	25 (100.0)	1.89 (0.99)	0.0	1.50	2.00	2.50	3.8	
			Placebo	34	33 (97.1)	1.74 (1.06)	0.0	1.00	1.83	2.50	4.2	
		Week 30	Tezepelumab	25	25 (100.0)	1.75 (0.95)	0.0	1.33	1.67	2.33	3.7	
			Placebo	34	33 (97.1)	1.76 (1.07)	0.0	1.17	1.83	2.33	4.2	
		Week 32	Tezepelumab	25	25 (100.0)	1.69 (0.96)	0.0	1.17	1.83	2.33	4.0	
			Placebo	34	33 (97.1)	1.73 (1.08)	0.0	1.17	1.83	2.33	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Absolute values	Week 34	Tezepelumab	25	25 (100.0)	1.75 (1.01)	0.0	0.83	2.00	2.50	3.8	
			Placebo	34	33 (97.1)	1.80 (1.05)	0.0	1.00	1.83	2.33	4.5	
		Week 36	Tezepelumab	25	25 (100.0)	1.81 (0.84)	0.0	1.50	2.00	2.33	3.7	
			Placebo	34	33 (97.1)	1.93 (1.10)	0.0	1.00	2.17	2.50	4.5	
		Week 38	Tezepelumab	25	25 (100.0)	1.73 (1.06)	0.0	1.33	1.83	2.17	4.5	
			Placebo	34	33 (97.1)	1.70 (1.05)	0.0	1.00	1.83	2.17	4.5	
		Week 40	Tezepelumab	25	25 (100.0)	1.74 (1.09)	0.0	0.67	1.83	2.50	3.7	
			Placebo	34	33 (97.1)	1.83 (0.96)	0.0	1.33	1.83	2.50	4.2	
		Week 42	Tezepelumab	25	25 (100.0)	1.65 (0.98)	0.0	1.00	1.67	2.33	3.8	
			Placebo	34	33 (97.1)	1.64 (0.82)	0.0	1.00	1.83	2.17	3.0	
		Week 44	Tezepelumab	25	25 (100.0)	1.75 (0.99)	0.0	0.83	2.00	2.33	3.8	
			Placebo	34	33 (97.1)	1.72 (0.92)	0.0	1.17	1.83	2.33	3.3	
		Week 46	Tezepelumab	25	25 (100.0)	1.75 (1.01)	0.0	1.00	1.83	2.33	3.8	
			Placebo	34	33 (97.1)	1.62 (0.80)	0.0	1.17	1.83	2.17	3.3	
		Week 48	Tezepelumab	25	25 (100.0)	1.80 (0.96)	0.0	1.17	2.00	2.33	3.8	
			Placebo	34	33 (97.1)	1.65 (0.86)	0.0	1.00	2.00	2.17	3.0	
		Week 50	Tezepelumab	25	25 (100.0)	1.67 (1.09)	0.0	0.83	1.50	2.33	4.2	
			Placebo	34	33 (97.1)	1.58 (0.83)	0.0	1.00	1.67	2.17	3.0	
		Week 52	Tezepelumab	25	25 (100.0)	1.79 (1.00)	0.5	1.00	1.50	2.33	4.3	
			Placebo	34	33 (97.1)	1.66 (0.93)	0.0	1.00	1.83	2.33	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 2	Tezepelumab	25	24 (96.0)	-0.54 (0.65)	-1.8	-1.17	-0.42	0.08	0.3	-0.19 [-0.72, 0.34]
			Placebo	34	32 (94.1)	-0.42 (0.59)	-2.2	-0.75	-0.25	0.00	0.3	
		Week 4	Tezepelumab	25	24 (96.0)	-0.80 (0.70)	-2.3	-1.08	-0.83	-0.42	0.2	-0.22 [-0.75, 0.31]
			Placebo	34	32 (94.1)	-0.61 (0.92)	-3.0	-1.25	-0.33	0.00	0.5	
		Week 6	Tezepelumab	25	24 (96.0)	-0.83 (0.73)	-2.5	-1.42	-0.83	-0.25	0.3	-0.18 [-0.71, 0.35]
			Placebo	34	32 (94.1)	-0.68 (0.88)	-3.3	-1.08	-0.42	-0.17	0.5	
		Week 8	Tezepelumab	25	24 (96.0)	-1.08 (0.81)	-2.7	-1.75	-1.00	-0.50	0.5	-0.34 [-0.88, 0.19]
			Placebo	34	32 (94.1)	-0.77 (0.94)	-3.2	-1.08	-0.67	-0.08	0.5	
		Week 10	Tezepelumab	25	24 (96.0)	-1.14 (0.77)	-2.5	-1.58	-1.17	-0.58	0.3	-0.43 [-0.96, 0.11]
			Placebo	34	32 (94.1)	-0.72 (1.11)	-3.3	-1.25	-0.50	-0.17	2.7	
		Week 12	Tezepelumab	25	24 (96.0)	-1.29 (0.88)	-3.0	-2.08	-1.17	-0.67	0.5	-0.43 [-0.96, 0.11]
			Placebo	34	32 (94.1)	-0.89 (1.00)	-3.3	-1.17	-0.75	-0.17	1.3	
		Week 14	Tezepelumab	25	24 (96.0)	-1.35 (0.89)	-3.7	-1.83	-1.33	-0.75	0.3	-0.51 [-1.05, 0.03]
			Placebo	34	32 (94.1)	-0.84 (1.06)	-3.2	-1.33	-0.83	-0.25	2.3	
		Week 16	Tezepelumab	25	24 (96.0)	-1.08 (1.00)	-2.7	-2.00	-1.00	-0.42	1.5	-0.29 [-0.82, 0.25]
			Placebo	34	32 (94.1)	-0.76 (1.17)	-3.2	-1.50	-0.50	0.00	2.3	
		Week 18	Tezepelumab	25	24 (96.0)	-1.10 (0.91)	-3.5	-1.75	-0.83	-0.50	0.0	-0.26 [-0.79, 0.27]
			Placebo	34	32 (94.1)	-0.84 (1.06)	-3.2	-1.50	-0.75	-0.17	2.3	
		Week 20	Tezepelumab	25	24 (96.0)	-1.08 (0.91)	-2.5	-1.83	-0.92	-0.50	0.7	-0.33 [-0.86, 0.20]
			Placebo	34	32 (94.1)	-0.73 (1.15)	-3.2	-1.25	-0.58	-0.17	2.3	
		Week 22	Tezepelumab	25	24 (96.0)	-1.22 (0.80)	-2.5	-1.92	-1.08	-0.67	0.5	-0.44 [-0.98, 0.10]
			Placebo	34	32 (94.1)	-0.79 (1.09)	-3.3	-1.25	-0.67	-0.33	2.3	
		Week 24	Tezepelumab	25	24 (96.0)	-1.06 (0.88)	-2.5	-1.75	-0.83	-0.50	0.7	-0.31 [-0.84, 0.22]
			Placebo	34	32 (94.1)	-0.75 (1.06)	-3.2	-1.33	-0.67	0.08	1.5	
		Week 26	Tezepelumab	25	24 (96.0)	-1.03 (0.96)	-2.5	-1.92	-0.92	-0.33	0.7	-0.23 [-0.76, 0.30]
			Placebo	34	32 (94.1)	-0.81 (0.99)	-2.8	-1.58	-0.67	-0.25	1.5	
		Week 28	Tezepelumab	25	25 (100.0)	-1.12 (0.93)	-2.5	-2.00	-1.00	-0.50	0.7	-0.18 [-0.70, 0.34]
			Placebo	34	33 (97.1)	-0.94 (1.03)	-2.8	-1.83	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	25	25 (100.0)	-1.25 (0.94)	-3.5	-1.83	-1.00	-0.67	0.7	-0.32 [-0.84, 0.20]
			Placebo	34	33 (97.1)	-0.91 (1.14)	-3.2	-1.33	-1.00	-0.33	2.0	
		Week 32	Tezepelumab	25	25 (100.0)	-1.31 (0.79)	-2.5	-2.17	-1.00	-0.67	0.5	-0.37 [-0.89, 0.16]
			Placebo	34	33 (97.1)	-0.95 (1.11)	-3.0	-1.50	-1.17	-0.33	1.5	
		Week 34	Tezepelumab	25	25 (100.0)	-1.26 (0.87)	-2.5	-2.00	-1.00	-0.67	0.5	-0.40 [-0.92, 0.13]
			Placebo	34	33 (97.1)	-0.87 (1.04)	-2.8	-1.50	-0.83	-0.17	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High	Change from baseline	Week 36	Tezepelumab	25	25 (100.0)	-1.20 (0.89)	-2.8	-1.83	-1.17	-0.67	0.3	-0.44 [-0.97, 0.08]
			Placebo	34	33 (97.1)	-0.74 (1.13)	-3.5	-1.33	-0.83	-0.17	1.5	
		Week 38	Tezepelumab	25	25 (100.0)	-1.27 (0.86)	-2.5	-2.00	-1.33	-0.83	0.3	-0.31 [-0.83, 0.22]
			Placebo	34	33 (97.1)	-0.98 (1.03)	-3.0	-1.67	-1.00	-0.67	1.5	
		Week 40	Tezepelumab	25	25 (100.0)	-1.27 (0.94)	-2.5	-2.17	-1.17	-0.67	0.5	-0.44 [-0.96, 0.09]
			Placebo	34	33 (97.1)	-0.84 (0.99)	-3.2	-1.33	-0.83	-0.33	1.5	
		Week 42	Tezepelumab	25	25 (100.0)	-1.36 (0.90)	-3.3	-2.00	-1.33	-0.67	0.5	-0.38 [-0.91, 0.14]
			Placebo	34	33 (97.1)	-1.04 (0.81)	-2.8	-1.50	-1.00	-0.50	0.5	
		Week 44	Tezepelumab	25	25 (100.0)	-1.26 (0.98)	-3.5	-2.00	-1.17	-0.67	0.7	-0.31 [-0.84, 0.21]
			Placebo	34	33 (97.1)	-0.95 (0.97)	-3.3	-1.50	-0.83	-0.33	1.2	
		Week 46	Tezepelumab	25	25 (100.0)	-1.26 (0.91)	-3.3	-2.17	-1.00	-0.67	0.5	-0.24 [-0.76, 0.29]
			Placebo	34	33 (97.1)	-1.06 (0.79)	-2.8	-1.50	-1.17	-0.83	0.8	
		Week 48	Tezepelumab	25	25 (100.0)	-1.21 (0.85)	-2.7	-2.00	-1.00	-0.67	0.3	-0.20 [-0.72, 0.32]
			Placebo	34	33 (97.1)	-1.03 (0.89)	-3.3	-1.33	-0.83	-0.50	0.5	
		Week 50	Tezepelumab	25	25 (100.0)	-1.33 (0.90)	-2.5	-2.00	-1.33	-1.00	0.5	-0.28 [-0.80, 0.24]
			Placebo	34	33 (97.1)	-1.10 (0.80)	-3.5	-1.67	-1.00	-0.67	0.5	
		Week 52	Tezepelumab	25	25 (100.0)	-1.21 (0.85)	-2.5	-1.67	-1.17	-0.67	0.5	-0.22 [-0.74, 0.30]
			Placebo	34	33 (97.1)	-1.02 (0.91)	-3.5	-1.67	-1.00	-0.50	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	26	26 (100.0)	2.82 (0.75)	1.7	2.33	2.83	3.17	4.5	
			Placebo	31	31 (100.0)	2.67 (0.74)	0.3	2.33	2.67	3.17	4.3	
		Week 2	Tezepelumab	26	23 (88.5)	2.43 (1.02)	0.0	1.50	2.67	3.00	3.8	
			Placebo	31	26 (83.9)	2.24 (0.86)	0.3	2.00	2.33	2.67	4.8	
		Week 4	Tezepelumab	26	23 (88.5)	2.22 (0.99)	0.2	1.67	2.50	3.00	3.5	
			Placebo	31	26 (83.9)	2.15 (1.08)	0.2	1.33	2.33	2.83	4.2	
		Week 6	Tezepelumab	26	23 (88.5)	2.17 (1.05)	0.0	1.50	2.50	2.83	4.0	
			Placebo	31	26 (83.9)	2.02 (1.24)	0.2	1.17	2.08	2.67	4.7	
		Week 8	Tezepelumab	26	23 (88.5)	2.17 (1.20)	0.0	1.50	2.33	2.83	4.8	
			Placebo	31	27 (87.1)	1.99 (1.21)	0.0	0.83	2.33	2.83	4.7	
		Week 10	Tezepelumab	26	23 (88.5)	2.01 (1.09)	0.0	1.33	2.17	2.83	4.3	
			Placebo	31	27 (87.1)	2.05 (1.21)	0.2	1.00	1.83	2.67	5.3	
		Week 12	Tezepelumab	26	23 (88.5)	2.03 (1.05)	0.0	1.50	2.17	2.67	4.3	
			Placebo	31	27 (87.1)	1.83 (1.19)	0.0	1.00	1.83	2.50	4.3	
		Week 14	Tezepelumab	26	23 (88.5)	1.96 (1.05)	0.0	1.50	2.00	2.50	4.3	
			Placebo	31	27 (87.1)	1.82 (1.21)	0.0	1.00	1.83	2.33	5.0	
		Week 16	Tezepelumab	26	23 (88.5)	2.01 (1.10)	0.0	1.33	2.17	2.50	4.3	
			Placebo	31	27 (87.1)	2.00 (1.27)	0.0	0.83	2.00	2.67	5.0	
		Week 18	Tezepelumab	26	24 (92.3)	1.99 (1.09)	0.0	1.50	2.17	2.50	4.3	
			Placebo	31	27 (87.1)	1.86 (1.36)	0.0	0.67	1.83	2.50	5.0	
		Week 20	Tezepelumab	26	24 (92.3)	2.05 (1.14)	0.0	1.67	1.83	2.50	5.0	
			Placebo	31	27 (87.1)	1.92 (1.24)	0.2	0.67	1.83	2.50	5.0	
		Week 22	Tezepelumab	26	24 (92.3)	2.09 (0.92)	0.0	1.75	2.17	2.42	4.3	
			Placebo	31	27 (87.1)	1.91 (1.27)	0.0	0.83	1.83	2.67	5.0	
		Week 24	Tezepelumab	26	24 (92.3)	2.04 (1.04)	0.0	1.67	1.92	2.58	4.3	
			Placebo	31	27 (87.1)	1.86 (1.19)	0.2	0.67	1.83	2.67	4.5	
		Week 26	Tezepelumab	26	25 (96.2)	2.10 (1.05)	0.0	1.50	2.17	2.67	4.3	
			Placebo	31	27 (87.1)	1.90 (1.26)	0.0	0.67	1.83	3.00	4.5	
		Week 28	Tezepelumab	26	26 (100.0)	1.98 (1.06)	0.0	1.50	2.00	2.50	4.3	
			Placebo	31	28 (90.3)	1.71 (1.28)	0.0	0.67	1.50	2.75	4.5	
		Week 30	Tezepelumab	26	26 (100.0)	2.06 (1.06)	0.0	1.67	2.00	2.50	4.3	
			Placebo	31	28 (90.3)	1.89 (1.31)	0.0	0.67	1.83	2.83	4.5	
		Week 32	Tezepelumab	26	26 (100.0)	2.01 (1.06)	0.0	1.50	2.00	2.67	4.3	
			Placebo	31	28 (90.3)	1.79 (1.23)	0.0	0.58	1.83	2.58	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low (< 20.9 ng/ml)	Absolute values	Week 34	Tezepelumab	26	26 (100.0)	2.04 (1.13)	0.0	1.33	2.08	2.67	4.3	
			Placebo	31	28 (90.3)	1.66 (1.24)	0.0	0.58	1.67	2.42	4.5	
		Week 36	Tezepelumab	26	26 (100.0)	2.01 (1.06)	0.0	1.17	2.00	2.67	4.3	
			Placebo	31	28 (90.3)	1.82 (1.29)	0.0	0.92	1.83	2.75	4.5	
		Week 38	Tezepelumab	26	26 (100.0)	2.06 (1.24)	0.0	1.00	1.92	2.67	4.5	
			Placebo	31	28 (90.3)	1.76 (1.22)	0.0	0.83	1.83	2.58	4.5	
		Week 40	Tezepelumab	26	26 (100.0)	2.06 (1.15)	0.0	1.50	2.00	2.67	4.3	
			Placebo	31	28 (90.3)	1.89 (1.38)	0.0	0.58	1.83	2.92	4.5	
		Week 42	Tezepelumab	26	26 (100.0)	2.02 (1.16)	0.0	1.50	1.83	2.67	4.3	
			Placebo	31	28 (90.3)	1.72 (1.21)	0.0	0.67	1.83	2.50	4.5	
		Week 44	Tezepelumab	26	26 (100.0)	2.03 (1.11)	0.0	1.33	2.08	2.67	4.3	
			Placebo	31	28 (90.3)	1.86 (1.28)	0.0	0.67	1.92	2.83	4.5	
		Week 46	Tezepelumab	26	26 (100.0)	2.01 (1.18)	0.0	1.00	2.08	2.83	4.3	
			Placebo	31	28 (90.3)	1.65 (1.12)	0.0	0.67	1.58	2.42	4.5	
		Week 48	Tezepelumab	26	26 (100.0)	2.04 (1.13)	0.0	1.17	2.00	2.67	4.3	
			Placebo	31	28 (90.3)	1.68 (1.23)	0.0	0.33	1.75	2.58	4.5	
		Week 50	Tezepelumab	26	26 (100.0)	1.97 (1.27)	0.0	1.00	1.75	2.83	4.3	
			Placebo	31	28 (90.3)	1.63 (1.22)	0.0	0.58	1.58	2.50	4.5	
		Week 52	Tezepelumab	26	26 (100.0)	2.03 (1.22)	0.0	1.33	1.92	2.67	4.3	
			Placebo	31	28 (90.3)	1.68 (1.28)	0.0	0.50	1.67	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 2	Tezepelumab	26	23 (88.5)	-0.51 (0.75)	-2.8	-0.83	-0.33	0.17	0.3	0.02 [-0.54, 0.59]
			Placebo	31	26 (83.9)	-0.53 (0.73)	-2.8	-1.00	-0.58	0.17	0.5	
		Week 4	Tezepelumab	26	23 (88.5)	-0.72 (0.68)	-2.0	-1.00	-0.67	-0.33	0.7	-0.12 [-0.68, 0.44]
			Placebo	31	26 (83.9)	-0.62 (1.00)	-3.0	-1.33	-0.42	0.17	1.2	
		Week 6	Tezepelumab	26	23 (88.5)	-0.77 (0.81)	-2.3	-1.33	-0.83	-0.17	1.2	-0.02 [-0.58, 0.54]
			Placebo	31	26 (83.9)	-0.75 (1.11)	-3.3	-1.67	-0.50	0.00	1.5	
		Week 8	Tezepelumab	26	23 (88.5)	-0.76 (1.01)	-2.7	-1.50	-0.83	-0.17	2.2	0.03 [-0.52, 0.59]
			Placebo	31	27 (87.1)	-0.80 (1.09)	-3.0	-1.17	-0.83	0.17	1.0	
		Week 10	Tezepelumab	26	23 (88.5)	-0.92 (0.80)	-2.7	-1.33	-1.00	-0.17	0.5	-0.18 [-0.73, 0.38]
			Placebo	31	27 (87.1)	-0.73 (1.22)	-3.2	-1.33	-0.67	-0.17	2.7	
		Week 12	Tezepelumab	26	23 (88.5)	-0.91 (0.80)	-2.3	-1.33	-1.00	-0.33	0.5	0.05 [-0.50, 0.61]
			Placebo	31	27 (87.1)	-0.96 (1.08)	-3.2	-1.33	-0.83	-0.33	1.3	
		Week 14	Tezepelumab	26	23 (88.5)	-0.97 (0.75)	-2.3	-1.50	-1.00	-0.50	0.5	-0.01 [-0.56, 0.55]
			Placebo	31	27 (87.1)	-0.96 (1.19)	-3.2	-1.67	-1.17	-0.33	2.3	
		Week 16	Tezepelumab	26	23 (88.5)	-0.92 (0.72)	-2.2	-1.00	-1.00	-0.50	0.5	-0.13 [-0.69, 0.42]
			Placebo	31	27 (87.1)	-0.78 (1.24)	-3.2	-1.50	-1.00	0.17	2.3	
		Week 18	Tezepelumab	26	24 (92.3)	-0.90 (0.75)	-2.3	-1.17	-0.83	-0.42	0.5	0.02 [-0.53, 0.57]
			Placebo	31	27 (87.1)	-0.92 (1.30)	-3.2	-1.83	-1.00	0.00	2.3	
		Week 20	Tezepelumab	26	24 (92.3)	-0.84 (0.82)	-2.2	-1.50	-0.75	-0.33	0.7	0.02 [-0.53, 0.57]
			Placebo	31	27 (87.1)	-0.86 (1.18)	-3.0	-1.83	-0.67	-0.17	2.3	
		Week 22	Tezepelumab	26	24 (92.3)	-0.80 (0.74)	-2.2	-1.25	-0.75	-0.33	0.5	0.07 [-0.48, 0.62]
			Placebo	31	27 (87.1)	-0.87 (1.20)	-3.2	-1.83	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	26	24 (92.3)	-0.85 (0.79)	-2.2	-1.42	-0.75	-0.33	0.7	0.07 [-0.48, 0.62]
			Placebo	31	27 (87.1)	-0.92 (1.15)	-3.2	-1.83	-0.83	0.17	1.5	
		Week 26	Tezepelumab	26	25 (96.2)	-0.74 (0.82)	-2.2	-1.00	-0.50	-0.17	0.7	0.15 [-0.40, 0.69]
			Placebo	31	27 (87.1)	-0.89 (1.16)	-3.2	-1.83	-0.83	0.17	1.5	
		Week 28	Tezepelumab	26	26 (100.0)	-0.84 (0.97)	-2.3	-1.67	-0.83	0.00	0.8	0.14 [-0.40, 0.67]
			Placebo	31	28 (90.3)	-0.98 (1.11)	-3.2	-1.67	-1.00	-0.33	1.5	
		Week 30	Tezepelumab	26	26 (100.0)	-0.76 (0.96)	-2.2	-1.50	-0.75	-0.17	1.8	0.05 [-0.48, 0.58]
			Placebo	31	28 (90.3)	-0.81 (1.18)	-3.2	-1.50	-1.00	-0.25	2.0	
		Week 32	Tezepelumab	26	26 (100.0)	-0.81 (0.83)	-2.2	-1.17	-0.67	-0.33	0.8	0.09 [-0.44, 0.63]
			Placebo	31	28 (90.3)	-0.90 (1.07)	-3.0	-1.42	-1.00	-0.33	1.5	
		Week 34	Tezepelumab	26	26 (100.0)	-0.78 (1.02)	-2.3	-1.50	-0.75	-0.17	2.0	0.24 [-0.30, 0.77]
			Placebo	31	28 (90.3)	-1.04 (1.13)	-3.2	-1.75	-1.00	-0.25	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Low (< 20.9 ng/ml)	Change from baseline	Week 36	Tezepelumab	26	26 (100.0)	-0.81 (0.86)	-2.2	-1.33	-0.83	-0.17	1.5	0.07 [-0.46, 0.61]
			Placebo	31	28 (90.3)	-0.88 (1.16)	-3.5	-1.33	-0.83	-0.17	1.5	
		Week 38	Tezepelumab	26	26 (100.0)	-0.76 (1.07)	-2.2	-1.67	-0.83	0.00	2.3	0.17 [-0.37, 0.70]
			Placebo	31	28 (90.3)	-0.94 (1.06)	-3.2	-1.33	-1.00	-0.25	1.5	
		Week 40	Tezepelumab	26	26 (100.0)	-0.76 (0.98)	-2.3	-1.17	-0.83	-0.17	1.7	0.04 [-0.49, 0.58]
			Placebo	31	28 (90.3)	-0.81 (1.23)	-3.2	-1.67	-0.67	0.17	1.5	
		Week 42	Tezepelumab	26	26 (100.0)	-0.80 (1.00)	-2.5	-1.17	-0.83	-0.17	2.0	0.17 [-0.36, 0.71]
			Placebo	31	28 (90.3)	-0.98 (1.04)	-2.8	-1.58	-1.00	-0.42	1.5	
		Week 44	Tezepelumab	26	26 (100.0)	-0.79 (0.90)	-2.2	-1.33	-0.83	-0.17	1.5	0.04 [-0.50, 0.57]
			Placebo	31	28 (90.3)	-0.83 (1.12)	-3.3	-1.58	-0.75	0.00	1.2	
		Week 46	Tezepelumab	26	26 (100.0)	-0.81 (0.99)	-2.7	-1.33	-0.75	-0.17	1.7	0.23 [-0.31, 0.77]
			Placebo	31	28 (90.3)	-1.04 (0.99)	-3.2	-1.67	-1.08	-0.33	0.8	
		Week 48	Tezepelumab	26	26 (100.0)	-0.78 (0.93)	-2.5	-1.50	-0.67	-0.33	1.8	0.23 [-0.30, 0.77]
			Placebo	31	28 (90.3)	-1.02 (1.08)	-3.3	-1.58	-0.92	-0.33	0.8	
		Week 50	Tezepelumab	26	26 (100.0)	-0.85 (1.11)	-2.7	-1.67	-0.83	-0.17	1.8	0.19 [-0.35, 0.72]
			Placebo	31	28 (90.3)	-1.07 (1.17)	-3.5	-1.83	-1.00	-0.42	1.5	
		Week 52	Tezepelumab	26	26 (100.0)	-0.79 (1.07)	-2.7	-1.33	-0.75	-0.17	1.8	0.19 [-0.34, 0.73]
			Placebo	31	28 (90.3)	-1.02 (1.23)	-3.5	-2.08	-0.92	-0.25	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	40	40 (100.0)	2.65 (0.88)	0.0	2.17	2.67	3.17	4.8	
			Placebo	34	34 (100.0)	2.74 (0.71)	1.3	2.33	2.75	3.00	4.7	
		Week 2	Tezepelumab	40	40 (100.0)	2.11 (0.92)	0.2	1.50	2.08	2.67	4.2	
			Placebo	34	32 (94.1)	2.33 (0.71)	1.0	1.92	2.33	2.83	4.7	
		Week 4	Tezepelumab	40	40 (100.0)	1.84 (0.90)	0.2	1.25	2.00	2.58	3.3	
			Placebo	34	32 (94.1)	2.15 (0.77)	0.7	1.58	2.33	2.67	3.5	
		Week 6	Tezepelumab	40	40 (100.0)	1.72 (0.95)	0.0	1.00	1.67	2.42	3.7	
			Placebo	34	32 (94.1)	2.17 (0.99)	0.2	1.75	2.25	2.75	5.5	
		Week 8	Tezepelumab	40	40 (100.0)	1.50 (0.98)	0.0	0.75	1.50	2.33	3.3	
			Placebo	34	32 (94.1)	2.12 (0.98)	0.0	1.75	2.17	2.75	4.7	
		Week 10	Tezepelumab	40	40 (100.0)	1.45 (1.04)	0.0	0.67	1.33	2.08	3.7	
			Placebo	34	32 (94.1)	2.08 (0.91)	0.0	1.83	2.17	2.75	4.0	
		Week 12	Tezepelumab	40	40 (100.0)	1.29 (0.96)	0.0	0.50	1.33	2.17	3.0	
			Placebo	34	32 (94.1)	1.89 (0.80)	0.0	1.42	2.00	2.50	2.8	
		Week 14	Tezepelumab	40	40 (100.0)	1.21 (0.96)	0.0	0.50	1.00	1.75	3.7	
			Placebo	34	32 (94.1)	1.77 (0.74)	0.0	1.33	1.83	2.17	3.0	
		Week 16	Tezepelumab	40	40 (100.0)	1.41 (1.08)	0.0	0.50	1.33	2.42	4.3	
			Placebo	34	32 (94.1)	1.92 (1.06)	0.0	1.33	2.00	2.58	4.8	
		Week 18	Tezepelumab	40	40 (100.0)	1.36 (0.92)	0.0	0.67	1.33	1.92	3.3	
			Placebo	34	32 (94.1)	1.88 (0.93)	0.0	1.25	1.92	2.50	3.8	
		Week 20	Tezepelumab	40	40 (100.0)	1.36 (0.98)	0.0	0.50	1.17	2.00	3.5	
			Placebo	34	32 (94.1)	2.01 (0.94)	0.0	1.33	2.17	2.75	3.8	
		Week 22	Tezepelumab	40	40 (100.0)	1.43 (0.92)	0.0	0.75	1.50	2.17	3.3	
			Placebo	34	32 (94.1)	1.94 (1.02)	0.0	1.25	2.00	2.50	3.8	
		Week 24	Tezepelumab	40	40 (100.0)	1.44 (1.01)	0.0	0.50	1.25	2.25	3.5	
			Placebo	34	32 (94.1)	2.09 (0.90)	0.0	1.67	2.17	2.58	3.8	
		Week 26	Tezepelumab	40	40 (100.0)	1.46 (1.02)	0.0	0.67	1.50	2.17	3.7	
			Placebo	34	32 (94.1)	1.94 (0.98)	0.0	1.17	1.83	2.67	4.0	
		Week 28	Tezepelumab	40	40 (100.0)	1.45 (1.07)	0.0	0.42	1.50	2.33	3.5	
			Placebo	34	32 (94.1)	2.07 (1.09)	0.0	1.25	2.17	2.67	4.0	
		Week 30	Tezepelumab	40	40 (100.0)	1.35 (0.97)	0.0	0.67	1.33	2.00	3.7	
			Placebo	34	32 (94.1)	1.90 (0.99)	0.0	1.17	2.00	2.58	3.8	
		Week 32	Tezepelumab	40	40 (100.0)	1.30 (0.98)	0.0	0.33	1.17	2.00	3.7	
			Placebo	34	32 (94.1)	1.92 (0.97)	0.0	1.17	1.92	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High (>= 20.9 ng/ml)	Absolute values	Week 34	Tezepelumab	40	40 (100.0)	1.38 (1.04)	0.0	0.58	1.17	2.25	4.2	
			Placebo	34	32 (94.1)	1.96 (0.94)	0.0	1.33	1.92	2.42	4.5	
		Week 36	Tezepelumab	40	40 (100.0)	1.35 (0.97)	0.0	0.50	1.50	2.08	3.7	
			Placebo	34	32 (94.1)	2.15 (0.95)	0.0	1.50	2.17	2.75	4.5	
		Week 38	Tezepelumab	40	40 (100.0)	1.35 (1.01)	0.0	0.42	1.42	2.17	3.5	
			Placebo	34	32 (94.1)	1.95 (0.98)	0.0	1.25	1.92	2.50	4.5	
		Week 40	Tezepelumab	40	40 (100.0)	1.32 (1.00)	0.0	0.33	1.33	2.17	3.2	
			Placebo	34	32 (94.1)	2.10 (0.87)	0.0	1.58	2.17	2.50	3.8	
		Week 42	Tezepelumab	40	40 (100.0)	1.30 (0.95)	0.0	0.50	1.08	2.17	3.3	
			Placebo	34	32 (94.1)	1.97 (0.83)	0.0	1.42	1.92	2.58	3.8	
		Week 44	Tezepelumab	40	40 (100.0)	1.35 (0.99)	0.0	0.42	1.42	2.33	3.0	
			Placebo	34	32 (94.1)	2.01 (0.84)	0.0	1.25	2.00	2.50	3.8	
		Week 46	Tezepelumab	40	40 (100.0)	1.38 (1.01)	0.0	0.67	1.17	2.25	3.7	
			Placebo	34	32 (94.1)	1.99 (0.82)	0.0	1.67	2.00	2.33	3.8	
		Week 48	Tezepelumab	40	40 (100.0)	1.37 (1.03)	0.0	0.58	1.17	2.25	4.0	
			Placebo	34	32 (94.1)	2.06 (0.84)	0.0	1.67	2.17	2.33	4.2	
		Week 50	Tezepelumab	40	40 (100.0)	1.32 (0.96)	0.0	0.58	1.17	2.25	4.0	
			Placebo	34	32 (94.1)	1.90 (0.73)	0.0	1.50	1.83	2.17	3.8	
		Week 52	Tezepelumab	40	40 (100.0)	1.33 (0.97)	0.0	0.50	1.17	2.25	4.0	
			Placebo	34	32 (94.1)	2.00 (0.76)	0.0	1.50	2.17	2.42	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 2	Tezepelumab	40	40 (100.0)	-0.53 (0.69)	-2.0	-1.08	-0.33	0.00	0.7	-0.23 [-0.69, 0.24]
			Placebo	34	32 (94.1)	-0.38 (0.65)	-2.2	-0.67	-0.33	0.00	1.0	
		Week 4	Tezepelumab	40	40 (100.0)	-0.81 (0.91)	-2.5	-1.33	-0.83	-0.17	2.3	-0.28 [-0.75, 0.18]
			Placebo	34	32 (94.1)	-0.56 (0.82)	-2.7	-1.08	-0.33	0.00	0.8	
		Week 6	Tezepelumab	40	40 (100.0)	-0.92 (1.01)	-2.7	-1.50	-1.00	-0.17	2.3	-0.40 [-0.87, 0.07]
			Placebo	34	32 (94.1)	-0.54 (0.87)	-2.8	-1.08	-0.42	-0.08	1.5	
		Week 8	Tezepelumab	40	40 (100.0)	-1.15 (1.04)	-3.0	-1.83	-1.00	-0.50	2.3	-0.56 [-1.04, -0.09]
			Placebo	34	32 (94.1)	-0.59 (0.92)	-3.2	-1.00	-0.50	0.00	1.0	
		Week 10	Tezepelumab	40	40 (100.0)	-1.19 (1.12)	-3.2	-2.00	-1.33	-0.50	2.3	-0.52 [-0.99, -0.05]
			Placebo	34	32 (94.1)	-0.63 (1.03)	-3.3	-1.17	-0.50	-0.17	2.5	
		Week 12	Tezepelumab	40	40 (100.0)	-1.36 (1.08)	-3.0	-2.17	-1.33	-0.67	2.3	-0.52 [-1.00, -0.05]
			Placebo	34	32 (94.1)	-0.83 (0.93)	-3.3	-1.33	-0.67	-0.25	1.3	
		Week 14	Tezepelumab	40	40 (100.0)	-1.43 (1.10)	-3.7	-2.08	-1.58	-0.75	2.3	-0.48 [-0.95, -0.01]
			Placebo	34	32 (94.1)	-0.95 (0.88)	-3.0	-1.42	-1.00	-0.58	1.2	
		Week 16	Tezepelumab	40	40 (100.0)	-1.23 (1.17)	-3.0	-2.17	-1.33	-0.50	2.3	-0.40 [-0.87, 0.07]
			Placebo	34	32 (94.1)	-0.79 (1.02)	-3.2	-1.25	-0.75	-0.25	2.3	
		Week 18	Tezepelumab	40	40 (100.0)	-1.28 (1.10)	-3.5	-1.92	-1.33	-0.67	2.3	-0.42 [-0.89, 0.05]
			Placebo	34	32 (94.1)	-0.83 (1.05)	-3.2	-1.58	-0.83	-0.17	2.3	
		Week 20	Tezepelumab	40	40 (100.0)	-1.29 (1.07)	-3.2	-2.00	-1.33	-0.67	2.3	-0.55 [-1.02, -0.07]
			Placebo	34	32 (94.1)	-0.70 (1.07)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	40	40 (100.0)	-1.21 (1.13)	-3.0	-2.17	-1.17	-0.67	2.3	-0.40 [-0.87, 0.07]
			Placebo	34	32 (94.1)	-0.78 (1.06)	-3.3	-1.17	-0.83	-0.25	2.3	
		Week 24	Tezepelumab	40	40 (100.0)	-1.20 (1.06)	-3.2	-2.00	-1.33	-0.58	2.3	-0.56 [-1.03, -0.08]
			Placebo	34	32 (94.1)	-0.62 (1.03)	-3.2	-1.33	-0.58	0.00	2.3	
		Week 26	Tezepelumab	40	40 (100.0)	-1.18 (1.12)	-2.8	-2.08	-1.25	-0.33	2.3	-0.37 [-0.84, 0.10]
			Placebo	34	32 (94.1)	-0.77 (1.12)	-2.8	-1.50	-1.08	-0.00	2.3	
		Week 28	Tezepelumab	40	40 (100.0)	-1.20 (1.14)	-3.2	-2.08	-1.25	-0.50	2.3	-0.48 [-0.95, -0.01]
			Placebo	34	32 (94.1)	-0.64 (1.19)	-2.8	-1.67	-0.67	0.08	2.3	
		Week 30	Tezepelumab	40	40 (100.0)	-1.30 (1.10)	-3.5	-2.08	-1.33	-0.67	2.3	-0.43 [-0.90, 0.04]
			Placebo	34	32 (94.1)	-0.82 (1.12)	-2.8	-1.42	-0.83	-0.17	2.3	
		Week 32	Tezepelumab	40	40 (100.0)	-1.35 (1.05)	-3.0	-2.17	-1.50	-0.83	2.3	-0.51 [-0.98, -0.04]
			Placebo	34	32 (94.1)	-0.80 (1.12)	-2.8	-1.50	-1.08	-0.25	2.3	
		Week 34	Tezepelumab	40	40 (100.0)	-1.27 (1.10)	-2.8	-2.17	-1.50	-0.67	2.3	-0.48 [-0.95, -0.01]
			Placebo	34	32 (94.1)	-0.75 (1.03)	-2.8	-1.33	-0.83	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
High (>= 20.9 ng/ml)	Change from baseline	Week 36	Tezepelumab	40	40 (100.0)	-1.30 (1.15)	-3.0	-2.17	-1.50	-0.50	2.3	-0.65 [-1.13, -0.17]
			Placebo	34	32 (94.1)	-0.57 (1.09)	-2.7	-1.25	-0.67	0.17	2.3	
		Week 38	Tezepelumab	40	40 (100.0)	-1.29 (1.09)	-3.0	-2.08	-1.33	-0.58	2.3	-0.48 [-0.95, -0.01]
			Placebo	34	32 (94.1)	-0.77 (1.11)	-2.5	-1.50	-0.83	0.08	2.3	
		Week 40	Tezepelumab	40	40 (100.0)	-1.33 (1.12)	-3.2	-2.33	-1.50	-0.67	2.3	-0.65 [-1.13, -0.18]
			Placebo	34	32 (94.1)	-0.61 (1.09)	-2.3	-1.33	-0.83	0.17	2.3	
		Week 42	Tezepelumab	40	40 (100.0)	-1.35 (1.10)	-3.3	-2.08	-1.50	-0.58	2.3	-0.57 [-1.04, -0.09]
			Placebo	34	32 (94.1)	-0.74 (1.03)	-2.3	-1.33	-1.00	-0.08	2.3	
		Week 44	Tezepelumab	40	40 (100.0)	-1.30 (1.16)	-3.5	-2.17	-1.42	-0.50	2.3	-0.53 [-1.00, -0.05]
			Placebo	34	32 (94.1)	-0.71 (1.08)	-2.3	-1.42	-0.83	0.00	2.3	
		Week 46	Tezepelumab	40	40 (100.0)	-1.27 (1.12)	-3.3	-2.08	-1.33	-0.58	2.3	-0.51 [-0.98, -0.04]
			Placebo	34	32 (94.1)	-0.72 (1.01)	-2.3	-1.25	-0.92	-0.42	2.3	
		Week 48	Tezepelumab	40	40 (100.0)	-1.28 (1.12)	-2.7	-2.17	-1.50	-0.50	2.3	-0.57 [-1.04, -0.10]
			Placebo	34	32 (94.1)	-0.66 (1.05)	-2.5	-1.25	-0.83	0.00	2.3	
		Week 50	Tezepelumab	40	40 (100.0)	-1.33 (1.05)	-2.7	-2.08	-1.50	-0.75	2.3	-0.54 [-1.01, -0.06]
			Placebo	34	32 (94.1)	-0.81 (0.84)	-2.3	-1.25	-0.92	-0.42	2.3	
		Week 52	Tezepelumab	40	40 (100.0)	-1.32 (1.05)	-2.7	-2.00	-1.50	-0.75	2.3	-0.61 [-1.09, -0.14]
			Placebo	34	32 (94.1)	-0.71 (0.88)	-2.3	-1.25	-0.83	-0.25	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.77 (0.87)	0.0	2.33	2.83	3.17	4.8	
			Placebo	60	60 (100.0)	2.68 (0.68)	0.3	2.33	2.67	3.00	4.5	
		Week 2	Tezepelumab	57	54 (94.7)	2.36 (0.91)	0.0	1.67	2.50	3.00	4.2	
			Placebo	60	53 (88.3)	2.23 (0.73)	0.3	1.83	2.33	2.67	4.8	
		Week 4	Tezepelumab	57	54 (94.7)	2.11 (0.89)	0.2	1.67	2.25	2.83	3.5	
			Placebo	60	53 (88.3)	2.07 (0.90)	0.2	1.50	2.33	2.67	4.2	
		Week 6	Tezepelumab	57	54 (94.7)	2.05 (0.93)	0.2	1.50	2.17	2.67	4.0	
			Placebo	60	53 (88.3)	2.01 (1.02)	0.2	1.17	2.17	2.67	4.7	
		Week 8	Tezepelumab	57	54 (94.7)	1.91 (1.05)	0.0	1.33	1.83	2.67	4.8	
			Placebo	60	54 (90.0)	2.01 (1.03)	0.0	1.17	2.08	2.67	4.7	
		Week 10	Tezepelumab	57	54 (94.7)	1.83 (1.02)	0.0	1.17	1.83	2.67	4.3	
			Placebo	60	54 (90.0)	2.00 (1.03)	0.0	1.50	2.08	2.50	5.3	
		Week 12	Tezepelumab	57	54 (94.7)	1.73 (0.97)	0.0	1.00	1.83	2.50	4.3	
			Placebo	60	54 (90.0)	1.84 (0.97)	0.0	1.00	2.00	2.33	4.3	
		Week 14	Tezepelumab	57	54 (94.7)	1.64 (1.02)	0.0	1.00	1.50	2.33	4.3	
			Placebo	60	54 (90.0)	1.76 (0.95)	0.0	1.17	1.83	2.17	5.0	
		Week 16	Tezepelumab	57	54 (94.7)	1.81 (1.07)	0.0	1.17	1.83	2.50	4.3	
			Placebo	60	54 (90.0)	1.89 (1.05)	0.0	1.00	2.00	2.67	5.0	
		Week 18	Tezepelumab	57	55 (96.5)	1.75 (0.99)	0.0	1.00	1.83	2.33	4.3	
			Placebo	60	54 (90.0)	1.78 (1.04)	0.0	1.00	1.83	2.33	5.0	
		Week 20	Tezepelumab	57	55 (96.5)	1.80 (1.05)	0.0	1.17	1.83	2.50	5.0	
			Placebo	60	54 (90.0)	1.89 (1.08)	0.0	1.17	1.83	2.67	5.0	
		Week 22	Tezepelumab	57	55 (96.5)	1.83 (0.92)	0.0	1.17	1.83	2.33	4.3	
			Placebo	60	54 (90.0)	1.84 (1.13)	0.0	1.00	2.00	2.50	5.0	
		Week 24	Tezepelumab	57	55 (96.5)	1.85 (1.00)	0.0	1.00	1.83	2.50	4.3	
			Placebo	60	54 (90.0)	1.93 (1.01)	0.0	1.33	2.00	2.50	4.5	
		Week 26	Tezepelumab	57	56 (98.2)	1.87 (1.03)	0.0	1.25	1.83	2.67	4.3	
			Placebo	60	54 (90.0)	1.84 (1.03)	0.0	1.00	1.75	2.50	4.5	
		Week 28	Tezepelumab	57	57 (100.0)	1.79 (1.04)	0.0	1.17	1.67	2.50	4.3	
			Placebo	60	55 (91.7)	1.85 (1.15)	0.0	1.00	1.83	2.50	4.5	
		Week 30	Tezepelumab	57	57 (100.0)	1.80 (1.02)	0.0	1.00	1.83	2.33	4.3	
			Placebo	60	55 (91.7)	1.81 (1.13)	0.0	0.83	1.83	2.67	4.5	
		Week 32	Tezepelumab	57	57 (100.0)	1.75 (1.02)	0.0	1.00	1.83	2.50	4.3	
			Placebo	60	55 (91.7)	1.77 (1.08)	0.0	1.00	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	57	57 (100.0)	1.81 (1.07)	0.0	1.00	1.83	2.50	4.3	
			Placebo	60	55 (91.7)	1.77 (1.07)	0.0	1.00	1.83	2.33	4.5	
		Week 36	Tezepelumab	57	57 (100.0)	1.74 (1.02)	0.0	1.17	1.67	2.50	4.3	
			Placebo	60	55 (91.7)	1.91 (1.12)	0.0	1.00	1.83	2.50	4.5	
		Week 38	Tezepelumab	57	57 (100.0)	1.81 (1.09)	0.0	1.00	1.83	2.67	4.5	
			Placebo	60	55 (91.7)	1.76 (1.07)	0.0	1.00	1.83	2.50	4.5	
		Week 40	Tezepelumab	57	57 (100.0)	1.76 (1.08)	0.0	1.00	1.83	2.67	4.3	
			Placebo	60	55 (91.7)	1.91 (1.08)	0.0	1.17	2.00	2.50	4.5	
		Week 42	Tezepelumab	57	57 (100.0)	1.73 (1.06)	0.0	1.00	1.67	2.50	4.3	
			Placebo	60	55 (91.7)	1.77 (1.01)	0.0	1.00	1.83	2.50	4.5	
		Week 44	Tezepelumab	57	57 (100.0)	1.74 (1.06)	0.0	0.83	1.67	2.67	4.3	
			Placebo	60	55 (91.7)	1.86 (1.00)	0.0	1.17	1.83	2.50	4.5	
		Week 46	Tezepelumab	57	57 (100.0)	1.77 (1.08)	0.0	1.00	1.83	2.50	4.3	
			Placebo	60	55 (91.7)	1.75 (0.95)	0.0	1.17	1.83	2.33	4.5	
		Week 48	Tezepelumab	57	57 (100.0)	1.75 (1.08)	0.0	1.00	1.83	2.50	4.3	
			Placebo	60	55 (91.7)	1.78 (1.02)	0.0	1.00	2.00	2.33	4.5	
		Week 50	Tezepelumab	57	57 (100.0)	1.73 (1.11)	0.0	1.00	1.67	2.33	4.3	
			Placebo	60	55 (91.7)	1.72 (0.94)	0.0	1.00	1.67	2.17	4.5	
		Week 52	Tezepelumab	57	57 (100.0)	1.74 (1.11)	0.0	1.00	1.67	2.50	4.3	
			Placebo	60	55 (91.7)	1.79 (0.99)	0.0	1.00	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 2	Tezepelumab	57	54 (94.7)	-0.46 (0.69)	-2.8	-0.83	-0.33	0.17	0.7	0.02 [-0.36, 0.40]
			Placebo	60	53 (88.3)	-0.47 (0.67)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	57	54 (94.7)	-0.71 (0.83)	-2.5	-1.17	-0.67	-0.17	2.3	-0.09 [-0.47, 0.29]
			Placebo	60	53 (88.3)	-0.63 (0.89)	-3.0	-1.17	-0.33	0.00	1.2	
		Week 6	Tezepelumab	57	54 (94.7)	-0.77 (0.93)	-2.7	-1.33	-0.83	-0.17	2.3	-0.09 [-0.46, 0.29]
			Placebo	60	53 (88.3)	-0.69 (0.94)	-3.3	-1.17	-0.50	-0.17	1.5	
		Week 8	Tezepelumab	57	54 (94.7)	-0.90 (1.06)	-3.0	-1.50	-0.83	-0.33	2.3	-0.20 [-0.58, 0.18]
			Placebo	60	54 (90.0)	-0.70 (0.96)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	57	54 (94.7)	-0.99 (1.02)	-3.2	-1.50	-1.00	-0.33	2.3	-0.27 [-0.65, 0.11]
			Placebo	60	54 (90.0)	-0.71 (1.05)	-3.3	-1.33	-0.50	-0.17	2.7	
		Week 12	Tezepelumab	57	54 (94.7)	-1.08 (1.01)	-3.0	-1.83	-1.17	-0.67	2.3	-0.21 [-0.59, 0.16]
			Placebo	60	54 (90.0)	-0.88 (0.92)	-3.3	-1.17	-0.75	-0.33	1.3	
		Week 14	Tezepelumab	57	54 (94.7)	-1.18 (1.05)	-3.7	-1.83	-1.17	-0.50	2.3	-0.23 [-0.61, 0.15]
			Placebo	60	54 (90.0)	-0.95 (0.97)	-3.2	-1.33	-1.00	-0.33	2.3	
		Week 16	Tezepelumab	57	54 (94.7)	-1.01 (1.06)	-3.0	-1.83	-1.00	-0.50	2.3	-0.18 [-0.56, 0.20]
			Placebo	60	54 (90.0)	-0.83 (1.01)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 18	Tezepelumab	57	55 (96.5)	-1.05 (1.01)	-3.5	-1.67	-1.00	-0.67	2.3	-0.12 [-0.50, 0.26]
			Placebo	60	54 (90.0)	-0.93 (1.02)	-3.2	-1.50	-0.92	-0.17	2.3	
		Week 20	Tezepelumab	57	55 (96.5)	-1.00 (1.02)	-3.2	-1.67	-0.83	-0.33	2.3	-0.16 [-0.54, 0.21]
			Placebo	60	54 (90.0)	-0.83 (1.07)	-3.2	-1.50	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	57	55 (96.5)	-0.97 (1.05)	-3.0	-1.67	-0.83	-0.50	2.3	-0.09 [-0.47, 0.28]
			Placebo	60	54 (90.0)	-0.87 (1.07)	-3.3	-1.50	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	57	55 (96.5)	-0.95 (0.99)	-3.2	-1.67	-0.83	-0.33	2.3	-0.16 [-0.54, 0.21]
			Placebo	60	54 (90.0)	-0.79 (1.02)	-3.2	-1.50	-0.75	0.00	1.5	
		Week 26	Tezepelumab	57	56 (98.2)	-0.91 (1.04)	-2.8	-1.83	-0.75	-0.17	2.3	-0.04 [-0.41, 0.34]
			Placebo	60	54 (90.0)	-0.87 (1.02)	-2.8	-1.50	-1.00	-0.17	1.5	
		Week 28	Tezepelumab	57	57 (100.0)	-0.99 (1.09)	-3.2	-2.00	-0.83	-0.17	2.3	-0.15 [-0.52, 0.22]
			Placebo	60	55 (91.7)	-0.82 (1.08)	-2.8	-1.67	-0.83	-0.17	1.5	
		Week 30	Tezepelumab	57	57 (100.0)	-0.98 (1.10)	-3.5	-1.83	-0.83	-0.17	2.3	-0.10 [-0.47, 0.27]
			Placebo	60	55 (91.7)	-0.86 (1.11)	-3.2	-1.50	-1.00	-0.17	2.0	
		Week 32	Tezepelumab	57	57 (100.0)	-1.02 (1.01)	-3.0	-1.83	-1.00	-0.50	2.3	-0.12 [-0.49, 0.25]
			Placebo	60	55 (91.7)	-0.90 (1.04)	-3.0	-1.50	-1.00	-0.33	1.5	
		Week 34	Tezepelumab	57	57 (100.0)	-0.96 (1.11)	-2.8	-1.83	-1.00	-0.17	2.3	-0.06 [-0.43, 0.31]
			Placebo	60	55 (91.7)	-0.90 (1.00)	-3.2	-1.50	-1.00	-0.17	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	57	57 (100.0)	-1.03 (1.09)	-3.0	-1.83	-1.17	-0.17	2.3	-0.24 [-0.62, 0.13]
			Placebo	60	55 (91.7)	-0.76 (1.09)	-3.5	-1.33	-0.83	0.00	1.5	
		Week 38	Tezepelumab	57	57 (100.0)	-0.96 (1.12)	-3.0	-2.00	-1.00	-0.17	2.3	-0.04 [-0.41, 0.33]
			Placebo	60	55 (91.7)	-0.91 (1.02)	-3.2	-1.67	-1.00	-0.17	1.5	
		Week 40	Tezepelumab	57	57 (100.0)	-1.01 (1.12)	-3.2	-2.00	-0.83	-0.33	2.3	-0.23 [-0.60, 0.15]
			Placebo	60	55 (91.7)	-0.76 (1.07)	-3.2	-1.33	-0.83	0.00	1.5	
		Week 42	Tezepelumab	57	57 (100.0)	-1.04 (1.12)	-3.3	-1.83	-0.83	-0.50	2.3	-0.14 [-0.51, 0.23]
			Placebo	60	55 (91.7)	-0.90 (0.98)	-2.8	-1.50	-1.00	-0.17	1.5	
		Week 44	Tezepelumab	57	57 (100.0)	-1.03 (1.12)	-3.5	-1.83	-1.00	-0.17	2.3	-0.21 [-0.58, 0.16]
			Placebo	60	55 (91.7)	-0.81 (1.00)	-3.3	-1.50	-0.83	0.00	1.5	
		Week 46	Tezepelumab	57	57 (100.0)	-1.01 (1.11)	-3.3	-2.00	-1.00	-0.17	2.3	-0.08 [-0.45, 0.29]
			Placebo	60	55 (91.7)	-0.92 (0.95)	-3.2	-1.50	-1.00	-0.33	1.3	
		Week 48	Tezepelumab	57	57 (100.0)	-1.02 (1.09)	-2.7	-2.00	-0.83	-0.50	2.3	-0.12 [-0.49, 0.25]
			Placebo	60	55 (91.7)	-0.89 (1.02)	-3.3	-1.50	-0.83	-0.33	1.7	
		Week 50	Tezepelumab	57	57 (100.0)	-1.04 (1.13)	-2.7	-2.00	-1.00	-0.33	2.3	-0.09 [-0.46, 0.28]
			Placebo	60	55 (91.7)	-0.95 (0.91)	-3.5	-1.50	-1.00	-0.33	1.5	
		Week 52	Tezepelumab	57	57 (100.0)	-1.04 (1.13)	-2.7	-2.00	-1.00	-0.33	2.3	-0.14 [-0.52, 0.23]
			Placebo	60	55 (91.7)	-0.88 (0.97)	-3.5	-1.50	-0.83	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.35 (0.33)	2.0	2.17	2.17	2.50	2.8	
			Placebo	5	5 (100.0)	3.10 (1.12)	1.5	3.00	3.17	3.17	4.7	
		Week 2	Tezepelumab	9	9 (100.0)	1.44 (0.91)	0.3	0.83	1.17	2.00	3.0	
			Placebo	5	5 (100.0)	2.97 (1.02)	2.2	2.33	2.50	3.17	4.7	
		Week 4	Tezepelumab	9	9 (100.0)	1.17 (0.90)	0.2	0.50	1.17	1.33	2.7	
			Placebo	5	5 (100.0)	3.00 (0.69)	2.2	2.33	3.50	3.50	3.5	
		Week 6	Tezepelumab	9	9 (100.0)	0.91 (0.91)	0.0	0.50	0.67	1.00	3.0	
			Placebo	5	5 (100.0)	3.07 (1.59)	1.2	2.33	3.00	3.33	5.5	
		Week 8	Tezepelumab	9	9 (100.0)	0.72 (0.87)	0.0	0.17	0.50	0.83	2.7	
			Placebo	5	5 (100.0)	2.60 (1.63)	0.2	2.33	2.67	3.17	4.7	
		Week 10	Tezepelumab	9	9 (100.0)	0.65 (0.95)	0.0	0.00	0.33	0.83	3.0	
			Placebo	5	5 (100.0)	2.77 (1.09)	1.0	2.83	3.00	3.00	4.0	
		Week 12	Tezepelumab	9	9 (100.0)	0.50 (0.88)	0.0	0.00	0.00	0.50	2.7	
			Placebo	5	5 (100.0)	2.10 (1.30)	0.0	1.67	2.83	2.83	3.2	
		Week 14	Tezepelumab	9	9 (100.0)	0.59 (0.77)	0.0	0.00	0.17	0.67	2.2	
			Placebo	5	5 (100.0)	2.10 (1.31)	0.0	1.67	2.67	3.00	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	0.59 (0.82)	0.0	0.00	0.33	0.83	2.5	
			Placebo	5	5 (100.0)	2.73 (1.88)	0.0	1.83	3.17	3.83	4.8	
		Week 18	Tezepelumab	9	9 (100.0)	0.70 (0.79)	0.0	0.00	0.50	1.17	2.0	
			Placebo	5	5 (100.0)	2.87 (1.76)	0.0	2.83	3.00	3.83	4.7	
		Week 20	Tezepelumab	9	9 (100.0)	0.48 (0.43)	0.0	0.00	0.50	0.83	1.2	
			Placebo	5	5 (100.0)	2.87 (0.62)	2.3	2.33	2.83	3.00	3.8	
		Week 22	Tezepelumab	9	9 (100.0)	0.76 (0.77)	0.0	0.00	0.67	1.33	2.2	
			Placebo	5	5 (100.0)	2.83 (0.82)	1.7	2.67	2.67	3.33	3.8	
		Week 24	Tezepelumab	9	9 (100.0)	0.56 (0.61)	0.0	0.00	0.50	0.67	1.8	
			Placebo	5	5 (100.0)	2.67 (1.22)	0.7	2.50	3.00	3.33	3.8	
		Week 26	Tezepelumab	9	9 (100.0)	0.70 (0.77)	0.0	0.00	0.50	1.33	2.2	
			Placebo	5	5 (100.0)	2.80 (1.59)	0.0	3.17	3.33	3.67	3.8	
		Week 28	Tezepelumab	9	9 (100.0)	0.83 (1.08)	0.0	0.00	0.33	1.17	2.7	
			Placebo	5	5 (100.0)	2.57 (1.49)	0.0	2.83	2.83	3.33	3.8	
		Week 30	Tezepelumab	9	9 (100.0)	0.59 (0.62)	0.0	0.00	0.67	1.17	1.5	
			Placebo	5	5 (100.0)	2.83 (0.77)	1.8	2.50	2.67	3.33	3.8	
		Week 32	Tezepelumab	9	9 (100.0)	0.44 (0.57)	0.0	0.00	0.17	0.67	1.7	
			Placebo	5	5 (100.0)	2.80 (0.82)	1.8	2.17	2.83	3.33	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	0.54 (0.73)	0.0	0.00	0.33	0.67	2.2	
			Placebo	5	5 (100.0)	2.40 (1.35)	0.3	2.17	2.33	3.33	3.8	
		Week 36	Tezepelumab	9	9 (100.0)	0.76 (0.83)	0.0	0.00	0.50	1.00	2.2	
			Placebo	5	5 (100.0)	2.93 (0.74)	1.8	2.83	2.83	3.33	3.8	
		Week 38	Tezepelumab	9	9 (100.0)	0.48 (0.79)	0.0	0.00	0.00	0.50	2.0	
			Placebo	5	5 (100.0)	2.97 (0.76)	1.8	2.67	3.17	3.33	3.8	
		Week 40	Tezepelumab	9	9 (100.0)	0.63 (0.87)	0.0	0.00	0.33	0.67	2.3	
			Placebo	5	5 (100.0)	3.03 (1.28)	0.8	3.17	3.33	3.83	4.0	
		Week 42	Tezepelumab	9	9 (100.0)	0.67 (0.84)	0.0	0.00	0.50	0.83	2.3	
			Placebo	5	5 (100.0)	2.80 (0.76)	2.0	2.33	2.50	3.33	3.8	
		Week 44	Tezepelumab	9	9 (100.0)	0.80 (0.88)	0.0	0.00	0.33	1.50	2.3	
			Placebo	5	5 (100.0)	2.80 (1.44)	0.5	2.33	3.33	3.83	4.0	
		Week 46	Tezepelumab	9	9 (100.0)	0.74 (1.00)	0.0	0.00	0.33	0.83	2.8	
			Placebo	5	5 (100.0)	2.83 (0.77)	2.0	2.17	2.83	3.33	3.8	
		Week 48	Tezepelumab	9	9 (100.0)	0.87 (1.04)	0.0	0.00	0.50	1.67	2.8	
			Placebo	5	5 (100.0)	3.00 (0.57)	2.5	2.67	2.67	3.33	3.8	
		Week 50	Tezepelumab	9	9 (100.0)	0.59 (0.72)	0.0	0.00	0.50	0.83	1.8	
			Placebo	5	5 (100.0)	2.43 (1.41)	0.2	2.33	2.50	3.33	3.8	
		Week 52	Tezepelumab	9	9 (100.0)	0.76 (0.74)	0.0	0.00	0.50	1.50	1.8	
			Placebo	5	5 (100.0)	2.53 (1.42)	0.2	2.50	2.83	3.33	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.91 (0.71)	-1.8	-1.33	-0.83	-0.33	0.2	-1.04 [-2.21, 0.13]
			Placebo	5	5 (100.0)	-0.13 (0.81)	-1.0	-0.83	0.00	0.17	1.0	
		Week 4	Tezepelumab	9	9 (100.0)	-1.19 (0.70)	-2.3	-1.50	-1.33	-0.83	-0.2	-1.39 [-2.61, -0.16]
			Placebo	5	5 (100.0)	-0.10 (0.92)	-1.2	-1.00	0.33	0.50	0.8	
		Week 6	Tezepelumab	9	9 (100.0)	-1.44 (0.82)	-2.5	-2.17	-1.50	-1.33	0.2	-1.35 [-2.57, -0.13]
			Placebo	5	5 (100.0)	-0.03 (1.39)	-2.0	-0.83	0.33	0.83	1.5	
		Week 8	Tezepelumab	9	9 (100.0)	-1.63 (0.67)	-2.5	-2.00	-1.83	-1.33	-0.2	-1.11 [-2.30, 0.07]
			Placebo	5	5 (100.0)	-0.50 (1.48)	-3.0	-0.50	0.00	0.17	0.8	
		Week 10	Tezepelumab	9	9 (100.0)	-1.70 (0.77)	-2.5	-2.17	-1.83	-1.67	0.2	-1.12 [-2.30, 0.06]
			Placebo	5	5 (100.0)	-0.33 (1.82)	-2.2	-1.67	-0.33	0.00	2.5	
		Week 12	Tezepelumab	9	9 (100.0)	-1.85 (0.69)	-2.5	-2.17	-2.17	-1.83	-0.2	-0.73 [-1.86, 0.40]
			Placebo	5	5 (100.0)	-1.00 (1.76)	-3.2	-1.83	-1.50	0.17	1.3	
		Week 14	Tezepelumab	9	9 (100.0)	-1.76 (0.52)	-2.3	-2.17	-1.83	-1.50	-0.7	-0.71 [-1.84, 0.42]
			Placebo	5	5 (100.0)	-1.00 (1.69)	-3.2	-1.67	-1.50	0.17	1.2	
		Week 16	Tezepelumab	9	9 (100.0)	-1.76 (0.63)	-2.5	-2.17	-1.83	-1.67	-0.3	-1.08 [-2.26, 0.09]
			Placebo	5	5 (100.0)	-0.37 (2.04)	-3.2	-1.33	0.17	0.17	2.3	
		Week 18	Tezepelumab	9	9 (100.0)	-1.65 (0.69)	-2.5	-2.00	-1.83	-1.67	-0.2	-1.00 [-2.16, 0.16]
			Placebo	5	5 (100.0)	-0.23 (2.25)	-3.2	-1.67	-0.17	1.50	2.3	
		Week 20	Tezepelumab	9	9 (100.0)	-1.87 (0.36)	-2.5	-2.00	-2.00	-1.67	-1.3	-1.76 [-3.06, -0.46]
			Placebo	5	5 (100.0)	-0.23 (1.53)	-1.7	-0.83	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	9	9 (100.0)	-1.59 (0.63)	-2.5	-2.00	-1.67	-1.33	-0.7	-1.29 [-2.50, -0.08]
			Placebo	5	5 (100.0)	-0.27 (1.54)	-1.5	-1.33	-0.50	-0.33	2.3	
		Week 24	Tezepelumab	9	9 (100.0)	-1.80 (0.43)	-2.5	-2.00	-1.67	-1.67	-1.0	-1.24 [-2.44, -0.04]
			Placebo	5	5 (100.0)	-0.43 (1.80)	-2.5	-1.33	-0.67	0.00	2.3	
		Week 26	Tezepelumab	9	9 (100.0)	-1.65 (0.75)	-2.5	-2.17	-1.50	-1.50	0.0	-1.01 [-2.17, 0.16]
			Placebo	5	5 (100.0)	-0.30 (2.07)	-3.2	-1.33	0.17	0.50	2.3	
		Week 28	Tezepelumab	9	9 (100.0)	-1.52 (0.97)	-2.5	-2.17	-2.00	-1.33	0.3	-0.70 [-1.83, 0.43]
			Placebo	5	5 (100.0)	-0.53 (2.00)	-3.2	-1.33	-0.33	-0.17	2.3	
		Week 30	Tezepelumab	9	9 (100.0)	-1.76 (0.49)	-2.5	-2.00	-1.83	-1.50	-0.8	-1.55 [-2.81, -0.29]
			Placebo	5	5 (100.0)	-0.27 (1.51)	-1.3	-1.33	-0.50	-0.50	2.3	
		Week 32	Tezepelumab	9	9 (100.0)	-1.91 (0.41)	-2.5	-2.17	-1.83	-1.83	-1.2	-1.69 [-2.97, -0.40]
			Placebo	5	5 (100.0)	-0.30 (1.55)	-1.3	-1.33	-1.00	-0.17	2.3	
		Week 34	Tezepelumab	9	9 (100.0)	-1.81 (0.53)	-2.5	-2.17	-2.00	-1.67	-0.7	-0.95 [-2.11, 0.21]
			Placebo	5	5 (100.0)	-0.70 (1.89)	-2.8	-1.33	-1.00	-0.67	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.59 (0.78)	-2.5	-2.17	-1.83	-1.33	0.0	-1.33 [-2.54, -0.11]
			Placebo	5	5 (100.0)	-0.17 (1.50)	-1.3	-1.33	-0.33	-0.17	2.3	
		Week 38	Tezepelumab	9	9 (100.0)	-1.87 (0.56)	-2.5	-2.17	-2.00	-1.67	-0.8	-1.77 [-3.07, -0.47]
			Placebo	5	5 (100.0)	-0.13 (1.50)	-1.3	-1.33	-0.33	0.00	2.3	
		Week 40	Tezepelumab	9	9 (100.0)	-1.72 (0.65)	-2.5	-2.17	-2.00	-1.50	-0.5	-1.40 [-2.63, -0.17]
			Placebo	5	5 (100.0)	-0.07 (1.83)	-2.3	-1.33	0.17	0.83	2.3	
		Week 42	Tezepelumab	9	9 (100.0)	-1.69 (0.61)	-2.5	-2.00	-2.00	-1.33	-0.5	-1.38 [-2.61, -0.16]
			Placebo	5	5 (100.0)	-0.30 (1.50)	-1.3	-1.17	-0.67	-0.67	2.3	
		Week 44	Tezepelumab	9	9 (100.0)	-1.56 (0.72)	-2.5	-2.17	-1.67	-1.00	-0.5	-0.99 [-2.16, 0.17]
			Placebo	5	5 (100.0)	-0.30 (1.94)	-2.7	-1.33	-0.67	0.83	2.3	
		Week 46	Tezepelumab	9	9 (100.0)	-1.61 (0.78)	-2.5	-2.17	-2.00	-1.33	0.0	-1.25 [-2.45, -0.05]
			Placebo	5	5 (100.0)	-0.27 (1.50)	-1.3	-1.17	-0.83	-0.33	2.3	
		Week 48	Tezepelumab	9	9 (100.0)	-1.48 (0.88)	-2.5	-2.00	-2.00	-1.17	0.0	-1.28 [-2.48, -0.07]
			Placebo	5	5 (100.0)	-0.10 (1.41)	-1.3	-0.50	-0.50	-0.50	2.3	
		Week 50	Tezepelumab	9	9 (100.0)	-1.76 (0.50)	-2.5	-2.00	-2.00	-1.33	-1.0	-0.92 [-2.07, 0.23]
			Placebo	5	5 (100.0)	-0.67 (1.93)	-3.0	-1.33	-0.67	-0.67	2.3	
		Week 52	Tezepelumab	9	9 (100.0)	-1.59 (0.47)	-2.2	-2.00	-1.67	-1.17	-1.0	-0.87 [-2.01, 0.28]
			Placebo	5	5 (100.0)	-0.57 (1.94)	-3.0	-1.33	-0.67	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	2.56 (0.46)	2.0	2.17	2.50	2.83	3.2	
			Placebo	14	14 (100.0)	2.70 (0.84)	0.3	2.67	3.00	3.17	3.5	
		Week 2	Tezepelumab	9	9 (100.0)	2.15 (0.68)	0.8	1.83	2.33	2.67	3.0	
			Placebo	14	12 (85.7)	2.49 (0.51)	1.5	2.17	2.50	2.83	3.3	
		Week 4	Tezepelumab	9	9 (100.0)	1.61 (0.79)	0.2	1.33	1.67	2.17	2.7	
			Placebo	14	12 (85.7)	2.76 (0.77)	1.8	2.17	2.50	3.42	4.2	
		Week 6	Tezepelumab	9	9 (100.0)	1.33 (0.58)	0.5	0.83	1.50	1.67	2.3	
			Placebo	14	12 (85.7)	2.63 (0.76)	1.2	2.25	2.83	3.00	3.8	
		Week 8	Tezepelumab	9	9 (100.0)	1.22 (0.75)	0.0	0.83	1.50	1.50	2.3	
			Placebo	14	13 (92.9)	2.36 (0.97)	0.2	2.00	2.33	2.83	3.7	
		Week 10	Tezepelumab	9	9 (100.0)	0.96 (0.77)	0.0	0.50	0.83	1.50	2.3	
			Placebo	14	13 (92.9)	2.35 (0.81)	1.0	2.00	2.33	2.83	4.0	
		Week 12	Tezepelumab	9	9 (100.0)	0.91 (0.81)	0.0	0.00	1.00	1.50	2.2	
			Placebo	14	13 (92.9)	2.38 (0.94)	0.0	2.00	2.50	2.67	4.2	
		Week 14	Tezepelumab	9	9 (100.0)	0.91 (0.62)	0.0	0.50	1.33	1.33	1.5	
			Placebo	14	13 (92.9)	1.95 (0.77)	0.0	1.83	2.17	2.33	3.2	
		Week 16	Tezepelumab	9	9 (100.0)	0.87 (0.50)	0.0	0.50	1.00	1.17	1.5	
			Placebo	14	13 (92.9)	2.31 (1.06)	0.0	2.00	2.50	2.67	3.8	
		Week 18	Tezepelumab	9	9 (100.0)	1.13 (0.60)	0.0	1.00	1.17	1.50	2.0	
			Placebo	14	13 (92.9)	2.29 (0.85)	0.0	2.17	2.33	2.67	3.8	
		Week 20	Tezepelumab	9	9 (100.0)	1.15 (0.78)	0.0	0.83	1.00	1.50	2.8	
			Placebo	14	13 (92.9)	2.40 (0.76)	1.0	2.17	2.50	2.67	3.8	
		Week 22	Tezepelumab	9	9 (100.0)	1.26 (0.90)	0.0	1.00	1.33	1.50	2.5	
			Placebo	14	13 (92.9)	2.49 (0.86)	0.8	2.00	2.67	3.00	3.8	
		Week 24	Tezepelumab	9	9 (100.0)	1.11 (0.75)	0.0	0.67	1.00	1.50	2.5	
			Placebo	14	13 (92.9)	2.40 (0.88)	0.7	2.00	2.33	3.00	3.8	
		Week 26	Tezepelumab	9	9 (100.0)	1.31 (0.73)	0.0	0.83	1.33	2.00	2.2	
			Placebo	14	13 (92.9)	2.31 (1.11)	0.0	1.50	2.33	3.17	3.8	
		Week 28	Tezepelumab	9	9 (100.0)	1.54 (0.90)	0.0	1.00	1.50	2.33	2.7	
			Placebo	14	14 (100.0)	2.15 (1.22)	0.0	1.33	2.33	3.00	3.8	
		Week 30	Tezepelumab	9	9 (100.0)	1.22 (0.72)	0.0	0.67	1.33	1.50	2.2	
			Placebo	14	14 (100.0)	2.24 (1.08)	0.0	1.67	2.33	3.00	3.8	
		Week 32	Tezepelumab	9	9 (100.0)	1.17 (0.77)	0.0	0.67	1.00	1.67	2.3	
			Placebo	14	14 (100.0)	2.32 (1.21)	0.0	1.50	2.33	3.00	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	9	9 (100.0)	1.26 (1.05)	0.0	0.67	1.00	2.17	2.7	
			Placebo	14	14 (100.0)	2.15 (1.28)	0.2	1.17	2.25	3.00	4.5	
		Week 36	Tezepelumab	9	9 (100.0)	1.37 (0.79)	0.0	0.83	1.50	2.00	2.5	
			Placebo	14	14 (100.0)	2.37 (1.24)	0.0	1.83	2.17	3.00	4.5	
		Week 38	Tezepelumab	9	9 (100.0)	1.37 (1.01)	0.0	0.50	1.50	2.00	2.7	
			Placebo	14	14 (100.0)	2.26 (1.20)	0.0	1.67	2.33	3.00	4.5	
		Week 40	Tezepelumab	9	9 (100.0)	1.15 (0.90)	0.0	0.67	1.00	2.00	2.3	
			Placebo	14	14 (100.0)	2.26 (1.17)	0.0	1.50	2.33	3.00	4.2	
		Week 42	Tezepelumab	9	9 (100.0)	1.24 (0.75)	0.0	0.83	1.00	1.67	2.3	
			Placebo	14	14 (100.0)	2.26 (1.13)	0.0	2.00	2.25	2.50	4.5	
		Week 44	Tezepelumab	9	9 (100.0)	1.33 (0.85)	0.0	0.83	1.50	1.67	2.7	
			Placebo	14	14 (100.0)	2.12 (1.15)	0.0	1.33	2.25	2.50	4.2	
		Week 46	Tezepelumab	9	9 (100.0)	1.39 (0.92)	0.0	0.83	1.00	1.83	2.8	
			Placebo	14	14 (100.0)	2.19 (0.91)	0.0	1.83	2.17	2.50	3.8	
		Week 48	Tezepelumab	9	9 (100.0)	1.37 (0.88)	0.0	1.00	1.00	2.00	2.8	
			Placebo	14	14 (100.0)	2.25 (1.01)	0.0	2.00	2.17	2.67	3.8	
		Week 50	Tezepelumab	9	9 (100.0)	1.06 (0.69)	0.0	0.67	1.00	1.50	2.3	
			Placebo	14	14 (100.0)	2.01 (1.09)	0.0	1.33	2.17	2.50	3.8	
		Week 52	Tezepelumab	9	9 (100.0)	1.06 (0.69)	0.0	0.67	1.00	1.50	2.3	
			Placebo	14	14 (100.0)	2.10 (1.16)	0.0	1.33	2.17	2.83	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 2	Tezepelumab	9	9 (100.0)	-0.41 (0.39)	-1.3	-0.50	-0.17	-0.17	-0.2	-0.06 [-0.92, 0.81]
			Placebo	14	12 (85.7)	-0.38 (0.64)	-1.5	-0.75	-0.42	0.00	1.0	
		Week 4	Tezepelumab	9	9 (100.0)	-0.94 (0.58)	-1.8	-1.33	-1.00	-0.50	-0.2	-1.20 [-2.14, -0.25]
			Placebo	14	12 (85.7)	-0.10 (0.79)	-1.3	-0.75	0.00	0.42	1.2	
		Week 6	Tezepelumab	9	9 (100.0)	-1.22 (0.63)	-2.2	-1.50	-1.33	-0.67	-0.2	-1.25 [-2.20, -0.30]
			Placebo	14	12 (85.7)	-0.24 (0.89)	-2.0	-0.67	-0.25	0.08	1.5	
		Week 8	Tezepelumab	9	9 (100.0)	-1.33 (0.60)	-2.0	-1.67	-1.33	-1.33	-0.2	-0.85 [-1.74, 0.04]
			Placebo	14	13 (92.9)	-0.53 (1.13)	-3.0	-1.00	-0.50	0.17	1.0	
		Week 10	Tezepelumab	9	9 (100.0)	-1.59 (0.55)	-2.2	-2.00	-1.83	-1.33	-0.7	-1.11 [-2.02, -0.19]
			Placebo	14	13 (92.9)	-0.54 (1.14)	-2.2	-1.17	-0.67	-0.33	2.5	
		Week 12	Tezepelumab	9	9 (100.0)	-1.65 (0.54)	-2.2	-2.00	-1.83	-1.33	-0.7	-1.24 [-2.17, -0.31]
			Placebo	14	13 (92.9)	-0.50 (1.11)	-3.2	-0.83	-0.67	0.00	1.3	
		Week 14	Tezepelumab	9	9 (100.0)	-1.65 (0.46)	-2.2	-2.00	-1.83	-1.50	-0.7	-0.85 [-1.74, 0.04]
			Placebo	14	13 (92.9)	-0.94 (1.01)	-3.2	-1.17	-0.83	-0.67	1.2	
		Week 16	Tezepelumab	9	9 (100.0)	-1.69 (0.45)	-2.2	-2.00	-1.83	-1.67	-0.7	-1.02 [-1.93, -0.11]
			Placebo	14	13 (92.9)	-0.58 (1.35)	-3.2	-1.17	-0.50	0.00	2.3	
		Week 18	Tezepelumab	9	9 (100.0)	-1.43 (0.64)	-2.2	-1.67	-1.67	-1.33	-0.2	-0.82 [-1.71, 0.06]
			Placebo	14	13 (92.9)	-0.59 (1.20)	-3.2	-1.00	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	9	9 (100.0)	-1.41 (0.59)	-2.0	-2.00	-1.50	-1.33	-0.3	-1.00 [-1.91, -0.10]
			Placebo	14	13 (92.9)	-0.49 (1.08)	-2.2	-1.00	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	9	9 (100.0)	-1.30 (0.73)	-2.2	-2.00	-1.50	-0.67	-0.3	-0.91 [-1.81, -0.02]
			Placebo	14	13 (92.9)	-0.40 (1.12)	-2.0	-1.00	-0.50	0.33	2.3	
		Week 24	Tezepelumab	9	9 (100.0)	-1.44 (0.62)	-2.3	-1.67	-1.50	-1.33	-0.3	-0.96 [-1.86, -0.06]
			Placebo	14	13 (92.9)	-0.49 (1.18)	-2.5	-1.17	-0.83	0.17	2.3	
		Week 26	Tezepelumab	9	9 (100.0)	-1.24 (0.72)	-2.3	-1.50	-1.33	-0.67	0.0	-0.58 [-1.45, 0.29]
			Placebo	14	13 (92.9)	-0.58 (1.36)	-3.2	-1.33	-0.83	0.33	2.3	
		Week 28	Tezepelumab	9	9 (100.0)	-1.02 (0.82)	-2.2	-1.50	-0.83	-0.67	0.3	-0.41 [-1.25, 0.44]
			Placebo	14	14 (100.0)	-0.55 (1.32)	-3.2	-1.17	-0.58	0.33	2.3	
		Week 30	Tezepelumab	9	9 (100.0)	-1.33 (0.62)	-2.5	-1.50	-1.33	-0.83	-0.7	-0.90 [-1.78, -0.02]
			Placebo	14	14 (100.0)	-0.46 (1.13)	-2.0	-1.17	-0.75	0.33	2.3	
		Week 32	Tezepelumab	9	9 (100.0)	-1.39 (0.55)	-2.2	-1.83	-1.50	-0.83	-0.7	-0.99 [-1.87, -0.10]
			Placebo	14	14 (100.0)	-0.38 (1.23)	-1.8	-1.33	-0.58	0.33	2.3	
		Week 34	Tezepelumab	9	9 (100.0)	-1.30 (0.83)	-2.5	-2.00	-1.50	-0.67	-0.2	-0.62 [-1.48, 0.24]
			Placebo	14	14 (100.0)	-0.55 (1.40)	-2.8	-1.50	-0.83	0.33	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	9	9 (100.0)	-1.19 (0.78)	-2.3	-1.67	-1.33	-0.67	0.0	-0.78 [-1.65, 0.09]
			Placebo	14	14 (100.0)	-0.33 (1.25)	-1.8	-1.33	-0.67	0.33	2.3	
		Week 38	Tezepelumab	9	9 (100.0)	-1.19 (0.67)	-2.0	-1.67	-1.33	-0.67	-0.2	-0.70 [-1.56, 0.16]
			Placebo	14	14 (100.0)	-0.44 (1.25)	-2.2	-1.17	-0.67	0.17	2.3	
		Week 40	Tezepelumab	9	9 (100.0)	-1.41 (0.72)	-2.5	-2.00	-1.50	-0.67	-0.5	-0.90 [-1.79, -0.02]
			Placebo	14	14 (100.0)	-0.44 (1.24)	-2.3	-1.33	-0.58	0.33	2.3	
		Week 42	Tezepelumab	9	9 (100.0)	-1.31 (0.59)	-2.2	-1.50	-1.50	-0.67	-0.5	-0.89 [-1.77, -0.01]
			Placebo	14	14 (100.0)	-0.44 (1.17)	-2.0	-1.17	-0.75	0.00	2.3	
		Week 44	Tezepelumab	9	9 (100.0)	-1.22 (0.80)	-2.7	-1.50	-1.33	-0.67	-0.2	-0.58 [-1.43, 0.28]
			Placebo	14	14 (100.0)	-0.58 (1.26)	-2.7	-1.17	-0.83	0.00	2.3	
		Week 46	Tezepelumab	9	9 (100.0)	-1.17 (0.75)	-2.2	-1.50	-1.33	-0.67	0.0	-0.72 [-1.59, 0.15]
			Placebo	14	14 (100.0)	-0.51 (0.99)	-1.5	-1.17	-0.83	0.00	2.3	
		Week 48	Tezepelumab	9	9 (100.0)	-1.19 (0.86)	-2.2	-2.00	-1.50	-0.50	0.0	-0.75 [-1.62, 0.12]
			Placebo	14	14 (100.0)	-0.45 (1.04)	-1.7	-1.17	-0.67	-0.33	2.3	
		Week 50	Tezepelumab	9	9 (100.0)	-1.50 (0.67)	-2.5	-2.00	-1.50	-1.17	-0.5	-0.78 [-1.65, 0.09]
			Placebo	14	14 (100.0)	-0.69 (1.21)	-3.0	-1.17	-0.92	-0.33	2.3	
		Week 52	Tezepelumab	9	9 (100.0)	-1.50 (0.67)	-2.5	-2.00	-1.50	-1.17	-0.5	-0.84 [-1.71, 0.04]
			Placebo	14	14 (100.0)	-0.61 (1.25)	-3.0	-1.17	-0.92	-0.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	57	57 (100.0)	2.74 (0.87)	0.0	2.33	2.67	3.17	4.8	
			Placebo	51	51 (100.0)	2.71 (0.70)	1.3	2.33	2.67	3.00	4.7	
		Week 2	Tezepelumab	57	54 (94.7)	2.24 (1.00)	0.0	1.50	2.42	3.00	4.2	
			Placebo	51	46 (90.2)	2.24 (0.83)	0.3	1.83	2.33	2.67	4.8	
		Week 4	Tezepelumab	57	54 (94.7)	2.04 (0.96)	0.2	1.33	2.25	2.83	3.5	
			Placebo	51	46 (90.2)	1.99 (0.89)	0.2	1.33	2.25	2.67	3.7	
		Week 6	Tezepelumab	57	54 (94.7)	1.98 (1.03)	0.0	1.17	2.17	2.67	4.0	
			Placebo	51	46 (90.2)	1.97 (1.14)	0.2	1.17	2.00	2.67	5.5	
		Week 8	Tezepelumab	57	54 (94.7)	1.83 (1.14)	0.0	0.83	1.83	2.67	4.8	
			Placebo	51	46 (90.2)	1.97 (1.11)	0.0	1.00	2.00	2.67	4.7	
		Week 10	Tezepelumab	57	54 (94.7)	1.77 (1.09)	0.0	0.83	1.83	2.67	4.3	
			Placebo	51	46 (90.2)	1.99 (1.10)	0.0	1.33	2.00	2.67	5.3	
		Week 12	Tezepelumab	57	54 (94.7)	1.67 (1.05)	0.0	0.67	1.83	2.50	4.3	
			Placebo	51	46 (90.2)	1.71 (0.96)	0.0	1.00	1.83	2.33	4.3	
		Week 14	Tezepelumab	57	54 (94.7)	1.58 (1.08)	0.0	0.67	1.58	2.33	4.3	
			Placebo	51	46 (90.2)	1.75 (1.03)	0.0	1.00	1.75	2.17	5.0	
		Week 16	Tezepelumab	57	54 (94.7)	1.76 (1.14)	0.0	0.67	1.83	2.50	4.3	
			Placebo	51	46 (90.2)	1.86 (1.16)	0.0	0.83	1.83	2.67	5.0	
		Week 18	Tezepelumab	57	55 (96.5)	1.68 (1.06)	0.0	0.67	1.83	2.33	4.3	
			Placebo	51	46 (90.2)	1.75 (1.18)	0.0	0.83	1.75	2.33	5.0	
		Week 20	Tezepelumab	57	55 (96.5)	1.69 (1.12)	0.0	0.83	1.83	2.50	5.0	
			Placebo	51	46 (90.2)	1.85 (1.13)	0.0	0.83	1.83	2.67	5.0	
		Week 22	Tezepelumab	57	55 (96.5)	1.75 (0.97)	0.0	0.83	1.83	2.33	4.3	
			Placebo	51	46 (90.2)	1.77 (1.16)	0.0	0.83	1.92	2.33	5.0	
		Week 24	Tezepelumab	57	55 (96.5)	1.76 (1.07)	0.0	1.00	1.83	2.50	4.3	
			Placebo	51	46 (90.2)	1.87 (1.06)	0.0	1.00	2.00	2.50	4.5	
		Week 26	Tezepelumab	57	56 (98.2)	1.77 (1.11)	0.0	1.00	1.83	2.67	4.3	
			Placebo	51	46 (90.2)	1.81 (1.09)	0.0	1.00	1.67	2.67	4.5	
		Week 28	Tezepelumab	57	57 (100.0)	1.68 (1.12)	0.0	0.83	1.67	2.50	4.3	
			Placebo	51	46 (90.2)	1.83 (1.18)	0.0	1.00	1.83	2.67	4.5	
		Week 30	Tezepelumab	57	57 (100.0)	1.70 (1.09)	0.0	0.83	1.67	2.33	4.3	
			Placebo	51	46 (90.2)	1.79 (1.15)	0.0	0.83	1.83	2.67	4.5	
		Week 32	Tezepelumab	57	57 (100.0)	1.64 (1.10)	0.0	0.67	1.83	2.50	4.3	
			Placebo	51	46 (90.2)	1.72 (1.03)	0.0	1.00	1.83	2.33	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	57	57 (100.0)	1.70 (1.12)	0.0	0.83	1.83	2.50	4.3	
			Placebo	51	46 (90.2)	1.72 (1.02)	0.0	1.00	1.83	2.33	4.5	
		Week 36	Tezepelumab	57	57 (100.0)	1.65 (1.09)	0.0	1.00	1.67	2.50	4.3	
			Placebo	51	46 (90.2)	1.88 (1.08)	0.0	1.00	1.83	2.67	4.5	
		Week 38	Tezepelumab	57	57 (100.0)	1.67 (1.17)	0.0	0.83	1.67	2.50	4.5	
			Placebo	51	46 (90.2)	1.74 (1.04)	0.0	1.00	1.83	2.33	4.5	
		Week 40	Tezepelumab	57	57 (100.0)	1.68 (1.13)	0.0	0.67	1.83	2.67	4.3	
			Placebo	51	46 (90.2)	1.92 (1.12)	0.0	1.17	2.00	2.50	4.5	
		Week 42	Tezepelumab	57	57 (100.0)	1.64 (1.13)	0.0	0.83	1.67	2.50	4.3	
			Placebo	51	46 (90.2)	1.73 (0.97)	0.0	1.00	1.83	2.50	4.5	
		Week 44	Tezepelumab	57	57 (100.0)	1.66 (1.11)	0.0	0.67	1.67	2.67	4.3	
			Placebo	51	46 (90.2)	1.88 (1.04)	0.0	1.17	1.83	2.67	4.5	
		Week 46	Tezepelumab	57	57 (100.0)	1.66 (1.15)	0.0	0.67	1.83	2.50	4.3	
			Placebo	51	46 (90.2)	1.73 (0.98)	0.0	1.00	1.83	2.33	4.5	
		Week 48	Tezepelumab	57	57 (100.0)	1.67 (1.14)	0.0	0.67	1.67	2.50	4.3	
			Placebo	51	46 (90.2)	1.77 (1.04)	0.0	1.00	2.00	2.33	4.5	
		Week 50	Tezepelumab	57	57 (100.0)	1.65 (1.17)	0.0	0.83	1.67	2.33	4.3	
			Placebo	51	46 (90.2)	1.70 (0.96)	0.0	1.00	1.67	2.33	4.5	
		Week 52	Tezepelumab	57	57 (100.0)	1.69 (1.15)	0.0	1.00	1.67	2.50	4.3	
			Placebo	51	46 (90.2)	1.78 (1.00)	0.0	1.00	1.83	2.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 2	Tezepelumab	57	54 (94.7)	-0.54 (0.75)	-2.8	-1.00	-0.42	0.17	0.7	-0.11 [-0.50, 0.28]
			Placebo	51	46 (90.2)	-0.46 (0.70)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	57	54 (94.7)	-0.75 (0.86)	-2.5	-1.17	-0.75	-0.17	2.3	-0.04 [-0.43, 0.36]
			Placebo	51	46 (90.2)	-0.71 (0.89)	-3.0	-1.33	-0.67	0.00	0.8	
		Week 6	Tezepelumab	57	54 (94.7)	-0.81 (0.97)	-2.7	-1.33	-0.83	-0.17	2.3	-0.07 [-0.46, 0.32]
			Placebo	51	46 (90.2)	-0.74 (0.99)	-3.3	-1.33	-0.58	0.00	1.5	
		Week 8	Tezepelumab	57	54 (94.7)	-0.95 (1.09)	-3.0	-1.67	-0.92	-0.33	2.3	-0.21 [-0.61, 0.18]
			Placebo	51	46 (90.2)	-0.73 (0.97)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	57	54 (94.7)	-1.01 (1.06)	-3.2	-1.67	-1.08	-0.17	2.3	-0.27 [-0.66, 0.13]
			Placebo	51	46 (90.2)	-0.72 (1.11)	-3.3	-1.33	-0.50	-0.17	2.7	
		Week 12	Tezepelumab	57	54 (94.7)	-1.12 (1.04)	-3.0	-2.00	-1.17	-0.50	2.3	-0.12 [-0.51, 0.27]
			Placebo	51	46 (90.2)	-1.00 (0.94)	-3.3	-1.67	-0.83	-0.33	1.3	
		Week 14	Tezepelumab	57	54 (94.7)	-1.20 (1.06)	-3.7	-2.00	-1.17	-0.50	2.3	-0.23 [-0.62, 0.17]
			Placebo	51	46 (90.2)	-0.96 (1.04)	-3.2	-1.50	-1.08	-0.33	2.3	
		Week 16	Tezepelumab	57	54 (94.7)	-1.02 (1.08)	-3.0	-2.00	-1.00	-0.33	2.3	-0.17 [-0.56, 0.23]
			Placebo	51	46 (90.2)	-0.85 (1.04)	-3.2	-1.33	-0.83	-0.17	2.3	
		Week 18	Tezepelumab	57	55 (96.5)	-1.09 (1.03)	-3.5	-1.83	-1.00	-0.67	2.3	-0.13 [-0.52, 0.27]
			Placebo	51	46 (90.2)	-0.95 (1.15)	-3.2	-1.83	-1.00	0.00	2.3	
		Week 20	Tezepelumab	57	55 (96.5)	-1.07 (1.05)	-3.2	-2.00	-1.00	-0.50	2.3	-0.20 [-0.59, 0.19]
			Placebo	51	46 (90.2)	-0.86 (1.12)	-3.2	-1.67	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	57	55 (96.5)	-1.02 (1.06)	-3.0	-1.83	-1.00	-0.50	2.3	-0.07 [-0.47, 0.32]
			Placebo	51	46 (90.2)	-0.94 (1.10)	-3.3	-1.50	-0.92	-0.33	2.3	
		Week 24	Tezepelumab	57	55 (96.5)	-1.01 (1.02)	-3.2	-1.83	-1.00	-0.33	2.3	-0.17 [-0.56, 0.22]
			Placebo	51	46 (90.2)	-0.83 (1.07)	-3.2	-1.50	-0.67	0.00	1.5	
		Week 26	Tezepelumab	57	56 (98.2)	-0.98 (1.07)	-2.8	-2.00	-0.92	-0.17	2.3	-0.08 [-0.47, 0.31]
			Placebo	51	46 (90.2)	-0.89 (1.06)	-2.8	-1.83	-1.00	-0.17	1.5	
		Week 28	Tezepelumab	57	57 (100.0)	-1.06 (1.13)	-3.2	-2.00	-1.00	-0.17	2.3	-0.17 [-0.56, 0.22]
			Placebo	51	46 (90.2)	-0.88 (1.11)	-2.8	-1.67	-1.00	-0.17	1.5	
		Week 30	Tezepelumab	57	57 (100.0)	-1.04 (1.13)	-3.5	-2.00	-1.00	-0.17	2.3	-0.11 [-0.50, 0.28]
			Placebo	51	46 (90.2)	-0.92 (1.14)	-3.2	-1.50	-1.08	-0.17	2.0	
		Week 32	Tezepelumab	57	57 (100.0)	-1.10 (1.05)	-3.0	-2.00	-1.00	-0.50	2.3	-0.11 [-0.50, 0.28]
			Placebo	51	46 (90.2)	-0.99 (1.01)	-3.0	-1.50	-1.17	-0.33	1.5	
		Week 34	Tezepelumab	57	57 (100.0)	-1.04 (1.13)	-2.8	-2.00	-1.17	-0.33	2.3	-0.05 [-0.44, 0.34]
			Placebo	51	46 (90.2)	-0.99 (0.96)	-3.2	-1.50	-1.00	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	57	57 (100.0)	-1.09 (1.11)	-3.0	-2.00	-1.17	-0.17	2.3	-0.24 [-0.63, 0.15]
			Placebo	51	46 (90.2)	-0.83 (1.08)	-3.5	-1.33	-0.83	-0.17	1.5	
		Week 38	Tezepelumab	57	57 (100.0)	-1.07 (1.16)	-3.0	-2.00	-1.17	-0.17	2.3	-0.09 [-0.48, 0.30]
			Placebo	51	46 (90.2)	-0.97 (1.00)	-3.2	-1.67	-0.92	-0.50	1.5	
		Week 40	Tezepelumab	57	57 (100.0)	-1.06 (1.14)	-3.2	-2.00	-1.00	-0.33	2.3	-0.24 [-0.63, 0.15]
			Placebo	51	46 (90.2)	-0.78 (1.12)	-3.2	-1.33	-0.75	0.00	1.5	
		Week 42	Tezepelumab	57	57 (100.0)	-1.10 (1.15)	-3.3	-2.00	-1.17	-0.50	2.3	-0.12 [-0.51, 0.27]
			Placebo	51	46 (90.2)	-0.97 (0.97)	-2.8	-1.50	-1.17	-0.17	1.3	
		Week 44	Tezepelumab	57	57 (100.0)	-1.08 (1.13)	-3.5	-2.00	-1.00	-0.33	2.3	-0.24 [-0.63, 0.15]
			Placebo	51	46 (90.2)	-0.82 (1.04)	-3.3	-1.50	-0.83	0.00	1.5	
		Week 46	Tezepelumab	57	57 (100.0)	-1.08 (1.13)	-3.3	-2.00	-1.00	-0.17	2.3	-0.09 [-0.48, 0.30]
			Placebo	51	46 (90.2)	-0.98 (0.99)	-3.2	-1.67	-1.00	-0.50	1.3	
		Week 48	Tezepelumab	57	57 (100.0)	-1.07 (1.11)	-2.7	-2.00	-1.00	-0.50	2.3	-0.12 [-0.51, 0.27]
			Placebo	51	46 (90.2)	-0.94 (1.06)	-3.3	-1.50	-0.83	-0.33	1.7	
		Week 50	Tezepelumab	57	57 (100.0)	-1.08 (1.14)	-2.7	-2.00	-1.17	-0.33	2.3	-0.08 [-0.47, 0.31]
			Placebo	51	46 (90.2)	-1.00 (0.94)	-3.5	-1.67	-1.00	-0.50	1.5	
		Week 52	Tezepelumab	57	57 (100.0)	-1.05 (1.13)	-2.7	-2.00	-1.00	-0.33	2.3	-0.11 [-0.50, 0.28]
			Placebo	51	46 (90.2)	-0.93 (1.00)	-3.5	-1.67	-0.83	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	51	51 (100.0)	2.79 (0.90)	0.0	2.33	2.83	3.33	4.8	
			Placebo	49	49 (100.0)	2.66 (0.65)	1.3	2.33	2.50	3.00	4.5	
		Week 2	Tezepelumab	51	48 (94.1)	2.36 (0.95)	0.0	1.67	2.50	3.00	4.2	
			Placebo	49	44 (89.8)	2.19 (0.76)	0.3	1.75	2.33	2.58	4.8	
		Week 4	Tezepelumab	51	48 (94.1)	2.17 (0.90)	0.2	1.67	2.33	2.83	3.5	
			Placebo	49	44 (89.8)	1.95 (0.88)	0.2	1.25	2.25	2.67	3.7	
		Week 6	Tezepelumab	51	48 (94.1)	2.11 (0.94)	0.2	1.50	2.17	2.67	4.0	
			Placebo	49	44 (89.8)	1.88 (1.03)	0.2	1.08	2.00	2.50	4.7	
		Week 8	Tezepelumab	51	48 (94.1)	1.98 (1.07)	0.0	1.33	1.92	2.67	4.8	
			Placebo	49	44 (89.8)	1.90 (1.05)	0.0	0.92	2.00	2.58	4.7	
		Week 10	Tezepelumab	51	48 (94.1)	1.91 (1.02)	0.0	1.25	1.92	2.67	4.3	
			Placebo	49	44 (89.8)	1.95 (1.11)	0.0	1.17	2.00	2.58	5.3	
		Week 12	Tezepelumab	51	48 (94.1)	1.80 (0.98)	0.0	1.08	2.00	2.50	4.3	
			Placebo	49	44 (89.8)	1.69 (0.97)	0.0	1.00	1.83	2.25	4.3	
		Week 14	Tezepelumab	51	48 (94.1)	1.72 (1.04)	0.0	1.00	1.75	2.33	4.3	
			Placebo	49	44 (89.8)	1.72 (1.03)	0.0	1.00	1.75	2.17	5.0	
		Week 16	Tezepelumab	51	48 (94.1)	1.92 (1.07)	0.0	1.33	1.83	2.50	4.3	
			Placebo	49	44 (89.8)	1.79 (1.10)	0.0	0.75	1.83	2.50	5.0	
		Week 18	Tezepelumab	51	49 (96.1)	1.83 (1.00)	0.0	1.00	1.83	2.50	4.3	
			Placebo	49	44 (89.8)	1.66 (1.10)	0.0	0.75	1.67	2.33	5.0	
		Week 20	Tezepelumab	51	49 (96.1)	1.86 (1.06)	0.0	1.17	1.83	2.50	5.0	
			Placebo	49	44 (89.8)	1.81 (1.14)	0.0	0.83	1.83	2.67	5.0	
		Week 22	Tezepelumab	51	49 (96.1)	1.88 (0.91)	0.0	1.50	2.00	2.33	4.3	
			Placebo	49	44 (89.8)	1.73 (1.16)	0.0	0.75	1.92	2.33	5.0	
		Week 24	Tezepelumab	51	49 (96.1)	1.92 (1.00)	0.0	1.17	2.00	2.67	4.3	
			Placebo	49	44 (89.8)	1.83 (1.06)	0.0	0.92	1.92	2.50	4.5	
		Week 26	Tezepelumab	51	50 (98.0)	1.94 (1.03)	0.0	1.33	1.92	2.67	4.3	
			Placebo	49	44 (89.8)	1.73 (1.05)	0.0	1.00	1.58	2.33	4.5	
		Week 28	Tezepelumab	51	51 (100.0)	1.84 (1.06)	0.0	1.33	1.83	2.50	4.3	
			Placebo	49	44 (89.8)	1.77 (1.17)	0.0	0.92	1.67	2.50	4.5	
		Week 30	Tezepelumab	51	51 (100.0)	1.86 (1.03)	0.0	1.17	1.83	2.50	4.3	
			Placebo	49	44 (89.8)	1.73 (1.14)	0.0	0.75	1.83	2.58	4.5	
		Week 32	Tezepelumab	51	51 (100.0)	1.81 (1.03)	0.0	1.17	1.83	2.50	4.3	
			Placebo	49	44 (89.8)	1.67 (1.02)	0.0	0.92	1.67	2.25	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Absolute values	Week 34	Tezepelumab	51	51 (100.0)	1.86 (1.07)	0.0	1.00	1.83	2.50	4.3	
			Placebo	49	44 (89.8)	1.67 (1.01)	0.0	0.92	1.75	2.25	4.5	
		Week 36	Tezepelumab	51	51 (100.0)	1.80 (1.03)	0.0	1.17	1.83	2.67	4.3	
			Placebo	49	44 (89.8)	1.82 (1.07)	0.0	1.00	1.83	2.50	4.5	
		Week 38	Tezepelumab	51	51 (100.0)	1.84 (1.11)	0.0	1.00	1.83	2.67	4.5	
			Placebo	49	44 (89.8)	1.67 (1.01)	0.0	1.00	1.75	2.17	4.5	
		Week 40	Tezepelumab	51	51 (100.0)	1.83 (1.09)	0.0	1.00	2.00	2.67	4.3	
			Placebo	49	44 (89.8)	1.84 (1.08)	0.0	1.17	1.92	2.50	4.5	
		Week 42	Tezepelumab	51	51 (100.0)	1.79 (1.08)	0.0	1.00	1.67	2.67	4.3	
			Placebo	49	44 (89.8)	1.68 (0.95)	0.0	1.00	1.75	2.33	4.5	
		Week 44	Tezepelumab	51	51 (100.0)	1.80 (1.06)	0.0	0.83	2.00	2.67	4.3	
			Placebo	49	44 (89.8)	1.80 (0.99)	0.0	1.08	1.83	2.50	4.5	
		Week 46	Tezepelumab	51	51 (100.0)	1.82 (1.09)	0.0	0.83	1.83	2.67	4.3	
			Placebo	49	44 (89.8)	1.67 (0.96)	0.0	1.00	1.75	2.17	4.5	
		Week 48	Tezepelumab	51	51 (100.0)	1.82 (1.10)	0.0	1.00	2.00	2.67	4.3	
			Placebo	49	44 (89.8)	1.71 (1.03)	0.0	1.00	1.92	2.25	4.5	
		Week 50	Tezepelumab	51	51 (100.0)	1.80 (1.12)	0.0	1.00	1.67	2.67	4.3	
			Placebo	49	44 (89.8)	1.65 (0.94)	0.0	1.00	1.67	2.17	4.5	
		Week 52	Tezepelumab	51	51 (100.0)	1.81 (1.12)	0.0	1.00	1.67	2.50	4.3	
			Placebo	49	44 (89.8)	1.72 (0.99)	0.0	1.00	1.75	2.42	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 2	Tezepelumab	51	48 (94.1)	-0.48 (0.73)	-2.8	-1.00	-0.33	0.17	0.7	-0.02 [-0.43, 0.39]
			Placebo	49	44 (89.8)	-0.47 (0.71)	-2.8	-0.83	-0.33	0.00	1.0	
		Week 4	Tezepelumab	51	48 (94.1)	-0.67 (0.86)	-2.5	-1.17	-0.67	-0.17	2.3	0.03 [-0.38, 0.44]
			Placebo	49	44 (89.8)	-0.70 (0.90)	-3.0	-1.42	-0.50	0.00	0.8	
		Week 6	Tezepelumab	51	48 (94.1)	-0.73 (0.95)	-2.7	-1.25	-0.75	-0.08	2.3	0.05 [-0.36, 0.46]
			Placebo	49	44 (89.8)	-0.77 (0.98)	-3.3	-1.42	-0.58	0.00	1.5	
		Week 8	Tezepelumab	51	48 (94.1)	-0.86 (1.09)	-3.0	-1.50	-0.83	-0.33	2.3	-0.11 [-0.52, 0.30]
			Placebo	49	44 (89.8)	-0.75 (0.98)	-3.2	-1.17	-0.67	0.00	1.0	
		Week 10	Tezepelumab	51	48 (94.1)	-0.93 (1.05)	-3.2	-1.42	-1.00	-0.17	2.3	-0.21 [-0.62, 0.20]
			Placebo	49	44 (89.8)	-0.70 (1.13)	-3.3	-1.33	-0.50	-0.08	2.7	
		Week 12	Tezepelumab	51	48 (94.1)	-1.04 (1.05)	-3.0	-1.58	-1.08	-0.50	2.3	-0.07 [-0.48, 0.34]
			Placebo	49	44 (89.8)	-0.97 (0.95)	-3.3	-1.50	-0.83	-0.33	1.3	
		Week 14	Tezepelumab	51	48 (94.1)	-1.12 (1.08)	-3.7	-1.83	-1.17	-0.42	2.3	-0.18 [-0.59, 0.23]
			Placebo	49	44 (89.8)	-0.93 (1.05)	-3.2	-1.42	-1.00	-0.33	2.3	
		Week 16	Tezepelumab	51	48 (94.1)	-0.92 (1.07)	-3.0	-1.33	-1.00	-0.33	2.3	-0.06 [-0.47, 0.35]
			Placebo	49	44 (89.8)	-0.86 (1.05)	-3.2	-1.42	-0.83	-0.17	2.3	
		Week 18	Tezepelumab	51	49 (96.1)	-0.99 (1.04)	-3.5	-1.50	-0.83	-0.50	2.3	-0.00 [-0.41, 0.41]
			Placebo	49	44 (89.8)	-0.99 (1.11)	-3.2	-1.83	-1.00	-0.08	2.3	
		Week 20	Tezepelumab	51	49 (96.1)	-0.96 (1.05)	-3.2	-1.67	-0.83	-0.33	2.3	-0.11 [-0.52, 0.30]
			Placebo	49	44 (89.8)	-0.84 (1.14)	-3.2	-1.58	-0.75	-0.17	2.3	
		Week 22	Tezepelumab	51	49 (96.1)	-0.94 (1.08)	-3.0	-1.50	-0.83	-0.50	2.3	-0.02 [-0.43, 0.39]
			Placebo	49	44 (89.8)	-0.92 (1.12)	-3.3	-1.67	-0.83	-0.33	2.3	
		Week 24	Tezepelumab	51	49 (96.1)	-0.90 (1.01)	-3.2	-1.67	-0.67	-0.33	2.3	-0.07 [-0.48, 0.34]
			Placebo	49	44 (89.8)	-0.83 (1.09)	-3.2	-1.50	-0.67	0.00	1.5	
		Week 26	Tezepelumab	51	50 (98.0)	-0.85 (1.06)	-2.8	-1.83	-0.67	0.00	2.3	0.06 [-0.35, 0.46]
			Placebo	49	44 (89.8)	-0.92 (1.06)	-2.8	-1.83	-1.00	-0.25	1.5	
		Week 28	Tezepelumab	51	51 (100.0)	-0.94 (1.13)	-3.2	-2.00	-0.83	0.00	2.3	-0.06 [-0.46, 0.35]
			Placebo	49	44 (89.8)	-0.88 (1.13)	-2.8	-1.75	-1.00	-0.17	1.5	
		Week 30	Tezepelumab	51	51 (100.0)	-0.93 (1.13)	-3.5	-1.83	-0.83	-0.17	2.3	-0.01 [-0.41, 0.40]
			Placebo	49	44 (89.8)	-0.92 (1.16)	-3.2	-1.67	-1.08	-0.17	2.0	
		Week 32	Tezepelumab	51	51 (100.0)	-0.98 (1.04)	-3.0	-1.83	-1.00	-0.33	2.3	0.00 [-0.40, 0.40]
			Placebo	49	44 (89.8)	-0.98 (1.04)	-3.0	-1.67	-1.17	-0.33	1.5	
		Week 34	Tezepelumab	51	51 (100.0)	-0.93 (1.14)	-2.8	-1.83	-1.00	-0.17	2.3	0.05 [-0.36, 0.45]
			Placebo	49	44 (89.8)	-0.98 (0.98)	-3.2	-1.50	-0.92	-0.33	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Yes	Change from baseline	Week 36	Tezepelumab	51	51 (100.0)	-0.98 (1.12)	-3.0	-1.83	-1.00	-0.17	2.3	-0.14 [-0.54, 0.26]
			Placebo	49	44 (89.8)	-0.83 (1.10)	-3.5	-1.33	-0.83	-0.08	1.5	
		Week 38	Tezepelumab	51	51 (100.0)	-0.95 (1.17)	-3.0	-2.00	-1.00	0.00	2.3	0.03 [-0.37, 0.43]
			Placebo	49	44 (89.8)	-0.98 (1.01)	-3.2	-1.67	-0.92	-0.50	1.5	
		Week 40	Tezepelumab	51	51 (100.0)	-0.96 (1.15)	-3.2	-2.00	-0.83	-0.17	2.3	-0.14 [-0.54, 0.27]
			Placebo	49	44 (89.8)	-0.81 (1.12)	-3.2	-1.50	-0.75	-0.08	1.5	
		Week 42	Tezepelumab	51	51 (100.0)	-1.00 (1.16)	-3.3	-1.83	-0.83	-0.17	2.3	-0.02 [-0.43, 0.38]
			Placebo	49	44 (89.8)	-0.97 (0.99)	-2.8	-1.58	-1.17	-0.17	1.3	
		Week 44	Tezepelumab	51	51 (100.0)	-0.98 (1.14)	-3.5	-1.83	-0.83	-0.17	2.3	-0.12 [-0.53, 0.28]
			Placebo	49	44 (89.8)	-0.85 (1.03)	-3.3	-1.50	-0.83	-0.08	1.5	
		Week 46	Tezepelumab	51	51 (100.0)	-0.97 (1.14)	-3.3	-2.00	-0.83	-0.17	2.3	0.01 [-0.39, 0.42]
			Placebo	49	44 (89.8)	-0.98 (1.01)	-3.2	-1.67	-1.00	-0.58	1.3	
		Week 48	Tezepelumab	51	51 (100.0)	-0.96 (1.12)	-2.7	-1.83	-0.83	-0.33	2.3	-0.02 [-0.43, 0.38]
			Placebo	49	44 (89.8)	-0.94 (1.08)	-3.3	-1.50	-0.83	-0.25	1.7	
		Week 50	Tezepelumab	51	51 (100.0)	-0.98 (1.15)	-2.7	-1.83	-1.00	-0.17	2.3	0.02 [-0.38, 0.42]
			Placebo	49	44 (89.8)	-1.00 (0.96)	-3.5	-1.67	-1.00	-0.50	1.5	
		Week 52	Tezepelumab	51	51 (100.0)	-0.97 (1.15)	-2.7	-1.83	-1.00	-0.17	2.3	-0.04 [-0.45, 0.36]
			Placebo	49	44 (89.8)	-0.93 (1.02)	-3.5	-1.67	-0.83	-0.25	1.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	15	15 (100.0)	2.47 (0.41)	2.0	2.17	2.50	2.83	3.2	
			Placebo	16	16 (100.0)	2.85 (0.92)	0.3	2.67	3.00	3.17	4.7	
		Week 2	Tezepelumab	15	15 (100.0)	1.80 (0.89)	0.3	0.83	1.83	2.67	3.0	
			Placebo	16	14 (87.5)	2.63 (0.75)	1.5	2.17	2.50	2.83	4.7	
		Week 4	Tezepelumab	15	15 (100.0)	1.36 (0.85)	0.2	0.50	1.33	2.17	2.7	
			Placebo	16	14 (87.5)	2.77 (0.76)	1.8	2.17	2.50	3.50	4.2	
		Week 6	Tezepelumab	15	15 (100.0)	1.14 (0.83)	0.0	0.50	1.00	1.67	3.0	
			Placebo	16	14 (87.5)	2.81 (1.05)	1.2	2.33	2.83	3.00	5.5	
		Week 8	Tezepelumab	15	15 (100.0)	1.00 (0.88)	0.0	0.17	0.83	1.50	2.7	
			Placebo	16	15 (93.8)	2.53 (1.07)	0.2	2.00	2.50	3.17	4.7	
		Week 10	Tezepelumab	15	15 (100.0)	0.87 (0.91)	0.0	0.00	0.67	1.50	3.0	
			Placebo	16	15 (93.8)	2.42 (0.78)	1.0	2.00	2.50	3.00	4.0	
		Week 12	Tezepelumab	15	15 (100.0)	0.78 (0.89)	0.0	0.00	0.50	1.50	2.7	
			Placebo	16	15 (93.8)	2.37 (0.90)	0.0	2.00	2.50	2.83	4.2	
		Week 14	Tezepelumab	15	15 (100.0)	0.76 (0.72)	0.0	0.00	0.67	1.33	2.2	
			Placebo	16	15 (93.8)	2.00 (0.77)	0.0	1.67	2.17	2.50	3.2	
		Week 16	Tezepelumab	15	15 (100.0)	0.72 (0.73)	0.0	0.00	0.50	1.17	2.5	
			Placebo	16	15 (93.8)	2.44 (1.19)	0.0	1.83	2.50	3.17	4.8	
		Week 18	Tezepelumab	15	15 (100.0)	0.86 (0.72)	0.0	0.00	1.00	1.50	2.0	
			Placebo	16	15 (93.8)	2.50 (1.01)	0.0	2.17	2.50	2.83	4.7	
		Week 20	Tezepelumab	15	15 (100.0)	0.82 (0.77)	0.0	0.00	0.83	1.17	2.8	
			Placebo	16	15 (93.8)	2.43 (0.72)	1.0	2.17	2.50	2.83	3.8	
		Week 22	Tezepelumab	15	15 (100.0)	1.02 (0.89)	0.0	0.00	1.00	1.50	2.5	
			Placebo	16	15 (93.8)	2.49 (0.86)	0.8	2.00	2.67	3.33	3.8	
		Week 24	Tezepelumab	15	15 (100.0)	0.84 (0.79)	0.0	0.00	0.67	1.50	2.5	
			Placebo	16	15 (93.8)	2.47 (0.85)	0.7	2.00	2.50	3.17	3.8	
		Week 26	Tezepelumab	15	15 (100.0)	0.92 (0.81)	0.0	0.00	0.83	1.50	2.2	
			Placebo	16	15 (93.8)	2.47 (1.11)	0.0	1.50	2.50	3.33	3.8	
		Week 28	Tezepelumab	15	15 (100.0)	1.02 (0.98)	0.0	0.00	1.00	2.00	2.7	
			Placebo	16	16 (100.0)	2.27 (1.18)	0.0	1.58	2.42	3.17	3.8	
		Week 30	Tezepelumab	15	15 (100.0)	0.86 (0.77)	0.0	0.00	0.67	1.50	2.2	
			Placebo	16	16 (100.0)	2.33 (1.04)	0.0	1.75	2.50	3.17	3.8	
		Week 32	Tezepelumab	15	15 (100.0)	0.79 (0.79)	0.0	0.00	0.67	1.50	2.3	
			Placebo	16	16 (100.0)	2.38 (1.16)	0.0	1.67	2.33	3.17	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Absolute values	Week 34	Tezepelumab	15	15 (100.0)	0.89 (0.96)	0.0	0.00	0.67	1.50	2.7	
			Placebo	16	16 (100.0)	2.23 (1.23)	0.2	1.42	2.25	3.17	4.5	
		Week 36	Tezepelumab	15	15 (100.0)	0.94 (0.84)	0.0	0.00	0.83	1.50	2.5	
			Placebo	16	16 (100.0)	2.46 (1.18)	0.0	1.83	2.33	3.17	4.5	
		Week 38	Tezepelumab	15	15 (100.0)	0.93 (1.03)	0.0	0.00	0.50	1.83	2.7	
			Placebo	16	16 (100.0)	2.39 (1.17)	0.0	1.75	2.50	3.17	4.5	
		Week 40	Tezepelumab	15	15 (100.0)	0.87 (0.88)	0.0	0.00	0.67	1.83	2.3	
			Placebo	16	16 (100.0)	2.44 (1.20)	0.0	1.58	2.67	3.25	4.2	
		Week 42	Tezepelumab	15	15 (100.0)	0.89 (0.82)	0.0	0.00	0.83	1.67	2.3	
			Placebo	16	16 (100.0)	2.34 (1.09)	0.0	2.00	2.42	2.75	4.5	
		Week 44	Tezepelumab	15	15 (100.0)	0.97 (0.90)	0.0	0.00	0.83	1.67	2.7	
			Placebo	16	16 (100.0)	2.31 (1.20)	0.0	1.50	2.33	3.17	4.2	
		Week 46	Tezepelumab	15	15 (100.0)	0.98 (0.97)	0.0	0.00	0.83	1.83	2.8	
			Placebo	16	16 (100.0)	2.30 (0.90)	0.0	1.92	2.25	2.92	3.8	
		Week 48	Tezepelumab	15	15 (100.0)	0.98 (0.92)	0.0	0.00	1.00	1.67	2.8	
			Placebo	16	16 (100.0)	2.34 (0.98)	0.0	2.08	2.33	2.83	3.8	
		Week 50	Tezepelumab	15	15 (100.0)	0.79 (0.76)	0.0	0.00	0.67	1.50	2.3	
			Placebo	16	16 (100.0)	2.13 (1.07)	0.0	1.67	2.17	2.75	3.8	
		Week 52	Tezepelumab	15	15 (100.0)	0.89 (0.75)	0.0	0.00	0.83	1.50	2.3	
			Placebo	16	16 (100.0)	2.20 (1.13)	0.0	1.75	2.17	2.92	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility											
No	Change from baseline	Week 2	Tezepelumab	15	15 (100.0)	-0.67 (0.63)	-1.8	-1.17	-0.50	-0.17	0.2	-0.46 [-1.20, 0.28]
			Placebo	16	14 (87.5)	-0.38 (0.61)	-1.5	-0.83	-0.42	0.00	1.0	
		Week 4	Tezepelumab	15	15 (100.0)	-1.11 (0.65)	-2.3	-1.50	-1.17	-0.50	-0.2	-1.20 [-1.99, -0.40]
			Placebo	16	14 (87.5)	-0.24 (0.81)	-1.3	-1.00	-0.17	0.33	1.2	
		Week 6	Tezepelumab	15	15 (100.0)	-1.32 (0.74)	-2.5	-1.83	-1.50	-0.67	0.2	-1.38 [-2.20, -0.56]
			Placebo	16	14 (87.5)	-0.20 (0.88)	-2.0	-0.83	-0.25	0.33	1.5	
		Week 8	Tezepelumab	15	15 (100.0)	-1.47 (0.68)	-2.5	-2.00	-1.50	-1.33	-0.2	-1.10 [-1.87, -0.33]
			Placebo	16	15 (93.8)	-0.49 (1.05)	-3.0	-1.00	-0.50	0.17	1.0	
		Week 10	Tezepelumab	15	15 (100.0)	-1.60 (0.69)	-2.5	-2.00	-1.83	-1.33	0.2	-1.09 [-1.86, -0.32]
			Placebo	16	15 (93.8)	-0.60 (1.10)	-2.2	-1.17	-0.67	-0.33	2.5	
		Week 12	Tezepelumab	15	15 (100.0)	-1.69 (0.65)	-2.5	-2.17	-2.00	-1.33	-0.2	-1.14 [-1.91, -0.36]
			Placebo	16	15 (93.8)	-0.66 (1.11)	-3.2	-1.17	-0.67	0.00	1.3	
		Week 14	Tezepelumab	15	15 (100.0)	-1.71 (0.50)	-2.3	-2.00	-1.83	-1.50	-0.7	-0.90 [-1.65, -0.14]
			Placebo	16	15 (93.8)	-1.02 (0.97)	-3.2	-1.67	-0.83	-0.67	1.2	
		Week 16	Tezepelumab	15	15 (100.0)	-1.74 (0.58)	-2.5	-2.17	-1.83	-1.67	-0.3	-1.17 [-1.95, -0.39]
			Placebo	16	15 (93.8)	-0.58 (1.28)	-3.2	-1.33	-0.50	0.17	2.3	
		Week 18	Tezepelumab	15	15 (100.0)	-1.61 (0.61)	-2.5	-2.00	-1.67	-1.33	-0.2	-1.09 [-1.86, -0.32]
			Placebo	16	15 (93.8)	-0.52 (1.28)	-3.2	-1.17	-0.67	-0.17	2.3	
		Week 20	Tezepelumab	15	15 (100.0)	-1.64 (0.57)	-2.5	-2.00	-1.67	-1.33	-0.3	-1.25 [-2.04, -0.46]
			Placebo	16	15 (93.8)	-0.59 (1.05)	-2.2	-1.17	-0.83	-0.17	2.3	
		Week 22	Tezepelumab	15	15 (100.0)	-1.44 (0.69)	-2.5	-2.00	-1.50	-0.67	-0.3	-0.99 [-1.75, -0.23]
			Placebo	16	15 (93.8)	-0.53 (1.10)	-2.0	-1.33	-0.50	0.33	2.3	
		Week 24	Tezepelumab	15	15 (100.0)	-1.62 (0.60)	-2.5	-2.00	-1.67	-1.33	-0.3	-1.19 [-1.97, -0.41]
			Placebo	16	15 (93.8)	-0.56 (1.12)	-2.5	-1.33	-0.83	0.17	2.3	
		Week 26	Tezepelumab	15	15 (100.0)	-1.54 (0.71)	-2.5	-2.17	-1.50	-1.17	0.0	-0.94 [-1.70, -0.18]
			Placebo	16	15 (93.8)	-0.56 (1.31)	-3.2	-1.33	-0.83	0.33	2.3	
		Week 28	Tezepelumab	15	15 (100.0)	-1.44 (0.84)	-2.5	-2.17	-1.67	-0.83	0.3	-0.81 [-1.54, -0.07]
			Placebo	16	16 (100.0)	-0.58 (1.24)	-3.2	-1.25	-0.58	0.08	2.3	
		Week 30	Tezepelumab	15	15 (100.0)	-1.61 (0.61)	-2.5	-2.00	-1.67	-1.00	-0.7	-1.24 [-2.01, -0.47]
			Placebo	16	16 (100.0)	-0.52 (1.07)	-2.0	-1.25	-0.75	0.00	2.3	
		Week 32	Tezepelumab	15	15 (100.0)	-1.68 (0.58)	-2.5	-2.17	-1.83	-1.17	-0.7	-1.28 [-2.06, -0.50]
			Placebo	16	16 (100.0)	-0.48 (1.18)	-1.8	-1.33	-0.83	0.08	2.3	
		Week 34	Tezepelumab	15	15 (100.0)	-1.58 (0.75)	-2.5	-2.17	-1.67	-0.67	-0.2	-0.88 [-1.62, -0.14]
			Placebo	16	16 (100.0)	-0.63 (1.32)	-2.8	-1.42	-1.00	0.08	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_ILSHP: Change from baseline in ACQ-6 score by study specific subgroups
DITTL

Subgroup	ACQ-6 score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Change from baseline	Week 36	Tezepelumab	15	15 (100.0)	-1.52 (0.76)	-2.5	-2.17	-1.67	-0.83	0.0	-1.12 [-1.88, -0.36]
			Placebo	16	16 (100.0)	-0.40 (1.19)	-1.8	-1.33	-0.67	0.08	2.3	
		Week 38	Tezepelumab	15	15 (100.0)	-1.53 (0.73)	-2.5	-2.00	-1.67	-0.83	-0.2	-1.07 [-1.83, -0.31]
			Placebo	16	16 (100.0)	-0.47 (1.19)	-2.2	-1.25	-0.67	0.08	2.3	
		Week 40	Tezepelumab	15	15 (100.0)	-1.60 (0.68)	-2.5	-2.17	-1.50	-1.00	-0.5	-1.19 [-1.96, -0.42]
			Placebo	16	16 (100.0)	-0.42 (1.22)	-2.3	-1.33	-0.58	0.33	2.3	
		Week 42	Tezepelumab	15	15 (100.0)	-1.58 (0.62)	-2.5	-2.00	-1.50	-1.17	-0.5	-1.18 [-1.95, -0.41]
			Placebo	16	16 (100.0)	-0.51 (1.11)	-2.0	-1.17	-0.75	-0.17	2.3	
		Week 44	Tezepelumab	15	15 (100.0)	-1.50 (0.77)	-2.7	-2.17	-1.50	-0.67	-0.2	-0.92 [-1.67, -0.18]
			Placebo	16	16 (100.0)	-0.54 (1.24)	-2.7	-1.25	-0.83	0.17	2.3	
		Week 46	Tezepelumab	15	15 (100.0)	-1.49 (0.76)	-2.5	-2.17	-1.50	-1.00	0.0	-1.08 [-1.84, -0.33]
			Placebo	16	16 (100.0)	-0.55 (0.95)	-1.5	-1.17	-0.83	-0.17	2.3	
		Week 48	Tezepelumab	15	15 (100.0)	-1.49 (0.80)	-2.5	-2.00	-2.00	-0.67	0.0	-1.08 [-1.84, -0.32]
			Placebo	16	16 (100.0)	-0.51 (0.99)	-1.7	-1.17	-0.67	-0.33	2.3	
		Week 50	Tezepelumab	15	15 (100.0)	-1.68 (0.63)	-2.5	-2.17	-2.00	-1.17	-0.5	-1.02 [-1.77, -0.27]
			Placebo	16	16 (100.0)	-0.73 (1.14)	-3.0	-1.25	-0.92	-0.33	2.3	
		Week 52	Tezepelumab	15	15 (100.0)	-1.58 (0.61)	-2.5	-2.00	-1.67	-1.00	-0.5	-0.97 [-1.72, -0.22]
			Placebo	16	16 (100.0)	-0.66 (1.18)	-3.0	-1.25	-0.92	-0.25	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5D_IBMP0: Decrease of at least 0.9 points in ACQ-5 score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in ACQ-5 score	Week 28	12	12 (100.0)	6 (50.0) [21.1, 78.9]	9	7 (77.8)	3 (33.3) [7.5, 70.1]	1.500 [0.508, 4.432]	2.000 [0.334, 11.969]	16.7 [-34.9, 68.2]	0.660 #
	Week 52	12	12 (100.0)	6 (50.0) [21.1, 78.9]	9	7 (77.8)	4 (44.4) [13.7, 78.8]	1.125 [0.447, 2.834]	1.250 [0.221, 7.084]	5.6 [-47.2, 58.3]	1.000 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H5I_IBMP0: Increase of at least 0.9 points in ACQ-5 score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in ACQ-5 score	Week 28	12	12 (100.0)	2 (16.7) [2.1, 48.4]	9	7 (77.8)	1 (11.1) [0.3, 48.2]	1.500 [0.160, 14.083]	1.600 [0.122, 20.993]	5.6 [-33.6, 44.7]	1.000 #
	Week 52	12	12 (100.0)	1 (8.3) [0.2, 38.5]	9	7 (77.8)	1 (11.1) [0.3, 48.2]	0.750 [0.054, 10.443]	0.727 [0.039, 13.452]	-2.8 [-38.3, 32.8]	1.000 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IBMH0: Course of ACQ-5 score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Baseline	Tezepelumab	12	12 (100.0)	2.82 (0.68)	1.8	2.30	2.80	3.20	4.2	
		Placebo	9	9 (100.0)	2.93 (0.55)	2.0	2.80	3.00	3.40	3.6	
	Week 2	Tezepelumab	12	10 (83.3)	2.12 (1.32)	0.0	1.20	2.60	2.80	3.8	
		Placebo	9	7 (77.8)	2.17 (0.90)	0.4	1.80	2.40	2.80	3.0	
	Week 4	Tezepelumab	12	10 (83.3)	2.08 (1.05)	0.2	1.40	2.20	3.00	3.4	
		Placebo	9	7 (77.8)	1.89 (0.92)	0.6	0.80	1.80	2.60	3.0	
	Week 6	Tezepelumab	12	10 (83.3)	1.74 (1.05)	0.0	1.40	1.60	2.80	3.2	
		Placebo	9	7 (77.8)	1.94 (1.56)	0.2	1.00	1.40	2.60	5.0	
	Week 8	Tezepelumab	12	10 (83.3)	2.04 (1.66)	0.0	0.80	1.60	3.20	5.2	
		Placebo	9	7 (77.8)	2.31 (1.19)	0.6	1.00	2.40	3.20	3.8	
	Week 10	Tezepelumab	12	10 (83.3)	1.80 (1.53)	0.0	0.60	1.50	2.80	4.8	
		Placebo	9	7 (77.8)	1.89 (0.99)	0.4	1.00	1.80	3.00	3.0	
	Week 12	Tezepelumab	12	10 (83.3)	1.82 (1.47)	0.0	0.60	1.80	2.60	4.8	
		Placebo	9	7 (77.8)	1.83 (0.89)	0.4	1.00	2.00	2.60	3.0	
	Week 14	Tezepelumab	12	10 (83.3)	1.66 (1.43)	0.0	0.40	1.50	2.00	4.8	
		Placebo	9	7 (77.8)	1.29 (0.62)	0.4	1.00	1.20	1.60	2.4	
	Week 16	Tezepelumab	12	10 (83.3)	1.84 (1.48)	0.0	0.80	1.90	2.80	4.8	
		Placebo	9	7 (77.8)	1.71 (0.59)	0.8	1.00	2.00	2.00	2.4	
	Week 18	Tezepelumab	12	11 (91.7)	1.85 (1.31)	0.0	1.00	1.80	2.60	4.8	
		Placebo	9	7 (77.8)	1.57 (1.20)	0.0	1.00	1.20	3.20	3.2	
	Week 20	Tezepelumab	12	11 (91.7)	1.76 (1.39)	0.0	0.60	1.80	2.60	4.8	
		Placebo	9	7 (77.8)	1.63 (1.34)	0.2	0.40	1.20	2.80	3.8	
	Week 22	Tezepelumab	12	11 (91.7)	1.93 (1.34)	0.0	1.00	1.80	2.60	4.8	
		Placebo	9	7 (77.8)	1.40 (1.33)	0.0	0.40	1.00	1.80	4.0	
	Week 24	Tezepelumab	12	11 (91.7)	1.76 (1.34)	0.0	0.80	1.80	2.60	4.8	
		Placebo	9	7 (77.8)	1.63 (1.38)	0.2	0.40	1.60	2.80	3.8	
	Week 26	Tezepelumab	12	12 (100.0)	1.88 (1.39)	0.0	0.80	1.90	2.80	4.8	
		Placebo	9	7 (77.8)	1.57 (1.32)	0.4	0.80	1.20	1.60	4.4	
	Week 28	Tezepelumab	12	12 (100.0)	1.85 (1.43)	0.0	0.70	1.70	2.90	4.8	
		Placebo	9	7 (77.8)	2.20 (1.54)	0.4	0.80	2.40	3.80	4.4	
	Week 30	Tezepelumab	12	12 (100.0)	2.02 (1.47)	0.0	0.80	2.10	2.80	4.8	
		Placebo	9	7 (77.8)	1.86 (1.24)	0.4	0.40	2.40	3.00	3.4	
	Week 32	Tezepelumab	12	12 (100.0)	2.02 (1.42)	0.0	1.00	2.20	2.90	4.8	
		Placebo	9	7 (77.8)	1.54 (0.96)	0.4	0.60	1.80	2.20	3.0	
	Week 34	Tezepelumab	12	12 (100.0)	1.98 (1.52)	0.0	0.90	1.70	2.90	4.8	
		Placebo	9	7 (77.8)	1.43 (1.20)	0.0	0.00	1.80	2.20	3.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IBMH0: Course of ACQ-5 score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-5 score	Week 36	Tezepelumab	12	12 (100.0)	1.93 (1.48)	0.0	0.90	1.70	3.00	4.8	
		Placebo	9	7 (77.8)	1.43 (1.46)	0.0	0.00	1.60	2.60	3.6	
	Week 38	Tezepelumab	12	12 (100.0)	1.97 (1.63)	0.0	0.70	1.60	3.00	4.8	
		Placebo	9	7 (77.8)	1.51 (1.34)	0.0	0.00	1.80	3.00	3.2	
	Week 40	Tezepelumab	12	12 (100.0)	2.03 (1.47)	0.0	0.90	1.90	3.00	4.8	
		Placebo	9	7 (77.8)	1.71 (1.55)	0.0	0.40	1.80	3.00	4.2	
	Week 42	Tezepelumab	12	12 (100.0)	2.08 (1.51)	0.0	0.90	1.90	3.00	4.8	
		Placebo	9	7 (77.8)	1.71 (1.38)	0.0	0.40	2.00	2.80	3.8	
	Week 44	Tezepelumab	12	12 (100.0)	2.03 (1.44)	0.0	0.90	1.90	3.00	4.8	
		Placebo	9	7 (77.8)	1.97 (1.22)	0.2	0.80	1.80	3.20	3.4	
	Week 46	Tezepelumab	12	12 (100.0)	2.05 (1.44)	0.0	1.00	2.00	3.00	4.8	
		Placebo	9	7 (77.8)	1.60 (1.48)	0.0	0.60	1.00	2.20	4.4	
	Week 48	Tezepelumab	12	12 (100.0)	2.07 (1.46)	0.0	1.00	1.90	3.00	4.8	
		Placebo	9	7 (77.8)	1.63 (1.62)	0.0	0.20	1.80	2.40	4.6	
	Week 50	Tezepelumab	12	12 (100.0)	1.95 (1.59)	0.0	0.50	2.00	3.00	4.8	
		Placebo	9	7 (77.8)	1.69 (1.31)	0.0	0.40	2.00	2.40	3.8	
	Week 52	Tezepelumab	12	12 (100.0)	1.92 (1.57)	0.0	0.50	2.00	2.90	4.8	
		Placebo	9	7 (77.8)	1.66 (1.30)	0.0	0.40	2.00	2.40	3.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IBMH0: Course of ACQ-5 score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 score	Week 2	Tezepelumab	12	10 (83.3)	-0.88 (1.07)	-3.2	-1.20	-0.70	-0.20	0.4	-0.05 [-1.02, 0.92]
		Placebo	9	7 (77.8)	-0.83 (0.92)	-2.8	-1.00	-0.40	-0.20	-0.2	
	Week 4	Tezepelumab	12	10 (83.3)	-0.92 (0.83)	-2.4	-1.40	-0.80	-0.20	0.2	0.22 [-0.75, 1.19]
		Placebo	9	7 (77.8)	-1.11 (0.92)	-3.0	-1.40	-1.00	-0.40	-0.2	
	Week 6	Tezepelumab	12	10 (83.3)	-1.26 (0.82)	-2.8	-1.60	-1.20	-0.80	0.0	-0.18 [-1.14, 0.79]
		Placebo	9	7 (77.8)	-1.06 (1.53)	-3.4	-1.80	-1.20	-0.40	1.6	
	Week 8	Tezepelumab	12	10 (83.3)	-0.96 (1.57)	-3.0	-2.00	-1.40	0.00	2.6	-0.19 [-1.16, 0.78]
		Placebo	9	7 (77.8)	-0.69 (1.26)	-3.0	-1.20	-0.80	0.20	1.0	
	Week 10	Tezepelumab	12	10 (83.3)	-1.20 (1.24)	-3.0	-2.20	-1.40	0.20	0.6	-0.07 [-1.04, 0.89]
		Placebo	9	7 (77.8)	-1.11 (1.06)	-3.2	-1.40	-1.20	-0.40	0.0	
	Week 12	Tezepelumab	12	10 (83.3)	-1.18 (1.11)	-2.6	-2.20	-1.20	-0.20	0.6	-0.01 [-0.97, 0.96]
		Placebo	9	7 (77.8)	-1.17 (0.94)	-3.2	-1.20	-0.80	-0.60	-0.4	
	Week 14	Tezepelumab	12	10 (83.3)	-1.34 (1.05)	-2.8	-2.20	-1.40	-0.80	0.6	0.38 [-0.60, 1.35]
		Placebo	9	7 (77.8)	-1.71 (0.89)	-3.2	-2.40	-1.60	-1.20	-0.4	
	Week 16	Tezepelumab	12	10 (83.3)	-1.16 (1.11)	-2.4	-2.20	-1.10	-0.40	0.6	0.13 [-0.84, 1.09]
		Placebo	9	7 (77.8)	-1.29 (0.76)	-2.8	-1.40	-1.20	-0.80	-0.4	
	Week 18	Tezepelumab	12	11 (91.7)	-1.05 (1.07)	-2.8	-2.20	-1.00	0.00	0.6	0.32 [-0.64, 1.27]
		Placebo	9	7 (77.8)	-1.43 (1.36)	-3.2	-2.40	-1.40	0.20	0.4	
	Week 20	Tezepelumab	12	11 (91.7)	-1.15 (1.09)	-2.6	-2.20	-1.00	-0.20	0.6	0.18 [-0.77, 1.13]
		Placebo	9	7 (77.8)	-1.37 (1.48)	-3.0	-2.80	-1.80	-0.20	1.0	
	Week 22	Tezepelumab	12	11 (91.7)	-0.98 (1.03)	-2.4	-2.20	-0.80	-0.20	0.6	0.51 [-0.46, 1.47]
		Placebo	9	7 (77.8)	-1.60 (1.47)	-3.2	-2.80	-1.80	-1.00	1.2	
	Week 24	Tezepelumab	12	11 (91.7)	-1.15 (1.03)	-2.4	-2.20	-1.20	-0.20	0.6	0.18 [-0.77, 1.13]
		Placebo	9	7 (77.8)	-1.37 (1.54)	-3.2	-3.00	-1.80	0.00	1.0	
	Week 26	Tezepelumab	12	12 (100.0)	-0.93 (1.17)	-2.6	-2.20	-0.70	0.00	0.6	0.39 [-0.55, 1.33]
		Placebo	9	7 (77.8)	-1.43 (1.43)	-2.4	-2.40	-1.80	-1.20	1.6	
	Week 28	Tezepelumab	12	12 (100.0)	-0.97 (1.41)	-2.8	-2.20	-1.10	0.50	1.0	-0.11 [-1.04, 0.82]
		Placebo	9	7 (77.8)	-0.80 (1.65)	-2.8	-2.40	-0.80	0.80	1.6	
	Week 30	Tezepelumab	12	12 (100.0)	-0.80 (1.41)	-2.6	-2.20	-0.60	0.10	2.0	0.25 [-0.69, 1.18]
		Placebo	9	7 (77.8)	-1.14 (1.36)	-3.2	-2.40	-0.60	-0.20	0.6	
	Week 32	Tezepelumab	12	12 (100.0)	-0.80 (1.16)	-2.4	-1.90	-0.80	0.20	1.0	0.59 [-0.37, 1.54]
		Placebo	9	7 (77.8)	-1.46 (1.05)	-3.0	-2.40	-1.20	-1.00	0.2	
	Week 34	Tezepelumab	12	12 (100.0)	-0.83 (1.44)	-2.4	-2.20	-1.00	0.10	2.2	0.54 [-0.41, 1.49]
		Placebo	9	7 (77.8)	-1.57 (1.26)	-3.2	-2.80	-1.40	-0.60	0.4	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IBMH0: Course of ACQ-5 score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-5 score	Week 36	Tezepelumab	12	12 (100.0)	-0.88 (1.31)	-2.4	-2.20	-1.20	0.20	1.6	0.49 [-0.46, 1.44]
		Placebo	9	7 (77.8)	-1.57 (1.55)	-3.6	-3.20	-1.40	-0.60	0.8	
	Week 38	Tezepelumab	12	12 (100.0)	-0.85 (1.55)	-2.6	-2.20	-1.30	0.20	2.6	0.43 [-0.52, 1.37]
		Placebo	9	7 (77.8)	-1.49 (1.39)	-3.2	-3.00	-1.40	0.20	0.2	
	Week 40	Tezepelumab	12	12 (100.0)	-0.78 (1.30)	-2.4	-1.90	-1.00	0.20	1.8	0.35 [-0.59, 1.29]
		Placebo	9	7 (77.8)	-1.29 (1.64)	-3.2	-2.80	-1.20	0.20	1.4	
	Week 42	Tezepelumab	12	12 (100.0)	-0.73 (1.37)	-2.4	-1.80	-1.00	0.20	2.2	0.40 [-0.54, 1.34]
		Placebo	9	7 (77.8)	-1.29 (1.42)	-2.8	-2.80	-1.20	-0.20	1.0	
	Week 44	Tezepelumab	12	12 (100.0)	-0.78 (1.25)	-2.4	-1.80	-1.00	0.20	1.6	0.19 [-0.74, 1.12]
		Placebo	9	7 (77.8)	-1.03 (1.36)	-3.4	-1.80	-1.20	0.00	0.6	
	Week 46	Tezepelumab	12	12 (100.0)	-0.77 (1.36)	-2.4	-2.20	-0.80	0.20	1.8	0.43 [-0.51, 1.38]
		Placebo	9	7 (77.8)	-1.40 (1.65)	-3.2	-2.80	-1.60	-0.60	1.6	
	Week 48	Tezepelumab	12	12 (100.0)	-0.75 (1.33)	-2.4	-1.90	-0.90	0.20	2.0	0.41 [-0.53, 1.36]
		Placebo	9	7 (77.8)	-1.37 (1.77)	-3.4	-3.20	-1.60	-0.40	1.8	
	Week 50	Tezepelumab	12	12 (100.0)	-0.87 (1.50)	-3.2	-2.20	-0.80	0.20	2.0	0.28 [-0.66, 1.22]
		Placebo	9	7 (77.8)	-1.31 (1.76)	-3.6	-2.80	-1.00	-0.40	1.6	
	Week 52	Tezepelumab	12	12 (100.0)	-0.90 (1.48)	-3.2	-2.20	-0.80	0.10	2.0	0.28 [-0.66, 1.22]
		Placebo	9	7 (77.8)	-1.34 (1.75)	-3.6	-2.80	-1.00	-0.40	1.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results
DITTB

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 4	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 6	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 8	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 10	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 12	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 14	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 16	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 18	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 20	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results
DITTB

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 24	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 26	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 28	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 30	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 32	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 34	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 36	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 38	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 40	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H5C_IBMC0: Change from baseline in ACQ-5 score - MMRM results
DITTB

Change from baseline in ACQ-5 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	5 (55.6)					
Week 44	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 46	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 50	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Figure PF2H5C_IBMG0: Course of ACQ-5 score
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
ACQ = asthma control questionnaire.
Source table: PT2H5C_IBMH0
Source Data: aacq, created on: 11AUG2022

Table PT2H6D_IBMP0: Decrease of at least 0.9 points in ACQ-6 score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in ACQ-6 score	Week 28	12	12 (100.0)	6 (50.0) [21.1, 78.9]	9	7 (77.8)	4 (44.4) [13.7, 78.8]	1.125 [0.447, 2.834]	1.250 [0.221, 7.084]	5.6 [-47.2, 58.3]	1.000 #
	Week 52	12	12 (100.0)	5 (41.7) [15.2, 72.3]	9	7 (77.8)	3 (33.3) [7.5, 70.1]	1.250 [0.399, 3.912]	1.429 [0.236, 8.637]	8.3 [-42.9, 59.6]	1.000 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H6I_IBMP0: Increase of at least 0.9 points in ACQ-6 score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in ACQ-6 score	Week 28	12	12 (100.0)	0 (0.0) [0.0, 26.5]	9	7 (77.8)	2 (22.2) [2.8, 60.0]	0.154 + [0.008, 2.859]	0.120 + [0.005, 2.852]	-22.2 [-59.1, 14.7]	0.171 #
	Week 52	12	12 (100.0)	1 (8.3) [0.2, 38.5]	9	7 (77.8)	1 (11.1) [0.3, 48.2]	0.750 [0.054, 10.443]	0.727 [0.039, 13.452]	-2.8 [-38.3, 32.8]	1.000 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. ACQ = asthma control questionnaire.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IBMH0: Course of ACQ-6 score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Baseline	Tezepelumab	12	12 (100.0)	2.65 (0.62)	1.7	2.25	2.75	3.08	3.8	
		Placebo	9	9 (100.0)	2.80 (0.59)	1.8	2.50	2.83	3.17	3.5	
	Week 2	Tezepelumab	12	10 (83.3)	2.05 (1.24)	0.0	1.17	2.50	2.83	3.5	
		Placebo	9	7 (77.8)	2.07 (0.89)	0.3	1.67	2.17	2.67	3.0	
	Week 4	Tezepelumab	12	10 (83.3)	1.98 (0.96)	0.3	1.17	2.17	2.83	3.2	
		Placebo	9	7 (77.8)	1.74 (0.97)	0.5	0.67	1.50	2.67	3.0	
	Week 6	Tezepelumab	12	10 (83.3)	1.67 (0.94)	0.0	1.33	1.75	2.50	3.0	
		Placebo	9	7 (77.8)	1.83 (1.48)	0.2	1.00	1.17	2.67	4.7	
	Week 8	Tezepelumab	12	10 (83.3)	1.95 (1.51)	0.0	0.83	1.58	3.00	4.8	
		Placebo	9	7 (77.8)	2.17 (1.15)	0.5	1.00	2.33	3.33	3.5	
	Week 10	Tezepelumab	12	10 (83.3)	1.70 (1.39)	0.0	0.83	1.33	2.83	4.3	
		Placebo	9	7 (77.8)	1.71 (0.99)	0.3	0.83	1.67	2.67	3.2	
	Week 12	Tezepelumab	12	10 (83.3)	1.72 (1.35)	0.0	0.50	1.67	2.50	4.3	
		Placebo	9	7 (77.8)	1.69 (0.82)	0.3	0.83	1.83	2.33	2.7	
	Week 14	Tezepelumab	12	10 (83.3)	1.53 (1.28)	0.0	0.50	1.33	2.00	4.3	
		Placebo	9	7 (77.8)	1.21 (0.62)	0.3	0.83	1.00	1.83	2.2	
	Week 16	Tezepelumab	12	10 (83.3)	1.72 (1.33)	0.0	0.67	1.75	2.50	4.3	
		Placebo	9	7 (77.8)	1.55 (0.58)	0.7	0.83	1.83	2.00	2.2	
	Week 18	Tezepelumab	12	11 (91.7)	1.74 (1.17)	0.0	0.83	1.67	2.33	4.3	
		Placebo	9	7 (77.8)	1.45 (1.13)	0.0	0.83	1.17	2.83	3.2	
	Week 20	Tezepelumab	12	11 (91.7)	1.70 (1.22)	0.0	1.00	1.83	2.33	4.3	
		Placebo	9	7 (77.8)	1.48 (1.24)	0.2	0.33	1.17	2.83	3.3	
	Week 22	Tezepelumab	12	11 (91.7)	1.79 (1.20)	0.0	1.00	1.83	2.50	4.3	
		Placebo	9	7 (77.8)	1.31 (1.24)	0.0	0.33	1.00	2.00	3.7	
	Week 24	Tezepelumab	12	11 (91.7)	1.65 (1.21)	0.0	0.83	1.83	2.33	4.3	
		Placebo	9	7 (77.8)	1.52 (1.30)	0.2	0.33	1.50	2.50	3.5	
	Week 26	Tezepelumab	12	12 (100.0)	1.75 (1.24)	0.0	0.92	1.83	2.58	4.3	
		Placebo	9	7 (77.8)	1.45 (1.22)	0.3	0.67	1.00	1.83	4.0	
	Week 28	Tezepelumab	12	12 (100.0)	1.71 (1.26)	0.0	0.83	1.50	2.58	4.3	
		Placebo	9	7 (77.8)	2.02 (1.47)	0.3	0.67	2.17	3.83	4.0	
	Week 30	Tezepelumab	12	12 (100.0)	1.88 (1.31)	0.0	0.92	1.92	2.58	4.3	
		Placebo	9	7 (77.8)	1.71 (1.15)	0.3	0.33	2.00	2.83	3.0	
	Week 32	Tezepelumab	12	12 (100.0)	1.86 (1.26)	0.0	1.08	2.08	2.67	4.3	
		Placebo	9	7 (77.8)	1.43 (0.90)	0.3	0.50	1.50	2.17	2.7	
	Week 34	Tezepelumab	12	12 (100.0)	1.86 (1.35)	0.0	1.00	1.67	2.67	4.3	
		Placebo	9	7 (77.8)	1.31 (1.09)	0.0	0.00	1.83	2.00	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IBMH0: Course of ACQ-6 score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
ACQ-6 score	Week 36	Tezepelumab	12	12 (100.0)	1.82 (1.31)	0.0	1.08	1.50	2.67	4.3	
		Placebo	9	7 (77.8)	1.31 (1.30)	0.0	0.00	1.83	2.33	3.2	
	Week 38	Tezepelumab	12	12 (100.0)	1.85 (1.43)	0.0	0.92	1.50	2.67	4.3	
		Placebo	9	7 (77.8)	1.38 (1.27)	0.0	0.00	1.50	2.67	3.2	
	Week 40	Tezepelumab	12	12 (100.0)	1.88 (1.32)	0.0	0.92	1.75	2.67	4.3	
		Placebo	9	7 (77.8)	1.55 (1.36)	0.0	0.33	2.00	2.50	3.7	
	Week 42	Tezepelumab	12	12 (100.0)	1.93 (1.33)	0.0	1.08	1.75	2.67	4.3	
		Placebo	9	7 (77.8)	1.55 (1.27)	0.0	0.33	1.67	2.83	3.3	
	Week 44	Tezepelumab	12	12 (100.0)	1.89 (1.28)	0.0	1.08	1.75	2.67	4.3	
		Placebo	9	7 (77.8)	1.83 (1.11)	0.2	0.67	2.00	3.00	3.0	
	Week 46	Tezepelumab	12	12 (100.0)	1.89 (1.29)	0.0	1.08	1.83	2.67	4.3	
		Placebo	9	7 (77.8)	1.45 (1.32)	0.0	0.50	1.00	2.33	3.8	
	Week 48	Tezepelumab	12	12 (100.0)	1.90 (1.30)	0.0	1.08	1.67	2.67	4.3	
		Placebo	9	7 (77.8)	1.50 (1.48)	0.0	0.17	1.67	2.17	4.2	
	Week 50	Tezepelumab	12	12 (100.0)	1.81 (1.41)	0.0	0.58	1.75	2.67	4.3	
		Placebo	9	7 (77.8)	1.60 (1.26)	0.0	0.33	1.83	2.17	3.7	
	Week 52	Tezepelumab	12	12 (100.0)	1.78 (1.39)	0.0	0.58	1.75	2.58	4.3	
		Placebo	9	7 (77.8)	1.67 (1.29)	0.0	0.33	2.17	2.33	3.7	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IBMH0: Course of ACQ-6 score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 score	Week 2	Tezepelumab	12	10 (83.3)	-0.78 (0.96)	-2.8	-1.17	-0.58	-0.17	0.3	-0.02 [-0.99, 0.94]
		Placebo	9	7 (77.8)	-0.76 (0.98)	-2.8	-0.83	-0.50	-0.17	0.2	
	Week 4	Tezepelumab	12	10 (83.3)	-0.85 (0.70)	-2.0	-1.17	-0.67	-0.33	0.2	0.30 [-0.67, 1.27]
		Placebo	9	7 (77.8)	-1.10 (0.97)	-3.0	-1.50	-1.00	-0.17	-0.2	
	Week 6	Tezepelumab	12	10 (83.3)	-1.17 (0.69)	-2.3	-1.33	-1.08	-0.83	-0.2	-0.15 [-1.12, 0.82]
		Placebo	9	7 (77.8)	-1.00 (1.52)	-3.3	-2.00	-1.17	-0.17	1.5	
	Week 8	Tezepelumab	12	10 (83.3)	-0.88 (1.35)	-2.7	-1.67	-1.08	-0.17	2.2	-0.16 [-1.13, 0.80]
		Placebo	9	7 (77.8)	-0.67 (1.29)	-3.0	-1.17	-0.83	0.50	1.0	
	Week 10	Tezepelumab	12	10 (83.3)	-1.13 (1.09)	-2.7	-2.17	-1.33	0.00	0.5	-0.01 [-0.98, 0.95]
		Placebo	9	7 (77.8)	-1.12 (1.10)	-3.2	-1.50	-1.17	-0.50	0.3	
	Week 12	Tezepelumab	12	10 (83.3)	-1.12 (0.99)	-2.3	-2.17	-1.08	-0.33	0.5	0.03 [-0.94, 0.99]
		Placebo	9	7 (77.8)	-1.14 (0.93)	-3.2	-1.33	-0.83	-0.67	-0.5	
	Week 14	Tezepelumab	12	10 (83.3)	-1.30 (0.94)	-2.3	-2.17	-1.33	-0.83	0.5	0.35 [-0.63, 1.32]
		Placebo	9	7 (77.8)	-1.62 (0.90)	-3.2	-2.17	-1.50	-1.00	-0.3	
	Week 16	Tezepelumab	12	10 (83.3)	-1.12 (0.95)	-2.3	-2.17	-1.00	-0.50	0.5	0.19 [-0.78, 1.16]
		Placebo	9	7 (77.8)	-1.29 (0.81)	-2.8	-1.67	-1.33	-0.67	-0.5	
	Week 18	Tezepelumab	12	11 (91.7)	-1.00 (0.93)	-2.3	-1.83	-1.00	-0.33	0.5	0.35 [-0.61, 1.30]
		Placebo	9	7 (77.8)	-1.38 (1.33)	-3.2	-2.33	-1.33	0.33	0.3	
	Week 20	Tezepelumab	12	11 (91.7)	-1.05 (0.94)	-2.3	-2.00	-0.83	-0.33	0.5	0.27 [-0.68, 1.22]
		Placebo	9	7 (77.8)	-1.36 (1.45)	-3.0	-2.83	-1.83	0.00	0.8	
	Week 22	Tezepelumab	12	11 (91.7)	-0.95 (0.92)	-2.3	-1.83	-0.83	-0.17	0.5	0.49 [-0.47, 1.45]
		Placebo	9	7 (77.8)	-1.52 (1.47)	-3.2	-2.83	-1.83	-0.83	1.2	
	Week 24	Tezepelumab	12	11 (91.7)	-1.09 (0.92)	-2.2	-2.00	-1.17	-0.33	0.5	0.18 [-0.77, 1.13]
		Placebo	9	7 (77.8)	-1.31 (1.55)	-3.2	-3.00	-1.67	0.00	1.0	
	Week 26	Tezepelumab	12	12 (100.0)	-0.90 (1.03)	-2.3	-2.08	-0.75	0.00	0.5	0.41 [-0.54, 1.35]
		Placebo	9	7 (77.8)	-1.38 (1.40)	-2.5	-2.50	-1.83	-1.00	1.5	
	Week 28	Tezepelumab	12	12 (100.0)	-0.94 (1.22)	-2.3	-2.08	-1.08	0.25	0.8	-0.10 [-1.03, 0.83]
		Placebo	9	7 (77.8)	-0.81 (1.63)	-2.8	-2.17	-1.00	1.00	1.5	
	Week 30	Tezepelumab	12	12 (100.0)	-0.78 (1.26)	-2.3	-2.08	-0.67	-0.08	1.8	0.27 [-0.67, 1.20]
		Placebo	9	7 (77.8)	-1.12 (1.29)	-3.2	-2.17	-0.50	-0.33	0.5	
	Week 32	Tezepelumab	12	12 (100.0)	-0.79 (1.02)	-2.3	-1.58	-0.67	-0.08	0.8	0.59 [-0.36, 1.54]
		Placebo	9	7 (77.8)	-1.40 (1.07)	-3.0	-2.33	-1.17	-0.67	0.2	
	Week 34	Tezepelumab	12	12 (100.0)	-0.79 (1.27)	-2.3	-1.92	-0.83	-0.17	2.0	0.58 [-0.38, 1.53]
		Placebo	9	7 (77.8)	-1.52 (1.26)	-3.2	-2.83	-1.33	-0.67	0.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IBMH0: Course of ACQ-6 score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in ACQ-6 score	Week 36	Tezepelumab	12	12 (100.0)	-0.83 (1.16)	-2.3	-1.83	-1.00	-0.08	1.5	0.54 [-0.41, 1.49]
		Placebo	9	7 (77.8)	-1.52 (1.49)	-3.5	-3.17	-1.00	-0.67	0.7	
	Week 38	Tezepelumab	12	12 (100.0)	-0.81 (1.35)	-2.3	-2.00	-1.00	-0.08	2.3	0.47 [-0.47, 1.42]
		Placebo	9	7 (77.8)	-1.45 (1.41)	-3.2	-3.00	-1.33	0.17	0.3	
	Week 40	Tezepelumab	12	12 (100.0)	-0.78 (1.17)	-2.3	-1.58	-1.00	-0.08	1.7	0.39 [-0.56, 1.33]
		Placebo	9	7 (77.8)	-1.29 (1.56)	-3.2	-2.83	-1.17	0.00	1.2	
	Week 42	Tezepelumab	12	12 (100.0)	-0.72 (1.23)	-2.3	-1.58	-0.83	-0.08	2.0	0.44 [-0.51, 1.38]
		Placebo	9	7 (77.8)	-1.29 (1.41)	-2.8	-2.83	-1.17	0.00	0.8	
	Week 44	Tezepelumab	12	12 (100.0)	-0.76 (1.13)	-2.3	-1.58	-0.83	-0.08	1.5	0.20 [-0.74, 1.13]
		Placebo	9	7 (77.8)	-1.00 (1.30)	-3.3	-1.67	-0.83	0.00	0.5	
	Week 46	Tezepelumab	12	12 (100.0)	-0.76 (1.22)	-2.3	-1.92	-0.83	0.00	1.7	0.46 [-0.49, 1.40]
		Placebo	9	7 (77.8)	-1.38 (1.56)	-3.2	-2.83	-1.67	-0.50	1.3	
	Week 48	Tezepelumab	12	12 (100.0)	-0.75 (1.19)	-2.3	-1.75	-0.83	-0.08	1.8	0.42 [-0.53, 1.36]
		Placebo	9	7 (77.8)	-1.33 (1.72)	-3.3	-3.17	-1.50	-0.50	1.7	
	Week 50	Tezepelumab	12	12 (100.0)	-0.85 (1.32)	-2.7	-2.08	-0.75	-0.08	1.8	0.27 [-0.67, 1.20]
		Placebo	9	7 (77.8)	-1.24 (1.71)	-3.5	-2.83	-0.67	-0.33	1.5	
	Week 52	Tezepelumab	12	12 (100.0)	-0.87 (1.30)	-2.7	-2.08	-0.75	-0.17	1.8	0.20 [-0.74, 1.13]
		Placebo	9	7 (77.8)	-1.17 (1.75)	-3.5	-2.83	-0.67	-0.17	1.5	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. ACQ = asthma control questionnaire.
Last observation carried forward is applied in case of missing values.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 2	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 4	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 6	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 8	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 10	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 12	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 14	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 16	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 18	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 20	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 22	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 24	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 26	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 28	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 30	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 32	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 34	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 36	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 38	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 40	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Table PT2H6C_IBMC0: Change from baseline in ACQ-6 score - MMRM results
DITTB

Change from baseline in ACQ-6 score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 42	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	5 (55.6)					
Week 44	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 46	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 50	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
ACQ = asthma control questionnaire.
Source Data: aacq, created on: 11AUG2022

Figure PF2H6C_IBMG0: Course of ACQ-6 score
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
ACQ = asthma control questionnaire.
Source table: PT2H6C_IBMH0
Source Data: aacq, created on: 11AUG2022

Table PT2VSI_IOMP0: Increase in EQ-5D-VAS of at least 15 points
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase in EQ-5D-VAS of at least 15 points	Week 52	137	121 (88.3)	58 (42.3) [33.9, 51.1]	138	120 (87.0)	43 (31.2) [23.6, 39.6]	1.359 [0.991, 1.863]	1.622 [0.989, 2.660]	11.2 [-0.9, 23.2]	0.055

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. VAS = visual analogue scale.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_IOSPK: Increase in EQ-5D-VAS of at least 15 points by key subgroups
DITT

Increase in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex										0.595
Male	50	42 (84.0)	22 (44.0) [30.0, 58.7]	44	41 (93.2)	16 (36.4) [22.4, 52.2]	1.210 [0.733, 1.996]	1.375 [0.599, 3.154]	7.6 [-14.3, 29.6]	0.454
Female	87	79 (90.8)	36 (41.4) [30.9, 52.4]	94	79 (84.0)	27 (28.7) [19.9, 39.0]	1.441 [0.961, 2.160]	1.752 [0.944, 3.249]	12.7 [-2.3, 27.6]	0.075
Age										0.915
< 65 years	114	101 (88.6)	49 (43.0) [33.7, 52.6]	118	104 (88.1)	37 (31.4) [23.1, 40.5]	1.371 [0.975, 1.927]	1.650 [0.964, 2.824]	11.6 [-1.6, 24.8]	0.067
>= 65 years	23	20 (87.0)	9 (39.1) [19.7, 61.5]	20	16 (80.0)	6 (30.0) [11.9, 54.3]	1.304 [0.562, 3.026]	1.500 [0.421, 5.347]	9.1 [-23.8, 42.1]	0.536
Exacerbations in the year before study										0.725
<= 2	105	93 (88.6)	44 (41.9) [32.3, 51.9]	110	97 (88.2)	33 (30.0) [21.6, 39.5]	1.397 [0.971, 2.009]	1.683 [0.959, 2.954]	11.9 [-1.8, 25.6]	0.069
> 2	32	28 (87.5)	14 (43.8) [26.4, 62.3]	28	23 (82.1)	10 (35.7) [18.6, 55.9]	1.225 [0.650, 2.308]	1.400 [0.494, 3.968]	8.0 [-20.0, 36.1]	0.530
Race		N<10	any level							NE
White	128	113 (88.3)	53 (41.4) [32.8, 50.4]	123	105 (85.4)	37 (30.1) [22.1, 39.0]				
Black or African American	3	3 (100.0)	2 (66.7) [9.4, 99.2]	6	6 (100.0)	1 (16.7) [0.4, 64.1]				
Asian	5	4 (80.0)	3 (60.0) [14.7, 94.7]	6	6 (100.0)	4 (66.7) [22.3, 95.7]				
Other	1	1 (100.0)	0 (0.0) [0.0, 97.5]	3	3 (100.0)	1 (33.3) [0.8, 90.6]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_IOSPK: Increase in EQ-5D-VAS of at least 15 points by key subgroups
DITT

	Tezepelumab			Placebo							
Increase in EQ-5D-VAS of at least 15 points / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Region										0.638	
Europe	78	72 (92.3)	35 (44.9) [33.6, 56.6]	80	67 (83.8)	26 (32.5) [22.4, 43.9]	1.381 [0.925, 2.060]	1.691 [0.886, 3.227]	12.4 [-4.0, 28.7]	0.111	
America	10	8 (80.0)	4 (40.0) [12.2, 73.8]	9	8 (88.9)	1 (11.1) [0.3, 48.2]	3.600 [0.488, 26.540]	5.333 [0.468, 60.797]	28.9 [-18.3, 76.1]	0.303	#
Asia/Pacific	5	4 (80.0)	3 (60.0) [14.7, 94.7]	6	6 (100.0)	4 (66.7) [22.3, 95.7]	0.900 [0.361, 2.241]	0.750 [0.064, 8.834]	-6.7 [-82.2, 68.8]	1.000	#
Rest of the world	44	37 (84.1)	16 (36.4) [22.4, 52.2]	43	39 (90.7)	12 (27.9) [15.3, 43.7]	1.303 [0.701, 2.421]	1.476 [0.596, 3.654]	8.5 [-13.4, 30.3]	0.401	
BMI		N<10	any level							NE	
< 18.5 kg/m**2	0			1	1 (100.0)	0 (0.0) [0.0, 97.5]					
18.5 - < 25.0 kg/m**2	39	34 (87.2)	20 (51.3) [34.8, 67.6]	43	38 (88.4)	15 (34.9) [21.0, 50.9]					
25.0 - < 30.0 kg/m**2	45	41 (91.1)	18 (40.0) [25.7, 55.7]	47	43 (91.5)	12 (25.5) [13.9, 40.3]					
>= 30.0 kg/m**2	53	46 (86.8)	20 (37.7) [24.8, 52.1]	47	38 (80.9)	16 (34.0) [20.9, 49.3]					
Baseline eosinophils - Low										0.454	
< 150 cells/uL	27	26 (96.3)	12 (44.4) [25.5, 64.7]	33	29 (87.9)	13 (39.4) [22.9, 57.9]	1.128 [0.621, 2.050]	1.231 [0.439, 3.452]	5.1 [-23.4, 33.5]	0.695	
>= 150 cells/uL	109	94 (86.2)	46 (42.2) [32.8, 52.0]	105	91 (86.7)	30 (28.6) [20.2, 38.2]	1.477 [1.016, 2.147]	1.825 [1.033, 3.225]	13.6 [0.0, 27.2]	0.038	*
Baseline eosinophils - High										0.263	
< 300 cells/uL	69	62 (89.9)	29 (42.0) [30.2, 54.5]	72	61 (84.7)	26 (36.1) [25.1, 48.3]	1.164 [0.770, 1.760]	1.283 [0.651, 2.527]	5.9 [-11.6, 23.4]	0.473	
>= 300 cells/uL	67	58 (86.6)	29 (43.3) [31.2, 56.0]	66	59 (89.4)	17 (25.8) [15.8, 38.0]	1.680 [1.027, 2.751]	2.200 [1.056, 4.580]	17.5 [0.1, 34.9]	0.034	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_IOSPK: Increase in EQ-5D-VAS of at least 15 points by key subgroups
DITT

Increase in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO										0.368	
< 25 ppb	78	66 (84.6)	30 (38.5) [27.7, 50.2]	74	63 (85.1)	24 (32.4) [22.0, 44.3]	1.186 [0.770, 1.827]	1.302 [0.668, 2.537]	6.0 [-10.5, 22.5]	0.439	
>= 25 ppb	57	53 (93.0)	26 (45.6) [32.4, 59.3]	63	56 (88.9)	18 (28.6) [17.9, 41.3]	1.596 [0.985, 2.586]	2.097 [0.985, 4.462]	17.0 [-1.7, 35.8]	0.054	
Baseline specific perennial FEIA status										0.670	
All negative	57	49 (86.0)	24 (42.1) [29.1, 55.9]	66	54 (81.8)	21 (31.8) [20.9, 44.4]	1.323 [0.830, 2.109]	1.558 [0.745, 3.260]	10.3 [-8.4, 29.0]	0.239	
Any positive	71	65 (91.5)	31 (43.7) [31.9, 56.0]	63	57 (90.5)	18 (28.6) [17.9, 41.3]	1.528 [0.954, 2.449]	1.938 [0.943, 3.981]	15.1 [-2.5, 32.6]	0.071	
Total serum IgE										0.971	
Low	35	31 (88.6)	13 (37.1) [21.5, 55.1]	32	26 (81.3)	9 (28.1) [13.7, 46.7]	1.321 [0.655, 2.664]	1.510 [0.538, 4.236]	9.0 [-16.3, 34.3]	0.436	
Normal	95	84 (88.4)	43 (45.3) [35.0, 55.8]	98	86 (87.8)	32 (32.7) [23.5, 42.9]	1.386 [0.967, 1.987]	1.706 [0.951, 3.059]	12.6 [-2.1, 27.3]	0.073	
High	7	6 (85.7)	2 (28.6) [3.7, 71.0]	8	8 (100.0)	2 (25.0) [3.2, 65.1]	1.143 [0.214, 6.114]	1.200 [0.121, 11.865]	3.6 [-54.8, 61.9]	1.000	#
OCS at baseline										0.143	
Yes	9	8 (88.9)	4 (44.4) [13.7, 78.8]	13	9 (69.2)	1 (7.7) [0.2, 36.0]	5.778 [0.767, 43.545]	9.600 [0.848, 108.717]	36.8 [-8.2, 81.7]	0.116	#
No	128	113 (88.3)	54 (42.2) [33.5, 51.2]	125	111 (88.8)	42 (33.6) [25.4, 42.6]	1.256 [0.913, 1.728]	1.442 [0.865, 2.403]	8.6 [-4.1, 21.3]	0.160	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_IOSPK: Increase in EQ-5D-VAS of at least 15 points by key subgroups
DITT

Increase in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
ICS dose level (at study entry)										0.728	
Medium/Low	70	62 (88.6)	27 (38.6) [27.2, 51.0]	73	65 (89.0)	22 (30.1) [19.9, 42.0]	1.280 [0.810, 2.023]	1.456 [0.727, 2.914]	8.4 [-8.5, 25.4]	0.290	
High	67	59 (88.1)	31 (46.3) [34.0, 58.9]	65	55 (84.6)	21 (32.3) [21.2, 45.1]	1.432 [0.926, 2.216]	1.804 [0.889, 3.661]	14.0 [-4.0, 32.0]	0.102	
LAMA use at baseline										0.160	
Yes	11	9 (81.8)	7 (63.6) [30.8, 89.1]	6	4 (66.7)	0 (0.0) [0.0, 45.9]	8.750 + [0.584, 131.073]	21.667 + [0.971, 483.268]	63.6 [22.3, 100.0]	0.035	*
No	126	112 (88.9)	51 (40.5) [31.8, 49.6]	132	116 (87.9)	43 (32.6) [24.7, 41.3]	1.243 [0.899, 1.718]	1.407 [0.846, 2.341]	7.9 [-4.6, 20.4]	0.188	
Tiotropium use at baseline										0.299	
Yes	9	8 (88.9)	6 (66.7) [29.9, 92.5]	3	2 (66.7)	0 (0.0) [0.0, 70.8]	5.200 + [0.374, 72.315]	13.000 + [0.511, 330.477]	66.7 [13.6, 100.0]	0.182	#
No	128	113 (88.3)	52 (40.6) [32.0, 49.7]	135	118 (87.4)	43 (31.9) [24.1, 40.4]	1.275 [0.923, 1.763]	1.464 [0.883, 2.427]	8.8 [-3.6, 21.1]	0.140	
Montelukast/ Cromoglicic acid use at baseline										0.526	
Yes	29	27 (93.1)	14 (48.3) [29.4, 67.5]	37	33 (89.2)	11 (29.7) [15.9, 47.0]	1.624 [0.871, 3.026]	2.206 [0.801, 6.079]	18.5 [-7.9, 45.0]	0.126	
No	108	94 (87.0)	44 (40.7) [31.4, 50.6]	101	87 (86.1)	32 (31.7) [22.8, 41.7]	1.286 [0.892, 1.854]	1.482 [0.840, 2.617]	9.1 [-4.9, 23.0]	0.175	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_IOSPP: Increase in EQ-5D-VAS of at least 15 points by study specific subgroups
DITT

Increase in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.985	
White	128	113 (88.3)	53 (41.4) [32.8, 50.4]	123	105 (85.4)	37 (30.1) [22.1, 39.0]	1.376 [0.981, 1.932]	1.643 [0.975, 2.768]	11.3 [-1.2, 23.9]	0.062	
Non-white	9	8 (88.9)	5 (55.6) [21.2, 86.3]	15	15 (100.0)	6 (40.0) [16.3, 67.7]	1.389 [0.593, 3.255]	1.875 [0.352, 9.981]	15.6 [-34.2, 65.3]	0.675	#
Region (cat. P)										0.326	
North America/Western EU	10	8 (80.0)	4 (40.0) [12.2, 73.8]	9	8 (88.9)	1 (11.1) [0.3, 48.2]	3.600 [0.488, 26.540]	5.333 [0.468, 60.797]	28.9 [-18.3, 76.1]	0.303	#
Rest of world	127	113 (89.0)	54 (42.5) [33.8, 51.6]	129	112 (86.8)	42 (32.6) [24.6, 41.4]	1.306 [0.948, 1.799]	1.532 [0.921, 2.550]	10.0 [-2.6, 22.5]	0.100	
Baseline eosinophils (cat. P)										0.397	
< 250 cells/uL	61	53 (86.9)	25 (41.0) [28.6, 54.3]	60	53 (88.3)	21 (35.0) [23.1, 48.4]	1.171 [0.741, 1.851]	1.290 [0.618, 2.692]	6.0 [-12.9, 24.9]	0.500	
>= 250 cells/uL	76	68 (89.5)	33 (43.4) [32.1, 55.3]	78	67 (85.9)	22 (28.2) [18.6, 39.5]	1.539 [0.994, 2.384]	1.953 [1.000, 3.818]	15.2 [-1.0, 31.5]	0.050	*
Baseline FENO (cat. P)										0.465	
< 24 ppb	75	63 (84.0)	29 (38.7) [27.6, 50.6]	72	61 (84.7)	23 (31.9) [21.4, 44.0]	1.210 [0.778, 1.882]	1.343 [0.681, 2.649]	6.7 [-10.0, 23.5]	0.396	
>= 24 ppb	60	56 (93.3)	27 (45.0) [32.1, 58.4]	65	58 (89.2)	19 (29.2) [18.6, 41.8]	1.539 [0.962, 2.464]	1.981 [0.947, 4.143]	15.8 [-2.6, 34.1]	0.069	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_IOSPP: Increase in EQ-5D-VAS of at least 15 points by study specific subgroups
DITT

Increase in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. M)										0.281	
< 22.0 ppb	65	55 (84.6)	22 (33.8) [22.6, 46.6]	62	53 (85.5)	19 (30.6) [19.6, 43.7]	1.104 [0.666, 1.831]	1.158 [0.550, 2.440]	3.2 [-14.6, 21.0]	0.701	
>= 22.0 ppb	70	64 (91.4)	34 (48.6) [36.4, 60.8]	75	66 (88.0)	23 (30.7) [20.5, 42.4]	1.584 [1.044, 2.403]	2.135 [1.083, 4.209]	17.9 [0.8, 35.0]	0.028	*
Baseline all FEIA status										0.574	
All negative	50	43 (86.0)	20 (40.0) [26.4, 54.8]	50	40 (80.0)	16 (32.0) [19.5, 46.7]	1.250 [0.737, 2.119]	1.417 [0.624, 3.218]	8.0 [-12.8, 28.8]	0.407	
Any positive	77	70 (90.9)	35 (45.5) [34.1, 57.2]	80	72 (90.0)	24 (30.0) [20.3, 41.3]	1.515 [1.001, 2.294]	1.944 [1.009, 3.746]	15.5 [-0.8, 31.7]	0.046	*
Th2 status										0.320	
Low	70	63 (90.0)	32 (45.7) [33.7, 58.1]	62	53 (85.5)	17 (27.4) [16.9, 40.2]	1.667 [1.033, 2.691]	2.229 [1.075, 4.624]	18.3 [0.7, 35.9]	0.031	*
High	65	57 (87.7)	26 (40.0) [28.0, 52.9]	75	66 (88.0)	25 (33.3) [22.9, 45.2]	1.200 [0.775, 1.858]	1.333 [0.668, 2.660]	6.7 [-10.8, 24.1]	0.415	
Baseline Periostin										0.178	
Low (< 20.9 ng/ml)	62	57 (91.9)	23 (37.1) [25.2, 50.3]	67	57 (85.1)	23 (34.3) [23.2, 46.9]	1.081 [0.680, 1.718]	1.128 [0.549, 2.320]	2.8 [-15.3, 20.9]	0.744	
High (>= 20.9 ng/ml)	74	63 (85.1)	35 (47.3) [35.6, 59.3]	71	63 (88.7)	20 (28.2) [18.1, 40.1]	1.679 [1.079, 2.614]	2.288 [1.148, 4.561]	19.1 [2.3, 36.0]	0.018	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_IOSPP: Increase in EQ-5D-VAS of at least 15 points by study specific subgroups
DITT

Increase in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility										0.381	
Yes	114	100 (87.7)	46 (40.4) [31.3, 49.9]	126	111 (88.1)	40 (31.7) [23.7, 40.6]	1.271 [0.905, 1.785]	1.454 [0.856, 2.470]	8.6 [-4.4, 21.6]	0.166	
No	23	21 (91.3)	12 (52.2) [30.6, 73.2]	12	9 (75.0)	3 (25.0) [5.5, 57.2]	2.087 [0.727, 5.995]	3.273 [0.700, 15.291]	27.2 [-11.1, 65.4]	0.129	
Maintenance OCS use at baseline										0.248	
Yes	9	8 (88.9)	4 (44.4) [13.7, 78.8]	14	10 (71.4)	2 (14.3) [1.8, 42.8]	3.111 [0.711, 13.618]	4.800 [0.655, 35.198]	30.2 [-16.2, 76.6]	0.162	#
No	128	113 (88.3)	54 (42.2) [33.5, 51.2]	124	110 (88.7)	41 (33.1) [24.9, 42.1]	1.276 [0.924, 1.761]	1.477 [0.885, 2.467]	9.1 [-3.6, 21.8]	0.136	
No chronic OCS use and current post-BD FEV1 reversibility										0.073	
Yes	108	95 (88.0)	43 (39.8) [30.5, 49.7]	115	103 (89.6)	39 (33.9) [25.3, 43.3]	1.174 [0.832, 1.657]	1.289 [0.747, 2.224]	5.9 [-7.6, 19.5]	0.362	
No	29	26 (89.7)	15 (51.7) [32.5, 70.6]	23	17 (73.9)	4 (17.4) [5.0, 38.8]	2.974 [1.142, 7.749]	5.089 [1.385, 18.696]	34.3 [6.5, 62.1]	0.011	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSD_IOMP0: Decrease in EQ-5D-VAS of at least 15 points
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease in EQ-5D-VAS of at least 15 points	Week 52	137	121 (88.3)	8 (5.8) [2.6, 11.2]	138	120 (87.0)	2 (1.4) [0.2, 5.1]	4.029 [0.871, 18.633]	4.217 [0.879, 20.231]	4.4 [-0.7, 9.5]	0.060 #

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. VAS = visual analogue scale.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: avas, created on: 11AUG2022

Table PT2VSD_IOSPK: Decrease in EQ-5D-VAS of at least 15 points by key subgroups
DITT

Decrease in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex		n<10	all levels							NE
Male	50	42 (84.0)	1 (2.0) [0.1, 10.6]	44	41 (93.2)	1 (2.3) [0.1, 12.0]				
Female	87	79 (90.8)	7 (8.0) [3.3, 15.9]	94	79 (84.0)	1 (1.1) [0.0, 5.8]				
Age		n<10	all levels							NE
< 65 years	114	101 (88.6)	6 (5.3) [2.0, 11.1]	118	104 (88.1)	2 (1.7) [0.2, 6.0]				
>= 65 years	23	20 (87.0)	2 (8.7) [1.1, 28.0]	20	16 (80.0)	0 (0.0) [0.0, 16.8]				
Exacerbations in the year before study		n<10	all levels							NE
<= 2	105	93 (88.6)	5 (4.8) [1.6, 10.8]	110	97 (88.2)	0 (0.0) [0.0, 3.3]				
> 2	32	28 (87.5)	3 (9.4) [2.0, 25.0]	28	23 (82.1)	2 (7.1) [0.9, 23.5]				
Race		N<10	any level							NE
White	128	113 (88.3)	8 (6.3) [2.7, 11.9]	123	105 (85.4)	2 (1.6) [0.2, 5.8]				
Black or African American	3	3 (100.0)	0 (0.0) [0.0, 70.8]	6	6 (100.0)	0 (0.0) [0.0, 45.9]				
Asian	5	4 (80.0)	0 (0.0) [0.0, 52.2]	6	6 (100.0)	0 (0.0) [0.0, 45.9]				
Other	1	1 (100.0)	0 (0.0) [0.0, 97.5]	3	3 (100.0)	0 (0.0) [0.0, 70.8]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSD_IOSPK: Decrease in EQ-5D-VAS of at least 15 points by key subgroups
DITT

Decrease in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Region		n<10	all levels							NE
Europe	78	72 (92.3)	7 (9.0) [3.7, 17.6]	80	67 (83.8)	2 (2.5) [0.3, 8.7]				
America	10	8 (80.0)	0 (0.0) [0.0, 30.8]	9	8 (88.9)	0 (0.0) [0.0, 33.6]				
Asia/Pacific	5	4 (80.0)	0 (0.0) [0.0, 52.2]	6	6 (100.0)	0 (0.0) [0.0, 45.9]				
Rest of the world	44	37 (84.1)	1 (2.3) [0.1, 12.0]	43	39 (90.7)	0 (0.0) [0.0, 8.2]				
BMI		N<10	any level							NE
< 18.5 kg/m**2	0			1	1 (100.0)	0 (0.0) [0.0, 97.5]				
18.5 - < 25.0 kg/m**2	39	34 (87.2)	1 (2.6) [0.1, 13.5]	43	38 (88.4)	0 (0.0) [0.0, 8.2]				
25.0 - < 30.0 kg/m**2	45	41 (91.1)	3 (6.7) [1.4, 18.3]	47	43 (91.5)	1 (2.1) [0.1, 11.3]				
>= 30.0 kg/m**2	53	46 (86.8)	4 (7.5) [2.1, 18.2]	47	38 (80.9)	1 (2.1) [0.1, 11.3]				
Baseline eosinophils - Low		n<10	all levels							NE
< 150 cells/uL	27	26 (96.3)	3 (11.1) [2.4, 29.2]	33	29 (87.9)	0 (0.0) [0.0, 10.6]				
>= 150 cells/uL	109	94 (86.2)	5 (4.6) [1.5, 10.4]	105	91 (86.7)	2 (1.9) [0.2, 6.7]				
Baseline eosinophils - High		n<10	all levels							NE
< 300 cells/uL	69	62 (89.9)	6 (8.7) [3.3, 18.0]	72	61 (84.7)	1 (1.4) [0.0, 7.5]				
>= 300 cells/uL	67	58 (86.6)	2 (3.0) [0.4, 10.4]	66	59 (89.4)	1 (1.5) [0.0, 8.2]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSD_IOSPK: Decrease in EQ-5D-VAS of at least 15 points by key subgroups
DITT

Decrease in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO		n<10	all levels							NE
< 25 ppb	78	66 (84.6)	7 (9.0) [3.7, 17.6]	74	63 (85.1)	1 (1.4) [0.0, 7.3]				
>= 25 ppb	57	53 (93.0)	1 (1.8) [0.0, 9.4]	63	56 (88.9)	1 (1.6) [0.0, 8.5]				
Baseline specific perennial FEIA status		n<10	all levels							NE
All negative	57	49 (86.0)	5 (8.8) [2.9, 19.3]	66	54 (81.8)	2 (3.0) [0.4, 10.5]				
Any positive	71	65 (91.5)	2 (2.8) [0.3, 9.8]	63	57 (90.5)	0 (0.0) [0.0, 5.7]				
Total serum IgE		n<10	all levels							NE
Low	35	31 (88.6)	4 (11.4) [3.2, 26.7]	32	26 (81.3)	2 (6.3) [0.8, 20.8]				
Normal	95	84 (88.4)	4 (4.2) [1.2, 10.4]	98	86 (87.8)	0 (0.0) [0.0, 3.7]				
High	7	6 (85.7)	0 (0.0) [0.0, 41.0]	8	8 (100.0)	0 (0.0) [0.0, 36.9]				
OCS at baseline		n<10	all levels							NE
Yes	9	8 (88.9)	0 (0.0) [0.0, 33.6]	13	9 (69.2)	1 (7.7) [0.2, 36.0]				
No	128	113 (88.3)	8 (6.3) [2.7, 11.9]	125	111 (88.8)	1 (0.8) [0.0, 4.4]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSD_IOSPK: Decrease in EQ-5D-VAS of at least 15 points by key subgroups
DITT

	Tezepelumab			Placebo						
Decrease in EQ-5D-VAS of at least 15 points / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)		n<10	all levels							NE
Medium/Low	70	62 (88.6)	2 (2.9) [0.3, 9.9]	73	65 (89.0)	0 (0.0) [0.0, 4.9]				
High	67	59 (88.1)	6 (9.0) [3.4, 18.5]	65	55 (84.6)	2 (3.1) [0.4, 10.7]				
LAMA use at baseline		n<10	all levels							NE
Yes	11	9 (81.8)	0 (0.0) [0.0, 28.5]	6	4 (66.7)	1 (16.7) [0.4, 64.1]				
No	126	112 (88.9)	8 (6.3) [2.8, 12.1]	132	116 (87.9)	1 (0.8) [0.0, 4.1]				
Tiotropium use at baseline										0.254
Yes	9	8 (88.9)	0 (0.0) [0.0, 33.6]	3	2 (66.7)	0 (0.0) [0.0, 70.8]	0.400 + [0.009, 16.915]	0.368 + [0.006, 22.388]	-7.5 + [-60.1, 45.1]	
No	128	113 (88.3)	8 (6.3) [2.7, 11.9]	135	118 (87.4)	2 (1.5) [0.2, 5.2]	4.219 [0.913, 19.493]	4.433 [0.923, 21.288]	4.8 [-0.7, 10.2]	0.055 #
Montelukast/ Cromoglicic acid use at baseline		n<10	all levels							NE
Yes	29	27 (93.1)	2 (6.9) [0.8, 22.8]	37	33 (89.2)	2 (5.4) [0.7, 18.2]				
No	108	94 (87.0)	6 (5.6) [2.1, 11.7]	101	87 (86.1)	0 (0.0) [0.0, 3.6]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSD_IOSPP: Decrease in EQ-5D-VAS of at least 15 points by study specific subgroups
DITT

Decrease in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.678	
White	128	113 (88.3)	8 (6.3) [2.7, 11.9]	123	105 (85.4)	2 (1.6) [0.2, 5.8]	3.844 [0.833, 17.744]	4.033 [0.839, 19.385]	4.6 [-0.9, 10.2]	0.103	#
Non-white	9	8 (88.9)	0 (0.0) [0.0, 33.6]	15	15 (100.0)	0 (0.0) [0.0, 21.8]	1.600 + [0.034, 74.402]	1.632 + [0.030, 89.282]	1.9 + [-22.2, 26.0]		
Region (cat. P)										0.476	
North America/Western EU	10	8 (80.0)	0 (0.0) [0.0, 30.8]	9	8 (88.9)	0 (0.0) [0.0, 33.6]	0.909 + [0.020, 41.676]	0.905 + [0.016, 50.244]	-0.5 + [-28.3, 27.4]		
Rest of world	127	113 (89.0)	8 (6.3) [2.8, 12.0]	129	112 (86.8)	2 (1.6) [0.2, 5.5]	4.063 [0.880, 18.764]	4.269 [0.889, 20.510]	4.7 [-0.8, 10.3]	0.059	#
Baseline eosinophils (cat. P)		n<10	all levels							NE	
< 250 cells/uL	61	53 (86.9)	4 (6.6) [1.8, 15.9]	60	53 (88.3)	0 (0.0) [0.0, 6.0]					
>= 250 cells/uL	76	68 (89.5)	4 (5.3) [1.5, 12.9]	78	67 (85.9)	2 (2.6) [0.3, 9.0]					
Baseline FENO (cat. P)		n<10	all levels							NE	
< 24 ppb	75	63 (84.0)	7 (9.3) [3.8, 18.3]	72	61 (84.7)	1 (1.4) [0.0, 7.5]					
>= 24 ppb	60	56 (93.3)	1 (1.7) [0.0, 8.9]	65	58 (89.2)	1 (1.5) [0.0, 8.3]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSD_IOSPP: Decrease in EQ-5D-VAS of at least 15 points by study specific subgroups
DITT

	Tezepelumab			Placebo						
Decrease in EQ-5D-VAS of at least 15 points / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)		n<10	all levels							NE
< 22.0 ppb	65	55 (84.6)	6 (9.2) [3.5, 19.0]	62	53 (85.5)	1 (1.6) [0.0, 8.7]				
>= 22.0 ppb	70	64 (91.4)	2 (2.9) [0.3, 9.9]	75	66 (88.0)	1 (1.3) [0.0, 7.2]				
Baseline all FEIA status		n<10	all levels							NE
All negative	50	43 (86.0)	5 (10.0) [3.3, 21.8]	50	40 (80.0)	2 (4.0) [0.5, 13.7]				
Any positive	77	70 (90.9)	2 (2.6) [0.3, 9.1]	80	72 (90.0)	0 (0.0) [0.0, 4.5]				
Th2 status		n<10	all levels							NE
Low	70	63 (90.0)	5 (7.1) [2.4, 15.9]	62	53 (85.5)	2 (3.2) [0.4, 11.2]				
High	65	57 (87.7)	3 (4.6) [1.0, 12.9]	75	66 (88.0)	0 (0.0) [0.0, 4.8]				
Baseline Periostin		n<10	all levels							NE
Low (< 20.9 ng/ml)	62	57 (91.9)	5 (8.1) [2.7, 17.8]	67	57 (85.1)	2 (3.0) [0.4, 10.4]				
High (>= 20.9 ng/ml)	74	63 (85.1)	3 (4.1) [0.8, 11.4]	71	63 (88.7)	0 (0.0) [0.0, 5.1]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSD_IOSPP: Decrease in EQ-5D-VAS of at least 15 points by study specific subgroups
DITT

Decrease in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility		n<10	all levels							NE
Yes	114	100 (87.7)	7 (6.1) [2.5, 12.2]	126	111 (88.1)	2 (1.6) [0.2, 5.6]				
No	23	21 (91.3)	1 (4.3) [0.1, 21.9]	12	9 (75.0)	0 (0.0) [0.0, 26.5]				
Maintenance OCS use at baseline		n<10	all levels							NE
Yes	9	8 (88.9)	0 (0.0) [0.0, 33.6]	14	10 (71.4)	1 (7.1) [0.2, 33.9]				
No	128	113 (88.3)	8 (6.3) [2.7, 11.9]	124	110 (88.7)	1 (0.8) [0.0, 4.4]				
No chronic OCS use and current post-BD FEV1 reversibility		n<10	all levels							NE
Yes	108	95 (88.0)	7 (6.5) [2.6, 12.9]	115	103 (89.6)	1 (0.9) [0.0, 4.7]				
No	29	26 (89.7)	1 (3.4) [0.1, 17.8]	23	17 (73.9)	1 (4.3) [0.1, 21.9]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMH0: Course of EQ-5D-VAS
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	137	123 (89.8)	60.6 (16.5)	20	49.0	60.0	72.0	100	
		Placebo	138	120 (87.0)	60.5 (15.0)	23	50.0	60.0	70.0	97	
	Week 1	Tezepelumab	137	126 (92.0)	64.6 (17.2)	13	51.0	64.5	76.0	100	
		Placebo	138	123 (89.1)	62.8 (17.3)	2	50.0	64.0	74.0	98	
	Week 2	Tezepelumab	137	128 (93.4)	63.1 (17.8)	20	50.0	61.0	75.0	100	
		Placebo	138	125 (90.6)	62.8 (17.2)	0	50.0	65.0	74.0	98	
	Week 3	Tezepelumab	137	128 (93.4)	66.4 (17.2)	18	52.5	67.5	79.5	100	
		Placebo	138	125 (90.6)	67.5 (16.4)	0	58.0	70.0	80.0	98	
	Week 4	Tezepelumab	137	129 (94.2)	67.4 (18.3)	14	53.0	67.0	81.0	100	
		Placebo	138	125 (90.6)	65.5 (17.1)	17	54.0	68.0	78.0	99	
	Week 5	Tezepelumab	137	129 (94.2)	68.2 (17.1)	29	55.0	68.0	81.0	100	
		Placebo	138	125 (90.6)	67.7 (17.6)	0	57.0	69.0	81.0	100	
	Week 6	Tezepelumab	137	129 (94.2)	68.2 (17.6)	19	55.0	68.0	84.0	100	
		Placebo	138	126 (91.3)	67.7 (17.2)	17	55.0	69.0	80.0	100	
	Week 7	Tezepelumab	137	129 (94.2)	67.5 (17.9)	21	53.0	69.0	81.0	100	
		Placebo	138	126 (91.3)	69.4 (16.1)	17	61.0	71.0	80.0	100	
	Week 8	Tezepelumab	137	129 (94.2)	68.0 (19.0)	20	54.0	68.0	85.0	100	
		Placebo	138	127 (92.0)	67.3 (17.5)	14	53.0	69.0	80.0	100	
	Week 9	Tezepelumab	137	129 (94.2)	68.5 (18.3)	19	53.0	68.0	84.0	100	
		Placebo	138	127 (92.0)	67.7 (16.6)	20	54.0	70.0	80.0	100	
	Week 10	Tezepelumab	137	129 (94.2)	67.9 (19.2)	19	52.0	68.0	85.0	100	
		Placebo	138	128 (92.8)	68.5 (17.1)	18	55.0	71.0	81.0	100	
	Week 11	Tezepelumab	137	129 (94.2)	68.2 (18.6)	18	54.0	68.0	84.0	100	
		Placebo	138	128 (92.8)	69.4 (16.2)	20	57.0	70.0	81.5	100	
	Week 12	Tezepelumab	137	129 (94.2)	69.6 (18.6)	26	55.0	70.0	84.0	100	
		Placebo	138	128 (92.8)	68.6 (18.0)	19	57.5	71.0	82.0	100	
	Week 13	Tezepelumab	137	129 (94.2)	69.5 (18.6)	19	55.0	70.0	85.0	100	
		Placebo	138	128 (92.8)	69.3 (16.0)	12	58.0	71.0	82.0	100	
	Week 14	Tezepelumab	137	130 (94.9)	70.5 (18.3)	20	56.0	70.0	86.0	100	
		Placebo	138	128 (92.8)	68.7 (16.5)	19	58.0	70.5	80.5	100	
	Week 15	Tezepelumab	137	130 (94.9)	69.8 (19.2)	12	53.0	70.0	86.0	100	
		Placebo	138	128 (92.8)	69.6 (16.6)	10	60.0	71.0	81.0	100	
	Week 16	Tezepelumab	137	130 (94.9)	69.1 (18.5)	28	55.0	69.0	85.0	100	
		Placebo	138	128 (92.8)	68.0 (16.9)	24	56.5	69.0	80.0	100	
	Week 17	Tezepelumab	137	130 (94.9)	69.9 (17.5)	9	57.0	70.5	83.0	100	
		Placebo	138	128 (92.8)	68.3 (18.0)	7	59.0	70.0	80.0	100	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMH0: Course of EQ-5D-VAS
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 18	Tezepelumab	137	131 (95.6)	69.2 (18.5)	14	55.0	71.0	83.0	100	
		Placebo	138	128 (92.8)	67.5 (18.0)	18	54.0	70.0	81.0	100	
	Week 19	Tezepelumab	137	131 (95.6)	69.5 (18.5)	20	53.0	71.0	85.0	100	
		Placebo	138	128 (92.8)	67.8 (18.1)	14	55.0	69.0	82.0	100	
	Week 20	Tezepelumab	137	131 (95.6)	69.2 (18.4)	18	55.0	70.0	83.0	100	
		Placebo	138	128 (92.8)	68.7 (18.0)	19	58.0	70.0	82.5	100	
	Week 21	Tezepelumab	137	131 (95.6)	69.0 (18.8)	11	53.0	68.0	85.0	100	
		Placebo	138	128 (92.8)	67.9 (17.7)	16	57.5	71.0	81.5	100	
	Week 22	Tezepelumab	137	131 (95.6)	68.9 (18.4)	19	54.0	68.0	84.0	100	
		Placebo	138	128 (92.8)	68.1 (17.7)	26	56.0	70.0	82.0	100	
	Week 23	Tezepelumab	137	131 (95.6)	70.1 (17.7)	15	55.0	72.0	84.0	100	
		Placebo	138	128 (92.8)	69.2 (17.2)	10	57.0	71.0	82.5	100	
	Week 24	Tezepelumab	137	131 (95.6)	70.4 (18.8)	13	53.0	71.0	85.0	100	
		Placebo	138	128 (92.8)	69.7 (17.0)	23	57.0	72.0	81.5	100	
	Week 25	Tezepelumab	137	131 (95.6)	69.2 (18.6)	19	53.0	70.0	83.0	100	
		Placebo	138	128 (92.8)	69.3 (17.0)	15	57.5	72.0	81.0	100	
	Week 26	Tezepelumab	137	132 (96.4)	70.4 (18.0)	19	55.5	72.5	85.0	100	
		Placebo	138	128 (92.8)	69.3 (17.5)	11	57.5	72.0	82.0	100	
	Week 27	Tezepelumab	137	132 (96.4)	69.9 (18.2)	13	54.0	70.5	85.0	100	
		Placebo	138	128 (92.8)	68.5 (16.9)	13	54.0	70.5	80.0	100	
	Week 28	Tezepelumab	137	132 (96.4)	70.6 (17.9)	8	59.0	72.0	83.0	100	
		Placebo	138	129 (93.5)	69.2 (17.9)	12	55.0	70.0	82.0	100	
	Week 29	Tezepelumab	137	132 (96.4)	70.6 (17.8)	7	55.0	71.5	86.0	100	
		Placebo	138	130 (94.2)	68.9 (17.9)	14	56.0	70.0	82.0	100	
	Week 30	Tezepelumab	137	133 (97.1)	70.7 (17.9)	9	57.0	73.0	85.0	100	
		Placebo	138	130 (94.2)	69.1 (17.1)	25	58.0	71.0	82.0	100	
	Week 31	Tezepelumab	137	133 (97.1)	71.0 (18.0)	18	55.0	71.0	86.0	100	
		Placebo	138	130 (94.2)	70.4 (16.8)	14	59.0	72.0	83.0	100	
	Week 32	Tezepelumab	137	133 (97.1)	71.3 (18.6)	9	58.0	74.0	87.0	100	
		Placebo	138	130 (94.2)	69.6 (17.3)	20	59.0	72.0	82.0	100	
	Week 33	Tezepelumab	137	133 (97.1)	71.3 (18.4)	11	55.0	74.0	85.0	100	
		Placebo	138	130 (94.2)	70.5 (17.6)	11	59.0	72.5	83.0	100	
	Week 34	Tezepelumab	137	133 (97.1)	71.3 (18.0)	10	56.0	73.0	85.0	100	
		Placebo	138	130 (94.2)	71.0 (17.8)	21	58.0	72.0	85.0	100	
	Week 35	Tezepelumab	137	133 (97.1)	71.1 (18.5)	7	56.0	73.0	87.0	100	
		Placebo	138	130 (94.2)	70.0 (17.6)	10	58.0	72.0	85.0	100	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMH0: Course of EQ-5D-VAS
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	137	133 (97.1)	71.5 (18.7)	17	56.0	72.0	88.0	100	
		Placebo	138	130 (94.2)	69.8 (17.3)	20	56.0	71.0	84.0	100	
	Week 37	Tezepelumab	137	133 (97.1)	71.3 (18.5)	17	56.0	75.0	87.0	100	
		Placebo	138	130 (94.2)	69.9 (17.3)	10	59.0	70.0	84.0	100	
	Week 38	Tezepelumab	137	133 (97.1)	71.0 (19.3)	13	53.0	75.0	87.0	100	
		Placebo	138	130 (94.2)	70.6 (17.5)	18	57.0	73.0	85.0	100	
	Week 39	Tezepelumab	137	133 (97.1)	70.6 (19.2)	11	55.0	73.0	86.0	100	
		Placebo	138	130 (94.2)	70.8 (18.4)	13	58.0	75.0	86.0	100	
	Week 40	Tezepelumab	137	133 (97.1)	72.0 (17.8)	18	60.0	75.0	84.0	100	
		Placebo	138	130 (94.2)	69.2 (17.7)	20	54.0	71.0	85.0	100	
	Week 41	Tezepelumab	137	133 (97.1)	72.0 (18.5)	11	57.0	73.0	87.0	100	
		Placebo	138	130 (94.2)	70.2 (17.5)	15	57.0	72.0	84.0	100	
	Week 42	Tezepelumab	137	133 (97.1)	71.8 (18.4)	9	59.0	73.0	86.0	100	
		Placebo	138	130 (94.2)	69.8 (17.8)	20	55.0	72.0	85.0	100	
	Week 43	Tezepelumab	137	133 (97.1)	71.8 (18.7)	13	56.0	73.0	85.0	100	
		Placebo	138	130 (94.2)	69.9 (18.0)	12	56.0	73.0	84.0	100	
	Week 44	Tezepelumab	137	133 (97.1)	71.5 (18.8)	21	55.0	73.0	86.0	100	
		Placebo	138	130 (94.2)	69.3 (18.1)	23	57.0	71.0	85.0	100	
	Week 45	Tezepelumab	137	134 (97.8)	71.7 (18.5)	22	56.0	73.0	86.0	100	
		Placebo	138	130 (94.2)	70.4 (17.5)	16	56.0	72.0	84.0	100	
	Week 46	Tezepelumab	137	134 (97.8)	71.3 (18.7)	14	57.0	73.0	87.0	100	
		Placebo	138	131 (94.9)	70.2 (17.8)	20	57.0	73.0	82.0	100	
	Week 47	Tezepelumab	137	134 (97.8)	71.7 (18.1)	19	56.0	75.0	86.0	100	
		Placebo	138	131 (94.9)	70.5 (17.1)	14	60.0	72.0	83.0	100	
	Week 48	Tezepelumab	137	134 (97.8)	72.2 (18.8)	9	58.0	75.0	87.0	100	
		Placebo	138	131 (94.9)	70.4 (18.1)	18	58.0	74.0	84.0	100	
	Week 49	Tezepelumab	137	134 (97.8)	71.9 (18.3)	19	59.0	73.0	86.0	100	
		Placebo	138	131 (94.9)	70.9 (17.6)	15	58.0	74.0	84.0	100	
	Week 50	Tezepelumab	137	134 (97.8)	72.1 (18.6)	19	59.0	73.5	87.0	100	
		Placebo	138	131 (94.9)	70.6 (18.2)	18	57.0	73.0	88.0	100	
	Week 51	Tezepelumab	137	134 (97.8)	71.7 (18.5)	19	58.0	74.0	87.0	100	
		Placebo	138	131 (94.9)	71.2 (17.8)	16	59.0	74.0	85.0	100	
	Week 52	Tezepelumab	137	134 (97.8)	71.8 (18.8)	19	58.0	74.0	86.0	100	
		Placebo	138	131 (94.9)	70.4 (18.2)	16	58.0	73.0	85.0	100	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMH0: Course of EQ-5D-VAS
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 1	Tezepelumab	137	120 (87.6)	4.5 (13.7)	-42	-3.0	4.0	11.5	51	0.16 [-0.09, 0.41]
		Placebo	138	120 (87.0)	2.3 (14.9)	-56	-5.5	3.0	10.0	38	
	Week 2	Tezepelumab	137	120 (87.6)	2.6 (15.9)	-60	-5.0	1.0	13.0	48	0.03 [-0.22, 0.28]
		Placebo	138	120 (87.0)	2.2 (16.2)	-58	-7.5	1.5	9.0	55	
	Week 3	Tezepelumab	137	120 (87.6)	6.1 (16.3)	-51	-3.0	6.0	13.5	48	-0.06 [-0.31, 0.19]
		Placebo	138	120 (87.0)	7.0 (16.0)	-58	-3.0	5.0	14.5	54	
	Week 4	Tezepelumab	137	120 (87.6)	7.5 (17.3)	-51	-2.5	8.0	19.0	50	0.12 [-0.13, 0.38]
		Placebo	138	120 (87.0)	5.5 (15.3)	-40	-5.0	5.0	11.5	63	
	Week 5	Tezepelumab	137	120 (87.6)	8.3 (17.2)	-51	-2.0	7.0	17.5	58	0.06 [-0.19, 0.32]
		Placebo	138	120 (87.0)	7.2 (17.4)	-58	-4.0	4.5	15.0	63	
	Week 6	Tezepelumab	137	120 (87.6)	8.2 (17.9)	-51	-3.0	8.5	19.5	51	0.04 [-0.21, 0.30]
		Placebo	138	120 (87.0)	7.5 (17.0)	-29	-4.0	5.0	15.0	56	
	Week 7	Tezepelumab	137	120 (87.6)	7.5 (17.9)	-51	-2.5	7.0	17.5	61	-0.10 [-0.36, 0.15]
		Placebo	138	120 (87.0)	9.2 (16.4)	-33	-1.0	7.0	18.5	60	
	Week 8	Tezepelumab	137	120 (87.6)	7.8 (18.8)	-59	-2.5	9.0	18.0	69	0.04 [-0.22, 0.29]
		Placebo	138	120 (87.0)	7.2 (17.6)	-36	-4.0	5.0	16.0	62	
	Week 9	Tezepelumab	137	120 (87.6)	8.5 (17.7)	-51	-3.0	7.5	19.0	63	0.06 [-0.19, 0.31]
		Placebo	138	120 (87.0)	7.5 (16.4)	-27	-4.0	5.0	15.0	56	
	Week 10	Tezepelumab	137	120 (87.6)	7.7 (19.2)	-51	-3.5	7.5	17.5	65	-0.05 [-0.30, 0.20]
		Placebo	138	120 (87.0)	8.6 (17.9)	-31	-1.5	5.5	19.5	65	
	Week 11	Tezepelumab	137	120 (87.6)	8.3 (19.3)	-51	-4.0	8.0	19.5	64	-0.05 [-0.30, 0.21]
		Placebo	138	120 (87.0)	9.2 (18.0)	-27	-3.0	6.5	19.0	67	
	Week 12	Tezepelumab	137	120 (87.6)	9.5 (19.0)	-51	-2.0	7.0	21.0	65	0.06 [-0.20, 0.31]
		Placebo	138	120 (87.0)	8.4 (18.7)	-39	-3.0	6.0	17.5	69	
	Week 13	Tezepelumab	137	120 (87.6)	9.5 (19.7)	-51	-3.0	8.0	21.0	63	0.01 [-0.24, 0.26]
		Placebo	138	120 (87.0)	9.3 (17.4)	-26	-2.0	5.0	20.0	62	
	Week 14	Tezepelumab	137	121 (88.3)	10.6 (19.0)	-51	-2.0	10.0	23.0	57	0.11 [-0.14, 0.36]
		Placebo	138	120 (87.0)	8.6 (17.3)	-29	-4.0	7.0	18.0	67	
	Week 15	Tezepelumab	137	121 (88.3)	10.2 (19.1)	-51	-2.0	11.0	22.0	57	0.05 [-0.20, 0.31]
		Placebo	138	120 (87.0)	9.3 (16.5)	-35	-2.5	8.0	20.0	68	
	Week 16	Tezepelumab	137	121 (88.3)	9.2 (18.9)	-51	-2.0	7.0	21.0	65	0.06 [-0.19, 0.32]
		Placebo	138	120 (87.0)	8.1 (16.6)	-28	-2.0	5.5	16.0	60	
	Week 17	Tezepelumab	137	121 (88.3)	9.9 (18.7)	-51	-2.0	11.0	22.0	59	0.09 [-0.16, 0.35]
		Placebo	138	120 (87.0)	8.2 (17.6)	-40	-3.0	5.5	19.5	58	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMH0: Course of EQ-5D-VAS
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 18	Tezepelumab	137	121 (88.3)	9.4 (19.2)	-51	-2.0	8.0	22.0	58	0.10 [-0.16, 0.35]
		Placebo	138	120 (87.0)	7.6 (18.6)	-41	-4.5	6.0	20.5	60	
	Week 19	Tezepelumab	137	121 (88.3)	9.9 (18.9)	-51	-2.0	10.0	22.0	62	0.11 [-0.14, 0.36]
		Placebo	138	120 (87.0)	7.8 (17.8)	-40	-3.5	6.0	18.5	55	
	Week 20	Tezepelumab	137	121 (88.3)	9.3 (19.6)	-51	-4.0	11.0	24.0	55	0.03 [-0.22, 0.28]
		Placebo	138	120 (87.0)	8.8 (16.3)	-32	-2.0	7.0	17.0	57	
	Week 21	Tezepelumab	137	121 (88.3)	9.0 (18.4)	-51	-2.0	9.0	21.0	52	0.06 [-0.20, 0.31]
		Placebo	138	120 (87.0)	8.0 (17.2)	-31	-3.0	5.0	17.5	58	
	Week 22	Tezepelumab	137	121 (88.3)	9.1 (19.6)	-51	-4.0	9.0	23.0	58	0.06 [-0.19, 0.31]
		Placebo	138	120 (87.0)	8.0 (17.7)	-25	-3.5	5.0	19.0	59	
	Week 23	Tezepelumab	137	121 (88.3)	10.3 (19.2)	-51	-2.0	11.0	25.0	56	0.07 [-0.19, 0.32]
		Placebo	138	120 (87.0)	9.1 (16.6)	-23	-2.0	6.0	18.5	62	
	Week 24	Tezepelumab	137	121 (88.3)	11.1 (19.5)	-51	-3.0	11.0	25.0	59	0.07 [-0.18, 0.32]
		Placebo	138	120 (87.0)	9.8 (17.3)	-65	-1.0	8.0	18.5	66	
	Week 25	Tezepelumab	137	121 (88.3)	9.6 (19.1)	-51	-3.0	8.0	22.0	60	0.04 [-0.21, 0.29]
		Placebo	138	120 (87.0)	9.0 (15.7)	-25	-2.5	7.0	18.5	62	
	Week 26	Tezepelumab	137	121 (88.3)	10.7 (18.7)	-43	-2.0	10.0	25.0	61	0.10 [-0.15, 0.35]
		Placebo	138	120 (87.0)	8.9 (16.9)	-53	-2.0	5.0	17.5	65	
	Week 27	Tezepelumab	137	121 (88.3)	10.3 (18.5)	-43	-3.0	11.0	23.0	61	0.11 [-0.15, 0.36]
		Placebo	138	120 (87.0)	8.4 (16.9)	-30	-4.0	6.0	18.5	60	
	Week 28	Tezepelumab	137	121 (88.3)	10.7 (18.8)	-43	-1.0	9.0	25.0	60	0.10 [-0.15, 0.36]
		Placebo	138	120 (87.0)	8.8 (16.9)	-30	-3.0	6.0	19.0	65	
	Week 29	Tezepelumab	137	121 (88.3)	10.6 (18.5)	-43	-2.0	10.0	25.0	56	0.10 [-0.15, 0.36]
		Placebo	138	120 (87.0)	8.7 (16.8)	-30	-3.0	6.5	19.0	61	
	Week 30	Tezepelumab	137	121 (88.3)	10.7 (18.3)	-43	-1.0	11.0	22.0	58	0.09 [-0.16, 0.34]
		Placebo	138	120 (87.0)	9.2 (16.6)	-22	-3.0	7.5	19.0	60	
	Week 31	Tezepelumab	137	121 (88.3)	10.9 (18.0)	-43	-2.0	11.0	24.0	61	0.06 [-0.20, 0.31]
		Placebo	138	120 (87.0)	10.0 (16.0)	-20	-2.5	8.0	18.0	57	
	Week 32	Tezepelumab	137	121 (88.3)	11.4 (19.5)	-43	-2.0	11.0	25.0	68	0.09 [-0.16, 0.34]
		Placebo	138	120 (87.0)	9.8 (16.5)	-30	-1.0	7.0	18.5	62	
	Week 33	Tezepelumab	137	121 (88.3)	11.3 (18.8)	-43	-2.0	11.0	26.0	60	0.06 [-0.20, 0.31]
		Placebo	138	120 (87.0)	10.4 (16.7)	-25	-2.5	7.5	21.5	64	
	Week 34	Tezepelumab	137	121 (88.3)	11.3 (19.4)	-43	-1.0	11.0	25.0	59	0.02 [-0.23, 0.27]
		Placebo	138	120 (87.0)	10.9 (16.6)	-24	-1.0	8.0	21.5	61	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMH0: Course of EQ-5D-VAS
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 35	Tezepelumab	137	121 (88.3)	11.2 (19.1)	-43	-2.0	12.0	25.0	58	0.08 [-0.17, 0.33]
		Placebo	138	120 (87.0)	9.8 (16.0)	-21	-1.5	8.0	20.0	55	
	Week 36	Tezepelumab	137	121 (88.3)	11.4 (19.9)	-43	-4.0	13.0	25.0	67	0.09 [-0.16, 0.35]
		Placebo	138	120 (87.0)	9.8 (15.6)	-21	-2.0	8.0	18.0	59	
	Week 37	Tezepelumab	137	121 (88.3)	11.4 (19.7)	-43	-3.0	11.0	24.0	68	0.10 [-0.15, 0.35]
		Placebo	138	120 (87.0)	9.6 (16.1)	-35	-2.0	8.0	19.0	55	
	Week 38	Tezepelumab	137	121 (88.3)	11.1 (19.8)	-43	-3.0	11.0	25.0	61	0.03 [-0.22, 0.28]
		Placebo	138	120 (87.0)	10.5 (16.6)	-26	-2.0	8.5	20.0	59	
	Week 39	Tezepelumab	137	121 (88.3)	10.5 (19.4)	-43	-2.0	10.0	25.0	58	-0.01 [-0.26, 0.25]
		Placebo	138	120 (87.0)	10.6 (17.4)	-25	-2.0	7.5	21.0	65	
	Week 40	Tezepelumab	137	121 (88.3)	11.9 (19.0)	-43	-1.0	12.0	25.0	58	0.14 [-0.11, 0.39]
		Placebo	138	120 (87.0)	9.3 (17.0)	-26	-3.0	6.5	19.0	59	
	Week 41	Tezepelumab	137	121 (88.3)	11.8 (19.6)	-43	-2.0	13.0	25.0	58	0.09 [-0.16, 0.34]
		Placebo	138	120 (87.0)	10.2 (16.4)	-20	-2.0	7.0	20.0	58	
	Week 42	Tezepelumab	137	121 (88.3)	11.8 (19.7)	-43	-3.0	14.0	25.0	59	0.10 [-0.15, 0.35]
		Placebo	138	120 (87.0)	10.0 (16.7)	-30	-2.0	7.0	18.5	58	
	Week 43	Tezepelumab	137	121 (88.3)	12.2 (19.1)	-43	-1.0	13.0	26.0	63	0.12 [-0.13, 0.37]
		Placebo	138	120 (87.0)	10.0 (16.4)	-29	-1.5	7.5	18.5	60	
	Week 44	Tezepelumab	137	121 (88.3)	11.7 (19.3)	-43	-2.0	13.0	26.0	55	0.12 [-0.14, 0.37]
		Placebo	138	120 (87.0)	9.6 (16.7)	-24	-1.5	7.0	17.0	61	
	Week 45	Tezepelumab	137	121 (88.3)	12.0 (18.9)	-43	-1.0	13.0	25.0	60	0.08 [-0.17, 0.33]
		Placebo	138	120 (87.0)	10.6 (16.3)	-22	-2.0	7.5	17.5	58	
	Week 46	Tezepelumab	137	121 (88.3)	11.5 (19.7)	-43	-2.0	12.0	26.0	66	0.06 [-0.19, 0.32]
		Placebo	138	120 (87.0)	10.3 (16.8)	-19	-2.0	9.0	17.0	61	
	Week 47	Tezepelumab	137	121 (88.3)	11.6 (18.9)	-43	-1.0	12.0	25.0	59	0.06 [-0.19, 0.31]
		Placebo	138	120 (87.0)	10.6 (16.6)	-22	-1.0	9.0	18.5	61	
	Week 48	Tezepelumab	137	121 (88.3)	12.3 (20.0)	-43	-3.0	15.0	26.0	65	0.09 [-0.16, 0.34]
		Placebo	138	120 (87.0)	10.7 (16.6)	-29	-1.5	9.0	18.0	59	
	Week 49	Tezepelumab	137	121 (88.3)	11.9 (19.3)	-43	-1.0	14.0	26.0	65	0.04 [-0.22, 0.29]
		Placebo	138	120 (87.0)	11.2 (16.9)	-16	-1.0	9.0	18.0	59	
	Week 50	Tezepelumab	137	121 (88.3)	11.7 (19.1)	-43	-2.0	13.0	25.0	59	0.05 [-0.20, 0.31]
		Placebo	138	120 (87.0)	10.7 (17.9)	-23	-1.5	8.0	19.5	61	
	Week 51	Tezepelumab	137	121 (88.3)	11.5 (19.1)	-43	-2.0	13.0	25.0	58	0.01 [-0.24, 0.26]
		Placebo	138	120 (87.0)	11.4 (17.1)	-26	-1.5	9.0	20.0	58	
	Week 52	Tezepelumab	137	121 (88.3)	11.7 (19.1)	-43	-3.0	13.0	25.0	58	0.06 [-0.19, 0.32]
		Placebo	138	120 (87.0)	10.5 (17.4)	-26	-3.0	7.5	19.0	65	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITT

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	137	120 (87.6)	4.6 (1.4)	(1.8, 7.4)	2.2 (2.0)	(-1.8, 6.2)	0.283
	Placebo	138	120 (87.0)	2.4 (1.4)	(-0.4, 5.3)			
Week 2	Tezepelumab	137	118 (86.1)	2.7 (1.4)	(-0.1, 5.5)	0.4 (2.0)	(-3.6, 4.4)	0.859
	Placebo	138	119 (86.2)	2.3 (1.4)	(-0.5, 5.2)			
Week 3	Tezepelumab	137	111 (81.0)	6.6 (1.5)	(3.7, 9.4)	-0.7 (2.1)	(-4.8, 3.3)	0.721
	Placebo	138	111 (80.4)	7.3 (1.5)	(4.4, 10.2)			
Week 4	Tezepelumab	137	109 (79.6)	8.2 (1.5)	(5.3, 11.1)	2.7 (2.1)	(-1.4, 6.7)	0.199
	Placebo	138	112 (81.2)	5.5 (1.5)	(2.7, 8.4)			
Week 5	Tezepelumab	137	109 (79.6)	9.0 (1.5)	(6.1, 11.9)	1.6 (2.1)	(-2.5, 5.7)	0.444
	Placebo	138	110 (79.7)	7.4 (1.5)	(4.5, 10.2)			
Week 6	Tezepelumab	137	109 (79.6)	9.1 (1.5)	(6.1, 12.0)	1.4 (2.1)	(-2.7, 5.5)	0.511
	Placebo	138	110 (79.7)	7.7 (1.5)	(4.8, 10.6)			
Week 7	Tezepelumab	137	107 (78.1)	8.3 (1.5)	(5.4, 11.2)	-1.3 (2.1)	(-5.5, 2.8)	0.527
	Placebo	138	110 (79.7)	9.6 (1.5)	(6.7, 12.5)			
Week 8	Tezepelumab	137	107 (78.1)	8.7 (1.5)	(5.7, 11.6)	1.4 (2.1)	(-2.8, 5.5)	0.521
	Placebo	138	111 (80.4)	7.3 (1.5)	(4.4, 10.2)			
Week 9	Tezepelumab	137	105 (76.6)	9.7 (1.5)	(6.7, 12.6)	1.9 (2.1)	(-2.3, 6.1)	0.369
	Placebo	138	111 (80.4)	7.8 (1.5)	(4.8, 10.7)			
Week 10	Tezepelumab	137	105 (76.6)	8.7 (1.5)	(5.7, 11.7)	-0.2 (2.1)	(-4.3, 4.0)	0.943
	Placebo	138	111 (80.4)	8.8 (1.5)	(5.9, 11.8)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITT

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	137	104 (75.9)	9.4 (1.5)	(6.4, 12.4)	-0.1 (2.1)	(-4.3, 4.1)	0.957
	Placebo	138	108 (78.3)	9.5 (1.5)	(6.6, 12.4)			
Week 12	Tezepelumab	137	104 (75.9)	10.8 (1.5)	(7.8, 13.8)	2.1 (2.1)	(-2.1, 6.3)	0.326
	Placebo	138	108 (78.3)	8.7 (1.5)	(5.8, 11.7)			
Week 13	Tezepelumab	137	104 (75.9)	10.8 (1.5)	(7.8, 13.7)	1.1 (2.1)	(-3.1, 5.3)	0.609
	Placebo	138	109 (79.0)	9.7 (1.5)	(6.7, 12.6)			
Week 14	Tezepelumab	137	105 (76.6)	12.2 (1.5)	(9.2, 15.2)	3.5 (2.1)	(-0.7, 7.7)	0.106
	Placebo	138	108 (78.3)	8.8 (1.5)	(5.8, 11.7)			
Week 15	Tezepelumab	137	105 (76.6)	11.7 (1.5)	(8.8, 14.7)	2.4 (2.1)	(-1.8, 6.6)	0.264
	Placebo	138	108 (78.3)	9.3 (1.5)	(6.4, 12.3)			
Week 16	Tezepelumab	137	106 (77.4)	10.7 (1.5)	(7.7, 13.7)	2.2 (2.1)	(-2.0, 6.4)	0.301
	Placebo	138	106 (76.8)	8.5 (1.5)	(5.5, 11.4)			
Week 17	Tezepelumab	137	104 (75.9)	11.4 (1.5)	(8.4, 14.4)	2.8 (2.2)	(-1.4, 7.0)	0.195
	Placebo	138	104 (75.4)	8.6 (1.5)	(5.7, 11.6)			
Week 18	Tezepelumab	137	104 (75.9)	10.8 (1.5)	(7.8, 13.8)	2.8 (2.1)	(-1.4, 7.0)	0.192
	Placebo	138	107 (77.5)	8.0 (1.5)	(5.1, 11.0)			
Week 19	Tezepelumab	137	105 (76.6)	11.4 (1.5)	(8.4, 14.4)	3.2 (2.2)	(-1.1, 7.4)	0.141
	Placebo	138	106 (76.8)	8.2 (1.5)	(5.3, 11.2)			
Week 20	Tezepelumab	137	105 (76.6)	10.7 (1.5)	(7.7, 13.7)	1.5 (2.2)	(-2.7, 5.8)	0.474
	Placebo	138	105 (76.1)	9.2 (1.5)	(6.2, 12.1)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITT

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	137	106 (77.4)	10.5 (1.5)	(7.5, 13.5)	2.2 (2.2)	(-2.0, 6.5)	0.299
	Placebo	138	107 (77.5)	8.2 (1.5)	(5.3, 11.2)			
Week 22	Tezepelumab	137	104 (75.9)	10.9 (1.5)	(7.9, 13.9)	2.7 (2.2)	(-1.5, 6.9)	0.209
	Placebo	138	106 (76.8)	8.2 (1.5)	(5.2, 11.2)			
Week 23	Tezepelumab	137	104 (75.9)	12.1 (1.5)	(9.1, 15.1)	2.6 (2.2)	(-1.7, 6.8)	0.233
	Placebo	138	101 (73.2)	9.5 (1.5)	(6.5, 12.5)			
Week 24	Tezepelumab	137	104 (75.9)	13.0 (1.5)	(9.9, 16.0)	2.4 (2.2)	(-1.9, 6.6)	0.269
	Placebo	138	105 (76.1)	10.6 (1.5)	(7.6, 13.6)			
Week 25	Tezepelumab	137	104 (75.9)	11.3 (1.5)	(8.3, 14.3)	1.8 (2.2)	(-2.5, 6.0)	0.416
	Placebo	138	104 (75.4)	9.5 (1.5)	(6.6, 12.5)			
Week 26	Tezepelumab	137	105 (76.6)	12.1 (1.5)	(9.0, 15.1)	2.5 (2.2)	(-1.8, 6.7)	0.251
	Placebo	138	104 (75.4)	9.6 (1.5)	(6.6, 12.6)			
Week 27	Tezepelumab	137	103 (75.2)	11.7 (1.5)	(8.6, 14.7)	2.6 (2.2)	(-1.6, 6.9)	0.223
	Placebo	138	104 (75.4)	9.0 (1.5)	(6.0, 12.0)			
Week 28	Tezepelumab	137	101 (73.7)	12.3 (1.5)	(9.3, 15.4)	2.7 (2.2)	(-1.5, 7.0)	0.206
	Placebo	138	104 (75.4)	9.6 (1.5)	(6.6, 12.6)			
Week 29	Tezepelumab	137	104 (75.9)	12.1 (1.5)	(9.1, 15.1)	2.6 (2.2)	(-1.6, 6.9)	0.224
	Placebo	138	103 (74.6)	9.4 (1.5)	(6.4, 12.4)			
Week 30	Tezepelumab	137	104 (75.9)	12.4 (1.5)	(9.4, 15.4)	2.4 (2.2)	(-1.8, 6.7)	0.261
	Placebo	138	103 (74.6)	10.0 (1.5)	(6.9, 13.0)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITT

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	137	104 (75.9)	12.7 (1.5)	(9.7, 15.8)	1.8 (2.2)	(-2.5, 6.1)	0.407
	Placebo	138	103 (74.6)	10.9 (1.5)	(7.9, 14.0)			
Week 32	Tezepelumab	137	105 (76.6)	13.2 (1.5)	(10.2, 16.2)	2.4 (2.2)	(-1.8, 6.7)	0.261
	Placebo	138	103 (74.6)	10.8 (1.5)	(7.7, 13.8)			
Week 33	Tezepelumab	137	104 (75.9)	13.1 (1.5)	(10.1, 16.1)	1.9 (2.2)	(-2.4, 6.2)	0.389
	Placebo	138	100 (72.5)	11.2 (1.5)	(8.2, 14.3)			
Week 34	Tezepelumab	137	104 (75.9)	13.2 (1.5)	(10.1, 16.2)	1.2 (2.2)	(-3.1, 5.4)	0.594
	Placebo	138	102 (73.9)	12.0 (1.5)	(9.0, 15.0)			
Week 35	Tezepelumab	137	103 (75.2)	13.1 (1.5)	(10.1, 16.2)	2.6 (2.2)	(-1.7, 6.9)	0.233
	Placebo	138	102 (73.9)	10.5 (1.5)	(7.5, 13.5)			
Week 36	Tezepelumab	137	104 (75.9)	13.3 (1.5)	(10.3, 16.3)	3.1 (2.2)	(-1.2, 7.4)	0.156
	Placebo	138	102 (73.9)	10.2 (1.5)	(7.2, 13.2)			
Week 37	Tezepelumab	137	104 (75.9)	13.2 (1.5)	(10.2, 16.3)	3.1 (2.2)	(-1.2, 7.3)	0.161
	Placebo	138	101 (73.2)	10.2 (1.5)	(7.2, 13.2)			
Week 38	Tezepelumab	137	103 (75.2)	12.9 (1.5)	(9.9, 15.9)	1.4 (2.2)	(-2.9, 5.6)	0.531
	Placebo	138	103 (74.6)	11.5 (1.5)	(8.5, 14.5)			
Week 39	Tezepelumab	137	104 (75.9)	12.3 (1.5)	(9.3, 15.3)	0.7 (2.2)	(-3.6, 5.0)	0.751
	Placebo	138	101 (73.2)	11.6 (1.5)	(8.6, 14.6)			
Week 40	Tezepelumab	137	104 (75.9)	13.8 (1.5)	(10.8, 16.9)	3.7 (2.2)	(-0.5, 8.0)	0.087
	Placebo	138	104 (75.4)	10.1 (1.5)	(7.1, 13.1)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITT

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	137	102 (74.5)	13.6 (1.6)	(10.6, 16.7)	2.3 (2.2)	(-1.9, 6.6)	0.283
	Placebo	138	103 (74.6)	11.3 (1.5)	(8.3, 14.3)			
Week 42	Tezepelumab	137	103 (75.2)	13.6 (1.6)	(10.6, 16.7)	2.9 (2.2)	(-1.4, 7.2)	0.187
	Placebo	138	99 (71.7)	10.7 (1.5)	(7.7, 13.8)			
Week 43	Tezepelumab	137	100 (73.0)	14.0 (1.6)	(11.0, 17.1)	3.0 (2.2)	(-1.3, 7.3)	0.173
	Placebo	138	100 (72.5)	11.1 (1.5)	(8.0, 14.1)			
Week 44	Tezepelumab	137	102 (74.5)	13.6 (1.6)	(10.6, 16.7)	3.2 (2.2)	(-1.1, 7.5)	0.148
	Placebo	138	101 (73.2)	10.5 (1.5)	(7.4, 13.5)			
Week 45	Tezepelumab	137	101 (73.7)	13.8 (1.6)	(10.8, 16.9)	2.3 (2.2)	(-2.0, 6.6)	0.299
	Placebo	138	100 (72.5)	11.6 (1.5)	(8.5, 14.6)			
Week 46	Tezepelumab	137	102 (74.5)	13.2 (1.6)	(10.2, 16.3)	2.1 (2.2)	(-2.2, 6.4)	0.347
	Placebo	138	102 (73.9)	11.2 (1.5)	(8.2, 14.2)			
Week 47	Tezepelumab	137	101 (73.7)	13.3 (1.6)	(10.3, 16.4)	1.9 (2.2)	(-2.4, 6.2)	0.379
	Placebo	138	101 (73.2)	11.4 (1.5)	(8.4, 14.4)			
Week 48	Tezepelumab	137	98 (71.5)	14.1 (1.6)	(11.1, 17.2)	2.6 (2.2)	(-1.7, 6.9)	0.240
	Placebo	138	102 (73.9)	11.5 (1.5)	(8.5, 14.6)			
Week 49	Tezepelumab	137	101 (73.7)	13.6 (1.6)	(10.6, 16.7)	1.3 (2.2)	(-3.0, 5.6)	0.550
	Placebo	138	97 (70.3)	12.3 (1.6)	(9.3, 15.3)			
Week 50	Tezepelumab	137	98 (71.5)	13.8 (1.6)	(10.7, 16.9)	2.1 (2.2)	(-2.3, 6.4)	0.348
	Placebo	138	102 (73.9)	11.7 (1.5)	(8.7, 14.7)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITT

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	137	91 (66.4)	13.6 (1.6)	(10.5, 16.8)	1.1 (2.2)	(-3.3, 5.4)	0.635
	Placebo	138	99 (71.7)	12.6 (1.6)	(9.5, 15.6)			
Week 52	Tezepelumab	137	33 (24.1)	14.0 (2.0)	(10.1, 17.9)	4.0 (2.8)	(-1.4, 9.4)	0.149
	Placebo	138	38 (27.5)	10.1 (1.9)	(6.3, 13.8)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Figure PF2VSC_IOMG0: Course of EQ-5D-VAS
DITT



Note: DITT = Dossier Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
VAS = visual analogue scale.
Source table: PT2VSC_IOMH0
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	50	42 (84.0)	64.05 (16.03)	29.0	50.00	70.00	75.00	93.0	
			Placebo	44	41 (93.2)	62.02 (14.54)	29.0	51.00	60.00	72.00	97.0	
		Week 4	Tezepelumab	50	47 (94.0)	71.70 (17.86)	40.0	55.00	74.00	89.00	100.0	
			Placebo	44	42 (95.5)	67.02 (18.06)	17.0	54.00	70.00	80.00	93.0	
		Week 8	Tezepelumab	50	47 (94.0)	72.19 (19.31)	37.0	55.00	75.00	93.00	100.0	
			Placebo	44	42 (95.5)	65.93 (17.16)	19.0	53.00	64.00	77.00	98.0	
		Week 12	Tezepelumab	50	47 (94.0)	74.02 (17.50)	41.0	60.00	75.00	89.00	100.0	
			Placebo	44	42 (95.5)	67.24 (17.45)	20.0	57.00	70.00	78.00	94.0	
		Week 20	Tezepelumab	50	47 (94.0)	72.38 (18.51)	25.0	60.00	71.00	90.00	100.0	
			Placebo	44	42 (95.5)	66.95 (18.70)	20.0	55.00	70.00	82.00	94.0	
		Week 28	Tezepelumab	50	48 (96.0)	73.42 (18.18)	29.0	60.00	74.00	89.50	100.0	
			Placebo	44	43 (97.7)	69.28 (18.12)	27.0	54.00	72.00	84.00	94.0	
		Week 40	Tezepelumab	50	49 (98.0)	75.18 (17.74)	32.0	65.00	79.00	88.00	100.0	
			Placebo	44	43 (97.7)	69.00 (18.71)	20.0	54.00	73.00	85.00	95.0	
		Week 52	Tezepelumab	50	49 (98.0)	75.04 (18.04)	27.0	62.00	74.00	90.00	100.0	
			Placebo	44	43 (97.7)	71.33 (17.69)	27.0	58.00	76.00	83.00	98.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	50	42 (84.0)	10.17 (15.28)	-20.0	0.00	11.00	18.00	47.0	0.32 [-0.11, 0.75]
			Placebo	44	41 (93.2)	5.51 (13.74)	-22.0	-6.00	7.00	14.00	44.0	
		Week 8	Tezepelumab	50	42 (84.0)	9.69 (14.55)	-30.0	0.00	11.00	21.00	38.0	0.37 [-0.06, 0.80]
			Placebo	44	41 (93.2)	4.24 (14.84)	-31.0	-6.00	2.00	12.00	43.0	
		Week 12	Tezepelumab	50	42 (84.0)	11.95 (13.86)	-14.0	1.00	10.50	23.00	41.0	0.45 [0.02, 0.89]
			Placebo	44	41 (93.2)	5.46 (14.68)	-25.0	-3.00	1.00	12.00	43.0	
		Week 20	Tezepelumab	50	42 (84.0)	10.31 (16.69)	-32.0	-1.00	12.00	25.00	41.0	0.32 [-0.12, 0.75]
			Placebo	44	41 (93.2)	5.10 (16.17)	-32.0	-5.00	4.00	15.00	43.0	
		Week 28	Tezepelumab	50	42 (84.0)	11.88 (15.53)	-13.0	1.00	11.00	25.00	50.0	0.34 [-0.09, 0.77]
			Placebo	44	41 (93.2)	6.59 (15.51)	-17.0	-5.00	5.00	15.00	41.0	
		Week 40	Tezepelumab	50	42 (84.0)	13.24 (16.40)	-19.0	3.00	13.00	26.00	46.0	0.40 [-0.03, 0.84]
			Placebo	44	41 (93.2)	6.71 (15.93)	-26.0	-3.00	4.00	15.00	41.0	
		Week 52	Tezepelumab	50	42 (84.0)	13.12 (16.53)	-24.0	4.00	15.00	25.00	49.0	0.27 [-0.16, 0.70]
			Placebo	44	41 (93.2)	8.85 (15.16)	-15.0	-3.00	7.00	17.00	43.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	87	81 (93.1)	58.83 (16.63)	20.0	49.00	57.00	70.00	100.0	
			Placebo	94	79 (84.0)	59.68 (15.19)	23.0	49.00	60.00	70.00	96.0	
		Week 4	Tezepelumab	87	82 (94.3)	64.88 (18.18)	14.0	51.00	65.00	78.00	100.0	
			Placebo	94	83 (88.3)	64.76 (16.60)	25.0	53.00	65.00	76.00	99.0	
		Week 8	Tezepelumab	87	82 (94.3)	65.61 (18.47)	20.0	54.00	62.00	85.00	100.0	
			Placebo	94	85 (90.4)	67.92 (17.73)	14.0	54.00	69.00	81.00	100.0	
		Week 12	Tezepelumab	87	82 (94.3)	67.01 (18.86)	26.0	50.00	68.00	82.00	100.0	
			Placebo	94	86 (91.5)	69.29 (18.36)	19.0	60.00	71.50	83.00	100.0	
		Week 20	Tezepelumab	87	84 (96.6)	67.40 (18.24)	18.0	54.00	70.00	81.00	100.0	
			Placebo	94	86 (91.5)	69.52 (17.63)	19.0	61.00	70.00	84.00	100.0	
		Week 28	Tezepelumab	87	84 (96.6)	68.95 (17.61)	8.0	54.50	71.00	82.00	100.0	
			Placebo	94	86 (91.5)	69.13 (17.95)	12.0	56.00	69.50	82.00	100.0	
		Week 40	Tezepelumab	87	84 (96.6)	70.18 (17.61)	18.0	56.50	73.00	83.00	100.0	
			Placebo	94	87 (92.6)	69.32 (17.32)	20.0	54.00	71.00	85.00	100.0	
		Week 52	Tezepelumab	87	85 (97.7)	70.00 (19.16)	19.0	52.00	73.00	85.00	100.0	
			Placebo	94	88 (93.6)	69.89 (18.57)	16.0	56.50	71.00	85.50	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	87	78 (89.7)	6.08 (18.27)	-51.0	-3.00	5.00	19.00	50.0	0.03 [-0.28, 0.35]
			Placebo	94	79 (84.0)	5.48 (16.11)	-40.0	-4.00	5.00	11.00	63.0	
		Week 8	Tezepelumab	87	78 (89.7)	6.77 (20.69)	-59.0	-3.00	5.50	17.00	69.0	-0.10 [-0.41, 0.22]
			Placebo	94	79 (84.0)	8.66 (18.81)	-36.0	-2.00	7.00	17.00	62.0	
		Week 12	Tezepelumab	87	78 (89.7)	8.17 (21.18)	-51.0	-5.00	6.50	20.00	65.0	-0.09 [-0.40, 0.23]
			Placebo	94	79 (84.0)	9.97 (20.44)	-39.0	-4.00	8.00	21.00	69.0	
		Week 20	Tezepelumab	87	79 (90.8)	8.80 (21.10)	-51.0	-5.00	9.00	24.00	55.0	-0.10 [-0.42, 0.21]
			Placebo	94	79 (84.0)	10.73 (16.21)	-25.0	0.00	9.00	20.00	57.0	
		Week 28	Tezepelumab	87	79 (90.8)	10.08 (20.43)	-43.0	-3.00	8.00	25.00	60.0	0.00 [-0.31, 0.32]
			Placebo	94	79 (84.0)	9.99 (17.58)	-30.0	-2.00	8.00	21.00	65.0	
		Week 40	Tezepelumab	87	79 (90.8)	11.14 (20.24)	-43.0	-3.00	11.00	25.00	58.0	0.02 [-0.29, 0.34]
			Placebo	94	79 (84.0)	10.67 (17.43)	-23.0	-3.00	8.00	21.00	59.0	
		Week 52	Tezepelumab	87	79 (90.8)	10.89 (20.45)	-43.0	-3.00	12.00	25.00	58.0	-0.02 [-0.34, 0.29]
			Placebo	94	79 (84.0)	11.35 (18.43)	-26.0	-3.00	8.00	22.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	114	103 (90.4)	61.50 (16.65)	20.0	50.00	61.00	73.00	100.0	
			Placebo	118	104 (88.1)	60.78 (15.25)	23.0	50.00	60.00	70.00	97.0	
		Week 4	Tezepelumab	114	107 (93.9)	68.26 (17.98)	14.0	53.00	68.00	84.00	100.0	
			Placebo	118	108 (91.5)	66.11 (17.71)	17.0	53.50	69.00	79.50	99.0	
		Week 8	Tezepelumab	114	107 (93.9)	69.20 (19.43)	20.0	54.00	70.00	87.00	100.0	
			Placebo	118	110 (93.2)	68.10 (17.40)	19.0	53.00	69.00	82.00	100.0	
		Week 12	Tezepelumab	114	107 (93.9)	71.08 (18.65)	26.0	56.00	72.00	87.00	100.0	
			Placebo	118	111 (94.1)	69.23 (18.34)	19.0	57.00	72.00	84.00	100.0	
		Week 20	Tezepelumab	114	108 (94.7)	70.63 (18.41)	18.0	59.50	70.50	85.00	100.0	
			Placebo	118	111 (94.1)	69.16 (18.32)	19.0	57.00	70.00	84.00	100.0	
		Week 28	Tezepelumab	114	109 (95.6)	71.15 (18.32)	8.0	59.00	72.00	83.00	100.0	
			Placebo	118	111 (94.1)	69.09 (18.04)	12.0	55.00	70.00	82.00	100.0	
		Week 40	Tezepelumab	114	110 (96.5)	72.69 (18.07)	18.0	61.00	75.00	87.00	100.0	
			Placebo	118	112 (94.9)	69.56 (17.93)	20.0	54.00	72.50	85.00	100.0	
		Week 52	Tezepelumab	114	111 (97.4)	72.50 (19.11)	19.0	60.00	75.00	87.00	100.0	
			Placebo	118	113 (95.8)	70.58 (18.51)	16.0	58.00	74.00	85.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	114	100 (87.7)	7.32 (15.63)	-40.0	-2.00	7.50	18.50	41.0	0.10 [-0.17, 0.38]
			Placebo	118	104 (88.1)	5.69 (15.47)	-40.0	-4.00	5.00	11.50	63.0	
		Week 8	Tezepelumab	114	100 (87.7)	7.88 (17.96)	-59.0	-2.50	9.00	18.50	69.0	0.01 [-0.26, 0.29]
			Placebo	118	104 (88.1)	7.65 (17.63)	-31.0	-4.00	5.00	16.50	62.0	
		Week 12	Tezepelumab	114	100 (87.7)	9.92 (17.79)	-34.0	-2.00	7.50	22.00	65.0	0.07 [-0.21, 0.34]
			Placebo	118	104 (88.1)	8.72 (18.57)	-34.0	-3.00	6.00	17.50	69.0	
		Week 20	Tezepelumab	114	101 (88.6)	9.76 (18.53)	-44.0	-4.00	12.00	24.00	51.0	0.04 [-0.23, 0.32]
			Placebo	118	104 (88.1)	9.04 (16.37)	-32.0	-2.00	7.00	17.50	57.0	
		Week 28	Tezepelumab	114	101 (88.6)	10.27 (18.62)	-43.0	-3.00	9.00	25.00	60.0	0.09 [-0.19, 0.36]
			Placebo	118	104 (88.1)	8.72 (16.46)	-20.0	-3.50	6.00	18.00	65.0	
		Week 40	Tezepelumab	114	101 (88.6)	11.65 (18.71)	-43.0	-2.00	13.00	25.00	58.0	0.12 [-0.16, 0.39]
			Placebo	118	104 (88.1)	9.59 (16.64)	-25.0	-3.00	8.00	19.00	59.0	
		Week 52	Tezepelumab	114	101 (88.6)	11.52 (18.82)	-43.0	-3.00	13.00	25.00	58.0	0.04 [-0.23, 0.32]
			Placebo	118	104 (88.1)	10.74 (17.47)	-26.0	-3.00	7.50	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	56.00 (15.56)	30.0	46.50	51.50	65.50	90.0	
			Placebo	20	16 (80.0)	58.56 (13.09)	33.0	50.00	53.00	70.00	79.0	
		Week 4	Tezepelumab	23	22 (95.7)	63.00 (19.61)	21.0	49.00	63.00	79.00	99.0	
			Placebo	20	17 (85.0)	61.76 (11.95)	45.0	54.00	59.00	67.00	87.0	
		Week 8	Tezepelumab	23	22 (95.7)	62.23 (15.75)	37.0	53.00	59.00	75.00	96.0	
			Placebo	20	17 (85.0)	61.82 (17.72)	14.0	60.00	63.00	75.00	81.0	
		Week 12	Tezepelumab	23	22 (95.7)	62.18 (16.96)	38.0	50.00	59.50	72.00	100.0	
			Placebo	20	17 (85.0)	64.65 (15.74)	31.0	58.00	62.00	74.00	90.0	
		Week 20	Tezepelumab	23	23 (100.0)	62.43 (17.29)	39.0	48.00	61.00	77.00	98.0	
			Placebo	20	17 (85.0)	65.53 (15.42)	30.0	60.00	64.00	80.00	92.0	
		Week 28	Tezepelumab	23	23 (100.0)	67.87 (15.70)	39.0	51.00	70.00	82.00	100.0	
			Placebo	20	18 (90.0)	69.72 (17.80)	30.0	57.00	71.00	84.00	93.0	
		Week 40	Tezepelumab	23	23 (100.0)	68.83 (16.19)	39.0	52.00	68.00	83.00	96.0	
			Placebo	20	18 (90.0)	67.06 (16.69)	43.0	54.00	68.50	79.00	95.0	
		Week 52	Tezepelumab	23	23 (100.0)	68.70 (17.60)	37.0	53.00	69.00	85.00	95.0	
			Placebo	20	18 (90.0)	68.94 (16.74)	38.0	58.00	71.50	81.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	8.45 (24.64)	-51.0	-5.00	10.50	21.50	50.0	0.21 [-0.45, 0.86]
			Placebo	20	16 (80.0)	4.19 (14.46)	-20.0	-6.00	5.50	13.00	32.0	
		Week 8	Tezepelumab	23	20 (87.0)	7.35 (22.87)	-51.0	-3.50	3.50	16.00	56.0	0.17 [-0.49, 0.83]
			Placebo	20	16 (80.0)	3.88 (17.70)	-36.0	-4.50	5.50	13.50	37.0	
		Week 12	Tezepelumab	23	20 (87.0)	7.35 (24.45)	-51.0	-2.50	2.50	16.50	58.0	0.03 [-0.62, 0.69]
			Placebo	20	16 (80.0)	6.56 (20.26)	-39.0	-1.50	6.00	17.50	50.0	
		Week 20	Tezepelumab	23	20 (87.0)	7.10 (24.84)	-51.0	-9.50	4.50	22.50	55.0	-0.01 [-0.67, 0.65]
			Placebo	20	16 (80.0)	7.31 (16.69)	-20.0	-4.00	7.00	13.50	49.0	
		Week 28	Tezepelumab	23	20 (87.0)	12.90 (20.21)	-14.0	-1.00	10.00	32.00	55.0	0.17 [-0.49, 0.83]
			Placebo	20	16 (80.0)	9.50 (20.19)	-30.0	0.00	8.00	21.50	54.0	
		Week 40	Tezepelumab	23	20 (87.0)	12.95 (20.64)	-21.0	-1.00	11.50	25.50	50.0	0.27 [-0.39, 0.93]
			Placebo	20	16 (80.0)	7.56 (19.47)	-26.0	-4.50	3.50	21.00	56.0	
		Week 52	Tezepelumab	23	20 (87.0)	12.35 (21.16)	-24.0	-1.00	12.00	25.00	56.0	0.18 [-0.48, 0.83]
			Placebo	20	16 (80.0)	8.94 (17.11)	-13.0	-3.50	8.00	16.50	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	105	94 (89.5)	60.06 (16.12)	29.0	49.00	60.00	72.00	100.0	
			Placebo	110	97 (88.2)	61.39 (15.14)	23.0	50.00	62.00	70.00	97.0	
		Week 4	Tezepelumab	105	100 (95.2)	67.48 (17.90)	21.0	53.50	67.00	80.50	100.0	
			Placebo	110	100 (90.9)	66.03 (17.15)	17.0	54.00	69.00	76.50	99.0	
		Week 8	Tezepelumab	105	100 (95.2)	67.05 (18.75)	20.0	53.50	65.00	84.00	100.0	
			Placebo	110	102 (92.7)	67.34 (18.03)	14.0	53.00	69.00	80.00	100.0	
		Week 12	Tezepelumab	105	100 (95.2)	68.36 (18.53)	26.0	52.50	68.00	82.00	100.0	
			Placebo	110	103 (93.6)	68.58 (17.60)	19.0	58.00	71.00	81.00	100.0	
		Week 20	Tezepelumab	105	101 (96.2)	68.25 (17.64)	18.0	55.00	65.00	81.00	100.0	
			Placebo	110	103 (93.6)	69.62 (16.91)	19.0	60.00	70.00	82.00	100.0	
		Week 28	Tezepelumab	105	102 (97.1)	69.51 (18.05)	8.0	55.00	70.00	83.00	100.0	
			Placebo	110	104 (94.5)	69.90 (17.40)	12.0	58.50	71.00	82.00	100.0	
		Week 40	Tezepelumab	105	103 (98.1)	71.36 (17.94)	18.0	58.00	74.00	84.00	100.0	
			Placebo	110	104 (94.5)	70.61 (17.06)	20.0	57.00	73.00	85.00	100.0	
		Week 52	Tezepelumab	105	103 (98.1)	71.13 (19.34)	19.0	54.00	74.00	86.00	100.0	
			Placebo	110	105 (95.5)	71.35 (17.51)	16.0	60.00	74.00	85.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	105	93 (88.6)	8.47 (16.53)	-51.0	-2.00	8.00	18.00	50.0	0.23 [-0.06, 0.51]
			Placebo	110	97 (88.2)	4.87 (15.37)	-40.0	-5.00	4.00	11.00	63.0	
		Week 8	Tezepelumab	105	93 (88.6)	7.51 (17.18)	-51.0	-3.00	7.00	16.00	56.0	0.08 [-0.21, 0.36]
			Placebo	110	97 (88.2)	6.21 (17.25)	-36.0	-4.00	5.00	14.00	57.0	
		Week 12	Tezepelumab	105	93 (88.6)	9.09 (18.54)	-51.0	-2.00	7.00	20.00	58.0	0.09 [-0.20, 0.37]
			Placebo	110	97 (88.2)	7.45 (17.92)	-39.0	-3.00	5.00	17.00	69.0	
		Week 20	Tezepelumab	105	93 (88.6)	9.04 (18.49)	-51.0	-3.00	11.00	22.00	55.0	0.02 [-0.27, 0.30]
			Placebo	110	97 (88.2)	8.77 (15.22)	-24.0	-2.00	7.00	17.00	57.0	
		Week 28	Tezepelumab	105	93 (88.6)	10.37 (17.82)	-41.0	-3.00	8.00	25.00	55.0	0.10 [-0.18, 0.39]
			Placebo	110	97 (88.2)	8.59 (16.48)	-30.0	-3.00	6.00	21.00	58.0	
		Week 40	Tezepelumab	105	93 (88.6)	11.95 (18.05)	-31.0	-2.00	12.00	25.00	56.0	0.14 [-0.14, 0.43]
			Placebo	110	97 (88.2)	9.49 (16.24)	-26.0	-2.00	6.00	19.00	59.0	
		Week 52	Tezepelumab	105	93 (88.6)	11.62 (17.79)	-30.0	-2.00	13.00	25.00	56.0	0.09 [-0.20, 0.37]
			Placebo	110	97 (88.2)	10.18 (16.04)	-13.0	-2.00	7.00	17.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	32	29 (90.6)	62.38 (18.03)	20.0	51.00	60.00	74.00	100.0	
			Placebo	28	23 (82.1)	56.65 (13.80)	32.0	48.00	57.00	65.00	86.0	
		Week 4	Tezepelumab	32	29 (90.6)	66.97 (19.92)	14.0	50.00	66.00	81.00	100.0	
			Placebo	28	25 (89.3)	63.48 (16.89)	23.0	51.00	61.00	80.00	94.0	
		Week 8	Tezepelumab	32	29 (90.6)	71.31 (19.71)	31.0	60.00	70.00	89.00	100.0	
			Placebo	28	25 (89.3)	66.92 (15.47)	45.0	53.00	62.00	80.00	94.0	
		Week 12	Tezepelumab	32	29 (90.6)	73.72 (18.63)	35.0	65.00	77.00	89.00	100.0	
			Placebo	28	25 (89.3)	68.76 (20.06)	20.0	57.00	70.00	84.00	100.0	
		Week 20	Tezepelumab	32	30 (93.8)	72.37 (20.85)	25.0	65.00	77.00	88.00	100.0	
			Placebo	28	25 (89.3)	64.80 (21.69)	20.0	51.00	68.00	83.00	95.0	
		Week 28	Tezepelumab	32	30 (93.8)	74.20 (17.07)	35.0	70.00	77.50	88.00	100.0	
			Placebo	28	25 (89.3)	66.16 (20.12)	30.0	50.00	64.00	85.00	97.0	
		Week 40	Tezepelumab	32	30 (93.8)	74.30 (17.21)	35.0	68.00	79.00	85.00	100.0	
			Placebo	28	26 (92.9)	63.65 (19.53)	20.0	48.00	63.00	78.00	95.0	
		Week 52	Tezepelumab	32	31 (96.9)	74.23 (17.19)	35.0	62.00	78.00	88.00	100.0	
			Placebo	28	26 (92.9)	66.35 (20.77)	21.0	51.00	65.00	80.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	32	27 (84.4)	4.19 (19.82)	-40.0	-12.00	8.00	20.00	31.0	-0.22 [-0.78, 0.34]
			Placebo	28	23 (82.1)	8.13 (14.95)	-22.0	3.00	8.00	12.00	51.0	
		Week 8	Tezepelumab	32	27 (84.4)	8.78 (23.77)	-59.0	0.00	10.00	22.00	69.0	-0.11 [-0.66, 0.45]
			Placebo	28	23 (82.1)	11.13 (18.98)	-22.0	-3.00	8.00	19.00	62.0	
		Week 12	Tezepelumab	32	27 (84.4)	10.89 (20.67)	-34.0	0.00	11.00	23.00	65.0	-0.08 [-0.64, 0.48]
			Placebo	28	23 (82.1)	12.57 (21.80)	-25.0	-4.00	11.00	24.00	68.0	
		Week 20	Tezepelumab	32	28 (87.5)	10.25 (23.35)	-44.0	-9.50	10.50	29.00	51.0	0.06 [-0.49, 0.61]
			Placebo	28	23 (82.1)	8.96 (20.86)	-32.0	-4.00	10.00	18.00	51.0	
		Week 28	Tezepelumab	32	28 (87.5)	11.82 (22.18)	-43.0	3.00	10.50	30.00	60.0	0.10 [-0.46, 0.65]
			Placebo	28	23 (82.1)	9.83 (18.98)	-15.0	-4.00	9.00	15.00	65.0	
		Week 40	Tezepelumab	32	28 (87.5)	11.61 (22.05)	-43.0	0.00	14.00	26.00	58.0	0.14 [-0.41, 0.70]
			Placebo	28	23 (82.1)	8.57 (20.14)	-25.0	-6.00	8.00	18.00	55.0	
		Week 52	Tezepelumab	32	28 (87.5)	11.79 (23.44)	-43.0	-6.00	14.00	29.50	58.0	-0.00 [-0.56, 0.55]
			Placebo	28	23 (82.1)	11.87 (22.47)	-26.0	-4.00	11.00	24.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	60.50 (16.71)	20.0	49.00	60.00	72.00	100.0	
			Placebo	123	105 (85.4)	61.22 (14.41)	23.0	50.00	60.00	70.00	97.0	
		Week 4	Tezepelumab	128	120 (93.8)	67.02 (18.39)	14.0	52.00	67.00	80.50	100.0	
			Placebo	123	110 (89.4)	65.65 (16.90)	17.0	54.00	68.50	77.00	99.0	
		Week 8	Tezepelumab	128	120 (93.8)	67.26 (18.93)	20.0	54.00	66.00	84.50	100.0	
			Placebo	123	112 (91.1)	67.21 (17.33)	14.0	53.50	69.00	79.50	100.0	
		Week 12	Tezepelumab	128	120 (93.8)	69.09 (18.65)	26.0	52.50	70.00	83.50	100.0	
			Placebo	123	113 (91.9)	68.17 (17.65)	19.0	57.00	71.00	80.00	100.0	
		Week 20	Tezepelumab	128	122 (95.3)	68.56 (18.41)	18.0	55.00	70.00	82.00	100.0	
			Placebo	123	113 (91.9)	68.85 (17.97)	19.0	58.00	70.00	82.00	100.0	
		Week 28	Tezepelumab	128	123 (96.1)	70.02 (18.01)	8.0	57.00	71.00	83.00	100.0	
			Placebo	123	114 (92.7)	69.26 (17.80)	12.0	56.00	70.50	82.00	100.0	
		Week 40	Tezepelumab	128	124 (96.9)	71.81 (17.94)	18.0	58.50	75.00	84.50	100.0	
			Placebo	123	115 (93.5)	69.31 (17.47)	20.0	55.00	71.00	81.00	100.0	
		Week 52	Tezepelumab	128	125 (97.7)	71.71 (18.93)	19.0	57.00	74.00	86.00	100.0	
			Placebo	123	116 (94.3)	69.89 (17.89)	16.0	58.50	73.00	83.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	128	112 (87.5)	7.24 (17.20)	-51.0	-2.00	7.50	18.00	50.0	0.14 [-0.12, 0.41]
			Placebo	123	105 (85.4)	4.96 (14.07)	-40.0	-5.00	5.00	11.00	44.0	
		Week 8	Tezepelumab	128	112 (87.5)	7.06 (18.86)	-59.0	-3.00	8.00	16.00	69.0	0.04 [-0.23, 0.30]
			Placebo	123	105 (85.4)	6.41 (16.40)	-36.0	-4.00	5.00	16.00	57.0	
		Week 12	Tezepelumab	128	112 (87.5)	9.05 (19.30)	-51.0	-2.00	7.00	20.00	65.0	0.10 [-0.17, 0.36]
			Placebo	123	105 (85.4)	7.26 (17.15)	-39.0	-4.00	5.00	17.00	59.0	
		Week 20	Tezepelumab	128	113 (88.3)	8.73 (19.46)	-51.0	-4.00	10.00	24.00	55.0	0.02 [-0.24, 0.29]
			Placebo	123	105 (85.4)	8.34 (15.87)	-32.0	-2.00	7.00	16.00	57.0	
		Week 28	Tezepelumab	128	113 (88.3)	10.17 (19.03)	-43.0	-3.00	9.00	25.00	60.0	0.11 [-0.15, 0.38]
			Placebo	123	105 (85.4)	8.20 (16.15)	-30.0	-3.00	6.00	20.00	58.0	
		Week 40	Tezepelumab	128	113 (88.3)	11.68 (19.24)	-43.0	-1.00	12.00	25.00	58.0	0.16 [-0.10, 0.43]
			Placebo	123	105 (85.4)	8.77 (16.17)	-26.0	-3.00	6.00	19.00	56.0	
		Week 52	Tezepelumab	128	113 (88.3)	11.56 (18.85)	-43.0	-2.00	13.00	25.00	58.0	0.13 [-0.14, 0.39]
			Placebo	123	105 (85.4)	9.33 (15.79)	-26.0	-3.00	6.00	18.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	61.67 (11.24)	52.0	52.00	59.00	74.00	74.0	
			Placebo	6	6 (100.0)	63.83 (20.48)	32.0	50.00	67.50	80.00	86.0	
		Week 4	Tezepelumab	3	3 (100.0)	78.33 (11.59)	66.0	66.00	80.00	89.00	89.0	
			Placebo	6	6 (100.0)	70.33 (20.83)	35.0	60.00	75.00	83.00	94.0	
		Week 8	Tezepelumab	3	3 (100.0)	88.00 (6.00)	82.0	82.00	88.00	94.00	94.0	
			Placebo	6	6 (100.0)	70.83 (19.30)	40.0	59.00	74.50	83.00	94.0	
		Week 12	Tezepelumab	3	3 (100.0)	82.00 (7.55)	75.0	75.00	81.00	90.00	90.0	
			Placebo	6	6 (100.0)	73.83 (23.04)	31.0	66.00	81.50	89.00	94.0	
		Week 20	Tezepelumab	3	3 (100.0)	83.00 (9.17)	75.0	75.00	81.00	93.00	93.0	
			Placebo	6	6 (100.0)	75.83 (21.39)	36.0	68.00	84.00	89.00	94.0	
		Week 28	Tezepelumab	3	3 (100.0)	84.67 (5.51)	81.0	81.00	82.00	91.00	91.0	
			Placebo	6	6 (100.0)	70.33 (20.48)	45.0	50.00	72.00	89.00	94.0	
		Week 40	Tezepelumab	3	3 (100.0)	76.33 (7.23)	68.0	68.00	80.00	81.00	81.0	
			Placebo	6	6 (100.0)	69.33 (22.67)	47.0	49.00	69.50	90.00	91.0	
		Week 52	Tezepelumab	3	3 (100.0)	76.33 (12.66)	62.0	62.00	81.00	86.00	86.0	
			Placebo	6	6 (100.0)	78.83 (22.96)	48.0	51.00	90.00	97.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	16.67 (21.39)	-8.0	-8.00	28.00	30.00	30.0	0.42 [-0.99, 1.82]
			Placebo	6	6 (100.0)	6.50 (25.54)	-25.0	-10.00	6.50	10.00	51.0	
		Week 8	Tezepelumab	3	3 (100.0)	26.33 (15.89)	8.0	8.00	35.00	36.00	36.0	0.86 [-0.59, 2.32]
			Placebo	6	6 (100.0)	7.00 (24.49)	-20.0	-11.00	6.50	9.00	51.0	
		Week 12	Tezepelumab	3	3 (100.0)	20.33 (18.56)	1.0	1.00	22.00	38.00	38.0	0.43 [-0.97, 1.84]
			Placebo	6	6 (100.0)	10.00 (25.57)	-29.0	5.00	8.50	16.00	51.0	
		Week 20	Tezepelumab	3	3 (100.0)	21.33 (20.01)	1.0	1.00	22.00	41.00	41.0	0.40 [-1.00, 1.81]
			Placebo	6	6 (100.0)	12.00 (24.17)	-24.0	5.00	11.00	18.00	51.0	
		Week 28	Tezepelumab	3	3 (100.0)	23.00 (15.52)	8.0	8.00	22.00	39.00	39.0	1.24 [-0.29, 2.77]
			Placebo	6	6 (100.0)	6.50 (12.26)	-15.0	0.00	11.00	14.00	18.0	
		Week 40	Tezepelumab	3	3 (100.0)	14.67 (8.08)	6.0	6.00	16.00	22.00	22.0	0.89 [-0.57, 2.36]
			Placebo	6	6 (100.0)	5.50 (11.00)	-11.0	-3.00	7.50	14.00	18.0	
		Week 52	Tezepelumab	3	3 (100.0)	14.67 (23.86)	-12.0	-12.00	22.00	34.00	34.0	-0.01 [-1.40, 1.37]
			Placebo	6	6 (100.0)	15.00 (26.30)	-12.0	1.00	11.00	14.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	64.75 (20.07)	35.0	53.50	72.50	76.00	79.0	
			Placebo	6	6 (100.0)	51.33 (16.21)	27.0	41.00	51.50	65.00	72.0	
		Week 4	Tezepelumab	5	5 (100.0)	73.00 (18.84)	53.0	60.00	66.00	92.00	94.0	
			Placebo	6	6 (100.0)	64.17 (20.55)	38.0	49.00	61.00	86.00	90.0	
		Week 8	Tezepelumab	5	5 (100.0)	77.80 (17.75)	60.0	60.00	78.00	95.00	96.0	
			Placebo	6	6 (100.0)	62.67 (19.66)	43.0	47.00	57.50	82.00	89.0	
		Week 12	Tezepelumab	5	5 (100.0)	76.20 (22.19)	48.0	60.00	78.00	97.00	98.0	
			Placebo	6	6 (100.0)	69.67 (20.01)	42.0	60.00	65.50	89.00	96.0	
		Week 20	Tezepelumab	5	5 (100.0)	80.80 (16.98)	61.0	65.00	85.00	96.00	97.0	
			Placebo	6	6 (100.0)	63.00 (16.97)	46.0	47.00	61.50	70.00	92.0	
		Week 28	Tezepelumab	5	5 (100.0)	79.40 (15.08)	60.0	71.00	77.00	94.00	95.0	
			Placebo	6	6 (100.0)	69.83 (16.14)	47.0	58.00	69.50	85.00	90.0	
		Week 40	Tezepelumab	5	5 (100.0)	79.40 (16.15)	60.0	70.00	75.00	94.00	98.0	
			Placebo	6	6 (100.0)	71.67 (19.06)	46.0	54.00	76.00	87.00	91.0	
		Week 52	Tezepelumab	5	5 (100.0)	78.80 (17.11)	60.0	61.00	88.00	88.00	97.0	
			Placebo	6	6 (100.0)	75.83 (19.30)	45.0	60.00	83.00	89.00	95.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	11.50 (22.04)	-20.0	-2.50	17.50	25.50	31.0	-0.05 [-1.32, 1.21]
			Placebo	6	6 (100.0)	12.83 (26.35)	-14.0	0.00	7.00	14.00	63.0	
		Week 8	Tezepelumab	5	4 (80.0)	17.50 (9.00)	5.0	11.00	20.00	24.00	25.0	0.33 [-0.95, 1.60]
			Placebo	6	6 (100.0)	11.33 (22.74)	-5.0	-3.00	2.00	17.00	55.0	
		Week 12	Tezepelumab	5	4 (80.0)	15.50 (8.54)	5.0	9.00	16.00	22.00	25.0	-0.13 [-1.40, 1.13]
			Placebo	6	6 (100.0)	18.33 (26.36)	-4.0	1.00	12.50	19.00	69.0	
		Week 20	Tezepelumab	5	4 (80.0)	21.00 (23.90)	-8.0	4.50	21.00	37.50	50.0	0.46 [-0.83, 1.74]
			Placebo	6	6 (100.0)	11.67 (17.96)	-6.0	-3.00	8.00	20.00	43.0	
		Week 28	Tezepelumab	5	4 (80.0)	19.50 (13.48)	4.0	9.50	19.00	29.50	36.0	0.06 [-1.21, 1.33]
			Placebo	6	6 (100.0)	18.50 (18.27)	-7.0	6.00	17.50	33.00	44.0	
		Week 40	Tezepelumab	5	4 (80.0)	19.50 (17.64)	-3.0	8.00	20.50	31.00	40.0	-0.04 [-1.30, 1.23]
			Placebo	6	6 (100.0)	20.33 (24.49)	-11.0	5.00	16.50	36.00	59.0	
		Week 52	Tezepelumab	5	4 (80.0)	18.75 (26.63)	-12.0	2.00	17.00	35.50	53.0	-0.24 [-1.51, 1.03]
			Placebo	6	6 (100.0)	24.50 (22.85)	-5.0	4.00	26.00	43.00	53.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	54.00	54.0	54.00	54.00	54.00	54.0	
			Placebo	3	3 (100.0)	46.33 (13.58)	32.0	32.00	48.00	59.00	59.0	
		Week 4	Tezepelumab	1	1 (100.0)	48.00	48.0	48.00	48.00	48.00	48.0	
			Placebo	3	3 (100.0)	53.67 (7.37)	48.0	48.00	51.00	62.00	62.0	
		Week 8	Tezepelumab	1	1 (100.0)	49.00	49.0	49.00	49.00	49.00	49.0	
			Placebo	3	3 (100.0)	71.33 (24.70)	45.0	45.00	75.00	94.00	94.0	
		Week 12	Tezepelumab	1	1 (100.0)	56.00	56.0	56.00	56.00	56.00	56.0	
			Placebo	3	3 (100.0)	73.00 (27.00)	46.0	46.00	73.00	100.00	100.0	
		Week 20	Tezepelumab	1	1 (100.0)	47.00	47.0	47.00	47.00	47.00	47.0	
			Placebo	3	3 (100.0)	59.33 (11.93)	46.0	46.00	63.00	69.00	69.0	
		Week 28	Tezepelumab	1	1 (100.0)	53.00	53.0	53.00	53.00	53.00	53.0	
			Placebo	3	3 (100.0)	62.33 (30.04)	44.0	44.00	46.00	97.00	97.0	
		Week 40	Tezepelumab	1	1 (100.0)	48.00	48.0	48.00	48.00	48.00	48.0	
			Placebo	3	3 (100.0)	60.33 (23.12)	46.0	46.00	48.00	87.00	87.0	
		Week 52	Tezepelumab	1	1 (100.0)	40.00	40.0	40.00	40.00	40.00	40.0	
			Placebo	3	3 (100.0)	60.67 (22.03)	46.0	46.00	50.00	86.00	86.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	-6.00	-6.0	-6.00	-6.00	-6.00	-6.0	NE
			Placebo	3	3 (100.0)	7.33 (7.51)	3.0	3.00	3.00	16.00	16.0	
		Week 8	Tezepelumab	1	1 (100.0)	-5.00	-5.0	-5.00	-5.00	-5.00	-5.0	NE
			Placebo	3	3 (100.0)	25.00 (33.42)	-3.0	-3.00	16.00	62.00	62.0	
		Week 12	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	NE
			Placebo	3	3 (100.0)	26.67 (36.68)	-2.0	-2.00	14.00	68.00	68.0	
		Week 20	Tezepelumab	1	1 (100.0)	-7.00	-7.0	-7.00	-7.00	-7.00	-7.0	NE
			Placebo	3	3 (100.0)	13.00 (21.00)	-2.0	-2.00	4.00	37.00	37.0	
		Week 28	Tezepelumab	1	1 (100.0)	-1.00	-1.0	-1.00	-1.00	-1.00	-1.0	NE
			Placebo	3	3 (100.0)	16.00 (42.93)	-15.0	-15.00	-2.00	65.00	65.0	
		Week 40	Tezepelumab	1	1 (100.0)	-6.00	-6.0	-6.00	-6.00	-6.00	-6.0	NE
			Placebo	3	3 (100.0)	14.00 (35.79)	-11.0	-11.00	-2.00	55.00	55.0	
		Week 52	Tezepelumab	1	1 (100.0)	-14.00	-14.0	-14.00	-14.00	-14.00	-14.0	NE
			Placebo	3	3 (100.0)	14.33 (34.53)	-9.0	-9.00	-2.00	54.00	54.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	78	73 (93.6)	61.08 (16.19)	34.0	50.00	60.00	72.00	100.0	
			Placebo	80	67 (83.8)	62.93 (15.30)	23.0	50.00	63.00	73.00	97.0	
		Week 4	Tezepelumab	78	74 (94.9)	67.88 (16.94)	30.0	53.00	67.00	81.00	100.0	
			Placebo	80	70 (87.5)	66.31 (16.60)	23.0	54.00	69.00	78.00	98.0	
		Week 8	Tezepelumab	78	74 (94.9)	66.46 (19.48)	20.0	51.00	66.00	84.00	100.0	
			Placebo	80	71 (88.8)	67.97 (16.40)	29.0	53.00	70.00	80.00	100.0	
		Week 12	Tezepelumab	78	74 (94.9)	68.32 (19.74)	26.0	52.00	69.50	85.00	100.0	
			Placebo	80	72 (90.0)	67.50 (18.73)	19.0	55.50	72.00	81.00	100.0	
		Week 20	Tezepelumab	78	76 (97.4)	67.93 (19.25)	18.0	54.00	69.00	82.00	100.0	
			Placebo	80	72 (90.0)	68.96 (18.88)	19.0	57.50	71.50	82.50	100.0	
		Week 28	Tezepelumab	78	77 (98.7)	70.04 (18.40)	8.0	59.00	72.00	83.00	100.0	
			Placebo	80	73 (91.3)	69.77 (17.97)	12.0	59.00	73.00	82.00	100.0	
		Week 40	Tezepelumab	78	77 (98.7)	71.82 (18.70)	18.0	60.00	75.00	85.00	100.0	
			Placebo	80	74 (92.5)	69.07 (17.76)	20.0	55.00	73.50	81.00	100.0	
		Week 52	Tezepelumab	78	77 (98.7)	71.35 (20.13)	19.0	53.00	75.00	86.00	100.0	
			Placebo	80	75 (93.8)	71.09 (18.42)	16.0	61.00	75.00	85.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	78	71 (91.0)	7.32 (18.23)	-51.0	-3.00	8.00	19.00	47.0	0.19 [-0.14, 0.53]
			Placebo	80	67 (83.8)	4.19 (13.99)	-26.0	-5.00	4.00	10.00	44.0	
		Week 8	Tezepelumab	78	71 (91.0)	5.86 (19.33)	-59.0	-3.00	7.00	20.00	40.0	0.00 [-0.33, 0.34]
			Placebo	80	67 (83.8)	5.82 (14.95)	-24.0	-5.00	4.00	14.00	43.0	
		Week 12	Tezepelumab	78	71 (91.0)	7.59 (19.73)	-51.0	-3.00	6.00	22.00	58.0	0.13 [-0.20, 0.47]
			Placebo	80	67 (83.8)	5.06 (18.31)	-39.0	-8.00	4.00	18.00	50.0	
		Week 20	Tezepelumab	78	72 (92.3)	7.15 (19.74)	-51.0	-5.50	8.50	24.50	48.0	0.02 [-0.31, 0.35]
			Placebo	80	67 (83.8)	6.79 (15.71)	-32.0	-4.00	7.00	15.00	49.0	
		Week 28	Tezepelumab	78	72 (92.3)	9.49 (19.11)	-43.0	-3.00	9.50	25.50	50.0	0.14 [-0.19, 0.47]
			Placebo	80	67 (83.8)	7.00 (16.35)	-30.0	-5.00	5.00	20.00	54.0	
		Week 40	Tezepelumab	78	72 (92.3)	10.85 (19.54)	-43.0	-2.00	12.00	26.00	56.0	0.23 [-0.11, 0.56]
			Placebo	80	67 (83.8)	6.67 (16.81)	-26.0	-5.00	5.00	19.00	56.0	
		Week 52	Tezepelumab	78	72 (92.3)	10.79 (19.93)	-43.0	-3.50	13.00	25.00	50.0	0.10 [-0.23, 0.44]
			Placebo	80	67 (83.8)	8.87 (16.82)	-26.0	-5.00	7.00	20.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	69.33 (16.14)	40.0	59.00	74.00	79.00	91.0	
			Placebo	9	8 (88.9)	64.50 (18.24)	32.0	54.50	64.50	80.00	86.0	
		Week 4	Tezepelumab	10	8 (80.0)	78.25 (15.05)	50.0	68.00	84.00	89.50	93.0	
			Placebo	9	8 (88.9)	72.50 (19.58)	35.0	61.00	77.00	87.50	94.0	
		Week 8	Tezepelumab	10	8 (80.0)	84.25 (15.19)	49.0	83.50	86.50	94.00	97.0	
			Placebo	9	8 (88.9)	75.00 (17.71)	40.0	67.00	79.00	87.00	94.0	
		Week 12	Tezepelumab	10	8 (80.0)	82.88 (8.53)	72.0	75.50	81.50	91.50	94.0	
			Placebo	9	8 (88.9)	74.63 (19.99)	31.0	69.50	78.50	88.00	94.0	
		Week 20	Tezepelumab	10	8 (80.0)	82.63 (8.12)	73.0	75.00	81.50	91.00	93.0	
			Placebo	9	8 (88.9)	74.63 (19.71)	36.0	65.50	76.50	91.50	94.0	
		Week 28	Tezepelumab	10	8 (80.0)	82.25 (7.61)	73.0	75.00	81.50	90.50	91.0	
			Placebo	9	8 (88.9)	69.25 (21.46)	44.0	47.50	69.50	91.00	94.0	
		Week 40	Tezepelumab	10	8 (80.0)	78.63 (9.46)	65.0	70.50	80.50	85.50	91.0	
			Placebo	9	8 (88.9)	67.63 (20.74)	47.0	48.50	64.50	89.00	90.0	
		Week 52	Tezepelumab	10	9 (90.0)	79.22 (9.68)	62.0	73.00	80.00	86.00	92.0	
			Placebo	9	8 (88.9)	73.00 (21.25)	48.0	50.50	76.00	93.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	10.63 (13.71)	-8.0	-0.50	9.50	22.50	30.0	0.15 [-0.83, 1.13]
			Placebo	9	8 (88.9)	8.00 (20.65)	-25.0	4.00	6.00	9.00	51.0	
		Week 8	Tezepelumab	10	8 (80.0)	16.63 (14.05)	-6.0	8.50	15.00	28.00	36.0	0.36 [-0.63, 1.35]
			Placebo	9	8 (88.9)	10.50 (19.50)	-20.0	5.50	8.50	12.50	51.0	
		Week 12	Tezepelumab	10	8 (80.0)	15.25 (15.69)	-9.0	3.50	16.00	27.00	38.0	0.27 [-0.71, 1.26]
			Placebo	9	8 (88.9)	10.13 (21.68)	-29.0	6.50	8.00	15.00	51.0	
		Week 20	Tezepelumab	10	8 (80.0)	15.00 (16.64)	-9.0	3.00	13.50	27.50	41.0	0.26 [-0.73, 1.24]
			Placebo	9	8 (88.9)	10.13 (20.84)	-24.0	2.50	8.50	16.00	51.0	
		Week 28	Tezepelumab	10	8 (80.0)	14.63 (17.21)	-16.0	6.50	13.00	27.50	39.0	0.65 [-0.36, 1.66]
			Placebo	9	8 (88.9)	4.75 (12.81)	-15.0	-4.50	8.00	14.00	18.0	
		Week 40	Tezepelumab	10	8 (80.0)	11.00 (13.98)	-10.0	0.50	13.00	19.00	33.0	0.63 [-0.38, 1.64]
			Placebo	9	8 (88.9)	3.13 (10.86)	-11.0	-7.00	4.00	12.00	18.0	
		Week 52	Tezepelumab	10	8 (80.0)	11.63 (18.09)	-12.0	-5.50	13.50	27.50	34.0	0.15 [-0.84, 1.13]
			Placebo	9	8 (88.9)	8.50 (24.48)	-12.0	-5.50	0.50	12.50	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	64.75 (20.07)	35.0	53.50	72.50	76.00	79.0	
			Placebo	6	6 (100.0)	51.33 (16.21)	27.0	41.00	51.50	65.00	72.0	
		Week 4	Tezepelumab	5	5 (100.0)	73.00 (18.84)	53.0	60.00	66.00	92.00	94.0	
			Placebo	6	6 (100.0)	64.17 (20.55)	38.0	49.00	61.00	86.00	90.0	
		Week 8	Tezepelumab	5	5 (100.0)	77.80 (17.75)	60.0	60.00	78.00	95.00	96.0	
			Placebo	6	6 (100.0)	62.67 (19.66)	43.0	47.00	57.50	82.00	89.0	
		Week 12	Tezepelumab	5	5 (100.0)	76.20 (22.19)	48.0	60.00	78.00	97.00	98.0	
			Placebo	6	6 (100.0)	69.67 (20.01)	42.0	60.00	65.50	89.00	96.0	
		Week 20	Tezepelumab	5	5 (100.0)	80.80 (16.98)	61.0	65.00	85.00	96.00	97.0	
			Placebo	6	6 (100.0)	63.00 (16.97)	46.0	47.00	61.50	70.00	92.0	
		Week 28	Tezepelumab	5	5 (100.0)	79.40 (15.08)	60.0	71.00	77.00	94.00	95.0	
			Placebo	6	6 (100.0)	69.83 (16.14)	47.0	58.00	69.50	85.00	90.0	
		Week 40	Tezepelumab	5	5 (100.0)	79.40 (16.15)	60.0	70.00	75.00	94.00	98.0	
			Placebo	6	6 (100.0)	71.67 (19.06)	46.0	54.00	76.00	87.00	91.0	
		Week 52	Tezepelumab	5	5 (100.0)	78.80 (17.11)	60.0	61.00	88.00	88.00	97.0	
			Placebo	6	6 (100.0)	75.83 (19.30)	45.0	60.00	83.00	89.00	95.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	11.50 (22.04)	-20.0	-2.50	17.50	25.50	31.0	-0.05 [-1.32, 1.21]
			Placebo	6	6 (100.0)	12.83 (26.35)	-14.0	0.00	7.00	14.00	63.0	
		Week 8	Tezepelumab	5	4 (80.0)	17.50 (9.00)	5.0	11.00	20.00	24.00	25.0	0.33 [-0.95, 1.60]
			Placebo	6	6 (100.0)	11.33 (22.74)	-5.0	-3.00	2.00	17.00	55.0	
		Week 12	Tezepelumab	5	4 (80.0)	15.50 (8.54)	5.0	9.00	16.00	22.00	25.0	-0.13 [-1.40, 1.13]
			Placebo	6	6 (100.0)	18.33 (26.36)	-4.0	1.00	12.50	19.00	69.0	
		Week 20	Tezepelumab	5	4 (80.0)	21.00 (23.90)	-8.0	4.50	21.00	37.50	50.0	0.46 [-0.83, 1.74]
			Placebo	6	6 (100.0)	11.67 (17.96)	-6.0	-3.00	8.00	20.00	43.0	
		Week 28	Tezepelumab	5	4 (80.0)	19.50 (13.48)	4.0	9.50	19.00	29.50	36.0	0.06 [-1.21, 1.33]
			Placebo	6	6 (100.0)	18.50 (18.27)	-7.0	6.00	17.50	33.00	44.0	
		Week 40	Tezepelumab	5	4 (80.0)	19.50 (17.64)	-3.0	8.00	20.50	31.00	40.0	-0.04 [-1.30, 1.23]
			Placebo	6	6 (100.0)	20.33 (24.49)	-11.0	5.00	16.50	36.00	59.0	
		Week 52	Tezepelumab	5	4 (80.0)	18.75 (26.63)	-12.0	2.00	17.00	35.50	53.0	-0.24 [-1.51, 1.03]
			Placebo	6	6 (100.0)	24.50 (22.85)	-5.0	4.00	26.00	43.00	53.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	44	37 (84.1)	57.11 (16.68)	20.0	49.00	57.00	70.00	100.0	
			Placebo	43	39 (90.7)	56.87 (12.55)	29.0	49.00	58.00	68.00	80.0	
		Week 4	Tezepelumab	44	42 (95.5)	63.71 (20.47)	14.0	49.00	64.50	75.00	100.0	
			Placebo	43	41 (95.3)	63.00 (17.02)	17.0	51.00	65.00	74.00	99.0	
		Week 8	Tezepelumab	44	42 (95.5)	66.48 (17.57)	25.0	55.00	64.50	79.00	100.0	
			Placebo	43	42 (97.7)	65.24 (19.02)	14.0	54.00	65.00	79.00	97.0	
		Week 12	Tezepelumab	44	42 (95.5)	68.43 (16.85)	39.0	52.00	68.50	81.00	100.0	
			Placebo	43	42 (97.7)	69.24 (16.50)	30.0	60.00	68.50	81.00	100.0	
		Week 20	Tezepelumab	44	42 (95.5)	67.52 (17.36)	39.0	55.00	65.00	81.00	100.0	
			Placebo	43	42 (97.7)	67.88 (16.34)	27.0	58.00	67.00	80.00	99.0	
		Week 28	Tezepelumab	44	42 (95.5)	68.29 (17.87)	29.0	52.00	66.50	82.00	100.0	
			Placebo	43	42 (97.7)	68.05 (18.03)	27.0	54.00	68.00	82.00	98.0	
		Week 40	Tezepelumab	44	43 (97.7)	70.30 (17.35)	39.0	52.00	73.00	82.00	100.0	
			Placebo	43	42 (97.7)	69.43 (17.53)	27.0	55.00	71.00	85.00	95.0	
		Week 52	Tezepelumab	44	43 (97.7)	70.37 (18.04)	32.0	55.00	71.00	85.00	100.0	
			Placebo	43	42 (97.7)	67.76 (17.47)	27.0	51.00	70.00	82.00	96.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	44	37 (84.1)	6.76 (16.28)	-30.0	-3.00	5.00	14.00	50.0	0.04 [-0.41, 0.49]
			Placebo	43	39 (90.7)	6.08 (14.44)	-40.0	-4.00	4.00	16.00	41.0	
		Week 8	Tezepelumab	44	37 (84.1)	8.54 (18.85)	-16.0	-2.00	4.00	15.00	69.0	0.02 [-0.43, 0.47]
			Placebo	43	39 (90.7)	8.10 (20.89)	-36.0	-3.00	7.00	21.00	62.0	
		Week 12	Tezepelumab	44	37 (84.1)	11.24 (18.89)	-15.0	-2.00	11.00	19.00	65.0	-0.06 [-0.51, 0.39]
			Placebo	43	39 (90.7)	12.36 (16.93)	-11.0	1.00	10.00	17.00	68.0	
		Week 20	Tezepelumab	44	37 (84.1)	11.05 (19.44)	-25.0	-3.00	11.00	20.00	55.0	-0.03 [-0.48, 0.42]
			Placebo	43	39 (90.7)	11.56 (16.41)	-22.0	2.00	7.00	24.00	57.0	
		Week 28	Tezepelumab	44	37 (84.1)	11.27 (19.32)	-14.0	-4.00	8.00	21.00	60.0	-0.00 [-0.45, 0.45]
			Placebo	43	39 (90.7)	11.31 (18.07)	-20.0	0.00	5.00	21.00	65.0	
		Week 40	Tezepelumab	44	37 (84.1)	13.22 (19.23)	-21.0	-1.00	11.00	21.00	58.0	-0.01 [-0.46, 0.44]
			Placebo	43	39 (90.7)	13.44 (15.91)	-8.0	3.00	11.00	22.00	55.0	
		Week 52	Tezepelumab	44	37 (84.1)	12.59 (17.53)	-18.0	-1.00	13.00	24.00	58.0	0.06 [-0.39, 0.51]
			Placebo	43	39 (90.7)	11.56 (15.35)	-8.0	1.00	9.00	18.00	54.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Placebo	1	1 (100.0)	23.00	23.0	23.00	23.00	23.00	23.0	
		Week 4	Placebo	1	1 (100.0)	25.00	25.0	25.00	25.00	25.00	25.0	
		Week 8	Placebo	1	1 (100.0)	48.00	48.0	48.00	48.00	48.00	48.0	
		Week 12	Placebo	1	1 (100.0)	19.00	19.0	19.00	19.00	19.00	19.0	
		Week 20	Placebo	1	1 (100.0)	19.00	19.0	19.00	19.00	19.00	19.0	
		Week 28	Placebo	1	1 (100.0)	12.00	12.0	12.00	12.00	12.00	12.0	
		Week 40	Placebo	1	1 (100.0)	20.00	20.0	20.00	20.00	20.00	20.0	
		Week 52	Placebo	1	1 (100.0)	16.00	16.0	16.00	16.00	16.00	16.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 4	Placebo	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
		Week 8	Placebo	1	1 (100.0)	25.00	25.0	25.00	25.00	25.00	25.0	
		Week 12	Placebo	1	1 (100.0)	-4.00	-4.0	-4.00	-4.00	-4.00	-4.0	
		Week 20	Placebo	1	1 (100.0)	-4.00	-4.0	-4.00	-4.00	-4.00	-4.0	
		Week 28	Placebo	1	1 (100.0)	-11.00	-11.0	-11.00	-11.00	-11.00	-11.0	
		Week 40	Placebo	1	1 (100.0)	-3.00	-3.0	-3.00	-3.00	-3.00	-3.0	
		Week 52	Placebo	1	1 (100.0)	-7.00	-7.0	-7.00	-7.00	-7.00	-7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	39	35 (89.7)	65.00 (18.98)	20.0	50.00	70.00	75.00	100.0	
			Placebo	43	38 (88.4)	63.63 (13.83)	27.0	52.00	67.50	72.00	85.0	
		Week 4	Tezepelumab	39	37 (94.9)	76.27 (17.60)	14.0	66.00	78.00	90.00	99.0	
			Placebo	43	40 (93.0)	67.88 (15.71)	17.0	58.00	70.00	79.00	93.0	
		Week 8	Tezepelumab	39	37 (94.9)	77.73 (15.00)	52.0	63.00	75.00	90.00	99.0	
			Placebo	43	40 (93.0)	69.08 (18.77)	14.0	57.50	73.00	81.50	100.0	
		Week 12	Tezepelumab	39	37 (94.9)	79.03 (14.51)	48.0	70.00	82.00	89.00	100.0	
			Placebo	43	40 (93.0)	71.13 (17.56)	30.0	60.00	74.00	84.00	100.0	
		Week 20	Tezepelumab	39	37 (94.9)	78.95 (14.49)	40.0	70.00	81.00	90.00	100.0	
			Placebo	43	40 (93.0)	73.80 (16.81)	27.0	67.00	75.50	85.50	100.0	
		Week 28	Tezepelumab	39	37 (94.9)	79.03 (14.07)	50.0	70.00	81.00	90.00	100.0	
			Placebo	43	41 (95.3)	73.66 (16.89)	27.0	68.00	74.00	86.00	100.0	
		Week 40	Tezepelumab	39	38 (97.4)	80.74 (13.77)	44.0	75.00	81.00	92.00	100.0	
			Placebo	43	41 (95.3)	74.02 (16.15)	27.0	69.00	75.00	86.00	100.0	
		Week 52	Tezepelumab	39	38 (97.4)	81.66 (13.85)	47.0	73.00	84.00	92.00	100.0	
			Placebo	43	42 (97.7)	74.69 (15.43)	27.0	69.00	75.00	87.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	39	34 (87.2)	12.65 (15.39)	-27.0	2.00	11.50	26.00	41.0	0.48 [0.01, 0.95]
			Placebo	43	38 (88.4)	5.26 (15.31)	-26.0	-4.00	4.50	10.00	63.0	
		Week 8	Tezepelumab	39	34 (87.2)	14.03 (19.53)	-16.0	-2.00	13.50	25.00	69.0	0.41 [-0.05, 0.88]
			Placebo	43	38 (88.4)	6.08 (18.95)	-36.0	-3.00	5.00	11.00	57.0	
		Week 12	Tezepelumab	39	34 (87.2)	15.53 (20.70)	-15.0	0.00	14.50	27.00	65.0	0.36 [-0.10, 0.83]
			Placebo	43	38 (88.4)	7.89 (21.17)	-39.0	-1.00	6.00	18.00	69.0	
		Week 20	Tezepelumab	39	34 (87.2)	15.74 (19.58)	-25.0	4.00	13.50	27.00	55.0	0.26 [-0.20, 0.72]
			Placebo	43	38 (88.4)	11.13 (15.86)	-20.0	3.00	9.00	20.00	57.0	
		Week 28	Tezepelumab	39	34 (87.2)	15.59 (19.29)	-16.0	2.00	16.00	26.00	60.0	0.30 [-0.17, 0.76]
			Placebo	43	38 (88.4)	10.13 (17.45)	-20.0	-2.00	6.00	21.00	58.0	
		Week 40	Tezepelumab	39	34 (87.2)	16.79 (19.51)	-21.0	3.00	15.00	28.00	58.0	0.30 [-0.16, 0.77]
			Placebo	43	38 (88.4)	11.05 (18.28)	-23.0	-1.00	8.00	20.00	59.0	
		Week 52	Tezepelumab	39	34 (87.2)	17.79 (19.64)	-18.0	5.00	19.50	27.00	58.0	0.36 [-0.11, 0.83]
			Placebo	43	38 (88.4)	11.11 (17.51)	-13.0	-3.00	7.50	22.00	53.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	45	41 (91.1)	61.22 (16.54)	29.0	49.00	61.00	73.00	100.0	
			Placebo	47	43 (91.5)	58.58 (14.54)	32.0	47.00	56.00	70.00	90.0	
		Week 4	Tezepelumab	45	44 (97.8)	67.89 (19.00)	27.0	53.00	66.00	82.50	100.0	
			Placebo	47	44 (93.6)	63.70 (18.65)	23.0	49.50	64.00	79.50	98.0	
		Week 8	Tezepelumab	45	44 (97.8)	67.41 (20.23)	25.0	51.50	63.50	86.00	100.0	
			Placebo	47	45 (95.7)	66.00 (16.21)	38.0	54.00	61.00	77.00	100.0	
		Week 12	Tezepelumab	45	44 (97.8)	68.23 (21.37)	35.0	50.00	66.00	87.50	100.0	
			Placebo	47	45 (95.7)	65.07 (17.17)	20.0	54.00	63.00	77.00	97.0	
		Week 20	Tezepelumab	45	44 (97.8)	69.48 (19.05)	35.0	53.50	67.00	85.50	100.0	
			Placebo	47	45 (95.7)	64.98 (17.60)	20.0	54.00	64.00	79.00	99.0	
		Week 28	Tezepelumab	45	44 (97.8)	72.34 (18.12)	35.0	59.50	75.50	88.00	100.0	
			Placebo	47	45 (95.7)	63.62 (16.15)	30.0	53.00	61.00	73.00	95.0	
		Week 40	Tezepelumab	45	44 (97.8)	73.20 (17.42)	35.0	60.50	79.50	85.00	100.0	
			Placebo	47	45 (95.7)	65.27 (16.86)	20.0	51.00	66.00	79.00	97.0	
		Week 52	Tezepelumab	45	45 (100.0)	72.04 (19.34)	33.0	53.00	75.00	86.00	100.0	
			Placebo	47	45 (95.7)	65.51 (17.08)	30.0	51.00	63.00	78.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	45	41 (91.1)	6.41 (18.08)	-51.0	-3.00	6.00	16.00	50.0	0.08 [-0.34, 0.51]
			Placebo	47	43 (91.5)	4.98 (16.29)	-40.0	-6.00	6.00	11.00	51.0	
		Week 8	Tezepelumab	45	41 (91.1)	5.85 (15.54)	-51.0	-1.00	5.00	15.00	47.0	-0.12 [-0.55, 0.31]
			Placebo	47	43 (91.5)	7.63 (13.82)	-10.0	-4.00	6.00	11.00	51.0	
		Week 12	Tezepelumab	45	41 (91.1)	6.54 (17.99)	-51.0	-2.00	6.00	19.00	51.0	-0.00 [-0.43, 0.43]
			Placebo	47	43 (91.5)	6.56 (15.40)	-25.0	-4.00	5.00	12.00	51.0	
		Week 20	Tezepelumab	45	41 (91.1)	8.02 (19.02)	-51.0	-3.00	6.00	20.00	49.0	0.09 [-0.34, 0.52]
			Placebo	47	43 (91.5)	6.47 (15.51)	-32.0	-3.00	7.00	14.00	51.0	
		Week 28	Tezepelumab	45	41 (91.1)	10.98 (16.84)	-16.0	-1.00	8.00	21.00	51.0	0.40 [-0.03, 0.83]
			Placebo	47	43 (91.5)	5.09 (12.24)	-17.0	-4.00	6.00	13.00	40.0	
		Week 40	Tezepelumab	45	41 (91.1)	11.85 (18.16)	-16.0	-3.00	11.00	25.00	53.0	0.31 [-0.12, 0.74]
			Placebo	47	43 (91.5)	6.93 (13.90)	-26.0	-4.00	5.00	16.00	40.0	
		Week 52	Tezepelumab	45	41 (91.1)	10.73 (17.20)	-24.0	-1.00	11.00	24.00	49.0	0.22 [-0.21, 0.65]
			Placebo	47	43 (91.5)	7.16 (15.13)	-15.0	-4.00	4.00	16.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	53	47 (88.7)	56.81 (13.87)	29.0	46.00	55.00	70.00	90.0	
			Placebo	47	38 (80.9)	60.47 (15.34)	32.0	50.00	58.50	70.00	97.0	
		Week 4	Tezepelumab	53	48 (90.6)	60.02 (15.04)	21.0	50.00	57.50	69.50	93.0	
			Placebo	47	40 (85.1)	66.18 (15.60)	29.0	56.50	66.50	75.50	99.0	
		Week 8	Tezepelumab	53	48 (90.6)	61.06 (17.60)	20.0	49.00	61.00	73.00	97.0	
			Placebo	47	41 (87.2)	67.34 (17.83)	29.0	53.00	65.00	82.00	97.0	
		Week 12	Tezepelumab	53	48 (90.6)	63.50 (15.98)	26.0	50.00	65.00	75.00	94.0	
			Placebo	47	42 (89.4)	71.21 (17.59)	31.0	62.00	73.00	88.00	100.0	
		Week 20	Tezepelumab	53	50 (94.3)	61.72 (17.29)	18.0	50.00	63.00	73.00	98.0	
			Placebo	47	42 (89.4)	68.95 (17.22)	22.0	60.00	67.50	85.00	99.0	
		Week 28	Tezepelumab	53	51 (96.2)	62.92 (17.24)	8.0	52.00	65.00	73.00	96.0	
			Placebo	47	42 (89.4)	72.12 (17.43)	32.0	63.00	74.50	87.00	97.0	
		Week 40	Tezepelumab	53	51 (96.2)	64.51 (17.74)	18.0	50.00	68.00	75.00	99.0	
			Placebo	47	43 (91.5)	69.91 (17.92)	34.0	53.00	71.00	89.00	94.0	
		Week 52	Tezepelumab	53	51 (96.2)	64.35 (18.53)	19.0	52.00	67.00	78.00	98.0	
			Placebo	47	43 (91.5)	72.47 (19.28)	21.0	53.00	77.00	89.00	98.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	53	45 (84.9)	4.62 (17.53)	-40.0	-6.00	5.00	17.00	47.0	-0.11 [-0.54, 0.32]
			Placebo	47	38 (80.9)	6.39 (14.65)	-25.0	-5.00	5.50	17.00	41.0	
		Week 8	Tezepelumab	53	45 (84.9)	4.84 (20.08)	-59.0	-5.00	7.00	19.00	38.0	-0.12 [-0.55, 0.31]
			Placebo	47	38 (80.9)	7.21 (20.30)	-31.0	-7.00	5.50	18.00	62.0	
		Week 12	Tezepelumab	53	45 (84.9)	7.62 (17.82)	-34.0	-2.00	8.00	17.00	41.0	-0.20 [-0.64, 0.23]
			Placebo	47	38 (80.9)	11.42 (19.84)	-29.0	-2.00	8.50	22.00	68.0	
		Week 20	Tezepelumab	53	46 (86.8)	5.74 (19.45)	-44.0	-9.00	7.50	20.00	41.0	-0.20 [-0.63, 0.23]
			Placebo	47	38 (80.9)	9.47 (17.84)	-25.0	-4.00	7.00	21.00	49.0	
		Week 28	Tezepelumab	53	46 (86.8)	6.85 (19.67)	-43.0	-6.00	8.00	20.00	50.0	-0.27 [-0.70, 0.16]
			Placebo	47	38 (80.9)	12.26 (20.12)	-30.0	-3.00	8.00	26.00	65.0	
		Week 40	Tezepelumab	53	46 (86.8)	8.24 (18.82)	-43.0	-2.00	11.00	20.00	40.0	-0.13 [-0.56, 0.30]
			Placebo	47	38 (80.9)	10.61 (18.90)	-20.0	-3.00	8.00	22.00	56.0	
		Week 52	Tezepelumab	53	46 (86.8)	7.96 (19.68)	-43.0	-7.00	12.50	25.00	45.0	-0.32 [-0.75, 0.12]
			Placebo	47	38 (80.9)	14.13 (19.18)	-26.0	-1.00	11.00	29.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	60.74 (14.99)	29.0	50.00	62.00	72.00	90.0	
			Placebo	33	29 (87.9)	58.03 (14.56)	32.0	47.00	53.00	70.00	90.0	
		Week 4	Tezepelumab	27	26 (96.3)	70.12 (14.27)	41.0	60.00	69.50	81.00	93.0	
			Placebo	33	30 (90.9)	64.47 (16.38)	33.0	54.00	64.50	75.00	98.0	
		Week 8	Tezepelumab	27	26 (96.3)	69.00 (16.94)	31.0	60.00	69.00	80.00	97.0	
			Placebo	33	30 (90.9)	68.87 (18.95)	29.0	56.00	67.00	88.00	100.0	
		Week 12	Tezepelumab	27	26 (96.3)	70.31 (16.09)	35.0	60.00	72.50	83.00	93.0	
			Placebo	33	30 (90.9)	68.87 (19.29)	31.0	57.00	67.50	88.00	100.0	
		Week 20	Tezepelumab	27	26 (96.3)	70.77 (15.23)	35.0	64.00	70.00	83.00	95.0	
			Placebo	33	30 (90.9)	69.73 (15.92)	34.0	61.00	68.00	85.00	99.0	
		Week 28	Tezepelumab	27	26 (96.3)	70.42 (17.50)	29.0	59.00	71.50	83.00	95.0	
			Placebo	33	30 (90.9)	72.27 (16.65)	40.0	62.00	68.50	90.00	98.0	
		Week 40	Tezepelumab	27	26 (96.3)	71.73 (16.36)	35.0	58.00	77.00	84.00	96.0	
			Placebo	33	31 (93.9)	71.35 (18.37)	42.0	54.00	71.00	90.00	97.0	
		Week 52	Tezepelumab	27	26 (96.3)	70.46 (15.80)	35.0	58.00	72.00	83.00	95.0	
			Placebo	33	31 (93.9)	69.87 (18.60)	37.0	52.00	70.00	87.00	93.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	27	26 (96.3)	9.81 (18.04)	-40.0	-2.00	10.00	26.00	47.0	0.17 [-0.36, 0.70]
			Placebo	33	29 (87.9)	7.07 (13.26)	-14.0	0.00	6.00	11.00	44.0	
		Week 8	Tezepelumab	27	26 (96.3)	8.69 (20.63)	-59.0	-3.00	12.00	21.00	38.0	-0.13 [-0.66, 0.40]
			Placebo	33	29 (87.9)	11.41 (20.09)	-22.0	0.00	6.00	18.00	62.0	
		Week 12	Tezepelumab	27	26 (96.3)	10.00 (18.42)	-31.0	-1.00	11.00	23.00	41.0	-0.06 [-0.59, 0.47]
			Placebo	33	29 (87.9)	11.24 (21.71)	-39.0	2.00	7.00	19.00	68.0	
		Week 20	Tezepelumab	27	26 (96.3)	10.46 (16.86)	-25.0	-1.00	14.50	22.00	41.0	-0.09 [-0.62, 0.44]
			Placebo	33	29 (87.9)	12.03 (16.84)	-13.0	0.00	9.00	20.00	57.0	
		Week 28	Tezepelumab	27	26 (96.3)	10.12 (19.96)	-43.0	-3.00	12.50	25.00	50.0	-0.21 [-0.74, 0.32]
			Placebo	33	29 (87.9)	14.17 (18.50)	-8.0	1.00	9.00	22.00	65.0	
		Week 40	Tezepelumab	27	26 (96.3)	11.42 (20.17)	-43.0	3.00	14.00	26.00	40.0	-0.16 [-0.69, 0.37]
			Placebo	33	29 (87.9)	14.55 (18.49)	-26.0	3.00	11.00	23.00	55.0	
		Week 52	Tezepelumab	27	26 (96.3)	10.15 (19.61)	-43.0	-2.00	13.00	25.00	45.0	-0.16 [-0.69, 0.37]
			Placebo	33	29 (87.9)	13.17 (17.70)	-13.0	1.00	11.00	17.00	54.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	109	95 (87.2)	60.66 (17.10)	20.0	49.00	60.00	73.00	100.0	
			Placebo	105	91 (86.7)	61.26 (15.07)	23.0	50.00	60.00	72.00	97.0	
		Week 4	Tezepelumab	109	102 (93.6)	66.72 (19.26)	14.0	50.00	66.00	81.00	100.0	
			Placebo	105	95 (90.5)	65.85 (17.34)	17.0	53.00	69.00	79.00	99.0	
		Week 8	Tezepelumab	109	102 (93.6)	67.88 (19.58)	20.0	53.00	66.50	85.00	100.0	
			Placebo	105	97 (92.4)	66.76 (17.10)	14.0	53.00	69.00	79.00	100.0	
		Week 12	Tezepelumab	109	102 (93.6)	69.56 (19.28)	26.0	52.00	70.00	85.00	100.0	
			Placebo	105	98 (93.3)	68.54 (17.72)	19.0	59.00	72.50	81.00	100.0	
		Week 20	Tezepelumab	109	104 (95.4)	68.95 (19.20)	18.0	54.50	70.50	84.00	100.0	
			Placebo	105	98 (93.3)	68.36 (18.60)	19.0	56.00	70.50	82.00	100.0	
		Week 28	Tezepelumab	109	105 (96.3)	70.80 (18.03)	8.0	59.00	72.00	83.00	100.0	
			Placebo	105	99 (94.3)	68.24 (18.29)	12.0	53.00	71.00	82.00	100.0	
		Week 40	Tezepelumab	109	106 (97.2)	72.29 (18.12)	18.0	60.00	74.50	85.00	100.0	
			Placebo	105	99 (94.3)	68.55 (17.56)	20.0	54.00	71.00	81.00	100.0	
		Week 52	Tezepelumab	109	107 (98.2)	72.36 (19.55)	19.0	59.00	75.00	88.00	100.0	
			Placebo	105	100 (95.2)	70.51 (18.21)	16.0	58.50	74.50	83.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	109	93 (85.3)	6.84 (17.26)	-51.0	-3.00	7.00	18.00	50.0	0.11 [-0.18, 0.40]
			Placebo	105	91 (86.7)	4.99 (15.91)	-40.0	-5.00	4.00	12.00	63.0	
		Week 8	Tezepelumab	109	93 (85.3)	7.59 (18.41)	-51.0	-2.00	9.00	17.00	69.0	0.10 [-0.19, 0.39]
			Placebo	105	91 (86.7)	5.79 (16.64)	-36.0	-4.00	5.00	14.00	55.0	
		Week 12	Tezepelumab	109	93 (85.3)	9.46 (19.28)	-51.0	-2.00	7.00	20.00	65.0	0.10 [-0.19, 0.39]
			Placebo	105	91 (86.7)	7.54 (17.72)	-34.0	-4.00	5.00	17.00	69.0	
		Week 20	Tezepelumab	109	94 (86.2)	9.10 (20.47)	-51.0	-6.00	10.00	25.00	55.0	0.07 [-0.22, 0.36]
			Placebo	105	91 (86.7)	7.78 (16.15)	-32.0	-3.00	7.00	15.00	51.0	
		Week 28	Tezepelumab	109	94 (86.2)	10.99 (18.67)	-41.0	-1.00	8.50	25.00	60.0	0.22 [-0.07, 0.51]
			Placebo	105	91 (86.7)	7.12 (16.11)	-30.0	-5.00	6.00	18.00	54.0	
		Week 40	Tezepelumab	109	94 (86.2)	12.13 (18.77)	-33.0	-3.00	11.00	25.00	58.0	0.26 [-0.03, 0.54]
			Placebo	105	91 (86.7)	7.65 (16.21)	-25.0	-4.00	5.00	16.00	59.0	
		Week 52	Tezepelumab	109	94 (86.2)	12.20 (19.15)	-30.0	-3.00	13.50	25.00	58.0	0.14 [-0.15, 0.43]
			Placebo	105	91 (86.7)	9.65 (17.26)	-26.0	-3.00	6.00	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	69	63 (91.3)	58.89 (15.96)	20.0	49.00	60.00	72.00	100.0	
			Placebo	72	61 (84.7)	60.30 (15.15)	23.0	50.00	60.00	70.00	90.0	
		Week 4	Tezepelumab	69	64 (92.8)	66.92 (17.34)	14.0	50.50	67.50	80.00	97.0	
			Placebo	72	62 (86.1)	65.85 (17.28)	17.0	56.00	67.50	75.00	99.0	
		Week 8	Tezepelumab	69	64 (92.8)	66.00 (17.88)	25.0	52.00	65.00	77.50	97.0	
			Placebo	72	63 (87.5)	67.71 (19.10)	14.0	53.00	69.00	83.00	100.0	
		Week 12	Tezepelumab	69	64 (92.8)	68.97 (16.70)	35.0	55.50	69.50	83.00	98.0	
			Placebo	72	63 (87.5)	68.52 (19.27)	19.0	54.00	70.00	86.00	100.0	
		Week 20	Tezepelumab	69	65 (94.2)	67.97 (17.37)	25.0	55.00	68.00	80.00	98.0	
			Placebo	72	63 (87.5)	68.95 (19.26)	19.0	60.00	70.00	85.00	99.0	
		Week 28	Tezepelumab	69	66 (95.7)	69.30 (16.59)	29.0	57.00	70.00	83.00	96.0	
			Placebo	72	64 (88.9)	69.41 (19.75)	12.0	55.00	69.00	86.50	98.0	
		Week 40	Tezepelumab	69	67 (97.1)	71.28 (17.74)	32.0	56.00	73.00	85.00	100.0	
			Placebo	72	65 (90.3)	70.68 (19.22)	20.0	54.00	73.00	89.00	97.0	
		Week 52	Tezepelumab	69	67 (97.1)	69.82 (19.35)	27.0	52.00	73.00	85.00	100.0	
			Placebo	72	66 (91.7)	71.08 (20.50)	16.0	58.00	73.50	88.00	98.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	69	62 (89.9)	8.65 (16.08)	-40.0	-2.00	8.00	19.00	47.0	0.19 [-0.17, 0.54]
			Placebo	72	61 (84.7)	5.89 (13.24)	-20.0	-5.00	6.00	10.00	44.0	
		Week 8	Tezepelumab	69	62 (89.9)	7.68 (20.07)	-59.0	-3.00	9.00	20.00	69.0	-0.00 [-0.36, 0.35]
			Placebo	72	61 (84.7)	7.72 (19.60)	-36.0	-4.00	5.00	18.00	62.0	
		Week 12	Tezepelumab	69	62 (89.9)	10.74 (18.98)	-34.0	-1.00	10.00	23.00	65.0	0.12 [-0.23, 0.47]
			Placebo	72	61 (84.7)	8.44 (19.73)	-39.0	-4.00	6.00	18.00	68.0	
		Week 20	Tezepelumab	69	62 (89.9)	9.63 (18.86)	-44.0	-4.00	12.00	24.00	51.0	0.04 [-0.31, 0.39]
			Placebo	72	61 (84.7)	8.89 (18.42)	-32.0	-4.00	7.00	20.00	57.0	
		Week 28	Tezepelumab	69	62 (89.9)	10.92 (19.21)	-43.0	-1.00	11.00	25.00	60.0	0.12 [-0.24, 0.47]
			Placebo	72	61 (84.7)	8.69 (19.50)	-30.0	-4.00	5.00	20.00	65.0	
		Week 40	Tezepelumab	69	62 (89.9)	12.13 (19.61)	-43.0	-1.00	15.00	26.00	58.0	0.07 [-0.29, 0.42]
			Placebo	72	61 (84.7)	10.84 (18.70)	-26.0	-3.00	7.00	21.00	56.0	
		Week 52	Tezepelumab	69	62 (89.9)	10.74 (20.16)	-43.0	-4.00	13.00	26.00	58.0	-0.02 [-0.37, 0.33]
			Placebo	72	61 (84.7)	11.15 (18.29)	-26.0	-3.00	11.00	18.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	62.59 (17.18)	30.0	49.00	63.00	74.00	100.0	
			Placebo	66	59 (89.4)	60.68 (14.87)	27.0	50.00	60.00	70.00	97.0	
		Week 4	Tezepelumab	67	64 (95.5)	67.89 (19.45)	21.0	53.50	66.50	87.00	100.0	
			Placebo	66	63 (95.5)	65.19 (16.98)	23.0	51.00	68.00	80.00	93.0	
		Week 8	Tezepelumab	67	64 (95.5)	70.22 (20.00)	20.0	55.00	69.50	87.00	100.0	
			Placebo	66	64 (97.0)	66.81 (15.91)	40.0	52.50	65.50	79.00	100.0	
		Week 12	Tezepelumab	67	64 (95.5)	70.45 (20.47)	26.0	52.00	70.50	88.50	100.0	
			Placebo	66	65 (98.5)	68.71 (16.88)	20.0	60.00	72.00	80.00	100.0	
		Week 20	Tezepelumab	67	65 (97.0)	70.66 (19.49)	18.0	57.00	75.00	85.00	100.0	
			Placebo	66	65 (98.5)	68.42 (16.74)	20.0	57.00	70.00	80.00	100.0	
		Week 28	Tezepelumab	67	65 (97.0)	72.17 (19.09)	8.0	60.00	74.00	85.00	100.0	
			Placebo	66	65 (98.5)	68.95 (16.10)	30.0	55.00	71.00	80.00	100.0	
		Week 40	Tezepelumab	67	65 (97.0)	73.11 (17.81)	18.0	65.00	75.00	84.00	100.0	
			Placebo	66	65 (98.5)	67.75 (16.11)	20.0	54.00	71.00	79.00	100.0	
		Week 52	Tezepelumab	67	66 (98.5)	74.20 (18.19)	19.0	64.00	74.50	88.00	100.0	
			Placebo	66	65 (98.5)	69.63 (15.71)	30.0	58.00	71.00	80.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	67	57 (85.1)	6.23 (18.79)	-51.0	-3.00	6.00	18.00	50.0	0.06 [-0.30, 0.43]
			Placebo	66	59 (89.4)	5.08 (17.25)	-40.0	-4.00	4.00	17.00	63.0	
		Week 8	Tezepelumab	67	57 (85.1)	8.00 (17.56)	-51.0	-1.00	9.00	17.00	56.0	0.09 [-0.28, 0.45]
			Placebo	66	59 (89.4)	6.56 (15.44)	-29.0	-3.00	5.00	12.00	55.0	
		Week 12	Tezepelumab	67	57 (85.1)	8.32 (19.15)	-51.0	-3.00	6.00	19.00	58.0	-0.01 [-0.37, 0.36]
			Placebo	66	59 (89.4)	8.42 (17.81)	-34.0	-2.00	6.00	17.00	69.0	
		Week 20	Tezepelumab	67	58 (86.6)	9.14 (20.70)	-51.0	-5.00	9.00	25.00	55.0	0.02 [-0.34, 0.39]
			Placebo	66	59 (89.4)	8.73 (14.06)	-25.0	-1.00	7.00	15.00	51.0	
		Week 28	Tezepelumab	67	58 (86.6)	10.67 (18.68)	-41.0	-3.00	8.00	25.00	55.0	0.10 [-0.26, 0.47]
			Placebo	66	59 (89.4)	8.97 (13.90)	-17.0	-2.00	7.00	18.00	44.0	
		Week 40	Tezepelumab	67	58 (86.6)	11.81 (18.49)	-31.0	-3.00	9.00	25.00	56.0	0.24 [-0.12, 0.61]
			Placebo	66	59 (89.4)	7.75 (14.96)	-25.0	-2.00	6.00	17.00	59.0	
		Week 52	Tezepelumab	67	58 (86.6)	12.84 (18.20)	-30.0	-2.00	14.50	24.00	56.0	0.17 [-0.19, 0.54]
			Placebo	66	59 (89.4)	9.83 (16.47)	-15.0	-3.00	6.00	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	78	68 (87.2)	59.24 (14.52)	29.0	49.00	58.50	72.00	90.0	
			Placebo	74	63 (85.1)	59.86 (15.42)	23.0	50.00	58.00	70.00	97.0	
		Week 4	Tezepelumab	78	71 (91.0)	66.27 (17.09)	21.0	53.00	67.00	79.00	100.0	
			Placebo	74	66 (89.2)	66.33 (15.82)	25.0	55.00	67.00	77.00	99.0	
		Week 8	Tezepelumab	78	71 (91.0)	65.65 (17.54)	20.0	54.00	65.00	77.00	100.0	
			Placebo	74	66 (89.2)	66.98 (17.48)	14.0	53.00	69.00	79.00	100.0	
		Week 12	Tezepelumab	78	71 (91.0)	68.08 (17.92)	26.0	52.00	70.00	82.00	100.0	
			Placebo	74	67 (90.5)	67.66 (18.74)	19.0	52.00	70.00	83.00	97.0	
		Week 20	Tezepelumab	78	72 (92.3)	67.58 (18.16)	18.0	55.50	68.00	79.50	100.0	
			Placebo	74	67 (90.5)	68.25 (18.30)	19.0	60.00	70.00	82.00	99.0	
		Week 28	Tezepelumab	78	73 (93.6)	68.51 (18.22)	8.0	54.00	70.00	82.00	100.0	
			Placebo	74	68 (91.9)	68.65 (19.04)	12.0	54.00	70.00	84.00	96.0	
		Week 40	Tezepelumab	78	74 (94.9)	69.24 (18.42)	18.0	52.00	71.00	83.00	100.0	
			Placebo	74	69 (93.2)	70.26 (17.50)	20.0	57.00	71.00	85.00	97.0	
		Week 52	Tezepelumab	78	75 (96.2)	68.87 (18.73)	19.0	53.00	73.00	83.00	100.0	
			Placebo	74	70 (94.6)	70.57 (19.10)	16.0	59.00	73.00	86.00	98.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	78	66 (84.6)	8.03 (17.79)	-40.0	-3.00	8.50	19.00	50.0	0.09 [-0.25, 0.44]
			Placebo	74	63 (85.1)	6.57 (13.19)	-20.0	-5.00	6.00	11.00	44.0	
		Week 8	Tezepelumab	78	66 (84.6)	6.68 (19.69)	-59.0	-6.00	7.00	20.00	47.0	-0.02 [-0.37, 0.32]
			Placebo	74	63 (85.1)	7.13 (15.69)	-36.0	-3.00	6.00	17.00	43.0	
		Week 12	Tezepelumab	78	66 (84.6)	9.32 (19.18)	-34.0	-2.00	7.00	22.00	58.0	0.06 [-0.28, 0.41]
			Placebo	74	63 (85.1)	8.16 (17.54)	-39.0	-4.00	7.00	20.00	50.0	
		Week 20	Tezepelumab	78	66 (84.6)	8.95 (20.09)	-44.0	-5.00	12.00	25.00	49.0	0.00 [-0.34, 0.35]
			Placebo	74	63 (85.1)	8.87 (15.96)	-25.0	-4.00	7.00	17.00	49.0	
		Week 28	Tezepelumab	78	66 (84.6)	10.03 (19.81)	-43.0	-3.00	10.50	25.00	51.0	0.09 [-0.26, 0.43]
			Placebo	74	63 (85.1)	8.43 (17.68)	-30.0	-4.00	6.00	22.00	54.0	
		Week 40	Tezepelumab	78	66 (84.6)	10.08 (19.72)	-43.0	-3.00	12.50	25.00	56.0	-0.04 [-0.39, 0.30]
			Placebo	74	63 (85.1)	10.84 (16.58)	-16.0	-3.00	7.00	22.00	56.0	
		Week 52	Tezepelumab	78	66 (84.6)	9.71 (20.07)	-43.0	-5.00	13.00	25.00	50.0	-0.06 [-0.41, 0.28]
			Placebo	74	63 (85.1)	10.89 (16.90)	-26.0	-3.00	9.00	20.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	57	53 (93.0)	62.58 (18.98)	20.0	51.00	63.00	75.00	100.0	
			Placebo	63	56 (88.9)	61.20 (14.65)	27.0	50.00	62.50	71.00	88.0	
		Week 4	Tezepelumab	57	56 (98.2)	68.79 (20.08)	14.0	51.50	66.00	89.50	100.0	
			Placebo	63	58 (92.1)	64.64 (18.61)	17.0	51.00	69.00	80.00	95.0	
		Week 8	Tezepelumab	57	56 (98.2)	71.14 (20.69)	25.0	53.50	72.00	89.50	100.0	
			Placebo	63	60 (95.2)	67.80 (17.71)	19.0	53.50	69.00	82.00	100.0	
		Week 12	Tezepelumab	57	56 (98.2)	71.82 (19.41)	33.0	55.00	72.00	89.50	100.0	
			Placebo	63	60 (95.2)	69.53 (17.41)	20.0	59.00	71.50	82.00	100.0	
		Week 20	Tezepelumab	57	57 (100.0)	71.26 (19.01)	34.0	55.00	75.00	85.00	100.0	
			Placebo	63	60 (95.2)	69.83 (17.02)	20.0	58.00	70.50	83.00	100.0	
		Week 28	Tezepelumab	57	57 (100.0)	73.44 (17.42)	32.0	60.00	73.00	90.00	100.0	
			Placebo	63	60 (95.2)	70.12 (16.68)	27.0	57.50	72.00	82.00	100.0	
		Week 40	Tezepelumab	57	57 (100.0)	75.54 (16.67)	32.0	65.00	79.00	90.00	100.0	
			Placebo	63	60 (95.2)	67.90 (18.16)	20.0	51.50	70.50	81.50	100.0	
		Week 52	Tezepelumab	57	57 (100.0)	75.46 (18.72)	25.0	64.00	80.00	91.00	100.0	
			Placebo	63	60 (95.2)	70.02 (17.47)	27.0	53.50	73.50	82.50	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	57	52 (91.2)	6.69 (17.15)	-51.0	-2.50	7.00	17.50	40.0	0.14 [-0.24, 0.51]
			Placebo	63	56 (88.9)	4.32 (17.51)	-40.0	-6.50	4.50	13.00	63.0	
		Week 8	Tezepelumab	57	52 (91.2)	9.15 (17.83)	-51.0	0.00	9.00	17.00	69.0	0.09 [-0.29, 0.47]
			Placebo	63	56 (88.9)	7.43 (19.75)	-31.0	-4.50	5.00	16.00	62.0	
		Week 12	Tezepelumab	57	52 (91.2)	9.92 (18.56)	-51.0	0.50	8.00	19.50	65.0	0.07 [-0.31, 0.45]
			Placebo	63	56 (88.9)	8.57 (20.26)	-34.0	-1.00	5.00	15.00	69.0	
		Week 20	Tezepelumab	57	53 (93.0)	9.64 (19.56)	-51.0	-4.00	10.00	24.00	55.0	0.01 [-0.37, 0.39]
			Placebo	63	56 (88.9)	9.46 (16.14)	-25.0	-1.50	7.00	17.50	57.0	
		Week 28	Tezepelumab	57	53 (93.0)	11.58 (17.77)	-16.0	-1.00	9.00	25.00	60.0	0.12 [-0.26, 0.49]
			Placebo	63	56 (88.9)	9.63 (16.07)	-15.0	-0.50	6.00	16.50	65.0	
		Week 40	Tezepelumab	57	53 (93.0)	13.81 (18.21)	-16.0	2.00	11.00	25.00	58.0	0.35 [-0.02, 0.73]
			Placebo	63	56 (88.9)	7.48 (17.50)	-26.0	-3.00	6.00	15.00	59.0	
		Week 52	Tezepelumab	57	53 (93.0)	13.57 (18.05)	-16.0	0.00	12.00	23.00	58.0	0.20 [-0.18, 0.58]
			Placebo	63	56 (88.9)	9.96 (18.14)	-15.0	-2.50	6.00	19.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	57.60 (14.07)	29.0	49.00	54.00	69.00	90.0	
			Placebo	66	54 (81.8)	58.04 (15.03)	23.0	48.00	55.00	69.00	97.0	
		Week 4	Tezepelumab	57	54 (94.7)	64.81 (18.15)	21.0	50.00	65.50	78.00	99.0	
			Placebo	66	58 (87.9)	62.93 (17.76)	17.0	53.00	64.00	74.00	99.0	
		Week 8	Tezepelumab	57	54 (94.7)	65.70 (17.82)	25.0	53.00	66.00	77.00	98.0	
			Placebo	66	60 (90.9)	63.87 (17.40)	14.0	52.00	64.50	75.00	100.0	
		Week 12	Tezepelumab	57	54 (94.7)	67.37 (18.23)	33.0	51.00	69.00	82.00	100.0	
			Placebo	66	60 (90.9)	64.88 (18.20)	19.0	56.50	68.50	76.50	97.0	
		Week 20	Tezepelumab	57	55 (96.5)	67.38 (17.76)	34.0	53.00	70.00	81.00	99.0	
			Placebo	66	60 (90.9)	64.37 (19.11)	19.0	56.00	67.00	78.00	99.0	
		Week 28	Tezepelumab	57	56 (98.2)	69.04 (17.32)	32.0	53.50	71.50	83.00	100.0	
			Placebo	66	60 (90.9)	66.40 (18.28)	12.0	55.00	69.00	81.00	95.0	
		Week 40	Tezepelumab	57	56 (98.2)	70.05 (17.42)	32.0	55.50	73.50	84.00	98.0	
			Placebo	66	61 (92.4)	65.62 (19.01)	20.0	53.00	70.00	79.00	97.0	
		Week 52	Tezepelumab	57	56 (98.2)	67.73 (18.70)	25.0	52.50	72.50	83.00	98.0	
			Placebo	66	62 (93.9)	66.42 (19.49)	16.0	51.00	70.00	80.00	96.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	7.56 (21.05)	-51.0	-3.50	6.50	21.50	50.0	0.14 [-0.25, 0.53]
			Placebo	66	54 (81.8)	5.04 (15.05)	-40.0	-4.00	4.50	10.00	41.0	
		Week 8	Tezepelumab	57	48 (84.2)	8.35 (20.23)	-59.0	-1.50	8.50	21.00	47.0	0.13 [-0.26, 0.52]
			Placebo	66	54 (81.8)	5.87 (16.93)	-36.0	-4.00	6.00	16.00	41.0	
		Week 12	Tezepelumab	57	48 (84.2)	10.13 (20.13)	-51.0	-1.00	10.00	25.50	51.0	0.17 [-0.22, 0.56]
			Placebo	66	54 (81.8)	6.80 (18.23)	-39.0	-4.00	6.00	20.00	50.0	
		Week 20	Tezepelumab	57	49 (86.0)	10.59 (19.43)	-51.0	-1.00	13.00	25.00	49.0	0.22 [-0.17, 0.60]
			Placebo	66	54 (81.8)	6.65 (17.14)	-32.0	-4.00	6.50	15.00	49.0	
		Week 28	Tezepelumab	57	49 (86.0)	11.88 (18.87)	-43.0	-1.00	8.00	26.00	51.0	0.20 [-0.19, 0.59]
			Placebo	66	54 (81.8)	8.37 (15.82)	-20.0	-4.00	5.00	17.00	54.0	
		Week 40	Tezepelumab	57	49 (86.0)	12.90 (19.52)	-43.0	-1.00	16.00	28.00	53.0	0.23 [-0.16, 0.61]
			Placebo	66	54 (81.8)	8.67 (18.07)	-26.0	-4.00	6.00	21.00	56.0	
		Week 52	Tezepelumab	57	49 (86.0)	10.71 (19.66)	-43.0	-2.00	13.00	25.00	46.0	0.08 [-0.30, 0.47]
			Placebo	66	54 (81.8)	9.20 (17.08)	-26.0	-4.00	6.00	20.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	71	66 (93.0)	62.77 (18.39)	20.0	50.00	65.00	75.00	100.0	
			Placebo	63	57 (90.5)	62.07 (14.86)	27.0	50.00	62.00	70.00	96.0	
		Week 4	Tezepelumab	71	67 (94.4)	69.15 (18.46)	14.0	55.00	70.00	84.00	100.0	
			Placebo	63	58 (92.1)	67.09 (15.84)	29.0	53.00	70.00	80.00	95.0	
		Week 8	Tezepelumab	71	67 (94.4)	69.34 (20.02)	20.0	54.00	69.00	86.00	100.0	
			Placebo	63	58 (92.1)	70.57 (16.26)	40.0	57.00	75.00	83.00	97.0	
		Week 12	Tezepelumab	71	67 (94.4)	70.91 (19.25)	26.0	56.00	72.00	88.00	100.0	
			Placebo	63	59 (93.7)	70.73 (17.25)	31.0	60.00	74.00	84.00	100.0	
		Week 20	Tezepelumab	71	67 (94.4)	70.70 (19.25)	18.0	60.00	71.00	85.00	100.0	
			Placebo	63	59 (93.7)	71.25 (15.42)	36.0	60.00	73.00	85.00	97.0	
		Week 28	Tezepelumab	71	67 (94.4)	71.82 (18.75)	8.0	59.00	73.00	85.00	100.0	
			Placebo	63	60 (95.2)	70.10 (16.87)	33.0	54.50	72.50	84.00	98.0	
		Week 40	Tezepelumab	71	68 (95.8)	73.71 (18.05)	18.0	60.50	77.50	89.00	100.0	
			Placebo	63	60 (95.2)	71.42 (16.17)	40.0	56.50	75.00	85.50	96.0	
		Week 52	Tezepelumab	71	69 (97.2)	75.03 (18.97)	19.0	61.00	80.00	88.00	100.0	
			Placebo	63	60 (95.2)	72.87 (16.26)	45.0	60.00	75.00	86.50	98.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	71	65 (91.5)	6.97 (14.49)	-23.0	-2.00	8.00	15.00	40.0	0.09 [-0.27, 0.44]
			Placebo	63	57 (90.5)	5.68 (15.43)	-25.0	-5.00	5.00	11.00	63.0	
		Week 8	Tezepelumab	71	65 (91.5)	7.17 (17.84)	-46.0	-3.00	9.00	15.00	69.0	-0.10 [-0.46, 0.26]
			Placebo	63	57 (90.5)	8.95 (17.71)	-20.0	-1.00	5.00	16.00	62.0	
		Week 12	Tezepelumab	71	65 (91.5)	8.78 (18.33)	-34.0	-2.00	6.00	17.00	65.0	-0.01 [-0.37, 0.34]
			Placebo	63	57 (90.5)	9.02 (19.89)	-29.0	-3.00	5.00	14.00	69.0	
		Week 20	Tezepelumab	71	65 (91.5)	8.49 (20.01)	-44.0	-7.00	9.00	20.00	55.0	-0.07 [-0.43, 0.28]
			Placebo	63	57 (90.5)	9.81 (15.67)	-24.0	-2.00	7.00	14.00	57.0	
		Week 28	Tezepelumab	71	65 (91.5)	9.72 (19.11)	-41.0	-3.00	10.00	21.00	60.0	0.09 [-0.27, 0.44]
			Placebo	63	57 (90.5)	8.05 (18.32)	-30.0	-3.00	6.00	18.00	65.0	
		Week 40	Tezepelumab	71	65 (91.5)	11.18 (18.97)	-33.0	-3.00	11.00	24.00	58.0	0.11 [-0.25, 0.47]
			Placebo	63	57 (90.5)	9.23 (16.52)	-17.0	-2.00	8.00	15.00	59.0	
		Week 52	Tezepelumab	71	65 (91.5)	12.51 (19.19)	-30.0	-3.00	13.00	24.00	58.0	0.08 [-0.27, 0.44]
			Placebo	63	57 (90.5)	10.91 (18.29)	-12.0	-2.00	7.00	17.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	35	31 (88.6)	59.68 (14.96)	20.0	51.00	59.00	72.00	90.0	
			Placebo	32	26 (81.3)	58.46 (16.84)	23.0	47.00	52.50	72.00	90.0	
		Week 4	Tezepelumab	35	33 (94.3)	65.36 (19.10)	14.0	50.00	66.00	80.00	91.0	
			Placebo	32	27 (84.4)	63.67 (19.37)	23.0	57.00	65.00	75.00	98.0	
		Week 8	Tezepelumab	35	33 (94.3)	65.91 (17.44)	31.0	55.00	62.00	80.00	95.0	
			Placebo	32	28 (87.5)	62.36 (19.80)	14.0	50.50	62.00	77.00	100.0	
		Week 12	Tezepelumab	35	33 (94.3)	69.33 (18.29)	33.0	53.00	70.00	84.00	98.0	
			Placebo	32	28 (87.5)	64.57 (22.30)	19.0	51.00	66.00	84.00	97.0	
		Week 20	Tezepelumab	35	34 (97.1)	67.62 (18.29)	34.0	53.00	70.00	82.00	97.0	
			Placebo	32	28 (87.5)	64.29 (24.69)	19.0	46.50	67.00	85.00	99.0	
		Week 28	Tezepelumab	35	35 (100.0)	68.77 (17.90)	32.0	51.00	75.00	83.00	95.0	
			Placebo	32	28 (87.5)	64.11 (22.72)	12.0	51.00	62.00	82.50	96.0	
		Week 40	Tezepelumab	35	35 (100.0)	69.46 (18.21)	32.0	51.00	74.00	85.00	93.0	
			Placebo	32	28 (87.5)	64.64 (22.32)	20.0	48.50	69.00	80.50	97.0	
		Week 52	Tezepelumab	35	35 (100.0)	68.54 (18.48)	25.0	53.00	73.00	85.00	93.0	
			Placebo	32	28 (87.5)	65.43 (22.19)	16.0	49.00	70.50	84.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	35	31 (88.6)	6.06 (19.00)	-40.0	-6.00	10.00	19.00	30.0	0.06 [-0.46, 0.59]
			Placebo	32	26 (81.3)	4.96 (14.61)	-22.0	-5.00	2.50	9.00	44.0	
		Week 8	Tezepelumab	35	31 (88.6)	6.65 (22.56)	-59.0	-6.00	4.00	19.00	69.0	0.13 [-0.39, 0.65]
			Placebo	32	26 (81.3)	3.96 (17.30)	-36.0	-4.00	8.00	10.00	43.0	
		Week 12	Tezepelumab	35	31 (88.6)	9.81 (20.29)	-31.0	-4.00	9.00	22.00	65.0	0.19 [-0.33, 0.71]
			Placebo	32	26 (81.3)	6.19 (16.98)	-39.0	-4.00	9.50	17.00	43.0	
		Week 20	Tezepelumab	35	31 (88.6)	8.06 (18.77)	-25.0	-5.00	6.00	24.00	51.0	0.12 [-0.41, 0.64]
			Placebo	32	26 (81.3)	5.88 (18.73)	-32.0	-4.00	8.50	20.00	43.0	
		Week 28	Tezepelumab	35	31 (88.6)	9.03 (21.41)	-43.0	-8.00	8.00	26.00	60.0	0.17 [-0.35, 0.69]
			Placebo	32	26 (81.3)	5.77 (15.65)	-20.0	-7.00	3.50	21.00	40.0	
		Week 40	Tezepelumab	35	31 (88.6)	8.71 (20.44)	-43.0	-6.00	11.00	23.00	58.0	0.11 [-0.41, 0.64]
			Placebo	32	26 (81.3)	6.54 (17.08)	-25.0	-6.00	4.00	18.00	45.0	
		Week 52	Tezepelumab	35	31 (88.6)	8.45 (20.60)	-43.0	-10.00	10.00	25.00	58.0	0.06 [-0.46, 0.58]
			Placebo	32	26 (81.3)	7.35 (16.20)	-26.0	-5.00	7.50	16.00	43.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	95	86 (90.5)	61.05 (17.16)	29.0	49.00	61.50	73.00	100.0	
			Placebo	98	86 (87.8)	61.27 (14.72)	27.0	50.00	60.00	70.00	97.0	
		Week 4	Tezepelumab	95	89 (93.7)	68.29 (18.51)	27.0	53.00	67.00	84.00	100.0	
			Placebo	98	90 (91.8)	66.10 (16.68)	17.0	53.00	68.50	80.00	99.0	
		Week 8	Tezepelumab	95	89 (93.7)	69.46 (19.79)	20.0	55.00	70.00	85.00	100.0	
			Placebo	98	91 (92.9)	69.00 (16.58)	19.0	56.00	71.00	81.00	100.0	
		Week 12	Tezepelumab	95	89 (93.7)	70.49 (18.88)	26.0	55.00	72.00	88.00	100.0	
			Placebo	98	92 (93.9)	69.98 (16.64)	30.0	59.00	72.50	82.00	100.0	
		Week 20	Tezepelumab	95	90 (94.7)	70.23 (18.95)	18.0	56.00	71.50	85.00	100.0	
			Placebo	98	92 (93.9)	70.21 (15.48)	27.0	60.00	70.00	82.50	100.0	
		Week 28	Tezepelumab	95	90 (94.7)	71.62 (18.40)	8.0	59.00	72.00	86.00	100.0	
			Placebo	98	93 (94.9)	70.91 (16.19)	27.0	61.00	72.00	82.00	100.0	
		Week 40	Tezepelumab	95	91 (95.8)	73.59 (17.92)	18.0	65.00	75.00	88.00	100.0	
			Placebo	98	94 (95.9)	70.86 (16.27)	27.0	55.00	72.50	85.00	100.0	
		Week 52	Tezepelumab	95	92 (96.8)	73.79 (19.09)	19.0	61.50	75.00	88.00	100.0	
			Placebo	98	95 (96.9)	72.05 (17.00)	27.0	58.00	74.00	86.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	95	83 (87.4)	8.11 (16.87)	-51.0	-2.00	8.00	18.00	50.0	0.16 [-0.15, 0.46]
			Placebo	98	86 (87.8)	5.55 (15.84)	-40.0	-5.00	5.00	12.00	63.0	
		Week 8	Tezepelumab	95	83 (87.4)	8.77 (17.73)	-51.0	-1.00	10.00	20.00	56.0	0.03 [-0.27, 0.33]
			Placebo	98	86 (87.8)	8.22 (17.81)	-31.0	-3.00	5.00	17.00	62.0	
		Week 12	Tezepelumab	95	83 (87.4)	10.10 (18.98)	-51.0	-1.00	8.00	22.00	58.0	0.05 [-0.25, 0.35]
			Placebo	98	86 (87.8)	9.10 (19.64)	-34.0	-3.00	6.00	20.00	69.0	
		Week 20	Tezepelumab	95	84 (88.4)	10.12 (20.19)	-51.0	-2.50	12.00	25.00	55.0	0.02 [-0.28, 0.32]
			Placebo	98	86 (87.8)	9.78 (15.81)	-24.0	-2.00	7.00	17.00	57.0	
		Week 28	Tezepelumab	95	84 (88.4)	11.51 (18.07)	-41.0	0.00	10.00	25.00	55.0	0.10 [-0.21, 0.40]
			Placebo	98	86 (87.8)	9.81 (17.47)	-30.0	-2.00	7.00	18.00	65.0	
		Week 40	Tezepelumab	95	84 (88.4)	13.45 (18.55)	-33.0	1.00	13.00	26.00	56.0	0.17 [-0.13, 0.47]
			Placebo	98	86 (87.8)	10.35 (17.31)	-26.0	-2.00	8.50	20.00	59.0	
		Week 52	Tezepelumab	95	84 (88.4)	13.39 (18.69)	-30.0	-1.00	15.00	25.00	56.0	0.10 [-0.20, 0.40]
			Placebo	98	86 (87.8)	11.60 (18.03)	-13.0	-2.00	8.50	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	59.17 (17.85)	34.0	45.00	61.00	74.00	80.0	
			Placebo	8	8 (100.0)	58.63 (11.40)	41.0	48.00	62.50	68.50	70.0	
		Week 4	Tezepelumab	7	7 (100.0)	65.00 (11.31)	48.0	55.00	67.00	75.00	80.0	
			Placebo	8	8 (100.0)	65.25 (14.42)	48.0	53.50	64.50	73.50	91.0	
		Week 8	Tezepelumab	7	7 (100.0)	59.43 (13.25)	45.0	45.00	60.00	74.00	75.0	
			Placebo	8	8 (100.0)	64.63 (17.94)	43.0	50.50	61.00	79.00	93.0	
		Week 12	Tezepelumab	7	7 (100.0)	58.86 (15.35)	35.0	44.00	60.00	70.00	79.0	
			Placebo	8	8 (100.0)	67.13 (16.91)	42.0	54.50	67.50	80.50	90.0	
		Week 20	Tezepelumab	7	7 (100.0)	63.43 (10.85)	47.0	60.00	61.00	68.00	83.0	
			Placebo	8	8 (100.0)	66.50 (16.41)	47.0	51.50	67.50	81.00	85.0	
		Week 28	Tezepelumab	7	7 (100.0)	66.14 (9.04)	53.0	60.00	68.00	70.00	81.0	
			Placebo	8	8 (100.0)	66.75 (17.29)	47.0	48.50	68.00	83.00	88.0	
		Week 40	Tezepelumab	7	7 (100.0)	64.43 (9.96)	48.0	60.00	65.00	70.00	80.0	
			Placebo	8	8 (100.0)	65.88 (14.79)	46.0	53.00	65.50	79.50	85.0	
		Week 52	Tezepelumab	7	7 (100.0)	62.71 (13.86)	40.0	50.00	68.00	70.00	81.0	
			Placebo	8	8 (100.0)	67.50 (15.61)	45.0	53.50	70.50	81.00	85.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	6.67 (17.20)	-13.0	-6.00	5.50	12.00	36.0	0.00 [-1.06, 1.06]
			Placebo	8	8 (100.0)	6.63 (12.70)	-12.0	-3.00	7.50	15.00	26.0	
		Week 8	Tezepelumab	7	6 (85.7)	0.17 (8.23)	-12.0	-5.00	0.00	7.00	11.0	-0.41 [-1.48, 0.66]
			Placebo	8	8 (100.0)	6.00 (17.36)	-12.0	-5.50	2.00	13.50	40.0	
		Week 12	Tezepelumab	7	6 (85.7)	-0.50 (7.56)	-12.0	-4.00	0.00	2.00	11.0	-0.72 [-1.81, 0.38]
			Placebo	8	8 (100.0)	8.50 (15.13)	-4.0	0.00	4.00	10.50	43.0	
		Week 20	Tezepelumab	7	6 (85.7)	4.67 (17.66)	-14.0	-12.00	4.00	20.00	26.0	-0.20 [-1.26, 0.86]
			Placebo	8	8 (100.0)	7.88 (14.61)	-10.0	-2.50	7.50	12.50	38.0	
		Week 28	Tezepelumab	7	6 (85.7)	8.00 (17.31)	-12.0	-4.00	6.00	16.00	36.0	-0.01 [-1.07, 1.05]
			Placebo	8	8 (100.0)	8.13 (15.34)	-16.0	1.00	6.00	15.00	37.0	
		Week 40	Tezepelumab	7	6 (85.7)	6.00 (16.19)	-12.0	-6.00	4.00	15.00	31.0	-0.09 [-1.15, 0.97]
			Placebo	8	8 (100.0)	7.25 (12.98)	-7.0	-2.50	6.50	11.50	34.0	
		Week 52	Tezepelumab	7	6 (85.7)	4.00 (16.19)	-14.0	-12.00	4.50	16.00	25.0	-0.33 [-1.40, 0.74]
			Placebo	8	8 (100.0)	8.88 (13.53)	-6.0	1.50	5.50	12.50	38.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	55.75 (16.36)	35.0	43.50	53.00	67.50	83.0	
			Placebo	13	9 (69.2)	58.78 (8.84)	45.0	50.00	60.00	65.00	70.0	
		Week 4	Tezepelumab	9	9 (100.0)	70.11 (14.49)	44.0	66.00	70.00	81.00	92.0	
			Placebo	13	11 (84.6)	58.36 (17.92)	23.0	48.00	54.00	69.00	91.0	
		Week 8	Tezepelumab	9	9 (100.0)	70.11 (22.03)	35.0	60.00	73.00	87.00	95.0	
			Placebo	13	12 (92.3)	63.25 (13.09)	48.0	53.00	61.50	67.00	93.0	
		Week 12	Tezepelumab	9	9 (100.0)	67.44 (23.42)	33.0	48.00	66.00	89.00	97.0	
			Placebo	13	12 (92.3)	60.17 (15.76)	20.0	55.50	63.00	68.00	86.0	
		Week 20	Tezepelumab	9	9 (100.0)	68.22 (24.12)	34.0	40.00	77.00	85.00	97.0	
			Placebo	13	12 (92.3)	58.75 (15.52)	20.0	52.50	60.50	69.00	82.0	
		Week 28	Tezepelumab	9	9 (100.0)	66.44 (22.36)	32.0	50.00	71.00	85.00	95.0	
			Placebo	13	13 (100.0)	64.69 (16.60)	30.0	54.00	68.00	73.00	92.0	
		Week 40	Tezepelumab	9	9 (100.0)	67.67 (22.73)	32.0	50.00	75.00	81.00	95.0	
			Placebo	13	13 (100.0)	60.92 (18.72)	20.0	53.00	61.00	71.00	95.0	
		Week 52	Tezepelumab	9	9 (100.0)	68.11 (24.62)	25.0	50.00	75.00	88.00	95.0	
			Placebo	13	13 (100.0)	62.00 (16.90)	30.0	48.00	64.00	73.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	12.63 (16.31)	-17.0	1.50	19.00	23.00	31.0	0.70 [-0.29, 1.68]
			Placebo	13	9 (69.2)	1.78 (14.88)	-22.0	-6.00	-1.00	9.00	26.0	
		Week 8	Tezepelumab	9	8 (88.9)	12.25 (12.83)	-10.0	3.50	15.50	22.50	25.0	0.51 [-0.46, 1.48]
			Placebo	13	9 (69.2)	5.67 (13.16)	-8.0	-1.00	1.00	6.00	32.0	
		Week 12	Tezepelumab	9	8 (88.9)	10.13 (14.68)	-10.0	-1.00	10.00	19.50	34.0	0.76 [-0.23, 1.76]
			Placebo	13	9 (69.2)	-0.11 (12.14)	-25.0	-4.00	1.00	4.00	16.0	
		Week 20	Tezepelumab	9	8 (88.9)	11.38 (22.74)	-11.0	-7.00	3.00	30.00	50.0	0.62 [-0.36, 1.60]
			Placebo	13	9 (69.2)	0.11 (13.06)	-25.0	-4.00	-1.00	7.00	21.0	
		Week 28	Tezepelumab	9	8 (88.9)	8.38 (19.35)	-13.0	-8.00	3.00	27.00	36.0	0.34 [-0.62, 1.30]
			Placebo	13	9 (69.2)	3.00 (12.04)	-15.0	-4.00	3.00	8.00	23.0	
		Week 40	Tezepelumab	9	8 (88.9)	11.00 (19.01)	-13.0	-8.00	14.50	24.00	40.0	0.58 [-0.39, 1.56]
			Placebo	13	9 (69.2)	1.44 (13.78)	-25.0	-4.00	2.00	8.00	23.0	
		Week 52	Tezepelumab	9	8 (88.9)	11.50 (23.16)	-13.0	-11.50	14.00	23.50	53.0	0.51 [-0.46, 1.48]
			Placebo	13	9 (69.2)	2.33 (11.29)	-15.0	-4.00	2.00	6.00	23.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	60.95 (16.58)	20.0	50.00	60.00	73.00	100.0	
			Placebo	125	111 (88.8)	60.62 (15.36)	23.0	50.00	60.00	72.00	97.0	
		Week 4	Tezepelumab	128	120 (93.8)	67.16 (18.58)	14.0	52.00	66.50	80.50	100.0	
			Placebo	125	114 (91.2)	66.21 (16.90)	17.0	55.00	68.50	79.00	99.0	
		Week 8	Tezepelumab	128	120 (93.8)	67.85 (18.82)	20.0	54.00	66.00	85.00	100.0	
			Placebo	125	115 (92.0)	67.68 (17.89)	14.0	53.00	70.00	81.00	100.0	
		Week 12	Tezepelumab	128	120 (93.8)	69.73 (18.32)	26.0	55.00	70.00	83.50	100.0	
			Placebo	125	116 (92.8)	69.49 (18.08)	19.0	58.50	72.50	83.00	100.0	
		Week 20	Tezepelumab	128	122 (95.3)	69.26 (18.06)	18.0	56.00	70.00	83.00	100.0	
			Placebo	125	116 (92.8)	69.71 (17.93)	19.0	60.00	70.00	84.00	100.0	
		Week 28	Tezepelumab	128	123 (96.1)	70.88 (17.58)	8.0	59.00	72.00	83.00	100.0	
			Placebo	125	116 (92.8)	69.68 (18.08)	12.0	55.50	71.00	84.00	100.0	
		Week 40	Tezepelumab	128	124 (96.9)	72.34 (17.42)	18.0	60.00	75.00	84.50	100.0	
			Placebo	125	117 (93.6)	70.14 (17.45)	20.0	55.00	73.00	85.00	100.0	
		Week 52	Tezepelumab	128	125 (97.7)	72.11 (18.46)	19.0	59.00	74.00	86.00	100.0	
			Placebo	125	118 (94.4)	71.28 (18.20)	16.0	59.00	75.00	86.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	112 (87.5)	7.14 (17.41)	-51.0	-2.50	6.50	18.00	50.0	0.08 [-0.18, 0.34]
			Placebo	125	111 (88.8)	5.79 (15.34)	-40.0	-5.00	5.00	12.00	63.0	
		Week 8	Tezepelumab	128	112 (87.5)	7.47 (19.11)	-59.0	-2.50	7.50	16.50	69.0	0.01 [-0.25, 0.27]
			Placebo	125	111 (88.8)	7.27 (17.97)	-36.0	-4.00	6.00	16.00	62.0	
		Week 12	Tezepelumab	128	112 (87.5)	9.45 (19.29)	-51.0	-2.00	7.00	21.00	65.0	0.02 [-0.25, 0.28]
			Placebo	125	111 (88.8)	9.13 (19.04)	-39.0	-3.00	7.00	19.00	69.0	
		Week 20	Tezepelumab	128	113 (88.3)	9.18 (19.49)	-51.0	-4.00	11.00	24.00	55.0	-0.02 [-0.28, 0.24]
			Placebo	125	111 (88.8)	9.51 (16.43)	-32.0	-2.00	8.00	18.00	57.0	
		Week 28	Tezepelumab	128	113 (88.3)	10.87 (18.87)	-43.0	-1.00	10.00	25.00	60.0	0.09 [-0.18, 0.35]
			Placebo	125	111 (88.8)	9.30 (17.20)	-30.0	-3.00	6.00	21.00	65.0	
		Week 40	Tezepelumab	128	113 (88.3)	11.93 (19.03)	-43.0	-1.00	12.00	25.00	58.0	0.11 [-0.15, 0.37]
			Placebo	125	111 (88.8)	9.95 (17.09)	-26.0	-3.00	7.00	20.00	59.0	
		Week 52	Tezepelumab	128	113 (88.3)	11.67 (18.95)	-43.0	-2.00	13.00	25.00	58.0	0.03 [-0.23, 0.29]
			Placebo	125	111 (88.8)	11.16 (17.63)	-26.0	-3.00	9.00	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	62.84 (15.60)	29.0	51.00	63.50	73.50	100.0	
			Placebo	73	65 (89.0)	61.86 (15.47)	23.0	50.00	65.00	72.00	97.0	
		Week 4	Tezepelumab	70	65 (92.9)	68.25 (17.41)	27.0	55.00	68.00	80.00	100.0	
			Placebo	73	67 (91.8)	65.55 (16.81)	25.0	53.00	68.00	79.00	98.0	
		Week 8	Tezepelumab	70	65 (92.9)	67.71 (18.74)	25.0	54.00	65.00	84.00	100.0	
			Placebo	73	68 (93.2)	68.32 (15.13)	38.0	57.00	71.00	79.00	100.0	
		Week 12	Tezepelumab	70	65 (92.9)	70.05 (18.32)	39.0	52.00	69.00	83.00	100.0	
			Placebo	73	69 (94.5)	68.86 (17.52)	19.0	59.00	73.00	80.00	99.0	
		Week 20	Tezepelumab	70	66 (94.3)	69.44 (17.59)	38.0	56.00	68.50	85.00	100.0	
			Placebo	73	69 (94.5)	69.91 (16.26)	19.0	60.00	70.00	80.00	99.0	
		Week 28	Tezepelumab	70	66 (94.3)	72.11 (16.27)	42.0	59.00	72.00	83.00	100.0	
			Placebo	73	69 (94.5)	69.10 (17.21)	12.0	58.00	71.00	82.00	98.0	
		Week 40	Tezepelumab	70	67 (95.7)	73.78 (16.37)	32.0	61.00	75.00	87.00	100.0	
			Placebo	73	70 (95.9)	70.56 (16.41)	20.0	57.00	74.50	82.00	97.0	
		Week 52	Tezepelumab	70	67 (95.7)	74.04 (17.67)	27.0	61.00	75.00	87.00	100.0	
			Placebo	73	71 (97.3)	70.59 (17.36)	16.0	58.00	71.00	85.00	98.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 4	Tezepelumab	70	61 (87.1)	6.98 (15.77)	-51.0	-2.00	6.00	15.00	50.0	0.18 [-0.17, 0.53]
			Placebo	73	65 (89.0)	4.18 (15.70)	-40.0	-5.00	3.00	10.00	63.0	
		Week 8	Tezepelumab	70	61 (87.1)	6.33 (17.61)	-51.0	-3.00	5.00	15.00	56.0	-0.04 [-0.39, 0.31]
			Placebo	73	65 (89.0)	7.03 (16.28)	-31.0	-4.00	5.00	14.00	57.0	
		Week 12	Tezepelumab	70	61 (87.1)	8.84 (18.74)	-51.0	-2.00	7.00	19.00	58.0	0.08 [-0.27, 0.43]
			Placebo	73	65 (89.0)	7.42 (18.56)	-39.0	-3.00	6.00	16.00	69.0	
		Week 20	Tezepelumab	70	62 (88.6)	8.24 (18.89)	-51.0	-3.00	10.00	19.00	55.0	-0.03 [-0.38, 0.32]
			Placebo	73	65 (89.0)	8.75 (15.75)	-24.0	-1.00	6.00	15.00	57.0	
		Week 28	Tezepelumab	70	62 (88.6)	10.92 (15.96)	-14.0	-1.00	8.50	23.00	55.0	0.19 [-0.16, 0.54]
			Placebo	73	65 (89.0)	7.77 (17.64)	-30.0	-4.00	5.00	18.00	58.0	
		Week 40	Tezepelumab	70	62 (88.6)	12.26 (17.24)	-21.0	-1.00	11.00	25.00	56.0	0.16 [-0.19, 0.51]
			Placebo	73	65 (89.0)	9.52 (16.82)	-26.0	-3.00	7.00	17.00	59.0	
		Week 52	Tezepelumab	70	62 (88.6)	12.40 (16.98)	-24.0	-1.00	12.50	25.00	56.0	0.16 [-0.19, 0.51]
			Placebo	73	65 (89.0)	9.69 (16.52)	-12.0	-3.00	6.00	17.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	58.19 (17.32)	20.0	49.00	53.00	72.00	100.0	
			Placebo	65	55 (84.6)	58.85 (14.28)	29.0	50.00	55.00	69.00	96.0	
		Week 4	Tezepelumab	67	64 (95.5)	66.47 (19.25)	14.0	50.00	66.50	82.50	100.0	
			Placebo	65	58 (89.2)	65.48 (17.50)	17.0	54.00	65.00	77.00	99.0	
		Week 8	Tezepelumab	67	64 (95.5)	68.31 (19.35)	20.0	55.00	70.00	86.00	100.0	
			Placebo	65	59 (90.8)	66.03 (19.95)	14.0	51.00	62.00	85.00	100.0	
		Week 12	Tezepelumab	67	64 (95.5)	69.08 (19.05)	26.0	56.00	70.00	84.50	100.0	
			Placebo	65	59 (90.8)	68.34 (18.75)	20.0	57.00	69.00	87.00	100.0	
		Week 20	Tezepelumab	67	65 (97.0)	68.94 (19.37)	18.0	55.00	71.00	82.00	100.0	
			Placebo	65	59 (90.8)	67.24 (19.80)	20.0	54.00	68.00	85.00	100.0	
		Week 28	Tezepelumab	67	66 (98.5)	69.05 (19.35)	8.0	53.00	71.00	83.00	100.0	
			Placebo	65	60 (92.3)	69.27 (18.88)	27.0	53.50	69.50	85.50	100.0	
		Week 40	Tezepelumab	67	66 (98.5)	70.24 (19.03)	18.0	53.00	74.50	84.00	100.0	
			Placebo	65	60 (92.3)	67.65 (19.16)	20.0	53.50	68.50	85.50	100.0	
		Week 52	Tezepelumab	67	67 (100.0)	69.64 (19.84)	19.0	53.00	73.00	85.00	100.0	
			Placebo	65	60 (92.3)	70.08 (19.35)	21.0	56.50	74.00	85.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 4	Tezepelumab	67	59 (88.1)	8.05 (18.93)	-40.0	-5.00	10.00	20.00	47.0	0.06 [-0.31, 0.43]
			Placebo	65	55 (84.6)	7.04 (14.78)	-26.0	-4.00	7.00	17.00	51.0	
		Week 8	Tezepelumab	67	59 (88.1)	9.31 (19.91)	-59.0	-1.00	12.00	20.00	69.0	0.10 [-0.26, 0.47]
			Placebo	65	55 (84.6)	7.29 (19.23)	-36.0	-5.00	4.00	19.00	62.0	
		Week 12	Tezepelumab	67	59 (88.1)	10.17 (19.34)	-34.0	-1.00	7.00	23.00	65.0	0.03 [-0.34, 0.40]
			Placebo	65	55 (84.6)	9.64 (19.03)	-34.0	-2.00	8.00	21.00	68.0	
		Week 20	Tezepelumab	67	59 (88.1)	10.46 (20.46)	-44.0	-7.00	12.00	25.00	51.0	0.08 [-0.28, 0.45]
			Placebo	65	55 (84.6)	8.87 (17.17)	-32.0	-4.00	8.00	21.00	51.0	
		Week 28	Tezepelumab	67	59 (88.1)	10.47 (21.57)	-43.0	-4.00	10.00	28.00	60.0	0.02 [-0.35, 0.39]
			Placebo	65	55 (84.6)	10.07 (16.08)	-20.0	-2.00	8.00	20.00	65.0	
		Week 40	Tezepelumab	67	59 (88.1)	11.46 (20.74)	-43.0	-4.00	13.00	26.00	58.0	0.12 [-0.24, 0.49]
			Placebo	65	55 (84.6)	9.07 (17.29)	-25.0	-3.00	5.00	21.00	55.0	
		Week 52	Tezepelumab	67	59 (88.1)	10.88 (21.30)	-43.0	-5.00	16.00	25.00	58.0	-0.03 [-0.40, 0.34]
			Placebo	65	55 (84.6)	11.45 (18.42)	-26.0	-3.00	10.00	23.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	11	9 (81.8)	52.67 (18.60)	20.0	42.00	51.00	72.00	75.0	
			Placebo	6	4 (66.7)	55.50 (9.57)	45.0	48.00	55.00	63.00	67.0	
		Week 4	Tezepelumab	11	11 (100.0)	59.18 (24.01)	14.0	45.00	66.00	75.00	92.0	
			Placebo	6	5 (83.3)	51.00 (20.92)	23.0	45.00	46.00	62.00	79.0	
		Week 8	Tezepelumab	11	11 (100.0)	73.27 (14.32)	45.0	65.00	72.00	89.00	95.0	
			Placebo	6	5 (83.3)	55.80 (18.62)	29.0	51.00	52.00	72.00	75.0	
		Week 12	Tezepelumab	11	11 (100.0)	70.55 (16.59)	45.0	58.00	75.00	84.00	97.0	
			Placebo	6	5 (83.3)	52.60 (25.21)	20.0	34.00	57.00	73.00	79.0	
		Week 20	Tezepelumab	11	11 (100.0)	71.09 (13.96)	45.0	63.00	70.00	77.00	97.0	
			Placebo	6	5 (83.3)	52.60 (21.87)	20.0	43.00	60.00	63.00	77.0	
		Week 28	Tezepelumab	11	11 (100.0)	73.73 (12.13)	45.0	70.00	74.00	80.00	95.0	
			Placebo	6	5 (83.3)	53.80 (19.19)	30.0	44.00	48.00	73.00	74.0	
		Week 40	Tezepelumab	11	11 (100.0)	74.18 (12.80)	45.0	68.00	77.00	84.00	94.0	
			Placebo	6	5 (83.3)	48.80 (20.81)	20.0	44.00	48.00	54.00	78.0	
		Week 52	Tezepelumab	11	11 (100.0)	72.45 (11.17)	45.0	70.00	73.00	80.00	88.0	
			Placebo	6	5 (83.3)	49.20 (15.27)	30.0	38.00	50.00	64.00	64.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	11	9 (81.8)	6.89 (21.51)	-27.0	-6.00	5.00	19.00	47.0	0.51 [-0.69, 1.71]
			Placebo	6	4 (66.7)	-3.25 (14.50)	-22.0	-14.00	-1.50	7.50	12.0	
		Week 8	Tezepelumab	11	9 (81.8)	24.22 (19.56)	0.0	15.00	20.00	23.00	69.0	1.23 [-0.06, 2.51]
			Placebo	6	4 (66.7)	1.25 (16.28)	-22.0	-8.50	5.50	11.00	16.0	
		Week 12	Tezepelumab	11	9 (81.8)	19.22 (22.11)	-4.0	4.00	15.00	25.00	65.0	1.08 [-0.18, 2.34]
			Placebo	6	4 (66.7)	-4.00 (19.92)	-25.0	-21.00	-2.50	13.00	14.0	
		Week 20	Tezepelumab	11	9 (81.8)	20.67 (17.90)	-14.0	13.00	25.00	25.00	51.0	1.47 [0.14, 2.80]
			Placebo	6	4 (66.7)	-4.75 (15.44)	-25.0	-16.50	-2.00	7.00	10.0	
		Week 28	Tezepelumab	11	9 (81.8)	23.78 (18.48)	-4.0	18.00	25.00	32.00	60.0	1.83 [0.43, 3.24]
			Placebo	6	4 (66.7)	-6.75 (10.21)	-15.0	-15.00	-9.00	1.50	6.0	
		Week 40	Tezepelumab	11	9 (81.8)	23.56 (18.11)	-4.0	20.00	22.00	28.00	58.0	1.83 [0.42, 3.23]
			Placebo	6	4 (66.7)	-8.00 (14.83)	-25.0	-18.00	-9.00	2.00	11.0	
		Week 52	Tezepelumab	11	9 (81.8)	22.78 (18.63)	-4.0	16.00	25.00	29.00	58.0	2.03 [0.58, 3.49]
			Placebo	6	4 (66.7)	-10.00 (5.29)	-15.0	-14.00	-11.00	-6.00	-3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	126	114 (90.5)	61.24 (16.30)	29.0	50.00	60.50	72.00	100.0	
			Placebo	132	116 (87.9)	60.66 (15.10)	23.0	50.00	60.00	70.00	97.0	
		Week 4	Tezepelumab	126	118 (93.7)	68.13 (17.61)	21.0	54.00	67.00	81.00	100.0	
			Placebo	132	120 (90.9)	66.13 (16.72)	17.0	54.00	68.50	78.50	99.0	
		Week 8	Tezepelumab	126	118 (93.7)	67.52 (19.33)	20.0	54.00	65.00	85.00	100.0	
			Placebo	132	122 (92.4)	67.73 (17.37)	14.0	54.00	69.00	81.00	100.0	
		Week 12	Tezepelumab	126	118 (93.7)	69.47 (18.86)	26.0	53.00	70.00	85.00	100.0	
			Placebo	132	123 (93.2)	69.27 (17.51)	19.0	59.00	71.00	83.00	100.0	
		Week 20	Tezepelumab	126	120 (95.2)	69.02 (18.82)	18.0	55.00	70.00	84.00	100.0	
			Placebo	132	123 (93.2)	69.33 (17.57)	19.0	58.00	70.00	83.00	100.0	
		Week 28	Tezepelumab	126	121 (96.0)	70.29 (18.32)	8.0	57.00	72.00	83.00	100.0	
			Placebo	132	124 (93.9)	69.80 (17.69)	12.0	56.50	70.50	84.00	100.0	
		Week 40	Tezepelumab	126	122 (96.8)	71.83 (18.17)	18.0	58.00	75.00	85.00	100.0	
			Placebo	132	125 (94.7)	70.03 (17.18)	20.0	55.00	72.00	85.00	100.0	
		Week 52	Tezepelumab	126	123 (97.6)	71.79 (19.42)	19.0	55.00	74.00	87.00	100.0	
			Placebo	132	126 (95.5)	71.20 (17.87)	16.0	59.00	74.00	85.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	126	111 (88.1)	7.56 (17.06)	-51.0	-2.00	8.00	19.00	50.0	0.11 [-0.15, 0.37]
			Placebo	132	116 (87.9)	5.79 (15.28)	-40.0	-4.50	5.00	11.50	63.0	
		Week 8	Tezepelumab	126	111 (88.1)	6.46 (18.14)	-59.0	-3.00	7.00	16.00	56.0	-0.05 [-0.31, 0.21]
			Placebo	132	116 (87.9)	7.35 (17.69)	-36.0	-4.00	5.00	16.50	62.0	
		Week 12	Tezepelumab	126	111 (88.1)	8.70 (18.58)	-51.0	-2.00	7.00	20.00	58.0	-0.01 [-0.27, 0.25]
			Placebo	132	116 (87.9)	8.86 (18.63)	-39.0	-3.00	6.00	18.00	69.0	
		Week 20	Tezepelumab	126	112 (88.9)	8.41 (19.54)	-51.0	-5.00	8.50	21.00	55.0	-0.05 [-0.31, 0.21]
			Placebo	132	116 (87.9)	9.28 (16.24)	-32.0	-2.00	7.00	17.50	57.0	
		Week 28	Tezepelumab	126	112 (88.9)	9.65 (18.54)	-43.0	-3.00	8.00	23.00	55.0	0.02 [-0.24, 0.28]
			Placebo	132	116 (87.9)	9.36 (16.87)	-30.0	-2.00	6.50	20.50	65.0	
		Week 40	Tezepelumab	126	112 (88.9)	10.93 (18.78)	-43.0	-2.50	11.00	25.00	56.0	0.06 [-0.20, 0.32]
			Placebo	132	116 (87.9)	9.91 (16.78)	-26.0	-2.00	7.00	19.50	59.0	
		Week 52	Tezepelumab	126	112 (88.9)	10.77 (18.98)	-43.0	-3.00	12.50	24.50	56.0	-0.02 [-0.28, 0.24]
			Placebo	132	116 (87.9)	11.21 (17.21)	-26.0	-2.00	8.50	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	52.88 (19.87)	20.0	40.50	50.50	73.00	75.0	
			Placebo	3	2 (66.7)	55.00 (5.66)	51.0	51.00	55.00	59.00	59.0	
		Week 4	Tezepelumab	9	9 (100.0)	60.00 (26.24)	14.0	48.00	70.00	75.00	92.0	
			Placebo	3	3 (100.0)	51.00 (9.54)	45.0	45.00	46.00	62.00	62.0	
		Week 8	Tezepelumab	9	9 (100.0)	76.67 (11.95)	60.0	69.00	74.00	89.00	95.0	
			Placebo	3	3 (100.0)	52.00 (23.00)	29.0	29.00	52.00	75.00	75.0	
		Week 12	Tezepelumab	9	9 (100.0)	74.78 (14.92)	46.0	70.00	76.00	84.00	97.0	
			Placebo	3	3 (100.0)	54.67 (19.60)	34.0	34.00	57.00	73.00	73.0	
		Week 20	Tezepelumab	9	9 (100.0)	74.89 (11.58)	60.0	70.00	71.00	77.00	97.0	
			Placebo	3	3 (100.0)	55.33 (10.79)	43.0	43.00	60.00	63.00	63.0	
		Week 28	Tezepelumab	9	9 (100.0)	77.44 (7.91)	70.0	71.00	77.00	80.00	95.0	
			Placebo	3	3 (100.0)	55.33 (16.29)	44.0	44.00	48.00	74.00	74.0	
		Week 40	Tezepelumab	9	9 (100.0)	77.67 (9.18)	65.0	70.00	78.00	84.00	94.0	
			Placebo	3	3 (100.0)	48.67 (5.03)	44.0	44.00	48.00	54.00	54.0	
		Week 52	Tezepelumab	9	9 (100.0)	74.67 (7.00)	64.0	70.00	73.00	78.00	88.0	
			Placebo	3	3 (100.0)	50.67 (13.01)	38.0	38.00	50.00	64.00	64.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	5.88 (22.77)	-27.0	-9.00	3.00	19.50	47.0	0.34 [-1.21, 1.90]
			Placebo	3	2 (66.7)	-1.50 (6.36)	-6.0	-6.00	-1.50	3.00	3.0	
		Week 8	Tezepelumab	9	8 (88.9)	24.75 (20.84)	0.0	14.50	19.50	30.50	69.0	1.28 [-0.39, 2.95]
			Placebo	3	2 (66.7)	-3.00 (26.87)	-22.0	-22.00	-3.00	16.00	16.0	
		Week 12	Tezepelumab	9	8 (88.9)	20.75 (23.13)	-4.0	2.00	17.50	33.00	65.0	0.97 [-0.65, 2.59]
			Placebo	3	2 (66.7)	-1.50 (21.92)	-17.0	-17.00	-1.50	14.00	14.0	
		Week 20	Tezepelumab	9	8 (88.9)	21.75 (18.81)	-14.0	13.50	25.00	30.00	51.0	1.33 [-0.35, 3.01]
			Placebo	3	2 (66.7)	-2.00 (8.49)	-8.0	-8.00	-2.00	4.00	4.0	
		Week 28	Tezepelumab	9	8 (88.9)	24.50 (19.63)	-4.0	12.50	25.50	32.00	60.0	1.80 [0.02, 3.58]
			Placebo	3	2 (66.7)	-9.00 (8.49)	-15.0	-15.00	-9.00	-3.00	-3.0	
		Week 40	Tezepelumab	9	8 (88.9)	23.88 (19.33)	-4.0	11.50	24.00	33.00	58.0	1.81 [0.03, 3.60]
			Placebo	3	2 (66.7)	-9.00 (2.83)	-11.0	-11.00	-9.00	-7.00	-7.0	
		Week 52	Tezepelumab	9	8 (88.9)	22.00 (19.76)	-4.0	7.00	25.00	29.00	58.0	1.78 [0.00, 3.56]
			Placebo	3	2 (66.7)	-11.00 (2.83)	-13.0	-13.00	-11.00	-9.00	-9.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	61.15 (16.26)	29.0	50.00	60.00	72.00	100.0	
			Placebo	135	118 (87.4)	60.58 (15.05)	23.0	50.00	60.00	70.00	97.0	
		Week 4	Tezepelumab	128	120 (93.8)	67.92 (17.59)	21.0	53.50	66.50	81.00	100.0	
			Placebo	135	122 (90.4)	65.88 (17.07)	17.0	54.00	68.50	79.00	99.0	
		Week 8	Tezepelumab	128	120 (93.8)	67.36 (19.28)	20.0	53.50	65.00	85.00	100.0	
			Placebo	135	124 (91.9)	67.63 (17.30)	14.0	53.50	69.00	80.50	100.0	
		Week 12	Tezepelumab	128	120 (93.8)	69.18 (18.86)	26.0	52.50	69.50	84.00	100.0	
			Placebo	135	125 (92.6)	68.95 (17.94)	19.0	59.00	71.00	82.00	100.0	
		Week 20	Tezepelumab	128	122 (95.3)	68.77 (18.79)	18.0	55.00	69.50	83.00	100.0	
			Placebo	135	125 (92.6)	69.00 (18.00)	19.0	58.00	70.00	83.00	100.0	
		Week 28	Tezepelumab	128	123 (96.1)	70.07 (18.31)	8.0	55.00	71.00	83.00	100.0	
			Placebo	135	126 (93.3)	69.51 (17.90)	12.0	56.00	70.50	84.00	100.0	
		Week 40	Tezepelumab	128	124 (96.9)	71.61 (18.18)	18.0	58.00	74.50	84.50	100.0	
			Placebo	135	127 (94.1)	69.70 (17.63)	20.0	55.00	72.00	85.00	100.0	
		Week 52	Tezepelumab	128	125 (97.7)	71.64 (19.42)	19.0	55.00	74.00	87.00	100.0	
			Placebo	135	128 (94.8)	70.82 (18.11)	16.0	58.50	74.00	85.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	112 (87.5)	7.63 (17.00)	-51.0	-2.00	8.00	18.50	50.0	0.12 [-0.13, 0.38]
			Placebo	135	118 (87.4)	5.61 (15.38)	-40.0	-5.00	5.00	12.00	63.0	
		Week 8	Tezepelumab	128	112 (87.5)	6.58 (18.10)	-59.0	-3.00	7.00	16.50	56.0	-0.04 [-0.30, 0.22]
			Placebo	135	118 (87.4)	7.32 (17.54)	-36.0	-4.00	5.00	16.00	62.0	
		Week 12	Tezepelumab	128	112 (87.5)	8.69 (18.50)	-51.0	-2.00	7.00	20.00	58.0	0.00 [-0.25, 0.26]
			Placebo	135	118 (87.4)	8.60 (18.74)	-39.0	-3.00	6.00	18.00	69.0	
		Week 20	Tezepelumab	128	113 (88.3)	8.44 (19.46)	-51.0	-5.00	9.00	20.00	55.0	-0.03 [-0.29, 0.23]
			Placebo	135	118 (87.4)	8.99 (16.41)	-32.0	-2.00	7.00	17.00	57.0	
		Week 28	Tezepelumab	128	113 (88.3)	9.73 (18.47)	-43.0	-3.00	8.00	23.00	55.0	0.03 [-0.22, 0.29]
			Placebo	135	118 (87.4)	9.13 (16.87)	-30.0	-2.00	6.00	20.00	65.0	
		Week 40	Tezepelumab	128	113 (88.3)	11.02 (18.72)	-43.0	-2.00	11.00	25.00	56.0	0.08 [-0.18, 0.34]
			Placebo	135	118 (87.4)	9.63 (16.94)	-26.0	-2.00	7.00	19.00	59.0	
		Week 52	Tezepelumab	128	113 (88.3)	10.93 (18.97)	-43.0	-3.00	13.00	25.00	56.0	0.00 [-0.25, 0.26]
			Placebo	135	118 (87.4)	10.86 (17.28)	-26.0	-2.00	8.00	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	58.19 (17.21)	34.0	42.00	60.00	72.00	100.0	
			Placebo	37	33 (89.2)	60.58 (14.90)	32.0	52.00	60.00	69.00	97.0	
		Week 4	Tezepelumab	29	29 (100.0)	66.62 (19.01)	30.0	50.00	67.00	80.00	100.0	
			Placebo	37	35 (94.6)	65.69 (18.61)	23.0	53.00	65.00	80.00	98.0	
		Week 8	Tezepelumab	29	29 (100.0)	66.00 (22.02)	20.0	49.00	65.00	84.00	100.0	
			Placebo	37	35 (94.6)	67.17 (18.01)	40.0	51.00	67.00	80.00	100.0	
		Week 12	Tezepelumab	29	29 (100.0)	66.52 (22.83)	26.0	47.00	68.00	89.00	100.0	
			Placebo	37	36 (97.3)	68.36 (20.25)	20.0	52.50	71.50	85.00	100.0	
		Week 20	Tezepelumab	29	29 (100.0)	69.41 (21.26)	18.0	55.00	77.00	83.00	100.0	
			Placebo	37	36 (97.3)	66.33 (20.72)	20.0	49.50	70.00	82.50	100.0	
		Week 28	Tezepelumab	29	29 (100.0)	67.52 (21.84)	8.0	50.00	73.00	81.00	100.0	
			Placebo	37	36 (97.3)	68.83 (19.49)	30.0	48.50	73.50	85.50	100.0	
		Week 40	Tezepelumab	29	29 (100.0)	69.41 (22.29)	18.0	52.00	75.00	85.00	100.0	
			Placebo	37	36 (97.3)	65.47 (19.86)	20.0	49.00	66.00	83.50	100.0	
		Week 52	Tezepelumab	29	29 (100.0)	69.59 (24.09)	19.0	50.00	75.00	88.00	100.0	
			Placebo	37	37 (100.0)	68.65 (19.43)	21.0	52.00	70.00	86.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	29	27 (93.1)	7.37 (14.40)	-19.0	-6.00	10.00	17.00	36.0	0.13 [-0.38, 0.63]
			Placebo	37	33 (89.2)	5.58 (14.27)	-25.0	-4.00	5.00	12.00	44.0	
		Week 8	Tezepelumab	29	27 (93.1)	6.63 (14.71)	-29.0	-3.00	9.00	17.00	37.0	-0.02 [-0.53, 0.49]
			Placebo	37	33 (89.2)	6.97 (18.27)	-22.0	-5.00	5.00	10.00	62.0	
		Week 12	Tezepelumab	29	27 (93.1)	6.70 (17.24)	-23.0	-5.00	4.00	16.00	58.0	-0.10 [-0.61, 0.41]
			Placebo	37	33 (89.2)	8.64 (21.26)	-29.0	-4.00	7.00	18.00	68.0	
		Week 20	Tezepelumab	29	27 (93.1)	10.52 (19.46)	-31.0	-5.00	10.00	26.00	50.0	0.21 [-0.30, 0.72]
			Placebo	37	33 (89.2)	6.45 (18.98)	-32.0	-4.00	8.00	14.00	49.0	
		Week 28	Tezepelumab	29	27 (93.1)	8.07 (19.82)	-41.0	-7.00	10.00	26.00	44.0	-0.03 [-0.54, 0.48]
			Placebo	37	33 (89.2)	8.64 (20.05)	-15.0	-7.00	6.00	15.00	65.0	
		Week 40	Tezepelumab	29	27 (93.1)	9.78 (19.70)	-31.0	-7.00	12.00	25.00	56.0	0.21 [-0.30, 0.72]
			Placebo	37	33 (89.2)	5.61 (20.43)	-25.0	-11.00	5.00	14.00	56.0	
		Week 52	Tezepelumab	29	27 (93.1)	10.41 (21.02)	-30.0	-10.00	16.00	24.00	53.0	0.10 [-0.41, 0.61]
			Placebo	37	33 (89.2)	8.30 (20.17)	-26.0	-5.00	3.00	18.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	61.29 (16.38)	20.0	50.50	60.00	72.50	100.0	
			Placebo	101	87 (86.1)	60.45 (15.06)	23.0	50.00	60.00	70.00	96.0	
		Week 4	Tezepelumab	108	100 (92.6)	67.58 (18.17)	14.0	53.50	66.50	81.00	100.0	
			Placebo	101	90 (89.1)	65.46 (16.53)	17.0	54.00	68.00	76.00	99.0	
		Week 8	Tezepelumab	108	100 (92.6)	68.59 (18.08)	25.0	55.00	68.50	85.00	100.0	
			Placebo	101	92 (91.1)	67.29 (17.40)	14.0	56.00	69.00	80.50	98.0	
		Week 12	Tezepelumab	108	100 (92.6)	70.45 (17.24)	35.0	58.00	70.00	83.00	100.0	
			Placebo	101	92 (91.1)	68.72 (17.19)	19.0	60.00	71.00	80.50	99.0	
		Week 20	Tezepelumab	108	102 (94.4)	69.13 (17.65)	34.0	56.00	68.50	85.00	100.0	
			Placebo	101	92 (91.1)	69.60 (16.78)	19.0	60.00	70.00	82.50	99.0	
		Week 28	Tezepelumab	108	103 (95.4)	71.44 (16.62)	29.0	59.00	72.00	85.00	100.0	
			Placebo	101	93 (92.1)	69.31 (17.41)	12.0	59.00	70.00	82.00	98.0	
		Week 40	Tezepelumab	108	104 (96.3)	72.75 (16.33)	35.0	60.50	75.00	84.00	100.0	
			Placebo	101	94 (93.1)	70.65 (16.72)	20.0	58.00	73.00	85.00	96.0	
		Week 52	Tezepelumab	108	105 (97.2)	72.47 (17.21)	32.0	61.00	74.00	85.00	100.0	
			Placebo	101	94 (93.1)	71.03 (17.80)	16.0	59.00	73.50	85.00	98.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	108	93 (86.1)	7.55 (18.16)	-51.0	-2.00	6.00	19.00	50.0	0.12 [-0.17, 0.42]
			Placebo	101	87 (86.1)	5.46 (15.73)	-40.0	-5.00	5.00	11.00	63.0	
		Week 8	Tezepelumab	108	93 (86.1)	8.13 (19.84)	-59.0	-2.00	9.00	19.00	69.0	0.05 [-0.24, 0.34]
			Placebo	101	87 (86.1)	7.22 (17.47)	-36.0	-4.00	6.00	17.00	57.0	
		Week 12	Tezepelumab	108	93 (86.1)	10.30 (19.45)	-51.0	-1.00	8.00	22.00	65.0	0.10 [-0.19, 0.40]
			Placebo	101	87 (86.1)	8.36 (17.81)	-39.0	-2.00	6.00	17.00	69.0	
		Week 20	Tezepelumab	108	94 (87.0)	8.98 (19.76)	-51.0	-4.00	11.50	24.00	55.0	-0.04 [-0.33, 0.25]
			Placebo	101	87 (86.1)	9.70 (15.26)	-22.0	-1.00	7.00	19.00	57.0	
		Week 28	Tezepelumab	108	94 (87.0)	11.46 (18.57)	-43.0	-1.00	9.00	25.00	60.0	0.15 [-0.14, 0.44]
			Placebo	101	87 (86.1)	8.90 (15.69)	-30.0	-2.00	7.00	21.00	58.0	
		Week 40	Tezepelumab	108	94 (87.0)	12.47 (18.80)	-43.0	-1.00	12.00	26.00	58.0	0.10 [-0.19, 0.39]
			Placebo	101	87 (86.1)	10.72 (15.36)	-26.0	-1.00	8.00	20.00	59.0	
		Week 52	Tezepelumab	108	94 (87.0)	12.02 (18.67)	-43.0	-2.00	13.00	25.00	58.0	0.04 [-0.25, 0.33]
			Placebo	101	87 (86.1)	11.33 (16.22)	-13.0	-2.00	9.00	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	60.50 (16.71)	20.0	49.00	60.00	72.00	100.0	
			Placebo	123	105 (85.4)	61.22 (14.41)	23.0	50.00	60.00	70.00	97.0	
		Week 4	Tezepelumab	128	120 (93.8)	67.02 (18.39)	14.0	52.00	67.00	80.50	100.0	
			Placebo	123	110 (89.4)	65.65 (16.90)	17.0	54.00	68.50	77.00	99.0	
		Week 8	Tezepelumab	128	120 (93.8)	67.26 (18.93)	20.0	54.00	66.00	84.50	100.0	
			Placebo	123	112 (91.1)	67.21 (17.33)	14.0	53.50	69.00	79.50	100.0	
		Week 12	Tezepelumab	128	120 (93.8)	69.09 (18.65)	26.0	52.50	70.00	83.50	100.0	
			Placebo	123	113 (91.9)	68.17 (17.65)	19.0	57.00	71.00	80.00	100.0	
		Week 20	Tezepelumab	128	122 (95.3)	68.56 (18.41)	18.0	55.00	70.00	82.00	100.0	
			Placebo	123	113 (91.9)	68.85 (17.97)	19.0	58.00	70.00	82.00	100.0	
		Week 28	Tezepelumab	128	123 (96.1)	70.02 (18.01)	8.0	57.00	71.00	83.00	100.0	
			Placebo	123	114 (92.7)	69.26 (17.80)	12.0	56.00	70.50	82.00	100.0	
		Week 40	Tezepelumab	128	124 (96.9)	71.81 (17.94)	18.0	58.50	75.00	84.50	100.0	
			Placebo	123	115 (93.5)	69.31 (17.47)	20.0	55.00	71.00	81.00	100.0	
		Week 52	Tezepelumab	128	125 (97.7)	71.71 (18.93)	19.0	57.00	74.00	86.00	100.0	
			Placebo	123	116 (94.3)	69.89 (17.89)	16.0	58.50	73.00	83.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	128	112 (87.5)	7.24 (17.20)	-51.0	-2.00	7.50	18.00	50.0	0.14 [-0.12, 0.41]
			Placebo	123	105 (85.4)	4.96 (14.07)	-40.0	-5.00	5.00	11.00	44.0	
		Week 8	Tezepelumab	128	112 (87.5)	7.06 (18.86)	-59.0	-3.00	8.00	16.00	69.0	0.04 [-0.23, 0.30]
			Placebo	123	105 (85.4)	6.41 (16.40)	-36.0	-4.00	5.00	16.00	57.0	
		Week 12	Tezepelumab	128	112 (87.5)	9.05 (19.30)	-51.0	-2.00	7.00	20.00	65.0	0.10 [-0.17, 0.36]
			Placebo	123	105 (85.4)	7.26 (17.15)	-39.0	-4.00	5.00	17.00	59.0	
		Week 20	Tezepelumab	128	113 (88.3)	8.73 (19.46)	-51.0	-4.00	10.00	24.00	55.0	0.02 [-0.24, 0.29]
			Placebo	123	105 (85.4)	8.34 (15.87)	-32.0	-2.00	7.00	16.00	57.0	
		Week 28	Tezepelumab	128	113 (88.3)	10.17 (19.03)	-43.0	-3.00	9.00	25.00	60.0	0.11 [-0.15, 0.38]
			Placebo	123	105 (85.4)	8.20 (16.15)	-30.0	-3.00	6.00	20.00	58.0	
		Week 40	Tezepelumab	128	113 (88.3)	11.68 (19.24)	-43.0	-1.00	12.00	25.00	58.0	0.16 [-0.10, 0.43]
			Placebo	123	105 (85.4)	8.77 (16.17)	-26.0	-3.00	6.00	19.00	56.0	
		Week 52	Tezepelumab	128	113 (88.3)	11.56 (18.85)	-43.0	-2.00	13.00	25.00	58.0	0.13 [-0.14, 0.39]
			Placebo	123	105 (85.4)	9.33 (15.79)	-26.0	-3.00	6.00	18.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	62.25 (14.91)	35.0	53.00	65.50	73.50	79.0	
			Placebo	15	15 (100.0)	55.33 (18.03)	27.0	41.00	52.00	72.00	86.0	
		Week 4	Tezepelumab	9	9 (100.0)	72.00 (17.28)	48.0	60.00	66.00	89.00	94.0	
			Placebo	15	15 (100.0)	64.53 (18.80)	35.0	49.00	62.00	83.00	94.0	
		Week 8	Tezepelumab	9	9 (100.0)	78.00 (17.59)	49.0	60.00	82.00	94.00	96.0	
			Placebo	15	15 (100.0)	67.67 (19.40)	40.0	47.00	69.00	83.00	94.0	
		Week 12	Tezepelumab	9	9 (100.0)	75.89 (18.00)	48.0	60.00	78.00	90.00	98.0	
			Placebo	15	15 (100.0)	72.00 (20.99)	31.0	60.00	73.00	89.00	100.0	
		Week 20	Tezepelumab	9	9 (100.0)	77.78 (17.30)	47.0	65.00	81.00	93.00	97.0	
			Placebo	15	15 (100.0)	67.40 (18.42)	36.0	47.00	68.00	85.00	94.0	
		Week 28	Tezepelumab	9	9 (100.0)	78.22 (14.74)	53.0	71.00	81.00	91.00	95.0	
			Placebo	15	15 (100.0)	68.53 (19.55)	44.0	47.00	68.00	89.00	97.0	
		Week 40	Tezepelumab	9	9 (100.0)	74.89 (15.73)	48.0	68.00	75.00	81.00	98.0	
			Placebo	15	15 (100.0)	68.47 (20.21)	46.0	48.00	66.00	89.00	91.0	
		Week 52	Tezepelumab	9	9 (100.0)	73.67 (18.63)	40.0	61.00	81.00	88.00	97.0	
			Placebo	15	15 (100.0)	74.00 (20.98)	45.0	50.00	86.00	91.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	11.25 (19.85)	-20.0	-7.00	17.50	29.00	31.0	0.10 [-0.76, 0.95]
			Placebo	15	15 (100.0)	9.20 (22.33)	-25.0	0.00	6.00	14.00	63.0	
		Week 8	Tezepelumab	9	8 (88.9)	18.00 (14.57)	-5.0	6.50	20.00	30.00	36.0	0.26 [-0.60, 1.12]
			Placebo	15	15 (100.0)	12.33 (24.60)	-20.0	-3.00	5.00	17.00	62.0	
		Week 12	Tezepelumab	9	8 (88.9)	15.63 (12.87)	1.0	3.50	16.00	23.50	38.0	-0.05 [-0.90, 0.81]
			Placebo	15	15 (100.0)	16.67 (26.75)	-29.0	1.00	9.00	19.00	69.0	
		Week 20	Tezepelumab	9	8 (88.9)	17.63 (21.41)	-8.0	-3.00	19.50	33.00	50.0	0.27 [-0.59, 1.14]
			Placebo	15	15 (100.0)	12.07 (19.68)	-24.0	-2.00	8.00	20.00	51.0	
		Week 28	Tezepelumab	9	8 (88.9)	18.25 (14.50)	-1.0	6.00	18.50	29.50	39.0	0.26 [-0.60, 1.12]
			Placebo	15	15 (100.0)	13.20 (21.66)	-15.0	-2.00	14.00	18.00	65.0	
		Week 40	Tezepelumab	9	8 (88.9)	14.50 (15.04)	-6.0	1.50	17.50	22.00	40.0	0.07 [-0.79, 0.93]
			Placebo	15	15 (100.0)	13.13 (22.09)	-11.0	-3.00	11.00	19.00	59.0	
		Week 52	Tezepelumab	9	8 (88.9)	13.13 (24.30)	-14.0	-12.00	17.00	28.00	53.0	-0.22 [-1.08, 0.64]
			Placebo	15	15 (100.0)	18.67 (25.06)	-12.0	-2.00	11.00	43.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	69.33 (16.14)	40.0	59.00	74.00	79.00	91.0	
			Placebo	9	8 (88.9)	64.50 (18.24)	32.0	54.50	64.50	80.00	86.0	
		Week 4	Tezepelumab	10	8 (80.0)	78.25 (15.05)	50.0	68.00	84.00	89.50	93.0	
			Placebo	9	8 (88.9)	72.50 (19.58)	35.0	61.00	77.00	87.50	94.0	
		Week 8	Tezepelumab	10	8 (80.0)	84.25 (15.19)	49.0	83.50	86.50	94.00	97.0	
			Placebo	9	8 (88.9)	75.00 (17.71)	40.0	67.00	79.00	87.00	94.0	
		Week 12	Tezepelumab	10	8 (80.0)	82.88 (8.53)	72.0	75.50	81.50	91.50	94.0	
			Placebo	9	8 (88.9)	74.63 (19.99)	31.0	69.50	78.50	88.00	94.0	
		Week 20	Tezepelumab	10	8 (80.0)	82.63 (8.12)	73.0	75.00	81.50	91.00	93.0	
			Placebo	9	8 (88.9)	74.63 (19.71)	36.0	65.50	76.50	91.50	94.0	
		Week 28	Tezepelumab	10	8 (80.0)	82.25 (7.61)	73.0	75.00	81.50	90.50	91.0	
			Placebo	9	8 (88.9)	69.25 (21.46)	44.0	47.50	69.50	91.00	94.0	
		Week 40	Tezepelumab	10	8 (80.0)	78.63 (9.46)	65.0	70.50	80.50	85.50	91.0	
			Placebo	9	8 (88.9)	67.63 (20.74)	47.0	48.50	64.50	89.00	90.0	
		Week 52	Tezepelumab	10	9 (90.0)	79.22 (9.68)	62.0	73.00	80.00	86.00	92.0	
			Placebo	9	8 (88.9)	73.00 (21.25)	48.0	50.50	76.00	93.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	10.63 (13.71)	-8.0	-0.50	9.50	22.50	30.0	0.15 [-0.83, 1.13]
			Placebo	9	8 (88.9)	8.00 (20.65)	-25.0	4.00	6.00	9.00	51.0	
		Week 8	Tezepelumab	10	8 (80.0)	16.63 (14.05)	-6.0	8.50	15.00	28.00	36.0	0.36 [-0.63, 1.35]
			Placebo	9	8 (88.9)	10.50 (19.50)	-20.0	5.50	8.50	12.50	51.0	
		Week 12	Tezepelumab	10	8 (80.0)	15.25 (15.69)	-9.0	3.50	16.00	27.00	38.0	0.27 [-0.71, 1.26]
			Placebo	9	8 (88.9)	10.13 (21.68)	-29.0	6.50	8.00	15.00	51.0	
		Week 20	Tezepelumab	10	8 (80.0)	15.00 (16.64)	-9.0	3.00	13.50	27.50	41.0	0.26 [-0.73, 1.24]
			Placebo	9	8 (88.9)	10.13 (20.84)	-24.0	2.50	8.50	16.00	51.0	
		Week 28	Tezepelumab	10	8 (80.0)	14.63 (17.21)	-16.0	6.50	13.00	27.50	39.0	0.65 [-0.36, 1.66]
			Placebo	9	8 (88.9)	4.75 (12.81)	-15.0	-4.50	8.00	14.00	18.0	
		Week 40	Tezepelumab	10	8 (80.0)	11.00 (13.98)	-10.0	0.50	13.00	19.00	33.0	0.63 [-0.38, 1.64]
			Placebo	9	8 (88.9)	3.13 (10.86)	-11.0	-7.00	4.00	12.00	18.0	
		Week 52	Tezepelumab	10	8 (80.0)	11.63 (18.09)	-12.0	-5.50	13.50	27.50	34.0	0.15 [-0.84, 1.13]
			Placebo	9	8 (88.9)	8.50 (24.48)	-12.0	-5.50	0.50	12.50	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	127	114 (89.8)	59.92 (16.45)	20.0	49.00	60.00	72.00	100.0	
			Placebo	129	112 (86.8)	60.20 (14.75)	23.0	50.00	60.00	70.00	97.0	
		Week 4	Tezepelumab	127	121 (95.3)	66.64 (18.31)	14.0	53.00	66.00	80.00	100.0	
			Placebo	129	117 (90.7)	65.04 (16.87)	17.0	53.00	67.00	76.00	99.0	
		Week 8	Tezepelumab	127	121 (95.3)	66.93 (18.76)	20.0	54.00	65.00	82.00	100.0	
			Placebo	129	119 (92.2)	66.74 (17.44)	14.0	53.00	67.00	80.00	100.0	
		Week 12	Tezepelumab	127	121 (95.3)	68.69 (18.79)	26.0	52.00	69.00	83.00	100.0	
			Placebo	129	120 (93.0)	68.22 (17.91)	19.0	57.00	70.50	81.50	100.0	
		Week 20	Tezepelumab	127	123 (96.9)	68.32 (18.58)	18.0	55.00	68.00	83.00	100.0	
			Placebo	129	120 (93.0)	68.28 (17.85)	19.0	57.50	70.00	82.00	100.0	
		Week 28	Tezepelumab	127	124 (97.6)	69.82 (18.10)	8.0	56.00	70.50	83.00	100.0	
			Placebo	129	121 (93.8)	69.17 (17.78)	12.0	56.00	70.00	82.00	100.0	
		Week 40	Tezepelumab	127	125 (98.4)	71.60 (18.10)	18.0	58.00	75.00	84.00	100.0	
			Placebo	129	122 (94.6)	69.32 (17.60)	20.0	55.00	71.00	82.00	100.0	
		Week 52	Tezepelumab	127	125 (98.4)	71.31 (19.25)	19.0	55.00	74.00	86.00	100.0	
			Placebo	129	123 (95.3)	70.19 (18.10)	16.0	58.00	73.00	85.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	127	112 (88.2)	7.29 (17.59)	-51.0	-3.00	7.50	19.00	50.0	0.12 [-0.14, 0.38]
			Placebo	129	112 (86.8)	5.31 (14.94)	-40.0	-5.00	4.50	12.00	63.0	
		Week 8	Tezepelumab	127	112 (88.2)	7.16 (18.94)	-59.0	-3.00	7.00	17.00	69.0	0.01 [-0.25, 0.28]
			Placebo	129	112 (86.8)	6.91 (17.54)	-36.0	-4.00	5.00	16.50	62.0	
		Week 12	Tezepelumab	127	112 (88.2)	9.08 (19.17)	-51.0	-2.00	7.00	20.00	65.0	0.04 [-0.22, 0.30]
			Placebo	129	112 (86.8)	8.31 (18.61)	-39.0	-3.50	5.50	18.00	69.0	
		Week 20	Tezepelumab	127	113 (89.0)	8.92 (19.82)	-51.0	-5.00	10.00	24.00	55.0	0.01 [-0.25, 0.27]
			Placebo	129	112 (86.8)	8.71 (16.10)	-32.0	-2.00	7.00	17.00	57.0	
		Week 28	Tezepelumab	127	113 (89.0)	10.42 (18.98)	-43.0	-3.00	9.00	25.00	60.0	0.07 [-0.19, 0.33]
			Placebo	129	112 (86.8)	9.12 (17.17)	-30.0	-3.00	6.00	21.00	65.0	
		Week 40	Tezepelumab	127	113 (89.0)	11.93 (19.31)	-43.0	-1.00	12.00	25.00	58.0	0.12 [-0.14, 0.38]
			Placebo	129	112 (86.8)	9.76 (17.27)	-26.0	-2.50	7.00	20.00	59.0	
		Week 52	Tezepelumab	127	113 (89.0)	11.66 (19.29)	-43.0	-3.00	13.00	25.00	58.0	0.06 [-0.21, 0.32]
			Placebo	129	112 (86.8)	10.64 (16.88)	-26.0	-3.00	8.00	20.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	61	54 (88.5)	58.91 (15.30)	20.0	49.00	60.00	72.00	94.0	
			Placebo	60	53 (88.3)	61.08 (14.29)	29.0	50.00	60.00	70.00	96.0	
		Week 4	Tezepelumab	61	57 (93.4)	67.33 (17.47)	14.0	57.00	68.00	79.00	99.0	
			Placebo	60	55 (91.7)	68.65 (16.42)	17.0	59.00	70.00	80.00	99.0	
		Week 8	Tezepelumab	61	57 (93.4)	68.21 (16.06)	32.0	58.00	65.00	80.00	97.0	
			Placebo	60	55 (91.7)	69.05 (18.09)	19.0	56.00	70.00	82.00	100.0	
		Week 12	Tezepelumab	61	57 (93.4)	68.77 (16.77)	35.0	56.00	68.00	82.00	100.0	
			Placebo	60	55 (91.7)	69.25 (17.43)	30.0	60.00	70.00	86.00	97.0	
		Week 20	Tezepelumab	61	58 (95.1)	68.33 (16.82)	34.0	55.00	67.00	83.00	98.0	
			Placebo	60	55 (91.7)	70.15 (17.31)	27.0	60.00	71.00	85.00	99.0	
		Week 28	Tezepelumab	61	59 (96.7)	69.25 (16.39)	29.0	57.00	70.00	83.00	100.0	
			Placebo	60	55 (91.7)	70.18 (17.15)	27.0	57.00	69.00	86.00	95.0	
		Week 40	Tezepelumab	61	60 (98.4)	71.57 (16.86)	35.0	58.50	73.50	84.50	100.0	
			Placebo	60	55 (91.7)	71.25 (17.87)	27.0	57.00	74.00	86.00	97.0	
		Week 52	Tezepelumab	61	60 (98.4)	70.47 (16.65)	35.0	57.50	70.50	85.50	100.0	
			Placebo	60	55 (91.7)	71.71 (17.16)	27.0	59.00	74.00	87.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	61	53 (86.9)	9.81 (16.85)	-30.0	-2.00	8.00	19.00	50.0	0.13 [-0.25, 0.51]
			Placebo	60	53 (88.3)	7.89 (13.24)	-20.0	0.00	7.00	14.00	44.0	
		Week 8	Tezepelumab	61	53 (86.9)	10.00 (20.20)	-46.0	-2.00	8.00	21.00	69.0	0.11 [-0.27, 0.49]
			Placebo	60	53 (88.3)	8.09 (14.21)	-22.0	-1.00	8.00	17.00	43.0	
		Week 12	Tezepelumab	61	53 (86.9)	10.75 (19.97)	-34.0	-1.00	10.00	22.00	65.0	0.14 [-0.24, 0.52]
			Placebo	60	53 (88.3)	8.15 (16.21)	-39.0	0.00	8.00	18.00	43.0	
		Week 20	Tezepelumab	61	53 (86.9)	10.38 (21.07)	-44.0	-3.00	8.00	24.00	55.0	0.05 [-0.33, 0.43]
			Placebo	60	53 (88.3)	9.43 (14.84)	-32.0	-1.00	8.00	19.00	43.0	
		Week 28	Tezepelumab	61	53 (86.9)	11.43 (20.12)	-33.0	-3.00	8.00	25.00	60.0	0.11 [-0.27, 0.49]
			Placebo	60	53 (88.3)	9.47 (15.40)	-30.0	-2.00	7.00	21.00	41.0	
		Week 40	Tezepelumab	61	53 (86.9)	13.06 (19.23)	-33.0	-1.00	15.00	26.00	58.0	0.14 [-0.24, 0.52]
			Placebo	60	53 (88.3)	10.64 (15.70)	-26.0	0.00	9.00	20.00	45.0	
		Week 52	Tezepelumab	61	53 (86.9)	11.72 (20.04)	-27.0	-3.00	13.00	25.00	58.0	0.03 [-0.35, 0.42]
			Placebo	60	53 (88.3)	11.11 (14.70)	-13.0	0.00	10.00	18.00	43.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	76	69 (90.8)	61.94 (17.46)	29.0	50.00	60.00	73.00	100.0	
			Placebo	78	67 (85.9)	60.01 (15.55)	23.0	49.00	60.00	73.00	97.0	
		Week 4	Tezepelumab	76	72 (94.7)	67.39 (19.04)	27.0	50.00	66.00	85.00	100.0	
			Placebo	78	70 (89.7)	63.06 (17.27)	23.0	50.00	63.00	74.00	93.0	
		Week 8	Tezepelumab	76	72 (94.7)	67.85 (21.11)	20.0	51.00	69.00	86.00	100.0	
			Placebo	78	72 (92.3)	65.89 (17.04)	14.0	52.00	64.50	78.00	100.0	
		Week 12	Tezepelumab	76	72 (94.7)	70.19 (20.05)	26.0	52.50	72.00	88.00	100.0	
			Placebo	78	73 (93.6)	68.14 (18.57)	19.0	57.00	71.00	82.00	100.0	
		Week 20	Tezepelumab	76	73 (96.1)	69.88 (19.69)	18.0	56.00	75.00	83.00	100.0	
			Placebo	78	73 (93.6)	67.58 (18.46)	19.0	57.00	70.00	81.00	100.0	
		Week 28	Tezepelumab	76	73 (96.1)	71.64 (19.04)	8.0	59.00	74.00	86.00	100.0	
			Placebo	78	74 (94.9)	68.43 (18.58)	12.0	55.00	71.00	82.00	100.0	
		Week 40	Tezepelumab	76	73 (96.1)	72.40 (18.57)	18.0	65.00	75.00	84.00	100.0	
			Placebo	78	75 (96.2)	67.72 (17.58)	20.0	53.00	71.00	81.00	100.0	
		Week 52	Tezepelumab	76	74 (97.4)	72.96 (20.50)	19.0	61.00	76.50	88.00	100.0	
			Placebo	78	76 (97.4)	69.38 (19.02)	16.0	53.50	72.00	83.50	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	76	67 (88.2)	5.69 (17.61)	-51.0	-3.00	8.00	16.00	41.0	0.12 [-0.22, 0.46]
			Placebo	78	67 (85.9)	3.60 (16.58)	-40.0	-6.00	2.00	10.00	63.0	
		Week 8	Tezepelumab	76	67 (88.2)	6.04 (17.49)	-59.0	-3.00	9.00	15.00	40.0	-0.02 [-0.36, 0.32]
			Placebo	78	67 (85.9)	6.40 (19.97)	-36.0	-4.00	4.00	12.00	62.0	
		Week 12	Tezepelumab	76	67 (88.2)	8.49 (18.22)	-51.0	-2.00	7.00	20.00	58.0	-0.01 [-0.35, 0.33]
			Placebo	78	67 (85.9)	8.66 (20.63)	-34.0	-4.00	4.00	17.00	69.0	
		Week 20	Tezepelumab	76	68 (89.5)	8.50 (18.53)	-51.0	-5.50	11.50	24.50	48.0	0.01 [-0.33, 0.35]
			Placebo	78	67 (85.9)	8.31 (17.55)	-25.0	-3.00	6.00	15.00	57.0	
		Week 28	Tezepelumab	76	68 (89.5)	10.13 (17.89)	-43.0	-1.00	10.00	24.00	44.0	0.10 [-0.24, 0.44]
			Placebo	78	67 (85.9)	8.31 (18.12)	-20.0	-5.00	5.00	15.00	65.0	
		Week 40	Tezepelumab	76	68 (89.5)	10.94 (18.83)	-43.0	-2.50	11.00	25.00	56.0	0.15 [-0.19, 0.48]
			Placebo	78	67 (85.9)	8.27 (17.96)	-25.0	-4.00	5.00	18.00	59.0	
		Week 52	Tezepelumab	76	68 (89.5)	11.62 (18.55)	-43.0	-1.50	13.50	25.00	50.0	0.08 [-0.25, 0.42]
			Placebo	78	67 (85.9)	10.01 (19.30)	-26.0	-4.00	6.00	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	75	65 (86.7)	59.28 (14.49)	29.0	49.00	58.00	72.00	90.0	
			Placebo	72	61 (84.7)	59.95 (15.36)	23.0	50.00	58.00	70.00	97.0	
		Week 4	Tezepelumab	75	68 (90.7)	65.84 (17.32)	21.0	52.00	66.50	79.00	100.0	
			Placebo	72	64 (88.9)	66.52 (15.93)	25.0	56.00	67.00	77.50	99.0	
		Week 8	Tezepelumab	75	68 (90.7)	65.06 (17.67)	20.0	54.00	64.00	76.50	100.0	
			Placebo	72	64 (88.9)	67.42 (17.52)	14.0	53.50	69.50	79.50	100.0	
		Week 12	Tezepelumab	75	68 (90.7)	67.60 (18.16)	26.0	51.50	68.50	82.00	100.0	
			Placebo	72	65 (90.3)	67.42 (18.78)	19.0	52.00	70.00	81.00	97.0	
		Week 20	Tezepelumab	75	69 (92.0)	67.42 (18.38)	18.0	55.00	68.00	79.00	100.0	
			Placebo	72	65 (90.3)	67.98 (18.11)	19.0	60.00	70.00	80.00	99.0	
		Week 28	Tezepelumab	75	70 (93.3)	68.37 (18.50)	8.0	53.00	70.00	82.00	100.0	
			Placebo	72	66 (91.7)	68.47 (18.93)	12.0	55.00	70.00	84.00	95.0	
		Week 40	Tezepelumab	75	71 (94.7)	69.21 (18.75)	18.0	52.00	72.00	84.00	100.0	
			Placebo	72	67 (93.1)	70.13 (17.48)	20.0	55.00	71.00	85.00	97.0	
		Week 52	Tezepelumab	75	72 (96.0)	68.49 (18.98)	19.0	53.00	72.00	83.50	100.0	
			Placebo	72	68 (94.4)	70.54 (19.24)	16.0	59.50	73.00	86.50	98.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	75	63 (84.0)	7.57 (17.68)	-40.0	-5.00	8.00	19.00	50.0	0.06 [-0.29, 0.41]
			Placebo	72	61 (84.7)	6.67 (13.34)	-20.0	-5.00	6.00	11.00	44.0	
		Week 8	Tezepelumab	75	63 (84.0)	6.02 (19.67)	-59.0	-6.00	6.00	20.00	47.0	-0.08 [-0.44, 0.27]
			Placebo	72	61 (84.7)	7.49 (15.14)	-36.0	-1.00	6.00	16.00	43.0	
		Week 12	Tezepelumab	75	63 (84.0)	8.78 (19.10)	-34.0	-3.00	7.00	22.00	58.0	0.05 [-0.30, 0.40]
			Placebo	72	61 (84.7)	7.82 (17.73)	-39.0	-4.00	7.00	19.00	50.0	
		Week 20	Tezepelumab	75	63 (84.0)	8.76 (20.51)	-44.0	-5.00	12.00	25.00	49.0	0.01 [-0.34, 0.37]
			Placebo	72	61 (84.7)	8.51 (16.07)	-25.0	-4.00	7.00	14.00	49.0	
		Week 28	Tezepelumab	75	63 (84.0)	9.87 (20.21)	-43.0	-3.00	10.00	25.00	51.0	0.09 [-0.26, 0.44]
			Placebo	72	61 (84.7)	8.13 (17.88)	-30.0	-4.00	6.00	22.00	54.0	
		Week 40	Tezepelumab	75	63 (84.0)	10.00 (19.96)	-43.0	-3.00	13.00	25.00	56.0	-0.03 [-0.39, 0.32]
			Placebo	72	61 (84.7)	10.62 (16.81)	-16.0	-3.00	6.00	22.00	56.0	
		Week 52	Tezepelumab	75	63 (84.0)	9.24 (19.98)	-43.0	-7.00	13.00	25.00	50.0	-0.08 [-0.43, 0.27]
			Placebo	72	61 (84.7)	10.77 (17.16)	-26.0	-3.00	8.00	20.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	60	56 (93.3)	62.36 (18.81)	20.0	50.50	63.50	74.50	100.0	
			Placebo	65	58 (89.2)	61.05 (14.76)	27.0	50.00	62.50	72.00	88.0	
		Week 4	Tezepelumab	60	59 (98.3)	69.15 (19.64)	14.0	53.00	70.00	89.00	100.0	
			Placebo	65	60 (92.3)	64.50 (18.41)	17.0	50.50	69.00	80.00	95.0	
		Week 8	Tezepelumab	60	59 (98.3)	71.54 (20.25)	25.0	54.00	74.00	89.00	100.0	
			Placebo	65	62 (95.4)	67.32 (17.67)	19.0	53.00	67.00	82.00	100.0	
		Week 12	Tezepelumab	60	59 (98.3)	72.19 (18.98)	33.0	55.00	75.00	89.00	100.0	
			Placebo	65	62 (95.4)	69.73 (17.38)	20.0	59.00	71.50	82.00	100.0	
		Week 20	Tezepelumab	60	60 (100.0)	71.27 (18.69)	34.0	55.50	75.00	85.00	100.0	
			Placebo	65	62 (95.4)	70.06 (17.25)	20.0	58.00	70.50	83.00	100.0	
		Week 28	Tezepelumab	60	60 (100.0)	73.35 (17.10)	32.0	59.50	74.00	89.00	100.0	
			Placebo	65	62 (95.4)	70.26 (16.88)	27.0	56.00	72.00	82.00	100.0	
		Week 40	Tezepelumab	60	60 (100.0)	75.27 (16.37)	32.0	65.00	78.50	89.00	100.0	
			Placebo	65	62 (95.4)	68.11 (18.18)	20.0	53.00	70.50	82.00	100.0	
		Week 52	Tezepelumab	60	60 (100.0)	75.58 (18.29)	25.0	64.00	80.50	91.00	100.0	
			Placebo	65	62 (95.4)	70.06 (17.35)	27.0	54.00	73.50	83.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	60	55 (91.7)	7.29 (17.34)	-51.0	-2.00	8.00	18.00	41.0	0.17 [-0.20, 0.54]
			Placebo	65	58 (89.2)	4.29 (17.24)	-40.0	-6.00	4.50	12.00	63.0	
		Week 8	Tezepelumab	60	55 (91.7)	9.78 (17.84)	-51.0	0.00	9.00	17.00	69.0	0.14 [-0.22, 0.51]
			Placebo	65	58 (89.2)	7.03 (20.07)	-31.0	-5.00	5.00	16.00	62.0	
		Week 12	Tezepelumab	60	55 (91.7)	10.51 (18.66)	-51.0	1.00	8.00	20.00	65.0	0.08 [-0.29, 0.45]
			Placebo	65	58 (89.2)	8.91 (19.99)	-34.0	-1.00	5.00	16.00	69.0	
		Week 20	Tezepelumab	60	56 (93.3)	9.82 (19.08)	-51.0	-3.00	10.50	22.00	55.0	-0.00 [-0.37, 0.37]
			Placebo	65	58 (89.2)	9.83 (16.00)	-25.0	-1.00	7.50	18.00	57.0	
		Week 28	Tezepelumab	60	56 (93.3)	11.68 (17.36)	-16.0	-0.50	9.00	23.50	60.0	0.11 [-0.26, 0.47]
			Placebo	65	58 (89.2)	9.90 (15.87)	-15.0	0.00	6.50	18.00	65.0	
		Week 40	Tezepelumab	60	56 (93.3)	13.70 (17.99)	-16.0	1.00	11.50	26.00	58.0	0.33 [-0.04, 0.70]
			Placebo	65	58 (89.2)	7.83 (17.29)	-26.0	-3.00	7.00	17.00	59.0	
		Week 52	Tezepelumab	60	56 (93.3)	13.89 (18.17)	-16.0	0.00	12.50	23.50	58.0	0.21 [-0.16, 0.58]
			Placebo	65	58 (89.2)	10.12 (17.85)	-15.0	-2.00	6.00	18.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	65	56 (86.2)	59.64 (14.06)	29.0	50.00	59.50	72.00	90.0	
			Placebo	62	53 (85.5)	59.36 (15.56)	23.0	50.00	57.00	70.00	97.0	
		Week 4	Tezepelumab	65	60 (92.3)	65.32 (16.80)	21.0	50.50	66.00	78.50	100.0	
			Placebo	62	56 (90.3)	65.57 (16.05)	25.0	54.50	66.00	76.00	99.0	
		Week 8	Tezepelumab	65	60 (92.3)	65.12 (17.31)	31.0	53.50	63.50	77.00	100.0	
			Placebo	62	56 (90.3)	66.68 (17.63)	14.0	53.50	68.00	78.50	100.0	
		Week 12	Tezepelumab	65	60 (92.3)	66.32 (17.15)	35.0	50.50	68.00	80.50	100.0	
			Placebo	62	57 (91.9)	66.81 (19.05)	19.0	51.00	70.00	81.00	97.0	
		Week 20	Tezepelumab	65	61 (93.8)	66.54 (17.22)	25.0	54.00	66.00	77.00	100.0	
			Placebo	62	57 (91.9)	67.65 (18.42)	19.0	60.00	70.00	80.00	99.0	
		Week 28	Tezepelumab	65	62 (95.4)	67.79 (17.10)	29.0	53.00	68.50	82.00	100.0	
			Placebo	62	58 (93.5)	68.07 (19.35)	12.0	55.00	69.50	84.00	95.0	
		Week 40	Tezepelumab	65	63 (96.9)	68.41 (17.96)	32.0	52.00	70.00	82.00	100.0	
			Placebo	62	58 (93.5)	69.79 (18.28)	20.0	54.00	71.00	85.00	97.0	
		Week 52	Tezepelumab	65	63 (96.9)	67.51 (18.30)	27.0	52.00	70.00	83.00	100.0	
			Placebo	62	59 (95.2)	70.31 (19.69)	16.0	57.00	73.00	87.00	98.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	65	55 (84.6)	6.35 (17.82)	-40.0	-5.00	6.00	18.00	50.0	0.00 [-0.37, 0.38]
			Placebo	62	53 (85.5)	6.28 (13.06)	-20.0	-5.00	5.00	11.00	41.0	
		Week 8	Tezepelumab	65	55 (84.6)	5.31 (19.76)	-59.0	-6.00	4.00	16.00	47.0	-0.11 [-0.49, 0.26]
			Placebo	62	53 (85.5)	7.30 (14.93)	-36.0	0.00	5.00	14.00	40.0	
		Week 12	Tezepelumab	65	55 (84.6)	6.64 (17.74)	-34.0	-4.00	5.00	19.00	51.0	-0.07 [-0.44, 0.31]
			Placebo	62	53 (85.5)	7.81 (18.13)	-39.0	-4.00	6.00	22.00	50.0	
		Week 20	Tezepelumab	65	55 (84.6)	7.07 (19.66)	-44.0	-6.00	2.00	22.00	49.0	-0.10 [-0.47, 0.28]
			Placebo	62	53 (85.5)	8.81 (16.14)	-25.0	-4.00	7.00	17.00	49.0	
		Week 28	Tezepelumab	65	55 (84.6)	8.53 (19.16)	-43.0	-7.00	8.00	23.00	51.0	0.02 [-0.36, 0.39]
			Placebo	62	53 (85.5)	8.23 (17.26)	-30.0	-4.00	6.00	21.00	54.0	
		Week 40	Tezepelumab	65	55 (84.6)	8.29 (18.70)	-43.0	-3.00	8.00	22.00	47.0	-0.13 [-0.51, 0.25]
			Placebo	62	53 (85.5)	10.58 (16.96)	-16.0	-3.00	6.00	22.00	56.0	
		Week 52	Tezepelumab	65	55 (84.6)	7.51 (19.11)	-43.0	-8.00	10.00	25.00	45.0	-0.16 [-0.54, 0.21]
			Placebo	62	53 (85.5)	10.49 (17.12)	-26.0	-3.00	8.00	18.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	70	65 (92.9)	61.62 (18.62)	20.0	49.00	63.00	74.00	100.0	
			Placebo	75	66 (88.0)	61.39 (14.62)	27.0	50.00	64.00	72.00	88.0	
		Week 4	Tezepelumab	70	67 (95.7)	69.22 (19.73)	14.0	53.00	70.00	89.00	100.0	
			Placebo	75	68 (90.7)	65.51 (18.09)	17.0	51.00	69.00	80.00	95.0	
		Week 8	Tezepelumab	70	67 (95.7)	70.72 (20.37)	20.0	55.00	73.00	89.00	100.0	
			Placebo	75	70 (93.3)	67.93 (17.55)	19.0	53.00	69.00	82.00	100.0	
		Week 12	Tezepelumab	70	67 (95.7)	72.79 (19.45)	26.0	56.00	75.00	90.00	100.0	
			Placebo	75	70 (93.3)	69.96 (17.25)	20.0	60.00	72.50	82.00	100.0	
		Week 20	Tezepelumab	70	68 (97.1)	71.60 (19.49)	18.0	56.50	75.00	86.00	100.0	
			Placebo	75	70 (93.3)	70.10 (17.06)	20.0	58.00	70.50	83.00	100.0	
		Week 28	Tezepelumab	70	68 (97.1)	73.29 (18.47)	8.0	60.00	75.00	89.00	100.0	
			Placebo	75	70 (93.3)	70.39 (16.70)	27.0	56.00	72.00	82.00	100.0	
		Week 40	Tezepelumab	70	68 (97.1)	75.29 (17.30)	18.0	65.00	79.50	89.00	100.0	
			Placebo	75	71 (94.7)	68.65 (17.47)	20.0	53.00	71.00	82.00	100.0	
		Week 52	Tezepelumab	70	69 (98.6)	75.55 (18.82)	19.0	66.00	81.00	91.00	100.0	
			Placebo	75	71 (94.7)	70.32 (17.18)	27.0	58.00	73.00	83.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	70	63 (90.0)	8.40 (17.20)	-51.0	-1.00	9.00	19.00	41.0	0.20 [-0.14, 0.55]
			Placebo	75	66 (88.0)	4.89 (17.04)	-40.0	-5.00	5.00	12.00	63.0	
		Week 8	Tezepelumab	70	63 (90.0)	9.92 (17.91)	-51.0	0.00	10.00	19.00	69.0	0.14 [-0.20, 0.49]
			Placebo	75	66 (88.0)	7.24 (19.66)	-31.0	-5.00	5.50	17.00	62.0	
		Week 12	Tezepelumab	70	63 (90.0)	12.16 (19.52)	-51.0	1.00	11.00	23.00	65.0	0.17 [-0.17, 0.52]
			Placebo	75	66 (88.0)	8.79 (19.43)	-34.0	-1.00	5.50	16.00	69.0	
		Week 20	Tezepelumab	70	64 (91.4)	11.14 (19.83)	-51.0	-1.00	12.00	25.00	55.0	0.10 [-0.25, 0.44]
			Placebo	75	66 (88.0)	9.42 (15.97)	-25.0	-2.00	7.00	17.00	57.0	
		Week 28	Tezepelumab	70	64 (91.4)	12.61 (18.55)	-41.0	0.00	10.50	26.50	60.0	0.17 [-0.17, 0.51]
			Placebo	75	66 (88.0)	9.61 (16.68)	-20.0	-2.00	6.50	18.00	65.0	
		Week 40	Tezepelumab	70	64 (91.4)	14.70 (19.03)	-31.0	2.00	12.50	28.00	58.0	0.36 [0.01, 0.71]
			Placebo	75	66 (88.0)	8.20 (17.14)	-26.0	-3.00	7.00	17.00	59.0	
		Week 52	Tezepelumab	70	64 (91.4)	14.80 (18.80)	-30.0	1.00	16.00	25.00	58.0	0.24 [-0.11, 0.58]
			Placebo	75	66 (88.0)	10.42 (17.80)	-15.0	-2.00	6.00	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	50	43 (86.0)	56.65 (14.67)	29.0	49.00	51.00	66.00	90.0	
			Placebo	50	40 (80.0)	57.48 (15.64)	23.0	47.00	53.50	69.50	97.0	
		Week 4	Tezepelumab	50	48 (96.0)	63.77 (18.35)	21.0	50.00	65.50	78.00	99.0	
			Placebo	50	42 (84.0)	63.36 (18.85)	17.0	55.00	66.50	75.00	99.0	
		Week 8	Tezepelumab	50	48 (96.0)	65.35 (18.19)	25.0	51.50	66.00	77.00	96.0	
			Placebo	50	44 (88.0)	64.91 (18.16)	14.0	52.50	67.00	77.00	98.0	
		Week 12	Tezepelumab	50	48 (96.0)	66.42 (18.30)	33.0	50.00	68.50	81.50	100.0	
			Placebo	50	44 (88.0)	64.84 (19.24)	19.0	55.50	69.00	77.50	94.0	
		Week 20	Tezepelumab	50	49 (98.0)	66.08 (17.52)	34.0	52.00	69.00	79.00	98.0	
			Placebo	50	44 (88.0)	66.14 (20.36)	19.0	60.00	70.00	81.50	95.0	
		Week 28	Tezepelumab	50	50 (100.0)	68.40 (17.33)	32.0	53.00	71.50	83.00	100.0	
			Placebo	50	44 (88.0)	67.05 (19.34)	12.0	57.50	70.00	82.00	93.0	
		Week 40	Tezepelumab	50	50 (100.0)	69.12 (17.38)	32.0	53.00	72.50	84.00	96.0	
			Placebo	50	45 (90.0)	65.53 (19.82)	20.0	53.00	70.00	79.00	95.0	
		Week 52	Tezepelumab	50	50 (100.0)	66.32 (18.55)	25.0	52.00	71.00	81.00	95.0	
			Placebo	50	46 (92.0)	66.30 (19.81)	16.0	58.00	70.50	80.00	96.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	50	42 (84.0)	7.05 (22.29)	-51.0	-5.00	6.50	26.00	50.0	0.05 [-0.39, 0.48]
			Placebo	50	40 (80.0)	6.15 (16.57)	-40.0	-4.00	5.50	20.50	41.0	
		Week 8	Tezepelumab	50	42 (84.0)	8.62 (21.32)	-59.0	-2.00	10.00	21.00	47.0	0.04 [-0.40, 0.47]
			Placebo	50	40 (80.0)	7.93 (17.94)	-36.0	-4.00	8.00	18.50	41.0	
		Week 12	Tezepelumab	50	42 (84.0)	9.71 (21.22)	-51.0	-2.00	8.00	29.00	51.0	0.10 [-0.33, 0.54]
			Placebo	50	40 (80.0)	7.58 (19.93)	-39.0	-4.00	6.50	24.00	50.0	
		Week 20	Tezepelumab	50	43 (86.0)	9.84 (20.32)	-51.0	-4.00	12.00	25.00	49.0	0.04 [-0.39, 0.47]
			Placebo	50	40 (80.0)	9.00 (18.30)	-32.0	-1.00	7.50	22.00	49.0	
		Week 28	Tezepelumab	50	43 (86.0)	11.81 (19.83)	-43.0	-1.00	8.00	27.00	51.0	0.12 [-0.31, 0.55]
			Placebo	50	40 (80.0)	9.60 (16.89)	-20.0	-2.50	5.50	22.50	54.0	
		Week 40	Tezepelumab	50	43 (86.0)	12.49 (20.47)	-43.0	-3.00	15.00	28.00	53.0	0.16 [-0.27, 0.59]
			Placebo	50	40 (80.0)	9.25 (19.44)	-26.0	-3.50	6.00	23.50	56.0	
		Week 52	Tezepelumab	50	43 (86.0)	9.77 (20.45)	-43.0	-7.00	10.00	27.00	46.0	-0.00 [-0.43, 0.43]
			Placebo	50	40 (80.0)	9.85 (17.35)	-26.0	-3.00	8.00	20.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	77	72 (93.5)	62.99 (17.70)	20.0	51.00	65.00	74.50	100.0	
			Placebo	80	72 (90.0)	61.75 (14.51)	27.0	50.00	60.00	71.00	96.0	
		Week 4	Tezepelumab	77	72 (93.5)	69.58 (18.26)	14.0	55.00	70.00	85.00	100.0	
			Placebo	80	75 (93.8)	66.27 (15.86)	29.0	51.00	68.00	80.00	98.0	
		Week 8	Tezepelumab	77	72 (93.5)	69.47 (19.67)	20.0	55.00	68.50	85.50	100.0	
			Placebo	80	75 (93.8)	68.92 (16.72)	40.0	54.00	71.00	82.00	100.0	
		Week 12	Tezepelumab	77	72 (93.5)	71.53 (19.00)	26.0	57.00	72.00	88.50	100.0	
			Placebo	80	76 (95.0)	69.91 (17.22)	31.0	59.50	71.50	82.50	100.0	
		Week 20	Tezepelumab	77	72 (93.5)	71.56 (19.11)	18.0	60.50	72.50	85.00	100.0	
			Placebo	80	76 (95.0)	69.16 (16.20)	34.0	55.50	70.00	82.50	100.0	
		Week 28	Tezepelumab	77	72 (93.5)	72.32 (18.54)	8.0	60.00	73.00	85.50	100.0	
			Placebo	80	77 (96.3)	69.35 (16.89)	33.0	53.00	70.00	82.00	100.0	
		Week 40	Tezepelumab	77	73 (94.8)	74.36 (17.82)	18.0	65.00	78.00	90.00	100.0	
			Placebo	80	77 (96.3)	70.64 (16.65)	40.0	54.00	73.00	86.00	100.0	
		Week 52	Tezepelumab	77	74 (96.1)	75.70 (18.67)	19.0	64.00	81.00	88.00	100.0	
			Placebo	80	77 (96.3)	71.95 (17.16)	39.0	57.00	75.00	86.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	77	70 (90.9)	7.29 (14.19)	-23.0	-2.00	7.00	16.00	40.0	0.15 [-0.18, 0.48]
			Placebo	80	72 (90.0)	5.10 (14.40)	-25.0	-5.00	5.00	10.50	63.0	
		Week 8	Tezepelumab	77	70 (90.9)	7.17 (17.42)	-46.0	-2.00	7.00	15.00	69.0	-0.02 [-0.35, 0.31]
			Placebo	80	72 (90.0)	7.46 (17.13)	-31.0	-3.00	4.00	13.50	62.0	
		Week 12	Tezepelumab	77	70 (90.9)	9.29 (17.86)	-34.0	-1.00	7.00	19.00	65.0	0.05 [-0.28, 0.38]
			Placebo	80	72 (90.0)	8.40 (18.67)	-29.0	-3.50	5.00	15.00	69.0	
		Week 20	Tezepelumab	77	70 (90.9)	9.24 (19.57)	-44.0	-5.00	10.50	24.00	55.0	0.06 [-0.27, 0.39]
			Placebo	80	72 (90.0)	8.13 (15.41)	-24.0	-3.00	7.00	14.00	57.0	
		Week 28	Tezepelumab	77	70 (90.9)	10.10 (18.60)	-41.0	-3.00	10.00	21.00	60.0	0.13 [-0.20, 0.46]
			Placebo	80	72 (90.0)	7.69 (17.28)	-30.0	-4.00	6.00	16.00	65.0	
		Week 40	Tezepelumab	77	70 (90.9)	11.76 (18.50)	-33.0	-2.00	12.00	25.00	58.0	0.16 [-0.17, 0.49]
			Placebo	80	72 (90.0)	9.04 (16.01)	-17.0	-3.00	7.50	16.00	59.0	
		Week 52	Tezepelumab	77	70 (90.9)	13.11 (18.73)	-30.0	-1.00	14.00	25.00	58.0	0.15 [-0.18, 0.48]
			Placebo	80	72 (90.0)	10.44 (17.92)	-12.0	-3.00	6.50	18.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	58.81 (16.09)	20.0	49.50	57.50	72.00	100.0	
			Placebo	62	53 (85.5)	58.17 (15.64)	23.0	48.00	60.00	70.00	96.0	
		Week 4	Tezepelumab	70	67 (95.7)	67.36 (18.68)	14.0	53.00	70.00	81.00	100.0	
			Placebo	62	54 (87.1)	61.17 (17.46)	17.0	51.00	62.50	72.00	98.0	
		Week 8	Tezepelumab	70	67 (95.7)	67.42 (18.87)	20.0	55.00	69.00	85.00	100.0	
			Placebo	62	56 (90.3)	64.18 (18.90)	14.0	51.50	65.00	78.50	100.0	
		Week 12	Tezepelumab	70	67 (95.7)	69.88 (18.60)	26.0	55.00	70.00	85.00	100.0	
			Placebo	62	56 (90.3)	64.95 (20.23)	19.0	53.00	65.50	79.00	100.0	
		Week 20	Tezepelumab	70	68 (97.1)	68.50 (18.45)	18.0	55.00	70.00	84.00	100.0	
			Placebo	62	56 (90.3)	66.09 (20.83)	19.0	57.00	68.00	81.50	99.0	
		Week 28	Tezepelumab	70	69 (98.6)	69.87 (18.87)	8.0	59.00	75.00	83.00	100.0	
			Placebo	62	56 (90.3)	66.46 (20.16)	12.0	55.00	67.50	83.00	98.0	
		Week 40	Tezepelumab	70	69 (98.6)	71.30 (18.34)	18.0	56.00	75.00	84.00	100.0	
			Placebo	62	57 (91.9)	65.58 (19.95)	20.0	50.00	69.00	79.00	97.0	
		Week 52	Tezepelumab	70	69 (98.6)	70.84 (19.46)	19.0	54.00	75.00	85.00	100.0	
			Placebo	62	57 (91.9)	66.37 (20.09)	16.0	51.00	70.00	83.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	70	63 (90.0)	8.41 (17.65)	-40.0	-4.00	10.00	19.00	47.0	0.34 [-0.03, 0.71]
			Placebo	62	53 (85.5)	2.83 (14.97)	-40.0	-5.00	3.00	9.00	44.0	
		Week 8	Tezepelumab	70	63 (90.0)	8.40 (20.41)	-59.0	-4.00	7.00	20.00	69.0	0.11 [-0.25, 0.48]
			Placebo	62	53 (85.5)	6.09 (19.75)	-36.0	-4.00	6.00	14.00	62.0	
		Week 12	Tezepelumab	70	63 (90.0)	10.92 (19.72)	-31.0	-2.00	10.00	23.00	65.0	0.20 [-0.16, 0.57]
			Placebo	62	53 (85.5)	6.79 (21.09)	-39.0	-4.00	6.00	17.00	68.0	
		Week 20	Tezepelumab	70	63 (90.0)	9.70 (19.34)	-32.0	-5.00	10.00	25.00	55.0	0.09 [-0.28, 0.45]
			Placebo	62	53 (85.5)	8.06 (18.60)	-32.0	-3.00	7.00	18.00	57.0	
		Week 28	Tezepelumab	70	63 (90.0)	10.95 (20.10)	-43.0	-3.00	10.00	26.00	60.0	0.13 [-0.24, 0.50]
			Placebo	62	53 (85.5)	8.42 (19.03)	-20.0	-4.00	4.00	21.00	65.0	
		Week 40	Tezepelumab	70	63 (90.0)	12.11 (20.09)	-43.0	-3.00	15.00	26.00	58.0	0.20 [-0.16, 0.57]
			Placebo	62	53 (85.5)	8.09 (19.39)	-26.0	-4.00	4.00	18.00	56.0	
		Week 52	Tezepelumab	70	63 (90.0)	12.11 (20.49)	-43.0	-4.00	16.00	27.00	58.0	0.14 [-0.22, 0.51]
			Placebo	62	53 (85.5)	9.34 (18.27)	-26.0	-4.00	6.00	17.00	56.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	65	58 (89.2)	62.09 (16.70)	33.0	49.00	62.50	75.00	100.0	
			Placebo	75	66 (88.0)	62.38 (14.34)	27.0	50.00	62.00	72.00	97.0	
		Week 4	Tezepelumab	65	60 (92.3)	68.15 (17.77)	30.0	53.50	66.00	83.50	100.0	
			Placebo	75	70 (93.3)	68.40 (15.80)	29.0	54.00	71.00	80.00	95.0	
		Week 8	Tezepelumab	65	60 (92.3)	69.45 (18.99)	32.0	54.50	68.00	85.00	100.0	
			Placebo	75	70 (93.3)	69.30 (15.81)	41.0	54.00	72.00	81.00	100.0	
		Week 12	Tezepelumab	65	60 (92.3)	70.05 (18.50)	35.0	55.00	70.00	84.00	100.0	
			Placebo	75	71 (94.7)	71.24 (15.64)	36.0	60.00	74.00	82.00	100.0	
		Week 20	Tezepelumab	65	61 (93.8)	70.82 (18.13)	25.0	57.00	73.00	82.00	100.0	
			Placebo	75	71 (94.7)	70.51 (15.22)	34.0	60.00	71.00	83.00	100.0	
		Week 28	Tezepelumab	65	61 (93.8)	71.25 (16.86)	42.0	59.00	71.00	82.00	100.0	
			Placebo	75	72 (96.0)	70.99 (15.79)	33.0	56.00	74.00	82.00	100.0	
		Week 40	Tezepelumab	65	62 (95.4)	72.84 (17.35)	32.0	61.00	73.50	88.00	100.0	
			Placebo	75	72 (96.0)	71.75 (15.20)	40.0	59.50	75.00	83.50	100.0	
		Week 52	Tezepelumab	65	63 (96.9)	72.65 (18.33)	27.0	60.00	73.00	87.00	100.0	
			Placebo	75	73 (97.3)	73.12 (16.02)	39.0	61.00	75.00	85.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	65	56 (86.2)	7.54 (15.35)	-27.0	-2.00	6.00	15.50	50.0	0.03 [-0.33, 0.39]
			Placebo	75	66 (88.0)	7.09 (14.85)	-20.0	-4.00	6.50	14.00	63.0	
		Week 8	Tezepelumab	65	56 (86.2)	8.16 (15.11)	-46.0	-0.50	9.00	15.00	47.0	0.04 [-0.31, 0.40]
			Placebo	75	66 (88.0)	7.52 (15.47)	-31.0	-3.00	5.00	16.00	55.0	
		Week 12	Tezepelumab	65	56 (86.2)	8.96 (16.46)	-34.0	-0.50	6.50	18.00	58.0	-0.03 [-0.38, 0.33]
			Placebo	75	66 (88.0)	9.42 (16.62)	-16.0	-1.00	5.50	19.00	69.0	
		Week 20	Tezepelumab	65	57 (87.7)	9.96 (18.58)	-44.0	-3.00	12.00	24.00	50.0	0.05 [-0.31, 0.40]
			Placebo	75	66 (88.0)	9.15 (14.41)	-22.0	-2.00	7.50	15.00	51.0	
		Week 28	Tezepelumab	65	57 (87.7)	10.61 (17.61)	-33.0	-1.00	9.00	23.00	51.0	0.11 [-0.24, 0.47]
			Placebo	75	66 (88.0)	8.79 (14.99)	-30.0	-1.00	7.00	18.00	44.0	
		Week 40	Tezepelumab	65	57 (87.7)	11.91 (17.82)	-33.0	2.00	11.00	25.00	56.0	0.12 [-0.23, 0.48]
			Placebo	75	66 (88.0)	9.89 (14.62)	-17.0	-1.00	8.50	19.00	59.0	
		Week 52	Tezepelumab	65	57 (87.7)	11.28 (17.85)	-27.0	-2.00	12.00	21.00	53.0	0.02 [-0.34, 0.37]
			Placebo	75	66 (88.0)	11.02 (16.48)	-12.0	-2.00	7.50	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	62	57 (91.9)	57.77 (15.00)	20.0	50.00	57.00	70.00	90.0	
			Placebo	67	57 (85.1)	59.91 (16.63)	23.0	47.00	60.00	70.00	97.0	
		Week 4	Tezepelumab	62	58 (93.5)	63.60 (15.53)	14.0	50.00	64.00	76.00	93.0	
			Placebo	67	59 (88.1)	66.20 (18.44)	17.0	54.00	70.00	79.00	99.0	
		Week 8	Tezepelumab	62	58 (93.5)	63.52 (17.08)	31.0	49.00	62.00	74.00	95.0	
			Placebo	67	60 (89.6)	67.78 (17.57)	19.0	52.50	69.00	83.00	100.0	
		Week 12	Tezepelumab	62	58 (93.5)	66.00 (16.54)	35.0	50.00	66.50	80.00	95.0	
			Placebo	67	61 (91.0)	66.87 (20.00)	19.0	51.00	72.00	80.00	100.0	
		Week 20	Tezepelumab	62	59 (95.2)	65.17 (16.24)	25.0	54.00	65.00	76.00	98.0	
			Placebo	67	61 (91.0)	66.61 (19.80)	19.0	54.00	70.00	83.00	99.0	
		Week 28	Tezepelumab	62	60 (96.8)	66.38 (15.83)	29.0	53.50	67.50	80.00	96.0	
			Placebo	67	62 (92.5)	67.53 (19.66)	12.0	50.00	70.00	84.00	97.0	
		Week 40	Tezepelumab	62	60 (96.8)	69.27 (17.22)	32.0	54.00	72.50	81.00	99.0	
			Placebo	67	63 (94.0)	69.67 (19.67)	20.0	53.00	73.00	86.00	97.0	
		Week 52	Tezepelumab	62	61 (98.4)	68.36 (18.17)	27.0	52.00	73.00	83.00	98.0	
			Placebo	67	64 (95.5)	71.34 (20.77)	16.0	57.50	74.50	88.00	98.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	62	57 (91.9)	6.16 (15.31)	-40.0	-2.00	6.00	16.00	47.0	-0.03 [-0.40, 0.34]
			Placebo	67	57 (85.1)	6.58 (14.86)	-22.0	-5.00	5.00	12.00	51.0	
		Week 8	Tezepelumab	62	57 (91.9)	6.07 (20.24)	-59.0	-3.00	2.00	15.00	69.0	-0.11 [-0.48, 0.26]
			Placebo	67	57 (85.1)	8.16 (18.09)	-31.0	-4.00	5.00	16.00	62.0	
		Week 12	Tezepelumab	62	57 (91.9)	8.60 (19.53)	-34.0	-2.00	7.00	20.00	65.0	0.06 [-0.31, 0.43]
			Placebo	67	57 (85.1)	7.37 (19.94)	-39.0	-5.00	5.00	18.00	68.0	
		Week 20	Tezepelumab	62	57 (91.9)	7.58 (19.19)	-44.0	-6.00	9.00	20.00	51.0	0.02 [-0.34, 0.39]
			Placebo	67	57 (85.1)	7.16 (17.92)	-32.0	-4.00	6.00	14.00	51.0	
		Week 28	Tezepelumab	62	57 (91.9)	8.86 (19.28)	-43.0	-6.00	8.00	23.00	60.0	0.08 [-0.28, 0.45]
			Placebo	67	57 (85.1)	7.33 (17.75)	-20.0	-5.00	4.00	17.00	65.0	
		Week 40	Tezepelumab	62	57 (91.9)	11.42 (19.83)	-43.0	-1.00	12.00	25.00	58.0	0.05 [-0.32, 0.41]
			Placebo	67	57 (85.1)	10.53 (18.11)	-26.0	-2.00	8.00	21.00	56.0	
		Week 52	Tezepelumab	62	57 (91.9)	10.63 (20.69)	-43.0	-4.00	11.00	25.00	58.0	-0.08 [-0.45, 0.28]
			Placebo	67	57 (85.1)	12.33 (19.47)	-26.0	-3.00	10.00	23.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	74	65 (87.8)	63.11 (17.65)	29.0	49.00	63.00	74.00	100.0	
			Placebo	71	63 (88.7)	61.00 (13.38)	27.0	50.00	60.00	72.00	96.0	
		Week 4	Tezepelumab	74	70 (94.6)	70.46 (19.99)	21.0	56.00	70.00	90.00	100.0	
			Placebo	71	66 (93.0)	64.91 (15.85)	29.0	51.00	65.00	77.00	93.0	
		Week 8	Tezepelumab	74	70 (94.6)	71.93 (19.79)	20.0	57.00	73.50	89.00	100.0	
			Placebo	71	67 (94.4)	66.79 (17.56)	14.0	54.00	65.00	80.00	100.0	
		Week 12	Tezepelumab	74	70 (94.6)	72.69 (19.87)	26.0	55.00	75.00	89.00	100.0	
			Placebo	71	67 (94.4)	70.21 (16.00)	31.0	60.00	71.00	82.00	100.0	
		Week 20	Tezepelumab	74	71 (95.9)	72.68 (19.60)	18.0	56.00	76.00	89.00	100.0	
			Placebo	71	67 (94.4)	70.57 (16.00)	30.0	60.00	70.00	82.00	100.0	
		Week 28	Tezepelumab	74	71 (95.9)	74.15 (18.94)	8.0	60.00	77.00	90.00	100.0	
			Placebo	71	67 (94.4)	70.70 (16.18)	30.0	58.00	71.00	82.00	100.0	
		Week 40	Tezepelumab	74	72 (97.3)	74.36 (18.10)	18.0	65.00	80.00	88.00	100.0	
			Placebo	71	67 (94.4)	68.79 (15.81)	34.0	55.00	70.00	80.00	100.0	
		Week 52	Tezepelumab	74	72 (97.3)	74.76 (19.17)	19.0	61.50	79.50	91.50	100.0	
			Placebo	71	67 (94.4)	69.42 (15.52)	38.0	58.00	70.00	82.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	74	62 (83.8)	8.73 (19.17)	-51.0	-3.00	10.00	24.00	50.0	0.24 [-0.11, 0.59]
			Placebo	71	63 (88.7)	4.51 (15.71)	-40.0	-5.00	5.00	11.00	63.0	
		Week 8	Tezepelumab	74	62 (83.8)	9.60 (17.35)	-51.0	0.00	10.50	21.00	56.0	0.19 [-0.16, 0.55]
			Placebo	71	63 (88.7)	6.24 (17.27)	-36.0	-3.00	5.00	16.00	57.0	
		Week 12	Tezepelumab	74	62 (83.8)	10.50 (18.64)	-51.0	-1.00	10.50	22.00	58.0	0.06 [-0.29, 0.41]
			Placebo	71	63 (88.7)	9.40 (17.67)	-34.0	-1.00	8.00	17.00	69.0	
		Week 20	Tezepelumab	74	63 (85.1)	11.06 (20.12)	-51.0	-2.00	12.00	25.00	55.0	0.04 [-0.31, 0.39]
			Placebo	71	63 (88.7)	10.30 (14.77)	-24.0	0.00	9.00	19.00	57.0	
		Week 28	Tezepelumab	74	63 (85.1)	12.41 (18.55)	-41.0	-1.00	10.00	28.00	55.0	0.13 [-0.22, 0.48]
			Placebo	71	63 (88.7)	10.17 (16.13)	-30.0	0.00	8.00	21.00	58.0	
		Week 40	Tezepelumab	74	63 (85.1)	12.32 (18.43)	-31.0	-2.00	13.00	26.00	53.0	0.24 [-0.11, 0.59]
			Placebo	71	63 (88.7)	8.22 (15.93)	-23.0	-3.00	5.00	17.00	59.0	
		Week 52	Tezepelumab	74	63 (85.1)	12.56 (17.90)	-30.0	-1.00	16.00	24.00	56.0	0.22 [-0.13, 0.57]
			Placebo	71	63 (88.7)	8.84 (15.17)	-13.0	-3.00	6.00	17.00	53.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	114	101 (88.6)	60.30 (17.05)	20.0	49.00	60.00	72.00	100.0	
			Placebo	126	111 (88.1)	60.55 (15.00)	23.0	50.00	60.00	70.00	97.0	
		Week 4	Tezepelumab	114	108 (94.7)	66.78 (18.77)	14.0	50.50	67.00	80.00	100.0	
			Placebo	126	115 (91.3)	66.13 (17.47)	17.0	54.00	69.00	79.00	99.0	
		Week 8	Tezepelumab	114	108 (94.7)	67.77 (19.22)	20.0	53.50	68.50	85.00	100.0	
			Placebo	126	117 (92.9)	67.41 (17.69)	14.0	53.00	69.00	80.00	100.0	
		Week 12	Tezepelumab	114	108 (94.7)	69.48 (18.42)	26.0	54.00	70.00	83.00	100.0	
			Placebo	126	118 (93.7)	69.00 (17.87)	19.0	59.00	71.50	82.00	100.0	
		Week 20	Tezepelumab	114	109 (95.6)	69.15 (18.25)	18.0	56.00	70.00	83.00	100.0	
			Placebo	126	118 (93.7)	69.01 (18.45)	19.0	58.00	70.00	84.00	100.0	
		Week 28	Tezepelumab	114	110 (96.5)	70.50 (17.75)	8.0	59.00	72.00	83.00	100.0	
			Placebo	126	119 (94.4)	69.30 (18.02)	12.0	55.00	70.00	84.00	100.0	
		Week 40	Tezepelumab	114	111 (97.4)	71.79 (17.53)	18.0	59.00	75.00	84.00	100.0	
			Placebo	126	120 (95.2)	69.64 (17.74)	20.0	54.50	72.50	85.00	100.0	
		Week 52	Tezepelumab	114	112 (98.2)	71.74 (19.02)	19.0	57.50	74.00	86.00	100.0	
			Placebo	126	121 (96.0)	70.56 (18.50)	16.0	58.00	74.00	85.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	114	100 (87.7)	7.06 (17.94)	-51.0	-3.00	8.00	18.00	50.0	0.07 [-0.20, 0.34]
			Placebo	126	111 (88.1)	5.92 (15.56)	-40.0	-5.00	5.00	12.00	63.0	
		Week 8	Tezepelumab	114	100 (87.7)	7.64 (19.96)	-59.0	-2.50	8.50	19.50	69.0	0.03 [-0.24, 0.30]
			Placebo	126	111 (88.1)	7.14 (17.40)	-36.0	-4.00	6.00	17.00	57.0	
		Week 12	Tezepelumab	114	100 (87.7)	9.52 (19.72)	-51.0	-2.00	7.00	22.00	65.0	0.04 [-0.23, 0.31]
			Placebo	126	111 (88.1)	8.69 (17.79)	-34.0	-1.00	7.00	18.00	69.0	
		Week 20	Tezepelumab	114	100 (87.7)	9.44 (20.30)	-51.0	-5.00	10.50	24.00	55.0	0.02 [-0.25, 0.29]
			Placebo	126	111 (88.1)	9.06 (16.51)	-32.0	-2.00	7.00	17.00	57.0	
		Week 28	Tezepelumab	114	100 (87.7)	10.76 (19.34)	-43.0	-1.00	9.50	24.50	60.0	0.10 [-0.17, 0.37]
			Placebo	126	111 (88.1)	8.95 (16.05)	-20.0	-2.00	6.00	20.00	58.0	
		Week 40	Tezepelumab	114	100 (87.7)	11.68 (19.63)	-43.0	-2.50	10.00	25.50	58.0	0.11 [-0.16, 0.38]
			Placebo	126	111 (88.1)	9.62 (16.64)	-26.0	-2.00	8.00	19.00	59.0	
		Week 52	Tezepelumab	114	100 (87.7)	11.61 (20.04)	-43.0	-3.00	13.00	25.50	58.0	0.05 [-0.22, 0.32]
			Placebo	126	111 (88.1)	10.65 (17.30)	-26.0	-3.00	8.00	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	23	22 (95.7)	62.05 (14.26)	38.0	50.00	60.50	72.00	86.0	
			Placebo	12	9 (75.0)	59.67 (15.26)	32.0	50.00	60.00	70.00	79.0	
		Week 4	Tezepelumab	23	21 (91.3)	70.38 (15.69)	49.0	60.00	66.00	87.00	94.0	
			Placebo	12	10 (83.3)	58.50 (9.26)	46.0	51.00	59.00	61.00	75.0	
		Week 8	Tezepelumab	23	21 (91.3)	69.24 (18.04)	35.0	59.00	61.00	87.00	96.0	
			Placebo	12	10 (83.3)	65.50 (15.77)	45.0	52.00	62.50	78.00	94.0	
		Week 12	Tezepelumab	23	21 (91.3)	70.00 (20.06)	33.0	55.00	69.00	87.00	98.0	
			Placebo	12	10 (83.3)	64.10 (20.22)	31.0	47.00	63.50	75.00	100.0	
		Week 20	Tezepelumab	23	22 (95.7)	69.41 (19.71)	34.0	55.00	71.50	85.00	98.0	
			Placebo	12	10 (83.3)	64.80 (10.34)	46.0	60.00	68.50	70.00	80.0	
		Week 28	Tezepelumab	23	22 (95.7)	70.95 (18.91)	32.0	55.00	72.50	88.00	96.0	
			Placebo	12	10 (83.3)	67.70 (17.70)	46.0	49.00	67.50	75.00	97.0	
		Week 40	Tezepelumab	23	22 (95.7)	73.18 (19.29)	32.0	60.00	76.00	90.00	98.0	
			Placebo	12	10 (83.3)	64.10 (17.55)	43.0	47.00	63.00	73.00	95.0	
		Week 52	Tezepelumab	23	22 (95.7)	72.36 (18.37)	25.0	60.00	78.00	87.00	97.0	
			Placebo	12	10 (83.3)	67.90 (15.18)	46.0	52.00	68.50	81.00	87.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	9.75 (14.02)	-17.0	0.50	8.50	19.50	40.0	0.73 [-0.08, 1.54]
			Placebo	12	9 (75.0)	0.22 (10.58)	-20.0	-5.00	3.00	5.00	16.0	
		Week 8	Tezepelumab	23	20 (87.0)	8.55 (11.27)	-10.0	-2.00	10.00	16.50	26.0	0.08 [-0.71, 0.87]
			Placebo	12	9 (75.0)	7.33 (21.28)	-7.0	-4.00	2.00	8.00	62.0	
		Week 12	Tezepelumab	23	20 (87.0)	9.35 (15.06)	-21.0	-2.50	9.00	20.00	36.0	0.20 [-0.59, 0.99]
			Placebo	12	9 (75.0)	5.22 (29.26)	-39.0	-5.00	-3.00	16.00	68.0	
		Week 20	Tezepelumab	23	21 (91.3)	8.76 (16.43)	-25.0	-2.00	11.00	25.00	31.0	0.19 [-0.59, 0.98]
			Placebo	12	9 (75.0)	5.67 (14.75)	-8.0	-4.00	-2.00	10.00	37.0	
		Week 28	Tezepelumab	23	21 (91.3)	10.43 (16.57)	-14.0	-3.00	8.00	25.00	40.0	0.16 [-0.63, 0.94]
			Placebo	12	9 (75.0)	7.33 (26.61)	-30.0	-7.00	-2.00	15.00	65.0	
		Week 40	Tezepelumab	23	21 (91.3)	12.76 (15.75)	-21.0	-1.00	16.00	23.00	40.0	0.41 [-0.38, 1.20]
			Placebo	12	9 (75.0)	5.56 (21.44)	-12.0	-5.00	-3.00	5.00	55.0	
		Week 52	Tezepelumab	23	21 (91.3)	11.90 (14.45)	-18.0	-1.00	16.00	24.00	30.0	0.20 [-0.58, 0.99]
			Placebo	12	9 (75.0)	8.67 (19.08)	-5.0	-3.00	1.00	17.00	54.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	55.75 (16.36)	35.0	43.50	53.00	67.50	83.0	
			Placebo	14	10 (71.4)	56.10 (11.88)	32.0	49.00	60.00	65.00	70.0	
		Week 4	Tezepelumab	9	9 (100.0)	70.11 (14.49)	44.0	66.00	70.00	81.00	92.0	
			Placebo	14	12 (85.7)	57.50 (17.35)	23.0	48.00	54.00	69.00	91.0	
		Week 8	Tezepelumab	9	9 (100.0)	70.11 (22.03)	35.0	60.00	73.00	87.00	95.0	
			Placebo	14	13 (92.9)	65.62 (15.16)	48.0	54.00	62.00	69.00	94.0	
		Week 12	Tezepelumab	9	9 (100.0)	67.44 (23.42)	33.0	48.00	66.00	89.00	97.0	
			Placebo	14	13 (92.9)	63.23 (18.70)	20.0	57.00	64.00	69.00	100.0	
		Week 20	Tezepelumab	9	9 (100.0)	68.22 (24.12)	34.0	40.00	77.00	85.00	97.0	
			Placebo	14	13 (92.9)	59.54 (15.13)	20.0	54.00	61.00	69.00	82.0	
		Week 28	Tezepelumab	9	9 (100.0)	66.44 (22.36)	32.0	50.00	71.00	85.00	95.0	
			Placebo	14	14 (100.0)	67.00 (18.14)	30.0	54.00	68.00	74.00	97.0	
		Week 40	Tezepelumab	9	9 (100.0)	67.67 (22.73)	32.0	50.00	75.00	81.00	95.0	
			Placebo	14	14 (100.0)	62.79 (19.29)	20.0	53.00	61.50	73.00	95.0	
		Week 52	Tezepelumab	9	9 (100.0)	68.11 (24.62)	25.0	50.00	75.00	88.00	95.0	
			Placebo	14	14 (100.0)	63.71 (17.46)	30.0	48.00	65.00	73.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	12.63 (16.31)	-17.0	1.50	19.00	23.00	31.0	0.61 [-0.34, 1.56]
			Placebo	14	10 (71.4)	3.20 (14.73)	-22.0	-6.00	0.00	16.00	26.0	
		Week 8	Tezepelumab	9	8 (88.9)	12.25 (12.83)	-10.0	3.50	15.50	22.50	25.0	0.05 [-0.88, 0.98]
			Placebo	14	10 (71.4)	11.30 (21.71)	-8.0	-1.00	1.50	23.00	62.0	
		Week 12	Tezepelumab	9	8 (88.9)	10.13 (14.68)	-10.0	-1.00	10.00	19.50	34.0	0.17 [-0.77, 1.10]
			Placebo	14	10 (71.4)	6.70 (24.39)	-25.0	-4.00	1.50	14.00	68.0	
		Week 20	Tezepelumab	9	8 (88.9)	11.38 (22.74)	-11.0	-7.00	3.00	30.00	50.0	0.38 [-0.55, 1.32]
			Placebo	14	10 (71.4)	3.80 (16.96)	-25.0	-4.00	1.00	12.00	37.0	
		Week 28	Tezepelumab	9	8 (88.9)	8.38 (19.35)	-13.0	-8.00	3.00	27.00	36.0	-0.04 [-0.97, 0.89]
			Placebo	14	10 (71.4)	9.20 (22.66)	-15.0	-4.00	3.00	18.00	65.0	
		Week 40	Tezepelumab	9	8 (88.9)	11.00 (19.01)	-13.0	-8.00	14.50	24.00	40.0	0.21 [-0.73, 1.14]
			Placebo	14	10 (71.4)	6.80 (21.34)	-25.0	-4.00	2.50	15.00	55.0	
		Week 52	Tezepelumab	9	8 (88.9)	11.50 (23.16)	-13.0	-11.50	14.00	23.50	53.0	0.19 [-0.74, 1.12]
			Placebo	14	10 (71.4)	7.50 (19.50)	-15.0	-4.00	3.50	13.00	54.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	60.95 (16.58)	20.0	50.00	60.00	73.00	100.0	
			Placebo	124	110 (88.7)	60.88 (15.18)	23.0	50.00	60.00	72.00	97.0	
		Week 4	Tezepelumab	128	120 (93.8)	67.16 (18.58)	14.0	52.00	66.50	80.50	100.0	
			Placebo	124	113 (91.1)	66.37 (16.89)	17.0	56.00	69.00	79.00	99.0	
		Week 8	Tezepelumab	128	120 (93.8)	67.85 (18.82)	20.0	54.00	66.00	85.00	100.0	
			Placebo	124	114 (91.9)	67.45 (17.80)	14.0	53.00	69.50	80.00	100.0	
		Week 12	Tezepelumab	128	120 (93.8)	69.73 (18.32)	26.0	55.00	70.00	83.50	100.0	
			Placebo	124	115 (92.7)	69.23 (17.93)	19.0	58.00	72.00	83.00	100.0	
		Week 20	Tezepelumab	128	122 (95.3)	69.26 (18.06)	18.0	56.00	70.00	83.00	100.0	
			Placebo	124	115 (92.7)	69.71 (18.01)	19.0	60.00	70.00	84.00	100.0	
		Week 28	Tezepelumab	128	123 (96.1)	70.88 (17.58)	8.0	59.00	72.00	83.00	100.0	
			Placebo	124	115 (92.7)	69.44 (17.97)	12.0	55.00	71.00	84.00	100.0	
		Week 40	Tezepelumab	128	124 (96.9)	72.34 (17.42)	18.0	60.00	75.00	84.50	100.0	
			Placebo	124	116 (93.5)	69.99 (17.45)	20.0	55.00	73.00	85.00	100.0	
		Week 52	Tezepelumab	128	125 (97.7)	72.11 (18.46)	19.0	59.00	74.00	86.00	100.0	
			Placebo	124	117 (94.4)	71.15 (18.23)	16.0	59.00	75.00	85.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	112 (87.5)	7.14 (17.41)	-51.0	-2.50	6.50	18.00	50.0	0.09 [-0.18, 0.35]
			Placebo	124	110 (88.7)	5.70 (15.38)	-40.0	-5.00	5.00	11.00	63.0	
		Week 8	Tezepelumab	128	112 (87.5)	7.47 (19.11)	-59.0	-2.50	7.50	16.50	69.0	0.04 [-0.22, 0.30]
			Placebo	124	110 (88.7)	6.77 (17.27)	-36.0	-4.00	5.50	16.00	57.0	
		Week 12	Tezepelumab	128	112 (87.5)	9.45 (19.29)	-51.0	-2.00	7.00	21.00	65.0	0.05 [-0.22, 0.31]
			Placebo	124	110 (88.7)	8.59 (18.27)	-39.0	-3.00	7.00	18.00	69.0	
		Week 20	Tezepelumab	128	113 (88.3)	9.18 (19.49)	-51.0	-4.00	11.00	24.00	55.0	-0.00 [-0.27, 0.26]
			Placebo	124	110 (88.7)	9.26 (16.30)	-32.0	-2.00	7.50	17.00	57.0	
		Week 28	Tezepelumab	128	113 (88.3)	10.87 (18.87)	-43.0	-1.00	10.00	25.00	60.0	0.12 [-0.15, 0.38]
			Placebo	124	110 (88.7)	8.79 (16.43)	-30.0	-3.00	6.00	20.00	58.0	
		Week 40	Tezepelumab	128	113 (88.3)	11.93 (19.03)	-43.0	-1.00	12.00	25.00	58.0	0.13 [-0.13, 0.40]
			Placebo	124	110 (88.7)	9.55 (16.62)	-26.0	-3.00	7.00	19.00	59.0	
		Week 52	Tezepelumab	128	113 (88.3)	11.67 (18.95)	-43.0	-2.00	13.00	25.00	58.0	0.05 [-0.21, 0.31]
			Placebo	124	110 (88.7)	10.77 (17.23)	-26.0	-3.00	8.50	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	60.80 (17.22)	20.0	49.00	60.50	73.00	100.0	
			Placebo	115	103 (89.6)	60.75 (15.37)	23.0	50.00	60.00	72.00	97.0	
		Week 4	Tezepelumab	108	102 (94.4)	66.63 (19.04)	14.0	50.00	66.50	80.00	100.0	
			Placebo	115	106 (92.2)	66.70 (17.27)	17.0	56.00	69.50	80.00	99.0	
		Week 8	Tezepelumab	108	102 (94.4)	67.77 (19.44)	20.0	53.00	68.00	85.00	100.0	
			Placebo	115	107 (93.0)	67.67 (18.04)	14.0	53.00	70.00	81.00	100.0	
		Week 12	Tezepelumab	108	102 (94.4)	69.77 (18.45)	26.0	55.00	70.50	83.00	100.0	
			Placebo	115	108 (93.9)	69.80 (17.78)	19.0	59.00	72.50	83.00	100.0	
		Week 20	Tezepelumab	108	103 (95.4)	69.27 (18.11)	18.0	56.00	69.00	83.00	100.0	
			Placebo	115	108 (93.9)	69.99 (18.33)	19.0	60.00	71.00	85.00	100.0	
		Week 28	Tezepelumab	108	104 (96.3)	70.81 (17.73)	8.0	59.00	72.00	83.00	100.0	
			Placebo	115	108 (93.9)	69.82 (18.04)	12.0	56.50	71.50	84.00	100.0	
		Week 40	Tezepelumab	108	105 (97.2)	72.20 (17.57)	18.0	60.00	75.00	84.00	100.0	
			Placebo	115	109 (94.8)	70.46 (17.35)	20.0	57.00	74.00	85.00	100.0	
		Week 52	Tezepelumab	108	106 (98.1)	71.98 (19.06)	19.0	58.00	74.00	86.00	100.0	
			Placebo	115	110 (95.7)	71.43 (18.36)	16.0	60.00	75.00	86.00	100.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	108	95 (88.0)	6.60 (18.05)	-51.0	-3.00	6.00	18.00	50.0	0.02 [-0.25, 0.30]
			Placebo	115	103 (89.6)	6.18 (15.59)	-40.0	-4.00	6.00	12.00	63.0	
		Week 8	Tezepelumab	108	95 (88.0)	7.35 (20.23)	-59.0	-3.00	7.00	17.00	69.0	0.01 [-0.27, 0.29]
			Placebo	115	103 (89.6)	7.16 (17.72)	-36.0	-4.00	6.00	17.00	57.0	
		Week 12	Tezepelumab	108	95 (88.0)	9.45 (19.96)	-51.0	-2.00	7.00	22.00	65.0	0.01 [-0.27, 0.28]
			Placebo	115	103 (89.6)	9.34 (18.00)	-34.0	-1.00	8.00	19.00	69.0	
		Week 20	Tezepelumab	108	95 (88.0)	9.18 (20.02)	-51.0	-5.00	11.00	24.00	55.0	-0.03 [-0.31, 0.25]
			Placebo	115	103 (89.6)	9.72 (16.57)	-32.0	-1.00	8.00	19.00	57.0	
		Week 28	Tezepelumab	108	95 (88.0)	10.77 (19.30)	-43.0	-1.00	10.00	23.00	60.0	0.08 [-0.20, 0.36]
			Placebo	115	103 (89.6)	9.34 (16.27)	-20.0	-2.00	6.00	21.00	58.0	
		Week 40	Tezepelumab	108	95 (88.0)	11.66 (19.57)	-43.0	-2.00	9.00	25.00	58.0	0.08 [-0.20, 0.36]
			Placebo	115	103 (89.6)	10.20 (16.71)	-26.0	-2.00	8.00	20.00	59.0	
		Week 52	Tezepelumab	108	95 (88.0)	11.41 (19.74)	-43.0	-3.00	13.00	25.00	58.0	0.01 [-0.27, 0.29]
			Placebo	115	103 (89.6)	11.23 (17.56)	-26.0	-3.00	10.00	20.00	65.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	59.93 (14.17)	35.0	50.00	59.00	71.00	86.0	
			Placebo	23	17 (73.9)	58.88 (12.39)	32.0	50.00	60.00	68.00	79.0	
		Week 4	Tezepelumab	29	27 (93.1)	70.15 (15.11)	44.0	60.00	69.00	84.00	94.0	
			Placebo	23	19 (82.6)	58.95 (14.57)	23.0	51.00	59.00	69.00	91.0	
		Week 8	Tezepelumab	29	27 (93.1)	68.89 (17.43)	35.0	59.00	65.00	87.00	96.0	
			Placebo	23	20 (87.0)	65.05 (14.47)	45.0	53.00	62.00	75.50	94.0	
		Week 12	Tezepelumab	29	27 (93.1)	68.78 (19.57)	33.0	50.00	66.00	87.00	98.0	
			Placebo	23	20 (87.0)	62.25 (18.45)	20.0	51.00	64.00	72.00	100.0	
		Week 20	Tezepelumab	29	28 (96.6)	68.89 (19.87)	34.0	52.50	72.00	85.00	98.0	
			Placebo	23	20 (87.0)	61.60 (14.16)	20.0	52.50	65.50	70.50	82.0	
		Week 28	Tezepelumab	29	28 (96.6)	69.71 (18.73)	32.0	53.50	70.50	85.50	96.0	
			Placebo	23	21 (91.3)	65.86 (17.45)	30.0	51.00	68.00	74.00	97.0	
		Week 40	Tezepelumab	29	28 (96.6)	71.36 (18.78)	32.0	57.50	75.00	84.50	98.0	
			Placebo	23	21 (91.3)	62.76 (18.65)	20.0	48.00	62.00	73.00	95.0	
		Week 52	Tezepelumab	29	28 (96.6)	71.32 (18.33)	25.0	57.50	75.00	86.00	97.0	
			Placebo	23	21 (91.3)	64.76 (16.85)	30.0	51.00	66.00	75.00	97.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IOSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITT

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	29	25 (86.2)	10.96 (14.03)	-17.0	2.00	10.00	20.00	40.0	0.71 [0.08, 1.35]
			Placebo	23	17 (73.9)	1.29 (12.87)	-22.0	-6.00	1.00	9.00	26.0	
		Week 8	Tezepelumab	29	25 (86.2)	9.48 (11.72)	-10.0	-1.00	10.00	19.00	26.0	0.16 [-0.45, 0.78]
			Placebo	23	17 (73.9)	7.12 (17.51)	-8.0	-3.00	2.00	8.00	62.0	
		Week 12	Tezepelumab	29	25 (86.2)	9.64 (14.95)	-21.0	-1.00	11.00	20.00	36.0	0.36 [-0.26, 0.99]
			Placebo	23	17 (73.9)	2.94 (22.52)	-39.0	-5.00	-1.00	14.00	68.0	
		Week 20	Tezepelumab	29	26 (89.7)	9.85 (18.44)	-25.0	-4.00	10.00	25.00	50.0	0.39 [-0.23, 1.01]
			Placebo	23	17 (73.9)	3.29 (14.13)	-25.0	-4.00	-1.00	10.00	37.0	
		Week 28	Tezepelumab	29	26 (89.7)	10.46 (17.36)	-14.0	-6.00	8.50	25.00	40.0	0.25 [-0.36, 0.87]
			Placebo	23	17 (73.9)	5.71 (20.65)	-30.0	-7.00	3.00	15.00	65.0	
		Week 40	Tezepelumab	29	26 (89.7)	12.62 (16.83)	-21.0	-1.00	16.50	25.00	40.0	0.50 [-0.12, 1.12]
			Placebo	23	17 (73.9)	3.94 (18.05)	-25.0	-5.00	-1.00	8.00	55.0	
		Week 52	Tezepelumab	29	26 (89.7)	12.58 (17.06)	-18.0	-1.00	17.00	25.00	53.0	0.39 [-0.22, 1.01]
			Placebo	23	17 (73.9)	6.06 (15.84)	-15.0	-3.00	2.00	13.00	54.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_ILMP0: Increase in EQ-5D-VAS of at least 15 points
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase in EQ-5D-VAS of at least 15 points	Week 52	66	58 (87.9)	31 (47.0) [34.6, 59.7]	65	55 (84.6)	21 (32.3) [21.2, 45.1]	1.454 [0.941, 2.247]	1.856 [0.913, 3.774]	14.7 [-3.4, 32.7]	0.088

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. VAS = visual analogue scale.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_ILSPK: Increase in EQ-5D-VAS of at least 15 points by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase in EQ-5D-VAS of at least 15 points / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.193	
Male	19	16 (84.2)	11 (57.9) [33.5, 79.7]	20	17 (85.0)	5 (25.0) [8.7, 49.1]	2.316 [0.989, 5.421]	4.125 [1.057, 16.097]	32.9 [-1.4, 67.2]	0.039	*
Female	47	42 (89.4)	20 (42.6) [28.3, 57.8]	45	38 (84.4)	16 (35.6) [21.9, 51.2]	1.197 [0.715, 2.003]	1.343 [0.579, 3.112]	7.0 [-15.1, 29.1]	0.494	
Age										0.404	
< 65 years	57	50 (87.7)	28 (49.1) [35.6, 62.7]	55	48 (87.3)	20 (36.4) [23.8, 50.4]	1.351 [0.872, 2.094]	1.690 [0.793, 3.598]	12.8 [-7.2, 32.7]	0.174	
>= 65 years	9	8 (88.9)	3 (33.3) [7.5, 70.1]	10	7 (70.0)	1 (10.0) [0.3, 44.5]	3.333 [0.418, 26.583]	4.500 [0.374, 54.155]	23.3 [-23.2, 69.9]	0.303	#
Exacerbations in the year before study										0.609	
<= 2	44	39 (88.6)	20 (45.5) [30.4, 61.2]	45	38 (84.4)	13 (28.9) [16.4, 44.3]	1.573 [0.898, 2.758]	2.051 [0.854, 4.927]	16.6 [-5.5, 38.6]	0.108	
> 2	22	19 (86.4)	11 (50.0) [28.2, 71.8]	20	17 (85.0)	8 (40.0) [19.1, 63.9]	1.250 [0.633, 2.468]	1.500 [0.441, 5.102]	10.0 [-24.7, 44.7]	0.521	
Race		N<10	any level							NE	
White	60	52 (86.7)	26 (43.3) [30.6, 56.8]	58	48 (82.8)	17 (29.3) [18.1, 42.7]					
Black or African American	2	2 (100.0)	2 (100.0) [15.8, 100.0]	2	2 (100.0)	1 (50.0) [1.3, 98.7]					
Asian	3	3 (100.0)	3 (100.0) [29.2, 100.0]	3	3 (100.0)	2 (66.7) [9.4, 99.2]					
Other	1	1 (100.0)	0 (0.0) [0.0, 97.5]	2	2 (100.0)	1 (50.0) [1.3, 98.7]					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_ILSPK: Increase in EQ-5D-VAS of at least 15 points by key subgroups
DITTL

Increase in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Region		N<10	any level							NE	
Europe	40	36 (90.0)	17 (42.5) [27.0, 59.1]	36	31 (86.1)	11 (30.6) [16.3, 48.1]					
America	6	5 (83.3)	3 (50.0) [11.8, 88.2]	4	3 (75.0)	1 (25.0) [0.6, 80.6]					
Asia/Pacific	3	3 (100.0)	3 (100.0) [29.2, 100.0]	3	3 (100.0)	2 (66.7) [9.4, 99.2]					
Rest of the world	17	14 (82.4)	8 (47.1) [23.0, 72.2]	22	18 (81.8)	7 (31.8) [13.9, 54.9]					
BMI										0.379	
18.5 - < 25.0 kg/m**2	15	14 (93.3)	10 (66.7) [38.4, 88.2]	21	17 (81.0)	6 (28.6) [11.3, 52.2]	2.333 [1.086, 5.015]	5.000 [1.195, 20.922]	38.1 [1.7, 74.5]	0.025	*
25.0 - < 30.0 kg/m**2	24	20 (83.3)	9 (37.5) [18.8, 59.4]	20	18 (90.0)	6 (30.0) [11.9, 54.3]	1.250 [0.537, 2.912]	1.400 [0.396, 4.955]	7.5 [-25.0, 40.0]	0.605	
>= 30.0 kg/m**2	27	24 (88.9)	12 (44.4) [25.5, 64.7]	24	20 (83.3)	9 (37.5) [18.8, 59.4]	1.185 [0.608, 2.309]	1.333 [0.434, 4.095]	6.9 [-23.9, 37.8]	0.618	
Baseline eosinophils - Low										0.644	
< 150 cells/uL	11	11 (100.0)	7 (63.6) [30.8, 89.1]	14	11 (78.6)	5 (35.7) [12.8, 64.9]	1.782 [0.775, 4.097]	3.150 [0.608, 16.311]	27.9 [-18.1, 74.0]	0.174	
>= 150 cells/uL	54	46 (85.2)	24 (44.4) [30.9, 58.6]	51	44 (86.3)	16 (31.4) [19.1, 45.9]	1.417 [0.856, 2.344]	1.750 [0.787, 3.890]	13.1 [-7.2, 33.4]	0.170	
Baseline eosinophils - High										0.826	
< 300 cells/uL	33	31 (93.9)	18 (54.5) [36.4, 71.9]	34	27 (79.4)	12 (35.3) [19.7, 53.5]	1.545 [0.890, 2.683]	2.200 [0.824, 5.873]	19.3 [-7.1, 45.6]	0.116	
>= 300 cells/uL	32	26 (81.3)	13 (40.6) [23.7, 59.4]	31	28 (90.3)	9 (29.0) [14.2, 48.0]	1.399 [0.701, 2.794]	1.673 [0.586, 4.772]	11.6 [-14.9, 38.1]	0.338	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_ILSPK: Increase in EQ-5D-VAS of at least 15 points by key subgroups
DITTL

Increase in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO										0.616	
< 25 ppb	39	32 (82.1)	16 (41.0) [25.6, 57.9]	30	23 (76.7)	9 (30.0) [14.7, 49.4]	1.368 [0.704, 2.655]	1.623 [0.592, 4.449]	11.0 [-14.4, 36.5]	0.348	
>= 25 ppb	27	26 (96.3)	15 (55.6) [35.3, 74.5]	34	31 (91.2)	11 (32.4) [17.4, 50.5]	1.717 [0.950, 3.103]	2.614 [0.919, 7.433]	23.2 [-4.6, 51.0]	0.071	
Baseline specific perennial FEIA status										0.475	
All negative	27	23 (85.2)	11 (40.7) [22.4, 61.2]	29	23 (79.3)	10 (34.5) [17.9, 54.3]	1.181 [0.600, 2.326]	1.306 [0.442, 3.863]	6.3 [-22.7, 35.2]	0.632	
Any positive	34	32 (94.1)	17 (50.0) [32.4, 67.6]	33	29 (87.9)	10 (30.3) [15.6, 48.7]	1.650 [0.890, 3.058]	2.300 [0.845, 6.262]	19.7 [-6.3, 45.7]	0.103	
Total serum IgE										0.922	
Low	23	20 (87.0)	9 (39.1) [19.7, 61.5]	14	11 (78.6)	4 (28.6) [8.4, 58.1]	1.370 [0.518, 3.622]	1.607 [0.384, 6.718]	10.6 [-26.1, 47.3]	0.724	#
Normal	40	35 (87.5)	21 (52.5) [36.1, 68.5]	44	37 (84.1)	16 (36.4) [22.4, 52.2]	1.444 [0.885, 2.356]	1.934 [0.808, 4.631]	16.1 [-7.3, 39.5]	0.139	
High	3	3 (100.0)	1 (33.3) [0.8, 90.6]	7	7 (100.0)	1 (14.3) [0.4, 57.9]	2.333 [0.208, 26.225]	3.000 [0.122, 73.642]	19.0 [-64.1, 100.0]	1.000	#
OCS at baseline										0.143	
Yes	9	8 (88.9)	4 (44.4) [13.7, 78.8]	13	9 (69.2)	1 (7.7) [0.2, 36.0]	5.778 [0.767, 43.545]	9.600 [0.848, 108.717]	36.8 [-8.2, 81.7]	0.116	#
No	57	50 (87.7)	27 (47.4) [34.0, 61.0]	52	46 (88.5)	20 (38.5) [25.3, 53.0]	1.232 [0.794, 1.911]	1.440 [0.671, 3.089]	8.9 [-11.4, 29.3]	0.351	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_ILSPK: Increase in EQ-5D-VAS of at least 15 points by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase in EQ-5D-VAS of at least 15 points / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline										0.290
Yes	7	6 (85.7)	5 (71.4) [29.0, 96.3]	3	2 (66.7)	0 (0.0) [0.0, 70.8]	5.500 + [0.395, 76.653]	15.400 + [0.557, 425.527]	71.4 [14.2, 100.0]	0.167 #
No	59	52 (88.1)	26 (44.1) [31.2, 57.6]	62	53 (85.5)	21 (33.9) [22.3, 47.0]	1.301 [0.829, 2.043]	1.538 [0.737, 3.209]	10.2 [-8.8, 29.1]	0.252
Tiotropium use at baseline		N<10	any level							NE
Yes	6	5 (83.3)	4 (66.7) [22.3, 95.7]	2	1 (50.0)	0 (0.0) [0.0, 84.2]				
No	60	53 (88.3)	27 (45.0) [32.1, 58.4]	63	54 (85.7)	21 (33.3) [22.0, 46.3]				
Montelukast/ Cromoglicic acid use at baseline										0.380
Yes	17	15 (88.2)	7 (41.2) [18.4, 67.1]	21	20 (95.2)	8 (38.1) [18.1, 61.6]	1.081 [0.492, 2.376]	1.138 [0.308, 4.204]	3.1 [-33.5, 39.7]	0.849
No	49	43 (87.8)	24 (49.0) [34.4, 63.7]	44	35 (79.5)	13 (29.5) [16.8, 45.2]	1.658 [0.968, 2.840]	2.289 [0.972, 5.389]	19.4 [-2.2, 41.0]	0.057

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_ILSPP: Increase in EQ-5D-VAS of at least 15 points by study specific subgroups
DITTL

Increase in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.976	
White	60	52 (86.7)	26 (43.3) [30.6, 56.8]	58	48 (82.8)	17 (29.3) [18.1, 42.7]	1.478 [0.903, 2.422]	1.844 [0.861, 3.951]	14.0 [-4.8, 32.9]	0.115	
Non-white	6	6 (100.0)	5 (83.3) [35.9, 99.6]	7	7 (100.0)	4 (57.1) [18.4, 90.1]	1.458 [0.700, 3.040]	3.750 [0.274, 51.373]	26.2 [-36.5, 88.9]	0.559	#
Region (cat. P)										0.730	
North America/Western EU	6	5 (83.3)	3 (50.0) [11.8, 88.2]	4	3 (75.0)	1 (25.0) [0.6, 80.6]	2.000 [0.306, 13.062]	3.000 [0.188, 47.963]	25.0 [-54.2, 100.0]	0.571	#
Rest of world	60	53 (88.3)	28 (46.7) [33.7, 60.0]	61	52 (85.2)	20 (32.8) [21.3, 46.0]	1.423 [0.908, 2.232]	1.794 [0.858, 3.748]	13.9 [-5.0, 32.8]	0.120	
Baseline eosinophils (cat. P)										0.309	
< 250 cells/uL	30	26 (86.7)	13 (43.3) [25.5, 62.6]	29	25 (86.2)	11 (37.9) [20.7, 57.7]	1.142 [0.615, 2.123]	1.251 [0.442, 3.545]	5.4 [-23.0, 33.8]	0.675	
>= 250 cells/uL	36	32 (88.9)	18 (50.0) [32.9, 67.1]	36	30 (83.3)	10 (27.8) [14.2, 45.2]	1.800 [0.968, 3.345]	2.600 [0.977, 6.922]	22.2 [-2.5, 46.9]	0.055	
Baseline FENO (cat. P)										0.716	
< 24 ppb	38	31 (81.6)	16 (42.1) [26.3, 59.2]	30	23 (76.7)	9 (30.0) [14.7, 49.4]	1.404 [0.724, 2.720]	1.697 [0.617, 4.669]	12.1 [-13.6, 37.8]	0.308	
>= 24 ppb	28	27 (96.4)	15 (53.6) [33.9, 72.5]	34	31 (91.2)	11 (32.4) [17.4, 50.5]	1.656 [0.912, 3.005]	2.413 [0.858, 6.781]	21.2 [-6.3, 48.7]	0.095	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_ILSPP: Increase in EQ-5D-VAS of at least 15 points by study specific subgroups
DITTL

Increase in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. M)										0.266	
< 22.0 ppb	32	26 (81.3)	12 (37.5) [21.1, 56.3]	27	21 (77.8)	9 (33.3) [16.5, 54.0]	1.125 [0.561, 2.257]	1.200 [0.410, 3.511]	4.2 [-23.7, 32.0]	0.741	
>= 22.0 ppb	34	32 (94.1)	19 (55.9) [37.9, 72.8]	37	33 (89.2)	11 (29.7) [15.9, 47.0]	1.880 [1.054, 3.352]	2.994 [1.127, 7.956]	26.2 [1.1, 51.2]	0.027	*
Baseline all FEIA status										0.707	
All negative	25	21 (84.0)	10 (40.0) [21.1, 61.3]	22	18 (81.8)	7 (31.8) [13.9, 54.9]	1.257 [0.578, 2.736]	1.429 [0.429, 4.753]	8.2 [-23.4, 39.8]	0.564	
Any positive	35	33 (94.3)	18 (51.4) [34.0, 68.6]	41	35 (85.4)	14 (34.1) [20.1, 50.6]	1.506 [0.884, 2.567]	2.042 [0.810, 5.151]	17.3 [-7.4, 41.9]	0.131	
Th2 status										0.217	
Low	41	36 (87.8)	20 (48.8) [32.9, 64.9]	30	25 (83.3)	7 (23.3) [9.9, 42.3]	2.091 [1.017, 4.297]	3.129 [1.101, 8.892]	25.4 [1.0, 49.9]	0.030	*
High	25	22 (88.0)	11 (44.0) [24.4, 65.1]	34	29 (85.3)	13 (38.2) [22.2, 56.4]	1.151 [0.622, 2.128]	1.269 [0.444, 3.626]	5.8 [-23.1, 34.6]	0.659	
Baseline Periostin										0.110	
Low (< 20.9 ng/ml)	26	23 (88.5)	11 (42.3) [23.4, 63.1]	31	25 (80.6)	13 (41.9) [24.5, 60.9]	1.009 [0.548, 1.858]	1.015 [0.353, 2.918]	0.4 [-28.9, 29.6]	0.978	
High (>= 20.9 ng/ml)	40	35 (87.5)	20 (50.0) [33.8, 66.2]	34	30 (88.2)	8 (23.5) [10.7, 41.2]	2.125 [1.076, 4.197]	3.250 [1.188, 8.888]	26.5 [2.7, 50.2]	0.020	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_ILSPP: Increase in EQ-5D-VAS of at least 15 points by study specific subgroups
DITTL

Increase in EQ-5D-VAS of at least 15 points / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility										0.330	
Yes	57	49 (86.0)	25 (43.9) [30.7, 57.6]	60	51 (85.0)	20 (33.3) [21.7, 46.7]	1.316 [0.828, 2.090]	1.563 [0.738, 3.306]	10.5 [-8.7, 29.8]	0.244	
No	9	9 (100.0)	6 (66.7) [29.9, 92.5]	5	4 (80.0)	1 (20.0) [0.5, 71.6]	3.333 [0.544, 20.427]	8.000 [0.598, 106.936]	46.7 [-15.6, 100.0]	0.266	#
Maintenance OCS use at baseline										0.256	
Yes	9	8 (88.9)	4 (44.4) [13.7, 78.8]	14	10 (71.4)	2 (14.3) [1.8, 42.8]	3.111 [0.711, 13.618]	4.800 [0.655, 35.198]	30.2 [-16.2, 76.6]	0.162	#
No	57	50 (87.7)	27 (47.4) [34.0, 61.0]	51	45 (88.2)	19 (37.3) [24.1, 51.9]	1.271 [0.811, 1.992]	1.516 [0.702, 3.273]	10.1 [-10.3, 30.5]	0.291	
No chronic OCS use and current post-BD FEV1 reversibility										0.047	i
Yes	51	44 (86.3)	22 (43.1) [29.3, 57.8]	49	43 (87.8)	19 (38.8) [25.2, 53.8]	1.112 [0.694, 1.784]	1.198 [0.539, 2.661]	4.4 [-16.9, 25.6]	0.659	
No	15	14 (93.3)	9 (60.0) [32.3, 83.7]	16	12 (75.0)	2 (12.5) [1.6, 38.3]	4.800 [1.231, 18.714]	10.500 [1.725, 63.913]	47.5 [11.4, 83.6]	0.007	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: avas, created on: 11AUG2022

Table PT2VSD_ILMP0: Decrease in EQ-5D-VAS of at least 15 points
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease in EQ-5D-VAS of at least 15 points	Week 52	66	58 (87.9)	6 (9.1) [3.4, 18.7]	65	55 (84.6)	2 (3.1) [0.4, 10.7]	2.955 [0.619, 14.106]	3.150 [0.612, 16.221]	6.0 [-3.6, 15.6]	0.274 #

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. VAS = visual analogue scale.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMH0: Course of EQ-5D-VAS
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	66	58 (87.9)	57.9 (17.3)	20	49.0	52.5	71.0	100	
		Placebo	65	55 (84.6)	58.9 (14.3)	29	50.0	55.0	69.0	96	
	Week 1	Tezepelumab	66	61 (92.4)	62.3 (17.7)	13	51.0	61.0	76.0	99	
		Placebo	65	56 (86.2)	63.1 (17.6)	18	50.0	63.5	75.5	98	
	Week 2	Tezepelumab	66	63 (95.5)	62.9 (17.9)	20	50.0	62.0	79.0	100	
		Placebo	65	58 (89.2)	61.9 (18.3)	19	48.0	59.0	75.0	96	
	Week 3	Tezepelumab	66	63 (95.5)	65.7 (17.1)	28	53.0	66.0	82.0	97	
		Placebo	65	58 (89.2)	67.7 (15.6)	30	56.0	67.0	81.0	94	
	Week 4	Tezepelumab	66	63 (95.5)	66.3 (19.4)	14	50.0	66.0	84.0	100	
		Placebo	65	58 (89.2)	65.5 (17.5)	17	54.0	65.0	77.0	99	
	Week 5	Tezepelumab	66	63 (95.5)	68.0 (17.3)	29	53.0	68.0	81.0	100	
		Placebo	65	58 (89.2)	67.4 (16.8)	21	57.0	69.0	80.0	100	
	Week 6	Tezepelumab	66	63 (95.5)	68.3 (17.4)	24	53.0	70.0	84.0	100	
		Placebo	65	58 (89.2)	68.0 (18.8)	17	55.0	69.0	84.0	100	
	Week 7	Tezepelumab	66	63 (95.5)	66.1 (18.3)	30	50.0	69.0	81.0	100	
		Placebo	65	58 (89.2)	69.4 (17.6)	17	61.0	70.0	85.0	100	
	Week 8	Tezepelumab	66	63 (95.5)	68.2 (19.5)	20	55.0	70.0	87.0	100	
		Placebo	65	59 (90.8)	66.0 (19.9)	14	51.0	62.0	85.0	100	
	Week 9	Tezepelumab	66	63 (95.5)	67.9 (19.1)	34	50.0	69.0	85.0	100	
		Placebo	65	59 (90.8)	67.1 (17.9)	26	54.0	69.0	83.0	100	
	Week 10	Tezepelumab	66	63 (95.5)	67.2 (19.1)	28	51.0	65.0	83.0	100	
		Placebo	65	59 (90.8)	69.3 (18.1)	28	55.0	72.0	85.0	100	
	Week 11	Tezepelumab	66	63 (95.5)	68.6 (19.4)	18	53.0	69.0	85.0	100	
		Placebo	65	59 (90.8)	69.1 (17.6)	20	56.0	69.0	84.0	100	
	Week 12	Tezepelumab	66	63 (95.5)	69.1 (19.2)	26	56.0	70.0	85.0	100	
		Placebo	65	59 (90.8)	68.3 (18.7)	20	57.0	69.0	87.0	100	
	Week 13	Tezepelumab	66	63 (95.5)	69.1 (18.9)	31	55.0	71.0	85.0	100	
		Placebo	65	59 (90.8)	70.1 (16.5)	28	57.0	71.0	84.0	100	
	Week 14	Tezepelumab	66	63 (95.5)	69.6 (19.9)	20	53.0	73.0	87.0	100	
		Placebo	65	59 (90.8)	69.5 (17.3)	19	58.0	70.0	83.0	100	
	Week 15	Tezepelumab	66	63 (95.5)	68.7 (20.7)	12	52.0	71.0	87.0	100	
		Placebo	65	59 (90.8)	69.6 (17.8)	12	60.0	71.0	83.0	100	
	Week 16	Tezepelumab	66	63 (95.5)	68.4 (19.5)	28	53.0	70.0	85.0	100	
		Placebo	65	59 (90.8)	67.1 (18.5)	27	54.0	65.0	83.0	100	
	Week 17	Tezepelumab	66	63 (95.5)	69.3 (18.6)	9	54.0	73.0	83.0	100	
		Placebo	65	59 (90.8)	68.3 (19.4)	7	59.0	69.0	83.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMH0: Course of EQ-5D-VAS
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 18	Tezepelumab	66	64 (97.0)	68.2 (19.0)	14	54.0	72.0	81.5	100	
		Placebo	65	59 (90.8)	66.9 (19.3)	23	54.0	66.0	83.0	100	
	Week 19	Tezepelumab	66	64 (97.0)	67.7 (18.9)	20	51.5	70.5	84.5	100	
		Placebo	65	59 (90.8)	67.3 (18.9)	22	54.0	69.0	83.0	100	
	Week 20	Tezepelumab	66	64 (97.0)	69.1 (19.5)	18	54.5	71.0	82.5	100	
		Placebo	65	59 (90.8)	67.2 (19.8)	20	54.0	68.0	85.0	100	
	Week 21	Tezepelumab	66	64 (97.0)	68.0 (20.2)	11	50.0	68.5	85.0	100	
		Placebo	65	59 (90.8)	67.3 (18.7)	16	54.0	69.0	84.0	100	
	Week 22	Tezepelumab	66	64 (97.0)	68.0 (18.5)	19	54.0	69.0	84.0	100	
		Placebo	65	59 (90.8)	67.7 (18.6)	26	53.0	69.0	83.0	100	
	Week 23	Tezepelumab	66	64 (97.0)	68.0 (18.0)	15	53.0	70.5	82.5	100	
		Placebo	65	59 (90.8)	68.8 (17.9)	24	54.0	70.0	84.0	100	
	Week 24	Tezepelumab	66	64 (97.0)	68.5 (20.1)	13	51.5	71.0	84.0	100	
		Placebo	65	59 (90.8)	68.9 (18.6)	26	55.0	70.0	83.0	100	
	Week 25	Tezepelumab	66	64 (97.0)	67.6 (19.7)	19	53.0	70.5	82.5	100	
		Placebo	65	59 (90.8)	68.6 (18.3)	22	54.0	71.0	83.0	100	
	Week 26	Tezepelumab	66	65 (98.5)	68.2 (19.0)	19	52.0	73.0	82.0	100	
		Placebo	65	59 (90.8)	68.1 (19.1)	20	51.0	69.0	82.0	100	
	Week 27	Tezepelumab	66	65 (98.5)	66.8 (19.6)	13	50.0	68.0	83.0	100	
		Placebo	65	59 (90.8)	68.2 (17.7)	22	54.0	70.0	81.0	100	
	Week 28	Tezepelumab	66	65 (98.5)	69.0 (19.5)	8	53.0	71.0	83.0	100	
		Placebo	65	60 (92.3)	69.3 (18.9)	27	53.5	69.5	85.5	100	
	Week 29	Tezepelumab	66	65 (98.5)	68.8 (19.6)	7	53.0	72.0	86.0	100	
		Placebo	65	60 (92.3)	68.4 (18.6)	19	54.5	70.0	82.0	100	
	Week 30	Tezepelumab	66	65 (98.5)	67.9 (18.7)	9	56.0	70.0	82.0	100	
		Placebo	65	60 (92.3)	68.1 (18.2)	25	57.5	69.0	82.0	100	
	Week 31	Tezepelumab	66	65 (98.5)	68.2 (18.7)	18	53.0	68.0	85.0	100	
		Placebo	65	60 (92.3)	70.4 (17.1)	27	59.5	71.5	84.0	100	
	Week 32	Tezepelumab	66	65 (98.5)	69.2 (20.0)	9	57.0	73.0	86.0	100	
		Placebo	65	60 (92.3)	68.2 (19.3)	20	54.0	71.0	82.5	100	
	Week 33	Tezepelumab	66	65 (98.5)	69.3 (19.4)	11	53.0	70.0	85.0	100	
		Placebo	65	60 (92.3)	69.7 (18.9)	20	55.0	72.0	82.5	100	
	Week 34	Tezepelumab	66	65 (98.5)	69.4 (18.9)	10	54.0	72.0	84.0	100	
		Placebo	65	60 (92.3)	70.5 (19.3)	23	55.0	72.0	89.5	100	
	Week 35	Tezepelumab	66	65 (98.5)	69.4 (19.3)	7	54.0	72.0	84.0	100	
		Placebo	65	60 (92.3)	68.5 (17.8)	27	55.5	69.5	81.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMH0: Course of EQ-5D-VAS
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	66	65 (98.5)	69.5 (19.3)	17	52.0	71.0	85.0	100	
		Placebo	65	60 (92.3)	68.2 (17.9)	27	55.0	69.0	81.0	100	
	Week 37	Tezepelumab	66	65 (98.5)	69.2 (19.2)	17	54.0	70.0	85.0	100	
		Placebo	65	60 (92.3)	68.3 (18.8)	10	55.0	69.0	82.5	100	
	Week 38	Tezepelumab	66	65 (98.5)	68.2 (20.5)	13	51.0	72.0	85.0	100	
		Placebo	65	60 (92.3)	70.0 (17.7)	27	57.5	72.5	81.0	100	
	Week 39	Tezepelumab	66	65 (98.5)	68.4 (20.4)	11	52.0	70.0	86.0	100	
		Placebo	65	60 (92.3)	70.0 (18.9)	20	58.5	74.0	84.5	100	
	Week 40	Tezepelumab	66	65 (98.5)	70.2 (19.2)	18	53.0	75.0	84.0	100	
		Placebo	65	60 (92.3)	67.7 (19.2)	20	53.5	68.5	85.5	100	
	Week 41	Tezepelumab	66	65 (98.5)	69.4 (19.9)	11	53.0	72.0	87.0	100	
		Placebo	65	60 (92.3)	69.0 (19.1)	27	54.5	72.0	84.5	100	
	Week 42	Tezepelumab	66	65 (98.5)	69.2 (19.5)	9	52.0	72.0	85.0	100	
		Placebo	65	60 (92.3)	68.8 (18.4)	27	54.5	71.5	83.5	100	
	Week 43	Tezepelumab	66	65 (98.5)	69.0 (19.7)	13	53.0	72.0	84.0	100	
		Placebo	65	60 (92.3)	68.5 (18.6)	18	55.0	70.5	82.0	100	
	Week 44	Tezepelumab	66	65 (98.5)	68.6 (19.3)	21	50.0	71.0	83.0	100	
		Placebo	65	60 (92.3)	67.2 (18.8)	23	54.5	68.0	85.0	100	
	Week 45	Tezepelumab	66	66 (100.0)	68.9 (19.1)	22	52.0	72.0	85.0	100	
		Placebo	65	60 (92.3)	69.8 (17.7)	25	56.5	71.0	84.5	100	
	Week 46	Tezepelumab	66	66 (100.0)	68.8 (19.0)	14	53.0	72.0	84.0	100	
		Placebo	65	60 (92.3)	68.8 (17.9)	27	55.5	69.5	82.5	100	
	Week 47	Tezepelumab	66	66 (100.0)	69.3 (18.7)	19	52.0	73.0	83.0	100	
		Placebo	65	60 (92.3)	69.3 (17.4)	27	58.5	71.5	83.5	100	
	Week 48	Tezepelumab	66	66 (100.0)	70.0 (20.1)	9	53.0	74.0	85.0	100	
		Placebo	65	60 (92.3)	68.1 (18.8)	27	53.5	70.0	82.0	100	
	Week 49	Tezepelumab	66	66 (100.0)	69.5 (19.3)	19	53.0	73.0	86.0	100	
		Placebo	65	60 (92.3)	70.7 (18.1)	27	54.0	74.0	84.0	100	
	Week 50	Tezepelumab	66	66 (100.0)	70.6 (19.2)	19	56.0	73.5	87.0	100	
		Placebo	65	60 (92.3)	69.1 (18.7)	27	54.0	70.0	85.0	100	
	Week 51	Tezepelumab	66	66 (100.0)	69.5 (20.0)	19	53.0	73.0	86.0	100	
		Placebo	65	60 (92.3)	71.1 (18.3)	21	59.5	74.0	85.5	100	
	Week 52	Tezepelumab	66	66 (100.0)	69.6 (20.0)	19	53.0	73.0	85.0	100	
		Placebo	65	60 (92.3)	70.1 (19.4)	21	56.5	74.0	85.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMH0: Course of EQ-5D-VAS
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 1	Tezepelumab	66	58 (87.9)	4.2 (13.6)	-24	-6.0	2.5	14.0	43	0.01 [-0.36, 0.38]
		Placebo	65	55 (84.6)	4.1 (14.0)	-36	-2.0	3.0	10.0	38	
	Week 2	Tezepelumab	66	58 (87.9)	4.1 (15.8)	-53	-6.0	5.0	17.0	33	0.08 [-0.29, 0.45]
		Placebo	65	55 (84.6)	2.9 (15.8)	-26	-7.0	3.0	10.0	51	
	Week 3	Tezepelumab	66	58 (87.9)	7.0 (15.1)	-29	-2.0	8.0	17.0	37	-0.13 [-0.50, 0.24]
		Placebo	65	55 (84.6)	9.0 (15.4)	-16	-2.0	6.0	18.0	51	
	Week 4	Tezepelumab	66	58 (87.9)	8.2 (19.1)	-40	-5.0	11.0	20.0	47	0.07 [-0.30, 0.44]
		Placebo	65	55 (84.6)	7.0 (14.8)	-26	-4.0	7.0	17.0	51	
	Week 5	Tezepelumab	66	58 (87.9)	9.8 (18.7)	-37	-1.0	10.0	20.0	58	0.08 [-0.29, 0.45]
		Placebo	65	55 (84.6)	8.5 (15.7)	-28	-2.0	6.0	15.0	51	
	Week 6	Tezepelumab	66	58 (87.9)	10.0 (18.9)	-30	-3.0	10.0	23.0	51	0.04 [-0.33, 0.41]
		Placebo	65	55 (84.6)	9.3 (17.4)	-29	-2.0	6.0	22.0	52	
	Week 7	Tezepelumab	66	58 (87.9)	7.5 (18.6)	-39	-3.0	10.0	20.0	61	-0.17 [-0.54, 0.20]
		Placebo	65	55 (84.6)	10.6 (17.2)	-33	-1.0	8.0	23.0	60	
	Week 8	Tezepelumab	66	58 (87.9)	9.5 (20.0)	-59	-1.0	12.0	20.0	69	0.11 [-0.26, 0.48]
		Placebo	65	55 (84.6)	7.3 (19.2)	-36	-5.0	4.0	19.0	62	
	Week 9	Tezepelumab	66	58 (87.9)	9.6 (17.5)	-36	-2.0	10.5	21.0	63	0.07 [-0.29, 0.44]
		Placebo	65	55 (84.6)	8.3 (17.7)	-27	-4.0	5.0	19.0	52	
	Week 10	Tezepelumab	66	58 (87.9)	8.5 (19.9)	-45	-4.0	9.0	24.0	65	-0.11 [-0.48, 0.26]
		Placebo	65	55 (84.6)	10.6 (18.0)	-26	-1.0	8.0	21.0	59	
	Week 11	Tezepelumab	66	58 (87.9)	10.3 (20.7)	-41	-2.0	11.5	24.0	64	-0.00 [-0.37, 0.36]
		Placebo	65	55 (84.6)	10.4 (17.9)	-27	-2.0	8.0	22.0	62	
	Week 12	Tezepelumab	66	58 (87.9)	10.4 (19.4)	-34	-1.0	8.0	23.0	65	0.04 [-0.33, 0.41]
		Placebo	65	55 (84.6)	9.6 (19.0)	-34	-2.0	8.0	21.0	68	
	Week 13	Tezepelumab	66	58 (87.9)	10.6 (20.3)	-44	-3.0	10.0	23.0	63	-0.05 [-0.42, 0.32]
		Placebo	65	55 (84.6)	11.6 (17.1)	-26	-1.0	7.0	24.0	62	
	Week 14	Tezepelumab	66	58 (87.9)	11.1 (19.6)	-38	-1.0	12.0	25.0	56	0.02 [-0.35, 0.39]
		Placebo	65	55 (84.6)	10.8 (17.5)	-25	-2.0	8.0	24.0	67	
	Week 15	Tezepelumab	66	58 (87.9)	11.1 (20.5)	-51	-2.0	14.0	25.0	56	0.00 [-0.37, 0.37]
		Placebo	65	55 (84.6)	11.1 (16.3)	-35	-1.0	10.0	22.0	68	
	Week 16	Tezepelumab	66	58 (87.9)	10.0 (20.0)	-37	-2.0	6.5	25.0	65	0.09 [-0.28, 0.46]
		Placebo	65	55 (84.6)	8.4 (16.9)	-28	-2.0	6.0	16.0	58	
	Week 17	Tezepelumab	66	58 (87.9)	10.9 (20.6)	-41	-1.0	12.5	30.0	59	0.06 [-0.31, 0.43]
		Placebo	65	55 (84.6)	9.7 (18.2)	-40	-2.0	7.0	21.0	58	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMH0: Course of EQ-5D-VAS
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 18	Tezepelumab	66	58 (87.9)	10.1 (20.3)	-40	-2.0	8.5	25.0	58	0.09 [-0.28, 0.46]
		Placebo	65	55 (84.6)	8.4 (18.5)	-32	-3.0	8.0	22.0	60	
	Week 19	Tezepelumab	66	58 (87.9)	9.7 (19.3)	-38	-3.0	9.0	22.0	62	0.05 [-0.31, 0.42]
		Placebo	65	55 (84.6)	8.7 (17.3)	-32	-2.0	8.0	20.0	52	
	Week 20	Tezepelumab	66	58 (87.9)	10.9 (20.4)	-44	-4.0	12.0	25.0	51	0.11 [-0.26, 0.48]
		Placebo	65	55 (84.6)	8.9 (17.2)	-32	-4.0	8.0	21.0	51	
	Week 21	Tezepelumab	66	58 (87.9)	9.5 (19.4)	-38	-1.0	10.0	23.0	49	0.03 [-0.34, 0.39]
		Placebo	65	55 (84.6)	9.1 (17.1)	-31	-2.0	6.0	20.0	54	
	Week 22	Tezepelumab	66	58 (87.9)	9.9 (19.8)	-34	-5.0	10.0	25.0	48	0.04 [-0.32, 0.41]
		Placebo	65	55 (84.6)	9.1 (17.2)	-25	-2.0	7.0	22.0	58	
	Week 23	Tezepelumab	66	58 (87.9)	10.0 (20.1)	-34	-2.0	10.5	26.0	56	-0.01 [-0.38, 0.36]
		Placebo	65	55 (84.6)	10.2 (17.2)	-23	-2.0	8.0	23.0	62	
	Week 24	Tezepelumab	66	58 (87.9)	11.2 (20.0)	-38	-3.0	12.0	25.0	51	0.04 [-0.33, 0.41]
		Placebo	65	55 (84.6)	10.4 (18.9)	-65	-1.0	8.0	23.0	66	
	Week 25	Tezepelumab	66	58 (87.9)	9.9 (21.0)	-37	-3.0	7.0	25.0	57	0.00 [-0.36, 0.37]
		Placebo	65	55 (84.6)	9.8 (15.7)	-25	-1.0	8.0	20.0	62	
	Week 26	Tezepelumab	66	58 (87.9)	9.9 (21.0)	-43	-3.0	10.5	27.0	56	0.03 [-0.34, 0.40]
		Placebo	65	55 (84.6)	9.4 (17.5)	-53	-1.0	8.0	18.0	65	
	Week 27	Tezepelumab	66	58 (87.9)	8.9 (20.3)	-43	-7.0	6.0	23.0	56	-0.03 [-0.40, 0.34]
		Placebo	65	55 (84.6)	9.5 (15.3)	-25	-2.0	6.0	20.0	60	
	Week 28	Tezepelumab	66	58 (87.9)	10.7 (21.7)	-43	-3.0	10.0	28.0	60	0.03 [-0.33, 0.40]
		Placebo	65	55 (84.6)	10.1 (16.1)	-20	-2.0	8.0	20.0	65	
	Week 29	Tezepelumab	66	58 (87.9)	10.1 (20.3)	-43	-2.0	11.5	25.0	45	0.05 [-0.32, 0.42]
		Placebo	65	55 (84.6)	9.2 (16.1)	-28	-3.0	8.0	19.0	61	
	Week 30	Tezepelumab	66	58 (87.9)	9.6 (19.7)	-43	-3.0	10.5	23.0	44	0.04 [-0.33, 0.40]
		Placebo	65	55 (84.6)	9.0 (16.3)	-22	-3.0	8.0	23.0	47	
	Week 31	Tezepelumab	66	58 (87.9)	9.8 (19.2)	-43	-4.0	11.5	25.0	44	-0.06 [-0.43, 0.31]
		Placebo	65	55 (84.6)	10.9 (15.9)	-20	-2.0	11.0	23.0	57	
	Week 32	Tezepelumab	66	58 (87.9)	11.3 (21.9)	-43	-3.0	12.0	29.0	68	0.09 [-0.28, 0.46]
		Placebo	65	55 (84.6)	9.6 (16.6)	-30	-2.0	8.0	21.0	53	
	Week 33	Tezepelumab	66	58 (87.9)	11.2 (21.0)	-43	-4.0	12.0	27.0	60	0.04 [-0.33, 0.41]
		Placebo	65	55 (84.6)	10.4 (16.9)	-25	-2.0	8.0	23.0	64	
	Week 34	Tezepelumab	66	58 (87.9)	11.3 (21.8)	-43	-1.0	12.5	30.0	58	-0.01 [-0.38, 0.36]
		Placebo	65	55 (84.6)	11.5 (16.9)	-24	-1.0	8.0	23.0	61	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMH0: Course of EQ-5D-VAS
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 35	Tezepelumab	66	58 (87.9)	11.2 (21.5)	-43	-3.0	12.0	27.0	55	0.11 [-0.25, 0.48]
		Placebo	65	55 (84.6)	9.1 (14.9)	-21	-2.0	8.0	20.0	44	
	Week 36	Tezepelumab	66	58 (87.9)	11.3 (21.6)	-43	-4.0	16.0	26.0	67	0.13 [-0.24, 0.50]
		Placebo	65	55 (84.6)	8.9 (14.8)	-21	-3.0	7.0	18.0	42	
	Week 37	Tezepelumab	66	58 (87.9)	11.2 (22.4)	-43	-7.0	13.5	26.0	68	0.12 [-0.25, 0.49]
		Placebo	65	55 (84.6)	8.9 (16.8)	-35	-2.0	6.0	23.0	43	
	Week 38	Tezepelumab	66	58 (87.9)	10.3 (21.8)	-43	-5.0	10.5	25.0	61	-0.02 [-0.39, 0.35]
		Placebo	65	55 (84.6)	10.7 (16.3)	-26	-2.0	7.0	21.0	57	
	Week 39	Tezepelumab	66	58 (87.9)	10.1 (21.1)	-43	-2.0	7.5	25.0	57	-0.04 [-0.41, 0.33]
		Placebo	65	55 (84.6)	10.9 (17.2)	-25	-2.0	7.0	24.0	65	
	Week 40	Tezepelumab	66	58 (87.9)	11.7 (20.8)	-43	-3.0	14.0	26.0	58	0.14 [-0.23, 0.51]
		Placebo	65	55 (84.6)	9.1 (17.3)	-25	-3.0	5.0	21.0	55	
	Week 41	Tezepelumab	66	58 (87.9)	10.9 (22.3)	-43	-6.0	14.5	26.0	58	0.03 [-0.34, 0.40]
		Placebo	65	55 (84.6)	10.3 (16.8)	-20	-2.0	6.0	22.0	56	
	Week 42	Tezepelumab	66	58 (87.9)	11.0 (21.5)	-43	-5.0	14.0	26.0	53	0.05 [-0.32, 0.42]
		Placebo	65	55 (84.6)	10.1 (16.8)	-30	-2.0	7.0	22.0	54	
	Week 43	Tezepelumab	66	58 (87.9)	11.2 (21.1)	-43	-3.0	15.5	28.0	55	0.09 [-0.28, 0.46]
		Placebo	65	55 (84.6)	9.5 (16.1)	-29	-2.0	6.0	20.0	57	
	Week 44	Tezepelumab	66	58 (87.9)	10.7 (20.8)	-43	-7.0	13.5	29.0	51	0.12 [-0.25, 0.49]
		Placebo	65	55 (84.6)	8.4 (17.4)	-24	-4.0	6.0	20.0	58	
	Week 45	Tezepelumab	66	58 (87.9)	10.7 (20.8)	-43	-4.0	15.0	26.0	60	-0.02 [-0.39, 0.35]
		Placebo	65	55 (84.6)	11.1 (16.8)	-22	-3.0	8.0	20.0	58	
	Week 46	Tezepelumab	66	58 (87.9)	11.0 (21.5)	-43	-6.0	15.5	26.0	66	0.05 [-0.32, 0.42]
		Placebo	65	55 (84.6)	10.0 (17.1)	-18	-3.0	7.0	19.0	58	
	Week 47	Tezepelumab	66	58 (87.9)	10.8 (21.4)	-43	-9.0	16.5	25.0	59	0.02 [-0.35, 0.39]
		Placebo	65	55 (84.6)	10.4 (17.2)	-18	-2.0	6.0	23.0	58	
	Week 48	Tezepelumab	66	58 (87.9)	11.9 (22.7)	-43	-7.0	18.0	29.0	65	0.12 [-0.25, 0.49]
		Placebo	65	55 (84.6)	9.5 (16.2)	-19	-2.0	8.0	16.0	58	
	Week 49	Tezepelumab	66	58 (87.9)	11.1 (21.8)	-43	-6.0	17.5	25.0	65	-0.04 [-0.41, 0.33]
		Placebo	65	55 (84.6)	11.9 (17.0)	-16	-2.0	9.0	23.0	58	
	Week 50	Tezepelumab	66	58 (87.9)	11.6 (21.1)	-43	-2.0	14.0	27.0	58	0.06 [-0.31, 0.43]
		Placebo	65	55 (84.6)	10.4 (19.3)	-23	-4.0	8.0	23.0	60	
	Week 51	Tezepelumab	66	58 (87.9)	10.9 (21.6)	-43	-5.0	16.0	25.0	58	-0.08 [-0.45, 0.29]
		Placebo	65	55 (84.6)	12.5 (18.0)	-26	-2.0	10.0	27.0	58	
	Week 52	Tezepelumab	66	58 (87.9)	11.1 (21.4)	-43	-5.0	17.0	25.0	58	-0.02 [-0.38, 0.35]
		Placebo	65	55 (84.6)	11.5 (18.4)	-26	-3.0	10.0	23.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	66	58 (87.9)	4.2 (2.2)	(-0.1, 8.5)	-0.3 (3.1)	(-6.5, 5.9)	0.925
	Placebo	65	55 (84.6)	4.5 (2.3)	(0.1, 9.0)			
Week 2	Tezepelumab	66	58 (87.9)	4.1 (2.2)	(-0.2, 8.4)	0.9 (3.1)	(-5.3, 7.0)	0.786
	Placebo	65	55 (84.6)	3.3 (2.3)	(-1.2, 7.7)			
Week 3	Tezepelumab	66	56 (84.8)	7.1 (2.2)	(2.8, 11.5)	-2.9 (3.2)	(-9.2, 3.3)	0.360
	Placebo	65	49 (75.4)	10.0 (2.3)	(5.5, 14.5)			
Week 4	Tezepelumab	66	54 (81.8)	8.3 (2.2)	(4.0, 12.7)	0.8 (3.2)	(-5.4, 7.1)	0.793
	Placebo	65	50 (76.9)	7.5 (2.3)	(3.0, 12.0)			
Week 5	Tezepelumab	66	54 (81.8)	9.9 (2.2)	(5.5, 14.2)	0.8 (3.2)	(-5.5, 7.1)	0.805
	Placebo	65	49 (75.4)	9.1 (2.3)	(4.5, 13.6)			
Week 6	Tezepelumab	66	54 (81.8)	10.2 (2.2)	(5.9, 14.6)	0.3 (3.2)	(-6.0, 6.7)	0.916
	Placebo	65	48 (73.8)	9.9 (2.3)	(5.3, 14.5)			
Week 7	Tezepelumab	66	54 (81.8)	7.7 (2.2)	(3.3, 12.0)	-3.7 (3.3)	(-10.1, 2.7)	0.252
	Placebo	65	49 (75.4)	11.4 (2.4)	(6.7, 16.0)			
Week 8	Tezepelumab	66	53 (80.3)	9.9 (2.2)	(5.5, 14.3)	2.2 (3.3)	(-4.2, 8.6)	0.493
	Placebo	65	49 (75.4)	7.7 (2.4)	(3.0, 12.3)			
Week 9	Tezepelumab	66	52 (78.8)	10.2 (2.3)	(5.8, 14.7)	1.4 (3.3)	(-5.1, 7.8)	0.674
	Placebo	65	48 (73.8)	8.8 (2.4)	(4.2, 13.5)			
Week 10	Tezepelumab	66	51 (77.3)	9.0 (2.3)	(4.6, 13.5)	-2.2 (3.3)	(-8.7, 4.2)	0.499
	Placebo	65	48 (73.8)	11.3 (2.4)	(6.6, 15.9)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	66	50 (75.8)	11.1 (2.3)	(6.6, 15.6)	0.0 (3.3)	(-6.5, 6.6)	0.992
	Placebo	65	46 (70.8)	11.1 (2.4)	(6.4, 15.8)			
Week 12	Tezepelumab	66	50 (75.8)	11.3 (2.3)	(6.8, 15.9)	1.2 (3.3)	(-5.4, 7.7)	0.728
	Placebo	65	46 (70.8)	10.2 (2.4)	(5.4, 14.9)			
Week 13	Tezepelumab	66	51 (77.3)	11.5 (2.3)	(7.0, 16.0)	-1.0 (3.3)	(-7.5, 5.6)	0.771
	Placebo	65	46 (70.8)	12.5 (2.4)	(7.7, 17.3)			
Week 14	Tezepelumab	66	51 (77.3)	12.1 (2.3)	(7.6, 16.6)	1.0 (3.4)	(-5.5, 7.6)	0.756
	Placebo	65	46 (70.8)	11.1 (2.4)	(6.3, 15.8)			
Week 15	Tezepelumab	66	50 (75.8)	12.0 (2.3)	(7.5, 16.6)	1.0 (3.4)	(-5.6, 7.6)	0.768
	Placebo	65	46 (70.8)	11.1 (2.4)	(6.3, 15.8)			
Week 16	Tezepelumab	66	50 (75.8)	11.0 (2.3)	(6.4, 15.6)	2.3 (3.4)	(-4.3, 8.9)	0.490
	Placebo	65	46 (70.8)	8.7 (2.4)	(3.9, 13.4)			
Week 17	Tezepelumab	66	51 (77.3)	12.0 (2.3)	(7.4, 16.5)	1.7 (3.4)	(-4.9, 8.3)	0.616
	Placebo	65	43 (66.2)	10.3 (2.5)	(5.4, 15.1)			
Week 18	Tezepelumab	66	51 (77.3)	11.1 (2.3)	(6.5, 15.7)	2.3 (3.4)	(-4.4, 8.9)	0.503
	Placebo	65	45 (69.2)	8.8 (2.5)	(4.0, 13.6)			
Week 19	Tezepelumab	66	50 (75.8)	10.4 (2.3)	(5.8, 15.0)	1.2 (3.4)	(-5.5, 7.8)	0.731
	Placebo	65	45 (69.2)	9.2 (2.5)	(4.4, 14.1)			
Week 20	Tezepelumab	66	50 (75.8)	11.7 (2.3)	(7.1, 16.3)	2.0 (3.4)	(-4.6, 8.7)	0.549
	Placebo	65	45 (69.2)	9.7 (2.5)	(4.8, 14.5)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	66	51 (77.3)	10.4 (2.3)	(5.8, 15.0)	0.7 (3.4)	(-5.9, 7.4)	0.827
	Placebo	65	46 (70.8)	9.7 (2.5)	(4.9, 14.5)			
Week 22	Tezepelumab	66	50 (75.8)	10.9 (2.3)	(6.3, 15.5)	1.2 (3.4)	(-5.5, 7.8)	0.735
	Placebo	65	45 (69.2)	9.8 (2.5)	(5.0, 14.6)			
Week 23	Tezepelumab	66	49 (74.2)	11.1 (2.4)	(6.5, 15.8)	-0.0 (3.4)	(-6.7, 6.6)	0.989
	Placebo	65	43 (66.2)	11.2 (2.5)	(6.3, 16.0)			
Week 24	Tezepelumab	66	50 (75.8)	12.6 (2.4)	(7.9, 17.2)	0.5 (3.4)	(-6.2, 7.1)	0.894
	Placebo	65	45 (69.2)	12.1 (2.5)	(7.3, 16.9)			
Week 25	Tezepelumab	66	50 (75.8)	11.1 (2.4)	(6.4, 15.7)	-0.1 (3.4)	(-6.8, 6.6)	0.982
	Placebo	65	44 (67.7)	11.1 (2.5)	(6.3, 16.0)			
Week 26	Tezepelumab	66	50 (75.8)	11.1 (2.4)	(6.5, 15.8)	0.2 (3.4)	(-6.5, 7.0)	0.942
	Placebo	65	44 (67.7)	10.9 (2.5)	(6.0, 15.8)			
Week 27	Tezepelumab	66	49 (74.2)	10.1 (2.4)	(5.5, 14.8)	-1.0 (3.4)	(-7.7, 5.8)	0.776
	Placebo	65	44 (67.7)	11.1 (2.5)	(6.2, 16.0)			
Week 28	Tezepelumab	66	47 (71.2)	12.5 (2.4)	(7.8, 17.2)	0.7 (3.5)	(-6.1, 7.5)	0.844
	Placebo	65	44 (67.7)	11.8 (2.5)	(7.0, 16.7)			
Week 29	Tezepelumab	66	48 (72.7)	11.7 (2.4)	(7.1, 16.4)	1.0 (3.5)	(-5.8, 7.8)	0.783
	Placebo	65	42 (64.6)	10.8 (2.5)	(5.8, 15.7)			
Week 30	Tezepelumab	66	48 (72.7)	11.4 (2.4)	(6.7, 16.0)	0.9 (3.5)	(-5.9, 7.7)	0.797
	Placebo	65	42 (64.6)	10.5 (2.5)	(5.5, 15.4)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	66	48 (72.7)	11.9 (2.4)	(7.2, 16.6)	-1.2 (3.5)	(-8.0, 5.6)	0.731
	Placebo	65	42 (64.6)	13.1 (2.5)	(8.1, 18.0)			
Week 32	Tezepelumab	66	49 (74.2)	13.4 (2.4)	(8.7, 18.1)	2.0 (3.5)	(-4.8, 8.8)	0.563
	Placebo	65	43 (66.2)	11.4 (2.5)	(6.5, 16.3)			
Week 33	Tezepelumab	66	49 (74.2)	13.4 (2.4)	(8.7, 18.1)	1.2 (3.5)	(-5.6, 8.1)	0.719
	Placebo	65	40 (61.5)	12.1 (2.5)	(7.2, 17.1)			
Week 34	Tezepelumab	66	49 (74.2)	13.5 (2.4)	(8.8, 18.2)	-0.2 (3.5)	(-7.0, 6.6)	0.954
	Placebo	65	42 (64.6)	13.7 (2.5)	(8.8, 18.6)			
Week 35	Tezepelumab	66	49 (74.2)	13.4 (2.4)	(8.7, 18.1)	2.9 (3.4)	(-3.8, 9.7)	0.397
	Placebo	65	44 (67.7)	10.5 (2.5)	(5.7, 15.4)			
Week 36	Tezepelumab	66	49 (74.2)	13.6 (2.4)	(8.9, 18.3)	3.9 (3.4)	(-2.9, 10.6)	0.259
	Placebo	65	44 (67.7)	9.7 (2.5)	(4.8, 14.6)			
Week 37	Tezepelumab	66	49 (74.2)	13.5 (2.4)	(8.8, 18.2)	3.2 (3.4)	(-3.6, 10.0)	0.353
	Placebo	65	43 (66.2)	10.3 (2.5)	(5.4, 15.1)			
Week 38	Tezepelumab	66	48 (72.7)	12.4 (2.4)	(7.7, 17.1)	-0.3 (3.4)	(-7.1, 6.4)	0.922
	Placebo	65	44 (67.7)	12.7 (2.5)	(7.9, 17.6)			
Week 39	Tezepelumab	66	49 (74.2)	12.2 (2.4)	(7.5, 16.9)	-0.6 (3.4)	(-7.4, 6.1)	0.857
	Placebo	65	42 (64.6)	12.8 (2.5)	(7.9, 17.7)			
Week 40	Tezepelumab	66	48 (72.7)	14.1 (2.4)	(9.4, 18.8)	3.6 (3.4)	(-3.1, 10.4)	0.292
	Placebo	65	45 (69.2)	10.5 (2.5)	(5.7, 15.3)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	66	47 (71.2)	13.1 (2.4)	(8.4, 17.8)	0.7 (3.4)	(-6.1, 7.4)	0.848
	Placebo	65	44 (67.7)	12.4 (2.5)	(7.6, 17.3)			
Week 42	Tezepelumab	66	48 (72.7)	13.2 (2.4)	(8.5, 17.9)	1.8 (3.5)	(-4.9, 8.6)	0.596
	Placebo	65	43 (66.2)	11.4 (2.5)	(6.5, 16.2)			
Week 43	Tezepelumab	66	47 (71.2)	13.5 (2.4)	(8.7, 18.2)	2.3 (3.5)	(-4.4, 9.1)	0.498
	Placebo	65	43 (66.2)	11.1 (2.5)	(6.2, 16.0)			
Week 44	Tezepelumab	66	47 (71.2)	12.8 (2.4)	(8.0, 17.5)	3.4 (3.5)	(-3.4, 10.1)	0.332
	Placebo	65	44 (67.7)	9.4 (2.5)	(4.6, 14.3)			
Week 45	Tezepelumab	66	48 (72.7)	12.9 (2.4)	(8.1, 17.6)	-0.1 (3.5)	(-6.8, 6.7)	0.988
	Placebo	65	45 (69.2)	12.9 (2.5)	(8.1, 17.8)			
Week 46	Tezepelumab	66	48 (72.7)	13.1 (2.4)	(8.4, 17.9)	1.6 (3.5)	(-5.2, 8.4)	0.639
	Placebo	65	45 (69.2)	11.5 (2.5)	(6.7, 16.4)			
Week 47	Tezepelumab	66	48 (72.7)	12.9 (2.4)	(8.1, 17.6)	0.7 (3.5)	(-6.1, 7.5)	0.831
	Placebo	65	43 (66.2)	12.1 (2.5)	(7.3, 17.0)			
Week 48	Tezepelumab	66	46 (69.7)	14.2 (2.4)	(9.5, 19.0)	3.5 (3.5)	(-3.4, 10.3)	0.320
	Placebo	65	44 (67.7)	10.8 (2.5)	(5.9, 15.6)			
Week 49	Tezepelumab	66	48 (72.7)	13.2 (2.4)	(8.5, 17.9)	-0.6 (3.5)	(-7.4, 6.2)	0.860
	Placebo	65	44 (67.7)	13.8 (2.5)	(8.9, 18.7)			
Week 50	Tezepelumab	66	46 (69.7)	14.2 (2.4)	(9.4, 18.9)	2.1 (3.5)	(-4.7, 8.9)	0.553
	Placebo	65	45 (69.2)	12.1 (2.5)	(7.3, 16.9)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTL

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	66	43 (65.2)	13.3 (2.5)	(8.5, 18.2)	-1.4 (3.5)	(-8.2, 5.4)	0.689
	Placebo	65	44 (67.7)	14.7 (2.5)	(9.9, 19.6)			
Week 52	Tezepelumab	66	14 (21.2)	13.9 (3.2)	(7.7, 20.2)	3.4 (4.5)	(-5.4, 12.1)	0.451
	Placebo	65	15 (23.1)	10.6 (3.1)	(4.4, 16.7)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Figure PF2VSC_ILMG0: Course of EQ-5D-VAS
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
VAS = visual analogue scale.
Source table: PT2VSC_ILMH0
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	19	16 (84.2)	55.4 (15.2)	29	43.5	52.5	68.0	80	
			Placebo	20	17 (85.0)	56.3 (12.9)	29	50.0	54.0	65.0	85	
		Week 4	Tezepelumab	19	18 (94.7)	67.6 (18.4)	40	50.0	69.0	86.0	94	
			Placebo	20	18 (90.0)	60.3 (20.5)	17	48.0	61.5	75.0	92	
		Week 8	Tezepelumab	19	18 (94.7)	68.2 (15.8)	40	60.0	70.0	77.0	96	
			Placebo	20	18 (90.0)	58.3 (17.7)	19	50.0	53.0	69.0	93	
		Week 12	Tezepelumab	19	18 (94.7)	69.9 (15.1)	41	60.0	70.0	80.0	98	
			Placebo	20	18 (90.0)	61.8 (19.7)	20	51.0	61.5	77.0	93	
		Week 20	Tezepelumab	19	18 (94.7)	68.8 (17.4)	25	64.0	67.0	79.0	96	
			Placebo	20	18 (90.0)	58.1 (20.1)	20	48.0	57.5	72.0	94	
		Week 28	Tezepelumab	19	19 (100.0)	67.5 (18.3)	29	52.0	68.0	82.0	94	
			Placebo	20	19 (95.0)	62.7 (19.4)	27	48.0	67.0	79.0	93	
		Week 40	Tezepelumab	19	19 (100.0)	70.4 (17.5)	40	56.0	74.0	82.0	98	
			Placebo	20	19 (95.0)	61.3 (21.3)	20	48.0	58.0	80.0	95	
		Week 52	Tezepelumab	19	19 (100.0)	69.6 (16.2)	35	58.0	68.0	83.0	97	
			Placebo	20	19 (95.0)	63.6 (19.0)	27	48.0	70.0	77.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	19	16 (84.2)	14.4 (18.9)	-20	2.5	14.0	28.0	47	0.59 [-0.11, 1.28]
			Placebo	20	17 (85.0)	4.8 (13.4)	-22	-5.0	4.0	17.0	25	
		Week 8	Tezepelumab	19	16 (84.2)	12.7 (14.9)	-12	1.0	12.5	23.0	38	0.76 [0.05, 1.47]
			Placebo	20	17 (85.0)	2.4 (12.2)	-14	-8.0	1.0	9.0	27	
		Week 12	Tezepelumab	19	16 (84.2)	15.1 (15.9)	-12	2.5	11.0	31.5	41	0.61 [-0.09, 1.31]
			Placebo	20	17 (85.0)	5.8 (14.8)	-25	-1.0	4.0	16.0	32	
		Week 20	Tezepelumab	19	16 (84.2)	14.5 (17.9)	-15	2.0	15.0	28.0	41	0.76 [0.05, 1.47]
			Placebo	20	17 (85.0)	1.7 (15.7)	-32	-5.0	3.0	12.0	30	
		Week 28	Tezepelumab	19	16 (84.2)	13.6 (19.9)	-13	-4.0	10.5	32.5	50	0.57 [-0.13, 1.26]
			Placebo	20	17 (85.0)	4.1 (13.3)	-16	-5.0	3.0	13.0	29	
		Week 40	Tezepelumab	19	16 (84.2)	16.9 (19.2)	-14	2.5	18.5	34.0	40	0.79 [0.08, 1.50]
			Placebo	20	17 (85.0)	3.4 (14.7)	-25	-3.0	4.0	14.0	30	
		Week 52	Tezepelumab	19	16 (84.2)	16.2 (17.9)	-13	3.0	20.5	27.5	45	0.70 [-0.00, 1.41]
			Placebo	20	17 (85.0)	5.3 (13.0)	-15	-2.0	2.0	16.0	29	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	47	42 (89.4)	58.9 (18.2)	20	49.0	53.0	72.0	100	
			Placebo	45	38 (84.4)	60.0 (14.9)	32	50.0	56.5	70.0	96	
		Week 4	Tezepelumab	47	45 (95.7)	65.8 (19.9)	14	50.0	66.0	81.0	100	
			Placebo	45	40 (88.9)	67.8 (15.7)	38	57.0	69.0	81.5	99	
		Week 8	Tezepelumab	47	45 (95.7)	68.2 (21.0)	20	53.0	70.0	88.0	100	
			Placebo	45	41 (91.1)	69.4 (20.1)	14	56.0	69.0	87.0	100	
		Week 12	Tezepelumab	47	45 (95.7)	68.7 (20.8)	26	51.0	72.0	87.0	100	
			Placebo	45	41 (91.1)	71.2 (17.8)	34	60.0	70.0	88.0	100	
		Week 20	Tezepelumab	47	46 (97.9)	69.2 (20.4)	18	53.0	74.0	85.0	100	
			Placebo	45	41 (91.1)	71.2 (18.5)	22	61.0	69.0	86.0	100	
		Week 28	Tezepelumab	47	46 (97.9)	69.7 (20.1)	8	53.0	74.0	85.0	100	
			Placebo	45	41 (91.1)	72.3 (18.1)	30	61.0	74.0	86.0	100	
		Week 40	Tezepelumab	47	46 (97.9)	70.2 (20.0)	18	52.0	75.0	85.0	100	
			Placebo	45	41 (91.1)	70.6 (17.6)	37	57.0	71.0	87.0	100	
		Week 52	Tezepelumab	47	47 (100.0)	69.6 (21.5)	19	52.0	75.0	88.0	100	
			Placebo	45	41 (91.1)	73.1 (19.0)	21	61.0	75.0	87.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	47	42 (89.4)	5.8 (18.8)	-40	-6.0	10.0	19.0	36	-0.13 [-0.57, 0.31]
			Placebo	45	38 (84.4)	8.0 (15.4)	-26	-2.0	7.0	16.0	51	
		Week 8	Tezepelumab	47	42 (89.4)	8.2 (21.7)	-59	-1.0	11.5	20.0	69	-0.06 [-0.50, 0.38]
			Placebo	45	38 (84.4)	9.5 (21.4)	-36	-3.0	6.0	23.0	62	
		Week 12	Tezepelumab	47	42 (89.4)	8.6 (20.5)	-34	-2.0	7.0	22.0	65	-0.13 [-0.57, 0.31]
			Placebo	45	38 (84.4)	11.4 (20.6)	-34	-2.0	8.0	25.0	68	
		Week 20	Tezepelumab	47	42 (89.4)	9.5 (21.3)	-44	-7.0	10.0	25.0	51	-0.13 [-0.57, 0.31]
			Placebo	45	38 (84.4)	12.1 (17.0)	-25	-2.0	10.0	23.0	51	
		Week 28	Tezepelumab	47	42 (89.4)	9.6 (22.4)	-43	-3.0	8.5	25.0	60	-0.16 [-0.60, 0.28]
			Placebo	45	38 (84.4)	12.8 (16.7)	-20	2.0	9.0	24.0	65	
		Week 40	Tezepelumab	47	42 (89.4)	9.8 (21.3)	-43	-5.0	11.5	25.0	58	-0.09 [-0.53, 0.35]
			Placebo	45	38 (84.4)	11.6 (17.9)	-23	-2.0	9.5	23.0	55	
		Week 52	Tezepelumab	47	42 (89.4)	9.2 (22.5)	-43	-10.0	12.5	25.0	58	-0.23 [-0.67, 0.21]
			Placebo	45	38 (84.4)	14.2 (19.9)	-26	-3.0	11.5	27.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	58.4 (18.3)	20	47.0	53.5	72.0	100	
			Placebo	55	48 (87.3)	59.5 (15.0)	29	49.5	57.5	70.0	96	
		Week 4	Tezepelumab	57	55 (96.5)	66.8 (19.0)	14	50.0	66.0	84.0	100	
			Placebo	55	50 (90.9)	66.7 (18.2)	17	54.0	69.0	81.0	99	
		Week 8	Tezepelumab	57	55 (96.5)	69.2 (20.0)	20	55.0	71.0	88.0	100	
			Placebo	55	51 (92.7)	68.3 (19.1)	19	51.0	65.0	87.0	100	
		Week 12	Tezepelumab	57	55 (96.5)	70.9 (19.1)	26	58.0	72.0	87.0	100	
			Placebo	55	51 (92.7)	69.6 (19.3)	20	57.0	70.0	88.0	100	
		Week 20	Tezepelumab	57	55 (96.5)	71.2 (19.5)	18	62.0	75.0	86.0	100	
			Placebo	55	51 (92.7)	68.7 (20.1)	20	55.0	69.0	85.0	100	
		Week 28	Tezepelumab	57	56 (98.2)	70.5 (20.0)	8	56.0	75.0	87.0	100	
			Placebo	55	51 (92.7)	69.9 (19.1)	27	53.0	70.0	86.0	100	
		Week 40	Tezepelumab	57	56 (98.2)	71.2 (19.4)	18	57.0	75.0	84.5	100	
			Placebo	55	51 (92.7)	68.7 (19.5)	20	53.0	71.0	86.0	100	
		Week 52	Tezepelumab	57	57 (100.0)	71.0 (19.8)	19	58.0	75.0	85.0	100	
			Placebo	55	51 (92.7)	71.3 (19.3)	21	60.0	75.0	86.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	57	50 (87.7)	8.1 (18.7)	-40	-4.0	11.0	26.0	40	0.05 [-0.35, 0.44]
			Placebo	55	48 (87.3)	7.3 (15.1)	-26	-1.5	7.0	16.5	51	
		Week 8	Tezepelumab	57	50 (87.7)	9.9 (20.7)	-59	-1.0	12.5	21.0	69	0.05 [-0.34, 0.45]
			Placebo	55	48 (87.3)	8.8 (18.7)	-24	-3.5	6.0	19.5	62	
		Week 12	Tezepelumab	57	50 (87.7)	11.8 (19.3)	-34	1.0	11.0	25.0	65	0.08 [-0.31, 0.48]
			Placebo	55	48 (87.3)	10.1 (19.8)	-34	-3.0	8.0	21.5	68	
		Week 20	Tezepelumab	57	50 (87.7)	12.8 (20.8)	-44	-2.0	13.0	26.0	51	0.16 [-0.24, 0.55]
			Placebo	55	48 (87.3)	9.8 (17.4)	-32	-3.0	9.0	21.0	51	
		Week 28	Tezepelumab	57	50 (87.7)	11.8 (22.6)	-43	-3.0	12.5	31.0	60	0.06 [-0.34, 0.46]
			Placebo	55	48 (87.3)	10.6 (16.3)	-16	-1.5	8.5	21.5	65	
		Week 40	Tezepelumab	57	50 (87.7)	12.6 (21.5)	-43	-3.0	17.0	30.0	58	0.14 [-0.26, 0.53]
			Placebo	55	48 (87.3)	9.9 (17.8)	-25	-2.5	8.0	21.5	55	
		Week 52	Tezepelumab	57	50 (87.7)	12.5 (21.8)	-43	-4.0	18.0	28.0	58	-0.01 [-0.40, 0.39]
			Placebo	55	48 (87.3)	12.6 (18.8)	-26	-2.0	11.0	23.5	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	54.6 (9.9)	39	50.0	51.5	62.0	71	
			Placebo	10	7 (70.0)	54.7 (7.3)	50	50.0	51.0	60.0	69	
		Week 4	Tezepelumab	9	8 (88.9)	63.4 (22.9)	21	50.0	66.0	82.5	89	
			Placebo	10	8 (80.0)	58.1 (10.0)	45	50.0	59.0	63.5	75	
		Week 8	Tezepelumab	9	8 (88.9)	61.6 (14.6)	39	54.0	57.5	73.5	84	
			Placebo	10	8 (80.0)	51.6 (20.4)	14	40.5	58.0	62.5	77	
		Week 12	Tezepelumab	9	8 (88.9)	56.4 (15.1)	38	44.5	53.5	68.5	80	
			Placebo	10	8 (80.0)	60.4 (12.8)	34	57.5	61.0	67.5	77	
		Week 20	Tezepelumab	9	9 (100.0)	56.0 (14.1)	39	48.0	53.0	64.0	79	
			Placebo	10	8 (80.0)	57.9 (15.6)	30	48.0	61.5	67.0	80	
		Week 28	Tezepelumab	9	9 (100.0)	60.1 (13.8)	39	50.0	60.0	71.0	82	
			Placebo	10	9 (90.0)	65.8 (18.5)	30	57.0	68.0	77.0	92	
		Week 40	Tezepelumab	9	9 (100.0)	64.4 (17.8)	39	51.0	65.0	77.0	93	
			Placebo	10	9 (90.0)	61.8 (16.9)	43	54.0	57.0	67.0	95	
		Week 52	Tezepelumab	9	9 (100.0)	61.2 (20.4)	37	52.0	53.0	69.0	93	
			Placebo	10	9 (90.0)	63.1 (19.3)	38	47.0	64.0	75.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	8.8 (22.9)	-30	-6.0	14.0	18.5	47	0.19 [-0.83, 1.21]
			Placebo	10	7 (70.0)	5.1 (12.9)	-9	-6.0	6.0	17.0	25	
		Week 8	Tezepelumab	9	8 (88.9)	7.0 (16.1)	-10	-5.5	3.5	16.0	38	0.55 [-0.49, 1.59]
			Placebo	10	7 (70.0)	-3.1 (20.8)	-36	-22.0	0.0	11.0	27	
		Week 12	Tezepelumab	9	8 (88.9)	1.8 (19.0)	-23	-8.5	-1.0	7.5	41	-0.26 [-1.28, 0.75]
			Placebo	10	7 (70.0)	6.1 (13.2)	-17	2.0	5.0	12.0	27	
		Week 20	Tezepelumab	9	8 (88.9)	-1.0 (12.8)	-13	-10.5	-4.0	4.5	25	-0.27 [-1.29, 0.75]
			Placebo	10	7 (70.0)	2.9 (15.6)	-20	-8.0	3.0	10.0	30	
		Week 28	Tezepelumab	9	8 (88.9)	3.9 (14.1)	-13	-5.5	1.5	10.0	32	-0.16 [-1.17, 0.86]
			Placebo	10	7 (70.0)	6.1 (15.0)	-20	-3.0	8.0	14.0	29	
		Week 40	Tezepelumab	9	8 (88.9)	6.3 (16.2)	-11	-5.5	2.0	15.0	38	0.19 [-0.82, 1.21]
			Placebo	10	7 (70.0)	3.4 (12.6)	-7	-7.0	2.0	4.0	30	
		Week 52	Tezepelumab	9	8 (88.9)	2.6 (17.5)	-24	-10.5	1.0	19.5	25	-0.05 [-1.07, 0.96]
			Placebo	10	7 (70.0)	3.4 (13.8)	-13	-6.0	1.0	13.0	28	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS	Treatment		N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	44	39 (88.6)	56.4 (15.8)	29	49.0	52.0	67.0	94	
			Placebo	45	38 (84.4)	60.1 (14.2)	29	50.0	56.0	70.0	96	
		Week 4	Tezepelumab	44	42 (95.5)	65.6 (18.7)	21	50.0	66.0	79.0	97	
			Placebo	45	39 (86.7)	66.6 (17.2)	17	54.0	69.0	76.0	99	
		Week 8	Tezepelumab	44	42 (95.5)	66.7 (18.2)	20	55.0	69.0	82.0	96	
			Placebo	45	40 (88.9)	65.9 (21.3)	14	52.0	62.5	86.0	100	
		Week 12	Tezepelumab	44	42 (95.5)	66.3 (18.7)	26	53.0	68.0	81.0	98	
			Placebo	45	40 (88.9)	68.9 (17.0)	30	60.0	69.0	85.0	100	
		Week 20	Tezepelumab	44	43 (97.7)	67.1 (18.1)	18	54.0	68.0	80.0	98	
			Placebo	45	40 (88.9)	69.2 (17.5)	27	58.5	68.5	84.5	100	
		Week 28	Tezepelumab	44	44 (100.0)	66.8 (19.7)	8	52.5	69.5	82.0	98	
			Placebo	45	41 (91.1)	70.7 (17.6)	27	59.0	71.0	84.0	100	
		Week 40	Tezepelumab	44	44 (100.0)	68.6 (19.2)	18	51.5	72.0	83.0	98	
			Placebo	45	41 (91.1)	69.3 (18.2)	27	55.0	71.0	85.0	100	
		Week 52	Tezepelumab	44	44 (100.0)	67.0 (20.2)	19	52.5	69.0	83.0	99	
			Placebo	45	41 (91.1)	70.9 (18.3)	27	59.0	74.0	85.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	44	39 (88.6)	9.6 (17.6)	-30	-4.0	12.0	19.0	47	0.22 [-0.23, 0.66]
			Placebo	45	38 (84.4)	6.2 (13.8)	-26	-5.0	6.5	17.0	41	
		Week 8	Tezepelumab	44	39 (88.6)	9.6 (15.1)	-29	-1.0	12.0	20.0	38	0.26 [-0.19, 0.71]
			Placebo	45	38 (84.4)	5.4 (17.9)	-36	-5.0	2.5	19.0	41	
		Week 12	Tezepelumab	44	39 (88.6)	9.6 (16.9)	-23	-1.0	7.0	22.0	41	0.05 [-0.39, 0.50]
			Placebo	45	38 (84.4)	8.7 (15.8)	-34	1.0	7.0	21.0	43	
		Week 20	Tezepelumab	44	39 (88.6)	10.6 (17.4)	-31	-4.0	12.0	25.0	41	0.09 [-0.36, 0.53]
			Placebo	45	38 (84.4)	9.3 (13.3)	-20	-2.0	9.0	19.0	39	
		Week 28	Tezepelumab	44	39 (88.6)	10.4 (19.8)	-41	-6.0	10.0	25.0	50	0.03 [-0.41, 0.48]
			Placebo	45	38 (84.4)	9.9 (13.5)	-20	2.0	8.0	20.0	37	
		Week 40	Tezepelumab	44	39 (88.6)	12.1 (18.6)	-31	-5.0	15.0	25.0	40	0.20 [-0.25, 0.64]
			Placebo	45	38 (84.4)	8.8 (14.6)	-20	-2.0	4.5	21.0	36	
		Week 52	Tezepelumab	44	39 (88.6)	10.4 (18.9)	-30	-10.0	16.0	25.0	45	-0.00 [-0.45, 0.44]
			Placebo	45	38 (84.4)	10.4 (14.7)	-13	-2.0	9.0	20.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS	Treatment		N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	22	19 (86.4)	61.1 (20.3)	20	47.0	60.0	75.0	100	
			Placebo	20	17 (85.0)	56.0 (14.6)	32	48.0	55.0	60.0	86	
		Week 4	Tezepelumab	22	21 (95.5)	67.8 (21.1)	14	50.0	70.0	87.0	100	
			Placebo	20	19 (95.0)	63.2 (18.4)	23	51.0	61.0	82.0	94	
		Week 8	Tezepelumab	22	21 (95.5)	71.3 (22.0)	31	60.0	71.0	90.0	100	
			Placebo	20	19 (95.0)	66.4 (17.3)	45	51.0	62.0	83.0	94	
		Week 12	Tezepelumab	22	21 (95.5)	74.7 (19.5)	35	65.0	81.0	89.0	100	
			Placebo	20	19 (95.0)	67.2 (22.4)	20	47.0	64.0	89.0	100	
		Week 20	Tezepelumab	22	21 (95.5)	73.1 (22.0)	25	66.0	81.0	88.0	100	
			Placebo	20	19 (95.0)	63.1 (24.0)	20	46.0	61.0	85.0	95	
		Week 28	Tezepelumab	22	21 (95.5)	73.6 (18.7)	35	60.0	78.0	88.0	100	
			Placebo	20	19 (95.0)	66.1 (21.6)	30	49.0	63.0	86.0	97	
		Week 40	Tezepelumab	22	21 (95.5)	73.7 (19.0)	35	68.0	78.0	85.0	100	
			Placebo	20	19 (95.0)	64.1 (21.1)	20	48.0	66.0	86.0	95	
		Week 52	Tezepelumab	22	22 (100.0)	74.9 (19.0)	35	69.0	78.5	90.0	100	
			Placebo	20	19 (95.0)	68.3 (21.9)	21	52.0	74.0	86.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	22	19 (86.4)	5.3 (22.1)	-40	-20.0	10.0	26.0	31	-0.19 [-0.84, 0.47]
			Placebo	20	17 (85.0)	8.9 (17.1)	-22	3.0	8.0	16.0	51	
		Week 8	Tezepelumab	22	19 (86.4)	9.1 (28.1)	-59	-1.0	14.0	23.0	69	-0.10 [-0.75, 0.56]
			Placebo	20	17 (85.0)	11.5 (21.9)	-22	-4.0	8.0	19.0	62	
		Week 12	Tezepelumab	22	19 (86.4)	12.1 (24.2)	-34	0.0	13.0	32.0	65	0.02 [-0.64, 0.67]
			Placebo	20	17 (85.0)	11.6 (25.2)	-25	-4.0	8.0	32.0	68	
		Week 20	Tezepelumab	22	19 (86.4)	11.4 (25.9)	-44	-11.0	10.0	34.0	51	0.14 [-0.52, 0.79]
			Placebo	20	17 (85.0)	7.9 (24.2)	-32	-4.0	8.0	32.0	51	
		Week 28	Tezepelumab	22	19 (86.4)	11.4 (25.6)	-43	0.0	9.0	33.0	60	0.04 [-0.62, 0.69]
			Placebo	20	17 (85.0)	10.5 (21.2)	-15	-4.0	8.0	18.0	65	
		Week 40	Tezepelumab	22	19 (86.4)	10.9 (25.3)	-43	0.0	13.0	33.0	58	0.05 [-0.60, 0.71]
			Placebo	20	17 (85.0)	9.6 (22.7)	-25	-6.0	8.0	25.0	55	
		Week 52	Tezepelumab	22	19 (86.4)	12.7 (26.2)	-43	-5.0	18.0	33.0	58	-0.04 [-0.70, 0.61]
			Placebo	20	17 (85.0)	13.8 (25.2)	-26	-4.0	11.0	30.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	57.8 (17.7)	20	48.0	52.0	70.5	100	
			Placebo	58	48 (82.8)	60.3 (13.2)	29	50.0	59.0	69.5	96	
		Week 4	Tezepelumab	60	57 (95.0)	65.1 (19.2)	14	50.0	66.0	79.0	100	
			Placebo	58	51 (87.9)	66.2 (17.1)	17	57.0	69.0	77.0	99	
		Week 8	Tezepelumab	60	57 (95.0)	66.9 (19.1)	20	55.0	70.0	84.0	100	
			Placebo	58	52 (89.7)	66.2 (19.6)	14	53.0	62.0	84.0	100	
		Week 12	Tezepelumab	60	57 (95.0)	68.1 (18.9)	26	56.0	70.0	83.0	100	
			Placebo	58	52 (89.7)	68.0 (18.4)	20	57.5	68.0	86.5	100	
		Week 20	Tezepelumab	60	58 (96.7)	67.6 (19.1)	18	54.0	70.0	81.0	100	
			Placebo	58	52 (89.7)	67.7 (20.0)	20	55.5	68.5	85.0	100	
		Week 28	Tezepelumab	60	59 (98.3)	67.8 (19.5)	8	52.0	70.0	83.0	100	
			Placebo	58	53 (91.4)	69.2 (18.6)	27	56.0	70.0	84.0	100	
		Week 40	Tezepelumab	60	59 (98.3)	69.5 (19.3)	18	52.0	74.0	84.0	100	
			Placebo	58	53 (91.4)	67.7 (19.2)	20	54.0	69.0	82.0	100	
		Week 52	Tezepelumab	60	60 (100.0)	68.6 (19.8)	19	53.0	70.5	84.0	100	
			Placebo	58	53 (91.4)	68.9 (18.7)	21	59.0	73.0	82.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	60	52 (86.7)	6.8 (19.2)	-40	-5.5	10.0	19.0	47	0.02 [-0.37, 0.42]
			Placebo	58	48 (82.8)	6.4 (14.1)	-26	-4.0	6.5	17.0	41	
		Week 8	Tezepelumab	60	52 (86.7)	8.0 (20.2)	-59	-1.0	10.5	19.5	69	0.11 [-0.29, 0.50]
			Placebo	58	48 (82.8)	6.0 (17.6)	-36	-6.0	5.0	19.0	41	
		Week 12	Tezepelumab	60	52 (86.7)	9.3 (19.9)	-34	-1.0	7.0	22.5	65	0.08 [-0.31, 0.47]
			Placebo	58	48 (82.8)	7.9 (17.3)	-34	-4.0	5.5	21.0	43	
		Week 20	Tezepelumab	60	52 (86.7)	9.3 (20.0)	-44	-6.5	10.0	25.0	51	0.07 [-0.32, 0.46]
			Placebo	58	48 (82.8)	8.0 (16.6)	-32	-4.0	8.5	20.0	39	
		Week 28	Tezepelumab	60	52 (86.7)	9.4 (22.1)	-43	-6.5	8.5	26.5	60	0.05 [-0.35, 0.44]
			Placebo	58	48 (82.8)	8.5 (14.6)	-20	-2.5	8.0	19.0	37	
		Week 40	Tezepelumab	60	52 (86.7)	10.9 (21.4)	-43	-4.0	12.5	28.0	58	0.17 [-0.23, 0.56]
			Placebo	58	48 (82.8)	7.7 (16.6)	-25	-4.0	4.0	21.0	45	
		Week 52	Tezepelumab	60	52 (86.7)	9.9 (21.2)	-43	-7.5	14.5	25.0	58	0.06 [-0.33, 0.46]
			Placebo	58	48 (82.8)	8.8 (15.6)	-26	-3.5	7.0	20.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	55.5 (4.9)	52	52.0	55.5	59.0	59	
			Placebo	2	2 (100.0)	59.0 (38.2)	32	32.0	59.0	86.0	86	
		Week 4	Tezepelumab	2	2 (100.0)	84.5 (6.4)	80	80.0	84.5	89.0	89	
			Placebo	2	2 (100.0)	88.5 (7.8)	83	83.0	88.5	94.0	94	
		Week 8	Tezepelumab	2	2 (100.0)	91.0 (4.2)	88	88.0	91.0	94.0	94	
			Placebo	2	2 (100.0)	88.5 (7.8)	83	83.0	88.5	94.0	94	
		Week 12	Tezepelumab	2	2 (100.0)	85.5 (6.4)	81	81.0	85.5	90.0	90	
			Placebo	2	2 (100.0)	88.5 (7.8)	83	83.0	88.5	94.0	94	
		Week 20	Tezepelumab	2	2 (100.0)	87.0 (8.5)	81	81.0	87.0	93.0	93	
			Placebo	2	2 (100.0)	88.5 (7.8)	83	83.0	88.5	94.0	94	
		Week 28	Tezepelumab	2	2 (100.0)	86.0 (7.1)	81	81.0	86.0	91.0	91	
			Placebo	2	2 (100.0)	72.0 (31.1)	50	50.0	72.0	94.0	94	
		Week 40	Tezepelumab	2	2 (100.0)	74.5 (9.2)	68	68.0	74.5	81.0	81	
			Placebo	2	2 (100.0)	70.0 (28.3)	50	50.0	70.0	90.0	90	
		Week 52	Tezepelumab	2	2 (100.0)	83.5 (3.5)	81	81.0	83.5	86.0	86	
			Placebo	2	2 (100.0)	97.0 (0.0)	97	97.0	97.0	97.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	2	2 (100.0)	29.0 (1.4)	28	28.0	29.0	30.0	30	-0.02 [-1.98, 1.94]
			Placebo	2	2 (100.0)	29.5 (30.4)	8	8.0	29.5	51.0	51	
		Week 8	Tezepelumab	2	2 (100.0)	35.5 (0.7)	35	35.0	35.5	36.0	36	0.28 [-1.70, 2.26]
			Placebo	2	2 (100.0)	29.5 (30.4)	8	8.0	29.5	51.0	51	
		Week 12	Tezepelumab	2	2 (100.0)	30.0 (11.3)	22	22.0	30.0	38.0	38	0.02 [-1.94, 1.98]
			Placebo	2	2 (100.0)	29.5 (30.4)	8	8.0	29.5	51.0	51	
		Week 20	Tezepelumab	2	2 (100.0)	31.5 (13.4)	22	22.0	31.5	41.0	41	0.09 [-1.88, 2.05]
			Placebo	2	2 (100.0)	29.5 (30.4)	8	8.0	29.5	51.0	51	
		Week 28	Tezepelumab	2	2 (100.0)	30.5 (12.0)	22	22.0	30.5	39.0	39	1.77 [-0.85, 4.39]
			Placebo	2	2 (100.0)	13.0 (7.1)	8	8.0	13.0	18.0	18	
		Week 40	Tezepelumab	2	2 (100.0)	19.0 (4.2)	16	16.0	19.0	22.0	22	1.05 [-1.16, 3.26]
			Placebo	2	2 (100.0)	11.0 (9.9)	4	4.0	11.0	18.0	18	
		Week 52	Tezepelumab	2	2 (100.0)	28.0 (8.5)	22	22.0	28.0	34.0	34	-0.36 [-2.35, 1.63]
			Placebo	2	2 (100.0)	38.0 (38.2)	11	11.0	38.0	65.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	62.0 (23.6)	35	35.0	72.0	79.0	79	
			Placebo	3	3 (100.0)	48.0 (6.1)	41	41.0	51.0	52.0	52	
		Week 4	Tezepelumab	3	3 (100.0)	84.0 (15.6)	66	66.0	92.0	94.0	94	
			Placebo	3	3 (100.0)	48.0 (9.5)	38	38.0	49.0	57.0	57	
		Week 8	Tezepelumab	3	3 (100.0)	83.7 (20.5)	60	60.0	95.0	96.0	96	
			Placebo	3	3 (100.0)	46.0 (2.6)	43	43.0	47.0	48.0	48	
		Week 12	Tezepelumab	3	3 (100.0)	81.0 (28.6)	48	48.0	97.0	98.0	98	
			Placebo	3	3 (100.0)	57.3 (14.2)	42	42.0	60.0	70.0	70	
		Week 20	Tezepelumab	3	3 (100.0)	92.7 (6.7)	85	85.0	96.0	97.0	97	
			Placebo	3	3 (100.0)	51.3 (8.4)	46	46.0	47.0	61.0	61	
		Week 28	Tezepelumab	3	3 (100.0)	86.7 (13.6)	71	71.0	94.0	95.0	95	
			Placebo	3	3 (100.0)	66.7 (19.0)	47	47.0	68.0	85.0	85	
		Week 40	Tezepelumab	3	3 (100.0)	89.0 (12.3)	75	75.0	94.0	98.0	98	
			Placebo	3	3 (100.0)	66.3 (20.5)	46	46.0	66.0	87.0	87	
		Week 52	Tezepelumab	3	3 (100.0)	91.0 (5.2)	88	88.0	88.0	97.0	97	
			Placebo	3	3 (100.0)	75.3 (26.7)	45	45.0	86.0	95.0	95	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	22.0 (8.2)	15	15.0	20.0	31.0	31	2.12 [-0.05, 4.30]
			Placebo	3	3 (100.0)	0.0 (12.2)	-14	-14.0	6.0	8.0	8	
		Week 8	Tezepelumab	3	3 (100.0)	21.7 (4.2)	17	17.0	23.0	25.0	25	6.08 [1.57, 10.58]
			Placebo	3	3 (100.0)	-2.0 (3.6)	-5	-5.0	-3.0	2.0	2	
		Week 12	Tezepelumab	3	3 (100.0)	19.0 (6.0)	13	13.0	19.0	25.0	25	1.26 [-0.57, 3.08]
			Placebo	3	3 (100.0)	9.3 (9.1)	1	1.0	8.0	19.0	19	
		Week 20	Tezepelumab	3	3 (100.0)	30.7 (17.2)	17	17.0	25.0	50.0	50	2.02 [-0.11, 4.15]
			Placebo	3	3 (100.0)	3.3 (8.3)	-6	-6.0	6.0	10.0	10	
		Week 28	Tezepelumab	3	3 (100.0)	24.7 (10.6)	15	15.0	23.0	36.0	36	0.49 [-1.14, 2.13]
			Placebo	3	3 (100.0)	18.7 (13.6)	6	6.0	17.0	33.0	33	
		Week 40	Tezepelumab	3	3 (100.0)	27.0 (11.4)	19	19.0	22.0	40.0	40	0.63 [-1.03, 2.28]
			Placebo	3	3 (100.0)	18.3 (15.9)	5	5.0	14.0	36.0	36	
		Week 52	Tezepelumab	3	3 (100.0)	29.0 (20.8)	16	16.0	18.0	53.0	53	0.08 [-1.52, 1.68]
			Placebo	3	3 (100.0)	27.3 (20.6)	4	4.0	35.0	43.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	54.0	54	54.0	54.0	54.0	54	
			Placebo	2	2 (100.0)	40.0 (11.3)	32	32.0	40.0	48.0	48	
		Week 4	Tezepelumab	1	1 (100.0)	48.0	48	48.0	48.0	48.0	48	
			Placebo	2	2 (100.0)	49.5 (2.1)	48	48.0	49.5	51.0	51	
		Week 8	Tezepelumab	1	1 (100.0)	49.0	49	49.0	49.0	49.0	49	
			Placebo	2	2 (100.0)	69.5 (34.6)	45	45.0	69.5	94.0	94	
		Week 12	Tezepelumab	1	1 (100.0)	56.0	56	56.0	56.0	56.0	56	
			Placebo	2	2 (100.0)	73.0 (38.2)	46	46.0	73.0	100.0	100	
		Week 20	Tezepelumab	1	1 (100.0)	47.0	47	47.0	47.0	47.0	47	
			Placebo	2	2 (100.0)	57.5 (16.3)	46	46.0	57.5	69.0	69	
		Week 28	Tezepelumab	1	1 (100.0)	53.0	53	53.0	53.0	53.0	53	
			Placebo	2	2 (100.0)	71.5 (36.1)	46	46.0	71.5	97.0	97	
		Week 40	Tezepelumab	1	1 (100.0)	48.0	48	48.0	48.0	48.0	48	
			Placebo	2	2 (100.0)	66.5 (29.0)	46	46.0	66.5	87.0	87	
		Week 52	Tezepelumab	1	1 (100.0)	40.0	40	40.0	40.0	40.0	40	
			Placebo	2	2 (100.0)	66.0 (28.3)	46	46.0	66.0	86.0	86	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	-6.0	-6	-6.0	-6.0	-6.0	-6	NE
			Placebo	2	2 (100.0)	9.5 (9.2)	3	3.0	9.5	16.0	16	
		Week 8	Tezepelumab	1	1 (100.0)	-5.0	-5	-5.0	-5.0	-5.0	-5	NE
			Placebo	2	2 (100.0)	29.5 (46.0)	-3	-3.0	29.5	62.0	62	
		Week 12	Tezepelumab	1	1 (100.0)	2.0	2	2.0	2.0	2.0	2	NE
			Placebo	2	2 (100.0)	33.0 (49.5)	-2	-2.0	33.0	68.0	68	
		Week 20	Tezepelumab	1	1 (100.0)	-7.0	-7	-7.0	-7.0	-7.0	-7	NE
			Placebo	2	2 (100.0)	17.5 (27.6)	-2	-2.0	17.5	37.0	37	
		Week 28	Tezepelumab	1	1 (100.0)	-1.0	-1	-1.0	-1.0	-1.0	-1	NE
			Placebo	2	2 (100.0)	31.5 (47.4)	-2	-2.0	31.5	65.0	65	
		Week 40	Tezepelumab	1	1 (100.0)	-6.0	-6	-6.0	-6.0	-6.0	-6	NE
			Placebo	2	2 (100.0)	26.5 (40.3)	-2	-2.0	26.5	55.0	55	
		Week 52	Tezepelumab	1	1 (100.0)	-14.0	-14	-14.0	-14.0	-14.0	-14	NE
			Placebo	2	2 (100.0)	26.0 (39.6)	-2	-2.0	26.0	54.0	54	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	40	36 (90.0)	60.1 (17.4)	34	49.5	54.5	72.5	100	
			Placebo	36	31 (86.1)	61.8 (13.6)	45	50.0	60.0	72.0	96	
		Week 4	Tezepelumab	40	38 (95.0)	67.5 (17.0)	30	53.0	66.0	81.0	100	
			Placebo	36	32 (88.9)	65.2 (16.2)	23	53.5	69.0	74.5	95	
		Week 8	Tezepelumab	40	38 (95.0)	65.3 (19.9)	20	53.0	66.5	77.0	100	
			Placebo	36	32 (88.9)	65.4 (18.1)	29	51.0	60.5	81.0	100	
		Week 12	Tezepelumab	40	38 (95.0)	67.2 (20.1)	26	56.0	68.5	85.0	100	
			Placebo	36	32 (88.9)	67.7 (19.2)	20	55.5	70.5	85.5	100	
		Week 20	Tezepelumab	40	39 (97.5)	67.6 (20.3)	18	54.0	70.0	81.0	100	
			Placebo	36	32 (88.9)	67.8 (21.0)	20	55.5	69.0	85.0	100	
		Week 28	Tezepelumab	40	40 (100.0)	68.4 (19.9)	8	56.0	70.0	83.0	100	
			Placebo	36	33 (91.7)	69.8 (18.2)	30	56.0	74.0	82.0	100	
		Week 40	Tezepelumab	40	40 (100.0)	70.2 (19.8)	18	54.5	74.5	84.5	100	
			Placebo	36	33 (91.7)	67.5 (19.5)	20	54.0	69.0	81.0	100	
		Week 52	Tezepelumab	40	40 (100.0)	67.6 (21.4)	19	51.5	70.0	84.0	100	
			Placebo	36	33 (91.7)	70.6 (19.1)	21	61.0	75.0	83.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	40	36 (90.0)	7.5 (20.3)	-40	-6.5	11.5	19.0	47	0.20 [-0.28, 0.68]
			Placebo	36	31 (86.1)	4.0 (13.4)	-26	-5.0	4.0	10.0	26	
		Week 8	Tezepelumab	40	36 (90.0)	5.3 (20.8)	-59	-5.0	10.0	20.0	38	0.07 [-0.41, 0.55]
			Placebo	36	31 (86.1)	4.0 (16.7)	-24	-7.0	2.0	10.0	41	
		Week 12	Tezepelumab	40	36 (90.0)	6.8 (20.0)	-34	-3.5	4.0	21.0	41	0.03 [-0.45, 0.51]
			Placebo	36	31 (86.1)	6.2 (18.8)	-34	-5.0	4.0	21.0	43	
		Week 20	Tezepelumab	40	36 (90.0)	7.1 (20.4)	-44	-8.0	9.0	25.0	41	0.04 [-0.44, 0.52]
			Placebo	36	31 (86.1)	6.3 (17.1)	-32	-4.0	7.0	17.0	39	
		Week 28	Tezepelumab	40	36 (90.0)	8.1 (22.7)	-43	-6.5	9.0	26.5	50	0.05 [-0.43, 0.53]
			Placebo	36	31 (86.1)	7.2 (14.2)	-16	-3.0	6.0	15.0	37	
		Week 40	Tezepelumab	40	36 (90.0)	9.0 (22.0)	-43	-6.0	12.5	25.5	40	0.19 [-0.29, 0.67]
			Placebo	36	31 (86.1)	5.2 (16.7)	-25	-7.0	4.0	20.0	34	
		Week 52	Tezepelumab	40	36 (90.0)	7.1 (21.8)	-43	-12.5	12.5	25.0	45	-0.05 [-0.53, 0.43]
			Placebo	36	31 (86.1)	8.1 (16.3)	-26	-4.0	8.0	20.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	62.4 (19.3)	40	52.0	59.0	70.0	91	
			Placebo	4	3 (75.0)	67.7 (30.9)	32	32.0	85.0	86.0	86	
		Week 4	Tezepelumab	6	5 (83.3)	75.8 (16.5)	50	70.0	80.0	89.0	90	
			Placebo	4	3 (75.0)	89.7 (5.9)	83	83.0	92.0	94.0	94	
		Week 8	Tezepelumab	6	5 (83.3)	80.2 (17.8)	49	85.0	85.0	88.0	94	
			Placebo	4	3 (75.0)	89.3 (5.7)	83	83.0	91.0	94.0	94	
		Week 12	Tezepelumab	6	5 (83.3)	80.2 (6.8)	72	76.0	81.0	82.0	90	
			Placebo	4	3 (75.0)	90.0 (6.1)	83	83.0	93.0	94.0	94	
		Week 20	Tezepelumab	6	5 (83.3)	80.8 (7.8)	73	75.0	81.0	82.0	93	
			Placebo	4	3 (75.0)	90.3 (6.4)	83	83.0	94.0	94.0	94	
		Week 28	Tezepelumab	6	5 (83.3)	79.0 (7.3)	73	75.0	75.0	81.0	91	
			Placebo	4	3 (75.0)	79.0 (25.1)	50	50.0	93.0	94.0	94	
		Week 40	Tezepelumab	6	5 (83.3)	73.6 (7.3)	65	68.0	73.0	81.0	81	
			Placebo	4	3 (75.0)	76.3 (22.8)	50	50.0	89.0	90.0	90	
		Week 52	Tezepelumab	6	6 (100.0)	78.2 (5.8)	70	73.0	79.5	81.0	86	
			Placebo	4	3 (75.0)	92.3 (8.1)	83	83.0	97.0	97.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	6	5 (83.3)	13.4 (14.9)	-1	0.0	10.0	28.0	30	-0.45 [-1.91, 1.00]
			Placebo	4	3 (75.0)	22.0 (25.1)	7	7.0	8.0	51.0	51	
		Week 8	Tezepelumab	6	5 (83.3)	17.8 (17.9)	-6	9.0	15.0	35.0	36	-0.19 [-1.62, 1.25]
			Placebo	4	3 (75.0)	21.7 (25.4)	6	6.0	8.0	51.0	51	
		Week 12	Tezepelumab	6	5 (83.3)	17.8 (19.3)	-9	6.0	22.0	32.0	38	-0.21 [-1.65, 1.22]
			Placebo	4	3 (75.0)	22.3 (24.8)	8	8.0	8.0	51.0	51	
		Week 20	Tezepelumab	6	5 (83.3)	18.4 (20.4)	-9	5.0	22.0	33.0	41	-0.20 [-1.63, 1.24]
			Placebo	4	3 (75.0)	22.7 (24.5)	8	8.0	9.0	51.0	51	
		Week 28	Tezepelumab	6	5 (83.3)	16.6 (22.3)	-16	5.0	22.0	33.0	39	0.28 [-1.16, 1.72]
			Placebo	4	3 (75.0)	11.3 (5.8)	8	8.0	8.0	18.0	18	
		Week 40	Tezepelumab	6	5 (83.3)	11.2 (18.2)	-10	-5.0	16.0	22.0	33	0.16 [-1.27, 1.60]
			Placebo	4	3 (75.0)	8.7 (8.1)	4	4.0	4.0	18.0	18	
		Week 52	Tezepelumab	6	5 (83.3)	15.6 (20.2)	-11	0.0	22.0	33.0	34	-0.34 [-1.79, 1.10]
			Placebo	4	3 (75.0)	24.7 (35.5)	-2	-2.0	11.0	65.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	62.0 (23.6)	35	35.0	72.0	79.0	79	
			Placebo	3	3 (100.0)	48.0 (6.1)	41	41.0	51.0	52.0	52	
		Week 4	Tezepelumab	3	3 (100.0)	84.0 (15.6)	66	66.0	92.0	94.0	94	
			Placebo	3	3 (100.0)	48.0 (9.5)	38	38.0	49.0	57.0	57	
		Week 8	Tezepelumab	3	3 (100.0)	83.7 (20.5)	60	60.0	95.0	96.0	96	
			Placebo	3	3 (100.0)	46.0 (2.6)	43	43.0	47.0	48.0	48	
		Week 12	Tezepelumab	3	3 (100.0)	81.0 (28.6)	48	48.0	97.0	98.0	98	
			Placebo	3	3 (100.0)	57.3 (14.2)	42	42.0	60.0	70.0	70	
		Week 20	Tezepelumab	3	3 (100.0)	92.7 (6.7)	85	85.0	96.0	97.0	97	
			Placebo	3	3 (100.0)	51.3 (8.4)	46	46.0	47.0	61.0	61	
		Week 28	Tezepelumab	3	3 (100.0)	86.7 (13.6)	71	71.0	94.0	95.0	95	
			Placebo	3	3 (100.0)	66.7 (19.0)	47	47.0	68.0	85.0	85	
		Week 40	Tezepelumab	3	3 (100.0)	89.0 (12.3)	75	75.0	94.0	98.0	98	
			Placebo	3	3 (100.0)	66.3 (20.5)	46	46.0	66.0	87.0	87	
		Week 52	Tezepelumab	3	3 (100.0)	91.0 (5.2)	88	88.0	88.0	97.0	97	
			Placebo	3	3 (100.0)	75.3 (26.7)	45	45.0	86.0	95.0	95	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	22.0 (8.2)	15	15.0	20.0	31.0	31	2.12 [-0.05, 4.30]
			Placebo	3	3 (100.0)	0.0 (12.2)	-14	-14.0	6.0	8.0	8	
		Week 8	Tezepelumab	3	3 (100.0)	21.7 (4.2)	17	17.0	23.0	25.0	25	6.08 [1.57, 10.58]
			Placebo	3	3 (100.0)	-2.0 (3.6)	-5	-5.0	-3.0	2.0	2	
		Week 12	Tezepelumab	3	3 (100.0)	19.0 (6.0)	13	13.0	19.0	25.0	25	1.26 [-0.57, 3.08]
			Placebo	3	3 (100.0)	9.3 (9.1)	1	1.0	8.0	19.0	19	
		Week 20	Tezepelumab	3	3 (100.0)	30.7 (17.2)	17	17.0	25.0	50.0	50	2.02 [-0.11, 4.15]
			Placebo	3	3 (100.0)	3.3 (8.3)	-6	-6.0	6.0	10.0	10	
		Week 28	Tezepelumab	3	3 (100.0)	24.7 (10.6)	15	15.0	23.0	36.0	36	0.49 [-1.14, 2.13]
			Placebo	3	3 (100.0)	18.7 (13.6)	6	6.0	17.0	33.0	33	
		Week 40	Tezepelumab	3	3 (100.0)	27.0 (11.4)	19	19.0	22.0	40.0	40	0.63 [-1.03, 2.28]
			Placebo	3	3 (100.0)	18.3 (15.9)	5	5.0	14.0	36.0	36	
		Week 52	Tezepelumab	3	3 (100.0)	29.0 (20.8)	16	16.0	18.0	53.0	53	0.08 [-1.52, 1.68]
			Placebo	3	3 (100.0)	27.3 (20.6)	4	4.0	35.0	43.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	17	14 (82.4)	49.7 (14.4)	20	47.0	51.0	60.0	72	
			Placebo	22	18 (81.8)	54.1 (11.5)	29	50.0	51.5	62.0	70	
		Week 4	Tezepelumab	17	17 (100.0)	57.8 (22.7)	14	44.0	62.0	74.0	92	
			Placebo	22	20 (90.9)	64.9 (18.3)	17	54.0	60.5	79.0	99	
		Week 8	Tezepelumab	17	17 (100.0)	68.4 (17.9)	39	55.0	70.0	82.0	95	
			Placebo	22	21 (95.5)	66.6 (22.3)	14	58.0	65.0	83.0	97	
		Week 12	Tezepelumab	17	17 (100.0)	67.8 (17.5)	39	51.0	70.0	81.0	94	
			Placebo	22	21 (95.5)	67.8 (18.3)	30	60.0	64.0	86.0	100	
		Week 20	Tezepelumab	17	17 (100.0)	64.9 (18.1)	39	52.0	65.0	81.0	94	
			Placebo	22	21 (95.5)	65.3 (17.9)	27	54.0	67.0	82.0	92	
		Week 28	Tezepelumab	17	17 (100.0)	64.6 (20.2)	29	50.0	60.0	82.0	93	
			Placebo	22	21 (95.5)	67.4 (20.1)	27	54.0	68.0	86.0	97	
		Week 40	Tezepelumab	17	17 (100.0)	66.2 (19.8)	39	50.0	68.0	82.0	95	
			Placebo	22	21 (95.5)	66.9 (19.2)	27	54.0	62.0	85.0	95	
		Week 52	Tezepelumab	17	17 (100.0)	67.6 (19.0)	32	53.0	69.0	80.0	94	
			Placebo	22	21 (95.5)	65.4 (18.5)	27	48.0	70.0	80.0	96	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	17	14 (82.4)	5.0 (18.3)	-30	-6.0	9.0	19.0	30	-0.36 [-1.07, 0.34]
			Placebo	22	18 (81.8)	10.9 (14.3)	-12	1.0	10.0	21.0	41	
		Week 8	Tezepelumab	17	14 (82.4)	14.7 (18.9)	-10	3.0	12.5	19.0	69	0.12 [-0.58, 0.82]
			Placebo	22	18 (81.8)	12.1 (22.5)	-36	-3.0	10.0	23.0	62	
		Week 12	Tezepelumab	17	14 (82.4)	15.2 (18.8)	-10	3.0	13.0	23.0	65	0.09 [-0.61, 0.79]
			Placebo	22	18 (81.8)	13.4 (19.4)	-10	1.0	11.0	25.0	68	
		Week 20	Tezepelumab	17	14 (82.4)	13.7 (19.1)	-11	1.0	11.5	26.0	51	0.10 [-0.60, 0.80]
			Placebo	22	18 (81.8)	12.0 (16.7)	-20	-2.0	10.5	26.0	37	
		Week 28	Tezepelumab	17	14 (82.4)	12.4 (20.5)	-13	-1.0	8.5	23.0	60	-0.05 [-0.75, 0.65]
			Placebo	22	18 (81.8)	13.4 (20.0)	-20	-2.0	10.0	24.0	65	
		Week 40	Tezepelumab	17	14 (82.4)	15.6 (19.7)	-13	0.0	14.0	33.0	58	0.07 [-0.62, 0.77]
			Placebo	22	18 (81.8)	14.2 (18.7)	-8	-2.0	8.5	25.0	55	
		Week 52	Tezepelumab	17	14 (82.4)	16.1 (19.4)	-13	0.0	18.5	29.0	58	0.21 [-0.49, 0.91]
			Placebo	22	18 (81.8)	12.3 (17.8)	-8	-2.0	8.5	24.0	54	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	60.6 (20.6)	20	49.0	61.0	73.0	94	
			Placebo	21	17 (81.0)	62.0 (14.2)	29	51.0	65.0	73.0	85	
		Week 4	Tezepelumab	15	15 (100.0)	75.7 (22.1)	14	66.0	88.0	90.0	97	
			Placebo	21	19 (90.5)	62.7 (18.6)	17	51.0	60.0	73.0	93	
		Week 8	Tezepelumab	15	15 (100.0)	81.2 (13.2)	60	70.0	85.0	94.0	96	
			Placebo	21	19 (90.5)	61.8 (23.0)	14	50.0	62.0	85.0	100	
		Week 12	Tezepelumab	15	15 (100.0)	79.2 (12.9)	48	70.0	81.0	89.0	97	
			Placebo	21	19 (90.5)	66.0 (18.5)	30	57.0	67.0	84.0	100	
		Week 20	Tezepelumab	15	15 (100.0)	81.7 (9.1)	65	75.0	81.0	88.0	98	
			Placebo	21	19 (90.5)	69.2 (21.9)	27	51.0	71.0	86.0	100	
		Week 28	Tezepelumab	15	15 (100.0)	80.0 (11.7)	50	75.0	81.0	90.0	98	
			Placebo	21	20 (95.2)	69.9 (20.8)	27	52.0	72.5	86.0	100	
		Week 40	Tezepelumab	15	15 (100.0)	81.2 (11.1)	50	78.0	81.0	90.0	97	
			Placebo	21	20 (95.2)	68.8 (20.4)	27	52.0	70.0	86.5	100	
		Week 52	Tezepelumab	15	15 (100.0)	80.7 (12.2)	50	73.0	80.0	92.0	99	
			Placebo	21	20 (95.2)	71.7 (20.1)	27	59.5	74.0	87.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	15	14 (93.3)	13.9 (17.7)	-27	3.0	16.5	27.0	40	0.75 [0.02, 1.48]
			Placebo	21	17 (81.0)	2.4 (12.9)	-26	-4.0	5.0	8.0	32	
		Week 8	Tezepelumab	15	14 (93.3)	19.6 (17.5)	-6	10.0	16.5	25.0	69	1.05 [0.30, 1.81]
			Placebo	21	17 (81.0)	0.4 (18.7)	-36	-10.0	-1.0	10.0	37	
		Week 12	Tezepelumab	15	14 (93.3)	17.6 (18.9)	-9	1.0	18.0	25.0	65	0.74 [0.01, 1.47]
			Placebo	21	17 (81.0)	4.3 (17.1)	-34	-4.0	4.0	11.0	38	
		Week 20	Tezepelumab	15	14 (93.3)	21.1 (17.4)	-9	8.0	20.0	30.0	51	0.75 [0.02, 1.48]
			Placebo	21	17 (81.0)	8.8 (15.4)	-20	-2.0	8.0	15.0	36	
		Week 28	Tezepelumab	15	14 (93.3)	18.6 (20.7)	-16	4.0	22.5	33.0	60	0.62 [-0.11, 1.34]
			Placebo	21	17 (81.0)	7.4 (15.6)	-20	-2.0	5.0	17.0	36	
		Week 40	Tezepelumab	15	14 (93.3)	19.7 (20.4)	-13	3.0	22.0	33.0	58	0.64 [-0.09, 1.37]
			Placebo	21	17 (81.0)	7.3 (18.5)	-23	-6.0	3.0	20.0	45	
		Week 52	Tezepelumab	15	14 (93.3)	19.1 (20.5)	-13	5.0	20.5	25.0	58	0.49 [-0.23, 1.21]
			Placebo	21	17 (81.0)	10.0 (17.2)	-13	-4.0	6.0	24.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	24	20 (83.3)	62.6 (15.6)	34	51.5	61.0	71.0	100	
			Placebo	20	18 (90.0)	55.7 (13.9)	32	49.0	51.0	62.0	86	
		Week 4	Tezepelumab	24	23 (95.8)	71.7 (16.2)	44	60.0	70.0	87.0	100	
			Placebo	20	18 (90.0)	64.6 (18.9)	23	49.0	62.0	80.0	94	
		Week 8	Tezepelumab	24	23 (95.8)	71.4 (18.2)	39	55.0	71.0	87.0	100	
			Placebo	20	18 (90.0)	66.9 (16.8)	43	54.0	61.0	83.0	94	
		Week 12	Tezepelumab	24	23 (95.8)	70.7 (22.1)	35	51.0	76.0	90.0	100	
			Placebo	20	18 (90.0)	66.7 (19.3)	20	58.0	62.5	83.0	94	
		Week 20	Tezepelumab	24	23 (95.8)	71.5 (20.3)	35	53.0	77.0	92.0	100	
			Placebo	20	18 (90.0)	62.9 (20.1)	20	53.0	62.0	80.0	94	
		Week 28	Tezepelumab	24	23 (95.8)	72.1 (19.9)	35	53.0	76.0	88.0	100	
			Placebo	20	18 (90.0)	62.8 (17.1)	30	50.0	60.0	70.0	94	
		Week 40	Tezepelumab	24	23 (95.8)	74.0 (19.7)	35	58.0	80.0	93.0	100	
			Placebo	20	18 (90.0)	64.1 (18.2)	20	54.0	62.0	80.0	90	
		Week 52	Tezepelumab	24	24 (100.0)	72.3 (20.6)	35	52.5	77.0	90.5	100	
			Placebo	20	18 (90.0)	65.4 (18.0)	30	51.0	64.0	77.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	24	20 (83.3)	9.1 (15.4)	-17	-3.0	11.5	18.5	36	0.01 [-0.62, 0.65]
			Placebo	20	18 (90.0)	8.9 (16.4)	-22	-1.0	7.5	21.0	51	
		Week 8	Tezepelumab	24	20 (83.3)	8.8 (12.4)	-16	-0.5	10.5	16.0	33	-0.17 [-0.81, 0.47]
			Placebo	20	18 (90.0)	11.2 (15.8)	-8	2.0	7.5	18.0	51	
		Week 12	Tezepelumab	24	20 (83.3)	7.5 (17.1)	-23	-1.5	6.5	19.5	37	-0.21 [-0.85, 0.43]
			Placebo	20	18 (90.0)	11.0 (16.7)	-25	1.0	10.5	18.0	51	
		Week 20	Tezepelumab	24	20 (83.3)	8.7 (17.4)	-16	-5.5	5.5	22.5	41	0.08 [-0.55, 0.72]
			Placebo	20	18 (90.0)	7.2 (18.6)	-32	-1.0	8.5	15.0	51	
		Week 28	Tezepelumab	24	20 (83.3)	9.2 (17.3)	-16	-5.0	6.5	21.0	37	0.14 [-0.50, 0.78]
			Placebo	20	18 (90.0)	7.1 (11.2)	-15	-1.0	8.5	14.0	29	
		Week 40	Tezepelumab	24	20 (83.3)	11.2 (17.0)	-16	-2.0	12.5	24.0	38	0.18 [-0.46, 0.82]
			Placebo	20	18 (90.0)	8.4 (13.3)	-25	4.0	8.5	16.0	30	
		Week 52	Tezepelumab	24	20 (83.3)	9.6 (18.0)	-24	-2.0	11.5	22.0	41	-0.01 [-0.64, 0.63]
			Placebo	20	18 (90.0)	9.7 (17.9)	-15	-2.0	8.0	18.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	27	24 (88.9)	52.4 (15.8)	29	39.5	51.0	59.0	90	
			Placebo	24	20 (83.3)	59.0 (14.8)	32	49.0	56.5	68.0	96	
		Week 4	Tezepelumab	27	25 (92.6)	55.8 (15.7)	21	49.0	50.0	67.0	86	
			Placebo	24	21 (87.5)	68.7 (15.4)	45	57.0	73.0	77.0	99	
		Week 8	Tezepelumab	27	25 (92.6)	57.5 (18.4)	20	46.0	58.0	71.0	88	
			Placebo	24	22 (91.7)	69.0 (19.8)	29	53.0	64.5	87.0	97	
		Week 12	Tezepelumab	27	25 (92.6)	61.5 (16.8)	26	50.0	60.0	71.0	90	
			Placebo	24	22 (91.7)	71.7 (18.9)	34	62.0	72.5	90.0	100	
		Week 20	Tezepelumab	27	26 (96.3)	59.7 (18.9)	18	47.0	63.5	70.0	93	
			Placebo	24	22 (91.7)	69.0 (17.9)	22	63.0	68.0	85.0	92	
		Week 28	Tezepelumab	27	27 (100.0)	60.3 (19.2)	8	50.0	62.0	73.0	91	
			Placebo	24	22 (91.7)	74.0 (17.7)	32	68.0	78.5	90.0	97	
		Week 40	Tezepelumab	27	27 (100.0)	61.0 (18.5)	18	47.0	68.0	74.0	93	
			Placebo	24	22 (91.7)	69.5 (19.3)	34	53.0	72.0	87.0	94	
		Week 52	Tezepelumab	27	27 (100.0)	61.1 (19.7)	19	51.0	63.0	78.0	93	
			Placebo	24	22 (91.7)	72.5 (19.9)	21	66.0	77.5	86.0	96	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	27	24 (88.9)	4.1 (22.2)	-40	-16.0	10.0	19.0	47	-0.27 [-0.87, 0.32]
			Placebo	24	20 (83.3)	9.3 (14.6)	-12	-3.0	8.0	22.0	41	
		Week 8	Tezepelumab	27	24 (88.9)	4.2 (24.6)	-59	-6.5	6.5	20.0	38	-0.24 [-0.83, 0.36]
			Placebo	24	20 (83.3)	9.7 (21.7)	-22	-6.0	1.5	26.0	62	
		Week 12	Tezepelumab	27	24 (88.9)	8.7 (21.2)	-34	-3.0	8.0	31.0	41	-0.20 [-0.79, 0.40]
			Placebo	24	20 (83.3)	13.0 (22.3)	-17	-3.0	4.5	27.5	68	
		Week 20	Tezepelumab	27	24 (88.9)	6.8 (22.9)	-44	-10.0	11.0	25.0	41	-0.18 [-0.77, 0.42]
			Placebo	24	20 (83.3)	10.4 (18.1)	-25	-4.0	8.0	23.5	39	
		Week 28	Tezepelumab	27	24 (88.9)	7.5 (25.0)	-43	-8.5	8.5	29.5	50	-0.34 [-0.93, 0.26]
			Placebo	24	20 (83.3)	15.1 (19.4)	-15	0.0	10.0	29.0	65	
		Week 40	Tezepelumab	27	24 (88.9)	7.5 (23.3)	-43	-8.5	13.5	23.5	40	-0.17 [-0.76, 0.42]
			Placebo	24	20 (83.3)	11.2 (19.8)	-20	-3.0	6.0	27.5	55	
		Week 52	Tezepelumab	27	24 (88.9)	7.8 (24.0)	-43	-12.5	15.5	28.5	45	-0.29 [-0.89, 0.31]
			Placebo	24	20 (83.3)	14.3 (20.4)	-26	-1.5	11.5	30.5	54	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	52.1 (16.7)	29	39.0	50.0	59.0	90	
			Placebo	14	11 (78.6)	56.4 (14.3)	32	50.0	53.0	63.0	88	
		Week 4	Tezepelumab	11	11 (100.0)	66.5 (16.6)	41	50.0	67.0	81.0	89	
			Placebo	14	12 (85.7)	63.3 (15.3)	45	51.0	59.0	73.0	95	
		Week 8	Tezepelumab	11	11 (100.0)	64.4 (19.6)	31	45.0	63.0	77.0	94	
			Placebo	14	12 (85.7)	67.5 (21.8)	29	50.0	64.5	89.0	94	
		Week 12	Tezepelumab	11	11 (100.0)	67.0 (17.1)	35	59.0	70.0	81.0	89	
			Placebo	14	12 (85.7)	68.2 (19.4)	34	57.5	66.5	81.0	100	
		Week 20	Tezepelumab	11	11 (100.0)	67.7 (14.4)	35	64.0	70.0	79.0	90	
			Placebo	14	12 (85.7)	66.4 (12.8)	43	60.5	67.5	70.0	89	
		Week 28	Tezepelumab	11	11 (100.0)	65.4 (20.5)	29	47.0	70.0	83.0	88	
			Placebo	14	12 (85.7)	71.0 (16.2)	48	61.5	68.5	82.0	97	
		Week 40	Tezepelumab	11	11 (100.0)	66.8 (17.8)	35	47.0	77.0	81.0	88	
			Placebo	14	12 (85.7)	68.8 (17.5)	43	55.5	68.5	87.0	92	
		Week 52	Tezepelumab	11	11 (100.0)	64.8 (15.3)	35	57.0	64.0	81.0	84	
			Placebo	14	12 (85.7)	69.3 (16.5)	38	58.0	73.0	85.5	87	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	11	11 (100.0)	14.5 (25.0)	-40	5.0	26.0	29.0	47	0.31 [-0.53, 1.16]
			Placebo	14	11 (78.6)	8.5 (10.2)	-6	4.0	6.0	16.0	26	
		Week 8	Tezepelumab	11	11 (100.0)	12.3 (28.6)	-59	-6.0	16.0	35.0	38	-0.01 [-0.85, 0.83]
			Placebo	14	11 (78.6)	12.5 (24.2)	-22	-3.0	6.0	32.0	62	
		Week 12	Tezepelumab	11	11 (100.0)	14.9 (22.6)	-31	-1.0	22.0	33.0	41	0.09 [-0.74, 0.93]
			Placebo	14	11 (78.6)	12.8 (22.5)	-17	2.0	6.0	25.0	68	
		Week 20	Tezepelumab	11	11 (100.0)	15.6 (20.1)	-20	-4.0	22.0	26.0	41	0.29 [-0.55, 1.14]
			Placebo	14	11 (78.6)	10.6 (13.2)	-8	-2.0	10.0	21.0	37	
		Week 28	Tezepelumab	11	11 (100.0)	13.3 (27.4)	-43	-11.0	23.0	32.0	50	-0.05 [-0.88, 0.79]
			Placebo	14	11 (78.6)	14.4 (19.5)	-7	2.0	9.0	23.0	65	
		Week 40	Tezepelumab	11	11 (100.0)	14.7 (27.2)	-43	-14.0	22.0	38.0	40	0.04 [-0.80, 0.87]
			Placebo	14	11 (78.6)	13.8 (19.8)	-12	2.0	6.0	23.0	55	
		Week 52	Tezepelumab	11	11 (100.0)	12.7 (25.8)	-43	-13.0	24.0	29.0	45	-0.03 [-0.87, 0.80]
			Placebo	14	11 (78.6)	13.5 (19.5)	-13	-3.0	13.0	23.0	54	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	54	46 (85.2)	59.4 (17.5)	20	49.0	57.0	72.0	100	
			Placebo	51	44 (86.3)	59.5 (14.4)	29	50.0	57.5	69.5	96	
		Week 4	Tezepelumab	54	51 (94.4)	66.4 (20.2)	14	50.0	66.0	87.0	100	
			Placebo	51	46 (90.2)	66.1 (18.1)	17	54.0	68.0	80.0	99	
		Week 8	Tezepelumab	54	51 (94.4)	69.3 (19.7)	20	55.0	71.0	87.0	100	
			Placebo	51	47 (92.2)	65.7 (19.7)	14	51.0	62.0	83.0	100	
		Week 12	Tezepelumab	54	51 (94.4)	69.9 (19.8)	26	56.0	72.0	87.0	100	
			Placebo	51	47 (92.2)	68.4 (18.8)	20	57.0	69.0	87.0	100	
		Week 20	Tezepelumab	54	52 (96.3)	69.7 (20.6)	18	54.0	75.0	85.5	100	
			Placebo	51	47 (92.2)	67.4 (21.3)	20	53.0	69.0	85.0	100	
		Week 28	Tezepelumab	54	53 (98.1)	70.1 (19.4)	8	53.0	73.0	85.0	100	
			Placebo	51	48 (94.1)	68.8 (19.6)	27	52.0	70.5	85.5	100	
		Week 40	Tezepelumab	54	53 (98.1)	71.3 (19.5)	18	58.0	75.0	85.0	100	
			Placebo	51	48 (94.1)	67.4 (19.7)	20	51.5	69.5	83.5	100	
		Week 52	Tezepelumab	54	54 (100.0)	70.9 (20.8)	19	53.0	75.0	88.0	100	
			Placebo	51	48 (94.1)	70.3 (20.2)	21	56.5	75.0	84.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	54	46 (85.2)	6.6 (17.6)	-30	-6.0	10.0	19.0	40	-0.00 [-0.42, 0.41]
			Placebo	51	44 (86.3)	6.7 (15.8)	-26	-4.0	7.0	17.0	51	
		Week 8	Tezepelumab	54	46 (85.2)	8.9 (18.0)	-46	-1.0	10.5	20.0	69	0.16 [-0.25, 0.58]
			Placebo	51	44 (86.3)	6.0 (17.9)	-36	-5.0	3.0	18.5	51	
		Week 12	Tezepelumab	54	46 (85.2)	9.6 (18.9)	-34	0.0	7.0	20.0	65	0.04 [-0.37, 0.45]
			Placebo	51	44 (86.3)	8.8 (18.3)	-34	-3.0	8.0	21.0	51	
		Week 20	Tezepelumab	54	46 (85.2)	10.0 (20.7)	-44	-7.0	10.0	25.0	51	0.08 [-0.34, 0.49]
			Placebo	51	44 (86.3)	8.4 (18.1)	-32	-4.0	8.0	19.0	51	
		Week 28	Tezepelumab	54	46 (85.2)	10.4 (20.6)	-41	-3.0	9.5	25.0	60	0.08 [-0.34, 0.49]
			Placebo	51	44 (86.3)	9.0 (15.2)	-20	-2.0	8.0	19.0	37	
		Week 40	Tezepelumab	54	46 (85.2)	11.3 (19.5)	-33	-3.0	12.5	25.0	58	0.19 [-0.23, 0.60]
			Placebo	51	44 (86.3)	7.9 (16.6)	-25	-3.5	4.5	19.0	45	
		Week 52	Tezepelumab	54	46 (85.2)	11.0 (20.7)	-30	-5.0	16.0	25.0	58	0.00 [-0.41, 0.42]
			Placebo	51	44 (86.3)	11.0 (18.3)	-26	-2.5	7.0	23.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	33	31 (93.9)	54.1 (16.0)	20	40.0	52.0	63.0	90	
			Placebo	34	27 (79.4)	58.4 (14.2)	29	50.0	58.0	66.0	88	
		Week 4	Tezepelumab	33	31 (93.9)	65.3 (18.8)	14	50.0	66.0	80.0	94	
			Placebo	34	28 (82.4)	65.4 (18.2)	17	55.5	61.5	75.0	99	
		Week 8	Tezepelumab	33	31 (93.9)	65.4 (18.9)	31	49.0	65.0	77.0	96	
			Placebo	34	29 (85.3)	65.2 (22.8)	14	53.0	61.0	87.0	97	
		Week 12	Tezepelumab	33	31 (93.9)	67.8 (18.3)	35	56.0	69.0	85.0	98	
			Placebo	34	29 (85.3)	67.4 (19.5)	30	54.0	64.0	87.0	100	
		Week 20	Tezepelumab	33	32 (97.0)	67.8 (18.7)	25	54.5	70.0	80.0	97	
			Placebo	34	29 (85.3)	65.9 (20.9)	22	55.0	68.0	85.0	94	
		Week 28	Tezepelumab	33	33 (100.0)	67.8 (18.2)	29	53.0	70.0	83.0	94	
			Placebo	34	30 (88.2)	68.7 (20.5)	27	53.0	68.5	90.0	97	
		Week 40	Tezepelumab	33	33 (100.0)	68.7 (18.3)	35	50.0	72.0	81.0	98	
			Placebo	34	30 (88.2)	69.7 (20.3)	27	54.0	70.0	90.0	96	
		Week 52	Tezepelumab	33	33 (100.0)	66.9 (19.8)	32	51.0	70.0	84.0	97	
			Placebo	34	30 (88.2)	70.0 (21.1)	21	54.0	73.5	86.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	33	31 (93.9)	11.1 (18.2)	-40	-2.0	14.0	27.0	47	0.22 [-0.30, 0.74]
			Placebo	34	27 (79.4)	7.7 (12.3)	-12	-4.0	7.0	11.0	41	
		Week 8	Tezepelumab	33	31 (93.9)	11.3 (24.2)	-59	-1.0	13.0	23.0	69	0.17 [-0.35, 0.68]
			Placebo	34	27 (79.4)	7.3 (22.4)	-36	-8.0	6.0	20.0	62	
		Week 12	Tezepelumab	33	31 (93.9)	13.7 (22.2)	-34	2.0	15.0	32.0	65	0.21 [-0.31, 0.72]
			Placebo	34	27 (79.4)	9.4 (19.7)	-19	-4.0	6.0	21.0	68	
		Week 20	Tezepelumab	33	31 (93.9)	13.4 (21.6)	-44	-4.0	17.0	26.0	51	0.28 [-0.24, 0.80]
			Placebo	34	27 (79.4)	7.8 (18.5)	-32	-4.0	8.0	21.0	38	
		Week 28	Tezepelumab	33	31 (93.9)	13.5 (23.4)	-43	-1.0	18.0	32.0	60	0.20 [-0.32, 0.72]
			Placebo	34	27 (79.4)	9.3 (18.7)	-20	-3.0	8.0	20.0	65	
		Week 40	Tezepelumab	33	31 (93.9)	13.6 (22.7)	-43	-3.0	19.0	33.0	58	0.10 [-0.42, 0.62]
			Placebo	34	27 (79.4)	11.5 (19.4)	-23	-7.0	6.0	23.0	55	
		Week 52	Tezepelumab	33	31 (93.9)	12.4 (23.8)	-43	-11.0	21.0	29.0	58	0.03 [-0.48, 0.55]
			Placebo	34	27 (79.4)	11.7 (19.0)	-26	-5.0	12.0	23.0	54	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	62.7 (18.3)	34	49.0	64.0	73.0	100	
			Placebo	31	28 (90.3)	59.3 (14.6)	32	49.5	53.5	70.0	96	
		Week 4	Tezepelumab	32	31 (96.9)	67.5 (20.4)	21	53.0	67.0	89.0	100	
			Placebo	31	30 (96.8)	65.6 (17.1)	23	51.0	68.0	80.0	92	
		Week 8	Tezepelumab	32	31 (96.9)	71.5 (20.0)	20	60.0	71.0	87.0	100	
			Placebo	31	30 (96.8)	66.8 (17.1)	43	51.0	62.0	79.0	100	
		Week 12	Tezepelumab	32	31 (96.9)	70.9 (20.2)	26	58.0	75.0	85.0	100	
			Placebo	31	30 (96.8)	69.3 (18.3)	20	60.0	70.5	86.0	100	
		Week 20	Tezepelumab	32	31 (96.9)	70.9 (20.5)	18	57.0	77.0	85.0	100	
			Placebo	31	30 (96.8)	68.5 (18.9)	20	53.0	69.0	84.0	100	
		Week 28	Tezepelumab	32	31 (96.9)	70.9 (21.1)	8	60.0	75.0	85.0	100	
			Placebo	31	30 (96.8)	69.8 (17.5)	30	57.0	72.5	82.0	100	
		Week 40	Tezepelumab	32	31 (96.9)	72.5 (20.2)	18	65.0	78.0	85.0	100	
			Placebo	31	30 (96.8)	65.6 (18.1)	20	50.0	67.5	78.0	100	
		Week 52	Tezepelumab	32	32 (100.0)	73.0 (20.1)	19	64.5	75.0	89.5	100	
			Placebo	31	30 (96.8)	70.2 (17.8)	30	61.0	74.5	82.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	32	26 (81.3)	4.6 (20.2)	-30	-13.0	1.5	19.0	40	-0.10 [-0.63, 0.44]
			Placebo	31	28 (90.3)	6.4 (17.1)	-26	-3.0	4.5	19.0	51	
		Week 8	Tezepelumab	32	26 (81.3)	7.6 (14.2)	-29	-1.0	11.5	19.0	26	0.02 [-0.51, 0.56]
			Placebo	31	28 (90.3)	7.3 (16.0)	-24	-3.0	2.0	14.5	51	
		Week 12	Tezepelumab	32	26 (81.3)	6.9 (15.4)	-23	-1.0	5.5	16.0	36	-0.17 [-0.71, 0.36]
			Placebo	31	28 (90.3)	9.9 (18.7)	-34	0.0	8.0	21.5	51	
		Week 20	Tezepelumab	32	26 (81.3)	8.2 (19.1)	-31	-9.0	6.5	25.0	50	-0.10 [-0.63, 0.44]
			Placebo	31	28 (90.3)	9.9 (16.0)	-25	-2.0	9.0	15.0	51	
		Week 28	Tezepelumab	32	26 (81.3)	7.8 (19.8)	-41	-6.0	6.5	23.0	40	-0.18 [-0.71, 0.36]
			Placebo	31	28 (90.3)	10.9 (13.4)	-15	0.5	8.5	21.0	36	
		Week 40	Tezepelumab	32	26 (81.3)	9.9 (18.8)	-31	-5.0	9.0	25.0	40	0.19 [-0.35, 0.72]
			Placebo	31	28 (90.3)	6.7 (15.0)	-25	-2.5	4.5	16.5	34	
		Week 52	Tezepelumab	32	26 (81.3)	10.1 (18.9)	-30	-2.0	14.0	21.0	53	-0.06 [-0.60, 0.47]
			Placebo	31	28 (90.3)	11.3 (18.2)	-15	-2.0	6.0	22.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	39	32 (82.1)	55.6 (14.9)	29	48.0	51.0	68.0	90	
			Placebo	30	23 (76.7)	58.2 (14.1)	41	50.0	51.0	65.0	96	
		Week 4	Tezepelumab	39	36 (92.3)	64.4 (17.9)	21	50.0	66.5	79.0	92	
			Placebo	30	25 (83.3)	67.5 (15.4)	45	57.0	60.0	77.0	99	
		Week 8	Tezepelumab	39	36 (92.3)	64.4 (18.8)	20	54.0	66.5	77.0	95	
			Placebo	30	25 (83.3)	64.8 (21.7)	14	52.0	60.0	83.0	97	
		Week 12	Tezepelumab	39	36 (92.3)	66.0 (18.7)	26	50.0	69.5	80.5	97	
			Placebo	30	25 (83.3)	67.9 (19.3)	34	57.0	62.0	88.0	95	
		Week 20	Tezepelumab	39	37 (94.9)	65.9 (19.8)	18	54.0	68.0	78.0	97	
			Placebo	30	25 (83.3)	67.5 (20.2)	22	55.0	64.0	85.0	94	
		Week 28	Tezepelumab	39	38 (97.4)	65.8 (20.0)	8	50.0	69.5	82.0	95	
			Placebo	30	26 (86.7)	69.9 (19.7)	30	53.0	71.5	91.0	94	
		Week 40	Tezepelumab	39	38 (97.4)	66.1 (19.2)	18	49.0	68.0	81.0	94	
			Placebo	30	26 (86.7)	70.9 (19.4)	37	54.0	72.0	90.0	95	
		Week 52	Tezepelumab	39	39 (100.0)	65.2 (19.0)	19	52.0	68.0	81.0	93	
			Placebo	30	26 (86.7)	71.0 (20.9)	21	52.0	77.5	86.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	39	32 (82.1)	8.9 (20.1)	-40	-3.5	13.5	26.0	47	-0.05 [-0.59, 0.48]
			Placebo	30	23 (76.7)	9.8 (12.2)	-11	4.0	8.0	17.0	41	
		Week 8	Tezepelumab	39	32 (82.1)	7.6 (22.5)	-59	-3.5	12.5	21.5	38	0.05 [-0.49, 0.58]
			Placebo	30	23 (76.7)	6.6 (18.5)	-36	-3.0	6.0	20.0	40	
		Week 12	Tezepelumab	39	32 (82.1)	9.4 (21.1)	-34	-4.5	11.0	27.5	41	-0.03 [-0.57, 0.50]
			Placebo	30	23 (76.7)	10.0 (17.7)	-17	-4.0	8.0	25.0	43	
		Week 20	Tezepelumab	39	32 (82.1)	9.7 (22.2)	-44	-9.5	12.5	25.0	41	0.00 [-0.53, 0.54]
			Placebo	30	23 (76.7)	9.7 (17.8)	-25	-4.0	9.0	26.0	39	
		Week 28	Tezepelumab	39	32 (82.1)	9.5 (23.5)	-43	-8.5	14.0	26.5	50	-0.03 [-0.56, 0.51]
			Placebo	30	23 (76.7)	10.1 (16.5)	-20	-3.0	8.0	24.0	37	
		Week 40	Tezepelumab	39	32 (82.1)	9.3 (22.2)	-43	-7.5	15.5	25.5	40	-0.14 [-0.68, 0.39]
			Placebo	30	23 (76.7)	12.3 (17.8)	-12	-4.0	4.0	32.0	45	
		Week 52	Tezepelumab	39	32 (82.1)	8.3 (22.4)	-43	-10.5	14.5	26.5	45	-0.15 [-0.69, 0.38]
			Placebo	30	23 (76.7)	11.5 (18.8)	-26	-5.0	11.0	30.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	27	26 (96.3)	60.7 (19.9)	20	50.0	60.5	73.0	100	
			Placebo	34	31 (91.2)	59.3 (14.8)	29	50.0	60.0	70.0	88	
		Week 4	Tezepelumab	27	27 (100.0)	68.9 (21.2)	14	50.0	66.0	90.0	100	
			Placebo	34	32 (94.1)	64.0 (19.3)	17	50.0	69.0	78.0	95	
		Week 8	Tezepelumab	27	27 (100.0)	73.3 (19.5)	35	55.0	75.0	90.0	100	
			Placebo	34	33 (97.1)	67.3 (19.0)	19	51.0	64.0	85.0	100	
		Week 12	Tezepelumab	27	27 (100.0)	73.2 (19.4)	33	58.0	75.0	90.0	100	
			Placebo	34	33 (97.1)	68.4 (18.9)	20	60.0	69.0	84.0	100	
		Week 20	Tezepelumab	27	27 (100.0)	73.4 (18.6)	34	60.0	80.0	87.0	100	
			Placebo	34	33 (97.1)	68.2 (18.8)	20	56.0	69.0	83.0	100	
		Week 28	Tezepelumab	27	27 (100.0)	73.6 (18.1)	32	60.0	77.0	90.0	100	
			Placebo	34	33 (97.1)	69.4 (18.5)	27	56.0	70.0	85.0	100	
		Week 40	Tezepelumab	27	27 (100.0)	76.0 (17.9)	32	65.0	80.0	92.0	100	
			Placebo	34	33 (97.1)	64.8 (19.1)	20	50.0	67.0	76.0	100	
		Week 52	Tezepelumab	27	27 (100.0)	76.1 (20.0)	25	64.0	80.0	92.0	100	
			Placebo	34	33 (97.1)	69.2 (18.6)	27	60.0	73.0	80.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	27	26 (96.3)	7.2 (18.1)	-27	-6.0	9.0	19.0	40	0.12 [-0.40, 0.65]
			Placebo	34	31 (91.2)	5.1 (16.5)	-26	-7.0	4.0	17.0	51	
		Week 8	Tezepelumab	27	26 (96.3)	11.8 (16.6)	-16	0.0	11.5	19.0	69	0.19 [-0.34, 0.71]
			Placebo	34	31 (91.2)	8.3 (20.1)	-24	-5.0	4.0	19.0	62	
		Week 12	Tezepelumab	27	26 (96.3)	11.7 (17.4)	-16	1.0	6.5	19.0	65	0.14 [-0.38, 0.66]
			Placebo	34	31 (91.2)	9.1 (20.5)	-34	-1.0	5.0	21.0	68	
		Week 20	Tezepelumab	27	26 (96.3)	12.3 (18.2)	-16	-2.0	10.0	26.0	51	0.16 [-0.36, 0.68]
			Placebo	34	31 (91.2)	9.6 (15.5)	-25	-2.0	8.0	21.0	51	
		Week 28	Tezepelumab	27	26 (96.3)	12.2 (19.6)	-16	-1.0	9.5	33.0	60	0.08 [-0.44, 0.61]
			Placebo	34	31 (91.2)	10.7 (15.8)	-15	-1.0	9.0	18.0	65	
		Week 40	Tezepelumab	27	26 (96.3)	14.7 (19.0)	-16	0.0	12.5	31.0	58	0.46 [-0.07, 0.99]
			Placebo	34	31 (91.2)	6.5 (17.0)	-25	-3.0	6.0	18.0	55	
		Week 52	Tezepelumab	27	26 (96.3)	14.7 (19.9)	-16	0.0	18.0	24.0	58	0.18 [-0.35, 0.70]
			Placebo	34	31 (91.2)	11.3 (18.7)	-15	-2.0	6.0	22.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	27	23 (85.2)	56.3 (13.8)	38	49.0	51.0	69.0	90	
			Placebo	29	23 (79.3)	55.6 (11.2)	29	50.0	53.0	63.0	80	
		Week 4	Tezepelumab	27	26 (96.3)	66.3 (17.6)	21	50.0	66.5	79.0	92	
			Placebo	29	26 (89.7)	61.1 (18.4)	17	51.0	60.0	74.0	99	
		Week 8	Tezepelumab	27	26 (96.3)	67.0 (17.6)	31	55.0	70.0	77.0	95	
			Placebo	29	27 (93.1)	59.6 (20.3)	14	50.0	56.0	75.0	97	
		Week 12	Tezepelumab	27	26 (96.3)	67.2 (19.2)	33	51.0	70.0	83.0	94	
			Placebo	29	27 (93.1)	63.0 (19.2)	20	54.0	67.0	75.0	91	
		Week 20	Tezepelumab	27	26 (96.3)	67.8 (19.2)	34	53.0	70.0	82.0	97	
			Placebo	29	27 (93.1)	61.0 (21.7)	20	46.0	64.0	81.0	95	
		Week 28	Tezepelumab	27	27 (100.0)	68.7 (18.8)	32	51.0	71.0	85.0	93	
			Placebo	29	27 (93.1)	63.6 (19.3)	27	49.0	68.0	80.0	93	
		Week 40	Tezepelumab	27	27 (100.0)	69.7 (18.8)	32	51.0	75.0	85.0	95	
			Placebo	29	27 (93.1)	61.9 (20.1)	20	48.0	66.0	76.0	95	
		Week 52	Tezepelumab	27	27 (100.0)	66.4 (20.0)	25	52.0	70.0	83.0	94	
			Placebo	29	27 (93.1)	63.6 (20.6)	21	47.0	68.0	80.0	96	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	7.9 (22.2)	-40	-5.0	15.0	26.0	47	0.10 [-0.48, 0.68]
			Placebo	29	23 (79.3)	6.0 (16.6)	-26	-4.0	6.0	21.0	41	
		Week 8	Tezepelumab	27	23 (85.2)	8.5 (21.1)	-59	-1.0	10.0	21.0	38	0.26 [-0.32, 0.84]
			Placebo	29	23 (79.3)	3.2 (20.5)	-36	-8.0	1.0	18.0	41	
		Week 12	Tezepelumab	27	23 (85.2)	8.5 (20.4)	-31	-5.0	7.0	31.0	41	0.08 [-0.50, 0.66]
			Placebo	29	23 (79.3)	6.9 (20.0)	-34	-4.0	6.0	21.0	43	
		Week 20	Tezepelumab	27	23 (85.2)	10.0 (19.6)	-20	-10.0	10.0	25.0	41	0.23 [-0.35, 0.81]
			Placebo	29	23 (79.3)	5.6 (19.7)	-32	-6.0	8.0	21.0	39	
		Week 28	Tezepelumab	27	23 (85.2)	10.3 (21.8)	-43	-6.0	8.0	32.0	50	0.16 [-0.42, 0.74]
			Placebo	29	23 (79.3)	7.3 (16.6)	-20	-5.0	6.0	17.0	36	
		Week 40	Tezepelumab	27	23 (85.2)	11.2 (21.4)	-43	-3.0	13.0	33.0	40	0.20 [-0.38, 0.78]
			Placebo	29	23 (79.3)	7.1 (20.1)	-25	-7.0	3.0	25.0	45	
		Week 52	Tezepelumab	27	23 (85.2)	8.8 (22.2)	-43	-10.0	13.0	25.0	45	0.01 [-0.57, 0.59]
			Placebo	29	23 (79.3)	8.6 (19.3)	-26	-6.0	6.0	24.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	59.5 (20.0)	20	44.5	59.0	72.5	100	
			Placebo	33	29 (87.9)	59.7 (15.8)	32	50.0	60.0	70.0	96	
		Week 4	Tezepelumab	34	33 (97.1)	66.0 (20.6)	14	50.0	66.0	81.0	100	
			Placebo	33	29 (87.9)	67.8 (15.7)	45	54.0	69.0	81.0	95	
		Week 8	Tezepelumab	34	33 (97.1)	67.8 (21.3)	20	49.0	68.0	85.0	100	
			Placebo	33	29 (87.9)	70.0 (17.8)	43	54.0	62.0	87.0	96	
		Week 12	Tezepelumab	34	33 (97.1)	69.3 (19.8)	26	56.0	70.0	85.0	100	
			Placebo	33	29 (87.9)	71.1 (17.0)	42	61.0	67.0	87.0	100	
		Week 20	Tezepelumab	34	33 (97.1)	69.5 (20.8)	18	60.0	71.0	83.0	100	
			Placebo	33	29 (87.9)	71.0 (16.0)	46	56.0	69.0	85.0	94	
		Week 28	Tezepelumab	34	33 (97.1)	68.6 (20.9)	8	53.0	71.0	83.0	100	
			Placebo	33	30 (90.9)	72.2 (17.2)	46	57.0	73.5	90.0	97	
		Week 40	Tezepelumab	34	33 (97.1)	70.2 (19.9)	18	56.0	73.0	81.0	100	
			Placebo	33	30 (90.9)	71.1 (17.0)	43	55.0	71.0	87.0	96	
		Week 52	Tezepelumab	34	34 (100.0)	71.1 (20.8)	19	57.0	75.5	88.0	100	
			Placebo	33	30 (90.9)	73.9 (16.4)	45	61.0	76.0	87.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	34	32 (94.1)	6.7 (16.9)	-23	-6.0	9.0	17.0	40	-0.09 [-0.59, 0.41]
			Placebo	33	29 (87.9)	8.1 (13.8)	-12	-1.0	7.0	16.0	51	
		Week 8	Tezepelumab	34	32 (94.1)	8.5 (19.7)	-46	-2.5	11.5	17.0	69	-0.09 [-0.60, 0.41]
			Placebo	33	29 (87.9)	10.3 (18.5)	-14	-1.0	6.0	20.0	62	
		Week 12	Tezepelumab	34	32 (94.1)	10.0 (18.9)	-34	1.0	6.5	20.5	65	-0.07 [-0.58, 0.43]
			Placebo	33	29 (87.9)	11.4 (19.1)	-16	-1.0	8.0	21.0	68	
		Week 20	Tezepelumab	34	32 (94.1)	10.1 (21.6)	-44	-5.5	11.0	25.5	51	-0.06 [-0.57, 0.44]
			Placebo	33	29 (87.9)	11.3 (15.2)	-10	-2.0	9.0	19.0	51	
		Week 28	Tezepelumab	34	32 (94.1)	9.4 (22.2)	-41	-5.5	10.0	23.0	60	-0.13 [-0.63, 0.38]
			Placebo	33	29 (87.9)	11.9 (16.2)	-16	2.0	8.0	20.0	65	
		Week 40	Tezepelumab	34	32 (94.1)	10.8 (21.3)	-33	-5.5	12.5	25.5	58	0.02 [-0.49, 0.52]
			Placebo	33	29 (87.9)	10.6 (15.5)	-17	2.0	8.0	20.0	55	
		Week 52	Tezepelumab	34	32 (94.1)	11.6 (21.7)	-30	-8.0	16.0	25.0	58	-0.09 [-0.59, 0.41]
			Placebo	33	29 (87.9)	13.4 (18.5)	-8	-1.0	10.0	22.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	56.4 (15.9)	20	50.0	52.0	69.5	90	
			Placebo	14	11 (78.6)	58.0 (13.7)	45	50.0	51.0	65.0	86	
		Week 4	Tezepelumab	23	21 (91.3)	61.4 (20.9)	14	50.0	60.0	78.0	91	
			Placebo	14	11 (78.6)	63.4 (19.4)	23	57.0	61.0	76.0	94	
		Week 8	Tezepelumab	23	21 (91.3)	65.5 (19.0)	31	55.0	65.0	87.0	94	
			Placebo	14	11 (78.6)	58.5 (24.5)	14	46.0	55.0	82.0	94	
		Week 12	Tezepelumab	23	21 (91.3)	67.7 (19.7)	33	51.0	69.0	84.0	97	
			Placebo	14	11 (78.6)	60.0 (23.8)	20	40.0	61.0	78.0	94	
		Week 20	Tezepelumab	23	22 (95.7)	66.2 (19.1)	34	53.0	70.0	81.0	97	
			Placebo	14	11 (78.6)	56.7 (29.1)	20	28.0	61.0	85.0	95	
		Week 28	Tezepelumab	23	23 (100.0)	66.1 (19.4)	32	50.0	67.0	81.0	95	
			Placebo	14	11 (78.6)	58.5 (23.8)	30	32.0	53.0	80.0	94	
		Week 40	Tezepelumab	23	23 (100.0)	67.1 (19.5)	32	51.0	68.0	84.0	93	
			Placebo	14	11 (78.6)	58.8 (24.7)	20	37.0	61.0	76.0	95	
		Week 52	Tezepelumab	23	23 (100.0)	65.4 (19.9)	25	52.0	66.0	84.0	93	
			Placebo	14	11 (78.6)	61.8 (24.6)	21	38.0	73.0	80.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	4.6 (21.2)	-40	-11.0	10.0	19.0	30	-0.04 [-0.78, 0.70]
			Placebo	14	11 (78.6)	5.4 (13.0)	-22	-4.0	8.0	10.0	26	
		Week 8	Tezepelumab	23	20 (87.0)	9.0 (26.1)	-59	-4.5	7.0	23.0	69	0.35 [-0.39, 1.09]
			Placebo	14	11 (78.6)	0.5 (18.9)	-36	-8.0	6.0	10.0	32	
		Week 12	Tezepelumab	23	20 (87.0)	10.6 (22.9)	-31	-3.5	8.0	26.0	65	0.42 [-0.33, 1.16]
			Placebo	14	11 (78.6)	2.0 (15.0)	-25	-10.0	8.0	14.0	21	
		Week 20	Tezepelumab	23	20 (87.0)	8.9 (20.1)	-20	-7.0	4.0	24.5	51	0.48 [-0.26, 1.23]
			Placebo	14	11 (78.6)	-1.3 (22.7)	-32	-25.0	-4.0	21.0	35	
		Week 28	Tezepelumab	23	20 (87.0)	8.8 (24.1)	-43	-8.5	8.0	26.5	60	0.39 [-0.36, 1.13]
			Placebo	14	11 (78.6)	0.5 (15.6)	-20	-15.0	-3.0	13.0	26	
		Week 40	Tezepelumab	23	20 (87.0)	8.3 (22.9)	-43	-8.0	12.0	22.5	58	0.34 [-0.40, 1.08]
			Placebo	14	11 (78.6)	0.8 (20.2)	-25	-10.0	-6.0	16.0	45	
		Week 52	Tezepelumab	23	20 (87.0)	7.9 (22.8)	-43	-11.5	11.5	22.5	58	0.19 [-0.55, 0.93]
			Placebo	14	11 (78.6)	3.8 (19.0)	-26	-13.0	-4.0	23.0	30	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	59.0 (18.1)	29	45.0	55.0	72.0	100	
			Placebo	44	37 (84.1)	59.4 (15.2)	29	50.0	57.0	69.0	96	
		Week 4	Tezepelumab	40	39 (97.5)	69.4 (18.7)	30	50.0	70.0	88.0	100	
			Placebo	44	40 (90.9)	66.3 (17.7)	17	52.5	69.0	80.5	99	
		Week 8	Tezepelumab	40	39 (97.5)	70.8 (19.9)	20	60.0	74.0	87.0	100	
			Placebo	44	41 (93.2)	68.4 (18.7)	19	53.0	65.0	85.0	100	
		Week 12	Tezepelumab	40	39 (97.5)	71.0 (18.9)	26	58.0	72.0	88.0	100	
			Placebo	44	41 (93.2)	70.9 (17.1)	30	60.0	70.0	87.0	100	
		Week 20	Tezepelumab	40	39 (97.5)	71.5 (20.0)	18	62.0	77.0	87.0	100	
			Placebo	44	41 (93.2)	70.5 (16.5)	27	60.0	69.0	85.0	100	
		Week 28	Tezepelumab	40	39 (97.5)	71.2 (20.2)	8	60.0	75.0	88.0	100	
			Placebo	44	42 (95.5)	72.7 (16.7)	27	61.0	72.5	86.0	100	
		Week 40	Tezepelumab	40	39 (97.5)	72.8 (19.3)	18	65.0	78.0	85.0	100	
			Placebo	44	42 (95.5)	70.2 (17.8)	27	54.0	70.0	87.0	100	
		Week 52	Tezepelumab	40	40 (100.0)	73.3 (19.7)	19	64.0	78.5	88.0	100	
			Placebo	44	42 (95.5)	73.1 (18.0)	27	61.0	74.5	87.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	40	35 (87.5)	10.4 (17.5)	-27	-1.0	13.0	26.0	47	0.17 [-0.29, 0.63]
			Placebo	44	37 (84.1)	7.6 (15.7)	-26	-2.0	6.0	17.0	51	
		Week 8	Tezepelumab	40	35 (87.5)	10.7 (16.5)	-46	2.0	14.0	21.0	38	0.07 [-0.39, 0.53]
			Placebo	44	37 (84.1)	9.5 (19.4)	-24	-3.0	6.0	20.0	62	
		Week 12	Tezepelumab	40	35 (87.5)	11.5 (17.9)	-34	1.0	12.0	25.0	41	-0.03 [-0.49, 0.44]
			Placebo	44	37 (84.1)	12.0 (20.3)	-34	1.0	8.0	25.0	68	
		Week 20	Tezepelumab	40	35 (87.5)	12.7 (20.8)	-44	0.0	13.0	26.0	50	0.03 [-0.43, 0.49]
			Placebo	44	37 (84.1)	12.2 (14.7)	-8	-2.0	10.0	21.0	51	
		Week 28	Tezepelumab	40	35 (87.5)	12.1 (20.5)	-41	0.0	11.0	31.0	50	-0.06 [-0.53, 0.40]
			Placebo	44	37 (84.1)	13.2 (15.3)	-8	2.0	9.0	24.0	65	
		Week 40	Tezepelumab	40	35 (87.5)	14.3 (19.6)	-33	3.0	18.0	33.0	40	0.15 [-0.31, 0.62]
			Placebo	44	37 (84.1)	11.6 (16.7)	-23	2.0	11.0	22.0	55	
		Week 52	Tezepelumab	40	35 (87.5)	14.2 (20.6)	-30	-1.0	19.0	29.0	53	-0.01 [-0.47, 0.45]
			Placebo	44	37 (84.1)	14.4 (18.6)	-13	-2.0	12.0	24.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	56.0 (23.1)	34	34.0	54.0	80.0	80	
			Placebo	7	7 (100.0)	57.4 (11.8)	41	47.0	60.0	70.0	70	
		Week 4	Tezepelumab	3	3 (100.0)	61.7 (11.9)	48	48.0	67.0	70.0	70	
			Placebo	7	7 (100.0)	64.0 (15.1)	48	49.0	60.0	73.0	91	
		Week 8	Tezepelumab	3	3 (100.0)	54.0 (12.3)	45	45.0	49.0	68.0	68	
			Placebo	7	7 (100.0)	63.7 (19.2)	43	48.0	60.0	87.0	93	
		Week 12	Tezepelumab	3	3 (100.0)	53.0 (16.7)	35	35.0	56.0	68.0	68	
			Placebo	7	7 (100.0)	66.6 (18.2)	42	48.0	64.0	86.0	90	
		Week 20	Tezepelumab	3	3 (100.0)	58.3 (10.6)	47	47.0	60.0	68.0	68	
			Placebo	7	7 (100.0)	64.6 (16.7)	47	48.0	56.0	82.0	85	
		Week 28	Tezepelumab	3	3 (100.0)	63.7 (9.3)	53	53.0	68.0	70.0	70	
			Placebo	7	7 (100.0)	65.9 (18.5)	47	48.0	63.0	84.0	88	
		Week 40	Tezepelumab	3	3 (100.0)	60.3 (10.8)	48	48.0	65.0	68.0	68	
			Placebo	7	7 (100.0)	66.3 (15.9)	46	48.0	68.0	81.0	85	
		Week 52	Tezepelumab	3	3 (100.0)	52.7 (14.2)	40	40.0	50.0	68.0	68	
			Placebo	7	7 (100.0)	65.1 (15.2)	45	48.0	66.0	78.0	85	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	5.7 (26.5)	-13	-13.0	-6.0	36.0	36	-0.05 [-1.40, 1.30]
			Placebo	7	7 (100.0)	6.6 (13.7)	-12	-5.0	8.0	21.0	26	
		Week 8	Tezepelumab	3	3 (100.0)	-2.0 (11.8)	-12	-12.0	-5.0	11.0	11	-0.48 [-1.85, 0.89]
			Placebo	7	7 (100.0)	6.3 (18.7)	-12	-10.0	2.0	23.0	40	
		Week 12	Tezepelumab	3	3 (100.0)	-3.0 (7.8)	-12	-12.0	1.0	2.0	2	-0.83 [-2.25, 0.58]
			Placebo	7	7 (100.0)	9.1 (16.2)	-4	-1.0	4.0	16.0	43	
		Week 20	Tezepelumab	3	3 (100.0)	2.3 (20.6)	-12	-12.0	-7.0	26.0	26	-0.28 [-1.64, 1.08]
			Placebo	7	7 (100.0)	7.1 (15.6)	-10	-4.0	6.0	12.0	38	
		Week 28	Tezepelumab	3	3 (100.0)	7.7 (25.1)	-12	-12.0	-1.0	36.0	36	-0.04 [-1.39, 1.31]
			Placebo	7	7 (100.0)	8.4 (16.5)	-16	-1.0	6.0	18.0	37	
		Week 40	Tezepelumab	3	3 (100.0)	4.3 (23.3)	-12	-12.0	-6.0	31.0	31	-0.28 [-1.64, 1.08]
			Placebo	7	7 (100.0)	8.9 (13.1)	-7	-1.0	8.0	15.0	34	
		Week 52	Tezepelumab	3	3 (100.0)	-3.3 (16.8)	-14	-14.0	-12.0	16.0	16	-0.74 [-2.14, 0.66]
			Placebo	7	7 (100.0)	7.7 (14.2)	-6	-1.0	5.0	8.0	38	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	55.8 (16.4)	35	43.5	53.0	67.5	83	
			Placebo	13	9 (69.2)	58.8 (8.8)	45	50.0	60.0	65.0	70	
		Week 4	Tezepelumab	9	9 (100.0)	70.1 (14.5)	44	66.0	70.0	81.0	92	
			Placebo	13	11 (84.6)	58.4 (17.9)	23	48.0	54.0	69.0	91	
		Week 8	Tezepelumab	9	9 (100.0)	70.1 (22.0)	35	60.0	73.0	87.0	95	
			Placebo	13	12 (92.3)	63.3 (13.1)	48	53.0	61.5	67.0	93	
		Week 12	Tezepelumab	9	9 (100.0)	67.4 (23.4)	33	48.0	66.0	89.0	97	
			Placebo	13	12 (92.3)	60.2 (15.8)	20	55.5	63.0	68.0	86	
		Week 20	Tezepelumab	9	9 (100.0)	68.2 (24.1)	34	40.0	77.0	85.0	97	
			Placebo	13	12 (92.3)	58.8 (15.5)	20	52.5	60.5	69.0	82	
		Week 28	Tezepelumab	9	9 (100.0)	66.4 (22.4)	32	50.0	71.0	85.0	95	
			Placebo	13	13 (100.0)	64.7 (16.6)	30	54.0	68.0	73.0	92	
		Week 40	Tezepelumab	9	9 (100.0)	67.7 (22.7)	32	50.0	75.0	81.0	95	
			Placebo	13	13 (100.0)	60.9 (18.7)	20	53.0	61.0	71.0	95	
		Week 52	Tezepelumab	9	9 (100.0)	68.1 (24.6)	25	50.0	75.0	88.0	95	
			Placebo	13	13 (100.0)	62.0 (16.9)	30	48.0	64.0	73.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	12.6 (16.3)	-17	1.5	19.0	23.0	31	0.70 [-0.29, 1.68]
			Placebo	13	9 (69.2)	1.8 (14.9)	-22	-6.0	-1.0	9.0	26	
		Week 8	Tezepelumab	9	8 (88.9)	12.3 (12.8)	-10	3.5	15.5	22.5	25	0.51 [-0.46, 1.48]
			Placebo	13	9 (69.2)	5.7 (13.2)	-8	-1.0	1.0	6.0	32	
		Week 12	Tezepelumab	9	8 (88.9)	10.1 (14.7)	-10	-1.0	10.0	19.5	34	0.76 [-0.23, 1.76]
			Placebo	13	9 (69.2)	-0.1 (12.1)	-25	-4.0	1.0	4.0	16	
		Week 20	Tezepelumab	9	8 (88.9)	11.4 (22.7)	-11	-7.0	3.0	30.0	50	0.62 [-0.36, 1.60]
			Placebo	13	9 (69.2)	0.1 (13.1)	-25	-4.0	-1.0	7.0	21	
		Week 28	Tezepelumab	9	8 (88.9)	8.4 (19.3)	-13	-8.0	3.0	27.0	36	0.34 [-0.62, 1.30]
			Placebo	13	9 (69.2)	3.0 (12.0)	-15	-4.0	3.0	8.0	23	
		Week 40	Tezepelumab	9	8 (88.9)	11.0 (19.0)	-13	-8.0	14.5	24.0	40	0.58 [-0.39, 1.56]
			Placebo	13	9 (69.2)	1.4 (13.8)	-25	-4.0	2.0	8.0	23	
		Week 52	Tezepelumab	9	8 (88.9)	11.5 (23.2)	-13	-11.5	14.0	23.5	53	0.51 [-0.46, 1.48]
			Placebo	13	9 (69.2)	2.3 (11.3)	-15	-4.0	2.0	6.0	23	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	58.3 (17.6)	20	49.0	52.5	71.0	100	
			Placebo	52	46 (88.5)	58.9 (15.2)	29	50.0	53.5	70.0	96	
		Week 4	Tezepelumab	57	54 (94.7)	65.7 (20.1)	14	50.0	66.0	86.0	100	
			Placebo	52	47 (90.4)	67.1 (17.2)	17	57.0	69.0	81.0	99	
		Week 8	Tezepelumab	57	54 (94.7)	67.9 (19.3)	20	55.0	69.5	85.0	100	
			Placebo	52	47 (90.4)	66.7 (21.4)	14	51.0	64.0	87.0	100	
		Week 12	Tezepelumab	57	54 (94.7)	69.3 (18.7)	26	56.0	70.5	84.0	100	
			Placebo	52	47 (90.4)	70.4 (19.0)	30	58.0	72.0	88.0	100	
		Week 20	Tezepelumab	57	55 (96.5)	69.2 (18.9)	18	55.0	70.0	82.0	100	
			Placebo	52	47 (90.4)	69.4 (20.3)	22	55.0	69.0	86.0	100	
		Week 28	Tezepelumab	57	56 (98.2)	69.4 (19.2)	8	53.0	72.0	83.0	100	
			Placebo	52	47 (90.4)	70.5 (19.4)	27	53.0	74.0	86.0	100	
		Week 40	Tezepelumab	57	56 (98.2)	70.7 (18.7)	18	54.5	74.5	84.0	100	
			Placebo	52	47 (90.4)	69.5 (19.1)	27	54.0	71.0	87.0	100	
		Week 52	Tezepelumab	57	57 (100.0)	69.9 (19.4)	19	54.0	73.0	84.0	100	
			Placebo	52	47 (90.4)	72.3 (19.6)	21	60.0	77.0	86.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	50 (87.7)	7.5 (19.5)	-40	-6.0	10.0	19.0	47	-0.03 [-0.44, 0.37]
			Placebo	52	46 (88.5)	8.1 (14.7)	-26	-1.0	7.0	17.0	51	
		Week 8	Tezepelumab	57	50 (87.7)	9.0 (21.0)	-59	-1.0	11.5	20.0	69	0.07 [-0.33, 0.47]
			Placebo	52	46 (88.5)	7.6 (20.3)	-36	-5.0	6.0	19.0	62	
		Week 12	Tezepelumab	57	50 (87.7)	10.5 (20.2)	-34	-1.0	8.0	23.0	65	-0.05 [-0.45, 0.35]
			Placebo	52	46 (88.5)	11.5 (19.6)	-34	-1.0	9.0	25.0	68	
		Week 20	Tezepelumab	57	50 (87.7)	10.8 (20.2)	-44	-4.0	12.5	25.0	51	0.01 [-0.39, 0.41]
			Placebo	52	46 (88.5)	10.6 (17.5)	-32	-2.0	9.5	21.0	51	
		Week 28	Tezepelumab	57	50 (87.7)	11.1 (22.2)	-43	-1.0	10.0	28.0	60	-0.02 [-0.42, 0.38]
			Placebo	52	46 (88.5)	11.5 (16.5)	-20	2.0	9.0	24.0	65	
		Week 40	Tezepelumab	57	50 (87.7)	11.8 (21.3)	-43	-1.0	14.0	30.0	58	0.06 [-0.34, 0.47]
			Placebo	52	46 (88.5)	10.6 (17.6)	-23	-2.0	7.0	22.0	55	
		Week 52	Tezepelumab	57	50 (87.7)	11.1 (21.3)	-43	-4.0	18.0	25.0	58	-0.11 [-0.51, 0.29]
			Placebo	52	46 (88.5)	13.2 (19.1)	-26	-2.0	11.0	27.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	50.3 (20.8)	20	39.0	48.0	72.0	75	
			Placebo	3	2 (66.7)	48.0 (4.2)	45	45.0	48.0	51.0	51	
		Week 4	Tezepelumab	7	7 (100.0)	60.9 (26.4)	14	48.0	66.0	86.0	92	
			Placebo	3	3 (100.0)	38.0 (13.0)	23	23.0	45.0	46.0	46	
		Week 8	Tezepelumab	7	7 (100.0)	78.6 (12.8)	60	69.0	77.0	89.0	95	
			Placebo	3	3 (100.0)	44.0 (13.0)	29	29.0	51.0	52.0	52	
		Week 12	Tezepelumab	7	7 (100.0)	77.0 (14.0)	58	60.0	80.0	85.0	97	
			Placebo	3	3 (100.0)	37.0 (18.7)	20	20.0	34.0	57.0	57	
		Week 20	Tezepelumab	7	7 (100.0)	75.7 (12.6)	63	64.0	71.0	88.0	97	
			Placebo	3	3 (100.0)	41.0 (20.1)	20	20.0	43.0	60.0	60	
		Week 28	Tezepelumab	7	7 (100.0)	77.1 (9.0)	69	70.0	77.0	80.0	95	
			Placebo	3	3 (100.0)	50.7 (22.1)	30	30.0	48.0	74.0	74	
		Week 40	Tezepelumab	7	7 (100.0)	78.4 (9.2)	65	72.0	78.0	85.0	94	
			Placebo	3	3 (100.0)	39.3 (17.5)	20	20.0	44.0	54.0	54	
		Week 52	Tezepelumab	7	7 (100.0)	75.1 (7.7)	64	70.0	73.0	80.0	88	
			Placebo	3	3 (100.0)	44.0 (17.8)	30	30.0	38.0	64.0	64	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	9.0 (25.1)	-27	-6.0	10.0	20.0	47	0.99 [-0.71, 2.68]
			Placebo	3	2 (66.7)	-14.0 (11.3)	-22	-22.0	-14.0	-6.0	-6	
		Week 8	Tezepelumab	7	6 (85.7)	29.8 (21.0)	14	15.0	21.5	38.0	69	1.82 [-0.09, 3.72]
			Placebo	3	2 (66.7)	-8.0 (19.8)	-22	-22.0	-8.0	6.0	6	
		Week 12	Tezepelumab	7	6 (85.7)	25.5 (24.1)	0	7.0	20.0	41.0	65	2.10 [0.11, 4.10]
			Placebo	3	2 (66.7)	-21.0 (5.7)	-25	-25.0	-21.0	-17.0	-17	
		Week 20	Tezepelumab	7	6 (85.7)	25.2 (14.1)	12	13.0	25.0	25.0	51	3.03 [0.69, 5.38]
			Placebo	3	2 (66.7)	-16.5 (12.0)	-25	-25.0	-16.5	-8.0	-8	
		Week 28	Tezepelumab	7	6 (85.7)	26.7 (19.2)	2	18.0	24.0	32.0	60	2.00 [0.04, 3.96]
			Placebo	3	2 (66.7)	-9.0 (8.5)	-15	-15.0	-9.0	-3.0	-3	
		Week 40	Tezepelumab	7	6 (85.7)	27.0 (18.8)	3	20.0	21.5	38.0	58	2.40 [0.30, 4.50]
			Placebo	3	2 (66.7)	-16.0 (12.7)	-25	-25.0	-16.0	-7.0	-7	
		Week 52	Tezepelumab	7	6 (85.7)	25.2 (19.6)	-2	16.0	25.0	29.0	58	2.19 [0.17, 4.22]
			Placebo	3	2 (66.7)	-14.0 (1.4)	-15	-15.0	-14.0	-13.0	-13	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	59	52 (88.1)	58.8 (16.9)	29	49.0	53.5	70.5	100	
			Placebo	62	53 (85.5)	59.3 (14.4)	29	50.0	57.0	69.0	96	
		Week 4	Tezepelumab	59	56 (94.9)	67.0 (18.5)	21	50.0	66.5	82.5	100	
			Placebo	62	55 (88.7)	67.0 (16.5)	17	57.0	69.0	80.0	99	
		Week 8	Tezepelumab	59	56 (94.9)	66.9 (19.9)	20	53.0	69.0	85.0	100	
			Placebo	62	56 (90.3)	67.2 (19.6)	14	53.0	63.0	86.0	100	
		Week 12	Tezepelumab	59	56 (94.9)	68.1 (19.6)	26	52.0	70.0	84.0	100	
			Placebo	62	56 (90.3)	70.0 (17.4)	30	60.0	69.5	87.0	100	
		Week 20	Tezepelumab	59	57 (96.6)	68.3 (20.1)	18	54.0	71.0	82.0	100	
			Placebo	62	56 (90.3)	68.6 (19.0)	22	55.5	69.0	85.0	100	
		Week 28	Tezepelumab	59	58 (98.3)	68.1 (20.2)	8	52.0	70.5	85.0	100	
			Placebo	62	57 (91.9)	70.2 (18.4)	27	56.0	70.0	86.0	100	
		Week 40	Tezepelumab	59	58 (98.3)	69.3 (19.9)	18	51.0	73.5	84.0	100	
			Placebo	62	57 (91.9)	69.1 (18.2)	27	54.0	71.0	86.0	100	
		Week 52	Tezepelumab	59	59 (100.0)	69.0 (20.9)	19	52.0	71.0	86.0	100	
			Placebo	62	57 (91.9)	71.5 (18.6)	21	60.0	75.0	85.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	59	52 (88.1)	8.1 (18.6)	-40	-4.5	11.0	22.5	40	0.01 [-0.37, 0.40]
			Placebo	62	53 (85.5)	7.8 (14.4)	-26	-1.0	7.0	17.0	51	
		Week 8	Tezepelumab	59	52 (88.1)	7.1 (18.7)	-59	-2.0	10.0	19.5	38	-0.04 [-0.42, 0.34]
			Placebo	62	53 (85.5)	7.9 (19.2)	-36	-4.0	4.0	19.0	62	
		Week 12	Tezepelumab	59	52 (88.1)	8.7 (18.3)	-34	-1.0	7.0	22.0	38	-0.12 [-0.50, 0.27]
			Placebo	62	53 (85.5)	10.8 (18.4)	-34	-1.0	8.0	21.0	68	
		Week 20	Tezepelumab	59	52 (88.1)	9.2 (20.4)	-44	-8.0	9.0	25.0	50	-0.03 [-0.41, 0.35]
			Placebo	62	53 (85.5)	9.8 (16.7)	-32	-2.0	9.0	21.0	51	
		Week 28	Tezepelumab	59	52 (88.1)	8.9 (21.3)	-43	-6.5	8.5	26.5	50	-0.10 [-0.48, 0.28]
			Placebo	62	53 (85.5)	10.8 (15.9)	-20	2.0	8.0	20.0	65	
		Week 40	Tezepelumab	59	52 (88.1)	10.0 (20.5)	-43	-5.5	12.5	25.5	40	-0.00 [-0.39, 0.38]
			Placebo	62	53 (85.5)	10.0 (16.8)	-23	-2.0	6.0	21.0	55	
		Week 52	Tezepelumab	59	52 (88.1)	9.5 (21.2)	-43	-10.5	14.5	24.5	53	-0.15 [-0.53, 0.24]
			Placebo	62	53 (85.5)	12.4 (18.1)	-26	-2.0	11.0	23.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	50.2 (23.2)	20	39.0	45.0	72.0	75	
			Placebo	2	1 (50.0)	51.0	51	51.0	51.0	51.0	51	
		Week 4	Tezepelumab	6	6 (100.0)	60.0 (28.8)	14	48.0	60.0	86.0	92	
			Placebo	2	2 (100.0)	45.5 (0.7)	45	45.0	45.5	46.0	46	
		Week 8	Tezepelumab	6	6 (100.0)	79.8 (13.5)	60	69.0	83.0	89.0	95	
			Placebo	2	2 (100.0)	40.5 (16.3)	29	29.0	40.5	52.0	52	
		Week 12	Tezepelumab	6	6 (100.0)	80.2 (12.3)	60	75.0	82.0	85.0	97	
			Placebo	2	2 (100.0)	45.5 (16.3)	34	34.0	45.5	57.0	57	
		Week 20	Tezepelumab	6	6 (100.0)	77.8 (12.4)	64	70.0	74.0	88.0	97	
			Placebo	2	2 (100.0)	51.5 (12.0)	43	43.0	51.5	60.0	60	
		Week 28	Tezepelumab	6	6 (100.0)	78.5 (9.0)	70	71.0	77.5	80.0	95	
			Placebo	2	2 (100.0)	61.0 (18.4)	48	48.0	61.0	74.0	74	
		Week 40	Tezepelumab	6	6 (100.0)	79.5 (9.6)	65	77.0	78.0	85.0	94	
			Placebo	2	2 (100.0)	49.0 (7.1)	44	44.0	49.0	54.0	54	
		Week 52	Tezepelumab	6	6 (100.0)	74.3 (8.1)	64	70.0	73.0	78.0	88	
			Placebo	2	2 (100.0)	51.0 (18.4)	38	38.0	51.0	64.0	64	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	6	5 (83.3)	7.8 (27.8)	-27	-6.0	5.0	20.0	47	NE
			Placebo	2	1 (50.0)	-6.0	-6	-6.0	-6.0	-6.0	-6	
		Week 8	Tezepelumab	6	5 (83.3)	31.8 (22.9)	14	15.0	23.0	38.0	69	NE
			Placebo	2	1 (50.0)	-22.0	-22	-22.0	-22.0	-22.0	-22	
		Week 12	Tezepelumab	6	5 (83.3)	29.2 (25.0)	0	15.0	25.0	41.0	65	NE
			Placebo	2	1 (50.0)	-17.0	-17	-17.0	-17.0	-17.0	-17	
		Week 20	Tezepelumab	6	5 (83.3)	27.8 (14.0)	13	25.0	25.0	25.0	51	NE
			Placebo	2	1 (50.0)	-8.0	-8	-8.0	-8.0	-8.0	-8	
		Week 28	Tezepelumab	6	5 (83.3)	28.4 (20.9)	2	23.0	25.0	32.0	60	NE
			Placebo	2	1 (50.0)	-3.0	-3	-3.0	-3.0	-3.0	-3	
		Week 40	Tezepelumab	6	5 (83.3)	28.2 (20.8)	3	20.0	22.0	38.0	58	NE
			Placebo	2	1 (50.0)	-7.0	-7	-7.0	-7.0	-7.0	-7	
		Week 52	Tezepelumab	6	5 (83.3)	24.4 (21.8)	-2	16.0	25.0	25.0	58	NE
			Placebo	2	1 (50.0)	-13.0	-13	-13.0	-13.0	-13.0	-13	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	58.6 (16.8)	29	49.0	53.0	70.0	100	
			Placebo	63	54 (85.7)	59.0 (14.4)	29	50.0	56.0	69.0	96	
		Week 4	Tezepelumab	60	57 (95.0)	67.0 (18.3)	21	50.0	66.0	81.0	100	
			Placebo	63	56 (88.9)	66.2 (17.4)	17	55.5	68.0	78.5	99	
		Week 8	Tezepelumab	60	57 (95.0)	67.0 (19.7)	20	53.0	70.0	85.0	100	
			Placebo	63	57 (90.5)	66.9 (19.6)	14	53.0	62.0	85.0	100	
		Week 12	Tezepelumab	60	57 (95.0)	67.9 (19.5)	26	53.0	70.0	83.0	100	
			Placebo	63	57 (90.5)	69.1 (18.4)	20	60.0	69.0	87.0	100	
		Week 20	Tezepelumab	60	58 (96.7)	68.2 (19.9)	18	54.0	70.5	82.0	100	
			Placebo	63	57 (90.5)	67.8 (19.9)	20	55.0	69.0	85.0	100	
		Week 28	Tezepelumab	60	59 (98.3)	68.1 (20.1)	8	52.0	70.0	85.0	100	
			Placebo	63	58 (92.1)	69.6 (19.0)	27	54.0	69.5	86.0	100	
		Week 40	Tezepelumab	60	59 (98.3)	69.3 (19.7)	18	51.0	73.0	84.0	100	
			Placebo	63	58 (92.1)	68.3 (19.1)	20	54.0	70.0	86.0	100	
		Week 52	Tezepelumab	60	60 (100.0)	69.2 (20.8)	19	52.5	72.0	85.5	100	
			Placebo	63	58 (92.1)	70.7 (19.2)	21	59.0	74.5	85.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	60	53 (88.3)	8.2 (18.4)	-40	-4.0	12.0	19.0	40	0.06 [-0.32, 0.43]
			Placebo	63	54 (85.7)	7.3 (14.8)	-26	-2.0	7.0	17.0	51	
		Week 8	Tezepelumab	60	53 (88.3)	7.4 (18.6)	-59	-1.0	10.0	20.0	38	-0.03 [-0.40, 0.35]
			Placebo	63	54 (85.7)	7.8 (19.0)	-36	-4.0	5.0	19.0	62	
		Week 12	Tezepelumab	60	53 (88.3)	8.6 (18.1)	-34	-1.0	7.0	22.0	38	-0.08 [-0.46, 0.30]
			Placebo	63	54 (85.7)	10.1 (18.9)	-34	-1.0	8.0	21.0	68	
		Week 20	Tezepelumab	60	53 (88.3)	9.3 (20.2)	-44	-7.0	10.0	25.0	50	0.01 [-0.37, 0.38]
			Placebo	63	54 (85.7)	9.2 (17.2)	-32	-2.0	8.5	21.0	51	
		Week 28	Tezepelumab	60	53 (88.3)	9.1 (21.2)	-43	-6.0	9.0	25.0	50	-0.07 [-0.45, 0.31]
			Placebo	63	54 (85.7)	10.3 (16.1)	-20	-1.0	8.0	20.0	65	
		Week 40	Tezepelumab	60	53 (88.3)	10.2 (20.3)	-43	-5.0	13.0	25.0	40	0.04 [-0.34, 0.42]
			Placebo	63	54 (85.7)	9.4 (17.3)	-25	-2.0	5.5	21.0	55	
		Week 52	Tezepelumab	60	53 (88.3)	9.9 (21.1)	-43	-10.0	16.0	25.0	53	-0.10 [-0.48, 0.28]
			Placebo	63	54 (85.7)	11.9 (18.3)	-26	-2.0	10.5	23.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	17	15 (88.2)	60.5 (20.2)	34	40.0	63.0	73.0	100	
			Placebo	21	20 (95.2)	57.6 (13.2)	32	49.5	54.5	68.5	88	
		Week 4	Tezepelumab	17	17 (100.0)	70.2 (18.4)	30	57.0	70.0	88.0	100	
			Placebo	21	21 (100.0)	62.5 (19.0)	23	48.0	59.0	75.0	95	
		Week 8	Tezepelumab	17	17 (100.0)	67.4 (24.2)	20	49.0	69.0	90.0	100	
			Placebo	21	21 (100.0)	63.1 (19.1)	43	50.0	53.0	75.0	100	
		Week 12	Tezepelumab	17	17 (100.0)	67.5 (23.8)	26	48.0	72.0	89.0	100	
			Placebo	21	21 (100.0)	65.2 (21.4)	20	51.0	60.0	86.0	100	
		Week 20	Tezepelumab	17	17 (100.0)	68.5 (23.5)	18	60.0	77.0	81.0	100	
			Placebo	21	21 (100.0)	61.5 (22.2)	20	48.0	63.0	81.0	100	
		Week 28	Tezepelumab	17	17 (100.0)	67.7 (23.9)	8	50.0	73.0	82.0	100	
			Placebo	21	21 (100.0)	67.5 (20.9)	30	48.0	70.0	85.0	100	
		Week 40	Tezepelumab	17	17 (100.0)	69.7 (23.9)	18	52.0	75.0	85.0	100	
			Placebo	21	21 (100.0)	61.6 (21.1)	20	48.0	55.0	76.0	100	
		Week 52	Tezepelumab	17	17 (100.0)	69.2 (26.0)	19	50.0	73.0	92.0	100	
			Placebo	21	21 (100.0)	66.0 (20.7)	21	52.0	70.0	77.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	17	15 (88.2)	8.3 (16.6)	-19	-7.0	10.0	19.0	36	0.17 [-0.50, 0.84]
			Placebo	21	20 (95.2)	5.8 (13.4)	-22	-3.0	5.5	16.5	32	
		Week 8	Tezepelumab	17	15 (88.2)	5.0 (14.3)	-29	-3.0	9.0	13.0	25	-0.06 [-0.73, 0.61]
			Placebo	21	20 (95.2)	6.1 (19.5)	-22	-7.0	0.5	13.5	62	
		Week 12	Tezepelumab	17	15 (88.2)	4.2 (13.9)	-23	-5.0	2.0	13.0	32	-0.20 [-0.87, 0.47]
			Placebo	21	20 (95.2)	8.0 (22.0)	-25	-6.5	3.0	19.5	68	
		Week 20	Tezepelumab	17	15 (88.2)	6.6 (20.8)	-31	-9.0	8.0	25.0	50	0.13 [-0.54, 0.80]
			Placebo	21	20 (95.2)	4.0 (19.0)	-32	-5.5	2.5	16.0	37	
		Week 28	Tezepelumab	17	15 (88.2)	5.0 (21.3)	-41	-12.0	4.0	23.0	36	-0.22 [-0.89, 0.45]
			Placebo	21	20 (95.2)	9.6 (20.2)	-15	-6.0	4.0	22.0	65	
		Week 40	Tezepelumab	17	15 (88.2)	6.7 (19.8)	-31	-11.0	7.0	22.0	40	0.11 [-0.56, 0.78]
			Placebo	21	20 (95.2)	4.4 (20.4)	-25	-11.0	3.0	15.5	55	
		Week 52	Tezepelumab	17	15 (88.2)	6.9 (21.5)	-30	-12.0	12.0	19.0	53	-0.08 [-0.75, 0.59]
			Placebo	21	20 (95.2)	8.6 (20.3)	-26	-5.5	4.5	22.0	54	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	49	43 (87.8)	57.0 (16.4)	20	49.0	52.0	70.0	94	
			Placebo	44	35 (79.5)	59.6 (15.0)	29	50.0	58.0	69.0	96	
		Week 4	Tezepelumab	49	46 (93.9)	64.9 (19.7)	14	50.0	64.5	81.0	97	
			Placebo	44	37 (84.1)	67.2 (16.7)	17	58.0	69.0	77.0	99	
		Week 8	Tezepelumab	49	46 (93.9)	68.5 (17.7)	31	55.0	70.0	85.0	96	
			Placebo	44	38 (86.4)	67.6 (20.5)	14	57.0	67.0	85.0	97	
		Week 12	Tezepelumab	49	46 (93.9)	69.7 (17.5)	35	58.0	70.0	83.0	98	
			Placebo	44	38 (86.4)	70.1 (17.2)	30	61.0	70.0	87.0	95	
		Week 20	Tezepelumab	49	47 (95.9)	69.3 (18.1)	34	54.0	70.0	86.0	98	
			Placebo	44	38 (86.4)	70.4 (17.9)	27	60.0	68.5	85.0	95	
		Week 28	Tezepelumab	49	48 (98.0)	69.5 (17.9)	29	53.0	70.5	85.5	98	
			Placebo	44	39 (88.6)	70.2 (17.9)	27	57.0	69.0	86.0	94	
		Week 40	Tezepelumab	49	48 (98.0)	70.4 (17.5)	35	54.5	74.5	82.5	98	
			Placebo	44	39 (88.6)	70.9 (17.5)	27	58.0	71.0	87.0	96	
		Week 52	Tezepelumab	49	49 (100.0)	69.8 (17.8)	32	57.0	71.0	83.0	99	
			Placebo	44	39 (88.6)	72.3 (18.5)	27	61.0	75.0	86.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHK: Change from baseline in EQ-5D-VAS by key subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	49	43 (87.8)	8.1 (20.1)	-40	-5.0	12.0	26.0	47	0.02 [-0.43, 0.47]
			Placebo	44	35 (79.5)	7.8 (15.6)	-26	-4.0	7.0	17.0	51	
		Week 8	Tezepelumab	49	43 (87.8)	11.0 (21.6)	-59	-1.0	14.0	22.0	69	0.15 [-0.30, 0.59]
			Placebo	44	35 (79.5)	8.0 (19.3)	-36	-3.0	6.0	20.0	51	
		Week 12	Tezepelumab	49	43 (87.8)	12.6 (20.7)	-34	-1.0	14.0	31.0	65	0.10 [-0.34, 0.55]
			Placebo	44	35 (79.5)	10.6 (17.4)	-34	1.0	8.0	22.0	51	
		Week 20	Tezepelumab	49	43 (87.8)	12.4 (20.3)	-44	-4.0	13.0	25.0	51	0.04 [-0.41, 0.49]
			Placebo	44	35 (79.5)	11.7 (15.6)	-20	-2.0	9.0	21.0	51	
		Week 28	Tezepelumab	49	43 (87.8)	12.7 (21.7)	-43	-1.0	15.0	31.0	60	0.13 [-0.32, 0.58]
			Placebo	44	35 (79.5)	10.3 (13.5)	-20	3.0	8.0	20.0	37	
		Week 40	Tezepelumab	49	43 (87.8)	13.5 (21.1)	-43	-1.0	18.0	30.0	58	0.09 [-0.35, 0.54]
			Placebo	44	35 (79.5)	11.8 (14.9)	-7	-2.0	8.0	22.0	45	
		Week 52	Tezepelumab	49	43 (87.8)	12.6 (21.4)	-43	-2.0	19.0	28.0	58	-0.03 [-0.47, 0.42]
			Placebo	44	35 (79.5)	13.1 (17.4)	-13	-2.0	11.0	23.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	57.8 (17.7)	20	48.0	52.0	70.5	100	
			Placebo	58	48 (82.8)	60.3 (13.2)	29	50.0	59.0	69.5	96	
		Week 4	Tezepelumab	60	57 (95.0)	65.1 (19.2)	14	50.0	66.0	79.0	100	
			Placebo	58	51 (87.9)	66.2 (17.1)	17	57.0	69.0	77.0	99	
		Week 8	Tezepelumab	60	57 (95.0)	66.9 (19.1)	20	55.0	70.0	84.0	100	
			Placebo	58	52 (89.7)	66.2 (19.6)	14	53.0	62.0	84.0	100	
		Week 12	Tezepelumab	60	57 (95.0)	68.1 (18.9)	26	56.0	70.0	83.0	100	
			Placebo	58	52 (89.7)	68.0 (18.4)	20	57.5	68.0	86.5	100	
		Week 20	Tezepelumab	60	58 (96.7)	67.6 (19.1)	18	54.0	70.0	81.0	100	
			Placebo	58	52 (89.7)	67.7 (20.0)	20	55.5	68.5	85.0	100	
		Week 28	Tezepelumab	60	59 (98.3)	67.8 (19.5)	8	52.0	70.0	83.0	100	
			Placebo	58	53 (91.4)	69.2 (18.6)	27	56.0	70.0	84.0	100	
		Week 40	Tezepelumab	60	59 (98.3)	69.5 (19.3)	18	52.0	74.0	84.0	100	
			Placebo	58	53 (91.4)	67.7 (19.2)	20	54.0	69.0	82.0	100	
		Week 52	Tezepelumab	60	60 (100.0)	68.6 (19.8)	19	53.0	70.5	84.0	100	
			Placebo	58	53 (91.4)	68.9 (18.7)	21	59.0	73.0	82.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	60	52 (86.7)	6.8 (19.2)	-40	-5.5	10.0	19.0	47	0.02 [-0.37, 0.42]
			Placebo	58	48 (82.8)	6.4 (14.1)	-26	-4.0	6.5	17.0	41	
		Week 8	Tezepelumab	60	52 (86.7)	8.0 (20.2)	-59	-1.0	10.5	19.5	69	0.11 [-0.29, 0.50]
			Placebo	58	48 (82.8)	6.0 (17.6)	-36	-6.0	5.0	19.0	41	
		Week 12	Tezepelumab	60	52 (86.7)	9.3 (19.9)	-34	-1.0	7.0	22.5	65	0.08 [-0.31, 0.47]
			Placebo	58	48 (82.8)	7.9 (17.3)	-34	-4.0	5.5	21.0	43	
		Week 20	Tezepelumab	60	52 (86.7)	9.3 (20.0)	-44	-6.5	10.0	25.0	51	0.07 [-0.32, 0.46]
			Placebo	58	48 (82.8)	8.0 (16.6)	-32	-4.0	8.5	20.0	39	
		Week 28	Tezepelumab	60	52 (86.7)	9.4 (22.1)	-43	-6.5	8.5	26.5	60	0.05 [-0.35, 0.44]
			Placebo	58	48 (82.8)	8.5 (14.6)	-20	-2.5	8.0	19.0	37	
		Week 40	Tezepelumab	60	52 (86.7)	10.9 (21.4)	-43	-4.0	12.5	28.0	58	0.17 [-0.23, 0.56]
			Placebo	58	48 (82.8)	7.7 (16.6)	-25	-4.0	4.0	21.0	45	
		Week 52	Tezepelumab	60	52 (86.7)	9.9 (21.2)	-43	-7.5	14.5	25.0	58	0.06 [-0.33, 0.46]
			Placebo	58	48 (82.8)	8.8 (15.6)	-26	-3.5	7.0	20.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	58.5 (15.6)	35	52.0	56.5	72.0	79	
			Placebo	7	7 (100.0)	48.9 (18.4)	32	32.0	48.0	52.0	86	
		Week 4	Tezepelumab	6	6 (100.0)	78.2 (18.0)	48	66.0	84.5	92.0	94	
			Placebo	7	7 (100.0)	60.0 (20.5)	38	48.0	51.0	83.0	94	
		Week 8	Tezepelumab	6	6 (100.0)	80.3 (20.5)	49	60.0	91.0	95.0	96	
			Placebo	7	7 (100.0)	64.9 (24.2)	43	45.0	48.0	94.0	94	
		Week 12	Tezepelumab	6	6 (100.0)	78.3 (21.4)	48	56.0	85.5	97.0	98	
			Placebo	7	7 (100.0)	70.7 (22.7)	42	46.0	70.0	94.0	100	
		Week 20	Tezepelumab	6	6 (100.0)	83.2 (18.8)	47	81.0	89.0	96.0	97	
			Placebo	7	7 (100.0)	63.7 (19.3)	46	46.0	61.0	83.0	94	
		Week 28	Tezepelumab	6	6 (100.0)	80.8 (16.4)	53	71.0	86.0	94.0	95	
			Placebo	7	7 (100.0)	69.6 (22.5)	46	47.0	68.0	94.0	97	
		Week 40	Tezepelumab	6	6 (100.0)	77.3 (18.3)	48	68.0	78.0	94.0	98	
			Placebo	7	7 (100.0)	67.4 (20.4)	46	46.0	66.0	87.0	90	
		Week 52	Tezepelumab	6	6 (100.0)	80.0 (20.3)	40	81.0	87.0	88.0	97	
			Placebo	7	7 (100.0)	78.9 (23.3)	45	46.0	86.0	97.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	6	6 (100.0)	19.7 (14.0)	-6	15.0	24.0	30.0	31	0.49 [-0.62, 1.60]
			Placebo	7	7 (100.0)	11.1 (19.8)	-14	3.0	8.0	16.0	51	
		Week 8	Tezepelumab	6	6 (100.0)	21.8 (15.0)	-5	17.0	24.0	35.0	36	0.25 [-0.84, 1.35]
			Placebo	7	7 (100.0)	16.0 (28.2)	-5	-3.0	2.0	51.0	62	
		Week 12	Tezepelumab	6	6 (100.0)	19.8 (12.1)	2	13.0	20.5	25.0	38	-0.09 [-1.19, 1.00]
			Placebo	7	7 (100.0)	21.9 (27.0)	-2	1.0	8.0	51.0	68	
		Week 20	Tezepelumab	6	6 (100.0)	24.7 (19.9)	-7	17.0	23.5	41.0	50	0.48 [-0.63, 1.59]
			Placebo	7	7 (100.0)	14.9 (21.1)	-6	-2.0	8.0	37.0	51	
		Week 28	Tezepelumab	6	6 (100.0)	22.3 (14.6)	-1	15.0	22.5	36.0	39	0.08 [-1.01, 1.17]
			Placebo	7	7 (100.0)	20.7 (22.5)	-2	6.0	17.0	33.0	65	
		Week 40	Tezepelumab	6	6 (100.0)	18.8 (14.8)	-6	16.0	20.5	22.0	40	0.01 [-1.08, 1.10]
			Placebo	7	7 (100.0)	18.6 (20.3)	-2	4.0	14.0	36.0	55	
		Week 52	Tezepelumab	6	6 (100.0)	21.5 (22.1)	-14	16.0	20.0	34.0	53	-0.35 [-1.45, 0.75]
			Placebo	7	7 (100.0)	30.0 (26.0)	-2	4.0	35.0	54.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	62.4 (19.3)	40	52.0	59.0	70.0	91	
			Placebo	4	3 (75.0)	67.7 (30.9)	32	32.0	85.0	86.0	86	
		Week 4	Tezepelumab	6	5 (83.3)	75.8 (16.5)	50	70.0	80.0	89.0	90	
			Placebo	4	3 (75.0)	89.7 (5.9)	83	83.0	92.0	94.0	94	
		Week 8	Tezepelumab	6	5 (83.3)	80.2 (17.8)	49	85.0	85.0	88.0	94	
			Placebo	4	3 (75.0)	89.3 (5.7)	83	83.0	91.0	94.0	94	
		Week 12	Tezepelumab	6	5 (83.3)	80.2 (6.8)	72	76.0	81.0	82.0	90	
			Placebo	4	3 (75.0)	90.0 (6.1)	83	83.0	93.0	94.0	94	
		Week 20	Tezepelumab	6	5 (83.3)	80.8 (7.8)	73	75.0	81.0	82.0	93	
			Placebo	4	3 (75.0)	90.3 (6.4)	83	83.0	94.0	94.0	94	
		Week 28	Tezepelumab	6	5 (83.3)	79.0 (7.3)	73	75.0	75.0	81.0	91	
			Placebo	4	3 (75.0)	79.0 (25.1)	50	50.0	93.0	94.0	94	
		Week 40	Tezepelumab	6	5 (83.3)	73.6 (7.3)	65	68.0	73.0	81.0	81	
			Placebo	4	3 (75.0)	76.3 (22.8)	50	50.0	89.0	90.0	90	
		Week 52	Tezepelumab	6	6 (100.0)	78.2 (5.8)	70	73.0	79.5	81.0	86	
			Placebo	4	3 (75.0)	92.3 (8.1)	83	83.0	97.0	97.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	6	5 (83.3)	13.4 (14.9)	-1	0.0	10.0	28.0	30	-0.45 [-1.91, 1.00]
			Placebo	4	3 (75.0)	22.0 (25.1)	7	7.0	8.0	51.0	51	
		Week 8	Tezepelumab	6	5 (83.3)	17.8 (17.9)	-6	9.0	15.0	35.0	36	-0.19 [-1.62, 1.25]
			Placebo	4	3 (75.0)	21.7 (25.4)	6	6.0	8.0	51.0	51	
		Week 12	Tezepelumab	6	5 (83.3)	17.8 (19.3)	-9	6.0	22.0	32.0	38	-0.21 [-1.65, 1.22]
			Placebo	4	3 (75.0)	22.3 (24.8)	8	8.0	8.0	51.0	51	
		Week 20	Tezepelumab	6	5 (83.3)	18.4 (20.4)	-9	5.0	22.0	33.0	41	-0.20 [-1.63, 1.24]
			Placebo	4	3 (75.0)	22.7 (24.5)	8	8.0	9.0	51.0	51	
		Week 28	Tezepelumab	6	5 (83.3)	16.6 (22.3)	-16	5.0	22.0	33.0	39	0.28 [-1.16, 1.72]
			Placebo	4	3 (75.0)	11.3 (5.8)	8	8.0	8.0	18.0	18	
		Week 40	Tezepelumab	6	5 (83.3)	11.2 (18.2)	-10	-5.0	16.0	22.0	33	0.16 [-1.27, 1.60]
			Placebo	4	3 (75.0)	8.7 (8.1)	4	4.0	4.0	18.0	18	
		Week 52	Tezepelumab	6	5 (83.3)	15.6 (20.2)	-11	0.0	22.0	33.0	34	-0.34 [-1.79, 1.10]
			Placebo	4	3 (75.0)	24.7 (35.5)	-2	-2.0	11.0	65.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	57.5 (17.3)	20	49.0	52.0	71.0	100	
			Placebo	61	52 (85.2)	58.3 (13.2)	29	50.0	54.5	67.5	96	
		Week 4	Tezepelumab	60	58 (96.7)	65.5 (19.5)	14	50.0	66.0	81.0	100	
			Placebo	61	55 (90.2)	64.2 (17.0)	17	51.0	61.0	75.0	99	
		Week 8	Tezepelumab	60	58 (96.7)	67.2 (19.4)	20	55.0	69.5	84.0	100	
			Placebo	61	56 (91.8)	64.8 (19.7)	14	51.0	61.0	82.5	100	
		Week 12	Tezepelumab	60	58 (96.7)	68.1 (19.6)	26	53.0	69.5	85.0	100	
			Placebo	61	56 (91.8)	67.2 (18.5)	20	57.0	67.0	85.0	100	
		Week 20	Tezepelumab	60	59 (98.3)	68.1 (19.9)	18	54.0	70.0	83.0	100	
			Placebo	61	56 (91.8)	66.0 (19.5)	20	53.5	67.0	84.0	100	
		Week 28	Tezepelumab	60	60 (100.0)	68.2 (20.0)	8	52.5	70.0	84.0	100	
			Placebo	61	57 (93.4)	68.8 (18.6)	27	54.0	69.0	84.0	100	
		Week 40	Tezepelumab	60	60 (100.0)	70.0 (19.9)	18	51.5	75.0	84.5	100	
			Placebo	61	57 (93.4)	67.2 (19.1)	20	54.0	68.0	82.0	100	
		Week 52	Tezepelumab	60	60 (100.0)	68.8 (20.7)	19	52.5	70.5	86.5	100	
			Placebo	61	57 (93.4)	68.9 (19.1)	21	54.0	73.0	83.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	60	53 (88.3)	7.7 (19.5)	-40	-6.0	12.0	19.0	47	0.09 [-0.29, 0.47]
			Placebo	61	52 (85.2)	6.2 (13.9)	-26	-4.0	6.0	16.5	41	
		Week 8	Tezepelumab	60	53 (88.3)	8.7 (20.2)	-59	-1.0	12.0	20.0	69	0.11 [-0.27, 0.50]
			Placebo	61	52 (85.2)	6.5 (18.8)	-36	-5.0	2.5	19.0	62	
		Week 12	Tezepelumab	60	53 (88.3)	9.7 (19.5)	-34	-1.0	7.0	22.0	65	0.04 [-0.34, 0.43]
			Placebo	61	52 (85.2)	8.9 (18.7)	-34	-3.0	5.5	21.0	68	
		Week 20	Tezepelumab	60	53 (88.3)	10.2 (20.4)	-44	-4.0	12.0	25.0	51	0.11 [-0.27, 0.50]
			Placebo	61	52 (85.2)	8.1 (16.6)	-32	-4.0	7.5	20.0	39	
		Week 28	Tezepelumab	60	53 (88.3)	10.2 (21.7)	-43	-3.0	10.0	25.0	60	0.01 [-0.37, 0.39]
			Placebo	61	52 (85.2)	10.0 (16.5)	-20	-2.0	8.0	21.5	65	
		Week 40	Tezepelumab	60	53 (88.3)	11.8 (21.2)	-43	-1.0	13.0	26.0	58	0.14 [-0.25, 0.52]
			Placebo	61	52 (85.2)	9.1 (17.7)	-25	-3.5	5.5	21.5	55	
		Week 52	Tezepelumab	60	53 (88.3)	10.7 (21.6)	-43	-5.0	16.0	25.0	58	0.00 [-0.38, 0.38]
			Placebo	61	52 (85.2)	10.7 (17.3)	-26	-3.0	9.0	22.5	54	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	30	26 (86.7)	53.6 (16.4)	20	45.0	51.5	63.0	94	
			Placebo	29	25 (86.2)	59.9 (14.5)	29	50.0	58.0	66.0	96	
		Week 4	Tezepelumab	30	28 (93.3)	63.6 (20.2)	14	50.0	66.0	78.5	97	
			Placebo	29	26 (89.7)	68.7 (18.1)	17	59.0	71.0	81.0	99	
		Week 8	Tezepelumab	30	28 (93.3)	66.9 (16.4)	32	56.5	64.0	78.0	96	
			Placebo	29	26 (89.7)	67.3 (21.8)	19	53.0	65.5	87.0	97	
		Week 12	Tezepelumab	30	28 (93.3)	65.8 (17.3)	35	50.5	67.0	80.5	95	
			Placebo	29	26 (89.7)	69.3 (19.4)	30	58.0	70.0	87.0	95	
		Week 20	Tezepelumab	30	29 (96.7)	66.0 (17.7)	34	54.0	65.0	79.0	98	
			Placebo	29	26 (89.7)	68.5 (19.7)	27	53.0	70.0	85.0	94	
		Week 28	Tezepelumab	30	30 (100.0)	65.9 (17.7)	29	51.0	66.5	81.0	98	
			Placebo	29	26 (89.7)	69.7 (19.1)	27	51.0	69.0	88.0	94	
		Week 40	Tezepelumab	30	30 (100.0)	67.1 (17.4)	35	51.0	68.0	80.0	97	
			Placebo	29	26 (89.7)	70.2 (20.7)	27	54.0	74.5	90.0	95	
		Week 52	Tezepelumab	30	30 (100.0)	66.2 (17.7)	35	52.0	64.5	81.0	99	
			Placebo	29	26 (89.7)	71.7 (19.3)	27	52.0	76.5	86.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	30	26 (86.7)	11.0 (18.6)	-30	-2.0	13.5	27.0	47	0.10 [-0.45, 0.65]
			Placebo	29	25 (86.2)	9.5 (13.0)	-12	3.0	7.0	21.0	41	
		Week 8	Tezepelumab	30	26 (86.7)	13.1 (21.8)	-46	-1.0	12.5	25.0	69	0.28 [-0.27, 0.83]
			Placebo	29	25 (86.2)	7.6 (17.1)	-22	-7.0	6.0	20.0	40	
		Week 12	Tezepelumab	30	26 (86.7)	12.2 (21.6)	-34	-1.0	12.5	30.0	65	0.14 [-0.40, 0.69]
			Placebo	29	25 (86.2)	9.4 (15.8)	-17	-2.0	8.0	21.0	43	
		Week 20	Tezepelumab	30	26 (86.7)	12.5 (22.9)	-44	-4.0	13.0	25.0	51	0.16 [-0.39, 0.71]
			Placebo	29	25 (86.2)	9.3 (16.6)	-32	-2.0	8.0	21.0	38	
		Week 28	Tezepelumab	30	26 (86.7)	12.7 (22.6)	-33	-1.0	8.5	32.0	60	0.11 [-0.44, 0.66]
			Placebo	29	25 (86.2)	10.6 (14.7)	-16	-2.0	8.0	23.0	37	
		Week 40	Tezepelumab	30	26 (86.7)	13.3 (22.1)	-33	-3.0	16.5	33.0	58	0.11 [-0.44, 0.66]
			Placebo	29	25 (86.2)	11.2 (17.3)	-20	-2.0	4.0	23.0	45	
		Week 52	Tezepelumab	30	26 (86.7)	12.3 (23.3)	-27	-11.0	15.5	28.0	58	-0.02 [-0.57, 0.53]
			Placebo	29	25 (86.2)	12.8 (15.7)	-13	-2.0	11.0	28.0	38	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	36	32 (88.9)	61.4 (17.5)	33	49.5	60.5	72.5	100	
			Placebo	36	30 (83.3)	58.0 (14.3)	32	49.0	52.5	70.0	85	
		Week 4	Tezepelumab	36	35 (97.2)	68.5 (18.7)	30	50.0	67.0	89.0	100	
			Placebo	36	32 (88.9)	62.9 (16.9)	23	49.0	60.0	75.5	93	
		Week 8	Tezepelumab	36	35 (97.2)	69.3 (21.8)	20	49.0	74.0	87.0	100	
			Placebo	36	33 (91.7)	65.1 (18.6)	14	51.0	61.0	79.0	100	
		Week 12	Tezepelumab	36	35 (97.2)	71.7 (20.5)	26	58.0	76.0	89.0	100	
			Placebo	36	33 (91.7)	67.5 (18.5)	20	57.0	67.0	83.0	100	
		Week 20	Tezepelumab	36	35 (97.2)	71.6 (20.8)	18	62.0	77.0	87.0	100	
			Placebo	36	33 (91.7)	66.2 (20.1)	20	56.0	67.0	83.0	100	
		Week 28	Tezepelumab	36	35 (97.2)	71.7 (20.8)	8	62.0	76.0	88.0	100	
			Placebo	36	34 (94.4)	68.9 (19.0)	30	56.0	70.5	82.0	100	
		Week 40	Tezepelumab	36	35 (97.2)	72.9 (20.4)	18	65.0	80.0	85.0	100	
			Placebo	36	34 (94.4)	65.7 (17.9)	20	53.0	66.5	76.0	100	
		Week 52	Tezepelumab	36	36 (100.0)	72.5 (21.5)	19	66.0	78.5	89.5	100	
			Placebo	36	34 (94.4)	68.9 (19.6)	21	60.0	69.5	82.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	36	32 (88.9)	5.8 (19.4)	-40	-7.0	10.0	18.5	40	0.05 [-0.45, 0.55]
			Placebo	36	30 (83.3)	5.0 (16.1)	-26	-4.0	4.5	11.0	51	
		Week 8	Tezepelumab	36	32 (88.9)	6.5 (18.3)	-59	-2.0	11.5	18.5	33	-0.03 [-0.53, 0.47]
			Placebo	36	30 (83.3)	7.0 (21.2)	-36	-4.0	3.0	10.0	62	
		Week 12	Tezepelumab	36	32 (88.9)	9.0 (17.7)	-31	0.0	7.0	21.0	37	-0.04 [-0.54, 0.46]
			Placebo	36	30 (83.3)	9.8 (21.6)	-34	-1.0	6.5	22.0	68	
		Week 20	Tezepelumab	36	32 (88.9)	9.5 (18.4)	-31	-6.5	12.0	25.0	41	0.06 [-0.44, 0.56]
			Placebo	36	30 (83.3)	8.5 (17.9)	-25	-4.0	8.5	15.0	51	
		Week 28	Tezepelumab	36	32 (88.9)	9.1 (21.1)	-43	-4.5	10.0	24.0	40	-0.03 [-0.53, 0.47]
			Placebo	36	30 (83.3)	9.6 (17.4)	-20	-1.0	8.5	15.0	65	
		Week 40	Tezepelumab	36	32 (88.9)	10.4 (20.0)	-43	-2.5	12.5	25.0	40	0.17 [-0.33, 0.67]
			Placebo	36	30 (83.3)	7.3 (17.3)	-25	-4.0	6.5	18.0	55	
		Week 52	Tezepelumab	36	32 (88.9)	10.2 (20.0)	-43	-3.5	17.0	24.5	41	-0.01 [-0.51, 0.49]
			Placebo	36	30 (83.3)	10.4 (20.6)	-26	-4.0	6.0	20.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	38	31 (81.6)	55.2 (14.9)	29	47.0	51.0	66.0	90	
			Placebo	30	23 (76.7)	58.2 (14.1)	41	50.0	51.0	65.0	96	
		Week 4	Tezepelumab	38	35 (92.1)	64.3 (18.2)	21	50.0	66.0	79.0	92	
			Placebo	30	25 (83.3)	67.5 (15.4)	45	57.0	60.0	77.0	99	
		Week 8	Tezepelumab	38	35 (92.1)	63.8 (18.8)	20	53.0	65.0	77.0	95	
			Placebo	30	25 (83.3)	64.8 (21.7)	14	52.0	60.0	83.0	97	
		Week 12	Tezepelumab	38	35 (92.1)	65.7 (18.9)	26	50.0	69.0	81.0	97	
			Placebo	30	25 (83.3)	67.9 (19.3)	34	57.0	62.0	88.0	95	
		Week 20	Tezepelumab	38	36 (94.7)	65.7 (20.0)	18	54.0	67.0	78.5	97	
			Placebo	30	25 (83.3)	67.5 (20.2)	22	55.0	64.0	85.0	94	
		Week 28	Tezepelumab	38	37 (97.4)	65.5 (20.2)	8	50.0	69.0	82.0	95	
			Placebo	30	26 (86.7)	69.9 (19.7)	30	53.0	71.5	91.0	94	
		Week 40	Tezepelumab	38	37 (97.4)	66.2 (19.5)	18	49.0	68.0	81.0	94	
			Placebo	30	26 (86.7)	70.9 (19.4)	37	54.0	72.0	90.0	95	
		Week 52	Tezepelumab	38	38 (100.0)	65.1 (19.2)	19	52.0	67.0	81.0	93	
			Placebo	30	26 (86.7)	71.0 (20.9)	21	52.0	77.5	86.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	38	31 (81.6)	9.2 (20.3)	-40	-5.0	14.0	26.0	47	-0.03 [-0.57, 0.50]
			Placebo	30	23 (76.7)	9.8 (12.2)	-11	4.0	8.0	17.0	41	
		Week 8	Tezepelumab	38	31 (81.6)	7.4 (22.9)	-59	-6.0	12.0	22.0	38	0.04 [-0.50, 0.58]
			Placebo	30	23 (76.7)	6.6 (18.5)	-36	-3.0	6.0	20.0	40	
		Week 12	Tezepelumab	38	31 (81.6)	9.5 (21.4)	-34	-7.0	12.0	30.0	41	-0.03 [-0.57, 0.51]
			Placebo	30	23 (76.7)	10.0 (17.7)	-17	-4.0	8.0	25.0	43	
		Week 20	Tezepelumab	38	31 (81.6)	9.8 (22.5)	-44	-10.0	13.0	25.0	41	0.01 [-0.53, 0.55]
			Placebo	30	23 (76.7)	9.7 (17.8)	-25	-4.0	9.0	26.0	39	
		Week 28	Tezepelumab	38	31 (81.6)	9.6 (23.9)	-43	-10.0	18.0	28.0	50	-0.02 [-0.56, 0.52]
			Placebo	30	23 (76.7)	10.1 (16.5)	-20	-3.0	8.0	24.0	37	
		Week 40	Tezepelumab	38	31 (81.6)	9.8 (22.4)	-43	-10.0	16.0	26.0	40	-0.12 [-0.66, 0.42]
			Placebo	30	23 (76.7)	12.3 (17.8)	-12	-4.0	4.0	32.0	45	
		Week 52	Tezepelumab	38	31 (81.6)	8.5 (22.7)	-43	-11.0	16.0	28.0	45	-0.14 [-0.68, 0.40]
			Placebo	30	23 (76.7)	11.5 (18.8)	-26	-5.0	11.0	30.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	28	27 (96.4)	61.1 (19.6)	20	50.0	61.0	73.0	100	
			Placebo	34	31 (91.2)	59.3 (14.8)	29	50.0	60.0	70.0	88	
		Week 4	Tezepelumab	28	28 (100.0)	68.9 (20.8)	14	51.5	68.0	90.0	100	
			Placebo	34	32 (94.1)	64.0 (19.3)	17	50.0	69.0	78.0	95	
		Week 8	Tezepelumab	28	28 (100.0)	73.8 (19.3)	35	55.0	78.5	89.5	100	
			Placebo	34	33 (97.1)	67.3 (19.0)	19	51.0	64.0	85.0	100	
		Week 12	Tezepelumab	28	28 (100.0)	73.3 (19.0)	33	58.0	75.5	89.5	100	
			Placebo	34	33 (97.1)	68.4 (18.9)	20	60.0	69.0	84.0	100	
		Week 20	Tezepelumab	28	28 (100.0)	73.4 (18.3)	34	61.0	79.5	86.0	100	
			Placebo	34	33 (97.1)	68.2 (18.8)	20	56.0	69.0	83.0	100	
		Week 28	Tezepelumab	28	28 (100.0)	73.7 (17.8)	32	61.0	76.0	89.0	100	
			Placebo	34	33 (97.1)	69.4 (18.5)	27	56.0	70.0	85.0	100	
		Week 40	Tezepelumab	28	28 (100.0)	75.6 (17.6)	32	65.0	79.0	91.0	100	
			Placebo	34	33 (97.1)	64.8 (19.1)	20	50.0	67.0	76.0	100	
		Week 52	Tezepelumab	28	28 (100.0)	75.9 (19.6)	25	66.5	79.0	92.0	100	
			Placebo	34	33 (97.1)	69.2 (18.6)	27	60.0	73.0	80.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	28	27 (96.4)	7.0 (17.8)	-27	-6.0	8.0	19.0	40	0.11 [-0.41, 0.63]
			Placebo	34	31 (91.2)	5.1 (16.5)	-26	-7.0	4.0	17.0	51	
		Week 8	Tezepelumab	28	27 (96.4)	11.9 (16.3)	-16	0.0	12.0	19.0	69	0.19 [-0.32, 0.71]
			Placebo	34	31 (91.2)	8.3 (20.1)	-24	-5.0	4.0	19.0	62	
		Week 12	Tezepelumab	28	27 (96.4)	11.5 (17.1)	-16	1.0	6.0	19.0	65	0.13 [-0.39, 0.64]
			Placebo	34	31 (91.2)	9.1 (20.5)	-34	-1.0	5.0	21.0	68	
		Week 20	Tezepelumab	28	27 (96.4)	12.1 (17.9)	-16	-2.0	10.0	26.0	51	0.15 [-0.37, 0.66]
			Placebo	34	31 (91.2)	9.6 (15.5)	-25	-2.0	8.0	21.0	51	
		Week 28	Tezepelumab	28	27 (96.4)	12.0 (19.2)	-16	-1.0	9.0	33.0	60	0.07 [-0.45, 0.59]
			Placebo	34	31 (91.2)	10.7 (15.8)	-15	-1.0	9.0	18.0	65	
		Week 40	Tezepelumab	28	27 (96.4)	13.9 (19.0)	-16	-1.0	12.0	31.0	58	0.42 [-0.11, 0.94]
			Placebo	34	31 (91.2)	6.5 (17.0)	-25	-3.0	6.0	18.0	55	
		Week 52	Tezepelumab	28	27 (96.4)	14.1 (19.8)	-16	0.0	18.0	24.0	58	0.15 [-0.37, 0.67]
			Placebo	34	31 (91.2)	11.3 (18.7)	-15	-2.0	6.0	22.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	55.9 (15.4)	29	49.0	51.5	66.0	90	
			Placebo	27	21 (77.8)	56.6 (13.4)	41	50.0	51.0	60.0	96	
		Week 4	Tezepelumab	32	30 (93.8)	64.0 (17.6)	21	50.0	66.0	79.0	92	
			Placebo	27	23 (85.2)	66.8 (15.1)	45	57.0	60.0	77.0	99	
		Week 8	Tezepelumab	32	30 (93.8)	64.9 (18.4)	31	53.0	66.5	77.0	95	
			Placebo	27	23 (85.2)	64.2 (21.8)	14	51.0	60.0	83.0	97	
		Week 12	Tezepelumab	32	30 (93.8)	65.2 (18.0)	35	50.0	68.5	80.0	97	
			Placebo	27	23 (85.2)	67.1 (19.3)	34	51.0	62.0	88.0	95	
		Week 20	Tezepelumab	32	31 (96.9)	65.5 (18.3)	25	54.0	68.0	78.0	97	
			Placebo	27	23 (85.2)	66.9 (20.2)	22	53.0	64.0	85.0	94	
		Week 28	Tezepelumab	32	32 (100.0)	65.6 (18.1)	29	50.0	68.5	81.5	95	
			Placebo	27	24 (88.9)	69.8 (19.4)	30	55.0	71.5	87.5	94	
		Week 40	Tezepelumab	32	32 (100.0)	65.8 (18.0)	35	48.0	68.0	81.0	94	
			Placebo	27	24 (88.9)	70.7 (19.7)	37	54.0	72.0	91.0	95	
		Week 52	Tezepelumab	32	32 (100.0)	64.3 (18.1)	32	51.5	64.5	80.5	93	
			Placebo	27	24 (88.9)	71.0 (21.5)	21	51.5	77.5	88.5	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	32	26 (81.3)	8.2 (20.7)	-40	-5.0	12.5	26.0	47	-0.14 [-0.72, 0.43]
			Placebo	27	21 (77.8)	10.7 (12.3)	-11	6.0	9.0	17.0	41	
		Week 8	Tezepelumab	32	26 (81.3)	7.7 (23.5)	-59	-6.0	11.0	22.0	38	0.01 [-0.57, 0.58]
			Placebo	27	21 (77.8)	7.5 (19.0)	-36	0.0	8.0	20.0	40	
		Week 12	Tezepelumab	32	26 (81.3)	8.0 (21.2)	-34	-7.0	8.5	25.0	41	-0.14 [-0.72, 0.43]
			Placebo	27	21 (77.8)	10.8 (18.2)	-17	-4.0	10.0	25.0	43	
		Week 20	Tezepelumab	32	26 (81.3)	8.8 (22.0)	-44	-10.0	12.0	25.0	41	-0.09 [-0.67, 0.48]
			Placebo	27	21 (77.8)	10.6 (18.2)	-25	-4.0	10.0	26.0	39	
		Week 28	Tezepelumab	32	26 (81.3)	8.9 (22.9)	-43	-10.0	9.0	25.0	50	-0.13 [-0.70, 0.45]
			Placebo	27	21 (77.8)	11.4 (16.3)	-20	2.0	8.0	24.0	37	
		Week 40	Tezepelumab	32	26 (81.3)	8.3 (21.6)	-43	-10.0	14.0	22.0	40	-0.26 [-0.84, 0.32]
			Placebo	27	21 (77.8)	13.6 (18.0)	-12	2.0	5.0	32.0	45	
		Week 52	Tezepelumab	32	26 (81.3)	7.2 (22.4)	-43	-11.0	11.5	25.0	45	-0.27 [-0.85, 0.30]
			Placebo	27	21 (77.8)	13.0 (19.1)	-26	-3.0	12.0	30.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	59.6 (18.8)	20	48.0	57.0	72.0	100	
			Placebo	37	33 (89.2)	60.2 (15.1)	29	50.0	62.0	70.0	88	
		Week 4	Tezepelumab	34	33 (97.1)	68.5 (20.9)	14	53.0	70.0	90.0	100	
			Placebo	37	34 (91.9)	64.7 (19.4)	17	51.0	69.0	80.0	95	
		Week 8	Tezepelumab	34	33 (97.1)	71.2 (20.2)	20	55.0	73.0	89.0	100	
			Placebo	37	35 (94.6)	67.6 (19.0)	19	51.0	64.0	87.0	100	
		Week 12	Tezepelumab	34	33 (97.1)	72.6 (19.9)	26	58.0	75.0	89.0	100	
			Placebo	37	35 (94.6)	68.9 (18.8)	20	60.0	69.0	86.0	100	
		Week 20	Tezepelumab	34	33 (97.1)	72.4 (20.3)	18	62.0	79.0	87.0	100	
			Placebo	37	35 (94.6)	68.6 (18.9)	20	55.0	69.0	84.0	100	
		Week 28	Tezepelumab	34	33 (97.1)	72.4 (20.5)	8	62.0	75.0	88.0	100	
			Placebo	37	35 (94.6)	69.5 (18.7)	27	54.0	70.0	86.0	100	
		Week 40	Tezepelumab	34	33 (97.1)	74.6 (19.5)	18	65.0	80.0	90.0	100	
			Placebo	37	35 (94.6)	65.3 (19.0)	20	50.0	67.0	78.0	100	
		Week 52	Tezepelumab	34	34 (100.0)	74.6 (20.7)	19	66.0	78.5	92.0	100	
			Placebo	37	35 (94.6)	69.3 (18.3)	27	59.0	73.0	83.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	34	32 (94.1)	8.2 (17.9)	-27	-5.0	10.0	19.0	40	0.19 [-0.29, 0.68]
			Placebo	37	33 (89.2)	4.8 (16.1)	-26	-5.0	4.0	16.0	51	
		Week 8	Tezepelumab	34	32 (94.1)	10.9 (17.0)	-29	-0.5	12.5	19.5	69	0.18 [-0.31, 0.67]
			Placebo	37	33 (89.2)	7.6 (19.8)	-24	-5.0	4.0	18.0	62	
		Week 12	Tezepelumab	34	32 (94.1)	12.4 (18.0)	-23	1.0	8.0	22.5	65	0.20 [-0.29, 0.69]
			Placebo	37	33 (89.2)	8.6 (20.0)	-34	-1.0	5.0	16.0	68	
		Week 20	Tezepelumab	34	32 (94.1)	12.6 (19.2)	-31	-1.0	11.5	25.5	51	0.21 [-0.28, 0.69]
			Placebo	37	33 (89.2)	9.0 (15.4)	-25	-2.0	8.0	17.0	51	
		Week 28	Tezepelumab	34	32 (94.1)	12.2 (20.9)	-41	-1.0	10.0	30.5	60	0.13 [-0.36, 0.61]
			Placebo	37	33 (89.2)	9.8 (16.0)	-16	-1.0	8.0	18.0	65	
		Week 40	Tezepelumab	34	32 (94.1)	14.5 (20.1)	-31	-0.5	15.0	32.0	58	0.46 [-0.03, 0.95]
			Placebo	37	33 (89.2)	6.0 (16.6)	-25	-3.0	4.0	15.0	55	
		Week 52	Tezepelumab	34	32 (94.1)	14.3 (20.3)	-30	0.0	18.5	25.0	58	0.20 [-0.28, 0.69]
			Placebo	37	33 (89.2)	10.4 (18.5)	-15	-2.0	6.0	20.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	25	21 (84.0)	55.8 (14.0)	38	49.0	51.0	61.0	90	
			Placebo	22	18 (81.8)	56.2 (12.6)	29	48.0	52.5	65.0	80	
		Week 4	Tezepelumab	25	24 (96.0)	65.5 (17.6)	21	50.0	66.5	78.5	92	
			Placebo	22	19 (86.4)	61.6 (19.9)	17	48.0	63.0	74.0	99	
		Week 8	Tezepelumab	25	24 (96.0)	67.4 (18.2)	31	57.5	70.0	82.0	95	
			Placebo	22	20 (90.9)	59.6 (22.6)	14	50.5	58.0	73.0	97	
		Week 12	Tezepelumab	25	24 (96.0)	66.9 (19.1)	33	51.5	70.0	82.0	94	
			Placebo	22	20 (90.9)	61.4 (21.4)	20	41.5	64.0	76.5	91	
		Week 20	Tezepelumab	25	24 (96.0)	67.2 (18.8)	34	52.5	70.0	81.5	94	
			Placebo	22	20 (90.9)	62.0 (24.7)	20	36.5	68.5	84.0	95	
		Week 28	Tezepelumab	25	25 (100.0)	68.4 (18.6)	32	53.0	71.0	83.0	93	
			Placebo	22	20 (90.9)	62.5 (21.1)	27	48.5	68.5	80.0	93	
		Week 40	Tezepelumab	25	25 (100.0)	69.5 (18.6)	32	53.0	75.0	83.0	95	
			Placebo	22	20 (90.9)	60.2 (21.4)	20	43.5	64.5	75.5	95	
		Week 52	Tezepelumab	25	25 (100.0)	66.0 (19.8)	25	53.0	70.0	80.0	94	
			Placebo	22	20 (90.9)	61.9 (20.6)	21	46.0	67.5	76.0	96	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	25	21 (84.0)	7.3 (23.1)	-40	-5.0	15.0	26.0	47	0.05 [-0.58, 0.68]
			Placebo	22	18 (81.8)	6.2 (17.8)	-26	-4.0	5.5	21.0	41	
		Week 8	Tezepelumab	25	21 (84.0)	9.2 (21.9)	-59	-1.0	13.0	21.0	38	0.26 [-0.38, 0.89]
			Placebo	22	18 (81.8)	3.5 (22.8)	-36	-10.0	3.5	19.0	41	
		Week 12	Tezepelumab	25	21 (84.0)	8.4 (21.1)	-31	-5.0	7.0	31.0	41	0.16 [-0.47, 0.79]
			Placebo	22	18 (81.8)	5.1 (21.6)	-34	-10.0	3.5	21.0	43	
		Week 20	Tezepelumab	25	21 (84.0)	9.8 (20.2)	-20	-10.0	10.0	25.0	41	0.19 [-0.44, 0.82]
			Placebo	22	18 (81.8)	5.8 (22.0)	-32	-8.0	7.0	21.0	39	
		Week 28	Tezepelumab	25	21 (84.0)	10.4 (22.6)	-43	-6.0	8.0	32.0	50	0.25 [-0.38, 0.88]
			Placebo	22	18 (81.8)	5.3 (17.1)	-20	-5.0	3.0	13.0	36	
		Week 40	Tezepelumab	25	21 (84.0)	11.3 (22.2)	-43	-3.0	13.0	33.0	40	0.31 [-0.32, 0.94]
			Placebo	22	18 (81.8)	4.7 (20.7)	-25	-7.0	0.0	21.0	45	
		Week 52	Tezepelumab	25	21 (84.0)	8.7 (23.0)	-43	-10.0	13.0	25.0	45	0.11 [-0.52, 0.74]
			Placebo	22	18 (81.8)	6.3 (18.1)	-26	-5.0	4.0	20.0	38	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	35	33 (94.3)	59.9 (19.8)	20	47.0	63.0	72.0	100	
			Placebo	41	35 (85.4)	59.1 (14.7)	32	50.0	55.0	70.0	96	
		Week 4	Tezepelumab	35	34 (97.1)	66.8 (20.8)	14	50.0	66.5	88.0	100	
			Placebo	41	37 (90.2)	66.9 (15.9)	38	54.0	67.0	80.0	95	
		Week 8	Tezepelumab	35	34 (97.1)	67.9 (21.0)	20	49.0	69.5	85.0	100	
			Placebo	41	37 (90.2)	68.8 (17.9)	43	53.0	62.0	85.0	100	
		Week 12	Tezepelumab	35	34 (97.1)	69.9 (19.9)	26	56.0	71.0	89.0	100	
			Placebo	41	37 (90.2)	71.3 (16.4)	42	60.0	70.0	87.0	100	
		Week 20	Tezepelumab	35	34 (97.1)	70.3 (21.0)	18	60.0	72.0	85.0	100	
			Placebo	41	37 (90.2)	69.4 (16.4)	46	55.0	67.0	85.0	100	
		Week 28	Tezepelumab	35	34 (97.1)	69.4 (21.0)	8	53.0	72.0	86.0	100	
			Placebo	41	38 (92.7)	72.0 (17.0)	46	57.0	71.5	88.0	100	
		Week 40	Tezepelumab	35	34 (97.1)	70.9 (20.0)	18	56.0	74.0	84.0	100	
			Placebo	41	38 (92.7)	71.0 (17.2)	43	55.0	71.0	87.0	100	
		Week 52	Tezepelumab	35	35 (100.0)	71.8 (20.8)	19	57.0	78.0	88.0	100	
			Placebo	41	38 (92.7)	73.6 (17.6)	44	59.0	77.0	87.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	35	33 (94.3)	7.1 (16.7)	-23	-6.0	10.0	18.0	40	-0.05 [-0.53, 0.42]
			Placebo	41	35 (85.4)	7.9 (13.4)	-14	-1.0	7.0	17.0	51	
		Week 8	Tezepelumab	35	33 (94.3)	8.2 (19.5)	-46	-1.0	11.0	17.0	69	-0.07 [-0.55, 0.40]
			Placebo	41	35 (85.4)	9.6 (17.6)	-14	-3.0	4.0	20.0	62	
		Week 12	Tezepelumab	35	33 (94.3)	10.3 (18.7)	-34	1.0	7.0	20.0	65	-0.10 [-0.58, 0.37]
			Placebo	41	35 (85.4)	12.2 (18.0)	-16	-1.0	8.0	22.0	68	
		Week 20	Tezepelumab	35	33 (94.3)	10.5 (21.4)	-44	-4.0	12.0	25.0	51	-0.01 [-0.49, 0.46]
			Placebo	41	35 (85.4)	10.8 (14.7)	-10	-2.0	9.0	19.0	51	
		Week 28	Tezepelumab	35	33 (94.3)	9.7 (21.9)	-41	-3.0	10.0	23.0	60	-0.15 [-0.63, 0.32]
			Placebo	41	35 (85.4)	12.7 (15.6)	-16	2.0	12.0	23.0	65	
		Week 40	Tezepelumab	35	33 (94.3)	11.2 (21.0)	-33	-5.0	13.0	25.0	58	-0.04 [-0.51, 0.44]
			Placebo	41	35 (85.4)	11.8 (15.5)	-17	2.0	11.0	22.0	55	
		Week 52	Tezepelumab	35	33 (94.3)	11.8 (21.4)	-30	-5.0	16.0	24.0	58	-0.12 [-0.60, 0.36]
			Placebo	41	35 (85.4)	14.3 (18.8)	-9	-2.0	11.0	27.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	41	36 (87.8)	56.9 (17.0)	20	49.0	52.0	68.0	100	
			Placebo	30	25 (83.3)	57.7 (15.4)	29	50.0	54.0	65.0	96	
		Week 4	Tezepelumab	41	39 (95.1)	66.3 (21.0)	14	50.0	66.0	86.0	100	
			Placebo	30	25 (83.3)	60.7 (17.9)	17	51.0	59.0	70.0	94	
		Week 8	Tezepelumab	41	39 (95.1)	69.0 (20.1)	20	55.0	71.0	88.0	100	
			Placebo	30	26 (86.7)	60.7 (22.1)	14	50.0	56.5	82.0	96	
		Week 12	Tezepelumab	41	39 (95.1)	70.8 (20.0)	26	56.0	80.0	88.0	100	
			Placebo	30	26 (86.7)	61.7 (20.9)	20	46.0	61.0	75.0	100	
		Week 20	Tezepelumab	41	40 (97.6)	70.0 (20.1)	18	54.5	71.0	86.5	100	
			Placebo	30	26 (86.7)	61.9 (23.1)	20	46.0	65.5	81.0	95	
		Week 28	Tezepelumab	41	41 (100.0)	69.0 (21.7)	8	53.0	73.0	86.0	100	
			Placebo	30	26 (86.7)	62.8 (21.3)	27	48.0	64.0	80.0	97	
		Week 40	Tezepelumab	41	41 (100.0)	70.3 (20.4)	18	51.0	75.0	85.0	100	
			Placebo	30	26 (86.7)	61.1 (21.0)	20	44.0	61.5	76.0	95	
		Week 52	Tezepelumab	41	41 (100.0)	69.8 (21.1)	19	53.0	75.0	86.0	100	
			Placebo	30	26 (86.7)	63.2 (21.0)	21	47.0	64.0	80.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	41	36 (87.8)	8.1 (19.3)	-40	-4.5	11.0	22.5	47	0.30 [-0.21, 0.81]
			Placebo	30	25 (83.3)	3.0 (13.3)	-26	-5.0	4.0	9.0	26	
		Week 8	Tezepelumab	41	36 (87.8)	10.9 (21.9)	-59	-1.0	12.5	21.5	69	0.37 [-0.14, 0.89]
			Placebo	30	25 (83.3)	2.8 (21.3)	-36	-8.0	0.0	8.0	62	
		Week 12	Tezepelumab	41	36 (87.8)	12.7 (20.4)	-31	-1.0	13.0	30.5	65	0.44 [-0.08, 0.95]
			Placebo	30	25 (83.3)	3.8 (20.5)	-34	-8.0	2.0	11.0	68	
		Week 20	Tezepelumab	41	36 (87.8)	12.2 (19.7)	-31	-2.0	11.0	25.0	51	0.42 [-0.09, 0.94]
			Placebo	30	25 (83.3)	4.1 (18.4)	-32	-4.0	7.0	15.0	37	
		Week 28	Tezepelumab	41	36 (87.8)	10.7 (22.5)	-43	-3.5	9.5	29.5	60	0.28 [-0.23, 0.79]
			Placebo	30	25 (83.3)	4.9 (18.2)	-20	-5.0	3.0	9.0	65	
		Week 40	Tezepelumab	41	36 (87.8)	11.5 (21.8)	-43	-4.5	16.5	25.5	58	0.37 [-0.14, 0.89]
			Placebo	30	25 (83.3)	3.7 (19.6)	-25	-7.0	-2.0	12.0	55	
		Week 52	Tezepelumab	41	36 (87.8)	11.8 (22.1)	-43	-7.0	19.0	28.5	58	0.28 [-0.23, 0.79]
			Placebo	30	25 (83.3)	6.1 (18.2)	-26	-5.0	-2.0	16.0	54	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	25	22 (88.0)	59.6 (18.1)	33	40.0	62.0	75.0	91	
			Placebo	34	29 (85.3)	59.9 (13.7)	32	50.0	57.0	70.0	88	
		Week 4	Tezepelumab	25	24 (96.0)	66.3 (16.8)	40	50.0	66.5	79.0	94	
			Placebo	34	32 (94.1)	68.2 (16.0)	38	55.5	69.5	80.5	95	
		Week 8	Tezepelumab	25	24 (96.0)	66.9 (18.9)	32	51.0	65.5	84.5	96	
			Placebo	34	32 (94.1)	69.4 (16.8)	43	53.5	66.5	86.0	100	
		Week 12	Tezepelumab	25	24 (96.0)	66.2 (17.8)	35	52.0	70.0	76.0	98	
			Placebo	34	32 (94.1)	73.1 (15.3)	42	61.5	71.5	87.5	100	
		Week 20	Tezepelumab	25	24 (96.0)	67.6 (18.8)	25	55.5	70.5	80.5	97	
			Placebo	34	32 (94.1)	71.1 (16.0)	46	58.0	70.0	85.5	100	
		Week 28	Tezepelumab	25	24 (96.0)	69.2 (15.4)	44	56.5	70.5	78.5	95	
			Placebo	34	33 (97.1)	73.7 (15.3)	47	63.0	74.0	86.0	100	
		Week 40	Tezepelumab	25	24 (96.0)	70.2 (17.2)	40	61.5	72.5	81.0	98	
			Placebo	34	33 (97.1)	72.0 (16.1)	46	55.0	71.0	86.0	100	
		Week 52	Tezepelumab	25	25 (100.0)	69.4 (18.4)	32	59.0	71.0	83.0	97	
			Placebo	34	33 (97.1)	74.8 (16.2)	44	66.0	77.0	86.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	25	22 (88.0)	8.2 (19.1)	-27	-7.0	11.5	20.0	40	-0.07 [-0.62, 0.49]
			Placebo	34	29 (85.3)	9.3 (14.5)	-14	0.0	7.0	17.0	51	
		Week 8	Tezepelumab	25	22 (88.0)	7.1 (16.7)	-46	-1.0	11.5	16.0	32	-0.18 [-0.74, 0.37]
			Placebo	34	29 (85.3)	10.1 (16.2)	-14	-1.0	6.0	20.0	51	
		Week 12	Tezepelumab	25	22 (88.0)	6.7 (17.5)	-34	0.0	6.0	19.0	35	-0.43 [-0.99, 0.13]
			Placebo	34	29 (85.3)	14.0 (16.6)	-16	2.0	11.0	25.0	51	
		Week 20	Tezepelumab	25	22 (88.0)	8.7 (21.7)	-44	-9.0	12.5	25.0	50	-0.20 [-0.76, 0.35]
			Placebo	34	29 (85.3)	12.4 (15.3)	-8	-1.0	10.0	19.0	51	
		Week 28	Tezepelumab	25	22 (88.0)	10.8 (20.7)	-33	-3.0	10.0	23.0	50	-0.18 [-0.74, 0.37]
			Placebo	34	29 (85.3)	13.8 (12.5)	-8	3.0	12.0	24.0	37	
		Week 40	Tezepelumab	25	22 (88.0)	12.1 (19.6)	-33	0.0	12.5	31.0	40	-0.04 [-0.59, 0.52]
			Placebo	34	29 (85.3)	12.8 (13.5)	-17	4.0	13.0	22.0	36	
		Week 52	Tezepelumab	25	22 (88.0)	10.0 (20.7)	-27	-5.0	14.0	21.0	53	-0.27 [-0.83, 0.28]
			Placebo	34	29 (85.3)	15.2 (17.5)	-9	2.0	12.0	24.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	26	23 (88.5)	52.0 (17.1)	20	39.0	51.0	61.0	90	
			Placebo	31	25 (80.6)	56.2 (15.4)	29	47.0	53.0	63.0	88	
		Week 4	Tezepelumab	26	23 (88.5)	57.9 (16.8)	14	49.0	55.0	67.0	87	
			Placebo	31	26 (83.9)	64.4 (20.5)	17	54.0	61.0	76.0	99	
		Week 8	Tezepelumab	26	23 (88.5)	60.7 (17.9)	31	46.0	60.0	71.0	90	
			Placebo	31	27 (87.1)	67.9 (19.9)	19	52.0	65.0	87.0	97	
		Week 12	Tezepelumab	26	23 (88.5)	62.3 (16.8)	35	48.0	59.0	80.0	90	
			Placebo	31	27 (87.1)	68.0 (20.6)	20	54.0	70.0	87.0	100	
		Week 20	Tezepelumab	26	24 (92.3)	61.3 (17.2)	25	47.5	63.5	73.0	93	
			Placebo	31	27 (87.1)	65.8 (21.8)	20	54.0	69.0	85.0	94	
		Week 28	Tezepelumab	26	25 (96.2)	63.0 (17.2)	29	47.0	65.0	75.0	91	
			Placebo	31	28 (90.3)	68.1 (20.6)	27	51.5	69.0	88.0	97	
		Week 40	Tezepelumab	26	25 (96.2)	65.2 (17.4)	35	48.0	68.0	78.0	93	
			Placebo	31	28 (90.3)	69.8 (21.6)	20	53.5	72.0	88.5	96	
		Week 52	Tezepelumab	26	26 (100.0)	64.1 (19.4)	32	48.0	64.0	80.0	93	
			Placebo	31	28 (90.3)	72.7 (22.5)	21	59.0	77.5	90.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	26	23 (88.5)	6.0 (20.2)	-40	-6.0	10.0	18.0	47	-0.16 [-0.73, 0.40]
			Placebo	31	25 (80.6)	9.0 (16.3)	-22	3.0	7.0	16.0	51	
		Week 8	Tezepelumab	26	23 (88.5)	8.8 (26.8)	-59	-5.0	10.0	20.0	69	-0.15 [-0.72, 0.41]
			Placebo	31	25 (80.6)	12.5 (21.0)	-14	-3.0	6.0	23.0	62	
		Week 12	Tezepelumab	26	23 (88.5)	10.4 (23.6)	-34	-1.0	7.0	30.0	65	-0.09 [-0.65, 0.48]
			Placebo	31	25 (80.6)	12.3 (21.4)	-25	-1.0	8.0	22.0	68	
		Week 20	Tezepelumab	26	23 (88.5)	8.7 (22.6)	-44	-9.0	12.0	25.0	51	-0.05 [-0.62, 0.51]
			Placebo	31	25 (80.6)	9.9 (20.9)	-32	-4.0	9.0	23.0	51	
		Week 28	Tezepelumab	26	23 (88.5)	10.4 (24.7)	-43	-7.0	8.0	28.0	60	-0.01 [-0.58, 0.55]
			Placebo	31	25 (80.6)	10.7 (18.5)	-15	-2.0	8.0	20.0	65	
		Week 40	Tezepelumab	26	23 (88.5)	11.7 (24.3)	-43	-3.0	13.0	30.0	58	-0.10 [-0.67, 0.47]
			Placebo	31	25 (80.6)	13.8 (19.2)	-25	2.0	14.0	23.0	55	
		Week 52	Tezepelumab	26	23 (88.5)	10.7 (25.7)	-43	-13.0	13.0	29.0	58	-0.26 [-0.83, 0.31]
			Placebo	31	25 (80.6)	16.9 (21.9)	-26	-1.0	16.0	32.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	61.8 (16.6)	34	49.0	61.0	72.0	100	
			Placebo	34	30 (88.2)	61.1 (13.1)	41	50.0	58.5	70.0	96	
		Week 4	Tezepelumab	40	40 (100.0)	71.2 (19.3)	21	58.5	70.5	89.5	100	
			Placebo	34	32 (94.1)	66.3 (15.0)	38	52.5	68.0	78.5	92	
		Week 8	Tezepelumab	40	40 (100.0)	72.5 (19.2)	20	60.0	74.5	88.0	100	
			Placebo	34	32 (94.1)	64.4 (20.2)	14	50.5	61.5	78.0	100	
		Week 12	Tezepelumab	40	40 (100.0)	72.9 (19.6)	26	60.0	76.0	89.0	100	
			Placebo	34	32 (94.1)	68.6 (17.4)	34	60.0	65.5	86.5	100	
		Week 20	Tezepelumab	40	40 (100.0)	73.8 (19.5)	18	62.0	78.5	88.5	100	
			Placebo	34	32 (94.1)	68.4 (18.2)	30	54.0	67.0	84.5	100	
		Week 28	Tezepelumab	40	40 (100.0)	72.8 (20.1)	8	60.0	76.5	88.0	100	
			Placebo	34	32 (94.1)	70.3 (17.5)	30	58.0	70.5	83.5	100	
		Week 40	Tezepelumab	40	40 (100.0)	73.4 (19.8)	18	65.0	80.0	87.5	100	
			Placebo	34	32 (94.1)	65.8 (16.8)	34	52.0	64.0	78.0	100	
		Week 52	Tezepelumab	40	40 (100.0)	73.2 (19.8)	19	62.0	74.0	89.5	100	
			Placebo	34	32 (94.1)	67.8 (16.1)	38	55.0	69.5	79.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	40	35 (87.5)	9.6 (18.5)	-30	-4.0	13.0	26.0	40	0.26 [-0.23, 0.75]
			Placebo	34	30 (88.2)	5.4 (13.4)	-26	-4.0	5.5	17.0	32	
		Week 8	Tezepelumab	40	35 (87.5)	9.9 (14.4)	-29	0.0	13.0	21.0	35	0.45 [-0.05, 0.94]
			Placebo	34	30 (88.2)	3.0 (16.8)	-36	-5.0	1.5	11.0	37	
		Week 12	Tezepelumab	40	35 (87.5)	10.4 (16.5)	-23	-1.0	10.0	23.0	37	0.18 [-0.31, 0.67]
			Placebo	34	30 (88.2)	7.4 (16.8)	-34	-2.0	6.5	16.0	43	
		Week 20	Tezepelumab	40	35 (87.5)	12.3 (19.0)	-31	-2.0	12.0	26.0	50	0.26 [-0.23, 0.75]
			Placebo	34	30 (88.2)	8.0 (13.6)	-20	-2.0	7.5	15.0	39	
		Week 28	Tezepelumab	40	35 (87.5)	10.9 (19.8)	-41	-3.0	10.0	31.0	40	0.08 [-0.41, 0.57]
			Placebo	34	30 (88.2)	9.5 (14.0)	-20	-1.0	8.0	18.0	36	
		Week 40	Tezepelumab	40	35 (87.5)	11.8 (18.6)	-31	-5.0	15.0	26.0	40	0.39 [-0.10, 0.89]
			Placebo	34	30 (88.2)	5.1 (14.7)	-23	-4.0	3.5	14.0	34	
		Week 52	Tezepelumab	40	35 (87.5)	11.4 (18.4)	-30	-2.0	18.0	24.0	53	0.27 [-0.22, 0.76]
			Placebo	34	30 (88.2)	6.9 (13.7)	-13	-4.0	4.5	15.0	43	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	57	49 (86.0)	57.2 (17.5)	20	49.0	52.0	70.0	100	
			Placebo	60	51 (85.0)	59.5 (14.2)	29	50.0	57.0	70.0	96	
		Week 4	Tezepelumab	57	54 (94.7)	64.7 (19.3)	14	50.0	66.0	79.0	100	
			Placebo	60	53 (88.3)	66.7 (17.8)	17	57.0	69.0	80.0	99	
		Week 8	Tezepelumab	57	54 (94.7)	66.8 (19.0)	20	53.0	69.5	84.0	100	
			Placebo	60	54 (90.0)	66.6 (20.0)	14	53.0	63.0	85.0	100	
		Week 12	Tezepelumab	57	54 (94.7)	67.3 (18.4)	26	53.0	69.5	81.0	100	
			Placebo	60	54 (90.0)	68.9 (18.5)	20	60.0	69.5	87.0	100	
		Week 20	Tezepelumab	57	55 (96.5)	67.5 (19.2)	18	54.0	70.0	82.0	100	
			Placebo	60	54 (90.0)	68.1 (20.3)	20	55.0	69.0	85.0	100	
		Week 28	Tezepelumab	57	56 (98.2)	67.3 (19.0)	8	52.5	70.0	82.0	100	
			Placebo	60	55 (91.7)	69.6 (18.8)	27	54.0	70.0	86.0	100	
		Week 40	Tezepelumab	57	56 (98.2)	68.6 (18.5)	18	51.5	72.5	81.0	100	
			Placebo	60	55 (91.7)	68.5 (19.2)	20	54.0	71.0	86.0	100	
		Week 52	Tezepelumab	57	57 (100.0)	68.5 (19.6)	19	53.0	71.0	84.0	100	
			Placebo	60	55 (91.7)	70.8 (19.6)	21	59.0	75.0	85.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	57	49 (86.0)	7.1 (19.5)	-40	-6.0	10.0	19.0	47	-0.01 [-0.40, 0.38]
			Placebo	60	51 (85.0)	7.2 (15.2)	-26	-4.0	7.0	17.0	51	
		Week 8	Tezepelumab	57	49 (86.0)	8.4 (21.4)	-59	-1.0	11.0	20.0	69	0.08 [-0.32, 0.47]
			Placebo	60	51 (85.0)	6.9 (18.2)	-36	-5.0	6.0	19.0	51	
		Week 12	Tezepelumab	57	49 (86.0)	9.1 (20.1)	-34	-1.0	6.0	22.0	65	-0.01 [-0.41, 0.38]
			Placebo	60	51 (85.0)	9.3 (17.6)	-34	-1.0	8.0	21.0	51	
		Week 20	Tezepelumab	57	49 (86.0)	9.8 (21.3)	-44	-9.0	10.0	25.0	51	0.04 [-0.35, 0.43]
			Placebo	60	51 (85.0)	9.0 (17.1)	-32	-2.0	9.0	21.0	51	
		Week 28	Tezepelumab	57	49 (86.0)	9.4 (22.5)	-43	-7.0	9.0	28.0	60	-0.02 [-0.42, 0.37]
			Placebo	60	51 (85.0)	9.8 (14.4)	-20	2.0	8.0	20.0	37	
		Week 40	Tezepelumab	57	49 (86.0)	10.4 (21.9)	-43	-5.0	11.0	30.0	58	0.07 [-0.32, 0.46]
			Placebo	60	51 (85.0)	9.1 (16.3)	-25	-2.0	6.0	21.0	45	
		Week 52	Tezepelumab	57	49 (86.0)	10.4 (22.7)	-43	-10.0	16.0	28.0	58	-0.05 [-0.44, 0.34]
			Placebo	60	51 (85.0)	11.5 (17.8)	-26	-2.0	11.0	23.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	62.0 (17.0)	38	50.0	61.0	79.0	83	
			Placebo	5	4 (80.0)	50.0 (13.9)	32	40.0	51.5	60.0	65	
		Week 4	Tezepelumab	9	9 (100.0)	76.2 (17.6)	50	60.0	87.0	90.0	94	
			Placebo	5	5 (100.0)	53.0 (6.7)	46	48.0	51.0	59.0	61	
		Week 8	Tezepelumab	9	9 (100.0)	77.0 (21.3)	35	60.0	87.0	95.0	96	
			Placebo	5	5 (100.0)	60.0 (19.9)	45	48.0	52.0	61.0	94	
		Week 12	Tezepelumab	9	9 (100.0)	79.7 (21.7)	33	70.0	87.0	97.0	98	
			Placebo	5	5 (100.0)	62.2 (22.1)	46	47.0	57.0	61.0	100	
		Week 20	Tezepelumab	9	9 (100.0)	79.0 (19.2)	34	75.0	81.0	92.0	97	
			Placebo	5	5 (100.0)	57.4 (9.0)	46	51.0	60.0	61.0	69	
		Week 28	Tezepelumab	9	9 (100.0)	79.9 (20.1)	32	75.0	88.0	94.0	95	
			Placebo	5	5 (100.0)	65.2 (21.0)	46	48.0	61.0	74.0	97	
		Week 40	Tezepelumab	9	9 (100.0)	80.7 (21.2)	32	75.0	90.0	94.0	98	
			Placebo	5	5 (100.0)	58.2 (17.6)	43	46.0	54.0	61.0	87	
		Week 52	Tezepelumab	9	9 (100.0)	77.1 (22.0)	25	70.0	84.0	90.0	97	
			Placebo	5	5 (100.0)	61.8 (15.3)	46	52.0	61.0	64.0	86	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	14.2 (16.1)	-17	7.0	15.0	20.0	40	0.66 [-0.55, 1.87]
			Placebo	5	4 (80.0)	4.8 (8.3)	-4	-0.5	3.5	10.0	16	
		Week 8	Tezepelumab	9	9 (100.0)	15.0 (9.2)	-3	10.0	15.0	23.0	26	0.16 [-1.02, 1.34]
			Placebo	5	4 (80.0)	12.0 (33.4)	-7	-5.5	-3.5	29.5	62	
		Week 12	Tezepelumab	9	9 (100.0)	17.7 (13.4)	-5	7.0	19.0	25.0	36	0.19 [-0.99, 1.37]
			Placebo	5	4 (80.0)	13.5 (36.4)	-8	-6.0	-3.0	33.0	68	
		Week 20	Tezepelumab	9	9 (100.0)	17.0 (13.6)	-4	6.0	25.0	25.0	31	0.65 [-0.56, 1.86]
			Placebo	5	4 (80.0)	6.8 (20.2)	-4	-4.0	-3.0	17.5	37	
		Week 28	Tezepelumab	9	9 (100.0)	17.9 (15.8)	-6	8.0	23.0	25.0	40	0.22 [-0.96, 1.40]
			Placebo	5	4 (80.0)	13.0 (34.7)	-7	-5.5	-3.0	31.5	65	
		Week 40	Tezepelumab	9	9 (100.0)	18.7 (12.3)	-6	13.0	20.0	23.0	40	0.49 [-0.71, 1.69]
			Placebo	5	4 (80.0)	9.3 (30.8)	-12	-8.0	-3.0	26.5	55	
		Week 52	Tezepelumab	9	9 (100.0)	15.1 (11.8)	-13	12.0	18.0	23.0	25	0.21 [-0.97, 1.40]
			Placebo	5	4 (80.0)	11.3 (28.5)	-4	-3.5	-2.5	26.0	54	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	55.8 (16.4)	35	43.5	53.0	67.5	83	
			Placebo	14	10 (71.4)	56.1 (11.9)	32	49.0	60.0	65.0	70	
		Week 4	Tezepelumab	9	9 (100.0)	70.1 (14.5)	44	66.0	70.0	81.0	92	
			Placebo	14	12 (85.7)	57.5 (17.3)	23	48.0	54.0	69.0	91	
		Week 8	Tezepelumab	9	9 (100.0)	70.1 (22.0)	35	60.0	73.0	87.0	95	
			Placebo	14	13 (92.9)	65.6 (15.2)	48	54.0	62.0	69.0	94	
		Week 12	Tezepelumab	9	9 (100.0)	67.4 (23.4)	33	48.0	66.0	89.0	97	
			Placebo	14	13 (92.9)	63.2 (18.7)	20	57.0	64.0	69.0	100	
		Week 20	Tezepelumab	9	9 (100.0)	68.2 (24.1)	34	40.0	77.0	85.0	97	
			Placebo	14	13 (92.9)	59.5 (15.1)	20	54.0	61.0	69.0	82	
		Week 28	Tezepelumab	9	9 (100.0)	66.4 (22.4)	32	50.0	71.0	85.0	95	
			Placebo	14	14 (100.0)	67.0 (18.1)	30	54.0	68.0	74.0	97	
		Week 40	Tezepelumab	9	9 (100.0)	67.7 (22.7)	32	50.0	75.0	81.0	95	
			Placebo	14	14 (100.0)	62.8 (19.3)	20	53.0	61.5	73.0	95	
		Week 52	Tezepelumab	9	9 (100.0)	68.1 (24.6)	25	50.0	75.0	88.0	95	
			Placebo	14	14 (100.0)	63.7 (17.5)	30	48.0	65.0	73.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	12.6 (16.3)	-17	1.5	19.0	23.0	31	0.61 [-0.34, 1.56]
			Placebo	14	10 (71.4)	3.2 (14.7)	-22	-6.0	0.0	16.0	26	
		Week 8	Tezepelumab	9	8 (88.9)	12.3 (12.8)	-10	3.5	15.5	22.5	25	0.05 [-0.88, 0.98]
			Placebo	14	10 (71.4)	11.3 (21.7)	-8	-1.0	1.5	23.0	62	
		Week 12	Tezepelumab	9	8 (88.9)	10.1 (14.7)	-10	-1.0	10.0	19.5	34	0.17 [-0.77, 1.10]
			Placebo	14	10 (71.4)	6.7 (24.4)	-25	-4.0	1.5	14.0	68	
		Week 20	Tezepelumab	9	8 (88.9)	11.4 (22.7)	-11	-7.0	3.0	30.0	50	0.38 [-0.55, 1.32]
			Placebo	14	10 (71.4)	3.8 (17.0)	-25	-4.0	1.0	12.0	37	
		Week 28	Tezepelumab	9	8 (88.9)	8.4 (19.3)	-13	-8.0	3.0	27.0	36	-0.04 [-0.97, 0.89]
			Placebo	14	10 (71.4)	9.2 (22.7)	-15	-4.0	3.0	18.0	65	
		Week 40	Tezepelumab	9	8 (88.9)	11.0 (19.0)	-13	-8.0	14.5	24.0	40	0.21 [-0.73, 1.14]
			Placebo	14	10 (71.4)	6.8 (21.3)	-25	-4.0	2.5	15.0	55	
		Week 52	Tezepelumab	9	8 (88.9)	11.5 (23.2)	-13	-11.5	14.0	23.5	53	0.19 [-0.74, 1.12]
			Placebo	14	10 (71.4)	7.5 (19.5)	-15	-4.0	3.5	13.0	54	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	58.3 (17.6)	20	49.0	52.5	71.0	100	
			Placebo	51	45 (88.2)	59.5 (14.8)	29	50.0	54.0	70.0	96	
		Week 4	Tezepelumab	57	54 (94.7)	65.7 (20.1)	14	50.0	66.0	86.0	100	
			Placebo	51	46 (90.2)	67.6 (17.1)	17	57.0	69.0	81.0	99	
		Week 8	Tezepelumab	57	54 (94.7)	67.9 (19.3)	20	55.0	69.5	85.0	100	
			Placebo	51	46 (90.2)	66.2 (21.2)	14	51.0	62.5	87.0	100	
		Week 12	Tezepelumab	57	54 (94.7)	69.3 (18.7)	26	56.0	70.5	84.0	100	
			Placebo	51	46 (90.2)	69.8 (18.7)	30	58.0	71.5	88.0	100	
		Week 20	Tezepelumab	57	55 (96.5)	69.2 (18.9)	18	55.0	70.0	82.0	100	
			Placebo	51	46 (90.2)	69.4 (20.5)	22	55.0	70.5	86.0	100	
		Week 28	Tezepelumab	57	56 (98.2)	69.4 (19.2)	8	53.0	72.0	83.0	100	
			Placebo	51	46 (90.2)	70.0 (19.2)	27	53.0	72.0	86.0	100	
		Week 40	Tezepelumab	57	56 (98.2)	70.7 (18.7)	18	54.5	74.5	84.0	100	
			Placebo	51	46 (90.2)	69.1 (19.1)	27	54.0	71.0	86.0	100	
		Week 52	Tezepelumab	57	57 (100.0)	69.9 (19.4)	19	54.0	73.0	84.0	100	
			Placebo	51	46 (90.2)	72.0 (19.7)	21	60.0	76.5	86.0	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	50 (87.7)	7.5 (19.5)	-40	-6.0	10.0	19.0	47	-0.02 [-0.43, 0.38]
			Placebo	51	45 (88.2)	7.9 (14.8)	-26	-1.0	7.0	17.0	51	
		Week 8	Tezepelumab	57	50 (87.7)	9.0 (21.0)	-59	-1.0	11.5	20.0	69	0.13 [-0.27, 0.53]
			Placebo	51	45 (88.2)	6.4 (18.8)	-36	-5.0	6.0	19.0	51	
		Week 12	Tezepelumab	57	50 (87.7)	10.5 (20.2)	-34	-1.0	8.0	23.0	65	0.01 [-0.39, 0.41]
			Placebo	51	45 (88.2)	10.3 (17.9)	-34	-1.0	8.0	22.0	51	
		Week 20	Tezepelumab	57	50 (87.7)	10.8 (20.2)	-44	-4.0	12.5	25.0	51	0.04 [-0.36, 0.45]
			Placebo	51	45 (88.2)	10.0 (17.2)	-32	-2.0	9.0	21.0	51	
		Week 28	Tezepelumab	57	50 (87.7)	11.1 (22.2)	-43	-1.0	10.0	28.0	60	0.04 [-0.36, 0.45]
			Placebo	51	45 (88.2)	10.3 (14.6)	-20	2.0	9.0	20.0	37	
		Week 40	Tezepelumab	57	50 (87.7)	11.8 (21.3)	-43	-1.0	14.0	30.0	58	0.12 [-0.29, 0.52]
			Placebo	51	45 (88.2)	9.6 (16.5)	-23	-2.0	6.0	21.0	45	
		Week 52	Tezepelumab	57	50 (87.7)	11.1 (21.3)	-43	-4.0	18.0	25.0	58	-0.06 [-0.47, 0.34]
			Placebo	51	45 (88.2)	12.3 (18.3)	-26	-2.0	11.0	24.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	51	44 (86.3)	57.9 (18.0)	20	48.0	52.5	70.5	100	
			Placebo	49	43 (87.8)	59.8 (15.0)	29	50.0	54.0	70.0	96	
		Week 4	Tezepelumab	51	48 (94.1)	64.1 (19.9)	14	50.0	64.5	79.0	100	
			Placebo	49	44 (89.8)	68.1 (17.3)	17	57.5	69.5	81.5	99	
		Week 8	Tezepelumab	51	48 (94.1)	66.6 (19.4)	20	53.0	68.5	84.5	100	
			Placebo	49	44 (89.8)	67.0 (21.3)	14	52.0	66.5	87.0	100	
		Week 12	Tezepelumab	51	48 (94.1)	67.6 (18.5)	26	54.5	70.0	81.5	100	
			Placebo	49	44 (89.8)	70.8 (18.4)	30	60.0	72.0	88.0	100	
		Week 20	Tezepelumab	51	49 (96.1)	67.5 (19.1)	18	54.0	68.0	81.0	100	
			Placebo	49	44 (89.8)	70.4 (20.5)	22	58.5	73.5	86.0	100	
		Week 28	Tezepelumab	51	50 (98.0)	67.5 (19.2)	8	53.0	70.0	82.0	100	
			Placebo	49	44 (89.8)	71.0 (19.0)	27	56.5	74.0	86.0	100	
		Week 40	Tezepelumab	51	50 (98.0)	69.0 (18.8)	18	52.0	72.5	82.0	100	
			Placebo	49	44 (89.8)	70.3 (18.8)	27	56.0	72.0	86.5	100	
		Week 52	Tezepelumab	51	51 (100.0)	68.6 (19.8)	19	53.0	71.0	84.0	100	
			Placebo	49	44 (89.8)	73.1 (19.5)	21	61.0	77.0	86.5	100	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	51	44 (86.3)	6.1 (19.9)	-40	-6.5	10.0	19.0	47	-0.11 [-0.54, 0.31]
			Placebo	49	43 (87.8)	8.1 (15.1)	-26	-2.0	7.0	17.0	51	
		Week 8	Tezepelumab	51	44 (86.3)	7.9 (22.1)	-59	-3.0	10.0	20.0	69	0.05 [-0.37, 0.47]
			Placebo	49	43 (87.8)	6.9 (19.0)	-36	-5.0	6.0	19.0	51	
		Week 12	Tezepelumab	51	44 (86.3)	8.9 (20.7)	-34	-1.0	6.0	22.5	65	-0.11 [-0.53, 0.31]
			Placebo	49	43 (87.8)	11.0 (18.0)	-34	1.0	10.0	25.0	51	
		Week 20	Tezepelumab	51	44 (86.3)	9.2 (20.8)	-44	-8.0	11.0	24.5	51	-0.07 [-0.49, 0.35]
			Placebo	49	43 (87.8)	10.6 (17.4)	-32	-2.0	10.0	21.0	51	
		Week 28	Tezepelumab	51	44 (86.3)	9.3 (22.7)	-43	-4.0	9.0	25.5	60	-0.09 [-0.51, 0.33]
			Placebo	49	43 (87.8)	11.0 (14.5)	-20	2.0	9.0	24.0	37	
		Week 40	Tezepelumab	51	44 (86.3)	10.3 (22.0)	-43	-4.0	9.5	30.5	58	-0.00 [-0.42, 0.42]
			Placebo	49	43 (87.8)	10.3 (16.4)	-23	-2.0	8.0	22.0	45	
		Week 52	Tezepelumab	51	44 (86.3)	9.8 (22.4)	-43	-8.0	14.5	27.0	58	-0.15 [-0.58, 0.27]
			Placebo	49	43 (87.8)	13.0 (18.4)	-26	-2.0	11.0	27.0	65	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	57.9 (15.6)	35	49.0	53.0	72.0	83	
			Placebo	16	12 (75.0)	55.3 (11.0)	32	48.5	57.5	63.5	70	
		Week 4	Tezepelumab	15	15 (100.0)	73.5 (16.2)	44	60.0	71.0	90.0	94	
			Placebo	16	14 (87.5)	57.1 (16.1)	23	48.0	54.0	69.0	91	
		Week 8	Tezepelumab	15	15 (100.0)	73.3 (19.5)	35	60.0	75.0	90.0	96	
			Placebo	16	15 (93.8)	63.1 (15.6)	45	51.0	61.0	69.0	94	
		Week 12	Tezepelumab	15	15 (100.0)	73.6 (21.3)	33	60.0	80.0	90.0	98	
			Placebo	16	15 (93.8)	61.0 (18.3)	20	48.0	62.0	69.0	100	
		Week 20	Tezepelumab	15	15 (100.0)	74.2 (20.6)	34	70.0	80.0	90.0	97	
			Placebo	16	15 (93.8)	58.1 (14.6)	20	51.0	60.0	69.0	82	
		Week 28	Tezepelumab	15	15 (100.0)	74.0 (20.4)	32	60.0	80.0	90.0	95	
			Placebo	16	16 (100.0)	64.5 (18.2)	30	49.5	65.5	73.5	97	
		Week 40	Tezepelumab	15	15 (100.0)	74.3 (20.5)	32	65.0	75.0	93.0	98	
			Placebo	16	16 (100.0)	60.5 (19.0)	20	48.0	57.5	72.0	95	
		Week 52	Tezepelumab	15	15 (100.0)	73.3 (20.8)	25	69.0	75.0	88.0	97	
			Placebo	16	16 (100.0)	61.9 (17.0)	30	48.0	62.5	73.0	97	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_ILSHP: Change from baseline in EQ-5D-VAS by study specific subgroups
DITTL

Subgroup	EQ-5D-VAS		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	15	14 (93.3)	14.8 (15.0)	-17	7.0	17.0	26.0	40	0.81 [0.01, 1.61]
			Placebo	16	12 (75.0)	3.3 (13.3)	-22	-5.0	2.0	12.5	26	
		Week 8	Tezepelumab	15	14 (93.3)	14.4 (10.7)	-10	10.0	16.0	23.0	26	0.36 [-0.42, 1.14]
			Placebo	16	12 (75.0)	8.6 (20.7)	-8	-3.5	0.5	14.5	62	
		Week 12	Tezepelumab	15	14 (93.3)	15.2 (14.3)	-10	7.0	14.5	25.0	36	0.56 [-0.22, 1.35]
			Placebo	16	12 (75.0)	4.8 (22.6)	-25	-6.0	0.0	9.0	68	
		Week 20	Tezepelumab	15	14 (93.3)	16.1 (18.6)	-11	-2.0	21.0	30.0	50	0.78 [-0.02, 1.58]
			Placebo	16	12 (75.0)	2.7 (15.6)	-25	-4.0	-1.5	9.5	37	
		Week 28	Tezepelumab	15	14 (93.3)	15.3 (18.0)	-13	-3.0	19.0	31.0	40	0.43 [-0.35, 1.21]
			Placebo	16	12 (75.0)	6.9 (21.2)	-15	-5.5	1.0	13.0	65	
		Week 40	Tezepelumab	15	14 (93.3)	16.3 (16.3)	-13	12.0	19.5	25.0	40	0.65 [-0.14, 1.44]
			Placebo	16	12 (75.0)	4.5 (20.2)	-25	-6.0	0.5	11.5	55	
		Week 52	Tezepelumab	15	14 (93.3)	15.2 (17.9)	-13	10.0	18.0	25.0	53	0.52 [-0.26, 1.31]
			Placebo	16	12 (75.0)	5.8 (18.1)	-15	-3.5	0.5	9.5	54	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSI_IBMP0: Increase in EQ-5D-VAS of at least 15 points
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase in EQ-5D-VAS of at least 15 points	Week 52	12	10 (83.3)	4 (33.3) [9.9, 65.1]	9	7 (77.8)	2 (22.2) [2.8, 60.0]	1.500 [0.348, 6.465]	1.750 [0.242, 12.642]	11.1 [-36.7, 58.9]	0.659 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. VAS = visual analogue scale.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: avas, created on: 11AUG2022

Table PT2VSD_IBMP0: Decrease in EQ-5D-VAS of at least 15 points
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease in EQ-5D-VAS of at least 15 points	Week 52	12	10 (83.3)	2 (16.7) [2.1, 48.4]	9	7 (77.8)	1 (11.1) [0.3, 48.2]	1.500 [0.160, 14.083]	1.600 [0.122, 20.993]	5.6 [-33.6, 44.7]	1.000 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. VAS = visual analogue scale.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMH0: Course of EQ-5D-VAS
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Baseline	Tezepelumab	12	10 (83.3)	61.4 (16.0)	38	51.0	55.5	72.0	90	
		Placebo	9	7 (77.8)	56.6 (14.4)	47	47.0	50.0	65.0	86	
	Week 1	Tezepelumab	12	10 (83.3)	67.7 (17.5)	31	56.0	77.0	80.0	83	
		Placebo	9	7 (77.8)	53.1 (25.7)	18	36.0	49.0	77.0	95	
	Week 2	Tezepelumab	12	10 (83.3)	64.0 (20.8)	31	49.0	69.5	82.0	85	
		Placebo	9	7 (77.8)	62.7 (19.7)	39	49.0	57.0	85.0	94	
	Week 3	Tezepelumab	12	10 (83.3)	70.7 (18.9)	38	53.0	75.0	86.0	90	
		Placebo	9	7 (77.8)	64.6 (21.4)	44	45.0	56.0	85.0	94	
	Week 4	Tezepelumab	12	10 (83.3)	69.8 (17.1)	50	50.0	72.0	87.0	91	
		Placebo	9	7 (77.8)	63.9 (15.6)	45	57.0	59.0	73.0	94	
	Week 5	Tezepelumab	12	10 (83.3)	72.4 (16.4)	45	58.0	77.0	85.0	92	
		Placebo	9	7 (77.8)	66.4 (16.3)	47	53.0	60.0	77.0	94	
	Week 6	Tezepelumab	12	10 (83.3)	67.5 (19.8)	24	58.0	72.5	85.0	85	
		Placebo	9	7 (77.8)	60.6 (23.7)	22	52.0	55.0	85.0	94	
	Week 7	Tezepelumab	12	10 (83.3)	67.8 (18.5)	30	54.0	70.5	84.0	91	
		Placebo	9	7 (77.8)	61.3 (26.0)	17	49.0	63.0	86.0	94	
	Week 8	Tezepelumab	12	10 (83.3)	69.2 (21.1)	31	58.0	68.0	88.0	94	
		Placebo	9	7 (77.8)	57.3 (29.1)	14	29.0	55.0	87.0	94	
	Week 9	Tezepelumab	12	10 (83.3)	69.8 (19.5)	40	58.0	73.0	86.0	93	
		Placebo	9	7 (77.8)	62.7 (23.1)	36	45.0	59.0	93.0	94	
	Week 10	Tezepelumab	12	10 (83.3)	66.9 (18.7)	35	49.0	73.0	83.0	85	
		Placebo	9	7 (77.8)	58.6 (24.5)	30	30.0	55.0	84.0	94	
	Week 11	Tezepelumab	12	10 (83.3)	69.0 (20.1)	35	52.0	75.0	87.0	90	
		Placebo	9	7 (77.8)	60.3 (21.7)	36	42.0	54.0	86.0	94	
	Week 12	Tezepelumab	12	10 (83.3)	71.4 (18.8)	35	59.0	75.0	87.0	92	
		Placebo	9	7 (77.8)	60.3 (23.9)	34	40.0	60.0	90.0	94	
	Week 13	Tezepelumab	12	10 (83.3)	70.8 (19.9)	35	59.0	74.0	88.0	92	
		Placebo	9	7 (77.8)	60.6 (20.8)	44	45.0	50.0	86.0	94	
	Week 14	Tezepelumab	12	10 (83.3)	71.1 (20.2)	35	55.0	77.5	85.0	94	
		Placebo	9	7 (77.8)	62.1 (20.9)	38	45.0	58.0	87.0	94	
	Week 15	Tezepelumab	12	10 (83.3)	69.8 (23.5)	35	42.0	75.0	90.0	95	
		Placebo	9	7 (77.8)	57.9 (26.9)	12	43.0	60.0	79.0	94	
	Week 16	Tezepelumab	12	10 (83.3)	69.4 (21.1)	35	58.0	74.5	88.0	92	
		Placebo	9	7 (77.8)	63.0 (21.2)	31	48.0	58.0	81.0	94	
	Week 17	Tezepelumab	12	10 (83.3)	67.2 (21.3)	35	52.0	71.0	87.0	91	
		Placebo	9	7 (77.8)	58.7 (30.4)	7	37.0	66.0	81.0	94	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMH0: Course of EQ-5D-VAS
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 18	Tezepelumab	12	11 (91.7)	69.6 (20.2)	35	50.0	73.0	89.0	93	
		Placebo	9	7 (77.8)	58.9 (25.8)	23	34.0	55.0	82.0	94	
	Week 19	Tezepelumab	12	11 (91.7)	67.6 (19.9)	35	48.0	67.0	87.0	90	
		Placebo	9	7 (77.8)	59.1 (27.5)	22	30.0	59.0	82.0	94	
	Week 20	Tezepelumab	12	11 (91.7)	71.7 (17.9)	35	62.0	70.0	86.0	97	
		Placebo	9	7 (77.8)	59.1 (29.0)	22	30.0	55.0	85.0	94	
	Week 21	Tezepelumab	12	11 (91.7)	71.9 (18.8)	35	63.0	75.0	88.0	93	
		Placebo	9	7 (77.8)	60.4 (29.4)	16	41.0	57.0	89.0	94	
	Week 22	Tezepelumab	12	11 (91.7)	71.2 (18.1)	35	60.0	75.0	85.0	92	
		Placebo	9	7 (77.8)	62.6 (26.6)	26	38.0	58.0	90.0	94	
	Week 23	Tezepelumab	12	11 (91.7)	70.5 (18.1)	35	58.0	75.0	85.0	92	
		Placebo	9	7 (77.8)	60.0 (26.4)	24	34.0	60.0	89.0	94	
	Week 24	Tezepelumab	12	11 (91.7)	72.0 (19.5)	35	60.0	75.0	90.0	93	
		Placebo	9	7 (77.8)	63.1 (24.8)	26	49.0	55.0	91.0	94	
	Week 25	Tezepelumab	12	11 (91.7)	69.5 (19.8)	35	53.0	75.0	87.0	93	
		Placebo	9	7 (77.8)	62.7 (26.8)	22	45.0	57.0	91.0	94	
	Week 26	Tezepelumab	12	12 (100.0)	69.6 (19.8)	35	51.0	76.0	84.5	95	
		Placebo	9	7 (77.8)	62.9 (22.5)	31	45.0	58.0	82.0	94	
	Week 27	Tezepelumab	12	12 (100.0)	68.3 (19.2)	35	53.5	72.0	82.0	92	
		Placebo	9	7 (77.8)	61.0 (24.5)	22	47.0	59.0	81.0	94	
	Week 28	Tezepelumab	12	12 (100.0)	69.0 (19.3)	35	53.0	70.0	85.5	93	
		Placebo	9	7 (77.8)	55.7 (24.5)	30	32.0	49.0	84.0	94	
	Week 29	Tezepelumab	12	12 (100.0)	69.1 (19.6)	35	51.5	72.5	88.0	92	
		Placebo	9	7 (77.8)	53.1 (25.9)	19	37.0	45.0	80.0	94	
	Week 30	Tezepelumab	12	12 (100.0)	66.1 (20.1)	35	47.5	62.0	85.0	94	
		Placebo	9	7 (77.8)	57.3 (24.4)	25	35.0	57.0	82.0	94	
	Week 31	Tezepelumab	12	12 (100.0)	67.6 (21.0)	35	47.0	72.0	85.5	92	
		Placebo	9	7 (77.8)	60.0 (23.1)	27	38.0	59.0	81.0	94	
	Week 32	Tezepelumab	12	12 (100.0)	68.1 (20.5)	35	52.0	70.5	87.0	92	
		Placebo	9	7 (77.8)	57.1 (26.6)	20	38.0	55.0	80.0	94	
	Week 33	Tezepelumab	12	12 (100.0)	70.0 (20.5)	35	53.0	72.0	89.5	94	
		Placebo	9	7 (77.8)	60.9 (23.4)	30	43.0	60.0	80.0	94	
	Week 34	Tezepelumab	12	12 (100.0)	69.7 (19.6)	35	53.0	74.5	85.5	93	
		Placebo	9	7 (77.8)	64.9 (27.0)	23	48.0	56.0	90.0	100	
	Week 35	Tezepelumab	12	12 (100.0)	69.6 (20.5)	35	54.0	70.5	88.5	94	
		Placebo	9	7 (77.8)	64.0 (25.7)	33	44.0	57.0	89.0	100	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMH0: Course of EQ-5D-VAS
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D-VAS	Week 36	Tezepelumab	12	12 (100.0)	71.1 (20.8)	35	52.5	74.5	90.0	94	
		Placebo	9	7 (77.8)	65.0 (26.4)	31	44.0	58.0	92.0	100	
	Week 37	Tezepelumab	12	12 (100.0)	70.2 (21.2)	35	51.5	74.0	91.0	93	
		Placebo	9	7 (77.8)	58.7 (22.8)	26	44.0	56.0	85.0	91	
	Week 38	Tezepelumab	12	12 (100.0)	70.2 (21.3)	35	51.5	72.0	89.5	96	
		Placebo	9	7 (77.8)	60.6 (20.5)	34	46.0	60.0	80.0	94	
	Week 39	Tezepelumab	12	12 (100.0)	71.1 (20.6)	35	54.0	74.5	89.5	95	
		Placebo	9	7 (77.8)	61.6 (27.1)	31	32.0	60.0	90.0	94	
	Week 40	Tezepelumab	12	12 (100.0)	70.4 (20.1)	35	52.5	71.0	90.5	93	
		Placebo	9	7 (77.8)	64.0 (24.3)	37	43.0	58.0	90.0	95	
	Week 41	Tezepelumab	12	12 (100.0)	68.6 (20.3)	35	52.0	66.5	89.0	94	
		Placebo	9	7 (77.8)	62.7 (26.3)	27	40.0	58.0	87.0	96	
	Week 42	Tezepelumab	12	12 (100.0)	69.7 (20.1)	35	54.0	69.0	90.0	94	
		Placebo	9	7 (77.8)	64.0 (24.5)	34	44.0	56.0	87.0	96	
	Week 43	Tezepelumab	12	12 (100.0)	69.1 (20.2)	35	51.0	73.0	87.0	93	
		Placebo	9	7 (77.8)	59.6 (25.5)	18	45.0	60.0	83.0	96	
	Week 44	Tezepelumab	12	12 (100.0)	69.7 (20.0)	35	53.5	73.5	87.5	93	
		Placebo	9	7 (77.8)	58.9 (24.6)	23	42.0	55.0	84.0	96	
	Week 45	Tezepelumab	12	12 (100.0)	69.6 (20.1)	35	52.0	76.5	86.0	93	
		Placebo	9	7 (77.8)	63.7 (27.1)	25	45.0	57.0	91.0	95	
	Week 46	Tezepelumab	12	12 (100.0)	66.7 (19.1)	35	49.0	68.0	82.5	93	
		Placebo	9	7 (77.8)	64.9 (26.2)	34	42.0	58.0	94.0	98	
	Week 47	Tezepelumab	12	12 (100.0)	67.1 (18.7)	35	51.0	70.5	82.5	93	
		Placebo	9	7 (77.8)	61.7 (26.2)	33	34.0	62.0	89.0	91	
	Week 48	Tezepelumab	12	12 (100.0)	68.9 (20.5)	35	49.5	70.5	89.0	93	
		Placebo	9	7 (77.8)	63.0 (28.5)	29	31.0	62.0	89.0	100	
	Week 49	Tezepelumab	12	12 (100.0)	68.1 (20.1)	35	51.5	68.5	88.0	93	
		Placebo	9	7 (77.8)	62.9 (23.9)	38	43.0	54.0	85.0	97	
	Week 50	Tezepelumab	12	12 (100.0)	69.2 (19.1)	35	53.5	69.5	87.5	93	
		Placebo	9	7 (77.8)	60.1 (19.8)	31	43.0	62.0	80.0	88	
	Week 51	Tezepelumab	12	12 (100.0)	67.4 (20.1)	35	53.0	61.0	88.0	93	
		Placebo	9	7 (77.8)	62.6 (26.5)	21	43.0	59.0	85.0	97	
	Week 52	Tezepelumab	12	12 (100.0)	67.8 (20.2)	35	51.0	64.5	88.0	93	
		Placebo	9	7 (77.8)	60.7 (27.8)	21	38.0	59.0	85.0	97	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMH0: Course of EQ-5D-VAS
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 1	Tezepelumab	12	10 (83.3)	6.3 (16.2)	-20	-7.0	7.5	19.0	30	0.53 [-0.45, 1.51]
		Placebo	9	7 (77.8)	-3.4 (21.1)	-32	-29.0	2.0	9.0	27	
	Week 2	Tezepelumab	12	10 (83.3)	2.6 (19.6)	-23	-11.0	-3.5	23.0	33	-0.20 [-1.17, 0.77]
		Placebo	9	7 (77.8)	6.1 (15.1)	-11	-6.0	8.0	10.0	35	
	Week 3	Tezepelumab	12	10 (83.3)	9.3 (20.0)	-21	-5.0	11.0	31.0	34	0.07 [-0.90, 1.03]
		Placebo	9	7 (77.8)	8.0 (18.9)	-9	-5.0	-3.0	31.0	38	
	Week 4	Tezepelumab	12	10 (83.3)	8.4 (23.0)	-40	-2.0	17.0	28.0	30	0.06 [-0.91, 1.02]
		Placebo	9	7 (77.8)	7.3 (10.7)	-6	-5.0	9.0	10.0	26	
	Week 5	Tezepelumab	12	10 (83.3)	11.0 (17.3)	-15	-2.0	12.5	20.0	38	0.07 [-0.89, 1.04]
		Placebo	9	7 (77.8)	9.9 (13.3)	-5	-4.0	8.0	27.0	28	
	Week 6	Tezepelumab	12	10 (83.3)	6.1 (21.5)	-28	-10.0	7.0	26.0	33	0.10 [-0.87, 1.07]
		Placebo	9	7 (77.8)	4.0 (20.6)	-29	-10.0	6.0	13.0	38	
	Week 7	Tezepelumab	12	10 (83.3)	6.4 (22.9)	-39	-4.0	13.5	25.0	34	0.07 [-0.89, 1.04]
		Placebo	9	7 (77.8)	4.7 (22.3)	-33	-2.0	2.0	21.0	39	
	Week 8	Tezepelumab	12	10 (83.3)	7.8 (29.1)	-59	-6.0	11.5	35.0	38	0.25 [-0.72, 1.22]
		Placebo	9	7 (77.8)	0.7 (25.9)	-36	-22.0	8.0	19.0	40	
	Week 9	Tezepelumab	12	10 (83.3)	8.4 (21.3)	-25	-12.0	14.5	22.0	36	0.11 [-0.86, 1.08]
		Placebo	9	7 (77.8)	6.1 (20.1)	-15	-6.0	0.0	15.0	46	
	Week 10	Tezepelumab	12	10 (83.3)	5.5 (23.5)	-41	-8.0	8.0	24.0	33	0.16 [-0.81, 1.12]
		Placebo	9	7 (77.8)	2.0 (20.8)	-21	-20.0	8.0	13.0	37	
	Week 11	Tezepelumab	12	10 (83.3)	7.6 (23.5)	-38	-10.0	13.5	26.0	35	0.18 [-0.79, 1.15]
		Placebo	9	7 (77.8)	3.7 (18.2)	-15	-11.0	6.0	8.0	39	
	Week 12	Tezepelumab	12	10 (83.3)	10.0 (22.6)	-31	-2.0	13.5	30.0	38	0.29 [-0.68, 1.26]
		Placebo	9	7 (77.8)	3.7 (19.7)	-17	-10.0	-4.0	10.0	43	
	Week 13	Tezepelumab	12	10 (83.3)	9.4 (23.2)	-31	-7.0	13.5	28.0	40	0.26 [-0.71, 1.23]
		Placebo	9	7 (77.8)	4.0 (16.2)	-7	-6.0	-3.0	8.0	39	
	Week 14	Tezepelumab	12	10 (83.3)	9.7 (20.1)	-16	-8.0	11.0	22.0	42	0.22 [-0.75, 1.19]
		Placebo	9	7 (77.8)	5.6 (17.0)	-9	-7.0	2.0	11.0	40	
	Week 15	Tezepelumab	12	10 (83.3)	8.4 (28.5)	-51	-10.0	16.0	29.0	43	0.27 [-0.70, 1.24]
		Placebo	9	7 (77.8)	1.3 (21.6)	-35	-8.0	-3.0	20.0	32	
	Week 16	Tezepelumab	12	10 (83.3)	8.0 (23.3)	-30	-14.0	12.0	22.0	38	0.07 [-0.89, 1.04]
		Placebo	9	7 (77.8)	6.4 (17.7)	-16	-9.0	8.0	23.0	34	
	Week 17	Tezepelumab	12	10 (83.3)	5.8 (23.5)	-36	-12.0	10.5	22.0	39	0.15 [-0.82, 1.12]
		Placebo	9	7 (77.8)	2.1 (25.5)	-40	-14.0	1.0	30.0	34	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMH0: Course of EQ-5D-VAS
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 18	Tezepelumab	12	10 (83.3)	7.9 (24.7)	-40	-7.0	15.0	22.0	40	0.24 [-0.73, 1.21]
		Placebo	9	7 (77.8)	2.3 (21.5)	-27	-13.0	-1.0	27.0	32	
	Week 19	Tezepelumab	12	10 (83.3)	8.2 (21.2)	-23	-9.0	13.0	22.0	35	0.26 [-0.72, 1.23]
		Placebo	9	7 (77.8)	2.6 (23.3)	-28	-17.0	-4.0	30.0	35	
	Week 20	Tezepelumab	12	10 (83.3)	10.0 (19.7)	-20	-4.0	13.0	24.0	41	0.34 [-0.64, 1.31]
		Placebo	9	7 (77.8)	2.6 (25.4)	-25	-20.0	-8.0	35.0	38	
	Week 21	Tezepelumab	12	10 (83.3)	10.2 (21.5)	-23	-7.0	14.5	25.0	40	0.27 [-0.70, 1.24]
		Placebo	9	7 (77.8)	3.9 (25.9)	-31	-9.0	-8.0	37.0	39	
	Week 22	Tezepelumab	12	10 (83.3)	9.4 (20.2)	-16	-10.0	13.5	28.0	33	0.16 [-0.81, 1.13]
		Placebo	9	7 (77.8)	6.0 (23.4)	-21	-12.0	-1.0	35.0	40	
	Week 23	Tezepelumab	12	10 (83.3)	8.6 (20.2)	-18	-12.0	13.5	27.0	33	0.25 [-0.72, 1.22]
		Placebo	9	7 (77.8)	3.4 (21.8)	-23	-16.0	-2.0	23.0	39	
	Week 24	Tezepelumab	12	10 (83.3)	10.3 (22.0)	-19	-10.0	17.0	32.0	38	0.17 [-0.80, 1.14]
		Placebo	9	7 (77.8)	6.6 (21.7)	-21	-10.0	0.0	29.0	41	
	Week 25	Tezepelumab	12	10 (83.3)	7.5 (24.6)	-37	-11.0	14.0	25.0	39	0.06 [-0.91, 1.02]
		Placebo	9	7 (77.8)	6.1 (23.7)	-25	-8.0	-1.0	34.0	41	
	Week 26	Tezepelumab	12	10 (83.3)	6.4 (26.2)	-43	-15.0	13.0	27.0	43	0.00 [-0.96, 0.97]
		Placebo	9	7 (77.8)	6.3 (18.8)	-16	-7.0	2.0	31.0	32	
	Week 27	Tezepelumab	12	10 (83.3)	6.1 (25.7)	-43	-10.0	11.5	25.0	40	0.07 [-0.90, 1.04]
		Placebo	9	7 (77.8)	4.4 (20.2)	-25	-6.0	-2.0	26.0	34	
	Week 28	Tezepelumab	12	10 (83.3)	7.4 (26.1)	-43	-11.0	14.5	28.0	39	0.35 [-0.63, 1.32]
		Placebo	9	7 (77.8)	-0.9 (19.7)	-20	-16.0	-3.0	8.0	37	
	Week 29	Tezepelumab	12	10 (83.3)	5.2 (24.5)	-43	-15.0	13.0	22.0	38	0.38 [-0.59, 1.36]
		Placebo	9	7 (77.8)	-3.4 (19.3)	-28	-14.0	-9.0	8.0	33	
	Week 30	Tezepelumab	12	10 (83.3)	5.1 (23.8)	-43	-12.0	12.5	22.0	37	0.20 [-0.77, 1.17]
		Placebo	9	7 (77.8)	0.7 (19.0)	-22	-16.0	-1.0	9.0	35	
	Week 31	Tezepelumab	12	10 (83.3)	6.3 (24.9)	-43	-12.0	13.0	25.0	33	0.13 [-0.84, 1.09]
		Placebo	9	7 (77.8)	3.4 (18.2)	-20	-13.0	7.0	14.0	34	
	Week 32	Tezepelumab	12	10 (83.3)	5.6 (24.8)	-43	-12.0	15.5	25.0	34	0.21 [-0.76, 1.18]
		Placebo	9	7 (77.8)	0.6 (22.2)	-30	-13.0	-8.0	24.0	33	
	Week 33	Tezepelumab	12	10 (83.3)	7.2 (25.4)	-43	-12.0	16.0	27.0	39	0.13 [-0.84, 1.09]
		Placebo	9	7 (77.8)	4.3 (18.7)	-17	-8.0	-5.0	29.0	30	
	Week 34	Tezepelumab	12	10 (83.3)	7.7 (26.7)	-43	-16.0	13.0	30.0	43	-0.02 [-0.99, 0.94]
		Placebo	9	7 (77.8)	8.3 (23.3)	-24	-10.0	6.0	35.0	40	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMH0: Course of EQ-5D-VAS
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in EQ-5D-VAS	Week 35	Tezepelumab	12	10 (83.3)	7.5 (25.1)	-43	-10.0	13.0	22.0	39	0.00 [-0.96, 0.97]
		Placebo	9	7 (77.8)	7.4 (21.4)	-14	-8.0	-6.0	33.0	39	
	Week 36	Tezepelumab	12	10 (83.3)	8.9 (26.7)	-43	-6.0	13.0	30.0	42	0.02 [-0.95, 0.98]
		Placebo	9	7 (77.8)	8.4 (22.5)	-16	-7.0	-3.0	35.0	42	
	Week 37	Tezepelumab	12	10 (83.3)	7.9 (27.1)	-43	-11.0	12.5	29.0	40	0.21 [-0.76, 1.18]
		Placebo	9	7 (77.8)	2.1 (26.9)	-26	-21.0	-7.0	38.0	41	
	Week 38	Tezepelumab	12	10 (83.3)	8.1 (26.7)	-43	-11.0	13.0	25.0	44	0.16 [-0.81, 1.12]
		Placebo	9	7 (77.8)	4.0 (25.2)	-26	-13.0	-5.0	33.0	44	
	Week 39	Tezepelumab	12	10 (83.3)	8.5 (26.9)	-43	-12.0	13.5	30.0	43	0.13 [-0.83, 1.10]
		Placebo	9	7 (77.8)	5.0 (24.5)	-18	-16.0	-5.0	34.0	44	
	Week 40	Tezepelumab	12	10 (83.3)	6.4 (24.9)	-43	-14.0	14.5	22.0	38	-0.04 [-1.01, 0.92]
		Placebo	9	7 (77.8)	7.4 (22.6)	-10	-7.0	-7.0	34.0	45	
	Week 41	Tezepelumab	12	10 (83.3)	5.7 (25.3)	-43	-15.0	9.5	22.0	40	-0.02 [-0.98, 0.95]
		Placebo	9	7 (77.8)	6.1 (22.6)	-20	-11.0	-2.0	36.0	37	
	Week 42	Tezepelumab	12	10 (83.3)	6.8 (24.9)	-43	-11.0	15.0	22.0	40	-0.03 [-0.99, 0.94]
		Placebo	9	7 (77.8)	7.4 (21.4)	-13	-9.0	-4.0	37.0	37	
	Week 43	Tezepelumab	12	10 (83.3)	7.0 (25.3)	-43	-12.0	14.0	27.0	37	0.17 [-0.80, 1.14]
		Placebo	9	7 (77.8)	3.0 (20.1)	-29	-6.0	1.0	14.0	36	
	Week 44	Tezepelumab	12	10 (83.3)	7.3 (25.1)	-43	-12.0	15.5	28.0	35	0.22 [-0.75, 1.19]
		Placebo	9	7 (77.8)	2.3 (19.1)	-24	-9.0	4.0	10.0	37	
	Week 45	Tezepelumab	12	10 (83.3)	7.3 (26.0)	-43	-14.0	14.0	33.0	34	0.01 [-0.96, 0.97]
		Placebo	9	7 (77.8)	7.1 (24.2)	-22	-8.0	-3.0	39.0	41	
	Week 46	Tezepelumab	12	10 (83.3)	6.9 (24.4)	-43	-10.0	14.0	26.0	33	-0.06 [-1.02, 0.91]
		Placebo	9	7 (77.8)	8.3 (22.8)	-13	-8.0	-5.0	35.0	44	
	Week 47	Tezepelumab	12	10 (83.3)	5.9 (25.2)	-43	-13.0	10.5	25.0	34	0.03 [-0.94, 1.00]
		Placebo	9	7 (77.8)	5.1 (23.3)	-17	-13.0	-3.0	36.0	39	
	Week 48	Tezepelumab	12	10 (83.3)	6.0 (25.5)	-43	-16.0	16.5	23.0	36	-0.02 [-0.98, 0.95]
		Placebo	9	7 (77.8)	6.4 (23.9)	-19	-18.0	-3.0	36.0	39	
	Week 49	Tezepelumab	12	10 (83.3)	6.3 (24.8)	-43	-16.0	14.5	22.0	38	0.00 [-0.97, 0.97]
		Placebo	9	7 (77.8)	6.3 (20.3)	-11	-9.0	-7.0	33.0	35	
	Week 50	Tezepelumab	12	10 (83.3)	5.6 (24.2)	-43	-14.0	11.0	22.0	34	0.08 [-0.88, 1.05]
		Placebo	9	7 (77.8)	3.6 (24.4)	-23	-16.0	-8.0	33.0	38	
	Week 51	Tezepelumab	12	10 (83.3)	4.8 (23.2)	-43	-14.0	11.5	21.0	34	-0.05 [-1.02, 0.91]
		Placebo	9	7 (77.8)	6.0 (22.4)	-26	-8.0	3.0	30.0	38	
	Week 52	Tezepelumab	12	10 (83.3)	5.2 (23.9)	-43	-13.0	11.5	22.0	34	0.04 [-0.92, 1.01]
		Placebo	9	7 (77.8)	4.1 (23.3)	-26	-13.0	-5.0	30.0	38	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. VAS = visual analogue scale.
Last observation carried forward is applied in case of missing values.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 1	Tezepelumab	12	10 (83.3)	8.4 (6.5)	(-4.4, 21.3)	12.2 (10.0)	(-7.7, 32.2)	0.226
	Placebo	9	7 (77.8)	-3.8 (7.7)	(-19.1, 11.5)			
Week 2	Tezepelumab	12	10 (83.3)	4.7 (6.5)	(-8.1, 17.6)	-1.0 (10.0)	(-21.0, 18.9)	0.918
	Placebo	9	7 (77.8)	5.8 (7.7)	(-9.5, 21.0)			
Week 3	Tezepelumab	12	10 (83.3)	11.4 (6.5)	(-1.4, 24.3)	3.8 (10.1)	(-16.4, 23.9)	0.711
	Placebo	9	6 (66.7)	7.7 (7.8)	(-7.8, 23.2)			
Week 4	Tezepelumab	12	10 (83.3)	10.5 (6.5)	(-2.3, 23.4)	3.9 (10.2)	(-16.4, 24.3)	0.701
	Placebo	9	6 (66.7)	6.6 (7.9)	(-9.1, 22.3)			
Week 5	Tezepelumab	12	10 (83.3)	13.1 (6.5)	(0.3, 26.0)	3.8 (10.3)	(-16.7, 24.2)	0.716
	Placebo	9	6 (66.7)	9.4 (8.0)	(-6.5, 25.2)			
Week 6	Tezepelumab	12	10 (83.3)	8.2 (6.5)	(-4.6, 21.1)	7.0 (10.4)	(-13.7, 27.8)	0.501
	Placebo	9	5 (55.6)	1.2 (8.1)	(-15.0, 17.4)			
Week 7	Tezepelumab	12	10 (83.3)	8.5 (6.5)	(-4.3, 21.4)	5.5 (10.4)	(-15.2, 26.2)	0.598
	Placebo	9	6 (66.7)	3.0 (8.1)	(-13.1, 19.1)			
Week 8	Tezepelumab	12	10 (83.3)	9.9 (6.5)	(-2.9, 22.8)	11.7 (10.4)	(-9.0, 32.5)	0.265
	Placebo	9	6 (66.7)	-1.8 (8.1)	(-18.0, 14.4)			
Week 9	Tezepelumab	12	9 (75.0)	11.8 (6.5)	(-1.2, 24.8)	7.3 (10.5)	(-13.6, 28.2)	0.488
	Placebo	9	6 (66.7)	4.4 (8.2)	(-11.8, 20.7)			
Week 10	Tezepelumab	12	9 (75.0)	8.3 (6.6)	(-4.8, 21.4)	8.8 (10.6)	(-12.2, 29.8)	0.409
	Placebo	9	6 (66.7)	-0.5 (8.2)	(-16.8, 15.8)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 11	Tezepelumab	12	8 (66.7)	11.0 (6.7)	(-2.4, 24.3)	9.6 (10.7)	(-11.6, 30.8)	0.372
	Placebo	9	6 (66.7)	1.4 (8.2)	(-14.9, 17.8)			
Week 12	Tezepelumab	12	8 (66.7)	14.1 (6.8)	(0.5, 27.6)	12.7 (10.8)	(-8.7, 34.1)	0.240
	Placebo	9	6 (66.7)	1.3 (8.2)	(-15.1, 17.7)			
Week 13	Tezepelumab	12	8 (66.7)	13.4 (6.9)	(-0.4, 27.1)	11.8 (10.8)	(-9.8, 33.3)	0.280
	Placebo	9	6 (66.7)	1.6 (8.3)	(-14.8, 18.0)			
Week 14	Tezepelumab	12	8 (66.7)	13.8 (7.0)	(-0.0, 27.7)	10.4 (10.9)	(-11.2, 32.1)	0.341
	Placebo	9	6 (66.7)	3.4 (8.3)	(-13.0, 19.8)			
Week 15	Tezepelumab	12	8 (66.7)	12.2 (7.0)	(-1.7, 26.2)	13.9 (10.9)	(-7.8, 35.6)	0.207
	Placebo	9	6 (66.7)	-1.6 (8.3)	(-18.1, 14.8)			
Week 16	Tezepelumab	12	8 (66.7)	11.8 (7.1)	(-2.3, 25.9)	7.4 (11.0)	(-14.3, 29.2)	0.498
	Placebo	9	6 (66.7)	4.3 (8.3)	(-12.1, 20.8)			
Week 17	Tezepelumab	12	8 (66.7)	9.1 (7.1)	(-5.0, 23.2)	9.7 (11.0)	(-12.1, 31.6)	0.377
	Placebo	9	6 (66.7)	-0.7 (8.3)	(-17.1, 15.8)			
Week 18	Tezepelumab	12	8 (66.7)	11.8 (7.1)	(-2.4, 25.9)	12.2 (11.0)	(-9.6, 34.1)	0.269
	Placebo	9	6 (66.7)	-0.5 (8.3)	(-17.0, 16.0)			
Week 19	Tezepelumab	12	8 (66.7)	12.2 (7.2)	(-2.1, 26.4)	12.3 (11.0)	(-9.6, 34.2)	0.268
	Placebo	9	6 (66.7)	-0.1 (8.3)	(-16.6, 16.3)			
Week 20	Tezepelumab	12	8 (66.7)	14.4 (7.2)	(0.2, 28.7)	14.5 (11.0)	(-7.4, 36.5)	0.191
	Placebo	9	6 (66.7)	-0.1 (8.3)	(-16.6, 16.4)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 21	Tezepelumab	12	8 (66.7)	14.7 (7.2)	(0.4, 29.0)	13.3 (11.0)	(-8.7, 35.2)	0.232
	Placebo	9	6 (66.7)	1.4 (8.3)	(-15.0, 17.9)			
Week 22	Tezepelumab	12	8 (66.7)	13.7 (7.2)	(-0.6, 28.1)	9.7 (11.0)	(-12.2, 31.7)	0.380
	Placebo	9	6 (66.7)	4.0 (8.3)	(-12.4, 20.4)			
Week 23	Tezepelumab	12	7 (58.3)	12.9 (7.3)	(-1.6, 27.3)	11.8 (11.1)	(-10.2, 33.8)	0.289
	Placebo	9	6 (66.7)	1.1 (8.3)	(-15.3, 17.5)			
Week 24	Tezepelumab	12	8 (66.7)	14.9 (7.2)	(0.6, 29.3)	10.1 (11.0)	(-11.8, 32.0)	0.363
	Placebo	9	6 (66.7)	4.8 (8.2)	(-11.6, 21.2)			
Week 25	Tezepelumab	12	8 (66.7)	11.4 (7.2)	(-2.9, 25.8)	8.0 (11.1)	(-14.0, 30.0)	0.472
	Placebo	9	5 (55.6)	3.4 (8.3)	(-13.1, 20.0)			
Week 26	Tezepelumab	12	8 (66.7)	10.1 (7.2)	(-4.3, 24.5)	5.4 (11.0)	(-16.5, 27.2)	0.628
	Placebo	9	6 (66.7)	4.7 (8.2)	(-11.6, 21.0)			
Week 27	Tezepelumab	12	7 (58.3)	10.2 (7.3)	(-4.4, 24.8)	7.5 (11.0)	(-14.4, 29.4)	0.499
	Placebo	9	6 (66.7)	2.7 (8.2)	(-13.5, 19.0)			
Week 28	Tezepelumab	12	7 (58.3)	12.5 (7.4)	(-2.2, 27.2)	15.8 (11.0)	(-6.1, 37.8)	0.155
	Placebo	9	6 (66.7)	-3.3 (8.1)	(-19.5, 12.9)			
Week 29	Tezepelumab	12	7 (58.3)	9.8 (7.5)	(-5.0, 24.7)	15.9 (11.0)	(-6.0, 37.9)	0.152
	Placebo	9	6 (66.7)	-6.1 (8.1)	(-22.2, 10.0)			
Week 30	Tezepelumab	12	7 (58.3)	10.1 (7.5)	(-4.8, 25.0)	11.2 (11.0)	(-10.8, 33.1)	0.315
	Placebo	9	6 (66.7)	-1.1 (8.0)	(-17.1, 14.9)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 31	Tezepelumab	12	7 (58.3)	12.2 (7.5)	(-2.8, 27.1)	9.8 (11.0)	(-12.1, 31.7)	0.375
	Placebo	9	6 (66.7)	2.3 (8.0)	(-13.5, 18.2)			
Week 32	Tezepelumab	12	7 (58.3)	11.5 (7.6)	(-3.6, 26.5)	12.2 (11.0)	(-9.6, 34.0)	0.269
	Placebo	9	6 (66.7)	-0.7 (7.9)	(-16.4, 15.0)			
Week 33	Tezepelumab	12	7 (58.3)	14.0 (7.6)	(-1.1, 29.1)	10.1 (10.9)	(-11.5, 31.8)	0.355
	Placebo	9	6 (66.7)	3.9 (7.8)	(-11.6, 19.4)			
Week 34	Tezepelumab	12	7 (58.3)	15.0 (7.6)	(-0.1, 30.1)	7.1 (10.8)	(-14.4, 28.6)	0.513
	Placebo	9	7 (77.8)	7.9 (7.7)	(-7.3, 23.2)			
Week 35	Tezepelumab	12	7 (58.3)	15.0 (7.6)	(-0.2, 30.1)	9.9 (10.9)	(-11.7, 31.6)	0.364
	Placebo	9	6 (66.7)	5.0 (7.8)	(-10.4, 20.5)			
Week 36	Tezepelumab	12	7 (58.3)	17.2 (7.6)	(2.0, 32.3)	12.8 (10.9)	(-8.8, 34.5)	0.242
	Placebo	9	6 (66.7)	4.3 (7.8)	(-11.1, 19.7)			
Week 37	Tezepelumab	12	7 (58.3)	15.9 (7.6)	(0.7, 31.1)	14.1 (10.8)	(-7.4, 35.7)	0.195
	Placebo	9	7 (77.8)	1.8 (7.7)	(-13.5, 17.0)			
Week 38	Tezepelumab	12	6 (50.0)	16.4 (7.7)	(1.1, 31.8)	10.2 (10.9)	(-11.6, 31.9)	0.354
	Placebo	9	6 (66.7)	6.2 (7.7)	(-9.2, 21.6)			
Week 39	Tezepelumab	12	7 (58.3)	17.1 (7.7)	(1.9, 32.3)	12.8 (10.9)	(-8.9, 34.5)	0.243
	Placebo	9	6 (66.7)	4.3 (7.7)	(-11.1, 19.7)			
Week 40	Tezepelumab	12	6 (50.0)	13.5 (7.8)	(-1.9, 29.0)	5.7 (11.0)	(-16.2, 27.5)	0.607
	Placebo	9	6 (66.7)	7.9 (7.7)	(-7.5, 23.3)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 41	Tezepelumab	12	6 (50.0)	12.3 (7.9)	(-3.3, 28.0)	6.6 (11.0)	(-15.3, 28.4)	0.552
	Placebo	9	7 (77.8)	5.8 (7.7)	(-9.5, 21.0)			
Week 42	Tezepelumab	12	6 (50.0)	14.1 (8.0)	(-1.7, 30.0)	8.4 (11.2)	(-13.9, 30.6)	0.457
	Placebo	9	5 (55.6)	5.8 (7.8)	(-9.8, 21.4)			
Week 43	Tezepelumab	12	6 (50.0)	14.4 (8.0)	(-1.5, 30.4)	12.0 (11.2)	(-10.2, 34.2)	0.287
	Placebo	9	6 (66.7)	2.5 (7.8)	(-12.9, 17.9)			
Week 44	Tezepelumab	12	5 (41.7)	15.3 (8.2)	(-1.0, 31.5)	13.3 (11.2)	(-8.9, 35.6)	0.237
	Placebo	9	7 (77.8)	1.9 (7.7)	(-13.3, 17.2)			
Week 45	Tezepelumab	12	6 (50.0)	14.9 (8.1)	(-1.2, 31.0)	8.1 (11.2)	(-14.1, 30.3)	0.469
	Placebo	9	7 (77.8)	6.8 (7.7)	(-8.5, 22.0)			
Week 46	Tezepelumab	12	6 (50.0)	14.2 (8.2)	(-2.0, 30.4)	6.3 (11.2)	(-16.0, 28.6)	0.575
	Placebo	9	7 (77.8)	7.9 (7.7)	(-7.3, 23.2)			
Week 47	Tezepelumab	12	6 (50.0)	12.5 (8.2)	(-3.7, 28.8)	8.5 (11.3)	(-13.9, 30.9)	0.453
	Placebo	9	6 (66.7)	4.0 (7.7)	(-11.4, 19.4)			
Week 48	Tezepelumab	12	6 (50.0)	12.7 (8.2)	(-3.6, 29.0)	6.8 (11.3)	(-15.6, 29.2)	0.548
	Placebo	9	6 (66.7)	5.9 (7.7)	(-9.5, 21.3)			
Week 49	Tezepelumab	12	6 (50.0)	13.2 (8.2)	(-3.2, 29.5)	7.2 (11.2)	(-15.1, 29.6)	0.521
	Placebo	9	7 (77.8)	5.9 (7.7)	(-9.3, 21.2)			
Week 50	Tezepelumab	12	6 (50.0)	12.0 (8.2)	(-4.4, 28.3)	8.8 (11.2)	(-13.6, 31.1)	0.437
	Placebo	9	7 (77.8)	3.2 (7.7)	(-12.1, 18.5)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Table PT2VSC_IBMC0: Change from baseline in EQ-5D-VAS - MMRM results
DITTB

Change from baseline in EQ-5D-VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 51	Tezepelumab	12	5 (41.7)	10.0 (8.4)	(-6.7, 26.7)	4.3 (11.4)	(-18.3, 27.0)	0.704
	Placebo	9	7 (77.8)	5.6 (7.7)	(-9.6, 20.9)			
Week 52	Tezepelumab	12	3 (25.0)	10.3 (9.2)	(-7.8, 28.4)	12.4 (13.1)	(-13.6, 38.3)	0.347
	Placebo	9	2 (22.2)	-2.1 (9.4)	(-20.6, 16.5)			

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. A first order regressive covariance structure was used.
VAS = visual analogue scale.
Source Data: avas, created on: 11AUG2022

Figure PF2VSC_IBMG0: Course of EQ-5D-VAS
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
VAS = visual analogue scale.
Source table: PT2VSC_IBMH0
Source Data: avas, created on: 11AUG2022

Table PT2QTI_IOMP0: Increase of at least 0.9 points in AQLQ+12 total score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 total score	Week 52	137	119 (86.9)	68 (49.6) [41.0, 58.3]	138	120 (87.0)	54 (39.1) [30.9, 47.8]	1.268 [0.970, 1.658]	1.533 [0.950, 2.474]	10.5 [-1.9, 22.9]	0.080

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_IOSPK: Increase of at least 0.9 points in AQLQ+12 total score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.130	
Male	50	41 (82.0)	23 (46.0) [31.8, 60.7]	44	41 (93.2)	21 (47.7) [32.5, 63.3]	0.964 [0.626, 1.483]	0.933 [0.414, 2.101]	-1.7 [-24.1, 20.6]	0.868	
Female	87	78 (89.7)	45 (51.7) [40.8, 62.6]	94	79 (84.0)	33 (35.1) [25.5, 45.6]	1.473 [1.047, 2.073]	1.981 [1.090, 3.597]	16.6 [1.3, 32.0]	0.024	*
Age										0.087	
< 65 years	114	101 (88.6)	57 (50.0) [40.5, 59.5]	118	104 (88.1)	51 (43.2) [34.1, 52.7]	1.157 [0.877, 1.525]	1.314 [0.783, 2.203]	6.8 [-6.9, 20.5]	0.302	
>= 65 years	23	18 (78.3)	11 (47.8) [26.8, 69.4]	20	16 (80.0)	3 (15.0) [3.2, 37.9]	3.188 [1.033, 9.843]	5.194 [1.188, 22.706]	32.8 [2.4, 63.2]	0.024	*
Exacerbations in the year before study										0.459	
<= 2	105	90 (85.7)	49 (46.7) [36.9, 56.7]	110	98 (89.1)	43 (39.1) [29.9, 48.9]	1.194 [0.875, 1.628]	1.363 [0.793, 2.344]	7.6 [-6.6, 21.7]	0.263	
> 2	32	29 (90.6)	19 (59.4) [40.6, 76.3]	28	22 (78.6)	11 (39.3) [21.5, 59.4]	1.511 [0.879, 2.600]	2.259 [0.802, 6.364]	20.1 [-8.1, 48.3]	0.124	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_IOSPK: Increase of at least 0.9 points in AQLQ+12 total score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race		N<10	any level							NE	
White	128	111 (86.7)	62 (48.4) [39.5, 57.4]	123	106 (86.2)	46 (37.4) [28.8, 46.6]					
Black or African American	3	3 (100.0)	3 (100.0) [29.2, 100.0]	6	5 (83.3)	3 (50.0) [11.8, 88.2]					
Asian	5	4 (80.0)	2 (40.0) [5.3, 85.3]	6	6 (100.0)	2 (33.3) [4.3, 77.7]					
Other	1	1 (100.0)	1 (100.0) [2.5, 100.0]	3	3 (100.0)	3 (100.0) [29.2, 100.0]					
Region										0.293	
Europe	78	72 (92.3)	43 (55.1) [43.4, 66.4]	80	68 (85.0)	29 (36.3) [25.8, 47.8]	1.521 [1.069, 2.164]	2.161 [1.142, 4.089]	18.9 [2.4, 35.4]	0.018	*
America	10	9 (90.0)	8 (80.0) [44.4, 97.5]	9	7 (77.8)	5 (55.6) [21.2, 86.3]	1.440 [0.743, 2.790]	3.200 [0.419, 24.417]	24.4 [-27.0, 75.8]	0.350	#
Asia/Pacific	5	4 (80.0)	2 (40.0) [5.3, 85.3]	6	6 (100.0)	2 (33.3) [4.3, 77.7]	1.200 [0.252, 5.709]	1.333 [0.113, 15.704]	6.7 [-68.8, 82.2]	1.000	#
Rest of the world	44	34 (77.3)	15 (34.1) [20.5, 49.9]	43	39 (90.7)	18 (41.9) [27.0, 57.9]	0.814 [0.474, 1.399]	0.718 [0.301, 1.713]	-7.8 [-30.4, 14.9]	0.458	
BMI		N<10	any level							NE	
< 18.5 kg/m**2	0			1	1 (100.0)	0 (0.0) [0.0, 97.5]					
18.5 - < 25.0 kg/m**2	39	34 (87.2)	23 (59.0) [42.1, 74.4]	43	38 (88.4)	20 (46.5) [31.2, 62.3]					
25.0 - < 30.0 kg/m**2	45	40 (88.9)	24 (53.3) [37.9, 68.3]	47	43 (91.5)	17 (36.2) [22.7, 51.5]					
>= 30.0 kg/m**2	53	45 (84.9)	21 (39.6) [26.5, 54.0]	47	38 (80.9)	17 (36.2) [22.7, 51.5]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_IOSPK: Increase of at least 0.9 points in AQLQ+12 total score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.202	
< 150 cells/uL	27	27 (100.0)	16 (59.3) [38.8, 77.6]	33	29 (87.9)	11 (33.3) [18.0, 51.8]	1.778 [1.000, 3.159]	2.909 [1.013, 8.355]	25.9 [-2.0, 53.8]	0.046	*
>= 150 cells/uL	109	91 (83.5)	52 (47.7) [38.1, 57.5]	105	91 (86.7)	43 (41.0) [31.5, 51.0]	1.165 [0.861, 1.576]	1.315 [0.766, 2.259]	6.8 [-7.5, 21.0]	0.321	
Baseline eosinophils - High										0.509	
< 300 cells/uL	69	59 (85.5)	35 (50.7) [38.4, 63.0]	72	61 (84.7)	31 (43.1) [31.4, 55.3]	1.178 [0.828, 1.677]	1.361 [0.701, 2.644]	7.7 [-10.2, 25.5]	0.363	
>= 300 cells/uL	67	59 (88.1)	33 (49.3) [36.8, 61.8]	66	59 (89.4)	23 (34.8) [23.5, 47.6]	1.413 [0.938, 2.129]	1.815 [0.904, 3.643]	14.4 [-3.7, 32.5]	0.094	
Baseline FENO										0.058	
< 25 ppb	78	67 (85.9)	33 (42.3) [31.2, 54.0]	74	63 (85.1)	32 (43.2) [31.8, 55.3]	0.978 [0.677, 1.413]	0.963 [0.506, 1.831]	-0.9 [-18.0, 16.1]	0.908	
>= 25 ppb	57	50 (87.7)	33 (57.9) [44.1, 70.9]	63	56 (88.9)	22 (34.9) [23.3, 48.0]	1.658 [1.108, 2.481]	2.563 [1.225, 5.361]	23.0 [3.9, 42.0]	0.012	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_IOSPK: Increase of at least 0.9 points in AQLQ+12 total score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.010	i
All negative	57	49 (86.0)	31 (54.4) [40.7, 67.6]	66	54 (81.8)	17 (25.8) [15.8, 38.0]	2.111 [1.315, 3.390]	3.437 [1.609, 7.341]	28.6 [10.3, 47.0]	0.001	*
Any positive	71	63 (88.7)	34 (47.9) [35.9, 60.1]	63	57 (90.5)	31 (49.2) [36.4, 62.1]	0.973 [0.686, 1.380]	0.949 [0.481, 1.870]	-1.3 [-19.8, 17.1]	0.879	
Total serum IgE										0.223	
Low	35	31 (88.6)	17 (48.6) [31.4, 66.0]	32	26 (81.3)	8 (25.0) [11.5, 43.4]	1.943 [0.974, 3.874]	2.833 [1.002, 8.009]	23.6 [-1.8, 48.9]	0.048	*
Normal	95	82 (86.3)	47 (49.5) [39.1, 59.9]	98	86 (87.8)	44 (44.9) [34.8, 55.3]	1.102 [0.817, 1.486]	1.202 [0.682, 2.116]	4.6 [-10.5, 19.7]	0.525	
High	7	6 (85.7)	4 (57.1) [18.4, 90.1]	8	8 (100.0)	2 (25.0) [3.2, 65.1]	2.286 [0.586, 8.914]	4.000 [0.447, 35.788]	32.1 [-28.6, 92.9]	0.315	#
OCS at baseline										0.250	
Yes	9	7 (77.8)	4 (44.4) [13.7, 78.8]	13	9 (69.2)	2 (15.4) [1.9, 45.4]	2.889 [0.665, 12.555]	4.400 [0.596, 32.501]	29.1 [-18.3, 76.4]	0.178	#
No	128	112 (87.5)	64 (50.0) [41.0, 59.0]	125	111 (88.8)	52 (41.6) [32.9, 50.8]	1.202 [0.917, 1.575]	1.404 [0.854, 2.307]	8.4 [-4.6, 21.4]	0.181	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_IOSPK: Increase of at least 0.9 points in AQLQ+12 total score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
ICS dose level (at study entry)										0.194	
Medium/Low	70	61 (87.1)	33 (47.1) [35.1, 59.4]	73	65 (89.0)	32 (43.8) [32.2, 55.9]	1.075 [0.751, 1.540]	1.143 [0.591, 2.208]	3.3 [-14.4, 21.0]	0.692	
High	67	58 (86.6)	35 (52.2) [39.7, 64.6]	65	55 (84.6)	22 (33.8) [22.6, 46.6]	1.543 [1.024, 2.325]	2.138 [1.059, 4.316]	18.4 [0.3, 36.5]	0.034	*
LAMA use at baseline										0.680	
Yes	11	9 (81.8)	6 (54.5) [23.4, 83.3]	6	4 (66.7)	2 (33.3) [4.3, 77.7]	1.636 [0.467, 5.732]	2.400 [0.303, 19.041]	21.2 [-39.5, 81.9]	0.620	#
No	126	110 (87.3)	62 (49.2) [40.2, 58.3]	132	116 (87.9)	52 (39.4) [31.0, 48.3]	1.249 [0.948, 1.646]	1.490 [0.910, 2.442]	9.8 [-3.0, 22.7]	0.113	
Tiotropium use at baseline										0.575	
Yes	9	8 (88.9)	6 (66.7) [29.9, 92.5]	3	2 (66.7)	1 (33.3) [0.8, 90.6]	2.000 [0.378, 10.578]	4.000 [0.250, 63.950]	33.3 [-50.5, 100.0]	0.523	#
No	128	111 (86.7)	62 (48.4) [39.5, 57.4]	135	118 (87.4)	53 (39.3) [31.0, 48.0]	1.234 [0.937, 1.625]	1.453 [0.891, 2.371]	9.2 [-3.5, 21.9]	0.134	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_IOSPK: Increase of at least 0.9 points in AQLQ+12 total score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline										0.775
Yes	29	25 (86.2)	16 (55.2) [35.7, 73.6]	37	32 (86.5)	15 (40.5) [24.8, 57.9]	1.361 [0.817, 2.266]	1.805 [0.675, 4.824]	14.6 [-12.5, 41.7]	0.241
No	108	94 (87.0)	52 (48.1) [38.4, 58.0]	101	88 (87.1)	39 (38.6) [29.1, 48.8]	1.247 [0.911, 1.707]	1.476 [0.851, 2.560]	9.5 [-4.8, 23.9]	0.166

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_IOSPP: Increase of at least 0.9 points in AQLQ+12 total score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.923	
White	128	111 (86.7)	62 (48.4) [39.5, 57.4]	123	106 (86.2)	46 (37.4) [28.8, 46.6]	1.295 [0.969, 1.731]	1.572 [0.950, 2.602]	11.0 [-1.9, 24.0]	0.078	
Non-white	9	8 (88.9)	6 (66.7) [29.9, 92.5]	15	14 (93.3)	8 (53.3) [26.6, 78.7]	1.250 [0.645, 2.422]	1.750 [0.314, 9.748]	13.3 [-35.4, 62.0]	0.678	#
Region (cat. P)										0.690	
North America/Western EU	10	9 (90.0)	8 (80.0) [44.4, 97.5]	9	7 (77.8)	5 (55.6) [21.2, 86.3]	1.440 [0.743, 2.790]	3.200 [0.419, 24.417]	24.4 [-27.0, 75.8]	0.350	#
Rest of world	127	110 (86.6)	60 (47.2) [38.3, 56.3]	129	113 (87.6)	49 (38.0) [29.6, 46.9]	1.244 [0.933, 1.657]	1.462 [0.889, 2.405]	9.3 [-3.6, 22.1]	0.135	
Baseline eosinophils (cat. P)										0.989	
< 250 cells/uL	61	53 (86.9)	31 (50.8) [37.7, 63.9]	60	52 (86.7)	24 (40.0) [27.6, 53.5]	1.270 [0.855, 1.888]	1.550 [0.754, 3.185]	10.8 [-8.5, 30.1]	0.234	
>= 250 cells/uL	76	66 (86.8)	37 (48.7) [37.0, 60.4]	78	68 (87.2)	30 (38.5) [27.7, 50.2]	1.266 [0.880, 1.821]	1.518 [0.800, 2.881]	10.2 [-6.7, 27.1]	0.202	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_IOSPP: Increase of at least 0.9 points in AQLQ+12 total score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. P)										0.093	
< 24 ppb	75	64 (85.3)	31 (41.3) [30.1, 53.3]	72	61 (84.7)	30 (41.7) [30.2, 53.9]	0.992 [0.676, 1.456]	0.986 [0.512, 1.901]	-0.3 [-17.6, 17.0]	0.967	
>= 24 ppb	60	53 (88.3)	35 (58.3) [44.9, 70.9]	65	58 (89.2)	24 (36.9) [25.3, 49.8]	1.580 [1.077, 2.317]	2.392 [1.165, 4.909]	21.4 [2.7, 40.1]	0.017	*
Baseline FENO (cat. M)										0.064	
< 22.0 ppb	65	55 (84.6)	24 (36.9) [25.3, 49.8]	62	53 (85.5)	25 (40.3) [28.1, 53.6]	0.916 [0.590, 1.420]	0.866 [0.424, 1.771]	-3.4 [-21.9, 15.1]	0.695	
>= 22.0 ppb	70	62 (88.6)	42 (60.0) [47.6, 71.5]	75	66 (88.0)	29 (38.7) [27.6, 50.6]	1.552 [1.101, 2.187]	2.379 [1.221, 4.635]	21.3 [4.0, 38.6]	0.010	*
Baseline all FEIA status										0.004	i
All negative	50	42 (84.0)	29 (58.0) [43.2, 71.8]	50	40 (80.0)	11 (22.0) [11.5, 36.0]	2.636 [1.487, 4.675]	4.896 [2.044, 11.728]	36.0 [16.1, 55.9]	<0.001	*
Any positive	77	69 (89.6)	36 (46.8) [35.3, 58.5]	80	72 (90.0)	38 (47.5) [36.2, 59.0]	0.984 [0.707, 1.371]	0.970 [0.518, 1.816]	-0.7 [-17.6, 16.1]	0.926	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_IOSPP: Increase of at least 0.9 points in AQLQ+12 total score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Th2 status										0.176	
Low	70	62 (88.6)	36 (51.4) [39.2, 63.6]	62	53 (85.5)	20 (32.3) [20.9, 45.3]	1.594 [1.041, 2.442]	2.224 [1.094, 4.520]	19.2 [1.1, 37.2]	0.027	*
High	65	56 (86.2)	31 (47.7) [35.1, 60.5]	75	66 (88.0)	33 (44.0) [32.5, 55.9]	1.084 [0.756, 1.554]	1.160 [0.596, 2.261]	3.7 [-14.3, 21.7]	0.663	
Baseline Periostin										0.389	
Low (< 20.9 ng/ml)	62	55 (88.7)	28 (45.2) [32.5, 58.3]	67	57 (85.1)	27 (40.3) [28.5, 53.0]	1.121 [0.751, 1.672]	1.220 [0.607, 2.454]	4.9 [-13.8, 23.5]	0.578	
High (>= 20.9 ng/ml)	74	63 (85.1)	40 (54.1) [42.1, 65.7]	71	63 (88.7)	27 (38.0) [26.8, 50.3]	1.421 [0.988, 2.045]	1.917 [0.989, 3.718]	16.0 [-1.4, 33.4]	0.054	
Current post-BD FEV1 reversibility										0.623	
Yes	114	99 (86.8)	56 (49.1) [39.6, 58.7]	126	111 (88.1)	50 (39.7) [31.1, 48.8]	1.238 [0.931, 1.646]	1.468 [0.879, 2.449]	9.4 [-3.9, 22.8]	0.142	
No	23	20 (87.0)	12 (52.2) [30.6, 73.2]	12	9 (75.0)	4 (33.3) [9.9, 65.1]	1.565 [0.642, 3.814]	2.182 [0.510, 9.325]	18.8 [-21.1, 58.8]	0.295	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_IOSPP: Increase of at least 0.9 points in AQLQ+12 total score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Maintenance OCS use at baseline										0.410	
Yes	9	7 (77.8)	4 (44.4) [13.7, 78.8]	14	10 (71.4)	3 (21.4) [4.7, 50.8]	2.074 [0.600, 7.173]	2.933 [0.469, 18.333]	23.0 [-25.0, 71.1]	0.363	#
No	128	112 (87.5)	64 (50.0) [41.0, 59.0]	124	110 (88.7)	51 (41.1) [32.4, 50.3]	1.216 [0.926, 1.597]	1.431 [0.870, 2.355]	8.9 [-4.2, 21.9]	0.158	
No chronic OCS use and current post-BD FEV1 reversibility										0.214	
Yes	108	95 (88.0)	53 (49.1) [39.3, 58.9]	115	103 (89.6)	48 (41.7) [32.6, 51.3]	1.176 [0.881, 1.570]	1.345 [0.793, 2.283]	7.3 [-6.6, 21.3]	0.273	
No	29	24 (82.8)	15 (51.7) [32.5, 70.6]	23	17 (73.9)	6 (26.1) [10.2, 48.4]	1.983 [0.916, 4.293]	3.036 [0.931, 9.897]	25.6 [-3.8, 55.1]	0.064	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IOMP0: Increase of at least 0.9 points in AQLQ+12 activity limitations score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 activity limitations score	Week 52	137	119 (86.9)	67 (48.9) [40.3, 57.6]	138	120 (87.0)	61 (44.2) [35.8, 52.9]	1.106 [0.858, 1.426]	1.208 [0.752, 1.942]	4.7 [-7.8, 17.2]	0.435

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IOMP0: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 environmental stimuli score	Week 52	137	119 (86.9)	66 (48.2) [39.6, 56.9]	138	120 (87.0)	48 (34.8) [26.9, 43.4]	1.385 [1.040, 1.845]	1.743 [1.073, 2.830]	13.4 [1.1, 25.7]	0.024 *

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IOSPK: Increase of at least 0.9 points in AQLQ+12 activity limitations score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.465	
Male	50	41 (82.0)	22 (44.0) [30.0, 58.7]	44	41 (93.2)	20 (45.5) [30.4, 61.2]	0.968 [0.617, 1.518]	0.943 [0.417, 2.130]	-1.5 [-23.7, 20.8]	0.888	
Female	87	78 (89.7)	45 (51.7) [40.8, 62.6]	94	79 (84.0)	41 (43.6) [33.4, 54.2]	1.186 [0.873, 1.611]	1.385 [0.771, 2.488]	8.1 [-7.5, 23.7]	0.276	
Age										0.049	i
< 65 years	114	101 (88.6)	56 (49.1) [39.6, 58.7]	118	104 (88.1)	58 (49.2) [39.8, 58.5]	0.999 [0.769, 1.299]	0.999 [0.597, 1.671]	-0.0 [-13.8, 13.7]	0.996	
>= 65 years	23	18 (78.3)	11 (47.8) [26.8, 69.4]	20	16 (80.0)	3 (15.0) [3.2, 37.9]	3.188 [1.033, 9.843]	5.194 [1.188, 22.706]	32.8 [2.4, 63.2]	0.024	*
Exacerbations in the year before study										0.347	
<= 2	105	90 (85.7)	47 (44.8) [35.0, 54.8]	110	98 (89.1)	48 (43.6) [34.2, 53.4]	1.026 [0.760, 1.385]	1.047 [0.611, 1.793]	1.1 [-13.1, 15.3]	0.868	
> 2	32	29 (90.6)	20 (62.5) [43.7, 78.9]	28	22 (78.6)	13 (46.4) [27.5, 66.1]	1.346 [0.833, 2.175]	1.923 [0.686, 5.394]	16.1 [-12.2, 44.4]	0.216	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IOSPK: Increase of at least 0.9 points in AQLQ+12 activity limitations score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race		N<10	any level							NE	
White	128	111 (86.7)	61 (47.7) [38.8, 56.7]	123	106 (86.2)	51 (41.5) [32.7, 50.7]					
Black or African American	3	3 (100.0)	3 (100.0) [29.2, 100.0]	6	5 (83.3)	4 (66.7) [22.3, 95.7]					
Asian	5	4 (80.0)	2 (40.0) [5.3, 85.3]	6	6 (100.0)	3 (50.0) [11.8, 88.2]					
Other	1	1 (100.0)	1 (100.0) [2.5, 100.0]	3	3 (100.0)	3 (100.0) [29.2, 100.0]					
Region										0.343	
Europe	78	72 (92.3)	42 (53.8) [42.2, 65.2]	80	68 (85.0)	32 (40.0) [29.2, 51.6]	1.346 [0.960, 1.887]	1.750 [0.931, 3.289]	13.8 [-2.8, 30.5]	0.082	
America	10	9 (90.0)	7 (70.0) [34.8, 93.3]	9	7 (77.8)	7 (77.8) [40.0, 97.2]	0.900 [0.527, 1.537]	0.667 [0.084, 5.301]	-7.8 [-57.6, 42.1]	1.000	#
Asia/Pacific	5	4 (80.0)	2 (40.0) [5.3, 85.3]	6	6 (100.0)	3 (50.0) [11.8, 88.2]	0.800 [0.210, 3.052]	0.667 [0.060, 7.352]	-10.0 [-87.0, 67.0]	1.000	#
Rest of the world	44	34 (77.3)	16 (36.4) [22.4, 52.2]	43	39 (90.7)	19 (44.2) [29.1, 60.1]	0.823 [0.492, 1.378]	0.722 [0.305, 1.706]	-7.8 [-30.7, 15.0]	0.460	
BMI		N<10	any level							NE	
< 18.5 kg/m**2	0			1	1 (100.0)	1 (100.0) [2.5, 100.0]					
18.5 - < 25.0 kg/m**2	39	34 (87.2)	21 (53.8) [37.2, 69.9]	43	38 (88.4)	21 (48.8) [33.3, 64.5]					
25.0 - < 30.0 kg/m**2	45	40 (88.9)	24 (53.3) [37.9, 68.3]	47	43 (91.5)	18 (38.3) [24.5, 53.6]					
>= 30.0 kg/m**2	53	45 (84.9)	22 (41.5) [28.1, 55.9]	47	38 (80.9)	21 (44.7) [30.2, 59.9]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IOSPK: Increase of at least 0.9 points in AQLQ+12 activity limitations score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.928	
< 150 cells/uL	27	27 (100.0)	14 (51.9) [31.9, 71.3]	33	29 (87.9)	15 (45.5) [28.1, 63.6]	1.141 [0.677, 1.921]	1.292 [0.466, 3.582]	6.4 [-22.3, 35.1]	0.625	
>= 150 cells/uL	109	91 (83.5)	53 (48.6) [38.9, 58.4]	105	91 (86.7)	46 (43.8) [34.1, 53.8]	1.110 [0.830, 1.483]	1.214 [0.709, 2.079]	4.8 [-9.5, 19.1]	0.481	
Baseline eosinophils - High										0.749	
< 300 cells/uL	69	59 (85.5)	35 (50.7) [38.4, 63.0]	72	61 (84.7)	34 (47.2) [35.3, 59.3]	1.074 [0.767, 1.505]	1.151 [0.594, 2.228]	3.5 [-14.4, 21.4]	0.679	
>= 300 cells/uL	67	59 (88.1)	32 (47.8) [35.4, 60.3]	66	59 (89.4)	27 (40.9) [29.0, 53.7]	1.167 [0.796, 1.713]	1.321 [0.665, 2.622]	6.9 [-11.5, 25.2]	0.428	
Baseline FENO										0.020	i
< 25 ppb	78	67 (85.9)	33 (42.3) [31.2, 54.0]	74	63 (85.1)	38 (51.4) [39.4, 63.1]	0.824 [0.586, 1.159]	0.695 [0.366, 1.318]	-9.0 [-26.2, 8.1]	0.266	
>= 25 ppb	57	50 (87.7)	32 (56.1) [42.4, 69.3]	63	56 (88.9)	23 (36.5) [24.7, 49.6]	1.538 [1.032, 2.290]	2.226 [1.070, 4.632]	19.6 [0.4, 38.8]	0.032	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IOSPK: Increase of at least 0.9 points in AQLQ+12 activity limitations score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										<0.001	i
All negative	57	49 (86.0)	32 (56.1) [42.4, 69.3]	66	54 (81.8)	17 (25.8) [15.8, 38.0]	2.180 [1.363, 3.485]	3.689 [1.725, 7.891]	30.4 [12.1, 48.7]	<0.001	*
Any positive	71	63 (88.7)	31 (43.7) [31.9, 56.0]	63	57 (90.5)	36 (57.1) [44.0, 69.5]	0.764 [0.544, 1.073]	0.581 [0.293, 1.153]	-13.5 [-31.8, 4.8]	0.121	
Total serum IgE										0.166	
Low	35	31 (88.6)	19 (54.3) [36.6, 71.2]	32	26 (81.3)	10 (31.3) [16.1, 50.0]	1.737 [0.956, 3.156]	2.613 [0.961, 7.105]	23.0 [-3.0, 49.1]	0.059	
Normal	95	82 (86.3)	45 (47.4) [37.0, 57.9]	98	86 (87.8)	49 (50.0) [39.7, 60.3]	0.947 [0.709, 1.266]	0.900 [0.512, 1.583]	-2.6 [-17.8, 12.5]	0.715	
High	7	6 (85.7)	3 (42.9) [9.9, 81.6]	8	8 (100.0)	2 (25.0) [3.2, 65.1]	1.714 [0.393, 7.485]	2.250 [0.251, 20.131]	17.9 [-42.9, 78.6]	0.608	#
OCS at baseline										0.165	
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	13	9 (69.2)	3 (23.1) [5.0, 53.8]	2.407 [0.761, 7.616]	4.167 [0.660, 26.290]	32.5 [-16.7, 81.6]	0.187	#
No	128	112 (87.5)	62 (48.4) [39.5, 57.4]	125	111 (88.8)	58 (46.4) [37.4, 55.5]	1.044 [0.805, 1.353]	1.085 [0.662, 1.778]	2.0 [-11.1, 15.1]	0.746	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IOSPK: Increase of at least 0.9 points in AQLQ+12 activity limitations score by key subgroups
DITT

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)										0.052
Medium/Low	70	61 (87.1)	32 (45.7) [33.7, 58.1]	73	65 (89.0)	38 (52.1) [40.0, 63.9]	0.878 [0.627, 1.230]	0.776 [0.402, 1.497]	-6.3 [-24.1, 11.4]	0.450
High	67	58 (86.6)	35 (52.2) [39.7, 64.6]	65	55 (84.6)	23 (35.4) [23.9, 48.2]	1.476 [0.989, 2.203]	1.997 [0.993, 4.017]	16.9 [-1.3, 35.0]	0.052
LAMA use at baseline										0.528
Yes	11	9 (81.8)	6 (54.5) [23.4, 83.3]	6	4 (66.7)	2 (33.3) [4.3, 77.7]	1.636 [0.467, 5.732]	2.400 [0.303, 19.041]	21.2 [-39.5, 81.9]	0.620 #
No	126	110 (87.3)	61 (48.4) [39.4, 57.5]	132	116 (87.9)	59 (44.7) [36.0, 53.6]	1.083 [0.834, 1.407]	1.161 [0.712, 1.895]	3.7 [-9.2, 16.7]	0.551
Tiotropium use at baseline										0.469
Yes	9	8 (88.9)	6 (66.7) [29.9, 92.5]	3	2 (66.7)	1 (33.3) [0.8, 90.6]	2.000 [0.378, 10.578]	4.000 [0.250, 63.950]	33.3 [-50.5, 100.0]	0.523 #
No	128	111 (86.7)	61 (47.7) [38.8, 56.7]	135	118 (87.4)	60 (44.4) [35.9, 53.2]	1.072 [0.825, 1.393]	1.138 [0.700, 1.849]	3.2 [-9.6, 16.0]	0.602

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IOSPK: Increase of at least 0.9 points in AQLQ+12 activity limitations score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline										0.527
Yes	29	25 (86.2)	16 (55.2) [35.7, 73.6]	37	32 (86.5)	16 (43.2) [27.1, 60.5]	1.276 [0.779, 2.091]	1.615 [0.607, 4.300]	11.9 [-15.3, 39.1]	0.340
No	108	94 (87.0)	51 (47.2) [37.5, 57.1]	101	88 (87.1)	45 (44.6) [34.7, 54.8]	1.060 [0.789, 1.424]	1.113 [0.646, 1.920]	2.7 [-11.8, 17.1]	0.700

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IOSPK: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex										0.073
Male	50	41 (82.0)	21 (42.0) [28.2, 56.8]	44	41 (93.2)	19 (43.2) [28.3, 59.0]	0.973 [0.608, 1.556]	0.953 [0.420, 2.162]	-1.2 [-23.4, 21.0]	0.908
Female	87	78 (89.7)	45 (51.7) [40.8, 62.6]	94	79 (84.0)	29 (30.9) [21.7, 41.2]	1.677 [1.165, 2.414]	2.401 [1.309, 4.406]	20.9 [5.7, 36.0]	0.004 *
Age										0.035 i
< 65 years	114	101 (88.6)	52 (45.6) [36.3, 55.2]	118	104 (88.1)	45 (38.1) [29.4, 47.5]	1.196 [0.882, 1.623]	1.361 [0.806, 2.296]	7.5 [-6.0, 21.0]	0.249
>= 65 years	23	18 (78.3)	14 (60.9) [38.5, 80.3]	20	16 (80.0)	3 (15.0) [3.2, 37.9]	4.058 [1.360, 12.112]	8.815 [1.995, 38.949]	45.9 [15.8, 75.9]	0.002 *
Exacerbations in the year before study										0.449
<= 2	105	90 (85.7)	50 (47.6) [37.8, 57.6]	110	98 (89.1)	40 (36.4) [27.4, 46.1]	1.310 [0.952, 1.800]	1.591 [0.922, 2.745]	11.3 [-2.8, 25.3]	0.095
> 2	32	29 (90.6)	16 (50.0) [31.9, 68.1]	28	22 (78.6)	8 (28.6) [13.2, 48.7]	1.750 [0.886, 3.456]	2.500 [0.855, 7.314]	21.4 [-6.0, 48.9]	0.094

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IOSPK: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race		N<10	any level							NE	
White	128	111 (86.7)	60 (46.9) [38.0, 55.9]	123	106 (86.2)	42 (34.1) [25.8, 43.2]					
Black or African American	3	3 (100.0)	3 (100.0) [29.2, 100.0]	6	5 (83.3)	3 (50.0) [11.8, 88.2]					
Asian	5	4 (80.0)	2 (40.0) [5.3, 85.3]	6	6 (100.0)	2 (33.3) [4.3, 77.7]					
Other	1	1 (100.0)	1 (100.0) [2.5, 100.0]	3	3 (100.0)	1 (33.3) [0.8, 90.6]					
Region										0.954	
Europe	78	72 (92.3)	39 (50.0) [38.5, 61.5]	80	68 (85.0)	27 (33.8) [23.6, 45.2]	1.481 [1.014, 2.164]	1.963 [1.033, 3.729]	16.3 [-0.2, 32.7]	0.039	*
America	10	9 (90.0)	6 (60.0) [26.2, 87.8]	9	7 (77.8)	4 (44.4) [13.7, 78.8]	1.350 [0.555, 3.283]	1.875 [0.302, 11.626]	15.6 [-39.5, 70.6]	0.656	#
Asia/Pacific	5	4 (80.0)	2 (40.0) [5.3, 85.3]	6	6 (100.0)	2 (33.3) [4.3, 77.7]	1.200 [0.252, 5.709]	1.333 [0.113, 15.704]	6.7 [-68.8, 82.2]	1.000	#
Rest of the world	44	34 (77.3)	19 (43.2) [28.3, 59.0]	43	39 (90.7)	15 (34.9) [21.0, 50.9]	1.238 [0.728, 2.105]	1.419 [0.597, 3.371]	8.3 [-14.4, 31.0]	0.430	
BMI		N<10	any level							NE	
< 18.5 kg/m**2	0			1	1 (100.0)	0 (0.0) [0.0, 97.5]					
18.5 - < 25.0 kg/m**2	39	34 (87.2)	20 (51.3) [34.8, 67.6]	43	38 (88.4)	18 (41.9) [27.0, 57.9]					
25.0 - < 30.0 kg/m**2	45	40 (88.9)	25 (55.6) [40.0, 70.4]	47	43 (91.5)	17 (36.2) [22.7, 51.5]					
>= 30.0 kg/m**2	53	45 (84.9)	21 (39.6) [26.5, 54.0]	47	38 (80.9)	13 (27.7) [15.6, 42.6]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IOSPK: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.327	
< 150 cells/uL	27	27 (100.0)	16 (59.3) [38.8, 77.6]	33	29 (87.9)	11 (33.3) [18.0, 51.8]	1.778 [1.000, 3.159]	2.909 [1.013, 8.355]	25.9 [-2.0, 53.8]	0.046	*
>= 150 cells/uL	109	91 (83.5)	49 (45.0) [35.4, 54.8]	105	91 (86.7)	37 (35.2) [26.2, 45.2]	1.276 [0.915, 1.778]	1.501 [0.866, 2.602]	9.7 [-4.3, 23.7]	0.148	
Baseline eosinophils - High										0.676	
< 300 cells/uL	69	59 (85.5)	35 (50.7) [38.4, 63.0]	72	61 (84.7)	28 (38.9) [27.6, 51.1]	1.304 [0.900, 1.891]	1.618 [0.829, 3.157]	11.8 [-5.9, 29.6]	0.159	
>= 300 cells/uL	67	59 (88.1)	30 (44.8) [32.6, 57.4]	66	59 (89.4)	20 (30.3) [19.6, 42.9]	1.478 [0.940, 2.323]	1.865 [0.915, 3.802]	14.5 [-3.3, 32.2]	0.086	
Baseline FENO										0.158	
< 25 ppb	78	67 (85.9)	35 (44.9) [33.6, 56.6]	74	63 (85.1)	29 (39.2) [28.0, 51.2]	1.145 [0.786, 1.667]	1.263 [0.662, 2.409]	5.7 [-11.3, 22.7]	0.480	
>= 25 ppb	57	50 (87.7)	30 (52.6) [39.0, 66.0]	63	56 (88.9)	19 (30.2) [19.2, 43.0]	1.745 [1.114, 2.735]	2.573 [1.218, 5.437]	22.5 [3.6, 41.4]	0.013	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IOSPK: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.181	
All negative	57	49 (86.0)	29 (50.9) [37.3, 64.4]	66	54 (81.8)	19 (28.8) [18.3, 41.3]	1.767 [1.119, 2.792]	2.562 [1.217, 5.392]	22.1 [3.5, 40.7]	0.013	*
Any positive	71	63 (88.7)	33 (46.5) [34.5, 58.7]	63	57 (90.5)	25 (39.7) [27.6, 52.8]	1.171 [0.790, 1.736]	1.320 [0.664, 2.624]	6.8 [-11.5, 25.0]	0.430	
Total serum IgE										0.353	
Low	35	31 (88.6)	19 (54.3) [36.6, 71.2]	32	26 (81.3)	9 (28.1) [13.7, 46.7]	1.930 [1.026, 3.631]	3.035 [1.097, 8.398]	26.2 [0.5, 51.8]	0.031	*
Normal	95	82 (86.3)	42 (44.2) [34.0, 54.8]	98	86 (87.8)	36 (36.7) [27.2, 47.1]	1.204 [0.853, 1.698]	1.365 [0.767, 2.430]	7.5 [-7.4, 22.3]	0.291	
High	7	6 (85.7)	5 (71.4) [29.0, 96.3]	8	8 (100.0)	3 (37.5) [8.5, 75.5]	1.905 [0.694, 5.229]	4.167 [0.473, 36.736]	33.9 [-26.8, 94.7]	0.315	#
OCS at baseline										0.161	
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	13	9 (69.2)	2 (15.4) [1.9, 45.4]	3.611 [0.888, 14.679]	6.875 [0.931, 50.782]	40.2 [-7.2, 87.5]	0.074	#
No	128	112 (87.5)	61 (47.7) [38.8, 56.7]	125	111 (88.8)	46 (36.8) [28.4, 45.9]	1.295 [0.966, 1.736]	1.564 [0.946, 2.584]	10.9 [-2.0, 23.7]	0.081	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IOSPK: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
ICS dose level (at study entry)										0.115	
Medium/Low	70	61 (87.1)	31 (44.3) [32.4, 56.7]	73	65 (89.0)	29 (39.7) [28.5, 51.9]	1.115 [0.758, 1.640]	1.206 [0.620, 2.345]	4.6 [-13.0, 22.1]	0.582	
High	67	58 (86.6)	35 (52.2) [39.7, 64.6]	65	55 (84.6)	19 (29.2) [18.6, 41.8]	1.787 [1.148, 2.781]	2.648 [1.292, 5.429]	23.0 [5.2, 40.8]	0.007	*
LAMA use at baseline										0.884	
Yes	11	9 (81.8)	3 (27.3) [6.0, 61.0]	6	4 (66.7)	1 (16.7) [0.4, 64.1]	1.636 [0.214, 12.495]	1.875 [0.150, 23.396]	10.6 [-42.0, 63.3]	1.000	#
No	126	110 (87.3)	63 (50.0) [41.0, 59.0]	132	116 (87.9)	47 (35.6) [27.5, 44.4]	1.404 [1.053, 1.874]	1.809 [1.098, 2.978]	14.4 [1.7, 27.1]	0.020	*
Tiotropium use at baseline										0.615	
Yes	9	8 (88.9)	3 (33.3) [7.5, 70.1]	3	2 (66.7)	0 (0.0) [0.0, 70.8]	2.800 + [0.183, 42.799]	3.769 + [0.148, 95.819]	33.3 [-19.7, 86.4]	0.509	#
No	128	111 (86.7)	63 (49.2) [40.3, 58.2]	135	118 (87.4)	48 (35.6) [27.5, 44.2]	1.384 [1.039, 1.845]	1.757 [1.072, 2.880]	13.7 [1.1, 26.3]	0.025	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IOSPK: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline										0.855
Yes	29	25 (86.2)	16 (55.2) [35.7, 73.6]	37	32 (86.5)	14 (37.8) [22.5, 55.2]	1.458 [0.860, 2.471]	2.022 [0.752, 5.433]	17.3 [-9.7, 44.3]	0.164
No	108	94 (87.0)	50 (46.3) [36.7, 56.2]	101	88 (87.1)	34 (33.7) [24.6, 43.8]	1.375 [0.978, 1.934]	1.699 [0.971, 2.973]	12.6 [-1.5, 26.8]	0.063

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IOSPP: Increase of at least 0.9 points in AQLQ+12 activity limitations score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.673	
White	128	111 (86.7)	61 (47.7) [38.8, 56.7]	123	106 (86.2)	51 (41.5) [32.7, 50.7]	1.149 [0.871, 1.517]	1.285 [0.780, 2.117]	6.2 [-6.9, 19.3]	0.325	
Non-white	9	8 (88.9)	6 (66.7) [29.9, 92.5]	15	14 (93.3)	10 (66.7) [38.4, 88.2]	1.000 [0.557, 1.794]	1.000 [0.173, 5.772]	0.0 [-47.8, 47.8]	1.000	#
Region (cat. P)										0.461	
North America/Western EU	10	9 (90.0)	7 (70.0) [34.8, 93.3]	9	7 (77.8)	7 (77.8) [40.0, 97.2]	0.900 [0.527, 1.537]	0.667 [0.084, 5.301]	-7.8 [-57.6, 42.1]	1.000	#
Rest of world	127	110 (86.6)	60 (47.2) [38.3, 56.3]	129	113 (87.6)	54 (41.9) [33.2, 50.9]	1.129 [0.858, 1.485]	1.244 [0.759, 2.038]	5.4 [-7.6, 18.3]	0.387	
Baseline eosinophils (cat. P)										0.934	
< 250 cells/uL	61	53 (86.9)	30 (49.2) [36.1, 62.3]	60	52 (86.7)	27 (45.0) [32.1, 58.4]	1.093 [0.748, 1.596]	1.183 [0.579, 2.417]	4.2 [-15.2, 23.6]	0.646	
>= 250 cells/uL	76	66 (86.8)	37 (48.7) [37.0, 60.4]	78	68 (87.2)	34 (43.6) [32.4, 55.3]	1.117 [0.793, 1.572]	1.228 [0.651, 2.316]	5.1 [-11.9, 22.1]	0.527	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IOSPP: Increase of at least 0.9 points in AQLQ+12 activity limitations score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. P)										0.051	
< 24 ppb	75	64 (85.3)	32 (42.7) [31.3, 54.6]	72	61 (84.7)	36 (50.0) [38.0, 62.0]	0.853 [0.602, 1.210]	0.744 [0.388, 1.426]	-7.3 [-24.8, 10.1]	0.374	
>= 24 ppb	60	53 (88.3)	33 (55.0) [41.6, 67.9]	65	58 (89.2)	25 (38.5) [26.7, 51.4]	1.430 [0.975, 2.098]	1.956 [0.959, 3.990]	16.5 [-2.3, 35.4]	0.065	
Baseline FENO (cat. M)										0.011	i
< 22.0 ppb	65	55 (84.6)	24 (36.9) [25.3, 49.8]	62	53 (85.5)	31 (50.0) [37.0, 63.0]	0.738 [0.493, 1.106]	0.585 [0.288, 1.189]	-13.1 [-31.8, 5.6]	0.139	
>= 22.0 ppb	70	62 (88.6)	41 (58.6) [46.2, 70.2]	75	66 (88.0)	30 (40.0) [28.9, 52.0]	1.464 [1.042, 2.057]	2.121 [1.093, 4.115]	18.6 [1.2, 36.0]	0.026	*
Baseline all FEIA status										<0.001	i
All negative	50	42 (84.0)	29 (58.0) [43.2, 71.8]	50	40 (80.0)	11 (22.0) [11.5, 36.0]	2.636 [1.487, 4.675]	4.896 [2.044, 11.728]	36.0 [16.1, 55.9]	<0.001	*
Any positive	77	69 (89.6)	34 (44.2) [32.8, 55.9]	80	72 (90.0)	43 (53.8) [42.2, 65.0]	0.822 [0.595, 1.135]	0.680 [0.363, 1.276]	-9.6 [-26.4, 7.2]	0.231	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IOSPP: Increase of at least 0.9 points in AQLQ+12 activity limitations score by study specific subgroups
DITT

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Th2 status										0.087
Low	70	62 (88.6)	36 (51.4) [39.2, 63.6]	62	53 (85.5)	22 (35.5) [23.7, 48.7]	1.449 [0.966, 2.174]	1.925 [0.956, 3.878]	15.9 [-2.3, 34.2]	0.066
High	65	56 (86.2)	30 (46.2) [33.7, 59.0]	75	66 (88.0)	38 (50.7) [38.9, 62.4]	0.911 [0.645, 1.286]	0.835 [0.429, 1.623]	-4.5 [-22.5, 13.5]	0.595
Baseline Periostin										0.243
Low (< 20.9 ng/ml)	62	55 (88.7)	27 (43.5) [31.0, 56.7]	67	57 (85.1)	31 (46.3) [34.0, 58.9]	0.941 [0.642, 1.381]	0.896 [0.447, 1.795]	-2.7 [-21.4, 16.0]	0.757
High (>= 20.9 ng/ml)	74	63 (85.1)	40 (54.1) [42.1, 65.7]	71	63 (88.7)	30 (42.3) [30.6, 54.6]	1.279 [0.907, 1.804]	1.608 [0.834, 3.099]	11.8 [-5.7, 29.3]	0.157
Current post-BD FEV1 reversibility										0.879
Yes	114	99 (86.8)	55 (48.2) [38.8, 57.8]	126	111 (88.1)	55 (43.7) [34.8, 52.8]	1.105 [0.840, 1.455]	1.203 [0.723, 2.002]	4.6 [-8.9, 18.0]	0.477
No	23	20 (87.0)	12 (52.2) [30.6, 73.2]	12	9 (75.0)	6 (50.0) [21.1, 78.9]	1.043 [0.524, 2.076]	1.091 [0.270, 4.408]	2.2 [-39.1, 43.4]	0.904

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IOSPP: Increase of at least 0.9 points in AQLQ+12 activity limitations score by study specific subgroups
DITT

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Maintenance OCS use at baseline										0.251
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	14	10 (71.4)	4 (28.6) [8.4, 58.1]	1.944 [0.706, 5.358]	3.125 [0.541, 18.038]	27.0 [-22.3, 76.3]	0.383 #
No	128	112 (87.5)	62 (48.4) [39.5, 57.4]	124	110 (88.7)	57 (46.0) [37.0, 55.1]	1.054 [0.811, 1.369]	1.104 [0.673, 1.811]	2.5 [-10.6, 15.6]	0.695
No chronic OCS use and current post-BD FEV1 reversibility										0.533
Yes	108	95 (88.0)	52 (48.1) [38.4, 58.0]	115	103 (89.6)	52 (45.2) [35.9, 54.8]	1.065 [0.804, 1.410]	1.125 [0.664, 1.905]	2.9 [-11.1, 16.9]	0.662
No	29	24 (82.8)	15 (51.7) [32.5, 70.6]	23	17 (73.9)	9 (39.1) [19.7, 61.5]	1.322 [0.712, 2.455]	1.667 [0.549, 5.056]	12.6 [-18.3, 43.5]	0.370

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IOSPP: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.648	
White	128	111 (86.7)	60 (46.9) [38.0, 55.9]	123	106 (86.2)	42 (34.1) [25.8, 43.2]	1.373 [1.010, 1.866]	1.702 [1.023, 2.832]	12.7 [-0.1, 25.6]	0.041	*
Non-white	9	8 (88.9)	6 (66.7) [29.9, 92.5]	15	14 (93.3)	6 (40.0) [16.3, 67.7]	1.667 [0.769, 3.610]	3.000 [0.533, 16.897]	26.7 [-21.8, 75.1]	0.400	#
Region (cat. P)										0.957	
North America/Western EU	10	9 (90.0)	6 (60.0) [26.2, 87.8]	9	7 (77.8)	4 (44.4) [13.7, 78.8]	1.350 [0.555, 3.283]	1.875 [0.302, 11.626]	15.6 [-39.5, 70.6]	0.656	#
Rest of world	127	110 (86.6)	60 (47.2) [38.3, 56.3]	129	113 (87.6)	44 (34.1) [26.0, 43.0]	1.385 [1.024, 1.874]	1.730 [1.045, 2.863]	13.1 [0.4, 25.8]	0.033	*
Baseline eosinophils (cat. P)										0.320	
< 250 cells/uL	61	53 (86.9)	33 (54.1) [40.8, 66.9]	60	52 (86.7)	20 (33.3) [21.7, 46.7]	1.623 [1.060, 2.485]	2.357 [1.129, 4.921]	20.8 [1.8, 39.7]	0.022	*
>= 250 cells/uL	76	66 (86.8)	33 (43.4) [32.1, 55.3]	78	68 (87.2)	28 (35.9) [25.3, 47.6]	1.210 [0.817, 1.790]	1.370 [0.717, 2.620]	7.5 [-9.2, 24.2]	0.341	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IOSPP: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. P)										0.150	
< 24 ppb	75	64 (85.3)	33 (44.0) [32.5, 55.9]	72	61 (84.7)	28 (38.9) [27.6, 51.1]	1.131 [0.769, 1.665]	1.235 [0.640, 2.383]	5.1 [-12.2, 22.4]	0.531	
>= 24 ppb	60	53 (88.3)	32 (53.3) [40.0, 66.3]	65	58 (89.2)	20 (30.8) [19.9, 43.4]	1.733 [1.122, 2.677]	2.571 [1.238, 5.342]	22.6 [4.1, 41.1]	0.011	*
Baseline FENO (cat. M)										0.180	
< 22.0 ppb	65	55 (84.6)	28 (43.1) [30.8, 56.0]	62	53 (85.5)	24 (38.7) [26.6, 51.9]	1.113 [0.731, 1.693]	1.198 [0.590, 2.434]	4.4 [-14.3, 23.0]	0.618	
>= 22.0 ppb	70	62 (88.6)	37 (52.9) [40.6, 64.9]	75	66 (88.0)	24 (32.0) [21.7, 43.8]	1.652 [1.110, 2.457]	2.383 [1.213, 4.679]	20.9 [3.7, 38.0]	0.011	*
Baseline all FEIA status										0.046	i
All negative	50	42 (84.0)	26 (52.0) [37.4, 66.3]	50	40 (80.0)	12 (24.0) [13.1, 38.2]	2.167 [1.237, 3.795]	3.431 [1.461, 8.057]	28.0 [7.8, 48.2]	0.004	*
Any positive	77	69 (89.6)	35 (45.5) [34.1, 57.2]	80	72 (90.0)	33 (41.3) [30.4, 52.8]	1.102 [0.770, 1.576]	1.187 [0.631, 2.233]	4.2 [-12.6, 21.0]	0.596	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IOSPP: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

	Tezepelumab			Placebo							
Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Th2 status										0.011	i
Low	70	62 (88.6)	39 (55.7) [43.3, 67.6]	62	53 (85.5)	16 (25.8) [15.5, 38.5]	2.159 [1.348, 3.457]	3.617 [1.728, 7.573]	29.9 [12.4, 47.4]	<0.001	*
High	65	56 (86.2)	26 (40.0) [28.0, 52.9]	75	66 (88.0)	31 (41.3) [30.1, 53.3]	0.968 [0.648, 1.446]	0.946 [0.481, 1.861]	-1.3 [-19.1, 16.4]	0.873	
Baseline Periostin										0.829	
Low (< 20.9 ng/ml)	62	55 (88.7)	30 (48.4) [35.5, 61.4]	67	57 (85.1)	24 (35.8) [24.5, 48.5]	1.351 [0.896, 2.037]	1.680 [0.830, 3.401]	12.6 [-5.9, 31.0]	0.150	
High (>= 20.9 ng/ml)	74	63 (85.1)	36 (48.6) [36.9, 60.6]	71	63 (88.7)	24 (33.8) [23.0, 46.0]	1.439 [0.964, 2.149]	1.855 [0.949, 3.627]	14.8 [-2.4, 32.1]	0.071	
Current post-BD FEV1 reversibility										0.968	
Yes	114	99 (86.8)	58 (50.9) [41.3, 60.4]	126	111 (88.1)	45 (35.7) [27.4, 44.7]	1.425 [1.060, 1.915]	1.864 [1.111, 3.127]	15.2 [1.9, 28.4]	0.018	*
No	23	20 (87.0)	8 (34.8) [16.4, 57.3]	12	9 (75.0)	3 (25.0) [5.5, 57.2]	1.391 [0.450, 4.301]	1.600 [0.335, 7.639]	9.8 [-27.8, 47.4]	0.709	#

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IOSPP: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Maintenance OCS use at baseline										0.266	
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	14	10 (71.4)	3 (21.4) [4.7, 50.8]	2.593 [0.812, 8.277]	4.583 [0.733, 28.646]	34.1 [-13.9, 82.2]	0.179	#
No	128	112 (87.5)	61 (47.7) [38.8, 56.7]	124	110 (88.7)	45 (36.3) [27.8, 45.4]	1.313 [0.977, 1.765]	1.598 [0.965, 2.647]	11.4 [-1.5, 24.3]	0.068	
No chronic OCS use and current post-BD FEV1 reversibility										0.461	
Yes	108	95 (88.0)	54 (50.0) [40.2, 59.8]	115	103 (89.6)	43 (37.4) [28.5, 46.9]	1.337 [0.988, 1.810]	1.674 [0.982, 2.856]	12.6 [-1.2, 26.4]	0.058	
No	29	24 (82.8)	12 (41.4) [23.5, 61.1]	23	17 (73.9)	5 (21.7) [7.5, 43.7]	1.903 [0.783, 4.627]	2.541 [0.738, 8.747]	19.6 [-8.9, 48.1]	0.138	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IOMP0: Increase of at least 0.9 points in AQLQ+12 emotional function score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 emotional function score	Week 52	137	119 (86.9)	66 (48.2) [39.6, 56.9]	138	120 (87.0)	54 (39.1) [30.9, 47.8]	1.231 [0.939, 1.614]	1.446 [0.896, 2.334]	9.0 [-3.4, 21.4]	0.131

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IOSPK: Increase of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.044	i
Male	50	41 (82.0)	20 (40.0) [26.4, 54.8]	44	41 (93.2)	21 (47.7) [32.5, 63.3]	0.838 [0.529, 1.327]	0.730 [0.322, 1.655]	-7.7 [-29.9, 14.5]	0.453	
Female	87	78 (89.7)	46 (52.9) [41.9, 63.7]	94	79 (84.0)	33 (35.1) [25.5, 45.6]	1.506 [1.073, 2.114]	2.074 [1.141, 3.768]	17.8 [2.4, 33.1]	0.016	*
Age										0.232	
< 65 years	114	101 (88.6)	56 (49.1) [39.6, 58.7]	118	104 (88.1)	50 (42.4) [33.3, 51.8]	1.159 [0.875, 1.536]	1.313 [0.782, 2.204]	6.7 [-6.9, 20.4]	0.303	
>= 65 years	23	18 (78.3)	10 (43.5) [23.2, 65.5]	20	16 (80.0)	4 (20.0) [5.7, 43.7]	2.174 [0.806, 5.866]	3.077 [0.781, 12.123]	23.5 [-8.0, 54.9]	0.105	
Exacerbations in the year before study										0.113	
<= 2	105	90 (85.7)	48 (45.7) [36.0, 55.7]	110	98 (89.1)	46 (41.8) [32.5, 51.6]	1.093 [0.807, 1.481]	1.172 [0.683, 2.009]	3.9 [-10.3, 18.1]	0.566	
> 2	32	29 (90.6)	18 (56.3) [37.7, 73.6]	28	22 (78.6)	8 (28.6) [13.2, 48.7]	1.969 [1.017, 3.811]	3.214 [1.095, 9.437]	27.7 [0.3, 55.0]	0.032	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IOSPK: Increase of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race		N<10	any level							NE	
White	128	111 (86.7)	60 (46.9) [38.0, 55.9]	123	106 (86.2)	47 (38.2) [29.6, 47.4]					
Black or African American	3	3 (100.0)	3 (100.0) [29.2, 100.0]	6	5 (83.3)	3 (50.0) [11.8, 88.2]					
Asian	5	4 (80.0)	2 (40.0) [5.3, 85.3]	6	6 (100.0)	2 (33.3) [4.3, 77.7]					
Other	1	1 (100.0)	1 (100.0) [2.5, 100.0]	3	3 (100.0)	2 (66.7) [9.4, 99.2]					
Region										0.797	
Europe	78	72 (92.3)	40 (51.3) [39.7, 62.8]	80	68 (85.0)	30 (37.5) [26.9, 49.0]	1.368 [0.958, 1.953]	1.754 [0.931, 3.307]	13.8 [-2.8, 30.4]	0.082	
America	10	9 (90.0)	8 (80.0) [44.4, 97.5]	9	7 (77.8)	6 (66.7) [29.9, 92.5]	1.200 [0.688, 2.093]	2.000 [0.250, 15.991]	13.3 [-36.8, 63.4]	0.628	#
Asia/Pacific	5	4 (80.0)	2 (40.0) [5.3, 85.3]	6	6 (100.0)	2 (33.3) [4.3, 77.7]	1.200 [0.252, 5.709]	1.333 [0.113, 15.704]	6.7 [-68.8, 82.2]	1.000	#
Rest of the world	44	34 (77.3)	16 (36.4) [22.4, 52.2]	43	39 (90.7)	16 (37.2) [23.0, 53.3]	0.977 [0.563, 1.695]	0.964 [0.403, 2.305]	-0.8 [-23.4, 21.7]	0.935	
BMI		N<10	any level							NE	
< 18.5 kg/m**2	0			1	1 (100.0)	0 (0.0) [0.0, 97.5]					
18.5 - < 25.0 kg/m**2	39	34 (87.2)	21 (53.8) [37.2, 69.9]	43	38 (88.4)	22 (51.2) [35.5, 66.7]					
25.0 - < 30.0 kg/m**2	45	40 (88.9)	24 (53.3) [37.9, 68.3]	47	43 (91.5)	18 (38.3) [24.5, 53.6]					
>= 30.0 kg/m**2	53	45 (84.9)	21 (39.6) [26.5, 54.0]	47	38 (80.9)	14 (29.8) [17.3, 44.9]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IOSPK: Increase of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.593	
< 150 cells/uL	27	27 (100.0)	14 (51.9) [31.9, 71.3]	33	29 (87.9)	12 (36.4) [20.4, 54.9]	1.426 [0.799, 2.546]	1.885 [0.669, 5.310]	15.5 [-12.9, 43.8]	0.232	
>= 150 cells/uL	109	91 (83.5)	52 (47.7) [38.1, 57.5]	105	91 (86.7)	42 (40.0) [30.6, 50.0]	1.193 [0.878, 1.619]	1.368 [0.796, 2.353]	7.7 [-6.5, 21.9]	0.257	
Baseline eosinophils - High										0.913	
< 300 cells/uL	69	59 (85.5)	34 (49.3) [37.0, 61.6]	72	61 (84.7)	29 (40.3) [28.9, 52.5]	1.223 [0.846, 1.770]	1.440 [0.739, 2.806]	9.0 [-8.8, 26.8]	0.284	
>= 300 cells/uL	67	59 (88.1)	32 (47.8) [35.4, 60.3]	66	59 (89.4)	25 (37.9) [26.2, 50.7]	1.261 [0.847, 1.877]	1.499 [0.752, 2.992]	9.9 [-8.4, 28.1]	0.251	
Baseline FENO										0.142	
< 25 ppb	78	67 (85.9)	32 (41.0) [30.0, 52.7]	74	63 (85.1)	30 (40.5) [29.3, 52.6]	1.012 [0.690, 1.485]	1.020 [0.534, 1.949]	0.5 [-16.5, 17.4]	0.952	
>= 25 ppb	57	50 (87.7)	33 (57.9) [44.1, 70.9]	63	56 (88.9)	24 (38.1) [26.1, 51.2]	1.520 [1.034, 2.233]	2.234 [1.075, 4.643]	19.8 [0.6, 39.0]	0.031	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IOSPK: Increase of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.023	i
All negative	57	49 (86.0)	29 (50.9) [37.3, 64.4]	66	54 (81.8)	18 (27.3) [17.0, 39.6]	1.865 [1.167, 2.983]	2.762 [1.304, 5.849]	23.6 [5.1, 42.1]	0.007	*
Any positive	71	63 (88.7)	33 (46.5) [34.5, 58.7]	63	57 (90.5)	31 (49.2) [36.4, 62.1]	0.945 [0.663, 1.346]	0.896 [0.454, 1.768]	-2.7 [-21.2, 15.7]	0.753	
Total serum IgE										0.061	
Low	35	31 (88.6)	18 (51.4) [34.0, 68.6]	32	26 (81.3)	6 (18.8) [7.2, 36.4]	2.743 [1.245, 6.043]	4.588 [1.515, 13.893]	32.7 [8.3, 57.0]	0.006	*
Normal	95	82 (86.3)	44 (46.3) [36.0, 56.8]	98	86 (87.8)	45 (45.9) [35.8, 56.3]	1.009 [0.743, 1.368]	1.016 [0.577, 1.790]	0.4 [-14.7, 15.5]	0.956	
High	7	6 (85.7)	4 (57.1) [18.4, 90.1]	8	8 (100.0)	3 (37.5) [8.5, 75.5]	1.524 [0.507, 4.582]	2.222 [0.280, 17.631]	19.6 [-43.4, 82.7]	0.619	#
OCS at baseline										0.453	
Yes	9	7 (77.8)	4 (44.4) [13.7, 78.8]	13	9 (69.2)	3 (23.1) [5.0, 53.8]	1.926 [0.562, 6.604]	2.667 [0.423, 16.826]	21.4 [-27.8, 70.5]	0.376	#
No	128	112 (87.5)	62 (48.4) [39.5, 57.4]	125	111 (88.8)	51 (40.8) [32.1, 49.9]	1.187 [0.900, 1.566]	1.363 [0.829, 2.241]	7.6 [-5.4, 20.6]	0.223	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IOSPK: Increase of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
ICS dose level (at study entry)										0.180	
Medium/Low	70	61 (87.1)	33 (47.1) [35.1, 59.4]	73	65 (89.0)	33 (45.2) [33.5, 57.3]	1.043 [0.732, 1.486]	1.081 [0.560, 2.087]	1.9 [-15.8, 19.7]	0.817	
High	67	58 (86.6)	33 (49.3) [36.8, 61.8]	65	55 (84.6)	21 (32.3) [21.2, 45.1]	1.525 [0.994, 2.338]	2.034 [1.003, 4.123]	16.9 [-1.1, 35.0]	0.049	*
LAMA use at baseline										0.878	
Yes	11	9 (81.8)	5 (45.5) [16.7, 76.6]	6	4 (66.7)	2 (33.3) [4.3, 77.7]	1.364 [0.370, 5.022]	1.667 [0.210, 13.223]	12.1 [-48.6, 72.8]	1.000	#
No	126	110 (87.3)	61 (48.4) [39.4, 57.5]	132	116 (87.9)	52 (39.4) [31.0, 48.3]	1.229 [0.931, 1.623]	1.444 [0.881, 2.366]	9.0 [-3.8, 21.9]	0.145	
Tiotropium use at baseline										0.932	
Yes	9	8 (88.9)	4 (44.4) [13.7, 78.8]	3	2 (66.7)	1 (33.3) [0.8, 90.6]	1.333 [0.230, 7.743]	1.600 [0.104, 24.703]	11.1 [-73.6, 95.8]	1.000	#
No	128	111 (86.7)	62 (48.4) [39.5, 57.4]	135	118 (87.4)	53 (39.3) [31.0, 48.0]	1.234 [0.937, 1.625]	1.453 [0.891, 2.371]	9.2 [-3.5, 21.9]	0.134	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IOSPK: Increase of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline										0.327
Yes	29	25 (86.2)	17 (58.6) [38.9, 76.5]	37	32 (86.5)	14 (37.8) [22.5, 55.2]	1.549 [0.927, 2.590]	2.327 [0.862, 6.287]	20.8 [-6.1, 47.6]	0.096
No	108	94 (87.0)	49 (45.4) [35.8, 55.2]	101	88 (87.1)	40 (39.6) [30.0, 49.8]	1.146 [0.834, 1.574]	1.267 [0.731, 2.195]	5.8 [-8.6, 20.1]	0.401

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IOSPP: Increase of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.698	
White	128	111 (86.7)	60 (46.9) [38.0, 55.9]	123	106 (86.2)	47 (38.2) [29.6, 47.4]	1.227 [0.917, 1.641]	1.427 [0.863, 2.359]	8.7 [-4.3, 21.6]	0.166	
Non-white	9	8 (88.9)	6 (66.7) [29.9, 92.5]	15	14 (93.3)	7 (46.7) [21.3, 73.4]	1.429 [0.701, 2.910]	2.286 [0.410, 12.732]	20.0 [-28.7, 68.7]	0.423	#
Region (cat. P)										0.944	
North America/Western EU	10	9 (90.0)	8 (80.0) [44.4, 97.5]	9	7 (77.8)	6 (66.7) [29.9, 92.5]	1.200 [0.688, 2.093]	2.000 [0.250, 15.991]	13.3 [-36.8, 63.4]	0.628	#
Rest of world	127	110 (86.6)	58 (45.7) [36.8, 54.7]	129	113 (87.6)	48 (37.2) [28.9, 46.2]	1.227 [0.915, 1.646]	1.418 [0.861, 2.337]	8.5 [-4.3, 21.3]	0.170	
Baseline eosinophils (cat. P)										0.955	
< 250 cells/uL	61	53 (86.9)	31 (50.8) [37.7, 63.9]	60	52 (86.7)	25 (41.7) [29.1, 55.1]	1.220 [0.827, 1.798]	1.447 [0.706, 2.966]	9.2 [-10.2, 28.5]	0.315	
>= 250 cells/uL	76	66 (86.8)	35 (46.1) [34.5, 57.9]	78	68 (87.2)	29 (37.2) [26.5, 48.9]	1.239 [0.849, 1.807]	1.442 [0.758, 2.746]	8.9 [-7.9, 25.7]	0.266	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IOSPP: Increase of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. P)										0.127	
< 24 ppb	75	64 (85.3)	30 (40.0) [28.9, 52.0]	72	61 (84.7)	29 (40.3) [28.9, 52.5]	0.993 [0.669, 1.474]	0.989 [0.511, 1.912]	-0.3 [-17.5, 16.9]	0.973	
>= 24 ppb	60	53 (88.3)	35 (58.3) [44.9, 70.9]	65	58 (89.2)	25 (38.5) [26.7, 51.4]	1.517 [1.043, 2.206]	2.240 [1.094, 4.585]	19.9 [1.1, 38.7]	0.027	*
Baseline FENO (cat. M)										0.043	i
< 22.0 ppb	65	55 (84.6)	24 (36.9) [25.3, 49.8]	62	53 (85.5)	26 (41.9) [29.5, 55.2]	0.880 [0.572, 1.356]	0.811 [0.397, 1.653]	-5.0 [-23.6, 13.5]	0.565	
>= 22.0 ppb	70	62 (88.6)	41 (58.6) [46.2, 70.2]	75	66 (88.0)	28 (37.3) [26.4, 49.3]	1.569 [1.102, 2.234]	2.373 [1.218, 4.624]	21.2 [4.0, 38.5]	0.011	*
Baseline all FEIA status										0.020	i
All negative	50	42 (84.0)	27 (54.0) [39.3, 68.2]	50	40 (80.0)	13 (26.0) [14.6, 40.3]	2.077 [1.219, 3.539]	3.341 [1.440, 7.753]	28.0 [7.6, 48.4]	0.004	*
Any positive	77	69 (89.6)	35 (45.5) [34.1, 57.2]	80	72 (90.0)	37 (46.3) [35.0, 57.8]	0.983 [0.699, 1.381]	0.968 [0.517, 1.815]	-0.8 [-17.7, 16.1]	0.921	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IOSPP: Increase of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Th2 status										0.019	i
Low	70	62 (88.6)	36 (51.4) [39.2, 63.6]	62	53 (85.5)	17 (27.4) [16.9, 40.2]	1.876 [1.179, 2.985]	2.803 [1.352, 5.808]	24.0 [6.4, 41.7]	0.005	*
High	65	56 (86.2)	29 (44.6) [32.3, 57.5]	75	66 (88.0)	36 (48.0) [36.3, 59.8]	0.929 [0.649, 1.331]	0.873 [0.448, 1.700]	-3.4 [-21.4, 14.6]	0.690	
Baseline Periostin										0.759	
Low (< 20.9 ng/ml)	62	55 (88.7)	30 (48.4) [35.5, 61.4]	67	57 (85.1)	25 (37.3) [25.8, 50.0]	1.297 [0.867, 1.940]	1.575 [0.780, 3.179]	11.1 [-7.5, 29.6]	0.206	
High (>= 20.9 ng/ml)	74	63 (85.1)	36 (48.6) [36.9, 60.6]	71	63 (88.7)	29 (40.8) [29.3, 53.2]	1.191 [0.827, 1.716]	1.372 [0.711, 2.647]	7.8 [-9.7, 25.3]	0.347	
Current post-BD FEV1 reversibility										0.571	
Yes	114	99 (86.8)	54 (47.4) [37.9, 56.9]	126	111 (88.1)	50 (39.7) [31.1, 48.8]	1.194 [0.894, 1.594]	1.368 [0.820, 2.284]	7.7 [-5.7, 21.1]	0.231	
No	23	20 (87.0)	12 (52.2) [30.6, 73.2]	12	9 (75.0)	4 (33.3) [9.9, 65.1]	1.565 [0.642, 3.814]	2.182 [0.510, 9.325]	18.8 [-21.1, 58.8]	0.295	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IOSPP: Increase of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITT

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Maintenance OCS use at baseline										0.383
Yes	9	7 (77.8)	4 (44.4) [13.7, 78.8]	14	10 (71.4)	3 (21.4) [4.7, 50.8]	2.074 [0.600, 7.173]	2.933 [0.469, 18.333]	23.0 [-25.0, 71.1]	0.363 #
No	128	112 (87.5)	62 (48.4) [39.5, 57.4]	124	110 (88.7)	51 (41.1) [32.4, 50.3]	1.178 [0.893, 1.552]	1.345 [0.817, 2.213]	7.3 [-5.7, 20.3]	0.244
No chronic OCS use and current post-BD FEV1 reversibility										0.326
Yes	108	95 (88.0)	51 (47.2) [37.5, 57.1]	115	103 (89.6)	47 (40.9) [31.8, 50.4]	1.155 [0.859, 1.555]	1.295 [0.762, 2.199]	6.4 [-7.6, 20.3]	0.341
No	29	24 (82.8)	15 (51.7) [32.5, 70.6]	23	17 (73.9)	7 (30.4) [13.2, 52.9]	1.700 [0.835, 3.460]	2.449 [0.776, 7.724]	21.3 [-8.8, 51.3]	0.126

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IOMP0: Increase of at least 0.9 points in AQLQ+12 symptom score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 symptom score	Week 52	137	119 (86.9)	72 (52.6) [43.9, 61.1]	138	120 (87.0)	60 (43.5) [35.1, 52.2]	1.209 [0.943, 1.549]	1.440 [0.895, 2.316]	9.1 [-3.4, 21.6]	0.133

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IOSPK: Increase of at least 0.9 points in AQLQ+12 symptom score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.119	
Male	50	41 (82.0)	23 (46.0) [31.8, 60.7]	44	41 (93.2)	22 (50.0) [34.6, 65.4]	0.920 [0.604, 1.402]	0.852 [0.378, 1.918]	-4.0 [-26.4, 18.4]	0.700	
Female	87	78 (89.7)	49 (56.3) [45.3, 66.9]	94	79 (84.0)	38 (40.4) [30.4, 51.0]	1.393 [1.025, 1.895]	1.900 [1.052, 3.431]	15.9 [0.4, 31.4]	0.033	*
Age										0.270	
< 65 years	114	101 (88.6)	61 (53.5) [43.9, 62.9]	118	104 (88.1)	55 (46.6) [37.4, 56.0]	1.148 [0.887, 1.486]	1.318 [0.787, 2.209]	6.9 [-6.8, 20.6]	0.294	
>= 65 years	23	18 (78.3)	11 (47.8) [26.8, 69.4]	20	16 (80.0)	5 (25.0) [8.7, 49.1]	1.913 [0.801, 4.570]	2.750 [0.748, 10.105]	22.8 [-9.7, 55.4]	0.127	
Exacerbations in the year before study										0.089	
<= 2	105	90 (85.7)	51 (48.6) [38.7, 58.5]	110	98 (89.1)	50 (45.5) [35.9, 55.2]	1.069 [0.804, 1.419]	1.133 [0.663, 1.937]	3.1 [-11.2, 17.4]	0.648	
> 2	32	29 (90.6)	21 (65.6) [46.8, 81.4]	28	22 (78.6)	10 (35.7) [18.6, 55.9]	1.838 [1.053, 3.206]	3.436 [1.187, 9.947]	29.9 [2.4, 57.5]	0.022	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IOSPK: Increase of at least 0.9 points in AQLQ+12 symptom score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race		N<10	any level							NE	
White	128	111 (86.7)	67 (52.3) [43.3, 61.2]	123	106 (86.2)	52 (42.3) [33.4, 51.5]					
Black or African American	3	3 (100.0)	2 (66.7) [9.4, 99.2]	6	5 (83.3)	3 (50.0) [11.8, 88.2]					
Asian	5	4 (80.0)	3 (60.0) [14.7, 94.7]	6	6 (100.0)	2 (33.3) [4.3, 77.7]					
Other	1	1 (100.0)	0 (0.0) [0.0, 97.5]	3	3 (100.0)	3 (100.0) [29.2, 100.0]					
Region										0.941	
Europe	78	72 (92.3)	41 (52.6) [40.9, 64.0]	80	68 (85.0)	36 (45.0) [33.8, 56.5]	1.168 [0.847, 1.610]	1.354 [0.724, 2.532]	7.6 [-9.2, 24.4]	0.343	
America	10	9 (90.0)	7 (70.0) [34.8, 93.3]	9	7 (77.8)	5 (55.6) [21.2, 86.3]	1.260 [0.619, 2.566]	1.867 [0.283, 12.310]	14.4 [-39.2, 68.1]	0.650	#
Asia/Pacific	5	4 (80.0)	3 (60.0) [14.7, 94.7]	6	6 (100.0)	2 (33.3) [4.3, 77.7]	1.800 [0.472, 6.867]	3.000 [0.255, 35.334]	26.7 [-48.8, 100.0]	0.567	#
Rest of the world	44	34 (77.3)	21 (47.7) [32.5, 63.3]	43	39 (90.7)	17 (39.5) [25.0, 55.6]	1.207 [0.746, 1.955]	1.396 [0.596, 3.269]	8.2 [-14.9, 31.3]	0.444	
BMI		N<10	any level							NE	
< 18.5 kg/m**2	0			1	1 (100.0)	1 (100.0) [2.5, 100.0]					
18.5 - < 25.0 kg/m**2	39	34 (87.2)	26 (66.7) [49.8, 80.9]	43	38 (88.4)	22 (51.2) [35.5, 66.7]					
25.0 - < 30.0 kg/m**2	45	40 (88.9)	25 (55.6) [40.0, 70.4]	47	43 (91.5)	16 (34.0) [20.9, 49.3]					
>= 30.0 kg/m**2	53	45 (84.9)	21 (39.6) [26.5, 54.0]	47	38 (80.9)	21 (44.7) [30.2, 59.9]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IOSPK: Increase of at least 0.9 points in AQLQ+12 symptom score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low										0.344
< 150 cells/uL	27	27 (100.0)	16 (59.3) [38.8, 77.6]	33	29 (87.9)	13 (39.4) [22.9, 57.9]	1.504 [0.889, 2.546]	2.238 [0.793, 6.317]	19.9 [-8.4, 48.2]	0.129
>= 150 cells/uL	109	91 (83.5)	55 (50.5) [40.7, 60.2]	105	91 (86.7)	47 (44.8) [35.0, 54.8]	1.127 [0.850, 1.495]	1.257 [0.734, 2.152]	5.7 [-8.6, 20.0]	0.405
Baseline eosinophils - High										0.234
< 300 cells/uL	69	59 (85.5)	35 (50.7) [38.4, 63.0]	72	61 (84.7)	35 (48.6) [36.7, 60.7]	1.043 [0.748, 1.455]	1.088 [0.562, 2.107]	2.1 [-15.8, 20.0]	0.803
>= 300 cells/uL	67	59 (88.1)	36 (53.7) [41.1, 66.0]	66	59 (89.4)	25 (37.9) [26.2, 50.7]	1.419 [0.970, 2.075]	1.905 [0.954, 3.802]	15.9 [-2.4, 34.1]	0.068
Baseline FENO										0.348
< 25 ppb	78	67 (85.9)	37 (47.4) [36.0, 59.1]	74	63 (85.1)	33 (44.6) [33.0, 56.6]	1.064 [0.753, 1.502]	1.121 [0.592, 2.123]	2.8 [-14.3, 20.0]	0.726
>= 25 ppb	57	50 (87.7)	33 (57.9) [44.1, 70.9]	63	56 (88.9)	27 (42.9) [30.5, 56.0]	1.351 [0.942, 1.938]	1.833 [0.888, 3.785]	15.0 [-4.3, 34.4]	0.101

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IOSPK: Increase of at least 0.9 points in AQLQ+12 symptom score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.014	i
All negative	57	49 (86.0)	32 (56.1) [42.4, 69.3]	66	54 (81.8)	20 (30.3) [19.6, 42.9]	1.853 [1.203, 2.853]	2.944 [1.403, 6.177]	25.8 [7.2, 44.5]	0.004	*
Any positive	71	63 (88.7)	36 (50.7) [38.6, 62.8]	63	57 (90.5)	34 (54.0) [40.9, 66.6]	0.940 [0.680, 1.298]	0.877 [0.445, 1.731]	-3.3 [-21.7, 15.2]	0.707	
Total serum IgE										0.432	
Low	35	31 (88.6)	18 (51.4) [34.0, 68.6]	32	26 (81.3)	10 (31.3) [16.1, 50.0]	1.646 [0.897, 3.018]	2.329 [0.858, 6.326]	20.2 [-5.9, 46.2]	0.097	
Normal	95	82 (86.3)	51 (53.7) [43.2, 64.0]	98	86 (87.8)	48 (49.0) [38.7, 59.3]	1.096 [0.832, 1.443]	1.207 [0.686, 2.125]	4.7 [-10.4, 19.8]	0.514	
High	7	6 (85.7)	3 (42.9) [9.9, 81.6]	8	8 (100.0)	2 (25.0) [3.2, 65.1]	1.714 [0.393, 7.485]	2.250 [0.251, 20.131]	17.9 [-42.9, 78.6]	0.608	#
OCS at baseline										0.109	
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	13	9 (69.2)	2 (15.4) [1.9, 45.4]	3.611 [0.888, 14.679]	6.875 [0.931, 50.782]	40.2 [-7.2, 87.5]	0.074	#
No	128	112 (87.5)	67 (52.3) [43.3, 61.2]	125	111 (88.8)	58 (46.4) [37.4, 55.5]	1.128 [0.878, 1.449]	1.269 [0.774, 2.079]	5.9 [-7.1, 19.0]	0.345	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IOSPK: Increase of at least 0.9 points in AQLQ+12 symptom score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
ICS dose level (at study entry)										0.303	
Medium/Low	70	61 (87.1)	36 (51.4) [39.2, 63.6]	73	65 (89.0)	35 (47.9) [36.1, 60.0]	1.073 [0.771, 1.492]	1.150 [0.596, 2.216]	3.5 [-14.3, 21.3]	0.678	
High	67	58 (86.6)	36 (53.7) [41.1, 66.0]	65	55 (84.6)	25 (38.5) [26.7, 51.4]	1.397 [0.956, 2.042]	1.858 [0.929, 3.716]	15.3 [-3.1, 33.6]	0.080	
LAMA use at baseline										0.443	
Yes	11	9 (81.8)	7 (63.6) [30.8, 89.1]	6	4 (66.7)	2 (33.3) [4.3, 77.7]	1.909 [0.566, 6.444]	3.500 [0.431, 28.447]	30.3 [-29.8, 90.4]	0.335	#
No	126	110 (87.3)	65 (51.6) [42.5, 60.6]	132	116 (87.9)	58 (43.9) [35.3, 52.8]	1.174 [0.909, 1.517]	1.360 [0.833, 2.219]	7.6 [-5.3, 20.6]	0.220	
Tiotropium use at baseline										0.539	
Yes	9	8 (88.9)	6 (66.7) [29.9, 92.5]	3	2 (66.7)	1 (33.3) [0.8, 90.6]	2.000 [0.378, 10.578]	4.000 [0.250, 63.950]	33.3 [-50.5, 100.0]	0.523	#
No	128	111 (86.7)	66 (51.6) [42.6, 60.5]	135	118 (87.4)	59 (43.7) [35.2, 52.5]	1.180 [0.915, 1.522]	1.371 [0.844, 2.228]	7.9 [-4.9, 20.7]	0.203	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IOSPK: Increase of at least 0.9 points in AQLQ+12 symptom score by key subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline										0.836
Yes	29	25 (86.2)	19 (65.5) [45.7, 82.1]	37	32 (86.5)	19 (51.4) [34.4, 68.1]	1.276 [0.847, 1.922]	1.800 [0.662, 4.898]	14.2 [-12.5, 40.9]	0.251
No	108	94 (87.0)	53 (49.1) [39.3, 58.9]	101	88 (87.1)	41 (40.6) [30.9, 50.8]	1.209 [0.892, 1.639]	1.410 [0.815, 2.439]	8.5 [-5.9, 22.9]	0.219

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IOSPP: Increase of at least 0.9 points in AQLQ+12 symptom score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.671	
White	128	111 (86.7)	67 (52.3) [43.3, 61.2]	123	106 (86.2)	52 (42.3) [33.4, 51.5]	1.238 [0.950, 1.613]	1.500 [0.911, 2.468]	10.1 [-3.0, 23.2]	0.111	
Non-white	9	8 (88.9)	5 (55.6) [21.2, 86.3]	15	14 (93.3)	8 (53.3) [26.6, 78.7]	1.042 [0.491, 2.210]	1.094 [0.208, 5.756]	2.2 [-47.8, 52.2]	1.000	#
Region (cat. P)										0.900	
North America/Western EU	10	9 (90.0)	7 (70.0) [34.8, 93.3]	9	7 (77.8)	5 (55.6) [21.2, 86.3]	1.260 [0.619, 2.566]	1.867 [0.283, 12.310]	14.4 [-39.2, 68.1]	0.650	#
Rest of world	127	110 (86.6)	65 (51.2) [42.2, 60.1]	129	113 (87.6)	55 (42.6) [34.0, 51.6]	1.200 [0.923, 1.561]	1.411 [0.862, 2.309]	8.5 [-4.4, 21.5]	0.172	
Baseline eosinophils (cat. P)										0.869	
< 250 cells/uL	61	53 (86.9)	30 (49.2) [36.1, 62.3]	60	52 (86.7)	25 (41.7) [29.1, 55.1]	1.180 [0.796, 1.749]	1.355 [0.661, 2.778]	7.5 [-11.8, 26.9]	0.409	
>= 250 cells/uL	76	66 (86.8)	42 (55.3) [43.4, 66.7]	78	68 (87.2)	35 (44.9) [33.6, 56.6]	1.232 [0.896, 1.693]	1.518 [0.804, 2.865]	10.4 [-6.6, 27.4]	0.199	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IOSPP: Increase of at least 0.9 points in AQLQ+12 symptom score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. P)										0.318	
< 24 ppb	75	64 (85.3)	35 (46.7) [35.1, 58.6]	72	61 (84.7)	32 (44.4) [32.7, 56.6]	1.050 [0.737, 1.496]	1.094 [0.571, 2.094]	2.2 [-15.2, 19.7]	0.788	
>= 24 ppb	60	53 (88.3)	35 (58.3) [44.9, 70.9]	65	58 (89.2)	28 (43.1) [30.8, 56.0]	1.354 [0.952, 1.925]	1.850 [0.909, 3.764]	15.3 [-3.7, 34.2]	0.090	
Baseline FENO (cat. M)										0.135	
< 22.0 ppb	65	55 (84.6)	28 (43.1) [30.8, 56.0]	62	53 (85.5)	28 (45.2) [32.5, 58.3]	0.954 [0.645, 1.411]	0.919 [0.456, 1.852]	-2.1 [-20.9, 16.8]	0.814	
>= 22.0 ppb	70	62 (88.6)	42 (60.0) [47.6, 71.5]	75	66 (88.0)	32 (42.7) [31.3, 54.6]	1.406 [1.016, 1.946]	2.016 [1.040, 3.907]	17.3 [-0.1, 34.7]	0.038	*
Baseline all FEIA status										0.023	i
All negative	50	42 (84.0)	29 (58.0) [43.2, 71.8]	50	40 (80.0)	15 (30.0) [17.9, 44.6]	1.933 [1.191, 3.139]	3.222 [1.412, 7.355]	28.0 [7.3, 48.7]	0.005	*
Any positive	77	69 (89.6)	38 (49.4) [37.8, 61.0]	80	72 (90.0)	40 (50.0) [38.6, 61.4]	0.987 [0.720, 1.352]	0.974 [0.521, 1.822]	-0.6 [-17.6, 16.3]	0.935	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IOSPP: Increase of at least 0.9 points in AQLQ+12 symptom score by study specific subgroups
DITT

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Th2 status										0.418	
Low	70	62 (88.6)	36 (51.4) [39.2, 63.6]	62	53 (85.5)	23 (37.1) [25.2, 50.3]	1.386 [0.933, 2.060]	1.795 [0.895, 3.603]	14.3 [-4.0, 32.6]	0.100	
High	65	56 (86.2)	35 (53.8) [41.0, 66.3]	75	66 (88.0)	36 (48.0) [36.3, 59.8]	1.122 [0.810, 1.554]	1.264 [0.650, 2.459]	5.8 [-12.2, 23.9]	0.492	
Baseline Periostin										0.170	
Low (< 20.9 ng/ml)	62	55 (88.7)	30 (48.4) [35.5, 61.4]	67	57 (85.1)	32 (47.8) [35.4, 60.3]	1.013 [0.708, 1.450]	1.025 [0.514, 2.047]	0.6 [-18.2, 19.4]	0.944	
High (>= 20.9 ng/ml)	74	63 (85.1)	42 (56.8) [44.7, 68.2]	71	63 (88.7)	28 (39.4) [28.0, 51.7]	1.439 [1.014, 2.043]	2.016 [1.040, 3.907]	17.3 [-0.1, 34.7]	0.038	*
Current post-BD FEV1 reversibility										0.312	
Yes	114	99 (86.8)	58 (50.9) [41.3, 60.4]	126	111 (88.1)	56 (44.4) [35.6, 53.6]	1.145 [0.878, 1.493]	1.295 [0.779, 2.152]	6.4 [-7.0, 19.9]	0.320	
No	23	20 (87.0)	14 (60.9) [38.5, 80.3]	12	9 (75.0)	4 (33.3) [9.9, 65.1]	1.826 [0.769, 4.335]	3.111 [0.720, 13.443]	27.5 [-12.1, 67.2]	0.127	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IOSPP: Increase of at least 0.9 points in AQLQ+12 symptom score by study specific subgroups
DITT

	Tezepelumab			Placebo							
Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Maintenance OCS use at baseline										0.175	
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	14	10 (71.4)	3 (21.4) [4.7, 50.8]	2.593 [0.812, 8.277]	4.583 [0.733, 28.646]	34.1 [-13.9, 82.2]	0.179	#
No	128	112 (87.5)	67 (52.3) [43.3, 61.2]	124	110 (88.7)	57 (46.0) [37.0, 55.1]	1.139 [0.885, 1.466]	1.291 [0.787, 2.118]	6.4 [-6.7, 19.5]	0.312	
No chronic OCS use and current post-BD FEV1 reversibility										0.074	
Yes	108	95 (88.0)	55 (50.9) [41.1, 60.7]	115	103 (89.6)	54 (47.0) [37.6, 56.5]	1.085 [0.829, 1.418]	1.172 [0.693, 1.983]	4.0 [-10.0, 18.0]	0.554	
No	29	24 (82.8)	17 (58.6) [38.9, 76.5]	23	17 (73.9)	6 (26.1) [10.2, 48.4]	2.247 [1.058, 4.771]	4.014 [1.223, 13.173]	32.5 [3.3, 61.8]	0.020	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTD_IOMP0: Decrease of at least 0.9 points in AQLQ+12 total score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 total score	Week 52	137	119 (86.9)	2 (1.5) [0.2, 5.2]	138	120 (87.0)	2 (1.4) [0.2, 5.1]	1.007 [0.144, 7.049]	1.007 [0.140, 7.255]	0.0 [-3.5, 3.6]	1.000 #

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAD_IOMP0: Decrease of at least 0.9 points in AQLQ+12 activity limitations score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 activity limitations score	Week 52	137	119 (86.9)	2 (1.5) [0.2, 5.2]	138	120 (87.0)	3 (2.2) [0.5, 6.2]	0.672 [0.114, 3.956]	0.667 [0.110, 4.053]	-0.7 [-4.6, 3.2]	1.000 #

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IOMP0: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score	Week 52	137	119 (86.9)	7 (5.1) [2.1, 10.2]	138	120 (87.0)	7 (5.1) [2.1, 10.2]	1.007 [0.363, 2.795]	1.008 [0.344, 2.954]	0.0 [-5.9, 6.0]	0.989

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IOSPK: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.317	
Male	50	41 (82.0)	3 (6.0) [1.3, 16.5]	44	41 (93.2)	1 (2.3) [0.1, 12.0]	2.640 [0.285, 24.469]	2.745 [0.275, 27.394]	3.7 [-6.3, 13.8]	0.620	#
Female	87	78 (89.7)	4 (4.6) [1.3, 11.4]	94	79 (84.0)	6 (6.4) [2.4, 13.4]	0.720 [0.210, 2.467]	0.707 [0.193, 2.594]	-1.8 [-9.5, 5.9]	0.749	#
Age										0.907	
< 65 years	114	101 (88.6)	6 (5.3) [2.0, 11.1]	118	104 (88.1)	6 (5.1) [1.9, 10.7]	1.035 [0.344, 3.116]	1.037 [0.324, 3.315]	0.2 [-6.4, 6.7]	0.951	
>= 65 years	23	18 (78.3)	1 (4.3) [0.1, 21.9]	20	16 (80.0)	1 (5.0) [0.1, 24.9]	0.870 [0.058, 13.020]	0.864 [0.051, 14.766]	-0.7 [-18.0, 16.7]	1.000	#
Exacerbations in the year before study		n<10	all levels							NE	
<= 2	105	90 (85.7)	5 (4.8) [1.6, 10.8]	110	98 (89.1)	3 (2.7) [0.6, 7.8]					
> 2	32	29 (90.6)	2 (6.3) [0.8, 20.8]	28	22 (78.6)	4 (14.3) [4.0, 32.7]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IOSPK: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10	any level							NE
White	128	111 (86.7)	7 (5.5) [2.2, 10.9]	123	106 (86.2)	6 (4.9) [1.8, 10.3]				
Black or African American	3	3 (100.0)	0 (0.0) [0.0, 70.8]	6	5 (83.3)	0 (0.0) [0.0, 45.9]				
Asian	5	4 (80.0)	0 (0.0) [0.0, 52.2]	6	6 (100.0)	1 (16.7) [0.4, 64.1]				
Other	1	1 (100.0)	0 (0.0) [0.0, 97.5]	3	3 (100.0)	0 (0.0) [0.0, 70.8]				
Region		n<10	all levels							NE
Europe	78	72 (92.3)	3 (3.8) [0.8, 10.8]	80	68 (85.0)	2 (2.5) [0.3, 8.7]				
America	10	9 (90.0)	0 (0.0) [0.0, 30.8]	9	7 (77.8)	0 (0.0) [0.0, 33.6]				
Asia/Pacific	5	4 (80.0)	0 (0.0) [0.0, 52.2]	6	6 (100.0)	1 (16.7) [0.4, 64.1]				
Rest of the world	44	34 (77.3)	4 (9.1) [2.5, 21.7]	43	39 (90.7)	4 (9.3) [2.6, 22.1]				
BMI		N<10	any level							NE
< 18.5 kg/m**2	0			1	1 (100.0)	0 (0.0) [0.0, 97.5]				
18.5 - < 25.0 kg/m**2	39	34 (87.2)	3 (7.7) [1.6, 20.9]	43	38 (88.4)	3 (7.0) [1.5, 19.1]				
25.0 - < 30.0 kg/m**2	45	40 (88.9)	3 (6.7) [1.4, 18.3]	47	43 (91.5)	2 (4.3) [0.5, 14.5]				
>= 30.0 kg/m**2	53	45 (84.9)	1 (1.9) [0.0, 10.1]	47	38 (80.9)	2 (4.3) [0.5, 14.5]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IOSPK: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.404	
< 150 cells/uL	27	27 (100.0)	2 (7.4) [0.9, 24.3]	33	29 (87.9)	1 (3.0) [0.1, 15.8]	2.444 [0.234, 25.528]	2.560 [0.219, 29.869]	4.4 [-10.5, 19.2]	0.583	#
>= 150 cells/uL	109	91 (83.5)	5 (4.6) [1.5, 10.4]	105	91 (86.7)	6 (5.7) [2.1, 12.0]	0.803 [0.253, 2.551]	0.793 [0.235, 2.682]	-1.1 [-8.0, 5.7]	0.710	
Baseline eosinophils - High		n<10	all levels							NE	
< 300 cells/uL	69	59 (85.5)	3 (4.3) [0.9, 12.2]	72	61 (84.7)	2 (2.8) [0.3, 9.7]					
>= 300 cells/uL	67	59 (88.1)	4 (6.0) [1.7, 14.6]	66	59 (89.4)	5 (7.6) [2.5, 16.8]					
Baseline FENO		n<10	all levels							NE	
< 25 ppb	78	67 (85.9)	5 (6.4) [2.1, 14.3]	74	63 (85.1)	4 (5.4) [1.5, 13.3]					
>= 25 ppb	57	50 (87.7)	2 (3.5) [0.4, 12.1]	63	56 (88.9)	3 (4.8) [1.0, 13.3]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IOSPK: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status		n<10	all levels							NE	
All negative	57	49 (86.0)	3 (5.3) [1.1, 14.6]	66	54 (81.8)	5 (7.6) [2.5, 16.8]					
Any positive	71	63 (88.7)	4 (5.6) [1.6, 13.8]	63	57 (90.5)	2 (3.2) [0.4, 11.0]					
Total serum IgE		n<10	all levels							NE	
Low	35	31 (88.6)	3 (8.6) [1.8, 23.1]	32	26 (81.3)	3 (9.4) [2.0, 25.0]					
Normal	95	82 (86.3)	3 (3.2) [0.7, 9.0]	98	86 (87.8)	4 (4.1) [1.1, 10.1]					
High	7	6 (85.7)	1 (14.3) [0.4, 57.9]	8	8 (100.0)	0 (0.0) [0.0, 36.9]					
OCS at baseline										0.593	
Yes	9	7 (77.8)	0 (0.0) [0.0, 33.6]	13	9 (69.2)	1 (7.7) [0.2, 36.0]	0.467 + [0.021, 10.318]	0.439 + [0.016, 12.010]	-7.7 [-31.6, 16.2]	1.000	#
No	128	112 (87.5)	7 (5.5) [2.2, 10.9]	125	111 (88.8)	6 (4.8) [1.8, 10.2]	1.139 [0.394, 3.296]	1.147 [0.375, 3.514]	0.7 [-5.6, 6.9]	0.810	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IOSPK: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
ICS dose level (at study entry)		n<10	all levels							NE	
Medium/Low	70	61 (87.1)	5 (7.1) [2.4, 15.9]	73	65 (89.0)	3 (4.1) [0.9, 11.5]					
High	67	58 (86.6)	2 (3.0) [0.4, 10.4]	65	55 (84.6)	4 (6.2) [1.7, 15.0]					
LAMA use at baseline										0.687	
Yes	11	9 (81.8)	1 (9.1) [0.2, 41.3]	6	4 (66.7)	0 (0.0) [0.0, 45.9]	1.750 + [0.082, 37.393]	1.857 + [0.065, 52.762]	9.1 [-20.8, 39.0]	1.000	#
No	126	110 (87.3)	6 (4.8) [1.8, 10.1]	132	116 (87.9)	7 (5.3) [2.2, 10.6]	0.898 [0.310, 2.599]	0.893 [0.292, 2.733]	-0.5 [-6.6, 5.6]	0.843	
Tiotropium use at baseline										0.861	
Yes	9	8 (88.9)	1 (11.1) [0.3, 48.2]	3	2 (66.7)	0 (0.0) [0.0, 70.8]	1.200 + [0.061, 23.701]	1.235 + [0.040, 38.300]	11.1 [-31.6, 53.9]	1.000	#
No	128	111 (86.7)	6 (4.7) [1.7, 9.9]	135	118 (87.4)	7 (5.2) [2.1, 10.4]	0.904 [0.312, 2.618]	0.899 [0.294, 2.751]	-0.5 [-6.5, 5.5]	0.853	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IOSPK: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Montelukast/ Cromoglicic acid use at baseline										0.673	
Yes	29	25 (86.2)	1 (3.4) [0.1, 17.8]	37	32 (86.5)	2 (5.4) [0.7, 18.2]	0.638 [0.061, 6.694]	0.625 [0.054, 7.253]	-2.0 [-14.9, 11.0]	1.000	#
No	108	94 (87.0)	6 (5.6) [2.1, 11.7]	101	88 (87.1)	5 (5.0) [1.6, 11.2]	1.122 [0.353, 3.563]	1.129 [0.334, 3.822]	0.6 [-6.4, 7.6]	0.845	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IOSPP: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.657	
White	128	111 (86.7)	7 (5.5) [2.2, 10.9]	123	106 (86.2)	6 (4.9) [1.8, 10.3]	1.121 [0.388, 3.242]	1.128 [0.368, 3.456]	0.6 [-5.7, 6.9]	0.833	
Non-white	9	8 (88.9)	0 (0.0) [0.0, 33.6]	15	14 (93.3)	1 (6.7) [0.2, 31.9]	0.533 + [0.024, 11.857]	0.509 + [0.019, 13.843]	-6.7 [-28.2, 14.8]	1.000	#
Region (cat. P)										0.956	
North America/Western EU	10	9 (90.0)	0 (0.0) [0.0, 30.8]	9	7 (77.8)	0 (0.0) [0.0, 33.6]	0.909 + [0.020, 41.676]	0.905 + [0.016, 50.244]	-0.5 + [-28.3, 27.4]		
Rest of world	127	110 (86.6)	7 (5.5) [2.2, 11.0]	129	113 (87.6)	7 (5.4) [2.2, 10.9]	1.016 [0.367, 2.813]	1.017 [0.346, 2.986]	0.1 [-6.3, 6.4]	0.976	
Baseline eosinophils (cat. P)		n<10	all levels							NE	
< 250 cells/uL	61	53 (86.9)	5 (8.2) [2.7, 18.1]	60	52 (86.7)	2 (3.3) [0.4, 11.5]					
>= 250 cells/uL	76	66 (86.8)	2 (2.6) [0.3, 9.2]	78	68 (87.2)	5 (6.4) [2.1, 14.3]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IOSPP: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. P)		n<10	all levels							NE
< 24 ppb	75	64 (85.3)	5 (6.7) [2.2, 14.9]	72	61 (84.7)	4 (5.6) [1.5, 13.6]				
>= 24 ppb	60	53 (88.3)	2 (3.3) [0.4, 11.5]	65	58 (89.2)	3 (4.6) [1.0, 12.9]				
Baseline FENO (cat. M)		n<10	all levels							NE
< 22.0 ppb	65	55 (84.6)	5 (7.7) [2.5, 17.0]	62	53 (85.5)	4 (6.5) [1.8, 15.7]				
>= 22.0 ppb	70	62 (88.6)	2 (2.9) [0.3, 9.9]	75	66 (88.0)	3 (4.0) [0.8, 11.2]				
Baseline all FEIA status		n<10	all levels							NE
All negative	50	42 (84.0)	3 (6.0) [1.3, 16.5]	50	40 (80.0)	4 (8.0) [2.2, 19.2]				
Any positive	77	69 (89.6)	4 (5.2) [1.4, 12.8]	80	72 (90.0)	3 (3.8) [0.8, 10.6]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IOSPP: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Th2 status		n<10	all levels							NE	
Low	70	62 (88.6)	3 (4.3) [0.9, 12.0]	62	53 (85.5)	5 (8.1) [2.7, 17.8]					
High	65	56 (86.2)	4 (6.2) [1.7, 15.0]	75	66 (88.0)	2 (2.7) [0.3, 9.3]					
Baseline Periostin		n<10	all levels							NE	
Low (< 20.9 ng/ml)	62	55 (88.7)	4 (6.5) [1.8, 15.7]	67	57 (85.1)	4 (6.0) [1.7, 14.6]					
High (>= 20.9 ng/ml)	74	63 (85.1)	3 (4.1) [0.8, 11.4]	71	63 (88.7)	3 (4.2) [0.9, 11.9]					
Current post-BD FEV1 reversibility										0.503	
Yes	114	99 (86.8)	5 (4.4) [1.4, 9.9]	126	111 (88.1)	5 (4.0) [1.3, 9.0]	1.105 [0.328, 3.719]	1.110 [0.313, 3.938]	0.4 [-5.5, 6.3]	1.000	#
No	23	20 (87.0)	2 (8.7) [1.1, 28.0]	12	9 (75.0)	2 (16.7) [2.1, 48.4]	0.522 [0.084, 3.257]	0.476 [0.058, 3.887]	-8.0 [-38.3, 22.4]	0.594	#

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IOSPP: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Maintenance OCS use at baseline										0.626	
Yes	9	7 (77.8)	0 (0.0) [0.0, 33.6]	14	10 (71.4)	1 (7.1) [0.2, 33.9]	0.500 + [0.023, 11.088]	0.474 + [0.017, 12.926]	-7.1 [-29.8, 15.5]	1.000	#
No	128	112 (87.5)	7 (5.5) [2.2, 10.9]	124	110 (88.7)	6 (4.8) [1.8, 10.2]	1.130 [0.391, 3.269]	1.138 [0.371, 3.485]	0.6 [-5.6, 6.9]	0.822	
No chronic OCS use and current post-BD FEV1 reversibility										0.796	
Yes	108	95 (88.0)	5 (4.6) [1.5, 10.5]	115	103 (89.6)	5 (4.3) [1.4, 9.9]	1.065 [0.317, 3.576]	1.068 [0.300, 3.797]	0.3 [-6.1, 6.6]	1.000	#
No	29	24 (82.8)	2 (6.9) [0.8, 22.8]	23	17 (73.9)	2 (8.7) [1.1, 28.0]	0.793 [0.121, 5.208]	0.778 [0.101, 5.989]	-1.8 [-20.5, 16.9]	1.000	#

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IOMP0: Decrease of at least 0.9 points in AQLQ+12 emotional function score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 emotional function score	Week 52	137	119 (86.9)	4 (2.9) [0.8, 7.3]	138	120 (87.0)	12 (8.7) [4.6, 14.7]	0.336 [0.111, 1.015]	0.316 [0.099, 1.005]	-5.8 [-12.0, 0.4]	0.041 *

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IOSPK: Decrease of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.634	
Male	50	41 (82.0)	1 (2.0) [0.1, 10.6]	44	41 (93.2)	4 (9.1) [2.5, 21.7]	0.220 [0.026, 1.895]	0.204 [0.022, 1.899]	-7.1 [-18.6, 4.4]	0.182	#
Female	87	78 (89.7)	3 (3.4) [0.7, 9.7]	94	79 (84.0)	8 (8.5) [3.7, 16.1]	0.405 [0.111, 1.478]	0.384 [0.098, 1.497]	-5.1 [-13.0, 2.9]	0.156	
Age										0.289	
< 65 years	114	101 (88.6)	4 (3.5) [1.0, 8.7]	118	104 (88.1)	8 (6.8) [3.0, 12.9]	0.518 [0.160, 1.671]	0.500 [0.146, 1.709]	-3.3 [-9.8, 3.2]	0.262	
>= 65 years	23	18 (78.3)	0 (0.0) [0.0, 14.8]	20	16 (80.0)	4 (20.0) [5.7, 43.7]	0.097 + [0.006, 1.702]	0.078 + [0.004, 1.549]	-20.0 [-42.2, 2.2]	0.039	*
Exacerbations in the year before study										0.646	
<= 2	105	90 (85.7)	3 (2.9) [0.6, 8.1]	110	98 (89.1)	8 (7.3) [3.2, 13.8]	0.393 [0.107, 1.441]	0.375 [0.097, 1.454]	-4.4 [-11.2, 2.3]	0.143	
> 2	32	29 (90.6)	1 (3.1) [0.1, 16.2]	28	22 (78.6)	4 (14.3) [4.0, 32.7]	0.219 [0.026, 1.844]	0.194 [0.020, 1.846]	-11.2 [-28.8, 6.5]	0.175	#

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IOSPK: Decrease of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10	any level							NE
White	128	111 (86.7)	4 (3.1) [0.9, 7.8]	123	106 (86.2)	11 (8.9) [4.5, 15.4]				
Black or African American	3	3 (100.0)	0 (0.0) [0.0, 70.8]	6	5 (83.3)	1 (16.7) [0.4, 64.1]				
Asian	5	4 (80.0)	0 (0.0) [0.0, 52.2]	6	6 (100.0)	0 (0.0) [0.0, 45.9]				
Other	1	1 (100.0)	0 (0.0) [0.0, 97.5]	3	3 (100.0)	0 (0.0) [0.0, 70.8]				
Region		n<10	all levels							NE
Europe	78	72 (92.3)	3 (3.8) [0.8, 10.8]	80	68 (85.0)	6 (7.5) [2.8, 15.6]				
America	10	9 (90.0)	0 (0.0) [0.0, 30.8]	9	7 (77.8)	1 (11.1) [0.3, 48.2]				
Asia/Pacific	5	4 (80.0)	0 (0.0) [0.0, 52.2]	6	6 (100.0)	0 (0.0) [0.0, 45.9]				
Rest of the world	44	34 (77.3)	1 (2.3) [0.1, 12.0]	43	39 (90.7)	5 (11.6) [3.9, 25.1]				
BMI		N<10	any level							NE
< 18.5 kg/m**2	0			1	1 (100.0)	0 (0.0) [0.0, 97.5]				
18.5 - < 25.0 kg/m**2	39	34 (87.2)	1 (2.6) [0.1, 13.5]	43	38 (88.4)	3 (7.0) [1.5, 19.1]				
25.0 - < 30.0 kg/m**2	45	40 (88.9)	0 (0.0) [0.0, 7.9]	47	43 (91.5)	5 (10.6) [3.5, 23.1]				
>= 30.0 kg/m**2	53	45 (84.9)	3 (5.7) [1.2, 15.7]	47	38 (80.9)	4 (8.5) [2.4, 20.4]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IOSPK: Decrease of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.573	
< 150 cells/uL	27	27 (100.0)	0 (0.0) [0.0, 12.8]	33	29 (87.9)	3 (9.1) [1.9, 24.3]	0.173 + [0.009, 3.218]	0.158 + [0.008, 3.207]	-9.1 [-22.3, 4.1]	0.245	#
>= 150 cells/uL	109	91 (83.5)	4 (3.7) [1.0, 9.1]	105	91 (86.7)	9 (8.6) [4.0, 15.6]	0.428 [0.136, 1.348]	0.406 [0.121, 1.363]	-4.9 [-12.2, 2.4]	0.134	
Baseline eosinophils - High		n<10	all levels							NE	
< 300 cells/uL	69	59 (85.5)	2 (2.9) [0.4, 10.1]	72	61 (84.7)	7 (9.7) [4.0, 19.0]					
>= 300 cells/uL	67	59 (88.1)	2 (3.0) [0.4, 10.4]	66	59 (89.4)	5 (7.6) [2.5, 16.8]					
Baseline FENO		n<10	all levels							NE	
< 25 ppb	78	67 (85.9)	4 (5.1) [1.4, 12.6]	74	63 (85.1)	5 (6.8) [2.2, 15.1]					
>= 25 ppb	57	50 (87.7)	0 (0.0) [0.0, 6.3]	63	56 (88.9)	6 (9.5) [3.6, 19.6]					

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IOSPK: Decrease of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.140	
All negative	57	49 (86.0)	1 (1.8) [0.0, 9.4]	66	54 (81.8)	9 (13.6) [6.4, 24.3]	0.129 [0.017, 0.985]	0.113 [0.014, 0.922]	-11.9 [-22.5, -1.3]	0.020	*
Any positive	71	63 (88.7)	3 (4.2) [0.9, 11.9]	63	57 (90.5)	3 (4.8) [1.0, 13.3]	0.887 [0.186, 4.239]	0.882 [0.172, 4.537]	-0.5 [-9.1, 8.0]	1.000	#
Total serum IgE										0.768	
Low	35	31 (88.6)	1 (2.9) [0.1, 14.9]	32	26 (81.3)	4 (12.5) [3.5, 29.0]	0.229 [0.027, 1.939]	0.206 [0.022, 1.949]	-9.6 [-25.4, 6.1]	0.185	#
Normal	95	82 (86.3)	3 (3.2) [0.7, 9.0]	98	86 (87.8)	8 (8.2) [3.6, 15.5]	0.387 [0.106, 1.415]	0.367 [0.094, 1.427]	-5.0 [-12.5, 2.5]	0.135	
High	7	6 (85.7)	0 (0.0) [0.0, 41.0]	8	8 (100.0)	0 (0.0) [0.0, 36.9]	1.125 + [0.025, 50.414]	1.133 + [0.020, 64.470]	0.7 + [-33.6, 35.0]		
OCS at baseline										0.835	
Yes	9	7 (77.8)	0 (0.0) [0.0, 33.6]	13	9 (69.2)	2 (15.4) [1.9, 45.4]	0.280 + [0.015, 5.222]	0.242 + [0.010, 5.682]	-15.4 [-44.4, 13.6]	0.494	#
No	128	112 (87.5)	4 (3.1) [0.9, 7.8]	125	111 (88.8)	10 (8.0) [3.9, 14.2]	0.391 [0.126, 1.213]	0.371 [0.113, 1.216]	-4.9 [-11.3, 1.5]	0.091	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IOSPK: Decrease of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
ICS dose level (at study entry)		n<10	all levels							NE	
Medium/Low	70	61 (87.1)	2 (2.9) [0.3, 9.9]	73	65 (89.0)	7 (9.6) [3.9, 18.8]					
High	67	58 (86.6)	2 (3.0) [0.4, 10.4]	65	55 (84.6)	5 (7.7) [2.5, 17.0]					
LAMA use at baseline										0.686	
Yes	11	9 (81.8)	0 (0.0) [0.0, 28.5]	6	4 (66.7)	1 (16.7) [0.4, 64.1]	0.194 + [0.009, 4.155]	0.159 + [0.006, 4.581]	-16.7 [-59.4, 26.0]	0.353	#
No	126	110 (87.3)	4 (3.2) [0.9, 7.9]	132	116 (87.9)	11 (8.3) [4.2, 14.4]	0.381 [0.125, 1.165]	0.361 [0.112, 1.164]	-5.2 [-11.6, 1.2]	0.077	
Tiotropium use at baseline										0.948	
Yes	9	8 (88.9)	0 (0.0) [0.0, 33.6]	3	2 (66.7)	0 (0.0) [0.0, 70.8]	0.400 + [0.009, 16.915]	0.368 + [0.006, 22.388]	-7.5 + [-60.1, 45.1]		
No	128	111 (86.7)	4 (3.1) [0.9, 7.8]	135	118 (87.4)	12 (8.9) [4.7, 15.0]	0.352 [0.116, 1.062]	0.331 [0.104, 1.053]	-5.8 [-12.2, 0.7]	0.051	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IOSPK: Decrease of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Montelukast/ Cromoglicic acid use at baseline										0.228	
Yes	29	25 (86.2)	2 (6.9) [0.8, 22.8]	37	32 (86.5)	3 (8.1) [1.7, 21.9]	0.851 [0.152, 4.759]	0.840 [0.131, 5.388]	-1.2 [-17.0, 14.6]	1.000	#
No	108	94 (87.0)	2 (1.9) [0.2, 6.5]	101	88 (87.1)	9 (8.9) [4.2, 16.2]	0.208 [0.046, 0.939]	0.193 [0.041, 0.915]	-7.1 [-14.1, 0.0]	0.023	*

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IOSPP: Decrease of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.802	
White	128	111 (86.7)	4 (3.1) [0.9, 7.8]	123	106 (86.2)	11 (8.9) [4.5, 15.4]	0.349 [0.114, 1.068]	0.328 [0.102, 1.061]	-5.8 [-12.5, 0.9]	0.052	
Non-white	9	8 (88.9)	0 (0.0) [0.0, 33.6]	15	14 (93.3)	1 (6.7) [0.2, 31.9]	0.533 + [0.024, 11.857]	0.509 + [0.019, 13.843]	-6.7 [-28.2, 14.8]	1.000	#
Region (cat. P)										0.906	
North America/Western EU	10	9 (90.0)	0 (0.0) [0.0, 30.8]	9	7 (77.8)	1 (11.1) [0.3, 48.2]	0.303 + [0.014, 6.619]	0.270 + [0.010, 7.508]	-11.1 [-42.2, 20.0]	0.474	#
Rest of world	127	110 (86.6)	4 (3.1) [0.9, 7.9]	129	113 (87.6)	11 (8.5) [4.3, 14.7]	0.369 [0.121, 1.130]	0.349 [0.108, 1.126]	-5.4 [-11.9, 1.1]	0.068	
Baseline eosinophils (cat. P)										0.527	
< 250 cells/uL	61	53 (86.9)	1 (1.6) [0.0, 8.8]	60	52 (86.7)	5 (8.3) [2.8, 18.4]	0.197 [0.024, 1.634]	0.183 [0.021, 1.619]	-6.7 [-16.0, 2.6]	0.114	#
>= 250 cells/uL	76	66 (86.8)	3 (3.9) [0.8, 11.1]	78	68 (87.2)	7 (9.0) [3.7, 17.6]	0.440 [0.118, 1.638]	0.417 [0.104, 1.676]	-5.0 [-14.0, 4.0]	0.328	#

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IOSPP: Decrease of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. P)		n<10	all levels							NE
< 24 ppb	75	64 (85.3)	4 (5.3) [1.5, 13.1]	72	61 (84.7)	5 (6.9) [2.3, 15.5]				
>= 24 ppb	60	53 (88.3)	0 (0.0) [0.0, 6.0]	65	58 (89.2)	6 (9.2) [3.5, 19.0]				
Baseline FENO (cat. M)		n<10	all levels							NE
< 22.0 ppb	65	55 (84.6)	3 (4.6) [1.0, 12.9]	62	53 (85.5)	4 (6.5) [1.8, 15.7]				
>= 22.0 ppb	70	62 (88.6)	1 (1.4) [0.0, 7.7]	75	66 (88.0)	7 (9.3) [3.8, 18.3]				
Baseline all FEIA status		n<10	all levels							NE
All negative	50	42 (84.0)	1 (2.0) [0.1, 10.6]	50	40 (80.0)	7 (14.0) [5.8, 26.7]				
Any positive	77	69 (89.6)	3 (3.9) [0.8, 11.0]	80	72 (90.0)	5 (6.3) [2.1, 14.0]				

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IOSPP: Decrease of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITT

Decrease of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Th2 status										0.131	
Low	70	62 (88.6)	2 (2.9) [0.3, 9.9]	62	53 (85.5)	10 (16.1) [8.0, 27.7]	0.177 [0.040, 0.778]	0.153 [0.032, 0.728]	-13.3 [-24.7, -1.8]	0.008	*
High	65	56 (86.2)	2 (3.1) [0.4, 10.7]	75	66 (88.0)	2 (2.7) [0.3, 9.3]	1.154 [0.167, 7.962]	1.159 [0.159, 8.466]	0.4 [-6.6, 7.4]	1.000	#
Baseline Periostin		n<10	all levels							NE	
Low (< 20.9 ng/ml)	62	55 (88.7)	2 (3.2) [0.4, 11.2]	67	57 (85.1)	5 (7.5) [2.5, 16.6]					
High (>= 20.9 ng/ml)	74	63 (85.1)	2 (2.7) [0.3, 9.4]	71	63 (88.7)	7 (9.9) [4.1, 19.3]					
Current post-BD FEV1 reversibility										0.384	
Yes	114	99 (86.8)	4 (3.5) [1.0, 8.7]	126	111 (88.1)	10 (7.9) [3.9, 14.1]	0.442 [0.143, 1.371]	0.422 [0.129, 1.384]	-4.4 [-11.1, 2.2]	0.145	
No	23	20 (87.0)	0 (0.0) [0.0, 14.8]	12	9 (75.0)	2 (16.7) [2.1, 48.4]	0.108 + [0.006, 2.091]	0.089 + [0.004, 2.028]	-16.7 [-44.1, 10.8]	0.111	#

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IOSPP: Decrease of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITT

	Tezepelumab			Placebo							
Decrease of at least 0.9 points in AQLQ+12 emotional function score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Maintenance OCS use at baseline										0.873	
Yes	9	7 (77.8)	0 (0.0) [0.0, 33.6]	14	10 (71.4)	2 (14.3) [1.8, 42.8]	0.300 + [0.016, 5.613]	0.263 + [0.011, 6.150]	-14.3 [-41.7, 13.2]	0.502	#
No	128	112 (87.5)	4 (3.1) [0.9, 7.8]	124	110 (88.7)	10 (8.1) [3.9, 14.3]	0.388 [0.125, 1.203]	0.368 [0.112, 1.205]	-4.9 [-11.4, 1.5]	0.088	
No chronic OCS use and current post-BD FEV1 reversibility										0.374	
Yes	108	95 (88.0)	4 (3.7) [1.0, 9.2]	115	103 (89.6)	9 (7.8) [3.6, 14.3]	0.473 [0.150, 1.492]	0.453 [0.135, 1.517]	-4.1 [-11.1, 2.8]	0.190	
No	29	24 (82.8)	0 (0.0) [0.0, 11.9]	23	17 (73.9)	3 (13.0) [2.8, 33.6]	0.114 + [0.006, 2.107]	0.099 + [0.005, 2.027]	-13.0 [-30.7, 4.6]	0.080	#

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMD_IOMP0: Decrease of at least 0.9 points in AQLQ+12 symptom score
DITT

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 symptom score	Week 52	137	119 (86.9)	2 (1.5) [0.2, 5.2]	138	120 (87.0)	4 (2.9) [0.8, 7.3]	0.504 [0.094, 2.705]	0.496 [0.089, 2.755]	-1.4 [-5.6, 2.7]	0.684 #

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOMH0: Course of AQLQ+12 total score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	137	123 (89.8)	4.20 (0.91)	1.5	3.72	4.28	4.69	6.8	
		Placebo	138	121 (87.7)	4.09 (0.87)	1.8	3.50	4.06	4.69	6.3	
	Week 4	Tezepelumab	137	126 (92.0)	4.91 (1.04)	1.4	4.13	4.97	5.66	7.0	
		Placebo	138	123 (89.1)	4.60 (0.97)	2.1	3.88	4.56	5.25	6.8	
	Week 8	Tezepelumab	137	128 (93.4)	5.11 (1.04)	2.7	4.25	5.08	5.92	7.0	
		Placebo	138	126 (91.3)	4.71 (1.04)	2.1	4.00	4.63	5.44	7.0	
	Week 12	Tezepelumab	137	128 (93.4)	5.28 (1.04)	2.8	4.42	5.23	6.16	7.0	
		Placebo	138	127 (92.0)	4.82 (1.05)	2.5	4.00	4.72	5.59	7.0	
	Week 16	Tezepelumab	137	128 (93.4)	5.24 (1.03)	2.6	4.38	5.19	6.03	7.0	
		Placebo	138	127 (92.0)	4.84 (1.11)	1.2	4.00	4.78	5.72	7.0	
	Week 20	Tezepelumab	137	129 (94.2)	5.23 (1.02)	3.2	4.31	5.22	6.06	7.0	
		Placebo	138	127 (92.0)	4.85 (1.10)	1.2	4.03	4.78	5.78	7.0	
	Week 24	Tezepelumab	137	129 (94.2)	5.27 (1.04)	2.4	4.41	5.16	6.03	7.0	
		Placebo	138	127 (92.0)	4.88 (1.13)	1.2	4.00	4.81	5.75	7.0	
	Week 28	Tezepelumab	137	131 (95.6)	5.28 (1.00)	3.3	4.47	5.19	6.03	7.0	
		Placebo	138	128 (92.8)	4.90 (1.20)	1.2	3.97	4.83	5.88	7.0	
	Week 32	Tezepelumab	137	132 (96.4)	5.33 (1.03)	2.6	4.47	5.41	6.00	7.0	
		Placebo	138	129 (93.5)	4.95 (1.13)	1.2	4.03	4.84	5.91	7.0	
	Week 36	Tezepelumab	137	132 (96.4)	5.34 (1.02)	3.2	4.59	5.30	6.19	7.0	
		Placebo	138	129 (93.5)	4.97 (1.12)	2.2	4.03	4.81	5.94	7.0	
	Week 40	Tezepelumab	137	132 (96.4)	5.34 (1.04)	2.6	4.55	5.27	6.06	7.0	
		Placebo	138	129 (93.5)	4.99 (1.13)	2.3	4.00	4.97	5.91	7.0	
	Week 44	Tezepelumab	137	132 (96.4)	5.38 (1.03)	2.8	4.55	5.31	6.20	7.0	
		Placebo	138	129 (93.5)	4.98 (1.16)	2.5	4.00	4.91	5.97	7.0	
	Week 48	Tezepelumab	137	132 (96.4)	5.39 (1.04)	2.9	4.50	5.36	6.19	7.0	
		Placebo	138	130 (94.2)	5.00 (1.11)	2.1	4.06	4.88	5.94	7.0	
	Week 52	Tezepelumab	137	132 (96.4)	5.37 (1.04)	2.8	4.52	5.31	6.22	7.0	
		Placebo	138	130 (94.2)	4.96 (1.12)	2.7	4.00	4.88	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOMH0: Course of AQLQ+12 total score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	137	117 (85.4)	0.74 (0.95)	-3.7	0.16	0.69	1.38	3.3	0.26 [0.00, 0.52]
		Placebo	138	119 (86.2)	0.52 (0.78)	-1.2	0.09	0.44	1.00	2.6	
	Week 8	Tezepelumab	137	119 (86.9)	0.90 (0.97)	-1.0	0.19	0.75	1.63	3.9	0.28 [0.03, 0.54]
		Placebo	138	120 (87.0)	0.64 (0.87)	-1.4	0.09	0.52	1.09	3.1	
	Week 12	Tezepelumab	137	119 (86.9)	1.07 (1.00)	-2.1	0.50	0.97	1.84	4.2	0.32 [0.07, 0.58]
		Placebo	138	120 (87.0)	0.75 (1.00)	-2.0	0.20	0.70	1.25	3.5	
	Week 16	Tezepelumab	137	119 (86.9)	1.05 (1.00)	-2.4	0.34	1.00	1.69	4.2	0.28 [0.02, 0.53]
		Placebo	138	120 (87.0)	0.77 (1.01)	-3.2	0.25	0.72	1.38	3.8	
	Week 20	Tezepelumab	137	119 (86.9)	1.04 (0.99)	-1.2	0.28	0.84	1.75	4.2	0.26 [0.00, 0.51]
		Placebo	138	120 (87.0)	0.79 (0.99)	-3.2	0.25	0.77	1.20	3.8	
	Week 24	Tezepelumab	137	119 (86.9)	1.11 (1.01)	-1.2	0.34	1.03	1.78	4.3	0.27 [0.02, 0.53]
		Placebo	138	120 (87.0)	0.82 (1.05)	-3.2	0.14	0.78	1.36	3.7	
	Week 28	Tezepelumab	137	119 (86.9)	1.10 (1.00)	-1.3	0.31	0.91	1.88	4.3	0.25 [0.00, 0.51]
		Placebo	138	120 (87.0)	0.83 (1.11)	-3.2	0.19	0.81	1.42	4.3	
	Week 32	Tezepelumab	137	119 (86.9)	1.13 (1.01)	-1.2	0.47	1.03	1.94	4.3	0.23 [-0.02, 0.49]
		Placebo	138	120 (87.0)	0.90 (1.02)	-3.2	0.31	0.77	1.44	3.6	
	Week 36	Tezepelumab	137	119 (86.9)	1.14 (1.07)	-1.3	0.41	0.94	1.97	4.3	0.22 [-0.04, 0.47]
		Placebo	138	120 (87.0)	0.91 (1.03)	-2.0	0.31	0.77	1.50	3.4	
	Week 40	Tezepelumab	137	119 (86.9)	1.14 (1.02)	-1.3	0.50	1.00	1.94	4.3	0.20 [-0.05, 0.45]
		Placebo	138	120 (87.0)	0.93 (1.08)	-2.0	0.27	0.78	1.63	4.3	
	Week 44	Tezepelumab	137	119 (86.9)	1.18 (1.03)	-1.1	0.53	1.03	1.88	4.3	0.26 [0.00, 0.51]
		Placebo	138	120 (87.0)	0.91 (1.10)	-2.0	0.16	0.83	1.44	4.1	
	Week 48	Tezepelumab	137	119 (86.9)	1.21 (1.03)	-1.1	0.50	1.06	2.06	4.3	0.27 [0.01, 0.52]
		Placebo	138	120 (87.0)	0.93 (1.04)	-2.0	0.17	0.84	1.63	3.5	
	Week 52	Tezepelumab	137	119 (86.9)	1.17 (1.04)	-1.2	0.44	1.06	2.06	4.3	0.26 [0.00, 0.51]
		Placebo	138	120 (87.0)	0.90 (1.04)	-2.0	0.17	0.81	1.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOMC0: Change from baseline in AQLQ+12 total score - MMRM results
DITT

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	137	117 (85.4)	0.76 (0.08)	(0.61, 0.91)	0.27 (0.11)	(0.06, 0.49)	0.011 *
	Placebo	138	118 (85.5)	0.48 (0.08)	(0.34, 0.63)			
Week 8	Tezepelumab	137	117 (85.4)	0.92 (0.08)	(0.76, 1.08)	0.30 (0.11)	(0.07, 0.52)	0.009 *
	Placebo	138	119 (86.2)	0.62 (0.08)	(0.47, 0.78)			
Week 12	Tezepelumab	137	116 (84.7)	1.10 (0.09)	(0.93, 1.27)	0.35 (0.12)	(0.12, 0.59)	0.004 *
	Placebo	138	115 (83.3)	0.74 (0.09)	(0.58, 0.91)			
Week 16	Tezepelumab	137	112 (81.8)	1.07 (0.09)	(0.90, 1.24)	0.33 (0.12)	(0.09, 0.57)	0.008 *
	Placebo	138	112 (81.2)	0.74 (0.09)	(0.57, 0.91)			
Week 20	Tezepelumab	137	107 (78.1)	1.08 (0.08)	(0.92, 1.25)	0.28 (0.12)	(0.05, 0.51)	0.018 *
	Placebo	138	109 (79.0)	0.80 (0.08)	(0.64, 0.97)			
Week 24	Tezepelumab	137	105 (76.6)	1.15 (0.09)	(0.98, 1.32)	0.32 (0.12)	(0.07, 0.56)	0.011 *
	Placebo	138	106 (76.8)	0.83 (0.09)	(0.66, 1.00)			
Week 28	Tezepelumab	137	101 (73.7)	1.12 (0.09)	(0.94, 1.30)	0.29 (0.13)	(0.03, 0.55)	0.027 *
	Placebo	138	105 (76.1)	0.83 (0.09)	(0.65, 1.01)			
Week 32	Tezepelumab	137	104 (75.9)	1.17 (0.09)	(1.00, 1.34)	0.26 (0.12)	(0.02, 0.50)	0.035 *
	Placebo	138	104 (75.4)	0.92 (0.09)	(0.75, 1.08)			
Week 36	Tezepelumab	137	104 (75.9)	1.18 (0.09)	(1.00, 1.36)	0.26 (0.13)	(0.01, 0.51)	0.045 *
	Placebo	138	103 (74.6)	0.92 (0.09)	(0.74, 1.10)			
Week 40	Tezepelumab	137	104 (75.9)	1.19 (0.09)	(1.00, 1.37)	0.24 (0.13)	(-0.02, 0.50)	0.068
	Placebo	138	105 (76.1)	0.95 (0.09)	(0.77, 1.13)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOMC0: Change from baseline in AQLQ+12 total score - MMRM results
DITT

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	137	102 (74.5)	1.23 (0.09)	(1.05, 1.42)	0.34 (0.13)	(0.08, 0.61)	0.011 *
	Placebo	138	103 (74.6)	0.89 (0.09)	(0.71, 1.07)			
Week 48	Tezepelumab	137	97 (70.8)	1.27 (0.09)	(1.09, 1.45)	0.33 (0.13)	(0.08, 0.59)	0.009 *
	Placebo	138	105 (76.1)	0.93 (0.09)	(0.76, 1.11)			
Week 52	Tezepelumab	137	41 (29.9)	1.18 (0.11)	(0.97, 1.40)	0.25 (0.15)	(-0.05, 0.55)	0.098
	Placebo	138	47 (34.1)	0.93 (0.11)	(0.72, 1.14)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QTC_IOMG0: Course of AQLQ+12 total score
DITT



Note: DITT = Dossier Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QTC_IOMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	50	42 (84.0)	4.28 (0.94)	2.7	3.75	4.30	4.81	6.8	
			Placebo	44	41 (93.2)	4.11 (0.84)	1.8	3.84	4.13	4.41	5.9	
		Week 4	Tezepelumab	50	46 (92.0)	5.06 (1.12)	3.0	4.03	5.02	5.94	6.9	
			Placebo	44	41 (93.2)	4.69 (1.06)	2.4	3.78	4.81	5.69	6.7	
		Week 8	Tezepelumab	50	46 (92.0)	5.19 (1.11)	3.2	4.19	5.19	6.19	7.0	
			Placebo	44	42 (95.5)	4.79 (1.03)	2.8	4.00	4.56	5.59	6.8	
		Week 12	Tezepelumab	50	46 (92.0)	5.30 (1.09)	3.1	4.31	5.34	6.34	7.0	
			Placebo	44	42 (95.5)	4.93 (1.05)	2.8	4.00	5.11	5.78	6.9	
		Week 16	Tezepelumab	50	46 (92.0)	5.29 (1.08)	3.5	4.31	5.28	6.19	7.0	
			Placebo	44	42 (95.5)	4.87 (1.20)	1.2	4.00	4.92	5.84	6.9	
		Week 20	Tezepelumab	50	46 (92.0)	5.32 (1.11)	3.2	4.31	5.36	6.09	7.0	
			Placebo	44	42 (95.5)	4.87 (1.23)	1.2	4.00	4.89	5.97	6.8	
		Week 24	Tezepelumab	50	46 (92.0)	5.34 (1.10)	3.3	4.38	5.33	6.06	7.0	
			Placebo	44	42 (95.5)	4.90 (1.30)	1.2	3.97	5.09	6.03	7.0	
		Week 28	Tezepelumab	50	47 (94.0)	5.35 (1.06)	3.6	4.31	5.34	6.22	7.0	
			Placebo	44	43 (97.7)	4.91 (1.35)	1.2	3.91	5.13	6.00	7.0	
		Week 32	Tezepelumab	50	48 (96.0)	5.42 (1.05)	3.6	4.44	5.55	6.22	7.0	
			Placebo	44	43 (97.7)	5.01 (1.24)	1.2	4.03	5.25	6.00	6.9	
		Week 36	Tezepelumab	50	48 (96.0)	5.39 (1.10)	3.5	4.47	5.42	6.33	7.0	
			Placebo	44	43 (97.7)	5.03 (1.26)	2.2	4.00	5.13	6.13	6.9	
		Week 40	Tezepelumab	50	48 (96.0)	5.40 (1.09)	3.6	4.41	5.39	6.38	7.0	
			Placebo	44	43 (97.7)	5.04 (1.21)	2.3	3.97	5.16	6.09	6.9	
		Week 44	Tezepelumab	50	48 (96.0)	5.47 (1.16)	3.0	4.44	5.53	6.47	7.0	
			Placebo	44	43 (97.7)	5.09 (1.25)	2.8	4.00	5.13	6.03	7.0	
		Week 48	Tezepelumab	50	48 (96.0)	5.43 (1.11)	3.4	4.44	5.38	6.47	7.0	
			Placebo	44	43 (97.7)	5.12 (1.24)	2.1	4.00	5.13	6.25	7.0	
		Week 52	Tezepelumab	50	48 (96.0)	5.38 (1.10)	3.4	4.41	5.38	6.23	7.0	
			Placebo	44	43 (97.7)	5.12 (1.19)	2.9	4.00	5.13	6.25	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	50	41 (82.0)	0.79 (0.90)	-1.3	0.31	0.66	1.44	3.0	0.21 [-0.23, 0.65]
			Placebo	44	40 (90.9)	0.61 (0.86)	-1.2	0.09	0.38	1.28	2.6	
		Week 8	Tezepelumab	50	41 (82.0)	0.92 (0.99)	-0.8	0.28	0.81	1.53	3.9	0.24 [-0.19, 0.68]
			Placebo	44	41 (93.2)	0.70 (0.83)	-0.8	0.16	0.50	1.09	3.1	
		Week 12	Tezepelumab	50	41 (82.0)	1.03 (1.00)	-0.9	0.47	0.94	1.44	4.2	0.19 [-0.24, 0.63]
			Placebo	44	41 (93.2)	0.84 (0.98)	-1.1	0.28	0.78	1.22	3.3	
		Week 16	Tezepelumab	50	41 (82.0)	1.06 (1.01)	-1.0	0.50	0.91	1.59	4.2	0.27 [-0.17, 0.70]
			Placebo	44	41 (93.2)	0.77 (1.08)	-3.2	0.34	0.69	1.59	3.2	
		Week 20	Tezepelumab	50	41 (82.0)	1.07 (1.00)	-0.6	0.47	0.91	1.66	4.2	0.29 [-0.15, 0.72]
			Placebo	44	41 (93.2)	0.78 (1.03)	-3.2	0.31	0.78	1.19	3.2	
		Week 24	Tezepelumab	50	41 (82.0)	1.13 (0.98)	-0.6	0.47	0.94	1.59	4.3	0.30 [-0.13, 0.74]
			Placebo	44	41 (93.2)	0.80 (1.18)	-3.2	0.31	0.78	1.56	3.2	
		Week 28	Tezepelumab	50	41 (82.0)	1.15 (1.00)	-0.6	0.41	1.00	1.72	4.3	0.34 [-0.10, 0.77]
			Placebo	44	41 (93.2)	0.78 (1.21)	-3.2	0.16	0.78	1.44	3.2	
		Week 32	Tezepelumab	50	41 (82.0)	1.18 (0.97)	-0.7	0.63	1.03	1.72	4.3	0.30 [-0.14, 0.73]
			Placebo	44	41 (93.2)	0.87 (1.09)	-3.2	0.28	0.81	1.50	2.9	
		Week 36	Tezepelumab	50	41 (82.0)	1.13 (1.10)	-1.0	0.34	0.91	2.06	4.3	0.22 [-0.21, 0.66]
			Placebo	44	41 (93.2)	0.89 (1.08)	-1.7	0.31	0.78	1.72	3.4	
		Week 40	Tezepelumab	50	41 (82.0)	1.17 (1.01)	-0.8	0.63	0.94	1.84	4.3	0.25 [-0.19, 0.68]
			Placebo	44	41 (93.2)	0.91 (1.08)	-1.6	0.34	0.78	1.72	3.6	
		Week 44	Tezepelumab	50	41 (82.0)	1.22 (1.06)	-0.8	0.66	1.03	1.84	4.3	0.26 [-0.18, 0.69]
			Placebo	44	41 (93.2)	0.94 (1.09)	-1.3	0.31	1.03	1.75	3.2	
		Week 48	Tezepelumab	50	41 (82.0)	1.21 (1.06)	-0.8	0.53	1.00	2.06	4.3	0.22 [-0.22, 0.65]
			Placebo	44	41 (93.2)	0.98 (1.08)	-1.8	0.34	0.94	1.66	3.3	
		Week 52	Tezepelumab	50	41 (82.0)	1.12 (1.09)	-0.8	0.44	0.94	1.66	4.3	0.13 [-0.31, 0.56]
			Placebo	44	41 (93.2)	0.98 (1.01)	-0.9	0.34	0.94	1.66	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	87	81 (93.1)	4.16 (0.90)	1.5	3.72	4.28	4.63	6.3	
			Placebo	94	80 (85.1)	4.08 (0.90)	1.9	3.47	4.06	4.69	6.3	
		Week 4	Tezepelumab	87	80 (92.0)	4.82 (0.98)	1.4	4.14	4.78	5.48	7.0	
			Placebo	94	82 (87.2)	4.56 (0.92)	2.1	3.97	4.50	5.13	6.8	
		Week 8	Tezepelumab	87	82 (94.3)	5.06 (1.01)	2.7	4.25	5.03	5.91	7.0	
			Placebo	94	84 (89.4)	4.67 (1.05)	2.1	3.98	4.64	5.33	7.0	
		Week 12	Tezepelumab	87	82 (94.3)	5.27 (1.02)	2.8	4.47	5.16	6.13	7.0	
			Placebo	94	85 (90.4)	4.77 (1.05)	2.5	4.03	4.63	5.53	7.0	
		Week 16	Tezepelumab	87	82 (94.3)	5.22 (1.00)	2.6	4.47	5.14	5.97	7.0	
			Placebo	94	85 (90.4)	4.83 (1.08)	2.5	3.97	4.75	5.69	7.0	
		Week 20	Tezepelumab	87	83 (95.4)	5.18 (0.96)	3.5	4.31	5.16	5.94	7.0	
			Placebo	94	85 (90.4)	4.84 (1.04)	2.4	4.03	4.72	5.56	7.0	
		Week 24	Tezepelumab	87	83 (95.4)	5.24 (1.01)	2.4	4.41	5.16	6.03	7.0	
			Placebo	94	85 (90.4)	4.87 (1.04)	2.3	4.09	4.72	5.59	7.0	
		Week 28	Tezepelumab	87	84 (96.6)	5.24 (0.98)	3.3	4.47	5.16	6.02	7.0	
			Placebo	94	85 (90.4)	4.89 (1.12)	2.2	4.00	4.72	5.75	7.0	
		Week 32	Tezepelumab	87	84 (96.6)	5.28 (1.01)	2.6	4.50	5.38	6.00	7.0	
			Placebo	94	86 (91.5)	4.92 (1.08)	2.3	4.03	4.69	5.75	7.0	
		Week 36	Tezepelumab	87	84 (96.6)	5.30 (0.97)	3.2	4.63	5.22	5.97	7.0	
			Placebo	94	86 (91.5)	4.93 (1.06)	2.6	4.03	4.72	5.75	7.0	
		Week 40	Tezepelumab	87	84 (96.6)	5.30 (1.01)	2.6	4.59	5.25	5.94	7.0	
			Placebo	94	86 (91.5)	4.96 (1.09)	2.5	4.00	4.91	5.75	7.0	
		Week 44	Tezepelumab	87	84 (96.6)	5.32 (0.96)	2.8	4.61	5.22	6.06	7.0	
			Placebo	94	86 (91.5)	4.92 (1.12)	2.5	4.00	4.84	5.72	7.0	
		Week 48	Tezepelumab	87	84 (96.6)	5.36 (0.99)	2.9	4.55	5.34	6.16	7.0	
			Placebo	94	87 (92.6)	4.93 (1.04)	2.8	4.13	4.81	5.63	7.0	
		Week 52	Tezepelumab	87	84 (96.6)	5.36 (1.02)	2.8	4.59	5.30	6.19	7.0	
			Placebo	94	87 (92.6)	4.89 (1.08)	2.7	4.00	4.81	5.63	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	87	76 (87.4)	0.71 (0.99)	-3.7	0.08	0.69	1.38	3.3	0.28 [-0.03, 0.60]
			Placebo	94	79 (84.0)	0.47 (0.74)	-1.2	0.06	0.44	0.91	2.6	
		Week 8	Tezepelumab	87	78 (89.7)	0.89 (0.97)	-1.0	0.13	0.73	1.63	3.8	0.30 [-0.01, 0.62]
			Placebo	94	79 (84.0)	0.61 (0.89)	-1.4	0.06	0.53	1.09	2.7	
		Week 12	Tezepelumab	87	78 (89.7)	1.10 (1.01)	-2.1	0.50	1.06	1.91	4.0	0.39 [0.07, 0.70]
			Placebo	94	79 (84.0)	0.70 (1.02)	-2.0	0.16	0.69	1.25	3.5	
		Week 16	Tezepelumab	87	78 (89.7)	1.04 (0.99)	-2.4	0.34	1.11	1.78	3.4	0.28 [-0.04, 0.59]
			Placebo	94	79 (84.0)	0.77 (0.98)	-2.0	0.16	0.78	1.38	3.8	
		Week 20	Tezepelumab	87	78 (89.7)	1.03 (1.00)	-1.2	0.28	0.78	1.81	3.4	0.24 [-0.08, 0.55]
			Placebo	94	79 (84.0)	0.80 (0.97)	-2.0	0.25	0.75	1.22	3.8	
		Week 24	Tezepelumab	87	78 (89.7)	1.09 (1.03)	-1.2	0.31	1.03	1.84	3.4	0.26 [-0.06, 0.57]
			Placebo	94	79 (84.0)	0.83 (0.99)	-2.0	0.13	0.81	1.34	3.7	
		Week 28	Tezepelumab	87	78 (89.7)	1.07 (1.00)	-1.3	0.31	0.88	1.97	3.4	0.21 [-0.11, 0.52]
			Placebo	94	79 (84.0)	0.85 (1.06)	-2.0	0.19	0.84	1.41	4.3	
		Week 32	Tezepelumab	87	78 (89.7)	1.11 (1.04)	-1.2	0.34	1.03	2.06	3.4	0.20 [-0.12, 0.51]
			Placebo	94	79 (84.0)	0.91 (0.98)	-2.0	0.31	0.72	1.41	3.6	
		Week 36	Tezepelumab	87	78 (89.7)	1.14 (1.06)	-1.3	0.44	1.03	1.91	3.4	0.22 [-0.10, 0.53]
			Placebo	94	79 (84.0)	0.91 (1.01)	-2.0	0.31	0.75	1.44	3.4	
		Week 40	Tezepelumab	87	78 (89.7)	1.13 (1.03)	-1.3	0.44	1.03	2.03	3.4	0.17 [-0.14, 0.49]
			Placebo	94	79 (84.0)	0.95 (1.09)	-2.0	0.25	0.78	1.59	4.3	
		Week 44	Tezepelumab	87	78 (89.7)	1.16 (1.01)	-1.1	0.50	1.08	1.88	3.4	0.26 [-0.06, 0.57]
			Placebo	94	79 (84.0)	0.89 (1.12)	-2.0	0.09	0.81	1.31	4.1	
		Week 48	Tezepelumab	87	78 (89.7)	1.20 (1.02)	-1.1	0.44	1.14	2.06	3.4	0.29 [-0.02, 0.61]
			Placebo	94	79 (84.0)	0.90 (1.03)	-2.0	0.09	0.81	1.53	3.5	
		Week 52	Tezepelumab	87	78 (89.7)	1.20 (1.01)	-1.2	0.44	1.17	2.06	3.4	0.33 [0.01, 0.64]
			Placebo	94	79 (84.0)	0.86 (1.05)	-2.0	0.06	0.75	1.44	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	114	103 (90.4)	4.20 (0.95)	1.5	3.72	4.31	4.69	6.8	
			Placebo	118	105 (89.0)	4.06 (0.90)	1.8	3.47	4.06	4.69	6.3	
		Week 4	Tezepelumab	114	106 (93.0)	4.92 (1.07)	1.4	4.13	4.97	5.66	7.0	
			Placebo	118	106 (89.8)	4.64 (0.99)	2.1	3.97	4.69	5.25	6.8	
		Week 8	Tezepelumab	114	108 (94.7)	5.13 (1.07)	2.7	4.30	5.09	5.95	7.0	
			Placebo	118	109 (92.4)	4.74 (1.08)	2.1	4.00	4.66	5.50	7.0	
		Week 12	Tezepelumab	114	108 (94.7)	5.33 (1.06)	2.8	4.42	5.31	6.25	7.0	
			Placebo	118	110 (93.2)	4.89 (1.08)	2.5	4.09	4.94	5.75	7.0	
		Week 16	Tezepelumab	114	108 (94.7)	5.29 (1.05)	2.6	4.41	5.27	6.09	7.0	
			Placebo	118	110 (93.2)	4.89 (1.14)	1.2	4.03	4.84	5.75	7.0	
		Week 20	Tezepelumab	114	108 (94.7)	5.29 (1.03)	3.2	4.34	5.23	6.13	7.0	
			Placebo	118	110 (93.2)	4.90 (1.11)	1.2	4.06	4.86	5.88	7.0	
		Week 24	Tezepelumab	114	108 (94.7)	5.32 (1.07)	2.4	4.41	5.33	6.09	7.0	
			Placebo	118	110 (93.2)	4.93 (1.15)	1.2	4.00	4.81	5.84	7.0	
		Week 28	Tezepelumab	114	110 (96.5)	5.31 (1.04)	3.3	4.44	5.34	6.03	7.0	
			Placebo	118	110 (93.2)	4.93 (1.20)	1.2	4.00	4.97	5.91	7.0	
		Week 32	Tezepelumab	114	111 (97.4)	5.37 (1.06)	2.6	4.44	5.53	6.13	7.0	
			Placebo	118	111 (94.1)	4.98 (1.14)	1.2	4.03	5.09	5.91	7.0	
		Week 36	Tezepelumab	114	111 (97.4)	5.36 (1.06)	3.2	4.59	5.38	6.22	7.0	
			Placebo	118	111 (94.1)	4.99 (1.13)	2.2	4.00	4.84	5.97	7.0	
		Week 40	Tezepelumab	114	111 (97.4)	5.38 (1.07)	2.6	4.53	5.28	6.25	7.0	
			Placebo	118	111 (94.1)	5.04 (1.12)	2.3	4.03	5.06	6.00	7.0	
		Week 44	Tezepelumab	114	111 (97.4)	5.39 (1.06)	2.8	4.50	5.38	6.25	7.0	
			Placebo	118	111 (94.1)	5.01 (1.16)	2.5	4.00	5.03	6.00	7.0	
		Week 48	Tezepelumab	114	111 (97.4)	5.39 (1.07)	2.9	4.47	5.38	6.25	7.0	
			Placebo	118	112 (94.9)	5.02 (1.11)	2.1	4.13	4.94	5.92	7.0	
		Week 52	Tezepelumab	114	111 (97.4)	5.37 (1.08)	2.8	4.47	5.31	6.25	7.0	
			Placebo	118	112 (94.9)	5.00 (1.11)	2.7	4.09	4.91	5.95	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	114	99 (86.8)	0.74 (0.97)	-3.7	0.09	0.66	1.44	3.3	0.18 [-0.10, 0.45]
			Placebo	118	103 (87.3)	0.58 (0.80)	-1.2	0.16	0.47	1.16	2.6	
		Week 8	Tezepelumab	114	101 (88.6)	0.91 (0.99)	-1.0	0.28	0.81	1.63	3.9	0.23 [-0.04, 0.51]
			Placebo	118	104 (88.1)	0.69 (0.90)	-1.4	0.16	0.58	1.22	3.1	
		Week 12	Tezepelumab	114	101 (88.6)	1.11 (1.01)	-2.1	0.53	1.06	1.84	4.2	0.26 [-0.02, 0.53]
			Placebo	118	104 (88.1)	0.85 (1.04)	-2.0	0.31	0.84	1.33	3.5	
		Week 16	Tezepelumab	114	101 (88.6)	1.07 (1.02)	-2.4	0.47	1.16	1.69	4.2	0.21 [-0.06, 0.49]
			Placebo	118	104 (88.1)	0.85 (1.05)	-3.2	0.33	0.78	1.42	3.8	
		Week 20	Tezepelumab	114	101 (88.6)	1.09 (1.02)	-1.2	0.38	0.97	1.78	4.2	0.21 [-0.06, 0.49]
			Placebo	118	104 (88.1)	0.87 (1.01)	-3.2	0.33	0.80	1.34	3.8	
		Week 24	Tezepelumab	114	101 (88.6)	1.13 (1.03)	-1.2	0.38	1.03	1.78	4.3	0.22 [-0.06, 0.49]
			Placebo	118	104 (88.1)	0.90 (1.07)	-3.2	0.31	0.91	1.52	3.7	
		Week 28	Tezepelumab	114	101 (88.6)	1.11 (1.01)	-1.3	0.31	0.91	1.88	4.3	0.19 [-0.09, 0.46]
			Placebo	118	104 (88.1)	0.91 (1.14)	-3.2	0.25	0.95	1.55	4.3	
		Week 32	Tezepelumab	114	101 (88.6)	1.16 (1.04)	-1.2	0.47	1.03	2.03	4.3	0.17 [-0.10, 0.44]
			Placebo	118	104 (88.1)	0.99 (1.03)	-3.2	0.44	0.83	1.53	3.6	
		Week 36	Tezepelumab	114	101 (88.6)	1.16 (1.10)	-1.3	0.41	0.94	2.06	4.3	0.17 [-0.11, 0.44]
			Placebo	118	104 (88.1)	0.98 (1.04)	-2.0	0.38	0.88	1.64	3.4	
		Week 40	Tezepelumab	114	101 (88.6)	1.17 (1.04)	-1.3	0.53	0.97	2.03	4.3	0.13 [-0.15, 0.40]
			Placebo	118	104 (88.1)	1.04 (1.08)	-2.0	0.36	1.00	1.67	4.3	
		Week 44	Tezepelumab	114	101 (88.6)	1.19 (1.04)	-1.1	0.53	1.03	1.94	4.3	0.18 [-0.09, 0.45]
			Placebo	118	104 (88.1)	1.00 (1.11)	-2.0	0.34	0.95	1.61	4.1	
		Week 48	Tezepelumab	114	101 (88.6)	1.20 (1.04)	-1.1	0.50	1.06	2.06	4.3	0.19 [-0.09, 0.46]
			Placebo	118	104 (88.1)	1.00 (1.05)	-2.0	0.28	0.95	1.66	3.5	
		Week 52	Tezepelumab	114	101 (88.6)	1.16 (1.04)	-1.2	0.44	1.06	2.06	4.3	0.16 [-0.11, 0.44]
			Placebo	118	104 (88.1)	0.99 (1.04)	-2.0	0.23	0.88	1.66	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	4.20 (0.75)	2.8	3.77	4.13	4.47	6.2	
			Placebo	20	16 (80.0)	4.31 (0.70)	3.2	3.88	4.14	4.70	5.8	
		Week 4	Tezepelumab	23	20 (87.0)	4.89 (0.88)	3.4	4.09	4.83	5.67	6.8	
			Placebo	20	17 (85.0)	4.36 (0.84)	3.3	3.63	4.16	5.13	5.8	
		Week 8	Tezepelumab	23	20 (87.0)	4.97 (0.92)	3.3	4.22	4.92	5.39	7.0	
			Placebo	20	17 (85.0)	4.57 (0.73)	3.3	4.00	4.47	5.09	5.8	
		Week 12	Tezepelumab	23	20 (87.0)	5.01 (0.93)	3.2	4.42	5.00	5.55	7.0	
			Placebo	20	17 (85.0)	4.40 (0.66)	3.7	3.91	4.19	4.69	6.1	
		Week 16	Tezepelumab	23	20 (87.0)	5.02 (0.90)	3.5	4.27	5.06	5.58	7.0	
			Placebo	20	17 (85.0)	4.54 (0.87)	3.3	3.94	4.25	5.03	6.1	
		Week 20	Tezepelumab	23	21 (91.3)	4.96 (0.89)	3.6	4.19	4.78	5.63	7.0	
			Placebo	20	17 (85.0)	4.54 (0.97)	2.4	4.00	4.44	5.03	6.6	
		Week 24	Tezepelumab	23	21 (91.3)	5.05 (0.90)	3.7	4.41	4.88	5.72	7.0	
			Placebo	20	17 (85.0)	4.58 (0.97)	2.4	3.88	4.78	5.19	6.2	
		Week 28	Tezepelumab	23	21 (91.3)	5.11 (0.83)	3.9	4.59	5.06	5.53	7.0	
			Placebo	20	18 (90.0)	4.68 (1.17)	2.2	3.91	4.56	5.59	6.8	
		Week 32	Tezepelumab	23	21 (91.3)	5.14 (0.80)	3.9	4.53	5.00	5.69	7.0	
			Placebo	20	18 (90.0)	4.73 (1.11)	2.7	4.03	4.44	5.56	6.9	
		Week 36	Tezepelumab	23	21 (91.3)	5.20 (0.75)	4.1	4.63	5.00	5.72	6.6	
			Placebo	20	18 (90.0)	4.84 (1.12)	3.0	4.16	4.44	5.69	6.9	
		Week 40	Tezepelumab	23	21 (91.3)	5.14 (0.86)	4.0	4.63	5.25	5.63	7.0	
			Placebo	20	18 (90.0)	4.68 (1.11)	2.5	3.88	4.59	5.41	6.9	
		Week 44	Tezepelumab	23	21 (91.3)	5.30 (0.88)	4.0	4.63	5.06	6.00	7.0	
			Placebo	20	18 (90.0)	4.76 (1.18)	2.8	3.91	4.61	5.69	6.9	
		Week 48	Tezepelumab	23	21 (91.3)	5.36 (0.86)	4.0	4.88	5.34	6.00	7.0	
			Placebo	20	18 (90.0)	4.87 (1.12)	3.2	4.00	4.63	6.06	6.8	
		Week 52	Tezepelumab	23	21 (91.3)	5.40 (0.86)	4.0	4.78	5.31	6.00	7.0	
			Placebo	20	18 (90.0)	4.73 (1.17)	2.7	3.97	4.22	5.72	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	23	18 (78.3)	0.77 (0.87)	-1.3	0.41	0.70	1.13	2.7	0.93 [0.22, 1.64]
			Placebo	20	16 (80.0)	0.10 (0.49)	-0.8	-0.28	0.19	0.45	0.9	
		Week 8	Tezepelumab	23	18 (78.3)	0.85 (0.90)	-0.8	0.19	0.72	1.56	3.0	0.76 [0.06, 1.45]
			Placebo	20	16 (80.0)	0.31 (0.46)	-0.4	-0.05	0.38	0.66	1.3	
		Week 12	Tezepelumab	23	18 (78.3)	0.85 (0.93)	-0.9	0.38	0.73	1.31	3.0	1.01 [0.29, 1.73]
			Placebo	20	16 (80.0)	0.12 (0.39)	-0.4	-0.22	0.20	0.38	0.9	
		Week 16	Tezepelumab	23	18 (78.3)	0.91 (0.88)	-0.6	0.28	0.72	1.59	3.0	0.93 [0.22, 1.64]
			Placebo	20	16 (80.0)	0.24 (0.47)	-0.5	-0.11	0.25	0.59	1.0	
		Week 20	Tezepelumab	23	18 (78.3)	0.80 (0.84)	-0.4	0.19	0.55	1.38	3.0	0.74 [0.05, 1.44]
			Placebo	20	16 (80.0)	0.26 (0.55)	-1.3	0.06	0.23	0.75	0.9	
		Week 24	Tezepelumab	23	18 (78.3)	0.96 (0.88)	-0.4	0.34	0.77	1.56	3.0	0.80 [0.10, 1.50]
			Placebo	20	16 (80.0)	0.30 (0.75)	-1.3	-0.23	0.20	0.78	2.1	
		Week 28	Tezepelumab	23	18 (78.3)	0.99 (0.91)	-0.6	0.34	0.88	1.44	3.0	0.88 [0.17, 1.59]
			Placebo	20	16 (80.0)	0.28 (0.69)	-1.5	-0.08	0.27	0.86	1.2	
		Week 32	Tezepelumab	23	18 (78.3)	0.98 (0.84)	-0.5	0.31	0.88	1.34	3.0	0.87 [0.17, 1.58]
			Placebo	20	16 (80.0)	0.32 (0.65)	-1.0	0.00	0.16	0.67	1.5	
		Week 36	Tezepelumab	23	18 (78.3)	1.01 (0.85)	-1.0	0.44	1.02	1.41	2.6	0.67 [-0.02, 1.36]
			Placebo	20	16 (80.0)	0.44 (0.85)	-0.7	0.03	0.25	0.73	3.0	
		Week 40	Tezepelumab	23	18 (78.3)	1.01 (0.94)	-0.8	0.31	1.00	1.38	3.0	0.83 [0.13, 1.53]
			Placebo	20	16 (80.0)	0.27 (0.81)	-1.2	-0.09	0.19	0.55	2.7	
		Week 44	Tezepelumab	23	18 (78.3)	1.13 (0.98)	-0.8	0.34	1.03	1.59	3.0	0.88 [0.17, 1.59]
			Placebo	20	16 (80.0)	0.32 (0.86)	-1.3	-0.08	0.16	0.55	2.7	
		Week 48	Tezepelumab	23	18 (78.3)	1.24 (0.99)	-0.8	0.69	1.19	1.81	3.0	0.86 [0.16, 1.57]
			Placebo	20	16 (80.0)	0.45 (0.83)	-0.5	-0.11	0.09	0.81	2.9	
		Week 52	Tezepelumab	23	18 (78.3)	1.21 (1.01)	-0.8	0.34	1.11	1.88	3.0	0.99 [0.28, 1.71]
			Placebo	20	16 (80.0)	0.31 (0.77)	-0.6	-0.14	0.06	0.66	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	105	94 (89.5)	4.26 (0.87)	2.2	3.75	4.30	4.75	6.8	
			Placebo	110	98 (89.1)	4.12 (0.86)	1.8	3.63	4.08	4.69	6.1	
		Week 4	Tezepelumab	105	96 (91.4)	4.92 (1.01)	3.0	4.13	4.89	5.66	7.0	
			Placebo	110	100 (90.9)	4.63 (1.01)	2.1	3.92	4.69	5.30	6.8	
		Week 8	Tezepelumab	105	97 (92.4)	5.10 (1.01)	2.8	4.34	5.00	5.91	7.0	
			Placebo	110	102 (92.7)	4.76 (1.05)	2.1	4.03	4.63	5.50	7.0	
		Week 12	Tezepelumab	105	97 (92.4)	5.26 (1.03)	3.1	4.38	5.22	6.09	7.0	
			Placebo	110	103 (93.6)	4.81 (1.06)	2.5	4.00	4.72	5.56	7.0	
		Week 16	Tezepelumab	105	97 (92.4)	5.22 (0.99)	3.5	4.38	5.09	6.00	7.0	
			Placebo	110	103 (93.6)	4.87 (1.06)	2.5	3.97	4.78	5.72	7.0	
		Week 20	Tezepelumab	105	98 (93.3)	5.21 (1.01)	3.5	4.31	5.14	6.06	7.0	
			Placebo	110	103 (93.6)	4.91 (1.05)	2.4	4.06	4.81	5.88	7.0	
		Week 24	Tezepelumab	105	98 (93.3)	5.23 (1.06)	2.4	4.38	5.11	6.00	7.0	
			Placebo	110	103 (93.6)	4.97 (1.09)	2.3	4.09	4.94	5.88	7.0	
		Week 28	Tezepelumab	105	99 (94.3)	5.23 (1.01)	3.3	4.34	5.16	6.03	7.0	
			Placebo	110	104 (94.5)	4.96 (1.13)	2.2	4.00	4.88	5.88	7.0	
		Week 32	Tezepelumab	105	100 (95.2)	5.30 (1.03)	2.6	4.45	5.34	6.00	7.0	
			Placebo	110	104 (94.5)	5.01 (1.11)	2.3	4.09	4.92	5.92	7.0	
		Week 36	Tezepelumab	105	100 (95.2)	5.32 (1.02)	3.2	4.56	5.19	6.14	7.0	
			Placebo	110	104 (94.5)	5.08 (1.11)	2.6	4.19	5.03	6.08	7.0	
		Week 40	Tezepelumab	105	100 (95.2)	5.32 (1.03)	3.2	4.47	5.25	6.06	7.0	
			Placebo	110	104 (94.5)	5.05 (1.12)	2.5	4.09	5.06	6.00	7.0	
		Week 44	Tezepelumab	105	100 (95.2)	5.35 (1.03)	3.0	4.48	5.17	6.22	7.0	
			Placebo	110	104 (94.5)	5.06 (1.17)	2.5	4.00	5.02	6.02	7.0	
		Week 48	Tezepelumab	105	100 (95.2)	5.36 (1.05)	2.9	4.47	5.33	6.20	7.0	
			Placebo	110	105 (95.5)	5.08 (1.12)	2.8	4.06	4.97	6.03	7.0	
		Week 52	Tezepelumab	105	100 (95.2)	5.36 (1.04)	2.9	4.47	5.31	6.22	7.0	
			Placebo	110	105 (95.5)	5.03 (1.13)	2.7	4.03	4.94	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	105	89 (84.8)	0.69 (0.85)	-1.3	0.09	0.66	1.25	3.3	0.20 [-0.09, 0.48]
			Placebo	110	98 (89.1)	0.53 (0.80)	-1.2	0.09	0.42	1.00	2.6	
		Week 8	Tezepelumab	105	90 (85.7)	0.84 (0.89)	-0.8	0.13	0.69	1.53	3.8	0.21 [-0.08, 0.49]
			Placebo	110	98 (89.1)	0.66 (0.84)	-1.0	0.16	0.56	1.09	3.1	
		Week 12	Tezepelumab	105	90 (85.7)	1.01 (0.94)	-0.9	0.38	0.89	1.69	4.0	0.29 [0.00, 0.58]
			Placebo	110	98 (89.1)	0.73 (0.97)	-2.0	0.19	0.64	1.22	3.4	
		Week 16	Tezepelumab	105	90 (85.7)	0.98 (0.87)	-0.8	0.34	0.81	1.59	3.4	0.22 [-0.07, 0.51]
			Placebo	110	98 (89.1)	0.79 (0.91)	-2.0	0.22	0.69	1.38	3.5	
		Week 20	Tezepelumab	105	90 (85.7)	0.98 (0.91)	-0.8	0.28	0.78	1.66	3.4	0.15 [-0.13, 0.44]
			Placebo	110	98 (89.1)	0.84 (0.88)	-1.3	0.25	0.77	1.22	3.8	
		Week 24	Tezepelumab	105	90 (85.7)	1.03 (0.94)	-1.1	0.31	0.95	1.72	3.4	0.14 [-0.14, 0.43]
			Placebo	110	98 (89.1)	0.89 (0.97)	-1.3	0.16	0.80	1.38	3.7	
		Week 28	Tezepelumab	105	90 (85.7)	1.01 (0.93)	-0.6	0.31	0.84	1.72	3.4	0.15 [-0.14, 0.44]
			Placebo	110	98 (89.1)	0.87 (0.99)	-1.5	0.19	0.81	1.44	4.3	
		Week 32	Tezepelumab	105	90 (85.7)	1.06 (0.95)	-0.7	0.34	1.03	1.78	3.4	0.15 [-0.14, 0.44]
			Placebo	110	98 (89.1)	0.92 (0.93)	-1.0	0.28	0.72	1.47	3.6	
		Week 36	Tezepelumab	105	90 (85.7)	1.08 (1.01)	-1.0	0.41	0.92	1.81	3.4	0.09 [-0.20, 0.37]
			Placebo	110	98 (89.1)	0.99 (0.97)	-0.8	0.31	0.75	1.63	3.4	
		Week 40	Tezepelumab	105	90 (85.7)	1.10 (0.97)	-0.8	0.44	0.95	1.84	3.4	0.13 [-0.15, 0.42]
			Placebo	110	98 (89.1)	0.97 (1.00)	-1.2	0.28	0.78	1.56	4.3	
		Week 44	Tezepelumab	105	90 (85.7)	1.10 (0.97)	-0.8	0.50	0.92	1.84	3.4	0.13 [-0.15, 0.42]
			Placebo	110	98 (89.1)	0.97 (1.03)	-1.3	0.28	0.83	1.50	4.1	
		Week 48	Tezepelumab	105	90 (85.7)	1.13 (0.97)	-0.8	0.44	1.00	2.06	3.4	0.15 [-0.14, 0.43]
			Placebo	110	98 (89.1)	0.99 (0.97)	-0.7	0.22	0.84	1.66	3.5	
		Week 52	Tezepelumab	105	90 (85.7)	1.11 (0.97)	-0.8	0.44	0.95	1.94	3.4	0.19 [-0.10, 0.47]
			Placebo	110	98 (89.1)	0.93 (0.98)	-0.7	0.22	0.80	1.50	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	32	29 (90.6)	3.99 (1.04)	1.5	3.22	4.28	4.56	6.1	
			Placebo	28	23 (82.1)	3.98 (0.94)	2.5	3.25	3.94	4.47	6.3	
		Week 4	Tezepelumab	32	30 (93.8)	4.90 (1.13)	1.4	4.13	5.02	5.69	6.6	
			Placebo	28	23 (82.1)	4.50 (0.78)	3.0	3.84	4.50	5.09	5.9	
		Week 8	Tezepelumab	32	31 (96.9)	5.12 (1.14)	2.7	4.03	5.22	6.09	6.7	
			Placebo	28	24 (85.7)	4.52 (1.00)	2.4	3.77	4.63	5.33	6.5	
		Week 12	Tezepelumab	32	31 (96.9)	5.34 (1.11)	2.8	4.50	5.25	6.47	6.9	
			Placebo	28	24 (85.7)	4.86 (0.98)	2.8	4.16	4.70	5.77	6.5	
		Week 16	Tezepelumab	32	31 (96.9)	5.32 (1.17)	2.6	4.38	5.59	6.09	7.0	
			Placebo	28	24 (85.7)	4.72 (1.32)	1.2	4.16	4.80	5.67	6.9	
		Week 20	Tezepelumab	32	31 (96.9)	5.31 (1.05)	3.2	4.31	5.59	6.13	7.0	
			Placebo	28	24 (85.7)	4.60 (1.27)	1.2	3.73	4.67	5.70	6.7	
		Week 24	Tezepelumab	32	31 (96.9)	5.39 (1.00)	3.5	4.47	5.59	6.13	7.0	
			Placebo	28	24 (85.7)	4.51 (1.24)	1.2	3.81	4.45	5.67	6.9	
		Week 28	Tezepelumab	32	32 (100.0)	5.44 (0.99)	3.6	4.61	5.64	6.06	7.0	
			Placebo	28	24 (85.7)	4.60 (1.44)	1.2	3.69	4.31	5.83	7.0	
		Week 32	Tezepelumab	32	32 (100.0)	5.43 (1.00)	3.6	4.61	5.70	6.11	7.0	
			Placebo	28	25 (89.3)	4.70 (1.23)	1.2	3.94	4.56	5.75	6.5	
		Week 36	Tezepelumab	32	32 (100.0)	5.39 (1.01)	3.4	4.70	5.61	6.20	7.0	
			Placebo	28	25 (89.3)	4.48 (1.07)	2.2	3.91	4.31	5.13	6.7	
		Week 40	Tezepelumab	32	32 (100.0)	5.39 (1.08)	2.6	4.67	5.52	6.11	7.0	
			Placebo	28	25 (89.3)	4.72 (1.13)	2.3	3.91	4.31	5.75	6.8	
		Week 44	Tezepelumab	32	32 (100.0)	5.47 (1.05)	2.8	4.81	5.72	6.14	7.0	
			Placebo	28	25 (89.3)	4.62 (1.06)	2.8	3.72	4.53	5.50	6.5	
		Week 48	Tezepelumab	32	32 (100.0)	5.47 (1.00)	3.5	4.78	5.72	6.19	7.0	
			Placebo	28	25 (89.3)	4.63 (1.00)	2.1	4.09	4.56	5.16	6.5	
		Week 52	Tezepelumab	32	32 (100.0)	5.41 (1.08)	2.8	4.73	5.48	6.27	7.0	
			Placebo	28	25 (89.3)	4.68 (1.03)	3.1	3.97	4.47	5.50	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	32	28 (87.5)	0.91 (1.24)	-3.7	0.53	1.05	1.52	3.0	0.43 [-0.14, 1.00]
			Placebo	28	21 (75.0)	0.46 (0.68)	-1.1	0.16	0.47	0.97	1.7	
		Week 8	Tezepelumab	32	29 (90.6)	1.08 (1.19)	-1.0	0.31	1.25	1.78	3.9	0.50 [-0.06, 1.06]
			Placebo	28	22 (78.6)	0.53 (0.98)	-1.4	-0.19	0.41	1.28	2.5	
		Week 12	Tezepelumab	32	29 (90.6)	1.28 (1.17)	-2.1	0.66	1.34	1.97	4.2	0.38 [-0.18, 0.94]
			Placebo	28	22 (78.6)	0.83 (1.17)	-1.7	0.22	0.81	1.59	3.5	
		Week 16	Tezepelumab	32	29 (90.6)	1.25 (1.30)	-2.4	0.63	1.31	1.84	4.2	0.41 [-0.15, 0.97]
			Placebo	28	22 (78.6)	0.69 (1.41)	-3.2	0.31	0.94	1.41	3.8	
		Week 20	Tezepelumab	32	29 (90.6)	1.26 (1.21)	-1.2	0.50	1.41	2.31	4.2	0.53 [-0.03, 1.09]
			Placebo	28	22 (78.6)	0.58 (1.36)	-3.2	0.44	0.83	1.09	3.2	
		Week 24	Tezepelumab	32	29 (90.6)	1.35 (1.19)	-1.2	0.53	1.34	2.28	4.3	0.66 [0.09, 1.23]
			Placebo	28	22 (78.6)	0.53 (1.34)	-3.2	0.13	0.77	1.13	2.8	
		Week 28	Tezepelumab	32	29 (90.6)	1.35 (1.15)	-1.3	0.63	1.31	2.34	4.3	0.53 [-0.03, 1.10]
			Placebo	28	22 (78.6)	0.64 (1.57)	-3.2	-0.31	0.84	1.41	4.0	
		Week 32	Tezepelumab	32	29 (90.6)	1.36 (1.17)	-1.2	0.66	1.34	2.19	4.3	0.45 [-0.11, 1.02]
			Placebo	28	22 (78.6)	0.79 (1.35)	-3.2	0.66	0.98	1.28	3.2	
		Week 36	Tezepelumab	32	29 (90.6)	1.31 (1.22)	-1.3	0.41	1.34	2.28	4.3	0.65 [0.08, 1.22]
			Placebo	28	22 (78.6)	0.52 (1.22)	-2.0	-0.19	0.92	1.44	2.3	
		Week 40	Tezepelumab	32	29 (90.6)	1.30 (1.17)	-1.3	0.63	1.09	2.03	4.3	0.39 [-0.17, 0.95]
			Placebo	28	22 (78.6)	0.79 (1.41)	-2.0	-0.16	0.84	1.88	3.8	
		Week 44	Tezepelumab	32	29 (90.6)	1.42 (1.17)	-1.1	0.59	1.41	2.06	4.3	0.64 [0.07, 1.20]
			Placebo	28	22 (78.6)	0.62 (1.36)	-2.0	-0.41	0.89	1.22	3.4	
		Week 48	Tezepelumab	32	29 (90.6)	1.43 (1.18)	-1.1	0.69	1.41	2.09	4.3	0.63 [0.06, 1.19]
			Placebo	28	22 (78.6)	0.66 (1.30)	-2.0	0.00	0.89	1.53	3.3	
		Week 52	Tezepelumab	32	29 (90.6)	1.35 (1.23)	-1.2	0.47	1.41	2.09	4.3	0.45 [-0.11, 1.02]
			Placebo	28	22 (78.6)	0.78 (1.29)	-2.0	0.00	0.89	1.53	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.20 (0.91)	1.5	3.72	4.28	4.69	6.8	
			Placebo	123	106 (86.2)	4.15 (0.86)	1.8	3.66	4.11	4.69	6.3	
		Week 4	Tezepelumab	128	117 (91.4)	4.88 (1.05)	1.4	4.06	4.91	5.66	7.0	
			Placebo	123	109 (88.6)	4.64 (0.98)	2.1	3.97	4.69	5.28	6.8	
		Week 8	Tezepelumab	128	119 (93.0)	5.08 (1.05)	2.7	4.19	5.03	5.91	7.0	
			Placebo	123	112 (91.1)	4.74 (1.02)	2.1	4.00	4.58	5.47	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.25 (1.05)	2.8	4.34	5.16	6.09	7.0	
			Placebo	123	113 (91.9)	4.79 (1.05)	2.5	4.00	4.63	5.56	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.22 (1.05)	2.6	4.38	5.13	6.06	7.0	
			Placebo	123	113 (91.9)	4.85 (1.10)	1.2	4.00	4.75	5.69	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.20 (1.03)	3.2	4.31	5.16	6.00	7.0	
			Placebo	123	113 (91.9)	4.86 (1.10)	1.2	4.06	4.78	5.75	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.24 (1.05)	2.4	4.36	5.13	6.02	7.0	
			Placebo	123	113 (91.9)	4.87 (1.15)	1.2	4.00	4.78	5.69	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.24 (1.01)	3.3	4.34	5.16	6.03	7.0	
			Placebo	123	114 (92.7)	4.84 (1.18)	1.2	3.97	4.70	5.78	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.29 (1.04)	2.6	4.44	5.34	6.00	7.0	
			Placebo	123	115 (93.5)	4.91 (1.15)	1.2	4.03	4.75	5.88	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.31 (1.03)	3.2	4.53	5.19	6.09	7.0	
			Placebo	123	115 (93.5)	4.97 (1.14)	2.2	4.00	4.75	6.00	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.30 (1.05)	2.6	4.47	5.25	6.06	7.0	
			Placebo	123	115 (93.5)	4.97 (1.12)	2.3	4.00	4.97	5.94	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.33 (1.05)	2.8	4.47	5.19	6.19	7.0	
			Placebo	123	115 (93.5)	4.97 (1.14)	2.5	4.00	4.88	5.88	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.35 (1.05)	2.9	4.47	5.28	6.25	7.0	
			Placebo	123	116 (94.3)	4.98 (1.11)	2.1	4.08	4.83	5.95	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.33 (1.05)	2.8	4.47	5.25	6.22	7.0	
			Placebo	123	116 (94.3)	4.95 (1.13)	2.7	4.00	4.81	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.70 (0.94)	-3.7	0.09	0.69	1.38	3.0	0.23 [-0.04, 0.50]
			Placebo	123	105 (85.4)	0.50 (0.79)	-1.2	0.09	0.44	0.97	2.6	
		Week 8	Tezepelumab	128	111 (86.7)	0.86 (0.94)	-1.0	0.13	0.75	1.56	3.9	0.27 [0.00, 0.54]
			Placebo	123	106 (86.2)	0.62 (0.84)	-1.4	0.16	0.55	1.03	3.1	
		Week 12	Tezepelumab	128	111 (86.7)	1.03 (0.97)	-2.1	0.50	0.97	1.75	4.2	0.37 [0.10, 0.64]
			Placebo	123	106 (86.2)	0.67 (0.97)	-2.0	0.13	0.61	1.22	3.3	
		Week 16	Tezepelumab	128	111 (86.7)	1.02 (0.98)	-2.4	0.34	0.91	1.69	4.2	0.29 [0.02, 0.56]
			Placebo	123	106 (86.2)	0.73 (0.97)	-3.2	0.22	0.73	1.38	3.2	
		Week 20	Tezepelumab	128	111 (86.7)	1.01 (0.97)	-1.2	0.28	0.81	1.69	4.2	0.26 [-0.01, 0.53]
			Placebo	123	106 (86.2)	0.76 (0.95)	-3.2	0.25	0.77	1.19	3.3	
		Week 24	Tezepelumab	128	111 (86.7)	1.07 (0.99)	-1.2	0.34	0.97	1.78	4.3	0.30 [0.03, 0.57]
			Placebo	123	106 (86.2)	0.77 (1.04)	-3.2	0.13	0.78	1.31	3.2	
		Week 28	Tezepelumab	128	111 (86.7)	1.05 (0.98)	-1.3	0.31	0.88	1.78	4.3	0.32 [0.05, 0.59]
			Placebo	123	106 (86.2)	0.72 (1.04)	-3.2	0.16	0.77	1.31	3.2	
		Week 32	Tezepelumab	128	111 (86.7)	1.10 (1.00)	-1.2	0.34	1.03	1.88	4.3	0.29 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.81 (0.99)	-3.2	0.25	0.72	1.41	3.4	
		Week 36	Tezepelumab	128	111 (86.7)	1.10 (1.05)	-1.3	0.34	0.94	1.91	4.3	0.23 [-0.04, 0.50]
			Placebo	123	106 (86.2)	0.86 (1.02)	-2.0	0.22	0.73	1.38	3.4	
		Week 40	Tezepelumab	128	111 (86.7)	1.10 (1.01)	-1.3	0.44	0.97	1.84	4.3	0.23 [-0.04, 0.49]
			Placebo	123	106 (86.2)	0.87 (1.03)	-2.0	0.25	0.78	1.50	3.6	
		Week 44	Tezepelumab	128	111 (86.7)	1.14 (1.01)	-1.1	0.50	1.03	1.88	4.3	0.28 [0.01, 0.55]
			Placebo	123	106 (86.2)	0.85 (1.03)	-2.0	0.22	0.83	1.38	3.5	
		Week 48	Tezepelumab	128	111 (86.7)	1.17 (1.02)	-1.1	0.44	1.06	2.06	4.3	0.30 [0.03, 0.56]
			Placebo	123	106 (86.2)	0.87 (1.01)	-2.0	0.16	0.83	1.50	3.5	
		Week 52	Tezepelumab	128	111 (86.7)	1.13 (1.02)	-1.2	0.44	1.03	2.00	4.3	0.29 [0.02, 0.56]
			Placebo	123	106 (86.2)	0.84 (0.99)	-2.0	0.16	0.80	1.41	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.72 (1.30)	2.2	2.22	4.38	4.56	4.6	
			Placebo	6	6 (100.0)	3.33 (0.55)	2.8	2.81	3.27	3.66	4.2	
		Week 4	Tezepelumab	3	3 (100.0)	5.71 (0.81)	5.0	5.00	5.53	6.59	6.6	
			Placebo	6	5 (83.3)	3.87 (0.93)	2.5	3.72	3.81	4.38	5.0	
		Week 8	Tezepelumab	3	3 (100.0)	5.89 (0.82)	5.0	5.03	5.97	6.66	6.7	
			Placebo	6	5 (83.3)	3.83 (1.34)	2.3	3.09	3.41	4.63	5.7	
		Week 12	Tezepelumab	3	3 (100.0)	5.82 (0.91)	4.8	4.78	6.22	6.47	6.5	
			Placebo	6	5 (83.3)	4.30 (1.18)	3.0	3.47	4.16	5.00	5.9	
		Week 16	Tezepelumab	3	3 (100.0)	5.21 (0.84)	4.3	4.25	5.59	5.78	5.8	
			Placebo	6	5 (83.3)	3.71 (1.24)	3.0	3.00	3.25	3.38	5.9	
		Week 20	Tezepelumab	3	3 (100.0)	5.83 (0.31)	5.6	5.63	5.69	6.19	6.2	
			Placebo	6	5 (83.3)	4.13 (1.09)	3.0	3.72	3.78	4.25	5.9	
		Week 24	Tezepelumab	3	3 (100.0)	5.90 (0.25)	5.6	5.63	5.94	6.13	6.1	
			Placebo	6	5 (83.3)	4.51 (0.84)	3.8	3.97	4.41	4.53	5.9	
		Week 28	Tezepelumab	3	3 (100.0)	5.99 (0.63)	5.6	5.63	5.63	6.72	6.7	
			Placebo	6	5 (83.3)	4.32 (1.05)	3.3	3.63	3.97	4.81	5.9	
		Week 32	Tezepelumab	3	3 (100.0)	5.56 (0.20)	5.3	5.34	5.63	5.72	5.7	
			Placebo	6	5 (83.3)	4.66 (0.86)	3.9	3.97	4.28	5.19	5.9	
		Week 36	Tezepelumab	3	3 (100.0)	5.53 (0.71)	4.8	4.78	5.63	6.19	6.2	
			Placebo	6	5 (83.3)	4.74 (0.75)	4.0	4.22	4.78	4.81	5.9	
		Week 40	Tezepelumab	3	3 (100.0)	5.73 (0.48)	5.3	5.31	5.63	6.25	6.3	
			Placebo	6	5 (83.3)	4.36 (0.92)	3.6	3.88	3.97	4.47	5.9	
		Week 44	Tezepelumab	3	3 (100.0)	5.66 (0.36)	5.3	5.31	5.63	6.03	6.0	
			Placebo	6	5 (83.3)	5.02 (1.38)	3.6	3.66	5.03	6.28	6.5	
		Week 48	Tezepelumab	3	3 (100.0)	5.80 (0.21)	5.6	5.63	5.75	6.03	6.0	
			Placebo	6	5 (83.3)	5.18 (1.41)	3.6	3.78	5.59	6.44	6.5	
		Week 52	Tezepelumab	3	3 (100.0)	5.80 (0.21)	5.6	5.63	5.75	6.03	6.0	
			Placebo	6	5 (83.3)	5.29 (1.50)	3.5	4.09	5.47	6.44	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.99 (1.34)	0.6	0.63	2.03	3.31	3.3	1.55 [-0.13, 3.23]
			Placebo	6	5 (83.3)	0.43 (0.79)	-0.3	0.06	0.16	0.53	1.7	
		Week 8	Tezepelumab	3	3 (100.0)	2.17 (1.55)	0.7	0.66	2.09	3.75	3.8	1.49 [-0.17, 3.15]
			Placebo	6	5 (83.3)	0.39 (0.97)	-0.5	-0.25	-0.19	1.38	1.5	
		Week 12	Tezepelumab	3	3 (100.0)	2.10 (1.81)	0.4	0.41	1.91	4.00	4.0	1.06 [-0.49, 2.61]
			Placebo	6	5 (83.3)	0.86 (0.68)	0.2	0.22	0.88	1.34	1.7	
		Week 16	Tezepelumab	3	3 (100.0)	1.49 (1.77)	-0.1	-0.13	1.22	3.38	3.4	0.98 [-0.55, 2.52]
			Placebo	6	5 (83.3)	0.26 (0.88)	-0.4	-0.28	-0.25	0.56	1.7	
		Week 20	Tezepelumab	3	3 (100.0)	2.11 (1.13)	1.3	1.31	1.63	3.41	3.4	1.63 [-0.07, 3.34]
			Placebo	6	5 (83.3)	0.69 (0.71)	-0.3	0.44	0.59	0.97	1.7	
		Week 24	Tezepelumab	3	3 (100.0)	2.18 (1.06)	1.6	1.56	1.56	3.41	3.4	1.42 [-0.22, 3.06]
			Placebo	6	5 (83.3)	1.07 (0.59)	0.5	0.72	0.75	1.69	1.7	
		Week 28	Tezepelumab	3	3 (100.0)	2.27 (1.08)	1.3	1.25	2.16	3.41	3.4	1.38 [-0.25, 3.01]
			Placebo	6	5 (83.3)	0.88 (0.97)	-0.4	0.34	0.72	1.69	2.0	
		Week 32	Tezepelumab	3	3 (100.0)	1.84 (1.38)	0.8	0.78	1.34	3.41	3.4	0.62 [-0.86, 2.09]
			Placebo	6	5 (83.3)	1.21 (0.79)	0.6	0.66	0.72	1.69	2.4	
		Week 36	Tezepelumab	3	3 (100.0)	1.81 (1.51)	0.4	0.41	1.63	3.41	3.4	0.51 [-0.95, 1.97]
			Placebo	6	5 (83.3)	1.29 (0.62)	0.6	0.72	1.50	1.69	2.0	
		Week 40	Tezepelumab	3	3 (100.0)	2.01 (1.33)	0.8	0.75	1.88	3.41	3.4	1.11 [-0.45, 2.67]
			Placebo	6	5 (83.3)	0.92 (0.75)	-0.1	0.59	0.72	1.66	1.7	
		Week 44	Tezepelumab	3	3 (100.0)	1.94 (1.35)	0.8	0.75	1.66	3.41	3.4	0.27 [-1.17, 1.71]
			Placebo	6	5 (83.3)	1.58 (1.37)	0.0	0.34	2.06	2.22	3.3	
		Week 48	Tezepelumab	3	3 (100.0)	2.08 (1.17)	1.2	1.19	1.66	3.41	3.4	0.25 [-1.18, 1.69]
			Placebo	6	5 (83.3)	1.74 (1.45)	-0.1	0.50	2.22	2.78	3.3	
		Week 52	Tezepelumab	3	3 (100.0)	2.08 (1.17)	1.2	1.19	1.66	3.41	3.4	0.16 [-1.27, 1.60]
			Placebo	6	5 (83.3)	1.85 (1.55)	-0.2	0.81	2.22	2.66	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	4.39 (0.93)	3.2	3.80	4.50	4.98	5.4	
			Placebo	6	6 (100.0)	4.38 (0.88)	2.7	4.28	4.53	5.06	5.2	
		Week 4	Tezepelumab	5	5 (100.0)	5.28 (0.77)	4.4	4.75	5.03	6.06	6.1	
			Placebo	6	6 (100.0)	4.96 (0.31)	4.5	4.69	5.03	5.25	5.3	
		Week 8	Tezepelumab	5	5 (100.0)	5.61 (0.57)	5.1	5.22	5.34	5.91	6.5	
			Placebo	6	6 (100.0)	5.06 (0.57)	4.3	4.75	5.02	5.22	6.0	
		Week 12	Tezepelumab	5	5 (100.0)	5.92 (0.74)	5.3	5.44	5.50	6.47	6.9	
			Placebo	6	6 (100.0)	5.56 (0.42)	5.1	5.22	5.44	6.00	6.1	
		Week 16	Tezepelumab	5	5 (100.0)	5.94 (0.60)	5.4	5.59	5.72	6.03	6.9	
			Placebo	6	6 (100.0)	5.55 (0.48)	5.0	5.09	5.58	5.88	6.2	
		Week 20	Tezepelumab	5	5 (100.0)	5.75 (0.98)	4.3	5.59	5.72	6.19	7.0	
			Placebo	6	6 (100.0)	5.22 (0.96)	3.7	5.00	5.11	5.97	6.5	
		Week 24	Tezepelumab	5	5 (100.0)	5.96 (0.68)	5.0	5.91	5.91	6.03	6.9	
			Placebo	6	6 (100.0)	5.40 (0.95)	3.9	4.81	5.50	6.28	6.4	
		Week 28	Tezepelumab	5	5 (100.0)	6.11 (0.51)	5.8	5.84	5.88	6.03	7.0	
			Placebo	6	6 (100.0)	6.07 (0.92)	4.9	5.25	6.16	6.97	7.0	
		Week 32	Tezepelumab	5	5 (100.0)	6.26 (0.49)	5.8	5.91	6.13	6.53	7.0	
			Placebo	6	6 (100.0)	5.81 (0.57)	5.3	5.31	5.73	6.31	6.5	
		Week 36	Tezepelumab	5	5 (100.0)	6.08 (0.81)	4.8	5.94	6.22	6.41	7.0	
			Placebo	6	6 (100.0)	5.35 (1.23)	3.3	4.81	5.48	6.06	6.9	
		Week 40	Tezepelumab	5	5 (100.0)	6.18 (0.60)	5.4	5.94	5.97	6.53	7.0	
			Placebo	6	6 (100.0)	5.61 (1.10)	4.3	4.91	5.30	6.88	7.0	
		Week 44	Tezepelumab	5	5 (100.0)	6.36 (0.46)	5.8	6.00	6.41	6.53	7.0	
			Placebo	6	6 (100.0)	5.26 (1.43)	3.5	4.00	5.13	6.81	7.0	
		Week 48	Tezepelumab	5	5 (100.0)	5.92 (0.89)	4.5	5.97	6.06	6.09	7.0	
			Placebo	6	6 (100.0)	5.24 (0.91)	4.0	4.78	5.23	5.47	6.8	
		Week 52	Tezepelumab	5	5 (100.0)	6.05 (0.95)	4.5	6.06	6.09	6.63	7.0	
			Placebo	6	6 (100.0)	5.14 (0.72)	4.0	4.78	5.23	5.47	6.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	1.02 (0.56)	0.5	0.56	0.97	1.48	1.7	0.63 [-0.67, 1.93]
			Placebo	6	6 (100.0)	0.58 (0.78)	-0.1	0.03	0.30	0.97	2.0	
		Week 8	Tezepelumab	5	4 (80.0)	1.28 (0.82)	0.5	0.58	1.30	1.98	2.0	0.71 [-0.60, 2.02]
			Placebo	6	6 (100.0)	0.68 (0.87)	0.0	0.16	0.33	0.88	2.3	
		Week 12	Tezepelumab	5	4 (80.0)	1.65 (0.77)	0.9	1.00	1.58	2.30	2.5	0.48 [-0.81, 1.76]
			Placebo	6	6 (100.0)	1.18 (1.10)	0.5	0.72	0.80	0.84	3.4	
		Week 16	Tezepelumab	5	4 (80.0)	1.68 (0.94)	0.6	0.89	1.80	2.47	2.5	0.46 [-0.83, 1.74]
			Placebo	6	6 (100.0)	1.17 (1.20)	0.3	0.50	0.64	1.41	3.5	
		Week 20	Tezepelumab	5	4 (80.0)	1.37 (1.36)	-0.3	0.25	1.61	2.48	2.5	0.36 [-0.92, 1.63]
			Placebo	6	6 (100.0)	0.84 (1.54)	-0.8	0.13	0.58	0.81	3.8	
		Week 24	Tezepelumab	5	4 (80.0)	1.59 (1.21)	0.5	0.55	1.56	2.63	2.8	0.41 [-0.87, 1.70]
			Placebo	6	6 (100.0)	1.02 (1.45)	-0.6	0.41	0.73	1.13	3.7	
		Week 28	Tezepelumab	5	4 (80.0)	1.78 (1.02)	0.6	0.92	1.89	2.64	2.7	0.07 [-1.20, 1.33]
			Placebo	6	6 (100.0)	1.69 (1.47)	0.2	0.63	1.44	2.19	4.3	
		Week 32	Tezepelumab	5	4 (80.0)	1.80 (0.93)	0.7	1.03	1.94	2.58	2.6	0.35 [-0.93, 1.62]
			Placebo	6	6 (100.0)	1.43 (1.16)	0.3	0.72	1.17	1.63	3.6	
		Week 36	Tezepelumab	5	4 (80.0)	1.60 (1.26)	0.3	0.53	1.69	2.67	2.8	0.44 [-0.84, 1.73]
			Placebo	6	6 (100.0)	0.97 (1.51)	-1.2	0.31	0.77	1.78	3.3	
		Week 40	Tezepelumab	5	4 (80.0)	1.70 (1.14)	0.6	0.72	1.72	2.67	2.8	0.31 [-0.96, 1.59]
			Placebo	6	6 (100.0)	1.23 (1.66)	-0.2	-0.16	0.86	1.72	4.3	
		Week 44	Tezepelumab	5	4 (80.0)	1.92 (1.24)	0.4	0.94	2.00	2.91	3.3	0.64 [-0.67, 1.94]
			Placebo	6	6 (100.0)	0.88 (1.84)	-1.0	-0.28	0.30	1.84	4.1	
		Week 48	Tezepelumab	5	4 (80.0)	1.52 (1.43)	-0.1	0.31	1.61	2.72	2.9	0.52 [-0.77, 1.81]
			Placebo	6	6 (100.0)	0.86 (1.16)	-0.5	0.06	0.63	1.59	2.8	
		Week 52	Tezepelumab	5	4 (80.0)	1.52 (1.43)	-0.1	0.31	1.61	2.72	2.9	0.61 [-0.69, 1.91]
			Placebo	6	6 (100.0)	0.76 (1.11)	-0.5	0.06	0.63	0.97	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	4.19	4.2	4.19	4.19	4.19	4.2	
			Placebo	3	3 (100.0)	2.91 (0.22)	2.7	2.66	3.00	3.06	3.1	
		Week 4	Tezepelumab	1	1 (100.0)	4.41	4.4	4.41	4.41	4.41	4.4	
			Placebo	3	3 (100.0)	3.83 (0.58)	3.3	3.25	3.84	4.41	4.4	
		Week 8	Tezepelumab	1	1 (100.0)	3.94	3.9	3.94	3.94	3.94	3.9	
			Placebo	3	3 (100.0)	4.45 (1.77)	2.4	2.41	5.44	5.50	5.5	
		Week 12	Tezepelumab	1	1 (100.0)	4.31	4.3	4.31	4.31	4.31	4.3	
			Placebo	3	3 (100.0)	5.40 (1.13)	4.3	4.25	5.44	6.50	6.5	
		Week 16	Tezepelumab	1	1 (100.0)	4.63	4.6	4.63	4.63	4.63	4.6	
			Placebo	3	3 (100.0)	5.05 (1.48)	4.1	4.06	4.34	6.75	6.8	
		Week 20	Tezepelumab	1	1 (100.0)	4.72	4.7	4.72	4.72	4.72	4.7	
			Placebo	3	3 (100.0)	4.93 (1.26)	3.8	3.75	4.78	6.25	6.3	
		Week 24	Tezepelumab	1	1 (100.0)	4.28	4.3	4.28	4.28	4.28	4.3	
			Placebo	3	3 (100.0)	4.92 (1.07)	3.8	3.75	5.16	5.84	5.8	
		Week 28	Tezepelumab	1	1 (100.0)	4.50	4.5	4.50	4.50	4.50	4.5	
			Placebo	3	3 (100.0)	5.50 (1.64)	3.8	3.75	5.75	7.00	7.0	
		Week 32	Tezepelumab	1	1 (100.0)	4.59	4.6	4.59	4.59	4.59	4.6	
			Placebo	3	3 (100.0)	5.17 (1.26)	3.8	3.75	5.59	6.16	6.2	
		Week 36	Tezepelumab	1	1 (100.0)	4.94	4.9	4.94	4.94	4.94	4.9	
			Placebo	3	3 (100.0)	4.53 (0.80)	3.8	3.75	4.50	5.34	5.3	
		Week 40	Tezepelumab	1	1 (100.0)	5.28	5.3	5.28	5.28	5.28	5.3	
			Placebo	3	3 (100.0)	5.45 (1.54)	3.8	3.75	5.84	6.75	6.8	
		Week 44	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	3	3 (100.0)	4.61 (1.55)	3.7	3.69	3.75	6.41	6.4	
		Week 48	Tezepelumab	1	1 (100.0)	5.34	5.3	5.34	5.34	5.34	5.3	
			Placebo	3	3 (100.0)	4.70 (0.90)	3.8	3.75	4.81	5.53	5.5	
		Week 52	Tezepelumab	1	1 (100.0)	5.34	5.3	5.34	5.34	5.34	5.3	
			Placebo	3	3 (100.0)	4.70 (0.90)	3.8	3.75	4.81	5.53	5.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	0.22	0.2	0.22	0.22	0.22	0.2	NE
			Placebo	3	3 (100.0)	0.93 (0.59)	0.3	0.25	1.19	1.34	1.3	
		Week 8	Tezepelumab	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	NE
			Placebo	3	3 (100.0)	1.54 (1.55)	-0.3	-0.25	2.38	2.50	2.5	
		Week 12	Tezepelumab	1	1 (100.0)	0.13	0.1	0.13	0.13	0.13	0.1	NE
			Placebo	3	3 (100.0)	2.49 (0.96)	1.6	1.59	2.38	3.50	3.5	
		Week 16	Tezepelumab	1	1 (100.0)	0.44	0.4	0.44	0.44	0.44	0.4	NE
			Placebo	3	3 (100.0)	2.15 (1.39)	1.3	1.28	1.41	3.75	3.8	
		Week 20	Tezepelumab	1	1 (100.0)	0.53	0.5	0.53	0.53	0.53	0.5	NE
			Placebo	3	3 (100.0)	2.02 (1.07)	1.1	1.09	1.78	3.19	3.2	
		Week 24	Tezepelumab	1	1 (100.0)	0.09	0.1	0.09	0.09	0.09	0.1	NE
			Placebo	3	3 (100.0)	2.01 (0.88)	1.1	1.09	2.09	2.84	2.8	
		Week 28	Tezepelumab	1	1 (100.0)	0.31	0.3	0.31	0.31	0.31	0.3	NE
			Placebo	3	3 (100.0)	2.59 (1.46)	1.1	1.09	2.69	4.00	4.0	
		Week 32	Tezepelumab	1	1 (100.0)	0.41	0.4	0.41	0.41	0.41	0.4	NE
			Placebo	3	3 (100.0)	2.26 (1.06)	1.1	1.09	2.53	3.16	3.2	
		Week 36	Tezepelumab	1	1 (100.0)	0.75	0.8	0.75	0.75	0.75	0.8	NE
			Placebo	3	3 (100.0)	1.63 (0.65)	1.1	1.09	1.44	2.34	2.3	
		Week 40	Tezepelumab	1	1 (100.0)	1.09	1.1	1.09	1.09	1.09	1.1	NE
			Placebo	3	3 (100.0)	2.54 (1.34)	1.1	1.09	2.78	3.75	3.8	
		Week 44	Tezepelumab	1	1 (100.0)	0.81	0.8	0.81	0.81	0.81	0.8	NE
			Placebo	3	3 (100.0)	1.71 (1.49)	0.6	0.63	1.09	3.41	3.4	
		Week 48	Tezepelumab	1	1 (100.0)	1.16	1.2	1.16	1.16	1.16	1.2	NE
			Placebo	3	3 (100.0)	1.79 (0.69)	1.1	1.09	1.81	2.47	2.5	
		Week 52	Tezepelumab	1	1 (100.0)	1.16	1.2	1.16	1.16	1.16	1.2	NE
			Placebo	3	3 (100.0)	1.79 (0.69)	1.1	1.09	1.81	2.47	2.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	78	73 (93.6)	4.17 (0.90)	1.5	3.72	4.19	4.63	6.8	
			Placebo	80	68 (85.0)	4.32 (0.82)	1.9	3.84	4.25	4.86	6.1	
		Week 4	Tezepelumab	78	74 (94.9)	4.77 (1.04)	1.4	3.94	4.70	5.66	6.8	
			Placebo	80	69 (86.3)	4.74 (0.98)	2.1	4.06	4.72	5.47	6.8	
		Week 8	Tezepelumab	78	75 (96.2)	5.03 (1.02)	2.7	4.19	5.06	5.84	7.0	
			Placebo	80	71 (88.8)	4.83 (1.01)	2.1	4.06	4.72	5.63	7.0	
		Week 12	Tezepelumab	78	75 (96.2)	5.18 (1.04)	2.8	4.31	5.16	6.06	7.0	
			Placebo	80	72 (90.0)	4.90 (1.06)	2.5	4.06	4.70	5.69	7.0	
		Week 16	Tezepelumab	78	75 (96.2)	5.12 (1.04)	2.6	4.25	5.09	6.03	7.0	
			Placebo	80	72 (90.0)	4.94 (1.11)	1.2	4.14	4.84	5.70	7.0	
		Week 20	Tezepelumab	78	76 (97.4)	5.15 (1.02)	3.2	4.25	5.14	6.00	7.0	
			Placebo	80	72 (90.0)	4.98 (1.07)	1.2	4.23	4.88	5.89	7.0	
		Week 24	Tezepelumab	78	76 (97.4)	5.19 (1.01)	3.5	4.27	5.09	6.00	7.0	
			Placebo	80	72 (90.0)	4.93 (1.15)	1.2	4.05	4.94	5.84	7.0	
		Week 28	Tezepelumab	78	77 (98.7)	5.15 (1.01)	3.3	4.25	5.16	6.00	7.0	
			Placebo	80	73 (91.3)	4.98 (1.20)	1.2	4.00	5.06	6.00	7.0	
		Week 32	Tezepelumab	78	77 (98.7)	5.19 (1.07)	2.6	4.25	5.22	5.94	7.0	
			Placebo	80	74 (92.5)	5.02 (1.14)	1.2	4.28	4.92	5.94	7.0	
		Week 36	Tezepelumab	78	77 (98.7)	5.21 (1.05)	3.2	4.41	5.06	6.00	7.0	
			Placebo	80	74 (92.5)	5.10 (1.13)	2.2	4.19	5.05	6.09	7.0	
		Week 40	Tezepelumab	78	77 (98.7)	5.26 (1.06)	2.6	4.38	5.25	6.00	7.0	
			Placebo	80	74 (92.5)	5.08 (1.08)	2.3	4.19	5.09	6.00	7.0	
		Week 44	Tezepelumab	78	77 (98.7)	5.26 (1.07)	2.8	4.47	5.16	6.06	7.0	
			Placebo	80	74 (92.5)	5.11 (1.12)	2.6	4.16	5.08	6.00	7.0	
		Week 48	Tezepelumab	78	77 (98.7)	5.27 (1.08)	2.9	4.47	5.28	6.16	7.0	
			Placebo	80	75 (93.8)	5.12 (1.11)	2.1	4.28	4.97	6.03	7.0	
		Week 52	Tezepelumab	78	77 (98.7)	5.24 (1.07)	2.8	4.47	5.22	6.16	7.0	
			Placebo	80	75 (93.8)	5.12 (1.10)	2.8	4.13	5.06	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	78	71 (91.0)	0.63 (0.96)	-3.7	0.06	0.63	1.41	2.4	0.20 [-0.13, 0.54]
			Placebo	80	67 (83.8)	0.45 (0.77)	-1.2	0.06	0.41	0.94	2.3	
		Week 8	Tezepelumab	78	72 (92.3)	0.84 (0.88)	-1.0	0.28	0.84	1.53	2.7	0.36 [0.02, 0.69]
			Placebo	80	68 (85.0)	0.55 (0.79)	-1.0	0.05	0.44	0.97	2.7	
		Week 12	Tezepelumab	78	72 (92.3)	0.99 (0.95)	-2.1	0.34	1.08	1.67	3.0	0.38 [0.04, 0.71]
			Placebo	80	68 (85.0)	0.63 (0.95)	-2.0	0.00	0.55	1.14	2.9	
		Week 16	Tezepelumab	78	72 (92.3)	0.94 (0.93)	-2.4	0.34	0.84	1.64	2.8	0.29 [-0.04, 0.63]
			Placebo	80	68 (85.0)	0.66 (0.97)	-3.2	0.22	0.72	1.27	2.8	
		Week 20	Tezepelumab	78	72 (92.3)	0.97 (0.93)	-1.2	0.23	0.88	1.64	2.7	0.29 [-0.05, 0.62]
			Placebo	80	68 (85.0)	0.71 (0.87)	-3.2	0.25	0.73	1.09	2.8	
		Week 24	Tezepelumab	78	72 (92.3)	1.01 (0.95)	-1.2	0.34	0.95	1.70	3.0	0.37 [0.04, 0.71]
			Placebo	80	68 (85.0)	0.65 (1.00)	-3.2	0.06	0.58	1.28	3.1	
		Week 28	Tezepelumab	78	72 (92.3)	0.99 (0.94)	-1.3	0.31	0.89	1.75	3.0	0.32 [-0.01, 0.65]
			Placebo	80	68 (85.0)	0.68 (1.03)	-3.2	0.13	0.61	1.36	3.1	
		Week 32	Tezepelumab	78	72 (92.3)	1.02 (0.98)	-1.2	0.33	1.03	1.75	2.8	0.29 [-0.05, 0.62]
			Placebo	80	68 (85.0)	0.75 (0.91)	-3.2	0.23	0.72	1.36	2.7	
		Week 36	Tezepelumab	78	72 (92.3)	1.03 (1.03)	-1.3	0.30	0.94	1.83	3.3	0.21 [-0.12, 0.54]
			Placebo	80	68 (85.0)	0.82 (0.98)	-1.7	0.23	0.63	1.47	3.0	
		Week 40	Tezepelumab	78	72 (92.3)	1.11 (0.98)	-1.3	0.47	1.05	1.89	2.9	0.32 [-0.01, 0.65]
			Placebo	80	68 (85.0)	0.80 (0.95)	-1.6	0.23	0.70	1.53	2.9	
		Week 44	Tezepelumab	78	72 (92.3)	1.10 (1.01)	-1.1	0.44	1.11	1.86	2.8	0.29 [-0.05, 0.62]
			Placebo	80	68 (85.0)	0.82 (0.96)	-1.3	0.16	0.80	1.33	3.1	
		Week 48	Tezepelumab	78	72 (92.3)	1.12 (1.02)	-1.1	0.44	1.06	2.06	2.9	0.29 [-0.04, 0.63]
			Placebo	80	68 (85.0)	0.83 (0.95)	-1.8	0.16	0.83	1.50	3.3	
		Week 52	Tezepelumab	78	72 (92.3)	1.08 (1.01)	-1.2	0.42	1.06	1.94	3.0	0.24 [-0.09, 0.58]
			Placebo	80	68 (85.0)	0.85 (0.90)	-0.9	0.19	0.80	1.41	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	3.95 (1.33)	2.0	2.66	4.38	4.56	5.7	
			Placebo	9	8 (88.9)	3.50 (0.75)	2.8	2.94	3.27	3.94	4.9	
		Week 4	Tezepelumab	10	8 (80.0)	5.81 (0.66)	5.0	5.36	5.64	6.28	6.9	
			Placebo	9	7 (77.8)	4.43 (1.15)	2.5	3.81	4.41	4.97	6.3	
		Week 8	Tezepelumab	10	9 (90.0)	5.84 (1.01)	3.6	5.81	5.97	6.59	7.0	
			Placebo	9	7 (77.8)	4.80 (1.58)	2.3	3.09	5.44	5.72	6.8	
		Week 12	Tezepelumab	10	9 (90.0)	5.98 (0.88)	4.3	5.94	6.22	6.47	7.0	
			Placebo	9	7 (77.8)	4.90 (1.41)	3.0	3.47	5.44	5.91	6.9	
		Week 16	Tezepelumab	10	9 (90.0)	5.74 (0.93)	4.3	5.59	5.91	6.09	6.9	
			Placebo	9	7 (77.8)	4.59 (1.56)	3.0	3.00	4.34	5.91	6.8	
		Week 20	Tezepelumab	10	9 (90.0)	5.92 (0.75)	4.3	5.69	5.94	6.19	6.9	
			Placebo	9	7 (77.8)	5.04 (1.50)	3.0	3.72	5.78	6.25	6.8	
		Week 24	Tezepelumab	10	9 (90.0)	5.91 (0.80)	4.3	5.63	5.94	6.13	7.0	
			Placebo	9	7 (77.8)	5.18 (1.17)	3.8	3.97	5.16	6.09	6.9	
		Week 28	Tezepelumab	10	10 (100.0)	6.02 (0.83)	4.3	5.63	5.92	6.72	7.0	
			Placebo	9	7 (77.8)	5.25 (1.16)	3.6	3.97	5.75	5.91	6.8	
		Week 32	Tezepelumab	10	10 (100.0)	5.80 (0.71)	4.3	5.63	5.80	5.94	7.0	
			Placebo	9	7 (77.8)	5.23 (0.97)	3.9	3.97	5.50	5.91	6.5	
		Week 36	Tezepelumab	10	10 (100.0)	5.77 (0.83)	4.3	5.34	5.78	6.44	7.0	
			Placebo	9	7 (77.8)	5.13 (0.82)	4.0	4.50	4.81	5.91	6.1	
		Week 40	Tezepelumab	10	10 (100.0)	5.92 (0.80)	4.3	5.31	6.00	6.63	7.0	
			Placebo	9	7 (77.8)	5.19 (1.04)	3.9	3.97	5.84	6.00	6.3	
		Week 44	Tezepelumab	10	10 (100.0)	5.91 (0.78)	4.3	5.53	5.98	6.22	7.0	
			Placebo	9	7 (77.8)	5.36 (1.26)	3.6	3.69	6.13	6.28	6.5	
		Week 48	Tezepelumab	10	10 (100.0)	5.98 (0.75)	4.3	5.69	5.98	6.28	7.0	
			Placebo	9	7 (77.8)	5.69 (0.92)	3.8	5.53	5.81	6.44	6.5	
		Week 52	Tezepelumab	10	10 (100.0)	6.06 (0.78)	4.3	5.75	5.98	6.78	7.0	
			Placebo	9	7 (77.8)	5.79 (0.92)	4.1	5.47	5.81	6.44	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	1.61 (1.33)	-0.5	0.66	1.59	2.80	3.3	0.64 [-0.41, 1.68]
			Placebo	9	7 (77.8)	0.83 (1.09)	-0.3	-0.19	0.53	1.72	2.6	
		Week 8	Tezepelumab	10	9 (90.0)	1.89 (1.35)	0.1	0.81	1.63	2.69	3.9	0.52 [-0.48, 1.53]
			Placebo	9	7 (77.8)	1.20 (1.30)	-0.5	-0.19	1.38	2.38	3.1	
		Week 12	Tezepelumab	10	9 (90.0)	2.03 (1.41)	0.3	0.94	1.91	2.69	4.2	0.56 [-0.45, 1.56]
			Placebo	9	7 (77.8)	1.29 (1.18)	0.2	0.22	0.88	2.38	3.3	
		Week 16	Tezepelumab	10	9 (90.0)	1.78 (1.44)	-0.1	0.81	1.47	2.59	4.2	0.59 [-0.42, 1.60]
			Placebo	9	7 (77.8)	0.99 (1.20)	-0.3	-0.25	0.78	1.69	3.2	
		Week 20	Tezepelumab	10	9 (90.0)	1.97 (1.30)	0.0	1.31	1.63	2.56	4.2	0.40 [-0.60, 1.40]
			Placebo	9	7 (77.8)	1.44 (1.33)	-0.3	0.44	0.97	3.19	3.2	
		Week 24	Tezepelumab	10	9 (90.0)	1.96 (1.39)	0.1	1.47	1.56	2.69	4.3	0.32 [-0.68, 1.31]
			Placebo	9	7 (77.8)	1.58 (0.93)	0.5	0.72	1.69	2.09	3.2	
		Week 28	Tezepelumab	10	9 (90.0)	2.00 (1.38)	0.2	1.25	2.16	2.69	4.3	0.28 [-0.71, 1.27]
			Placebo	9	7 (77.8)	1.65 (1.05)	0.3	0.72	1.69	2.69	3.2	
		Week 32	Tezepelumab	10	9 (90.0)	1.75 (1.38)	0.2	0.78	1.47	2.34	4.3	0.10 [-0.89, 1.09]
			Placebo	9	7 (77.8)	1.63 (0.99)	0.6	0.66	1.69	2.53	2.9	
		Week 36	Tezepelumab	10	9 (90.0)	1.74 (1.54)	-0.3	0.41	1.63	2.34	4.3	0.17 [-0.82, 1.16]
			Placebo	9	7 (77.8)	1.53 (0.61)	0.7	0.88	1.50	2.00	2.5	
		Week 40	Tezepelumab	10	9 (90.0)	1.89 (1.44)	-0.4	0.78	1.88	2.44	4.3	0.24 [-0.75, 1.23]
			Placebo	9	7 (77.8)	1.59 (0.87)	0.6	0.72	1.66	2.63	2.8	
		Week 44	Tezepelumab	10	9 (90.0)	1.93 (1.40)	-0.2	0.88	1.66	2.69	4.3	0.13 [-0.86, 1.12]
			Placebo	9	7 (77.8)	1.76 (1.07)	0.3	0.63	2.06	2.63	3.3	
		Week 48	Tezepelumab	10	9 (90.0)	2.00 (1.32)	0.0	1.19	1.66	2.66	4.3	-0.07 [-1.06, 0.92]
			Placebo	9	7 (77.8)	2.08 (1.01)	0.5	0.88	2.47	2.78	3.3	
		Week 52	Tezepelumab	10	9 (90.0)	2.03 (1.28)	0.2	1.19	1.66	2.66	4.3	-0.13 [-1.12, 0.86]
			Placebo	9	7 (77.8)	2.18 (1.04)	0.8	0.88	2.47	2.66	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	4.39 (0.93)	3.2	3.80	4.50	4.98	5.4	
			Placebo	6	6 (100.0)	4.38 (0.88)	2.7	4.28	4.53	5.06	5.2	
		Week 4	Tezepelumab	5	5 (100.0)	5.28 (0.77)	4.4	4.75	5.03	6.06	6.1	
			Placebo	6	6 (100.0)	4.96 (0.31)	4.5	4.69	5.03	5.25	5.3	
		Week 8	Tezepelumab	5	5 (100.0)	5.61 (0.57)	5.1	5.22	5.34	5.91	6.5	
			Placebo	6	6 (100.0)	5.06 (0.57)	4.3	4.75	5.02	5.22	6.0	
		Week 12	Tezepelumab	5	5 (100.0)	5.92 (0.74)	5.3	5.44	5.50	6.47	6.9	
			Placebo	6	6 (100.0)	5.56 (0.42)	5.1	5.22	5.44	6.00	6.1	
		Week 16	Tezepelumab	5	5 (100.0)	5.94 (0.60)	5.4	5.59	5.72	6.03	6.9	
			Placebo	6	6 (100.0)	5.55 (0.48)	5.0	5.09	5.58	5.88	6.2	
		Week 20	Tezepelumab	5	5 (100.0)	5.75 (0.98)	4.3	5.59	5.72	6.19	7.0	
			Placebo	6	6 (100.0)	5.22 (0.96)	3.7	5.00	5.11	5.97	6.5	
		Week 24	Tezepelumab	5	5 (100.0)	5.96 (0.68)	5.0	5.91	5.91	6.03	6.9	
			Placebo	6	6 (100.0)	5.40 (0.95)	3.9	4.81	5.50	6.28	6.4	
		Week 28	Tezepelumab	5	5 (100.0)	6.11 (0.51)	5.8	5.84	5.88	6.03	7.0	
			Placebo	6	6 (100.0)	6.07 (0.92)	4.9	5.25	6.16	6.97	7.0	
		Week 32	Tezepelumab	5	5 (100.0)	6.26 (0.49)	5.8	5.91	6.13	6.53	7.0	
			Placebo	6	6 (100.0)	5.81 (0.57)	5.3	5.31	5.73	6.31	6.5	
		Week 36	Tezepelumab	5	5 (100.0)	6.08 (0.81)	4.8	5.94	6.22	6.41	7.0	
			Placebo	6	6 (100.0)	5.35 (1.23)	3.3	4.81	5.48	6.06	6.9	
		Week 40	Tezepelumab	5	5 (100.0)	6.18 (0.60)	5.4	5.94	5.97	6.53	7.0	
			Placebo	6	6 (100.0)	5.61 (1.10)	4.3	4.91	5.30	6.88	7.0	
		Week 44	Tezepelumab	5	5 (100.0)	6.36 (0.46)	5.8	6.00	6.41	6.53	7.0	
			Placebo	6	6 (100.0)	5.26 (1.43)	3.5	4.00	5.13	6.81	7.0	
		Week 48	Tezepelumab	5	5 (100.0)	5.92 (0.89)	4.5	5.97	6.06	6.09	7.0	
			Placebo	6	6 (100.0)	5.24 (0.91)	4.0	4.78	5.23	5.47	6.8	
		Week 52	Tezepelumab	5	5 (100.0)	6.05 (0.95)	4.5	6.06	6.09	6.63	7.0	
			Placebo	6	6 (100.0)	5.14 (0.72)	4.0	4.78	5.23	5.47	6.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	1.02 (0.56)	0.5	0.56	0.97	1.48	1.7	0.63 [-0.67, 1.93]
			Placebo	6	6 (100.0)	0.58 (0.78)	-0.1	0.03	0.30	0.97	2.0	
		Week 8	Tezepelumab	5	4 (80.0)	1.28 (0.82)	0.5	0.58	1.30	1.98	2.0	0.71 [-0.60, 2.02]
			Placebo	6	6 (100.0)	0.68 (0.87)	0.0	0.16	0.33	0.88	2.3	
		Week 12	Tezepelumab	5	4 (80.0)	1.65 (0.77)	0.9	1.00	1.58	2.30	2.5	0.48 [-0.81, 1.76]
			Placebo	6	6 (100.0)	1.18 (1.10)	0.5	0.72	0.80	0.84	3.4	
		Week 16	Tezepelumab	5	4 (80.0)	1.68 (0.94)	0.6	0.89	1.80	2.47	2.5	0.46 [-0.83, 1.74]
			Placebo	6	6 (100.0)	1.17 (1.20)	0.3	0.50	0.64	1.41	3.5	
		Week 20	Tezepelumab	5	4 (80.0)	1.37 (1.36)	-0.3	0.25	1.61	2.48	2.5	0.36 [-0.92, 1.63]
			Placebo	6	6 (100.0)	0.84 (1.54)	-0.8	0.13	0.58	0.81	3.8	
		Week 24	Tezepelumab	5	4 (80.0)	1.59 (1.21)	0.5	0.55	1.56	2.63	2.8	0.41 [-0.87, 1.70]
			Placebo	6	6 (100.0)	1.02 (1.45)	-0.6	0.41	0.73	1.13	3.7	
		Week 28	Tezepelumab	5	4 (80.0)	1.78 (1.02)	0.6	0.92	1.89	2.64	2.7	0.07 [-1.20, 1.33]
			Placebo	6	6 (100.0)	1.69 (1.47)	0.2	0.63	1.44	2.19	4.3	
		Week 32	Tezepelumab	5	4 (80.0)	1.80 (0.93)	0.7	1.03	1.94	2.58	2.6	0.35 [-0.93, 1.62]
			Placebo	6	6 (100.0)	1.43 (1.16)	0.3	0.72	1.17	1.63	3.6	
		Week 36	Tezepelumab	5	4 (80.0)	1.60 (1.26)	0.3	0.53	1.69	2.67	2.8	0.44 [-0.84, 1.73]
			Placebo	6	6 (100.0)	0.97 (1.51)	-1.2	0.31	0.77	1.78	3.3	
		Week 40	Tezepelumab	5	4 (80.0)	1.70 (1.14)	0.6	0.72	1.72	2.67	2.8	0.31 [-0.96, 1.59]
			Placebo	6	6 (100.0)	1.23 (1.66)	-0.2	-0.16	0.86	1.72	4.3	
		Week 44	Tezepelumab	5	4 (80.0)	1.92 (1.24)	0.4	0.94	2.00	2.91	3.3	0.64 [-0.67, 1.94]
			Placebo	6	6 (100.0)	0.88 (1.84)	-1.0	-0.28	0.30	1.84	4.1	
		Week 48	Tezepelumab	5	4 (80.0)	1.52 (1.43)	-0.1	0.31	1.61	2.72	2.9	0.52 [-0.77, 1.81]
			Placebo	6	6 (100.0)	0.86 (1.16)	-0.5	0.06	0.63	1.59	2.8	
		Week 52	Tezepelumab	5	4 (80.0)	1.52 (1.43)	-0.1	0.31	1.61	2.72	2.9	0.61 [-0.69, 1.91]
			Placebo	6	6 (100.0)	0.76 (1.11)	-0.5	0.06	0.63	0.97	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	44	37 (84.1)	4.29 (0.84)	2.3	3.75	4.31	4.81	6.3	
			Placebo	43	39 (90.7)	3.76 (0.85)	1.8	3.00	3.88	4.34	6.3	
		Week 4	Tezepelumab	44	39 (88.6)	4.95 (1.05)	3.2	4.03	4.97	5.75	7.0	
			Placebo	43	41 (95.3)	4.35 (0.95)	2.4	3.72	4.16	5.06	6.8	
		Week 8	Tezepelumab	44	39 (88.6)	5.02 (1.08)	2.8	4.34	4.88	5.91	7.0	
			Placebo	43	42 (97.7)	4.44 (1.01)	2.4	3.81	4.34	5.25	6.9	
		Week 12	Tezepelumab	44	39 (88.6)	5.24 (1.05)	3.1	4.31	4.97	6.00	7.0	
			Placebo	43	42 (97.7)	4.58 (0.97)	2.7	3.97	4.30	5.09	6.8	
		Week 16	Tezepelumab	44	39 (88.6)	5.28 (1.03)	3.7	4.47	5.09	6.00	7.0	
			Placebo	43	42 (97.7)	4.61 (1.06)	2.5	3.97	4.44	5.59	6.8	
		Week 20	Tezepelumab	44	39 (88.6)	5.17 (1.02)	3.6	4.31	4.81	5.88	7.0	
			Placebo	43	42 (97.7)	4.54 (1.07)	2.4	3.94	4.23	5.09	6.8	
		Week 24	Tezepelumab	44	39 (88.6)	5.20 (1.13)	2.4	4.47	5.00	6.03	7.0	
			Placebo	43	42 (97.7)	4.67 (1.09)	2.4	3.97	4.41	5.59	6.8	
		Week 28	Tezepelumab	44	39 (88.6)	5.24 (0.98)	3.7	4.53	4.97	6.03	7.0	
			Placebo	43	42 (97.7)	4.53 (1.12)	2.2	3.78	4.27	5.31	7.0	
		Week 32	Tezepelumab	44	40 (90.9)	5.37 (0.97)	3.8	4.55	5.31	6.05	7.0	
			Placebo	43	42 (97.7)	4.65 (1.14)	2.7	4.00	4.19	5.72	6.9	
		Week 36	Tezepelumab	44	40 (90.9)	5.39 (0.96)	3.8	4.63	5.34	6.08	7.0	
			Placebo	43	42 (97.7)	4.65 (1.12)	2.6	3.97	4.28	5.44	6.9	
		Week 40	Tezepelumab	44	40 (90.9)	5.24 (1.03)	3.2	4.58	5.00	5.81	7.0	
			Placebo	43	42 (97.7)	4.72 (1.19)	2.5	3.88	4.38	5.63	7.0	
		Week 44	Tezepelumab	44	40 (90.9)	5.35 (0.99)	3.9	4.58	5.13	5.92	7.0	
			Placebo	43	42 (97.7)	4.64 (1.14)	2.5	3.88	4.38	5.75	7.0	
		Week 48	Tezepelumab	44	40 (90.9)	5.39 (0.99)	4.0	4.48	5.17	6.19	7.0	
			Placebo	43	42 (97.7)	4.62 (1.06)	2.9	3.97	4.27	5.34	7.0	
		Week 52	Tezepelumab	44	40 (90.9)	5.37 (0.99)	4.0	4.48	5.09	6.16	7.0	
			Placebo	43	42 (97.7)	4.52 (1.10)	2.7	3.75	4.22	5.34	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	44	34 (77.3)	0.73 (0.78)	-0.8	0.31	0.70	1.09	2.7	0.23 [-0.23, 0.69]
			Placebo	43	39 (90.7)	0.55 (0.74)	-1.1	0.13	0.50	1.16	2.6	
		Week 8	Tezepelumab	44	34 (77.3)	0.71 (0.93)	-0.8	0.00	0.48	1.41	3.0	0.02 [-0.44, 0.48]
			Placebo	43	39 (90.7)	0.70 (0.90)	-1.4	0.16	0.69	1.16	2.7	
		Week 12	Tezepelumab	44	34 (77.3)	0.93 (0.89)	-0.8	0.50	0.70	1.69	3.0	0.14 [-0.32, 0.60]
			Placebo	43	39 (90.7)	0.79 (1.03)	-1.7	0.25	0.88	1.34	3.5	
		Week 16	Tezepelumab	44	34 (77.3)	1.00 (0.93)	-1.0	0.53	0.95	1.66	3.0	0.15 [-0.31, 0.61]
			Placebo	43	39 (90.7)	0.86 (1.02)	-2.0	0.16	0.97	1.44	3.8	
		Week 20	Tezepelumab	44	34 (77.3)	0.92 (0.91)	-0.8	0.31	0.67	1.75	3.0	0.12 [-0.34, 0.58]
			Placebo	43	39 (90.7)	0.81 (1.02)	-2.0	0.25	0.78	1.34	3.3	
		Week 24	Tezepelumab	44	34 (77.3)	1.02 (0.92)	-1.1	0.31	0.91	1.63	3.0	0.06 [-0.40, 0.52]
			Placebo	43	39 (90.7)	0.95 (1.06)	-2.0	0.47	0.91	1.56	3.2	
		Week 28	Tezepelumab	44	34 (77.3)	0.99 (0.89)	-0.6	0.31	0.69	1.69	3.0	0.19 [-0.27, 0.65]
			Placebo	43	39 (90.7)	0.80 (1.13)	-2.0	0.16	0.84	1.25	4.0	
		Week 32	Tezepelumab	44	34 (77.3)	1.14 (0.94)	-0.7	0.47	0.89	2.06	3.0	0.19 [-0.27, 0.65]
			Placebo	43	39 (90.7)	0.94 (1.12)	-2.0	0.34	1.00	1.41	3.4	
		Week 36	Tezepelumab	44	34 (77.3)	1.14 (0.95)	-0.5	0.44	0.88	1.72	3.3	0.20 [-0.26, 0.66]
			Placebo	43	39 (90.7)	0.94 (1.09)	-2.0	0.22	1.00	1.38	3.4	
		Week 40	Tezepelumab	44	34 (77.3)	0.97 (0.90)	-0.7	0.31	0.83	1.38	3.0	-0.04 [-0.50, 0.42]
			Placebo	43	39 (90.7)	1.01 (1.21)	-2.0	0.28	1.00	1.50	3.8	
		Week 44	Tezepelumab	44	34 (77.3)	1.07 (0.84)	-0.8	0.53	0.83	1.59	3.0	0.15 [-0.31, 0.61]
			Placebo	43	39 (90.7)	0.92 (1.19)	-2.0	0.09	0.88	1.47	3.5	
		Week 48	Tezepelumab	44	34 (77.3)	1.13 (0.85)	-0.7	0.53	0.83	1.81	3.0	0.24 [-0.23, 0.70]
			Placebo	43	39 (90.7)	0.90 (1.10)	-2.0	0.09	0.81	1.56	3.5	
		Week 52	Tezepelumab	44	34 (77.3)	1.08 (0.91)	-0.8	0.44	0.78	1.88	3.0	0.28 [-0.18, 0.75]
			Placebo	43	39 (90.7)	0.79 (1.12)	-2.0	-0.06	0.72	1.41	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Placebo	1	1 (100.0)	1.91	1.9	1.91	1.91	1.91	1.9	
		Week 4	Placebo	1	1 (100.0)	2.06	2.1	2.06	2.06	2.06	2.1	
		Week 8	Placebo	1	1 (100.0)	2.09	2.1	2.09	2.09	2.09	2.1	
		Week 12	Placebo	1	1 (100.0)	2.53	2.5	2.53	2.53	2.53	2.5	
		Week 16	Placebo	1	1 (100.0)	3.22	3.2	3.22	3.22	3.22	3.2	
		Week 20	Placebo	1	1 (100.0)	2.94	2.9	2.94	2.94	2.94	2.9	
		Week 24	Placebo	1	1 (100.0)	2.31	2.3	2.31	2.31	2.31	2.3	
		Week 28	Placebo	1	1 (100.0)	3.50	3.5	3.50	3.50	3.50	3.5	
		Week 32	Placebo	1	1 (100.0)	2.31	2.3	2.31	2.31	2.31	2.3	
		Week 36	Placebo	1	1 (100.0)	3.03	3.0	3.03	3.03	3.03	3.0	
		Week 40	Placebo	1	1 (100.0)	2.91	2.9	2.91	2.91	2.91	2.9	
		Week 44	Placebo	1	1 (100.0)	2.63	2.6	2.63	2.63	2.63	2.6	
		Week 48	Placebo	1	1 (100.0)	2.75	2.8	2.75	2.75	2.75	2.8	
		Week 52	Placebo	1	1 (100.0)	2.75	2.8	2.75	2.75	2.75	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 4	Placebo	1	1 (100.0)	0.16	0.2	0.16	0.16	0.16	0.2	
		Week 8	Placebo	1	1 (100.0)	0.19	0.2	0.19	0.19	0.19	0.2	
		Week 12	Placebo	1	1 (100.0)	0.63	0.6	0.63	0.63	0.63	0.6	
		Week 16	Placebo	1	1 (100.0)	1.31	1.3	1.31	1.31	1.31	1.3	
		Week 20	Placebo	1	1 (100.0)	1.03	1.0	1.03	1.03	1.03	1.0	
		Week 24	Placebo	1	1 (100.0)	0.41	0.4	0.41	0.41	0.41	0.4	
		Week 28	Placebo	1	1 (100.0)	1.59	1.6	1.59	1.59	1.59	1.6	
		Week 32	Placebo	1	1 (100.0)	0.41	0.4	0.41	0.41	0.41	0.4	
		Week 36	Placebo	1	1 (100.0)	1.13	1.1	1.13	1.13	1.13	1.1	
		Week 40	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 44	Placebo	1	1 (100.0)	0.72	0.7	0.72	0.72	0.72	0.7	
		Week 48	Placebo	1	1 (100.0)	0.84	0.8	0.84	0.84	0.84	0.8	
		Week 52	Placebo	1	1 (100.0)	0.84	0.8	0.84	0.84	0.84	0.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	39	35 (89.7)	4.43 (1.02)	2.2	3.72	4.47	5.13	6.8	
			Placebo	43	38 (88.4)	4.14 (1.00)	1.8	3.41	4.31	4.94	5.8	
		Week 4	Tezepelumab	39	36 (92.3)	5.40 (0.97)	3.7	4.50	5.58	6.23	7.0	
			Placebo	43	40 (93.0)	4.73 (0.95)	2.4	4.25	4.75	5.33	6.7	
		Week 8	Tezepelumab	39	37 (94.9)	5.56 (0.92)	3.3	4.88	5.63	6.25	7.0	
			Placebo	43	40 (93.0)	4.91 (1.10)	2.4	4.09	4.97	5.77	7.0	
		Week 12	Tezepelumab	39	37 (94.9)	5.86 (0.87)	4.1	5.25	5.97	6.59	7.0	
			Placebo	43	40 (93.0)	5.03 (1.08)	2.7	4.14	5.23	5.89	7.0	
		Week 16	Tezepelumab	39	37 (94.9)	5.73 (0.89)	4.0	5.25	5.66	6.47	7.0	
			Placebo	43	40 (93.0)	5.11 (1.17)	2.5	4.08	5.34	5.91	7.0	
		Week 20	Tezepelumab	39	37 (94.9)	5.73 (0.91)	4.1	5.06	5.88	6.41	7.0	
			Placebo	43	40 (93.0)	5.07 (1.25)	2.4	4.13	5.08	5.98	7.0	
		Week 24	Tezepelumab	39	37 (94.9)	5.83 (0.85)	4.3	5.22	5.94	6.50	7.0	
			Placebo	43	40 (93.0)	5.10 (1.23)	2.4	3.98	5.52	6.06	7.0	
		Week 28	Tezepelumab	39	37 (94.9)	5.79 (0.88)	3.8	5.22	5.84	6.66	7.0	
			Placebo	43	41 (95.3)	5.16 (1.31)	2.2	4.00	5.59	6.00	7.0	
		Week 32	Tezepelumab	39	38 (97.4)	5.82 (0.92)	2.6	5.34	5.89	6.38	7.0	
			Placebo	43	41 (95.3)	5.21 (1.24)	2.7	4.13	5.50	6.19	7.0	
		Week 36	Tezepelumab	39	38 (97.4)	5.92 (0.89)	3.2	5.44	5.94	6.69	7.0	
			Placebo	43	41 (95.3)	5.18 (1.29)	2.6	4.16	5.44	6.16	7.0	
		Week 40	Tezepelumab	39	38 (97.4)	5.87 (0.91)	4.0	5.13	5.94	6.59	7.0	
			Placebo	43	41 (95.3)	5.23 (1.27)	2.5	4.28	5.38	6.13	7.0	
		Week 44	Tezepelumab	39	38 (97.4)	5.92 (0.85)	4.3	5.25	5.95	6.72	7.0	
			Placebo	43	41 (95.3)	5.14 (1.29)	2.5	4.00	5.31	6.00	7.0	
		Week 48	Tezepelumab	39	38 (97.4)	5.95 (0.86)	4.1	5.22	6.08	6.72	7.0	
			Placebo	43	42 (97.7)	5.14 (1.17)	2.9	4.19	5.17	5.97	7.0	
		Week 52	Tezepelumab	39	38 (97.4)	5.89 (0.85)	4.1	5.09	6.00	6.63	7.0	
			Placebo	43	42 (97.7)	5.14 (1.16)	2.7	4.09	5.30	5.97	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	39	33 (84.6)	1.08 (0.84)	-0.6	0.59	0.88	1.72	3.3	0.63 [0.16, 1.11]
			Placebo	43	38 (88.4)	0.59 (0.71)	-0.9	0.16	0.47	1.00	2.0	
		Week 8	Tezepelumab	39	34 (87.2)	1.14 (0.96)	-0.5	0.44	1.31	1.78	3.8	0.36 [-0.10, 0.83]
			Placebo	43	38 (88.4)	0.81 (0.82)	-1.0	0.22	0.83	1.16	2.6	
		Week 12	Tezepelumab	39	34 (87.2)	1.42 (0.98)	-0.8	0.75	1.27	2.06	4.0	0.53 [0.05, 1.00]
			Placebo	43	38 (88.4)	0.90 (0.96)	-2.0	0.50	0.94	1.25	3.4	
		Week 16	Tezepelumab	39	34 (87.2)	1.28 (1.01)	-1.0	0.63	1.38	2.00	3.4	0.29 [-0.17, 0.76]
			Placebo	43	38 (88.4)	0.99 (0.95)	-2.0	0.59	0.95	1.50	3.5	
		Week 20	Tezepelumab	39	34 (87.2)	1.28 (1.01)	-0.8	0.50	1.34	2.09	3.4	0.31 [-0.16, 0.77]
			Placebo	43	38 (88.4)	0.97 (1.03)	-1.3	0.41	0.89	1.66	3.8	
		Week 24	Tezepelumab	39	34 (87.2)	1.39 (0.97)	-0.6	0.66	1.31	2.09	3.4	0.38 [-0.09, 0.85]
			Placebo	43	38 (88.4)	1.02 (0.99)	-1.3	0.41	1.09	1.59	3.7	
		Week 28	Tezepelumab	39	34 (87.2)	1.35 (0.99)	-0.6	0.63	1.36	2.06	3.4	0.30 [-0.17, 0.76]
			Placebo	43	38 (88.4)	1.04 (1.07)	-1.5	0.56	1.02	1.66	4.3	
		Week 32	Tezepelumab	39	34 (87.2)	1.35 (0.97)	-0.7	0.66	1.31	2.22	3.4	0.27 [-0.20, 0.73]
			Placebo	43	38 (88.4)	1.09 (0.95)	-1.0	0.56	1.03	1.50	3.6	
		Week 36	Tezepelumab	39	34 (87.2)	1.45 (1.08)	-0.8	0.66	1.41	2.50	3.4	0.37 [-0.09, 0.84]
			Placebo	43	38 (88.4)	1.06 (1.00)	-1.2	0.41	1.05	1.69	3.4	
		Week 40	Tezepelumab	39	34 (87.2)	1.37 (1.01)	-0.7	0.66	1.13	2.16	3.4	0.24 [-0.22, 0.71]
			Placebo	43	38 (88.4)	1.12 (1.07)	-1.2	0.34	1.03	1.88	4.3	
		Week 44	Tezepelumab	39	34 (87.2)	1.42 (0.98)	-0.8	0.66	1.30	2.06	3.4	0.40 [-0.06, 0.87]
			Placebo	43	38 (88.4)	1.00 (1.06)	-1.1	0.34	1.13	1.56	4.1	
		Week 48	Tezepelumab	39	34 (87.2)	1.50 (0.97)	-0.7	0.69	1.41	2.25	3.4	0.53 [0.06, 1.01]
			Placebo	43	38 (88.4)	0.99 (0.94)	-0.7	0.34	1.02	1.66	3.5	
		Week 52	Tezepelumab	39	34 (87.2)	1.39 (1.05)	-0.8	0.66	1.22	2.16	3.4	0.40 [-0.07, 0.86]
			Placebo	43	38 (88.4)	1.00 (0.93)	-0.7	0.41	0.98	1.53	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	45	41 (91.1)	4.12 (1.03)	1.5	3.59	4.28	4.63	6.3	
			Placebo	47	43 (91.5)	4.26 (0.78)	2.5	3.88	4.13	4.44	6.3	
		Week 4	Tezepelumab	45	43 (95.6)	4.94 (0.98)	3.2	4.13	5.09	5.69	6.9	
			Placebo	47	43 (91.5)	4.60 (0.96)	2.8	3.84	4.44	5.31	6.4	
		Week 8	Tezepelumab	45	43 (95.6)	5.07 (1.13)	2.7	4.09	5.16	5.84	7.0	
			Placebo	47	45 (95.7)	4.75 (0.91)	3.1	4.03	4.59	5.28	6.8	
		Week 12	Tezepelumab	45	43 (95.6)	5.20 (1.19)	2.8	4.09	5.28	6.19	7.0	
			Placebo	47	45 (95.7)	4.77 (1.00)	2.8	4.00	4.59	5.56	7.0	
		Week 16	Tezepelumab	45	43 (95.6)	5.23 (1.14)	2.6	4.16	5.16	6.31	7.0	
			Placebo	47	45 (95.7)	4.73 (1.14)	1.2	3.97	4.66	5.63	7.0	
		Week 20	Tezepelumab	45	43 (95.6)	5.22 (1.10)	3.6	4.13	5.16	6.22	7.0	
			Placebo	47	45 (95.7)	4.77 (1.13)	1.2	4.00	4.66	5.44	7.0	
		Week 24	Tezepelumab	45	43 (95.6)	5.19 (1.16)	2.4	4.13	5.03	6.31	7.0	
			Placebo	47	45 (95.7)	4.76 (1.16)	1.2	4.00	4.69	5.47	7.0	
		Week 28	Tezepelumab	45	44 (97.8)	5.33 (1.03)	3.9	4.47	5.17	6.22	7.0	
			Placebo	47	45 (95.7)	4.78 (1.21)	1.2	3.97	4.47	5.66	7.0	
		Week 32	Tezepelumab	45	44 (97.8)	5.38 (1.10)	3.6	4.53	5.34	6.30	7.0	
			Placebo	47	45 (95.7)	4.80 (1.09)	1.2	4.00	4.81	5.81	7.0	
		Week 36	Tezepelumab	45	44 (97.8)	5.31 (1.03)	3.4	4.50	5.17	6.17	7.0	
			Placebo	47	45 (95.7)	4.79 (1.06)	2.2	4.00	4.44	5.72	7.0	
		Week 40	Tezepelumab	45	44 (97.8)	5.39 (1.09)	2.6	4.63	5.27	6.33	7.0	
			Placebo	47	45 (95.7)	4.82 (1.00)	2.3	4.00	4.91	5.59	7.0	
		Week 44	Tezepelumab	45	44 (97.8)	5.39 (1.09)	2.8	4.55	5.33	6.28	7.0	
			Placebo	47	45 (95.7)	4.92 (1.05)	2.8	4.00	4.88	5.72	7.0	
		Week 48	Tezepelumab	45	44 (97.8)	5.36 (1.06)	3.5	4.39	5.31	6.31	7.0	
			Placebo	47	45 (95.7)	4.91 (1.10)	2.1	4.00	4.78	5.75	7.0	
		Week 52	Tezepelumab	45	44 (97.8)	5.38 (1.12)	2.8	4.39	5.17	6.47	7.0	
			Placebo	47	45 (95.7)	4.93 (1.09)	3.3	4.00	4.78	5.66	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	45	40 (88.9)	0.82 (0.95)	-1.3	0.36	0.78	1.44	3.0	0.49 [0.05, 0.93]
			Placebo	47	42 (89.4)	0.38 (0.85)	-1.2	-0.09	0.25	0.97	2.6	
		Week 8	Tezepelumab	45	40 (88.9)	0.89 (1.03)	-0.9	0.23	0.72	1.61	3.9	0.40 [-0.04, 0.83]
			Placebo	47	43 (91.5)	0.52 (0.86)	-1.4	0.03	0.41	0.94	3.1	
		Week 12	Tezepelumab	45	40 (88.9)	1.04 (1.08)	-0.9	0.50	0.89	1.72	4.2	0.50 [0.06, 0.93]
			Placebo	47	43 (91.5)	0.53 (0.97)	-1.7	-0.06	0.38	1.25	3.3	
		Week 16	Tezepelumab	45	40 (88.9)	1.07 (1.03)	-0.9	0.41	0.98	1.78	4.2	0.56 [0.12, 0.99]
			Placebo	47	43 (91.5)	0.49 (1.08)	-3.2	-0.09	0.50	1.25	3.2	
		Week 20	Tezepelumab	45	40 (88.9)	1.10 (1.11)	-0.9	0.28	0.95	1.81	4.2	0.53 [0.09, 0.96]
			Placebo	47	43 (91.5)	0.53 (1.05)	-3.2	0.09	0.63	1.00	3.2	
		Week 24	Tezepelumab	45	40 (88.9)	1.07 (1.16)	-1.1	0.16	0.89	1.83	4.3	0.48 [0.04, 0.92]
			Placebo	47	43 (91.5)	0.53 (1.12)	-3.2	-0.03	0.53	0.94	3.2	
		Week 28	Tezepelumab	45	40 (88.9)	1.17 (1.10)	-0.9	0.33	1.19	1.92	4.3	0.56 [0.12, 1.00]
			Placebo	47	43 (91.5)	0.55 (1.13)	-3.2	0.06	0.50	1.25	3.2	
		Week 32	Tezepelumab	45	40 (88.9)	1.25 (1.17)	-0.9	0.50	1.23	2.20	4.3	0.62 [0.18, 1.06]
			Placebo	47	43 (91.5)	0.57 (1.04)	-3.2	0.06	0.56	1.28	2.9	
		Week 36	Tezepelumab	45	40 (88.9)	1.17 (1.20)	-1.0	0.33	1.17	2.06	4.3	0.56 [0.13, 1.00]
			Placebo	47	43 (91.5)	0.55 (0.97)	-2.0	0.13	0.53	1.28	2.6	
		Week 40	Tezepelumab	45	40 (88.9)	1.25 (1.16)	-0.9	0.55	1.28	2.08	4.3	0.62 [0.18, 1.06]
			Placebo	47	43 (91.5)	0.59 (0.94)	-2.0	0.03	0.69	1.28	2.6	
		Week 44	Tezepelumab	45	40 (88.9)	1.26 (1.16)	-0.9	0.61	1.31	2.11	4.3	0.51 [0.07, 0.94]
			Placebo	47	43 (91.5)	0.70 (1.07)	-2.0	0.03	0.53	1.38	3.3	
		Week 48	Tezepelumab	45	40 (88.9)	1.25 (1.16)	-0.9	0.47	1.23	2.13	4.3	0.50 [0.06, 0.94]
			Placebo	47	43 (91.5)	0.69 (1.08)	-2.0	0.06	0.69	1.41	3.3	
		Week 52	Tezepelumab	45	40 (88.9)	1.25 (1.15)	-0.9	0.42	1.23	2.16	4.3	0.50 [0.06, 0.94]
			Placebo	47	43 (91.5)	0.70 (1.07)	-2.0	-0.06	0.69	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	53	47 (88.7)	4.10 (0.69)	2.0	3.72	4.16	4.47	5.3	
			Placebo	47	39 (83.0)	3.91 (0.76)	2.7	3.31	3.84	4.38	6.1	
		Week 4	Tezepelumab	53	47 (88.7)	4.51 (0.99)	1.4	3.84	4.41	5.19	6.9	
			Placebo	47	39 (83.0)	4.54 (0.94)	2.5	3.84	4.41	5.13	6.8	
		Week 8	Tezepelumab	53	48 (90.6)	4.80 (0.94)	3.0	4.14	4.58	5.39	7.0	
			Placebo	47	40 (85.1)	4.54 (1.03)	2.3	3.92	4.44	5.27	6.9	
		Week 12	Tezepelumab	53	48 (90.6)	4.91 (0.83)	3.0	4.31	4.78	5.39	7.0	
			Placebo	47	41 (87.2)	4.74 (1.00)	2.7	4.09	4.63	5.44	6.8	
		Week 16	Tezepelumab	53	48 (90.6)	4.88 (0.88)	2.7	4.31	4.61	5.56	6.9	
			Placebo	47	41 (87.2)	4.75 (0.99)	3.0	4.06	4.75	5.16	6.8	
		Week 20	Tezepelumab	53	49 (92.5)	4.87 (0.86)	3.2	4.31	4.63	5.50	6.9	
			Placebo	47	41 (87.2)	4.78 (0.86)	3.6	4.06	4.69	5.03	6.7	
		Week 24	Tezepelumab	53	49 (92.5)	4.93 (0.90)	3.3	4.25	4.69	5.66	7.0	
			Placebo	47	41 (87.2)	4.87 (0.90)	3.2	4.22	4.78	5.53	6.8	
		Week 28	Tezepelumab	53	50 (94.3)	4.86 (0.89)	3.3	4.22	4.66	5.41	7.0	
			Placebo	47	41 (87.2)	4.80 (1.04)	2.9	3.97	4.69	5.66	7.0	
		Week 32	Tezepelumab	53	50 (94.3)	4.91 (0.86)	2.9	4.19	4.72	5.72	6.7	
			Placebo	47	42 (89.4)	4.92 (0.98)	3.3	4.09	4.67	5.75	6.9	
		Week 36	Tezepelumab	53	50 (94.3)	4.92 (0.89)	3.3	4.38	4.77	5.50	6.8	
			Placebo	47	42 (89.4)	5.00 (0.97)	3.3	4.22	4.77	5.75	6.9	
		Week 40	Tezepelumab	53	50 (94.3)	4.89 (0.89)	3.2	4.19	4.92	5.41	6.8	
			Placebo	47	42 (89.4)	4.99 (1.06)	3.3	4.13	4.64	5.84	6.8	
		Week 44	Tezepelumab	53	50 (94.3)	4.95 (0.92)	3.0	4.31	4.81	5.81	7.0	
			Placebo	47	42 (89.4)	4.93 (1.11)	2.8	4.00	4.78	6.00	6.8	
		Week 48	Tezepelumab	53	50 (94.3)	4.98 (0.96)	2.9	4.22	4.95	5.75	7.0	
			Placebo	47	42 (89.4)	5.00 (1.00)	3.4	4.13	4.75	6.00	7.0	
		Week 52	Tezepelumab	53	50 (94.3)	4.97 (0.95)	2.9	4.22	5.03	5.75	7.0	
			Placebo	47	42 (89.4)	4.89 (1.07)	2.7	4.09	4.73	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	53	44 (83.0)	0.41 (0.95)	-3.7	-0.05	0.33	0.83	2.6	-0.22 [-0.65, 0.22]
			Placebo	47	38 (80.9)	0.60 (0.76)	-1.2	0.16	0.50	1.16	2.6	
		Week 8	Tezepelumab	53	45 (84.9)	0.73 (0.91)	-1.0	0.00	0.69	1.28	2.7	0.13 [-0.31, 0.56]
			Placebo	47	38 (80.9)	0.61 (0.91)	-1.0	-0.19	0.52	1.09	2.7	
		Week 12	Tezepelumab	53	45 (84.9)	0.85 (0.89)	-2.1	0.16	0.81	1.44	2.7	-0.00 [-0.43, 0.43]
			Placebo	47	38 (80.9)	0.85 (1.08)	-1.0	0.19	0.69	1.34	3.5	
		Week 16	Tezepelumab	53	45 (84.9)	0.85 (0.93)	-2.4	0.34	0.72	1.38	2.8	-0.01 [-0.44, 0.42]
			Placebo	47	38 (80.9)	0.86 (0.94)	-0.6	0.22	0.81	1.38	3.8	
		Week 20	Tezepelumab	53	45 (84.9)	0.82 (0.84)	-1.2	0.22	0.75	1.53	2.6	-0.10 [-0.53, 0.33]
			Placebo	47	38 (80.9)	0.90 (0.83)	-0.2	0.31	0.70	1.22	3.2	
		Week 24	Tezepelumab	53	45 (84.9)	0.92 (0.85)	-1.2	0.31	0.84	1.56	2.7	-0.06 [-0.49, 0.37]
			Placebo	47	38 (80.9)	0.98 (0.99)	-1.2	0.28	0.83	1.72	2.9	
		Week 28	Tezepelumab	53	45 (84.9)	0.83 (0.85)	-1.3	0.31	0.66	1.25	2.7	-0.07 [-0.50, 0.36]
			Placebo	47	38 (80.9)	0.90 (1.11)	-1.5	0.16	0.84	1.41	4.0	
		Week 32	Tezepelumab	53	45 (84.9)	0.87 (0.85)	-1.2	0.31	0.88	1.38	2.7	-0.24 [-0.68, 0.19]
			Placebo	47	38 (80.9)	1.09 (0.98)	-0.2	0.34	0.75	1.78	3.2	
		Week 36	Tezepelumab	53	45 (84.9)	0.87 (0.87)	-1.3	0.28	0.81	1.44	2.6	-0.29 [-0.72, 0.14]
			Placebo	47	38 (80.9)	1.15 (1.05)	-0.3	0.38	0.80	1.97	3.4	
		Week 40	Tezepelumab	53	45 (84.9)	0.88 (0.85)	-1.3	0.31	0.81	1.34	2.7	-0.25 [-0.68, 0.19]
			Placebo	47	38 (80.9)	1.13 (1.19)	-1.0	0.38	0.86	2.00	3.8	
		Week 44	Tezepelumab	53	45 (84.9)	0.93 (0.89)	-1.1	0.28	0.81	1.44	2.7	-0.11 [-0.55, 0.32]
			Placebo	47	38 (80.9)	1.05 (1.19)	-1.3	0.22	0.72	1.78	3.4	
		Week 48	Tezepelumab	53	45 (84.9)	0.95 (0.90)	-1.1	0.44	0.81	1.34	2.7	-0.20 [-0.63, 0.23]
			Placebo	47	38 (80.9)	1.14 (1.07)	-0.2	0.22	0.95	1.78	3.3	
		Week 52	Tezepelumab	53	45 (84.9)	0.93 (0.88)	-1.2	0.44	0.81	1.34	2.7	-0.11 [-0.55, 0.32]
			Placebo	47	38 (80.9)	1.04 (1.10)	-0.6	0.19	0.81	1.81	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	4.23 (0.87)	2.2	3.75	4.31	4.91	6.2	
			Placebo	33	29 (87.9)	4.16 (0.84)	2.7	3.66	4.13	4.59	6.1	
		Week 4	Tezepelumab	27	27 (100.0)	4.85 (0.97)	3.0	4.16	4.72	5.53	6.9	
			Placebo	33	30 (90.9)	4.63 (0.96)	3.3	3.84	4.70	5.09	6.8	
		Week 8	Tezepelumab	27	27 (100.0)	5.08 (0.96)	3.3	4.50	4.81	5.97	7.0	
			Placebo	33	30 (90.9)	4.94 (0.98)	3.1	4.09	5.03	5.50	6.8	
		Week 12	Tezepelumab	27	27 (100.0)	5.27 (0.86)	4.1	4.47	5.28	5.88	7.0	
			Placebo	33	30 (90.9)	5.00 (1.03)	3.4	4.00	4.86	5.78	7.0	
		Week 16	Tezepelumab	27	27 (100.0)	5.20 (0.88)	4.0	4.47	5.00	5.72	6.9	
			Placebo	33	30 (90.9)	5.00 (1.07)	3.0	4.06	4.91	5.84	7.0	
		Week 20	Tezepelumab	27	27 (100.0)	5.16 (0.90)	4.1	4.34	4.91	5.75	7.0	
			Placebo	33	30 (90.9)	4.95 (1.00)	3.7	4.03	4.69	5.56	7.0	
		Week 24	Tezepelumab	27	27 (100.0)	5.33 (0.90)	4.1	4.47	5.50	5.94	7.0	
			Placebo	33	30 (90.9)	5.01 (1.06)	3.6	4.19	4.67	5.84	7.0	
		Week 28	Tezepelumab	27	27 (100.0)	5.18 (0.89)	3.7	4.47	5.19	5.66	7.0	
			Placebo	33	30 (90.9)	5.04 (1.28)	3.3	4.00	4.70	6.00	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	5.22 (0.80)	3.9	4.47	5.34	5.84	6.7	
			Placebo	33	31 (93.9)	4.98 (1.11)	3.3	4.00	4.47	6.03	7.0	
		Week 36	Tezepelumab	27	27 (100.0)	5.25 (0.88)	3.8	4.47	5.19	5.75	7.0	
			Placebo	33	31 (93.9)	5.04 (1.08)	3.8	4.16	4.44	5.72	7.0	
		Week 40	Tezepelumab	27	27 (100.0)	5.18 (0.86)	3.9	4.47	5.19	5.63	7.0	
			Placebo	33	31 (93.9)	5.00 (1.20)	3.5	3.91	4.72	6.00	7.0	
		Week 44	Tezepelumab	27	27 (100.0)	5.22 (0.92)	3.7	4.47	5.09	5.88	7.0	
			Placebo	33	31 (93.9)	5.00 (1.25)	2.8	4.00	4.75	6.34	7.0	
		Week 48	Tezepelumab	27	27 (100.0)	5.27 (0.88)	4.0	4.47	5.22	5.94	7.0	
			Placebo	33	31 (93.9)	5.00 (1.19)	3.4	4.00	4.69	6.16	7.0	
		Week 52	Tezepelumab	27	27 (100.0)	5.26 (0.86)	4.1	4.47	5.16	5.94	7.0	
			Placebo	33	31 (93.9)	4.88 (1.19)	3.1	3.97	4.28	5.84	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	27	27 (100.0)	0.62 (0.95)	-1.3	0.00	0.47	1.28	3.3	0.14 [-0.38, 0.67]
			Placebo	33	29 (87.9)	0.51 (0.63)	-0.8	0.16	0.44	0.88	2.0	
		Week 8	Tezepelumab	27	27 (100.0)	0.85 (1.07)	-1.0	0.06	0.75	1.47	3.8	0.03 [-0.49, 0.56]
			Placebo	33	29 (87.9)	0.82 (0.82)	-0.3	0.19	0.66	1.25	2.7	
		Week 12	Tezepelumab	27	27 (100.0)	1.05 (0.98)	-0.9	0.53	0.94	1.41	4.0	0.18 [-0.35, 0.70]
			Placebo	33	29 (87.9)	0.87 (0.97)	-1.0	0.25	0.88	1.31	3.5	
		Week 16	Tezepelumab	27	27 (100.0)	0.97 (1.00)	-1.0	0.34	1.00	1.66	3.4	0.11 [-0.42, 0.63]
			Placebo	33	29 (87.9)	0.87 (0.90)	-0.4	0.28	0.78	1.25	3.8	
		Week 20	Tezepelumab	27	27 (100.0)	0.93 (0.98)	-0.8	0.16	0.84	1.56	3.4	0.12 [-0.41, 0.64]
			Placebo	33	29 (87.9)	0.82 (0.83)	-0.2	0.34	0.59	1.22	3.3	
		Week 24	Tezepelumab	27	27 (100.0)	1.10 (0.93)	-0.4	0.31	1.03	1.59	3.4	0.23 [-0.29, 0.76]
			Placebo	33	29 (87.9)	0.88 (0.95)	-0.3	0.13	0.75	1.22	3.2	
		Week 28	Tezepelumab	27	27 (100.0)	0.95 (0.97)	-0.6	0.28	0.91	1.44	3.4	0.03 [-0.49, 0.56]
			Placebo	33	29 (87.9)	0.92 (1.07)	-0.5	0.19	0.78	1.28	4.0	
		Week 32	Tezepelumab	27	27 (100.0)	0.99 (0.91)	-0.6	0.31	1.03	1.47	3.4	0.10 [-0.43, 0.62]
			Placebo	33	29 (87.9)	0.90 (0.87)	-0.2	0.31	0.66	1.28	3.4	
		Week 36	Tezepelumab	27	27 (100.0)	1.03 (1.02)	-1.0	0.31	0.94	1.63	3.4	0.08 [-0.44, 0.61]
			Placebo	33	29 (87.9)	0.95 (0.89)	-0.4	0.31	1.00	1.38	3.4	
		Week 40	Tezepelumab	27	27 (100.0)	0.95 (0.99)	-0.8	0.13	0.94	1.81	3.4	0.04 [-0.48, 0.56]
			Placebo	33	29 (87.9)	0.91 (1.05)	-0.7	0.28	0.69	1.31	3.8	
		Week 44	Tezepelumab	27	27 (100.0)	0.99 (0.99)	-0.8	0.22	0.84	1.88	3.4	0.12 [-0.41, 0.64]
			Placebo	33	29 (87.9)	0.87 (1.15)	-1.3	0.00	0.53	1.47	3.5	
		Week 48	Tezepelumab	27	27 (100.0)	1.05 (0.99)	-0.8	0.28	0.97	2.06	3.4	0.17 [-0.36, 0.69]
			Placebo	33	29 (87.9)	0.88 (0.96)	-0.2	0.00	0.75	1.50	3.5	
		Week 52	Tezepelumab	27	27 (100.0)	1.03 (1.01)	-0.8	0.34	0.97	2.06	3.4	0.22 [-0.30, 0.75]
			Placebo	33	29 (87.9)	0.81 (0.97)	-0.5	-0.06	0.75	1.25	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	109	95 (87.2)	4.19 (0.94)	1.5	3.66	4.25	4.66	6.8	
			Placebo	105	92 (87.6)	4.07 (0.89)	1.8	3.47	4.06	4.69	6.3	
		Week 4	Tezepelumab	109	98 (89.9)	4.92 (1.06)	1.4	4.06	4.98	5.66	7.0	
			Placebo	105	93 (88.6)	4.59 (0.98)	2.1	3.97	4.50	5.25	6.8	
		Week 8	Tezepelumab	109	100 (91.7)	5.13 (1.07)	2.7	4.19	5.11	5.92	7.0	
			Placebo	105	96 (91.4)	4.64 (1.05)	2.1	3.94	4.56	5.38	7.0	
		Week 12	Tezepelumab	109	100 (91.7)	5.29 (1.09)	2.8	4.33	5.23	6.25	7.0	
			Placebo	105	97 (92.4)	4.77 (1.05)	2.5	4.06	4.63	5.56	7.0	
		Week 16	Tezepelumab	109	100 (91.7)	5.26 (1.08)	2.6	4.33	5.28	6.09	7.0	
			Placebo	105	97 (92.4)	4.79 (1.13)	1.2	3.97	4.75	5.69	7.0	
		Week 20	Tezepelumab	109	101 (92.7)	5.26 (1.05)	3.2	4.31	5.22	6.13	7.0	
			Placebo	105	97 (92.4)	4.82 (1.13)	1.2	4.03	4.81	5.78	7.0	
		Week 24	Tezepelumab	109	101 (92.7)	5.26 (1.08)	2.4	4.34	5.13	6.06	7.0	
			Placebo	105	97 (92.4)	4.84 (1.15)	1.2	4.00	4.81	5.69	7.0	
		Week 28	Tezepelumab	109	103 (94.5)	5.31 (1.04)	3.3	4.34	5.34	6.09	7.0	
			Placebo	105	98 (93.3)	4.85 (1.18)	1.2	3.97	4.86	5.88	7.0	
		Week 32	Tezepelumab	109	104 (95.4)	5.37 (1.08)	2.6	4.45	5.55	6.16	7.0	
			Placebo	105	98 (93.3)	4.94 (1.15)	1.2	4.03	5.05	5.88	7.0	
		Week 36	Tezepelumab	109	104 (95.4)	5.36 (1.06)	3.2	4.61	5.34	6.23	7.0	
			Placebo	105	98 (93.3)	4.94 (1.14)	2.2	4.00	4.83	5.97	7.0	
		Week 40	Tezepelumab	109	104 (95.4)	5.38 (1.08)	2.6	4.63	5.30	6.25	7.0	
			Placebo	105	98 (93.3)	4.99 (1.11)	2.3	4.16	5.03	5.91	7.0	
		Week 44	Tezepelumab	109	104 (95.4)	5.42 (1.06)	2.8	4.55	5.39	6.33	7.0	
			Placebo	105	98 (93.3)	4.97 (1.14)	2.5	4.00	5.02	5.97	7.0	
		Week 48	Tezepelumab	109	104 (95.4)	5.41 (1.08)	2.9	4.50	5.36	6.34	7.0	
			Placebo	105	99 (94.3)	4.99 (1.08)	2.1	4.16	4.91	5.94	7.0	
		Week 52	Tezepelumab	109	104 (95.4)	5.40 (1.09)	2.8	4.52	5.36	6.30	7.0	
			Placebo	105	99 (94.3)	4.99 (1.10)	2.7	4.09	4.91	5.94	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	109	89 (81.7)	0.78 (0.96)	-3.7	0.31	0.72	1.44	3.0	0.29 [-0.01, 0.58]
			Placebo	105	90 (85.7)	0.52 (0.82)	-1.2	0.06	0.42	1.03	2.6	
		Week 8	Tezepelumab	109	91 (83.5)	0.93 (0.95)	-1.0	0.28	0.81	1.63	3.9	0.38 [0.08, 0.67]
			Placebo	105	91 (86.7)	0.58 (0.88)	-1.4	0.06	0.50	1.00	3.1	
		Week 12	Tezepelumab	109	91 (83.5)	1.09 (1.02)	-2.1	0.47	1.06	1.88	4.2	0.37 [0.08, 0.66]
			Placebo	105	91 (86.7)	0.71 (1.02)	-2.0	0.19	0.63	1.22	3.4	
		Week 16	Tezepelumab	109	91 (83.5)	1.08 (1.00)	-2.4	0.34	1.13	1.78	4.2	0.33 [0.03, 0.62]
			Placebo	105	91 (86.7)	0.74 (1.05)	-3.2	0.22	0.72	1.41	3.5	
		Week 20	Tezepelumab	109	91 (83.5)	1.09 (1.00)	-1.2	0.28	0.91	1.81	4.2	0.30 [0.01, 0.59]
			Placebo	105	91 (86.7)	0.78 (1.03)	-3.2	0.25	0.78	1.19	3.8	
		Week 24	Tezepelumab	109	91 (83.5)	1.11 (1.04)	-1.2	0.34	0.97	1.81	4.3	0.29 [-0.00, 0.58]
			Placebo	105	91 (86.7)	0.81 (1.09)	-3.2	0.16	0.81	1.38	3.7	
		Week 28	Tezepelumab	109	91 (83.5)	1.15 (1.01)	-1.3	0.41	0.91	1.97	4.3	0.33 [0.03, 0.62]
			Placebo	105	91 (86.7)	0.80 (1.13)	-3.2	0.19	0.84	1.44	4.3	
		Week 32	Tezepelumab	109	91 (83.5)	1.19 (1.05)	-1.2	0.50	1.03	2.09	4.3	0.27 [-0.02, 0.57]
			Placebo	105	91 (86.7)	0.90 (1.06)	-3.2	0.31	0.78	1.50	3.6	
		Week 36	Tezepelumab	109	91 (83.5)	1.17 (1.09)	-1.3	0.41	1.00	2.06	4.3	0.26 [-0.03, 0.55]
			Placebo	105	91 (86.7)	0.89 (1.07)	-2.0	0.28	0.75	1.63	3.4	
		Week 40	Tezepelumab	109	91 (83.5)	1.21 (1.03)	-1.3	0.59	1.03	2.06	4.3	0.25 [-0.04, 0.54]
			Placebo	105	91 (86.7)	0.94 (1.10)	-2.0	0.25	0.84	1.66	4.3	
		Week 44	Tezepelumab	109	91 (83.5)	1.24 (1.04)	-1.1	0.59	1.25	1.94	4.3	0.30 [0.01, 0.59]
			Placebo	105	91 (86.7)	0.92 (1.10)	-2.0	0.22	0.88	1.41	4.1	
		Week 48	Tezepelumab	109	91 (83.5)	1.25 (1.05)	-1.1	0.53	1.16	2.13	4.3	0.29 [0.00, 0.58]
			Placebo	105	91 (86.7)	0.94 (1.07)	-2.0	0.19	0.94	1.66	3.3	
		Week 52	Tezepelumab	109	91 (83.5)	1.22 (1.05)	-1.2	0.50	1.16	2.09	4.3	0.27 [-0.02, 0.56]
			Placebo	105	91 (86.7)	0.93 (1.06)	-2.0	0.19	0.84	1.66	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	69	63 (91.3)	4.23 (0.83)	2.0	3.88	4.31	4.69	6.3	
			Placebo	72	61 (84.7)	4.16 (0.88)	1.8	3.63	4.19	4.69	6.1	
		Week 4	Tezepelumab	69	60 (87.0)	4.84 (1.08)	1.4	4.13	4.73	5.63	7.0	
			Placebo	72	61 (84.7)	4.67 (1.01)	2.1	3.97	4.72	5.31	6.8	
		Week 8	Tezepelumab	69	61 (88.4)	5.05 (1.01)	2.8	4.25	4.97	5.91	7.0	
			Placebo	72	63 (87.5)	4.86 (1.04)	2.1	4.03	4.97	5.72	6.9	
		Week 12	Tezepelumab	69	61 (88.4)	5.32 (0.99)	3.0	4.50	5.28	6.22	7.0	
			Placebo	72	63 (87.5)	4.96 (1.05)	2.5	4.09	4.88	5.81	7.0	
		Week 16	Tezepelumab	69	61 (88.4)	5.19 (0.99)	2.7	4.47	5.09	5.88	7.0	
			Placebo	72	63 (87.5)	4.97 (1.16)	1.2	4.06	5.03	5.84	7.0	
		Week 20	Tezepelumab	69	62 (89.9)	5.17 (1.03)	3.2	4.34	5.05	5.91	7.0	
			Placebo	72	63 (87.5)	4.94 (1.14)	1.2	4.19	4.81	5.91	7.0	
		Week 24	Tezepelumab	69	62 (89.9)	5.28 (0.98)	3.5	4.47	5.09	6.00	7.0	
			Placebo	72	63 (87.5)	4.98 (1.19)	1.2	4.19	5.06	5.91	7.0	
		Week 28	Tezepelumab	69	63 (91.3)	5.23 (1.00)	3.6	4.34	5.16	5.94	7.0	
			Placebo	72	64 (88.9)	5.03 (1.30)	1.2	4.06	5.14	5.98	7.0	
		Week 32	Tezepelumab	69	64 (92.8)	5.31 (0.96)	3.6	4.47	5.31	5.95	7.0	
			Placebo	72	65 (90.3)	5.04 (1.23)	1.2	4.16	5.25	6.03	7.0	
		Week 36	Tezepelumab	69	64 (92.8)	5.32 (1.01)	3.2	4.55	5.19	6.19	7.0	
			Placebo	72	65 (90.3)	5.16 (1.14)	2.6	4.22	5.25	6.16	7.0	
		Week 40	Tezepelumab	69	64 (92.8)	5.32 (1.00)	3.2	4.59	5.25	6.00	7.0	
			Placebo	72	65 (90.3)	5.15 (1.17)	2.5	4.16	5.34	6.00	7.0	
		Week 44	Tezepelumab	69	64 (92.8)	5.31 (1.05)	3.0	4.47	5.11	6.03	7.0	
			Placebo	72	65 (90.3)	5.17 (1.21)	2.6	4.19	5.13	6.28	7.0	
		Week 48	Tezepelumab	69	64 (92.8)	5.38 (1.01)	3.4	4.50	5.34	6.11	7.0	
			Placebo	72	66 (91.7)	5.13 (1.17)	2.8	4.13	5.00	6.19	7.0	
		Week 52	Tezepelumab	69	64 (92.8)	5.38 (1.01)	3.4	4.53	5.30	6.16	7.0	
			Placebo	72	66 (91.7)	5.11 (1.18)	2.8	4.09	5.00	6.25	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High											
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	69	58 (84.1)	0.60 (1.01)	-3.7	0.03	0.61	1.22	3.3	0.09 [-0.28, 0.45]
			Placebo	72	60 (83.3)	0.53 (0.72)	-1.1	0.14	0.44	0.94	2.6	
		Week 8	Tezepelumab	69	59 (85.5)	0.83 (0.93)	-1.0	0.28	0.69	1.63	3.8	0.11 [-0.25, 0.47]
			Placebo	72	61 (84.7)	0.73 (0.83)	-1.0	0.16	0.66	1.16	2.7	
		Week 12	Tezepelumab	69	59 (85.5)	1.11 (0.99)	-2.1	0.56	1.06	1.84	4.0	0.28 [-0.08, 0.64]
			Placebo	72	61 (84.7)	0.83 (0.98)	-2.0	0.28	0.88	1.31	3.5	
		Week 16	Tezepelumab	69	59 (85.5)	0.98 (0.98)	-2.4	0.44	0.84	1.69	3.4	0.14 [-0.22, 0.50]
			Placebo	72	61 (84.7)	0.84 (1.04)	-3.2	0.41	0.91	1.41	3.8	
		Week 20	Tezepelumab	69	59 (85.5)	0.95 (0.98)	-1.2	0.22	0.75	1.66	3.4	0.15 [-0.21, 0.51]
			Placebo	72	61 (84.7)	0.80 (0.95)	-3.2	0.41	0.81	1.22	3.3	
		Week 24	Tezepelumab	69	59 (85.5)	1.07 (0.90)	-1.2	0.34	1.03	1.81	3.4	0.23 [-0.13, 0.59]
			Placebo	72	61 (84.7)	0.85 (1.05)	-3.2	0.31	0.91	1.28	3.2	
		Week 28	Tezepelumab	69	59 (85.5)	1.03 (0.96)	-1.3	0.31	0.91	1.84	3.4	0.16 [-0.20, 0.52]
			Placebo	72	61 (84.7)	0.87 (1.11)	-3.2	0.25	1.00	1.41	4.0	
		Week 32	Tezepelumab	69	59 (85.5)	1.07 (0.95)	-1.2	0.34	1.03	1.69	3.4	0.17 [-0.19, 0.53]
			Placebo	72	61 (84.7)	0.91 (1.01)	-3.2	0.41	0.84	1.41	3.4	
		Week 36	Tezepelumab	69	59 (85.5)	1.08 (1.04)	-1.3	0.31	0.94	1.91	3.4	0.06 [-0.29, 0.42]
			Placebo	72	61 (84.7)	1.01 (1.02)	-1.7	0.41	1.00	1.56	3.4	
		Week 40	Tezepelumab	69	59 (85.5)	1.09 (1.00)	-1.3	0.28	0.97	2.03	3.4	0.08 [-0.28, 0.44]
			Placebo	72	61 (84.7)	1.01 (1.07)	-1.2	0.28	0.97	1.69	3.8	
		Week 44	Tezepelumab	69	59 (85.5)	1.07 (1.00)	-1.1	0.47	0.91	1.94	3.4	0.06 [-0.30, 0.42]
			Placebo	72	61 (84.7)	1.00 (1.09)	-1.3	0.31	0.97	1.56	3.5	
		Week 48	Tezepelumab	69	59 (85.5)	1.15 (0.98)	-1.1	0.44	1.06	2.06	3.4	0.18 [-0.18, 0.54]
			Placebo	72	61 (84.7)	0.98 (1.01)	-0.9	0.16	0.94	1.59	3.5	
		Week 52	Tezepelumab	69	59 (85.5)	1.14 (0.99)	-1.2	0.41	1.06	2.06	3.4	0.16 [-0.19, 0.52]
			Placebo	72	61 (84.7)	0.97 (1.02)	-0.9	0.22	0.94	1.53	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	4.16 (1.01)	1.5	3.59	4.09	4.66	6.8	
			Placebo	66	60 (90.9)	4.02 (0.87)	2.2	3.41	3.98	4.52	6.3	
		Week 4	Tezepelumab	67	65 (97.0)	4.97 (1.01)	3.2	4.16	5.00	5.66	6.9	
			Placebo	66	62 (93.9)	4.54 (0.93)	2.4	3.84	4.47	5.16	6.7	
		Week 8	Tezepelumab	67	66 (98.5)	5.18 (1.08)	2.7	4.19	5.20	5.94	7.0	
			Placebo	66	63 (95.5)	4.57 (1.02)	2.3	3.94	4.41	5.16	7.0	
		Week 12	Tezepelumab	67	66 (98.5)	5.25 (1.10)	2.8	4.31	5.23	6.13	7.0	
			Placebo	66	64 (97.0)	4.69 (1.03)	2.7	3.92	4.48	5.45	7.0	
		Week 16	Tezepelumab	67	66 (98.5)	5.30 (1.08)	2.6	4.25	5.36	6.09	7.0	
			Placebo	66	64 (97.0)	4.72 (1.06)	2.5	3.95	4.63	5.50	7.0	
		Week 20	Tezepelumab	67	66 (98.5)	5.30 (1.02)	3.6	4.31	5.42	6.09	7.0	
			Placebo	66	64 (97.0)	4.77 (1.06)	2.5	3.97	4.77	5.44	7.0	
		Week 24	Tezepelumab	67	66 (98.5)	5.28 (1.11)	2.4	4.34	5.33	6.06	7.0	
			Placebo	66	64 (97.0)	4.79 (1.06)	2.7	3.97	4.69	5.52	7.0	
		Week 28	Tezepelumab	67	67 (100.0)	5.34 (1.02)	3.3	4.53	5.44	6.09	7.0	
			Placebo	66	64 (97.0)	4.76 (1.08)	2.8	3.94	4.52	5.72	7.0	
		Week 32	Tezepelumab	67	67 (100.0)	5.36 (1.10)	2.6	4.44	5.66	6.13	7.0	
			Placebo	66	64 (97.0)	4.85 (1.03)	2.7	3.98	4.72	5.70	7.0	
		Week 36	Tezepelumab	67	67 (100.0)	5.36 (1.04)	3.3	4.59	5.34	6.19	7.0	
			Placebo	66	64 (97.0)	4.77 (1.08)	2.2	3.98	4.58	5.59	7.0	
		Week 40	Tezepelumab	67	67 (100.0)	5.36 (1.08)	2.6	4.47	5.31	6.25	7.0	
			Placebo	66	64 (97.0)	4.83 (1.07)	2.3	3.97	4.61	5.75	7.0	
		Week 44	Tezepelumab	67	67 (100.0)	5.44 (1.02)	2.8	4.59	5.41	6.31	7.0	
			Placebo	66	64 (97.0)	4.78 (1.08)	2.5	3.97	4.59	5.69	7.0	
		Week 48	Tezepelumab	67	67 (100.0)	5.39 (1.07)	2.9	4.44	5.38	6.25	7.0	
			Placebo	66	64 (97.0)	4.85 (1.02)	2.1	4.02	4.77	5.66	7.0	
		Week 52	Tezepelumab	67	67 (100.0)	5.36 (1.08)	2.8	4.44	5.38	6.25	7.0	
			Placebo	66	64 (97.0)	4.81 (1.04)	2.7	3.97	4.77	5.56	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	67	58 (86.6)	0.88 (0.89)	-1.0	0.38	0.80	1.47	3.0	0.43 [0.07, 0.80]
			Placebo	66	59 (89.4)	0.50 (0.84)	-1.2	0.03	0.41	1.16	2.6	
		Week 8	Tezepelumab	67	59 (88.1)	0.99 (1.02)	-0.9	0.19	0.97	1.69	3.9	0.47 [0.10, 0.83]
			Placebo	66	59 (89.4)	0.54 (0.90)	-1.4	-0.03	0.50	0.94	3.1	
		Week 12	Tezepelumab	67	59 (88.1)	1.05 (1.03)	-0.9	0.38	0.97	1.75	4.2	0.38 [0.01, 0.74]
			Placebo	66	59 (89.4)	0.66 (1.03)	-1.7	0.16	0.50	1.13	3.4	
		Week 16	Tezepelumab	67	59 (88.1)	1.12 (1.02)	-0.9	0.34	1.25	1.84	4.2	0.42 [0.05, 0.78]
			Placebo	66	59 (89.4)	0.70 (0.99)	-2.0	0.09	0.59	1.38	3.5	
		Week 20	Tezepelumab	67	59 (88.1)	1.15 (1.01)	-0.9	0.31	1.19	1.84	4.2	0.36 [0.00, 0.73]
			Placebo	66	59 (89.4)	0.78 (1.04)	-2.0	0.19	0.72	1.19	3.8	
		Week 24	Tezepelumab	67	59 (88.1)	1.16 (1.11)	-1.1	0.22	1.13	1.78	4.3	0.33 [-0.04, 0.69]
			Placebo	66	59 (89.4)	0.80 (1.06)	-2.0	0.09	0.75	1.56	3.7	
		Week 28	Tezepelumab	67	59 (88.1)	1.17 (1.04)	-0.9	0.38	1.00	1.97	4.3	0.36 [-0.00, 0.72]
			Placebo	66	59 (89.4)	0.78 (1.12)	-2.0	0.16	0.56	1.47	4.3	
		Week 32	Tezepelumab	67	59 (88.1)	1.21 (1.08)	-0.9	0.50	1.09	2.13	4.3	0.30 [-0.06, 0.66]
			Placebo	66	59 (89.4)	0.89 (1.03)	-2.0	0.28	0.72	1.50	3.6	
		Week 36	Tezepelumab	67	59 (88.1)	1.20 (1.10)	-0.9	0.41	1.00	2.16	4.3	0.38 [0.01, 0.74]
			Placebo	66	59 (89.4)	0.79 (1.04)	-2.0	0.22	0.63	1.44	3.3	
		Week 40	Tezepelumab	67	59 (88.1)	1.21 (1.05)	-0.9	0.59	1.03	1.94	4.3	0.33 [-0.04, 0.69]
			Placebo	66	59 (89.4)	0.86 (1.10)	-2.0	0.22	0.75	1.50	4.3	
		Week 44	Tezepelumab	67	59 (88.1)	1.30 (1.06)	-0.9	0.53	1.34	1.88	4.3	0.46 [0.09, 0.82]
			Placebo	66	59 (89.4)	0.80 (1.11)	-2.0	0.09	0.69	1.34	4.1	
		Week 48	Tezepelumab	67	59 (88.1)	1.26 (1.09)	-0.9	0.50	1.06	2.09	4.3	0.35 [-0.01, 0.71]
			Placebo	66	59 (89.4)	0.88 (1.08)	-2.0	0.19	0.78	1.66	3.3	
		Week 52	Tezepelumab	67	59 (88.1)	1.21 (1.09)	-0.9	0.44	1.06	2.09	4.3	0.35 [-0.01, 0.71]
			Placebo	66	59 (89.4)	0.83 (1.06)	-2.0	0.16	0.69	1.41	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	78	68 (87.2)	4.27 (0.77)	2.2	3.80	4.34	4.78	6.3	
			Placebo	74	63 (85.1)	4.05 (0.81)	1.9	3.56	4.06	4.66	5.8	
		Week 4	Tezepelumab	78	72 (92.3)	4.81 (1.03)	1.4	4.05	4.83	5.64	6.9	
			Placebo	74	66 (89.2)	4.60 (0.96)	2.1	3.97	4.45	5.25	6.8	
		Week 8	Tezepelumab	78	72 (92.3)	5.05 (0.92)	3.0	4.30	4.98	5.84	7.0	
			Placebo	74	66 (89.2)	4.72 (1.02)	2.1	4.00	4.67	5.31	6.9	
		Week 12	Tezepelumab	78	72 (92.3)	5.28 (0.97)	3.0	4.47	5.31	6.05	7.0	
			Placebo	74	67 (90.5)	4.78 (1.04)	2.5	4.00	4.63	5.56	7.0	
		Week 16	Tezepelumab	78	72 (92.3)	5.15 (0.96)	2.7	4.41	5.11	5.92	7.0	
			Placebo	74	67 (90.5)	4.88 (1.00)	2.5	4.00	4.84	5.72	7.0	
		Week 20	Tezepelumab	78	73 (93.6)	5.13 (0.98)	3.2	4.31	5.03	5.88	7.0	
			Placebo	74	67 (90.5)	4.87 (1.01)	2.4	4.00	4.81	5.56	7.0	
		Week 24	Tezepelumab	78	73 (93.6)	5.19 (0.99)	3.3	4.41	5.09	5.94	7.0	
			Placebo	74	67 (90.5)	4.92 (1.08)	2.3	4.00	4.84	5.66	7.0	
		Week 28	Tezepelumab	78	75 (96.2)	5.20 (0.99)	3.6	4.31	5.16	6.00	7.0	
			Placebo	74	68 (91.9)	4.88 (1.10)	2.2	4.00	4.73	5.77	7.0	
		Week 32	Tezepelumab	78	76 (97.4)	5.24 (0.99)	2.9	4.42	5.31	5.95	7.0	
			Placebo	74	69 (93.2)	4.95 (1.09)	2.3	4.03	4.81	5.91	7.0	
		Week 36	Tezepelumab	78	76 (97.4)	5.25 (1.03)	3.2	4.44	5.27	6.11	7.0	
			Placebo	74	69 (93.2)	5.02 (1.08)	2.6	4.00	5.03	5.94	7.0	
		Week 40	Tezepelumab	78	76 (97.4)	5.20 (1.01)	3.2	4.42	5.25	5.95	7.0	
			Placebo	74	69 (93.2)	5.01 (1.05)	2.5	4.16	5.06	5.84	7.0	
		Week 44	Tezepelumab	78	76 (97.4)	5.21 (1.01)	3.0	4.47	5.16	5.98	7.0	
			Placebo	74	69 (93.2)	5.02 (1.13)	2.5	4.00	4.88	5.88	7.0	
		Week 48	Tezepelumab	78	76 (97.4)	5.24 (1.02)	2.9	4.47	5.14	6.08	7.0	
			Placebo	74	70 (94.6)	5.07 (1.08)	2.8	4.13	4.98	6.03	7.0	
		Week 52	Tezepelumab	78	76 (97.4)	5.23 (1.01)	2.9	4.47	5.11	5.97	7.0	
			Placebo	74	70 (94.6)	4.97 (1.14)	2.7	3.97	4.91	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	78	67 (85.9)	0.54 (0.97)	-3.7	0.00	0.59	1.00	3.3	-0.07 [-0.42, 0.27]
			Placebo	74	63 (85.1)	0.60 (0.79)	-1.2	0.16	0.47	1.00	2.6	
		Week 8	Tezepelumab	78	67 (85.9)	0.76 (0.91)	-1.0	0.13	0.66	1.34	3.8	0.06 [-0.28, 0.41]
			Placebo	74	63 (85.1)	0.71 (0.83)	-1.0	0.16	0.66	1.16	3.1	
		Week 12	Tezepelumab	78	67 (85.9)	0.99 (0.96)	-2.1	0.47	0.94	1.47	4.0	0.22 [-0.13, 0.56]
			Placebo	74	63 (85.1)	0.78 (0.96)	-2.0	0.28	0.72	1.22	3.3	
		Week 16	Tezepelumab	78	67 (85.9)	0.88 (0.93)	-2.4	0.34	0.72	1.47	3.4	0.00 [-0.34, 0.35]
			Placebo	74	63 (85.1)	0.88 (0.87)	-2.0	0.28	0.94	1.38	3.2	
		Week 20	Tezepelumab	78	67 (85.9)	0.87 (0.95)	-1.2	0.22	0.69	1.63	3.4	-0.01 [-0.35, 0.33]
			Placebo	74	63 (85.1)	0.88 (0.83)	-1.3	0.41	0.78	1.22	3.2	
		Week 24	Tezepelumab	78	67 (85.9)	0.97 (0.89)	-1.2	0.31	0.88	1.56	3.4	0.05 [-0.30, 0.39]
			Placebo	74	63 (85.1)	0.92 (0.89)	-1.3	0.38	0.91	1.34	3.2	
		Week 28	Tezepelumab	78	67 (85.9)	0.96 (0.93)	-1.3	0.31	0.72	1.72	3.4	0.12 [-0.22, 0.46]
			Placebo	74	63 (85.1)	0.85 (0.89)	-1.5	0.19	0.84	1.31	3.2	
		Week 32	Tezepelumab	78	67 (85.9)	0.97 (0.94)	-1.2	0.31	0.97	1.53	3.4	0.01 [-0.33, 0.36]
			Placebo	74	63 (85.1)	0.95 (0.81)	-1.0	0.44	0.97	1.41	3.0	
		Week 36	Tezepelumab	78	67 (85.9)	0.97 (1.02)	-1.3	0.25	0.88	1.63	3.4	-0.05 [-0.40, 0.29]
			Placebo	74	63 (85.1)	1.02 (0.91)	-0.7	0.38	1.00	1.50	3.0	
		Week 40	Tezepelumab	78	67 (85.9)	0.93 (0.97)	-1.3	0.25	0.75	1.59	3.4	-0.08 [-0.42, 0.27]
			Placebo	74	63 (85.1)	1.01 (0.92)	-1.2	0.38	0.97	1.66	2.9	
		Week 44	Tezepelumab	78	67 (85.9)	0.93 (0.96)	-1.1	0.28	0.75	1.59	3.4	-0.06 [-0.41, 0.28]
			Placebo	74	63 (85.1)	0.99 (0.99)	-1.3	0.31	0.97	1.47	3.1	
		Week 48	Tezepelumab	78	67 (85.9)	0.98 (0.97)	-1.1	0.34	0.84	1.69	3.4	-0.07 [-0.42, 0.27]
			Placebo	74	63 (85.1)	1.05 (0.93)	-0.5	0.22	1.00	1.66	3.3	
		Week 52	Tezepelumab	78	67 (85.9)	0.95 (0.96)	-1.2	0.34	0.81	1.63	3.4	-0.02 [-0.36, 0.33]
			Placebo	74	63 (85.1)	0.96 (0.94)	-0.6	0.19	0.91	1.50	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	57	53 (93.0)	4.11 (1.09)	1.5	3.59	4.25	4.63	6.8	
			Placebo	63	57 (90.5)	4.13 (0.96)	1.8	3.47	4.06	4.72	6.3	
		Week 4	Tezepelumab	57	52 (91.2)	5.07 (1.05)	3.2	4.28	5.09	5.83	7.0	
			Placebo	63	57 (90.5)	4.60 (0.99)	2.4	3.84	4.69	5.19	6.8	
		Week 8	Tezepelumab	57	54 (94.7)	5.19 (1.21)	2.7	4.19	5.14	6.25	7.0	
			Placebo	63	59 (93.7)	4.72 (1.07)	2.3	3.97	4.63	5.53	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.29 (1.16)	2.8	4.34	5.16	6.44	7.0	
			Placebo	63	59 (93.7)	4.88 (1.06)	2.7	4.06	5.06	5.72	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.37 (1.13)	2.6	4.34	5.38	6.47	7.0	
			Placebo	63	59 (93.7)	4.86 (1.14)	2.9	4.00	4.75	5.72	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.37 (1.07)	3.6	4.34	5.41	6.13	7.0	
			Placebo	63	59 (93.7)	4.90 (1.11)	2.9	4.19	4.75	5.97	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.37 (1.13)	2.4	4.34	5.33	6.25	7.0	
			Placebo	63	59 (93.7)	4.89 (1.08)	2.7	4.00	4.69	5.84	7.0	
		Week 28	Tezepelumab	57	54 (94.7)	5.40 (1.04)	3.3	4.50	5.44	6.22	7.0	
			Placebo	63	59 (93.7)	4.99 (1.23)	2.8	3.94	5.06	5.94	7.0	
		Week 32	Tezepelumab	57	54 (94.7)	5.45 (1.09)	2.6	4.59	5.67	6.34	7.0	
			Placebo	63	59 (93.7)	5.02 (1.09)	2.9	4.09	5.09	5.88	7.0	
		Week 36	Tezepelumab	57	54 (94.7)	5.46 (1.01)	3.4	4.78	5.30	6.34	7.0	
			Placebo	63	59 (93.7)	4.94 (1.15)	2.2	4.19	4.78	6.06	7.0	
		Week 40	Tezepelumab	57	54 (94.7)	5.53 (1.07)	2.6	4.84	5.36	6.53	7.0	
			Placebo	63	59 (93.7)	5.00 (1.21)	2.3	3.97	4.97	6.09	7.0	
		Week 44	Tezepelumab	57	54 (94.7)	5.61 (1.04)	2.8	4.84	5.73	6.47	7.0	
			Placebo	63	59 (93.7)	4.96 (1.20)	2.8	3.91	5.00	6.00	7.0	
		Week 48	Tezepelumab	57	54 (94.7)	5.58 (1.05)	3.2	4.88	5.52	6.47	7.0	
			Placebo	63	59 (93.7)	4.94 (1.12)	2.1	4.00	4.75	5.91	7.0	
		Week 52	Tezepelumab	57	54 (94.7)	5.56 (1.08)	2.8	4.72	5.45	6.47	7.0	
			Placebo	63	59 (93.7)	4.98 (1.10)	2.9	4.09	4.81	5.94	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	1.04 (0.87)	-0.9	0.44	1.03	1.70	3.0	0.76 [0.36, 1.16]
			Placebo	63	56 (88.9)	0.42 (0.77)	-1.2	-0.03	0.34	1.06	2.0	
		Week 8	Tezepelumab	57	50 (87.7)	1.09 (1.05)	-0.9	0.19	1.16	1.78	3.9	0.52 [0.13, 0.90]
			Placebo	63	56 (88.9)	0.59 (0.90)	-1.4	0.00	0.42	1.00	2.6	
		Week 12	Tezepelumab	57	50 (87.7)	1.18 (1.07)	-0.9	0.50	1.14	2.06	4.2	0.43 [0.04, 0.81]
			Placebo	63	56 (88.9)	0.73 (1.06)	-1.7	0.14	0.64	1.28	3.5	
		Week 16	Tezepelumab	57	50 (87.7)	1.27 (1.06)	-0.9	0.53	1.39	2.03	4.2	0.52 [0.13, 0.91]
			Placebo	63	56 (88.9)	0.72 (1.03)	-2.0	0.16	0.64	1.34	3.8	
		Week 20	Tezepelumab	57	50 (87.7)	1.27 (1.03)	-0.9	0.53	1.23	1.97	4.2	0.49 [0.10, 0.88]
			Placebo	63	56 (88.9)	0.76 (1.02)	-2.0	0.19	0.70	1.13	3.8	
		Week 24	Tezepelumab	57	50 (87.7)	1.28 (1.14)	-1.1	0.53	1.34	2.22	4.3	0.44 [0.06, 0.83]
			Placebo	63	56 (88.9)	0.78 (1.09)	-2.0	0.06	0.77	1.58	3.7	
		Week 28	Tezepelumab	57	50 (87.7)	1.28 (1.07)	-0.9	0.50	1.09	2.13	4.3	0.35 [-0.03, 0.74]
			Placebo	63	56 (88.9)	0.87 (1.22)	-2.0	0.16	0.75	1.72	4.3	
		Week 32	Tezepelumab	57	50 (87.7)	1.35 (1.08)	-0.9	0.63	1.23	2.34	4.3	0.41 [0.02, 0.79]
			Placebo	63	56 (88.9)	0.91 (1.09)	-2.0	0.23	0.72	1.56	3.6	
		Week 36	Tezepelumab	57	50 (87.7)	1.35 (1.11)	-0.9	0.66	1.30	2.34	4.3	0.48 [0.09, 0.87]
			Placebo	63	56 (88.9)	0.82 (1.10)	-2.0	0.19	0.67	1.56	3.4	
		Week 40	Tezepelumab	57	50 (87.7)	1.42 (1.04)	-0.9	0.81	1.09	2.44	4.3	0.47 [0.08, 0.85]
			Placebo	63	56 (88.9)	0.89 (1.23)	-2.0	0.16	0.73	1.61	4.3	
		Week 44	Tezepelumab	57	50 (87.7)	1.51 (1.05)	-0.9	0.84	1.38	2.34	4.3	0.59 [0.20, 0.98]
			Placebo	63	56 (88.9)	0.84 (1.21)	-2.0	0.05	0.69	1.48	4.1	
		Week 48	Tezepelumab	57	50 (87.7)	1.49 (1.06)	-0.9	0.81	1.31	2.41	4.3	0.60 [0.21, 0.99]
			Placebo	63	56 (88.9)	0.83 (1.13)	-2.0	0.17	0.64	1.63	3.5	
		Week 52	Tezepelumab	57	50 (87.7)	1.45 (1.08)	-0.9	0.72	1.23	2.41	4.3	0.52 [0.14, 0.91]
			Placebo	63	56 (88.9)	0.87 (1.13)	-2.0	0.17	0.72	1.58	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.15 (0.72)	2.3	3.78	4.06	4.63	6.2	
			Placebo	66	54 (81.8)	4.07 (1.00)	1.8	3.47	4.11	4.59	6.3	
		Week 4	Tezepelumab	57	55 (96.5)	4.84 (0.90)	3.0	4.13	4.78	5.44	6.8	
			Placebo	66	57 (86.4)	4.44 (1.02)	2.1	3.81	4.38	5.09	6.8	
		Week 8	Tezepelumab	57	55 (96.5)	5.04 (0.91)	2.8	4.28	5.00	5.84	7.0	
			Placebo	66	60 (90.9)	4.54 (1.00)	2.1	3.94	4.36	5.13	6.9	
		Week 12	Tezepelumab	57	55 (96.5)	5.27 (0.94)	3.7	4.56	5.09	5.91	7.0	
			Placebo	66	60 (90.9)	4.62 (1.03)	2.5	3.97	4.38	5.33	7.0	
		Week 16	Tezepelumab	57	55 (96.5)	5.22 (0.93)	3.9	4.38	5.13	5.81	7.0	
			Placebo	66	60 (90.9)	4.60 (1.13)	1.2	3.94	4.55	5.34	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.21 (0.99)	3.5	4.34	5.25	5.88	7.0	
			Placebo	66	60 (90.9)	4.56 (1.16)	1.2	3.95	4.44	5.09	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.18 (1.04)	2.4	4.34	4.97	6.00	7.0	
			Placebo	66	60 (90.9)	4.54 (1.19)	1.2	3.88	4.39	5.48	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.23 (0.97)	3.3	4.50	5.17	5.91	7.0	
			Placebo	66	60 (90.9)	4.58 (1.23)	1.2	3.86	4.31	5.63	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.23 (0.94)	3.8	4.47	5.13	5.86	7.0	
			Placebo	66	61 (92.4)	4.55 (1.17)	1.2	3.97	4.31	5.50	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.21 (0.98)	3.2	4.53	5.02	5.78	7.0	
			Placebo	66	61 (92.4)	4.58 (1.14)	2.2	3.97	4.28	5.44	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.27 (0.95)	3.7	4.59	5.13	5.86	7.0	
			Placebo	66	61 (92.4)	4.63 (1.14)	2.3	3.88	4.34	5.63	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.21 (1.00)	3.0	4.48	5.05	5.94	7.0	
			Placebo	66	61 (92.4)	4.56 (1.09)	2.5	3.91	4.34	5.16	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.27 (1.00)	3.2	4.48	5.17	6.06	7.0	
			Placebo	66	62 (93.9)	4.63 (1.09)	2.1	3.97	4.31	5.34	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.26 (1.00)	3.2	4.52	5.14	6.06	7.0	
			Placebo	66	62 (93.9)	4.57 (1.11)	2.7	3.91	4.20	5.50	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	57	49 (86.0)	0.77 (0.75)	-1.3	0.25	0.69	1.41	2.7	0.52 [0.13, 0.92]
			Placebo	66	53 (80.3)	0.39 (0.73)	-1.1	0.03	0.31	0.72	2.6	
		Week 8	Tezepelumab	57	49 (86.0)	0.88 (0.92)	-1.0	0.31	0.72	1.59	3.0	0.46 [0.07, 0.85]
			Placebo	66	54 (81.8)	0.51 (0.72)	-1.4	0.16	0.36	0.97	2.7	
		Week 12	Tezepelumab	57	49 (86.0)	1.10 (0.91)	-0.9	0.56	0.97	1.84	3.0	0.60 [0.20, 0.99]
			Placebo	66	54 (81.8)	0.56 (0.90)	-1.7	-0.03	0.52	1.00	2.9	
		Week 16	Tezepelumab	57	49 (86.0)	1.06 (0.95)	-1.0	0.34	1.25	1.69	3.0	0.54 [0.15, 0.94]
			Placebo	66	54 (81.8)	0.54 (0.96)	-3.2	0.06	0.64	1.16	2.5	
		Week 20	Tezepelumab	57	49 (86.0)	1.09 (0.92)	-0.5	0.31	1.22	1.78	3.0	0.59 [0.20, 0.99]
			Placebo	66	54 (81.8)	0.53 (0.95)	-3.2	0.13	0.63	1.03	2.5	
		Week 24	Tezepelumab	57	49 (86.0)	1.07 (0.97)	-1.1	0.31	1.03	1.81	3.0	0.56 [0.16, 0.95]
			Placebo	66	54 (81.8)	0.51 (1.05)	-3.2	0.09	0.66	1.06	2.6	
		Week 28	Tezepelumab	57	49 (86.0)	1.11 (0.93)	-0.6	0.31	1.00	1.78	3.0	0.55 [0.16, 0.94]
			Placebo	66	54 (81.8)	0.55 (1.10)	-3.2	0.09	0.52	1.31	2.8	
		Week 32	Tezepelumab	57	49 (86.0)	1.15 (0.95)	-0.6	0.47	1.06	1.88	3.0	0.61 [0.21, 1.00]
			Placebo	66	54 (81.8)	0.56 (1.01)	-3.2	0.06	0.52	1.09	2.9	
		Week 36	Tezepelumab	57	49 (86.0)	1.12 (1.03)	-1.0	0.41	1.06	1.84	3.3	0.55 [0.15, 0.94]
			Placebo	66	54 (81.8)	0.56 (1.01)	-2.0	0.13	0.45	1.06	3.4	
		Week 40	Tezepelumab	57	49 (86.0)	1.17 (0.95)	-0.8	0.44	1.06	1.88	3.0	0.54 [0.15, 0.93]
			Placebo	66	54 (81.8)	0.62 (1.07)	-2.0	0.03	0.52	1.31	3.6	
		Week 44	Tezepelumab	57	49 (86.0)	1.11 (0.97)	-0.8	0.53	1.13	1.84	3.0	0.61 [0.22, 1.01]
			Placebo	66	54 (81.8)	0.51 (0.98)	-2.0	-0.06	0.48	1.13	3.2	
		Week 48	Tezepelumab	57	49 (86.0)	1.20 (0.94)	-0.8	0.63	1.13	2.06	3.0	0.63 [0.23, 1.02]
			Placebo	66	54 (81.8)	0.59 (1.01)	-2.0	0.00	0.64	1.06	3.3	
		Week 52	Tezepelumab	57	49 (86.0)	1.18 (0.97)	-0.8	0.44	1.06	2.06	3.0	0.65 [0.25, 1.05]
			Placebo	66	54 (81.8)	0.54 (0.99)	-2.0	-0.06	0.33	1.06	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	71	66 (93.0)	4.26 (1.03)	1.5	3.63	4.36	4.91	6.8	
			Placebo	63	58 (92.1)	4.10 (0.76)	2.7	3.63	4.05	4.69	6.1	
		Week 4	Tezepelumab	71	63 (88.7)	4.97 (1.17)	1.4	3.94	5.09	5.75	7.0	
			Placebo	63	57 (90.5)	4.72 (0.92)	2.5	4.00	4.69	5.28	6.8	
		Week 8	Tezepelumab	71	65 (91.5)	5.15 (1.16)	2.7	4.13	5.16	6.09	7.0	
			Placebo	63	57 (90.5)	4.85 (1.02)	2.3	4.25	4.78	5.59	6.8	
		Week 12	Tezepelumab	71	65 (91.5)	5.28 (1.15)	2.8	4.31	5.38	6.28	7.0	
			Placebo	63	58 (92.1)	4.95 (1.01)	2.9	4.22	4.97	5.75	6.9	
		Week 16	Tezepelumab	71	65 (91.5)	5.25 (1.12)	2.6	4.34	5.31	6.06	7.0	
			Placebo	63	58 (92.1)	5.01 (1.05)	3.0	4.16	4.98	5.75	6.9	
		Week 20	Tezepelumab	71	65 (91.5)	5.27 (1.06)	3.2	4.31	5.22	6.09	7.0	
			Placebo	63	58 (92.1)	5.05 (0.93)	3.0	4.25	5.02	5.88	6.8	
		Week 24	Tezepelumab	71	65 (91.5)	5.35 (1.05)	3.5	4.47	5.50	6.06	7.0	
			Placebo	63	58 (92.1)	5.11 (0.93)	3.6	4.41	5.14	5.88	6.9	
		Week 28	Tezepelumab	71	66 (93.0)	5.33 (1.06)	3.6	4.34	5.41	6.19	7.0	
			Placebo	63	59 (93.7)	5.17 (1.06)	2.7	4.31	5.25	5.97	7.0	
		Week 32	Tezepelumab	71	67 (94.4)	5.41 (1.10)	2.6	4.56	5.66	6.19	7.0	
			Placebo	63	59 (93.7)	5.28 (0.93)	3.5	4.56	5.31	6.09	6.9	
		Week 36	Tezepelumab	71	67 (94.4)	5.43 (1.06)	3.3	4.59	5.47	6.19	7.0	
			Placebo	63	59 (93.7)	5.27 (0.94)	3.5	4.50	5.19	6.00	6.9	
		Week 40	Tezepelumab	71	67 (94.4)	5.42 (1.12)	2.6	4.44	5.50	6.25	7.0	
			Placebo	63	59 (93.7)	5.30 (0.99)	3.5	4.41	5.34	6.09	7.0	
		Week 44	Tezepelumab	71	67 (94.4)	5.50 (1.07)	2.8	4.63	5.66	6.34	7.0	
			Placebo	63	59 (93.7)	5.29 (1.07)	3.5	4.22	5.25	6.28	7.0	
		Week 48	Tezepelumab	71	67 (94.4)	5.48 (1.09)	2.9	4.44	5.56	6.28	7.0	
			Placebo	63	59 (93.7)	5.29 (0.95)	3.5	4.53	5.34	6.00	7.0	
		Week 52	Tezepelumab	71	67 (94.4)	5.44 (1.11)	2.8	4.44	5.47	6.28	7.0	
			Placebo	63	59 (93.7)	5.31 (0.97)	3.5	4.72	5.41	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	71	61 (85.9)	0.69 (1.01)	-3.7	0.22	0.69	1.28	2.6	0.11 [-0.26, 0.47]
			Placebo	63	57 (90.5)	0.59 (0.85)	-1.2	0.09	0.50	1.25	2.6	
		Week 8	Tezepelumab	71	63 (88.7)	0.87 (0.89)	-1.0	0.28	0.81	1.53	2.7	0.16 [-0.20, 0.52]
			Placebo	63	57 (90.5)	0.72 (0.96)	-1.0	0.03	0.63	1.16	3.1	
		Week 12	Tezepelumab	71	63 (88.7)	1.01 (0.95)	-2.1	0.47	1.06	1.75	2.7	0.15 [-0.21, 0.51]
			Placebo	63	57 (90.5)	0.86 (1.08)	-2.0	0.31	0.84	1.25	3.5	
		Week 16	Tezepelumab	71	63 (88.7)	0.98 (0.94)	-2.4	0.50	0.81	1.59	2.6	0.08 [-0.28, 0.44]
			Placebo	63	57 (90.5)	0.90 (1.06)	-2.0	0.31	0.78	1.44	3.8	
		Week 20	Tezepelumab	71	63 (88.7)	0.99 (0.93)	-1.2	0.31	0.78	1.66	2.7	0.05 [-0.31, 0.41]
			Placebo	63	57 (90.5)	0.94 (0.96)	-0.8	0.34	0.81	1.19	3.8	
		Week 24	Tezepelumab	71	63 (88.7)	1.08 (0.95)	-1.2	0.47	0.97	1.78	3.0	0.08 [-0.28, 0.44]
			Placebo	63	57 (90.5)	1.01 (0.97)	-0.8	0.38	0.91	1.59	3.7	
		Week 28	Tezepelumab	71	63 (88.7)	1.04 (0.96)	-1.3	0.38	0.84	1.97	2.7	0.00 [-0.36, 0.36]
			Placebo	63	57 (90.5)	1.03 (1.09)	-0.9	0.34	0.97	1.72	4.3	
		Week 32	Tezepelumab	71	63 (88.7)	1.09 (0.95)	-1.2	0.50	1.00	1.94	2.6	-0.06 [-0.42, 0.30]
			Placebo	63	57 (90.5)	1.15 (0.94)	-0.7	0.56	0.97	1.72	3.6	
		Week 36	Tezepelumab	71	63 (88.7)	1.11 (1.02)	-1.3	0.41	0.91	2.06	2.8	-0.03 [-0.39, 0.32]
			Placebo	63	57 (90.5)	1.14 (0.96)	-0.8	0.53	1.00	1.72	3.4	
		Week 40	Tezepelumab	71	63 (88.7)	1.10 (0.99)	-1.3	0.59	0.94	1.94	2.9	-0.07 [-0.43, 0.29]
			Placebo	63	57 (90.5)	1.17 (1.05)	-0.8	0.59	1.03	1.72	4.3	
		Week 44	Tezepelumab	71	63 (88.7)	1.19 (0.99)	-1.1	0.53	1.00	2.00	3.3	0.02 [-0.33, 0.38]
			Placebo	63	57 (90.5)	1.16 (1.10)	-0.7	0.47	1.09	1.75	4.1	
		Week 48	Tezepelumab	71	63 (88.7)	1.17 (1.02)	-1.1	0.50	1.03	2.13	2.9	0.01 [-0.35, 0.37]
			Placebo	63	57 (90.5)	1.16 (0.98)	-0.7	0.41	1.00	1.69	3.5	
		Week 52	Tezepelumab	71	63 (88.7)	1.11 (1.02)	-1.2	0.44	1.03	2.00	3.0	-0.07 [-0.42, 0.29]
			Placebo	63	57 (90.5)	1.18 (1.00)	-0.6	0.47	0.97	1.72	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	35	31 (88.6)	4.25 (0.81)	2.2	3.72	4.41	4.81	6.2	
			Placebo	32	26 (81.3)	4.22 (0.95)	1.9	3.66	4.27	4.84	6.3	
		Week 4	Tezepelumab	35	33 (94.3)	5.07 (0.96)	3.3	4.16	5.00	5.81	6.7	
			Placebo	32	26 (81.3)	4.65 (1.11)	2.1	3.97	4.70	5.50	6.7	
		Week 8	Tezepelumab	35	33 (94.3)	5.15 (0.96)	3.4	4.28	5.06	5.97	6.7	
			Placebo	32	28 (87.5)	4.64 (1.16)	2.1	3.83	4.59	5.23	6.8	
		Week 12	Tezepelumab	35	33 (94.3)	5.41 (0.94)	3.9	4.63	5.34	6.22	7.0	
			Placebo	32	28 (87.5)	4.78 (1.14)	2.5	4.02	4.64	5.55	7.0	
		Week 16	Tezepelumab	35	33 (94.3)	5.38 (0.89)	4.0	4.63	5.50	6.09	6.9	
			Placebo	32	28 (87.5)	4.72 (1.34)	1.2	3.94	4.77	5.63	7.0	
		Week 20	Tezepelumab	35	34 (97.1)	5.26 (0.93)	3.8	4.47	5.25	5.88	7.0	
			Placebo	32	28 (87.5)	4.73 (1.42)	1.2	3.97	4.56	5.94	7.0	
		Week 24	Tezepelumab	35	34 (97.1)	5.39 (0.94)	4.0	4.63	5.33	6.03	7.0	
			Placebo	32	28 (87.5)	4.64 (1.54)	1.2	3.73	4.47	5.80	7.0	
		Week 28	Tezepelumab	35	35 (100.0)	5.31 (1.00)	3.3	4.63	5.19	6.03	7.0	
			Placebo	32	28 (87.5)	4.44 (1.39)	1.2	3.69	4.22	5.33	7.0	
		Week 32	Tezepelumab	35	35 (100.0)	5.26 (0.96)	3.9	4.47	5.34	6.00	7.0	
			Placebo	32	28 (87.5)	4.67 (1.41)	1.2	3.98	4.42	5.73	7.0	
		Week 36	Tezepelumab	35	35 (100.0)	5.35 (1.01)	3.5	4.59	5.19	6.19	7.0	
			Placebo	32	28 (87.5)	4.84 (1.36)	2.2	4.00	4.42	6.03	7.0	
		Week 40	Tezepelumab	35	35 (100.0)	5.25 (0.94)	3.7	4.66	5.13	5.84	7.0	
			Placebo	32	28 (87.5)	4.71 (1.33)	2.3	3.81	4.42	5.92	7.0	
		Week 44	Tezepelumab	35	35 (100.0)	5.31 (0.95)	3.8	4.63	5.38	5.91	7.0	
			Placebo	32	28 (87.5)	4.78 (1.27)	2.6	3.92	4.48	5.66	7.0	
		Week 48	Tezepelumab	35	35 (100.0)	5.35 (1.01)	3.2	4.63	5.38	6.09	7.0	
			Placebo	32	28 (87.5)	4.72 (1.36)	2.1	3.91	4.31	6.06	7.0	
		Week 52	Tezepelumab	35	35 (100.0)	5.33 (0.98)	3.2	4.69	5.22	6.09	7.0	
			Placebo	32	28 (87.5)	4.65 (1.25)	2.7	3.92	4.30	5.50	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	35	31 (88.6)	0.90 (0.90)	-1.3	0.38	0.97	1.56	3.3	0.50 [-0.04, 1.04]
			Placebo	32	25 (78.1)	0.49 (0.71)	-1.1	0.16	0.34	0.88	1.9	
		Week 8	Tezepelumab	35	31 (88.6)	0.89 (1.06)	-1.0	0.00	0.94	1.69	3.8	0.44 [-0.08, 0.97]
			Placebo	32	26 (81.3)	0.46 (0.87)	-1.4	-0.09	0.34	0.81	2.7	
		Week 12	Tezepelumab	35	31 (88.6)	1.15 (0.99)	-0.9	0.50	1.09	1.84	4.0	0.55 [0.02, 1.08]
			Placebo	32	26 (81.3)	0.59 (1.02)	-1.7	0.16	0.55	1.31	2.9	
		Week 16	Tezepelumab	35	31 (88.6)	1.14 (0.95)	-1.0	0.59	1.38	1.78	3.4	0.56 [0.03, 1.09]
			Placebo	32	26 (81.3)	0.53 (1.23)	-3.2	0.03	0.86	1.38	2.1	
		Week 20	Tezepelumab	35	31 (88.6)	1.01 (0.97)	-0.8	0.31	0.75	1.69	3.4	0.40 [-0.12, 0.93]
			Placebo	32	26 (81.3)	0.55 (1.32)	-3.2	0.13	0.63	1.34	2.8	
		Week 24	Tezepelumab	35	31 (88.6)	1.17 (0.92)	-0.5	0.47	1.13	1.81	3.4	0.60 [0.07, 1.13]
			Placebo	32	26 (81.3)	0.46 (1.44)	-3.2	-0.22	0.61	1.34	3.1	
		Week 28	Tezepelumab	35	31 (88.6)	1.11 (0.96)	-0.6	0.31	1.03	1.72	3.4	0.77 [0.23, 1.31]
			Placebo	32	26 (81.3)	0.24 (1.31)	-3.2	-0.16	0.31	1.13	3.1	
		Week 32	Tezepelumab	35	31 (88.6)	1.04 (0.96)	-0.6	0.34	1.03	1.69	3.4	0.49 [-0.04, 1.02]
			Placebo	32	26 (81.3)	0.49 (1.26)	-3.2	0.06	0.58	1.19	3.0	
		Week 36	Tezepelumab	35	31 (88.6)	1.13 (1.02)	-1.0	0.34	1.00	1.69	3.4	0.41 [-0.12, 0.94]
			Placebo	32	26 (81.3)	0.67 (1.21)	-2.0	0.31	0.72	1.28	3.0	
		Week 40	Tezepelumab	35	31 (88.6)	1.04 (0.95)	-0.8	0.31	0.97	1.69	3.4	0.47 [-0.06, 1.00]
			Placebo	32	26 (81.3)	0.53 (1.23)	-2.0	-0.16	0.45	1.50	2.8	
		Week 44	Tezepelumab	35	31 (88.6)	1.10 (0.96)	-0.8	0.50	1.09	1.84	3.4	0.46 [-0.07, 0.99]
			Placebo	32	26 (81.3)	0.61 (1.21)	-2.0	-0.16	0.55	1.19	3.1	
		Week 48	Tezepelumab	35	31 (88.6)	1.16 (0.97)	-0.8	0.44	1.19	1.78	3.4	0.57 [0.04, 1.10]
			Placebo	32	26 (81.3)	0.54 (1.22)	-2.0	-0.13	0.47	1.25	3.1	
		Week 52	Tezepelumab	35	31 (88.6)	1.13 (1.00)	-0.8	0.34	1.19	1.78	3.4	0.65 [0.11, 1.18]
			Placebo	32	26 (81.3)	0.46 (1.07)	-2.0	-0.16	0.31	1.06	3.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	95	86 (90.5)	4.18 (0.95)	1.5	3.66	4.22	4.56	6.8	
			Placebo	98	87 (88.8)	4.05 (0.88)	1.8	3.41	4.06	4.69	6.1	
		Week 4	Tezepelumab	95	86 (90.5)	4.87 (1.09)	1.4	4.06	4.97	5.66	7.0	
			Placebo	98	89 (90.8)	4.56 (0.94)	2.4	3.84	4.44	5.16	6.8	
		Week 8	Tezepelumab	95	88 (92.6)	5.11 (1.09)	2.7	4.30	5.09	5.91	7.0	
			Placebo	98	90 (91.8)	4.73 (1.02)	2.3	4.03	4.69	5.50	7.0	
		Week 12	Tezepelumab	95	88 (92.6)	5.26 (1.09)	2.8	4.47	5.17	6.09	7.0	
			Placebo	98	91 (92.9)	4.82 (1.05)	2.7	3.97	4.78	5.72	7.0	
		Week 16	Tezepelumab	95	88 (92.6)	5.21 (1.09)	2.6	4.36	5.14	6.03	7.0	
			Placebo	98	91 (92.9)	4.85 (1.07)	2.5	4.00	4.75	5.72	7.0	
		Week 20	Tezepelumab	95	88 (92.6)	5.24 (1.06)	3.2	4.31	5.20	6.09	7.0	
			Placebo	98	91 (92.9)	4.86 (1.03)	2.5	4.03	4.78	5.78	7.0	
		Week 24	Tezepelumab	95	88 (92.6)	5.25 (1.09)	2.4	4.34	5.14	6.05	7.0	
			Placebo	98	91 (92.9)	4.94 (1.00)	2.9	4.00	4.84	5.81	7.0	
		Week 28	Tezepelumab	95	89 (93.7)	5.29 (1.02)	3.6	4.44	5.31	6.03	7.0	
			Placebo	98	92 (93.9)	5.02 (1.15)	2.7	4.00	4.88	5.98	7.0	
		Week 32	Tezepelumab	95	90 (94.7)	5.36 (1.07)	2.6	4.47	5.44	6.09	7.0	
			Placebo	98	93 (94.9)	5.01 (1.06)	2.7	4.03	4.84	5.94	7.0	
		Week 36	Tezepelumab	95	90 (94.7)	5.33 (1.04)	3.2	4.59	5.34	6.19	7.0	
			Placebo	98	93 (94.9)	4.99 (1.08)	2.6	4.03	4.81	5.97	7.0	
		Week 40	Tezepelumab	95	90 (94.7)	5.37 (1.09)	2.6	4.47	5.30	6.25	7.0	
			Placebo	98	93 (94.9)	5.06 (1.08)	2.7	4.03	5.00	6.00	7.0	
		Week 44	Tezepelumab	95	90 (94.7)	5.41 (1.08)	2.8	4.53	5.30	6.31	7.0	
			Placebo	98	93 (94.9)	5.03 (1.14)	2.5	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	95	90 (94.7)	5.41 (1.07)	2.9	4.47	5.36	6.31	7.0	
			Placebo	98	94 (95.9)	5.07 (1.03)	2.9	4.13	4.98	5.94	7.0	
		Week 52	Tezepelumab	95	90 (94.7)	5.39 (1.08)	2.8	4.47	5.38	6.28	7.0	
			Placebo	98	94 (95.9)	5.05 (1.09)	2.7	4.03	5.02	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	95	80 (84.2)	0.70 (0.99)	-3.7	0.16	0.66	1.28	3.0	0.23 [-0.07, 0.54]
			Placebo	98	86 (87.8)	0.50 (0.79)	-1.2	0.06	0.44	1.00	2.6	
		Week 8	Tezepelumab	95	82 (86.3)	0.93 (0.95)	-1.0	0.31	0.73	1.59	3.9	0.27 [-0.04, 0.57]
			Placebo	98	86 (87.8)	0.69 (0.85)	-1.0	0.16	0.56	1.09	3.1	
		Week 12	Tezepelumab	95	82 (86.3)	1.08 (1.01)	-2.1	0.50	0.97	1.75	4.2	0.29 [-0.01, 0.60]
			Placebo	98	86 (87.8)	0.78 (1.02)	-2.0	0.19	0.72	1.22	3.5	
		Week 16	Tezepelumab	95	82 (86.3)	1.04 (1.02)	-2.4	0.34	0.84	1.69	4.2	0.23 [-0.07, 0.53]
			Placebo	98	86 (87.8)	0.82 (0.94)	-2.0	0.28	0.72	1.38	3.8	
		Week 20	Tezepelumab	95	82 (86.3)	1.08 (1.01)	-1.2	0.28	0.94	1.78	4.2	0.25 [-0.05, 0.56]
			Placebo	98	86 (87.8)	0.84 (0.88)	-0.8	0.28	0.77	1.09	3.8	
		Week 24	Tezepelumab	95	82 (86.3)	1.12 (1.05)	-1.2	0.34	1.00	1.84	4.3	0.20 [-0.10, 0.50]
			Placebo	98	86 (87.8)	0.92 (0.91)	-0.8	0.28	0.88	1.38	3.7	
		Week 28	Tezepelumab	95	82 (86.3)	1.12 (1.02)	-1.3	0.38	0.91	1.97	4.3	0.13 [-0.18, 0.43]
			Placebo	98	86 (87.8)	0.99 (1.02)	-0.9	0.25	0.97	1.47	4.3	
		Week 32	Tezepelumab	95	82 (86.3)	1.19 (1.04)	-1.2	0.50	1.09	2.09	4.3	0.20 [-0.10, 0.50]
			Placebo	98	86 (87.8)	1.00 (0.93)	-0.8	0.31	0.81	1.50	3.6	
		Week 36	Tezepelumab	95	82 (86.3)	1.15 (1.09)	-1.3	0.41	0.98	2.16	4.3	0.18 [-0.12, 0.49]
			Placebo	98	86 (87.8)	0.96 (0.98)	-1.2	0.22	0.77	1.56	3.4	
		Week 40	Tezepelumab	95	82 (86.3)	1.20 (1.05)	-1.3	0.59	1.02	2.06	4.3	0.15 [-0.15, 0.46]
			Placebo	98	86 (87.8)	1.04 (1.03)	-0.8	0.34	0.88	1.66	4.3	
		Week 44	Tezepelumab	95	82 (86.3)	1.23 (1.05)	-1.1	0.53	1.13	2.00	4.3	0.22 [-0.08, 0.53]
			Placebo	98	86 (87.8)	0.99 (1.07)	-1.3	0.31	0.95	1.47	4.1	
		Week 48	Tezepelumab	95	82 (86.3)	1.24 (1.06)	-1.1	0.53	1.06	2.13	4.3	0.20 [-0.10, 0.50]
			Placebo	98	86 (87.8)	1.04 (0.97)	-0.7	0.31	0.95	1.66	3.5	
		Week 52	Tezepelumab	95	82 (86.3)	1.20 (1.06)	-1.2	0.50	1.06	2.13	4.3	0.17 [-0.13, 0.48]
			Placebo	98	86 (87.8)	1.03 (1.00)	-0.7	0.22	0.94	1.66	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	4.23 (1.08)	2.3	3.81	4.55	5.06	5.1	
			Placebo	8	8 (100.0)	4.08 (0.42)	3.4	3.83	4.11	4.31	4.8	
		Week 4	Tezepelumab	7	7 (100.0)	4.68 (0.77)	3.8	3.84	4.56	5.66	5.7	
			Placebo	8	8 (100.0)	4.88 (0.78)	3.8	4.22	5.02	5.39	6.0	
		Week 8	Tezepelumab	7	7 (100.0)	4.88 (0.96)	3.9	4.00	4.59	5.97	6.2	
			Placebo	8	8 (100.0)	4.79 (0.83)	3.9	4.25	4.42	5.39	6.3	
		Week 12	Tezepelumab	7	7 (100.0)	4.96 (0.89)	4.1	4.31	4.38	5.84	6.3	
			Placebo	8	8 (100.0)	5.02 (0.69)	4.3	4.61	4.92	5.16	6.5	
		Week 16	Tezepelumab	7	7 (100.0)	4.98 (0.87)	4.2	4.19	4.63	5.88	6.3	
			Placebo	8	8 (100.0)	5.16 (0.74)	4.1	4.67	5.05	5.63	6.5	
		Week 20	Tezepelumab	7	7 (100.0)	5.06 (0.88)	4.1	4.19	4.72	5.91	6.3	
			Placebo	8	8 (100.0)	5.13 (0.58)	4.2	4.91	5.06	5.33	6.3	
		Week 24	Tezepelumab	7	7 (100.0)	4.99 (1.00)	3.9	4.09	4.53	5.94	6.3	
			Placebo	8	8 (100.0)	5.00 (0.77)	3.8	4.56	4.97	5.36	6.4	
		Week 28	Tezepelumab	7	7 (100.0)	5.07 (0.90)	4.1	4.34	4.53	5.94	6.3	
			Placebo	8	8 (100.0)	5.05 (0.67)	4.0	4.64	5.09	5.42	6.1	
		Week 32	Tezepelumab	7	7 (100.0)	5.27 (0.93)	4.4	4.44	4.72	6.25	6.5	
			Placebo	8	8 (100.0)	5.23 (0.70)	4.1	4.84	5.22	5.61	6.4	
		Week 36	Tezepelumab	7	7 (100.0)	5.34 (0.87)	4.2	4.59	4.97	6.25	6.4	
			Placebo	8	8 (100.0)	5.14 (0.83)	3.8	4.73	5.08	5.53	6.6	
		Week 40	Tezepelumab	7	7 (100.0)	5.36 (0.93)	4.1	4.44	5.28	6.25	6.5	
			Placebo	8	8 (100.0)	5.18 (0.75)	4.1	4.69	5.23	5.47	6.5	
		Week 44	Tezepelumab	7	7 (100.0)	5.35 (0.92)	4.2	4.38	5.06	6.25	6.5	
			Placebo	8	8 (100.0)	5.02 (0.99)	3.9	3.98	5.23	5.59	6.6	
		Week 48	Tezepelumab	7	7 (100.0)	5.27 (0.84)	4.2	4.44	5.34	6.00	6.3	
			Placebo	8	8 (100.0)	5.09 (0.94)	3.8	4.61	4.94	5.44	7.0	
		Week 52	Tezepelumab	7	7 (100.0)	5.35 (0.97)	4.2	4.38	5.34	6.25	6.6	
			Placebo	8	8 (100.0)	5.08 (0.93)	3.8	4.61	4.92	5.39	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	0.44 (0.71)	-0.6	0.03	0.44	0.75	1.5	-0.43 [-1.50, 0.64]
			Placebo	8	8 (100.0)	0.80 (0.92)	-0.5	0.09	0.77	1.42	2.3	
		Week 8	Tezepelumab	7	6 (85.7)	0.56 (0.88)	-0.5	-0.25	0.59	1.28	1.7	-0.15 [-1.21, 0.91]
			Placebo	8	8 (100.0)	0.71 (1.06)	-0.4	-0.13	0.41	1.45	2.6	
		Week 12	Tezepelumab	7	6 (85.7)	0.65 (1.02)	-0.8	0.13	0.55	1.44	2.1	-0.30 [-1.37, 0.76]
			Placebo	8	8 (100.0)	0.94 (0.88)	-0.0	0.31	0.81	1.23	2.8	
		Week 16	Tezepelumab	7	6 (85.7)	0.67 (0.93)	-0.8	0.34	0.63	1.34	1.9	-0.45 [-1.53, 0.62]
			Placebo	8	8 (100.0)	1.08 (0.91)	0.0	0.50	0.75	1.69	2.8	
		Week 20	Tezepelumab	7	6 (85.7)	0.71 (0.86)	-0.6	0.28	0.69	1.34	1.9	-0.43 [-1.50, 0.64]
			Placebo	8	8 (100.0)	1.05 (0.72)	0.2	0.67	0.80	1.38	2.5	
		Week 24	Tezepelumab	7	6 (85.7)	0.60 (0.89)	-0.6	0.09	0.50	1.34	1.8	-0.35 [-1.42, 0.72]
			Placebo	8	8 (100.0)	0.92 (0.90)	-0.0	0.27	0.66	1.42	2.7	
		Week 28	Tezepelumab	7	6 (85.7)	0.70 (0.92)	-0.6	0.25	0.59	1.34	2.0	-0.30 [-1.37, 0.76]
			Placebo	8	8 (100.0)	0.96 (0.83)	-0.3	0.47	0.88	1.48	2.4	
		Week 32	Tezepelumab	7	6 (85.7)	0.83 (1.03)	-0.7	0.41	0.75	1.34	2.4	-0.35 [-1.42, 0.71]
			Placebo	8	8 (100.0)	1.15 (0.81)	0.3	0.58	0.88	1.67	2.7	
		Week 36	Tezepelumab	7	6 (85.7)	0.93 (1.06)	-0.5	0.41	0.84	1.34	2.7	-0.14 [-1.20, 0.92]
			Placebo	8	8 (100.0)	1.06 (0.92)	0.4	0.42	0.66	1.53	2.9	
		Week 40	Tezepelumab	7	6 (85.7)	0.93 (1.09)	-0.7	0.31	1.02	1.34	2.6	-0.17 [-1.23, 0.89]
			Placebo	8	8 (100.0)	1.10 (0.86)	-0.2	0.77	0.84	1.45	2.8	
		Week 44	Tezepelumab	7	6 (85.7)	0.92 (1.15)	-0.8	0.41	0.88	1.34	2.8	-0.02 [-1.07, 1.04]
			Placebo	8	8 (100.0)	0.93 (1.10)	-0.4	0.14	0.70	1.64	2.9	
		Week 48	Tezepelumab	7	6 (85.7)	0.92 (1.04)	-0.7	0.34	1.05	1.34	2.4	-0.09 [-1.15, 0.97]
			Placebo	8	8 (100.0)	1.01 (1.03)	0.2	0.38	0.64	1.31	3.3	
		Week 52	Tezepelumab	7	6 (85.7)	0.91 (1.05)	-0.8	0.34	1.05	1.34	2.4	-0.09 [-1.15, 0.97]
			Placebo	8	8 (100.0)	1.00 (1.03)	0.2	0.36	0.64	1.27	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.10 (0.90)	2.8	3.41	4.13	4.77	5.4	
			Placebo	13	9 (69.2)	4.52 (0.73)	3.8	4.22	4.34	4.69	6.3	
		Week 4	Tezepelumab	9	8 (88.9)	4.95 (0.88)	3.3	4.53	4.98	5.61	6.1	
			Placebo	13	11 (84.6)	4.77 (0.96)	3.0	3.88	4.88	5.53	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.46 (1.05)	3.6	4.86	5.53	6.23	6.8	
			Placebo	13	12 (92.3)	4.53 (0.77)	3.3	3.84	4.47	5.23	5.6	
		Week 12	Tezepelumab	9	8 (88.9)	5.54 (1.05)	4.2	4.59	5.41	6.53	7.0	
			Placebo	13	12 (92.3)	4.49 (0.89)	2.8	3.91	4.59	5.11	5.8	
		Week 16	Tezepelumab	9	8 (88.9)	5.70 (0.90)	4.4	5.06	5.70	6.41	6.9	
			Placebo	13	12 (92.3)	4.77 (0.93)	2.9	4.28	4.83	5.36	6.4	
		Week 20	Tezepelumab	9	8 (88.9)	5.25 (1.14)	3.8	4.27	5.11	6.33	6.8	
			Placebo	13	12 (92.3)	4.72 (0.91)	2.9	4.14	4.88	5.31	6.4	
		Week 24	Tezepelumab	9	8 (88.9)	5.41 (1.07)	4.3	4.47	5.27	6.39	6.8	
			Placebo	13	12 (92.3)	4.67 (1.08)	2.7	4.05	4.36	5.55	6.4	
		Week 28	Tezepelumab	9	8 (88.9)	5.16 (1.10)	3.3	4.58	5.03	5.95	6.8	
			Placebo	13	13 (100.0)	4.79 (1.14)	2.8	4.00	4.34	5.69	6.8	
		Week 32	Tezepelumab	9	8 (88.9)	5.34 (1.17)	3.9	4.36	5.20	6.39	6.9	
			Placebo	13	13 (100.0)	4.91 (1.13)	3.2	4.19	4.56	5.72	6.9	
		Week 36	Tezepelumab	9	8 (88.9)	5.25 (1.13)	3.5	4.36	5.45	6.08	6.8	
			Placebo	13	13 (100.0)	4.88 (1.26)	2.2	4.22	4.69	5.69	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.41 (1.17)	3.8	4.55	5.30	6.38	7.0	
			Placebo	13	13 (100.0)	4.78 (1.29)	2.3	4.13	4.31	5.44	6.9	
		Week 44	Tezepelumab	9	8 (88.9)	5.41 (1.00)	4.2	4.55	5.31	6.23	6.8	
			Placebo	13	13 (100.0)	4.89 (1.16)	2.8	4.22	4.75	5.81	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.29 (1.17)	3.2	4.45	5.63	6.08	6.8	
			Placebo	13	13 (100.0)	4.81 (1.27)	2.1	4.22	4.56	5.41	6.8	
		Week 52	Tezepelumab	9	8 (88.9)	5.38 (1.20)	3.2	4.45	5.91	6.19	6.7	
			Placebo	13	13 (100.0)	4.88 (1.13)	3.3	4.22	4.47	5.41	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.85 (0.41)	0.3	0.50	0.69	1.28	1.4	0.76 [-0.27, 1.79]
			Placebo	13	9 (69.2)	0.28 (0.93)	-1.1	-0.47	0.50	0.66	1.6	
		Week 8	Tezepelumab	9	7 (77.8)	1.34 (0.65)	0.5	0.69	1.56	1.94	2.1	1.39 [0.27, 2.50]
			Placebo	13	9 (69.2)	0.20 (0.93)	-1.4	-0.41	0.19	0.84	1.7	
		Week 12	Tezepelumab	9	7 (77.8)	1.46 (0.60)	0.7	0.91	1.44	2.09	2.1	1.83 [0.63, 3.03]
			Placebo	13	9 (69.2)	-0.05 (0.96)	-1.7	-0.97	0.31	0.78	0.9	
		Week 16	Tezepelumab	9	7 (77.8)	1.62 (0.74)	0.6	0.69	1.72	2.44	2.4	1.19 [0.11, 2.27]
			Placebo	13	9 (69.2)	0.40 (1.20)	-2.0	0.31	0.66	1.00	1.7	
		Week 20	Tezepelumab	9	7 (77.8)	1.33 (0.84)	0.2	0.69	1.41	2.31	2.4	0.94 [-0.11, 1.98]
			Placebo	13	9 (69.2)	0.35 (1.19)	-2.0	-0.16	0.69	0.81	1.7	
		Week 24	Tezepelumab	9	7 (77.8)	1.51 (0.83)	0.6	0.69	1.66	2.28	2.8	0.97 [-0.08, 2.03]
			Placebo	13	9 (69.2)	0.40 (1.33)	-2.0	-0.16	0.78	1.56	1.8	
		Week 28	Tezepelumab	9	7 (77.8)	1.17 (0.95)	0.4	0.53	0.69	2.34	2.7	0.76 [-0.27, 1.78]
			Placebo	13	9 (69.2)	0.30 (1.26)	-2.0	-0.31	0.78	1.25	1.7	
		Week 32	Tezepelumab	9	7 (77.8)	1.43 (0.78)	0.7	0.72	1.09	2.19	2.6	0.90 [-0.14, 1.94]
			Placebo	13	9 (69.2)	0.47 (1.24)	-2.0	-0.16	0.78	1.41	1.7	
		Week 36	Tezepelumab	9	7 (77.8)	1.35 (0.85)	0.7	0.72	0.84	2.28	2.8	0.82 [-0.21, 1.85]
			Placebo	13	9 (69.2)	0.37 (1.41)	-2.0	-0.16	0.78	1.09	2.1	
		Week 40	Tezepelumab	9	7 (77.8)	1.47 (0.87)	0.6	0.69	1.03	2.31	2.8	0.96 [-0.09, 2.01]
			Placebo	13	9 (69.2)	0.31 (1.41)	-2.0	-0.16	0.72	1.50	2.0	
		Week 44	Tezepelumab	9	7 (77.8)	1.47 (1.00)	0.4	0.69	1.13	2.38	3.3	0.93 [-0.11, 1.98]
			Placebo	13	9 (69.2)	0.34 (1.35)	-2.0	-0.41	0.53	1.72	1.9	
		Week 48	Tezepelumab	9	7 (77.8)	1.37 (1.04)	0.4	0.44	0.69	2.34	2.9	0.87 [-0.17, 1.91]
			Placebo	13	9 (69.2)	0.27 (1.41)	-2.0	-0.16	0.72	0.81	2.2	
		Week 52	Tezepelumab	9	7 (77.8)	1.46 (0.95)	0.4	0.69	1.22	2.22	2.9	0.94 [-0.10, 1.99]
			Placebo	13	9 (69.2)	0.40 (1.24)	-2.0	-0.16	0.72	0.81	2.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.21 (0.92)	1.5	3.72	4.28	4.69	6.8	
			Placebo	125	112 (89.6)	4.05 (0.88)	1.8	3.47	4.06	4.69	6.1	
		Week 4	Tezepelumab	128	118 (92.2)	4.91 (1.05)	1.4	4.13	4.97	5.66	7.0	
			Placebo	125	112 (89.6)	4.59 (0.97)	2.1	3.91	4.48	5.22	6.8	
		Week 8	Tezepelumab	128	120 (93.8)	5.09 (1.04)	2.7	4.22	5.03	5.92	7.0	
			Placebo	125	114 (91.2)	4.73 (1.06)	2.1	4.00	4.64	5.50	7.0	
		Week 12	Tezepelumab	128	120 (93.8)	5.26 (1.04)	2.8	4.36	5.20	6.11	7.0	
			Placebo	125	115 (92.0)	4.86 (1.06)	2.5	4.03	4.78	5.72	7.0	
		Week 16	Tezepelumab	128	120 (93.8)	5.21 (1.03)	2.6	4.36	5.14	6.02	7.0	
			Placebo	125	115 (92.0)	4.85 (1.13)	1.2	3.97	4.75	5.75	7.0	
		Week 20	Tezepelumab	128	121 (94.5)	5.23 (1.01)	3.2	4.34	5.22	5.94	7.0	
			Placebo	125	115 (92.0)	4.86 (1.12)	1.2	4.00	4.78	5.88	7.0	
		Week 24	Tezepelumab	128	121 (94.5)	5.26 (1.04)	2.4	4.38	5.16	6.00	7.0	
			Placebo	125	115 (92.0)	4.90 (1.13)	1.2	4.00	4.81	5.81	7.0	
		Week 28	Tezepelumab	128	123 (96.1)	5.29 (1.00)	3.6	4.44	5.19	6.03	7.0	
			Placebo	125	115 (92.0)	4.91 (1.21)	1.2	3.97	4.84	5.91	7.0	
		Week 32	Tezepelumab	128	124 (96.9)	5.33 (1.02)	2.6	4.47	5.41	6.00	7.0	
			Placebo	125	116 (92.8)	4.95 (1.14)	1.2	4.02	4.84	5.91	7.0	
		Week 36	Tezepelumab	128	124 (96.9)	5.34 (1.01)	3.2	4.59	5.30	6.19	7.0	
			Placebo	125	116 (92.8)	4.98 (1.11)	2.6	4.00	4.81	5.95	7.0	
		Week 40	Tezepelumab	128	124 (96.9)	5.33 (1.03)	2.6	4.55	5.27	6.06	7.0	
			Placebo	125	116 (92.8)	5.01 (1.11)	2.5	4.00	4.98	5.92	7.0	
		Week 44	Tezepelumab	128	124 (96.9)	5.38 (1.04)	2.8	4.55	5.31	6.20	7.0	
			Placebo	125	116 (92.8)	4.99 (1.16)	2.5	4.00	4.95	6.00	7.0	
		Week 48	Tezepelumab	128	124 (96.9)	5.39 (1.03)	2.9	4.50	5.34	6.23	7.0	
			Placebo	125	117 (93.6)	5.02 (1.09)	2.8	4.03	4.91	5.94	7.0	
		Week 52	Tezepelumab	128	124 (96.9)	5.37 (1.04)	2.8	4.52	5.30	6.22	7.0	
			Placebo	125	117 (93.6)	4.97 (1.12)	2.7	4.00	4.91	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	110 (85.9)	0.73 (0.98)	-3.7	0.09	0.67	1.41	3.3	0.23 [-0.04, 0.49]
			Placebo	125	110 (88.0)	0.53 (0.77)	-1.2	0.09	0.42	1.00	2.6	
		Week 8	Tezepelumab	128	112 (87.5)	0.87 (0.98)	-1.0	0.13	0.73	1.56	3.9	0.21 [-0.05, 0.48]
			Placebo	125	111 (88.8)	0.67 (0.85)	-1.0	0.16	0.53	1.16	3.1	
		Week 12	Tezepelumab	128	112 (87.5)	1.05 (1.02)	-2.1	0.47	0.95	1.77	4.2	0.23 [-0.03, 0.50]
			Placebo	125	111 (88.8)	0.82 (0.98)	-2.0	0.22	0.72	1.31	3.5	
		Week 16	Tezepelumab	128	112 (87.5)	1.01 (1.00)	-2.4	0.34	0.88	1.67	4.2	0.21 [-0.05, 0.47]
			Placebo	125	111 (88.8)	0.80 (0.99)	-3.2	0.22	0.72	1.38	3.8	
		Week 20	Tezepelumab	128	112 (87.5)	1.03 (1.00)	-1.2	0.28	0.83	1.72	4.2	0.20 [-0.06, 0.47]
			Placebo	125	111 (88.8)	0.83 (0.97)	-3.2	0.25	0.78	1.22	3.8	
		Week 24	Tezepelumab	128	112 (87.5)	1.08 (1.01)	-1.2	0.33	1.00	1.78	4.3	0.22 [-0.04, 0.48]
			Placebo	125	111 (88.8)	0.86 (1.03)	-3.2	0.16	0.78	1.34	3.7	
		Week 28	Tezepelumab	128	112 (87.5)	1.09 (1.00)	-1.3	0.31	0.95	1.86	4.3	0.21 [-0.05, 0.48]
			Placebo	125	111 (88.8)	0.87 (1.10)	-3.2	0.19	0.84	1.44	4.3	
		Week 32	Tezepelumab	128	112 (87.5)	1.12 (1.03)	-1.2	0.38	1.03	1.91	4.3	0.18 [-0.08, 0.45]
			Placebo	125	111 (88.8)	0.93 (0.99)	-3.2	0.31	0.75	1.47	3.6	
		Week 36	Tezepelumab	128	112 (87.5)	1.12 (1.08)	-1.3	0.33	0.97	1.94	4.3	0.17 [-0.10, 0.43]
			Placebo	125	111 (88.8)	0.95 (0.99)	-1.7	0.31	0.75	1.50	3.4	
		Week 40	Tezepelumab	128	112 (87.5)	1.12 (1.03)	-1.3	0.44	0.97	1.86	4.3	0.13 [-0.13, 0.40]
			Placebo	125	111 (88.8)	0.98 (1.04)	-1.2	0.28	0.84	1.66	4.3	
		Week 44	Tezepelumab	128	112 (87.5)	1.16 (1.03)	-1.1	0.52	1.03	1.88	4.3	0.20 [-0.06, 0.46]
			Placebo	125	111 (88.8)	0.95 (1.08)	-1.3	0.25	0.84	1.41	4.1	
		Week 48	Tezepelumab	128	112 (87.5)	1.20 (1.03)	-1.1	0.50	1.06	2.06	4.3	0.21 [-0.05, 0.47]
			Placebo	125	111 (88.8)	0.98 (0.99)	-0.9	0.19	0.91	1.66	3.5	
		Week 52	Tezepelumab	128	112 (87.5)	1.15 (1.04)	-1.2	0.44	1.06	1.97	4.3	0.20 [-0.06, 0.47]
			Placebo	125	111 (88.8)	0.94 (1.01)	-0.9	0.19	0.84	1.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	4.29 (0.92)	1.5	3.80	4.36	4.78	6.8	
			Placebo	73	66 (90.4)	3.95 (0.91)	1.9	3.28	3.95	4.56	5.9	
		Week 4	Tezepelumab	70	65 (92.9)	5.00 (1.04)	3.2	4.22	4.97	5.72	7.0	
			Placebo	73	66 (90.4)	4.46 (0.98)	2.1	3.81	4.41	5.16	6.7	
		Week 8	Tezepelumab	70	65 (92.9)	5.13 (1.05)	2.7	4.44	5.03	5.84	7.0	
			Placebo	73	67 (91.8)	4.60 (1.07)	2.1	3.91	4.56	5.44	6.8	
		Week 12	Tezepelumab	70	65 (92.9)	5.28 (1.09)	2.8	4.47	5.34	5.97	7.0	
			Placebo	73	68 (93.2)	4.71 (1.07)	2.5	3.97	4.55	5.63	7.0	
		Week 16	Tezepelumab	70	65 (92.9)	5.25 (1.04)	2.6	4.38	5.19	6.00	7.0	
			Placebo	73	68 (93.2)	4.74 (1.05)	2.5	3.95	4.61	5.72	7.0	
		Week 20	Tezepelumab	70	65 (92.9)	5.25 (1.02)	3.6	4.34	5.22	5.94	7.0	
			Placebo	73	68 (93.2)	4.84 (1.03)	2.5	4.02	4.66	5.67	7.0	
		Week 24	Tezepelumab	70	65 (92.9)	5.30 (1.06)	2.4	4.47	5.22	6.00	7.0	
			Placebo	73	68 (93.2)	4.90 (1.06)	2.3	4.00	4.80	5.73	7.0	
		Week 28	Tezepelumab	70	65 (92.9)	5.34 (0.97)	3.8	4.47	5.31	6.03	7.0	
			Placebo	73	68 (93.2)	4.85 (1.12)	2.7	3.97	4.50	5.83	7.0	
		Week 32	Tezepelumab	70	66 (94.3)	5.39 (1.00)	2.6	4.56	5.58	6.00	7.0	
			Placebo	73	69 (94.5)	4.91 (1.09)	2.3	4.00	4.66	5.88	7.0	
		Week 36	Tezepelumab	70	66 (94.3)	5.34 (0.99)	3.2	4.63	5.22	6.00	7.0	
			Placebo	73	69 (94.5)	5.01 (1.11)	2.6	4.09	4.75	6.00	7.0	
		Week 40	Tezepelumab	70	66 (94.3)	5.41 (1.02)	2.6	4.63	5.39	6.06	7.0	
			Placebo	73	69 (94.5)	4.98 (1.07)	2.7	4.00	4.91	5.88	7.0	
		Week 44	Tezepelumab	70	66 (94.3)	5.46 (1.04)	2.8	4.63	5.39	6.34	7.0	
			Placebo	73	69 (94.5)	4.95 (1.19)	2.5	4.00	4.88	6.00	7.0	
		Week 48	Tezepelumab	70	66 (94.3)	5.45 (1.02)	3.4	4.53	5.38	6.31	7.0	
			Placebo	73	70 (95.9)	5.00 (1.09)	2.8	4.03	4.94	5.91	7.0	
		Week 52	Tezepelumab	70	66 (94.3)	5.42 (1.03)	2.8	4.53	5.34	6.22	7.0	
			Placebo	73	70 (95.9)	4.90 (1.13)	2.7	3.97	4.91	5.81	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 4	Tezepelumab	70	61 (87.1)	0.75 (0.88)	-1.3	0.16	0.63	1.25	3.0	0.29 [-0.06, 0.64]
			Placebo	73	65 (89.0)	0.51 (0.77)	-1.2	0.06	0.44	1.03	2.0	
		Week 8	Tezepelumab	70	61 (87.1)	0.87 (0.94)	-0.8	0.19	0.72	1.34	3.9	0.24 [-0.11, 0.59]
			Placebo	73	65 (89.0)	0.65 (0.84)	-1.0	0.09	0.53	1.19	2.7	
		Week 12	Tezepelumab	70	61 (87.1)	1.01 (0.98)	-0.9	0.41	0.94	1.47	4.2	0.23 [-0.12, 0.58]
			Placebo	73	65 (89.0)	0.78 (1.00)	-2.0	0.19	0.69	1.31	3.4	
		Week 16	Tezepelumab	70	61 (87.1)	0.99 (0.97)	-1.0	0.34	0.84	1.47	4.2	0.19 [-0.16, 0.54]
			Placebo	73	65 (89.0)	0.80 (0.93)	-2.0	0.22	0.78	1.38	3.5	
		Week 20	Tezepelumab	70	61 (87.1)	0.99 (0.99)	-0.8	0.25	0.81	1.63	4.2	0.08 [-0.27, 0.43]
			Placebo	73	65 (89.0)	0.91 (0.91)	-0.8	0.25	0.81	1.22	3.8	
		Week 24	Tezepelumab	70	61 (87.1)	1.05 (0.99)	-1.1	0.34	0.91	1.69	4.3	0.08 [-0.27, 0.43]
			Placebo	73	65 (89.0)	0.98 (0.94)	-0.8	0.38	0.94	1.38	3.7	
		Week 28	Tezepelumab	70	61 (87.1)	1.07 (0.96)	-0.6	0.31	0.88	1.69	4.3	0.15 [-0.20, 0.50]
			Placebo	73	65 (89.0)	0.92 (1.02)	-0.9	0.19	0.78	1.44	4.3	
		Week 32	Tezepelumab	70	61 (87.1)	1.10 (0.97)	-0.6	0.50	1.03	1.69	4.3	0.10 [-0.25, 0.45]
			Placebo	73	65 (89.0)	1.01 (0.97)	-0.8	0.31	0.78	1.50	3.6	
		Week 36	Tezepelumab	70	61 (87.1)	1.05 (1.02)	-1.0	0.34	0.94	1.69	4.3	-0.05 [-0.40, 0.30]
			Placebo	73	65 (89.0)	1.10 (1.02)	-0.8	0.31	1.00	1.72	3.4	
		Week 40	Tezepelumab	70	61 (87.1)	1.11 (0.98)	-0.8	0.44	0.94	1.81	4.3	0.04 [-0.31, 0.39]
			Placebo	73	65 (89.0)	1.07 (1.05)	-0.8	0.34	0.91	1.66	4.3	
		Week 44	Tezepelumab	70	61 (87.1)	1.17 (0.98)	-0.8	0.53	1.13	1.81	4.3	0.12 [-0.22, 0.47]
			Placebo	73	65 (89.0)	1.04 (1.10)	-1.3	0.34	0.97	1.50	4.1	
		Week 48	Tezepelumab	70	61 (87.1)	1.17 (0.99)	-0.8	0.53	0.94	1.94	4.3	0.09 [-0.26, 0.44]
			Placebo	73	65 (89.0)	1.08 (1.02)	-0.7	0.31	0.94	1.66	3.5	
		Week 52	Tezepelumab	70	61 (87.1)	1.11 (0.99)	-0.8	0.44	0.94	1.88	4.3	0.12 [-0.23, 0.47]
			Placebo	73	65 (89.0)	0.99 (1.03)	-0.7	0.16	0.88	1.53	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	4.10 (0.90)	2.0	3.63	4.09	4.63	6.3	
			Placebo	65	55 (84.6)	4.26 (0.81)	1.8	3.75	4.28	4.72	6.3	
		Week 4	Tezepelumab	67	61 (91.0)	4.81 (1.04)	1.4	4.03	4.97	5.66	6.8	
			Placebo	65	57 (87.7)	4.77 (0.93)	2.4	4.06	4.81	5.28	6.8	
		Week 8	Tezepelumab	67	63 (94.0)	5.09 (1.05)	3.0	4.16	5.13	5.97	6.8	
			Placebo	65	59 (90.8)	4.84 (1.00)	2.4	4.22	4.75	5.53	7.0	
		Week 12	Tezepelumab	67	63 (94.0)	5.28 (1.00)	3.0	4.38	5.16	6.22	7.0	
			Placebo	65	59 (90.8)	4.96 (1.01)	2.8	4.22	4.94	5.56	7.0	
		Week 16	Tezepelumab	67	63 (94.0)	5.24 (1.02)	2.7	4.38	5.19	6.09	7.0	
			Placebo	65	59 (90.8)	4.95 (1.19)	1.2	4.13	4.94	5.72	7.0	
		Week 20	Tezepelumab	67	64 (95.5)	5.21 (1.02)	3.2	4.31	5.20	6.09	7.0	
			Placebo	65	59 (90.8)	4.87 (1.18)	1.2	4.03	4.88	5.88	7.0	
		Week 24	Tezepelumab	67	64 (95.5)	5.24 (1.03)	3.3	4.36	5.14	6.06	7.0	
			Placebo	65	59 (90.8)	4.85 (1.21)	1.2	4.00	4.81	5.75	7.0	
		Week 28	Tezepelumab	67	66 (98.5)	5.22 (1.04)	3.3	4.47	5.17	6.03	7.0	
			Placebo	65	60 (92.3)	4.95 (1.28)	1.2	3.98	4.97	5.94	7.0	
		Week 32	Tezepelumab	67	66 (98.5)	5.28 (1.06)	2.9	4.34	5.27	6.09	7.0	
			Placebo	65	60 (92.3)	5.00 (1.19)	1.2	4.13	5.11	5.91	7.0	
		Week 36	Tezepelumab	67	66 (98.5)	5.33 (1.05)	3.3	4.59	5.36	6.22	7.0	
			Placebo	65	60 (92.3)	4.92 (1.15)	2.2	4.00	4.84	5.83	7.0	
		Week 40	Tezepelumab	67	66 (98.5)	5.27 (1.06)	3.2	4.44	5.25	6.06	7.0	
			Placebo	65	60 (92.3)	5.00 (1.19)	2.3	4.02	5.06	6.00	7.0	
		Week 44	Tezepelumab	67	66 (98.5)	5.29 (1.02)	3.5	4.34	5.19	6.16	7.0	
			Placebo	65	60 (92.3)	5.00 (1.13)	2.8	4.02	5.00	5.89	7.0	
		Week 48	Tezepelumab	67	66 (98.5)	5.32 (1.06)	2.9	4.44	5.31	6.16	7.0	
			Placebo	65	60 (92.3)	4.99 (1.13)	2.1	4.16	4.80	5.98	7.0	
		Week 52	Tezepelumab	67	66 (98.5)	5.32 (1.06)	2.9	4.38	5.23	6.22	7.0	
			Placebo	65	60 (92.3)	5.04 (1.11)	2.9	4.11	4.80	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 4	Tezepelumab	67	56 (83.6)	0.73 (1.04)	-3.7	0.16	0.73	1.42	3.3	0.23 [-0.15, 0.60]
			Placebo	65	54 (83.1)	0.52 (0.80)	-1.2	0.13	0.44	0.94	2.6	
		Week 8	Tezepelumab	67	58 (86.6)	0.94 (1.01)	-1.0	0.28	0.81	1.75	3.8	0.33 [-0.04, 0.70]
			Placebo	65	55 (84.6)	0.62 (0.90)	-1.4	0.09	0.50	1.00	3.1	
		Week 12	Tezepelumab	67	58 (86.6)	1.14 (1.03)	-2.1	0.56	1.17	1.91	4.0	0.41 [0.04, 0.79]
			Placebo	65	55 (84.6)	0.71 (1.02)	-1.7	0.22	0.72	1.22	3.5	
		Week 16	Tezepelumab	67	58 (86.6)	1.11 (1.03)	-2.4	0.50	1.23	1.78	3.4	0.36 [-0.02, 0.73]
			Placebo	65	55 (84.6)	0.73 (1.11)	-3.2	0.31	0.72	1.16	3.8	
		Week 20	Tezepelumab	67	58 (86.6)	1.11 (1.01)	-1.2	0.41	1.05	1.78	3.4	0.44 [0.07, 0.81]
			Placebo	65	55 (84.6)	0.65 (1.06)	-3.2	0.19	0.72	1.09	3.2	
		Week 24	Tezepelumab	67	58 (86.6)	1.16 (1.02)	-1.2	0.34	1.34	1.78	3.4	0.48 [0.11, 0.85]
			Placebo	65	55 (84.6)	0.64 (1.15)	-3.2	0.09	0.72	1.22	3.2	
		Week 28	Tezepelumab	67	58 (86.6)	1.12 (1.04)	-1.3	0.31	0.95	1.97	3.4	0.37 [-0.01, 0.74]
			Placebo	65	55 (84.6)	0.71 (1.21)	-3.2	0.09	0.84	1.25	4.0	
		Week 32	Tezepelumab	67	58 (86.6)	1.17 (1.07)	-1.2	0.34	1.05	2.19	3.4	0.37 [0.00, 0.75]
			Placebo	65	55 (84.6)	0.77 (1.07)	-3.2	0.25	0.72	1.38	3.2	
		Week 36	Tezepelumab	67	58 (86.6)	1.23 (1.11)	-1.3	0.53	1.03	2.25	3.4	0.52 [0.15, 0.90]
			Placebo	65	55 (84.6)	0.68 (1.00)	-2.0	0.19	0.66	1.19	2.9	
		Week 40	Tezepelumab	67	58 (86.6)	1.18 (1.07)	-1.3	0.56	1.05	2.06	3.4	0.38 [0.00, 0.75]
			Placebo	65	55 (84.6)	0.77 (1.10)	-2.0	0.06	0.78	1.50	3.8	
		Week 44	Tezepelumab	67	58 (86.6)	1.20 (1.08)	-1.1	0.59	0.97	2.06	3.4	0.41 [0.04, 0.78]
			Placebo	65	55 (84.6)	0.75 (1.09)	-2.0	-0.03	0.75	1.31	3.4	
		Week 48	Tezepelumab	67	58 (86.6)	1.24 (1.08)	-1.1	0.44	1.17	2.13	3.4	0.46 [0.09, 0.84]
			Placebo	65	55 (84.6)	0.75 (1.04)	-2.0	0.09	0.72	1.38	3.3	
		Week 52	Tezepelumab	67	58 (86.6)	1.23 (1.08)	-1.2	0.47	1.17	2.13	3.4	0.41 [0.03, 0.78]
			Placebo	65	55 (84.6)	0.80 (1.04)	-2.0	0.19	0.72	1.41	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	11	9 (81.8)	4.42 (0.56)	3.8	3.94	4.28	4.69	5.4	
			Placebo	6	4 (66.7)	3.58 (0.37)	3.1	3.31	3.70	3.84	3.8	
		Week 4	Tezepelumab	11	11 (100.0)	4.78 (0.95)	3.8	3.84	4.56	5.69	6.5	
			Placebo	6	5 (83.3)	4.01 (0.74)	3.0	3.47	4.41	4.47	4.7	
		Week 8	Tezepelumab	11	11 (100.0)	5.22 (0.76)	4.2	4.59	5.19	5.91	6.5	
			Placebo	6	5 (83.3)	4.22 (0.98)	3.3	3.56	3.72	5.09	5.4	
		Week 12	Tezepelumab	11	11 (100.0)	5.35 (0.81)	4.2	4.91	5.16	6.28	6.6	
			Placebo	6	5 (83.3)	4.11 (0.98)	2.8	3.84	4.00	4.53	5.4	
		Week 16	Tezepelumab	11	11 (100.0)	5.20 (0.82)	3.9	4.31	5.19	6.03	6.5	
			Placebo	6	5 (83.3)	4.19 (0.90)	2.9	4.06	4.25	4.34	5.4	
		Week 20	Tezepelumab	11	11 (100.0)	4.99 (0.81)	3.5	4.31	5.25	5.72	6.2	
			Placebo	6	5 (83.3)	4.28 (1.21)	2.9	3.91	4.00	4.28	6.3	
		Week 24	Tezepelumab	11	11 (100.0)	5.16 (0.71)	4.2	4.34	5.50	5.75	6.0	
			Placebo	6	5 (83.3)	3.89 (0.90)	2.7	3.59	3.94	4.09	5.2	
		Week 28	Tezepelumab	11	11 (100.0)	5.12 (0.73)	3.8	4.53	5.19	5.72	6.0	
			Placebo	6	5 (83.3)	3.83 (1.25)	2.7	2.78	3.94	4.00	5.8	
		Week 32	Tezepelumab	11	11 (100.0)	5.11 (0.76)	4.0	4.34	5.25	5.72	6.1	
			Placebo	6	5 (83.3)	4.27 (0.90)	3.2	3.84	4.19	4.56	5.6	
		Week 36	Tezepelumab	11	11 (100.0)	5.16 (0.59)	4.2	4.72	5.09	5.53	6.2	
			Placebo	6	5 (83.3)	4.03 (1.09)	2.2	4.16	4.16	4.50	5.1	
		Week 40	Tezepelumab	11	11 (100.0)	5.18 (0.60)	4.2	4.63	5.25	5.66	6.0	
			Placebo	6	5 (83.3)	4.31 (1.49)	2.3	3.88	3.91	5.69	5.8	
		Week 44	Tezepelumab	11	11 (100.0)	5.09 (0.62)	4.1	4.38	5.19	5.66	5.8	
			Placebo	6	5 (83.3)	4.07 (0.98)	2.8	3.69	3.78	4.75	5.3	
		Week 48	Tezepelumab	11	11 (100.0)	5.20 (0.70)	4.2	4.56	5.16	5.69	6.5	
			Placebo	6	5 (83.3)	4.23 (1.35)	2.1	3.84	4.56	5.09	5.5	
		Week 52	Tezepelumab	11	11 (100.0)	5.20 (0.71)	4.2	4.56	5.16	5.69	6.5	
			Placebo	6	5 (83.3)	4.38 (0.92)	3.3	3.88	4.16	5.09	5.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	11	9 (81.8)	0.59 (0.73)	-0.6	0.25	0.47	1.00	1.8	0.02 [-1.15, 1.20]
			Placebo	6	4 (66.7)	0.57 (0.97)	-0.8	0.02	0.89	1.13	1.3	
		Week 8	Tezepelumab	11	9 (81.8)	0.84 (0.77)	-0.5	0.31	0.94	1.38	1.8	0.08 [-1.10, 1.26]
			Placebo	6	4 (66.7)	0.77 (1.31)	-0.6	-0.28	0.63	1.81	2.4	
		Week 12	Tezepelumab	11	9 (81.8)	0.95 (0.75)	-0.8	0.97	1.09	1.31	1.9	0.35 [-0.84, 1.54]
			Placebo	6	4 (66.7)	0.60 (1.46)	-1.1	-0.47	0.56	1.67	2.4	
		Week 16	Tezepelumab	11	9 (81.8)	0.79 (0.80)	-0.8	0.53	1.00	1.31	1.8	0.21 [-0.97, 1.39]
			Placebo	6	4 (66.7)	0.59 (1.24)	-1.0	-0.38	0.75	1.56	1.8	
		Week 20	Tezepelumab	11	9 (81.8)	0.57 (0.67)	-0.6	0.50	0.78	0.91	1.4	-0.21 [-1.39, 0.97]
			Placebo	6	4 (66.7)	0.79 (1.74)	-0.9	-0.38	0.44	1.95	3.2	
		Week 24	Tezepelumab	11	9 (81.8)	0.77 (0.66)	-0.6	0.53	0.97	1.28	1.6	0.56 [-0.64, 1.76]
			Placebo	6	4 (66.7)	0.26 (1.38)	-1.2	-0.72	0.06	1.23	2.1	
		Week 28	Tezepelumab	11	9 (81.8)	0.70 (0.64)	-0.6	0.63	0.91	1.03	1.3	0.47 [-0.72, 1.67]
			Placebo	6	4 (66.7)	0.20 (1.73)	-1.1	-0.98	-0.41	1.39	2.7	
		Week 32	Tezepelumab	11	9 (81.8)	0.72 (0.67)	-0.7	0.53	1.03	1.06	1.4	0.01 [-1.17, 1.19]
			Placebo	6	4 (66.7)	0.71 (1.40)	-0.7	-0.34	0.50	1.77	2.5	
		Week 36	Tezepelumab	11	9 (81.8)	0.78 (0.53)	-0.5	0.78	0.81	1.03	1.3	0.40 [-0.79, 1.59]
			Placebo	6	4 (66.7)	0.42 (1.48)	-1.6	-0.66	0.88	1.50	1.6	
		Week 40	Tezepelumab	11	9 (81.8)	0.80 (0.61)	-0.7	0.69	0.97	1.06	1.3	-0.03 [-1.21, 1.15]
			Placebo	6	4 (66.7)	0.84 (2.00)	-1.6	-0.78	1.08	2.45	2.8	
		Week 44	Tezepelumab	11	9 (81.8)	0.74 (0.69)	-0.8	0.44	0.97	1.13	1.5	0.49 [-0.70, 1.69]
			Placebo	6	4 (66.7)	0.32 (1.17)	-1.0	-0.55	0.28	1.19	1.8	
		Week 48	Tezepelumab	11	9 (81.8)	0.92 (0.70)	-0.7	0.69	1.06	1.34	1.8	0.31 [-0.87, 1.50]
			Placebo	6	4 (66.7)	0.56 (1.85)	-1.8	-0.88	0.77	2.00	2.5	
		Week 52	Tezepelumab	11	9 (81.8)	0.91 (0.72)	-0.8	0.69	1.06	1.34	1.8	0.05 [-1.13, 1.23]
			Placebo	6	4 (66.7)	0.86 (1.40)	-0.6	-0.28	0.78	2.00	2.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	126	114 (90.5)	4.18 (0.94)	1.5	3.66	4.30	4.66	6.8	
			Placebo	132	117 (88.6)	4.11 (0.88)	1.8	3.50	4.13	4.69	6.3	
		Week 4	Tezepelumab	126	115 (91.3)	4.92 (1.05)	1.4	4.13	4.97	5.66	7.0	
			Placebo	132	118 (89.4)	4.63 (0.97)	2.1	3.97	4.69	5.25	6.8	
		Week 8	Tezepelumab	126	117 (92.9)	5.10 (1.07)	2.7	4.19	5.06	5.94	7.0	
			Placebo	132	121 (91.7)	4.73 (1.04)	2.1	4.00	4.63	5.50	7.0	
		Week 12	Tezepelumab	126	117 (92.9)	5.27 (1.06)	2.8	4.38	5.25	6.13	7.0	
			Placebo	132	122 (92.4)	4.85 (1.04)	2.5	4.06	4.80	5.66	7.0	
		Week 16	Tezepelumab	126	117 (92.9)	5.25 (1.05)	2.6	4.38	5.19	6.03	7.0	
			Placebo	132	122 (92.4)	4.87 (1.12)	1.2	4.00	4.81	5.72	7.0	
		Week 20	Tezepelumab	126	118 (93.7)	5.25 (1.03)	3.2	4.31	5.20	6.09	7.0	
			Placebo	132	122 (92.4)	4.88 (1.09)	1.2	4.06	4.81	5.78	7.0	
		Week 24	Tezepelumab	126	118 (93.7)	5.28 (1.07)	2.4	4.41	5.14	6.06	7.0	
			Placebo	132	122 (92.4)	4.92 (1.12)	1.2	4.00	4.81	5.81	7.0	
		Week 28	Tezepelumab	126	120 (95.2)	5.30 (1.03)	3.3	4.45	5.20	6.06	7.0	
			Placebo	132	123 (93.2)	4.94 (1.18)	1.2	4.00	4.88	5.91	7.0	
		Week 32	Tezepelumab	126	121 (96.0)	5.35 (1.05)	2.6	4.47	5.41	6.09	7.0	
			Placebo	132	124 (93.9)	4.98 (1.14)	1.2	4.06	4.92	5.92	7.0	
		Week 36	Tezepelumab	126	121 (96.0)	5.35 (1.05)	3.2	4.59	5.34	6.19	7.0	
			Placebo	132	124 (93.9)	5.00 (1.11)	2.6	4.02	4.83	5.98	7.0	
		Week 40	Tezepelumab	126	121 (96.0)	5.35 (1.07)	2.6	4.53	5.28	6.22	7.0	
			Placebo	132	124 (93.9)	5.02 (1.11)	2.5	4.02	4.98	5.97	7.0	
		Week 44	Tezepelumab	126	121 (96.0)	5.40 (1.06)	2.8	4.56	5.31	6.31	7.0	
			Placebo	132	124 (93.9)	5.01 (1.16)	2.5	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	126	121 (96.0)	5.40 (1.06)	2.9	4.50	5.38	6.25	7.0	
			Placebo	132	125 (94.7)	5.03 (1.09)	2.8	4.09	4.91	5.97	7.0	
		Week 52	Tezepelumab	126	121 (96.0)	5.39 (1.07)	2.8	4.50	5.34	6.25	7.0	
			Placebo	132	125 (94.7)	4.99 (1.12)	2.7	4.03	4.91	5.94	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	126	108 (85.7)	0.75 (0.97)	-3.7	0.16	0.69	1.39	3.3	0.27 [0.01, 0.54]
			Placebo	132	115 (87.1)	0.51 (0.78)	-1.2	0.09	0.41	1.00	2.6	
		Week 8	Tezepelumab	126	110 (87.3)	0.91 (0.99)	-1.0	0.13	0.75	1.63	3.9	0.29 [0.03, 0.56]
			Placebo	132	116 (87.9)	0.63 (0.85)	-1.4	0.13	0.52	1.06	3.1	
		Week 12	Tezepelumab	126	110 (87.3)	1.08 (1.02)	-2.1	0.47	0.94	1.84	4.2	0.33 [0.06, 0.59]
			Placebo	132	116 (87.9)	0.76 (0.99)	-2.0	0.22	0.70	1.25	3.5	
		Week 16	Tezepelumab	126	110 (87.3)	1.07 (1.01)	-2.4	0.34	1.00	1.72	4.2	0.29 [0.03, 0.55]
			Placebo	132	116 (87.9)	0.78 (1.01)	-3.2	0.28	0.72	1.38	3.8	
		Week 20	Tezepelumab	126	110 (87.3)	1.08 (1.01)	-1.2	0.28	0.94	1.78	4.2	0.30 [0.04, 0.56]
			Placebo	132	116 (87.9)	0.79 (0.96)	-3.2	0.27	0.78	1.20	3.8	
		Week 24	Tezepelumab	126	110 (87.3)	1.13 (1.03)	-1.2	0.34	1.03	1.84	4.3	0.28 [0.02, 0.54]
			Placebo	132	116 (87.9)	0.84 (1.04)	-3.2	0.16	0.80	1.36	3.7	
		Week 28	Tezepelumab	126	110 (87.3)	1.13 (1.01)	-1.3	0.31	0.89	1.97	4.3	0.27 [0.00, 0.53]
			Placebo	132	116 (87.9)	0.85 (1.09)	-3.2	0.19	0.84	1.42	4.3	
		Week 32	Tezepelumab	126	110 (87.3)	1.17 (1.03)	-1.2	0.47	1.03	2.03	4.3	0.26 [-0.00, 0.52]
			Placebo	132	116 (87.9)	0.90 (1.01)	-3.2	0.31	0.77	1.44	3.6	
		Week 36	Tezepelumab	126	110 (87.3)	1.16 (1.09)	-1.3	0.34	1.02	2.06	4.3	0.23 [-0.03, 0.49]
			Placebo	132	116 (87.9)	0.92 (1.01)	-2.0	0.31	0.77	1.50	3.4	
		Week 40	Tezepelumab	126	110 (87.3)	1.17 (1.04)	-1.3	0.44	1.00	2.03	4.3	0.23 [-0.04, 0.49]
			Placebo	132	116 (87.9)	0.94 (1.05)	-2.0	0.28	0.78	1.58	4.3	
		Week 44	Tezepelumab	126	110 (87.3)	1.22 (1.04)	-1.1	0.53	1.11	2.00	4.3	0.27 [0.01, 0.53]
			Placebo	132	116 (87.9)	0.93 (1.10)	-2.0	0.23	0.84	1.44	4.1	
		Week 48	Tezepelumab	126	110 (87.3)	1.23 (1.05)	-1.1	0.44	1.08	2.09	4.3	0.28 [0.02, 0.54]
			Placebo	132	116 (87.9)	0.94 (1.01)	-2.0	0.19	0.84	1.63	3.5	
		Week 52	Tezepelumab	126	110 (87.3)	1.19 (1.06)	-1.2	0.44	1.08	2.06	4.3	0.27 [0.01, 0.54]
			Placebo	132	116 (87.9)	0.90 (1.03)	-2.0	0.19	0.81	1.47	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.48 (0.57)	3.8	4.03	4.38	4.91	5.4	
			Placebo	3	2 (66.7)	3.45 (0.55)	3.1	3.06	3.45	3.84	3.8	
		Week 4	Tezepelumab	9	9 (100.0)	5.00 (0.91)	3.8	4.28	4.72	5.69	6.5	
			Placebo	3	3 (100.0)	4.20 (0.65)	3.5	3.47	4.41	4.72	4.7	
		Week 8	Tezepelumab	9	9 (100.0)	5.44 (0.65)	4.6	4.81	5.38	5.91	6.5	
			Placebo	3	3 (100.0)	4.75 (0.91)	3.7	3.72	5.09	5.44	5.4	
		Week 12	Tezepelumab	9	9 (100.0)	5.52 (0.78)	4.3	5.03	5.31	6.28	6.6	
			Placebo	3	3 (100.0)	4.43 (0.88)	3.8	3.84	4.00	5.44	5.4	
		Week 16	Tezepelumab	9	9 (100.0)	5.45 (0.67)	4.3	5.09	5.25	6.03	6.5	
			Placebo	3	3 (100.0)	4.22 (0.14)	4.1	4.06	4.25	4.34	4.3	
		Week 20	Tezepelumab	9	9 (100.0)	5.25 (0.62)	4.3	4.78	5.28	5.72	6.2	
			Placebo	3	3 (100.0)	4.72 (1.33)	3.9	3.91	4.00	6.25	6.3	
		Week 24	Tezepelumab	9	9 (100.0)	5.38 (0.58)	4.3	5.16	5.59	5.75	6.0	
			Placebo	3	3 (100.0)	4.28 (0.80)	3.6	3.59	4.09	5.16	5.2	
		Week 28	Tezepelumab	9	9 (100.0)	5.36 (0.53)	4.5	5.16	5.38	5.72	6.0	
			Placebo	3	3 (100.0)	4.56 (1.03)	3.9	3.94	4.00	5.75	5.8	
		Week 32	Tezepelumab	9	9 (100.0)	5.33 (0.64)	4.3	4.91	5.63	5.72	6.1	
			Placebo	3	3 (100.0)	4.54 (0.93)	3.8	3.84	4.19	5.59	5.6	
		Week 36	Tezepelumab	9	9 (100.0)	5.31 (0.51)	4.6	5.00	5.44	5.53	6.2	
			Placebo	3	3 (100.0)	4.27 (0.20)	4.2	4.16	4.16	4.50	4.5	
		Week 40	Tezepelumab	9	9 (100.0)	5.36 (0.50)	4.4	5.13	5.44	5.66	6.0	
			Placebo	3	3 (100.0)	4.54 (1.13)	3.9	3.88	3.91	5.84	5.8	
		Week 44	Tezepelumab	9	9 (100.0)	5.30 (0.46)	4.4	5.03	5.41	5.66	5.8	
			Placebo	3	3 (100.0)	4.07 (0.59)	3.7	3.69	3.78	4.75	4.8	
		Week 48	Tezepelumab	9	9 (100.0)	5.39 (0.63)	4.4	5.00	5.22	5.69	6.5	
			Placebo	3	3 (100.0)	4.65 (0.85)	3.8	3.84	4.56	5.53	5.5	
		Week 52	Tezepelumab	9	9 (100.0)	5.38 (0.64)	4.4	5.00	5.22	5.69	6.5	
			Placebo	3	3 (100.0)	4.52 (0.89)	3.9	3.88	4.16	5.53	5.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	0.68 (0.73)	-0.6	0.33	0.56	1.20	1.8	-0.63 [-2.21, 0.95]
			Placebo	3	2 (66.7)	1.11 (0.33)	0.9	0.88	1.11	1.34	1.3	
		Week 8	Tezepelumab	9	8 (88.9)	0.91 (0.79)	-0.5	0.41	1.02	1.58	1.8	-1.15 [-2.79, 0.50]
			Placebo	3	2 (66.7)	1.81 (0.80)	1.3	1.25	1.81	2.38	2.4	
		Week 12	Tezepelumab	9	8 (88.9)	0.95 (0.80)	-0.8	0.81	1.11	1.33	1.9	-0.34 [-1.90, 1.22]
			Placebo	3	2 (66.7)	1.27 (1.57)	0.2	0.16	1.27	2.38	2.4	
		Week 16	Tezepelumab	9	8 (88.9)	0.89 (0.80)	-0.8	0.58	1.14	1.34	1.8	0.17 [-1.38, 1.72]
			Placebo	3	2 (66.7)	0.75 (0.75)	0.2	0.22	0.75	1.28	1.3	
		Week 20	Tezepelumab	9	8 (88.9)	0.69 (0.59)	-0.6	0.56	0.78	1.00	1.4	-1.04 [-2.67, 0.59]
			Placebo	3	2 (66.7)	1.67 (2.14)	0.2	0.16	1.67	3.19	3.2	
		Week 24	Tezepelumab	9	8 (88.9)	0.84 (0.68)	-0.6	0.58	1.00	1.30	1.6	-0.10 [-1.65, 1.45]
			Placebo	3	2 (66.7)	0.92 (1.66)	-0.3	-0.25	0.92	2.09	2.1	
		Week 28	Tezepelumab	9	8 (88.9)	0.80 (0.61)	-0.6	0.75	0.95	1.16	1.3	-0.68 [-2.26, 0.90]
			Placebo	3	2 (66.7)	1.39 (1.83)	0.1	0.09	1.39	2.69	2.7	
		Week 32	Tezepelumab	9	8 (88.9)	0.80 (0.66)	-0.7	0.63	1.03	1.20	1.4	-0.52 [-2.09, 1.05]
			Placebo	3	2 (66.7)	1.27 (1.79)	0.0	0.00	1.27	2.53	2.5	
		Week 36	Tezepelumab	9	8 (88.9)	0.78 (0.56)	-0.5	0.78	0.86	1.13	1.3	-0.16 [-1.71, 1.39]
			Placebo	3	2 (66.7)	0.88 (0.80)	0.3	0.31	0.88	1.44	1.4	
		Week 40	Tezepelumab	9	8 (88.9)	0.81 (0.65)	-0.7	0.77	1.00	1.16	1.3	-0.65 [-2.23, 0.93]
			Placebo	3	2 (66.7)	1.41 (1.94)	0.0	0.03	1.41	2.78	2.8	
		Week 44	Tezepelumab	9	8 (88.9)	0.81 (0.71)	-0.8	0.64	0.97	1.25	1.5	0.77 [-0.82, 2.36]
			Placebo	3	2 (66.7)	0.28 (0.49)	-0.1	-0.06	0.28	0.63	0.6	
		Week 48	Tezepelumab	9	8 (88.9)	0.95 (0.74)	-0.7	0.83	1.06	1.38	1.8	-0.30 [-1.86, 1.25]
			Placebo	3	2 (66.7)	1.23 (1.75)	0.0	0.00	1.23	2.47	2.5	
		Week 52	Tezepelumab	9	8 (88.9)	0.95 (0.76)	-0.8	0.83	1.06	1.38	1.8	-0.33 [-1.88, 1.23]
			Placebo	3	2 (66.7)	1.25 (1.72)	0.0	0.03	1.25	2.47	2.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.18 (0.93)	1.5	3.66	4.28	4.66	6.8	
			Placebo	135	119 (88.1)	4.10 (0.88)	1.8	3.50	4.09	4.69	6.3	
		Week 4	Tezepelumab	128	117 (91.4)	4.90 (1.05)	1.4	4.13	4.97	5.66	7.0	
			Placebo	135	120 (88.9)	4.61 (0.98)	2.1	3.92	4.63	5.25	6.8	
		Week 8	Tezepelumab	128	119 (93.0)	5.08 (1.06)	2.7	4.19	5.03	5.94	7.0	
			Placebo	135	123 (91.1)	4.71 (1.05)	2.1	4.00	4.63	5.50	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.26 (1.06)	2.8	4.34	5.22	6.13	7.0	
			Placebo	135	124 (91.9)	4.83 (1.05)	2.5	4.05	4.75	5.63	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.23 (1.05)	2.6	4.38	5.16	6.03	7.0	
			Placebo	135	124 (91.9)	4.86 (1.12)	1.2	3.98	4.81	5.72	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.23 (1.04)	3.2	4.31	5.17	6.09	7.0	
			Placebo	135	124 (91.9)	4.85 (1.10)	1.2	4.05	4.80	5.77	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.27 (1.07)	2.4	4.36	5.13	6.06	7.0	
			Placebo	135	124 (91.9)	4.89 (1.13)	1.2	4.00	4.81	5.78	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.27 (1.03)	3.3	4.34	5.19	6.03	7.0	
			Placebo	135	125 (92.6)	4.91 (1.20)	1.2	3.97	4.84	5.88	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.33 (1.05)	2.6	4.47	5.41	6.09	7.0	
			Placebo	135	126 (93.3)	4.96 (1.14)	1.2	4.03	4.84	5.91	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.34 (1.04)	3.2	4.53	5.25	6.19	7.0	
			Placebo	135	126 (93.3)	4.98 (1.13)	2.2	4.00	4.83	5.97	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.34 (1.07)	2.6	4.47	5.25	6.22	7.0	
			Placebo	135	126 (93.3)	5.00 (1.13)	2.3	4.00	4.98	5.94	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.38 (1.06)	2.8	4.50	5.31	6.31	7.0	
			Placebo	135	126 (93.3)	5.00 (1.16)	2.5	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.39 (1.06)	2.9	4.47	5.38	6.25	7.0	
			Placebo	135	127 (94.1)	5.00 (1.11)	2.1	4.06	4.91	5.97	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.37 (1.07)	2.8	4.47	5.31	6.25	7.0	
			Placebo	135	127 (94.1)	4.97 (1.12)	2.7	4.00	4.91	5.94	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.75 (0.97)	-3.7	0.16	0.69	1.38	3.3	0.27 [0.01, 0.54]
			Placebo	135	117 (86.7)	0.51 (0.78)	-1.2	0.09	0.41	0.97	2.6	
		Week 8	Tezepelumab	128	111 (86.7)	0.90 (0.99)	-1.0	0.13	0.75	1.63	3.9	0.30 [0.04, 0.57]
			Placebo	135	118 (87.4)	0.62 (0.86)	-1.4	0.09	0.50	1.03	3.1	
		Week 12	Tezepelumab	128	111 (86.7)	1.08 (1.02)	-2.1	0.47	0.94	1.84	4.2	0.34 [0.08, 0.60]
			Placebo	135	118 (87.4)	0.74 (1.00)	-2.0	0.22	0.70	1.25	3.5	
		Week 16	Tezepelumab	128	111 (86.7)	1.06 (1.01)	-2.4	0.34	0.91	1.72	4.2	0.28 [0.02, 0.54]
			Placebo	135	118 (87.4)	0.77 (1.02)	-3.2	0.28	0.72	1.38	3.8	
		Week 20	Tezepelumab	128	111 (86.7)	1.07 (1.01)	-1.2	0.28	0.91	1.78	4.2	0.30 [0.04, 0.56]
			Placebo	135	118 (87.4)	0.78 (0.97)	-3.2	0.25	0.77	1.19	3.8	
		Week 24	Tezepelumab	128	111 (86.7)	1.13 (1.03)	-1.2	0.34	1.03	1.84	4.3	0.29 [0.03, 0.55]
			Placebo	135	118 (87.4)	0.82 (1.05)	-3.2	0.16	0.78	1.34	3.7	
		Week 28	Tezepelumab	128	111 (86.7)	1.12 (1.02)	-1.3	0.31	0.88	1.97	4.3	0.28 [0.02, 0.54]
			Placebo	135	118 (87.4)	0.82 (1.11)	-3.2	0.19	0.81	1.41	4.3	
		Week 32	Tezepelumab	128	111 (86.7)	1.16 (1.03)	-1.2	0.41	1.03	2.03	4.3	0.26 [0.00, 0.52]
			Placebo	135	118 (87.4)	0.89 (1.01)	-3.2	0.31	0.77	1.41	3.6	
		Week 36	Tezepelumab	128	111 (86.7)	1.16 (1.09)	-1.3	0.34	1.00	2.06	4.3	0.24 [-0.02, 0.50]
			Placebo	135	118 (87.4)	0.91 (1.03)	-2.0	0.31	0.77	1.50	3.4	
		Week 40	Tezepelumab	128	111 (86.7)	1.17 (1.04)	-1.3	0.44	1.00	2.03	4.3	0.23 [-0.03, 0.49]
			Placebo	135	118 (87.4)	0.93 (1.07)	-2.0	0.28	0.78	1.59	4.3	
		Week 44	Tezepelumab	128	111 (86.7)	1.21 (1.04)	-1.1	0.53	1.09	2.00	4.3	0.27 [0.01, 0.53]
			Placebo	135	118 (87.4)	0.92 (1.11)	-2.0	0.22	0.84	1.47	4.1	
		Week 48	Tezepelumab	128	111 (86.7)	1.22 (1.05)	-1.1	0.44	1.06	2.09	4.3	0.29 [0.03, 0.55]
			Placebo	135	118 (87.4)	0.92 (1.04)	-2.0	0.19	0.84	1.59	3.5	
		Week 52	Tezepelumab	128	111 (86.7)	1.19 (1.05)	-1.2	0.44	1.06	2.06	4.3	0.28 [0.02, 0.54]
			Placebo	135	118 (87.4)	0.90 (1.03)	-2.0	0.19	0.81	1.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	3.90 (0.94)	2.0	3.34	3.75	4.50	6.1	
			Placebo	37	33 (89.2)	4.16 (0.79)	2.8	3.63	4.13	4.69	6.1	
		Week 4	Tezepelumab	29	26 (89.7)	4.81 (1.00)	3.3	3.94	4.70	5.66	6.9	
			Placebo	37	33 (89.2)	4.64 (1.06)	2.5	3.97	4.75	5.25	6.8	
		Week 8	Tezepelumab	29	27 (93.1)	5.14 (1.09)	3.0	4.00	5.16	5.94	7.0	
			Placebo	37	34 (91.9)	4.79 (1.09)	2.3	3.94	4.84	5.50	7.0	
		Week 12	Tezepelumab	29	27 (93.1)	5.34 (1.06)	3.8	4.34	5.34	6.28	7.0	
			Placebo	37	35 (94.6)	4.99 (1.14)	2.8	4.16	5.13	5.66	7.0	
		Week 16	Tezepelumab	29	27 (93.1)	5.28 (1.02)	3.5	4.38	5.28	6.03	7.0	
			Placebo	37	35 (94.6)	4.98 (1.23)	1.2	4.25	5.13	5.72	7.0	
		Week 20	Tezepelumab	29	27 (93.1)	5.35 (1.04)	3.2	4.31	5.59	6.19	7.0	
			Placebo	37	35 (94.6)	4.94 (1.20)	1.2	4.19	4.88	5.88	7.0	
		Week 24	Tezepelumab	29	27 (93.1)	5.30 (1.22)	2.4	4.34	5.59	6.25	7.0	
			Placebo	37	35 (94.6)	4.88 (1.25)	1.2	3.97	4.81	5.66	7.0	
		Week 28	Tezepelumab	29	27 (93.1)	5.26 (1.09)	3.3	4.31	5.41	6.03	7.0	
			Placebo	37	35 (94.6)	5.05 (1.42)	1.2	4.03	5.16	6.06	7.0	
		Week 32	Tezepelumab	29	27 (93.1)	5.35 (1.07)	2.9	4.41	5.69	5.94	7.0	
			Placebo	37	35 (94.6)	5.09 (1.18)	1.2	4.41	5.25	6.00	7.0	
		Week 36	Tezepelumab	29	27 (93.1)	5.34 (1.10)	3.3	4.38	5.59	6.19	7.0	
			Placebo	37	35 (94.6)	4.89 (1.15)	2.2	4.03	4.81	5.72	7.0	
		Week 40	Tezepelumab	29	27 (93.1)	5.44 (1.10)	3.5	4.34	5.59	6.25	7.0	
			Placebo	37	35 (94.6)	5.06 (1.14)	2.3	4.25	5.06	5.91	7.0	
		Week 44	Tezepelumab	29	27 (93.1)	5.40 (1.12)	3.0	4.34	5.69	6.25	7.0	
			Placebo	37	35 (94.6)	5.07 (1.14)	2.8	4.00	5.06	6.03	7.0	
		Week 48	Tezepelumab	29	27 (93.1)	5.28 (1.21)	2.9	4.34	5.50	6.16	7.0	
			Placebo	37	36 (97.3)	5.09 (1.07)	2.1	4.58	4.95	5.61	7.0	
		Week 52	Tezepelumab	29	27 (93.1)	5.32 (1.23)	2.9	4.34	5.69	6.25	7.0	
			Placebo	37	36 (97.3)	5.13 (1.01)	3.3	4.50	5.00	5.72	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	29	24 (82.8)	0.94 (0.86)	-0.9	0.45	0.80	1.58	2.6	0.51 [-0.03, 1.06]
			Placebo	37	31 (83.8)	0.53 (0.76)	-1.1	0.06	0.34	1.16	1.8	
		Week 8	Tezepelumab	29	25 (86.2)	1.21 (0.95)	-0.9	0.56	1.28	1.78	2.7	0.62 [0.08, 1.15]
			Placebo	37	32 (86.5)	0.64 (0.89)	-0.8	0.13	0.44	1.06	2.7	
		Week 12	Tezepelumab	29	25 (86.2)	1.39 (0.93)	-0.9	0.78	1.44	2.06	2.7	0.48 [-0.05, 1.01]
			Placebo	37	32 (86.5)	0.91 (1.04)	-1.1	0.34	0.75	1.23	3.5	
		Week 16	Tezepelumab	29	25 (86.2)	1.31 (0.90)	-0.9	0.59	1.34	1.94	2.6	0.42 [-0.11, 0.95]
			Placebo	37	32 (86.5)	0.87 (1.16)	-3.2	0.50	0.78	1.58	3.8	
		Week 20	Tezepelumab	29	25 (86.2)	1.42 (0.94)	-0.9	0.78	1.56	2.19	2.7	0.55 [0.01, 1.08]
			Placebo	37	32 (86.5)	0.83 (1.16)	-3.2	0.25	0.78	1.66	3.2	
		Week 24	Tezepelumab	29	25 (86.2)	1.37 (1.12)	-1.1	0.56	1.66	2.31	3.0	0.51 [-0.03, 1.04]
			Placebo	37	32 (86.5)	0.76 (1.27)	-3.2	0.11	0.77	1.66	3.1	
		Week 28	Tezepelumab	29	25 (86.2)	1.31 (1.01)	-0.9	0.53	1.31	2.34	2.7	0.29 [-0.24, 0.81]
			Placebo	37	32 (86.5)	0.95 (1.44)	-3.2	0.27	0.95	1.91	4.0	
		Week 32	Tezepelumab	29	25 (86.2)	1.43 (1.02)	-0.9	0.72	1.69	2.34	2.6	0.40 [-0.12, 0.93]
			Placebo	37	32 (86.5)	0.99 (1.16)	-3.2	0.31	0.98	1.67	3.2	
		Week 36	Tezepelumab	29	25 (86.2)	1.41 (1.07)	-0.9	0.72	1.34	2.44	2.8	0.59 [0.06, 1.13]
			Placebo	37	32 (86.5)	0.77 (1.10)	-1.7	0.14	0.78	1.53	2.9	
		Week 40	Tezepelumab	29	25 (86.2)	1.51 (1.05)	-0.9	0.63	1.81	2.44	2.9	0.48 [-0.05, 1.01]
			Placebo	37	32 (86.5)	0.96 (1.22)	-1.6	0.13	1.03	1.83	3.8	
		Week 44	Tezepelumab	29	25 (86.2)	1.49 (1.15)	-0.9	0.59	1.50	2.44	3.3	0.48 [-0.05, 1.01]
			Placebo	37	32 (86.5)	0.94 (1.13)	-1.0	0.16	1.05	1.61	3.4	
		Week 48	Tezepelumab	29	25 (86.2)	1.37 (1.17)	-0.9	0.50	1.41	2.41	2.9	0.37 [-0.15, 0.90]
			Placebo	37	32 (86.5)	0.95 (1.09)	-1.8	0.28	0.84	1.52	3.1	
		Week 52	Tezepelumab	29	25 (86.2)	1.42 (1.18)	-0.9	0.50	1.41	2.44	3.0	0.37 [-0.16, 0.90]
			Placebo	37	32 (86.5)	1.01 (1.03)	-0.9	0.28	0.84	1.63	3.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	4.28 (0.89)	1.5	3.84	4.34	4.72	6.8	
			Placebo	101	88 (87.1)	4.06 (0.91)	1.8	3.47	4.06	4.64	6.3	
		Week 4	Tezepelumab	108	100 (92.6)	4.94 (1.05)	1.4	4.16	4.97	5.69	7.0	
			Placebo	101	90 (89.1)	4.59 (0.94)	2.1	3.84	4.47	5.19	6.8	
		Week 8	Tezepelumab	108	101 (93.5)	5.10 (1.03)	2.7	4.28	5.00	5.91	7.0	
			Placebo	101	92 (91.1)	4.69 (1.03)	2.1	4.00	4.58	5.39	6.9	
		Week 12	Tezepelumab	108	101 (93.5)	5.26 (1.04)	2.8	4.47	5.19	6.09	7.0	
			Placebo	101	92 (91.1)	4.76 (1.01)	2.5	3.98	4.61	5.56	6.9	
		Week 16	Tezepelumab	108	101 (93.5)	5.23 (1.04)	2.6	4.44	5.19	6.03	7.0	
			Placebo	101	92 (91.1)	4.79 (1.07)	2.5	3.98	4.75	5.73	6.9	
		Week 20	Tezepelumab	108	102 (94.4)	5.20 (1.01)	3.5	4.31	5.09	6.06	7.0	
			Placebo	101	92 (91.1)	4.82 (1.06)	2.4	4.02	4.77	5.66	6.8	
		Week 24	Tezepelumab	108	102 (94.4)	5.26 (1.00)	3.3	4.41	5.13	6.00	7.0	
			Placebo	101	92 (91.1)	4.88 (1.08)	2.3	4.00	4.77	5.78	6.9	
		Week 28	Tezepelumab	108	104 (96.3)	5.29 (0.99)	3.7	4.48	5.19	6.03	7.0	
			Placebo	101	93 (92.1)	4.84 (1.11)	2.2	3.97	4.69	5.72	7.0	
		Week 32	Tezepelumab	108	105 (97.2)	5.33 (1.02)	2.6	4.47	5.34	6.00	7.0	
			Placebo	101	94 (93.1)	4.90 (1.12)	2.3	4.00	4.72	5.88	6.9	
		Week 36	Tezepelumab	108	105 (97.2)	5.34 (1.00)	3.2	4.59	5.19	6.19	7.0	
			Placebo	101	94 (93.1)	5.00 (1.12)	2.6	4.00	4.77	6.00	6.9	
		Week 40	Tezepelumab	108	105 (97.2)	5.31 (1.02)	2.6	4.56	5.25	6.06	7.0	
			Placebo	101	94 (93.1)	4.97 (1.12)	2.5	4.00	4.97	5.94	7.0	
		Week 44	Tezepelumab	108	105 (97.2)	5.37 (1.02)	2.8	4.56	5.25	6.19	7.0	
			Placebo	101	94 (93.1)	4.94 (1.17)	2.5	4.00	4.81	5.97	7.0	
		Week 48	Tezepelumab	108	105 (97.2)	5.41 (0.99)	3.5	4.53	5.34	6.22	7.0	
			Placebo	101	94 (93.1)	4.96 (1.12)	2.8	4.00	4.83	6.00	7.0	
		Week 52	Tezepelumab	108	105 (97.2)	5.38 (0.99)	2.8	4.56	5.28	6.22	7.0	
			Placebo	101	94 (93.1)	4.90 (1.16)	2.7	3.97	4.81	5.94	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	108	93 (86.1)	0.69 (0.97)	-3.7	0.06	0.66	1.31	3.3	0.20 [-0.09, 0.49]
			Placebo	101	88 (87.1)	0.51 (0.79)	-1.2	0.11	0.44	0.97	2.6	
		Week 8	Tezepelumab	108	94 (87.0)	0.82 (0.97)	-1.0	0.09	0.69	1.41	3.9	0.20 [-0.10, 0.49]
			Placebo	101	88 (87.1)	0.64 (0.86)	-1.4	0.08	0.61	1.09	3.1	
		Week 12	Tezepelumab	108	94 (87.0)	0.99 (1.01)	-2.1	0.47	0.89	1.66	4.2	0.30 [0.01, 0.59]
			Placebo	101	88 (87.1)	0.69 (0.99)	-2.0	0.17	0.66	1.25	3.4	
		Week 16	Tezepelumab	108	94 (87.0)	0.98 (1.01)	-2.4	0.34	0.83	1.59	4.2	0.24 [-0.05, 0.54]
			Placebo	101	88 (87.1)	0.74 (0.96)	-2.0	0.13	0.70	1.28	3.5	
		Week 20	Tezepelumab	108	94 (87.0)	0.95 (0.99)	-1.2	0.28	0.75	1.63	4.2	0.18 [-0.11, 0.47]
			Placebo	101	88 (87.1)	0.78 (0.92)	-2.0	0.25	0.70	1.13	3.8	
		Week 24	Tezepelumab	108	94 (87.0)	1.04 (0.97)	-1.2	0.31	0.92	1.59	4.3	0.20 [-0.10, 0.49]
			Placebo	101	88 (87.1)	0.85 (0.97)	-2.0	0.19	0.83	1.28	3.7	
		Week 28	Tezepelumab	108	94 (87.0)	1.04 (0.99)	-1.3	0.31	0.88	1.72	4.3	0.26 [-0.03, 0.55]
			Placebo	101	88 (87.1)	0.78 (0.98)	-2.0	0.17	0.73	1.27	4.3	
		Week 32	Tezepelumab	108	94 (87.0)	1.06 (1.00)	-1.2	0.34	1.02	1.69	4.3	0.19 [-0.10, 0.49]
			Placebo	101	88 (87.1)	0.87 (0.96)	-2.0	0.30	0.72	1.39	3.6	
		Week 36	Tezepelumab	108	94 (87.0)	1.06 (1.06)	-1.3	0.31	0.91	1.72	4.3	0.10 [-0.19, 0.39]
			Placebo	101	88 (87.1)	0.96 (1.00)	-2.0	0.33	0.75	1.47	3.4	
		Week 40	Tezepelumab	108	94 (87.0)	1.05 (1.00)	-1.3	0.44	0.94	1.69	4.3	0.12 [-0.17, 0.41]
			Placebo	101	88 (87.1)	0.93 (1.03)	-2.0	0.30	0.77	1.48	4.3	
		Week 44	Tezepelumab	108	94 (87.0)	1.10 (0.98)	-1.1	0.50	0.94	1.81	4.3	0.20 [-0.09, 0.49]
			Placebo	101	88 (87.1)	0.89 (1.10)	-2.0	0.17	0.77	1.39	4.1	
		Week 48	Tezepelumab	108	94 (87.0)	1.16 (0.99)	-1.1	0.50	1.06	1.94	4.3	0.24 [-0.05, 0.53]
			Placebo	101	88 (87.1)	0.92 (1.03)	-2.0	0.16	0.84	1.66	3.5	
		Week 52	Tezepelumab	108	94 (87.0)	1.10 (0.99)	-1.2	0.44	1.02	1.78	4.3	0.24 [-0.06, 0.53]
			Placebo	101	88 (87.1)	0.86 (1.04)	-2.0	0.13	0.78	1.41	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.20 (0.91)	1.5	3.72	4.28	4.69	6.8	
			Placebo	123	106 (86.2)	4.15 (0.86)	1.8	3.66	4.11	4.69	6.3	
		Week 4	Tezepelumab	128	117 (91.4)	4.88 (1.05)	1.4	4.06	4.91	5.66	7.0	
			Placebo	123	109 (88.6)	4.64 (0.98)	2.1	3.97	4.69	5.28	6.8	
		Week 8	Tezepelumab	128	119 (93.0)	5.08 (1.05)	2.7	4.19	5.03	5.91	7.0	
			Placebo	123	112 (91.1)	4.74 (1.02)	2.1	4.00	4.58	5.47	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.25 (1.05)	2.8	4.34	5.16	6.09	7.0	
			Placebo	123	113 (91.9)	4.79 (1.05)	2.5	4.00	4.63	5.56	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.22 (1.05)	2.6	4.38	5.13	6.06	7.0	
			Placebo	123	113 (91.9)	4.85 (1.10)	1.2	4.00	4.75	5.69	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.20 (1.03)	3.2	4.31	5.16	6.00	7.0	
			Placebo	123	113 (91.9)	4.86 (1.10)	1.2	4.06	4.78	5.75	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.24 (1.05)	2.4	4.36	5.13	6.02	7.0	
			Placebo	123	113 (91.9)	4.87 (1.15)	1.2	4.00	4.78	5.69	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.24 (1.01)	3.3	4.34	5.16	6.03	7.0	
			Placebo	123	114 (92.7)	4.84 (1.18)	1.2	3.97	4.70	5.78	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.29 (1.04)	2.6	4.44	5.34	6.00	7.0	
			Placebo	123	115 (93.5)	4.91 (1.15)	1.2	4.03	4.75	5.88	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.31 (1.03)	3.2	4.53	5.19	6.09	7.0	
			Placebo	123	115 (93.5)	4.97 (1.14)	2.2	4.00	4.75	6.00	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.30 (1.05)	2.6	4.47	5.25	6.06	7.0	
			Placebo	123	115 (93.5)	4.97 (1.12)	2.3	4.00	4.97	5.94	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.33 (1.05)	2.8	4.47	5.19	6.19	7.0	
			Placebo	123	115 (93.5)	4.97 (1.14)	2.5	4.00	4.88	5.88	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.35 (1.05)	2.9	4.47	5.28	6.25	7.0	
			Placebo	123	116 (94.3)	4.98 (1.11)	2.1	4.08	4.83	5.95	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.33 (1.05)	2.8	4.47	5.25	6.22	7.0	
			Placebo	123	116 (94.3)	4.95 (1.13)	2.7	4.00	4.81	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.70 (0.94)	-3.7	0.09	0.69	1.38	3.0	0.23 [-0.04, 0.50]
			Placebo	123	105 (85.4)	0.50 (0.79)	-1.2	0.09	0.44	0.97	2.6	
		Week 8	Tezepelumab	128	111 (86.7)	0.86 (0.94)	-1.0	0.13	0.75	1.56	3.9	0.27 [0.00, 0.54]
			Placebo	123	106 (86.2)	0.62 (0.84)	-1.4	0.16	0.55	1.03	3.1	
		Week 12	Tezepelumab	128	111 (86.7)	1.03 (0.97)	-2.1	0.50	0.97	1.75	4.2	0.37 [0.10, 0.64]
			Placebo	123	106 (86.2)	0.67 (0.97)	-2.0	0.13	0.61	1.22	3.3	
		Week 16	Tezepelumab	128	111 (86.7)	1.02 (0.98)	-2.4	0.34	0.91	1.69	4.2	0.29 [0.02, 0.56]
			Placebo	123	106 (86.2)	0.73 (0.97)	-3.2	0.22	0.73	1.38	3.2	
		Week 20	Tezepelumab	128	111 (86.7)	1.01 (0.97)	-1.2	0.28	0.81	1.69	4.2	0.26 [-0.01, 0.53]
			Placebo	123	106 (86.2)	0.76 (0.95)	-3.2	0.25	0.77	1.19	3.3	
		Week 24	Tezepelumab	128	111 (86.7)	1.07 (0.99)	-1.2	0.34	0.97	1.78	4.3	0.30 [0.03, 0.57]
			Placebo	123	106 (86.2)	0.77 (1.04)	-3.2	0.13	0.78	1.31	3.2	
		Week 28	Tezepelumab	128	111 (86.7)	1.05 (0.98)	-1.3	0.31	0.88	1.78	4.3	0.32 [0.05, 0.59]
			Placebo	123	106 (86.2)	0.72 (1.04)	-3.2	0.16	0.77	1.31	3.2	
		Week 32	Tezepelumab	128	111 (86.7)	1.10 (1.00)	-1.2	0.34	1.03	1.88	4.3	0.29 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.81 (0.99)	-3.2	0.25	0.72	1.41	3.4	
		Week 36	Tezepelumab	128	111 (86.7)	1.10 (1.05)	-1.3	0.34	0.94	1.91	4.3	0.23 [-0.04, 0.50]
			Placebo	123	106 (86.2)	0.86 (1.02)	-2.0	0.22	0.73	1.38	3.4	
		Week 40	Tezepelumab	128	111 (86.7)	1.10 (1.01)	-1.3	0.44	0.97	1.84	4.3	0.23 [-0.04, 0.49]
			Placebo	123	106 (86.2)	0.87 (1.03)	-2.0	0.25	0.78	1.50	3.6	
		Week 44	Tezepelumab	128	111 (86.7)	1.14 (1.01)	-1.1	0.50	1.03	1.88	4.3	0.28 [0.01, 0.55]
			Placebo	123	106 (86.2)	0.85 (1.03)	-2.0	0.22	0.83	1.38	3.5	
		Week 48	Tezepelumab	128	111 (86.7)	1.17 (1.02)	-1.1	0.44	1.06	2.06	4.3	0.30 [0.03, 0.56]
			Placebo	123	106 (86.2)	0.87 (1.01)	-2.0	0.16	0.83	1.50	3.5	
		Week 52	Tezepelumab	128	111 (86.7)	1.13 (1.02)	-1.2	0.44	1.03	2.00	4.3	0.29 [0.02, 0.56]
			Placebo	123	106 (86.2)	0.84 (0.99)	-2.0	0.16	0.80	1.41	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.11 (0.98)	2.2	3.67	4.41	4.56	5.4	
			Placebo	15	15 (100.0)	3.66 (0.89)	2.7	2.81	3.28	4.47	5.2	
		Week 4	Tezepelumab	9	9 (100.0)	5.33 (0.79)	4.4	4.75	5.03	6.06	6.6	
			Placebo	15	14 (93.3)	4.33 (0.82)	2.5	3.81	4.45	5.00	5.3	
		Week 8	Tezepelumab	9	9 (100.0)	5.51 (0.84)	3.9	5.09	5.34	5.97	6.7	
			Placebo	15	14 (93.3)	4.49 (1.22)	2.3	3.41	4.86	5.44	6.0	
		Week 12	Tezepelumab	9	9 (100.0)	5.71 (0.87)	4.3	5.25	5.50	6.47	6.9	
			Placebo	15	14 (93.3)	5.07 (1.03)	3.0	4.25	5.27	5.91	6.5	
		Week 16	Tezepelumab	9	9 (100.0)	5.55 (0.77)	4.3	5.44	5.59	5.78	6.9	
			Placebo	15	14 (93.3)	4.79 (1.28)	3.0	3.38	5.03	5.88	6.8	
		Week 20	Tezepelumab	9	9 (100.0)	5.66 (0.80)	4.3	5.59	5.69	6.19	7.0	
			Placebo	15	14 (93.3)	4.77 (1.10)	3.0	3.75	4.89	5.91	6.5	
		Week 24	Tezepelumab	9	9 (100.0)	5.75 (0.74)	4.3	5.63	5.91	6.03	6.9	
			Placebo	15	14 (93.3)	4.98 (0.95)	3.8	3.97	4.98	5.84	6.4	
		Week 28	Tezepelumab	9	9 (100.0)	5.89 (0.71)	4.5	5.63	5.84	6.03	7.0	
			Placebo	15	14 (93.3)	5.32 (1.32)	3.3	3.97	5.45	6.66	7.0	
		Week 32	Tezepelumab	9	9 (100.0)	5.84 (0.68)	4.6	5.63	5.78	6.13	7.0	
			Placebo	15	14 (93.3)	5.26 (0.94)	3.8	4.28	5.34	6.09	6.5	
		Week 36	Tezepelumab	9	9 (100.0)	5.77 (0.79)	4.8	4.94	5.94	6.22	7.0	
			Placebo	15	14 (93.3)	4.96 (0.99)	3.3	4.22	4.81	5.59	6.9	
		Week 40	Tezepelumab	9	9 (100.0)	5.93 (0.59)	5.3	5.44	5.94	6.25	7.0	
			Placebo	15	14 (93.3)	5.13 (1.20)	3.6	3.97	4.98	5.91	7.0	
		Week 44	Tezepelumab	9	9 (100.0)	5.97 (0.62)	5.0	5.63	6.00	6.41	7.0	
			Placebo	15	14 (93.3)	5.03 (1.34)	3.5	3.69	5.08	6.41	7.0	
		Week 48	Tezepelumab	9	9 (100.0)	5.82 (0.66)	4.5	5.63	5.97	6.06	7.0	
			Placebo	15	14 (93.3)	5.10 (1.05)	3.6	3.97	5.23	5.59	6.8	
		Week 52	Tezepelumab	9	9 (100.0)	5.89 (0.72)	4.5	5.63	6.03	6.09	7.0	
			Placebo	15	14 (93.3)	5.10 (1.04)	3.5	4.09	5.23	5.53	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	1.29 (1.03)	0.2	0.55	0.97	1.86	3.3	0.82 [-0.09, 1.72]
			Placebo	15	14 (93.3)	0.60 (0.72)	-0.3	0.06	0.33	1.19	2.0	
		Week 8	Tezepelumab	9	8 (88.9)	1.42 (1.27)	-0.3	0.58	1.30	2.06	3.8	0.58 [-0.31, 1.47]
			Placebo	15	14 (93.3)	0.76 (1.07)	-0.5	-0.19	0.33	1.50	2.5	
		Week 12	Tezepelumab	9	8 (88.9)	1.63 (1.27)	0.1	0.67	1.48	2.30	4.0	0.25 [-0.62, 1.12]
			Placebo	15	14 (93.3)	1.34 (1.07)	0.2	0.72	0.86	1.69	3.5	
		Week 16	Tezepelumab	9	8 (88.9)	1.45 (1.20)	-0.1	0.53	1.19	2.47	3.4	0.32 [-0.56, 1.19]
			Placebo	15	14 (93.3)	1.06 (1.27)	-0.4	0.34	0.64	1.41	3.8	
		Week 20	Tezepelumab	9	8 (88.9)	1.54 (1.21)	-0.3	0.66	1.47	2.48	3.4	0.41 [-0.47, 1.29]
			Placebo	15	14 (93.3)	1.04 (1.24)	-0.8	0.41	0.78	1.69	3.8	
		Week 24	Tezepelumab	9	8 (88.9)	1.62 (1.19)	0.1	0.55	1.56	2.63	3.4	0.33 [-0.55, 1.20]
			Placebo	15	14 (93.3)	1.25 (1.10)	-0.6	0.53	1.02	1.72	3.7	
		Week 28	Tezepelumab	9	8 (88.9)	1.78 (1.09)	0.3	0.92	1.70	2.64	3.4	0.15 [-0.72, 1.02]
			Placebo	15	14 (93.3)	1.59 (1.37)	-0.4	0.63	1.39	2.19	4.3	
		Week 32	Tezepelumab	9	8 (88.9)	1.64 (1.08)	0.4	0.75	1.34	2.58	3.4	0.11 [-0.76, 0.98]
			Placebo	15	14 (93.3)	1.53 (1.02)	0.3	0.72	1.23	2.38	3.6	
		Week 36	Tezepelumab	9	8 (88.9)	1.57 (1.21)	0.3	0.58	1.22	2.67	3.4	0.31 [-0.56, 1.19]
			Placebo	15	14 (93.3)	1.23 (1.06)	-1.2	0.56	1.27	1.78	3.3	
		Week 40	Tezepelumab	9	8 (88.9)	1.74 (1.07)	0.6	0.81	1.48	2.67	3.4	0.26 [-0.61, 1.14]
			Placebo	15	14 (93.3)	1.40 (1.38)	-0.2	0.59	1.02	1.72	4.3	
		Week 44	Tezepelumab	9	8 (88.9)	1.79 (1.16)	0.4	0.78	1.55	2.91	3.4	0.34 [-0.53, 1.22]
			Placebo	15	14 (93.3)	1.30 (1.54)	-1.0	0.06	0.86	2.22	4.1	
		Week 48	Tezepelumab	9	8 (88.9)	1.68 (1.18)	-0.1	0.92	1.42	2.72	3.4	0.26 [-0.61, 1.13]
			Placebo	15	14 (93.3)	1.37 (1.20)	-0.5	0.50	1.34	2.47	3.3	
		Week 52	Tezepelumab	9	8 (88.9)	1.68 (1.18)	-0.1	0.92	1.42	2.72	3.4	0.26 [-0.62, 1.13]
			Placebo	15	14 (93.3)	1.37 (1.26)	-0.5	0.50	1.03	2.47	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	3.95 (1.33)	2.0	2.66	4.38	4.56	5.7	
			Placebo	9	8 (88.9)	3.50 (0.75)	2.8	2.94	3.27	3.94	4.9	
		Week 4	Tezepelumab	10	8 (80.0)	5.81 (0.66)	5.0	5.36	5.64	6.28	6.9	
			Placebo	9	7 (77.8)	4.43 (1.15)	2.5	3.81	4.41	4.97	6.3	
		Week 8	Tezepelumab	10	9 (90.0)	5.84 (1.01)	3.6	5.81	5.97	6.59	7.0	
			Placebo	9	7 (77.8)	4.80 (1.58)	2.3	3.09	5.44	5.72	6.8	
		Week 12	Tezepelumab	10	9 (90.0)	5.98 (0.88)	4.3	5.94	6.22	6.47	7.0	
			Placebo	9	7 (77.8)	4.90 (1.41)	3.0	3.47	5.44	5.91	6.9	
		Week 16	Tezepelumab	10	9 (90.0)	5.74 (0.93)	4.3	5.59	5.91	6.09	6.9	
			Placebo	9	7 (77.8)	4.59 (1.56)	3.0	3.00	4.34	5.91	6.8	
		Week 20	Tezepelumab	10	9 (90.0)	5.92 (0.75)	4.3	5.69	5.94	6.19	6.9	
			Placebo	9	7 (77.8)	5.04 (1.50)	3.0	3.72	5.78	6.25	6.8	
		Week 24	Tezepelumab	10	9 (90.0)	5.91 (0.80)	4.3	5.63	5.94	6.13	7.0	
			Placebo	9	7 (77.8)	5.18 (1.17)	3.8	3.97	5.16	6.09	6.9	
		Week 28	Tezepelumab	10	10 (100.0)	6.02 (0.83)	4.3	5.63	5.92	6.72	7.0	
			Placebo	9	7 (77.8)	5.25 (1.16)	3.6	3.97	5.75	5.91	6.8	
		Week 32	Tezepelumab	10	10 (100.0)	5.80 (0.71)	4.3	5.63	5.80	5.94	7.0	
			Placebo	9	7 (77.8)	5.23 (0.97)	3.9	3.97	5.50	5.91	6.5	
		Week 36	Tezepelumab	10	10 (100.0)	5.77 (0.83)	4.3	5.34	5.78	6.44	7.0	
			Placebo	9	7 (77.8)	5.13 (0.82)	4.0	4.50	4.81	5.91	6.1	
		Week 40	Tezepelumab	10	10 (100.0)	5.92 (0.80)	4.3	5.31	6.00	6.63	7.0	
			Placebo	9	7 (77.8)	5.19 (1.04)	3.9	3.97	5.84	6.00	6.3	
		Week 44	Tezepelumab	10	10 (100.0)	5.91 (0.78)	4.3	5.53	5.98	6.22	7.0	
			Placebo	9	7 (77.8)	5.36 (1.26)	3.6	3.69	6.13	6.28	6.5	
		Week 48	Tezepelumab	10	10 (100.0)	5.98 (0.75)	4.3	5.69	5.98	6.28	7.0	
			Placebo	9	7 (77.8)	5.69 (0.92)	3.8	5.53	5.81	6.44	6.5	
		Week 52	Tezepelumab	10	10 (100.0)	6.06 (0.78)	4.3	5.75	5.98	6.78	7.0	
			Placebo	9	7 (77.8)	5.79 (0.92)	4.1	5.47	5.81	6.44	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	1.61 (1.33)	-0.5	0.66	1.59	2.80	3.3	0.64 [-0.41, 1.68]
			Placebo	9	7 (77.8)	0.83 (1.09)	-0.3	-0.19	0.53	1.72	2.6	
		Week 8	Tezepelumab	10	9 (90.0)	1.89 (1.35)	0.1	0.81	1.63	2.69	3.9	0.52 [-0.48, 1.53]
			Placebo	9	7 (77.8)	1.20 (1.30)	-0.5	-0.19	1.38	2.38	3.1	
		Week 12	Tezepelumab	10	9 (90.0)	2.03 (1.41)	0.3	0.94	1.91	2.69	4.2	0.56 [-0.45, 1.56]
			Placebo	9	7 (77.8)	1.29 (1.18)	0.2	0.22	0.88	2.38	3.3	
		Week 16	Tezepelumab	10	9 (90.0)	1.78 (1.44)	-0.1	0.81	1.47	2.59	4.2	0.59 [-0.42, 1.60]
			Placebo	9	7 (77.8)	0.99 (1.20)	-0.3	-0.25	0.78	1.69	3.2	
		Week 20	Tezepelumab	10	9 (90.0)	1.97 (1.30)	0.0	1.31	1.63	2.56	4.2	0.40 [-0.60, 1.40]
			Placebo	9	7 (77.8)	1.44 (1.33)	-0.3	0.44	0.97	3.19	3.2	
		Week 24	Tezepelumab	10	9 (90.0)	1.96 (1.39)	0.1	1.47	1.56	2.69	4.3	0.32 [-0.68, 1.31]
			Placebo	9	7 (77.8)	1.58 (0.93)	0.5	0.72	1.69	2.09	3.2	
		Week 28	Tezepelumab	10	9 (90.0)	2.00 (1.38)	0.2	1.25	2.16	2.69	4.3	0.28 [-0.71, 1.27]
			Placebo	9	7 (77.8)	1.65 (1.05)	0.3	0.72	1.69	2.69	3.2	
		Week 32	Tezepelumab	10	9 (90.0)	1.75 (1.38)	0.2	0.78	1.47	2.34	4.3	0.10 [-0.89, 1.09]
			Placebo	9	7 (77.8)	1.63 (0.99)	0.6	0.66	1.69	2.53	2.9	
		Week 36	Tezepelumab	10	9 (90.0)	1.74 (1.54)	-0.3	0.41	1.63	2.34	4.3	0.17 [-0.82, 1.16]
			Placebo	9	7 (77.8)	1.53 (0.61)	0.7	0.88	1.50	2.00	2.5	
		Week 40	Tezepelumab	10	9 (90.0)	1.89 (1.44)	-0.4	0.78	1.88	2.44	4.3	0.24 [-0.75, 1.23]
			Placebo	9	7 (77.8)	1.59 (0.87)	0.6	0.72	1.66	2.63	2.8	
		Week 44	Tezepelumab	10	9 (90.0)	1.93 (1.40)	-0.2	0.88	1.66	2.69	4.3	0.13 [-0.86, 1.12]
			Placebo	9	7 (77.8)	1.76 (1.07)	0.3	0.63	2.06	2.63	3.3	
		Week 48	Tezepelumab	10	9 (90.0)	2.00 (1.32)	0.0	1.19	1.66	2.66	4.3	-0.07 [-1.06, 0.92]
			Placebo	9	7 (77.8)	2.08 (1.01)	0.5	0.88	2.47	2.78	3.3	
		Week 52	Tezepelumab	10	9 (90.0)	2.03 (1.28)	0.2	1.19	1.66	2.66	4.3	-0.13 [-1.12, 0.86]
			Placebo	9	7 (77.8)	2.18 (1.04)	0.8	0.88	2.47	2.66	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	127	114 (89.8)	4.22 (0.88)	1.5	3.72	4.27	4.69	6.8	
			Placebo	129	113 (87.6)	4.13 (0.87)	1.8	3.63	4.13	4.69	6.3	
		Week 4	Tezepelumab	127	118 (92.9)	4.85 (1.03)	1.4	4.06	4.80	5.66	7.0	
			Placebo	129	116 (89.9)	4.61 (0.96)	2.1	3.92	4.63	5.25	6.8	
		Week 8	Tezepelumab	127	119 (93.7)	5.05 (1.03)	2.7	4.19	5.03	5.91	7.0	
			Placebo	129	119 (92.2)	4.71 (1.01)	2.1	4.00	4.59	5.34	7.0	
		Week 12	Tezepelumab	127	119 (93.7)	5.23 (1.04)	2.8	4.34	5.16	6.06	7.0	
			Placebo	129	120 (93.0)	4.82 (1.03)	2.5	4.02	4.70	5.58	7.0	
		Week 16	Tezepelumab	127	119 (93.7)	5.21 (1.03)	2.6	4.38	5.13	6.03	7.0	
			Placebo	129	120 (93.0)	4.86 (1.09)	1.2	4.00	4.78	5.70	7.0	
		Week 20	Tezepelumab	127	120 (94.5)	5.18 (1.02)	3.2	4.31	5.14	5.91	7.0	
			Placebo	129	120 (93.0)	4.84 (1.08)	1.2	4.05	4.78	5.61	7.0	
		Week 24	Tezepelumab	127	120 (94.5)	5.22 (1.05)	2.4	4.36	5.11	6.02	7.0	
			Placebo	129	120 (93.0)	4.86 (1.13)	1.2	4.00	4.80	5.67	7.0	
		Week 28	Tezepelumab	127	121 (95.3)	5.22 (1.00)	3.3	4.44	5.16	6.00	7.0	
			Placebo	129	121 (93.8)	4.88 (1.20)	1.2	3.97	4.75	5.78	7.0	
		Week 32	Tezepelumab	127	122 (96.1)	5.29 (1.04)	2.6	4.44	5.31	6.00	7.0	
			Placebo	129	122 (94.6)	4.93 (1.14)	1.2	4.03	4.80	5.91	7.0	
		Week 36	Tezepelumab	127	122 (96.1)	5.30 (1.02)	3.2	4.59	5.17	6.09	7.0	
			Placebo	129	122 (94.6)	4.96 (1.14)	2.2	4.00	4.78	5.97	7.0	
		Week 40	Tezepelumab	127	122 (96.1)	5.29 (1.04)	2.6	4.47	5.25	6.00	7.0	
			Placebo	129	122 (94.6)	4.98 (1.13)	2.3	4.00	4.97	5.91	7.0	
		Week 44	Tezepelumab	127	122 (96.1)	5.33 (1.04)	2.8	4.50	5.19	6.19	7.0	
			Placebo	129	122 (94.6)	4.95 (1.16)	2.5	4.00	4.88	5.81	7.0	
		Week 48	Tezepelumab	127	122 (96.1)	5.34 (1.04)	2.9	4.47	5.28	6.16	7.0	
			Placebo	129	123 (95.3)	4.96 (1.10)	2.1	4.03	4.81	5.91	7.0	
		Week 52	Tezepelumab	127	122 (96.1)	5.31 (1.04)	2.8	4.47	5.23	6.16	7.0	
			Placebo	129	123 (95.3)	4.92 (1.11)	2.7	3.97	4.78	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	127	109 (85.8)	0.68 (0.90)	-3.7	0.16	0.66	1.31	2.7	0.22 [-0.05, 0.48]
			Placebo	129	112 (86.8)	0.50 (0.76)	-1.2	0.09	0.42	0.97	2.6	
		Week 8	Tezepelumab	127	110 (86.6)	0.82 (0.90)	-1.0	0.13	0.70	1.53	3.0	0.25 [-0.01, 0.51]
			Placebo	129	113 (87.6)	0.60 (0.83)	-1.4	0.09	0.50	1.00	2.7	
		Week 12	Tezepelumab	127	110 (86.6)	1.00 (0.93)	-2.1	0.50	0.95	1.69	3.0	0.29 [0.03, 0.56]
			Placebo	129	113 (87.6)	0.72 (0.99)	-2.0	0.19	0.69	1.22	3.5	
		Week 16	Tezepelumab	127	110 (86.6)	0.99 (0.93)	-2.4	0.34	0.88	1.69	3.0	0.24 [-0.03, 0.50]
			Placebo	129	113 (87.6)	0.76 (1.00)	-3.2	0.28	0.72	1.38	3.8	
		Week 20	Tezepelumab	127	110 (86.6)	0.97 (0.93)	-1.2	0.28	0.78	1.69	3.0	0.23 [-0.03, 0.50]
			Placebo	129	113 (87.6)	0.75 (0.95)	-3.2	0.25	0.75	1.16	3.8	
		Week 24	Tezepelumab	127	110 (86.6)	1.04 (0.94)	-1.2	0.34	0.95	1.72	3.0	0.26 [-0.00, 0.52]
			Placebo	129	113 (87.6)	0.78 (1.05)	-3.2	0.13	0.78	1.28	3.7	
		Week 28	Tezepelumab	127	110 (86.6)	1.02 (0.93)	-1.3	0.31	0.88	1.72	3.0	0.24 [-0.02, 0.51]
			Placebo	129	113 (87.6)	0.77 (1.10)	-3.2	0.16	0.78	1.34	4.3	
		Week 32	Tezepelumab	127	110 (86.6)	1.08 (0.97)	-1.2	0.47	1.03	1.88	3.0	0.24 [-0.03, 0.50]
			Placebo	129	113 (87.6)	0.85 (1.00)	-3.2	0.28	0.75	1.41	3.6	
		Week 36	Tezepelumab	127	110 (86.6)	1.09 (1.01)	-1.3	0.41	0.92	1.84	3.3	0.21 [-0.05, 0.48]
			Placebo	129	113 (87.6)	0.87 (1.04)	-2.0	0.28	0.72	1.38	3.4	
		Week 40	Tezepelumab	127	110 (86.6)	1.08 (0.96)	-1.3	0.44	0.97	1.84	3.0	0.19 [-0.08, 0.45]
			Placebo	129	113 (87.6)	0.89 (1.08)	-2.0	0.25	0.78	1.50	4.3	
		Week 44	Tezepelumab	127	110 (86.6)	1.12 (0.97)	-1.1	0.50	1.02	1.84	3.3	0.26 [-0.01, 0.52]
			Placebo	129	113 (87.6)	0.85 (1.09)	-2.0	0.09	0.81	1.38	4.1	
		Week 48	Tezepelumab	127	110 (86.6)	1.14 (0.98)	-1.1	0.44	1.05	2.06	3.0	0.28 [0.02, 0.55]
			Placebo	129	113 (87.6)	0.86 (1.00)	-2.0	0.16	0.81	1.50	3.5	
		Week 52	Tezepelumab	127	110 (86.6)	1.10 (0.99)	-1.2	0.44	1.00	1.94	3.0	0.28 [0.02, 0.54]
			Placebo	129	113 (87.6)	0.82 (0.99)	-2.0	0.09	0.75	1.41	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	61	54 (88.5)	4.26 (0.78)	2.2	3.88	4.31	4.69	6.3	
			Placebo	60	53 (88.3)	4.08 (0.85)	1.8	3.56	4.13	4.59	6.1	
		Week 4	Tezepelumab	61	56 (91.8)	4.86 (1.03)	1.4	4.22	4.78	5.59	6.9	
			Placebo	60	53 (88.3)	4.72 (0.97)	2.4	3.97	4.72	5.41	6.8	
		Week 8	Tezepelumab	61	57 (93.4)	5.11 (0.89)	3.3	4.47	5.00	5.66	7.0	
			Placebo	60	54 (90.0)	4.81 (0.99)	2.4	4.09	4.73	5.59	6.9	
		Week 12	Tezepelumab	61	57 (93.4)	5.21 (0.91)	3.0	4.56	5.19	5.78	7.0	
			Placebo	60	54 (90.0)	4.89 (0.98)	3.0	4.09	4.73	5.53	7.0	
		Week 16	Tezepelumab	61	57 (93.4)	5.13 (0.92)	2.7	4.47	5.03	5.69	7.0	
			Placebo	60	54 (90.0)	4.88 (1.12)	1.2	4.00	4.95	5.72	7.0	
		Week 20	Tezepelumab	61	58 (95.1)	5.13 (0.88)	3.7	4.47	5.03	5.69	7.0	
			Placebo	60	54 (90.0)	4.83 (1.07)	1.2	4.03	4.75	5.56	7.0	
		Week 24	Tezepelumab	61	58 (95.1)	5.17 (1.01)	2.4	4.47	5.08	5.91	7.0	
			Placebo	60	54 (90.0)	4.86 (1.18)	1.2	3.97	4.88	5.69	7.0	
		Week 28	Tezepelumab	61	59 (96.7)	5.15 (0.91)	3.7	4.47	5.06	5.72	7.0	
			Placebo	60	54 (90.0)	4.81 (1.27)	1.2	3.94	4.70	5.78	7.0	
		Week 32	Tezepelumab	61	60 (98.4)	5.25 (0.87)	3.9	4.50	5.27	5.86	7.0	
			Placebo	60	54 (90.0)	4.91 (1.13)	1.2	4.03	4.67	5.75	7.0	
		Week 36	Tezepelumab	61	60 (98.4)	5.29 (0.90)	3.8	4.61	5.09	5.98	7.0	
			Placebo	60	54 (90.0)	5.01 (1.10)	2.6	4.00	5.03	5.81	7.0	
		Week 40	Tezepelumab	61	60 (98.4)	5.23 (0.92)	3.7	4.52	5.20	5.81	7.0	
			Placebo	60	54 (90.0)	4.96 (1.09)	2.9	3.97	5.08	5.84	7.0	
		Week 44	Tezepelumab	61	60 (98.4)	5.28 (0.95)	3.7	4.63	5.11	5.95	7.0	
			Placebo	60	54 (90.0)	5.00 (1.17)	2.8	4.00	5.03	5.88	7.0	
		Week 48	Tezepelumab	61	60 (98.4)	5.35 (0.91)	3.6	4.70	5.34	6.00	7.0	
			Placebo	60	54 (90.0)	4.98 (1.13)	2.9	4.00	4.75	5.91	7.0	
		Week 52	Tezepelumab	61	60 (98.4)	5.35 (0.90)	3.6	4.75	5.20	6.00	7.0	
			Placebo	60	54 (90.0)	4.93 (1.11)	2.9	3.97	4.75	5.84	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)											
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	61	52 (85.2)	0.65 (1.07)	-3.7	0.13	0.66	1.23	3.3	0.04 [-0.35, 0.43]
			Placebo	60	51 (85.0)	0.62 (0.75)	-0.9	0.16	0.50	1.00	2.6	
		Week 8	Tezepelumab	61	53 (86.9)	0.84 (0.96)	-1.0	0.06	0.72	1.56	3.8	0.13 [-0.25, 0.51]
			Placebo	60	52 (86.7)	0.72 (0.76)	-1.0	0.22	0.67	1.09	2.7	
		Week 12	Tezepelumab	61	53 (86.9)	0.95 (0.99)	-2.1	0.47	0.78	1.41	4.0	0.18 [-0.20, 0.57]
			Placebo	60	52 (86.7)	0.78 (0.91)	-2.0	0.27	0.91	1.23	2.9	
		Week 16	Tezepelumab	61	53 (86.9)	0.89 (1.02)	-2.4	0.28	0.84	1.59	3.4	0.11 [-0.28, 0.49]
			Placebo	60	52 (86.7)	0.79 (0.98)	-3.2	0.45	0.95	1.38	2.8	
		Week 20	Tezepelumab	61	53 (86.9)	0.88 (0.95)	-1.2	0.25	0.69	1.56	3.4	0.16 [-0.23, 0.54]
			Placebo	60	52 (86.7)	0.74 (0.91)	-3.2	0.23	0.81	1.20	2.8	
		Week 24	Tezepelumab	61	53 (86.9)	0.96 (0.97)	-1.2	0.34	0.88	1.59	3.4	0.18 [-0.21, 0.56]
			Placebo	60	52 (86.7)	0.79 (1.01)	-3.2	0.25	0.94	1.30	3.1	
		Week 28	Tezepelumab	61	53 (86.9)	0.92 (0.96)	-1.3	0.31	0.84	1.69	3.4	0.19 [-0.19, 0.58]
			Placebo	60	52 (86.7)	0.73 (1.01)	-3.2	0.23	0.98	1.22	3.1	
		Week 32	Tezepelumab	61	53 (86.9)	0.98 (0.95)	-1.2	0.34	1.03	1.59	3.4	0.16 [-0.22, 0.54]
			Placebo	60	52 (86.7)	0.84 (0.88)	-3.2	0.31	1.00	1.38	2.7	
		Week 36	Tezepelumab	61	53 (86.9)	1.01 (0.99)	-1.3	0.34	0.88	1.63	3.4	0.07 [-0.31, 0.46]
			Placebo	60	52 (86.7)	0.95 (0.90)	-1.7	0.36	1.00	1.44	3.0	
		Week 40	Tezepelumab	61	53 (86.9)	0.98 (0.95)	-1.3	0.31	0.94	1.69	3.4	0.08 [-0.30, 0.47]
			Placebo	60	52 (86.7)	0.90 (0.89)	-1.0	0.28	0.98	1.45	2.8	
		Week 44	Tezepelumab	61	53 (86.9)	1.02 (0.98)	-1.1	0.47	0.84	1.66	3.4	0.08 [-0.30, 0.47]
			Placebo	60	52 (86.7)	0.94 (0.99)	-1.3	0.20	0.98	1.48	3.1	
		Week 48	Tezepelumab	61	53 (86.9)	1.10 (0.96)	-1.1	0.44	1.06	1.72	3.4	0.19 [-0.19, 0.58]
			Placebo	60	52 (86.7)	0.91 (0.92)	-0.9	0.16	0.89	1.52	3.3	
		Week 52	Tezepelumab	61	53 (86.9)	1.07 (0.96)	-1.2	0.41	0.97	1.69	3.4	0.23 [-0.16, 0.61]
			Placebo	60	52 (86.7)	0.86 (0.93)	-0.9	0.06	0.81	1.33	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	76	69 (90.8)	4.15 (1.01)	1.5	3.63	4.09	4.63	6.8	
			Placebo	78	68 (87.2)	4.09 (0.90)	1.9	3.48	3.98	4.69	6.3	
		Week 4	Tezepelumab	76	70 (92.1)	4.95 (1.05)	3.2	4.03	5.09	5.69	7.0	
			Placebo	78	70 (89.7)	4.52 (0.97)	2.1	3.84	4.47	5.19	6.7	
		Week 8	Tezepelumab	76	71 (93.4)	5.11 (1.16)	2.7	4.09	5.16	6.09	7.0	
			Placebo	78	72 (92.3)	4.64 (1.07)	2.1	3.91	4.56	5.39	7.0	
		Week 12	Tezepelumab	76	71 (93.4)	5.34 (1.14)	2.8	4.31	5.50	6.31	7.0	
			Placebo	78	73 (93.6)	4.78 (1.09)	2.5	3.97	4.72	5.59	7.0	
		Week 16	Tezepelumab	76	71 (93.4)	5.34 (1.11)	2.6	4.31	5.31	6.25	7.0	
			Placebo	78	73 (93.6)	4.81 (1.11)	2.5	4.00	4.69	5.72	7.0	
		Week 20	Tezepelumab	76	71 (93.4)	5.32 (1.11)	3.2	4.28	5.44	6.25	7.0	
			Placebo	78	73 (93.6)	4.87 (1.13)	2.4	4.03	4.78	5.88	7.0	
		Week 24	Tezepelumab	76	71 (93.4)	5.35 (1.07)	3.5	4.34	5.28	6.25	7.0	
			Placebo	78	73 (93.6)	4.90 (1.10)	2.3	4.09	4.78	5.81	7.0	
		Week 28	Tezepelumab	76	72 (94.7)	5.39 (1.07)	3.3	4.34	5.44	6.25	7.0	
			Placebo	78	74 (94.9)	4.96 (1.15)	2.2	4.00	4.89	5.94	7.0	
		Week 32	Tezepelumab	76	72 (94.7)	5.40 (1.14)	2.6	4.44	5.64	6.36	7.0	
			Placebo	78	75 (96.2)	4.98 (1.14)	2.3	4.03	5.00	5.94	7.0	
		Week 36	Tezepelumab	76	72 (94.7)	5.38 (1.11)	3.2	4.59	5.45	6.23	7.0	
			Placebo	78	75 (96.2)	4.94 (1.15)	2.2	4.03	4.75	6.03	7.0	
		Week 40	Tezepelumab	76	72 (94.7)	5.43 (1.12)	2.6	4.58	5.53	6.47	7.0	
			Placebo	78	75 (96.2)	5.01 (1.16)	2.3	4.13	4.91	6.09	7.0	
		Week 44	Tezepelumab	76	72 (94.7)	5.45 (1.10)	2.8	4.52	5.61	6.34	7.0	
			Placebo	78	75 (96.2)	4.96 (1.16)	2.5	4.00	4.88	6.00	7.0	
		Week 48	Tezepelumab	76	72 (94.7)	5.41 (1.13)	2.9	4.44	5.48	6.39	7.0	
			Placebo	78	76 (97.4)	5.01 (1.10)	2.1	4.19	4.94	5.95	7.0	
		Week 52	Tezepelumab	76	72 (94.7)	5.39 (1.15)	2.8	4.41	5.42	6.34	7.0	
			Placebo	78	76 (97.4)	4.99 (1.13)	2.7	4.13	4.92	5.95	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)											
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	76	65 (85.5)	0.81 (0.86)	-0.9	0.16	0.69	1.47	3.0	0.45 [0.11, 0.79]
			Placebo	78	68 (87.2)	0.44 (0.80)	-1.2	0.06	0.34	0.97	2.6	
		Week 8	Tezepelumab	76	66 (86.8)	0.95 (0.99)	-1.0	0.28	0.81	1.69	3.9	0.39 [0.05, 0.73]
			Placebo	78	68 (87.2)	0.57 (0.94)	-1.4	0.02	0.38	1.09	3.1	
		Week 12	Tezepelumab	76	66 (86.8)	1.17 (1.01)	-0.9	0.53	1.14	1.88	4.2	0.42 [0.08, 0.77]
			Placebo	78	68 (87.2)	0.73 (1.08)	-1.7	0.17	0.53	1.25	3.5	
		Week 16	Tezepelumab	76	66 (86.8)	1.17 (0.96)	-0.9	0.53	1.14	1.88	4.2	0.41 [0.07, 0.75]
			Placebo	78	68 (87.2)	0.76 (1.04)	-2.0	0.13	0.58	1.36	3.8	
		Week 20	Tezepelumab	76	66 (86.8)	1.18 (1.02)	-0.9	0.38	1.20	1.97	4.2	0.33 [-0.01, 0.68]
			Placebo	78	68 (87.2)	0.83 (1.05)	-2.0	0.25	0.73	1.25	3.8	
		Week 24	Tezepelumab	76	66 (86.8)	1.22 (1.03)	-0.9	0.53	1.20	1.97	4.3	0.35 [0.01, 0.69]
			Placebo	78	68 (87.2)	0.85 (1.09)	-2.0	0.14	0.73	1.66	3.7	
		Week 28	Tezepelumab	76	66 (86.8)	1.23 (1.01)	-0.9	0.50	1.14	2.03	4.3	0.30 [-0.04, 0.65]
			Placebo	78	68 (87.2)	0.90 (1.19)	-2.0	0.17	0.61	1.67	4.3	
		Week 32	Tezepelumab	76	66 (86.8)	1.26 (1.05)	-0.9	0.53	1.17	2.22	4.3	0.29 [-0.05, 0.63]
			Placebo	78	68 (87.2)	0.94 (1.11)	-2.0	0.28	0.72	1.75	3.6	
		Week 36	Tezepelumab	76	66 (86.8)	1.23 (1.12)	-0.9	0.41	1.02	2.19	4.3	0.32 [-0.02, 0.66]
			Placebo	78	68 (87.2)	0.88 (1.12)	-2.0	0.25	0.59	1.67	3.4	
		Week 40	Tezepelumab	76	66 (86.8)	1.28 (1.06)	-0.9	0.63	1.05	2.16	4.3	0.28 [-0.06, 0.62]
			Placebo	78	68 (87.2)	0.96 (1.21)	-2.0	0.25	0.72	1.69	4.3	
		Week 44	Tezepelumab	76	66 (86.8)	1.31 (1.05)	-0.9	0.53	1.36	2.16	4.3	0.38 [0.04, 0.72]
			Placebo	78	68 (87.2)	0.88 (1.19)	-2.0	0.16	0.70	1.39	4.1	
		Week 48	Tezepelumab	76	66 (86.8)	1.29 (1.08)	-0.9	0.50	1.08	2.25	4.3	0.32 [-0.02, 0.66]
			Placebo	78	68 (87.2)	0.94 (1.13)	-2.0	0.17	0.83	1.70	3.5	
		Week 52	Tezepelumab	76	66 (86.8)	1.25 (1.09)	-0.9	0.44	1.09	2.22	4.3	0.28 [-0.06, 0.62]
			Placebo	78	68 (87.2)	0.94 (1.11)	-2.0	0.19	0.81	1.72	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	75	65 (86.7)	4.24 (0.76)	2.2	3.78	4.34	4.69	6.3	
			Placebo	72	61 (84.7)	4.07 (0.80)	1.9	3.63	4.13	4.66	5.8	
		Week 4	Tezepelumab	75	69 (92.0)	4.81 (1.04)	1.4	4.03	4.78	5.63	6.9	
			Placebo	72	64 (88.9)	4.61 (0.97)	2.1	3.98	4.45	5.27	6.8	
		Week 8	Tezepelumab	75	69 (92.0)	5.03 (0.93)	3.0	4.25	4.97	5.84	7.0	
			Placebo	72	64 (88.9)	4.76 (1.01)	2.1	4.02	4.73	5.31	6.9	
		Week 12	Tezepelumab	75	69 (92.0)	5.23 (0.96)	3.0	4.47	5.28	6.00	7.0	
			Placebo	72	65 (90.3)	4.79 (1.06)	2.5	4.00	4.63	5.56	7.0	
		Week 16	Tezepelumab	75	69 (92.0)	5.14 (0.97)	2.7	4.38	5.09	5.94	7.0	
			Placebo	72	65 (90.3)	4.88 (1.00)	2.5	4.00	4.84	5.69	7.0	
		Week 20	Tezepelumab	75	70 (93.3)	5.09 (0.99)	3.2	4.28	4.89	5.88	7.0	
			Placebo	72	65 (90.3)	4.86 (0.99)	2.4	4.03	4.81	5.50	7.0	
		Week 24	Tezepelumab	75	70 (93.3)	5.18 (1.00)	3.3	4.38	5.06	5.97	7.0	
			Placebo	72	65 (90.3)	4.92 (1.06)	2.3	4.00	4.84	5.63	7.0	
		Week 28	Tezepelumab	75	72 (96.0)	5.17 (1.00)	3.6	4.30	5.09	5.97	7.0	
			Placebo	72	66 (91.7)	4.91 (1.10)	2.2	4.00	4.80	5.78	7.0	
		Week 32	Tezepelumab	75	73 (97.3)	5.22 (1.00)	2.9	4.41	5.28	5.97	7.0	
			Placebo	72	67 (93.1)	4.93 (1.07)	2.3	4.03	4.81	5.91	7.0	
		Week 36	Tezepelumab	75	73 (97.3)	5.27 (1.02)	3.3	4.47	5.19	6.19	7.0	
			Placebo	72	67 (93.1)	5.01 (1.06)	2.6	4.00	5.03	5.94	7.0	
		Week 40	Tezepelumab	75	73 (97.3)	5.17 (1.02)	3.2	4.38	5.22	5.88	7.0	
			Placebo	72	67 (93.1)	5.00 (1.03)	2.5	4.16	5.06	5.84	7.0	
		Week 44	Tezepelumab	75	73 (97.3)	5.21 (1.03)	3.0	4.47	5.13	5.97	7.0	
			Placebo	72	67 (93.1)	5.01 (1.12)	2.5	4.00	4.88	5.88	7.0	
		Week 48	Tezepelumab	75	73 (97.3)	5.21 (1.03)	2.9	4.47	5.09	6.06	7.0	
			Placebo	72	68 (94.4)	5.06 (1.08)	2.8	4.13	4.98	6.02	7.0	
		Week 52	Tezepelumab	75	73 (97.3)	5.19 (1.01)	2.9	4.47	5.03	5.94	7.0	
			Placebo	72	68 (94.4)	4.99 (1.14)	2.7	3.98	4.94	5.95	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	75	64 (85.3)	0.56 (0.99)	-3.7	0.02	0.59	1.08	3.3	-0.03 [-0.38, 0.32]
			Placebo	72	61 (84.7)	0.58 (0.80)	-1.2	0.16	0.47	0.94	2.6	
		Week 8	Tezepelumab	75	64 (85.3)	0.77 (0.92)	-1.0	0.20	0.67	1.36	3.8	0.06 [-0.29, 0.41]
			Placebo	72	61 (84.7)	0.72 (0.83)	-1.0	0.16	0.66	1.09	3.1	
		Week 12	Tezepelumab	75	64 (85.3)	0.97 (0.95)	-2.1	0.48	0.94	1.45	4.0	0.22 [-0.13, 0.57]
			Placebo	72	61 (84.7)	0.76 (0.97)	-2.0	0.28	0.72	1.22	3.3	
		Week 16	Tezepelumab	75	64 (85.3)	0.90 (0.95)	-2.4	0.34	0.75	1.50	3.4	0.05 [-0.30, 0.40]
			Placebo	72	61 (84.7)	0.85 (0.87)	-2.0	0.28	0.88	1.38	3.2	
		Week 20	Tezepelumab	75	64 (85.3)	0.86 (0.95)	-1.2	0.22	0.69	1.59	3.4	0.02 [-0.33, 0.37]
			Placebo	72	61 (84.7)	0.84 (0.80)	-1.3	0.41	0.78	1.22	3.2	
		Week 24	Tezepelumab	75	64 (85.3)	0.98 (0.90)	-1.2	0.33	1.00	1.58	3.4	0.10 [-0.25, 0.45]
			Placebo	72	61 (84.7)	0.89 (0.87)	-1.3	0.38	0.91	1.31	3.2	
		Week 28	Tezepelumab	75	64 (85.3)	0.95 (0.94)	-1.3	0.31	0.70	1.70	3.4	0.11 [-0.24, 0.46]
			Placebo	72	61 (84.7)	0.85 (0.90)	-1.5	0.25	0.84	1.31	3.2	
		Week 32	Tezepelumab	75	64 (85.3)	0.97 (0.96)	-1.2	0.31	1.00	1.61	3.4	0.07 [-0.28, 0.42]
			Placebo	72	61 (84.7)	0.91 (0.78)	-1.0	0.44	0.81	1.41	2.9	
		Week 36	Tezepelumab	75	64 (85.3)	1.02 (1.01)	-1.3	0.30	0.91	1.66	3.4	0.04 [-0.31, 0.39]
			Placebo	72	61 (84.7)	0.98 (0.89)	-0.7	0.38	0.97	1.44	3.0	
		Week 40	Tezepelumab	75	64 (85.3)	0.93 (0.96)	-1.3	0.25	0.72	1.55	3.4	-0.04 [-0.40, 0.31]
			Placebo	72	61 (84.7)	0.97 (0.90)	-1.2	0.38	0.94	1.59	2.9	
		Week 44	Tezepelumab	75	64 (85.3)	0.96 (0.97)	-1.1	0.30	0.78	1.64	3.4	-0.00 [-0.35, 0.35]
			Placebo	72	61 (84.7)	0.96 (0.97)	-1.3	0.31	0.94	1.34	3.1	
		Week 48	Tezepelumab	75	64 (85.3)	0.98 (0.97)	-1.1	0.38	0.83	1.66	3.4	-0.04 [-0.39, 0.31]
			Placebo	72	61 (84.7)	1.02 (0.92)	-0.5	0.22	0.97	1.53	3.3	
		Week 52	Tezepelumab	75	64 (85.3)	0.94 (0.96)	-1.2	0.34	0.75	1.55	3.4	-0.02 [-0.37, 0.33]
			Placebo	72	61 (84.7)	0.96 (0.95)	-0.6	0.19	0.84	1.50	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	60	56 (93.3)	4.15 (1.08)	1.5	3.61	4.27	4.67	6.8	
			Placebo	65	59 (90.8)	4.10 (0.96)	1.8	3.38	4.06	4.72	6.3	
		Week 4	Tezepelumab	60	55 (91.7)	5.06 (1.04)	3.2	4.28	5.09	5.72	7.0	
			Placebo	65	59 (90.8)	4.59 (0.98)	2.4	3.84	4.69	5.19	6.8	
		Week 8	Tezepelumab	60	57 (95.0)	5.21 (1.19)	2.7	4.19	5.16	6.16	7.0	
			Placebo	65	61 (93.8)	4.68 (1.07)	2.3	3.88	4.59	5.50	7.0	
		Week 12	Tezepelumab	60	57 (95.0)	5.35 (1.16)	2.8	4.38	5.22	6.44	7.0	
			Placebo	65	61 (93.8)	4.87 (1.05)	2.7	4.09	5.06	5.59	7.0	
		Week 16	Tezepelumab	60	57 (95.0)	5.37 (1.11)	2.6	4.38	5.44	6.38	7.0	
			Placebo	65	61 (93.8)	4.86 (1.14)	2.9	4.00	4.75	5.72	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.40 (1.05)	3.6	4.47	5.44	6.13	7.0	
			Placebo	65	61 (93.8)	4.91 (1.13)	2.9	4.19	4.75	5.97	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.38 (1.10)	2.4	4.44	5.38	6.25	7.0	
			Placebo	65	61 (93.8)	4.90 (1.11)	2.7	4.00	4.69	5.84	7.0	
		Week 28	Tezepelumab	60	57 (95.0)	5.43 (1.02)	3.3	4.53	5.44	6.09	7.0	
			Placebo	65	61 (93.8)	4.95 (1.22)	2.8	3.94	4.88	5.88	7.0	
		Week 32	Tezepelumab	60	57 (95.0)	5.46 (1.06)	2.6	4.63	5.69	6.09	7.0	
			Placebo	65	61 (93.8)	5.03 (1.11)	2.9	4.09	5.09	5.88	7.0	
		Week 36	Tezepelumab	60	57 (95.0)	5.43 (1.03)	3.2	4.78	5.34	6.19	7.0	
			Placebo	65	61 (93.8)	4.96 (1.17)	2.2	4.19	4.78	6.06	7.0	
		Week 40	Tezepelumab	60	57 (95.0)	5.55 (1.05)	2.6	4.84	5.41	6.53	7.0	
			Placebo	65	61 (93.8)	5.01 (1.22)	2.3	3.97	4.97	6.09	7.0	
		Week 44	Tezepelumab	60	57 (95.0)	5.59 (1.03)	2.8	4.84	5.66	6.47	7.0	
			Placebo	65	61 (93.8)	4.97 (1.21)	2.8	3.91	5.00	6.00	7.0	
		Week 48	Tezepelumab	60	57 (95.0)	5.60 (1.03)	3.2	4.88	5.69	6.41	7.0	
			Placebo	65	61 (93.8)	4.95 (1.13)	2.1	4.06	4.75	5.91	7.0	
		Week 52	Tezepelumab	60	57 (95.0)	5.59 (1.06)	2.8	4.88	5.75	6.47	7.0	
			Placebo	65	61 (93.8)	4.96 (1.09)	2.9	4.09	4.78	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	60	51 (85.0)	0.98 (0.88)	-0.9	0.41	0.91	1.69	3.0	0.66 [0.27, 1.05]
			Placebo	65	58 (89.2)	0.44 (0.76)	-1.2	0.03	0.38	1.16	2.0	
		Week 8	Tezepelumab	60	53 (88.3)	1.06 (1.03)	-0.9	0.19	1.00	1.78	3.9	0.49 [0.12, 0.87]
			Placebo	65	58 (89.2)	0.58 (0.90)	-1.4	0.00	0.42	1.00	2.6	
		Week 12	Tezepelumab	60	53 (88.3)	1.19 (1.08)	-0.9	0.50	1.09	2.06	4.2	0.42 [0.04, 0.79]
			Placebo	65	58 (89.2)	0.75 (1.05)	-1.7	0.16	0.72	1.31	3.5	
		Week 16	Tezepelumab	60	53 (88.3)	1.22 (1.05)	-0.9	0.50	1.28	1.91	4.2	0.45 [0.08, 0.83]
			Placebo	65	58 (89.2)	0.75 (1.03)	-2.0	0.22	0.67	1.41	3.8	
		Week 20	Tezepelumab	60	53 (88.3)	1.25 (1.03)	-0.9	0.53	1.19	1.97	4.2	0.43 [0.06, 0.81]
			Placebo	65	58 (89.2)	0.80 (1.04)	-2.0	0.19	0.72	1.16	3.8	
		Week 24	Tezepelumab	60	53 (88.3)	1.24 (1.13)	-1.1	0.53	0.97	2.13	4.3	0.38 [0.00, 0.75]
			Placebo	65	58 (89.2)	0.82 (1.11)	-2.0	0.09	0.77	1.59	3.7	
		Week 28	Tezepelumab	60	53 (88.3)	1.27 (1.06)	-0.9	0.50	1.03	2.13	4.3	0.35 [-0.02, 0.73]
			Placebo	65	58 (89.2)	0.87 (1.20)	-2.0	0.16	0.75	1.72	4.3	
		Week 32	Tezepelumab	60	53 (88.3)	1.32 (1.06)	-0.9	0.63	1.13	2.22	4.3	0.34 [-0.04, 0.71]
			Placebo	65	58 (89.2)	0.95 (1.10)	-2.0	0.25	0.72	1.63	3.6	
		Week 36	Tezepelumab	60	53 (88.3)	1.27 (1.14)	-0.9	0.66	0.94	2.34	4.3	0.36 [-0.02, 0.73]
			Placebo	65	58 (89.2)	0.87 (1.12)	-2.0	0.19	0.70	1.63	3.4	
		Week 40	Tezepelumab	60	53 (88.3)	1.40 (1.06)	-0.9	0.81	1.09	2.44	4.3	0.41 [0.03, 0.78]
			Placebo	65	58 (89.2)	0.93 (1.24)	-2.0	0.19	0.77	1.66	4.3	
		Week 44	Tezepelumab	60	53 (88.3)	1.44 (1.05)	-0.9	0.84	1.38	2.31	4.3	0.49 [0.11, 0.87]
			Placebo	65	58 (89.2)	0.88 (1.22)	-2.0	0.09	0.72	1.56	4.1	
		Week 48	Tezepelumab	60	53 (88.3)	1.47 (1.06)	-0.9	0.81	1.25	2.34	4.3	0.54 [0.16, 0.92]
			Placebo	65	58 (89.2)	0.87 (1.14)	-2.0	0.19	0.69	1.66	3.5	
		Week 52	Tezepelumab	60	53 (88.3)	1.43 (1.08)	-0.9	0.72	1.22	2.34	4.3	0.51 [0.13, 0.89]
			Placebo	65	58 (89.2)	0.87 (1.11)	-2.0	0.19	0.77	1.44	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	65	56 (86.2)	4.26 (0.78)	2.2	3.80	4.23	4.80	6.3	
			Placebo	62	53 (85.5)	4.07 (0.82)	1.9	3.56	4.13	4.66	5.8	
		Week 4	Tezepelumab	65	60 (92.3)	4.81 (1.05)	1.4	4.03	4.83	5.59	6.9	
			Placebo	62	56 (90.3)	4.55 (0.97)	2.1	3.97	4.41	5.17	6.8	
		Week 8	Tezepelumab	65	60 (92.3)	5.05 (0.91)	3.4	4.25	4.84	5.88	7.0	
			Placebo	62	56 (90.3)	4.67 (0.98)	2.1	4.00	4.67	5.22	6.9	
		Week 12	Tezepelumab	65	60 (92.3)	5.20 (0.96)	3.0	4.41	5.14	5.92	7.0	
			Placebo	62	57 (91.9)	4.69 (1.01)	2.5	4.00	4.53	5.50	7.0	
		Week 16	Tezepelumab	65	60 (92.3)	5.10 (0.98)	2.7	4.33	5.05	5.80	7.0	
			Placebo	62	57 (91.9)	4.79 (0.99)	2.5	3.97	4.75	5.41	7.0	
		Week 20	Tezepelumab	65	61 (93.8)	5.01 (0.96)	3.2	4.22	4.78	5.72	7.0	
			Placebo	62	57 (91.9)	4.79 (0.98)	2.4	4.00	4.78	5.44	7.0	
		Week 24	Tezepelumab	65	61 (93.8)	5.12 (0.99)	3.3	4.25	5.03	5.81	7.0	
			Placebo	62	57 (91.9)	4.83 (1.03)	2.3	4.00	4.81	5.59	7.0	
		Week 28	Tezepelumab	65	62 (95.4)	5.07 (0.96)	3.6	4.25	4.88	5.75	7.0	
			Placebo	62	58 (93.5)	4.79 (1.06)	2.2	4.00	4.66	5.72	7.0	
		Week 32	Tezepelumab	65	63 (96.9)	5.14 (0.93)	3.6	4.25	5.03	5.88	7.0	
			Placebo	62	58 (93.5)	4.88 (1.06)	2.3	4.00	4.73	5.75	7.0	
		Week 36	Tezepelumab	65	63 (96.9)	5.18 (0.98)	3.5	4.41	5.00	5.97	7.0	
			Placebo	62	58 (93.5)	4.96 (1.07)	2.6	4.00	4.78	5.91	7.0	
		Week 40	Tezepelumab	65	63 (96.9)	5.07 (0.98)	3.2	4.28	5.03	5.78	7.0	
			Placebo	62	58 (93.5)	4.95 (1.07)	2.5	4.00	4.94	5.75	7.0	
		Week 44	Tezepelumab	65	63 (96.9)	5.11 (1.01)	3.0	4.31	5.00	5.88	7.0	
			Placebo	62	58 (93.5)	4.96 (1.08)	2.5	4.00	4.88	5.81	7.0	
		Week 48	Tezepelumab	65	63 (96.9)	5.12 (0.97)	3.4	4.28	5.00	5.81	7.0	
			Placebo	62	59 (95.2)	5.03 (1.08)	2.8	4.13	4.97	6.00	7.0	
		Week 52	Tezepelumab	65	63 (96.9)	5.11 (0.96)	3.4	4.34	5.00	5.84	7.0	
			Placebo	62	59 (95.2)	4.96 (1.12)	2.7	4.00	4.91	5.84	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	65	55 (84.6)	0.55 (1.02)	-3.7	0.00	0.59	1.22	3.3	0.03 [-0.35, 0.41]
			Placebo	62	53 (85.5)	0.52 (0.76)	-1.2	0.16	0.44	0.91	2.6	
		Week 8	Tezepelumab	65	55 (84.6)	0.77 (0.94)	-1.0	0.13	0.66	1.41	3.8	0.17 [-0.21, 0.55]
			Placebo	62	53 (85.5)	0.63 (0.75)	-1.0	0.16	0.56	1.03	2.7	
		Week 12	Tezepelumab	65	55 (84.6)	0.92 (0.96)	-2.1	0.47	0.78	1.41	4.0	0.27 [-0.11, 0.65]
			Placebo	62	53 (85.5)	0.67 (0.89)	-2.0	0.28	0.66	1.09	2.9	
		Week 16	Tezepelumab	65	55 (84.6)	0.84 (0.97)	-2.4	0.34	0.69	1.38	3.4	0.09 [-0.28, 0.47]
			Placebo	62	53 (85.5)	0.75 (0.84)	-2.0	0.22	0.78	1.25	2.8	
		Week 20	Tezepelumab	65	55 (84.6)	0.75 (0.93)	-1.2	0.16	0.56	1.41	3.4	-0.03 [-0.41, 0.34]
			Placebo	62	53 (85.5)	0.78 (0.73)	-1.3	0.41	0.78	1.19	2.5	
		Week 24	Tezepelumab	65	55 (84.6)	0.91 (0.90)	-1.2	0.31	0.69	1.56	3.4	0.13 [-0.25, 0.51]
			Placebo	62	53 (85.5)	0.80 (0.81)	-1.3	0.31	0.75	1.22	2.7	
		Week 28	Tezepelumab	65	55 (84.6)	0.86 (0.93)	-1.3	0.28	0.66	1.41	3.4	0.15 [-0.23, 0.53]
			Placebo	62	53 (85.5)	0.72 (0.82)	-1.5	0.19	0.78	1.19	2.8	
		Week 32	Tezepelumab	65	55 (84.6)	0.89 (0.89)	-1.2	0.31	0.78	1.38	3.4	0.08 [-0.30, 0.46]
			Placebo	62	53 (85.5)	0.83 (0.74)	-1.0	0.41	0.81	1.25	2.7	
		Week 36	Tezepelumab	65	55 (84.6)	0.92 (0.97)	-1.3	0.28	0.84	1.41	3.4	0.01 [-0.37, 0.38]
			Placebo	62	53 (85.5)	0.92 (0.85)	-0.7	0.31	0.97	1.34	3.0	
		Week 40	Tezepelumab	65	55 (84.6)	0.82 (0.94)	-1.3	0.13	0.69	1.38	3.4	-0.10 [-0.47, 0.28]
			Placebo	62	53 (85.5)	0.91 (0.90)	-1.2	0.28	0.94	1.41	2.9	
		Week 44	Tezepelumab	65	55 (84.6)	0.85 (0.96)	-1.1	0.22	0.75	1.41	3.4	-0.06 [-0.43, 0.32]
			Placebo	62	53 (85.5)	0.90 (0.87)	-0.7	0.25	0.94	1.31	2.9	
		Week 48	Tezepelumab	65	55 (84.6)	0.88 (0.93)	-1.1	0.31	0.69	1.34	3.4	-0.10 [-0.48, 0.28]
			Placebo	62	53 (85.5)	0.97 (0.88)	-0.5	0.16	0.94	1.50	3.3	
		Week 52	Tezepelumab	65	55 (84.6)	0.85 (0.94)	-1.2	0.28	0.69	1.34	3.4	-0.05 [-0.42, 0.33]
			Placebo	62	53 (85.5)	0.89 (0.90)	-0.6	0.09	0.84	1.41	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	70	65 (92.9)	4.15 (1.03)	1.5	3.63	4.31	4.63	6.8	
			Placebo	75	67 (89.3)	4.10 (0.92)	1.8	3.47	3.97	4.69	6.3	
		Week 4	Tezepelumab	70	64 (91.4)	5.02 (1.04)	3.2	4.22	5.09	5.72	7.0	
			Placebo	75	67 (89.3)	4.65 (0.98)	2.4	3.84	4.69	5.31	6.8	
		Week 8	Tezepelumab	70	66 (94.3)	5.17 (1.17)	2.7	4.19	5.14	6.09	7.0	
			Placebo	75	69 (92.0)	4.76 (1.09)	2.3	3.97	4.63	5.59	7.0	
		Week 12	Tezepelumab	70	66 (94.3)	5.36 (1.13)	2.8	4.38	5.34	6.28	7.0	
			Placebo	75	69 (92.0)	4.94 (1.07)	2.7	4.09	5.06	5.78	7.0	
		Week 16	Tezepelumab	70	66 (94.3)	5.37 (1.08)	2.6	4.44	5.41	6.31	7.0	
			Placebo	75	69 (92.0)	4.94 (1.13)	2.9	4.06	4.84	5.84	7.0	
		Week 20	Tezepelumab	70	66 (94.3)	5.44 (1.04)	3.6	4.50	5.55	6.19	7.0	
			Placebo	75	69 (92.0)	4.96 (1.11)	2.9	4.19	4.81	5.97	7.0	
		Week 24	Tezepelumab	70	66 (94.3)	5.41 (1.10)	2.4	4.47	5.44	6.25	7.0	
			Placebo	75	69 (92.0)	4.98 (1.12)	2.7	4.09	4.94	5.88	7.0	
		Week 28	Tezepelumab	70	67 (95.7)	5.48 (1.03)	3.3	4.53	5.44	6.28	7.0	
			Placebo	75	69 (92.0)	5.05 (1.22)	2.8	3.97	5.06	5.97	7.0	
		Week 32	Tezepelumab	70	67 (95.7)	5.50 (1.10)	2.6	4.63	5.69	6.38	7.0	
			Placebo	75	70 (93.3)	5.06 (1.10)	2.9	4.09	5.16	6.00	7.0	
		Week 36	Tezepelumab	70	67 (95.7)	5.48 (1.05)	3.2	4.78	5.44	6.34	7.0	
			Placebo	75	70 (93.3)	5.01 (1.15)	2.2	4.19	4.83	6.13	7.0	
		Week 40	Tezepelumab	70	67 (95.7)	5.59 (1.05)	2.6	4.88	5.66	6.56	7.0	
			Placebo	75	70 (93.3)	5.04 (1.17)	2.3	4.03	5.03	6.09	7.0	
		Week 44	Tezepelumab	70	67 (95.7)	5.62 (1.02)	2.8	4.88	5.81	6.47	7.0	
			Placebo	75	70 (93.3)	5.01 (1.22)	2.8	3.97	5.02	6.00	7.0	
		Week 48	Tezepelumab	70	67 (95.7)	5.63 (1.05)	2.9	4.91	5.75	6.47	7.0	
			Placebo	75	70 (93.3)	4.99 (1.12)	2.1	4.06	4.81	5.94	7.0	
		Week 52	Tezepelumab	70	67 (95.7)	5.61 (1.08)	2.8	4.94	5.75	6.47	7.0	
			Placebo	75	70 (93.3)	4.99 (1.12)	2.9	4.03	4.83	5.97	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	70	60 (85.7)	0.93 (0.87)	-0.9	0.36	0.84	1.52	3.0	0.51 [0.15, 0.86]
			Placebo	75	66 (88.0)	0.51 (0.80)	-1.2	0.06	0.41	1.16	2.6	
		Week 8	Tezepelumab	70	62 (88.6)	1.01 (1.01)	-0.9	0.19	0.95	1.75	3.9	0.36 [0.01, 0.71]
			Placebo	75	66 (88.0)	0.67 (0.95)	-1.4	0.00	0.48	1.25	3.1	
		Week 12	Tezepelumab	70	62 (88.6)	1.21 (1.04)	-0.9	0.50	1.23	1.97	4.2	0.36 [0.01, 0.71]
			Placebo	75	66 (88.0)	0.83 (1.09)	-1.7	0.16	0.75	1.38	3.5	
		Week 16	Tezepelumab	70	62 (88.6)	1.22 (1.00)	-0.9	0.50	1.39	1.91	4.2	0.37 [0.02, 0.72]
			Placebo	75	66 (88.0)	0.84 (1.03)	-2.0	0.31	0.72	1.44	3.8	
		Week 20	Tezepelumab	70	62 (88.6)	1.29 (1.00)	-0.9	0.53	1.36	2.09	4.2	0.42 [0.07, 0.77]
			Placebo	75	66 (88.0)	0.86 (1.06)	-2.0	0.22	0.75	1.22	3.8	
		Week 24	Tezepelumab	70	62 (88.6)	1.27 (1.08)	-1.1	0.53	1.39	2.09	4.3	0.33 [-0.02, 0.68]
			Placebo	75	66 (88.0)	0.90 (1.12)	-2.0	0.09	0.80	1.59	3.7	
		Week 28	Tezepelumab	70	62 (88.6)	1.31 (1.02)	-0.9	0.53	1.33	2.13	4.3	0.30 [-0.05, 0.65]
			Placebo	75	66 (88.0)	0.97 (1.21)	-2.0	0.19	0.94	1.72	4.3	
		Week 32	Tezepelumab	70	62 (88.6)	1.34 (1.08)	-0.9	0.63	1.41	2.25	4.3	0.30 [-0.05, 0.65]
			Placebo	75	66 (88.0)	1.02 (1.09)	-2.0	0.28	0.73	1.72	3.6	
		Week 36	Tezepelumab	70	62 (88.6)	1.32 (1.14)	-0.9	0.66	1.34	2.34	4.3	0.34 [-0.01, 0.69]
			Placebo	75	66 (88.0)	0.94 (1.12)	-2.0	0.31	0.73	1.66	3.4	
		Week 40	Tezepelumab	70	62 (88.6)	1.42 (1.03)	-0.9	0.81	1.19	2.34	4.3	0.40 [0.05, 0.75]
			Placebo	75	66 (88.0)	0.98 (1.20)	-2.0	0.25	0.78	1.66	4.3	
		Week 44	Tezepelumab	70	62 (88.6)	1.47 (1.01)	-0.9	0.84	1.41	2.19	4.3	0.46 [0.11, 0.82]
			Placebo	75	66 (88.0)	0.94 (1.25)	-2.0	0.09	0.77	1.66	4.1	
		Week 48	Tezepelumab	70	62 (88.6)	1.48 (1.05)	-0.9	0.81	1.56	2.31	4.3	0.51 [0.16, 0.86]
			Placebo	75	66 (88.0)	0.92 (1.14)	-2.0	0.19	0.72	1.66	3.5	
		Week 52	Tezepelumab	70	62 (88.6)	1.44 (1.06)	-0.9	0.72	1.28	2.31	4.3	0.46 [0.11, 0.81]
			Placebo	75	66 (88.0)	0.94 (1.12)	-2.0	0.19	0.80	1.72	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	50	43 (86.0)	4.06 (0.73)	2.3	3.72	4.03	4.41	6.2	
			Placebo	50	40 (80.0)	4.08 (1.04)	1.8	3.47	4.11	4.61	6.3	
		Week 4	Tezepelumab	50	48 (96.0)	4.77 (0.91)	3.0	4.09	4.70	5.36	6.8	
			Placebo	50	41 (82.0)	4.41 (1.08)	2.1	3.81	4.38	5.09	6.8	
		Week 8	Tezepelumab	50	48 (96.0)	5.02 (0.92)	2.8	4.25	5.00	5.84	7.0	
			Placebo	50	44 (88.0)	4.53 (1.05)	2.1	3.94	4.41	5.16	6.9	
		Week 12	Tezepelumab	50	48 (96.0)	5.26 (0.96)	3.7	4.52	5.22	5.89	7.0	
			Placebo	50	44 (88.0)	4.54 (1.02)	2.5	3.94	4.36	5.17	6.8	
		Week 16	Tezepelumab	50	48 (96.0)	5.20 (0.94)	3.9	4.33	5.14	5.77	7.0	
			Placebo	50	44 (88.0)	4.55 (1.19)	1.2	3.88	4.48	5.34	6.9	
		Week 20	Tezepelumab	50	48 (96.0)	5.18 (0.99)	3.5	4.31	5.27	5.88	7.0	
			Placebo	50	44 (88.0)	4.58 (1.23)	1.2	3.98	4.44	5.41	6.8	
		Week 24	Tezepelumab	50	48 (96.0)	5.16 (1.05)	2.4	4.23	5.00	5.97	7.0	
			Placebo	50	44 (88.0)	4.47 (1.25)	1.2	3.84	4.30	5.52	6.9	
		Week 28	Tezepelumab	50	49 (98.0)	5.20 (0.96)	3.3	4.53	5.19	5.81	7.0	
			Placebo	50	44 (88.0)	4.47 (1.27)	1.2	3.83	4.22	5.63	6.8	
		Week 32	Tezepelumab	50	49 (98.0)	5.21 (0.93)	3.8	4.34	5.22	5.84	7.0	
			Placebo	50	45 (90.0)	4.46 (1.22)	1.2	3.91	4.31	5.50	6.8	
		Week 36	Tezepelumab	50	49 (98.0)	5.18 (0.97)	3.2	4.59	5.00	5.72	7.0	
			Placebo	50	45 (90.0)	4.57 (1.18)	2.2	4.00	4.38	5.44	6.8	
		Week 40	Tezepelumab	50	49 (98.0)	5.25 (0.93)	3.7	4.63	5.13	5.84	7.0	
			Placebo	50	45 (90.0)	4.59 (1.18)	2.3	3.88	4.34	5.63	6.8	
		Week 44	Tezepelumab	50	49 (98.0)	5.18 (0.99)	3.0	4.50	5.03	5.91	7.0	
			Placebo	50	45 (90.0)	4.53 (1.13)	2.5	3.97	4.31	5.50	6.8	
		Week 48	Tezepelumab	50	49 (98.0)	5.22 (1.00)	3.2	4.50	5.13	6.03	7.0	
			Placebo	50	46 (92.0)	4.57 (1.13)	2.1	3.97	4.31	5.50	6.8	
		Week 52	Tezepelumab	50	49 (98.0)	5.23 (0.99)	3.2	4.56	5.16	6.03	7.0	
			Placebo	50	46 (92.0)	4.53 (1.12)	2.7	3.91	4.20	5.63	6.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	50	42 (84.0)	0.80 (0.76)	-1.3	0.31	0.70	1.41	2.7	0.52 [0.08, 0.97]
			Placebo	50	39 (78.0)	0.40 (0.78)	-1.1	0.06	0.31	0.69	2.6	
		Week 8	Tezepelumab	50	42 (84.0)	0.95 (0.92)	-1.0	0.38	0.78	1.63	3.0	0.51 [0.07, 0.96]
			Placebo	50	40 (80.0)	0.51 (0.76)	-1.4	0.16	0.39	0.95	2.7	
		Week 12	Tezepelumab	50	42 (84.0)	1.18 (0.91)	-0.9	0.56	1.11	1.97	3.0	0.74 [0.29, 1.19]
			Placebo	50	40 (80.0)	0.51 (0.90)	-1.7	0.02	0.48	0.97	2.9	
		Week 16	Tezepelumab	50	42 (84.0)	1.13 (0.95)	-1.0	0.34	1.30	1.78	3.0	0.62 [0.18, 1.07]
			Placebo	50	40 (80.0)	0.51 (1.04)	-3.2	0.06	0.67	1.19	2.5	
		Week 20	Tezepelumab	50	42 (84.0)	1.15 (0.90)	-0.5	0.41	1.28	1.78	3.0	0.62 [0.18, 1.06]
			Placebo	50	40 (80.0)	0.55 (1.05)	-3.2	0.14	0.69	1.08	2.5	
		Week 24	Tezepelumab	50	42 (84.0)	1.14 (0.96)	-1.1	0.34	1.20	1.81	3.0	0.68 [0.23, 1.12]
			Placebo	50	40 (80.0)	0.43 (1.13)	-3.2	-0.11	0.48	1.17	2.5	
		Week 28	Tezepelumab	50	42 (84.0)	1.19 (0.90)	-0.6	0.53	1.13	1.78	3.0	0.73 [0.28, 1.17]
			Placebo	50	40 (80.0)	0.43 (1.17)	-3.2	-0.03	0.42	1.20	2.8	
		Week 32	Tezepelumab	50	42 (84.0)	1.23 (0.93)	-0.6	0.69	1.16	1.88	3.0	0.79 [0.34, 1.24]
			Placebo	50	40 (80.0)	0.44 (1.06)	-3.2	0.00	0.48	1.05	2.6	
		Week 36	Tezepelumab	50	42 (84.0)	1.19 (1.02)	-1.0	0.69	1.16	1.84	3.3	0.64 [0.20, 1.09]
			Placebo	50	40 (80.0)	0.54 (1.01)	-2.0	0.11	0.47	1.08	2.9	
		Week 40	Tezepelumab	50	42 (84.0)	1.25 (0.92)	-0.8	0.69	1.17	1.88	3.0	0.69 [0.24, 1.13]
			Placebo	50	40 (80.0)	0.57 (1.07)	-2.0	0.14	0.52	1.19	2.9	
		Week 44	Tezepelumab	50	42 (84.0)	1.18 (0.95)	-0.8	0.69	1.27	1.84	3.0	0.73 [0.28, 1.18]
			Placebo	50	40 (80.0)	0.47 (0.99)	-2.0	-0.08	0.55	1.11	2.9	
		Week 48	Tezepelumab	50	42 (84.0)	1.26 (0.93)	-0.8	0.69	1.25	2.06	3.0	0.76 [0.32, 1.21]
			Placebo	50	40 (80.0)	0.51 (1.02)	-2.0	-0.03	0.47	1.06	3.1	
		Week 52	Tezepelumab	50	42 (84.0)	1.25 (0.95)	-0.8	0.69	1.25	2.06	3.0	0.79 [0.34, 1.24]
			Placebo	50	40 (80.0)	0.49 (0.97)	-2.0	-0.02	0.23	1.00	3.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	77	72 (93.5)	4.31 (1.00)	1.5	3.67	4.44	4.91	6.8	
			Placebo	80	73 (91.3)	4.11 (0.79)	2.5	3.63	4.06	4.69	6.1	
		Week 4	Tezepelumab	77	69 (89.6)	5.00 (1.14)	1.4	4.22	5.16	5.75	7.0	
			Placebo	80	74 (92.5)	4.69 (0.91)	2.5	4.00	4.69	5.28	6.8	
		Week 8	Tezepelumab	77	71 (92.2)	5.16 (1.14)	2.7	4.19	5.16	6.09	7.0	
			Placebo	80	74 (92.5)	4.81 (1.02)	2.3	4.19	4.73	5.53	7.0	
		Week 12	Tezepelumab	77	71 (92.2)	5.29 (1.12)	2.8	4.34	5.25	6.28	7.0	
			Placebo	80	75 (93.8)	4.96 (1.04)	2.7	4.16	5.09	5.78	7.0	
		Week 16	Tezepelumab	77	71 (92.2)	5.26 (1.11)	2.6	4.38	5.28	6.09	7.0	
			Placebo	80	75 (93.8)	4.97 (1.06)	3.0	4.06	4.94	5.75	7.0	
		Week 20	Tezepelumab	77	71 (92.2)	5.29 (1.06)	3.2	4.34	5.22	6.19	7.0	
			Placebo	80	75 (93.8)	4.96 (0.97)	3.0	4.19	4.88	5.88	7.0	
		Week 24	Tezepelumab	77	71 (92.2)	5.36 (1.05)	3.5	4.47	5.38	6.13	7.0	
			Placebo	80	75 (93.8)	5.06 (0.97)	3.3	4.22	4.97	5.84	7.0	
		Week 28	Tezepelumab	77	72 (93.5)	5.35 (1.06)	3.6	4.39	5.41	6.20	7.0	
			Placebo	80	76 (95.0)	5.13 (1.09)	2.7	4.25	5.17	5.95	7.0	
		Week 32	Tezepelumab	77	73 (94.8)	5.42 (1.09)	2.6	4.56	5.63	6.19	7.0	
			Placebo	80	76 (95.0)	5.20 (0.98)	3.5	4.25	5.25	6.02	7.0	
		Week 36	Tezepelumab	77	73 (94.8)	5.43 (1.06)	3.3	4.59	5.47	6.19	7.0	
			Placebo	80	76 (95.0)	5.15 (1.02)	3.3	4.19	5.13	5.95	7.0	
		Week 40	Tezepelumab	77	73 (94.8)	5.43 (1.12)	2.6	4.47	5.44	6.25	7.0	
			Placebo	80	76 (95.0)	5.21 (1.04)	3.5	4.23	5.19	6.00	7.0	
		Week 44	Tezepelumab	77	73 (94.8)	5.50 (1.07)	2.8	4.63	5.59	6.34	7.0	
			Placebo	80	76 (95.0)	5.18 (1.10)	3.5	4.08	5.13	6.08	7.0	
		Week 48	Tezepelumab	77	73 (94.8)	5.49 (1.08)	2.9	4.47	5.53	6.28	7.0	
			Placebo	80	76 (95.0)	5.20 (0.99)	3.5	4.39	5.14	6.00	7.0	
		Week 52	Tezepelumab	77	73 (94.8)	5.45 (1.11)	2.8	4.47	5.44	6.28	7.0	
			Placebo	80	76 (95.0)	5.20 (1.04)	3.4	4.31	5.14	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	77	67 (87.0)	0.68 (0.99)	-3.7	0.16	0.66	1.28	2.6	0.14 [-0.19, 0.48]
			Placebo	80	72 (90.0)	0.55 (0.80)	-1.2	0.08	0.48	1.02	2.6	
		Week 8	Tezepelumab	77	69 (89.6)	0.84 (0.89)	-1.0	0.28	0.81	1.53	2.7	0.17 [-0.16, 0.50]
			Placebo	80	72 (90.0)	0.69 (0.91)	-1.0	0.06	0.58	1.20	3.1	
		Week 12	Tezepelumab	77	69 (89.6)	0.97 (0.94)	-2.1	0.38	0.94	1.66	2.7	0.13 [-0.20, 0.46]
			Placebo	80	72 (90.0)	0.84 (1.05)	-2.0	0.30	0.77	1.36	3.5	
		Week 16	Tezepelumab	77	69 (89.6)	0.95 (0.94)	-2.4	0.47	0.81	1.59	2.6	0.09 [-0.24, 0.42]
			Placebo	80	72 (90.0)	0.87 (1.00)	-2.0	0.31	0.73	1.42	3.8	
		Week 20	Tezepelumab	77	69 (89.6)	0.97 (0.94)	-1.2	0.28	0.78	1.66	2.7	0.11 [-0.22, 0.44]
			Placebo	80	72 (90.0)	0.87 (0.92)	-0.8	0.30	0.78	1.17	3.8	
		Week 24	Tezepelumab	77	69 (89.6)	1.04 (0.96)	-1.2	0.34	0.94	1.78	3.0	0.08 [-0.25, 0.41]
			Placebo	80	72 (90.0)	0.97 (0.94)	-0.8	0.34	0.91	1.52	3.7	
		Week 28	Tezepelumab	77	69 (89.6)	1.01 (0.97)	-1.3	0.31	0.78	1.97	2.7	-0.01 [-0.34, 0.32]
			Placebo	80	72 (90.0)	1.02 (1.04)	-0.9	0.34	0.98	1.67	4.3	
		Week 32	Tezepelumab	77	69 (89.6)	1.06 (0.97)	-1.2	0.41	0.91	1.94	2.6	-0.05 [-0.38, 0.28]
			Placebo	80	72 (90.0)	1.11 (0.92)	-0.7	0.53	0.97	1.59	3.6	
		Week 36	Tezepelumab	77	69 (89.6)	1.07 (1.03)	-1.3	0.31	0.91	2.06	2.8	0.02 [-0.31, 0.35]
			Placebo	80	72 (90.0)	1.05 (0.99)	-1.2	0.41	0.92	1.67	3.4	
		Week 40	Tezepelumab	77	69 (89.6)	1.06 (1.00)	-1.3	0.53	0.94	1.94	2.9	-0.04 [-0.37, 0.29]
			Placebo	80	72 (90.0)	1.11 (1.05)	-0.8	0.47	0.98	1.69	4.3	
		Week 44	Tezepelumab	77	69 (89.6)	1.14 (1.01)	-1.1	0.50	0.97	2.00	3.3	0.07 [-0.26, 0.40]
			Placebo	80	72 (90.0)	1.07 (1.09)	-1.0	0.33	0.98	1.73	4.1	
		Week 48	Tezepelumab	77	69 (89.6)	1.14 (1.03)	-1.1	0.44	1.00	2.09	2.9	0.03 [-0.30, 0.36]
			Placebo	80	72 (90.0)	1.10 (0.98)	-0.7	0.41	1.00	1.66	3.5	
		Week 52	Tezepelumab	77	69 (89.6)	1.08 (1.03)	-1.2	0.41	1.00	2.00	3.0	-0.01 [-0.34, 0.32]
			Placebo	80	72 (90.0)	1.09 (1.02)	-0.6	0.34	0.97	1.69	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	4.19 (0.85)	1.5	3.75	4.31	4.63	6.3	
			Placebo	62	53 (85.5)	4.11 (0.95)	1.8	3.50	4.13	4.69	6.3	
		Week 4	Tezepelumab	70	65 (92.9)	4.90 (0.91)	3.3	4.16	4.91	5.66	6.9	
			Placebo	62	53 (85.5)	4.48 (1.02)	2.1	3.84	4.50	5.19	6.7	
		Week 8	Tezepelumab	70	66 (94.3)	5.05 (1.03)	2.7	4.25	5.02	5.94	7.0	
			Placebo	62	56 (90.3)	4.64 (1.11)	2.1	3.95	4.73	5.33	6.8	
		Week 12	Tezepelumab	70	66 (94.3)	5.32 (0.99)	2.8	4.53	5.31	6.19	7.0	
			Placebo	62	56 (90.3)	4.74 (1.04)	2.5	4.00	4.63	5.48	7.0	
		Week 16	Tezepelumab	70	66 (94.3)	5.24 (0.99)	2.6	4.38	5.22	5.97	7.0	
			Placebo	62	56 (90.3)	4.73 (1.21)	1.2	3.97	4.72	5.72	7.0	
		Week 20	Tezepelumab	70	67 (95.7)	5.21 (1.01)	3.5	4.22	5.22	5.91	7.0	
			Placebo	62	56 (90.3)	4.76 (1.20)	1.2	4.00	4.64	5.56	7.0	
		Week 24	Tezepelumab	70	67 (95.7)	5.31 (0.98)	3.5	4.44	5.28	6.03	7.0	
			Placebo	62	56 (90.3)	4.71 (1.26)	1.2	3.97	4.53	5.58	7.0	
		Week 28	Tezepelumab	70	68 (97.1)	5.25 (1.02)	3.3	4.45	5.17	6.02	7.0	
			Placebo	62	56 (90.3)	4.65 (1.24)	1.2	3.94	4.47	5.59	7.0	
		Week 32	Tezepelumab	70	68 (97.1)	5.27 (0.99)	2.9	4.45	5.34	5.92	7.0	
			Placebo	62	57 (91.9)	4.73 (1.21)	1.2	4.00	4.44	5.50	7.0	
		Week 36	Tezepelumab	70	68 (97.1)	5.30 (1.05)	3.2	4.48	5.19	6.14	7.0	
			Placebo	62	57 (91.9)	4.83 (1.17)	2.2	4.00	4.50	5.69	7.0	
		Week 40	Tezepelumab	70	68 (97.1)	5.27 (1.02)	2.6	4.59	5.20	5.97	7.0	
			Placebo	62	57 (91.9)	4.77 (1.20)	2.3	3.88	4.56	5.66	7.0	
		Week 44	Tezepelumab	70	68 (97.1)	5.29 (1.02)	2.8	4.47	5.22	6.06	7.0	
			Placebo	62	57 (91.9)	4.78 (1.20)	2.6	3.97	4.53	5.69	7.0	
		Week 48	Tezepelumab	70	68 (97.1)	5.34 (1.06)	2.9	4.50	5.31	6.16	7.0	
			Placebo	62	57 (91.9)	4.74 (1.17)	2.1	3.97	4.53	5.59	7.0	
		Week 52	Tezepelumab	70	68 (97.1)	5.31 (1.06)	2.8	4.53	5.19	6.16	7.0	
			Placebo	62	57 (91.9)	4.69 (1.13)	2.7	3.97	4.31	5.47	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	70	61 (87.1)	0.81 (0.86)	-1.3	0.22	0.72	1.38	3.3	0.51 [0.13, 0.88]
			Placebo	62	52 (83.9)	0.40 (0.74)	-1.1	0.06	0.39	0.80	2.0	
		Week 8	Tezepelumab	70	62 (88.6)	0.85 (0.97)	-1.0	0.28	0.69	1.53	3.8	0.31 [-0.06, 0.68]
			Placebo	62	53 (85.5)	0.56 (0.88)	-1.4	0.06	0.47	1.03	2.7	
		Week 12	Tezepelumab	70	62 (88.6)	1.12 (0.95)	-0.9	0.50	1.02	1.84	4.0	0.47 [0.09, 0.84]
			Placebo	62	53 (85.5)	0.66 (1.04)	-2.0	0.13	0.72	1.25	3.5	
		Week 16	Tezepelumab	70	62 (88.6)	1.03 (0.92)	-1.0	0.44	1.11	1.69	3.4	0.37 [0.00, 0.74]
			Placebo	62	53 (85.5)	0.65 (1.14)	-3.2	0.09	0.88	1.31	3.8	
		Week 20	Tezepelumab	70	62 (88.6)	1.03 (1.00)	-0.9	0.25	0.81	1.75	3.4	0.33 [-0.04, 0.70]
			Placebo	62	53 (85.5)	0.69 (1.08)	-3.2	0.16	0.81	1.22	3.3	
		Week 24	Tezepelumab	70	62 (88.6)	1.15 (0.97)	-0.9	0.34	1.03	1.84	3.4	0.47 [0.10, 0.84]
			Placebo	62	53 (85.5)	0.64 (1.20)	-3.2	-0.03	0.75	1.22	3.2	
		Week 28	Tezepelumab	70	62 (88.6)	1.11 (0.97)	-0.9	0.31	1.00	1.88	3.4	0.50 [0.13, 0.87]
			Placebo	62	53 (85.5)	0.56 (1.21)	-3.2	-0.09	0.56	1.13	4.0	
		Week 32	Tezepelumab	70	62 (88.6)	1.11 (0.98)	-0.9	0.47	1.03	1.88	3.4	0.41 [0.04, 0.78]
			Placebo	62	53 (85.5)	0.68 (1.13)	-3.2	0.19	0.66	1.13	3.4	
		Week 36	Tezepelumab	70	62 (88.6)	1.14 (1.06)	-1.0	0.41	0.97	1.97	3.4	0.36 [-0.01, 0.73]
			Placebo	62	53 (85.5)	0.76 (1.10)	-2.0	0.19	0.63	1.28	3.4	
		Week 40	Tezepelumab	70	62 (88.6)	1.12 (0.97)	-0.9	0.50	0.97	2.03	3.4	0.39 [0.02, 0.76]
			Placebo	62	53 (85.5)	0.71 (1.17)	-2.0	-0.06	0.72	1.41	3.8	
		Week 44	Tezepelumab	70	62 (88.6)	1.14 (0.98)	-0.9	0.50	0.95	1.88	3.4	0.40 [0.02, 0.77]
			Placebo	62	53 (85.5)	0.71 (1.20)	-2.0	-0.06	0.56	1.19	3.5	
		Week 48	Tezepelumab	70	62 (88.6)	1.20 (1.03)	-0.9	0.44	1.09	2.06	3.4	0.50 [0.13, 0.87]
			Placebo	62	53 (85.5)	0.67 (1.10)	-2.0	0.00	0.53	1.25	3.5	
		Week 52	Tezepelumab	70	62 (88.6)	1.17 (1.03)	-0.9	0.41	1.06	2.06	3.4	0.52 [0.15, 0.89]
			Placebo	62	53 (85.5)	0.63 (1.05)	-2.0	-0.06	0.59	1.13	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	65	58 (89.2)	4.21 (0.99)	2.0	3.63	4.27	4.91	6.8	
			Placebo	75	67 (89.3)	4.07 (0.83)	2.2	3.47	4.03	4.69	6.1	
		Week 4	Tezepelumab	65	59 (90.8)	4.95 (1.18)	1.4	4.03	5.09	5.69	7.0	
			Placebo	75	69 (92.0)	4.66 (0.90)	2.4	4.00	4.56	5.25	6.8	
		Week 8	Tezepelumab	65	60 (92.3)	5.19 (1.07)	3.2	4.30	5.13	6.00	7.0	
			Placebo	75	69 (92.0)	4.74 (0.96)	2.4	4.03	4.56	5.50	7.0	
		Week 12	Tezepelumab	65	60 (92.3)	5.28 (1.10)	3.0	4.36	5.17	6.14	7.0	
			Placebo	75	70 (93.3)	4.86 (1.04)	2.7	4.09	4.94	5.72	7.0	
		Week 16	Tezepelumab	65	60 (92.3)	5.28 (1.08)	2.7	4.41	5.23	6.08	7.0	
			Placebo	75	70 (93.3)	4.91 (1.02)	2.5	4.16	4.86	5.72	7.0	
		Week 20	Tezepelumab	65	60 (92.3)	5.29 (1.04)	3.2	4.34	5.41	6.09	7.0	
			Placebo	75	70 (93.3)	4.90 (1.00)	2.5	4.03	4.88	5.88	7.0	
		Week 24	Tezepelumab	65	60 (92.3)	5.27 (1.11)	2.4	4.42	5.17	6.05	7.0	
			Placebo	75	70 (93.3)	4.99 (0.98)	3.1	4.00	4.98	5.84	7.0	
		Week 28	Tezepelumab	65	61 (93.8)	5.31 (1.01)	3.6	4.47	5.34	6.09	7.0	
			Placebo	75	71 (94.7)	5.07 (1.13)	2.7	4.00	5.16	6.00	7.0	
		Week 32	Tezepelumab	65	62 (95.4)	5.41 (1.08)	2.6	4.47	5.55	6.25	7.0	
			Placebo	75	71 (94.7)	5.10 (1.03)	2.7	4.09	5.19	6.00	7.0	
		Week 36	Tezepelumab	65	62 (95.4)	5.39 (0.99)	3.5	4.63	5.36	6.19	7.0	
			Placebo	75	71 (94.7)	5.06 (1.08)	2.6	4.03	5.03	6.03	7.0	
		Week 40	Tezepelumab	65	62 (95.4)	5.41 (1.07)	3.2	4.47	5.36	6.25	7.0	
			Placebo	75	71 (94.7)	5.14 (1.03)	2.7	4.19	5.13	6.00	7.0	
		Week 44	Tezepelumab	65	62 (95.4)	5.47 (1.05)	3.0	4.59	5.56	6.31	7.0	
			Placebo	75	71 (94.7)	5.11 (1.11)	2.5	4.00	5.09	6.03	7.0	
		Week 48	Tezepelumab	65	62 (95.4)	5.43 (1.02)	3.4	4.47	5.42	6.22	7.0	
			Placebo	75	72 (96.0)	5.17 (1.01)	2.9	4.39	5.11	6.03	7.0	
		Week 52	Tezepelumab	65	62 (95.4)	5.42 (1.03)	3.4	4.47	5.42	6.25	7.0	
			Placebo	75	72 (96.0)	5.16 (1.06)	2.7	4.16	5.14	6.02	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	65	55 (84.6)	0.67 (1.06)	-3.7	0.16	0.66	1.41	3.0	0.11 [-0.25, 0.46]
			Placebo	75	66 (88.0)	0.57 (0.77)	-1.2	0.09	0.47	1.03	2.6	
		Week 8	Tezepelumab	65	56 (86.2)	0.96 (0.98)	-1.0	0.22	0.81	1.70	3.9	0.33 [-0.03, 0.69]
			Placebo	75	66 (88.0)	0.67 (0.83)	-1.0	0.09	0.55	1.16	3.1	
		Week 12	Tezepelumab	65	56 (86.2)	1.05 (1.05)	-2.1	0.50	1.02	1.77	4.2	0.25 [-0.11, 0.61]
			Placebo	75	66 (88.0)	0.80 (0.96)	-1.0	0.28	0.67	1.16	3.4	
		Week 16	Tezepelumab	65	56 (86.2)	1.08 (1.08)	-2.4	0.42	0.88	1.78	4.2	0.24 [-0.11, 0.60]
			Placebo	75	66 (88.0)	0.84 (0.88)	-0.6	0.31	0.70	1.41	3.5	
		Week 20	Tezepelumab	65	56 (86.2)	1.07 (0.99)	-1.2	0.39	0.94	1.70	4.2	0.24 [-0.11, 0.60]
			Placebo	75	66 (88.0)	0.85 (0.89)	-0.8	0.25	0.73	1.16	3.8	
		Week 24	Tezepelumab	65	56 (86.2)	1.08 (1.06)	-1.2	0.36	0.95	1.66	4.3	0.14 [-0.22, 0.49]
			Placebo	75	66 (88.0)	0.95 (0.89)	-0.7	0.31	0.80	1.56	3.7	
		Week 28	Tezepelumab	65	56 (86.2)	1.07 (1.03)	-1.3	0.34	0.86	1.80	4.3	0.06 [-0.29, 0.42]
			Placebo	75	66 (88.0)	1.01 (0.98)	-0.9	0.31	0.95	1.72	4.3	
		Week 32	Tezepelumab	65	56 (86.2)	1.15 (1.07)	-1.2	0.41	1.03	2.06	4.3	0.11 [-0.24, 0.47]
			Placebo	75	66 (88.0)	1.05 (0.87)	-0.7	0.44	0.83	1.50	3.6	
		Week 36	Tezepelumab	65	56 (86.2)	1.12 (1.09)	-1.3	0.31	0.92	1.98	4.3	0.12 [-0.24, 0.47]
			Placebo	75	66 (88.0)	1.00 (0.95)	-1.2	0.38	0.77	1.63	3.4	
		Week 40	Tezepelumab	65	56 (86.2)	1.16 (1.09)	-1.3	0.50	1.03	1.91	4.3	0.07 [-0.29, 0.42]
			Placebo	75	66 (88.0)	1.09 (0.97)	-0.8	0.47	0.84	1.66	4.3	
		Week 44	Tezepelumab	65	56 (86.2)	1.21 (1.08)	-1.1	0.63	1.22	1.86	4.3	0.16 [-0.19, 0.52]
			Placebo	75	66 (88.0)	1.04 (0.99)	-1.0	0.34	0.98	1.56	4.1	
		Week 48	Tezepelumab	65	56 (86.2)	1.18 (1.04)	-1.1	0.53	1.05	1.97	4.3	0.08 [-0.28, 0.43]
			Placebo	75	66 (88.0)	1.11 (0.94)	-0.7	0.41	0.94	1.66	3.3	
		Week 52	Tezepelumab	65	56 (86.2)	1.14 (1.05)	-1.2	0.47	1.05	1.77	4.3	0.05 [-0.31, 0.40]
			Placebo	75	66 (88.0)	1.10 (0.97)	-0.6	0.34	0.91	1.66	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	62	57 (91.9)	4.14 (0.71)	2.7	3.72	4.19	4.66	5.3	
			Placebo	67	57 (85.1)	4.17 (0.85)	1.8	3.69	4.19	4.69	6.1	
		Week 4	Tezepelumab	62	56 (90.3)	4.61 (1.03)	1.4	3.86	4.58	5.19	6.7	
			Placebo	67	58 (86.6)	4.63 (1.05)	2.1	4.00	4.45	5.47	6.8	
		Week 8	Tezepelumab	62	56 (90.3)	4.81 (0.93)	3.2	4.09	4.64	5.39	6.7	
			Placebo	67	60 (89.6)	4.76 (1.03)	2.1	3.98	4.64	5.52	6.9	
		Week 12	Tezepelumab	62	56 (90.3)	5.01 (0.98)	3.0	4.31	4.94	5.67	7.0	
			Placebo	67	61 (91.0)	4.84 (1.15)	2.5	3.97	4.69	5.81	7.0	
		Week 16	Tezepelumab	62	56 (90.3)	4.91 (0.95)	2.7	4.16	4.80	5.64	6.9	
			Placebo	67	61 (91.0)	4.87 (1.18)	1.2	3.97	4.84	5.72	7.0	
		Week 20	Tezepelumab	62	57 (91.9)	4.92 (0.92)	3.2	4.16	4.78	5.44	7.0	
			Placebo	67	61 (91.0)	4.83 (1.10)	1.2	4.19	4.78	5.88	7.0	
		Week 24	Tezepelumab	62	57 (91.9)	5.04 (0.93)	3.5	4.22	4.88	5.66	7.0	
			Placebo	67	61 (91.0)	4.91 (1.16)	1.2	4.19	4.94	5.75	7.0	
		Week 28	Tezepelumab	62	59 (95.2)	4.97 (0.92)	3.6	4.22	4.78	5.44	7.0	
			Placebo	67	62 (92.5)	4.94 (1.25)	1.2	4.00	5.05	5.97	7.0	
		Week 32	Tezepelumab	62	59 (95.2)	5.06 (0.95)	3.6	4.16	4.97	5.81	7.0	
			Placebo	67	63 (94.0)	4.96 (1.20)	1.2	4.00	5.03	5.94	7.0	
		Week 36	Tezepelumab	62	59 (95.2)	5.08 (0.97)	3.5	4.25	4.94	5.97	7.0	
			Placebo	67	63 (94.0)	5.03 (1.14)	2.2	4.16	5.13	5.97	7.0	
		Week 40	Tezepelumab	62	59 (95.2)	5.04 (0.93)	3.2	4.19	5.03	5.59	7.0	
			Placebo	67	63 (94.0)	5.06 (1.16)	2.3	4.00	5.16	6.00	7.0	
		Week 44	Tezepelumab	62	59 (95.2)	5.08 (0.97)	3.0	4.19	5.03	5.88	7.0	
			Placebo	67	63 (94.0)	5.12 (1.18)	2.6	4.16	5.09	6.19	7.0	
		Week 48	Tezepelumab	62	59 (95.2)	5.12 (0.94)	3.4	4.22	5.13	5.94	7.0	
			Placebo	67	64 (95.5)	5.08 (1.17)	2.1	4.16	4.98	6.17	7.0	
		Week 52	Tezepelumab	62	59 (95.2)	5.11 (0.95)	3.4	4.22	5.03	5.91	7.0	
			Placebo	67	64 (95.5)	5.08 (1.19)	2.8	4.11	4.94	6.17	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	62	55 (88.7)	0.49 (0.95)	-3.7	0.00	0.47	0.97	3.0	-0.02 [-0.39, 0.36]
			Placebo	67	56 (83.6)	0.51 (0.82)	-1.2	0.08	0.36	0.97	2.6	
		Week 8	Tezepelumab	62	55 (88.7)	0.70 (0.93)	-1.0	0.00	0.69	1.28	3.9	0.06 [-0.31, 0.43]
			Placebo	67	57 (85.1)	0.64 (0.88)	-1.0	0.09	0.50	1.16	2.7	
		Week 12	Tezepelumab	62	55 (88.7)	0.90 (0.96)	-2.1	0.47	0.81	1.41	4.2	0.15 [-0.23, 0.52]
			Placebo	67	57 (85.1)	0.75 (1.11)	-2.0	-0.03	0.66	1.31	3.5	
		Week 16	Tezepelumab	62	55 (88.7)	0.79 (0.96)	-2.4	0.34	0.72	1.38	4.2	0.02 [-0.35, 0.40]
			Placebo	67	57 (85.1)	0.76 (1.13)	-3.2	0.06	0.72	1.44	3.8	
		Week 20	Tezepelumab	62	55 (88.7)	0.79 (0.93)	-1.2	0.22	0.69	1.41	4.2	0.08 [-0.29, 0.45]
			Placebo	67	57 (85.1)	0.72 (0.96)	-3.2	0.13	0.69	1.25	2.8	
		Week 24	Tezepelumab	62	55 (88.7)	0.92 (0.93)	-1.2	0.31	0.88	1.56	4.3	0.12 [-0.25, 0.49]
			Placebo	67	57 (85.1)	0.81 (1.07)	-3.2	0.13	0.78	1.34	3.1	
		Week 28	Tezepelumab	62	55 (88.7)	0.85 (0.93)	-1.3	0.31	0.66	1.41	4.3	0.05 [-0.32, 0.42]
			Placebo	67	57 (85.1)	0.80 (1.16)	-3.2	0.16	0.72	1.44	4.0	
		Week 32	Tezepelumab	62	55 (88.7)	0.92 (0.95)	-1.2	0.34	0.91	1.41	4.3	0.07 [-0.30, 0.44]
			Placebo	67	57 (85.1)	0.85 (1.04)	-3.2	0.28	0.72	1.47	3.2	
		Week 36	Tezepelumab	62	55 (88.7)	0.94 (1.00)	-1.3	0.31	0.84	1.47	4.3	0.04 [-0.33, 0.41]
			Placebo	67	57 (85.1)	0.91 (1.03)	-1.7	0.22	0.75	1.56	3.4	
		Week 40	Tezepelumab	62	55 (88.7)	0.92 (0.96)	-1.3	0.31	0.84	1.41	4.3	-0.03 [-0.40, 0.34]
			Placebo	67	57 (85.1)	0.95 (1.07)	-1.6	0.28	0.91	1.66	3.8	
		Week 44	Tezepelumab	62	55 (88.7)	0.95 (0.96)	-1.1	0.47	0.84	1.38	4.3	-0.04 [-0.41, 0.34]
			Placebo	67	57 (85.1)	0.99 (1.15)	-1.1	0.09	0.88	1.72	3.4	
		Week 48	Tezepelumab	62	55 (88.7)	1.00 (0.94)	-1.1	0.50	0.94	1.38	4.3	0.05 [-0.33, 0.42]
			Placebo	67	57 (85.1)	0.95 (1.08)	-1.8	0.22	0.94	1.66	3.3	
		Week 52	Tezepelumab	62	55 (88.7)	0.97 (0.95)	-1.2	0.44	0.91	1.38	4.3	0.00 [-0.37, 0.37]
			Placebo	67	57 (85.1)	0.97 (1.09)	-0.9	0.22	0.84	1.66	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	74	65 (87.8)	4.25 (1.07)	1.5	3.66	4.31	4.81	6.8	
			Placebo	71	64 (90.1)	4.02 (0.90)	2.2	3.38	3.95	4.69	6.3	
		Week 4	Tezepelumab	74	69 (93.2)	5.17 (0.99)	3.3	4.41	5.19	5.81	7.0	
			Placebo	71	65 (91.5)	4.58 (0.90)	2.4	3.84	4.72	5.19	6.7	
		Week 8	Tezepelumab	74	71 (95.9)	5.35 (1.07)	2.7	4.53	5.34	6.16	7.0	
			Placebo	71	66 (93.0)	4.67 (1.05)	2.3	4.00	4.58	5.44	7.0	
		Week 12	Tezepelumab	74	71 (95.9)	5.51 (1.05)	2.8	4.63	5.50	6.34	7.0	
			Placebo	71	66 (93.0)	4.81 (0.95)	2.7	4.13	4.80	5.50	7.0	
		Week 16	Tezepelumab	74	71 (95.9)	5.52 (1.02)	2.6	4.66	5.59	6.34	7.0	
			Placebo	71	66 (93.0)	4.82 (1.05)	2.5	4.00	4.75	5.72	7.0	
		Week 20	Tezepelumab	74	71 (95.9)	5.50 (1.02)	3.6	4.59	5.63	6.25	7.0	
			Placebo	71	66 (93.0)	4.87 (1.11)	2.4	4.00	4.80	5.66	7.0	
		Week 24	Tezepelumab	74	71 (95.9)	5.47 (1.10)	2.4	4.47	5.63	6.31	7.0	
			Placebo	71	66 (93.0)	4.85 (1.10)	2.4	3.97	4.73	5.66	7.0	
		Week 28	Tezepelumab	74	71 (95.9)	5.54 (1.01)	3.3	4.63	5.63	6.28	7.0	
			Placebo	71	66 (93.0)	4.86 (1.15)	2.2	3.94	4.77	5.75	7.0	
		Week 32	Tezepelumab	74	72 (97.3)	5.56 (1.04)	2.6	4.70	5.72	6.34	7.0	
			Placebo	71	66 (93.0)	4.94 (1.08)	2.7	4.03	4.77	5.88	7.0	
		Week 36	Tezepelumab	74	72 (97.3)	5.56 (1.01)	3.2	4.78	5.61	6.38	7.0	
			Placebo	71	66 (93.0)	4.91 (1.11)	2.6	4.00	4.77	5.91	7.0	
		Week 40	Tezepelumab	74	72 (97.3)	5.59 (1.06)	2.6	4.84	5.66	6.55	7.0	
			Placebo	71	66 (93.0)	4.92 (1.09)	2.5	3.97	4.91	5.84	7.0	
		Week 44	Tezepelumab	74	72 (97.3)	5.63 (1.03)	2.8	4.78	5.73	6.47	7.0	
			Placebo	71	66 (93.0)	4.84 (1.13)	2.5	3.97	4.69	5.72	7.0	
		Week 48	Tezepelumab	74	72 (97.3)	5.61 (1.07)	2.9	4.80	5.69	6.56	7.0	
			Placebo	71	66 (93.0)	4.91 (1.04)	2.9	4.00	4.77	5.75	7.0	
		Week 52	Tezepelumab	74	72 (97.3)	5.60 (1.08)	2.8	4.80	5.72	6.50	7.0	
			Placebo	71	66 (93.0)	4.86 (1.04)	2.7	3.97	4.78	5.66	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	74	61 (82.4)	0.98 (0.90)	-1.3	0.41	0.88	1.53	3.3	0.56 [0.20, 0.92]
			Placebo	71	63 (88.7)	0.52 (0.75)	-1.2	0.09	0.47	1.00	2.6	
		Week 8	Tezepelumab	74	63 (85.1)	1.09 (0.98)	-0.9	0.38	1.09	1.75	3.8	0.49 [0.14, 0.85]
			Placebo	71	63 (88.7)	0.64 (0.86)	-1.4	0.09	0.56	1.09	3.1	
		Week 12	Tezepelumab	74	63 (85.1)	1.25 (1.01)	-0.9	0.50	1.25	2.06	4.0	0.51 [0.16, 0.87]
			Placebo	71	63 (88.7)	0.75 (0.90)	-1.7	0.28	0.72	1.19	3.4	
		Week 16	Tezepelumab	74	63 (85.1)	1.29 (0.97)	-0.9	0.53	1.41	1.97	3.4	0.54 [0.19, 0.90]
			Placebo	71	63 (88.7)	0.78 (0.90)	-2.0	0.31	0.72	1.22	3.5	
		Week 20	Tezepelumab	74	63 (85.1)	1.28 (1.00)	-0.9	0.41	1.41	2.09	3.4	0.43 [0.07, 0.78]
			Placebo	71	63 (88.7)	0.85 (1.01)	-2.0	0.31	0.78	1.09	3.8	
		Week 24	Tezepelumab	74	63 (85.1)	1.28 (1.05)	-1.1	0.50	1.44	2.13	3.4	0.42 [0.07, 0.78]
			Placebo	71	63 (88.7)	0.84 (1.04)	-2.0	0.22	0.78	1.38	3.7	
		Week 28	Tezepelumab	74	63 (85.1)	1.32 (1.01)	-0.9	0.56	1.34	2.13	3.4	0.45 [0.10, 0.80]
			Placebo	71	63 (88.7)	0.85 (1.08)	-2.0	0.19	0.84	1.38	4.3	
		Week 32	Tezepelumab	74	63 (85.1)	1.34 (1.03)	-0.9	0.53	1.38	2.25	3.4	0.40 [0.04, 0.75]
			Placebo	71	63 (88.7)	0.94 (1.00)	-2.0	0.31	0.78	1.41	3.6	
		Week 36	Tezepelumab	74	63 (85.1)	1.32 (1.10)	-1.0	0.50	1.34	2.34	3.4	0.39 [0.03, 0.74]
			Placebo	71	63 (88.7)	0.91 (1.03)	-2.0	0.31	0.81	1.44	3.4	
		Week 40	Tezepelumab	74	63 (85.1)	1.35 (1.04)	-0.9	0.66	1.34	2.31	3.4	0.41 [0.05, 0.76]
			Placebo	71	63 (88.7)	0.92 (1.10)	-2.0	0.25	0.78	1.50	4.3	
		Week 44	Tezepelumab	74	63 (85.1)	1.40 (1.04)	-0.9	0.66	1.44	2.25	3.4	0.54 [0.18, 0.89]
			Placebo	71	63 (88.7)	0.83 (1.06)	-2.0	0.25	0.69	1.34	4.1	
		Week 48	Tezepelumab	74	63 (85.1)	1.40 (1.08)	-0.9	0.66	1.47	2.31	3.4	0.47 [0.11, 0.82]
			Placebo	71	63 (88.7)	0.91 (1.01)	-2.0	0.16	0.72	1.59	3.5	
		Week 52	Tezepelumab	74	63 (85.1)	1.35 (1.09)	-0.9	0.44	1.31	2.31	3.4	0.49 [0.14, 0.84]
			Placebo	71	63 (88.7)	0.84 (0.99)	-2.0	0.16	0.81	1.41	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	114	101 (88.6)	4.17 (0.89)	2.0	3.66	4.25	4.63	6.8	
			Placebo	126	112 (88.9)	4.08 (0.84)	1.8	3.59	4.06	4.67	6.1	
		Week 4	Tezepelumab	114	105 (92.1)	4.87 (1.05)	1.4	4.06	4.91	5.66	7.0	
			Placebo	126	113 (89.7)	4.62 (0.98)	2.1	3.97	4.69	5.25	6.8	
		Week 8	Tezepelumab	114	107 (93.9)	5.04 (1.03)	2.8	4.19	5.00	5.84	7.0	
			Placebo	126	116 (92.1)	4.73 (1.03)	2.1	4.00	4.61	5.47	7.0	
		Week 12	Tezepelumab	114	107 (93.9)	5.23 (1.02)	3.0	4.34	5.16	6.06	7.0	
			Placebo	126	117 (92.9)	4.82 (1.06)	2.5	4.00	4.72	5.56	7.0	
		Week 16	Tezepelumab	114	107 (93.9)	5.18 (1.01)	2.7	4.31	5.09	5.94	7.0	
			Placebo	126	117 (92.9)	4.85 (1.12)	1.2	4.00	4.78	5.72	7.0	
		Week 20	Tezepelumab	114	108 (94.7)	5.15 (1.02)	3.2	4.30	5.05	5.88	7.0	
			Placebo	126	117 (92.9)	4.87 (1.12)	1.2	4.03	4.81	5.88	7.0	
		Week 24	Tezepelumab	114	108 (94.7)	5.20 (1.01)	3.3	4.34	5.06	5.98	7.0	
			Placebo	126	117 (92.9)	4.88 (1.15)	1.2	4.00	4.81	5.75	7.0	
		Week 28	Tezepelumab	114	110 (96.5)	5.23 (1.00)	3.6	4.44	5.16	6.00	7.0	
			Placebo	126	118 (93.7)	4.90 (1.20)	1.2	3.97	4.86	5.88	7.0	
		Week 32	Tezepelumab	114	111 (97.4)	5.25 (1.02)	2.6	4.44	5.25	5.94	7.0	
			Placebo	126	119 (94.4)	4.95 (1.15)	1.2	4.03	4.84	5.91	7.0	
		Week 36	Tezepelumab	114	111 (97.4)	5.28 (1.01)	3.2	4.53	5.09	6.03	7.0	
			Placebo	126	119 (94.4)	4.97 (1.14)	2.2	4.00	4.81	5.97	7.0	
		Week 40	Tezepelumab	114	111 (97.4)	5.28 (1.01)	3.2	4.47	5.22	6.00	7.0	
			Placebo	126	119 (94.4)	5.00 (1.13)	2.3	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	114	111 (97.4)	5.33 (1.03)	3.0	4.47	5.19	6.16	7.0	
			Placebo	126	119 (94.4)	4.98 (1.17)	2.5	4.00	4.91	6.00	7.0	
		Week 48	Tezepelumab	114	111 (97.4)	5.35 (1.04)	2.9	4.47	5.28	6.22	7.0	
			Placebo	126	120 (95.2)	5.00 (1.12)	2.1	4.05	4.91	5.92	7.0	
		Week 52	Tezepelumab	114	111 (97.4)	5.34 (1.03)	2.9	4.47	5.19	6.22	7.0	
			Placebo	126	120 (95.2)	4.97 (1.14)	2.7	3.98	4.91	5.95	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	114	97 (85.1)	0.72 (0.98)	-3.7	0.06	0.66	1.28	3.3	0.21 [-0.07, 0.48]
			Placebo	126	110 (87.3)	0.53 (0.79)	-1.2	0.06	0.44	1.00	2.6	
		Week 8	Tezepelumab	114	99 (86.8)	0.85 (0.99)	-1.0	0.13	0.69	1.53	3.9	0.20 [-0.07, 0.47]
			Placebo	126	111 (88.1)	0.66 (0.85)	-1.0	0.16	0.50	1.16	3.1	
		Week 12	Tezepelumab	114	99 (86.8)	1.03 (1.02)	-2.1	0.47	0.91	1.78	4.2	0.29 [0.01, 0.56]
			Placebo	126	111 (88.1)	0.75 (0.97)	-2.0	0.19	0.66	1.25	3.4	
		Week 16	Tezepelumab	114	99 (86.8)	1.00 (1.01)	-2.4	0.34	0.81	1.69	4.2	0.22 [-0.05, 0.49]
			Placebo	126	111 (88.1)	0.78 (0.97)	-3.2	0.28	0.72	1.38	3.5	
		Week 20	Tezepelumab	114	99 (86.8)	0.97 (1.01)	-1.2	0.22	0.75	1.75	4.2	0.16 [-0.11, 0.43]
			Placebo	126	111 (88.1)	0.82 (0.98)	-3.2	0.25	0.78	1.22	3.8	
		Week 24	Tezepelumab	114	99 (86.8)	1.06 (0.99)	-1.2	0.34	0.91	1.78	4.3	0.23 [-0.05, 0.50]
			Placebo	126	111 (88.1)	0.83 (1.03)	-3.2	0.13	0.78	1.38	3.7	
		Week 28	Tezepelumab	114	99 (86.8)	1.07 (1.01)	-1.3	0.31	0.88	1.88	4.3	0.23 [-0.04, 0.50]
			Placebo	126	111 (88.1)	0.83 (1.07)	-3.2	0.19	0.78	1.44	4.3	
		Week 32	Tezepelumab	114	99 (86.8)	1.07 (1.03)	-1.2	0.34	1.00	1.88	4.3	0.16 [-0.11, 0.44]
			Placebo	126	111 (88.1)	0.90 (0.99)	-3.2	0.28	0.78	1.47	3.6	
		Week 36	Tezepelumab	114	99 (86.8)	1.10 (1.09)	-1.3	0.31	0.91	2.06	4.3	0.19 [-0.09, 0.46]
			Placebo	126	111 (88.1)	0.91 (0.99)	-1.7	0.31	0.75	1.50	3.4	
		Week 40	Tezepelumab	114	99 (86.8)	1.11 (1.04)	-1.3	0.44	0.94	2.03	4.3	0.15 [-0.12, 0.43]
			Placebo	126	111 (88.1)	0.95 (1.03)	-1.6	0.28	0.84	1.66	4.3	
		Week 44	Tezepelumab	114	99 (86.8)	1.15 (1.05)	-1.1	0.50	0.94	1.88	4.3	0.22 [-0.05, 0.50]
			Placebo	126	111 (88.1)	0.92 (1.06)	-1.3	0.09	0.84	1.47	4.1	
		Week 48	Tezepelumab	114	99 (86.8)	1.19 (1.05)	-1.1	0.50	1.06	2.09	4.3	0.24 [-0.03, 0.51]
			Placebo	126	111 (88.1)	0.94 (1.02)	-1.8	0.16	0.84	1.66	3.5	
		Week 52	Tezepelumab	114	99 (86.8)	1.16 (1.06)	-1.2	0.44	1.03	2.06	4.3	0.24 [-0.03, 0.51]
			Placebo	126	111 (88.1)	0.92 (1.02)	-0.9	0.16	0.81	1.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	23	22 (95.7)	4.33 (1.04)	1.5	3.72	4.45	5.22	6.2	
			Placebo	12	9 (75.0)	4.19 (1.26)	2.7	3.16	4.13	5.25	6.3	
		Week 4	Tezepelumab	23	21 (91.3)	5.12 (0.98)	3.3	4.28	5.19	6.06	6.8	
			Placebo	12	10 (83.3)	4.38 (0.87)	3.3	3.72	4.11	5.19	5.5	
		Week 8	Tezepelumab	23	21 (91.3)	5.44 (1.07)	2.7	4.81	5.34	6.25	6.8	
			Placebo	12	10 (83.3)	4.47 (1.15)	2.4	3.72	4.83	5.22	6.0	
		Week 12	Tezepelumab	23	21 (91.3)	5.54 (1.13)	2.8	4.97	5.44	6.44	7.0	
			Placebo	12	10 (83.3)	4.86 (0.87)	3.8	4.16	4.70	5.66	6.5	
		Week 16	Tezepelumab	23	21 (91.3)	5.57 (1.11)	2.6	5.00	5.56	6.53	6.9	
			Placebo	12	10 (83.3)	4.78 (1.09)	3.0	4.06	4.66	5.41	6.8	
		Week 20	Tezepelumab	23	21 (91.3)	5.68 (0.87)	4.0	5.25	5.75	6.19	7.0	
			Placebo	12	10 (83.3)	4.58 (0.77)	3.7	3.91	4.45	5.38	5.9	
		Week 24	Tezepelumab	23	21 (91.3)	5.63 (1.13)	2.4	5.16	5.91	6.25	7.0	
			Placebo	12	10 (83.3)	4.86 (0.89)	3.8	4.09	4.84	5.66	6.2	
		Week 28	Tezepelumab	23	21 (91.3)	5.52 (0.99)	3.3	5.03	5.53	6.03	7.0	
			Placebo	12	10 (83.3)	4.89 (1.30)	3.6	3.75	4.31	6.06	7.0	
		Week 32	Tezepelumab	23	21 (91.3)	5.77 (0.99)	3.6	5.41	5.94	6.47	7.0	
			Placebo	12	10 (83.3)	4.92 (0.91)	3.8	4.19	4.67	5.94	6.2	
		Week 36	Tezepelumab	23	21 (91.3)	5.62 (1.05)	3.4	5.09	5.91	6.34	7.0	
			Placebo	12	10 (83.3)	4.99 (0.92)	3.8	4.16	5.06	5.78	6.2	
		Week 40	Tezepelumab	23	21 (91.3)	5.65 (1.14)	2.6	5.25	5.81	6.50	7.0	
			Placebo	12	10 (83.3)	4.86 (1.16)	3.5	3.88	4.61	5.88	6.8	
		Week 44	Tezepelumab	23	21 (91.3)	5.63 (1.06)	2.8	5.03	5.84	6.38	7.0	
			Placebo	12	10 (83.3)	4.92 (1.07)	3.5	3.75	5.20	5.72	6.4	
		Week 48	Tezepelumab	23	21 (91.3)	5.57 (1.04)	3.2	5.22	5.94	6.16	7.0	
			Placebo	12	10 (83.3)	4.93 (0.99)	3.8	4.13	4.69	6.06	6.3	
		Week 52	Tezepelumab	23	21 (91.3)	5.54 (1.10)	2.8	5.22	5.94	6.28	7.0	
			Placebo	12	10 (83.3)	4.86 (0.90)	3.8	4.13	4.56	5.72	6.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	0.86 (0.83)	-1.3	0.36	0.80	1.56	2.2	0.75 [-0.07, 1.56]
			Placebo	12	9 (75.0)	0.28 (0.61)	-1.1	0.25	0.25	0.53	1.2	
		Week 8	Tezepelumab	23	20 (87.0)	1.17 (0.85)	-0.8	0.67	1.30	1.77	2.4	0.88 [0.06, 1.70]
			Placebo	12	9 (75.0)	0.36 (1.07)	-1.4	-0.19	0.53	0.75	2.5	
		Week 12	Tezepelumab	23	20 (87.0)	1.27 (0.89)	-0.9	0.81	1.41	1.95	2.7	0.46 [-0.34, 1.26]
			Placebo	12	9 (75.0)	0.78 (1.41)	-1.7	0.53	0.88	0.97	3.5	
		Week 16	Tezepelumab	23	20 (87.0)	1.30 (0.91)	-0.6	0.73	1.42	1.75	2.8	0.58 [-0.22, 1.38]
			Placebo	12	9 (75.0)	0.65 (1.52)	-2.0	0.03	0.72	0.88	3.8	
		Week 20	Tezepelumab	23	20 (87.0)	1.40 (0.84)	-0.4	0.78	1.55	1.83	2.7	1.04 [0.20, 1.87]
			Placebo	12	9 (75.0)	0.47 (1.04)	-2.0	0.44	0.63	0.91	1.8	
		Week 24	Tezepelumab	23	20 (87.0)	1.34 (1.06)	-1.1	0.64	1.61	1.97	3.0	0.51 [-0.28, 1.31]
			Placebo	12	9 (75.0)	0.75 (1.36)	-2.0	0.38	0.94	1.09	2.8	
		Week 28	Tezepelumab	23	20 (87.0)	1.23 (0.94)	-0.6	0.58	1.20	1.73	3.0	0.37 [-0.42, 1.16]
			Placebo	12	9 (75.0)	0.79 (1.62)	-2.0	0.34	1.09	1.31	4.0	
		Week 32	Tezepelumab	23	20 (87.0)	1.45 (0.89)	-0.5	0.88	1.58	2.08	2.8	0.62 [-0.19, 1.42]
			Placebo	12	9 (75.0)	0.81 (1.35)	-2.0	0.56	0.72	1.25	3.2	
		Week 36	Tezepelumab	23	20 (87.0)	1.30 (0.96)	-1.0	0.77	1.34	1.77	3.3	0.37 [-0.42, 1.16]
			Placebo	12	9 (75.0)	0.89 (1.47)	-2.0	0.41	1.09	1.50	3.0	
		Week 40	Tezepelumab	23	20 (87.0)	1.33 (0.93)	-0.8	0.81	1.39	1.88	2.8	0.46 [-0.33, 1.26]
			Placebo	12	9 (75.0)	0.77 (1.69)	-2.0	0.22	0.59	1.09	3.8	
		Week 44	Tezepelumab	23	20 (87.0)	1.31 (0.92)	-0.8	0.81	1.39	1.92	2.7	0.49 [-0.31, 1.28]
			Placebo	12	9 (75.0)	0.74 (1.61)	-2.0	0.34	0.44	1.09	3.4	
		Week 48	Tezepelumab	23	20 (87.0)	1.28 (0.94)	-0.8	0.55	1.41	1.88	2.8	0.46 [-0.34, 1.26]
			Placebo	12	9 (75.0)	0.78 (1.33)	-2.0	0.50	0.91	1.09	2.9	
		Week 52	Tezepelumab	23	20 (87.0)	1.20 (0.93)	-0.8	0.55	1.27	1.67	2.8	0.44 [-0.35, 1.24]
			Placebo	12	9 (75.0)	0.74 (1.26)	-2.0	0.59	0.81	1.09	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.10 (0.90)	2.8	3.41	4.13	4.77	5.4	
			Placebo	14	10 (71.4)	4.37 (0.84)	3.0	3.94	4.31	4.69	6.3	
		Week 4	Tezepelumab	9	8 (88.9)	4.95 (0.88)	3.3	4.53	4.98	5.61	6.1	
			Placebo	14	12 (85.7)	4.65 (1.02)	3.0	3.67	4.86	5.36	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.46 (1.05)	3.6	4.86	5.53	6.23	6.8	
			Placebo	14	13 (92.9)	4.61 (0.78)	3.3	3.88	4.56	5.31	5.6	
		Week 12	Tezepelumab	9	8 (88.9)	5.54 (1.05)	4.2	4.59	5.41	6.53	7.0	
			Placebo	14	13 (92.9)	4.64 (1.02)	2.8	3.97	4.59	5.13	6.5	
		Week 16	Tezepelumab	9	8 (88.9)	5.70 (0.90)	4.4	5.06	5.70	6.41	6.9	
			Placebo	14	13 (92.9)	4.92 (1.04)	2.9	4.31	4.88	5.59	6.8	
		Week 20	Tezepelumab	9	8 (88.9)	5.25 (1.14)	3.8	4.27	5.11	6.33	6.8	
			Placebo	14	13 (92.9)	4.73 (0.87)	2.9	4.22	4.88	5.13	6.4	
		Week 24	Tezepelumab	9	8 (88.9)	5.41 (1.07)	4.3	4.47	5.27	6.39	6.8	
			Placebo	14	13 (92.9)	4.76 (1.08)	2.7	4.09	4.41	5.59	6.4	
		Week 28	Tezepelumab	9	8 (88.9)	5.16 (1.10)	3.3	4.58	5.03	5.95	6.8	
			Placebo	14	14 (100.0)	4.94 (1.25)	2.8	4.00	4.73	5.72	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.34 (1.17)	3.9	4.36	5.20	6.39	6.9	
			Placebo	14	14 (100.0)	5.00 (1.13)	3.2	4.19	4.84	6.09	6.9	
		Week 36	Tezepelumab	9	8 (88.9)	5.25 (1.13)	3.5	4.36	5.45	6.08	6.8	
			Placebo	14	14 (100.0)	4.92 (1.22)	2.2	4.22	4.86	5.69	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.41 (1.17)	3.8	4.55	5.30	6.38	7.0	
			Placebo	14	14 (100.0)	4.92 (1.34)	2.3	4.13	4.72	6.19	6.9	
		Week 44	Tezepelumab	9	8 (88.9)	5.41 (1.00)	4.2	4.55	5.31	6.23	6.8	
			Placebo	14	14 (100.0)	5.00 (1.19)	2.8	4.22	4.94	5.97	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.29 (1.17)	3.2	4.45	5.63	6.08	6.8	
			Placebo	14	14 (100.0)	4.81 (1.22)	2.1	4.22	4.66	5.41	6.8	
		Week 52	Tezepelumab	9	8 (88.9)	5.38 (1.20)	3.2	4.45	5.91	6.19	6.7	
			Placebo	14	14 (100.0)	4.87 (1.09)	3.3	4.22	4.61	5.41	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.85 (0.41)	0.3	0.50	0.69	1.28	1.4	0.79 [-0.22, 1.80]
			Placebo	14	10 (71.4)	0.28 (0.87)	-1.1	-0.47	0.41	0.66	1.6	
		Week 8	Tezepelumab	9	7 (77.8)	1.34 (0.65)	0.5	0.69	1.56	1.94	2.1	0.94 [-0.09, 1.96]
			Placebo	14	10 (71.4)	0.43 (1.14)	-1.4	-0.41	0.41	0.94	2.5	
		Week 12	Tezepelumab	9	7 (77.8)	1.46 (0.60)	0.7	0.91	1.44	2.09	2.1	0.98 [-0.05, 2.01]
			Placebo	14	10 (71.4)	0.31 (1.44)	-1.7	-0.97	0.31	0.84	3.5	
		Week 16	Tezepelumab	9	7 (77.8)	1.62 (0.74)	0.6	0.69	1.72	2.44	2.4	0.69 [-0.31, 1.69]
			Placebo	14	10 (71.4)	0.73 (1.55)	-2.0	0.31	0.72	1.66	3.8	
		Week 20	Tezepelumab	9	7 (77.8)	1.33 (0.84)	0.2	0.69	1.41	2.31	2.4	0.78 [-0.22, 1.79]
			Placebo	14	10 (71.4)	0.49 (1.21)	-2.0	-0.16	0.73	1.59	1.8	
		Week 24	Tezepelumab	9	7 (77.8)	1.51 (0.83)	0.6	0.69	1.66	2.28	2.8	0.69 [-0.31, 1.69]
			Placebo	14	10 (71.4)	0.64 (1.47)	-2.0	-0.16	0.84	1.72	2.8	
		Week 28	Tezepelumab	9	7 (77.8)	1.17 (0.95)	0.4	0.53	0.69	2.34	2.7	0.35 [-0.63, 1.32]
			Placebo	14	10 (71.4)	0.67 (1.67)	-2.0	-0.31	0.91	1.47	4.0	
		Week 32	Tezepelumab	9	7 (77.8)	1.43 (0.78)	0.7	0.72	1.09	2.19	2.6	0.57 [-0.42, 1.55]
			Placebo	14	10 (71.4)	0.74 (1.45)	-2.0	-0.16	1.09	1.50	3.2	
		Week 36	Tezepelumab	9	7 (77.8)	1.35 (0.85)	0.7	0.72	0.84	2.28	2.8	0.63 [-0.37, 1.62]
			Placebo	14	10 (71.4)	0.57 (1.47)	-2.0	-0.16	0.89	1.72	2.3	
		Week 40	Tezepelumab	9	7 (77.8)	1.47 (0.87)	0.6	0.69	1.03	2.31	2.8	0.57 [-0.42, 1.56]
			Placebo	14	10 (71.4)	0.65 (1.72)	-2.0	-0.16	0.75	1.72	3.8	
		Week 44	Tezepelumab	9	7 (77.8)	1.47 (1.00)	0.4	0.69	1.13	2.38	3.3	0.59 [-0.40, 1.58]
			Placebo	14	10 (71.4)	0.65 (1.60)	-2.0	-0.41	0.66	1.75	3.4	
		Week 48	Tezepelumab	9	7 (77.8)	1.37 (1.04)	0.4	0.44	0.69	2.34	2.9	0.74 [-0.26, 1.74]
			Placebo	14	10 (71.4)	0.43 (1.41)	-2.0	-0.16	0.75	1.72	2.2	
		Week 52	Tezepelumab	9	7 (77.8)	1.46 (0.95)	0.4	0.69	1.22	2.22	2.9	0.81 [-0.20, 1.82]
			Placebo	14	10 (71.4)	0.54 (1.25)	-2.0	-0.16	0.75	1.72	2.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.21 (0.92)	1.5	3.72	4.28	4.69	6.8	
			Placebo	124	111 (89.5)	4.06 (0.88)	1.8	3.47	4.06	4.69	6.1	
		Week 4	Tezepelumab	128	118 (92.2)	4.91 (1.05)	1.4	4.13	4.97	5.66	7.0	
			Placebo	124	111 (89.5)	4.60 (0.97)	2.1	3.97	4.50	5.25	6.8	
		Week 8	Tezepelumab	128	120 (93.8)	5.09 (1.04)	2.7	4.22	5.03	5.92	7.0	
			Placebo	124	113 (91.1)	4.72 (1.07)	2.1	4.00	4.63	5.44	7.0	
		Week 12	Tezepelumab	128	120 (93.8)	5.26 (1.04)	2.8	4.36	5.20	6.11	7.0	
			Placebo	124	114 (91.9)	4.84 (1.05)	2.5	4.03	4.75	5.66	7.0	
		Week 16	Tezepelumab	128	120 (93.8)	5.21 (1.03)	2.6	4.36	5.14	6.02	7.0	
			Placebo	124	114 (91.9)	4.83 (1.12)	1.2	3.97	4.75	5.72	7.0	
		Week 20	Tezepelumab	128	121 (94.5)	5.23 (1.01)	3.2	4.34	5.22	5.94	7.0	
			Placebo	124	114 (91.9)	4.87 (1.13)	1.2	4.00	4.77	5.88	7.0	
		Week 24	Tezepelumab	128	121 (94.5)	5.26 (1.04)	2.4	4.38	5.16	6.00	7.0	
			Placebo	124	114 (91.9)	4.89 (1.14)	1.2	4.00	4.81	5.75	7.0	
		Week 28	Tezepelumab	128	123 (96.1)	5.29 (1.00)	3.6	4.44	5.19	6.03	7.0	
			Placebo	124	114 (91.9)	4.89 (1.20)	1.2	3.97	4.83	5.88	7.0	
		Week 32	Tezepelumab	128	124 (96.9)	5.33 (1.02)	2.6	4.47	5.41	6.00	7.0	
			Placebo	124	115 (92.7)	4.94 (1.14)	1.2	4.00	4.84	5.91	7.0	
		Week 36	Tezepelumab	128	124 (96.9)	5.34 (1.01)	3.2	4.59	5.30	6.19	7.0	
			Placebo	124	115 (92.7)	4.97 (1.12)	2.6	4.00	4.81	5.97	7.0	
		Week 40	Tezepelumab	128	124 (96.9)	5.33 (1.03)	2.6	4.55	5.27	6.06	7.0	
			Placebo	124	115 (92.7)	5.00 (1.10)	2.5	4.00	4.97	5.91	7.0	
		Week 44	Tezepelumab	128	124 (96.9)	5.38 (1.04)	2.8	4.55	5.31	6.20	7.0	
			Placebo	124	115 (92.7)	4.97 (1.16)	2.5	4.00	4.91	6.00	7.0	
		Week 48	Tezepelumab	128	124 (96.9)	5.39 (1.03)	2.9	4.50	5.34	6.23	7.0	
			Placebo	124	116 (93.5)	5.02 (1.09)	2.8	4.02	4.91	5.95	7.0	
		Week 52	Tezepelumab	128	124 (96.9)	5.37 (1.04)	2.8	4.52	5.30	6.22	7.0	
			Placebo	124	116 (93.5)	4.98 (1.13)	2.7	3.98	4.91	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	110 (85.9)	0.73 (0.98)	-3.7	0.09	0.67	1.41	3.3	0.22 [-0.04, 0.49]
			Placebo	124	109 (87.9)	0.54 (0.77)	-1.2	0.09	0.44	1.00	2.6	
		Week 8	Tezepelumab	128	112 (87.5)	0.87 (0.98)	-1.0	0.13	0.73	1.56	3.9	0.23 [-0.03, 0.50]
			Placebo	124	110 (88.7)	0.66 (0.84)	-1.0	0.16	0.52	1.09	3.1	
		Week 12	Tezepelumab	128	112 (87.5)	1.05 (1.02)	-2.1	0.47	0.95	1.77	4.2	0.26 [-0.00, 0.53]
			Placebo	124	110 (88.7)	0.79 (0.95)	-2.0	0.22	0.72	1.25	3.4	
		Week 16	Tezepelumab	128	112 (87.5)	1.01 (1.00)	-2.4	0.34	0.88	1.67	4.2	0.24 [-0.02, 0.51]
			Placebo	124	110 (88.7)	0.77 (0.96)	-3.2	0.22	0.72	1.38	3.5	
		Week 20	Tezepelumab	128	112 (87.5)	1.03 (1.00)	-1.2	0.28	0.83	1.72	4.2	0.21 [-0.05, 0.48]
			Placebo	124	110 (88.7)	0.82 (0.97)	-3.2	0.25	0.77	1.19	3.8	
		Week 24	Tezepelumab	128	112 (87.5)	1.08 (1.01)	-1.2	0.33	1.00	1.78	4.3	0.24 [-0.03, 0.50]
			Placebo	124	110 (88.7)	0.84 (1.01)	-3.2	0.16	0.78	1.31	3.7	
		Week 28	Tezepelumab	128	112 (87.5)	1.09 (1.00)	-1.3	0.31	0.95	1.86	4.3	0.24 [-0.02, 0.51]
			Placebo	124	110 (88.7)	0.84 (1.06)	-3.2	0.19	0.81	1.41	4.3	
		Week 32	Tezepelumab	128	112 (87.5)	1.12 (1.03)	-1.2	0.38	1.03	1.91	4.3	0.20 [-0.06, 0.47]
			Placebo	124	110 (88.7)	0.91 (0.98)	-3.2	0.31	0.73	1.41	3.6	
		Week 36	Tezepelumab	128	112 (87.5)	1.12 (1.08)	-1.3	0.33	0.97	1.94	4.3	0.18 [-0.08, 0.44]
			Placebo	124	110 (88.7)	0.94 (0.98)	-1.7	0.31	0.75	1.50	3.4	
		Week 40	Tezepelumab	128	112 (87.5)	1.12 (1.03)	-1.3	0.44	0.97	1.86	4.3	0.16 [-0.10, 0.42]
			Placebo	124	110 (88.7)	0.96 (1.01)	-1.2	0.28	0.81	1.59	4.3	
		Week 44	Tezepelumab	128	112 (87.5)	1.16 (1.03)	-1.1	0.52	1.03	1.88	4.3	0.22 [-0.04, 0.49]
			Placebo	124	110 (88.7)	0.93 (1.05)	-1.3	0.25	0.84	1.38	4.1	
		Week 48	Tezepelumab	128	112 (87.5)	1.20 (1.03)	-1.1	0.50	1.06	2.06	4.3	0.22 [-0.05, 0.48]
			Placebo	124	110 (88.7)	0.97 (1.00)	-0.9	0.19	0.89	1.59	3.5	
		Week 52	Tezepelumab	128	112 (87.5)	1.15 (1.04)	-1.2	0.44	1.06	1.97	4.3	0.21 [-0.05, 0.47]
			Placebo	124	110 (88.7)	0.94 (1.01)	-0.9	0.19	0.83	1.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	4.18 (0.90)	2.0	3.69	4.27	4.64	6.8	
			Placebo	115	104 (90.4)	4.06 (0.87)	1.8	3.48	4.06	4.67	6.1	
		Week 4	Tezepelumab	108	100 (92.6)	4.86 (1.07)	1.4	4.03	4.94	5.66	7.0	
			Placebo	115	104 (90.4)	4.60 (0.98)	2.1	3.97	4.50	5.22	6.8	
		Week 8	Tezepelumab	108	102 (94.4)	5.02 (1.04)	2.8	4.19	4.98	5.84	7.0	
			Placebo	115	106 (92.2)	4.75 (1.05)	2.1	4.00	4.63	5.50	7.0	
		Week 12	Tezepelumab	108	102 (94.4)	5.23 (1.03)	3.0	4.34	5.16	6.06	7.0	
			Placebo	115	107 (93.0)	4.85 (1.07)	2.5	4.00	4.72	5.72	7.0	
		Week 16	Tezepelumab	108	102 (94.4)	5.15 (1.01)	2.7	4.28	5.09	5.94	7.0	
			Placebo	115	107 (93.0)	4.85 (1.14)	1.2	3.97	4.75	5.75	7.0	
		Week 20	Tezepelumab	108	103 (95.4)	5.15 (1.02)	3.2	4.31	5.06	5.88	7.0	
			Placebo	115	107 (93.0)	4.88 (1.14)	1.2	4.00	4.78	5.91	7.0	
		Week 24	Tezepelumab	108	103 (95.4)	5.20 (1.02)	3.3	4.34	5.09	6.00	7.0	
			Placebo	115	107 (93.0)	4.89 (1.15)	1.2	4.00	4.81	5.81	7.0	
		Week 28	Tezepelumab	108	105 (97.2)	5.23 (1.01)	3.6	4.34	5.16	6.00	7.0	
			Placebo	115	107 (93.0)	4.90 (1.20)	1.2	3.97	4.84	5.88	7.0	
		Week 32	Tezepelumab	108	106 (98.1)	5.25 (1.02)	2.6	4.44	5.27	5.94	7.0	
			Placebo	115	108 (93.9)	4.94 (1.15)	1.2	4.02	4.84	5.89	7.0	
		Week 36	Tezepelumab	108	106 (98.1)	5.28 (1.01)	3.2	4.53	5.13	6.03	7.0	
			Placebo	115	108 (93.9)	4.96 (1.13)	2.6	4.00	4.78	5.95	7.0	
		Week 40	Tezepelumab	108	106 (98.1)	5.28 (1.01)	3.2	4.47	5.23	6.00	7.0	
			Placebo	115	108 (93.9)	5.01 (1.11)	2.5	4.00	4.98	5.95	7.0	
		Week 44	Tezepelumab	108	106 (98.1)	5.32 (1.03)	3.0	4.47	5.22	6.06	7.0	
			Placebo	115	108 (93.9)	4.98 (1.17)	2.5	4.00	4.89	6.00	7.0	
		Week 48	Tezepelumab	108	106 (98.1)	5.34 (1.04)	2.9	4.47	5.27	6.22	7.0	
			Placebo	115	109 (94.8)	5.01 (1.10)	2.8	4.03	4.91	5.91	7.0	
		Week 52	Tezepelumab	108	106 (98.1)	5.33 (1.04)	2.9	4.47	5.19	6.22	7.0	
			Placebo	115	109 (94.8)	4.97 (1.14)	2.7	3.97	4.91	5.94	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility											
Yes	Change from baseline	Week 4	Tezepelumab	108	93 (86.1)	0.70 (1.00)	-3.7	0.06	0.66	1.28	3.3	0.18 [-0.10, 0.46]
			Placebo	115	102 (88.7)	0.54 (0.79)	-1.2	0.06	0.42	1.00	2.6	
		Week 8	Tezepelumab	108	95 (88.0)	0.82 (0.99)	-1.0	0.09	0.66	1.41	3.9	0.15 [-0.13, 0.42]
			Placebo	115	103 (89.6)	0.68 (0.86)	-1.0	0.16	0.50	1.19	3.1	
		Week 12	Tezepelumab	108	95 (88.0)	1.02 (1.03)	-2.1	0.41	0.88	1.75	4.2	0.22 [-0.06, 0.50]
			Placebo	115	103 (89.6)	0.79 (0.98)	-2.0	0.19	0.69	1.31	3.4	
		Week 16	Tezepelumab	108	95 (88.0)	0.96 (1.00)	-2.4	0.34	0.81	1.63	4.2	0.17 [-0.10, 0.45]
			Placebo	115	103 (89.6)	0.79 (0.98)	-3.2	0.22	0.72	1.38	3.5	
		Week 20	Tezepelumab	108	95 (88.0)	0.95 (1.01)	-1.2	0.22	0.75	1.66	4.2	0.12 [-0.16, 0.40]
			Placebo	115	103 (89.6)	0.83 (0.99)	-3.2	0.25	0.78	1.22	3.8	
		Week 24	Tezepelumab	108	95 (88.0)	1.03 (0.99)	-1.2	0.31	0.91	1.66	4.3	0.19 [-0.09, 0.47]
			Placebo	115	103 (89.6)	0.84 (1.03)	-3.2	0.16	0.78	1.34	3.7	
		Week 28	Tezepelumab	108	95 (88.0)	1.04 (1.01)	-1.3	0.31	0.88	1.88	4.3	0.19 [-0.09, 0.47]
			Placebo	115	103 (89.6)	0.85 (1.08)	-3.2	0.19	0.78	1.44	4.3	
		Week 32	Tezepelumab	108	95 (88.0)	1.05 (1.03)	-1.2	0.34	1.00	1.88	4.3	0.13 [-0.15, 0.41]
			Placebo	115	103 (89.6)	0.91 (1.00)	-3.2	0.31	0.75	1.47	3.6	
		Week 36	Tezepelumab	108	95 (88.0)	1.07 (1.09)	-1.3	0.28	0.91	2.06	4.3	0.14 [-0.14, 0.42]
			Placebo	115	103 (89.6)	0.93 (0.98)	-1.7	0.31	0.75	1.50	3.4	
		Week 40	Tezepelumab	108	95 (88.0)	1.08 (1.04)	-1.3	0.44	0.94	1.88	4.3	0.11 [-0.17, 0.38]
			Placebo	115	103 (89.6)	0.97 (1.01)	-1.2	0.28	0.91	1.66	4.3	
		Week 44	Tezepelumab	108	95 (88.0)	1.13 (1.04)	-1.1	0.50	0.91	1.88	4.3	0.17 [-0.10, 0.45]
			Placebo	115	103 (89.6)	0.94 (1.06)	-1.3	0.22	0.84	1.41	4.1	
		Week 48	Tezepelumab	108	95 (88.0)	1.16 (1.05)	-1.1	0.44	1.03	2.06	4.3	0.18 [-0.10, 0.46]
			Placebo	115	103 (89.6)	0.97 (1.01)	-0.9	0.16	0.88	1.66	3.5	
		Week 52	Tezepelumab	108	95 (88.0)	1.13 (1.06)	-1.2	0.44	1.00	2.00	4.3	0.19 [-0.09, 0.47]
			Placebo	115	103 (89.6)	0.93 (1.03)	-0.9	0.16	0.84	1.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	4.25 (0.97)	1.5	3.72	4.44	5.06	6.2	
			Placebo	23	17 (73.9)	4.24 (0.92)	2.7	3.84	4.28	4.69	6.3	
		Week 4	Tezepelumab	29	26 (89.7)	5.09 (0.91)	3.3	4.44	5.08	5.84	6.8	
			Placebo	23	19 (82.6)	4.61 (0.92)	3.0	3.81	4.84	5.47	6.0	
		Week 8	Tezepelumab	29	26 (89.7)	5.44 (1.00)	2.7	4.81	5.34	6.25	6.8	
			Placebo	23	20 (87.0)	4.53 (0.96)	2.4	3.84	4.67	5.27	6.0	
		Week 12	Tezepelumab	29	26 (89.7)	5.50 (1.07)	2.8	4.81	5.39	6.44	7.0	
			Placebo	23	20 (87.0)	4.70 (0.90)	2.8	4.13	4.70	5.33	6.5	
		Week 16	Tezepelumab	29	26 (89.7)	5.59 (1.04)	2.6	5.00	5.58	6.53	6.9	
			Placebo	23	20 (87.0)	4.83 (1.01)	2.9	4.16	4.91	5.50	6.8	
		Week 20	Tezepelumab	29	26 (89.7)	5.55 (0.95)	3.8	4.78	5.66	6.19	7.0	
			Placebo	23	20 (87.0)	4.71 (0.85)	2.9	4.06	4.83	5.41	6.4	
		Week 24	Tezepelumab	29	26 (89.7)	5.55 (1.11)	2.4	4.63	5.81	6.25	7.0	
			Placebo	23	20 (87.0)	4.81 (1.01)	2.7	4.05	4.81	5.63	6.4	
		Week 28	Tezepelumab	29	26 (89.7)	5.48 (0.98)	3.3	4.63	5.48	6.03	7.0	
			Placebo	23	21 (91.3)	4.89 (1.22)	2.8	3.97	4.34	5.72	7.0	
		Week 32	Tezepelumab	29	26 (89.7)	5.65 (1.01)	3.6	4.91	5.84	6.47	7.0	
			Placebo	23	21 (91.3)	4.98 (1.04)	3.2	4.19	4.69	5.94	6.9	
		Week 36	Tezepelumab	29	26 (89.7)	5.55 (1.04)	3.4	5.00	5.70	6.34	7.0	
			Placebo	23	21 (91.3)	4.99 (1.14)	2.2	4.22	5.03	5.78	6.9	
		Week 40	Tezepelumab	29	26 (89.7)	5.58 (1.11)	2.6	5.03	5.69	6.50	7.0	
			Placebo	23	21 (91.3)	4.89 (1.24)	2.3	3.91	4.91	5.88	6.9	
		Week 44	Tezepelumab	29	26 (89.7)	5.59 (1.05)	2.8	4.78	5.80	6.41	7.0	
			Placebo	23	21 (91.3)	4.94 (1.14)	2.8	3.88	5.13	5.81	6.9	
		Week 48	Tezepelumab	29	26 (89.7)	5.56 (1.02)	3.2	5.03	5.84	6.16	7.0	
			Placebo	23	21 (91.3)	4.90 (1.18)	2.1	4.22	4.75	6.06	6.8	
		Week 52	Tezepelumab	29	26 (89.7)	5.53 (1.06)	2.8	5.03	5.84	6.28	7.0	
			Placebo	23	21 (91.3)	4.93 (1.04)	3.3	4.16	4.75	5.72	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IOSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITT

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	29	24 (82.8)	0.90 (0.77)	-1.3	0.44	0.98	1.53	2.2	0.73 [0.09, 1.37]
			Placebo	23	17 (73.9)	0.36 (0.70)	-1.1	0.25	0.47	0.56	1.6	
		Week 8	Tezepelumab	29	24 (82.8)	1.23 (0.82)	-0.8	0.77	1.44	1.86	2.4	1.00 [0.34, 1.66]
			Placebo	23	17 (73.9)	0.38 (0.90)	-1.4	-0.19	0.53	0.75	2.5	
		Week 12	Tezepelumab	29	24 (82.8)	1.30 (0.86)	-0.9	0.80	1.41	1.98	2.7	0.81 [0.17, 1.46]
			Placebo	23	17 (73.9)	0.49 (1.17)	-1.7	0.25	0.75	0.88	3.5	
		Week 16	Tezepelumab	29	24 (82.8)	1.39 (0.90)	-0.6	0.77	1.52	1.86	2.8	0.69 [0.05, 1.33]
			Placebo	23	17 (73.9)	0.67 (1.21)	-2.0	0.31	0.72	1.00	3.8	
		Week 20	Tezepelumab	29	24 (82.8)	1.40 (0.86)	-0.4	0.77	1.55	2.14	2.7	0.96 [0.30, 1.61]
			Placebo	23	17 (73.9)	0.55 (0.93)	-2.0	0.44	0.69	0.91	1.8	
		Week 24	Tezepelumab	29	24 (82.8)	1.39 (1.04)	-1.1	0.67	1.61	2.16	3.0	0.61 [-0.03, 1.24]
			Placebo	23	17 (73.9)	0.72 (1.19)	-2.0	0.13	0.91	1.56	2.8	
		Week 28	Tezepelumab	29	24 (82.8)	1.30 (0.95)	-0.6	0.64	1.20	2.06	3.0	0.54 [-0.09, 1.18]
			Placebo	23	17 (73.9)	0.70 (1.32)	-2.0	-0.16	1.03	1.31	4.0	
		Week 32	Tezepelumab	29	24 (82.8)	1.48 (0.88)	-0.5	0.80	1.58	2.16	2.8	0.69 [0.05, 1.33]
			Placebo	23	17 (73.9)	0.79 (1.12)	-2.0	0.31	0.78	1.41	3.2	
		Week 36	Tezepelumab	29	24 (82.8)	1.38 (0.95)	-1.0	0.77	1.39	1.91	3.3	0.54 [-0.09, 1.17]
			Placebo	23	17 (73.9)	0.78 (1.30)	-2.0	0.38	1.00	1.50	3.0	
		Week 40	Tezepelumab	29	24 (82.8)	1.39 (0.93)	-0.8	0.83	1.39	1.98	2.8	0.60 [-0.03, 1.24]
			Placebo	23	17 (73.9)	0.69 (1.43)	-2.0	-0.16	0.69	1.50	3.8	
		Week 44	Tezepelumab	29	24 (82.8)	1.40 (0.96)	-0.8	0.83	1.39	2.02	3.3	0.62 [-0.01, 1.26]
			Placebo	23	17 (73.9)	0.69 (1.35)	-2.0	-0.16	0.53	1.72	3.4	
		Week 48	Tezepelumab	29	24 (82.8)	1.40 (0.96)	-0.8	0.67	1.55	2.14	2.9	0.67 [0.03, 1.30]
			Placebo	23	17 (73.9)	0.68 (1.23)	-2.0	0.19	0.81	1.09	2.9	
		Week 52	Tezepelumab	29	24 (82.8)	1.33 (0.96)	-0.8	0.67	1.33	2.14	2.9	0.60 [-0.03, 1.24]
			Placebo	23	17 (73.9)	0.72 (1.08)	-2.0	0.19	0.81	1.09	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOMH0: Course of AQLQ+12 activity limitations score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	137	123 (89.8)	4.29 (0.92)	1.9	3.73	4.27	4.82	7.0	
		Placebo	138	121 (87.7)	4.15 (0.88)	2.0	3.55	4.09	4.55	6.2	
	Week 4	Tezepelumab	137	126 (92.0)	4.96 (1.09)	1.6	4.18	4.91	5.82	7.0	
		Placebo	138	123 (89.1)	4.63 (1.03)	2.5	3.91	4.55	5.45	7.0	
	Week 8	Tezepelumab	137	128 (93.4)	5.15 (1.10)	1.6	4.27	5.18	6.09	7.0	
		Placebo	138	126 (91.3)	4.77 (1.11)	2.2	4.00	4.64	5.64	7.0	
	Week 12	Tezepelumab	137	128 (93.4)	5.33 (1.12)	1.7	4.55	5.27	6.27	7.0	
		Placebo	138	127 (92.0)	4.89 (1.11)	2.8	4.00	4.73	5.91	7.0	
	Week 16	Tezepelumab	137	128 (93.4)	5.28 (1.08)	2.6	4.32	5.27	6.18	7.0	
		Placebo	138	127 (92.0)	4.94 (1.17)	1.1	4.00	4.82	5.91	7.0	
	Week 20	Tezepelumab	137	129 (94.2)	5.23 (1.15)	1.8	4.36	5.27	6.09	7.0	
		Placebo	138	127 (92.0)	4.90 (1.14)	1.1	4.09	4.73	5.82	7.0	
	Week 24	Tezepelumab	137	129 (94.2)	5.30 (1.14)	1.6	4.36	5.27	6.27	7.0	
		Placebo	138	127 (92.0)	4.95 (1.17)	1.1	4.09	4.82	5.91	7.0	
	Week 28	Tezepelumab	137	131 (95.6)	5.31 (1.10)	2.1	4.36	5.36	6.18	7.0	
		Placebo	138	128 (92.8)	4.94 (1.24)	1.1	4.00	4.82	6.00	7.0	
	Week 32	Tezepelumab	137	132 (96.4)	5.36 (1.10)	1.6	4.45	5.45	6.18	7.0	
		Placebo	138	129 (93.5)	4.99 (1.17)	1.1	4.09	4.82	6.00	7.0	
	Week 36	Tezepelumab	137	132 (96.4)	5.34 (1.09)	1.9	4.45	5.45	6.18	7.0	
		Placebo	138	129 (93.5)	5.01 (1.16)	2.4	4.09	4.82	6.09	7.0	
	Week 40	Tezepelumab	137	132 (96.4)	5.38 (1.08)	2.1	4.41	5.36	6.18	7.0	
		Placebo	138	129 (93.5)	5.03 (1.18)	2.0	4.09	5.00	6.00	7.0	
	Week 44	Tezepelumab	137	132 (96.4)	5.41 (1.09)	2.4	4.45	5.41	6.27	7.0	
		Placebo	138	129 (93.5)	5.04 (1.19)	2.5	4.00	4.91	6.00	7.0	
	Week 48	Tezepelumab	137	132 (96.4)	5.43 (1.09)	2.6	4.41	5.50	6.41	7.0	
		Placebo	138	130 (94.2)	5.04 (1.14)	2.3	4.09	5.00	5.91	7.0	
	Week 52	Tezepelumab	137	132 (96.4)	5.40 (1.11)	1.8	4.50	5.45	6.27	7.0	
		Placebo	138	130 (94.2)	5.03 (1.14)	2.7	4.00	5.00	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOMH0: Course of AQLQ+12 activity limitations score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	137	117 (85.4)	0.70 (1.00)	-2.8	0.00	0.64	1.27	3.2	0.23 [-0.02, 0.49]
		Placebo	138	119 (86.2)	0.49 (0.86)	-1.5	-0.09	0.36	0.91	2.6	
	Week 8	Tezepelumab	137	119 (86.9)	0.85 (1.04)	-1.5	0.09	0.82	1.55	3.7	0.22 [-0.04, 0.47]
		Placebo	138	120 (87.0)	0.64 (0.91)	-1.7	0.00	0.59	1.09	3.3	
	Week 12	Tezepelumab	137	119 (86.9)	1.03 (1.04)	-1.5	0.36	1.00	1.55	4.2	0.27 [0.01, 0.52]
		Placebo	138	120 (87.0)	0.76 (1.01)	-1.9	0.14	0.82	1.18	3.7	
	Week 16	Tezepelumab	137	119 (86.9)	1.01 (1.04)	-1.7	0.27	0.91	1.55	3.5	0.19 [-0.07, 0.44]
		Placebo	138	120 (87.0)	0.81 (1.05)	-3.2	0.27	0.82	1.45	3.9	
	Week 20	Tezepelumab	137	119 (86.9)	0.95 (1.10)	-2.1	0.18	0.91	1.73	3.5	0.15 [-0.10, 0.41]
		Placebo	138	120 (87.0)	0.79 (1.03)	-3.2	0.18	0.73	1.27	4.0	
	Week 24	Tezepelumab	137	119 (86.9)	1.05 (1.05)	-1.4	0.27	1.00	1.64	3.5	0.21 [-0.04, 0.46]
		Placebo	138	120 (87.0)	0.83 (1.07)	-3.2	0.23	0.82	1.45	3.8	
	Week 28	Tezepelumab	137	119 (86.9)	1.05 (1.06)	-1.1	0.18	0.91	1.82	3.5	0.22 [-0.04, 0.47]
		Placebo	138	120 (87.0)	0.81 (1.11)	-3.2	0.14	0.82	1.50	4.0	
	Week 32	Tezepelumab	137	119 (86.9)	1.08 (1.04)	-1.1	0.36	1.00	1.82	3.5	0.20 [-0.06, 0.45]
		Placebo	138	120 (87.0)	0.87 (1.06)	-3.2	0.27	0.86	1.55	3.6	
	Week 36	Tezepelumab	137	119 (86.9)	1.06 (1.08)	-0.9	0.18	1.00	1.73	3.5	0.15 [-0.10, 0.41]
		Placebo	138	120 (87.0)	0.90 (1.07)	-1.8	0.18	0.86	1.50	3.5	
	Week 40	Tezepelumab	137	119 (86.9)	1.10 (1.04)	-1.0	0.36	1.09	1.82	3.5	0.17 [-0.08, 0.43]
		Placebo	138	120 (87.0)	0.91 (1.13)	-1.6	0.18	0.82	1.55	4.0	
	Week 44	Tezepelumab	137	119 (86.9)	1.14 (1.06)	-1.1	0.27	1.00	1.82	3.5	0.21 [-0.04, 0.47]
		Placebo	138	120 (87.0)	0.91 (1.12)	-1.6	0.18	0.86	1.55	3.9	
	Week 48	Tezepelumab	137	119 (86.9)	1.17 (1.05)	-1.0	0.36	1.09	1.91	3.5	0.24 [-0.01, 0.50]
		Placebo	138	120 (87.0)	0.91 (1.06)	-1.6	0.18	0.82	1.45	3.6	
	Week 52	Tezepelumab	137	119 (86.9)	1.12 (1.07)	-1.2	0.36	1.00	1.91	3.5	0.19 [-0.07, 0.44]
		Placebo	138	120 (87.0)	0.92 (1.06)	-1.6	0.18	0.91	1.50	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
DITT

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	137	117 (85.4)	0.73 (0.08)	(0.57, 0.89)	0.28 (0.12)	(0.05, 0.51)	0.015 *
	Placebo	138	118 (85.5)	0.45 (0.08)	(0.29, 0.61)			
Week 8	Tezepelumab	137	117 (85.4)	0.87 (0.09)	(0.70, 1.04)	0.26 (0.12)	(0.02, 0.50)	0.037 *
	Placebo	138	119 (86.2)	0.62 (0.09)	(0.45, 0.79)			
Week 12	Tezepelumab	137	116 (84.7)	1.07 (0.09)	(0.89, 1.24)	0.32 (0.13)	(0.06, 0.57)	0.014 *
	Placebo	138	115 (83.3)	0.75 (0.09)	(0.57, 0.93)			
Week 16	Tezepelumab	137	112 (81.8)	1.04 (0.09)	(0.85, 1.22)	0.26 (0.13)	(0.00, 0.52)	0.048 *
	Placebo	138	112 (81.2)	0.78 (0.09)	(0.60, 0.96)			
Week 20	Tezepelumab	137	107 (78.1)	0.99 (0.09)	(0.80, 1.17)	0.19 (0.13)	(-0.07, 0.44)	0.149
	Placebo	138	109 (79.0)	0.80 (0.09)	(0.62, 0.98)			
Week 24	Tezepelumab	137	105 (76.6)	1.10 (0.09)	(0.91, 1.28)	0.26 (0.13)	(0.00, 0.52)	0.047 *
	Placebo	138	106 (76.8)	0.83 (0.09)	(0.65, 1.02)			
Week 28	Tezepelumab	137	101 (73.7)	1.07 (0.10)	(0.88, 1.26)	0.26 (0.14)	(-0.01, 0.52)	0.059
	Placebo	138	105 (76.1)	0.81 (0.10)	(0.63, 1.00)			
Week 32	Tezepelumab	137	104 (75.9)	1.12 (0.09)	(0.94, 1.30)	0.24 (0.13)	(-0.02, 0.49)	0.066
	Placebo	138	104 (75.4)	0.89 (0.09)	(0.71, 1.06)			
Week 36	Tezepelumab	137	104 (75.9)	1.10 (0.10)	(0.91, 1.29)	0.20 (0.14)	(-0.07, 0.46)	0.150
	Placebo	138	103 (74.6)	0.91 (0.10)	(0.72, 1.09)			
Week 40	Tezepelumab	137	104 (75.9)	1.15 (0.10)	(0.96, 1.34)	0.22 (0.14)	(-0.04, 0.49)	0.099
	Placebo	138	105 (76.1)	0.92 (0.10)	(0.74, 1.11)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
DITT

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	137	102 (74.5)	1.19 (0.10)	(1.00, 1.39)	0.31 (0.14)	(0.04, 0.58)	0.026 *
	Placebo	138	103 (74.6)	0.89 (0.10)	(0.70, 1.08)			
Week 48	Tezepelumab	137	97 (70.8)	1.24 (0.09)	(1.06, 1.43)	0.34 (0.13)	(0.08, 0.60)	0.011 *
	Placebo	138	105 (76.1)	0.91 (0.09)	(0.72, 1.09)			
Week 52	Tezepelumab	137	41 (29.9)	1.10 (0.12)	(0.86, 1.33)	0.11 (0.17)	(-0.22, 0.43)	0.516
	Placebo	138	47 (34.1)	0.99 (0.11)	(0.76, 1.21)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QAC_IOMG0: Course of AQLQ+12 activity limitations score
DITT



Note: DITT = Dossier Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QAC_IOMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	50	42 (84.0)	4.38 (0.85)	3.2	3.73	4.23	4.73	7.0	
			Placebo	44	41 (93.2)	4.11 (0.87)	2.3	3.64	4.00	4.36	6.2	
		Week 4	Tezepelumab	50	46 (92.0)	5.16 (1.12)	3.1	4.18	5.23	6.00	7.0	
			Placebo	44	41 (93.2)	4.75 (1.15)	2.5	3.82	4.64	6.00	6.9	
		Week 8	Tezepelumab	50	46 (92.0)	5.27 (1.12)	3.2	4.27	5.23	6.18	7.0	
			Placebo	44	42 (95.5)	4.86 (1.09)	3.2	4.00	4.68	5.91	7.0	
		Week 12	Tezepelumab	50	46 (92.0)	5.37 (1.11)	3.2	4.64	5.32	6.27	7.0	
			Placebo	44	42 (95.5)	5.00 (1.14)	2.8	4.00	4.91	6.18	7.0	
		Week 16	Tezepelumab	50	46 (92.0)	5.39 (1.10)	3.5	4.36	5.41	6.45	7.0	
			Placebo	44	42 (95.5)	4.99 (1.26)	1.1	4.00	5.05	6.00	7.0	
		Week 20	Tezepelumab	50	46 (92.0)	5.36 (1.16)	3.5	4.27	5.36	6.45	7.0	
			Placebo	44	42 (95.5)	4.93 (1.25)	1.1	3.91	4.91	6.00	6.9	
		Week 24	Tezepelumab	50	46 (92.0)	5.41 (1.11)	3.5	4.36	5.64	6.36	7.0	
			Placebo	44	42 (95.5)	4.99 (1.32)	1.1	3.91	5.23	6.00	7.0	
		Week 28	Tezepelumab	50	47 (94.0)	5.42 (1.09)	3.5	4.36	5.45	6.27	7.0	
			Placebo	44	43 (97.7)	4.93 (1.41)	1.1	3.82	5.09	6.00	7.0	
		Week 32	Tezepelumab	50	48 (96.0)	5.47 (1.03)	3.5	4.41	5.59	6.27	7.0	
			Placebo	44	43 (97.7)	5.07 (1.27)	1.1	4.00	5.45	6.00	7.0	
		Week 36	Tezepelumab	50	48 (96.0)	5.43 (1.09)	3.5	4.36	5.50	6.32	7.0	
			Placebo	44	43 (97.7)	5.12 (1.25)	2.4	4.00	5.18	6.18	7.0	
		Week 40	Tezepelumab	50	48 (96.0)	5.48 (1.09)	3.5	4.55	5.41	6.45	7.0	
			Placebo	44	43 (97.7)	5.11 (1.25)	2.5	4.00	5.27	6.09	7.0	
		Week 44	Tezepelumab	50	48 (96.0)	5.54 (1.12)	3.5	4.55	5.77	6.50	7.0	
			Placebo	44	43 (97.7)	5.18 (1.26)	2.9	4.00	5.27	6.09	7.0	
		Week 48	Tezepelumab	50	48 (96.0)	5.48 (1.13)	3.3	4.41	5.45	6.55	7.0	
			Placebo	44	43 (97.7)	5.14 (1.24)	2.4	4.00	5.18	6.18	7.0	
		Week 52	Tezepelumab	50	48 (96.0)	5.41 (1.12)	3.3	4.41	5.41	6.23	7.0	
			Placebo	44	43 (97.7)	5.18 (1.17)	2.9	4.18	5.09	6.18	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	50	41 (82.0)	0.82 (0.99)	-1.4	0.00	0.64	1.55	2.9	0.16 [-0.28, 0.59]
			Placebo	44	40 (90.9)	0.67 (0.97)	-1.0	0.00	0.45	1.64	2.6	
		Week 8	Tezepelumab	50	41 (82.0)	0.93 (1.06)	-1.2	0.27	0.82	1.55	3.5	0.16 [-0.27, 0.59]
			Placebo	44	41 (93.2)	0.78 (0.84)	-0.5	0.09	0.73	1.18	2.6	
		Week 12	Tezepelumab	50	41 (82.0)	1.05 (1.02)	-0.9	0.18	1.00	1.55	3.5	0.13 [-0.30, 0.57]
			Placebo	44	41 (93.2)	0.92 (0.95)	-1.0	0.27	0.82	1.18	3.0	
		Week 16	Tezepelumab	50	41 (82.0)	1.10 (1.09)	-1.7	0.55	1.09	1.64	3.5	0.19 [-0.24, 0.63]
			Placebo	44	41 (93.2)	0.89 (1.10)	-3.2	0.36	0.82	1.64	2.7	
		Week 20	Tezepelumab	50	41 (82.0)	1.06 (1.05)	-0.8	0.36	0.91	1.55	3.5	0.20 [-0.23, 0.63]
			Placebo	44	41 (93.2)	0.85 (1.03)	-3.2	0.36	0.73	1.36	2.6	
		Week 24	Tezepelumab	50	41 (82.0)	1.15 (1.03)	-0.8	0.36	1.09	1.73	3.5	0.23 [-0.21, 0.66]
			Placebo	44	41 (93.2)	0.90 (1.18)	-3.2	0.36	0.82	1.82	3.0	
		Week 28	Tezepelumab	50	41 (82.0)	1.18 (1.02)	-0.8	0.64	1.18	1.82	3.5	0.34 [-0.09, 0.78]
			Placebo	44	41 (93.2)	0.80 (1.20)	-3.2	0.09	0.82	1.55	3.0	
		Week 32	Tezepelumab	50	41 (82.0)	1.18 (0.94)	-1.0	0.64	1.09	1.55	3.5	0.24 [-0.19, 0.68]
			Placebo	44	41 (93.2)	0.93 (1.08)	-3.2	0.36	0.91	1.55	2.7	
		Week 36	Tezepelumab	50	41 (82.0)	1.13 (1.05)	-0.9	0.36	1.00	1.91	3.5	0.14 [-0.29, 0.57]
			Placebo	44	41 (93.2)	0.98 (1.09)	-1.8	0.27	0.91	1.73	3.3	
		Week 40	Tezepelumab	50	41 (82.0)	1.19 (0.98)	-0.9	0.64	1.18	1.64	3.5	0.20 [-0.23, 0.63]
			Placebo	44	41 (93.2)	0.98 (1.09)	-1.4	0.36	0.82	1.64	3.5	
		Week 44	Tezepelumab	50	41 (82.0)	1.25 (1.03)	-1.1	0.55	1.18	2.00	3.5	0.21 [-0.23, 0.64]
			Placebo	44	41 (93.2)	1.03 (1.07)	-1.4	0.36	0.91	1.82	3.0	
		Week 48	Tezepelumab	50	41 (82.0)	1.20 (1.03)	-1.0	0.55	1.09	2.00	3.5	0.19 [-0.24, 0.63]
			Placebo	44	41 (93.2)	1.00 (1.09)	-1.5	0.27	0.91	1.73	3.4	
		Week 52	Tezepelumab	50	41 (82.0)	1.08 (1.09)	-1.2	0.55	1.00	1.64	3.5	0.03 [-0.40, 0.47]
			Placebo	44	41 (93.2)	1.05 (1.02)	-1.4	0.45	0.82	1.73	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	87	81 (93.1)	4.24 (0.95)	1.9	3.73	4.27	4.82	6.3	
			Placebo	94	80 (85.1)	4.17 (0.88)	2.0	3.55	4.18	4.64	6.2	
		Week 4	Tezepelumab	87	80 (92.0)	4.85 (1.06)	1.6	4.14	4.91	5.50	7.0	
			Placebo	94	82 (87.2)	4.57 (0.97)	2.6	3.91	4.55	5.18	7.0	
		Week 8	Tezepelumab	87	82 (94.3)	5.08 (1.08)	1.6	4.27	5.00	6.00	7.0	
			Placebo	94	84 (89.4)	4.72 (1.12)	2.2	4.00	4.59	5.45	7.0	
		Week 12	Tezepelumab	87	82 (94.3)	5.30 (1.13)	1.7	4.55	5.18	6.27	7.0	
			Placebo	94	85 (90.4)	4.84 (1.09)	2.8	4.00	4.73	5.91	7.0	
		Week 16	Tezepelumab	87	82 (94.3)	5.23 (1.07)	2.6	4.27	5.23	6.09	7.0	
			Placebo	94	85 (90.4)	4.91 (1.14)	2.6	4.00	4.73	5.82	7.0	
		Week 20	Tezepelumab	87	83 (95.4)	5.16 (1.14)	1.8	4.36	5.18	6.09	7.0	
			Placebo	94	85 (90.4)	4.89 (1.09)	2.1	4.09	4.64	5.73	7.0	
		Week 24	Tezepelumab	87	83 (95.4)	5.24 (1.16)	1.6	4.27	5.18	6.27	7.0	
			Placebo	94	85 (90.4)	4.92 (1.10)	2.0	4.18	4.73	5.82	7.0	
		Week 28	Tezepelumab	87	84 (96.6)	5.24 (1.10)	2.1	4.36	5.27	6.09	7.0	
			Placebo	94	85 (90.4)	4.94 (1.16)	2.0	4.00	4.73	5.91	7.0	
		Week 32	Tezepelumab	87	84 (96.6)	5.30 (1.14)	1.6	4.45	5.36	6.18	7.0	
			Placebo	94	86 (91.5)	4.95 (1.12)	1.7	4.09	4.64	5.91	7.0	
		Week 36	Tezepelumab	87	84 (96.6)	5.29 (1.10)	1.9	4.45	5.45	6.18	7.0	
			Placebo	94	86 (91.5)	4.96 (1.11)	2.5	4.09	4.73	6.00	7.0	
		Week 40	Tezepelumab	87	84 (96.6)	5.32 (1.09)	2.1	4.41	5.23	6.18	7.0	
			Placebo	94	86 (91.5)	4.99 (1.15)	2.0	4.09	4.91	5.82	7.0	
		Week 44	Tezepelumab	87	84 (96.6)	5.33 (1.08)	2.4	4.45	5.36	6.27	7.0	
			Placebo	94	86 (91.5)	4.97 (1.16)	2.5	4.00	4.77	5.82	7.0	
		Week 48	Tezepelumab	87	84 (96.6)	5.40 (1.07)	2.6	4.41	5.55	6.27	7.0	
			Placebo	94	87 (92.6)	4.99 (1.09)	2.3	4.09	4.91	5.91	7.0	
		Week 52	Tezepelumab	87	84 (96.6)	5.40 (1.11)	1.8	4.64	5.55	6.27	7.0	
			Placebo	94	87 (92.6)	4.95 (1.12)	2.7	3.91	5.00	5.73	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	87	76 (87.4)	0.64 (1.00)	-2.8	0.00	0.55	1.27	3.2	0.27 [-0.05, 0.59]
			Placebo	94	79 (84.0)	0.39 (0.79)	-1.5	-0.09	0.36	0.82	2.5	
		Week 8	Tezepelumab	87	78 (89.7)	0.80 (1.03)	-1.5	0.00	0.68	1.45	3.7	0.24 [-0.07, 0.56]
			Placebo	94	79 (84.0)	0.56 (0.95)	-1.7	0.00	0.55	1.09	3.3	
		Week 12	Tezepelumab	87	78 (89.7)	1.03 (1.06)	-1.5	0.36	1.00	1.55	4.2	0.33 [0.02, 0.65]
			Placebo	94	79 (84.0)	0.68 (1.04)	-1.9	0.00	0.64	1.18	3.7	
		Week 16	Tezepelumab	87	78 (89.7)	0.96 (1.02)	-1.6	0.27	0.91	1.55	3.5	0.18 [-0.13, 0.50]
			Placebo	94	79 (84.0)	0.77 (1.02)	-1.9	0.18	0.82	1.27	3.9	
		Week 20	Tezepelumab	87	78 (89.7)	0.90 (1.13)	-2.1	0.09	0.86	1.73	3.5	0.13 [-0.18, 0.44]
			Placebo	94	79 (84.0)	0.76 (1.03)	-1.6	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	87	78 (89.7)	1.00 (1.06)	-1.4	0.18	0.95	1.64	3.5	0.20 [-0.11, 0.51]
			Placebo	94	79 (84.0)	0.80 (1.02)	-1.6	0.18	0.82	1.36	3.8	
		Week 28	Tezepelumab	87	78 (89.7)	0.97 (1.07)	-1.1	0.09	0.86	1.73	3.5	0.15 [-0.17, 0.46]
			Placebo	94	79 (84.0)	0.82 (1.06)	-1.6	0.18	0.82	1.36	4.0	
		Week 32	Tezepelumab	87	78 (89.7)	1.03 (1.09)	-1.1	0.18	0.95	1.91	3.5	0.17 [-0.14, 0.49]
			Placebo	94	79 (84.0)	0.85 (1.05)	-1.8	0.27	0.82	1.45	3.6	
		Week 36	Tezepelumab	87	78 (89.7)	1.03 (1.11)	-0.7	0.00	0.91	1.73	3.5	0.16 [-0.16, 0.47]
			Placebo	94	79 (84.0)	0.86 (1.07)	-1.6	0.18	0.82	1.45	3.5	
		Week 40	Tezepelumab	87	78 (89.7)	1.06 (1.07)	-1.0	0.18	1.00	1.82	3.5	0.16 [-0.15, 0.47]
			Placebo	94	79 (84.0)	0.88 (1.15)	-1.6	0.18	0.82	1.45	4.0	
		Week 44	Tezepelumab	87	78 (89.7)	1.08 (1.07)	-0.7	0.18	1.00	1.73	3.5	0.21 [-0.10, 0.53]
			Placebo	94	79 (84.0)	0.84 (1.14)	-1.6	0.09	0.73	1.36	3.9	
		Week 48	Tezepelumab	87	78 (89.7)	1.16 (1.07)	-0.7	0.27	1.23	1.91	3.5	0.27 [-0.04, 0.58]
			Placebo	94	79 (84.0)	0.87 (1.05)	-1.6	0.18	0.82	1.27	3.6	
		Week 52	Tezepelumab	87	78 (89.7)	1.14 (1.07)	-0.7	0.27	1.05	1.91	3.5	0.26 [-0.05, 0.58]
			Placebo	94	79 (84.0)	0.85 (1.08)	-1.6	0.09	0.91	1.27	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	114	103 (90.4)	4.30 (0.96)	1.9	3.73	4.27	4.82	7.0	
			Placebo	118	105 (89.0)	4.13 (0.88)	2.0	3.64	4.09	4.45	6.2	
		Week 4	Tezepelumab	114	106 (93.0)	4.96 (1.14)	1.6	4.09	4.95	5.82	7.0	
			Placebo	118	106 (89.8)	4.70 (1.05)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	114	108 (94.7)	5.16 (1.14)	1.6	4.27	5.18	6.09	7.0	
			Placebo	118	109 (92.4)	4.82 (1.14)	2.2	4.00	4.64	5.64	7.0	
		Week 12	Tezepelumab	114	108 (94.7)	5.38 (1.15)	1.7	4.59	5.27	6.36	7.0	
			Placebo	118	110 (93.2)	5.00 (1.11)	2.8	4.09	4.91	6.00	7.0	
		Week 16	Tezepelumab	114	108 (94.7)	5.32 (1.12)	2.6	4.27	5.36	6.27	7.0	
			Placebo	118	110 (93.2)	5.02 (1.18)	1.1	4.09	4.91	6.00	7.0	
		Week 20	Tezepelumab	114	108 (94.7)	5.28 (1.19)	1.8	4.32	5.32	6.27	7.0	
			Placebo	118	110 (93.2)	4.99 (1.13)	1.1	4.09	4.82	5.91	7.0	
		Week 24	Tezepelumab	114	108 (94.7)	5.33 (1.19)	1.6	4.27	5.41	6.27	7.0	
			Placebo	118	110 (93.2)	5.02 (1.17)	1.1	4.18	4.95	6.00	7.0	
		Week 28	Tezepelumab	114	110 (96.5)	5.34 (1.15)	2.1	4.36	5.45	6.27	7.0	
			Placebo	118	110 (93.2)	5.01 (1.23)	1.1	4.00	4.95	6.00	7.0	
		Week 32	Tezepelumab	114	111 (97.4)	5.40 (1.15)	1.6	4.36	5.73	6.27	7.0	
			Placebo	118	111 (94.1)	5.06 (1.14)	1.1	4.09	5.00	6.00	7.0	
		Week 36	Tezepelumab	114	111 (97.4)	5.36 (1.16)	1.9	4.36	5.55	6.27	7.0	
			Placebo	118	111 (94.1)	5.07 (1.15)	2.4	4.09	4.91	6.09	7.0	
		Week 40	Tezepelumab	114	111 (97.4)	5.42 (1.13)	2.1	4.36	5.45	6.27	7.0	
			Placebo	118	111 (94.1)	5.12 (1.15)	2.5	4.09	5.18	6.09	7.0	
		Week 44	Tezepelumab	114	111 (97.4)	5.41 (1.15)	2.4	4.36	5.45	6.36	7.0	
			Placebo	118	111 (94.1)	5.11 (1.17)	2.7	4.00	5.09	6.00	7.0	
		Week 48	Tezepelumab	114	111 (97.4)	5.43 (1.14)	2.6	4.36	5.55	6.45	7.0	
			Placebo	118	112 (94.9)	5.09 (1.12)	2.4	4.14	5.05	6.00	7.0	
		Week 52	Tezepelumab	114	111 (97.4)	5.39 (1.17)	1.8	4.36	5.45	6.36	7.0	
			Placebo	118	112 (94.9)	5.08 (1.13)	2.7	4.14	5.09	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	114	99 (86.8)	0.69 (1.02)	-2.8	0.00	0.55	1.45	3.2	0.13 [-0.15, 0.40]
			Placebo	118	103 (87.3)	0.56 (0.88)	-1.5	0.09	0.45	1.09	2.6	
		Week 8	Tezepelumab	114	101 (88.6)	0.85 (1.07)	-1.5	0.00	0.73	1.55	3.7	0.14 [-0.13, 0.42]
			Placebo	118	104 (88.1)	0.70 (0.94)	-1.7	0.00	0.68	1.27	3.3	
		Week 12	Tezepelumab	114	101 (88.6)	1.08 (1.07)	-1.5	0.36	1.09	1.64	4.2	0.19 [-0.09, 0.46]
			Placebo	118	104 (88.1)	0.88 (1.01)	-1.9	0.27	0.91	1.27	3.7	
		Week 16	Tezepelumab	114	101 (88.6)	1.03 (1.08)	-1.7	0.27	1.00	1.64	3.5	0.11 [-0.17, 0.38]
			Placebo	118	104 (88.1)	0.92 (1.05)	-3.2	0.36	0.91	1.59	3.9	
		Week 20	Tezepelumab	114	101 (88.6)	0.99 (1.14)	-2.1	0.18	1.00	1.73	3.5	0.09 [-0.18, 0.36]
			Placebo	118	104 (88.1)	0.90 (1.03)	-3.2	0.27	0.82	1.45	4.0	
		Week 24	Tezepelumab	114	101 (88.6)	1.06 (1.09)	-1.4	0.27	1.09	1.64	3.5	0.13 [-0.14, 0.41]
			Placebo	118	104 (88.1)	0.92 (1.07)	-3.2	0.36	0.91	1.55	3.8	
		Week 28	Tezepelumab	114	101 (88.6)	1.06 (1.08)	-1.1	0.18	0.91	1.82	3.5	0.14 [-0.13, 0.41]
			Placebo	118	104 (88.1)	0.91 (1.12)	-3.2	0.32	0.86	1.55	4.0	
		Week 32	Tezepelumab	114	101 (88.6)	1.11 (1.07)	-1.1	0.36	1.09	1.91	3.5	0.12 [-0.16, 0.39]
			Placebo	118	104 (88.1)	0.98 (1.05)	-3.2	0.36	0.95	1.55	3.6	
		Week 36	Tezepelumab	114	101 (88.6)	1.07 (1.12)	-0.9	0.18	1.00	1.73	3.5	0.08 [-0.20, 0.35]
			Placebo	118	104 (88.1)	0.99 (1.05)	-1.8	0.32	0.91	1.68	3.5	
		Week 40	Tezepelumab	114	101 (88.6)	1.12 (1.07)	-1.0	0.27	1.09	1.82	3.5	0.07 [-0.20, 0.35]
			Placebo	118	104 (88.1)	1.04 (1.08)	-1.6	0.27	0.95	1.68	4.0	
		Week 44	Tezepelumab	114	101 (88.6)	1.13 (1.08)	-1.1	0.27	1.00	1.82	3.5	0.10 [-0.18, 0.37]
			Placebo	118	104 (88.1)	1.02 (1.11)	-1.6	0.36	0.95	1.68	3.9	
		Week 48	Tezepelumab	114	101 (88.6)	1.15 (1.07)	-1.0	0.36	1.00	1.91	3.5	0.14 [-0.13, 0.42]
			Placebo	118	104 (88.1)	1.00 (1.06)	-1.6	0.27	1.00	1.64	3.6	
		Week 52	Tezepelumab	114	101 (88.6)	1.09 (1.09)	-1.2	0.27	1.00	1.82	3.5	0.08 [-0.20, 0.35]
			Placebo	118	104 (88.1)	1.01 (1.05)	-1.6	0.27	1.00	1.64	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	4.24 (0.68)	3.1	3.91	4.09	4.45	5.8	
			Placebo	20	16 (80.0)	4.25 (0.88)	2.7	3.55	4.23	4.68	6.1	
		Week 4	Tezepelumab	23	20 (87.0)	4.96 (0.81)	3.8	4.32	4.91	5.36	7.0	
			Placebo	20	17 (85.0)	4.20 (0.83)	3.3	3.45	4.00	4.82	6.1	
		Week 8	Tezepelumab	23	20 (87.0)	5.06 (0.85)	3.7	4.41	5.05	5.50	7.0	
			Placebo	20	17 (85.0)	4.42 (0.81)	2.8	3.91	4.18	5.09	6.0	
		Week 12	Tezepelumab	23	20 (87.0)	5.06 (0.91)	3.2	4.45	5.14	5.64	7.0	
			Placebo	20	17 (85.0)	4.18 (0.80)	3.1	3.55	4.00	4.64	6.3	
		Week 16	Tezepelumab	23	20 (87.0)	5.07 (0.83)	3.9	4.41	5.18	5.45	7.0	
			Placebo	20	17 (85.0)	4.40 (0.99)	2.9	3.91	4.09	5.18	6.5	
		Week 20	Tezepelumab	23	21 (91.3)	5.00 (0.88)	3.5	4.36	4.91	5.73	7.0	
			Placebo	20	17 (85.0)	4.33 (1.04)	2.1	3.82	4.27	4.91	6.7	
		Week 24	Tezepelumab	23	21 (91.3)	5.13 (0.84)	3.9	4.55	5.00	5.73	7.0	
			Placebo	20	17 (85.0)	4.48 (1.07)	2.0	3.91	4.55	5.27	6.1	
		Week 28	Tezepelumab	23	21 (91.3)	5.13 (0.78)	4.0	4.64	5.00	5.64	7.0	
			Placebo	20	18 (90.0)	4.53 (1.26)	2.0	3.73	4.45	5.18	6.8	
		Week 32	Tezepelumab	23	21 (91.3)	5.16 (0.76)	3.9	4.64	5.00	5.64	7.0	
			Placebo	20	18 (90.0)	4.58 (1.28)	1.7	4.00	4.14	5.18	7.0	
		Week 36	Tezepelumab	23	21 (91.3)	5.23 (0.68)	4.2	4.73	5.09	5.55	6.8	
			Placebo	20	18 (90.0)	4.68 (1.19)	2.5	3.91	4.45	5.45	6.9	
		Week 40	Tezepelumab	23	21 (91.3)	5.19 (0.81)	3.8	4.91	5.09	5.64	7.0	
			Placebo	20	18 (90.0)	4.46 (1.21)	2.0	3.73	4.18	5.27	6.9	
		Week 44	Tezepelumab	23	21 (91.3)	5.39 (0.78)	3.9	4.91	5.36	6.00	7.0	
			Placebo	20	18 (90.0)	4.59 (1.24)	2.5	3.82	4.41	5.27	7.0	
		Week 48	Tezepelumab	23	21 (91.3)	5.45 (0.79)	3.9	4.91	5.45	5.73	7.0	
			Placebo	20	18 (90.0)	4.72 (1.21)	2.3	3.82	4.64	5.73	6.8	
		Week 52	Tezepelumab	23	21 (91.3)	5.48 (0.72)	4.0	5.18	5.45	5.73	7.0	
			Placebo	20	18 (90.0)	4.70 (1.15)	2.9	3.91	4.41	5.73	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	23	18 (78.3)	0.79 (0.88)	-1.4	0.55	0.82	1.18	3.1	1.11 [0.39, 1.84]
			Placebo	20	16 (80.0)	-0.02 (0.49)	-1.0	-0.23	0.00	0.36	0.7	
		Week 8	Tezepelumab	23	18 (78.3)	0.84 (0.84)	-0.6	0.18	0.82	1.18	3.1	0.88 [0.17, 1.59]
			Placebo	20	16 (80.0)	0.20 (0.58)	-1.3	-0.05	0.27	0.59	1.1	
		Week 12	Tezepelumab	23	18 (78.3)	0.79 (0.86)	-0.5	0.36	0.45	1.18	3.1	1.13 [0.40, 1.86]
			Placebo	20	16 (80.0)	-0.05 (0.58)	-1.4	-0.27	0.00	0.18	1.2	
		Week 16	Tezepelumab	23	18 (78.3)	0.88 (0.79)	-0.4	0.36	0.82	1.27	3.1	0.97 [0.26, 1.68]
			Placebo	20	16 (80.0)	0.14 (0.74)	-1.0	-0.64	0.14	0.59	1.5	
		Week 20	Tezepelumab	23	18 (78.3)	0.73 (0.89)	-0.6	0.09	0.77	1.00	3.1	0.79 [0.09, 1.49]
			Placebo	20	16 (80.0)	0.10 (0.68)	-1.5	-0.32	0.18	0.68	1.0	
		Week 24	Tezepelumab	23	18 (78.3)	0.99 (0.84)	-0.3	0.36	0.82	1.45	3.1	0.86 [0.16, 1.57]
			Placebo	20	16 (80.0)	0.24 (0.92)	-1.5	-0.18	0.14	0.55	2.5	
		Week 28	Tezepelumab	23	18 (78.3)	0.94 (0.90)	-0.5	0.45	0.91	1.36	3.1	0.88 [0.17, 1.59]
			Placebo	20	16 (80.0)	0.18 (0.82)	-1.5	-0.32	-0.05	0.68	1.7	
		Week 32	Tezepelumab	23	18 (78.3)	0.95 (0.85)	-0.3	0.36	0.77	1.36	3.1	0.88 [0.18, 1.59]
			Placebo	20	16 (80.0)	0.18 (0.89)	-1.8	-0.41	0.27	0.77	1.5	
		Week 36	Tezepelumab	23	18 (78.3)	1.00 (0.86)	-0.8	0.64	0.82	1.73	2.9	0.72 [0.03, 1.42]
			Placebo	20	16 (80.0)	0.30 (1.08)	-1.0	-0.50	0.09	0.86	3.3	
		Week 40	Tezepelumab	23	18 (78.3)	1.01 (0.88)	-0.5	0.36	1.00	1.36	3.1	0.92 [0.21, 1.63]
			Placebo	20	16 (80.0)	0.10 (1.11)	-1.5	-0.45	0.00	0.68	3.1	
		Week 44	Tezepelumab	23	18 (78.3)	1.19 (0.95)	-0.5	0.36	1.09	1.82	3.1	1.10 [0.37, 1.82]
			Placebo	20	16 (80.0)	0.17 (0.90)	-1.1	-0.55	0.14	0.68	2.5	
		Week 48	Tezepelumab	23	18 (78.3)	1.29 (0.96)	-0.5	0.82	1.23	1.73	3.1	1.00 [0.28, 1.71]
			Placebo	20	16 (80.0)	0.34 (0.94)	-1.3	-0.05	0.18	0.59	3.2	
		Week 52	Tezepelumab	23	18 (78.3)	1.25 (0.95)	-0.5	0.64	1.09	2.09	3.1	0.99 [0.28, 1.71]
			Placebo	20	16 (80.0)	0.32 (0.91)	-0.8	-0.32	0.27	0.64	3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	105	94 (89.5)	4.33 (0.90)	2.1	3.91	4.27	4.82	7.0	
			Placebo	110	98 (89.1)	4.18 (0.89)	2.0	3.64	4.18	4.64	6.2	
		Week 4	Tezepelumab	105	96 (91.4)	4.95 (1.07)	3.1	4.09	4.91	5.77	7.0	
			Placebo	110	100 (90.9)	4.67 (1.08)	2.5	3.91	4.59	5.45	7.0	
		Week 8	Tezepelumab	105	97 (92.4)	5.15 (1.06)	2.9	4.27	5.00	6.00	7.0	
			Placebo	110	102 (92.7)	4.83 (1.12)	2.2	4.00	4.64	5.64	7.0	
		Week 12	Tezepelumab	105	97 (92.4)	5.29 (1.10)	3.2	4.36	5.18	6.27	7.0	
			Placebo	110	103 (93.6)	4.90 (1.13)	2.8	4.00	4.73	5.91	7.0	
		Week 16	Tezepelumab	105	97 (92.4)	5.24 (1.08)	3.4	4.27	5.09	6.09	7.0	
			Placebo	110	103 (93.6)	4.97 (1.12)	2.9	4.00	4.82	6.00	7.0	
		Week 20	Tezepelumab	105	98 (93.3)	5.20 (1.11)	2.1	4.36	5.23	6.00	7.0	
			Placebo	110	103 (93.6)	4.97 (1.11)	2.1	4.09	4.82	5.82	7.0	
		Week 24	Tezepelumab	105	98 (93.3)	5.26 (1.17)	1.6	4.27	5.18	6.27	7.0	
			Placebo	110	103 (93.6)	5.04 (1.13)	2.0	4.18	4.91	6.00	7.0	
		Week 28	Tezepelumab	105	99 (94.3)	5.25 (1.10)	2.9	4.36	5.27	6.09	7.0	
			Placebo	110	104 (94.5)	5.01 (1.18)	2.0	4.00	4.82	6.00	7.0	
		Week 32	Tezepelumab	105	100 (95.2)	5.32 (1.09)	2.5	4.36	5.36	6.18	7.0	
			Placebo	110	104 (94.5)	5.06 (1.15)	1.7	4.09	4.91	6.00	7.0	
		Week 36	Tezepelumab	105	100 (95.2)	5.33 (1.08)	3.0	4.41	5.36	6.18	7.0	
			Placebo	110	104 (94.5)	5.12 (1.14)	2.5	4.09	4.95	6.09	7.0	
		Week 40	Tezepelumab	105	100 (95.2)	5.35 (1.07)	3.2	4.36	5.32	6.18	7.0	
			Placebo	110	104 (94.5)	5.09 (1.18)	2.0	4.00	5.09	6.09	7.0	
		Week 44	Tezepelumab	105	100 (95.2)	5.36 (1.10)	3.0	4.41	5.36	6.27	7.0	
			Placebo	110	104 (94.5)	5.11 (1.20)	2.5	4.00	5.00	6.05	7.0	
		Week 48	Tezepelumab	105	100 (95.2)	5.38 (1.12)	2.6	4.36	5.36	6.41	7.0	
			Placebo	110	105 (95.5)	5.11 (1.15)	2.3	4.00	5.09	6.00	7.0	
		Week 52	Tezepelumab	105	100 (95.2)	5.37 (1.10)	2.6	4.41	5.45	6.18	7.0	
			Placebo	110	105 (95.5)	5.08 (1.14)	2.9	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	105	89 (84.8)	0.65 (0.95)	-1.4	0.00	0.55	1.27	3.2	0.16 [-0.13, 0.44]
			Placebo	110	98 (89.1)	0.51 (0.89)	-1.5	-0.09	0.36	0.91	2.6	
		Week 8	Tezepelumab	105	90 (85.7)	0.81 (0.98)	-1.5	0.09	0.68	1.45	3.7	0.16 [-0.12, 0.45]
			Placebo	110	98 (89.1)	0.66 (0.90)	-1.7	0.00	0.55	1.09	3.3	
		Week 12	Tezepelumab	105	90 (85.7)	0.98 (1.01)	-0.9	0.36	0.91	1.45	4.2	0.24 [-0.05, 0.52]
			Placebo	110	98 (89.1)	0.74 (1.00)	-1.9	0.09	0.68	1.18	3.7	
		Week 16	Tezepelumab	105	90 (85.7)	0.94 (0.97)	-1.3	0.18	0.86	1.55	3.5	0.12 [-0.16, 0.41]
			Placebo	110	98 (89.1)	0.82 (0.96)	-1.9	0.27	0.68	1.45	3.9	
		Week 20	Tezepelumab	105	90 (85.7)	0.90 (1.07)	-2.1	0.18	0.86	1.64	3.5	0.06 [-0.22, 0.35]
			Placebo	110	98 (89.1)	0.83 (0.96)	-1.5	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	105	90 (85.7)	0.99 (1.03)	-1.4	0.18	0.91	1.64	3.5	0.10 [-0.19, 0.38]
			Placebo	110	98 (89.1)	0.90 (1.02)	-1.5	0.27	0.82	1.55	3.8	
		Week 28	Tezepelumab	105	90 (85.7)	0.98 (1.04)	-1.1	0.09	0.82	1.73	3.5	0.13 [-0.16, 0.42]
			Placebo	110	98 (89.1)	0.84 (0.99)	-1.5	0.18	0.77	1.45	4.0	
		Week 32	Tezepelumab	105	90 (85.7)	1.03 (1.02)	-1.1	0.36	0.91	1.64	3.5	0.13 [-0.16, 0.41]
			Placebo	110	98 (89.1)	0.90 (1.00)	-1.8	0.27	0.82	1.55	3.6	
		Week 36	Tezepelumab	105	90 (85.7)	1.03 (1.05)	-0.9	0.18	0.95	1.73	3.5	0.06 [-0.22, 0.35]
			Placebo	110	98 (89.1)	0.96 (1.04)	-1.2	0.18	0.82	1.64	3.5	
		Week 40	Tezepelumab	105	90 (85.7)	1.06 (1.00)	-1.0	0.27	1.00	1.73	3.5	0.12 [-0.17, 0.41]
			Placebo	110	98 (89.1)	0.93 (1.08)	-1.5	0.18	0.82	1.45	4.0	
		Week 44	Tezepelumab	105	90 (85.7)	1.06 (1.03)	-1.1	0.27	0.95	1.73	3.5	0.11 [-0.17, 0.40]
			Placebo	110	98 (89.1)	0.94 (1.08)	-1.2	0.27	0.82	1.64	3.9	
		Week 48	Tezepelumab	105	90 (85.7)	1.10 (1.04)	-1.0	0.36	1.00	1.91	3.5	0.15 [-0.14, 0.43]
			Placebo	110	98 (89.1)	0.95 (1.02)	-1.3	0.18	0.82	1.45	3.6	
		Week 52	Tezepelumab	105	90 (85.7)	1.06 (1.03)	-1.2	0.27	0.91	1.82	3.5	0.15 [-0.14, 0.43]
			Placebo	110	98 (89.1)	0.91 (1.01)	-1.2	0.18	0.82	1.45	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	32	29 (90.6)	4.15 (0.98)	1.9	3.64	4.09	4.64	6.2	
			Placebo	28	23 (82.1)	4.00 (0.82)	2.6	3.27	3.91	4.45	6.0	
		Week 4	Tezepelumab	32	30 (93.8)	4.98 (1.17)	1.6	4.18	5.27	5.82	6.9	
			Placebo	28	23 (82.1)	4.42 (0.78)	3.2	3.82	4.27	5.00	5.8	
		Week 8	Tezepelumab	32	31 (96.9)	5.15 (1.21)	1.6	4.27	5.27	6.09	6.9	
			Placebo	28	24 (85.7)	4.52 (1.06)	2.3	3.68	4.64	5.18	6.7	
		Week 12	Tezepelumab	32	31 (96.9)	5.43 (1.19)	1.7	4.91	5.36	6.36	7.0	
			Placebo	28	24 (85.7)	4.86 (1.02)	2.8	4.05	4.73	5.77	6.5	
		Week 16	Tezepelumab	32	31 (96.9)	5.44 (1.09)	2.6	5.00	5.55	6.18	7.0	
			Placebo	28	24 (85.7)	4.78 (1.40)	1.1	4.00	5.00	5.77	7.0	
		Week 20	Tezepelumab	32	31 (96.9)	5.35 (1.25)	1.8	4.27	5.64	6.27	7.0	
			Placebo	28	24 (85.7)	4.62 (1.25)	1.1	4.00	4.45	5.55	6.7	
		Week 24	Tezepelumab	32	31 (96.9)	5.44 (1.06)	3.0	4.82	5.55	6.27	7.0	
			Placebo	28	24 (85.7)	4.53 (1.26)	1.1	3.95	4.32	5.45	6.9	
		Week 28	Tezepelumab	32	32 (100.0)	5.49 (1.09)	2.1	4.91	5.68	6.27	7.0	
			Placebo	28	24 (85.7)	4.63 (1.47)	1.1	3.77	4.68	5.91	7.0	
		Week 32	Tezepelumab	32	32 (100.0)	5.49 (1.14)	1.6	4.86	5.82	6.32	7.0	
			Placebo	28	25 (89.3)	4.71 (1.25)	1.1	4.09	4.55	5.82	6.5	
		Week 36	Tezepelumab	32	32 (100.0)	5.39 (1.16)	1.9	4.55	5.55	6.32	7.0	
			Placebo	28	25 (89.3)	4.58 (1.16)	2.4	3.91	4.45	5.36	6.5	
		Week 40	Tezepelumab	32	32 (100.0)	5.49 (1.14)	2.1	4.95	5.55	6.36	7.0	
			Placebo	28	25 (89.3)	4.77 (1.17)	2.5	4.09	4.36	5.64	6.8	
		Week 44	Tezepelumab	32	32 (100.0)	5.56 (1.08)	2.4	5.18	5.59	6.32	7.0	
			Placebo	28	25 (89.3)	4.74 (1.13)	2.9	3.91	4.55	5.55	6.6	
		Week 48	Tezepelumab	32	32 (100.0)	5.58 (0.98)	3.5	4.95	5.77	6.36	7.0	
			Placebo	28	25 (89.3)	4.74 (1.06)	2.4	4.09	4.55	5.45	6.6	
		Week 52	Tezepelumab	32	32 (100.0)	5.50 (1.16)	1.8	4.95	5.73	6.45	7.0	
			Placebo	28	25 (89.3)	4.82 (1.11)	2.7	4.09	4.55	5.64	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	32	28 (87.5)	0.86 (1.14)	-2.8	0.23	1.00	1.45	2.9	0.49 [-0.09, 1.06]
			Placebo	28	21 (75.0)	0.38 (0.69)	-1.5	0.09	0.36	0.82	1.7	
		Week 8	Tezepelumab	32	29 (90.6)	0.95 (1.21)	-1.3	0.09	1.09	1.64	3.5	0.38 [-0.18, 0.94]
			Placebo	28	22 (78.6)	0.52 (1.00)	-1.3	-0.18	0.68	1.00	2.5	
		Week 12	Tezepelumab	32	29 (90.6)	1.21 (1.15)	-1.5	0.36	1.45	1.82	3.5	0.34 [-0.22, 0.89]
			Placebo	28	22 (78.6)	0.83 (1.09)	-1.3	0.27	0.91	1.27	3.3	
		Week 16	Tezepelumab	32	29 (90.6)	1.21 (1.22)	-1.7	0.55	1.45	1.64	3.5	0.35 [-0.21, 0.90]
			Placebo	28	22 (78.6)	0.76 (1.39)	-3.2	0.64	1.00	1.55	3.5	
		Week 20	Tezepelumab	32	29 (90.6)	1.13 (1.21)	-0.7	0.27	1.09	2.00	3.5	0.43 [-0.14, 0.99]
			Placebo	28	22 (78.6)	0.60 (1.30)	-3.2	0.09	0.91	1.27	2.7	
		Week 24	Tezepelumab	32	29 (90.6)	1.24 (1.11)	-0.7	0.64	1.09	1.82	3.5	0.59 [0.02, 1.16]
			Placebo	28	22 (78.6)	0.54 (1.27)	-3.2	0.09	0.82	1.27	2.9	
		Week 28	Tezepelumab	32	29 (90.6)	1.26 (1.09)	-0.8	0.64	1.27	2.00	3.5	0.45 [-0.11, 1.02]
			Placebo	28	22 (78.6)	0.67 (1.55)	-3.2	-0.18	0.95	1.55	3.7	
		Week 32	Tezepelumab	32	29 (90.6)	1.26 (1.12)	-0.7	0.64	1.09	1.91	3.5	0.40 [-0.16, 0.96]
			Placebo	28	22 (78.6)	0.77 (1.33)	-3.2	0.55	1.00	1.64	3.3	
		Week 36	Tezepelumab	32	29 (90.6)	1.17 (1.19)	-0.7	0.36	1.27	1.91	3.5	0.46 [-0.10, 1.02]
			Placebo	28	22 (78.6)	0.62 (1.20)	-1.8	0.09	0.91	1.18	2.7	
		Week 40	Tezepelumab	32	29 (90.6)	1.24 (1.15)	-0.9	0.45	1.27	1.82	3.5	0.32 [-0.23, 0.88]
			Placebo	28	22 (78.6)	0.83 (1.34)	-1.6	0.18	0.95	1.64	3.5	
		Week 44	Tezepelumab	32	29 (90.6)	1.37 (1.13)	-0.7	0.45	1.36	2.09	3.5	0.51 [-0.05, 1.08]
			Placebo	28	22 (78.6)	0.75 (1.30)	-1.6	-0.27	0.91	1.36	3.4	
		Week 48	Tezepelumab	32	29 (90.6)	1.40 (1.09)	-0.7	0.45	1.45	1.91	3.5	0.55 [-0.02, 1.11]
			Placebo	28	22 (78.6)	0.76 (1.26)	-1.6	0.09	1.00	1.36	3.2	
		Week 52	Tezepelumab	32	29 (90.6)	1.28 (1.19)	-1.2	0.45	1.36	1.91	3.5	0.27 [-0.28, 0.83]
			Placebo	28	22 (78.6)	0.95 (1.27)	-1.6	0.09	1.09	2.00	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.30 (0.91)	1.9	3.73	4.27	4.73	7.0	
			Placebo	123	106 (86.2)	4.20 (0.86)	2.0	3.73	4.14	4.64	6.2	
		Week 4	Tezepelumab	128	117 (91.4)	4.94 (1.11)	1.6	4.09	4.91	5.82	7.0	
			Placebo	123	109 (88.6)	4.66 (1.05)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	128	119 (93.0)	5.12 (1.12)	1.6	4.27	5.09	6.09	7.0	
			Placebo	123	112 (91.1)	4.78 (1.08)	2.3	4.00	4.59	5.50	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.30 (1.13)	1.7	4.36	5.27	6.27	7.0	
			Placebo	123	113 (91.9)	4.85 (1.10)	2.8	4.00	4.64	5.91	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.27 (1.10)	2.6	4.27	5.27	6.18	7.0	
			Placebo	123	113 (91.9)	4.94 (1.15)	1.1	4.00	4.82	5.91	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.20 (1.15)	1.8	4.27	5.23	6.09	7.0	
			Placebo	123	113 (91.9)	4.89 (1.15)	1.1	4.09	4.64	5.73	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.26 (1.16)	1.6	4.27	5.18	6.27	7.0	
			Placebo	123	113 (91.9)	4.92 (1.18)	1.1	4.18	4.73	5.82	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.26 (1.10)	2.1	4.36	5.27	6.09	7.0	
			Placebo	123	114 (92.7)	4.89 (1.24)	1.1	3.91	4.77	6.00	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.32 (1.11)	1.6	4.36	5.36	6.18	7.0	
			Placebo	123	115 (93.5)	4.94 (1.19)	1.1	4.00	4.73	6.00	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.31 (1.10)	1.9	4.36	5.45	6.18	7.0	
			Placebo	123	115 (93.5)	5.01 (1.17)	2.4	4.00	4.82	6.09	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.34 (1.10)	2.1	4.36	5.27	6.18	7.0	
			Placebo	123	115 (93.5)	5.00 (1.18)	2.0	4.00	4.91	6.00	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.37 (1.11)	2.4	4.45	5.36	6.27	7.0	
			Placebo	123	115 (93.5)	5.02 (1.18)	2.5	4.00	4.91	6.00	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.41 (1.10)	2.6	4.36	5.45	6.45	7.0	
			Placebo	123	116 (94.3)	5.02 (1.15)	2.3	4.00	4.95	5.91	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.37 (1.12)	1.8	4.45	5.45	6.27	7.0	
			Placebo	123	116 (94.3)	4.99 (1.15)	2.7	4.00	4.91	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.67 (0.99)	-2.8	0.00	0.55	1.27	3.2	0.20 [-0.07, 0.47]
			Placebo	123	105 (85.4)	0.48 (0.88)	-1.5	-0.09	0.36	0.91	2.6	
		Week 8	Tezepelumab	128	111 (86.7)	0.81 (1.02)	-1.5	0.00	0.73	1.45	3.5	0.21 [-0.06, 0.48]
			Placebo	123	106 (86.2)	0.61 (0.88)	-1.7	0.00	0.59	1.09	2.8	
		Week 12	Tezepelumab	128	111 (86.7)	0.99 (1.02)	-1.5	0.36	1.00	1.55	3.5	0.32 [0.05, 0.59]
			Placebo	123	106 (86.2)	0.67 (0.98)	-1.9	0.09	0.64	1.18	3.1	
		Week 16	Tezepelumab	128	111 (86.7)	0.98 (1.03)	-1.7	0.27	0.91	1.55	3.5	0.20 [-0.06, 0.47]
			Placebo	123	106 (86.2)	0.77 (1.01)	-3.2	0.18	0.82	1.45	3.3	
		Week 20	Tezepelumab	128	111 (86.7)	0.92 (1.09)	-2.1	0.09	0.91	1.64	3.5	0.17 [-0.10, 0.43]
			Placebo	123	106 (86.2)	0.74 (1.00)	-3.2	0.18	0.73	1.27	3.4	
		Week 24	Tezepelumab	128	111 (86.7)	1.02 (1.04)	-1.4	0.18	1.00	1.64	3.5	0.24 [-0.03, 0.50]
			Placebo	123	106 (86.2)	0.77 (1.07)	-3.2	0.18	0.73	1.45	3.2	
		Week 28	Tezepelumab	128	111 (86.7)	0.99 (1.04)	-1.1	0.18	0.91	1.73	3.5	0.26 [-0.01, 0.53]
			Placebo	123	106 (86.2)	0.72 (1.06)	-3.2	0.09	0.77	1.36	3.1	
		Week 32	Tezepelumab	128	111 (86.7)	1.04 (1.03)	-1.1	0.27	1.00	1.82	3.5	0.26 [-0.01, 0.52]
			Placebo	123	106 (86.2)	0.78 (1.04)	-3.2	0.18	0.77	1.45	3.5	
		Week 36	Tezepelumab	128	111 (86.7)	1.03 (1.08)	-0.9	0.18	1.00	1.73	3.5	0.17 [-0.10, 0.43]
			Placebo	123	106 (86.2)	0.85 (1.07)	-1.8	0.18	0.82	1.45	3.5	
		Week 40	Tezepelumab	128	111 (86.7)	1.06 (1.03)	-1.0	0.27	1.00	1.73	3.5	0.20 [-0.06, 0.47]
			Placebo	123	106 (86.2)	0.85 (1.09)	-1.6	0.18	0.82	1.45	3.6	
		Week 44	Tezepelumab	128	111 (86.7)	1.10 (1.04)	-1.1	0.27	1.00	1.73	3.5	0.24 [-0.02, 0.51]
			Placebo	123	106 (86.2)	0.84 (1.06)	-1.6	0.18	0.82	1.45	3.6	
		Week 48	Tezepelumab	128	111 (86.7)	1.14 (1.05)	-1.0	0.36	1.09	1.91	3.5	0.28 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.85 (1.03)	-1.6	0.18	0.82	1.27	3.6	
		Week 52	Tezepelumab	128	111 (86.7)	1.08 (1.06)	-1.2	0.27	1.00	1.82	3.5	0.23 [-0.03, 0.50]
			Placebo	123	106 (86.2)	0.84 (1.01)	-1.6	0.18	0.82	1.27	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	4.06 (1.63)	2.2	2.18	5.00	5.00	5.0	
			Placebo	6	6 (100.0)	3.38 (0.58)	2.5	3.09	3.32	3.82	4.2	
		Week 4	Tezepelumab	3	3 (100.0)	5.85 (0.92)	5.3	5.27	5.36	6.91	6.9	
			Placebo	6	5 (83.3)	3.87 (0.76)	2.6	3.73	4.09	4.27	4.6	
		Week 8	Tezepelumab	3	3 (100.0)	5.88 (0.59)	5.3	5.27	5.91	6.45	6.5	
			Placebo	6	5 (83.3)	3.85 (1.24)	2.2	3.55	3.73	4.18	5.6	
		Week 12	Tezepelumab	3	3 (100.0)	6.00 (0.71)	5.2	5.18	6.36	6.45	6.5	
			Placebo	6	5 (83.3)	4.36 (1.34)	2.8	3.45	4.09	5.45	6.0	
		Week 16	Tezepelumab	3	3 (100.0)	5.45 (0.24)	5.2	5.18	5.55	5.64	5.6	
			Placebo	6	5 (83.3)	3.78 (1.35)	2.6	3.00	3.18	4.09	6.0	
		Week 20	Tezepelumab	3	3 (100.0)	6.00 (0.33)	5.6	5.64	6.09	6.27	6.3	
			Placebo	6	5 (83.3)	4.36 (1.10)	3.0	3.64	4.45	4.91	5.8	
		Week 24	Tezepelumab	3	3 (100.0)	5.88 (0.23)	5.6	5.64	5.91	6.09	6.1	
			Placebo	6	5 (83.3)	4.64 (0.77)	4.0	4.09	4.27	5.00	5.8	
		Week 28	Tezepelumab	3	3 (100.0)	6.18 (0.72)	5.6	5.64	5.91	7.00	7.0	
			Placebo	6	5 (83.3)	4.44 (0.81)	3.8	4.00	4.09	4.45	5.8	
		Week 32	Tezepelumab	3	3 (100.0)	5.85 (0.23)	5.6	5.64	5.82	6.09	6.1	
			Placebo	6	5 (83.3)	4.91 (0.73)	4.1	4.27	5.00	5.36	5.8	
		Week 36	Tezepelumab	3	3 (100.0)	5.82 (0.48)	5.5	5.45	5.64	6.36	6.4	
			Placebo	6	5 (83.3)	4.91 (0.68)	4.1	4.55	4.73	5.36	5.8	
		Week 40	Tezepelumab	3	3 (100.0)	5.85 (0.53)	5.5	5.45	5.64	6.45	6.5	
			Placebo	6	5 (83.3)	4.42 (0.83)	3.6	4.09	4.18	4.36	5.8	
		Week 44	Tezepelumab	3	3 (100.0)	5.70 (0.28)	5.5	5.45	5.64	6.00	6.0	
			Placebo	6	5 (83.3)	5.25 (1.22)	3.9	4.27	5.09	6.36	6.6	
		Week 48	Tezepelumab	3	3 (100.0)	5.97 (0.32)	5.6	5.64	6.00	6.27	6.3	
			Placebo	6	5 (83.3)	5.36 (1.35)	3.5	4.36	5.82	6.45	6.6	
		Week 52	Tezepelumab	3	3 (100.0)	5.97 (0.32)	5.6	5.64	6.00	6.27	6.3	
			Placebo	6	5 (83.3)	5.65 (1.28)	3.6	5.45	5.73	6.45	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.79 (1.37)	0.4	0.36	1.91	3.09	3.1	1.56 [-0.12, 3.24]
			Placebo	6	5 (83.3)	0.44 (0.44)	-0.1	0.09	0.45	0.82	0.9	
		Week 8	Tezepelumab	3	3 (100.0)	1.82 (1.76)	0.3	0.27	1.45	3.73	3.7	1.20 [-0.39, 2.78]
			Placebo	6	5 (83.3)	0.42 (0.71)	-0.4	-0.09	0.36	0.73	1.5	
		Week 12	Tezepelumab	3	3 (100.0)	1.94 (2.04)	0.2	0.18	1.45	4.18	4.2	0.75 [-0.74, 2.24]
			Placebo	6	5 (83.3)	0.93 (0.80)	0.0	0.27	0.91	1.64	1.8	
		Week 16	Tezepelumab	3	3 (100.0)	1.39 (1.79)	0.2	0.18	0.55	3.45	3.5	0.81 [-0.70, 2.31]
			Placebo	6	5 (83.3)	0.35 (0.96)	-0.5	-0.45	0.27	0.64	1.8	
		Week 20	Tezepelumab	3	3 (100.0)	1.94 (1.32)	1.1	1.09	1.27	3.45	3.5	1.01 [-0.53, 2.55]
			Placebo	6	5 (83.3)	0.93 (0.80)	-0.5	1.09	1.09	1.27	1.6	
		Week 24	Tezepelumab	3	3 (100.0)	1.82 (1.42)	0.9	0.91	1.09	3.45	3.5	0.68 [-0.80, 2.16]
			Placebo	6	5 (83.3)	1.20 (0.48)	0.6	0.82	1.18	1.64	1.7	
		Week 28	Tezepelumab	3	3 (100.0)	2.12 (1.28)	0.9	0.91	2.00	3.45	3.5	1.15 [-0.42, 2.73]
			Placebo	6	5 (83.3)	1.00 (0.77)	0.0	0.64	0.82	1.64	1.9	
		Week 32	Tezepelumab	3	3 (100.0)	1.79 (1.45)	0.8	0.82	1.09	3.45	3.5	0.31 [-1.13, 1.76]
			Placebo	6	5 (83.3)	1.47 (0.68)	0.6	1.09	1.55	1.64	2.5	
		Week 36	Tezepelumab	3	3 (100.0)	1.76 (1.54)	0.5	0.45	1.36	3.45	3.5	0.26 [-1.18, 1.70]
			Placebo	6	5 (83.3)	1.47 (0.76)	0.6	0.73	1.64	2.18	2.2	
		Week 40	Tezepelumab	3	3 (100.0)	1.79 (1.53)	0.5	0.45	1.45	3.45	3.5	0.73 [-0.76, 2.22]
			Placebo	6	5 (83.3)	0.98 (0.81)	-0.2	0.64	1.00	1.64	1.8	
		Week 44	Tezepelumab	3	3 (100.0)	1.64 (1.60)	0.5	0.45	1.00	3.45	3.5	-0.14 [-1.57, 1.30]
			Placebo	6	5 (83.3)	1.82 (1.18)	0.5	0.73	2.18	2.55	3.2	
		Week 48	Tezepelumab	3	3 (100.0)	1.91 (1.35)	1.0	1.00	1.27	3.45	3.5	-0.01 [-1.44, 1.42]
			Placebo	6	5 (83.3)	1.93 (1.49)	-0.3	1.18	2.27	3.18	3.3	
		Week 52	Tezepelumab	3	3 (100.0)	1.91 (1.35)	1.0	1.00	1.27	3.45	3.5	-0.22 [-1.65, 1.22]
			Placebo	6	5 (83.3)	2.22 (1.45)	-0.2	2.27	2.27	3.18	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	4.43 (0.96)	3.6	3.82	4.14	5.05	5.8	
			Placebo	6	6 (100.0)	4.53 (0.87)	3.0	4.27	4.73	5.09	5.4	
		Week 4	Tezepelumab	5	5 (100.0)	5.15 (0.75)	4.5	4.64	4.64	5.82	6.1	
			Placebo	6	6 (100.0)	5.20 (0.39)	4.5	4.91	5.36	5.45	5.5	
		Week 8	Tezepelumab	5	5 (100.0)	5.56 (0.55)	5.1	5.18	5.27	5.91	6.4	
			Placebo	6	6 (100.0)	5.48 (0.79)	4.2	5.00	5.64	6.18	6.3	
		Week 12	Tezepelumab	5	5 (100.0)	5.85 (0.90)	5.0	5.18	5.45	6.64	7.0	
			Placebo	6	6 (100.0)	5.92 (0.51)	5.3	5.55	5.91	6.18	6.7	
		Week 16	Tezepelumab	5	5 (100.0)	5.85 (0.74)	5.2	5.36	5.55	6.18	7.0	
			Placebo	6	6 (100.0)	5.88 (0.64)	4.9	5.64	5.91	6.00	6.9	
		Week 20	Tezepelumab	5	5 (100.0)	5.62 (1.27)	3.6	5.45	5.64	6.36	7.0	
			Placebo	6	6 (100.0)	5.55 (1.05)	3.8	5.09	5.77	5.82	7.0	
		Week 24	Tezepelumab	5	5 (100.0)	5.96 (0.78)	4.8	5.91	6.00	6.09	7.0	
			Placebo	6	6 (100.0)	5.74 (1.06)	4.1	4.91	5.95	6.73	6.8	
		Week 28	Tezepelumab	5	5 (100.0)	6.20 (0.50)	5.8	5.82	6.00	6.36	7.0	
			Placebo	6	6 (100.0)	6.11 (0.94)	4.6	5.45	6.32	6.91	7.0	
		Week 32	Tezepelumab	5	5 (100.0)	6.25 (0.49)	5.7	5.91	6.27	6.36	7.0	
			Placebo	6	6 (100.0)	6.11 (0.54)	5.5	5.64	6.05	6.64	6.8	
		Week 36	Tezepelumab	5	5 (100.0)	6.00 (1.00)	4.4	6.00	6.09	6.55	7.0	
			Placebo	6	6 (100.0)	5.47 (1.31)	3.3	4.64	5.86	6.36	6.8	
		Week 40	Tezepelumab	5	5 (100.0)	6.11 (0.61)	5.3	6.00	6.09	6.18	7.0	
			Placebo	6	6 (100.0)	5.80 (1.15)	4.1	5.09	5.86	6.91	7.0	
		Week 44	Tezepelumab	5	5 (100.0)	6.31 (0.41)	6.0	6.00	6.18	6.36	7.0	
			Placebo	6	6 (100.0)	5.39 (1.48)	3.4	4.00	5.55	6.91	7.0	
		Week 48	Tezepelumab	5	5 (100.0)	5.85 (0.93)	4.5	5.64	6.00	6.18	7.0	
			Placebo	6	6 (100.0)	5.30 (0.96)	3.8	4.82	5.27	6.18	6.5	
		Week 52	Tezepelumab	5	5 (100.0)	6.00 (0.94)	4.5	6.00	6.18	6.36	7.0	
			Placebo	6	6 (100.0)	5.29 (0.94)	3.8	4.82	5.27	6.18	6.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	0.84 (0.75)	0.0	0.32	0.77	1.36	1.8	0.18 [-1.08, 1.45]
			Placebo	6	6 (100.0)	0.67 (1.04)	-0.5	0.18	0.32	1.09	2.5	
		Week 8	Tezepelumab	5	4 (80.0)	1.23 (0.86)	0.1	0.59	1.36	1.86	2.1	0.25 [-1.02, 1.52]
			Placebo	6	6 (100.0)	0.95 (1.19)	-0.2	0.55	0.64	0.82	3.3	
		Week 12	Tezepelumab	5	4 (80.0)	1.64 (0.80)	0.8	1.14	1.50	2.14	2.7	0.23 [-1.04, 1.50]
			Placebo	6	6 (100.0)	1.39 (1.16)	0.8	0.82	0.86	1.27	3.7	
		Week 16	Tezepelumab	5	4 (80.0)	1.59 (0.99)	0.4	0.86	1.64	2.32	2.7	0.20 [-1.07, 1.47]
			Placebo	6	6 (100.0)	1.35 (1.34)	0.5	0.55	0.68	1.73	3.9	
		Week 20	Tezepelumab	5	4 (80.0)	1.23 (1.40)	-0.4	0.09	1.27	2.36	2.7	0.14 [-1.12, 1.41]
			Placebo	6	6 (100.0)	1.02 (1.53)	-0.5	0.45	0.68	0.73	4.0	
		Week 24	Tezepelumab	5	4 (80.0)	1.55 (1.19)	0.3	0.55	1.59	2.55	2.7	0.26 [-1.02, 1.53]
			Placebo	6	6 (100.0)	1.21 (1.37)	-0.2	0.55	0.86	1.36	3.8	
		Week 28	Tezepelumab	5	4 (80.0)	1.86 (0.95)	0.5	1.18	2.09	2.55	2.7	0.22 [-1.05, 1.49]
			Placebo	6	6 (100.0)	1.58 (1.44)	0.3	0.36	1.18	2.45	4.0	
		Week 32	Tezepelumab	5	4 (80.0)	1.82 (0.94)	0.5	1.14	2.00	2.50	2.7	0.23 [-1.04, 1.50]
			Placebo	6	6 (100.0)	1.58 (1.12)	0.5	0.82	1.27	1.91	3.6	
		Week 36	Tezepelumab	5	4 (80.0)	1.55 (1.17)	0.4	0.55	1.55	2.55	2.7	0.45 [-0.84, 1.73]
			Placebo	6	6 (100.0)	0.94 (1.45)	-1.0	0.27	0.77	1.45	3.4	
		Week 40	Tezepelumab	5	4 (80.0)	1.66 (1.17)	0.2	0.73	1.86	2.59	2.7	0.28 [-0.99, 1.55]
			Placebo	6	6 (100.0)	1.27 (1.48)	-0.2	0.27	1.00	1.55	4.0	
		Week 44	Tezepelumab	5	4 (80.0)	1.91 (1.20)	0.2	1.09	2.36	2.73	2.7	0.67 [-0.63, 1.98]
			Placebo	6	6 (100.0)	0.86 (1.72)	-0.9	-0.36	0.45	1.64	3.9	
		Week 48	Tezepelumab	5	4 (80.0)	1.48 (1.24)	0.4	0.41	1.41	2.55	2.7	0.69 [-0.62, 2.00]
			Placebo	6	6 (100.0)	0.77 (0.86)	-0.5	0.36	0.77	1.09	2.1	
		Week 52	Tezepelumab	5	4 (80.0)	1.48 (1.24)	0.4	0.41	1.41	2.55	2.7	0.71 [-0.61, 2.02]
			Placebo	6	6 (100.0)	0.76 (0.86)	-0.5	0.36	0.73	1.09	2.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	3.73	3.7	3.73	3.73	3.73	3.7	
			Placebo	3	3 (100.0)	3.03 (0.34)	2.6	2.64	3.18	3.27	3.3	
		Week 4	Tezepelumab	1	1 (100.0)	4.18	4.2	4.18	4.18	4.18	4.2	
			Placebo	3	3 (100.0)	3.52 (0.32)	3.2	3.18	3.55	3.82	3.8	
		Week 8	Tezepelumab	1	1 (100.0)	4.18	4.2	4.18	4.18	4.18	4.2	
			Placebo	3	3 (100.0)	4.27 (1.74)	2.3	2.27	5.09	5.45	5.5	
		Week 12	Tezepelumab	1	1 (100.0)	4.09	4.1	4.09	4.09	4.09	4.1	
			Placebo	3	3 (100.0)	5.21 (1.19)	4.3	4.27	4.82	6.55	6.5	
		Week 16	Tezepelumab	1	1 (100.0)	4.09	4.1	4.09	4.09	4.09	4.1	
			Placebo	3	3 (100.0)	4.88 (1.61)	3.8	3.82	4.09	6.73	6.7	
		Week 20	Tezepelumab	1	1 (100.0)	4.73	4.7	4.73	4.73	4.73	4.7	
			Placebo	3	3 (100.0)	4.88 (0.69)	4.1	4.09	5.18	5.36	5.4	
		Week 24	Tezepelumab	1	1 (100.0)	4.45	4.5	4.45	4.45	4.45	4.5	
			Placebo	3	3 (100.0)	4.73 (1.26)	3.9	3.91	4.09	6.18	6.2	
		Week 28	Tezepelumab	1	1 (100.0)	4.27	4.3	4.27	4.27	4.27	4.3	
			Placebo	3	3 (100.0)	5.36 (1.49)	4.1	4.09	5.00	7.00	7.0	
		Week 32	Tezepelumab	1	1 (100.0)	4.18	4.2	4.18	4.18	4.18	4.2	
			Placebo	3	3 (100.0)	5.00 (1.35)	4.1	4.09	4.36	6.55	6.5	
		Week 36	Tezepelumab	1	1 (100.0)	4.45	4.5	4.45	4.45	4.45	4.5	
			Placebo	3	3 (100.0)	4.55 (1.29)	3.5	3.55	4.09	6.00	6.0	
		Week 40	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	3	3 (100.0)	5.52 (1.37)	4.1	4.09	5.64	6.82	6.8	
		Week 44	Tezepelumab	1	1 (100.0)	4.45	4.5	4.45	4.45	4.45	4.5	
			Placebo	3	3 (100.0)	4.76 (1.65)	3.5	3.55	4.09	6.64	6.6	
		Week 48	Tezepelumab	1	1 (100.0)	4.73	4.7	4.73	4.73	4.73	4.7	
			Placebo	3	3 (100.0)	4.88 (0.77)	4.1	4.09	4.91	5.64	5.6	
		Week 52	Tezepelumab	1	1 (100.0)	4.73	4.7	4.73	4.73	4.73	4.7	
			Placebo	3	3 (100.0)	4.88 (0.77)	4.1	4.09	4.91	5.64	5.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	0.45	0.5	0.45	0.45	0.45	0.5	NE
			Placebo	3	3 (100.0)	0.48 (0.52)	-0.1	-0.09	0.64	0.91	0.9	
		Week 8	Tezepelumab	1	1 (100.0)	0.45	0.5	0.45	0.45	0.45	0.5	NE
			Placebo	3	3 (100.0)	1.24 (1.87)	-0.9	-0.91	2.18	2.45	2.5	
		Week 12	Tezepelumab	1	1 (100.0)	0.36	0.4	0.36	0.36	0.36	0.4	NE
			Placebo	3	3 (100.0)	2.18 (1.09)	1.1	1.09	2.18	3.27	3.3	
		Week 16	Tezepelumab	1	1 (100.0)	0.36	0.4	0.36	0.36	0.36	0.4	NE
			Placebo	3	3 (100.0)	1.85 (1.40)	0.9	0.91	1.18	3.45	3.5	
		Week 20	Tezepelumab	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	NE
			Placebo	3	3 (100.0)	1.85 (0.91)	0.9	0.91	1.91	2.73	2.7	
		Week 24	Tezepelumab	1	1 (100.0)	0.73	0.7	0.73	0.73	0.73	0.7	NE
			Placebo	3	3 (100.0)	1.70 (1.07)	0.9	0.91	1.27	2.91	2.9	
		Week 28	Tezepelumab	1	1 (100.0)	0.55	0.5	0.55	0.55	0.55	0.5	NE
			Placebo	3	3 (100.0)	2.33 (1.41)	0.9	0.91	2.36	3.73	3.7	
		Week 32	Tezepelumab	1	1 (100.0)	0.45	0.5	0.45	0.45	0.45	0.5	NE
			Placebo	3	3 (100.0)	1.97 (1.20)	0.9	0.91	1.73	3.27	3.3	
		Week 36	Tezepelumab	1	1 (100.0)	0.73	0.7	0.73	0.73	0.73	0.7	NE
			Placebo	3	3 (100.0)	1.52 (1.05)	0.9	0.91	0.91	2.73	2.7	
		Week 40	Tezepelumab	1	1 (100.0)	1.27	1.3	1.27	1.27	1.27	1.3	NE
			Placebo	3	3 (100.0)	2.48 (1.39)	0.9	0.91	3.00	3.55	3.5	
		Week 44	Tezepelumab	1	1 (100.0)	0.73	0.7	0.73	0.73	0.73	0.7	NE
			Placebo	3	3 (100.0)	1.73 (1.42)	0.9	0.91	0.91	3.36	3.4	
		Week 48	Tezepelumab	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	NE
			Placebo	3	3 (100.0)	1.85 (0.81)	0.9	0.91	2.27	2.36	2.4	
		Week 52	Tezepelumab	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	NE
			Placebo	3	3 (100.0)	1.85 (0.81)	0.9	0.91	2.27	2.36	2.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	78	73 (93.6)	4.22 (0.87)	1.9	3.73	4.18	4.64	7.0	
			Placebo	80	68 (85.0)	4.32 (0.87)	2.0	3.82	4.18	4.77	6.2	
		Week 4	Tezepelumab	78	74 (94.9)	4.76 (1.08)	1.6	4.00	4.55	5.36	7.0	
			Placebo	80	69 (86.3)	4.76 (1.05)	2.7	3.91	4.64	5.64	7.0	
		Week 8	Tezepelumab	78	75 (96.2)	5.04 (1.13)	1.6	4.18	5.09	6.00	7.0	
			Placebo	80	71 (88.8)	4.84 (1.09)	2.3	4.00	4.73	5.82	7.0	
		Week 12	Tezepelumab	78	75 (96.2)	5.19 (1.15)	1.7	4.18	5.18	6.09	7.0	
			Placebo	80	72 (90.0)	4.96 (1.10)	2.8	4.09	4.68	6.00	7.0	
		Week 16	Tezepelumab	78	75 (96.2)	5.14 (1.10)	2.6	4.27	5.18	6.00	7.0	
			Placebo	80	72 (90.0)	5.02 (1.13)	1.1	4.09	5.00	5.95	7.0	
		Week 20	Tezepelumab	78	76 (97.4)	5.11 (1.19)	1.8	4.27	5.23	6.00	7.0	
			Placebo	80	72 (90.0)	5.00 (1.12)	1.1	4.18	4.77	6.00	7.0	
		Week 24	Tezepelumab	78	76 (97.4)	5.17 (1.12)	2.9	4.27	5.14	6.05	7.0	
			Placebo	80	72 (90.0)	4.97 (1.18)	1.1	4.18	4.91	5.86	7.0	
		Week 28	Tezepelumab	78	77 (98.7)	5.16 (1.13)	2.1	4.27	5.18	6.00	7.0	
			Placebo	80	73 (91.3)	4.97 (1.25)	1.1	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	78	77 (98.7)	5.20 (1.19)	1.6	4.27	5.36	6.00	7.0	
			Placebo	80	74 (92.5)	5.03 (1.15)	1.1	4.09	4.82	6.00	7.0	
		Week 36	Tezepelumab	78	77 (98.7)	5.22 (1.16)	1.9	4.27	5.36	6.09	7.0	
			Placebo	80	74 (92.5)	5.12 (1.14)	2.4	4.27	5.00	6.09	7.0	
		Week 40	Tezepelumab	78	77 (98.7)	5.29 (1.13)	2.1	4.36	5.36	6.18	7.0	
			Placebo	80	74 (92.5)	5.07 (1.12)	2.5	4.18	5.05	6.00	7.0	
		Week 44	Tezepelumab	78	77 (98.7)	5.30 (1.14)	2.4	4.27	5.36	6.18	7.0	
			Placebo	80	74 (92.5)	5.14 (1.13)	2.9	4.09	5.05	6.00	7.0	
		Week 48	Tezepelumab	78	77 (98.7)	5.31 (1.13)	2.6	4.27	5.36	6.27	7.0	
			Placebo	80	75 (93.8)	5.12 (1.12)	2.4	4.18	5.09	6.00	7.0	
		Week 52	Tezepelumab	78	77 (98.7)	5.25 (1.16)	1.8	4.36	5.36	6.09	7.0	
			Placebo	80	75 (93.8)	5.11 (1.12)	2.7	4.18	5.00	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	78	71 (91.0)	0.59 (0.92)	-2.8	0.00	0.55	1.27	2.5	0.12 [-0.22, 0.45]
			Placebo	80	67 (83.8)	0.48 (0.90)	-1.5	0.00	0.36	0.91	2.6	
		Week 8	Tezepelumab	78	72 (92.3)	0.82 (0.91)	-1.3	0.05	0.82	1.50	2.7	0.30 [-0.04, 0.63]
			Placebo	80	68 (85.0)	0.56 (0.87)	-1.7	-0.09	0.55	1.05	2.6	
		Week 12	Tezepelumab	78	72 (92.3)	0.97 (0.95)	-1.5	0.32	1.05	1.55	3.0	0.29 [-0.04, 0.62]
			Placebo	80	68 (85.0)	0.69 (0.99)	-1.9	0.05	0.59	1.18	3.0	
		Week 16	Tezepelumab	78	72 (92.3)	0.94 (0.93)	-1.6	0.27	0.86	1.55	2.8	0.21 [-0.13, 0.54]
			Placebo	80	68 (85.0)	0.74 (1.02)	-3.2	0.23	0.77	1.45	2.7	
		Week 20	Tezepelumab	78	72 (92.3)	0.90 (0.96)	-1.1	0.18	0.91	1.55	2.6	0.17 [-0.16, 0.50]
			Placebo	80	68 (85.0)	0.74 (0.95)	-3.2	0.18	0.64	1.27	2.6	
		Week 24	Tezepelumab	78	72 (92.3)	0.98 (0.96)	-0.7	0.23	1.09	1.64	3.0	0.27 [-0.07, 0.60]
			Placebo	80	68 (85.0)	0.71 (1.08)	-3.2	0.09	0.64	1.41	3.0	
		Week 28	Tezepelumab	78	72 (92.3)	0.97 (0.94)	-0.8	0.23	0.91	1.64	2.9	0.29 [-0.04, 0.62]
			Placebo	80	68 (85.0)	0.68 (1.08)	-3.2	0.00	0.82	1.27	3.0	
		Week 32	Tezepelumab	78	72 (92.3)	0.99 (0.99)	-1.1	0.27	1.09	1.59	2.8	0.24 [-0.09, 0.58]
			Placebo	80	68 (85.0)	0.75 (0.99)	-3.2	0.14	0.73	1.36	2.7	
		Week 36	Tezepelumab	78	72 (92.3)	1.02 (1.01)	-0.8	0.23	1.09	1.64	3.2	0.17 [-0.16, 0.51]
			Placebo	80	68 (85.0)	0.84 (1.04)	-1.8	0.18	0.73	1.45	3.3	
		Week 40	Tezepelumab	78	72 (92.3)	1.10 (0.97)	-0.9	0.32	1.14	1.77	2.9	0.31 [-0.02, 0.65]
			Placebo	80	68 (85.0)	0.79 (1.02)	-1.5	0.18	0.77	1.45	3.1	
		Week 44	Tezepelumab	78	72 (92.3)	1.11 (1.01)	-0.7	0.32	1.18	1.73	2.9	0.27 [-0.07, 0.60]
			Placebo	80	68 (85.0)	0.85 (0.99)	-1.4	0.27	0.86	1.45	3.0	
		Week 48	Tezepelumab	78	72 (92.3)	1.14 (1.02)	-0.7	0.41	1.14	1.95	3.1	0.31 [-0.03, 0.64]
			Placebo	80	68 (85.0)	0.83 (1.00)	-1.5	0.18	0.82	1.32	3.4	
		Week 52	Tezepelumab	78	72 (92.3)	1.07 (1.01)	-0.7	0.27	1.05	1.73	3.1	0.24 [-0.10, 0.57]
			Placebo	80	68 (85.0)	0.84 (0.95)	-1.4	0.18	0.82	1.32	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	4.25 (1.31)	2.2	3.45	4.82	5.00	5.6	
			Placebo	9	8 (88.9)	3.65 (1.02)	2.5	2.86	3.32	4.41	5.5	
		Week 4	Tezepelumab	10	8 (80.0)	6.03 (0.67)	5.3	5.36	6.05	6.64	6.9	
			Placebo	9	7 (77.8)	4.48 (1.32)	2.6	3.55	4.27	5.45	6.7	
		Week 8	Tezepelumab	10	9 (90.0)	5.99 (0.98)	3.8	5.91	6.00	6.55	7.0	
			Placebo	9	7 (77.8)	4.84 (1.66)	2.2	3.55	5.09	6.27	7.0	
		Week 12	Tezepelumab	10	9 (90.0)	6.21 (0.71)	4.9	6.27	6.36	6.55	7.0	
			Placebo	9	7 (77.8)	4.90 (1.53)	2.8	3.45	4.82	6.09	7.0	
		Week 16	Tezepelumab	10	9 (90.0)	6.00 (0.74)	4.9	5.55	6.00	6.55	7.0	
			Placebo	9	7 (77.8)	4.51 (1.74)	2.6	3.00	3.82	6.00	6.9	
		Week 20	Tezepelumab	10	9 (90.0)	6.08 (0.67)	4.9	5.64	6.18	6.27	7.0	
			Placebo	9	7 (77.8)	5.06 (1.43)	3.0	3.64	5.36	6.27	6.9	
		Week 24	Tezepelumab	10	9 (90.0)	6.08 (0.66)	4.9	5.73	6.09	6.27	7.0	
			Placebo	9	7 (77.8)	5.04 (1.26)	3.9	4.00	4.27	6.27	6.9	
		Week 28	Tezepelumab	10	10 (100.0)	6.16 (0.69)	4.9	5.64	6.14	7.00	7.0	
			Placebo	9	7 (77.8)	5.25 (1.16)	4.0	4.09	5.00	6.45	6.9	
		Week 32	Tezepelumab	10	10 (100.0)	5.94 (0.65)	4.9	5.64	6.00	6.27	7.0	
			Placebo	9	7 (77.8)	5.16 (0.98)	4.1	4.27	5.00	5.91	6.6	
		Week 36	Tezepelumab	10	10 (100.0)	5.93 (0.61)	4.9	5.55	5.86	6.36	7.0	
			Placebo	9	7 (77.8)	5.18 (1.10)	3.5	4.09	5.36	6.36	6.4	
		Week 40	Tezepelumab	10	10 (100.0)	6.16 (0.69)	4.9	5.64	6.27	6.73	7.0	
			Placebo	9	7 (77.8)	5.29 (1.06)	4.1	4.18	5.64	6.18	6.7	
		Week 44	Tezepelumab	10	10 (100.0)	6.01 (0.67)	4.9	5.64	5.91	6.36	7.0	
			Placebo	9	7 (77.8)	5.53 (1.35)	3.5	3.91	6.36	6.64	6.7	
		Week 48	Tezepelumab	10	10 (100.0)	6.13 (0.61)	4.9	5.82	6.14	6.45	7.0	
			Placebo	9	7 (77.8)	5.92 (0.94)	4.4	4.91	6.45	6.64	6.6	
		Week 52	Tezepelumab	10	10 (100.0)	6.25 (0.63)	4.9	6.00	6.27	6.82	7.0	
			Placebo	9	7 (77.8)	6.12 (0.76)	4.9	5.45	6.45	6.64	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	1.55 (1.32)	-0.3	0.32	1.64	2.82	3.1	0.74 [-0.32, 1.79]
			Placebo	9	7 (77.8)	0.75 (0.70)	0.0	0.09	0.82	0.91	2.1	
		Week 8	Tezepelumab	10	9 (90.0)	1.74 (1.29)	0.3	0.91	1.45	2.82	3.7	0.52 [-0.48, 1.53]
			Placebo	9	7 (77.8)	1.12 (1.04)	-0.4	0.36	0.82	2.36	2.5	
		Week 12	Tezepelumab	10	9 (90.0)	1.96 (1.36)	0.2	0.91	1.45	2.82	4.2	0.66 [-0.36, 1.68]
			Placebo	9	7 (77.8)	1.17 (0.95)	0.0	0.27	0.91	2.18	2.4	
		Week 16	Tezepelumab	10	9 (90.0)	1.75 (1.34)	0.2	0.55	1.45	2.73	3.5	0.79 [-0.24, 1.82]
			Placebo	9	7 (77.8)	0.78 (1.07)	-0.5	-0.45	0.64	1.82	2.3	
		Week 20	Tezepelumab	10	9 (90.0)	1.83 (1.30)	-0.2	1.09	1.45	2.73	3.5	0.41 [-0.59, 1.41]
			Placebo	9	7 (77.8)	1.34 (1.04)	-0.5	0.82	1.27	2.27	2.7	
		Week 24	Tezepelumab	10	9 (90.0)	1.83 (1.29)	0.1	0.91	1.45	2.82	3.5	0.49 [-0.51, 1.50]
			Placebo	9	7 (77.8)	1.31 (0.60)	0.6	0.82	1.27	1.73	2.3	
		Week 28	Tezepelumab	10	9 (90.0)	1.90 (1.30)	0.0	0.91	2.00	2.82	3.5	0.35 [-0.65, 1.35]
			Placebo	9	7 (77.8)	1.52 (0.71)	0.6	0.82	1.64	2.27	2.4	
		Week 32	Tezepelumab	10	9 (90.0)	1.61 (1.26)	0.3	0.82	1.09	2.55	3.5	0.17 [-0.82, 1.16]
			Placebo	9	7 (77.8)	1.43 (0.73)	0.5	0.64	1.64	2.00	2.5	
		Week 36	Tezepelumab	10	9 (90.0)	1.66 (1.40)	-0.1	0.45	1.45	2.55	3.5	0.18 [-0.81, 1.17]
			Placebo	9	7 (77.8)	1.45 (0.64)	0.6	0.91	1.64	2.18	2.2	
		Week 40	Tezepelumab	10	9 (90.0)	1.85 (1.28)	0.3	0.64	1.45	2.82	3.5	0.26 [-0.73, 1.25]
			Placebo	9	7 (77.8)	1.56 (0.85)	0.6	0.73	1.64	2.09	3.0	
		Week 44	Tezepelumab	10	9 (90.0)	1.78 (1.34)	0.0	0.73	1.45	2.82	3.5	-0.02 [-1.01, 0.96]
			Placebo	9	7 (77.8)	1.81 (0.94)	0.7	0.91	2.09	2.55	3.2	
		Week 48	Tezepelumab	10	9 (90.0)	1.91 (1.18)	0.4	1.00	1.45	2.73	3.5	-0.27 [-1.27, 0.72]
			Placebo	9	7 (77.8)	2.19 (0.84)	1.2	1.18	2.27	3.18	3.3	
		Week 52	Tezepelumab	10	9 (90.0)	1.93 (1.15)	0.5	1.00	1.45	2.73	3.5	-0.46 [-1.46, 0.55]
			Placebo	9	7 (77.8)	2.39 (0.78)	1.2	2.00	2.27	3.18	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	4.43 (0.96)	3.6	3.82	4.14	5.05	5.8	
			Placebo	6	6 (100.0)	4.53 (0.87)	3.0	4.27	4.73	5.09	5.4	
		Week 4	Tezepelumab	5	5 (100.0)	5.15 (0.75)	4.5	4.64	4.64	5.82	6.1	
			Placebo	6	6 (100.0)	5.20 (0.39)	4.5	4.91	5.36	5.45	5.5	
		Week 8	Tezepelumab	5	5 (100.0)	5.56 (0.55)	5.1	5.18	5.27	5.91	6.4	
			Placebo	6	6 (100.0)	5.48 (0.79)	4.2	5.00	5.64	6.18	6.3	
		Week 12	Tezepelumab	5	5 (100.0)	5.85 (0.90)	5.0	5.18	5.45	6.64	7.0	
			Placebo	6	6 (100.0)	5.92 (0.51)	5.3	5.55	5.91	6.18	6.7	
		Week 16	Tezepelumab	5	5 (100.0)	5.85 (0.74)	5.2	5.36	5.55	6.18	7.0	
			Placebo	6	6 (100.0)	5.88 (0.64)	4.9	5.64	5.91	6.00	6.9	
		Week 20	Tezepelumab	5	5 (100.0)	5.62 (1.27)	3.6	5.45	5.64	6.36	7.0	
			Placebo	6	6 (100.0)	5.55 (1.05)	3.8	5.09	5.77	5.82	7.0	
		Week 24	Tezepelumab	5	5 (100.0)	5.96 (0.78)	4.8	5.91	6.00	6.09	7.0	
			Placebo	6	6 (100.0)	5.74 (1.06)	4.1	4.91	5.95	6.73	6.8	
		Week 28	Tezepelumab	5	5 (100.0)	6.20 (0.50)	5.8	5.82	6.00	6.36	7.0	
			Placebo	6	6 (100.0)	6.11 (0.94)	4.6	5.45	6.32	6.91	7.0	
		Week 32	Tezepelumab	5	5 (100.0)	6.25 (0.49)	5.7	5.91	6.27	6.36	7.0	
			Placebo	6	6 (100.0)	6.11 (0.54)	5.5	5.64	6.05	6.64	6.8	
		Week 36	Tezepelumab	5	5 (100.0)	6.00 (1.00)	4.4	6.00	6.09	6.55	7.0	
			Placebo	6	6 (100.0)	5.47 (1.31)	3.3	4.64	5.86	6.36	6.8	
		Week 40	Tezepelumab	5	5 (100.0)	6.11 (0.61)	5.3	6.00	6.09	6.18	7.0	
			Placebo	6	6 (100.0)	5.80 (1.15)	4.1	5.09	5.86	6.91	7.0	
		Week 44	Tezepelumab	5	5 (100.0)	6.31 (0.41)	6.0	6.00	6.18	6.36	7.0	
			Placebo	6	6 (100.0)	5.39 (1.48)	3.4	4.00	5.55	6.91	7.0	
		Week 48	Tezepelumab	5	5 (100.0)	5.85 (0.93)	4.5	5.64	6.00	6.18	7.0	
			Placebo	6	6 (100.0)	5.30 (0.96)	3.8	4.82	5.27	6.18	6.5	
		Week 52	Tezepelumab	5	5 (100.0)	6.00 (0.94)	4.5	6.00	6.18	6.36	7.0	
			Placebo	6	6 (100.0)	5.29 (0.94)	3.8	4.82	5.27	6.18	6.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	0.84 (0.75)	0.0	0.32	0.77	1.36	1.8	0.18 [-1.08, 1.45]
			Placebo	6	6 (100.0)	0.67 (1.04)	-0.5	0.18	0.32	1.09	2.5	
		Week 8	Tezepelumab	5	4 (80.0)	1.23 (0.86)	0.1	0.59	1.36	1.86	2.1	0.25 [-1.02, 1.52]
			Placebo	6	6 (100.0)	0.95 (1.19)	-0.2	0.55	0.64	0.82	3.3	
		Week 12	Tezepelumab	5	4 (80.0)	1.64 (0.80)	0.8	1.14	1.50	2.14	2.7	0.23 [-1.04, 1.50]
			Placebo	6	6 (100.0)	1.39 (1.16)	0.8	0.82	0.86	1.27	3.7	
		Week 16	Tezepelumab	5	4 (80.0)	1.59 (0.99)	0.4	0.86	1.64	2.32	2.7	0.20 [-1.07, 1.47]
			Placebo	6	6 (100.0)	1.35 (1.34)	0.5	0.55	0.68	1.73	3.9	
		Week 20	Tezepelumab	5	4 (80.0)	1.23 (1.40)	-0.4	0.09	1.27	2.36	2.7	0.14 [-1.12, 1.41]
			Placebo	6	6 (100.0)	1.02 (1.53)	-0.5	0.45	0.68	0.73	4.0	
		Week 24	Tezepelumab	5	4 (80.0)	1.55 (1.19)	0.3	0.55	1.59	2.55	2.7	0.26 [-1.02, 1.53]
			Placebo	6	6 (100.0)	1.21 (1.37)	-0.2	0.55	0.86	1.36	3.8	
		Week 28	Tezepelumab	5	4 (80.0)	1.86 (0.95)	0.5	1.18	2.09	2.55	2.7	0.22 [-1.05, 1.49]
			Placebo	6	6 (100.0)	1.58 (1.44)	0.3	0.36	1.18	2.45	4.0	
		Week 32	Tezepelumab	5	4 (80.0)	1.82 (0.94)	0.5	1.14	2.00	2.50	2.7	0.23 [-1.04, 1.50]
			Placebo	6	6 (100.0)	1.58 (1.12)	0.5	0.82	1.27	1.91	3.6	
		Week 36	Tezepelumab	5	4 (80.0)	1.55 (1.17)	0.4	0.55	1.55	2.55	2.7	0.45 [-0.84, 1.73]
			Placebo	6	6 (100.0)	0.94 (1.45)	-1.0	0.27	0.77	1.45	3.4	
		Week 40	Tezepelumab	5	4 (80.0)	1.66 (1.17)	0.2	0.73	1.86	2.59	2.7	0.28 [-0.99, 1.55]
			Placebo	6	6 (100.0)	1.27 (1.48)	-0.2	0.27	1.00	1.55	4.0	
		Week 44	Tezepelumab	5	4 (80.0)	1.91 (1.20)	0.2	1.09	2.36	2.73	2.7	0.67 [-0.63, 1.98]
			Placebo	6	6 (100.0)	0.86 (1.72)	-0.9	-0.36	0.45	1.64	3.9	
		Week 48	Tezepelumab	5	4 (80.0)	1.48 (1.24)	0.4	0.41	1.41	2.55	2.7	0.69 [-0.62, 2.00]
			Placebo	6	6 (100.0)	0.77 (0.86)	-0.5	0.36	0.77	1.09	2.1	
		Week 52	Tezepelumab	5	4 (80.0)	1.48 (1.24)	0.4	0.41	1.41	2.55	2.7	0.71 [-0.61, 2.02]
			Placebo	6	6 (100.0)	0.76 (0.86)	-0.5	0.36	0.73	1.09	2.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	44	37 (84.1)	4.43 (0.92)	2.6	3.91	4.27	5.09	6.2	
			Placebo	43	39 (90.7)	3.90 (0.77)	2.3	3.36	3.91	4.36	6.0	
		Week 4	Tezepelumab	44	39 (88.6)	5.10 (1.09)	3.3	4.18	4.91	6.00	7.0	
			Placebo	43	41 (95.3)	4.35 (0.97)	2.5	3.73	4.09	5.09	6.9	
		Week 8	Tezepelumab	44	39 (88.6)	5.11 (1.03)	3.2	4.36	4.91	6.09	7.0	
			Placebo	43	42 (97.7)	4.53 (1.06)	2.3	3.82	4.36	5.18	7.0	
		Week 12	Tezepelumab	44	39 (88.6)	5.33 (1.06)	3.4	4.55	5.27	6.36	7.0	
			Placebo	43	42 (97.7)	4.63 (1.03)	3.0	3.91	4.45	5.45	6.8	
		Week 16	Tezepelumab	44	39 (88.6)	5.32 (1.08)	3.9	4.27	5.09	6.27	7.0	
			Placebo	43	42 (97.7)	4.73 (1.14)	2.9	3.91	4.55	5.55	6.7	
		Week 20	Tezepelumab	44	39 (88.6)	5.24 (1.07)	3.5	4.36	5.09	6.09	7.0	
			Placebo	43	42 (97.7)	4.62 (1.10)	2.1	3.91	4.41	5.36	6.7	
		Week 24	Tezepelumab	44	39 (88.6)	5.28 (1.23)	1.6	4.36	5.18	6.55	7.0	
			Placebo	43	42 (97.7)	4.77 (1.14)	2.0	4.00	4.68	5.73	6.9	
		Week 28	Tezepelumab	44	39 (88.6)	5.27 (1.04)	3.5	4.45	5.18	6.27	7.0	
			Placebo	43	42 (97.7)	4.67 (1.19)	2.0	3.82	4.59	5.64	7.0	
		Week 32	Tezepelumab	44	40 (90.9)	5.42 (0.97)	3.9	4.64	5.27	6.32	7.0	
			Placebo	43	42 (97.7)	4.74 (1.22)	1.7	4.00	4.32	5.55	7.0	
		Week 36	Tezepelumab	44	40 (90.9)	5.36 (1.03)	3.3	4.50	5.14	6.27	7.0	
			Placebo	43	42 (97.7)	4.74 (1.17)	2.5	4.00	4.41	6.00	6.9	
		Week 40	Tezepelumab	44	40 (90.9)	5.28 (1.03)	3.7	4.50	5.09	6.00	7.0	
			Placebo	43	42 (97.7)	4.81 (1.27)	2.0	3.91	4.45	5.91	7.0	
		Week 44	Tezepelumab	44	40 (90.9)	5.36 (1.06)	3.5	4.55	5.23	6.27	7.0	
			Placebo	43	42 (97.7)	4.73 (1.22)	2.5	3.91	4.45	5.82	7.0	
		Week 48	Tezepelumab	44	40 (90.9)	5.43 (1.05)	3.7	4.50	5.18	6.45	7.0	
			Placebo	43	42 (97.7)	4.72 (1.14)	2.3	3.91	4.45	5.73	7.0	
		Week 52	Tezepelumab	44	40 (90.9)	5.40 (1.02)	3.7	4.59	5.18	6.18	7.0	
			Placebo	43	42 (97.7)	4.67 (1.13)	2.9	3.82	4.36	5.73	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	44	34 (77.3)	0.72 (1.03)	-1.1	0.00	0.64	1.18	3.2	0.33 [-0.13, 0.79]
			Placebo	43	39 (90.7)	0.41 (0.81)	-1.5	-0.09	0.36	0.82	2.5	
		Week 8	Tezepelumab	44	34 (77.3)	0.62 (1.15)	-1.5	-0.09	0.64	1.09	3.1	-0.02 [-0.48, 0.44]
			Placebo	43	39 (90.7)	0.64 (0.92)	-1.3	0.00	0.64	1.18	2.8	
		Week 12	Tezepelumab	44	34 (77.3)	0.85 (1.07)	-0.9	0.00	0.82	1.36	3.1	0.14 [-0.32, 0.60]
			Placebo	43	39 (90.7)	0.70 (1.03)	-1.3	0.18	0.82	1.27	3.3	
		Week 16	Tezepelumab	44	34 (77.3)	0.87 (1.13)	-1.7	0.18	0.91	1.45	3.1	0.02 [-0.44, 0.48]
			Placebo	43	39 (90.7)	0.85 (1.06)	-1.6	0.18	0.91	1.27	3.5	
		Week 20	Tezepelumab	44	34 (77.3)	0.80 (1.23)	-2.1	0.00	0.68	1.73	3.3	0.05 [-0.41, 0.51]
			Placebo	43	39 (90.7)	0.75 (1.08)	-1.6	0.00	0.73	1.45	3.4	
		Week 24	Tezepelumab	44	34 (77.3)	0.95 (1.11)	-1.4	0.09	0.77	1.55	3.2	0.05 [-0.41, 0.51]
			Placebo	43	39 (90.7)	0.90 (1.06)	-1.6	0.27	0.82	1.55	3.2	
		Week 28	Tezepelumab	44	34 (77.3)	0.88 (1.12)	-1.1	0.09	0.77	1.55	3.2	0.07 [-0.39, 0.53]
			Placebo	43	39 (90.7)	0.80 (1.11)	-1.6	0.09	0.73	1.36	3.7	
		Week 32	Tezepelumab	44	34 (77.3)	1.05 (1.07)	-1.0	0.36	0.82	1.91	3.2	0.14 [-0.32, 0.60]
			Placebo	43	39 (90.7)	0.89 (1.18)	-1.8	0.18	0.91	1.55	3.5	
		Week 36	Tezepelumab	44	34 (77.3)	0.93 (1.13)	-0.9	0.00	0.82	1.73	3.0	0.04 [-0.42, 0.50]
			Placebo	43	39 (90.7)	0.89 (1.15)	-1.6	0.18	0.91	1.64	3.5	
		Week 40	Tezepelumab	44	34 (77.3)	0.84 (1.02)	-1.0	0.09	0.86	1.18	3.1	-0.11 [-0.57, 0.35]
			Placebo	43	39 (90.7)	0.96 (1.27)	-1.6	0.09	0.91	1.64	3.6	
		Week 44	Tezepelumab	44	34 (77.3)	0.92 (1.01)	-1.1	0.18	0.82	1.55	3.2	0.06 [-0.40, 0.52]
			Placebo	43	39 (90.7)	0.85 (1.22)	-1.6	-0.09	0.73	1.64	3.6	
		Week 48	Tezepelumab	44	34 (77.3)	1.01 (1.02)	-1.0	0.27	0.91	1.55	3.2	0.15 [-0.31, 0.61]
			Placebo	43	39 (90.7)	0.85 (1.12)	-1.6	0.09	0.82	1.27	3.6	
		Week 52	Tezepelumab	44	34 (77.3)	0.95 (1.10)	-1.2	0.18	0.82	1.55	3.3	0.12 [-0.34, 0.58]
			Placebo	43	39 (90.7)	0.81 (1.14)	-1.6	0.00	0.82	1.27	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Placebo	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
		Week 4	Placebo	1	1 (100.0)	2.73	2.7	2.73	2.73	2.73	2.7	
		Week 8	Placebo	1	1 (100.0)	2.27	2.3	2.27	2.27	2.27	2.3	
		Week 12	Placebo	1	1 (100.0)	3.09	3.1	3.09	3.09	3.09	3.1	
		Week 16	Placebo	1	1 (100.0)	3.91	3.9	3.91	3.91	3.91	3.9	
		Week 20	Placebo	1	1 (100.0)	3.91	3.9	3.91	3.91	3.91	3.9	
		Week 24	Placebo	1	1 (100.0)	3.27	3.3	3.27	3.27	3.27	3.3	
		Week 28	Placebo	1	1 (100.0)	3.73	3.7	3.73	3.73	3.73	3.7	
		Week 32	Placebo	1	1 (100.0)	3.27	3.3	3.27	3.27	3.27	3.3	
		Week 36	Placebo	1	1 (100.0)	3.45	3.5	3.45	3.45	3.45	3.5	
		Week 40	Placebo	1	1 (100.0)	3.36	3.4	3.36	3.36	3.36	3.4	
		Week 44	Placebo	1	1 (100.0)	3.18	3.2	3.18	3.18	3.18	3.2	
		Week 48	Placebo	1	1 (100.0)	3.18	3.2	3.18	3.18	3.18	3.2	
		Week 52	Placebo	1	1 (100.0)	3.18	3.2	3.18	3.18	3.18	3.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 4	Placebo	1	1 (100.0)	0.73	0.7	0.73	0.73	0.73	0.7	
		Week 8	Placebo	1	1 (100.0)	0.27	0.3	0.27	0.27	0.27	0.3	
		Week 12	Placebo	1	1 (100.0)	1.09	1.1	1.09	1.09	1.09	1.1	
		Week 16	Placebo	1	1 (100.0)	1.91	1.9	1.91	1.91	1.91	1.9	
		Week 20	Placebo	1	1 (100.0)	1.91	1.9	1.91	1.91	1.91	1.9	
		Week 24	Placebo	1	1 (100.0)	1.27	1.3	1.27	1.27	1.27	1.3	
		Week 28	Placebo	1	1 (100.0)	1.73	1.7	1.73	1.73	1.73	1.7	
		Week 32	Placebo	1	1 (100.0)	1.27	1.3	1.27	1.27	1.27	1.3	
		Week 36	Placebo	1	1 (100.0)	1.45	1.5	1.45	1.45	1.45	1.5	
		Week 40	Placebo	1	1 (100.0)	1.36	1.4	1.36	1.36	1.36	1.4	
		Week 44	Placebo	1	1 (100.0)	1.18	1.2	1.18	1.18	1.18	1.2	
		Week 48	Placebo	1	1 (100.0)	1.18	1.2	1.18	1.18	1.18	1.2	
		Week 52	Placebo	1	1 (100.0)	1.18	1.2	1.18	1.18	1.18	1.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	39	35 (89.7)	4.64 (1.07)	2.2	3.82	4.55	5.45	7.0	
			Placebo	43	38 (88.4)	4.27 (0.95)	2.3	3.45	4.27	5.27	5.9	
		Week 4	Tezepelumab	39	36 (92.3)	5.42 (1.02)	3.3	4.59	5.32	6.23	7.0	
			Placebo	43	40 (93.0)	4.74 (1.03)	2.5	4.05	4.73	5.41	7.0	
		Week 8	Tezepelumab	39	37 (94.9)	5.59 (0.97)	3.3	5.00	5.55	6.18	7.0	
			Placebo	43	40 (93.0)	4.96 (1.21)	2.8	4.00	4.95	6.14	7.0	
		Week 12	Tezepelumab	39	37 (94.9)	5.92 (0.90)	3.7	5.18	6.00	6.64	7.0	
			Placebo	43	40 (93.0)	5.13 (1.13)	3.3	4.09	5.23	6.09	7.0	
		Week 16	Tezepelumab	39	37 (94.9)	5.80 (0.98)	3.6	5.18	6.00	6.73	7.0	
			Placebo	43	40 (93.0)	5.22 (1.20)	2.9	4.23	5.45	6.23	7.0	
		Week 20	Tezepelumab	39	37 (94.9)	5.73 (1.08)	2.1	5.09	5.91	6.64	7.0	
			Placebo	43	40 (93.0)	5.12 (1.27)	2.1	4.09	5.14	6.18	7.0	
		Week 24	Tezepelumab	39	37 (94.9)	5.86 (1.02)	3.2	5.09	6.00	6.91	7.0	
			Placebo	43	40 (93.0)	5.14 (1.27)	2.0	4.14	5.27	6.09	7.0	
		Week 28	Tezepelumab	39	37 (94.9)	5.86 (0.92)	3.6	5.18	6.00	6.64	7.0	
			Placebo	43	41 (95.3)	5.20 (1.35)	2.0	4.00	5.27	6.45	7.0	
		Week 32	Tezepelumab	39	38 (97.4)	5.86 (0.98)	2.5	5.27	6.00	6.55	7.0	
			Placebo	43	41 (95.3)	5.25 (1.30)	1.7	4.27	5.55	6.18	7.0	
		Week 36	Tezepelumab	39	38 (97.4)	5.93 (0.92)	3.5	5.45	6.00	6.73	7.0	
			Placebo	43	41 (95.3)	5.21 (1.27)	2.5	4.45	5.27	6.36	7.0	
		Week 40	Tezepelumab	39	38 (97.4)	5.86 (1.00)	3.2	5.09	6.00	6.91	7.0	
			Placebo	43	41 (95.3)	5.25 (1.31)	2.0	4.09	5.36	6.18	7.0	
		Week 44	Tezepelumab	39	38 (97.4)	5.92 (0.93)	3.8	5.36	6.05	6.91	7.0	
			Placebo	43	41 (95.3)	5.17 (1.29)	2.5	4.09	5.27	6.18	7.0	
		Week 48	Tezepelumab	39	38 (97.4)	5.99 (0.92)	3.5	5.18	6.18	6.82	7.0	
			Placebo	43	42 (97.7)	5.16 (1.19)	2.3	4.27	5.23	6.00	7.0	
		Week 52	Tezepelumab	39	38 (97.4)	5.90 (0.91)	3.5	5.18	6.00	6.64	7.0	
			Placebo	43	42 (97.7)	5.21 (1.14)	3.1	4.27	5.23	6.09	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	39	33 (84.6)	0.90 (1.01)	-1.1	0.18	1.00	1.45	3.1	0.42 [-0.05, 0.90]
			Placebo	43	38 (88.4)	0.48 (0.98)	-1.5	-0.18	0.27	1.09	2.6	
		Week 8	Tezepelumab	39	34 (87.2)	0.97 (1.21)	-1.5	0.09	1.18	1.64	3.7	0.19 [-0.27, 0.66]
			Placebo	43	38 (88.4)	0.75 (1.06)	-1.7	0.09	0.77	1.27	3.3	
		Week 12	Tezepelumab	39	34 (87.2)	1.28 (1.14)	-0.9	0.55	1.36	2.09	4.2	0.36 [-0.11, 0.82]
			Placebo	43	38 (88.4)	0.89 (1.10)	-1.9	0.36	0.91	1.27	3.7	
		Week 16	Tezepelumab	39	34 (87.2)	1.16 (1.20)	-1.7	0.36	1.45	1.91	3.5	0.14 [-0.32, 0.60]
			Placebo	43	38 (88.4)	1.00 (1.08)	-1.9	0.45	0.95	1.64	3.9	
		Week 20	Tezepelumab	39	34 (87.2)	1.08 (1.27)	-2.1	0.55	1.09	2.00	3.5	0.15 [-0.32, 0.61]
			Placebo	43	38 (88.4)	0.90 (1.19)	-1.5	0.27	0.82	1.55	4.0	
		Week 24	Tezepelumab	39	34 (87.2)	1.21 (1.14)	-0.8	0.27	1.27	2.36	3.5	0.24 [-0.22, 0.71]
			Placebo	43	38 (88.4)	0.94 (1.10)	-1.5	0.45	1.00	1.55	3.8	
		Week 28	Tezepelumab	39	34 (87.2)	1.22 (1.19)	-1.1	0.45	1.32	2.27	3.5	0.22 [-0.25, 0.68]
			Placebo	43	38 (88.4)	0.97 (1.12)	-1.5	0.64	1.00	1.55	4.0	
		Week 32	Tezepelumab	39	34 (87.2)	1.20 (1.10)	-1.0	0.36	1.18	2.27	3.5	0.18 [-0.28, 0.65]
			Placebo	43	38 (88.4)	1.00 (1.14)	-1.8	0.45	0.91	1.64	3.6	
		Week 36	Tezepelumab	39	34 (87.2)	1.27 (1.16)	-0.9	0.00	1.32	2.36	3.5	0.27 [-0.20, 0.73]
			Placebo	43	38 (88.4)	0.96 (1.11)	-1.2	0.18	1.00	1.73	3.5	
		Week 40	Tezepelumab	39	34 (87.2)	1.17 (1.18)	-1.0	0.18	1.14	2.36	3.5	0.13 [-0.34, 0.59]
			Placebo	43	38 (88.4)	1.02 (1.21)	-1.5	0.27	1.05	1.73	4.0	
		Week 44	Tezepelumab	39	34 (87.2)	1.22 (1.10)	-1.1	0.18	1.27	2.27	3.5	0.28 [-0.19, 0.74]
			Placebo	43	38 (88.4)	0.91 (1.15)	-1.2	0.27	0.95	1.45	3.9	
		Week 48	Tezepelumab	39	34 (87.2)	1.34 (1.12)	-1.0	0.36	1.45	2.36	3.5	0.42 [-0.05, 0.89]
			Placebo	43	38 (88.4)	0.90 (0.97)	-1.3	0.27	0.86	1.36	3.6	
		Week 52	Tezepelumab	39	34 (87.2)	1.20 (1.20)	-1.2	0.27	1.27	2.18	3.5	0.23 [-0.23, 0.70]
			Placebo	43	38 (88.4)	0.95 (0.93)	-1.2	0.45	0.95	1.55	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	45	41 (91.1)	4.18 (0.94)	1.9	3.73	4.09	4.55	6.1	
			Placebo	47	43 (91.5)	4.29 (0.83)	2.6	3.82	4.18	4.45	6.2	
		Week 4	Tezepelumab	45	43 (95.6)	5.03 (1.07)	3.1	4.09	5.18	6.00	7.0	
			Placebo	47	43 (91.5)	4.65 (1.02)	2.9	3.91	4.55	5.45	6.7	
		Week 8	Tezepelumab	45	43 (95.6)	5.11 (1.18)	1.6	4.18	5.18	6.00	7.0	
			Placebo	47	45 (95.7)	4.84 (0.98)	3.6	4.00	4.64	5.64	7.0	
		Week 12	Tezepelumab	45	43 (95.6)	5.26 (1.24)	1.7	4.18	5.27	6.27	7.0	
			Placebo	47	45 (95.7)	4.85 (1.09)	2.8	4.00	4.73	5.91	7.0	
		Week 16	Tezepelumab	45	43 (95.6)	5.26 (1.14)	2.6	4.27	5.27	6.27	7.0	
			Placebo	47	45 (95.7)	4.82 (1.20)	1.1	3.91	4.64	5.82	7.0	
		Week 20	Tezepelumab	45	43 (95.6)	5.18 (1.21)	1.8	4.27	5.18	6.09	7.0	
			Placebo	47	45 (95.7)	4.81 (1.20)	1.1	4.00	4.45	5.73	7.0	
		Week 24	Tezepelumab	45	43 (95.6)	5.19 (1.24)	1.6	4.27	5.18	6.27	7.0	
			Placebo	47	45 (95.7)	4.82 (1.24)	1.1	4.00	4.64	5.82	7.0	
		Week 28	Tezepelumab	45	44 (97.8)	5.31 (1.12)	2.1	4.41	5.32	6.18	7.0	
			Placebo	47	45 (95.7)	4.83 (1.27)	1.1	3.91	4.64	5.82	7.0	
		Week 32	Tezepelumab	45	44 (97.8)	5.39 (1.17)	1.6	4.55	5.41	6.23	7.0	
			Placebo	47	45 (95.7)	4.84 (1.13)	1.1	4.00	4.64	5.82	7.0	
		Week 36	Tezepelumab	45	44 (97.8)	5.32 (1.13)	1.9	4.41	5.41	6.14	7.0	
			Placebo	47	45 (95.7)	4.85 (1.12)	2.4	4.00	4.64	6.00	7.0	
		Week 40	Tezepelumab	45	44 (97.8)	5.43 (1.11)	2.1	4.73	5.32	6.18	7.0	
			Placebo	47	45 (95.7)	4.89 (1.08)	2.5	4.00	4.91	5.82	7.0	
		Week 44	Tezepelumab	45	44 (97.8)	5.42 (1.15)	2.4	4.45	5.36	6.41	7.0	
			Placebo	47	45 (95.7)	4.99 (1.15)	2.9	4.00	4.73	5.91	7.0	
		Week 48	Tezepelumab	45	44 (97.8)	5.43 (1.07)	3.5	4.36	5.41	6.36	7.0	
			Placebo	47	45 (95.7)	4.93 (1.18)	2.4	4.00	4.82	5.82	7.0	
		Week 52	Tezepelumab	45	44 (97.8)	5.42 (1.18)	1.8	4.55	5.32	6.41	7.0	
			Placebo	47	45 (95.7)	4.99 (1.13)	2.9	3.91	4.82	5.64	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	45	40 (88.9)	0.85 (0.99)	-1.4	0.09	0.91	1.50	3.1	0.49 [0.05, 0.93]
			Placebo	47	42 (89.4)	0.40 (0.85)	-1.5	-0.09	0.36	0.91	2.2	
		Week 8	Tezepelumab	45	40 (88.9)	0.88 (1.05)	-0.9	0.14	0.77	1.55	3.5	0.32 [-0.12, 0.75]
			Placebo	47	43 (91.5)	0.58 (0.81)	-1.3	-0.09	0.55	1.09	2.6	
		Week 12	Tezepelumab	45	40 (88.9)	1.03 (1.03)	-0.7	0.36	1.09	1.59	3.5	0.47 [0.04, 0.91]
			Placebo	47	43 (91.5)	0.57 (0.92)	-1.3	0.00	0.36	1.18	3.0	
		Week 16	Tezepelumab	45	40 (88.9)	1.06 (1.01)	-0.7	0.32	0.95	1.59	3.5	0.51 [0.07, 0.94]
			Placebo	47	43 (91.5)	0.54 (1.05)	-3.2	-0.09	0.45	1.27	2.4	
		Week 20	Tezepelumab	45	40 (88.9)	1.02 (1.10)	-0.7	-0.05	0.91	1.68	3.5	0.46 [0.02, 0.89]
			Placebo	47	43 (91.5)	0.54 (1.00)	-3.2	0.18	0.55	1.09	2.5	
		Week 24	Tezepelumab	45	40 (88.9)	1.04 (1.09)	-1.4	0.14	1.09	1.64	3.5	0.44 [0.00, 0.87]
			Placebo	47	43 (91.5)	0.55 (1.13)	-3.2	0.00	0.45	1.45	3.0	
		Week 28	Tezepelumab	45	40 (88.9)	1.11 (1.07)	-0.7	0.32	1.09	1.82	3.5	0.50 [0.06, 0.94]
			Placebo	47	43 (91.5)	0.56 (1.12)	-3.2	0.00	0.36	1.18	3.0	
		Week 32	Tezepelumab	45	40 (88.9)	1.19 (1.14)	-1.1	0.41	1.09	1.95	3.5	0.57 [0.13, 1.01]
			Placebo	47	43 (91.5)	0.58 (1.02)	-3.2	0.00	0.55	1.36	2.4	
		Week 36	Tezepelumab	45	40 (88.9)	1.13 (1.14)	-0.8	0.23	1.09	1.82	3.5	0.52 [0.08, 0.95]
			Placebo	47	43 (91.5)	0.58 (0.97)	-1.8	0.09	0.55	1.18	2.5	
		Week 40	Tezepelumab	45	40 (88.9)	1.22 (1.05)	-0.7	0.32	1.23	1.86	3.5	0.61 [0.17, 1.05]
			Placebo	47	43 (91.5)	0.62 (0.93)	-1.6	0.09	0.64	1.36	2.4	
		Week 44	Tezepelumab	45	40 (88.9)	1.26 (1.13)	-0.7	0.36	1.36	1.95	3.5	0.48 [0.04, 0.92]
			Placebo	47	43 (91.5)	0.73 (1.08)	-1.6	0.00	0.64	1.45	3.2	
		Week 48	Tezepelumab	45	40 (88.9)	1.27 (1.10)	-0.7	0.50	1.32	2.00	3.5	0.54 [0.11, 0.98]
			Placebo	47	43 (91.5)	0.67 (1.09)	-1.6	-0.09	0.64	1.27	3.2	
		Week 52	Tezepelumab	45	40 (88.9)	1.23 (1.11)	-0.7	0.55	1.14	2.09	3.5	0.47 [0.03, 0.91]
			Placebo	47	43 (91.5)	0.72 (1.07)	-1.6	0.09	0.73	1.27	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	53	47 (88.7)	4.13 (0.69)	2.1	3.73	4.18	4.55	5.4	
			Placebo	47	39 (83.0)	3.93 (0.77)	2.5	3.36	3.91	4.36	6.2	
		Week 4	Tezepelumab	53	47 (88.7)	4.54 (1.03)	1.6	3.82	4.36	5.36	6.9	
			Placebo	47	39 (83.0)	4.54 (1.03)	2.6	3.82	4.27	5.18	7.0	
		Week 8	Tezepelumab	53	48 (90.6)	4.84 (1.01)	2.9	4.14	4.64	5.50	7.0	
			Placebo	47	40 (85.1)	4.55 (1.07)	2.2	3.82	4.41	5.14	7.0	
		Week 12	Tezepelumab	53	48 (90.6)	4.94 (0.97)	3.0	4.18	4.86	5.55	7.0	
			Placebo	47	41 (87.2)	4.76 (1.07)	2.8	4.09	4.64	5.45	6.8	
		Week 16	Tezepelumab	53	48 (90.6)	4.91 (0.96)	2.8	4.18	4.77	5.64	6.9	
			Placebo	47	41 (87.2)	4.81 (1.09)	2.6	4.00	4.73	5.45	6.9	
		Week 20	Tezepelumab	53	49 (92.5)	4.90 (1.01)	2.8	4.18	4.82	5.73	6.9	
			Placebo	47	41 (87.2)	4.82 (0.92)	3.2	4.09	4.64	5.27	6.7	
		Week 24	Tezepelumab	53	49 (92.5)	4.97 (1.01)	2.9	4.27	4.73	5.82	7.0	
			Placebo	47	41 (87.2)	4.94 (0.97)	3.2	4.18	4.91	5.55	6.9	
		Week 28	Tezepelumab	53	50 (94.3)	4.90 (1.03)	2.9	4.09	4.59	5.73	7.0	
			Placebo	47	41 (87.2)	4.83 (1.07)	3.2	4.00	4.64	5.55	7.0	
		Week 32	Tezepelumab	53	50 (94.3)	4.96 (0.98)	2.9	4.18	4.86	5.91	6.7	
			Placebo	47	42 (89.4)	4.94 (1.05)	3.2	4.09	4.64	6.00	7.0	
		Week 36	Tezepelumab	53	50 (94.3)	4.91 (0.99)	3.0	4.18	4.73	5.82	6.7	
			Placebo	47	42 (89.4)	5.03 (1.06)	3.2	4.09	5.05	6.00	6.9	
		Week 40	Tezepelumab	53	50 (94.3)	4.98 (0.97)	3.3	4.18	5.00	5.73	7.0	
			Placebo	47	42 (89.4)	5.00 (1.12)	3.2	4.09	4.86	5.82	7.0	
		Week 44	Tezepelumab	53	50 (94.3)	5.02 (1.01)	3.0	4.18	4.91	5.82	7.0	
			Placebo	47	42 (89.4)	5.01 (1.14)	3.2	4.00	5.00	5.91	6.9	
		Week 48	Tezepelumab	53	50 (94.3)	5.01 (1.04)	2.6	4.18	5.00	5.91	6.9	
			Placebo	47	42 (89.4)	5.08 (1.03)	3.5	4.18	4.86	5.91	7.0	
		Week 52	Tezepelumab	53	50 (94.3)	5.01 (1.04)	2.6	4.18	4.95	5.91	6.9	
			Placebo	47	42 (89.4)	4.94 (1.13)	2.7	4.09	4.95	5.82	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	53	44 (83.0)	0.42 (0.95)	-2.8	0.00	0.32	0.73	3.2	-0.19 [-0.62, 0.25]
			Placebo	47	38 (80.9)	0.58 (0.76)	-0.9	0.09	0.55	0.91	2.5	
		Week 8	Tezepelumab	53	45 (84.9)	0.73 (0.90)	-1.3	0.00	0.64	1.09	2.9	0.15 [-0.28, 0.58]
			Placebo	47	38 (80.9)	0.60 (0.89)	-0.9	0.00	0.41	1.09	2.6	
		Week 12	Tezepelumab	53	45 (84.9)	0.85 (0.96)	-1.5	0.18	0.82	1.27	3.1	0.01 [-0.42, 0.44]
			Placebo	47	38 (80.9)	0.83 (1.03)	-1.2	0.18	0.77	1.27	3.3	
		Week 16	Tezepelumab	53	45 (84.9)	0.84 (0.93)	-1.6	0.27	0.73	1.27	3.0	-0.07 [-0.50, 0.37]
			Placebo	47	38 (80.9)	0.91 (0.96)	-0.7	0.36	0.91	1.45	3.5	
		Week 20	Tezepelumab	53	45 (84.9)	0.80 (0.97)	-0.9	0.18	0.64	1.27	2.8	-0.15 [-0.58, 0.29]
			Placebo	47	38 (80.9)	0.94 (0.83)	-0.5	0.36	0.91	1.27	2.7	
		Week 24	Tezepelumab	53	45 (84.9)	0.94 (0.95)	-0.6	0.36	0.73	1.36	3.2	-0.09 [-0.52, 0.35]
			Placebo	47	38 (80.9)	1.02 (0.93)	-0.9	0.27	1.00	1.36	2.9	
		Week 28	Tezepelumab	53	45 (84.9)	0.85 (0.93)	-0.8	0.18	0.73	1.18	3.2	-0.05 [-0.49, 0.38]
			Placebo	47	38 (80.9)	0.91 (1.06)	-1.1	0.18	0.91	1.36	3.7	
		Week 32	Tezepelumab	53	45 (84.9)	0.89 (0.89)	-0.6	0.36	0.82	1.27	2.9	-0.19 [-0.63, 0.24]
			Placebo	47	38 (80.9)	1.07 (0.99)	-0.6	0.36	1.05	1.55	3.3	
		Week 36	Tezepelumab	53	45 (84.9)	0.84 (0.94)	-0.7	0.18	0.73	1.27	3.2	-0.32 [-0.76, 0.11]
			Placebo	47	38 (80.9)	1.17 (1.10)	-0.6	0.45	0.91	2.18	3.3	
		Week 40	Tezepelumab	53	45 (84.9)	0.94 (0.91)	-0.9	0.36	0.82	1.36	2.9	-0.18 [-0.61, 0.26]
			Placebo	47	38 (80.9)	1.12 (1.21)	-1.0	0.18	0.86	2.00	3.5	
		Week 44	Tezepelumab	53	45 (84.9)	0.96 (0.95)	-0.6	0.27	0.82	1.27	3.0	-0.13 [-0.57, 0.30]
			Placebo	47	38 (80.9)	1.10 (1.13)	-0.8	0.36	0.91	1.91	3.4	
		Week 48	Tezepelumab	53	45 (84.9)	0.96 (0.94)	-0.6	0.36	0.82	1.36	3.0	-0.22 [-0.66, 0.21]
			Placebo	47	38 (80.9)	1.19 (1.10)	-0.5	0.27	0.95	2.18	3.4	
		Week 52	Tezepelumab	53	45 (84.9)	0.95 (0.92)	-0.6	0.36	0.82	1.36	3.0	-0.15 [-0.58, 0.29]
			Placebo	47	38 (80.9)	1.10 (1.16)	-0.6	0.18	0.91	2.18	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	4.33 (0.93)	2.2	3.73	4.27	4.91	6.2	
			Placebo	33	29 (87.9)	4.23 (0.90)	2.6	3.64	4.00	4.64	6.2	
		Week 4	Tezepelumab	27	27 (100.0)	4.83 (0.92)	3.1	4.18	4.55	5.36	6.9	
			Placebo	33	30 (90.9)	4.62 (1.07)	3.2	3.91	4.50	5.18	7.0	
		Week 8	Tezepelumab	27	27 (100.0)	5.09 (1.00)	3.3	4.45	4.82	6.09	7.0	
			Placebo	33	30 (90.9)	4.99 (1.01)	3.5	4.00	4.86	5.64	7.0	
		Week 12	Tezepelumab	27	27 (100.0)	5.33 (0.87)	3.9	4.64	5.18	6.00	7.0	
			Placebo	33	30 (90.9)	5.05 (1.17)	3.2	4.00	4.91	6.00	7.0	
		Week 16	Tezepelumab	27	27 (100.0)	5.24 (0.86)	4.1	4.45	5.09	5.91	6.9	
			Placebo	33	30 (90.9)	5.07 (1.16)	2.6	4.09	4.91	6.00	7.0	
		Week 20	Tezepelumab	27	27 (100.0)	5.13 (0.94)	3.9	4.27	4.82	5.82	7.0	
			Placebo	33	30 (90.9)	4.99 (1.01)	3.8	4.09	4.86	5.73	7.0	
		Week 24	Tezepelumab	27	27 (100.0)	5.37 (0.97)	3.9	4.36	5.55	6.18	7.0	
			Placebo	33	30 (90.9)	5.11 (1.15)	3.5	4.18	4.86	6.00	7.0	
		Week 28	Tezepelumab	27	27 (100.0)	5.23 (0.94)	3.9	4.36	5.27	6.00	7.0	
			Placebo	33	30 (90.9)	5.08 (1.27)	3.6	3.91	4.77	6.09	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	5.23 (0.86)	3.6	4.27	5.36	6.00	6.7	
			Placebo	33	31 (93.9)	5.11 (1.13)	3.7	4.00	4.82	6.00	7.0	
		Week 36	Tezepelumab	27	27 (100.0)	5.23 (0.94)	3.8	4.27	5.45	6.00	7.0	
			Placebo	33	31 (93.9)	5.12 (1.16)	3.7	4.00	4.64	6.09	7.0	
		Week 40	Tezepelumab	27	27 (100.0)	5.21 (0.95)	3.7	4.36	5.36	5.82	7.0	
			Placebo	33	31 (93.9)	5.06 (1.28)	3.3	3.91	5.09	6.00	7.0	
		Week 44	Tezepelumab	27	27 (100.0)	5.27 (0.93)	3.9	4.36	5.36	6.00	7.0	
			Placebo	33	31 (93.9)	5.05 (1.28)	3.2	3.91	4.55	6.55	7.0	
		Week 48	Tezepelumab	27	27 (100.0)	5.30 (0.88)	4.1	4.36	5.27	5.91	7.0	
			Placebo	33	31 (93.9)	5.08 (1.25)	3.4	3.91	4.73	6.18	7.0	
		Week 52	Tezepelumab	27	27 (100.0)	5.29 (0.86)	4.2	4.36	5.27	5.91	7.0	
			Placebo	33	31 (93.9)	4.99 (1.31)	2.7	3.82	4.91	6.18	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	27	27 (100.0)	0.49 (1.06)	-1.4	-0.27	0.55	1.18	3.1	0.08 [-0.45, 0.60]
			Placebo	33	29 (87.9)	0.42 (0.76)	-1.0	-0.09	0.18	0.82	2.1	
		Week 8	Tezepelumab	27	27 (100.0)	0.76 (1.28)	-1.5	-0.09	0.73	1.45	3.7	-0.04 [-0.56, 0.49]
			Placebo	33	29 (87.9)	0.80 (0.88)	-1.3	0.27	0.73	1.18	2.8	
		Week 12	Tezepelumab	27	27 (100.0)	1.00 (1.13)	-0.7	0.27	1.00	1.55	4.2	0.13 [-0.40, 0.65]
			Placebo	33	29 (87.9)	0.86 (1.10)	-1.4	0.27	0.91	1.27	3.3	
		Week 16	Tezepelumab	27	27 (100.0)	0.91 (1.15)	-1.7	0.00	0.91	1.45	3.5	0.04 [-0.48, 0.57]
			Placebo	33	29 (87.9)	0.86 (1.00)	-1.0	0.36	0.82	1.27	3.5	
		Week 20	Tezepelumab	27	27 (100.0)	0.80 (1.19)	-2.1	-0.09	0.64	1.55	3.5	0.00 [-0.52, 0.53]
			Placebo	33	29 (87.9)	0.80 (0.89)	-1.0	0.18	0.73	1.09	3.4	
		Week 24	Tezepelumab	27	27 (100.0)	1.04 (1.11)	-0.6	0.09	1.09	1.64	3.5	0.13 [-0.40, 0.65]
			Placebo	33	29 (87.9)	0.91 (0.99)	-0.8	0.27	0.91	1.36	3.2	
		Week 28	Tezepelumab	27	27 (100.0)	0.89 (1.15)	-0.6	-0.18	1.09	1.55	3.5	-0.00 [-0.53, 0.52]
			Placebo	33	29 (87.9)	0.89 (1.03)	-0.5	0.09	0.82	1.36	3.7	
		Week 32	Tezepelumab	27	27 (100.0)	0.89 (1.07)	-1.1	-0.09	0.91	1.55	3.5	-0.06 [-0.58, 0.46]
			Placebo	33	29 (87.9)	0.95 (0.97)	-0.6	0.36	0.91	1.45	3.5	
		Week 36	Tezepelumab	27	27 (100.0)	0.90 (1.15)	-0.8	-0.09	1.09	1.64	3.5	-0.05 [-0.58, 0.47]
			Placebo	33	29 (87.9)	0.95 (1.03)	-0.7	0.36	0.91	1.45	3.5	
		Week 40	Tezepelumab	27	27 (100.0)	0.87 (1.19)	-1.0	-0.18	1.00	1.64	3.5	-0.02 [-0.55, 0.50]
			Placebo	33	29 (87.9)	0.90 (1.10)	-1.0	0.09	0.82	1.45	3.6	
		Week 44	Tezepelumab	27	27 (100.0)	0.94 (1.12)	-0.6	-0.09	0.82	1.64	3.5	0.08 [-0.45, 0.60]
			Placebo	33	29 (87.9)	0.85 (1.17)	-0.8	0.18	0.73	1.45	3.6	
		Week 48	Tezepelumab	27	27 (100.0)	0.97 (1.14)	-0.6	-0.09	1.00	1.64	3.5	0.08 [-0.44, 0.61]
			Placebo	33	29 (87.9)	0.88 (1.04)	-0.5	0.00	0.91	1.27	3.6	
		Week 52	Tezepelumab	27	27 (100.0)	0.95 (1.17)	-1.2	-0.09	1.00	1.64	3.5	0.08 [-0.45, 0.60]
			Placebo	33	29 (87.9)	0.87 (1.10)	-0.8	0.00	0.91	1.27	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	109	95 (87.2)	4.28 (0.92)	1.9	3.73	4.18	4.73	7.0	
			Placebo	105	92 (87.6)	4.12 (0.87)	2.0	3.55	4.14	4.50	6.2	
		Week 4	Tezepelumab	109	98 (89.9)	4.99 (1.14)	1.6	4.09	5.00	5.82	7.0	
			Placebo	105	93 (88.6)	4.63 (1.03)	2.5	3.91	4.55	5.45	6.9	
		Week 8	Tezepelumab	109	100 (91.7)	5.17 (1.13)	1.6	4.27	5.18	6.09	7.0	
			Placebo	105	96 (91.4)	4.70 (1.14)	2.2	3.95	4.45	5.45	7.0	
		Week 12	Tezepelumab	109	100 (91.7)	5.33 (1.18)	1.7	4.32	5.27	6.36	7.0	
			Placebo	105	97 (92.4)	4.84 (1.09)	2.8	4.00	4.64	5.91	7.0	
		Week 16	Tezepelumab	109	100 (91.7)	5.30 (1.14)	2.6	4.27	5.36	6.27	7.0	
			Placebo	105	97 (92.4)	4.90 (1.18)	1.1	4.00	4.82	5.91	7.0	
		Week 20	Tezepelumab	109	101 (92.7)	5.27 (1.20)	1.8	4.36	5.27	6.27	7.0	
			Placebo	105	97 (92.4)	4.88 (1.18)	1.1	4.09	4.73	5.82	7.0	
		Week 24	Tezepelumab	109	101 (92.7)	5.28 (1.19)	1.6	4.27	5.18	6.27	7.0	
			Placebo	105	97 (92.4)	4.90 (1.18)	1.1	4.09	4.82	5.82	7.0	
		Week 28	Tezepelumab	109	103 (94.5)	5.34 (1.14)	2.1	4.36	5.45	6.27	7.0	
			Placebo	105	98 (93.3)	4.90 (1.24)	1.1	4.00	4.82	5.91	7.0	
		Week 32	Tezepelumab	109	104 (95.4)	5.40 (1.16)	1.6	4.50	5.59	6.32	7.0	
			Placebo	105	98 (93.3)	4.95 (1.19)	1.1	4.09	4.77	5.91	7.0	
		Week 36	Tezepelumab	109	104 (95.4)	5.38 (1.14)	1.9	4.45	5.45	6.27	7.0	
			Placebo	105	98 (93.3)	4.98 (1.16)	2.4	4.09	4.82	6.09	7.0	
		Week 40	Tezepelumab	109	104 (95.4)	5.43 (1.12)	2.1	4.68	5.36	6.27	7.0	
			Placebo	105	98 (93.3)	5.02 (1.15)	2.0	4.09	4.95	6.00	7.0	
		Week 44	Tezepelumab	109	104 (95.4)	5.45 (1.14)	2.4	4.55	5.45	6.41	7.0	
			Placebo	105	98 (93.3)	5.03 (1.17)	2.5	4.00	5.05	6.00	7.0	
		Week 48	Tezepelumab	109	104 (95.4)	5.46 (1.14)	2.6	4.55	5.55	6.45	7.0	
			Placebo	105	99 (94.3)	5.03 (1.11)	2.3	4.18	5.00	5.91	7.0	
		Week 52	Tezepelumab	109	104 (95.4)	5.44 (1.17)	1.8	4.64	5.50	6.41	7.0	
			Placebo	105	99 (94.3)	5.04 (1.09)	2.9	4.18	5.00	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	109	89 (81.7)	0.76 (0.98)	-2.8	0.09	0.64	1.36	3.2	0.27 [-0.03, 0.56]
			Placebo	105	90 (85.7)	0.51 (0.89)	-1.5	0.00	0.36	0.91	2.6	
		Week 8	Tezepelumab	109	91 (83.5)	0.88 (0.97)	-0.9	0.09	0.82	1.55	3.5	0.31 [0.02, 0.60]
			Placebo	105	91 (86.7)	0.58 (0.92)	-1.7	-0.09	0.55	1.00	3.3	
		Week 12	Tezepelumab	109	91 (83.5)	1.05 (1.03)	-1.5	0.36	1.00	1.64	3.5	0.32 [0.03, 0.62]
			Placebo	105	91 (86.7)	0.73 (0.99)	-1.9	0.09	0.64	1.18	3.7	
		Week 16	Tezepelumab	109	91 (83.5)	1.04 (1.02)	-1.6	0.27	1.00	1.55	3.5	0.24 [-0.06, 0.53]
			Placebo	105	91 (86.7)	0.80 (1.06)	-3.2	0.18	0.82	1.55	3.9	
		Week 20	Tezepelumab	109	91 (83.5)	1.01 (1.08)	-1.1	0.27	0.91	1.82	3.5	0.21 [-0.08, 0.50]
			Placebo	105	91 (86.7)	0.79 (1.07)	-3.2	0.18	0.73	1.36	4.0	
		Week 24	Tezepelumab	109	91 (83.5)	1.06 (1.05)	-1.4	0.27	1.00	1.73	3.5	0.24 [-0.05, 0.53]
			Placebo	105	91 (86.7)	0.81 (1.10)	-3.2	0.18	0.82	1.55	3.8	
		Week 28	Tezepelumab	109	91 (83.5)	1.10 (1.03)	-1.1	0.45	0.91	2.00	3.5	0.29 [0.00, 0.59]
			Placebo	105	91 (86.7)	0.79 (1.13)	-3.2	0.18	0.82	1.55	4.0	
		Week 32	Tezepelumab	109	91 (83.5)	1.15 (1.03)	-1.0	0.45	1.00	1.91	3.5	0.28 [-0.01, 0.57]
			Placebo	105	91 (86.7)	0.85 (1.09)	-3.2	0.18	0.82	1.55	3.6	
		Week 36	Tezepelumab	109	91 (83.5)	1.12 (1.07)	-0.9	0.27	1.00	1.91	3.5	0.22 [-0.07, 0.51]
			Placebo	105	91 (86.7)	0.88 (1.09)	-1.8	0.18	0.82	1.55	3.4	
		Week 40	Tezepelumab	109	91 (83.5)	1.18 (0.99)	-0.9	0.45	1.09	1.91	3.5	0.24 [-0.05, 0.53]
			Placebo	105	91 (86.7)	0.92 (1.14)	-1.6	0.27	0.82	1.64	4.0	
		Week 44	Tezepelumab	109	91 (83.5)	1.20 (1.04)	-1.1	0.36	1.09	2.00	3.5	0.26 [-0.03, 0.55]
			Placebo	105	91 (86.7)	0.92 (1.11)	-1.6	0.18	0.91	1.55	3.9	
		Week 48	Tezepelumab	109	91 (83.5)	1.23 (1.03)	-1.0	0.45	1.18	2.00	3.5	0.29 [0.00, 0.59]
			Placebo	105	91 (86.7)	0.92 (1.08)	-1.6	0.18	0.82	1.55	3.4	
		Week 52	Tezepelumab	109	91 (83.5)	1.17 (1.05)	-1.2	0.36	1.00	2.00	3.5	0.22 [-0.07, 0.51]
			Placebo	105	91 (86.7)	0.94 (1.05)	-1.6	0.18	0.91	1.55	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	69	63 (91.3)	4.29 (0.83)	2.2	3.91	4.27	4.73	6.2	
			Placebo	72	61 (84.7)	4.25 (0.95)	2.0	3.64	4.18	4.91	6.2	
		Week 4	Tezepelumab	69	60 (87.0)	4.83 (1.10)	1.6	4.18	4.59	5.59	7.0	
			Placebo	72	61 (84.7)	4.65 (1.08)	2.5	3.91	4.55	5.36	7.0	
		Week 8	Tezepelumab	69	61 (88.4)	5.07 (1.01)	3.3	4.27	5.00	6.00	7.0	
			Placebo	72	63 (87.5)	4.89 (1.10)	2.3	4.00	4.82	5.82	7.0	
		Week 12	Tezepelumab	69	61 (88.4)	5.36 (0.99)	3.0	4.64	5.18	6.18	7.0	
			Placebo	72	63 (87.5)	5.01 (1.13)	3.1	4.00	4.82	6.00	7.0	
		Week 16	Tezepelumab	69	61 (88.4)	5.19 (0.99)	2.8	4.36	5.18	6.00	7.0	
			Placebo	72	63 (87.5)	5.07 (1.23)	1.1	4.09	5.27	6.09	7.0	
		Week 20	Tezepelumab	69	62 (89.9)	5.17 (1.06)	2.8	4.27	5.09	5.91	7.0	
			Placebo	72	63 (87.5)	4.96 (1.18)	1.1	4.09	4.82	5.91	7.0	
		Week 24	Tezepelumab	69	62 (89.9)	5.30 (1.01)	3.8	4.36	5.14	6.09	7.0	
			Placebo	72	63 (87.5)	5.05 (1.28)	1.1	4.18	5.18	6.09	7.0	
		Week 28	Tezepelumab	69	63 (91.3)	5.27 (1.02)	3.5	4.36	5.27	6.00	7.0	
			Placebo	72	64 (88.9)	5.09 (1.34)	1.1	4.00	5.09	6.18	7.0	
		Week 32	Tezepelumab	69	64 (92.8)	5.32 (0.98)	3.3	4.36	5.36	6.00	7.0	
			Placebo	72	65 (90.3)	5.11 (1.28)	1.1	4.09	5.36	6.00	7.0	
		Week 36	Tezepelumab	69	64 (92.8)	5.32 (1.01)	3.5	4.41	5.45	6.09	7.0	
			Placebo	72	65 (90.3)	5.23 (1.21)	2.5	4.09	5.36	6.27	7.0	
		Week 40	Tezepelumab	69	64 (92.8)	5.36 (0.99)	3.5	4.41	5.36	6.00	7.0	
			Placebo	72	65 (90.3)	5.19 (1.28)	2.0	4.09	5.27	6.27	7.0	
		Week 44	Tezepelumab	69	64 (92.8)	5.38 (1.02)	3.7	4.45	5.45	6.00	7.0	
			Placebo	72	65 (90.3)	5.21 (1.26)	2.5	4.09	5.27	6.27	7.0	
		Week 48	Tezepelumab	69	64 (92.8)	5.40 (1.01)	3.3	4.36	5.50	6.18	7.0	
			Placebo	72	66 (91.7)	5.19 (1.22)	2.3	4.27	5.36	6.09	7.0	
		Week 52	Tezepelumab	69	64 (92.8)	5.41 (1.00)	3.3	4.45	5.50	6.14	7.0	
			Placebo	72	66 (91.7)	5.20 (1.23)	2.7	4.00	5.36	6.18	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	69	58 (84.1)	0.53 (1.05)	-2.8	-0.09	0.55	1.27	3.1	0.12 [-0.25, 0.48]
			Placebo	72	60 (83.3)	0.42 (0.81)	-1.5	-0.14	0.32	0.82	2.5	
		Week 8	Tezepelumab	69	59 (85.5)	0.78 (1.04)	-1.5	0.00	0.64	1.45	3.7	0.12 [-0.24, 0.48]
			Placebo	72	61 (84.7)	0.66 (0.90)	-1.7	0.00	0.64	1.18	2.8	
		Week 12	Tezepelumab	69	59 (85.5)	1.08 (1.04)	-1.5	0.36	1.09	1.64	4.2	0.28 [-0.08, 0.64]
			Placebo	72	61 (84.7)	0.78 (1.02)	-1.9	0.18	0.91	1.18	3.3	
		Week 16	Tezepelumab	69	59 (85.5)	0.92 (1.04)	-1.7	0.27	0.91	1.45	3.5	0.07 [-0.28, 0.43]
			Placebo	72	61 (84.7)	0.84 (1.10)	-3.2	0.36	1.00	1.45	3.5	
		Week 20	Tezepelumab	69	59 (85.5)	0.88 (1.12)	-2.1	0.18	0.82	1.55	3.5	0.13 [-0.23, 0.49]
			Placebo	72	61 (84.7)	0.73 (1.06)	-3.2	0.18	0.73	1.27	3.4	
		Week 24	Tezepelumab	69	59 (85.5)	1.03 (0.98)	-0.6	0.27	0.91	1.64	3.5	0.19 [-0.17, 0.55]
			Placebo	72	61 (84.7)	0.82 (1.17)	-3.2	0.18	0.91	1.36	3.2	
		Week 28	Tezepelumab	69	59 (85.5)	0.99 (1.08)	-1.1	0.00	1.00	1.64	3.5	0.13 [-0.22, 0.49]
			Placebo	72	61 (84.7)	0.84 (1.16)	-3.2	0.18	0.82	1.45	3.7	
		Week 32	Tezepelumab	69	59 (85.5)	1.02 (1.01)	-1.1	0.36	0.91	1.64	3.5	0.13 [-0.23, 0.49]
			Placebo	72	61 (84.7)	0.88 (1.12)	-3.2	0.45	0.91	1.45	3.5	
		Week 36	Tezepelumab	69	59 (85.5)	1.02 (1.07)	-0.8	0.18	0.91	1.64	3.5	0.02 [-0.34, 0.38]
			Placebo	72	61 (84.7)	0.99 (1.14)	-1.8	0.27	1.00	1.64	3.5	
		Week 40	Tezepelumab	69	59 (85.5)	1.06 (1.07)	-1.0	0.27	1.00	1.73	3.5	0.09 [-0.27, 0.45]
			Placebo	72	61 (84.7)	0.96 (1.20)	-1.5	0.18	1.00	1.55	3.6	
		Week 44	Tezepelumab	69	59 (85.5)	1.06 (1.04)	-0.6	0.18	1.00	1.64	3.5	0.10 [-0.26, 0.46]
			Placebo	72	61 (84.7)	0.96 (1.14)	-1.4	0.27	0.91	1.55	3.6	
		Week 48	Tezepelumab	69	59 (85.5)	1.12 (1.04)	-0.6	0.36	1.09	1.82	3.5	0.16 [-0.20, 0.52]
			Placebo	72	61 (84.7)	0.94 (1.11)	-1.4	0.09	1.00	1.45	3.6	
		Week 52	Tezepelumab	69	59 (85.5)	1.10 (1.06)	-1.2	0.36	1.09	1.64	3.5	0.11 [-0.25, 0.46]
			Placebo	72	61 (84.7)	0.99 (1.11)	-1.4	0.18	1.00	1.64	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	4.29 (1.01)	1.9	3.55	4.18	4.82	7.0	
			Placebo	66	60 (90.9)	4.04 (0.79)	2.5	3.50	4.00	4.41	6.0	
		Week 4	Tezepelumab	67	65 (97.0)	5.07 (1.09)	3.1	4.09	5.09	5.82	7.0	
			Placebo	66	62 (93.9)	4.60 (1.00)	2.6	3.91	4.55	5.45	6.9	
		Week 8	Tezepelumab	67	66 (98.5)	5.22 (1.18)	1.6	4.36	5.27	6.09	7.0	
			Placebo	66	63 (95.5)	4.65 (1.11)	2.2	3.91	4.36	5.36	7.0	
		Week 12	Tezepelumab	67	66 (98.5)	5.31 (1.23)	1.7	4.27	5.32	6.36	7.0	
			Placebo	66	64 (97.0)	4.78 (1.08)	2.8	4.00	4.64	5.55	7.0	
		Week 16	Tezepelumab	67	66 (98.5)	5.37 (1.17)	2.6	4.27	5.45	6.45	7.0	
			Placebo	66	64 (97.0)	4.81 (1.11)	2.9	4.00	4.64	5.64	7.0	
		Week 20	Tezepelumab	67	66 (98.5)	5.31 (1.23)	1.8	4.36	5.36	6.36	7.0	
			Placebo	66	64 (97.0)	4.85 (1.10)	3.0	3.91	4.68	5.73	7.0	
		Week 24	Tezepelumab	67	66 (98.5)	5.30 (1.27)	1.6	4.27	5.41	6.45	7.0	
			Placebo	66	64 (97.0)	4.84 (1.06)	2.7	4.05	4.64	5.73	7.0	
		Week 28	Tezepelumab	67	67 (100.0)	5.36 (1.18)	2.1	4.45	5.55	6.36	7.0	
			Placebo	66	64 (97.0)	4.79 (1.13)	2.5	3.91	4.68	5.73	7.0	
		Week 32	Tezepelumab	67	67 (100.0)	5.41 (1.22)	1.6	4.45	5.73	6.45	7.0	
			Placebo	66	64 (97.0)	4.87 (1.05)	3.1	4.00	4.64	5.73	7.0	
		Week 36	Tezepelumab	67	67 (100.0)	5.37 (1.18)	1.9	4.45	5.45	6.27	7.0	
			Placebo	66	64 (97.0)	4.80 (1.07)	2.4	4.00	4.64	5.55	7.0	
		Week 40	Tezepelumab	67	67 (100.0)	5.41 (1.18)	2.1	4.36	5.45	6.45	7.0	
			Placebo	66	64 (97.0)	4.87 (1.06)	2.5	4.05	4.73	5.68	7.0	
		Week 44	Tezepelumab	67	67 (100.0)	5.45 (1.17)	2.4	4.55	5.36	6.45	7.0	
			Placebo	66	64 (97.0)	4.86 (1.11)	2.7	4.00	4.73	5.68	7.0	
		Week 48	Tezepelumab	67	67 (100.0)	5.46 (1.17)	2.6	4.64	5.55	6.45	7.0	
			Placebo	66	64 (97.0)	4.88 (1.03)	2.4	4.05	4.82	5.77	7.0	
		Week 52	Tezepelumab	67	67 (100.0)	5.40 (1.21)	1.8	4.64	5.45	6.45	7.0	
			Placebo	66	64 (97.0)	4.85 (1.01)	2.9	4.05	4.77	5.68	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	67	58 (86.6)	0.87 (0.92)	-0.8	0.18	0.82	1.36	3.2	0.34 [-0.02, 0.71]
			Placebo	66	59 (89.4)	0.56 (0.91)	-1.5	0.09	0.36	1.09	2.6	
		Week 8	Tezepelumab	67	59 (88.1)	0.93 (1.05)	-0.9	0.09	0.91	1.64	3.5	0.32 [-0.04, 0.69]
			Placebo	66	59 (89.4)	0.61 (0.94)	-1.3	-0.09	0.55	1.00	3.3	
		Week 12	Tezepelumab	67	59 (88.1)	1.00 (1.06)	-0.9	0.18	0.91	1.55	3.5	0.26 [-0.10, 0.62]
			Placebo	66	59 (89.4)	0.73 (1.01)	-1.3	0.09	0.64	1.18	3.7	
		Week 16	Tezepelumab	67	59 (88.1)	1.10 (1.05)	-1.3	0.27	1.09	1.73	3.5	0.31 [-0.05, 0.68]
			Placebo	66	59 (89.4)	0.78 (0.99)	-1.6	0.18	0.64	1.55	3.9	
		Week 20	Tezepelumab	67	59 (88.1)	1.05 (1.09)	-1.1	0.18	1.00	1.91	3.5	0.19 [-0.17, 0.55]
			Placebo	66	59 (89.4)	0.85 (1.00)	-1.6	0.18	0.73	1.36	4.0	
		Week 24	Tezepelumab	67	59 (88.1)	1.08 (1.13)	-1.4	0.18	1.09	1.82	3.5	0.23 [-0.13, 0.60]
			Placebo	66	59 (89.4)	0.84 (0.97)	-1.6	0.27	0.82	1.55	3.8	
		Week 28	Tezepelumab	67	59 (88.1)	1.12 (1.04)	-0.8	0.45	0.91	2.00	3.5	0.32 [-0.04, 0.69]
			Placebo	66	59 (89.4)	0.78 (1.06)	-1.6	0.09	0.64	1.55	4.0	
		Week 32	Tezepelumab	67	59 (88.1)	1.16 (1.08)	-1.0	0.36	1.09	2.18	3.5	0.28 [-0.09, 0.64]
			Placebo	66	59 (89.4)	0.87 (1.00)	-1.6	0.09	0.64	1.55	3.6	
		Week 36	Tezepelumab	67	59 (88.1)	1.12 (1.11)	-0.9	0.18	1.00	1.91	3.5	0.30 [-0.06, 0.67]
			Placebo	66	59 (89.4)	0.80 (1.01)	-1.6	0.18	0.73	1.45	3.4	
		Week 40	Tezepelumab	67	59 (88.1)	1.16 (1.01)	-0.9	0.36	1.09	1.91	3.5	0.28 [-0.08, 0.64]
			Placebo	66	59 (89.4)	0.87 (1.05)	-1.6	0.18	0.73	1.45	4.0	
		Week 44	Tezepelumab	67	59 (88.1)	1.22 (1.08)	-1.1	0.36	1.18	2.00	3.5	0.34 [-0.02, 0.70]
			Placebo	66	59 (89.4)	0.85 (1.10)	-1.6	0.18	0.73	1.55	3.9	
		Week 48	Tezepelumab	67	59 (88.1)	1.23 (1.08)	-1.0	0.36	1.18	2.27	3.5	0.34 [-0.03, 0.70]
			Placebo	66	59 (89.4)	0.88 (1.02)	-1.6	0.18	0.82	1.45	3.4	
		Week 52	Tezepelumab	67	59 (88.1)	1.14 (1.10)	-1.2	0.27	1.00	2.09	3.5	0.28 [-0.09, 0.64]
			Placebo	66	59 (89.4)	0.85 (1.01)	-1.6	0.18	0.82	1.27	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	78	68 (87.2)	4.37 (0.82)	2.2	3.91	4.27	4.86	6.2	
			Placebo	74	63 (85.1)	4.13 (0.81)	2.0	3.55	4.09	4.64	5.9	
		Week 4	Tezepelumab	78	72 (92.3)	4.82 (1.08)	1.6	4.09	4.82	5.41	7.0	
			Placebo	74	66 (89.2)	4.62 (1.04)	2.6	3.91	4.50	5.36	6.9	
		Week 8	Tezepelumab	78	72 (92.3)	5.05 (0.97)	2.9	4.27	5.00	5.95	7.0	
			Placebo	74	66 (89.2)	4.75 (1.10)	2.3	4.00	4.45	5.55	7.0	
		Week 12	Tezepelumab	78	72 (92.3)	5.32 (1.01)	3.0	4.64	5.23	6.23	7.0	
			Placebo	74	67 (90.5)	4.84 (1.11)	3.1	4.00	4.45	5.91	7.0	
		Week 16	Tezepelumab	78	72 (92.3)	5.19 (1.02)	2.8	4.27	5.23	6.05	7.0	
			Placebo	74	67 (90.5)	4.96 (1.05)	2.9	4.00	4.82	5.91	7.0	
		Week 20	Tezepelumab	78	73 (93.6)	5.12 (1.06)	2.8	4.27	5.00	6.00	7.0	
			Placebo	74	67 (90.5)	4.87 (1.07)	2.1	4.00	4.64	5.73	7.0	
		Week 24	Tezepelumab	78	73 (93.6)	5.20 (1.08)	2.9	4.27	5.00	6.09	7.0	
			Placebo	74	67 (90.5)	4.97 (1.15)	2.0	4.00	4.91	5.91	7.0	
		Week 28	Tezepelumab	78	75 (96.2)	5.20 (1.06)	3.2	4.27	5.09	6.09	7.0	
			Placebo	74	68 (91.9)	4.92 (1.15)	2.0	4.00	4.73	5.91	7.0	
		Week 32	Tezepelumab	78	76 (97.4)	5.28 (1.05)	2.9	4.36	5.36	6.18	7.0	
			Placebo	74	69 (93.2)	5.00 (1.13)	1.7	4.00	4.73	6.00	7.0	
		Week 36	Tezepelumab	78	76 (97.4)	5.25 (1.07)	3.0	4.36	5.36	6.14	7.0	
			Placebo	74	69 (93.2)	5.05 (1.11)	2.5	4.09	4.82	6.00	7.0	
		Week 40	Tezepelumab	78	76 (97.4)	5.23 (1.02)	3.3	4.36	5.09	6.00	7.0	
			Placebo	74	69 (93.2)	5.04 (1.14)	2.0	4.18	5.09	5.91	7.0	
		Week 44	Tezepelumab	78	76 (97.4)	5.24 (1.03)	3.0	4.36	5.36	6.00	7.0	
			Placebo	74	69 (93.2)	5.05 (1.19)	2.5	4.00	4.91	6.00	7.0	
		Week 48	Tezepelumab	78	76 (97.4)	5.26 (1.05)	2.6	4.32	5.27	6.18	7.0	
			Placebo	74	70 (94.6)	5.13 (1.14)	2.3	4.09	5.14	6.09	7.0	
		Week 52	Tezepelumab	78	76 (97.4)	5.26 (1.03)	2.6	4.36	5.32	6.05	7.0	
			Placebo	74	70 (94.6)	5.05 (1.15)	2.7	4.00	5.05	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	78	67 (85.9)	0.45 (0.99)	-2.8	-0.18	0.55	1.18	3.1	-0.08 [-0.43, 0.26]
			Placebo	74	63 (85.1)	0.53 (0.87)	-1.5	0.00	0.45	1.09	2.6	
		Week 8	Tezepelumab	78	67 (85.9)	0.66 (0.99)	-1.5	0.00	0.64	1.18	3.7	0.02 [-0.33, 0.36]
			Placebo	74	63 (85.1)	0.65 (0.87)	-1.7	0.09	0.64	1.09	2.6	
		Week 12	Tezepelumab	78	67 (85.9)	0.94 (1.00)	-1.5	0.27	0.91	1.45	4.2	0.19 [-0.15, 0.54]
			Placebo	74	63 (85.1)	0.75 (1.00)	-1.9	0.09	0.82	1.18	3.0	
		Week 16	Tezepelumab	78	67 (85.9)	0.82 (1.01)	-1.7	0.18	0.82	1.45	3.5	-0.06 [-0.40, 0.29]
			Placebo	74	63 (85.1)	0.88 (0.92)	-1.9	0.36	1.00	1.45	2.7	
		Week 20	Tezepelumab	78	67 (85.9)	0.77 (1.07)	-2.1	0.00	0.64	1.45	3.5	-0.03 [-0.38, 0.31]
			Placebo	74	63 (85.1)	0.80 (0.92)	-1.5	0.18	0.73	1.27	2.6	
		Week 24	Tezepelumab	78	67 (85.9)	0.90 (0.98)	-0.6	0.09	0.82	1.45	3.5	0.01 [-0.33, 0.36]
			Placebo	74	63 (85.1)	0.88 (0.97)	-1.5	0.36	0.91	1.36	3.0	
		Week 28	Tezepelumab	78	67 (85.9)	0.89 (1.04)	-1.1	0.00	0.91	1.64	3.5	0.08 [-0.26, 0.43]
			Placebo	74	63 (85.1)	0.81 (0.93)	-1.5	0.27	0.82	1.36	3.0	
		Week 32	Tezepelumab	78	67 (85.9)	0.91 (1.00)	-1.1	0.18	0.82	1.45	3.5	0.01 [-0.33, 0.36]
			Placebo	74	63 (85.1)	0.90 (0.90)	-1.8	0.45	1.00	1.45	2.7	
		Week 36	Tezepelumab	78	67 (85.9)	0.89 (1.03)	-0.8	0.18	0.73	1.45	3.5	-0.08 [-0.42, 0.26]
			Placebo	74	63 (85.1)	0.97 (1.00)	-1.2	0.18	1.00	1.55	3.3	
		Week 40	Tezepelumab	78	67 (85.9)	0.87 (1.01)	-1.0	0.18	0.82	1.36	3.5	-0.08 [-0.43, 0.26]
			Placebo	74	63 (85.1)	0.96 (1.04)	-1.5	0.27	1.00	1.45	3.1	
		Week 44	Tezepelumab	78	67 (85.9)	0.88 (0.99)	-0.6	0.18	0.82	1.55	3.5	-0.06 [-0.40, 0.29]
			Placebo	74	63 (85.1)	0.94 (1.06)	-1.2	0.18	1.00	1.55	3.0	
		Week 48	Tezepelumab	78	67 (85.9)	0.92 (1.01)	-0.6	0.18	0.82	1.55	3.5	-0.10 [-0.44, 0.25]
			Placebo	74	63 (85.1)	1.02 (0.99)	-1.3	0.27	1.09	1.45	3.4	
		Week 52	Tezepelumab	78	67 (85.9)	0.89 (1.01)	-1.2	0.18	0.82	1.45	3.5	-0.08 [-0.42, 0.27]
			Placebo	74	63 (85.1)	0.97 (0.97)	-1.2	0.36	1.09	1.36	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	57	53 (93.0)	4.20 (1.04)	1.9	3.64	4.18	4.64	7.0	
			Placebo	63	57 (90.5)	4.17 (0.96)	2.3	3.64	4.00	4.45	6.2	
		Week 4	Tezepelumab	57	52 (91.2)	5.17 (1.11)	3.1	4.23	5.23	6.05	7.0	
			Placebo	63	57 (90.5)	4.64 (1.03)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.28 (1.26)	1.6	4.36	5.27	6.36	7.0	
			Placebo	63	59 (93.7)	4.80 (1.14)	2.2	4.00	4.82	5.91	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.34 (1.27)	1.7	4.36	5.27	6.45	7.0	
			Placebo	63	59 (93.7)	4.96 (1.12)	2.8	4.09	4.82	6.09	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.42 (1.17)	2.6	4.45	5.36	6.45	7.0	
			Placebo	63	59 (93.7)	4.97 (1.22)	2.6	4.00	4.91	6.00	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.38 (1.26)	1.8	4.55	5.36	6.36	7.0	
			Placebo	63	59 (93.7)	5.01 (1.12)	3.0	4.18	4.82	6.09	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.42 (1.24)	1.6	4.55	5.55	6.55	7.0	
			Placebo	63	59 (93.7)	4.98 (1.11)	2.7	4.09	4.73	6.00	7.0	
		Week 28	Tezepelumab	57	54 (94.7)	5.45 (1.15)	2.1	4.64	5.59	6.36	7.0	
			Placebo	63	59 (93.7)	5.03 (1.26)	2.5	3.91	4.91	6.27	7.0	
		Week 32	Tezepelumab	57	54 (94.7)	5.48 (1.19)	1.6	4.82	5.77	6.27	7.0	
			Placebo	63	59 (93.7)	5.06 (1.12)	3.1	4.09	5.00	5.91	7.0	
		Week 36	Tezepelumab	57	54 (94.7)	5.48 (1.15)	1.9	4.73	5.50	6.27	7.0	
			Placebo	63	59 (93.7)	5.02 (1.19)	2.4	4.09	4.82	6.18	7.0	
		Week 40	Tezepelumab	57	54 (94.7)	5.59 (1.16)	2.1	5.00	5.55	6.55	7.0	
			Placebo	63	59 (93.7)	5.05 (1.21)	2.5	4.00	4.91	6.18	7.0	
		Week 44	Tezepelumab	57	54 (94.7)	5.65 (1.16)	2.4	4.91	5.91	6.64	7.0	
			Placebo	63	59 (93.7)	5.05 (1.18)	3.1	4.00	4.91	5.91	7.0	
		Week 48	Tezepelumab	57	54 (94.7)	5.66 (1.12)	3.1	5.00	5.82	6.55	7.0	
			Placebo	63	59 (93.7)	4.98 (1.12)	2.4	4.09	4.82	5.91	7.0	
		Week 52	Tezepelumab	57	54 (94.7)	5.59 (1.21)	1.8	4.91	5.82	6.55	7.0	
			Placebo	63	59 (93.7)	5.05 (1.11)	3.1	4.18	5.00	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	1.07 (0.92)	-0.7	0.36	1.09	1.59	3.2	0.71 [0.31, 1.11]
			Placebo	63	56 (88.9)	0.44 (0.86)	-1.5	-0.09	0.27	0.91	2.5	
		Week 8	Tezepelumab	57	50 (87.7)	1.09 (1.08)	-0.9	0.45	1.00	1.73	3.5	0.44 [0.05, 0.82]
			Placebo	63	56 (88.9)	0.64 (0.96)	-1.3	-0.09	0.59	1.09	3.3	
		Week 12	Tezepelumab	57	50 (87.7)	1.15 (1.11)	-0.9	0.36	1.09	2.09	3.5	0.34 [-0.04, 0.73]
			Placebo	63	56 (88.9)	0.78 (1.05)	-1.3	0.14	0.73	1.27	3.7	
		Week 16	Tezepelumab	57	50 (87.7)	1.25 (1.07)	-1.3	0.64	1.32	1.91	3.5	0.41 [0.03, 0.80]
			Placebo	63	56 (88.9)	0.81 (1.06)	-1.6	0.18	0.64	1.55	3.9	
		Week 20	Tezepelumab	57	50 (87.7)	1.19 (1.13)	-1.1	0.55	1.05	2.18	3.5	0.32 [-0.06, 0.70]
			Placebo	63	56 (88.9)	0.85 (1.02)	-1.6	0.27	0.68	1.27	4.0	
		Week 24	Tezepelumab	57	50 (87.7)	1.24 (1.14)	-1.4	0.64	1.14	2.00	3.5	0.36 [-0.02, 0.75]
			Placebo	63	56 (88.9)	0.84 (1.06)	-1.6	0.18	0.82	1.50	3.8	
		Week 28	Tezepelumab	57	50 (87.7)	1.25 (1.06)	-0.8	0.55	1.09	2.09	3.5	0.33 [-0.06, 0.71]
			Placebo	63	56 (88.9)	0.89 (1.18)	-1.6	0.05	0.82	1.77	4.0	
		Week 32	Tezepelumab	57	50 (87.7)	1.30 (1.09)	-1.0	0.64	1.18	2.27	3.5	0.35 [-0.04, 0.73]
			Placebo	63	56 (88.9)	0.92 (1.10)	-1.6	0.14	0.59	1.64	3.6	
		Week 36	Tezepelumab	57	50 (87.7)	1.29 (1.14)	-0.9	0.36	1.18	2.36	3.5	0.37 [-0.01, 0.76]
			Placebo	63	56 (88.9)	0.87 (1.11)	-1.6	0.18	0.73	1.59	3.5	
		Week 40	Tezepelumab	57	50 (87.7)	1.40 (1.03)	-0.9	0.73	1.32	2.36	3.5	0.44 [0.05, 0.82]
			Placebo	63	56 (88.9)	0.91 (1.19)	-1.6	0.18	0.73	1.68	4.0	
		Week 44	Tezepelumab	57	50 (87.7)	1.47 (1.07)	-1.1	0.73	1.55	2.36	3.5	0.50 [0.11, 0.88]
			Placebo	63	56 (88.9)	0.91 (1.16)	-1.6	0.27	0.82	1.55	3.9	
		Week 48	Tezepelumab	57	50 (87.7)	1.49 (1.06)	-1.0	0.73	1.45	2.36	3.5	0.60 [0.21, 0.99]
			Placebo	63	56 (88.9)	0.83 (1.11)	-1.6	0.18	0.77	1.59	3.6	
		Week 52	Tezepelumab	57	50 (87.7)	1.39 (1.11)	-1.2	0.73	1.36	2.36	3.5	0.44 [0.05, 0.83]
			Placebo	63	56 (88.9)	0.90 (1.12)	-1.6	0.14	0.82	1.68	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.15 (0.78)	2.1	3.73	4.14	4.55	6.2	
			Placebo	66	54 (81.8)	4.14 (0.92)	2.0	3.55	4.05	4.55	6.1	
		Week 4	Tezepelumab	57	55 (96.5)	4.84 (1.02)	3.1	4.00	4.82	5.45	7.0	
			Placebo	66	57 (86.4)	4.44 (1.04)	2.5	3.82	4.18	5.00	7.0	
		Week 8	Tezepelumab	57	55 (96.5)	5.07 (0.97)	3.0	4.45	5.00	5.91	7.0	
			Placebo	66	60 (90.9)	4.59 (1.03)	2.3	3.91	4.41	5.14	7.0	
		Week 12	Tezepelumab	57	55 (96.5)	5.29 (1.03)	3.4	4.36	5.18	6.18	7.0	
			Placebo	66	60 (90.9)	4.69 (1.06)	2.8	4.00	4.59	5.55	7.0	
		Week 16	Tezepelumab	57	55 (96.5)	5.22 (1.02)	3.5	4.27	5.18	6.18	7.0	
			Placebo	66	60 (90.9)	4.68 (1.19)	1.1	3.91	4.45	5.45	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.24 (1.10)	2.8	4.27	5.27	6.09	7.0	
			Placebo	66	60 (90.9)	4.60 (1.18)	1.1	3.91	4.36	5.32	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.18 (1.16)	1.6	4.27	5.09	6.27	7.0	
			Placebo	66	60 (90.9)	4.60 (1.20)	1.1	3.91	4.50	5.32	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.22 (1.05)	2.9	4.32	5.27	6.05	7.0	
			Placebo	66	60 (90.9)	4.63 (1.25)	1.1	3.86	4.41	5.36	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.26 (1.02)	3.3	4.41	5.23	6.09	7.0	
			Placebo	66	61 (92.4)	4.60 (1.18)	1.1	4.00	4.27	5.45	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.21 (1.07)	3.2	4.32	5.14	5.95	7.0	
			Placebo	66	61 (92.4)	4.60 (1.16)	2.4	3.91	4.36	5.45	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.29 (1.00)	3.5	4.36	5.18	6.05	7.0	
			Placebo	66	61 (92.4)	4.66 (1.19)	2.0	3.91	4.36	5.64	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.22 (1.05)	3.5	4.32	5.23	6.00	7.0	
			Placebo	66	61 (92.4)	4.58 (1.12)	2.5	3.91	4.45	5.27	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.28 (1.06)	3.1	4.32	5.23	6.18	7.0	
			Placebo	66	62 (93.9)	4.65 (1.12)	2.3	3.91	4.45	5.45	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.27 (1.04)	3.1	4.36	5.18	6.14	7.0	
			Placebo	66	62 (93.9)	4.62 (1.12)	2.7	3.82	4.36	5.45	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	57	49 (86.0)	0.76 (0.95)	-1.4	0.18	0.64	1.36	3.2	0.51 [0.11, 0.90]
			Placebo	66	53 (80.3)	0.32 (0.82)	-1.5	-0.18	0.27	0.73	2.5	
		Week 8	Tezepelumab	57	49 (86.0)	0.91 (1.02)	-1.3	0.27	0.91	1.45	3.1	0.48 [0.09, 0.87]
			Placebo	66	54 (81.8)	0.48 (0.74)	-1.3	0.00	0.36	1.00	2.6	
		Week 12	Tezepelumab	57	49 (86.0)	1.12 (1.00)	-0.5	0.36	1.18	1.64	3.1	0.60 [0.21, 1.00]
			Placebo	66	54 (81.8)	0.55 (0.90)	-1.4	0.00	0.55	1.09	2.9	
		Week 16	Tezepelumab	57	49 (86.0)	1.07 (1.05)	-1.7	0.36	1.09	1.55	3.1	0.49 [0.09, 0.88]
			Placebo	66	54 (81.8)	0.56 (1.05)	-3.2	-0.09	0.68	1.27	2.5	
		Week 20	Tezepelumab	57	49 (86.0)	1.11 (1.09)	-0.9	0.36	1.00	1.91	3.3	0.59 [0.19, 0.98]
			Placebo	66	54 (81.8)	0.50 (0.99)	-3.2	0.00	0.64	1.09	2.4	
		Week 24	Tezepelumab	57	49 (86.0)	1.10 (1.10)	-1.4	0.36	1.09	1.73	3.2	0.57 [0.17, 0.96]
			Placebo	66	54 (81.8)	0.49 (1.04)	-3.2	0.00	0.45	1.18	2.5	
		Week 28	Tezepelumab	57	49 (86.0)	1.11 (1.03)	-0.6	0.45	1.09	1.64	3.2	0.54 [0.15, 0.94]
			Placebo	66	54 (81.8)	0.53 (1.09)	-3.2	0.00	0.59	1.18	2.8	
		Week 32	Tezepelumab	57	49 (86.0)	1.18 (1.09)	-1.1	0.45	1.09	2.00	3.2	0.63 [0.23, 1.02]
			Placebo	66	54 (81.8)	0.51 (1.06)	-3.2	-0.09	0.55	1.09	2.6	
		Week 36	Tezepelumab	57	49 (86.0)	1.12 (1.12)	-0.8	0.27	1.09	1.73	3.2	0.56 [0.17, 0.96]
			Placebo	66	54 (81.8)	0.51 (1.04)	-1.8	0.00	0.45	1.09	3.3	
		Week 40	Tezepelumab	57	49 (86.0)	1.19 (1.00)	-0.6	0.45	1.09	1.82	3.1	0.58 [0.19, 0.98]
			Placebo	66	54 (81.8)	0.58 (1.09)	-1.6	-0.09	0.36	1.27	3.5	
		Week 44	Tezepelumab	57	49 (86.0)	1.12 (1.05)	-0.6	0.27	1.18	1.64	3.2	0.65 [0.26, 1.05]
			Placebo	66	54 (81.8)	0.45 (0.99)	-1.6	-0.36	0.36	1.09	2.9	
		Week 48	Tezepelumab	57	49 (86.0)	1.21 (1.03)	-0.6	0.64	1.27	1.64	3.2	0.68 [0.29, 1.08]
			Placebo	66	54 (81.8)	0.52 (0.98)	-1.6	0.00	0.41	1.18	3.4	
		Week 52	Tezepelumab	57	49 (86.0)	1.18 (1.06)	-1.2	0.64	1.18	1.64	3.3	0.63 [0.24, 1.03]
			Placebo	66	54 (81.8)	0.53 (0.99)	-1.6	0.00	0.36	1.18	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	71	66 (93.0)	4.40 (0.98)	1.9	3.73	4.32	5.00	7.0	
			Placebo	63	58 (92.1)	4.15 (0.84)	2.5	3.45	4.05	4.55	6.2	
		Week 4	Tezepelumab	71	63 (88.7)	5.05 (1.18)	1.6	4.09	5.09	5.91	7.0	
			Placebo	63	57 (90.5)	4.77 (1.03)	2.6	4.00	4.55	5.45	7.0	
		Week 8	Tezepelumab	71	65 (91.5)	5.20 (1.20)	1.6	4.18	5.18	6.09	7.0	
			Placebo	63	57 (90.5)	4.89 (1.15)	2.2	4.09	4.82	6.09	7.0	
		Week 12	Tezepelumab	71	65 (91.5)	5.34 (1.21)	1.7	4.55	5.36	6.36	7.0	
			Placebo	63	58 (92.1)	5.03 (1.12)	2.8	4.09	4.86	6.09	7.0	
		Week 16	Tezepelumab	71	65 (91.5)	5.33 (1.14)	2.6	4.36	5.45	6.18	7.0	
			Placebo	63	58 (92.1)	5.13 (1.13)	2.6	4.09	5.00	6.09	7.0	
		Week 20	Tezepelumab	71	65 (91.5)	5.24 (1.22)	1.8	4.36	5.27	6.27	7.0	
			Placebo	63	58 (92.1)	5.12 (1.02)	3.0	4.36	4.95	6.00	7.0	
		Week 24	Tezepelumab	71	65 (91.5)	5.39 (1.13)	2.9	4.45	5.64	6.18	7.0	
			Placebo	63	58 (92.1)	5.20 (1.03)	2.8	4.18	5.23	6.09	6.9	
		Week 28	Tezepelumab	71	66 (93.0)	5.41 (1.15)	2.1	4.45	5.59	6.36	7.0	
			Placebo	63	59 (93.7)	5.21 (1.14)	2.7	4.27	5.09	6.27	7.0	
		Week 32	Tezepelumab	71	67 (94.4)	5.46 (1.17)	1.6	4.64	5.73	6.27	7.0	
			Placebo	63	59 (93.7)	5.33 (1.02)	3.6	4.36	5.36	6.18	7.0	
		Week 36	Tezepelumab	71	67 (94.4)	5.45 (1.13)	1.9	4.45	5.64	6.27	7.0	
			Placebo	63	59 (93.7)	5.36 (1.00)	3.5	4.64	5.27	6.27	7.0	
		Week 40	Tezepelumab	71	67 (94.4)	5.49 (1.16)	2.1	4.82	5.82	6.27	7.0	
			Placebo	63	59 (93.7)	5.37 (1.04)	3.3	4.55	5.27	6.18	7.0	
		Week 44	Tezepelumab	71	67 (94.4)	5.56 (1.13)	2.4	4.91	5.82	6.45	7.0	
			Placebo	63	59 (93.7)	5.39 (1.10)	3.5	4.36	5.36	6.45	7.0	
		Week 48	Tezepelumab	71	67 (94.4)	5.56 (1.12)	2.6	4.64	5.82	6.55	7.0	
			Placebo	63	59 (93.7)	5.36 (1.00)	3.5	4.73	5.36	6.09	7.0	
		Week 52	Tezepelumab	71	67 (94.4)	5.50 (1.19)	1.8	4.64	5.82	6.45	7.0	
			Placebo	63	59 (93.7)	5.39 (1.00)	3.6	4.73	5.45	6.09	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	71	61 (85.9)	0.63 (0.96)	-2.8	0.00	0.55	1.27	2.7	0.03 [-0.33, 0.40]
			Placebo	63	57 (90.5)	0.60 (0.90)	-1.5	0.09	0.45	1.09	2.6	
		Week 8	Tezepelumab	71	63 (88.7)	0.77 (0.93)	-0.9	0.00	0.73	1.45	2.8	0.05 [-0.31, 0.41]
			Placebo	63	57 (90.5)	0.72 (1.04)	-1.7	-0.09	0.73	1.18	3.3	
		Week 12	Tezepelumab	71	63 (88.7)	0.93 (0.97)	-1.5	0.27	1.00	1.45	2.8	0.04 [-0.32, 0.40]
			Placebo	63	57 (90.5)	0.89 (1.08)	-1.9	0.18	0.82	1.18	3.7	
		Week 16	Tezepelumab	71	63 (88.7)	0.93 (0.96)	-1.6	0.27	0.91	1.45	2.7	-0.05 [-0.41, 0.31]
			Placebo	63	57 (90.5)	0.98 (1.04)	-1.9	0.36	0.91	1.55	3.9	
		Week 20	Tezepelumab	71	63 (88.7)	0.83 (0.99)	-1.1	0.18	0.73	1.55	2.7	-0.14 [-0.50, 0.22]
			Placebo	63	57 (90.5)	0.97 (1.03)	-1.3	0.27	0.82	1.45	4.0	
		Week 24	Tezepelumab	71	63 (88.7)	0.98 (0.97)	-0.8	0.27	1.00	1.64	2.9	-0.07 [-0.43, 0.29]
			Placebo	63	57 (90.5)	1.05 (1.04)	-1.5	0.45	1.00	1.73	3.8	
		Week 28	Tezepelumab	71	63 (88.7)	0.98 (1.00)	-1.1	0.18	0.82	1.82	2.8	-0.05 [-0.41, 0.31]
			Placebo	63	57 (90.5)	1.04 (1.09)	-1.3	0.36	1.00	1.73	4.0	
		Week 32	Tezepelumab	71	63 (88.7)	1.00 (0.93)	-1.0	0.36	1.00	1.64	2.7	-0.16 [-0.52, 0.20]
			Placebo	63	57 (90.5)	1.15 (0.99)	-1.2	0.45	1.09	1.55	3.6	
		Week 36	Tezepelumab	71	63 (88.7)	1.00 (1.00)	-0.9	0.18	1.00	1.91	2.8	-0.18 [-0.54, 0.17]
			Placebo	63	57 (90.5)	1.19 (1.02)	-1.2	0.45	1.00	2.00	3.5	
		Week 40	Tezepelumab	71	63 (88.7)	1.03 (0.98)	-0.9	0.27	1.00	1.73	2.8	-0.17 [-0.53, 0.19]
			Placebo	63	57 (90.5)	1.20 (1.07)	-1.2	0.64	1.00	1.73	4.0	
		Week 44	Tezepelumab	71	63 (88.7)	1.12 (1.01)	-1.1	0.36	1.00	2.00	2.9	-0.09 [-0.45, 0.27]
			Placebo	63	57 (90.5)	1.22 (1.11)	-1.2	0.45	1.00	1.91	3.9	
		Week 48	Tezepelumab	71	63 (88.7)	1.12 (1.02)	-1.0	0.36	1.00	2.00	3.1	-0.06 [-0.42, 0.30]
			Placebo	63	57 (90.5)	1.19 (1.04)	-1.2	0.55	1.09	1.91	3.6	
		Week 52	Tezepelumab	71	63 (88.7)	1.03 (1.03)	-1.2	0.18	0.82	1.91	3.1	-0.18 [-0.54, 0.17]
			Placebo	63	57 (90.5)	1.22 (1.03)	-1.2	0.55	1.09	1.91	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	35	31 (88.6)	4.35 (0.97)	2.1	3.91	4.45	5.00	6.2	
			Placebo	32	26 (81.3)	4.22 (0.93)	2.0	3.64	4.23	4.55	6.0	
		Week 4	Tezepelumab	35	33 (94.3)	5.13 (1.01)	3.2	4.27	5.00	6.00	6.9	
			Placebo	32	26 (81.3)	4.56 (1.16)	2.7	3.55	4.50	5.45	6.9	
		Week 8	Tezepelumab	35	33 (94.3)	5.18 (1.00)	3.0	4.36	5.09	6.09	6.8	
			Placebo	32	28 (87.5)	4.57 (1.21)	2.3	3.77	4.18	5.41	7.0	
		Week 12	Tezepelumab	35	33 (94.3)	5.45 (1.00)	3.5	4.73	5.27	6.36	7.0	
			Placebo	32	28 (87.5)	4.77 (1.24)	2.8	3.82	4.77	5.68	7.0	
		Week 16	Tezepelumab	35	33 (94.3)	5.38 (0.91)	3.6	4.55	5.45	6.00	6.8	
			Placebo	32	28 (87.5)	4.73 (1.38)	1.1	3.91	4.68	5.59	7.0	
		Week 20	Tezepelumab	35	34 (97.1)	5.31 (0.99)	3.5	4.36	5.36	6.00	7.0	
			Placebo	32	28 (87.5)	4.70 (1.44)	1.1	3.91	4.50	5.82	7.0	
		Week 24	Tezepelumab	35	34 (97.1)	5.44 (1.02)	3.9	4.45	5.41	6.27	7.0	
			Placebo	32	28 (87.5)	4.63 (1.55)	1.1	3.45	4.50	5.86	7.0	
		Week 28	Tezepelumab	35	35 (100.0)	5.34 (1.01)	2.9	4.45	5.36	6.00	7.0	
			Placebo	32	28 (87.5)	4.45 (1.39)	1.1	3.77	4.41	5.36	7.0	
		Week 32	Tezepelumab	35	35 (100.0)	5.31 (0.99)	3.4	4.36	5.36	6.00	7.0	
			Placebo	32	28 (87.5)	4.65 (1.45)	1.1	3.95	4.45	5.73	7.0	
		Week 36	Tezepelumab	35	35 (100.0)	5.38 (1.04)	3.2	4.45	5.36	6.27	7.0	
			Placebo	32	28 (87.5)	4.77 (1.38)	2.4	3.86	4.59	5.95	7.0	
		Week 40	Tezepelumab	35	35 (100.0)	5.30 (0.96)	3.5	4.45	5.18	6.00	7.0	
			Placebo	32	28 (87.5)	4.63 (1.41)	2.0	3.68	4.27	5.86	7.0	
		Week 44	Tezepelumab	35	35 (100.0)	5.39 (0.94)	3.8	4.45	5.36	6.00	7.0	
			Placebo	32	28 (87.5)	4.76 (1.32)	2.5	3.91	4.55	5.68	7.0	
		Week 48	Tezepelumab	35	35 (100.0)	5.43 (1.03)	3.1	4.45	5.45	6.36	7.0	
			Placebo	32	28 (87.5)	4.67 (1.40)	2.3	3.82	4.36	5.73	7.0	
		Week 52	Tezepelumab	35	35 (100.0)	5.42 (0.97)	3.1	4.91	5.45	6.27	7.0	
			Placebo	32	28 (87.5)	4.67 (1.23)	2.9	3.77	4.36	5.45	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	35	31 (88.6)	0.85 (0.94)	-1.4	0.09	1.09	1.55	3.1	0.48 [-0.05, 1.01]
			Placebo	32	25 (78.1)	0.41 (0.91)	-1.5	-0.18	0.27	0.73	2.6	
		Week 8	Tezepelumab	35	31 (88.6)	0.79 (1.14)	-1.5	0.09	0.91	1.45	3.7	0.39 [-0.14, 0.91]
			Placebo	32	26 (81.3)	0.38 (0.98)	-1.3	-0.09	0.23	1.09	2.6	
		Week 12	Tezepelumab	35	31 (88.6)	1.07 (1.07)	-0.7	0.36	1.18	1.64	4.2	0.45 [-0.07, 0.98]
			Placebo	32	26 (81.3)	0.57 (1.14)	-1.4	-0.18	0.86	1.27	3.0	
		Week 16	Tezepelumab	35	31 (88.6)	1.03 (1.01)	-1.7	0.36	1.18	1.55	3.5	0.43 [-0.10, 0.96]
			Placebo	32	26 (81.3)	0.53 (1.33)	-3.2	-0.64	0.77	1.36	2.7	
		Week 20	Tezepelumab	35	31 (88.6)	0.93 (1.15)	-2.1	0.09	0.91	1.64	3.5	0.34 [-0.19, 0.86]
			Placebo	32	26 (81.3)	0.50 (1.38)	-3.2	-0.36	0.73	1.27	2.6	
		Week 24	Tezepelumab	35	31 (88.6)	1.13 (0.99)	-0.3	0.36	1.09	1.64	3.5	0.56 [0.03, 1.09]
			Placebo	32	26 (81.3)	0.44 (1.45)	-3.2	-0.55	0.82	1.27	3.0	
		Week 28	Tezepelumab	35	31 (88.6)	1.01 (1.05)	-0.5	0.09	0.91	1.64	3.5	0.66 [0.12, 1.19]
			Placebo	32	26 (81.3)	0.24 (1.28)	-3.2	-0.36	0.50	1.09	3.0	
		Week 32	Tezepelumab	35	31 (88.6)	0.96 (1.05)	-0.4	0.09	0.82	1.64	3.5	0.42 [-0.11, 0.95]
			Placebo	32	26 (81.3)	0.46 (1.36)	-3.2	-0.45	0.64	1.27	2.7	
		Week 36	Tezepelumab	35	31 (88.6)	1.05 (1.10)	-0.8	0.18	1.00	1.64	3.5	0.39 [-0.13, 0.92]
			Placebo	32	26 (81.3)	0.58 (1.28)	-1.8	-0.36	0.73	1.45	2.7	
		Week 40	Tezepelumab	35	31 (88.6)	0.97 (1.09)	-1.0	0.36	0.82	1.64	3.5	0.44 [-0.09, 0.97]
			Placebo	32	26 (81.3)	0.44 (1.35)	-1.6	-0.55	0.41	1.45	2.7	
		Week 44	Tezepelumab	35	31 (88.6)	1.07 (1.04)	-0.5	0.27	1.09	1.64	3.5	0.44 [-0.09, 0.96]
			Placebo	32	26 (81.3)	0.57 (1.27)	-1.6	-0.45	0.55	1.27	3.0	
		Week 48	Tezepelumab	35	31 (88.6)	1.14 (1.05)	-0.5	0.36	1.27	1.64	3.5	0.58 [0.04, 1.11]
			Placebo	32	26 (81.3)	0.48 (1.26)	-1.6	-0.27	0.41	1.18	3.0	
		Week 52	Tezepelumab	35	31 (88.6)	1.11 (1.09)	-1.2	0.45	1.18	1.64	3.5	0.58 [0.05, 1.11]
			Placebo	32	26 (81.3)	0.47 (1.11)	-1.6	-0.27	0.36	1.09	3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	95	86 (90.5)	4.26 (0.90)	1.9	3.73	4.18	4.64	7.0	
			Placebo	98	87 (88.8)	4.13 (0.90)	2.3	3.45	4.00	4.64	6.2	
		Week 4	Tezepelumab	95	86 (90.5)	4.91 (1.15)	1.6	4.00	4.91	5.82	7.0	
			Placebo	98	89 (90.8)	4.64 (1.02)	2.5	3.91	4.55	5.36	7.0	
		Week 8	Tezepelumab	95	88 (92.6)	5.15 (1.15)	1.6	4.32	5.18	6.09	7.0	
			Placebo	98	90 (91.8)	4.84 (1.08)	2.2	4.00	4.86	5.64	7.0	
		Week 12	Tezepelumab	95	88 (92.6)	5.31 (1.17)	1.7	4.45	5.23	6.27	7.0	
			Placebo	98	91 (92.9)	4.94 (1.09)	2.8	4.00	4.73	6.00	7.0	
		Week 16	Tezepelumab	95	88 (92.6)	5.27 (1.15)	2.6	4.27	5.27	6.23	7.0	
			Placebo	98	91 (92.9)	4.99 (1.13)	2.6	4.00	4.82	6.00	7.0	
		Week 20	Tezepelumab	95	88 (92.6)	5.21 (1.22)	1.8	4.27	5.23	6.23	7.0	
			Placebo	98	91 (92.9)	4.95 (1.06)	3.0	4.09	4.73	5.82	7.0	
		Week 24	Tezepelumab	95	88 (92.6)	5.27 (1.20)	1.6	4.27	5.23	6.23	7.0	
			Placebo	98	91 (92.9)	5.03 (1.05)	2.8	4.18	4.91	6.00	7.0	
		Week 28	Tezepelumab	95	89 (93.7)	5.31 (1.14)	2.1	4.36	5.45	6.27	7.0	
			Placebo	98	92 (93.9)	5.08 (1.18)	2.7	4.00	4.95	6.05	7.0	
		Week 32	Tezepelumab	95	90 (94.7)	5.39 (1.16)	1.6	4.55	5.55	6.27	7.0	
			Placebo	98	93 (94.9)	5.08 (1.09)	3.1	4.09	4.82	6.00	7.0	
		Week 36	Tezepelumab	95	90 (94.7)	5.33 (1.14)	1.9	4.45	5.45	6.18	7.0	
			Placebo	98	93 (94.9)	5.08 (1.10)	3.1	4.09	4.82	6.09	7.0	
		Week 40	Tezepelumab	95	90 (94.7)	5.41 (1.15)	2.1	4.36	5.45	6.27	7.0	
			Placebo	98	93 (94.9)	5.14 (1.11)	3.1	4.09	5.09	6.09	7.0	
		Week 44	Tezepelumab	95	90 (94.7)	5.43 (1.16)	2.4	4.55	5.45	6.36	7.0	
			Placebo	98	93 (94.9)	5.12 (1.16)	2.7	4.00	5.09	6.00	7.0	
		Week 48	Tezepelumab	95	90 (94.7)	5.45 (1.13)	2.6	4.36	5.55	6.45	7.0	
			Placebo	98	94 (95.9)	5.15 (1.05)	3.1	4.27	5.09	6.00	7.0	
		Week 52	Tezepelumab	95	90 (94.7)	5.41 (1.17)	1.8	4.45	5.50	6.27	7.0	
			Placebo	98	94 (95.9)	5.13 (1.11)	2.7	4.18	5.09	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	95	80 (84.2)	0.66 (1.04)	-2.8	0.00	0.55	1.27	3.2	0.17 [-0.13, 0.48]
			Placebo	98	86 (87.8)	0.50 (0.85)	-1.5	0.00	0.36	0.91	2.5	
		Week 8	Tezepelumab	95	82 (86.3)	0.89 (1.02)	-0.9	0.09	0.73	1.55	3.5	0.18 [-0.12, 0.48]
			Placebo	98	86 (87.8)	0.72 (0.87)	-1.7	0.00	0.73	1.09	3.3	
		Week 12	Tezepelumab	95	82 (86.3)	1.05 (1.04)	-1.5	0.36	1.00	1.55	3.5	0.23 [-0.07, 0.53]
			Placebo	98	86 (87.8)	0.82 (0.99)	-1.9	0.18	0.73	1.18	3.7	
		Week 16	Tezepelumab	95	82 (86.3)	1.03 (1.06)	-1.6	0.18	0.91	1.55	3.5	0.15 [-0.16, 0.45]
			Placebo	98	86 (87.8)	0.88 (0.96)	-1.9	0.27	0.82	1.45	3.9	
		Week 20	Tezepelumab	95	82 (86.3)	0.98 (1.10)	-1.1	0.18	0.91	1.73	3.5	0.13 [-0.17, 0.43]
			Placebo	98	86 (87.8)	0.85 (0.91)	-1.3	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	95	82 (86.3)	1.06 (1.08)	-1.4	0.27	1.05	1.73	3.5	0.13 [-0.17, 0.43]
			Placebo	98	86 (87.8)	0.93 (0.93)	-1.5	0.27	0.82	1.45	3.8	
		Week 28	Tezepelumab	95	82 (86.3)	1.09 (1.07)	-1.1	0.27	1.05	1.91	3.5	0.12 [-0.18, 0.42]
			Placebo	98	86 (87.8)	0.97 (1.00)	-1.3	0.18	0.86	1.55	4.0	
		Week 32	Tezepelumab	95	82 (86.3)	1.15 (1.04)	-1.1	0.45	1.09	1.91	3.5	0.18 [-0.13, 0.48]
			Placebo	98	86 (87.8)	0.98 (0.95)	-1.2	0.36	0.91	1.55	3.6	
		Week 36	Tezepelumab	95	82 (86.3)	1.08 (1.08)	-0.7	0.18	1.00	1.91	3.5	0.10 [-0.20, 0.40]
			Placebo	98	86 (87.8)	0.97 (1.02)	-1.2	0.18	0.91	1.55	3.5	
		Week 40	Tezepelumab	95	82 (86.3)	1.17 (1.02)	-0.9	0.36	1.09	1.91	3.5	0.12 [-0.18, 0.43]
			Placebo	98	86 (87.8)	1.04 (1.05)	-1.2	0.27	0.91	1.55	4.0	
		Week 44	Tezepelumab	95	82 (86.3)	1.19 (1.06)	-0.7	0.27	1.05	2.00	3.5	0.18 [-0.12, 0.48]
			Placebo	98	86 (87.8)	1.00 (1.07)	-1.2	0.27	0.91	1.64	3.9	
		Week 48	Tezepelumab	95	82 (86.3)	1.21 (1.06)	-0.7	0.36	1.09	2.00	3.5	0.17 [-0.13, 0.48]
			Placebo	98	86 (87.8)	1.04 (0.99)	-1.2	0.27	1.00	1.64	3.6	
		Week 52	Tezepelumab	95	82 (86.3)	1.15 (1.06)	-0.7	0.36	1.00	2.00	3.5	0.09 [-0.21, 0.40]
			Placebo	98	86 (87.8)	1.05 (1.03)	-1.2	0.18	1.00	1.64	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	4.35 (1.06)	2.6	3.73	4.64	5.18	5.3	
			Placebo	8	8 (100.0)	4.06 (0.35)	3.5	3.86	4.05	4.32	4.5	
		Week 4	Tezepelumab	7	7 (100.0)	4.77 (0.74)	4.1	4.09	4.64	5.73	5.8	
			Placebo	8	8 (100.0)	4.66 (0.86)	3.6	3.91	4.50	5.45	5.9	
		Week 8	Tezepelumab	7	7 (100.0)	4.92 (0.94)	4.1	4.18	4.45	6.00	6.4	
			Placebo	8	8 (100.0)	4.61 (1.10)	3.1	4.09	4.23	5.36	6.5	
		Week 12	Tezepelumab	7	7 (100.0)	4.99 (0.93)	4.1	4.18	5.00	5.73	6.6	
			Placebo	8	8 (100.0)	4.80 (0.86)	3.9	4.09	4.68	5.18	6.5	
		Week 16	Tezepelumab	7	7 (100.0)	4.97 (0.96)	4.1	4.09	4.73	5.91	6.5	
			Placebo	8	8 (100.0)	5.06 (0.83)	3.9	4.50	5.00	5.45	6.6	
		Week 20	Tezepelumab	7	7 (100.0)	5.09 (0.87)	4.2	4.36	4.73	5.82	6.5	
			Placebo	8	8 (100.0)	5.10 (0.79)	4.1	4.64	5.00	5.41	6.6	
		Week 24	Tezepelumab	7	7 (100.0)	5.05 (1.04)	3.9	4.27	4.45	5.91	6.5	
			Placebo	8	8 (100.0)	5.08 (0.90)	3.9	4.41	5.00	5.64	6.6	
		Week 28	Tezepelumab	7	7 (100.0)	5.09 (1.01)	4.0	4.27	4.64	6.00	6.5	
			Placebo	8	8 (100.0)	5.06 (1.09)	3.2	4.45	5.00	5.82	6.7	
		Week 32	Tezepelumab	7	7 (100.0)	5.23 (1.01)	4.2	4.18	5.09	6.27	6.5	
			Placebo	8	8 (100.0)	5.18 (0.91)	3.6	4.68	5.27	5.68	6.5	
		Week 36	Tezepelumab	7	7 (100.0)	5.31 (0.94)	4.3	4.36	5.45	6.09	6.5	
			Placebo	8	8 (100.0)	5.14 (0.93)	3.8	4.64	5.00	5.59	6.8	
		Week 40	Tezepelumab	7	7 (100.0)	5.36 (0.90)	4.3	4.36	5.18	6.18	6.5	
			Placebo	8	8 (100.0)	5.17 (0.83)	4.1	4.68	5.14	5.41	6.8	
		Week 44	Tezepelumab	7	7 (100.0)	5.27 (1.00)	4.1	4.27	5.36	6.18	6.5	
			Placebo	8	8 (100.0)	5.09 (1.04)	3.8	4.14	5.18	5.68	6.9	
		Week 48	Tezepelumab	7	7 (100.0)	5.21 (0.89)	4.2	4.27	5.09	6.00	6.5	
			Placebo	8	8 (100.0)	5.06 (0.96)	4.0	4.45	4.82	5.45	7.0	
		Week 52	Tezepelumab	7	7 (100.0)	5.29 (1.02)	4.0	4.27	5.09	6.36	6.5	
			Placebo	8	8 (100.0)	5.06 (0.94)	4.0	4.45	4.91	5.36	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	0.44 (0.62)	-0.4	0.00	0.45	0.64	1.5	-0.21 [-1.27, 0.85]
			Placebo	8	8 (100.0)	0.60 (0.86)	-0.6	-0.09	0.64	1.32	1.7	
		Week 8	Tezepelumab	7	6 (85.7)	0.53 (0.81)	-0.7	0.00	0.64	1.09	1.5	-0.03 [-1.08, 1.03]
			Placebo	8	8 (100.0)	0.56 (1.14)	-0.8	-0.23	0.23	1.50	2.3	
		Week 12	Tezepelumab	7	6 (85.7)	0.64 (1.12)	-0.9	0.09	0.45	1.36	2.4	-0.11 [-1.17, 0.95]
			Placebo	8	8 (100.0)	0.74 (0.76)	0.0	0.09	0.77	0.91	2.4	
		Week 16	Tezepelumab	7	6 (85.7)	0.59 (1.08)	-1.1	0.18	0.55	1.27	2.1	-0.44 [-1.51, 0.63]
			Placebo	8	8 (100.0)	1.00 (0.82)	-0.1	0.50	0.73	1.59	2.5	
		Week 20	Tezepelumab	7	6 (85.7)	0.68 (0.95)	-0.8	0.09	0.82	1.27	1.9	-0.44 [-1.51, 0.64]
			Placebo	8	8 (100.0)	1.05 (0.73)	0.4	0.55	0.77	1.45	2.5	
		Week 24	Tezepelumab	7	6 (85.7)	0.56 (0.91)	-0.8	-0.18	0.73	1.27	1.6	-0.52 [-1.60, 0.56]
			Placebo	8	8 (100.0)	1.02 (0.88)	0.1	0.36	0.68	1.77	2.5	
		Week 28	Tezepelumab	7	6 (85.7)	0.62 (0.99)	-0.8	-0.09	0.68	1.27	2.0	-0.36 [-1.43, 0.71]
			Placebo	8	8 (100.0)	1.00 (1.08)	-0.7	0.32	0.82	1.95	2.5	
		Week 32	Tezepelumab	7	6 (85.7)	0.71 (1.14)	-1.0	0.36	0.59	1.27	2.5	-0.42 [-1.49, 0.65]
			Placebo	8	8 (100.0)	1.12 (0.86)	-0.3	0.68	0.95	1.82	2.4	
		Week 36	Tezepelumab	7	6 (85.7)	0.83 (1.22)	-0.9	0.27	0.77	1.27	2.8	-0.24 [-1.30, 0.83]
			Placebo	8	8 (100.0)	1.08 (0.89)	0.3	0.41	0.77	1.68	2.6	
		Week 40	Tezepelumab	7	6 (85.7)	0.88 (1.15)	-0.9	0.27	1.05	1.27	2.5	-0.25 [-1.31, 0.82]
			Placebo	8	8 (100.0)	1.11 (0.77)	0.2	0.68	0.82	1.55	2.6	
		Week 44	Tezepelumab	7	6 (85.7)	0.77 (1.26)	-1.1	0.18	0.77	1.27	2.7	-0.24 [-1.30, 0.83]
			Placebo	8	8 (100.0)	1.03 (0.99)	-0.4	0.36	0.86	1.73	2.7	
		Week 48	Tezepelumab	7	6 (85.7)	0.79 (1.15)	-1.0	0.18	0.91	1.27	2.5	-0.21 [-1.27, 0.85]
			Placebo	8	8 (100.0)	1.00 (0.92)	0.3	0.36	0.68	1.41	2.8	
		Week 52	Tezepelumab	7	6 (85.7)	0.76 (1.21)	-1.2	0.18	0.91	1.27	2.5	-0.24 [-1.30, 0.83]
			Placebo	8	8 (100.0)	1.00 (0.88)	0.3	0.45	0.68	1.32	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.31 (1.22)	2.1	3.86	4.18	5.18	5.9	
			Placebo	13	9 (69.2)	4.35 (0.67)	3.8	3.91	4.27	4.36	6.0	
		Week 4	Tezepelumab	9	8 (88.9)	5.01 (0.88)	3.2	4.68	5.14	5.73	5.8	
			Placebo	13	11 (84.6)	4.60 (0.85)	3.2	3.91	4.55	5.36	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.47 (1.19)	3.0	5.09	5.59	6.27	6.8	
			Placebo	13	12 (92.3)	4.45 (0.83)	3.1	3.95	4.18	5.05	6.0	
		Week 12	Tezepelumab	9	8 (88.9)	5.50 (1.22)	3.5	4.73	5.41	6.64	7.0	
			Placebo	13	12 (92.3)	4.41 (0.87)	2.8	3.91	4.50	5.18	5.5	
		Week 16	Tezepelumab	9	8 (88.9)	5.65 (1.08)	3.6	5.09	5.68	6.55	6.9	
			Placebo	13	12 (92.3)	4.80 (0.92)	3.0	4.41	4.73	5.32	6.6	
		Week 20	Tezepelumab	9	8 (88.9)	5.24 (1.34)	3.5	3.95	5.27	6.55	6.8	
			Placebo	13	12 (92.3)	4.68 (0.93)	3.2	4.05	4.55	5.23	6.6	
		Week 24	Tezepelumab	9	8 (88.9)	5.44 (1.14)	3.9	4.50	5.45	6.41	6.9	
			Placebo	13	12 (92.3)	4.70 (1.16)	2.7	4.00	4.32	5.77	6.6	
		Week 28	Tezepelumab	9	8 (88.9)	5.35 (1.29)	2.9	4.73	5.45	6.36	6.8	
			Placebo	13	13 (100.0)	4.73 (1.34)	2.5	3.82	4.36	5.73	6.7	
		Week 32	Tezepelumab	9	8 (88.9)	5.44 (1.26)	3.4	4.64	5.41	6.55	7.0	
			Placebo	13	13 (100.0)	4.87 (1.22)	3.3	3.82	4.55	5.55	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.48 (1.27)	3.2	4.77	5.50	6.64	6.8	
			Placebo	13	13 (100.0)	4.88 (1.28)	2.4	4.36	4.64	6.00	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.48 (1.19)	3.5	4.77	5.50	6.41	7.0	
			Placebo	13	13 (100.0)	4.76 (1.25)	2.5	3.91	4.36	5.55	6.9	
		Week 44	Tezepelumab	9	8 (88.9)	5.60 (1.12)	3.8	4.77	5.64	6.64	6.9	
			Placebo	13	13 (100.0)	4.92 (1.16)	3.1	4.27	4.91	5.64	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.50 (1.22)	3.1	4.82	5.86	6.36	6.8	
			Placebo	13	13 (100.0)	4.78 (1.24)	2.4	4.18	4.73	5.73	6.8	
		Week 52	Tezepelumab	9	8 (88.9)	5.51 (1.23)	3.1	4.82	5.86	6.41	6.8	
			Placebo	13	13 (100.0)	4.87 (1.10)	3.5	4.18	4.36	5.73	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.65 (0.51)	-0.1	0.00	0.82	1.09	1.2	0.45 [-0.55, 1.45]
			Placebo	13	9 (69.2)	0.27 (1.01)	-1.5	-0.36	0.36	0.64	1.7	
		Week 8	Tezepelumab	9	7 (77.8)	1.12 (0.71)	0.1	0.82	0.91	1.64	2.4	0.95 [-0.10, 2.00]
			Placebo	13	9 (69.2)	0.24 (1.05)	-1.3	-0.18	-0.09	1.00	2.1	
		Week 12	Tezepelumab	9	7 (77.8)	1.21 (0.67)	0.4	0.82	1.09	1.55	2.5	1.39 [0.27, 2.50]
			Placebo	13	9 (69.2)	0.01 (0.98)	-1.3	-1.00	0.09	0.82	1.3	
		Week 16	Tezepelumab	9	7 (77.8)	1.35 (0.78)	0.4	0.82	1.09	1.91	2.7	0.70 [-0.32, 1.72]
			Placebo	13	9 (69.2)	0.62 (1.20)	-1.6	0.55	0.82	1.09	2.4	
		Week 20	Tezepelumab	9	7 (77.8)	1.10 (1.07)	-0.6	0.55	0.82	2.00	2.6	0.55 [-0.46, 1.55]
			Placebo	13	9 (69.2)	0.46 (1.25)	-1.6	-0.55	0.73	0.82	2.4	
		Week 24	Tezepelumab	9	7 (77.8)	1.35 (0.89)	0.3	0.64	1.00	2.36	2.5	0.63 [-0.38, 1.65]
			Placebo	13	9 (69.2)	0.58 (1.43)	-1.6	-0.55	0.82	1.82	2.4	
		Week 28	Tezepelumab	9	7 (77.8)	1.18 (0.91)	0.5	0.55	0.82	2.36	2.6	0.60 [-0.42, 1.61]
			Placebo	13	9 (69.2)	0.42 (1.48)	-1.6	-0.73	0.82	1.64	2.4	
		Week 32	Tezepelumab	9	7 (77.8)	1.31 (0.79)	0.5	0.64	1.09	2.27	2.5	0.69 [-0.33, 1.71]
			Placebo	13	9 (69.2)	0.54 (1.33)	-1.6	-0.55	0.82	1.55	2.4	
		Week 36	Tezepelumab	9	7 (77.8)	1.32 (0.78)	0.7	0.82	0.91	2.36	2.5	0.67 [-0.35, 1.69]
			Placebo	13	9 (69.2)	0.53 (1.43)	-1.6	-0.55	0.82	1.36	2.4	
		Week 40	Tezepelumab	9	7 (77.8)	1.32 (0.88)	0.2	0.82	1.09	2.45	2.5	0.75 [-0.28, 1.77]
			Placebo	13	9 (69.2)	0.43 (1.38)	-1.6	-0.55	0.64	1.64	2.4	
		Week 44	Tezepelumab	9	7 (77.8)	1.47 (0.97)	0.2	0.82	1.09	2.73	2.7	0.76 [-0.26, 1.79]
			Placebo	13	9 (69.2)	0.56 (1.34)	-1.6	-0.55	0.73	1.64	2.4	
		Week 48	Tezepelumab	9	7 (77.8)	1.34 (0.88)	0.4	0.64	1.00	2.36	2.6	0.81 [-0.22, 1.84]
			Placebo	13	9 (69.2)	0.38 (1.37)	-1.6	-0.55	0.82	1.09	2.4	
		Week 52	Tezepelumab	9	7 (77.8)	1.35 (0.80)	0.4	0.82	1.00	2.36	2.5	0.76 [-0.27, 1.79]
			Placebo	13	9 (69.2)	0.56 (1.19)	-1.6	0.09	0.82	1.09	2.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.29 (0.90)	1.9	3.73	4.27	4.82	7.0	
			Placebo	125	112 (89.6)	4.13 (0.89)	2.0	3.50	4.09	4.59	6.2	
		Week 4	Tezepelumab	128	118 (92.2)	4.96 (1.11)	1.6	4.09	4.91	5.82	7.0	
			Placebo	125	112 (89.6)	4.63 (1.05)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	128	120 (93.8)	5.13 (1.09)	1.6	4.27	5.09	6.09	7.0	
			Placebo	125	114 (91.2)	4.80 (1.13)	2.2	4.00	4.64	5.64	7.0	
		Week 12	Tezepelumab	128	120 (93.8)	5.32 (1.11)	1.7	4.45	5.27	6.27	7.0	
			Placebo	125	115 (92.0)	4.94 (1.12)	2.8	4.00	4.73	6.00	7.0	
		Week 16	Tezepelumab	128	120 (93.8)	5.26 (1.08)	2.6	4.27	5.23	6.14	7.0	
			Placebo	125	115 (92.0)	4.95 (1.20)	1.1	4.00	4.82	6.00	7.0	
		Week 20	Tezepelumab	128	121 (94.5)	5.23 (1.14)	1.8	4.36	5.27	6.09	7.0	
			Placebo	125	115 (92.0)	4.93 (1.16)	1.1	4.09	4.73	5.82	7.0	
		Week 24	Tezepelumab	128	121 (94.5)	5.29 (1.15)	1.6	4.36	5.27	6.27	7.0	
			Placebo	125	115 (92.0)	4.97 (1.17)	1.1	4.09	4.91	5.91	7.0	
		Week 28	Tezepelumab	128	123 (96.1)	5.30 (1.09)	2.1	4.36	5.36	6.09	7.0	
			Placebo	125	115 (92.0)	4.96 (1.23)	1.1	4.00	4.82	6.00	7.0	
		Week 32	Tezepelumab	128	124 (96.9)	5.36 (1.10)	1.6	4.41	5.45	6.18	7.0	
			Placebo	125	116 (92.8)	5.01 (1.17)	1.1	4.09	4.82	6.00	7.0	
		Week 36	Tezepelumab	128	124 (96.9)	5.33 (1.09)	1.9	4.41	5.45	6.18	7.0	
			Placebo	125	116 (92.8)	5.03 (1.15)	2.5	4.05	4.82	6.09	7.0	
		Week 40	Tezepelumab	128	124 (96.9)	5.38 (1.08)	2.1	4.36	5.36	6.18	7.0	
			Placebo	125	116 (92.8)	5.06 (1.17)	2.0	4.09	5.05	6.05	7.0	
		Week 44	Tezepelumab	128	124 (96.9)	5.40 (1.09)	2.4	4.45	5.41	6.27	7.0	
			Placebo	125	116 (92.8)	5.05 (1.20)	2.5	4.00	4.91	6.00	7.0	
		Week 48	Tezepelumab	128	124 (96.9)	5.43 (1.08)	2.6	4.36	5.45	6.41	7.0	
			Placebo	125	117 (93.6)	5.07 (1.13)	2.3	4.09	5.00	6.00	7.0	
		Week 52	Tezepelumab	128	124 (96.9)	5.40 (1.10)	1.8	4.45	5.45	6.27	7.0	
			Placebo	125	117 (93.6)	5.05 (1.15)	2.7	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	110 (85.9)	0.70 (1.02)	-2.8	0.00	0.55	1.36	3.2	0.21 [-0.05, 0.48]
			Placebo	125	110 (88.0)	0.50 (0.85)	-1.5	0.00	0.36	0.91	2.6	
		Week 8	Tezepelumab	128	112 (87.5)	0.83 (1.06)	-1.5	0.00	0.68	1.50	3.7	0.17 [-0.10, 0.43]
			Placebo	125	111 (88.8)	0.67 (0.90)	-1.7	0.00	0.64	1.09	3.3	
		Week 12	Tezepelumab	128	112 (87.5)	1.02 (1.06)	-1.5	0.32	1.00	1.59	4.2	0.20 [-0.06, 0.46]
			Placebo	125	111 (88.8)	0.82 (0.99)	-1.9	0.18	0.82	1.27	3.7	
		Week 16	Tezepelumab	128	112 (87.5)	0.98 (1.05)	-1.7	0.23	0.91	1.55	3.5	0.15 [-0.11, 0.41]
			Placebo	125	111 (88.8)	0.83 (1.04)	-3.2	0.27	0.82	1.45	3.9	
		Week 20	Tezepelumab	128	112 (87.5)	0.94 (1.11)	-2.1	0.14	0.91	1.68	3.5	0.12 [-0.14, 0.38]
			Placebo	125	111 (88.8)	0.82 (1.01)	-3.2	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	128	112 (87.5)	1.03 (1.06)	-1.4	0.23	1.05	1.64	3.5	0.17 [-0.09, 0.44]
			Placebo	125	111 (88.8)	0.85 (1.04)	-3.2	0.27	0.82	1.45	3.8	
		Week 28	Tezepelumab	128	112 (87.5)	1.04 (1.07)	-1.1	0.18	1.00	1.82	3.5	0.18 [-0.08, 0.44]
			Placebo	125	111 (88.8)	0.84 (1.07)	-3.2	0.18	0.82	1.45	4.0	
		Week 32	Tezepelumab	128	112 (87.5)	1.07 (1.06)	-1.1	0.32	1.00	1.82	3.5	0.16 [-0.11, 0.42]
			Placebo	125	111 (88.8)	0.90 (1.04)	-3.2	0.36	0.91	1.55	3.6	
		Week 36	Tezepelumab	128	112 (87.5)	1.04 (1.10)	-0.9	0.18	1.00	1.73	3.5	0.11 [-0.15, 0.37]
			Placebo	125	111 (88.8)	0.93 (1.04)	-1.8	0.18	0.91	1.55	3.5	
		Week 40	Tezepelumab	128	112 (87.5)	1.09 (1.05)	-1.0	0.32	1.05	1.77	3.5	0.12 [-0.14, 0.39]
			Placebo	125	111 (88.8)	0.95 (1.10)	-1.5	0.27	0.82	1.55	4.0	
		Week 44	Tezepelumab	128	112 (87.5)	1.11 (1.06)	-1.1	0.27	1.00	1.82	3.5	0.17 [-0.10, 0.43]
			Placebo	125	111 (88.8)	0.93 (1.10)	-1.4	0.18	0.91	1.55	3.9	
		Week 48	Tezepelumab	128	112 (87.5)	1.16 (1.07)	-1.0	0.36	1.09	1.91	3.5	0.20 [-0.07, 0.46]
			Placebo	125	111 (88.8)	0.96 (1.03)	-1.4	0.18	0.91	1.45	3.6	
		Week 52	Tezepelumab	128	112 (87.5)	1.10 (1.09)	-1.2	0.27	1.00	1.86	3.5	0.14 [-0.12, 0.41]
			Placebo	125	111 (88.8)	0.95 (1.04)	-1.4	0.18	0.91	1.55	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	4.42 (0.92)	1.9	3.91	4.27	4.95	7.0	
			Placebo	73	66 (90.4)	4.01 (0.93)	2.0	3.36	4.00	4.45	6.1	
		Week 4	Tezepelumab	70	65 (92.9)	5.04 (1.13)	3.1	4.18	4.91	6.00	7.0	
			Placebo	73	66 (90.4)	4.52 (1.03)	2.6	3.82	4.23	5.27	6.9	
		Week 8	Tezepelumab	70	65 (92.9)	5.15 (1.13)	1.6	4.36	5.09	6.00	7.0	
			Placebo	73	67 (91.8)	4.69 (1.14)	2.2	3.91	4.36	5.64	7.0	
		Week 12	Tezepelumab	70	65 (92.9)	5.31 (1.19)	1.7	4.27	5.36	6.27	7.0	
			Placebo	73	68 (93.2)	4.82 (1.11)	2.8	4.00	4.59	5.91	7.0	
		Week 16	Tezepelumab	70	65 (92.9)	5.28 (1.11)	2.6	4.27	5.36	6.09	7.0	
			Placebo	73	68 (93.2)	4.85 (1.11)	2.6	3.95	4.64	5.86	7.0	
		Week 20	Tezepelumab	70	65 (92.9)	5.23 (1.19)	1.8	4.36	5.36	6.00	7.0	
			Placebo	73	68 (93.2)	4.89 (1.05)	3.0	3.95	4.59	5.73	7.0	
		Week 24	Tezepelumab	70	65 (92.9)	5.30 (1.21)	1.6	4.36	5.36	6.18	7.0	
			Placebo	73	68 (93.2)	4.95 (1.09)	2.8	4.09	4.73	5.91	7.0	
		Week 28	Tezepelumab	70	65 (92.9)	5.35 (1.12)	2.1	4.36	5.45	6.09	7.0	
			Placebo	73	68 (93.2)	4.90 (1.14)	2.7	4.00	4.64	5.95	7.0	
		Week 32	Tezepelumab	70	66 (94.3)	5.40 (1.12)	1.6	4.64	5.73	6.18	7.0	
			Placebo	73	69 (94.5)	4.95 (1.09)	3.1	4.00	4.64	5.91	7.0	
		Week 36	Tezepelumab	70	66 (94.3)	5.33 (1.13)	1.9	4.45	5.41	6.18	7.0	
			Placebo	73	69 (94.5)	5.04 (1.11)	3.2	4.09	4.73	6.09	7.0	
		Week 40	Tezepelumab	70	66 (94.3)	5.44 (1.11)	2.1	4.73	5.45	6.18	7.0	
			Placebo	73	69 (94.5)	5.01 (1.09)	3.2	4.00	4.91	6.00	7.0	
		Week 44	Tezepelumab	70	66 (94.3)	5.49 (1.12)	2.4	4.55	5.64	6.27	7.0	
			Placebo	73	69 (94.5)	5.01 (1.19)	2.7	4.00	4.73	6.00	7.0	
		Week 48	Tezepelumab	70	66 (94.3)	5.49 (1.08)	3.3	4.64	5.55	6.45	7.0	
			Placebo	73	70 (95.9)	5.06 (1.08)	3.2	4.09	5.00	5.91	7.0	
		Week 52	Tezepelumab	70	66 (94.3)	5.44 (1.13)	1.8	4.64	5.55	6.18	7.0	
			Placebo	73	70 (95.9)	4.98 (1.12)	2.7	4.00	4.95	5.82	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 4	Tezepelumab	70	61 (87.1)	0.66 (1.01)	-1.4	0.00	0.55	1.27	3.2	0.15 [-0.20, 0.50]
			Placebo	73	65 (89.0)	0.52 (0.86)	-1.5	-0.09	0.36	0.91	2.6	
		Week 8	Tezepelumab	70	61 (87.1)	0.76 (1.08)	-1.5	0.00	0.64	1.27	3.5	0.07 [-0.28, 0.42]
			Placebo	73	65 (89.0)	0.68 (0.94)	-1.7	0.00	0.64	1.09	3.3	
		Week 12	Tezepelumab	70	61 (87.1)	0.91 (1.04)	-0.7	0.00	0.91	1.45	3.5	0.08 [-0.27, 0.43]
			Placebo	73	65 (89.0)	0.82 (1.05)	-1.9	0.18	0.82	1.18	3.7	
		Week 16	Tezepelumab	70	61 (87.1)	0.90 (1.04)	-1.7	0.18	0.91	1.45	3.5	0.05 [-0.30, 0.40]
			Placebo	73	65 (89.0)	0.85 (1.03)	-1.9	0.27	0.91	1.45	3.9	
		Week 20	Tezepelumab	70	61 (87.1)	0.84 (1.11)	-2.1	0.00	0.91	1.55	3.5	-0.05 [-0.40, 0.30]
			Placebo	73	65 (89.0)	0.89 (1.02)	-1.3	0.27	0.91	1.27	4.0	
		Week 24	Tezepelumab	70	61 (87.1)	0.93 (1.05)	-1.4	0.09	0.91	1.55	3.5	-0.03 [-0.38, 0.32]
			Placebo	73	65 (89.0)	0.96 (1.01)	-1.5	0.36	1.00	1.45	3.8	
		Week 28	Tezepelumab	70	61 (87.1)	0.95 (1.05)	-1.1	0.18	0.91	1.55	3.5	0.04 [-0.31, 0.39]
			Placebo	73	65 (89.0)	0.91 (1.02)	-1.3	0.18	0.73	1.55	4.0	
		Week 32	Tezepelumab	70	61 (87.1)	1.01 (1.01)	-1.1	0.36	1.00	1.45	3.5	0.04 [-0.31, 0.38]
			Placebo	73	65 (89.0)	0.97 (1.01)	-1.2	0.36	0.91	1.55	3.6	
		Week 36	Tezepelumab	70	61 (87.1)	0.92 (1.07)	-0.8	0.09	0.91	1.55	3.5	-0.14 [-0.49, 0.21]
			Placebo	73	65 (89.0)	1.07 (1.10)	-1.2	0.27	0.91	1.64	3.5	
		Week 40	Tezepelumab	70	61 (87.1)	1.02 (1.03)	-1.0	0.27	1.00	1.64	3.5	-0.01 [-0.36, 0.34]
			Placebo	73	65 (89.0)	1.04 (1.14)	-1.5	0.27	1.00	1.55	4.0	
		Week 44	Tezepelumab	70	61 (87.1)	1.08 (1.03)	-0.6	0.18	1.00	1.73	3.5	0.05 [-0.30, 0.40]
			Placebo	73	65 (89.0)	1.02 (1.12)	-1.2	0.18	0.91	1.55	3.9	
		Week 48	Tezepelumab	70	61 (87.1)	1.09 (1.04)	-0.6	0.27	1.00	1.73	3.5	0.01 [-0.34, 0.36]
			Placebo	73	65 (89.0)	1.08 (1.04)	-1.2	0.27	1.09	1.64	3.6	
		Week 52	Tezepelumab	70	61 (87.1)	1.01 (1.07)	-1.2	0.18	0.91	1.64	3.5	-0.02 [-0.36, 0.33]
			Placebo	73	65 (89.0)	1.02 (1.07)	-1.2	0.18	1.00	1.45	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	4.15 (0.90)	2.1	3.64	4.09	4.55	6.3	
			Placebo	65	55 (84.6)	4.31 (0.78)	2.3	3.82	4.27	4.64	6.2	
		Week 4	Tezepelumab	67	61 (91.0)	4.87 (1.05)	1.6	4.18	4.91	5.73	6.9	
			Placebo	65	57 (87.7)	4.75 (1.03)	2.5	4.00	4.55	5.45	7.0	
		Week 8	Tezepelumab	67	63 (94.0)	5.14 (1.07)	2.9	4.18	5.27	6.09	6.9	
			Placebo	65	59 (90.8)	4.85 (1.07)	2.3	4.09	4.73	5.64	7.0	
		Week 12	Tezepelumab	67	63 (94.0)	5.35 (1.04)	3.0	4.64	5.18	6.36	7.0	
			Placebo	65	59 (90.8)	4.98 (1.11)	2.8	4.09	4.91	6.00	7.0	
		Week 16	Tezepelumab	67	63 (94.0)	5.29 (1.06)	2.8	4.36	5.27	6.18	7.0	
			Placebo	65	59 (90.8)	5.03 (1.25)	1.1	4.09	4.91	6.00	7.0	
		Week 20	Tezepelumab	67	64 (95.5)	5.23 (1.10)	2.8	4.27	5.14	6.27	7.0	
			Placebo	65	59 (90.8)	4.92 (1.25)	1.1	4.09	4.82	5.91	7.0	
		Week 24	Tezepelumab	67	64 (95.5)	5.30 (1.08)	2.9	4.32	5.18	6.27	7.0	
			Placebo	65	59 (90.8)	4.94 (1.27)	1.1	4.09	5.00	5.82	7.0	
		Week 28	Tezepelumab	67	66 (98.5)	5.27 (1.08)	2.9	4.36	5.23	6.27	7.0	
			Placebo	65	60 (92.3)	4.99 (1.36)	1.1	3.91	5.09	6.00	7.0	
		Week 32	Tezepelumab	67	66 (98.5)	5.32 (1.09)	2.9	4.36	5.27	6.18	7.0	
			Placebo	65	60 (92.3)	5.05 (1.26)	1.1	4.09	5.09	6.00	7.0	
		Week 36	Tezepelumab	67	66 (98.5)	5.35 (1.07)	3.0	4.45	5.45	6.18	7.0	
			Placebo	65	60 (92.3)	4.98 (1.22)	2.4	4.05	4.95	6.00	7.0	
		Week 40	Tezepelumab	67	66 (98.5)	5.33 (1.06)	3.3	4.36	5.18	6.18	7.0	
			Placebo	65	60 (92.3)	5.05 (1.28)	2.0	4.09	5.09	6.14	7.0	
		Week 44	Tezepelumab	67	66 (98.5)	5.33 (1.07)	3.0	4.45	5.36	6.27	7.0	
			Placebo	65	60 (92.3)	5.07 (1.20)	2.5	4.05	5.14	5.95	7.0	
		Week 48	Tezepelumab	67	66 (98.5)	5.38 (1.09)	2.6	4.36	5.41	6.36	7.0	
			Placebo	65	60 (92.3)	5.02 (1.21)	2.3	4.05	4.95	6.05	7.0	
		Week 52	Tezepelumab	67	66 (98.5)	5.37 (1.10)	2.6	4.36	5.27	6.36	7.0	
			Placebo	65	60 (92.3)	5.08 (1.17)	2.9	4.05	5.00	6.05	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 4	Tezepelumab	67	56 (83.6)	0.74 (1.00)	-2.8	0.00	0.73	1.45	3.1	0.32 [-0.06, 0.70]
			Placebo	65	54 (83.1)	0.44 (0.86)	-1.5	0.00	0.36	0.82	2.5	
		Week 8	Tezepelumab	67	58 (86.6)	0.94 (1.00)	-1.3	0.27	0.91	1.55	3.7	0.38 [0.01, 0.75]
			Placebo	65	55 (84.6)	0.58 (0.89)	-1.3	-0.09	0.55	1.00	2.6	
		Week 12	Tezepelumab	67	58 (86.6)	1.17 (1.04)	-1.5	0.45	1.09	1.73	4.2	0.48 [0.11, 0.86]
			Placebo	65	55 (84.6)	0.68 (0.97)	-1.3	0.09	0.73	1.18	3.3	
		Week 16	Tezepelumab	67	58 (86.6)	1.11 (1.04)	-1.6	0.36	1.05	1.82	3.5	0.33 [-0.04, 0.70]
			Placebo	65	55 (84.6)	0.76 (1.08)	-3.2	0.27	0.82	1.55	3.5	
		Week 20	Tezepelumab	67	58 (86.6)	1.08 (1.09)	-0.9	0.36	0.95	1.91	3.5	0.38 [0.01, 0.75]
			Placebo	65	55 (84.6)	0.67 (1.04)	-3.2	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	67	58 (86.6)	1.18 (1.05)	-0.8	0.36	1.09	1.91	3.5	0.46 [0.09, 0.84]
			Placebo	65	55 (84.6)	0.68 (1.13)	-3.2	0.09	0.64	1.45	2.9	
		Week 28	Tezepelumab	67	58 (86.6)	1.14 (1.06)	-0.8	0.45	1.00	2.00	3.5	0.39 [0.02, 0.77]
			Placebo	65	55 (84.6)	0.70 (1.20)	-3.2	0.09	0.82	1.36	3.7	
		Week 32	Tezepelumab	67	58 (86.6)	1.16 (1.08)	-1.0	0.36	0.95	1.91	3.5	0.37 [-0.01, 0.74]
			Placebo	65	55 (84.6)	0.76 (1.11)	-3.2	0.27	0.82	1.55	3.3	
		Week 36	Tezepelumab	67	58 (86.6)	1.21 (1.09)	-0.9	0.45	1.05	1.91	3.5	0.49 [0.11, 0.86]
			Placebo	65	55 (84.6)	0.69 (1.02)	-1.8	0.09	0.73	1.27	2.7	
		Week 40	Tezepelumab	67	58 (86.6)	1.18 (1.05)	-0.9	0.36	1.09	1.91	3.5	0.39 [0.01, 0.76]
			Placebo	65	55 (84.6)	0.77 (1.10)	-1.6	0.18	0.73	1.64	3.5	
		Week 44	Tezepelumab	67	58 (86.6)	1.19 (1.09)	-1.1	0.36	1.05	1.91	3.5	0.39 [0.01, 0.76]
			Placebo	65	55 (84.6)	0.77 (1.11)	-1.6	0.09	0.73	1.55	3.4	
		Week 48	Tezepelumab	67	58 (86.6)	1.26 (1.07)	-1.0	0.45	1.18	2.00	3.5	0.51 [0.14, 0.89]
			Placebo	65	55 (84.6)	0.71 (1.06)	-1.6	0.09	0.82	1.27	3.2	
		Week 52	Tezepelumab	67	58 (86.6)	1.23 (1.07)	-1.2	0.55	1.18	1.91	3.5	0.41 [0.04, 0.79]
			Placebo	65	55 (84.6)	0.80 (1.04)	-1.6	0.09	0.82	1.55	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	11	9 (81.8)	4.40 (0.70)	3.7	3.82	4.27	4.55	5.8	
			Placebo	6	4 (66.7)	3.45 (0.61)	2.6	3.00	3.59	3.91	4.0	
		Week 4	Tezepelumab	11	11 (100.0)	4.65 (0.94)	3.5	3.64	4.73	5.36	6.3	
			Placebo	6	5 (83.3)	3.56 (0.34)	3.2	3.36	3.55	3.64	4.1	
		Week 8	Tezepelumab	11	11 (100.0)	5.13 (0.86)	3.5	4.45	5.27	5.91	6.2	
			Placebo	6	5 (83.3)	3.98 (0.66)	3.4	3.64	3.91	3.91	5.1	
		Week 12	Tezepelumab	11	11 (100.0)	5.29 (0.96)	3.5	4.73	5.27	6.27	6.6	
			Placebo	6	5 (83.3)	3.87 (0.81)	2.8	3.36	3.91	4.45	4.8	
		Week 16	Tezepelumab	11	11 (100.0)	5.12 (0.95)	3.5	4.09	5.27	6.00	6.2	
			Placebo	6	5 (83.3)	4.16 (0.91)	3.0	3.82	4.00	4.55	5.5	
		Week 20	Tezepelumab	11	11 (100.0)	4.97 (1.09)	2.8	4.36	5.09	5.82	6.4	
			Placebo	6	5 (83.3)	4.13 (0.79)	3.2	3.91	4.09	4.09	5.4	
		Week 24	Tezepelumab	11	11 (100.0)	5.05 (0.92)	3.5	4.18	5.18	5.73	6.4	
			Placebo	6	5 (83.3)	3.64 (0.59)	2.7	3.45	3.82	3.91	4.3	
		Week 28	Tezepelumab	11	11 (100.0)	5.06 (0.93)	3.5	4.36	5.27	5.73	6.4	
			Placebo	6	5 (83.3)	3.62 (1.00)	2.5	2.73	3.91	3.91	5.0	
		Week 32	Tezepelumab	11	11 (100.0)	5.02 (1.01)	3.3	4.18	5.27	5.82	6.4	
			Placebo	6	5 (83.3)	4.07 (0.49)	3.3	4.00	4.18	4.36	4.5	
		Week 36	Tezepelumab	11	11 (100.0)	5.13 (0.83)	3.5	4.36	5.45	5.55	6.5	
			Placebo	6	5 (83.3)	3.84 (1.00)	2.4	3.55	3.82	4.45	5.0	
		Week 40	Tezepelumab	11	11 (100.0)	5.12 (0.78)	3.5	4.36	5.36	5.64	6.0	
			Placebo	6	5 (83.3)	4.35 (1.28)	2.5	3.91	4.09	5.55	5.6	
		Week 44	Tezepelumab	11	11 (100.0)	5.00 (0.84)	3.5	4.09	5.36	5.55	6.0	
			Placebo	6	5 (83.3)	4.20 (1.01)	3.1	3.55	3.91	4.91	5.5	
		Week 48	Tezepelumab	11	11 (100.0)	5.12 (0.90)	3.5	4.18	5.18	5.55	6.5	
			Placebo	6	5 (83.3)	4.24 (1.19)	2.4	3.82	4.73	4.91	5.4	
		Week 52	Tezepelumab	11	11 (100.0)	5.10 (0.92)	3.5	4.09	5.18	5.55	6.5	
			Placebo	6	5 (83.3)	4.45 (0.68)	3.7	3.91	4.36	4.91	5.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	11	9 (81.8)	0.49 (0.65)	-0.4	0.00	0.55	0.82	1.7	0.62 [-0.58, 1.83]
			Placebo	6	4 (66.7)	0.09 (0.63)	-0.6	-0.32	0.05	0.50	0.9	
		Week 8	Tezepelumab	11	9 (81.8)	0.85 (0.83)	-0.7	0.27	1.00	1.55	1.8	0.30 [-0.88, 1.49]
			Placebo	6	4 (66.7)	0.55 (1.36)	-0.6	-0.41	0.18	1.50	2.5	
		Week 12	Tezepelumab	11	9 (81.8)	0.98 (0.78)	-0.9	0.82	1.18	1.45	1.8	0.59 [-0.61, 1.80]
			Placebo	6	4 (66.7)	0.41 (1.33)	-1.0	-0.50	0.23	1.32	2.2	
		Week 16	Tezepelumab	11	9 (81.8)	0.78 (0.88)	-1.1	0.36	1.09	1.45	1.5	0.18 [-1.00, 1.36]
			Placebo	6	4 (66.7)	0.61 (1.01)	-0.8	-0.09	0.91	1.32	1.5	
		Week 20	Tezepelumab	11	9 (81.8)	0.62 (0.93)	-0.9	0.55	0.64	1.45	1.5	-0.10 [-1.28, 1.08]
			Placebo	6	4 (66.7)	0.73 (1.45)	-0.6	-0.27	0.41	1.73	2.7	
		Week 24	Tezepelumab	11	9 (81.8)	0.78 (0.85)	-0.8	0.27	0.64	1.36	2.0	0.85 [-0.38, 2.08]
			Placebo	6	4 (66.7)	0.02 (0.97)	-1.1	-0.64	-0.05	0.68	1.3	
		Week 28	Tezepelumab	11	9 (81.8)	0.75 (0.79)	-0.8	0.55	1.09	1.36	1.5	0.58 [-0.62, 1.78]
			Placebo	6	4 (66.7)	0.09 (1.74)	-1.3	-1.27	-0.36	1.45	2.4	
		Week 32	Tezepelumab	11	9 (81.8)	0.71 (0.90)	-1.0	0.55	1.00	1.27	1.8	0.23 [-0.96, 1.41]
			Placebo	6	4 (66.7)	0.50 (0.95)	-0.5	-0.18	0.41	1.18	1.7	
		Week 36	Tezepelumab	11	9 (81.8)	0.87 (0.73)	-0.9	0.73	1.09	1.27	1.6	0.74 [-0.48, 1.96]
			Placebo	6	4 (66.7)	0.23 (1.15)	-1.5	-0.50	0.68	0.95	1.0	
		Week 40	Tezepelumab	11	9 (81.8)	0.82 (0.77)	-0.9	0.64	1.27	1.36	1.4	-0.16 [-1.34, 1.02]
			Placebo	6	4 (66.7)	1.00 (1.78)	-1.3	-0.27	1.14	2.27	3.0	
		Week 44	Tezepelumab	11	9 (81.8)	0.75 (0.87)	-1.1	0.18	1.09	1.36	1.5	0.20 [-0.98, 1.38]
			Placebo	6	4 (66.7)	0.57 (0.96)	-0.7	-0.09	0.73	1.23	1.5	
		Week 48	Tezepelumab	11	9 (81.8)	0.91 (0.87)	-1.0	0.36	1.27	1.36	1.9	0.22 [-0.96, 1.41]
			Placebo	6	4 (66.7)	0.66 (1.59)	-1.5	-0.50	0.91	1.82	2.3	
		Week 52	Tezepelumab	11	9 (81.8)	0.89 (0.92)	-1.2	0.36	1.27	1.36	1.9	-0.14 [-1.32, 1.04]
			Placebo	6	4 (66.7)	1.02 (1.00)	0.1	0.23	0.86	1.82	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	126	114 (90.5)	4.28 (0.93)	1.9	3.73	4.23	4.82	7.0	
			Placebo	132	117 (88.6)	4.17 (0.88)	2.0	3.64	4.18	4.64	6.2	
		Week 4	Tezepelumab	126	115 (91.3)	4.99 (1.10)	1.6	4.18	5.00	5.82	7.0	
			Placebo	132	118 (89.4)	4.67 (1.03)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	126	117 (92.9)	5.15 (1.12)	1.6	4.27	5.18	6.09	7.0	
			Placebo	132	121 (91.7)	4.80 (1.11)	2.2	4.00	4.64	5.64	7.0	
		Week 12	Tezepelumab	126	117 (92.9)	5.33 (1.13)	1.7	4.55	5.27	6.27	7.0	
			Placebo	132	122 (92.4)	4.93 (1.10)	2.8	4.00	4.77	6.00	7.0	
		Week 16	Tezepelumab	126	117 (92.9)	5.30 (1.10)	2.6	4.36	5.27	6.27	7.0	
			Placebo	132	122 (92.4)	4.97 (1.18)	1.1	4.00	4.91	6.00	7.0	
		Week 20	Tezepelumab	126	118 (93.7)	5.26 (1.15)	1.8	4.27	5.27	6.18	7.0	
			Placebo	132	122 (92.4)	4.94 (1.14)	1.1	4.09	4.77	5.82	7.0	
		Week 24	Tezepelumab	126	118 (93.7)	5.32 (1.16)	1.6	4.36	5.32	6.27	7.0	
			Placebo	132	122 (92.4)	5.00 (1.16)	1.1	4.18	4.91	5.91	7.0	
		Week 28	Tezepelumab	126	120 (95.2)	5.33 (1.11)	2.1	4.36	5.41	6.23	7.0	
			Placebo	132	123 (93.2)	4.99 (1.22)	1.1	4.00	4.91	6.00	7.0	
		Week 32	Tezepelumab	126	121 (96.0)	5.39 (1.11)	1.6	4.45	5.55	6.18	7.0	
			Placebo	132	124 (93.9)	5.03 (1.18)	1.1	4.09	4.91	6.00	7.0	
		Week 36	Tezepelumab	126	121 (96.0)	5.36 (1.12)	1.9	4.45	5.45	6.27	7.0	
			Placebo	132	124 (93.9)	5.06 (1.14)	2.5	4.09	4.82	6.09	7.0	
		Week 40	Tezepelumab	126	121 (96.0)	5.41 (1.11)	2.1	4.45	5.36	6.27	7.0	
			Placebo	132	124 (93.9)	5.06 (1.17)	2.0	4.09	5.05	6.05	7.0	
		Week 44	Tezepelumab	126	121 (96.0)	5.45 (1.11)	2.4	4.45	5.45	6.36	7.0	
			Placebo	132	124 (93.9)	5.07 (1.19)	2.5	4.00	4.95	6.00	7.0	
		Week 48	Tezepelumab	126	121 (96.0)	5.46 (1.10)	2.6	4.45	5.55	6.45	7.0	
			Placebo	132	125 (94.7)	5.07 (1.13)	2.3	4.09	5.00	6.00	7.0	
		Week 52	Tezepelumab	126	121 (96.0)	5.43 (1.12)	1.8	4.55	5.45	6.27	7.0	
			Placebo	132	125 (94.7)	5.05 (1.15)	2.7	4.09	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	126	108 (85.7)	0.72 (1.02)	-2.8	0.00	0.64	1.36	3.2	0.23 [-0.03, 0.49]
			Placebo	132	115 (87.1)	0.50 (0.86)	-1.5	-0.09	0.36	0.91	2.6	
		Week 8	Tezepelumab	126	110 (87.3)	0.85 (1.06)	-1.5	0.00	0.73	1.45	3.7	0.21 [-0.05, 0.47]
			Placebo	132	116 (87.9)	0.64 (0.90)	-1.7	0.00	0.64	1.09	3.3	
		Week 12	Tezepelumab	126	110 (87.3)	1.04 (1.07)	-1.5	0.36	1.00	1.64	4.2	0.26 [-0.00, 0.52]
			Placebo	132	116 (87.9)	0.77 (1.01)	-1.9	0.18	0.82	1.18	3.7	
		Week 16	Tezepelumab	126	110 (87.3)	1.02 (1.05)	-1.7	0.27	0.91	1.55	3.5	0.20 [-0.07, 0.46]
			Placebo	132	116 (87.9)	0.82 (1.05)	-3.2	0.27	0.82	1.50	3.9	
		Week 20	Tezepelumab	126	110 (87.3)	0.98 (1.11)	-2.1	0.18	0.91	1.73	3.5	0.18 [-0.08, 0.44]
			Placebo	132	116 (87.9)	0.79 (1.02)	-3.2	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	126	110 (87.3)	1.08 (1.07)	-1.4	0.27	1.05	1.73	3.5	0.20 [-0.06, 0.46]
			Placebo	132	116 (87.9)	0.86 (1.07)	-3.2	0.27	0.82	1.45	3.8	
		Week 28	Tezepelumab	126	110 (87.3)	1.07 (1.07)	-1.1	0.18	0.91	1.91	3.5	0.22 [-0.05, 0.48]
			Placebo	132	116 (87.9)	0.84 (1.08)	-3.2	0.18	0.82	1.50	4.0	
		Week 32	Tezepelumab	126	110 (87.3)	1.11 (1.05)	-1.1	0.36	1.00	1.91	3.5	0.21 [-0.05, 0.47]
			Placebo	132	116 (87.9)	0.89 (1.06)	-3.2	0.32	0.91	1.55	3.6	
		Week 36	Tezepelumab	126	110 (87.3)	1.08 (1.11)	-0.8	0.18	0.95	1.91	3.5	0.14 [-0.12, 0.40]
			Placebo	132	116 (87.9)	0.92 (1.07)	-1.8	0.18	0.86	1.59	3.5	
		Week 40	Tezepelumab	126	110 (87.3)	1.12 (1.06)	-1.0	0.36	1.05	1.82	3.5	0.20 [-0.06, 0.46]
			Placebo	132	116 (87.9)	0.91 (1.11)	-1.6	0.18	0.82	1.50	4.0	
		Week 44	Tezepelumab	126	110 (87.3)	1.17 (1.07)	-0.7	0.27	1.00	1.91	3.5	0.23 [-0.03, 0.49]
			Placebo	132	116 (87.9)	0.92 (1.12)	-1.6	0.18	0.86	1.59	3.9	
		Week 48	Tezepelumab	126	110 (87.3)	1.19 (1.07)	-0.7	0.36	1.05	2.00	3.5	0.26 [-0.01, 0.52]
			Placebo	132	116 (87.9)	0.92 (1.05)	-1.6	0.18	0.82	1.45	3.6	
		Week 52	Tezepelumab	126	110 (87.3)	1.14 (1.08)	-1.2	0.27	1.00	1.91	3.5	0.20 [-0.06, 0.47]
			Placebo	132	116 (87.9)	0.92 (1.06)	-1.6	0.18	0.91	1.50	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.49 (0.70)	3.7	4.00	4.32	4.86	5.8	
			Placebo	3	2 (66.7)	3.00 (0.51)	2.6	2.64	3.00	3.36	3.4	
		Week 4	Tezepelumab	9	9 (100.0)	4.90 (0.86)	3.6	4.27	4.82	5.36	6.3	
			Placebo	3	3 (100.0)	3.52 (0.14)	3.4	3.36	3.55	3.64	3.6	
		Week 8	Tezepelumab	9	9 (100.0)	5.37 (0.68)	4.5	4.82	5.36	5.91	6.2	
			Placebo	3	3 (100.0)	4.30 (0.68)	3.9	3.91	3.91	5.09	5.1	
		Week 12	Tezepelumab	9	9 (100.0)	5.56 (0.78)	4.3	5.00	5.55	6.27	6.6	
			Placebo	3	3 (100.0)	4.03 (0.73)	3.4	3.36	3.91	4.82	4.8	
		Week 16	Tezepelumab	9	9 (100.0)	5.43 (0.71)	4.1	5.18	5.45	6.00	6.2	
			Placebo	3	3 (100.0)	4.12 (0.38)	3.8	3.82	4.00	4.55	4.5	
		Week 20	Tezepelumab	9	9 (100.0)	5.37 (0.66)	4.4	4.82	5.27	5.82	6.4	
			Placebo	3	3 (100.0)	4.45 (0.79)	3.9	3.91	4.09	5.36	5.4	
		Week 24	Tezepelumab	9	9 (100.0)	5.32 (0.74)	4.1	5.09	5.45	5.73	6.4	
			Placebo	3	3 (100.0)	3.88 (0.41)	3.5	3.45	3.91	4.27	4.3	
		Week 28	Tezepelumab	9	9 (100.0)	5.40 (0.58)	4.4	5.09	5.45	5.73	6.4	
			Placebo	3	3 (100.0)	4.27 (0.63)	3.9	3.91	3.91	5.00	5.0	
		Week 32	Tezepelumab	9	9 (100.0)	5.39 (0.66)	4.2	5.09	5.36	5.82	6.4	
			Placebo	3	3 (100.0)	4.30 (0.28)	4.0	4.00	4.36	4.55	4.5	
		Week 36	Tezepelumab	9	9 (100.0)	5.40 (0.60)	4.3	5.45	5.45	5.55	6.5	
			Placebo	3	3 (100.0)	3.94 (0.47)	3.5	3.55	3.82	4.45	4.5	
		Week 40	Tezepelumab	9	9 (100.0)	5.38 (0.52)	4.3	5.18	5.55	5.64	6.0	
			Placebo	3	3 (100.0)	4.55 (0.95)	3.9	3.91	4.09	5.64	5.6	
		Week 44	Tezepelumab	9	9 (100.0)	5.31 (0.53)	4.1	5.18	5.45	5.55	6.0	
			Placebo	3	3 (100.0)	4.12 (0.71)	3.5	3.55	3.91	4.91	4.9	
		Week 48	Tezepelumab	9	9 (100.0)	5.41 (0.66)	4.2	5.18	5.45	5.55	6.5	
			Placebo	3	3 (100.0)	4.48 (0.58)	3.8	3.82	4.73	4.91	4.9	
		Week 52	Tezepelumab	9	9 (100.0)	5.39 (0.71)	4.0	5.18	5.45	5.55	6.5	
			Placebo	3	3 (100.0)	4.33 (0.59)	3.7	3.73	4.36	4.91	4.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	0.57 (0.66)	-0.4	0.09	0.55	0.95	1.7	0.17 [-1.38, 1.73]
			Placebo	3	2 (66.7)	0.45 (0.64)	0.0	0.00	0.45	0.91	0.9	
		Week 8	Tezepelumab	9	8 (88.9)	0.84 (0.89)	-0.7	0.18	1.05	1.59	1.8	-0.69 [-2.27, 0.90]
			Placebo	3	2 (66.7)	1.50 (1.35)	0.5	0.55	1.50	2.45	2.5	
		Week 12	Tezepelumab	9	8 (88.9)	0.98 (0.83)	-0.9	0.82	1.18	1.45	1.8	-0.12 [-1.67, 1.43]
			Placebo	3	2 (66.7)	1.09 (1.54)	0.0	0.00	1.09	2.18	2.2	
		Week 16	Tezepelumab	9	8 (88.9)	0.85 (0.91)	-1.1	0.45	1.27	1.45	1.5	-0.07 [-1.62, 1.48]
			Placebo	3	2 (66.7)	0.91 (0.39)	0.6	0.64	0.91	1.18	1.2	
		Week 20	Tezepelumab	9	8 (88.9)	0.81 (0.78)	-0.8	0.55	0.86	1.45	1.5	-1.04 [-2.67, 0.59]
			Placebo	3	2 (66.7)	1.73 (1.41)	0.7	0.73	1.73	2.73	2.7	
		Week 24	Tezepelumab	9	8 (88.9)	0.82 (0.90)	-0.8	0.27	1.00	1.41	2.0	0.15 [-1.40, 1.70]
			Placebo	3	2 (66.7)	0.68 (0.84)	0.1	0.09	0.68	1.27	1.3	
		Week 28	Tezepelumab	9	8 (88.9)	0.86 (0.76)	-0.8	0.64	1.09	1.36	1.5	-0.70 [-2.29, 0.89]
			Placebo	3	2 (66.7)	1.45 (1.29)	0.5	0.55	1.45	2.36	2.4	
		Week 32	Tezepelumab	9	8 (88.9)	0.85 (0.84)	-1.0	0.64	1.05	1.32	1.8	-0.39 [-1.96, 1.17]
			Placebo	3	2 (66.7)	1.18 (0.77)	0.6	0.64	1.18	1.73	1.7	
		Week 36	Tezepelumab	9	8 (88.9)	0.90 (0.78)	-0.9	0.82	1.14	1.27	1.6	0.29 [-1.26, 1.85]
			Placebo	3	2 (66.7)	0.68 (0.32)	0.5	0.45	0.68	0.91	0.9	
		Week 40	Tezepelumab	9	8 (88.9)	0.84 (0.82)	-0.9	0.50	1.27	1.36	1.4	-1.07 [-2.71, 0.56]
			Placebo	3	2 (66.7)	1.86 (1.61)	0.7	0.73	1.86	3.00	3.0	
		Week 44	Tezepelumab	9	8 (88.9)	0.84 (0.89)	-1.1	0.59	1.18	1.36	1.5	0.14 [-1.41, 1.69]
			Placebo	3	2 (66.7)	0.73 (0.26)	0.5	0.55	0.73	0.91	0.9	
		Week 48	Tezepelumab	9	8 (88.9)	0.98 (0.91)	-1.0	0.73	1.32	1.41	1.9	-0.40 [-1.96, 1.16]
			Placebo	3	2 (66.7)	1.36 (1.29)	0.5	0.45	1.36	2.27	2.3	
		Week 52	Tezepelumab	9	8 (88.9)	0.95 (0.97)	-1.2	0.73	1.32	1.41	1.9	-0.36 [-1.92, 1.20]
			Placebo	3	2 (66.7)	1.32 (1.35)	0.4	0.36	1.32	2.27	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.28 (0.93)	1.9	3.73	4.18	4.82	7.0	
			Placebo	135	119 (88.1)	4.17 (0.87)	2.0	3.64	4.09	4.64	6.2	
		Week 4	Tezepelumab	128	117 (91.4)	4.97 (1.11)	1.6	4.18	4.91	5.82	7.0	
			Placebo	135	120 (88.9)	4.66 (1.03)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	128	119 (93.0)	5.13 (1.12)	1.6	4.27	5.09	6.09	7.0	
			Placebo	135	123 (91.1)	4.78 (1.12)	2.2	4.00	4.64	5.64	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.31 (1.14)	1.7	4.36	5.18	6.27	7.0	
			Placebo	135	124 (91.9)	4.91 (1.11)	2.8	4.00	4.73	5.95	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.27 (1.11)	2.6	4.27	5.27	6.27	7.0	
			Placebo	135	124 (91.9)	4.96 (1.18)	1.1	4.00	4.91	5.95	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.22 (1.17)	1.8	4.27	5.27	6.14	7.0	
			Placebo	135	124 (91.9)	4.91 (1.15)	1.1	4.09	4.73	5.82	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.30 (1.17)	1.6	4.27	5.23	6.27	7.0	
			Placebo	135	124 (91.9)	4.97 (1.17)	1.1	4.14	4.91	5.91	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.30 (1.13)	2.1	4.36	5.36	6.18	7.0	
			Placebo	135	125 (92.6)	4.96 (1.25)	1.1	4.00	4.82	6.00	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.36 (1.13)	1.6	4.36	5.45	6.18	7.0	
			Placebo	135	126 (93.3)	5.01 (1.18)	1.1	4.09	4.82	6.00	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.34 (1.12)	1.9	4.36	5.45	6.27	7.0	
			Placebo	135	126 (93.3)	5.04 (1.16)	2.4	4.09	4.82	6.09	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.38 (1.12)	2.1	4.36	5.36	6.27	7.0	
			Placebo	135	126 (93.3)	5.04 (1.18)	2.0	4.09	5.05	6.00	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.42 (1.12)	2.4	4.45	5.36	6.36	7.0	
			Placebo	135	126 (93.3)	5.06 (1.20)	2.5	4.00	4.95	6.00	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.43 (1.11)	2.6	4.36	5.55	6.45	7.0	
			Placebo	135	127 (94.1)	5.06 (1.15)	2.3	4.09	5.00	6.00	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.40 (1.13)	1.8	4.45	5.45	6.27	7.0	
			Placebo	135	127 (94.1)	5.05 (1.14)	2.7	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.71 (1.02)	-2.8	0.00	0.64	1.36	3.2	0.24 [-0.02, 0.50]
			Placebo	135	117 (86.7)	0.49 (0.86)	-1.5	-0.09	0.36	0.91	2.6	
		Week 8	Tezepelumab	128	111 (86.7)	0.85 (1.05)	-1.5	0.00	0.73	1.45	3.7	0.23 [-0.03, 0.49]
			Placebo	135	118 (87.4)	0.62 (0.91)	-1.7	0.00	0.59	1.09	3.3	
		Week 12	Tezepelumab	128	111 (86.7)	1.04 (1.06)	-1.5	0.36	1.00	1.64	4.2	0.28 [0.02, 0.54]
			Placebo	135	118 (87.4)	0.75 (1.01)	-1.9	0.18	0.82	1.18	3.7	
		Week 16	Tezepelumab	128	111 (86.7)	1.02 (1.05)	-1.7	0.27	0.91	1.55	3.5	0.20 [-0.06, 0.46]
			Placebo	135	118 (87.4)	0.81 (1.05)	-3.2	0.27	0.82	1.45	3.9	
		Week 20	Tezepelumab	128	111 (86.7)	0.96 (1.12)	-2.1	0.09	0.91	1.73	3.5	0.18 [-0.08, 0.44]
			Placebo	135	118 (87.4)	0.77 (1.02)	-3.2	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	128	111 (86.7)	1.07 (1.06)	-1.4	0.27	1.00	1.73	3.5	0.22 [-0.04, 0.48]
			Placebo	135	118 (87.4)	0.83 (1.08)	-3.2	0.27	0.82	1.45	3.8	
		Week 28	Tezepelumab	128	111 (86.7)	1.06 (1.08)	-1.1	0.18	0.91	1.91	3.5	0.24 [-0.02, 0.50]
			Placebo	135	118 (87.4)	0.80 (1.11)	-3.2	0.09	0.82	1.45	4.0	
		Week 32	Tezepelumab	128	111 (86.7)	1.10 (1.06)	-1.1	0.36	1.00	1.91	3.5	0.22 [-0.04, 0.48]
			Placebo	135	118 (87.4)	0.87 (1.07)	-3.2	0.27	0.86	1.55	3.6	
		Week 36	Tezepelumab	128	111 (86.7)	1.07 (1.11)	-0.8	0.18	0.91	1.91	3.5	0.16 [-0.10, 0.42]
			Placebo	135	118 (87.4)	0.90 (1.08)	-1.8	0.18	0.86	1.55	3.5	
		Week 40	Tezepelumab	128	111 (86.7)	1.12 (1.05)	-1.0	0.36	1.00	1.82	3.5	0.20 [-0.06, 0.46]
			Placebo	135	118 (87.4)	0.90 (1.12)	-1.6	0.18	0.82	1.55	4.0	
		Week 44	Tezepelumab	128	111 (86.7)	1.16 (1.07)	-0.7	0.27	1.00	1.91	3.5	0.23 [-0.03, 0.49]
			Placebo	135	118 (87.4)	0.91 (1.13)	-1.6	0.18	0.86	1.55	3.9	
		Week 48	Tezepelumab	128	111 (86.7)	1.19 (1.07)	-0.7	0.36	1.00	2.00	3.5	0.26 [0.00, 0.52]
			Placebo	135	118 (87.4)	0.91 (1.06)	-1.6	0.18	0.82	1.45	3.6	
		Week 52	Tezepelumab	128	111 (86.7)	1.13 (1.08)	-1.2	0.27	1.00	1.91	3.5	0.20 [-0.06, 0.46]
			Placebo	135	118 (87.4)	0.91 (1.06)	-1.6	0.18	0.91	1.45	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	4.03 (1.00)	2.1	3.36	4.00	4.55	5.9	
			Placebo	37	33 (89.2)	4.23 (0.89)	2.5	3.82	4.09	4.64	6.2	
		Week 4	Tezepelumab	29	26 (89.7)	4.78 (1.02)	3.2	3.91	4.77	5.73	6.9	
			Placebo	37	33 (89.2)	4.73 (1.11)	2.6	3.91	4.82	5.45	7.0	
		Week 8	Tezepelumab	29	27 (93.1)	5.11 (1.14)	2.9	4.00	5.27	6.00	7.0	
			Placebo	37	34 (91.9)	4.88 (1.10)	2.2	4.00	4.91	5.64	7.0	
		Week 12	Tezepelumab	29	27 (93.1)	5.32 (1.13)	3.4	4.64	5.18	6.27	7.0	
			Placebo	37	35 (94.6)	5.09 (1.14)	2.8	4.36	5.09	6.00	7.0	
		Week 16	Tezepelumab	29	27 (93.1)	5.33 (1.09)	3.4	4.36	5.45	6.18	7.0	
			Placebo	37	35 (94.6)	5.09 (1.28)	1.1	4.09	5.45	6.00	7.0	
		Week 20	Tezepelumab	29	27 (93.1)	5.37 (1.10)	3.2	4.55	5.36	6.36	7.0	
			Placebo	37	35 (94.6)	4.99 (1.23)	1.1	4.09	5.18	5.82	7.0	
		Week 24	Tezepelumab	29	27 (93.1)	5.29 (1.35)	1.6	4.27	5.45	6.27	7.0	
			Placebo	37	35 (94.6)	4.93 (1.33)	1.1	3.91	5.00	5.91	7.0	
		Week 28	Tezepelumab	29	27 (93.1)	5.31 (1.20)	2.9	4.09	5.55	6.36	7.0	
			Placebo	37	35 (94.6)	5.06 (1.44)	1.1	4.09	5.09	6.18	7.0	
		Week 32	Tezepelumab	29	27 (93.1)	5.37 (1.08)	2.9	4.91	5.45	5.91	7.0	
			Placebo	37	35 (94.6)	5.12 (1.23)	1.1	4.36	5.09	6.00	7.0	
		Week 36	Tezepelumab	29	27 (93.1)	5.36 (1.21)	3.0	4.45	5.55	6.45	7.0	
			Placebo	37	35 (94.6)	4.97 (1.22)	2.4	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	29	27 (93.1)	5.47 (1.17)	3.3	4.36	5.64	6.45	7.0	
			Placebo	37	35 (94.6)	5.11 (1.20)	2.5	4.09	5.27	6.00	7.0	
		Week 44	Tezepelumab	29	27 (93.1)	5.44 (1.20)	3.0	4.36	5.64	6.36	7.0	
			Placebo	37	35 (94.6)	5.19 (1.17)	2.9	4.00	5.27	6.00	7.0	
		Week 48	Tezepelumab	29	27 (93.1)	5.37 (1.28)	2.6	4.36	5.55	6.55	7.0	
			Placebo	37	36 (97.3)	5.15 (1.14)	2.4	4.45	5.14	5.82	7.0	
		Week 52	Tezepelumab	29	27 (93.1)	5.38 (1.30)	2.6	4.36	5.55	6.55	7.0	
			Placebo	37	36 (97.3)	5.20 (1.07)	2.9	4.36	5.14	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	29	24 (82.8)	0.78 (0.84)	-0.7	0.18	0.59	1.18	2.7	0.26 [-0.28, 0.79]
			Placebo	37	31 (83.8)	0.56 (0.83)	-0.7	0.00	0.36	1.45	2.1	
		Week 8	Tezepelumab	29	25 (86.2)	1.04 (0.93)	-0.7	0.45	0.91	1.64	2.8	0.41 [-0.12, 0.93]
			Placebo	37	32 (86.5)	0.67 (0.89)	-0.6	0.00	0.55	1.14	2.6	
		Week 12	Tezepelumab	29	25 (86.2)	1.22 (0.94)	-0.7	0.55	1.09	1.73	2.8	0.28 [-0.24, 0.81]
			Placebo	37	32 (86.5)	0.95 (0.98)	-1.0	0.27	0.82	1.23	3.3	
		Week 16	Tezepelumab	29	25 (86.2)	1.22 (0.89)	-0.7	0.64	1.18	1.91	2.7	0.29 [-0.24, 0.81]
			Placebo	37	32 (86.5)	0.91 (1.18)	-3.2	0.55	0.91	1.68	3.5	
		Week 20	Tezepelumab	29	25 (86.2)	1.28 (0.95)	-0.7	0.55	1.27	2.00	2.7	0.42 [-0.11, 0.95]
			Placebo	37	32 (86.5)	0.83 (1.15)	-3.2	0.18	0.77	1.77	2.7	
		Week 24	Tezepelumab	29	25 (86.2)	1.21 (1.13)	-1.4	0.36	1.27	1.82	2.9	0.38 [-0.15, 0.91]
			Placebo	37	32 (86.5)	0.75 (1.28)	-3.2	0.14	0.82	1.64	3.0	
		Week 28	Tezepelumab	29	25 (86.2)	1.22 (0.99)	-0.7	0.45	0.91	2.00	2.8	0.26 [-0.27, 0.78]
			Placebo	37	32 (86.5)	0.89 (1.44)	-3.2	0.18	1.00	1.86	3.7	
		Week 32	Tezepelumab	29	25 (86.2)	1.29 (0.98)	-0.7	0.73	1.18	2.27	2.7	0.32 [-0.21, 0.85]
			Placebo	37	32 (86.5)	0.94 (1.20)	-3.2	0.32	1.05	1.73	3.3	
		Week 36	Tezepelumab	29	25 (86.2)	1.29 (1.02)	-0.7	0.45	1.09	2.27	2.8	0.47 [-0.06, 1.00]
			Placebo	37	32 (86.5)	0.78 (1.12)	-1.8	0.14	0.82	1.36	3.0	
		Week 40	Tezepelumab	29	25 (86.2)	1.39 (1.03)	-0.7	0.55	1.36	2.45	2.8	0.38 [-0.14, 0.91]
			Placebo	37	32 (86.5)	0.95 (1.22)	-1.4	0.27	0.82	1.73	3.5	
		Week 44	Tezepelumab	29	25 (86.2)	1.39 (1.09)	-0.7	0.45	1.36	2.45	2.9	0.34 [-0.19, 0.86]
			Placebo	37	32 (86.5)	1.01 (1.14)	-1.4	0.36	1.05	1.64	3.4	
		Week 48	Tezepelumab	29	25 (86.2)	1.31 (1.12)	-0.7	0.45	1.27	2.45	3.1	0.30 [-0.23, 0.83]
			Placebo	37	32 (86.5)	0.97 (1.18)	-1.5	0.14	1.05	1.45	3.4	
		Week 52	Tezepelumab	29	25 (86.2)	1.33 (1.14)	-0.7	0.36	1.27	2.45	3.1	0.27 [-0.26, 0.79]
			Placebo	37	32 (86.5)	1.03 (1.12)	-1.4	0.14	0.95	1.64	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	4.36 (0.88)	1.9	3.91	4.27	4.82	7.0	
			Placebo	101	88 (87.1)	4.12 (0.87)	2.0	3.50	4.09	4.55	6.1	
		Week 4	Tezepelumab	108	100 (92.6)	5.01 (1.11)	1.6	4.23	4.91	5.95	7.0	
			Placebo	101	90 (89.1)	4.59 (1.01)	2.5	3.91	4.50	5.27	7.0	
		Week 8	Tezepelumab	108	101 (93.5)	5.16 (1.09)	1.6	4.36	5.09	6.09	7.0	
			Placebo	101	92 (91.1)	4.73 (1.12)	2.3	4.00	4.45	5.59	7.0	
		Week 12	Tezepelumab	108	101 (93.5)	5.33 (1.12)	1.7	4.55	5.27	6.27	7.0	
			Placebo	101	92 (91.1)	4.82 (1.09)	3.0	4.00	4.64	5.91	7.0	
		Week 16	Tezepelumab	108	101 (93.5)	5.27 (1.08)	2.6	4.27	5.18	6.18	7.0	
			Placebo	101	92 (91.1)	4.88 (1.13)	2.6	4.00	4.64	5.91	7.0	
		Week 20	Tezepelumab	108	102 (94.4)	5.20 (1.16)	1.8	4.27	5.27	6.09	7.0	
			Placebo	101	92 (91.1)	4.87 (1.11)	2.1	4.05	4.64	5.77	7.0	
		Week 24	Tezepelumab	108	102 (94.4)	5.30 (1.09)	3.0	4.36	5.18	6.27	7.0	
			Placebo	101	92 (91.1)	4.95 (1.11)	2.0	4.14	4.73	5.86	6.9	
		Week 28	Tezepelumab	108	104 (96.3)	5.31 (1.07)	2.1	4.36	5.27	6.14	7.0	
			Placebo	101	93 (92.1)	4.90 (1.16)	2.0	4.00	4.73	5.91	7.0	
		Week 32	Tezepelumab	108	105 (97.2)	5.36 (1.11)	1.6	4.45	5.55	6.18	7.0	
			Placebo	101	94 (93.1)	4.95 (1.15)	1.7	4.00	4.64	5.91	7.0	
		Week 36	Tezepelumab	108	105 (97.2)	5.34 (1.07)	1.9	4.45	5.45	6.18	7.0	
			Placebo	101	94 (93.1)	5.03 (1.14)	2.5	4.09	4.77	6.09	7.0	
		Week 40	Tezepelumab	108	105 (97.2)	5.36 (1.07)	2.1	4.45	5.27	6.18	7.0	
			Placebo	101	94 (93.1)	5.00 (1.18)	2.0	4.00	4.82	6.00	7.0	
		Week 44	Tezepelumab	108	105 (97.2)	5.40 (1.07)	2.4	4.45	5.36	6.27	7.0	
			Placebo	101	94 (93.1)	4.98 (1.20)	2.5	4.00	4.73	6.00	7.0	
		Week 48	Tezepelumab	108	105 (97.2)	5.45 (1.04)	3.5	4.45	5.45	6.27	7.0	
			Placebo	101	94 (93.1)	5.00 (1.14)	2.3	4.00	4.82	6.00	7.0	
		Week 52	Tezepelumab	108	105 (97.2)	5.41 (1.06)	1.8	4.55	5.45	6.27	7.0	
			Placebo	101	94 (93.1)	4.97 (1.16)	2.7	4.00	4.91	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	108	93 (86.1)	0.68 (1.04)	-2.8	0.00	0.64	1.36	3.2	0.23 [-0.06, 0.52]
			Placebo	101	88 (87.1)	0.46 (0.87)	-1.5	-0.09	0.36	0.86	2.6	
		Week 8	Tezepelumab	108	94 (87.0)	0.79 (1.06)	-1.5	0.00	0.68	1.45	3.7	0.17 [-0.12, 0.46]
			Placebo	101	88 (87.1)	0.62 (0.93)	-1.7	0.00	0.64	1.09	3.3	
		Week 12	Tezepelumab	108	94 (87.0)	0.99 (1.07)	-1.5	0.27	0.91	1.55	4.2	0.28 [-0.01, 0.57]
			Placebo	101	88 (87.1)	0.69 (1.02)	-1.9	0.00	0.77	1.18	3.7	
		Week 16	Tezepelumab	108	94 (87.0)	0.95 (1.07)	-1.7	0.18	0.91	1.55	3.5	0.17 [-0.12, 0.46]
			Placebo	101	88 (87.1)	0.77 (1.00)	-1.9	0.18	0.77	1.32	3.9	
		Week 20	Tezepelumab	108	94 (87.0)	0.87 (1.13)	-2.1	0.00	0.82	1.55	3.5	0.09 [-0.20, 0.38]
			Placebo	101	88 (87.1)	0.77 (0.98)	-1.6	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	108	94 (87.0)	1.01 (1.03)	-0.8	0.18	0.91	1.55	3.5	0.15 [-0.14, 0.44]
			Placebo	101	88 (87.1)	0.86 (0.99)	-1.6	0.27	0.82	1.36	3.8	
		Week 28	Tezepelumab	108	94 (87.0)	1.00 (1.07)	-1.1	0.09	0.95	1.64	3.5	0.21 [-0.08, 0.50]
			Placebo	101	88 (87.1)	0.78 (0.97)	-1.6	0.14	0.73	1.36	4.0	
		Week 32	Tezepelumab	108	94 (87.0)	1.03 (1.06)	-1.1	0.27	0.95	1.64	3.5	0.17 [-0.12, 0.46]
			Placebo	101	88 (87.1)	0.85 (1.01)	-1.8	0.27	0.82	1.45	3.6	
		Week 36	Tezepelumab	108	94 (87.0)	1.00 (1.10)	-0.9	0.09	0.91	1.64	3.5	0.06 [-0.23, 0.35]
			Placebo	101	88 (87.1)	0.94 (1.06)	-1.6	0.18	0.91	1.55	3.5	
		Week 40	Tezepelumab	108	94 (87.0)	1.03 (1.03)	-1.0	0.36	1.00	1.64	3.5	0.12 [-0.17, 0.41]
			Placebo	101	88 (87.1)	0.90 (1.10)	-1.6	0.18	0.82	1.45	4.0	
		Week 44	Tezepelumab	108	94 (87.0)	1.07 (1.04)	-1.1	0.27	1.00	1.64	3.5	0.19 [-0.10, 0.48]
			Placebo	101	88 (87.1)	0.87 (1.11)	-1.6	0.18	0.73	1.50	3.9	
		Week 48	Tezepelumab	108	94 (87.0)	1.13 (1.04)	-1.0	0.36	1.09	1.64	3.5	0.23 [-0.06, 0.53]
			Placebo	101	88 (87.1)	0.89 (1.03)	-1.6	0.18	0.82	1.45	3.6	
		Week 52	Tezepelumab	108	94 (87.0)	1.06 (1.05)	-1.2	0.36	1.00	1.64	3.5	0.17 [-0.12, 0.46]
			Placebo	101	88 (87.1)	0.88 (1.04)	-1.6	0.18	0.91	1.45	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.30 (0.91)	1.9	3.73	4.27	4.73	7.0	
			Placebo	123	106 (86.2)	4.20 (0.86)	2.0	3.73	4.14	4.64	6.2	
		Week 4	Tezepelumab	128	117 (91.4)	4.94 (1.11)	1.6	4.09	4.91	5.82	7.0	
			Placebo	123	109 (88.6)	4.66 (1.05)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	128	119 (93.0)	5.12 (1.12)	1.6	4.27	5.09	6.09	7.0	
			Placebo	123	112 (91.1)	4.78 (1.08)	2.3	4.00	4.59	5.50	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.30 (1.13)	1.7	4.36	5.27	6.27	7.0	
			Placebo	123	113 (91.9)	4.85 (1.10)	2.8	4.00	4.64	5.91	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.27 (1.10)	2.6	4.27	5.27	6.18	7.0	
			Placebo	123	113 (91.9)	4.94 (1.15)	1.1	4.00	4.82	5.91	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.20 (1.15)	1.8	4.27	5.23	6.09	7.0	
			Placebo	123	113 (91.9)	4.89 (1.15)	1.1	4.09	4.64	5.73	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.26 (1.16)	1.6	4.27	5.18	6.27	7.0	
			Placebo	123	113 (91.9)	4.92 (1.18)	1.1	4.18	4.73	5.82	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.26 (1.10)	2.1	4.36	5.27	6.09	7.0	
			Placebo	123	114 (92.7)	4.89 (1.24)	1.1	3.91	4.77	6.00	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.32 (1.11)	1.6	4.36	5.36	6.18	7.0	
			Placebo	123	115 (93.5)	4.94 (1.19)	1.1	4.00	4.73	6.00	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.31 (1.10)	1.9	4.36	5.45	6.18	7.0	
			Placebo	123	115 (93.5)	5.01 (1.17)	2.4	4.00	4.82	6.09	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.34 (1.10)	2.1	4.36	5.27	6.18	7.0	
			Placebo	123	115 (93.5)	5.00 (1.18)	2.0	4.00	4.91	6.00	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.37 (1.11)	2.4	4.45	5.36	6.27	7.0	
			Placebo	123	115 (93.5)	5.02 (1.18)	2.5	4.00	4.91	6.00	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.41 (1.10)	2.6	4.36	5.45	6.45	7.0	
			Placebo	123	116 (94.3)	5.02 (1.15)	2.3	4.00	4.95	5.91	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.37 (1.12)	1.8	4.45	5.45	6.27	7.0	
			Placebo	123	116 (94.3)	4.99 (1.15)	2.7	4.00	4.91	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.67 (0.99)	-2.8	0.00	0.55	1.27	3.2	0.20 [-0.07, 0.47]
			Placebo	123	105 (85.4)	0.48 (0.88)	-1.5	-0.09	0.36	0.91	2.6	
		Week 8	Tezepelumab	128	111 (86.7)	0.81 (1.02)	-1.5	0.00	0.73	1.45	3.5	0.21 [-0.06, 0.48]
			Placebo	123	106 (86.2)	0.61 (0.88)	-1.7	0.00	0.59	1.09	2.8	
		Week 12	Tezepelumab	128	111 (86.7)	0.99 (1.02)	-1.5	0.36	1.00	1.55	3.5	0.32 [0.05, 0.59]
			Placebo	123	106 (86.2)	0.67 (0.98)	-1.9	0.09	0.64	1.18	3.1	
		Week 16	Tezepelumab	128	111 (86.7)	0.98 (1.03)	-1.7	0.27	0.91	1.55	3.5	0.20 [-0.06, 0.47]
			Placebo	123	106 (86.2)	0.77 (1.01)	-3.2	0.18	0.82	1.45	3.3	
		Week 20	Tezepelumab	128	111 (86.7)	0.92 (1.09)	-2.1	0.09	0.91	1.64	3.5	0.17 [-0.10, 0.43]
			Placebo	123	106 (86.2)	0.74 (1.00)	-3.2	0.18	0.73	1.27	3.4	
		Week 24	Tezepelumab	128	111 (86.7)	1.02 (1.04)	-1.4	0.18	1.00	1.64	3.5	0.24 [-0.03, 0.50]
			Placebo	123	106 (86.2)	0.77 (1.07)	-3.2	0.18	0.73	1.45	3.2	
		Week 28	Tezepelumab	128	111 (86.7)	0.99 (1.04)	-1.1	0.18	0.91	1.73	3.5	0.26 [-0.01, 0.53]
			Placebo	123	106 (86.2)	0.72 (1.06)	-3.2	0.09	0.77	1.36	3.1	
		Week 32	Tezepelumab	128	111 (86.7)	1.04 (1.03)	-1.1	0.27	1.00	1.82	3.5	0.26 [-0.01, 0.52]
			Placebo	123	106 (86.2)	0.78 (1.04)	-3.2	0.18	0.77	1.45	3.5	
		Week 36	Tezepelumab	128	111 (86.7)	1.03 (1.08)	-0.9	0.18	1.00	1.73	3.5	0.17 [-0.10, 0.43]
			Placebo	123	106 (86.2)	0.85 (1.07)	-1.8	0.18	0.82	1.45	3.5	
		Week 40	Tezepelumab	128	111 (86.7)	1.06 (1.03)	-1.0	0.27	1.00	1.73	3.5	0.20 [-0.06, 0.47]
			Placebo	123	106 (86.2)	0.85 (1.09)	-1.6	0.18	0.82	1.45	3.6	
		Week 44	Tezepelumab	128	111 (86.7)	1.10 (1.04)	-1.1	0.27	1.00	1.73	3.5	0.24 [-0.02, 0.51]
			Placebo	123	106 (86.2)	0.84 (1.06)	-1.6	0.18	0.82	1.45	3.6	
		Week 48	Tezepelumab	128	111 (86.7)	1.14 (1.05)	-1.0	0.36	1.09	1.91	3.5	0.28 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.85 (1.03)	-1.6	0.18	0.82	1.27	3.6	
		Week 52	Tezepelumab	128	111 (86.7)	1.08 (1.06)	-1.2	0.27	1.00	1.82	3.5	0.23 [-0.03, 0.50]
			Placebo	123	106 (86.2)	0.84 (1.01)	-1.6	0.18	0.82	1.27	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.20 (1.11)	2.2	3.68	4.14	5.00	5.8	
			Placebo	15	15 (100.0)	3.77 (0.91)	2.5	3.09	3.45	4.36	5.4	
		Week 4	Tezepelumab	9	9 (100.0)	5.27 (0.88)	4.2	4.64	5.27	5.82	6.9	
			Placebo	15	14 (93.3)	4.36 (0.91)	2.6	3.73	4.41	5.27	5.5	
		Week 8	Tezepelumab	9	9 (100.0)	5.52 (0.72)	4.2	5.18	5.27	5.91	6.5	
			Placebo	15	14 (93.3)	4.64 (1.33)	2.2	3.73	5.05	5.64	6.3	
		Week 12	Tezepelumab	9	9 (100.0)	5.71 (0.95)	4.1	5.18	5.45	6.45	7.0	
			Placebo	15	14 (93.3)	5.21 (1.17)	2.8	4.27	5.50	6.00	6.7	
		Week 16	Tezepelumab	9	9 (100.0)	5.53 (0.79)	4.1	5.18	5.55	5.64	7.0	
			Placebo	15	14 (93.3)	4.92 (1.43)	2.6	3.82	5.27	6.00	6.9	
		Week 20	Tezepelumab	9	9 (100.0)	5.65 (0.99)	3.6	5.45	5.64	6.27	7.0	
			Placebo	15	14 (93.3)	4.98 (1.08)	3.0	4.09	5.14	5.82	7.0	
		Week 24	Tezepelumab	9	9 (100.0)	5.77 (0.75)	4.5	5.64	5.91	6.09	7.0	
			Placebo	15	14 (93.3)	5.13 (1.08)	3.9	4.09	4.95	6.00	6.8	
		Week 28	Tezepelumab	9	9 (100.0)	5.98 (0.82)	4.3	5.82	5.91	6.36	7.0	
			Placebo	15	14 (93.3)	5.35 (1.21)	3.8	4.09	5.23	6.73	7.0	
		Week 32	Tezepelumab	9	9 (100.0)	5.89 (0.76)	4.2	5.73	5.91	6.27	7.0	
			Placebo	15	14 (93.3)	5.44 (0.96)	4.1	4.36	5.55	6.18	6.8	
		Week 36	Tezepelumab	9	9 (100.0)	5.77 (0.90)	4.4	5.45	6.00	6.36	7.0	
			Placebo	15	14 (93.3)	5.07 (1.10)	3.3	4.09	5.05	6.00	6.8	
		Week 40	Tezepelumab	9	9 (100.0)	5.90 (0.62)	5.0	5.45	6.00	6.18	7.0	
			Placebo	15	14 (93.3)	5.25 (1.20)	3.6	4.09	5.23	6.36	7.0	
		Week 44	Tezepelumab	9	9 (100.0)	5.90 (0.70)	4.5	5.64	6.00	6.18	7.0	
			Placebo	15	14 (93.3)	5.21 (1.34)	3.4	4.00	5.27	6.64	7.0	
		Week 48	Tezepelumab	9	9 (100.0)	5.77 (0.78)	4.5	5.64	6.00	6.18	7.0	
			Placebo	15	14 (93.3)	5.23 (1.02)	3.5	4.36	5.27	6.18	6.6	
		Week 52	Tezepelumab	9	9 (100.0)	5.85 (0.80)	4.5	5.64	6.00	6.27	7.0	
			Placebo	15	14 (93.3)	5.33 (1.01)	3.6	4.82	5.45	6.18	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	1.15 (1.04)	0.0	0.41	0.77	1.86	3.1	0.71 [-0.19, 1.60]
			Placebo	15	14 (93.3)	0.55 (0.73)	-0.5	0.09	0.41	0.91	2.5	
		Week 8	Tezepelumab	9	8 (88.9)	1.35 (1.19)	0.1	0.36	1.27	1.86	3.7	0.45 [-0.43, 1.33]
			Placebo	15	14 (93.3)	0.82 (1.16)	-0.9	-0.09	0.64	1.45	3.3	
		Week 12	Tezepelumab	9	8 (88.9)	1.59 (1.32)	0.2	0.59	1.45	2.14	4.2	0.17 [-0.70, 1.04]
			Placebo	15	14 (93.3)	1.40 (1.06)	0.0	0.82	1.00	1.82	3.7	
		Week 16	Tezepelumab	9	8 (88.9)	1.36 (1.23)	0.2	0.36	0.95	2.32	3.5	0.21 [-0.66, 1.08]
			Placebo	15	14 (93.3)	1.10 (1.28)	-0.5	0.55	0.73	1.73	3.9	
		Week 20	Tezepelumab	9	8 (88.9)	1.47 (1.22)	-0.4	0.77	1.18	2.36	3.5	0.26 [-0.62, 1.13]
			Placebo	15	14 (93.3)	1.16 (1.17)	-0.5	0.64	1.00	1.64	4.0	
		Week 24	Tezepelumab	9	8 (88.9)	1.55 (1.14)	0.3	0.77	1.00	2.55	3.5	0.22 [-0.65, 1.09]
			Placebo	15	14 (93.3)	1.31 (1.01)	-0.2	0.82	1.05	1.64	3.8	
		Week 28	Tezepelumab	9	8 (88.9)	1.80 (1.06)	0.5	0.73	1.91	2.55	3.5	0.22 [-0.65, 1.09]
			Placebo	15	14 (93.3)	1.53 (1.24)	0.0	0.64	1.23	2.36	4.0	
		Week 32	Tezepelumab	9	8 (88.9)	1.64 (1.10)	0.5	0.68	1.41	2.50	3.5	0.01 [-0.86, 0.88]
			Placebo	15	14 (93.3)	1.62 (0.94)	0.5	0.91	1.50	1.91	3.6	
		Week 36	Tezepelumab	9	8 (88.9)	1.52 (1.18)	0.4	0.59	1.05	2.55	3.5	0.24 [-0.63, 1.11]
			Placebo	15	14 (93.3)	1.25 (1.11)	-1.0	0.64	0.95	2.18	3.4	
		Week 40	Tezepelumab	9	8 (88.9)	1.66 (1.13)	0.2	0.86	1.36	2.59	3.5	0.19 [-0.68, 1.06]
			Placebo	15	14 (93.3)	1.43 (1.30)	-0.2	0.64	1.14	1.82	4.0	
		Week 44	Tezepelumab	9	8 (88.9)	1.66 (1.23)	0.2	0.59	1.50	2.73	3.5	0.20 [-0.68, 1.07]
			Placebo	15	14 (93.3)	1.39 (1.45)	-0.9	0.45	0.91	2.55	3.9	
		Week 48	Tezepelumab	9	8 (88.9)	1.58 (1.13)	0.4	0.73	1.14	2.55	3.5	0.14 [-0.73, 1.01]
			Placebo	15	14 (93.3)	1.42 (1.19)	-0.5	0.45	1.14	2.27	3.3	
		Week 52	Tezepelumab	9	8 (88.9)	1.58 (1.13)	0.4	0.73	1.14	2.55	3.5	0.06 [-0.81, 0.92]
			Placebo	15	14 (93.3)	1.51 (1.23)	-0.5	0.45	1.59	2.27	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	4.25 (1.31)	2.2	3.45	4.82	5.00	5.6	
			Placebo	9	8 (88.9)	3.65 (1.02)	2.5	2.86	3.32	4.41	5.5	
		Week 4	Tezepelumab	10	8 (80.0)	6.03 (0.67)	5.3	5.36	6.05	6.64	6.9	
			Placebo	9	7 (77.8)	4.48 (1.32)	2.6	3.55	4.27	5.45	6.7	
		Week 8	Tezepelumab	10	9 (90.0)	5.99 (0.98)	3.8	5.91	6.00	6.55	7.0	
			Placebo	9	7 (77.8)	4.84 (1.66)	2.2	3.55	5.09	6.27	7.0	
		Week 12	Tezepelumab	10	9 (90.0)	6.21 (0.71)	4.9	6.27	6.36	6.55	7.0	
			Placebo	9	7 (77.8)	4.90 (1.53)	2.8	3.45	4.82	6.09	7.0	
		Week 16	Tezepelumab	10	9 (90.0)	6.00 (0.74)	4.9	5.55	6.00	6.55	7.0	
			Placebo	9	7 (77.8)	4.51 (1.74)	2.6	3.00	3.82	6.00	6.9	
		Week 20	Tezepelumab	10	9 (90.0)	6.08 (0.67)	4.9	5.64	6.18	6.27	7.0	
			Placebo	9	7 (77.8)	5.06 (1.43)	3.0	3.64	5.36	6.27	6.9	
		Week 24	Tezepelumab	10	9 (90.0)	6.08 (0.66)	4.9	5.73	6.09	6.27	7.0	
			Placebo	9	7 (77.8)	5.04 (1.26)	3.9	4.00	4.27	6.27	6.9	
		Week 28	Tezepelumab	10	10 (100.0)	6.16 (0.69)	4.9	5.64	6.14	7.00	7.0	
			Placebo	9	7 (77.8)	5.25 (1.16)	4.0	4.09	5.00	6.45	6.9	
		Week 32	Tezepelumab	10	10 (100.0)	5.94 (0.65)	4.9	5.64	6.00	6.27	7.0	
			Placebo	9	7 (77.8)	5.16 (0.98)	4.1	4.27	5.00	5.91	6.6	
		Week 36	Tezepelumab	10	10 (100.0)	5.93 (0.61)	4.9	5.55	5.86	6.36	7.0	
			Placebo	9	7 (77.8)	5.18 (1.10)	3.5	4.09	5.36	6.36	6.4	
		Week 40	Tezepelumab	10	10 (100.0)	6.16 (0.69)	4.9	5.64	6.27	6.73	7.0	
			Placebo	9	7 (77.8)	5.29 (1.06)	4.1	4.18	5.64	6.18	6.7	
		Week 44	Tezepelumab	10	10 (100.0)	6.01 (0.67)	4.9	5.64	5.91	6.36	7.0	
			Placebo	9	7 (77.8)	5.53 (1.35)	3.5	3.91	6.36	6.64	6.7	
		Week 48	Tezepelumab	10	10 (100.0)	6.13 (0.61)	4.9	5.82	6.14	6.45	7.0	
			Placebo	9	7 (77.8)	5.92 (0.94)	4.4	4.91	6.45	6.64	6.6	
		Week 52	Tezepelumab	10	10 (100.0)	6.25 (0.63)	4.9	6.00	6.27	6.82	7.0	
			Placebo	9	7 (77.8)	6.12 (0.76)	4.9	5.45	6.45	6.64	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	1.55 (1.32)	-0.3	0.32	1.64	2.82	3.1	0.74 [-0.32, 1.79]
			Placebo	9	7 (77.8)	0.75 (0.70)	0.0	0.09	0.82	0.91	2.1	
		Week 8	Tezepelumab	10	9 (90.0)	1.74 (1.29)	0.3	0.91	1.45	2.82	3.7	0.52 [-0.48, 1.53]
			Placebo	9	7 (77.8)	1.12 (1.04)	-0.4	0.36	0.82	2.36	2.5	
		Week 12	Tezepelumab	10	9 (90.0)	1.96 (1.36)	0.2	0.91	1.45	2.82	4.2	0.66 [-0.36, 1.68]
			Placebo	9	7 (77.8)	1.17 (0.95)	0.0	0.27	0.91	2.18	2.4	
		Week 16	Tezepelumab	10	9 (90.0)	1.75 (1.34)	0.2	0.55	1.45	2.73	3.5	0.79 [-0.24, 1.82]
			Placebo	9	7 (77.8)	0.78 (1.07)	-0.5	-0.45	0.64	1.82	2.3	
		Week 20	Tezepelumab	10	9 (90.0)	1.83 (1.30)	-0.2	1.09	1.45	2.73	3.5	0.41 [-0.59, 1.41]
			Placebo	9	7 (77.8)	1.34 (1.04)	-0.5	0.82	1.27	2.27	2.7	
		Week 24	Tezepelumab	10	9 (90.0)	1.83 (1.29)	0.1	0.91	1.45	2.82	3.5	0.49 [-0.51, 1.50]
			Placebo	9	7 (77.8)	1.31 (0.60)	0.6	0.82	1.27	1.73	2.3	
		Week 28	Tezepelumab	10	9 (90.0)	1.90 (1.30)	0.0	0.91	2.00	2.82	3.5	0.35 [-0.65, 1.35]
			Placebo	9	7 (77.8)	1.52 (0.71)	0.6	0.82	1.64	2.27	2.4	
		Week 32	Tezepelumab	10	9 (90.0)	1.61 (1.26)	0.3	0.82	1.09	2.55	3.5	0.17 [-0.82, 1.16]
			Placebo	9	7 (77.8)	1.43 (0.73)	0.5	0.64	1.64	2.00	2.5	
		Week 36	Tezepelumab	10	9 (90.0)	1.66 (1.40)	-0.1	0.45	1.45	2.55	3.5	0.18 [-0.81, 1.17]
			Placebo	9	7 (77.8)	1.45 (0.64)	0.6	0.91	1.64	2.18	2.2	
		Week 40	Tezepelumab	10	9 (90.0)	1.85 (1.28)	0.3	0.64	1.45	2.82	3.5	0.26 [-0.73, 1.25]
			Placebo	9	7 (77.8)	1.56 (0.85)	0.6	0.73	1.64	2.09	3.0	
		Week 44	Tezepelumab	10	9 (90.0)	1.78 (1.34)	0.0	0.73	1.45	2.82	3.5	-0.02 [-1.01, 0.96]
			Placebo	9	7 (77.8)	1.81 (0.94)	0.7	0.91	2.09	2.55	3.2	
		Week 48	Tezepelumab	10	9 (90.0)	1.91 (1.18)	0.4	1.00	1.45	2.73	3.5	-0.27 [-1.27, 0.72]
			Placebo	9	7 (77.8)	2.19 (0.84)	1.2	1.18	2.27	3.18	3.3	
		Week 52	Tezepelumab	10	9 (90.0)	1.93 (1.15)	0.5	1.00	1.45	2.73	3.5	-0.46 [-1.46, 0.55]
			Placebo	9	7 (77.8)	2.39 (0.78)	1.2	2.00	2.27	3.18	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	127	114 (89.8)	4.29 (0.89)	1.9	3.73	4.23	4.64	7.0	
			Placebo	129	113 (87.6)	4.18 (0.86)	2.0	3.64	4.09	4.55	6.2	
		Week 4	Tezepelumab	127	118 (92.9)	4.89 (1.08)	1.6	4.09	4.86	5.73	7.0	
			Placebo	129	116 (89.9)	4.64 (1.02)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	127	119 (93.7)	5.08 (1.08)	1.6	4.27	5.09	6.00	7.0	
			Placebo	129	119 (92.2)	4.76 (1.08)	2.3	4.00	4.64	5.55	7.0	
		Week 12	Tezepelumab	127	119 (93.7)	5.26 (1.11)	1.7	4.36	5.18	6.18	7.0	
			Placebo	129	120 (93.0)	4.89 (1.09)	2.8	4.00	4.73	5.91	7.0	
		Week 16	Tezepelumab	127	119 (93.7)	5.23 (1.09)	2.6	4.27	5.18	6.09	7.0	
			Placebo	129	120 (93.0)	4.96 (1.14)	1.1	4.00	4.86	5.91	7.0	
		Week 20	Tezepelumab	127	120 (94.5)	5.17 (1.15)	1.8	4.27	5.18	6.00	7.0	
			Placebo	129	120 (93.0)	4.89 (1.13)	1.1	4.09	4.73	5.73	7.0	
		Week 24	Tezepelumab	127	120 (94.5)	5.24 (1.15)	1.6	4.27	5.18	6.23	7.0	
			Placebo	129	120 (93.0)	4.94 (1.17)	1.1	4.14	4.86	5.86	7.0	
		Week 28	Tezepelumab	127	121 (95.3)	5.24 (1.10)	2.1	4.36	5.27	6.00	7.0	
			Placebo	129	121 (93.8)	4.92 (1.25)	1.1	3.91	4.82	6.00	7.0	
		Week 32	Tezepelumab	127	122 (96.1)	5.32 (1.12)	1.6	4.36	5.36	6.18	7.0	
			Placebo	129	122 (94.6)	4.98 (1.18)	1.1	4.00	4.77	6.00	7.0	
		Week 36	Tezepelumab	127	122 (96.1)	5.29 (1.11)	1.9	4.36	5.36	6.18	7.0	
			Placebo	129	122 (94.6)	5.00 (1.16)	2.4	4.00	4.77	6.09	7.0	
		Week 40	Tezepelumab	127	122 (96.1)	5.32 (1.09)	2.1	4.36	5.27	6.18	7.0	
			Placebo	129	122 (94.6)	5.01 (1.19)	2.0	4.00	4.95	6.00	7.0	
		Week 44	Tezepelumab	127	122 (96.1)	5.36 (1.11)	2.4	4.45	5.36	6.27	7.0	
			Placebo	129	122 (94.6)	5.01 (1.18)	2.5	4.00	4.86	6.00	7.0	
		Week 48	Tezepelumab	127	122 (96.1)	5.37 (1.10)	2.6	4.36	5.36	6.36	7.0	
			Placebo	129	123 (95.3)	4.99 (1.13)	2.3	4.00	4.91	5.91	7.0	
		Week 52	Tezepelumab	127	122 (96.1)	5.33 (1.11)	1.8	4.45	5.36	6.18	7.0	
			Placebo	129	123 (95.3)	4.97 (1.13)	2.7	4.00	4.91	5.82	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	127	109 (85.8)	0.64 (0.95)	-2.8	0.00	0.55	1.27	3.2	0.19 [-0.08, 0.45]
			Placebo	129	112 (86.8)	0.47 (0.87)	-1.5	-0.09	0.36	0.91	2.6	
		Week 8	Tezepelumab	127	110 (86.6)	0.77 (0.99)	-1.5	0.00	0.68	1.45	3.1	0.18 [-0.09, 0.44]
			Placebo	129	113 (87.6)	0.61 (0.90)	-1.7	0.00	0.55	1.09	3.3	
		Week 12	Tezepelumab	127	110 (86.6)	0.96 (0.98)	-1.5	0.36	1.00	1.55	3.1	0.23 [-0.04, 0.49]
			Placebo	129	113 (87.6)	0.73 (1.01)	-1.9	0.09	0.82	1.18	3.7	
		Week 16	Tezepelumab	127	110 (86.6)	0.95 (1.00)	-1.7	0.27	0.91	1.55	3.1	0.13 [-0.13, 0.39]
			Placebo	129	113 (87.6)	0.81 (1.05)	-3.2	0.27	0.82	1.45	3.9	
		Week 20	Tezepelumab	127	110 (86.6)	0.88 (1.06)	-2.1	0.09	0.86	1.64	3.3	0.12 [-0.14, 0.38]
			Placebo	129	113 (87.6)	0.76 (1.02)	-3.2	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	127	110 (86.6)	0.99 (1.01)	-1.4	0.27	0.95	1.64	3.2	0.18 [-0.08, 0.44]
			Placebo	129	113 (87.6)	0.80 (1.09)	-3.2	0.18	0.82	1.36	3.8	
		Week 28	Tezepelumab	127	110 (86.6)	0.98 (1.01)	-1.1	0.18	0.91	1.73	3.2	0.20 [-0.07, 0.46]
			Placebo	129	113 (87.6)	0.77 (1.11)	-3.2	0.09	0.82	1.36	4.0	
		Week 32	Tezepelumab	127	110 (86.6)	1.04 (1.02)	-1.1	0.36	1.00	1.82	3.2	0.19 [-0.07, 0.45]
			Placebo	129	113 (87.6)	0.84 (1.07)	-3.2	0.27	0.82	1.45	3.6	
		Week 36	Tezepelumab	127	110 (86.6)	1.01 (1.05)	-0.9	0.18	0.91	1.73	3.2	0.14 [-0.12, 0.40]
			Placebo	129	113 (87.6)	0.86 (1.09)	-1.8	0.18	0.82	1.45	3.5	
		Week 40	Tezepelumab	127	110 (86.6)	1.04 (1.00)	-1.0	0.27	1.00	1.64	3.1	0.16 [-0.11, 0.42]
			Placebo	129	113 (87.6)	0.87 (1.13)	-1.6	0.18	0.82	1.45	4.0	
		Week 44	Tezepelumab	127	110 (86.6)	1.08 (1.02)	-1.1	0.27	1.00	1.73	3.2	0.22 [-0.04, 0.48]
			Placebo	129	113 (87.6)	0.85 (1.11)	-1.6	0.18	0.82	1.45	3.9	
		Week 48	Tezepelumab	127	110 (86.6)	1.11 (1.03)	-1.0	0.36	1.05	1.82	3.2	0.27 [0.01, 0.53]
			Placebo	129	113 (87.6)	0.83 (1.03)	-1.6	0.18	0.82	1.27	3.6	
		Week 52	Tezepelumab	127	110 (86.6)	1.05 (1.04)	-1.2	0.27	1.00	1.64	3.3	0.22 [-0.05, 0.48]
			Placebo	129	113 (87.6)	0.83 (1.00)	-1.6	0.18	0.82	1.27	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	61	54 (88.5)	4.37 (0.85)	2.2	3.91	4.27	5.00	6.3	
			Placebo	60	53 (88.3)	4.18 (0.88)	2.3	3.45	4.09	4.64	6.2	
		Week 4	Tezepelumab	61	56 (91.8)	4.90 (1.04)	1.6	4.23	4.77	5.73	7.0	
			Placebo	60	53 (88.3)	4.71 (1.08)	2.5	3.91	4.55	5.36	7.0	
		Week 8	Tezepelumab	61	57 (93.4)	5.15 (0.91)	3.3	4.45	5.09	5.91	7.0	
			Placebo	60	54 (90.0)	4.83 (1.10)	2.3	4.00	4.64	5.64	7.0	
		Week 12	Tezepelumab	61	57 (93.4)	5.23 (0.95)	3.0	4.64	5.18	5.82	7.0	
			Placebo	60	54 (90.0)	4.93 (1.09)	3.2	4.00	4.73	6.00	7.0	
		Week 16	Tezepelumab	61	57 (93.4)	5.13 (0.94)	2.8	4.36	5.09	5.82	7.0	
			Placebo	60	54 (90.0)	4.92 (1.20)	1.1	3.91	4.91	5.91	7.0	
		Week 20	Tezepelumab	61	58 (95.1)	5.14 (0.94)	3.5	4.36	5.05	5.82	7.0	
			Placebo	60	54 (90.0)	4.85 (1.12)	1.1	4.09	4.64	5.73	7.0	
		Week 24	Tezepelumab	61	58 (95.1)	5.20 (1.10)	1.6	4.36	5.18	6.00	7.0	
			Placebo	60	54 (90.0)	4.93 (1.25)	1.1	3.91	4.73	6.00	7.0	
		Week 28	Tezepelumab	61	59 (96.7)	5.16 (0.98)	3.5	4.36	5.09	5.91	7.0	
			Placebo	60	54 (90.0)	4.90 (1.32)	1.1	4.00	4.73	6.00	7.0	
		Week 32	Tezepelumab	61	60 (98.4)	5.27 (0.91)	3.6	4.36	5.27	6.00	7.0	
			Placebo	60	54 (90.0)	4.96 (1.18)	1.1	4.09	4.73	5.91	7.0	
		Week 36	Tezepelumab	61	60 (98.4)	5.26 (0.97)	3.3	4.41	5.36	6.00	7.0	
			Placebo	60	54 (90.0)	5.06 (1.15)	2.5	4.00	5.09	6.09	7.0	
		Week 40	Tezepelumab	61	60 (98.4)	5.24 (0.97)	3.5	4.36	5.09	5.91	7.0	
			Placebo	60	54 (90.0)	5.00 (1.19)	2.9	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	61	60 (98.4)	5.31 (0.97)	3.5	4.45	5.36	6.00	7.0	
			Placebo	60	54 (90.0)	5.03 (1.22)	2.9	4.00	4.73	6.00	7.0	
		Week 48	Tezepelumab	61	60 (98.4)	5.35 (0.93)	3.7	4.36	5.36	6.00	7.0	
			Placebo	60	54 (90.0)	5.04 (1.20)	2.9	4.00	4.86	6.09	7.0	
		Week 52	Tezepelumab	61	60 (98.4)	5.37 (0.91)	3.7	4.64	5.36	6.00	7.0	
			Placebo	60	54 (90.0)	5.03 (1.19)	2.9	3.91	4.86	6.09	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	61	52 (85.2)	0.57 (1.08)	-2.8	-0.05	0.55	1.27	3.1	0.04 [-0.34, 0.43]
			Placebo	60	51 (85.0)	0.53 (0.84)	-1.5	0.00	0.45	0.91	2.5	
		Week 8	Tezepelumab	61	53 (86.9)	0.76 (1.07)	-1.5	0.00	0.64	1.45	3.7	0.10 [-0.28, 0.48]
			Placebo	60	52 (86.7)	0.66 (0.87)	-1.7	0.14	0.73	1.09	2.6	
		Week 12	Tezepelumab	61	53 (86.9)	0.86 (1.04)	-1.5	0.36	0.82	1.55	4.2	0.13 [-0.25, 0.52]
			Placebo	60	52 (86.7)	0.73 (0.94)	-1.9	0.23	0.86	1.18	3.0	
		Week 16	Tezepelumab	61	53 (86.9)	0.80 (1.07)	-1.7	0.18	0.82	1.45	3.5	0.05 [-0.33, 0.43]
			Placebo	60	52 (86.7)	0.75 (1.00)	-3.2	0.50	0.91	1.27	2.5	
		Week 20	Tezepelumab	61	53 (86.9)	0.77 (1.11)	-2.1	-0.09	0.73	1.36	3.5	0.09 [-0.29, 0.48]
			Placebo	60	52 (86.7)	0.67 (0.99)	-3.2	0.18	0.73	1.27	2.5	
		Week 24	Tezepelumab	61	53 (86.9)	0.88 (1.06)	-1.4	0.09	0.73	1.64	3.5	0.10 [-0.28, 0.49]
			Placebo	60	52 (86.7)	0.77 (1.07)	-3.2	0.32	0.82	1.36	3.0	
		Week 28	Tezepelumab	61	53 (86.9)	0.83 (1.07)	-1.1	0.00	0.73	1.45	3.5	0.08 [-0.30, 0.46]
			Placebo	60	52 (86.7)	0.74 (1.05)	-3.2	0.14	0.82	1.32	3.0	
		Week 32	Tezepelumab	61	53 (86.9)	0.89 (1.01)	-1.1	0.27	0.82	1.36	3.5	0.09 [-0.29, 0.48]
			Placebo	60	52 (86.7)	0.80 (0.92)	-3.2	0.55	0.91	1.36	2.6	
		Week 36	Tezepelumab	61	53 (86.9)	0.89 (1.03)	-0.8	0.18	0.73	1.45	3.5	-0.02 [-0.40, 0.36]
			Placebo	60	52 (86.7)	0.91 (0.99)	-1.8	0.32	0.95	1.41	3.3	
		Week 40	Tezepelumab	61	53 (86.9)	0.88 (1.03)	-1.0	0.27	1.00	1.36	3.5	0.02 [-0.36, 0.41]
			Placebo	60	52 (86.7)	0.85 (1.03)	-1.5	0.32	0.86	1.45	3.1	
		Week 44	Tezepelumab	61	53 (86.9)	0.94 (1.00)	-0.6	0.27	0.82	1.55	3.5	0.06 [-0.32, 0.44]
			Placebo	60	52 (86.7)	0.87 (1.02)	-1.4	0.36	0.86	1.50	3.0	
		Week 48	Tezepelumab	61	53 (86.9)	1.00 (1.00)	-0.6	0.36	1.00	1.55	3.5	0.11 [-0.27, 0.50]
			Placebo	60	52 (86.7)	0.89 (0.96)	-1.4	0.18	0.95	1.27	3.2	
		Week 52	Tezepelumab	61	53 (86.9)	0.99 (1.00)	-1.2	0.45	1.00	1.55	3.5	0.12 [-0.26, 0.50]
			Placebo	60	52 (86.7)	0.88 (1.00)	-1.4	0.27	0.91	1.27	3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	76	69 (90.8)	4.23 (0.97)	1.9	3.73	4.09	4.64	7.0	
			Placebo	78	68 (87.2)	4.12 (0.88)	2.0	3.59	4.05	4.50	6.2	
		Week 4	Tezepelumab	76	70 (92.1)	5.01 (1.14)	3.1	4.00	5.05	5.91	7.0	
			Placebo	78	70 (89.7)	4.57 (1.00)	2.6	3.91	4.55	5.45	6.9	
		Week 8	Tezepelumab	76	71 (93.4)	5.15 (1.23)	1.6	4.18	5.18	6.09	7.0	
			Placebo	78	72 (92.3)	4.72 (1.12)	2.2	3.95	4.55	5.45	7.0	
		Week 12	Tezepelumab	76	71 (93.4)	5.41 (1.23)	1.7	4.27	5.45	6.55	7.0	
			Placebo	78	73 (93.6)	4.87 (1.13)	2.8	4.00	4.73	5.91	7.0	
		Week 16	Tezepelumab	76	71 (93.4)	5.41 (1.18)	2.6	4.27	5.45	6.45	7.0	
			Placebo	78	73 (93.6)	4.95 (1.16)	2.9	4.09	4.82	6.00	7.0	
		Week 20	Tezepelumab	76	71 (93.4)	5.31 (1.29)	1.8	4.27	5.36	6.36	7.0	
			Placebo	78	73 (93.6)	4.94 (1.16)	2.1	4.09	4.82	6.00	7.0	
		Week 24	Tezepelumab	76	71 (93.4)	5.38 (1.18)	2.9	4.27	5.45	6.55	7.0	
			Placebo	78	73 (93.6)	4.96 (1.12)	2.0	4.18	4.91	5.82	7.0	
		Week 28	Tezepelumab	76	72 (94.7)	5.43 (1.18)	2.1	4.45	5.64	6.41	7.0	
			Placebo	78	74 (94.9)	4.97 (1.19)	2.0	4.00	4.86	6.00	7.0	
		Week 32	Tezepelumab	76	72 (94.7)	5.44 (1.24)	1.6	4.50	5.77	6.55	7.0	
			Placebo	78	75 (96.2)	5.02 (1.17)	1.7	4.09	4.82	6.00	7.0	
		Week 36	Tezepelumab	76	72 (94.7)	5.41 (1.19)	1.9	4.45	5.55	6.36	7.0	
			Placebo	78	75 (96.2)	4.98 (1.17)	2.4	4.09	4.73	6.09	7.0	
		Week 40	Tezepelumab	76	72 (94.7)	5.50 (1.17)	2.1	4.68	5.64	6.55	7.0	
			Placebo	78	75 (96.2)	5.05 (1.17)	2.0	4.09	5.00	6.09	7.0	
		Week 44	Tezepelumab	76	72 (94.7)	5.49 (1.19)	2.4	4.55	5.73	6.55	7.0	
			Placebo	78	75 (96.2)	5.05 (1.18)	2.5	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	76	72 (94.7)	5.49 (1.20)	2.6	4.45	5.64	6.55	7.0	
			Placebo	78	76 (97.4)	5.04 (1.10)	2.3	4.27	5.00	5.86	7.0	
		Week 52	Tezepelumab	76	72 (94.7)	5.43 (1.25)	1.8	4.45	5.55	6.50	7.0	
			Placebo	78	76 (97.4)	5.03 (1.11)	2.7	4.18	5.05	5.82	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	76	65 (85.5)	0.81 (0.92)	-0.7	0.00	0.82	1.36	3.2	0.39 [0.05, 0.74]
			Placebo	78	68 (87.2)	0.45 (0.88)	-1.5	-0.09	0.36	0.91	2.6	
		Week 8	Tezepelumab	76	66 (86.8)	0.92 (1.02)	-1.3	0.18	0.86	1.55	3.5	0.31 [-0.04, 0.65]
			Placebo	78	68 (87.2)	0.62 (0.96)	-1.3	-0.09	0.41	1.09	3.3	
		Week 12	Tezepelumab	76	66 (86.8)	1.17 (1.03)	-0.9	0.55	1.09	1.73	3.5	0.37 [0.03, 0.72]
			Placebo	78	68 (87.2)	0.78 (1.07)	-1.3	0.05	0.64	1.27	3.7	
		Week 16	Tezepelumab	76	66 (86.8)	1.17 (0.99)	-1.1	0.36	1.23	1.82	3.5	0.30 [-0.04, 0.64]
			Placebo	78	68 (87.2)	0.86 (1.09)	-1.6	0.18	0.59	1.64	3.9	
		Week 20	Tezepelumab	76	66 (86.8)	1.10 (1.08)	-1.1	0.27	1.00	1.91	3.5	0.21 [-0.13, 0.55]
			Placebo	78	68 (87.2)	0.88 (1.06)	-1.6	0.18	0.73	1.45	4.0	
		Week 24	Tezepelumab	76	66 (86.8)	1.19 (1.03)	-0.8	0.36	1.18	1.82	3.5	0.30 [-0.04, 0.64]
			Placebo	78	68 (87.2)	0.88 (1.08)	-1.6	0.18	0.82	1.55	3.8	
		Week 28	Tezepelumab	76	66 (86.8)	1.22 (1.02)	-0.8	0.45	1.14	2.00	3.5	0.33 [-0.01, 0.67]
			Placebo	78	68 (87.2)	0.86 (1.15)	-1.6	0.14	0.68	1.68	4.0	
		Week 32	Tezepelumab	76	66 (86.8)	1.23 (1.05)	-1.0	0.45	1.18	2.00	3.5	0.27 [-0.07, 0.61]
			Placebo	78	68 (87.2)	0.93 (1.16)	-1.8	0.09	0.59	1.73	3.6	
		Week 36	Tezepelumab	76	66 (86.8)	1.20 (1.11)	-0.9	0.27	1.09	2.09	3.5	0.28 [-0.06, 0.62]
			Placebo	78	68 (87.2)	0.89 (1.14)	-1.6	0.18	0.73	1.64	3.5	
		Week 40	Tezepelumab	76	66 (86.8)	1.28 (1.02)	-0.9	0.45	1.27	2.18	3.5	0.29 [-0.05, 0.63]
			Placebo	78	68 (87.2)	0.96 (1.20)	-1.6	0.18	0.77	1.73	4.0	
		Week 44	Tezepelumab	76	66 (86.8)	1.29 (1.08)	-1.1	0.36	1.27	2.27	3.5	0.32 [-0.02, 0.66]
			Placebo	78	68 (87.2)	0.93 (1.19)	-1.6	0.18	0.86	1.59	3.9	
		Week 48	Tezepelumab	76	66 (86.8)	1.31 (1.09)	-1.0	0.45	1.27	2.36	3.5	0.34 [-0.00, 0.68]
			Placebo	78	68 (87.2)	0.93 (1.14)	-1.6	0.18	0.82	1.68	3.6	
		Week 52	Tezepelumab	76	66 (86.8)	1.21 (1.12)	-1.2	0.27	1.00	2.36	3.5	0.24 [-0.10, 0.58]
			Placebo	78	68 (87.2)	0.95 (1.10)	-1.6	0.18	0.86	1.68	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	75	65 (86.7)	4.34 (0.81)	2.2	3.91	4.27	4.82	6.2	
			Placebo	72	61 (84.7)	4.15 (0.81)	2.0	3.55	4.09	4.64	5.9	
		Week 4	Tezepelumab	75	69 (92.0)	4.82 (1.07)	1.6	4.09	4.73	5.36	7.0	
			Placebo	72	64 (88.9)	4.62 (1.05)	2.6	3.91	4.50	5.32	6.9	
		Week 8	Tezepelumab	75	69 (92.0)	5.05 (0.96)	2.9	4.27	5.00	5.91	7.0	
			Placebo	72	64 (88.9)	4.79 (1.10)	2.3	4.00	4.50	5.59	7.0	
		Week 12	Tezepelumab	75	69 (92.0)	5.28 (1.01)	3.0	4.64	5.18	6.09	7.0	
			Placebo	72	65 (90.3)	4.84 (1.12)	3.1	4.00	4.45	5.91	7.0	
		Week 16	Tezepelumab	75	69 (92.0)	5.19 (1.02)	2.8	4.27	5.18	6.09	7.0	
			Placebo	72	65 (90.3)	4.96 (1.05)	2.9	4.00	4.82	5.82	7.0	
		Week 20	Tezepelumab	75	70 (93.3)	5.09 (1.08)	2.8	4.27	4.86	6.00	7.0	
			Placebo	72	65 (90.3)	4.86 (1.05)	2.1	4.00	4.64	5.73	7.0	
		Week 24	Tezepelumab	75	70 (93.3)	5.19 (1.09)	2.9	4.27	4.95	6.09	7.0	
			Placebo	72	65 (90.3)	4.97 (1.13)	2.0	4.18	4.91	5.82	7.0	
		Week 28	Tezepelumab	75	72 (96.0)	5.17 (1.07)	3.2	4.23	4.95	6.14	7.0	
			Placebo	72	66 (91.7)	4.94 (1.16)	2.0	4.00	4.82	5.91	7.0	
		Week 32	Tezepelumab	75	73 (97.3)	5.26 (1.06)	2.9	4.36	5.36	6.18	7.0	
			Placebo	72	67 (93.1)	4.98 (1.12)	1.7	4.00	4.73	6.00	7.0	
		Week 36	Tezepelumab	75	73 (97.3)	5.26 (1.06)	3.0	4.36	5.36	6.18	7.0	
			Placebo	72	67 (93.1)	5.04 (1.10)	2.5	4.00	4.82	6.00	7.0	
		Week 40	Tezepelumab	75	73 (97.3)	5.19 (1.03)	3.3	4.36	5.09	6.00	7.0	
			Placebo	72	67 (93.1)	5.03 (1.13)	2.0	4.09	5.09	5.91	7.0	
		Week 44	Tezepelumab	75	73 (97.3)	5.24 (1.04)	3.0	4.36	5.36	6.00	7.0	
			Placebo	72	67 (93.1)	5.04 (1.18)	2.5	4.00	4.91	6.00	7.0	
		Week 48	Tezepelumab	75	73 (97.3)	5.23 (1.06)	2.6	4.27	5.18	6.18	7.0	
			Placebo	72	68 (94.4)	5.12 (1.13)	2.3	4.05	5.14	6.09	7.0	
		Week 52	Tezepelumab	75	73 (97.3)	5.22 (1.04)	2.6	4.36	5.18	6.00	7.0	
			Placebo	72	68 (94.4)	5.06 (1.16)	2.7	4.00	5.05	6.05	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	75	64 (85.3)	0.48 (1.00)	-2.8	-0.09	0.55	1.18	3.1	-0.03 [-0.39, 0.32]
			Placebo	72	61 (84.7)	0.51 (0.87)	-1.5	0.00	0.45	0.82	2.6	
		Week 8	Tezepelumab	75	64 (85.3)	0.68 (1.00)	-1.5	0.00	0.64	1.23	3.7	0.02 [-0.33, 0.37]
			Placebo	72	61 (84.7)	0.66 (0.88)	-1.7	0.09	0.64	1.09	2.6	
		Week 12	Tezepelumab	75	64 (85.3)	0.92 (0.99)	-1.5	0.23	0.91	1.45	4.2	0.18 [-0.17, 0.53]
			Placebo	72	61 (84.7)	0.74 (1.01)	-1.9	0.09	0.82	1.18	3.0	
		Week 16	Tezepelumab	75	64 (85.3)	0.85 (1.02)	-1.7	0.18	0.82	1.45	3.5	-0.01 [-0.36, 0.34]
			Placebo	72	61 (84.7)	0.86 (0.92)	-1.9	0.36	1.00	1.36	2.7	
		Week 20	Tezepelumab	75	64 (85.3)	0.77 (1.08)	-2.1	0.05	0.59	1.45	3.5	-0.01 [-0.36, 0.34]
			Placebo	72	61 (84.7)	0.77 (0.91)	-1.5	0.18	0.73	1.27	2.6	
		Week 24	Tezepelumab	75	64 (85.3)	0.91 (1.00)	-0.6	0.09	0.86	1.45	3.5	0.04 [-0.31, 0.39]
			Placebo	72	61 (84.7)	0.87 (0.97)	-1.5	0.36	0.91	1.36	3.0	
		Week 28	Tezepelumab	75	64 (85.3)	0.88 (1.06)	-1.1	0.00	0.91	1.59	3.5	0.07 [-0.28, 0.42]
			Placebo	72	61 (84.7)	0.81 (0.94)	-1.5	0.27	0.82	1.36	3.0	
		Week 32	Tezepelumab	75	64 (85.3)	0.92 (1.02)	-1.1	0.14	0.82	1.55	3.5	0.06 [-0.30, 0.41]
			Placebo	72	61 (84.7)	0.87 (0.88)	-1.8	0.45	1.00	1.36	2.7	
		Week 36	Tezepelumab	75	64 (85.3)	0.92 (1.04)	-0.8	0.18	0.77	1.50	3.5	-0.01 [-0.36, 0.34]
			Placebo	72	61 (84.7)	0.94 (0.99)	-1.2	0.18	1.00	1.45	3.3	
		Week 40	Tezepelumab	75	64 (85.3)	0.86 (1.01)	-1.0	0.14	0.86	1.36	3.5	-0.07 [-0.42, 0.28]
			Placebo	72	61 (84.7)	0.93 (1.04)	-1.5	0.27	1.00	1.45	3.1	
		Week 44	Tezepelumab	75	64 (85.3)	0.91 (1.00)	-0.6	0.18	0.82	1.55	3.5	0.00 [-0.35, 0.35]
			Placebo	72	61 (84.7)	0.91 (1.05)	-1.2	0.18	0.91	1.55	3.0	
		Week 48	Tezepelumab	75	64 (85.3)	0.91 (1.01)	-0.6	0.14	0.86	1.50	3.5	-0.08 [-0.43, 0.27]
			Placebo	72	61 (84.7)	0.99 (0.98)	-1.3	0.27	1.09	1.36	3.4	
		Week 52	Tezepelumab	75	64 (85.3)	0.88 (1.02)	-1.2	0.18	0.86	1.41	3.5	-0.08 [-0.44, 0.27]
			Placebo	72	61 (84.7)	0.97 (0.98)	-1.2	0.36	1.09	1.36	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	60	56 (93.3)	4.24 (1.04)	1.9	3.68	4.18	4.73	7.0	
			Placebo	65	59 (90.8)	4.15 (0.95)	2.3	3.55	4.00	4.45	6.2	
		Week 4	Tezepelumab	60	55 (91.7)	5.15 (1.11)	3.1	4.18	5.27	6.00	7.0	
			Placebo	65	59 (90.8)	4.64 (1.03)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	60	57 (95.0)	5.27 (1.25)	1.6	4.36	5.27	6.36	7.0	
			Placebo	65	61 (93.8)	4.76 (1.13)	2.2	4.00	4.73	5.82	7.0	
		Week 12	Tezepelumab	60	57 (95.0)	5.39 (1.26)	1.7	4.55	5.36	6.45	7.0	
			Placebo	65	61 (93.8)	4.95 (1.11)	2.8	4.09	4.82	6.00	7.0	
		Week 16	Tezepelumab	60	57 (95.0)	5.40 (1.17)	2.6	4.45	5.45	6.45	7.0	
			Placebo	65	61 (93.8)	4.97 (1.22)	2.6	4.00	4.91	6.00	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.40 (1.23)	1.8	4.64	5.36	6.27	7.0	
			Placebo	65	61 (93.8)	5.01 (1.14)	3.0	4.18	4.82	6.09	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.42 (1.22)	1.6	4.55	5.55	6.45	7.0	
			Placebo	65	61 (93.8)	4.98 (1.13)	2.7	4.09	4.73	6.00	7.0	
		Week 28	Tezepelumab	60	57 (95.0)	5.48 (1.13)	2.1	4.82	5.64	6.18	7.0	
			Placebo	65	61 (93.8)	5.00 (1.24)	2.5	3.91	4.82	6.00	7.0	
		Week 32	Tezepelumab	60	57 (95.0)	5.49 (1.16)	1.6	4.82	5.82	6.18	7.0	
			Placebo	65	61 (93.8)	5.07 (1.14)	3.1	4.09	5.00	5.91	7.0	
		Week 36	Tezepelumab	60	57 (95.0)	5.45 (1.15)	1.9	4.73	5.55	6.27	7.0	
			Placebo	65	61 (93.8)	5.03 (1.20)	2.4	4.09	4.82	6.18	7.0	
		Week 40	Tezepelumab	60	57 (95.0)	5.62 (1.14)	2.1	5.00	5.91	6.55	7.0	
			Placebo	65	61 (93.8)	5.06 (1.22)	2.5	4.09	4.91	6.18	7.0	
		Week 44	Tezepelumab	60	57 (95.0)	5.62 (1.15)	2.4	4.91	5.82	6.55	7.0	
			Placebo	65	61 (93.8)	5.07 (1.19)	3.1	4.00	4.91	5.91	7.0	
		Week 48	Tezepelumab	60	57 (95.0)	5.68 (1.09)	3.1	5.00	6.00	6.55	7.0	
			Placebo	65	61 (93.8)	4.99 (1.13)	2.4	4.09	4.82	5.91	7.0	
		Week 52	Tezepelumab	60	57 (95.0)	5.62 (1.18)	1.8	4.91	6.00	6.45	7.0	
			Placebo	65	61 (93.8)	5.03 (1.09)	3.1	4.18	5.00	5.73	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	60	51 (85.0)	1.00 (0.95)	-0.7	0.27	1.00	1.55	3.2	0.60 [0.21, 0.98]
			Placebo	65	58 (89.2)	0.46 (0.85)	-1.5	-0.09	0.32	0.91	2.5	
		Week 8	Tezepelumab	60	53 (88.3)	1.04 (1.07)	-0.9	0.36	0.91	1.64	3.5	0.41 [0.04, 0.79]
			Placebo	65	58 (89.2)	0.63 (0.95)	-1.3	-0.09	0.59	1.00	3.3	
		Week 12	Tezepelumab	60	53 (88.3)	1.16 (1.11)	-0.9	0.36	1.09	2.09	3.5	0.35 [-0.02, 0.73]
			Placebo	65	58 (89.2)	0.79 (1.03)	-1.3	0.18	0.82	1.27	3.7	
		Week 16	Tezepelumab	60	53 (88.3)	1.19 (1.07)	-1.3	0.55	1.27	1.82	3.5	0.33 [-0.04, 0.71]
			Placebo	65	58 (89.2)	0.83 (1.06)	-1.6	0.18	0.64	1.55	3.9	
		Week 20	Tezepelumab	60	53 (88.3)	1.17 (1.12)	-1.1	0.55	1.00	2.00	3.5	0.28 [-0.10, 0.65]
			Placebo	65	58 (89.2)	0.87 (1.03)	-1.6	0.27	0.68	1.27	4.0	
		Week 24	Tezepelumab	60	53 (88.3)	1.21 (1.12)	-1.4	0.64	1.09	1.91	3.5	0.31 [-0.06, 0.69]
			Placebo	65	58 (89.2)	0.86 (1.06)	-1.6	0.18	0.82	1.55	3.8	
		Week 28	Tezepelumab	60	53 (88.3)	1.25 (1.05)	-0.8	0.55	1.09	2.09	3.5	0.33 [-0.05, 0.70]
			Placebo	65	58 (89.2)	0.88 (1.16)	-1.6	0.09	0.82	1.73	4.0	
		Week 32	Tezepelumab	60	53 (88.3)	1.26 (1.06)	-1.0	0.64	1.09	2.27	3.5	0.29 [-0.09, 0.66]
			Placebo	65	58 (89.2)	0.95 (1.11)	-1.6	0.18	0.64	1.73	3.6	
		Week 36	Tezepelumab	60	53 (88.3)	1.22 (1.15)	-0.9	0.27	1.09	2.27	3.5	0.28 [-0.10, 0.65]
			Placebo	65	58 (89.2)	0.90 (1.11)	-1.6	0.18	0.77	1.73	3.5	
		Week 40	Tezepelumab	60	53 (88.3)	1.39 (1.03)	-0.9	0.73	1.27	2.36	3.5	0.40 [0.02, 0.77]
			Placebo	65	58 (89.2)	0.94 (1.19)	-1.6	0.18	0.77	1.73	4.0	
		Week 44	Tezepelumab	60	53 (88.3)	1.40 (1.08)	-1.1	0.64	1.27	2.36	3.5	0.40 [0.03, 0.78]
			Placebo	65	58 (89.2)	0.94 (1.17)	-1.6	0.27	0.82	1.64	3.9	
		Week 48	Tezepelumab	60	53 (88.3)	1.46 (1.05)	-1.0	0.73	1.36	2.36	3.5	0.55 [0.17, 0.93]
			Placebo	65	58 (89.2)	0.87 (1.12)	-1.6	0.18	0.82	1.64	3.6	
		Week 52	Tezepelumab	60	53 (88.3)	1.38 (1.09)	-1.2	0.73	1.36	2.36	3.5	0.43 [0.05, 0.81]
			Placebo	65	58 (89.2)	0.91 (1.10)	-1.6	0.18	0.82	1.64	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	65	56 (86.2)	4.37 (0.85)	2.2	3.91	4.27	4.95	6.2	
			Placebo	62	53 (85.5)	4.12 (0.82)	2.0	3.55	4.09	4.64	5.9	
		Week 4	Tezepelumab	65	60 (92.3)	4.81 (1.07)	1.6	4.09	4.82	5.36	7.0	
			Placebo	62	56 (90.3)	4.52 (1.02)	2.6	3.91	4.23	5.14	6.9	
		Week 8	Tezepelumab	65	60 (92.3)	5.08 (0.94)	3.4	4.27	4.95	5.95	7.0	
			Placebo	62	56 (90.3)	4.66 (1.03)	2.3	4.00	4.41	5.32	7.0	
		Week 12	Tezepelumab	65	60 (92.3)	5.25 (1.01)	3.0	4.32	5.09	6.09	7.0	
			Placebo	62	57 (91.9)	4.74 (1.07)	3.1	3.91	4.36	5.55	7.0	
		Week 16	Tezepelumab	65	60 (92.3)	5.14 (1.02)	2.8	4.27	5.05	5.95	7.0	
			Placebo	62	57 (91.9)	4.84 (1.01)	2.9	4.00	4.73	5.55	7.0	
		Week 20	Tezepelumab	65	61 (93.8)	5.01 (1.04)	2.8	4.27	4.82	5.91	7.0	
			Placebo	62	57 (91.9)	4.78 (1.04)	2.1	3.91	4.55	5.64	7.0	
		Week 24	Tezepelumab	65	61 (93.8)	5.13 (1.07)	3.5	4.27	4.82	6.09	7.0	
			Placebo	62	57 (91.9)	4.85 (1.10)	2.0	4.00	4.73	5.73	7.0	
		Week 28	Tezepelumab	65	62 (95.4)	5.07 (1.03)	3.5	4.18	4.86	5.82	7.0	
			Placebo	62	58 (93.5)	4.80 (1.12)	2.0	4.00	4.64	5.82	7.0	
		Week 32	Tezepelumab	65	63 (96.9)	5.19 (1.00)	3.3	4.36	5.18	6.00	7.0	
			Placebo	62	58 (93.5)	4.90 (1.12)	1.7	4.00	4.64	5.91	7.0	
		Week 36	Tezepelumab	65	63 (96.9)	5.18 (1.03)	3.7	4.27	4.91	6.09	7.0	
			Placebo	62	58 (93.5)	4.97 (1.09)	2.5	4.00	4.73	6.00	7.0	
		Week 40	Tezepelumab	65	63 (96.9)	5.10 (0.98)	3.5	4.36	5.00	5.82	7.0	
			Placebo	62	58 (93.5)	4.95 (1.15)	2.0	4.00	4.91	5.82	7.0	
		Week 44	Tezepelumab	65	63 (96.9)	5.16 (1.00)	3.7	4.27	5.09	6.00	7.0	
			Placebo	62	58 (93.5)	4.98 (1.14)	2.5	4.00	4.86	6.00	7.0	
		Week 48	Tezepelumab	65	63 (96.9)	5.15 (1.01)	3.3	4.27	5.18	5.91	7.0	
			Placebo	62	59 (95.2)	5.05 (1.13)	2.3	4.00	5.09	6.00	7.0	
		Week 52	Tezepelumab	65	63 (96.9)	5.14 (0.97)	3.3	4.27	5.09	5.82	7.0	
			Placebo	62	59 (95.2)	5.00 (1.13)	2.9	3.91	4.91	5.91	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	65	55 (84.6)	0.44 (1.03)	-2.8	-0.18	0.45	1.18	3.1	-0.00 [-0.38, 0.37]
			Placebo	62	53 (85.5)	0.44 (0.87)	-1.5	-0.18	0.36	0.73	2.6	
		Week 8	Tezepelumab	65	55 (84.6)	0.68 (1.04)	-1.5	0.00	0.64	1.27	3.7	0.13 [-0.25, 0.50]
			Placebo	62	53 (85.5)	0.56 (0.84)	-1.7	0.09	0.55	1.00	2.6	
		Week 12	Tezepelumab	65	55 (84.6)	0.86 (1.02)	-1.5	0.09	0.82	1.36	4.2	0.20 [-0.18, 0.58]
			Placebo	62	53 (85.5)	0.66 (0.97)	-1.9	0.00	0.82	1.09	2.9	
		Week 16	Tezepelumab	65	55 (84.6)	0.77 (1.04)	-1.7	0.18	0.64	1.27	3.5	0.00 [-0.37, 0.38]
			Placebo	62	53 (85.5)	0.77 (0.93)	-1.9	0.27	0.91	1.27	2.7	
		Week 20	Tezepelumab	65	55 (84.6)	0.65 (1.07)	-2.1	-0.09	0.55	1.27	3.5	-0.09 [-0.47, 0.29]
			Placebo	62	53 (85.5)	0.74 (0.88)	-1.5	0.18	0.73	1.27	2.6	
		Week 24	Tezepelumab	65	55 (84.6)	0.83 (1.00)	-0.6	0.00	0.73	1.36	3.5	0.05 [-0.33, 0.43]
			Placebo	62	53 (85.5)	0.78 (0.96)	-1.5	0.27	0.82	1.27	2.6	
		Week 28	Tezepelumab	65	55 (84.6)	0.77 (1.05)	-1.1	0.00	0.73	1.36	3.5	0.08 [-0.30, 0.46]
			Placebo	62	53 (85.5)	0.69 (0.91)	-1.5	0.09	0.64	1.27	2.8	
		Week 32	Tezepelumab	65	55 (84.6)	0.84 (0.99)	-1.1	0.09	0.82	1.36	3.5	0.05 [-0.32, 0.43]
			Placebo	62	53 (85.5)	0.79 (0.90)	-1.8	0.36	0.91	1.27	2.7	
		Week 36	Tezepelumab	65	55 (84.6)	0.82 (1.02)	-0.8	0.18	0.73	1.27	3.5	-0.05 [-0.43, 0.32]
			Placebo	62	53 (85.5)	0.88 (1.00)	-1.2	0.18	0.91	1.45	3.3	
		Week 40	Tezepelumab	65	55 (84.6)	0.75 (1.00)	-1.0	0.09	0.64	1.27	3.5	-0.11 [-0.49, 0.26]
			Placebo	62	53 (85.5)	0.87 (1.08)	-1.5	0.18	0.91	1.45	3.1	
		Week 44	Tezepelumab	65	55 (84.6)	0.80 (1.00)	-0.6	0.18	0.55	1.36	3.5	-0.06 [-0.44, 0.32]
			Placebo	62	53 (85.5)	0.87 (1.00)	-1.2	0.09	0.91	1.45	2.9	
		Week 48	Tezepelumab	65	55 (84.6)	0.81 (0.99)	-0.6	0.09	0.64	1.36	3.5	-0.12 [-0.50, 0.26]
			Placebo	62	53 (85.5)	0.93 (0.99)	-1.3	0.18	1.09	1.27	3.4	
		Week 52	Tezepelumab	65	55 (84.6)	0.78 (1.00)	-1.2	0.18	0.64	1.27	3.5	-0.12 [-0.50, 0.25]
			Placebo	62	53 (85.5)	0.90 (0.99)	-1.2	0.18	1.00	1.27	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	70	65 (92.9)	4.23 (0.99)	1.9	3.64	4.18	4.64	7.0	
			Placebo	75	67 (89.3)	4.17 (0.93)	2.3	3.64	4.00	4.55	6.2	
		Week 4	Tezepelumab	70	64 (91.4)	5.12 (1.11)	3.1	4.18	5.14	6.00	7.0	
			Placebo	75	67 (89.3)	4.72 (1.04)	2.5	3.91	4.64	5.45	7.0	
		Week 8	Tezepelumab	70	66 (94.3)	5.22 (1.24)	1.6	4.36	5.27	6.18	7.0	
			Placebo	75	69 (92.0)	4.87 (1.17)	2.2	4.00	4.82	6.00	7.0	
		Week 12	Tezepelumab	70	66 (94.3)	5.40 (1.22)	1.7	4.55	5.41	6.36	7.0	
			Placebo	75	69 (92.0)	5.02 (1.14)	2.8	4.09	4.91	6.09	7.0	
		Week 16	Tezepelumab	70	66 (94.3)	5.42 (1.14)	2.6	4.55	5.50	6.45	7.0	
			Placebo	75	69 (92.0)	5.07 (1.21)	2.6	4.09	5.00	6.27	7.0	
		Week 20	Tezepelumab	70	66 (94.3)	5.43 (1.22)	1.8	4.64	5.45	6.36	7.0	
			Placebo	75	69 (92.0)	5.06 (1.12)	3.0	4.27	4.91	6.18	7.0	
		Week 24	Tezepelumab	70	66 (94.3)	5.44 (1.21)	1.6	4.55	5.64	6.45	7.0	
			Placebo	75	69 (92.0)	5.08 (1.14)	2.7	4.18	5.00	6.09	7.0	
		Week 28	Tezepelumab	70	67 (95.7)	5.53 (1.13)	2.1	4.82	5.64	6.36	7.0	
			Placebo	75	69 (92.0)	5.12 (1.25)	2.5	4.00	5.09	6.36	7.0	
		Week 32	Tezepelumab	70	67 (95.7)	5.52 (1.19)	1.6	4.82	5.82	6.36	7.0	
			Placebo	75	70 (93.3)	5.13 (1.12)	3.1	4.18	5.09	6.00	7.0	
		Week 36	Tezepelumab	70	67 (95.7)	5.50 (1.15)	1.9	4.73	5.55	6.27	7.0	
			Placebo	75	70 (93.3)	5.09 (1.18)	2.4	4.09	4.91	6.27	7.0	
		Week 40	Tezepelumab	70	67 (95.7)	5.64 (1.13)	2.1	5.00	5.91	6.55	7.0	
			Placebo	75	70 (93.3)	5.12 (1.18)	2.5	4.09	5.09	6.09	7.0	
		Week 44	Tezepelumab	70	67 (95.7)	5.64 (1.15)	2.4	4.91	5.82	6.55	7.0	
			Placebo	75	70 (93.3)	5.11 (1.22)	3.1	4.00	4.95	6.18	7.0	
		Week 48	Tezepelumab	70	67 (95.7)	5.68 (1.11)	2.6	5.00	6.00	6.55	7.0	
			Placebo	75	70 (93.3)	5.07 (1.13)	2.4	4.18	4.91	5.91	7.0	
		Week 52	Tezepelumab	70	67 (95.7)	5.64 (1.19)	1.8	5.00	6.00	6.55	7.0	
			Placebo	75	70 (93.3)	5.08 (1.13)	2.7	4.18	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	70	60 (85.7)	0.96 (0.92)	-0.7	0.27	0.86	1.55	3.2	0.49 [0.13, 0.84]
			Placebo	75	66 (88.0)	0.52 (0.86)	-1.5	0.00	0.36	0.91	2.5	
		Week 8	Tezepelumab	70	62 (88.6)	0.99 (1.04)	-0.9	0.27	0.91	1.64	3.5	0.28 [-0.07, 0.63]
			Placebo	75	66 (88.0)	0.71 (0.97)	-1.3	-0.09	0.73	1.27	3.3	
		Week 12	Tezepelumab	70	62 (88.6)	1.18 (1.06)	-0.9	0.36	1.09	1.91	3.5	0.32 [-0.03, 0.67]
			Placebo	75	66 (88.0)	0.84 (1.05)	-1.3	0.18	0.82	1.27	3.7	
		Week 16	Tezepelumab	70	62 (88.6)	1.21 (1.02)	-1.3	0.55	1.32	1.91	3.5	0.30 [-0.05, 0.64]
			Placebo	75	66 (88.0)	0.91 (1.03)	-1.6	0.27	0.82	1.64	3.9	
		Week 20	Tezepelumab	70	62 (88.6)	1.21 (1.08)	-1.1	0.55	1.09	2.00	3.5	0.30 [-0.05, 0.65]
			Placebo	75	66 (88.0)	0.89 (1.03)	-1.6	0.27	0.82	1.27	4.0	
		Week 24	Tezepelumab	70	62 (88.6)	1.23 (1.08)	-1.4	0.64	1.18	1.91	3.5	0.28 [-0.07, 0.63]
			Placebo	75	66 (88.0)	0.94 (1.05)	-1.6	0.27	0.82	1.55	3.8	
		Week 28	Tezepelumab	70	62 (88.6)	1.29 (1.02)	-0.8	0.64	1.23	2.09	3.5	0.29 [-0.05, 0.64]
			Placebo	75	66 (88.0)	0.97 (1.14)	-1.6	0.18	0.82	1.82	4.0	
		Week 32	Tezepelumab	70	62 (88.6)	1.29 (1.06)	-1.0	0.64	1.27	2.27	3.5	0.27 [-0.08, 0.61]
			Placebo	75	66 (88.0)	1.01 (1.06)	-1.6	0.27	0.82	1.73	3.6	
		Week 36	Tezepelumab	70	62 (88.6)	1.26 (1.12)	-0.9	0.27	1.27	2.27	3.5	0.28 [-0.07, 0.63]
			Placebo	75	66 (88.0)	0.95 (1.09)	-1.6	0.27	0.82	1.73	3.5	
		Week 40	Tezepelumab	70	62 (88.6)	1.40 (0.99)	-0.9	0.73	1.32	2.36	3.5	0.39 [0.04, 0.74]
			Placebo	75	66 (88.0)	0.99 (1.14)	-1.6	0.27	0.82	1.73	4.0	
		Week 44	Tezepelumab	70	62 (88.6)	1.42 (1.05)	-1.1	0.73	1.55	2.36	3.5	0.40 [0.05, 0.75]
			Placebo	75	66 (88.0)	0.97 (1.18)	-1.6	0.27	0.82	1.64	3.9	
		Week 48	Tezepelumab	70	62 (88.6)	1.47 (1.03)	-1.0	0.73	1.55	2.36	3.5	0.51 [0.16, 0.86]
			Placebo	75	66 (88.0)	0.93 (1.10)	-1.6	0.18	0.82	1.73	3.6	
		Week 52	Tezepelumab	70	62 (88.6)	1.40 (1.07)	-1.2	0.73	1.36	2.36	3.5	0.40 [0.05, 0.75]
			Placebo	75	66 (88.0)	0.97 (1.08)	-1.6	0.18	0.82	1.73	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	50	43 (86.0)	4.09 (0.81)	2.1	3.73	4.09	4.45	6.2	
			Placebo	50	40 (80.0)	4.13 (0.95)	2.0	3.55	4.00	4.55	6.1	
		Week 4	Tezepelumab	50	48 (96.0)	4.76 (1.03)	3.1	3.91	4.64	5.36	7.0	
			Placebo	50	41 (82.0)	4.38 (1.07)	2.5	3.64	4.18	4.82	7.0	
		Week 8	Tezepelumab	50	48 (96.0)	5.04 (0.99)	3.0	4.36	5.00	5.86	7.0	
			Placebo	50	44 (88.0)	4.54 (1.05)	2.3	3.91	4.41	5.05	7.0	
		Week 12	Tezepelumab	50	48 (96.0)	5.29 (1.04)	3.4	4.45	5.27	6.14	7.0	
			Placebo	50	44 (88.0)	4.61 (1.01)	2.8	3.95	4.59	5.23	6.9	
		Week 16	Tezepelumab	50	48 (96.0)	5.21 (1.03)	3.5	4.27	5.23	6.05	7.0	
			Placebo	50	44 (88.0)	4.63 (1.22)	1.1	3.91	4.45	5.45	7.0	
		Week 20	Tezepelumab	50	48 (96.0)	5.23 (1.10)	2.8	4.27	5.32	6.05	7.0	
			Placebo	50	44 (88.0)	4.58 (1.24)	1.1	3.91	4.36	5.32	6.9	
		Week 24	Tezepelumab	50	48 (96.0)	5.15 (1.18)	1.6	4.23	5.00	6.18	7.0	
			Placebo	50	44 (88.0)	4.50 (1.24)	1.1	3.64	4.45	5.27	6.9	
		Week 28	Tezepelumab	50	49 (98.0)	5.20 (1.04)	2.9	4.27	5.36	6.00	7.0	
			Placebo	50	44 (88.0)	4.51 (1.29)	1.1	3.73	4.36	5.27	6.9	
		Week 32	Tezepelumab	50	49 (98.0)	5.25 (1.01)	3.3	4.45	5.36	6.09	7.0	
			Placebo	50	45 (90.0)	4.48 (1.19)	1.1	3.91	4.27	5.27	7.0	
		Week 36	Tezepelumab	50	49 (98.0)	5.20 (1.06)	3.2	4.27	5.36	5.82	7.0	
			Placebo	50	45 (90.0)	4.57 (1.18)	2.4	3.91	4.45	5.36	6.9	
		Week 40	Tezepelumab	50	49 (98.0)	5.27 (0.98)	3.5	4.36	5.18	5.91	7.0	
			Placebo	50	45 (90.0)	4.60 (1.21)	2.0	3.91	4.36	5.55	6.9	
		Week 44	Tezepelumab	50	49 (98.0)	5.20 (1.04)	3.5	4.27	5.27	6.00	7.0	
			Placebo	50	45 (90.0)	4.54 (1.13)	2.5	3.91	4.45	5.27	7.0	
		Week 48	Tezepelumab	50	49 (98.0)	5.24 (1.06)	3.1	4.27	5.18	6.18	7.0	
			Placebo	50	46 (92.0)	4.58 (1.12)	2.3	3.91	4.55	5.36	6.9	
		Week 52	Tezepelumab	50	49 (98.0)	5.25 (1.04)	3.1	4.36	5.27	6.09	7.0	
			Placebo	50	46 (92.0)	4.57 (1.09)	2.7	3.91	4.36	5.36	6.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	50	42 (84.0)	0.75 (0.96)	-1.4	0.18	0.64	1.27	3.2	0.47 [0.03, 0.92]
			Placebo	50	39 (78.0)	0.31 (0.87)	-1.5	-0.27	0.18	0.73	2.5	
		Week 8	Tezepelumab	50	42 (84.0)	0.94 (1.04)	-1.3	0.27	0.91	1.55	3.1	0.52 [0.08, 0.96]
			Placebo	50	40 (80.0)	0.46 (0.81)	-1.3	0.05	0.36	1.00	2.6	
		Week 12	Tezepelumab	50	42 (84.0)	1.19 (0.99)	-0.5	0.36	1.18	1.64	3.1	0.70 [0.25, 1.14]
			Placebo	50	40 (80.0)	0.52 (0.92)	-1.4	0.00	0.41	1.09	2.9	
		Week 16	Tezepelumab	50	42 (84.0)	1.11 (1.05)	-1.7	0.36	1.14	1.55	3.1	0.54 [0.10, 0.99]
			Placebo	50	40 (80.0)	0.53 (1.12)	-3.2	-0.00	0.59	1.32	2.5	
		Week 20	Tezepelumab	50	42 (84.0)	1.17 (1.07)	-0.9	0.36	1.09	1.91	3.3	0.62 [0.18, 1.07]
			Placebo	50	40 (80.0)	0.50 (1.09)	-3.2	0.09	0.64	1.09	2.4	
		Week 24	Tezepelumab	50	42 (84.0)	1.14 (1.10)	-1.4	0.36	1.09	1.73	3.2	0.66 [0.22, 1.11]
			Placebo	50	40 (80.0)	0.40 (1.13)	-3.2	-0.14	0.45	1.18	2.5	
		Week 28	Tezepelumab	50	42 (84.0)	1.16 (1.00)	-0.5	0.45	1.14	1.64	3.2	0.69 [0.24, 1.13]
			Placebo	50	40 (80.0)	0.42 (1.17)	-3.2	-0.05	0.50	1.09	2.8	
		Week 32	Tezepelumab	50	42 (84.0)	1.24 (1.07)	-1.1	0.64	1.09	2.00	3.2	0.79 [0.34, 1.24]
			Placebo	50	40 (80.0)	0.39 (1.11)	-3.2	-0.18	0.50	1.00	2.6	
		Week 36	Tezepelumab	50	42 (84.0)	1.18 (1.09)	-0.8	0.45	1.14	1.73	3.2	0.66 [0.22, 1.10]
			Placebo	50	40 (80.0)	0.47 (1.05)	-1.8	-0.09	0.41	1.14	3.0	
		Week 40	Tezepelumab	50	42 (84.0)	1.24 (0.97)	-0.5	0.82	1.23	1.82	3.1	0.70 [0.26, 1.15]
			Placebo	50	40 (80.0)	0.52 (1.09)	-1.6	-0.05	0.36	1.27	2.9	
		Week 44	Tezepelumab	50	42 (84.0)	1.16 (1.02)	-0.5	0.45	1.18	1.64	3.2	0.75 [0.30, 1.20]
			Placebo	50	40 (80.0)	0.41 (0.99)	-1.6	-0.36	0.36	1.05	2.9	
		Week 48	Tezepelumab	50	42 (84.0)	1.25 (1.01)	-0.5	0.73	1.27	1.64	3.2	0.79 [0.34, 1.24]
			Placebo	50	40 (80.0)	0.45 (1.01)	-1.6	-0.05	0.36	1.09	3.4	
		Week 52	Tezepelumab	50	42 (84.0)	1.23 (1.04)	-1.2	0.73	1.23	1.64	3.3	0.74 [0.29, 1.18]
			Placebo	50	40 (80.0)	0.50 (0.96)	-1.6	0.05	0.32	1.14	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	77	72 (93.5)	4.41 (0.95)	1.9	3.91	4.36	4.95	7.0	
			Placebo	80	73 (91.3)	4.17 (0.84)	2.5	3.73	4.09	4.64	6.2	
		Week 4	Tezepelumab	77	69 (89.6)	5.08 (1.16)	1.6	4.18	5.09	5.91	7.0	
			Placebo	80	74 (92.5)	4.74 (1.01)	2.6	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	77	71 (92.2)	5.21 (1.18)	1.6	4.18	5.18	6.09	7.0	
			Placebo	80	74 (92.5)	4.89 (1.13)	2.2	4.09	4.77	6.00	7.0	
		Week 12	Tezepelumab	77	71 (92.2)	5.34 (1.19)	1.7	4.36	5.27	6.36	7.0	
			Placebo	80	75 (93.8)	5.03 (1.14)	2.8	4.00	4.91	6.09	7.0	
		Week 16	Tezepelumab	77	71 (92.2)	5.33 (1.14)	2.6	4.36	5.36	6.18	7.0	
			Placebo	80	75 (93.8)	5.09 (1.14)	2.6	4.09	4.91	6.00	7.0	
		Week 20	Tezepelumab	77	71 (92.2)	5.25 (1.21)	1.8	4.36	5.27	6.27	7.0	
			Placebo	80	75 (93.8)	5.04 (1.05)	3.0	4.09	4.91	6.00	7.0	
		Week 24	Tezepelumab	77	71 (92.2)	5.40 (1.13)	2.9	4.36	5.55	6.27	7.0	
			Placebo	80	75 (93.8)	5.16 (1.06)	2.8	4.09	5.18	6.00	7.0	
		Week 28	Tezepelumab	77	72 (93.5)	5.42 (1.15)	2.1	4.41	5.50	6.36	7.0	
			Placebo	80	76 (95.0)	5.18 (1.15)	2.7	4.09	5.09	6.14	7.0	
		Week 32	Tezepelumab	77	73 (94.8)	5.46 (1.17)	1.6	4.64	5.73	6.27	7.0	
			Placebo	80	76 (95.0)	5.27 (1.05)	3.5	4.23	5.36	6.14	7.0	
		Week 36	Tezepelumab	77	73 (94.8)	5.44 (1.14)	1.9	4.45	5.55	6.27	7.0	
			Placebo	80	76 (95.0)	5.24 (1.08)	3.3	4.23	5.09	6.18	7.0	
		Week 40	Tezepelumab	77	73 (94.8)	5.49 (1.16)	2.1	4.82	5.73	6.27	7.0	
			Placebo	80	76 (95.0)	5.28 (1.10)	3.3	4.18	5.27	6.18	7.0	
		Week 44	Tezepelumab	77	73 (94.8)	5.55 (1.14)	2.4	4.73	5.82	6.45	7.0	
			Placebo	80	76 (95.0)	5.27 (1.14)	3.3	4.09	5.27	6.23	7.0	
		Week 48	Tezepelumab	77	73 (94.8)	5.56 (1.12)	2.6	4.64	5.82	6.55	7.0	
			Placebo	80	76 (95.0)	5.27 (1.06)	3.5	4.27	5.18	6.09	7.0	
		Week 52	Tezepelumab	77	73 (94.8)	5.50 (1.19)	1.8	4.64	5.73	6.45	7.0	
			Placebo	80	76 (95.0)	5.28 (1.08)	3.1	4.27	5.36	6.09	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	77	67 (87.0)	0.64 (0.96)	-2.8	0.00	0.55	1.27	2.7	0.11 [-0.22, 0.44]
			Placebo	80	72 (90.0)	0.54 (0.86)	-1.5	0.05	0.41	0.91	2.6	
		Week 8	Tezepelumab	77	69 (89.6)	0.77 (0.93)	-0.9	0.00	0.73	1.45	2.8	0.07 [-0.26, 0.40]
			Placebo	80	72 (90.0)	0.71 (0.95)	-1.7	0.00	0.73	1.14	3.3	
		Week 12	Tezepelumab	77	69 (89.6)	0.92 (0.98)	-1.5	0.09	1.00	1.45	2.8	0.07 [-0.26, 0.40]
			Placebo	80	72 (90.0)	0.85 (1.04)	-1.9	0.18	0.82	1.23	3.7	
		Week 16	Tezepelumab	77	69 (89.6)	0.92 (0.97)	-1.6	0.27	0.91	1.45	2.7	-0.00 [-0.33, 0.33]
			Placebo	80	72 (90.0)	0.93 (1.01)	-1.9	0.32	0.86	1.55	3.9	
		Week 20	Tezepelumab	77	69 (89.6)	0.84 (1.01)	-1.1	0.18	0.73	1.55	2.7	-0.06 [-0.39, 0.27]
			Placebo	80	72 (90.0)	0.89 (0.98)	-1.3	0.23	0.73	1.32	4.0	
		Week 24	Tezepelumab	77	69 (89.6)	0.97 (0.98)	-0.8	0.27	1.00	1.64	2.9	-0.03 [-0.36, 0.30]
			Placebo	80	72 (90.0)	1.01 (0.98)	-1.5	0.36	0.91	1.55	3.8	
		Week 28	Tezepelumab	77	69 (89.6)	0.98 (1.02)	-1.1	0.18	0.82	1.82	2.8	-0.03 [-0.36, 0.30]
			Placebo	80	72 (90.0)	1.01 (1.03)	-1.3	0.36	1.00	1.64	4.0	
		Week 32	Tezepelumab	77	69 (89.6)	1.00 (0.95)	-1.0	0.36	1.00	1.64	2.7	-0.12 [-0.45, 0.22]
			Placebo	80	72 (90.0)	1.11 (0.96)	-1.2	0.45	1.09	1.55	3.6	
		Week 36	Tezepelumab	77	69 (89.6)	0.98 (1.03)	-0.9	0.18	0.91	1.91	2.8	-0.10 [-0.43, 0.23]
			Placebo	80	72 (90.0)	1.08 (1.04)	-1.2	0.36	0.91	1.77	3.5	
		Week 40	Tezepelumab	77	69 (89.6)	1.02 (1.00)	-0.9	0.27	1.00	1.73	2.8	-0.09 [-0.42, 0.24]
			Placebo	80	72 (90.0)	1.12 (1.08)	-1.2	0.45	0.95	1.68	4.0	
		Week 44	Tezepelumab	77	69 (89.6)	1.10 (1.04)	-1.1	0.27	1.00	2.00	2.9	0.00 [-0.33, 0.33]
			Placebo	80	72 (90.0)	1.10 (1.11)	-1.2	0.41	0.95	1.77	3.9	
		Week 48	Tezepelumab	77	69 (89.6)	1.11 (1.04)	-1.0	0.36	1.00	2.00	3.1	0.01 [-0.32, 0.34]
			Placebo	80	72 (90.0)	1.10 (1.03)	-1.2	0.41	1.09	1.73	3.6	
		Week 52	Tezepelumab	77	69 (89.6)	1.02 (1.05)	-1.2	0.18	0.82	1.91	3.1	-0.09 [-0.42, 0.24]
			Placebo	80	72 (90.0)	1.12 (1.06)	-1.2	0.45	1.09	1.77	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	4.27 (0.91)	1.9	3.82	4.23	4.68	6.3	
			Placebo	62	53 (85.5)	4.14 (0.91)	2.0	3.55	4.18	4.55	6.0	
		Week 4	Tezepelumab	70	65 (92.9)	4.90 (1.01)	3.1	4.18	4.91	5.73	6.9	
			Placebo	62	53 (85.5)	4.45 (1.07)	2.5	3.73	4.45	5.09	7.0	
		Week 8	Tezepelumab	70	66 (94.3)	5.06 (1.11)	1.6	4.27	5.00	6.09	7.0	
			Placebo	62	56 (90.3)	4.64 (1.14)	2.2	3.91	4.59	5.45	7.0	
		Week 12	Tezepelumab	70	66 (94.3)	5.32 (1.11)	1.7	4.55	5.27	6.27	7.0	
			Placebo	62	56 (90.3)	4.78 (1.13)	2.8	3.95	4.73	5.50	7.0	
		Week 16	Tezepelumab	70	66 (94.3)	5.22 (1.07)	2.6	4.27	5.32	6.00	7.0	
			Placebo	62	56 (90.3)	4.76 (1.29)	1.1	3.91	4.55	5.68	7.0	
		Week 20	Tezepelumab	70	67 (95.7)	5.16 (1.18)	1.8	4.27	5.27	6.00	7.0	
			Placebo	62	56 (90.3)	4.77 (1.22)	1.1	4.09	4.50	5.59	7.0	
		Week 24	Tezepelumab	70	67 (95.7)	5.32 (1.11)	2.9	4.27	5.36	6.27	7.0	
			Placebo	62	56 (90.3)	4.74 (1.28)	1.1	3.95	4.55	5.73	7.0	
		Week 28	Tezepelumab	70	68 (97.1)	5.24 (1.13)	2.1	4.32	5.32	6.05	7.0	
			Placebo	62	56 (90.3)	4.66 (1.23)	1.1	3.91	4.55	5.36	7.0	
		Week 32	Tezepelumab	70	68 (97.1)	5.23 (1.13)	1.6	4.36	5.32	6.00	7.0	
			Placebo	62	57 (91.9)	4.77 (1.23)	1.1	4.09	4.55	5.55	7.0	
		Week 36	Tezepelumab	70	68 (97.1)	5.27 (1.14)	1.9	4.36	5.41	6.18	7.0	
			Placebo	62	57 (91.9)	4.82 (1.20)	2.4	4.00	4.64	5.64	7.0	
		Week 40	Tezepelumab	70	68 (97.1)	5.28 (1.09)	2.1	4.36	5.32	6.18	7.0	
			Placebo	62	57 (91.9)	4.75 (1.27)	2.0	3.91	4.36	5.82	7.0	
		Week 44	Tezepelumab	70	68 (97.1)	5.30 (1.10)	2.4	4.36	5.36	6.05	7.0	
			Placebo	62	57 (91.9)	4.80 (1.22)	2.5	3.91	4.55	5.64	7.0	
		Week 48	Tezepelumab	70	68 (97.1)	5.36 (1.11)	2.6	4.32	5.41	6.32	7.0	
			Placebo	62	57 (91.9)	4.78 (1.20)	2.3	3.91	4.55	5.73	7.0	
		Week 52	Tezepelumab	70	68 (97.1)	5.32 (1.13)	1.8	4.45	5.41	6.18	7.0	
			Placebo	62	57 (91.9)	4.75 (1.14)	2.7	3.91	4.55	5.64	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	70	61 (87.1)	0.74 (0.91)	-1.4	0.00	0.64	1.27	3.1	0.44 [0.06, 0.81]
			Placebo	62	52 (83.9)	0.35 (0.88)	-1.5	-0.18	0.27	0.77	2.6	
		Week 8	Tezepelumab	70	62 (88.6)	0.79 (1.06)	-1.5	0.09	0.73	1.45	3.7	0.25 [-0.12, 0.62]
			Placebo	62	53 (85.5)	0.54 (0.97)	-1.7	-0.09	0.36	1.09	2.8	
		Week 12	Tezepelumab	70	62 (88.6)	1.07 (1.05)	-0.7	0.36	1.18	1.64	4.2	0.37 [0.00, 0.74]
			Placebo	62	53 (85.5)	0.67 (1.11)	-1.9	0.00	0.82	1.18	3.3	
		Week 16	Tezepelumab	70	62 (88.6)	0.95 (1.04)	-1.7	0.27	0.91	1.55	3.5	0.27 [-0.10, 0.63]
			Placebo	62	53 (85.5)	0.65 (1.22)	-3.2	0.18	0.82	1.36	3.5	
		Week 20	Tezepelumab	70	62 (88.6)	0.91 (1.15)	-2.1	-0.09	0.91	1.64	3.5	0.22 [-0.15, 0.59]
			Placebo	62	53 (85.5)	0.66 (1.14)	-3.2	0.18	0.73	1.27	3.4	
		Week 24	Tezepelumab	70	62 (88.6)	1.10 (1.04)	-0.7	0.36	1.09	1.73	3.5	0.41 [0.04, 0.78]
			Placebo	62	53 (85.5)	0.63 (1.23)	-3.2	0.09	0.82	1.27	3.2	
		Week 28	Tezepelumab	70	62 (88.6)	1.02 (1.07)	-0.7	0.00	0.91	1.82	3.5	0.42 [0.05, 0.79]
			Placebo	62	53 (85.5)	0.55 (1.19)	-3.2	0.00	0.64	1.18	3.7	
		Week 32	Tezepelumab	70	62 (88.6)	0.99 (1.05)	-1.1	0.09	0.86	1.82	3.5	0.28 [-0.09, 0.64]
			Placebo	62	53 (85.5)	0.68 (1.23)	-3.2	0.09	0.82	1.27	3.5	
		Week 36	Tezepelumab	70	62 (88.6)	1.05 (1.09)	-0.8	0.18	1.05	1.64	3.5	0.29 [-0.08, 0.66]
			Placebo	62	53 (85.5)	0.72 (1.19)	-1.8	0.09	0.73	1.36	3.5	
		Week 40	Tezepelumab	70	62 (88.6)	1.06 (1.06)	-1.0	0.27	1.05	1.73	3.5	0.35 [-0.01, 0.72]
			Placebo	62	53 (85.5)	0.65 (1.27)	-1.6	-0.18	0.73	1.45	3.6	
		Week 44	Tezepelumab	70	62 (88.6)	1.07 (1.04)	-0.7	0.18	1.05	1.73	3.5	0.34 [-0.03, 0.71]
			Placebo	62	53 (85.5)	0.69 (1.24)	-1.6	-0.36	0.73	1.18	3.6	
		Week 48	Tezepelumab	70	62 (88.6)	1.16 (1.06)	-0.7	0.36	1.23	1.82	3.5	0.43 [0.06, 0.80]
			Placebo	62	53 (85.5)	0.68 (1.18)	-1.6	0.00	0.55	1.27	3.6	
		Week 52	Tezepelumab	70	62 (88.6)	1.11 (1.08)	-1.2	0.36	1.14	1.82	3.5	0.39 [0.02, 0.77]
			Placebo	62	53 (85.5)	0.68 (1.12)	-1.6	0.00	0.55	1.27	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	65	58 (89.2)	4.33 (0.94)	2.4	3.64	4.27	4.82	7.0	
			Placebo	75	67 (89.3)	4.15 (0.86)	2.6	3.73	4.00	4.64	6.2	
		Week 4	Tezepelumab	65	59 (90.8)	5.03 (1.20)	1.6	4.00	5.09	6.00	7.0	
			Placebo	75	69 (92.0)	4.73 (0.97)	2.6	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	65	60 (92.3)	5.25 (1.09)	3.2	4.27	5.27	6.14	7.0	
			Placebo	75	69 (92.0)	4.84 (1.06)	3.0	4.00	4.64	5.82	7.0	
		Week 12	Tezepelumab	65	60 (92.3)	5.35 (1.14)	3.0	4.50	5.18	6.32	7.0	
			Placebo	75	70 (93.3)	4.95 (1.08)	3.0	4.00	4.68	6.00	7.0	
		Week 16	Tezepelumab	65	60 (92.3)	5.38 (1.11)	2.8	4.36	5.32	6.27	7.0	
			Placebo	75	70 (93.3)	5.05 (1.06)	3.0	4.09	4.95	5.91	7.0	
		Week 20	Tezepelumab	65	60 (92.3)	5.32 (1.13)	2.1	4.41	5.27	6.23	7.0	
			Placebo	75	70 (93.3)	4.99 (1.06)	3.0	4.00	4.86	5.82	7.0	
		Week 24	Tezepelumab	65	60 (92.3)	5.30 (1.19)	1.6	4.36	5.32	6.18	7.0	
			Placebo	75	70 (93.3)	5.09 (1.05)	2.8	4.18	5.18	6.00	7.0	
		Week 28	Tezepelumab	65	61 (93.8)	5.37 (1.07)	3.5	4.45	5.36	6.27	7.0	
			Placebo	75	71 (94.7)	5.13 (1.20)	2.7	4.00	5.09	6.18	7.0	
		Week 32	Tezepelumab	65	62 (95.4)	5.51 (1.07)	2.5	4.55	5.59	6.27	7.0	
			Placebo	75	71 (94.7)	5.15 (1.08)	3.1	4.09	5.27	6.00	7.0	
		Week 36	Tezepelumab	65	62 (95.4)	5.42 (1.06)	3.3	4.45	5.50	6.27	7.0	
			Placebo	75	71 (94.7)	5.15 (1.10)	3.2	4.09	5.00	6.18	7.0	
		Week 40	Tezepelumab	65	62 (95.4)	5.49 (1.09)	3.2	4.64	5.45	6.45	7.0	
			Placebo	75	71 (94.7)	5.22 (1.05)	3.4	4.18	5.18	6.09	7.0	
		Week 44	Tezepelumab	65	62 (95.4)	5.51 (1.08)	3.5	4.55	5.64	6.36	7.0	
			Placebo	75	71 (94.7)	5.21 (1.14)	2.7	4.00	5.27	6.09	7.0	
		Week 48	Tezepelumab	65	62 (95.4)	5.49 (1.07)	3.3	4.64	5.55	6.45	7.0	
			Placebo	75	72 (96.0)	5.22 (1.04)	3.3	4.27	5.14	6.09	7.0	
		Week 52	Tezepelumab	65	62 (95.4)	5.47 (1.09)	3.3	4.64	5.50	6.36	7.0	
			Placebo	75	72 (96.0)	5.22 (1.09)	3.1	4.27	5.09	6.09	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	65	55 (84.6)	0.65 (1.10)	-2.8	0.00	0.55	1.36	3.2	0.09 [-0.27, 0.45]
			Placebo	75	66 (88.0)	0.56 (0.81)	-1.0	0.09	0.36	0.91	2.5	
		Week 8	Tezepelumab	65	56 (86.2)	0.91 (1.03)	-0.9	0.05	0.91	1.55	3.5	0.24 [-0.12, 0.60]
			Placebo	75	66 (88.0)	0.69 (0.84)	-0.8	0.00	0.68	1.00	3.3	
		Week 12	Tezepelumab	65	56 (86.2)	1.01 (1.05)	-1.5	0.27	0.95	1.50	3.5	0.21 [-0.15, 0.57]
			Placebo	75	66 (88.0)	0.80 (0.92)	-0.7	0.18	0.73	1.18	3.7	
		Week 16	Tezepelumab	65	56 (86.2)	1.07 (1.06)	-1.6	0.27	1.00	1.77	3.5	0.16 [-0.20, 0.52]
			Placebo	75	66 (88.0)	0.92 (0.87)	-0.7	0.36	0.82	1.55	3.9	
		Week 20	Tezepelumab	65	56 (86.2)	1.00 (1.07)	-1.1	0.23	0.91	1.73	3.5	0.13 [-0.23, 0.49]
			Placebo	75	66 (88.0)	0.87 (0.91)	-1.3	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	65	56 (86.2)	1.01 (1.08)	-1.4	0.23	1.00	1.59	3.5	0.04 [-0.31, 0.40]
			Placebo	75	66 (88.0)	0.97 (0.90)	-1.1	0.36	0.82	1.55	3.8	
		Week 28	Tezepelumab	65	56 (86.2)	1.06 (1.06)	-1.1	0.41	0.95	1.86	3.5	0.06 [-0.29, 0.42]
			Placebo	75	66 (88.0)	1.00 (0.98)	-1.3	0.27	0.95	1.73	4.0	
		Week 32	Tezepelumab	65	56 (86.2)	1.16 (1.03)	-1.0	0.50	1.09	1.77	3.5	0.16 [-0.19, 0.52]
			Placebo	75	66 (88.0)	1.01 (0.87)	-0.4	0.36	0.95	1.55	3.6	
		Week 36	Tezepelumab	65	56 (86.2)	1.06 (1.09)	-0.9	0.27	0.91	1.95	3.5	0.04 [-0.31, 0.40]
			Placebo	75	66 (88.0)	1.02 (0.95)	-1.0	0.27	0.91	1.55	3.4	
		Week 40	Tezepelumab	65	56 (86.2)	1.13 (1.03)	-0.9	0.41	1.05	1.77	3.5	0.03 [-0.32, 0.39]
			Placebo	75	66 (88.0)	1.10 (0.94)	-0.5	0.36	0.91	1.55	4.0	
		Week 44	Tezepelumab	65	56 (86.2)	1.17 (1.06)	-1.1	0.45	1.00	2.05	3.5	0.11 [-0.24, 0.47]
			Placebo	75	66 (88.0)	1.06 (0.98)	-0.9	0.36	0.95	1.64	3.9	
		Week 48	Tezepelumab	65	56 (86.2)	1.16 (1.04)	-1.0	0.41	1.00	2.00	3.5	0.08 [-0.28, 0.44]
			Placebo	75	66 (88.0)	1.08 (0.92)	-0.7	0.27	1.05	1.64	3.4	
		Week 52	Tezepelumab	65	56 (86.2)	1.09 (1.05)	-1.2	0.32	0.95	1.82	3.5	0.00 [-0.35, 0.36]
			Placebo	75	66 (88.0)	1.09 (0.96)	-0.7	0.45	1.05	1.73	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	62	57 (91.9)	4.31 (0.75)	2.6	3.73	4.27	4.73	6.2	
			Placebo	67	57 (85.1)	4.24 (0.89)	2.0	3.82	4.18	4.73	6.2	
		Week 4	Tezepelumab	62	56 (90.3)	4.67 (1.04)	1.6	3.95	4.50	5.36	6.9	
			Placebo	67	58 (86.6)	4.66 (1.12)	2.5	3.91	4.45	5.55	7.0	
		Week 8	Tezepelumab	62	56 (90.3)	4.87 (0.96)	3.2	4.14	4.64	5.64	6.9	
			Placebo	67	60 (89.6)	4.82 (1.08)	2.3	4.00	4.36	5.64	7.0	
		Week 12	Tezepelumab	62	56 (90.3)	5.06 (0.99)	3.0	4.27	5.05	5.86	7.0	
			Placebo	67	61 (91.0)	4.93 (1.17)	2.8	4.00	4.64	6.00	7.0	
		Week 16	Tezepelumab	62	56 (90.3)	4.95 (0.97)	2.8	4.14	4.77	5.86	7.0	
			Placebo	67	61 (91.0)	4.99 (1.21)	1.1	4.09	4.82	6.00	7.0	
		Week 20	Tezepelumab	62	57 (91.9)	4.94 (0.98)	2.8	4.18	4.73	5.73	7.0	
			Placebo	67	61 (91.0)	4.88 (1.15)	1.1	4.09	4.64	5.82	7.0	
		Week 24	Tezepelumab	62	57 (91.9)	5.12 (0.99)	3.5	4.27	5.09	5.91	7.0	
			Placebo	67	61 (91.0)	4.99 (1.21)	1.1	4.18	4.91	6.00	7.0	
		Week 28	Tezepelumab	62	59 (95.2)	5.03 (0.96)	3.5	4.27	4.82	5.64	7.0	
			Placebo	67	62 (92.5)	5.00 (1.31)	1.1	4.00	4.95	6.00	7.0	
		Week 32	Tezepelumab	62	59 (95.2)	5.13 (1.00)	3.3	4.27	5.09	6.00	7.0	
			Placebo	67	63 (94.0)	5.03 (1.20)	1.1	4.09	4.82	6.00	7.0	
		Week 36	Tezepelumab	62	59 (95.2)	5.09 (1.01)	3.5	4.27	4.91	6.00	7.0	
			Placebo	67	63 (94.0)	5.09 (1.19)	2.4	4.09	4.82	6.18	7.0	
		Week 40	Tezepelumab	62	59 (95.2)	5.11 (0.95)	3.5	4.36	5.00	5.82	7.0	
			Placebo	67	63 (94.0)	5.12 (1.22)	2.5	4.00	5.18	6.09	7.0	
		Week 44	Tezepelumab	62	59 (95.2)	5.16 (0.98)	3.5	4.27	5.36	6.00	7.0	
			Placebo	67	63 (94.0)	5.18 (1.20)	2.9	4.09	5.09	6.27	7.0	
		Week 48	Tezepelumab	62	59 (95.2)	5.17 (0.99)	3.3	4.27	5.27	5.91	7.0	
			Placebo	67	64 (95.5)	5.14 (1.20)	2.4	4.05	5.18	6.09	7.0	
		Week 52	Tezepelumab	62	59 (95.2)	5.17 (1.00)	3.3	4.27	5.18	6.00	7.0	
			Placebo	67	64 (95.5)	5.13 (1.23)	2.7	3.91	5.05	6.18	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	62	55 (88.7)	0.40 (0.92)	-2.8	-0.18	0.45	1.00	2.9	-0.08 [-0.46, 0.29]
			Placebo	67	56 (83.6)	0.48 (0.90)	-1.5	-0.14	0.36	0.82	2.5	
		Week 8	Tezepelumab	62	55 (88.7)	0.60 (0.99)	-1.5	0.00	0.64	1.36	3.5	-0.02 [-0.39, 0.35]
			Placebo	67	57 (85.1)	0.62 (0.93)	-1.7	-0.09	0.55	1.27	2.6	
		Week 12	Tezepelumab	62	55 (88.7)	0.80 (0.96)	-1.5	0.18	0.82	1.36	3.5	0.03 [-0.34, 0.40]
			Placebo	67	57 (85.1)	0.77 (1.11)	-1.9	0.09	0.82	1.27	3.3	
		Week 16	Tezepelumab	62	55 (88.7)	0.68 (0.99)	-1.7	0.18	0.73	1.27	3.5	-0.13 [-0.50, 0.24]
			Placebo	67	57 (85.1)	0.82 (1.14)	-3.2	0.18	0.91	1.55	3.5	
		Week 20	Tezepelumab	62	55 (88.7)	0.66 (1.02)	-2.1	0.00	0.73	1.18	3.5	-0.04 [-0.41, 0.33]
			Placebo	67	57 (85.1)	0.70 (1.08)	-3.2	0.18	0.73	1.36	2.5	
		Week 24	Tezepelumab	62	55 (88.7)	0.84 (0.97)	-0.8	0.09	0.73	1.45	3.5	0.03 [-0.34, 0.40]
			Placebo	67	57 (85.1)	0.82 (1.15)	-3.2	0.18	0.82	1.55	3.0	
		Week 28	Tezepelumab	62	55 (88.7)	0.76 (0.99)	-1.1	0.00	0.73	1.36	3.5	-0.03 [-0.40, 0.34]
			Placebo	67	57 (85.1)	0.80 (1.20)	-3.2	0.00	0.82	1.45	3.7	
		Week 32	Tezepelumab	62	55 (88.7)	0.84 (0.96)	-1.1	0.27	0.82	1.36	3.5	0.00 [-0.37, 0.37]
			Placebo	67	57 (85.1)	0.84 (1.10)	-3.2	0.18	0.91	1.55	3.3	
		Week 36	Tezepelumab	62	55 (88.7)	0.80 (1.00)	-0.9	0.09	0.73	1.45	3.5	-0.09 [-0.46, 0.28]
			Placebo	67	57 (85.1)	0.90 (1.10)	-1.8	0.18	0.82	1.64	3.3	
		Week 40	Tezepelumab	62	55 (88.7)	0.83 (0.97)	-1.0	0.18	0.91	1.45	3.5	-0.10 [-0.47, 0.27]
			Placebo	67	57 (85.1)	0.94 (1.11)	-1.4	0.18	0.91	1.55	3.5	
		Week 44	Tezepelumab	62	55 (88.7)	0.88 (0.96)	-1.1	0.18	0.91	1.55	3.5	-0.10 [-0.47, 0.27]
			Placebo	67	57 (85.1)	0.98 (1.17)	-1.4	0.18	0.91	1.82	3.4	
		Week 48	Tezepelumab	62	55 (88.7)	0.91 (1.00)	-1.0	0.18	0.82	1.64	3.5	-0.03 [-0.40, 0.34]
			Placebo	67	57 (85.1)	0.94 (1.13)	-1.5	0.09	1.00	1.45	3.4	
		Week 52	Tezepelumab	62	55 (88.7)	0.89 (1.01)	-1.2	0.18	0.82	1.64	3.5	-0.08 [-0.45, 0.29]
			Placebo	67	57 (85.1)	0.97 (1.13)	-1.4	0.18	1.00	1.55	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	74	65 (87.8)	4.28 (1.05)	1.9	3.73	4.18	4.82	7.0	
			Placebo	71	64 (90.1)	4.07 (0.86)	2.5	3.45	4.00	4.50	6.1	
		Week 4	Tezepelumab	74	69 (93.2)	5.20 (1.08)	3.1	4.27	5.27	6.00	7.0	
			Placebo	71	65 (91.5)	4.59 (0.96)	2.6	3.91	4.64	5.36	6.9	
		Week 8	Tezepelumab	74	71 (95.9)	5.38 (1.15)	1.6	4.73	5.36	6.36	7.0	
			Placebo	71	66 (93.0)	4.72 (1.14)	2.2	3.91	4.73	5.45	7.0	
		Week 12	Tezepelumab	74	71 (95.9)	5.55 (1.17)	1.7	4.91	5.73	6.64	7.0	
			Placebo	71	66 (93.0)	4.85 (1.05)	2.8	4.00	4.82	5.55	7.0	
		Week 16	Tezepelumab	74	71 (95.9)	5.56 (1.09)	2.6	4.73	5.55	6.45	7.0	
			Placebo	71	66 (93.0)	4.89 (1.15)	2.6	4.00	4.91	5.73	7.0	
		Week 20	Tezepelumab	74	71 (95.9)	5.49 (1.22)	1.8	4.55	5.64	6.55	7.0	
			Placebo	71	66 (93.0)	4.93 (1.14)	2.1	4.00	4.82	5.73	7.0	
		Week 24	Tezepelumab	74	71 (95.9)	5.46 (1.24)	1.6	4.55	5.64	6.55	7.0	
			Placebo	71	66 (93.0)	4.90 (1.14)	2.0	4.00	4.73	5.82	7.0	
		Week 28	Tezepelumab	74	71 (95.9)	5.55 (1.15)	2.1	4.82	5.73	6.45	7.0	
			Placebo	71	66 (93.0)	4.89 (1.18)	2.0	4.00	4.77	5.91	7.0	
		Week 32	Tezepelumab	74	72 (97.3)	5.56 (1.15)	1.6	4.86	5.73	6.50	7.0	
			Placebo	71	66 (93.0)	4.96 (1.15)	1.7	4.09	4.73	5.91	7.0	
		Week 36	Tezepelumab	74	72 (97.3)	5.56 (1.13)	1.9	4.91	5.55	6.50	7.0	
			Placebo	71	66 (93.0)	4.94 (1.13)	2.5	4.00	4.77	6.00	7.0	
		Week 40	Tezepelumab	74	72 (97.3)	5.61 (1.14)	2.1	4.91	5.73	6.55	7.0	
			Placebo	71	66 (93.0)	4.94 (1.14)	2.0	4.09	4.91	5.82	7.0	
		Week 44	Tezepelumab	74	72 (97.3)	5.63 (1.14)	2.4	4.86	5.77	6.55	7.0	
			Placebo	71	66 (93.0)	4.90 (1.18)	2.5	4.00	4.86	5.73	7.0	
		Week 48	Tezepelumab	74	72 (97.3)	5.65 (1.12)	2.6	4.91	5.68	6.55	7.0	
			Placebo	71	66 (93.0)	4.94 (1.08)	2.3	4.09	4.82	5.82	7.0	
		Week 52	Tezepelumab	74	72 (97.3)	5.60 (1.16)	1.8	4.91	5.73	6.55	7.0	
			Placebo	71	66 (93.0)	4.93 (1.05)	2.9	4.09	4.91	5.73	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	74	61 (82.4)	0.99 (0.99)	-1.4	0.27	1.00	1.55	3.2	0.54 [0.18, 0.89]
			Placebo	71	63 (88.7)	0.49 (0.83)	-1.5	0.00	0.36	0.91	2.6	
		Week 8	Tezepelumab	74	63 (85.1)	1.08 (1.04)	-0.7	0.27	1.00	1.73	3.7	0.44 [0.08, 0.79]
			Placebo	71	63 (88.7)	0.65 (0.91)	-1.3	0.00	0.64	1.00	3.3	
		Week 12	Tezepelumab	74	63 (85.1)	1.26 (1.07)	-0.7	0.36	1.27	2.09	4.2	0.51 [0.15, 0.86]
			Placebo	71	63 (88.7)	0.75 (0.93)	-1.3	0.18	0.82	1.18	3.7	
		Week 16	Tezepelumab	74	63 (85.1)	1.31 (1.00)	-0.7	0.45	1.36	2.00	3.5	0.51 [0.15, 0.86]
			Placebo	71	63 (88.7)	0.81 (0.97)	-1.6	0.27	0.73	1.45	3.9	
		Week 20	Tezepelumab	74	63 (85.1)	1.23 (1.11)	-1.1	0.36	1.09	2.18	3.5	0.34 [-0.01, 0.69]
			Placebo	71	63 (88.7)	0.87 (0.98)	-1.6	0.36	0.73	1.27	4.0	
		Week 24	Tezepelumab	74	63 (85.1)	1.25 (1.09)	-1.4	0.36	1.18	2.27	3.5	0.39 [0.04, 0.74]
			Placebo	71	63 (88.7)	0.84 (1.01)	-1.6	0.27	0.82	1.45	3.8	
		Week 28	Tezepelumab	74	63 (85.1)	1.31 (1.05)	-0.7	0.45	1.27	2.27	3.5	0.46 [0.11, 0.82]
			Placebo	71	63 (88.7)	0.83 (1.03)	-1.6	0.18	0.82	1.55	4.0	
		Week 32	Tezepelumab	74	63 (85.1)	1.31 (1.07)	-0.7	0.45	1.09	2.36	3.5	0.38 [0.03, 0.73]
			Placebo	71	63 (88.7)	0.91 (1.03)	-1.8	0.36	0.82	1.55	3.6	
		Week 36	Tezepelumab	74	63 (85.1)	1.30 (1.11)	-0.8	0.36	1.27	2.36	3.5	0.37 [0.02, 0.72]
			Placebo	71	63 (88.7)	0.89 (1.05)	-1.6	0.18	0.91	1.45	3.5	
		Week 40	Tezepelumab	74	63 (85.1)	1.34 (1.05)	-0.7	0.45	1.27	2.36	3.5	0.41 [0.06, 0.76]
			Placebo	71	63 (88.7)	0.89 (1.15)	-1.6	0.18	0.82	1.55	4.0	
		Week 44	Tezepelumab	74	63 (85.1)	1.37 (1.09)	-0.7	0.36	1.36	2.36	3.5	0.50 [0.14, 0.85]
			Placebo	71	63 (88.7)	0.83 (1.07)	-1.6	0.36	0.82	1.45	3.9	
		Week 48	Tezepelumab	74	63 (85.1)	1.41 (1.06)	-0.7	0.64	1.36	2.36	3.5	0.51 [0.15, 0.86]
			Placebo	71	63 (88.7)	0.88 (1.01)	-1.6	0.27	0.82	1.27	3.6	
		Week 52	Tezepelumab	74	63 (85.1)	1.32 (1.09)	-0.7	0.45	1.27	2.45	3.5	0.43 [0.08, 0.78]
			Placebo	71	63 (88.7)	0.87 (0.99)	-1.6	0.27	0.82	1.27	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	114	101 (88.6)	4.27 (0.88)	2.2	3.73	4.18	4.64	7.0	
			Placebo	126	112 (88.9)	4.15 (0.86)	2.0	3.64	4.09	4.55	6.2	
		Week 4	Tezepelumab	114	105 (92.1)	4.94 (1.10)	1.6	4.09	4.91	5.73	7.0	
			Placebo	126	113 (89.7)	4.66 (1.05)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	114	107 (93.9)	5.11 (1.05)	2.9	4.27	5.09	6.00	7.0	
			Placebo	126	116 (92.1)	4.80 (1.10)	2.2	4.00	4.64	5.64	7.0	
		Week 12	Tezepelumab	114	107 (93.9)	5.30 (1.05)	3.0	4.36	5.27	6.18	7.0	
			Placebo	126	117 (92.9)	4.90 (1.12)	2.8	4.00	4.73	5.91	7.0	
		Week 16	Tezepelumab	114	107 (93.9)	5.24 (1.05)	2.8	4.27	5.27	6.00	7.0	
			Placebo	126	117 (92.9)	4.96 (1.18)	1.1	4.00	4.91	5.91	7.0	
		Week 20	Tezepelumab	114	108 (94.7)	5.17 (1.12)	2.1	4.27	5.14	6.00	7.0	
			Placebo	126	117 (92.9)	4.93 (1.16)	1.1	4.09	4.82	5.82	7.0	
		Week 24	Tezepelumab	114	108 (94.7)	5.24 (1.09)	2.9	4.27	5.14	6.14	7.0	
			Placebo	126	117 (92.9)	4.94 (1.19)	1.1	4.09	4.91	5.91	7.0	
		Week 28	Tezepelumab	114	110 (96.5)	5.28 (1.05)	3.2	4.36	5.27	6.00	7.0	
			Placebo	126	118 (93.7)	4.94 (1.25)	1.1	4.00	4.86	6.00	7.0	
		Week 32	Tezepelumab	114	111 (97.4)	5.30 (1.05)	2.5	4.36	5.27	6.09	7.0	
			Placebo	126	119 (94.4)	4.99 (1.19)	1.1	4.00	4.82	6.00	7.0	
		Week 36	Tezepelumab	114	111 (97.4)	5.31 (1.03)	3.0	4.36	5.45	6.09	7.0	
			Placebo	126	119 (94.4)	5.00 (1.18)	2.4	4.00	4.82	6.09	7.0	
		Week 40	Tezepelumab	114	111 (97.4)	5.34 (1.04)	3.2	4.36	5.18	6.18	7.0	
			Placebo	126	119 (94.4)	5.04 (1.19)	2.0	4.00	5.09	6.00	7.0	
		Week 44	Tezepelumab	114	111 (97.4)	5.37 (1.06)	3.0	4.45	5.36	6.27	7.0	
			Placebo	126	119 (94.4)	5.04 (1.21)	2.5	4.00	4.91	6.00	7.0	
		Week 48	Tezepelumab	114	111 (97.4)	5.40 (1.08)	2.6	4.36	5.45	6.36	7.0	
			Placebo	126	120 (95.2)	5.04 (1.16)	2.3	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	114	111 (97.4)	5.39 (1.07)	2.6	4.45	5.45	6.18	7.0	
			Placebo	126	120 (95.2)	5.03 (1.16)	2.7	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	114	97 (85.1)	0.69 (1.04)	-2.8	0.00	0.55	1.27	3.2	0.19 [-0.09, 0.46]
			Placebo	126	110 (87.3)	0.52 (0.86)	-1.5	0.00	0.36	0.91	2.6	
		Week 8	Tezepelumab	114	99 (86.8)	0.82 (1.06)	-1.5	0.00	0.73	1.45	3.7	0.16 [-0.11, 0.43]
			Placebo	126	111 (88.1)	0.66 (0.89)	-1.7	0.00	0.55	1.09	3.3	
		Week 12	Tezepelumab	114	99 (86.8)	1.02 (1.06)	-1.5	0.27	1.00	1.55	4.2	0.25 [-0.02, 0.53]
			Placebo	126	111 (88.1)	0.76 (0.98)	-1.9	0.09	0.64	1.27	3.7	
		Week 16	Tezepelumab	114	99 (86.8)	0.97 (1.07)	-1.7	0.18	0.91	1.55	3.5	0.14 [-0.14, 0.41]
			Placebo	126	111 (88.1)	0.83 (1.01)	-3.2	0.27	0.82	1.55	3.9	
		Week 20	Tezepelumab	114	99 (86.8)	0.90 (1.14)	-2.1	0.00	0.91	1.73	3.5	0.09 [-0.18, 0.36]
			Placebo	126	111 (88.1)	0.81 (1.02)	-3.2	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	114	99 (86.8)	1.02 (1.05)	-0.8	0.18	0.91	1.64	3.5	0.19 [-0.09, 0.46]
			Placebo	126	111 (88.1)	0.83 (1.04)	-3.2	0.18	0.82	1.45	3.8	
		Week 28	Tezepelumab	114	99 (86.8)	1.04 (1.08)	-1.1	0.09	1.00	1.82	3.5	0.22 [-0.05, 0.49]
			Placebo	126	111 (88.1)	0.81 (1.07)	-3.2	0.18	0.82	1.36	4.0	
		Week 32	Tezepelumab	114	99 (86.8)	1.04 (1.05)	-1.1	0.27	1.00	1.73	3.5	0.16 [-0.11, 0.43]
			Placebo	126	111 (88.1)	0.87 (1.04)	-3.2	0.27	0.82	1.55	3.6	
		Week 36	Tezepelumab	114	99 (86.8)	1.05 (1.10)	-0.9	0.18	0.91	1.73	3.5	0.16 [-0.12, 0.43]
			Placebo	126	111 (88.1)	0.88 (1.03)	-1.8	0.18	0.82	1.45	3.5	
		Week 40	Tezepelumab	114	99 (86.8)	1.08 (1.05)	-1.0	0.27	1.00	1.82	3.5	0.15 [-0.13, 0.42]
			Placebo	126	111 (88.1)	0.92 (1.08)	-1.5	0.18	0.82	1.55	4.0	
		Week 44	Tezepelumab	114	99 (86.8)	1.12 (1.08)	-1.1	0.27	1.00	1.91	3.5	0.19 [-0.08, 0.46]
			Placebo	126	111 (88.1)	0.91 (1.08)	-1.4	0.18	0.82	1.55	3.9	
		Week 48	Tezepelumab	114	99 (86.8)	1.15 (1.08)	-1.0	0.36	1.09	2.00	3.5	0.23 [-0.04, 0.50]
			Placebo	126	111 (88.1)	0.91 (1.04)	-1.5	0.18	0.82	1.45	3.6	
		Week 52	Tezepelumab	114	99 (86.8)	1.13 (1.10)	-1.2	0.36	1.00	1.91	3.5	0.20 [-0.07, 0.47]
			Placebo	126	111 (88.1)	0.91 (1.02)	-1.4	0.18	0.82	1.45	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	23	22 (95.7)	4.37 (1.07)	1.9	3.91	4.36	5.18	5.9	
			Placebo	12	9 (75.0)	4.14 (1.16)	2.7	3.18	3.82	5.09	6.0	
		Week 4	Tezepelumab	23	21 (91.3)	5.07 (1.08)	3.1	4.27	5.00	6.00	6.8	
			Placebo	12	10 (83.3)	4.21 (0.75)	3.2	3.64	4.05	4.82	5.5	
		Week 8	Tezepelumab	23	21 (91.3)	5.34 (1.31)	1.6	4.73	5.18	6.36	6.9	
			Placebo	12	10 (83.3)	4.40 (1.20)	2.3	3.55	4.41	5.27	6.5	
		Week 12	Tezepelumab	23	21 (91.3)	5.45 (1.43)	1.7	4.91	5.27	6.64	7.0	
			Placebo	12	10 (83.3)	4.82 (0.99)	3.9	4.00	4.50	5.55	6.5	
		Week 16	Tezepelumab	23	21 (91.3)	5.52 (1.24)	2.6	4.82	5.45	6.45	7.0	
			Placebo	12	10 (83.3)	4.71 (1.19)	2.6	4.09	4.45	5.45	6.7	
		Week 20	Tezepelumab	23	21 (91.3)	5.55 (1.24)	1.8	5.00	5.73	6.45	7.0	
			Placebo	12	10 (83.3)	4.65 (0.80)	3.7	4.09	4.41	5.18	6.2	
		Week 24	Tezepelumab	23	21 (91.3)	5.58 (1.40)	1.6	5.18	5.91	6.64	7.0	
			Placebo	12	10 (83.3)	4.96 (0.95)	4.0	4.27	4.50	5.82	6.6	
		Week 28	Tezepelumab	23	21 (91.3)	5.43 (1.35)	2.1	5.09	5.73	6.36	7.0	
			Placebo	12	10 (83.3)	4.93 (1.23)	3.6	4.00	4.41	6.18	7.0	
		Week 32	Tezepelumab	23	21 (91.3)	5.68 (1.32)	1.6	5.27	6.00	6.55	7.0	
			Placebo	12	10 (83.3)	5.04 (1.03)	4.1	4.27	4.64	6.27	6.6	
		Week 36	Tezepelumab	23	21 (91.3)	5.50 (1.42)	1.9	4.91	6.00	6.55	7.0	
			Placebo	12	10 (83.3)	5.13 (0.93)	3.9	4.36	5.00	6.00	6.3	
		Week 40	Tezepelumab	23	21 (91.3)	5.61 (1.32)	2.1	5.27	6.00	6.64	7.0	
			Placebo	12	10 (83.3)	4.87 (1.11)	3.3	4.09	4.64	5.82	6.8	
		Week 44	Tezepelumab	23	21 (91.3)	5.61 (1.26)	2.4	5.09	6.00	6.55	7.0	
			Placebo	12	10 (83.3)	4.96 (1.04)	3.5	4.09	4.82	6.00	6.6	
		Week 48	Tezepelumab	23	21 (91.3)	5.61 (1.13)	3.1	5.18	5.91	6.45	7.0	
			Placebo	12	10 (83.3)	5.08 (0.92)	3.8	4.36	5.14	5.82	6.5	
		Week 52	Tezepelumab	23	21 (91.3)	5.46 (1.33)	1.8	4.91	5.91	6.36	7.0	
			Placebo	12	10 (83.3)	5.07 (0.89)	3.8	4.36	5.18	5.73	6.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	0.75 (0.82)	-1.4	0.18	0.68	1.36	2.2	0.77 [-0.04, 1.59]
			Placebo	12	9 (75.0)	0.13 (0.74)	-1.5	-0.09	0.36	0.64	0.9	
		Week 8	Tezepelumab	23	20 (87.0)	1.00 (0.92)	-0.6	0.18	0.95	1.86	2.5	0.67 [-0.13, 1.48]
			Placebo	12	9 (75.0)	0.31 (1.22)	-1.3	-0.91	0.64	1.00	2.2	
		Week 12	Tezepelumab	23	20 (87.0)	1.13 (0.96)	-0.5	0.50	1.09	1.68	2.7	0.32 [-0.48, 1.11]
			Placebo	12	9 (75.0)	0.78 (1.40)	-1.4	0.91	1.09	1.18	3.3	
		Week 16	Tezepelumab	23	20 (87.0)	1.19 (0.91)	-0.4	0.64	0.95	1.55	2.8	0.54 [-0.26, 1.34]
			Placebo	12	9 (75.0)	0.59 (1.50)	-1.6	-0.55	0.91	1.18	3.5	
		Week 20	Tezepelumab	23	20 (87.0)	1.21 (0.89)	-0.1	0.59	1.05	1.86	2.7	0.64 [-0.16, 1.45]
			Placebo	12	9 (75.0)	0.59 (1.14)	-1.6	0.64	1.00	1.09	1.9	
		Week 24	Tezepelumab	23	20 (87.0)	1.22 (1.08)	-1.4	0.50	1.36	1.82	3.0	0.27 [-0.52, 1.06]
			Placebo	12	9 (75.0)	0.90 (1.44)	-1.6	0.64	0.91	1.55	2.9	
		Week 28	Tezepelumab	23	20 (87.0)	1.06 (0.95)	-0.5	0.45	0.82	1.50	2.9	0.14 [-0.65, 0.93]
			Placebo	12	9 (75.0)	0.90 (1.53)	-1.6	-0.18	0.91	1.55	3.7	
		Week 32	Tezepelumab	23	20 (87.0)	1.30 (1.00)	-0.3	0.59	1.23	2.09	2.8	0.31 [-0.48, 1.11]
			Placebo	12	9 (75.0)	0.95 (1.40)	-1.6	0.91	1.09	1.55	3.3	
		Week 36	Tezepelumab	23	20 (87.0)	1.12 (1.02)	-0.8	0.45	1.09	1.55	3.1	0.05 [-0.74, 0.83]
			Placebo	12	9 (75.0)	1.06 (1.61)	-1.6	0.09	1.18	2.18	3.3	
		Week 40	Tezepelumab	23	20 (87.0)	1.23 (0.97)	-0.5	0.55	1.27	1.77	2.8	0.32 [-0.47, 1.11]
			Placebo	12	9 (75.0)	0.84 (1.65)	-1.6	-0.09	0.91	1.00	3.5	
		Week 44	Tezepelumab	23	20 (87.0)	1.23 (0.94)	-0.5	0.50	1.32	1.77	2.7	0.35 [-0.44, 1.14]
			Placebo	12	9 (75.0)	0.83 (1.55)	-1.6	-0.27	0.91	1.36	3.4	
		Week 48	Tezepelumab	23	20 (87.0)	1.26 (0.92)	-0.5	0.64	1.36	1.77	2.9	0.26 [-0.53, 1.05]
			Placebo	12	9 (75.0)	0.98 (1.39)	-1.6	0.18	1.18	1.45	3.2	
		Week 52	Tezepelumab	23	20 (87.0)	1.07 (0.95)	-0.5	0.32	0.95	1.45	2.9	0.05 [-0.74, 0.84]
			Placebo	12	9 (75.0)	1.01 (1.49)	-1.6	0.00	1.18	2.27	3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.31 (1.22)	2.1	3.86	4.18	5.18	5.9	
			Placebo	14	10 (71.4)	4.25 (0.72)	3.3	3.91	4.14	4.36	6.0	
		Week 4	Tezepelumab	9	8 (88.9)	5.01 (0.88)	3.2	4.68	5.14	5.73	5.8	
			Placebo	14	12 (85.7)	4.48 (0.91)	3.2	3.77	4.50	5.27	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.47 (1.19)	3.0	5.09	5.59	6.27	6.8	
			Placebo	14	13 (92.9)	4.52 (0.84)	3.1	4.00	4.27	5.09	6.0	
		Week 12	Tezepelumab	9	8 (88.9)	5.50 (1.22)	3.5	4.73	5.41	6.64	7.0	
			Placebo	14	13 (92.9)	4.57 (1.02)	2.8	3.91	4.73	5.27	6.5	
		Week 16	Tezepelumab	9	8 (88.9)	5.65 (1.08)	3.6	5.09	5.68	6.55	6.9	
			Placebo	14	13 (92.9)	4.95 (1.03)	3.0	4.45	4.91	5.55	6.7	
		Week 20	Tezepelumab	9	8 (88.9)	5.24 (1.34)	3.5	3.95	5.27	6.55	6.8	
			Placebo	14	13 (92.9)	4.72 (0.91)	3.2	4.18	4.73	5.18	6.6	
		Week 24	Tezepelumab	9	8 (88.9)	5.44 (1.14)	3.9	4.50	5.45	6.41	6.9	
			Placebo	14	13 (92.9)	4.81 (1.18)	2.7	4.18	4.36	5.82	6.6	
		Week 28	Tezepelumab	9	8 (88.9)	5.35 (1.29)	2.9	4.73	5.45	6.36	6.8	
			Placebo	14	14 (100.0)	4.90 (1.42)	2.5	3.82	4.73	6.00	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.44 (1.26)	3.4	4.64	5.41	6.55	7.0	
			Placebo	14	14 (100.0)	4.99 (1.25)	3.3	3.82	4.82	6.18	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.48 (1.27)	3.2	4.77	5.50	6.64	6.8	
			Placebo	14	14 (100.0)	4.96 (1.26)	2.4	4.36	4.82	6.00	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.48 (1.19)	3.5	4.77	5.50	6.41	7.0	
			Placebo	14	14 (100.0)	4.90 (1.32)	2.5	3.91	4.73	5.73	6.9	
		Week 44	Tezepelumab	9	8 (88.9)	5.60 (1.12)	3.8	4.77	5.64	6.64	6.9	
			Placebo	14	14 (100.0)	5.05 (1.20)	3.1	4.27	5.00	5.91	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.50 (1.22)	3.1	4.82	5.86	6.36	6.8	
			Placebo	14	14 (100.0)	4.84 (1.21)	2.4	4.18	4.73	5.73	6.8	
		Week 52	Tezepelumab	9	8 (88.9)	5.51 (1.23)	3.1	4.82	5.86	6.41	6.8	
			Placebo	14	14 (100.0)	4.92 (1.07)	3.5	4.18	4.55	5.73	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.65 (0.51)	-0.1	0.00	0.82	1.09	1.2	0.51 [-0.47, 1.49]
			Placebo	14	10 (71.4)	0.24 (0.96)	-1.5	-0.36	0.23	0.64	1.7	
		Week 8	Tezepelumab	9	7 (77.8)	1.12 (0.71)	0.1	0.82	0.91	1.64	2.4	0.67 [-0.32, 1.67]
			Placebo	14	10 (71.4)	0.44 (1.16)	-1.3	-0.18	0.18	1.18	2.2	
		Week 12	Tezepelumab	9	7 (77.8)	1.21 (0.67)	0.4	0.82	1.09	1.55	2.5	0.75 [-0.25, 1.76]
			Placebo	14	10 (71.4)	0.34 (1.39)	-1.3	-1.00	0.14	1.18	3.3	
		Week 16	Tezepelumab	9	7 (77.8)	1.35 (0.78)	0.4	0.82	1.09	1.91	2.7	0.37 [-0.61, 1.34]
			Placebo	14	10 (71.4)	0.90 (1.45)	-1.6	0.55	0.86	1.64	3.5	
		Week 20	Tezepelumab	9	7 (77.8)	1.10 (1.07)	-0.6	0.55	0.82	2.00	2.6	0.42 [-0.56, 1.39]
			Placebo	14	10 (71.4)	0.61 (1.26)	-1.6	-0.55	0.77	1.82	2.4	
		Week 24	Tezepelumab	9	7 (77.8)	1.35 (0.89)	0.3	0.64	1.00	2.36	2.5	0.41 [-0.57, 1.39]
			Placebo	14	10 (71.4)	0.81 (1.54)	-1.6	-0.55	0.95	2.09	2.9	
		Week 28	Tezepelumab	9	7 (77.8)	1.18 (0.91)	0.5	0.55	0.82	2.36	2.6	0.29 [-0.68, 1.26]
			Placebo	14	10 (71.4)	0.75 (1.75)	-1.6	-0.73	1.09	1.82	3.7	
		Week 32	Tezepelumab	9	7 (77.8)	1.31 (0.79)	0.5	0.64	1.09	2.27	2.5	0.39 [-0.58, 1.37]
			Placebo	14	10 (71.4)	0.81 (1.53)	-1.6	-0.55	1.18	1.55	3.3	
		Week 36	Tezepelumab	9	7 (77.8)	1.32 (0.78)	0.7	0.82	0.91	2.36	2.5	0.45 [-0.53, 1.43]
			Placebo	14	10 (71.4)	0.75 (1.52)	-1.6	-0.55	0.95	2.00	2.7	
		Week 40	Tezepelumab	9	7 (77.8)	1.32 (0.88)	0.2	0.82	1.09	2.45	2.5	0.42 [-0.56, 1.40]
			Placebo	14	10 (71.4)	0.75 (1.63)	-1.6	-0.55	0.73	1.73	3.5	
		Week 44	Tezepelumab	9	7 (77.8)	1.47 (0.97)	0.2	0.82	1.09	2.73	2.7	0.47 [-0.51, 1.45]
			Placebo	14	10 (71.4)	0.84 (1.54)	-1.6	-0.55	0.77	2.00	3.4	
		Week 48	Tezepelumab	9	7 (77.8)	1.34 (0.88)	0.4	0.64	1.00	2.36	2.6	0.61 [-0.38, 1.60]
			Placebo	14	10 (71.4)	0.58 (1.43)	-1.6	-0.55	0.82	1.73	2.4	
		Week 52	Tezepelumab	9	7 (77.8)	1.35 (0.80)	0.4	0.82	1.00	2.36	2.5	0.56 [-0.43, 1.54]
			Placebo	14	10 (71.4)	0.74 (1.26)	-1.6	0.09	0.82	1.73	2.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.29 (0.90)	1.9	3.73	4.27	4.82	7.0	
			Placebo	124	111 (89.5)	4.14 (0.89)	2.0	3.55	4.09	4.64	6.2	
		Week 4	Tezepelumab	128	118 (92.2)	4.96 (1.11)	1.6	4.09	4.91	5.82	7.0	
			Placebo	124	111 (89.5)	4.64 (1.05)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	128	120 (93.8)	5.13 (1.09)	1.6	4.27	5.09	6.09	7.0	
			Placebo	124	113 (91.1)	4.79 (1.14)	2.2	4.00	4.64	5.64	7.0	
		Week 12	Tezepelumab	128	120 (93.8)	5.32 (1.11)	1.7	4.45	5.27	6.27	7.0	
			Placebo	124	114 (91.9)	4.93 (1.11)	2.8	4.00	4.73	6.00	7.0	
		Week 16	Tezepelumab	128	120 (93.8)	5.26 (1.08)	2.6	4.27	5.23	6.14	7.0	
			Placebo	124	114 (91.9)	4.93 (1.19)	1.1	4.00	4.82	6.00	7.0	
		Week 20	Tezepelumab	128	121 (94.5)	5.23 (1.14)	1.8	4.36	5.27	6.09	7.0	
			Placebo	124	114 (91.9)	4.93 (1.16)	1.1	4.09	4.73	5.82	7.0	
		Week 24	Tezepelumab	128	121 (94.5)	5.29 (1.15)	1.6	4.36	5.27	6.27	7.0	
			Placebo	124	114 (91.9)	4.96 (1.17)	1.1	4.09	4.86	5.91	7.0	
		Week 28	Tezepelumab	128	123 (96.1)	5.30 (1.09)	2.1	4.36	5.36	6.09	7.0	
			Placebo	124	114 (91.9)	4.95 (1.22)	1.1	4.00	4.82	6.00	7.0	
		Week 32	Tezepelumab	128	124 (96.9)	5.36 (1.10)	1.6	4.41	5.45	6.18	7.0	
			Placebo	124	115 (92.7)	4.99 (1.17)	1.1	4.09	4.82	6.00	7.0	
		Week 36	Tezepelumab	128	124 (96.9)	5.33 (1.09)	1.9	4.41	5.45	6.18	7.0	
			Placebo	124	115 (92.7)	5.02 (1.15)	2.5	4.00	4.82	6.09	7.0	
		Week 40	Tezepelumab	128	124 (96.9)	5.38 (1.08)	2.1	4.36	5.36	6.18	7.0	
			Placebo	124	115 (92.7)	5.04 (1.16)	2.0	4.09	5.00	6.00	7.0	
		Week 44	Tezepelumab	128	124 (96.9)	5.40 (1.09)	2.4	4.45	5.41	6.27	7.0	
			Placebo	124	115 (92.7)	5.04 (1.20)	2.5	4.00	4.91	6.00	7.0	
		Week 48	Tezepelumab	128	124 (96.9)	5.43 (1.08)	2.6	4.36	5.45	6.41	7.0	
			Placebo	124	116 (93.5)	5.07 (1.13)	2.3	4.05	5.00	6.00	7.0	
		Week 52	Tezepelumab	128	124 (96.9)	5.40 (1.10)	1.8	4.45	5.45	6.27	7.0	
			Placebo	124	116 (93.5)	5.04 (1.15)	2.7	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	110 (85.9)	0.70 (1.02)	-2.8	0.00	0.55	1.36	3.2	0.21 [-0.06, 0.47]
			Placebo	124	109 (87.9)	0.51 (0.85)	-1.5	0.00	0.36	0.91	2.6	
		Week 8	Tezepelumab	128	112 (87.5)	0.83 (1.06)	-1.5	0.00	0.68	1.50	3.7	0.18 [-0.08, 0.44]
			Placebo	124	110 (88.7)	0.65 (0.89)	-1.7	0.00	0.64	1.09	3.3	
		Week 12	Tezepelumab	128	112 (87.5)	1.02 (1.06)	-1.5	0.32	1.00	1.59	4.2	0.22 [-0.04, 0.49]
			Placebo	124	110 (88.7)	0.80 (0.97)	-1.9	0.18	0.82	1.18	3.7	
		Week 16	Tezepelumab	128	112 (87.5)	0.98 (1.05)	-1.7	0.23	0.91	1.55	3.5	0.18 [-0.09, 0.44]
			Placebo	124	110 (88.7)	0.80 (1.01)	-3.2	0.27	0.82	1.45	3.9	
		Week 20	Tezepelumab	128	112 (87.5)	0.94 (1.11)	-2.1	0.14	0.91	1.68	3.5	0.13 [-0.13, 0.39]
			Placebo	124	110 (88.7)	0.81 (1.01)	-3.2	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	128	112 (87.5)	1.03 (1.06)	-1.4	0.23	1.05	1.64	3.5	0.19 [-0.07, 0.46]
			Placebo	124	110 (88.7)	0.83 (1.03)	-3.2	0.27	0.82	1.36	3.8	
		Week 28	Tezepelumab	128	112 (87.5)	1.04 (1.07)	-1.1	0.18	1.00	1.82	3.5	0.21 [-0.06, 0.47]
			Placebo	124	110 (88.7)	0.82 (1.04)	-3.2	0.18	0.82	1.36	4.0	
		Week 32	Tezepelumab	128	112 (87.5)	1.07 (1.06)	-1.1	0.32	1.00	1.82	3.5	0.18 [-0.08, 0.44]
			Placebo	124	110 (88.7)	0.88 (1.02)	-3.2	0.36	0.86	1.45	3.6	
		Week 36	Tezepelumab	128	112 (87.5)	1.04 (1.10)	-0.9	0.18	1.00	1.73	3.5	0.12 [-0.14, 0.39]
			Placebo	124	110 (88.7)	0.91 (1.03)	-1.8	0.18	0.86	1.45	3.5	
		Week 40	Tezepelumab	128	112 (87.5)	1.09 (1.05)	-1.0	0.32	1.05	1.77	3.5	0.15 [-0.11, 0.41]
			Placebo	124	110 (88.7)	0.93 (1.08)	-1.5	0.27	0.82	1.45	4.0	
		Week 44	Tezepelumab	128	112 (87.5)	1.11 (1.06)	-1.1	0.27	1.00	1.82	3.5	0.19 [-0.07, 0.45]
			Placebo	124	110 (88.7)	0.91 (1.08)	-1.4	0.18	0.91	1.45	3.9	
		Week 48	Tezepelumab	128	112 (87.5)	1.16 (1.07)	-1.0	0.36	1.09	1.91	3.5	0.21 [-0.06, 0.47]
			Placebo	124	110 (88.7)	0.94 (1.03)	-1.4	0.18	0.86	1.45	3.6	
		Week 52	Tezepelumab	128	112 (87.5)	1.10 (1.09)	-1.2	0.27	1.00	1.86	3.5	0.16 [-0.11, 0.42]
			Placebo	124	110 (88.7)	0.94 (1.04)	-1.4	0.18	0.91	1.45	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	4.28 (0.90)	2.2	3.73	4.23	4.68	7.0	
			Placebo	115	104 (90.4)	4.15 (0.89)	2.0	3.55	4.09	4.55	6.2	
		Week 4	Tezepelumab	108	100 (92.6)	4.93 (1.12)	1.6	4.09	4.91	5.77	7.0	
			Placebo	115	104 (90.4)	4.66 (1.07)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	108	102 (94.4)	5.09 (1.06)	2.9	4.18	5.05	6.00	7.0	
			Placebo	115	106 (92.2)	4.83 (1.12)	2.2	4.00	4.64	5.64	7.0	
		Week 12	Tezepelumab	108	102 (94.4)	5.30 (1.06)	3.0	4.27	5.27	6.18	7.0	
			Placebo	115	107 (93.0)	4.94 (1.13)	2.8	4.00	4.73	6.00	7.0	
		Week 16	Tezepelumab	108	102 (94.4)	5.22 (1.06)	2.8	4.27	5.18	6.00	7.0	
			Placebo	115	107 (93.0)	4.96 (1.19)	1.1	4.00	4.91	6.00	7.0	
		Week 20	Tezepelumab	108	103 (95.4)	5.18 (1.12)	2.1	4.27	5.18	6.00	7.0	
			Placebo	115	107 (93.0)	4.94 (1.18)	1.1	4.00	4.82	5.91	7.0	
		Week 24	Tezepelumab	108	103 (95.4)	5.24 (1.09)	2.9	4.27	5.18	6.18	7.0	
			Placebo	115	107 (93.0)	4.96 (1.19)	1.1	4.09	4.91	5.91	7.0	
		Week 28	Tezepelumab	108	105 (97.2)	5.28 (1.06)	3.2	4.36	5.27	6.00	7.0	
			Placebo	115	107 (93.0)	4.95 (1.23)	1.1	4.00	4.82	6.00	7.0	
		Week 32	Tezepelumab	108	106 (98.1)	5.30 (1.06)	2.5	4.36	5.32	6.09	7.0	
			Placebo	115	108 (93.9)	4.99 (1.18)	1.1	4.05	4.82	5.95	7.0	
		Week 36	Tezepelumab	108	106 (98.1)	5.31 (1.04)	3.0	4.36	5.45	6.09	7.0	
			Placebo	115	108 (93.9)	5.01 (1.16)	2.5	4.00	4.77	6.09	7.0	
		Week 40	Tezepelumab	108	106 (98.1)	5.33 (1.05)	3.2	4.36	5.23	6.18	7.0	
			Placebo	115	108 (93.9)	5.06 (1.18)	2.0	4.05	5.05	6.05	7.0	
		Week 44	Tezepelumab	108	106 (98.1)	5.36 (1.07)	3.0	4.36	5.36	6.18	7.0	
			Placebo	115	108 (93.9)	5.05 (1.21)	2.5	4.00	4.91	6.00	7.0	
		Week 48	Tezepelumab	108	106 (98.1)	5.39 (1.09)	2.6	4.36	5.41	6.36	7.0	
			Placebo	115	109 (94.8)	5.06 (1.14)	2.3	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	108	106 (98.1)	5.38 (1.08)	2.6	4.36	5.45	6.18	7.0	
			Placebo	115	109 (94.8)	5.03 (1.16)	2.7	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	108	93 (86.1)	0.68 (1.06)	-2.8	0.00	0.55	1.27	3.2	0.17 [-0.11, 0.45]
			Placebo	115	102 (88.7)	0.52 (0.87)	-1.5	0.00	0.36	0.91	2.6	
		Week 8	Tezepelumab	108	95 (88.0)	0.79 (1.07)	-1.5	0.00	0.64	1.45	3.7	0.11 [-0.17, 0.39]
			Placebo	115	103 (89.6)	0.68 (0.88)	-1.7	0.00	0.64	1.09	3.3	
		Week 12	Tezepelumab	108	95 (88.0)	1.00 (1.07)	-1.5	0.27	1.00	1.55	4.2	0.20 [-0.08, 0.48]
			Placebo	115	103 (89.6)	0.80 (0.98)	-1.9	0.18	0.73	1.27	3.7	
		Week 16	Tezepelumab	108	95 (88.0)	0.94 (1.07)	-1.7	0.18	0.91	1.55	3.5	0.11 [-0.17, 0.39]
			Placebo	115	103 (89.6)	0.82 (1.02)	-3.2	0.27	0.82	1.55	3.9	
		Week 20	Tezepelumab	108	95 (88.0)	0.89 (1.13)	-2.1	0.00	0.91	1.64	3.5	0.07 [-0.21, 0.35]
			Placebo	115	103 (89.6)	0.81 (1.03)	-3.2	0.18	0.73	1.27	4.0	
		Week 24	Tezepelumab	108	95 (88.0)	1.00 (1.05)	-0.8	0.18	0.91	1.64	3.5	0.17 [-0.11, 0.45]
			Placebo	115	103 (89.6)	0.82 (1.03)	-3.2	0.18	0.82	1.36	3.8	
		Week 28	Tezepelumab	108	95 (88.0)	1.02 (1.08)	-1.1	0.09	1.00	1.82	3.5	0.19 [-0.09, 0.47]
			Placebo	115	103 (89.6)	0.81 (1.06)	-3.2	0.18	0.82	1.36	4.0	
		Week 32	Tezepelumab	108	95 (88.0)	1.01 (1.05)	-1.1	0.27	1.00	1.64	3.5	0.13 [-0.14, 0.41]
			Placebo	115	103 (89.6)	0.87 (1.03)	-3.2	0.27	0.82	1.45	3.6	
		Week 36	Tezepelumab	108	95 (88.0)	1.02 (1.11)	-0.9	0.18	0.91	1.73	3.5	0.13 [-0.15, 0.40]
			Placebo	115	103 (89.6)	0.89 (1.02)	-1.8	0.18	0.82	1.45	3.5	
		Week 40	Tezepelumab	108	95 (88.0)	1.05 (1.06)	-1.0	0.27	1.00	1.64	3.5	0.11 [-0.17, 0.39]
			Placebo	115	103 (89.6)	0.94 (1.08)	-1.5	0.27	0.82	1.55	4.0	
		Week 44	Tezepelumab	108	95 (88.0)	1.09 (1.08)	-1.1	0.27	1.00	1.82	3.5	0.15 [-0.12, 0.43]
			Placebo	115	103 (89.6)	0.92 (1.09)	-1.4	0.18	0.91	1.55	3.9	
		Week 48	Tezepelumab	108	95 (88.0)	1.13 (1.09)	-1.0	0.36	1.00	1.91	3.5	0.19 [-0.09, 0.47]
			Placebo	115	103 (89.6)	0.93 (1.03)	-1.4	0.18	0.82	1.45	3.6	
		Week 52	Tezepelumab	108	95 (88.0)	1.10 (1.10)	-1.2	0.27	1.00	1.91	3.5	0.17 [-0.11, 0.45]
			Placebo	115	103 (89.6)	0.92 (1.03)	-1.4	0.18	0.91	1.45	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	4.33 (0.98)	1.9	3.91	4.27	4.91	5.9	
			Placebo	23	17 (73.9)	4.14 (0.84)	2.7	3.82	4.00	4.64	6.0	
		Week 4	Tezepelumab	29	26 (89.7)	5.07 (0.99)	3.1	4.45	5.00	5.82	6.8	
			Placebo	23	19 (82.6)	4.45 (0.83)	3.2	3.82	4.45	5.18	6.0	
		Week 8	Tezepelumab	29	26 (89.7)	5.39 (1.21)	1.6	4.82	5.27	6.36	6.9	
			Placebo	23	20 (87.0)	4.44 (1.03)	2.3	3.77	4.18	5.18	6.5	
		Week 12	Tezepelumab	29	26 (89.7)	5.44 (1.32)	1.7	4.91	5.23	6.64	7.0	
			Placebo	23	20 (87.0)	4.62 (0.96)	2.8	3.95	4.50	5.36	6.5	
		Week 16	Tezepelumab	29	26 (89.7)	5.55 (1.15)	2.6	4.91	5.50	6.45	7.0	
			Placebo	23	20 (87.0)	4.79 (1.07)	2.6	4.23	4.64	5.50	6.7	
		Week 20	Tezepelumab	29	26 (89.7)	5.45 (1.24)	1.8	4.82	5.55	6.45	7.0	
			Placebo	23	20 (87.0)	4.72 (0.88)	3.2	4.14	4.45	5.27	6.6	
		Week 24	Tezepelumab	29	26 (89.7)	5.53 (1.32)	1.6	4.91	5.77	6.64	7.0	
			Placebo	23	20 (87.0)	4.87 (1.09)	2.7	4.14	4.50	5.82	6.6	
		Week 28	Tezepelumab	29	26 (89.7)	5.43 (1.26)	2.1	4.82	5.73	6.36	7.0	
			Placebo	23	21 (91.3)	4.88 (1.31)	2.5	3.91	4.45	6.00	7.0	
		Week 32	Tezepelumab	29	26 (89.7)	5.62 (1.25)	1.6	5.09	5.86	6.55	7.0	
			Placebo	23	21 (91.3)	4.99 (1.16)	3.3	4.09	4.73	6.18	7.0	
		Week 36	Tezepelumab	29	26 (89.7)	5.49 (1.32)	1.9	4.91	5.73	6.55	7.0	
			Placebo	23	21 (91.3)	5.04 (1.16)	2.4	4.36	5.00	6.00	6.9	
		Week 40	Tezepelumab	29	26 (89.7)	5.58 (1.23)	2.1	5.00	5.86	6.64	7.0	
			Placebo	23	21 (91.3)	4.87 (1.20)	2.5	4.09	4.91	5.73	6.9	
		Week 44	Tezepelumab	29	26 (89.7)	5.61 (1.19)	2.4	4.91	5.86	6.55	7.0	
			Placebo	23	21 (91.3)	4.97 (1.13)	3.1	4.09	4.91	5.91	6.9	
		Week 48	Tezepelumab	29	26 (89.7)	5.62 (1.07)	3.1	5.09	5.82	6.45	7.0	
			Placebo	23	21 (91.3)	4.94 (1.15)	2.4	4.18	4.73	5.73	6.8	
		Week 52	Tezepelumab	29	26 (89.7)	5.49 (1.23)	1.8	4.91	5.82	6.36	7.0	
			Placebo	23	21 (91.3)	5.01 (1.03)	3.5	4.18	4.91	5.73	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IOSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITT

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	29	24 (82.8)	0.77 (0.75)	-1.4	0.36	0.77	1.27	2.2	0.62 [-0.02, 1.25]
			Placebo	23	17 (73.9)	0.30 (0.78)	-1.5	-0.09	0.36	0.64	1.7	
		Week 8	Tezepelumab	29	24 (82.8)	1.08 (0.89)	-0.6	0.45	1.05	1.86	2.5	0.73 [0.09, 1.37]
			Placebo	23	17 (73.9)	0.37 (1.07)	-1.3	-0.18	0.45	1.00	2.2	
		Week 12	Tezepelumab	29	24 (82.8)	1.16 (0.94)	-0.5	0.50	1.09	1.68	2.7	0.63 [-0.01, 1.27]
			Placebo	23	17 (73.9)	0.49 (1.20)	-1.4	0.00	0.91	1.18	3.3	
		Week 16	Tezepelumab	29	24 (82.8)	1.26 (0.90)	-0.4	0.77	1.05	1.73	2.8	0.50 [-0.13, 1.14]
			Placebo	23	17 (73.9)	0.73 (1.23)	-1.6	0.55	0.91	1.18	3.5	
		Week 20	Tezepelumab	29	24 (82.8)	1.21 (0.96)	-0.6	0.59	1.05	2.09	2.7	0.55 [-0.08, 1.19]
			Placebo	23	17 (73.9)	0.65 (1.06)	-1.6	0.45	0.82	1.09	2.4	
		Week 24	Tezepelumab	29	24 (82.8)	1.28 (1.06)	-1.4	0.64	1.36	2.09	3.0	0.34 [-0.28, 0.97]
			Placebo	23	17 (73.9)	0.88 (1.31)	-1.6	0.27	0.91	1.82	2.9	
		Week 28	Tezepelumab	29	24 (82.8)	1.15 (0.96)	-0.5	0.50	0.82	1.91	2.9	0.30 [-0.32, 0.93]
			Placebo	23	17 (73.9)	0.80 (1.41)	-1.6	-0.36	0.91	1.64	3.7	
		Week 32	Tezepelumab	29	24 (82.8)	1.35 (0.98)	-0.3	0.64	1.23	2.32	2.8	0.43 [-0.20, 1.06]
			Placebo	23	17 (73.9)	0.88 (1.24)	-1.6	-0.27	1.09	1.55	3.3	
		Week 36	Tezepelumab	29	24 (82.8)	1.20 (1.01)	-0.8	0.68	1.09	2.00	3.1	0.23 [-0.40, 0.85]
			Placebo	23	17 (73.9)	0.94 (1.42)	-1.6	0.09	1.09	2.00	3.3	
		Week 40	Tezepelumab	29	24 (82.8)	1.30 (0.96)	-0.5	0.73	1.27	2.09	2.8	0.45 [-0.18, 1.08]
			Placebo	23	17 (73.9)	0.77 (1.42)	-1.6	-0.09	0.82	1.64	3.5	
		Week 44	Tezepelumab	29	24 (82.8)	1.33 (0.96)	-0.5	0.59	1.32	2.09	2.7	0.45 [-0.18, 1.08]
			Placebo	23	17 (73.9)	0.83 (1.33)	-1.6	-0.27	0.82	1.64	3.4	
		Week 48	Tezepelumab	29	24 (82.8)	1.36 (0.91)	-0.5	0.68	1.36	2.14	2.9	0.50 [-0.13, 1.13]
			Placebo	23	17 (73.9)	0.82 (1.28)	-1.6	0.18	0.91	1.45	3.2	
		Week 52	Tezepelumab	29	24 (82.8)	1.19 (0.95)	-0.5	0.50	1.18	1.73	2.9	0.25 [-0.38, 0.87]
			Placebo	23	17 (73.9)	0.93 (1.22)	-1.6	0.09	0.91	1.73	3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOMH0: Course of AQLQ+12 environmental stimuli score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli score	Baseline	Tezepelumab	137	123 (89.8)	4.23 (1.15)	1.0	3.50	4.25	5.00	7.0	
		Placebo	138	121 (87.7)	4.09 (1.21)	1.5	3.25	4.00	5.00	7.0	
	Week 4	Tezepelumab	137	126 (92.0)	4.90 (1.20)	1.0	4.00	5.00	5.75	7.0	
		Placebo	138	123 (89.1)	4.59 (1.21)	1.3	3.75	4.75	5.50	7.0	
	Week 8	Tezepelumab	137	128 (93.4)	5.10 (1.20)	1.0	4.25	5.13	5.75	7.0	
		Placebo	138	126 (91.3)	4.70 (1.31)	1.0	3.75	4.75	5.75	7.0	
	Week 12	Tezepelumab	137	128 (93.4)	5.24 (1.22)	1.0	4.50	5.25	6.25	7.0	
		Placebo	138	127 (92.0)	4.76 (1.19)	1.3	4.00	4.75	5.75	7.0	
	Week 16	Tezepelumab	137	128 (93.4)	5.18 (1.20)	1.0	4.50	5.13	6.00	7.0	
		Placebo	138	127 (92.0)	4.75 (1.28)	1.3	4.00	4.75	5.75	7.0	
	Week 20	Tezepelumab	137	129 (94.2)	5.15 (1.25)	1.0	4.50	5.00	6.00	7.0	
		Placebo	138	127 (92.0)	4.78 (1.28)	1.3	4.00	4.75	5.75	7.0	
	Week 24	Tezepelumab	137	129 (94.2)	5.25 (1.21)	1.0	4.50	5.00	6.25	7.0	
		Placebo	138	127 (92.0)	4.72 (1.35)	1.0	4.00	4.75	5.75	7.0	
	Week 28	Tezepelumab	137	131 (95.6)	5.21 (1.26)	1.0	4.50	5.00	6.25	7.0	
		Placebo	138	128 (92.8)	4.83 (1.38)	1.3	4.00	4.88	6.00	7.0	
	Week 32	Tezepelumab	137	132 (96.4)	5.29 (1.25)	1.0	4.50	5.25	6.00	7.0	
		Placebo	138	129 (93.5)	4.89 (1.35)	1.3	4.00	5.00	6.00	7.0	
	Week 36	Tezepelumab	137	132 (96.4)	5.29 (1.26)	1.0	4.50	5.25	6.25	7.0	
		Placebo	138	129 (93.5)	4.84 (1.38)	1.0	4.00	5.00	6.00	7.0	
	Week 40	Tezepelumab	137	132 (96.4)	5.33 (1.20)	1.3	4.50	5.38	6.25	7.0	
		Placebo	138	129 (93.5)	4.91 (1.35)	1.0	4.00	5.00	5.75	7.0	
	Week 44	Tezepelumab	137	132 (96.4)	5.36 (1.22)	1.0	4.50	5.25	6.38	7.0	
		Placebo	138	129 (93.5)	4.87 (1.34)	1.3	4.00	4.75	6.00	7.0	
	Week 48	Tezepelumab	137	132 (96.4)	5.34 (1.22)	1.0	4.50	5.50	6.25	7.0	
		Placebo	138	130 (94.2)	4.92 (1.30)	1.0	4.00	5.00	6.00	7.0	
	Week 52	Tezepelumab	137	132 (96.4)	5.31 (1.26)	1.0	4.50	5.50	6.25	7.0	
		Placebo	138	130 (94.2)	4.84 (1.33)	1.0	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOMH0: Course of AQLQ+12 environmental stimuli score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	137	117 (85.4)	0.69 (1.15)	-4.0	0.00	0.75	1.25	4.0	0.18 [-0.08, 0.43]
		Placebo	138	119 (86.2)	0.50 (0.96)	-2.5	0.00	0.50	1.25	3.0	
	Week 8	Tezepelumab	137	119 (86.9)	0.87 (1.15)	-1.5	0.00	0.75	1.75	4.3	0.20 [-0.05, 0.46]
		Placebo	138	120 (87.0)	0.65 (1.05)	-1.8	0.00	0.50	1.25	3.3	
	Week 12	Tezepelumab	137	119 (86.9)	1.02 (1.15)	-2.3	0.25	1.00	1.75	4.8	0.28 [0.02, 0.53]
		Placebo	138	120 (87.0)	0.71 (1.07)	-1.8	0.00	0.75	1.25	4.3	
	Week 16	Tezepelumab	137	119 (86.9)	0.96 (1.18)	-2.8	0.00	0.75	1.75	3.5	0.25 [-0.00, 0.51]
		Placebo	138	120 (87.0)	0.69 (1.04)	-1.8	0.00	0.50	1.25	3.0	
	Week 20	Tezepelumab	137	119 (86.9)	0.95 (1.18)	-1.8	0.00	0.75	1.75	3.5	0.20 [-0.05, 0.46]
		Placebo	138	120 (87.0)	0.73 (1.03)	-2.3	0.00	0.63	1.25	3.0	
	Week 24	Tezepelumab	137	119 (86.9)	1.05 (1.15)	-1.5	0.25	1.00	2.00	3.5	0.32 [0.07, 0.58]
		Placebo	138	120 (87.0)	0.68 (1.13)	-2.8	-0.13	0.63	1.50	3.8	
	Week 28	Tezepelumab	137	119 (86.9)	1.01 (1.16)	-1.5	0.25	0.75	1.75	3.5	0.21 [-0.04, 0.46]
		Placebo	138	120 (87.0)	0.77 (1.15)	-2.8	0.00	0.75	1.50	4.0	
	Week 32	Tezepelumab	137	119 (86.9)	1.08 (1.18)	-1.3	0.25	1.00	1.75	3.5	0.19 [-0.07, 0.44]
		Placebo	138	120 (87.0)	0.87 (1.09)	-1.8	0.00	0.75	1.75	3.8	
	Week 36	Tezepelumab	137	119 (86.9)	1.09 (1.22)	-1.8	0.25	1.00	2.00	3.5	0.23 [-0.02, 0.49]
		Placebo	138	120 (87.0)	0.80 (1.23)	-2.8	0.00	0.50	1.50	3.8	
	Week 40	Tezepelumab	137	119 (86.9)	1.13 (1.16)	-1.5	0.25	1.00	2.00	3.5	0.23 [-0.02, 0.48]
		Placebo	138	120 (87.0)	0.86 (1.22)	-2.5	0.00	0.75	1.63	4.3	
	Week 44	Tezepelumab	137	119 (86.9)	1.16 (1.19)	-1.5	0.25	1.00	2.00	3.8	0.29 [0.04, 0.55]
		Placebo	138	120 (87.0)	0.81 (1.21)	-1.5	0.00	0.63	1.50	3.8	
	Week 48	Tezepelumab	137	119 (86.9)	1.15 (1.21)	-1.8	0.25	1.00	2.00	3.8	0.24 [-0.02, 0.49]
		Placebo	138	120 (87.0)	0.86 (1.23)	-2.8	0.00	0.75	1.50	4.0	
	Week 52	Tezepelumab	137	119 (86.9)	1.10 (1.22)	-1.8	0.25	1.00	2.00	3.8	0.26 [0.01, 0.52]
		Placebo	138	120 (87.0)	0.78 (1.20)	-2.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
DITT

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	137	117 (85.4)	0.72 (0.09)	(0.55, 0.90)	0.23 (0.13)	(-0.01, 0.48)	0.065
	Placebo	138	118 (85.5)	0.49 (0.09)	(0.31, 0.66)			
Week 8	Tezepelumab	137	117 (85.4)	0.91 (0.09)	(0.72, 1.09)	0.27 (0.13)	(0.01, 0.53)	0.043 *
	Placebo	138	119 (86.2)	0.63 (0.09)	(0.45, 0.82)			
Week 12	Tezepelumab	137	116 (84.7)	1.05 (0.09)	(0.87, 1.24)	0.34 (0.13)	(0.08, 0.60)	0.009 *
	Placebo	138	115 (83.3)	0.71 (0.09)	(0.53, 0.89)			
Week 16	Tezepelumab	137	112 (81.8)	1.00 (0.10)	(0.81, 1.19)	0.34 (0.13)	(0.07, 0.60)	0.013 *
	Placebo	138	112 (81.2)	0.66 (0.09)	(0.47, 0.85)			
Week 20	Tezepelumab	137	107 (78.1)	0.99 (0.10)	(0.80, 1.18)	0.24 (0.14)	(-0.02, 0.51)	0.073
	Placebo	138	109 (79.0)	0.74 (0.10)	(0.56, 0.93)			
Week 24	Tezepelumab	137	105 (76.6)	1.10 (0.10)	(0.91, 1.30)	0.42 (0.14)	(0.15, 0.70)	0.003 *
	Placebo	138	106 (76.8)	0.68 (0.10)	(0.48, 0.87)			
Week 28	Tezepelumab	137	101 (73.7)	1.03 (0.11)	(0.83, 1.24)	0.27 (0.15)	(-0.02, 0.56)	0.071
	Placebo	138	105 (76.1)	0.77 (0.10)	(0.56, 0.97)			
Week 32	Tezepelumab	137	104 (75.9)	1.13 (0.10)	(0.93, 1.32)	0.25 (0.14)	(-0.03, 0.53)	0.082
	Placebo	138	104 (75.4)	0.88 (0.10)	(0.68, 1.08)			
Week 36	Tezepelumab	137	104 (75.9)	1.14 (0.11)	(0.92, 1.35)	0.36 (0.15)	(0.05, 0.66)	0.021 *
	Placebo	138	103 (74.6)	0.78 (0.11)	(0.57, 0.99)			
Week 40	Tezepelumab	137	104 (75.9)	1.18 (0.11)	(0.98, 1.39)	0.33 (0.15)	(0.04, 0.62)	0.028 *
	Placebo	138	105 (76.1)	0.85 (0.10)	(0.65, 1.06)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
DITT

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	137	102 (74.5)	1.22 (0.11)	(1.01, 1.43)	0.44 (0.15)	(0.14, 0.73)	0.004 *
	Placebo	138	103 (74.6)	0.78 (0.11)	(0.57, 0.99)			
Week 48	Tezepelumab	137	97 (70.8)	1.21 (0.11)	(1.00, 1.42)	0.36 (0.15)	(0.06, 0.65)	0.017 *
	Placebo	138	105 (76.1)	0.86 (0.10)	(0.65, 1.06)			
Week 52	Tezepelumab	137	41 (29.9)	1.11 (0.13)	(0.86, 1.36)	0.32 (0.18)	(-0.03, 0.68)	0.071
	Placebo	138	47 (34.1)	0.79 (0.12)	(0.54, 1.03)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QEC_IOMG0: Course of AQLQ+12 environmental stimuli score
DITT



Note: DITT = Dossier Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QEC_IOMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	50	42 (84.0)	4.41 (1.21)	1.0	3.75	4.25	5.00	7.0	
			Placebo	44	41 (93.2)	4.01 (1.25)	1.5	3.25	4.00	4.75	7.0	
		Week 4	Tezepelumab	50	46 (92.0)	5.09 (1.27)	1.0	4.00	5.00	6.00	7.0	
			Placebo	44	41 (93.2)	4.66 (1.31)	2.0	4.00	4.75	5.50	7.0	
		Week 8	Tezepelumab	50	46 (92.0)	5.26 (1.21)	1.0	4.50	5.13	6.25	7.0	
			Placebo	44	42 (95.5)	4.71 (1.27)	2.3	3.75	4.63	5.75	7.0	
		Week 12	Tezepelumab	50	46 (92.0)	5.24 (1.27)	1.0	4.50	5.38	6.00	7.0	
			Placebo	44	42 (95.5)	4.88 (1.17)	2.0	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	50	46 (92.0)	5.29 (1.22)	1.0	4.50	5.25	6.25	7.0	
			Placebo	44	42 (95.5)	4.79 (1.46)	1.3	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	50	46 (92.0)	5.38 (1.23)	1.0	4.50	5.25	6.25	7.0	
			Placebo	44	42 (95.5)	4.72 (1.49)	1.3	3.50	4.75	6.00	7.0	
		Week 24	Tezepelumab	50	46 (92.0)	5.33 (1.25)	1.0	4.25	5.38	6.25	7.0	
			Placebo	44	42 (95.5)	4.59 (1.59)	1.3	3.25	4.75	5.75	7.0	
		Week 28	Tezepelumab	50	47 (94.0)	5.31 (1.22)	1.0	4.50	5.25	6.25	7.0	
			Placebo	44	43 (97.7)	4.80 (1.50)	1.3	4.00	4.75	6.00	7.0	
		Week 32	Tezepelumab	50	48 (96.0)	5.46 (1.14)	2.5	4.63	5.50	6.25	7.0	
			Placebo	44	43 (97.7)	4.92 (1.40)	1.3	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	50	48 (96.0)	5.38 (1.27)	1.0	4.50	5.13	6.50	7.0	
			Placebo	44	43 (97.7)	4.84 (1.55)	1.8	4.00	5.00	6.25	7.0	
		Week 40	Tezepelumab	50	48 (96.0)	5.41 (1.23)	1.3	4.50	5.38	6.38	7.0	
			Placebo	44	43 (97.7)	4.87 (1.48)	1.8	3.75	5.00	6.00	7.0	
		Week 44	Tezepelumab	50	48 (96.0)	5.45 (1.28)	1.0	4.50	5.50	6.50	7.0	
			Placebo	44	43 (97.7)	4.84 (1.47)	1.8	3.75	4.25	6.00	7.0	
		Week 48	Tezepelumab	50	48 (96.0)	5.48 (1.19)	2.0	4.50	5.50	6.75	7.0	
			Placebo	44	43 (97.7)	4.97 (1.46)	1.8	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	50	48 (96.0)	5.43 (1.17)	2.0	4.50	5.50	6.38	7.0	
			Placebo	44	43 (97.7)	4.97 (1.39)	1.8	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	50	41 (82.0)	0.62 (1.08)	-2.3	0.00	0.75	1.00	3.3	-0.04 [-0.48, 0.40]
			Placebo	44	40 (90.9)	0.66 (0.97)	-2.0	0.13	0.50	1.50	2.5	
		Week 8	Tezepelumab	50	41 (82.0)	0.85 (1.12)	-1.5	0.25	0.75	1.25	3.5	0.11 [-0.32, 0.55]
			Placebo	44	41 (93.2)	0.73 (1.02)	-1.8	0.00	0.75	1.25	3.0	
		Week 12	Tezepelumab	50	41 (82.0)	0.83 (1.11)	-2.0	0.25	0.75	1.25	3.5	-0.06 [-0.49, 0.37]
			Placebo	44	41 (93.2)	0.90 (1.13)	-1.8	0.25	1.00	1.25	4.3	
		Week 16	Tezepelumab	50	41 (82.0)	0.91 (1.18)	-2.3	0.25	0.75	1.50	3.5	0.11 [-0.33, 0.54]
			Placebo	44	41 (93.2)	0.79 (1.12)	-1.8	0.00	0.75	1.50	3.0	
		Week 20	Tezepelumab	50	41 (82.0)	0.99 (1.12)	-1.0	0.25	0.75	1.75	3.5	0.23 [-0.20, 0.67]
			Placebo	44	41 (93.2)	0.74 (1.04)	-2.3	0.25	0.75	1.25	3.0	
		Week 24	Tezepelumab	50	41 (82.0)	0.95 (1.15)	-1.0	0.25	0.75	1.75	3.5	0.31 [-0.12, 0.75]
			Placebo	44	41 (93.2)	0.59 (1.19)	-2.8	0.00	0.75	1.50	3.3	
		Week 28	Tezepelumab	50	41 (82.0)	0.98 (1.17)	-1.5	0.25	0.75	1.75	3.5	0.18 [-0.25, 0.62]
			Placebo	44	41 (93.2)	0.76 (1.21)	-1.8	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	50	41 (82.0)	1.10 (1.15)	-1.3	0.25	1.00	1.75	3.5	0.21 [-0.23, 0.64]
			Placebo	44	41 (93.2)	0.87 (1.11)	-1.8	0.00	0.75	1.75	3.5	
		Week 36	Tezepelumab	50	41 (82.0)	0.98 (1.24)	-1.8	0.25	0.75	1.75	3.5	0.14 [-0.29, 0.58]
			Placebo	44	41 (93.2)	0.80 (1.26)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	50	41 (82.0)	1.02 (1.16)	-1.5	0.25	0.75	1.75	3.5	0.16 [-0.27, 0.59]
			Placebo	44	41 (93.2)	0.83 (1.29)	-2.5	0.00	0.50	1.75	4.3	
		Week 44	Tezepelumab	50	41 (82.0)	1.05 (1.19)	-1.5	0.25	1.00	1.75	3.5	0.24 [-0.19, 0.68]
			Placebo	44	41 (93.2)	0.77 (1.17)	-1.5	0.00	0.75	1.50	3.5	
		Week 48	Tezepelumab	50	41 (82.0)	1.12 (1.22)	-1.8	0.50	1.00	2.00	3.5	0.17 [-0.27, 0.60]
			Placebo	44	41 (93.2)	0.92 (1.20)	-2.8	0.25	0.75	1.50	3.5	
		Week 52	Tezepelumab	50	41 (82.0)	1.01 (1.24)	-1.8	0.50	1.00	1.75	3.5	0.08 [-0.35, 0.51]
			Placebo	44	41 (93.2)	0.92 (1.04)	-1.3	0.25	0.75	1.50	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	87	81 (93.1)	4.13 (1.11)	1.0	3.50	4.00	5.00	6.8	
			Placebo	94	80 (85.1)	4.13 (1.19)	1.5	3.25	4.00	5.00	6.5	
		Week 4	Tezepelumab	87	80 (92.0)	4.80 (1.16)	1.3	4.13	5.00	5.75	7.0	
			Placebo	94	82 (87.2)	4.56 (1.16)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	87	82 (94.3)	5.00 (1.20)	1.0	4.25	5.13	5.75	7.0	
			Placebo	94	84 (89.4)	4.70 (1.34)	1.0	4.00	4.75	5.63	7.0	
		Week 12	Tezepelumab	87	82 (94.3)	5.23 (1.20)	1.0	4.50	5.25	6.25	7.0	
			Placebo	94	85 (90.4)	4.70 (1.20)	1.3	4.00	4.75	5.50	7.0	
		Week 16	Tezepelumab	87	82 (94.3)	5.11 (1.19)	1.0	4.50	5.00	5.75	7.0	
			Placebo	94	85 (90.4)	4.74 (1.19)	1.3	4.00	4.75	5.50	7.0	
		Week 20	Tezepelumab	87	83 (95.4)	5.03 (1.25)	1.0	4.25	5.00	6.00	7.0	
			Placebo	94	85 (90.4)	4.80 (1.18)	1.5	4.00	4.75	5.50	7.0	
		Week 24	Tezepelumab	87	83 (95.4)	5.21 (1.20)	1.0	4.50	5.00	6.25	7.0	
			Placebo	94	85 (90.4)	4.79 (1.23)	1.0	4.00	4.75	5.50	7.0	
		Week 28	Tezepelumab	87	84 (96.6)	5.15 (1.29)	1.0	4.38	5.00	6.00	7.0	
			Placebo	94	85 (90.4)	4.84 (1.32)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	87	84 (96.6)	5.19 (1.31)	1.0	4.50	5.25	6.00	7.0	
			Placebo	94	86 (91.5)	4.88 (1.33)	1.3	4.00	4.88	6.00	7.0	
		Week 36	Tezepelumab	87	84 (96.6)	5.24 (1.26)	1.0	4.50	5.50	6.13	7.0	
			Placebo	94	86 (91.5)	4.85 (1.30)	1.0	4.00	5.00	5.75	7.0	
		Week 40	Tezepelumab	87	84 (96.6)	5.29 (1.19)	2.0	4.50	5.38	6.25	7.0	
			Placebo	94	86 (91.5)	4.93 (1.29)	1.0	4.00	5.00	5.75	7.0	
		Week 44	Tezepelumab	87	84 (96.6)	5.31 (1.20)	1.3	4.50	5.25	6.25	7.0	
			Placebo	94	86 (91.5)	4.89 (1.27)	1.3	4.00	4.75	5.75	7.0	
		Week 48	Tezepelumab	87	84 (96.6)	5.26 (1.23)	1.0	4.50	5.38	6.25	7.0	
			Placebo	94	87 (92.6)	4.89 (1.22)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	87	84 (96.6)	5.24 (1.31)	1.0	4.50	5.38	6.25	7.0	
			Placebo	94	87 (92.6)	4.78 (1.31)	1.0	4.00	5.00	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	87	76 (87.4)	0.73 (1.20)	-4.0	0.00	0.50	1.50	4.0	0.28 [-0.03, 0.60]
			Placebo	94	79 (84.0)	0.43 (0.96)	-2.5	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	87	78 (89.7)	0.88 (1.16)	-1.3	0.00	0.75	1.75	4.3	0.25 [-0.07, 0.56]
			Placebo	94	79 (84.0)	0.61 (1.06)	-1.5	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	87	78 (89.7)	1.12 (1.17)	-2.3	0.25	1.00	2.00	4.8	0.46 [0.14, 0.78]
			Placebo	94	79 (84.0)	0.61 (1.03)	-1.3	0.00	0.50	1.25	3.0	
		Week 16	Tezepelumab	87	78 (89.7)	0.99 (1.19)	-2.8	0.00	0.88	1.75	3.3	0.33 [0.01, 0.64]
			Placebo	94	79 (84.0)	0.63 (1.00)	-1.3	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	87	78 (89.7)	0.93 (1.21)	-1.8	0.00	0.75	1.75	3.3	0.18 [-0.13, 0.50]
			Placebo	94	79 (84.0)	0.72 (1.04)	-1.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	87	78 (89.7)	1.10 (1.16)	-1.5	0.25	1.00	2.00	3.5	0.33 [0.01, 0.64]
			Placebo	94	79 (84.0)	0.73 (1.09)	-1.5	-0.25	0.50	1.50	3.8	
		Week 28	Tezepelumab	87	78 (89.7)	1.03 (1.16)	-1.5	0.25	1.00	2.00	3.3	0.22 [-0.09, 0.54]
			Placebo	94	79 (84.0)	0.77 (1.12)	-2.8	0.00	0.75	1.25	3.8	
		Week 32	Tezepelumab	87	78 (89.7)	1.07 (1.21)	-1.3	0.00	1.13	2.00	3.5	0.18 [-0.13, 0.49]
			Placebo	94	79 (84.0)	0.86 (1.09)	-1.5	0.00	0.75	1.75	3.8	
		Week 36	Tezepelumab	87	78 (89.7)	1.14 (1.22)	-1.3	0.25	1.25	2.00	3.5	0.28 [-0.03, 0.60]
			Placebo	94	79 (84.0)	0.80 (1.22)	-2.3	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	87	78 (89.7)	1.19 (1.17)	-1.3	0.25	1.25	2.25	3.3	0.27 [-0.05, 0.58]
			Placebo	94	79 (84.0)	0.87 (1.19)	-1.5	0.25	0.75	1.50	4.3	
		Week 44	Tezepelumab	87	78 (89.7)	1.21 (1.20)	-1.5	0.50	1.25	2.00	3.8	0.32 [0.00, 0.63]
			Placebo	94	79 (84.0)	0.83 (1.23)	-1.5	0.00	0.50	1.50	3.8	
		Week 48	Tezepelumab	87	78 (89.7)	1.17 (1.21)	-1.3	0.25	1.13	2.00	3.8	0.27 [-0.04, 0.59]
			Placebo	94	79 (84.0)	0.83 (1.25)	-1.5	0.00	0.75	1.25	4.0	
		Week 52	Tezepelumab	87	78 (89.7)	1.14 (1.21)	-1.3	0.25	1.13	2.00	3.8	0.35 [0.04, 0.67]
			Placebo	94	79 (84.0)	0.71 (1.27)	-2.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	114	103 (90.4)	4.24 (1.15)	1.0	3.50	4.25	5.00	7.0	
			Placebo	118	105 (89.0)	4.12 (1.20)	1.5	3.25	4.00	5.00	7.0	
		Week 4	Tezepelumab	114	106 (93.0)	4.91 (1.20)	1.3	4.00	5.00	5.75	7.0	
			Placebo	118	106 (89.8)	4.63 (1.21)	1.3	4.00	4.75	5.50	7.0	
		Week 8	Tezepelumab	114	108 (94.7)	5.13 (1.20)	1.0	4.38	5.13	6.00	7.0	
			Placebo	118	109 (92.4)	4.74 (1.29)	1.0	4.00	4.75	5.75	7.0	
		Week 12	Tezepelumab	114	108 (94.7)	5.28 (1.22)	1.0	4.50	5.38	6.25	7.0	
			Placebo	118	110 (93.2)	4.86 (1.20)	1.3	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	114	108 (94.7)	5.22 (1.18)	1.0	4.50	5.25	6.00	7.0	
			Placebo	118	110 (93.2)	4.83 (1.28)	1.3	4.00	5.00	5.75	7.0	
		Week 20	Tezepelumab	114	108 (94.7)	5.22 (1.24)	1.0	4.50	5.13	6.25	7.0	
			Placebo	118	110 (93.2)	4.85 (1.27)	1.3	4.00	4.88	5.75	7.0	
		Week 24	Tezepelumab	114	108 (94.7)	5.28 (1.21)	1.0	4.25	5.00	6.25	7.0	
			Placebo	118	110 (93.2)	4.79 (1.35)	1.3	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	114	110 (96.5)	5.22 (1.26)	1.0	4.50	5.13	6.25	7.0	
			Placebo	118	110 (93.2)	4.91 (1.39)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	114	111 (97.4)	5.34 (1.30)	1.0	4.50	5.50	6.25	7.0	
			Placebo	118	111 (94.1)	4.98 (1.31)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	114	111 (97.4)	5.34 (1.27)	1.0	4.50	5.25	6.50	7.0	
			Placebo	118	111 (94.1)	4.92 (1.34)	1.5	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	114	111 (97.4)	5.39 (1.19)	2.0	4.50	5.50	6.50	7.0	
			Placebo	118	111 (94.1)	5.00 (1.32)	1.5	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	114	111 (97.4)	5.39 (1.21)	1.3	4.50	5.25	6.50	7.0	
			Placebo	118	111 (94.1)	4.95 (1.30)	1.8	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	114	111 (97.4)	5.35 (1.22)	1.0	4.50	5.50	6.25	7.0	
			Placebo	118	112 (94.9)	4.97 (1.30)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	114	111 (97.4)	5.32 (1.28)	1.0	4.50	5.50	6.50	7.0	
			Placebo	118	112 (94.9)	4.92 (1.29)	1.5	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	114	99 (86.8)	0.68 (1.16)	-4.0	0.00	0.50	1.25	4.0	0.17 [-0.10, 0.45]
			Placebo	118	103 (87.3)	0.50 (1.01)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	114	101 (88.6)	0.88 (1.16)	-1.5	0.00	0.75	1.75	4.3	0.21 [-0.06, 0.49]
			Placebo	118	104 (88.1)	0.64 (1.05)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	114	101 (88.6)	1.04 (1.15)	-2.3	0.25	0.75	1.75	4.8	0.24 [-0.04, 0.51]
			Placebo	118	104 (88.1)	0.77 (1.11)	-1.8	0.00	0.75	1.25	4.3	
		Week 16	Tezepelumab	114	101 (88.6)	0.99 (1.19)	-2.8	0.25	0.75	1.75	3.5	0.23 [-0.05, 0.50]
			Placebo	118	104 (88.1)	0.73 (1.09)	-1.8	0.00	0.63	1.38	3.0	
		Week 20	Tezepelumab	114	101 (88.6)	0.99 (1.19)	-1.8	0.25	0.75	1.75	3.5	0.21 [-0.06, 0.48]
			Placebo	118	104 (88.1)	0.75 (1.07)	-2.3	0.00	0.75	1.50	3.0	
		Week 24	Tezepelumab	114	101 (88.6)	1.06 (1.18)	-1.5	0.25	1.00	2.00	3.5	0.29 [0.02, 0.57]
			Placebo	118	104 (88.1)	0.72 (1.15)	-2.8	0.00	0.75	1.50	3.8	
		Week 28	Tezepelumab	114	101 (88.6)	1.00 (1.18)	-1.5	0.00	0.75	1.75	3.5	0.15 [-0.13, 0.42]
			Placebo	118	104 (88.1)	0.83 (1.19)	-2.8	0.00	0.88	1.50	4.0	
		Week 32	Tezepelumab	114	101 (88.6)	1.11 (1.21)	-1.3	0.25	1.00	2.00	3.5	0.14 [-0.13, 0.42]
			Placebo	118	104 (88.1)	0.95 (1.11)	-1.8	0.13	1.00	1.75	3.8	
		Week 36	Tezepelumab	114	101 (88.6)	1.12 (1.26)	-1.3	0.25	1.00	2.25	3.5	0.20 [-0.07, 0.48]
			Placebo	118	104 (88.1)	0.86 (1.25)	-2.8	0.00	0.63	1.50	3.8	
		Week 40	Tezepelumab	114	101 (88.6)	1.16 (1.18)	-1.3	0.25	1.00	2.00	3.5	0.19 [-0.09, 0.46]
			Placebo	118	104 (88.1)	0.93 (1.21)	-2.5	0.25	0.75	1.75	4.3	
		Week 44	Tezepelumab	114	101 (88.6)	1.17 (1.21)	-1.5	0.25	1.00	2.00	3.8	0.24 [-0.03, 0.51]
			Placebo	118	104 (88.1)	0.88 (1.23)	-1.5	0.00	0.75	1.63	3.8	
		Week 48	Tezepelumab	114	101 (88.6)	1.13 (1.23)	-1.3	0.25	1.00	2.00	3.8	0.19 [-0.08, 0.47]
			Placebo	118	104 (88.1)	0.90 (1.23)	-2.8	0.13	0.75	1.50	3.8	
		Week 52	Tezepelumab	114	101 (88.6)	1.08 (1.24)	-1.5	0.25	1.00	2.00	3.8	0.19 [-0.08, 0.47]
			Placebo	118	104 (88.1)	0.85 (1.18)	-1.3	0.00	0.63	1.38	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	4.18 (1.19)	1.0	3.88	4.13	5.00	6.0	
			Placebo	20	16 (80.0)	3.84 (1.23)	1.5	3.38	3.88	5.00	5.8	
		Week 4	Tezepelumab	23	20 (87.0)	4.85 (1.24)	1.0	4.25	4.75	5.75	6.8	
			Placebo	20	17 (85.0)	4.35 (1.20)	2.3	3.50	4.75	5.50	5.8	
		Week 8	Tezepelumab	23	20 (87.0)	4.93 (1.26)	1.0	4.25	5.00	5.75	7.0	
			Placebo	20	17 (85.0)	4.46 (1.48)	1.5	3.50	4.75	5.50	6.5	
		Week 12	Tezepelumab	23	20 (87.0)	5.00 (1.25)	1.0	4.38	5.25	5.63	7.0	
			Placebo	20	17 (85.0)	4.12 (0.91)	2.3	3.75	4.00	4.50	5.8	
		Week 16	Tezepelumab	23	20 (87.0)	4.95 (1.30)	1.0	4.50	4.88	5.75	7.0	
			Placebo	20	17 (85.0)	4.25 (1.20)	1.5	4.00	4.25	5.00	6.3	
		Week 20	Tezepelumab	23	21 (91.3)	4.83 (1.28)	1.0	4.25	4.75	5.75	7.0	
			Placebo	20	17 (85.0)	4.32 (1.29)	1.5	3.75	4.50	5.00	6.5	
		Week 24	Tezepelumab	23	21 (91.3)	5.13 (1.25)	1.0	4.75	5.25	5.75	7.0	
			Placebo	20	17 (85.0)	4.26 (1.35)	1.0	3.75	4.25	5.25	6.8	
		Week 28	Tezepelumab	23	21 (91.3)	5.13 (1.29)	1.0	4.50	5.00	5.75	7.0	
			Placebo	20	18 (90.0)	4.35 (1.27)	1.8	3.75	4.38	5.00	6.5	
		Week 32	Tezepelumab	23	21 (91.3)	5.04 (0.94)	2.5	4.75	5.00	5.75	7.0	
			Placebo	20	18 (90.0)	4.35 (1.48)	1.3	3.75	4.25	5.00	7.0	
		Week 36	Tezepelumab	23	21 (91.3)	5.01 (1.18)	1.0	4.50	5.00	5.75	6.5	
			Placebo	20	18 (90.0)	4.36 (1.58)	1.0	3.75	4.25	5.25	6.8	
		Week 40	Tezepelumab	23	21 (91.3)	5.01 (1.23)	1.3	4.25	5.00	6.00	7.0	
			Placebo	20	18 (90.0)	4.35 (1.49)	1.0	4.00	4.50	5.25	6.8	
		Week 44	Tezepelumab	23	21 (91.3)	5.20 (1.33)	1.0	4.75	5.25	6.00	7.0	
			Placebo	20	18 (90.0)	4.39 (1.51)	1.3	3.50	4.13	5.25	6.8	
		Week 48	Tezepelumab	23	21 (91.3)	5.31 (1.20)	2.0	4.50	5.25	6.25	7.0	
			Placebo	20	18 (90.0)	4.60 (1.31)	2.0	4.00	4.38	6.00	6.5	
		Week 52	Tezepelumab	23	21 (91.3)	5.26 (1.17)	2.0	4.50	5.25	6.25	7.0	
			Placebo	20	18 (90.0)	4.35 (1.52)	1.0	4.00	4.38	5.25	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	23	18 (78.3)	0.75 (1.16)	-2.3	0.00	0.75	1.25	2.5	0.20 [-0.48, 0.87]
			Placebo	20	16 (80.0)	0.56 (0.64)	-0.5	0.13	0.50	0.75	2.0	
		Week 8	Tezepelumab	23	18 (78.3)	0.82 (1.07)	-1.5	0.00	0.88	1.50	2.5	0.14 [-0.54, 0.81]
			Placebo	20	16 (80.0)	0.67 (1.06)	-1.5	-0.13	0.88	1.38	3.0	
		Week 12	Tezepelumab	23	18 (78.3)	0.89 (1.17)	-2.0	0.00	1.13	1.50	2.5	0.61 [-0.08, 1.30]
			Placebo	20	16 (80.0)	0.30 (0.65)	-1.0	0.00	0.50	0.63	1.8	
		Week 16	Tezepelumab	23	18 (78.3)	0.85 (1.18)	-1.5	0.00	0.88	1.50	3.3	0.44 [-0.24, 1.12]
			Placebo	20	16 (80.0)	0.42 (0.65)	-0.5	0.00	0.38	0.88	1.8	
		Week 20	Tezepelumab	23	18 (78.3)	0.69 (1.07)	-1.0	0.00	0.75	1.25	2.5	0.18 [-0.50, 0.85]
			Placebo	20	16 (80.0)	0.53 (0.73)	-0.5	0.00	0.50	0.88	2.5	
		Week 24	Tezepelumab	23	18 (78.3)	1.00 (1.05)	-1.0	0.25	1.00	2.00	2.5	0.57 [-0.12, 1.26]
			Placebo	20	16 (80.0)	0.42 (0.98)	-0.5	-0.25	0.13	0.88	3.3	
		Week 28	Tezepelumab	23	18 (78.3)	1.06 (1.10)	-1.5	0.25	1.00	1.50	3.0	0.69 [-0.00, 1.38]
			Placebo	20	16 (80.0)	0.39 (0.79)	-0.8	0.00	0.25	0.75	2.8	
		Week 32	Tezepelumab	23	18 (78.3)	0.90 (1.00)	-1.3	0.50	1.00	1.50	2.5	0.63 [-0.06, 1.33]
			Placebo	20	16 (80.0)	0.33 (0.78)	-1.0	-0.13	0.25	0.63	2.0	
		Week 36	Tezepelumab	23	18 (78.3)	0.92 (1.03)	-1.8	0.50	1.25	1.50	2.3	0.50 [-0.18, 1.18]
			Placebo	20	16 (80.0)	0.41 (1.02)	-1.3	-0.25	0.25	0.75	3.3	
		Week 40	Tezepelumab	23	18 (78.3)	0.99 (1.06)	-1.5	0.25	1.13	1.50	2.8	0.55 [-0.14, 1.23]
			Placebo	20	16 (80.0)	0.38 (1.18)	-1.0	-0.25	0.25	0.63	4.3	
		Week 44	Tezepelumab	23	18 (78.3)	1.08 (1.09)	-1.5	0.00	1.25	1.50	2.8	0.71 [0.02, 1.41]
			Placebo	20	16 (80.0)	0.34 (0.97)	-1.3	-0.13	0.25	0.75	3.3	
		Week 48	Tezepelumab	23	18 (78.3)	1.26 (1.15)	-1.8	1.00	1.25	2.00	3.0	0.55 [-0.14, 1.24]
			Placebo	20	16 (80.0)	0.63 (1.19)	-0.8	0.00	0.38	0.75	4.0	
		Week 52	Tezepelumab	23	18 (78.3)	1.17 (1.09)	-1.8	1.00	1.38	1.50	3.0	0.71 [0.01, 1.41]
			Placebo	20	16 (80.0)	0.33 (1.27)	-2.3	-0.38	0.25	0.75	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	105	94 (89.5)	4.24 (1.13)	1.0	3.50	4.25	5.00	7.0	
			Placebo	110	98 (89.1)	4.03 (1.21)	1.5	3.25	4.00	5.00	7.0	
		Week 4	Tezepelumab	105	96 (91.4)	4.93 (1.15)	1.0	4.13	5.00	5.75	7.0	
			Placebo	110	100 (90.9)	4.56 (1.29)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	105	97 (92.4)	5.06 (1.22)	1.0	4.25	5.00	5.75	7.0	
			Placebo	110	102 (92.7)	4.66 (1.37)	1.0	3.75	4.75	5.75	7.0	
		Week 12	Tezepelumab	105	97 (92.4)	5.20 (1.20)	1.0	4.50	5.25	6.25	7.0	
			Placebo	110	103 (93.6)	4.70 (1.26)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	105	97 (92.4)	5.15 (1.21)	1.0	4.50	5.00	6.00	7.0	
			Placebo	110	103 (93.6)	4.76 (1.30)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	105	98 (93.3)	5.13 (1.27)	1.0	4.50	5.00	6.25	7.0	
			Placebo	110	103 (93.6)	4.79 (1.28)	1.5	4.00	4.75	5.75	7.0	
		Week 24	Tezepelumab	105	98 (93.3)	5.20 (1.27)	1.0	4.25	5.00	6.25	7.0	
			Placebo	110	103 (93.6)	4.75 (1.37)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	105	99 (94.3)	5.16 (1.28)	1.0	4.25	5.00	6.25	7.0	
			Placebo	110	104 (94.5)	4.88 (1.36)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	105	100 (95.2)	5.25 (1.26)	1.0	4.50	5.25	6.13	7.0	
			Placebo	110	104 (94.5)	4.90 (1.37)	1.3	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	105	100 (95.2)	5.27 (1.29)	1.0	4.50	5.00	6.25	7.0	
			Placebo	110	104 (94.5)	4.89 (1.43)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	105	100 (95.2)	5.30 (1.23)	1.3	4.50	5.25	6.25	7.0	
			Placebo	110	104 (94.5)	4.90 (1.43)	1.0	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	105	100 (95.2)	5.31 (1.28)	1.0	4.50	5.25	6.38	7.0	
			Placebo	110	104 (94.5)	4.85 (1.42)	1.3	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	105	100 (95.2)	5.32 (1.28)	1.0	4.50	5.25	6.25	7.0	
			Placebo	110	105 (95.5)	4.94 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	105	100 (95.2)	5.31 (1.27)	1.0	4.50	5.38	6.38	7.0	
			Placebo	110	105 (95.5)	4.83 (1.41)	1.0	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	105	89 (84.8)	0.71 (1.09)	-2.3	0.00	0.75	1.25	4.0	0.15 [-0.13, 0.44]
			Placebo	110	98 (89.1)	0.55 (0.97)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	105	90 (85.7)	0.83 (1.12)	-1.5	0.00	0.75	1.75	4.3	0.16 [-0.13, 0.44]
			Placebo	110	98 (89.1)	0.67 (1.03)	-1.8	0.00	0.63	1.25	3.0	
		Week 12	Tezepelumab	105	90 (85.7)	0.99 (1.14)	-2.0	0.25	0.75	1.75	4.8	0.25 [-0.04, 0.54]
			Placebo	110	98 (89.1)	0.71 (1.08)	-1.8	0.00	0.63	1.25	4.3	
		Week 16	Tezepelumab	105	90 (85.7)	0.95 (1.09)	-1.5	0.00	0.75	1.50	3.5	0.18 [-0.10, 0.47]
			Placebo	110	98 (89.1)	0.76 (0.97)	-1.5	0.00	0.75	1.25	3.0	
		Week 20	Tezepelumab	105	90 (85.7)	0.94 (1.15)	-1.8	0.00	0.75	1.75	3.3	0.13 [-0.15, 0.42]
			Placebo	110	98 (89.1)	0.80 (0.95)	-1.3	0.00	0.75	1.25	3.0	
		Week 24	Tezepelumab	105	90 (85.7)	1.00 (1.10)	-1.5	0.25	1.00	1.75	3.5	0.23 [-0.06, 0.52]
			Placebo	110	98 (89.1)	0.76 (1.02)	-1.0	0.00	0.75	1.50	3.3	
		Week 28	Tezepelumab	105	90 (85.7)	0.98 (1.13)	-1.5	0.25	0.75	1.75	3.5	0.10 [-0.18, 0.39]
			Placebo	110	98 (89.1)	0.87 (1.04)	-1.5	0.25	0.75	1.50	4.0	
		Week 32	Tezepelumab	105	90 (85.7)	1.06 (1.16)	-1.3	0.25	1.00	1.75	3.5	0.13 [-0.16, 0.42]
			Placebo	110	98 (89.1)	0.91 (1.06)	-1.3	0.00	0.75	1.75	3.5	
		Week 36	Tezepelumab	105	90 (85.7)	1.08 (1.23)	-1.8	0.25	1.00	2.00	3.5	0.16 [-0.13, 0.44]
			Placebo	110	98 (89.1)	0.89 (1.15)	-2.0	0.00	0.63	1.50	3.8	
		Week 40	Tezepelumab	105	90 (85.7)	1.11 (1.13)	-1.5	0.25	1.00	2.00	3.5	0.20 [-0.09, 0.49]
			Placebo	110	98 (89.1)	0.89 (1.16)	-1.8	0.00	0.75	1.50	4.3	
		Week 44	Tezepelumab	105	90 (85.7)	1.11 (1.17)	-1.5	0.25	1.00	2.00	3.8	0.23 [-0.06, 0.51]
			Placebo	110	98 (89.1)	0.85 (1.15)	-1.5	0.00	0.63	1.50	3.5	
		Week 48	Tezepelumab	105	90 (85.7)	1.13 (1.18)	-1.8	0.50	1.00	2.00	3.8	0.17 [-0.12, 0.45]
			Placebo	110	98 (89.1)	0.93 (1.12)	-1.5	0.25	0.75	1.50	4.0	
		Week 52	Tezepelumab	105	90 (85.7)	1.10 (1.17)	-1.8	0.50	1.00	2.00	3.8	0.26 [-0.03, 0.55]
			Placebo	110	98 (89.1)	0.81 (1.13)	-2.3	0.00	0.50	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	32	29 (90.6)	4.20 (1.22)	1.0	3.50	4.25	5.25	6.5	
			Placebo	28	23 (82.1)	4.35 (1.19)	2.3	3.25	4.50	5.25	6.5	
		Week 4	Tezepelumab	32	30 (93.8)	4.83 (1.39)	1.3	4.00	5.25	5.75	7.0	
			Placebo	28	23 (82.1)	4.75 (0.75)	3.5	4.00	4.75	5.25	6.0	
		Week 8	Tezepelumab	32	31 (96.9)	5.19 (1.15)	1.0	4.75	5.25	5.75	7.0	
			Placebo	28	24 (85.7)	4.89 (1.03)	2.8	4.25	5.00	5.63	6.5	
		Week 12	Tezepelumab	32	31 (96.9)	5.34 (1.29)	1.3	4.75	5.50	6.25	7.0	
			Placebo	28	24 (85.7)	5.02 (0.77)	3.3	4.50	5.25	5.50	6.3	
		Week 16	Tezepelumab	32	31 (96.9)	5.26 (1.16)	2.5	4.50	5.25	6.00	7.0	
			Placebo	28	24 (85.7)	4.73 (1.18)	1.3	4.00	5.00	5.38	6.5	
		Week 20	Tezepelumab	32	31 (96.9)	5.22 (1.20)	1.8	4.50	5.50	6.00	7.0	
			Placebo	28	24 (85.7)	4.73 (1.30)	1.3	3.88	5.00	5.25	7.0	
		Week 24	Tezepelumab	32	31 (96.9)	5.43 (0.99)	3.8	4.75	5.50	6.25	7.0	
			Placebo	28	24 (85.7)	4.63 (1.32)	1.3	4.25	4.75	5.25	7.0	
		Week 28	Tezepelumab	32	32 (100.0)	5.37 (1.23)	1.0	4.63	5.75	6.00	7.0	
			Placebo	28	24 (85.7)	4.61 (1.47)	1.3	3.75	4.75	5.63	7.0	
		Week 32	Tezepelumab	32	32 (100.0)	5.41 (1.26)	1.0	4.50	5.75	6.00	7.0	
			Placebo	28	25 (89.3)	4.85 (1.25)	1.3	4.50	4.75	5.50	7.0	
		Week 36	Tezepelumab	32	32 (100.0)	5.37 (1.18)	1.3	4.63	5.50	6.25	7.0	
			Placebo	28	25 (89.3)	4.64 (1.15)	2.0	4.00	4.75	5.25	7.0	
		Week 40	Tezepelumab	32	32 (100.0)	5.44 (1.13)	2.3	4.50	5.75	6.38	7.0	
			Placebo	28	25 (89.3)	4.95 (1.01)	2.3	4.50	5.00	5.50	7.0	
		Week 44	Tezepelumab	32	32 (100.0)	5.53 (1.05)	2.8	4.75	5.75	6.38	7.0	
			Placebo	28	25 (89.3)	4.96 (0.94)	3.0	4.25	5.00	5.50	7.0	
		Week 48	Tezepelumab	32	32 (100.0)	5.44 (1.02)	3.5	4.50	5.75	6.25	7.0	
			Placebo	28	25 (89.3)	4.83 (1.07)	2.0	4.50	5.00	5.25	7.0	
		Week 52	Tezepelumab	32	32 (100.0)	5.30 (1.24)	1.0	4.50	5.75	6.13	7.0	
			Placebo	28	25 (89.3)	4.90 (0.99)	3.0	4.25	4.75	5.25	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	32	28 (87.5)	0.65 (1.35)	-4.0	0.00	0.50	1.25	2.8	0.29 [-0.28, 0.86]
			Placebo	28	21 (75.0)	0.31 (0.94)	-1.3	-0.25	0.25	0.75	2.5	
		Week 8	Tezepelumab	32	29 (90.6)	0.99 (1.22)	-1.5	0.00	0.75	1.75	3.5	0.35 [-0.21, 0.91]
			Placebo	28	22 (78.6)	0.57 (1.16)	-1.3	0.00	0.38	1.25	3.3	
		Week 12	Tezepelumab	32	29 (90.6)	1.09 (1.21)	-2.3	0.25	1.00	2.00	3.5	0.37 [-0.19, 0.93]
			Placebo	28	22 (78.6)	0.67 (1.03)	-1.3	0.00	0.75	1.25	2.5	
		Week 16	Tezepelumab	32	29 (90.6)	1.02 (1.46)	-2.8	0.25	1.00	2.00	3.3	0.48 [-0.08, 1.04]
			Placebo	28	22 (78.6)	0.35 (1.30)	-1.8	-1.00	0.38	1.00	3.0	
		Week 20	Tezepelumab	32	29 (90.6)	0.98 (1.28)	-1.3	0.00	1.00	1.75	3.5	0.44 [-0.12, 1.00]
			Placebo	28	22 (78.6)	0.41 (1.33)	-2.3	-0.75	0.50	1.50	2.3	
		Week 24	Tezepelumab	32	29 (90.6)	1.20 (1.30)	-1.3	0.25	1.25	2.00	3.5	0.62 [0.05, 1.19]
			Placebo	28	22 (78.6)	0.34 (1.49)	-2.8	-0.75	0.50	1.00	3.8	
		Week 28	Tezepelumab	32	29 (90.6)	1.11 (1.26)	-1.5	0.25	1.00	2.00	3.5	0.58 [0.01, 1.14]
			Placebo	28	22 (78.6)	0.33 (1.48)	-2.8	-0.75	0.38	1.25	3.8	
		Week 32	Tezepelumab	32	29 (90.6)	1.16 (1.25)	-1.3	0.25	1.00	2.00	3.5	0.39 [-0.17, 0.95]
			Placebo	28	22 (78.6)	0.67 (1.25)	-1.8	0.00	0.88	1.00	3.8	
		Week 36	Tezepelumab	32	29 (90.6)	1.13 (1.22)	-1.3	0.25	1.00	2.00	3.5	0.53 [-0.03, 1.10]
			Placebo	28	22 (78.6)	0.41 (1.51)	-2.8	-0.25	0.50	1.00	3.8	
		Week 40	Tezepelumab	32	29 (90.6)	1.18 (1.27)	-1.3	0.25	1.00	2.00	3.5	0.33 [-0.22, 0.89]
			Placebo	28	22 (78.6)	0.73 (1.47)	-2.5	0.00	0.75	1.75	3.8	
		Week 44	Tezepelumab	32	29 (90.6)	1.32 (1.27)	-1.3	0.50	1.25	2.25	3.8	0.51 [-0.06, 1.07]
			Placebo	28	22 (78.6)	0.64 (1.46)	-1.3	-0.75	0.63	1.25	3.8	
		Week 48	Tezepelumab	32	29 (90.6)	1.23 (1.33)	-1.3	0.25	1.25	2.25	3.5	0.48 [-0.08, 1.04]
			Placebo	28	22 (78.6)	0.53 (1.60)	-2.8	-0.75	0.38	1.25	3.8	
		Week 52	Tezepelumab	32	29 (90.6)	1.08 (1.38)	-1.5	0.00	1.00	2.00	3.5	0.29 [-0.26, 0.85]
			Placebo	28	22 (78.6)	0.66 (1.49)	-1.3	-0.25	0.25	1.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.24 (1.13)	1.0	3.50	4.25	5.00	7.0	
			Placebo	123	106 (86.2)	4.08 (1.24)	1.5	3.25	4.00	5.00	7.0	
		Week 4	Tezepelumab	128	117 (91.4)	4.85 (1.21)	1.0	4.00	5.00	5.75	7.0	
			Placebo	123	109 (88.6)	4.59 (1.23)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	128	119 (93.0)	5.05 (1.23)	1.0	4.25	5.00	5.75	7.0	
			Placebo	123	112 (91.1)	4.67 (1.33)	1.0	3.88	4.75	5.75	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.19 (1.24)	1.0	4.50	5.25	6.25	7.0	
			Placebo	123	113 (91.9)	4.71 (1.22)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.16 (1.22)	1.0	4.50	5.00	6.00	7.0	
			Placebo	123	113 (91.9)	4.73 (1.31)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.13 (1.27)	1.0	4.38	5.00	6.00	7.0	
			Placebo	123	113 (91.9)	4.72 (1.30)	1.3	4.00	4.75	5.75	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.22 (1.23)	1.0	4.38	5.00	6.25	7.0	
			Placebo	123	113 (91.9)	4.67 (1.40)	1.0	4.00	4.50	5.75	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.16 (1.28)	1.0	4.50	5.00	6.25	7.0	
			Placebo	123	114 (92.7)	4.75 (1.39)	1.3	4.00	4.75	6.00	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.25 (1.27)	1.0	4.50	5.25	6.00	7.0	
			Placebo	123	115 (93.5)	4.82 (1.38)	1.3	4.00	4.75	6.00	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.25 (1.28)	1.0	4.50	5.25	6.25	7.0	
			Placebo	123	115 (93.5)	4.77 (1.42)	1.0	4.00	4.75	6.00	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.27 (1.21)	1.3	4.50	5.25	6.25	7.0	
			Placebo	123	115 (93.5)	4.85 (1.38)	1.0	4.00	5.00	5.75	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.30 (1.23)	1.0	4.50	5.25	6.25	7.0	
			Placebo	123	115 (93.5)	4.82 (1.35)	1.3	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.30 (1.23)	1.0	4.50	5.25	6.25	7.0	
			Placebo	123	116 (94.3)	4.86 (1.33)	1.0	4.00	4.88	6.00	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.26 (1.27)	1.0	4.50	5.25	6.25	7.0	
			Placebo	123	116 (94.3)	4.80 (1.35)	1.0	4.00	4.75	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.63 (1.13)	-4.0	0.00	0.50	1.25	3.3	0.11 [-0.16, 0.38]
			Placebo	123	105 (85.4)	0.51 (0.97)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	128	111 (86.7)	0.82 (1.11)	-1.5	0.00	0.75	1.75	3.5	0.17 [-0.09, 0.44]
			Placebo	123	106 (86.2)	0.63 (1.04)	-1.8	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	128	111 (86.7)	0.96 (1.11)	-2.3	0.25	1.00	1.75	3.5	0.26 [-0.01, 0.53]
			Placebo	123	106 (86.2)	0.68 (1.09)	-1.8	0.00	0.50	1.25	4.3	
		Week 16	Tezepelumab	128	111 (86.7)	0.93 (1.17)	-2.8	0.00	0.75	1.50	3.5	0.23 [-0.04, 0.49]
			Placebo	123	106 (86.2)	0.68 (1.04)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	128	111 (86.7)	0.92 (1.16)	-1.8	0.00	0.75	1.75	3.5	0.21 [-0.05, 0.48]
			Placebo	123	106 (86.2)	0.69 (1.02)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	128	111 (86.7)	1.01 (1.14)	-1.5	0.25	1.00	2.00	3.5	0.33 [0.06, 0.60]
			Placebo	123	106 (86.2)	0.64 (1.11)	-2.8	-0.25	0.50	1.50	3.3	
		Week 28	Tezepelumab	128	111 (86.7)	0.95 (1.14)	-1.5	0.25	0.75	1.75	3.5	0.22 [-0.05, 0.49]
			Placebo	123	106 (86.2)	0.70 (1.13)	-2.8	0.00	0.75	1.25	4.0	
		Week 32	Tezepelumab	128	111 (86.7)	1.04 (1.18)	-1.3	0.00	1.00	1.75	3.5	0.21 [-0.06, 0.47]
			Placebo	123	106 (86.2)	0.80 (1.08)	-1.8	0.00	0.75	1.50	3.5	
		Week 36	Tezepelumab	128	111 (86.7)	1.05 (1.21)	-1.8	0.25	1.00	2.00	3.5	0.25 [-0.02, 0.52]
			Placebo	123	106 (86.2)	0.75 (1.22)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	128	111 (86.7)	1.07 (1.14)	-1.5	0.25	1.00	2.00	3.5	0.22 [-0.05, 0.48]
			Placebo	123	106 (86.2)	0.81 (1.21)	-2.5	0.00	0.63	1.25	4.3	
		Week 44	Tezepelumab	128	111 (86.7)	1.09 (1.16)	-1.5	0.25	1.00	2.00	3.8	0.28 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.76 (1.16)	-1.5	0.00	0.50	1.25	3.5	
		Week 48	Tezepelumab	128	111 (86.7)	1.09 (1.17)	-1.8	0.25	1.00	2.00	3.5	0.24 [-0.03, 0.50]
			Placebo	123	106 (86.2)	0.81 (1.20)	-2.8	0.00	0.75	1.25	4.0	
		Week 52	Tezepelumab	128	111 (86.7)	1.04 (1.18)	-1.8	0.25	1.00	1.75	3.5	0.24 [-0.02, 0.51]
			Placebo	123	106 (86.2)	0.75 (1.15)	-2.3	0.00	0.50	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.67 (1.70)	1.8	1.75	4.25	5.00	5.0	
			Placebo	6	6 (100.0)	3.46 (0.49)	3.0	3.00	3.38	3.75	4.3	
		Week 4	Tezepelumab	3	3 (100.0)	5.83 (1.13)	4.8	4.75	5.75	7.00	7.0	
			Placebo	6	5 (83.3)	3.75 (1.17)	2.5	3.00	3.50	4.25	5.5	
		Week 8	Tezepelumab	3	3 (100.0)	5.92 (0.88)	5.0	5.00	6.00	6.75	6.8	
			Placebo	6	5 (83.3)	4.20 (1.34)	3.0	3.00	3.75	5.50	5.8	
		Week 12	Tezepelumab	3	3 (100.0)	6.00 (1.09)	4.8	4.75	6.50	6.75	6.8	
			Placebo	6	5 (83.3)	4.45 (0.60)	3.8	4.00	4.50	4.75	5.3	
		Week 16	Tezepelumab	3	3 (100.0)	4.92 (0.29)	4.8	4.75	4.75	5.25	5.3	
			Placebo	6	5 (83.3)	3.95 (0.76)	3.3	3.75	3.75	3.75	5.3	
		Week 20	Tezepelumab	3	3 (100.0)	5.25 (0.66)	4.8	4.75	5.00	6.00	6.0	
			Placebo	6	5 (83.3)	4.60 (0.93)	3.3	4.00	5.25	5.25	5.3	
		Week 24	Tezepelumab	3	3 (100.0)	5.75 (0.75)	5.0	5.00	5.75	6.50	6.5	
			Placebo	6	5 (83.3)	4.70 (0.72)	3.5	4.75	4.75	5.25	5.3	
		Week 28	Tezepelumab	3	3 (100.0)	5.92 (1.01)	5.0	5.00	5.75	7.00	7.0	
			Placebo	6	5 (83.3)	4.45 (0.91)	3.3	3.75	4.75	5.25	5.3	
		Week 32	Tezepelumab	3	3 (100.0)	5.67 (0.58)	5.0	5.00	6.00	6.00	6.0	
			Placebo	6	5 (83.3)	5.05 (0.41)	4.5	4.75	5.25	5.25	5.5	
		Week 36	Tezepelumab	3	3 (100.0)	5.42 (0.95)	4.8	4.75	5.00	6.50	6.5	
			Placebo	6	5 (83.3)	5.10 (0.70)	4.5	4.75	4.75	5.25	6.3	
		Week 40	Tezepelumab	3	3 (100.0)	6.08 (1.01)	5.0	5.00	6.25	7.00	7.0	
			Placebo	6	5 (83.3)	4.55 (0.69)	3.5	4.25	4.75	5.00	5.3	
		Week 44	Tezepelumab	3	3 (100.0)	6.00 (1.00)	5.0	5.00	6.00	7.00	7.0	
			Placebo	6	5 (83.3)	5.10 (1.14)	4.0	4.25	4.75	5.75	6.8	
		Week 48	Tezepelumab	3	3 (100.0)	5.92 (0.88)	5.0	5.00	6.00	6.75	6.8	
			Placebo	6	5 (83.3)	5.40 (1.02)	4.3	4.50	5.75	5.75	6.8	
		Week 52	Tezepelumab	3	3 (100.0)	5.92 (0.88)	5.0	5.00	6.00	6.75	6.8	
			Placebo	6	5 (83.3)	5.00 (1.69)	3.0	3.50	5.75	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	2.17 (1.76)	0.5	0.50	2.00	4.00	4.0	1.27 [-0.34, 2.87]
			Placebo	6	5 (83.3)	0.35 (1.24)	-0.8	0.00	0.00	0.00	2.5	
		Week 8	Tezepelumab	3	3 (100.0)	2.25 (1.80)	0.8	0.75	1.75	4.25	4.3	1.03 [-0.52, 2.57]
			Placebo	6	5 (83.3)	0.80 (1.16)	-0.3	0.00	0.25	1.50	2.5	
		Week 12	Tezepelumab	3	3 (100.0)	2.33 (2.18)	0.5	0.50	1.75	4.75	4.8	0.99 [-0.55, 2.53]
			Placebo	6	5 (83.3)	1.05 (0.37)	0.5	1.00	1.00	1.25	1.5	
		Week 16	Tezepelumab	3	3 (100.0)	1.25 (1.64)	-0.3	-0.25	1.00	3.00	3.0	0.71 [-0.77, 2.20]
			Placebo	6	5 (83.3)	0.55 (0.33)	0.3	0.25	0.50	0.75	1.0	
		Week 20	Tezepelumab	3	3 (100.0)	1.58 (1.76)	-0.3	-0.25	1.75	3.25	3.3	0.32 [-1.12, 1.76]
			Placebo	6	5 (83.3)	1.20 (0.80)	0.3	0.75	1.00	1.75	2.3	
		Week 24	Tezepelumab	3	3 (100.0)	2.08 (1.01)	1.5	1.50	1.50	3.25	3.3	1.07 [-0.48, 2.62]
			Placebo	6	5 (83.3)	1.30 (0.54)	0.5	1.00	1.50	1.75	1.8	
		Week 28	Tezepelumab	3	3 (100.0)	2.25 (0.90)	1.5	1.50	2.00	3.25	3.3	1.34 [-0.28, 2.96]
			Placebo	6	5 (83.3)	1.05 (0.89)	-0.3	0.75	1.00	1.75	2.0	
		Week 32	Tezepelumab	3	3 (100.0)	2.00 (1.15)	1.0	1.00	1.75	3.25	3.3	0.42 [-1.03, 1.87]
			Placebo	6	5 (83.3)	1.65 (0.63)	1.0	1.00	1.75	2.25	2.3	
		Week 36	Tezepelumab	3	3 (100.0)	1.75 (1.39)	0.5	0.50	1.50	3.25	3.3	0.05 [-1.38, 1.48]
			Placebo	6	5 (83.3)	1.70 (0.65)	1.0	1.50	1.50	1.75	2.8	
		Week 40	Tezepelumab	3	3 (100.0)	2.42 (0.72)	2.0	2.00	2.00	3.25	3.3	2.02 [0.19, 3.85]
			Placebo	6	5 (83.3)	1.15 (0.58)	0.5	0.75	1.00	1.75	1.8	
		Week 44	Tezepelumab	3	3 (100.0)	2.33 (0.80)	1.8	1.75	2.00	3.25	3.3	0.59 [-0.88, 2.06]
			Placebo	6	5 (83.3)	1.70 (1.19)	0.8	1.00	1.50	1.50	3.8	
		Week 48	Tezepelumab	3	3 (100.0)	2.25 (0.87)	1.8	1.75	1.75	3.25	3.3	0.24 [-1.20, 1.68]
			Placebo	6	5 (83.3)	2.00 (1.13)	1.0	1.25	1.50	2.50	3.8	
		Week 52	Tezepelumab	3	3 (100.0)	2.25 (0.87)	1.8	1.75	1.75	3.25	3.3	0.44 [-1.01, 1.89]
			Placebo	6	5 (83.3)	1.60 (1.71)	0.0	0.00	1.50	2.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	4.63 (1.27)	3.0	3.63	4.88	5.63	5.8	
			Placebo	6	6 (100.0)	4.58 (0.77)	3.8	3.75	4.63	5.25	5.5	
		Week 4	Tezepelumab	5	5 (100.0)	5.65 (0.84)	4.3	5.75	5.75	6.00	6.5	
			Placebo	6	6 (100.0)	5.17 (0.38)	4.8	4.75	5.25	5.50	5.5	
		Week 8	Tezepelumab	5	5 (100.0)	5.70 (0.37)	5.3	5.50	5.75	5.75	6.3	
			Placebo	6	6 (100.0)	5.25 (0.89)	3.8	5.00	5.38	5.50	6.5	
		Week 12	Tezepelumab	5	5 (100.0)	5.95 (0.60)	5.3	5.50	6.00	6.25	6.8	
			Placebo	6	6 (100.0)	5.58 (0.66)	4.8	5.25	5.38	6.25	6.5	
		Week 16	Tezepelumab	5	5 (100.0)	6.00 (0.61)	5.5	5.50	6.00	6.00	7.0	
			Placebo	6	6 (100.0)	5.63 (0.54)	5.0	5.25	5.50	6.25	6.3	
		Week 20	Tezepelumab	5	5 (100.0)	5.90 (0.76)	5.0	5.50	5.75	6.25	7.0	
			Placebo	6	6 (100.0)	5.50 (1.10)	4.0	5.00	5.25	6.50	7.0	
		Week 24	Tezepelumab	5	5 (100.0)	5.90 (0.68)	5.0	5.50	6.00	6.25	6.8	
			Placebo	6	6 (100.0)	5.33 (0.75)	4.3	4.75	5.38	6.00	6.3	
		Week 28	Tezepelumab	5	5 (100.0)	6.10 (0.52)	5.8	5.75	6.00	6.00	7.0	
			Placebo	6	6 (100.0)	6.13 (0.86)	5.0	5.25	6.25	7.00	7.0	
		Week 32	Tezepelumab	5	5 (100.0)	6.30 (0.67)	5.5	6.00	6.00	7.00	7.0	
			Placebo	6	6 (100.0)	5.83 (0.68)	5.0	5.25	5.88	6.25	6.8	
		Week 36	Tezepelumab	5	5 (100.0)	6.20 (0.78)	5.3	5.75	6.00	7.00	7.0	
			Placebo	6	6 (100.0)	5.58 (0.90)	4.3	5.25	5.50	6.00	7.0	
		Week 40	Tezepelumab	5	5 (100.0)	6.25 (0.68)	5.8	5.75	5.75	7.00	7.0	
			Placebo	6	6 (100.0)	5.88 (0.95)	5.0	5.00	5.63	7.00	7.0	
		Week 44	Tezepelumab	5	5 (100.0)	6.50 (0.59)	5.8	6.00	6.75	7.00	7.0	
			Placebo	6	6 (100.0)	5.50 (1.21)	4.0	4.50	5.38	6.75	7.0	
		Week 48	Tezepelumab	5	5 (100.0)	5.95 (0.82)	4.8	5.75	6.00	6.25	7.0	
			Placebo	6	6 (100.0)	5.21 (0.97)	4.3	4.50	5.13	5.25	7.0	
		Week 52	Tezepelumab	5	5 (100.0)	6.10 (0.95)	4.8	5.75	6.00	7.00	7.0	
			Placebo	6	6 (100.0)	5.00 (0.55)	4.3	4.50	5.13	5.25	5.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	1.00 (0.74)	0.0	0.50	1.13	1.50	1.8	0.50 [-0.78, 1.79]
			Placebo	6	6 (100.0)	0.58 (0.88)	-0.5	0.00	0.50	1.25	1.8	
		Week 8	Tezepelumab	5	4 (80.0)	1.06 (1.23)	0.0	0.00	1.00	2.13	2.3	0.41 [-0.87, 1.69]
			Placebo	6	6 (100.0)	0.67 (0.77)	0.0	0.00	0.50	1.25	1.8	
		Week 12	Tezepelumab	5	4 (80.0)	1.31 (1.25)	0.0	0.25	1.38	2.38	2.5	0.32 [-0.96, 1.59]
			Placebo	6	6 (100.0)	1.00 (0.79)	0.0	0.50	0.88	1.50	2.3	
		Week 16	Tezepelumab	5	4 (80.0)	1.38 (1.48)	-0.3	0.13	1.50	2.63	2.8	0.32 [-0.96, 1.59]
			Placebo	6	6 (100.0)	1.04 (0.66)	0.3	0.50	1.00	1.50	2.0	
		Week 20	Tezepelumab	5	4 (80.0)	1.19 (1.68)	-0.5	-0.25	1.25	2.63	2.8	0.19 [-1.08, 1.45]
			Placebo	6	6 (100.0)	0.92 (1.30)	-1.3	0.50	1.13	1.25	2.8	
		Week 24	Tezepelumab	5	4 (80.0)	1.19 (1.55)	-0.5	-0.13	1.38	2.50	2.5	0.36 [-0.92, 1.64]
			Placebo	6	6 (100.0)	0.75 (0.97)	-1.0	0.50	0.88	1.50	1.8	
		Week 28	Tezepelumab	5	4 (80.0)	1.50 (1.59)	0.0	0.13	1.50	2.88	3.0	-0.03 [-1.30, 1.23]
			Placebo	6	6 (100.0)	1.54 (0.87)	0.3	1.25	1.38	2.25	2.8	
		Week 32	Tezepelumab	5	4 (80.0)	1.50 (1.31)	0.3	0.38	1.50	2.63	2.8	0.27 [-1.00, 1.54]
			Placebo	6	6 (100.0)	1.25 (0.61)	0.3	1.00	1.25	1.75	2.0	
		Week 36	Tezepelumab	5	4 (80.0)	1.38 (1.60)	-0.3	0.00	1.50	2.75	2.8	0.29 [-0.98, 1.56]
			Placebo	6	6 (100.0)	1.00 (1.08)	-1.0	0.50	1.50	1.75	1.8	
		Week 40	Tezepelumab	5	4 (80.0)	1.44 (1.52)	0.0	0.13	1.50	2.75	2.8	0.11 [-1.15, 1.38]
			Placebo	6	6 (100.0)	1.29 (1.14)	-0.3	0.25	1.38	2.25	2.8	
		Week 44	Tezepelumab	5	4 (80.0)	1.75 (1.79)	0.0	0.25	1.63	3.25	3.8	0.56 [-0.73, 1.85]
			Placebo	6	6 (100.0)	0.92 (1.27)	-0.8	0.00	0.88	2.00	2.5	
		Week 48	Tezepelumab	5	4 (80.0)	1.25 (1.78)	-0.8	-0.25	1.50	2.75	2.8	0.48 [-0.81, 1.77]
			Placebo	6	6 (100.0)	0.63 (0.90)	-1.0	0.25	0.88	1.25	1.5	
		Week 52	Tezepelumab	5	4 (80.0)	1.25 (1.78)	-0.8	-0.25	1.50	2.75	2.8	0.66 [-0.64, 1.97]
			Placebo	6	6 (100.0)	0.42 (0.80)	-1.0	0.25	0.50	1.00	1.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	
			Placebo	3	3 (100.0)	4.75 (1.30)	3.3	3.25	5.50	5.50	5.5	
		Week 4	Tezepelumab	1	1 (100.0)	4.50	4.5	4.50	4.50	4.50	4.5	
			Placebo	3	3 (100.0)	5.00 (0.66)	4.5	4.50	4.75	5.75	5.8	
		Week 8	Tezepelumab	1	1 (100.0)	4.50	4.5	4.50	4.50	4.50	4.5	
			Placebo	3	3 (100.0)	5.75 (0.90)	4.8	4.75	6.00	6.50	6.5	
		Week 12	Tezepelumab	1	1 (100.0)	4.50	4.5	4.50	4.50	4.50	4.5	
			Placebo	3	3 (100.0)	5.33 (0.52)	4.8	4.75	5.50	5.75	5.8	
		Week 16	Tezepelumab	1	1 (100.0)	4.25	4.3	4.25	4.25	4.25	4.3	
			Placebo	3	3 (100.0)	5.00 (1.09)	4.3	4.25	4.50	6.25	6.3	
		Week 20	Tezepelumab	1	1 (100.0)	3.75	3.8	3.75	3.75	3.75	3.8	
			Placebo	3	3 (100.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 24	Tezepelumab	1	1 (100.0)	4.00	4.0	4.00	4.00	4.00	4.0	
			Placebo	3	3 (100.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 28	Tezepelumab	1	1 (100.0)	4.25	4.3	4.25	4.25	4.25	4.3	
			Placebo	3	3 (100.0)	5.83 (1.13)	4.8	4.75	5.75	7.00	7.0	
		Week 32	Tezepelumab	1	1 (100.0)	4.00	4.0	4.00	4.00	4.00	4.0	
			Placebo	3	3 (100.0)	5.75 (1.15)	4.8	4.75	5.50	7.00	7.0	
		Week 36	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	3	3 (100.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 40	Tezepelumab	1	1 (100.0)	5.50	5.5	5.50	5.50	5.50	5.5	
			Placebo	3	3 (100.0)	5.75 (1.15)	4.8	4.75	5.50	7.00	7.0	
		Week 44	Tezepelumab	1	1 (100.0)	5.25	5.3	5.25	5.25	5.25	5.3	
			Placebo	3	3 (100.0)	5.42 (1.38)	4.5	4.50	4.75	7.00	7.0	
		Week 48	Tezepelumab	1	1 (100.0)	6.25	6.3	6.25	6.25	6.25	6.3	
			Placebo	3	3 (100.0)	5.83 (1.13)	4.8	4.75	5.75	7.00	7.0	
		Week 52	Tezepelumab	1	1 (100.0)	6.25	6.3	6.25	6.25	6.25	6.3	
			Placebo	3	3 (100.0)	5.83 (1.13)	4.8	4.75	5.75	7.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	NE
			Placebo	3	3 (100.0)	0.25 (1.00)	-0.8	-0.75	0.25	1.25	1.3	
		Week 8	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	NE
			Placebo	3	3 (100.0)	1.00 (2.05)	-0.8	-0.75	0.50	3.25	3.3	
		Week 12	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	NE
			Placebo	3	3 (100.0)	0.58 (1.70)	-0.8	-0.75	0.00	2.50	2.5	
		Week 16	Tezepelumab	1	1 (100.0)	1.75	1.8	1.75	1.75	1.75	1.8	NE
			Placebo	3	3 (100.0)	0.25 (2.38)	-1.3	-1.25	-1.00	3.00	3.0	
		Week 20	Tezepelumab	1	1 (100.0)	1.25	1.3	1.25	1.25	1.25	1.3	NE
			Placebo	3	3 (100.0)	0.92 (1.46)	-0.8	-0.75	1.50	2.00	2.0	
		Week 24	Tezepelumab	1	1 (100.0)	1.50	1.5	1.50	1.50	1.50	1.5	NE
			Placebo	3	3 (100.0)	0.92 (2.47)	-0.8	-0.75	-0.25	3.75	3.8	
		Week 28	Tezepelumab	1	1 (100.0)	1.75	1.8	1.75	1.75	1.75	1.8	NE
			Placebo	3	3 (100.0)	1.08 (2.36)	-0.8	-0.75	0.25	3.75	3.8	
		Week 32	Tezepelumab	1	1 (100.0)	1.50	1.5	1.50	1.50	1.50	1.5	NE
			Placebo	3	3 (100.0)	1.00 (2.41)	-0.8	-0.75	0.00	3.75	3.8	
		Week 36	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	NE
			Placebo	3	3 (100.0)	0.92 (2.47)	-0.8	-0.75	-0.25	3.75	3.8	
		Week 40	Tezepelumab	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	NE
			Placebo	3	3 (100.0)	1.00 (2.41)	-0.8	-0.75	0.00	3.75	3.8	
		Week 44	Tezepelumab	1	1 (100.0)	2.75	2.8	2.75	2.75	2.75	2.8	NE
			Placebo	3	3 (100.0)	0.67 (2.67)	-1.0	-1.00	-0.75	3.75	3.8	
		Week 48	Tezepelumab	1	1 (100.0)	3.75	3.8	3.75	3.75	3.75	3.8	NE
			Placebo	3	3 (100.0)	1.08 (2.36)	-0.8	-0.75	0.25	3.75	3.8	
		Week 52	Tezepelumab	1	1 (100.0)	3.75	3.8	3.75	3.75	3.75	3.8	NE
			Placebo	3	3 (100.0)	1.08 (2.36)	-0.8	-0.75	0.25	3.75	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	78	73 (93.6)	4.14 (1.14)	1.0	3.50	4.25	4.75	6.8	
			Placebo	80	68 (85.0)	4.26 (1.19)	1.5	3.50	4.25	5.13	6.3	
		Week 4	Tezepelumab	78	74 (94.9)	4.64 (1.28)	1.0	3.75	4.75	5.75	7.0	
			Placebo	80	69 (86.3)	4.70 (1.20)	1.3	3.75	4.75	5.50	6.8	
		Week 8	Tezepelumab	78	75 (96.2)	4.93 (1.30)	1.0	4.25	5.00	5.75	7.0	
			Placebo	80	71 (88.8)	4.78 (1.28)	1.8	3.75	4.75	5.75	7.0	
		Week 12	Tezepelumab	78	75 (96.2)	5.05 (1.33)	1.0	4.25	5.00	6.00	7.0	
			Placebo	80	72 (90.0)	4.86 (1.20)	1.8	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	78	75 (96.2)	4.99 (1.29)	1.0	4.25	5.00	6.00	7.0	
			Placebo	80	72 (90.0)	4.84 (1.26)	1.3	4.00	4.88	5.75	7.0	
		Week 20	Tezepelumab	78	76 (97.4)	5.02 (1.37)	1.0	4.25	5.00	6.00	7.0	
			Placebo	80	72 (90.0)	4.81 (1.26)	1.3	4.00	4.75	5.75	7.0	
		Week 24	Tezepelumab	78	76 (97.4)	5.07 (1.33)	1.0	4.00	5.00	6.00	7.0	
			Placebo	80	72 (90.0)	4.70 (1.38)	1.3	3.75	5.00	5.75	7.0	
		Week 28	Tezepelumab	78	77 (98.7)	4.98 (1.39)	1.0	4.25	5.00	6.00	7.0	
			Placebo	80	73 (91.3)	4.89 (1.41)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	78	77 (98.7)	5.08 (1.38)	1.0	4.25	5.00	6.00	7.0	
			Placebo	80	74 (92.5)	4.94 (1.36)	1.3	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	78	77 (98.7)	5.07 (1.41)	1.0	4.25	5.00	6.00	7.0	
			Placebo	80	74 (92.5)	4.91 (1.38)	1.5	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	78	77 (98.7)	5.13 (1.31)	1.3	4.25	5.00	6.00	7.0	
			Placebo	80	74 (92.5)	4.98 (1.32)	1.5	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	78	77 (98.7)	5.16 (1.33)	1.0	4.25	5.25	6.25	7.0	
			Placebo	80	74 (92.5)	4.97 (1.26)	2.0	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	78	77 (98.7)	5.18 (1.32)	1.0	4.25	5.25	6.25	7.0	
			Placebo	80	75 (93.8)	5.03 (1.31)	1.0	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	78	77 (98.7)	5.12 (1.36)	1.0	4.25	5.00	6.25	7.0	
			Placebo	80	75 (93.8)	5.02 (1.24)	1.8	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	78	71 (91.0)	0.54 (1.11)	-4.0	0.00	0.50	1.25	3.0	0.07 [-0.27, 0.40]
			Placebo	80	67 (83.8)	0.46 (1.02)	-2.5	-0.25	0.50	1.25	2.5	
		Week 8	Tezepelumab	78	72 (92.3)	0.80 (1.09)	-1.5	0.00	0.75	1.75	3.3	0.22 [-0.11, 0.55]
			Placebo	80	68 (85.0)	0.57 (1.05)	-1.5	-0.13	0.25	1.25	3.0	
		Week 12	Tezepelumab	78	72 (92.3)	0.92 (1.11)	-2.3	0.25	0.88	1.63	3.0	0.23 [-0.10, 0.56]
			Placebo	80	68 (85.0)	0.67 (1.12)	-1.3	0.00	0.50	1.25	4.3	
		Week 16	Tezepelumab	78	72 (92.3)	0.88 (1.12)	-2.8	0.25	0.75	1.50	3.0	0.24 [-0.10, 0.57]
			Placebo	80	68 (85.0)	0.62 (1.09)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	78	72 (92.3)	0.89 (1.10)	-1.8	0.00	0.88	1.63	3.0	0.27 [-0.06, 0.61]
			Placebo	80	68 (85.0)	0.60 (1.04)	-2.3	0.00	0.50	1.13	3.0	
		Week 24	Tezepelumab	78	72 (92.3)	0.94 (1.15)	-1.5	0.13	1.00	1.88	3.5	0.39 [0.06, 0.73]
			Placebo	80	68 (85.0)	0.49 (1.16)	-2.8	-0.25	0.25	1.13	3.3	
		Week 28	Tezepelumab	78	72 (92.3)	0.88 (1.11)	-1.5	0.00	0.75	1.75	3.0	0.19 [-0.14, 0.52]
			Placebo	80	68 (85.0)	0.65 (1.24)	-2.8	0.00	0.63	1.50	4.0	
		Week 32	Tezepelumab	78	72 (92.3)	0.97 (1.17)	-1.3	0.00	1.00	1.75	3.5	0.20 [-0.13, 0.54]
			Placebo	80	68 (85.0)	0.74 (1.09)	-1.8	0.00	0.50	1.50	3.5	
		Week 36	Tezepelumab	78	72 (92.3)	0.95 (1.19)	-1.8	0.25	0.75	2.00	3.5	0.21 [-0.12, 0.55]
			Placebo	80	68 (85.0)	0.69 (1.27)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	78	72 (92.3)	1.04 (1.13)	-1.5	0.25	1.00	2.00	3.3	0.24 [-0.09, 0.57]
			Placebo	80	68 (85.0)	0.75 (1.27)	-2.5	0.00	0.50	1.38	4.3	
		Week 44	Tezepelumab	78	72 (92.3)	1.07 (1.18)	-1.5	0.25	1.00	2.00	3.8	0.31 [-0.02, 0.64]
			Placebo	80	68 (85.0)	0.71 (1.16)	-1.5	0.00	0.38	1.25	3.5	
		Week 48	Tezepelumab	78	72 (92.3)	1.09 (1.20)	-1.8	0.25	1.00	2.00	3.8	0.24 [-0.10, 0.57]
			Placebo	80	68 (85.0)	0.80 (1.25)	-2.8	0.00	0.63	1.38	4.0	
		Week 52	Tezepelumab	78	72 (92.3)	1.02 (1.17)	-1.8	0.00	1.00	2.00	3.8	0.21 [-0.12, 0.54]
			Placebo	80	68 (85.0)	0.79 (1.10)	-1.3	0.00	0.50	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	4.28 (1.36)	1.8	3.50	4.25	5.25	6.0	
			Placebo	9	8 (88.9)	4.09 (0.88)	3.0	3.38	4.00	4.75	5.5	
		Week 4	Tezepelumab	10	8 (80.0)	5.84 (0.77)	4.8	5.38	5.63	6.50	7.0	
			Placebo	9	7 (77.8)	4.50 (1.30)	2.5	3.50	4.50	5.50	6.5	
		Week 8	Tezepelumab	10	9 (90.0)	5.86 (1.00)	4.0	5.25	6.00	6.75	7.0	
			Placebo	9	7 (77.8)	5.21 (1.37)	3.0	3.75	5.50	6.00	7.0	
		Week 12	Tezepelumab	10	9 (90.0)	6.03 (0.92)	4.5	5.75	6.25	6.75	7.0	
			Placebo	9	7 (77.8)	5.07 (1.08)	3.8	4.00	5.25	5.50	7.0	
		Week 16	Tezepelumab	10	9 (90.0)	5.61 (0.88)	4.5	4.75	5.75	6.00	7.0	
			Placebo	9	7 (77.8)	4.64 (1.27)	3.3	3.75	4.50	5.25	7.0	
		Week 20	Tezepelumab	10	9 (90.0)	5.61 (0.86)	4.5	5.00	5.50	6.00	7.0	
			Placebo	9	7 (77.8)	5.36 (1.41)	3.3	4.00	5.25	7.00	7.0	
		Week 24	Tezepelumab	10	9 (90.0)	5.83 (0.86)	4.5	5.50	5.75	6.50	7.0	
			Placebo	9	7 (77.8)	5.46 (0.80)	4.8	4.75	5.25	6.00	7.0	
		Week 28	Tezepelumab	10	10 (100.0)	6.05 (0.94)	4.5	5.25	6.00	7.00	7.0	
			Placebo	9	7 (77.8)	5.25 (1.13)	3.3	4.75	5.25	5.75	7.0	
		Week 32	Tezepelumab	10	10 (100.0)	5.93 (0.77)	4.5	5.75	6.00	6.25	7.0	
			Placebo	9	7 (77.8)	5.46 (0.81)	4.5	4.75	5.50	5.75	7.0	
		Week 36	Tezepelumab	10	10 (100.0)	5.88 (0.91)	4.5	5.00	6.00	6.50	7.0	
			Placebo	9	7 (77.8)	5.54 (0.82)	4.8	4.75	5.25	6.25	7.0	
		Week 40	Tezepelumab	10	10 (100.0)	6.08 (0.87)	4.5	5.50	6.25	7.00	7.0	
			Placebo	9	7 (77.8)	5.32 (0.86)	4.3	4.75	5.25	5.50	7.0	
		Week 44	Tezepelumab	10	10 (100.0)	6.08 (0.84)	4.5	5.75	6.13	7.00	7.0	
			Placebo	9	7 (77.8)	5.50 (1.08)	4.3	4.50	5.50	6.75	7.0	
		Week 48	Tezepelumab	10	10 (100.0)	6.05 (0.83)	4.5	5.75	6.13	6.75	7.0	
			Placebo	9	7 (77.8)	5.71 (0.67)	4.5	5.50	5.75	6.00	6.8	
		Week 52	Tezepelumab	10	10 (100.0)	6.13 (0.85)	4.5	5.75	6.25	6.75	7.0	
			Placebo	9	7 (77.8)	5.61 (1.05)	3.5	5.50	5.75	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	1.47 (1.75)	-0.5	-0.13	1.25	3.00	4.0	0.71 [-0.34, 1.76]
			Placebo	9	7 (77.8)	0.36 (1.34)	-0.8	-0.75	0.00	2.00	2.5	
		Week 8	Tezepelumab	10	9 (90.0)	1.58 (1.73)	0.0	0.00	0.75	3.50	4.3	0.34 [-0.65, 1.34]
			Placebo	9	7 (77.8)	1.07 (1.11)	-0.3	0.25	0.50	2.50	2.5	
		Week 12	Tezepelumab	10	9 (90.0)	1.75 (1.74)	0.0	0.50	1.00	3.50	4.8	0.58 [-0.43, 1.59]
			Placebo	9	7 (77.8)	0.93 (0.83)	0.0	0.25	1.00	1.25	2.5	
		Week 16	Tezepelumab	10	9 (90.0)	1.33 (1.51)	-0.3	0.00	1.00	3.00	3.5	0.62 [-0.39, 1.64]
			Placebo	9	7 (77.8)	0.50 (1.07)	-1.0	0.00	0.25	1.00	2.5	
		Week 20	Tezepelumab	10	9 (90.0)	1.33 (1.67)	-0.5	-0.25	1.00	3.25	3.5	0.09 [-0.90, 1.08]
			Placebo	9	7 (77.8)	1.21 (0.76)	0.3	0.75	1.00	1.75	2.5	
		Week 24	Tezepelumab	10	9 (90.0)	1.56 (1.56)	-0.5	0.50	1.50	3.25	3.5	0.18 [-0.81, 1.17]
			Placebo	9	7 (77.8)	1.32 (0.86)	-0.3	1.00	1.50	1.75	2.5	
		Week 28	Tezepelumab	10	9 (90.0)	1.67 (1.49)	-0.5	0.50	1.50	3.25	3.5	0.43 [-0.57, 1.43]
			Placebo	9	7 (77.8)	1.11 (1.01)	-0.3	0.25	1.00	2.00	2.5	
		Week 32	Tezepelumab	10	9 (90.0)	1.53 (1.36)	-0.3	0.50	1.00	2.75	3.5	0.17 [-0.82, 1.16]
			Placebo	9	7 (77.8)	1.32 (0.89)	0.0	0.75	1.00	2.25	2.5	
		Week 36	Tezepelumab	10	9 (90.0)	1.53 (1.51)	-0.5	0.50	1.00	3.25	3.5	0.10 [-0.89, 1.09]
			Placebo	9	7 (77.8)	1.39 (1.07)	-0.3	0.50	1.50	2.50	2.8	
		Week 40	Tezepelumab	10	9 (90.0)	1.75 (1.47)	-0.5	0.50	2.00	3.25	3.5	0.46 [-0.54, 1.46]
			Placebo	9	7 (77.8)	1.18 (0.86)	0.0	0.50	1.00	1.75	2.5	
		Week 44	Tezepelumab	10	9 (90.0)	1.78 (1.38)	0.0	0.50	1.75	3.25	3.5	0.29 [-0.70, 1.29]
			Placebo	9	7 (77.8)	1.36 (1.51)	-1.0	0.50	1.50	2.50	3.8	
		Week 48	Tezepelumab	10	9 (90.0)	1.75 (1.39)	-0.3	0.75	1.75	3.25	3.5	0.14 [-0.85, 1.12]
			Placebo	9	7 (77.8)	1.57 (1.21)	0.3	0.50	1.50	2.50	3.8	
		Week 52	Tezepelumab	10	9 (90.0)	1.78 (1.35)	0.0	0.75	1.75	3.25	3.5	0.23 [-0.76, 1.22]
			Placebo	9	7 (77.8)	1.46 (1.42)	0.0	0.25	1.50	2.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	4.63 (1.27)	3.0	3.63	4.88	5.63	5.8	
			Placebo	6	6 (100.0)	4.58 (0.77)	3.8	3.75	4.63	5.25	5.5	
		Week 4	Tezepelumab	5	5 (100.0)	5.65 (0.84)	4.3	5.75	5.75	6.00	6.5	
			Placebo	6	6 (100.0)	5.17 (0.38)	4.8	4.75	5.25	5.50	5.5	
		Week 8	Tezepelumab	5	5 (100.0)	5.70 (0.37)	5.3	5.50	5.75	5.75	6.3	
			Placebo	6	6 (100.0)	5.25 (0.89)	3.8	5.00	5.38	5.50	6.5	
		Week 12	Tezepelumab	5	5 (100.0)	5.95 (0.60)	5.3	5.50	6.00	6.25	6.8	
			Placebo	6	6 (100.0)	5.58 (0.66)	4.8	5.25	5.38	6.25	6.5	
		Week 16	Tezepelumab	5	5 (100.0)	6.00 (0.61)	5.5	5.50	6.00	6.00	7.0	
			Placebo	6	6 (100.0)	5.63 (0.54)	5.0	5.25	5.50	6.25	6.3	
		Week 20	Tezepelumab	5	5 (100.0)	5.90 (0.76)	5.0	5.50	5.75	6.25	7.0	
			Placebo	6	6 (100.0)	5.50 (1.10)	4.0	5.00	5.25	6.50	7.0	
		Week 24	Tezepelumab	5	5 (100.0)	5.90 (0.68)	5.0	5.50	6.00	6.25	6.8	
			Placebo	6	6 (100.0)	5.33 (0.75)	4.3	4.75	5.38	6.00	6.3	
		Week 28	Tezepelumab	5	5 (100.0)	6.10 (0.52)	5.8	5.75	6.00	6.00	7.0	
			Placebo	6	6 (100.0)	6.13 (0.86)	5.0	5.25	6.25	7.00	7.0	
		Week 32	Tezepelumab	5	5 (100.0)	6.30 (0.67)	5.5	6.00	6.00	7.00	7.0	
			Placebo	6	6 (100.0)	5.83 (0.68)	5.0	5.25	5.88	6.25	6.8	
		Week 36	Tezepelumab	5	5 (100.0)	6.20 (0.78)	5.3	5.75	6.00	7.00	7.0	
			Placebo	6	6 (100.0)	5.58 (0.90)	4.3	5.25	5.50	6.00	7.0	
		Week 40	Tezepelumab	5	5 (100.0)	6.25 (0.68)	5.8	5.75	5.75	7.00	7.0	
			Placebo	6	6 (100.0)	5.88 (0.95)	5.0	5.00	5.63	7.00	7.0	
		Week 44	Tezepelumab	5	5 (100.0)	6.50 (0.59)	5.8	6.00	6.75	7.00	7.0	
			Placebo	6	6 (100.0)	5.50 (1.21)	4.0	4.50	5.38	6.75	7.0	
		Week 48	Tezepelumab	5	5 (100.0)	5.95 (0.82)	4.8	5.75	6.00	6.25	7.0	
			Placebo	6	6 (100.0)	5.21 (0.97)	4.3	4.50	5.13	5.25	7.0	
		Week 52	Tezepelumab	5	5 (100.0)	6.10 (0.95)	4.8	5.75	6.00	7.00	7.0	
			Placebo	6	6 (100.0)	5.00 (0.55)	4.3	4.50	5.13	5.25	5.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	1.00 (0.74)	0.0	0.50	1.13	1.50	1.8	0.50 [-0.78, 1.79]
			Placebo	6	6 (100.0)	0.58 (0.88)	-0.5	0.00	0.50	1.25	1.8	
		Week 8	Tezepelumab	5	4 (80.0)	1.06 (1.23)	0.0	0.00	1.00	2.13	2.3	0.41 [-0.87, 1.69]
			Placebo	6	6 (100.0)	0.67 (0.77)	0.0	0.00	0.50	1.25	1.8	
		Week 12	Tezepelumab	5	4 (80.0)	1.31 (1.25)	0.0	0.25	1.38	2.38	2.5	0.32 [-0.96, 1.59]
			Placebo	6	6 (100.0)	1.00 (0.79)	0.0	0.50	0.88	1.50	2.3	
		Week 16	Tezepelumab	5	4 (80.0)	1.38 (1.48)	-0.3	0.13	1.50	2.63	2.8	0.32 [-0.96, 1.59]
			Placebo	6	6 (100.0)	1.04 (0.66)	0.3	0.50	1.00	1.50	2.0	
		Week 20	Tezepelumab	5	4 (80.0)	1.19 (1.68)	-0.5	-0.25	1.25	2.63	2.8	0.19 [-1.08, 1.45]
			Placebo	6	6 (100.0)	0.92 (1.30)	-1.3	0.50	1.13	1.25	2.8	
		Week 24	Tezepelumab	5	4 (80.0)	1.19 (1.55)	-0.5	-0.13	1.38	2.50	2.5	0.36 [-0.92, 1.64]
			Placebo	6	6 (100.0)	0.75 (0.97)	-1.0	0.50	0.88	1.50	1.8	
		Week 28	Tezepelumab	5	4 (80.0)	1.50 (1.59)	0.0	0.13	1.50	2.88	3.0	-0.03 [-1.30, 1.23]
			Placebo	6	6 (100.0)	1.54 (0.87)	0.3	1.25	1.38	2.25	2.8	
		Week 32	Tezepelumab	5	4 (80.0)	1.50 (1.31)	0.3	0.38	1.50	2.63	2.8	0.27 [-1.00, 1.54]
			Placebo	6	6 (100.0)	1.25 (0.61)	0.3	1.00	1.25	1.75	2.0	
		Week 36	Tezepelumab	5	4 (80.0)	1.38 (1.60)	-0.3	0.00	1.50	2.75	2.8	0.29 [-0.98, 1.56]
			Placebo	6	6 (100.0)	1.00 (1.08)	-1.0	0.50	1.50	1.75	1.8	
		Week 40	Tezepelumab	5	4 (80.0)	1.44 (1.52)	0.0	0.13	1.50	2.75	2.8	0.11 [-1.15, 1.38]
			Placebo	6	6 (100.0)	1.29 (1.14)	-0.3	0.25	1.38	2.25	2.8	
		Week 44	Tezepelumab	5	4 (80.0)	1.75 (1.79)	0.0	0.25	1.63	3.25	3.8	0.56 [-0.73, 1.85]
			Placebo	6	6 (100.0)	0.92 (1.27)	-0.8	0.00	0.88	2.00	2.5	
		Week 48	Tezepelumab	5	4 (80.0)	1.25 (1.78)	-0.8	-0.25	1.50	2.75	2.8	0.48 [-0.81, 1.77]
			Placebo	6	6 (100.0)	0.63 (0.90)	-1.0	0.25	0.88	1.25	1.5	
		Week 52	Tezepelumab	5	4 (80.0)	1.25 (1.78)	-0.8	-0.25	1.50	2.75	2.8	0.66 [-0.64, 1.97]
			Placebo	6	6 (100.0)	0.42 (0.80)	-1.0	0.25	0.50	1.00	1.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	44	37 (84.1)	4.35 (1.12)	2.5	3.75	4.25	5.25	7.0	
			Placebo	43	39 (90.7)	3.71 (1.28)	1.5	2.75	3.75	4.50	7.0	
		Week 4	Tezepelumab	44	39 (88.6)	5.11 (1.01)	3.0	4.25	5.00	5.75	7.0	
			Placebo	43	41 (95.3)	4.34 (1.26)	2.0	3.50	4.25	5.25	7.0	
		Week 8	Tezepelumab	44	39 (88.6)	5.15 (1.03)	2.5	4.50	5.00	5.75	7.0	
			Placebo	43	42 (97.7)	4.40 (1.38)	1.0	3.75	4.50	5.25	7.0	
		Week 12	Tezepelumab	44	39 (88.6)	5.33 (1.02)	3.0	4.75	5.25	6.00	7.0	
			Placebo	43	42 (97.7)	4.42 (1.17)	1.3	3.75	4.50	5.25	6.8	
		Week 16	Tezepelumab	44	39 (88.6)	5.32 (1.05)	3.8	4.50	5.25	6.25	7.0	
			Placebo	43	42 (97.7)	4.50 (1.34)	1.3	4.00	4.38	5.25	7.0	
		Week 20	Tezepelumab	44	39 (88.6)	5.21 (1.09)	3.0	4.50	5.00	6.25	7.0	
			Placebo	43	42 (97.7)	4.52 (1.29)	1.5	4.00	4.50	5.25	7.0	
		Week 24	Tezepelumab	44	39 (88.6)	5.38 (1.00)	3.8	4.75	5.00	6.25	7.0	
			Placebo	43	42 (97.7)	4.54 (1.40)	1.0	4.00	4.50	5.25	7.0	
		Week 28	Tezepelumab	44	39 (88.6)	5.33 (0.97)	3.8	4.50	5.00	6.25	7.0	
			Placebo	43	42 (97.7)	4.47 (1.31)	2.0	3.75	4.25	5.25	7.0	
		Week 32	Tezepelumab	44	40 (90.9)	5.41 (1.01)	3.5	4.75	5.25	6.00	7.0	
			Placebo	43	42 (97.7)	4.58 (1.39)	1.3	3.75	4.13	5.25	7.0	
		Week 36	Tezepelumab	44	40 (90.9)	5.46 (0.94)	3.8	4.75	5.50	6.25	7.0	
			Placebo	43	42 (97.7)	4.52 (1.45)	1.0	4.00	4.50	5.25	7.0	
		Week 40	Tezepelumab	44	40 (90.9)	5.41 (0.97)	4.0	4.63	5.25	6.13	7.0	
			Placebo	43	42 (97.7)	4.58 (1.45)	1.0	4.00	4.63	5.50	7.0	
		Week 44	Tezepelumab	44	40 (90.9)	5.43 (1.00)	3.8	4.75	5.25	6.38	7.0	
			Placebo	43	42 (97.7)	4.51 (1.46)	1.3	4.00	4.00	5.50	7.0	
		Week 48	Tezepelumab	44	40 (90.9)	5.41 (1.06)	2.5	4.50	5.38	6.25	7.0	
			Placebo	43	42 (97.7)	4.54 (1.32)	1.8	4.00	4.50	5.25	7.0	
		Week 52	Tezepelumab	44	40 (90.9)	5.38 (1.08)	2.5	4.50	5.25	6.13	7.0	
			Placebo	43	42 (97.7)	4.38 (1.49)	1.0	3.50	4.38	5.25	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	44	34 (77.3)	0.80 (1.07)	-1.3	0.25	0.75	1.75	2.5	0.22 [-0.24, 0.69]
			Placebo	43	39 (90.7)	0.59 (0.83)	-1.3	0.00	0.50	1.00	3.0	
		Week 8	Tezepelumab	44	34 (77.3)	0.81 (1.05)	-1.5	0.00	0.75	1.75	2.5	0.09 [-0.37, 0.55]
			Placebo	43	39 (90.7)	0.71 (1.09)	-1.8	0.00	0.75	1.25	3.3	
		Week 12	Tezepelumab	44	34 (77.3)	0.99 (1.03)	-1.0	0.25	1.00	1.75	2.8	0.28 [-0.18, 0.74]
			Placebo	43	39 (90.7)	0.69 (1.08)	-1.8	0.00	0.75	1.25	2.8	
		Week 16	Tezepelumab	44	34 (77.3)	0.99 (1.21)	-2.3	0.00	1.13	2.00	3.3	0.20 [-0.26, 0.66]
			Placebo	43	39 (90.7)	0.78 (1.00)	-1.3	0.00	0.75	1.50	3.0	
		Week 20	Tezepelumab	44	34 (77.3)	0.93 (1.15)	-1.3	0.25	0.75	1.75	3.5	0.10 [-0.36, 0.56]
			Placebo	43	39 (90.7)	0.83 (1.02)	-1.3	0.25	0.75	1.50	3.0	
		Week 24	Tezepelumab	44	34 (77.3)	1.13 (1.00)	-0.8	0.50	1.00	2.00	3.3	0.22 [-0.24, 0.69]
			Placebo	43	39 (90.7)	0.89 (1.08)	-1.3	0.00	0.75	1.50	3.8	
		Week 28	Tezepelumab	44	34 (77.3)	1.07 (1.09)	-1.0	0.25	0.88	1.75	3.3	0.26 [-0.20, 0.73]
			Placebo	43	39 (90.7)	0.79 (1.01)	-1.3	0.25	0.75	1.25	3.8	
		Week 32	Tezepelumab	44	34 (77.3)	1.16 (1.15)	-0.8	0.25	1.13	1.75	3.5	0.18 [-0.28, 0.64]
			Placebo	43	39 (90.7)	0.96 (1.18)	-1.3	0.25	0.75	1.75	3.8	
		Week 36	Tezepelumab	44	34 (77.3)	1.23 (1.17)	-1.0	0.50	1.13	2.00	3.5	0.30 [-0.16, 0.77]
			Placebo	43	39 (90.7)	0.87 (1.21)	-1.3	0.00	0.75	1.50	3.8	
		Week 40	Tezepelumab	44	34 (77.3)	1.12 (1.11)	-1.0	0.25	1.00	1.75	3.3	0.18 [-0.28, 0.64]
			Placebo	43	39 (90.7)	0.91 (1.19)	-1.3	0.25	0.75	1.25	3.8	
		Week 44	Tezepelumab	44	34 (77.3)	1.11 (1.09)	-1.0	0.25	1.25	1.75	3.3	0.21 [-0.25, 0.67]
			Placebo	43	39 (90.7)	0.87 (1.25)	-1.5	0.00	0.75	1.25	3.8	
		Week 48	Tezepelumab	44	34 (77.3)	1.12 (1.13)	-1.0	0.50	1.00	1.75	3.5	0.20 [-0.26, 0.66]
			Placebo	43	39 (90.7)	0.88 (1.22)	-1.3	0.00	0.75	1.25	3.8	
		Week 52	Tezepelumab	44	34 (77.3)	1.05 (1.22)	-1.5	0.50	1.00	1.50	3.5	0.27 [-0.19, 0.74]
			Placebo	43	39 (90.7)	0.70 (1.35)	-2.3	-0.25	0.50	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Placebo	1	1 (100.0)	2.25	2.3	2.25	2.25	2.25	2.3	
		Week 4	Placebo	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
		Week 8	Placebo	1	1 (100.0)	1.75	1.8	1.75	1.75	1.75	1.8	
		Week 12	Placebo	1	1 (100.0)	1.75	1.8	1.75	1.75	1.75	1.8	
		Week 16	Placebo	1	1 (100.0)	3.25	3.3	3.25	3.25	3.25	3.3	
		Week 20	Placebo	1	1 (100.0)	2.75	2.8	2.75	2.75	2.75	2.8	
		Week 24	Placebo	1	1 (100.0)	1.50	1.5	1.50	1.50	1.50	1.5	
		Week 28	Placebo	1	1 (100.0)	3.50	3.5	3.50	3.50	3.50	3.5	
		Week 32	Placebo	1	1 (100.0)	1.75	1.8	1.75	1.75	1.75	1.8	
		Week 36	Placebo	1	1 (100.0)	2.75	2.8	2.75	2.75	2.75	2.8	
		Week 40	Placebo	1	1 (100.0)	2.25	2.3	2.25	2.25	2.25	2.3	
		Week 44	Placebo	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
		Week 48	Placebo	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
		Week 52	Placebo	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 4	Placebo	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	
		Week 8	Placebo	1	1 (100.0)	-0.50	-0.5	-0.50	-0.50	-0.50	-0.5	
		Week 12	Placebo	1	1 (100.0)	-0.50	-0.5	-0.50	-0.50	-0.50	-0.5	
		Week 16	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 20	Placebo	1	1 (100.0)	0.50	0.5	0.50	0.50	0.50	0.5	
		Week 24	Placebo	1	1 (100.0)	-0.75	-0.8	-0.75	-0.75	-0.75	-0.8	
		Week 28	Placebo	1	1 (100.0)	1.25	1.3	1.25	1.25	1.25	1.3	
		Week 32	Placebo	1	1 (100.0)	-0.50	-0.5	-0.50	-0.50	-0.50	-0.5	
		Week 36	Placebo	1	1 (100.0)	0.50	0.5	0.50	0.50	0.50	0.5	
		Week 40	Placebo	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 44	Placebo	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	
		Week 48	Placebo	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	
		Week 52	Placebo	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	39	35 (89.7)	4.60 (1.28)	1.8	4.00	4.75	5.50	6.8	
			Placebo	43	38 (88.4)	4.08 (1.32)	1.5	3.25	4.25	5.00	6.3	
		Week 4	Tezepelumab	39	36 (92.3)	5.39 (1.10)	3.3	4.63	5.50	6.25	7.0	
			Placebo	43	40 (93.0)	4.71 (1.22)	2.0	3.88	5.13	5.50	6.8	
		Week 8	Tezepelumab	39	37 (94.9)	5.48 (1.02)	3.5	4.50	5.75	6.25	7.0	
			Placebo	43	40 (93.0)	4.98 (1.40)	1.5	4.13	5.25	5.88	7.0	
		Week 12	Tezepelumab	39	37 (94.9)	5.76 (1.03)	3.0	5.25	5.75	6.50	7.0	
			Placebo	43	40 (93.0)	4.96 (1.25)	2.0	4.13	5.00	6.00	7.0	
		Week 16	Tezepelumab	39	37 (94.9)	5.64 (1.02)	3.8	4.75	5.75	6.25	7.0	
			Placebo	43	40 (93.0)	5.05 (1.37)	1.5	4.13	5.13	6.13	7.0	
		Week 20	Tezepelumab	39	37 (94.9)	5.59 (1.08)	3.5	4.75	5.75	6.50	7.0	
			Placebo	43	40 (93.0)	4.97 (1.47)	1.5	4.00	5.00	6.25	7.0	
		Week 24	Tezepelumab	39	37 (94.9)	5.80 (0.98)	3.8	5.00	6.00	6.75	7.0	
			Placebo	43	40 (93.0)	4.86 (1.50)	1.0	4.13	5.25	6.00	7.0	
		Week 28	Tezepelumab	39	37 (94.9)	5.67 (1.07)	3.0	5.00	5.75	6.50	7.0	
			Placebo	43	41 (95.3)	5.16 (1.51)	1.5	4.00	5.75	6.25	7.0	
		Week 32	Tezepelumab	39	38 (97.4)	5.75 (1.12)	2.3	5.00	6.00	6.75	7.0	
			Placebo	43	41 (95.3)	5.19 (1.49)	1.3	4.00	5.50	6.25	7.0	
		Week 36	Tezepelumab	39	38 (97.4)	5.80 (1.09)	3.0	5.00	6.00	7.00	7.0	
			Placebo	43	41 (95.3)	5.06 (1.60)	1.0	4.00	5.50	6.50	7.0	
		Week 40	Tezepelumab	39	38 (97.4)	5.70 (1.12)	2.8	5.00	5.75	7.00	7.0	
			Placebo	43	41 (95.3)	5.14 (1.53)	1.0	4.00	5.50	6.50	7.0	
		Week 44	Tezepelumab	39	38 (97.4)	5.82 (1.06)	3.5	5.00	5.88	7.00	7.0	
			Placebo	43	41 (95.3)	5.09 (1.53)	1.3	4.00	5.50	6.00	7.0	
		Week 48	Tezepelumab	39	38 (97.4)	5.80 (1.13)	3.0	5.00	6.00	7.00	7.0	
			Placebo	43	42 (97.7)	5.13 (1.35)	1.8	4.25	5.13	6.00	7.0	
		Week 52	Tezepelumab	39	38 (97.4)	5.70 (1.13)	3.0	5.00	5.75	7.00	7.0	
			Placebo	43	42 (97.7)	5.05 (1.33)	1.8	4.00	5.25	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	39	33 (84.6)	0.82 (1.13)	-1.0	0.00	0.50	1.75	4.0	0.19 [-0.28, 0.66]
			Placebo	43	38 (88.4)	0.63 (0.88)	-1.0	0.00	0.63	1.25	2.5	
		Week 8	Tezepelumab	39	34 (87.2)	0.90 (1.18)	-1.5	0.00	0.75	1.75	4.3	-0.03 [-0.49, 0.43]
			Placebo	43	38 (88.4)	0.93 (0.83)	-0.8	0.25	1.00	1.50	2.8	
		Week 12	Tezepelumab	39	34 (87.2)	1.15 (1.20)	-1.0	0.25	0.75	2.25	4.8	0.25 [-0.22, 0.71]
			Placebo	43	38 (88.4)	0.89 (0.90)	-1.3	0.25	1.00	1.50	2.3	
		Week 16	Tezepelumab	39	34 (87.2)	1.01 (1.16)	-2.3	0.25	0.88	2.00	3.0	0.03 [-0.44, 0.49]
			Placebo	43	38 (88.4)	0.99 (0.90)	-0.8	0.50	1.00	1.50	3.0	
		Week 20	Tezepelumab	39	34 (87.2)	0.96 (1.24)	-1.3	0.00	1.00	2.00	3.3	0.03 [-0.44, 0.49]
			Placebo	43	38 (88.4)	0.93 (1.07)	-1.3	0.25	0.88	1.50	2.8	
		Week 24	Tezepelumab	39	34 (87.2)	1.18 (1.08)	-0.8	0.50	1.13	2.00	3.5	0.34 [-0.13, 0.80]
			Placebo	43	38 (88.4)	0.84 (0.95)	-1.0	0.00	1.00	1.50	2.8	
		Week 28	Tezepelumab	39	34 (87.2)	1.10 (1.18)	-1.0	0.25	1.00	2.00	3.3	-0.03 [-0.50, 0.43]
			Placebo	43	38 (88.4)	1.13 (0.99)	-1.0	0.50	1.25	1.75	3.0	
		Week 32	Tezepelumab	39	34 (87.2)	1.13 (1.12)	-0.8	0.25	1.25	1.75	3.3	-0.01 [-0.47, 0.46]
			Placebo	43	38 (88.4)	1.14 (1.00)	-1.3	0.50	1.25	1.75	3.5	
		Week 36	Tezepelumab	39	34 (87.2)	1.18 (1.16)	-1.0	0.25	1.13	2.00	3.3	0.14 [-0.33, 0.60]
			Placebo	43	38 (88.4)	1.03 (1.15)	-1.0	0.25	0.88	1.75	3.5	
		Week 40	Tezepelumab	39	34 (87.2)	1.05 (1.08)	-1.0	0.25	1.00	1.75	3.3	-0.05 [-0.51, 0.41]
			Placebo	43	38 (88.4)	1.11 (1.11)	-1.0	0.25	1.00	2.00	3.5	
		Week 44	Tezepelumab	39	34 (87.2)	1.13 (1.15)	-1.0	0.25	1.00	1.75	3.8	0.10 [-0.36, 0.57]
			Placebo	43	38 (88.4)	1.01 (1.14)	-1.5	0.25	1.00	2.00	3.5	
		Week 48	Tezepelumab	39	34 (87.2)	1.20 (1.12)	-1.0	0.25	1.00	2.00	3.3	0.11 [-0.35, 0.57]
			Placebo	43	38 (88.4)	1.07 (1.17)	-1.0	0.25	1.00	2.00	3.5	
		Week 52	Tezepelumab	39	34 (87.2)	1.04 (1.21)	-1.5	0.25	1.00	1.75	3.3	0.06 [-0.40, 0.52]
			Placebo	43	38 (88.4)	0.97 (1.18)	-1.0	0.25	0.75	2.00	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	45	41 (91.1)	4.20 (1.24)	1.0	3.50	4.25	5.00	7.0	
			Placebo	47	43 (91.5)	4.23 (1.17)	2.0	3.50	4.00	4.75	7.0	
		Week 4	Tezepelumab	45	43 (95.6)	4.85 (1.28)	1.0	4.00	5.00	5.75	6.8	
			Placebo	47	43 (91.5)	4.64 (1.20)	1.3	4.00	4.75	5.50	7.0	
		Week 8	Tezepelumab	45	43 (95.6)	4.99 (1.34)	1.0	4.25	5.25	6.00	7.0	
			Placebo	47	45 (95.7)	4.68 (1.17)	2.3	4.00	4.75	5.50	7.0	
		Week 12	Tezepelumab	45	43 (95.6)	5.12 (1.36)	1.0	4.25	5.25	6.25	7.0	
			Placebo	47	45 (95.7)	4.85 (1.10)	2.5	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	45	43 (95.6)	5.12 (1.25)	1.0	4.50	5.25	6.00	7.0	
			Placebo	47	45 (95.7)	4.71 (1.29)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	45	43 (95.6)	5.09 (1.35)	1.0	4.25	5.00	6.00	7.0	
			Placebo	47	45 (95.7)	4.72 (1.27)	1.3	4.00	4.50	5.50	7.0	
		Week 24	Tezepelumab	45	43 (95.6)	5.16 (1.27)	1.0	4.25	5.00	6.25	7.0	
			Placebo	47	45 (95.7)	4.64 (1.33)	1.3	4.00	4.75	5.50	7.0	
		Week 28	Tezepelumab	45	44 (97.8)	5.23 (1.37)	1.0	4.50	5.25	6.25	7.0	
			Placebo	47	45 (95.7)	4.73 (1.37)	1.3	4.00	4.50	5.75	7.0	
		Week 32	Tezepelumab	45	44 (97.8)	5.26 (1.35)	1.0	4.50	5.25	6.25	7.0	
			Placebo	47	45 (95.7)	4.78 (1.27)	1.3	4.00	4.75	6.00	7.0	
		Week 36	Tezepelumab	45	44 (97.8)	5.22 (1.37)	1.0	4.25	5.50	6.00	7.0	
			Placebo	47	45 (95.7)	4.71 (1.30)	1.8	4.00	4.50	5.50	7.0	
		Week 40	Tezepelumab	45	44 (97.8)	5.37 (1.31)	1.3	4.38	5.50	6.50	7.0	
			Placebo	47	45 (95.7)	4.75 (1.25)	1.8	4.00	4.75	5.25	7.0	
		Week 44	Tezepelumab	45	44 (97.8)	5.35 (1.31)	1.0	4.25	5.50	6.25	7.0	
			Placebo	47	45 (95.7)	4.80 (1.21)	2.0	4.00	4.25	5.75	7.0	
		Week 48	Tezepelumab	45	44 (97.8)	5.31 (1.26)	2.0	4.25	5.38	6.25	7.0	
			Placebo	47	45 (95.7)	4.81 (1.25)	2.0	4.00	4.50	5.75	7.0	
		Week 52	Tezepelumab	45	44 (97.8)	5.31 (1.42)	1.0	4.38	5.50	6.63	7.0	
			Placebo	47	45 (95.7)	4.83 (1.26)	1.8	4.00	4.50	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	45	40 (88.9)	0.68 (1.20)	-2.3	-0.25	0.75	1.50	3.0	0.25 [-0.18, 0.69]
			Placebo	47	42 (89.4)	0.40 (0.99)	-2.5	0.00	0.25	1.00	2.5	
		Week 8	Tezepelumab	45	40 (88.9)	0.78 (1.22)	-1.5	0.00	0.50	1.75	3.5	0.26 [-0.17, 0.70]
			Placebo	47	43 (91.5)	0.48 (1.04)	-1.8	-0.25	0.50	1.00	3.0	
		Week 12	Tezepelumab	45	40 (88.9)	0.93 (1.28)	-2.0	0.00	0.88	1.63	3.5	0.25 [-0.19, 0.68]
			Placebo	47	43 (91.5)	0.64 (1.04)	-1.8	0.00	0.50	1.25	3.3	
		Week 16	Tezepelumab	45	40 (88.9)	0.96 (1.24)	-1.5	0.00	0.75	1.75	3.3	0.41 [-0.03, 0.84]
			Placebo	47	43 (91.5)	0.49 (1.02)	-1.8	0.00	0.50	1.25	2.5	
		Week 20	Tezepelumab	45	40 (88.9)	0.94 (1.28)	-1.0	0.00	0.75	1.88	3.5	0.37 [-0.06, 0.81]
			Placebo	47	43 (91.5)	0.52 (0.96)	-2.3	0.00	0.50	1.00	3.0	
		Week 24	Tezepelumab	45	40 (88.9)	1.00 (1.32)	-1.0	0.00	0.75	2.25	3.5	0.47 [0.03, 0.90]
			Placebo	47	43 (91.5)	0.44 (1.08)	-2.8	-0.25	0.25	1.00	3.3	
		Week 28	Tezepelumab	45	40 (88.9)	1.04 (1.19)	-1.5	0.13	1.00	1.75	3.5	0.47 [0.03, 0.90]
			Placebo	47	43 (91.5)	0.53 (0.99)	-1.8	0.00	0.50	1.00	3.3	
		Week 32	Tezepelumab	45	40 (88.9)	1.08 (1.33)	-1.3	0.00	1.00	2.13	3.5	0.42 [-0.01, 0.86]
			Placebo	47	43 (91.5)	0.58 (0.98)	-1.8	-0.25	0.50	1.25	2.5	
		Week 36	Tezepelumab	45	40 (88.9)	1.06 (1.40)	-1.8	-0.13	1.00	2.00	3.5	0.45 [0.02, 0.89]
			Placebo	47	43 (91.5)	0.50 (1.05)	-2.8	0.00	0.50	1.25	2.8	
		Week 40	Tezepelumab	45	40 (88.9)	1.18 (1.32)	-1.5	0.13	1.25	2.25	3.5	0.55 [0.11, 0.98]
			Placebo	47	43 (91.5)	0.54 (1.02)	-2.5	0.00	0.50	1.00	2.5	
		Week 44	Tezepelumab	45	40 (88.9)	1.19 (1.31)	-1.5	0.00	1.25	2.13	3.8	0.48 [0.05, 0.92]
			Placebo	47	43 (91.5)	0.60 (1.13)	-1.5	0.00	0.25	1.25	3.8	
		Week 48	Tezepelumab	45	40 (88.9)	1.14 (1.36)	-1.8	0.00	1.25	2.13	3.5	0.43 [-0.01, 0.86]
			Placebo	47	43 (91.5)	0.62 (1.11)	-2.8	0.00	0.75	1.00	3.8	
		Week 52	Tezepelumab	45	40 (88.9)	1.13 (1.36)	-1.8	0.00	1.25	2.13	3.5	0.41 [-0.02, 0.85]
			Placebo	47	43 (91.5)	0.64 (1.00)	-1.3	0.00	0.75	1.00	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	53	47 (88.7)	3.97 (0.89)	1.8	3.50	4.00	4.50	5.8	
			Placebo	47	39 (83.0)	3.98 (1.12)	1.5	3.25	4.00	5.00	6.0	
		Week 4	Tezepelumab	53	47 (88.7)	4.58 (1.11)	1.3	4.00	4.50	5.50	7.0	
			Placebo	47	39 (83.0)	4.49 (1.16)	2.3	3.75	4.50	5.25	7.0	
		Week 8	Tezepelumab	53	48 (90.6)	4.89 (1.16)	1.0	4.13	4.88	5.75	7.0	
			Placebo	47	40 (85.1)	4.53 (1.30)	1.0	3.75	4.50	5.50	7.0	
		Week 12	Tezepelumab	53	48 (90.6)	4.94 (1.12)	1.0	4.25	4.75	5.75	7.0	
			Placebo	47	41 (87.2)	4.54 (1.12)	1.3	4.00	4.50	5.25	6.8	
		Week 16	Tezepelumab	53	48 (90.6)	4.87 (1.19)	1.0	4.38	4.75	5.38	7.0	
			Placebo	47	41 (87.2)	4.54 (1.13)	1.3	3.75	4.50	5.00	6.8	
		Week 20	Tezepelumab	53	49 (92.5)	4.88 (1.21)	1.0	4.25	4.75	5.75	7.0	
			Placebo	47	41 (87.2)	4.70 (1.07)	2.0	4.00	4.75	5.25	7.0	
		Week 24	Tezepelumab	53	49 (92.5)	4.92 (1.19)	1.0	4.25	5.00	5.75	7.0	
			Placebo	47	41 (87.2)	4.76 (1.16)	1.8	4.00	4.75	5.25	7.0	
		Week 28	Tezepelumab	53	50 (94.3)	4.85 (1.21)	1.0	4.25	4.75	5.50	7.0	
			Placebo	47	41 (87.2)	4.64 (1.22)	1.3	4.00	4.75	5.25	7.0	
		Week 32	Tezepelumab	53	50 (94.3)	4.97 (1.18)	1.0	4.25	5.00	5.75	7.0	
			Placebo	47	42 (89.4)	4.80 (1.19)	2.5	4.00	4.63	5.50	7.0	
		Week 36	Tezepelumab	53	50 (94.3)	4.97 (1.17)	1.0	4.50	4.75	6.00	7.0	
			Placebo	47	42 (89.4)	4.83 (1.22)	1.5	4.00	5.00	5.25	7.0	
		Week 40	Tezepelumab	53	50 (94.3)	5.02 (1.09)	2.0	4.50	4.88	5.75	7.0	
			Placebo	47	42 (89.4)	4.92 (1.23)	1.5	4.25	4.75	5.75	7.0	
		Week 44	Tezepelumab	53	50 (94.3)	5.04 (1.18)	1.3	4.50	5.00	6.00	7.0	
			Placebo	47	42 (89.4)	4.81 (1.21)	2.3	4.00	4.75	5.50	7.0	
		Week 48	Tezepelumab	53	50 (94.3)	5.03 (1.16)	1.0	4.50	5.00	6.00	7.0	
			Placebo	47	42 (89.4)	4.89 (1.24)	1.0	4.25	4.75	6.00	7.0	
		Week 52	Tezepelumab	53	50 (94.3)	5.02 (1.14)	1.0	4.50	5.00	6.00	7.0	
			Placebo	47	42 (89.4)	4.71 (1.36)	1.0	4.00	4.75	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	53	44 (83.0)	0.61 (1.15)	-4.0	0.00	0.50	1.13	3.3	0.09 [-0.35, 0.52]
			Placebo	47	38 (80.9)	0.51 (1.03)	-1.8	-0.25	0.38	1.25	3.0	
		Week 8	Tezepelumab	53	45 (84.9)	0.93 (1.07)	-1.3	0.25	0.75	1.75	3.5	0.31 [-0.13, 0.74]
			Placebo	47	38 (80.9)	0.59 (1.21)	-1.5	-0.25	0.38	1.50	3.3	
		Week 12	Tezepelumab	53	45 (84.9)	1.00 (1.00)	-2.3	0.50	1.00	1.50	3.5	0.33 [-0.11, 0.76]
			Placebo	47	38 (80.9)	0.63 (1.25)	-1.3	-0.25	0.50	1.25	4.3	
		Week 16	Tezepelumab	53	45 (84.9)	0.93 (1.17)	-2.8	0.25	1.00	1.50	3.5	0.29 [-0.14, 0.73]
			Placebo	47	38 (80.9)	0.59 (1.17)	-1.3	-0.25	0.38	1.25	3.0	
		Week 20	Tezepelumab	53	45 (84.9)	0.94 (1.05)	-1.8	0.25	0.75	1.75	3.3	0.18 [-0.25, 0.61]
			Placebo	47	38 (80.9)	0.76 (1.07)	-1.3	0.00	0.63	1.75	3.0	
		Week 24	Tezepelumab	53	45 (84.9)	0.99 (1.07)	-1.5	0.50	1.00	1.50	3.5	0.14 [-0.29, 0.57]
			Placebo	47	38 (80.9)	0.83 (1.30)	-1.5	-0.25	0.50	1.75	3.8	
		Week 28	Tezepelumab	53	45 (84.9)	0.92 (1.14)	-1.5	0.25	0.75	1.50	3.5	0.20 [-0.23, 0.64]
			Placebo	47	38 (80.9)	0.66 (1.39)	-2.8	-0.25	0.50	1.50	4.0	
		Week 32	Tezepelumab	53	45 (84.9)	1.05 (1.11)	-1.3	0.50	1.00	1.75	3.3	0.08 [-0.35, 0.51]
			Placebo	47	38 (80.9)	0.95 (1.24)	-1.5	0.00	0.88	2.00	3.8	
		Week 36	Tezepelumab	53	45 (84.9)	1.04 (1.12)	-1.3	0.25	0.75	2.00	3.5	0.09 [-0.34, 0.52]
			Placebo	47	38 (80.9)	0.93 (1.45)	-2.3	0.00	0.50	2.25	3.8	
		Week 40	Tezepelumab	53	45 (84.9)	1.14 (1.09)	-1.3	0.25	1.00	2.00	3.5	0.12 [-0.31, 0.56]
			Placebo	47	38 (80.9)	0.99 (1.46)	-1.5	0.00	0.50	2.00	4.3	
		Week 44	Tezepelumab	53	45 (84.9)	1.16 (1.14)	-1.5	0.25	1.00	2.00	3.5	0.23 [-0.20, 0.66]
			Placebo	47	38 (80.9)	0.87 (1.35)	-1.3	0.00	0.50	1.50	3.8	
		Week 48	Tezepelumab	53	45 (84.9)	1.12 (1.16)	-1.3	0.50	0.75	2.00	3.8	0.13 [-0.30, 0.57]
			Placebo	47	38 (80.9)	0.95 (1.39)	-1.5	0.25	0.50	2.00	4.0	
		Week 52	Tezepelumab	53	45 (84.9)	1.11 (1.11)	-1.3	0.50	0.75	2.00	3.8	0.27 [-0.17, 0.70]
			Placebo	47	38 (80.9)	0.77 (1.41)	-2.3	0.00	0.50	1.00	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	4.03 (1.07)	1.8	3.50	4.00	4.75	6.5	
			Placebo	33	29 (87.9)	4.12 (1.08)	2.3	3.50	3.75	5.00	6.0	
		Week 4	Tezepelumab	27	27 (100.0)	4.67 (1.01)	3.3	3.75	4.50	5.25	7.0	
			Placebo	33	30 (90.9)	4.74 (1.08)	2.8	3.75	5.00	5.50	6.8	
		Week 8	Tezepelumab	27	27 (100.0)	5.02 (0.94)	3.5	4.50	5.00	5.75	7.0	
			Placebo	33	30 (90.9)	4.98 (1.20)	3.0	4.00	5.00	6.00	6.8	
		Week 12	Tezepelumab	27	27 (100.0)	5.03 (1.04)	3.0	4.25	5.00	5.75	7.0	
			Placebo	33	30 (90.9)	4.91 (1.07)	3.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	27	27 (100.0)	4.98 (0.95)	3.5	4.25	4.75	5.50	7.0	
			Placebo	33	30 (90.9)	4.96 (1.07)	3.3	4.00	4.63	6.00	7.0	
		Week 20	Tezepelumab	27	27 (100.0)	5.00 (1.01)	3.5	4.00	5.00	5.75	7.0	
			Placebo	33	30 (90.9)	5.03 (1.11)	3.3	4.00	4.88	6.00	7.0	
		Week 24	Tezepelumab	27	27 (100.0)	5.20 (0.99)	3.5	4.50	5.00	6.00	7.0	
			Placebo	33	30 (90.9)	5.00 (1.22)	3.3	4.00	4.63	6.00	7.0	
		Week 28	Tezepelumab	27	27 (100.0)	5.02 (0.94)	3.5	4.50	5.00	5.50	7.0	
			Placebo	33	30 (90.9)	4.95 (1.36)	3.0	3.75	4.50	6.00	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	5.09 (0.94)	3.3	4.50	5.00	5.75	6.8	
			Placebo	33	31 (93.9)	5.00 (1.27)	2.8	4.00	4.50	6.00	7.0	
		Week 36	Tezepelumab	27	27 (100.0)	5.10 (0.99)	3.3	4.50	4.75	6.00	7.0	
			Placebo	33	31 (93.9)	5.06 (1.24)	3.3	4.00	4.50	6.25	7.0	
		Week 40	Tezepelumab	27	27 (100.0)	5.09 (0.93)	3.8	4.50	5.00	5.75	7.0	
			Placebo	33	31 (93.9)	5.02 (1.22)	3.0	4.00	4.50	6.00	7.0	
		Week 44	Tezepelumab	27	27 (100.0)	5.17 (1.04)	3.5	4.50	5.00	6.00	7.0	
			Placebo	33	31 (93.9)	5.13 (1.30)	3.0	4.00	4.75	6.50	7.0	
		Week 48	Tezepelumab	27	27 (100.0)	5.14 (1.01)	3.3	4.25	5.00	6.00	7.0	
			Placebo	33	31 (93.9)	5.13 (1.21)	3.3	4.00	4.75	6.50	7.0	
		Week 52	Tezepelumab	27	27 (100.0)	5.08 (0.95)	3.3	4.25	5.00	6.00	7.0	
			Placebo	33	31 (93.9)	4.90 (1.24)	3.0	4.00	4.50	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	27	27 (100.0)	0.64 (1.20)	-2.3	0.00	0.50	1.25	4.0	-0.02 [-0.55, 0.50]
			Placebo	33	29 (87.9)	0.66 (0.78)	-1.3	0.00	0.50	1.25	2.3	
		Week 8	Tezepelumab	27	27 (100.0)	0.99 (1.36)	-1.5	0.00	1.00	1.75	4.3	0.06 [-0.46, 0.59]
			Placebo	33	29 (87.9)	0.91 (1.01)	-1.0	0.25	0.75	1.25	3.3	
		Week 12	Tezepelumab	27	27 (100.0)	1.00 (1.30)	-2.0	0.25	1.00	1.50	4.8	0.15 [-0.37, 0.68]
			Placebo	33	29 (87.9)	0.83 (0.94)	-0.8	0.25	0.75	1.25	3.3	
		Week 16	Tezepelumab	27	27 (100.0)	0.95 (1.30)	-2.3	0.25	0.75	2.00	3.5	0.08 [-0.45, 0.60]
			Placebo	33	29 (87.9)	0.87 (0.84)	-1.0	0.50	0.75	1.25	3.0	
		Week 20	Tezepelumab	27	27 (100.0)	0.97 (1.22)	-1.3	0.00	1.00	1.75	3.3	0.01 [-0.51, 0.54]
			Placebo	33	29 (87.9)	0.96 (0.96)	-1.3	0.25	1.00	1.25	3.0	
		Week 24	Tezepelumab	27	27 (100.0)	1.18 (1.13)	-1.0	0.25	1.25	2.00	3.5	0.24 [-0.29, 0.76]
			Placebo	33	29 (87.9)	0.91 (1.14)	-1.5	0.25	1.00	1.50	3.8	
		Week 28	Tezepelumab	27	27 (100.0)	0.99 (1.25)	-1.5	0.00	1.00	2.00	3.5	0.11 [-0.41, 0.64]
			Placebo	33	29 (87.9)	0.85 (1.19)	-2.8	0.25	0.75	1.25	3.8	
		Week 32	Tezepelumab	27	27 (100.0)	1.06 (1.14)	-1.3	0.00	1.00	2.00	3.3	0.08 [-0.44, 0.60]
			Placebo	33	29 (87.9)	0.97 (1.11)	-1.5	0.25	1.00	1.50	3.8	
		Week 36	Tezepelumab	27	27 (100.0)	1.07 (1.26)	-1.8	0.25	0.75	2.25	3.5	0.05 [-0.48, 0.57]
			Placebo	33	29 (87.9)	1.02 (1.22)	-2.3	0.25	1.00	1.50	3.8	
		Week 40	Tezepelumab	27	27 (100.0)	1.06 (1.23)	-1.5	0.25	1.00	2.00	3.5	0.09 [-0.43, 0.62]
			Placebo	33	29 (87.9)	0.96 (1.08)	-1.5	0.50	0.75	1.25	3.8	
		Week 44	Tezepelumab	27	27 (100.0)	1.14 (1.24)	-1.5	0.00	1.25	2.25	3.5	0.12 [-0.40, 0.65]
			Placebo	33	29 (87.9)	0.99 (1.21)	-1.3	0.25	1.00	1.50	3.8	
		Week 48	Tezepelumab	27	27 (100.0)	1.11 (1.24)	-1.8	0.25	1.00	2.00	3.5	0.07 [-0.45, 0.60]
			Placebo	33	29 (87.9)	1.03 (1.07)	-1.3	0.25	1.00	1.25	3.8	
		Week 52	Tezepelumab	27	27 (100.0)	1.06 (1.28)	-1.8	0.25	1.00	2.00	3.5	0.20 [-0.33, 0.72]
			Placebo	33	29 (87.9)	0.82 (1.14)	-1.3	0.25	0.50	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	109	95 (87.2)	4.29 (1.17)	1.0	3.50	4.25	5.25	7.0	
			Placebo	105	92 (87.6)	4.08 (1.25)	1.5	3.25	4.13	5.00	7.0	
		Week 4	Tezepelumab	109	98 (89.9)	4.97 (1.25)	1.0	4.25	5.00	5.75	7.0	
			Placebo	105	93 (88.6)	4.55 (1.25)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	109	100 (91.7)	5.12 (1.27)	1.0	4.25	5.25	6.00	7.0	
			Placebo	105	96 (91.4)	4.61 (1.34)	1.0	3.75	4.75	5.50	7.0	
		Week 12	Tezepelumab	109	100 (91.7)	5.30 (1.27)	1.0	4.50	5.50	6.25	7.0	
			Placebo	105	97 (92.4)	4.71 (1.22)	1.3	4.00	4.75	5.50	7.0	
		Week 16	Tezepelumab	109	100 (91.7)	5.23 (1.26)	1.0	4.50	5.25	6.00	7.0	
			Placebo	105	97 (92.4)	4.69 (1.33)	1.3	4.00	4.75	5.50	7.0	
		Week 20	Tezepelumab	109	101 (92.7)	5.20 (1.31)	1.0	4.50	5.25	6.25	7.0	
			Placebo	105	97 (92.4)	4.70 (1.33)	1.3	4.00	4.75	5.50	7.0	
		Week 24	Tezepelumab	109	101 (92.7)	5.27 (1.27)	1.0	4.50	5.25	6.25	7.0	
			Placebo	105	97 (92.4)	4.64 (1.39)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	109	103 (94.5)	5.26 (1.34)	1.0	4.50	5.25	6.25	7.0	
			Placebo	105	98 (93.3)	4.79 (1.39)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	109	104 (95.4)	5.35 (1.33)	1.0	4.50	5.50	6.25	7.0	
			Placebo	105	98 (93.3)	4.86 (1.37)	1.3	4.00	5.13	6.00	7.0	
		Week 36	Tezepelumab	109	104 (95.4)	5.34 (1.32)	1.0	4.50	5.50	6.38	7.0	
			Placebo	105	98 (93.3)	4.78 (1.42)	1.0	4.00	5.00	5.75	7.0	
		Week 40	Tezepelumab	109	104 (95.4)	5.39 (1.26)	1.3	4.50	5.50	6.50	7.0	
			Placebo	105	98 (93.3)	4.87 (1.40)	1.0	4.00	5.00	5.75	7.0	
		Week 44	Tezepelumab	109	104 (95.4)	5.42 (1.27)	1.0	4.75	5.50	6.50	7.0	
			Placebo	105	98 (93.3)	4.79 (1.34)	1.3	4.00	4.75	5.75	7.0	
		Week 48	Tezepelumab	109	104 (95.4)	5.39 (1.27)	1.0	4.50	5.50	6.38	7.0	
			Placebo	105	99 (94.3)	4.85 (1.33)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	109	104 (95.4)	5.37 (1.33)	1.0	4.50	5.50	6.50	7.0	
			Placebo	105	99 (94.3)	4.82 (1.37)	1.0	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	109	89 (81.7)	0.71 (1.15)	-4.0	0.00	0.75	1.75	3.0	0.24 [-0.06, 0.53]
			Placebo	105	90 (85.7)	0.45 (1.02)	-2.5	-0.25	0.25	1.25	3.0	
		Week 8	Tezepelumab	109	91 (83.5)	0.84 (1.09)	-1.3	0.00	0.75	1.75	3.5	0.26 [-0.03, 0.55]
			Placebo	105	91 (86.7)	0.56 (1.05)	-1.8	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	109	91 (83.5)	1.02 (1.12)	-2.3	0.25	1.00	1.75	3.5	0.32 [0.03, 0.61]
			Placebo	105	91 (86.7)	0.67 (1.11)	-1.8	0.00	0.50	1.25	4.3	
		Week 16	Tezepelumab	109	91 (83.5)	0.97 (1.16)	-2.8	0.00	1.00	1.75	3.3	0.30 [0.01, 0.60]
			Placebo	105	91 (86.7)	0.63 (1.09)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	109	91 (83.5)	0.94 (1.18)	-1.8	0.00	0.75	1.75	3.5	0.26 [-0.03, 0.55]
			Placebo	105	91 (86.7)	0.65 (1.05)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	109	91 (83.5)	1.02 (1.17)	-1.5	0.25	1.00	2.00	3.5	0.36 [0.07, 0.65]
			Placebo	105	91 (86.7)	0.61 (1.12)	-2.8	-0.25	0.50	1.50	3.3	
		Week 28	Tezepelumab	109	91 (83.5)	1.02 (1.15)	-1.5	0.25	0.75	1.75	3.5	0.24 [-0.05, 0.53]
			Placebo	105	91 (86.7)	0.74 (1.14)	-1.8	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	109	91 (83.5)	1.09 (1.21)	-1.3	0.25	1.00	1.75	3.5	0.22 [-0.07, 0.52]
			Placebo	105	91 (86.7)	0.83 (1.09)	-1.8	0.00	0.75	1.75	3.5	
		Week 36	Tezepelumab	109	91 (83.5)	1.09 (1.22)	-1.3	0.25	1.00	2.00	3.5	0.29 [-0.00, 0.58]
			Placebo	105	91 (86.7)	0.73 (1.23)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	109	91 (83.5)	1.15 (1.16)	-1.3	0.25	1.00	2.00	3.5	0.27 [-0.03, 0.56]
			Placebo	105	91 (86.7)	0.82 (1.26)	-2.5	0.00	0.75	1.75	4.3	
		Week 44	Tezepelumab	109	91 (83.5)	1.17 (1.19)	-1.5	0.25	1.00	2.00	3.8	0.35 [0.06, 0.64]
			Placebo	105	91 (86.7)	0.75 (1.21)	-1.5	0.00	0.50	1.50	3.8	
		Week 48	Tezepelumab	109	91 (83.5)	1.15 (1.21)	-1.3	0.25	1.00	2.00	3.8	0.28 [-0.02, 0.57]
			Placebo	105	91 (86.7)	0.81 (1.27)	-2.8	0.00	0.75	1.50	4.0	
		Week 52	Tezepelumab	109	91 (83.5)	1.10 (1.21)	-1.3	0.25	1.00	1.75	3.8	0.28 [-0.01, 0.57]
			Placebo	105	91 (86.7)	0.77 (1.22)	-2.3	0.00	0.50	1.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	69	63 (91.3)	4.21 (1.02)	1.8	3.50	4.25	5.00	6.8	
			Placebo	72	61 (84.7)	4.05 (1.17)	1.5	3.25	4.00	5.00	7.0	
		Week 4	Tezepelumab	69	60 (87.0)	4.81 (1.12)	1.3	4.00	4.75	5.63	7.0	
			Placebo	72	61 (84.7)	4.59 (1.31)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	69	61 (88.4)	5.00 (1.05)	1.8	4.25	5.00	5.75	7.0	
			Placebo	72	63 (87.5)	4.78 (1.34)	1.5	3.75	5.00	5.75	7.0	
		Week 12	Tezepelumab	69	61 (88.4)	5.24 (1.11)	3.0	4.50	5.25	6.25	7.0	
			Placebo	72	63 (87.5)	4.76 (1.15)	1.8	4.00	4.75	5.50	7.0	
		Week 16	Tezepelumab	69	61 (88.4)	5.10 (1.08)	2.0	4.50	5.00	6.00	7.0	
			Placebo	72	63 (87.5)	4.86 (1.25)	1.3	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	69	62 (89.9)	5.08 (1.19)	1.0	4.25	5.00	6.00	7.0	
			Placebo	72	63 (87.5)	4.84 (1.28)	1.3	4.00	4.75	5.75	7.0	
		Week 24	Tezepelumab	69	62 (89.9)	5.24 (1.14)	1.3	4.50	5.00	6.25	7.0	
			Placebo	72	63 (87.5)	4.79 (1.43)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	69	63 (91.3)	5.15 (1.13)	1.5	4.25	5.00	6.00	7.0	
			Placebo	72	64 (88.9)	4.91 (1.41)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	69	64 (92.8)	5.23 (1.13)	1.5	4.50	5.13	6.00	7.0	
			Placebo	72	65 (90.3)	4.95 (1.44)	1.3	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	69	64 (92.8)	5.26 (1.14)	1.8	4.50	5.13	6.25	7.0	
			Placebo	72	65 (90.3)	5.00 (1.34)	1.0	4.00	5.00	6.25	7.0	
		Week 40	Tezepelumab	69	64 (92.8)	5.34 (1.11)	2.3	4.50	5.13	6.25	7.0	
			Placebo	72	65 (90.3)	5.02 (1.32)	1.0	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	69	64 (92.8)	5.30 (1.21)	1.3	4.50	5.00	6.50	7.0	
			Placebo	72	65 (90.3)	5.01 (1.38)	1.3	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	69	64 (92.8)	5.34 (1.11)	2.3	4.50	5.25	6.25	7.0	
			Placebo	72	66 (91.7)	5.11 (1.23)	2.0	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	69	64 (92.8)	5.33 (1.10)	2.3	4.50	5.13	6.25	7.0	
			Placebo	72	66 (91.7)	4.99 (1.27)	2.0	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	69	58 (84.1)	0.64 (1.18)	-4.0	0.00	0.75	1.25	4.0	0.09 [-0.27, 0.45]
			Placebo	72	60 (83.3)	0.54 (0.91)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	69	59 (85.5)	0.83 (1.16)	-1.5	0.00	0.75	1.75	4.3	0.04 [-0.31, 0.40]
			Placebo	72	61 (84.7)	0.78 (1.03)	-1.8	0.00	0.75	1.25	3.3	
		Week 12	Tezepelumab	69	59 (85.5)	1.07 (1.17)	-2.3	0.25	1.00	1.75	4.8	0.29 [-0.07, 0.65]
			Placebo	72	61 (84.7)	0.75 (1.04)	-1.8	0.00	0.75	1.25	3.3	
		Week 16	Tezepelumab	69	59 (85.5)	0.92 (1.18)	-2.8	0.25	1.00	1.50	3.5	0.08 [-0.28, 0.44]
			Placebo	72	61 (84.7)	0.84 (0.96)	-1.8	0.25	0.75	1.25	3.0	
		Week 20	Tezepelumab	69	59 (85.5)	0.90 (1.18)	-1.8	0.25	0.75	1.50	3.5	0.06 [-0.29, 0.42]
			Placebo	72	61 (84.7)	0.83 (0.98)	-1.8	0.25	0.75	1.25	3.0	
		Week 24	Tezepelumab	69	59 (85.5)	1.06 (1.11)	-1.5	0.25	1.00	2.00	3.5	0.26 [-0.10, 0.62]
			Placebo	72	61 (84.7)	0.77 (1.14)	-1.8	0.00	0.75	1.25	3.8	
		Week 28	Tezepelumab	69	59 (85.5)	1.00 (1.13)	-1.5	0.25	1.00	1.75	3.5	0.13 [-0.23, 0.49]
			Placebo	72	61 (84.7)	0.85 (1.12)	-2.8	0.25	0.75	1.25	3.8	
		Week 32	Tezepelumab	69	59 (85.5)	1.05 (1.14)	-1.3	0.25	1.00	1.75	3.5	0.11 [-0.25, 0.47]
			Placebo	72	61 (84.7)	0.92 (1.08)	-1.8	0.25	1.00	1.50	3.8	
		Week 36	Tezepelumab	69	59 (85.5)	1.07 (1.25)	-1.8	0.25	1.00	2.00	3.5	0.09 [-0.26, 0.45]
			Placebo	72	61 (84.7)	0.95 (1.16)	-2.3	0.25	0.75	1.50	3.8	
		Week 40	Tezepelumab	69	59 (85.5)	1.17 (1.19)	-1.5	0.25	1.00	2.25	3.5	0.17 [-0.19, 0.53]
			Placebo	72	61 (84.7)	0.98 (1.17)	-1.5	0.25	0.75	1.50	4.3	
		Week 44	Tezepelumab	69	59 (85.5)	1.11 (1.21)	-1.5	0.25	1.00	2.00	3.5	0.15 [-0.21, 0.51]
			Placebo	72	61 (84.7)	0.93 (1.19)	-1.5	0.25	0.75	1.50	3.8	
		Week 48	Tezepelumab	69	59 (85.5)	1.17 (1.22)	-1.8	0.50	1.00	2.00	3.8	0.10 [-0.26, 0.46]
			Placebo	72	61 (84.7)	1.05 (1.17)	-1.3	0.25	1.00	1.50	4.0	
		Week 52	Tezepelumab	69	59 (85.5)	1.14 (1.22)	-1.8	0.50	1.00	2.00	3.8	0.17 [-0.19, 0.53]
			Placebo	72	61 (84.7)	0.93 (1.18)	-1.3	0.00	0.75	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	4.25 (1.29)	1.0	3.50	4.25	5.25	7.0	
			Placebo	66	60 (90.9)	4.13 (1.25)	1.5	3.38	4.13	5.00	6.5	
		Week 4	Tezepelumab	67	65 (97.0)	4.99 (1.29)	1.0	4.25	5.00	5.75	7.0	
			Placebo	66	62 (93.9)	4.60 (1.11)	2.0	4.00	4.75	5.50	6.8	
		Week 8	Tezepelumab	67	66 (98.5)	5.19 (1.34)	1.0	4.25	5.25	6.00	7.0	
			Placebo	66	63 (95.5)	4.62 (1.29)	1.0	3.75	4.75	5.50	7.0	
		Week 12	Tezepelumab	67	66 (98.5)	5.24 (1.33)	1.0	4.50	5.50	6.25	7.0	
			Placebo	66	64 (97.0)	4.76 (1.23)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	67	66 (98.5)	5.25 (1.31)	1.0	4.50	5.38	6.25	7.0	
			Placebo	66	64 (97.0)	4.65 (1.30)	1.3	4.00	4.50	5.63	7.0	
		Week 20	Tezepelumab	67	66 (98.5)	5.23 (1.31)	1.0	4.50	5.25	6.25	7.0	
			Placebo	66	64 (97.0)	4.71 (1.29)	1.8	4.00	4.63	5.63	7.0	
		Week 24	Tezepelumab	67	66 (98.5)	5.28 (1.29)	1.0	4.50	5.25	6.25	7.0	
			Placebo	66	64 (97.0)	4.66 (1.28)	1.5	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	67	67 (100.0)	5.26 (1.39)	1.0	4.50	5.50	6.25	7.0	
			Placebo	66	64 (97.0)	4.75 (1.36)	1.3	4.00	4.75	5.88	7.0	
		Week 32	Tezepelumab	67	67 (100.0)	5.35 (1.38)	1.0	4.50	5.50	6.25	7.0	
			Placebo	66	64 (97.0)	4.84 (1.26)	2.3	4.00	4.88	6.00	7.0	
		Week 36	Tezepelumab	67	67 (100.0)	5.32 (1.38)	1.0	4.50	5.50	6.50	7.0	
			Placebo	66	64 (97.0)	4.69 (1.42)	1.5	4.00	4.75	5.63	7.0	
		Week 40	Tezepelumab	67	67 (100.0)	5.32 (1.30)	1.3	4.50	5.50	6.25	7.0	
			Placebo	66	64 (97.0)	4.79 (1.39)	1.5	4.00	5.00	5.75	7.0	
		Week 44	Tezepelumab	67	67 (100.0)	5.43 (1.25)	1.0	4.75	5.75	6.25	7.0	
			Placebo	66	64 (97.0)	4.73 (1.29)	1.8	4.00	4.75	5.75	7.0	
		Week 48	Tezepelumab	67	67 (100.0)	5.34 (1.33)	1.0	4.50	5.50	6.25	7.0	
			Placebo	66	64 (97.0)	4.72 (1.35)	1.0	4.00	4.88	5.88	7.0	
		Week 52	Tezepelumab	67	67 (100.0)	5.29 (1.41)	1.0	4.50	5.50	6.50	7.0	
			Placebo	66	64 (97.0)	4.69 (1.39)	1.0	4.00	4.88	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	67	58 (86.6)	0.75 (1.15)	-2.0	0.00	0.50	1.75	3.0	0.26 [-0.11, 0.62]
			Placebo	66	59 (89.4)	0.47 (1.02)	-2.0	-0.25	0.25	1.25	2.5	
		Week 8	Tezepelumab	67	59 (88.1)	0.92 (1.15)	-1.0	0.00	0.75	1.75	3.5	0.37 [0.00, 0.73]
			Placebo	66	59 (89.4)	0.51 (1.06)	-1.5	-0.25	0.25	1.25	2.8	
		Week 12	Tezepelumab	67	59 (88.1)	0.97 (1.15)	-1.0	0.25	0.75	1.75	3.5	0.27 [-0.10, 0.63]
			Placebo	66	59 (89.4)	0.67 (1.10)	-1.3	0.00	0.50	1.25	4.3	
		Week 16	Tezepelumab	67	59 (88.1)	1.01 (1.20)	-1.0	0.00	0.75	2.00	3.3	0.42 [0.05, 0.78]
			Placebo	66	59 (89.4)	0.53 (1.10)	-1.5	-0.25	0.25	1.25	3.0	
		Week 20	Tezepelumab	67	59 (88.1)	1.00 (1.19)	-1.0	0.00	0.75	2.00	3.5	0.34 [-0.03, 0.70]
			Placebo	66	59 (89.4)	0.62 (1.08)	-2.3	0.00	0.50	1.50	2.8	
		Week 24	Tezepelumab	67	59 (88.1)	1.05 (1.21)	-1.0	0.00	1.00	2.25	3.5	0.39 [0.03, 0.76]
			Placebo	66	59 (89.4)	0.59 (1.12)	-2.8	-0.25	0.50	1.50	2.5	
		Week 28	Tezepelumab	67	59 (88.1)	1.03 (1.21)	-1.0	0.00	0.75	2.25	3.5	0.28 [-0.08, 0.65]
			Placebo	66	59 (89.4)	0.69 (1.18)	-1.5	-0.25	0.50	1.50	4.0	
		Week 32	Tezepelumab	67	59 (88.1)	1.12 (1.24)	-1.0	0.00	1.00	2.25	3.5	0.27 [-0.10, 0.63]
			Placebo	66	59 (89.4)	0.81 (1.11)	-1.3	0.00	0.75	1.75	3.5	
		Week 36	Tezepelumab	67	59 (88.1)	1.10 (1.21)	-1.0	0.25	1.00	2.00	3.5	0.37 [0.00, 0.73]
			Placebo	66	59 (89.4)	0.64 (1.29)	-2.8	-0.25	0.50	1.50	3.8	
		Week 40	Tezepelumab	67	59 (88.1)	1.08 (1.15)	-1.0	0.25	1.00	2.00	3.5	0.29 [-0.08, 0.65]
			Placebo	66	59 (89.4)	0.73 (1.26)	-2.5	0.00	0.50	1.75	4.3	
		Week 44	Tezepelumab	67	59 (88.1)	1.21 (1.20)	-1.0	0.25	1.25	2.00	3.8	0.44 [0.08, 0.81]
			Placebo	66	59 (89.4)	0.68 (1.23)	-1.5	-0.25	0.25	1.50	3.8	
		Week 48	Tezepelumab	67	59 (88.1)	1.12 (1.21)	-1.0	0.25	1.00	2.00	3.5	0.37 [0.00, 0.73]
			Placebo	66	59 (89.4)	0.67 (1.27)	-2.8	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	67	59 (88.1)	1.05 (1.23)	-1.3	0.00	1.00	1.75	3.5	0.35 [-0.01, 0.71]
			Placebo	66	59 (89.4)	0.62 (1.21)	-2.3	-0.25	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	78	68 (87.2)	4.33 (0.99)	1.8	3.75	4.25	5.00	7.0	
			Placebo	74	63 (85.1)	3.86 (1.16)	1.5	3.25	4.00	4.75	6.0	
		Week 4	Tezepelumab	78	72 (92.3)	4.81 (1.11)	1.3	4.00	4.75	5.75	7.0	
			Placebo	74	66 (89.2)	4.44 (1.21)	1.3	3.75	4.50	5.25	7.0	
		Week 8	Tezepelumab	78	72 (92.3)	5.07 (0.99)	1.8	4.25	5.00	5.75	7.0	
			Placebo	74	66 (89.2)	4.59 (1.38)	1.5	3.75	4.75	5.50	7.0	
		Week 12	Tezepelumab	78	72 (92.3)	5.24 (1.08)	3.0	4.38	5.25	6.25	7.0	
			Placebo	74	67 (90.5)	4.59 (1.21)	1.8	4.00	4.50	5.25	7.0	
		Week 16	Tezepelumab	78	72 (92.3)	5.07 (1.04)	2.0	4.50	5.00	5.88	7.0	
			Placebo	74	67 (90.5)	4.69 (1.22)	1.5	4.00	4.50	5.50	7.0	
		Week 20	Tezepelumab	78	73 (93.6)	5.08 (1.11)	1.0	4.25	5.00	5.75	7.0	
			Placebo	74	67 (90.5)	4.64 (1.18)	1.5	4.00	4.75	5.25	7.0	
		Week 24	Tezepelumab	78	73 (93.6)	5.23 (1.13)	1.3	4.25	5.00	6.00	7.0	
			Placebo	74	67 (90.5)	4.68 (1.36)	1.0	4.00	4.50	5.75	7.0	
		Week 28	Tezepelumab	78	75 (96.2)	5.16 (1.13)	1.5	4.25	5.00	6.00	7.0	
			Placebo	74	68 (91.9)	4.70 (1.30)	1.3	4.00	4.88	5.75	7.0	
		Week 32	Tezepelumab	78	76 (97.4)	5.22 (1.12)	1.5	4.50	5.13	6.00	7.0	
			Placebo	74	69 (93.2)	4.70 (1.35)	1.3	4.00	4.50	6.00	7.0	
		Week 36	Tezepelumab	78	76 (97.4)	5.21 (1.13)	1.8	4.38	5.00	6.00	7.0	
			Placebo	74	69 (93.2)	4.70 (1.41)	1.0	4.00	4.50	5.50	7.0	
		Week 40	Tezepelumab	78	76 (97.4)	5.25 (1.08)	2.3	4.50	5.00	6.00	7.0	
			Placebo	74	69 (93.2)	4.78 (1.34)	1.0	4.00	4.75	5.75	7.0	
		Week 44	Tezepelumab	78	76 (97.4)	5.27 (1.15)	1.3	4.50	5.25	6.25	7.0	
			Placebo	74	69 (93.2)	4.80 (1.35)	1.3	4.00	4.75	5.75	7.0	
		Week 48	Tezepelumab	78	76 (97.4)	5.25 (1.10)	2.3	4.38	5.00	6.13	7.0	
			Placebo	74	70 (94.6)	4.82 (1.31)	1.0	4.00	4.75	6.00	7.0	
		Week 52	Tezepelumab	78	76 (97.4)	5.23 (1.07)	2.3	4.50	5.00	6.00	7.0	
			Placebo	74	70 (94.6)	4.70 (1.35)	1.0	4.00	4.75	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	78	67 (85.9)	0.47 (1.14)	-4.0	0.00	0.50	1.00	4.0	-0.14 [-0.48, 0.21]
			Placebo	74	63 (85.1)	0.62 (1.02)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	78	67 (85.9)	0.72 (1.09)	-1.5	0.00	0.75	1.50	4.3	-0.05 [-0.40, 0.29]
			Placebo	74	63 (85.1)	0.78 (1.09)	-1.5	0.00	0.75	1.50	3.0	
		Week 12	Tezepelumab	78	67 (85.9)	0.92 (1.10)	-2.3	0.25	1.00	1.50	4.8	0.11 [-0.23, 0.46]
			Placebo	74	63 (85.1)	0.79 (1.16)	-1.3	0.00	0.75	1.25	4.3	
		Week 16	Tezepelumab	78	67 (85.9)	0.76 (1.11)	-2.8	0.00	0.75	1.50	3.0	-0.10 [-0.45, 0.24]
			Placebo	74	63 (85.1)	0.87 (1.05)	-1.5	0.25	1.00	1.50	3.0	
		Week 20	Tezepelumab	78	67 (85.9)	0.76 (1.13)	-1.8	0.00	0.75	1.50	3.3	-0.06 [-0.40, 0.28]
			Placebo	74	63 (85.1)	0.83 (1.00)	-1.3	0.25	0.75	1.25	3.0	
		Week 24	Tezepelumab	78	67 (85.9)	0.94 (1.06)	-1.5	0.25	1.00	1.75	3.3	0.07 [-0.27, 0.42]
			Placebo	74	63 (85.1)	0.86 (1.09)	-1.5	0.00	0.75	1.50	3.3	
		Week 28	Tezepelumab	78	67 (85.9)	0.87 (1.07)	-1.5	0.25	0.75	1.75	3.3	0.02 [-0.33, 0.36]
			Placebo	74	63 (85.1)	0.85 (1.14)	-2.8	0.25	0.75	1.50	4.0	
		Week 32	Tezepelumab	78	67 (85.9)	0.91 (1.12)	-1.3	0.00	1.00	1.75	3.3	0.02 [-0.32, 0.36]
			Placebo	74	63 (85.1)	0.88 (1.05)	-1.5	0.25	0.75	1.75	3.5	
		Week 36	Tezepelumab	78	67 (85.9)	0.90 (1.15)	-1.8	0.25	0.75	1.75	3.3	0.02 [-0.33, 0.36]
			Placebo	74	63 (85.1)	0.88 (1.26)	-2.3	0.00	0.75	1.75	3.8	
		Week 40	Tezepelumab	78	67 (85.9)	0.95 (1.10)	-1.5	0.25	1.00	1.75	3.3	0.01 [-0.33, 0.36]
			Placebo	74	63 (85.1)	0.94 (1.24)	-1.8	0.25	0.75	2.00	4.3	
		Week 44	Tezepelumab	78	67 (85.9)	0.96 (1.12)	-1.5	0.00	1.00	1.75	3.3	0.03 [-0.31, 0.37]
			Placebo	74	63 (85.1)	0.93 (1.21)	-1.3	0.00	0.75	1.75	3.5	
		Week 48	Tezepelumab	78	67 (85.9)	0.96 (1.10)	-1.8	0.25	1.00	1.75	3.3	-0.00 [-0.35, 0.34]
			Placebo	74	63 (85.1)	0.96 (1.21)	-1.5	0.25	1.00	1.50	4.0	
		Week 52	Tezepelumab	78	67 (85.9)	0.91 (1.11)	-1.8	0.00	1.00	1.75	3.3	0.07 [-0.28, 0.41]
			Placebo	74	63 (85.1)	0.83 (1.22)	-2.3	0.00	0.75	1.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	57	53 (93.0)	4.11 (1.31)	1.0	3.50	4.00	5.25	6.8	
			Placebo	63	57 (90.5)	4.36 (1.22)	1.5	3.50	4.25	5.50	7.0	
		Week 4	Tezepelumab	57	52 (91.2)	5.07 (1.32)	1.0	4.50	5.25	5.88	7.0	
			Placebo	63	57 (90.5)	4.77 (1.19)	2.0	4.00	5.00	5.50	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.14 (1.46)	1.0	4.25	5.25	6.25	7.0	
			Placebo	63	59 (93.7)	4.85 (1.22)	1.0	4.00	5.00	5.75	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.23 (1.41)	1.0	4.50	5.38	6.25	7.0	
			Placebo	63	59 (93.7)	4.96 (1.14)	1.3	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.31 (1.39)	1.0	4.50	5.50	6.25	7.0	
			Placebo	63	59 (93.7)	4.89 (1.26)	1.3	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.24 (1.43)	1.0	4.50	5.25	6.50	7.0	
			Placebo	63	59 (93.7)	4.99 (1.30)	1.8	4.00	5.00	6.25	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.27 (1.34)	1.0	4.50	5.25	6.50	7.0	
			Placebo	63	59 (93.7)	4.83 (1.28)	1.5	4.00	5.00	5.75	7.0	
		Week 28	Tezepelumab	57	54 (94.7)	5.28 (1.45)	1.0	4.50	5.50	6.25	7.0	
			Placebo	63	59 (93.7)	5.03 (1.39)	2.3	4.00	5.25	6.25	7.0	
		Week 32	Tezepelumab	57	54 (94.7)	5.38 (1.45)	1.0	4.75	5.50	6.50	7.0	
			Placebo	63	59 (93.7)	5.18 (1.22)	2.8	4.00	5.25	6.25	7.0	
		Week 36	Tezepelumab	57	54 (94.7)	5.42 (1.44)	1.0	4.75	5.50	6.75	7.0	
			Placebo	63	59 (93.7)	5.05 (1.33)	1.8	4.25	5.00	6.25	7.0	
		Week 40	Tezepelumab	57	54 (94.7)	5.44 (1.38)	1.3	4.50	5.75	6.50	7.0	
			Placebo	63	59 (93.7)	5.08 (1.36)	1.8	4.00	5.25	6.00	7.0	
		Week 44	Tezepelumab	57	54 (94.7)	5.50 (1.34)	1.0	4.75	5.88	6.50	7.0	
			Placebo	63	59 (93.7)	4.98 (1.33)	1.8	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	57	54 (94.7)	5.48 (1.39)	1.0	4.75	5.75	6.50	7.0	
			Placebo	63	59 (93.7)	5.06 (1.28)	1.8	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	57	54 (94.7)	5.43 (1.51)	1.0	4.50	5.75	6.50	7.0	
			Placebo	63	59 (93.7)	5.03 (1.31)	1.5	4.00	5.25	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	1.03 (1.11)	-1.3	0.25	1.00	1.88	3.3	0.65 [0.25, 1.04]
			Placebo	63	56 (88.9)	0.38 (0.89)	-2.0	0.00	0.25	1.00	2.5	
		Week 8	Tezepelumab	57	50 (87.7)	1.07 (1.21)	-1.0	0.00	0.88	2.00	3.5	0.50 [0.11, 0.88]
			Placebo	63	56 (88.9)	0.52 (1.00)	-1.8	0.00	0.50	1.00	3.3	
		Week 12	Tezepelumab	57	50 (87.7)	1.14 (1.23)	-1.0	0.25	1.00	2.25	3.5	0.49 [0.10, 0.87]
			Placebo	63	56 (88.9)	0.60 (0.96)	-1.8	0.00	0.63	1.25	2.5	
		Week 16	Tezepelumab	57	50 (87.7)	1.22 (1.24)	-1.0	0.25	1.00	2.50	3.5	0.63 [0.24, 1.03]
			Placebo	63	56 (88.9)	0.52 (0.96)	-1.5	0.00	0.50	1.13	3.0	
		Week 20	Tezepelumab	57	50 (87.7)	1.16 (1.21)	-0.8	0.25	0.88	2.00	3.5	0.46 [0.07, 0.84]
			Placebo	63	56 (88.9)	0.65 (1.03)	-2.3	0.00	0.50	1.25	2.8	
		Week 24	Tezepelumab	57	50 (87.7)	1.18 (1.27)	-0.8	0.25	1.00	2.25	3.5	0.55 [0.16, 0.94]
			Placebo	63	56 (88.9)	0.53 (1.12)	-2.8	-0.25	0.38	1.50	3.8	
		Week 28	Tezepelumab	57	50 (87.7)	1.20 (1.26)	-0.8	0.25	1.00	2.25	3.5	0.40 [0.01, 0.78]
			Placebo	63	56 (88.9)	0.72 (1.12)	-1.5	0.00	0.63	1.50	3.8	
		Week 32	Tezepelumab	57	50 (87.7)	1.30 (1.24)	-0.8	0.25	1.25	2.25	3.5	0.35 [-0.04, 0.73]
			Placebo	63	56 (88.9)	0.89 (1.11)	-1.3	0.00	0.75	1.75	3.8	
		Week 36	Tezepelumab	57	50 (87.7)	1.34 (1.29)	-1.0	0.25	1.00	2.25	3.5	0.48 [0.10, 0.87]
			Placebo	63	56 (88.9)	0.73 (1.21)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	57	50 (87.7)	1.36 (1.22)	-1.0	0.25	1.25	2.50	3.5	0.48 [0.10, 0.87]
			Placebo	63	56 (88.9)	0.77 (1.20)	-2.5	0.00	0.50	1.50	3.8	
		Week 44	Tezepelumab	57	50 (87.7)	1.42 (1.24)	-1.0	0.50	1.25	2.50	3.8	0.61 [0.22, 1.00]
			Placebo	63	56 (88.9)	0.67 (1.22)	-1.5	0.00	0.38	1.25	3.8	
		Week 48	Tezepelumab	57	50 (87.7)	1.40 (1.32)	-1.0	0.50	1.13	2.50	3.8	0.51 [0.12, 0.89]
			Placebo	63	56 (88.9)	0.75 (1.26)	-2.8	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	57	50 (87.7)	1.34 (1.33)	-1.3	0.50	1.00	2.50	3.8	0.49 [0.10, 0.87]
			Placebo	63	56 (88.9)	0.72 (1.19)	-1.3	0.00	0.50	1.13	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.16 (0.99)	1.8	3.50	4.13	4.75	6.5	
			Placebo	66	54 (81.8)	3.87 (1.31)	1.5	2.75	3.88	4.75	6.5	
		Week 4	Tezepelumab	57	55 (96.5)	4.79 (1.02)	2.0	4.00	4.75	5.50	7.0	
			Placebo	66	57 (86.4)	4.45 (1.20)	2.0	3.75	4.50	5.25	7.0	
		Week 8	Tezepelumab	57	55 (96.5)	4.90 (1.14)	1.0	4.25	5.00	5.75	7.0	
			Placebo	66	60 (90.9)	4.43 (1.34)	1.0	3.75	4.50	5.50	7.0	
		Week 12	Tezepelumab	57	55 (96.5)	5.10 (1.15)	1.0	4.50	5.00	5.75	7.0	
			Placebo	66	60 (90.9)	4.52 (1.18)	1.3	4.00	4.50	5.38	7.0	
		Week 16	Tezepelumab	57	55 (96.5)	5.13 (1.19)	1.0	4.50	5.00	6.00	7.0	
			Placebo	66	60 (90.9)	4.46 (1.30)	1.3	4.00	4.25	5.38	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.06 (1.34)	1.0	4.25	5.00	6.00	7.0	
			Placebo	66	60 (90.9)	4.43 (1.35)	1.3	3.63	4.25	5.25	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.10 (1.32)	1.0	4.00	5.00	6.25	7.0	
			Placebo	66	60 (90.9)	4.31 (1.37)	1.0	3.75	4.25	5.25	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.12 (1.24)	1.0	4.50	5.00	6.00	7.0	
			Placebo	66	60 (90.9)	4.45 (1.40)	1.3	3.63	4.13	5.50	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.13 (1.30)	1.0	4.50	5.00	6.00	7.0	
			Placebo	66	61 (92.4)	4.38 (1.36)	1.3	3.75	4.00	5.25	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.07 (1.30)	1.0	4.25	5.00	6.00	7.0	
			Placebo	66	61 (92.4)	4.38 (1.35)	1.0	4.00	4.25	5.25	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.23 (1.20)	2.0	4.38	5.00	6.25	7.0	
			Placebo	66	61 (92.4)	4.48 (1.34)	1.0	3.75	4.50	5.50	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.15 (1.27)	1.3	4.25	5.00	6.13	7.0	
			Placebo	66	61 (92.4)	4.40 (1.25)	1.3	3.75	4.00	5.25	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.12 (1.32)	1.0	4.13	5.13	6.25	7.0	
			Placebo	66	62 (93.9)	4.47 (1.26)	1.0	4.00	4.25	5.25	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.13 (1.31)	1.0	4.25	5.13	6.13	7.0	
			Placebo	66	62 (93.9)	4.42 (1.30)	1.0	4.00	4.25	5.25	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	57	49 (86.0)	0.67 (0.99)	-2.3	0.25	0.75	1.25	2.5	0.11 [-0.28, 0.49]
			Placebo	66	53 (80.3)	0.58 (0.87)	-1.3	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	57	49 (86.0)	0.73 (1.12)	-1.5	0.00	0.75	1.75	2.8	0.11 [-0.28, 0.50]
			Placebo	66	54 (81.8)	0.62 (0.96)	-1.3	0.00	0.63	1.25	3.0	
		Week 12	Tezepelumab	57	49 (86.0)	0.94 (1.06)	-2.0	0.25	1.00	1.50	3.0	0.26 [-0.12, 0.65]
			Placebo	66	54 (81.8)	0.66 (1.03)	-1.3	0.00	0.63	1.25	4.3	
		Week 16	Tezepelumab	57	49 (86.0)	0.98 (1.19)	-2.3	0.00	1.00	1.50	3.3	0.35 [-0.04, 0.74]
			Placebo	66	54 (81.8)	0.59 (1.00)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	57	49 (86.0)	0.95 (1.18)	-1.8	0.00	1.00	1.75	3.5	0.32 [-0.07, 0.71]
			Placebo	66	54 (81.8)	0.60 (1.02)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	57	49 (86.0)	0.96 (1.16)	-1.5	0.00	1.00	2.00	3.3	0.42 [0.03, 0.81]
			Placebo	66	54 (81.8)	0.49 (1.11)	-2.8	-0.25	0.63	1.25	3.0	
		Week 28	Tezepelumab	57	49 (86.0)	1.03 (1.16)	-1.5	0.00	1.25	1.75	3.3	0.36 [-0.03, 0.75]
			Placebo	66	54 (81.8)	0.62 (1.12)	-1.8	0.00	0.75	1.25	4.0	
		Week 32	Tezepelumab	57	49 (86.0)	1.06 (1.21)	-1.3	0.00	1.25	1.75	3.5	0.40 [0.01, 0.80]
			Placebo	66	54 (81.8)	0.60 (1.04)	-1.8	-0.25	0.63	1.25	3.5	
		Week 36	Tezepelumab	57	49 (86.0)	1.01 (1.30)	-1.8	0.00	1.25	2.00	3.5	0.35 [-0.04, 0.74]
			Placebo	66	54 (81.8)	0.58 (1.16)	-2.8	0.00	0.50	1.00	3.8	
		Week 40	Tezepelumab	57	49 (86.0)	1.16 (1.17)	-1.5	0.25	1.25	2.25	3.3	0.41 [0.02, 0.81]
			Placebo	66	54 (81.8)	0.66 (1.22)	-2.5	0.00	0.50	1.25	4.3	
		Week 44	Tezepelumab	57	49 (86.0)	1.04 (1.16)	-1.5	0.00	1.25	1.75	3.0	0.45 [0.06, 0.84]
			Placebo	66	54 (81.8)	0.55 (1.04)	-1.5	0.00	0.25	1.25	3.5	
		Week 48	Tezepelumab	57	49 (86.0)	1.05 (1.22)	-1.8	-0.25	1.25	2.00	3.5	0.35 [-0.04, 0.74]
			Placebo	66	54 (81.8)	0.63 (1.19)	-2.8	0.00	0.63	1.25	3.5	
		Week 52	Tezepelumab	57	49 (86.0)	1.04 (1.22)	-1.8	0.00	1.25	1.75	3.5	0.40 [0.01, 0.79]
			Placebo	66	54 (81.8)	0.57 (1.14)	-2.3	-0.25	0.50	1.25	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	71	66 (93.0)	4.33 (1.25)	1.0	3.75	4.25	5.25	7.0	
			Placebo	63	58 (92.1)	4.30 (1.07)	2.0	3.50	4.25	5.25	7.0	
		Week 4	Tezepelumab	71	63 (88.7)	4.97 (1.37)	1.0	4.00	5.25	6.00	7.0	
			Placebo	63	57 (90.5)	4.74 (1.23)	1.3	4.00	4.75	5.50	7.0	
		Week 8	Tezepelumab	71	65 (91.5)	5.22 (1.27)	1.0	4.25	5.25	6.25	7.0	
			Placebo	63	57 (90.5)	4.93 (1.20)	2.3	4.00	5.00	5.75	7.0	
		Week 12	Tezepelumab	71	65 (91.5)	5.32 (1.31)	1.0	4.50	5.75	6.25	7.0	
			Placebo	63	58 (92.1)	4.98 (1.10)	2.5	4.25	5.00	5.75	7.0	
		Week 16	Tezepelumab	71	65 (91.5)	5.20 (1.24)	1.0	4.50	5.25	6.00	7.0	
			Placebo	63	58 (92.1)	5.01 (1.18)	2.0	4.25	5.00	6.00	7.0	
		Week 20	Tezepelumab	71	65 (91.5)	5.24 (1.21)	1.0	4.50	5.25	6.25	7.0	
			Placebo	63	58 (92.1)	5.08 (1.08)	2.3	4.25	5.00	5.75	7.0	
		Week 24	Tezepelumab	71	65 (91.5)	5.37 (1.16)	1.0	4.75	5.50	6.25	7.0	
			Placebo	63	58 (92.1)	5.07 (1.18)	2.0	4.50	5.25	6.00	7.0	
		Week 28	Tezepelumab	71	66 (93.0)	5.29 (1.34)	1.0	4.25	5.38	6.25	7.0	
			Placebo	63	59 (93.7)	5.19 (1.26)	1.5	4.50	5.25	6.00	7.0	
		Week 32	Tezepelumab	71	67 (94.4)	5.44 (1.25)	1.0	4.75	5.75	6.25	7.0	
			Placebo	63	59 (93.7)	5.37 (1.17)	2.3	4.50	5.50	6.00	7.0	
		Week 36	Tezepelumab	71	67 (94.4)	5.48 (1.25)	1.0	4.50	5.75	6.50	7.0	
			Placebo	63	59 (93.7)	5.25 (1.23)	1.8	4.50	5.25	6.25	7.0	
		Week 40	Tezepelumab	71	67 (94.4)	5.47 (1.23)	1.3	4.50	5.75	6.50	7.0	
			Placebo	63	59 (93.7)	5.33 (1.22)	1.8	4.50	5.50	6.25	7.0	
		Week 44	Tezepelumab	71	67 (94.4)	5.56 (1.20)	1.0	4.75	5.75	6.50	7.0	
			Placebo	63	59 (93.7)	5.28 (1.23)	2.0	4.25	5.50	6.50	7.0	
		Week 48	Tezepelumab	71	67 (94.4)	5.54 (1.14)	2.0	4.75	5.75	6.50	7.0	
			Placebo	63	59 (93.7)	5.34 (1.14)	2.0	4.50	5.50	6.00	7.0	
		Week 52	Tezepelumab	71	67 (94.4)	5.47 (1.25)	1.0	4.50	5.75	6.50	7.0	
			Placebo	63	59 (93.7)	5.28 (1.20)	1.8	4.50	5.25	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	71	61 (85.9)	0.64 (1.17)	-4.0	0.00	0.75	1.50	3.3	0.19 [-0.17, 0.55]
			Placebo	63	57 (90.5)	0.43 (1.09)	-2.5	0.00	0.25	1.25	2.5	
		Week 8	Tezepelumab	71	63 (88.7)	0.90 (1.05)	-1.3	0.00	0.75	1.75	3.5	0.25 [-0.11, 0.61]
			Placebo	63	57 (90.5)	0.62 (1.11)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	71	63 (88.7)	1.00 (1.11)	-2.3	0.25	0.75	1.75	3.5	0.26 [-0.10, 0.62]
			Placebo	63	57 (90.5)	0.71 (1.11)	-1.8	0.00	0.50	1.50	3.0	
		Week 16	Tezepelumab	71	63 (88.7)	0.89 (1.14)	-2.8	0.00	0.75	1.50	3.5	0.15 [-0.21, 0.50]
			Placebo	63	57 (90.5)	0.72 (1.13)	-1.5	0.00	0.50	1.50	3.0	
		Week 20	Tezepelumab	71	63 (88.7)	0.92 (1.10)	-1.3	0.25	0.75	1.75	3.3	0.12 [-0.24, 0.48]
			Placebo	63	57 (90.5)	0.79 (1.06)	-1.3	0.00	0.75	1.50	2.8	
		Week 24	Tezepelumab	71	63 (88.7)	1.05 (1.12)	-1.3	0.25	1.00	2.00	3.5	0.24 [-0.12, 0.60]
			Placebo	63	57 (90.5)	0.79 (1.12)	-1.5	0.00	0.50	1.50	3.8	
		Week 28	Tezepelumab	71	63 (88.7)	0.94 (1.12)	-1.5	0.25	0.75	1.75	3.5	0.05 [-0.30, 0.41]
			Placebo	63	57 (90.5)	0.88 (1.19)	-2.8	0.00	0.75	1.50	3.8	
		Week 32	Tezepelumab	71	63 (88.7)	1.08 (1.12)	-1.3	0.25	1.00	1.75	3.5	0.01 [-0.35, 0.37]
			Placebo	63	57 (90.5)	1.06 (1.14)	-1.5	0.25	1.00	1.75	3.8	
		Week 36	Tezepelumab	71	63 (88.7)	1.12 (1.13)	-1.3	0.25	1.00	2.00	3.5	0.15 [-0.21, 0.51]
			Placebo	63	57 (90.5)	0.93 (1.31)	-2.3	0.00	0.50	1.75	3.8	
		Week 40	Tezepelumab	71	63 (88.7)	1.10 (1.13)	-1.3	0.25	1.00	2.00	3.5	0.07 [-0.29, 0.43]
			Placebo	63	57 (90.5)	1.02 (1.24)	-1.8	0.25	0.75	1.75	4.3	
		Week 44	Tezepelumab	71	63 (88.7)	1.19 (1.18)	-1.3	0.25	1.00	2.00	3.8	0.18 [-0.18, 0.54]
			Placebo	63	57 (90.5)	0.97 (1.30)	-1.5	0.00	0.75	2.00	3.8	
		Week 48	Tezepelumab	71	63 (88.7)	1.19 (1.19)	-1.3	0.25	1.00	2.00	3.8	0.13 [-0.23, 0.49]
			Placebo	63	57 (90.5)	1.04 (1.27)	-1.3	0.25	0.75	1.50	4.0	
		Week 52	Tezepelumab	71	63 (88.7)	1.09 (1.21)	-1.3	0.25	1.00	2.00	3.8	0.10 [-0.26, 0.46]
			Placebo	63	57 (90.5)	0.96 (1.25)	-1.3	0.25	0.75	1.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	35	31 (88.6)	4.18 (1.15)	1.8	3.50	4.25	5.00	6.5	
			Placebo	32	26 (81.3)	3.96 (1.23)	1.5	3.00	4.00	4.75	6.5	
		Week 4	Tezepelumab	35	33 (94.3)	4.97 (1.12)	2.0	4.25	5.00	5.75	7.0	
			Placebo	32	26 (81.3)	4.63 (1.20)	2.0	3.75	5.00	5.50	6.8	
		Week 8	Tezepelumab	35	33 (94.3)	5.11 (1.14)	1.0	4.50	5.25	5.75	6.8	
			Placebo	32	28 (87.5)	4.63 (1.47)	1.5	3.75	4.75	5.75	7.0	
		Week 12	Tezepelumab	35	33 (94.3)	5.25 (1.27)	1.0	4.50	5.25	6.50	7.0	
			Placebo	32	28 (87.5)	4.70 (1.24)	1.8	4.00	4.63	5.50	7.0	
		Week 16	Tezepelumab	35	33 (94.3)	5.20 (1.19)	1.0	4.50	5.25	6.00	7.0	
			Placebo	32	28 (87.5)	4.58 (1.33)	1.3	4.00	4.50	5.25	7.0	
		Week 20	Tezepelumab	35	34 (97.1)	5.01 (1.19)	1.3	4.25	5.00	5.75	7.0	
			Placebo	32	28 (87.5)	4.56 (1.45)	1.3	3.88	4.75	5.38	7.0	
		Week 24	Tezepelumab	35	34 (97.1)	5.32 (1.27)	1.0	4.50	5.00	6.50	7.0	
			Placebo	32	28 (87.5)	4.37 (1.66)	1.0	3.63	4.38	5.38	7.0	
		Week 28	Tezepelumab	35	35 (100.0)	5.21 (1.25)	1.0	4.50	5.00	6.25	7.0	
			Placebo	32	28 (87.5)	4.38 (1.32)	1.3	3.75	4.13	5.25	7.0	
		Week 32	Tezepelumab	35	35 (100.0)	5.16 (1.24)	1.0	4.50	5.00	6.00	7.0	
			Placebo	32	28 (87.5)	4.58 (1.48)	1.3	4.00	4.50	5.25	7.0	
		Week 36	Tezepelumab	35	35 (100.0)	5.19 (1.25)	1.0	4.25	5.00	6.25	7.0	
			Placebo	32	28 (87.5)	4.66 (1.48)	1.0	4.00	4.38	5.50	7.0	
		Week 40	Tezepelumab	35	35 (100.0)	5.18 (1.20)	2.0	4.25	5.00	6.00	7.0	
			Placebo	32	28 (87.5)	4.62 (1.43)	1.0	3.88	4.50	5.38	7.0	
		Week 44	Tezepelumab	35	35 (100.0)	5.24 (1.23)	2.0	4.25	5.00	6.50	7.0	
			Placebo	32	28 (87.5)	4.68 (1.38)	1.3	4.00	4.38	5.63	7.0	
		Week 48	Tezepelumab	35	35 (100.0)	5.20 (1.33)	1.0	4.00	5.25	6.25	7.0	
			Placebo	32	28 (87.5)	4.59 (1.38)	2.0	4.00	4.25	5.75	7.0	
		Week 52	Tezepelumab	35	35 (100.0)	5.15 (1.29)	1.0	4.25	5.00	6.25	7.0	
			Placebo	32	28 (87.5)	4.43 (1.36)	1.0	3.88	4.25	5.25	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	35	31 (88.6)	0.87 (1.23)	-2.3	0.25	0.75	1.75	4.0	0.18 [-0.35, 0.71]
			Placebo	32	25 (78.1)	0.68 (0.81)	-1.3	0.25	0.50	1.25	2.5	
		Week 8	Tezepelumab	35	31 (88.6)	0.92 (1.32)	-1.5	0.00	0.75	1.75	4.3	0.16 [-0.36, 0.68]
			Placebo	32	26 (81.3)	0.72 (1.11)	-1.3	0.00	0.63	1.50	3.0	
		Week 12	Tezepelumab	35	31 (88.6)	1.07 (1.33)	-2.0	0.25	1.00	2.25	4.8	0.26 [-0.27, 0.78]
			Placebo	32	26 (81.3)	0.76 (1.07)	-1.3	0.25	0.75	1.25	3.3	
		Week 16	Tezepelumab	35	31 (88.6)	1.04 (1.33)	-2.3	0.00	1.25	2.00	3.3	0.33 [-0.20, 0.85]
			Placebo	32	26 (81.3)	0.63 (1.12)	-1.8	0.25	0.75	1.25	2.8	
		Week 20	Tezepelumab	35	31 (88.6)	0.82 (1.23)	-1.3	-0.25	0.75	1.75	3.3	0.15 [-0.37, 0.67]
			Placebo	32	26 (81.3)	0.63 (1.25)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	35	31 (88.6)	1.15 (1.13)	-1.0	0.25	1.25	2.00	3.3	0.57 [0.04, 1.10]
			Placebo	32	26 (81.3)	0.43 (1.37)	-2.8	-0.50	0.50	1.00	3.3	
		Week 28	Tezepelumab	35	31 (88.6)	1.08 (1.23)	-1.5	0.25	1.25	2.00	3.3	0.53 [0.00, 1.06]
			Placebo	32	26 (81.3)	0.45 (1.11)	-1.8	0.00	0.50	1.00	3.3	
		Week 32	Tezepelumab	35	31 (88.6)	1.01 (1.21)	-1.3	-0.25	1.25	2.00	3.3	0.29 [-0.23, 0.82]
			Placebo	32	26 (81.3)	0.66 (1.12)	-1.8	-0.25	0.63	1.25	2.8	
		Week 36	Tezepelumab	35	31 (88.6)	1.06 (1.25)	-1.8	0.25	1.25	2.25	3.3	0.26 [-0.27, 0.78]
			Placebo	32	26 (81.3)	0.74 (1.19)	-2.8	0.25	0.75	1.50	2.8	
		Week 40	Tezepelumab	35	31 (88.6)	1.08 (1.18)	-1.5	0.25	1.25	2.00	3.3	0.34 [-0.18, 0.87]
			Placebo	32	26 (81.3)	0.68 (1.16)	-2.5	0.25	0.63	1.25	2.8	
		Week 44	Tezepelumab	35	31 (88.6)	1.14 (1.28)	-1.5	0.00	1.25	2.25	3.3	0.30 [-0.22, 0.83]
			Placebo	32	26 (81.3)	0.76 (1.21)	-1.3	0.00	0.50	1.50	3.3	
		Week 48	Tezepelumab	35	31 (88.6)	1.09 (1.28)	-1.8	0.00	1.25	2.00	3.3	0.32 [-0.20, 0.85]
			Placebo	32	26 (81.3)	0.67 (1.31)	-2.8	0.00	0.75	1.25	3.3	
		Week 52	Tezepelumab	35	31 (88.6)	1.03 (1.33)	-1.8	0.00	1.25	2.00	3.3	0.43 [-0.10, 0.95]
			Placebo	32	26 (81.3)	0.50 (1.16)	-2.3	0.00	0.25	1.00	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	95	86 (90.5)	4.26 (1.15)	1.0	3.50	4.25	5.00	7.0	
			Placebo	98	87 (88.8)	4.13 (1.22)	1.5	3.50	4.00	5.00	7.0	
		Week 4	Tezepelumab	95	86 (90.5)	4.88 (1.27)	1.0	4.00	5.00	5.75	7.0	
			Placebo	98	89 (90.8)	4.59 (1.23)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	95	88 (92.6)	5.08 (1.25)	1.0	4.25	5.00	5.88	7.0	
			Placebo	98	90 (91.8)	4.71 (1.31)	1.0	3.75	4.75	5.75	7.0	
		Week 12	Tezepelumab	95	88 (92.6)	5.22 (1.23)	1.0	4.50	5.25	6.25	7.0	
			Placebo	98	91 (92.9)	4.75 (1.21)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	95	88 (92.6)	5.15 (1.23)	1.0	4.50	5.00	6.00	7.0	
			Placebo	98	91 (92.9)	4.77 (1.30)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	95	88 (92.6)	5.20 (1.29)	1.0	4.50	5.25	6.25	7.0	
			Placebo	98	91 (92.9)	4.83 (1.26)	1.8	4.00	4.75	6.00	7.0	
		Week 24	Tezepelumab	95	88 (92.6)	5.22 (1.21)	1.0	4.25	5.25	6.13	7.0	
			Placebo	98	91 (92.9)	4.85 (1.24)	1.5	4.00	5.00	5.75	7.0	
		Week 28	Tezepelumab	95	89 (93.7)	5.19 (1.30)	1.0	4.50	5.00	6.25	7.0	
			Placebo	98	92 (93.9)	4.94 (1.42)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	95	90 (94.7)	5.32 (1.27)	1.0	4.50	5.50	6.25	7.0	
			Placebo	98	93 (94.9)	4.96 (1.34)	2.3	4.00	4.75	6.00	7.0	
		Week 36	Tezepelumab	95	90 (94.7)	5.30 (1.28)	1.0	4.50	5.38	6.25	7.0	
			Placebo	98	93 (94.9)	4.90 (1.39)	1.5	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	95	90 (94.7)	5.36 (1.21)	1.3	4.50	5.50	6.25	7.0	
			Placebo	98	93 (94.9)	4.98 (1.35)	1.5	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	95	90 (94.7)	5.38 (1.24)	1.0	4.75	5.25	6.25	7.0	
			Placebo	98	93 (94.9)	4.93 (1.34)	1.8	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	95	90 (94.7)	5.36 (1.19)	2.0	4.50	5.38	6.25	7.0	
			Placebo	98	94 (95.9)	5.01 (1.28)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	95	90 (94.7)	5.33 (1.26)	1.0	4.50	5.50	6.25	7.0	
			Placebo	98	94 (95.9)	4.96 (1.33)	1.5	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	95	80 (84.2)	0.61 (1.13)	-4.0	0.00	0.50	1.25	3.3	0.15 [-0.15, 0.46]
			Placebo	98	86 (87.8)	0.45 (0.96)	-2.5	0.00	0.25	1.25	3.0	
		Week 8	Tezepelumab	95	82 (86.3)	0.83 (1.08)	-1.3	0.00	0.50	1.75	3.5	0.21 [-0.10, 0.51]
			Placebo	98	86 (87.8)	0.61 (1.03)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	95	82 (86.3)	0.98 (1.08)	-2.3	0.25	0.75	1.50	3.5	0.30 [-0.01, 0.60]
			Placebo	98	86 (87.8)	0.65 (1.07)	-1.8	0.00	0.50	1.25	4.3	
		Week 16	Tezepelumab	95	82 (86.3)	0.91 (1.12)	-2.8	0.00	0.75	1.50	3.5	0.24 [-0.06, 0.54]
			Placebo	98	86 (87.8)	0.66 (1.01)	-1.5	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	95	82 (86.3)	0.98 (1.17)	-1.8	0.25	0.75	1.75	3.5	0.22 [-0.08, 0.53]
			Placebo	98	86 (87.8)	0.74 (0.98)	-1.3	0.00	0.75	1.25	3.0	
		Week 24	Tezepelumab	95	82 (86.3)	1.01 (1.17)	-1.5	0.25	0.75	1.75	3.5	0.21 [-0.09, 0.52]
			Placebo	98	86 (87.8)	0.77 (1.03)	-1.5	0.00	0.75	1.50	3.8	
		Week 28	Tezepelumab	95	82 (86.3)	0.96 (1.14)	-1.5	0.25	0.75	1.75	3.5	0.11 [-0.19, 0.41]
			Placebo	98	86 (87.8)	0.84 (1.16)	-2.8	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	95	82 (86.3)	1.09 (1.17)	-1.3	0.25	1.00	1.75	3.5	0.17 [-0.14, 0.47]
			Placebo	98	86 (87.8)	0.90 (1.09)	-1.5	0.00	0.75	1.75	3.8	
		Week 36	Tezepelumab	95	82 (86.3)	1.07 (1.19)	-1.3	0.25	0.75	2.00	3.5	0.21 [-0.09, 0.51]
			Placebo	98	86 (87.8)	0.81 (1.26)	-2.3	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	95	82 (86.3)	1.12 (1.13)	-1.3	0.25	1.00	2.00	3.5	0.19 [-0.11, 0.50]
			Placebo	98	86 (87.8)	0.89 (1.25)	-1.8	0.00	0.63	1.75	4.3	
		Week 44	Tezepelumab	95	82 (86.3)	1.13 (1.13)	-1.5	0.25	1.00	1.75	3.8	0.27 [-0.04, 0.57]
			Placebo	98	86 (87.8)	0.81 (1.22)	-1.5	0.00	0.75	1.50	3.8	
		Week 48	Tezepelumab	95	82 (86.3)	1.13 (1.14)	-1.3	0.50	1.00	2.00	3.5	0.19 [-0.12, 0.49]
			Placebo	98	86 (87.8)	0.91 (1.19)	-1.5	0.25	0.75	1.50	4.0	
		Week 52	Tezepelumab	95	82 (86.3)	1.07 (1.13)	-1.3	0.25	1.00	1.75	3.5	0.19 [-0.12, 0.49]
			Placebo	98	86 (87.8)	0.85 (1.20)	-1.3	0.00	0.63	1.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	3.96 (1.26)	2.5	2.50	4.25	4.75	5.5	
			Placebo	8	8 (100.0)	4.00 (1.04)	2.8	3.25	3.63	4.88	5.8	
		Week 4	Tezepelumab	7	7 (100.0)	4.93 (0.72)	4.0	4.50	4.50	5.75	5.8	
			Placebo	8	8 (100.0)	4.53 (1.06)	2.5	3.88	4.75	5.50	5.5	
		Week 8	Tezepelumab	7	7 (100.0)	5.25 (0.98)	4.3	4.50	5.00	5.75	7.0	
			Placebo	8	8 (100.0)	4.81 (0.86)	3.8	4.00	4.88	5.38	6.3	
		Week 12	Tezepelumab	7	7 (100.0)	5.36 (0.96)	4.5	4.50	5.25	6.00	7.0	
			Placebo	8	8 (100.0)	5.09 (0.78)	4.0	4.38	5.25	5.63	6.3	
		Week 16	Tezepelumab	7	7 (100.0)	5.36 (1.00)	4.3	4.50	5.50	6.00	7.0	
			Placebo	8	8 (100.0)	5.16 (0.65)	4.0	5.00	5.00	5.50	6.3	
		Week 20	Tezepelumab	7	7 (100.0)	5.29 (1.11)	3.8	4.50	5.00	6.25	7.0	
			Placebo	8	8 (100.0)	4.88 (0.82)	3.5	4.38	5.00	5.50	5.8	
		Week 24	Tezepelumab	7	7 (100.0)	5.29 (1.09)	4.0	4.25	5.00	6.25	7.0	
			Placebo	8	8 (100.0)	4.53 (1.37)	2.5	3.50	4.88	5.38	6.3	
		Week 28	Tezepelumab	7	7 (100.0)	5.36 (0.97)	4.3	4.50	5.25	6.00	7.0	
			Placebo	8	8 (100.0)	5.06 (0.69)	4.0	4.50	5.13	5.63	6.0	
		Week 32	Tezepelumab	7	7 (100.0)	5.61 (1.16)	4.0	4.75	5.75	7.00	7.0	
			Placebo	8	8 (100.0)	5.19 (0.85)	3.3	5.13	5.25	5.75	6.0	
		Week 36	Tezepelumab	7	7 (100.0)	5.68 (1.12)	4.3	4.50	6.00	7.00	7.0	
			Placebo	8	8 (100.0)	4.91 (0.98)	3.0	4.50	5.00	5.50	6.3	
		Week 40	Tezepelumab	7	7 (100.0)	5.71 (1.08)	4.3	4.50	5.75	7.00	7.0	
			Placebo	8	8 (100.0)	5.06 (1.13)	3.3	4.25	5.38	5.75	6.5	
		Week 44	Tezepelumab	7	7 (100.0)	5.82 (1.02)	4.5	4.75	6.00	7.00	7.0	
			Placebo	8	8 (100.0)	4.91 (1.19)	3.3	3.75	5.25	5.75	6.5	
		Week 48	Tezepelumab	7	7 (100.0)	5.82 (0.89)	4.5	4.75	6.00	6.25	7.0	
			Placebo	8	8 (100.0)	4.94 (1.14)	3.0	4.50	4.88	5.38	7.0	
		Week 52	Tezepelumab	7	7 (100.0)	5.89 (1.05)	4.3	4.75	6.00	7.00	7.0	
			Placebo	8	8 (100.0)	4.88 (1.20)	3.0	4.25	4.75	5.50	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	0.83 (1.14)	-1.0	0.25	0.88	2.00	2.0	0.23 [-0.83, 1.29]
			Placebo	8	8 (100.0)	0.53 (1.44)	-2.0	-0.50	0.88	1.63	2.3	
		Week 8	Tezepelumab	7	6 (85.7)	1.21 (1.18)	-1.0	1.00	1.50	2.00	2.3	0.34 [-0.72, 1.41]
			Placebo	8	8 (100.0)	0.81 (1.13)	-0.3	0.00	0.38	1.50	3.0	
		Week 12	Tezepelumab	7	6 (85.7)	1.29 (1.35)	-1.0	0.75	1.50	2.25	2.8	0.16 [-0.90, 1.23]
			Placebo	8	8 (100.0)	1.09 (1.08)	-0.5	0.38	1.13	1.63	3.0	
		Week 16	Tezepelumab	7	6 (85.7)	1.29 (1.39)	-1.0	0.75	1.38	2.25	3.0	0.11 [-0.95, 1.17]
			Placebo	8	8 (100.0)	1.16 (1.11)	0.0	0.13	1.00	2.00	3.0	
		Week 20	Tezepelumab	7	6 (85.7)	1.17 (1.17)	-0.8	0.75	1.13	2.25	2.5	0.29 [-0.78, 1.35]
			Placebo	8	8 (100.0)	0.88 (0.90)	0.0	0.13	0.63	1.63	2.3	
		Week 24	Tezepelumab	7	6 (85.7)	1.17 (1.20)	-0.8	0.50	1.25	2.25	2.5	0.52 [-0.56, 1.60]
			Placebo	8	8 (100.0)	0.53 (1.24)	-0.8	-0.25	0.00	1.25	3.0	
		Week 28	Tezepelumab	7	6 (85.7)	1.29 (1.25)	-0.8	0.75	1.38	2.25	2.8	0.20 [-0.86, 1.26]
			Placebo	8	8 (100.0)	1.06 (1.06)	-0.3	0.13	1.13	1.75	2.8	
		Week 32	Tezepelumab	7	6 (85.7)	1.42 (1.42)	-0.8	1.00	1.25	2.25	3.5	0.19 [-0.88, 1.25]
			Placebo	8	8 (100.0)	1.19 (1.08)	0.0	0.13	1.13	2.13	2.8	
		Week 36	Tezepelumab	7	6 (85.7)	1.50 (1.60)	-1.0	0.50	1.75	2.50	3.5	0.44 [-0.63, 1.52]
			Placebo	8	8 (100.0)	0.91 (1.11)	-0.3	0.00	0.75	1.50	3.0	
		Week 40	Tezepelumab	7	6 (85.7)	1.54 (1.62)	-1.0	0.50	1.75	3.00	3.3	0.36 [-0.71, 1.43]
			Placebo	8	8 (100.0)	1.06 (1.06)	0.0	0.38	0.75	1.50	3.3	
		Week 44	Tezepelumab	7	6 (85.7)	1.67 (1.65)	-1.0	1.00	1.75	2.75	3.8	0.54 [-0.54, 1.62]
			Placebo	8	8 (100.0)	0.91 (1.19)	0.0	0.13	0.38	1.50	3.3	
		Week 48	Tezepelumab	7	6 (85.7)	1.79 (1.77)	-1.0	1.00	1.75	3.50	3.8	0.54 [-0.54, 1.63]
			Placebo	8	8 (100.0)	0.94 (1.41)	-0.3	-0.13	0.50	1.63	3.8	
		Week 52	Tezepelumab	7	6 (85.7)	1.75 (1.85)	-1.3	1.00	1.75	3.50	3.8	0.57 [-0.51, 1.65]
			Placebo	8	8 (100.0)	0.88 (1.27)	-0.3	0.13	0.50	1.13	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.94 (1.25)	1.8	3.13	4.13	4.75	5.8	
			Placebo	13	9 (69.2)	5.14 (1.11)	3.5	4.50	4.75	5.75	7.0	
		Week 4	Tezepelumab	9	8 (88.9)	4.88 (1.26)	2.0	4.63	5.38	5.63	5.8	
			Placebo	13	11 (84.6)	5.27 (0.96)	3.5	5.25	5.25	5.75	7.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.25 (1.80)	1.0	5.38	5.63	6.00	7.0	
			Placebo	13	12 (92.3)	4.85 (1.00)	3.0	4.25	5.13	5.38	6.5	
		Week 12	Tezepelumab	9	8 (88.9)	5.31 (1.85)	1.0	5.38	5.50	6.38	7.0	
			Placebo	13	12 (92.3)	5.06 (0.86)	3.5	4.50	5.50	5.63	5.8	
		Week 16	Tezepelumab	9	8 (88.9)	5.41 (1.92)	1.0	5.38	5.50	6.75	7.0	
			Placebo	13	12 (92.3)	5.13 (1.05)	3.3	4.25	5.25	5.75	7.0	
		Week 20	Tezepelumab	9	8 (88.9)	4.94 (1.88)	1.3	3.88	5.50	6.25	7.0	
			Placebo	13	12 (92.3)	5.02 (1.28)	2.5	4.25	5.13	5.88	7.0	
		Week 24	Tezepelumab	9	8 (88.9)	5.13 (1.86)	1.0	4.75	5.50	6.38	6.8	
			Placebo	13	12 (92.3)	4.81 (1.47)	2.0	4.00	4.75	5.88	7.0	
		Week 28	Tezepelumab	9	8 (88.9)	5.25 (1.86)	1.0	5.00	5.88	6.13	7.0	
			Placebo	13	13 (100.0)	5.08 (1.22)	3.0	4.50	4.75	6.00	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.09 (1.89)	1.0	4.50	5.50	6.38	7.0	
			Placebo	13	13 (100.0)	5.33 (1.21)	3.0	4.50	5.25	6.00	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.16 (1.95)	1.0	4.63	5.63	6.38	7.0	
			Placebo	13	13 (100.0)	5.08 (1.53)	2.0	4.50	5.00	6.25	7.0	
		Week 40	Tezepelumab	9	8 (88.9)	5.44 (1.56)	2.0	5.13	5.75	6.38	7.0	
			Placebo	13	13 (100.0)	5.12 (1.41)	2.3	4.50	5.25	6.00	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.44 (1.53)	2.0	5.13	5.88	6.38	6.8	
			Placebo	13	13 (100.0)	5.38 (1.24)	3.0	4.50	5.25	6.50	7.0	
		Week 48	Tezepelumab	9	8 (88.9)	5.25 (1.86)	1.0	5.00	5.88	6.13	7.0	
			Placebo	13	13 (100.0)	5.06 (1.46)	2.0	4.50	5.00	6.00	7.0	
		Week 52	Tezepelumab	9	8 (88.9)	5.25 (1.84)	1.0	5.00	5.88	6.38	6.5	
			Placebo	13	13 (100.0)	5.25 (1.24)	3.0	4.50	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	1.07 (0.84)	0.0	0.25	1.25	1.50	2.5	0.77 [-0.26, 1.80]
			Placebo	13	9 (69.2)	0.25 (1.21)	-2.0	0.00	0.50	0.75	2.0	
		Week 8	Tezepelumab	9	7 (77.8)	1.39 (1.34)	-0.8	0.00	1.75	2.25	3.0	1.05 [-0.01, 2.11]
			Placebo	13	9 (69.2)	0.06 (1.23)	-1.8	-1.00	0.00	1.25	1.8	
		Week 12	Tezepelumab	9	7 (77.8)	1.50 (1.27)	-0.8	0.50	2.00	2.25	3.0	1.14 [0.07, 2.22]
			Placebo	13	9 (69.2)	0.14 (1.13)	-1.8	-0.75	0.25	1.00	1.8	
		Week 16	Tezepelumab	9	7 (77.8)	1.64 (1.60)	-0.8	-0.25	2.50	3.00	3.3	1.09 [0.03, 2.16]
			Placebo	13	9 (69.2)	0.19 (1.07)	-1.5	0.00	0.25	1.00	1.8	
		Week 20	Tezepelumab	9	7 (77.8)	1.29 (1.33)	-0.5	0.00	1.25	2.50	2.8	0.82 [-0.21, 1.85]
			Placebo	13	9 (69.2)	0.19 (1.33)	-2.3	0.00	0.25	1.25	2.0	
		Week 24	Tezepelumab	9	7 (77.8)	1.46 (1.29)	-0.8	0.25	2.00	2.50	2.8	1.03 [-0.03, 2.09]
			Placebo	13	9 (69.2)	0.06 (1.41)	-2.8	-0.25	0.00	1.50	1.5	
		Week 28	Tezepelumab	9	7 (77.8)	1.57 (1.46)	-0.8	0.00	2.25	2.75	3.0	1.11 [0.04, 2.18]
			Placebo	13	9 (69.2)	0.17 (1.10)	-1.3	-0.25	0.00	0.75	2.3	
		Week 32	Tezepelumab	9	7 (77.8)	1.43 (1.32)	-0.8	0.25	1.50	2.50	3.0	0.81 [-0.22, 1.84]
			Placebo	13	9 (69.2)	0.50 (1.00)	-1.3	0.00	0.25	1.50	1.8	
		Week 36	Tezepelumab	9	7 (77.8)	1.57 (1.39)	-0.8	0.25	2.25	2.75	3.0	0.99 [-0.07, 2.04]
			Placebo	13	9 (69.2)	0.14 (1.50)	-2.8	0.00	0.25	1.00	2.5	
		Week 40	Tezepelumab	9	7 (77.8)	1.75 (1.25)	0.0	0.25	2.25	2.75	3.0	1.16 [0.08, 2.24]
			Placebo	13	9 (69.2)	0.19 (1.40)	-2.5	0.00	0.25	0.75	2.0	
		Week 44	Tezepelumab	9	7 (77.8)	1.75 (1.35)	0.0	0.25	2.00	2.75	3.8	0.95 [-0.10, 2.00]
			Placebo	13	9 (69.2)	0.53 (1.24)	-1.3	0.00	0.25	1.25	2.5	
		Week 48	Tezepelumab	9	7 (77.8)	1.57 (1.40)	-0.8	0.25	2.00	2.75	3.0	1.04 [-0.02, 2.10]
			Placebo	13	9 (69.2)	0.08 (1.46)	-2.8	0.00	0.25	0.75	2.5	
		Week 52	Tezepelumab	9	7 (77.8)	1.57 (1.40)	-0.8	0.25	2.00	2.75	3.0	1.01 [-0.05, 2.07]
			Placebo	13	9 (69.2)	0.36 (1.02)	-1.3	0.00	0.25	0.75	2.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.25 (1.14)	1.0	3.50	4.25	5.00	7.0	
			Placebo	125	112 (89.6)	4.00 (1.18)	1.5	3.25	4.00	5.00	6.3	
		Week 4	Tezepelumab	128	118 (92.2)	4.90 (1.21)	1.0	4.00	5.00	5.75	7.0	
			Placebo	125	112 (89.6)	4.53 (1.21)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	128	120 (93.8)	5.09 (1.16)	1.0	4.25	5.00	5.75	7.0	
			Placebo	125	114 (91.2)	4.68 (1.35)	1.0	3.75	4.75	5.75	7.0	
		Week 12	Tezepelumab	128	120 (93.8)	5.23 (1.18)	1.0	4.50	5.25	6.25	7.0	
			Placebo	125	115 (92.0)	4.73 (1.22)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	128	120 (93.8)	5.16 (1.14)	1.0	4.50	5.00	6.00	7.0	
			Placebo	125	115 (92.0)	4.71 (1.29)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	128	121 (94.5)	5.17 (1.20)	1.0	4.50	5.00	6.00	7.0	
			Placebo	125	115 (92.0)	4.75 (1.29)	1.3	4.00	4.75	5.50	7.0	
		Week 24	Tezepelumab	128	121 (94.5)	5.26 (1.17)	1.0	4.50	5.00	6.25	7.0	
			Placebo	125	115 (92.0)	4.71 (1.35)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	128	123 (96.1)	5.21 (1.23)	1.0	4.50	5.00	6.25	7.0	
			Placebo	125	115 (92.0)	4.80 (1.40)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	128	124 (96.9)	5.30 (1.21)	1.0	4.50	5.25	6.00	7.0	
			Placebo	125	116 (92.8)	4.84 (1.36)	1.3	4.00	4.75	6.00	7.0	
		Week 36	Tezepelumab	128	124 (96.9)	5.30 (1.21)	1.0	4.50	5.25	6.25	7.0	
			Placebo	125	116 (92.8)	4.82 (1.37)	1.0	4.00	4.88	5.88	7.0	
		Week 40	Tezepelumab	128	124 (96.9)	5.32 (1.18)	1.3	4.50	5.25	6.25	7.0	
			Placebo	125	116 (92.8)	4.89 (1.35)	1.0	4.00	5.00	5.75	7.0	
		Week 44	Tezepelumab	128	124 (96.9)	5.36 (1.21)	1.0	4.50	5.25	6.38	7.0	
			Placebo	125	116 (92.8)	4.81 (1.34)	1.3	4.00	4.75	5.88	7.0	
		Week 48	Tezepelumab	128	124 (96.9)	5.35 (1.17)	2.0	4.50	5.25	6.25	7.0	
			Placebo	125	117 (93.6)	4.90 (1.29)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	128	124 (96.9)	5.31 (1.22)	1.0	4.50	5.25	6.25	7.0	
			Placebo	125	117 (93.6)	4.80 (1.34)	1.0	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	110 (85.9)	0.67 (1.17)	-4.0	0.00	0.50	1.25	4.0	0.13 [-0.13, 0.40]
			Placebo	125	110 (88.0)	0.53 (0.95)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	128	112 (87.5)	0.84 (1.13)	-1.5	0.00	0.75	1.75	4.3	0.13 [-0.13, 0.40]
			Placebo	125	111 (88.8)	0.70 (1.02)	-1.5	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	128	112 (87.5)	0.99 (1.14)	-2.3	0.25	0.88	1.75	4.8	0.21 [-0.05, 0.48]
			Placebo	125	111 (88.8)	0.75 (1.06)	-1.3	0.00	0.75	1.25	4.3	
		Week 16	Tezepelumab	128	112 (87.5)	0.92 (1.15)	-2.8	0.00	0.75	1.50	3.5	0.18 [-0.08, 0.44]
			Placebo	125	111 (88.8)	0.73 (1.03)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	128	112 (87.5)	0.93 (1.17)	-1.8	0.00	0.75	1.75	3.5	0.15 [-0.12, 0.41]
			Placebo	125	111 (88.8)	0.77 (1.00)	-1.8	0.00	0.75	1.25	3.0	
		Week 24	Tezepelumab	128	112 (87.5)	1.02 (1.14)	-1.5	0.25	1.00	1.88	3.5	0.26 [-0.00, 0.53]
			Placebo	125	111 (88.8)	0.73 (1.09)	-1.8	0.00	0.75	1.50	3.8	
		Week 28	Tezepelumab	128	112 (87.5)	0.98 (1.14)	-1.5	0.25	0.75	1.75	3.5	0.14 [-0.12, 0.40]
			Placebo	125	111 (88.8)	0.82 (1.14)	-2.8	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	128	112 (87.5)	1.06 (1.18)	-1.3	0.13	1.00	1.75	3.5	0.14 [-0.12, 0.41]
			Placebo	125	111 (88.8)	0.90 (1.10)	-1.8	0.00	0.75	1.75	3.8	
		Week 36	Tezepelumab	128	112 (87.5)	1.06 (1.21)	-1.8	0.25	1.00	2.00	3.5	0.17 [-0.10, 0.43]
			Placebo	125	111 (88.8)	0.86 (1.20)	-2.3	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	128	112 (87.5)	1.09 (1.15)	-1.5	0.25	1.00	2.00	3.5	0.15 [-0.11, 0.42]
			Placebo	125	111 (88.8)	0.91 (1.19)	-1.8	0.25	0.75	1.75	4.3	
		Week 44	Tezepelumab	128	112 (87.5)	1.12 (1.18)	-1.5	0.25	1.00	2.00	3.8	0.24 [-0.02, 0.51]
			Placebo	125	111 (88.8)	0.83 (1.21)	-1.5	0.00	0.75	1.50	3.8	
		Week 48	Tezepelumab	128	112 (87.5)	1.13 (1.20)	-1.8	0.25	1.00	2.00	3.8	0.17 [-0.09, 0.43]
			Placebo	125	111 (88.8)	0.92 (1.19)	-1.5	0.25	0.75	1.50	4.0	
		Week 52	Tezepelumab	128	112 (87.5)	1.07 (1.21)	-1.8	0.25	1.00	1.75	3.8	0.21 [-0.05, 0.47]
			Placebo	125	111 (88.8)	0.81 (1.21)	-2.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	4.43 (1.19)	1.0	3.63	4.50	5.25	7.0	
			Placebo	73	66 (90.4)	3.84 (1.15)	1.5	3.00	4.00	4.75	6.3	
		Week 4	Tezepelumab	70	65 (92.9)	5.00 (1.28)	1.0	4.25	5.00	6.00	7.0	
			Placebo	73	66 (90.4)	4.38 (1.17)	1.3	3.75	4.50	5.25	6.8	
		Week 8	Tezepelumab	70	65 (92.9)	5.05 (1.26)	1.0	4.25	5.00	5.75	7.0	
			Placebo	73	67 (91.8)	4.51 (1.32)	1.0	3.75	4.50	5.50	7.0	
		Week 12	Tezepelumab	70	65 (92.9)	5.22 (1.31)	1.0	4.50	5.25	6.25	7.0	
			Placebo	73	68 (93.2)	4.62 (1.21)	1.3	4.00	4.50	5.50	7.0	
		Week 16	Tezepelumab	70	65 (92.9)	5.20 (1.22)	1.0	4.50	5.00	6.00	7.0	
			Placebo	73	68 (93.2)	4.64 (1.17)	1.3	4.00	4.50	5.50	7.0	
		Week 20	Tezepelumab	70	65 (92.9)	5.18 (1.28)	1.0	4.50	5.25	6.25	7.0	
			Placebo	73	68 (93.2)	4.72 (1.17)	1.8	4.00	4.50	5.50	7.0	
		Week 24	Tezepelumab	70	65 (92.9)	5.28 (1.18)	1.0	4.50	5.25	6.25	7.0	
			Placebo	73	68 (93.2)	4.66 (1.22)	1.5	4.00	4.50	5.50	7.0	
		Week 28	Tezepelumab	70	65 (92.9)	5.22 (1.30)	1.0	4.50	5.25	6.00	7.0	
			Placebo	73	68 (93.2)	4.68 (1.26)	1.5	4.00	4.38	5.75	7.0	
		Week 32	Tezepelumab	70	66 (94.3)	5.31 (1.25)	1.0	4.50	5.38	6.00	7.0	
			Placebo	73	69 (94.5)	4.76 (1.23)	1.8	4.00	4.50	6.00	7.0	
		Week 36	Tezepelumab	70	66 (94.3)	5.29 (1.30)	1.0	4.50	5.50	6.25	7.0	
			Placebo	73	69 (94.5)	4.82 (1.29)	1.8	4.00	4.50	5.75	7.0	
		Week 40	Tezepelumab	70	66 (94.3)	5.36 (1.27)	1.3	4.50	5.63	6.25	7.0	
			Placebo	73	69 (94.5)	4.80 (1.24)	1.8	4.00	4.75	5.75	7.0	
		Week 44	Tezepelumab	70	66 (94.3)	5.42 (1.27)	1.0	4.50	5.38	6.50	7.0	
			Placebo	73	69 (94.5)	4.73 (1.27)	1.8	4.00	4.50	5.75	7.0	
		Week 48	Tezepelumab	70	66 (94.3)	5.36 (1.24)	2.0	4.50	5.50	6.25	7.0	
			Placebo	73	70 (95.9)	4.85 (1.24)	1.8	4.00	4.88	6.00	7.0	
		Week 52	Tezepelumab	70	66 (94.3)	5.28 (1.33)	1.0	4.50	5.50	6.25	7.0	
			Placebo	73	70 (95.9)	4.65 (1.33)	1.0	4.00	4.63	5.50	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 4	Tezepelumab	70	61 (87.1)	0.60 (1.05)	-2.3	0.00	0.50	1.00	3.3	0.05 [-0.30, 0.40]
			Placebo	73	65 (89.0)	0.55 (0.90)	-2.5	0.00	0.50	1.25	2.5	
		Week 8	Tezepelumab	70	61 (87.1)	0.65 (1.02)	-1.5	0.00	0.50	1.25	3.5	-0.04 [-0.39, 0.31]
			Placebo	73	65 (89.0)	0.69 (0.94)	-1.5	0.00	0.75	1.25	3.0	
		Week 12	Tezepelumab	70	61 (87.1)	0.82 (1.08)	-2.0	0.25	0.75	1.25	3.5	0.00 [-0.35, 0.35]
			Placebo	73	65 (89.0)	0.82 (1.08)	-1.3	0.00	0.75	1.25	4.3	
		Week 16	Tezepelumab	70	61 (87.1)	0.81 (1.09)	-2.3	0.00	0.75	1.50	3.5	-0.01 [-0.36, 0.34]
			Placebo	73	65 (89.0)	0.82 (1.03)	-1.5	0.25	0.75	1.50	3.0	
		Week 20	Tezepelumab	70	61 (87.1)	0.79 (1.11)	-1.3	0.00	0.75	1.50	3.5	-0.11 [-0.46, 0.24]
			Placebo	73	65 (89.0)	0.90 (0.97)	-1.3	0.25	0.75	1.50	3.0	
		Week 24	Tezepelumab	70	61 (87.1)	0.89 (1.05)	-1.0	0.25	0.75	1.50	3.5	0.03 [-0.32, 0.38]
			Placebo	73	65 (89.0)	0.85 (1.03)	-0.8	0.00	0.75	1.50	3.3	
		Week 28	Tezepelumab	70	61 (87.1)	0.83 (1.04)	-1.5	0.25	0.75	1.25	3.5	-0.03 [-0.38, 0.32]
			Placebo	73	65 (89.0)	0.86 (1.04)	-1.3	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	70	61 (87.1)	0.90 (1.05)	-1.3	0.00	0.75	1.50	3.5	-0.09 [-0.44, 0.26]
			Placebo	73	65 (89.0)	0.99 (1.11)	-1.3	0.25	1.00	1.75	3.5	
		Week 36	Tezepelumab	70	61 (87.1)	0.89 (1.14)	-1.8	0.25	0.75	1.50	3.5	-0.11 [-0.46, 0.24]
			Placebo	73	65 (89.0)	1.03 (1.22)	-2.0	0.25	0.75	1.75	3.8	
		Week 40	Tezepelumab	70	61 (87.1)	0.95 (1.12)	-1.5	0.25	0.75	1.75	3.5	-0.04 [-0.39, 0.31]
			Placebo	73	65 (89.0)	0.99 (1.21)	-1.8	0.25	0.75	1.75	4.3	
		Week 44	Tezepelumab	70	61 (87.1)	0.98 (1.10)	-1.5	0.00	1.00	1.75	3.5	0.07 [-0.28, 0.42]
			Placebo	73	65 (89.0)	0.91 (1.20)	-1.5	0.00	0.75	1.75	3.5	
		Week 48	Tezepelumab	70	61 (87.1)	0.95 (1.11)	-1.8	0.25	1.00	1.75	3.5	-0.07 [-0.42, 0.28]
			Placebo	73	65 (89.0)	1.03 (1.15)	-1.3	0.25	1.00	2.00	4.0	
		Week 52	Tezepelumab	70	61 (87.1)	0.84 (1.13)	-1.8	0.00	1.00	1.50	3.5	0.02 [-0.33, 0.36]
			Placebo	73	65 (89.0)	0.83 (1.17)	-2.3	0.00	0.50	1.50	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	4.01 (1.07)	1.8	3.25	4.00	4.75	6.8	
			Placebo	65	55 (84.6)	4.38 (1.22)	1.5	3.50	4.25	5.50	7.0	
		Week 4	Tezepelumab	67	61 (91.0)	4.80 (1.11)	1.3	4.00	5.00	5.75	7.0	
			Placebo	65	57 (87.7)	4.84 (1.21)	2.0	4.25	5.00	5.50	7.0	
		Week 8	Tezepelumab	67	63 (94.0)	5.14 (1.15)	1.0	4.25	5.25	6.00	7.0	
			Placebo	65	59 (90.8)	4.91 (1.29)	1.5	4.00	5.00	5.75	7.0	
		Week 12	Tezepelumab	67	63 (94.0)	5.26 (1.14)	1.0	4.50	5.50	6.25	7.0	
			Placebo	65	59 (90.8)	4.92 (1.16)	2.0	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	67	63 (94.0)	5.15 (1.18)	1.0	4.50	5.25	6.00	7.0	
			Placebo	65	59 (90.8)	4.88 (1.38)	1.3	4.00	5.00	5.75	7.0	
		Week 20	Tezepelumab	67	64 (95.5)	5.13 (1.23)	1.0	4.50	5.00	5.88	7.0	
			Placebo	65	59 (90.8)	4.84 (1.41)	1.3	4.00	5.00	5.75	7.0	
		Week 24	Tezepelumab	67	64 (95.5)	5.22 (1.25)	1.0	4.50	5.00	6.25	7.0	
			Placebo	65	59 (90.8)	4.80 (1.50)	1.0	4.25	5.00	5.75	7.0	
		Week 28	Tezepelumab	67	66 (98.5)	5.20 (1.24)	1.0	4.50	5.00	6.25	7.0	
			Placebo	65	60 (92.3)	5.00 (1.49)	1.3	4.13	5.25	6.00	7.0	
		Week 32	Tezepelumab	67	66 (98.5)	5.27 (1.26)	1.0	4.50	5.13	6.00	7.0	
			Placebo	65	60 (92.3)	5.04 (1.47)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	67	66 (98.5)	5.29 (1.22)	1.0	4.50	5.13	6.25	7.0	
			Placebo	65	60 (92.3)	4.87 (1.49)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	67	66 (98.5)	5.30 (1.13)	2.0	4.50	5.25	6.00	7.0	
			Placebo	65	60 (92.3)	5.04 (1.48)	1.0	4.00	5.25	6.13	7.0	
		Week 44	Tezepelumab	67	66 (98.5)	5.31 (1.18)	1.3	4.50	5.25	6.25	7.0	
			Placebo	65	60 (92.3)	5.03 (1.41)	1.3	4.00	5.13	6.13	7.0	
		Week 48	Tezepelumab	67	66 (98.5)	5.33 (1.20)	1.0	4.50	5.25	6.25	7.0	
			Placebo	65	60 (92.3)	5.00 (1.37)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	67	66 (98.5)	5.34 (1.19)	1.0	4.50	5.38	6.25	7.0	
			Placebo	65	60 (92.3)	5.07 (1.32)	1.8	4.25	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 4	Tezepelumab	67	56 (83.6)	0.79 (1.26)	-4.0	0.00	0.75	1.75	4.0	0.30 [-0.08, 0.68]
			Placebo	65	54 (83.1)	0.45 (1.04)	-2.0	-0.25	0.38	1.00	3.0	
		Week 8	Tezepelumab	67	58 (86.6)	1.10 (1.23)	-1.3	0.25	1.13	2.00	4.3	0.42 [0.05, 0.79]
			Placebo	65	55 (84.6)	0.60 (1.17)	-1.8	-0.25	0.50	1.25	3.3	
		Week 12	Tezepelumab	67	58 (86.6)	1.22 (1.20)	-2.3	0.25	1.25	2.25	4.8	0.58 [0.20, 0.96]
			Placebo	65	55 (84.6)	0.57 (1.05)	-1.8	-0.25	0.75	1.25	3.0	
		Week 16	Tezepelumab	67	58 (86.6)	1.13 (1.26)	-2.8	0.25	1.13	2.25	3.3	0.52 [0.14, 0.89]
			Placebo	65	55 (84.6)	0.53 (1.04)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	67	58 (86.6)	1.12 (1.23)	-1.8	0.25	1.13	2.25	3.5	0.52 [0.15, 0.90]
			Placebo	65	55 (84.6)	0.51 (1.07)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	67	58 (86.6)	1.22 (1.24)	-1.5	0.25	1.50	2.25	3.5	0.61 [0.23, 0.98]
			Placebo	65	55 (84.6)	0.48 (1.21)	-2.8	-0.25	0.50	1.25	3.8	
		Week 28	Tezepelumab	67	58 (86.6)	1.20 (1.26)	-1.5	0.25	1.38	2.25	3.3	0.43 [0.06, 0.80]
			Placebo	65	55 (84.6)	0.66 (1.27)	-2.8	0.00	0.75	1.25	3.8	
		Week 32	Tezepelumab	67	58 (86.6)	1.28 (1.29)	-1.3	0.25	1.50	2.25	3.5	0.47 [0.10, 0.85]
			Placebo	65	55 (84.6)	0.72 (1.07)	-1.8	0.00	0.75	1.25	3.8	
		Week 36	Tezepelumab	67	58 (86.6)	1.29 (1.28)	-1.3	0.25	1.50	2.25	3.5	0.61 [0.23, 0.99]
			Placebo	65	55 (84.6)	0.54 (1.20)	-2.8	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	67	58 (86.6)	1.32 (1.19)	-1.3	0.25	1.50	2.25	3.3	0.52 [0.14, 0.89]
			Placebo	65	55 (84.6)	0.70 (1.22)	-2.5	0.00	0.75	1.25	3.8	
		Week 44	Tezepelumab	67	58 (86.6)	1.34 (1.27)	-1.5	0.50	1.50	2.25	3.8	0.52 [0.15, 0.90]
			Placebo	65	55 (84.6)	0.69 (1.22)	-1.5	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	67	58 (86.6)	1.36 (1.28)	-1.3	0.50	1.50	2.25	3.8	0.54 [0.17, 0.92]
			Placebo	65	55 (84.6)	0.66 (1.30)	-2.8	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	67	58 (86.6)	1.36 (1.26)	-1.3	0.50	1.50	2.25	3.8	0.51 [0.14, 0.89]
			Placebo	65	55 (84.6)	0.72 (1.23)	-1.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	11	9 (81.8)	4.31 (0.93)	2.8	4.00	4.25	4.75	5.8	
			Placebo	6	4 (66.7)	4.00 (1.43)	2.3	2.88	4.13	5.13	5.5	
		Week 4	Tezepelumab	11	11 (100.0)	4.52 (1.16)	3.0	3.25	4.50	5.75	6.3	
			Placebo	6	5 (83.3)	4.50 (0.95)	3.5	3.50	4.75	5.25	5.5	
		Week 8	Tezepelumab	11	11 (100.0)	4.68 (1.28)	1.8	4.25	4.50	5.75	6.3	
			Placebo	6	5 (83.3)	4.50 (1.65)	2.8	3.50	3.75	6.00	6.5	
		Week 12	Tezepelumab	11	11 (100.0)	5.02 (1.00)	3.5	4.50	4.75	6.25	6.5	
			Placebo	6	5 (83.3)	4.65 (0.91)	3.8	4.00	4.25	5.50	5.8	
		Week 16	Tezepelumab	11	11 (100.0)	4.73 (1.16)	2.0	4.50	4.75	5.50	6.8	
			Placebo	6	5 (83.3)	4.25 (0.73)	3.3	4.00	4.25	4.50	5.3	
		Week 20	Tezepelumab	11	11 (100.0)	4.45 (1.38)	1.0	3.50	5.00	5.00	6.0	
			Placebo	6	5 (83.3)	4.15 (1.69)	2.5	3.50	3.75	4.00	7.0	
		Week 24	Tezepelumab	11	11 (100.0)	4.73 (1.41)	1.3	4.00	5.00	6.00	6.3	
			Placebo	6	5 (83.3)	3.70 (1.20)	2.0	3.25	3.75	4.25	5.3	
		Week 28	Tezepelumab	11	11 (100.0)	4.59 (1.19)	1.5	4.00	4.75	5.50	5.8	
			Placebo	6	5 (83.3)	3.75 (1.53)	1.5	3.50	3.75	4.25	5.8	
		Week 32	Tezepelumab	11	11 (100.0)	4.59 (1.30)	1.5	4.00	4.75	5.50	6.0	
			Placebo	6	5 (83.3)	4.45 (0.67)	3.8	4.00	4.50	4.50	5.5	
		Week 36	Tezepelumab	11	11 (100.0)	4.50 (1.17)	1.8	4.00	4.50	5.25	6.0	
			Placebo	6	5 (83.3)	3.75 (1.16)	2.0	3.75	3.75	4.00	5.3	
		Week 40	Tezepelumab	11	11 (100.0)	4.64 (1.00)	2.3	4.25	5.00	5.25	5.8	
			Placebo	6	5 (83.3)	4.10 (1.21)	2.3	4.00	4.00	4.75	5.5	
		Week 44	Tezepelumab	11	11 (100.0)	4.48 (1.27)	1.3	4.25	4.75	5.00	6.0	
			Placebo	6	5 (83.3)	4.45 (0.65)	3.5	4.25	4.50	4.75	5.3	
		Week 48	Tezepelumab	11	11 (100.0)	4.57 (1.21)	2.3	3.75	4.50	5.75	6.3	
			Placebo	6	5 (83.3)	4.25 (1.40)	2.0	4.00	4.75	4.75	5.8	
		Week 52	Tezepelumab	11	11 (100.0)	4.55 (1.22)	2.3	3.75	4.50	5.75	6.3	
			Placebo	6	5 (83.3)	4.70 (0.65)	4.0	4.50	4.50	4.75	5.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	11	9 (81.8)	0.31 (0.93)	-1.0	0.00	0.25	0.75	2.0	-0.44 [-1.63, 0.75]
			Placebo	6	4 (66.7)	0.75 (1.17)	-0.8	-0.13	0.88	1.63	2.0	
		Week 8	Tezepelumab	11	9 (81.8)	0.36 (1.06)	-1.0	0.00	0.25	1.00	2.0	-0.31 [-1.50, 0.87]
			Placebo	6	4 (66.7)	0.75 (1.66)	-1.0	-0.25	0.50	1.75	3.0	
		Week 12	Tezepelumab	11	9 (81.8)	0.75 (0.90)	-1.0	0.50	0.75	1.25	2.3	-0.14 [-1.32, 1.04]
			Placebo	6	4 (66.7)	0.88 (0.85)	0.0	0.25	0.75	1.50	2.0	
		Week 16	Tezepelumab	11	9 (81.8)	0.44 (1.04)	-1.0	-0.25	0.50	0.75	2.5	0.10 [-1.08, 1.27]
			Placebo	6	4 (66.7)	0.31 (2.03)	-1.5	-1.25	-0.13	1.88	3.0	
		Week 20	Tezepelumab	11	9 (81.8)	0.08 (0.97)	-1.8	-0.50	0.00	0.75	1.3	-0.18 [-1.37, 1.00]
			Placebo	6	4 (66.7)	0.31 (1.77)	-2.3	-0.88	1.00	1.50	1.5	
		Week 24	Tezepelumab	11	9 (81.8)	0.42 (1.12)	-1.5	-0.25	0.50	1.25	2.0	0.67 [-0.54, 1.88]
			Placebo	6	4 (66.7)	-0.44 (1.63)	-2.8	-1.50	0.00	0.63	1.0	
		Week 28	Tezepelumab	11	9 (81.8)	0.28 (0.85)	-1.3	0.00	0.50	1.00	1.3	0.79 [-0.43, 2.01]
			Placebo	6	4 (66.7)	-0.38 (0.75)	-1.3	-1.00	-0.25	0.25	0.3	
		Week 32	Tezepelumab	11	9 (81.8)	0.28 (0.91)	-1.3	-0.25	0.25	1.00	1.3	-0.18 [-1.36, 1.00]
			Placebo	6	4 (66.7)	0.44 (0.90)	-0.3	-0.13	0.13	1.00	1.8	
		Week 36	Tezepelumab	11	9 (81.8)	0.22 (0.79)	-1.0	0.00	0.25	0.75	1.3	0.41 [-0.78, 1.60]
			Placebo	6	4 (66.7)	-0.25 (1.81)	-2.8	-1.50	0.13	1.00	1.5	
		Week 40	Tezepelumab	11	9 (81.8)	0.31 (0.72)	-1.0	0.00	0.25	1.00	1.0	0.15 [-1.03, 1.33]
			Placebo	6	4 (66.7)	0.13 (2.06)	-2.5	-1.25	0.25	1.50	2.5	
		Week 44	Tezepelumab	11	9 (81.8)	0.19 (0.93)	-1.5	0.00	0.50	0.75	1.3	-0.05 [-1.23, 1.13]
			Placebo	6	4 (66.7)	0.25 (1.55)	-1.0	-0.75	-0.25	1.25	2.5	
		Week 48	Tezepelumab	11	9 (81.8)	0.33 (0.90)	-1.0	-0.25	0.25	1.00	1.5	0.15 [-1.03, 1.33]
			Placebo	6	4 (66.7)	0.13 (2.17)	-2.8	-1.25	0.38	1.50	2.5	
		Week 52	Tezepelumab	11	9 (81.8)	0.31 (0.95)	-1.3	-0.25	0.25	1.00	1.5	-0.43 [-1.62, 0.76]
			Placebo	6	4 (66.7)	0.75 (1.21)	-0.3	0.00	0.38	1.50	2.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	126	114 (90.5)	4.22 (1.17)	1.0	3.50	4.25	5.00	7.0	
			Placebo	132	117 (88.6)	4.09 (1.20)	1.5	3.25	4.00	5.00	7.0	
		Week 4	Tezepelumab	126	115 (91.3)	4.94 (1.21)	1.0	4.25	5.00	5.75	7.0	
			Placebo	132	118 (89.4)	4.60 (1.22)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	126	117 (92.9)	5.13 (1.20)	1.0	4.25	5.25	6.00	7.0	
			Placebo	132	121 (91.7)	4.71 (1.31)	1.0	4.00	4.75	5.75	7.0	
		Week 12	Tezepelumab	126	117 (92.9)	5.26 (1.24)	1.0	4.50	5.25	6.25	7.0	
			Placebo	132	122 (92.4)	4.76 (1.20)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	126	117 (92.9)	5.22 (1.20)	1.0	4.50	5.25	6.00	7.0	
			Placebo	132	122 (92.4)	4.77 (1.29)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	126	118 (93.7)	5.22 (1.22)	1.0	4.50	5.25	6.25	7.0	
			Placebo	132	122 (92.4)	4.80 (1.26)	1.3	4.00	4.75	5.75	7.0	
		Week 24	Tezepelumab	126	118 (93.7)	5.30 (1.19)	1.0	4.50	5.25	6.25	7.0	
			Placebo	132	122 (92.4)	4.76 (1.35)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	126	120 (95.2)	5.26 (1.26)	1.0	4.50	5.25	6.25	7.0	
			Placebo	132	123 (93.2)	4.87 (1.36)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	126	121 (96.0)	5.35 (1.24)	1.0	4.50	5.50	6.25	7.0	
			Placebo	132	124 (93.9)	4.91 (1.37)	1.3	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	126	121 (96.0)	5.36 (1.25)	1.0	4.50	5.50	6.25	7.0	
			Placebo	132	124 (93.9)	4.89 (1.38)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	126	121 (96.0)	5.39 (1.20)	1.3	4.50	5.50	6.50	7.0	
			Placebo	132	124 (93.9)	4.94 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	126	121 (96.0)	5.44 (1.19)	1.0	4.75	5.25	6.50	7.0	
			Placebo	132	124 (93.9)	4.89 (1.36)	1.3	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	126	121 (96.0)	5.42 (1.20)	1.0	4.50	5.50	6.25	7.0	
			Placebo	132	125 (94.7)	4.94 (1.29)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	126	121 (96.0)	5.38 (1.24)	1.0	4.50	5.50	6.50	7.0	
			Placebo	132	125 (94.7)	4.85 (1.36)	1.0	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	126	108 (85.7)	0.72 (1.17)	-4.0	0.00	0.75	1.38	4.0	0.21 [-0.05, 0.48]
			Placebo	132	115 (87.1)	0.50 (0.96)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	126	110 (87.3)	0.91 (1.15)	-1.5	0.00	0.75	1.75	4.3	0.25 [-0.01, 0.51]
			Placebo	132	116 (87.9)	0.64 (1.03)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	126	110 (87.3)	1.04 (1.17)	-2.3	0.25	1.00	1.75	4.8	0.30 [0.04, 0.56]
			Placebo	132	116 (87.9)	0.70 (1.08)	-1.8	0.00	0.75	1.25	4.3	
		Week 16	Tezepelumab	126	110 (87.3)	1.01 (1.19)	-2.8	0.00	1.00	1.75	3.5	0.28 [0.02, 0.54]
			Placebo	132	116 (87.9)	0.70 (1.00)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	126	110 (87.3)	1.02 (1.17)	-1.3	0.25	0.88	1.75	3.5	0.26 [-0.01, 0.52]
			Placebo	132	116 (87.9)	0.74 (1.01)	-1.8	0.00	0.63	1.25	3.0	
		Week 24	Tezepelumab	126	110 (87.3)	1.10 (1.15)	-1.3	0.25	1.00	2.00	3.5	0.34 [0.08, 0.60]
			Placebo	132	116 (87.9)	0.72 (1.09)	-1.8	0.00	0.75	1.50	3.8	
		Week 28	Tezepelumab	126	110 (87.3)	1.07 (1.16)	-1.5	0.25	1.00	2.00	3.5	0.23 [-0.03, 0.49]
			Placebo	132	116 (87.9)	0.81 (1.14)	-2.8	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	126	110 (87.3)	1.15 (1.18)	-1.3	0.25	1.00	2.00	3.5	0.23 [-0.03, 0.50]
			Placebo	132	116 (87.9)	0.88 (1.10)	-1.8	0.00	0.75	1.75	3.8	
		Week 36	Tezepelumab	126	110 (87.3)	1.16 (1.23)	-1.8	0.25	1.13	2.25	3.5	0.26 [0.00, 0.53]
			Placebo	132	116 (87.9)	0.84 (1.20)	-2.3	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	126	110 (87.3)	1.20 (1.17)	-1.5	0.25	1.25	2.00	3.5	0.27 [0.01, 0.53]
			Placebo	132	116 (87.9)	0.88 (1.18)	-1.8	0.13	0.75	1.63	4.3	
		Week 44	Tezepelumab	126	110 (87.3)	1.24 (1.18)	-1.5	0.25	1.25	2.00	3.8	0.35 [0.08, 0.61]
			Placebo	132	116 (87.9)	0.83 (1.20)	-1.5	0.00	0.75	1.50	3.8	
		Week 48	Tezepelumab	126	110 (87.3)	1.22 (1.21)	-1.8	0.50	1.00	2.00	3.8	0.28 [0.01, 0.54]
			Placebo	132	116 (87.9)	0.89 (1.19)	-1.5	0.00	0.75	1.50	4.0	
		Week 52	Tezepelumab	126	110 (87.3)	1.16 (1.22)	-1.8	0.50	1.00	2.00	3.8	0.31 [0.05, 0.58]
			Placebo	132	116 (87.9)	0.78 (1.20)	-2.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.50 (0.78)	3.5	4.00	4.25	5.13	5.8	
			Placebo	3	2 (66.7)	4.50 (1.41)	3.5	3.50	4.50	5.50	5.5	
		Week 4	Tezepelumab	9	9 (100.0)	4.64 (1.17)	3.3	3.50	4.50	5.75	6.3	
			Placebo	3	3 (100.0)	4.58 (1.01)	3.5	3.50	4.75	5.50	5.5	
		Week 8	Tezepelumab	9	9 (100.0)	5.03 (0.91)	3.5	4.50	5.00	5.75	6.3	
			Placebo	3	3 (100.0)	5.33 (1.61)	3.5	3.50	6.00	6.50	6.5	
		Week 12	Tezepelumab	9	9 (100.0)	5.25 (0.93)	3.8	4.75	5.25	6.25	6.5	
			Placebo	3	3 (100.0)	4.42 (0.95)	3.8	3.75	4.00	5.50	5.5	
		Week 16	Tezepelumab	9	9 (100.0)	5.06 (0.80)	4.3	4.50	4.75	5.50	6.8	
			Placebo	3	3 (100.0)	4.25 (0.25)	4.0	4.00	4.25	4.50	4.5	
		Week 20	Tezepelumab	9	9 (100.0)	4.83 (0.86)	3.5	4.75	5.00	5.00	6.0	
			Placebo	3	3 (100.0)	4.83 (1.89)	3.5	3.50	4.00	7.00	7.0	
		Week 24	Tezepelumab	9	9 (100.0)	5.14 (0.88)	3.8	4.75	5.00	6.00	6.3	
			Placebo	3	3 (100.0)	4.42 (0.76)	3.8	3.75	4.25	5.25	5.3	
		Week 28	Tezepelumab	9	9 (100.0)	4.94 (0.66)	4.0	4.75	5.00	5.50	5.8	
			Placebo	3	3 (100.0)	4.58 (1.04)	3.8	3.75	4.25	5.75	5.8	
		Week 32	Tezepelumab	9	9 (100.0)	4.94 (0.88)	3.3	4.75	5.00	5.50	6.0	
			Placebo	3	3 (100.0)	4.58 (0.88)	3.8	3.75	4.50	5.50	5.5	
		Week 36	Tezepelumab	9	9 (100.0)	4.81 (0.82)	3.8	4.25	4.50	5.25	6.0	
			Placebo	3	3 (100.0)	4.33 (0.80)	3.8	3.75	4.00	5.25	5.3	
		Week 40	Tezepelumab	9	9 (100.0)	4.92 (0.66)	3.8	4.50	5.00	5.25	5.8	
			Placebo	3	3 (100.0)	4.50 (0.87)	4.0	4.00	4.00	5.50	5.5	
		Week 44	Tezepelumab	9	9 (100.0)	4.83 (0.75)	3.5	4.50	4.75	5.00	6.0	
			Placebo	3	3 (100.0)	4.42 (0.88)	3.5	3.50	4.50	5.25	5.3	
		Week 48	Tezepelumab	9	9 (100.0)	4.83 (1.05)	3.3	4.00	5.00	5.75	6.3	
			Placebo	3	3 (100.0)	4.83 (0.88)	4.0	4.00	4.75	5.75	5.8	
		Week 52	Tezepelumab	9	9 (100.0)	4.81 (1.06)	3.3	4.00	5.00	5.75	6.3	
			Placebo	3	3 (100.0)	4.75 (0.90)	4.0	4.00	4.50	5.75	5.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	0.31 (1.00)	-1.0	-0.38	0.13	1.00	2.0	-0.27 [-1.82, 1.29]
			Placebo	3	2 (66.7)	0.63 (1.94)	-0.8	-0.75	0.63	2.00	2.0	
		Week 8	Tezepelumab	9	8 (88.9)	0.53 (0.99)	-1.0	0.00	0.25	1.38	2.0	-1.09 [-2.73, 0.55]
			Placebo	3	2 (66.7)	1.75 (1.77)	0.5	0.50	1.75	3.00	3.0	
		Week 12	Tezepelumab	9	8 (88.9)	0.75 (0.96)	-1.0	0.38	0.63	1.38	2.3	0.55 [-1.02, 2.12]
			Placebo	3	2 (66.7)	0.25 (0.35)	0.0	0.00	0.25	0.50	0.5	
		Week 16	Tezepelumab	9	8 (88.9)	0.59 (1.01)	-1.0	0.13	0.63	0.88	2.5	0.69 [-0.89, 2.28]
			Placebo	3	2 (66.7)	-0.13 (1.24)	-1.0	-1.00	-0.13	0.75	0.8	
		Week 20	Tezepelumab	9	8 (88.9)	0.31 (0.73)	-0.8	-0.25	0.38	0.88	1.3	-0.95 [-2.56, 0.67]
			Placebo	3	2 (66.7)	1.00 (0.71)	0.5	0.50	1.00	1.50	1.5	
		Week 24	Tezepelumab	9	8 (88.9)	0.66 (0.92)	-0.8	0.00	0.63	1.38	2.0	0.76 [-0.84, 2.35]
			Placebo	3	2 (66.7)	0.00 (0.35)	-0.3	-0.25	0.00	0.25	0.3	
		Week 28	Tezepelumab	9	8 (88.9)	0.47 (0.67)	-0.8	0.00	0.63	1.00	1.3	0.35 [-1.21, 1.91]
			Placebo	3	2 (66.7)	0.25 (0.00)	0.3	0.25	0.25	0.25	0.3	
		Week 32	Tezepelumab	9	8 (88.9)	0.47 (0.76)	-0.8	-0.13	0.63	1.13	1.3	0.48 [-1.09, 2.05]
			Placebo	3	2 (66.7)	0.13 (0.18)	0.0	0.00	0.13	0.25	0.3	
		Week 36	Tezepelumab	9	8 (88.9)	0.38 (0.69)	-1.0	0.13	0.38	0.88	1.3	0.37 [-1.19, 1.93]
			Placebo	3	2 (66.7)	0.13 (0.53)	-0.3	-0.25	0.13	0.50	0.5	
		Week 40	Tezepelumab	9	8 (88.9)	0.41 (0.69)	-1.0	0.13	0.50	1.00	1.0	0.24 [-1.32, 1.79]
			Placebo	3	2 (66.7)	0.25 (0.35)	0.0	0.00	0.25	0.50	0.5	
		Week 44	Tezepelumab	9	8 (88.9)	0.41 (0.72)	-1.0	0.00	0.63	0.88	1.3	1.26 [-0.41, 2.93]
			Placebo	3	2 (66.7)	-0.50 (0.71)	-1.0	-1.00	-0.50	0.00	0.0	
		Week 48	Tezepelumab	9	8 (88.9)	0.44 (0.90)	-1.0	-0.25	0.50	1.25	1.5	0.07 [-1.48, 1.62]
			Placebo	3	2 (66.7)	0.38 (0.18)	0.3	0.25	0.38	0.50	0.5	
		Week 52	Tezepelumab	9	8 (88.9)	0.41 (0.96)	-1.3	-0.25	0.50	1.25	1.5	0.03 [-1.51, 1.58]
			Placebo	3	2 (66.7)	0.38 (0.18)	0.3	0.25	0.38	0.50	0.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.21 (1.17)	1.0	3.50	4.25	5.00	7.0	
			Placebo	135	119 (88.1)	4.08 (1.21)	1.5	3.25	4.00	5.00	7.0	
		Week 4	Tezepelumab	128	117 (91.4)	4.92 (1.21)	1.0	4.25	5.00	5.75	7.0	
			Placebo	135	120 (88.9)	4.59 (1.21)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	128	119 (93.0)	5.10 (1.23)	1.0	4.25	5.25	6.00	7.0	
			Placebo	135	123 (91.1)	4.68 (1.31)	1.0	3.75	4.75	5.75	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.24 (1.24)	1.0	4.50	5.25	6.25	7.0	
			Placebo	135	124 (91.9)	4.77 (1.19)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.18 (1.22)	1.0	4.50	5.25	6.00	7.0	
			Placebo	135	124 (91.9)	4.76 (1.29)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.18 (1.27)	1.0	4.50	5.13	6.25	7.0	
			Placebo	135	124 (91.9)	4.77 (1.27)	1.3	4.00	4.75	5.63	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.26 (1.24)	1.0	4.50	5.13	6.25	7.0	
			Placebo	135	124 (91.9)	4.73 (1.37)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.23 (1.30)	1.0	4.50	5.25	6.25	7.0	
			Placebo	135	125 (92.6)	4.83 (1.39)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.32 (1.28)	1.0	4.50	5.25	6.25	7.0	
			Placebo	135	126 (93.3)	4.90 (1.36)	1.3	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.33 (1.28)	1.0	4.50	5.50	6.25	7.0	
			Placebo	135	126 (93.3)	4.86 (1.39)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.36 (1.23)	1.3	4.50	5.50	6.50	7.0	
			Placebo	135	126 (93.3)	4.92 (1.36)	1.0	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.40 (1.25)	1.0	4.50	5.25	6.50	7.0	
			Placebo	135	126 (93.3)	4.88 (1.35)	1.3	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.38 (1.22)	1.0	4.50	5.50	6.25	7.0	
			Placebo	135	127 (94.1)	4.92 (1.31)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.35 (1.27)	1.0	4.50	5.50	6.50	7.0	
			Placebo	135	127 (94.1)	4.84 (1.34)	1.0	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.72 (1.16)	-4.0	0.00	0.75	1.25	4.0	0.21 [-0.06, 0.47]
			Placebo	135	117 (86.7)	0.50 (0.96)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	128	111 (86.7)	0.90 (1.16)	-1.5	0.00	0.75	1.75	4.3	0.24 [-0.02, 0.50]
			Placebo	135	118 (87.4)	0.63 (1.03)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	128	111 (86.7)	1.04 (1.17)	-2.3	0.25	1.00	1.75	4.8	0.29 [0.03, 0.55]
			Placebo	135	118 (87.4)	0.71 (1.08)	-1.8	0.00	0.75	1.25	4.3	
		Week 16	Tezepelumab	128	111 (86.7)	0.99 (1.19)	-2.8	0.00	1.00	1.75	3.5	0.26 [0.00, 0.52]
			Placebo	135	118 (87.4)	0.70 (1.04)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	128	111 (86.7)	0.99 (1.19)	-1.8	0.25	0.75	1.75	3.5	0.24 [-0.02, 0.50]
			Placebo	135	118 (87.4)	0.72 (1.04)	-2.3	0.00	0.63	1.25	3.0	
		Week 24	Tezepelumab	128	111 (86.7)	1.08 (1.17)	-1.5	0.25	1.00	2.00	3.5	0.34 [0.08, 0.60]
			Placebo	135	118 (87.4)	0.69 (1.13)	-2.8	0.00	0.75	1.50	3.8	
		Week 28	Tezepelumab	128	111 (86.7)	1.05 (1.18)	-1.5	0.25	1.00	2.00	3.5	0.23 [-0.03, 0.49]
			Placebo	135	118 (87.4)	0.78 (1.16)	-2.8	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	128	111 (86.7)	1.13 (1.20)	-1.3	0.25	1.00	2.00	3.5	0.22 [-0.04, 0.48]
			Placebo	135	118 (87.4)	0.88 (1.10)	-1.8	0.00	0.75	1.75	3.8	
		Week 36	Tezepelumab	128	111 (86.7)	1.14 (1.24)	-1.8	0.25	1.00	2.25	3.5	0.26 [0.00, 0.52]
			Placebo	135	118 (87.4)	0.81 (1.24)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	128	111 (86.7)	1.18 (1.17)	-1.5	0.25	1.25	2.00	3.5	0.26 [0.00, 0.52]
			Placebo	135	118 (87.4)	0.87 (1.22)	-2.5	0.00	0.75	1.75	4.3	
		Week 44	Tezepelumab	128	111 (86.7)	1.21 (1.20)	-1.5	0.25	1.25	2.00	3.8	0.32 [0.06, 0.58]
			Placebo	135	118 (87.4)	0.83 (1.21)	-1.5	0.00	0.75	1.50	3.8	
		Week 48	Tezepelumab	128	111 (86.7)	1.20 (1.22)	-1.8	0.50	1.00	2.00	3.8	0.27 [0.01, 0.53]
			Placebo	135	118 (87.4)	0.87 (1.24)	-2.8	0.00	0.75	1.50	4.0	
		Week 52	Tezepelumab	128	111 (86.7)	1.15 (1.22)	-1.8	0.25	1.00	2.00	3.8	0.30 [0.04, 0.56]
			Placebo	135	118 (87.4)	0.79 (1.21)	-2.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	3.96 (1.09)	1.8	3.25	4.00	4.75	6.0	
			Placebo	37	33 (89.2)	4.39 (1.23)	1.5	3.50	4.25	5.25	7.0	
		Week 4	Tezepelumab	29	26 (89.7)	4.88 (1.24)	2.0	4.00	5.13	5.75	7.0	
			Placebo	37	33 (89.2)	4.62 (1.18)	1.3	3.75	4.75	5.25	7.0	
		Week 8	Tezepelumab	29	27 (93.1)	5.20 (1.28)	1.0	4.25	5.25	5.75	7.0	
			Placebo	37	34 (91.9)	4.76 (1.29)	2.3	3.75	5.00	5.50	7.0	
		Week 12	Tezepelumab	29	27 (93.1)	5.39 (1.36)	1.0	4.50	5.75	6.25	7.0	
			Placebo	37	35 (94.6)	5.09 (1.08)	2.5	4.25	5.25	5.75	7.0	
		Week 16	Tezepelumab	29	27 (93.1)	5.42 (1.28)	1.0	4.50	5.50	6.25	7.0	
			Placebo	37	35 (94.6)	4.94 (1.32)	1.3	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	29	27 (93.1)	5.41 (1.24)	1.3	5.00	5.50	6.50	7.0	
			Placebo	37	35 (94.6)	4.95 (1.41)	1.3	3.75	5.00	6.00	7.0	
		Week 24	Tezepelumab	29	27 (93.1)	5.37 (1.38)	1.0	4.50	5.50	6.50	7.0	
			Placebo	37	35 (94.6)	4.88 (1.39)	1.3	4.00	5.00	5.75	7.0	
		Week 28	Tezepelumab	29	27 (93.1)	5.30 (1.35)	1.0	4.50	5.50	6.25	7.0	
			Placebo	37	35 (94.6)	5.07 (1.53)	1.3	4.25	5.25	6.25	7.0	
		Week 32	Tezepelumab	29	27 (93.1)	5.34 (1.31)	1.0	4.75	5.75	6.25	7.0	
			Placebo	37	35 (94.6)	5.11 (1.32)	1.3	4.25	5.25	6.00	7.0	
		Week 36	Tezepelumab	29	27 (93.1)	5.44 (1.36)	1.0	4.50	5.75	6.50	7.0	
			Placebo	37	35 (94.6)	4.88 (1.27)	2.0	4.00	5.00	5.75	7.0	
		Week 40	Tezepelumab	29	27 (93.1)	5.50 (1.20)	2.0	4.50	5.75	6.50	7.0	
			Placebo	37	35 (94.6)	5.15 (1.15)	2.3	4.50	5.25	5.75	7.0	
		Week 44	Tezepelumab	29	27 (93.1)	5.44 (1.29)	2.0	4.50	5.75	6.50	7.0	
			Placebo	37	35 (94.6)	5.12 (1.09)	3.5	4.25	5.00	5.75	7.0	
		Week 48	Tezepelumab	29	27 (93.1)	5.29 (1.48)	1.0	4.25	5.75	6.25	7.0	
			Placebo	37	36 (97.3)	5.15 (1.15)	2.0	4.38	5.00	5.75	7.0	
		Week 52	Tezepelumab	29	27 (93.1)	5.28 (1.46)	1.0	4.25	5.75	6.25	7.0	
			Placebo	37	36 (97.3)	5.24 (1.04)	3.3	4.50	5.13	5.88	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	29	24 (82.8)	1.02 (1.07)	-1.3	0.25	1.00	1.75	3.3	0.71 [0.16, 1.26]
			Placebo	37	31 (83.8)	0.24 (1.11)	-2.5	-0.50	0.25	1.00	2.3	
		Week 8	Tezepelumab	29	25 (86.2)	1.29 (1.17)	-0.8	0.25	1.00	2.25	3.5	0.74 [0.20, 1.28]
			Placebo	37	32 (86.5)	0.44 (1.14)	-1.8	-0.25	0.25	1.00	3.3	
		Week 12	Tezepelumab	29	25 (86.2)	1.43 (1.14)	-0.8	0.50	1.50	2.25	3.5	0.51 [-0.02, 1.04]
			Placebo	37	32 (86.5)	0.84 (1.19)	-1.8	0.00	0.75	1.38	4.3	
		Week 16	Tezepelumab	29	25 (86.2)	1.47 (1.23)	-0.8	0.50	1.50	2.50	3.5	0.68 [0.14, 1.22]
			Placebo	37	32 (86.5)	0.63 (1.24)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	29	25 (86.2)	1.47 (1.10)	-0.5	0.75	1.50	2.50	3.3	0.70 [0.16, 1.24]
			Placebo	37	32 (86.5)	0.65 (1.22)	-2.3	0.00	0.75	1.50	3.0	
		Week 24	Tezepelumab	29	25 (86.2)	1.42 (1.22)	-0.8	0.25	1.50	2.50	3.5	0.67 [0.13, 1.21]
			Placebo	37	32 (86.5)	0.55 (1.34)	-2.8	0.00	0.63	1.13	3.8	
		Week 28	Tezepelumab	29	25 (86.2)	1.38 (1.25)	-0.8	0.25	1.25	2.25	3.5	0.45 [-0.08, 0.98]
			Placebo	37	32 (86.5)	0.75 (1.51)	-2.8	0.00	0.75	1.25	4.0	
		Week 32	Tezepelumab	29	25 (86.2)	1.43 (1.21)	-0.8	0.75	1.50	2.50	3.5	0.51 [-0.03, 1.04]
			Placebo	37	32 (86.5)	0.80 (1.26)	-1.8	0.00	0.88	1.50	3.8	
		Week 36	Tezepelumab	29	25 (86.2)	1.54 (1.24)	-0.8	0.50	1.75	2.25	3.5	0.73 [0.19, 1.27]
			Placebo	37	32 (86.5)	0.56 (1.40)	-2.8	0.00	0.38	1.25	3.8	
		Week 40	Tezepelumab	29	25 (86.2)	1.57 (1.17)	-0.3	0.25	1.75	2.75	3.5	0.55 [0.02, 1.08]
			Placebo	37	32 (86.5)	0.85 (1.41)	-2.5	0.00	0.63	1.75	4.3	
		Week 44	Tezepelumab	29	25 (86.2)	1.53 (1.24)	-0.3	0.25	1.25	2.50	3.8	0.58 [0.05, 1.11]
			Placebo	37	32 (86.5)	0.78 (1.33)	-1.5	0.00	0.75	1.25	3.8	
		Week 48	Tezepelumab	29	25 (86.2)	1.39 (1.33)	-1.0	0.25	1.25	2.50	3.5	0.42 [-0.11, 0.94]
			Placebo	37	32 (86.5)	0.82 (1.40)	-2.8	0.13	0.75	1.13	3.8	
		Week 52	Tezepelumab	29	25 (86.2)	1.39 (1.32)	-1.0	0.25	1.25	2.50	3.5	0.36 [-0.17, 0.89]
			Placebo	37	32 (86.5)	0.92 (1.27)	-1.3	0.13	0.75	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	4.30 (1.16)	1.0	3.75	4.25	5.13	7.0	
			Placebo	101	88 (87.1)	3.97 (1.19)	1.5	3.25	4.00	4.75	6.5	
		Week 4	Tezepelumab	108	100 (92.6)	4.91 (1.20)	1.0	4.25	5.00	5.75	7.0	
			Placebo	101	90 (89.1)	4.58 (1.22)	2.0	4.00	4.75	5.50	7.0	
		Week 8	Tezepelumab	108	101 (93.5)	5.07 (1.19)	1.0	4.25	5.00	6.00	7.0	
			Placebo	101	92 (91.1)	4.68 (1.33)	1.0	4.00	4.75	5.75	7.0	
		Week 12	Tezepelumab	108	101 (93.5)	5.20 (1.18)	1.0	4.50	5.25	6.00	7.0	
			Placebo	101	92 (91.1)	4.64 (1.21)	1.3	4.00	4.63	5.50	7.0	
		Week 16	Tezepelumab	108	101 (93.5)	5.11 (1.17)	1.0	4.50	5.00	6.00	7.0	
			Placebo	101	92 (91.1)	4.68 (1.26)	1.3	4.00	4.50	5.50	7.0	
		Week 20	Tezepelumab	108	102 (94.4)	5.09 (1.25)	1.0	4.25	5.00	6.00	7.0	
			Placebo	101	92 (91.1)	4.71 (1.23)	1.5	4.00	4.75	5.50	7.0	
		Week 24	Tezepelumab	108	102 (94.4)	5.22 (1.17)	1.0	4.25	5.00	6.00	7.0	
			Placebo	101	92 (91.1)	4.66 (1.34)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	108	104 (96.3)	5.19 (1.24)	1.0	4.50	5.00	6.13	7.0	
			Placebo	101	93 (92.1)	4.74 (1.32)	1.3	4.00	4.75	6.00	7.0	
		Week 32	Tezepelumab	108	105 (97.2)	5.28 (1.24)	1.0	4.50	5.25	6.00	7.0	
			Placebo	101	94 (93.1)	4.81 (1.36)	1.3	4.00	4.75	6.00	7.0	
		Week 36	Tezepelumab	108	105 (97.2)	5.25 (1.23)	1.0	4.50	5.00	6.25	7.0	
			Placebo	101	94 (93.1)	4.83 (1.43)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	108	105 (97.2)	5.29 (1.20)	1.3	4.50	5.25	6.25	7.0	
			Placebo	101	94 (93.1)	4.82 (1.42)	1.0	4.00	4.75	6.00	7.0	
		Week 44	Tezepelumab	108	105 (97.2)	5.35 (1.21)	1.0	4.50	5.25	6.25	7.0	
			Placebo	101	94 (93.1)	4.78 (1.41)	1.3	4.00	4.63	6.00	7.0	
		Week 48	Tezepelumab	108	105 (97.2)	5.36 (1.15)	2.0	4.50	5.25	6.25	7.0	
			Placebo	101	94 (93.1)	4.83 (1.35)	1.0	4.00	4.75	6.00	7.0	
		Week 52	Tezepelumab	108	105 (97.2)	5.32 (1.21)	1.0	4.50	5.25	6.25	7.0	
			Placebo	101	94 (93.1)	4.69 (1.41)	1.0	4.00	4.63	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	108	93 (86.1)	0.61 (1.16)	-4.0	0.00	0.50	1.25	4.0	0.01 [-0.28, 0.30]
			Placebo	101	88 (87.1)	0.60 (0.90)	-1.8	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	108	94 (87.0)	0.76 (1.12)	-1.5	0.00	0.50	1.50	4.3	0.03 [-0.26, 0.32]
			Placebo	101	88 (87.1)	0.72 (1.01)	-1.5	0.00	0.75	1.25	3.0	
		Week 12	Tezepelumab	108	94 (87.0)	0.91 (1.14)	-2.3	0.25	0.75	1.50	4.8	0.23 [-0.06, 0.52]
			Placebo	101	88 (87.1)	0.66 (1.02)	-1.3	0.00	0.63	1.25	3.0	
		Week 16	Tezepelumab	108	94 (87.0)	0.83 (1.14)	-2.8	0.00	0.75	1.50	3.3	0.12 [-0.17, 0.41]
			Placebo	101	88 (87.1)	0.70 (0.97)	-1.5	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	108	94 (87.0)	0.81 (1.16)	-1.8	0.00	0.75	1.50	3.5	0.05 [-0.24, 0.34]
			Placebo	101	88 (87.1)	0.75 (0.96)	-1.3	0.25	0.50	1.25	3.0	
		Week 24	Tezepelumab	108	94 (87.0)	0.95 (1.12)	-1.5	0.25	0.88	1.75	3.5	0.21 [-0.08, 0.50]
			Placebo	101	88 (87.1)	0.73 (1.04)	-1.3	-0.25	0.63	1.50	3.3	
		Week 28	Tezepelumab	108	94 (87.0)	0.91 (1.12)	-1.5	0.25	0.75	1.50	3.5	0.13 [-0.16, 0.42]
			Placebo	101	88 (87.1)	0.78 (0.99)	-1.3	0.00	0.75	1.50	2.8	
		Week 32	Tezepelumab	108	94 (87.0)	0.99 (1.16)	-1.3	0.00	1.00	1.75	3.5	0.09 [-0.20, 0.38]
			Placebo	101	88 (87.1)	0.89 (1.04)	-1.3	0.25	0.75	1.75	3.5	
		Week 36	Tezepelumab	108	94 (87.0)	0.97 (1.20)	-1.8	0.25	0.75	2.00	3.5	0.07 [-0.22, 0.36]
			Placebo	101	88 (87.1)	0.89 (1.16)	-2.0	0.13	0.75	1.63	3.5	
		Week 40	Tezepelumab	108	94 (87.0)	1.01 (1.14)	-1.5	0.25	1.00	1.75	3.5	0.14 [-0.16, 0.43]
			Placebo	101	88 (87.1)	0.86 (1.15)	-1.8	0.13	0.75	1.50	4.3	
		Week 44	Tezepelumab	108	94 (87.0)	1.06 (1.17)	-1.5	0.25	1.00	2.00	3.5	0.21 [-0.08, 0.50]
			Placebo	101	88 (87.1)	0.82 (1.17)	-1.5	0.00	0.50	1.50	3.8	
		Week 48	Tezepelumab	108	94 (87.0)	1.09 (1.18)	-1.8	0.25	1.00	2.00	3.8	0.18 [-0.11, 0.47]
			Placebo	101	88 (87.1)	0.88 (1.17)	-1.5	0.00	0.75	1.50	4.0	
		Week 52	Tezepelumab	108	94 (87.0)	1.02 (1.18)	-1.8	0.25	1.00	1.75	3.8	0.25 [-0.04, 0.54]
			Placebo	101	88 (87.1)	0.73 (1.17)	-2.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.24 (1.13)	1.0	3.50	4.25	5.00	7.0	
			Placebo	123	106 (86.2)	4.08 (1.24)	1.5	3.25	4.00	5.00	7.0	
		Week 4	Tezepelumab	128	117 (91.4)	4.85 (1.21)	1.0	4.00	5.00	5.75	7.0	
			Placebo	123	109 (88.6)	4.59 (1.23)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	128	119 (93.0)	5.05 (1.23)	1.0	4.25	5.00	5.75	7.0	
			Placebo	123	112 (91.1)	4.67 (1.33)	1.0	3.88	4.75	5.75	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.19 (1.24)	1.0	4.50	5.25	6.25	7.0	
			Placebo	123	113 (91.9)	4.71 (1.22)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.16 (1.22)	1.0	4.50	5.00	6.00	7.0	
			Placebo	123	113 (91.9)	4.73 (1.31)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.13 (1.27)	1.0	4.38	5.00	6.00	7.0	
			Placebo	123	113 (91.9)	4.72 (1.30)	1.3	4.00	4.75	5.75	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.22 (1.23)	1.0	4.38	5.00	6.25	7.0	
			Placebo	123	113 (91.9)	4.67 (1.40)	1.0	4.00	4.50	5.75	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.16 (1.28)	1.0	4.50	5.00	6.25	7.0	
			Placebo	123	114 (92.7)	4.75 (1.39)	1.3	4.00	4.75	6.00	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.25 (1.27)	1.0	4.50	5.25	6.00	7.0	
			Placebo	123	115 (93.5)	4.82 (1.38)	1.3	4.00	4.75	6.00	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.25 (1.28)	1.0	4.50	5.25	6.25	7.0	
			Placebo	123	115 (93.5)	4.77 (1.42)	1.0	4.00	4.75	6.00	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.27 (1.21)	1.3	4.50	5.25	6.25	7.0	
			Placebo	123	115 (93.5)	4.85 (1.38)	1.0	4.00	5.00	5.75	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.30 (1.23)	1.0	4.50	5.25	6.25	7.0	
			Placebo	123	115 (93.5)	4.82 (1.35)	1.3	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.30 (1.23)	1.0	4.50	5.25	6.25	7.0	
			Placebo	123	116 (94.3)	4.86 (1.33)	1.0	4.00	4.88	6.00	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.26 (1.27)	1.0	4.50	5.25	6.25	7.0	
			Placebo	123	116 (94.3)	4.80 (1.35)	1.0	4.00	4.75	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.63 (1.13)	-4.0	0.00	0.50	1.25	3.3	0.11 [-0.16, 0.38]
			Placebo	123	105 (85.4)	0.51 (0.97)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	128	111 (86.7)	0.82 (1.11)	-1.5	0.00	0.75	1.75	3.5	0.17 [-0.09, 0.44]
			Placebo	123	106 (86.2)	0.63 (1.04)	-1.8	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	128	111 (86.7)	0.96 (1.11)	-2.3	0.25	1.00	1.75	3.5	0.26 [-0.01, 0.53]
			Placebo	123	106 (86.2)	0.68 (1.09)	-1.8	0.00	0.50	1.25	4.3	
		Week 16	Tezepelumab	128	111 (86.7)	0.93 (1.17)	-2.8	0.00	0.75	1.50	3.5	0.23 [-0.04, 0.49]
			Placebo	123	106 (86.2)	0.68 (1.04)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	128	111 (86.7)	0.92 (1.16)	-1.8	0.00	0.75	1.75	3.5	0.21 [-0.05, 0.48]
			Placebo	123	106 (86.2)	0.69 (1.02)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	128	111 (86.7)	1.01 (1.14)	-1.5	0.25	1.00	2.00	3.5	0.33 [0.06, 0.60]
			Placebo	123	106 (86.2)	0.64 (1.11)	-2.8	-0.25	0.50	1.50	3.3	
		Week 28	Tezepelumab	128	111 (86.7)	0.95 (1.14)	-1.5	0.25	0.75	1.75	3.5	0.22 [-0.05, 0.49]
			Placebo	123	106 (86.2)	0.70 (1.13)	-2.8	0.00	0.75	1.25	4.0	
		Week 32	Tezepelumab	128	111 (86.7)	1.04 (1.18)	-1.3	0.00	1.00	1.75	3.5	0.21 [-0.06, 0.47]
			Placebo	123	106 (86.2)	0.80 (1.08)	-1.8	0.00	0.75	1.50	3.5	
		Week 36	Tezepelumab	128	111 (86.7)	1.05 (1.21)	-1.8	0.25	1.00	2.00	3.5	0.25 [-0.02, 0.52]
			Placebo	123	106 (86.2)	0.75 (1.22)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	128	111 (86.7)	1.07 (1.14)	-1.5	0.25	1.00	2.00	3.5	0.22 [-0.05, 0.48]
			Placebo	123	106 (86.2)	0.81 (1.21)	-2.5	0.00	0.63	1.25	4.3	
		Week 44	Tezepelumab	128	111 (86.7)	1.09 (1.16)	-1.5	0.25	1.00	2.00	3.8	0.28 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.76 (1.16)	-1.5	0.00	0.50	1.25	3.5	
		Week 48	Tezepelumab	128	111 (86.7)	1.09 (1.17)	-1.8	0.25	1.00	2.00	3.5	0.24 [-0.03, 0.50]
			Placebo	123	106 (86.2)	0.81 (1.20)	-2.8	0.00	0.75	1.25	4.0	
		Week 52	Tezepelumab	128	111 (86.7)	1.04 (1.18)	-1.8	0.25	1.00	1.75	3.5	0.24 [-0.02, 0.51]
			Placebo	123	106 (86.2)	0.75 (1.15)	-2.3	0.00	0.50	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.00 (1.45)	1.8	2.75	4.25	5.25	5.8	
			Placebo	15	15 (100.0)	4.17 (0.95)	3.0	3.25	3.75	5.25	5.5	
		Week 4	Tezepelumab	9	9 (100.0)	5.58 (0.92)	4.3	4.75	5.75	6.00	7.0	
			Placebo	15	14 (93.3)	4.63 (1.00)	2.5	4.25	4.75	5.50	5.8	
		Week 8	Tezepelumab	9	9 (100.0)	5.64 (0.67)	4.5	5.25	5.75	6.00	6.8	
			Placebo	15	14 (93.3)	4.98 (1.18)	3.0	3.75	5.38	5.75	6.5	
		Week 12	Tezepelumab	9	9 (100.0)	5.81 (0.85)	4.5	5.25	6.00	6.50	6.8	
			Placebo	15	14 (93.3)	5.13 (0.78)	3.8	4.75	5.25	5.50	6.5	
		Week 16	Tezepelumab	9	9 (100.0)	5.44 (0.83)	4.3	4.75	5.50	6.00	7.0	
			Placebo	15	14 (93.3)	4.89 (1.03)	3.3	3.75	5.13	5.75	6.3	
		Week 20	Tezepelumab	9	9 (100.0)	5.44 (0.95)	3.8	5.00	5.50	6.00	7.0	
			Placebo	15	14 (93.3)	5.21 (1.08)	3.3	4.75	5.25	5.50	7.0	
		Week 24	Tezepelumab	9	9 (100.0)	5.64 (0.87)	4.0	5.00	5.75	6.25	6.8	
			Placebo	15	14 (93.3)	5.18 (0.86)	3.5	4.75	5.25	5.50	7.0	
		Week 28	Tezepelumab	9	9 (100.0)	5.83 (0.87)	4.3	5.75	5.75	6.00	7.0	
			Placebo	15	14 (93.3)	5.46 (1.17)	3.3	4.75	5.25	6.50	7.0	
		Week 32	Tezepelumab	9	9 (100.0)	5.83 (0.94)	4.0	5.50	6.00	6.00	7.0	
			Placebo	15	14 (93.3)	5.54 (0.76)	4.5	5.00	5.38	6.25	7.0	
		Week 36	Tezepelumab	9	9 (100.0)	5.81 (0.87)	4.8	5.00	5.75	6.50	7.0	
			Placebo	15	14 (93.3)	5.43 (0.86)	4.3	4.75	5.25	6.00	7.0	
		Week 40	Tezepelumab	9	9 (100.0)	6.11 (0.74)	5.0	5.75	5.75	7.00	7.0	
			Placebo	15	14 (93.3)	5.38 (1.05)	3.5	4.75	5.13	6.00	7.0	
		Week 44	Tezepelumab	9	9 (100.0)	6.19 (0.78)	5.0	5.75	6.00	7.00	7.0	
			Placebo	15	14 (93.3)	5.34 (1.14)	4.0	4.50	4.88	6.75	7.0	
		Week 48	Tezepelumab	9	9 (100.0)	5.97 (0.73)	4.8	5.75	6.00	6.25	7.0	
			Placebo	15	14 (93.3)	5.41 (0.97)	4.3	4.50	5.25	5.75	7.0	
		Week 52	Tezepelumab	9	9 (100.0)	6.06 (0.81)	4.8	5.75	6.00	6.75	7.0	
			Placebo	15	14 (93.3)	5.18 (1.15)	3.0	4.50	5.25	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	1.56 (1.22)	0.0	0.75	1.50	2.00	4.0	1.07 [0.14, 1.99]
			Placebo	15	14 (93.3)	0.43 (0.97)	-0.8	0.00	0.00	1.25	2.5	
		Week 8	Tezepelumab	9	8 (88.9)	1.63 (1.40)	0.0	0.38	1.88	2.13	4.3	0.68 [-0.22, 1.57]
			Placebo	15	14 (93.3)	0.79 (1.14)	-0.8	0.00	0.38	1.50	3.3	
		Week 12	Tezepelumab	9	8 (88.9)	1.78 (1.51)	0.0	0.50	1.88	2.38	4.8	0.75 [-0.15, 1.65]
			Placebo	15	14 (93.3)	0.93 (0.87)	-0.8	0.50	1.00	1.50	2.5	
		Week 16	Tezepelumab	9	8 (88.9)	1.38 (1.32)	-0.3	0.13	1.38	2.63	3.0	0.58 [-0.31, 1.47]
			Placebo	15	14 (93.3)	0.70 (1.09)	-1.3	0.25	0.63	1.25	3.0	
		Week 20	Tezepelumab	9	8 (88.9)	1.34 (1.46)	-0.5	-0.13	1.50	2.63	3.3	0.26 [-0.61, 1.14]
			Placebo	15	14 (93.3)	1.02 (1.09)	-1.3	0.50	1.13	1.75	2.8	
		Week 24	Tezepelumab	9	8 (88.9)	1.56 (1.23)	-0.5	0.88	1.50	2.50	3.3	0.48 [-0.40, 1.36]
			Placebo	15	14 (93.3)	0.98 (1.21)	-1.0	0.50	1.00	1.75	3.8	
		Week 28	Tezepelumab	9	8 (88.9)	1.81 (1.21)	0.0	0.88	1.88	2.88	3.3	0.45 [-0.43, 1.33]
			Placebo	15	14 (93.3)	1.27 (1.21)	-0.8	0.25	1.25	2.00	3.8	
		Week 32	Tezepelumab	9	8 (88.9)	1.69 (1.08)	0.3	0.75	1.63	2.63	3.3	0.32 [-0.56, 1.19]
			Placebo	15	14 (93.3)	1.34 (1.11)	-0.8	1.00	1.25	2.00	3.8	
		Week 36	Tezepelumab	9	8 (88.9)	1.66 (1.34)	-0.3	0.38	2.00	2.75	3.3	0.33 [-0.55, 1.20]
			Placebo	15	14 (93.3)	1.23 (1.28)	-1.0	0.50	1.50	1.75	3.8	
		Week 40	Tezepelumab	9	8 (88.9)	2.00 (1.24)	0.0	1.13	2.38	2.88	3.3	0.67 [-0.23, 1.56]
			Placebo	15	14 (93.3)	1.18 (1.23)	-0.8	0.25	1.13	1.75	3.8	
		Week 44	Tezepelumab	9	8 (88.9)	2.09 (1.31)	0.0	1.13	2.38	3.00	3.8	0.65 [-0.24, 1.54]
			Placebo	15	14 (93.3)	1.14 (1.53)	-1.0	0.00	1.25	2.00	3.8	
		Week 48	Tezepelumab	9	8 (88.9)	1.94 (1.53)	-0.8	1.00	2.25	3.00	3.8	0.50 [-0.38, 1.38]
			Placebo	15	14 (93.3)	1.21 (1.40)	-1.0	0.25	1.13	1.50	3.8	
		Week 52	Tezepelumab	9	8 (88.9)	1.94 (1.53)	-0.8	1.00	2.25	3.00	3.8	0.63 [-0.26, 1.52]
			Placebo	15	14 (93.3)	0.98 (1.52)	-1.0	0.00	0.50	1.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	4.28 (1.36)	1.8	3.50	4.25	5.25	6.0	
			Placebo	9	8 (88.9)	4.09 (0.88)	3.0	3.38	4.00	4.75	5.5	
		Week 4	Tezepelumab	10	8 (80.0)	5.84 (0.77)	4.8	5.38	5.63	6.50	7.0	
			Placebo	9	7 (77.8)	4.50 (1.30)	2.5	3.50	4.50	5.50	6.5	
		Week 8	Tezepelumab	10	9 (90.0)	5.86 (1.00)	4.0	5.25	6.00	6.75	7.0	
			Placebo	9	7 (77.8)	5.21 (1.37)	3.0	3.75	5.50	6.00	7.0	
		Week 12	Tezepelumab	10	9 (90.0)	6.03 (0.92)	4.5	5.75	6.25	6.75	7.0	
			Placebo	9	7 (77.8)	5.07 (1.08)	3.8	4.00	5.25	5.50	7.0	
		Week 16	Tezepelumab	10	9 (90.0)	5.61 (0.88)	4.5	4.75	5.75	6.00	7.0	
			Placebo	9	7 (77.8)	4.64 (1.27)	3.3	3.75	4.50	5.25	7.0	
		Week 20	Tezepelumab	10	9 (90.0)	5.61 (0.86)	4.5	5.00	5.50	6.00	7.0	
			Placebo	9	7 (77.8)	5.36 (1.41)	3.3	4.00	5.25	7.00	7.0	
		Week 24	Tezepelumab	10	9 (90.0)	5.83 (0.86)	4.5	5.50	5.75	6.50	7.0	
			Placebo	9	7 (77.8)	5.46 (0.80)	4.8	4.75	5.25	6.00	7.0	
		Week 28	Tezepelumab	10	10 (100.0)	6.05 (0.94)	4.5	5.25	6.00	7.00	7.0	
			Placebo	9	7 (77.8)	5.25 (1.13)	3.3	4.75	5.25	5.75	7.0	
		Week 32	Tezepelumab	10	10 (100.0)	5.93 (0.77)	4.5	5.75	6.00	6.25	7.0	
			Placebo	9	7 (77.8)	5.46 (0.81)	4.5	4.75	5.50	5.75	7.0	
		Week 36	Tezepelumab	10	10 (100.0)	5.88 (0.91)	4.5	5.00	6.00	6.50	7.0	
			Placebo	9	7 (77.8)	5.54 (0.82)	4.8	4.75	5.25	6.25	7.0	
		Week 40	Tezepelumab	10	10 (100.0)	6.08 (0.87)	4.5	5.50	6.25	7.00	7.0	
			Placebo	9	7 (77.8)	5.32 (0.86)	4.3	4.75	5.25	5.50	7.0	
		Week 44	Tezepelumab	10	10 (100.0)	6.08 (0.84)	4.5	5.75	6.13	7.00	7.0	
			Placebo	9	7 (77.8)	5.50 (1.08)	4.3	4.50	5.50	6.75	7.0	
		Week 48	Tezepelumab	10	10 (100.0)	6.05 (0.83)	4.5	5.75	6.13	6.75	7.0	
			Placebo	9	7 (77.8)	5.71 (0.67)	4.5	5.50	5.75	6.00	6.8	
		Week 52	Tezepelumab	10	10 (100.0)	6.13 (0.85)	4.5	5.75	6.25	6.75	7.0	
			Placebo	9	7 (77.8)	5.61 (1.05)	3.5	5.50	5.75	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	1.47 (1.75)	-0.5	-0.13	1.25	3.00	4.0	0.71 [-0.34, 1.76]
			Placebo	9	7 (77.8)	0.36 (1.34)	-0.8	-0.75	0.00	2.00	2.5	
		Week 8	Tezepelumab	10	9 (90.0)	1.58 (1.73)	0.0	0.00	0.75	3.50	4.3	0.34 [-0.65, 1.34]
			Placebo	9	7 (77.8)	1.07 (1.11)	-0.3	0.25	0.50	2.50	2.5	
		Week 12	Tezepelumab	10	9 (90.0)	1.75 (1.74)	0.0	0.50	1.00	3.50	4.8	0.58 [-0.43, 1.59]
			Placebo	9	7 (77.8)	0.93 (0.83)	0.0	0.25	1.00	1.25	2.5	
		Week 16	Tezepelumab	10	9 (90.0)	1.33 (1.51)	-0.3	0.00	1.00	3.00	3.5	0.62 [-0.39, 1.64]
			Placebo	9	7 (77.8)	0.50 (1.07)	-1.0	0.00	0.25	1.00	2.5	
		Week 20	Tezepelumab	10	9 (90.0)	1.33 (1.67)	-0.5	-0.25	1.00	3.25	3.5	0.09 [-0.90, 1.08]
			Placebo	9	7 (77.8)	1.21 (0.76)	0.3	0.75	1.00	1.75	2.5	
		Week 24	Tezepelumab	10	9 (90.0)	1.56 (1.56)	-0.5	0.50	1.50	3.25	3.5	0.18 [-0.81, 1.17]
			Placebo	9	7 (77.8)	1.32 (0.86)	-0.3	1.00	1.50	1.75	2.5	
		Week 28	Tezepelumab	10	9 (90.0)	1.67 (1.49)	-0.5	0.50	1.50	3.25	3.5	0.43 [-0.57, 1.43]
			Placebo	9	7 (77.8)	1.11 (1.01)	-0.3	0.25	1.00	2.00	2.5	
		Week 32	Tezepelumab	10	9 (90.0)	1.53 (1.36)	-0.3	0.50	1.00	2.75	3.5	0.17 [-0.82, 1.16]
			Placebo	9	7 (77.8)	1.32 (0.89)	0.0	0.75	1.00	2.25	2.5	
		Week 36	Tezepelumab	10	9 (90.0)	1.53 (1.51)	-0.5	0.50	1.00	3.25	3.5	0.10 [-0.89, 1.09]
			Placebo	9	7 (77.8)	1.39 (1.07)	-0.3	0.50	1.50	2.50	2.8	
		Week 40	Tezepelumab	10	9 (90.0)	1.75 (1.47)	-0.5	0.50	2.00	3.25	3.5	0.46 [-0.54, 1.46]
			Placebo	9	7 (77.8)	1.18 (0.86)	0.0	0.50	1.00	1.75	2.5	
		Week 44	Tezepelumab	10	9 (90.0)	1.78 (1.38)	0.0	0.50	1.75	3.25	3.5	0.29 [-0.70, 1.29]
			Placebo	9	7 (77.8)	1.36 (1.51)	-1.0	0.50	1.50	2.50	3.8	
		Week 48	Tezepelumab	10	9 (90.0)	1.75 (1.39)	-0.3	0.75	1.75	3.25	3.5	0.14 [-0.85, 1.12]
			Placebo	9	7 (77.8)	1.57 (1.21)	0.3	0.50	1.50	2.50	3.8	
		Week 52	Tezepelumab	10	9 (90.0)	1.78 (1.35)	0.0	0.75	1.75	3.25	3.5	0.23 [-0.76, 1.22]
			Placebo	9	7 (77.8)	1.46 (1.42)	0.0	0.25	1.50	2.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	127	114 (89.8)	4.22 (1.14)	1.0	3.50	4.25	5.00	7.0	
			Placebo	129	113 (87.6)	4.09 (1.23)	1.5	3.25	4.00	5.00	7.0	
		Week 4	Tezepelumab	127	118 (92.9)	4.84 (1.20)	1.0	4.00	5.00	5.75	7.0	
			Placebo	129	116 (89.9)	4.60 (1.21)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	127	119 (93.7)	5.04 (1.20)	1.0	4.25	5.00	5.75	7.0	
			Placebo	129	119 (92.2)	4.67 (1.31)	1.0	3.75	4.75	5.75	7.0	
		Week 12	Tezepelumab	127	119 (93.7)	5.18 (1.22)	1.0	4.50	5.25	6.00	7.0	
			Placebo	129	120 (93.0)	4.74 (1.20)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	127	119 (93.7)	5.14 (1.21)	1.0	4.50	5.00	6.00	7.0	
			Placebo	129	120 (93.0)	4.76 (1.28)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	127	120 (94.5)	5.12 (1.27)	1.0	4.25	5.00	6.00	7.0	
			Placebo	129	120 (93.0)	4.74 (1.27)	1.3	4.00	4.75	5.50	7.0	
		Week 24	Tezepelumab	127	120 (94.5)	5.21 (1.23)	1.0	4.25	5.00	6.25	7.0	
			Placebo	129	120 (93.0)	4.68 (1.37)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	127	121 (95.3)	5.14 (1.26)	1.0	4.25	5.00	6.00	7.0	
			Placebo	129	121 (93.8)	4.80 (1.39)	1.3	4.00	4.75	6.00	7.0	
		Week 32	Tezepelumab	127	122 (96.1)	5.24 (1.27)	1.0	4.50	5.25	6.00	7.0	
			Placebo	129	122 (94.6)	4.86 (1.37)	1.3	4.00	4.75	6.00	7.0	
		Week 36	Tezepelumab	127	122 (96.1)	5.24 (1.27)	1.0	4.50	5.25	6.25	7.0	
			Placebo	129	122 (94.6)	4.81 (1.40)	1.0	4.00	4.88	6.00	7.0	
		Week 40	Tezepelumab	127	122 (96.1)	5.27 (1.21)	1.3	4.50	5.25	6.00	7.0	
			Placebo	129	122 (94.6)	4.89 (1.38)	1.0	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	127	122 (96.1)	5.31 (1.24)	1.0	4.50	5.25	6.25	7.0	
			Placebo	129	122 (94.6)	4.84 (1.34)	1.3	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	127	122 (96.1)	5.29 (1.23)	1.0	4.50	5.25	6.25	7.0	
			Placebo	129	123 (95.3)	4.87 (1.31)	1.0	4.00	4.75	6.00	7.0	
		Week 52	Tezepelumab	127	122 (96.1)	5.24 (1.27)	1.0	4.50	5.25	6.25	7.0	
			Placebo	129	123 (95.3)	4.80 (1.34)	1.0	4.00	4.75	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	127	109 (85.8)	0.64 (1.09)	-4.0	0.00	0.75	1.25	3.0	0.12 [-0.14, 0.38]
			Placebo	129	112 (86.8)	0.51 (0.94)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	127	110 (86.6)	0.81 (1.08)	-1.5	0.00	0.75	1.75	3.3	0.18 [-0.08, 0.44]
			Placebo	129	113 (87.6)	0.62 (1.04)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	127	110 (86.6)	0.96 (1.08)	-2.3	0.25	1.00	1.75	3.0	0.24 [-0.02, 0.51]
			Placebo	129	113 (87.6)	0.69 (1.08)	-1.8	0.00	0.75	1.25	4.3	
		Week 16	Tezepelumab	127	110 (86.6)	0.93 (1.15)	-2.8	0.00	0.75	1.50	3.3	0.22 [-0.05, 0.48]
			Placebo	129	113 (87.6)	0.70 (1.04)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	127	110 (86.6)	0.92 (1.13)	-1.8	0.00	0.75	1.75	3.5	0.20 [-0.06, 0.47]
			Placebo	129	113 (87.6)	0.69 (1.04)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	127	110 (86.6)	1.01 (1.11)	-1.5	0.25	1.00	2.00	3.5	0.33 [0.06, 0.59]
			Placebo	129	113 (87.6)	0.64 (1.13)	-2.8	-0.25	0.50	1.50	3.8	
		Week 28	Tezepelumab	127	110 (86.6)	0.96 (1.12)	-1.5	0.25	0.75	1.75	3.3	0.18 [-0.08, 0.45]
			Placebo	129	113 (87.6)	0.75 (1.16)	-2.8	0.00	0.75	1.25	4.0	
		Week 32	Tezepelumab	127	110 (86.6)	1.05 (1.17)	-1.3	0.00	1.00	1.75	3.5	0.18 [-0.08, 0.45]
			Placebo	129	113 (87.6)	0.84 (1.10)	-1.8	0.00	0.75	1.50	3.8	
		Week 36	Tezepelumab	127	110 (86.6)	1.05 (1.20)	-1.8	0.25	1.00	2.00	3.5	0.24 [-0.03, 0.50]
			Placebo	129	113 (87.6)	0.77 (1.23)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	127	110 (86.6)	1.08 (1.13)	-1.5	0.25	1.00	2.00	3.3	0.21 [-0.06, 0.47]
			Placebo	129	113 (87.6)	0.84 (1.24)	-2.5	0.00	0.75	1.50	4.3	
		Week 44	Tezepelumab	127	110 (86.6)	1.11 (1.17)	-1.5	0.25	1.00	2.00	3.8	0.28 [0.02, 0.55]
			Placebo	129	113 (87.6)	0.77 (1.19)	-1.5	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	127	110 (86.6)	1.10 (1.19)	-1.8	0.25	1.00	2.00	3.8	0.24 [-0.03, 0.50]
			Placebo	129	113 (87.6)	0.82 (1.22)	-2.8	0.00	0.75	1.25	4.0	
		Week 52	Tezepelumab	127	110 (86.6)	1.04 (1.20)	-1.8	0.25	1.00	2.00	3.8	0.26 [-0.01, 0.52]
			Placebo	129	113 (87.6)	0.74 (1.18)	-2.3	0.00	0.50	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	61	54 (88.5)	4.13 (0.98)	1.8	3.50	4.00	4.75	6.5	
			Placebo	60	53 (88.3)	4.03 (1.12)	2.0	3.50	4.00	5.00	6.0	
		Week 4	Tezepelumab	61	56 (91.8)	4.86 (1.09)	1.3	4.25	4.75	5.75	7.0	
			Placebo	60	53 (88.3)	4.74 (1.16)	2.0	4.00	5.00	5.50	7.0	
		Week 8	Tezepelumab	61	57 (93.4)	5.04 (0.91)	3.5	4.25	5.00	5.75	7.0	
			Placebo	60	54 (90.0)	4.89 (1.20)	2.3	4.00	5.00	5.75	7.0	
		Week 12	Tezepelumab	61	57 (93.4)	5.13 (0.99)	3.0	4.50	5.00	5.75	7.0	
			Placebo	60	54 (90.0)	4.89 (1.06)	2.5	4.00	4.75	5.50	7.0	
		Week 16	Tezepelumab	61	57 (93.4)	5.11 (1.00)	2.5	4.50	5.00	6.00	7.0	
			Placebo	60	54 (90.0)	4.85 (1.19)	1.3	4.00	5.00	5.50	7.0	
		Week 20	Tezepelumab	61	58 (95.1)	5.02 (0.96)	3.5	4.25	5.00	5.75	7.0	
			Placebo	60	54 (90.0)	4.76 (1.15)	1.3	4.00	4.75	5.50	7.0	
		Week 24	Tezepelumab	61	58 (95.1)	5.20 (1.01)	3.5	4.25	5.00	6.00	7.0	
			Placebo	60	54 (90.0)	4.76 (1.31)	1.3	4.00	4.88	5.50	7.0	
		Week 28	Tezepelumab	61	59 (96.7)	5.14 (0.98)	3.5	4.25	5.00	5.75	7.0	
			Placebo	60	54 (90.0)	4.69 (1.41)	1.3	4.00	4.75	5.75	7.0	
		Week 32	Tezepelumab	61	60 (98.4)	5.22 (0.98)	3.3	4.50	5.00	6.00	7.0	
			Placebo	60	54 (90.0)	4.81 (1.26)	1.3	4.00	4.63	5.50	7.0	
		Week 36	Tezepelumab	61	60 (98.4)	5.28 (0.98)	3.3	4.50	5.00	6.00	7.0	
			Placebo	60	54 (90.0)	4.87 (1.22)	1.8	4.00	4.75	5.75	7.0	
		Week 40	Tezepelumab	61	60 (98.4)	5.29 (1.03)	3.8	4.50	5.00	6.00	7.0	
			Placebo	60	54 (90.0)	4.90 (1.16)	1.8	4.00	4.88	5.75	7.0	
		Week 44	Tezepelumab	61	60 (98.4)	5.29 (1.07)	3.5	4.38	5.00	6.13	7.0	
			Placebo	60	54 (90.0)	4.90 (1.25)	2.0	4.00	4.75	5.75	7.0	
		Week 48	Tezepelumab	61	60 (98.4)	5.30 (1.06)	2.5	4.50	5.25	6.13	7.0	
			Placebo	60	54 (90.0)	4.91 (1.21)	2.0	4.00	4.75	6.00	7.0	
		Week 52	Tezepelumab	61	60 (98.4)	5.29 (1.06)	2.5	4.50	5.13	6.00	7.0	
			Placebo	60	54 (90.0)	4.78 (1.18)	1.8	4.00	4.75	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	61	52 (85.2)	0.72 (1.33)	-4.0	0.00	0.75	1.25	4.0	0.04 [-0.35, 0.42]
			Placebo	60	51 (85.0)	0.68 (0.89)	-1.3	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	61	53 (86.9)	0.87 (1.18)	-1.5	0.25	0.75	1.75	4.3	-0.00 [-0.38, 0.38]
			Placebo	60	52 (86.7)	0.88 (0.96)	-1.0	0.25	0.75	1.50	3.0	
		Week 12	Tezepelumab	61	53 (86.9)	0.98 (1.22)	-2.3	0.25	1.00	1.75	4.8	0.12 [-0.27, 0.50]
			Placebo	60	52 (86.7)	0.85 (1.03)	-1.3	0.13	1.00	1.25	3.3	
		Week 16	Tezepelumab	61	53 (86.9)	0.97 (1.29)	-2.8	0.25	1.00	1.75	3.5	0.14 [-0.25, 0.52]
			Placebo	60	52 (86.7)	0.81 (1.00)	-1.8	0.25	0.75	1.38	3.0	
		Week 20	Tezepelumab	61	53 (86.9)	0.87 (1.14)	-1.3	0.00	0.75	1.75	3.3	0.12 [-0.26, 0.50]
			Placebo	60	52 (86.7)	0.74 (1.05)	-1.8	0.13	0.75	1.25	3.0	
		Week 24	Tezepelumab	61	53 (86.9)	1.08 (1.10)	-1.3	0.25	1.00	2.00	3.5	0.27 [-0.11, 0.66]
			Placebo	60	52 (86.7)	0.77 (1.12)	-1.8	0.00	0.75	1.50	3.3	
		Week 28	Tezepelumab	61	53 (86.9)	1.02 (1.19)	-1.5	0.25	1.00	2.00	3.5	0.28 [-0.11, 0.66]
			Placebo	60	52 (86.7)	0.70 (1.13)	-2.8	0.13	0.75	1.25	3.3	
		Week 32	Tezepelumab	61	53 (86.9)	1.07 (1.17)	-1.3	0.25	1.00	1.75	3.3	0.24 [-0.15, 0.62]
			Placebo	60	52 (86.7)	0.82 (0.97)	-1.8	0.25	0.88	1.50	3.0	
		Week 36	Tezepelumab	61	53 (86.9)	1.13 (1.22)	-1.8	0.50	1.25	2.00	3.5	0.21 [-0.17, 0.60]
			Placebo	60	52 (86.7)	0.88 (1.09)	-2.3	0.25	0.75	1.50	3.3	
		Week 40	Tezepelumab	61	53 (86.9)	1.16 (1.24)	-1.5	0.25	1.25	2.25	3.5	0.21 [-0.17, 0.60]
			Placebo	60	52 (86.7)	0.91 (1.06)	-1.5	0.25	0.75	1.38	4.3	
		Week 44	Tezepelumab	61	53 (86.9)	1.16 (1.26)	-1.5	0.25	1.25	2.25	3.8	0.20 [-0.18, 0.58]
			Placebo	60	52 (86.7)	0.92 (1.14)	-1.3	0.13	0.75	1.50	3.3	
		Week 48	Tezepelumab	61	53 (86.9)	1.16 (1.29)	-1.8	0.50	1.25	2.00	3.8	0.20 [-0.19, 0.58]
			Placebo	60	52 (86.7)	0.93 (1.07)	-1.3	0.25	0.75	1.25	4.0	
		Week 52	Tezepelumab	61	53 (86.9)	1.13 (1.28)	-1.8	0.50	1.25	2.00	3.8	0.29 [-0.10, 0.67]
			Placebo	60	52 (86.7)	0.79 (1.06)	-1.3	0.25	0.50	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	76	69 (90.8)	4.30 (1.27)	1.0	3.50	4.25	5.25	7.0	
			Placebo	78	68 (87.2)	4.13 (1.28)	1.5	3.25	4.13	5.00	7.0	
		Week 4	Tezepelumab	76	70 (92.1)	4.94 (1.29)	1.0	4.00	5.13	5.75	7.0	
			Placebo	78	70 (89.7)	4.48 (1.24)	1.3	3.75	4.50	5.50	7.0	
		Week 8	Tezepelumab	76	71 (93.4)	5.14 (1.40)	1.0	4.25	5.25	6.00	7.0	
			Placebo	78	72 (92.3)	4.56 (1.39)	1.0	3.75	4.50	5.50	7.0	
		Week 12	Tezepelumab	76	71 (93.4)	5.32 (1.38)	1.0	4.50	5.50	6.25	7.0	
			Placebo	78	73 (93.6)	4.66 (1.27)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	76	71 (93.4)	5.23 (1.34)	1.0	4.50	5.25	6.00	7.0	
			Placebo	78	73 (93.6)	4.68 (1.34)	1.3	4.00	4.50	5.75	7.0	
		Week 20	Tezepelumab	76	71 (93.4)	5.26 (1.44)	1.0	4.50	5.25	6.50	7.0	
			Placebo	78	73 (93.6)	4.79 (1.38)	1.5	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	76	71 (93.4)	5.29 (1.36)	1.0	4.50	5.25	6.50	7.0	
			Placebo	78	73 (93.6)	4.69 (1.39)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	76	72 (94.7)	5.26 (1.46)	1.0	4.50	5.50	6.38	7.0	
			Placebo	78	74 (94.9)	4.93 (1.35)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	76	72 (94.7)	5.35 (1.45)	1.0	4.50	5.63	6.50	7.0	
			Placebo	78	75 (96.2)	4.96 (1.41)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	76	72 (94.7)	5.30 (1.46)	1.0	4.50	5.50	6.50	7.0	
			Placebo	78	75 (96.2)	4.83 (1.50)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	76	72 (94.7)	5.37 (1.33)	1.3	4.50	5.50	6.50	7.0	
			Placebo	78	75 (96.2)	4.92 (1.48)	1.0	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	76	72 (94.7)	5.42 (1.35)	1.0	4.75	5.75	6.50	7.0	
			Placebo	78	75 (96.2)	4.85 (1.41)	1.3	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	76	72 (94.7)	5.38 (1.34)	1.0	4.50	5.50	6.50	7.0	
			Placebo	78	76 (97.4)	4.92 (1.37)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	76	72 (94.7)	5.33 (1.41)	1.0	4.50	5.50	6.50	7.0	
			Placebo	78	76 (97.4)	4.89 (1.44)	1.0	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	76	65 (85.5)	0.67 (1.00)	-1.3	0.00	0.50	1.25	3.0	0.30 [-0.04, 0.64]
			Placebo	78	68 (87.2)	0.37 (1.00)	-2.5	-0.25	0.25	1.00	2.5	
		Week 8	Tezepelumab	76	66 (86.8)	0.87 (1.13)	-1.0	0.00	0.63	1.75	3.5	0.36 [0.02, 0.70]
			Placebo	78	68 (87.2)	0.47 (1.09)	-1.8	-0.13	0.25	1.25	3.3	
		Week 12	Tezepelumab	76	66 (86.8)	1.05 (1.10)	-1.0	0.25	0.88	1.75	3.5	0.41 [0.07, 0.75]
			Placebo	78	68 (87.2)	0.60 (1.10)	-1.8	0.00	0.50	1.25	4.3	
		Week 16	Tezepelumab	76	66 (86.8)	0.96 (1.09)	-1.0	0.00	0.75	1.50	3.3	0.34 [0.00, 0.68]
			Placebo	78	68 (87.2)	0.59 (1.07)	-1.5	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	76	66 (86.8)	1.01 (1.21)	-1.8	0.00	0.88	1.75	3.5	0.26 [-0.08, 0.60]
			Placebo	78	68 (87.2)	0.72 (1.02)	-2.3	0.00	0.50	1.38	2.8	
		Week 24	Tezepelumab	76	66 (86.8)	1.03 (1.20)	-1.5	0.25	1.00	2.00	3.5	0.36 [0.02, 0.70]
			Placebo	78	68 (87.2)	0.61 (1.13)	-2.8	-0.25	0.50	1.50	3.8	
		Week 28	Tezepelumab	76	66 (86.8)	1.00 (1.15)	-1.3	0.25	0.75	1.75	3.5	0.16 [-0.18, 0.49]
			Placebo	78	68 (87.2)	0.82 (1.17)	-1.3	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	76	66 (86.8)	1.09 (1.20)	-1.3	0.25	1.00	1.75	3.5	0.16 [-0.18, 0.50]
			Placebo	78	68 (87.2)	0.90 (1.18)	-1.3	0.00	0.75	1.75	3.8	
		Week 36	Tezepelumab	76	66 (86.8)	1.06 (1.23)	-1.0	0.25	0.88	2.00	3.5	0.24 [-0.10, 0.58]
			Placebo	78	68 (87.2)	0.74 (1.33)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	76	66 (86.8)	1.11 (1.11)	-1.0	0.25	1.00	2.00	3.5	0.24 [-0.10, 0.58]
			Placebo	78	68 (87.2)	0.81 (1.33)	-2.5	0.00	0.50	1.88	4.3	
		Week 44	Tezepelumab	76	66 (86.8)	1.16 (1.14)	-1.5	0.25	1.00	2.00	3.8	0.36 [0.02, 0.70]
			Placebo	78	68 (87.2)	0.72 (1.26)	-1.5	-0.13	0.38	1.25	3.8	
		Week 48	Tezepelumab	76	66 (86.8)	1.14 (1.15)	-1.0	0.25	1.00	2.00	3.5	0.27 [-0.07, 0.61]
			Placebo	78	68 (87.2)	0.81 (1.34)	-2.8	0.00	0.63	1.63	3.8	
		Week 52	Tezepelumab	76	66 (86.8)	1.07 (1.18)	-1.3	0.25	0.88	2.00	3.5	0.24 [-0.10, 0.58]
			Placebo	78	68 (87.2)	0.77 (1.30)	-2.3	0.00	0.50	1.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	75	65 (86.7)	4.31 (0.99)	1.8	3.75	4.25	5.00	7.0	
			Placebo	72	61 (84.7)	3.88 (1.16)	1.5	3.25	4.00	4.75	6.0	
		Week 4	Tezepelumab	75	69 (92.0)	4.79 (1.13)	1.3	4.00	4.75	5.75	7.0	
			Placebo	72	64 (88.9)	4.44 (1.23)	1.3	3.75	4.50	5.25	7.0	
		Week 8	Tezepelumab	75	69 (92.0)	5.04 (1.01)	1.8	4.25	5.00	5.75	7.0	
			Placebo	72	64 (88.9)	4.60 (1.40)	1.5	3.75	4.75	5.63	7.0	
		Week 12	Tezepelumab	75	69 (92.0)	5.20 (1.07)	3.0	4.25	5.25	6.00	7.0	
			Placebo	72	65 (90.3)	4.58 (1.23)	1.8	4.00	4.50	5.25	7.0	
		Week 16	Tezepelumab	75	69 (92.0)	5.05 (1.06)	2.0	4.50	5.00	5.75	7.0	
			Placebo	72	65 (90.3)	4.68 (1.24)	1.5	4.00	4.50	5.50	7.0	
		Week 20	Tezepelumab	75	70 (93.3)	5.05 (1.12)	1.0	4.25	5.00	5.75	7.0	
			Placebo	72	65 (90.3)	4.62 (1.19)	1.5	4.00	4.75	5.25	7.0	
		Week 24	Tezepelumab	75	70 (93.3)	5.23 (1.15)	1.3	4.25	5.00	6.25	7.0	
			Placebo	72	65 (90.3)	4.66 (1.36)	1.0	4.00	4.50	5.50	7.0	
		Week 28	Tezepelumab	75	72 (96.0)	5.13 (1.14)	1.5	4.25	5.00	5.88	7.0	
			Placebo	72	66 (91.7)	4.70 (1.32)	1.3	4.00	4.88	5.75	7.0	
		Week 32	Tezepelumab	75	73 (97.3)	5.21 (1.14)	1.5	4.50	5.00	6.00	7.0	
			Placebo	72	67 (93.1)	4.68 (1.35)	1.3	4.00	4.50	6.00	7.0	
		Week 36	Tezepelumab	75	73 (97.3)	5.22 (1.12)	1.8	4.50	5.00	6.00	7.0	
			Placebo	72	67 (93.1)	4.67 (1.40)	1.0	4.00	4.50	5.50	7.0	
		Week 40	Tezepelumab	75	73 (97.3)	5.22 (1.09)	2.3	4.50	5.00	6.00	7.0	
			Placebo	72	67 (93.1)	4.75 (1.34)	1.0	4.00	4.75	5.75	7.0	
		Week 44	Tezepelumab	75	73 (97.3)	5.26 (1.17)	1.3	4.50	5.25	6.25	7.0	
			Placebo	72	67 (93.1)	4.78 (1.34)	1.3	4.00	4.75	5.75	7.0	
		Week 48	Tezepelumab	75	73 (97.3)	5.22 (1.11)	2.3	4.25	5.00	6.00	7.0	
			Placebo	72	68 (94.4)	4.81 (1.32)	1.0	4.00	4.75	6.00	7.0	
		Week 52	Tezepelumab	75	73 (97.3)	5.20 (1.08)	2.3	4.50	5.00	6.00	7.0	
			Placebo	72	68 (94.4)	4.71 (1.37)	1.0	4.00	4.75	5.88	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	75	64 (85.3)	0.48 (1.16)	-4.0	0.00	0.50	1.13	4.0	-0.10 [-0.45, 0.25]
			Placebo	72	61 (84.7)	0.59 (1.03)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	75	64 (85.3)	0.72 (1.11)	-1.5	0.00	0.63	1.50	4.3	-0.03 [-0.38, 0.32]
			Placebo	72	61 (84.7)	0.76 (1.09)	-1.5	0.00	0.75	1.50	3.0	
		Week 12	Tezepelumab	75	64 (85.3)	0.89 (1.10)	-2.3	0.25	0.88	1.50	4.8	0.12 [-0.23, 0.47]
			Placebo	72	61 (84.7)	0.76 (1.16)	-1.3	0.00	0.50	1.25	4.3	
		Week 16	Tezepelumab	75	64 (85.3)	0.76 (1.13)	-2.8	0.00	0.75	1.50	3.0	-0.08 [-0.43, 0.28]
			Placebo	72	61 (84.7)	0.84 (1.06)	-1.5	0.25	0.75	1.25	3.0	
		Week 20	Tezepelumab	75	64 (85.3)	0.76 (1.13)	-1.8	0.00	0.75	1.50	3.3	-0.03 [-0.38, 0.32]
			Placebo	72	61 (84.7)	0.79 (0.99)	-1.3	0.25	0.75	1.25	3.0	
		Week 24	Tezepelumab	75	64 (85.3)	0.96 (1.07)	-1.5	0.25	1.00	1.75	3.3	0.14 [-0.22, 0.49]
			Placebo	72	61 (84.7)	0.81 (1.07)	-1.5	0.00	0.75	1.50	3.3	
		Week 28	Tezepelumab	75	64 (85.3)	0.86 (1.09)	-1.5	0.25	0.75	1.63	3.3	0.03 [-0.32, 0.38]
			Placebo	72	61 (84.7)	0.83 (1.15)	-2.8	0.25	0.75	1.25	4.0	
		Week 32	Tezepelumab	75	64 (85.3)	0.92 (1.13)	-1.3	0.00	1.00	1.75	3.3	0.07 [-0.28, 0.42]
			Placebo	72	61 (84.7)	0.84 (1.03)	-1.5	0.25	0.75	1.50	3.5	
		Week 36	Tezepelumab	75	64 (85.3)	0.94 (1.14)	-1.8	0.25	0.75	1.88	3.3	0.10 [-0.25, 0.45]
			Placebo	72	61 (84.7)	0.82 (1.24)	-2.3	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	75	64 (85.3)	0.95 (1.09)	-1.5	0.25	1.00	1.75	3.3	0.05 [-0.30, 0.40]
			Placebo	72	61 (84.7)	0.89 (1.23)	-1.8	0.25	0.75	1.25	4.3	
		Week 44	Tezepelumab	75	64 (85.3)	0.98 (1.14)	-1.5	0.13	1.00	1.88	3.3	0.08 [-0.27, 0.43]
			Placebo	72	61 (84.7)	0.88 (1.20)	-1.3	0.00	0.75	1.50	3.5	
		Week 48	Tezepelumab	75	64 (85.3)	0.95 (1.11)	-1.8	0.25	1.00	1.75	3.3	0.02 [-0.33, 0.37]
			Placebo	72	61 (84.7)	0.92 (1.21)	-1.5	0.25	0.75	1.50	4.0	
		Week 52	Tezepelumab	75	64 (85.3)	0.89 (1.12)	-1.8	0.13	1.00	1.75	3.3	0.07 [-0.28, 0.42]
			Placebo	72	61 (84.7)	0.81 (1.23)	-2.3	0.00	0.75	1.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	60	56 (93.3)	4.15 (1.30)	1.0	3.50	4.00	5.25	6.8	
			Placebo	65	59 (90.8)	4.32 (1.23)	1.5	3.50	4.25	5.50	7.0	
		Week 4	Tezepelumab	60	55 (91.7)	5.07 (1.29)	1.0	4.50	5.25	5.75	7.0	
			Placebo	65	59 (90.8)	4.76 (1.17)	2.0	4.00	5.00	5.50	7.0	
		Week 8	Tezepelumab	60	57 (95.0)	5.17 (1.43)	1.0	4.50	5.25	6.25	7.0	
			Placebo	65	61 (93.8)	4.84 (1.20)	1.0	4.00	5.00	5.75	7.0	
		Week 12	Tezepelumab	60	57 (95.0)	5.29 (1.40)	1.0	4.50	5.50	6.25	7.0	
			Placebo	65	61 (93.8)	4.95 (1.13)	1.3	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	60	57 (95.0)	5.33 (1.36)	1.0	4.50	5.50	6.25	7.0	
			Placebo	65	61 (93.8)	4.88 (1.25)	1.3	4.00	5.00	5.75	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.27 (1.40)	1.0	4.50	5.50	6.25	7.0	
			Placebo	65	61 (93.8)	5.00 (1.29)	1.8	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.28 (1.31)	1.0	4.50	5.25	6.25	7.0	
			Placebo	65	61 (93.8)	4.85 (1.28)	1.5	4.00	5.00	5.75	7.0	
		Week 28	Tezepelumab	60	57 (95.0)	5.32 (1.42)	1.0	4.75	5.50	6.25	7.0	
			Placebo	65	61 (93.8)	5.02 (1.37)	2.3	4.00	5.00	6.25	7.0	
		Week 32	Tezepelumab	60	57 (95.0)	5.39 (1.41)	1.0	4.75	5.50	6.25	7.0	
			Placebo	65	61 (93.8)	5.19 (1.22)	2.8	4.25	5.25	6.25	7.0	
		Week 36	Tezepelumab	60	57 (95.0)	5.39 (1.44)	1.0	4.75	5.50	6.50	7.0	
			Placebo	65	61 (93.8)	5.07 (1.33)	1.8	4.25	5.00	6.25	7.0	
		Week 40	Tezepelumab	60	57 (95.0)	5.47 (1.35)	1.3	4.75	5.75	6.50	7.0	
			Placebo	65	61 (93.8)	5.10 (1.35)	1.8	4.25	5.25	6.00	7.0	
		Week 44	Tezepelumab	60	57 (95.0)	5.51 (1.31)	1.0	4.75	6.00	6.50	7.0	
			Placebo	65	61 (93.8)	5.00 (1.33)	1.8	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	60	57 (95.0)	5.50 (1.35)	1.0	4.75	5.75	6.50	7.0	
			Placebo	65	61 (93.8)	5.06 (1.27)	1.8	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	60	57 (95.0)	5.46 (1.47)	1.0	4.50	5.75	6.50	7.0	
			Placebo	65	61 (93.8)	5.01 (1.29)	1.5	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	60	51 (85.0)	0.98 (1.10)	-1.3	0.25	0.75	1.75	3.3	0.57 [0.18, 0.95]
			Placebo	65	58 (89.2)	0.41 (0.89)	-2.0	0.00	0.25	1.00	2.5	
		Week 8	Tezepelumab	60	53 (88.3)	1.04 (1.18)	-1.0	0.00	1.00	2.00	3.5	0.45 [0.08, 0.83]
			Placebo	65	58 (89.2)	0.55 (1.01)	-1.8	0.00	0.50	1.00	3.3	
		Week 12	Tezepelumab	60	53 (88.3)	1.15 (1.23)	-1.0	0.25	1.00	2.25	3.5	0.47 [0.09, 0.84]
			Placebo	65	58 (89.2)	0.64 (0.98)	-1.8	0.00	0.75	1.25	2.5	
		Week 16	Tezepelumab	60	53 (88.3)	1.19 (1.21)	-1.0	0.25	1.00	2.00	3.5	0.58 [0.20, 0.96]
			Placebo	65	58 (89.2)	0.56 (0.96)	-1.5	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	60	53 (88.3)	1.15 (1.21)	-0.8	0.25	1.00	2.00	3.5	0.39 [0.02, 0.77]
			Placebo	65	58 (89.2)	0.70 (1.04)	-2.3	0.00	0.63	1.50	2.8	
		Week 24	Tezepelumab	60	53 (88.3)	1.14 (1.26)	-0.8	0.25	1.00	2.25	3.5	0.46 [0.09, 0.84]
			Placebo	65	58 (89.2)	0.59 (1.14)	-2.8	-0.25	0.50	1.50	3.8	
		Week 28	Tezepelumab	60	53 (88.3)	1.19 (1.23)	-0.8	0.25	1.00	2.25	3.5	0.37 [-0.00, 0.75]
			Placebo	65	58 (89.2)	0.75 (1.11)	-1.5	0.00	0.75	1.50	3.8	
		Week 32	Tezepelumab	60	53 (88.3)	1.26 (1.23)	-0.8	0.25	1.25	2.25	3.5	0.28 [-0.10, 0.65]
			Placebo	65	58 (89.2)	0.94 (1.12)	-1.3	0.00	0.88	1.75	3.8	
		Week 36	Tezepelumab	60	53 (88.3)	1.25 (1.32)	-1.0	0.25	1.00	2.25	3.5	0.36 [-0.01, 0.74]
			Placebo	65	58 (89.2)	0.79 (1.23)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	60	53 (88.3)	1.34 (1.22)	-1.0	0.25	1.25	2.50	3.5	0.42 [0.04, 0.80]
			Placebo	65	58 (89.2)	0.83 (1.22)	-2.5	0.00	0.63	1.75	3.8	
		Week 44	Tezepelumab	60	53 (88.3)	1.38 (1.22)	-1.0	0.50	1.25	2.25	3.8	0.52 [0.15, 0.90]
			Placebo	65	58 (89.2)	0.73 (1.24)	-1.5	0.00	0.50	1.50	3.8	
		Week 48	Tezepelumab	60	53 (88.3)	1.38 (1.30)	-1.0	0.50	1.25	2.25	3.8	0.46 [0.08, 0.83]
			Placebo	65	58 (89.2)	0.80 (1.26)	-2.8	0.00	0.50	1.50	3.8	
		Week 52	Tezepelumab	60	53 (88.3)	1.33 (1.31)	-1.3	0.50	1.00	2.25	3.8	0.47 [0.09, 0.84]
			Placebo	65	58 (89.2)	0.75 (1.19)	-1.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	65	56 (86.2)	4.29 (1.02)	1.8	3.75	4.25	5.00	7.0	
			Placebo	62	53 (85.5)	3.83 (1.21)	1.5	2.75	4.00	4.75	6.0	
		Week 4	Tezepelumab	65	60 (92.3)	4.83 (1.11)	1.3	4.00	4.75	5.75	7.0	
			Placebo	62	56 (90.3)	4.37 (1.22)	1.3	3.75	4.50	5.25	7.0	
		Week 8	Tezepelumab	65	60 (92.3)	5.07 (1.04)	1.8	4.25	5.00	5.75	7.0	
			Placebo	62	56 (90.3)	4.46 (1.38)	1.5	3.50	4.63	5.38	7.0	
		Week 12	Tezepelumab	65	60 (92.3)	5.17 (1.06)	3.0	4.25	5.00	6.13	7.0	
			Placebo	62	57 (91.9)	4.43 (1.17)	1.8	4.00	4.50	5.25	7.0	
		Week 16	Tezepelumab	65	60 (92.3)	4.99 (1.09)	2.0	4.25	4.75	5.75	7.0	
			Placebo	62	57 (91.9)	4.54 (1.20)	1.5	4.00	4.50	5.25	7.0	
		Week 20	Tezepelumab	65	61 (93.8)	4.97 (1.12)	1.0	4.00	5.00	5.75	7.0	
			Placebo	62	57 (91.9)	4.54 (1.17)	1.5	4.00	4.50	5.25	7.0	
		Week 24	Tezepelumab	65	61 (93.8)	5.16 (1.17)	1.3	4.25	5.00	6.00	7.0	
			Placebo	62	57 (91.9)	4.53 (1.31)	1.0	4.00	4.50	5.25	7.0	
		Week 28	Tezepelumab	65	62 (95.4)	5.04 (1.11)	1.5	4.25	5.00	5.75	7.0	
			Placebo	62	58 (93.5)	4.52 (1.27)	1.3	4.00	4.50	5.50	7.0	
		Week 32	Tezepelumab	65	63 (96.9)	5.13 (1.11)	1.5	4.25	5.00	6.00	7.0	
			Placebo	62	58 (93.5)	4.58 (1.31)	1.3	4.00	4.50	5.50	7.0	
		Week 36	Tezepelumab	65	63 (96.9)	5.14 (1.13)	1.8	4.25	5.00	6.00	7.0	
			Placebo	62	58 (93.5)	4.60 (1.41)	1.0	4.00	4.50	5.50	7.0	
		Week 40	Tezepelumab	65	63 (96.9)	5.13 (1.08)	2.3	4.25	5.00	5.75	7.0	
			Placebo	62	58 (93.5)	4.68 (1.38)	1.0	4.00	4.75	5.75	7.0	
		Week 44	Tezepelumab	65	63 (96.9)	5.16 (1.19)	1.3	4.25	5.00	6.00	7.0	
			Placebo	62	58 (93.5)	4.70 (1.32)	1.3	4.00	4.75	5.75	7.0	
		Week 48	Tezepelumab	65	63 (96.9)	5.13 (1.10)	2.3	4.25	5.00	6.00	7.0	
			Placebo	62	59 (95.2)	4.75 (1.35)	1.0	4.00	4.75	6.00	7.0	
		Week 52	Tezepelumab	65	63 (96.9)	5.11 (1.07)	2.3	4.25	5.00	6.00	7.0	
			Placebo	62	59 (95.2)	4.64 (1.39)	1.0	4.00	4.75	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	65	55 (84.6)	0.53 (1.19)	-4.0	0.00	0.50	1.25	4.0	-0.04 [-0.42, 0.33]
			Placebo	62	53 (85.5)	0.58 (1.05)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	65	55 (84.6)	0.76 (1.15)	-1.5	0.00	0.75	1.75	4.3	0.08 [-0.29, 0.46]
			Placebo	62	53 (85.5)	0.67 (1.06)	-1.5	0.00	0.50	1.50	3.0	
		Week 12	Tezepelumab	65	55 (84.6)	0.88 (1.14)	-2.3	0.25	0.75	1.50	4.8	0.19 [-0.19, 0.57]
			Placebo	62	53 (85.5)	0.67 (1.13)	-1.3	0.00	0.50	1.25	4.3	
		Week 16	Tezepelumab	65	55 (84.6)	0.72 (1.20)	-2.8	0.00	0.75	1.50	3.0	-0.02 [-0.40, 0.35]
			Placebo	62	53 (85.5)	0.75 (1.09)	-1.5	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	65	55 (84.6)	0.69 (1.18)	-1.8	0.00	0.75	1.50	3.3	-0.06 [-0.44, 0.32]
			Placebo	62	53 (85.5)	0.75 (0.95)	-1.3	0.25	0.50	1.25	3.0	
		Week 24	Tezepelumab	65	55 (84.6)	0.91 (1.11)	-1.5	0.25	1.00	1.75	3.3	0.16 [-0.22, 0.54]
			Placebo	62	53 (85.5)	0.74 (1.04)	-1.5	0.00	0.50	1.25	3.3	
		Week 28	Tezepelumab	65	55 (84.6)	0.81 (1.11)	-1.5	0.00	0.75	1.50	3.3	0.12 [-0.26, 0.50]
			Placebo	62	53 (85.5)	0.68 (1.13)	-2.8	0.00	0.75	1.25	4.0	
		Week 32	Tezepelumab	65	55 (84.6)	0.88 (1.15)	-1.3	0.00	0.75	1.75	3.3	0.12 [-0.26, 0.49]
			Placebo	62	53 (85.5)	0.75 (1.03)	-1.5	0.25	0.50	1.25	3.5	
		Week 36	Tezepelumab	65	55 (84.6)	0.90 (1.17)	-1.8	0.25	0.75	1.75	3.3	0.08 [-0.30, 0.46]
			Placebo	62	53 (85.5)	0.80 (1.23)	-2.3	0.25	0.75	1.50	3.8	
		Week 40	Tezepelumab	65	55 (84.6)	0.89 (1.13)	-1.5	0.25	0.75	2.00	3.3	0.03 [-0.35, 0.40]
			Placebo	62	53 (85.5)	0.86 (1.27)	-1.8	0.25	0.75	1.25	4.3	
		Week 44	Tezepelumab	65	55 (84.6)	0.90 (1.19)	-1.5	0.00	1.00	2.00	3.3	0.03 [-0.35, 0.40]
			Placebo	62	53 (85.5)	0.87 (1.14)	-1.3	0.00	0.75	1.50	3.5	
		Week 48	Tezepelumab	65	55 (84.6)	0.89 (1.14)	-1.8	0.00	0.75	1.75	3.3	-0.02 [-0.40, 0.35]
			Placebo	62	53 (85.5)	0.92 (1.23)	-1.5	0.25	0.75	1.25	4.0	
		Week 52	Tezepelumab	65	55 (84.6)	0.85 (1.16)	-1.8	0.00	1.00	1.50	3.3	0.06 [-0.32, 0.43]
			Placebo	62	53 (85.5)	0.78 (1.24)	-2.3	0.00	0.75	1.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	70	65 (92.9)	4.19 (1.24)	1.0	3.50	4.25	5.25	6.8	
			Placebo	75	67 (89.3)	4.31 (1.17)	1.5	3.50	4.25	5.25	7.0	
		Week 4	Tezepelumab	70	64 (91.4)	5.00 (1.29)	1.0	4.25	5.25	5.75	7.0	
			Placebo	75	67 (89.3)	4.78 (1.17)	2.0	4.00	5.00	5.50	7.0	
		Week 8	Tezepelumab	70	66 (94.3)	5.13 (1.36)	1.0	4.50	5.25	6.00	7.0	
			Placebo	75	69 (92.0)	4.93 (1.22)	1.0	4.00	5.00	5.75	7.0	
		Week 12	Tezepelumab	70	66 (94.3)	5.30 (1.37)	1.0	4.50	5.50	6.25	7.0	
			Placebo	75	69 (92.0)	5.04 (1.14)	1.3	4.25	5.00	5.75	7.0	
		Week 16	Tezepelumab	70	66 (94.3)	5.34 (1.28)	1.0	4.50	5.50	6.25	7.0	
			Placebo	75	69 (92.0)	4.98 (1.25)	1.3	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	70	66 (94.3)	5.31 (1.36)	1.0	4.50	5.50	6.25	7.0	
			Placebo	75	69 (92.0)	5.03 (1.27)	1.8	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	70	66 (94.3)	5.33 (1.27)	1.0	4.50	5.25	6.25	7.0	
			Placebo	75	69 (92.0)	4.93 (1.32)	1.5	4.00	5.00	6.00	7.0	
		Week 28	Tezepelumab	70	67 (95.7)	5.38 (1.39)	1.0	4.75	5.50	6.25	7.0	
			Placebo	75	69 (92.0)	5.14 (1.35)	2.3	4.00	5.25	6.25	7.0	
		Week 32	Tezepelumab	70	67 (95.7)	5.44 (1.39)	1.0	4.75	5.75	6.50	7.0	
			Placebo	75	70 (93.3)	5.21 (1.25)	2.8	4.25	5.25	6.25	7.0	
		Week 36	Tezepelumab	70	67 (95.7)	5.44 (1.38)	1.0	4.75	5.50	6.50	7.0	
			Placebo	75	70 (93.3)	5.08 (1.32)	1.8	4.25	5.00	6.25	7.0	
		Week 40	Tezepelumab	70	67 (95.7)	5.52 (1.30)	1.3	4.75	5.75	6.50	7.0	
			Placebo	75	70 (93.3)	5.12 (1.31)	1.8	4.50	5.25	6.00	7.0	
		Week 44	Tezepelumab	70	67 (95.7)	5.57 (1.25)	1.0	4.75	6.00	6.50	7.0	
			Placebo	75	70 (93.3)	5.03 (1.35)	1.8	4.00	4.88	6.00	7.0	
		Week 48	Tezepelumab	70	67 (95.7)	5.55 (1.31)	1.0	4.75	5.75	6.50	7.0	
			Placebo	75	70 (93.3)	5.08 (1.25)	1.8	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	70	67 (95.7)	5.50 (1.41)	1.0	4.50	5.75	6.50	7.0	
			Placebo	75	70 (93.3)	5.03 (1.27)	1.5	4.25	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	70	60 (85.7)	0.86 (1.12)	-1.3	0.00	0.75	1.75	3.3	0.41 [0.05, 0.76]
			Placebo	75	66 (88.0)	0.45 (0.90)	-2.0	0.00	0.25	1.00	2.5	
		Week 8	Tezepelumab	70	62 (88.6)	0.96 (1.15)	-1.0	0.00	0.75	2.00	3.5	0.29 [-0.06, 0.64]
			Placebo	75	66 (88.0)	0.64 (1.05)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	70	62 (88.6)	1.13 (1.17)	-1.0	0.25	1.00	2.25	3.5	0.36 [0.01, 0.71]
			Placebo	75	66 (88.0)	0.73 (1.03)	-1.8	0.00	0.75	1.25	3.3	
		Week 16	Tezepelumab	70	62 (88.6)	1.16 (1.13)	-1.0	0.25	1.00	2.00	3.5	0.47 [0.11, 0.82]
			Placebo	75	66 (88.0)	0.67 (0.97)	-1.5	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	70	62 (88.6)	1.15 (1.14)	-0.8	0.25	1.00	2.00	3.5	0.37 [0.02, 0.72]
			Placebo	75	66 (88.0)	0.74 (1.07)	-2.3	0.00	0.75	1.50	3.0	
		Week 24	Tezepelumab	70	62 (88.6)	1.16 (1.19)	-0.8	0.25	1.00	2.25	3.5	0.41 [0.06, 0.76]
			Placebo	75	66 (88.0)	0.67 (1.17)	-2.8	-0.25	0.75	1.50	3.8	
		Week 28	Tezepelumab	70	62 (88.6)	1.18 (1.19)	-0.8	0.25	1.00	2.00	3.5	0.26 [-0.09, 0.61]
			Placebo	75	66 (88.0)	0.88 (1.13)	-1.5	0.00	0.75	1.50	3.8	
		Week 32	Tezepelumab	70	62 (88.6)	1.25 (1.19)	-0.8	0.25	1.25	2.00	3.5	0.22 [-0.13, 0.57]
			Placebo	75	66 (88.0)	1.00 (1.10)	-1.3	0.00	1.00	1.75	3.8	
		Week 36	Tezepelumab	70	62 (88.6)	1.25 (1.26)	-1.0	0.25	1.13	2.25	3.5	0.34 [-0.00, 0.69]
			Placebo	75	66 (88.0)	0.82 (1.24)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	70	62 (88.6)	1.33 (1.16)	-1.0	0.25	1.25	2.25	3.5	0.40 [0.05, 0.75]
			Placebo	75	66 (88.0)	0.86 (1.19)	-2.5	0.00	0.63	1.75	3.8	
		Week 44	Tezepelumab	70	62 (88.6)	1.39 (1.15)	-1.0	0.50	1.25	2.25	3.8	0.51 [0.16, 0.87]
			Placebo	75	66 (88.0)	0.76 (1.28)	-1.5	0.00	0.50	1.50	3.8	
		Week 48	Tezepelumab	70	62 (88.6)	1.38 (1.24)	-1.0	0.50	1.25	2.25	3.8	0.45 [0.10, 0.80]
			Placebo	75	66 (88.0)	0.82 (1.24)	-2.8	0.00	0.63	1.50	3.8	
		Week 52	Tezepelumab	70	62 (88.6)	1.31 (1.25)	-1.3	0.50	1.00	2.25	3.8	0.43 [0.08, 0.78]
			Placebo	75	66 (88.0)	0.78 (1.18)	-1.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	50	43 (86.0)	4.05 (1.02)	1.8	3.50	4.00	4.75	6.5	
			Placebo	50	40 (80.0)	3.88 (1.37)	1.5	2.88	4.00	4.75	6.5	
		Week 4	Tezepelumab	50	48 (96.0)	4.73 (1.04)	2.0	3.88	4.75	5.50	7.0	
			Placebo	50	41 (82.0)	4.51 (1.26)	2.0	3.75	4.75	5.25	7.0	
		Week 8	Tezepelumab	50	48 (96.0)	4.88 (1.17)	1.0	4.25	5.00	5.75	7.0	
			Placebo	50	44 (88.0)	4.45 (1.38)	1.5	3.63	4.50	5.63	7.0	
		Week 12	Tezepelumab	50	48 (96.0)	5.08 (1.19)	1.0	4.38	5.00	5.88	7.0	
			Placebo	50	44 (88.0)	4.52 (1.18)	1.8	4.00	4.50	5.50	7.0	
		Week 16	Tezepelumab	50	48 (96.0)	5.11 (1.23)	1.0	4.50	5.00	6.00	7.0	
			Placebo	50	44 (88.0)	4.43 (1.33)	1.3	4.00	4.25	5.38	7.0	
		Week 20	Tezepelumab	50	48 (96.0)	5.03 (1.36)	1.0	4.25	5.00	6.00	7.0	
			Placebo	50	44 (88.0)	4.41 (1.46)	1.3	3.50	4.25	5.25	7.0	
		Week 24	Tezepelumab	50	48 (96.0)	5.07 (1.34)	1.0	4.00	5.00	6.13	7.0	
			Placebo	50	44 (88.0)	4.21 (1.47)	1.0	3.63	4.00	5.25	7.0	
		Week 28	Tezepelumab	50	49 (98.0)	5.07 (1.25)	1.0	4.50	5.00	6.00	7.0	
			Placebo	50	44 (88.0)	4.36 (1.45)	1.3	3.50	4.00	5.50	7.0	
		Week 32	Tezepelumab	50	49 (98.0)	5.11 (1.32)	1.0	4.50	5.00	6.00	7.0	
			Placebo	50	45 (90.0)	4.32 (1.41)	1.3	3.75	4.00	5.25	7.0	
		Week 36	Tezepelumab	50	49 (98.0)	5.01 (1.31)	1.0	4.25	5.00	6.00	7.0	
			Placebo	50	45 (90.0)	4.38 (1.44)	1.0	4.00	4.25	5.25	7.0	
		Week 40	Tezepelumab	50	49 (98.0)	5.22 (1.20)	2.0	4.50	5.00	6.25	7.0	
			Placebo	50	45 (90.0)	4.47 (1.36)	1.0	3.75	4.50	5.50	7.0	
		Week 44	Tezepelumab	50	49 (98.0)	5.12 (1.29)	1.3	4.25	5.00	6.00	7.0	
			Placebo	50	45 (90.0)	4.42 (1.32)	1.3	3.75	4.00	5.25	7.0	
		Week 48	Tezepelumab	50	49 (98.0)	5.06 (1.34)	1.0	4.00	5.00	6.25	7.0	
			Placebo	50	46 (92.0)	4.45 (1.33)	1.0	4.00	4.25	5.25	7.0	
		Week 52	Tezepelumab	50	49 (98.0)	5.07 (1.33)	1.0	4.25	5.00	6.00	7.0	
			Placebo	50	46 (92.0)	4.41 (1.31)	1.0	4.00	4.25	5.25	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	50	42 (84.0)	0.72 (1.02)	-2.3	0.25	0.75	1.25	2.5	0.07 [-0.37, 0.50]
			Placebo	50	39 (78.0)	0.65 (0.92)	-1.3	0.00	0.75	1.25	3.0	
		Week 8	Tezepelumab	50	42 (84.0)	0.82 (1.14)	-1.5	0.00	0.75	1.75	2.8	0.16 [-0.27, 0.59]
			Placebo	50	40 (80.0)	0.65 (0.99)	-1.3	-0.13	0.63	1.25	3.0	
		Week 12	Tezepelumab	50	42 (84.0)	1.02 (1.09)	-2.0	0.50	1.00	1.50	3.0	0.32 [-0.12, 0.75]
			Placebo	50	40 (80.0)	0.68 (1.08)	-1.3	0.00	0.63	1.25	4.3	
		Week 16	Tezepelumab	50	42 (84.0)	1.08 (1.22)	-2.3	0.50	1.25	2.00	3.3	0.44 [0.00, 0.88]
			Placebo	50	40 (80.0)	0.57 (1.09)	-1.8	-0.25	0.50	1.25	3.0	
		Week 20	Tezepelumab	50	42 (84.0)	1.03 (1.18)	-1.8	0.00	1.25	1.75	3.5	0.39 [-0.04, 0.83]
			Placebo	50	40 (80.0)	0.58 (1.10)	-2.3	-0.13	0.50	1.25	3.0	
		Week 24	Tezepelumab	50	42 (84.0)	1.04 (1.17)	-1.5	0.25	1.13	2.00	3.3	0.59 [0.15, 1.03]
			Placebo	50	40 (80.0)	0.35 (1.17)	-2.8	-0.50	0.25	1.00	3.0	
		Week 28	Tezepelumab	50	42 (84.0)	1.09 (1.18)	-1.5	0.25	1.25	2.00	3.3	0.50 [0.06, 0.94]
			Placebo	50	40 (80.0)	0.49 (1.21)	-1.8	-0.13	0.38	1.25	4.0	
		Week 32	Tezepelumab	50	42 (84.0)	1.15 (1.20)	-1.3	0.25	1.25	2.00	3.5	0.57 [0.13, 1.01]
			Placebo	50	40 (80.0)	0.50 (1.10)	-1.8	-0.25	0.50	1.13	3.5	
		Week 36	Tezepelumab	50	42 (84.0)	1.05 (1.33)	-1.8	0.00	1.25	2.00	3.5	0.41 [-0.03, 0.85]
			Placebo	50	40 (80.0)	0.53 (1.23)	-2.8	-0.13	0.50	0.88	3.8	
		Week 40	Tezepelumab	50	42 (84.0)	1.27 (1.12)	-1.5	0.50	1.38	2.25	3.3	0.57 [0.13, 1.02]
			Placebo	50	40 (80.0)	0.60 (1.23)	-2.5	0.00	0.50	1.25	4.3	
		Week 44	Tezepelumab	50	42 (84.0)	1.13 (1.15)	-1.5	0.50	1.25	2.00	3.0	0.54 [0.10, 0.98]
			Placebo	50	40 (80.0)	0.52 (1.12)	-1.5	-0.25	0.25	1.00	3.5	
		Week 48	Tezepelumab	50	42 (84.0)	1.10 (1.23)	-1.8	0.50	1.25	2.00	3.5	0.44 [0.00, 0.88]
			Placebo	50	40 (80.0)	0.54 (1.27)	-2.8	-0.13	0.50	1.00	3.5	
		Week 52	Tezepelumab	50	42 (84.0)	1.10 (1.23)	-1.8	0.50	1.38	2.00	3.5	0.48 [0.04, 0.92]
			Placebo	50	40 (80.0)	0.53 (1.17)	-2.3	-0.25	0.38	1.00	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	77	72 (93.5)	4.38 (1.21)	1.0	3.75	4.38	5.25	7.0	
			Placebo	80	73 (91.3)	4.23 (1.10)	2.0	3.50	4.25	5.00	7.0	
		Week 4	Tezepelumab	77	69 (89.6)	5.00 (1.34)	1.0	4.25	5.25	5.75	7.0	
			Placebo	80	74 (92.5)	4.65 (1.20)	1.3	4.00	4.75	5.50	7.0	
		Week 8	Tezepelumab	77	71 (92.2)	5.21 (1.25)	1.0	4.25	5.25	6.25	7.0	
			Placebo	80	74 (92.5)	4.84 (1.24)	1.0	4.00	4.88	5.75	7.0	
		Week 12	Tezepelumab	77	71 (92.2)	5.32 (1.28)	1.0	4.50	5.50	6.25	7.0	
			Placebo	80	75 (93.8)	4.91 (1.15)	1.3	4.25	5.00	5.75	7.0	
		Week 16	Tezepelumab	77	71 (92.2)	5.21 (1.22)	1.0	4.50	5.25	6.00	7.0	
			Placebo	80	75 (93.8)	4.94 (1.22)	1.3	4.00	5.00	5.75	7.0	
		Week 20	Tezepelumab	77	71 (92.2)	5.25 (1.22)	1.0	4.50	5.25	6.25	7.0	
			Placebo	80	75 (93.8)	4.98 (1.11)	2.3	4.00	5.00	5.75	7.0	
		Week 24	Tezepelumab	77	71 (92.2)	5.38 (1.16)	1.0	4.50	5.25	6.25	7.0	
			Placebo	80	75 (93.8)	4.99 (1.17)	2.0	4.25	5.00	6.00	7.0	
		Week 28	Tezepelumab	77	72 (93.5)	5.31 (1.33)	1.0	4.38	5.38	6.25	7.0	
			Placebo	80	76 (95.0)	5.11 (1.28)	1.5	4.25	5.25	6.00	7.0	
		Week 32	Tezepelumab	77	73 (94.8)	5.43 (1.24)	1.0	4.75	5.50	6.25	7.0	
			Placebo	80	76 (95.0)	5.21 (1.24)	2.3	4.38	5.25	6.00	7.0	
		Week 36	Tezepelumab	77	73 (94.8)	5.48 (1.25)	1.0	4.50	5.75	6.50	7.0	
			Placebo	80	76 (95.0)	5.09 (1.26)	1.8	4.25	5.25	6.00	7.0	
		Week 40	Tezepelumab	77	73 (94.8)	5.46 (1.23)	1.3	4.50	5.75	6.50	7.0	
			Placebo	80	76 (95.0)	5.18 (1.29)	1.8	4.38	5.25	6.13	7.0	
		Week 44	Tezepelumab	77	73 (94.8)	5.54 (1.20)	1.0	4.75	5.50	6.50	7.0	
			Placebo	80	76 (95.0)	5.10 (1.26)	2.0	4.00	5.00	6.13	7.0	
		Week 48	Tezepelumab	77	73 (94.8)	5.54 (1.14)	2.0	4.75	5.75	6.50	7.0	
			Placebo	80	76 (95.0)	5.19 (1.18)	2.0	4.50	5.13	6.00	7.0	
		Week 52	Tezepelumab	77	73 (94.8)	5.48 (1.25)	1.0	4.50	5.75	6.50	7.0	
			Placebo	80	76 (95.0)	5.13 (1.27)	1.5	4.38	5.25	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	77	67 (87.0)	0.62 (1.15)	-4.0	0.00	0.50	1.50	3.3	0.19 [-0.14, 0.53]
			Placebo	80	72 (90.0)	0.41 (1.02)	-2.5	-0.13	0.25	1.25	2.5	
		Week 8	Tezepelumab	77	69 (89.6)	0.83 (1.06)	-1.3	0.00	0.75	1.75	3.5	0.20 [-0.13, 0.53]
			Placebo	80	72 (90.0)	0.61 (1.07)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	77	69 (89.6)	0.95 (1.10)	-2.3	0.25	0.75	1.75	3.5	0.23 [-0.11, 0.56]
			Placebo	80	72 (90.0)	0.70 (1.06)	-1.8	0.00	0.63	1.38	3.0	
		Week 16	Tezepelumab	77	69 (89.6)	0.84 (1.13)	-2.8	0.00	0.75	1.50	3.5	0.11 [-0.22, 0.44]
			Placebo	80	72 (90.0)	0.72 (1.05)	-1.5	0.00	0.50	1.38	3.0	
		Week 20	Tezepelumab	77	69 (89.6)	0.88 (1.12)	-1.3	0.00	0.75	1.75	3.3	0.10 [-0.23, 0.43]
			Placebo	80	72 (90.0)	0.77 (1.00)	-1.3	0.25	0.75	1.25	2.8	
		Week 24	Tezepelumab	77	69 (89.6)	1.00 (1.13)	-1.3	0.25	0.75	1.75	3.5	0.17 [-0.16, 0.51]
			Placebo	80	72 (90.0)	0.81 (1.06)	-1.5	0.00	0.75	1.50	3.8	
		Week 28	Tezepelumab	77	69 (89.6)	0.91 (1.12)	-1.5	0.25	0.75	1.75	3.5	0.01 [-0.32, 0.34]
			Placebo	80	72 (90.0)	0.91 (1.10)	-2.8	0.25	0.88	1.50	3.8	
		Week 32	Tezepelumab	77	69 (89.6)	1.02 (1.14)	-1.3	0.25	1.00	1.75	3.5	-0.01 [-0.34, 0.32]
			Placebo	80	72 (90.0)	1.03 (1.07)	-1.5	0.25	1.00	1.75	3.8	
		Week 36	Tezepelumab	77	69 (89.6)	1.07 (1.14)	-1.3	0.25	1.00	2.00	3.5	0.14 [-0.19, 0.47]
			Placebo	80	72 (90.0)	0.90 (1.24)	-2.3	0.00	0.50	1.63	3.8	
		Week 40	Tezepelumab	77	69 (89.6)	1.03 (1.17)	-1.3	0.25	1.00	1.75	3.5	0.04 [-0.29, 0.37]
			Placebo	80	72 (90.0)	0.99 (1.22)	-1.8	0.25	0.75	1.75	4.3	
		Week 44	Tezepelumab	77	69 (89.6)	1.13 (1.20)	-1.3	0.25	1.00	2.00	3.8	0.18 [-0.15, 0.51]
			Placebo	80	72 (90.0)	0.91 (1.22)	-1.5	0.00	0.75	1.63	3.8	
		Week 48	Tezepelumab	77	69 (89.6)	1.13 (1.20)	-1.3	0.25	1.00	2.00	3.8	0.11 [-0.22, 0.44]
			Placebo	80	72 (90.0)	1.00 (1.19)	-1.3	0.25	0.75	1.50	4.0	
		Week 52	Tezepelumab	77	69 (89.6)	1.04 (1.21)	-1.3	0.25	1.00	1.75	3.8	0.11 [-0.23, 0.44]
			Placebo	80	72 (90.0)	0.92 (1.21)	-1.3	0.13	0.75	1.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	4.04 (1.12)	1.0	3.50	4.00	4.75	6.5	
			Placebo	62	53 (85.5)	4.14 (1.19)	1.5	3.25	4.00	5.00	6.5	
		Week 4	Tezepelumab	70	65 (92.9)	4.79 (1.11)	1.5	4.00	5.00	5.75	7.0	
			Placebo	62	53 (85.5)	4.59 (1.17)	2.0	3.75	5.00	5.25	6.8	
		Week 8	Tezepelumab	70	66 (94.3)	4.96 (1.22)	1.0	4.50	5.00	5.75	7.0	
			Placebo	62	56 (90.3)	4.74 (1.30)	1.5	3.88	4.75	5.75	7.0	
		Week 12	Tezepelumab	70	66 (94.3)	5.17 (1.22)	1.0	4.50	5.25	6.25	7.0	
			Placebo	62	56 (90.3)	4.76 (1.10)	1.8	4.00	4.75	5.50	7.0	
		Week 16	Tezepelumab	70	66 (94.3)	5.08 (1.18)	1.0	4.50	5.00	6.00	7.0	
			Placebo	62	56 (90.3)	4.70 (1.20)	1.3	4.00	4.50	5.50	7.0	
		Week 20	Tezepelumab	70	67 (95.7)	4.99 (1.30)	1.0	4.25	5.00	6.00	7.0	
			Placebo	62	56 (90.3)	4.75 (1.29)	1.3	4.00	4.75	5.38	7.0	
		Week 24	Tezepelumab	70	67 (95.7)	5.23 (1.27)	1.0	4.25	5.00	6.25	7.0	
			Placebo	62	56 (90.3)	4.67 (1.45)	1.0	4.00	4.63	5.63	7.0	
		Week 28	Tezepelumab	70	68 (97.1)	5.07 (1.33)	1.0	4.25	5.00	6.00	7.0	
			Placebo	62	56 (90.3)	4.69 (1.32)	1.3	3.88	4.75	5.63	7.0	
		Week 32	Tezepelumab	70	68 (97.1)	5.13 (1.34)	1.0	4.25	5.00	6.00	7.0	
			Placebo	62	57 (91.9)	4.72 (1.40)	1.3	4.00	4.50	5.50	7.0	
		Week 36	Tezepelumab	70	68 (97.1)	5.14 (1.34)	1.0	4.25	5.00	6.13	7.0	
			Placebo	62	57 (91.9)	4.82 (1.40)	1.0	4.00	4.50	6.00	7.0	
		Week 40	Tezepelumab	70	68 (97.1)	5.19 (1.21)	2.0	4.25	5.00	6.00	7.0	
			Placebo	62	57 (91.9)	4.79 (1.33)	1.0	4.00	4.75	5.75	7.0	
		Week 44	Tezepelumab	70	68 (97.1)	5.21 (1.23)	1.3	4.50	5.00	6.25	7.0	
			Placebo	62	57 (91.9)	4.79 (1.33)	1.3	4.00	4.50	5.75	7.0	
		Week 48	Tezepelumab	70	68 (97.1)	5.24 (1.25)	1.0	4.25	5.00	6.25	7.0	
			Placebo	62	57 (91.9)	4.79 (1.28)	2.0	4.00	4.50	6.00	7.0	
		Week 52	Tezepelumab	70	68 (97.1)	5.17 (1.31)	1.0	4.25	5.00	6.25	7.0	
			Placebo	62	57 (91.9)	4.66 (1.30)	1.0	4.00	4.50	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	70	61 (87.1)	0.84 (1.10)	-2.3	0.25	0.75	1.25	4.0	0.38 [0.01, 0.75]
			Placebo	62	52 (83.9)	0.46 (0.86)	-1.3	0.00	0.50	1.13	2.5	
		Week 8	Tezepelumab	70	62 (88.6)	0.95 (1.22)	-1.5	0.00	1.00	1.75	4.3	0.25 [-0.11, 0.62]
			Placebo	62	53 (85.5)	0.67 (1.02)	-1.3	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	70	62 (88.6)	1.16 (1.18)	-2.0	0.25	1.00	2.00	4.8	0.46 [0.08, 0.83]
			Placebo	62	53 (85.5)	0.66 (0.97)	-1.3	0.00	0.75	1.25	3.3	
		Week 16	Tezepelumab	70	62 (88.6)	1.06 (1.19)	-2.3	0.25	0.88	2.00	3.5	0.43 [0.06, 0.80]
			Placebo	62	53 (85.5)	0.58 (1.00)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	70	62 (88.6)	0.99 (1.23)	-1.8	0.00	0.75	2.00	3.5	0.29 [-0.08, 0.66]
			Placebo	62	53 (85.5)	0.65 (1.12)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	70	62 (88.6)	1.23 (1.20)	-1.5	0.25	1.25	2.25	3.5	0.54 [0.17, 0.92]
			Placebo	62	53 (85.5)	0.57 (1.25)	-2.8	-0.25	0.50	1.25	3.8	
		Week 28	Tezepelumab	70	62 (88.6)	1.10 (1.22)	-1.5	0.25	1.13	2.00	3.5	0.44 [0.07, 0.81]
			Placebo	62	53 (85.5)	0.58 (1.19)	-2.8	0.00	0.75	1.25	3.8	
		Week 32	Tezepelumab	70	62 (88.6)	1.16 (1.23)	-1.3	0.25	1.25	2.25	3.5	0.41 [0.04, 0.78]
			Placebo	62	53 (85.5)	0.66 (1.19)	-1.8	0.00	0.50	1.25	3.8	
		Week 36	Tezepelumab	70	62 (88.6)	1.17 (1.32)	-1.8	0.25	1.25	2.25	3.5	0.34 [-0.03, 0.71]
			Placebo	62	53 (85.5)	0.72 (1.29)	-2.8	0.25	0.75	1.50	3.8	
		Week 40	Tezepelumab	70	62 (88.6)	1.24 (1.18)	-1.5	0.25	1.25	2.25	3.5	0.47 [0.10, 0.84]
			Placebo	62	53 (85.5)	0.68 (1.19)	-2.5	0.00	0.75	1.25	3.8	
		Week 44	Tezepelumab	70	62 (88.6)	1.25 (1.23)	-1.5	0.50	1.25	2.25	3.5	0.46 [0.09, 0.83]
			Placebo	62	53 (85.5)	0.68 (1.24)	-1.5	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	70	62 (88.6)	1.29 (1.29)	-1.8	0.25	1.38	2.25	3.8	0.48 [0.10, 0.85]
			Placebo	62	53 (85.5)	0.68 (1.25)	-2.8	0.00	0.75	1.25	3.8	
		Week 52	Tezepelumab	70	62 (88.6)	1.22 (1.32)	-1.8	0.25	1.25	2.00	3.8	0.52 [0.14, 0.89]
			Placebo	62	53 (85.5)	0.57 (1.20)	-2.3	0.00	0.50	1.00	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	65	58 (89.2)	4.42 (1.16)	1.0	3.75	4.38	5.25	7.0	
			Placebo	75	67 (89.3)	4.05 (1.24)	1.5	3.25	4.00	5.00	7.0	
		Week 4	Tezepelumab	65	59 (90.8)	5.04 (1.31)	1.0	4.25	5.25	6.00	7.0	
			Placebo	75	69 (92.0)	4.56 (1.22)	1.3	3.75	4.50	5.50	7.0	
		Week 8	Tezepelumab	65	60 (92.3)	5.25 (1.20)	1.0	4.25	5.25	6.13	7.0	
			Placebo	75	69 (92.0)	4.63 (1.31)	1.0	3.75	4.75	5.50	7.0	
		Week 12	Tezepelumab	65	60 (92.3)	5.33 (1.24)	1.0	4.50	5.38	6.25	7.0	
			Placebo	75	70 (93.3)	4.73 (1.25)	1.3	4.00	4.88	5.75	7.0	
		Week 16	Tezepelumab	65	60 (92.3)	5.30 (1.23)	1.0	4.50	5.25	6.13	7.0	
			Placebo	75	70 (93.3)	4.77 (1.33)	1.3	4.00	5.00	5.75	7.0	
		Week 20	Tezepelumab	65	60 (92.3)	5.35 (1.18)	1.0	4.50	5.25	6.25	7.0	
			Placebo	75	70 (93.3)	4.77 (1.27)	1.8	4.00	4.75	5.75	7.0	
		Week 24	Tezepelumab	65	60 (92.3)	5.30 (1.17)	1.0	4.50	5.25	6.13	7.0	
			Placebo	75	70 (93.3)	4.74 (1.26)	1.5	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	65	61 (93.8)	5.35 (1.19)	1.0	4.50	5.25	6.25	7.0	
			Placebo	75	71 (94.7)	4.91 (1.41)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	65	62 (95.4)	5.46 (1.16)	2.3	4.50	5.50	6.25	7.0	
			Placebo	75	71 (94.7)	5.00 (1.28)	2.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	65	62 (95.4)	5.48 (1.17)	1.0	4.50	5.63	6.25	7.0	
			Placebo	75	71 (94.7)	4.84 (1.37)	1.5	4.00	5.00	5.75	7.0	
		Week 40	Tezepelumab	65	62 (95.4)	5.47 (1.20)	1.3	4.50	5.75	6.25	7.0	
			Placebo	75	71 (94.7)	4.97 (1.36)	1.5	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	65	62 (95.4)	5.51 (1.22)	1.0	4.75	5.75	6.50	7.0	
			Placebo	75	71 (94.7)	4.90 (1.34)	1.8	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	65	62 (95.4)	5.44 (1.19)	2.0	4.50	5.63	6.25	7.0	
			Placebo	75	72 (96.0)	4.99 (1.30)	1.0	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	65	62 (95.4)	5.44 (1.20)	2.0	4.50	5.50	6.50	7.0	
			Placebo	75	72 (96.0)	4.95 (1.34)	1.5	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	65	55 (84.6)	0.55 (1.20)	-4.0	0.00	0.50	1.25	2.8	0.05 [-0.31, 0.40]
			Placebo	75	66 (88.0)	0.50 (1.01)	-2.5	0.00	0.38	1.25	2.5	
		Week 8	Tezepelumab	65	56 (86.2)	0.81 (1.05)	-1.3	0.00	0.63	1.75	3.5	0.20 [-0.15, 0.56]
			Placebo	75	66 (88.0)	0.60 (1.05)	-1.8	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	65	56 (86.2)	0.90 (1.09)	-2.3	0.25	0.75	1.50	3.5	0.17 [-0.19, 0.52]
			Placebo	75	66 (88.0)	0.71 (1.13)	-1.8	0.00	0.63	1.50	4.3	
		Week 16	Tezepelumab	65	56 (86.2)	0.88 (1.17)	-2.8	0.00	0.88	1.50	3.3	0.13 [-0.22, 0.49]
			Placebo	75	66 (88.0)	0.73 (1.05)	-1.5	0.00	0.50	1.50	3.0	
		Week 20	Tezepelumab	65	56 (86.2)	0.93 (1.11)	-1.3	0.13	0.75	1.75	3.5	0.18 [-0.18, 0.53]
			Placebo	75	66 (88.0)	0.75 (0.93)	-1.3	0.00	0.63	1.25	2.8	
		Week 24	Tezepelumab	65	56 (86.2)	0.88 (1.07)	-1.3	0.13	0.75	1.50	3.5	0.14 [-0.22, 0.50]
			Placebo	75	66 (88.0)	0.73 (0.98)	-1.0	0.00	0.75	1.50	3.3	
		Week 28	Tezepelumab	65	56 (86.2)	0.92 (1.10)	-1.5	0.25	0.75	1.38	3.5	0.03 [-0.33, 0.38]
			Placebo	75	66 (88.0)	0.89 (1.09)	-1.3	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	65	56 (86.2)	1.01 (1.14)	-1.3	0.13	1.00	1.75	3.5	0.01 [-0.35, 0.36]
			Placebo	75	66 (88.0)	1.00 (0.97)	-1.0	0.25	1.00	1.75	3.5	
		Week 36	Tezepelumab	65	56 (86.2)	1.03 (1.11)	-1.3	0.25	0.88	1.88	3.5	0.17 [-0.19, 0.52]
			Placebo	75	66 (88.0)	0.84 (1.17)	-2.0	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	65	56 (86.2)	1.01 (1.16)	-1.3	0.25	1.00	1.88	3.5	0.04 [-0.31, 0.40]
			Placebo	75	66 (88.0)	0.96 (1.21)	-1.8	0.00	0.63	2.00	4.3	
		Week 44	Tezepelumab	65	56 (86.2)	1.05 (1.16)	-1.3	0.13	0.88	1.75	3.8	0.15 [-0.21, 0.51]
			Placebo	75	66 (88.0)	0.88 (1.16)	-1.5	0.00	0.63	1.75	3.8	
		Week 48	Tezepelumab	65	56 (86.2)	1.00 (1.11)	-1.3	0.25	0.88	1.75	3.5	0.02 [-0.33, 0.38]
			Placebo	75	66 (88.0)	0.97 (1.18)	-1.5	0.25	0.75	1.50	4.0	
		Week 52	Tezepelumab	65	56 (86.2)	0.96 (1.11)	-1.3	0.25	0.75	1.63	3.5	0.03 [-0.32, 0.39]
			Placebo	75	66 (88.0)	0.92 (1.16)	-1.3	0.25	0.75	1.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	62	57 (91.9)	4.14 (0.96)	1.0	3.75	4.00	4.75	6.5	
			Placebo	67	57 (85.1)	4.15 (1.11)	1.5	3.50	4.25	4.75	7.0	
		Week 4	Tezepelumab	62	56 (90.3)	4.58 (1.18)	1.0	3.88	4.63	5.50	7.0	
			Placebo	67	58 (86.6)	4.68 (1.20)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	62	56 (90.3)	4.88 (1.11)	1.0	4.13	5.00	5.75	7.0	
			Placebo	67	60 (89.6)	4.69 (1.22)	1.8	3.75	4.75	5.63	7.0	
		Week 12	Tezepelumab	62	56 (90.3)	5.02 (1.17)	1.0	4.38	5.00	5.75	7.0	
			Placebo	67	61 (91.0)	4.80 (1.17)	1.8	4.00	4.50	5.75	7.0	
		Week 16	Tezepelumab	62	56 (90.3)	4.81 (1.15)	1.0	4.25	4.75	5.50	7.0	
			Placebo	67	61 (91.0)	4.79 (1.26)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	62	57 (91.9)	4.87 (1.19)	1.0	4.25	5.00	5.75	7.0	
			Placebo	67	61 (91.0)	4.69 (1.16)	1.3	4.00	4.75	5.25	7.0	
		Week 24	Tezepelumab	62	57 (91.9)	4.97 (1.23)	1.0	4.00	5.00	5.75	7.0	
			Placebo	67	61 (91.0)	4.74 (1.33)	1.3	4.00	4.50	5.50	7.0	
		Week 28	Tezepelumab	62	59 (95.2)	4.89 (1.17)	1.0	4.25	4.75	5.50	7.0	
			Placebo	67	62 (92.5)	4.85 (1.33)	1.3	4.00	4.75	6.00	7.0	
		Week 32	Tezepelumab	62	59 (95.2)	5.07 (1.15)	1.5	4.25	5.00	6.00	7.0	
			Placebo	67	63 (94.0)	4.92 (1.34)	1.3	4.00	4.75	6.00	7.0	
		Week 36	Tezepelumab	62	59 (95.2)	5.05 (1.20)	1.0	4.50	5.00	6.00	7.0	
			Placebo	67	63 (94.0)	4.85 (1.27)	2.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	62	59 (95.2)	5.05 (1.15)	1.3	4.25	5.00	6.00	7.0	
			Placebo	67	63 (94.0)	4.99 (1.23)	2.3	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	62	59 (95.2)	5.10 (1.26)	1.0	4.50	5.00	6.25	7.0	
			Placebo	67	63 (94.0)	5.01 (1.26)	2.0	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	62	59 (95.2)	5.09 (1.09)	2.0	4.50	5.00	6.00	7.0	
			Placebo	67	64 (95.5)	5.02 (1.26)	2.0	4.13	5.00	6.00	7.0	
		Week 52	Tezepelumab	62	59 (95.2)	5.08 (1.10)	2.0	4.50	5.00	6.00	7.0	
			Placebo	67	64 (95.5)	4.99 (1.25)	2.0	4.00	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	62	55 (88.7)	0.49 (1.10)	-4.0	0.00	0.50	1.25	2.8	-0.05 [-0.43, 0.32]
			Placebo	67	56 (83.6)	0.55 (1.01)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	62	55 (88.7)	0.80 (1.10)	-1.5	0.00	0.75	1.75	3.5	0.17 [-0.20, 0.54]
			Placebo	67	57 (85.1)	0.61 (1.13)	-1.8	-0.25	0.50	1.25	3.3	
		Week 12	Tezepelumab	62	55 (88.7)	0.94 (1.05)	-2.3	0.25	1.00	1.75	3.5	0.17 [-0.20, 0.54]
			Placebo	67	57 (85.1)	0.75 (1.23)	-1.8	0.00	0.75	1.25	4.3	
		Week 16	Tezepelumab	62	55 (88.7)	0.73 (1.15)	-2.8	0.00	0.75	1.50	3.3	0.02 [-0.35, 0.39]
			Placebo	67	57 (85.1)	0.70 (1.16)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	62	55 (88.7)	0.78 (1.08)	-1.8	0.25	0.75	1.50	3.5	0.17 [-0.20, 0.54]
			Placebo	67	57 (85.1)	0.60 (1.07)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	62	55 (88.7)	0.88 (1.06)	-1.5	0.25	0.75	1.50	3.5	0.20 [-0.17, 0.57]
			Placebo	67	57 (85.1)	0.65 (1.21)	-2.8	0.00	0.50	1.50	3.8	
		Week 28	Tezepelumab	62	55 (88.7)	0.79 (1.02)	-1.5	0.25	0.75	1.50	3.5	0.07 [-0.30, 0.44]
			Placebo	67	57 (85.1)	0.71 (1.28)	-2.8	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	62	55 (88.7)	0.96 (1.10)	-1.3	0.25	1.00	1.75	3.5	0.11 [-0.26, 0.48]
			Placebo	67	57 (85.1)	0.83 (1.18)	-1.8	0.00	0.75	1.75	3.8	
		Week 36	Tezepelumab	62	55 (88.7)	0.94 (1.11)	-1.3	0.25	0.75	1.75	3.5	0.17 [-0.20, 0.54]
			Placebo	67	57 (85.1)	0.73 (1.31)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	62	55 (88.7)	0.98 (1.12)	-1.3	0.25	0.75	1.75	3.5	0.09 [-0.28, 0.46]
			Placebo	67	57 (85.1)	0.87 (1.29)	-2.5	0.25	0.75	1.75	4.3	
		Week 44	Tezepelumab	62	55 (88.7)	1.02 (1.17)	-1.5	0.25	1.00	2.00	3.5	0.12 [-0.25, 0.49]
			Placebo	67	57 (85.1)	0.87 (1.33)	-1.5	0.00	0.75	1.50	3.8	
		Week 48	Tezepelumab	62	55 (88.7)	1.01 (1.09)	-1.3	0.50	1.00	1.75	3.8	0.10 [-0.27, 0.48]
			Placebo	67	57 (85.1)	0.89 (1.32)	-2.8	0.00	0.75	1.50	3.8	
		Week 52	Tezepelumab	62	55 (88.7)	0.99 (1.12)	-1.5	0.50	1.00	1.50	3.8	0.10 [-0.27, 0.47]
			Placebo	67	57 (85.1)	0.87 (1.27)	-1.3	0.00	0.75	1.50	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	74	65 (87.8)	4.30 (1.30)	1.0	3.50	4.25	5.25	7.0	
			Placebo	71	64 (90.1)	4.03 (1.29)	1.5	3.25	4.00	5.00	6.5	
		Week 4	Tezepelumab	74	69 (93.2)	5.17 (1.17)	1.5	4.50	5.25	6.00	7.0	
			Placebo	71	65 (91.5)	4.52 (1.21)	2.0	3.75	4.75	5.50	6.8	
		Week 8	Tezepelumab	74	71 (95.9)	5.27 (1.26)	1.0	4.50	5.50	6.00	7.0	
			Placebo	71	66 (93.0)	4.71 (1.40)	1.0	4.00	4.75	5.75	7.0	
		Week 12	Tezepelumab	74	71 (95.9)	5.42 (1.25)	1.0	4.75	5.50	6.50	7.0	
			Placebo	71	66 (93.0)	4.72 (1.21)	1.3	4.00	4.75	5.50	7.0	
		Week 16	Tezepelumab	74	71 (95.9)	5.48 (1.17)	1.0	4.75	5.50	6.25	7.0	
			Placebo	71	66 (93.0)	4.72 (1.30)	1.3	4.00	4.88	5.50	7.0	
		Week 20	Tezepelumab	74	71 (95.9)	5.38 (1.26)	1.3	4.50	5.50	6.50	7.0	
			Placebo	71	66 (93.0)	4.86 (1.39)	1.5	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	74	71 (95.9)	5.48 (1.16)	1.0	4.75	5.50	6.50	7.0	
			Placebo	71	66 (93.0)	4.70 (1.39)	1.0	4.00	4.88	5.75	7.0	
		Week 28	Tezepelumab	74	71 (95.9)	5.47 (1.30)	1.0	4.75	5.75	6.50	7.0	
			Placebo	71	66 (93.0)	4.81 (1.43)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	74	72 (97.3)	5.48 (1.32)	1.0	4.75	5.75	6.50	7.0	
			Placebo	71	66 (93.0)	4.87 (1.37)	1.3	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	74	72 (97.3)	5.50 (1.29)	1.0	4.50	5.63	6.75	7.0	
			Placebo	71	66 (93.0)	4.84 (1.49)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	74	72 (97.3)	5.57 (1.21)	2.0	4.63	5.75	6.63	7.0	
			Placebo	71	66 (93.0)	4.83 (1.47)	1.0	4.00	5.00	5.75	7.0	
		Week 44	Tezepelumab	74	72 (97.3)	5.59 (1.17)	2.0	4.75	5.75	6.63	7.0	
			Placebo	71	66 (93.0)	4.74 (1.40)	1.3	4.00	4.75	5.75	7.0	
		Week 48	Tezepelumab	74	72 (97.3)	5.56 (1.29)	1.0	4.50	5.88	6.63	7.0	
			Placebo	71	66 (93.0)	4.82 (1.34)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	74	72 (97.3)	5.50 (1.36)	1.0	4.50	5.75	6.50	7.0	
			Placebo	71	66 (93.0)	4.70 (1.40)	1.0	4.00	4.88	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	74	61 (82.4)	0.89 (1.17)	-2.3	0.25	0.75	1.75	4.0	0.41 [0.05, 0.76]
			Placebo	71	63 (88.7)	0.46 (0.93)	-2.0	-0.25	0.50	1.00	2.5	
		Week 8	Tezepelumab	74	63 (85.1)	0.94 (1.20)	-1.5	0.00	0.75	1.75	4.3	0.24 [-0.11, 0.59]
			Placebo	71	63 (88.7)	0.68 (0.97)	-1.5	0.00	0.75	1.25	3.0	
		Week 12	Tezepelumab	74	63 (85.1)	1.10 (1.25)	-2.0	0.25	1.00	2.25	4.8	0.39 [0.04, 0.74]
			Placebo	71	63 (88.7)	0.67 (0.91)	-1.0	0.00	0.50	1.25	2.5	
		Week 16	Tezepelumab	74	63 (85.1)	1.19 (1.18)	-1.5	0.25	1.00	2.25	3.5	0.49 [0.13, 0.84]
			Placebo	71	63 (88.7)	0.67 (0.93)	-1.3	0.00	0.50	1.25	2.8	
		Week 20	Tezepelumab	74	63 (85.1)	1.11 (1.24)	-1.0	0.00	1.00	2.25	3.5	0.24 [-0.11, 0.59]
			Placebo	71	63 (88.7)	0.84 (1.00)	-1.3	0.00	0.75	1.50	2.8	
		Week 24	Tezepelumab	74	63 (85.1)	1.21 (1.23)	-1.0	0.25	1.25	2.25	3.5	0.44 [0.08, 0.79]
			Placebo	71	63 (88.7)	0.71 (1.05)	-1.3	-0.25	0.75	1.50	3.3	
		Week 28	Tezepelumab	74	63 (85.1)	1.21 (1.25)	-1.5	0.25	1.25	2.25	3.5	0.34 [-0.01, 0.70]
			Placebo	71	63 (88.7)	0.82 (1.02)	-1.5	0.25	0.75	1.25	3.0	
		Week 32	Tezepelumab	74	63 (85.1)	1.21 (1.25)	-1.3	0.25	1.25	2.25	3.5	0.27 [-0.08, 0.62]
			Placebo	71	63 (88.7)	0.90 (1.02)	-1.3	0.00	0.75	1.75	3.5	
		Week 36	Tezepelumab	74	63 (85.1)	1.23 (1.31)	-1.8	0.25	1.25	2.25	3.5	0.30 [-0.06, 0.65]
			Placebo	71	63 (88.7)	0.87 (1.16)	-1.3	0.00	0.75	1.50	3.5	
		Week 40	Tezepelumab	74	63 (85.1)	1.28 (1.20)	-1.5	0.25	1.25	2.25	3.5	0.37 [0.02, 0.72]
			Placebo	71	63 (88.7)	0.84 (1.15)	-1.3	0.00	0.75	1.50	4.3	
		Week 44	Tezepelumab	74	63 (85.1)	1.29 (1.21)	-1.5	0.25	1.25	2.25	3.8	0.47 [0.11, 0.82]
			Placebo	71	63 (88.7)	0.75 (1.10)	-1.3	0.00	0.50	1.25	3.5	
		Week 48	Tezepelumab	74	63 (85.1)	1.28 (1.31)	-1.8	0.25	1.50	2.25	3.5	0.36 [0.01, 0.71]
			Placebo	71	63 (88.7)	0.84 (1.14)	-1.5	0.25	0.50	1.25	4.0	
		Week 52	Tezepelumab	74	63 (85.1)	1.20 (1.31)	-1.8	0.00	1.25	2.25	3.5	0.41 [0.06, 0.76]
			Placebo	71	63 (88.7)	0.70 (1.13)	-2.3	0.00	0.50	1.25	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	114	101 (88.6)	4.22 (1.09)	1.0	3.50	4.25	5.00	7.0	
			Placebo	126	112 (88.9)	4.05 (1.18)	1.5	3.25	4.00	5.00	7.0	
		Week 4	Tezepelumab	114	105 (92.1)	4.90 (1.17)	1.0	4.00	5.00	5.75	7.0	
			Placebo	126	113 (89.7)	4.60 (1.23)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	114	107 (93.9)	5.10 (1.10)	1.0	4.25	5.00	5.75	7.0	
			Placebo	126	116 (92.1)	4.70 (1.34)	1.0	3.88	4.75	5.75	7.0	
		Week 12	Tezepelumab	114	107 (93.9)	5.23 (1.11)	1.0	4.50	5.25	6.00	7.0	
			Placebo	126	117 (92.9)	4.76 (1.22)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	114	107 (93.9)	5.12 (1.11)	1.0	4.50	5.00	6.00	7.0	
			Placebo	126	117 (92.9)	4.75 (1.31)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	114	108 (94.7)	5.12 (1.17)	1.0	4.38	5.00	6.00	7.0	
			Placebo	126	117 (92.9)	4.77 (1.33)	1.3	4.00	4.75	5.75	7.0	
		Week 24	Tezepelumab	114	108 (94.7)	5.22 (1.16)	1.0	4.38	5.00	6.00	7.0	
			Placebo	126	117 (92.9)	4.68 (1.38)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	114	110 (96.5)	5.20 (1.18)	1.0	4.50	5.00	6.00	7.0	
			Placebo	126	118 (93.7)	4.82 (1.40)	1.3	4.00	4.88	6.00	7.0	
		Week 32	Tezepelumab	114	111 (97.4)	5.27 (1.13)	1.5	4.50	5.25	6.00	7.0	
			Placebo	126	119 (94.4)	4.88 (1.38)	1.3	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	114	111 (97.4)	5.27 (1.15)	1.0	4.50	5.25	6.25	7.0	
			Placebo	126	119 (94.4)	4.82 (1.41)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	114	111 (97.4)	5.30 (1.12)	1.3	4.50	5.25	6.00	7.0	
			Placebo	126	119 (94.4)	4.89 (1.39)	1.0	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	114	111 (97.4)	5.36 (1.18)	1.0	4.50	5.25	6.25	7.0	
			Placebo	126	119 (94.4)	4.85 (1.37)	1.3	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	114	111 (97.4)	5.38 (1.13)	2.0	4.50	5.50	6.25	7.0	
			Placebo	126	120 (95.2)	4.88 (1.33)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	114	111 (97.4)	5.34 (1.12)	2.0	4.50	5.25	6.25	7.0	
			Placebo	126	120 (95.2)	4.82 (1.36)	1.0	4.00	4.88	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	114	97 (85.1)	0.70 (1.16)	-4.0	0.00	0.75	1.25	4.0	0.15 [-0.13, 0.42]
			Placebo	126	110 (87.3)	0.54 (0.97)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	114	99 (86.8)	0.87 (1.13)	-1.5	0.00	0.75	1.75	4.3	0.19 [-0.09, 0.46]
			Placebo	126	111 (88.1)	0.68 (1.02)	-1.8	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	114	99 (86.8)	1.02 (1.13)	-2.3	0.25	1.00	1.75	4.8	0.25 [-0.02, 0.52]
			Placebo	126	111 (88.1)	0.74 (1.05)	-1.8	0.00	0.75	1.25	4.3	
		Week 16	Tezepelumab	114	99 (86.8)	0.91 (1.14)	-2.8	0.00	0.75	1.50	3.5	0.18 [-0.09, 0.45]
			Placebo	126	111 (88.1)	0.72 (1.00)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	114	99 (86.8)	0.92 (1.17)	-1.8	0.00	0.75	1.75	3.5	0.16 [-0.11, 0.43]
			Placebo	126	111 (88.1)	0.75 (1.00)	-2.3	0.00	0.75	1.25	3.0	
		Week 24	Tezepelumab	114	99 (86.8)	1.02 (1.13)	-1.5	0.25	1.00	1.75	3.5	0.32 [0.04, 0.59]
			Placebo	126	111 (88.1)	0.68 (1.05)	-2.8	0.00	0.75	1.50	3.3	
		Week 28	Tezepelumab	114	99 (86.8)	1.02 (1.15)	-1.5	0.25	1.00	1.75	3.5	0.20 [-0.07, 0.47]
			Placebo	126	111 (88.1)	0.80 (1.05)	-1.8	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	114	99 (86.8)	1.08 (1.16)	-1.3	0.25	1.00	1.75	3.5	0.17 [-0.10, 0.44]
			Placebo	126	111 (88.1)	0.89 (1.04)	-1.8	0.00	0.75	1.75	3.5	
		Week 36	Tezepelumab	114	99 (86.8)	1.09 (1.21)	-1.3	0.25	1.00	2.00	3.5	0.24 [-0.04, 0.51]
			Placebo	126	111 (88.1)	0.81 (1.15)	-2.8	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	114	99 (86.8)	1.12 (1.14)	-1.3	0.25	1.00	2.00	3.5	0.22 [-0.06, 0.49]
			Placebo	126	111 (88.1)	0.87 (1.14)	-2.5	0.00	0.75	1.75	4.3	
		Week 44	Tezepelumab	114	99 (86.8)	1.17 (1.18)	-1.5	0.25	1.25	2.00	3.8	0.30 [0.02, 0.57]
			Placebo	126	111 (88.1)	0.83 (1.16)	-1.5	0.00	0.75	1.50	3.8	
		Week 48	Tezepelumab	114	99 (86.8)	1.20 (1.18)	-1.3	0.50	1.00	2.00	3.8	0.29 [0.02, 0.57]
			Placebo	126	111 (88.1)	0.86 (1.16)	-2.8	0.00	0.75	1.50	3.8	
		Week 52	Tezepelumab	114	99 (86.8)	1.15 (1.19)	-1.5	0.50	1.00	2.00	3.8	0.31 [0.03, 0.58]
			Placebo	126	111 (88.1)	0.79 (1.14)	-2.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	23	22 (95.7)	4.27 (1.42)	1.0	3.50	4.25	5.25	6.8	
			Placebo	12	9 (75.0)	4.58 (1.43)	2.0	3.50	4.75	5.50	6.5	
		Week 4	Tezepelumab	23	21 (91.3)	4.90 (1.40)	1.5	4.25	5.50	6.00	6.8	
			Placebo	12	10 (83.3)	4.50 (0.97)	2.8	3.50	4.63	5.25	5.8	
		Week 8	Tezepelumab	23	21 (91.3)	5.10 (1.67)	1.0	4.50	5.75	6.25	7.0	
			Placebo	12	10 (83.3)	4.75 (0.95)	3.5	3.75	4.88	5.25	6.5	
		Week 12	Tezepelumab	23	21 (91.3)	5.25 (1.72)	1.0	4.50	5.75	6.50	7.0	
			Placebo	12	10 (83.3)	4.73 (0.72)	3.8	4.25	4.75	5.50	5.8	
		Week 16	Tezepelumab	23	21 (91.3)	5.45 (1.57)	1.0	4.75	5.75	6.50	7.0	
			Placebo	12	10 (83.3)	4.75 (0.85)	3.8	4.00	4.75	5.25	6.3	
		Week 20	Tezepelumab	23	21 (91.3)	5.33 (1.62)	1.3	5.00	5.75	6.50	7.0	
			Placebo	12	10 (83.3)	4.88 (0.58)	3.5	4.75	5.00	5.25	5.5	
		Week 24	Tezepelumab	23	21 (91.3)	5.43 (1.46)	1.0	5.00	5.75	6.50	7.0	
			Placebo	12	10 (83.3)	5.20 (0.85)	4.3	4.50	5.13	5.25	7.0	
		Week 28	Tezepelumab	23	21 (91.3)	5.23 (1.68)	1.0	4.75	5.75	6.25	7.0	
			Placebo	12	10 (83.3)	4.95 (1.22)	3.3	4.25	4.88	5.50	7.0	
		Week 32	Tezepelumab	23	21 (91.3)	5.37 (1.81)	1.0	5.00	5.75	7.00	7.0	
			Placebo	12	10 (83.3)	5.08 (0.91)	4.0	4.50	4.75	5.25	7.0	
		Week 36	Tezepelumab	23	21 (91.3)	5.38 (1.75)	1.0	4.75	5.75	7.00	7.0	
			Placebo	12	10 (83.3)	5.15 (1.00)	3.8	4.75	5.25	5.50	7.0	
		Week 40	Tezepelumab	23	21 (91.3)	5.48 (1.57)	2.0	4.50	5.75	7.00	7.0	
			Placebo	12	10 (83.3)	5.15 (0.91)	4.0	4.50	5.13	5.25	7.0	
		Week 44	Tezepelumab	23	21 (91.3)	5.38 (1.47)	2.0	4.50	5.75	6.50	7.0	
			Placebo	12	10 (83.3)	5.18 (0.73)	4.3	4.75	5.25	5.25	7.0	
		Week 48	Tezepelumab	23	21 (91.3)	5.15 (1.60)	1.0	4.25	5.75	6.25	7.0	
			Placebo	12	10 (83.3)	5.40 (0.82)	4.5	4.75	5.13	6.00	7.0	
		Week 52	Tezepelumab	23	21 (91.3)	5.13 (1.86)	1.0	4.25	5.75	6.50	7.0	
			Placebo	12	10 (83.3)	5.15 (0.95)	3.5	4.75	5.13	5.25	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	0.66 (1.12)	-2.3	0.00	0.50	1.38	3.0	0.61 [-0.20, 1.41]
			Placebo	12	9 (75.0)	0.03 (0.84)	-1.3	-0.25	0.25	0.50	1.3	
		Week 8	Tezepelumab	23	20 (87.0)	0.86 (1.27)	-1.5	0.00	0.63	2.00	3.0	0.42 [-0.37, 1.22]
			Placebo	12	9 (75.0)	0.31 (1.41)	-1.3	-0.75	0.25	0.75	3.3	
		Week 12	Tezepelumab	23	20 (87.0)	1.01 (1.30)	-2.0	0.25	0.75	2.25	3.0	0.59 [-0.21, 1.39]
			Placebo	12	9 (75.0)	0.25 (1.27)	-1.0	-0.75	-0.50	1.25	2.5	
		Week 16	Tezepelumab	23	20 (87.0)	1.23 (1.38)	-1.5	0.13	1.25	2.75	3.0	0.69 [-0.11, 1.50]
			Placebo	12	9 (75.0)	0.25 (1.46)	-1.3	-1.00	0.25	1.00	3.0	
		Week 20	Tezepelumab	23	20 (87.0)	1.09 (1.22)	-1.0	0.13	0.75	2.38	2.8	0.50 [-0.30, 1.30]
			Placebo	12	9 (75.0)	0.44 (1.42)	-1.3	-0.75	0.50	1.75	2.5	
		Week 24	Tezepelumab	23	20 (87.0)	1.19 (1.28)	-1.0	0.25	0.75	2.50	3.0	0.31 [-0.48, 1.10]
			Placebo	12	9 (75.0)	0.72 (1.93)	-1.5	-0.75	0.25	1.75	3.8	
		Week 28	Tezepelumab	23	20 (87.0)	0.99 (1.25)	-1.5	0.13	0.75	2.25	2.8	0.36 [-0.44, 1.15]
			Placebo	12	9 (75.0)	0.44 (2.04)	-2.8	-0.75	0.00	1.75	3.8	
		Week 32	Tezepelumab	23	20 (87.0)	1.09 (1.30)	-1.3	0.00	1.00	2.38	3.0	0.37 [-0.42, 1.16]
			Placebo	12	9 (75.0)	0.56 (1.70)	-1.5	-0.75	0.50	1.50	3.8	
		Week 36	Tezepelumab	23	20 (87.0)	1.10 (1.32)	-1.8	0.25	0.88	2.25	3.0	0.24 [-0.55, 1.03]
			Placebo	12	9 (75.0)	0.72 (2.11)	-2.3	-0.75	0.50	2.75	3.8	
		Week 40	Tezepelumab	23	20 (87.0)	1.20 (1.29)	-1.5	0.25	1.13	2.63	3.0	0.33 [-0.47, 1.12]
			Placebo	12	9 (75.0)	0.69 (2.03)	-1.5	-0.75	0.25	0.75	4.3	
		Week 44	Tezepelumab	23	20 (87.0)	1.10 (1.29)	-1.5	0.13	0.75	2.38	3.0	0.35 [-0.44, 1.15]
			Placebo	12	9 (75.0)	0.58 (1.81)	-1.3	-0.75	0.25	0.75	3.8	
		Week 48	Tezepelumab	23	20 (87.0)	0.90 (1.37)	-1.8	-0.13	0.75	2.25	2.8	0.01 [-0.78, 0.79]
			Placebo	12	9 (75.0)	0.89 (1.95)	-1.3	-0.75	0.75	1.50	4.0	
		Week 52	Tezepelumab	23	20 (87.0)	0.84 (1.34)	-1.8	0.00	0.63	2.25	2.8	0.13 [-0.66, 0.92]
			Placebo	12	9 (75.0)	0.64 (1.84)	-1.3	-0.75	0.25	1.50	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.94 (1.25)	1.8	3.13	4.13	4.75	5.8	
			Placebo	14	10 (71.4)	4.95 (1.21)	3.3	4.25	4.75	5.75	7.0	
		Week 4	Tezepelumab	9	8 (88.9)	4.88 (1.26)	2.0	4.63	5.38	5.63	5.8	
			Placebo	14	12 (85.7)	5.21 (0.95)	3.5	4.88	5.25	5.63	7.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.25 (1.80)	1.0	5.38	5.63	6.00	7.0	
			Placebo	14	13 (92.9)	4.98 (1.06)	3.0	4.75	5.25	5.50	6.5	
		Week 12	Tezepelumab	9	8 (88.9)	5.31 (1.85)	1.0	5.38	5.50	6.38	7.0	
			Placebo	14	13 (92.9)	5.12 (0.85)	3.5	5.25	5.50	5.75	5.8	
		Week 16	Tezepelumab	9	8 (88.9)	5.41 (1.92)	1.0	5.38	5.50	6.75	7.0	
			Placebo	14	13 (92.9)	5.21 (1.05)	3.3	4.50	5.25	5.75	7.0	
		Week 20	Tezepelumab	9	8 (88.9)	4.94 (1.88)	1.3	3.88	5.50	6.25	7.0	
			Placebo	14	13 (92.9)	5.04 (1.22)	2.5	4.50	5.25	5.75	7.0	
		Week 24	Tezepelumab	9	8 (88.9)	5.13 (1.86)	1.0	4.75	5.50	6.38	6.8	
			Placebo	14	13 (92.9)	4.98 (1.54)	2.0	4.25	5.00	6.00	7.0	
		Week 28	Tezepelumab	9	8 (88.9)	5.25 (1.86)	1.0	5.00	5.88	6.13	7.0	
			Placebo	14	14 (100.0)	5.21 (1.28)	3.0	4.50	5.00	6.25	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.09 (1.89)	1.0	4.50	5.50	6.38	7.0	
			Placebo	14	14 (100.0)	5.45 (1.25)	3.0	4.50	5.50	6.75	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.16 (1.95)	1.0	4.63	5.63	6.38	7.0	
			Placebo	14	14 (100.0)	5.21 (1.56)	2.0	4.50	5.13	6.75	7.0	
		Week 40	Tezepelumab	9	8 (88.9)	5.44 (1.56)	2.0	5.13	5.75	6.38	7.0	
			Placebo	14	14 (100.0)	5.25 (1.45)	2.3	4.50	5.38	6.50	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.44 (1.53)	2.0	5.13	5.88	6.38	6.8	
			Placebo	14	14 (100.0)	5.50 (1.27)	3.0	4.50	5.50	6.75	7.0	
		Week 48	Tezepelumab	9	8 (88.9)	5.25 (1.86)	1.0	5.00	5.88	6.13	7.0	
			Placebo	14	14 (100.0)	5.20 (1.50)	2.0	4.50	5.13	6.50	7.0	
		Week 52	Tezepelumab	9	8 (88.9)	5.25 (1.84)	1.0	5.00	5.88	6.38	6.5	
			Placebo	14	14 (100.0)	5.38 (1.28)	3.0	4.50	5.13	7.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	1.07 (0.84)	0.0	0.25	1.25	1.50	2.5	0.68 [-0.31, 1.68]
			Placebo	14	10 (71.4)	0.35 (1.18)	-2.0	0.00	0.63	1.00	2.0	
		Week 8	Tezepelumab	9	7 (77.8)	1.39 (1.34)	-0.8	0.00	1.75	2.25	3.0	0.70 [-0.30, 1.69]
			Placebo	14	10 (71.4)	0.38 (1.54)	-1.8	-1.00	0.25	1.25	3.3	
		Week 12	Tezepelumab	9	7 (77.8)	1.50 (1.27)	-0.8	0.50	2.00	2.25	3.0	0.87 [-0.14, 1.89]
			Placebo	14	10 (71.4)	0.38 (1.30)	-1.8	-0.75	0.50	1.00	2.5	
		Week 16	Tezepelumab	9	7 (77.8)	1.64 (1.60)	-0.8	-0.25	2.50	3.00	3.3	0.80 [-0.20, 1.81]
			Placebo	14	10 (71.4)	0.48 (1.35)	-1.5	0.00	0.25	1.25	3.0	
		Week 20	Tezepelumab	9	7 (77.8)	1.29 (1.33)	-0.5	0.00	1.25	2.50	2.8	0.67 [-0.33, 1.67]
			Placebo	14	10 (71.4)	0.38 (1.38)	-2.3	0.00	0.25	1.50	2.0	
		Week 24	Tezepelumab	9	7 (77.8)	1.46 (1.29)	-0.8	0.25	2.00	2.50	2.8	0.65 [-0.34, 1.64]
			Placebo	14	10 (71.4)	0.43 (1.77)	-2.8	-0.25	0.13	1.50	3.8	
		Week 28	Tezepelumab	9	7 (77.8)	1.57 (1.46)	-0.8	0.00	2.25	2.75	3.0	0.70 [-0.30, 1.69]
			Placebo	14	10 (71.4)	0.53 (1.53)	-1.3	-0.25	0.13	1.00	3.8	
		Week 32	Tezepelumab	9	7 (77.8)	1.43 (1.32)	-0.8	0.25	1.50	2.50	3.0	0.44 [-0.54, 1.42]
			Placebo	14	10 (71.4)	0.83 (1.39)	-1.3	0.00	0.63	1.50	3.8	
		Week 36	Tezepelumab	9	7 (77.8)	1.57 (1.39)	-0.8	0.25	2.25	2.75	3.0	0.65 [-0.35, 1.64]
			Placebo	14	10 (71.4)	0.50 (1.81)	-2.8	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	9	7 (77.8)	1.75 (1.25)	0.0	0.25	2.25	2.75	3.0	0.77 [-0.23, 1.77]
			Placebo	14	10 (71.4)	0.55 (1.74)	-2.5	0.00	0.50	1.75	3.8	
		Week 44	Tezepelumab	9	7 (77.8)	1.75 (1.35)	0.0	0.25	2.00	2.75	3.8	0.61 [-0.38, 1.60]
			Placebo	14	10 (71.4)	0.85 (1.55)	-1.3	0.00	0.25	2.25	3.8	
		Week 48	Tezepelumab	9	7 (77.8)	1.57 (1.40)	-0.8	0.25	2.00	2.75	3.0	0.68 [-0.32, 1.68]
			Placebo	14	10 (71.4)	0.45 (1.80)	-2.8	0.00	0.25	1.00	3.8	
		Week 52	Tezepelumab	9	7 (77.8)	1.57 (1.40)	-0.8	0.25	2.00	2.75	3.0	0.61 [-0.38, 1.60]
			Placebo	14	10 (71.4)	0.70 (1.44)	-1.3	0.00	0.25	1.00	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.25 (1.14)	1.0	3.50	4.25	5.00	7.0	
			Placebo	124	111 (89.5)	4.01 (1.18)	1.5	3.25	4.00	5.00	6.3	
		Week 4	Tezepelumab	128	118 (92.2)	4.90 (1.21)	1.0	4.00	5.00	5.75	7.0	
			Placebo	124	111 (89.5)	4.53 (1.22)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	128	120 (93.8)	5.09 (1.16)	1.0	4.25	5.00	5.75	7.0	
			Placebo	124	113 (91.1)	4.67 (1.34)	1.0	3.75	4.75	5.75	7.0	
		Week 12	Tezepelumab	128	120 (93.8)	5.23 (1.18)	1.0	4.50	5.25	6.25	7.0	
			Placebo	124	114 (91.9)	4.72 (1.22)	1.3	4.00	4.75	5.50	7.0	
		Week 16	Tezepelumab	128	120 (93.8)	5.16 (1.14)	1.0	4.50	5.00	6.00	7.0	
			Placebo	124	114 (91.9)	4.70 (1.29)	1.3	4.00	4.63	5.50	7.0	
		Week 20	Tezepelumab	128	121 (94.5)	5.17 (1.20)	1.0	4.50	5.00	6.00	7.0	
			Placebo	124	114 (91.9)	4.75 (1.29)	1.3	4.00	4.75	5.50	7.0	
		Week 24	Tezepelumab	128	121 (94.5)	5.26 (1.17)	1.0	4.50	5.00	6.25	7.0	
			Placebo	124	114 (91.9)	4.69 (1.34)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	128	123 (96.1)	5.21 (1.23)	1.0	4.50	5.00	6.25	7.0	
			Placebo	124	114 (91.9)	4.78 (1.39)	1.3	4.00	4.88	6.00	7.0	
		Week 32	Tezepelumab	128	124 (96.9)	5.30 (1.21)	1.0	4.50	5.25	6.00	7.0	
			Placebo	124	115 (92.7)	4.83 (1.35)	1.3	4.00	4.75	6.00	7.0	
		Week 36	Tezepelumab	128	124 (96.9)	5.30 (1.21)	1.0	4.50	5.25	6.25	7.0	
			Placebo	124	115 (92.7)	4.80 (1.36)	1.0	4.00	4.75	5.75	7.0	
		Week 40	Tezepelumab	128	124 (96.9)	5.32 (1.18)	1.3	4.50	5.25	6.25	7.0	
			Placebo	124	115 (92.7)	4.87 (1.34)	1.0	4.00	5.00	5.75	7.0	
		Week 44	Tezepelumab	128	124 (96.9)	5.36 (1.21)	1.0	4.50	5.25	6.38	7.0	
			Placebo	124	115 (92.7)	4.80 (1.33)	1.3	4.00	4.75	5.75	7.0	
		Week 48	Tezepelumab	128	124 (96.9)	5.35 (1.17)	2.0	4.50	5.25	6.25	7.0	
			Placebo	124	116 (93.5)	4.88 (1.28)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	128	124 (96.9)	5.31 (1.22)	1.0	4.50	5.25	6.25	7.0	
			Placebo	124	116 (93.5)	4.78 (1.33)	1.0	4.00	4.88	5.88	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	110 (85.9)	0.67 (1.17)	-4.0	0.00	0.50	1.25	4.0	0.14 [-0.12, 0.41]
			Placebo	124	109 (87.9)	0.52 (0.95)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	128	112 (87.5)	0.84 (1.13)	-1.5	0.00	0.75	1.75	4.3	0.16 [-0.11, 0.42]
			Placebo	124	110 (88.7)	0.67 (1.00)	-1.5	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	128	112 (87.5)	0.99 (1.14)	-2.3	0.25	0.88	1.75	4.8	0.23 [-0.04, 0.49]
			Placebo	124	110 (88.7)	0.74 (1.05)	-1.3	0.00	0.75	1.25	4.3	
		Week 16	Tezepelumab	128	112 (87.5)	0.92 (1.15)	-2.8	0.00	0.75	1.50	3.5	0.20 [-0.06, 0.46]
			Placebo	124	110 (88.7)	0.70 (1.01)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	128	112 (87.5)	0.93 (1.17)	-1.8	0.00	0.75	1.75	3.5	0.16 [-0.11, 0.42]
			Placebo	124	110 (88.7)	0.76 (1.00)	-1.8	0.00	0.75	1.25	3.0	
		Week 24	Tezepelumab	128	112 (87.5)	1.02 (1.14)	-1.5	0.25	1.00	1.88	3.5	0.29 [0.03, 0.55]
			Placebo	124	110 (88.7)	0.70 (1.06)	-1.8	0.00	0.75	1.50	3.3	
		Week 28	Tezepelumab	128	112 (87.5)	0.98 (1.14)	-1.5	0.25	0.75	1.75	3.5	0.16 [-0.10, 0.43]
			Placebo	124	110 (88.7)	0.79 (1.11)	-2.8	0.00	0.75	1.50	4.0	
		Week 32	Tezepelumab	128	112 (87.5)	1.06 (1.18)	-1.3	0.13	1.00	1.75	3.5	0.17 [-0.09, 0.43]
			Placebo	124	110 (88.7)	0.87 (1.07)	-1.8	0.00	0.75	1.75	3.5	
		Week 36	Tezepelumab	128	112 (87.5)	1.06 (1.21)	-1.8	0.25	1.00	2.00	3.5	0.19 [-0.07, 0.46]
			Placebo	124	110 (88.7)	0.83 (1.17)	-2.3	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	128	112 (87.5)	1.09 (1.15)	-1.5	0.25	1.00	2.00	3.5	0.18 [-0.08, 0.44]
			Placebo	124	110 (88.7)	0.88 (1.17)	-1.8	0.25	0.75	1.50	4.3	
		Week 44	Tezepelumab	128	112 (87.5)	1.12 (1.18)	-1.5	0.25	1.00	2.00	3.8	0.27 [0.01, 0.53]
			Placebo	124	110 (88.7)	0.80 (1.18)	-1.5	0.00	0.75	1.50	3.8	
		Week 48	Tezepelumab	128	112 (87.5)	1.13 (1.20)	-1.8	0.25	1.00	2.00	3.8	0.19 [-0.07, 0.46]
			Placebo	124	110 (88.7)	0.90 (1.17)	-1.5	0.25	0.75	1.50	4.0	
		Week 52	Tezepelumab	128	112 (87.5)	1.07 (1.21)	-1.8	0.25	1.00	1.75	3.8	0.24 [-0.03, 0.50]
			Placebo	124	110 (88.7)	0.79 (1.18)	-2.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	4.23 (1.10)	1.0	3.50	4.13	5.00	7.0	
			Placebo	115	104 (90.4)	3.98 (1.17)	1.5	3.25	4.00	4.88	6.3	
		Week 4	Tezepelumab	108	100 (92.6)	4.89 (1.19)	1.0	4.00	4.88	5.75	7.0	
			Placebo	115	104 (90.4)	4.53 (1.23)	1.3	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	108	102 (94.4)	5.07 (1.12)	1.0	4.25	5.00	5.75	7.0	
			Placebo	115	106 (92.2)	4.67 (1.37)	1.0	3.75	4.75	5.75	7.0	
		Week 12	Tezepelumab	108	102 (94.4)	5.21 (1.13)	1.0	4.50	5.25	6.00	7.0	
			Placebo	115	107 (93.0)	4.73 (1.25)	1.3	4.00	4.75	5.75	7.0	
		Week 16	Tezepelumab	108	102 (94.4)	5.08 (1.11)	1.0	4.50	5.00	6.00	7.0	
			Placebo	115	107 (93.0)	4.71 (1.32)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	108	103 (95.4)	5.12 (1.17)	1.0	4.50	5.00	6.00	7.0	
			Placebo	115	107 (93.0)	4.73 (1.33)	1.3	4.00	4.50	5.75	7.0	
		Week 24	Tezepelumab	108	103 (95.4)	5.21 (1.18)	1.0	4.25	5.00	6.00	7.0	
			Placebo	115	107 (93.0)	4.67 (1.37)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	108	105 (97.2)	5.18 (1.18)	1.0	4.25	5.00	6.00	7.0	
			Placebo	115	107 (93.0)	4.79 (1.41)	1.3	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	108	106 (98.1)	5.27 (1.14)	1.5	4.50	5.25	6.00	7.0	
			Placebo	115	108 (93.9)	4.82 (1.38)	1.3	4.00	4.88	6.00	7.0	
		Week 36	Tezepelumab	108	106 (98.1)	5.27 (1.16)	1.0	4.50	5.13	6.25	7.0	
			Placebo	115	108 (93.9)	4.78 (1.39)	1.0	4.00	4.75	5.88	7.0	
		Week 40	Tezepelumab	108	106 (98.1)	5.28 (1.14)	1.3	4.50	5.25	6.00	7.0	
			Placebo	115	108 (93.9)	4.86 (1.38)	1.0	4.00	5.00	5.75	7.0	
		Week 44	Tezepelumab	108	106 (98.1)	5.33 (1.19)	1.0	4.50	5.25	6.25	7.0	
			Placebo	115	108 (93.9)	4.79 (1.37)	1.3	4.00	4.50	6.00	7.0	
		Week 48	Tezepelumab	108	106 (98.1)	5.36 (1.14)	2.0	4.50	5.25	6.25	7.0	
			Placebo	115	109 (94.8)	4.86 (1.30)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	108	106 (98.1)	5.33 (1.13)	2.0	4.50	5.25	6.25	7.0	
			Placebo	115	109 (94.8)	4.77 (1.36)	1.0	4.00	4.75	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	108	93 (86.1)	0.67 (1.17)	-4.0	0.00	0.50	1.25	4.0	0.11 [-0.17, 0.39]
			Placebo	115	102 (88.7)	0.55 (0.96)	-2.5	0.00	0.50	1.25	3.0	
		Week 8	Tezepelumab	108	95 (88.0)	0.83 (1.13)	-1.5	0.00	0.75	1.75	4.3	0.11 [-0.17, 0.39]
			Placebo	115	103 (89.6)	0.71 (1.00)	-1.5	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	108	95 (88.0)	0.98 (1.13)	-2.3	0.25	0.75	1.50	4.8	0.18 [-0.10, 0.46]
			Placebo	115	103 (89.6)	0.78 (1.04)	-1.3	0.00	0.75	1.25	4.3	
		Week 16	Tezepelumab	108	95 (88.0)	0.85 (1.11)	-2.8	0.00	0.75	1.50	3.5	0.10 [-0.18, 0.38]
			Placebo	115	103 (89.6)	0.75 (1.00)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	108	95 (88.0)	0.89 (1.17)	-1.8	0.00	0.75	1.75	3.5	0.10 [-0.18, 0.38]
			Placebo	115	103 (89.6)	0.78 (0.98)	-1.8	0.25	0.75	1.25	3.0	
		Week 24	Tezepelumab	108	95 (88.0)	0.98 (1.13)	-1.5	0.25	1.00	1.75	3.5	0.25 [-0.03, 0.53]
			Placebo	115	103 (89.6)	0.71 (1.01)	-1.8	0.00	0.75	1.50	3.3	
		Week 28	Tezepelumab	108	95 (88.0)	0.96 (1.13)	-1.5	0.25	0.75	1.75	3.5	0.12 [-0.16, 0.40]
			Placebo	115	103 (89.6)	0.83 (1.05)	-1.8	0.25	0.75	1.50	4.0	
		Week 32	Tezepelumab	108	95 (88.0)	1.05 (1.17)	-1.3	0.25	1.00	1.75	3.5	0.13 [-0.15, 0.41]
			Placebo	115	103 (89.6)	0.91 (1.05)	-1.8	0.25	0.75	1.75	3.5	
		Week 36	Tezepelumab	108	95 (88.0)	1.04 (1.21)	-1.3	0.25	1.00	2.00	3.5	0.17 [-0.11, 0.45]
			Placebo	115	103 (89.6)	0.85 (1.11)	-2.0	0.00	0.50	1.50	3.8	
		Week 40	Tezepelumab	108	95 (88.0)	1.07 (1.13)	-1.3	0.25	1.00	2.00	3.5	0.14 [-0.14, 0.42]
			Placebo	115	103 (89.6)	0.91 (1.12)	-1.8	0.25	0.75	1.75	4.3	
		Week 44	Tezepelumab	108	95 (88.0)	1.12 (1.16)	-1.5	0.25	1.00	2.00	3.8	0.24 [-0.04, 0.52]
			Placebo	115	103 (89.6)	0.83 (1.17)	-1.5	0.00	0.75	1.50	3.8	
		Week 48	Tezepelumab	108	95 (88.0)	1.15 (1.17)	-1.3	0.50	1.00	2.00	3.8	0.22 [-0.06, 0.49]
			Placebo	115	103 (89.6)	0.91 (1.13)	-1.5	0.25	0.75	1.50	3.8	
		Week 52	Tezepelumab	108	95 (88.0)	1.10 (1.19)	-1.5	0.25	1.00	1.75	3.8	0.25 [-0.03, 0.53]
			Placebo	115	103 (89.6)	0.81 (1.16)	-2.3	0.00	0.50	1.25	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	4.22 (1.32)	1.0	3.50	4.25	5.25	6.8	
			Placebo	23	17 (73.9)	4.76 (1.25)	2.0	4.25	4.75	5.50	7.0	
		Week 4	Tezepelumab	29	26 (89.7)	4.95 (1.27)	1.5	4.25	5.38	5.75	6.8	
			Placebo	23	19 (82.6)	4.96 (1.02)	2.8	4.50	5.25	5.50	7.0	
		Week 8	Tezepelumab	29	26 (89.7)	5.20 (1.52)	1.0	4.50	5.63	6.25	7.0	
			Placebo	23	20 (87.0)	4.85 (0.95)	3.0	4.25	5.00	5.38	6.5	
		Week 12	Tezepelumab	29	26 (89.7)	5.33 (1.56)	1.0	4.50	5.50	6.50	7.0	
			Placebo	23	20 (87.0)	4.94 (0.79)	3.5	4.25	5.25	5.50	5.8	
		Week 16	Tezepelumab	29	26 (89.7)	5.55 (1.45)	1.0	5.00	5.75	6.50	7.0	
			Placebo	23	20 (87.0)	4.99 (0.99)	3.3	4.13	5.00	5.75	7.0	
		Week 20	Tezepelumab	29	26 (89.7)	5.30 (1.54)	1.3	5.00	5.50	6.50	7.0	
			Placebo	23	20 (87.0)	5.01 (0.99)	2.5	4.63	5.13	5.50	7.0	
		Week 24	Tezepelumab	29	26 (89.7)	5.43 (1.35)	1.0	5.00	5.50	6.50	7.0	
			Placebo	23	20 (87.0)	5.01 (1.27)	2.0	4.50	5.00	5.88	7.0	
		Week 28	Tezepelumab	29	26 (89.7)	5.34 (1.56)	1.0	4.75	5.75	6.25	7.0	
			Placebo	23	21 (91.3)	5.05 (1.24)	3.0	4.50	4.75	6.00	7.0	
		Week 32	Tezepelumab	29	26 (89.7)	5.37 (1.66)	1.0	4.75	5.50	6.75	7.0	
			Placebo	23	21 (91.3)	5.25 (1.12)	3.0	4.50	5.25	6.00	7.0	
		Week 36	Tezepelumab	29	26 (89.7)	5.39 (1.63)	1.0	4.75	5.63	6.75	7.0	
			Placebo	23	21 (91.3)	5.17 (1.33)	2.0	4.75	5.25	6.25	7.0	
		Week 40	Tezepelumab	29	26 (89.7)	5.53 (1.44)	2.0	4.75	5.75	7.00	7.0	
			Placebo	23	21 (91.3)	5.18 (1.23)	2.3	4.50	5.25	6.00	7.0	
		Week 44	Tezepelumab	29	26 (89.7)	5.49 (1.38)	2.0	4.75	5.75	6.75	7.0	
			Placebo	23	21 (91.3)	5.30 (1.08)	3.0	4.75	5.25	5.75	7.0	
		Week 48	Tezepelumab	29	26 (89.7)	5.28 (1.50)	1.0	4.50	5.75	6.25	7.0	
			Placebo	23	21 (91.3)	5.23 (1.27)	2.0	4.50	5.00	6.00	7.0	
		Week 52	Tezepelumab	29	26 (89.7)	5.24 (1.71)	1.0	4.50	5.75	6.50	7.0	
			Placebo	23	21 (91.3)	5.24 (1.14)	3.0	4.50	5.00	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IOSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITT

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	29	24 (82.8)	0.79 (1.10)	-2.3	0.13	0.75	1.38	3.0	0.54 [-0.09, 1.18]
			Placebo	23	17 (73.9)	0.22 (0.98)	-2.0	0.00	0.50	0.75	2.0	
		Week 8	Tezepelumab	29	24 (82.8)	1.03 (1.23)	-1.5	0.00	1.25	2.00	3.0	0.61 [-0.02, 1.25]
			Placebo	23	17 (73.9)	0.26 (1.28)	-1.8	-0.75	0.25	1.25	3.3	
		Week 12	Tezepelumab	29	24 (82.8)	1.17 (1.24)	-2.0	0.38	1.13	2.25	3.0	0.74 [0.10, 1.39]
			Placebo	23	17 (73.9)	0.26 (1.16)	-1.8	-0.75	0.25	1.00	2.5	
		Week 16	Tezepelumab	29	24 (82.8)	1.42 (1.36)	-1.5	0.38	1.50	2.75	3.3	0.85 [0.20, 1.50]
			Placebo	23	17 (73.9)	0.31 (1.22)	-1.5	-0.50	0.25	1.00	3.0	
		Week 20	Tezepelumab	29	24 (82.8)	1.19 (1.18)	-1.0	0.25	1.00	2.50	2.8	0.62 [-0.01, 1.26]
			Placebo	23	17 (73.9)	0.41 (1.32)	-2.3	-0.25	0.25	1.50	2.5	
		Week 24	Tezepelumab	29	24 (82.8)	1.32 (1.22)	-1.0	0.38	1.13	2.50	3.0	0.59 [-0.05, 1.22]
			Placebo	23	17 (73.9)	0.49 (1.68)	-2.8	-0.50	0.25	1.50	3.8	
		Week 28	Tezepelumab	29	24 (82.8)	1.22 (1.28)	-1.5	0.25	1.25	2.50	3.0	0.58 [-0.06, 1.21]
			Placebo	23	17 (73.9)	0.40 (1.59)	-2.8	-0.25	0.00	1.00	3.8	
		Week 32	Tezepelumab	29	24 (82.8)	1.22 (1.24)	-1.3	0.13	1.38	2.38	3.0	0.46 [-0.17, 1.09]
			Placebo	23	17 (73.9)	0.63 (1.32)	-1.5	-0.25	0.50	1.50	3.8	
		Week 36	Tezepelumab	29	24 (82.8)	1.27 (1.28)	-1.8	0.25	1.38	2.25	3.0	0.49 [-0.14, 1.12]
			Placebo	23	17 (73.9)	0.53 (1.80)	-2.8	-0.25	0.25	1.25	3.8	
		Week 40	Tezepelumab	29	24 (82.8)	1.38 (1.27)	-1.5	0.25	1.25	2.75	3.0	0.57 [-0.07, 1.20]
			Placebo	23	17 (73.9)	0.54 (1.71)	-2.5	0.00	0.25	0.75	4.3	
		Week 44	Tezepelumab	29	24 (82.8)	1.33 (1.34)	-1.5	0.25	1.13	2.63	3.8	0.48 [-0.15, 1.11]
			Placebo	23	17 (73.9)	0.66 (1.48)	-1.3	0.00	0.25	1.25	3.8	
		Week 48	Tezepelumab	29	24 (82.8)	1.15 (1.40)	-1.8	0.13	1.13	2.50	3.0	0.36 [-0.26, 0.99]
			Placebo	23	17 (73.9)	0.59 (1.72)	-2.8	0.00	0.25	1.00	4.0	
		Week 52	Tezepelumab	29	24 (82.8)	1.07 (1.36)	-1.8	0.13	0.88	2.50	3.0	0.34 [-0.29, 0.96]
			Placebo	23	17 (73.9)	0.60 (1.43)	-1.3	0.00	0.25	1.00	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOMH0: Course of AQLQ+12 emotional function score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	137	123 (89.8)	4.33 (1.15)	1.4	3.60	4.20	5.20	6.8	
		Placebo	138	121 (87.7)	4.24 (1.23)	1.0	3.60	4.20	5.00	7.0	
	Week 4	Tezepelumab	137	126 (92.0)	4.98 (1.19)	1.2	4.00	5.00	6.00	7.0	
		Placebo	138	123 (89.1)	4.69 (1.31)	1.4	3.80	4.80	5.60	7.0	
	Week 8	Tezepelumab	137	128 (93.4)	5.17 (1.20)	1.8	4.40	5.10	6.10	7.0	
		Placebo	138	126 (91.3)	4.82 (1.31)	1.0	4.00	4.80	5.80	7.0	
	Week 12	Tezepelumab	137	128 (93.4)	5.36 (1.17)	2.0	4.40	5.40	6.40	7.0	
		Placebo	138	127 (92.0)	4.89 (1.32)	1.4	4.00	4.60	6.00	7.0	
	Week 16	Tezepelumab	137	128 (93.4)	5.31 (1.16)	2.2	4.40	5.50	6.20	7.0	
		Placebo	138	127 (92.0)	4.89 (1.37)	1.0	4.00	5.00	6.00	7.0	
	Week 20	Tezepelumab	137	129 (94.2)	5.36 (1.16)	1.0	4.40	5.60	6.20	7.0	
		Placebo	138	127 (92.0)	4.94 (1.32)	1.0	4.00	5.00	6.00	7.0	
	Week 24	Tezepelumab	137	129 (94.2)	5.35 (1.17)	1.6	4.40	5.40	6.20	7.0	
		Placebo	138	127 (92.0)	5.01 (1.31)	1.0	4.00	5.00	6.00	7.0	
	Week 28	Tezepelumab	137	131 (95.6)	5.43 (1.08)	2.8	4.60	5.60	6.20	7.0	
		Placebo	138	128 (92.8)	4.96 (1.40)	1.0	4.00	5.00	6.00	7.0	
	Week 32	Tezepelumab	137	132 (96.4)	5.40 (1.15)	1.8	4.60	5.60	6.20	7.0	
		Placebo	138	129 (93.5)	4.99 (1.38)	1.0	4.00	5.00	6.00	7.0	
	Week 36	Tezepelumab	137	132 (96.4)	5.49 (1.15)	2.8	4.60	5.70	6.40	7.0	
		Placebo	138	129 (93.5)	5.04 (1.33)	1.6	4.00	5.00	6.00	7.0	
	Week 40	Tezepelumab	137	132 (96.4)	5.38 (1.21)	1.8	4.60	5.40	6.40	7.0	
		Placebo	138	129 (93.5)	5.04 (1.36)	1.6	4.00	5.00	6.20	7.0	
	Week 44	Tezepelumab	137	132 (96.4)	5.49 (1.15)	2.6	4.60	5.60	6.40	7.0	
		Placebo	138	129 (93.5)	5.04 (1.42)	1.4	4.00	5.00	6.20	7.0	
	Week 48	Tezepelumab	137	132 (96.4)	5.48 (1.15)	1.8	4.60	5.60	6.40	7.0	
		Placebo	138	130 (94.2)	5.04 (1.37)	1.2	4.00	4.90	6.40	7.0	
	Week 52	Tezepelumab	137	132 (96.4)	5.46 (1.16)	1.8	4.60	5.60	6.40	7.0	
		Placebo	138	130 (94.2)	4.97 (1.42)	1.2	4.00	4.80	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOMH0: Course of AQLQ+12 emotional function score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	137	117 (85.4)	0.68 (1.20)	-4.2	0.00	0.60	1.60	3.8	0.21 [-0.05, 0.46]
		Placebo	138	119 (86.2)	0.45 (1.07)	-2.8	-0.20	0.40	1.00	3.6	
	Week 8	Tezepelumab	137	119 (86.9)	0.83 (1.24)	-2.2	0.00	0.80	1.60	5.0	0.19 [-0.06, 0.45]
		Placebo	138	120 (87.0)	0.59 (1.18)	-2.0	-0.20	0.60	1.20	4.0	
	Week 12	Tezepelumab	137	119 (86.9)	1.02 (1.24)	-2.4	0.20	0.80	1.80	5.4	0.27 [0.02, 0.53]
		Placebo	138	120 (87.0)	0.68 (1.26)	-2.2	0.00	0.70	1.40	4.4	
	Week 16	Tezepelumab	137	119 (86.9)	0.98 (1.21)	-2.8	0.20	1.00	1.60	5.2	0.26 [0.01, 0.52]
		Placebo	138	120 (87.0)	0.66 (1.23)	-3.4	0.00	0.60	1.40	4.4	
	Week 20	Tezepelumab	137	119 (86.9)	1.05 (1.23)	-1.4	0.20	1.00	2.00	5.2	0.27 [0.01, 0.52]
		Placebo	138	120 (87.0)	0.73 (1.23)	-3.4	0.00	0.80	1.40	5.2	
	Week 24	Tezepelumab	137	119 (86.9)	1.03 (1.25)	-1.4	0.00	0.80	2.00	5.4	0.18 [-0.07, 0.44]
		Placebo	138	120 (87.0)	0.80 (1.28)	-3.4	0.00	0.70	1.60	4.2	
	Week 28	Tezepelumab	137	119 (86.9)	1.09 (1.22)	-1.4	0.20	0.80	2.00	5.4	0.26 [0.01, 0.52]
		Placebo	138	120 (87.0)	0.74 (1.39)	-3.4	0.00	0.80	1.60	5.2	
	Week 32	Tezepelumab	137	119 (86.9)	1.05 (1.25)	-1.6	0.20	1.00	2.00	5.4	0.21 [-0.05, 0.46]
		Placebo	138	120 (87.0)	0.78 (1.31)	-3.4	-0.20	0.80	1.60	5.4	
	Week 36	Tezepelumab	137	119 (86.9)	1.15 (1.32)	-1.6	0.20	1.00	2.00	5.4	0.26 [0.01, 0.52]
		Placebo	138	120 (87.0)	0.81 (1.23)	-2.0	0.00	0.60	1.60	4.2	
	Week 40	Tezepelumab	137	119 (86.9)	1.05 (1.30)	-2.4	0.00	1.00	2.00	5.4	0.16 [-0.09, 0.41]
		Placebo	138	120 (87.0)	0.84 (1.36)	-2.0	0.00	0.80	1.50	5.4	
	Week 44	Tezepelumab	137	119 (86.9)	1.13 (1.26)	-1.4	0.20	1.20	2.00	5.4	0.23 [-0.02, 0.49]
		Placebo	138	120 (87.0)	0.82 (1.39)	-2.2	-0.20	0.80	1.60	5.2	
	Week 48	Tezepelumab	137	119 (86.9)	1.13 (1.26)	-1.4	0.20	1.00	2.00	5.4	0.24 [-0.02, 0.49]
		Placebo	138	120 (87.0)	0.82 (1.33)	-2.2	-0.10	0.80	1.60	5.0	
	Week 52	Tezepelumab	137	119 (86.9)	1.10 (1.28)	-1.6	0.00	1.00	2.00	5.4	0.26 [0.01, 0.52]
		Placebo	138	120 (87.0)	0.75 (1.39)	-2.6	-0.20	0.80	1.40	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
DITT

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	137	117 (85.4)	0.69 (0.10)	(0.50, 0.88)	0.29 (0.14)	(0.02, 0.55)	0.036 *
	Placebo	138	118 (85.5)	0.40 (0.10)	(0.21, 0.59)			
Week 8	Tezepelumab	137	117 (85.4)	0.84 (0.10)	(0.64, 1.04)	0.27 (0.14)	(-0.01, 0.55)	0.059
	Placebo	138	119 (86.2)	0.57 (0.10)	(0.37, 0.76)			
Week 12	Tezepelumab	137	116 (84.7)	1.03 (0.10)	(0.83, 1.23)	0.37 (0.14)	(0.09, 0.65)	0.011 *
	Placebo	138	115 (83.3)	0.66 (0.10)	(0.46, 0.86)			
Week 16	Tezepelumab	137	112 (81.8)	0.99 (0.10)	(0.79, 1.19)	0.38 (0.14)	(0.10, 0.67)	0.008 *
	Placebo	138	112 (81.2)	0.61 (0.10)	(0.41, 0.81)			
Week 20	Tezepelumab	137	107 (78.1)	1.09 (0.10)	(0.90, 1.29)	0.38 (0.14)	(0.10, 0.66)	0.008 *
	Placebo	138	109 (79.0)	0.72 (0.10)	(0.52, 0.91)			
Week 24	Tezepelumab	137	105 (76.6)	1.06 (0.10)	(0.86, 1.26)	0.26 (0.14)	(-0.03, 0.54)	0.076
	Placebo	138	106 (76.8)	0.80 (0.10)	(0.60, 1.00)			
Week 28	Tezepelumab	137	101 (73.7)	1.12 (0.11)	(0.91, 1.33)	0.38 (0.15)	(0.08, 0.68)	0.013 *
	Placebo	138	105 (76.1)	0.74 (0.11)	(0.53, 0.95)			
Week 32	Tezepelumab	137	104 (75.9)	1.07 (0.11)	(0.86, 1.28)	0.27 (0.15)	(-0.02, 0.57)	0.068
	Placebo	138	104 (75.4)	0.80 (0.10)	(0.59, 1.00)			
Week 36	Tezepelumab	137	104 (75.9)	1.18 (0.11)	(0.98, 1.39)	0.37 (0.15)	(0.07, 0.66)	0.014 *
	Placebo	138	103 (74.6)	0.82 (0.11)	(0.61, 1.02)			
Week 40	Tezepelumab	137	104 (75.9)	1.07 (0.11)	(0.85, 1.29)	0.23 (0.16)	(-0.08, 0.54)	0.146
	Placebo	138	105 (76.1)	0.84 (0.11)	(0.62, 1.06)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
DITT

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	137	102 (74.5)	1.16 (0.11)	(0.94, 1.38)	0.36 (0.16)	(0.05, 0.68)	0.023 *
	Placebo	138	103 (74.6)	0.79 (0.11)	(0.58, 1.01)			
Week 48	Tezepelumab	137	97 (70.8)	1.17 (0.11)	(0.96, 1.39)	0.37 (0.15)	(0.07, 0.67)	0.017 *
	Placebo	138	105 (76.1)	0.81 (0.11)	(0.60, 1.02)			
Week 52	Tezepelumab	137	41 (29.9)	1.12 (0.14)	(0.85, 1.39)	0.29 (0.19)	(-0.08, 0.67)	0.123
	Placebo	138	47 (34.1)	0.83 (0.13)	(0.57, 1.09)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QGC_IOMG0: Course of AQLQ+12 emotional function score
DITT



Note: DITT = Dossier Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QGC_IOMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	50	42 (84.0)	4.34 (1.17)	1.6	3.60	4.20	5.00	6.8	
			Placebo	44	41 (93.2)	4.41 (1.26)	1.0	3.60	4.40	5.20	7.0	
		Week 4	Tezepelumab	50	46 (92.0)	5.08 (1.28)	1.6	4.00	5.10	6.00	7.0	
			Placebo	44	41 (93.2)	4.89 (1.45)	1.6	3.80	5.20	6.00	7.0	
		Week 8	Tezepelumab	50	46 (92.0)	5.15 (1.29)	1.8	4.20	5.20	6.40	7.0	
			Placebo	44	42 (95.5)	5.04 (1.26)	3.0	4.00	4.80	6.00	7.0	
		Week 12	Tezepelumab	50	46 (92.0)	5.26 (1.28)	2.0	4.20	5.20	6.40	7.0	
			Placebo	44	42 (95.5)	5.11 (1.33)	1.8	4.20	5.10	6.20	7.0	
		Week 16	Tezepelumab	50	46 (92.0)	5.23 (1.26)	2.2	4.20	5.40	6.20	7.0	
			Placebo	44	42 (95.5)	4.99 (1.43)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	50	46 (92.0)	5.30 (1.34)	1.0	4.60	5.70	6.00	7.0	
			Placebo	44	42 (95.5)	5.05 (1.45)	1.0	4.00	5.10	6.20	7.0	
		Week 24	Tezepelumab	50	46 (92.0)	5.32 (1.31)	1.6	4.40	5.60	6.20	7.0	
			Placebo	44	42 (95.5)	5.10 (1.55)	1.0	4.00	5.60	6.20	7.0	
		Week 28	Tezepelumab	50	47 (94.0)	5.40 (1.12)	2.8	4.40	5.40	6.20	7.0	
			Placebo	44	43 (97.7)	5.14 (1.55)	1.0	4.00	5.40	6.40	7.0	
		Week 32	Tezepelumab	50	48 (96.0)	5.42 (1.22)	1.8	4.60	5.70	6.20	7.0	
			Placebo	44	43 (97.7)	5.13 (1.51)	1.0	4.00	5.60	6.40	7.0	
		Week 36	Tezepelumab	50	48 (96.0)	5.45 (1.28)	2.8	4.50	5.80	6.60	7.0	
			Placebo	44	43 (97.7)	5.20 (1.49)	1.6	4.00	5.60	6.60	7.0	
		Week 40	Tezepelumab	50	48 (96.0)	5.38 (1.27)	2.0	4.30	5.50	6.40	7.0	
			Placebo	44	43 (97.7)	5.23 (1.46)	1.6	4.00	5.40	6.60	7.0	
		Week 44	Tezepelumab	50	48 (96.0)	5.54 (1.25)	2.8	4.50	5.90	6.60	7.0	
			Placebo	44	43 (97.7)	5.27 (1.48)	1.8	4.00	5.60	6.60	7.0	
		Week 48	Tezepelumab	50	48 (96.0)	5.45 (1.27)	1.8	4.60	5.80	6.40	7.0	
			Placebo	44	43 (97.7)	5.29 (1.53)	1.4	4.00	5.80	6.80	7.0	
		Week 52	Tezepelumab	50	48 (96.0)	5.42 (1.20)	1.8	4.60	5.80	6.20	7.0	
			Placebo	44	43 (97.7)	5.27 (1.50)	2.0	4.00	5.80	6.80	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	50	41 (82.0)	0.75 (1.03)	-1.6	0.00	0.60	1.60	3.6	0.22 [-0.22, 0.65]
			Placebo	44	40 (90.9)	0.51 (1.20)	-2.8	0.00	0.50	1.30	3.0	
		Week 8	Tezepelumab	50	41 (82.0)	0.81 (1.23)	-1.4	-0.20	0.80	1.60	5.0	0.14 [-0.30, 0.57]
			Placebo	44	41 (93.2)	0.65 (1.21)	-1.8	0.00	0.40	1.40	4.0	
		Week 12	Tezepelumab	50	41 (82.0)	0.92 (1.25)	-1.6	0.40	0.80	1.60	5.4	0.16 [-0.27, 0.60]
			Placebo	44	41 (93.2)	0.71 (1.30)	-2.2	0.00	0.60	1.60	4.4	
		Week 16	Tezepelumab	50	41 (82.0)	0.93 (1.17)	-1.4	0.20	1.00	1.40	5.2	0.28 [-0.16, 0.71]
			Placebo	44	41 (93.2)	0.58 (1.34)	-3.4	0.00	0.60	1.40	4.4	
		Week 20	Tezepelumab	50	41 (82.0)	0.99 (1.19)	-0.8	0.20	1.00	1.60	5.2	0.28 [-0.15, 0.72]
			Placebo	44	41 (93.2)	0.64 (1.27)	-3.4	0.00	0.60	1.20	4.2	
		Week 24	Tezepelumab	50	41 (82.0)	1.02 (1.18)	-0.8	0.40	1.00	1.60	5.4	0.25 [-0.18, 0.69]
			Placebo	44	41 (93.2)	0.69 (1.42)	-3.4	0.00	0.80	1.40	4.2	
		Week 28	Tezepelumab	50	41 (82.0)	1.05 (1.15)	-0.8	0.20	1.00	1.60	5.4	0.27 [-0.17, 0.70]
			Placebo	44	41 (93.2)	0.70 (1.44)	-3.4	0.20	0.80	1.40	4.4	
		Week 32	Tezepelumab	50	41 (82.0)	1.06 (1.22)	-1.2	0.20	1.00	1.60	5.4	0.28 [-0.15, 0.72]
			Placebo	44	41 (93.2)	0.69 (1.38)	-3.4	-0.20	0.80	1.60	4.2	
		Week 36	Tezepelumab	50	41 (82.0)	1.09 (1.29)	-0.8	0.20	1.00	2.00	5.4	0.27 [-0.17, 0.70]
			Placebo	44	41 (93.2)	0.75 (1.29)	-2.0	0.00	0.60	1.60	3.8	
		Week 40	Tezepelumab	50	41 (82.0)	1.05 (1.24)	-1.0	0.00	0.80	2.00	5.4	0.20 [-0.23, 0.64]
			Placebo	44	41 (93.2)	0.80 (1.32)	-2.0	0.00	1.00	1.40	4.0	
		Week 44	Tezepelumab	50	41 (82.0)	1.16 (1.28)	-1.4	0.20	1.00	2.00	5.4	0.26 [-0.17, 0.70]
			Placebo	44	41 (93.2)	0.81 (1.33)	-2.2	0.00	1.00	1.80	3.6	
		Week 48	Tezepelumab	50	41 (82.0)	1.09 (1.30)	-1.4	0.20	1.00	2.00	5.4	0.19 [-0.24, 0.63]
			Placebo	44	41 (93.2)	0.83 (1.37)	-2.2	0.00	1.00	1.60	3.8	
		Week 52	Tezepelumab	50	41 (82.0)	1.04 (1.30)	-1.0	0.20	0.80	1.80	5.4	0.16 [-0.27, 0.59]
			Placebo	44	41 (93.2)	0.83 (1.34)	-2.0	0.00	1.00	1.40	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	87	81 (93.1)	4.33 (1.15)	1.4	3.80	4.40	5.20	6.4	
			Placebo	94	80 (85.1)	4.15 (1.22)	1.4	3.60	4.20	4.90	7.0	
		Week 4	Tezepelumab	87	80 (92.0)	4.92 (1.14)	1.2	4.00	5.00	5.80	7.0	
			Placebo	94	82 (87.2)	4.59 (1.24)	1.4	3.80	4.60	5.60	7.0	
		Week 8	Tezepelumab	87	82 (94.3)	5.18 (1.16)	2.0	4.40	5.00	6.00	7.0	
			Placebo	94	84 (89.4)	4.71 (1.33)	1.0	4.00	4.90	5.60	7.0	
		Week 12	Tezepelumab	87	82 (94.3)	5.41 (1.12)	2.8	4.40	5.50	6.40	7.0	
			Placebo	94	85 (90.4)	4.78 (1.31)	1.4	4.00	4.60	5.80	7.0	
		Week 16	Tezepelumab	87	82 (94.3)	5.36 (1.10)	2.6	4.40	5.60	6.20	7.0	
			Placebo	94	85 (90.4)	4.84 (1.35)	1.2	4.00	4.80	5.80	7.0	
		Week 20	Tezepelumab	87	83 (95.4)	5.40 (1.05)	2.8	4.40	5.60	6.40	7.0	
			Placebo	94	85 (90.4)	4.89 (1.25)	1.4	4.00	5.00	5.80	7.0	
		Week 24	Tezepelumab	87	83 (95.4)	5.36 (1.10)	2.8	4.40	5.40	6.40	7.0	
			Placebo	94	85 (90.4)	4.97 (1.18)	1.4	4.20	4.80	6.00	7.0	
		Week 28	Tezepelumab	87	84 (96.6)	5.44 (1.06)	2.8	4.60	5.60	6.30	7.0	
			Placebo	94	85 (90.4)	4.87 (1.31)	1.6	4.00	4.80	6.00	7.0	
		Week 32	Tezepelumab	87	84 (96.6)	5.38 (1.11)	2.4	4.40	5.60	6.30	7.0	
			Placebo	94	86 (91.5)	4.91 (1.31)	1.2	4.00	4.80	6.00	7.0	
		Week 36	Tezepelumab	87	84 (96.6)	5.51 (1.07)	2.8	4.70	5.60	6.20	7.0	
			Placebo	94	86 (91.5)	4.96 (1.24)	1.8	4.00	4.80	5.80	7.0	
		Week 40	Tezepelumab	87	84 (96.6)	5.39 (1.18)	1.8	4.60	5.40	6.40	7.0	
			Placebo	94	86 (91.5)	4.95 (1.30)	1.6	4.00	4.80	6.00	7.0	
		Week 44	Tezepelumab	87	84 (96.6)	5.46 (1.09)	2.6	4.70	5.50	6.40	7.0	
			Placebo	94	86 (91.5)	4.93 (1.38)	1.4	4.00	4.90	6.00	7.0	
		Week 48	Tezepelumab	87	84 (96.6)	5.49 (1.08)	2.6	4.60	5.60	6.40	7.0	
			Placebo	94	87 (92.6)	4.92 (1.28)	1.2	4.00	4.80	6.00	7.0	
		Week 52	Tezepelumab	87	84 (96.6)	5.48 (1.15)	2.6	4.60	5.60	6.40	7.0	
			Placebo	94	87 (92.6)	4.82 (1.37)	1.2	4.00	4.60	5.80	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	87	76 (87.4)	0.65 (1.29)	-4.2	0.00	0.60	1.60	3.8	0.20 [-0.12, 0.52]
			Placebo	94	79 (84.0)	0.42 (1.01)	-2.2	-0.20	0.40	1.00	3.6	
		Week 8	Tezepelumab	87	78 (89.7)	0.84 (1.26)	-2.2	0.20	0.70	1.60	4.4	0.22 [-0.09, 0.54]
			Placebo	94	79 (84.0)	0.56 (1.16)	-2.0	-0.20	0.60	1.20	3.4	
		Week 12	Tezepelumab	87	78 (89.7)	1.07 (1.24)	-2.4	0.20	1.00	2.00	3.8	0.33 [0.01, 0.64]
			Placebo	94	79 (84.0)	0.66 (1.24)	-2.0	0.00	0.80	1.40	4.4	
		Week 16	Tezepelumab	87	78 (89.7)	1.01 (1.24)	-2.8	0.00	1.00	2.00	4.0	0.25 [-0.06, 0.57]
			Placebo	94	79 (84.0)	0.70 (1.18)	-1.8	0.00	0.60	1.40	4.0	
		Week 20	Tezepelumab	87	78 (89.7)	1.09 (1.25)	-1.4	0.20	1.00	2.00	4.6	0.26 [-0.06, 0.57]
			Placebo	94	79 (84.0)	0.77 (1.22)	-2.2	0.00	0.80	1.40	5.2	
		Week 24	Tezepelumab	87	78 (89.7)	1.03 (1.29)	-1.4	0.00	0.80	2.00	4.6	0.15 [-0.17, 0.46]
			Placebo	94	79 (84.0)	0.85 (1.20)	-1.4	0.00	0.60	1.60	4.2	
		Week 28	Tezepelumab	87	78 (89.7)	1.10 (1.27)	-1.4	0.00	0.80	2.00	4.6	0.26 [-0.06, 0.57]
			Placebo	94	79 (84.0)	0.76 (1.38)	-2.2	-0.20	0.80	1.60	5.2	
		Week 32	Tezepelumab	87	78 (89.7)	1.04 (1.28)	-1.6	0.00	1.00	2.00	4.6	0.17 [-0.14, 0.48]
			Placebo	94	79 (84.0)	0.83 (1.27)	-1.4	-0.20	0.80	1.60	5.4	
		Week 36	Tezepelumab	87	78 (89.7)	1.18 (1.34)	-1.6	0.40	1.10	2.00	4.6	0.26 [-0.05, 0.58]
			Placebo	94	79 (84.0)	0.85 (1.21)	-1.4	0.00	0.60	1.60	4.2	
		Week 40	Tezepelumab	87	78 (89.7)	1.05 (1.33)	-2.4	0.00	1.00	2.00	4.6	0.14 [-0.17, 0.45]
			Placebo	94	79 (84.0)	0.86 (1.38)	-1.6	-0.20	0.80	1.60	5.4	
		Week 44	Tezepelumab	87	78 (89.7)	1.12 (1.26)	-1.4	0.20	1.20	1.80	4.6	0.22 [-0.09, 0.53]
			Placebo	94	79 (84.0)	0.82 (1.42)	-1.8	-0.20	0.80	1.40	5.2	
		Week 48	Tezepelumab	87	78 (89.7)	1.15 (1.25)	-1.4	0.20	1.20	2.00	4.6	0.26 [-0.05, 0.58]
			Placebo	94	79 (84.0)	0.82 (1.32)	-1.4	-0.20	0.60	1.60	5.0	
		Week 52	Tezepelumab	87	78 (89.7)	1.13 (1.27)	-1.6	0.00	1.20	2.00	4.6	0.31 [-0.00, 0.63]
			Placebo	94	79 (84.0)	0.70 (1.42)	-2.6	-0.40	0.60	1.40	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	114	103 (90.4)	4.33 (1.17)	1.4	3.60	4.40	5.20	6.8	
			Placebo	118	105 (89.0)	4.16 (1.23)	1.0	3.60	4.20	4.80	7.0	
		Week 4	Tezepelumab	114	106 (93.0)	5.03 (1.17)	1.2	4.00	5.00	6.00	7.0	
			Placebo	118	106 (89.8)	4.72 (1.29)	1.4	3.80	4.80	5.60	7.0	
		Week 8	Tezepelumab	114	108 (94.7)	5.21 (1.20)	2.0	4.50	5.20	6.20	7.0	
			Placebo	118	109 (92.4)	4.80 (1.34)	1.0	4.00	4.80	5.80	7.0	
		Week 12	Tezepelumab	114	108 (94.7)	5.43 (1.15)	2.6	4.50	5.50	6.40	7.0	
			Placebo	118	110 (93.2)	4.89 (1.34)	1.4	4.00	4.90	6.00	7.0	
		Week 16	Tezepelumab	114	108 (94.7)	5.38 (1.15)	2.6	4.40	5.60	6.20	7.0	
			Placebo	118	110 (93.2)	4.90 (1.41)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	114	108 (94.7)	5.46 (1.12)	2.4	4.60	5.60	6.40	7.0	
			Placebo	118	110 (93.2)	4.96 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	114	108 (94.7)	5.42 (1.14)	2.0	4.60	5.40	6.40	7.0	
			Placebo	118	110 (93.2)	5.02 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 28	Tezepelumab	114	110 (96.5)	5.49 (1.06)	2.8	4.60	5.60	6.40	7.0	
			Placebo	118	110 (93.2)	4.97 (1.43)	1.0	4.00	5.10	6.00	7.0	
		Week 32	Tezepelumab	114	111 (97.4)	5.47 (1.13)	2.4	4.60	5.80	6.40	7.0	
			Placebo	118	111 (94.1)	4.99 (1.40)	1.0	4.00	5.00	6.20	7.0	
		Week 36	Tezepelumab	114	111 (97.4)	5.54 (1.16)	2.8	4.60	5.80	6.60	7.0	
			Placebo	118	111 (94.1)	5.00 (1.34)	1.6	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	114	111 (97.4)	5.45 (1.18)	1.8	4.60	5.60	6.40	7.0	
			Placebo	118	111 (94.1)	5.07 (1.38)	1.6	4.00	5.00	6.40	7.0	
		Week 44	Tezepelumab	114	111 (97.4)	5.53 (1.13)	2.6	4.80	5.60	6.40	7.0	
			Placebo	118	111 (94.1)	5.04 (1.42)	1.4	4.00	5.20	6.20	7.0	
		Week 48	Tezepelumab	114	111 (97.4)	5.52 (1.13)	2.6	4.60	5.80	6.40	7.0	
			Placebo	118	112 (94.9)	5.01 (1.39)	1.2	4.00	4.90	6.10	7.0	
		Week 52	Tezepelumab	114	111 (97.4)	5.49 (1.13)	2.6	4.60	5.80	6.40	7.0	
			Placebo	118	112 (94.9)	4.99 (1.41)	1.2	4.00	4.80	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	114	99 (86.8)	0.72 (1.23)	-4.2	0.00	0.60	1.60	3.8	0.15 [-0.13, 0.43]
			Placebo	118	103 (87.3)	0.55 (1.01)	-2.8	0.00	0.60	1.20	3.6	
		Week 8	Tezepelumab	114	101 (88.6)	0.85 (1.26)	-2.2	0.00	0.80	1.60	5.0	0.17 [-0.11, 0.44]
			Placebo	118	104 (88.1)	0.65 (1.17)	-2.0	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	114	101 (88.6)	1.07 (1.23)	-2.4	0.20	1.00	1.80	5.4	0.25 [-0.02, 0.53]
			Placebo	118	104 (88.1)	0.76 (1.25)	-2.2	0.00	0.80	1.40	4.4	
		Week 16	Tezepelumab	114	101 (88.6)	1.02 (1.23)	-2.8	0.20	1.00	1.80	5.2	0.22 [-0.06, 0.49]
			Placebo	118	104 (88.1)	0.75 (1.24)	-3.4	0.20	0.80	1.40	4.4	
		Week 20	Tezepelumab	114	101 (88.6)	1.14 (1.24)	-1.4	0.20	1.00	2.00	5.2	0.25 [-0.02, 0.53]
			Placebo	118	104 (88.1)	0.82 (1.22)	-3.4	0.20	0.80	1.40	5.2	
		Week 24	Tezepelumab	114	101 (88.6)	1.09 (1.25)	-1.4	0.20	1.00	2.00	5.4	0.16 [-0.12, 0.43]
			Placebo	118	104 (88.1)	0.89 (1.29)	-3.4	0.00	0.80	1.60	4.2	
		Week 28	Tezepelumab	114	101 (88.6)	1.13 (1.23)	-1.4	0.20	0.80	2.00	5.4	0.22 [-0.05, 0.50]
			Placebo	118	104 (88.1)	0.84 (1.40)	-3.4	0.00	0.80	1.60	5.2	
		Week 32	Tezepelumab	114	101 (88.6)	1.10 (1.27)	-1.6	0.20	1.00	2.00	5.4	0.18 [-0.10, 0.45]
			Placebo	118	104 (88.1)	0.88 (1.31)	-3.4	0.00	0.90	1.60	5.4	
		Week 36	Tezepelumab	114	101 (88.6)	1.19 (1.36)	-1.6	0.20	1.00	2.00	5.4	0.25 [-0.03, 0.52]
			Placebo	118	104 (88.1)	0.88 (1.21)	-2.0	0.20	0.80	1.60	3.8	
		Week 40	Tezepelumab	114	101 (88.6)	1.11 (1.29)	-2.4	0.20	1.00	2.00	5.4	0.12 [-0.15, 0.40]
			Placebo	118	104 (88.1)	0.95 (1.34)	-2.0	0.00	1.00	1.70	5.4	
		Week 44	Tezepelumab	114	101 (88.6)	1.17 (1.25)	-1.4	0.40	1.20	2.00	5.4	0.19 [-0.08, 0.47]
			Placebo	118	104 (88.1)	0.92 (1.35)	-2.0	0.00	1.00	1.70	5.2	
		Week 48	Tezepelumab	114	101 (88.6)	1.16 (1.27)	-1.4	0.20	1.20	2.00	5.4	0.21 [-0.07, 0.48]
			Placebo	118	104 (88.1)	0.89 (1.31)	-2.2	0.00	0.80	1.60	5.0	
		Week 52	Tezepelumab	114	101 (88.6)	1.13 (1.28)	-1.6	0.20	1.20	2.00	5.4	0.19 [-0.08, 0.47]
			Placebo	118	104 (88.1)	0.87 (1.33)	-2.0	-0.10	0.80	1.50	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	4.33 (1.09)	1.6	3.90	4.10	5.00	6.8	
			Placebo	20	16 (80.0)	4.75 (1.14)	2.4	3.90	5.00	5.60	6.2	
		Week 4	Tezepelumab	23	20 (87.0)	4.67 (1.26)	1.6	4.00	4.80	5.80	6.6	
			Placebo	20	17 (85.0)	4.47 (1.45)	1.6	3.40	4.60	5.80	6.8	
		Week 8	Tezepelumab	23	20 (87.0)	4.91 (1.19)	1.8	4.20	4.80	5.60	7.0	
			Placebo	20	17 (85.0)	4.94 (1.13)	2.6	4.40	5.20	5.60	7.0	
		Week 12	Tezepelumab	23	20 (87.0)	4.96 (1.22)	2.0	4.30	4.90	6.00	7.0	
			Placebo	20	17 (85.0)	4.87 (1.21)	2.6	4.00	4.60	5.40	7.0	
		Week 16	Tezepelumab	23	20 (87.0)	4.94 (1.12)	2.2	4.30	4.50	5.90	7.0	
			Placebo	20	17 (85.0)	4.81 (1.15)	2.8	4.00	4.60	5.20	7.0	
		Week 20	Tezepelumab	23	21 (91.3)	4.86 (1.26)	1.0	4.20	4.80	6.00	7.0	
			Placebo	20	17 (85.0)	4.85 (1.15)	3.0	4.00	4.80	5.40	7.0	
		Week 24	Tezepelumab	23	21 (91.3)	4.95 (1.27)	1.6	4.20	4.60	5.80	7.0	
			Placebo	20	17 (85.0)	4.92 (1.02)	3.2	4.20	4.80	5.20	6.8	
		Week 28	Tezepelumab	23	21 (91.3)	5.11 (1.11)	2.8	4.20	5.00	6.00	7.0	
			Placebo	20	18 (90.0)	4.94 (1.22)	3.2	4.00	4.60	5.40	7.0	
		Week 32	Tezepelumab	23	21 (91.3)	5.01 (1.18)	1.8	4.20	5.00	6.00	7.0	
			Placebo	20	18 (90.0)	5.00 (1.24)	3.0	4.20	4.70	6.00	7.0	
		Week 36	Tezepelumab	23	21 (91.3)	5.23 (1.06)	2.8	4.40	5.20	6.00	6.8	
			Placebo	20	18 (90.0)	5.24 (1.31)	3.0	4.40	5.10	6.60	7.0	
		Week 40	Tezepelumab	23	21 (91.3)	5.02 (1.29)	2.4	4.00	5.00	6.00	7.0	
			Placebo	20	18 (90.0)	4.90 (1.28)	2.8	4.00	4.80	5.60	7.0	
		Week 44	Tezepelumab	23	21 (91.3)	5.27 (1.24)	3.0	4.20	5.00	6.40	7.0	
			Placebo	20	18 (90.0)	5.06 (1.48)	2.8	3.60	5.00	6.60	7.0	
		Week 48	Tezepelumab	23	21 (91.3)	5.27 (1.27)	1.8	4.40	5.00	6.20	7.0	
			Placebo	20	18 (90.0)	5.22 (1.30)	3.2	4.00	4.90	6.60	7.0	
		Week 52	Tezepelumab	23	21 (91.3)	5.28 (1.31)	1.8	4.40	5.40	6.20	7.0	
			Placebo	20	18 (90.0)	4.80 (1.54)	2.2	3.60	4.70	5.80	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	23	18 (78.3)	0.48 (1.08)	-1.6	0.00	0.50	0.80	2.6	0.61 [-0.08, 1.30]
			Placebo	20	16 (80.0)	-0.24 (1.26)	-2.2	-1.60	0.10	0.60	1.8	
		Week 8	Tezepelumab	23	18 (78.3)	0.72 (1.18)	-1.2	0.20	0.40	1.60	3.0	0.40 [-0.28, 1.08]
			Placebo	20	16 (80.0)	0.25 (1.19)	-1.6	-0.70	0.20	1.20	2.0	
		Week 12	Tezepelumab	23	18 (78.3)	0.71 (1.29)	-1.6	-0.20	0.40	1.00	3.0	0.47 [-0.22, 1.15]
			Placebo	20	16 (80.0)	0.14 (1.15)	-1.8	-0.80	0.30	1.00	2.0	
		Week 16	Tezepelumab	23	18 (78.3)	0.76 (1.10)	-1.0	0.00	0.60	1.40	3.0	0.65 [-0.05, 1.34]
			Placebo	20	16 (80.0)	0.08 (1.00)	-1.6	-0.80	0.10	0.70	2.0	
		Week 20	Tezepelumab	23	18 (78.3)	0.59 (1.08)	-0.8	-0.40	0.60	1.00	3.0	0.44 [-0.25, 1.12]
			Placebo	20	16 (80.0)	0.10 (1.16)	-2.2	-0.80	0.10	0.80	2.0	
		Week 24	Tezepelumab	23	18 (78.3)	0.69 (1.24)	-1.4	0.00	0.40	1.80	3.0	0.44 [-0.24, 1.13]
			Placebo	20	16 (80.0)	0.18 (1.05)	-1.4	-0.80	0.20	0.70	2.4	
		Week 28	Tezepelumab	23	18 (78.3)	0.82 (1.20)	-1.0	0.00	0.70	2.00	3.0	0.60 [-0.08, 1.29]
			Placebo	20	16 (80.0)	0.10 (1.18)	-2.2	-0.60	0.10	1.10	2.0	
		Week 32	Tezepelumab	23	18 (78.3)	0.73 (1.14)	-1.0	0.00	0.40	1.20	3.0	0.51 [-0.18, 1.19]
			Placebo	20	16 (80.0)	0.16 (1.10)	-1.4	-0.70	-0.20	1.00	2.0	
		Week 36	Tezepelumab	23	18 (78.3)	0.91 (1.04)	-0.8	0.40	0.90	1.60	3.2	0.42 [-0.26, 1.10]
			Placebo	20	16 (80.0)	0.41 (1.34)	-1.0	-0.50	0.20	1.10	4.2	
		Week 40	Tezepelumab	23	18 (78.3)	0.69 (1.31)	-1.2	-0.20	0.90	1.20	3.4	0.48 [-0.20, 1.17]
			Placebo	20	16 (80.0)	0.06 (1.28)	-1.6	-0.80	-0.10	0.80	3.2	
		Week 44	Tezepelumab	23	18 (78.3)	0.91 (1.31)	-1.0	-0.20	0.90	1.80	3.2	0.53 [-0.15, 1.22]
			Placebo	20	16 (80.0)	0.16 (1.49)	-2.2	-0.60	-0.30	0.80	4.2	
		Week 48	Tezepelumab	23	18 (78.3)	0.96 (1.24)	-0.8	-0.20	1.00	2.00	3.4	0.46 [-0.23, 1.14]
			Placebo	20	16 (80.0)	0.35 (1.43)	-1.8	-0.60	0.20	1.10	4.0	
		Week 52	Tezepelumab	23	18 (78.3)	0.92 (1.30)	-0.8	0.00	1.00	2.00	3.4	0.71 [0.01, 1.40]
			Placebo	20	16 (80.0)	-0.09 (1.55)	-2.6	-1.10	-0.40	0.90	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	105	94 (89.5)	4.44 (1.07)	1.6	4.00	4.40	5.20	6.8	
			Placebo	110	98 (89.1)	4.33 (1.19)	1.0	3.60	4.30	5.20	7.0	
		Week 4	Tezepelumab	105	96 (91.4)	4.98 (1.19)	1.6	4.00	5.00	6.00	7.0	
			Placebo	110	100 (90.9)	4.75 (1.34)	1.4	3.80	4.80	5.80	7.0	
		Week 8	Tezepelumab	105	97 (92.4)	5.16 (1.19)	1.8	4.40	5.20	6.00	7.0	
			Placebo	110	102 (92.7)	4.93 (1.30)	1.4	4.00	5.00	6.00	7.0	
		Week 12	Tezepelumab	105	97 (92.4)	5.33 (1.14)	2.0	4.40	5.20	6.40	7.0	
			Placebo	110	103 (93.6)	4.90 (1.35)	1.4	4.00	4.60	6.00	7.0	
		Week 16	Tezepelumab	105	97 (92.4)	5.32 (1.09)	2.2	4.40	5.40	6.00	7.0	
			Placebo	110	103 (93.6)	4.93 (1.34)	1.8	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	105	98 (93.3)	5.33 (1.16)	1.0	4.40	5.40	6.20	7.0	
			Placebo	110	103 (93.6)	5.00 (1.28)	1.8	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	105	98 (93.3)	5.33 (1.17)	1.6	4.40	5.40	6.20	7.0	
			Placebo	110	103 (93.6)	5.11 (1.27)	1.4	4.00	5.00	6.20	7.0	
		Week 28	Tezepelumab	105	99 (94.3)	5.39 (1.06)	2.8	4.40	5.40	6.20	7.0	
			Placebo	110	104 (94.5)	5.02 (1.33)	1.6	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	105	100 (95.2)	5.38 (1.16)	1.8	4.60	5.60	6.30	7.0	
			Placebo	110	104 (94.5)	5.06 (1.34)	1.2	4.00	5.10	6.20	7.0	
		Week 36	Tezepelumab	105	100 (95.2)	5.48 (1.15)	2.8	4.60	5.60	6.50	7.0	
			Placebo	110	104 (94.5)	5.19 (1.31)	1.8	4.00	5.20	6.40	7.0	
		Week 40	Tezepelumab	105	100 (95.2)	5.38 (1.19)	1.8	4.50	5.40	6.40	7.0	
			Placebo	110	104 (94.5)	5.13 (1.34)	1.6	4.00	5.00	6.40	7.0	
		Week 44	Tezepelumab	105	100 (95.2)	5.49 (1.12)	2.8	4.60	5.50	6.40	7.0	
			Placebo	110	104 (94.5)	5.16 (1.41)	1.4	4.00	5.20	6.60	7.0	
		Week 48	Tezepelumab	105	100 (95.2)	5.48 (1.13)	1.8	4.60	5.60	6.40	7.0	
			Placebo	110	105 (95.5)	5.16 (1.36)	1.2	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	105	100 (95.2)	5.47 (1.12)	1.8	4.60	5.60	6.40	7.0	
			Placebo	110	105 (95.5)	5.06 (1.43)	1.2	4.00	5.00	6.40	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	105	89 (84.8)	0.59 (1.05)	-1.8	0.00	0.60	1.40	3.8	0.15 [-0.14, 0.43]
			Placebo	110	98 (89.1)	0.44 (1.05)	-2.8	0.00	0.40	1.20	3.0	
		Week 8	Tezepelumab	105	90 (85.7)	0.73 (1.13)	-2.2	0.20	0.60	1.40	4.4	0.08 [-0.20, 0.37]
			Placebo	110	98 (89.1)	0.63 (1.14)	-1.8	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	105	90 (85.7)	0.91 (1.12)	-1.6	0.20	0.80	1.60	3.8	0.24 [-0.04, 0.53]
			Placebo	110	98 (89.1)	0.63 (1.21)	-2.2	0.00	0.60	1.40	4.4	
		Week 16	Tezepelumab	105	90 (85.7)	0.91 (1.02)	-1.0	0.20	0.80	1.40	4.0	0.24 [-0.04, 0.53]
			Placebo	110	98 (89.1)	0.64 (1.15)	-2.0	0.00	0.60	1.40	4.4	
		Week 20	Tezepelumab	105	90 (85.7)	0.94 (1.06)	-0.8	0.20	0.80	1.60	4.6	0.19 [-0.09, 0.48]
			Placebo	110	98 (89.1)	0.73 (1.12)	-2.2	0.00	0.60	1.20	4.2	
		Week 24	Tezepelumab	105	90 (85.7)	0.93 (1.11)	-1.4	0.20	0.80	1.60	4.6	0.08 [-0.20, 0.37]
			Placebo	110	98 (89.1)	0.83 (1.21)	-2.2	0.00	0.70	1.60	4.2	
		Week 28	Tezepelumab	105	90 (85.7)	0.96 (1.07)	-1.0	0.20	0.80	1.80	4.6	0.20 [-0.09, 0.49]
			Placebo	110	98 (89.1)	0.73 (1.28)	-2.2	0.00	0.80	1.40	5.2	
		Week 32	Tezepelumab	105	90 (85.7)	0.95 (1.15)	-1.6	0.20	1.00	1.60	4.6	0.15 [-0.14, 0.44]
			Placebo	110	98 (89.1)	0.77 (1.18)	-2.0	-0.20	0.70	1.40	4.2	
		Week 36	Tezepelumab	105	90 (85.7)	1.05 (1.19)	-1.0	0.20	1.00	2.00	4.6	0.13 [-0.15, 0.42]
			Placebo	110	98 (89.1)	0.89 (1.19)	-2.0	0.20	0.60	1.60	4.2	
		Week 40	Tezepelumab	105	90 (85.7)	0.96 (1.22)	-2.4	0.20	0.80	1.60	4.6	0.09 [-0.19, 0.38]
			Placebo	110	98 (89.1)	0.85 (1.26)	-2.0	0.00	0.80	1.40	5.2	
		Week 44	Tezepelumab	105	90 (85.7)	1.04 (1.17)	-1.4	0.20	1.00	1.80	4.6	0.13 [-0.15, 0.42]
			Placebo	110	98 (89.1)	0.87 (1.31)	-2.2	-0.20	1.00	1.60	5.2	
		Week 48	Tezepelumab	105	90 (85.7)	1.04 (1.14)	-1.4	0.20	1.00	1.80	4.6	0.14 [-0.14, 0.43]
			Placebo	110	98 (89.1)	0.87 (1.23)	-2.0	0.00	0.80	1.60	4.0	
		Week 52	Tezepelumab	105	90 (85.7)	1.02 (1.15)	-1.4	0.20	1.00	1.80	4.6	0.21 [-0.08, 0.49]
			Placebo	110	98 (89.1)	0.76 (1.31)	-2.6	-0.20	0.80	1.40	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	32	29 (90.6)	3.98 (1.33)	1.4	3.40	4.00	4.80	6.2	
			Placebo	28	23 (82.1)	3.83 (1.36)	1.4	3.00	3.80	4.40	7.0	
		Week 4	Tezepelumab	32	30 (93.8)	4.95 (1.20)	1.2	4.20	5.00	5.80	7.0	
			Placebo	28	23 (82.1)	4.43 (1.19)	1.6	3.60	4.60	5.00	6.6	
		Week 8	Tezepelumab	32	31 (96.9)	5.19 (1.25)	3.0	4.20	5.00	6.20	7.0	
			Placebo	28	24 (85.7)	4.36 (1.27)	1.0	3.70	4.70	5.20	6.4	
		Week 12	Tezepelumab	32	31 (96.9)	5.44 (1.27)	2.8	4.20	5.60	6.60	7.0	
			Placebo	28	24 (85.7)	4.87 (1.19)	1.8	4.00	4.80	6.00	6.6	
		Week 16	Tezepelumab	32	31 (96.9)	5.28 (1.37)	2.6	4.20	5.60	6.60	7.0	
			Placebo	28	24 (85.7)	4.71 (1.52)	1.0	4.10	4.60	5.80	7.0	
		Week 20	Tezepelumab	32	31 (96.9)	5.46 (1.18)	2.8	4.60	5.80	6.20	7.0	
			Placebo	28	24 (85.7)	4.70 (1.48)	1.0	4.00	5.00	5.80	6.8	
		Week 24	Tezepelumab	32	31 (96.9)	5.41 (1.21)	2.8	4.40	5.80	6.40	7.0	
			Placebo	28	24 (85.7)	4.57 (1.39)	1.0	3.90	4.50	5.50	7.0	
		Week 28	Tezepelumab	32	32 (100.0)	5.56 (1.15)	2.8	4.60	5.70	6.40	7.0	
			Placebo	28	24 (85.7)	4.70 (1.64)	1.0	3.60	4.50	6.10	7.0	
		Week 32	Tezepelumab	32	32 (100.0)	5.43 (1.12)	2.8	4.50	5.80	6.20	7.0	
			Placebo	28	25 (89.3)	4.68 (1.50)	1.0	4.00	4.60	6.00	6.8	
		Week 36	Tezepelumab	32	32 (100.0)	5.53 (1.16)	2.8	4.70	6.00	6.30	7.0	
			Placebo	28	25 (89.3)	4.39 (1.24)	1.6	4.00	4.40	4.80	6.6	
		Week 40	Tezepelumab	32	32 (100.0)	5.40 (1.27)	2.6	4.60	5.80	6.30	7.0	
			Placebo	28	25 (89.3)	4.67 (1.41)	1.6	3.60	4.60	5.60	6.8	
		Week 44	Tezepelumab	32	32 (100.0)	5.49 (1.25)	2.6	4.70	6.00	6.40	7.0	
			Placebo	28	25 (89.3)	4.55 (1.38)	1.6	3.60	4.60	5.40	6.8	
		Week 48	Tezepelumab	32	32 (100.0)	5.48 (1.22)	2.6	4.40	6.00	6.30	7.0	
			Placebo	28	25 (89.3)	4.55 (1.33)	1.4	4.00	4.40	5.40	6.8	
		Week 52	Tezepelumab	32	32 (100.0)	5.44 (1.30)	2.8	4.40	5.90	6.30	7.0	
			Placebo	28	25 (89.3)	4.56 (1.33)	1.8	3.80	4.40	5.60	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	32	28 (87.5)	0.96 (1.58)	-4.2	0.40	1.10	1.80	3.6	0.34 [-0.23, 0.91]
			Placebo	28	21 (75.0)	0.48 (1.19)	-2.0	-0.20	0.40	1.00	3.6	
		Week 8	Tezepelumab	32	29 (90.6)	1.14 (1.52)	-1.2	-0.20	1.00	2.00	5.0	0.49 [-0.07, 1.06]
			Placebo	28	22 (78.6)	0.43 (1.35)	-2.0	-0.40	0.00	1.20	3.4	
		Week 12	Tezepelumab	32	29 (90.6)	1.36 (1.54)	-2.4	0.20	1.20	2.20	5.4	0.30 [-0.26, 0.86]
			Placebo	28	22 (78.6)	0.91 (1.47)	-1.8	-0.20	0.80	2.00	4.4	
		Week 16	Tezepelumab	32	29 (90.6)	1.20 (1.68)	-2.8	-0.20	1.40	2.00	5.2	0.28 [-0.28, 0.84]
			Placebo	28	22 (78.6)	0.74 (1.59)	-3.4	0.20	0.80	1.60	4.0	
		Week 20	Tezepelumab	32	29 (90.6)	1.41 (1.62)	-1.4	0.00	1.40	2.40	5.2	0.42 [-0.14, 0.98]
			Placebo	28	22 (78.6)	0.73 (1.69)	-3.4	0.00	0.80	1.40	5.2	
		Week 24	Tezepelumab	32	29 (90.6)	1.34 (1.59)	-1.4	0.00	1.40	2.00	5.4	0.44 [-0.12, 1.01]
			Placebo	28	22 (78.6)	0.65 (1.55)	-3.4	0.00	0.70	1.60	4.2	
		Week 28	Tezepelumab	32	29 (90.6)	1.46 (1.57)	-1.4	0.00	1.40	2.40	5.4	0.38 [-0.18, 0.94]
			Placebo	28	22 (78.6)	0.81 (1.85)	-3.4	-0.60	1.00	2.00	4.8	
		Week 32	Tezepelumab	32	29 (90.6)	1.36 (1.51)	-1.4	0.00	1.40	2.20	5.4	0.33 [-0.23, 0.89]
			Placebo	28	22 (78.6)	0.82 (1.79)	-3.4	0.00	0.80	1.80	5.4	
		Week 36	Tezepelumab	32	29 (90.6)	1.45 (1.64)	-1.6	0.40	1.40	2.20	5.4	0.65 [0.08, 1.22]
			Placebo	28	22 (78.6)	0.45 (1.38)	-2.0	-0.60	0.60	1.60	3.2	
		Week 40	Tezepelumab	32	29 (90.6)	1.31 (1.51)	-1.4	0.00	1.40	2.00	5.4	0.33 [-0.23, 0.88]
			Placebo	28	22 (78.6)	0.78 (1.76)	-2.0	-0.80	0.90	1.80	5.4	
		Week 44	Tezepelumab	32	29 (90.6)	1.41 (1.51)	-1.4	0.20	1.40	2.40	5.4	0.52 [-0.04, 1.09]
			Placebo	28	22 (78.6)	0.57 (1.70)	-1.8	-1.00	0.80	1.60	4.2	
		Week 48	Tezepelumab	32	29 (90.6)	1.41 (1.57)	-1.4	0.00	1.40	2.20	5.4	0.49 [-0.07, 1.05]
			Placebo	28	22 (78.6)	0.61 (1.74)	-2.2	-0.60	0.50	1.40	5.0	
		Week 52	Tezepelumab	32	29 (90.6)	1.34 (1.60)	-1.6	-0.20	1.40	2.20	5.4	0.41 [-0.15, 0.97]
			Placebo	28	22 (78.6)	0.67 (1.74)	-1.6	-0.60	0.50	1.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.37 (1.14)	1.4	3.80	4.20	5.20	6.8	
			Placebo	123	106 (86.2)	4.38 (1.18)	1.0	3.60	4.20	5.20	7.0	
		Week 4	Tezepelumab	128	117 (91.4)	4.96 (1.21)	1.2	4.00	5.00	6.00	7.0	
			Placebo	123	109 (88.6)	4.77 (1.33)	1.4	3.80	4.80	5.80	7.0	
		Week 8	Tezepelumab	128	119 (93.0)	5.15 (1.20)	1.8	4.20	5.00	6.00	7.0	
			Placebo	123	112 (91.1)	4.91 (1.26)	1.4	4.00	4.90	5.80	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.34 (1.19)	2.0	4.40	5.40	6.40	7.0	
			Placebo	123	113 (91.9)	4.90 (1.35)	1.4	4.00	4.60	6.00	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.29 (1.16)	2.2	4.40	5.40	6.20	7.0	
			Placebo	123	113 (91.9)	4.93 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.32 (1.17)	1.0	4.40	5.50	6.20	7.0	
			Placebo	123	113 (91.9)	5.01 (1.29)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.31 (1.19)	1.6	4.40	5.40	6.20	7.0	
			Placebo	123	113 (91.9)	5.04 (1.32)	1.0	4.20	5.00	6.00	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.38 (1.09)	2.8	4.40	5.40	6.20	7.0	
			Placebo	123	114 (92.7)	4.94 (1.35)	1.0	4.00	4.80	6.00	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.35 (1.17)	1.8	4.40	5.60	6.20	7.0	
			Placebo	123	115 (93.5)	4.99 (1.36)	1.0	4.00	5.00	6.20	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.46 (1.16)	2.8	4.60	5.60	6.40	7.0	
			Placebo	123	115 (93.5)	5.10 (1.32)	1.6	4.00	5.20	6.20	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.33 (1.23)	1.8	4.40	5.40	6.20	7.0	
			Placebo	123	115 (93.5)	5.06 (1.33)	1.6	4.00	5.00	6.20	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.44 (1.17)	2.6	4.60	5.60	6.40	7.0	
			Placebo	123	115 (93.5)	5.07 (1.39)	1.4	4.00	5.20	6.20	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.44 (1.17)	1.8	4.60	5.60	6.40	7.0	
			Placebo	123	116 (94.3)	5.07 (1.35)	1.2	4.00	4.90	6.30	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.42 (1.18)	1.8	4.60	5.60	6.20	7.0	
			Placebo	123	116 (94.3)	5.00 (1.41)	1.2	4.00	4.80	6.10	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.62 (1.18)	-4.2	0.00	0.60	1.40	3.6	0.19 [-0.08, 0.46]
			Placebo	123	105 (85.4)	0.41 (1.04)	-2.8	-0.20	0.40	1.00	3.0	
		Week 8	Tezepelumab	128	111 (86.7)	0.77 (1.17)	-1.4	0.00	0.60	1.60	5.0	0.17 [-0.09, 0.44]
			Placebo	123	106 (86.2)	0.57 (1.13)	-1.8	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	128	111 (86.7)	0.95 (1.22)	-2.4	0.20	0.80	1.80	5.4	0.31 [0.05, 0.58]
			Placebo	123	106 (86.2)	0.58 (1.20)	-2.2	0.00	0.60	1.40	4.4	
		Week 16	Tezepelumab	128	111 (86.7)	0.92 (1.17)	-2.8	0.00	1.00	1.60	5.2	0.28 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.58 (1.15)	-3.4	0.00	0.60	1.20	4.4	
		Week 20	Tezepelumab	128	111 (86.7)	0.97 (1.16)	-1.4	0.20	0.80	1.80	5.2	0.25 [-0.02, 0.52]
			Placebo	123	106 (86.2)	0.69 (1.11)	-3.4	0.20	0.70	1.20	4.2	
		Week 24	Tezepelumab	128	111 (86.7)	0.96 (1.17)	-1.4	0.00	0.80	1.80	5.4	0.20 [-0.06, 0.47]
			Placebo	123	106 (86.2)	0.72 (1.22)	-3.4	0.00	0.60	1.40	4.2	
		Week 28	Tezepelumab	128	111 (86.7)	0.99 (1.15)	-1.4	0.00	0.80	1.80	5.4	0.33 [0.06, 0.60]
			Placebo	123	106 (86.2)	0.60 (1.25)	-3.4	0.00	0.60	1.20	4.4	
		Week 32	Tezepelumab	128	111 (86.7)	0.97 (1.21)	-1.6	0.00	1.00	1.80	5.4	0.25 [-0.02, 0.51]
			Placebo	123	106 (86.2)	0.68 (1.20)	-3.4	-0.20	0.60	1.40	4.2	
		Week 36	Tezepelumab	128	111 (86.7)	1.08 (1.28)	-1.6	0.20	1.00	2.00	5.4	0.25 [-0.01, 0.52]
			Placebo	123	106 (86.2)	0.76 (1.19)	-2.0	0.00	0.60	1.40	4.2	
		Week 40	Tezepelumab	128	111 (86.7)	0.96 (1.26)	-2.4	0.00	0.80	1.80	5.4	0.18 [-0.09, 0.45]
			Placebo	123	106 (86.2)	0.74 (1.23)	-2.0	-0.20	0.80	1.40	4.0	
		Week 44	Tezepelumab	128	111 (86.7)	1.04 (1.21)	-1.4	0.20	1.00	1.80	5.4	0.25 [-0.01, 0.52]
			Placebo	123	106 (86.2)	0.73 (1.26)	-2.2	-0.20	0.80	1.40	4.2	
		Week 48	Tezepelumab	128	111 (86.7)	1.05 (1.21)	-1.4	0.20	1.00	2.00	5.4	0.26 [-0.01, 0.53]
			Placebo	123	106 (86.2)	0.74 (1.22)	-2.2	0.00	0.80	1.40	4.0	
		Week 52	Tezepelumab	128	111 (86.7)	1.02 (1.22)	-1.6	0.00	1.00	1.80	5.4	0.28 [0.01, 0.55]
			Placebo	123	106 (86.2)	0.66 (1.29)	-2.6	-0.20	0.80	1.40	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	2.87 (1.01)	1.8	1.80	3.00	3.80	3.8	
			Placebo	6	6 (100.0)	2.90 (0.73)	2.0	2.60	2.80	3.00	4.2	
		Week 4	Tezepelumab	3	3 (100.0)	5.47 (0.81)	4.6	4.60	5.60	6.20	6.2	
			Placebo	6	5 (83.3)	3.68 (1.32)	2.2	2.80	3.60	4.20	5.6	
		Week 8	Tezepelumab	3	3 (100.0)	6.00 (1.11)	4.8	4.80	6.20	7.00	7.0	
			Placebo	6	5 (83.3)	3.52 (2.11)	1.0	2.20	3.00	5.60	5.8	
		Week 12	Tezepelumab	3	3 (100.0)	5.47 (1.40)	4.0	4.00	5.60	6.80	6.8	
			Placebo	6	5 (83.3)	4.08 (1.35)	2.6	3.60	3.60	4.40	6.2	
		Week 16	Tezepelumab	3	3 (100.0)	5.13 (1.70)	3.2	3.20	5.80	6.40	6.4	
			Placebo	6	5 (83.3)	3.56 (2.07)	1.2	2.00	3.40	5.00	6.2	
		Week 20	Tezepelumab	3	3 (100.0)	6.27 (0.81)	5.4	5.40	6.40	7.00	7.0	
			Placebo	6	5 (83.3)	3.68 (1.97)	1.4	2.20	3.60	5.00	6.2	
		Week 24	Tezepelumab	3	3 (100.0)	6.07 (0.31)	5.8	5.80	6.00	6.40	6.4	
			Placebo	6	5 (83.3)	4.20 (1.46)	2.2	3.60	4.40	4.60	6.2	
		Week 28	Tezepelumab	3	3 (100.0)	6.33 (0.70)	5.6	5.60	6.40	7.00	7.0	
			Placebo	6	5 (83.3)	3.88 (1.93)	1.6	2.20	4.40	5.00	6.2	
		Week 32	Tezepelumab	3	3 (100.0)	5.53 (0.76)	5.0	5.00	5.20	6.40	6.4	
			Placebo	6	5 (83.3)	3.88 (2.01)	1.6	2.00	4.40	5.20	6.2	
		Week 36	Tezepelumab	3	3 (100.0)	5.73 (0.99)	4.6	4.60	6.20	6.40	6.4	
			Placebo	6	5 (83.3)	4.12 (1.69)	1.8	3.20	4.40	5.00	6.2	
		Week 40	Tezepelumab	3	3 (100.0)	5.93 (0.50)	5.4	5.40	6.00	6.40	6.4	
			Placebo	6	5 (83.3)	3.84 (1.71)	1.6	3.00	4.00	4.40	6.2	
		Week 44	Tezepelumab	3	3 (100.0)	5.93 (0.50)	5.4	5.40	6.00	6.40	6.4	
			Placebo	6	5 (83.3)	4.52 (2.40)	1.6	2.40	5.20	6.60	6.8	
		Week 48	Tezepelumab	3	3 (100.0)	5.93 (0.50)	5.4	5.40	6.00	6.40	6.4	
			Placebo	6	5 (83.3)	4.80 (2.28)	1.8	3.00	5.60	6.80	6.8	
		Week 52	Tezepelumab	3	3 (100.0)	5.93 (0.50)	5.4	5.40	6.00	6.40	6.4	
			Placebo	6	5 (83.3)	4.68 (2.39)	1.8	2.60	5.20	6.80	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	2.60 (1.11)	1.6	1.60	2.40	3.80	3.8	1.53 [-0.14, 3.20]
			Placebo	6	5 (83.3)	0.60 (1.39)	-0.4	-0.20	0.00	0.60	3.0	
		Week 8	Tezepelumab	3	3 (100.0)	3.13 (1.30)	1.8	1.80	3.20	4.40	4.4	1.55 [-0.13, 3.23]
			Placebo	6	5 (83.3)	0.44 (1.92)	-2.0	-0.40	0.00	1.60	3.0	
		Week 12	Tezepelumab	3	3 (100.0)	2.60 (1.44)	1.0	1.00	3.00	3.80	3.8	1.54 [-0.14, 3.22]
			Placebo	6	5 (83.3)	1.00 (0.76)	0.0	0.60	1.00	1.40	2.0	
		Week 16	Tezepelumab	3	3 (100.0)	2.27 (1.92)	0.2	0.20	2.60	4.00	4.0	0.96 [-0.57, 2.49]
			Placebo	6	5 (83.3)	0.48 (1.84)	-1.8	-1.00	0.80	2.00	2.4	
		Week 20	Tezepelumab	3	3 (100.0)	3.40 (1.11)	2.4	2.40	3.20	4.60	4.6	1.79 [0.04, 3.55]
			Placebo	6	5 (83.3)	0.60 (1.74)	-1.6	-0.80	1.00	2.00	2.4	
		Week 24	Tezepelumab	3	3 (100.0)	3.20 (1.31)	2.0	2.00	3.00	4.60	4.6	1.66 [-0.05, 3.37]
			Placebo	6	5 (83.3)	1.12 (1.22)	-0.8	0.60	1.80	2.00	2.0	
		Week 28	Tezepelumab	3	3 (100.0)	3.47 (1.03)	2.6	2.60	3.20	4.60	4.6	1.71 [-0.01, 3.44]
			Placebo	6	5 (83.3)	0.80 (1.76)	-1.4	-0.80	1.80	2.00	2.4	
		Week 32	Tezepelumab	3	3 (100.0)	2.67 (1.75)	1.2	1.20	2.20	4.60	4.6	1.03 [-0.52, 2.57]
			Placebo	6	5 (83.3)	0.80 (1.85)	-1.4	-1.00	1.80	2.00	2.6	
		Week 36	Tezepelumab	3	3 (100.0)	2.87 (1.55)	1.6	1.60	2.40	4.60	4.6	1.20 [-0.38, 2.78]
			Placebo	6	5 (83.3)	1.04 (1.51)	-1.2	0.20	1.80	2.00	2.4	
		Week 40	Tezepelumab	3	3 (100.0)	3.07 (1.50)	1.6	1.60	3.00	4.60	4.6	1.58 [-0.11, 3.27]
			Placebo	6	5 (83.3)	0.76 (1.44)	-1.4	0.00	1.40	1.80	2.0	
		Week 44	Tezepelumab	3	3 (100.0)	3.07 (1.50)	1.6	1.60	3.00	4.60	4.6	0.77 [-0.72, 2.27]
			Placebo	6	5 (83.3)	1.44 (2.35)	-1.4	-0.60	2.40	2.60	4.2	
		Week 48	Tezepelumab	3	3 (100.0)	3.07 (1.50)	1.6	1.60	3.00	4.60	4.6	0.67 [-0.81, 2.15]
			Placebo	6	5 (83.3)	1.72 (2.24)	-1.2	0.00	2.60	3.00	4.2	
		Week 52	Tezepelumab	3	3 (100.0)	3.07 (1.50)	1.6	1.60	3.00	4.60	4.6	0.70 [-0.78, 2.19]
			Placebo	6	5 (83.3)	1.60 (2.33)	-1.2	-0.40	2.60	2.60	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	4.10 (1.31)	2.2	3.30	4.50	4.90	5.2	
			Placebo	6	6 (100.0)	4.17 (1.22)	1.8	4.20	4.40	5.00	5.2	
		Week 4	Tezepelumab	5	5 (100.0)	5.16 (1.00)	4.2	4.20	5.00	6.20	6.2	
			Placebo	6	6 (100.0)	4.57 (0.61)	3.6	4.20	4.70	5.00	5.2	
		Week 8	Tezepelumab	5	5 (100.0)	5.56 (0.82)	4.6	5.20	5.20	6.20	6.6	
			Placebo	6	6 (100.0)	4.70 (0.92)	3.4	4.00	4.80	5.20	6.0	
		Week 12	Tezepelumab	5	5 (100.0)	5.80 (0.86)	5.0	5.20	5.40	6.40	7.0	
			Placebo	6	6 (100.0)	5.07 (0.52)	4.2	5.00	5.10	5.20	5.8	
		Week 16	Tezepelumab	5	5 (100.0)	5.92 (0.74)	5.0	5.60	5.80	6.20	7.0	
			Placebo	6	6 (100.0)	5.20 (0.51)	4.4	5.00	5.20	5.60	5.8	
		Week 20	Tezepelumab	5	5 (100.0)	5.72 (1.04)	4.2	5.40	5.80	6.20	7.0	
			Placebo	6	6 (100.0)	4.70 (0.97)	3.2	4.20	4.70	5.60	5.8	
		Week 24	Tezepelumab	5	5 (100.0)	6.04 (0.71)	5.0	6.00	6.00	6.20	7.0	
			Placebo	6	6 (100.0)	5.13 (0.99)	3.4	5.00	5.10	6.00	6.2	
		Week 28	Tezepelumab	5	5 (100.0)	6.16 (0.48)	5.8	6.00	6.00	6.00	7.0	
			Placebo	6	6 (100.0)	6.00 (1.03)	5.0	5.00	6.00	7.00	7.0	
		Week 32	Tezepelumab	5	5 (100.0)	6.28 (0.50)	5.8	6.00	6.00	6.60	7.0	
			Placebo	6	6 (100.0)	5.53 (0.62)	5.0	5.00	5.40	5.80	6.6	
		Week 36	Tezepelumab	5	5 (100.0)	6.08 (0.83)	4.8	6.00	6.00	6.60	7.0	
			Placebo	6	6 (100.0)	5.03 (1.28)	3.0	4.80	5.00	5.40	7.0	
		Week 40	Tezepelumab	5	5 (100.0)	6.08 (0.72)	5.4	5.40	6.00	6.60	7.0	
			Placebo	6	6 (100.0)	5.43 (1.24)	4.4	4.40	4.90	7.00	7.0	
		Week 44	Tezepelumab	5	5 (100.0)	6.32 (0.54)	5.8	6.00	6.00	6.80	7.0	
			Placebo	6	6 (100.0)	5.20 (1.48)	3.6	4.00	4.80	7.00	7.0	
		Week 48	Tezepelumab	5	5 (100.0)	5.96 (0.96)	4.4	6.00	6.00	6.40	7.0	
			Placebo	6	6 (100.0)	4.97 (1.08)	4.0	4.20	4.80	5.00	7.0	
		Week 52	Tezepelumab	5	5 (100.0)	6.04 (1.02)	4.4	6.00	6.00	6.80	7.0	
			Placebo	6	6 (100.0)	4.83 (0.78)	4.0	4.20	4.80	5.00	6.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	1.30 (0.74)	0.4	0.70	1.40	1.90	2.0	1.14 [-0.24, 2.52]
			Placebo	6	6 (100.0)	0.40 (0.82)	-0.2	-0.20	0.00	1.00	1.8	
		Week 8	Tezepelumab	5	4 (80.0)	1.55 (0.89)	0.6	0.80	1.60	2.30	2.4	1.00 [-0.36, 2.35]
			Placebo	6	6 (100.0)	0.53 (1.09)	-1.0	-0.20	0.60	1.00	2.2	
		Week 12	Tezepelumab	5	4 (80.0)	1.90 (1.06)	0.8	1.00	1.90	2.80	3.0	0.81 [-0.51, 2.14]
			Placebo	6	6 (100.0)	0.90 (1.32)	-0.2	-0.20	0.80	0.80	3.4	
		Week 16	Tezepelumab	5	4 (80.0)	2.05 (1.15)	1.0	1.10	1.90	3.00	3.4	0.75 [-0.57, 2.07]
			Placebo	6	6 (100.0)	1.03 (1.47)	-0.2	0.00	0.60	1.40	3.8	
		Week 20	Tezepelumab	5	4 (80.0)	1.60 (1.62)	-0.4	0.30	1.80	2.90	3.2	0.60 [-0.70, 1.90]
			Placebo	6	6 (100.0)	0.53 (1.87)	-1.2	-0.80	0.20	0.80	4.0	
		Week 24	Tezepelumab	5	4 (80.0)	1.90 (1.59)	0.4	0.60	1.70	3.20	3.8	0.55 [-0.75, 1.84]
			Placebo	6	6 (100.0)	0.97 (1.78)	-1.0	-0.20	0.80	1.20	4.2	
		Week 28	Tezepelumab	5	4 (80.0)	2.10 (1.25)	0.8	1.10	2.00	3.10	3.6	0.16 [-1.11, 1.43]
			Placebo	6	6 (100.0)	1.83 (1.89)	-0.2	0.80	1.40	2.40	5.2	
		Week 32	Tezepelumab	5	4 (80.0)	2.10 (1.25)	0.8	1.10	2.00	3.10	3.6	0.57 [-0.73, 1.86]
			Placebo	6	6 (100.0)	1.37 (1.32)	0.0	0.60	1.10	1.60	3.8	
		Week 36	Tezepelumab	5	4 (80.0)	1.85 (1.65)	0.2	0.50	1.70	3.20	3.8	0.58 [-0.72, 1.87]
			Placebo	6	6 (100.0)	0.87 (1.74)	-1.4	-0.20	0.60	2.00	3.6	
		Week 40	Tezepelumab	5	4 (80.0)	1.85 (1.24)	0.8	0.80	1.70	2.90	3.2	0.32 [-0.96, 1.59]
			Placebo	6	6 (100.0)	1.27 (2.11)	-0.4	0.00	0.40	2.00	5.2	
		Week 44	Tezepelumab	5	4 (80.0)	2.10 (1.40)	0.6	1.00	2.00	3.20	3.8	0.54 [-0.75, 1.83]
			Placebo	6	6 (100.0)	1.03 (2.25)	-0.8	-0.20	0.00	2.00	5.2	
		Week 48	Tezepelumab	5	4 (80.0)	1.75 (1.79)	-0.2	0.30	1.70	3.20	3.8	0.59 [-0.70, 1.89]
			Placebo	6	6 (100.0)	0.80 (1.47)	-0.4	-0.20	0.10	2.00	3.2	
		Week 52	Tezepelumab	5	4 (80.0)	1.75 (1.79)	-0.2	0.30	1.70	3.20	3.8	0.70 [-0.61, 2.01]
			Placebo	6	6 (100.0)	0.67 (1.37)	-0.4	-0.20	0.10	1.20	3.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	3	3 (100.0)	2.13 (0.81)	1.4	1.40	2.00	3.00	3.0	
		Week 4	Tezepelumab	1	1 (100.0)	4.40	4.4	4.40	4.40	4.40	4.4	
			Placebo	3	3 (100.0)	3.80 (1.06)	3.0	3.00	3.40	5.00	5.0	
		Week 8	Tezepelumab	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
			Placebo	3	3 (100.0)	4.00 (1.74)	2.0	2.00	4.80	5.20	5.2	
		Week 12	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	3	3 (100.0)	5.47 (1.33)	4.0	4.00	5.80	6.60	6.6	
		Week 16	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	3	3 (100.0)	5.00 (1.73)	4.0	4.00	4.00	7.00	7.0	
		Week 20	Tezepelumab	1	1 (100.0)	5.80	5.8	5.80	5.80	5.80	5.8	
			Placebo	3	3 (100.0)	4.87 (1.55)	3.6	3.60	4.40	6.60	6.6	
		Week 24	Tezepelumab	1	1 (100.0)	4.00	4.0	4.00	4.00	4.00	4.0	
			Placebo	3	3 (100.0)	4.87 (1.10)	3.6	3.60	5.40	5.60	5.6	
		Week 28	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	3	3 (100.0)	5.60 (1.78)	3.6	3.60	6.20	7.00	7.0	
		Week 32	Tezepelumab	1	1 (100.0)	5.60	5.6	5.60	5.60	5.60	5.6	
			Placebo	3	3 (100.0)	5.47 (1.67)	3.6	3.60	6.00	6.80	6.8	
		Week 36	Tezepelumab	1	1 (100.0)	6.00	6.0	6.00	6.00	6.00	6.0	
			Placebo	3	3 (100.0)	4.20 (0.53)	3.6	3.60	4.40	4.60	4.6	
		Week 40	Tezepelumab	1	1 (100.0)	6.40	6.4	6.40	6.40	6.40	6.4	
			Placebo	3	3 (100.0)	5.67 (1.79)	3.6	3.60	6.60	6.80	6.8	
		Week 44	Tezepelumab	1	1 (100.0)	6.20	6.2	6.20	6.20	6.20	6.2	
			Placebo	3	3 (100.0)	4.73 (1.33)	3.6	3.60	4.40	6.20	6.2	
		Week 48	Tezepelumab	1	1 (100.0)	6.40	6.4	6.40	6.40	6.40	6.4	
			Placebo	3	3 (100.0)	4.53 (1.62)	3.6	3.60	3.60	6.40	6.4	
		Week 52	Tezepelumab	1	1 (100.0)	6.40	6.4	6.40	6.40	6.40	6.4	
			Placebo	3	3 (100.0)	4.53 (1.62)	3.6	3.60	3.60	6.40	6.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	-0.60	-0.6	-0.60	-0.60	-0.60	-0.6	NE
			Placebo	3	3 (100.0)	1.67 (1.81)	0.0	0.00	1.40	3.60	3.6	
		Week 8	Tezepelumab	1	1 (100.0)	-2.20	-2.2	-2.20	-2.20	-2.20	-2.2	NE
			Placebo	3	3 (100.0)	1.87 (1.72)	0.0	0.00	2.20	3.40	3.4	
		Week 12	Tezepelumab	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	NE
			Placebo	3	3 (100.0)	3.33 (1.22)	2.0	2.00	3.60	4.40	4.4	
		Week 16	Tezepelumab	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	NE
			Placebo	3	3 (100.0)	2.87 (1.03)	2.0	2.00	2.60	4.00	4.0	
		Week 20	Tezepelumab	1	1 (100.0)	0.80	0.8	0.80	0.80	0.80	0.8	NE
			Placebo	3	3 (100.0)	2.73 (2.14)	1.4	1.40	1.60	5.20	5.2	
		Week 24	Tezepelumab	1	1 (100.0)	-1.00	-1.0	-1.00	-1.00	-1.00	-1.0	NE
			Placebo	3	3 (100.0)	2.73 (1.33)	1.6	1.60	2.40	4.20	4.2	
		Week 28	Tezepelumab	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	NE
			Placebo	3	3 (100.0)	3.47 (1.67)	1.6	1.60	4.00	4.80	4.8	
		Week 32	Tezepelumab	1	1 (100.0)	0.60	0.6	0.60	0.60	0.60	0.6	NE
			Placebo	3	3 (100.0)	3.33 (1.92)	1.6	1.60	3.00	5.40	5.4	
		Week 36	Tezepelumab	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	NE
			Placebo	3	3 (100.0)	2.07 (0.99)	1.4	1.40	1.60	3.20	3.2	
		Week 40	Tezepelumab	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	NE
			Placebo	3	3 (100.0)	3.53 (1.90)	1.6	1.60	3.60	5.40	5.4	
		Week 44	Tezepelumab	1	1 (100.0)	1.20	1.2	1.20	1.20	1.20	1.2	NE
			Placebo	3	3 (100.0)	2.60 (0.87)	1.6	1.60	3.00	3.20	3.2	
		Week 48	Tezepelumab	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	NE
			Placebo	3	3 (100.0)	2.40 (2.31)	0.6	0.60	1.60	5.00	5.0	
		Week 52	Tezepelumab	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	NE
			Placebo	3	3 (100.0)	2.40 (2.31)	0.6	0.60	1.60	5.00	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	78	73 (93.6)	4.39 (1.15)	1.4	3.60	4.20	5.20	6.8	
			Placebo	80	68 (85.0)	4.66 (1.12)	1.6	3.90	4.60	5.50	7.0	
		Week 4	Tezepelumab	78	74 (94.9)	4.94 (1.21)	1.2	4.00	5.00	5.80	7.0	
			Placebo	80	69 (86.3)	4.93 (1.30)	1.4	3.80	4.80	6.00	7.0	
		Week 8	Tezepelumab	78	75 (96.2)	5.18 (1.16)	1.8	4.40	5.20	6.00	7.0	
			Placebo	80	71 (88.8)	5.03 (1.26)	1.4	4.00	5.00	6.00	7.0	
		Week 12	Tezepelumab	78	75 (96.2)	5.37 (1.12)	2.0	4.40	5.40	6.40	7.0	
			Placebo	80	72 (90.0)	5.03 (1.34)	1.4	4.20	5.00	6.20	7.0	
		Week 16	Tezepelumab	78	75 (96.2)	5.30 (1.14)	2.2	4.40	5.40	6.20	7.0	
			Placebo	80	72 (90.0)	5.06 (1.37)	1.0	4.10	5.00	6.00	7.0	
		Week 20	Tezepelumab	78	76 (97.4)	5.36 (1.14)	1.0	4.60	5.60	6.20	7.0	
			Placebo	80	72 (90.0)	5.19 (1.27)	1.0	4.40	5.00	6.30	7.0	
		Week 24	Tezepelumab	78	76 (97.4)	5.33 (1.13)	1.6	4.50	5.40	6.20	7.0	
			Placebo	80	72 (90.0)	5.12 (1.35)	1.0	4.20	5.20	6.20	7.0	
		Week 28	Tezepelumab	78	77 (98.7)	5.37 (1.04)	2.8	4.40	5.60	6.20	7.0	
			Placebo	80	73 (91.3)	5.12 (1.38)	1.0	4.00	5.40	6.20	7.0	
		Week 32	Tezepelumab	78	77 (98.7)	5.36 (1.16)	1.8	4.60	5.60	6.20	7.0	
			Placebo	80	74 (92.5)	5.11 (1.39)	1.0	4.00	5.10	6.20	7.0	
		Week 36	Tezepelumab	78	77 (98.7)	5.45 (1.14)	2.8	4.60	5.60	6.20	7.0	
			Placebo	80	74 (92.5)	5.23 (1.33)	1.6	4.20	5.40	6.40	7.0	
		Week 40	Tezepelumab	78	77 (98.7)	5.39 (1.15)	2.4	4.60	5.60	6.20	7.0	
			Placebo	80	74 (92.5)	5.21 (1.34)	1.6	4.20	5.20	6.40	7.0	
		Week 44	Tezepelumab	78	77 (98.7)	5.45 (1.18)	2.6	4.60	5.60	6.40	7.0	
			Placebo	80	74 (92.5)	5.26 (1.40)	1.4	4.20	5.40	6.60	7.0	
		Week 48	Tezepelumab	78	77 (98.7)	5.42 (1.20)	1.8	4.60	5.60	6.20	7.0	
			Placebo	80	75 (93.8)	5.22 (1.37)	1.2	4.00	5.20	6.40	7.0	
		Week 52	Tezepelumab	78	77 (98.7)	5.39 (1.21)	1.8	4.60	5.80	6.20	7.0	
			Placebo	80	75 (93.8)	5.24 (1.37)	1.2	4.20	5.40	6.60	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	78	71 (91.0)	0.58 (1.24)	-4.2	0.00	0.60	1.60	3.6	0.25 [-0.08, 0.59]
			Placebo	80	67 (83.8)	0.30 (1.04)	-2.8	-0.20	0.40	1.00	2.2	
		Week 8	Tezepelumab	78	72 (92.3)	0.77 (1.16)	-2.2	0.20	0.80	1.50	3.6	0.33 [-0.01, 0.66]
			Placebo	80	68 (85.0)	0.41 (1.05)	-1.8	-0.20	0.40	1.00	3.0	
		Week 12	Tezepelumab	78	72 (92.3)	0.96 (1.16)	-2.4	0.20	0.80	1.60	3.6	0.44 [0.10, 0.78]
			Placebo	80	68 (85.0)	0.45 (1.13)	-2.2	-0.20	0.50	1.20	3.0	
		Week 16	Tezepelumab	78	72 (92.3)	0.88 (1.15)	-2.8	0.00	1.00	1.60	3.4	0.38 [0.05, 0.72]
			Placebo	80	68 (85.0)	0.45 (1.08)	-3.4	0.00	0.60	1.10	2.8	
		Week 20	Tezepelumab	78	72 (92.3)	0.95 (1.17)	-1.4	0.00	0.90	1.60	4.4	0.33 [-0.01, 0.66]
			Placebo	80	68 (85.0)	0.59 (1.03)	-3.4	0.00	0.60	1.20	3.0	
		Week 24	Tezepelumab	78	72 (92.3)	0.91 (1.16)	-1.4	0.00	0.80	1.70	3.8	0.35 [0.02, 0.68]
			Placebo	80	68 (85.0)	0.51 (1.16)	-3.4	0.00	0.40	1.30	3.0	
		Week 28	Tezepelumab	78	72 (92.3)	0.98 (1.15)	-1.4	0.10	0.80	1.90	4.2	0.41 [0.07, 0.74]
			Placebo	80	68 (85.0)	0.50 (1.19)	-3.4	0.00	0.40	1.30	3.0	
		Week 32	Tezepelumab	78	72 (92.3)	0.95 (1.19)	-1.6	0.10	1.00	1.60	3.2	0.39 [0.05, 0.72]
			Placebo	80	68 (85.0)	0.51 (1.12)	-3.4	-0.20	0.60	1.20	2.6	
		Week 36	Tezepelumab	78	72 (92.3)	1.04 (1.32)	-1.6	0.00	1.00	1.90	4.4	0.34 [0.00, 0.67]
			Placebo	80	68 (85.0)	0.61 (1.17)	-2.0	-0.20	0.50	1.40	4.2	
		Week 40	Tezepelumab	78	72 (92.3)	0.99 (1.18)	-1.4	0.00	1.00	1.70	3.4	0.33 [-0.01, 0.66]
			Placebo	80	68 (85.0)	0.60 (1.19)	-2.0	-0.20	0.70	1.40	3.2	
		Week 44	Tezepelumab	78	72 (92.3)	1.03 (1.23)	-1.4	0.00	1.10	1.80	3.6	0.33 [-0.01, 0.66]
			Placebo	80	68 (85.0)	0.63 (1.23)	-2.2	-0.20	0.70	1.20	4.2	
		Week 48	Tezepelumab	78	72 (92.3)	1.01 (1.22)	-1.4	0.00	1.00	1.90	3.6	0.36 [0.03, 0.70]
			Placebo	80	68 (85.0)	0.58 (1.18)	-2.2	-0.20	0.60	1.40	4.0	
		Week 52	Tezepelumab	78	72 (92.3)	0.99 (1.22)	-1.6	0.00	1.00	1.80	3.6	0.31 [-0.03, 0.64]
			Placebo	80	68 (85.0)	0.62 (1.17)	-2.0	-0.10	0.70	1.40	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	3.47 (1.62)	1.4	1.80	3.80	4.80	6.0	
			Placebo	9	8 (88.9)	2.88 (1.06)	1.4	2.30	2.60	3.60	4.6	
		Week 4	Tezepelumab	10	8 (80.0)	5.65 (0.80)	4.6	5.00	5.60	6.20	7.0	
			Placebo	9	7 (77.8)	4.26 (1.33)	2.2	2.80	4.40	5.60	5.6	
		Week 8	Tezepelumab	10	9 (90.0)	5.78 (1.26)	3.0	5.40	6.00	6.60	7.0	
			Placebo	9	7 (77.8)	4.51 (2.09)	1.0	2.20	5.60	5.80	6.6	
		Week 12	Tezepelumab	10	9 (90.0)	5.69 (1.43)	2.8	5.60	6.00	6.80	7.0	
			Placebo	9	7 (77.8)	4.89 (1.62)	2.6	3.60	5.40	6.20	7.0	
		Week 16	Tezepelumab	10	9 (90.0)	5.51 (1.50)	2.8	5.60	6.00	6.40	7.0	
			Placebo	9	7 (77.8)	4.69 (1.99)	1.2	3.40	5.00	6.20	7.0	
		Week 20	Tezepelumab	10	9 (90.0)	5.96 (1.32)	2.8	5.60	6.40	6.80	7.0	
			Placebo	9	7 (77.8)	5.09 (1.96)	1.4	3.60	6.00	6.60	6.8	
		Week 24	Tezepelumab	10	9 (90.0)	5.71 (1.27)	2.8	5.20	6.00	6.40	7.0	
			Placebo	9	7 (77.8)	5.11 (1.54)	2.2	4.40	5.60	6.20	6.8	
		Week 28	Tezepelumab	10	10 (100.0)	5.96 (1.28)	2.8	5.60	6.20	7.00	7.0	
			Placebo	9	7 (77.8)	5.29 (1.61)	2.2	4.40	6.00	6.20	7.0	
		Week 32	Tezepelumab	10	10 (100.0)	5.52 (1.28)	2.8	5.00	5.80	6.40	7.0	
			Placebo	9	7 (77.8)	5.20 (1.81)	1.6	4.40	5.40	6.80	6.8	
		Week 36	Tezepelumab	10	10 (100.0)	5.62 (1.31)	2.8	4.80	6.10	6.40	7.0	
			Placebo	9	7 (77.8)	4.91 (1.59)	1.8	4.40	5.00	6.20	6.4	
		Week 40	Tezepelumab	10	10 (100.0)	5.72 (1.22)	2.8	5.40	6.00	6.40	7.0	
			Placebo	9	7 (77.8)	5.00 (1.81)	1.6	4.00	6.00	6.20	6.8	
		Week 44	Tezepelumab	10	10 (100.0)	5.82 (1.23)	2.8	5.40	6.10	6.40	7.0	
			Placebo	9	7 (77.8)	5.23 (1.80)	1.6	4.40	6.00	6.60	6.8	
		Week 48	Tezepelumab	10	10 (100.0)	5.80 (1.23)	2.8	5.40	6.00	6.40	7.0	
			Placebo	9	7 (77.8)	5.63 (1.76)	1.8	5.60	6.40	6.80	6.8	
		Week 52	Tezepelumab	10	10 (100.0)	5.88 (1.23)	2.8	5.40	6.00	6.80	7.0	
			Placebo	9	7 (77.8)	5.60 (1.79)	1.8	5.20	6.40	6.80	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	1.93 (1.55)	-1.2	1.50	1.90	3.00	3.8	0.40 [-0.63, 1.42]
			Placebo	9	7 (77.8)	1.26 (1.83)	-0.4	-0.20	0.00	3.00	3.6	
		Week 8	Tezepelumab	10	9 (90.0)	2.31 (1.69)	-0.6	1.60	2.00	3.20	5.0	0.42 [-0.58, 1.42]
			Placebo	9	7 (77.8)	1.51 (2.17)	-2.0	-0.40	1.60	3.40	4.0	
		Week 12	Tezepelumab	10	9 (90.0)	2.22 (1.66)	-0.2	1.40	2.00	3.00	5.4	0.19 [-0.80, 1.19]
			Placebo	9	7 (77.8)	1.89 (1.82)	0.0	0.60	1.00	4.40	4.4	
		Week 16	Tezepelumab	10	9 (90.0)	2.04 (1.75)	-0.4	1.20	2.00	2.60	5.2	0.20 [-0.79, 1.19]
			Placebo	9	7 (77.8)	1.69 (1.91)	-1.8	0.80	2.00	2.60	4.4	
		Week 20	Tezepelumab	10	9 (90.0)	2.49 (1.68)	-0.4	1.80	2.20	3.20	5.2	0.21 [-0.78, 1.20]
			Placebo	9	7 (77.8)	2.09 (2.22)	-1.6	1.00	2.00	4.20	5.2	
		Week 24	Tezepelumab	10	9 (90.0)	2.24 (1.92)	-0.8	1.40	2.00	3.00	5.4	0.07 [-0.92, 1.06]
			Placebo	9	7 (77.8)	2.11 (1.72)	-0.8	1.40	2.00	4.20	4.2	
		Week 28	Tezepelumab	10	9 (90.0)	2.40 (1.83)	-0.4	1.40	2.20	3.20	5.4	0.06 [-0.93, 1.05]
			Placebo	9	7 (77.8)	2.29 (1.89)	-0.8	1.40	2.00	4.40	4.8	
		Week 32	Tezepelumab	10	9 (90.0)	1.93 (2.00)	-0.6	1.20	1.60	2.20	5.4	-0.13 [-1.12, 0.86]
			Placebo	9	7 (77.8)	2.20 (2.22)	-1.4	0.80	2.00	4.20	5.4	
		Week 36	Tezepelumab	10	9 (90.0)	2.07 (2.00)	-1.0	1.40	2.00	2.40	5.4	0.08 [-0.91, 1.07]
			Placebo	9	7 (77.8)	1.91 (1.60)	-1.2	1.40	2.00	3.20	3.8	
		Week 40	Tezepelumab	10	9 (90.0)	2.18 (1.98)	-1.2	1.40	2.00	3.00	5.4	0.09 [-0.90, 1.08]
			Placebo	9	7 (77.8)	2.00 (2.08)	-1.4	1.40	1.80	3.40	5.4	
		Week 44	Tezepelumab	10	9 (90.0)	2.29 (1.89)	-1.0	1.40	2.00	3.00	5.4	0.03 [-0.96, 1.02]
			Placebo	9	7 (77.8)	2.23 (1.82)	-1.4	1.40	2.60	3.40	4.2	
		Week 48	Tezepelumab	10	9 (90.0)	2.27 (1.90)	-1.0	1.40	2.00	3.00	5.4	-0.18 [-1.17, 0.81]
			Placebo	9	7 (77.8)	2.63 (2.12)	-1.2	1.00	3.00	4.20	5.0	
		Week 52	Tezepelumab	10	9 (90.0)	2.31 (1.82)	-0.6	1.40	2.00	3.00	5.4	-0.15 [-1.14, 0.84]
			Placebo	9	7 (77.8)	2.60 (2.14)	-1.2	1.00	2.60	4.40	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	4.10 (1.31)	2.2	3.30	4.50	4.90	5.2	
			Placebo	6	6 (100.0)	4.17 (1.22)	1.8	4.20	4.40	5.00	5.2	
		Week 4	Tezepelumab	5	5 (100.0)	5.16 (1.00)	4.2	4.20	5.00	6.20	6.2	
			Placebo	6	6 (100.0)	4.57 (0.61)	3.6	4.20	4.70	5.00	5.2	
		Week 8	Tezepelumab	5	5 (100.0)	5.56 (0.82)	4.6	5.20	5.20	6.20	6.6	
			Placebo	6	6 (100.0)	4.70 (0.92)	3.4	4.00	4.80	5.20	6.0	
		Week 12	Tezepelumab	5	5 (100.0)	5.80 (0.86)	5.0	5.20	5.40	6.40	7.0	
			Placebo	6	6 (100.0)	5.07 (0.52)	4.2	5.00	5.10	5.20	5.8	
		Week 16	Tezepelumab	5	5 (100.0)	5.92 (0.74)	5.0	5.60	5.80	6.20	7.0	
			Placebo	6	6 (100.0)	5.20 (0.51)	4.4	5.00	5.20	5.60	5.8	
		Week 20	Tezepelumab	5	5 (100.0)	5.72 (1.04)	4.2	5.40	5.80	6.20	7.0	
			Placebo	6	6 (100.0)	4.70 (0.97)	3.2	4.20	4.70	5.60	5.8	
		Week 24	Tezepelumab	5	5 (100.0)	6.04 (0.71)	5.0	6.00	6.00	6.20	7.0	
			Placebo	6	6 (100.0)	5.13 (0.99)	3.4	5.00	5.10	6.00	6.2	
		Week 28	Tezepelumab	5	5 (100.0)	6.16 (0.48)	5.8	6.00	6.00	6.00	7.0	
			Placebo	6	6 (100.0)	6.00 (1.03)	5.0	5.00	6.00	7.00	7.0	
		Week 32	Tezepelumab	5	5 (100.0)	6.28 (0.50)	5.8	6.00	6.00	6.60	7.0	
			Placebo	6	6 (100.0)	5.53 (0.62)	5.0	5.00	5.40	5.80	6.6	
		Week 36	Tezepelumab	5	5 (100.0)	6.08 (0.83)	4.8	6.00	6.00	6.60	7.0	
			Placebo	6	6 (100.0)	5.03 (1.28)	3.0	4.80	5.00	5.40	7.0	
		Week 40	Tezepelumab	5	5 (100.0)	6.08 (0.72)	5.4	5.40	6.00	6.60	7.0	
			Placebo	6	6 (100.0)	5.43 (1.24)	4.4	4.40	4.90	7.00	7.0	
		Week 44	Tezepelumab	5	5 (100.0)	6.32 (0.54)	5.8	6.00	6.00	6.80	7.0	
			Placebo	6	6 (100.0)	5.20 (1.48)	3.6	4.00	4.80	7.00	7.0	
		Week 48	Tezepelumab	5	5 (100.0)	5.96 (0.96)	4.4	6.00	6.00	6.40	7.0	
			Placebo	6	6 (100.0)	4.97 (1.08)	4.0	4.20	4.80	5.00	7.0	
		Week 52	Tezepelumab	5	5 (100.0)	6.04 (1.02)	4.4	6.00	6.00	6.80	7.0	
			Placebo	6	6 (100.0)	4.83 (0.78)	4.0	4.20	4.80	5.00	6.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	1.30 (0.74)	0.4	0.70	1.40	1.90	2.0	1.14 [-0.24, 2.52]
			Placebo	6	6 (100.0)	0.40 (0.82)	-0.2	-0.20	0.00	1.00	1.8	
		Week 8	Tezepelumab	5	4 (80.0)	1.55 (0.89)	0.6	0.80	1.60	2.30	2.4	1.00 [-0.36, 2.35]
			Placebo	6	6 (100.0)	0.53 (1.09)	-1.0	-0.20	0.60	1.00	2.2	
		Week 12	Tezepelumab	5	4 (80.0)	1.90 (1.06)	0.8	1.00	1.90	2.80	3.0	0.81 [-0.51, 2.14]
			Placebo	6	6 (100.0)	0.90 (1.32)	-0.2	-0.20	0.80	0.80	3.4	
		Week 16	Tezepelumab	5	4 (80.0)	2.05 (1.15)	1.0	1.10	1.90	3.00	3.4	0.75 [-0.57, 2.07]
			Placebo	6	6 (100.0)	1.03 (1.47)	-0.2	0.00	0.60	1.40	3.8	
		Week 20	Tezepelumab	5	4 (80.0)	1.60 (1.62)	-0.4	0.30	1.80	2.90	3.2	0.60 [-0.70, 1.90]
			Placebo	6	6 (100.0)	0.53 (1.87)	-1.2	-0.80	0.20	0.80	4.0	
		Week 24	Tezepelumab	5	4 (80.0)	1.90 (1.59)	0.4	0.60	1.70	3.20	3.8	0.55 [-0.75, 1.84]
			Placebo	6	6 (100.0)	0.97 (1.78)	-1.0	-0.20	0.80	1.20	4.2	
		Week 28	Tezepelumab	5	4 (80.0)	2.10 (1.25)	0.8	1.10	2.00	3.10	3.6	0.16 [-1.11, 1.43]
			Placebo	6	6 (100.0)	1.83 (1.89)	-0.2	0.80	1.40	2.40	5.2	
		Week 32	Tezepelumab	5	4 (80.0)	2.10 (1.25)	0.8	1.10	2.00	3.10	3.6	0.57 [-0.73, 1.86]
			Placebo	6	6 (100.0)	1.37 (1.32)	0.0	0.60	1.10	1.60	3.8	
		Week 36	Tezepelumab	5	4 (80.0)	1.85 (1.65)	0.2	0.50	1.70	3.20	3.8	0.58 [-0.72, 1.87]
			Placebo	6	6 (100.0)	0.87 (1.74)	-1.4	-0.20	0.60	2.00	3.6	
		Week 40	Tezepelumab	5	4 (80.0)	1.85 (1.24)	0.8	0.80	1.70	2.90	3.2	0.32 [-0.96, 1.59]
			Placebo	6	6 (100.0)	1.27 (2.11)	-0.4	0.00	0.40	2.00	5.2	
		Week 44	Tezepelumab	5	4 (80.0)	2.10 (1.40)	0.6	1.00	2.00	3.20	3.8	0.54 [-0.75, 1.83]
			Placebo	6	6 (100.0)	1.03 (2.25)	-0.8	-0.20	0.00	2.00	5.2	
		Week 48	Tezepelumab	5	4 (80.0)	1.75 (1.79)	-0.2	0.30	1.70	3.20	3.8	0.59 [-0.70, 1.89]
			Placebo	6	6 (100.0)	0.80 (1.47)	-0.4	-0.20	0.10	2.00	3.2	
		Week 52	Tezepelumab	5	4 (80.0)	1.75 (1.79)	-0.2	0.30	1.70	3.20	3.8	0.70 [-0.61, 2.01]
			Placebo	6	6 (100.0)	0.67 (1.37)	-0.4	-0.20	0.10	1.20	3.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	44	37 (84.1)	4.46 (0.94)	2.0	4.00	4.40	5.00	6.8	
			Placebo	43	39 (90.7)	3.78 (1.12)	1.0	3.00	3.80	4.40	7.0	
		Week 4	Tezepelumab	44	39 (88.6)	4.88 (1.22)	2.8	4.00	4.80	6.00	7.0	
			Placebo	43	41 (95.3)	4.38 (1.36)	1.6	3.60	4.20	5.00	7.0	
		Week 8	Tezepelumab	44	39 (88.6)	4.95 (1.29)	2.0	4.20	4.80	6.00	7.0	
			Placebo	43	42 (97.7)	4.54 (1.27)	1.8	3.80	4.60	5.20	7.0	
		Week 12	Tezepelumab	44	39 (88.6)	5.20 (1.25)	2.6	4.20	4.80	6.20	7.0	
			Placebo	43	42 (97.7)	4.63 (1.30)	2.0	4.00	4.40	5.80	7.0	
		Week 16	Tezepelumab	44	39 (88.6)	5.21 (1.16)	3.2	4.20	4.80	6.20	7.0	
			Placebo	43	42 (97.7)	4.58 (1.33)	2.0	3.80	4.60	5.60	7.0	
		Week 20	Tezepelumab	44	39 (88.6)	5.18 (1.16)	2.4	4.40	5.00	6.00	7.0	
			Placebo	43	42 (97.7)	4.53 (1.25)	2.2	4.00	4.40	5.60	7.0	
		Week 24	Tezepelumab	44	39 (88.6)	5.20 (1.26)	2.0	4.00	5.00	6.40	7.0	
			Placebo	43	42 (97.7)	4.79 (1.24)	2.6	4.00	4.60	5.60	7.0	
		Week 28	Tezepelumab	44	39 (88.6)	5.30 (1.10)	3.4	4.40	5.00	6.40	7.0	
			Placebo	43	42 (97.7)	4.49 (1.30)	1.6	3.60	4.20	5.20	7.0	
		Week 32	Tezepelumab	44	40 (90.9)	5.32 (1.14)	3.0	4.20	5.60	6.30	7.0	
			Placebo	43	42 (97.7)	4.65 (1.31)	2.0	4.00	4.40	6.00	7.0	
		Week 36	Tezepelumab	44	40 (90.9)	5.46 (1.17)	3.4	4.40	5.60	6.60	7.0	
			Placebo	43	42 (97.7)	4.71 (1.28)	2.2	4.00	4.40	5.80	7.0	
		Week 40	Tezepelumab	44	40 (90.9)	5.21 (1.34)	1.8	4.20	5.00	6.50	7.0	
			Placebo	43	42 (97.7)	4.70 (1.31)	2.2	3.60	4.70	5.60	7.0	
		Week 44	Tezepelumab	44	40 (90.9)	5.39 (1.11)	3.6	4.40	5.10	6.40	7.0	
			Placebo	43	42 (97.7)	4.61 (1.34)	2.2	3.60	4.40	6.00	7.0	
		Week 48	Tezepelumab	44	40 (90.9)	5.45 (1.05)	3.6	4.60	5.20	6.30	7.0	
			Placebo	43	42 (97.7)	4.64 (1.30)	2.4	3.80	4.30	5.20	7.0	
		Week 52	Tezepelumab	44	40 (90.9)	5.41 (1.07)	3.6	4.50	5.00	6.50	7.0	
			Placebo	43	42 (97.7)	4.40 (1.37)	2.2	3.60	4.00	5.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	44	34 (77.3)	0.52 (0.90)	-1.2	0.00	0.60	1.00	2.2	-0.04 [-0.50, 0.42]
			Placebo	43	39 (90.7)	0.56 (0.95)	-2.2	0.00	0.60	1.20	2.8	
		Week 8	Tezepelumab	44	34 (77.3)	0.47 (1.04)	-1.4	-0.20	0.40	1.00	3.0	-0.26 [-0.72, 0.20]
			Placebo	43	39 (90.7)	0.75 (1.12)	-1.4	-0.20	0.80	1.60	3.2	
		Week 12	Tezepelumab	44	34 (77.3)	0.73 (1.12)	-1.6	0.20	0.50	1.80	3.0	-0.08 [-0.54, 0.38]
			Placebo	43	39 (90.7)	0.83 (1.23)	-2.0	0.00	1.00	1.80	3.6	
		Week 16	Tezepelumab	44	34 (77.3)	0.79 (1.03)	-1.4	0.00	0.60	1.60	3.0	0.01 [-0.45, 0.47]
			Placebo	43	39 (90.7)	0.78 (1.24)	-1.6	0.20	1.00	1.60	4.0	
		Week 20	Tezepelumab	44	34 (77.3)	0.84 (0.93)	-0.6	0.20	0.70	1.40	3.0	0.08 [-0.38, 0.54]
			Placebo	43	39 (90.7)	0.75 (1.14)	-2.2	0.20	0.80	1.60	3.2	
		Week 24	Tezepelumab	44	34 (77.3)	0.85 (1.00)	-1.4	0.00	0.80	1.60	3.0	-0.17 [-0.63, 0.29]
			Placebo	43	39 (90.7)	1.03 (1.16)	-1.0	0.20	1.00	1.80	3.4	
		Week 28	Tezepelumab	44	34 (77.3)	0.85 (0.94)	-1.0	0.00	0.80	1.60	3.0	0.11 [-0.35, 0.57]
			Placebo	43	39 (90.7)	0.72 (1.34)	-2.2	-0.20	1.00	1.20	4.0	
		Week 32	Tezepelumab	44	34 (77.3)	0.89 (1.04)	-1.2	0.00	0.80	1.80	3.0	-0.02 [-0.48, 0.44]
			Placebo	43	39 (90.7)	0.91 (1.25)	-1.2	-0.20	1.00	1.80	3.4	
		Week 36	Tezepelumab	44	34 (77.3)	1.06 (0.97)	-0.8	0.40	0.90	2.00	3.4	0.11 [-0.35, 0.57]
			Placebo	43	39 (90.7)	0.95 (1.11)	-1.0	0.20	0.80	1.60	3.6	
		Week 40	Tezepelumab	44	34 (77.3)	0.78 (1.19)	-2.4	0.00	0.70	1.60	3.2	-0.15 [-0.61, 0.31]
			Placebo	43	39 (90.7)	0.96 (1.27)	-1.4	0.00	1.00	1.60	4.0	
		Week 44	Tezepelumab	44	34 (77.3)	0.91 (0.93)	-0.6	0.20	0.80	1.60	3.0	0.05 [-0.41, 0.51]
			Placebo	43	39 (90.7)	0.86 (1.30)	-1.8	-0.20	0.80	1.80	3.6	
		Week 48	Tezepelumab	44	34 (77.3)	1.01 (0.93)	-0.6	0.40	0.80	1.80	3.0	0.08 [-0.38, 0.54]
			Placebo	43	39 (90.7)	0.92 (1.18)	-1.2	0.00	0.80	1.60	3.8	
		Week 52	Tezepelumab	44	34 (77.3)	0.93 (1.02)	-1.0	0.20	0.80	1.80	3.0	0.23 [-0.23, 0.69]
			Placebo	43	39 (90.7)	0.64 (1.40)	-2.6	-0.40	0.60	1.60	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Placebo	1	1 (100.0)	1.60	1.6	1.60	1.60	1.60	1.6	
		Week 4	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 8	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 12	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 16	Placebo	1	1 (100.0)	1.80	1.8	1.80	1.80	1.80	1.8	
		Week 20	Placebo	1	1 (100.0)	1.80	1.8	1.80	1.80	1.80	1.8	
		Week 24	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 28	Placebo	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	
		Week 32	Placebo	1	1 (100.0)	1.20	1.2	1.20	1.20	1.20	1.2	
		Week 36	Placebo	1	1 (100.0)	1.80	1.8	1.80	1.80	1.80	1.8	
		Week 40	Placebo	1	1 (100.0)	1.60	1.6	1.60	1.60	1.60	1.6	
		Week 44	Placebo	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	
		Week 48	Placebo	1	1 (100.0)	1.20	1.2	1.20	1.20	1.20	1.2	
		Week 52	Placebo	1	1 (100.0)	1.20	1.2	1.20	1.20	1.20	1.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 4	Placebo	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	
		Week 8	Placebo	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	
		Week 12	Placebo	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	
		Week 16	Placebo	1	1 (100.0)	0.20	0.2	0.20	0.20	0.20	0.2	
		Week 20	Placebo	1	1 (100.0)	0.20	0.2	0.20	0.20	0.20	0.2	
		Week 24	Placebo	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	
		Week 28	Placebo	1	1 (100.0)	0.40	0.4	0.40	0.40	0.40	0.4	
		Week 32	Placebo	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	
		Week 36	Placebo	1	1 (100.0)	0.20	0.2	0.20	0.20	0.20	0.2	
		Week 40	Placebo	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 44	Placebo	1	1 (100.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	
		Week 48	Placebo	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	
		Week 52	Placebo	1	1 (100.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	39	35 (89.7)	4.38 (1.19)	1.8	3.60	4.20	5.20	6.6	
			Placebo	43	38 (88.4)	4.24 (1.32)	1.0	3.40	4.40	5.00	7.0	
		Week 4	Tezepelumab	39	36 (92.3)	5.45 (1.09)	3.2	4.40	5.60	6.30	7.0	
			Placebo	43	40 (93.0)	4.77 (1.24)	1.6	3.90	4.80	5.60	7.0	
		Week 8	Tezepelumab	39	37 (94.9)	5.56 (1.01)	3.2	4.80	5.60	6.40	7.0	
			Placebo	43	40 (93.0)	5.11 (1.25)	1.8	4.00	5.00	6.10	7.0	
		Week 12	Tezepelumab	39	37 (94.9)	5.88 (0.95)	3.8	5.20	6.00	6.80	7.0	
			Placebo	43	40 (93.0)	5.16 (1.30)	2.0	4.20	5.20	6.20	7.0	
		Week 16	Tezepelumab	39	37 (94.9)	5.71 (0.93)	4.0	5.00	6.00	6.60	7.0	
			Placebo	43	40 (93.0)	5.19 (1.37)	2.2	4.10	5.50	6.20	7.0	
		Week 20	Tezepelumab	39	37 (94.9)	5.86 (0.89)	4.0	5.40	6.00	6.60	7.0	
			Placebo	43	40 (93.0)	5.19 (1.35)	2.2	4.20	5.50	6.10	7.0	
		Week 24	Tezepelumab	39	37 (94.9)	5.92 (0.84)	3.4	5.40	6.00	6.40	7.0	
			Placebo	43	40 (93.0)	5.31 (1.34)	2.6	4.40	5.70	6.40	7.0	
		Week 28	Tezepelumab	39	37 (94.9)	5.87 (0.83)	4.2	5.20	6.00	6.40	7.0	
			Placebo	43	41 (95.3)	5.27 (1.41)	2.6	4.00	5.60	6.60	7.0	
		Week 32	Tezepelumab	39	38 (97.4)	5.80 (1.04)	2.4	5.40	6.00	6.60	7.0	
			Placebo	43	41 (95.3)	5.29 (1.34)	2.2	4.40	5.60	6.20	7.0	
		Week 36	Tezepelumab	39	38 (97.4)	6.07 (0.95)	3.0	5.60	6.10	7.00	7.0	
			Placebo	43	41 (95.3)	5.22 (1.44)	2.2	4.00	5.20	6.60	7.0	
		Week 40	Tezepelumab	39	38 (97.4)	5.95 (0.93)	4.0	5.20	6.00	6.80	7.0	
			Placebo	43	41 (95.3)	5.32 (1.34)	2.2	4.20	5.40	6.60	7.0	
		Week 44	Tezepelumab	39	38 (97.4)	6.02 (0.83)	4.0	5.40	6.20	6.80	7.0	
			Placebo	43	41 (95.3)	5.26 (1.40)	2.2	4.20	5.60	6.60	7.0	
		Week 48	Tezepelumab	39	38 (97.4)	6.04 (0.86)	4.0	5.80	6.00	6.80	7.0	
			Placebo	43	42 (97.7)	5.21 (1.36)	2.4	4.20	5.10	6.60	7.0	
		Week 52	Tezepelumab	39	38 (97.4)	5.94 (0.88)	4.2	5.00	6.00	6.80	7.0	
			Placebo	43	42 (97.7)	5.12 (1.34)	2.6	4.00	4.90	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	39	33 (84.6)	1.19 (1.01)	-1.0	0.60	1.00	1.80	3.8	0.76 [0.28, 1.25]
			Placebo	43	38 (88.4)	0.51 (0.78)	-1.2	-0.20	0.50	1.00	2.2	
		Week 8	Tezepelumab	39	34 (87.2)	1.17 (1.12)	-0.6	0.60	1.00	2.20	4.4	0.25 [-0.21, 0.72]
			Placebo	43	38 (88.4)	0.90 (1.04)	-1.0	0.00	1.00	1.80	3.2	
		Week 12	Tezepelumab	39	34 (87.2)	1.48 (1.16)	-1.0	0.60	1.40	2.40	3.8	0.51 [0.04, 0.98]
			Placebo	43	38 (88.4)	0.92 (1.06)	-1.2	0.00	0.90	1.60	3.4	
		Week 16	Tezepelumab	39	34 (87.2)	1.32 (1.19)	-1.4	0.60	1.10	2.00	4.0	0.33 [-0.14, 0.80]
			Placebo	43	38 (88.4)	0.94 (1.12)	-1.6	0.20	1.00	1.60	3.8	
		Week 20	Tezepelumab	39	34 (87.2)	1.44 (1.18)	-0.6	0.60	1.20	2.40	4.6	0.42 [-0.05, 0.88]
			Placebo	43	38 (88.4)	0.94 (1.22)	-2.2	0.20	1.00	1.60	4.0	
		Week 24	Tezepelumab	39	34 (87.2)	1.51 (1.22)	-0.4	0.60	1.20	2.40	4.6	0.33 [-0.14, 0.80]
			Placebo	43	38 (88.4)	1.11 (1.18)	-1.2	0.20	1.20	2.00	4.2	
		Week 28	Tezepelumab	39	34 (87.2)	1.43 (1.19)	-0.4	0.60	1.10	2.20	4.6	0.30 [-0.17, 0.76]
			Placebo	43	38 (88.4)	1.04 (1.41)	-2.2	0.20	1.20	1.80	5.2	
		Week 32	Tezepelumab	39	34 (87.2)	1.34 (1.26)	-0.8	0.40	1.30	2.20	4.6	0.24 [-0.22, 0.71]
			Placebo	43	38 (88.4)	1.05 (1.13)	-1.4	0.40	1.10	1.60	3.8	
		Week 36	Tezepelumab	39	34 (87.2)	1.61 (1.36)	-1.0	0.60	1.30	2.80	4.6	0.50 [0.03, 0.97]
			Placebo	43	38 (88.4)	0.97 (1.17)	-1.4	0.20	0.90	1.80	3.6	
		Week 40	Tezepelumab	39	34 (87.2)	1.46 (1.27)	-0.6	0.60	1.10	2.60	4.6	0.29 [-0.18, 0.75]
			Placebo	43	38 (88.4)	1.09 (1.29)	-1.4	0.20	1.20	1.80	5.2	
		Week 44	Tezepelumab	39	34 (87.2)	1.52 (1.21)	-0.4	0.60	1.40	2.20	4.6	0.43 [-0.04, 0.89]
			Placebo	43	38 (88.4)	0.99 (1.27)	-1.8	0.20	1.10	1.60	5.2	
		Week 48	Tezepelumab	39	34 (87.2)	1.59 (1.22)	-0.6	0.60	1.80	2.20	4.6	0.57 [0.09, 1.04]
			Placebo	43	38 (88.4)	0.93 (1.14)	-1.4	0.00	1.00	1.80	3.2	
		Week 52	Tezepelumab	39	34 (87.2)	1.46 (1.35)	-1.0	0.60	1.60	2.20	4.6	0.47 [0.00, 0.94]
			Placebo	43	38 (88.4)	0.84 (1.26)	-2.6	0.00	1.00	1.60	3.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	45	41 (91.1)	4.26 (1.38)	1.4	3.60	4.40	5.00	6.8	
			Placebo	47	43 (91.5)	4.53 (1.15)	2.2	3.80	4.40	5.40	7.0	
		Week 4	Tezepelumab	45	43 (95.6)	5.03 (1.21)	1.6	4.00	5.00	6.00	7.0	
			Placebo	47	43 (91.5)	4.80 (1.41)	1.6	3.80	5.00	5.80	7.0	
		Week 8	Tezepelumab	45	43 (95.6)	5.18 (1.35)	1.8	4.00	5.40	6.20	7.0	
			Placebo	47	45 (95.7)	4.93 (1.21)	2.6	4.00	5.00	5.80	7.0	
		Week 12	Tezepelumab	45	43 (95.6)	5.37 (1.33)	2.0	4.20	5.60	6.60	7.0	
			Placebo	47	45 (95.7)	4.92 (1.31)	1.8	4.00	4.60	6.00	7.0	
		Week 16	Tezepelumab	45	43 (95.6)	5.44 (1.28)	2.2	4.20	5.80	6.60	7.0	
			Placebo	47	45 (95.7)	4.92 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	45	43 (95.6)	5.39 (1.34)	1.0	4.20	5.80	6.40	7.0	
			Placebo	47	45 (95.7)	5.03 (1.34)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	45	43 (95.6)	5.31 (1.32)	1.6	4.20	5.40	6.60	7.0	
			Placebo	47	45 (95.7)	5.01 (1.32)	1.0	4.00	5.00	6.00	7.0	
		Week 28	Tezepelumab	45	44 (97.8)	5.54 (1.19)	2.8	4.30	5.80	6.40	7.0	
			Placebo	47	45 (95.7)	4.95 (1.36)	1.0	4.00	4.80	6.00	7.0	
		Week 32	Tezepelumab	45	44 (97.8)	5.49 (1.25)	1.8	4.60	5.80	6.60	7.0	
			Placebo	47	45 (95.7)	4.97 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	45	44 (97.8)	5.54 (1.16)	2.8	4.40	5.80	6.50	7.0	
			Placebo	47	45 (95.7)	5.00 (1.26)	1.6	4.00	5.00	5.80	7.0	
		Week 40	Tezepelumab	45	44 (97.8)	5.45 (1.25)	2.4	4.40	5.50	6.50	7.0	
			Placebo	47	45 (95.7)	4.96 (1.29)	1.6	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	45	44 (97.8)	5.54 (1.27)	2.6	4.40	5.90	6.60	7.0	
			Placebo	47	45 (95.7)	5.14 (1.32)	1.8	4.00	5.20	6.00	7.0	
		Week 48	Tezepelumab	45	44 (97.8)	5.47 (1.23)	1.8	4.60	5.70	6.50	7.0	
			Placebo	47	45 (95.7)	5.10 (1.35)	1.4	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	45	44 (97.8)	5.48 (1.33)	1.8	4.50	5.80	6.80	7.0	
			Placebo	47	45 (95.7)	5.10 (1.39)	2.0	4.00	5.00	6.40	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	45	40 (88.9)	0.74 (1.20)	-1.6	0.00	0.50	1.60	3.6	0.35 [-0.08, 0.79]
			Placebo	47	42 (89.4)	0.30 (1.29)	-2.8	-0.20	0.30	1.00	3.0	
		Week 8	Tezepelumab	45	40 (88.9)	0.84 (1.29)	-1.4	0.20	0.60	1.80	5.0	0.31 [-0.12, 0.74]
			Placebo	47	43 (91.5)	0.46 (1.21)	-1.8	-0.20	0.40	1.20	4.0	
		Week 12	Tezepelumab	45	40 (88.9)	1.02 (1.38)	-1.6	0.20	0.80	1.90	5.4	0.44 [0.00, 0.88]
			Placebo	47	43 (91.5)	0.43 (1.29)	-2.2	-0.20	0.40	1.20	4.4	
		Week 16	Tezepelumab	45	40 (88.9)	1.08 (1.26)	-1.0	0.20	1.00	1.90	5.2	0.50 [0.07, 0.94]
			Placebo	47	43 (91.5)	0.43 (1.30)	-3.4	-0.40	0.40	1.20	4.4	
		Week 20	Tezepelumab	45	40 (88.9)	1.09 (1.39)	-0.8	0.00	1.10	2.00	5.2	0.40 [-0.03, 0.84]
			Placebo	47	43 (91.5)	0.55 (1.28)	-3.4	0.00	0.60	1.20	4.2	
		Week 24	Tezepelumab	45	40 (88.9)	0.99 (1.36)	-1.4	0.00	0.70	2.00	5.4	0.34 [-0.09, 0.78]
			Placebo	47	43 (91.5)	0.53 (1.28)	-3.4	-0.20	0.40	1.40	4.2	
		Week 28	Tezepelumab	45	40 (88.9)	1.21 (1.36)	-1.0	0.20	1.20	2.00	5.4	0.55 [0.11, 0.99]
			Placebo	47	43 (91.5)	0.48 (1.29)	-3.4	0.00	0.60	1.20	4.4	
		Week 32	Tezepelumab	45	40 (88.9)	1.18 (1.39)	-1.2	0.20	1.10	2.20	5.4	0.51 [0.07, 0.94]
			Placebo	47	43 (91.5)	0.50 (1.29)	-3.4	-0.20	0.40	1.40	4.2	
		Week 36	Tezepelumab	45	40 (88.9)	1.23 (1.45)	-1.0	0.20	1.30	2.00	5.4	0.54 [0.10, 0.98]
			Placebo	47	43 (91.5)	0.53 (1.16)	-2.0	-0.40	0.60	1.20	3.8	
		Week 40	Tezepelumab	45	40 (88.9)	1.13 (1.42)	-1.2	0.10	1.10	2.00	5.4	0.49 [0.05, 0.93]
			Placebo	47	43 (91.5)	0.50 (1.15)	-2.0	-0.40	0.60	1.20	3.4	
		Week 44	Tezepelumab	45	40 (88.9)	1.20 (1.39)	-1.0	0.20	1.40	2.00	5.4	0.38 [-0.05, 0.82]
			Placebo	47	43 (91.5)	0.68 (1.33)	-2.0	-0.20	0.60	1.40	4.2	
		Week 48	Tezepelumab	45	40 (88.9)	1.16 (1.35)	-1.0	0.10	1.20	2.10	5.4	0.40 [-0.04, 0.83]
			Placebo	47	43 (91.5)	0.63 (1.33)	-2.2	-0.20	0.60	1.40	4.2	
		Week 52	Tezepelumab	45	40 (88.9)	1.16 (1.35)	-0.8	0.10	1.30	2.10	5.4	0.40 [-0.03, 0.84]
			Placebo	47	43 (91.5)	0.62 (1.35)	-2.0	-0.40	0.80	1.40	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	53	47 (88.7)	4.35 (0.89)	1.4	3.80	4.20	5.20	6.2	
			Placebo	47	39 (83.0)	3.98 (1.14)	1.4	3.00	4.00	4.60	6.6	
		Week 4	Tezepelumab	53	47 (88.7)	4.57 (1.12)	1.2	3.80	4.40	5.60	7.0	
			Placebo	47	39 (83.0)	4.57 (1.21)	2.2	3.60	4.60	5.60	7.0	
		Week 8	Tezepelumab	53	48 (90.6)	4.85 (1.12)	2.6	4.10	4.80	5.60	7.0	
			Placebo	47	40 (85.1)	4.50 (1.33)	1.0	3.60	4.60	5.20	7.0	
		Week 12	Tezepelumab	53	48 (90.6)	4.95 (1.03)	2.8	4.20	4.80	5.70	7.0	
			Placebo	47	41 (87.2)	4.69 (1.24)	1.6	4.00	4.40	5.60	6.8	
		Week 16	Tezepelumab	53	48 (90.6)	4.88 (1.08)	2.6	4.20	4.90	5.70	7.0	
			Placebo	47	41 (87.2)	4.63 (1.30)	1.2	4.00	4.60	5.20	7.0	
		Week 20	Tezepelumab	53	49 (92.5)	4.96 (1.03)	2.4	4.40	4.80	5.80	7.0	
			Placebo	47	41 (87.2)	4.69 (1.16)	1.4	4.00	4.80	5.20	6.6	
		Week 24	Tezepelumab	53	49 (92.5)	4.94 (1.09)	2.0	4.20	5.20	5.80	7.0	
			Placebo	47	41 (87.2)	4.80 (1.13)	2.2	4.00	4.60	5.60	7.0	
		Week 28	Tezepelumab	53	50 (94.3)	5.00 (0.99)	2.8	4.20	5.00	5.60	7.0	
			Placebo	47	41 (87.2)	4.74 (1.34)	1.6	3.80	4.60	5.80	7.0	
		Week 32	Tezepelumab	53	50 (94.3)	5.00 (1.02)	2.6	4.20	5.00	6.00	6.6	
			Placebo	47	42 (89.4)	4.80 (1.31)	1.6	4.00	4.50	6.00	7.0	
		Week 36	Tezepelumab	53	50 (94.3)	5.00 (1.07)	2.8	4.40	5.00	5.80	7.0	
			Placebo	47	42 (89.4)	4.97 (1.22)	1.8	4.40	4.70	5.80	7.0	
		Week 40	Tezepelumab	53	50 (94.3)	4.90 (1.17)	1.8	4.00	5.00	5.80	6.8	
			Placebo	47	42 (89.4)	4.94 (1.36)	1.6	3.80	4.80	6.40	7.0	
		Week 44	Tezepelumab	53	50 (94.3)	5.05 (1.09)	2.8	4.20	5.00	6.00	7.0	
			Placebo	47	42 (89.4)	4.82 (1.44)	1.6	4.00	4.60	6.20	7.0	
		Week 48	Tezepelumab	53	50 (94.3)	5.05 (1.11)	2.6	4.40	5.10	6.00	7.0	
			Placebo	47	42 (89.4)	4.90 (1.31)	1.8	4.00	4.70	6.20	7.0	
		Week 52	Tezepelumab	53	50 (94.3)	5.07 (1.07)	2.6	4.40	5.20	5.80	7.0	
			Placebo	47	42 (89.4)	4.77 (1.44)	1.8	3.80	4.50	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	53	44 (83.0)	0.25 (1.20)	-4.2	-0.40	0.20	0.90	2.4	-0.27 [-0.71, 0.16]
			Placebo	47	38 (80.9)	0.56 (1.08)	-2.2	0.00	0.60	1.20	3.6	
		Week 8	Tezepelumab	53	45 (84.9)	0.56 (1.26)	-2.2	-0.20	0.40	1.40	3.6	0.08 [-0.35, 0.51]
			Placebo	47	38 (80.9)	0.46 (1.25)	-2.0	-0.40	0.40	1.20	3.4	
		Week 12	Tezepelumab	53	45 (84.9)	0.67 (1.07)	-2.4	0.00	0.40	1.20	3.4	-0.06 [-0.49, 0.37]
			Placebo	47	38 (80.9)	0.75 (1.38)	-2.0	0.00	0.60	1.40	4.4	
		Week 16	Tezepelumab	53	45 (84.9)	0.64 (1.12)	-2.8	-0.20	0.60	1.20	3.0	-0.01 [-0.44, 0.42]
			Placebo	47	38 (80.9)	0.65 (1.25)	-1.8	0.00	0.60	1.40	4.0	
		Week 20	Tezepelumab	53	45 (84.9)	0.73 (1.04)	-1.4	0.00	0.60	1.40	3.2	0.01 [-0.42, 0.44]
			Placebo	47	38 (80.9)	0.72 (1.21)	-1.6	0.00	0.70	1.20	5.2	
		Week 24	Tezepelumab	53	45 (84.9)	0.70 (1.07)	-1.4	-0.20	0.60	1.40	3.0	-0.08 [-0.51, 0.35]
			Placebo	47	38 (80.9)	0.80 (1.34)	-2.2	0.00	0.50	1.60	4.2	
		Week 28	Tezepelumab	53	45 (84.9)	0.72 (1.03)	-1.4	0.00	0.60	1.20	3.2	-0.03 [-0.46, 0.40]
			Placebo	47	38 (80.9)	0.76 (1.47)	-2.0	-0.20	0.40	1.60	4.8	
		Week 32	Tezepelumab	53	45 (84.9)	0.72 (1.05)	-1.6	0.00	0.80	1.40	3.0	-0.12 [-0.55, 0.31]
			Placebo	47	38 (80.9)	0.86 (1.45)	-1.4	-0.20	0.60	1.80	5.4	
		Week 36	Tezepelumab	53	45 (84.9)	0.73 (1.04)	-1.6	0.00	0.80	1.20	3.0	-0.22 [-0.66, 0.21]
			Placebo	47	38 (80.9)	1.00 (1.34)	-1.2	0.20	0.50	1.80	4.2	
		Week 40	Tezepelumab	53	45 (84.9)	0.67 (1.11)	-2.4	0.00	0.80	1.40	3.0	-0.24 [-0.67, 0.20]
			Placebo	47	38 (80.9)	0.98 (1.59)	-1.6	0.00	0.80	1.80	5.4	
		Week 44	Tezepelumab	53	45 (84.9)	0.76 (1.10)	-1.4	0.00	0.80	1.40	3.0	-0.04 [-0.47, 0.39]
			Placebo	47	38 (80.9)	0.82 (1.57)	-2.2	-0.40	0.70	2.00	4.2	
		Week 48	Tezepelumab	53	45 (84.9)	0.76 (1.11)	-1.4	0.00	0.80	1.40	3.2	-0.16 [-0.60, 0.27]
			Placebo	47	38 (80.9)	0.97 (1.51)	-1.8	0.00	0.60	1.60	5.0	
		Week 52	Tezepelumab	53	45 (84.9)	0.76 (1.08)	-1.6	0.00	0.80	1.40	3.2	-0.04 [-0.47, 0.39]
			Placebo	47	38 (80.9)	0.82 (1.57)	-1.8	-0.20	0.60	1.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	4.59 (1.12)	1.8	4.00	4.60	5.40	6.8	
			Placebo	33	29 (87.9)	4.31 (0.96)	2.8	3.80	4.20	5.00	6.6	
		Week 4	Tezepelumab	27	27 (100.0)	5.11 (1.03)	3.2	4.20	5.20	6.00	7.0	
			Placebo	33	30 (90.9)	4.63 (1.23)	1.6	4.00	4.70	5.60	7.0	
		Week 8	Tezepelumab	27	27 (100.0)	5.39 (0.92)	3.2	4.80	5.20	6.20	7.0	
			Placebo	33	30 (90.9)	4.89 (1.42)	1.0	4.00	5.10	6.00	7.0	
		Week 12	Tezepelumab	27	27 (100.0)	5.49 (0.85)	3.8	5.00	5.40	6.20	7.0	
			Placebo	33	30 (90.9)	5.06 (1.19)	2.6	4.00	4.80	5.80	7.0	
		Week 16	Tezepelumab	27	27 (100.0)	5.41 (0.91)	4.0	4.60	5.60	6.00	7.0	
			Placebo	33	30 (90.9)	4.98 (1.43)	1.2	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	27	27 (100.0)	5.50 (0.93)	4.0	4.60	5.60	6.40	7.0	
			Placebo	33	30 (90.9)	4.89 (1.36)	1.4	4.00	4.80	5.60	7.0	
		Week 24	Tezepelumab	27	27 (100.0)	5.57 (0.89)	4.0	4.60	5.80	6.20	7.0	
			Placebo	33	30 (90.9)	5.03 (1.23)	2.2	4.00	4.80	6.00	7.0	
		Week 28	Tezepelumab	27	27 (100.0)	5.47 (0.92)	4.0	4.80	5.40	6.20	7.0	
			Placebo	33	30 (90.9)	5.01 (1.49)	1.6	4.00	4.80	6.60	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	5.53 (0.87)	3.6	5.00	5.80	6.20	6.8	
			Placebo	33	31 (93.9)	4.84 (1.41)	1.6	4.00	4.40	6.00	7.0	
		Week 36	Tezepelumab	27	27 (100.0)	5.61 (0.95)	3.4	4.80	5.80	6.20	7.0	
			Placebo	33	31 (93.9)	4.97 (1.36)	1.8	4.00	4.60	6.00	7.0	
		Week 40	Tezepelumab	27	27 (100.0)	5.46 (0.92)	4.0	4.60	5.60	6.20	7.0	
			Placebo	33	31 (93.9)	4.90 (1.44)	1.6	4.00	4.80	6.00	7.0	
		Week 44	Tezepelumab	27	27 (100.0)	5.54 (0.99)	3.4	4.80	5.80	6.20	7.0	
			Placebo	33	31 (93.9)	4.92 (1.54)	1.6	3.80	4.60	6.40	7.0	
		Week 48	Tezepelumab	27	27 (100.0)	5.61 (0.90)	3.8	4.80	6.00	6.20	7.0	
			Placebo	33	31 (93.9)	4.88 (1.41)	1.8	4.00	4.40	6.40	7.0	
		Week 52	Tezepelumab	27	27 (100.0)	5.59 (0.88)	4.0	4.80	6.00	6.20	7.0	
			Placebo	33	31 (93.9)	4.70 (1.44)	1.8	3.80	4.40	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	27	27 (100.0)	0.53 (1.17)	-1.6	-0.20	0.40	1.00	3.8	0.16 [-0.36, 0.69]
			Placebo	33	29 (87.9)	0.35 (0.97)	-2.2	0.00	0.40	0.80	2.0	
		Week 8	Tezepelumab	27	27 (100.0)	0.81 (1.26)	-1.2	-0.20	0.80	1.60	4.4	0.16 [-0.36, 0.69]
			Placebo	33	29 (87.9)	0.61 (1.21)	-2.0	0.00	0.60	1.20	3.2	
		Week 12	Tezepelumab	27	27 (100.0)	0.90 (1.08)	-1.6	0.20	0.60	1.80	3.8	0.13 [-0.40, 0.65]
			Placebo	33	29 (87.9)	0.77 (1.11)	-1.2	0.20	0.80	1.20	3.6	
		Week 16	Tezepelumab	27	27 (100.0)	0.82 (1.23)	-1.4	0.00	1.00	1.20	4.0	0.12 [-0.41, 0.64]
			Placebo	33	29 (87.9)	0.68 (1.16)	-1.8	0.00	0.40	1.20	4.0	
		Week 20	Tezepelumab	27	27 (100.0)	0.92 (1.22)	-0.8	-0.20	1.00	1.40	4.6	0.29 [-0.23, 0.82]
			Placebo	33	29 (87.9)	0.58 (1.10)	-1.6	-0.20	0.60	1.20	3.2	
		Week 24	Tezepelumab	27	27 (100.0)	0.99 (1.15)	-0.8	0.20	0.80	1.60	4.6	0.23 [-0.30, 0.75]
			Placebo	33	29 (87.9)	0.73 (1.08)	-1.0	0.00	0.60	1.20	3.2	
		Week 28	Tezepelumab	27	27 (100.0)	0.88 (1.18)	-0.8	0.00	0.60	1.60	4.6	0.13 [-0.39, 0.66]
			Placebo	33	29 (87.9)	0.72 (1.26)	-1.4	-0.20	0.80	1.20	4.0	
		Week 32	Tezepelumab	27	27 (100.0)	0.94 (1.17)	-1.0	0.00	1.00	1.60	4.6	0.31 [-0.21, 0.84]
			Placebo	33	29 (87.9)	0.57 (1.17)	-1.4	-0.20	0.40	1.20	3.2	
		Week 36	Tezepelumab	27	27 (100.0)	1.03 (1.25)	-0.8	0.00	0.80	1.80	4.6	0.29 [-0.23, 0.82]
			Placebo	33	29 (87.9)	0.69 (1.07)	-1.2	-0.20	0.60	1.40	3.2	
		Week 40	Tezepelumab	27	27 (100.0)	0.87 (1.23)	-1.0	0.00	0.60	1.40	4.6	0.21 [-0.32, 0.73]
			Placebo	33	29 (87.9)	0.61 (1.28)	-1.6	-0.20	0.60	1.20	3.6	
		Week 44	Tezepelumab	27	27 (100.0)	0.96 (1.23)	-1.0	0.00	0.80	1.80	4.6	0.28 [-0.25, 0.80]
			Placebo	33	29 (87.9)	0.59 (1.43)	-2.2	-0.40	0.40	1.20	3.2	
		Week 48	Tezepelumab	27	27 (100.0)	1.02 (1.20)	-0.8	0.00	1.00	2.00	4.6	0.38 [-0.15, 0.91]
			Placebo	33	29 (87.9)	0.57 (1.19)	-1.8	-0.20	0.60	1.20	3.2	
		Week 52	Tezepelumab	27	27 (100.0)	1.00 (1.22)	-0.8	0.00	1.00	2.00	4.6	0.48 [-0.05, 1.01]
			Placebo	33	29 (87.9)	0.42 (1.20)	-1.8	-0.40	0.60	1.20	3.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	109	95 (87.2)	4.25 (1.16)	1.4	3.60	4.20	5.00	6.8	
			Placebo	105	92 (87.6)	4.21 (1.31)	1.0	3.60	4.20	5.20	7.0	
		Week 4	Tezepelumab	109	98 (89.9)	4.94 (1.24)	1.2	4.00	5.00	6.00	7.0	
			Placebo	105	93 (88.6)	4.71 (1.35)	1.4	3.80	4.80	5.80	7.0	
		Week 8	Tezepelumab	109	100 (91.7)	5.12 (1.26)	1.8	4.20	5.00	6.00	7.0	
			Placebo	105	96 (91.4)	4.80 (1.28)	1.4	4.00	4.80	5.70	7.0	
		Week 12	Tezepelumab	109	100 (91.7)	5.34 (1.25)	2.0	4.40	5.40	6.40	7.0	
			Placebo	105	97 (92.4)	4.84 (1.36)	1.4	4.00	4.60	6.00	7.0	
		Week 16	Tezepelumab	109	100 (91.7)	5.29 (1.22)	2.2	4.40	5.50	6.20	7.0	
			Placebo	105	97 (92.4)	4.86 (1.36)	1.0	4.00	4.80	5.80	7.0	
		Week 20	Tezepelumab	109	101 (92.7)	5.33 (1.22)	1.0	4.40	5.60	6.20	7.0	
			Placebo	105	97 (92.4)	4.96 (1.31)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	109	101 (92.7)	5.30 (1.23)	1.6	4.40	5.40	6.20	7.0	
			Placebo	105	97 (92.4)	5.00 (1.34)	1.0	4.20	5.00	6.00	7.0	
		Week 28	Tezepelumab	109	103 (94.5)	5.43 (1.11)	2.8	4.40	5.60	6.40	7.0	
			Placebo	105	98 (93.3)	4.95 (1.37)	1.0	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	109	104 (95.4)	5.37 (1.21)	1.8	4.40	5.60	6.30	7.0	
			Placebo	105	98 (93.3)	5.03 (1.37)	1.0	4.00	5.20	6.20	7.0	
		Week 36	Tezepelumab	109	104 (95.4)	5.46 (1.20)	2.8	4.40	5.70	6.60	7.0	
			Placebo	105	98 (93.3)	5.06 (1.33)	1.6	4.00	5.00	6.20	7.0	
		Week 40	Tezepelumab	109	104 (95.4)	5.38 (1.27)	1.8	4.50	5.40	6.40	7.0	
			Placebo	105	98 (93.3)	5.09 (1.34)	1.6	4.00	5.00	6.40	7.0	
		Week 44	Tezepelumab	109	104 (95.4)	5.49 (1.19)	2.6	4.60	5.60	6.50	7.0	
			Placebo	105	98 (93.3)	5.08 (1.38)	1.4	4.00	5.20	6.20	7.0	
		Week 48	Tezepelumab	109	104 (95.4)	5.45 (1.21)	1.8	4.60	5.60	6.40	7.0	
			Placebo	105	99 (94.3)	5.09 (1.36)	1.2	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	109	104 (95.4)	5.44 (1.23)	1.8	4.60	5.60	6.40	7.0	
			Placebo	105	99 (94.3)	5.05 (1.41)	1.2	4.00	5.00	6.40	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	109	89 (81.7)	0.74 (1.22)	-4.2	0.00	0.60	1.60	3.6	0.23 [-0.07, 0.52]
			Placebo	105	90 (85.7)	0.48 (1.11)	-2.8	-0.20	0.40	1.20	3.6	
		Week 8	Tezepelumab	109	91 (83.5)	0.86 (1.24)	-2.2	0.20	0.80	1.60	5.0	0.22 [-0.07, 0.51]
			Placebo	105	91 (86.7)	0.59 (1.17)	-1.8	-0.20	0.40	1.20	4.0	
		Week 12	Tezepelumab	109	91 (83.5)	1.07 (1.28)	-2.4	0.20	1.00	2.00	5.4	0.33 [0.03, 0.62]
			Placebo	105	91 (86.7)	0.65 (1.30)	-2.2	0.00	0.60	1.40	4.4	
		Week 16	Tezepelumab	109	91 (83.5)	1.04 (1.21)	-2.8	0.20	1.00	1.80	5.2	0.32 [0.02, 0.61]
			Placebo	105	91 (86.7)	0.65 (1.26)	-3.4	0.00	0.80	1.40	4.4	
		Week 20	Tezepelumab	109	91 (83.5)	1.11 (1.23)	-1.4	0.20	1.00	2.00	5.2	0.27 [-0.02, 0.56]
			Placebo	105	91 (86.7)	0.77 (1.28)	-3.4	0.20	0.80	1.40	5.2	
		Week 24	Tezepelumab	109	91 (83.5)	1.07 (1.26)	-1.4	0.00	1.00	2.00	5.4	0.19 [-0.10, 0.49]
			Placebo	105	91 (86.7)	0.82 (1.34)	-3.4	0.00	0.80	1.60	4.2	
		Week 28	Tezepelumab	109	91 (83.5)	1.17 (1.22)	-1.4	0.40	1.00	2.00	5.4	0.31 [0.02, 0.61]
			Placebo	105	91 (86.7)	0.75 (1.44)	-3.4	0.00	0.80	1.60	5.2	
		Week 32	Tezepelumab	109	91 (83.5)	1.10 (1.28)	-1.6	0.20	1.00	2.00	5.4	0.19 [-0.10, 0.48]
			Placebo	105	91 (86.7)	0.85 (1.35)	-3.4	0.00	0.80	1.60	5.4	
		Week 36	Tezepelumab	109	91 (83.5)	1.19 (1.35)	-1.6	0.20	1.00	2.00	5.4	0.26 [-0.03, 0.55]
			Placebo	105	91 (86.7)	0.85 (1.28)	-2.0	0.00	0.60	1.60	4.2	
		Week 40	Tezepelumab	109	91 (83.5)	1.13 (1.30)	-2.4	0.20	1.00	2.00	5.4	0.16 [-0.13, 0.45]
			Placebo	105	91 (86.7)	0.91 (1.38)	-2.0	0.00	0.80	1.60	5.4	
		Week 44	Tezepelumab	109	91 (83.5)	1.20 (1.27)	-1.4	0.40	1.20	2.00	5.4	0.23 [-0.06, 0.52]
			Placebo	105	91 (86.7)	0.89 (1.37)	-2.0	0.00	1.00	1.60	5.2	
		Week 48	Tezepelumab	109	91 (83.5)	1.18 (1.28)	-1.4	0.20	1.20	2.00	5.4	0.21 [-0.08, 0.50]
			Placebo	105	91 (86.7)	0.90 (1.37)	-2.2	0.00	0.80	1.60	5.0	
		Week 52	Tezepelumab	109	91 (83.5)	1.14 (1.29)	-1.6	0.20	1.20	2.00	5.4	0.22 [-0.08, 0.51]
			Placebo	105	91 (86.7)	0.85 (1.43)	-2.6	-0.20	0.80	1.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	69	63 (91.3)	4.46 (1.04)	1.4	4.00	4.40	5.20	6.8	
			Placebo	72	61 (84.7)	4.37 (1.16)	1.0	3.80	4.40	5.00	6.6	
		Week 4	Tezepelumab	69	60 (87.0)	4.99 (1.23)	1.2	4.10	5.00	6.00	7.0	
			Placebo	72	61 (84.7)	4.79 (1.40)	1.4	4.00	4.80	5.80	7.0	
		Week 8	Tezepelumab	69	61 (88.4)	5.21 (1.22)	2.0	4.60	5.20	6.20	7.0	
			Placebo	72	63 (87.5)	5.00 (1.42)	1.0	4.00	5.00	6.00	7.0	
		Week 12	Tezepelumab	69	61 (88.4)	5.47 (1.14)	2.8	4.60	5.40	6.60	7.0	
			Placebo	72	63 (87.5)	5.15 (1.35)	1.4	4.20	5.20	6.60	7.0	
		Week 16	Tezepelumab	69	61 (88.4)	5.33 (1.11)	2.6	4.40	5.40	6.20	7.0	
			Placebo	72	63 (87.5)	5.05 (1.48)	1.0	4.20	5.20	6.20	7.0	
		Week 20	Tezepelumab	69	62 (89.9)	5.40 (1.15)	2.8	4.60	5.60	6.40	7.0	
			Placebo	72	63 (87.5)	5.03 (1.43)	1.0	4.20	5.00	6.20	7.0	
		Week 24	Tezepelumab	69	62 (89.9)	5.41 (1.09)	2.8	4.60	5.60	6.20	7.0	
			Placebo	72	63 (87.5)	5.13 (1.40)	1.0	4.40	5.00	6.40	7.0	
		Week 28	Tezepelumab	69	63 (91.3)	5.41 (1.10)	2.8	4.60	5.40	6.20	7.0	
			Placebo	72	64 (88.9)	5.08 (1.52)	1.0	4.00	5.20	6.40	7.0	
		Week 32	Tezepelumab	69	64 (92.8)	5.49 (1.08)	2.8	4.60	5.80	6.40	7.0	
			Placebo	72	65 (90.3)	5.06 (1.52)	1.0	4.00	5.00	6.40	7.0	
		Week 36	Tezepelumab	69	64 (92.8)	5.50 (1.15)	2.8	4.60	5.80	6.20	7.0	
			Placebo	72	65 (90.3)	5.21 (1.43)	1.8	4.40	5.20	6.60	7.0	
		Week 40	Tezepelumab	69	64 (92.8)	5.48 (1.16)	1.8	4.90	5.60	6.40	7.0	
			Placebo	72	65 (90.3)	5.18 (1.43)	1.6	4.20	5.00	6.60	7.0	
		Week 44	Tezepelumab	69	64 (92.8)	5.49 (1.18)	2.8	4.70	5.80	6.40	7.0	
			Placebo	72	65 (90.3)	5.25 (1.52)	1.4	4.20	5.40	6.60	7.0	
		Week 48	Tezepelumab	69	64 (92.8)	5.55 (1.14)	2.6	4.70	5.90	6.40	7.0	
			Placebo	72	66 (91.7)	5.14 (1.49)	1.2	4.00	4.80	6.80	7.0	
		Week 52	Tezepelumab	69	64 (92.8)	5.56 (1.13)	2.8	4.70	5.80	6.40	7.0	
			Placebo	72	66 (91.7)	5.05 (1.55)	1.2	4.00	4.80	6.80	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	69	58 (84.1)	0.54 (1.29)	-4.2	-0.20	0.60	1.40	3.8	0.09 [-0.27, 0.46]
			Placebo	72	60 (83.3)	0.43 (0.98)	-2.2	0.00	0.40	1.00	2.8	
		Week 8	Tezepelumab	69	59 (85.5)	0.77 (1.28)	-2.2	-0.20	0.60	1.60	4.4	0.08 [-0.28, 0.44]
			Placebo	72	61 (84.7)	0.67 (1.14)	-2.0	0.00	0.60	1.40	3.2	
		Week 12	Tezepelumab	69	59 (85.5)	1.04 (1.21)	-2.4	0.20	1.00	1.80	3.8	0.19 [-0.17, 0.55]
			Placebo	72	61 (84.7)	0.81 (1.15)	-2.0	0.20	0.80	1.40	3.6	
		Week 16	Tezepelumab	69	59 (85.5)	0.91 (1.23)	-2.8	0.00	1.00	1.80	4.0	0.16 [-0.20, 0.52]
			Placebo	72	61 (84.7)	0.71 (1.21)	-3.4	0.20	0.80	1.40	4.0	
		Week 20	Tezepelumab	69	59 (85.5)	0.96 (1.20)	-1.4	-0.20	1.00	1.60	4.6	0.24 [-0.12, 0.60]
			Placebo	72	61 (84.7)	0.68 (1.15)	-3.4	0.20	0.80	1.20	3.2	
		Week 24	Tezepelumab	69	59 (85.5)	0.96 (1.14)	-1.4	0.20	0.80	1.80	4.6	0.15 [-0.20, 0.51]
			Placebo	72	61 (84.7)	0.78 (1.22)	-3.4	0.20	0.80	1.60	3.4	
		Week 28	Tezepelumab	69	59 (85.5)	0.98 (1.16)	-1.4	0.00	0.80	1.60	4.6	0.22 [-0.14, 0.58]
			Placebo	72	61 (84.7)	0.71 (1.33)	-3.4	0.00	0.80	1.40	4.0	
		Week 32	Tezepelumab	69	59 (85.5)	1.02 (1.17)	-1.6	0.20	1.00	1.60	4.6	0.26 [-0.10, 0.62]
			Placebo	72	61 (84.7)	0.70 (1.27)	-3.4	-0.20	0.80	1.60	3.4	
		Week 36	Tezepelumab	69	59 (85.5)	1.02 (1.24)	-1.6	0.00	1.00	1.80	4.6	0.14 [-0.21, 0.50]
			Placebo	72	61 (84.7)	0.84 (1.22)	-1.4	0.00	0.80	1.40	4.2	
		Week 40	Tezepelumab	69	59 (85.5)	1.02 (1.28)	-2.4	0.00	1.00	2.00	4.6	0.15 [-0.21, 0.51]
			Placebo	72	61 (84.7)	0.82 (1.31)	-1.6	0.00	1.00	1.60	4.0	
		Week 44	Tezepelumab	69	59 (85.5)	1.01 (1.22)	-1.4	0.00	1.20	1.80	4.6	0.12 [-0.24, 0.48]
			Placebo	72	61 (84.7)	0.86 (1.37)	-2.2	-0.20	1.00	1.40	4.2	
		Week 48	Tezepelumab	69	59 (85.5)	1.08 (1.19)	-1.4	0.20	1.00	2.00	4.6	0.26 [-0.10, 0.61]
			Placebo	72	61 (84.7)	0.76 (1.27)	-1.8	0.00	0.80	1.60	4.0	
		Week 52	Tezepelumab	69	59 (85.5)	1.07 (1.21)	-1.6	0.00	1.00	2.00	4.6	0.29 [-0.07, 0.65]
			Placebo	72	61 (84.7)	0.69 (1.39)	-2.6	-0.40	0.80	1.40	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	4.18 (1.26)	1.4	3.40	4.00	5.00	6.8	
			Placebo	66	60 (90.9)	4.10 (1.31)	1.4	3.40	4.00	4.60	7.0	
		Week 4	Tezepelumab	67	65 (97.0)	4.96 (1.17)	1.6	4.00	5.00	6.00	7.0	
			Placebo	66	62 (93.9)	4.59 (1.22)	1.6	3.80	4.60	5.60	7.0	
		Week 8	Tezepelumab	67	66 (98.5)	5.15 (1.18)	1.8	4.20	5.10	6.00	7.0	
			Placebo	66	63 (95.5)	4.64 (1.17)	1.8	4.00	4.60	5.40	7.0	
		Week 12	Tezepelumab	67	66 (98.5)	5.28 (1.20)	2.0	4.40	5.30	6.20	7.0	
			Placebo	66	64 (97.0)	4.64 (1.25)	1.6	4.00	4.60	5.60	7.0	
		Week 16	Tezepelumab	67	66 (98.5)	5.31 (1.21)	2.2	4.20	5.60	6.20	7.0	
			Placebo	66	64 (97.0)	4.73 (1.24)	2.2	4.00	4.60	5.80	7.0	
		Week 20	Tezepelumab	67	66 (98.5)	5.34 (1.18)	1.0	4.40	5.50	6.20	7.0	
			Placebo	66	64 (97.0)	4.86 (1.20)	2.2	4.00	5.00	5.70	7.0	
		Week 24	Tezepelumab	67	66 (98.5)	5.31 (1.24)	1.6	4.40	5.40	6.20	7.0	
			Placebo	66	64 (97.0)	4.89 (1.20)	2.4	4.00	4.80	6.00	7.0	
		Week 28	Tezepelumab	67	67 (100.0)	5.47 (1.05)	2.8	4.60	5.60	6.40	7.0	
			Placebo	66	64 (97.0)	4.84 (1.26)	2.6	3.70	4.90	6.00	7.0	
		Week 32	Tezepelumab	67	67 (100.0)	5.32 (1.22)	1.8	4.40	5.60	6.20	7.0	
			Placebo	66	64 (97.0)	4.92 (1.22)	2.2	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	67	67 (100.0)	5.48 (1.16)	2.8	4.60	5.60	6.60	7.0	
			Placebo	66	64 (97.0)	4.86 (1.21)	1.6	4.00	4.70	5.80	7.0	
		Week 40	Tezepelumab	67	67 (100.0)	5.32 (1.25)	2.0	4.40	5.40	6.20	7.0	
			Placebo	66	64 (97.0)	4.91 (1.28)	1.6	4.00	4.80	6.00	7.0	
		Week 44	Tezepelumab	67	67 (100.0)	5.50 (1.13)	2.6	4.60	5.60	6.60	7.0	
			Placebo	66	64 (97.0)	4.84 (1.29)	1.8	4.00	4.60	6.00	7.0	
		Week 48	Tezepelumab	67	67 (100.0)	5.41 (1.16)	1.8	4.60	5.60	6.40	7.0	
			Placebo	66	64 (97.0)	4.94 (1.24)	1.4	4.00	5.00	5.90	7.0	
		Week 52	Tezepelumab	67	67 (100.0)	5.38 (1.20)	1.8	4.60	5.40	6.20	7.0	
			Placebo	66	64 (97.0)	4.88 (1.28)	2.0	4.00	4.80	5.90	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	67	58 (86.6)	0.84 (1.11)	-1.4	0.20	0.70	1.60	3.6	0.33 [-0.03, 0.70]
			Placebo	66	59 (89.4)	0.46 (1.17)	-2.8	-0.20	0.40	1.20	3.6	
		Week 8	Tezepelumab	67	59 (88.1)	0.92 (1.19)	-1.4	0.20	0.80	1.60	5.0	0.34 [-0.03, 0.70]
			Placebo	66	59 (89.4)	0.52 (1.22)	-1.8	-0.20	0.40	1.20	4.0	
		Week 12	Tezepelumab	67	59 (88.1)	1.03 (1.27)	-1.6	0.20	0.80	1.80	5.4	0.37 [0.01, 0.74]
			Placebo	66	59 (89.4)	0.54 (1.35)	-2.2	-0.20	0.40	1.20	4.4	
		Week 16	Tezepelumab	67	59 (88.1)	1.08 (1.19)	-0.8	0.20	0.80	1.60	5.2	0.39 [0.02, 0.75]
			Placebo	66	59 (89.4)	0.61 (1.26)	-2.0	-0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	67	59 (88.1)	1.17 (1.25)	-0.6	0.20	1.00	2.00	5.2	0.31 [-0.05, 0.67]
			Placebo	66	59 (89.4)	0.77 (1.32)	-2.0	0.00	0.60	1.40	5.2	
		Week 24	Tezepelumab	67	59 (88.1)	1.14 (1.33)	-0.8	0.00	1.00	2.00	5.4	0.24 [-0.12, 0.61]
			Placebo	66	59 (89.4)	0.81 (1.35)	-2.2	0.00	0.60	1.60	4.2	
		Week 28	Tezepelumab	67	59 (88.1)	1.22 (1.26)	-0.6	0.40	0.80	2.00	5.4	0.33 [-0.04, 0.69]
			Placebo	66	59 (89.4)	0.78 (1.46)	-2.0	-0.20	0.60	1.60	5.2	
		Week 32	Tezepelumab	67	59 (88.1)	1.11 (1.34)	-1.4	0.20	1.00	2.00	5.4	0.18 [-0.18, 0.54]
			Placebo	66	59 (89.4)	0.86 (1.34)	-2.0	0.00	0.80	1.60	5.4	
		Week 36	Tezepelumab	67	59 (88.1)	1.29 (1.41)	-1.0	0.40	1.00	2.20	5.4	0.38 [0.01, 0.74]
			Placebo	66	59 (89.4)	0.78 (1.26)	-2.0	0.00	0.60	1.60	3.8	
		Week 40	Tezepelumab	67	59 (88.1)	1.12 (1.30)	-1.2	0.20	0.80	2.00	5.4	0.20 [-0.16, 0.56]
			Placebo	66	59 (89.4)	0.85 (1.41)	-2.0	0.00	0.80	1.40	5.4	
		Week 44	Tezepelumab	67	59 (88.1)	1.27 (1.29)	-1.0	0.40	1.20	2.00	5.4	0.37 [0.00, 0.73]
			Placebo	66	59 (89.4)	0.78 (1.41)	-2.0	-0.20	0.60	1.60	5.2	
		Week 48	Tezepelumab	67	59 (88.1)	1.21 (1.33)	-1.4	0.40	1.00	2.00	5.4	0.24 [-0.12, 0.60]
			Placebo	66	59 (89.4)	0.88 (1.40)	-2.2	-0.20	0.80	1.60	5.0	
		Week 52	Tezepelumab	67	59 (88.1)	1.15 (1.34)	-1.4	0.20	1.00	2.00	5.4	0.25 [-0.11, 0.61]
			Placebo	66	59 (89.4)	0.81 (1.40)	-2.0	-0.20	0.60	1.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	78	68 (87.2)	4.46 (0.98)	1.8	3.90	4.20	5.20	6.8	
			Placebo	74	63 (85.1)	4.29 (1.16)	1.6	3.80	4.20	5.00	7.0	
		Week 4	Tezepelumab	78	72 (92.3)	4.91 (1.15)	1.2	4.00	5.00	5.80	7.0	
			Placebo	74	66 (89.2)	4.72 (1.27)	1.4	4.00	4.70	5.60	7.0	
		Week 8	Tezepelumab	78	72 (92.3)	5.16 (1.04)	2.6	4.50	5.00	6.00	7.0	
			Placebo	74	66 (89.2)	4.87 (1.25)	1.4	4.00	5.00	5.60	7.0	
		Week 12	Tezepelumab	78	72 (92.3)	5.38 (1.07)	3.0	4.40	5.50	6.30	7.0	
			Placebo	74	67 (90.5)	4.85 (1.33)	1.4	4.00	4.60	6.00	7.0	
		Week 16	Tezepelumab	78	72 (92.3)	5.23 (1.07)	2.6	4.30	5.40	6.00	7.0	
			Placebo	74	67 (90.5)	4.93 (1.23)	1.8	4.00	4.80	5.80	7.0	
		Week 20	Tezepelumab	78	73 (93.6)	5.27 (1.10)	2.4	4.40	5.40	6.00	7.0	
			Placebo	74	67 (90.5)	4.99 (1.17)	1.8	4.00	5.00	5.80	7.0	
		Week 24	Tezepelumab	78	73 (93.6)	5.30 (1.09)	2.0	4.40	5.40	6.00	7.0	
			Placebo	74	67 (90.5)	5.08 (1.21)	1.4	4.20	5.00	6.00	7.0	
		Week 28	Tezepelumab	78	75 (96.2)	5.37 (1.04)	3.2	4.40	5.40	6.20	7.0	
			Placebo	74	68 (91.9)	4.94 (1.26)	2.0	4.00	4.80	6.00	7.0	
		Week 32	Tezepelumab	78	76 (97.4)	5.36 (1.05)	2.6	4.50	5.60	6.00	7.0	
			Placebo	74	69 (93.2)	5.02 (1.27)	1.2	4.00	5.00	6.20	7.0	
		Week 36	Tezepelumab	78	76 (97.4)	5.39 (1.16)	3.0	4.40	5.70	6.20	7.0	
			Placebo	74	69 (93.2)	5.13 (1.28)	1.8	4.00	5.20	6.20	7.0	
		Week 40	Tezepelumab	78	76 (97.4)	5.27 (1.20)	1.8	4.20	5.40	6.20	7.0	
			Placebo	74	69 (93.2)	5.06 (1.21)	1.6	4.20	5.00	6.00	7.0	
		Week 44	Tezepelumab	78	76 (97.4)	5.34 (1.12)	2.8	4.40	5.40	6.20	7.0	
			Placebo	74	69 (93.2)	5.13 (1.34)	1.4	4.00	5.20	6.40	7.0	
		Week 48	Tezepelumab	78	76 (97.4)	5.36 (1.12)	2.6	4.40	5.50	6.20	7.0	
			Placebo	74	70 (94.6)	5.14 (1.34)	1.2	4.00	4.90	6.40	7.0	
		Week 52	Tezepelumab	78	76 (97.4)	5.33 (1.09)	2.6	4.40	5.40	6.20	7.0	
			Placebo	74	70 (94.6)	5.00 (1.42)	1.2	4.00	4.80	6.40	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	78	67 (85.9)	0.44 (1.24)	-4.2	-0.20	0.40	1.00	3.8	-0.04 [-0.38, 0.31]
			Placebo	74	63 (85.1)	0.49 (1.03)	-2.2	0.00	0.60	1.00	3.0	
		Week 8	Tezepelumab	78	67 (85.9)	0.69 (1.20)	-1.2	-0.20	0.60	1.40	4.4	0.07 [-0.28, 0.41]
			Placebo	74	63 (85.1)	0.61 (1.15)	-1.6	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	78	67 (85.9)	0.90 (1.18)	-2.4	0.20	0.80	1.80	3.8	0.22 [-0.12, 0.57]
			Placebo	74	63 (85.1)	0.63 (1.19)	-2.0	0.00	0.60	1.20	4.4	
		Week 16	Tezepelumab	78	67 (85.9)	0.76 (1.18)	-2.8	0.00	0.80	1.40	4.0	0.07 [-0.28, 0.41]
			Placebo	74	63 (85.1)	0.68 (1.03)	-1.6	0.00	0.80	1.20	4.4	
		Week 20	Tezepelumab	78	67 (85.9)	0.84 (1.18)	-1.4	-0.20	0.80	1.40	4.6	0.08 [-0.27, 0.42]
			Placebo	74	63 (85.1)	0.76 (1.04)	-2.2	0.20	0.80	1.20	4.2	
		Week 24	Tezepelumab	78	67 (85.9)	0.87 (1.14)	-1.4	0.00	0.60	1.60	4.6	0.02 [-0.32, 0.37]
			Placebo	74	63 (85.1)	0.84 (1.07)	-1.4	0.20	0.80	1.40	4.2	
		Week 28	Tezepelumab	78	67 (85.9)	0.89 (1.16)	-1.4	0.00	0.80	1.60	4.6	0.19 [-0.15, 0.53]
			Placebo	74	63 (85.1)	0.68 (1.12)	-2.2	0.00	0.80	1.20	4.4	
		Week 32	Tezepelumab	78	67 (85.9)	0.87 (1.18)	-1.6	0.00	1.00	1.40	4.6	0.07 [-0.27, 0.42]
			Placebo	74	63 (85.1)	0.78 (1.05)	-1.4	0.00	0.80	1.40	4.2	
		Week 36	Tezepelumab	78	67 (85.9)	0.90 (1.29)	-1.6	0.00	0.80	1.80	4.6	0.02 [-0.32, 0.37]
			Placebo	74	63 (85.1)	0.88 (1.15)	-1.4	0.20	0.80	1.60	4.2	
		Week 40	Tezepelumab	78	67 (85.9)	0.81 (1.27)	-2.4	0.00	0.80	1.60	4.6	-0.00 [-0.35, 0.34]
			Placebo	74	63 (85.1)	0.81 (1.10)	-1.6	0.00	0.80	1.40	3.4	
		Week 44	Tezepelumab	78	67 (85.9)	0.82 (1.21)	-1.4	-0.20	0.80	1.60	4.6	-0.03 [-0.38, 0.31]
			Placebo	74	63 (85.1)	0.86 (1.21)	-2.2	0.00	1.00	1.40	4.2	
		Week 48	Tezepelumab	78	67 (85.9)	0.87 (1.21)	-1.4	0.00	0.80	1.80	4.6	-0.01 [-0.36, 0.33]
			Placebo	74	63 (85.1)	0.88 (1.19)	-1.8	0.00	0.80	1.60	4.0	
		Week 52	Tezepelumab	78	67 (85.9)	0.83 (1.23)	-1.6	0.00	0.80	1.80	4.6	0.07 [-0.27, 0.42]
			Placebo	74	63 (85.1)	0.74 (1.29)	-2.6	-0.20	0.80	1.40	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	57	53 (93.0)	4.15 (1.35)	1.4	3.40	4.40	5.00	6.6	
			Placebo	63	57 (90.5)	4.18 (1.33)	1.0	3.40	4.20	5.00	7.0	
		Week 4	Tezepelumab	57	52 (91.2)	5.06 (1.28)	1.6	4.00	5.00	6.10	7.0	
			Placebo	63	57 (90.5)	4.65 (1.37)	1.6	3.60	4.80	5.60	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.18 (1.42)	1.8	4.00	5.20	6.60	7.0	
			Placebo	63	59 (93.7)	4.79 (1.38)	1.0	3.80	4.80	6.00	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.35 (1.32)	2.0	4.40	5.20	6.60	7.0	
			Placebo	63	59 (93.7)	4.95 (1.33)	1.8	4.00	5.20	6.00	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.41 (1.28)	2.2	4.40	5.60	6.60	7.0	
			Placebo	63	59 (93.7)	4.91 (1.45)	1.2	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.47 (1.25)	1.0	4.60	5.80	6.60	7.0	
			Placebo	63	59 (93.7)	4.96 (1.40)	1.4	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.41 (1.31)	1.6	4.40	5.40	6.60	7.0	
			Placebo	63	59 (93.7)	4.99 (1.33)	2.2	4.00	4.80	6.20	7.0	
		Week 28	Tezepelumab	57	54 (94.7)	5.51 (1.15)	2.8	4.60	5.60	6.40	7.0	
			Placebo	63	59 (93.7)	5.06 (1.46)	1.6	3.80	5.40	6.20	7.0	
		Week 32	Tezepelumab	57	54 (94.7)	5.44 (1.30)	1.8	4.60	5.70	6.40	7.0	
			Placebo	63	59 (93.7)	5.02 (1.41)	1.6	4.00	5.20	6.00	7.0	
		Week 36	Tezepelumab	57	54 (94.7)	5.63 (1.14)	2.8	5.00	5.80	6.60	7.0	
			Placebo	63	59 (93.7)	4.96 (1.38)	1.6	4.00	4.80	6.00	7.0	
		Week 40	Tezepelumab	57	54 (94.7)	5.54 (1.23)	2.4	4.80	5.60	6.80	7.0	
			Placebo	63	59 (93.7)	5.05 (1.52)	1.6	4.00	5.00	6.60	7.0	
		Week 44	Tezepelumab	57	54 (94.7)	5.69 (1.18)	2.6	5.00	6.00	6.60	7.0	
			Placebo	63	59 (93.7)	4.98 (1.51)	1.6	4.00	5.00	6.20	7.0	
		Week 48	Tezepelumab	57	54 (94.7)	5.63 (1.20)	1.8	4.80	5.80	6.80	7.0	
			Placebo	63	59 (93.7)	4.95 (1.41)	1.4	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	57	54 (94.7)	5.63 (1.26)	1.8	4.80	5.80	6.80	7.0	
			Placebo	63	59 (93.7)	4.96 (1.43)	1.8	4.00	5.00	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	1.02 (1.10)	-1.0	0.20	1.00	1.70	3.6	0.55 [0.16, 0.95]
			Placebo	63	56 (88.9)	0.40 (1.13)	-2.8	-0.20	0.40	1.10	3.6	
		Week 8	Tezepelumab	57	50 (87.7)	1.02 (1.31)	-2.2	0.20	1.00	2.00	5.0	0.33 [-0.05, 0.72]
			Placebo	63	56 (88.9)	0.60 (1.21)	-2.0	-0.10	0.50	1.20	3.4	
		Week 12	Tezepelumab	57	50 (87.7)	1.20 (1.33)	-1.6	0.40	1.10	2.20	5.4	0.34 [-0.04, 0.73]
			Placebo	63	56 (88.9)	0.75 (1.33)	-2.2	-0.10	0.80	1.50	4.4	
		Week 16	Tezepelumab	57	50 (87.7)	1.27 (1.24)	-0.8	0.40	1.20	2.20	5.2	0.44 [0.05, 0.82]
			Placebo	63	56 (88.9)	0.71 (1.33)	-2.0	-0.10	0.60	1.40	4.0	
		Week 20	Tezepelumab	57	50 (87.7)	1.34 (1.27)	-0.6	0.60	1.20	2.20	5.2	0.44 [0.05, 0.82]
			Placebo	63	56 (88.9)	0.77 (1.33)	-2.0	-0.10	0.70	1.60	5.2	
		Week 24	Tezepelumab	57	50 (87.7)	1.25 (1.39)	-1.4	0.00	1.10	2.20	5.4	0.31 [-0.08, 0.69]
			Placebo	63	56 (88.9)	0.82 (1.39)	-2.2	-0.20	0.60	1.80	4.2	
		Week 28	Tezepelumab	57	50 (87.7)	1.36 (1.29)	-1.0	0.60	1.20	2.20	5.4	0.32 [-0.06, 0.71]
			Placebo	63	56 (88.9)	0.89 (1.56)	-2.0	-0.20	0.80	1.80	5.2	
		Week 32	Tezepelumab	57	50 (87.7)	1.29 (1.34)	-1.2	0.40	1.30	2.20	5.4	0.31 [-0.07, 0.70]
			Placebo	63	56 (88.9)	0.85 (1.46)	-2.0	-0.20	0.80	1.70	5.4	
		Week 36	Tezepelumab	57	50 (87.7)	1.48 (1.32)	-0.8	0.60	1.30	2.20	5.4	0.53 [0.14, 0.92]
			Placebo	63	56 (88.9)	0.78 (1.31)	-2.0	-0.20	0.60	1.60	3.6	
		Week 40	Tezepelumab	57	50 (87.7)	1.38 (1.29)	-1.2	0.60	1.10	2.00	5.4	0.33 [-0.06, 0.71]
			Placebo	63	56 (88.9)	0.90 (1.60)	-2.0	-0.20	1.00	1.80	5.4	
		Week 44	Tezepelumab	57	50 (87.7)	1.54 (1.25)	-0.6	0.80	1.40	2.20	5.4	0.52 [0.13, 0.90]
			Placebo	63	56 (88.9)	0.80 (1.56)	-2.0	-0.30	0.70	1.80	5.2	
		Week 48	Tezepelumab	57	50 (87.7)	1.48 (1.27)	-0.6	0.60	1.40	2.20	5.4	0.50 [0.11, 0.89]
			Placebo	63	56 (88.9)	0.79 (1.48)	-2.2	-0.20	0.60	1.60	5.0	
		Week 52	Tezepelumab	57	50 (87.7)	1.45 (1.29)	-0.6	0.60	1.40	2.20	5.4	0.48 [0.09, 0.86]
			Placebo	63	56 (88.9)	0.79 (1.49)	-2.0	-0.20	0.60	1.50	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.42 (0.97)	2.0	3.80	4.40	5.20	6.8	
			Placebo	66	54 (81.8)	4.34 (1.29)	1.0	3.60	4.40	5.00	7.0	
		Week 4	Tezepelumab	57	55 (96.5)	4.92 (1.02)	2.8	4.00	4.80	6.00	7.0	
			Placebo	66	57 (86.4)	4.53 (1.42)	1.4	3.80	4.40	5.60	7.0	
		Week 8	Tezepelumab	57	55 (96.5)	5.19 (1.05)	2.0	4.60	5.00	6.20	7.0	
			Placebo	66	60 (90.9)	4.62 (1.25)	1.4	3.80	4.60	5.40	7.0	
		Week 12	Tezepelumab	57	55 (96.5)	5.42 (1.07)	3.4	4.60	5.20	6.40	7.0	
			Placebo	66	60 (90.9)	4.73 (1.35)	1.4	4.00	4.60	5.80	7.0	
		Week 16	Tezepelumab	57	55 (96.5)	5.31 (1.03)	3.2	4.40	5.00	6.20	7.0	
			Placebo	66	60 (90.9)	4.68 (1.40)	1.0	4.00	4.60	5.80	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.41 (1.03)	3.2	4.60	5.40	6.20	7.0	
			Placebo	66	60 (90.9)	4.69 (1.37)	1.0	4.00	4.70	5.70	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.36 (1.07)	3.4	4.40	5.20	6.20	7.0	
			Placebo	66	60 (90.9)	4.75 (1.40)	1.0	4.00	4.60	6.00	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.45 (1.02)	3.4	4.60	5.50	6.20	7.0	
			Placebo	66	60 (90.9)	4.68 (1.44)	1.0	3.70	4.40	6.00	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.39 (0.97)	3.4	4.60	5.40	6.20	7.0	
			Placebo	66	61 (92.4)	4.66 (1.40)	1.0	4.00	4.40	6.00	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.45 (1.06)	3.0	4.60	5.60	6.20	7.0	
			Placebo	66	61 (92.4)	4.76 (1.37)	1.6	4.00	4.60	5.80	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.40 (1.03)	3.6	4.60	5.40	6.20	7.0	
			Placebo	66	61 (92.4)	4.71 (1.38)	1.6	4.00	4.60	5.60	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.40 (1.10)	2.8	4.60	5.40	6.40	7.0	
			Placebo	66	61 (92.4)	4.69 (1.39)	1.4	4.00	4.40	5.80	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.45 (1.04)	2.8	4.60	5.60	6.20	7.0	
			Placebo	66	62 (93.9)	4.72 (1.38)	1.2	4.00	4.30	5.80	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.44 (1.06)	3.2	4.60	5.60	6.20	7.0	
			Placebo	66	62 (93.9)	4.57 (1.43)	1.2	3.80	4.20	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	57	49 (86.0)	0.60 (0.89)	-1.6	0.00	0.40	1.20	2.4	0.43 [0.03, 0.82]
			Placebo	66	53 (80.3)	0.20 (1.02)	-2.2	-0.20	0.20	0.80	2.8	
		Week 8	Tezepelumab	57	49 (86.0)	0.77 (1.09)	-1.2	0.20	0.60	1.40	3.6	0.44 [0.05, 0.83]
			Placebo	66	54 (81.8)	0.32 (0.96)	-1.6	-0.20	0.20	1.00	2.8	
		Week 12	Tezepelumab	57	49 (86.0)	0.98 (1.10)	-1.6	0.20	1.00	1.60	3.4	0.52 [0.13, 0.92]
			Placebo	66	54 (81.8)	0.41 (1.08)	-2.0	-0.20	0.40	1.00	2.8	
		Week 16	Tezepelumab	57	49 (86.0)	0.87 (1.11)	-1.4	0.20	1.00	1.60	3.0	0.47 [0.07, 0.86]
			Placebo	66	54 (81.8)	0.35 (1.10)	-3.4	0.00	0.40	1.00	2.8	
		Week 20	Tezepelumab	57	49 (86.0)	1.03 (1.02)	-0.8	0.40	1.00	1.60	3.0	0.61 [0.21, 1.00]
			Placebo	66	54 (81.8)	0.39 (1.09)	-3.4	-0.20	0.50	1.20	2.4	
		Week 24	Tezepelumab	57	49 (86.0)	0.96 (1.11)	-1.4	0.00	1.00	1.60	3.0	0.44 [0.04, 0.83]
			Placebo	66	54 (81.8)	0.45 (1.20)	-3.4	-0.20	0.40	1.20	3.4	
		Week 28	Tezepelumab	57	49 (86.0)	1.07 (1.05)	-1.0	0.40	1.00	2.00	3.0	0.56 [0.17, 0.96]
			Placebo	66	54 (81.8)	0.40 (1.29)	-3.4	-0.20	0.40	1.20	3.4	
		Week 32	Tezepelumab	57	49 (86.0)	1.03 (1.04)	-1.0	0.40	1.00	1.80	3.0	0.57 [0.18, 0.96]
			Placebo	66	54 (81.8)	0.39 (1.19)	-3.4	-0.20	0.30	1.20	3.4	
		Week 36	Tezepelumab	57	49 (86.0)	1.09 (1.09)	-1.0	0.40	1.20	1.80	3.8	0.57 [0.18, 0.96]
			Placebo	66	54 (81.8)	0.47 (1.07)	-2.0	-0.20	0.40	1.20	3.6	
		Week 40	Tezepelumab	57	49 (86.0)	1.00 (1.14)	-1.2	0.00	1.00	1.80	3.2	0.48 [0.09, 0.87]
			Placebo	66	54 (81.8)	0.44 (1.20)	-2.0	-0.40	0.40	1.20	4.0	
		Week 44	Tezepelumab	57	49 (86.0)	1.01 (1.13)	-1.4	0.20	1.00	1.60	3.0	0.55 [0.16, 0.94]
			Placebo	66	54 (81.8)	0.38 (1.15)	-2.2	-0.40	0.40	1.20	3.6	
		Week 48	Tezepelumab	57	49 (86.0)	1.09 (1.08)	-1.4	0.40	1.00	1.80	3.2	0.59 [0.19, 0.98]
			Placebo	66	54 (81.8)	0.43 (1.17)	-2.2	-0.40	0.40	1.20	3.8	
		Week 52	Tezepelumab	57	49 (86.0)	1.06 (1.12)	-1.0	0.40	1.00	1.80	3.2	0.65 [0.26, 1.05]
			Placebo	66	54 (81.8)	0.27 (1.29)	-2.6	-0.60	0.20	1.20	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	71	66 (93.0)	4.30 (1.22)	1.4	3.60	4.20	5.00	6.8	
			Placebo	63	58 (92.1)	4.15 (1.25)	1.4	3.40	4.20	5.20	7.0	
		Week 4	Tezepelumab	71	63 (88.7)	5.05 (1.34)	1.2	4.00	5.40	6.00	7.0	
			Placebo	63	57 (90.5)	4.79 (1.23)	2.2	4.00	4.80	5.60	7.0	
		Week 8	Tezepelumab	71	65 (91.5)	5.12 (1.35)	1.8	4.00	5.20	6.00	7.0	
			Placebo	63	57 (90.5)	4.94 (1.34)	1.0	4.20	5.00	5.80	7.0	
		Week 12	Tezepelumab	71	65 (91.5)	5.31 (1.29)	2.0	4.40	5.60	6.40	7.0	
			Placebo	63	58 (92.1)	4.95 (1.25)	1.6	4.00	4.70	6.00	7.0	
		Week 16	Tezepelumab	71	65 (91.5)	5.30 (1.26)	2.2	4.20	5.60	6.20	7.0	
			Placebo	63	58 (92.1)	5.00 (1.32)	1.2	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	71	65 (91.5)	5.35 (1.23)	1.0	4.40	5.60	6.00	7.0	
			Placebo	63	58 (92.1)	5.10 (1.18)	1.4	4.40	5.00	6.00	7.0	
		Week 24	Tezepelumab	71	65 (91.5)	5.33 (1.22)	1.6	4.40	5.40	6.20	7.0	
			Placebo	63	58 (92.1)	5.16 (1.14)	2.2	4.40	5.00	6.00	7.0	
		Week 28	Tezepelumab	71	66 (93.0)	5.39 (1.15)	2.8	4.40	5.60	6.20	7.0	
			Placebo	63	59 (93.7)	5.19 (1.28)	1.6	4.40	5.20	6.00	7.0	
		Week 32	Tezepelumab	71	67 (94.4)	5.38 (1.29)	1.8	4.40	5.80	6.40	7.0	
			Placebo	63	59 (93.7)	5.24 (1.29)	1.6	4.40	5.60	6.20	7.0	
		Week 36	Tezepelumab	71	67 (94.4)	5.50 (1.22)	2.8	4.80	5.80	6.40	7.0	
			Placebo	63	59 (93.7)	5.21 (1.23)	1.8	4.40	5.40	6.00	7.0	
		Week 40	Tezepelumab	71	67 (94.4)	5.40 (1.31)	1.8	4.40	5.60	6.40	7.0	
			Placebo	63	59 (93.7)	5.31 (1.29)	1.6	4.40	5.40	6.40	7.0	
		Week 44	Tezepelumab	71	67 (94.4)	5.53 (1.20)	2.6	5.00	6.00	6.40	7.0	
			Placebo	63	59 (93.7)	5.28 (1.38)	1.6	4.20	5.60	6.60	7.0	
		Week 48	Tezepelumab	71	67 (94.4)	5.46 (1.25)	1.8	4.60	5.80	6.40	7.0	
			Placebo	63	59 (93.7)	5.26 (1.27)	1.8	4.40	5.40	6.40	7.0	
		Week 52	Tezepelumab	71	67 (94.4)	5.43 (1.26)	1.8	4.40	5.80	6.40	7.0	
			Placebo	63	59 (93.7)	5.29 (1.31)	1.8	4.40	5.40	6.40	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	71	61 (85.9)	0.74 (1.29)	-4.2	0.00	0.80	1.60	3.6	0.11 [-0.25, 0.47]
			Placebo	63	57 (90.5)	0.60 (1.12)	-2.8	0.00	0.60	1.20	3.6	
		Week 8	Tezepelumab	71	63 (88.7)	0.80 (1.21)	-2.2	-0.20	0.80	2.00	3.4	0.04 [-0.32, 0.40]
			Placebo	63	57 (90.5)	0.75 (1.30)	-2.0	0.00	0.80	1.40	4.0	
		Week 12	Tezepelumab	71	63 (88.7)	1.00 (1.22)	-2.4	0.20	0.80	2.00	3.6	0.14 [-0.22, 0.50]
			Placebo	63	57 (90.5)	0.82 (1.37)	-2.2	0.00	0.80	1.40	4.4	
		Week 16	Tezepelumab	71	63 (88.7)	0.99 (1.16)	-2.8	0.20	1.00	2.00	3.4	0.12 [-0.24, 0.48]
			Placebo	63	57 (90.5)	0.84 (1.32)	-2.0	0.20	0.80	1.40	4.4	
		Week 20	Tezepelumab	71	63 (88.7)	1.03 (1.21)	-1.4	0.00	1.00	2.00	4.4	0.09 [-0.27, 0.45]
			Placebo	63	57 (90.5)	0.93 (1.28)	-2.0	0.40	0.80	1.40	5.2	
		Week 24	Tezepelumab	71	63 (88.7)	1.00 (1.21)	-1.4	0.00	0.80	2.00	3.8	0.01 [-0.35, 0.37]
			Placebo	63	57 (90.5)	0.99 (1.27)	-2.0	0.20	0.80	1.80	4.2	
		Week 28	Tezepelumab	71	63 (88.7)	1.04 (1.19)	-1.4	0.20	0.80	2.00	4.2	0.04 [-0.32, 0.40]
			Placebo	63	57 (90.5)	0.99 (1.45)	-2.0	0.20	0.80	1.60	5.2	
		Week 32	Tezepelumab	71	63 (88.7)	1.00 (1.23)	-1.4	0.20	1.00	2.00	3.6	-0.04 [-0.40, 0.32]
			Placebo	63	57 (90.5)	1.05 (1.34)	-2.0	0.40	1.20	1.60	5.4	
		Week 36	Tezepelumab	71	63 (88.7)	1.14 (1.35)	-1.6	0.20	1.00	2.20	4.4	0.09 [-0.27, 0.45]
			Placebo	63	57 (90.5)	1.01 (1.30)	-2.0	0.20	1.00	1.80	4.2	
		Week 40	Tezepelumab	71	63 (88.7)	1.03 (1.27)	-2.4	0.20	1.00	2.00	3.4	-0.07 [-0.43, 0.29]
			Placebo	63	57 (90.5)	1.12 (1.45)	-2.0	0.20	1.20	1.80	5.4	
		Week 44	Tezepelumab	71	63 (88.7)	1.16 (1.21)	-1.4	0.20	1.20	2.00	3.8	0.06 [-0.30, 0.41]
			Placebo	63	57 (90.5)	1.08 (1.48)	-2.0	0.40	1.00	1.80	5.2	
		Week 48	Tezepelumab	71	63 (88.7)	1.09 (1.25)	-1.4	0.00	1.00	2.20	3.8	0.02 [-0.34, 0.38]
			Placebo	63	57 (90.5)	1.06 (1.38)	-2.0	0.20	0.80	1.80	5.0	
		Week 52	Tezepelumab	71	63 (88.7)	1.05 (1.25)	-1.6	0.00	1.00	2.00	3.8	-0.03 [-0.39, 0.33]
			Placebo	63	57 (90.5)	1.09 (1.39)	-2.0	0.20	1.00	1.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	35	31 (88.6)	4.50 (1.08)	1.8	3.80	4.60	5.40	6.8	
			Placebo	32	26 (81.3)	4.54 (1.32)	1.6	3.80	4.40	5.20	7.0	
		Week 4	Tezepelumab	35	33 (94.3)	5.18 (1.11)	3.0	4.20	5.20	6.00	7.0	
			Placebo	32	26 (81.3)	4.88 (1.53)	1.4	4.00	4.90	6.00	7.0	
		Week 8	Tezepelumab	35	33 (94.3)	5.31 (1.06)	3.4	4.60	5.00	6.20	7.0	
			Placebo	32	28 (87.5)	4.86 (1.44)	1.4	3.90	4.80	5.90	7.0	
		Week 12	Tezepelumab	35	33 (94.3)	5.59 (1.04)	4.0	4.60	5.60	6.60	7.0	
			Placebo	32	28 (87.5)	4.96 (1.49)	1.4	4.00	4.70	6.30	7.0	
		Week 16	Tezepelumab	35	33 (94.3)	5.51 (0.99)	4.0	4.60	5.60	6.20	7.0	
			Placebo	32	28 (87.5)	4.78 (1.63)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	35	34 (97.1)	5.51 (1.03)	4.0	4.60	5.70	6.20	7.0	
			Placebo	32	28 (87.5)	4.82 (1.66)	1.0	4.00	4.80	6.40	7.0	
		Week 24	Tezepelumab	35	34 (97.1)	5.58 (1.02)	3.6	4.60	5.80	6.40	7.0	
			Placebo	32	28 (87.5)	4.80 (1.71)	1.0	3.80	4.90	6.40	7.0	
		Week 28	Tezepelumab	35	35 (100.0)	5.57 (1.08)	4.0	4.60	5.60	6.40	7.0	
			Placebo	32	28 (87.5)	4.50 (1.73)	1.0	3.40	4.20	6.10	7.0	
		Week 32	Tezepelumab	35	35 (100.0)	5.44 (1.02)	3.8	4.60	5.60	6.40	7.0	
			Placebo	32	28 (87.5)	4.69 (1.71)	1.0	3.90	4.80	6.10	7.0	
		Week 36	Tezepelumab	35	35 (100.0)	5.68 (1.01)	3.8	4.60	6.00	6.40	7.0	
			Placebo	32	28 (87.5)	4.95 (1.57)	1.6	4.00	4.90	6.40	7.0	
		Week 40	Tezepelumab	35	35 (100.0)	5.42 (1.06)	3.8	4.40	5.40	6.40	7.0	
			Placebo	32	28 (87.5)	4.76 (1.56)	1.6	3.50	4.80	6.10	7.0	
		Week 44	Tezepelumab	35	35 (100.0)	5.48 (1.05)	4.0	4.40	5.40	6.40	7.0	
			Placebo	32	28 (87.5)	4.88 (1.63)	1.4	3.70	4.90	6.30	7.0	
		Week 48	Tezepelumab	35	35 (100.0)	5.59 (1.08)	3.8	4.60	5.80	6.60	7.0	
			Placebo	32	28 (87.5)	4.89 (1.67)	1.2	4.00	4.70	6.70	7.0	
		Week 52	Tezepelumab	35	35 (100.0)	5.53 (1.10)	4.0	4.40	5.60	6.80	7.0	
			Placebo	32	28 (87.5)	4.61 (1.63)	1.2	3.60	4.40	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	35	31 (88.6)	0.78 (1.27)	-1.8	0.00	0.60	1.80	3.8	0.36 [-0.17, 0.89]
			Placebo	32	25 (78.1)	0.38 (0.87)	-2.0	-0.20	0.20	1.00	2.0	
		Week 8	Tezepelumab	35	31 (88.6)	0.81 (1.40)	-1.2	-0.20	0.60	1.60	4.4	0.34 [-0.19, 0.86]
			Placebo	32	26 (81.3)	0.39 (1.00)	-1.2	-0.20	0.00	1.00	3.0	
		Week 12	Tezepelumab	35	31 (88.6)	1.07 (1.28)	-1.6	0.20	1.00	2.00	3.8	0.49 [-0.04, 1.02]
			Placebo	32	26 (81.3)	0.49 (1.06)	-1.8	-0.20	0.50	1.20	3.0	
		Week 16	Tezepelumab	35	31 (88.6)	1.01 (1.30)	-1.4	0.00	1.00	2.00	4.0	0.57 [0.04, 1.10]
			Placebo	32	26 (81.3)	0.28 (1.24)	-3.4	-0.20	0.30	1.20	2.0	
		Week 20	Tezepelumab	35	31 (88.6)	1.02 (1.31)	-0.8	0.00	1.00	1.60	4.6	0.49 [-0.04, 1.02]
			Placebo	32	26 (81.3)	0.35 (1.41)	-3.4	-0.20	0.20	1.20	3.0	
		Week 24	Tezepelumab	35	31 (88.6)	1.08 (1.29)	-1.4	0.00	1.00	2.00	4.6	0.55 [0.02, 1.09]
			Placebo	32	26 (81.3)	0.32 (1.46)	-3.4	-0.40	0.20	1.20	3.2	
		Week 28	Tezepelumab	35	31 (88.6)	1.11 (1.36)	-1.0	0.00	0.80	2.00	4.6	0.79 [0.25, 1.34]
			Placebo	32	26 (81.3)	0.02 (1.41)	-3.4	-0.80	0.00	1.00	3.0	
		Week 32	Tezepelumab	35	31 (88.6)	0.95 (1.29)	-1.6	0.00	1.00	1.60	4.6	0.57 [0.04, 1.11]
			Placebo	32	26 (81.3)	0.21 (1.29)	-3.4	-0.40	0.00	1.00	2.8	
		Week 36	Tezepelumab	35	31 (88.6)	1.21 (1.30)	-1.0	0.40	1.00	1.80	4.6	0.58 [0.05, 1.12]
			Placebo	32	26 (81.3)	0.48 (1.16)	-2.0	-0.20	0.20	1.20	3.2	
		Week 40	Tezepelumab	35	31 (88.6)	0.94 (1.30)	-1.2	0.00	0.80	1.60	4.6	0.51 [-0.02, 1.04]
			Placebo	32	26 (81.3)	0.30 (1.20)	-2.0	-0.40	0.00	1.20	2.6	
		Week 44	Tezepelumab	35	31 (88.6)	0.98 (1.28)	-1.0	0.00	1.20	1.60	4.6	0.43 [-0.10, 0.96]
			Placebo	32	26 (81.3)	0.43 (1.27)	-1.8	-0.40	0.00	1.20	3.0	
		Week 48	Tezepelumab	35	31 (88.6)	1.12 (1.23)	-0.8	0.00	1.20	2.00	4.6	0.56 [0.02, 1.09]
			Placebo	32	26 (81.3)	0.42 (1.29)	-2.2	-0.40	0.10	1.00	3.2	
		Week 52	Tezepelumab	35	31 (88.6)	1.03 (1.34)	-1.0	0.00	1.20	2.00	4.6	0.70 [0.16, 1.24]
			Placebo	32	26 (81.3)	0.12 (1.26)	-2.6	-0.60	-0.20	0.80	3.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	95	86 (90.5)	4.28 (1.17)	1.4	3.60	4.20	5.00	6.8	
			Placebo	98	87 (88.8)	4.13 (1.23)	1.0	3.40	4.20	5.00	6.6	
		Week 4	Tezepelumab	95	86 (90.5)	4.93 (1.24)	1.2	4.00	5.00	6.00	7.0	
			Placebo	98	89 (90.8)	4.58 (1.24)	1.6	3.80	4.60	5.60	7.0	
		Week 8	Tezepelumab	95	88 (92.6)	5.16 (1.26)	1.8	4.40	5.20	6.10	7.0	
			Placebo	98	90 (91.8)	4.80 (1.28)	1.0	4.00	5.00	5.60	7.0	
		Week 12	Tezepelumab	95	88 (92.6)	5.30 (1.24)	2.0	4.40	5.40	6.30	7.0	
			Placebo	98	91 (92.9)	4.85 (1.29)	1.6	4.00	4.60	5.80	7.0	
		Week 16	Tezepelumab	95	88 (92.6)	5.27 (1.24)	2.2	4.40	5.50	6.20	7.0	
			Placebo	98	91 (92.9)	4.89 (1.31)	1.2	4.00	4.80	6.00	7.0	
		Week 20	Tezepelumab	95	88 (92.6)	5.32 (1.23)	1.0	4.40	5.50	6.40	7.0	
			Placebo	98	91 (92.9)	4.94 (1.23)	1.4	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	95	88 (92.6)	5.29 (1.23)	1.6	4.40	5.40	6.20	7.0	
			Placebo	98	91 (92.9)	5.07 (1.17)	2.2	4.20	5.00	6.00	7.0	
		Week 28	Tezepelumab	95	89 (93.7)	5.40 (1.10)	2.8	4.60	5.60	6.20	7.0	
			Placebo	98	92 (93.9)	5.09 (1.29)	2.2	4.00	5.20	6.00	7.0	
		Week 32	Tezepelumab	95	90 (94.7)	5.38 (1.23)	1.8	4.40	5.80	6.20	7.0	
			Placebo	98	93 (94.9)	5.07 (1.26)	1.6	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	95	90 (94.7)	5.42 (1.21)	2.8	4.60	5.60	6.40	7.0	
			Placebo	98	93 (94.9)	5.06 (1.25)	1.8	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	95	90 (94.7)	5.37 (1.28)	1.8	4.60	5.60	6.40	7.0	
			Placebo	98	93 (94.9)	5.11 (1.30)	1.6	4.20	5.00	6.40	7.0	
		Week 44	Tezepelumab	95	90 (94.7)	5.50 (1.21)	2.6	4.80	5.70	6.40	7.0	
			Placebo	98	93 (94.9)	5.10 (1.35)	1.6	4.00	5.20	6.20	7.0	
		Week 48	Tezepelumab	95	90 (94.7)	5.44 (1.19)	1.8	4.60	5.60	6.40	7.0	
			Placebo	98	94 (95.9)	5.09 (1.28)	1.8	4.00	5.00	6.20	7.0	
		Week 52	Tezepelumab	95	90 (94.7)	5.43 (1.20)	1.8	4.60	5.70	6.20	7.0	
			Placebo	98	94 (95.9)	5.07 (1.35)	1.8	4.00	4.90	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	95	80 (84.2)	0.66 (1.20)	-4.2	0.00	0.60	1.50	3.6	0.20 [-0.11, 0.50]
			Placebo	98	86 (87.8)	0.42 (1.16)	-2.8	-0.20	0.40	1.00	3.6	
		Week 8	Tezepelumab	95	82 (86.3)	0.87 (1.16)	-1.4	0.20	0.80	1.60	5.0	0.18 [-0.13, 0.48]
			Placebo	98	86 (87.8)	0.66 (1.25)	-2.0	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	95	82 (86.3)	1.01 (1.24)	-2.4	0.20	0.80	1.80	5.4	0.22 [-0.09, 0.52]
			Placebo	98	86 (87.8)	0.73 (1.34)	-2.2	0.00	0.80	1.60	4.4	
		Week 16	Tezepelumab	95	82 (86.3)	0.99 (1.19)	-2.8	0.20	0.80	1.60	5.2	0.19 [-0.11, 0.49]
			Placebo	98	86 (87.8)	0.76 (1.26)	-2.0	0.20	0.80	1.40	4.4	
		Week 20	Tezepelumab	95	82 (86.3)	1.07 (1.22)	-1.4	0.20	0.90	2.00	5.2	0.21 [-0.09, 0.52]
			Placebo	98	86 (87.8)	0.81 (1.21)	-2.0	0.20	0.80	1.40	5.2	
		Week 24	Tezepelumab	95	82 (86.3)	1.04 (1.24)	-1.4	0.20	0.80	2.00	5.4	0.07 [-0.23, 0.38]
			Placebo	98	86 (87.8)	0.95 (1.23)	-2.0	0.20	0.80	1.60	4.2	
		Week 28	Tezepelumab	95	82 (86.3)	1.10 (1.19)	-1.4	0.40	0.80	2.00	5.4	0.10 [-0.20, 0.41]
			Placebo	98	86 (87.8)	0.96 (1.37)	-2.0	0.20	1.00	1.80	5.2	
		Week 32	Tezepelumab	95	82 (86.3)	1.09 (1.25)	-1.4	0.20	1.00	2.00	5.4	0.10 [-0.21, 0.40]
			Placebo	98	86 (87.8)	0.96 (1.31)	-2.0	0.00	1.00	1.80	5.4	
		Week 36	Tezepelumab	95	82 (86.3)	1.13 (1.34)	-1.6	0.20	1.00	2.00	5.4	0.15 [-0.15, 0.46]
			Placebo	98	86 (87.8)	0.93 (1.28)	-2.0	0.20	0.80	1.80	4.2	
		Week 40	Tezepelumab	95	82 (86.3)	1.09 (1.31)	-2.4	0.20	1.00	2.00	5.4	0.07 [-0.23, 0.38]
			Placebo	98	86 (87.8)	0.99 (1.41)	-2.0	0.00	0.90	1.80	5.4	
		Week 44	Tezepelumab	95	82 (86.3)	1.19 (1.26)	-1.4	0.40	1.20	2.00	5.4	0.17 [-0.13, 0.48]
			Placebo	98	86 (87.8)	0.95 (1.43)	-2.2	0.20	1.00	1.80	5.2	
		Week 48	Tezepelumab	95	82 (86.3)	1.14 (1.28)	-1.4	0.20	1.00	2.00	5.4	0.14 [-0.16, 0.44]
			Placebo	98	86 (87.8)	0.96 (1.37)	-2.0	0.00	0.80	1.80	5.0	
		Week 52	Tezepelumab	95	82 (86.3)	1.12 (1.27)	-1.6	0.20	1.00	2.00	5.4	0.13 [-0.17, 0.44]
			Placebo	98	86 (87.8)	0.94 (1.43)	-2.0	0.00	1.00	1.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	4.13 (1.39)	1.6	3.80	4.50	5.00	5.4	
			Placebo	8	8 (100.0)	4.38 (0.98)	2.8	3.80	4.20	5.30	5.6	
		Week 4	Tezepelumab	7	7 (100.0)	4.60 (0.86)	3.4	4.00	4.40	5.60	5.8	
			Placebo	8	8 (100.0)	5.25 (1.30)	3.2	4.30	5.40	6.20	7.0	
		Week 8	Tezepelumab	7	7 (100.0)	4.63 (1.09)	2.8	4.00	5.00	5.40	6.0	
			Placebo	8	8 (100.0)	4.95 (1.34)	3.0	4.10	4.70	6.00	7.0	
		Week 12	Tezepelumab	7	7 (100.0)	4.97 (0.71)	4.2	4.40	5.00	5.80	6.0	
			Placebo	8	8 (100.0)	5.08 (1.18)	3.6	4.30	4.80	5.90	7.0	
		Week 16	Tezepelumab	7	7 (100.0)	4.89 (0.69)	4.0	4.20	5.00	5.40	6.0	
			Placebo	8	8 (100.0)	5.23 (1.19)	3.6	4.40	5.00	6.20	7.0	
		Week 20	Tezepelumab	7	7 (100.0)	5.20 (0.77)	4.0	4.40	5.40	5.80	6.0	
			Placebo	8	8 (100.0)	5.40 (1.05)	3.8	4.80	5.20	6.20	7.0	
		Week 24	Tezepelumab	7	7 (100.0)	4.91 (1.00)	3.8	4.00	5.00	6.00	6.2	
			Placebo	8	8 (100.0)	5.03 (1.28)	2.8	4.40	4.90	5.90	7.0	
		Week 28	Tezepelumab	7	7 (100.0)	5.11 (0.76)	4.0	4.40	5.00	6.00	6.0	
			Placebo	8	8 (100.0)	5.13 (1.09)	3.8	4.30	4.90	5.90	7.0	
		Week 32	Tezepelumab	7	7 (100.0)	5.40 (0.73)	4.6	4.80	5.40	6.00	6.6	
			Placebo	8	8 (100.0)	5.10 (1.44)	2.6	4.20	5.30	6.10	7.0	
		Week 36	Tezepelumab	7	7 (100.0)	5.46 (0.85)	4.0	5.00	5.40	6.00	6.6	
			Placebo	8	8 (100.0)	5.03 (1.54)	2.2	4.30	5.00	6.20	7.0	
		Week 40	Tezepelumab	7	7 (100.0)	5.43 (0.99)	3.8	4.80	5.40	6.40	6.6	
			Placebo	8	8 (100.0)	5.33 (1.30)	3.4	4.30	5.40	6.40	7.0	
		Week 44	Tezepelumab	7	7 (100.0)	5.49 (0.97)	3.8	5.00	5.40	6.20	6.8	
			Placebo	8	8 (100.0)	5.00 (1.59)	2.6	3.70	5.20	6.30	7.0	
		Week 48	Tezepelumab	7	7 (100.0)	5.34 (0.99)	3.8	4.60	5.40	6.40	6.4	
			Placebo	8	8 (100.0)	5.08 (1.44)	2.8	4.30	4.80	6.30	7.0	
		Week 52	Tezepelumab	7	7 (100.0)	5.43 (1.05)	3.8	4.60	5.40	6.40	6.8	
			Placebo	8	8 (100.0)	5.05 (1.43)	2.8	4.30	4.80	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	0.53 (1.05)	-0.6	-0.60	0.50	1.60	1.8	-0.44 [-1.52, 0.63]
			Placebo	8	8 (100.0)	0.88 (0.49)	0.4	0.40	0.80	1.30	1.6	
		Week 8	Tezepelumab	7	6 (85.7)	0.40 (1.60)	-2.2	-0.40	0.60	1.40	2.4	-0.14 [-1.20, 0.92]
			Placebo	8	8 (100.0)	0.58 (0.95)	-1.2	0.00	0.90	1.30	1.4	
		Week 12	Tezepelumab	7	6 (85.7)	0.83 (1.35)	-1.0	0.00	0.70	1.80	2.8	0.13 [-0.93, 1.19]
			Placebo	8	8 (100.0)	0.70 (0.80)	-0.6	0.00	1.00	1.30	1.6	
		Week 16	Tezepelumab	7	6 (85.7)	0.73 (1.20)	-0.8	0.00	0.60	1.40	2.6	-0.13 [-1.19, 0.93]
			Placebo	8	8 (100.0)	0.85 (0.64)	-0.2	0.40	1.00	1.40	1.4	
		Week 20	Tezepelumab	7	6 (85.7)	0.97 (1.10)	-0.4	0.20	0.90	1.40	2.8	-0.07 [-1.13, 0.98]
			Placebo	8	8 (100.0)	1.03 (0.43)	0.2	0.80	1.10	1.30	1.6	
		Week 24	Tezepelumab	7	6 (85.7)	0.57 (1.26)	-1.0	-0.40	0.50	1.40	2.4	-0.09 [-1.14, 0.97]
			Placebo	8	8 (100.0)	0.65 (0.70)	-0.4	0.00	0.80	1.30	1.4	
		Week 28	Tezepelumab	7	6 (85.7)	0.83 (1.17)	-0.4	0.00	0.60	1.40	2.8	0.10 [-0.96, 1.15]
			Placebo	8	8 (100.0)	0.75 (0.57)	-0.4	0.50	0.80	1.20	1.4	
		Week 32	Tezepelumab	7	6 (85.7)	1.07 (1.29)	-0.8	0.60	1.00	1.40	3.2	0.34 [-0.73, 1.41]
			Placebo	8	8 (100.0)	0.73 (0.72)	-0.4	0.10	1.00	1.30	1.4	
		Week 36	Tezepelumab	7	6 (85.7)	1.13 (1.37)	-0.4	0.20	1.00	1.40	3.6	0.46 [-0.62, 1.53]
			Placebo	8	8 (100.0)	0.65 (0.75)	-0.6	0.10	0.80	1.30	1.4	
		Week 40	Tezepelumab	7	6 (85.7)	1.10 (1.38)	-0.6	0.00	1.20	1.40	3.4	0.14 [-0.92, 1.20]
			Placebo	8	8 (100.0)	0.95 (0.76)	-0.8	0.80	1.20	1.40	1.6	
		Week 44	Tezepelumab	7	6 (85.7)	1.13 (1.40)	-0.4	0.00	1.10	1.40	3.6	0.41 [-0.66, 1.49]
			Placebo	8	8 (100.0)	0.63 (1.09)	-1.6	0.20	0.90	1.30	1.8	
		Week 48	Tezepelumab	7	6 (85.7)	1.03 (1.25)	-0.6	0.00	1.20	1.40	3.0	0.35 [-0.72, 1.42]
			Placebo	8	8 (100.0)	0.70 (0.66)	-0.2	0.20	0.60	1.30	1.6	
		Week 52	Tezepelumab	7	6 (85.7)	1.07 (1.20)	-0.4	0.00	1.20	1.40	3.0	0.42 [-0.65, 1.49]
			Placebo	8	8 (100.0)	0.68 (0.68)	-0.2	0.10	0.60	1.30	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.08 (1.04)	2.2	3.60	4.10	4.70	5.6	
			Placebo	13	9 (69.2)	4.53 (1.06)	3.4	4.20	4.20	4.60	7.0	
		Week 4	Tezepelumab	9	8 (88.9)	5.00 (0.96)	3.8	4.10	5.00	5.90	6.2	
			Placebo	13	11 (84.6)	5.02 (1.58)	1.6	3.80	4.80	6.40	7.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.50 (1.04)	4.0	4.70	5.60	6.20	7.0	
			Placebo	13	12 (92.3)	4.75 (1.27)	3.0	3.80	4.80	5.60	7.0	
		Week 12	Tezepelumab	9	8 (88.9)	5.55 (1.08)	4.0	4.70	5.60	6.40	7.0	
			Placebo	13	12 (92.3)	4.65 (1.47)	1.8	3.60	4.50	6.10	7.0	
		Week 16	Tezepelumab	9	8 (88.9)	5.85 (1.06)	4.0	5.20	5.90	6.80	7.0	
			Placebo	13	12 (92.3)	4.95 (1.21)	2.6	4.30	4.80	5.90	7.0	
		Week 20	Tezepelumab	9	8 (88.9)	5.35 (1.02)	4.0	4.50	5.20	6.30	6.8	
			Placebo	13	12 (92.3)	5.10 (1.08)	3.0	4.50	4.90	5.90	7.0	
		Week 24	Tezepelumab	9	8 (88.9)	5.48 (1.12)	4.0	4.50	5.60	6.30	7.0	
			Placebo	13	12 (92.3)	4.93 (1.18)	2.8	4.30	4.70	5.80	7.0	
		Week 28	Tezepelumab	9	8 (88.9)	5.33 (0.99)	4.0	4.50	5.30	6.20	6.6	
			Placebo	13	13 (100.0)	4.97 (1.28)	2.6	4.40	4.60	6.00	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.43 (1.04)	4.0	4.60	5.40	6.20	7.0	
			Placebo	13	13 (100.0)	5.05 (1.39)	2.2	4.40	4.60	6.00	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.43 (1.09)	4.0	4.40	5.60	6.20	7.0	
			Placebo	13	13 (100.0)	5.03 (1.48)	1.6	4.40	4.80	6.00	7.0	
		Week 40	Tezepelumab	9	8 (88.9)	5.25 (1.20)	3.8	4.20	5.10	6.30	7.0	
			Placebo	13	13 (100.0)	4.88 (1.57)	1.6	4.20	4.60	6.00	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.45 (1.09)	4.0	4.50	5.50	6.30	7.0	
			Placebo	13	13 (100.0)	4.89 (1.59)	1.8	4.40	4.60	6.00	7.0	
		Week 48	Tezepelumab	9	8 (88.9)	5.25 (0.94)	4.0	4.30	5.50	6.00	6.4	
			Placebo	13	13 (100.0)	4.97 (1.58)	1.4	4.40	4.80	6.00	7.0	
		Week 52	Tezepelumab	9	8 (88.9)	5.43 (1.12)	4.0	4.30	5.70	6.20	7.0	
			Placebo	13	13 (100.0)	4.97 (1.47)	2.0	4.40	4.80	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.89 (0.75)	0.2	0.20	0.60	1.80	2.0	0.41 [-0.59, 1.41]
			Placebo	13	9 (69.2)	0.47 (1.19)	-2.0	0.20	0.40	1.60	1.8	
		Week 8	Tezepelumab	9	7 (77.8)	1.34 (0.67)	0.4	1.00	1.20	2.00	2.4	0.94 [-0.11, 1.98]
			Placebo	13	9 (69.2)	0.40 (1.20)	-1.2	-0.60	0.60	1.20	1.8	
		Week 12	Tezepelumab	9	7 (77.8)	1.43 (0.98)	0.2	0.40	1.40	2.20	3.0	1.15 [0.08, 2.23]
			Placebo	13	9 (69.2)	0.09 (1.28)	-1.8	-0.80	0.00	1.20	1.8	
		Week 16	Tezepelumab	9	7 (77.8)	1.66 (1.02)	0.4	1.00	1.40	2.60	3.4	1.13 [0.06, 2.21]
			Placebo	13	9 (69.2)	0.49 (1.04)	-1.0	0.00	0.40	1.40	1.8	
		Week 20	Tezepelumab	9	7 (77.8)	1.43 (0.98)	0.4	0.60	1.20	2.20	3.2	0.78 [-0.25, 1.81]
			Placebo	13	9 (69.2)	0.64 (1.03)	-1.0	-0.20	0.80	1.60	1.8	
		Week 24	Tezepelumab	9	7 (77.8)	1.49 (1.30)	0.0	0.40	1.40	2.40	3.8	0.75 [-0.28, 1.77]
			Placebo	13	9 (69.2)	0.58 (1.15)	-1.0	-0.20	0.60	1.40	2.2	
		Week 28	Tezepelumab	9	7 (77.8)	1.34 (1.19)	0.4	0.60	0.80	2.40	3.6	0.80 [-0.23, 1.83]
			Placebo	13	9 (69.2)	0.42 (1.11)	-1.0	-0.40	0.60	1.20	1.8	
		Week 32	Tezepelumab	9	7 (77.8)	1.46 (1.14)	0.4	0.40	1.40	2.20	3.6	0.73 [-0.29, 1.75]
			Placebo	13	9 (69.2)	0.56 (1.30)	-1.4	-0.40	1.20	1.80	1.8	
		Week 36	Tezepelumab	9	7 (77.8)	1.54 (1.14)	0.4	0.80	1.20	2.20	3.8	0.85 [-0.19, 1.88]
			Placebo	13	9 (69.2)	0.44 (1.40)	-2.0	-0.20	1.00	1.20	2.4	
		Week 40	Tezepelumab	9	7 (77.8)	1.26 (1.18)	-0.2	0.40	0.80	2.40	3.2	0.66 [-0.36, 1.67]
			Placebo	13	9 (69.2)	0.38 (1.45)	-2.0	-0.80	0.60	1.60	2.2	
		Week 44	Tezepelumab	9	7 (77.8)	1.49 (1.28)	0.2	0.40	1.40	2.40	3.8	0.94 [-0.11, 1.99]
			Placebo	13	9 (69.2)	0.16 (1.51)	-1.8	-1.00	-0.20	1.80	1.8	
		Week 48	Tezepelumab	9	7 (77.8)	1.29 (1.33)	0.0	0.40	0.80	2.20	3.8	0.65 [-0.37, 1.66]
			Placebo	13	9 (69.2)	0.38 (1.46)	-2.2	-0.20	0.60	1.20	2.6	
		Week 52	Tezepelumab	9	7 (77.8)	1.49 (1.20)	0.4	0.40	1.40	2.20	3.8	0.81 [-0.22, 1.84]
			Placebo	13	9 (69.2)	0.44 (1.34)	-1.6	-0.20	0.60	1.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.35 (1.16)	1.4	3.80	4.40	5.20	6.8	
			Placebo	125	112 (89.6)	4.21 (1.25)	1.0	3.60	4.20	5.00	7.0	
		Week 4	Tezepelumab	128	118 (92.2)	4.97 (1.21)	1.2	4.00	5.00	6.00	7.0	
			Placebo	125	112 (89.6)	4.66 (1.29)	1.4	3.80	4.60	5.60	7.0	
		Week 8	Tezepelumab	128	120 (93.8)	5.15 (1.21)	1.8	4.30	5.10	6.00	7.0	
			Placebo	125	114 (91.2)	4.83 (1.32)	1.0	4.00	4.80	5.80	7.0	
		Week 12	Tezepelumab	128	120 (93.8)	5.35 (1.18)	2.0	4.40	5.40	6.40	7.0	
			Placebo	125	115 (92.0)	4.92 (1.31)	1.4	4.00	4.80	6.00	7.0	
		Week 16	Tezepelumab	128	120 (93.8)	5.28 (1.16)	2.2	4.40	5.40	6.10	7.0	
			Placebo	125	115 (92.0)	4.88 (1.39)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	128	121 (94.5)	5.36 (1.17)	1.0	4.40	5.60	6.20	7.0	
			Placebo	125	115 (92.0)	4.93 (1.34)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	128	121 (94.5)	5.34 (1.18)	1.6	4.40	5.40	6.20	7.0	
			Placebo	125	115 (92.0)	5.02 (1.32)	1.0	4.00	5.00	6.00	7.0	
		Week 28	Tezepelumab	128	123 (96.1)	5.43 (1.09)	2.8	4.60	5.60	6.20	7.0	
			Placebo	125	115 (92.0)	4.96 (1.41)	1.0	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	128	124 (96.9)	5.39 (1.16)	1.8	4.60	5.60	6.20	7.0	
			Placebo	125	116 (92.8)	4.98 (1.38)	1.0	4.00	5.00	6.10	7.0	
		Week 36	Tezepelumab	128	124 (96.9)	5.49 (1.15)	2.8	4.60	5.70	6.40	7.0	
			Placebo	125	116 (92.8)	5.04 (1.32)	1.8	4.00	5.00	6.10	7.0	
		Week 40	Tezepelumab	128	124 (96.9)	5.39 (1.21)	1.8	4.60	5.50	6.40	7.0	
			Placebo	125	116 (92.8)	5.06 (1.34)	1.6	4.00	5.00	6.30	7.0	
		Week 44	Tezepelumab	128	124 (96.9)	5.49 (1.16)	2.6	4.60	5.60	6.40	7.0	
			Placebo	125	116 (92.8)	5.06 (1.41)	1.4	4.00	5.10	6.40	7.0	
		Week 48	Tezepelumab	128	124 (96.9)	5.49 (1.16)	1.8	4.60	5.70	6.40	7.0	
			Placebo	125	117 (93.6)	5.05 (1.35)	1.2	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	128	124 (96.9)	5.46 (1.17)	1.8	4.60	5.60	6.40	7.0	
			Placebo	125	117 (93.6)	4.97 (1.42)	1.2	4.00	4.80	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	110 (85.9)	0.67 (1.23)	-4.2	0.00	0.60	1.60	3.8	0.20 [-0.07, 0.46]
			Placebo	125	110 (88.0)	0.44 (1.07)	-2.8	-0.20	0.40	1.00	3.6	
		Week 8	Tezepelumab	128	112 (87.5)	0.80 (1.27)	-2.2	0.00	0.60	1.60	5.0	0.15 [-0.11, 0.42]
			Placebo	125	111 (88.8)	0.61 (1.18)	-2.0	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	128	112 (87.5)	0.99 (1.26)	-2.4	0.20	0.80	1.80	5.4	0.21 [-0.05, 0.48]
			Placebo	125	111 (88.8)	0.73 (1.25)	-2.2	0.00	0.80	1.40	4.4	
		Week 16	Tezepelumab	128	112 (87.5)	0.94 (1.22)	-2.8	0.00	0.90	1.60	5.2	0.21 [-0.05, 0.48]
			Placebo	125	111 (88.8)	0.67 (1.25)	-3.4	0.00	0.60	1.40	4.4	
		Week 20	Tezepelumab	128	112 (87.5)	1.03 (1.24)	-1.4	0.10	0.90	1.90	5.2	0.24 [-0.03, 0.50]
			Placebo	125	111 (88.8)	0.73 (1.25)	-3.4	0.00	0.80	1.40	5.2	
		Week 24	Tezepelumab	128	112 (87.5)	1.00 (1.25)	-1.4	0.00	0.80	2.00	5.4	0.15 [-0.12, 0.41]
			Placebo	125	111 (88.8)	0.81 (1.29)	-3.4	0.00	0.80	1.60	4.2	
		Week 28	Tezepelumab	128	112 (87.5)	1.07 (1.23)	-1.4	0.00	0.90	2.00	5.4	0.23 [-0.04, 0.49]
			Placebo	125	111 (88.8)	0.77 (1.41)	-3.4	0.00	0.80	1.60	5.2	
		Week 32	Tezepelumab	128	112 (87.5)	1.02 (1.26)	-1.6	0.00	1.00	2.00	5.4	0.17 [-0.09, 0.44]
			Placebo	125	111 (88.8)	0.80 (1.31)	-3.4	-0.20	0.80	1.60	5.4	
		Week 36	Tezepelumab	128	112 (87.5)	1.13 (1.33)	-1.6	0.20	1.00	2.00	5.4	0.22 [-0.04, 0.48]
			Placebo	125	111 (88.8)	0.84 (1.22)	-2.0	0.00	0.60	1.60	4.2	
		Week 40	Tezepelumab	128	112 (87.5)	1.04 (1.31)	-2.4	0.00	1.00	2.00	5.4	0.12 [-0.14, 0.39]
			Placebo	125	111 (88.8)	0.87 (1.35)	-2.0	0.00	0.80	1.40	5.4	
		Week 44	Tezepelumab	128	112 (87.5)	1.11 (1.26)	-1.4	0.20	1.20	2.00	5.4	0.18 [-0.08, 0.44]
			Placebo	125	111 (88.8)	0.87 (1.37)	-2.2	-0.20	0.80	1.60	5.2	
		Week 48	Tezepelumab	128	112 (87.5)	1.12 (1.26)	-1.4	0.20	1.00	2.00	5.4	0.20 [-0.06, 0.47]
			Placebo	125	111 (88.8)	0.86 (1.32)	-2.0	0.00	0.80	1.60	5.0	
		Week 52	Tezepelumab	128	112 (87.5)	1.07 (1.28)	-1.6	0.00	1.00	2.00	5.4	0.23 [-0.04, 0.49]
			Placebo	125	111 (88.8)	0.77 (1.40)	-2.6	-0.20	0.80	1.40	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	4.38 (1.15)	1.4	3.80	4.40	5.10	6.8	
			Placebo	73	66 (90.4)	4.11 (1.29)	1.4	3.00	4.10	5.00	7.0	
		Week 4	Tezepelumab	70	65 (92.9)	5.07 (1.22)	1.6	4.20	5.00	6.00	7.0	
			Placebo	73	66 (90.4)	4.51 (1.31)	1.4	3.60	4.40	5.60	7.0	
		Week 8	Tezepelumab	70	65 (92.9)	5.18 (1.22)	1.8	4.60	5.20	6.00	7.0	
			Placebo	73	67 (91.8)	4.69 (1.43)	1.0	3.80	4.60	5.60	7.0	
		Week 12	Tezepelumab	70	65 (92.9)	5.36 (1.18)	2.0	4.40	5.40	6.40	7.0	
			Placebo	73	68 (93.2)	4.70 (1.38)	1.4	4.00	4.60	5.80	7.0	
		Week 16	Tezepelumab	70	65 (92.9)	5.32 (1.12)	2.2	4.40	5.40	6.00	7.0	
			Placebo	73	68 (93.2)	4.72 (1.43)	1.2	3.90	4.60	6.00	7.0	
		Week 20	Tezepelumab	70	65 (92.9)	5.34 (1.17)	1.0	4.40	5.40	6.00	7.0	
			Placebo	73	68 (93.2)	4.87 (1.38)	1.4	4.00	4.80	6.00	7.0	
		Week 24	Tezepelumab	70	65 (92.9)	5.41 (1.13)	1.6	4.60	5.40	6.20	7.0	
			Placebo	73	68 (93.2)	5.02 (1.33)	1.4	4.00	4.80	6.00	7.0	
		Week 28	Tezepelumab	70	65 (92.9)	5.49 (1.04)	2.8	4.60	5.60	6.20	7.0	
			Placebo	73	68 (93.2)	4.86 (1.45)	1.6	3.90	4.70	6.10	7.0	
		Week 32	Tezepelumab	70	66 (94.3)	5.45 (1.13)	1.8	4.80	5.80	6.20	7.0	
			Placebo	73	69 (94.5)	4.90 (1.42)	1.2	4.00	4.80	6.20	7.0	
		Week 36	Tezepelumab	70	66 (94.3)	5.49 (1.08)	2.8	4.80	5.80	6.20	7.0	
			Placebo	73	69 (94.5)	5.02 (1.39)	1.8	4.00	5.00	6.20	7.0	
		Week 40	Tezepelumab	70	66 (94.3)	5.49 (1.11)	2.4	4.80	5.60	6.20	7.0	
			Placebo	73	69 (94.5)	5.01 (1.42)	1.6	4.00	4.80	6.20	7.0	
		Week 44	Tezepelumab	70	66 (94.3)	5.58 (1.15)	2.6	4.80	5.80	6.40	7.0	
			Placebo	73	69 (94.5)	5.02 (1.51)	1.4	4.00	5.00	6.40	7.0	
		Week 48	Tezepelumab	70	66 (94.3)	5.56 (1.14)	1.8	4.80	5.90	6.40	7.0	
			Placebo	73	70 (95.9)	5.03 (1.42)	1.2	4.00	4.80	6.40	7.0	
		Week 52	Tezepelumab	70	66 (94.3)	5.50 (1.17)	1.8	4.60	5.80	6.20	7.0	
			Placebo	73	70 (95.9)	4.91 (1.49)	1.2	4.00	4.70	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 4	Tezepelumab	70	61 (87.1)	0.76 (1.08)	-1.6	0.20	0.60	1.60	3.6	0.35 [-0.00, 0.70]
			Placebo	73	65 (89.0)	0.38 (1.10)	-2.8	-0.20	0.40	1.00	3.6	
		Week 8	Tezepelumab	70	61 (87.1)	0.84 (1.19)	-1.4	0.20	0.60	1.60	5.0	0.23 [-0.12, 0.58]
			Placebo	73	65 (89.0)	0.57 (1.19)	-2.0	-0.20	0.40	1.20	3.4	
		Week 12	Tezepelumab	70	61 (87.1)	1.02 (1.24)	-1.6	0.20	0.80	1.80	5.4	0.32 [-0.03, 0.67]
			Placebo	73	65 (89.0)	0.62 (1.27)	-2.2	0.00	0.60	1.40	4.4	
		Week 16	Tezepelumab	70	61 (87.1)	1.00 (1.16)	-1.4	0.20	0.80	1.60	5.2	0.33 [-0.02, 0.68]
			Placebo	73	65 (89.0)	0.61 (1.17)	-2.0	0.00	0.80	1.20	3.8	
		Week 20	Tezepelumab	70	61 (87.1)	1.00 (1.26)	-0.8	0.20	0.80	1.80	5.2	0.18 [-0.17, 0.54]
			Placebo	73	65 (89.0)	0.77 (1.23)	-2.0	0.20	0.60	1.20	5.2	
		Week 24	Tezepelumab	70	61 (87.1)	1.06 (1.21)	-0.8	0.20	0.80	2.00	5.4	0.11 [-0.24, 0.46]
			Placebo	73	65 (89.0)	0.93 (1.26)	-2.0	0.20	1.00	1.60	4.2	
		Week 28	Tezepelumab	70	61 (87.1)	1.13 (1.21)	-0.8	0.20	0.80	2.00	5.4	0.28 [-0.07, 0.63]
			Placebo	73	65 (89.0)	0.77 (1.38)	-2.0	0.00	0.80	1.40	5.2	
		Week 32	Tezepelumab	70	61 (87.1)	1.09 (1.21)	-1.2	0.20	1.00	2.00	5.4	0.20 [-0.15, 0.55]
			Placebo	73	65 (89.0)	0.82 (1.35)	-2.0	-0.20	1.00	1.60	5.4	
		Week 36	Tezepelumab	70	61 (87.1)	1.11 (1.26)	-1.0	0.20	1.00	2.00	5.4	0.14 [-0.21, 0.49]
			Placebo	73	65 (89.0)	0.93 (1.33)	-2.0	0.00	1.00	1.60	4.2	
		Week 40	Tezepelumab	70	61 (87.1)	1.10 (1.22)	-1.0	0.20	0.80	2.00	5.4	0.13 [-0.22, 0.48]
			Placebo	73	65 (89.0)	0.92 (1.43)	-2.0	0.00	1.00	1.40	5.4	
		Week 44	Tezepelumab	70	61 (87.1)	1.18 (1.23)	-1.4	0.40	1.20	2.00	5.4	0.18 [-0.17, 0.53]
			Placebo	73	65 (89.0)	0.93 (1.48)	-2.2	-0.20	1.00	1.80	5.2	
		Week 48	Tezepelumab	70	61 (87.1)	1.18 (1.23)	-1.4	0.20	1.00	2.00	5.4	0.19 [-0.16, 0.54]
			Placebo	73	65 (89.0)	0.93 (1.41)	-2.0	0.00	1.00	1.60	5.0	
		Week 52	Tezepelumab	70	61 (87.1)	1.10 (1.26)	-1.0	0.20	1.00	2.00	5.4	0.21 [-0.14, 0.56]
			Placebo	73	65 (89.0)	0.81 (1.44)	-2.0	-0.20	1.00	1.40	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	4.28 (1.16)	1.4	3.60	4.20	5.20	6.4	
			Placebo	65	55 (84.6)	4.39 (1.16)	1.0	3.80	4.20	5.20	7.0	
		Week 4	Tezepelumab	67	61 (91.0)	4.88 (1.16)	1.2	4.00	4.80	5.80	7.0	
			Placebo	65	57 (87.7)	4.90 (1.29)	1.6	4.20	4.80	5.80	7.0	
		Week 8	Tezepelumab	67	63 (94.0)	5.16 (1.19)	2.8	4.20	5.00	6.20	7.0	
			Placebo	65	59 (90.8)	4.97 (1.15)	2.0	4.20	5.00	5.80	7.0	
		Week 12	Tezepelumab	67	63 (94.0)	5.36 (1.17)	2.8	4.40	5.40	6.40	7.0	
			Placebo	65	59 (90.8)	5.11 (1.22)	1.8	4.20	5.20	6.20	7.0	
		Week 16	Tezepelumab	67	63 (94.0)	5.30 (1.20)	2.6	4.40	5.60	6.20	7.0	
			Placebo	65	59 (90.8)	5.08 (1.29)	1.0	4.40	5.00	6.00	7.0	
		Week 20	Tezepelumab	67	64 (95.5)	5.38 (1.15)	2.4	4.50	5.60	6.30	7.0	
			Placebo	65	59 (90.8)	5.03 (1.25)	1.0	4.20	5.00	6.00	7.0	
		Week 24	Tezepelumab	67	64 (95.5)	5.28 (1.23)	2.0	4.20	5.40	6.30	7.0	
			Placebo	65	59 (90.8)	4.99 (1.29)	1.0	4.40	5.00	6.00	7.0	
		Week 28	Tezepelumab	67	66 (98.5)	5.37 (1.12)	2.8	4.40	5.40	6.40	7.0	
			Placebo	65	60 (92.3)	5.08 (1.33)	1.0	4.20	5.20	6.00	7.0	
		Week 32	Tezepelumab	67	66 (98.5)	5.34 (1.17)	2.6	4.40	5.50	6.40	7.0	
			Placebo	65	60 (92.3)	5.09 (1.33)	1.0	4.10	5.20	6.00	7.0	
		Week 36	Tezepelumab	67	66 (98.5)	5.48 (1.22)	2.8	4.60	5.60	6.60	7.0	
			Placebo	65	60 (92.3)	5.06 (1.28)	1.6	4.40	5.00	6.00	7.0	
		Week 40	Tezepelumab	67	66 (98.5)	5.28 (1.29)	1.8	4.20	5.40	6.40	7.0	
			Placebo	65	60 (92.3)	5.09 (1.30)	1.6	4.30	5.00	6.30	7.0	
		Week 44	Tezepelumab	67	66 (98.5)	5.40 (1.15)	2.8	4.40	5.40	6.40	7.0	
			Placebo	65	60 (92.3)	5.07 (1.32)	1.8	4.00	5.10	6.20	7.0	
		Week 48	Tezepelumab	67	66 (98.5)	5.39 (1.16)	2.6	4.60	5.40	6.40	7.0	
			Placebo	65	60 (92.3)	5.06 (1.32)	1.4	4.00	5.00	6.10	7.0	
		Week 52	Tezepelumab	67	66 (98.5)	5.42 (1.16)	2.6	4.60	5.40	6.40	7.0	
			Placebo	65	60 (92.3)	5.03 (1.35)	2.0	4.00	4.80	6.10	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 4	Tezepelumab	67	56 (83.6)	0.60 (1.33)	-4.2	-0.20	0.60	1.60	3.8	0.06 [-0.32, 0.43]
			Placebo	65	54 (83.1)	0.53 (1.04)	-2.2	0.00	0.40	1.20	3.0	
		Week 8	Tezepelumab	67	58 (86.6)	0.82 (1.31)	-2.2	-0.20	0.90	1.60	4.4	0.16 [-0.21, 0.53]
			Placebo	65	55 (84.6)	0.62 (1.17)	-1.6	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	67	58 (86.6)	1.01 (1.26)	-2.4	0.20	1.00	1.80	3.8	0.22 [-0.15, 0.59]
			Placebo	65	55 (84.6)	0.74 (1.24)	-1.8	0.00	0.80	1.60	4.4	
		Week 16	Tezepelumab	67	58 (86.6)	0.96 (1.28)	-2.8	0.00	1.00	1.80	4.0	0.19 [-0.18, 0.56]
			Placebo	65	55 (84.6)	0.72 (1.31)	-3.4	0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	67	58 (86.6)	1.11 (1.20)	-1.4	0.40	1.10	2.00	4.6	0.36 [-0.02, 0.73]
			Placebo	65	55 (84.6)	0.68 (1.25)	-3.4	0.00	0.80	1.60	4.2	
		Week 24	Tezepelumab	67	58 (86.6)	0.99 (1.30)	-1.4	0.00	1.00	1.80	4.6	0.27 [-0.10, 0.64]
			Placebo	65	55 (84.6)	0.64 (1.30)	-3.4	0.00	0.40	1.60	4.2	
		Week 28	Tezepelumab	67	58 (86.6)	1.04 (1.25)	-1.4	0.00	0.80	1.80	4.6	0.24 [-0.13, 0.61]
			Placebo	65	55 (84.6)	0.72 (1.42)	-3.4	0.00	0.80	1.60	4.4	
		Week 32	Tezepelumab	67	58 (86.6)	1.01 (1.31)	-1.6	0.00	0.90	2.00	4.6	0.22 [-0.15, 0.59]
			Placebo	65	55 (84.6)	0.73 (1.26)	-3.4	-0.20	0.80	1.40	4.2	
		Week 36	Tezepelumab	67	58 (86.6)	1.19 (1.39)	-1.6	0.00	1.20	2.00	4.6	0.41 [0.04, 0.79]
			Placebo	65	55 (84.6)	0.67 (1.11)	-2.0	0.00	0.60	1.40	3.8	
		Week 40	Tezepelumab	67	58 (86.6)	1.00 (1.38)	-2.4	0.00	1.00	2.00	4.6	0.20 [-0.17, 0.57]
			Placebo	65	55 (84.6)	0.73 (1.27)	-2.0	-0.40	0.80	1.60	3.6	
		Week 44	Tezepelumab	67	58 (86.6)	1.07 (1.31)	-1.4	0.00	1.20	1.60	4.6	0.30 [-0.07, 0.67]
			Placebo	65	55 (84.6)	0.68 (1.26)	-1.8	-0.40	0.60	1.20	4.2	
		Week 48	Tezepelumab	67	58 (86.6)	1.08 (1.30)	-1.4	0.20	1.10	1.80	4.6	0.30 [-0.07, 0.67]
			Placebo	65	55 (84.6)	0.70 (1.23)	-2.2	-0.20	0.60	1.40	4.2	
		Week 52	Tezepelumab	67	58 (86.6)	1.09 (1.31)	-1.6	0.00	1.20	1.80	4.6	0.32 [-0.05, 0.69]
			Placebo	65	55 (84.6)	0.67 (1.34)	-2.6	-0.20	0.60	1.40	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	11	9 (81.8)	4.64 (0.66)	3.6	4.00	4.80	5.20	5.4	
			Placebo	6	4 (66.7)	3.20 (1.21)	1.4	2.50	3.70	3.90	4.0	
		Week 4	Tezepelumab	11	11 (100.0)	4.91 (1.04)	4.0	4.00	4.80	5.80	7.0	
			Placebo	6	5 (83.3)	4.20 (1.62)	1.6	3.80	4.80	5.00	5.8	
		Week 8	Tezepelumab	11	11 (100.0)	5.49 (0.82)	4.4	4.80	5.60	6.20	7.0	
			Placebo	6	5 (83.3)	4.24 (0.99)	3.0	3.80	4.00	4.80	5.6	
		Week 12	Tezepelumab	11	11 (100.0)	5.53 (0.91)	4.4	4.60	5.40	6.40	7.0	
			Placebo	6	5 (83.3)	4.40 (1.54)	1.8	4.60	4.60	5.20	5.8	
		Week 16	Tezepelumab	11	11 (100.0)	5.40 (0.94)	4.0	4.60	5.60	6.20	6.8	
			Placebo	6	5 (83.3)	4.12 (1.03)	2.6	4.00	4.00	4.60	5.4	
		Week 20	Tezepelumab	11	11 (100.0)	5.27 (0.73)	4.0	4.60	5.00	6.00	6.2	
			Placebo	6	5 (83.3)	4.56 (1.32)	3.0	4.00	4.40	4.80	6.6	
		Week 24	Tezepelumab	11	11 (100.0)	5.38 (0.90)	3.4	4.80	5.80	6.00	6.4	
			Placebo	6	5 (83.3)	4.28 (1.05)	2.8	3.80	4.40	4.80	5.6	
		Week 28	Tezepelumab	11	11 (100.0)	5.42 (0.72)	4.4	4.80	5.20	6.00	6.4	
			Placebo	6	5 (83.3)	3.96 (1.49)	2.6	2.60	4.00	4.40	6.2	
		Week 32	Tezepelumab	11	11 (100.0)	5.35 (0.89)	3.6	4.60	5.20	6.00	6.4	
			Placebo	6	5 (83.3)	4.40 (1.67)	2.2	3.80	4.40	4.80	6.8	
		Week 36	Tezepelumab	11	11 (100.0)	5.40 (0.71)	4.0	4.80	5.60	6.00	6.2	
			Placebo	6	5 (83.3)	4.20 (1.52)	1.6	4.40	4.60	4.80	5.6	
		Week 40	Tezepelumab	11	11 (100.0)	5.51 (0.74)	4.6	4.80	5.40	6.20	6.8	
			Placebo	6	5 (83.3)	4.44 (2.05)	1.6	3.60	4.20	6.00	6.8	
		Week 44	Tezepelumab	11	11 (100.0)	5.47 (0.68)	4.6	4.80	5.40	6.20	6.4	
			Placebo	6	5 (83.3)	4.08 (1.46)	1.8	3.60	4.40	5.20	5.4	
		Week 48	Tezepelumab	11	11 (100.0)	5.55 (0.82)	4.2	4.80	5.80	6.00	7.0	
			Placebo	6	5 (83.3)	4.40 (1.89)	1.4	4.00	4.80	5.40	6.4	
		Week 52	Tezepelumab	11	11 (100.0)	5.56 (0.80)	4.2	5.00	5.80	6.00	7.0	
			Placebo	6	5 (83.3)	4.32 (1.63)	2.0	3.60	4.80	4.80	6.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	11	9 (81.8)	0.47 (0.84)	-0.6	0.00	0.40	0.80	2.2	-0.45 [-1.64, 0.74]
			Placebo	6	4 (66.7)	1.10 (2.34)	-2.0	-0.50	1.40	2.70	3.6	
		Week 8	Tezepelumab	11	9 (81.8)	0.91 (0.90)	-0.4	0.40	0.80	1.00	2.4	-0.16 [-1.34, 1.02]
			Placebo	6	4 (66.7)	1.10 (1.79)	-0.6	-0.30	0.80	2.50	3.4	
		Week 12	Tezepelumab	11	9 (81.8)	0.84 (0.84)	-1.0	0.80	1.00	1.00	2.2	-0.20 [-1.38, 0.98]
			Placebo	6	4 (66.7)	1.15 (2.54)	-1.8	-0.50	1.00	2.80	4.4	
		Week 16	Tezepelumab	11	9 (81.8)	0.71 (0.88)	-0.8	0.40	0.80	1.00	2.0	-0.08 [-1.26, 1.10]
			Placebo	6	4 (66.7)	0.80 (1.61)	-1.0	-0.50	0.80	2.10	2.6	
		Week 20	Tezepelumab	11	9 (81.8)	0.60 (0.49)	-0.4	0.40	0.80	1.00	1.0	-0.48 [-1.68, 0.71]
			Placebo	6	4 (66.7)	1.30 (2.65)	-0.6	-0.30	0.30	2.90	5.2	
		Week 24	Tezepelumab	11	9 (81.8)	0.71 (0.74)	-0.4	0.40	0.60	1.20	1.8	-0.18 [-1.36, 1.00]
			Placebo	6	4 (66.7)	0.95 (2.24)	-0.8	-0.50	0.20	2.40	4.2	
		Week 28	Tezepelumab	11	9 (81.8)	0.76 (0.55)	-0.4	0.60	0.80	1.00	1.6	0.07 [-1.11, 1.25]
			Placebo	6	4 (66.7)	0.65 (2.82)	-1.2	-1.10	-0.50	2.40	4.8	
		Week 32	Tezepelumab	11	9 (81.8)	0.71 (0.71)	-0.8	0.80	0.80	1.00	1.6	-0.29 [-1.48, 0.89]
			Placebo	6	4 (66.7)	1.20 (2.97)	-1.4	-0.80	0.40	3.20	5.4	
		Week 36	Tezepelumab	11	9 (81.8)	0.76 (0.54)	-0.4	0.60	0.80	1.20	1.4	-0.08 [-1.25, 1.10]
			Placebo	6	4 (66.7)	0.85 (2.22)	-2.0	-0.80	1.10	2.50	3.2	
		Week 40	Tezepelumab	11	9 (81.8)	0.89 (0.68)	-0.6	0.80	1.00	1.00	2.0	-0.23 [-1.41, 0.95]
			Placebo	6	4 (66.7)	1.30 (3.24)	-2.0	-1.20	0.90	3.80	5.4	
		Week 44	Tezepelumab	11	9 (81.8)	0.84 (0.60)	-0.4	0.60	0.80	1.20	1.6	0.24 [-0.94, 1.43]
			Placebo	6	4 (66.7)	0.55 (2.09)	-1.8	-1.10	0.50	2.20	3.0	
		Week 48	Tezepelumab	11	9 (81.8)	0.98 (0.82)	-0.6	0.60	1.00	1.20	2.2	0.02 [-1.16, 1.19]
			Placebo	6	4 (66.7)	0.95 (3.01)	-2.2	-1.10	0.50	3.00	5.0	
		Week 52	Tezepelumab	11	9 (81.8)	1.00 (0.77)	-0.4	0.60	1.00	1.20	2.2	0.00 [-1.18, 1.18]
			Placebo	6	4 (66.7)	1.00 (2.87)	-1.6	-1.00	0.30	3.00	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	126	114 (90.5)	4.31 (1.18)	1.4	3.60	4.20	5.00	6.8	
			Placebo	132	117 (88.6)	4.27 (1.22)	1.0	3.60	4.20	5.00	7.0	
		Week 4	Tezepelumab	126	115 (91.3)	4.98 (1.21)	1.2	4.00	5.00	6.00	7.0	
			Placebo	132	118 (89.4)	4.71 (1.30)	1.4	3.80	4.70	5.60	7.0	
		Week 8	Tezepelumab	126	117 (92.9)	5.14 (1.23)	1.8	4.20	5.00	6.00	7.0	
			Placebo	132	121 (91.7)	4.84 (1.32)	1.0	4.00	5.00	5.80	7.0	
		Week 12	Tezepelumab	126	117 (92.9)	5.34 (1.20)	2.0	4.40	5.40	6.40	7.0	
			Placebo	132	122 (92.4)	4.91 (1.31)	1.4	4.00	4.70	6.00	7.0	
		Week 16	Tezepelumab	126	117 (92.9)	5.30 (1.18)	2.2	4.40	5.40	6.20	7.0	
			Placebo	132	122 (92.4)	4.92 (1.38)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	126	118 (93.7)	5.37 (1.19)	1.0	4.40	5.60	6.40	7.0	
			Placebo	132	122 (92.4)	4.96 (1.32)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	126	118 (93.7)	5.34 (1.20)	1.6	4.40	5.40	6.20	7.0	
			Placebo	132	122 (92.4)	5.04 (1.31)	1.0	4.20	5.00	6.00	7.0	
		Week 28	Tezepelumab	126	120 (95.2)	5.43 (1.11)	2.8	4.40	5.60	6.20	7.0	
			Placebo	132	123 (93.2)	5.00 (1.38)	1.0	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	126	121 (96.0)	5.40 (1.17)	1.8	4.60	5.60	6.20	7.0	
			Placebo	132	124 (93.9)	5.01 (1.37)	1.0	4.00	5.00	6.10	7.0	
		Week 36	Tezepelumab	126	121 (96.0)	5.50 (1.18)	2.8	4.60	5.80	6.60	7.0	
			Placebo	132	124 (93.9)	5.07 (1.32)	1.8	4.00	5.00	6.20	7.0	
		Week 40	Tezepelumab	126	121 (96.0)	5.37 (1.24)	1.8	4.40	5.40	6.40	7.0	
			Placebo	132	124 (93.9)	5.07 (1.33)	1.6	4.00	5.00	6.30	7.0	
		Week 44	Tezepelumab	126	121 (96.0)	5.49 (1.19)	2.6	4.60	5.60	6.40	7.0	
			Placebo	132	124 (93.9)	5.08 (1.41)	1.4	4.00	5.10	6.40	7.0	
		Week 48	Tezepelumab	126	121 (96.0)	5.47 (1.18)	1.8	4.60	5.60	6.40	7.0	
			Placebo	132	125 (94.7)	5.07 (1.35)	1.2	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	126	121 (96.0)	5.45 (1.19)	1.8	4.60	5.60	6.40	7.0	
			Placebo	132	125 (94.7)	4.99 (1.41)	1.2	4.00	4.80	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	126	108 (85.7)	0.70 (1.23)	-4.2	0.00	0.60	1.60	3.8	0.25 [-0.02, 0.51]
			Placebo	132	115 (87.1)	0.42 (1.02)	-2.8	-0.20	0.40	1.00	3.0	
		Week 8	Tezepelumab	126	110 (87.3)	0.82 (1.27)	-2.2	0.00	0.70	1.60	5.0	0.20 [-0.06, 0.46]
			Placebo	132	116 (87.9)	0.58 (1.16)	-2.0	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	126	110 (87.3)	1.03 (1.27)	-2.4	0.20	0.80	1.80	5.4	0.30 [0.04, 0.56]
			Placebo	132	116 (87.9)	0.66 (1.21)	-2.2	0.00	0.60	1.40	4.4	
		Week 16	Tezepelumab	126	110 (87.3)	1.00 (1.24)	-2.8	0.20	1.00	1.80	5.2	0.28 [0.02, 0.54]
			Placebo	132	116 (87.9)	0.66 (1.23)	-3.4	0.00	0.60	1.40	4.4	
		Week 20	Tezepelumab	126	110 (87.3)	1.09 (1.26)	-1.4	0.20	1.00	2.00	5.2	0.31 [0.05, 0.58]
			Placebo	132	116 (87.9)	0.71 (1.18)	-3.4	0.10	0.80	1.40	4.2	
		Week 24	Tezepelumab	126	110 (87.3)	1.05 (1.28)	-1.4	0.00	1.00	2.00	5.4	0.21 [-0.05, 0.47]
			Placebo	132	116 (87.9)	0.79 (1.25)	-3.4	0.00	0.80	1.60	4.2	
		Week 28	Tezepelumab	126	110 (87.3)	1.11 (1.26)	-1.4	0.00	0.90	2.00	5.4	0.28 [0.02, 0.54]
			Placebo	132	116 (87.9)	0.75 (1.34)	-3.4	0.00	0.80	1.60	5.2	
		Week 32	Tezepelumab	126	110 (87.3)	1.08 (1.29)	-1.6	0.20	1.00	2.00	5.4	0.25 [-0.02, 0.51]
			Placebo	132	116 (87.9)	0.77 (1.24)	-3.4	-0.20	0.80	1.60	4.2	
		Week 36	Tezepelumab	126	110 (87.3)	1.18 (1.36)	-1.6	0.20	1.00	2.00	5.4	0.29 [0.03, 0.55]
			Placebo	132	116 (87.9)	0.81 (1.20)	-2.0	0.00	0.60	1.60	4.2	
		Week 40	Tezepelumab	126	110 (87.3)	1.06 (1.34)	-2.4	0.00	0.80	2.00	5.4	0.19 [-0.08, 0.45]
			Placebo	132	116 (87.9)	0.82 (1.28)	-2.0	0.00	0.80	1.40	5.2	
		Week 44	Tezepelumab	126	110 (87.3)	1.15 (1.30)	-1.4	0.20	1.20	2.00	5.4	0.24 [-0.02, 0.51]
			Placebo	132	116 (87.9)	0.83 (1.37)	-2.2	-0.20	0.80	1.60	5.2	
		Week 48	Tezepelumab	126	110 (87.3)	1.14 (1.29)	-1.4	0.20	1.00	2.00	5.4	0.26 [-0.01, 0.52]
			Placebo	132	116 (87.9)	0.82 (1.26)	-2.0	-0.10	0.80	1.60	4.2	
		Week 52	Tezepelumab	126	110 (87.3)	1.10 (1.31)	-1.6	0.00	1.00	2.00	5.4	0.28 [0.02, 0.54]
			Placebo	132	116 (87.9)	0.74 (1.33)	-2.6	-0.20	0.80	1.40	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.68 (0.70)	3.6	4.00	5.00	5.20	5.4	
			Placebo	3	2 (66.7)	2.70 (1.84)	1.4	1.40	2.70	4.00	4.0	
		Week 4	Tezepelumab	9	9 (100.0)	5.11 (1.04)	4.0	4.20	4.80	5.80	7.0	
			Placebo	3	3 (100.0)	4.87 (1.01)	3.8	3.80	5.00	5.80	5.8	
		Week 8	Tezepelumab	9	9 (100.0)	5.67 (0.80)	4.4	5.00	5.60	6.20	7.0	
			Placebo	3	3 (100.0)	4.80 (0.80)	4.0	4.00	4.80	5.60	5.6	
		Week 12	Tezepelumab	9	9 (100.0)	5.64 (0.96)	4.4	5.00	5.60	6.40	7.0	
			Placebo	3	3 (100.0)	5.20 (0.60)	4.6	4.60	5.20	5.80	5.8	
		Week 16	Tezepelumab	9	9 (100.0)	5.64 (0.85)	4.4	5.00	5.60	6.20	6.8	
			Placebo	3	3 (100.0)	4.20 (0.35)	4.0	4.00	4.00	4.60	4.6	
		Week 20	Tezepelumab	9	9 (100.0)	5.42 (0.73)	4.0	5.00	5.60	6.00	6.2	
			Placebo	3	3 (100.0)	5.13 (1.33)	4.0	4.00	4.80	6.60	6.6	
		Week 24	Tezepelumab	9	9 (100.0)	5.53 (0.93)	3.4	5.20	5.80	6.00	6.4	
			Placebo	3	3 (100.0)	4.73 (0.90)	3.8	3.80	4.80	5.60	5.6	
		Week 28	Tezepelumab	9	9 (100.0)	5.58 (0.70)	4.4	5.00	5.80	6.00	6.4	
			Placebo	3	3 (100.0)	4.87 (1.17)	4.0	4.00	4.40	6.20	6.2	
		Week 32	Tezepelumab	9	9 (100.0)	5.44 (0.95)	3.6	5.00	6.00	6.00	6.4	
			Placebo	3	3 (100.0)	5.00 (1.59)	3.8	3.80	4.40	6.80	6.8	
		Week 36	Tezepelumab	9	9 (100.0)	5.47 (0.73)	4.0	5.00	5.80	6.00	6.2	
			Placebo	3	3 (100.0)	4.60 (0.20)	4.4	4.40	4.60	4.80	4.8	
		Week 40	Tezepelumab	9	9 (100.0)	5.62 (0.75)	4.6	5.00	5.80	6.20	6.8	
			Placebo	3	3 (100.0)	4.87 (1.70)	3.6	3.60	4.20	6.80	6.8	
		Week 44	Tezepelumab	9	9 (100.0)	5.62 (0.65)	4.8	5.00	5.80	6.20	6.4	
			Placebo	3	3 (100.0)	4.47 (0.90)	3.6	3.60	4.40	5.40	5.4	
		Week 48	Tezepelumab	9	9 (100.0)	5.64 (0.84)	4.2	5.00	5.80	6.00	7.0	
			Placebo	3	3 (100.0)	5.27 (1.21)	4.0	4.00	5.40	6.40	6.4	
		Week 52	Tezepelumab	9	9 (100.0)	5.67 (0.82)	4.2	5.00	5.80	6.00	7.0	
			Placebo	3	3 (100.0)	4.93 (1.40)	3.6	3.60	4.80	6.40	6.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	0.58 (0.82)	-0.6	0.10	0.50	0.90	2.2	-2.38 [-4.32, -0.44]
			Placebo	3	2 (66.7)	2.70 (1.27)	1.8	1.80	2.70	3.60	3.6	
		Week 8	Tezepelumab	9	8 (88.9)	0.98 (0.93)	-0.4	0.40	0.90	1.60	2.4	-1.55 [-3.28, 0.17]
			Placebo	3	2 (66.7)	2.50 (1.27)	1.6	1.60	2.50	3.40	3.4	
		Week 12	Tezepelumab	9	8 (88.9)	0.83 (0.90)	-1.0	0.60	1.00	1.10	2.2	-1.70 [-3.46, 0.06]
			Placebo	3	2 (66.7)	2.80 (2.26)	1.2	1.20	2.80	4.40	4.4	
		Week 16	Tezepelumab	9	8 (88.9)	0.85 (0.83)	-0.8	0.60	0.90	1.30	2.0	-0.44 [-2.01, 1.12]
			Placebo	3	2 (66.7)	1.30 (1.84)	0.0	0.00	1.30	2.60	2.6	
		Week 20	Tezepelumab	9	8 (88.9)	0.65 (0.50)	-0.4	0.40	0.90	1.00	1.0	-1.41 [-3.11, 0.29]
			Placebo	3	2 (66.7)	2.60 (3.68)	0.0	0.00	2.60	5.20	5.2	
		Week 24	Tezepelumab	9	8 (88.9)	0.75 (0.78)	-0.4	0.20	0.70	1.40	1.8	-0.95 [-2.56, 0.67]
			Placebo	3	2 (66.7)	2.00 (3.11)	-0.2	-0.20	2.00	4.20	4.2	
		Week 28	Tezepelumab	9	8 (88.9)	0.80 (0.58)	-0.4	0.70	0.80	1.10	1.6	-1.22 [-2.88, 0.44]
			Placebo	3	2 (66.7)	2.40 (3.39)	0.0	0.00	2.40	4.80	4.8	
		Week 32	Tezepelumab	9	8 (88.9)	0.70 (0.76)	-0.8	0.40	0.90	1.10	1.6	-1.21 [-2.87, 0.45]
			Placebo	3	2 (66.7)	2.60 (3.96)	-0.2	-0.20	2.60	5.40	5.4	
		Week 36	Tezepelumab	9	8 (88.9)	0.70 (0.55)	-0.4	0.50	0.80	1.00	1.4	-1.27 [-2.94, 0.40]
			Placebo	3	2 (66.7)	1.80 (1.98)	0.4	0.40	1.80	3.20	3.2	
		Week 40	Tezepelumab	9	8 (88.9)	0.88 (0.72)	-0.6	0.70	1.00	1.10	2.0	-1.02 [-2.64, 0.61]
			Placebo	3	2 (66.7)	2.50 (4.10)	-0.4	-0.40	2.50	5.40	5.4	
		Week 44	Tezepelumab	9	8 (88.9)	0.88 (0.63)	-0.4	0.60	1.00	1.30	1.6	-0.41 [-1.97, 1.15]
			Placebo	3	2 (66.7)	1.30 (2.40)	-0.4	-0.40	1.30	3.00	3.0	
		Week 48	Tezepelumab	9	8 (88.9)	0.95 (0.87)	-0.6	0.60	0.90	1.50	2.2	-1.04 [-2.67, 0.59]
			Placebo	3	2 (66.7)	2.50 (3.54)	0.0	0.00	2.50	5.00	5.0	
		Week 52	Tezepelumab	9	8 (88.9)	0.98 (0.82)	-0.4	0.60	0.90	1.50	2.2	-0.85 [-2.46, 0.75]
			Placebo	3	2 (66.7)	2.30 (3.82)	-0.4	-0.40	2.30	5.00	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.31 (1.17)	1.4	3.60	4.20	5.00	6.8	
			Placebo	135	119 (88.1)	4.26 (1.22)	1.0	3.60	4.20	5.00	7.0	
		Week 4	Tezepelumab	128	117 (91.4)	4.97 (1.20)	1.2	4.00	5.00	6.00	7.0	
			Placebo	135	120 (88.9)	4.69 (1.32)	1.4	3.80	4.70	5.60	7.0	
		Week 8	Tezepelumab	128	119 (93.0)	5.13 (1.22)	1.8	4.20	5.00	6.00	7.0	
			Placebo	135	123 (91.1)	4.82 (1.32)	1.0	4.00	4.80	5.80	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.34 (1.19)	2.0	4.40	5.40	6.40	7.0	
			Placebo	135	124 (91.9)	4.88 (1.33)	1.4	4.00	4.60	6.00	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.29 (1.18)	2.2	4.40	5.40	6.20	7.0	
			Placebo	135	124 (91.9)	4.90 (1.38)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.36 (1.19)	1.0	4.40	5.60	6.40	7.0	
			Placebo	135	124 (91.9)	4.94 (1.32)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.33 (1.19)	1.6	4.40	5.40	6.20	7.0	
			Placebo	135	124 (91.9)	5.02 (1.32)	1.0	4.10	5.00	6.00	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.42 (1.10)	2.8	4.40	5.60	6.20	7.0	
			Placebo	135	125 (92.6)	4.96 (1.40)	1.0	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.39 (1.16)	1.8	4.60	5.60	6.20	7.0	
			Placebo	135	126 (93.3)	4.99 (1.38)	1.0	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.49 (1.17)	2.8	4.60	5.60	6.60	7.0	
			Placebo	135	126 (93.3)	5.05 (1.35)	1.6	4.00	5.00	6.20	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.37 (1.23)	1.8	4.40	5.40	6.40	7.0	
			Placebo	135	126 (93.3)	5.05 (1.36)	1.6	4.00	5.00	6.20	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.48 (1.18)	2.6	4.60	5.60	6.40	7.0	
			Placebo	135	126 (93.3)	5.06 (1.43)	1.4	4.00	5.10	6.40	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.46 (1.17)	1.8	4.60	5.60	6.40	7.0	
			Placebo	135	127 (94.1)	5.04 (1.38)	1.2	4.00	4.80	6.40	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.44 (1.18)	1.8	4.60	5.60	6.40	7.0	
			Placebo	135	127 (94.1)	4.97 (1.43)	1.2	4.00	4.80	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.69 (1.23)	-4.2	0.00	0.60	1.60	3.8	0.25 [-0.01, 0.51]
			Placebo	135	117 (86.7)	0.41 (1.03)	-2.8	-0.20	0.40	1.00	3.0	
		Week 8	Tezepelumab	128	111 (86.7)	0.82 (1.27)	-2.2	0.00	0.60	1.60	5.0	0.21 [-0.05, 0.47]
			Placebo	135	118 (87.4)	0.56 (1.15)	-2.0	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	128	111 (86.7)	1.03 (1.27)	-2.4	0.20	0.80	1.80	5.4	0.31 [0.05, 0.58]
			Placebo	135	118 (87.4)	0.64 (1.22)	-2.2	0.00	0.60	1.40	4.4	
		Week 16	Tezepelumab	128	111 (86.7)	0.99 (1.24)	-2.8	0.00	1.00	1.80	5.2	0.28 [0.02, 0.54]
			Placebo	135	118 (87.4)	0.65 (1.23)	-3.4	0.00	0.60	1.40	4.4	
		Week 20	Tezepelumab	128	111 (86.7)	1.08 (1.26)	-1.4	0.20	1.00	2.00	5.2	0.32 [0.06, 0.58]
			Placebo	135	118 (87.4)	0.69 (1.17)	-3.4	0.00	0.80	1.40	4.2	
		Week 24	Tezepelumab	128	111 (86.7)	1.05 (1.28)	-1.4	0.00	1.00	2.00	5.4	0.22 [-0.04, 0.48]
			Placebo	135	118 (87.4)	0.77 (1.25)	-3.4	0.00	0.70	1.60	4.2	
		Week 28	Tezepelumab	128	111 (86.7)	1.11 (1.26)	-1.4	0.00	0.80	2.00	5.4	0.30 [0.04, 0.56]
			Placebo	135	118 (87.4)	0.72 (1.35)	-3.4	0.00	0.80	1.60	5.2	
		Week 32	Tezepelumab	128	111 (86.7)	1.07 (1.28)	-1.6	0.20	1.00	2.00	5.4	0.26 [-0.00, 0.52]
			Placebo	135	118 (87.4)	0.75 (1.24)	-3.4	-0.20	0.80	1.60	4.2	
		Week 36	Tezepelumab	128	111 (86.7)	1.18 (1.35)	-1.6	0.20	1.00	2.00	5.4	0.30 [0.04, 0.56]
			Placebo	135	118 (87.4)	0.80 (1.22)	-2.0	0.00	0.60	1.60	4.2	
		Week 40	Tezepelumab	128	111 (86.7)	1.06 (1.33)	-2.4	0.00	0.80	2.00	5.4	0.19 [-0.07, 0.45]
			Placebo	135	118 (87.4)	0.81 (1.30)	-2.0	0.00	0.80	1.40	5.2	
		Week 44	Tezepelumab	128	111 (86.7)	1.15 (1.30)	-1.4	0.20	1.20	2.00	5.4	0.25 [-0.01, 0.51]
			Placebo	135	118 (87.4)	0.81 (1.38)	-2.2	-0.20	0.80	1.60	5.2	
		Week 48	Tezepelumab	128	111 (86.7)	1.14 (1.29)	-1.4	0.20	1.00	2.00	5.4	0.27 [0.01, 0.53]
			Placebo	135	118 (87.4)	0.79 (1.28)	-2.2	-0.20	0.80	1.60	4.2	
		Week 52	Tezepelumab	128	111 (86.7)	1.10 (1.31)	-1.6	0.00	1.00	2.00	5.4	0.29 [0.03, 0.55]
			Placebo	135	118 (87.4)	0.72 (1.34)	-2.6	-0.20	0.80	1.40	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	3.99 (1.17)	1.4	3.40	4.20	4.80	6.2	
			Placebo	37	33 (89.2)	4.25 (1.13)	1.4	3.60	4.20	5.00	6.6	
		Week 4	Tezepelumab	29	26 (89.7)	4.97 (1.07)	3.2	4.00	5.60	5.80	7.0	
			Placebo	37	33 (89.2)	4.73 (1.37)	1.6	3.80	4.80	6.00	7.0	
		Week 8	Tezepelumab	29	27 (93.1)	5.26 (1.19)	3.0	4.40	5.60	6.00	7.0	
			Placebo	37	34 (91.9)	4.86 (1.24)	2.2	4.00	4.90	5.40	7.0	
		Week 12	Tezepelumab	29	27 (93.1)	5.50 (1.20)	2.8	4.40	5.80	6.60	7.0	
			Placebo	37	35 (94.6)	4.97 (1.45)	1.6	4.20	5.00	6.00	7.0	
		Week 16	Tezepelumab	29	27 (93.1)	5.37 (1.20)	2.8	4.40	5.60	6.20	7.0	
			Placebo	37	35 (94.6)	4.94 (1.40)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	29	27 (93.1)	5.45 (1.21)	2.8	4.40	5.60	6.20	7.0	
			Placebo	37	35 (94.6)	4.99 (1.35)	1.0	4.40	5.00	6.00	7.0	
		Week 24	Tezepelumab	29	27 (93.1)	5.40 (1.29)	2.8	4.20	5.80	6.40	7.0	
			Placebo	37	35 (94.6)	4.94 (1.37)	1.0	4.40	5.00	6.00	7.0	
		Week 28	Tezepelumab	29	27 (93.1)	5.42 (1.21)	2.8	4.40	5.80	6.20	7.0	
			Placebo	37	35 (94.6)	5.12 (1.55)	1.0	4.00	5.20	6.40	7.0	
		Week 32	Tezepelumab	29	27 (93.1)	5.46 (1.24)	2.6	4.80	5.80	6.20	7.0	
			Placebo	37	35 (94.6)	5.08 (1.36)	1.0	4.20	5.20	6.00	7.0	
		Week 36	Tezepelumab	29	27 (93.1)	5.56 (1.28)	2.8	4.60	6.00	6.60	7.0	
			Placebo	37	35 (94.6)	4.93 (1.28)	1.6	4.00	4.80	6.00	7.0	
		Week 40	Tezepelumab	29	27 (93.1)	5.45 (1.28)	2.8	4.40	5.60	6.20	7.0	
			Placebo	37	35 (94.6)	5.02 (1.34)	1.6	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	29	27 (93.1)	5.56 (1.30)	2.8	5.20	6.00	6.40	7.0	
			Placebo	37	35 (94.6)	5.08 (1.30)	1.8	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	29	27 (93.1)	5.33 (1.38)	2.6	4.40	5.80	6.20	7.0	
			Placebo	37	36 (97.3)	5.04 (1.26)	1.4	4.10	4.90	5.80	7.0	
		Week 52	Tezepelumab	29	27 (93.1)	5.44 (1.36)	2.6	4.40	5.80	6.20	7.0	
			Placebo	37	36 (97.3)	5.06 (1.22)	2.0	4.10	4.80	5.90	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	29	24 (82.8)	1.03 (1.07)	-0.8	0.20	1.00	1.90	3.0	0.50 [-0.04, 1.04]
			Placebo	37	31 (83.8)	0.47 (1.17)	-2.2	-0.20	0.40	1.00	3.6	
		Week 8	Tezepelumab	29	25 (86.2)	1.26 (1.22)	-1.0	0.60	1.20	2.20	3.6	0.57 [0.04, 1.11]
			Placebo	37	32 (86.5)	0.59 (1.11)	-1.6	0.00	0.40	1.10	3.4	
		Week 12	Tezepelumab	29	25 (86.2)	1.46 (1.21)	-0.6	0.40	1.40	2.40	3.6	0.50 [-0.03, 1.03]
			Placebo	37	32 (86.5)	0.79 (1.41)	-2.0	0.00	0.80	1.30	4.4	
		Week 16	Tezepelumab	29	25 (86.2)	1.33 (1.20)	-0.6	0.80	1.20	2.20	3.4	0.48 [-0.05, 1.01]
			Placebo	37	32 (86.5)	0.70 (1.37)	-3.4	0.20	0.80	1.40	4.0	
		Week 20	Tezepelumab	29	25 (86.2)	1.44 (1.22)	-0.6	0.80	1.40	2.20	3.4	0.52 [-0.01, 1.05]
			Placebo	37	32 (86.5)	0.73 (1.47)	-3.4	-0.10	0.80	1.40	5.2	
		Week 24	Tezepelumab	29	25 (86.2)	1.38 (1.34)	-0.8	0.60	1.40	2.20	3.8	0.48 [-0.05, 1.01]
			Placebo	37	32 (86.5)	0.68 (1.52)	-3.4	-0.20	0.70	1.40	4.2	
		Week 28	Tezepelumab	29	25 (86.2)	1.40 (1.26)	-0.6	0.80	1.40	2.40	3.6	0.33 [-0.20, 0.86]
			Placebo	37	32 (86.5)	0.90 (1.70)	-3.4	0.00	1.00	1.90	4.8	
		Week 32	Tezepelumab	29	25 (86.2)	1.47 (1.34)	-1.4	0.80	1.40	2.40	3.6	0.42 [-0.11, 0.95]
			Placebo	37	32 (86.5)	0.86 (1.54)	-3.4	0.10	0.80	1.50	5.4	
		Week 36	Tezepelumab	29	25 (86.2)	1.55 (1.43)	-1.0	0.80	1.40	2.80	3.8	0.67 [0.13, 1.21]
			Placebo	37	32 (86.5)	0.66 (1.24)	-2.0	-0.10	0.60	1.50	3.2	
		Week 40	Tezepelumab	29	25 (86.2)	1.44 (1.37)	-1.2	0.80	1.40	2.80	3.4	0.44 [-0.09, 0.97]
			Placebo	37	32 (86.5)	0.79 (1.55)	-2.0	-0.30	0.80	1.70	5.4	
		Week 44	Tezepelumab	29	25 (86.2)	1.56 (1.43)	-1.4	0.80	1.60	2.60	3.8	0.56 [0.02, 1.09]
			Placebo	37	32 (86.5)	0.81 (1.27)	-1.8	-0.20	0.90	1.60	3.2	
		Week 48	Tezepelumab	29	25 (86.2)	1.34 (1.52)	-1.4	0.40	1.40	2.20	3.8	0.41 [-0.12, 0.94]
			Placebo	37	32 (86.5)	0.75 (1.37)	-2.2	-0.10	0.70	1.30	5.0	
		Week 52	Tezepelumab	29	25 (86.2)	1.44 (1.44)	-1.4	0.80	1.40	2.40	3.8	0.47 [-0.06, 1.00]
			Placebo	37	32 (86.5)	0.79 (1.34)	-1.6	-0.10	0.70	1.30	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	4.43 (1.13)	1.4	3.80	4.40	5.20	6.8	
			Placebo	101	88 (87.1)	4.23 (1.28)	1.0	3.60	4.20	5.00	7.0	
		Week 4	Tezepelumab	108	100 (92.6)	4.98 (1.22)	1.2	4.00	5.00	6.00	7.0	
			Placebo	101	90 (89.1)	4.68 (1.30)	1.4	3.80	4.70	5.60	7.0	
		Week 8	Tezepelumab	108	101 (93.5)	5.14 (1.21)	1.8	4.40	5.00	6.20	7.0	
			Placebo	101	92 (91.1)	4.80 (1.34)	1.0	4.00	4.80	5.80	7.0	
		Week 12	Tezepelumab	108	101 (93.5)	5.32 (1.17)	2.0	4.40	5.40	6.40	7.0	
			Placebo	101	92 (91.1)	4.86 (1.27)	1.4	4.00	4.60	5.80	7.0	
		Week 16	Tezepelumab	108	101 (93.5)	5.30 (1.15)	2.2	4.40	5.40	6.20	7.0	
			Placebo	101	92 (91.1)	4.87 (1.37)	1.2	4.00	4.90	6.00	7.0	
		Week 20	Tezepelumab	108	102 (94.4)	5.34 (1.15)	1.0	4.40	5.40	6.20	7.0	
			Placebo	101	92 (91.1)	4.93 (1.32)	1.4	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	108	102 (94.4)	5.33 (1.15)	1.6	4.40	5.20	6.20	7.0	
			Placebo	101	92 (91.1)	5.03 (1.29)	1.4	4.00	5.00	6.10	7.0	
		Week 28	Tezepelumab	108	104 (96.3)	5.43 (1.05)	2.8	4.60	5.40	6.20	7.0	
			Placebo	101	93 (92.1)	4.90 (1.34)	1.6	4.00	4.80	6.00	7.0	
		Week 32	Tezepelumab	108	105 (97.2)	5.38 (1.13)	1.8	4.60	5.60	6.20	7.0	
			Placebo	101	94 (93.1)	4.95 (1.39)	1.2	4.00	5.00	6.20	7.0	
		Week 36	Tezepelumab	108	105 (97.2)	5.47 (1.11)	2.8	4.60	5.60	6.40	7.0	
			Placebo	101	94 (93.1)	5.08 (1.35)	1.8	4.00	5.20	6.20	7.0	
		Week 40	Tezepelumab	108	105 (97.2)	5.37 (1.19)	1.8	4.60	5.40	6.40	7.0	
			Placebo	101	94 (93.1)	5.05 (1.38)	1.6	4.00	5.00	6.40	7.0	
		Week 44	Tezepelumab	108	105 (97.2)	5.47 (1.11)	2.6	4.60	5.60	6.40	7.0	
			Placebo	101	94 (93.1)	5.03 (1.47)	1.4	4.00	5.10	6.40	7.0	
		Week 48	Tezepelumab	108	105 (97.2)	5.51 (1.09)	1.8	4.60	5.60	6.40	7.0	
			Placebo	101	94 (93.1)	5.04 (1.42)	1.2	4.00	4.90	6.40	7.0	
		Week 52	Tezepelumab	108	105 (97.2)	5.46 (1.11)	1.8	4.60	5.60	6.40	7.0	
			Placebo	101	94 (93.1)	4.93 (1.50)	1.2	4.00	4.70	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	108	93 (86.1)	0.59 (1.22)	-4.2	0.00	0.60	1.40	3.8	0.14 [-0.16, 0.43]
			Placebo	101	88 (87.1)	0.44 (1.04)	-2.8	-0.10	0.40	1.10	3.0	
		Week 8	Tezepelumab	108	94 (87.0)	0.71 (1.23)	-2.2	0.00	0.60	1.40	5.0	0.10 [-0.19, 0.39]
			Placebo	101	88 (87.1)	0.59 (1.21)	-2.0	-0.20	0.60	1.30	4.0	
		Week 12	Tezepelumab	108	94 (87.0)	0.90 (1.23)	-2.4	0.20	0.80	1.60	5.4	0.22 [-0.07, 0.51]
			Placebo	101	88 (87.1)	0.64 (1.20)	-2.2	-0.10	0.60	1.40	4.4	
		Week 16	Tezepelumab	108	94 (87.0)	0.89 (1.21)	-2.8	0.00	0.80	1.60	5.2	0.20 [-0.09, 0.49]
			Placebo	101	88 (87.1)	0.65 (1.19)	-2.0	0.00	0.60	1.40	4.4	
		Week 20	Tezepelumab	108	94 (87.0)	0.95 (1.22)	-1.4	0.20	0.80	1.60	5.2	0.19 [-0.10, 0.48]
			Placebo	101	88 (87.1)	0.73 (1.15)	-2.2	0.20	0.60	1.30	4.2	
		Week 24	Tezepelumab	108	94 (87.0)	0.94 (1.21)	-1.4	0.00	0.70	1.60	5.4	0.08 [-0.21, 0.37]
			Placebo	101	88 (87.1)	0.84 (1.19)	-2.0	0.00	0.70	1.60	4.2	
		Week 28	Tezepelumab	108	94 (87.0)	1.00 (1.20)	-1.4	0.00	0.80	1.80	5.4	0.26 [-0.04, 0.55]
			Placebo	101	88 (87.1)	0.69 (1.27)	-2.2	0.00	0.70	1.40	5.2	
		Week 32	Tezepelumab	108	94 (87.0)	0.94 (1.21)	-1.6	0.00	0.80	1.60	5.4	0.15 [-0.14, 0.44]
			Placebo	101	88 (87.1)	0.75 (1.22)	-2.0	-0.20	0.70	1.60	4.2	
		Week 36	Tezepelumab	108	94 (87.0)	1.04 (1.28)	-1.6	0.20	0.90	1.80	5.4	0.14 [-0.15, 0.43]
			Placebo	101	88 (87.1)	0.87 (1.23)	-2.0	0.10	0.70	1.60	4.2	
		Week 40	Tezepelumab	108	94 (87.0)	0.94 (1.26)	-2.4	0.00	0.80	1.60	5.4	0.07 [-0.22, 0.36]
			Placebo	101	88 (87.1)	0.85 (1.29)	-2.0	0.00	0.80	1.40	5.2	
		Week 44	Tezepelumab	108	94 (87.0)	1.01 (1.20)	-1.4	0.20	0.90	1.60	5.4	0.15 [-0.14, 0.44]
			Placebo	101	88 (87.1)	0.82 (1.43)	-2.2	-0.20	0.80	1.60	5.2	
		Week 48	Tezepelumab	108	94 (87.0)	1.08 (1.18)	-1.4	0.20	1.00	1.80	5.4	0.18 [-0.11, 0.47]
			Placebo	101	88 (87.1)	0.85 (1.32)	-2.0	-0.10	0.80	1.60	4.2	
		Week 52	Tezepelumab	108	94 (87.0)	1.00 (1.22)	-1.6	0.00	1.00	1.80	5.4	0.21 [-0.08, 0.50]
			Placebo	101	88 (87.1)	0.73 (1.41)	-2.6	-0.20	0.80	1.50	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.37 (1.14)	1.4	3.80	4.20	5.20	6.8	
			Placebo	123	106 (86.2)	4.38 (1.18)	1.0	3.60	4.20	5.20	7.0	
		Week 4	Tezepelumab	128	117 (91.4)	4.96 (1.21)	1.2	4.00	5.00	6.00	7.0	
			Placebo	123	109 (88.6)	4.77 (1.33)	1.4	3.80	4.80	5.80	7.0	
		Week 8	Tezepelumab	128	119 (93.0)	5.15 (1.20)	1.8	4.20	5.00	6.00	7.0	
			Placebo	123	112 (91.1)	4.91 (1.26)	1.4	4.00	4.90	5.80	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.34 (1.19)	2.0	4.40	5.40	6.40	7.0	
			Placebo	123	113 (91.9)	4.90 (1.35)	1.4	4.00	4.60	6.00	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.29 (1.16)	2.2	4.40	5.40	6.20	7.0	
			Placebo	123	113 (91.9)	4.93 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.32 (1.17)	1.0	4.40	5.50	6.20	7.0	
			Placebo	123	113 (91.9)	5.01 (1.29)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.31 (1.19)	1.6	4.40	5.40	6.20	7.0	
			Placebo	123	113 (91.9)	5.04 (1.32)	1.0	4.20	5.00	6.00	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.38 (1.09)	2.8	4.40	5.40	6.20	7.0	
			Placebo	123	114 (92.7)	4.94 (1.35)	1.0	4.00	4.80	6.00	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.35 (1.17)	1.8	4.40	5.60	6.20	7.0	
			Placebo	123	115 (93.5)	4.99 (1.36)	1.0	4.00	5.00	6.20	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.46 (1.16)	2.8	4.60	5.60	6.40	7.0	
			Placebo	123	115 (93.5)	5.10 (1.32)	1.6	4.00	5.20	6.20	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.33 (1.23)	1.8	4.40	5.40	6.20	7.0	
			Placebo	123	115 (93.5)	5.06 (1.33)	1.6	4.00	5.00	6.20	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.44 (1.17)	2.6	4.60	5.60	6.40	7.0	
			Placebo	123	115 (93.5)	5.07 (1.39)	1.4	4.00	5.20	6.20	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.44 (1.17)	1.8	4.60	5.60	6.40	7.0	
			Placebo	123	116 (94.3)	5.07 (1.35)	1.2	4.00	4.90	6.30	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.42 (1.18)	1.8	4.60	5.60	6.20	7.0	
			Placebo	123	116 (94.3)	5.00 (1.41)	1.2	4.00	4.80	6.10	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.62 (1.18)	-4.2	0.00	0.60	1.40	3.6	0.19 [-0.08, 0.46]
			Placebo	123	105 (85.4)	0.41 (1.04)	-2.8	-0.20	0.40	1.00	3.0	
		Week 8	Tezepelumab	128	111 (86.7)	0.77 (1.17)	-1.4	0.00	0.60	1.60	5.0	0.17 [-0.09, 0.44]
			Placebo	123	106 (86.2)	0.57 (1.13)	-1.8	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	128	111 (86.7)	0.95 (1.22)	-2.4	0.20	0.80	1.80	5.4	0.31 [0.05, 0.58]
			Placebo	123	106 (86.2)	0.58 (1.20)	-2.2	0.00	0.60	1.40	4.4	
		Week 16	Tezepelumab	128	111 (86.7)	0.92 (1.17)	-2.8	0.00	1.00	1.60	5.2	0.28 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.58 (1.15)	-3.4	0.00	0.60	1.20	4.4	
		Week 20	Tezepelumab	128	111 (86.7)	0.97 (1.16)	-1.4	0.20	0.80	1.80	5.2	0.25 [-0.02, 0.52]
			Placebo	123	106 (86.2)	0.69 (1.11)	-3.4	0.20	0.70	1.20	4.2	
		Week 24	Tezepelumab	128	111 (86.7)	0.96 (1.17)	-1.4	0.00	0.80	1.80	5.4	0.20 [-0.06, 0.47]
			Placebo	123	106 (86.2)	0.72 (1.22)	-3.4	0.00	0.60	1.40	4.2	
		Week 28	Tezepelumab	128	111 (86.7)	0.99 (1.15)	-1.4	0.00	0.80	1.80	5.4	0.33 [0.06, 0.60]
			Placebo	123	106 (86.2)	0.60 (1.25)	-3.4	0.00	0.60	1.20	4.4	
		Week 32	Tezepelumab	128	111 (86.7)	0.97 (1.21)	-1.6	0.00	1.00	1.80	5.4	0.25 [-0.02, 0.51]
			Placebo	123	106 (86.2)	0.68 (1.20)	-3.4	-0.20	0.60	1.40	4.2	
		Week 36	Tezepelumab	128	111 (86.7)	1.08 (1.28)	-1.6	0.20	1.00	2.00	5.4	0.25 [-0.01, 0.52]
			Placebo	123	106 (86.2)	0.76 (1.19)	-2.0	0.00	0.60	1.40	4.2	
		Week 40	Tezepelumab	128	111 (86.7)	0.96 (1.26)	-2.4	0.00	0.80	1.80	5.4	0.18 [-0.09, 0.45]
			Placebo	123	106 (86.2)	0.74 (1.23)	-2.0	-0.20	0.80	1.40	4.0	
		Week 44	Tezepelumab	128	111 (86.7)	1.04 (1.21)	-1.4	0.20	1.00	1.80	5.4	0.25 [-0.01, 0.52]
			Placebo	123	106 (86.2)	0.73 (1.26)	-2.2	-0.20	0.80	1.40	4.2	
		Week 48	Tezepelumab	128	111 (86.7)	1.05 (1.21)	-1.4	0.20	1.00	2.00	5.4	0.26 [-0.01, 0.53]
			Placebo	123	106 (86.2)	0.74 (1.22)	-2.2	0.00	0.80	1.40	4.0	
		Week 52	Tezepelumab	128	111 (86.7)	1.02 (1.22)	-1.6	0.00	1.00	1.80	5.4	0.28 [0.01, 0.55]
			Placebo	123	106 (86.2)	0.66 (1.29)	-2.6	-0.20	0.80	1.40	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.75 (1.29)	1.8	2.60	4.10	4.80	5.2	
			Placebo	15	15 (100.0)	3.25 (1.22)	1.4	2.00	3.00	4.40	5.2	
		Week 4	Tezepelumab	9	9 (100.0)	5.18 (0.88)	4.2	4.40	5.00	6.20	6.2	
			Placebo	15	14 (93.3)	4.09 (1.02)	2.2	3.40	4.20	5.00	5.6	
		Week 8	Tezepelumab	9	9 (100.0)	5.40 (1.28)	2.8	4.80	5.20	6.20	7.0	
			Placebo	15	14 (93.3)	4.13 (1.57)	1.0	3.00	4.70	5.20	6.0	
		Week 12	Tezepelumab	9	9 (100.0)	5.60 (0.97)	4.0	5.00	5.40	6.40	7.0	
			Placebo	15	14 (93.3)	4.80 (1.13)	2.6	4.00	5.00	5.80	6.6	
		Week 16	Tezepelumab	9	9 (100.0)	5.56 (1.09)	3.2	5.00	5.80	6.20	7.0	
			Placebo	15	14 (93.3)	4.57 (1.58)	1.2	4.00	5.00	5.60	7.0	
		Week 20	Tezepelumab	9	9 (100.0)	5.91 (0.88)	4.2	5.40	5.80	6.40	7.0	
			Placebo	15	14 (93.3)	4.37 (1.49)	1.4	3.60	4.40	5.60	6.6	
		Week 24	Tezepelumab	9	9 (100.0)	5.82 (0.86)	4.0	5.80	6.00	6.20	7.0	
			Placebo	15	14 (93.3)	4.74 (1.19)	2.2	3.60	5.00	5.60	6.2	
		Week 28	Tezepelumab	9	9 (100.0)	6.09 (0.64)	5.0	5.80	6.00	6.40	7.0	
			Placebo	15	14 (93.3)	5.16 (1.74)	1.6	4.40	5.10	6.80	7.0	
		Week 32	Tezepelumab	9	9 (100.0)	5.96 (0.65)	5.0	5.60	6.00	6.40	7.0	
			Placebo	15	14 (93.3)	4.93 (1.57)	1.6	4.40	5.20	6.00	6.8	
		Week 36	Tezepelumab	9	9 (100.0)	5.96 (0.79)	4.6	6.00	6.00	6.40	7.0	
			Placebo	15	14 (93.3)	4.53 (1.33)	1.8	3.60	4.70	5.00	7.0	
		Week 40	Tezepelumab	9	9 (100.0)	6.07 (0.58)	5.4	5.40	6.00	6.40	7.0	
			Placebo	15	14 (93.3)	4.91 (1.64)	1.6	4.00	4.60	6.60	7.0	
		Week 44	Tezepelumab	9	9 (100.0)	6.18 (0.49)	5.4	6.00	6.00	6.40	7.0	
			Placebo	15	14 (93.3)	4.86 (1.73)	1.6	3.60	4.80	6.60	7.0	
		Week 48	Tezepelumab	9	9 (100.0)	6.00 (0.74)	4.4	6.00	6.00	6.40	7.0	
			Placebo	15	14 (93.3)	4.81 (1.58)	1.8	3.60	4.80	6.40	7.0	
		Week 52	Tezepelumab	9	9 (100.0)	6.04 (0.78)	4.4	6.00	6.00	6.40	7.0	
			Placebo	15	14 (93.3)	4.71 (1.55)	1.8	3.60	4.80	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	1.55 (1.33)	-0.6	0.70	1.70	2.20	3.8	0.62 [-0.27, 1.51]
			Placebo	15	14 (93.3)	0.74 (1.27)	-0.4	-0.20	0.00	1.40	3.6	
		Week 8	Tezepelumab	9	8 (88.9)	1.68 (1.97)	-2.2	0.80	2.00	2.80	4.4	0.52 [-0.36, 1.40]
			Placebo	15	14 (93.3)	0.79 (1.55)	-2.0	-0.20	0.60	2.20	3.4	
		Week 12	Tezepelumab	9	8 (88.9)	1.93 (1.34)	0.0	0.90	1.90	3.00	3.8	0.33 [-0.54, 1.21]
			Placebo	15	14 (93.3)	1.46 (1.45)	-0.2	0.60	0.90	2.00	4.4	
		Week 16	Tezepelumab	9	8 (88.9)	1.88 (1.48)	0.0	0.60	1.90	3.00	4.0	0.40 [-0.48, 1.27]
			Placebo	15	14 (93.3)	1.23 (1.70)	-1.8	0.00	1.10	2.40	4.0	
		Week 20	Tezepelumab	9	8 (88.9)	2.18 (1.61)	-0.4	0.90	2.50	3.20	4.6	0.62 [-0.27, 1.51]
			Placebo	15	14 (93.3)	1.03 (1.96)	-1.6	-0.80	0.90	2.00	5.2	
		Week 24	Tezepelumab	9	8 (88.9)	2.03 (1.87)	-1.0	0.60	2.30	3.40	4.6	0.37 [-0.50, 1.25]
			Placebo	15	14 (93.3)	1.40 (1.57)	-1.0	0.60	1.40	2.00	4.2	
		Week 28	Tezepelumab	9	8 (88.9)	2.35 (1.53)	0.0	1.10	2.60	3.40	4.6	0.30 [-0.58, 1.17]
			Placebo	15	14 (93.3)	1.81 (1.95)	-1.4	0.80	1.90	2.40	5.2	
		Week 32	Tezepelumab	9	8 (88.9)	2.13 (1.41)	0.6	1.00	1.80	3.10	4.6	0.32 [-0.55, 1.20]
			Placebo	15	14 (93.3)	1.59 (1.81)	-1.4	0.60	1.60	2.60	5.4	
		Week 36	Tezepelumab	9	8 (88.9)	2.13 (1.52)	0.2	0.90	2.00	3.20	4.6	0.62 [-0.27, 1.51]
			Placebo	15	14 (93.3)	1.19 (1.50)	-1.4	0.20	1.50	2.00	3.6	
		Week 40	Tezepelumab	9	8 (88.9)	2.25 (1.33)	0.8	1.10	2.10	3.10	4.6	0.37 [-0.50, 1.25]
			Placebo	15	14 (93.3)	1.57 (2.02)	-1.4	0.00	1.50	2.00	5.4	
		Week 44	Tezepelumab	9	8 (88.9)	2.35 (1.39)	0.6	1.30	2.10	3.40	4.6	0.45 [-0.43, 1.34]
			Placebo	15	14 (93.3)	1.51 (2.04)	-1.4	-0.20	1.80	3.00	5.2	
		Week 48	Tezepelumab	9	8 (88.9)	2.20 (1.60)	-0.2	1.10	2.10	3.40	4.6	0.40 [-0.47, 1.28]
			Placebo	15	14 (93.3)	1.47 (1.90)	-1.2	-0.20	1.10	3.00	5.0	
		Week 52	Tezepelumab	9	8 (88.9)	2.20 (1.60)	-0.2	1.10	2.10	3.40	4.6	0.46 [-0.42, 1.34]
			Placebo	15	14 (93.3)	1.37 (1.92)	-1.2	-0.20	0.90	2.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	3.47 (1.62)	1.4	1.80	3.80	4.80	6.0	
			Placebo	9	8 (88.9)	2.88 (1.06)	1.4	2.30	2.60	3.60	4.6	
		Week 4	Tezepelumab	10	8 (80.0)	5.65 (0.80)	4.6	5.00	5.60	6.20	7.0	
			Placebo	9	7 (77.8)	4.26 (1.33)	2.2	2.80	4.40	5.60	5.6	
		Week 8	Tezepelumab	10	9 (90.0)	5.78 (1.26)	3.0	5.40	6.00	6.60	7.0	
			Placebo	9	7 (77.8)	4.51 (2.09)	1.0	2.20	5.60	5.80	6.6	
		Week 12	Tezepelumab	10	9 (90.0)	5.69 (1.43)	2.8	5.60	6.00	6.80	7.0	
			Placebo	9	7 (77.8)	4.89 (1.62)	2.6	3.60	5.40	6.20	7.0	
		Week 16	Tezepelumab	10	9 (90.0)	5.51 (1.50)	2.8	5.60	6.00	6.40	7.0	
			Placebo	9	7 (77.8)	4.69 (1.99)	1.2	3.40	5.00	6.20	7.0	
		Week 20	Tezepelumab	10	9 (90.0)	5.96 (1.32)	2.8	5.60	6.40	6.80	7.0	
			Placebo	9	7 (77.8)	5.09 (1.96)	1.4	3.60	6.00	6.60	6.8	
		Week 24	Tezepelumab	10	9 (90.0)	5.71 (1.27)	2.8	5.20	6.00	6.40	7.0	
			Placebo	9	7 (77.8)	5.11 (1.54)	2.2	4.40	5.60	6.20	6.8	
		Week 28	Tezepelumab	10	10 (100.0)	5.96 (1.28)	2.8	5.60	6.20	7.00	7.0	
			Placebo	9	7 (77.8)	5.29 (1.61)	2.2	4.40	6.00	6.20	7.0	
		Week 32	Tezepelumab	10	10 (100.0)	5.52 (1.28)	2.8	5.00	5.80	6.40	7.0	
			Placebo	9	7 (77.8)	5.20 (1.81)	1.6	4.40	5.40	6.80	6.8	
		Week 36	Tezepelumab	10	10 (100.0)	5.62 (1.31)	2.8	4.80	6.10	6.40	7.0	
			Placebo	9	7 (77.8)	4.91 (1.59)	1.8	4.40	5.00	6.20	6.4	
		Week 40	Tezepelumab	10	10 (100.0)	5.72 (1.22)	2.8	5.40	6.00	6.40	7.0	
			Placebo	9	7 (77.8)	5.00 (1.81)	1.6	4.00	6.00	6.20	6.8	
		Week 44	Tezepelumab	10	10 (100.0)	5.82 (1.23)	2.8	5.40	6.10	6.40	7.0	
			Placebo	9	7 (77.8)	5.23 (1.80)	1.6	4.40	6.00	6.60	6.8	
		Week 48	Tezepelumab	10	10 (100.0)	5.80 (1.23)	2.8	5.40	6.00	6.40	7.0	
			Placebo	9	7 (77.8)	5.63 (1.76)	1.8	5.60	6.40	6.80	6.8	
		Week 52	Tezepelumab	10	10 (100.0)	5.88 (1.23)	2.8	5.40	6.00	6.80	7.0	
			Placebo	9	7 (77.8)	5.60 (1.79)	1.8	5.20	6.40	6.80	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	1.93 (1.55)	-1.2	1.50	1.90	3.00	3.8	0.40 [-0.63, 1.42]
			Placebo	9	7 (77.8)	1.26 (1.83)	-0.4	-0.20	0.00	3.00	3.6	
		Week 8	Tezepelumab	10	9 (90.0)	2.31 (1.69)	-0.6	1.60	2.00	3.20	5.0	0.42 [-0.58, 1.42]
			Placebo	9	7 (77.8)	1.51 (2.17)	-2.0	-0.40	1.60	3.40	4.0	
		Week 12	Tezepelumab	10	9 (90.0)	2.22 (1.66)	-0.2	1.40	2.00	3.00	5.4	0.19 [-0.80, 1.19]
			Placebo	9	7 (77.8)	1.89 (1.82)	0.0	0.60	1.00	4.40	4.4	
		Week 16	Tezepelumab	10	9 (90.0)	2.04 (1.75)	-0.4	1.20	2.00	2.60	5.2	0.20 [-0.79, 1.19]
			Placebo	9	7 (77.8)	1.69 (1.91)	-1.8	0.80	2.00	2.60	4.4	
		Week 20	Tezepelumab	10	9 (90.0)	2.49 (1.68)	-0.4	1.80	2.20	3.20	5.2	0.21 [-0.78, 1.20]
			Placebo	9	7 (77.8)	2.09 (2.22)	-1.6	1.00	2.00	4.20	5.2	
		Week 24	Tezepelumab	10	9 (90.0)	2.24 (1.92)	-0.8	1.40	2.00	3.00	5.4	0.07 [-0.92, 1.06]
			Placebo	9	7 (77.8)	2.11 (1.72)	-0.8	1.40	2.00	4.20	4.2	
		Week 28	Tezepelumab	10	9 (90.0)	2.40 (1.83)	-0.4	1.40	2.20	3.20	5.4	0.06 [-0.93, 1.05]
			Placebo	9	7 (77.8)	2.29 (1.89)	-0.8	1.40	2.00	4.40	4.8	
		Week 32	Tezepelumab	10	9 (90.0)	1.93 (2.00)	-0.6	1.20	1.60	2.20	5.4	-0.13 [-1.12, 0.86]
			Placebo	9	7 (77.8)	2.20 (2.22)	-1.4	0.80	2.00	4.20	5.4	
		Week 36	Tezepelumab	10	9 (90.0)	2.07 (2.00)	-1.0	1.40	2.00	2.40	5.4	0.08 [-0.91, 1.07]
			Placebo	9	7 (77.8)	1.91 (1.60)	-1.2	1.40	2.00	3.20	3.8	
		Week 40	Tezepelumab	10	9 (90.0)	2.18 (1.98)	-1.2	1.40	2.00	3.00	5.4	0.09 [-0.90, 1.08]
			Placebo	9	7 (77.8)	2.00 (2.08)	-1.4	1.40	1.80	3.40	5.4	
		Week 44	Tezepelumab	10	9 (90.0)	2.29 (1.89)	-1.0	1.40	2.00	3.00	5.4	0.03 [-0.96, 1.02]
			Placebo	9	7 (77.8)	2.23 (1.82)	-1.4	1.40	2.60	3.40	4.2	
		Week 48	Tezepelumab	10	9 (90.0)	2.27 (1.90)	-1.0	1.40	2.00	3.00	5.4	-0.18 [-1.17, 0.81]
			Placebo	9	7 (77.8)	2.63 (2.12)	-1.2	1.00	3.00	4.20	5.0	
		Week 52	Tezepelumab	10	9 (90.0)	2.31 (1.82)	-0.6	1.40	2.00	3.00	5.4	-0.15 [-1.14, 0.84]
			Placebo	9	7 (77.8)	2.60 (2.14)	-1.2	1.00	2.60	4.40	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	127	114 (89.8)	4.40 (1.08)	1.4	3.80	4.40	5.20	6.8	
			Placebo	129	113 (87.6)	4.33 (1.19)	1.0	3.60	4.20	5.00	7.0	
		Week 4	Tezepelumab	127	118 (92.9)	4.93 (1.20)	1.2	4.00	5.00	6.00	7.0	
			Placebo	129	116 (89.9)	4.72 (1.31)	1.4	3.80	4.80	5.80	7.0	
		Week 8	Tezepelumab	127	119 (93.7)	5.12 (1.19)	1.8	4.20	5.00	6.00	7.0	
			Placebo	129	119 (92.2)	4.84 (1.26)	1.4	4.00	4.80	5.80	7.0	
		Week 12	Tezepelumab	127	119 (93.7)	5.33 (1.16)	2.0	4.40	5.20	6.40	7.0	
			Placebo	129	120 (93.0)	4.89 (1.31)	1.4	4.00	4.60	6.00	7.0	
		Week 16	Tezepelumab	127	119 (93.7)	5.30 (1.13)	2.2	4.40	5.40	6.20	7.0	
			Placebo	129	120 (93.0)	4.90 (1.34)	1.0	4.00	5.00	5.90	7.0	
		Week 20	Tezepelumab	127	120 (94.5)	5.32 (1.14)	1.0	4.40	5.40	6.10	7.0	
			Placebo	129	120 (93.0)	4.94 (1.28)	1.0	4.00	5.00	5.90	7.0	
		Week 24	Tezepelumab	127	120 (94.5)	5.32 (1.17)	1.6	4.40	5.40	6.20	7.0	
			Placebo	129	120 (93.0)	5.00 (1.30)	1.0	4.00	5.00	6.00	7.0	
		Week 28	Tezepelumab	127	121 (95.3)	5.38 (1.05)	2.8	4.40	5.40	6.20	7.0	
			Placebo	129	121 (93.8)	4.94 (1.39)	1.0	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	127	122 (96.1)	5.39 (1.14)	1.8	4.60	5.60	6.20	7.0	
			Placebo	129	122 (94.6)	4.98 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	127	122 (96.1)	5.48 (1.14)	2.8	4.60	5.60	6.40	7.0	
			Placebo	129	122 (94.6)	5.04 (1.32)	1.6	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	127	122 (96.1)	5.36 (1.21)	1.8	4.40	5.40	6.20	7.0	
			Placebo	129	122 (94.6)	5.05 (1.34)	1.6	4.00	5.00	6.40	7.0	
		Week 44	Tezepelumab	127	122 (96.1)	5.46 (1.14)	2.6	4.60	5.60	6.40	7.0	
			Placebo	129	122 (94.6)	5.03 (1.40)	1.4	4.00	5.00	6.20	7.0	
		Week 48	Tezepelumab	127	122 (96.1)	5.45 (1.14)	1.8	4.60	5.60	6.40	7.0	
			Placebo	129	123 (95.3)	5.01 (1.35)	1.2	4.00	4.80	6.00	7.0	
		Week 52	Tezepelumab	127	122 (96.1)	5.42 (1.16)	1.8	4.60	5.60	6.20	7.0	
			Placebo	129	123 (95.3)	4.93 (1.40)	1.2	4.00	4.80	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	127	109 (85.8)	0.59 (1.13)	-4.2	0.00	0.60	1.40	3.6	0.18 [-0.08, 0.45]
			Placebo	129	112 (86.8)	0.39 (1.00)	-2.8	-0.10	0.40	1.00	2.8	
		Week 8	Tezepelumab	127	110 (86.6)	0.71 (1.13)	-2.2	0.00	0.60	1.40	3.6	0.16 [-0.11, 0.42]
			Placebo	129	113 (87.6)	0.54 (1.08)	-1.8	-0.20	0.60	1.20	3.2	
		Week 12	Tezepelumab	127	110 (86.6)	0.92 (1.16)	-2.4	0.20	0.80	1.80	3.6	0.27 [0.01, 0.53]
			Placebo	129	113 (87.6)	0.60 (1.18)	-2.2	0.00	0.60	1.40	3.6	
		Week 16	Tezepelumab	127	110 (86.6)	0.89 (1.13)	-2.8	0.00	0.90	1.60	3.4	0.26 [-0.00, 0.52]
			Placebo	129	113 (87.6)	0.60 (1.16)	-3.4	0.00	0.60	1.20	4.0	
		Week 20	Tezepelumab	127	110 (86.6)	0.94 (1.11)	-1.4	0.20	0.80	1.60	4.4	0.26 [0.00, 0.53]
			Placebo	129	113 (87.6)	0.64 (1.11)	-3.4	0.00	0.60	1.20	4.0	
		Week 24	Tezepelumab	127	110 (86.6)	0.93 (1.13)	-1.4	0.00	0.80	1.60	3.8	0.18 [-0.08, 0.45]
			Placebo	129	113 (87.6)	0.71 (1.21)	-3.4	0.00	0.60	1.40	4.2	
		Week 28	Tezepelumab	127	110 (86.6)	0.98 (1.10)	-1.4	0.00	0.80	1.80	4.2	0.27 [0.01, 0.54]
			Placebo	129	113 (87.6)	0.65 (1.31)	-3.4	0.00	0.80	1.40	5.2	
		Week 32	Tezepelumab	127	110 (86.6)	0.98 (1.16)	-1.6	0.20	1.00	1.80	3.6	0.24 [-0.02, 0.50]
			Placebo	129	113 (87.6)	0.69 (1.19)	-3.4	-0.20	0.60	1.40	3.8	
		Week 36	Tezepelumab	127	110 (86.6)	1.07 (1.23)	-1.6	0.20	1.00	2.00	4.4	0.27 [0.01, 0.54]
			Placebo	129	113 (87.6)	0.75 (1.18)	-2.0	0.00	0.60	1.40	4.2	
		Week 40	Tezepelumab	127	110 (86.6)	0.96 (1.19)	-2.4	0.00	0.80	1.80	3.4	0.16 [-0.11, 0.42]
			Placebo	129	113 (87.6)	0.76 (1.28)	-2.0	0.00	0.80	1.40	5.2	
		Week 44	Tezepelumab	127	110 (86.6)	1.03 (1.16)	-1.4	0.20	1.00	1.80	3.8	0.24 [-0.02, 0.51]
			Placebo	129	113 (87.6)	0.73 (1.31)	-2.2	-0.20	0.80	1.40	5.2	
		Week 48	Tezepelumab	127	110 (86.6)	1.04 (1.16)	-1.4	0.20	1.00	2.00	3.8	0.28 [0.02, 0.54]
			Placebo	129	113 (87.6)	0.71 (1.20)	-2.2	-0.20	0.60	1.40	4.0	
		Week 52	Tezepelumab	127	110 (86.6)	1.00 (1.18)	-1.6	0.00	1.00	1.80	3.8	0.30 [0.04, 0.56]
			Placebo	129	113 (87.6)	0.63 (1.26)	-2.6	-0.20	0.60	1.40	4.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	61	54 (88.5)	4.45 (0.98)	1.8	4.00	4.50	5.00	6.8	
			Placebo	60	53 (88.3)	4.12 (1.11)	1.0	3.60	4.20	4.80	6.6	
		Week 4	Tezepelumab	61	56 (91.8)	4.96 (1.15)	1.2	4.20	4.80	5.90	7.0	
			Placebo	60	53 (88.3)	4.71 (1.25)	1.6	4.00	4.60	5.60	7.0	
		Week 8	Tezepelumab	61	57 (93.4)	5.22 (1.09)	2.6	4.60	5.00	6.20	7.0	
			Placebo	60	54 (90.0)	4.80 (1.28)	1.0	4.00	4.80	5.60	7.0	
		Week 12	Tezepelumab	61	57 (93.4)	5.33 (1.03)	3.0	4.40	5.20	6.00	7.0	
			Placebo	60	54 (90.0)	4.91 (1.15)	2.6	4.00	4.60	5.80	7.0	
		Week 16	Tezepelumab	61	57 (93.4)	5.25 (1.08)	2.6	4.40	5.40	6.00	7.0	
			Placebo	60	54 (90.0)	4.86 (1.37)	1.0	4.00	4.70	5.80	7.0	
		Week 20	Tezepelumab	61	58 (95.1)	5.33 (1.05)	2.4	4.40	5.40	6.00	7.0	
			Placebo	60	54 (90.0)	4.83 (1.30)	1.0	4.00	4.80	5.80	7.0	
		Week 24	Tezepelumab	61	58 (95.1)	5.35 (1.08)	2.0	4.40	5.50	6.00	7.0	
			Placebo	60	54 (90.0)	4.87 (1.37)	1.0	4.00	4.80	6.00	7.0	
		Week 28	Tezepelumab	61	59 (96.7)	5.38 (0.98)	4.0	4.60	5.40	6.20	7.0	
			Placebo	60	54 (90.0)	4.77 (1.40)	1.0	4.00	4.50	6.00	7.0	
		Week 32	Tezepelumab	61	60 (98.4)	5.44 (0.96)	3.6	4.60	5.60	6.10	7.0	
			Placebo	60	54 (90.0)	4.83 (1.34)	1.0	4.00	4.80	6.00	7.0	
		Week 36	Tezepelumab	61	60 (98.4)	5.54 (1.02)	3.4	4.70	5.60	6.20	7.0	
			Placebo	60	54 (90.0)	4.95 (1.32)	1.8	4.00	4.90	6.00	7.0	
		Week 40	Tezepelumab	61	60 (98.4)	5.34 (1.10)	2.0	4.30	5.40	6.10	7.0	
			Placebo	60	54 (90.0)	4.90 (1.32)	1.6	4.00	4.80	6.00	7.0	
		Week 44	Tezepelumab	61	60 (98.4)	5.51 (1.04)	3.4	4.60	5.60	6.40	7.0	
			Placebo	60	54 (90.0)	4.97 (1.41)	1.6	4.00	4.60	6.00	7.0	
		Week 48	Tezepelumab	61	60 (98.4)	5.58 (0.96)	3.8	4.80	5.80	6.20	7.0	
			Placebo	60	54 (90.0)	4.91 (1.33)	1.8	4.00	4.70	6.00	7.0	
		Week 52	Tezepelumab	61	60 (98.4)	5.56 (0.99)	3.8	4.80	5.80	6.20	7.0	
			Placebo	60	54 (90.0)	4.85 (1.35)	1.8	4.00	4.70	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	61	52 (85.2)	0.58 (1.33)	-4.2	0.00	0.60	1.50	3.8	0.03 [-0.35, 0.42]
			Placebo	60	51 (85.0)	0.55 (0.96)	-2.2	0.00	0.60	1.20	2.8	
		Week 8	Tezepelumab	61	53 (86.9)	0.77 (1.33)	-2.2	-0.20	0.60	1.60	4.4	0.10 [-0.28, 0.48]
			Placebo	60	52 (86.7)	0.65 (1.09)	-2.0	0.00	0.80	1.20	3.0	
		Week 12	Tezepelumab	61	53 (86.9)	0.89 (1.26)	-2.4	0.20	0.60	1.80	3.8	0.13 [-0.26, 0.51]
			Placebo	60	52 (86.7)	0.75 (1.05)	-1.6	0.00	0.80	1.50	3.0	
		Week 16	Tezepelumab	61	53 (86.9)	0.84 (1.26)	-2.8	0.00	1.00	1.60	4.0	0.12 [-0.26, 0.51]
			Placebo	60	52 (86.7)	0.69 (1.17)	-3.4	0.10	1.00	1.40	2.8	
		Week 20	Tezepelumab	61	53 (86.9)	0.93 (1.24)	-1.4	0.00	0.80	1.40	4.6	0.22 [-0.16, 0.61]
			Placebo	60	52 (86.7)	0.67 (1.11)	-3.4	0.00	0.80	1.30	3.0	
		Week 24	Tezepelumab	61	53 (86.9)	0.94 (1.28)	-1.4	0.00	0.80	1.60	4.6	0.17 [-0.22, 0.55]
			Placebo	60	52 (86.7)	0.73 (1.23)	-3.4	0.10	0.80	1.60	3.0	
		Week 28	Tezepelumab	61	53 (86.9)	0.94 (1.25)	-1.4	0.00	0.60	1.60	4.6	0.25 [-0.14, 0.63]
			Placebo	60	52 (86.7)	0.63 (1.23)	-3.4	0.00	0.90	1.30	3.0	
		Week 32	Tezepelumab	61	53 (86.9)	0.97 (1.23)	-1.6	0.00	1.00	1.60	4.6	0.23 [-0.16, 0.61]
			Placebo	60	52 (86.7)	0.70 (1.13)	-3.4	-0.10	1.00	1.60	2.8	
		Week 36	Tezepelumab	61	53 (86.9)	1.08 (1.24)	-1.6	0.40	1.00	1.80	4.6	0.22 [-0.16, 0.61]
			Placebo	60	52 (86.7)	0.82 (1.16)	-1.4	0.00	0.90	1.60	4.2	
		Week 40	Tezepelumab	61	53 (86.9)	0.91 (1.26)	-1.4	0.00	0.80	1.60	4.6	0.12 [-0.26, 0.50]
			Placebo	60	52 (86.7)	0.77 (1.17)	-1.6	-0.10	1.00	1.50	3.2	
		Week 44	Tezepelumab	61	53 (86.9)	1.02 (1.29)	-1.4	0.00	1.00	1.80	4.6	0.14 [-0.24, 0.52]
			Placebo	60	52 (86.7)	0.83 (1.33)	-2.2	-0.20	1.00	1.60	4.2	
		Week 48	Tezepelumab	61	53 (86.9)	1.11 (1.23)	-1.4	0.20	1.00	2.00	4.6	0.28 [-0.10, 0.66]
			Placebo	60	52 (86.7)	0.77 (1.21)	-1.8	-0.10	0.80	1.60	4.0	
		Week 52	Tezepelumab	61	53 (86.9)	1.07 (1.28)	-1.6	0.00	1.00	2.00	4.6	0.29 [-0.10, 0.67]
			Placebo	60	52 (86.7)	0.71 (1.24)	-1.8	-0.20	0.80	1.40	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	76	69 (90.8)	4.24 (1.26)	1.4	3.60	4.20	5.20	6.8	
			Placebo	78	68 (87.2)	4.33 (1.32)	1.4	3.50	4.20	5.30	7.0	
		Week 4	Tezepelumab	76	70 (92.1)	4.99 (1.23)	1.6	4.00	5.00	6.00	7.0	
			Placebo	78	70 (89.7)	4.67 (1.37)	1.4	3.80	4.80	5.60	7.0	
		Week 8	Tezepelumab	76	71 (93.4)	5.13 (1.29)	1.8	4.00	5.40	6.00	7.0	
			Placebo	78	72 (92.3)	4.84 (1.34)	1.4	3.90	4.90	5.90	7.0	
		Week 12	Tezepelumab	76	71 (93.4)	5.39 (1.28)	2.0	4.40	5.80	6.40	7.0	
			Placebo	78	73 (93.6)	4.88 (1.44)	1.4	4.00	5.00	6.00	7.0	
		Week 16	Tezepelumab	76	71 (93.4)	5.36 (1.22)	2.2	4.40	5.60	6.20	7.0	
			Placebo	78	73 (93.6)	4.91 (1.38)	1.8	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	76	71 (93.4)	5.38 (1.25)	1.0	4.40	5.60	6.40	7.0	
			Placebo	78	73 (93.6)	5.02 (1.34)	1.8	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	76	71 (93.4)	5.34 (1.25)	1.6	4.40	5.40	6.40	7.0	
			Placebo	78	73 (93.6)	5.11 (1.26)	1.4	4.20	5.00	6.00	7.0	
		Week 28	Tezepelumab	76	72 (94.7)	5.47 (1.16)	2.8	4.40	5.70	6.40	7.0	
			Placebo	78	74 (94.9)	5.11 (1.38)	1.6	4.00	5.20	6.20	7.0	
		Week 32	Tezepelumab	76	72 (94.7)	5.36 (1.29)	1.8	4.40	5.60	6.30	7.0	
			Placebo	78	75 (96.2)	5.10 (1.40)	1.2	4.00	5.20	6.20	7.0	
		Week 36	Tezepelumab	76	72 (94.7)	5.45 (1.25)	2.8	4.30	5.80	6.60	7.0	
			Placebo	78	75 (96.2)	5.10 (1.34)	1.6	4.00	5.00	6.20	7.0	
		Week 40	Tezepelumab	76	72 (94.7)	5.42 (1.29)	1.8	4.60	5.60	6.60	7.0	
			Placebo	78	75 (96.2)	5.15 (1.39)	1.6	4.20	5.00	6.60	7.0	
		Week 44	Tezepelumab	76	72 (94.7)	5.48 (1.24)	2.6	4.70	5.60	6.60	7.0	
			Placebo	78	75 (96.2)	5.10 (1.44)	1.4	4.00	5.20	6.40	7.0	
		Week 48	Tezepelumab	76	72 (94.7)	5.39 (1.29)	1.8	4.50	5.60	6.40	7.0	
			Placebo	78	76 (97.4)	5.14 (1.41)	1.2	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	76	72 (94.7)	5.37 (1.29)	1.8	4.40	5.60	6.40	7.0	
			Placebo	78	76 (97.4)	5.05 (1.47)	1.2	4.00	5.00	6.40	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	76	65 (85.5)	0.76 (1.10)	-1.2	0.00	0.60	1.60	3.6	0.35 [0.00, 0.69]
			Placebo	78	68 (87.2)	0.37 (1.15)	-2.8	-0.20	0.40	1.00	3.6	
		Week 8	Tezepelumab	76	66 (86.8)	0.88 (1.18)	-1.4	0.20	0.80	1.60	5.0	0.27 [-0.07, 0.61]
			Placebo	78	68 (87.2)	0.55 (1.24)	-1.8	-0.20	0.40	1.20	4.0	
		Week 12	Tezepelumab	76	66 (86.8)	1.12 (1.23)	-1.6	0.40	1.00	2.00	5.4	0.37 [0.03, 0.72]
			Placebo	78	68 (87.2)	0.63 (1.40)	-2.2	-0.10	0.60	1.40	4.4	
		Week 16	Tezepelumab	76	66 (86.8)	1.09 (1.17)	-1.2	0.20	1.00	1.80	5.2	0.37 [0.03, 0.71]
			Placebo	78	68 (87.2)	0.64 (1.29)	-2.0	-0.20	0.60	1.30	4.4	
		Week 20	Tezepelumab	76	66 (86.8)	1.15 (1.22)	-0.6	0.20	1.00	2.20	5.2	0.30 [-0.04, 0.64]
			Placebo	78	68 (87.2)	0.77 (1.33)	-2.2	0.10	0.70	1.40	5.2	
		Week 24	Tezepelumab	76	66 (86.8)	1.10 (1.23)	-0.8	0.20	1.00	2.00	5.4	0.20 [-0.14, 0.54]
			Placebo	78	68 (87.2)	0.84 (1.32)	-2.0	0.00	0.60	1.50	4.2	
		Week 28	Tezepelumab	76	66 (86.8)	1.21 (1.20)	-0.6	0.20	1.00	2.00	5.4	0.27 [-0.07, 0.61]
			Placebo	78	68 (87.2)	0.83 (1.50)	-2.2	-0.10	0.60	1.80	5.2	
		Week 32	Tezepelumab	76	66 (86.8)	1.12 (1.28)	-1.4	0.20	1.00	2.20	5.4	0.20 [-0.14, 0.54]
			Placebo	78	68 (87.2)	0.85 (1.43)	-2.0	-0.20	0.60	1.70	5.4	
		Week 36	Tezepelumab	76	66 (86.8)	1.20 (1.39)	-1.0	0.20	1.00	2.20	5.4	0.29 [-0.05, 0.63]
			Placebo	78	68 (87.2)	0.81 (1.29)	-2.0	0.00	0.60	1.60	3.8	
		Week 40	Tezepelumab	76	66 (86.8)	1.16 (1.33)	-2.4	0.20	1.00	2.00	5.4	0.19 [-0.15, 0.53]
			Placebo	78	68 (87.2)	0.89 (1.49)	-2.0	0.00	0.80	1.60	5.4	
		Week 44	Tezepelumab	76	66 (86.8)	1.22 (1.24)	-1.4	0.40	1.20	2.00	5.4	0.31 [-0.03, 0.65]
			Placebo	78	68 (87.2)	0.81 (1.43)	-2.0	-0.20	0.60	1.40	5.2	
		Week 48	Tezepelumab	76	66 (86.8)	1.15 (1.30)	-1.4	0.20	1.00	2.00	5.4	0.21 [-0.13, 0.55]
			Placebo	78	68 (87.2)	0.86 (1.43)	-2.2	-0.10	0.60	1.40	5.0	
		Week 52	Tezepelumab	76	66 (86.8)	1.12 (1.29)	-1.4	0.20	1.00	2.00	5.4	0.25 [-0.09, 0.59]
			Placebo	78	68 (87.2)	0.77 (1.50)	-2.6	-0.20	0.60	1.40	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	75	65 (86.7)	4.44 (0.98)	1.8	3.80	4.20	5.20	6.8	
			Placebo	72	61 (84.7)	4.33 (1.15)	1.6	3.80	4.20	5.00	7.0	
		Week 4	Tezepelumab	75	69 (92.0)	4.90 (1.16)	1.2	4.00	5.00	5.80	7.0	
			Placebo	72	64 (88.9)	4.74 (1.28)	1.4	4.00	4.70	5.70	7.0	
		Week 8	Tezepelumab	75	69 (92.0)	5.14 (1.06)	2.6	4.40	5.00	6.00	7.0	
			Placebo	72	64 (88.9)	4.92 (1.24)	1.4	4.00	5.00	5.60	7.0	
		Week 12	Tezepelumab	75	69 (92.0)	5.34 (1.07)	3.0	4.40	5.40	6.20	7.0	
			Placebo	72	65 (90.3)	4.86 (1.35)	1.4	4.00	4.60	6.00	7.0	
		Week 16	Tezepelumab	75	69 (92.0)	5.22 (1.09)	2.6	4.20	5.40	6.00	7.0	
			Placebo	72	65 (90.3)	4.94 (1.24)	1.8	4.00	4.80	5.80	7.0	
		Week 20	Tezepelumab	75	70 (93.3)	5.24 (1.11)	2.4	4.40	5.20	6.00	7.0	
			Placebo	72	65 (90.3)	4.98 (1.16)	1.8	4.20	5.00	5.60	7.0	
		Week 24	Tezepelumab	75	70 (93.3)	5.29 (1.11)	2.0	4.40	5.40	6.00	7.0	
			Placebo	72	65 (90.3)	5.09 (1.17)	1.4	4.40	5.00	6.00	7.0	
		Week 28	Tezepelumab	75	72 (96.0)	5.35 (1.06)	3.2	4.30	5.40	6.20	7.0	
			Placebo	72	66 (91.7)	4.99 (1.25)	2.0	4.00	4.90	6.00	7.0	
		Week 32	Tezepelumab	75	73 (97.3)	5.35 (1.07)	2.6	4.40	5.60	6.00	7.0	
			Placebo	72	67 (93.1)	5.01 (1.27)	1.2	4.00	5.00	6.20	7.0	
		Week 36	Tezepelumab	75	73 (97.3)	5.42 (1.15)	3.0	4.40	5.80	6.20	7.0	
			Placebo	72	67 (93.1)	5.12 (1.27)	1.8	4.00	5.20	6.20	7.0	
		Week 40	Tezepelumab	75	73 (97.3)	5.25 (1.21)	1.8	4.20	5.40	6.20	7.0	
			Placebo	72	67 (93.1)	5.07 (1.21)	1.6	4.20	5.00	6.00	7.0	
		Week 44	Tezepelumab	75	73 (97.3)	5.35 (1.14)	2.8	4.40	5.40	6.20	7.0	
			Placebo	72	67 (93.1)	5.13 (1.35)	1.4	4.00	5.20	6.40	7.0	
		Week 48	Tezepelumab	75	73 (97.3)	5.34 (1.13)	2.6	4.40	5.40	6.20	7.0	
			Placebo	72	68 (94.4)	5.13 (1.33)	1.2	4.00	4.90	6.40	7.0	
		Week 52	Tezepelumab	75	73 (97.3)	5.31 (1.11)	2.6	4.40	5.40	6.20	7.0	
			Placebo	72	68 (94.4)	5.03 (1.43)	1.2	4.00	4.80	6.40	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	75	64 (85.3)	0.46 (1.25)	-4.2	-0.10	0.40	1.20	3.8	-0.01 [-0.36, 0.35]
			Placebo	72	61 (84.7)	0.47 (1.04)	-2.2	0.00	0.60	1.00	3.0	
		Week 8	Tezepelumab	75	64 (85.3)	0.70 (1.22)	-1.2	-0.20	0.60	1.40	4.4	0.07 [-0.28, 0.42]
			Placebo	72	61 (84.7)	0.62 (1.15)	-1.6	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	75	64 (85.3)	0.88 (1.17)	-2.4	0.20	0.80	1.70	3.8	0.23 [-0.12, 0.59]
			Placebo	72	61 (84.7)	0.60 (1.20)	-2.0	0.00	0.60	1.20	4.4	
		Week 16	Tezepelumab	75	64 (85.3)	0.77 (1.19)	-2.8	0.00	0.80	1.50	4.0	0.10 [-0.25, 0.45]
			Placebo	72	61 (84.7)	0.66 (1.04)	-1.6	0.00	0.60	1.20	4.4	
		Week 20	Tezepelumab	75	64 (85.3)	0.83 (1.18)	-1.4	-0.10	0.80	1.40	4.6	0.11 [-0.24, 0.46]
			Placebo	72	61 (84.7)	0.71 (1.02)	-2.2	0.20	0.80	1.20	4.2	
		Week 24	Tezepelumab	75	64 (85.3)	0.89 (1.14)	-1.4	0.00	0.60	1.70	4.6	0.08 [-0.27, 0.43]
			Placebo	72	61 (84.7)	0.80 (1.04)	-1.4	0.20	0.80	1.40	4.2	
		Week 28	Tezepelumab	75	64 (85.3)	0.89 (1.16)	-1.4	0.00	0.70	1.60	4.6	0.18 [-0.17, 0.53]
			Placebo	72	61 (84.7)	0.69 (1.13)	-2.2	0.00	0.80	1.20	4.4	
		Week 32	Tezepelumab	75	64 (85.3)	0.88 (1.20)	-1.6	0.00	0.90	1.50	4.6	0.13 [-0.22, 0.48]
			Placebo	72	61 (84.7)	0.73 (1.02)	-1.4	0.00	0.80	1.40	4.2	
		Week 36	Tezepelumab	75	64 (85.3)	0.96 (1.28)	-1.6	0.00	0.80	1.80	4.6	0.12 [-0.24, 0.47]
			Placebo	72	61 (84.7)	0.82 (1.12)	-1.4	0.20	0.80	1.40	4.2	
		Week 40	Tezepelumab	75	64 (85.3)	0.81 (1.26)	-2.4	0.00	0.70	1.60	4.6	0.03 [-0.32, 0.38]
			Placebo	72	61 (84.7)	0.77 (1.09)	-1.6	0.00	0.80	1.40	3.4	
		Week 44	Tezepelumab	75	64 (85.3)	0.85 (1.22)	-1.4	-0.10	0.80	1.60	4.6	0.03 [-0.33, 0.38]
			Placebo	72	61 (84.7)	0.82 (1.21)	-2.2	0.00	1.00	1.20	4.2	
		Week 48	Tezepelumab	75	64 (85.3)	0.87 (1.20)	-1.4	0.00	0.80	1.80	4.6	0.04 [-0.31, 0.39]
			Placebo	72	61 (84.7)	0.83 (1.16)	-1.8	0.00	0.80	1.40	4.0	
		Week 52	Tezepelumab	75	64 (85.3)	0.82 (1.23)	-1.6	0.00	0.80	1.70	4.6	0.08 [-0.27, 0.43]
			Placebo	72	61 (84.7)	0.72 (1.31)	-2.6	-0.20	0.80	1.40	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	60	56 (93.3)	4.20 (1.34)	1.4	3.50	4.40	5.00	6.6	
			Placebo	65	59 (90.8)	4.14 (1.33)	1.0	3.40	4.20	5.00	7.0	
		Week 4	Tezepelumab	60	55 (91.7)	5.06 (1.25)	1.6	4.00	5.00	6.00	7.0	
			Placebo	65	59 (90.8)	4.63 (1.36)	1.6	3.60	4.80	5.60	7.0	
		Week 8	Tezepelumab	60	57 (95.0)	5.20 (1.38)	1.8	4.20	5.20	6.60	7.0	
			Placebo	65	61 (93.8)	4.74 (1.38)	1.0	3.80	4.80	5.80	7.0	
		Week 12	Tezepelumab	60	57 (95.0)	5.40 (1.31)	2.0	4.40	5.40	6.60	7.0	
			Placebo	65	61 (93.8)	4.93 (1.31)	1.8	4.00	5.20	6.00	7.0	
		Week 16	Tezepelumab	60	57 (95.0)	5.41 (1.25)	2.2	4.40	5.60	6.60	7.0	
			Placebo	65	61 (93.8)	4.90 (1.44)	1.2	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.50 (1.22)	1.0	4.60	5.80	6.40	7.0	
			Placebo	65	61 (93.8)	4.96 (1.40)	1.4	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.41 (1.27)	1.6	4.60	5.40	6.40	7.0	
			Placebo	65	61 (93.8)	4.99 (1.35)	2.2	4.00	4.80	6.20	7.0	
		Week 28	Tezepelumab	60	57 (95.0)	5.53 (1.12)	2.8	4.60	5.60	6.40	7.0	
			Placebo	65	61 (93.8)	5.00 (1.47)	1.6	3.80	5.20	6.20	7.0	
		Week 32	Tezepelumab	60	57 (95.0)	5.45 (1.27)	1.8	4.60	5.60	6.40	7.0	
			Placebo	65	61 (93.8)	5.03 (1.41)	1.6	4.00	5.20	6.00	7.0	
		Week 36	Tezepelumab	60	57 (95.0)	5.58 (1.17)	2.8	5.00	5.80	6.60	7.0	
			Placebo	65	61 (93.8)	4.98 (1.39)	1.6	4.00	4.80	6.00	7.0	
		Week 40	Tezepelumab	60	57 (95.0)	5.55 (1.21)	2.4	4.80	5.60	6.60	7.0	
			Placebo	65	61 (93.8)	5.05 (1.51)	1.6	4.00	5.00	6.60	7.0	
		Week 44	Tezepelumab	60	57 (95.0)	5.67 (1.16)	2.6	5.00	6.00	6.60	7.0	
			Placebo	65	61 (93.8)	4.98 (1.49)	1.6	4.00	5.00	6.20	7.0	
		Week 48	Tezepelumab	60	57 (95.0)	5.64 (1.18)	1.8	4.80	5.80	6.60	7.0	
			Placebo	65	61 (93.8)	4.97 (1.42)	1.4	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	60	57 (95.0)	5.65 (1.23)	1.8	4.80	5.80	6.80	7.0	
			Placebo	65	61 (93.8)	4.93 (1.42)	1.8	4.00	4.80	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	60	51 (85.0)	0.96 (1.11)	-1.2	0.20	1.00	1.60	3.6	0.48 [0.10, 0.86]
			Placebo	65	58 (89.2)	0.42 (1.11)	-2.8	-0.20	0.40	1.20	3.6	
		Week 8	Tezepelumab	60	53 (88.3)	0.99 (1.29)	-2.2	0.20	1.00	2.00	5.0	0.32 [-0.06, 0.69]
			Placebo	65	58 (89.2)	0.60 (1.21)	-2.0	-0.20	0.50	1.20	3.4	
		Week 12	Tezepelumab	60	53 (88.3)	1.21 (1.33)	-1.6	0.40	1.00	2.20	5.4	0.33 [-0.05, 0.70]
			Placebo	65	58 (89.2)	0.77 (1.32)	-2.2	0.00	0.80	1.60	4.4	
		Week 16	Tezepelumab	60	53 (88.3)	1.23 (1.22)	-0.8	0.40	1.20	2.00	5.2	0.39 [0.01, 0.77]
			Placebo	65	58 (89.2)	0.73 (1.32)	-2.0	0.00	0.70	1.40	4.0	
		Week 20	Tezepelumab	60	53 (88.3)	1.32 (1.26)	-0.6	0.60	1.20	2.20	5.2	0.39 [0.01, 0.77]
			Placebo	65	58 (89.2)	0.81 (1.34)	-2.0	0.00	0.80	1.60	5.2	
		Week 24	Tezepelumab	60	53 (88.3)	1.20 (1.38)	-1.4	0.00	1.00	2.20	5.4	0.24 [-0.13, 0.62]
			Placebo	65	58 (89.2)	0.86 (1.40)	-2.2	-0.20	0.70	1.80	4.2	
		Week 28	Tezepelumab	60	53 (88.3)	1.33 (1.28)	-1.0	0.60	1.20	2.00	5.4	0.32 [-0.05, 0.70]
			Placebo	65	58 (89.2)	0.87 (1.54)	-2.0	-0.20	0.80	1.80	5.2	
		Week 32	Tezepelumab	60	53 (88.3)	1.26 (1.32)	-1.2	0.40	1.20	2.20	5.4	0.25 [-0.12, 0.63]
			Placebo	65	58 (89.2)	0.90 (1.46)	-2.0	-0.20	0.90	1.80	5.4	
		Week 36	Tezepelumab	60	53 (88.3)	1.38 (1.37)	-1.0	0.60	1.20	2.20	5.4	0.40 [0.02, 0.77]
			Placebo	65	58 (89.2)	0.84 (1.33)	-2.0	-0.20	0.60	1.80	3.6	
		Week 40	Tezepelumab	60	53 (88.3)	1.34 (1.32)	-1.2	0.60	1.00	2.00	5.4	0.28 [-0.10, 0.65]
			Placebo	65	58 (89.2)	0.93 (1.59)	-2.0	-0.20	1.10	1.80	5.4	
		Week 44	Tezepelumab	60	53 (88.3)	1.46 (1.27)	-1.0	0.80	1.40	2.20	5.4	0.43 [0.05, 0.81]
			Placebo	65	58 (89.2)	0.85 (1.55)	-2.0	-0.20	0.80	1.80	5.2	
		Week 48	Tezepelumab	60	53 (88.3)	1.44 (1.29)	-1.0	0.60	1.40	2.20	5.4	0.42 [0.05, 0.80]
			Placebo	65	58 (89.2)	0.85 (1.50)	-2.2	-0.20	0.60	1.80	5.0	
		Week 52	Tezepelumab	60	53 (88.3)	1.42 (1.29)	-0.6	0.60	1.40	2.20	5.4	0.45 [0.07, 0.83]
			Placebo	65	58 (89.2)	0.80 (1.47)	-2.0	-0.20	0.60	1.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	65	56 (86.2)	4.44 (1.01)	1.8	3.80	4.20	5.20	6.8	
			Placebo	62	53 (85.5)	4.32 (1.11)	1.6	3.80	4.20	5.00	7.0	
		Week 4	Tezepelumab	65	60 (92.3)	4.92 (1.16)	1.2	4.00	5.00	5.90	7.0	
			Placebo	62	56 (90.3)	4.68 (1.28)	1.4	4.00	4.60	5.60	7.0	
		Week 8	Tezepelumab	65	60 (92.3)	5.16 (1.04)	2.6	4.40	5.00	6.10	7.0	
			Placebo	62	56 (90.3)	4.81 (1.20)	1.4	4.00	4.90	5.40	7.0	
		Week 12	Tezepelumab	65	60 (92.3)	5.29 (1.10)	3.0	4.40	5.30	6.20	7.0	
			Placebo	62	57 (91.9)	4.73 (1.32)	1.4	4.00	4.60	5.80	7.0	
		Week 16	Tezepelumab	65	60 (92.3)	5.19 (1.12)	2.6	4.20	5.30	6.00	7.0	
			Placebo	62	57 (91.9)	4.81 (1.19)	1.8	4.00	4.60	5.80	7.0	
		Week 20	Tezepelumab	65	61 (93.8)	5.14 (1.11)	2.4	4.40	5.00	6.00	7.0	
			Placebo	62	57 (91.9)	4.87 (1.10)	1.8	4.00	5.00	5.40	7.0	
		Week 24	Tezepelumab	65	61 (93.8)	5.25 (1.11)	2.0	4.40	5.40	6.00	7.0	
			Placebo	62	57 (91.9)	4.97 (1.09)	1.4	4.20	4.80	6.00	7.0	
		Week 28	Tezepelumab	65	62 (95.4)	5.28 (1.03)	3.2	4.20	5.30	6.20	7.0	
			Placebo	62	58 (93.5)	4.86 (1.22)	2.0	4.00	4.60	6.00	7.0	
		Week 32	Tezepelumab	65	63 (96.9)	5.28 (1.00)	3.4	4.40	5.40	6.00	7.0	
			Placebo	62	58 (93.5)	4.94 (1.24)	1.2	4.00	4.90	6.00	7.0	
		Week 36	Tezepelumab	65	63 (96.9)	5.34 (1.12)	3.2	4.40	5.60	6.20	7.0	
			Placebo	62	58 (93.5)	5.09 (1.23)	1.8	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	65	63 (96.9)	5.14 (1.18)	1.8	4.00	5.40	6.00	7.0	
			Placebo	62	58 (93.5)	5.00 (1.24)	1.6	4.20	4.80	6.00	7.0	
		Week 44	Tezepelumab	65	63 (96.9)	5.26 (1.14)	2.8	4.00	5.40	6.20	7.0	
			Placebo	62	58 (93.5)	5.05 (1.31)	1.4	4.00	5.00	6.20	7.0	
		Week 48	Tezepelumab	65	63 (96.9)	5.26 (1.09)	2.6	4.40	5.40	6.00	7.0	
			Placebo	62	59 (95.2)	5.10 (1.29)	1.2	4.00	4.80	6.20	7.0	
		Week 52	Tezepelumab	65	63 (96.9)	5.23 (1.07)	3.2	4.40	5.00	6.20	7.0	
			Placebo	62	59 (95.2)	4.97 (1.38)	1.2	4.00	4.80	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	65	55 (84.6)	0.47 (1.26)	-4.2	0.00	0.40	1.00	3.8	0.05 [-0.33, 0.42]
			Placebo	62	53 (85.5)	0.42 (0.98)	-2.2	0.00	0.60	1.00	2.8	
		Week 8	Tezepelumab	65	55 (84.6)	0.72 (1.23)	-1.2	-0.20	0.60	1.40	4.4	0.18 [-0.20, 0.56]
			Placebo	62	53 (85.5)	0.51 (0.99)	-1.6	-0.20	0.60	1.20	2.8	
		Week 12	Tezepelumab	65	55 (84.6)	0.82 (1.17)	-2.4	0.20	0.80	1.60	3.8	0.31 [-0.07, 0.69]
			Placebo	62	53 (85.5)	0.48 (1.01)	-2.0	0.00	0.60	1.00	2.6	
		Week 16	Tezepelumab	65	55 (84.6)	0.73 (1.23)	-2.8	0.00	0.60	1.40	4.0	0.18 [-0.20, 0.56]
			Placebo	62	53 (85.5)	0.54 (0.94)	-1.6	0.00	0.60	1.20	2.8	
		Week 20	Tezepelumab	65	55 (84.6)	0.73 (1.17)	-1.4	-0.20	0.40	1.40	4.6	0.12 [-0.26, 0.49]
			Placebo	62	53 (85.5)	0.61 (0.92)	-2.2	0.20	0.60	1.20	2.4	
		Week 24	Tezepelumab	65	55 (84.6)	0.84 (1.15)	-1.4	0.00	0.60	1.60	4.6	0.14 [-0.23, 0.52]
			Placebo	62	53 (85.5)	0.69 (0.92)	-1.4	0.20	0.80	1.20	2.8	
		Week 28	Tezepelumab	65	55 (84.6)	0.83 (1.16)	-1.4	0.00	0.60	1.40	4.6	0.25 [-0.13, 0.63]
			Placebo	62	53 (85.5)	0.56 (1.03)	-2.2	0.00	0.80	1.20	2.8	
		Week 32	Tezepelumab	65	55 (84.6)	0.81 (1.11)	-1.4	0.00	0.80	1.40	4.6	0.14 [-0.23, 0.52]
			Placebo	62	53 (85.5)	0.66 (0.91)	-1.4	0.00	0.80	1.20	2.8	
		Week 36	Tezepelumab	65	55 (84.6)	0.88 (1.22)	-1.6	0.00	0.80	1.60	4.6	0.08 [-0.30, 0.46]
			Placebo	62	53 (85.5)	0.79 (1.00)	-1.4	0.20	0.80	1.40	4.2	
		Week 40	Tezepelumab	65	55 (84.6)	0.70 (1.21)	-2.4	0.00	0.60	1.40	4.6	-0.01 [-0.38, 0.37]
			Placebo	62	53 (85.5)	0.71 (1.07)	-1.6	0.00	0.80	1.20	3.2	
		Week 44	Tezepelumab	65	55 (84.6)	0.76 (1.20)	-1.4	-0.20	0.60	1.40	4.6	0.01 [-0.37, 0.39]
			Placebo	62	53 (85.5)	0.75 (1.07)	-1.4	-0.20	1.00	1.20	4.2	
		Week 48	Tezepelumab	65	55 (84.6)	0.79 (1.16)	-1.4	0.00	0.80	1.60	4.6	-0.01 [-0.38, 0.37]
			Placebo	62	53 (85.5)	0.80 (1.05)	-1.4	0.00	0.80	1.40	4.0	
		Week 52	Tezepelumab	65	55 (84.6)	0.75 (1.20)	-1.6	0.00	0.80	1.60	4.6	0.09 [-0.29, 0.46]
			Placebo	62	53 (85.5)	0.65 (1.19)	-2.6	-0.20	0.80	1.40	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	70	65 (92.9)	4.23 (1.27)	1.4	3.60	4.40	5.00	6.6	
			Placebo	75	67 (89.3)	4.17 (1.34)	1.0	3.40	4.20	5.00	7.0	
		Week 4	Tezepelumab	70	64 (91.4)	5.03 (1.24)	1.6	4.00	5.00	6.00	7.0	
			Placebo	75	67 (89.3)	4.70 (1.35)	1.6	3.60	4.80	5.80	7.0	
		Week 8	Tezepelumab	70	66 (94.3)	5.17 (1.35)	1.8	4.20	5.20	6.20	7.0	
			Placebo	75	69 (92.0)	4.85 (1.40)	1.0	3.80	4.80	6.00	7.0	
		Week 12	Tezepelumab	70	66 (94.3)	5.44 (1.25)	2.0	4.60	5.50	6.60	7.0	
			Placebo	75	69 (92.0)	5.03 (1.33)	1.8	4.00	5.20	6.00	7.0	
		Week 16	Tezepelumab	70	66 (94.3)	5.41 (1.20)	2.2	4.40	5.60	6.40	7.0	
			Placebo	75	69 (92.0)	5.01 (1.44)	1.2	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	70	66 (94.3)	5.55 (1.19)	1.0	4.80	5.80	6.60	7.0	
			Placebo	75	69 (92.0)	5.06 (1.41)	1.4	4.00	5.00	6.20	7.0	
		Week 24	Tezepelumab	70	66 (94.3)	5.43 (1.25)	1.6	4.60	5.40	6.40	7.0	
			Placebo	75	69 (92.0)	5.10 (1.39)	2.2	4.00	5.20	6.40	7.0	
		Week 28	Tezepelumab	70	67 (95.7)	5.57 (1.12)	2.8	4.80	5.80	6.40	7.0	
			Placebo	75	69 (92.0)	5.11 (1.46)	1.6	4.00	5.40	6.20	7.0	
		Week 32	Tezepelumab	70	67 (95.7)	5.50 (1.29)	1.8	4.60	5.80	6.60	7.0	
			Placebo	75	70 (93.3)	5.08 (1.41)	1.6	4.00	5.50	6.20	7.0	
		Week 36	Tezepelumab	70	67 (95.7)	5.63 (1.18)	2.8	5.00	5.80	6.60	7.0	
			Placebo	75	70 (93.3)	5.03 (1.41)	1.6	4.00	4.90	6.40	7.0	
		Week 40	Tezepelumab	70	67 (95.7)	5.61 (1.21)	2.4	4.80	6.00	6.60	7.0	
			Placebo	75	70 (93.3)	5.11 (1.46)	1.6	4.00	5.00	6.60	7.0	
		Week 44	Tezepelumab	70	67 (95.7)	5.70 (1.14)	2.6	5.00	6.00	6.60	7.0	
			Placebo	75	70 (93.3)	5.07 (1.51)	1.6	4.00	5.20	6.60	7.0	
		Week 48	Tezepelumab	70	67 (95.7)	5.67 (1.19)	1.8	5.00	6.00	6.80	7.0	
			Placebo	75	70 (93.3)	5.02 (1.44)	1.4	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	70	67 (95.7)	5.67 (1.23)	1.8	5.00	5.80	6.80	7.0	
			Placebo	75	70 (93.3)	4.99 (1.47)	1.8	4.00	4.90	6.40	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	70	60 (85.7)	0.87 (1.14)	-1.8	0.10	0.80	1.60	3.6	0.35 [0.00, 0.71]
			Placebo	75	66 (88.0)	0.47 (1.15)	-2.8	-0.20	0.40	1.20	3.6	
		Week 8	Tezepelumab	70	62 (88.6)	0.93 (1.28)	-2.2	0.20	0.90	2.00	5.0	0.19 [-0.15, 0.54]
			Placebo	75	66 (88.0)	0.68 (1.30)	-2.0	-0.20	0.60	1.40	4.0	
		Week 12	Tezepelumab	70	62 (88.6)	1.22 (1.30)	-1.6	0.40	1.10	2.20	5.4	0.27 [-0.08, 0.62]
			Placebo	75	66 (88.0)	0.85 (1.41)	-2.2	0.00	0.80	1.80	4.4	
		Week 16	Tezepelumab	70	62 (88.6)	1.19 (1.19)	-0.8	0.40	1.20	2.00	5.2	0.30 [-0.05, 0.65]
			Placebo	75	66 (88.0)	0.82 (1.33)	-2.0	0.20	0.80	1.60	4.4	
		Week 20	Tezepelumab	70	62 (88.6)	1.34 (1.24)	-0.6	0.60	1.20	2.20	5.2	0.35 [0.00, 0.70]
			Placebo	75	66 (88.0)	0.88 (1.35)	-2.0	0.00	0.80	1.60	5.2	
		Week 24	Tezepelumab	70	62 (88.6)	1.19 (1.34)	-1.4	0.00	1.00	2.00	5.4	0.18 [-0.16, 0.53]
			Placebo	75	66 (88.0)	0.94 (1.42)	-2.2	0.00	0.70	2.00	4.2	
		Week 28	Tezepelumab	70	62 (88.6)	1.32 (1.26)	-1.0	0.60	1.20	2.00	5.4	0.26 [-0.08, 0.61]
			Placebo	75	66 (88.0)	0.95 (1.53)	-2.0	0.00	0.90	1.80	5.2	
		Week 32	Tezepelumab	70	62 (88.6)	1.26 (1.36)	-1.6	0.40	1.40	2.20	5.4	0.23 [-0.12, 0.57]
			Placebo	75	66 (88.0)	0.94 (1.47)	-2.0	-0.20	0.90	1.80	5.4	
		Week 36	Tezepelumab	70	62 (88.6)	1.39 (1.39)	-1.0	0.60	1.30	2.20	5.4	0.38 [0.03, 0.73]
			Placebo	75	66 (88.0)	0.87 (1.38)	-2.0	-0.20	0.60	1.80	3.8	
		Week 40	Tezepelumab	70	62 (88.6)	1.36 (1.32)	-1.2	0.60	1.30	2.20	5.4	0.27 [-0.07, 0.62]
			Placebo	75	66 (88.0)	0.97 (1.54)	-2.0	-0.20	1.10	1.80	5.4	
		Week 44	Tezepelumab	70	62 (88.6)	1.45 (1.25)	-1.0	0.80	1.40	2.20	5.4	0.38 [0.03, 0.73]
			Placebo	75	66 (88.0)	0.90 (1.59)	-2.2	-0.20	0.80	1.80	5.2	
		Week 48	Tezepelumab	70	62 (88.6)	1.43 (1.29)	-1.4	0.60	1.40	2.20	5.4	0.40 [0.05, 0.75]
			Placebo	75	66 (88.0)	0.87 (1.52)	-2.2	-0.20	0.60	1.80	5.0	
		Week 52	Tezepelumab	70	62 (88.6)	1.40 (1.30)	-1.4	0.60	1.40	2.20	5.4	0.39 [0.04, 0.74]
			Placebo	75	66 (88.0)	0.85 (1.53)	-2.0	-0.20	0.60	1.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	50	43 (86.0)	4.30 (0.98)	2.0	3.60	4.20	5.00	6.8	
			Placebo	50	40 (80.0)	4.40 (1.33)	1.0	3.70	4.40	5.00	7.0	
		Week 4	Tezepelumab	50	48 (96.0)	4.85 (1.03)	2.8	4.00	4.80	5.70	7.0	
			Placebo	50	41 (82.0)	4.55 (1.44)	1.4	3.60	4.80	5.80	7.0	
		Week 8	Tezepelumab	50	48 (96.0)	5.18 (1.07)	2.0	4.60	5.00	6.00	7.0	
			Placebo	50	44 (88.0)	4.67 (1.24)	1.4	3.80	4.70	5.50	7.0	
		Week 12	Tezepelumab	50	48 (96.0)	5.43 (1.09)	3.4	4.60	5.20	6.50	7.0	
			Placebo	50	44 (88.0)	4.70 (1.36)	1.4	4.00	4.50	5.90	7.0	
		Week 16	Tezepelumab	50	48 (96.0)	5.32 (1.04)	3.2	4.40	5.10	6.10	7.0	
			Placebo	50	44 (88.0)	4.65 (1.44)	1.0	3.80	4.60	5.80	7.0	
		Week 20	Tezepelumab	50	48 (96.0)	5.42 (1.02)	3.2	4.60	5.70	6.20	7.0	
			Placebo	50	44 (88.0)	4.79 (1.38)	1.0	4.00	4.90	5.70	7.0	
		Week 24	Tezepelumab	50	48 (96.0)	5.38 (1.06)	3.4	4.50	5.40	6.20	7.0	
			Placebo	50	44 (88.0)	4.72 (1.46)	1.0	4.00	4.60	6.00	7.0	
		Week 28	Tezepelumab	50	49 (98.0)	5.47 (1.00)	3.4	4.60	5.60	6.20	7.0	
			Placebo	50	44 (88.0)	4.59 (1.49)	1.0	3.60	4.30	6.00	7.0	
		Week 32	Tezepelumab	50	49 (98.0)	5.38 (0.97)	3.4	4.60	5.40	6.20	7.0	
			Placebo	50	45 (90.0)	4.57 (1.46)	1.0	4.00	4.40	6.00	7.0	
		Week 36	Tezepelumab	50	49 (98.0)	5.44 (1.06)	3.0	4.60	5.60	6.20	7.0	
			Placebo	50	45 (90.0)	4.76 (1.42)	1.6	4.00	4.60	6.00	7.0	
		Week 40	Tezepelumab	50	49 (98.0)	5.42 (0.99)	3.8	4.60	5.40	6.20	7.0	
			Placebo	50	45 (90.0)	4.68 (1.42)	1.6	3.80	4.80	5.60	7.0	
		Week 44	Tezepelumab	50	49 (98.0)	5.40 (1.09)	2.8	4.60	5.40	6.40	7.0	
			Placebo	50	45 (90.0)	4.67 (1.45)	1.4	3.80	4.60	6.00	7.0	
		Week 48	Tezepelumab	50	49 (98.0)	5.43 (1.04)	2.8	4.60	5.60	6.20	7.0	
			Placebo	50	46 (92.0)	4.70 (1.46)	1.2	3.80	4.50	6.00	7.0	
		Week 52	Tezepelumab	50	49 (98.0)	5.45 (1.05)	3.2	4.60	5.60	6.20	7.0	
			Placebo	50	46 (92.0)	4.55 (1.43)	1.2	3.60	4.20	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	50	42 (84.0)	0.66 (0.90)	-1.6	0.00	0.50	1.40	2.4	0.47 [0.03, 0.91]
			Placebo	50	39 (78.0)	0.20 (1.06)	-2.2	-0.20	0.20	0.60	2.8	
		Week 8	Tezepelumab	50	42 (84.0)	0.88 (1.09)	-1.2	0.20	0.70	1.60	3.6	0.50 [0.06, 0.94]
			Placebo	50	40 (80.0)	0.36 (0.98)	-1.6	-0.20	0.20	1.10	2.8	
		Week 12	Tezepelumab	50	42 (84.0)	1.10 (1.08)	-1.6	0.40	1.00	1.80	3.4	0.70 [0.25, 1.14]
			Placebo	50	40 (80.0)	0.37 (1.03)	-1.8	-0.30	0.30	1.00	2.6	
		Week 16	Tezepelumab	50	42 (84.0)	0.99 (1.10)	-1.4	0.40	1.00	1.60	3.0	0.61 [0.17, 1.06]
			Placebo	50	40 (80.0)	0.31 (1.13)	-3.4	-0.10	0.40	1.00	2.8	
		Week 20	Tezepelumab	50	42 (84.0)	1.16 (0.98)	-0.8	0.40	1.20	2.00	3.0	0.67 [0.22, 1.11]
			Placebo	50	40 (80.0)	0.46 (1.14)	-3.4	0.00	0.60	1.20	2.4	
		Week 24	Tezepelumab	50	42 (84.0)	1.10 (1.05)	-0.8	0.40	1.00	1.80	3.0	0.63 [0.18, 1.07]
			Placebo	50	40 (80.0)	0.38 (1.26)	-3.4	-0.30	0.20	1.30	2.8	
		Week 28	Tezepelumab	50	42 (84.0)	1.21 (0.99)	-0.8	0.60	1.00	2.00	3.0	0.82 [0.37, 1.27]
			Placebo	50	40 (80.0)	0.25 (1.34)	-3.4	-0.40	0.30	1.20	2.8	
		Week 32	Tezepelumab	50	42 (84.0)	1.15 (1.02)	-1.0	0.40	1.20	2.00	3.0	0.82 [0.37, 1.27]
			Placebo	50	40 (80.0)	0.24 (1.21)	-3.4	-0.50	0.10	1.00	2.8	
		Week 36	Tezepelumab	50	42 (84.0)	1.20 (1.08)	-1.0	0.60	1.20	2.00	3.8	0.73 [0.29, 1.18]
			Placebo	50	40 (80.0)	0.42 (1.03)	-2.0	-0.30	0.40	1.10	2.6	
		Week 40	Tezepelumab	50	42 (84.0)	1.15 (1.08)	-1.0	0.40	1.00	2.00	3.2	0.68 [0.24, 1.13]
			Placebo	50	40 (80.0)	0.38 (1.20)	-2.0	-0.40	0.40	1.40	2.8	
		Week 44	Tezepelumab	50	42 (84.0)	1.13 (1.10)	-1.4	0.40	1.20	1.80	3.0	0.75 [0.30, 1.20]
			Placebo	50	40 (80.0)	0.30 (1.13)	-2.2	-0.40	0.40	1.10	2.8	
		Week 48	Tezepelumab	50	42 (84.0)	1.20 (1.07)	-1.4	0.40	1.20	2.00	3.2	0.78 [0.33, 1.23]
			Placebo	50	40 (80.0)	0.33 (1.18)	-2.2	-0.60	0.40	1.30	2.8	
		Week 52	Tezepelumab	50	42 (84.0)	1.20 (1.09)	-1.0	0.40	1.20	2.00	3.2	0.86 [0.41, 1.32]
			Placebo	50	40 (80.0)	0.19 (1.25)	-2.6	-0.70	0.10	1.10	2.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	77	72 (93.5)	4.37 (1.20)	1.4	3.80	4.40	5.20	6.8	
			Placebo	80	73 (91.3)	4.16 (1.22)	1.4	3.40	4.20	5.00	7.0	
		Week 4	Tezepelumab	77	69 (89.6)	5.09 (1.30)	1.2	4.20	5.40	6.00	7.0	
			Placebo	80	74 (92.5)	4.74 (1.27)	1.6	3.80	4.60	5.60	7.0	
		Week 8	Tezepelumab	77	71 (92.2)	5.15 (1.31)	1.8	4.00	5.20	6.00	7.0	
			Placebo	80	74 (92.5)	4.88 (1.34)	1.0	4.00	5.00	5.80	7.0	
		Week 12	Tezepelumab	77	71 (92.2)	5.33 (1.26)	2.0	4.40	5.40	6.40	7.0	
			Placebo	80	75 (93.8)	4.95 (1.28)	1.6	4.00	5.00	6.00	7.0	
		Week 16	Tezepelumab	77	71 (92.2)	5.31 (1.23)	2.2	4.20	5.60	6.20	7.0	
			Placebo	80	75 (93.8)	4.98 (1.33)	1.2	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	77	71 (92.2)	5.37 (1.22)	1.0	4.40	5.60	6.20	7.0	
			Placebo	80	75 (93.8)	4.98 (1.25)	1.4	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	77	71 (92.2)	5.34 (1.21)	1.6	4.40	5.40	6.20	7.0	
			Placebo	80	75 (93.8)	5.11 (1.18)	2.2	4.20	5.00	6.00	7.0	
		Week 28	Tezepelumab	77	72 (93.5)	5.40 (1.14)	2.8	4.40	5.60	6.20	7.0	
			Placebo	80	76 (95.0)	5.16 (1.29)	1.6	4.10	5.20	6.10	7.0	
		Week 32	Tezepelumab	77	73 (94.8)	5.39 (1.27)	1.8	4.60	5.80	6.40	7.0	
			Placebo	80	76 (95.0)	5.19 (1.29)	1.6	4.20	5.40	6.20	7.0	
		Week 36	Tezepelumab	77	73 (94.8)	5.51 (1.22)	2.8	4.80	5.80	6.40	7.0	
			Placebo	80	76 (95.0)	5.14 (1.25)	1.8	4.30	5.20	6.00	7.0	
		Week 40	Tezepelumab	77	73 (94.8)	5.41 (1.31)	1.8	4.60	5.60	6.40	7.0	
			Placebo	80	76 (95.0)	5.22 (1.31)	1.6	4.20	5.20	6.40	7.0	
		Week 44	Tezepelumab	77	73 (94.8)	5.54 (1.20)	2.6	5.00	5.80	6.40	7.0	
			Placebo	80	76 (95.0)	5.19 (1.38)	1.6	4.00	5.30	6.60	7.0	
		Week 48	Tezepelumab	77	73 (94.8)	5.48 (1.23)	1.8	4.60	5.60	6.40	7.0	
			Placebo	80	76 (95.0)	5.19 (1.27)	1.8	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	77	73 (94.8)	5.44 (1.25)	1.8	4.60	5.80	6.40	7.0	
			Placebo	80	76 (95.0)	5.17 (1.37)	1.8	4.10	5.00	6.40	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	77	67 (87.0)	0.70 (1.26)	-4.2	0.00	0.60	1.60	3.6	0.14 [-0.19, 0.47]
			Placebo	80	72 (90.0)	0.54 (1.10)	-2.8	0.00	0.40	1.20	3.6	
		Week 8	Tezepelumab	77	69 (89.6)	0.77 (1.18)	-2.2	-0.20	0.80	1.60	3.4	0.07 [-0.26, 0.40]
			Placebo	80	72 (90.0)	0.68 (1.26)	-2.0	0.00	0.70	1.30	4.0	
		Week 12	Tezepelumab	77	69 (89.6)	0.95 (1.20)	-2.4	0.20	0.80	1.80	3.6	0.13 [-0.20, 0.46]
			Placebo	80	72 (90.0)	0.79 (1.35)	-2.2	0.00	0.80	1.50	4.4	
		Week 16	Tezepelumab	77	69 (89.6)	0.92 (1.16)	-2.8	0.00	0.80	1.60	3.4	0.10 [-0.23, 0.43]
			Placebo	80	72 (90.0)	0.80 (1.28)	-2.0	0.00	0.80	1.40	4.4	
		Week 20	Tezepelumab	77	69 (89.6)	0.98 (1.20)	-1.4	0.00	0.80	1.80	4.4	0.14 [-0.19, 0.47]
			Placebo	80	72 (90.0)	0.81 (1.25)	-2.0	0.20	0.80	1.40	5.2	
		Week 24	Tezepelumab	77	69 (89.6)	0.94 (1.20)	-1.4	0.00	0.80	2.00	3.8	-0.00 [-0.33, 0.33]
			Placebo	80	72 (90.0)	0.95 (1.23)	-2.0	0.10	0.80	1.60	4.2	
		Week 28	Tezepelumab	77	69 (89.6)	0.99 (1.18)	-1.4	0.00	0.80	2.00	4.2	-0.00 [-0.33, 0.33]
			Placebo	80	72 (90.0)	0.99 (1.37)	-2.0	0.20	0.80	1.60	5.2	
		Week 32	Tezepelumab	77	69 (89.6)	0.95 (1.21)	-1.4	0.00	0.80	1.80	3.6	-0.06 [-0.39, 0.27]
			Placebo	80	72 (90.0)	1.03 (1.29)	-2.0	0.20	1.10	1.70	5.4	
		Week 36	Tezepelumab	77	69 (89.6)	1.07 (1.34)	-1.6	0.00	1.00	2.00	4.4	0.09 [-0.24, 0.42]
			Placebo	80	72 (90.0)	0.96 (1.29)	-2.0	0.10	0.90	1.80	4.2	
		Week 40	Tezepelumab	77	69 (89.6)	0.97 (1.26)	-2.4	0.00	0.80	2.00	3.4	-0.06 [-0.39, 0.27]
			Placebo	80	72 (90.0)	1.05 (1.42)	-2.0	0.00	1.00	1.70	5.4	
		Week 44	Tezepelumab	77	69 (89.6)	1.09 (1.21)	-1.4	0.20	1.20	2.00	3.8	0.06 [-0.27, 0.39]
			Placebo	80	72 (90.0)	1.02 (1.44)	-2.0	0.00	1.00	1.80	5.2	
		Week 48	Tezepelumab	77	69 (89.6)	1.04 (1.23)	-1.4	0.00	1.00	2.00	3.8	0.02 [-0.31, 0.35]
			Placebo	80	72 (90.0)	1.02 (1.33)	-2.0	0.00	0.80	1.70	5.0	
		Week 52	Tezepelumab	77	69 (89.6)	0.99 (1.24)	-1.6	0.00	1.00	2.00	3.8	-0.00 [-0.33, 0.33]
			Placebo	80	72 (90.0)	1.00 (1.41)	-2.0	0.00	1.00	1.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	4.42 (1.09)	1.4	3.90	4.40	5.10	6.8	
			Placebo	62	53 (85.5)	4.28 (1.29)	1.0	3.60	4.20	5.00	7.0	
		Week 4	Tezepelumab	70	65 (92.9)	5.07 (1.02)	2.8	4.20	5.00	6.00	7.0	
			Placebo	62	53 (85.5)	4.49 (1.41)	1.4	3.60	4.80	5.60	7.0	
		Week 8	Tezepelumab	70	66 (94.3)	5.21 (1.19)	2.0	4.60	5.10	6.20	7.0	
			Placebo	62	56 (90.3)	4.67 (1.40)	1.0	3.90	4.90	5.50	7.0	
		Week 12	Tezepelumab	70	66 (94.3)	5.51 (1.05)	3.8	4.60	5.50	6.40	7.0	
			Placebo	62	56 (90.3)	4.77 (1.31)	1.4	4.00	4.60	5.70	7.0	
		Week 16	Tezepelumab	70	66 (94.3)	5.44 (1.04)	3.2	4.40	5.60	6.20	7.0	
			Placebo	62	56 (90.3)	4.69 (1.48)	1.0	4.00	4.60	5.80	7.0	
		Week 20	Tezepelumab	70	67 (95.7)	5.46 (1.04)	3.2	4.60	5.60	6.40	7.0	
			Placebo	62	56 (90.3)	4.75 (1.46)	1.0	4.00	4.80	5.70	7.0	
		Week 24	Tezepelumab	70	67 (95.7)	5.49 (1.04)	3.2	4.60	5.60	6.40	7.0	
			Placebo	62	56 (90.3)	4.75 (1.44)	1.0	4.00	4.60	5.70	7.0	
		Week 28	Tezepelumab	70	68 (97.1)	5.50 (1.05)	3.4	4.60	5.60	6.30	7.0	
			Placebo	62	56 (90.3)	4.62 (1.50)	1.0	3.70	4.50	6.00	7.0	
		Week 32	Tezepelumab	70	68 (97.1)	5.49 (1.00)	2.6	4.70	5.60	6.40	7.0	
			Placebo	62	57 (91.9)	4.63 (1.49)	1.0	4.00	4.60	5.80	7.0	
		Week 36	Tezepelumab	70	68 (97.1)	5.59 (1.08)	3.0	4.80	5.80	6.40	7.0	
			Placebo	62	57 (91.9)	4.77 (1.44)	1.6	4.00	4.60	5.80	7.0	
		Week 40	Tezepelumab	70	68 (97.1)	5.45 (1.11)	2.6	4.60	5.50	6.40	7.0	
			Placebo	62	57 (91.9)	4.71 (1.45)	1.6	3.60	4.80	6.00	7.0	
		Week 44	Tezepelumab	70	68 (97.1)	5.47 (1.10)	2.6	4.60	5.50	6.40	7.0	
			Placebo	62	57 (91.9)	4.74 (1.51)	1.4	3.60	4.60	6.00	7.0	
		Week 48	Tezepelumab	70	68 (97.1)	5.54 (1.10)	2.6	4.60	5.80	6.40	7.0	
			Placebo	62	57 (91.9)	4.69 (1.48)	1.2	3.80	4.40	6.00	7.0	
		Week 52	Tezepelumab	70	68 (97.1)	5.48 (1.15)	2.6	4.60	5.60	6.40	7.0	
			Placebo	62	57 (91.9)	4.53 (1.49)	1.2	3.60	4.40	5.80	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	70	61 (87.1)	0.76 (1.17)	-1.8	0.00	0.60	1.40	3.8	0.47 [0.10, 0.85]
			Placebo	62	52 (83.9)	0.23 (1.02)	-2.2	-0.20	0.30	1.00	2.0	
		Week 8	Tezepelumab	70	62 (88.6)	0.78 (1.29)	-2.2	0.00	0.60	1.60	4.4	0.27 [-0.09, 0.64]
			Placebo	62	53 (85.5)	0.44 (1.14)	-2.0	-0.20	0.20	1.20	3.2	
		Week 12	Tezepelumab	70	62 (88.6)	1.07 (1.18)	-1.6	0.20	0.80	2.00	3.8	0.45 [0.08, 0.82]
			Placebo	62	53 (85.5)	0.54 (1.16)	-1.8	-0.20	0.60	1.20	3.6	
		Week 16	Tezepelumab	70	62 (88.6)	0.99 (1.15)	-1.4	0.20	1.00	1.80	4.0	0.45 [0.08, 0.82]
			Placebo	62	53 (85.5)	0.45 (1.27)	-3.4	0.00	0.40	1.20	4.0	
		Week 20	Tezepelumab	70	62 (88.6)	1.06 (1.23)	-0.8	0.20	1.00	1.80	4.6	0.43 [0.06, 0.80]
			Placebo	62	53 (85.5)	0.52 (1.26)	-3.4	-0.20	0.60	1.20	3.2	
		Week 24	Tezepelumab	70	62 (88.6)	1.07 (1.21)	-1.4	0.40	0.90	2.00	4.6	0.44 [0.07, 0.82]
			Placebo	62	53 (85.5)	0.51 (1.33)	-3.4	-0.20	0.20	1.40	3.2	
		Week 28	Tezepelumab	70	62 (88.6)	1.12 (1.22)	-1.0	0.20	0.90	2.00	4.6	0.55 [0.18, 0.93]
			Placebo	62	53 (85.5)	0.38 (1.45)	-3.4	-0.40	0.40	1.20	4.0	
		Week 32	Tezepelumab	70	62 (88.6)	1.10 (1.19)	-1.6	0.40	1.00	2.00	4.6	0.55 [0.17, 0.92]
			Placebo	62	53 (85.5)	0.41 (1.34)	-3.4	-0.60	0.40	1.20	3.2	
		Week 36	Tezepelumab	70	62 (88.6)	1.20 (1.27)	-1.0	0.40	1.00	2.00	4.6	0.53 [0.15, 0.90]
			Placebo	62	53 (85.5)	0.54 (1.23)	-2.0	-0.40	0.40	1.40	3.2	
		Week 40	Tezepelumab	70	62 (88.6)	1.05 (1.21)	-1.2	0.00	1.00	2.00	4.6	0.44 [0.07, 0.81]
			Placebo	62	53 (85.5)	0.49 (1.36)	-2.0	-0.40	0.60	1.40	3.6	
		Week 44	Tezepelumab	70	62 (88.6)	1.07 (1.15)	-1.0	0.20	1.00	1.80	4.6	0.44 [0.07, 0.81]
			Placebo	62	53 (85.5)	0.50 (1.44)	-2.2	-0.60	0.40	1.40	3.4	
		Week 48	Tezepelumab	70	62 (88.6)	1.15 (1.17)	-1.4	0.20	1.20	2.00	4.6	0.55 [0.18, 0.93]
			Placebo	62	53 (85.5)	0.46 (1.33)	-2.2	-0.40	0.40	1.20	3.2	
		Week 52	Tezepelumab	70	62 (88.6)	1.09 (1.21)	-1.4	0.00	1.20	2.00	4.6	0.60 [0.23, 0.98]
			Placebo	62	53 (85.5)	0.31 (1.38)	-2.6	-0.60	0.00	1.20	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	65	58 (89.2)	4.25 (1.22)	1.4	3.40	4.20	5.20	6.8	
			Placebo	75	67 (89.3)	4.21 (1.21)	1.4	3.60	4.20	5.20	6.6	
		Week 4	Tezepelumab	65	59 (90.8)	4.93 (1.35)	1.2	4.00	4.80	6.20	7.0	
			Placebo	75	69 (92.0)	4.81 (1.20)	2.2	4.00	4.60	5.80	7.0	
		Week 8	Tezepelumab	65	60 (92.3)	5.14 (1.23)	1.8	4.40	5.20	6.00	7.0	
			Placebo	75	69 (92.0)	4.91 (1.21)	1.8	4.00	4.80	5.80	7.0	
		Week 12	Tezepelumab	65	60 (92.3)	5.24 (1.28)	2.0	4.40	5.20	6.30	7.0	
			Placebo	75	70 (93.3)	4.96 (1.32)	1.6	4.00	5.10	6.00	7.0	
		Week 16	Tezepelumab	65	60 (92.3)	5.20 (1.27)	2.2	4.30	5.40	6.10	7.0	
			Placebo	75	70 (93.3)	5.02 (1.25)	2.2	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	65	60 (92.3)	5.28 (1.28)	1.0	4.50	5.40	6.10	7.0	
			Placebo	75	70 (93.3)	5.07 (1.18)	2.2	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	65	60 (92.3)	5.22 (1.31)	1.6	4.30	5.40	6.20	7.0	
			Placebo	75	70 (93.3)	5.19 (1.14)	3.0	4.20	5.20	6.00	7.0	
		Week 28	Tezepelumab	65	61 (93.8)	5.35 (1.13)	2.8	4.40	5.40	6.20	7.0	
			Placebo	75	71 (94.7)	5.21 (1.24)	2.6	4.00	5.40	6.20	7.0	
		Week 32	Tezepelumab	65	62 (95.4)	5.30 (1.30)	1.8	4.20	5.60	6.20	7.0	
			Placebo	75	71 (94.7)	5.25 (1.21)	2.2	4.00	5.60	6.20	7.0	
		Week 36	Tezepelumab	65	62 (95.4)	5.39 (1.23)	2.8	4.40	5.60	6.60	7.0	
			Placebo	75	71 (94.7)	5.23 (1.20)	2.2	4.20	5.20	6.20	7.0	
		Week 40	Tezepelumab	65	62 (95.4)	5.32 (1.33)	1.8	4.40	5.40	6.20	7.0	
			Placebo	75	71 (94.7)	5.29 (1.22)	2.2	4.40	5.20	6.40	7.0	
		Week 44	Tezepelumab	65	62 (95.4)	5.51 (1.22)	2.8	4.60	5.70	6.40	7.0	
			Placebo	75	71 (94.7)	5.26 (1.29)	2.2	4.00	5.60	6.60	7.0	
		Week 48	Tezepelumab	65	62 (95.4)	5.40 (1.22)	1.8	4.60	5.60	6.20	7.0	
			Placebo	75	72 (96.0)	5.29 (1.22)	2.4	4.10	5.30	6.40	7.0	
		Week 52	Tezepelumab	65	62 (95.4)	5.42 (1.20)	1.8	4.60	5.70	6.20	7.0	
			Placebo	75	72 (96.0)	5.28 (1.27)	2.4	4.10	5.40	6.40	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	65	55 (84.6)	0.61 (1.25)	-4.2	0.00	0.60	1.60	3.6	0.03 [-0.33, 0.39]
			Placebo	75	66 (88.0)	0.58 (1.07)	-2.8	0.00	0.50	1.20	3.6	
		Week 8	Tezepelumab	65	56 (86.2)	0.90 (1.21)	-1.4	0.20	0.80	1.60	5.0	0.18 [-0.18, 0.54]
			Placebo	75	66 (88.0)	0.68 (1.18)	-1.8	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	65	56 (86.2)	0.98 (1.31)	-2.4	0.20	0.90	1.80	5.4	0.17 [-0.19, 0.53]
			Placebo	75	66 (88.0)	0.76 (1.32)	-2.2	0.00	0.80	1.40	4.4	
		Week 16	Tezepelumab	65	56 (86.2)	0.97 (1.30)	-2.8	0.10	0.80	1.60	5.2	0.14 [-0.21, 0.50]
			Placebo	75	66 (88.0)	0.80 (1.16)	-2.0	0.20	0.70	1.40	4.4	
		Week 20	Tezepelumab	65	56 (86.2)	1.05 (1.24)	-1.4	0.20	0.90	2.00	5.2	0.16 [-0.20, 0.51]
			Placebo	75	66 (88.0)	0.86 (1.20)	-2.0	0.20	0.80	1.40	5.2	
		Week 24	Tezepelumab	65	56 (86.2)	0.99 (1.31)	-1.4	-0.20	0.90	2.00	5.4	-0.00 [-0.36, 0.35]
			Placebo	75	66 (88.0)	0.99 (1.19)	-2.0	0.20	0.90	1.60	4.2	
		Week 28	Tezepelumab	65	56 (86.2)	1.04 (1.25)	-1.4	0.00	0.80	1.90	5.4	0.03 [-0.33, 0.38]
			Placebo	75	66 (88.0)	1.00 (1.28)	-2.0	0.20	0.90	1.60	5.2	
		Week 32	Tezepelumab	65	56 (86.2)	0.97 (1.33)	-1.4	0.00	0.80	1.90	5.4	-0.06 [-0.42, 0.30]
			Placebo	75	66 (88.0)	1.05 (1.19)	-2.0	0.20	1.10	1.60	5.4	
		Week 36	Tezepelumab	65	56 (86.2)	1.08 (1.38)	-1.6	0.10	0.90	2.00	5.4	0.06 [-0.30, 0.41]
			Placebo	75	66 (88.0)	1.01 (1.19)	-2.0	0.40	0.90	1.80	4.2	
		Week 40	Tezepelumab	65	56 (86.2)	1.03 (1.41)	-2.4	0.10	0.80	1.90	5.4	-0.04 [-0.40, 0.31]
			Placebo	75	66 (88.0)	1.08 (1.29)	-2.0	0.20	1.00	1.40	5.4	
		Week 44	Tezepelumab	65	56 (86.2)	1.17 (1.38)	-1.4	0.20	1.20	2.00	5.4	0.09 [-0.26, 0.45]
			Placebo	75	66 (88.0)	1.05 (1.29)	-2.0	0.40	1.00	1.60	5.2	
		Week 48	Tezepelumab	65	56 (86.2)	1.08 (1.36)	-1.4	0.20	1.00	1.90	5.4	0.00 [-0.35, 0.36]
			Placebo	75	66 (88.0)	1.08 (1.27)	-2.0	0.20	1.00	1.60	5.0	
		Week 52	Tezepelumab	65	56 (86.2)	1.08 (1.35)	-1.6	0.20	1.00	1.80	5.4	0.01 [-0.35, 0.37]
			Placebo	75	66 (88.0)	1.07 (1.30)	-2.0	0.20	1.00	1.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	62	57 (91.9)	4.26 (0.99)	1.6	3.60	4.20	5.00	6.2	
			Placebo	67	57 (85.1)	4.41 (1.12)	1.0	3.80	4.40	5.20	6.6	
		Week 4	Tezepelumab	62	56 (90.3)	4.71 (1.24)	1.2	4.00	4.80	5.60	7.0	
			Placebo	67	58 (86.6)	4.77 (1.37)	1.4	3.80	4.80	6.00	7.0	
		Week 8	Tezepelumab	62	56 (90.3)	4.89 (1.23)	1.8	4.00	4.80	5.80	7.0	
			Placebo	67	60 (89.6)	4.92 (1.28)	1.4	4.00	5.00	5.90	7.0	
		Week 12	Tezepelumab	62	56 (90.3)	5.09 (1.21)	2.0	4.20	5.00	6.00	7.0	
			Placebo	67	61 (91.0)	4.90 (1.43)	1.4	4.00	4.60	6.20	7.0	
		Week 16	Tezepelumab	62	56 (90.3)	4.99 (1.12)	2.2	4.10	4.90	6.00	7.0	
			Placebo	67	61 (91.0)	4.97 (1.45)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	62	57 (91.9)	5.07 (1.15)	1.0	4.40	5.00	6.00	7.0	
			Placebo	67	61 (91.0)	4.98 (1.33)	1.0	4.20	5.00	6.00	7.0	
		Week 24	Tezepelumab	62	57 (91.9)	5.10 (1.11)	1.6	4.20	5.20	6.00	7.0	
			Placebo	67	61 (91.0)	5.07 (1.37)	1.0	4.40	5.00	6.20	7.0	
		Week 28	Tezepelumab	62	59 (95.2)	5.12 (1.05)	2.8	4.20	5.00	6.00	7.0	
			Placebo	67	62 (92.5)	4.96 (1.48)	1.0	4.00	5.10	6.20	7.0	
		Week 32	Tezepelumab	62	59 (95.2)	5.14 (1.13)	1.8	4.20	5.00	6.00	7.0	
			Placebo	67	63 (94.0)	5.01 (1.46)	1.0	4.00	5.00	6.20	7.0	
		Week 36	Tezepelumab	62	59 (95.2)	5.23 (1.12)	2.8	4.20	5.40	6.00	7.0	
			Placebo	67	63 (94.0)	5.09 (1.33)	1.6	4.20	5.00	6.00	7.0	
		Week 40	Tezepelumab	62	59 (95.2)	5.12 (1.14)	1.8	4.20	5.20	6.00	7.0	
			Placebo	67	63 (94.0)	5.10 (1.40)	1.6	4.00	5.00	6.40	7.0	
		Week 44	Tezepelumab	62	59 (95.2)	5.19 (1.13)	2.8	4.00	5.00	6.20	7.0	
			Placebo	67	63 (94.0)	5.23 (1.47)	1.4	4.00	5.60	6.60	7.0	
		Week 48	Tezepelumab	62	59 (95.2)	5.22 (1.15)	1.8	4.40	5.20	6.00	7.0	
			Placebo	67	64 (95.5)	5.10 (1.46)	1.2	4.00	4.90	6.60	7.0	
		Week 52	Tezepelumab	62	59 (95.2)	5.21 (1.13)	1.8	4.40	5.00	6.00	7.0	
			Placebo	67	64 (95.5)	5.11 (1.49)	1.2	4.00	4.80	6.70	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	62	55 (88.7)	0.48 (1.26)	-4.2	-0.20	0.40	1.40	3.6	0.07 [-0.31, 0.44]
			Placebo	67	56 (83.6)	0.40 (1.07)	-2.2	0.00	0.40	1.00	3.0	
		Week 8	Tezepelumab	62	55 (88.7)	0.65 (1.33)	-2.2	-0.20	0.60	1.40	5.0	0.07 [-0.30, 0.44]
			Placebo	67	57 (85.1)	0.56 (1.12)	-1.6	-0.20	0.40	1.20	3.0	
		Week 12	Tezepelumab	62	55 (88.7)	0.85 (1.27)	-2.4	0.20	0.80	1.60	5.4	0.20 [-0.18, 0.57]
			Placebo	67	57 (85.1)	0.60 (1.26)	-2.0	-0.20	0.60	1.20	3.6	
		Week 16	Tezepelumab	62	55 (88.7)	0.75 (1.26)	-2.8	-0.20	0.80	1.60	5.2	0.08 [-0.29, 0.46]
			Placebo	67	57 (85.1)	0.64 (1.27)	-3.4	0.00	0.60	1.40	4.0	
		Week 20	Tezepelumab	62	55 (88.7)	0.82 (1.19)	-1.4	-0.20	0.80	1.40	5.2	0.17 [-0.20, 0.54]
			Placebo	67	57 (85.1)	0.62 (1.06)	-3.4	0.00	0.80	1.20	3.0	
		Week 24	Tezepelumab	62	55 (88.7)	0.85 (1.20)	-1.4	0.00	0.80	1.60	5.4	0.11 [-0.26, 0.48]
			Placebo	67	57 (85.1)	0.72 (1.21)	-3.4	-0.20	0.60	1.60	3.4	
		Week 28	Tezepelumab	62	55 (88.7)	0.87 (1.20)	-1.4	0.00	0.60	1.60	5.4	0.22 [-0.15, 0.60]
			Placebo	67	57 (85.1)	0.58 (1.31)	-3.4	0.00	0.60	1.20	4.0	
		Week 32	Tezepelumab	62	55 (88.7)	0.86 (1.23)	-1.6	0.00	0.80	1.60	5.4	0.16 [-0.21, 0.53]
			Placebo	67	57 (85.1)	0.66 (1.24)	-3.4	-0.20	0.60	1.60	3.4	
		Week 36	Tezepelumab	62	55 (88.7)	0.96 (1.30)	-1.6	0.00	1.00	1.60	5.4	0.20 [-0.17, 0.57]
			Placebo	67	57 (85.1)	0.71 (1.12)	-2.0	0.00	0.60	1.40	3.6	
		Week 40	Tezepelumab	62	55 (88.7)	0.86 (1.26)	-2.4	0.00	0.80	1.60	5.4	0.09 [-0.28, 0.46]
			Placebo	67	57 (85.1)	0.75 (1.25)	-2.0	0.00	0.80	1.40	4.0	
		Week 44	Tezepelumab	62	55 (88.7)	0.92 (1.22)	-1.4	0.00	1.00	1.60	5.4	0.06 [-0.31, 0.43]
			Placebo	67	57 (85.1)	0.84 (1.37)	-1.8	-0.20	1.00	1.60	4.2	
		Week 48	Tezepelumab	62	55 (88.7)	0.96 (1.20)	-1.4	0.20	1.00	1.60	5.4	0.19 [-0.18, 0.56]
			Placebo	67	57 (85.1)	0.72 (1.26)	-2.2	-0.20	0.80	1.40	4.2	
		Week 52	Tezepelumab	62	55 (88.7)	0.94 (1.21)	-1.6	0.00	1.00	1.60	5.4	0.15 [-0.22, 0.52]
			Placebo	67	57 (85.1)	0.75 (1.31)	-1.6	-0.20	0.80	1.40	4.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	74	65 (87.8)	4.40 (1.28)	1.4	3.80	4.40	5.20	6.8	
			Placebo	71	64 (90.1)	4.08 (1.32)	1.4	3.20	4.00	5.00	7.0	
		Week 4	Tezepelumab	74	69 (93.2)	5.21 (1.11)	2.8	4.20	5.40	6.00	7.0	
			Placebo	71	65 (91.5)	4.62 (1.26)	1.6	3.60	4.60	5.60	7.0	
		Week 8	Tezepelumab	74	71 (95.9)	5.39 (1.15)	2.0	4.60	5.60	6.20	7.0	
			Placebo	71	66 (93.0)	4.73 (1.34)	1.0	4.00	4.80	5.60	7.0	
		Week 12	Tezepelumab	74	71 (95.9)	5.59 (1.11)	2.8	4.40	5.60	6.40	7.0	
			Placebo	71	66 (93.0)	4.88 (1.22)	2.0	4.00	4.90	5.80	7.0	
		Week 16	Tezepelumab	74	71 (95.9)	5.56 (1.14)	2.8	4.40	5.80	6.60	7.0	
			Placebo	71	66 (93.0)	4.81 (1.30)	1.2	4.00	4.60	5.80	7.0	
		Week 20	Tezepelumab	74	71 (95.9)	5.61 (1.12)	2.4	4.60	5.80	6.40	7.0	
			Placebo	71	66 (93.0)	4.91 (1.32)	1.4	4.00	4.90	5.80	7.0	
		Week 24	Tezepelumab	74	71 (95.9)	5.54 (1.20)	2.0	4.60	5.80	6.60	7.0	
			Placebo	71	66 (93.0)	4.95 (1.25)	2.2	4.00	4.90	6.00	7.0	
		Week 28	Tezepelumab	74	71 (95.9)	5.69 (1.04)	2.8	5.00	6.00	6.40	7.0	
			Placebo	71	66 (93.0)	4.96 (1.32)	2.2	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	74	72 (97.3)	5.61 (1.14)	2.4	4.80	5.80	6.40	7.0	
			Placebo	71	66 (93.0)	4.97 (1.30)	1.6	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	74	72 (97.3)	5.71 (1.13)	2.8	4.90	6.00	6.60	7.0	
			Placebo	71	66 (93.0)	4.99 (1.34)	1.8	4.00	4.90	6.20	7.0	
		Week 40	Tezepelumab	74	72 (97.3)	5.61 (1.23)	2.0	4.80	5.90	6.60	7.0	
			Placebo	71	66 (93.0)	4.99 (1.33)	1.6	4.00	4.90	6.20	7.0	
		Week 44	Tezepelumab	74	72 (97.3)	5.75 (1.12)	2.6	5.00	6.00	6.60	7.0	
			Placebo	71	66 (93.0)	4.87 (1.36)	1.6	4.00	4.60	6.00	7.0	
		Week 48	Tezepelumab	74	72 (97.3)	5.69 (1.12)	2.6	4.80	6.00	6.60	7.0	
			Placebo	71	66 (93.0)	4.98 (1.30)	1.8	4.00	4.90	6.00	7.0	
		Week 52	Tezepelumab	74	72 (97.3)	5.67 (1.16)	2.6	4.70	5.90	6.80	7.0	
			Placebo	71	66 (93.0)	4.83 (1.35)	1.8	4.00	4.80	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	74	61 (82.4)	0.88 (1.13)	-1.6	0.20	0.80	1.60	3.8	0.36 [0.01, 0.72]
			Placebo	71	63 (88.7)	0.48 (1.08)	-2.8	-0.20	0.40	1.20	3.6	
		Week 8	Tezepelumab	74	63 (85.1)	0.99 (1.17)	-1.2	0.20	0.80	2.00	4.4	0.31 [-0.05, 0.66]
			Placebo	71	63 (88.7)	0.62 (1.24)	-2.0	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	74	63 (85.1)	1.18 (1.21)	-1.6	0.20	1.00	2.20	3.8	0.35 [-0.01, 0.70]
			Placebo	71	63 (88.7)	0.75 (1.26)	-2.2	0.00	0.80	1.40	4.4	
		Week 16	Tezepelumab	74	63 (85.1)	1.18 (1.15)	-1.0	0.20	1.20	2.20	4.0	0.42 [0.07, 0.78]
			Placebo	71	63 (88.7)	0.68 (1.21)	-2.0	0.00	0.80	1.40	4.4	
		Week 20	Tezepelumab	74	63 (85.1)	1.27 (1.24)	-0.8	0.20	1.20	2.20	4.6	0.34 [-0.01, 0.70]
			Placebo	71	63 (88.7)	0.82 (1.38)	-2.2	0.20	0.80	1.60	5.2	
		Week 24	Tezepelumab	74	63 (85.1)	1.18 (1.29)	-1.4	0.20	1.00	2.20	4.6	0.24 [-0.11, 0.59]
			Placebo	71	63 (88.7)	0.86 (1.34)	-2.2	0.00	0.80	1.60	4.2	
		Week 28	Tezepelumab	74	63 (85.1)	1.28 (1.23)	-1.0	0.60	1.20	2.20	4.6	0.29 [-0.06, 0.64]
			Placebo	71	63 (88.7)	0.89 (1.46)	-2.2	0.00	1.00	1.60	5.2	
		Week 32	Tezepelumab	74	63 (85.1)	1.22 (1.27)	-1.4	0.20	1.40	2.20	4.6	0.25 [-0.10, 0.60]
			Placebo	71	63 (88.7)	0.89 (1.36)	-2.0	-0.20	0.80	1.60	5.4	
		Week 36	Tezepelumab	74	63 (85.1)	1.32 (1.34)	-1.0	0.40	1.20	2.20	4.6	0.31 [-0.04, 0.67]
			Placebo	71	63 (88.7)	0.90 (1.33)	-2.0	-0.20	0.80	1.80	4.2	
		Week 40	Tezepelumab	74	63 (85.1)	1.22 (1.32)	-1.2	0.20	1.00	2.20	4.6	0.22 [-0.13, 0.57]
			Placebo	71	63 (88.7)	0.91 (1.46)	-2.0	-0.20	1.00	1.60	5.4	
		Week 44	Tezepelumab	74	63 (85.1)	1.32 (1.29)	-1.0	0.40	1.40	2.20	4.6	0.38 [0.03, 0.74]
			Placebo	71	63 (88.7)	0.80 (1.41)	-2.2	-0.20	0.80	1.60	5.2	
		Week 48	Tezepelumab	74	63 (85.1)	1.29 (1.31)	-1.4	0.40	1.40	2.20	4.6	0.28 [-0.07, 0.63]
			Placebo	71	63 (88.7)	0.91 (1.40)	-2.0	0.00	0.80	1.80	5.0	
		Week 52	Tezepelumab	74	63 (85.1)	1.24 (1.33)	-1.4	0.20	1.40	2.20	4.6	0.35 [0.00, 0.70]
			Placebo	71	63 (88.7)	0.74 (1.47)	-2.6	-0.20	0.60	1.60	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	114	101 (88.6)	4.26 (1.13)	1.4	3.60	4.20	5.00	6.8	
			Placebo	126	112 (88.9)	4.24 (1.19)	1.0	3.60	4.20	5.00	7.0	
		Week 4	Tezepelumab	114	105 (92.1)	4.88 (1.20)	1.2	4.00	4.80	6.00	7.0	
			Placebo	126	113 (89.7)	4.71 (1.30)	1.4	3.80	4.80	5.60	7.0	
		Week 8	Tezepelumab	114	107 (93.9)	5.05 (1.20)	1.8	4.20	5.00	6.00	7.0	
			Placebo	126	116 (92.1)	4.84 (1.25)	1.4	4.00	4.80	5.70	7.0	
		Week 12	Tezepelumab	114	107 (93.9)	5.29 (1.20)	2.0	4.40	5.40	6.20	7.0	
			Placebo	126	117 (92.9)	4.85 (1.32)	1.4	4.00	4.60	5.80	7.0	
		Week 16	Tezepelumab	114	107 (93.9)	5.22 (1.16)	2.2	4.40	5.40	6.00	7.0	
			Placebo	126	117 (92.9)	4.87 (1.33)	1.0	4.00	5.00	5.80	7.0	
		Week 20	Tezepelumab	114	108 (94.7)	5.25 (1.19)	1.0	4.40	5.40	6.00	7.0	
			Placebo	126	117 (92.9)	4.95 (1.30)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	114	108 (94.7)	5.24 (1.20)	1.6	4.40	5.20	6.20	7.0	
			Placebo	126	117 (92.9)	5.00 (1.30)	1.0	4.00	5.00	6.00	7.0	
		Week 28	Tezepelumab	114	110 (96.5)	5.33 (1.10)	2.8	4.40	5.40	6.20	7.0	
			Placebo	126	118 (93.7)	4.95 (1.37)	1.0	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	114	111 (97.4)	5.29 (1.17)	1.8	4.40	5.60	6.20	7.0	
			Placebo	126	119 (94.4)	4.99 (1.36)	1.0	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	114	111 (97.4)	5.36 (1.17)	2.8	4.40	5.60	6.20	7.0	
			Placebo	126	119 (94.4)	5.03 (1.30)	1.6	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	114	111 (97.4)	5.32 (1.22)	1.8	4.40	5.40	6.20	7.0	
			Placebo	126	119 (94.4)	5.05 (1.33)	1.6	4.00	5.00	6.20	7.0	
		Week 44	Tezepelumab	114	111 (97.4)	5.41 (1.15)	2.8	4.40	5.40	6.40	7.0	
			Placebo	126	119 (94.4)	5.03 (1.39)	1.4	4.00	5.00	6.20	7.0	
		Week 48	Tezepelumab	114	111 (97.4)	5.40 (1.17)	1.8	4.60	5.40	6.40	7.0	
			Placebo	126	120 (95.2)	5.04 (1.35)	1.2	4.00	4.80	6.30	7.0	
		Week 52	Tezepelumab	114	111 (97.4)	5.39 (1.16)	1.8	4.60	5.40	6.40	7.0	
			Placebo	126	120 (95.2)	4.97 (1.41)	1.2	4.00	4.80	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	114	97 (85.1)	0.63 (1.21)	-4.2	0.00	0.60	1.40	3.8	0.15 [-0.12, 0.42]
			Placebo	126	110 (87.3)	0.45 (1.11)	-2.8	-0.20	0.40	1.20	3.6	
		Week 8	Tezepelumab	114	99 (86.8)	0.75 (1.27)	-2.2	-0.20	0.60	1.60	5.0	0.11 [-0.16, 0.38]
			Placebo	126	111 (88.1)	0.61 (1.17)	-1.8	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	114	99 (86.8)	0.98 (1.25)	-2.4	0.20	0.80	1.80	5.4	0.27 [0.00, 0.55]
			Placebo	126	111 (88.1)	0.64 (1.25)	-2.2	0.00	0.60	1.40	4.4	
		Week 16	Tezepelumab	114	99 (86.8)	0.93 (1.25)	-2.8	0.00	0.80	1.60	5.2	0.24 [-0.03, 0.51]
			Placebo	126	111 (88.1)	0.64 (1.20)	-3.4	0.00	0.60	1.40	4.4	
		Week 20	Tezepelumab	114	99 (86.8)	0.99 (1.23)	-1.4	0.00	0.80	1.80	5.2	0.21 [-0.06, 0.48]
			Placebo	126	111 (88.1)	0.74 (1.24)	-3.4	0.00	0.60	1.40	5.2	
		Week 24	Tezepelumab	114	99 (86.8)	0.97 (1.27)	-1.4	0.00	0.80	2.00	5.4	0.14 [-0.13, 0.41]
			Placebo	126	111 (88.1)	0.79 (1.28)	-3.4	0.00	0.60	1.60	4.2	
		Week 28	Tezepelumab	114	99 (86.8)	1.03 (1.23)	-1.4	0.00	0.80	2.00	5.4	0.23 [-0.04, 0.51]
			Placebo	126	111 (88.1)	0.73 (1.38)	-3.4	0.00	0.80	1.40	5.2	
		Week 32	Tezepelumab	114	99 (86.8)	0.99 (1.29)	-1.6	0.00	1.00	2.00	5.4	0.16 [-0.11, 0.43]
			Placebo	126	111 (88.1)	0.78 (1.30)	-3.4	-0.20	0.80	1.60	5.4	
		Week 36	Tezepelumab	114	99 (86.8)	1.06 (1.32)	-1.6	0.00	1.00	2.00	5.4	0.20 [-0.07, 0.48]
			Placebo	126	111 (88.1)	0.81 (1.20)	-2.0	0.00	0.60	1.60	3.8	
		Week 40	Tezepelumab	114	99 (86.8)	1.03 (1.36)	-2.4	0.00	0.80	2.00	5.4	0.14 [-0.13, 0.41]
			Placebo	126	111 (88.1)	0.84 (1.33)	-2.0	0.00	0.80	1.40	5.4	
		Week 44	Tezepelumab	114	99 (86.8)	1.10 (1.31)	-1.4	0.00	1.00	2.00	5.4	0.22 [-0.05, 0.49]
			Placebo	126	111 (88.1)	0.81 (1.34)	-2.2	-0.20	0.80	1.60	5.2	
		Week 48	Tezepelumab	114	99 (86.8)	1.11 (1.30)	-1.4	0.20	1.00	2.00	5.4	0.21 [-0.06, 0.48]
			Placebo	126	111 (88.1)	0.83 (1.32)	-2.2	0.00	0.80	1.60	5.0	
		Week 52	Tezepelumab	114	99 (86.8)	1.07 (1.32)	-1.6	0.00	1.00	2.00	5.4	0.24 [-0.04, 0.51]
			Placebo	126	111 (88.1)	0.75 (1.39)	-2.6	-0.20	0.80	1.40	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	23	22 (95.7)	4.65 (1.22)	1.4	4.00	4.80	5.40	6.8	
			Placebo	12	9 (75.0)	4.24 (1.81)	2.0	3.00	4.20	5.40	7.0	
		Week 4	Tezepelumab	23	21 (91.3)	5.46 (1.05)	3.2	5.00	5.60	6.20	7.0	
			Placebo	12	10 (83.3)	4.50 (1.54)	2.8	3.00	4.20	6.00	6.8	
		Week 8	Tezepelumab	23	21 (91.3)	5.75 (1.03)	3.4	5.00	5.60	6.60	7.0	
			Placebo	12	10 (83.3)	4.54 (1.90)	1.0	3.60	5.10	5.80	7.0	
		Week 12	Tezepelumab	23	21 (91.3)	5.73 (0.99)	4.2	5.00	5.60	6.60	7.0	
			Placebo	12	10 (83.3)	5.34 (1.24)	3.6	4.00	5.50	6.40	7.0	
		Week 16	Tezepelumab	23	21 (91.3)	5.75 (1.07)	3.2	5.00	5.80	6.80	7.0	
			Placebo	12	10 (83.3)	5.08 (1.82)	1.2	4.00	5.40	6.60	7.0	
		Week 20	Tezepelumab	23	21 (91.3)	5.92 (0.82)	4.0	5.40	6.00	6.40	7.0	
			Placebo	12	10 (83.3)	4.86 (1.61)	1.4	4.40	4.90	6.00	7.0	
		Week 24	Tezepelumab	23	21 (91.3)	5.91 (0.87)	4.2	5.20	6.00	6.80	7.0	
			Placebo	12	10 (83.3)	5.10 (1.47)	2.2	4.40	5.10	6.00	7.0	
		Week 28	Tezepelumab	23	21 (91.3)	5.91 (0.81)	4.2	5.60	6.00	6.40	7.0	
			Placebo	12	10 (83.3)	5.10 (1.74)	2.2	3.60	5.20	6.60	7.0	
		Week 32	Tezepelumab	23	21 (91.3)	5.96 (0.85)	4.2	5.60	6.00	6.60	7.0	
			Placebo	12	10 (83.3)	4.96 (1.62)	1.6	4.20	5.20	6.20	6.8	
		Week 36	Tezepelumab	23	21 (91.3)	6.16 (0.72)	4.6	5.80	6.00	6.80	7.0	
			Placebo	12	10 (83.3)	5.08 (1.72)	1.8	3.60	5.40	6.60	7.0	
		Week 40	Tezepelumab	23	21 (91.3)	5.75 (1.11)	2.6	5.40	6.00	6.60	7.0	
			Placebo	12	10 (83.3)	4.96 (1.78)	1.6	3.60	5.30	6.60	7.0	
		Week 44	Tezepelumab	23	21 (91.3)	5.90 (1.11)	2.6	5.60	6.00	6.80	7.0	
			Placebo	12	10 (83.3)	5.20 (1.80)	1.6	3.60	5.80	6.60	7.0	
		Week 48	Tezepelumab	23	21 (91.3)	5.86 (0.98)	4.0	5.60	6.00	6.40	7.0	
			Placebo	12	10 (83.3)	5.04 (1.72)	1.8	3.60	5.50	6.40	7.0	
		Week 52	Tezepelumab	23	21 (91.3)	5.84 (1.11)	2.8	5.80	6.00	6.80	7.0	
			Placebo	12	10 (83.3)	4.90 (1.64)	1.8	3.60	5.20	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	0.95 (1.17)	-1.6	0.20	1.00	1.70	3.6	0.60 [-0.20, 1.41]
			Placebo	12	9 (75.0)	0.33 (0.53)	-0.4	0.00	0.40	0.60	1.4	
		Week 8	Tezepelumab	23	20 (87.0)	1.21 (1.04)	-1.2	0.60	1.10	1.80	3.6	0.77 [-0.04, 1.58]
			Placebo	12	9 (75.0)	0.36 (1.28)	-2.0	0.00	0.80	1.00	2.2	
		Week 12	Tezepelumab	23	20 (87.0)	1.20 (1.19)	-1.6	0.40	1.30	1.80	3.4	0.02 [-0.77, 0.81]
			Placebo	12	9 (75.0)	1.18 (1.21)	-0.8	0.60	1.00	1.60	3.6	
		Week 16	Tezepelumab	23	20 (87.0)	1.22 (1.02)	-1.0	0.50	1.20	1.70	3.0	0.26 [-0.52, 1.05]
			Placebo	12	9 (75.0)	0.89 (1.67)	-1.8	0.40	1.20	1.20	4.0	
		Week 20	Tezepelumab	23	20 (87.0)	1.36 (1.19)	-0.8	0.70	1.10	2.00	4.4	0.62 [-0.18, 1.42]
			Placebo	12	9 (75.0)	0.62 (1.20)	-1.6	0.40	0.80	1.40	2.0	
		Week 24	Tezepelumab	23	20 (87.0)	1.33 (1.14)	-0.8	0.60	1.30	2.30	3.2	0.38 [-0.42, 1.17]
			Placebo	12	9 (75.0)	0.89 (1.26)	-1.0	0.20	1.40	1.60	2.4	
		Week 28	Tezepelumab	23	20 (87.0)	1.34 (1.21)	-0.8	0.60	1.00	2.30	4.2	0.30 [-0.49, 1.09]
			Placebo	12	9 (75.0)	0.93 (1.62)	-1.0	-0.60	1.20	1.60	4.0	
		Week 32	Tezepelumab	23	20 (87.0)	1.36 (1.02)	-1.0	0.80	1.40	2.00	3.2	0.50 [-0.30, 1.30]
			Placebo	12	9 (75.0)	0.78 (1.44)	-1.4	0.00	1.00	1.60	3.0	
		Week 36	Tezepelumab	23	20 (87.0)	1.57 (1.27)	-0.8	0.70	1.30	2.40	4.4	0.50 [-0.30, 1.30]
			Placebo	12	9 (75.0)	0.87 (1.69)	-1.2	-0.60	1.40	1.60	4.2	
		Week 40	Tezepelumab	23	20 (87.0)	1.14 (0.98)	-1.0	0.60	1.10	1.60	3.0	0.27 [-0.52, 1.06]
			Placebo	12	9 (75.0)	0.80 (1.81)	-1.4	-1.00	0.40	1.60	3.6	
		Week 44	Tezepelumab	23	20 (87.0)	1.28 (1.01)	-1.0	0.60	1.40	1.90	3.0	0.26 [-0.53, 1.05]
			Placebo	12	9 (75.0)	0.93 (1.93)	-1.4	-1.00	1.00	1.60	4.2	
		Week 48	Tezepelumab	23	20 (87.0)	1.26 (1.09)	-0.8	0.50	1.30	2.00	3.2	0.40 [-0.39, 1.20]
			Placebo	12	9 (75.0)	0.76 (1.58)	-1.2	-0.20	0.60	1.60	4.0	
		Week 52	Tezepelumab	23	20 (87.0)	1.22 (1.07)	-0.8	0.50	1.40	1.80	3.2	0.47 [-0.33, 1.27]
			Placebo	12	9 (75.0)	0.67 (1.42)	-1.2	-0.20	0.60	1.40	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.08 (1.04)	2.2	3.60	4.10	4.70	5.6	
			Placebo	14	10 (71.4)	4.38 (1.11)	3.0	3.60	4.20	4.60	7.0	
		Week 4	Tezepelumab	9	8 (88.9)	5.00 (0.96)	3.8	4.10	5.00	5.90	6.2	
			Placebo	14	12 (85.7)	4.85 (1.61)	1.6	3.80	4.80	6.20	7.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.50 (1.04)	4.0	4.70	5.60	6.20	7.0	
			Placebo	14	13 (92.9)	4.78 (1.22)	3.0	4.00	5.00	5.40	7.0	
		Week 12	Tezepelumab	9	8 (88.9)	5.55 (1.08)	4.0	4.70	5.60	6.40	7.0	
			Placebo	14	13 (92.9)	4.80 (1.51)	1.8	3.60	4.60	6.20	7.0	
		Week 16	Tezepelumab	9	8 (88.9)	5.85 (1.06)	4.0	5.20	5.90	6.80	7.0	
			Placebo	14	13 (92.9)	5.11 (1.29)	2.6	4.40	5.00	6.00	7.0	
		Week 20	Tezepelumab	9	8 (88.9)	5.35 (1.02)	4.0	4.50	5.20	6.30	6.8	
			Placebo	14	13 (92.9)	5.05 (1.05)	3.0	4.40	4.80	5.80	7.0	
		Week 24	Tezepelumab	9	8 (88.9)	5.48 (1.12)	4.0	4.50	5.60	6.30	7.0	
			Placebo	14	13 (92.9)	4.97 (1.14)	2.8	4.40	4.80	5.60	7.0	
		Week 28	Tezepelumab	9	8 (88.9)	5.33 (0.99)	4.0	4.50	5.30	6.20	6.6	
			Placebo	14	14 (100.0)	5.11 (1.34)	2.6	4.40	4.70	6.20	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.43 (1.04)	4.0	4.60	5.40	6.20	7.0	
			Placebo	14	14 (100.0)	5.11 (1.36)	2.2	4.40	5.10	6.00	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.43 (1.09)	4.0	4.40	5.60	6.20	7.0	
			Placebo	14	14 (100.0)	4.99 (1.43)	1.6	4.40	4.70	6.00	7.0	
		Week 40	Tezepelumab	9	8 (88.9)	5.25 (1.20)	3.8	4.20	5.10	6.30	7.0	
			Placebo	14	14 (100.0)	5.00 (1.58)	1.6	4.20	4.70	6.60	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.45 (1.09)	4.0	4.50	5.50	6.30	7.0	
			Placebo	14	14 (100.0)	4.99 (1.57)	1.8	4.40	5.00	6.20	7.0	
		Week 48	Tezepelumab	9	8 (88.9)	5.25 (0.94)	4.0	4.30	5.50	6.00	6.4	
			Placebo	14	14 (100.0)	4.87 (1.56)	1.4	4.00	4.70	6.00	7.0	
		Week 52	Tezepelumab	9	8 (88.9)	5.43 (1.12)	4.0	4.30	5.70	6.20	7.0	
			Placebo	14	14 (100.0)	4.87 (1.46)	2.0	4.00	4.70	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.89 (0.75)	0.2	0.20	0.60	1.80	2.0	0.47 [-0.51, 1.45]
			Placebo	14	10 (71.4)	0.42 (1.13)	-2.0	0.00	0.40	1.60	1.8	
		Week 8	Tezepelumab	9	7 (77.8)	1.34 (0.67)	0.4	1.00	1.20	2.00	2.4	0.71 [-0.29, 1.71]
			Placebo	14	10 (71.4)	0.58 (1.27)	-1.2	-0.60	0.90	1.80	2.2	
		Week 12	Tezepelumab	9	7 (77.8)	1.43 (0.98)	0.2	0.40	1.40	2.20	3.0	0.70 [-0.30, 1.70]
			Placebo	14	10 (71.4)	0.44 (1.64)	-1.8	-0.80	0.10	1.80	3.6	
		Week 16	Tezepelumab	9	7 (77.8)	1.66 (1.02)	0.4	1.00	1.40	2.60	3.4	0.62 [-0.37, 1.61]
			Placebo	14	10 (71.4)	0.84 (1.48)	-1.0	0.00	0.80	1.40	4.0	
		Week 20	Tezepelumab	9	7 (77.8)	1.43 (0.98)	0.4	0.60	1.20	2.20	3.2	0.72 [-0.28, 1.72]
			Placebo	14	10 (71.4)	0.72 (1.00)	-1.0	-0.20	1.00	1.60	1.8	
		Week 24	Tezepelumab	9	7 (77.8)	1.49 (1.30)	0.0	0.40	1.40	2.40	3.8	0.58 [-0.41, 1.57]
			Placebo	14	10 (71.4)	0.76 (1.22)	-1.0	-0.20	0.90	1.80	2.4	
		Week 28	Tezepelumab	9	7 (77.8)	1.34 (1.19)	0.4	0.60	0.80	2.40	3.6	0.40 [-0.58, 1.37]
			Placebo	14	10 (71.4)	0.78 (1.54)	-1.0	-0.40	0.80	1.80	4.0	
		Week 32	Tezepelumab	9	7 (77.8)	1.46 (1.14)	0.4	0.40	1.40	2.20	3.6	0.49 [-0.49, 1.47]
			Placebo	14	10 (71.4)	0.80 (1.45)	-1.4	-0.40	1.30	1.80	3.0	
		Week 36	Tezepelumab	9	7 (77.8)	1.54 (1.14)	0.4	0.80	1.20	2.20	3.8	0.79 [-0.22, 1.79]
			Placebo	14	10 (71.4)	0.54 (1.36)	-2.0	-0.20	1.00	1.40	2.4	
		Week 40	Tezepelumab	9	7 (77.8)	1.26 (1.18)	-0.2	0.40	0.80	2.40	3.2	0.37 [-0.61, 1.34]
			Placebo	14	10 (71.4)	0.70 (1.71)	-2.0	-0.80	0.90	1.80	3.6	
		Week 44	Tezepelumab	9	7 (77.8)	1.49 (1.28)	0.2	0.40	1.40	2.40	3.8	0.66 [-0.34, 1.65]
			Placebo	14	10 (71.4)	0.46 (1.72)	-1.8	-1.00	0.50	1.80	3.2	
		Week 48	Tezepelumab	9	7 (77.8)	1.29 (1.33)	0.0	0.40	0.80	2.20	3.8	0.65 [-0.34, 1.64]
			Placebo	14	10 (71.4)	0.40 (1.38)	-2.2	-0.20	0.60	1.20	2.6	
		Week 52	Tezepelumab	9	7 (77.8)	1.49 (1.20)	0.4	0.40	1.40	2.20	3.8	0.83 [-0.18, 1.84]
			Placebo	14	10 (71.4)	0.46 (1.26)	-1.6	-0.20	0.60	1.20	2.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.35 (1.16)	1.4	3.80	4.40	5.20	6.8	
			Placebo	124	111 (89.5)	4.22 (1.25)	1.0	3.60	4.20	5.00	7.0	
		Week 4	Tezepelumab	128	118 (92.2)	4.97 (1.21)	1.2	4.00	5.00	6.00	7.0	
			Placebo	124	111 (89.5)	4.67 (1.28)	1.4	3.80	4.60	5.60	7.0	
		Week 8	Tezepelumab	128	120 (93.8)	5.15 (1.21)	1.8	4.30	5.10	6.00	7.0	
			Placebo	124	113 (91.1)	4.82 (1.32)	1.0	4.00	4.80	5.80	7.0	
		Week 12	Tezepelumab	128	120 (93.8)	5.35 (1.18)	2.0	4.40	5.40	6.40	7.0	
			Placebo	124	114 (91.9)	4.90 (1.30)	1.4	4.00	4.80	5.80	7.0	
		Week 16	Tezepelumab	128	120 (93.8)	5.28 (1.16)	2.2	4.40	5.40	6.10	7.0	
			Placebo	124	114 (91.9)	4.86 (1.38)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	128	121 (94.5)	5.36 (1.17)	1.0	4.40	5.60	6.20	7.0	
			Placebo	124	114 (91.9)	4.93 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	128	121 (94.5)	5.34 (1.18)	1.6	4.40	5.40	6.20	7.0	
			Placebo	124	114 (91.9)	5.01 (1.33)	1.0	4.00	5.00	6.00	7.0	
		Week 28	Tezepelumab	128	123 (96.1)	5.43 (1.09)	2.8	4.60	5.60	6.20	7.0	
			Placebo	124	114 (91.9)	4.94 (1.41)	1.0	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	128	124 (96.9)	5.39 (1.16)	1.8	4.60	5.60	6.20	7.0	
			Placebo	124	115 (92.7)	4.97 (1.38)	1.0	4.00	5.00	6.20	7.0	
		Week 36	Tezepelumab	128	124 (96.9)	5.49 (1.15)	2.8	4.60	5.70	6.40	7.0	
			Placebo	124	115 (92.7)	5.04 (1.33)	1.8	4.00	5.00	6.20	7.0	
		Week 40	Tezepelumab	128	124 (96.9)	5.39 (1.21)	1.8	4.60	5.50	6.40	7.0	
			Placebo	124	115 (92.7)	5.05 (1.34)	1.6	4.00	5.00	6.20	7.0	
		Week 44	Tezepelumab	128	124 (96.9)	5.49 (1.16)	2.6	4.60	5.60	6.40	7.0	
			Placebo	124	115 (92.7)	5.05 (1.41)	1.4	4.00	5.00	6.40	7.0	
		Week 48	Tezepelumab	128	124 (96.9)	5.49 (1.16)	1.8	4.60	5.70	6.40	7.0	
			Placebo	124	116 (93.5)	5.06 (1.35)	1.2	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	128	124 (96.9)	5.46 (1.17)	1.8	4.60	5.60	6.40	7.0	
			Placebo	124	116 (93.5)	4.98 (1.42)	1.2	4.00	4.80	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	110 (85.9)	0.67 (1.23)	-4.2	0.00	0.60	1.60	3.8	0.19 [-0.07, 0.46]
			Placebo	124	109 (87.9)	0.45 (1.07)	-2.8	-0.20	0.40	1.00	3.6	
		Week 8	Tezepelumab	128	112 (87.5)	0.80 (1.27)	-2.2	0.00	0.60	1.60	5.0	0.17 [-0.10, 0.43]
			Placebo	124	110 (88.7)	0.59 (1.17)	-2.0	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	128	112 (87.5)	0.99 (1.26)	-2.4	0.20	0.80	1.80	5.4	0.24 [-0.03, 0.50]
			Placebo	124	110 (88.7)	0.70 (1.22)	-2.2	0.00	0.80	1.40	4.4	
		Week 16	Tezepelumab	128	112 (87.5)	0.94 (1.22)	-2.8	0.00	0.90	1.60	5.2	0.24 [-0.02, 0.51]
			Placebo	124	110 (88.7)	0.64 (1.21)	-3.4	0.00	0.60	1.40	4.4	
		Week 20	Tezepelumab	128	112 (87.5)	1.03 (1.24)	-1.4	0.10	0.90	1.90	5.2	0.24 [-0.02, 0.51]
			Placebo	124	110 (88.7)	0.73 (1.26)	-3.4	0.00	0.70	1.20	5.2	
		Week 24	Tezepelumab	128	112 (87.5)	1.00 (1.25)	-1.4	0.00	0.80	2.00	5.4	0.16 [-0.10, 0.42]
			Placebo	124	110 (88.7)	0.80 (1.29)	-3.4	0.00	0.70	1.60	4.2	
		Week 28	Tezepelumab	128	112 (87.5)	1.07 (1.23)	-1.4	0.00	0.90	2.00	5.4	0.25 [-0.01, 0.52]
			Placebo	124	110 (88.7)	0.74 (1.38)	-3.4	0.00	0.80	1.60	5.2	
		Week 32	Tezepelumab	128	112 (87.5)	1.02 (1.26)	-1.6	0.00	1.00	2.00	5.4	0.19 [-0.07, 0.45]
			Placebo	124	110 (88.7)	0.78 (1.30)	-3.4	-0.20	0.80	1.60	5.4	
		Week 36	Tezepelumab	128	112 (87.5)	1.13 (1.33)	-1.6	0.20	1.00	2.00	5.4	0.22 [-0.04, 0.49]
			Placebo	124	110 (88.7)	0.84 (1.22)	-2.0	0.00	0.60	1.60	4.2	
		Week 40	Tezepelumab	128	112 (87.5)	1.04 (1.31)	-2.4	0.00	1.00	2.00	5.4	0.14 [-0.12, 0.41]
			Placebo	124	110 (88.7)	0.85 (1.33)	-2.0	0.00	0.80	1.40	5.4	
		Week 44	Tezepelumab	128	112 (87.5)	1.11 (1.26)	-1.4	0.20	1.20	2.00	5.4	0.20 [-0.07, 0.46]
			Placebo	124	110 (88.7)	0.85 (1.36)	-2.2	-0.20	0.80	1.40	5.2	
		Week 48	Tezepelumab	128	112 (87.5)	1.12 (1.26)	-1.4	0.20	1.00	2.00	5.4	0.20 [-0.06, 0.47]
			Placebo	124	110 (88.7)	0.86 (1.33)	-2.0	0.00	0.80	1.60	5.0	
		Week 52	Tezepelumab	128	112 (87.5)	1.07 (1.28)	-1.6	0.00	1.00	2.00	5.4	0.22 [-0.04, 0.49]
			Placebo	124	110 (88.7)	0.77 (1.40)	-2.6	-0.20	0.80	1.40	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	4.29 (1.14)	1.4	3.60	4.20	5.00	6.8	
			Placebo	115	104 (90.4)	4.24 (1.22)	1.0	3.60	4.20	5.00	7.0	
		Week 4	Tezepelumab	108	100 (92.6)	4.88 (1.22)	1.2	4.00	4.80	6.00	7.0	
			Placebo	115	104 (90.4)	4.68 (1.27)	1.4	3.80	4.70	5.60	7.0	
		Week 8	Tezepelumab	108	102 (94.4)	5.05 (1.22)	1.8	4.20	5.00	6.00	7.0	
			Placebo	115	106 (92.2)	4.86 (1.25)	1.4	4.00	4.80	5.80	7.0	
		Week 12	Tezepelumab	108	102 (94.4)	5.29 (1.21)	2.0	4.40	5.40	6.20	7.0	
			Placebo	115	107 (93.0)	4.89 (1.31)	1.4	4.00	4.80	5.80	7.0	
		Week 16	Tezepelumab	108	102 (94.4)	5.20 (1.16)	2.2	4.40	5.30	6.00	7.0	
			Placebo	115	107 (93.0)	4.87 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	108	103 (95.4)	5.27 (1.20)	1.0	4.40	5.40	6.00	7.0	
			Placebo	115	107 (93.0)	4.94 (1.32)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	108	103 (95.4)	5.24 (1.20)	1.6	4.40	5.20	6.20	7.0	
			Placebo	115	107 (93.0)	5.02 (1.31)	1.0	4.00	5.00	6.00	7.0	
		Week 28	Tezepelumab	108	105 (97.2)	5.34 (1.11)	2.8	4.40	5.40	6.20	7.0	
			Placebo	115	107 (93.0)	4.95 (1.38)	1.0	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	108	106 (98.1)	5.30 (1.18)	1.8	4.40	5.60	6.20	7.0	
			Placebo	115	108 (93.9)	4.99 (1.36)	1.0	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	108	106 (98.1)	5.37 (1.18)	2.8	4.40	5.60	6.20	7.0	
			Placebo	115	108 (93.9)	5.04 (1.28)	1.8	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	108	106 (98.1)	5.33 (1.22)	1.8	4.40	5.40	6.20	7.0	
			Placebo	115	108 (93.9)	5.07 (1.30)	1.6	4.00	5.00	6.20	7.0	
		Week 44	Tezepelumab	108	106 (98.1)	5.43 (1.15)	2.8	4.60	5.40	6.40	7.0	
			Placebo	115	108 (93.9)	5.06 (1.36)	1.4	4.00	5.00	6.30	7.0	
		Week 48	Tezepelumab	108	106 (98.1)	5.41 (1.18)	1.8	4.60	5.40	6.40	7.0	
			Placebo	115	109 (94.8)	5.06 (1.32)	1.2	4.00	5.00	6.20	7.0	
		Week 52	Tezepelumab	108	106 (98.1)	5.39 (1.17)	1.8	4.60	5.40	6.40	7.0	
			Placebo	115	109 (94.8)	4.98 (1.40)	1.2	4.00	4.80	6.20	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	108	93 (86.1)	0.60 (1.22)	-4.2	0.00	0.60	1.40	3.8	0.14 [-0.15, 0.42]
			Placebo	115	102 (88.7)	0.45 (1.10)	-2.8	-0.20	0.40	1.00	3.6	
		Week 8	Tezepelumab	108	95 (88.0)	0.72 (1.28)	-2.2	-0.20	0.60	1.60	5.0	0.09 [-0.19, 0.37]
			Placebo	115	103 (89.6)	0.61 (1.18)	-1.8	-0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	108	95 (88.0)	0.96 (1.25)	-2.4	0.20	0.80	1.80	5.4	0.23 [-0.05, 0.51]
			Placebo	115	103 (89.6)	0.67 (1.25)	-2.2	0.00	0.60	1.40	4.4	
		Week 16	Tezepelumab	108	95 (88.0)	0.89 (1.23)	-2.8	0.00	0.80	1.60	5.2	0.20 [-0.08, 0.48]
			Placebo	115	103 (89.6)	0.64 (1.22)	-3.4	0.00	0.60	1.40	4.4	
		Week 20	Tezepelumab	108	95 (88.0)	0.97 (1.23)	-1.4	0.00	0.80	1.80	5.2	0.19 [-0.09, 0.47]
			Placebo	115	103 (89.6)	0.73 (1.27)	-3.4	0.00	0.60	1.20	5.2	
		Week 24	Tezepelumab	108	95 (88.0)	0.94 (1.25)	-1.4	0.00	0.80	1.80	5.4	0.12 [-0.16, 0.40]
			Placebo	115	103 (89.6)	0.79 (1.31)	-3.4	0.00	0.60	1.60	4.2	
		Week 28	Tezepelumab	108	95 (88.0)	1.00 (1.21)	-1.4	0.00	0.80	2.00	5.4	0.20 [-0.08, 0.48]
			Placebo	115	103 (89.6)	0.74 (1.40)	-3.4	0.00	0.80	1.40	5.2	
		Week 32	Tezepelumab	108	95 (88.0)	0.96 (1.28)	-1.6	0.00	1.00	1.80	5.4	0.13 [-0.15, 0.41]
			Placebo	115	103 (89.6)	0.78 (1.31)	-3.4	-0.20	0.80	1.40	5.4	
		Week 36	Tezepelumab	108	95 (88.0)	1.03 (1.31)	-1.6	0.00	1.00	2.00	5.4	0.17 [-0.11, 0.44]
			Placebo	115	103 (89.6)	0.82 (1.19)	-2.0	0.00	0.60	1.60	3.8	
		Week 40	Tezepelumab	108	95 (88.0)	1.01 (1.35)	-2.4	0.00	0.80	2.00	5.4	0.11 [-0.16, 0.39]
			Placebo	115	103 (89.6)	0.86 (1.32)	-2.0	0.00	0.80	1.40	5.4	
		Week 44	Tezepelumab	108	95 (88.0)	1.07 (1.30)	-1.4	0.00	1.00	2.00	5.4	0.17 [-0.11, 0.45]
			Placebo	115	103 (89.6)	0.85 (1.33)	-2.2	-0.20	0.80	1.40	5.2	
		Week 48	Tezepelumab	108	95 (88.0)	1.07 (1.29)	-1.4	0.00	1.00	2.00	5.4	0.17 [-0.11, 0.45]
			Placebo	115	103 (89.6)	0.85 (1.31)	-2.0	0.00	0.80	1.60	5.0	
		Week 52	Tezepelumab	108	95 (88.0)	1.03 (1.31)	-1.6	0.00	1.00	2.00	5.4	0.20 [-0.08, 0.48]
			Placebo	115	103 (89.6)	0.76 (1.41)	-2.6	-0.20	0.80	1.40	5.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	4.47 (1.21)	1.4	3.80	4.40	5.20	6.8	
			Placebo	23	17 (73.9)	4.24 (1.33)	2.0	3.40	4.20	4.60	7.0	
		Week 4	Tezepelumab	29	26 (89.7)	5.34 (1.03)	3.2	4.60	5.50	6.20	7.0	
			Placebo	23	19 (82.6)	4.73 (1.55)	1.6	3.40	4.80	6.00	7.0	
		Week 8	Tezepelumab	29	26 (89.7)	5.65 (1.03)	3.4	5.00	5.60	6.60	7.0	
			Placebo	23	20 (87.0)	4.63 (1.60)	1.0	3.60	5.00	5.60	7.0	
		Week 12	Tezepelumab	29	26 (89.7)	5.62 (1.01)	4.0	4.80	5.40	6.60	7.0	
			Placebo	23	20 (87.0)	4.92 (1.43)	1.8	3.80	4.60	6.20	7.0	
		Week 16	Tezepelumab	29	26 (89.7)	5.75 (1.06)	3.2	5.00	5.70	6.80	7.0	
			Placebo	23	20 (87.0)	4.98 (1.53)	1.2	4.10	5.00	6.00	7.0	
		Week 20	Tezepelumab	29	26 (89.7)	5.74 (0.91)	4.0	5.00	5.90	6.40	7.0	
			Placebo	23	20 (87.0)	4.95 (1.36)	1.4	4.40	4.90	5.90	7.0	
		Week 24	Tezepelumab	29	26 (89.7)	5.76 (0.96)	4.0	5.20	6.00	6.60	7.0	
			Placebo	23	20 (87.0)	4.97 (1.34)	2.2	4.30	4.80	6.00	7.0	
		Week 28	Tezepelumab	29	26 (89.7)	5.77 (0.88)	4.0	5.20	6.00	6.40	7.0	
			Placebo	23	21 (91.3)	5.01 (1.51)	2.2	4.00	4.60	6.60	7.0	
		Week 32	Tezepelumab	29	26 (89.7)	5.79 (0.93)	4.0	5.00	6.00	6.40	7.0	
			Placebo	23	21 (91.3)	4.99 (1.51)	1.6	4.20	4.60	6.20	7.0	
		Week 36	Tezepelumab	29	26 (89.7)	5.97 (0.87)	4.0	5.60	6.00	6.60	7.0	
			Placebo	23	21 (91.3)	5.02 (1.61)	1.6	4.40	4.80	6.60	7.0	
		Week 40	Tezepelumab	29	26 (89.7)	5.59 (1.14)	2.6	4.80	5.80	6.60	7.0	
			Placebo	23	21 (91.3)	4.90 (1.68)	1.6	3.60	4.80	6.60	7.0	
		Week 44	Tezepelumab	29	26 (89.7)	5.75 (1.13)	2.6	5.20	6.00	6.60	7.0	
			Placebo	23	21 (91.3)	4.96 (1.72)	1.6	3.60	5.40	6.20	7.0	
		Week 48	Tezepelumab	29	26 (89.7)	5.75 (0.99)	4.0	5.40	6.00	6.40	7.0	
			Placebo	23	21 (91.3)	4.93 (1.66)	1.4	4.00	4.80	6.40	7.0	
		Week 52	Tezepelumab	29	26 (89.7)	5.73 (1.10)	2.8	5.40	6.00	6.40	7.0	
			Placebo	23	21 (91.3)	4.90 (1.57)	1.8	4.00	4.80	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IOSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITT

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	29	24 (82.8)	0.99 (1.11)	-1.6	0.20	1.00	1.80	3.6	0.53 [-0.10, 1.16]
			Placebo	23	17 (73.9)	0.45 (0.90)	-2.0	0.20	0.40	0.60	1.8	
		Week 8	Tezepelumab	29	24 (82.8)	1.25 (1.00)	-1.2	0.60	1.10	2.00	3.6	0.73 [0.08, 1.37]
			Placebo	23	17 (73.9)	0.47 (1.17)	-2.0	0.00	0.80	1.20	2.2	
		Week 12	Tezepelumab	29	24 (82.8)	1.24 (1.19)	-1.6	0.40	1.30	2.10	3.4	0.42 [-0.21, 1.05]
			Placebo	23	17 (73.9)	0.72 (1.32)	-1.8	0.00	0.80	1.60	3.6	
		Week 16	Tezepelumab	29	24 (82.8)	1.35 (1.08)	-1.0	0.50	1.30	1.90	3.4	0.47 [-0.16, 1.10]
			Placebo	23	17 (73.9)	0.79 (1.34)	-1.8	0.20	1.20	1.40	4.0	
		Week 20	Tezepelumab	29	24 (82.8)	1.40 (1.18)	-0.8	0.60	1.10	2.10	4.4	0.60 [-0.04, 1.23]
			Placebo	23	17 (73.9)	0.73 (1.03)	-1.6	0.40	0.80	1.60	2.0	
		Week 24	Tezepelumab	29	24 (82.8)	1.38 (1.22)	-0.8	0.50	1.30	2.50	3.8	0.46 [-0.17, 1.09]
			Placebo	23	17 (73.9)	0.84 (1.13)	-1.0	0.00	1.20	1.60	2.4	
		Week 28	Tezepelumab	29	24 (82.8)	1.41 (1.24)	-0.8	0.60	1.00	2.50	4.2	0.49 [-0.14, 1.12]
			Placebo	23	17 (73.9)	0.78 (1.35)	-1.0	-0.40	1.00	1.60	4.0	
		Week 32	Tezepelumab	29	24 (82.8)	1.41 (1.09)	-1.0	0.70	1.40	2.10	3.6	0.54 [-0.09, 1.18]
			Placebo	23	17 (73.9)	0.76 (1.31)	-1.4	-0.20	1.20	1.80	3.0	
		Week 36	Tezepelumab	29	24 (82.8)	1.63 (1.28)	-0.8	0.70	1.30	2.40	4.4	0.63 [-0.00, 1.27]
			Placebo	23	17 (73.9)	0.75 (1.51)	-2.0	-0.20	1.00	1.60	4.2	
		Week 40	Tezepelumab	29	24 (82.8)	1.19 (1.07)	-1.0	0.60	1.10	1.80	3.2	0.39 [-0.24, 1.01]
			Placebo	23	17 (73.9)	0.68 (1.60)	-2.0	-0.80	0.60	1.60	3.6	
		Week 44	Tezepelumab	29	24 (82.8)	1.35 (1.12)	-1.0	0.60	1.40	2.00	3.8	0.51 [-0.12, 1.14]
			Placebo	23	17 (73.9)	0.64 (1.73)	-1.8	-1.00	1.00	1.80	4.2	
		Week 48	Tezepelumab	29	24 (82.8)	1.38 (1.15)	-0.8	0.50	1.40	2.10	3.8	0.55 [-0.08, 1.19]
			Placebo	23	17 (73.9)	0.66 (1.48)	-2.2	-0.20	0.60	1.60	4.0	
		Week 52	Tezepelumab	29	24 (82.8)	1.34 (1.13)	-0.8	0.50	1.40	2.00	3.8	0.57 [-0.06, 1.21]
			Placebo	23	17 (73.9)	0.65 (1.32)	-1.6	-0.20	0.60	1.40	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOMH0: Course of AQLQ+12 symptom score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	137	123 (89.8)	4.05 (1.00)	1.3	3.50	4.00	4.67	6.8	
		Placebo	138	121 (87.7)	3.98 (0.90)	1.5	3.42	4.00	4.50	6.3	
	Week 4	Tezepelumab	137	126 (92.0)	4.84 (1.06)	1.3	4.08	4.79	5.58	7.0	
		Placebo	138	123 (89.1)	4.55 (0.95)	1.8	3.92	4.58	5.25	6.7	
	Week 8	Tezepelumab	137	128 (93.4)	5.05 (1.08)	2.0	4.21	5.00	5.83	7.0	
		Placebo	138	126 (91.3)	4.62 (1.05)	1.9	4.00	4.50	5.33	7.0	
	Week 12	Tezepelumab	137	128 (93.4)	5.22 (1.07)	2.8	4.33	5.21	6.08	7.0	
		Placebo	138	127 (92.0)	4.75 (1.07)	2.1	4.00	4.67	5.58	7.0	
	Week 16	Tezepelumab	137	128 (93.4)	5.20 (1.10)	2.3	4.33	5.25	6.00	7.0	
		Placebo	138	127 (92.0)	4.77 (1.12)	1.3	4.00	4.67	5.58	7.0	
	Week 20	Tezepelumab	137	129 (94.2)	5.20 (1.07)	2.3	4.33	5.17	6.00	7.0	
		Placebo	138	127 (92.0)	4.79 (1.13)	1.3	4.08	4.75	5.58	7.0	
	Week 24	Tezepelumab	137	129 (94.2)	5.22 (1.08)	1.8	4.42	5.17	6.00	7.0	
		Placebo	138	127 (92.0)	4.82 (1.15)	1.3	4.00	4.67	5.75	7.0	
	Week 28	Tezepelumab	137	131 (95.6)	5.22 (1.05)	3.2	4.42	5.08	6.00	7.0	
		Placebo	138	128 (92.8)	4.85 (1.20)	1.3	4.00	4.75	5.88	7.0	
	Week 32	Tezepelumab	137	132 (96.4)	5.29 (1.07)	2.8	4.38	5.29	6.04	7.0	
		Placebo	138	129 (93.5)	4.91 (1.14)	1.3	4.00	4.92	5.83	7.0	
	Week 36	Tezepelumab	137	132 (96.4)	5.28 (1.07)	2.9	4.50	5.25	6.08	7.0	
		Placebo	138	129 (93.5)	4.93 (1.16)	2.4	4.00	4.83	6.00	7.0	
	Week 40	Tezepelumab	137	132 (96.4)	5.28 (1.09)	2.3	4.42	5.33	6.04	7.0	
		Placebo	138	129 (93.5)	4.96 (1.12)	2.3	4.00	4.92	5.92	7.0	
	Week 44	Tezepelumab	137	132 (96.4)	5.30 (1.09)	2.3	4.46	5.33	6.08	7.0	
		Placebo	138	129 (93.5)	4.93 (1.18)	2.3	4.00	4.75	5.92	7.0	
	Week 48	Tezepelumab	137	132 (96.4)	5.32 (1.09)	2.8	4.46	5.21	6.21	7.0	
		Placebo	138	130 (94.2)	4.96 (1.12)	2.2	4.00	4.88	5.83	7.0	
	Week 52	Tezepelumab	137	132 (96.4)	5.33 (1.08)	2.8	4.50	5.17	6.21	7.0	
		Placebo	138	130 (94.2)	4.94 (1.12)	2.5	4.00	4.83	5.83	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOMH0: Course of AQLQ+12 symptom score
DITT

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	137	117 (85.4)	0.82 (1.02)	-4.3	0.25	0.83	1.50	3.1	0.26 [0.00, 0.52]
		Placebo	138	119 (86.2)	0.57 (0.85)	-1.8	0.08	0.50	1.17	3.3	
	Week 8	Tezepelumab	137	119 (86.9)	0.99 (1.06)	-1.9	0.25	0.92	1.75	4.1	0.33 [0.07, 0.59]
		Placebo	138	120 (87.0)	0.66 (0.94)	-1.8	0.08	0.54	1.17	3.6	
	Week 12	Tezepelumab	137	119 (86.9)	1.15 (1.10)	-2.6	0.33	1.08	2.00	4.5	0.32 [0.06, 0.58]
		Placebo	138	120 (87.0)	0.79 (1.17)	-3.1	0.13	0.79	1.25	4.0	
	Week 16	Tezepelumab	137	119 (86.9)	1.14 (1.10)	-2.9	0.42	1.08	2.00	4.6	0.29 [0.04, 0.55]
		Placebo	138	120 (87.0)	0.81 (1.17)	-3.5	0.17	0.92	1.42	4.2	
	Week 20	Tezepelumab	137	119 (86.9)	1.16 (1.10)	-1.8	0.33	1.00	2.00	4.7	0.29 [0.03, 0.54]
		Placebo	138	120 (87.0)	0.84 (1.12)	-3.5	0.21	0.83	1.33	3.8	
	Week 24	Tezepelumab	137	119 (86.9)	1.21 (1.11)	-1.6	0.42	1.08	2.08	4.8	0.29 [0.03, 0.54]
		Placebo	138	120 (87.0)	0.88 (1.18)	-3.5	0.17	0.83	1.42	4.1	
	Week 28	Tezepelumab	137	119 (86.9)	1.17 (1.10)	-1.7	0.42	1.00	2.00	4.9	0.24 [-0.02, 0.49]
		Placebo	138	120 (87.0)	0.89 (1.24)	-3.5	0.17	0.83	1.54	4.7	
	Week 32	Tezepelumab	137	119 (86.9)	1.24 (1.16)	-1.6	0.42	1.08	2.08	4.8	0.23 [-0.03, 0.48]
		Placebo	138	120 (87.0)	0.98 (1.13)	-3.5	0.33	1.00	1.50	4.0	
	Week 36	Tezepelumab	137	119 (86.9)	1.21 (1.19)	-1.7	0.33	1.08	2.08	4.8	0.19 [-0.06, 0.45]
		Placebo	138	120 (87.0)	0.99 (1.15)	-3.0	0.25	1.00	1.67	3.8	
	Week 40	Tezepelumab	137	119 (86.9)	1.23 (1.13)	-1.7	0.42	1.08	2.08	4.8	0.18 [-0.07, 0.44]
		Placebo	138	120 (87.0)	1.02 (1.16)	-3.0	0.33	1.00	1.63	4.7	
	Week 44	Tezepelumab	137	119 (86.9)	1.25 (1.14)	-1.8	0.50	1.17	2.08	4.8	0.24 [-0.02, 0.49]
		Placebo	138	120 (87.0)	0.98 (1.19)	-3.0	0.21	1.00	1.67	4.3	
	Week 48	Tezepelumab	137	119 (86.9)	1.29 (1.12)	-1.6	0.42	1.17	2.08	4.8	0.24 [-0.01, 0.50]
		Placebo	138	120 (87.0)	1.01 (1.13)	-3.0	0.25	1.08	1.67	4.2	
	Week 52	Tezepelumab	137	119 (86.9)	1.27 (1.12)	-1.6	0.42	1.08	2.17	4.8	0.25 [-0.01, 0.50]
		Placebo	138	120 (87.0)	0.99 (1.12)	-3.0	0.25	0.88	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
DITT

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	137	117 (85.4)	0.83 (0.08)	(0.68, 0.99)	0.29 (0.11)	(0.07, 0.51)	0.011 *
	Placebo	138	118 (85.5)	0.54 (0.08)	(0.39, 0.70)			
Week 8	Tezepelumab	137	117 (85.4)	1.01 (0.09)	(0.84, 1.17)	0.36 (0.12)	(0.13, 0.60)	0.003 *
	Placebo	138	119 (86.2)	0.64 (0.08)	(0.48, 0.81)			
Week 12	Tezepelumab	137	116 (84.7)	1.18 (0.09)	(0.99, 1.36)	0.39 (0.13)	(0.13, 0.65)	0.003 *
	Placebo	138	115 (83.3)	0.78 (0.09)	(0.60, 0.96)			
Week 16	Tezepelumab	137	112 (81.8)	1.16 (0.09)	(0.98, 1.35)	0.38 (0.13)	(0.12, 0.64)	0.005 *
	Placebo	138	112 (81.2)	0.79 (0.09)	(0.60, 0.97)			
Week 20	Tezepelumab	137	107 (78.1)	1.21 (0.09)	(1.03, 1.38)	0.35 (0.13)	(0.10, 0.59)	0.006 *
	Placebo	138	109 (79.0)	0.86 (0.09)	(0.69, 1.04)			
Week 24	Tezepelumab	137	105 (76.6)	1.26 (0.09)	(1.07, 1.45)	0.38 (0.13)	(0.12, 0.64)	0.005 *
	Placebo	138	106 (76.8)	0.88 (0.09)	(0.70, 1.07)			
Week 28	Tezepelumab	137	101 (73.7)	1.21 (0.10)	(1.02, 1.41)	0.31 (0.14)	(0.03, 0.58)	0.028 *
	Placebo	138	105 (76.1)	0.91 (0.10)	(0.71, 1.10)			
Week 32	Tezepelumab	137	104 (75.9)	1.29 (0.09)	(1.10, 1.47)	0.28 (0.13)	(0.03, 0.54)	0.030 *
	Placebo	138	104 (75.4)	1.00 (0.09)	(0.82, 1.18)			
Week 36	Tezepelumab	137	104 (75.9)	1.27 (0.10)	(1.07, 1.46)	0.25 (0.14)	(-0.02, 0.52)	0.067
	Placebo	138	103 (74.6)	1.01 (0.10)	(0.82, 1.20)			
Week 40	Tezepelumab	137	104 (75.9)	1.28 (0.10)	(1.09, 1.46)	0.23 (0.13)	(-0.03, 0.50)	0.084
	Placebo	138	105 (76.1)	1.04 (0.09)	(0.85, 1.23)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
DITT

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	137	102 (74.5)	1.31 (0.10)	(1.11, 1.50)	0.34 (0.14)	(0.07, 0.62)	0.015 *
	Placebo	138	103 (74.6)	0.97 (0.10)	(0.77, 1.16)			
Week 48	Tezepelumab	137	97 (70.8)	1.35 (0.09)	(1.16, 1.54)	0.32 (0.13)	(0.06, 0.58)	0.018 *
	Placebo	138	105 (76.1)	1.03 (0.09)	(0.85, 1.22)			
Week 52	Tezepelumab	137	41 (29.9)	1.27 (0.11)	(1.06, 1.49)	0.29 (0.15)	(-0.01, 0.59)	0.059
	Placebo	138	47 (34.1)	0.98 (0.11)	(0.77, 1.19)			

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QMC_IOMG0: Course of AQLQ+12 symptom score
DITT



Note: DITT = Dossier Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QMC_IOMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	50	42 (84.0)	4.12 (1.05)	1.9	3.50	4.08	4.75	6.8	
			Placebo	44	41 (93.2)	4.03 (0.83)	1.7	3.67	4.00	4.50	5.7	
		Week 4	Tezepelumab	50	46 (92.0)	4.96 (1.17)	2.6	3.92	4.92	6.00	6.9	
			Placebo	44	41 (93.2)	4.55 (0.99)	2.6	3.92	4.58	5.25	6.4	
		Week 8	Tezepelumab	50	46 (92.0)	5.11 (1.13)	3.0	4.08	5.08	6.08	7.0	
			Placebo	44	42 (95.5)	4.64 (1.01)	2.1	4.00	4.50	5.42	6.5	
		Week 12	Tezepelumab	50	46 (92.0)	5.26 (1.11)	2.8	4.25	5.33	6.08	7.0	
			Placebo	44	42 (95.5)	4.81 (1.08)	2.1	4.00	4.96	5.67	6.8	
		Week 16	Tezepelumab	50	46 (92.0)	5.22 (1.14)	3.0	4.33	5.21	6.08	7.0	
			Placebo	44	42 (95.5)	4.75 (1.13)	1.3	4.00	4.58	5.58	6.7	
		Week 20	Tezepelumab	50	46 (92.0)	5.27 (1.15)	2.3	4.33	5.17	6.08	7.0	
			Placebo	44	42 (95.5)	4.78 (1.17)	1.3	4.00	4.88	5.67	6.8	
		Week 24	Tezepelumab	50	46 (92.0)	5.29 (1.14)	3.1	4.42	5.21	6.08	7.0	
			Placebo	44	42 (95.5)	4.84 (1.26)	1.3	4.00	5.04	5.92	7.0	
		Week 28	Tezepelumab	50	47 (94.0)	5.28 (1.14)	3.2	4.42	5.33	6.08	7.0	
			Placebo	44	43 (97.7)	4.84 (1.31)	1.3	4.00	5.08	6.00	7.0	
		Week 32	Tezepelumab	50	48 (96.0)	5.36 (1.15)	2.8	4.42	5.46	6.29	7.0	
			Placebo	44	43 (97.7)	4.93 (1.21)	1.3	4.00	5.17	6.00	6.8	
		Week 36	Tezepelumab	50	48 (96.0)	5.35 (1.19)	2.9	4.42	5.38	6.42	7.0	
			Placebo	44	43 (97.7)	4.95 (1.25)	2.4	4.00	5.08	6.00	7.0	
		Week 40	Tezepelumab	50	48 (96.0)	5.34 (1.14)	2.9	4.42	5.50	6.38	7.0	
			Placebo	44	43 (97.7)	4.97 (1.15)	2.3	4.00	5.17	6.00	7.0	
		Week 44	Tezepelumab	50	48 (96.0)	5.38 (1.26)	2.3	4.58	5.50	6.54	7.0	
			Placebo	44	43 (97.7)	5.02 (1.25)	2.5	4.00	5.17	6.00	7.0	
		Week 48	Tezepelumab	50	48 (96.0)	5.37 (1.16)	3.1	4.50	5.17	6.38	7.0	
			Placebo	44	43 (97.7)	5.09 (1.19)	2.2	4.00	5.17	5.92	7.0	
		Week 52	Tezepelumab	50	48 (96.0)	5.33 (1.17)	3.0	4.50	5.17	6.42	7.0	
			Placebo	44	43 (97.7)	5.05 (1.19)	2.8	4.00	5.17	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	50	41 (82.0)	0.84 (0.92)	-0.8	0.25	0.58	1.50	2.9	0.28 [-0.16, 0.72]
			Placebo	44	40 (90.9)	0.58 (0.94)	-1.8	0.08	0.50	1.29	3.1	
		Week 8	Tezepelumab	50	41 (82.0)	0.99 (1.02)	-0.6	0.25	0.92	1.50	4.1	0.36 [-0.08, 0.79]
			Placebo	44	41 (93.2)	0.64 (0.92)	-0.8	0.08	0.42	1.25	3.6	
		Week 12	Tezepelumab	50	41 (82.0)	1.13 (1.08)	-0.8	0.33	0.92	1.92	4.5	0.29 [-0.15, 0.72]
			Placebo	44	41 (93.2)	0.81 (1.15)	-1.6	0.08	0.83	1.25	3.8	
		Week 16	Tezepelumab	50	41 (82.0)	1.12 (1.06)	-0.9	0.42	1.00	1.67	4.6	0.34 [-0.10, 0.77]
			Placebo	44	41 (93.2)	0.74 (1.18)	-3.5	0.17	0.67	1.58	3.7	
		Week 20	Tezepelumab	50	41 (82.0)	1.14 (1.09)	-0.5	0.33	1.00	1.92	4.6	0.33 [-0.11, 0.76]
			Placebo	44	41 (93.2)	0.78 (1.14)	-3.5	0.25	0.83	1.25	3.8	
		Week 24	Tezepelumab	50	41 (82.0)	1.22 (1.07)	-0.4	0.50	1.00	1.92	4.8	0.32 [-0.12, 0.76]
			Placebo	44	41 (93.2)	0.84 (1.29)	-3.5	0.25	0.83	1.50	3.9	
		Week 28	Tezepelumab	50	41 (82.0)	1.21 (1.10)	-0.4	0.58	0.92	2.00	4.8	0.35 [-0.09, 0.78]
			Placebo	44	41 (93.2)	0.78 (1.34)	-3.5	0.08	0.75	1.67	3.8	
		Week 32	Tezepelumab	50	41 (82.0)	1.25 (1.12)	-0.8	0.67	1.08	1.92	4.8	0.31 [-0.12, 0.75]
			Placebo	44	41 (93.2)	0.89 (1.20)	-3.5	0.25	1.00	1.58	3.4	
		Week 36	Tezepelumab	50	41 (82.0)	1.21 (1.24)	-0.9	0.33	1.00	2.08	4.8	0.25 [-0.18, 0.69]
			Placebo	44	41 (93.2)	0.90 (1.19)	-2.3	0.00	1.08	1.67	3.8	
		Week 40	Tezepelumab	50	41 (82.0)	1.25 (1.12)	-0.8	0.58	1.08	2.00	4.8	0.29 [-0.14, 0.73]
			Placebo	44	41 (93.2)	0.92 (1.12)	-1.4	0.25	0.92	1.67	3.7	
		Week 44	Tezepelumab	50	41 (82.0)	1.28 (1.21)	-1.8	0.58	1.17	2.08	4.8	0.26 [-0.18, 0.69]
			Placebo	44	41 (93.2)	0.97 (1.18)	-1.3	0.08	1.08	1.67	3.8	
		Week 48	Tezepelumab	50	41 (82.0)	1.30 (1.14)	-0.7	0.58	1.08	2.00	4.8	0.22 [-0.21, 0.66]
			Placebo	44	41 (93.2)	1.04 (1.15)	-1.5	0.08	1.00	1.67	3.8	
		Week 52	Tezepelumab	50	41 (82.0)	1.21 (1.15)	-0.7	0.42	0.92	1.67	4.8	0.18 [-0.26, 0.61]
			Placebo	44	41 (93.2)	1.01 (1.13)	-1.1	0.17	0.92	1.67	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	87	81 (93.1)	4.01 (0.98)	1.3	3.50	4.00	4.58	6.7	
			Placebo	94	80 (85.1)	3.95 (0.94)	1.5	3.42	4.04	4.54	6.3	
		Week 4	Tezepelumab	87	80 (92.0)	4.77 (0.99)	1.3	4.08	4.75	5.38	7.0	
			Placebo	94	82 (87.2)	4.54 (0.94)	1.8	4.00	4.58	5.17	6.7	
		Week 8	Tezepelumab	87	82 (94.3)	5.02 (1.06)	2.0	4.25	5.00	5.83	7.0	
			Placebo	94	84 (89.4)	4.61 (1.07)	1.9	4.00	4.50	5.29	7.0	
		Week 12	Tezepelumab	87	82 (94.3)	5.20 (1.06)	3.0	4.33	5.13	6.08	7.0	
			Placebo	94	85 (90.4)	4.73 (1.07)	2.4	4.00	4.67	5.50	7.0	
		Week 16	Tezepelumab	87	82 (94.3)	5.19 (1.09)	2.3	4.33	5.33	6.00	7.0	
			Placebo	94	85 (90.4)	4.78 (1.12)	2.1	4.00	4.75	5.50	7.0	
		Week 20	Tezepelumab	87	83 (95.4)	5.17 (1.02)	3.4	4.25	5.17	5.92	7.0	
			Placebo	94	85 (90.4)	4.80 (1.11)	2.1	4.08	4.67	5.50	7.0	
		Week 24	Tezepelumab	87	83 (95.4)	5.19 (1.05)	1.8	4.42	5.17	5.92	7.0	
			Placebo	94	85 (90.4)	4.81 (1.10)	2.1	4.00	4.67	5.50	7.0	
		Week 28	Tezepelumab	87	84 (96.6)	5.19 (1.00)	3.6	4.42	5.00	5.88	7.0	
			Placebo	94	85 (90.4)	4.86 (1.15)	1.8	4.00	4.75	5.75	7.0	
		Week 32	Tezepelumab	87	84 (96.6)	5.25 (1.03)	2.8	4.38	5.17	6.00	7.0	
			Placebo	94	86 (91.5)	4.90 (1.11)	2.1	4.08	4.83	5.75	7.0	
		Week 36	Tezepelumab	87	84 (96.6)	5.25 (1.01)	3.2	4.50	5.21	5.92	7.0	
			Placebo	94	86 (91.5)	4.93 (1.12)	2.5	4.08	4.71	6.00	7.0	
		Week 40	Tezepelumab	87	84 (96.6)	5.25 (1.06)	2.3	4.50	5.29	5.92	7.0	
			Placebo	94	86 (91.5)	4.96 (1.12)	2.4	4.00	4.83	5.92	7.0	
		Week 44	Tezepelumab	87	84 (96.6)	5.26 (0.99)	3.2	4.42	5.33	5.88	7.0	
			Placebo	94	86 (91.5)	4.88 (1.15)	2.3	4.00	4.75	5.92	7.0	
		Week 48	Tezepelumab	87	84 (96.6)	5.29 (1.06)	2.8	4.42	5.25	6.17	7.0	
			Placebo	94	87 (92.6)	4.90 (1.08)	2.4	4.00	4.83	5.75	7.0	
		Week 52	Tezepelumab	87	84 (96.6)	5.32 (1.03)	2.8	4.54	5.21	6.17	7.0	
			Placebo	94	87 (92.6)	4.89 (1.09)	2.5	4.00	4.75	5.83	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	87	76 (87.4)	0.81 (1.08)	-4.3	0.13	0.83	1.42	3.1	0.25 [-0.07, 0.56]
			Placebo	94	79 (84.0)	0.57 (0.81)	-1.3	0.17	0.50	1.08	3.3	
		Week 8	Tezepelumab	87	78 (89.7)	0.99 (1.09)	-1.9	0.25	0.96	1.83	3.3	0.32 [0.00, 0.63]
			Placebo	94	79 (84.0)	0.67 (0.95)	-1.8	0.08	0.58	1.17	3.3	
		Week 12	Tezepelumab	87	78 (89.7)	1.17 (1.12)	-2.6	0.42	1.13	2.00	3.7	0.34 [0.02, 0.65]
			Placebo	94	79 (84.0)	0.78 (1.19)	-3.1	0.17	0.75	1.25	4.0	
		Week 16	Tezepelumab	87	78 (89.7)	1.16 (1.13)	-2.9	0.42	1.25	2.08	3.4	0.27 [-0.04, 0.58]
			Placebo	94	79 (84.0)	0.84 (1.18)	-3.1	0.17	0.92	1.42	4.2	
		Week 20	Tezepelumab	87	78 (89.7)	1.17 (1.11)	-1.8	0.42	1.04	2.00	4.7	0.26 [-0.05, 0.58]
			Placebo	94	79 (84.0)	0.87 (1.11)	-3.0	0.17	0.83	1.33	3.8	
		Week 24	Tezepelumab	87	78 (89.7)	1.20 (1.14)	-1.6	0.42	1.21	2.17	3.7	0.27 [-0.05, 0.58]
			Placebo	94	79 (84.0)	0.89 (1.12)	-3.0	0.17	0.83	1.42	4.1	
		Week 28	Tezepelumab	87	78 (89.7)	1.15 (1.11)	-1.7	0.42	1.00	2.00	4.9	0.18 [-0.14, 0.49]
			Placebo	94	79 (84.0)	0.95 (1.19)	-3.0	0.17	0.83	1.50	4.7	
		Week 32	Tezepelumab	87	78 (89.7)	1.23 (1.18)	-1.6	0.42	1.13	2.17	4.6	0.18 [-0.13, 0.50]
			Placebo	94	79 (84.0)	1.02 (1.09)	-3.0	0.33	1.00	1.50	4.0	
		Week 36	Tezepelumab	87	78 (89.7)	1.22 (1.17)	-1.7	0.33	1.29	2.08	3.8	0.16 [-0.15, 0.47]
			Placebo	94	79 (84.0)	1.03 (1.12)	-3.0	0.25	1.00	1.67	3.8	
		Week 40	Tezepelumab	87	78 (89.7)	1.22 (1.14)	-1.7	0.33	1.08	2.08	3.3	0.13 [-0.19, 0.44]
			Placebo	94	79 (84.0)	1.07 (1.18)	-3.0	0.42	1.00	1.58	4.7	
		Week 44	Tezepelumab	87	78 (89.7)	1.24 (1.11)	-1.6	0.42	1.17	2.08	3.3	0.22 [-0.09, 0.54]
			Placebo	94	79 (84.0)	0.98 (1.20)	-3.0	0.33	1.00	1.58	4.3	
		Week 48	Tezepelumab	87	78 (89.7)	1.28 (1.11)	-1.6	0.42	1.33	2.08	3.4	0.25 [-0.06, 0.56]
			Placebo	94	79 (84.0)	1.00 (1.13)	-3.0	0.25	1.08	1.58	4.2	
		Week 52	Tezepelumab	87	78 (89.7)	1.30 (1.11)	-1.6	0.42	1.25	2.17	3.4	0.28 [-0.03, 0.60]
			Placebo	94	79 (84.0)	0.99 (1.12)	-3.0	0.25	0.83	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	114	103 (90.4)	4.04 (1.05)	1.3	3.50	4.08	4.67	6.8	
			Placebo	118	105 (89.0)	3.92 (0.93)	1.5	3.42	4.00	4.50	6.3	
		Week 4	Tezepelumab	114	106 (93.0)	4.83 (1.09)	1.3	3.92	4.79	5.58	7.0	
			Placebo	118	106 (89.8)	4.56 (0.95)	1.8	4.00	4.58	5.25	6.7	
		Week 8	Tezepelumab	114	108 (94.7)	5.08 (1.11)	2.0	4.17	5.04	5.88	7.0	
			Placebo	118	109 (92.4)	4.63 (1.08)	1.9	4.00	4.50	5.33	7.0	
		Week 12	Tezepelumab	114	108 (94.7)	5.26 (1.09)	2.8	4.29	5.33	6.25	7.0	
			Placebo	118	110 (93.2)	4.79 (1.12)	2.1	4.00	4.88	5.67	7.0	
		Week 16	Tezepelumab	114	108 (94.7)	5.23 (1.13)	2.3	4.33	5.33	6.08	7.0	
			Placebo	118	110 (93.2)	4.79 (1.15)	1.3	4.00	4.75	5.58	7.0	
		Week 20	Tezepelumab	114	108 (94.7)	5.24 (1.09)	2.3	4.38	5.25	6.04	7.0	
			Placebo	118	110 (93.2)	4.81 (1.15)	1.3	4.08	4.75	5.67	7.0	
		Week 24	Tezepelumab	114	108 (94.7)	5.27 (1.10)	1.8	4.42	5.25	6.00	7.0	
			Placebo	118	110 (93.2)	4.85 (1.16)	1.3	4.00	4.67	5.92	7.0	
		Week 28	Tezepelumab	114	110 (96.5)	5.24 (1.08)	3.2	4.42	5.13	6.08	7.0	
			Placebo	118	110 (93.2)	4.86 (1.20)	1.3	4.00	4.83	5.92	7.0	
		Week 32	Tezepelumab	114	111 (97.4)	5.31 (1.11)	2.8	4.42	5.42	6.08	7.0	
			Placebo	118	111 (94.1)	4.91 (1.14)	1.3	4.00	5.00	5.83	7.0	
		Week 36	Tezepelumab	114	111 (97.4)	5.30 (1.11)	2.9	4.50	5.33	6.08	7.0	
			Placebo	118	111 (94.1)	4.93 (1.16)	2.4	4.00	4.83	6.00	7.0	
		Week 40	Tezepelumab	114	111 (97.4)	5.30 (1.13)	2.3	4.42	5.33	6.08	7.0	
			Placebo	118	111 (94.1)	4.97 (1.11)	2.3	4.00	4.92	6.00	7.0	
		Week 44	Tezepelumab	114	111 (97.4)	5.32 (1.13)	2.3	4.50	5.33	6.25	7.0	
			Placebo	118	111 (94.1)	4.93 (1.17)	2.3	4.00	4.83	5.92	7.0	
		Week 48	Tezepelumab	114	111 (97.4)	5.32 (1.13)	2.8	4.42	5.17	6.25	7.0	
			Placebo	118	112 (94.9)	4.96 (1.10)	2.2	4.00	4.92	5.79	7.0	
		Week 52	Tezepelumab	114	111 (97.4)	5.31 (1.11)	2.8	4.50	5.17	6.17	7.0	
			Placebo	118	112 (94.9)	4.96 (1.12)	2.5	4.00	4.83	5.88	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	114	99 (86.8)	0.81 (1.04)	-4.3	0.17	0.75	1.50	3.1	0.18 [-0.09, 0.46]
			Placebo	118	103 (87.3)	0.63 (0.85)	-1.3	0.17	0.50	1.25	3.3	
		Week 8	Tezepelumab	114	101 (88.6)	1.00 (1.08)	-1.9	0.25	1.00	1.75	4.1	0.28 [0.00, 0.55]
			Placebo	118	104 (88.1)	0.71 (0.97)	-1.8	0.13	0.58	1.25	3.6	
		Week 12	Tezepelumab	114	101 (88.6)	1.19 (1.13)	-2.6	0.42	1.08	2.00	4.5	0.26 [-0.01, 0.54]
			Placebo	118	104 (88.1)	0.88 (1.22)	-3.1	0.29	0.88	1.42	4.0	
		Week 16	Tezepelumab	114	101 (88.6)	1.17 (1.12)	-2.9	0.42	1.08	2.00	4.6	0.24 [-0.03, 0.52]
			Placebo	118	104 (88.1)	0.88 (1.22)	-3.5	0.29	0.92	1.54	4.2	
		Week 20	Tezepelumab	114	101 (88.6)	1.19 (1.13)	-1.8	0.33	1.08	2.00	4.7	0.24 [-0.03, 0.52]
			Placebo	118	104 (88.1)	0.91 (1.15)	-3.5	0.25	0.92	1.58	3.8	
		Week 24	Tezepelumab	114	101 (88.6)	1.24 (1.13)	-1.6	0.42	1.17	2.08	4.8	0.24 [-0.03, 0.52]
			Placebo	118	104 (88.1)	0.96 (1.21)	-3.5	0.25	0.88	1.54	4.1	
		Week 28	Tezepelumab	114	101 (88.6)	1.19 (1.13)	-1.7	0.42	1.00	2.00	4.9	0.18 [-0.09, 0.46]
			Placebo	118	104 (88.1)	0.97 (1.27)	-3.5	0.25	0.88	1.67	4.7	
		Week 32	Tezepelumab	114	101 (88.6)	1.26 (1.20)	-1.6	0.50	1.08	2.17	4.8	0.18 [-0.10, 0.45]
			Placebo	118	104 (88.1)	1.05 (1.16)	-3.5	0.33	1.00	1.67	4.0	
		Week 36	Tezepelumab	114	101 (88.6)	1.24 (1.22)	-1.7	0.33	1.08	2.17	4.8	0.16 [-0.12, 0.43]
			Placebo	118	104 (88.1)	1.05 (1.18)	-3.0	0.29	1.08	1.71	3.8	
		Week 40	Tezepelumab	114	101 (88.6)	1.25 (1.15)	-1.7	0.42	1.08	2.17	4.8	0.12 [-0.15, 0.40]
			Placebo	118	104 (88.1)	1.10 (1.18)	-3.0	0.46	1.13	1.75	4.7	
		Week 44	Tezepelumab	114	101 (88.6)	1.26 (1.16)	-1.8	0.58	1.17	2.08	4.8	0.18 [-0.09, 0.46]
			Placebo	118	104 (88.1)	1.05 (1.21)	-3.0	0.33	1.00	1.67	4.3	
		Week 48	Tezepelumab	114	101 (88.6)	1.28 (1.14)	-1.6	0.42	1.08	2.08	4.8	0.17 [-0.10, 0.45]
			Placebo	118	104 (88.1)	1.08 (1.15)	-3.0	0.33	1.08	1.67	4.2	
		Week 52	Tezepelumab	114	101 (88.6)	1.26 (1.13)	-1.6	0.42	1.08	2.08	4.8	0.17 [-0.11, 0.44]
			Placebo	118	104 (88.1)	1.07 (1.15)	-3.0	0.29	0.92	1.71	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	4.11 (0.74)	3.2	3.75	4.00	4.58	6.3	
			Placebo	20	16 (80.0)	4.34 (0.58)	3.3	4.08	4.29	4.67	5.4	
		Week 4	Tezepelumab	23	20 (87.0)	4.92 (0.90)	3.6	4.08	4.83	5.63	6.8	
			Placebo	20	17 (85.0)	4.46 (1.00)	2.6	3.42	4.58	5.25	5.9	
		Week 8	Tezepelumab	23	20 (87.0)	4.94 (0.93)	3.9	4.25	4.63	5.46	7.0	
			Placebo	20	17 (85.0)	4.58 (0.84)	3.2	3.92	4.58	5.33	5.8	
		Week 12	Tezepelumab	23	20 (87.0)	5.00 (0.95)	3.2	4.33	5.08	5.54	7.0	
			Placebo	20	17 (85.0)	4.49 (0.70)	3.2	4.08	4.42	5.08	5.8	
		Week 16	Tezepelumab	23	20 (87.0)	5.03 (0.94)	3.4	4.33	5.17	5.50	7.0	
			Placebo	20	17 (85.0)	4.65 (0.93)	3.4	4.00	4.33	5.50	6.4	
		Week 20	Tezepelumab	23	21 (91.3)	5.01 (0.92)	3.4	4.25	5.00	5.67	7.0	
			Placebo	20	17 (85.0)	4.67 (1.01)	2.4	4.00	4.67	5.42	6.3	
		Week 24	Tezepelumab	23	21 (91.3)	5.00 (0.96)	3.4	4.33	4.83	5.33	7.0	
			Placebo	20	17 (85.0)	4.64 (1.05)	2.2	4.00	4.75	5.33	6.4	
		Week 28	Tezepelumab	23	21 (91.3)	5.10 (0.88)	3.8	4.33	5.00	5.58	7.0	
			Placebo	20	18 (90.0)	4.81 (1.24)	1.8	4.08	4.71	5.58	6.8	
		Week 32	Tezepelumab	23	21 (91.3)	5.20 (0.83)	4.0	4.33	5.08	5.92	7.0	
			Placebo	20	18 (90.0)	4.89 (1.14)	2.9	3.83	4.79	5.83	6.8	
		Week 36	Tezepelumab	23	21 (91.3)	5.21 (0.85)	4.1	4.50	5.08	6.00	6.7	
			Placebo	20	18 (90.0)	4.98 (1.21)	2.8	4.17	4.63	6.42	6.9	
		Week 40	Tezepelumab	23	21 (91.3)	5.19 (0.86)	4.0	4.33	5.33	5.83	7.0	
			Placebo	20	18 (90.0)	4.89 (1.22)	2.5	4.00	4.75	5.83	7.0	
		Week 44	Tezepelumab	23	21 (91.3)	5.25 (0.92)	4.0	4.33	5.08	6.08	7.0	
			Placebo	20	18 (90.0)	4.93 (1.26)	2.5	4.08	4.71	6.17	6.9	
		Week 48	Tezepelumab	23	21 (91.3)	5.34 (0.86)	4.0	4.67	5.42	6.00	7.0	
			Placebo	20	18 (90.0)	4.95 (1.25)	2.4	4.00	4.75	6.08	6.9	
		Week 52	Tezepelumab	23	21 (91.3)	5.42 (0.90)	4.0	4.75	5.17	6.25	7.0	
			Placebo	20	18 (90.0)	4.87 (1.14)	3.3	4.00	4.50	5.83	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	23	18 (78.3)	0.88 (0.93)	-0.8	0.25	0.88	1.33	2.8	0.80 [0.10, 1.50]
			Placebo	20	16 (80.0)	0.20 (0.76)	-1.8	0.04	0.42	0.75	1.0	
		Week 8	Tezepelumab	23	18 (78.3)	0.94 (0.95)	-0.6	0.25	0.63	1.50	3.0	0.77 [0.07, 1.47]
			Placebo	20	16 (80.0)	0.31 (0.64)	-0.9	-0.12	0.33	0.71	1.3	
		Week 12	Tezepelumab	23	18 (78.3)	0.96 (0.98)	-0.7	0.33	0.88	1.33	3.0	0.93 [0.22, 1.64]
			Placebo	20	16 (80.0)	0.21 (0.57)	-0.7	-0.25	0.29	0.63	1.1	
		Week 16	Tezepelumab	23	18 (78.3)	1.01 (0.99)	-0.4	0.33	0.88	1.58	3.0	0.77 [0.07, 1.47]
			Placebo	20	16 (80.0)	0.35 (0.70)	-1.2	-0.04	0.38	0.88	1.3	
		Week 20	Tezepelumab	23	18 (78.3)	0.98 (0.93)	-0.4	0.33	0.79	1.58	3.0	0.71 [0.01, 1.40]
			Placebo	20	16 (80.0)	0.39 (0.71)	-1.1	-0.08	0.46	0.88	1.5	
		Week 24	Tezepelumab	23	18 (78.3)	1.02 (1.00)	-0.4	0.42	0.92	1.42	3.0	0.73 [0.03, 1.43]
			Placebo	20	16 (80.0)	0.36 (0.80)	-1.3	-0.13	0.58	0.88	1.5	
		Week 28	Tezepelumab	23	18 (78.3)	1.10 (0.95)	-0.3	0.42	0.88	1.58	3.0	0.77 [0.07, 1.46]
			Placebo	20	16 (80.0)	0.40 (0.86)	-1.8	-0.17	0.54	1.04	1.6	
		Week 32	Tezepelumab	23	18 (78.3)	1.13 (0.89)	-0.3	0.42	1.13	1.75	3.0	0.76 [0.06, 1.46]
			Placebo	20	16 (80.0)	0.50 (0.75)	-0.8	-0.08	0.79	1.08	1.5	
		Week 36	Tezepelumab	23	18 (78.3)	1.08 (0.98)	-0.9	0.42	1.17	1.58	3.2	0.54 [-0.14, 1.23]
			Placebo	20	16 (80.0)	0.59 (0.83)	-0.8	0.04	0.33	1.25	2.3	
		Week 40	Tezepelumab	23	18 (78.3)	1.14 (1.04)	-0.8	0.25	1.00	1.58	3.4	0.68 [-0.01, 1.38]
			Placebo	20	16 (80.0)	0.48 (0.85)	-1.0	-0.13	0.63	1.25	1.6	
		Week 44	Tezepelumab	23	18 (78.3)	1.18 (1.07)	-0.8	0.33	1.13	1.83	3.3	0.67 [-0.02, 1.36]
			Placebo	20	16 (80.0)	0.51 (0.93)	-1.3	-0.25	0.42	1.29	1.9	
		Week 48	Tezepelumab	23	18 (78.3)	1.31 (1.06)	-0.7	0.50	1.25	2.17	3.2	0.79 [0.09, 1.49]
			Placebo	20	16 (80.0)	0.54 (0.88)	-1.1	-0.17	0.38	1.42	1.8	
		Week 52	Tezepelumab	23	18 (78.3)	1.31 (1.13)	-0.7	0.50	1.17	2.25	3.6	0.90 [0.19, 1.61]
			Placebo	20	16 (80.0)	0.47 (0.66)	-0.7	-0.13	0.38	0.96	1.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	105	94 (89.5)	4.13 (0.92)	2.0	3.58	4.00	4.67	6.8	
			Placebo	110	98 (89.1)	3.99 (0.87)	1.7	3.50	4.08	4.50	5.9	
		Week 4	Tezepelumab	105	96 (91.4)	4.85 (1.02)	2.6	4.08	4.75	5.58	7.0	
			Placebo	110	100 (90.9)	4.55 (0.96)	1.8	3.96	4.58	5.25	6.7	
		Week 8	Tezepelumab	105	97 (92.4)	5.06 (1.02)	2.7	4.25	4.92	5.83	7.0	
			Placebo	110	102 (92.7)	4.66 (1.04)	2.1	4.00	4.50	5.42	7.0	
		Week 12	Tezepelumab	105	97 (92.4)	5.22 (1.07)	2.8	4.33	5.17	6.08	7.0	
			Placebo	110	103 (93.6)	4.74 (1.06)	2.4	4.00	4.67	5.50	7.0	
		Week 16	Tezepelumab	105	97 (92.4)	5.19 (1.04)	3.3	4.33	5.17	5.92	7.0	
			Placebo	110	103 (93.6)	4.79 (1.04)	2.2	4.08	4.67	5.58	7.0	
		Week 20	Tezepelumab	105	98 (93.3)	5.19 (1.05)	3.3	4.33	5.08	6.00	7.0	
			Placebo	110	103 (93.6)	4.86 (1.03)	2.3	4.17	4.75	5.58	7.0	
		Week 24	Tezepelumab	105	98 (93.3)	5.19 (1.09)	1.8	4.42	5.08	6.00	7.0	
			Placebo	110	103 (93.6)	4.91 (1.07)	2.1	4.08	4.75	5.75	7.0	
		Week 28	Tezepelumab	105	99 (94.3)	5.17 (1.03)	3.2	4.42	5.00	6.00	7.0	
			Placebo	110	104 (94.5)	4.93 (1.12)	1.8	4.04	4.83	5.75	7.0	
		Week 32	Tezepelumab	105	100 (95.2)	5.26 (1.08)	2.8	4.33	5.13	6.04	7.0	
			Placebo	110	104 (94.5)	4.97 (1.07)	2.1	4.08	4.96	5.83	7.0	
		Week 36	Tezepelumab	105	100 (95.2)	5.27 (1.08)	2.9	4.42	5.13	6.13	7.0	
			Placebo	110	104 (94.5)	5.07 (1.10)	2.5	4.17	5.08	6.00	7.0	
		Week 40	Tezepelumab	105	100 (95.2)	5.28 (1.09)	2.3	4.42	5.21	6.00	7.0	
			Placebo	110	104 (94.5)	5.04 (1.08)	2.4	4.13	4.96	6.00	7.0	
		Week 44	Tezepelumab	105	100 (95.2)	5.28 (1.09)	2.3	4.46	5.25	6.08	7.0	
			Placebo	110	104 (94.5)	5.05 (1.16)	2.3	4.08	5.00	6.00	7.0	
		Week 48	Tezepelumab	105	100 (95.2)	5.30 (1.10)	2.8	4.42	5.17	6.21	7.0	
			Placebo	110	105 (95.5)	5.07 (1.10)	2.4	4.17	5.08	5.92	7.0	
		Week 52	Tezepelumab	105	100 (95.2)	5.32 (1.09)	2.8	4.50	5.17	6.21	7.0	
			Placebo	110	105 (95.5)	5.04 (1.08)	2.5	4.08	4.92	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	105	89 (84.8)	0.76 (0.86)	-0.8	0.08	0.58	1.42	3.1	0.21 [-0.08, 0.50]
			Placebo	110	98 (89.1)	0.57 (0.87)	-1.8	0.08	0.50	1.17	3.3	
		Week 8	Tezepelumab	105	90 (85.7)	0.93 (0.93)	-0.8	0.25	0.88	1.50	3.3	0.26 [-0.02, 0.55]
			Placebo	110	98 (89.1)	0.68 (0.91)	-1.0	0.08	0.58	1.17	3.6	
		Week 12	Tezepelumab	105	90 (85.7)	1.09 (1.02)	-0.8	0.33	0.96	1.92	3.7	0.29 [0.00, 0.58]
			Placebo	110	98 (89.1)	0.78 (1.11)	-3.1	0.17	0.75	1.25	3.8	
		Week 16	Tezepelumab	105	90 (85.7)	1.07 (0.97)	-0.8	0.33	0.96	1.83	3.3	0.24 [-0.05, 0.53]
			Placebo	110	98 (89.1)	0.83 (1.03)	-3.1	0.17	0.83	1.33	3.7	
		Week 20	Tezepelumab	105	90 (85.7)	1.08 (0.96)	-0.8	0.33	1.00	1.92	3.3	0.18 [-0.11, 0.47]
			Placebo	110	98 (89.1)	0.90 (0.97)	-1.1	0.25	0.83	1.25	3.8	
		Week 24	Tezepelumab	105	90 (85.7)	1.11 (1.02)	-1.6	0.33	1.00	2.08	3.3	0.15 [-0.14, 0.44]
			Placebo	110	98 (89.1)	0.96 (1.06)	-1.3	0.25	0.83	1.42	4.1	
		Week 28	Tezepelumab	105	90 (85.7)	1.08 (0.97)	-0.8	0.33	0.92	2.00	3.3	0.12 [-0.17, 0.41]
			Placebo	110	98 (89.1)	0.95 (1.10)	-1.8	0.25	0.83	1.50	4.7	
		Week 32	Tezepelumab	105	90 (85.7)	1.14 (1.04)	-0.8	0.33	1.08	2.08	3.3	0.13 [-0.15, 0.42]
			Placebo	110	98 (89.1)	1.01 (1.02)	-0.9	0.25	0.92	1.50	4.0	
		Week 36	Tezepelumab	105	90 (85.7)	1.14 (1.10)	-0.9	0.17	1.00	2.08	3.8	0.03 [-0.25, 0.32]
			Placebo	110	98 (89.1)	1.10 (1.04)	-0.8	0.25	1.00	1.67	3.8	
		Week 40	Tezepelumab	105	90 (85.7)	1.18 (1.07)	-0.9	0.33	1.04	2.08	3.4	0.10 [-0.19, 0.39]
			Placebo	110	98 (89.1)	1.07 (1.05)	-1.0	0.50	1.00	1.58	4.7	
		Week 44	Tezepelumab	105	90 (85.7)	1.17 (1.06)	-1.8	0.42	1.13	2.08	3.3	0.08 [-0.20, 0.37]
			Placebo	110	98 (89.1)	1.08 (1.09)	-1.4	0.33	1.04	1.67	4.3	
		Week 48	Tezepelumab	105	90 (85.7)	1.20 (1.04)	-0.8	0.33	1.08	2.00	3.4	0.10 [-0.18, 0.39]
			Placebo	110	98 (89.1)	1.10 (1.07)	-1.1	0.33	1.08	1.67	4.2	
		Week 52	Tezepelumab	105	90 (85.7)	1.20 (1.03)	-0.8	0.42	1.00	2.00	3.6	0.13 [-0.15, 0.42]
			Placebo	110	98 (89.1)	1.06 (1.05)	-0.9	0.25	0.92	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	32	29 (90.6)	3.78 (1.20)	1.3	3.17	4.08	4.67	6.2	
			Placebo	28	23 (82.1)	3.89 (1.07)	1.5	3.42	3.83	4.58	6.3	
		Week 4	Tezepelumab	32	30 (93.8)	4.81 (1.18)	1.3	3.92	4.92	5.83	6.5	
			Placebo	28	23 (82.1)	4.51 (0.94)	2.7	3.75	4.67	5.17	6.2	
		Week 8	Tezepelumab	32	31 (96.9)	5.04 (1.25)	2.0	3.75	5.25	6.08	6.8	
			Placebo	28	24 (85.7)	4.46 (1.09)	1.9	3.88	4.50	5.25	6.4	
		Week 12	Tezepelumab	32	31 (96.9)	5.23 (1.12)	3.0	4.42	5.25	6.42	6.8	
			Placebo	28	24 (85.7)	4.80 (1.16)	2.1	4.04	4.63	5.88	6.7	
		Week 16	Tezepelumab	32	31 (96.9)	5.24 (1.29)	2.3	4.42	5.42	6.25	7.0	
			Placebo	28	24 (85.7)	4.66 (1.44)	1.3	3.88	4.83	5.83	7.0	
		Week 20	Tezepelumab	32	31 (96.9)	5.25 (1.13)	2.3	4.42	5.42	5.92	7.0	
			Placebo	28	24 (85.7)	4.49 (1.46)	1.3	3.38	4.54	5.71	6.7	
		Week 24	Tezepelumab	32	31 (96.9)	5.34 (1.06)	3.1	4.42	5.50	6.17	7.0	
			Placebo	28	24 (85.7)	4.42 (1.40)	1.3	3.50	4.17	5.75	6.8	
		Week 28	Tezepelumab	32	32 (100.0)	5.38 (1.10)	3.2	4.50	5.67	6.21	6.9	
			Placebo	28	24 (85.7)	4.53 (1.51)	1.3	3.29	4.29	5.96	7.0	
		Week 32	Tezepelumab	32	32 (100.0)	5.39 (1.05)	2.9	4.54	5.67	6.04	7.0	
			Placebo	28	25 (89.3)	4.64 (1.38)	1.3	3.42	4.92	5.75	6.7	
		Week 36	Tezepelumab	32	32 (100.0)	5.34 (1.05)	2.9	4.58	5.46	6.00	7.0	
			Placebo	28	25 (89.3)	4.38 (1.25)	2.4	3.42	4.00	5.08	6.8	
		Week 40	Tezepelumab	32	32 (100.0)	5.29 (1.10)	3.1	4.46	5.46	6.08	7.0	
			Placebo	28	25 (89.3)	4.63 (1.24)	2.3	3.67	4.42	5.75	6.7	
		Week 44	Tezepelumab	32	32 (100.0)	5.37 (1.12)	3.1	4.50	5.67	6.13	7.0	
			Placebo	28	25 (89.3)	4.42 (1.15)	2.5	3.58	4.17	5.50	6.3	
		Week 48	Tezepelumab	32	32 (100.0)	5.38 (1.08)	3.3	4.58	5.46	6.17	7.0	
			Placebo	28	25 (89.3)	4.49 (1.06)	2.2	3.83	4.25	5.08	6.5	
		Week 52	Tezepelumab	32	32 (100.0)	5.35 (1.06)	3.0	4.58	5.25	6.17	7.0	
			Placebo	28	25 (89.3)	4.52 (1.19)	2.8	3.67	4.25	5.33	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	32	28 (87.5)	1.02 (1.41)	-4.3	0.46	1.33	1.75	3.1	0.37 [-0.20, 0.94]
			Placebo	28	21 (75.0)	0.58 (0.76)	-1.1	0.25	0.58	0.92	1.9	
		Week 8	Tezepelumab	32	29 (90.6)	1.19 (1.39)	-1.9	0.50	1.50	2.00	4.1	0.51 [-0.06, 1.07]
			Placebo	28	22 (78.6)	0.55 (1.06)	-1.8	0.00	0.42	1.17	2.7	
		Week 12	Tezepelumab	32	29 (90.6)	1.36 (1.33)	-2.6	0.83	1.58	2.00	4.5	0.37 [-0.18, 0.93]
			Placebo	28	22 (78.6)	0.84 (1.46)	-2.8	0.00	0.83	1.67	4.0	
		Week 16	Tezepelumab	32	29 (90.6)	1.37 (1.43)	-2.9	0.92	1.58	2.08	4.6	0.42 [-0.14, 0.98]
			Placebo	28	22 (78.6)	0.72 (1.71)	-3.5	0.17	1.04	1.58	4.2	
		Week 20	Tezepelumab	32	29 (90.6)	1.41 (1.44)	-1.8	0.67	1.33	2.17	4.7	0.56 [-0.01, 1.12]
			Placebo	28	22 (78.6)	0.56 (1.62)	-3.5	0.08	0.88	1.67	3.3	
		Week 24	Tezepelumab	32	29 (90.6)	1.50 (1.33)	-1.6	0.92	1.42	2.33	4.8	0.68 [0.11, 1.25]
			Placebo	28	22 (78.6)	0.52 (1.58)	-3.5	0.00	0.71	1.67	2.8	
		Week 28	Tezepelumab	32	29 (90.6)	1.47 (1.42)	-1.7	0.83	1.42	2.00	4.9	0.54 [-0.03, 1.10]
			Placebo	28	22 (78.6)	0.64 (1.74)	-3.5	0.00	0.88	1.67	4.3	
		Week 32	Tezepelumab	32	29 (90.6)	1.53 (1.44)	-1.6	0.75	1.25	2.33	4.8	0.46 [-0.11, 1.02]
			Placebo	28	22 (78.6)	0.85 (1.54)	-3.5	0.92	1.08	1.67	2.9	
		Week 36	Tezepelumab	32	29 (90.6)	1.45 (1.42)	-1.7	0.75	1.50	2.33	4.8	0.68 [0.11, 1.25]
			Placebo	28	22 (78.6)	0.49 (1.44)	-3.0	-0.42	1.04	1.67	2.3	
		Week 40	Tezepelumab	32	29 (90.6)	1.39 (1.30)	-1.7	0.75	1.17	2.17	4.8	0.43 [-0.14, 0.99]
			Placebo	28	22 (78.6)	0.78 (1.58)	-3.0	-0.25	1.08	1.92	4.0	
		Week 44	Tezepelumab	32	29 (90.6)	1.51 (1.33)	-1.6	0.92	1.50	2.33	4.8	0.71 [0.13, 1.28]
			Placebo	28	22 (78.6)	0.52 (1.48)	-3.0	-0.67	0.67	1.33	3.4	
		Week 48	Tezepelumab	32	29 (90.6)	1.53 (1.32)	-1.6	0.83	1.58	2.33	4.8	0.68 [0.11, 1.25]
			Placebo	28	22 (78.6)	0.63 (1.33)	-3.0	0.17	0.83	1.50	2.8	
		Week 52	Tezepelumab	32	29 (90.6)	1.51 (1.37)	-1.6	0.83	1.58	2.42	4.8	0.58 [0.01, 1.14]
			Placebo	28	22 (78.6)	0.71 (1.38)	-3.0	0.17	0.63	1.58	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.04 (1.01)	1.3	3.50	4.00	4.67	6.8	
			Placebo	123	106 (86.2)	4.03 (0.87)	1.7	3.50	4.08	4.58	6.3	
		Week 4	Tezepelumab	128	117 (91.4)	4.80 (1.07)	1.3	3.92	4.75	5.58	7.0	
			Placebo	123	109 (88.6)	4.58 (0.96)	1.8	3.92	4.58	5.25	6.7	
		Week 8	Tezepelumab	128	119 (93.0)	5.02 (1.09)	2.0	4.17	4.92	5.83	7.0	
			Placebo	123	112 (91.1)	4.66 (1.02)	2.1	4.00	4.50	5.38	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.18 (1.08)	2.8	4.25	5.17	6.08	7.0	
			Placebo	123	113 (91.9)	4.72 (1.07)	2.1	4.00	4.67	5.50	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.17 (1.11)	2.3	4.33	5.17	6.00	7.0	
			Placebo	123	113 (91.9)	4.77 (1.09)	1.3	4.08	4.67	5.58	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.17 (1.08)	2.3	4.25	5.08	5.96	7.0	
			Placebo	123	113 (91.9)	4.81 (1.10)	1.3	4.08	4.75	5.50	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.19 (1.09)	1.8	4.42	5.08	6.00	7.0	
			Placebo	123	113 (91.9)	4.81 (1.16)	1.3	4.00	4.67	5.75	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.18 (1.07)	3.2	4.33	5.00	6.00	7.0	
			Placebo	123	114 (92.7)	4.80 (1.17)	1.3	4.00	4.75	5.75	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.25 (1.08)	2.8	4.33	5.17	6.08	7.0	
			Placebo	123	115 (93.5)	4.88 (1.15)	1.3	4.00	4.92	5.75	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.26 (1.09)	2.9	4.42	5.17	6.08	7.0	
			Placebo	123	115 (93.5)	4.94 (1.17)	2.4	4.00	4.83	6.00	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.24 (1.10)	2.3	4.42	5.17	6.00	7.0	
			Placebo	123	115 (93.5)	4.95 (1.11)	2.3	4.00	4.92	5.92	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.26 (1.10)	2.3	4.33	5.33	6.08	7.0	
			Placebo	123	115 (93.5)	4.94 (1.16)	2.3	4.00	4.75	5.92	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.29 (1.11)	2.8	4.42	5.17	6.25	7.0	
			Placebo	123	116 (94.3)	4.96 (1.11)	2.2	4.00	4.83	5.79	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.29 (1.09)	2.8	4.50	5.17	6.17	7.0	
			Placebo	123	116 (94.3)	4.93 (1.12)	2.5	4.00	4.79	5.83	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.79 (1.02)	-4.3	0.25	0.75	1.50	3.1	0.24 [-0.03, 0.51]
			Placebo	123	105 (85.4)	0.57 (0.86)	-1.8	0.17	0.50	1.17	3.3	
		Week 8	Tezepelumab	128	111 (86.7)	0.97 (1.04)	-1.9	0.25	0.92	1.67	4.1	0.31 [0.05, 0.58]
			Placebo	123	106 (86.2)	0.66 (0.92)	-1.8	0.17	0.58	1.17	3.6	
		Week 12	Tezepelumab	128	111 (86.7)	1.13 (1.09)	-2.6	0.33	1.08	1.92	4.5	0.38 [0.11, 0.64]
			Placebo	123	106 (86.2)	0.71 (1.14)	-3.1	0.08	0.75	1.25	3.8	
		Week 16	Tezepelumab	128	111 (86.7)	1.13 (1.09)	-2.9	0.42	1.08	1.92	4.6	0.32 [0.05, 0.58]
			Placebo	123	106 (86.2)	0.78 (1.12)	-3.5	0.17	0.92	1.42	3.7	
		Week 20	Tezepelumab	128	111 (86.7)	1.14 (1.10)	-1.8	0.33	1.00	2.00	4.7	0.29 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.83 (1.07)	-3.5	0.25	0.83	1.25	3.8	
		Week 24	Tezepelumab	128	111 (86.7)	1.18 (1.11)	-1.6	0.42	1.08	2.08	4.8	0.31 [0.04, 0.58]
			Placebo	123	106 (86.2)	0.83 (1.16)	-3.5	0.17	0.83	1.42	3.9	
		Week 28	Tezepelumab	128	111 (86.7)	1.15 (1.11)	-1.7	0.42	1.00	2.00	4.9	0.32 [0.05, 0.58]
			Placebo	123	106 (86.2)	0.79 (1.16)	-3.5	0.08	0.79	1.33	3.8	
		Week 32	Tezepelumab	128	111 (86.7)	1.22 (1.17)	-1.6	0.42	1.08	2.08	4.8	0.28 [0.01, 0.54]
			Placebo	123	106 (86.2)	0.91 (1.10)	-3.5	0.33	0.96	1.33	3.5	
		Week 36	Tezepelumab	128	111 (86.7)	1.20 (1.19)	-1.7	0.33	1.08	2.08	4.8	0.21 [-0.06, 0.48]
			Placebo	123	106 (86.2)	0.96 (1.14)	-3.0	0.17	1.00	1.58	3.8	
		Week 40	Tezepelumab	128	111 (86.7)	1.21 (1.13)	-1.7	0.42	1.08	2.08	4.8	0.21 [-0.05, 0.48]
			Placebo	123	106 (86.2)	0.97 (1.10)	-3.0	0.33	1.00	1.58	3.7	
		Week 44	Tezepelumab	128	111 (86.7)	1.23 (1.14)	-1.8	0.50	1.17	2.08	4.8	0.25 [-0.02, 0.52]
			Placebo	123	106 (86.2)	0.95 (1.12)	-3.0	0.33	1.00	1.58	3.8	
		Week 48	Tezepelumab	128	111 (86.7)	1.27 (1.12)	-1.6	0.42	1.17	2.08	4.8	0.27 [0.00, 0.54]
			Placebo	123	106 (86.2)	0.97 (1.11)	-3.0	0.25	1.04	1.58	4.2	
		Week 52	Tezepelumab	128	111 (86.7)	1.26 (1.12)	-1.6	0.42	1.08	2.08	4.8	0.28 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.94 (1.08)	-3.0	0.25	0.83	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.78 (1.04)	2.6	2.58	4.33	4.42	4.4	
			Placebo	6	6 (100.0)	3.42 (0.66)	2.4	3.00	3.42	4.00	4.3	
		Week 4	Tezepelumab	3	3 (100.0)	5.64 (0.71)	4.9	4.92	5.67	6.33	6.3	
			Placebo	6	5 (83.3)	3.98 (0.99)	2.4	4.00	4.08	4.25	5.2	
		Week 8	Tezepelumab	3	3 (100.0)	5.83 (0.88)	4.9	4.92	5.92	6.67	6.7	
			Placebo	6	5 (83.3)	3.82 (1.31)	2.3	3.33	3.42	4.33	5.8	
		Week 12	Tezepelumab	3	3 (100.0)	5.75 (0.87)	4.8	4.75	6.25	6.25	6.3	
			Placebo	6	5 (83.3)	4.28 (1.21)	3.0	3.25	4.25	5.00	5.9	
		Week 16	Tezepelumab	3	3 (100.0)	5.11 (1.41)	3.5	3.50	5.75	6.08	6.1	
			Placebo	6	5 (83.3)	3.62 (1.44)	2.1	2.83	3.42	3.83	5.9	
		Week 20	Tezepelumab	3	3 (100.0)	5.69 (0.49)	5.3	5.33	5.50	6.25	6.3	
			Placebo	6	5 (83.3)	3.95 (1.44)	2.1	3.50	3.92	4.17	6.1	
		Week 24	Tezepelumab	3	3 (100.0)	5.89 (0.35)	5.5	5.50	6.00	6.17	6.2	
			Placebo	6	5 (83.3)	4.47 (1.05)	3.4	3.67	4.50	4.67	6.1	
		Week 28	Tezepelumab	3	3 (100.0)	5.69 (0.49)	5.3	5.33	5.50	6.25	6.3	
			Placebo	6	5 (83.3)	4.35 (1.16)	3.3	3.42	4.00	4.92	6.1	
		Week 32	Tezepelumab	3	3 (100.0)	5.28 (0.38)	4.8	4.83	5.50	5.50	5.5	
			Placebo	6	5 (83.3)	4.62 (1.06)	3.4	3.92	4.42	5.25	6.1	
		Week 36	Tezepelumab	3	3 (100.0)	5.22 (0.87)	4.3	4.25	5.50	5.92	5.9	
			Placebo	6	5 (83.3)	4.72 (0.98)	3.4	4.25	4.83	5.00	6.1	
		Week 40	Tezepelumab	3	3 (100.0)	5.42 (0.79)	4.6	4.58	5.50	6.17	6.2	
			Placebo	6	5 (83.3)	4.47 (1.02)	3.4	3.83	4.42	4.58	6.1	
		Week 44	Tezepelumab	3	3 (100.0)	5.39 (0.76)	4.6	4.58	5.50	6.08	6.1	
			Placebo	6	5 (83.3)	4.98 (1.24)	3.5	4.00	5.00	6.17	6.3	
		Week 48	Tezepelumab	3	3 (100.0)	5.56 (0.50)	5.1	5.08	5.50	6.08	6.1	
			Placebo	6	5 (83.3)	5.10 (1.30)	3.7	3.83	5.33	6.17	6.5	
		Week 52	Tezepelumab	3	3 (100.0)	5.56 (0.50)	5.1	5.08	5.50	6.08	6.1	
			Placebo	6	5 (83.3)	5.32 (1.43)	3.8	4.00	5.25	6.50	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.86 (1.30)	0.5	0.50	2.00	3.08	3.1	1.43 [-0.21, 3.08]
			Placebo	6	5 (83.3)	0.37 (0.89)	-0.6	0.00	0.00	0.67	1.8	
		Week 8	Tezepelumab	3	3 (100.0)	2.06 (1.44)	0.5	0.50	2.33	3.33	3.3	1.61 [-0.08, 3.31]
			Placebo	6	5 (83.3)	0.20 (0.97)	-0.8	-0.58	-0.08	0.92	1.5	
		Week 12	Tezepelumab	3	3 (100.0)	1.97 (1.67)	0.3	0.33	1.92	3.67	3.7	1.14 [-0.43, 2.71]
			Placebo	6	5 (83.3)	0.67 (0.75)	-0.2	0.00	0.83	1.00	1.7	
		Week 16	Tezepelumab	3	3 (100.0)	1.33 (2.07)	-0.9	-0.92	1.75	3.17	3.2	0.85 [-0.66, 2.36]
			Placebo	6	5 (83.3)	0.00 (1.25)	-1.3	-1.17	0.42	0.42	1.7	
		Week 20	Tezepelumab	3	3 (100.0)	1.92 (1.00)	0.9	0.92	1.92	2.92	2.9	1.42 [-0.22, 3.06]
			Placebo	6	5 (83.3)	0.33 (1.17)	-1.3	0.08	0.17	0.92	1.8	
		Week 24	Tezepelumab	3	3 (100.0)	2.11 (0.71)	1.6	1.58	1.83	2.92	2.9	1.58 [-0.11, 3.26]
			Placebo	6	5 (83.3)	0.85 (0.84)	0.0	0.25	0.50	1.67	1.8	
		Week 28	Tezepelumab	3	3 (100.0)	1.92 (1.00)	0.9	0.92	1.92	2.92	2.9	1.09 [-0.47, 2.64]
			Placebo	6	5 (83.3)	0.73 (1.13)	-0.7	0.00	0.58	1.83	1.9	
		Week 32	Tezepelumab	3	3 (100.0)	1.50 (1.26)	0.5	0.50	1.08	2.92	2.9	0.44 [-1.01, 1.90]
			Placebo	6	5 (83.3)	1.00 (1.05)	-0.1	0.00	1.00	1.83	2.3	
		Week 36	Tezepelumab	3	3 (100.0)	1.44 (1.55)	-0.2	-0.17	1.58	2.92	2.9	0.30 [-1.14, 1.74]
			Placebo	6	5 (83.3)	1.10 (0.90)	0.0	0.25	1.58	1.83	1.8	
		Week 40	Tezepelumab	3	3 (100.0)	1.64 (1.34)	0.3	0.25	1.75	2.92	2.9	0.74 [-0.75, 2.23]
			Placebo	6	5 (83.3)	0.85 (0.91)	-0.2	0.00	1.00	1.58	1.8	
		Week 44	Tezepelumab	3	3 (100.0)	1.61 (1.33)	0.3	0.25	1.67	2.92	2.9	0.19 [-1.25, 1.62]
			Placebo	6	5 (83.3)	1.37 (1.31)	-0.5	0.58	2.00	2.00	2.8	
		Week 48	Tezepelumab	3	3 (100.0)	1.78 (1.09)	0.8	0.75	1.67	2.92	2.9	0.23 [-1.21, 1.67]
			Placebo	6	5 (83.3)	1.48 (1.36)	-0.3	0.42	2.25	2.33	2.8	
		Week 52	Tezepelumab	3	3 (100.0)	1.78 (1.09)	0.8	0.75	1.67	2.92	2.9	0.06 [-1.37, 1.49]
			Placebo	6	5 (83.3)	1.70 (1.49)	-0.2	0.58	2.25	2.25	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	4.40 (0.83)	3.2	3.92	4.71	4.88	5.0	
			Placebo	6	6 (100.0)	4.26 (0.98)	2.3	4.42	4.46	4.92	5.0	
		Week 4	Tezepelumab	5	5 (100.0)	5.33 (0.85)	4.5	4.75	4.92	6.17	6.3	
			Placebo	6	6 (100.0)	4.83 (0.47)	4.1	4.50	4.96	5.25	5.3	
		Week 8	Tezepelumab	5	5 (100.0)	5.63 (0.60)	5.1	5.25	5.42	5.83	6.6	
			Placebo	6	6 (100.0)	4.75 (0.57)	4.3	4.25	4.63	5.00	5.8	
		Week 12	Tezepelumab	5	5 (100.0)	6.02 (0.64)	5.3	5.58	5.83	6.42	6.9	
			Placebo	6	6 (100.0)	5.42 (0.39)	4.9	5.00	5.46	5.83	5.8	
		Week 16	Tezepelumab	5	5 (100.0)	6.02 (0.48)	5.7	5.67	5.92	6.00	6.8	
			Placebo	6	6 (100.0)	5.38 (0.50)	4.6	5.00	5.50	5.83	5.8	
		Week 20	Tezepelumab	5	5 (100.0)	5.83 (0.82)	4.7	5.67	5.75	6.17	6.9	
			Placebo	6	6 (100.0)	5.04 (0.95)	3.6	4.67	4.92	6.08	6.1	
		Week 24	Tezepelumab	5	5 (100.0)	5.95 (0.61)	5.3	5.67	5.92	6.00	6.9	
			Placebo	6	6 (100.0)	5.22 (0.94)	3.8	4.67	5.29	5.92	6.4	
		Week 28	Tezepelumab	5	5 (100.0)	6.00 (0.56)	5.7	5.75	5.75	5.83	7.0	
			Placebo	6	6 (100.0)	6.06 (0.91)	5.1	5.17	6.04	7.00	7.0	
		Week 32	Tezepelumab	5	5 (100.0)	6.25 (0.48)	5.8	6.00	6.00	6.58	6.9	
			Placebo	6	6 (100.0)	5.65 (0.62)	4.8	5.25	5.67	6.17	6.3	
		Week 36	Tezepelumab	5	5 (100.0)	6.10 (0.70)	5.1	5.92	6.08	6.42	7.0	
			Placebo	6	6 (100.0)	5.29 (1.29)	3.2	4.83	5.33	6.08	7.0	
		Week 40	Tezepelumab	5	5 (100.0)	6.25 (0.59)	5.5	6.00	6.08	6.67	7.0	
			Placebo	6	6 (100.0)	5.42 (1.19)	4.2	4.42	5.08	6.75	7.0	
		Week 44	Tezepelumab	5	5 (100.0)	6.37 (0.50)	5.8	6.00	6.50	6.58	7.0	
			Placebo	6	6 (100.0)	5.07 (1.50)	3.2	4.00	4.79	6.67	7.0	
		Week 48	Tezepelumab	5	5 (100.0)	5.95 (0.89)	4.5	6.00	6.08	6.25	6.9	
			Placebo	6	6 (100.0)	5.31 (1.00)	4.0	4.83	5.04	6.08	6.8	
		Week 52	Tezepelumab	5	5 (100.0)	6.08 (0.94)	4.5	6.08	6.25	6.67	6.9	
			Placebo	6	6 (100.0)	5.17 (0.78)	4.0	4.83	5.04	6.00	6.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	1.08 (0.62)	0.2	0.75	1.33	1.42	1.5	0.82 [-0.51, 2.14]
			Placebo	6	6 (100.0)	0.57 (0.64)	0.1	0.17	0.29	0.83	1.8	
		Week 8	Tezepelumab	5	4 (80.0)	1.29 (0.73)	0.5	0.67	1.38	1.92	1.9	1.05 [-0.32, 2.41]
			Placebo	6	6 (100.0)	0.49 (0.79)	-0.3	0.00	0.21	0.83	1.9	
		Week 12	Tezepelumab	5	4 (80.0)	1.67 (0.67)	0.8	1.13	1.79	2.21	2.3	0.51 [-0.78, 1.80]
			Placebo	6	6 (100.0)	1.15 (1.17)	0.5	0.50	0.75	0.92	3.5	
		Week 16	Tezepelumab	5	4 (80.0)	1.71 (0.74)	1.0	1.08	1.67	2.33	2.5	0.55 [-0.74, 1.84]
			Placebo	6	6 (100.0)	1.11 (1.25)	0.1	0.42	0.63	1.42	3.5	
		Week 20	Tezepelumab	5	4 (80.0)	1.46 (1.18)	-0.1	0.54	1.71	2.38	2.5	0.47 [-0.82, 1.75]
			Placebo	6	6 (100.0)	0.78 (1.61)	-0.8	-0.17	0.38	1.17	3.8	
		Week 24	Tezepelumab	5	4 (80.0)	1.63 (1.05)	0.5	0.75	1.63	2.50	2.8	0.46 [-0.82, 1.75]
			Placebo	6	6 (100.0)	0.96 (1.64)	-0.7	0.25	0.54	1.00	4.1	
		Week 28	Tezepelumab	5	4 (80.0)	1.67 (0.92)	0.8	0.88	1.63	2.46	2.6	-0.09 [-1.36, 1.18]
			Placebo	6	6 (100.0)	1.79 (1.61)	0.2	0.67	1.54	2.17	4.7	
		Week 32	Tezepelumab	5	4 (80.0)	1.77 (0.76)	1.0	1.13	1.75	2.42	2.6	0.32 [-0.95, 1.59]
			Placebo	6	6 (100.0)	1.39 (1.39)	0.3	0.33	1.04	1.67	4.0	
		Week 36	Tezepelumab	5	4 (80.0)	1.62 (1.11)	0.3	0.71	1.71	2.54	2.8	0.39 [-0.89, 1.67]
			Placebo	6	6 (100.0)	1.03 (1.71)	-1.3	0.25	0.67	2.08	3.8	
		Week 40	Tezepelumab	5	4 (80.0)	1.75 (1.04)	0.8	0.88	1.67	2.63	2.9	0.36 [-0.91, 1.64]
			Placebo	6	6 (100.0)	1.15 (1.92)	-0.6	-0.25	0.63	1.83	4.7	
		Week 44	Tezepelumab	5	4 (80.0)	1.92 (1.15)	0.8	1.00	1.79	2.83	3.3	0.63 [-0.67, 1.93]
			Placebo	6	6 (100.0)	0.81 (2.06)	-1.3	-0.42	0.04	2.08	4.3	
		Week 48	Tezepelumab	5	4 (80.0)	1.54 (1.45)	-0.3	0.42	1.67	2.67	3.1	0.33 [-0.95, 1.60]
			Placebo	6	6 (100.0)	1.04 (1.56)	-0.4	-0.17	0.58	1.92	3.8	
		Week 52	Tezepelumab	5	4 (80.0)	1.54 (1.45)	-0.3	0.42	1.67	2.67	3.1	0.43 [-0.85, 1.71]
			Placebo	6	6 (100.0)	0.90 (1.50)	-0.4	-0.17	0.58	1.08	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	4.83	4.8	4.83	4.83	4.83	4.8	
			Placebo	3	3 (100.0)	2.50 (0.93)	1.5	1.50	2.67	3.33	3.3	
		Week 4	Tezepelumab	1	1 (100.0)	4.58	4.6	4.58	4.58	4.58	4.6	
			Placebo	3	3 (100.0)	3.75 (0.96)	3.0	3.00	3.42	4.83	4.8	
		Week 8	Tezepelumab	1	1 (100.0)	4.00	4.0	4.00	4.00	4.00	4.0	
			Placebo	3	3 (100.0)	4.36 (2.13)	1.9	1.92	5.33	5.83	5.8	
		Week 12	Tezepelumab	1	1 (100.0)	4.17	4.2	4.17	4.17	4.17	4.2	
			Placebo	3	3 (100.0)	5.56 (1.27)	4.2	4.17	5.83	6.67	6.7	
		Week 16	Tezepelumab	1	1 (100.0)	5.08	5.1	5.08	5.08	5.08	5.1	
			Placebo	3	3 (100.0)	5.25 (1.45)	4.0	4.00	4.92	6.83	6.8	
		Week 20	Tezepelumab	1	1 (100.0)	4.58	4.6	4.58	4.58	4.58	4.6	
			Placebo	3	3 (100.0)	4.75 (1.77)	3.2	3.17	4.42	6.67	6.7	
		Week 24	Tezepelumab	1	1 (100.0)	4.33	4.3	4.33	4.33	4.33	4.3	
			Placebo	3	3 (100.0)	4.86 (1.51)	3.2	3.17	5.33	6.08	6.1	
		Week 28	Tezepelumab	1	1 (100.0)	4.58	4.6	4.58	4.58	4.58	4.6	
			Placebo	3	3 (100.0)	5.47 (2.03)	3.2	3.17	6.25	7.00	7.0	
		Week 32	Tezepelumab	1	1 (100.0)	4.75	4.8	4.75	4.75	4.75	4.8	
			Placebo	3	3 (100.0)	5.00 (1.62)	3.2	3.17	5.58	6.25	6.3	
		Week 36	Tezepelumab	1	1 (100.0)	4.92	4.9	4.92	4.92	4.92	4.9	
			Placebo	3	3 (100.0)	4.28 (0.99)	3.2	3.17	4.58	5.08	5.1	
		Week 40	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	3	3 (100.0)	5.19 (1.81)	3.2	3.17	5.75	6.67	6.7	
		Week 44	Tezepelumab	1	1 (100.0)	4.92	4.9	4.92	4.92	4.92	4.9	
			Placebo	3	3 (100.0)	4.17 (1.66)	3.2	3.17	3.25	6.08	6.1	
		Week 48	Tezepelumab	1	1 (100.0)	5.17	5.2	5.17	5.17	5.17	5.2	
			Placebo	3	3 (100.0)	4.22 (1.29)	3.2	3.17	3.83	5.67	5.7	
		Week 52	Tezepelumab	1	1 (100.0)	5.17	5.2	5.17	5.17	5.17	5.2	
			Placebo	3	3 (100.0)	4.22 (1.29)	3.2	3.17	3.83	5.67	5.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	NE
			Placebo	3	3 (100.0)	1.25 (0.82)	0.3	0.33	1.50	1.92	1.9	
		Week 8	Tezepelumab	1	1 (100.0)	-0.83	-0.8	-0.83	-0.83	-0.83	-0.8	NE
			Placebo	3	3 (100.0)	1.86 (1.25)	0.4	0.42	2.50	2.67	2.7	
		Week 12	Tezepelumab	1	1 (100.0)	-0.67	-0.7	-0.67	-0.67	-0.67	-0.7	NE
			Placebo	3	3 (100.0)	3.06 (0.82)	2.5	2.50	2.67	4.00	4.0	
		Week 16	Tezepelumab	1	1 (100.0)	0.25	0.3	0.25	0.25	0.25	0.3	NE
			Placebo	3	3 (100.0)	2.75 (1.31)	1.6	1.58	2.50	4.17	4.2	
		Week 20	Tezepelumab	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	NE
			Placebo	3	3 (100.0)	2.25 (0.94)	1.7	1.67	1.75	3.33	3.3	
		Week 24	Tezepelumab	1	1 (100.0)	-0.50	-0.5	-0.50	-0.50	-0.50	-0.5	NE
			Placebo	3	3 (100.0)	2.36 (0.60)	1.7	1.67	2.67	2.75	2.8	
		Week 28	Tezepelumab	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	NE
			Placebo	3	3 (100.0)	2.97 (1.33)	1.7	1.67	2.92	4.33	4.3	
		Week 32	Tezepelumab	1	1 (100.0)	-0.08	-0.1	-0.08	-0.08	-0.08	-0.1	NE
			Placebo	3	3 (100.0)	2.50 (0.72)	1.7	1.67	2.92	2.92	2.9	
		Week 36	Tezepelumab	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	NE
			Placebo	3	3 (100.0)	1.78 (0.13)	1.7	1.67	1.75	1.92	1.9	
		Week 40	Tezepelumab	1	1 (100.0)	0.17	0.2	0.17	0.17	0.17	0.2	NE
			Placebo	3	3 (100.0)	2.69 (1.19)	1.7	1.67	2.42	4.00	4.0	
		Week 44	Tezepelumab	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	NE
			Placebo	3	3 (100.0)	1.67 (1.75)	-0.1	-0.08	1.67	3.42	3.4	
		Week 48	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	3	3 (100.0)	1.72 (0.59)	1.2	1.17	1.67	2.33	2.3	
		Week 52	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	3	3 (100.0)	1.72 (0.59)	1.2	1.17	1.67	2.33	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	78	73 (93.6)	4.06 (1.02)	1.3	3.58	4.00	4.67	6.8	
			Placebo	80	68 (85.0)	4.21 (0.84)	1.8	3.67	4.33	4.71	5.9	
		Week 4	Tezepelumab	78	74 (94.9)	4.75 (1.04)	1.3	3.92	4.67	5.58	6.8	
			Placebo	80	69 (86.3)	4.65 (0.99)	1.8	4.00	4.67	5.25	6.7	
		Week 8	Tezepelumab	78	75 (96.2)	5.00 (1.04)	2.0	4.17	4.83	5.75	7.0	
			Placebo	80	71 (88.8)	4.76 (1.03)	2.3	4.08	4.67	5.50	7.0	
		Week 12	Tezepelumab	78	75 (96.2)	5.13 (1.06)	3.0	4.25	5.08	5.92	7.0	
			Placebo	80	72 (90.0)	4.80 (1.11)	2.1	4.00	4.67	5.58	7.0	
		Week 16	Tezepelumab	78	75 (96.2)	5.07 (1.13)	2.3	4.25	5.08	6.00	7.0	
			Placebo	80	72 (90.0)	4.86 (1.14)	1.3	4.17	4.79	5.54	7.0	
		Week 20	Tezepelumab	78	76 (97.4)	5.14 (1.08)	2.3	4.29	5.08	5.92	7.0	
			Placebo	80	72 (90.0)	4.94 (1.05)	1.3	4.25	4.88	5.71	7.0	
		Week 24	Tezepelumab	78	76 (97.4)	5.18 (1.03)	3.1	4.42	5.04	6.00	7.0	
			Placebo	80	72 (90.0)	4.88 (1.14)	1.3	4.08	4.71	5.75	7.0	
		Week 28	Tezepelumab	78	77 (98.7)	5.10 (1.05)	3.2	4.17	5.00	6.00	7.0	
			Placebo	80	73 (91.3)	4.96 (1.17)	1.3	4.08	4.92	5.92	7.0	
		Week 32	Tezepelumab	78	77 (98.7)	5.15 (1.10)	2.8	4.33	5.00	5.92	7.0	
			Placebo	80	74 (92.5)	5.00 (1.14)	1.3	4.25	5.00	5.83	7.0	
		Week 36	Tezepelumab	78	77 (98.7)	5.14 (1.09)	2.9	4.25	5.00	6.00	7.0	
			Placebo	80	74 (92.5)	5.09 (1.17)	2.4	4.17	5.13	6.00	7.0	
		Week 40	Tezepelumab	78	77 (98.7)	5.22 (1.09)	2.9	4.42	5.08	6.00	7.0	
			Placebo	80	74 (92.5)	5.06 (1.07)	2.3	4.08	5.08	6.00	7.0	
		Week 44	Tezepelumab	78	77 (98.7)	5.17 (1.13)	2.3	4.33	5.08	6.08	7.0	
			Placebo	80	74 (92.5)	5.07 (1.15)	2.5	4.17	5.08	6.00	7.0	
		Week 48	Tezepelumab	78	77 (98.7)	5.20 (1.14)	2.8	4.25	5.17	6.17	7.0	
			Placebo	80	75 (93.8)	5.12 (1.09)	2.2	4.25	5.08	6.00	7.0	
		Week 52	Tezepelumab	78	77 (98.7)	5.19 (1.10)	2.8	4.25	5.17	6.00	7.0	
			Placebo	80	75 (93.8)	5.12 (1.10)	2.8	4.17	5.08	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	78	71 (91.0)	0.73 (1.07)	-4.3	0.08	0.58	1.50	3.1	0.25 [-0.09, 0.58]
			Placebo	80	67 (83.8)	0.49 (0.85)	-1.8	0.08	0.50	0.92	3.3	
		Week 8	Tezepelumab	78	72 (92.3)	0.91 (1.03)	-1.9	0.25	0.96	1.50	3.0	0.34 [0.00, 0.67]
			Placebo	80	68 (85.0)	0.58 (0.87)	-1.0	0.08	0.50	1.17	3.3	
		Week 12	Tezepelumab	78	72 (92.3)	1.05 (1.10)	-2.6	0.29	1.04	1.88	3.3	0.37 [0.04, 0.70]
			Placebo	80	68 (85.0)	0.64 (1.10)	-3.1	-0.04	0.67	1.17	3.8	
		Week 16	Tezepelumab	78	72 (92.3)	0.99 (1.07)	-2.9	0.33	1.00	1.58	3.4	0.27 [-0.06, 0.60]
			Placebo	80	68 (85.0)	0.69 (1.14)	-3.5	0.17	0.79	1.33	3.6	
		Week 20	Tezepelumab	78	72 (92.3)	1.07 (1.13)	-1.8	0.17	0.92	2.00	4.7	0.28 [-0.06, 0.61]
			Placebo	80	68 (85.0)	0.78 (0.96)	-3.5	0.25	0.83	1.25	3.3	
		Week 24	Tezepelumab	78	72 (92.3)	1.11 (1.08)	-1.6	0.33	1.00	1.96	3.7	0.37 [0.03, 0.70]
			Placebo	80	68 (85.0)	0.72 (1.07)	-3.5	0.04	0.83	1.25	3.6	
		Week 28	Tezepelumab	78	72 (92.3)	1.06 (1.11)	-1.7	0.29	0.92	2.00	4.9	0.26 [-0.07, 0.59]
			Placebo	80	68 (85.0)	0.77 (1.11)	-3.5	0.08	0.71	1.38	3.4	
		Week 32	Tezepelumab	78	72 (92.3)	1.09 (1.16)	-1.6	0.33	1.00	1.92	4.6	0.22 [-0.12, 0.55]
			Placebo	80	68 (85.0)	0.85 (1.02)	-3.5	0.29	0.92	1.33	3.5	
		Week 36	Tezepelumab	78	72 (92.3)	1.07 (1.17)	-1.7	0.17	0.96	2.04	3.4	0.12 [-0.21, 0.45]
			Placebo	80	68 (85.0)	0.93 (1.09)	-2.3	0.21	0.92	1.54	3.8	
		Week 40	Tezepelumab	78	72 (92.3)	1.18 (1.12)	-1.7	0.33	1.08	2.08	3.4	0.26 [-0.07, 0.59]
			Placebo	80	68 (85.0)	0.90 (1.02)	-1.4	0.29	0.83	1.58	3.4	
		Week 44	Tezepelumab	78	72 (92.3)	1.12 (1.16)	-1.8	0.38	1.08	2.08	3.3	0.20 [-0.13, 0.53]
			Placebo	80	68 (85.0)	0.90 (1.02)	-1.3	0.33	0.92	1.42	3.7	
		Week 48	Tezepelumab	78	72 (92.3)	1.16 (1.14)	-1.6	0.33	1.08	2.04	3.4	0.19 [-0.14, 0.53]
			Placebo	80	68 (85.0)	0.95 (1.01)	-1.5	0.29	0.92	1.46	4.2	
		Week 52	Tezepelumab	78	72 (92.3)	1.15 (1.14)	-1.6	0.33	1.04	2.00	3.6	0.17 [-0.16, 0.50]
			Placebo	80	68 (85.0)	0.97 (1.01)	-1.1	0.29	0.92	1.38	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	3.77 (1.40)	1.4	2.58	4.33	4.50	5.5	
			Placebo	9	8 (88.9)	3.42 (0.71)	2.4	2.96	3.38	3.83	4.6	
		Week 4	Tezepelumab	10	8 (80.0)	5.66 (0.73)	4.9	5.04	5.46	6.21	6.9	
			Placebo	9	7 (77.8)	4.44 (1.11)	2.4	4.08	4.33	5.17	6.0	
		Week 8	Tezepelumab	10	9 (90.0)	5.73 (1.00)	3.6	5.75	5.83	6.17	7.0	
			Placebo	9	7 (77.8)	4.75 (1.52)	2.3	3.33	5.25	5.83	6.5	
		Week 12	Tezepelumab	10	9 (90.0)	5.87 (0.83)	4.4	5.67	6.08	6.25	7.0	
			Placebo	9	7 (77.8)	4.85 (1.42)	3.0	3.25	4.92	5.92	6.8	
		Week 16	Tezepelumab	10	9 (90.0)	5.63 (1.05)	3.5	5.67	5.83	6.08	6.8	
			Placebo	9	7 (77.8)	4.62 (1.58)	2.1	3.42	4.92	5.92	6.6	
		Week 20	Tezepelumab	10	9 (90.0)	5.85 (0.73)	4.4	5.50	6.00	6.25	6.8	
			Placebo	9	7 (77.8)	4.89 (1.78)	2.1	3.50	5.25	6.67	6.8	
		Week 24	Tezepelumab	10	9 (90.0)	5.87 (0.79)	4.4	5.50	5.75	6.17	7.0	
			Placebo	9	7 (77.8)	5.25 (1.33)	3.4	3.67	6.00	6.08	6.8	
		Week 28	Tezepelumab	10	10 (100.0)	5.91 (0.82)	4.4	5.42	5.75	6.75	7.0	
			Placebo	9	7 (77.8)	5.25 (1.21)	3.4	4.00	5.42	6.25	6.7	
		Week 32	Tezepelumab	10	10 (100.0)	5.76 (0.78)	4.4	5.50	5.75	6.42	6.9	
			Placebo	9	7 (77.8)	5.24 (1.05)	3.4	4.42	5.25	6.17	6.3	
		Week 36	Tezepelumab	10	10 (100.0)	5.64 (0.92)	4.3	5.17	5.58	6.58	6.9	
			Placebo	9	7 (77.8)	5.04 (0.82)	3.4	4.83	5.08	5.50	6.1	
		Week 40	Tezepelumab	10	10 (100.0)	5.72 (0.88)	4.4	4.83	5.83	6.42	6.9	
			Placebo	9	7 (77.8)	5.14 (1.01)	3.4	4.42	5.75	6.00	6.1	
		Week 44	Tezepelumab	10	10 (100.0)	5.81 (0.87)	4.4	5.50	5.79	6.50	7.0	
			Placebo	9	7 (77.8)	5.21 (1.18)	3.3	4.00	5.75	6.17	6.3	
		Week 48	Tezepelumab	10	10 (100.0)	5.90 (0.81)	4.4	5.50	5.88	6.50	7.0	
			Placebo	9	7 (77.8)	5.49 (0.85)	3.8	5.25	5.67	6.17	6.5	
		Week 52	Tezepelumab	10	10 (100.0)	5.94 (0.83)	4.4	5.50	5.96	6.75	7.0	
			Placebo	9	7 (77.8)	5.62 (0.96)	4.0	5.25	5.67	6.50	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	1.59 (1.22)	-0.4	0.79	1.58	2.67	3.1	0.56 [-0.47, 1.60]
			Placebo	9	7 (77.8)	0.88 (1.31)	-0.6	-0.25	0.67	1.75	3.1	
		Week 8	Tezepelumab	10	9 (90.0)	1.96 (1.29)	0.3	0.83	2.17	2.50	4.1	0.56 [-0.45, 1.57]
			Placebo	9	7 (77.8)	1.19 (1.49)	-0.8	-0.08	0.92	2.50	3.6	
		Week 12	Tezepelumab	10	9 (90.0)	2.10 (1.45)	0.3	1.08	1.92	3.00	4.5	0.56 [-0.45, 1.57]
			Placebo	9	7 (77.8)	1.29 (1.47)	-0.2	0.00	0.83	2.50	3.8	
		Week 16	Tezepelumab	10	9 (90.0)	1.86 (1.64)	-0.9	0.83	1.75	3.00	4.6	0.50 [-0.50, 1.51]
			Placebo	9	7 (77.8)	1.06 (1.53)	-1.3	0.42	1.00	1.67	3.7	
		Week 20	Tezepelumab	10	9 (90.0)	2.08 (1.28)	0.5	1.00	1.92	2.92	4.6	0.49 [-0.52, 1.49]
			Placebo	9	7 (77.8)	1.33 (1.82)	-1.3	0.08	0.92	3.33	3.8	
		Week 24	Tezepelumab	10	9 (90.0)	2.10 (1.41)	0.3	1.58	1.83	2.92	4.8	0.30 [-0.70, 1.29]
			Placebo	9	7 (77.8)	1.69 (1.36)	0.0	0.25	1.67	2.75	3.9	
		Week 28	Tezepelumab	10	9 (90.0)	2.05 (1.45)	0.3	0.92	1.92	2.92	4.8	0.25 [-0.74, 1.25]
			Placebo	9	7 (77.8)	1.69 (1.33)	0.0	0.58	1.83	2.92	3.8	
		Week 32	Tezepelumab	10	9 (90.0)	1.89 (1.46)	0.3	0.83	1.58	2.92	4.8	0.15 [-0.84, 1.14]
			Placebo	9	7 (77.8)	1.68 (1.23)	0.0	0.50	1.83	2.92	3.3	
		Week 36	Tezepelumab	10	9 (90.0)	1.75 (1.69)	-0.3	0.17	1.58	2.92	4.8	0.20 [-0.79, 1.19]
			Placebo	9	7 (77.8)	1.48 (0.84)	0.0	0.75	1.75	1.83	2.6	
		Week 40	Tezepelumab	10	9 (90.0)	1.84 (1.62)	-0.7	1.00	1.75	2.92	4.8	0.19 [-0.80, 1.18]
			Placebo	9	7 (77.8)	1.58 (0.93)	0.0	1.00	1.58	2.42	2.8	
		Week 44	Tezepelumab	10	9 (90.0)	1.96 (1.53)	0.0	0.92	1.67	2.92	4.8	0.23 [-0.76, 1.22]
			Placebo	9	7 (77.8)	1.65 (1.08)	-0.1	0.58	2.00	2.75	2.8	
		Week 48	Tezepelumab	10	9 (90.0)	2.06 (1.41)	0.2	1.17	1.67	2.92	4.8	0.11 [-0.88, 1.10]
			Placebo	9	7 (77.8)	1.93 (0.97)	0.4	0.67	2.33	2.75	2.8	
		Week 52	Tezepelumab	10	9 (90.0)	2.08 (1.39)	0.3	1.17	1.67	2.92	4.8	0.02 [-0.97, 1.01]
			Placebo	9	7 (77.8)	2.06 (1.09)	0.6	0.67	2.25	2.75	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	5	4 (80.0)	4.40 (0.83)	3.2	3.92	4.71	4.88	5.0	
			Placebo	6	6 (100.0)	4.26 (0.98)	2.3	4.42	4.46	4.92	5.0	
		Week 4	Tezepelumab	5	5 (100.0)	5.33 (0.85)	4.5	4.75	4.92	6.17	6.3	
			Placebo	6	6 (100.0)	4.83 (0.47)	4.1	4.50	4.96	5.25	5.3	
		Week 8	Tezepelumab	5	5 (100.0)	5.63 (0.60)	5.1	5.25	5.42	5.83	6.6	
			Placebo	6	6 (100.0)	4.75 (0.57)	4.3	4.25	4.63	5.00	5.8	
		Week 12	Tezepelumab	5	5 (100.0)	6.02 (0.64)	5.3	5.58	5.83	6.42	6.9	
			Placebo	6	6 (100.0)	5.42 (0.39)	4.9	5.00	5.46	5.83	5.8	
		Week 16	Tezepelumab	5	5 (100.0)	6.02 (0.48)	5.7	5.67	5.92	6.00	6.8	
			Placebo	6	6 (100.0)	5.38 (0.50)	4.6	5.00	5.50	5.83	5.8	
		Week 20	Tezepelumab	5	5 (100.0)	5.83 (0.82)	4.7	5.67	5.75	6.17	6.9	
			Placebo	6	6 (100.0)	5.04 (0.95)	3.6	4.67	4.92	6.08	6.1	
		Week 24	Tezepelumab	5	5 (100.0)	5.95 (0.61)	5.3	5.67	5.92	6.00	6.9	
			Placebo	6	6 (100.0)	5.22 (0.94)	3.8	4.67	5.29	5.92	6.4	
		Week 28	Tezepelumab	5	5 (100.0)	6.00 (0.56)	5.7	5.75	5.75	5.83	7.0	
			Placebo	6	6 (100.0)	6.06 (0.91)	5.1	5.17	6.04	7.00	7.0	
		Week 32	Tezepelumab	5	5 (100.0)	6.25 (0.48)	5.8	6.00	6.00	6.58	6.9	
			Placebo	6	6 (100.0)	5.65 (0.62)	4.8	5.25	5.67	6.17	6.3	
		Week 36	Tezepelumab	5	5 (100.0)	6.10 (0.70)	5.1	5.92	6.08	6.42	7.0	
			Placebo	6	6 (100.0)	5.29 (1.29)	3.2	4.83	5.33	6.08	7.0	
		Week 40	Tezepelumab	5	5 (100.0)	6.25 (0.59)	5.5	6.00	6.08	6.67	7.0	
			Placebo	6	6 (100.0)	5.42 (1.19)	4.2	4.42	5.08	6.75	7.0	
		Week 44	Tezepelumab	5	5 (100.0)	6.37 (0.50)	5.8	6.00	6.50	6.58	7.0	
			Placebo	6	6 (100.0)	5.07 (1.50)	3.2	4.00	4.79	6.67	7.0	
		Week 48	Tezepelumab	5	5 (100.0)	5.95 (0.89)	4.5	6.00	6.08	6.25	6.9	
			Placebo	6	6 (100.0)	5.31 (1.00)	4.0	4.83	5.04	6.08	6.8	
		Week 52	Tezepelumab	5	5 (100.0)	6.08 (0.94)	4.5	6.08	6.25	6.67	6.9	
			Placebo	6	6 (100.0)	5.17 (0.78)	4.0	4.83	5.04	6.00	6.1	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	5	4 (80.0)	1.08 (0.62)	0.2	0.75	1.33	1.42	1.5	0.82 [-0.51, 2.14]
			Placebo	6	6 (100.0)	0.57 (0.64)	0.1	0.17	0.29	0.83	1.8	
		Week 8	Tezepelumab	5	4 (80.0)	1.29 (0.73)	0.5	0.67	1.38	1.92	1.9	1.05 [-0.32, 2.41]
			Placebo	6	6 (100.0)	0.49 (0.79)	-0.3	0.00	0.21	0.83	1.9	
		Week 12	Tezepelumab	5	4 (80.0)	1.67 (0.67)	0.8	1.13	1.79	2.21	2.3	0.51 [-0.78, 1.80]
			Placebo	6	6 (100.0)	1.15 (1.17)	0.5	0.50	0.75	0.92	3.5	
		Week 16	Tezepelumab	5	4 (80.0)	1.71 (0.74)	1.0	1.08	1.67	2.33	2.5	0.55 [-0.74, 1.84]
			Placebo	6	6 (100.0)	1.11 (1.25)	0.1	0.42	0.63	1.42	3.5	
		Week 20	Tezepelumab	5	4 (80.0)	1.46 (1.18)	-0.1	0.54	1.71	2.38	2.5	0.47 [-0.82, 1.75]
			Placebo	6	6 (100.0)	0.78 (1.61)	-0.8	-0.17	0.38	1.17	3.8	
		Week 24	Tezepelumab	5	4 (80.0)	1.63 (1.05)	0.5	0.75	1.63	2.50	2.8	0.46 [-0.82, 1.75]
			Placebo	6	6 (100.0)	0.96 (1.64)	-0.7	0.25	0.54	1.00	4.1	
		Week 28	Tezepelumab	5	4 (80.0)	1.67 (0.92)	0.8	0.88	1.63	2.46	2.6	-0.09 [-1.36, 1.18]
			Placebo	6	6 (100.0)	1.79 (1.61)	0.2	0.67	1.54	2.17	4.7	
		Week 32	Tezepelumab	5	4 (80.0)	1.77 (0.76)	1.0	1.13	1.75	2.42	2.6	0.32 [-0.95, 1.59]
			Placebo	6	6 (100.0)	1.39 (1.39)	0.3	0.33	1.04	1.67	4.0	
		Week 36	Tezepelumab	5	4 (80.0)	1.62 (1.11)	0.3	0.71	1.71	2.54	2.8	0.39 [-0.89, 1.67]
			Placebo	6	6 (100.0)	1.03 (1.71)	-1.3	0.25	0.67	2.08	3.8	
		Week 40	Tezepelumab	5	4 (80.0)	1.75 (1.04)	0.8	0.88	1.67	2.63	2.9	0.36 [-0.91, 1.64]
			Placebo	6	6 (100.0)	1.15 (1.92)	-0.6	-0.25	0.63	1.83	4.7	
		Week 44	Tezepelumab	5	4 (80.0)	1.92 (1.15)	0.8	1.00	1.79	2.83	3.3	0.63 [-0.67, 1.93]
			Placebo	6	6 (100.0)	0.81 (2.06)	-1.3	-0.42	0.04	2.08	4.3	
		Week 48	Tezepelumab	5	4 (80.0)	1.54 (1.45)	-0.3	0.42	1.67	2.67	3.1	0.33 [-0.95, 1.60]
			Placebo	6	6 (100.0)	1.04 (1.56)	-0.4	-0.17	0.58	1.92	3.8	
		Week 52	Tezepelumab	5	4 (80.0)	1.54 (1.45)	-0.3	0.42	1.67	2.67	3.1	0.43 [-0.85, 1.71]
			Placebo	6	6 (100.0)	0.90 (1.50)	-0.4	-0.17	0.58	1.08	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	44	37 (84.1)	4.06 (0.90)	2.0	3.50	4.00	4.50	6.6	
			Placebo	43	39 (90.7)	3.63 (0.91)	1.5	3.17	3.75	4.17	6.3	
		Week 4	Tezepelumab	44	39 (88.6)	4.79 (1.11)	2.8	3.92	4.75	5.50	7.0	
			Placebo	43	41 (95.3)	4.34 (0.90)	2.3	3.67	4.33	5.00	6.5	
		Week 8	Tezepelumab	44	39 (88.6)	4.94 (1.16)	2.7	4.08	4.83	6.08	7.0	
			Placebo	43	42 (97.7)	4.34 (1.01)	1.9	3.75	4.42	5.00	6.7	
		Week 12	Tezepelumab	44	39 (88.6)	5.15 (1.13)	2.8	4.25	5.08	6.08	7.0	
			Placebo	43	42 (97.7)	4.56 (0.99)	2.4	4.00	4.38	5.08	6.8	
		Week 16	Tezepelumab	44	39 (88.6)	5.25 (1.07)	3.4	4.33	5.25	6.00	7.0	
			Placebo	43	42 (97.7)	4.55 (1.04)	2.2	4.00	4.46	5.25	6.8	
		Week 20	Tezepelumab	44	39 (88.6)	5.10 (1.08)	3.3	4.17	5.00	5.83	7.0	
			Placebo	43	42 (97.7)	4.49 (1.13)	2.3	4.00	4.21	5.25	6.9	
		Week 24	Tezepelumab	44	39 (88.6)	5.06 (1.20)	1.8	4.17	4.92	6.00	7.0	
			Placebo	43	42 (97.7)	4.59 (1.15)	2.2	3.92	4.46	5.33	7.0	
		Week 28	Tezepelumab	44	39 (88.6)	5.17 (1.08)	3.2	4.42	5.00	5.92	7.0	
			Placebo	43	42 (97.7)	4.44 (1.15)	1.8	3.67	4.17	5.17	7.0	
		Week 32	Tezepelumab	44	40 (90.9)	5.32 (1.05)	2.8	4.42	5.17	6.08	7.0	
			Placebo	43	42 (97.7)	4.59 (1.13)	2.4	3.92	4.29	5.58	7.0	
		Week 36	Tezepelumab	44	40 (90.9)	5.37 (1.07)	2.9	4.63	5.38	6.33	7.0	
			Placebo	43	42 (97.7)	4.59 (1.14)	2.5	4.00	4.33	5.33	7.0	
		Week 40	Tezepelumab	44	40 (90.9)	5.17 (1.11)	2.3	4.29	5.00	5.88	7.0	
			Placebo	43	42 (97.7)	4.69 (1.20)	2.4	3.83	4.54	5.50	7.0	
		Week 44	Tezepelumab	44	40 (90.9)	5.31 (1.03)	3.7	4.38	5.29	5.96	7.0	
			Placebo	43	42 (97.7)	4.61 (1.17)	2.3	3.83	4.42	5.67	7.0	
		Week 48	Tezepelumab	44	40 (90.9)	5.32 (1.03)	3.7	4.54	5.04	6.29	7.0	
			Placebo	43	42 (97.7)	4.55 (1.12)	2.4	3.83	4.33	5.25	7.0	
		Week 52	Tezepelumab	44	40 (90.9)	5.33 (1.03)	3.7	4.63	5.04	6.33	7.0	
			Placebo	43	42 (97.7)	4.48 (1.08)	2.5	3.83	4.29	5.17	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	44	34 (77.3)	0.79 (0.83)	-0.7	0.33	0.83	1.42	2.8	0.16 [-0.30, 0.62]
			Placebo	43	39 (90.7)	0.66 (0.80)	-1.1	0.17	0.50	1.17	2.4	
		Week 8	Tezepelumab	44	34 (77.3)	0.87 (1.01)	-0.7	0.00	0.79	1.67	3.0	0.15 [-0.31, 0.61]
			Placebo	43	39 (90.7)	0.72 (0.96)	-1.8	0.25	0.58	1.25	2.7	
		Week 12	Tezepelumab	44	34 (77.3)	1.07 (0.96)	-0.8	0.42	0.92	1.92	3.0	0.15 [-0.31, 0.61]
			Placebo	43	39 (90.7)	0.90 (1.24)	-2.8	0.25	1.00	1.50	4.0	
		Week 16	Tezepelumab	44	34 (77.3)	1.22 (0.96)	-0.5	0.42	1.33	2.08	3.0	0.27 [-0.19, 0.73]
			Placebo	43	39 (90.7)	0.93 (1.18)	-3.0	0.17	1.17	1.67	4.2	
		Week 20	Tezepelumab	44	34 (77.3)	1.06 (0.87)	-0.5	0.42	1.00	1.75	3.0	0.18 [-0.28, 0.64]
			Placebo	43	39 (90.7)	0.87 (1.17)	-3.0	0.08	1.00	1.58	3.4	
		Week 24	Tezepelumab	44	34 (77.3)	1.11 (1.02)	-1.6	0.42	1.04	1.92	3.0	0.11 [-0.35, 0.57]
			Placebo	43	39 (90.7)	0.99 (1.22)	-3.0	0.33	0.92	1.67	3.4	
		Week 28	Tezepelumab	44	34 (77.3)	1.12 (0.91)	-0.4	0.42	1.13	1.67	3.0	0.26 [-0.20, 0.72]
			Placebo	43	39 (90.7)	0.82 (1.31)	-3.0	0.08	0.92	1.25	4.3	
		Week 32	Tezepelumab	44	34 (77.3)	1.31 (1.06)	-0.8	0.42	1.13	2.08	3.1	0.27 [-0.19, 0.73]
			Placebo	43	39 (90.7)	1.00 (1.22)	-3.0	0.25	1.08	1.50	3.4	
		Week 36	Tezepelumab	44	34 (77.3)	1.33 (1.07)	-0.6	0.42	1.25	2.08	3.8	0.29 [-0.17, 0.76]
			Placebo	43	39 (90.7)	0.99 (1.20)	-3.0	0.08	1.08	1.67	3.8	
		Week 40	Tezepelumab	44	34 (77.3)	1.11 (0.99)	-0.9	0.50	1.04	1.83	3.0	0.01 [-0.45, 0.47]
			Placebo	43	39 (90.7)	1.10 (1.29)	-3.0	0.50	1.17	1.67	4.0	
		Week 44	Tezepelumab	44	34 (77.3)	1.26 (0.91)	-0.5	0.58	1.17	2.00	3.0	0.22 [-0.24, 0.68]
			Placebo	43	39 (90.7)	1.01 (1.32)	-3.0	0.08	1.17	1.67	3.8	
		Week 48	Tezepelumab	44	34 (77.3)	1.31 (0.90)	-0.3	0.50	1.17	2.00	3.0	0.33 [-0.13, 0.79]
			Placebo	43	39 (90.7)	0.94 (1.25)	-3.0	0.08	1.17	1.67	3.8	
		Week 52	Tezepelumab	44	34 (77.3)	1.28 (0.91)	-0.3	0.67	1.00	2.25	3.0	0.40 [-0.07, 0.86]
			Placebo	43	39 (90.7)	0.86 (1.18)	-3.0	0.08	0.75	1.67	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Absolute values	Baseline	Placebo	1	1 (100.0)	1.83	1.8	1.83	1.83	1.83	1.8	
		Week 4	Placebo	1	1 (100.0)	1.75	1.8	1.75	1.75	1.75	1.8	
		Week 8	Placebo	1	1 (100.0)	2.33	2.3	2.33	2.33	2.33	2.3	
		Week 12	Placebo	1	1 (100.0)	2.75	2.8	2.75	2.75	2.75	2.8	
		Week 16	Placebo	1	1 (100.0)	3.17	3.2	3.17	3.17	3.17	3.2	
		Week 20	Placebo	1	1 (100.0)	2.58	2.6	2.58	2.58	2.58	2.6	
		Week 24	Placebo	1	1 (100.0)	2.08	2.1	2.08	2.08	2.08	2.1	
		Week 28	Placebo	1	1 (100.0)	3.92	3.9	3.92	3.92	3.92	3.9	
		Week 32	Placebo	1	1 (100.0)	2.08	2.1	2.08	2.08	2.08	2.1	
		Week 36	Placebo	1	1 (100.0)	3.25	3.3	3.25	3.25	3.25	3.3	
		Week 40	Placebo	1	1 (100.0)	3.25	3.3	3.25	3.25	3.25	3.3	
		Week 44	Placebo	1	1 (100.0)	2.83	2.8	2.83	2.83	2.83	2.8	
		Week 48	Placebo	1	1 (100.0)	3.25	3.3	3.25	3.25	3.25	3.3	
		Week 52	Placebo	1	1 (100.0)	3.25	3.3	3.25	3.25	3.25	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
< 18.5 kg/m**2	Change from baseline	Week 4	Placebo	1	1 (100.0)	-0.08	-0.1	-0.08	-0.08	-0.08	-0.1	
		Week 8	Placebo	1	1 (100.0)	0.50	0.5	0.50	0.50	0.50	0.5	
		Week 12	Placebo	1	1 (100.0)	0.92	0.9	0.92	0.92	0.92	0.9	
		Week 16	Placebo	1	1 (100.0)	1.33	1.3	1.33	1.33	1.33	1.3	
		Week 20	Placebo	1	1 (100.0)	0.75	0.8	0.75	0.75	0.75	0.8	
		Week 24	Placebo	1	1 (100.0)	0.25	0.3	0.25	0.25	0.25	0.3	
		Week 28	Placebo	1	1 (100.0)	2.08	2.1	2.08	2.08	2.08	2.1	
		Week 32	Placebo	1	1 (100.0)	0.25	0.3	0.25	0.25	0.25	0.3	
		Week 36	Placebo	1	1 (100.0)	1.42	1.4	1.42	1.42	1.42	1.4	
		Week 40	Placebo	1	1 (100.0)	1.42	1.4	1.42	1.42	1.42	1.4	
		Week 44	Placebo	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	
		Week 48	Placebo	1	1 (100.0)	1.42	1.4	1.42	1.42	1.42	1.4	
		Week 52	Placebo	1	1 (100.0)	1.42	1.4	1.42	1.42	1.42	1.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	39	35 (89.7)	4.19 (1.04)	2.3	3.58	4.00	4.92	6.8	
			Placebo	43	38 (88.4)	4.00 (1.02)	1.7	3.50	4.21	4.67	5.9	
		Week 4	Tezepelumab	39	36 (92.3)	5.37 (0.98)	3.3	4.67	5.46	6.21	7.0	
			Placebo	43	40 (93.0)	4.71 (0.94)	2.3	4.13	4.83	5.25	6.4	
		Week 8	Tezepelumab	39	37 (94.9)	5.56 (0.91)	3.4	5.00	5.67	6.08	7.0	
			Placebo	43	40 (93.0)	4.76 (1.11)	2.1	4.04	4.75	5.75	7.0	
		Week 12	Tezepelumab	39	37 (94.9)	5.82 (0.94)	3.8	5.42	6.00	6.58	7.0	
			Placebo	43	40 (93.0)	4.92 (1.13)	2.4	4.04	5.00	5.83	7.0	
		Week 16	Tezepelumab	39	37 (94.9)	5.69 (0.93)	3.8	5.25	5.75	6.42	7.0	
			Placebo	43	40 (93.0)	4.98 (1.22)	2.2	4.08	5.25	5.83	7.0	
		Week 20	Tezepelumab	39	37 (94.9)	5.73 (0.93)	3.8	5.08	5.83	6.58	7.0	
			Placebo	43	40 (93.0)	5.01 (1.27)	2.3	4.17	5.08	6.08	7.0	
		Week 24	Tezepelumab	39	37 (94.9)	5.77 (0.88)	3.8	5.17	5.83	6.58	7.0	
			Placebo	43	40 (93.0)	5.04 (1.27)	2.2	4.04	5.29	6.00	7.0	
		Week 28	Tezepelumab	39	37 (94.9)	5.75 (0.91)	3.8	5.42	5.75	6.67	7.0	
			Placebo	43	41 (95.3)	5.07 (1.34)	1.8	3.92	5.42	6.00	7.0	
		Week 32	Tezepelumab	39	38 (97.4)	5.82 (0.90)	2.9	5.33	5.88	6.58	7.0	
			Placebo	43	41 (95.3)	5.16 (1.23)	2.4	4.08	5.50	6.17	7.0	
		Week 36	Tezepelumab	39	38 (97.4)	5.90 (0.91)	3.2	5.33	5.92	6.58	7.0	
			Placebo	43	41 (95.3)	5.17 (1.35)	2.5	4.00	5.33	6.25	7.0	
		Week 40	Tezepelumab	39	38 (97.4)	5.89 (0.89)	4.1	5.50	5.88	6.67	7.0	
			Placebo	43	41 (95.3)	5.20 (1.32)	2.4	4.17	5.17	6.33	7.0	
		Week 44	Tezepelumab	39	38 (97.4)	5.93 (0.85)	4.3	5.33	5.88	6.75	7.0	
			Placebo	43	41 (95.3)	5.09 (1.33)	2.3	4.00	5.33	6.08	7.0	
		Week 48	Tezepelumab	39	38 (97.4)	5.93 (0.86)	4.3	5.17	6.04	6.75	7.0	
			Placebo	43	42 (97.7)	5.08 (1.24)	2.4	4.00	5.13	6.00	7.0	
		Week 52	Tezepelumab	39	38 (97.4)	5.91 (0.85)	4.5	5.17	6.04	6.67	7.0	
			Placebo	43	42 (97.7)	5.11 (1.22)	2.5	4.00	5.21	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	39	33 (84.6)	1.29 (0.83)	-0.6	0.83	1.33	1.75	3.1	0.74 [0.26, 1.22]
			Placebo	43	38 (88.4)	0.71 (0.73)	-0.9	0.17	0.67	1.25	2.3	
		Week 8	Tezepelumab	39	34 (87.2)	1.36 (0.88)	-0.3	0.83	1.33	2.00	3.3	0.66 [0.19, 1.14]
			Placebo	43	38 (88.4)	0.80 (0.81)	-0.8	0.42	0.67	1.17	2.7	
		Week 12	Tezepelumab	39	34 (87.2)	1.60 (1.02)	-0.6	1.08	1.75	2.08	3.7	0.64 [0.16, 1.11]
			Placebo	43	38 (88.4)	0.92 (1.10)	-3.1	0.50	1.08	1.33	3.5	
		Week 16	Tezepelumab	39	34 (87.2)	1.47 (1.07)	-0.5	0.42	1.63	2.17	3.3	0.42 [-0.04, 0.89]
			Placebo	43	38 (88.4)	1.01 (1.08)	-3.1	0.67	1.13	1.42	3.5	
		Week 20	Tezepelumab	39	34 (87.2)	1.50 (1.00)	-0.4	0.50	1.58	2.33	3.3	0.44 [-0.02, 0.91]
			Placebo	43	38 (88.4)	1.05 (1.03)	-1.1	0.42	1.08	1.75	3.8	
		Week 24	Tezepelumab	39	34 (87.2)	1.57 (0.98)	-0.4	0.92	1.63	2.17	3.3	0.46 [-0.01, 0.93]
			Placebo	43	38 (88.4)	1.11 (1.04)	-1.3	0.58	1.17	1.42	4.1	
		Week 28	Tezepelumab	39	34 (87.2)	1.52 (0.90)	-0.4	1.00	1.50	2.08	3.3	0.43 [-0.04, 0.90]
			Placebo	43	38 (88.4)	1.08 (1.11)	-1.8	0.58	1.04	1.58	4.7	
		Week 32	Tezepelumab	39	34 (87.2)	1.57 (0.99)	-0.3	1.00	1.54	2.42	3.3	0.40 [-0.07, 0.87]
			Placebo	43	38 (88.4)	1.18 (0.94)	-0.9	0.58	1.17	1.50	4.0	
		Week 36	Tezepelumab	39	34 (87.2)	1.63 (1.11)	-0.8	0.75	1.79	2.50	3.4	0.41 [-0.06, 0.88]
			Placebo	43	38 (88.4)	1.19 (1.05)	-1.3	0.67	1.25	1.92	3.8	
		Week 40	Tezepelumab	39	34 (87.2)	1.62 (1.00)	-0.4	1.00	1.63	2.25	3.4	0.38 [-0.08, 0.85]
			Placebo	43	38 (88.4)	1.22 (1.09)	-1.0	0.50	1.21	1.83	4.7	
		Week 44	Tezepelumab	39	34 (87.2)	1.65 (0.99)	-0.5	0.83	1.63	2.33	3.3	0.53 [0.06, 1.00]
			Placebo	43	38 (88.4)	1.10 (1.09)	-1.4	0.42	1.17	1.58	4.3	
		Week 48	Tezepelumab	39	34 (87.2)	1.71 (0.96)	-0.3	1.08	1.75	2.42	3.4	0.63 [0.16, 1.11]
			Placebo	43	38 (88.4)	1.07 (1.06)	-1.1	0.25	1.17	1.75	3.8	
		Week 52	Tezepelumab	39	34 (87.2)	1.64 (0.98)	-0.3	0.92	1.58	2.33	3.6	0.54 [0.07, 1.01]
			Placebo	43	38 (88.4)	1.11 (1.01)	-0.9	0.42	1.13	1.75	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	45	41 (91.1)	3.97 (1.08)	1.3	3.42	4.00	4.67	6.3	
			Placebo	47	43 (91.5)	4.13 (0.79)	2.4	3.67	4.08	4.58	6.3	
		Week 4	Tezepelumab	45	43 (95.6)	4.85 (0.99)	2.9	3.92	4.92	5.58	6.9	
			Placebo	47	43 (91.5)	4.46 (0.91)	2.6	3.92	4.33	5.25	6.1	
		Week 8	Tezepelumab	45	43 (95.6)	5.01 (1.14)	2.7	3.92	5.25	5.83	7.0	
			Placebo	47	45 (95.7)	4.61 (0.92)	2.8	4.00	4.50	5.33	6.5	
		Week 12	Tezepelumab	45	43 (95.6)	5.11 (1.23)	2.8	4.00	5.08	6.17	7.0	
			Placebo	47	45 (95.7)	4.61 (1.05)	2.1	4.00	4.50	5.25	6.9	
		Week 16	Tezepelumab	45	43 (95.6)	5.15 (1.26)	2.3	4.00	5.25	6.25	7.0	
			Placebo	47	45 (95.7)	4.57 (1.15)	1.3	4.00	4.58	5.42	7.0	
		Week 20	Tezepelumab	45	43 (95.6)	5.22 (1.16)	3.3	4.08	5.17	6.25	7.0	
			Placebo	47	45 (95.7)	4.64 (1.14)	1.3	4.00	4.67	5.33	7.0	
		Week 24	Tezepelumab	45	43 (95.6)	5.15 (1.24)	1.8	4.17	4.92	6.50	7.0	
			Placebo	47	45 (95.7)	4.63 (1.16)	1.3	4.00	4.58	5.33	7.0	
		Week 28	Tezepelumab	45	44 (97.8)	5.28 (1.15)	3.2	4.38	5.04	6.46	7.0	
			Placebo	47	45 (95.7)	4.67 (1.21)	1.3	4.00	4.58	5.42	7.0	
		Week 32	Tezepelumab	45	44 (97.8)	5.37 (1.18)	2.8	4.29	5.33	6.46	7.0	
			Placebo	47	45 (95.7)	4.68 (1.07)	1.3	4.00	4.67	5.33	6.9	
		Week 36	Tezepelumab	45	44 (97.8)	5.22 (1.15)	2.9	4.29	5.08	6.33	7.0	
			Placebo	47	45 (95.7)	4.66 (1.07)	2.4	4.00	4.33	5.42	7.0	
		Week 40	Tezepelumab	45	44 (97.8)	5.34 (1.14)	3.2	4.33	5.33	6.33	7.0	
			Placebo	47	45 (95.7)	4.73 (0.97)	2.3	4.00	4.75	5.50	7.0	
		Week 44	Tezepelumab	45	44 (97.8)	5.31 (1.13)	3.2	4.33	5.38	6.33	7.0	
			Placebo	47	45 (95.7)	4.82 (1.03)	2.5	4.00	4.58	5.75	7.0	
		Week 48	Tezepelumab	45	44 (97.8)	5.26 (1.15)	3.3	4.33	5.04	6.33	7.0	
			Placebo	47	45 (95.7)	4.85 (1.06)	2.2	4.00	4.83	5.67	7.0	
		Week 52	Tezepelumab	45	44 (97.8)	5.31 (1.13)	3.6	4.33	5.04	6.50	7.0	
			Placebo	47	45 (95.7)	4.83 (1.08)	2.8	4.00	4.75	5.67	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	45	40 (88.9)	0.87 (0.99)	-1.4	0.29	0.88	1.50	3.1	0.52 [0.08, 0.96]
			Placebo	47	42 (89.4)	0.37 (0.92)	-1.8	0.00	0.25	0.92	3.1	
		Week 8	Tezepelumab	45	40 (88.9)	0.97 (1.10)	-1.4	0.21	0.83	1.63	4.1	0.45 [0.01, 0.89]
			Placebo	47	43 (91.5)	0.50 (0.99)	-1.8	-0.08	0.33	1.17	3.6	
		Week 12	Tezepelumab	45	40 (88.9)	1.08 (1.18)	-1.4	0.38	0.92	2.00	4.5	0.50 [0.07, 0.94]
			Placebo	47	43 (91.5)	0.50 (1.15)	-2.8	-0.25	0.50	1.17	3.8	
		Week 16	Tezepelumab	45	40 (88.9)	1.12 (1.12)	-1.4	0.46	1.00	1.92	4.6	0.55 [0.11, 0.99]
			Placebo	47	43 (91.5)	0.46 (1.30)	-3.5	-0.08	0.50	1.17	3.7	
		Week 20	Tezepelumab	45	40 (88.9)	1.24 (1.28)	-1.4	0.42	1.21	2.00	4.7	0.56 [0.12, 1.00]
			Placebo	47	43 (91.5)	0.53 (1.26)	-3.5	0.00	0.58	1.17	3.8	
		Week 24	Tezepelumab	45	40 (88.9)	1.16 (1.32)	-1.6	0.21	1.04	2.21	4.8	0.49 [0.05, 0.92]
			Placebo	47	43 (91.5)	0.52 (1.30)	-3.5	-0.08	0.42	1.17	3.9	
		Week 28	Tezepelumab	45	40 (88.9)	1.26 (1.34)	-1.4	0.38	0.92	2.21	4.9	0.51 [0.07, 0.95]
			Placebo	47	43 (91.5)	0.57 (1.34)	-3.5	0.00	0.58	1.17	3.8	
		Week 32	Tezepelumab	45	40 (88.9)	1.40 (1.39)	-1.4	0.42	1.29	2.33	4.8	0.62 [0.18, 1.06]
			Placebo	47	43 (91.5)	0.58 (1.24)	-3.5	0.00	0.58	1.08	3.3	
		Week 36	Tezepelumab	45	40 (88.9)	1.21 (1.39)	-1.4	0.04	1.17	2.17	4.8	0.51 [0.07, 0.95]
			Placebo	47	43 (91.5)	0.56 (1.20)	-3.0	0.00	0.42	1.17	3.5	
		Week 40	Tezepelumab	45	40 (88.9)	1.34 (1.30)	-1.4	0.46	1.50	2.33	4.8	0.59 [0.15, 1.03]
			Placebo	47	43 (91.5)	0.63 (1.12)	-3.0	0.00	0.67	1.25	3.2	
		Week 44	Tezepelumab	45	40 (88.9)	1.32 (1.28)	-1.4	0.50	1.29	2.21	4.8	0.49 [0.06, 0.93]
			Placebo	47	43 (91.5)	0.72 (1.18)	-3.0	0.00	0.58	1.67	3.3	
		Week 48	Tezepelumab	45	40 (88.9)	1.29 (1.28)	-1.4	0.33	1.33	2.21	4.8	0.44 [0.00, 0.87]
			Placebo	47	43 (91.5)	0.75 (1.22)	-3.0	0.00	0.67	1.58	3.3	
		Week 52	Tezepelumab	45	40 (88.9)	1.35 (1.29)	-1.4	0.38	1.25	2.38	4.8	0.50 [0.06, 0.93]
			Placebo	47	43 (91.5)	0.73 (1.23)	-3.0	0.00	0.67	1.58	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	53	47 (88.7)	4.01 (0.90)	1.4	3.58	4.17	4.58	5.6	
			Placebo	47	39 (83.0)	3.83 (0.84)	1.5	3.33	3.83	4.42	5.8	
		Week 4	Tezepelumab	53	47 (88.7)	4.43 (1.02)	1.3	3.75	4.50	4.92	6.9	
			Placebo	47	39 (83.0)	4.54 (0.93)	2.4	3.92	4.58	5.17	6.7	
		Week 8	Tezepelumab	53	48 (90.6)	4.70 (1.01)	2.0	4.13	4.54	5.42	7.0	
			Placebo	47	40 (85.1)	4.55 (1.08)	1.9	3.92	4.50	5.38	6.8	
		Week 12	Tezepelumab	53	48 (90.6)	4.86 (0.81)	3.0	4.25	4.75	5.42	7.0	
			Placebo	47	41 (87.2)	4.80 (1.01)	3.0	4.08	4.67	5.58	6.8	
		Week 16	Tezepelumab	53	48 (90.6)	4.87 (0.94)	2.7	4.33	4.88	5.42	6.9	
			Placebo	47	41 (87.2)	4.81 (0.94)	2.8	4.25	4.67	5.42	6.8	
		Week 20	Tezepelumab	53	49 (92.5)	4.79 (0.91)	2.3	4.17	4.58	5.42	6.8	
			Placebo	47	41 (87.2)	4.79 (0.90)	3.2	4.17	4.67	5.25	6.9	
		Week 24	Tezepelumab	53	49 (92.5)	4.88 (0.89)	3.1	4.17	4.75	5.58	7.0	
			Placebo	47	41 (87.2)	4.87 (0.91)	3.2	4.25	4.67	5.50	7.0	
		Week 28	Tezepelumab	53	50 (94.3)	4.77 (0.86)	3.2	4.17	4.58	5.25	7.0	
			Placebo	47	41 (87.2)	4.86 (1.03)	2.9	4.08	4.75	5.67	7.0	
		Week 32	Tezepelumab	53	50 (94.3)	4.82 (0.88)	2.8	4.17	4.83	5.50	6.7	
			Placebo	47	42 (89.4)	4.98 (1.00)	2.8	4.25	4.96	5.58	7.0	
		Week 36	Tezepelumab	53	50 (94.3)	4.87 (0.91)	2.9	4.25	4.79	5.67	6.9	
			Placebo	47	42 (89.4)	5.04 (0.99)	3.2	4.25	4.83	5.92	7.0	
		Week 40	Tezepelumab	53	50 (94.3)	4.77 (0.93)	2.3	4.25	4.63	5.42	6.9	
			Placebo	47	42 (89.4)	5.01 (1.01)	3.2	4.25	4.83	5.83	6.8	
		Week 44	Tezepelumab	53	50 (94.3)	4.83 (1.00)	2.3	4.17	4.71	5.50	7.0	
			Placebo	47	42 (89.4)	4.94 (1.15)	2.5	4.00	4.75	6.08	6.8	
		Week 48	Tezepelumab	53	50 (94.3)	4.91 (0.99)	2.8	4.17	5.00	5.58	7.0	
			Placebo	47	42 (89.4)	5.01 (1.03)	3.2	4.25	4.83	5.92	6.9	
		Week 52	Tezepelumab	53	50 (94.3)	4.89 (0.98)	2.8	4.17	4.88	5.58	7.0	
			Placebo	47	42 (89.4)	4.94 (1.04)	2.8	4.08	4.79	5.83	6.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	53	44 (83.0)	0.42 (1.04)	-4.3	-0.08	0.46	0.83	2.4	-0.27 [-0.71, 0.17]
			Placebo	47	38 (80.9)	0.68 (0.87)	-1.3	0.25	0.50	1.08	3.3	
		Week 8	Tezepelumab	53	45 (84.9)	0.73 (1.09)	-1.9	0.17	0.67	1.42	2.7	0.03 [-0.41, 0.46]
			Placebo	47	38 (80.9)	0.70 (1.01)	-1.0	0.17	0.58	1.17	3.3	
		Week 12	Tezepelumab	53	45 (84.9)	0.88 (1.01)	-2.6	0.33	0.92	1.25	3.0	-0.09 [-0.52, 0.34]
			Placebo	47	38 (80.9)	0.98 (1.25)	-1.0	0.17	0.83	1.25	4.0	
		Week 16	Tezepelumab	53	45 (84.9)	0.92 (1.08)	-2.9	0.33	0.83	1.50	3.4	-0.07 [-0.50, 0.36]
			Placebo	47	38 (80.9)	0.99 (1.06)	-1.2	0.17	0.96	1.58	4.2	
		Week 20	Tezepelumab	53	45 (84.9)	0.82 (0.91)	-1.8	0.17	0.75	1.33	3.0	-0.17 [-0.60, 0.26]
			Placebo	47	38 (80.9)	0.98 (0.97)	-0.4	0.17	0.79	1.67	3.3	
		Week 24	Tezepelumab	53	45 (84.9)	0.97 (0.93)	-1.6	0.42	0.92	1.50	3.0	-0.09 [-0.52, 0.34]
			Placebo	47	38 (80.9)	1.06 (1.11)	-1.2	0.25	0.83	1.50	3.6	
		Week 28	Tezepelumab	53	45 (84.9)	0.83 (0.92)	-1.7	0.25	0.75	1.25	3.0	-0.19 [-0.63, 0.24]
			Placebo	47	38 (80.9)	1.04 (1.19)	-1.6	0.25	0.79	1.67	4.3	
		Week 32	Tezepelumab	53	45 (84.9)	0.85 (0.94)	-1.6	0.33	0.92	1.42	3.2	-0.40 [-0.83, 0.04]
			Placebo	47	38 (80.9)	1.24 (1.06)	-0.6	0.42	1.04	1.92	3.5	
		Week 36	Tezepelumab	53	45 (84.9)	0.90 (0.95)	-1.7	0.08	0.92	1.58	3.0	-0.36 [-0.80, 0.07]
			Placebo	47	38 (80.9)	1.26 (1.06)	-0.2	0.33	1.08	1.75	3.8	
		Week 40	Tezepelumab	53	45 (84.9)	0.83 (0.94)	-1.7	0.25	0.92	1.17	3.0	-0.39 [-0.83, 0.04]
			Placebo	47	38 (80.9)	1.25 (1.19)	-1.0	0.50	1.17	1.75	4.0	
		Week 44	Tezepelumab	53	45 (84.9)	0.89 (1.02)	-1.8	0.33	0.92	1.50	3.3	-0.23 [-0.66, 0.21]
			Placebo	47	38 (80.9)	1.15 (1.28)	-1.3	0.25	1.08	1.75	3.8	
		Week 48	Tezepelumab	53	45 (84.9)	0.95 (0.98)	-1.6	0.33	0.83	1.42	3.1	-0.28 [-0.71, 0.16]
			Placebo	47	38 (80.9)	1.24 (1.09)	-0.6	0.42	1.13	1.75	4.2	
		Week 52	Tezepelumab	53	45 (84.9)	0.92 (0.97)	-1.6	0.33	0.83	1.42	3.1	-0.25 [-0.68, 0.19]
			Placebo	47	38 (80.9)	1.17 (1.07)	-0.3	0.42	0.92	1.67	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	27	27 (100.0)	4.05 (0.92)	2.1	3.75	4.08	4.67	6.3	
			Placebo	33	29 (87.9)	4.06 (0.81)	2.7	3.50	4.17	4.50	5.8	
		Week 4	Tezepelumab	27	27 (100.0)	4.83 (1.11)	2.6	3.92	4.75	5.67	6.9	
			Placebo	33	30 (90.9)	4.61 (0.97)	2.6	4.00	4.75	5.25	6.7	
		Week 8	Tezepelumab	27	27 (100.0)	4.96 (1.13)	2.0	4.25	4.83	5.67	7.0	
			Placebo	33	30 (90.9)	4.91 (0.95)	3.3	4.00	5.00	5.67	6.8	
		Week 12	Tezepelumab	27	27 (100.0)	5.21 (0.98)	3.6	4.50	5.25	5.92	7.0	
			Placebo	33	30 (90.9)	4.96 (1.02)	3.2	4.08	4.92	5.75	6.9	
		Week 16	Tezepelumab	27	27 (100.0)	5.15 (0.97)	3.6	4.42	5.08	5.83	7.0	
			Placebo	33	30 (90.9)	4.97 (1.04)	2.8	4.08	4.79	5.83	7.0	
		Week 20	Tezepelumab	27	27 (100.0)	5.09 (0.97)	3.6	4.25	5.00	5.83	7.0	
			Placebo	33	30 (90.9)	4.91 (1.04)	3.5	4.00	4.58	5.75	7.0	
		Week 24	Tezepelumab	27	27 (100.0)	5.23 (0.99)	3.6	4.42	5.33	6.00	7.0	
			Placebo	33	30 (90.9)	4.93 (1.02)	3.6	4.08	4.63	5.42	7.0	
		Week 28	Tezepelumab	27	27 (100.0)	5.07 (1.00)	3.4	4.33	5.00	5.75	7.0	
			Placebo	33	30 (90.9)	5.06 (1.26)	3.2	4.00	4.75	6.00	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	5.12 (0.90)	3.6	4.33	5.08	5.92	6.7	
			Placebo	33	31 (93.9)	4.90 (1.12)	2.8	4.00	4.75	6.00	6.9	
		Week 36	Tezepelumab	27	27 (100.0)	5.18 (0.94)	3.6	4.50	5.25	5.75	7.0	
			Placebo	33	31 (93.9)	5.00 (1.08)	3.8	4.00	4.58	6.00	7.0	
		Week 40	Tezepelumab	27	27 (100.0)	5.06 (0.93)	3.6	4.42	5.00	5.58	7.0	
			Placebo	33	31 (93.9)	4.99 (1.16)	3.4	4.00	4.92	6.00	7.0	
		Week 44	Tezepelumab	27	27 (100.0)	5.06 (1.04)	3.5	4.17	4.75	5.83	7.0	
			Placebo	33	31 (93.9)	4.95 (1.28)	2.5	4.00	4.67	6.08	7.0	
		Week 48	Tezepelumab	27	27 (100.0)	5.15 (1.01)	3.6	4.25	5.17	5.83	7.0	
			Placebo	33	31 (93.9)	4.94 (1.23)	3.3	3.92	4.50	6.08	7.0	
		Week 52	Tezepelumab	27	27 (100.0)	5.15 (1.00)	3.6	4.50	5.00	5.58	7.0	
			Placebo	33	31 (93.9)	4.85 (1.20)	2.8	4.00	4.50	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low											
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	27	27 (100.0)	0.78 (0.87)	-0.8	0.25	0.58	1.33	3.1	0.22 [-0.31, 0.74]
			Placebo	33	29 (87.9)	0.60 (0.75)	-1.8	0.25	0.58	0.92	2.3	
		Week 8	Tezepelumab	27	27 (100.0)	0.90 (1.01)	-1.9	0.33	0.92	1.42	3.3	0.01 [-0.52, 0.53]
			Placebo	33	29 (87.9)	0.90 (0.89)	-0.6	0.33	0.83	1.25	2.7	
		Week 12	Tezepelumab	27	27 (100.0)	1.16 (0.94)	-0.5	0.42	1.08	1.83	3.7	0.22 [-0.31, 0.74]
			Placebo	33	29 (87.9)	0.95 (1.02)	-0.8	0.42	0.92	1.33	4.0	
		Week 16	Tezepelumab	27	27 (100.0)	1.10 (0.90)	-0.3	0.42	1.00	2.08	3.2	0.15 [-0.37, 0.68]
			Placebo	33	29 (87.9)	0.95 (1.01)	-1.2	0.42	0.92	1.42	4.2	
		Week 20	Tezepelumab	27	27 (100.0)	1.03 (0.88)	-0.3	0.33	0.92	2.00	2.9	0.15 [-0.38, 0.67]
			Placebo	33	29 (87.9)	0.90 (0.93)	-0.4	0.17	0.75	1.25	3.4	
		Week 24	Tezepelumab	27	27 (100.0)	1.18 (0.85)	-0.3	0.42	1.00	1.92	2.9	0.29 [-0.24, 0.82]
			Placebo	33	29 (87.9)	0.91 (1.00)	-0.8	0.25	0.83	1.33	3.4	
		Week 28	Tezepelumab	27	27 (100.0)	1.02 (0.89)	-0.3	0.33	0.92	1.50	2.9	-0.02 [-0.55, 0.50]
			Placebo	33	29 (87.9)	1.04 (1.16)	-0.7	0.50	0.83	1.25	4.3	
		Week 32	Tezepelumab	27	27 (100.0)	1.07 (0.91)	-0.5	0.42	0.92	1.75	3.0	0.12 [-0.41, 0.64]
			Placebo	33	29 (87.9)	0.96 (0.91)	-0.6	0.33	1.00	1.25	3.4	
		Week 36	Tezepelumab	27	27 (100.0)	1.13 (1.02)	-0.9	0.42	0.92	2.08	3.3	0.11 [-0.42, 0.63]
			Placebo	33	29 (87.9)	1.03 (0.87)	-0.2	0.25	0.92	1.42	3.4	
		Week 40	Tezepelumab	27	27 (100.0)	1.01 (0.92)	-0.8	0.25	0.92	1.92	2.9	-0.01 [-0.54, 0.51]
			Placebo	33	29 (87.9)	1.02 (1.10)	-0.8	0.42	0.83	1.42	4.0	
		Week 44	Tezepelumab	27	27 (100.0)	1.01 (0.96)	-0.8	0.33	0.92	1.75	2.9	0.05 [-0.47, 0.57]
			Placebo	33	29 (87.9)	0.96 (1.21)	-1.3	0.17	0.67	1.67	3.5	
		Week 48	Tezepelumab	27	27 (100.0)	1.10 (0.94)	-0.7	0.33	1.08	1.75	2.9	0.13 [-0.39, 0.66]
			Placebo	33	29 (87.9)	0.97 (1.02)	-0.6	0.33	0.67	1.50	3.5	
		Week 52	Tezepelumab	27	27 (100.0)	1.10 (0.92)	-0.7	0.33	0.92	1.58	2.9	0.20 [-0.32, 0.73]
			Placebo	33	29 (87.9)	0.91 (0.98)	-0.3	0.33	0.67	1.25	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	109	95 (87.2)	4.05 (1.03)	1.3	3.50	4.00	4.67	6.8	
			Placebo	105	92 (87.6)	3.95 (0.93)	1.5	3.42	4.00	4.54	6.3	
		Week 4	Tezepelumab	109	98 (89.9)	4.84 (1.05)	1.3	4.08	4.79	5.58	7.0	
			Placebo	105	93 (88.6)	4.52 (0.95)	1.8	3.92	4.58	5.25	6.5	
		Week 8	Tezepelumab	109	100 (91.7)	5.09 (1.07)	2.7	4.21	5.08	5.83	7.0	
			Placebo	105	96 (91.4)	4.53 (1.06)	1.9	3.92	4.50	5.25	7.0	
		Week 12	Tezepelumab	109	100 (91.7)	5.22 (1.11)	2.8	4.29	5.21	6.21	7.0	
			Placebo	105	97 (92.4)	4.69 (1.09)	2.1	4.00	4.58	5.50	7.0	
		Week 16	Tezepelumab	109	100 (91.7)	5.22 (1.14)	2.3	4.33	5.33	6.08	7.0	
			Placebo	105	97 (92.4)	4.71 (1.14)	1.3	4.00	4.67	5.50	7.0	
		Week 20	Tezepelumab	109	101 (92.7)	5.23 (1.10)	2.3	4.33	5.25	6.00	7.0	
			Placebo	105	97 (92.4)	4.75 (1.15)	1.3	4.08	4.75	5.42	7.0	
		Week 24	Tezepelumab	109	101 (92.7)	5.22 (1.11)	1.8	4.42	5.17	6.00	7.0	
			Placebo	105	97 (92.4)	4.79 (1.19)	1.3	4.00	4.67	5.75	7.0	
		Week 28	Tezepelumab	109	103 (94.5)	5.26 (1.07)	3.2	4.42	5.17	6.08	7.0	
			Placebo	105	98 (93.3)	4.79 (1.18)	1.3	4.00	4.79	5.75	7.0	
		Week 32	Tezepelumab	109	104 (95.4)	5.33 (1.11)	2.8	4.46	5.46	6.17	7.0	
			Placebo	105	98 (93.3)	4.91 (1.15)	1.3	4.08	5.00	5.75	7.0	
		Week 36	Tezepelumab	109	104 (95.4)	5.31 (1.11)	2.9	4.46	5.25	6.25	7.0	
			Placebo	105	98 (93.3)	4.91 (1.19)	2.4	4.00	4.92	6.00	7.0	
		Week 40	Tezepelumab	109	104 (95.4)	5.34 (1.13)	2.3	4.42	5.42	6.08	7.0	
			Placebo	105	98 (93.3)	4.95 (1.11)	2.3	4.00	4.92	5.92	7.0	
		Week 44	Tezepelumab	109	104 (95.4)	5.36 (1.11)	2.3	4.58	5.42	6.25	7.0	
			Placebo	105	98 (93.3)	4.92 (1.15)	2.3	4.00	4.96	5.92	7.0	
		Week 48	Tezepelumab	109	104 (95.4)	5.36 (1.12)	2.8	4.50	5.25	6.33	7.0	
			Placebo	105	99 (94.3)	4.97 (1.08)	2.2	4.17	4.92	5.83	7.0	
		Week 52	Tezepelumab	109	104 (95.4)	5.37 (1.10)	2.8	4.58	5.29	6.29	7.0	
			Placebo	105	99 (94.3)	4.97 (1.10)	2.5	4.00	4.92	5.83	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	109	89 (81.7)	0.83 (1.07)	-4.3	0.17	0.83	1.50	3.1	0.27 [-0.03, 0.56]
			Placebo	105	90 (85.7)	0.56 (0.89)	-1.3	0.08	0.50	1.17	3.3	
		Week 8	Tezepelumab	109	91 (83.5)	1.03 (1.08)	-1.4	0.25	1.00	1.92	4.1	0.44 [0.14, 0.73]
			Placebo	105	91 (86.7)	0.58 (0.95)	-1.8	0.08	0.42	1.17	3.6	
		Week 12	Tezepelumab	109	91 (83.5)	1.15 (1.16)	-2.6	0.33	1.08	2.00	4.5	0.35 [0.06, 0.64]
			Placebo	105	91 (86.7)	0.74 (1.22)	-3.1	0.08	0.67	1.25	3.8	
		Week 16	Tezepelumab	109	91 (83.5)	1.16 (1.17)	-2.9	0.42	1.08	2.00	4.6	0.33 [0.03, 0.62]
			Placebo	105	91 (86.7)	0.76 (1.22)	-3.5	0.17	0.92	1.42	3.7	
		Week 20	Tezepelumab	109	91 (83.5)	1.19 (1.16)	-1.8	0.33	1.08	2.00	4.7	0.32 [0.03, 0.61]
			Placebo	105	91 (86.7)	0.82 (1.17)	-3.5	0.25	0.92	1.42	3.8	
		Week 24	Tezepelumab	109	91 (83.5)	1.21 (1.19)	-1.6	0.42	1.08	2.17	4.8	0.29 [-0.00, 0.58]
			Placebo	105	91 (86.7)	0.86 (1.23)	-3.5	0.17	0.83	1.50	4.1	
		Week 28	Tezepelumab	109	91 (83.5)	1.22 (1.17)	-1.7	0.42	1.00	2.08	4.9	0.31 [0.02, 0.60]
			Placebo	105	91 (86.7)	0.84 (1.26)	-3.5	0.17	0.83	1.58	4.7	
		Week 32	Tezepelumab	109	91 (83.5)	1.29 (1.23)	-1.6	0.42	1.17	2.17	4.8	0.25 [-0.04, 0.54]
			Placebo	105	91 (86.7)	0.98 (1.19)	-3.5	0.25	1.00	1.67	4.0	
		Week 36	Tezepelumab	109	91 (83.5)	1.24 (1.24)	-1.7	0.17	1.17	2.17	4.8	0.21 [-0.08, 0.51]
			Placebo	105	91 (86.7)	0.98 (1.22)	-3.0	0.08	1.08	1.75	3.8	
		Week 40	Tezepelumab	109	91 (83.5)	1.29 (1.19)	-1.7	0.50	1.08	2.25	4.8	0.23 [-0.06, 0.52]
			Placebo	105	91 (86.7)	1.02 (1.19)	-3.0	0.33	1.00	1.67	4.7	
		Week 44	Tezepelumab	109	91 (83.5)	1.32 (1.19)	-1.8	0.58	1.25	2.17	4.8	0.28 [-0.01, 0.58]
			Placebo	105	91 (86.7)	0.98 (1.19)	-3.0	0.25	1.00	1.67	4.3	
		Week 48	Tezepelumab	109	91 (83.5)	1.34 (1.17)	-1.6	0.50	1.17	2.25	4.8	0.27 [-0.03, 0.56]
			Placebo	105	91 (86.7)	1.02 (1.17)	-3.0	0.25	1.08	1.67	4.2	
		Week 52	Tezepelumab	109	91 (83.5)	1.32 (1.18)	-1.6	0.42	1.08	2.25	4.8	0.26 [-0.03, 0.55]
			Placebo	105	91 (86.7)	1.02 (1.16)	-3.0	0.25	0.92	1.67	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	69	63 (91.3)	4.09 (0.98)	1.4	3.75	4.17	4.67	6.6	
			Placebo	72	61 (84.7)	4.03 (0.87)	1.7	3.50	4.17	4.50	5.9	
		Week 4	Tezepelumab	69	60 (87.0)	4.79 (1.14)	1.3	3.96	4.75	5.63	7.0	
			Placebo	72	61 (84.7)	4.66 (0.95)	1.8	4.25	4.83	5.25	6.7	
		Week 8	Tezepelumab	69	61 (88.4)	4.98 (1.12)	2.0	4.25	4.83	5.67	7.0	
			Placebo	72	63 (87.5)	4.80 (1.00)	2.1	4.08	5.00	5.50	6.8	
		Week 12	Tezepelumab	69	61 (88.4)	5.25 (1.07)	3.0	4.25	5.25	6.25	7.0	
			Placebo	72	63 (87.5)	4.91 (1.05)	2.5	4.08	5.00	5.75	6.9	
		Week 16	Tezepelumab	69	61 (88.4)	5.16 (1.08)	2.7	4.33	5.08	5.92	7.0	
			Placebo	72	63 (87.5)	4.88 (1.14)	1.3	4.17	4.92	5.75	7.0	
		Week 20	Tezepelumab	69	62 (89.9)	5.10 (1.11)	2.3	4.25	4.92	6.00	7.0	
			Placebo	72	63 (87.5)	4.91 (1.15)	1.3	4.17	4.83	5.92	7.0	
		Week 24	Tezepelumab	69	62 (89.9)	5.21 (1.05)	3.1	4.42	5.04	6.00	7.0	
			Placebo	72	63 (87.5)	4.91 (1.18)	1.3	4.17	4.92	5.75	7.0	
		Week 28	Tezepelumab	69	63 (91.3)	5.14 (1.08)	3.2	4.33	5.00	5.92	7.0	
			Placebo	72	64 (88.9)	4.99 (1.30)	1.3	4.04	4.96	6.00	7.0	
		Week 32	Tezepelumab	69	64 (92.8)	5.24 (1.06)	2.9	4.33	5.08	6.00	7.0	
			Placebo	72	65 (90.3)	4.99 (1.21)	1.3	4.08	5.00	6.00	6.9	
		Week 36	Tezepelumab	69	64 (92.8)	5.27 (1.10)	2.9	4.46	5.25	6.04	7.0	
			Placebo	72	65 (90.3)	5.14 (1.17)	2.5	4.25	5.08	6.08	7.0	
		Week 40	Tezepelumab	69	64 (92.8)	5.20 (1.14)	2.3	4.46	5.13	6.00	7.0	
			Placebo	72	65 (90.3)	5.13 (1.15)	2.5	4.08	5.17	6.08	7.0	
		Week 44	Tezepelumab	69	64 (92.8)	5.18 (1.19)	2.3	4.29	5.08	6.04	7.0	
			Placebo	72	65 (90.3)	5.14 (1.21)	2.5	4.17	5.17	6.25	7.0	
		Week 48	Tezepelumab	69	64 (92.8)	5.30 (1.12)	3.1	4.42	5.17	6.33	7.0	
			Placebo	72	66 (91.7)	5.08 (1.21)	2.4	4.00	5.08	6.08	7.0	
		Week 52	Tezepelumab	69	64 (92.8)	5.30 (1.13)	3.0	4.50	5.13	6.38	7.0	
			Placebo	72	66 (91.7)	5.09 (1.16)	2.8	4.08	5.08	6.08	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High											
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	69	58 (84.1)	0.69 (1.05)	-4.3	0.08	0.58	1.50	3.1	0.02 [-0.34, 0.38]
			Placebo	72	60 (83.3)	0.66 (0.82)	-1.8	0.17	0.50	1.17	3.3	
		Week 8	Tezepelumab	69	59 (85.5)	0.90 (0.98)	-1.9	0.33	0.92	1.50	3.3	0.10 [-0.26, 0.46]
			Placebo	72	61 (84.7)	0.81 (0.89)	-0.9	0.33	0.67	1.17	3.3	
		Week 12	Tezepelumab	69	59 (85.5)	1.17 (1.08)	-2.6	0.42	1.00	2.00	3.7	0.23 [-0.13, 0.59]
			Placebo	72	61 (84.7)	0.92 (1.15)	-3.1	0.33	1.00	1.33	4.0	
		Week 16	Tezepelumab	69	59 (85.5)	1.08 (1.03)	-2.9	0.42	1.00	2.08	3.2	0.18 [-0.18, 0.53]
			Placebo	72	61 (84.7)	0.89 (1.20)	-3.5	0.42	1.00	1.50	4.2	
		Week 20	Tezepelumab	69	59 (85.5)	1.03 (1.00)	-1.8	0.33	0.83	2.00	3.0	0.12 [-0.24, 0.47]
			Placebo	72	61 (84.7)	0.91 (1.04)	-3.5	0.25	0.92	1.33	3.4	
		Week 24	Tezepelumab	69	59 (85.5)	1.15 (0.97)	-1.6	0.42	1.00	2.00	3.0	0.22 [-0.14, 0.58]
			Placebo	72	61 (84.7)	0.92 (1.11)	-3.5	0.33	0.92	1.33	3.6	
		Week 28	Tezepelumab	69	59 (85.5)	1.10 (0.99)	-1.7	0.33	0.92	2.00	3.0	0.12 [-0.24, 0.48]
			Placebo	72	61 (84.7)	0.97 (1.21)	-3.5	0.50	1.00	1.58	4.3	
		Week 32	Tezepelumab	69	59 (85.5)	1.15 (1.04)	-1.6	0.42	1.00	1.92	3.1	0.13 [-0.23, 0.49]
			Placebo	72	61 (84.7)	1.01 (1.09)	-3.5	0.42	1.08	1.50	3.5	
		Week 36	Tezepelumab	69	59 (85.5)	1.17 (1.15)	-1.7	0.33	1.00	2.08	3.8	0.04 [-0.32, 0.39]
			Placebo	72	61 (84.7)	1.13 (1.09)	-2.3	0.25	1.17	1.67	3.8	
		Week 40	Tezepelumab	69	59 (85.5)	1.12 (1.07)	-1.7	0.25	1.00	2.17	3.0	-0.02 [-0.38, 0.34]
			Placebo	72	61 (84.7)	1.14 (1.07)	-1.1	0.50	1.17	1.67	4.0	
		Week 44	Tezepelumab	69	59 (85.5)	1.08 (1.11)	-1.8	0.33	0.92	2.08	3.0	-0.04 [-0.40, 0.31]
			Placebo	72	61 (84.7)	1.13 (1.14)	-1.3	0.50	1.17	1.75	3.8	
		Week 48	Tezepelumab	69	59 (85.5)	1.22 (1.05)	-1.6	0.33	1.08	2.17	3.0	0.14 [-0.22, 0.50]
			Placebo	72	61 (84.7)	1.07 (1.08)	-1.1	0.33	1.17	1.67	4.2	
		Week 52	Tezepelumab	69	59 (85.5)	1.20 (1.04)	-1.6	0.33	1.08	2.17	3.0	0.10 [-0.26, 0.46]
			Placebo	72	61 (84.7)	1.09 (1.05)	-1.1	0.33	1.08	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	4.01 (1.04)	1.3	3.42	4.00	4.58	6.8	
			Placebo	66	60 (90.9)	3.92 (0.94)	1.5	3.29	4.00	4.54	6.3	
		Week 4	Tezepelumab	67	65 (97.0)	4.88 (0.99)	2.9	4.08	4.83	5.58	6.9	
			Placebo	66	62 (93.9)	4.44 (0.95)	2.3	3.67	4.33	5.17	6.4	
		Week 8	Tezepelumab	67	66 (98.5)	5.14 (1.04)	2.8	4.33	5.17	5.83	7.0	
			Placebo	66	63 (95.5)	4.44 (1.06)	1.9	3.83	4.33	5.17	7.0	
		Week 12	Tezepelumab	67	66 (98.5)	5.20 (1.09)	2.8	4.33	5.25	6.08	7.0	
			Placebo	66	64 (97.0)	4.60 (1.08)	2.1	3.92	4.42	5.46	7.0	
		Week 16	Tezepelumab	67	66 (98.5)	5.24 (1.14)	2.3	4.33	5.38	6.08	7.0	
			Placebo	66	64 (97.0)	4.66 (1.09)	2.1	4.00	4.46	5.38	7.0	
		Week 20	Tezepelumab	67	66 (98.5)	5.30 (1.03)	3.3	4.50	5.38	6.00	7.0	
			Placebo	66	64 (97.0)	4.67 (1.10)	2.1	4.00	4.50	5.25	7.0	
		Week 24	Tezepelumab	67	66 (98.5)	5.24 (1.12)	1.8	4.42	5.17	6.00	7.0	
			Placebo	66	64 (97.0)	4.73 (1.11)	2.8	3.96	4.67	5.54	7.0	
		Week 28	Tezepelumab	67	67 (100.0)	5.30 (1.03)	3.2	4.42	5.33	6.08	7.0	
			Placebo	66	64 (97.0)	4.71 (1.09)	2.8	3.92	4.63	5.58	7.0	
		Week 32	Tezepelumab	67	67 (100.0)	5.34 (1.09)	2.8	4.50	5.50	6.08	7.0	
			Placebo	66	64 (97.0)	4.82 (1.06)	2.4	4.00	4.92	5.63	7.0	
		Week 36	Tezepelumab	67	67 (100.0)	5.31 (1.06)	2.9	4.50	5.25	6.17	7.0	
			Placebo	66	64 (97.0)	4.73 (1.12)	2.4	4.00	4.71	5.54	7.0	
		Week 40	Tezepelumab	67	67 (100.0)	5.35 (1.05)	3.2	4.42	5.42	6.08	7.0	
			Placebo	66	64 (97.0)	4.78 (1.07)	2.3	4.00	4.63	5.75	7.0	
		Week 44	Tezepelumab	67	67 (100.0)	5.42 (0.99)	3.2	4.58	5.42	6.17	7.0	
			Placebo	66	64 (97.0)	4.71 (1.11)	2.3	4.00	4.42	5.71	7.0	
		Week 48	Tezepelumab	67	67 (100.0)	5.33 (1.08)	2.8	4.58	5.25	6.17	7.0	
			Placebo	66	64 (97.0)	4.84 (1.01)	2.2	4.00	4.79	5.67	7.0	
		Week 52	Tezepelumab	67	67 (100.0)	5.35 (1.04)	2.8	4.67	5.33	6.17	7.0	
			Placebo	66	64 (97.0)	4.79 (1.06)	2.5	4.00	4.75	5.67	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High											
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	67	58 (86.6)	0.95 (0.99)	-1.4	0.25	0.92	1.50	3.1	0.50 [0.13, 0.86]
			Placebo	66	59 (89.4)	0.48 (0.88)	-1.3	0.00	0.42	1.17	3.1	
		Week 8	Tezepelumab	67	59 (88.1)	1.09 (1.14)	-1.4	0.17	1.17	2.00	4.1	0.56 [0.19, 0.93]
			Placebo	66	59 (89.4)	0.50 (0.97)	-1.8	0.00	0.42	1.00	3.6	
		Week 12	Tezepelumab	67	59 (88.1)	1.14 (1.14)	-1.4	0.33	1.08	1.92	4.5	0.41 [0.05, 0.78]
			Placebo	66	59 (89.4)	0.65 (1.19)	-2.8	0.00	0.58	1.08	3.8	
		Week 16	Tezepelumab	67	59 (88.1)	1.20 (1.18)	-1.4	0.42	1.08	2.00	4.6	0.40 [0.04, 0.77]
			Placebo	66	59 (89.4)	0.73 (1.15)	-3.0	0.17	0.58	1.42	3.7	
		Week 20	Tezepelumab	67	59 (88.1)	1.28 (1.20)	-1.4	0.50	1.17	2.08	4.7	0.43 [0.07, 0.80]
			Placebo	66	59 (89.4)	0.77 (1.20)	-3.0	0.08	0.67	1.33	3.8	
		Week 24	Tezepelumab	67	59 (88.1)	1.26 (1.25)	-1.6	0.33	1.17	2.17	4.8	0.34 [-0.02, 0.71]
			Placebo	66	59 (89.4)	0.83 (1.25)	-3.0	0.00	0.83	1.50	4.1	
		Week 28	Tezepelumab	67	59 (88.1)	1.25 (1.22)	-1.4	0.42	1.00	2.00	4.9	0.35 [-0.02, 0.71]
			Placebo	66	59 (89.4)	0.81 (1.27)	-3.0	0.08	0.67	1.50	4.7	
		Week 32	Tezepelumab	67	59 (88.1)	1.32 (1.27)	-1.4	0.50	1.08	2.08	4.8	0.31 [-0.05, 0.67]
			Placebo	66	59 (89.4)	0.94 (1.17)	-3.0	0.25	0.83	1.58	4.0	
		Week 36	Tezepelumab	67	59 (88.1)	1.26 (1.25)	-1.4	0.17	1.17	2.17	4.8	0.34 [-0.02, 0.71]
			Placebo	66	59 (89.4)	0.84 (1.19)	-3.0	0.08	0.75	1.67	3.8	
		Week 40	Tezepelumab	67	59 (88.1)	1.34 (1.20)	-1.4	0.50	1.08	2.08	4.8	0.37 [0.00, 0.73]
			Placebo	66	59 (89.4)	0.89 (1.24)	-3.0	0.08	0.83	1.58	4.7	
		Week 44	Tezepelumab	67	59 (88.1)	1.41 (1.16)	-1.4	0.58	1.25	2.17	4.8	0.50 [0.14, 0.87]
			Placebo	66	59 (89.4)	0.81 (1.22)	-3.0	0.08	0.83	1.50	4.3	
		Week 48	Tezepelumab	67	59 (88.1)	1.35 (1.20)	-1.4	0.50	1.17	2.00	4.8	0.33 [-0.03, 0.70]
			Placebo	66	59 (89.4)	0.95 (1.19)	-3.0	0.25	0.92	1.67	3.8	
		Week 52	Tezepelumab	67	59 (88.1)	1.34 (1.21)	-1.4	0.42	1.08	2.00	4.8	0.38 [0.02, 0.74]
			Placebo	66	59 (89.4)	0.89 (1.18)	-3.0	0.25	0.75	1.58	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	78	68 (87.2)	4.08 (0.85)	1.9	3.75	4.08	4.67	6.3	
			Placebo	74	63 (85.1)	3.93 (0.87)	1.8	3.42	4.00	4.50	5.9	
		Week 4	Tezepelumab	78	72 (92.3)	4.77 (1.07)	1.3	4.00	4.79	5.54	6.9	
			Placebo	74	66 (89.2)	4.59 (0.94)	1.8	4.00	4.71	5.25	6.5	
		Week 8	Tezepelumab	78	72 (92.3)	5.00 (1.00)	2.0	4.25	5.00	5.75	7.0	
			Placebo	74	66 (89.2)	4.68 (0.99)	2.3	4.00	4.58	5.42	6.7	
		Week 12	Tezepelumab	78	72 (92.3)	5.21 (1.03)	3.0	4.29	5.25	6.04	7.0	
			Placebo	74	67 (90.5)	4.76 (1.06)	2.4	4.00	4.67	5.58	6.9	
		Week 16	Tezepelumab	78	72 (92.3)	5.11 (1.03)	2.7	4.33	5.13	5.92	7.0	
			Placebo	74	67 (90.5)	4.85 (1.03)	2.2	4.08	4.92	5.58	7.0	
		Week 20	Tezepelumab	78	73 (93.6)	5.09 (1.06)	2.3	4.25	5.00	5.92	7.0	
			Placebo	74	67 (90.5)	4.89 (1.05)	2.3	4.08	4.83	5.58	7.0	
		Week 24	Tezepelumab	78	73 (93.6)	5.13 (1.03)	3.1	4.33	5.00	6.00	7.0	
			Placebo	74	67 (90.5)	4.90 (1.11)	2.1	4.08	4.75	5.75	7.0	
		Week 28	Tezepelumab	78	75 (96.2)	5.14 (1.04)	3.2	4.33	5.00	5.92	7.0	
			Placebo	74	68 (91.9)	4.86 (1.11)	1.8	4.00	4.75	5.92	7.0	
		Week 32	Tezepelumab	78	76 (97.4)	5.17 (1.06)	2.8	4.29	5.08	6.00	7.0	
			Placebo	74	69 (93.2)	4.95 (1.10)	2.1	4.08	5.00	5.83	7.0	
		Week 36	Tezepelumab	78	76 (97.4)	5.22 (1.10)	2.9	4.33	5.25	6.08	7.0	
			Placebo	74	69 (93.2)	5.05 (1.12)	2.5	4.08	5.17	6.00	7.0	
		Week 40	Tezepelumab	78	76 (97.4)	5.12 (1.11)	2.3	4.25	5.08	5.96	7.0	
			Placebo	74	69 (93.2)	5.03 (1.06)	2.4	4.25	5.00	5.92	7.0	
		Week 44	Tezepelumab	78	76 (97.4)	5.12 (1.11)	2.3	4.21	5.08	6.00	7.0	
			Placebo	74	69 (93.2)	5.01 (1.14)	2.3	4.00	4.92	6.00	7.0	
		Week 48	Tezepelumab	78	76 (97.4)	5.16 (1.11)	2.8	4.21	5.08	6.04	7.0	
			Placebo	74	70 (94.6)	5.07 (1.10)	2.4	4.17	5.08	5.92	7.0	
		Week 52	Tezepelumab	78	76 (97.4)	5.16 (1.11)	2.8	4.29	5.04	6.04	7.0	
			Placebo	74	70 (94.6)	4.98 (1.13)	2.5	4.00	4.92	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	78	67 (85.9)	0.68 (1.04)	-4.3	0.08	0.58	1.42	3.1	-0.03 [-0.38, 0.31]
			Placebo	74	63 (85.1)	0.71 (0.86)	-1.3	0.17	0.58	1.25	3.3	
		Week 8	Tezepelumab	78	67 (85.9)	0.89 (0.98)	-1.9	0.25	0.92	1.50	3.3	0.12 [-0.22, 0.47]
			Placebo	74	63 (85.1)	0.78 (0.91)	-1.0	0.25	0.58	1.25	3.6	
		Week 12	Tezepelumab	78	67 (85.9)	1.10 (1.05)	-2.6	0.33	0.92	1.83	3.7	0.21 [-0.14, 0.55]
			Placebo	74	63 (85.1)	0.88 (1.12)	-3.1	0.33	0.92	1.25	3.8	
		Week 16	Tezepelumab	78	67 (85.9)	1.02 (1.00)	-2.9	0.33	0.92	1.67	3.3	0.06 [-0.28, 0.41]
			Placebo	74	63 (85.1)	0.96 (1.05)	-3.1	0.42	1.00	1.50	3.7	
		Week 20	Tezepelumab	78	67 (85.9)	1.01 (0.97)	-1.8	0.33	0.92	1.75	3.3	-0.01 [-0.35, 0.34]
			Placebo	74	63 (85.1)	1.02 (0.95)	-1.1	0.42	1.00	1.58	3.8	
		Week 24	Tezepelumab	78	67 (85.9)	1.08 (0.92)	-1.6	0.42	1.00	1.67	3.3	0.07 [-0.28, 0.41]
			Placebo	74	63 (85.1)	1.02 (1.01)	-1.3	0.33	0.83	1.42	3.9	
		Week 28	Tezepelumab	78	67 (85.9)	1.07 (0.93)	-1.7	0.42	0.92	1.67	3.3	0.12 [-0.22, 0.47]
			Placebo	74	63 (85.1)	0.95 (1.01)	-1.8	0.25	0.92	1.42	3.8	
		Week 32	Tezepelumab	78	67 (85.9)	1.07 (1.02)	-1.6	0.33	1.00	1.75	3.3	-0.02 [-0.36, 0.33]
			Placebo	74	63 (85.1)	1.09 (0.94)	-0.8	0.42	1.08	1.58	3.5	
		Week 36	Tezepelumab	78	67 (85.9)	1.10 (1.08)	-1.7	0.25	1.00	2.08	3.4	-0.08 [-0.42, 0.26]
			Placebo	74	63 (85.1)	1.19 (1.01)	-0.8	0.42	1.17	1.75	3.8	
		Week 40	Tezepelumab	78	67 (85.9)	1.03 (1.05)	-1.7	0.25	1.00	2.00	3.3	-0.12 [-0.46, 0.23]
			Placebo	74	63 (85.1)	1.15 (0.98)	-1.0	0.50	1.17	1.75	3.4	
		Week 44	Tezepelumab	78	67 (85.9)	1.02 (1.05)	-1.8	0.33	0.92	1.83	3.2	-0.10 [-0.44, 0.25]
			Placebo	74	63 (85.1)	1.12 (1.05)	-1.3	0.33	1.17	1.83	3.7	
		Week 48	Tezepelumab	78	67 (85.9)	1.09 (1.04)	-1.6	0.33	0.92	2.00	3.4	-0.09 [-0.43, 0.26]
			Placebo	74	63 (85.1)	1.18 (1.02)	-1.1	0.50	1.17	1.75	4.2	
		Week 52	Tezepelumab	78	67 (85.9)	1.06 (1.01)	-1.6	0.33	0.92	1.67	3.4	-0.03 [-0.38, 0.31]
			Placebo	74	63 (85.1)	1.10 (1.00)	-0.7	0.42	0.92	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	57	53 (93.0)	4.01 (1.19)	1.3	3.17	4.00	4.67	6.8	
			Placebo	63	57 (90.5)	4.01 (0.95)	1.5	3.42	4.00	4.50	6.3	
		Week 4	Tezepelumab	57	52 (91.2)	4.97 (1.06)	2.9	4.08	4.92	5.83	7.0	
			Placebo	63	57 (90.5)	4.49 (0.98)	2.4	3.92	4.50	5.17	6.7	
		Week 8	Tezepelumab	57	54 (94.7)	5.14 (1.19)	2.7	4.00	5.13	6.08	7.0	
			Placebo	63	59 (93.7)	4.57 (1.12)	1.9	3.75	4.50	5.33	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.25 (1.16)	2.8	4.33	5.25	6.25	7.0	
			Placebo	63	59 (93.7)	4.75 (1.11)	2.1	3.92	4.67	5.75	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.32 (1.20)	2.3	4.33	5.42	6.33	7.0	
			Placebo	63	59 (93.7)	4.74 (1.14)	2.1	4.00	4.50	5.58	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.35 (1.09)	3.3	4.50	5.38	6.17	7.0	
			Placebo	63	59 (93.7)	4.74 (1.12)	2.1	4.00	4.42	5.67	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.35 (1.16)	1.8	4.42	5.46	6.25	7.0	
			Placebo	63	59 (93.7)	4.79 (1.11)	2.8	3.92	4.67	5.75	7.0	
		Week 28	Tezepelumab	57	54 (94.7)	5.33 (1.09)	3.2	4.42	5.25	6.17	7.0	
			Placebo	63	59 (93.7)	4.90 (1.24)	2.8	3.92	4.92	5.83	7.0	
		Week 32	Tezepelumab	57	54 (94.7)	5.46 (1.08)	2.8	4.67	5.50	6.25	7.0	
			Placebo	63	59 (93.7)	4.92 (1.09)	2.8	4.00	4.92	5.75	7.0	
		Week 36	Tezepelumab	57	54 (94.7)	5.38 (1.06)	2.9	4.58	5.21	6.33	7.0	
			Placebo	63	59 (93.7)	4.84 (1.17)	2.4	4.00	4.75	5.83	7.0	
		Week 40	Tezepelumab	57	54 (94.7)	5.51 (1.04)	3.2	4.75	5.58	6.42	7.0	
			Placebo	63	59 (93.7)	4.90 (1.19)	2.3	4.00	4.58	6.00	7.0	
		Week 44	Tezepelumab	57	54 (94.7)	5.57 (1.03)	3.2	4.75	5.54	6.50	7.0	
			Placebo	63	59 (93.7)	4.85 (1.22)	2.5	4.00	4.50	5.92	7.0	
		Week 48	Tezepelumab	57	54 (94.7)	5.53 (1.04)	3.3	4.67	5.54	6.33	7.0	
			Placebo	63	59 (93.7)	4.86 (1.14)	2.2	4.00	4.75	5.75	7.0	
		Week 52	Tezepelumab	57	54 (94.7)	5.55 (1.00)	3.8	4.75	5.42	6.42	7.0	
			Placebo	63	59 (93.7)	4.92 (1.11)	2.8	4.00	4.75	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	1.03 (0.98)	-1.4	0.29	1.17	1.67	3.1	0.68 [0.28, 1.07]
			Placebo	63	56 (88.9)	0.42 (0.82)	-1.8	0.00	0.33	0.96	1.9	
		Week 8	Tezepelumab	57	50 (87.7)	1.12 (1.18)	-1.4	0.08	1.17	2.00	4.1	0.54 [0.15, 0.93]
			Placebo	63	56 (88.9)	0.55 (0.96)	-1.8	-0.04	0.42	1.00	2.7	
		Week 12	Tezepelumab	57	50 (87.7)	1.22 (1.20)	-1.4	0.42	1.25	2.08	4.5	0.42 [0.03, 0.80]
			Placebo	63	56 (88.9)	0.71 (1.24)	-2.8	-0.04	0.75	1.29	4.0	
		Week 16	Tezepelumab	57	50 (87.7)	1.30 (1.24)	-1.4	0.42	1.46	2.17	4.6	0.48 [0.09, 0.87]
			Placebo	63	56 (88.9)	0.72 (1.18)	-3.0	0.17	0.67	1.38	4.2	
		Week 20	Tezepelumab	57	50 (87.7)	1.34 (1.26)	-1.4	0.42	1.25	2.25	4.7	0.52 [0.13, 0.91]
			Placebo	63	56 (88.9)	0.72 (1.13)	-3.0	0.08	0.71	1.25	3.8	
		Week 24	Tezepelumab	57	50 (87.7)	1.35 (1.33)	-1.6	0.42	1.38	2.33	4.8	0.44 [0.06, 0.83]
			Placebo	63	56 (88.9)	0.79 (1.21)	-3.0	0.00	0.83	1.46	4.1	
		Week 28	Tezepelumab	57	50 (87.7)	1.31 (1.31)	-1.4	0.42	1.00	2.25	4.9	0.30 [-0.08, 0.69]
			Placebo	63	56 (88.9)	0.90 (1.35)	-3.0	0.08	0.83	1.67	4.7	
		Week 32	Tezepelumab	57	50 (87.7)	1.44 (1.31)	-1.4	0.50	1.38	2.33	4.8	0.42 [0.03, 0.80]
			Placebo	63	56 (88.9)	0.93 (1.17)	-3.0	0.25	0.88	1.42	4.0	
		Week 36	Tezepelumab	57	50 (87.7)	1.36 (1.33)	-1.4	0.33	1.29	2.33	4.8	0.43 [0.04, 0.81]
			Placebo	63	56 (88.9)	0.83 (1.19)	-3.0	0.08	0.83	1.63	3.8	
		Week 40	Tezepelumab	57	50 (87.7)	1.49 (1.21)	-1.4	0.58	1.38	2.33	4.8	0.46 [0.07, 0.85]
			Placebo	63	56 (88.9)	0.90 (1.31)	-3.0	0.04	0.79	1.58	4.7	
		Week 44	Tezepelumab	57	50 (87.7)	1.56 (1.20)	-1.4	0.83	1.54	2.42	4.8	0.56 [0.18, 0.95]
			Placebo	63	56 (88.9)	0.85 (1.30)	-3.0	0.17	0.79	1.58	4.3	
		Week 48	Tezepelumab	57	50 (87.7)	1.52 (1.20)	-1.4	0.58	1.54	2.42	4.8	0.55 [0.16, 0.94]
			Placebo	63	56 (88.9)	0.86 (1.21)	-3.0	0.13	0.79	1.46	3.8	
		Week 52	Tezepelumab	57	50 (87.7)	1.53 (1.23)	-1.4	0.58	1.46	2.50	4.8	0.50 [0.11, 0.89]
			Placebo	63	56 (88.9)	0.92 (1.22)	-3.0	0.17	0.83	1.63	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.04 (0.80)	2.0	3.75	4.08	4.50	6.3	
			Placebo	66	54 (81.8)	3.97 (1.00)	1.7	3.33	4.13	4.50	6.3	
		Week 4	Tezepelumab	57	55 (96.5)	4.83 (0.90)	2.6	4.08	4.75	5.50	6.8	
			Placebo	66	57 (86.4)	4.41 (1.05)	1.8	3.67	4.42	5.17	6.5	
		Week 8	Tezepelumab	57	55 (96.5)	5.00 (1.00)	2.0	4.33	5.00	5.67	7.0	
			Placebo	66	60 (90.9)	4.49 (1.01)	2.1	3.92	4.38	5.21	6.7	
		Week 12	Tezepelumab	57	55 (96.5)	5.24 (0.99)	3.2	4.42	5.17	5.75	7.0	
			Placebo	66	60 (90.9)	4.55 (1.07)	2.1	3.92	4.33	5.42	6.9	
		Week 16	Tezepelumab	57	55 (96.5)	5.22 (1.03)	3.4	4.33	5.25	5.92	7.0	
			Placebo	66	60 (90.9)	4.53 (1.13)	1.3	3.96	4.42	5.38	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.16 (1.05)	3.4	4.33	5.08	5.92	7.0	
			Placebo	66	60 (90.9)	4.52 (1.18)	1.3	4.00	4.33	5.17	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.14 (1.11)	1.8	4.42	5.08	6.00	7.0	
			Placebo	66	60 (90.9)	4.47 (1.21)	1.3	3.83	4.25	5.29	6.9	
		Week 28	Tezepelumab	57	56 (98.2)	5.18 (1.02)	3.3	4.46	5.04	5.83	7.0	
			Placebo	66	60 (90.9)	4.53 (1.24)	1.3	3.92	4.25	5.46	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.18 (1.00)	3.5	4.33	5.08	5.88	7.0	
			Placebo	66	61 (92.4)	4.52 (1.20)	1.3	3.83	4.33	5.50	6.9	
		Week 36	Tezepelumab	57	56 (98.2)	5.16 (1.05)	3.2	4.33	5.04	5.88	7.0	
			Placebo	66	61 (92.4)	4.54 (1.19)	2.4	3.83	4.25	5.42	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.21 (1.04)	2.9	4.50	5.21	5.92	7.0	
			Placebo	66	61 (92.4)	4.62 (1.12)	2.3	3.83	4.42	5.42	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.15 (1.10)	2.3	4.42	5.17	5.96	7.0	
			Placebo	66	61 (92.4)	4.54 (1.14)	2.3	3.92	4.33	5.42	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.22 (1.07)	3.1	4.46	5.21	6.04	7.0	
			Placebo	66	62 (93.9)	4.62 (1.11)	2.2	4.00	4.50	5.33	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.23 (1.07)	3.1	4.50	5.17	6.04	7.0	
			Placebo	66	62 (93.9)	4.57 (1.10)	2.5	3.92	4.38	5.33	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	57	49 (86.0)	0.88 (0.77)	-0.8	0.33	0.75	1.42	2.8	0.52 [0.13, 0.92]
			Placebo	66	53 (80.3)	0.47 (0.79)	-1.8	0.08	0.42	0.92	2.4	
		Week 8	Tezepelumab	57	49 (86.0)	0.95 (1.04)	-1.9	0.33	0.92	1.58	3.0	0.41 [0.02, 0.80]
			Placebo	66	54 (81.8)	0.56 (0.83)	-1.8	0.08	0.46	1.17	2.6	
		Week 12	Tezepelumab	57	49 (86.0)	1.19 (1.01)	-0.8	0.42	1.08	2.08	3.3	0.56 [0.17, 0.96]
			Placebo	66	54 (81.8)	0.60 (1.08)	-2.8	-0.08	0.67	1.17	3.2	
		Week 16	Tezepelumab	57	49 (86.0)	1.16 (1.06)	-0.9	0.33	1.25	2.08	3.4	0.54 [0.15, 0.93]
			Placebo	66	54 (81.8)	0.59 (1.07)	-3.5	0.08	0.71	1.33	2.4	
		Week 20	Tezepelumab	57	49 (86.0)	1.14 (0.98)	-0.8	0.42	1.00	2.00	3.3	0.51 [0.12, 0.91]
			Placebo	66	54 (81.8)	0.59 (1.12)	-3.5	0.08	0.75	1.25	2.5	
		Week 24	Tezepelumab	57	49 (86.0)	1.13 (1.07)	-1.6	0.33	1.00	2.08	3.3	0.50 [0.11, 0.90]
			Placebo	66	54 (81.8)	0.55 (1.21)	-3.5	-0.08	0.79	1.25	3.0	
		Week 28	Tezepelumab	57	49 (86.0)	1.17 (0.98)	-0.8	0.42	0.92	2.08	3.3	0.49 [0.10, 0.88]
			Placebo	66	54 (81.8)	0.61 (1.26)	-3.5	0.08	0.79	1.25	3.3	
		Week 32	Tezepelumab	57	49 (86.0)	1.20 (1.03)	-0.8	0.50	1.17	1.92	3.3	0.51 [0.12, 0.91]
			Placebo	66	54 (81.8)	0.65 (1.13)	-3.5	0.17	0.92	1.17	3.4	
		Week 36	Tezepelumab	57	49 (86.0)	1.17 (1.11)	-0.9	0.33	1.25	2.00	3.8	0.47 [0.08, 0.86]
			Placebo	66	54 (81.8)	0.64 (1.17)	-3.0	0.00	0.71	1.25	3.8	
		Week 40	Tezepelumab	57	49 (86.0)	1.23 (1.05)	-0.8	0.50	1.08	2.08	3.3	0.45 [0.06, 0.84]
			Placebo	66	54 (81.8)	0.73 (1.17)	-3.0	0.08	0.71	1.42	3.7	
		Week 44	Tezepelumab	57	49 (86.0)	1.17 (1.10)	-1.8	0.50	1.33	2.00	3.3	0.49 [0.10, 0.89]
			Placebo	66	54 (81.8)	0.62 (1.15)	-3.0	0.08	0.67	1.25	3.8	
		Week 48	Tezepelumab	57	49 (86.0)	1.29 (1.02)	-0.8	0.67	1.33	2.00	3.4	0.54 [0.14, 0.93]
			Placebo	66	54 (81.8)	0.70 (1.16)	-3.0	-0.08	0.79	1.33	3.8	
		Week 52	Tezepelumab	57	49 (86.0)	1.27 (1.04)	-0.8	0.50	1.17	2.08	3.4	0.58 [0.18, 0.97]
			Placebo	66	54 (81.8)	0.65 (1.09)	-3.0	0.00	0.67	1.17	3.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	71	66 (93.0)	4.10 (1.14)	1.3	3.42	4.00	4.83	6.8	
			Placebo	63	58 (92.1)	3.97 (0.85)	1.5	3.50	4.00	4.58	5.9	
		Week 4	Tezepelumab	71	63 (88.7)	4.86 (1.21)	1.3	3.92	4.83	5.67	7.0	
			Placebo	63	57 (90.5)	4.64 (0.86)	2.4	4.08	4.67	5.25	6.7	
		Week 8	Tezepelumab	71	65 (91.5)	5.09 (1.18)	2.8	4.00	5.08	6.08	7.0	
			Placebo	63	57 (90.5)	4.74 (1.03)	1.9	4.17	4.58	5.42	6.8	
		Week 12	Tezepelumab	71	65 (91.5)	5.19 (1.16)	2.8	4.17	5.17	6.25	7.0	
			Placebo	63	58 (92.1)	4.87 (1.05)	2.5	4.17	4.96	5.67	6.8	
		Week 16	Tezepelumab	71	65 (91.5)	5.17 (1.18)	2.3	4.33	5.33	6.08	7.0	
			Placebo	63	58 (92.1)	4.91 (1.07)	2.1	4.17	5.00	5.58	6.8	
		Week 20	Tezepelumab	71	65 (91.5)	5.26 (1.11)	2.3	4.42	5.42	6.00	7.0	
			Placebo	63	58 (92.1)	4.95 (0.97)	2.1	4.17	4.96	5.75	6.9	
		Week 24	Tezepelumab	71	65 (91.5)	5.32 (1.06)	3.1	4.42	5.25	6.08	7.0	
			Placebo	63	58 (92.1)	5.03 (0.94)	3.2	4.25	5.04	5.92	6.9	
		Week 28	Tezepelumab	71	66 (93.0)	5.25 (1.11)	3.2	4.33	5.29	6.08	7.0	
			Placebo	63	59 (93.7)	5.11 (1.06)	3.0	4.17	5.08	5.92	7.0	
		Week 32	Tezepelumab	71	67 (94.4)	5.37 (1.13)	2.8	4.67	5.58	6.25	7.0	
			Placebo	63	59 (93.7)	5.21 (0.91)	3.2	4.42	5.25	6.00	6.9	
		Week 36	Tezepelumab	71	67 (94.4)	5.35 (1.11)	2.9	4.50	5.25	6.08	7.0	
			Placebo	63	59 (93.7)	5.23 (0.96)	3.2	4.42	5.17	6.00	7.0	
		Week 40	Tezepelumab	71	67 (94.4)	5.35 (1.16)	2.3	4.42	5.58	6.33	7.0	
			Placebo	63	59 (93.7)	5.22 (1.00)	3.2	4.42	5.25	6.00	7.0	
		Week 44	Tezepelumab	71	67 (94.4)	5.42 (1.10)	3.1	4.42	5.50	6.50	7.0	
			Placebo	63	59 (93.7)	5.21 (1.08)	3.1	4.25	5.33	6.08	7.0	
		Week 48	Tezepelumab	71	67 (94.4)	5.38 (1.14)	2.8	4.33	5.33	6.33	7.0	
			Placebo	63	59 (93.7)	5.22 (0.98)	3.2	4.25	5.25	6.00	7.0	
		Week 52	Tezepelumab	71	67 (94.4)	5.38 (1.12)	2.8	4.42	5.42	6.25	7.0	
			Placebo	63	59 (93.7)	5.25 (1.00)	3.2	4.25	5.25	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	71	61 (85.9)	0.74 (1.13)	-4.3	0.17	0.83	1.50	3.1	0.10 [-0.26, 0.46]
			Placebo	63	57 (90.5)	0.64 (0.94)	-1.3	0.08	0.50	1.25	3.3	
		Week 8	Tezepelumab	71	63 (88.7)	0.97 (1.00)	-1.4	0.25	1.00	1.75	3.0	0.24 [-0.12, 0.60]
			Placebo	63	57 (90.5)	0.74 (0.99)	-1.0	0.17	0.67	1.17	3.6	
		Week 12	Tezepelumab	71	63 (88.7)	1.08 (1.07)	-2.6	0.42	1.08	1.83	3.0	0.16 [-0.20, 0.52]
			Placebo	63	57 (90.5)	0.89 (1.27)	-3.1	0.33	0.83	1.25	4.0	
		Week 16	Tezepelumab	71	63 (88.7)	1.06 (1.04)	-2.9	0.42	1.00	1.75	3.0	0.12 [-0.24, 0.47]
			Placebo	63	57 (90.5)	0.92 (1.28)	-3.1	0.33	0.92	1.58	4.2	
		Week 20	Tezepelumab	71	63 (88.7)	1.14 (1.11)	-1.8	0.33	1.08	1.92	4.7	0.16 [-0.20, 0.52]
			Placebo	63	57 (90.5)	0.97 (1.05)	-1.3	0.25	0.83	1.33	3.8	
		Week 24	Tezepelumab	71	63 (88.7)	1.21 (1.07)	-1.6	0.42	1.08	2.08	3.7	0.16 [-0.20, 0.51]
			Placebo	63	57 (90.5)	1.05 (1.07)	-0.7	0.25	0.92	1.50	4.1	
		Week 28	Tezepelumab	71	63 (88.7)	1.11 (1.12)	-1.7	0.42	1.00	2.00	4.9	0.01 [-0.35, 0.37]
			Placebo	63	57 (90.5)	1.10 (1.20)	-0.7	0.25	0.83	1.67	4.7	
		Week 32	Tezepelumab	71	63 (88.7)	1.21 (1.16)	-1.6	0.42	1.00	2.17	4.6	0.01 [-0.35, 0.37]
			Placebo	63	57 (90.5)	1.21 (1.05)	-0.8	0.50	1.08	1.67	4.0	
		Week 36	Tezepelumab	71	63 (88.7)	1.19 (1.18)	-1.7	0.33	1.00	2.08	3.3	-0.03 [-0.38, 0.33]
			Placebo	63	57 (90.5)	1.22 (1.04)	-0.7	0.33	1.17	1.83	3.8	
		Week 40	Tezepelumab	71	63 (88.7)	1.19 (1.13)	-1.7	0.42	1.08	2.08	3.4	-0.03 [-0.38, 0.33]
			Placebo	63	57 (90.5)	1.21 (1.11)	-0.7	0.58	1.17	1.67	4.7	
		Week 44	Tezepelumab	71	63 (88.7)	1.26 (1.09)	-1.6	0.50	1.17	2.17	3.3	0.05 [-0.31, 0.41]
			Placebo	63	57 (90.5)	1.21 (1.14)	-0.8	0.50	1.17	1.83	4.3	
		Week 48	Tezepelumab	71	63 (88.7)	1.23 (1.13)	-1.6	0.42	1.08	2.25	3.2	0.02 [-0.34, 0.38]
			Placebo	63	57 (90.5)	1.21 (1.03)	-0.7	0.42	1.17	1.67	4.2	
		Week 52	Tezepelumab	71	63 (88.7)	1.22 (1.13)	-1.6	0.42	1.00	2.17	3.6	-0.02 [-0.38, 0.33]
			Placebo	63	57 (90.5)	1.24 (1.08)	-0.7	0.50	1.17	1.75	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	35	31 (88.6)	4.07 (0.79)	2.3	3.75	4.08	4.50	6.3	
			Placebo	32	26 (81.3)	4.18 (0.92)	1.8	3.58	4.29	4.75	6.3	
		Week 4	Tezepelumab	35	33 (94.3)	5.00 (0.96)	3.5	4.08	5.00	5.83	6.6	
			Placebo	32	26 (81.3)	4.65 (1.14)	1.8	4.00	4.71	5.33	6.4	
		Week 8	Tezepelumab	35	33 (94.3)	5.08 (1.11)	2.0	4.33	5.17	5.92	6.8	
			Placebo	32	28 (87.5)	4.61 (1.13)	2.3	3.88	4.50	5.42	6.5	
		Week 12	Tezepelumab	35	33 (94.3)	5.34 (1.03)	3.6	4.42	5.50	6.25	7.0	
			Placebo	32	28 (87.5)	4.74 (1.14)	2.1	4.04	4.63	5.46	6.9	
		Week 16	Tezepelumab	35	33 (94.3)	5.38 (1.04)	3.6	4.33	5.50	6.08	7.0	
			Placebo	32	28 (87.5)	4.73 (1.39)	1.3	4.00	4.79	5.83	7.0	
		Week 20	Tezepelumab	35	34 (97.1)	5.19 (1.05)	3.6	4.17	5.13	5.92	7.0	
			Placebo	32	28 (87.5)	4.77 (1.49)	1.3	3.96	4.79	6.13	7.0	
		Week 24	Tezepelumab	35	34 (97.1)	5.29 (1.04)	3.6	4.33	5.38	6.00	7.0	
			Placebo	32	28 (87.5)	4.68 (1.61)	1.3	3.67	4.54	6.25	7.0	
		Week 28	Tezepelumab	35	35 (100.0)	5.21 (1.12)	3.3	4.17	5.17	6.17	7.0	
			Placebo	32	28 (87.5)	4.42 (1.45)	1.3	3.42	4.33	5.04	7.0	
		Week 32	Tezepelumab	35	35 (100.0)	5.18 (1.07)	3.5	4.17	5.00	6.08	7.0	
			Placebo	32	28 (87.5)	4.71 (1.46)	1.3	3.96	4.75	6.08	7.0	
		Week 36	Tezepelumab	35	35 (100.0)	5.24 (1.11)	3.3	4.25	5.25	6.17	7.0	
			Placebo	32	28 (87.5)	4.92 (1.45)	2.4	4.00	4.50	6.46	7.0	
		Week 40	Tezepelumab	35	35 (100.0)	5.15 (1.06)	2.9	4.33	5.17	5.67	7.0	
			Placebo	32	28 (87.5)	4.79 (1.37)	2.3	3.79	4.54	6.04	7.0	
		Week 44	Tezepelumab	35	35 (100.0)	5.18 (1.10)	3.0	4.17	5.33	5.83	7.0	
			Placebo	32	28 (87.5)	4.79 (1.30)	2.5	3.92	4.63	6.08	7.0	
		Week 48	Tezepelumab	35	35 (100.0)	5.23 (1.12)	3.1	4.25	5.17	6.17	7.0	
			Placebo	32	28 (87.5)	4.74 (1.38)	2.2	3.71	4.54	6.21	7.0	
		Week 52	Tezepelumab	35	35 (100.0)	5.23 (1.10)	3.1	4.33	5.17	6.17	7.0	
			Placebo	32	28 (87.5)	4.73 (1.24)	2.8	3.92	4.46	5.54	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	35	31 (88.6)	1.01 (0.89)	-0.8	0.25	1.17	1.67	3.1	0.56 [0.03, 1.10]
			Placebo	32	25 (78.1)	0.55 (0.71)	-1.1	0.17	0.58	1.00	1.8	
		Week 8	Tezepelumab	35	31 (88.6)	1.00 (1.15)	-1.9	0.25	0.92	2.00	3.3	0.51 [-0.02, 1.04]
			Placebo	32	26 (81.3)	0.46 (0.92)	-1.8	0.00	0.54	1.17	2.4	
		Week 12	Tezepelumab	35	31 (88.6)	1.27 (1.06)	-0.8	0.42	1.25	2.00	3.7	0.60 [0.07, 1.13]
			Placebo	32	26 (81.3)	0.60 (1.18)	-2.8	-0.08	0.83	1.25	2.7	
		Week 16	Tezepelumab	35	31 (88.6)	1.32 (1.02)	-0.8	0.50	1.42	2.08	3.3	0.59 [0.06, 1.13]
			Placebo	32	26 (81.3)	0.59 (1.45)	-3.5	0.00	0.92	1.42	2.3	
		Week 20	Tezepelumab	35	31 (88.6)	1.14 (0.97)	-0.8	0.42	0.92	2.00	3.3	0.40 [-0.13, 0.92]
			Placebo	32	26 (81.3)	0.64 (1.55)	-3.5	0.08	0.79	1.67	3.3	
		Week 24	Tezepelumab	35	31 (88.6)	1.26 (0.94)	-0.8	0.50	1.25	1.92	3.3	0.54 [0.01, 1.07]
			Placebo	32	26 (81.3)	0.55 (1.66)	-3.5	0.08	0.42	1.83	3.4	
		Week 28	Tezepelumab	35	31 (88.6)	1.21 (0.94)	-0.8	0.58	1.00	2.00	3.3	0.76 [0.22, 1.30]
			Placebo	32	26 (81.3)	0.26 (1.55)	-3.5	-0.33	0.33	1.42	3.3	
		Week 32	Tezepelumab	35	31 (88.6)	1.15 (1.01)	-0.8	0.50	1.08	1.92	3.3	0.46 [-0.07, 0.99]
			Placebo	32	26 (81.3)	0.58 (1.47)	-3.5	0.08	0.79	1.33	3.4	
		Week 36	Tezepelumab	35	31 (88.6)	1.19 (1.04)	-0.9	0.42	1.42	2.00	3.4	0.31 [-0.22, 0.83]
			Placebo	32	26 (81.3)	0.80 (1.45)	-3.0	0.25	1.04	1.75	3.4	
		Week 40	Tezepelumab	35	31 (88.6)	1.14 (0.97)	-0.8	0.50	1.08	1.67	3.3	0.39 [-0.13, 0.92]
			Placebo	32	26 (81.3)	0.67 (1.45)	-3.0	-0.58	1.04	1.75	3.3	
		Week 44	Tezepelumab	35	31 (88.6)	1.18 (1.02)	-0.8	0.50	1.17	2.00	3.2	0.42 [-0.10, 0.95]
			Placebo	32	26 (81.3)	0.67 (1.40)	-3.0	-0.25	0.75	1.50	3.3	
		Week 48	Tezepelumab	35	31 (88.6)	1.23 (1.02)	-0.8	0.50	1.42	2.00	3.4	0.51 [-0.02, 1.04]
			Placebo	32	26 (81.3)	0.61 (1.42)	-3.0	-0.25	0.54	1.50	3.3	
		Week 52	Tezepelumab	35	31 (88.6)	1.22 (0.99)	-0.8	0.58	1.00	2.00	3.4	0.56 [0.03, 1.09]
			Placebo	32	26 (81.3)	0.58 (1.26)	-3.0	-0.17	0.54	1.25	3.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	95	86 (90.5)	4.03 (1.07)	1.3	3.50	4.00	4.67	6.8	
			Placebo	98	87 (88.8)	3.91 (0.92)	1.5	3.33	4.00	4.50	5.9	
		Week 4	Tezepelumab	95	86 (90.5)	4.80 (1.11)	1.3	4.00	4.75	5.50	7.0	
			Placebo	98	89 (90.8)	4.47 (0.91)	2.3	3.92	4.50	5.17	6.7	
		Week 8	Tezepelumab	95	88 (92.6)	5.06 (1.08)	2.7	4.21	5.00	5.83	7.0	
			Placebo	98	90 (91.8)	4.60 (1.05)	1.9	4.00	4.50	5.33	7.0	
		Week 12	Tezepelumab	95	88 (92.6)	5.21 (1.09)	2.8	4.33	5.17	6.13	7.0	
			Placebo	98	91 (92.9)	4.72 (1.08)	2.4	3.92	4.67	5.67	7.0	
		Week 16	Tezepelumab	95	88 (92.6)	5.16 (1.13)	2.3	4.33	5.17	5.96	7.0	
			Placebo	98	91 (92.9)	4.74 (1.06)	2.1	4.00	4.58	5.50	7.0	
		Week 20	Tezepelumab	95	88 (92.6)	5.23 (1.08)	2.3	4.46	5.25	6.00	7.0	
			Placebo	98	91 (92.9)	4.77 (1.04)	2.1	4.08	4.58	5.50	7.0	
		Week 24	Tezepelumab	95	88 (92.6)	5.23 (1.10)	1.8	4.42	5.13	6.00	7.0	
			Placebo	98	91 (92.9)	4.84 (1.01)	2.8	4.00	4.67	5.75	7.0	
		Week 28	Tezepelumab	95	89 (93.7)	5.25 (1.04)	3.2	4.50	5.00	6.00	7.0	
			Placebo	98	92 (93.9)	4.97 (1.14)	2.8	4.00	4.96	5.96	7.0	
		Week 32	Tezepelumab	95	90 (94.7)	5.34 (1.08)	2.8	4.58	5.46	6.00	7.0	
			Placebo	98	93 (94.9)	4.93 (1.06)	2.4	4.08	5.00	5.83	7.0	
		Week 36	Tezepelumab	95	90 (94.7)	5.31 (1.08)	2.9	4.50	5.25	6.08	7.0	
			Placebo	98	93 (94.9)	4.91 (1.10)	2.5	4.00	4.83	6.00	7.0	
		Week 40	Tezepelumab	95	90 (94.7)	5.34 (1.11)	2.3	4.50	5.33	6.17	7.0	
			Placebo	98	93 (94.9)	4.99 (1.08)	2.4	4.08	4.92	5.92	7.0	
		Week 44	Tezepelumab	95	90 (94.7)	5.36 (1.10)	2.3	4.58	5.42	6.25	7.0	
			Placebo	98	93 (94.9)	4.96 (1.17)	2.3	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	95	90 (94.7)	5.37 (1.10)	2.8	4.50	5.29	6.33	7.0	
			Placebo	98	94 (95.9)	5.01 (1.05)	2.8	4.00	5.04	5.83	7.0	
		Week 52	Tezepelumab	95	90 (94.7)	5.37 (1.08)	2.8	4.58	5.33	6.25	7.0	
			Placebo	98	94 (95.9)	4.99 (1.10)	2.5	4.00	5.13	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	95	80 (84.2)	0.79 (1.08)	-4.3	0.25	0.67	1.50	3.1	0.26 [-0.05, 0.56]
			Placebo	98	86 (87.8)	0.54 (0.86)	-1.8	0.08	0.50	1.17	3.1	
		Week 8	Tezepelumab	95	82 (86.3)	1.03 (1.04)	-1.4	0.25	0.96	1.83	4.1	0.33 [0.03, 0.64]
			Placebo	98	86 (87.8)	0.70 (0.92)	-1.0	0.17	0.54	1.17	3.6	
		Week 12	Tezepelumab	95	82 (86.3)	1.17 (1.13)	-2.6	0.42	1.08	2.00	4.5	0.31 [0.01, 0.61]
			Placebo	98	86 (87.8)	0.81 (1.17)	-3.1	0.08	0.75	1.25	4.0	
		Week 16	Tezepelumab	95	82 (86.3)	1.12 (1.15)	-2.9	0.42	1.04	1.92	4.6	0.26 [-0.05, 0.56]
			Placebo	98	86 (87.8)	0.84 (1.08)	-3.1	0.17	0.92	1.42	4.2	
		Week 20	Tezepelumab	95	82 (86.3)	1.21 (1.16)	-1.8	0.33	1.08	2.00	4.7	0.32 [0.01, 0.62]
			Placebo	98	86 (87.8)	0.88 (0.97)	-1.3	0.25	0.83	1.33	3.8	
		Week 24	Tezepelumab	95	82 (86.3)	1.24 (1.18)	-1.6	0.42	1.13	2.17	4.8	0.26 [-0.04, 0.56]
			Placebo	98	86 (87.8)	0.96 (0.99)	-0.7	0.25	0.83	1.42	4.1	
		Week 28	Tezepelumab	95	82 (86.3)	1.20 (1.18)	-1.7	0.33	1.00	2.08	4.9	0.12 [-0.19, 0.42]
			Placebo	98	86 (87.8)	1.07 (1.11)	-0.7	0.25	0.96	1.67	4.7	
		Week 32	Tezepelumab	95	82 (86.3)	1.31 (1.23)	-1.6	0.42	1.17	2.17	4.8	0.23 [-0.08, 0.53]
			Placebo	98	86 (87.8)	1.06 (0.99)	-0.9	0.33	1.00	1.58	4.0	
		Week 36	Tezepelumab	95	82 (86.3)	1.26 (1.27)	-1.7	0.25	1.17	2.33	4.8	0.21 [-0.10, 0.51]
			Placebo	98	86 (87.8)	1.02 (1.04)	-1.3	0.08	0.96	1.67	3.8	
		Week 40	Tezepelumab	95	82 (86.3)	1.30 (1.20)	-1.7	0.42	1.13	2.25	4.8	0.17 [-0.14, 0.47]
			Placebo	98	86 (87.8)	1.11 (1.06)	-0.8	0.50	1.00	1.67	4.7	
		Week 44	Tezepelumab	95	82 (86.3)	1.32 (1.19)	-1.8	0.50	1.25	2.17	4.8	0.22 [-0.08, 0.52]
			Placebo	98	86 (87.8)	1.07 (1.10)	-1.4	0.33	1.08	1.67	4.3	
		Week 48	Tezepelumab	95	82 (86.3)	1.35 (1.17)	-1.6	0.50	1.21	2.33	4.8	0.21 [-0.09, 0.52]
			Placebo	98	86 (87.8)	1.12 (1.00)	-0.9	0.33	1.13	1.67	3.8	
		Week 52	Tezepelumab	95	82 (86.3)	1.34 (1.19)	-1.6	0.42	1.13	2.33	4.8	0.21 [-0.09, 0.51]
			Placebo	98	86 (87.8)	1.10 (1.03)	-0.9	0.42	0.96	1.67	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	4.26 (1.13)	2.3	3.58	4.83	5.00	5.1	
			Placebo	8	8 (100.0)	4.01 (0.62)	2.8	3.71	4.17	4.46	4.7	
		Week 4	Tezepelumab	7	7 (100.0)	4.56 (0.86)	3.5	3.58	4.58	5.58	5.7	
			Placebo	8	8 (100.0)	5.05 (0.66)	3.9	4.63	5.21	5.38	6.1	
		Week 8	Tezepelumab	7	7 (100.0)	4.81 (1.02)	3.8	3.83	4.58	6.00	6.1	
			Placebo	8	8 (100.0)	4.88 (0.64)	4.3	4.42	4.58	5.33	6.1	
		Week 12	Tezepelumab	7	7 (100.0)	4.81 (1.09)	3.5	3.92	4.25	5.92	6.1	
			Placebo	8	8 (100.0)	5.18 (0.69)	4.2	4.83	5.21	5.29	6.6	
		Week 16	Tezepelumab	7	7 (100.0)	4.89 (1.06)	3.3	4.00	5.08	5.83	6.1	
			Placebo	8	8 (100.0)	5.24 (0.60)	4.6	4.75	5.08	5.67	6.3	
		Week 20	Tezepelumab	7	7 (100.0)	4.89 (1.05)	3.5	3.92	4.58	6.00	6.1	
			Placebo	8	8 (100.0)	5.14 (0.40)	4.8	4.83	5.08	5.25	6.0	
		Week 24	Tezepelumab	7	7 (100.0)	4.87 (1.02)	3.7	3.92	4.42	6.00	6.1	
			Placebo	8	8 (100.0)	5.07 (0.59)	4.6	4.67	4.92	5.25	6.3	
		Week 28	Tezepelumab	7	7 (100.0)	4.93 (0.97)	3.8	4.00	4.58	5.92	6.1	
			Placebo	8	8 (100.0)	5.00 (0.42)	4.3	4.75	5.08	5.29	5.5	
		Week 32	Tezepelumab	7	7 (100.0)	5.14 (1.06)	3.9	4.17	4.75	6.08	6.6	
			Placebo	8	8 (100.0)	5.34 (0.41)	4.9	5.13	5.21	5.46	6.3	
		Week 36	Tezepelumab	7	7 (100.0)	5.20 (0.96)	4.1	4.17	4.92	6.08	6.4	
			Placebo	8	8 (100.0)	5.28 (0.59)	4.8	4.83	5.13	5.50	6.5	
		Week 40	Tezepelumab	7	7 (100.0)	5.21 (1.03)	4.0	4.33	5.00	6.08	6.7	
			Placebo	8	8 (100.0)	5.17 (0.61)	4.0	4.96	5.21	5.42	6.2	
		Week 44	Tezepelumab	7	7 (100.0)	5.20 (1.00)	4.2	4.33	4.92	6.08	6.6	
			Placebo	8	8 (100.0)	4.99 (0.89)	3.7	4.29	5.13	5.50	6.4	
		Week 48	Tezepelumab	7	7 (100.0)	5.11 (0.95)	4.0	4.00	5.17	6.00	6.1	
			Placebo	8	8 (100.0)	5.19 (0.78)	4.3	4.75	5.04	5.33	6.9	
		Week 52	Tezepelumab	7	7 (100.0)	5.20 (1.08)	4.0	4.00	5.17	6.08	6.7	
			Placebo	8	8 (100.0)	5.18 (0.80)	4.3	4.75	4.92	5.42	6.9	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	0.26 (0.70)	-0.6	-0.25	0.25	0.58	1.3	-0.79 [-1.90, 0.31]
			Placebo	8	8 (100.0)	1.04 (1.14)	-0.4	0.33	0.88	1.50	3.3	
		Week 8	Tezepelumab	7	6 (85.7)	0.44 (0.88)	-0.8	-0.25	0.58	1.08	1.5	-0.39 [-1.46, 0.68]
			Placebo	8	8 (100.0)	0.86 (1.19)	-0.2	0.00	0.42	1.46	3.3	
		Week 12	Tezepelumab	7	6 (85.7)	0.37 (0.83)	-0.7	-0.58	0.58	1.08	1.3	-0.74 [-1.84, 0.36]
			Placebo	8	8 (100.0)	1.17 (1.21)	0.0	0.38	0.83	1.54	3.8	
		Week 16	Tezepelumab	7	6 (85.7)	0.50 (0.59)	-0.5	0.25	0.58	1.00	1.1	-0.77 [-1.87, 0.33]
			Placebo	8	8 (100.0)	1.23 (1.14)	0.2	0.38	0.88	1.79	3.6	
		Week 20	Tezepelumab	7	6 (85.7)	0.49 (0.71)	-0.4	-0.25	0.63	1.08	1.3	-0.75 [-1.85, 0.35]
			Placebo	8	8 (100.0)	1.12 (0.94)	0.1	0.67	0.96	1.21	3.3	
		Week 24	Tezepelumab	7	6 (85.7)	0.47 (0.80)	-0.5	-0.42	0.63	1.08	1.4	-0.58 [-1.66, 0.51]
			Placebo	8	8 (100.0)	1.06 (1.15)	0.0	0.21	0.88	1.38	3.6	
		Week 28	Tezepelumab	7	6 (85.7)	0.53 (0.76)	-0.4	-0.25	0.63	1.08	1.5	-0.56 [-1.64, 0.52]
			Placebo	8	8 (100.0)	0.99 (0.86)	0.1	0.42	0.75	1.38	2.8	
		Week 32	Tezepelumab	7	6 (85.7)	0.64 (0.75)	-0.3	-0.08	0.75	1.08	1.7	-0.79 [-1.89, 0.32]
			Placebo	8	8 (100.0)	1.33 (0.97)	0.4	0.83	1.00	1.54	3.5	
		Week 36	Tezepelumab	7	6 (85.7)	0.74 (0.70)	-0.1	0.08	0.75	1.08	1.8	-0.54 [-1.62, 0.54]
			Placebo	8	8 (100.0)	1.27 (1.15)	0.3	0.46	0.96	1.63	3.8	
		Week 40	Tezepelumab	7	6 (85.7)	0.71 (0.86)	-0.4	0.17	0.67	1.08	2.1	-0.44 [-1.52, 0.63]
			Placebo	8	8 (100.0)	1.16 (1.10)	-0.5	0.75	1.00	1.42	3.4	
		Week 44	Tezepelumab	7	6 (85.7)	0.71 (0.89)	-0.5	0.08	0.75	1.08	2.1	-0.22 [-1.29, 0.84]
			Placebo	8	8 (100.0)	0.98 (1.40)	-0.8	-0.00	0.88	1.63	3.7	
		Week 48	Tezepelumab	7	6 (85.7)	0.69 (0.72)	-0.3	0.33	0.67	1.08	1.8	-0.45 [-1.52, 0.63]
			Placebo	8	8 (100.0)	1.18 (1.28)	0.3	0.54	0.71	1.25	4.2	
		Week 52	Tezepelumab	7	6 (85.7)	0.69 (0.72)	-0.3	0.33	0.67	1.08	1.8	-0.43 [-1.50, 0.65]
			Placebo	8	8 (100.0)	1.17 (1.32)	0.3	0.38	0.71	1.38	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.97 (0.72)	3.2	3.29	3.88	4.63	5.0	
			Placebo	13	9 (69.2)	4.46 (0.74)	3.7	4.08	4.33	4.50	6.3	
		Week 4	Tezepelumab	9	8 (88.9)	4.90 (0.98)	3.6	4.42	4.63	5.54	6.4	
			Placebo	13	11 (84.6)	4.66 (1.02)	2.7	3.92	5.17	5.25	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.52 (0.92)	4.3	4.83	5.38	6.29	6.8	
			Placebo	13	12 (92.3)	4.42 (0.71)	2.9	4.08	4.58	4.92	5.4	
		Week 12	Tezepelumab	9	8 (88.9)	5.64 (0.99)	4.3	4.88	5.46	6.54	7.0	
			Placebo	13	12 (92.3)	4.31 (1.08)	2.1	3.50	4.25	5.13	6.0	
		Week 16	Tezepelumab	9	8 (88.9)	5.79 (0.78)	4.3	5.46	5.83	6.25	6.9	
			Placebo	13	12 (92.3)	4.54 (1.03)	2.8	3.79	4.67	5.46	6.0	
		Week 20	Tezepelumab	9	8 (88.9)	5.33 (1.08)	3.8	4.25	5.67	6.08	6.8	
			Placebo	13	12 (92.3)	4.50 (0.94)	2.8	3.83	4.54	5.25	5.8	
		Week 24	Tezepelumab	9	8 (88.9)	5.45 (1.12)	4.0	4.25	5.83	6.29	6.8	
			Placebo	13	12 (92.3)	4.49 (1.04)	2.8	3.71	4.54	5.29	6.0	
		Week 28	Tezepelumab	9	8 (88.9)	4.88 (1.12)	3.8	3.96	4.46	5.79	6.8	
			Placebo	13	13 (100.0)	4.66 (1.09)	2.8	3.83	4.58	5.17	6.8	
		Week 32	Tezepelumab	9	8 (88.9)	5.28 (1.17)	3.7	4.29	5.29	6.33	6.8	
			Placebo	13	13 (100.0)	4.76 (1.15)	3.0	3.83	5.17	5.58	6.8	
		Week 36	Tezepelumab	9	8 (88.9)	5.01 (1.15)	3.7	4.21	4.54	6.00	6.9	
			Placebo	13	13 (100.0)	4.76 (1.24)	2.4	3.83	4.83	5.42	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.40 (1.24)	4.1	4.29	5.25	6.50	7.0	
			Placebo	13	13 (100.0)	4.66 (1.33)	2.3	3.83	4.42	5.58	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.20 (1.08)	4.1	4.25	4.92	6.13	6.9	
			Placebo	13	13 (100.0)	4.69 (1.23)	2.5	3.83	4.50	5.67	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.14 (1.26)	3.7	4.04	5.04	6.17	6.9	
			Placebo	13	13 (100.0)	4.69 (1.28)	2.2	4.00	4.75	5.17	6.9	
		Week 52	Tezepelumab	9	8 (88.9)	5.27 (1.22)	3.7	4.04	5.58	6.17	6.9	
			Placebo	13	13 (100.0)	4.72 (1.23)	2.8	3.83	4.75	5.17	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.94 (0.58)	0.2	0.33	1.33	1.33	1.6	0.94 [-0.11, 1.98]
			Placebo	13	9 (69.2)	0.21 (0.90)	-1.1	-0.42	0.33	0.67	1.5	
		Week 8	Tezepelumab	9	7 (77.8)	1.54 (0.70)	0.5	0.83	1.92	2.00	2.3	1.67 [0.51, 2.84]
			Placebo	13	9 (69.2)	0.13 (0.93)	-1.8	-0.08	0.33	0.42	1.4	
		Week 12	Tezepelumab	9	7 (77.8)	1.70 (0.70)	0.5	1.25	1.83	2.17	2.6	1.80 [0.61, 2.99]
			Placebo	13	9 (69.2)	-0.21 (1.27)	-2.8	-0.83	0.17	0.83	1.0	
		Week 16	Tezepelumab	9	7 (77.8)	1.85 (0.79)	0.5	1.00	2.08	2.50	2.6	1.31 [0.21, 2.42]
			Placebo	13	9 (69.2)	0.22 (1.48)	-3.0	-0.08	0.33	1.25	1.8	
		Week 20	Tezepelumab	9	7 (77.8)	1.52 (0.78)	0.5	0.67	1.58	2.25	2.5	1.15 [0.08, 2.23]
			Placebo	13	9 (69.2)	0.17 (1.40)	-3.0	-0.08	0.75	0.83	1.7	
		Week 24	Tezepelumab	9	7 (77.8)	1.68 (0.84)	0.5	1.00	2.00	2.33	2.8	1.13 [0.06, 2.20]
			Placebo	13	9 (69.2)	0.27 (1.48)	-3.0	0.08	0.67	1.17	1.8	
		Week 28	Tezepelumab	9	7 (77.8)	0.94 (1.03)	-0.5	0.50	0.58	2.00	2.6	0.60 [-0.41, 1.62]
			Placebo	13	9 (69.2)	0.19 (1.40)	-3.0	0.08	0.83	0.92	1.7	
		Week 32	Tezepelumab	9	7 (77.8)	1.54 (0.75)	0.5	1.00	1.42	2.33	2.6	0.97 [-0.08, 2.02]
			Placebo	13	9 (69.2)	0.37 (1.44)	-3.0	0.08	0.83	1.17	1.7	
		Week 36	Tezepelumab	9	7 (77.8)	1.23 (0.99)	-0.2	0.50	1.08	2.08	2.8	0.72 [-0.31, 1.74]
			Placebo	13	9 (69.2)	0.27 (1.55)	-3.0	0.08	0.67	1.08	2.0	
		Week 40	Tezepelumab	9	7 (77.8)	1.61 (0.92)	0.5	1.00	1.08	2.58	2.9	1.03 [-0.03, 2.09]
			Placebo	13	9 (69.2)	0.20 (1.62)	-3.0	-0.50	0.83	1.25	2.1	
		Week 44	Tezepelumab	9	7 (77.8)	1.38 (1.03)	0.5	0.50	1.00	2.08	3.3	0.89 [-0.15, 1.93]
			Placebo	13	9 (69.2)	0.16 (1.58)	-3.0	-0.83	0.58	1.58	1.7	
		Week 48	Tezepelumab	9	7 (77.8)	1.37 (1.22)	-0.1	0.33	1.08	2.58	3.1	0.81 [-0.22, 1.85]
			Placebo	13	9 (69.2)	0.19 (1.59)	-3.0	0.08	0.42	0.83	2.3	
		Week 52	Tezepelumab	9	7 (77.8)	1.52 (1.06)	0.3	0.50	1.08	2.58	3.1	0.94 [-0.11, 1.99]
			Placebo	13	9 (69.2)	0.26 (1.52)	-3.0	0.08	0.42	0.83	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.05 (1.02)	1.3	3.50	4.08	4.67	6.8	
			Placebo	125	112 (89.6)	3.94 (0.91)	1.5	3.42	4.00	4.54	5.9	
		Week 4	Tezepelumab	128	118 (92.2)	4.84 (1.07)	1.3	4.00	4.83	5.58	7.0	
			Placebo	125	112 (89.6)	4.53 (0.95)	1.8	3.96	4.54	5.21	6.7	
		Week 8	Tezepelumab	128	120 (93.8)	5.02 (1.08)	2.0	4.17	4.96	5.83	7.0	
			Placebo	125	114 (91.2)	4.64 (1.08)	1.9	4.00	4.50	5.42	7.0	
		Week 12	Tezepelumab	128	120 (93.8)	5.19 (1.08)	2.8	4.25	5.17	6.08	7.0	
			Placebo	125	115 (92.0)	4.80 (1.07)	2.4	4.00	4.67	5.58	7.0	
		Week 16	Tezepelumab	128	120 (93.8)	5.16 (1.11)	2.3	4.33	5.17	5.96	7.0	
			Placebo	125	115 (92.0)	4.79 (1.13)	1.3	4.00	4.75	5.58	7.0	
		Week 20	Tezepelumab	128	121 (94.5)	5.19 (1.07)	2.3	4.33	5.08	5.92	7.0	
			Placebo	125	115 (92.0)	4.82 (1.14)	1.3	4.08	4.75	5.75	7.0	
		Week 24	Tezepelumab	128	121 (94.5)	5.21 (1.08)	1.8	4.42	5.17	6.00	7.0	
			Placebo	125	115 (92.0)	4.85 (1.16)	1.3	4.00	4.67	5.92	7.0	
		Week 28	Tezepelumab	128	123 (96.1)	5.24 (1.05)	3.2	4.42	5.08	6.00	7.0	
			Placebo	125	115 (92.0)	4.87 (1.22)	1.3	4.00	4.75	5.92	7.0	
		Week 32	Tezepelumab	128	124 (96.9)	5.29 (1.07)	2.8	4.46	5.29	6.04	7.0	
			Placebo	125	116 (92.8)	4.93 (1.14)	1.3	4.08	4.92	5.88	7.0	
		Week 36	Tezepelumab	128	124 (96.9)	5.30 (1.07)	2.9	4.50	5.25	6.13	7.0	
			Placebo	125	116 (92.8)	4.95 (1.15)	2.5	4.00	4.83	6.00	7.0	
		Week 40	Tezepelumab	128	124 (96.9)	5.27 (1.08)	2.3	4.46	5.33	6.00	7.0	
			Placebo	125	116 (92.8)	4.99 (1.10)	2.4	4.04	4.92	6.00	7.0	
		Week 44	Tezepelumab	128	124 (96.9)	5.31 (1.10)	2.3	4.50	5.33	6.08	7.0	
			Placebo	125	116 (92.8)	4.95 (1.17)	2.3	4.00	4.79	6.00	7.0	
		Week 48	Tezepelumab	128	124 (96.9)	5.33 (1.08)	2.8	4.50	5.21	6.21	7.0	
			Placebo	125	117 (93.6)	4.99 (1.10)	2.4	4.00	4.92	5.92	7.0	
		Week 52	Tezepelumab	128	124 (96.9)	5.33 (1.07)	2.8	4.54	5.17	6.21	7.0	
			Placebo	125	117 (93.6)	4.97 (1.11)	2.5	4.00	4.83	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	110 (85.9)	0.81 (1.04)	-4.3	0.17	0.79	1.50	3.1	0.22 [-0.05, 0.48]
			Placebo	125	110 (88.0)	0.60 (0.85)	-1.8	0.17	0.50	1.17	3.3	
		Week 8	Tezepelumab	128	112 (87.5)	0.96 (1.07)	-1.9	0.25	0.92	1.67	4.1	0.25 [-0.01, 0.52]
			Placebo	125	111 (88.8)	0.70 (0.93)	-1.0	0.08	0.58	1.17	3.6	
		Week 12	Tezepelumab	128	112 (87.5)	1.12 (1.12)	-2.6	0.33	1.04	1.92	4.5	0.22 [-0.04, 0.48]
			Placebo	125	111 (88.8)	0.87 (1.13)	-3.1	0.25	0.83	1.33	4.0	
		Week 16	Tezepelumab	128	112 (87.5)	1.10 (1.11)	-2.9	0.38	1.08	1.75	4.6	0.22 [-0.05, 0.48]
			Placebo	125	111 (88.8)	0.86 (1.14)	-3.5	0.17	0.92	1.42	4.2	
		Week 20	Tezepelumab	128	112 (87.5)	1.13 (1.11)	-1.8	0.33	1.00	1.96	4.7	0.22 [-0.05, 0.48]
			Placebo	125	111 (88.8)	0.89 (1.08)	-3.5	0.25	0.92	1.42	3.8	
		Week 24	Tezepelumab	128	112 (87.5)	1.18 (1.12)	-1.6	0.42	1.08	2.00	4.8	0.22 [-0.04, 0.48]
			Placebo	125	111 (88.8)	0.93 (1.14)	-3.5	0.17	0.83	1.42	4.1	
		Week 28	Tezepelumab	128	112 (87.5)	1.19 (1.11)	-1.7	0.42	1.00	2.00	4.9	0.20 [-0.06, 0.47]
			Placebo	125	111 (88.8)	0.95 (1.21)	-3.5	0.25	0.83	1.58	4.7	
		Week 32	Tezepelumab	128	112 (87.5)	1.22 (1.18)	-1.6	0.42	1.08	2.08	4.8	0.17 [-0.09, 0.43]
			Placebo	125	111 (88.8)	1.03 (1.09)	-3.5	0.33	1.00	1.58	4.0	
		Week 36	Tezepelumab	128	112 (87.5)	1.21 (1.20)	-1.7	0.29	1.13	2.08	4.8	0.14 [-0.12, 0.41]
			Placebo	125	111 (88.8)	1.05 (1.10)	-2.3	0.25	1.08	1.67	3.8	
		Week 40	Tezepelumab	128	112 (87.5)	1.21 (1.14)	-1.7	0.33	1.08	2.08	4.8	0.11 [-0.16, 0.37]
			Placebo	125	111 (88.8)	1.08 (1.10)	-1.1	0.33	1.00	1.67	4.7	
		Week 44	Tezepelumab	128	112 (87.5)	1.24 (1.15)	-1.8	0.42	1.17	2.08	4.8	0.18 [-0.09, 0.44]
			Placebo	125	111 (88.8)	1.04 (1.13)	-1.4	0.33	1.00	1.67	4.3	
		Week 48	Tezepelumab	128	112 (87.5)	1.28 (1.12)	-1.6	0.46	1.17	2.08	4.8	0.18 [-0.08, 0.45]
			Placebo	125	111 (88.8)	1.08 (1.07)	-1.1	0.33	1.08	1.67	4.2	
		Week 52	Tezepelumab	128	112 (87.5)	1.26 (1.13)	-1.6	0.42	1.08	2.13	4.8	0.18 [-0.08, 0.45]
			Placebo	125	111 (88.8)	1.05 (1.06)	-1.1	0.25	0.92	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	4.10 (1.00)	1.3	3.54	4.00	4.67	6.8	
			Placebo	73	66 (90.4)	3.85 (0.91)	1.8	3.33	3.83	4.42	5.9	
		Week 4	Tezepelumab	70	65 (92.9)	4.94 (1.02)	2.9	4.08	4.83	5.67	7.0	
			Placebo	73	66 (90.4)	4.40 (0.97)	1.8	3.67	4.38	5.17	6.4	
		Week 8	Tezepelumab	70	65 (92.9)	5.11 (1.01)	2.7	4.33	5.00	5.83	7.0	
			Placebo	73	67 (91.8)	4.52 (1.01)	2.3	3.92	4.33	5.25	6.5	
		Week 12	Tezepelumab	70	65 (92.9)	5.25 (1.08)	2.8	4.33	5.25	6.00	7.0	
			Placebo	73	68 (93.2)	4.64 (1.08)	2.4	4.00	4.54	5.58	6.9	
		Week 16	Tezepelumab	70	65 (92.9)	5.20 (1.10)	2.3	4.33	5.25	5.92	7.0	
			Placebo	73	68 (93.2)	4.69 (1.02)	2.2	4.00	4.50	5.50	7.0	
		Week 20	Tezepelumab	70	65 (92.9)	5.26 (1.04)	3.3	4.50	5.25	5.92	7.0	
			Placebo	73	68 (93.2)	4.82 (1.04)	2.3	4.13	4.67	5.54	7.0	
		Week 24	Tezepelumab	70	65 (92.9)	5.27 (1.09)	1.8	4.50	5.17	6.00	7.0	
			Placebo	73	68 (93.2)	4.89 (1.08)	2.1	4.04	4.67	5.83	7.0	
		Week 28	Tezepelumab	70	65 (92.9)	5.31 (0.99)	3.2	4.50	5.17	6.00	7.0	
			Placebo	73	68 (93.2)	4.86 (1.12)	2.9	4.00	4.67	5.92	7.0	
		Week 32	Tezepelumab	70	66 (94.3)	5.37 (1.02)	2.8	4.58	5.50	6.00	7.0	
			Placebo	73	69 (94.5)	4.92 (1.11)	2.1	4.00	5.00	5.83	7.0	
		Week 36	Tezepelumab	70	66 (94.3)	5.31 (1.03)	2.9	4.50	5.25	6.08	7.0	
			Placebo	73	69 (94.5)	5.04 (1.14)	2.5	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	70	66 (94.3)	5.36 (1.02)	3.2	4.50	5.50	6.00	7.0	
			Placebo	73	69 (94.5)	5.00 (1.07)	2.4	4.00	4.83	6.00	7.0	
		Week 44	Tezepelumab	70	66 (94.3)	5.41 (1.08)	2.3	4.58	5.42	6.17	7.0	
			Placebo	73	69 (94.5)	4.95 (1.21)	2.3	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	70	66 (94.3)	5.40 (1.04)	3.3	4.58	5.38	6.25	7.0	
			Placebo	73	70 (95.9)	4.99 (1.09)	2.9	4.00	4.96	5.83	7.0	
		Week 52	Tezepelumab	70	66 (94.3)	5.41 (1.01)	3.5	4.58	5.25	6.25	7.0	
			Placebo	73	70 (95.9)	4.90 (1.13)	2.5	4.00	4.83	5.83	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
Medium/Low	Change from baseline	Week 4	Tezepelumab	70	61 (87.1)	0.88 (0.94)	-0.8	0.25	0.58	1.50	3.1	0.38 [0.03, 0.73]
			Placebo	73	65 (89.0)	0.54 (0.84)	-1.8	0.08	0.50	1.25	2.3	
		Week 8	Tezepelumab	70	61 (87.1)	1.05 (1.02)	-0.7	0.33	0.92	1.58	4.1	0.42 [0.06, 0.77]
			Placebo	73	65 (89.0)	0.65 (0.86)	-0.9	0.08	0.50	1.25	2.7	
		Week 12	Tezepelumab	70	61 (87.1)	1.17 (1.08)	-0.8	0.33	0.92	2.00	4.5	0.34 [-0.01, 0.69]
			Placebo	73	65 (89.0)	0.79 (1.13)	-3.1	0.17	0.92	1.33	3.5	
		Week 16	Tezepelumab	70	61 (87.1)	1.12 (1.08)	-0.9	0.33	1.08	1.83	4.6	0.27 [-0.08, 0.62]
			Placebo	73	65 (89.0)	0.84 (1.04)	-3.1	0.33	0.92	1.50	3.5	
		Week 20	Tezepelumab	70	61 (87.1)	1.18 (1.12)	-0.5	0.33	1.00	1.83	4.7	0.20 [-0.16, 0.55]
			Placebo	73	65 (89.0)	0.98 (0.97)	-0.8	0.25	0.83	1.42	3.8	
		Week 24	Tezepelumab	70	61 (87.1)	1.21 (1.14)	-1.6	0.42	1.00	2.08	4.8	0.14 [-0.21, 0.49]
			Placebo	73	65 (89.0)	1.05 (1.03)	-0.7	0.33	0.83	1.50	4.1	
		Week 28	Tezepelumab	70	61 (87.1)	1.23 (1.10)	-0.3	0.42	1.00	1.83	4.9	0.18 [-0.17, 0.53]
			Placebo	73	65 (89.0)	1.02 (1.14)	-0.7	0.17	0.83	1.58	4.7	
		Week 32	Tezepelumab	70	61 (87.1)	1.27 (1.18)	-0.8	0.42	1.17	1.92	4.8	0.14 [-0.21, 0.49]
			Placebo	73	65 (89.0)	1.12 (1.06)	-0.9	0.33	1.00	1.58	4.0	
		Week 36	Tezepelumab	70	61 (87.1)	1.20 (1.18)	-0.9	0.33	1.17	2.00	4.8	-0.03 [-0.38, 0.32]
			Placebo	73	65 (89.0)	1.23 (1.10)	-0.7	0.25	1.25	1.83	3.8	
		Week 40	Tezepelumab	70	61 (87.1)	1.25 (1.08)	-0.8	0.42	1.25	2.00	4.8	0.06 [-0.29, 0.40]
			Placebo	73	65 (89.0)	1.19 (1.10)	-0.8	0.50	1.17	1.67	4.7	
		Week 44	Tezepelumab	70	61 (87.1)	1.30 (1.13)	-1.8	0.58	1.25	2.08	4.8	0.14 [-0.21, 0.49]
			Placebo	73	65 (89.0)	1.13 (1.17)	-1.4	0.17	1.17	1.83	4.3	
		Week 48	Tezepelumab	70	61 (87.1)	1.32 (1.08)	-0.7	0.50	1.17	2.08	4.8	0.14 [-0.21, 0.49]
			Placebo	73	65 (89.0)	1.17 (1.09)	-0.9	0.25	1.17	1.75	3.8	
		Week 52	Tezepelumab	70	61 (87.1)	1.29 (1.09)	-0.7	0.42	1.08	2.08	4.8	0.19 [-0.16, 0.54]
			Placebo	73	65 (89.0)	1.08 (1.08)	-0.9	0.17	0.92	1.58	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Absolute values	Baseline	Tezepelumab	67	59 (88.1)	4.00 (1.01)	1.4	3.42	4.08	4.67	6.7	
			Placebo	65	55 (84.6)	4.12 (0.88)	1.5	3.67	4.25	4.58	6.3	
		Week 4	Tezepelumab	67	61 (91.0)	4.74 (1.10)	1.3	3.92	4.75	5.58	6.8	
			Placebo	65	57 (87.7)	4.71 (0.92)	2.7	4.17	4.67	5.25	6.7	
		Week 8	Tezepelumab	67	63 (94.0)	4.99 (1.15)	2.0	4.08	4.83	5.83	6.8	
			Placebo	65	59 (90.8)	4.74 (1.08)	1.9	4.17	4.67	5.42	7.0	
		Week 12	Tezepelumab	67	63 (94.0)	5.19 (1.08)	3.0	4.33	5.17	6.17	7.0	
			Placebo	65	59 (90.8)	4.88 (1.06)	2.1	4.17	4.83	5.58	7.0	
		Week 16	Tezepelumab	67	63 (94.0)	5.21 (1.11)	2.7	4.33	5.25	6.08	7.0	
			Placebo	65	59 (90.8)	4.86 (1.23)	1.3	4.08	4.75	5.83	7.0	
		Week 20	Tezepelumab	67	64 (95.5)	5.15 (1.10)	2.3	4.29	5.00	6.00	7.0	
			Placebo	65	59 (90.8)	4.76 (1.22)	1.3	4.00	4.75	5.58	7.0	
		Week 24	Tezepelumab	67	64 (95.5)	5.18 (1.07)	3.1	4.38	5.13	6.08	7.0	
			Placebo	65	59 (90.8)	4.74 (1.23)	1.3	3.83	4.67	5.75	7.0	
		Week 28	Tezepelumab	67	66 (98.5)	5.13 (1.11)	3.2	4.17	5.00	6.08	7.0	
			Placebo	65	60 (92.3)	4.84 (1.30)	1.3	3.96	4.88	5.75	7.0	
		Week 32	Tezepelumab	67	66 (98.5)	5.21 (1.12)	2.8	4.33	5.08	6.08	7.0	
			Placebo	65	60 (92.3)	4.90 (1.17)	1.3	4.04	4.92	5.75	7.0	
		Week 36	Tezepelumab	67	66 (98.5)	5.26 (1.12)	2.9	4.33	5.21	6.17	7.0	
			Placebo	65	60 (92.3)	4.81 (1.18)	2.4	4.00	4.71	5.83	7.0	
		Week 40	Tezepelumab	67	66 (98.5)	5.20 (1.16)	2.3	4.33	5.08	6.08	7.0	
			Placebo	65	60 (92.3)	4.91 (1.19)	2.3	4.00	4.96	5.92	7.0	
		Week 44	Tezepelumab	67	66 (98.5)	5.20 (1.10)	3.0	4.33	5.08	6.08	7.0	
			Placebo	65	60 (92.3)	4.90 (1.15)	2.5	4.04	4.79	5.88	7.0	
		Week 48	Tezepelumab	67	66 (98.5)	5.24 (1.14)	2.8	4.33	5.13	6.17	7.0	
			Placebo	65	60 (92.3)	4.93 (1.15)	2.2	4.08	4.79	5.83	7.0	
		Week 52	Tezepelumab	67	66 (98.5)	5.24 (1.14)	2.8	4.33	5.17	6.17	7.0	
			Placebo	65	60 (92.3)	4.99 (1.12)	2.8	4.17	4.79	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: ICS dose level (at study entry)												
High	Change from baseline	Week 4	Tezepelumab	67	56 (83.6)	0.75 (1.10)	-4.3	0.08	0.92	1.42	3.1	0.14 [-0.23, 0.52]
			Placebo	65	54 (83.1)	0.61 (0.88)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	67	58 (86.6)	0.93 (1.11)	-1.9	0.25	1.00	1.83	3.3	0.25 [-0.12, 0.62]
			Placebo	65	55 (84.6)	0.67 (1.03)	-1.8	0.08	0.67	1.17	3.6	
		Week 12	Tezepelumab	67	58 (86.6)	1.14 (1.14)	-2.6	0.42	1.08	1.92	3.7	0.30 [-0.07, 0.67]
			Placebo	65	55 (84.6)	0.78 (1.23)	-2.8	0.08	0.75	1.17	4.0	
		Week 16	Tezepelumab	67	58 (86.6)	1.17 (1.13)	-2.9	0.50	1.08	2.08	3.3	0.32 [-0.05, 0.69]
			Placebo	65	55 (84.6)	0.77 (1.32)	-3.5	0.17	0.83	1.33	4.2	
		Week 20	Tezepelumab	67	58 (86.6)	1.13 (1.09)	-1.8	0.42	1.04	2.08	3.3	0.39 [0.01, 0.76]
			Placebo	65	55 (84.6)	0.68 (1.26)	-3.5	0.08	0.83	1.33	3.8	
		Week 24	Tezepelumab	67	58 (86.6)	1.20 (1.09)	-1.6	0.50	1.17	2.00	3.3	0.45 [0.07, 0.82]
			Placebo	65	55 (84.6)	0.67 (1.31)	-3.5	0.00	0.83	1.25	3.9	
		Week 28	Tezepelumab	67	58 (86.6)	1.11 (1.11)	-1.7	0.33	1.00	2.00	3.3	0.31 [-0.06, 0.68]
			Placebo	65	55 (84.6)	0.73 (1.34)	-3.5	0.08	0.83	1.33	4.3	
		Week 32	Tezepelumab	67	58 (86.6)	1.20 (1.15)	-1.6	0.50	1.08	2.17	3.3	0.34 [-0.04, 0.71]
			Placebo	65	55 (84.6)	0.81 (1.19)	-3.5	0.33	0.92	1.25	3.5	
		Week 36	Tezepelumab	67	58 (86.6)	1.23 (1.20)	-1.7	0.25	1.08	2.17	3.4	0.45 [0.08, 0.83]
			Placebo	65	55 (84.6)	0.70 (1.14)	-3.0	0.08	0.83	1.25	3.8	
		Week 40	Tezepelumab	67	58 (86.6)	1.21 (1.20)	-1.7	0.33	1.08	2.25	3.4	0.32 [-0.05, 0.70]
			Placebo	65	55 (84.6)	0.82 (1.21)	-3.0	0.00	0.83	1.58	4.0	
		Week 44	Tezepelumab	67	58 (86.6)	1.20 (1.16)	-1.6	0.50	1.13	2.08	3.3	0.35 [-0.02, 0.72]
			Placebo	65	55 (84.6)	0.79 (1.19)	-3.0	0.25	0.83	1.58	3.7	
		Week 48	Tezepelumab	67	58 (86.6)	1.25 (1.17)	-1.6	0.33	1.13	2.17	3.4	0.36 [-0.01, 0.73]
			Placebo	65	55 (84.6)	0.83 (1.16)	-3.0	0.25	0.83	1.50	4.2	
		Week 52	Tezepelumab	67	58 (86.6)	1.25 (1.17)	-1.6	0.42	1.08	2.17	3.6	0.31 [-0.06, 0.68]
			Placebo	65	55 (84.6)	0.89 (1.16)	-3.0	0.25	0.83	1.67	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	11	9 (81.8)	4.38 (0.46)	3.8	4.08	4.33	4.83	5.0	
			Placebo	6	4 (66.7)	3.71 (0.44)	3.3	3.42	3.58	4.00	4.3	
		Week 4	Tezepelumab	11	11 (100.0)	4.94 (0.98)	3.6	4.25	4.58	5.83	6.5	
			Placebo	6	5 (83.3)	4.18 (1.18)	2.7	3.17	4.83	5.00	5.3	
		Week 8	Tezepelumab	11	11 (100.0)	5.36 (0.71)	4.5	4.58	5.25	5.83	6.6	
			Placebo	6	5 (83.3)	4.33 (1.27)	2.9	3.50	3.92	5.50	5.8	
		Week 12	Tezepelumab	11	11 (100.0)	5.43 (0.78)	4.3	4.92	5.33	6.42	6.7	
			Placebo	6	5 (83.3)	4.03 (1.39)	2.1	3.50	4.08	4.67	5.8	
		Week 16	Tezepelumab	11	11 (100.0)	5.34 (0.73)	4.3	4.58	5.17	6.00	6.7	
			Placebo	6	5 (83.3)	4.22 (1.02)	2.8	3.92	4.08	4.92	5.4	
		Week 20	Tezepelumab	11	11 (100.0)	5.08 (0.70)	3.8	4.50	5.08	5.58	6.2	
			Placebo	6	5 (83.3)	4.33 (1.45)	2.8	3.67	3.92	4.58	6.7	
		Week 24	Tezepelumab	11	11 (100.0)	5.31 (0.56)	4.4	4.92	5.17	5.83	6.2	
			Placebo	6	5 (83.3)	4.02 (1.25)	2.8	3.58	3.58	4.08	6.1	
		Week 28	Tezepelumab	11	11 (100.0)	5.23 (0.65)	4.4	4.58	5.08	5.83	6.4	
			Placebo	6	5 (83.3)	3.98 (1.36)	2.8	3.00	3.83	4.00	6.3	
		Week 32	Tezepelumab	11	11 (100.0)	5.25 (0.60)	4.3	4.58	5.25	5.83	6.0	
			Placebo	6	5 (83.3)	4.33 (1.29)	3.0	3.67	3.75	5.00	6.3	
		Week 36	Tezepelumab	11	11 (100.0)	5.30 (0.56)	4.6	4.75	5.25	5.67	6.2	
			Placebo	6	5 (83.3)	4.23 (1.21)	2.4	3.75	4.42	5.08	5.5	
		Week 40	Tezepelumab	11	11 (100.0)	5.30 (0.54)	4.4	4.83	5.33	5.67	6.1	
			Placebo	6	5 (83.3)	4.30 (1.57)	2.3	3.75	3.75	5.75	6.0	
		Week 44	Tezepelumab	11	11 (100.0)	5.23 (0.49)	4.3	4.75	5.33	5.67	5.8	
			Placebo	6	5 (83.3)	3.82 (1.06)	2.5	3.25	3.83	4.17	5.3	
		Week 48	Tezepelumab	11	11 (100.0)	5.35 (0.59)	4.5	5.00	5.33	5.58	6.5	
			Placebo	6	5 (83.3)	4.13 (1.35)	2.2	3.75	4.00	5.08	5.7	
		Week 52	Tezepelumab	11	11 (100.0)	5.35 (0.59)	4.5	5.00	5.33	5.58	6.5	
			Placebo	6	5 (83.3)	4.23 (1.16)	2.8	3.58	4.08	5.08	5.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	11	9 (81.8)	0.82 (0.88)	-0.6	0.08	1.17	1.33	2.1	0.10 [-1.08, 1.28]
			Placebo	6	4 (66.7)	0.73 (1.19)	-1.0	-0.04	1.21	1.50	1.5	
		Week 8	Tezepelumab	11	9 (81.8)	0.96 (0.74)	-0.3	0.33	1.08	1.50	1.8	0.14 [-1.04, 1.32]
			Placebo	6	4 (66.7)	0.83 (1.36)	-0.8	-0.17	0.79	1.83	2.5	
		Week 12	Tezepelumab	11	9 (81.8)	1.04 (0.72)	-0.6	1.00	1.33	1.42	1.8	0.52 [-0.68, 1.72]
			Placebo	6	4 (66.7)	0.46 (1.76)	-1.6	-0.92	0.46	1.83	2.5	
		Week 16	Tezepelumab	11	9 (81.8)	0.94 (0.73)	-0.5	0.58	1.00	1.42	1.8	0.38 [-0.81, 1.57]
			Placebo	6	4 (66.7)	0.58 (1.38)	-0.9	-0.58	0.67	1.75	1.9	
		Week 20	Tezepelumab	11	9 (81.8)	0.67 (0.66)	-0.4	0.17	0.83	1.08	1.7	-0.11 [-1.29, 1.07]
			Placebo	6	4 (66.7)	0.79 (1.88)	-0.8	-0.63	0.33	2.21	3.3	
		Week 24	Tezepelumab	11	9 (81.8)	0.92 (0.58)	-0.4	0.92	1.00	1.33	1.5	0.49 [-0.70, 1.69]
			Placebo	6	4 (66.7)	0.42 (1.69)	-0.9	-0.83	-0.08	1.67	2.8	
		Week 28	Tezepelumab	11	9 (81.8)	0.79 (0.63)	-0.4	0.50	0.92	1.00	1.6	0.45 [-0.74, 1.64]
			Placebo	6	4 (66.7)	0.31 (1.75)	-0.8	-0.67	-0.42	1.29	2.9	
		Week 32	Tezepelumab	11	9 (81.8)	0.88 (0.60)	-0.3	0.67	1.00	1.08	1.9	0.08 [-1.09, 1.26]
			Placebo	6	4 (66.7)	0.79 (1.74)	-0.7	-0.63	0.46	2.21	2.9	
		Week 36	Tezepelumab	11	9 (81.8)	0.90 (0.54)	-0.1	0.67	1.00	1.33	1.5	0.27 [-0.91, 1.46]
			Placebo	6	4 (66.7)	0.65 (1.52)	-1.3	-0.58	0.92	1.88	2.0	
		Week 40	Tezepelumab	11	9 (81.8)	0.91 (0.59)	-0.4	0.75	1.00	1.00	1.6	0.15 [-1.03, 1.33]
			Placebo	6	4 (66.7)	0.73 (2.03)	-1.4	-1.00	0.92	2.46	2.5	
		Week 44	Tezepelumab	11	9 (81.8)	0.87 (0.65)	-0.5	0.75	0.83	1.17	1.8	0.97 [-0.27, 2.22]
			Placebo	6	4 (66.7)	0.02 (1.29)	-1.2	-0.83	-0.29	0.88	1.8	
		Week 48	Tezepelumab	11	9 (81.8)	1.09 (0.61)	-0.3	1.00	1.08	1.50	1.7	0.59 [-0.61, 1.79]
			Placebo	6	4 (66.7)	0.46 (1.80)	-1.5	-1.04	0.50	1.96	2.3	
		Week 52	Tezepelumab	11	9 (81.8)	1.09 (0.61)	-0.3	1.00	1.08	1.50	1.7	0.43 [-0.76, 1.62]
			Placebo	6	4 (66.7)	0.69 (1.52)	-0.9	-0.58	0.67	1.96	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	126	114 (90.5)	4.02 (1.03)	1.3	3.50	4.00	4.67	6.8	
			Placebo	132	117 (88.6)	3.99 (0.92)	1.5	3.42	4.08	4.58	6.3	
		Week 4	Tezepelumab	126	115 (91.3)	4.83 (1.07)	1.3	4.00	4.83	5.58	7.0	
			Placebo	132	118 (89.4)	4.56 (0.94)	1.8	4.00	4.58	5.25	6.7	
		Week 8	Tezepelumab	126	117 (92.9)	5.03 (1.11)	2.0	4.17	5.00	5.83	7.0	
			Placebo	132	121 (91.7)	4.63 (1.04)	1.9	4.00	4.50	5.33	7.0	
		Week 12	Tezepelumab	126	117 (92.9)	5.20 (1.10)	2.8	4.25	5.17	6.08	7.0	
			Placebo	132	122 (92.4)	4.78 (1.06)	2.4	4.00	4.75	5.58	7.0	
		Week 16	Tezepelumab	126	117 (92.9)	5.19 (1.13)	2.3	4.33	5.25	6.00	7.0	
			Placebo	132	122 (92.4)	4.79 (1.12)	1.3	4.00	4.71	5.58	7.0	
		Week 20	Tezepelumab	126	118 (93.7)	5.21 (1.10)	2.3	4.25	5.21	6.00	7.0	
			Placebo	132	122 (92.4)	4.81 (1.11)	1.3	4.08	4.75	5.58	7.0	
		Week 24	Tezepelumab	126	118 (93.7)	5.22 (1.12)	1.8	4.33	5.13	6.00	7.0	
			Placebo	132	122 (92.4)	4.85 (1.14)	1.3	4.00	4.71	5.75	7.0	
		Week 28	Tezepelumab	126	120 (95.2)	5.22 (1.08)	3.2	4.33	5.08	6.04	7.0	
			Placebo	132	123 (93.2)	4.89 (1.19)	1.3	4.00	4.83	5.92	7.0	
		Week 32	Tezepelumab	126	121 (96.0)	5.29 (1.10)	2.8	4.33	5.33	6.08	7.0	
			Placebo	132	124 (93.9)	4.93 (1.13)	1.3	4.08	4.96	5.83	7.0	
		Week 36	Tezepelumab	126	121 (96.0)	5.28 (1.11)	2.9	4.33	5.17	6.17	7.0	
			Placebo	132	124 (93.9)	4.96 (1.15)	2.5	4.00	4.83	6.00	7.0	
		Week 40	Tezepelumab	126	121 (96.0)	5.28 (1.13)	2.3	4.42	5.33	6.08	7.0	
			Placebo	132	124 (93.9)	4.99 (1.10)	2.4	4.00	4.92	5.96	7.0	
		Week 44	Tezepelumab	126	121 (96.0)	5.31 (1.13)	2.3	4.42	5.33	6.25	7.0	
			Placebo	132	124 (93.9)	4.97 (1.16)	2.3	4.00	4.88	6.00	7.0	
		Week 48	Tezepelumab	126	121 (96.0)	5.32 (1.12)	2.8	4.42	5.17	6.25	7.0	
			Placebo	132	125 (94.7)	4.99 (1.10)	2.4	4.00	4.92	5.92	7.0	
		Week 52	Tezepelumab	126	121 (96.0)	5.32 (1.11)	2.8	4.50	5.17	6.25	7.0	
			Placebo	132	125 (94.7)	4.97 (1.11)	2.5	4.00	4.83	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	126	108 (85.7)	0.82 (1.03)	-4.3	0.25	0.79	1.50	3.1	0.27 [0.00, 0.53]
			Placebo	132	115 (87.1)	0.57 (0.84)	-1.8	0.08	0.50	1.17	3.3	
		Week 8	Tezepelumab	126	110 (87.3)	0.99 (1.09)	-1.9	0.25	0.92	1.92	4.1	0.34 [0.07, 0.60]
			Placebo	132	116 (87.9)	0.65 (0.93)	-1.8	0.08	0.54	1.17	3.6	
		Week 12	Tezepelumab	126	110 (87.3)	1.16 (1.13)	-2.6	0.33	1.08	2.00	4.5	0.32 [0.05, 0.58]
			Placebo	132	116 (87.9)	0.80 (1.16)	-3.1	0.17	0.79	1.25	4.0	
		Week 16	Tezepelumab	126	110 (87.3)	1.16 (1.13)	-2.9	0.42	1.08	2.08	4.6	0.30 [0.04, 0.56]
			Placebo	132	116 (87.9)	0.82 (1.17)	-3.5	0.17	0.92	1.42	4.2	
		Week 20	Tezepelumab	126	110 (87.3)	1.20 (1.12)	-1.8	0.33	1.08	2.00	4.7	0.32 [0.06, 0.58]
			Placebo	132	116 (87.9)	0.84 (1.09)	-3.5	0.25	0.83	1.33	3.8	
		Week 24	Tezepelumab	126	110 (87.3)	1.23 (1.14)	-1.6	0.42	1.17	2.17	4.8	0.29 [0.03, 0.55]
			Placebo	132	116 (87.9)	0.89 (1.16)	-3.5	0.17	0.83	1.42	4.1	
		Week 28	Tezepelumab	126	110 (87.3)	1.20 (1.13)	-1.7	0.42	1.00	2.08	4.9	0.25 [-0.01, 0.51]
			Placebo	132	116 (87.9)	0.91 (1.22)	-3.5	0.25	0.83	1.54	4.7	
		Week 32	Tezepelumab	126	110 (87.3)	1.27 (1.19)	-1.6	0.42	1.17	2.17	4.8	0.25 [-0.02, 0.51]
			Placebo	132	116 (87.9)	0.98 (1.11)	-3.5	0.33	1.00	1.50	4.0	
		Week 36	Tezepelumab	126	110 (87.3)	1.24 (1.22)	-1.7	0.25	1.17	2.17	4.8	0.20 [-0.06, 0.46]
			Placebo	132	116 (87.9)	1.00 (1.14)	-3.0	0.25	1.00	1.67	3.8	
		Week 40	Tezepelumab	126	110 (87.3)	1.26 (1.16)	-1.7	0.33	1.13	2.17	4.8	0.20 [-0.06, 0.46]
			Placebo	132	116 (87.9)	1.03 (1.13)	-3.0	0.33	1.00	1.58	4.7	
		Week 44	Tezepelumab	126	110 (87.3)	1.28 (1.17)	-1.8	0.42	1.21	2.17	4.8	0.23 [-0.03, 0.50]
			Placebo	132	116 (87.9)	1.01 (1.18)	-3.0	0.33	1.00	1.67	4.3	
		Week 48	Tezepelumab	126	110 (87.3)	1.30 (1.15)	-1.6	0.42	1.17	2.17	4.8	0.24 [-0.02, 0.50]
			Placebo	132	116 (87.9)	1.03 (1.11)	-3.0	0.29	1.08	1.67	4.2	
		Week 52	Tezepelumab	126	110 (87.3)	1.29 (1.16)	-1.6	0.42	1.08	2.25	4.8	0.25 [-0.01, 0.51]
			Placebo	132	116 (87.9)	1.00 (1.11)	-3.0	0.25	0.88	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.39 (0.50)	3.8	3.96	4.33	4.88	5.0	
			Placebo	3	2 (66.7)	3.83 (0.71)	3.3	3.33	3.83	4.33	4.3	
		Week 4	Tezepelumab	9	9 (100.0)	5.17 (0.92)	3.9	4.58	5.00	5.83	6.5	
			Placebo	3	3 (100.0)	4.42 (1.10)	3.2	3.17	4.83	5.25	5.3	
		Week 8	Tezepelumab	9	9 (100.0)	5.54 (0.65)	4.6	5.17	5.67	5.83	6.6	
			Placebo	3	3 (100.0)	4.94 (1.26)	3.5	3.50	5.50	5.83	5.8	
		Week 12	Tezepelumab	9	9 (100.0)	5.54 (0.80)	4.3	5.08	5.42	6.42	6.7	
			Placebo	3	3 (100.0)	4.47 (1.21)	3.5	3.50	4.08	5.83	5.8	
		Week 16	Tezepelumab	9	9 (100.0)	5.51 (0.70)	4.3	5.17	5.42	6.00	6.7	
			Placebo	3	3 (100.0)	4.31 (0.54)	3.9	3.92	4.08	4.92	4.9	
		Week 20	Tezepelumab	9	9 (100.0)	5.20 (0.73)	3.8	5.00	5.42	5.58	6.2	
			Placebo	3	3 (100.0)	4.75 (1.66)	3.7	3.67	3.92	6.67	6.7	
		Week 24	Tezepelumab	9	9 (100.0)	5.44 (0.54)	4.4	5.17	5.50	5.83	6.2	
			Placebo	3	3 (100.0)	4.42 (1.44)	3.6	3.58	3.58	6.08	6.1	
		Week 28	Tezepelumab	9	9 (100.0)	5.38 (0.62)	4.4	5.00	5.33	5.83	6.4	
			Placebo	3	3 (100.0)	4.69 (1.35)	3.8	3.83	4.00	6.25	6.3	
		Week 32	Tezepelumab	9	9 (100.0)	5.35 (0.61)	4.3	5.08	5.58	5.83	6.0	
			Placebo	3	3 (100.0)	4.56 (1.47)	3.7	3.67	3.75	6.25	6.3	
		Week 36	Tezepelumab	9	9 (100.0)	5.33 (0.56)	4.6	4.83	5.25	5.58	6.2	
			Placebo	3	3 (100.0)	4.42 (0.67)	3.8	3.75	4.42	5.08	5.1	
		Week 40	Tezepelumab	9	9 (100.0)	5.37 (0.55)	4.4	5.08	5.33	5.67	6.1	
			Placebo	3	3 (100.0)	4.42 (1.15)	3.8	3.75	3.75	5.75	5.8	
		Week 44	Tezepelumab	9	9 (100.0)	5.31 (0.48)	4.3	5.25	5.42	5.67	5.8	
			Placebo	3	3 (100.0)	3.75 (0.46)	3.3	3.25	3.83	4.17	4.2	
		Week 48	Tezepelumab	9	9 (100.0)	5.44 (0.60)	4.5	5.00	5.42	5.58	6.5	
			Placebo	3	3 (100.0)	4.47 (1.04)	3.8	3.75	4.00	5.67	5.7	
		Week 52	Tezepelumab	9	9 (100.0)	5.44 (0.60)	4.5	5.00	5.42	5.58	6.5	
			Placebo	3	3 (100.0)	4.44 (1.09)	3.6	3.58	4.08	5.67	5.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	0.94 (0.87)	-0.6	0.29	1.25	1.46	2.1	-0.33 [-1.88, 1.23]
			Placebo	3	2 (66.7)	1.21 (0.41)	0.9	0.92	1.21	1.50	1.5	
		Week 8	Tezepelumab	9	8 (88.9)	1.06 (0.72)	-0.3	0.58	1.29	1.58	1.8	-1.02 [-2.65, 0.61]
			Placebo	3	2 (66.7)	1.83 (0.94)	1.2	1.17	1.83	2.50	2.5	
		Week 12	Tezepelumab	9	8 (88.9)	1.04 (0.77)	-0.6	0.75	1.33	1.50	1.8	-0.08 [-1.63, 1.47]
			Placebo	3	2 (66.7)	1.13 (1.94)	-0.3	-0.25	1.13	2.50	2.5	
		Week 16	Tezepelumab	9	8 (88.9)	1.03 (0.72)	-0.5	0.79	1.21	1.50	1.8	0.45 [-1.12, 2.01]
			Placebo	3	2 (66.7)	0.67 (1.30)	-0.3	-0.25	0.67	1.58	1.6	
		Week 20	Tezepelumab	9	8 (88.9)	0.73 (0.67)	-0.4	0.25	0.92	1.13	1.7	-0.65 [-2.23, 0.94]
			Placebo	3	2 (66.7)	1.46 (2.65)	-0.4	-0.42	1.46	3.33	3.3	
		Week 24	Tezepelumab	9	8 (88.9)	0.96 (0.60)	-0.4	0.92	1.00	1.38	1.5	-0.04 [-1.59, 1.51]
			Placebo	3	2 (66.7)	1.00 (2.47)	-0.8	-0.75	1.00	2.75	2.8	
		Week 28	Tezepelumab	9	8 (88.9)	0.86 (0.63)	-0.4	0.67	0.96	1.25	1.6	-0.43 [-1.99, 1.14]
			Placebo	3	2 (66.7)	1.29 (2.30)	-0.3	-0.33	1.29	2.92	2.9	
		Week 32	Tezepelumab	9	8 (88.9)	0.91 (0.64)	-0.3	0.71	1.00	1.13	1.9	-0.25 [-1.80, 1.31]
			Placebo	3	2 (66.7)	1.17 (2.47)	-0.6	-0.58	1.17	2.92	2.9	
		Week 36	Tezepelumab	9	8 (88.9)	0.84 (0.55)	-0.1	0.50	0.88	1.29	1.5	-0.11 [-1.66, 1.44]
			Placebo	3	2 (66.7)	0.92 (1.18)	0.1	0.08	0.92	1.75	1.8	
		Week 40	Tezepelumab	9	8 (88.9)	0.90 (0.62)	-0.4	0.75	0.96	1.29	1.6	-0.02 [-1.57, 1.53]
			Placebo	3	2 (66.7)	0.92 (2.12)	-0.6	-0.58	0.92	2.42	2.4	
		Week 44	Tezepelumab	9	8 (88.9)	0.89 (0.70)	-0.5	0.67	0.88	1.33	1.8	1.79 [0.01, 3.57]
			Placebo	3	2 (66.7)	-0.29 (0.29)	-0.5	-0.50	-0.29	-0.08	-0.1	
		Week 48	Tezepelumab	9	8 (88.9)	1.10 (0.65)	-0.3	0.96	1.25	1.54	1.7	0.24 [-1.31, 1.80]
			Placebo	3	2 (66.7)	0.88 (2.06)	-0.6	-0.58	0.88	2.33	2.3	
		Week 52	Tezepelumab	9	8 (88.9)	1.10 (0.65)	-0.3	0.96	1.25	1.54	1.7	0.07 [-1.48, 1.62]
			Placebo	3	2 (66.7)	1.04 (1.83)	-0.3	-0.25	1.04	2.33	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.03 (1.02)	1.3	3.50	4.00	4.67	6.8	
			Placebo	135	119 (88.1)	3.98 (0.91)	1.5	3.42	4.00	4.58	6.3	
		Week 4	Tezepelumab	128	117 (91.4)	4.82 (1.07)	1.3	4.00	4.75	5.58	7.0	
			Placebo	135	120 (88.9)	4.55 (0.95)	1.8	3.96	4.58	5.25	6.7	
		Week 8	Tezepelumab	128	119 (93.0)	5.02 (1.10)	2.0	4.17	4.92	5.83	7.0	
			Placebo	135	123 (91.1)	4.61 (1.04)	1.9	4.00	4.50	5.33	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.20 (1.09)	2.8	4.25	5.17	6.08	7.0	
			Placebo	135	124 (91.9)	4.76 (1.07)	2.1	4.00	4.67	5.58	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.18 (1.12)	2.3	4.33	5.25	6.00	7.0	
			Placebo	135	124 (91.9)	4.78 (1.13)	1.3	4.00	4.71	5.58	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.20 (1.09)	2.3	4.29	5.13	6.00	7.0	
			Placebo	135	124 (91.9)	4.79 (1.12)	1.3	4.08	4.75	5.54	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.21 (1.11)	1.8	4.38	5.08	6.00	7.0	
			Placebo	135	124 (91.9)	4.83 (1.15)	1.3	4.00	4.67	5.75	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.21 (1.08)	3.2	4.33	5.04	6.00	7.0	
			Placebo	135	125 (92.6)	4.86 (1.20)	1.3	4.00	4.75	5.83	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.28 (1.10)	2.8	4.33	5.17	6.08	7.0	
			Placebo	135	126 (93.3)	4.92 (1.13)	1.3	4.08	4.96	5.83	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.28 (1.10)	2.9	4.33	5.17	6.17	7.0	
			Placebo	135	126 (93.3)	4.95 (1.17)	2.4	4.00	4.83	6.00	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.28 (1.12)	2.3	4.42	5.33	6.08	7.0	
			Placebo	135	126 (93.3)	4.97 (1.12)	2.3	4.00	4.92	6.00	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.30 (1.12)	2.3	4.42	5.33	6.25	7.0	
			Placebo	135	126 (93.3)	4.96 (1.18)	2.3	4.00	4.88	6.00	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.31 (1.12)	2.8	4.42	5.17	6.25	7.0	
			Placebo	135	127 (94.1)	4.97 (1.12)	2.2	4.00	4.92	5.92	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.32 (1.10)	2.8	4.50	5.17	6.25	7.0	
			Placebo	135	127 (94.1)	4.96 (1.12)	2.5	4.00	4.83	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.81 (1.03)	-4.3	0.25	0.75	1.50	3.1	0.26 [-0.00, 0.52]
			Placebo	135	117 (86.7)	0.56 (0.85)	-1.8	0.08	0.50	1.17	3.3	
		Week 8	Tezepelumab	128	111 (86.7)	0.98 (1.08)	-1.9	0.25	0.92	1.92	4.1	0.34 [0.08, 0.60]
			Placebo	135	118 (87.4)	0.64 (0.93)	-1.8	0.08	0.50	1.17	3.6	
		Week 12	Tezepelumab	128	111 (86.7)	1.16 (1.13)	-2.6	0.33	1.08	2.00	4.5	0.33 [0.07, 0.59]
			Placebo	135	118 (87.4)	0.78 (1.17)	-3.1	0.17	0.79	1.25	4.0	
		Week 16	Tezepelumab	128	111 (86.7)	1.15 (1.13)	-2.9	0.42	1.08	2.08	4.6	0.29 [0.03, 0.55]
			Placebo	135	118 (87.4)	0.81 (1.18)	-3.5	0.17	0.92	1.42	4.2	
		Week 20	Tezepelumab	128	111 (86.7)	1.19 (1.12)	-1.8	0.33	1.08	2.00	4.7	0.32 [0.06, 0.58]
			Placebo	135	118 (87.4)	0.83 (1.09)	-3.5	0.25	0.83	1.33	3.8	
		Week 24	Tezepelumab	128	111 (86.7)	1.22 (1.14)	-1.6	0.42	1.17	2.17	4.8	0.30 [0.04, 0.56]
			Placebo	135	118 (87.4)	0.87 (1.17)	-3.5	0.17	0.83	1.42	4.1	
		Week 28	Tezepelumab	128	111 (86.7)	1.19 (1.13)	-1.7	0.42	1.00	2.08	4.9	0.26 [0.00, 0.52]
			Placebo	135	118 (87.4)	0.88 (1.23)	-3.5	0.17	0.83	1.50	4.7	
		Week 32	Tezepelumab	128	111 (86.7)	1.26 (1.18)	-1.6	0.42	1.17	2.17	4.8	0.25 [-0.01, 0.51]
			Placebo	135	118 (87.4)	0.97 (1.11)	-3.5	0.33	1.00	1.50	4.0	
		Week 36	Tezepelumab	128	111 (86.7)	1.24 (1.22)	-1.7	0.25	1.17	2.17	4.8	0.21 [-0.05, 0.47]
			Placebo	135	118 (87.4)	0.99 (1.15)	-3.0	0.25	1.00	1.67	3.8	
		Week 40	Tezepelumab	128	111 (86.7)	1.25 (1.16)	-1.7	0.33	1.08	2.17	4.8	0.20 [-0.06, 0.46]
			Placebo	135	118 (87.4)	1.02 (1.15)	-3.0	0.33	1.00	1.58	4.7	
		Week 44	Tezepelumab	128	111 (86.7)	1.28 (1.16)	-1.8	0.42	1.17	2.17	4.8	0.24 [-0.02, 0.50]
			Placebo	135	118 (87.4)	1.00 (1.19)	-3.0	0.33	1.00	1.67	4.3	
		Week 48	Tezepelumab	128	111 (86.7)	1.30 (1.15)	-1.6	0.42	1.17	2.17	4.8	0.25 [-0.01, 0.51]
			Placebo	135	118 (87.4)	1.01 (1.12)	-3.0	0.25	1.08	1.67	4.2	
		Week 52	Tezepelumab	128	111 (86.7)	1.28 (1.15)	-1.6	0.42	1.08	2.25	4.8	0.26 [-0.00, 0.52]
			Placebo	135	118 (87.4)	0.99 (1.11)	-3.0	0.25	0.88	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	3.73 (1.04)	1.4	3.25	3.67	4.42	6.2	
			Placebo	37	33 (89.2)	3.98 (0.73)	2.4	3.50	4.00	4.50	5.8	
		Week 4	Tezepelumab	29	26 (89.7)	4.74 (1.00)	3.5	3.92	4.63	5.58	6.9	
			Placebo	37	33 (89.2)	4.54 (1.04)	2.4	3.92	4.58	5.25	6.7	
		Week 8	Tezepelumab	29	27 (93.1)	5.10 (1.10)	2.8	4.25	5.08	6.00	7.0	
			Placebo	37	34 (91.9)	4.68 (1.13)	2.3	4.08	4.67	5.42	7.0	
		Week 12	Tezepelumab	29	27 (93.1)	5.29 (1.11)	3.5	4.25	5.33	6.25	7.0	
			Placebo	37	35 (94.6)	4.87 (1.22)	2.1	4.00	4.92	5.83	7.0	
		Week 16	Tezepelumab	29	27 (93.1)	5.15 (1.13)	3.0	4.33	5.17	6.00	7.0	
			Placebo	37	35 (94.6)	4.92 (1.24)	1.3	4.17	5.17	5.75	7.0	
		Week 20	Tezepelumab	29	27 (93.1)	5.28 (1.14)	2.3	4.25	5.67	6.00	7.0	
			Placebo	37	35 (94.6)	4.87 (1.18)	1.3	4.25	5.00	5.50	7.0	
		Week 24	Tezepelumab	29	27 (93.1)	5.26 (1.30)	1.8	4.17	5.83	6.17	7.0	
			Placebo	37	35 (94.6)	4.81 (1.23)	1.3	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	29	27 (93.1)	5.14 (1.14)	3.2	4.08	5.33	6.08	7.0	
			Placebo	37	35 (94.6)	5.01 (1.41)	1.3	4.00	5.17	6.17	7.0	
		Week 32	Tezepelumab	29	27 (93.1)	5.29 (1.17)	2.8	4.33	5.75	6.00	7.0	
			Placebo	37	35 (94.6)	5.06 (1.17)	1.3	4.33	5.17	5.75	7.0	
		Week 36	Tezepelumab	29	27 (93.1)	5.19 (1.16)	2.9	4.17	5.25	6.08	7.0	
			Placebo	37	35 (94.6)	4.81 (1.18)	2.4	4.00	4.83	5.58	7.0	
		Week 40	Tezepelumab	29	27 (93.1)	5.39 (1.15)	3.1	4.33	5.67	6.08	7.0	
			Placebo	37	35 (94.6)	5.00 (1.14)	2.3	4.00	5.08	6.00	7.0	
		Week 44	Tezepelumab	29	27 (93.1)	5.29 (1.21)	2.3	4.33	5.50	6.08	7.0	
			Placebo	37	35 (94.6)	4.94 (1.20)	2.5	4.00	5.08	5.75	7.0	
		Week 48	Tezepelumab	29	27 (93.1)	5.18 (1.24)	2.8	4.00	5.33	6.25	7.0	
			Placebo	37	36 (97.3)	5.03 (1.07)	2.2	4.17	4.96	5.58	7.0	
		Week 52	Tezepelumab	29	27 (93.1)	5.23 (1.27)	2.8	4.00	5.42	6.25	7.0	
			Placebo	37	36 (97.3)	5.06 (1.06)	2.8	4.21	4.96	5.71	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline											
Yes	Change from baseline	Week 4	Tezepelumab	29	24 (82.8)	1.03 (0.99)	-1.4	0.33	1.00	1.83	2.5	0.49 [-0.06, 1.03]
			Placebo	37	31 (83.8)	0.61 (0.73)	-1.0	0.25	0.58	1.25	1.6	
		Week 8	Tezepelumab	29	25 (86.2)	1.32 (1.04)	-1.4	0.83	1.42	2.17	3.0	0.61 [0.07, 1.14]
			Placebo	37	32 (86.5)	0.70 (0.99)	-0.9	0.08	0.58	1.29	2.7	
		Week 12	Tezepelumab	29	25 (86.2)	1.50 (1.08)	-1.4	0.83	1.42	2.25	3.0	0.48 [-0.05, 1.01]
			Placebo	37	32 (86.5)	0.95 (1.19)	-1.6	0.42	0.79	1.50	4.0	
		Week 16	Tezepelumab	29	25 (86.2)	1.34 (1.05)	-1.4	0.75	1.33	2.08	3.0	0.31 [-0.21, 0.84]
			Placebo	37	32 (86.5)	0.97 (1.27)	-3.5	0.50	0.92	1.71	4.2	
		Week 20	Tezepelumab	29	25 (86.2)	1.51 (1.05)	-1.4	0.92	1.58	2.33	3.0	0.50 [-0.03, 1.03]
			Placebo	37	32 (86.5)	0.93 (1.24)	-3.5	0.50	0.92	1.67	3.3	
		Week 24	Tezepelumab	29	25 (86.2)	1.49 (1.26)	-1.6	0.92	1.50	2.50	3.0	0.47 [-0.06, 1.00]
			Placebo	37	32 (86.5)	0.86 (1.36)	-3.5	0.21	0.83	1.67	3.3	
		Week 28	Tezepelumab	29	25 (86.2)	1.33 (1.12)	-1.4	0.67	1.50	2.08	3.0	0.19 [-0.34, 0.71]
			Placebo	37	32 (86.5)	1.08 (1.52)	-3.5	0.42	1.04	2.00	4.3	
		Week 32	Tezepelumab	29	25 (86.2)	1.54 (1.16)	-1.4	1.00	1.92	2.42	3.0	0.34 [-0.18, 0.87]
			Placebo	37	32 (86.5)	1.14 (1.20)	-3.5	0.67	1.00	2.08	2.9	
		Week 36	Tezepelumab	29	25 (86.2)	1.42 (1.18)	-1.4	0.75	1.50	2.33	3.2	0.47 [-0.06, 1.00]
			Placebo	37	32 (86.5)	0.86 (1.20)	-2.3	0.17	1.04	1.71	3.2	
		Week 40	Tezepelumab	29	25 (86.2)	1.62 (1.16)	-1.4	1.00	1.92	2.50	3.4	0.45 [-0.08, 0.98]
			Placebo	37	32 (86.5)	1.07 (1.27)	-1.4	0.04	1.21	2.08	4.0	
		Week 44	Tezepelumab	29	25 (86.2)	1.53 (1.30)	-1.8	0.75	1.83	2.42	3.3	0.43 [-0.10, 0.96]
			Placebo	37	32 (86.5)	0.99 (1.22)	-1.3	0.21	1.00	1.71	3.4	
		Week 48	Tezepelumab	29	25 (86.2)	1.44 (1.27)	-1.4	0.75	1.50	2.50	3.2	0.31 [-0.21, 0.84]
			Placebo	37	32 (86.5)	1.07 (1.10)	-1.5	0.50	1.08	1.63	3.4	
		Week 52	Tezepelumab	29	25 (86.2)	1.50 (1.29)	-1.4	0.92	1.50	2.58	3.6	0.33 [-0.20, 0.85]
			Placebo	37	32 (86.5)	1.12 (1.07)	-1.1	0.50	1.13	1.88	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	4.14 (0.98)	1.3	3.75	4.08	4.71	6.8	
			Placebo	101	88 (87.1)	3.97 (0.97)	1.5	3.42	4.08	4.54	6.3	
		Week 4	Tezepelumab	108	100 (92.6)	4.87 (1.08)	1.3	4.08	4.88	5.63	7.0	
			Placebo	101	90 (89.1)	4.55 (0.92)	1.8	4.00	4.58	5.17	6.5	
		Week 8	Tezepelumab	108	101 (93.5)	5.04 (1.08)	2.0	4.17	5.00	5.83	7.0	
			Placebo	101	92 (91.1)	4.60 (1.02)	1.9	4.00	4.50	5.33	6.7	
		Week 12	Tezepelumab	108	101 (93.5)	5.20 (1.07)	2.8	4.33	5.17	6.08	7.0	
			Placebo	101	92 (91.1)	4.71 (1.01)	2.4	4.00	4.63	5.54	6.8	
		Week 16	Tezepelumab	108	101 (93.5)	5.22 (1.10)	2.3	4.33	5.25	6.00	7.0	
			Placebo	101	92 (91.1)	4.71 (1.07)	2.1	4.00	4.58	5.58	7.0	
		Week 20	Tezepelumab	108	102 (94.4)	5.18 (1.05)	3.3	4.33	5.08	5.92	7.0	
			Placebo	101	92 (91.1)	4.76 (1.11)	2.1	4.04	4.67	5.63	6.9	
		Week 24	Tezepelumab	108	102 (94.4)	5.22 (1.02)	3.3	4.42	5.08	6.00	7.0	
			Placebo	101	92 (91.1)	4.82 (1.12)	2.1	4.00	4.67	5.83	7.0	
		Week 28	Tezepelumab	108	104 (96.3)	5.24 (1.03)	3.2	4.46	5.04	6.00	7.0	
			Placebo	101	93 (92.1)	4.79 (1.12)	1.8	4.00	4.67	5.75	7.0	
		Week 32	Tezepelumab	108	105 (97.2)	5.29 (1.05)	2.8	4.50	5.17	6.08	7.0	
			Placebo	101	94 (93.1)	4.85 (1.13)	2.1	4.00	4.79	5.83	7.0	
		Week 36	Tezepelumab	108	105 (97.2)	5.31 (1.05)	2.9	4.50	5.17	6.08	7.0	
			Placebo	101	94 (93.1)	4.98 (1.15)	2.5	4.08	4.83	6.00	7.0	
		Week 40	Tezepelumab	108	105 (97.2)	5.25 (1.08)	2.3	4.50	5.08	6.00	7.0	
			Placebo	101	94 (93.1)	4.95 (1.12)	2.4	4.00	4.92	5.92	7.0	
		Week 44	Tezepelumab	108	105 (97.2)	5.31 (1.06)	3.0	4.50	5.33	6.08	7.0	
			Placebo	101	94 (93.1)	4.92 (1.18)	2.3	4.00	4.71	6.00	7.0	
		Week 48	Tezepelumab	108	105 (97.2)	5.36 (1.05)	3.1	4.50	5.17	6.17	7.0	
			Placebo	101	94 (93.1)	4.94 (1.14)	2.4	4.00	4.79	5.92	7.0	
		Week 52	Tezepelumab	108	105 (97.2)	5.35 (1.03)	3.1	4.58	5.17	6.17	7.0	
			Placebo	101	94 (93.1)	4.90 (1.14)	2.5	4.00	4.75	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITT

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline											
No	Change from baseline	Week 4	Tezepelumab	108	93 (86.1)	0.77 (1.03)	-4.3	0.08	0.83	1.42	3.1	0.21 [-0.08, 0.50]
			Placebo	101	88 (87.1)	0.56 (0.89)	-1.8	0.08	0.50	1.04	3.3	
		Week 8	Tezepelumab	108	94 (87.0)	0.90 (1.06)	-1.9	0.17	0.83	1.67	4.1	0.26 [-0.03, 0.55]
			Placebo	101	88 (87.1)	0.64 (0.92)	-1.8	0.13	0.54	1.17	3.6	
		Week 12	Tezepelumab	108	94 (87.0)	1.06 (1.10)	-2.6	0.33	0.92	1.83	4.5	0.29 [-0.00, 0.58]
			Placebo	101	88 (87.1)	0.73 (1.17)	-3.1	0.04	0.79	1.25	3.8	
		Week 16	Tezepelumab	108	94 (87.0)	1.09 (1.11)	-2.9	0.42	1.00	1.83	4.6	0.30 [0.01, 0.59]
			Placebo	101	88 (87.1)	0.75 (1.14)	-3.1	0.13	0.83	1.33	3.7	
		Week 20	Tezepelumab	108	94 (87.0)	1.06 (1.10)	-1.8	0.33	0.92	1.92	4.7	0.23 [-0.06, 0.53]
			Placebo	101	88 (87.1)	0.81 (1.07)	-3.0	0.13	0.83	1.25	3.8	
		Week 24	Tezepelumab	108	94 (87.0)	1.13 (1.06)	-1.6	0.42	1.00	1.83	4.8	0.23 [-0.06, 0.52]
			Placebo	101	88 (87.1)	0.88 (1.11)	-3.0	0.17	0.83	1.38	4.1	
		Week 28	Tezepelumab	108	94 (87.0)	1.13 (1.10)	-1.7	0.33	0.92	2.00	4.9	0.28 [-0.02, 0.57]
			Placebo	101	88 (87.1)	0.82 (1.12)	-3.0	0.08	0.71	1.33	4.7	
		Week 32	Tezepelumab	108	94 (87.0)	1.16 (1.15)	-1.6	0.42	1.00	1.92	4.8	0.21 [-0.08, 0.50]
			Placebo	101	88 (87.1)	0.92 (1.10)	-3.0	0.21	0.96	1.33	4.0	
		Week 36	Tezepelumab	108	94 (87.0)	1.16 (1.19)	-1.7	0.25	1.00	2.08	4.8	0.11 [-0.18, 0.40]
			Placebo	101	88 (87.1)	1.04 (1.13)	-3.0	0.25	1.00	1.67	3.8	
		Week 40	Tezepelumab	108	94 (87.0)	1.12 (1.11)	-1.7	0.33	1.00	2.00	4.8	0.11 [-0.18, 0.40]
			Placebo	101	88 (87.1)	1.00 (1.12)	-3.0	0.33	1.00	1.58	4.7	
		Week 44	Tezepelumab	108	94 (87.0)	1.18 (1.09)	-1.6	0.42	1.17	2.00	4.8	0.18 [-0.11, 0.47]
			Placebo	101	88 (87.1)	0.97 (1.18)	-3.0	0.21	1.00	1.58	4.3	
		Week 48	Tezepelumab	108	94 (87.0)	1.24 (1.08)	-1.6	0.42	1.08	2.00	4.8	0.23 [-0.06, 0.52]
			Placebo	101	88 (87.1)	0.99 (1.15)	-3.0	0.21	1.04	1.67	4.2	
		Week 52	Tezepelumab	108	94 (87.0)	1.21 (1.07)	-1.6	0.42	1.00	2.00	4.8	0.24 [-0.05, 0.53]
			Placebo	101	88 (87.1)	0.95 (1.14)	-3.0	0.21	0.79	1.50	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.04 (1.01)	1.3	3.50	4.00	4.67	6.8	
			Placebo	123	106 (86.2)	4.03 (0.87)	1.7	3.50	4.08	4.58	6.3	
		Week 4	Tezepelumab	128	117 (91.4)	4.80 (1.07)	1.3	3.92	4.75	5.58	7.0	
			Placebo	123	109 (88.6)	4.58 (0.96)	1.8	3.92	4.58	5.25	6.7	
		Week 8	Tezepelumab	128	119 (93.0)	5.02 (1.09)	2.0	4.17	4.92	5.83	7.0	
			Placebo	123	112 (91.1)	4.66 (1.02)	2.1	4.00	4.50	5.38	7.0	
		Week 12	Tezepelumab	128	119 (93.0)	5.18 (1.08)	2.8	4.25	5.17	6.08	7.0	
			Placebo	123	113 (91.9)	4.72 (1.07)	2.1	4.00	4.67	5.50	7.0	
		Week 16	Tezepelumab	128	119 (93.0)	5.17 (1.11)	2.3	4.33	5.17	6.00	7.0	
			Placebo	123	113 (91.9)	4.77 (1.09)	1.3	4.08	4.67	5.58	7.0	
		Week 20	Tezepelumab	128	120 (93.8)	5.17 (1.08)	2.3	4.25	5.08	5.96	7.0	
			Placebo	123	113 (91.9)	4.81 (1.10)	1.3	4.08	4.75	5.50	7.0	
		Week 24	Tezepelumab	128	120 (93.8)	5.19 (1.09)	1.8	4.42	5.08	6.00	7.0	
			Placebo	123	113 (91.9)	4.81 (1.16)	1.3	4.00	4.67	5.75	7.0	
		Week 28	Tezepelumab	128	122 (95.3)	5.18 (1.07)	3.2	4.33	5.00	6.00	7.0	
			Placebo	123	114 (92.7)	4.80 (1.17)	1.3	4.00	4.75	5.75	7.0	
		Week 32	Tezepelumab	128	123 (96.1)	5.25 (1.08)	2.8	4.33	5.17	6.08	7.0	
			Placebo	123	115 (93.5)	4.88 (1.15)	1.3	4.00	4.92	5.75	7.0	
		Week 36	Tezepelumab	128	123 (96.1)	5.26 (1.09)	2.9	4.42	5.17	6.08	7.0	
			Placebo	123	115 (93.5)	4.94 (1.17)	2.4	4.00	4.83	6.00	7.0	
		Week 40	Tezepelumab	128	123 (96.1)	5.24 (1.10)	2.3	4.42	5.17	6.00	7.0	
			Placebo	123	115 (93.5)	4.95 (1.11)	2.3	4.00	4.92	5.92	7.0	
		Week 44	Tezepelumab	128	123 (96.1)	5.26 (1.10)	2.3	4.33	5.33	6.08	7.0	
			Placebo	123	115 (93.5)	4.94 (1.16)	2.3	4.00	4.75	5.92	7.0	
		Week 48	Tezepelumab	128	123 (96.1)	5.29 (1.11)	2.8	4.42	5.17	6.25	7.0	
			Placebo	123	116 (94.3)	4.96 (1.11)	2.2	4.00	4.83	5.79	7.0	
		Week 52	Tezepelumab	128	123 (96.1)	5.29 (1.09)	2.8	4.50	5.17	6.17	7.0	
			Placebo	123	116 (94.3)	4.93 (1.12)	2.5	4.00	4.79	5.83	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	128	109 (85.2)	0.79 (1.02)	-4.3	0.25	0.75	1.50	3.1	0.24 [-0.03, 0.51]
			Placebo	123	105 (85.4)	0.57 (0.86)	-1.8	0.17	0.50	1.17	3.3	
		Week 8	Tezepelumab	128	111 (86.7)	0.97 (1.04)	-1.9	0.25	0.92	1.67	4.1	0.31 [0.05, 0.58]
			Placebo	123	106 (86.2)	0.66 (0.92)	-1.8	0.17	0.58	1.17	3.6	
		Week 12	Tezepelumab	128	111 (86.7)	1.13 (1.09)	-2.6	0.33	1.08	1.92	4.5	0.38 [0.11, 0.64]
			Placebo	123	106 (86.2)	0.71 (1.14)	-3.1	0.08	0.75	1.25	3.8	
		Week 16	Tezepelumab	128	111 (86.7)	1.13 (1.09)	-2.9	0.42	1.08	1.92	4.6	0.32 [0.05, 0.58]
			Placebo	123	106 (86.2)	0.78 (1.12)	-3.5	0.17	0.92	1.42	3.7	
		Week 20	Tezepelumab	128	111 (86.7)	1.14 (1.10)	-1.8	0.33	1.00	2.00	4.7	0.29 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.83 (1.07)	-3.5	0.25	0.83	1.25	3.8	
		Week 24	Tezepelumab	128	111 (86.7)	1.18 (1.11)	-1.6	0.42	1.08	2.08	4.8	0.31 [0.04, 0.58]
			Placebo	123	106 (86.2)	0.83 (1.16)	-3.5	0.17	0.83	1.42	3.9	
		Week 28	Tezepelumab	128	111 (86.7)	1.15 (1.11)	-1.7	0.42	1.00	2.00	4.9	0.32 [0.05, 0.58]
			Placebo	123	106 (86.2)	0.79 (1.16)	-3.5	0.08	0.79	1.33	3.8	
		Week 32	Tezepelumab	128	111 (86.7)	1.22 (1.17)	-1.6	0.42	1.08	2.08	4.8	0.28 [0.01, 0.54]
			Placebo	123	106 (86.2)	0.91 (1.10)	-3.5	0.33	0.96	1.33	3.5	
		Week 36	Tezepelumab	128	111 (86.7)	1.20 (1.19)	-1.7	0.33	1.08	2.08	4.8	0.21 [-0.06, 0.48]
			Placebo	123	106 (86.2)	0.96 (1.14)	-3.0	0.17	1.00	1.58	3.8	
		Week 40	Tezepelumab	128	111 (86.7)	1.21 (1.13)	-1.7	0.42	1.08	2.08	4.8	0.21 [-0.05, 0.48]
			Placebo	123	106 (86.2)	0.97 (1.10)	-3.0	0.33	1.00	1.58	3.7	
		Week 44	Tezepelumab	128	111 (86.7)	1.23 (1.14)	-1.8	0.50	1.17	2.08	4.8	0.25 [-0.02, 0.52]
			Placebo	123	106 (86.2)	0.95 (1.12)	-3.0	0.33	1.00	1.58	3.8	
		Week 48	Tezepelumab	128	111 (86.7)	1.27 (1.12)	-1.6	0.42	1.17	2.08	4.8	0.27 [0.00, 0.54]
			Placebo	123	106 (86.2)	0.97 (1.11)	-3.0	0.25	1.04	1.58	4.2	
		Week 52	Tezepelumab	128	111 (86.7)	1.26 (1.12)	-1.6	0.42	1.08	2.08	4.8	0.28 [0.02, 0.55]
			Placebo	123	106 (86.2)	0.94 (1.08)	-3.0	0.25	0.83	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.22 (0.87)	2.6	3.75	4.54	4.79	5.0	
			Placebo	15	15 (100.0)	3.57 (1.04)	1.5	2.67	3.42	4.42	5.0	
		Week 4	Tezepelumab	9	9 (100.0)	5.35 (0.77)	4.5	4.75	4.92	6.17	6.3	
			Placebo	15	14 (93.3)	4.30 (0.88)	2.4	4.00	4.38	5.08	5.3	
		Week 8	Tezepelumab	9	9 (100.0)	5.52 (0.84)	4.0	5.08	5.42	5.92	6.7	
			Placebo	15	14 (93.3)	4.33 (1.24)	1.9	3.42	4.42	5.33	5.8	
		Week 12	Tezepelumab	9	9 (100.0)	5.72 (0.87)	4.2	5.33	5.83	6.25	6.9	
			Placebo	15	14 (93.3)	5.04 (1.05)	3.0	4.25	5.21	5.83	6.7	
		Week 16	Tezepelumab	9	9 (100.0)	5.61 (0.92)	3.5	5.67	5.75	6.00	6.8	
			Placebo	15	14 (93.3)	4.72 (1.34)	2.1	3.83	4.96	5.83	6.8	
		Week 20	Tezepelumab	9	9 (100.0)	5.65 (0.75)	4.6	5.33	5.67	6.17	6.9	
			Placebo	15	14 (93.3)	4.59 (1.31)	2.1	3.58	4.54	6.08	6.7	
		Week 24	Tezepelumab	9	9 (100.0)	5.75 (0.71)	4.3	5.50	5.92	6.00	6.9	
			Placebo	15	14 (93.3)	4.88 (1.07)	3.2	3.75	4.96	5.92	6.4	
		Week 28	Tezepelumab	9	9 (100.0)	5.74 (0.65)	4.6	5.50	5.75	5.83	7.0	
			Placebo	15	14 (93.3)	5.32 (1.41)	3.2	4.00	5.33	6.58	7.0	
		Week 32	Tezepelumab	9	9 (100.0)	5.76 (0.72)	4.8	5.50	5.75	6.00	6.9	
			Placebo	15	14 (93.3)	5.14 (1.06)	3.2	4.42	5.25	6.08	6.3	
		Week 36	Tezepelumab	9	9 (100.0)	5.68 (0.83)	4.3	5.08	5.92	6.08	7.0	
			Placebo	15	14 (93.3)	4.87 (1.12)	3.2	4.25	4.92	5.42	7.0	
		Week 40	Tezepelumab	9	9 (100.0)	5.83 (0.77)	4.6	5.50	6.00	6.17	7.0	
			Placebo	15	14 (93.3)	5.03 (1.25)	3.2	4.17	4.83	6.08	7.0	
		Week 44	Tezepelumab	9	9 (100.0)	5.88 (0.79)	4.6	5.50	6.00	6.50	7.0	
			Placebo	15	14 (93.3)	4.85 (1.38)	3.2	3.50	4.79	6.17	7.0	
		Week 48	Tezepelumab	9	9 (100.0)	5.73 (0.73)	4.5	5.17	6.00	6.08	6.9	
			Placebo	15	14 (93.3)	5.00 (1.16)	3.2	3.83	5.04	6.08	6.8	
		Week 52	Tezepelumab	9	9 (100.0)	5.81 (0.79)	4.5	5.17	6.08	6.25	6.9	
			Placebo	15	14 (93.3)	5.02 (1.15)	3.2	4.00	5.04	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	1.21 (1.07)	-0.3	0.33	1.33	1.75	3.1	0.63 [-0.26, 1.52]
			Placebo	15	14 (93.3)	0.64 (0.79)	-0.6	0.08	0.33	1.50	1.9	
		Week 8	Tezepelumab	9	8 (88.9)	1.31 (1.31)	-0.8	0.50	1.38	2.13	3.3	0.54 [-0.35, 1.42]
			Placebo	15	14 (93.3)	0.68 (1.10)	-0.8	-0.08	0.38	1.50	2.7	
		Week 12	Tezepelumab	9	8 (88.9)	1.49 (1.33)	-0.7	0.58	1.67	2.21	3.7	0.08 [-0.79, 0.95]
			Placebo	15	14 (93.3)	1.39 (1.29)	-0.2	0.50	0.92	2.50	4.0	
		Week 16	Tezepelumab	9	8 (88.9)	1.39 (1.31)	-0.9	0.63	1.46	2.33	3.2	0.22 [-0.65, 1.09]
			Placebo	15	14 (93.3)	1.07 (1.56)	-1.3	0.42	0.63	1.67	4.2	
		Week 20	Tezepelumab	9	8 (88.9)	1.42 (1.18)	-0.3	0.42	1.54	2.38	2.9	0.35 [-0.52, 1.23]
			Placebo	15	14 (93.3)	0.93 (1.45)	-1.3	0.08	0.75	1.75	3.8	
		Week 24	Tezepelumab	9	8 (88.9)	1.54 (1.16)	-0.5	0.75	1.71	2.50	2.9	0.26 [-0.62, 1.13]
			Placebo	15	14 (93.3)	1.22 (1.30)	-0.7	0.25	0.92	1.83	4.1	
		Week 28	Tezepelumab	9	8 (88.9)	1.52 (1.08)	-0.3	0.88	1.42	2.46	2.9	-0.10 [-0.97, 0.77]
			Placebo	15	14 (93.3)	1.67 (1.55)	-0.7	0.58	1.75	2.17	4.7	
		Week 32	Tezepelumab	9	8 (88.9)	1.44 (1.05)	-0.1	0.75	1.17	2.42	2.9	-0.04 [-0.91, 0.83]
			Placebo	15	14 (93.3)	1.49 (1.22)	-0.1	0.33	1.46	2.25	4.0	
		Week 36	Tezepelumab	9	8 (88.9)	1.36 (1.22)	-0.2	0.21	1.33	2.54	2.9	0.12 [-0.75, 0.99]
			Placebo	15	14 (93.3)	1.21 (1.22)	-1.3	0.25	1.63	1.83	3.8	
		Week 40	Tezepelumab	9	8 (88.9)	1.51 (1.13)	0.2	0.50	1.38	2.63	2.9	0.10 [-0.77, 0.96]
			Placebo	15	14 (93.3)	1.38 (1.55)	-0.6	0.00	1.29	1.83	4.7	
		Week 44	Tezepelumab	9	8 (88.9)	1.57 (1.21)	0.1	0.50	1.46	2.63	3.3	0.25 [-0.62, 1.12]
			Placebo	15	14 (93.3)	1.19 (1.66)	-1.3	-0.25	1.13	2.08	4.3	
		Week 48	Tezepelumab	9	8 (88.9)	1.48 (1.21)	-0.3	0.54	1.38	2.58	3.1	0.11 [-0.76, 0.98]
			Placebo	15	14 (93.3)	1.35 (1.28)	-0.4	0.42	1.42	2.33	3.8	
		Week 52	Tezepelumab	9	8 (88.9)	1.48 (1.21)	-0.3	0.54	1.38	2.58	3.1	0.09 [-0.78, 0.96]
			Placebo	15	14 (93.3)	1.36 (1.33)	-0.4	0.50	1.13	2.25	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	10	9 (90.0)	3.77 (1.40)	1.4	2.58	4.33	4.50	5.5	
			Placebo	9	8 (88.9)	3.42 (0.71)	2.4	2.96	3.38	3.83	4.6	
		Week 4	Tezepelumab	10	8 (80.0)	5.66 (0.73)	4.9	5.04	5.46	6.21	6.9	
			Placebo	9	7 (77.8)	4.44 (1.11)	2.4	4.08	4.33	5.17	6.0	
		Week 8	Tezepelumab	10	9 (90.0)	5.73 (1.00)	3.6	5.75	5.83	6.17	7.0	
			Placebo	9	7 (77.8)	4.75 (1.52)	2.3	3.33	5.25	5.83	6.5	
		Week 12	Tezepelumab	10	9 (90.0)	5.87 (0.83)	4.4	5.67	6.08	6.25	7.0	
			Placebo	9	7 (77.8)	4.85 (1.42)	3.0	3.25	4.92	5.92	6.8	
		Week 16	Tezepelumab	10	9 (90.0)	5.63 (1.05)	3.5	5.67	5.83	6.08	6.8	
			Placebo	9	7 (77.8)	4.62 (1.58)	2.1	3.42	4.92	5.92	6.6	
		Week 20	Tezepelumab	10	9 (90.0)	5.85 (0.73)	4.4	5.50	6.00	6.25	6.8	
			Placebo	9	7 (77.8)	4.89 (1.78)	2.1	3.50	5.25	6.67	6.8	
		Week 24	Tezepelumab	10	9 (90.0)	5.87 (0.79)	4.4	5.50	5.75	6.17	7.0	
			Placebo	9	7 (77.8)	5.25 (1.33)	3.4	3.67	6.00	6.08	6.8	
		Week 28	Tezepelumab	10	10 (100.0)	5.91 (0.82)	4.4	5.42	5.75	6.75	7.0	
			Placebo	9	7 (77.8)	5.25 (1.21)	3.4	4.00	5.42	6.25	6.7	
		Week 32	Tezepelumab	10	10 (100.0)	5.76 (0.78)	4.4	5.50	5.75	6.42	6.9	
			Placebo	9	7 (77.8)	5.24 (1.05)	3.4	4.42	5.25	6.17	6.3	
		Week 36	Tezepelumab	10	10 (100.0)	5.64 (0.92)	4.3	5.17	5.58	6.58	6.9	
			Placebo	9	7 (77.8)	5.04 (0.82)	3.4	4.83	5.08	5.50	6.1	
		Week 40	Tezepelumab	10	10 (100.0)	5.72 (0.88)	4.4	4.83	5.83	6.42	6.9	
			Placebo	9	7 (77.8)	5.14 (1.01)	3.4	4.42	5.75	6.00	6.1	
		Week 44	Tezepelumab	10	10 (100.0)	5.81 (0.87)	4.4	5.50	5.79	6.50	7.0	
			Placebo	9	7 (77.8)	5.21 (1.18)	3.3	4.00	5.75	6.17	6.3	
		Week 48	Tezepelumab	10	10 (100.0)	5.90 (0.81)	4.4	5.50	5.88	6.50	7.0	
			Placebo	9	7 (77.8)	5.49 (0.85)	3.8	5.25	5.67	6.17	6.5	
		Week 52	Tezepelumab	10	10 (100.0)	5.94 (0.83)	4.4	5.50	5.96	6.75	7.0	
			Placebo	9	7 (77.8)	5.62 (0.96)	4.0	5.25	5.67	6.50	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	10	8 (80.0)	1.59 (1.22)	-0.4	0.79	1.58	2.67	3.1	0.56 [-0.47, 1.60]
			Placebo	9	7 (77.8)	0.88 (1.31)	-0.6	-0.25	0.67	1.75	3.1	
		Week 8	Tezepelumab	10	9 (90.0)	1.96 (1.29)	0.3	0.83	2.17	2.50	4.1	0.56 [-0.45, 1.57]
			Placebo	9	7 (77.8)	1.19 (1.49)	-0.8	-0.08	0.92	2.50	3.6	
		Week 12	Tezepelumab	10	9 (90.0)	2.10 (1.45)	0.3	1.08	1.92	3.00	4.5	0.56 [-0.45, 1.57]
			Placebo	9	7 (77.8)	1.29 (1.47)	-0.2	0.00	0.83	2.50	3.8	
		Week 16	Tezepelumab	10	9 (90.0)	1.86 (1.64)	-0.9	0.83	1.75	3.00	4.6	0.50 [-0.50, 1.51]
			Placebo	9	7 (77.8)	1.06 (1.53)	-1.3	0.42	1.00	1.67	3.7	
		Week 20	Tezepelumab	10	9 (90.0)	2.08 (1.28)	0.5	1.00	1.92	2.92	4.6	0.49 [-0.52, 1.49]
			Placebo	9	7 (77.8)	1.33 (1.82)	-1.3	0.08	0.92	3.33	3.8	
		Week 24	Tezepelumab	10	9 (90.0)	2.10 (1.41)	0.3	1.58	1.83	2.92	4.8	0.30 [-0.70, 1.29]
			Placebo	9	7 (77.8)	1.69 (1.36)	0.0	0.25	1.67	2.75	3.9	
		Week 28	Tezepelumab	10	9 (90.0)	2.05 (1.45)	0.3	0.92	1.92	2.92	4.8	0.25 [-0.74, 1.25]
			Placebo	9	7 (77.8)	1.69 (1.33)	0.0	0.58	1.83	2.92	3.8	
		Week 32	Tezepelumab	10	9 (90.0)	1.89 (1.46)	0.3	0.83	1.58	2.92	4.8	0.15 [-0.84, 1.14]
			Placebo	9	7 (77.8)	1.68 (1.23)	0.0	0.50	1.83	2.92	3.3	
		Week 36	Tezepelumab	10	9 (90.0)	1.75 (1.69)	-0.3	0.17	1.58	2.92	4.8	0.20 [-0.79, 1.19]
			Placebo	9	7 (77.8)	1.48 (0.84)	0.0	0.75	1.75	1.83	2.6	
		Week 40	Tezepelumab	10	9 (90.0)	1.84 (1.62)	-0.7	1.00	1.75	2.92	4.8	0.19 [-0.80, 1.18]
			Placebo	9	7 (77.8)	1.58 (0.93)	0.0	1.00	1.58	2.42	2.8	
		Week 44	Tezepelumab	10	9 (90.0)	1.96 (1.53)	0.0	0.92	1.67	2.92	4.8	0.23 [-0.76, 1.22]
			Placebo	9	7 (77.8)	1.65 (1.08)	-0.1	0.58	2.00	2.75	2.8	
		Week 48	Tezepelumab	10	9 (90.0)	2.06 (1.41)	0.2	1.17	1.67	2.92	4.8	0.11 [-0.88, 1.10]
			Placebo	9	7 (77.8)	1.93 (0.97)	0.4	0.67	2.33	2.75	2.8	
		Week 52	Tezepelumab	10	9 (90.0)	2.08 (1.39)	0.3	1.17	1.67	2.92	4.8	0.02 [-0.97, 1.01]
			Placebo	9	7 (77.8)	2.06 (1.09)	0.6	0.67	2.25	2.75	3.6	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	127	114 (89.8)	4.07 (0.97)	1.3	3.50	4.00	4.67	6.8	
			Placebo	129	113 (87.6)	4.02 (0.91)	1.5	3.50	4.08	4.58	6.3	
		Week 4	Tezepelumab	127	118 (92.9)	4.79 (1.06)	1.3	3.92	4.75	5.58	7.0	
			Placebo	129	116 (89.9)	4.55 (0.95)	1.8	3.92	4.58	5.25	6.7	
		Week 8	Tezepelumab	127	119 (93.7)	5.00 (1.07)	2.0	4.17	4.92	5.83	7.0	
			Placebo	129	119 (92.2)	4.61 (1.02)	1.9	4.00	4.50	5.33	7.0	
		Week 12	Tezepelumab	127	119 (93.7)	5.17 (1.08)	2.8	4.25	5.17	6.08	7.0	
			Placebo	129	120 (93.0)	4.75 (1.06)	2.1	4.00	4.67	5.54	7.0	
		Week 16	Tezepelumab	127	119 (93.7)	5.17 (1.10)	2.3	4.33	5.17	6.00	7.0	
			Placebo	129	120 (93.0)	4.78 (1.09)	1.3	4.04	4.67	5.58	7.0	
		Week 20	Tezepelumab	127	120 (94.5)	5.15 (1.07)	2.3	4.25	5.08	5.92	7.0	
			Placebo	129	120 (93.0)	4.78 (1.09)	1.3	4.08	4.71	5.46	7.0	
		Week 24	Tezepelumab	127	120 (94.5)	5.18 (1.08)	1.8	4.38	5.08	6.00	7.0	
			Placebo	129	120 (93.0)	4.79 (1.14)	1.3	4.00	4.67	5.67	7.0	
		Week 28	Tezepelumab	127	121 (95.3)	5.16 (1.05)	3.2	4.33	5.00	5.92	7.0	
			Placebo	129	121 (93.8)	4.83 (1.20)	1.3	4.00	4.75	5.75	7.0	
		Week 32	Tezepelumab	127	122 (96.1)	5.25 (1.08)	2.8	4.33	5.17	6.00	7.0	
			Placebo	129	122 (94.6)	4.89 (1.14)	1.3	4.00	4.92	5.75	7.0	
		Week 36	Tezepelumab	127	122 (96.1)	5.26 (1.08)	2.9	4.50	5.13	6.08	7.0	
			Placebo	129	122 (94.6)	4.93 (1.18)	2.4	4.00	4.79	6.00	7.0	
		Week 40	Tezepelumab	127	122 (96.1)	5.25 (1.10)	2.3	4.42	5.21	6.00	7.0	
			Placebo	129	122 (94.6)	4.95 (1.13)	2.3	4.00	4.92	5.92	7.0	
		Week 44	Tezepelumab	127	122 (96.1)	5.26 (1.10)	2.3	4.33	5.29	6.08	7.0	
			Placebo	129	122 (94.6)	4.91 (1.18)	2.3	4.00	4.75	5.92	7.0	
		Week 48	Tezepelumab	127	122 (96.1)	5.27 (1.10)	2.8	4.42	5.17	6.17	7.0	
			Placebo	129	123 (95.3)	4.93 (1.12)	2.2	4.00	4.83	5.83	7.0	
		Week 52	Tezepelumab	127	122 (96.1)	5.28 (1.08)	2.8	4.50	5.17	6.17	7.0	
			Placebo	129	123 (95.3)	4.91 (1.12)	2.5	4.00	4.75	5.83	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	127	109 (85.8)	0.76 (0.99)	-4.3	0.17	0.67	1.42	3.1	0.23 [-0.04, 0.49]
			Placebo	129	112 (86.8)	0.56 (0.82)	-1.8	0.17	0.50	1.13	3.3	
		Week 8	Tezepelumab	127	110 (86.6)	0.91 (1.01)	-1.9	0.25	0.92	1.67	3.0	0.30 [0.03, 0.56]
			Placebo	129	113 (87.6)	0.63 (0.89)	-1.8	0.08	0.50	1.17	3.3	
		Week 12	Tezepelumab	127	110 (86.6)	1.08 (1.04)	-2.6	0.33	1.04	1.92	3.3	0.29 [0.02, 0.55]
			Placebo	129	113 (87.6)	0.76 (1.15)	-3.1	0.17	0.75	1.25	4.0	
		Week 16	Tezepelumab	127	110 (86.6)	1.08 (1.03)	-2.9	0.42	1.08	1.83	3.4	0.26 [0.00, 0.53]
			Placebo	129	113 (87.6)	0.79 (1.16)	-3.5	0.17	0.92	1.42	4.2	
		Week 20	Tezepelumab	127	110 (86.6)	1.08 (1.05)	-1.8	0.33	1.00	1.92	4.7	0.26 [-0.01, 0.52]
			Placebo	129	113 (87.6)	0.81 (1.06)	-3.5	0.25	0.83	1.25	3.8	
		Week 24	Tezepelumab	127	110 (86.6)	1.13 (1.06)	-1.6	0.42	1.00	2.00	3.7	0.28 [0.01, 0.54]
			Placebo	129	113 (87.6)	0.83 (1.15)	-3.5	0.17	0.83	1.33	4.1	
		Week 28	Tezepelumab	127	110 (86.6)	1.10 (1.05)	-1.7	0.42	0.96	2.00	4.9	0.23 [-0.04, 0.49]
			Placebo	129	113 (87.6)	0.84 (1.22)	-3.5	0.17	0.83	1.42	4.7	
		Week 32	Tezepelumab	127	110 (86.6)	1.18 (1.12)	-1.6	0.42	1.08	2.08	4.6	0.22 [-0.04, 0.49]
			Placebo	129	113 (87.6)	0.93 (1.11)	-3.5	0.33	1.00	1.50	4.0	
		Week 36	Tezepelumab	127	110 (86.6)	1.17 (1.14)	-1.7	0.33	1.08	2.08	3.8	0.18 [-0.08, 0.45]
			Placebo	129	113 (87.6)	0.96 (1.16)	-3.0	0.25	1.00	1.58	3.8	
		Week 40	Tezepelumab	127	110 (86.6)	1.18 (1.08)	-1.7	0.42	1.08	2.08	3.4	0.17 [-0.09, 0.44]
			Placebo	129	113 (87.6)	0.98 (1.17)	-3.0	0.33	0.92	1.58	4.7	
		Week 44	Tezepelumab	127	110 (86.6)	1.19 (1.09)	-1.8	0.50	1.17	2.08	3.3	0.23 [-0.04, 0.49]
			Placebo	129	113 (87.6)	0.93 (1.19)	-3.0	0.17	1.00	1.58	4.3	
		Week 48	Tezepelumab	127	110 (86.6)	1.22 (1.08)	-1.6	0.42	1.08	2.08	3.4	0.24 [-0.02, 0.51]
			Placebo	129	113 (87.6)	0.96 (1.12)	-3.0	0.25	1.00	1.58	4.2	
		Week 52	Tezepelumab	127	110 (86.6)	1.21 (1.08)	-1.6	0.42	1.04	2.08	3.6	0.26 [-0.01, 0.52]
			Placebo	129	113 (87.6)	0.93 (1.09)	-3.0	0.25	0.83	1.42	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	61	54 (88.5)	4.12 (0.89)	2.1	3.75	4.08	4.67	6.7	
			Placebo	60	53 (88.3)	4.00 (0.91)	1.5	3.50	4.17	4.50	5.9	
		Week 4	Tezepelumab	61	56 (91.8)	4.80 (1.06)	1.3	4.08	4.75	5.50	6.9	
			Placebo	60	53 (88.3)	4.72 (0.93)	2.6	4.08	4.83	5.25	6.7	
		Week 8	Tezepelumab	61	57 (93.4)	5.05 (0.93)	3.4	4.33	4.92	5.58	7.0	
			Placebo	60	54 (90.0)	4.77 (0.98)	1.9	4.08	4.67	5.42	6.8	
		Week 12	Tezepelumab	61	57 (93.4)	5.16 (0.96)	3.0	4.42	5.17	5.83	7.0	
			Placebo	60	54 (90.0)	4.84 (1.00)	2.8	4.08	4.79	5.58	6.9	
		Week 16	Tezepelumab	61	57 (93.4)	5.08 (1.01)	2.7	4.33	5.08	5.83	7.0	
			Placebo	60	54 (90.0)	4.87 (1.11)	1.3	4.08	4.92	5.75	7.0	
		Week 20	Tezepelumab	61	58 (95.1)	5.07 (0.93)	3.6	4.33	5.04	5.67	7.0	
			Placebo	60	54 (90.0)	4.83 (1.11)	1.3	4.00	4.67	5.75	7.0	
		Week 24	Tezepelumab	61	58 (95.1)	5.07 (1.08)	1.8	4.33	5.00	5.83	7.0	
			Placebo	60	54 (90.0)	4.82 (1.17)	1.3	4.00	4.67	5.75	7.0	
		Week 28	Tezepelumab	61	59 (96.7)	5.05 (0.98)	3.3	4.33	5.00	5.75	7.0	
			Placebo	60	54 (90.0)	4.78 (1.25)	1.3	4.00	4.58	5.92	7.0	
		Week 32	Tezepelumab	61	60 (98.4)	5.17 (0.94)	3.5	4.33	5.04	5.92	7.0	
			Placebo	60	54 (90.0)	4.93 (1.13)	1.3	4.00	4.92	5.92	6.9	
		Week 36	Tezepelumab	61	60 (98.4)	5.21 (0.96)	3.3	4.50	5.08	5.92	7.0	
			Placebo	60	54 (90.0)	5.04 (1.15)	2.5	4.00	5.04	6.00	7.0	
		Week 40	Tezepelumab	61	60 (98.4)	5.14 (0.99)	2.9	4.46	5.00	5.88	7.0	
			Placebo	60	54 (90.0)	4.98 (1.10)	2.8	4.00	4.92	6.00	7.0	
		Week 44	Tezepelumab	61	60 (98.4)	5.17 (1.05)	3.0	4.29	5.08	5.92	7.0	
			Placebo	60	54 (90.0)	5.03 (1.19)	2.5	4.00	4.96	6.08	7.0	
		Week 48	Tezepelumab	61	60 (98.4)	5.27 (1.00)	3.1	4.50	5.17	6.00	7.0	
			Placebo	60	54 (90.0)	4.98 (1.14)	2.8	4.00	4.83	6.00	7.0	
		Week 52	Tezepelumab	61	60 (98.4)	5.26 (0.99)	3.1	4.63	5.08	6.00	7.0	
			Placebo	60	54 (90.0)	4.92 (1.14)	2.8	4.00	4.63	6.00	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	61	52 (85.2)	0.74 (1.10)	-4.3	0.29	0.58	1.38	3.1	0.03 [-0.35, 0.42]
			Placebo	60	51 (85.0)	0.71 (0.88)	-1.8	0.17	0.67	1.25	3.3	
		Week 8	Tezepelumab	61	53 (86.9)	0.93 (0.95)	-1.4	0.33	0.92	1.50	3.3	0.19 [-0.20, 0.57]
			Placebo	60	52 (86.7)	0.76 (0.81)	-0.8	0.33	0.67	1.17	3.3	
		Week 12	Tezepelumab	61	53 (86.9)	1.04 (1.07)	-2.6	0.33	0.92	1.83	3.7	0.22 [-0.17, 0.60]
			Placebo	60	52 (86.7)	0.80 (1.12)	-3.1	0.21	0.92	1.29	3.8	
		Week 16	Tezepelumab	61	53 (86.9)	0.98 (1.08)	-2.9	0.33	0.83	1.75	3.2	0.11 [-0.28, 0.49]
			Placebo	60	52 (86.7)	0.86 (1.18)	-3.5	0.42	1.08	1.46	3.6	
		Week 20	Tezepelumab	61	53 (86.9)	0.96 (0.94)	-1.8	0.33	0.83	1.75	3.0	0.14 [-0.24, 0.53]
			Placebo	60	52 (86.7)	0.82 (1.03)	-3.5	0.17	0.83	1.25	3.3	
		Week 24	Tezepelumab	61	53 (86.9)	1.00 (1.02)	-1.6	0.33	0.92	1.67	3.0	0.17 [-0.22, 0.55]
			Placebo	60	52 (86.7)	0.83 (1.09)	-3.5	0.29	0.92	1.33	3.6	
		Week 28	Tezepelumab	61	53 (86.9)	0.97 (0.94)	-1.7	0.42	0.83	1.50	3.0	0.19 [-0.20, 0.57]
			Placebo	60	52 (86.7)	0.78 (1.08)	-3.5	0.13	0.88	1.29	3.3	
		Week 32	Tezepelumab	61	53 (86.9)	1.04 (1.00)	-1.6	0.33	1.00	1.75	3.0	0.11 [-0.27, 0.49]
			Placebo	60	52 (86.7)	0.93 (1.01)	-3.5	0.38	1.08	1.33	3.5	
		Week 36	Tezepelumab	61	53 (86.9)	1.07 (1.06)	-1.7	0.33	1.00	2.00	3.3	0.01 [-0.37, 0.39]
			Placebo	60	52 (86.7)	1.06 (1.00)	-2.3	0.29	1.13	1.67	3.8	
		Week 40	Tezepelumab	61	53 (86.9)	1.03 (1.00)	-1.7	0.25	0.92	1.83	3.0	0.04 [-0.34, 0.43]
			Placebo	60	52 (86.7)	0.99 (0.93)	-1.1	0.46	1.17	1.58	3.4	
		Week 44	Tezepelumab	61	53 (86.9)	1.04 (1.05)	-1.6	0.33	0.92	1.75	3.3	0.00 [-0.38, 0.38]
			Placebo	60	52 (86.7)	1.04 (1.05)	-1.3	0.25	1.17	1.71	3.7	
		Week 48	Tezepelumab	61	53 (86.9)	1.16 (1.01)	-1.6	0.33	1.08	1.75	3.1	0.17 [-0.22, 0.55]
			Placebo	60	52 (86.7)	0.99 (1.00)	-1.1	0.13	1.13	1.63	4.2	
		Week 52	Tezepelumab	61	53 (86.9)	1.13 (0.99)	-1.6	0.33	1.00	1.67	3.1	0.20 [-0.18, 0.59]
			Placebo	60	52 (86.7)	0.93 (1.01)	-1.1	0.17	0.71	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	76	69 (90.8)	4.00 (1.09)	1.3	3.42	4.00	4.67	6.8	
			Placebo	78	68 (87.2)	3.96 (0.90)	1.8	3.38	3.96	4.54	6.3	
		Week 4	Tezepelumab	76	70 (92.1)	4.88 (1.06)	2.8	3.92	4.88	5.67	7.0	
			Placebo	78	70 (89.7)	4.41 (0.95)	1.8	3.75	4.46	5.17	6.4	
		Week 8	Tezepelumab	76	71 (93.4)	5.06 (1.19)	2.0	4.08	5.17	6.08	7.0	
			Placebo	78	72 (92.3)	4.51 (1.09)	2.3	3.75	4.46	5.33	7.0	
		Week 12	Tezepelumab	76	71 (93.4)	5.27 (1.16)	2.8	4.25	5.42	6.42	7.0	
			Placebo	78	73 (93.6)	4.69 (1.13)	2.1	3.92	4.67	5.58	7.0	
		Week 16	Tezepelumab	76	71 (93.4)	5.30 (1.17)	2.3	4.33	5.42	6.25	7.0	
			Placebo	78	73 (93.6)	4.69 (1.13)	2.1	4.00	4.58	5.50	7.0	
		Week 20	Tezepelumab	76	71 (93.4)	5.31 (1.16)	2.3	4.33	5.50	6.25	7.0	
			Placebo	78	73 (93.6)	4.76 (1.15)	2.1	4.08	4.75	5.42	7.0	
		Week 24	Tezepelumab	76	71 (93.4)	5.35 (1.07)	3.1	4.42	5.25	6.25	7.0	
			Placebo	78	73 (93.6)	4.82 (1.14)	2.1	4.00	4.67	5.75	7.0	
		Week 28	Tezepelumab	76	72 (94.7)	5.36 (1.09)	3.2	4.42	5.46	6.29	7.0	
			Placebo	78	74 (94.9)	4.91 (1.17)	1.8	4.00	4.88	5.83	7.0	
		Week 32	Tezepelumab	76	72 (94.7)	5.39 (1.17)	2.8	4.46	5.54	6.29	7.0	
			Placebo	78	75 (96.2)	4.90 (1.15)	2.1	4.00	5.00	5.75	7.0	
		Week 36	Tezepelumab	76	72 (94.7)	5.35 (1.16)	2.9	4.38	5.33	6.33	7.0	
			Placebo	78	75 (96.2)	4.86 (1.17)	2.4	4.00	4.83	5.92	7.0	
		Week 40	Tezepelumab	76	72 (94.7)	5.40 (1.16)	2.3	4.42	5.54	6.50	7.0	
			Placebo	78	75 (96.2)	4.95 (1.14)	2.3	4.00	4.83	5.83	7.0	
		Week 44	Tezepelumab	76	72 (94.7)	5.42 (1.12)	2.3	4.58	5.50	6.33	7.0	
			Placebo	78	75 (96.2)	4.85 (1.17)	2.3	4.00	4.67	5.92	7.0	
		Week 48	Tezepelumab	76	72 (94.7)	5.36 (1.16)	2.8	4.38	5.33	6.38	7.0	
			Placebo	78	76 (97.4)	4.95 (1.10)	2.2	4.00	4.96	5.75	7.0	
		Week 52	Tezepelumab	76	72 (94.7)	5.38 (1.15)	2.8	4.46	5.42	6.38	7.0	
			Placebo	78	76 (97.4)	4.96 (1.11)	2.5	4.00	4.92	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	76	65 (85.5)	0.88 (0.95)	-1.4	0.17	0.83	1.58	3.1	0.46 [0.11, 0.80]
			Placebo	78	68 (87.2)	0.48 (0.82)	-1.3	0.00	0.42	1.04	3.1	
		Week 8	Tezepelumab	76	66 (86.8)	1.04 (1.15)	-1.9	0.17	1.04	1.92	4.1	0.42 [0.08, 0.77]
			Placebo	78	68 (87.2)	0.58 (1.02)	-1.8	0.00	0.42	1.21	3.6	
		Week 12	Tezepelumab	76	66 (86.8)	1.24 (1.13)	-1.4	0.42	1.21	2.00	4.5	0.39 [0.05, 0.74]
			Placebo	78	68 (87.2)	0.78 (1.22)	-2.8	0.04	0.67	1.21	4.0	
		Week 16	Tezepelumab	76	66 (86.8)	1.28 (1.11)	-1.4	0.42	1.13	2.08	4.6	0.44 [0.10, 0.78]
			Placebo	78	68 (87.2)	0.77 (1.18)	-3.0	0.17	0.63	1.42	4.2	
		Week 20	Tezepelumab	76	66 (86.8)	1.31 (1.20)	-1.4	0.42	1.29	2.17	4.7	0.39 [0.04, 0.73]
			Placebo	78	68 (87.2)	0.85 (1.18)	-3.0	0.25	0.83	1.54	3.8	
		Week 24	Tezepelumab	76	66 (86.8)	1.37 (1.16)	-1.4	0.50	1.29	2.25	4.8	0.38 [0.04, 0.72]
			Placebo	78	68 (87.2)	0.92 (1.25)	-3.0	0.13	0.83	1.54	4.1	
		Week 28	Tezepelumab	76	66 (86.8)	1.33 (1.20)	-1.4	0.42	1.33	2.08	4.9	0.28 [-0.06, 0.62]
			Placebo	78	68 (87.2)	0.98 (1.35)	-3.0	0.21	0.79	1.67	4.7	
		Week 32	Tezepelumab	76	66 (86.8)	1.39 (1.25)	-1.4	0.50	1.33	2.25	4.8	0.31 [-0.03, 0.65]
			Placebo	78	68 (87.2)	1.01 (1.21)	-3.0	0.25	0.88	1.63	4.0	
		Week 36	Tezepelumab	76	66 (86.8)	1.33 (1.28)	-1.4	0.33	1.21	2.33	4.8	0.31 [-0.03, 0.65]
			Placebo	78	68 (87.2)	0.94 (1.25)	-3.0	0.17	0.83	1.71	3.8	
		Week 40	Tezepelumab	76	66 (86.8)	1.39 (1.21)	-1.4	0.58	1.21	2.25	4.8	0.27 [-0.07, 0.61]
			Placebo	78	68 (87.2)	1.04 (1.31)	-3.0	0.33	0.83	1.67	4.7	
		Week 44	Tezepelumab	76	66 (86.8)	1.42 (1.18)	-1.8	0.75	1.38	2.25	4.8	0.40 [0.06, 0.74]
			Placebo	78	68 (87.2)	0.93 (1.29)	-3.0	0.21	0.83	1.58	4.3	
		Week 48	Tezepelumab	76	66 (86.8)	1.39 (1.20)	-1.4	0.50	1.21	2.25	4.8	0.30 [-0.05, 0.64]
			Placebo	78	68 (87.2)	1.03 (1.23)	-3.0	0.29	1.04	1.67	3.8	
		Week 52	Tezepelumab	76	66 (86.8)	1.39 (1.22)	-1.4	0.42	1.13	2.42	4.8	0.28 [-0.06, 0.62]
			Placebo	78	68 (87.2)	1.04 (1.20)	-3.0	0.25	0.92	1.67	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	75	65 (86.7)	4.05 (0.84)	1.9	3.75	4.08	4.58	6.3	
			Placebo	72	61 (84.7)	3.96 (0.86)	1.8	3.42	4.08	4.50	5.9	
		Week 4	Tezepelumab	75	69 (92.0)	4.75 (1.08)	1.3	3.92	4.75	5.50	6.9	
			Placebo	72	64 (88.9)	4.61 (0.94)	1.8	4.00	4.71	5.25	6.5	
		Week 8	Tezepelumab	75	69 (92.0)	4.98 (1.01)	2.0	4.25	4.92	5.67	7.0	
			Placebo	72	64 (88.9)	4.72 (0.98)	2.3	4.08	4.58	5.42	6.7	
		Week 12	Tezepelumab	75	69 (92.0)	5.16 (1.02)	3.0	4.25	5.17	6.00	7.0	
			Placebo	72	65 (90.3)	4.77 (1.07)	2.4	4.08	4.67	5.58	6.9	
		Week 16	Tezepelumab	75	69 (92.0)	5.09 (1.04)	2.7	4.33	5.08	5.92	7.0	
			Placebo	72	65 (90.3)	4.86 (1.02)	2.2	4.17	4.92	5.50	7.0	
		Week 20	Tezepelumab	75	70 (93.3)	5.04 (1.06)	2.3	4.17	4.92	5.83	7.0	
			Placebo	72	65 (90.3)	4.88 (1.02)	2.3	4.17	4.83	5.42	7.0	
		Week 24	Tezepelumab	75	70 (93.3)	5.11 (1.04)	3.1	4.25	4.92	6.00	7.0	
			Placebo	72	65 (90.3)	4.89 (1.07)	2.1	4.17	4.75	5.58	7.0	
		Week 28	Tezepelumab	75	72 (96.0)	5.11 (1.05)	3.2	4.33	5.00	5.79	7.0	
			Placebo	72	66 (91.7)	4.91 (1.09)	1.8	4.00	4.79	5.92	7.0	
		Week 32	Tezepelumab	75	73 (97.3)	5.14 (1.08)	2.8	4.25	5.00	6.00	7.0	
			Placebo	72	67 (93.1)	4.94 (1.07)	2.1	4.08	5.00	5.83	6.9	
		Week 36	Tezepelumab	75	73 (97.3)	5.24 (1.09)	2.9	4.33	5.25	6.08	7.0	
			Placebo	72	67 (93.1)	5.05 (1.10)	2.5	4.08	5.17	6.00	7.0	
		Week 40	Tezepelumab	75	73 (97.3)	5.09 (1.11)	2.3	4.25	5.08	5.83	7.0	
			Placebo	72	67 (93.1)	5.02 (1.04)	2.4	4.25	5.00	5.92	7.0	
		Week 44	Tezepelumab	75	73 (97.3)	5.11 (1.13)	2.3	4.17	5.08	6.00	7.0	
			Placebo	72	67 (93.1)	5.00 (1.13)	2.3	4.00	4.92	6.00	7.0	
		Week 48	Tezepelumab	75	73 (97.3)	5.12 (1.12)	2.8	4.17	5.00	5.83	7.0	
			Placebo	72	68 (94.4)	5.06 (1.09)	2.4	4.21	5.08	5.92	7.0	
		Week 52	Tezepelumab	75	73 (97.3)	5.12 (1.12)	2.8	4.25	5.00	5.92	7.0	
			Placebo	72	68 (94.4)	5.01 (1.12)	2.5	4.04	5.00	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	75	64 (85.3)	0.70 (1.06)	-4.3	0.08	0.58	1.42	3.1	0.00 [-0.35, 0.35]
			Placebo	72	61 (84.7)	0.70 (0.87)	-1.3	0.17	0.58	1.25	3.3	
		Week 8	Tezepelumab	75	64 (85.3)	0.90 (1.00)	-1.9	0.25	0.92	1.50	3.3	0.12 [-0.23, 0.47]
			Placebo	72	61 (84.7)	0.79 (0.90)	-1.0	0.33	0.58	1.25	3.6	
		Week 12	Tezepelumab	75	64 (85.3)	1.09 (1.04)	-2.6	0.33	0.96	1.83	3.7	0.22 [-0.13, 0.57]
			Placebo	72	61 (84.7)	0.85 (1.13)	-3.1	0.33	0.92	1.17	3.8	
		Week 16	Tezepelumab	75	64 (85.3)	1.04 (1.02)	-2.9	0.33	1.00	1.71	3.3	0.10 [-0.25, 0.45]
			Placebo	72	61 (84.7)	0.94 (1.05)	-3.1	0.42	1.00	1.50	3.7	
		Week 20	Tezepelumab	75	64 (85.3)	1.00 (0.97)	-1.8	0.33	0.88	1.71	3.3	0.02 [-0.33, 0.37]
			Placebo	72	61 (84.7)	0.98 (0.92)	-1.1	0.42	1.00	1.58	3.8	
		Week 24	Tezepelumab	75	64 (85.3)	1.10 (0.94)	-1.6	0.42	1.00	1.75	3.3	0.12 [-0.23, 0.47]
			Placebo	72	61 (84.7)	0.99 (0.98)	-1.3	0.33	0.83	1.42	3.9	
		Week 28	Tezepelumab	75	64 (85.3)	1.07 (0.94)	-1.7	0.42	0.96	1.63	3.3	0.11 [-0.25, 0.46]
			Placebo	72	61 (84.7)	0.97 (1.02)	-1.8	0.33	0.92	1.42	3.8	
		Week 32	Tezepelumab	75	64 (85.3)	1.08 (1.04)	-1.6	0.38	1.00	1.79	3.3	0.03 [-0.32, 0.38]
			Placebo	72	61 (84.7)	1.05 (0.91)	-0.8	0.42	1.08	1.50	3.5	
		Week 36	Tezepelumab	75	64 (85.3)	1.15 (1.07)	-1.7	0.33	1.08	2.08	3.4	0.00 [-0.35, 0.36]
			Placebo	72	61 (84.7)	1.15 (0.99)	-0.8	0.42	1.17	1.67	3.8	
		Week 40	Tezepelumab	75	64 (85.3)	1.04 (1.04)	-1.7	0.25	1.00	1.92	3.3	-0.08 [-0.43, 0.27]
			Placebo	72	61 (84.7)	1.12 (0.96)	-1.0	0.50	1.17	1.75	3.4	
		Week 44	Tezepelumab	75	64 (85.3)	1.04 (1.06)	-1.8	0.33	1.00	1.92	3.2	-0.05 [-0.40, 0.30]
			Placebo	72	61 (84.7)	1.09 (1.04)	-1.3	0.33	1.17	1.75	3.7	
		Week 48	Tezepelumab	75	64 (85.3)	1.09 (1.04)	-1.6	0.33	0.96	1.88	3.4	-0.06 [-0.41, 0.29]
			Placebo	72	61 (84.7)	1.15 (1.02)	-1.1	0.50	1.17	1.67	4.2	
		Week 52	Tezepelumab	75	64 (85.3)	1.06 (1.01)	-1.6	0.29	0.92	1.67	3.4	-0.05 [-0.40, 0.30]
			Placebo	72	61 (84.7)	1.10 (1.01)	-0.7	0.42	0.92	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	60	56 (93.3)	4.06 (1.18)	1.3	3.29	4.00	4.75	6.8	
			Placebo	65	59 (90.8)	3.98 (0.95)	1.5	3.42	4.00	4.50	6.3	
		Week 4	Tezepelumab	60	55 (91.7)	4.97 (1.04)	2.9	4.08	4.92	5.83	7.0	
			Placebo	65	59 (90.8)	4.48 (0.97)	2.4	3.67	4.50	5.17	6.7	
		Week 8	Tezepelumab	60	57 (95.0)	5.16 (1.17)	2.7	4.08	5.17	6.08	7.0	
			Placebo	65	61 (93.8)	4.53 (1.12)	1.9	3.75	4.42	5.33	7.0	
		Week 12	Tezepelumab	60	57 (95.0)	5.30 (1.16)	2.8	4.33	5.42	6.25	7.0	
			Placebo	65	61 (93.8)	4.75 (1.09)	2.1	3.92	4.67	5.67	7.0	
		Week 16	Tezepelumab	60	57 (95.0)	5.34 (1.17)	2.3	4.42	5.42	6.25	7.0	
			Placebo	65	61 (93.8)	4.73 (1.14)	2.1	4.00	4.50	5.58	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.39 (1.08)	3.3	4.50	5.50	6.17	7.0	
			Placebo	65	61 (93.8)	4.75 (1.16)	2.1	4.00	4.42	5.67	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.36 (1.13)	1.8	4.42	5.50	6.08	7.0	
			Placebo	65	61 (93.8)	4.80 (1.15)	2.8	3.92	4.67	5.75	7.0	
		Week 28	Tezepelumab	60	57 (95.0)	5.36 (1.07)	3.2	4.42	5.42	6.17	7.0	
			Placebo	65	61 (93.8)	4.85 (1.24)	2.8	3.92	4.67	5.75	7.0	
		Week 32	Tezepelumab	60	57 (95.0)	5.47 (1.05)	2.8	4.75	5.50	6.25	7.0	
			Placebo	65	61 (93.8)	4.93 (1.12)	2.8	4.00	4.92	5.75	7.0	
		Week 36	Tezepelumab	60	57 (95.0)	5.35 (1.07)	2.9	4.58	5.25	6.17	7.0	
			Placebo	65	61 (93.8)	4.85 (1.19)	2.4	4.00	4.75	5.83	7.0	
		Week 40	Tezepelumab	60	57 (95.0)	5.53 (1.03)	3.2	4.75	5.67	6.42	7.0	
			Placebo	65	61 (93.8)	4.91 (1.21)	2.3	4.00	4.58	6.00	7.0	
		Week 44	Tezepelumab	60	57 (95.0)	5.56 (1.01)	3.2	4.75	5.50	6.50	7.0	
			Placebo	65	61 (93.8)	4.86 (1.24)	2.5	4.00	4.50	5.92	7.0	
		Week 48	Tezepelumab	60	57 (95.0)	5.56 (1.02)	3.3	4.75	5.67	6.33	7.0	
			Placebo	65	61 (93.8)	4.87 (1.14)	2.2	4.00	4.75	5.75	7.0	
		Week 52	Tezepelumab	60	57 (95.0)	5.58 (0.98)	3.8	4.75	5.58	6.42	7.0	
			Placebo	65	61 (93.8)	4.89 (1.12)	2.8	4.00	4.75	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	60	51 (85.0)	0.98 (0.98)	-1.4	0.25	1.08	1.67	3.1	0.60 [0.22, 0.99]
			Placebo	65	58 (89.2)	0.45 (0.82)	-1.8	0.00	0.42	1.00	1.9	
		Week 8	Tezepelumab	60	53 (88.3)	1.10 (1.15)	-1.4	0.17	1.17	2.00	4.1	0.53 [0.15, 0.91]
			Placebo	65	58 (89.2)	0.54 (0.96)	-1.8	-0.08	0.42	1.00	2.7	
		Week 12	Tezepelumab	60	53 (88.3)	1.23 (1.20)	-1.4	0.42	1.25	2.08	4.5	0.40 [0.03, 0.78]
			Placebo	65	58 (89.2)	0.74 (1.22)	-2.8	0.00	0.75	1.33	4.0	
		Week 16	Tezepelumab	60	53 (88.3)	1.27 (1.21)	-1.4	0.42	1.33	2.17	4.6	0.43 [0.06, 0.81]
			Placebo	65	58 (89.2)	0.75 (1.17)	-3.0	0.17	0.75	1.42	4.2	
		Week 20	Tezepelumab	60	53 (88.3)	1.33 (1.23)	-1.4	0.50	1.25	2.25	4.7	0.47 [0.10, 0.85]
			Placebo	65	58 (89.2)	0.77 (1.16)	-3.0	0.08	0.79	1.25	3.8	
		Week 24	Tezepelumab	60	53 (88.3)	1.32 (1.30)	-1.6	0.42	1.25	2.33	4.8	0.38 [0.01, 0.76]
			Placebo	65	58 (89.2)	0.83 (1.24)	-3.0	0.00	0.83	1.50	4.1	
		Week 28	Tezepelumab	60	53 (88.3)	1.29 (1.29)	-1.4	0.42	1.00	2.17	4.9	0.31 [-0.06, 0.68]
			Placebo	65	58 (89.2)	0.89 (1.33)	-3.0	0.08	0.83	1.67	4.7	
		Week 32	Tezepelumab	60	53 (88.3)	1.41 (1.28)	-1.4	0.50	1.33	2.25	4.8	0.36 [-0.02, 0.73]
			Placebo	65	58 (89.2)	0.97 (1.19)	-3.0	0.25	0.96	1.50	4.0	
		Week 36	Tezepelumab	60	53 (88.3)	1.28 (1.34)	-1.4	0.17	1.17	2.33	4.8	0.32 [-0.05, 0.69]
			Placebo	65	58 (89.2)	0.87 (1.22)	-3.0	0.08	0.83	1.67	3.8	
		Week 40	Tezepelumab	60	53 (88.3)	1.46 (1.22)	-1.4	0.58	1.33	2.33	4.8	0.40 [0.02, 0.77]
			Placebo	65	58 (89.2)	0.95 (1.32)	-3.0	0.08	0.83	1.58	4.7	
		Week 44	Tezepelumab	60	53 (88.3)	1.50 (1.19)	-1.4	0.83	1.50	2.33	4.8	0.48 [0.11, 0.86]
			Placebo	65	58 (89.2)	0.89 (1.31)	-3.0	0.25	0.83	1.58	4.3	
		Week 48	Tezepelumab	60	53 (88.3)	1.50 (1.19)	-1.4	0.58	1.50	2.42	4.8	0.50 [0.12, 0.88]
			Placebo	65	58 (89.2)	0.91 (1.22)	-3.0	0.17	0.83	1.58	3.8	
		Week 52	Tezepelumab	60	53 (88.3)	1.51 (1.21)	-1.4	0.58	1.42	2.50	4.8	0.49 [0.12, 0.87]
			Placebo	65	58 (89.2)	0.92 (1.20)	-3.0	0.17	0.83	1.58	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	65	56 (86.2)	4.07 (0.86)	1.9	3.75	4.04	4.67	6.3	
			Placebo	62	53 (85.5)	4.01 (0.87)	1.8	3.50	4.17	4.58	5.9	
		Week 4	Tezepelumab	65	60 (92.3)	4.76 (1.12)	1.3	3.92	4.75	5.54	6.9	
			Placebo	62	56 (90.3)	4.58 (0.95)	1.8	4.00	4.63	5.25	6.5	
		Week 8	Tezepelumab	65	60 (92.3)	4.98 (1.01)	2.0	4.25	4.83	5.67	7.0	
			Placebo	62	56 (90.3)	4.69 (0.96)	2.3	4.08	4.58	5.38	6.7	
		Week 12	Tezepelumab	65	60 (92.3)	5.13 (1.02)	3.0	4.25	5.08	5.88	7.0	
			Placebo	62	57 (91.9)	4.71 (1.02)	2.4	4.08	4.67	5.50	6.9	
		Week 16	Tezepelumab	65	60 (92.3)	5.07 (1.06)	2.7	4.33	5.08	5.92	7.0	
			Placebo	62	57 (91.9)	4.80 (1.04)	2.2	4.00	4.83	5.50	7.0	
		Week 20	Tezepelumab	65	61 (93.8)	4.95 (1.04)	2.3	4.17	4.75	5.58	7.0	
			Placebo	62	57 (91.9)	4.85 (1.02)	2.3	4.08	4.83	5.42	7.0	
		Week 24	Tezepelumab	65	61 (93.8)	5.04 (1.02)	3.1	4.25	4.83	5.67	7.0	
			Placebo	62	57 (91.9)	4.84 (1.07)	2.1	4.00	4.75	5.58	6.9	
		Week 28	Tezepelumab	65	62 (95.4)	5.01 (1.01)	3.2	4.33	4.96	5.58	7.0	
			Placebo	62	58 (93.5)	4.83 (1.06)	1.8	4.00	4.75	5.67	7.0	
		Week 32	Tezepelumab	65	63 (96.9)	5.05 (1.00)	2.9	4.17	4.92	5.92	7.0	
			Placebo	62	58 (93.5)	4.93 (1.07)	2.1	4.08	4.88	5.83	6.9	
		Week 36	Tezepelumab	65	63 (96.9)	5.14 (1.06)	2.9	4.25	5.08	6.08	7.0	
			Placebo	62	58 (93.5)	5.01 (1.11)	2.5	4.08	5.00	6.00	7.0	
		Week 40	Tezepelumab	65	63 (96.9)	4.98 (1.08)	2.3	4.17	4.83	5.67	7.0	
			Placebo	62	58 (93.5)	5.03 (1.07)	2.4	4.25	5.00	6.00	7.0	
		Week 44	Tezepelumab	65	63 (96.9)	4.99 (1.12)	2.3	4.17	4.75	5.75	7.0	
			Placebo	62	58 (93.5)	4.99 (1.10)	2.3	4.00	4.88	6.00	7.0	
		Week 48	Tezepelumab	65	63 (96.9)	5.02 (1.05)	3.1	4.17	4.83	5.67	7.0	
			Placebo	62	59 (95.2)	5.09 (1.08)	2.4	4.25	5.08	6.00	7.0	
		Week 52	Tezepelumab	65	63 (96.9)	5.03 (1.07)	3.0	4.17	4.92	5.83	7.0	
			Placebo	62	59 (95.2)	5.02 (1.09)	2.5	4.08	4.92	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	65	55 (84.6)	0.69 (1.11)	-4.3	0.08	0.58	1.42	3.1	0.07 [-0.31, 0.44]
			Placebo	62	53 (85.5)	0.62 (0.82)	-1.3	0.17	0.50	1.00	3.3	
		Week 8	Tezepelumab	65	55 (84.6)	0.88 (1.02)	-1.9	0.25	0.83	1.50	3.3	0.18 [-0.20, 0.55]
			Placebo	62	53 (85.5)	0.72 (0.83)	-1.0	0.25	0.58	1.17	3.3	
		Week 12	Tezepelumab	65	55 (84.6)	1.03 (1.06)	-2.6	0.33	0.92	1.83	3.7	0.26 [-0.12, 0.64]
			Placebo	62	53 (85.5)	0.75 (1.05)	-3.1	0.33	0.83	1.17	3.8	
		Week 16	Tezepelumab	65	55 (84.6)	0.99 (1.03)	-2.9	0.33	0.92	1.58	3.3	0.15 [-0.23, 0.53]
			Placebo	62	53 (85.5)	0.83 (1.00)	-3.1	0.33	1.00	1.33	3.6	
		Week 20	Tezepelumab	65	55 (84.6)	0.87 (0.94)	-1.8	0.25	0.75	1.50	3.3	-0.03 [-0.41, 0.35]
			Placebo	62	53 (85.5)	0.90 (0.84)	-1.1	0.42	0.83	1.50	3.3	
		Week 24	Tezepelumab	65	55 (84.6)	1.02 (0.93)	-1.6	0.33	0.92	1.58	3.3	0.14 [-0.24, 0.52]
			Placebo	62	53 (85.5)	0.89 (0.90)	-1.3	0.25	0.83	1.42	3.6	
		Week 28	Tezepelumab	65	55 (84.6)	0.97 (0.94)	-1.7	0.25	0.92	1.50	3.3	0.14 [-0.24, 0.52]
			Placebo	62	53 (85.5)	0.84 (0.89)	-1.8	0.25	0.83	1.25	3.2	
		Week 32	Tezepelumab	65	55 (84.6)	0.98 (0.95)	-1.6	0.33	0.92	1.58	3.3	0.03 [-0.35, 0.41]
			Placebo	62	53 (85.5)	0.95 (0.80)	-0.8	0.42	1.00	1.33	3.5	
		Week 36	Tezepelumab	65	55 (84.6)	1.05 (1.01)	-1.7	0.33	1.00	1.75	3.4	-0.01 [-0.38, 0.37]
			Placebo	62	53 (85.5)	1.05 (0.89)	-0.8	0.42	1.08	1.58	3.8	
		Week 40	Tezepelumab	65	55 (84.6)	0.92 (1.02)	-1.7	0.25	0.92	1.58	3.3	-0.14 [-0.52, 0.24]
			Placebo	62	53 (85.5)	1.06 (0.92)	-1.0	0.58	1.17	1.58	3.4	
		Week 44	Tezepelumab	65	55 (84.6)	0.91 (1.05)	-1.8	0.25	0.92	1.50	3.2	-0.10 [-0.48, 0.28]
			Placebo	62	53 (85.5)	1.01 (0.92)	-0.7	0.33	1.17	1.58	3.7	
		Week 48	Tezepelumab	65	55 (84.6)	0.97 (0.98)	-1.6	0.25	0.92	1.50	3.4	-0.13 [-0.51, 0.25]
			Placebo	62	53 (85.5)	1.10 (0.96)	-1.1	0.50	1.17	1.58	4.2	
		Week 52	Tezepelumab	65	55 (84.6)	0.96 (0.97)	-1.6	0.25	0.92	1.50	3.4	-0.07 [-0.45, 0.31]
			Placebo	62	53 (85.5)	1.03 (0.93)	-0.7	0.42	0.92	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	70	65 (92.9)	4.04 (1.13)	1.3	3.42	4.00	4.67	6.8	
			Placebo	75	67 (89.3)	3.94 (0.93)	1.5	3.42	3.92	4.50	6.3	
		Week 4	Tezepelumab	70	64 (91.4)	4.93 (1.02)	2.9	4.08	4.96	5.67	7.0	
			Placebo	75	67 (89.3)	4.52 (0.96)	2.4	3.83	4.50	5.25	6.7	
		Week 8	Tezepelumab	70	66 (94.3)	5.13 (1.15)	2.7	4.08	5.17	5.92	7.0	
			Placebo	75	69 (92.0)	4.57 (1.12)	1.9	3.83	4.42	5.33	7.0	
		Week 12	Tezepelumab	70	66 (94.3)	5.31 (1.13)	2.8	4.33	5.46	6.25	7.0	
			Placebo	75	69 (92.0)	4.79 (1.13)	2.1	3.92	4.92	5.75	7.0	
		Week 16	Tezepelumab	70	66 (94.3)	5.32 (1.14)	2.3	4.42	5.42	6.25	7.0	
			Placebo	75	69 (92.0)	4.79 (1.11)	2.1	4.08	4.58	5.58	7.0	
		Week 20	Tezepelumab	70	66 (94.3)	5.43 (1.06)	3.3	4.50	5.63	6.25	7.0	
			Placebo	75	69 (92.0)	4.79 (1.14)	2.1	4.17	4.58	5.67	7.0	
		Week 24	Tezepelumab	70	66 (94.3)	5.39 (1.12)	1.8	4.42	5.54	6.25	7.0	
			Placebo	75	69 (92.0)	4.85 (1.14)	2.8	4.00	4.67	5.75	7.0	
		Week 28	Tezepelumab	70	67 (95.7)	5.42 (1.07)	3.2	4.42	5.58	6.17	7.0	
			Placebo	75	69 (92.0)	4.92 (1.25)	2.8	3.92	4.92	5.92	7.0	
		Week 32	Tezepelumab	70	67 (95.7)	5.51 (1.10)	2.8	4.75	5.58	6.42	7.0	
			Placebo	75	70 (93.3)	4.95 (1.12)	2.8	4.00	5.00	5.83	7.0	
		Week 36	Tezepelumab	70	67 (95.7)	5.43 (1.10)	2.9	4.58	5.33	6.33	7.0	
			Placebo	75	70 (93.3)	4.90 (1.17)	2.4	4.00	4.83	5.92	7.0	
		Week 40	Tezepelumab	70	67 (95.7)	5.56 (1.04)	3.2	4.75	5.67	6.58	7.0	
			Placebo	75	70 (93.3)	4.92 (1.16)	2.3	4.00	4.75	5.92	7.0	
		Week 44	Tezepelumab	70	67 (95.7)	5.60 (1.01)	3.2	4.75	5.58	6.50	7.0	
			Placebo	75	70 (93.3)	4.89 (1.25)	2.5	4.00	4.63	5.92	7.0	
		Week 48	Tezepelumab	70	67 (95.7)	5.59 (1.07)	2.8	4.75	5.67	6.50	7.0	
			Placebo	75	70 (93.3)	4.88 (1.14)	2.2	4.00	4.75	5.75	7.0	
		Week 52	Tezepelumab	70	67 (95.7)	5.59 (1.03)	2.8	4.75	5.58	6.50	7.0	
			Placebo	75	70 (93.3)	4.90 (1.15)	2.8	4.00	4.75	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	70	60 (85.7)	0.95 (0.94)	-1.4	0.29	0.96	1.54	3.1	0.46 [0.11, 0.82]
			Placebo	75	66 (88.0)	0.54 (0.88)	-1.8	0.00	0.50	1.17	3.1	
		Week 8	Tezepelumab	70	62 (88.6)	1.09 (1.11)	-1.4	0.25	1.08	1.92	4.1	0.43 [0.08, 0.78]
			Placebo	75	66 (88.0)	0.63 (1.02)	-1.8	0.08	0.42	1.00	3.6	
		Week 12	Tezepelumab	70	62 (88.6)	1.26 (1.16)	-1.4	0.42	1.33	2.08	4.5	0.35 [0.00, 0.70]
			Placebo	75	66 (88.0)	0.84 (1.27)	-2.8	0.00	0.79	1.58	4.0	
		Week 16	Tezepelumab	70	62 (88.6)	1.27 (1.17)	-1.4	0.42	1.42	2.08	4.6	0.35 [0.00, 0.70]
			Placebo	75	66 (88.0)	0.85 (1.20)	-3.0	0.17	0.88	1.58	4.2	
		Week 20	Tezepelumab	70	62 (88.6)	1.39 (1.19)	-1.4	0.50	1.46	2.25	4.7	0.45 [0.10, 0.80]
			Placebo	75	66 (88.0)	0.86 (1.19)	-3.0	0.17	0.83	1.33	3.8	
		Week 24	Tezepelumab	70	62 (88.6)	1.36 (1.24)	-1.6	0.42	1.46	2.33	4.8	0.34 [-0.01, 0.69]
			Placebo	75	66 (88.0)	0.93 (1.26)	-3.0	0.00	0.83	1.58	4.1	
		Week 28	Tezepelumab	70	62 (88.6)	1.35 (1.22)	-1.4	0.42	1.38	2.17	4.9	0.27 [-0.08, 0.62]
			Placebo	75	66 (88.0)	1.00 (1.37)	-3.0	0.17	0.83	1.67	4.7	
		Week 32	Tezepelumab	70	62 (88.6)	1.46 (1.29)	-1.4	0.50	1.42	2.42	4.8	0.31 [-0.04, 0.66]
			Placebo	75	66 (88.0)	1.06 (1.22)	-3.0	0.25	1.00	1.67	4.0	
		Week 36	Tezepelumab	70	62 (88.6)	1.36 (1.33)	-1.4	0.17	1.42	2.33	4.8	0.29 [-0.06, 0.64]
			Placebo	75	66 (88.0)	0.99 (1.27)	-3.0	0.08	0.96	1.75	3.8	
		Week 40	Tezepelumab	70	62 (88.6)	1.50 (1.18)	-1.4	0.58	1.63	2.33	4.8	0.39 [0.04, 0.74]
			Placebo	75	66 (88.0)	1.02 (1.31)	-3.0	0.25	0.83	1.67	4.7	
		Week 44	Tezepelumab	70	62 (88.6)	1.55 (1.15)	-1.4	0.83	1.58	2.33	4.8	0.45 [0.10, 0.80]
			Placebo	75	66 (88.0)	0.98 (1.36)	-3.0	0.25	0.88	1.67	4.3	
		Week 48	Tezepelumab	70	62 (88.6)	1.54 (1.18)	-1.4	0.58	1.63	2.42	4.8	0.47 [0.12, 0.82]
			Placebo	75	66 (88.0)	0.97 (1.24)	-3.0	0.17	0.83	1.67	3.8	
		Week 52	Tezepelumab	70	62 (88.6)	1.53 (1.19)	-1.4	0.58	1.58	2.50	4.8	0.44 [0.09, 0.79]
			Placebo	75	66 (88.0)	1.00 (1.24)	-3.0	0.17	0.83	1.67	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	50	43 (86.0)	3.93 (0.79)	2.0	3.58	4.08	4.33	6.3	
			Placebo	50	40 (80.0)	3.97 (1.05)	1.7	3.38	4.00	4.54	6.3	
		Week 4	Tezepelumab	50	48 (96.0)	4.76 (0.92)	2.6	4.08	4.58	5.50	6.8	
			Placebo	50	41 (82.0)	4.36 (1.15)	1.8	3.58	4.50	5.17	6.5	
		Week 8	Tezepelumab	50	48 (96.0)	4.98 (1.02)	2.0	4.33	4.96	5.63	7.0	
			Placebo	50	44 (88.0)	4.50 (1.08)	2.1	3.92	4.38	5.33	6.7	
		Week 12	Tezepelumab	50	48 (96.0)	5.21 (1.02)	3.2	4.38	5.13	5.71	7.0	
			Placebo	50	44 (88.0)	4.42 (1.08)	2.1	3.83	4.25	5.13	6.8	
		Week 16	Tezepelumab	50	48 (96.0)	5.18 (1.06)	3.4	4.33	5.17	5.92	7.0	
			Placebo	50	44 (88.0)	4.49 (1.22)	1.3	3.83	4.29	5.50	7.0	
		Week 20	Tezepelumab	50	48 (96.0)	5.10 (1.05)	3.4	4.17	5.08	5.83	7.0	
			Placebo	50	44 (88.0)	4.53 (1.27)	1.3	3.96	4.38	5.29	6.8	
		Week 24	Tezepelumab	50	48 (96.0)	5.10 (1.13)	1.8	4.29	5.04	6.00	7.0	
			Placebo	50	44 (88.0)	4.43 (1.28)	1.3	3.83	4.25	5.29	6.8	
		Week 28	Tezepelumab	50	49 (98.0)	5.13 (1.02)	3.3	4.42	5.00	5.75	7.0	
			Placebo	50	44 (88.0)	4.43 (1.25)	1.3	3.92	4.08	5.42	6.6	
		Week 32	Tezepelumab	50	49 (98.0)	5.13 (1.00)	3.5	4.33	5.08	5.83	7.0	
			Placebo	50	45 (90.0)	4.44 (1.27)	1.3	3.75	4.25	5.58	6.7	
		Week 36	Tezepelumab	50	49 (98.0)	5.12 (1.05)	3.2	4.25	5.00	5.83	7.0	
			Placebo	50	45 (90.0)	4.56 (1.23)	2.4	4.00	4.33	5.58	6.8	
		Week 40	Tezepelumab	50	49 (98.0)	5.17 (1.04)	2.9	4.42	5.17	5.92	7.0	
			Placebo	50	45 (90.0)	4.57 (1.17)	2.3	3.75	4.42	5.50	6.6	
		Week 44	Tezepelumab	50	49 (98.0)	5.10 (1.11)	2.3	4.17	5.08	5.83	7.0	
			Placebo	50	45 (90.0)	4.51 (1.17)	2.3	3.92	4.33	5.50	6.8	
		Week 48	Tezepelumab	50	49 (98.0)	5.16 (1.07)	3.1	4.42	5.17	5.83	7.0	
			Placebo	50	46 (92.0)	4.55 (1.15)	2.2	3.75	4.42	5.33	6.7	
		Week 52	Tezepelumab	50	49 (98.0)	5.18 (1.07)	3.1	4.50	5.17	6.00	7.0	
			Placebo	50	46 (92.0)	4.52 (1.13)	2.5	3.67	4.33	5.50	6.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	50	42 (84.0)	0.92 (0.78)	-0.8	0.33	0.83	1.50	2.8	0.56 [0.11, 1.00]
			Placebo	50	39 (78.0)	0.47 (0.85)	-1.8	0.17	0.50	1.00	2.4	
		Week 8	Tezepelumab	50	42 (84.0)	1.03 (1.05)	-1.9	0.33	1.04	1.83	3.0	0.46 [0.02, 0.90]
			Placebo	50	40 (80.0)	0.59 (0.85)	-1.8	0.17	0.50	1.17	2.6	
		Week 12	Tezepelumab	50	42 (84.0)	1.26 (1.04)	-0.8	0.42	1.21	2.17	3.3	0.72 [0.27, 1.16]
			Placebo	50	40 (80.0)	0.50 (1.09)	-2.8	-0.08	0.67	1.13	3.2	
		Week 16	Tezepelumab	50	42 (84.0)	1.23 (1.08)	-0.9	0.42	1.29	2.17	3.4	0.59 [0.15, 1.03]
			Placebo	50	40 (80.0)	0.57 (1.17)	-3.5	0.08	0.88	1.33	2.4	
		Week 20	Tezepelumab	50	42 (84.0)	1.17 (0.99)	-0.8	0.42	1.04	2.00	3.3	0.50 [0.06, 0.94]
			Placebo	50	40 (80.0)	0.62 (1.22)	-3.5	0.25	0.88	1.29	2.5	
		Week 24	Tezepelumab	50	42 (84.0)	1.20 (1.09)	-1.6	0.50	1.08	2.33	3.3	0.58 [0.14, 1.02]
			Placebo	50	40 (80.0)	0.51 (1.29)	-3.5	-0.08	0.83	1.29	3.0	
		Week 28	Tezepelumab	50	42 (84.0)	1.23 (0.98)	-0.8	0.50	1.00	2.08	3.3	0.64 [0.19, 1.08]
			Placebo	50	40 (80.0)	0.49 (1.31)	-3.5	-0.04	0.71	1.21	3.2	
		Week 32	Tezepelumab	50	42 (84.0)	1.27 (1.03)	-0.8	0.67	1.17	1.92	3.3	0.65 [0.20, 1.09]
			Placebo	50	40 (80.0)	0.56 (1.17)	-3.5	0.17	0.92	1.17	2.6	
		Week 36	Tezepelumab	50	42 (84.0)	1.23 (1.12)	-0.9	0.50	1.33	2.00	3.8	0.51 [0.07, 0.95]
			Placebo	50	40 (80.0)	0.65 (1.16)	-3.0	0.08	0.88	1.29	3.2	
		Week 40	Tezepelumab	50	42 (84.0)	1.30 (1.04)	-0.8	0.58	1.13	2.08	3.3	0.55 [0.11, 0.99]
			Placebo	50	40 (80.0)	0.68 (1.19)	-3.0	0.17	0.75	1.42	3.1	
		Week 44	Tezepelumab	50	42 (84.0)	1.23 (1.11)	-1.8	0.58	1.38	2.00	3.3	0.57 [0.13, 1.02]
			Placebo	50	40 (80.0)	0.59 (1.12)	-3.0	0.17	0.88	1.25	3.1	
		Week 48	Tezepelumab	50	42 (84.0)	1.34 (1.04)	-0.8	0.75	1.38	2.08	3.4	0.65 [0.20, 1.09]
			Placebo	50	40 (80.0)	0.62 (1.18)	-3.0	-0.04	0.79	1.29	3.4	
		Week 52	Tezepelumab	50	42 (84.0)	1.34 (1.04)	-0.8	0.75	1.33	2.08	3.4	0.69 [0.24, 1.13]
			Placebo	50	40 (80.0)	0.60 (1.10)	-3.0	0.04	0.63	1.17	3.4	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	77	72 (93.5)	4.16 (1.11)	1.3	3.50	4.04	4.83	6.8	
			Placebo	80	73 (91.3)	3.98 (0.84)	1.5	3.50	4.00	4.58	5.9	
		Week 4	Tezepelumab	77	69 (89.6)	4.90 (1.18)	1.3	4.00	4.92	5.67	7.0	
			Placebo	80	74 (92.5)	4.63 (0.85)	2.4	4.08	4.58	5.25	6.7	
		Week 8	Tezepelumab	77	71 (92.2)	5.12 (1.15)	2.8	4.08	5.17	6.08	7.0	
			Placebo	80	74 (92.5)	4.70 (1.02)	1.9	4.08	4.58	5.42	7.0	
		Week 12	Tezepelumab	77	71 (92.2)	5.22 (1.13)	2.8	4.25	5.25	6.25	7.0	
			Placebo	80	75 (93.8)	4.91 (1.05)	2.5	4.17	4.92	5.67	7.0	
		Week 16	Tezepelumab	77	71 (92.2)	5.20 (1.16)	2.3	4.33	5.33	6.08	7.0	
			Placebo	80	75 (93.8)	4.88 (1.05)	2.1	4.17	4.83	5.58	7.0	
		Week 20	Tezepelumab	77	71 (92.2)	5.29 (1.11)	2.3	4.42	5.42	6.08	7.0	
			Placebo	80	75 (93.8)	4.88 (0.99)	2.1	4.17	4.75	5.58	7.0	
		Week 24	Tezepelumab	77	71 (92.2)	5.33 (1.05)	3.1	4.42	5.25	6.08	7.0	
			Placebo	80	75 (93.8)	4.96 (1.00)	3.0	4.08	4.92	5.75	7.0	
		Week 28	Tezepelumab	77	72 (93.5)	5.28 (1.10)	3.2	4.42	5.29	6.13	7.0	
			Placebo	80	76 (95.0)	5.08 (1.11)	3.0	4.17	5.08	5.96	7.0	
		Week 32	Tezepelumab	77	73 (94.8)	5.39 (1.13)	2.8	4.67	5.50	6.25	7.0	
			Placebo	80	76 (95.0)	5.14 (0.96)	3.2	4.38	5.13	5.96	7.0	
		Week 36	Tezepelumab	77	73 (94.8)	5.37 (1.11)	2.9	4.50	5.25	6.08	7.0	
			Placebo	80	76 (95.0)	5.09 (1.05)	3.2	4.17	5.13	6.00	7.0	
		Week 40	Tezepelumab	77	73 (94.8)	5.37 (1.15)	2.3	4.50	5.58	6.33	7.0	
			Placebo	80	76 (95.0)	5.14 (1.03)	3.2	4.29	5.17	5.96	7.0	
		Week 44	Tezepelumab	77	73 (94.8)	5.43 (1.10)	3.1	4.50	5.50	6.50	7.0	
			Placebo	80	76 (95.0)	5.11 (1.12)	3.1	4.13	5.08	6.04	7.0	
		Week 48	Tezepelumab	77	73 (94.8)	5.41 (1.13)	2.8	4.50	5.50	6.33	7.0	
			Placebo	80	76 (95.0)	5.16 (1.01)	3.2	4.21	5.17	5.92	7.0	
		Week 52	Tezepelumab	77	73 (94.8)	5.40 (1.11)	2.8	4.50	5.42	6.25	7.0	
			Placebo	80	76 (95.0)	5.16 (1.04)	3.1	4.25	5.17	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	77	67 (87.0)	0.72 (1.09)	-4.3	0.08	0.58	1.50	3.1	0.11 [-0.22, 0.44]
			Placebo	80	72 (90.0)	0.61 (0.88)	-1.3	0.08	0.50	1.25	3.3	
		Week 8	Tezepelumab	77	69 (89.6)	0.94 (0.99)	-1.4	0.25	0.92	1.67	3.0	0.23 [-0.10, 0.56]
			Placebo	80	72 (90.0)	0.71 (0.97)	-1.0	0.08	0.63	1.17	3.6	
		Week 12	Tezepelumab	77	69 (89.6)	1.04 (1.05)	-2.6	0.33	0.92	1.83	3.0	0.12 [-0.21, 0.45]
			Placebo	80	72 (90.0)	0.91 (1.23)	-3.1	0.33	0.83	1.42	4.0	
		Week 16	Tezepelumab	77	69 (89.6)	1.02 (1.04)	-2.9	0.42	1.00	1.75	3.0	0.12 [-0.21, 0.45]
			Placebo	80	72 (90.0)	0.89 (1.20)	-3.1	0.17	0.83	1.58	4.2	
		Week 20	Tezepelumab	77	69 (89.6)	1.12 (1.09)	-1.8	0.33	1.00	1.92	4.7	0.20 [-0.13, 0.53]
			Placebo	80	72 (90.0)	0.90 (1.03)	-1.3	0.17	0.83	1.29	3.8	
		Week 24	Tezepelumab	77	69 (89.6)	1.16 (1.07)	-1.6	0.42	1.08	2.00	3.7	0.16 [-0.17, 0.49]
			Placebo	80	72 (90.0)	0.99 (1.06)	-0.7	0.21	0.83	1.50	4.1	
		Week 28	Tezepelumab	77	69 (89.6)	1.09 (1.12)	-1.7	0.33	1.00	2.00	4.9	-0.00 [-0.33, 0.33]
			Placebo	80	72 (90.0)	1.09 (1.17)	-0.7	0.21	0.88	1.67	4.7	
		Week 32	Tezepelumab	77	69 (89.6)	1.17 (1.15)	-1.6	0.33	1.00	2.08	4.6	0.01 [-0.32, 0.34]
			Placebo	80	72 (90.0)	1.16 (1.04)	-0.8	0.42	1.00	1.67	4.0	
		Week 36	Tezepelumab	77	69 (89.6)	1.15 (1.17)	-1.7	0.25	1.00	2.08	3.3	0.03 [-0.30, 0.36]
			Placebo	80	72 (90.0)	1.12 (1.10)	-1.3	0.25	1.08	1.79	3.8	
		Week 40	Tezepelumab	77	69 (89.6)	1.14 (1.13)	-1.7	0.33	1.00	2.08	3.4	-0.01 [-0.34, 0.32]
			Placebo	80	72 (90.0)	1.16 (1.12)	-0.7	0.50	1.08	1.67	4.7	
		Week 44	Tezepelumab	77	69 (89.6)	1.21 (1.10)	-1.6	0.42	1.17	2.17	3.3	0.08 [-0.25, 0.41]
			Placebo	80	72 (90.0)	1.13 (1.17)	-1.3	0.25	1.08	1.79	4.3	
		Week 48	Tezepelumab	77	69 (89.6)	1.20 (1.12)	-1.6	0.42	1.08	2.08	3.2	0.03 [-0.30, 0.36]
			Placebo	80	72 (90.0)	1.17 (1.05)	-0.7	0.42	1.17	1.67	4.2	
		Week 52	Tezepelumab	77	69 (89.6)	1.18 (1.12)	-1.6	0.33	1.00	2.17	3.6	0.01 [-0.32, 0.34]
			Placebo	80	72 (90.0)	1.17 (1.09)	-0.7	0.42	1.00	1.71	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	70	64 (91.4)	4.08 (0.90)	1.3	3.71	4.13	4.50	6.7	
			Placebo	62	53 (85.5)	4.01 (0.99)	1.5	3.42	4.08	4.67	6.3	
		Week 4	Tezepelumab	70	65 (92.9)	4.86 (0.90)	3.5	4.08	4.75	5.58	6.9	
			Placebo	62	53 (85.5)	4.47 (1.06)	1.8	3.75	4.67	5.25	6.4	
		Week 8	Tezepelumab	70	66 (94.3)	5.02 (1.10)	2.0	4.08	4.92	5.83	7.0	
			Placebo	62	56 (90.3)	4.59 (1.15)	1.9	3.92	4.67	5.33	6.5	
		Week 12	Tezepelumab	70	66 (94.3)	5.28 (1.02)	3.6	4.42	5.25	6.17	7.0	
			Placebo	62	56 (90.3)	4.67 (1.09)	2.1	4.00	4.58	5.42	6.9	
		Week 16	Tezepelumab	70	66 (94.3)	5.23 (1.08)	2.3	4.33	5.21	6.00	7.0	
			Placebo	62	56 (90.3)	4.73 (1.25)	1.3	4.00	4.58	5.83	7.0	
		Week 20	Tezepelumab	70	67 (95.7)	5.21 (1.03)	3.6	4.33	5.08	6.00	7.0	
			Placebo	62	56 (90.3)	4.77 (1.28)	1.3	4.00	4.71	5.75	7.0	
		Week 24	Tezepelumab	70	67 (95.7)	5.26 (1.01)	3.6	4.33	5.08	6.00	7.0	
			Placebo	62	56 (90.3)	4.70 (1.31)	1.3	4.00	4.58	5.38	7.0	
		Week 28	Tezepelumab	70	68 (97.1)	5.23 (1.06)	3.3	4.38	5.08	6.08	7.0	
			Placebo	62	56 (90.3)	4.62 (1.30)	1.3	3.96	4.38	5.50	7.0	
		Week 32	Tezepelumab	70	68 (97.1)	5.25 (1.03)	2.8	4.42	5.13	6.00	7.0	
			Placebo	62	57 (91.9)	4.74 (1.26)	1.3	4.00	4.75	5.67	7.0	
		Week 36	Tezepelumab	70	68 (97.1)	5.26 (1.10)	3.2	4.42	5.17	6.13	7.0	
			Placebo	62	57 (91.9)	4.86 (1.24)	2.4	4.00	4.58	5.92	7.0	
		Week 40	Tezepelumab	70	68 (97.1)	5.21 (1.06)	2.9	4.42	5.13	5.92	7.0	
			Placebo	62	57 (91.9)	4.81 (1.23)	2.3	3.92	4.67	5.92	7.0	
		Week 44	Tezepelumab	70	68 (97.1)	5.23 (1.09)	3.0	4.29	5.17	6.00	7.0	
			Placebo	62	57 (91.9)	4.79 (1.26)	2.5	4.00	4.58	5.92	7.0	
		Week 48	Tezepelumab	70	68 (97.1)	5.27 (1.14)	2.8	4.42	5.17	6.29	7.0	
			Placebo	62	57 (91.9)	4.71 (1.22)	2.2	3.83	4.50	5.67	7.0	
		Week 52	Tezepelumab	70	68 (97.1)	5.27 (1.11)	2.8	4.50	5.17	6.21	7.0	
			Placebo	62	57 (91.9)	4.69 (1.16)	2.8	4.00	4.50	5.50	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	70	61 (87.1)	0.89 (0.89)	-1.4	0.33	0.83	1.50	3.1	0.45 [0.08, 0.83]
			Placebo	62	52 (83.9)	0.50 (0.83)	-1.8	0.13	0.50	1.00	2.3	
		Week 8	Tezepelumab	70	62 (88.6)	0.91 (1.06)	-1.9	0.25	0.92	1.67	3.3	0.30 [-0.07, 0.67]
			Placebo	62	53 (85.5)	0.61 (0.94)	-1.8	0.00	0.58	1.17	2.7	
		Week 12	Tezepelumab	70	62 (88.6)	1.17 (1.03)	-1.4	0.42	1.08	2.00	3.7	0.42 [0.05, 0.79]
			Placebo	62	53 (85.5)	0.69 (1.25)	-3.1	0.00	0.83	1.33	4.0	
		Week 16	Tezepelumab	70	62 (88.6)	1.12 (0.97)	-1.4	0.42	1.08	1.75	3.3	0.32 [-0.05, 0.68]
			Placebo	62	53 (85.5)	0.76 (1.34)	-3.5	0.42	1.00	1.42	4.2	
		Week 20	Tezepelumab	70	62 (88.6)	1.14 (1.08)	-1.4	0.33	0.92	2.00	4.7	0.30 [-0.07, 0.67]
			Placebo	62	53 (85.5)	0.79 (1.24)	-3.5	0.17	0.92	1.33	3.4	
		Week 24	Tezepelumab	70	62 (88.6)	1.20 (1.02)	-1.4	0.42	1.00	2.00	3.7	0.40 [0.03, 0.77]
			Placebo	62	53 (85.5)	0.73 (1.33)	-3.5	0.08	0.83	1.42	3.4	
		Week 28	Tezepelumab	70	62 (88.6)	1.18 (1.07)	-1.4	0.50	0.92	2.00	4.9	0.45 [0.08, 0.82]
			Placebo	62	53 (85.5)	0.64 (1.37)	-3.5	0.00	0.58	1.33	4.3	
		Week 32	Tezepelumab	70	62 (88.6)	1.20 (1.12)	-1.4	0.50	1.08	1.92	4.6	0.34 [-0.03, 0.71]
			Placebo	62	53 (85.5)	0.80 (1.23)	-3.5	0.25	1.00	1.33	3.4	
		Week 36	Tezepelumab	70	62 (88.6)	1.20 (1.15)	-1.4	0.33	1.04	2.08	3.8	0.26 [-0.11, 0.63]
			Placebo	62	53 (85.5)	0.89 (1.21)	-3.0	0.25	1.08	1.58	3.4	
		Week 40	Tezepelumab	70	62 (88.6)	1.17 (1.01)	-1.4	0.42	1.00	1.92	3.3	0.26 [-0.10, 0.63]
			Placebo	62	53 (85.5)	0.87 (1.26)	-3.0	0.08	1.00	1.58	4.0	
		Week 44	Tezepelumab	70	62 (88.6)	1.18 (1.05)	-1.4	0.50	1.08	2.08	3.2	0.31 [-0.06, 0.68]
			Placebo	62	53 (85.5)	0.82 (1.30)	-3.0	0.08	0.92	1.50	3.5	
		Week 48	Tezepelumab	70	62 (88.6)	1.24 (1.11)	-1.4	0.33	1.04	2.17	3.4	0.42 [0.05, 0.79]
			Placebo	62	53 (85.5)	0.76 (1.19)	-3.0	0.08	0.67	1.50	3.5	
		Week 52	Tezepelumab	70	62 (88.6)	1.24 (1.10)	-1.4	0.42	1.00	2.17	3.4	0.45 [0.08, 0.82]
			Placebo	62	53 (85.5)	0.74 (1.13)	-3.0	0.08	0.67	1.25	3.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	65	58 (89.2)	4.02 (1.12)	1.4	3.33	4.00	4.75	6.8	
			Placebo	75	67 (89.3)	3.95 (0.84)	1.8	3.33	4.00	4.50	5.8	
		Week 4	Tezepelumab	65	59 (90.8)	4.85 (1.22)	1.3	3.92	4.92	5.75	7.0	
			Placebo	75	69 (92.0)	4.57 (0.84)	2.3	4.00	4.50	5.17	6.7	
		Week 8	Tezepelumab	65	60 (92.3)	5.13 (1.06)	3.0	4.25	5.13	5.83	7.0	
			Placebo	75	69 (92.0)	4.62 (0.94)	2.3	4.08	4.50	5.25	7.0	
		Week 12	Tezepelumab	65	60 (92.3)	5.21 (1.12)	2.8	4.25	5.21	6.08	7.0	
			Placebo	75	70 (93.3)	4.79 (1.05)	2.4	4.00	4.75	5.67	7.0	
		Week 16	Tezepelumab	65	60 (92.3)	5.21 (1.12)	2.7	4.33	5.33	6.04	7.0	
			Placebo	75	70 (93.3)	4.78 (1.00)	2.1	4.17	4.75	5.50	7.0	
		Week 20	Tezepelumab	65	60 (92.3)	5.24 (1.10)	2.3	4.38	5.33	6.00	7.0	
			Placebo	75	70 (93.3)	4.78 (0.98)	2.1	4.17	4.71	5.33	7.0	
		Week 24	Tezepelumab	65	60 (92.3)	5.24 (1.14)	1.8	4.42	5.21	6.00	7.0	
			Placebo	75	70 (93.3)	4.89 (0.99)	2.9	4.00	4.83	5.75	7.0	
		Week 28	Tezepelumab	65	61 (93.8)	5.22 (1.07)	3.2	4.42	5.08	6.00	7.0	
			Placebo	75	71 (94.7)	5.01 (1.10)	2.9	4.08	5.08	5.92	7.0	
		Week 32	Tezepelumab	65	62 (95.4)	5.35 (1.12)	2.8	4.42	5.54	6.08	7.0	
			Placebo	75	71 (94.7)	5.02 (1.01)	2.4	4.08	5.00	5.83	7.0	
		Week 36	Tezepelumab	65	62 (95.4)	5.34 (1.06)	2.9	4.50	5.29	6.08	7.0	
			Placebo	75	71 (94.7)	4.98 (1.10)	2.5	4.00	5.08	6.00	7.0	
		Week 40	Tezepelumab	65	62 (95.4)	5.36 (1.13)	2.3	4.42	5.54	6.17	7.0	
			Placebo	75	71 (94.7)	5.06 (1.02)	2.4	4.17	5.08	5.83	7.0	
		Week 44	Tezepelumab	65	62 (95.4)	5.39 (1.10)	2.3	4.58	5.46	6.25	7.0	
			Placebo	75	71 (94.7)	5.02 (1.10)	2.3	4.08	5.08	6.00	7.0	
		Week 48	Tezepelumab	65	62 (95.4)	5.37 (1.04)	3.3	4.50	5.38	6.17	7.0	
			Placebo	75	72 (96.0)	5.14 (0.99)	2.9	4.21	5.17	5.88	7.0	
		Week 52	Tezepelumab	65	62 (95.4)	5.38 (1.06)	3.0	4.50	5.42	6.17	7.0	
			Placebo	75	72 (96.0)	5.12 (1.05)	2.5	4.13	5.21	5.88	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	65	55 (84.6)	0.75 (1.15)	-4.3	-0.08	0.83	1.50	2.9	0.15 [-0.21, 0.51]
			Placebo	75	66 (88.0)	0.61 (0.85)	-1.3	0.08	0.50	1.17	3.3	
		Week 8	Tezepelumab	65	56 (86.2)	1.10 (1.07)	-1.4	0.25	1.08	1.92	4.1	0.43 [0.07, 0.79]
			Placebo	75	66 (88.0)	0.67 (0.92)	-1.0	0.17	0.46	1.17	3.6	
		Week 12	Tezepelumab	65	56 (86.2)	1.16 (1.18)	-2.6	0.38	1.08	1.96	4.5	0.29 [-0.07, 0.65]
			Placebo	75	66 (88.0)	0.84 (1.10)	-1.2	0.17	0.71	1.17	3.8	
		Week 16	Tezepelumab	65	56 (86.2)	1.20 (1.23)	-2.9	0.42	1.08	2.08	4.6	0.33 [-0.03, 0.69]
			Placebo	75	66 (88.0)	0.83 (1.03)	-1.3	0.17	0.67	1.42	3.7	
		Week 20	Tezepelumab	65	56 (86.2)	1.20 (1.12)	-1.8	0.38	1.13	1.92	4.6	0.33 [-0.03, 0.69]
			Placebo	75	66 (88.0)	0.85 (1.00)	-1.3	0.25	0.75	1.25	3.8	
		Week 24	Tezepelumab	65	56 (86.2)	1.24 (1.20)	-1.6	0.46	1.21	2.13	4.8	0.24 [-0.12, 0.60]
			Placebo	75	66 (88.0)	0.98 (1.04)	-0.7	0.25	0.83	1.42	4.1	
		Week 28	Tezepelumab	65	56 (86.2)	1.16 (1.16)	-1.7	0.29	1.00	2.04	4.8	0.08 [-0.28, 0.43]
			Placebo	75	66 (88.0)	1.07 (1.10)	-0.7	0.25	0.88	1.67	4.7	
		Week 32	Tezepelumab	65	56 (86.2)	1.27 (1.22)	-1.6	0.38	1.13	2.21	4.8	0.16 [-0.20, 0.52]
			Placebo	75	66 (88.0)	1.10 (1.02)	-0.8	0.33	1.00	1.58	4.0	
		Week 36	Tezepelumab	65	56 (86.2)	1.23 (1.25)	-1.7	0.08	1.13	2.13	4.8	0.15 [-0.20, 0.51]
			Placebo	75	66 (88.0)	1.05 (1.09)	-1.3	0.25	0.92	1.67	3.8	
		Week 40	Tezepelumab	65	56 (86.2)	1.28 (1.26)	-1.7	0.33	1.17	2.21	4.8	0.14 [-0.22, 0.50]
			Placebo	75	66 (88.0)	1.12 (1.07)	-0.7	0.50	0.88	1.67	4.7	
		Week 44	Tezepelumab	65	56 (86.2)	1.31 (1.24)	-1.8	0.46	1.21	2.08	4.8	0.20 [-0.16, 0.56]
			Placebo	75	66 (88.0)	1.08 (1.08)	-1.3	0.33	1.04	1.67	4.3	
		Week 48	Tezepelumab	65	56 (86.2)	1.32 (1.14)	-1.6	0.54	1.21	1.96	4.8	0.11 [-0.25, 0.47]
			Placebo	75	66 (88.0)	1.20 (1.04)	-0.7	0.50	1.08	1.67	4.2	
		Week 52	Tezepelumab	65	56 (86.2)	1.28 (1.15)	-1.6	0.42	1.13	1.92	4.8	0.09 [-0.26, 0.45]
			Placebo	75	66 (88.0)	1.18 (1.08)	-0.7	0.58	0.96	1.67	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	62	57 (91.9)	3.94 (0.84)	1.9	3.50	4.00	4.67	5.6	
			Placebo	67	57 (85.1)	4.01 (0.88)	1.7	3.50	4.08	4.50	5.9	
		Week 4	Tezepelumab	62	56 (90.3)	4.51 (1.07)	1.3	3.75	4.54	5.08	6.6	
			Placebo	67	58 (86.6)	4.52 (1.01)	1.8	3.92	4.63	5.17	6.7	
		Week 8	Tezepelumab	62	56 (90.3)	4.71 (1.02)	2.0	4.00	4.58	5.54	6.7	
			Placebo	67	60 (89.6)	4.67 (1.05)	2.1	4.04	4.50	5.46	6.8	
		Week 12	Tezepelumab	62	56 (90.3)	4.93 (1.03)	2.8	4.17	4.75	5.63	7.0	
			Placebo	67	61 (91.0)	4.73 (1.21)	2.1	3.83	4.67	5.67	6.9	
		Week 16	Tezepelumab	62	56 (90.3)	4.86 (1.04)	2.7	4.08	4.71	5.50	7.0	
			Placebo	67	61 (91.0)	4.74 (1.23)	1.3	4.00	4.92	5.50	7.0	
		Week 20	Tezepelumab	62	57 (91.9)	4.85 (1.00)	2.3	4.08	4.58	5.42	7.0	
			Placebo	67	61 (91.0)	4.76 (1.14)	1.3	4.17	4.67	5.75	7.0	
		Week 24	Tezepelumab	62	57 (91.9)	4.97 (0.96)	3.1	4.17	4.75	5.67	7.0	
			Placebo	67	61 (91.0)	4.83 (1.17)	1.3	4.08	4.67	5.75	7.0	
		Week 28	Tezepelumab	62	59 (95.2)	4.89 (0.99)	3.2	4.17	4.58	5.58	7.0	
			Placebo	67	62 (92.5)	4.90 (1.24)	1.3	4.00	4.88	6.00	7.0	
		Week 32	Tezepelumab	62	59 (95.2)	4.96 (1.03)	2.8	4.17	4.83	5.83	7.0	
			Placebo	67	63 (94.0)	4.88 (1.22)	1.3	4.00	4.83	6.00	6.9	
		Week 36	Tezepelumab	62	59 (95.2)	5.03 (1.06)	2.9	4.17	5.00	5.92	7.0	
			Placebo	67	63 (94.0)	5.01 (1.18)	2.4	4.00	5.08	6.00	7.0	
		Week 40	Tezepelumab	62	59 (95.2)	4.94 (1.06)	2.3	4.08	4.92	5.67	7.0	
			Placebo	67	63 (94.0)	5.01 (1.16)	2.3	4.00	5.08	6.00	7.0	
		Week 44	Tezepelumab	62	59 (95.2)	4.95 (1.08)	2.3	4.17	4.75	5.75	7.0	
			Placebo	67	63 (94.0)	5.05 (1.20)	2.5	4.08	5.08	6.08	7.0	
		Week 48	Tezepelumab	62	59 (95.2)	5.04 (1.03)	3.1	4.17	5.08	5.83	7.0	
			Placebo	67	64 (95.5)	5.04 (1.18)	2.2	4.00	5.08	6.00	7.0	
		Week 52	Tezepelumab	62	59 (95.2)	5.02 (1.04)	3.0	4.17	5.00	5.83	7.0	
			Placebo	67	64 (95.5)	5.04 (1.21)	2.8	4.00	5.00	6.04	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	62	55 (88.7)	0.59 (1.05)	-4.3	-0.08	0.50	1.33	2.9	0.02 [-0.35, 0.39]
			Placebo	67	56 (83.6)	0.57 (0.90)	-1.8	0.08	0.50	1.21	3.3	
		Week 8	Tezepelumab	62	55 (88.7)	0.77 (1.03)	-1.9	0.17	0.75	1.25	4.1	0.07 [-0.30, 0.44]
			Placebo	67	57 (85.1)	0.70 (0.93)	-1.0	0.25	0.58	1.17	3.3	
		Week 12	Tezepelumab	62	55 (88.7)	1.00 (1.12)	-2.6	0.33	0.92	1.75	4.5	0.17 [-0.20, 0.54]
			Placebo	67	57 (85.1)	0.79 (1.31)	-3.1	-0.08	0.92	1.25	4.0	
		Week 16	Tezepelumab	62	55 (88.7)	0.93 (1.06)	-2.9	0.42	0.75	1.42	4.6	0.12 [-0.25, 0.49]
			Placebo	67	57 (85.1)	0.79 (1.33)	-3.5	0.17	0.92	1.50	4.2	
		Week 20	Tezepelumab	62	55 (88.7)	0.91 (1.02)	-1.8	0.17	0.75	1.50	4.6	0.09 [-0.28, 0.46]
			Placebo	67	57 (85.1)	0.82 (1.06)	-3.5	0.25	0.83	1.42	3.3	
		Week 24	Tezepelumab	62	55 (88.7)	1.04 (1.04)	-1.6	0.33	0.92	1.58	4.8	0.14 [-0.23, 0.51]
			Placebo	67	57 (85.1)	0.89 (1.15)	-3.5	0.17	0.83	1.50	3.6	
		Week 28	Tezepelumab	62	55 (88.7)	0.96 (1.04)	-1.7	0.25	0.83	1.50	4.8	0.03 [-0.34, 0.40]
			Placebo	67	57 (85.1)	0.92 (1.26)	-3.5	0.25	0.75	1.58	4.3	
		Week 32	Tezepelumab	62	55 (88.7)	1.00 (1.11)	-1.6	0.33	0.92	1.58	4.8	0.05 [-0.32, 0.42]
			Placebo	67	57 (85.1)	0.94 (1.17)	-3.5	0.25	0.92	1.67	3.5	
		Week 36	Tezepelumab	62	55 (88.7)	1.07 (1.13)	-1.7	0.08	1.00	1.58	4.8	0.01 [-0.36, 0.38]
			Placebo	67	57 (85.1)	1.05 (1.16)	-2.3	0.25	1.00	1.67	3.8	
		Week 40	Tezepelumab	62	55 (88.7)	1.01 (1.11)	-1.7	0.25	1.00	1.50	4.8	-0.06 [-0.43, 0.31]
			Placebo	67	57 (85.1)	1.07 (1.15)	-1.4	0.33	1.00	1.75	4.0	
		Week 44	Tezepelumab	62	55 (88.7)	1.00 (1.14)	-1.8	0.25	1.08	1.50	4.8	-0.08 [-0.45, 0.29]
			Placebo	67	57 (85.1)	1.09 (1.21)	-1.4	0.17	1.17	1.83	3.8	
		Week 48	Tezepelumab	62	55 (88.7)	1.10 (1.06)	-1.6	0.42	1.00	1.50	4.8	0.01 [-0.36, 0.38]
			Placebo	67	57 (85.1)	1.08 (1.14)	-1.5	0.33	1.17	1.58	4.2	
		Week 52	Tezepelumab	62	55 (88.7)	1.06 (1.05)	-1.6	0.42	0.92	1.50	4.8	-0.03 [-0.40, 0.34]
			Placebo	67	57 (85.1)	1.10 (1.18)	-1.1	0.25	1.00	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	74	65 (87.8)	4.13 (1.13)	1.3	3.58	4.00	4.67	6.8	
			Placebo	71	64 (90.1)	3.95 (0.93)	1.5	3.38	4.00	4.58	6.3	
		Week 4	Tezepelumab	74	69 (93.2)	5.12 (0.98)	3.3	4.42	5.00	5.83	7.0	
			Placebo	71	65 (91.5)	4.57 (0.90)	2.3	4.00	4.50	5.25	6.4	
		Week 8	Tezepelumab	74	71 (95.9)	5.34 (1.05)	2.7	4.58	5.42	6.08	7.0	
			Placebo	71	66 (93.0)	4.58 (1.05)	1.9	3.92	4.50	5.25	7.0	
		Week 12	Tezepelumab	74	71 (95.9)	5.46 (1.06)	3.2	4.50	5.58	6.42	7.0	
			Placebo	71	66 (93.0)	4.78 (0.94)	2.4	4.08	4.75	5.42	7.0	
		Week 16	Tezepelumab	74	71 (95.9)	5.48 (1.08)	2.3	4.75	5.67	6.25	7.0	
			Placebo	71	66 (93.0)	4.80 (1.02)	2.2	4.08	4.58	5.58	7.0	
		Week 20	Tezepelumab	74	71 (95.9)	5.50 (1.03)	3.4	4.58	5.67	6.33	7.0	
			Placebo	71	66 (93.0)	4.81 (1.12)	2.3	4.00	4.75	5.50	7.0	
		Week 24	Tezepelumab	74	71 (95.9)	5.44 (1.13)	1.8	4.58	5.50	6.33	7.0	
			Placebo	71	66 (93.0)	4.81 (1.14)	2.2	3.92	4.67	5.58	7.0	
		Week 28	Tezepelumab	74	71 (95.9)	5.50 (1.03)	3.8	4.58	5.58	6.42	7.0	
			Placebo	71	66 (93.0)	4.81 (1.18)	1.8	4.00	4.75	5.58	7.0	
		Week 32	Tezepelumab	74	72 (97.3)	5.57 (1.03)	2.8	4.92	5.67	6.29	7.0	
			Placebo	71	66 (93.0)	4.93 (1.06)	2.4	4.08	4.96	5.75	7.0	
		Week 36	Tezepelumab	74	72 (97.3)	5.51 (1.04)	3.2	4.67	5.50	6.42	7.0	
			Placebo	71	66 (93.0)	4.86 (1.15)	2.5	4.00	4.83	5.58	7.0	
		Week 40	Tezepelumab	74	72 (97.3)	5.57 (1.04)	3.2	4.67	5.67	6.58	7.0	
			Placebo	71	66 (93.0)	4.91 (1.09)	2.4	4.08	4.83	5.75	7.0	
		Week 44	Tezepelumab	74	72 (97.3)	5.61 (1.02)	3.2	4.79	5.54	6.50	7.0	
			Placebo	71	66 (93.0)	4.81 (1.15)	2.3	4.00	4.63	5.67	7.0	
		Week 48	Tezepelumab	74	72 (97.3)	5.55 (1.09)	2.8	4.75	5.63	6.63	7.0	
			Placebo	71	66 (93.0)	4.89 (1.05)	2.4	4.00	4.79	5.67	7.0	
		Week 52	Tezepelumab	74	72 (97.3)	5.59 (1.05)	2.8	4.75	5.58	6.54	7.0	
			Placebo	71	66 (93.0)	4.85 (1.02)	2.5	4.00	4.79	5.67	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	74	61 (82.4)	1.05 (0.93)	-1.4	0.42	1.08	1.67	3.1	0.54 [0.18, 0.90]
			Placebo	71	63 (88.7)	0.58 (0.81)	-1.2	0.17	0.50	1.17	3.1	
		Week 8	Tezepelumab	74	63 (85.1)	1.20 (1.04)	-1.4	0.33	1.17	2.00	3.3	0.58 [0.23, 0.94]
			Placebo	71	63 (88.7)	0.62 (0.95)	-1.8	0.08	0.50	1.17	3.6	
		Week 12	Tezepelumab	74	63 (85.1)	1.32 (1.07)	-1.4	0.42	1.33	2.17	3.7	0.50 [0.14, 0.85]
			Placebo	71	63 (88.7)	0.79 (1.05)	-2.8	0.17	0.75	1.33	3.8	
		Week 16	Tezepelumab	74	63 (85.1)	1.35 (1.11)	-1.4	0.42	1.50	2.17	3.4	0.49 [0.13, 0.84]
			Placebo	71	63 (88.7)	0.83 (1.02)	-3.0	0.17	0.92	1.42	3.7	
		Week 20	Tezepelumab	74	63 (85.1)	1.40 (1.11)	-1.4	0.50	1.58	2.25	4.7	0.47 [0.12, 0.82]
			Placebo	71	63 (88.7)	0.86 (1.17)	-3.0	0.08	0.83	1.25	3.8	
		Week 24	Tezepelumab	74	63 (85.1)	1.37 (1.15)	-1.6	0.50	1.42	2.33	3.7	0.43 [0.07, 0.78]
			Placebo	71	63 (88.7)	0.87 (1.21)	-3.0	0.25	0.83	1.42	4.1	
		Week 28	Tezepelumab	74	63 (85.1)	1.38 (1.13)	-1.4	0.50	1.33	2.17	4.9	0.44 [0.08, 0.79]
			Placebo	71	63 (88.7)	0.86 (1.23)	-3.0	0.08	0.83	1.50	4.7	
		Week 32	Tezepelumab	74	63 (85.1)	1.47 (1.16)	-1.4	0.50	1.42	2.33	4.6	0.41 [0.06, 0.76]
			Placebo	71	63 (88.7)	1.01 (1.09)	-3.0	0.33	1.00	1.50	4.0	
		Week 36	Tezepelumab	74	63 (85.1)	1.37 (1.22)	-1.4	0.33	1.50	2.33	3.8	0.37 [0.01, 0.72]
			Placebo	71	63 (88.7)	0.93 (1.14)	-3.0	0.25	1.00	1.67	3.8	
		Week 40	Tezepelumab	74	63 (85.1)	1.45 (1.12)	-1.4	0.58	1.67	2.25	3.4	0.41 [0.06, 0.77]
			Placebo	71	63 (88.7)	0.97 (1.18)	-3.0	0.33	1.00	1.58	4.7	
		Week 44	Tezepelumab	74	63 (85.1)	1.49 (1.09)	-1.4	0.58	1.67	2.33	3.3	0.55 [0.20, 0.91]
			Placebo	71	63 (88.7)	0.87 (1.17)	-3.0	0.33	0.92	1.50	4.3	
		Week 48	Tezepelumab	74	63 (85.1)	1.47 (1.15)	-1.4	0.50	1.67	2.42	3.2	0.46 [0.11, 0.81]
			Placebo	71	63 (88.7)	0.95 (1.12)	-3.0	0.25	0.83	1.67	3.8	
		Week 52	Tezepelumab	74	63 (85.1)	1.47 (1.16)	-1.4	0.50	1.67	2.50	3.6	0.52 [0.16, 0.87]
			Placebo	71	63 (88.7)	0.90 (1.06)	-3.0	0.25	0.83	1.58	3.8	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	114	101 (88.6)	4.02 (0.98)	1.4	3.50	4.00	4.58	6.8	
			Placebo	126	112 (88.9)	3.97 (0.86)	1.7	3.42	4.00	4.50	5.9	
		Week 4	Tezepelumab	114	105 (92.1)	4.79 (1.07)	1.3	3.92	4.83	5.58	7.0	
			Placebo	126	113 (89.7)	4.55 (0.95)	1.8	4.00	4.58	5.25	6.7	
		Week 8	Tezepelumab	114	107 (93.9)	4.96 (1.10)	2.0	4.17	4.92	5.83	7.0	
			Placebo	126	116 (92.1)	4.64 (1.04)	2.1	4.00	4.50	5.38	7.0	
		Week 12	Tezepelumab	114	107 (93.9)	5.14 (1.07)	2.8	4.25	5.08	6.08	7.0	
			Placebo	126	117 (92.9)	4.75 (1.08)	2.1	4.00	4.67	5.58	7.0	
		Week 16	Tezepelumab	114	107 (93.9)	5.13 (1.08)	2.7	4.33	5.17	5.92	7.0	
			Placebo	126	117 (92.9)	4.77 (1.12)	1.3	4.08	4.67	5.58	7.0	
		Week 20	Tezepelumab	114	108 (94.7)	5.09 (1.07)	2.3	4.21	5.00	5.92	7.0	
			Placebo	126	117 (92.9)	4.83 (1.13)	1.3	4.17	4.75	5.67	7.0	
		Week 24	Tezepelumab	114	108 (94.7)	5.15 (1.04)	3.1	4.38	5.00	6.00	7.0	
			Placebo	126	117 (92.9)	4.84 (1.16)	1.3	4.00	4.67	5.92	7.0	
		Week 28	Tezepelumab	114	110 (96.5)	5.16 (1.05)	3.2	4.42	5.00	5.92	7.0	
			Placebo	126	118 (93.7)	4.86 (1.19)	1.3	4.00	4.79	5.75	7.0	
		Week 32	Tezepelumab	114	111 (97.4)	5.17 (1.07)	2.8	4.33	5.00	6.00	7.0	
			Placebo	126	119 (94.4)	4.92 (1.14)	1.3	4.00	4.92	5.83	7.0	
		Week 36	Tezepelumab	114	111 (97.4)	5.23 (1.08)	2.9	4.42	5.08	6.08	7.0	
			Placebo	126	119 (94.4)	4.95 (1.16)	2.4	4.00	4.83	6.00	7.0	
		Week 40	Tezepelumab	114	111 (97.4)	5.20 (1.07)	2.3	4.42	5.00	6.00	7.0	
			Placebo	126	119 (94.4)	4.98 (1.11)	2.3	4.00	4.92	6.00	7.0	
		Week 44	Tezepelumab	114	111 (97.4)	5.24 (1.10)	2.3	4.33	5.08	6.08	7.0	
			Placebo	126	119 (94.4)	4.95 (1.17)	2.3	4.00	4.75	5.92	7.0	
		Week 48	Tezepelumab	114	111 (97.4)	5.27 (1.09)	2.8	4.42	5.08	6.25	7.0	
			Placebo	126	120 (95.2)	4.99 (1.11)	2.2	4.04	4.92	5.88	7.0	
		Week 52	Tezepelumab	114	111 (97.4)	5.27 (1.10)	2.8	4.50	5.08	6.25	7.0	
			Placebo	126	120 (95.2)	4.98 (1.11)	2.5	4.00	4.83	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	114	97 (85.1)	0.78 (1.03)	-4.3	0.25	0.83	1.42	3.1	0.21 [-0.06, 0.49]
			Placebo	126	110 (87.3)	0.58 (0.86)	-1.8	0.08	0.50	1.17	3.3	
		Week 8	Tezepelumab	114	99 (86.8)	0.90 (1.06)	-1.9	0.25	0.92	1.58	4.1	0.23 [-0.04, 0.50]
			Placebo	126	111 (88.1)	0.68 (0.92)	-1.0	0.08	0.58	1.17	3.6	
		Week 12	Tezepelumab	114	99 (86.8)	1.08 (1.11)	-2.6	0.33	1.00	1.83	4.5	0.26 [-0.01, 0.53]
			Placebo	126	111 (88.1)	0.79 (1.11)	-3.1	0.08	0.75	1.25	3.8	
		Week 16	Tezepelumab	114	99 (86.8)	1.08 (1.11)	-2.9	0.33	1.00	1.83	4.6	0.24 [-0.03, 0.51]
			Placebo	126	111 (88.1)	0.81 (1.10)	-3.5	0.17	0.92	1.42	3.7	
		Week 20	Tezepelumab	114	99 (86.8)	1.05 (1.07)	-1.8	0.33	0.92	1.92	4.6	0.15 [-0.12, 0.42]
			Placebo	126	111 (88.1)	0.88 (1.09)	-3.5	0.25	0.92	1.33	3.8	
		Week 24	Tezepelumab	114	99 (86.8)	1.14 (1.08)	-1.6	0.42	1.00	1.92	4.8	0.22 [-0.06, 0.49]
			Placebo	126	111 (88.1)	0.90 (1.15)	-3.5	0.17	0.83	1.42	4.1	
		Week 28	Tezepelumab	114	99 (86.8)	1.12 (1.06)	-1.7	0.33	1.00	2.00	4.8	0.19 [-0.08, 0.47]
			Placebo	126	111 (88.1)	0.90 (1.18)	-3.5	0.17	0.83	1.58	4.7	
		Week 32	Tezepelumab	114	99 (86.8)	1.13 (1.13)	-1.6	0.33	1.00	1.92	4.8	0.13 [-0.14, 0.40]
			Placebo	126	111 (88.1)	0.99 (1.08)	-3.5	0.33	0.92	1.50	4.0	
		Week 36	Tezepelumab	114	99 (86.8)	1.17 (1.20)	-1.7	0.25	1.00	2.08	4.8	0.14 [-0.13, 0.41]
			Placebo	126	111 (88.1)	1.01 (1.11)	-2.3	0.25	1.00	1.67	3.8	
		Week 40	Tezepelumab	114	99 (86.8)	1.16 (1.14)	-1.7	0.33	1.00	2.08	4.8	0.11 [-0.16, 0.38]
			Placebo	126	111 (88.1)	1.04 (1.09)	-1.4	0.33	1.00	1.67	4.7	
		Week 44	Tezepelumab	114	99 (86.8)	1.21 (1.16)	-1.8	0.42	1.17	2.08	4.8	0.18 [-0.09, 0.45]
			Placebo	126	111 (88.1)	1.00 (1.13)	-1.4	0.25	1.00	1.67	4.3	
		Week 48	Tezepelumab	114	99 (86.8)	1.26 (1.14)	-1.6	0.42	1.08	2.17	4.8	0.19 [-0.08, 0.46]
			Placebo	126	111 (88.1)	1.05 (1.10)	-1.5	0.25	1.08	1.67	4.2	
		Week 52	Tezepelumab	114	99 (86.8)	1.24 (1.14)	-1.6	0.42	1.00	2.17	4.8	0.19 [-0.08, 0.46]
			Placebo	126	111 (88.1)	1.03 (1.09)	-1.1	0.25	0.92	1.67	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	23	22 (95.7)	4.17 (1.12)	1.3	3.58	4.29	4.83	6.3	
			Placebo	12	9 (75.0)	4.09 (1.44)	1.5	3.42	4.25	5.08	6.3	
		Week 4	Tezepelumab	23	21 (91.3)	5.10 (0.96)	3.6	4.50	4.75	6.00	6.8	
			Placebo	12	10 (83.3)	4.44 (1.00)	3.0	3.42	4.54	5.17	5.9	
		Week 8	Tezepelumab	23	21 (91.3)	5.52 (0.84)	4.0	4.83	5.58	6.25	6.8	
			Placebo	12	10 (83.3)	4.41 (1.18)	1.9	3.50	4.58	5.33	5.8	
		Week 12	Tezepelumab	23	21 (91.3)	5.64 (1.01)	3.8	4.92	5.67	6.42	7.0	
			Placebo	12	10 (83.3)	4.74 (1.01)	3.5	4.17	4.50	5.42	6.7	
		Week 16	Tezepelumab	23	21 (91.3)	5.58 (1.16)	2.3	5.08	5.92	6.33	6.9	
			Placebo	12	10 (83.3)	4.74 (1.10)	3.3	3.92	4.58	5.33	6.8	
		Week 20	Tezepelumab	23	21 (91.3)	5.81 (0.81)	3.8	5.58	5.92	6.17	6.9	
			Placebo	12	10 (83.3)	4.32 (0.97)	3.2	3.50	4.25	5.25	6.0	
		Week 24	Tezepelumab	23	21 (91.3)	5.63 (1.19)	1.8	5.50	5.75	6.00	7.0	
			Placebo	12	10 (83.3)	4.54 (1.01)	3.2	3.58	4.96	5.42	5.6	
		Week 28	Tezepelumab	23	21 (91.3)	5.55 (1.03)	3.8	5.00	5.67	6.17	7.0	
			Placebo	12	10 (83.3)	4.74 (1.42)	3.2	3.75	4.08	5.92	7.0	
		Week 32	Tezepelumab	23	21 (91.3)	5.90 (0.86)	3.8	5.58	5.92	6.58	7.0	
			Placebo	12	10 (83.3)	4.74 (1.09)	3.2	3.67	4.92	5.58	6.3	
		Week 36	Tezepelumab	23	21 (91.3)	5.58 (0.99)	3.8	4.92	5.67	6.17	7.0	
			Placebo	12	10 (83.3)	4.77 (1.24)	3.2	3.75	4.79	6.00	6.5	
		Week 40	Tezepelumab	23	21 (91.3)	5.71 (1.09)	3.2	5.50	5.83	6.67	7.0	
			Placebo	12	10 (83.3)	4.72 (1.32)	3.2	3.42	4.63	5.83	6.7	
		Week 44	Tezepelumab	23	21 (91.3)	5.62 (1.04)	3.2	5.25	5.67	6.25	7.0	
			Placebo	12	10 (83.3)	4.68 (1.29)	3.1	3.25	4.63	6.08	6.3	
		Week 48	Tezepelumab	23	21 (91.3)	5.56 (1.10)	3.3	4.75	6.00	6.17	7.0	
			Placebo	12	10 (83.3)	4.60 (1.21)	3.2	3.83	4.13	5.75	6.5	
		Week 52	Tezepelumab	23	21 (91.3)	5.61 (0.94)	3.8	5.42	5.67	6.17	7.0	
			Placebo	12	10 (83.3)	4.55 (1.20)	3.2	3.58	4.13	5.75	6.5	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	1.00 (1.00)	-0.8	0.25	0.92	1.75	3.1	0.54 [-0.26, 1.34]
			Placebo	12	9 (75.0)	0.49 (0.78)	-1.1	0.33	0.67	0.75	1.9	
		Week 8	Tezepelumab	23	20 (87.0)	1.41 (0.99)	-0.6	0.83	1.63	2.17	2.8	0.96 [0.13, 1.79]
			Placebo	12	9 (75.0)	0.42 (1.13)	-1.8	0.33	0.42	0.58	2.7	
		Week 12	Tezepelumab	23	20 (87.0)	1.52 (1.02)	-0.5	0.75	1.75	2.21	3.3	0.55 [-0.25, 1.35]
			Placebo	12	9 (75.0)	0.79 (1.86)	-2.8	0.17	0.83	1.08	4.0	
		Week 16	Tezepelumab	23	20 (87.0)	1.47 (1.04)	-0.3	0.83	1.46	2.13	3.4	0.53 [-0.27, 1.33]
			Placebo	12	9 (75.0)	0.74 (1.97)	-3.0	-0.08	0.58	1.50	4.2	
		Week 20	Tezepelumab	23	20 (87.0)	1.70 (1.10)	-0.3	1.04	1.71	2.21	4.7	1.17 [0.32, 2.01]
			Placebo	12	9 (75.0)	0.30 (1.40)	-3.0	0.08	0.50	0.83	1.8	
		Week 24	Tezepelumab	23	20 (87.0)	1.51 (1.26)	-1.6	0.79	1.67	2.29	3.7	0.71 [-0.10, 1.52]
			Placebo	12	9 (75.0)	0.56 (1.55)	-3.0	0.25	0.83	1.17	2.7	
		Week 28	Tezepelumab	23	20 (87.0)	1.43 (1.30)	-0.5	0.54	1.50	2.13	4.9	0.45 [-0.35, 1.24]
			Placebo	12	9 (75.0)	0.75 (1.92)	-3.0	0.00	0.75	1.33	4.3	
		Week 32	Tezepelumab	23	20 (87.0)	1.75 (1.19)	-0.3	1.04	1.75	2.33	4.6	0.74 [-0.07, 1.55]
			Placebo	12	9 (75.0)	0.77 (1.62)	-3.0	1.00	1.08	1.25	2.9	
		Week 36	Tezepelumab	23	20 (87.0)	1.43 (1.12)	-0.9	0.67	1.50	2.08	3.4	0.50 [-0.30, 1.30]
			Placebo	12	9 (75.0)	0.79 (1.61)	-3.0	0.25	1.25	1.67	2.3	
		Week 40	Tezepelumab	23	20 (87.0)	1.55 (1.04)	-0.8	0.88	1.63	2.33	3.3	0.61 [-0.19, 1.41]
			Placebo	12	9 (75.0)	0.73 (1.88)	-3.0	0.08	1.00	1.58	4.0	
		Week 44	Tezepelumab	23	20 (87.0)	1.46 (1.04)	-0.8	0.67	1.54	2.13	3.3	0.63 [-0.18, 1.43]
			Placebo	12	9 (75.0)	0.64 (1.80)	-3.0	0.00	0.75	1.67	3.4	
		Week 48	Tezepelumab	23	20 (87.0)	1.42 (1.05)	-0.7	0.54	1.50	2.04	3.4	0.72 [-0.09, 1.53]
			Placebo	12	9 (75.0)	0.57 (1.44)	-3.0	0.50	0.67	1.33	1.8	
		Week 52	Tezepelumab	23	20 (87.0)	1.45 (1.07)	-0.7	0.63	1.42	2.13	3.4	0.75 [-0.07, 1.56]
			Placebo	12	9 (75.0)	0.56 (1.41)	-3.0	0.58	0.67	1.33	1.7	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.97 (0.72)	3.2	3.29	3.88	4.63	5.0	
			Placebo	14	10 (71.4)	4.28 (0.90)	2.7	4.00	4.29	4.50	6.3	
		Week 4	Tezepelumab	9	8 (88.9)	4.90 (0.98)	3.6	4.42	4.63	5.54	6.4	
			Placebo	14	12 (85.7)	4.52 (1.09)	2.7	3.54	4.92	5.25	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.52 (0.92)	4.3	4.83	5.38	6.29	6.8	
			Placebo	14	13 (92.9)	4.49 (0.72)	2.9	4.25	4.67	5.08	5.4	
		Week 12	Tezepelumab	9	8 (88.9)	5.64 (0.99)	4.3	4.88	5.46	6.54	7.0	
			Placebo	14	13 (92.9)	4.49 (1.23)	2.1	3.50	4.33	5.17	6.7	
		Week 16	Tezepelumab	9	8 (88.9)	5.79 (0.78)	4.3	5.46	5.83	6.25	6.9	
			Placebo	14	13 (92.9)	4.72 (1.17)	2.8	3.92	4.67	5.75	6.8	
		Week 20	Tezepelumab	9	8 (88.9)	5.33 (1.08)	3.8	4.25	5.67	6.08	6.8	
			Placebo	14	13 (92.9)	4.49 (0.90)	2.8	4.00	4.42	5.25	5.8	
		Week 24	Tezepelumab	9	8 (88.9)	5.45 (1.12)	4.0	4.25	5.83	6.29	6.8	
			Placebo	14	13 (92.9)	4.56 (1.02)	2.8	3.83	4.67	5.33	6.0	
		Week 28	Tezepelumab	9	8 (88.9)	4.88 (1.12)	3.8	3.96	4.46	5.79	6.8	
			Placebo	14	14 (100.0)	4.83 (1.22)	2.8	3.83	4.83	5.58	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.28 (1.17)	3.7	4.29	5.29	6.33	6.8	
			Placebo	14	14 (100.0)	4.82 (1.13)	3.0	3.83	5.17	5.58	6.8	
		Week 36	Tezepelumab	9	8 (88.9)	5.01 (1.15)	3.7	4.21	4.54	6.00	6.9	
			Placebo	14	14 (100.0)	4.74 (1.19)	2.4	3.83	4.79	5.42	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.40 (1.24)	4.1	4.29	5.25	6.50	7.0	
			Placebo	14	14 (100.0)	4.80 (1.38)	2.3	3.83	4.79	5.75	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.20 (1.08)	4.1	4.25	4.92	6.13	6.9	
			Placebo	14	14 (100.0)	4.79 (1.23)	2.5	3.83	4.83	5.75	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.14 (1.26)	3.7	4.04	5.04	6.17	6.9	
			Placebo	14	14 (100.0)	4.62 (1.25)	2.2	3.83	4.58	5.17	6.9	
		Week 52	Tezepelumab	9	8 (88.9)	5.27 (1.22)	3.7	4.04	5.58	6.17	6.9	
			Placebo	14	14 (100.0)	4.66 (1.20)	2.8	3.83	4.63	5.17	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.94 (0.58)	0.2	0.33	1.33	1.33	1.6	0.95 [-0.07, 1.98]
			Placebo	14	10 (71.4)	0.23 (0.85)	-1.1	-0.42	0.33	0.67	1.5	
		Week 8	Tezepelumab	9	7 (77.8)	1.54 (0.70)	0.5	0.83	1.92	2.00	2.3	1.13 [0.08, 2.17]
			Placebo	14	10 (71.4)	0.38 (1.19)	-1.8	-0.08	0.38	1.00	2.7	
		Week 12	Tezepelumab	9	7 (77.8)	1.70 (0.70)	0.5	1.25	1.83	2.17	2.6	1.03 [-0.01, 2.06]
			Placebo	14	10 (71.4)	0.21 (1.79)	-2.8	-0.83	0.25	0.83	4.0	
		Week 16	Tezepelumab	9	7 (77.8)	1.85 (0.79)	0.5	1.00	2.08	2.50	2.6	0.80 [-0.21, 1.81]
			Placebo	14	10 (71.4)	0.62 (1.88)	-3.0	-0.08	0.58	1.67	4.2	
		Week 20	Tezepelumab	9	7 (77.8)	1.52 (0.78)	0.5	0.67	1.58	2.25	2.5	1.00 [-0.03, 2.03]
			Placebo	14	10 (71.4)	0.33 (1.41)	-3.0	-0.08	0.79	1.25	1.8	
		Week 24	Tezepelumab	9	7 (77.8)	1.68 (0.84)	0.5	1.00	2.00	2.33	2.8	0.87 [-0.14, 1.89]
			Placebo	14	10 (71.4)	0.51 (1.59)	-3.0	0.08	0.75	1.67	2.7	
		Week 28	Tezepelumab	9	7 (77.8)	0.94 (1.03)	-0.5	0.50	0.58	2.00	2.6	0.22 [-0.75, 1.18]
			Placebo	14	10 (71.4)	0.60 (1.86)	-3.0	0.08	0.83	1.08	4.3	
		Week 32	Tezepelumab	9	7 (77.8)	1.54 (0.75)	0.5	1.00	1.42	2.33	2.6	0.69 [-0.30, 1.69]
			Placebo	14	10 (71.4)	0.62 (1.58)	-3.0	0.08	0.96	1.33	2.9	
		Week 36	Tezepelumab	9	7 (77.8)	1.23 (0.99)	-0.2	0.50	1.08	2.08	2.8	0.59 [-0.40, 1.57]
			Placebo	14	10 (71.4)	0.43 (1.55)	-3.0	0.08	0.75	1.67	2.0	
		Week 40	Tezepelumab	9	7 (77.8)	1.61 (0.92)	0.5	1.00	1.08	2.58	2.9	0.64 [-0.36, 1.63]
			Placebo	14	10 (71.4)	0.58 (1.94)	-3.0	-0.50	0.83	1.67	4.0	
		Week 44	Tezepelumab	9	7 (77.8)	1.38 (1.03)	0.5	0.50	1.00	2.08	3.3	0.58 [-0.41, 1.57]
			Placebo	14	10 (71.4)	0.48 (1.81)	-3.0	-0.83	0.71	1.67	3.4	
		Week 48	Tezepelumab	9	7 (77.8)	1.37 (1.22)	-0.1	0.33	1.08	2.58	3.1	0.76 [-0.24, 1.76]
			Placebo	14	10 (71.4)	0.29 (1.53)	-3.0	0.08	0.58	1.17	2.3	
		Week 52	Tezepelumab	9	7 (77.8)	1.52 (1.06)	0.3	0.50	1.08	2.58	3.1	0.89 [-0.13, 1.91]
			Placebo	14	10 (71.4)	0.35 (1.47)	-3.0	0.08	0.58	1.17	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	128	115 (89.8)	4.05 (1.02)	1.3	3.50	4.08	4.67	6.8	
			Placebo	124	111 (89.5)	3.95 (0.90)	1.5	3.42	4.00	4.58	5.9	
		Week 4	Tezepelumab	128	118 (92.2)	4.84 (1.07)	1.3	4.00	4.83	5.58	7.0	
			Placebo	124	111 (89.5)	4.55 (0.94)	1.8	4.00	4.58	5.25	6.7	
		Week 8	Tezepelumab	128	120 (93.8)	5.02 (1.08)	2.0	4.17	4.96	5.83	7.0	
			Placebo	124	113 (91.1)	4.64 (1.08)	1.9	4.00	4.50	5.42	7.0	
		Week 12	Tezepelumab	128	120 (93.8)	5.19 (1.08)	2.8	4.25	5.17	6.08	7.0	
			Placebo	124	114 (91.9)	4.78 (1.06)	2.4	4.00	4.67	5.58	7.0	
		Week 16	Tezepelumab	128	120 (93.8)	5.16 (1.11)	2.3	4.33	5.17	5.96	7.0	
			Placebo	124	114 (91.9)	4.77 (1.12)	1.3	4.00	4.71	5.58	7.0	
		Week 20	Tezepelumab	128	121 (94.5)	5.19 (1.07)	2.3	4.33	5.08	5.92	7.0	
			Placebo	124	114 (91.9)	4.82 (1.15)	1.3	4.08	4.75	5.75	7.0	
		Week 24	Tezepelumab	128	121 (94.5)	5.21 (1.08)	1.8	4.42	5.17	6.00	7.0	
			Placebo	124	114 (91.9)	4.85 (1.16)	1.3	4.00	4.67	5.92	7.0	
		Week 28	Tezepelumab	128	123 (96.1)	5.24 (1.05)	3.2	4.42	5.08	6.00	7.0	
			Placebo	124	114 (91.9)	4.86 (1.21)	1.3	4.00	4.75	5.92	7.0	
		Week 32	Tezepelumab	128	124 (96.9)	5.29 (1.07)	2.8	4.46	5.29	6.04	7.0	
			Placebo	124	115 (92.7)	4.92 (1.14)	1.3	4.08	4.92	5.92	7.0	
		Week 36	Tezepelumab	128	124 (96.9)	5.30 (1.07)	2.9	4.50	5.25	6.13	7.0	
			Placebo	124	115 (92.7)	4.96 (1.16)	2.5	4.00	4.83	6.00	7.0	
		Week 40	Tezepelumab	128	124 (96.9)	5.27 (1.08)	2.3	4.46	5.33	6.00	7.0	
			Placebo	124	115 (92.7)	4.98 (1.09)	2.4	4.00	4.92	6.00	7.0	
		Week 44	Tezepelumab	128	124 (96.9)	5.31 (1.10)	2.3	4.50	5.33	6.08	7.0	
			Placebo	124	115 (92.7)	4.94 (1.18)	2.3	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	128	124 (96.9)	5.33 (1.08)	2.8	4.50	5.21	6.21	7.0	
			Placebo	124	116 (93.5)	5.00 (1.10)	2.4	4.00	4.96	5.92	7.0	
		Week 52	Tezepelumab	128	124 (96.9)	5.33 (1.07)	2.8	4.54	5.17	6.21	7.0	
			Placebo	124	116 (93.5)	4.98 (1.11)	2.5	4.00	4.88	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	128	110 (85.9)	0.81 (1.04)	-4.3	0.17	0.79	1.50	3.1	0.22 [-0.05, 0.48]
			Placebo	124	109 (87.9)	0.61 (0.85)	-1.8	0.17	0.50	1.17	3.3	
		Week 8	Tezepelumab	128	112 (87.5)	0.96 (1.07)	-1.9	0.25	0.92	1.67	4.1	0.27 [0.01, 0.54]
			Placebo	124	110 (88.7)	0.68 (0.91)	-1.0	0.08	0.58	1.17	3.6	
		Week 12	Tezepelumab	128	112 (87.5)	1.12 (1.12)	-2.6	0.33	1.04	1.92	4.5	0.25 [-0.01, 0.51]
			Placebo	124	110 (88.7)	0.84 (1.10)	-3.1	0.25	0.83	1.33	3.8	
		Week 16	Tezepelumab	128	112 (87.5)	1.10 (1.11)	-2.9	0.38	1.08	1.75	4.6	0.25 [-0.02, 0.51]
			Placebo	124	110 (88.7)	0.83 (1.10)	-3.5	0.17	0.92	1.42	3.7	
		Week 20	Tezepelumab	128	112 (87.5)	1.13 (1.11)	-1.8	0.33	1.00	1.96	4.7	0.22 [-0.04, 0.49]
			Placebo	124	110 (88.7)	0.89 (1.08)	-3.5	0.25	0.88	1.33	3.8	
		Week 24	Tezepelumab	128	112 (87.5)	1.18 (1.12)	-1.6	0.42	1.08	2.00	4.8	0.24 [-0.03, 0.50]
			Placebo	124	110 (88.7)	0.91 (1.14)	-3.5	0.17	0.83	1.42	4.1	
		Week 28	Tezepelumab	128	112 (87.5)	1.19 (1.11)	-1.7	0.42	1.00	2.00	4.9	0.23 [-0.03, 0.50]
			Placebo	124	110 (88.7)	0.92 (1.18)	-3.5	0.25	0.83	1.58	4.7	
		Week 32	Tezepelumab	128	112 (87.5)	1.22 (1.18)	-1.6	0.42	1.08	2.08	4.8	0.19 [-0.08, 0.45]
			Placebo	124	110 (88.7)	1.01 (1.08)	-3.5	0.33	1.00	1.50	4.0	
		Week 36	Tezepelumab	128	112 (87.5)	1.21 (1.20)	-1.7	0.29	1.13	2.08	4.8	0.15 [-0.11, 0.41]
			Placebo	124	110 (88.7)	1.04 (1.10)	-2.3	0.25	1.04	1.67	3.8	
		Week 40	Tezepelumab	128	112 (87.5)	1.21 (1.14)	-1.7	0.33	1.08	2.08	4.8	0.13 [-0.13, 0.40]
			Placebo	124	110 (88.7)	1.06 (1.07)	-1.1	0.33	1.00	1.58	4.7	
		Week 44	Tezepelumab	128	112 (87.5)	1.24 (1.15)	-1.8	0.42	1.17	2.08	4.8	0.20 [-0.07, 0.46]
			Placebo	124	110 (88.7)	1.02 (1.12)	-1.4	0.33	1.00	1.67	4.3	
		Week 48	Tezepelumab	128	112 (87.5)	1.28 (1.12)	-1.6	0.46	1.17	2.08	4.8	0.18 [-0.08, 0.45]
			Placebo	124	110 (88.7)	1.08 (1.07)	-1.1	0.33	1.08	1.67	4.2	
		Week 52	Tezepelumab	128	112 (87.5)	1.26 (1.13)	-1.6	0.42	1.08	2.13	4.8	0.19 [-0.08, 0.45]
			Placebo	124	110 (88.7)	1.05 (1.07)	-1.1	0.25	0.92	1.58	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	108	96 (88.9)	4.03 (0.99)	1.4	3.50	4.00	4.58	6.8	
			Placebo	115	104 (90.4)	3.95 (0.88)	1.7	3.42	4.00	4.50	5.9	
		Week 4	Tezepelumab	108	100 (92.6)	4.79 (1.09)	1.3	3.92	4.83	5.58	7.0	
			Placebo	115	104 (90.4)	4.54 (0.95)	1.8	3.96	4.54	5.21	6.7	
		Week 8	Tezepelumab	108	102 (94.4)	4.94 (1.11)	2.0	4.08	4.83	5.83	7.0	
			Placebo	115	106 (92.2)	4.65 (1.06)	2.1	4.00	4.50	5.50	7.0	
		Week 12	Tezepelumab	108	102 (94.4)	5.13 (1.08)	2.8	4.25	5.08	6.08	7.0	
			Placebo	115	107 (93.0)	4.78 (1.08)	2.4	4.00	4.67	5.58	7.0	
		Week 16	Tezepelumab	108	102 (94.4)	5.10 (1.08)	2.7	4.33	5.08	5.92	7.0	
			Placebo	115	107 (93.0)	4.77 (1.14)	1.3	4.00	4.67	5.58	7.0	
		Week 20	Tezepelumab	108	103 (95.4)	5.09 (1.07)	2.3	4.25	5.00	5.92	7.0	
			Placebo	115	107 (93.0)	4.84 (1.16)	1.3	4.08	4.75	5.92	7.0	
		Week 24	Tezepelumab	108	103 (95.4)	5.15 (1.04)	3.1	4.42	5.00	6.00	7.0	
			Placebo	115	107 (93.0)	4.86 (1.18)	1.3	4.00	4.67	5.92	7.0	
		Week 28	Tezepelumab	108	105 (97.2)	5.16 (1.04)	3.2	4.42	5.00	5.92	7.0	
			Placebo	115	107 (93.0)	4.86 (1.21)	1.3	4.00	4.75	5.92	7.0	
		Week 32	Tezepelumab	108	106 (98.1)	5.19 (1.07)	2.8	4.33	5.04	6.00	7.0	
			Placebo	115	108 (93.9)	4.92 (1.15)	1.3	4.04	4.92	5.96	7.0	
		Week 36	Tezepelumab	108	106 (98.1)	5.23 (1.08)	2.9	4.50	5.08	6.08	7.0	
			Placebo	115	108 (93.9)	4.95 (1.16)	2.5	4.00	4.83	6.00	7.0	
		Week 40	Tezepelumab	108	106 (98.1)	5.20 (1.07)	2.3	4.42	5.00	6.00	7.0	
			Placebo	115	108 (93.9)	4.99 (1.09)	2.4	4.04	4.92	6.00	7.0	
		Week 44	Tezepelumab	108	106 (98.1)	5.25 (1.09)	2.3	4.42	5.17	6.08	7.0	
			Placebo	115	108 (93.9)	4.96 (1.17)	2.3	4.00	4.75	6.00	7.0	
		Week 48	Tezepelumab	108	106 (98.1)	5.27 (1.08)	2.8	4.50	5.08	6.17	7.0	
			Placebo	115	109 (94.8)	5.00 (1.09)	2.4	4.00	4.92	5.92	7.0	
		Week 52	Tezepelumab	108	106 (98.1)	5.27 (1.09)	2.8	4.50	5.08	6.17	7.0	
			Placebo	115	109 (94.8)	4.98 (1.11)	2.5	4.00	4.83	5.92	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	108	93 (86.1)	0.76 (1.04)	-4.3	0.17	0.75	1.42	3.1	0.18 [-0.11, 0.46]
			Placebo	115	102 (88.7)	0.60 (0.87)	-1.8	0.08	0.50	1.17	3.3	
		Week 8	Tezepelumab	108	95 (88.0)	0.88 (1.06)	-1.9	0.17	0.83	1.50	4.1	0.17 [-0.11, 0.45]
			Placebo	115	103 (89.6)	0.70 (0.94)	-1.0	0.08	0.58	1.25	3.6	
		Week 12	Tezepelumab	108	95 (88.0)	1.06 (1.12)	-2.6	0.33	0.92	1.83	4.5	0.20 [-0.08, 0.48]
			Placebo	115	103 (89.6)	0.84 (1.11)	-3.1	0.25	0.83	1.33	3.8	
		Week 16	Tezepelumab	108	95 (88.0)	1.05 (1.11)	-2.9	0.33	1.00	1.75	4.6	0.20 [-0.08, 0.47]
			Placebo	115	103 (89.6)	0.83 (1.12)	-3.5	0.17	0.92	1.42	3.7	
		Week 20	Tezepelumab	108	95 (88.0)	1.03 (1.08)	-1.8	0.25	0.92	1.83	4.6	0.11 [-0.17, 0.39]
			Placebo	115	103 (89.6)	0.91 (1.10)	-3.5	0.25	0.92	1.42	3.8	
		Week 24	Tezepelumab	108	95 (88.0)	1.13 (1.08)	-1.6	0.33	1.00	1.83	4.8	0.18 [-0.10, 0.46]
			Placebo	115	103 (89.6)	0.92 (1.17)	-3.5	0.17	0.83	1.42	4.1	
		Week 28	Tezepelumab	108	95 (88.0)	1.11 (1.07)	-1.7	0.33	1.00	2.00	4.8	0.16 [-0.12, 0.44]
			Placebo	115	103 (89.6)	0.93 (1.20)	-3.5	0.25	0.83	1.58	4.7	
		Week 32	Tezepelumab	108	95 (88.0)	1.12 (1.14)	-1.6	0.33	1.00	1.92	4.8	0.10 [-0.18, 0.38]
			Placebo	115	103 (89.6)	1.01 (1.11)	-3.5	0.33	0.92	1.58	4.0	
		Week 36	Tezepelumab	108	95 (88.0)	1.15 (1.21)	-1.7	0.17	1.00	2.08	4.8	0.10 [-0.18, 0.38]
			Placebo	115	103 (89.6)	1.03 (1.12)	-2.3	0.25	1.00	1.67	3.8	
		Week 40	Tezepelumab	108	95 (88.0)	1.14 (1.15)	-1.7	0.33	1.00	2.08	4.8	0.06 [-0.22, 0.34]
			Placebo	115	103 (89.6)	1.08 (1.08)	-1.1	0.42	1.00	1.67	4.7	
		Week 44	Tezepelumab	108	95 (88.0)	1.19 (1.16)	-1.8	0.42	1.17	2.08	4.8	0.13 [-0.15, 0.41]
			Placebo	115	103 (89.6)	1.04 (1.13)	-1.4	0.33	1.00	1.67	4.3	
		Week 48	Tezepelumab	108	95 (88.0)	1.22 (1.13)	-1.6	0.42	1.08	2.08	4.8	0.13 [-0.15, 0.41]
			Placebo	115	103 (89.6)	1.08 (1.10)	-1.1	0.25	1.08	1.67	4.2	
		Week 52	Tezepelumab	108	95 (88.0)	1.20 (1.13)	-1.6	0.33	1.00	2.08	4.8	0.13 [-0.15, 0.41]
			Placebo	115	103 (89.6)	1.06 (1.10)	-1.1	0.25	0.92	1.67	4.2	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	29	27 (93.1)	4.10 (1.05)	1.3	3.42	4.08	4.83	6.3	
			Placebo	23	17 (73.9)	4.16 (1.04)	1.5	3.75	4.25	4.75	6.3	
		Week 4	Tezepelumab	29	26 (89.7)	5.06 (0.93)	3.6	4.50	4.75	6.00	6.8	
			Placebo	23	19 (82.6)	4.60 (0.99)	2.7	3.92	4.67	5.25	6.0	
		Week 8	Tezepelumab	29	26 (89.7)	5.49 (0.84)	4.0	4.83	5.50	6.25	6.8	
			Placebo	23	20 (87.0)	4.45 (0.95)	1.9	4.08	4.63	5.13	5.8	
		Week 12	Tezepelumab	29	26 (89.7)	5.56 (0.99)	3.8	4.83	5.63	6.42	7.0	
			Placebo	23	20 (87.0)	4.60 (1.05)	2.1	4.04	4.50	5.25	6.7	
		Week 16	Tezepelumab	29	26 (89.7)	5.58 (1.10)	2.3	5.08	5.67	6.33	6.9	
			Placebo	23	20 (87.0)	4.74 (1.03)	2.8	3.96	4.71	5.54	6.8	
		Week 20	Tezepelumab	29	26 (89.7)	5.64 (0.94)	3.8	5.25	5.71	6.17	6.9	
			Placebo	23	20 (87.0)	4.51 (0.92)	2.8	3.83	4.46	5.25	6.0	
		Week 24	Tezepelumab	29	26 (89.7)	5.52 (1.20)	1.8	4.92	5.71	6.00	7.0	
			Placebo	23	20 (87.0)	4.63 (0.98)	2.8	3.75	4.92	5.42	6.0	
		Week 28	Tezepelumab	29	26 (89.7)	5.45 (1.06)	3.8	4.33	5.67	6.17	7.0	
			Placebo	23	21 (91.3)	4.81 (1.21)	2.8	3.83	4.58	5.75	7.0	
		Week 32	Tezepelumab	29	26 (89.7)	5.71 (0.99)	3.7	5.25	5.88	6.58	7.0	
			Placebo	23	21 (91.3)	4.87 (1.07)	3.0	4.00	5.17	5.58	6.8	
		Week 36	Tezepelumab	29	26 (89.7)	5.49 (1.04)	3.7	4.58	5.63	6.17	7.0	
			Placebo	23	21 (91.3)	4.88 (1.20)	2.4	4.00	5.00	5.75	6.9	
		Week 40	Tezepelumab	29	26 (89.7)	5.60 (1.13)	3.2	4.50	5.75	6.67	7.0	
			Placebo	23	21 (91.3)	4.80 (1.30)	2.3	3.83	4.83	5.75	7.0	
		Week 44	Tezepelumab	29	26 (89.7)	5.54 (1.09)	3.2	4.92	5.58	6.50	7.0	
			Placebo	23	21 (91.3)	4.78 (1.24)	2.5	3.83	5.08	5.75	6.9	
		Week 48	Tezepelumab	29	26 (89.7)	5.52 (1.13)	3.3	4.33	5.88	6.25	7.0	
			Placebo	23	21 (91.3)	4.75 (1.23)	2.2	3.83	4.75	5.75	6.9	
		Week 52	Tezepelumab	29	26 (89.7)	5.57 (1.01)	3.7	4.75	5.71	6.25	7.0	
			Placebo	23	21 (91.3)	4.77 (1.18)	2.8	3.83	4.75	5.75	7.0	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IOSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITT

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	29	24 (82.8)	1.03 (0.92)	-0.8	0.33	1.25	1.71	3.1	0.69 [0.05, 1.33]
			Placebo	23	17 (73.9)	0.44 (0.77)	-1.1	0.25	0.50	0.75	1.9	
		Week 8	Tezepelumab	29	24 (82.8)	1.44 (0.94)	-0.6	0.83	1.67	2.00	2.8	1.13 [0.46, 1.80]
			Placebo	23	17 (73.9)	0.39 (0.91)	-1.8	0.17	0.42	0.58	2.7	
		Week 12	Tezepelumab	29	24 (82.8)	1.51 (0.96)	-0.5	0.75	1.71	2.17	3.3	0.86 [0.21, 1.51]
			Placebo	23	17 (73.9)	0.47 (1.49)	-2.8	0.08	0.33	0.83	4.0	
		Week 16	Tezepelumab	29	24 (82.8)	1.52 (1.01)	-0.3	0.83	1.54	2.17	3.4	0.67 [0.04, 1.31]
			Placebo	23	17 (73.9)	0.69 (1.52)	-3.0	-0.08	0.58	1.50	4.2	
		Week 20	Tezepelumab	29	24 (82.8)	1.65 (1.07)	-0.3	0.88	1.71	2.21	4.7	1.12 [0.45, 1.79]
			Placebo	23	17 (73.9)	0.42 (1.13)	-3.0	0.08	0.75	0.83	1.8	
		Week 24	Tezepelumab	29	24 (82.8)	1.52 (1.20)	-1.6	0.79	1.67	2.29	3.7	0.75 [0.10, 1.39]
			Placebo	23	17 (73.9)	0.61 (1.24)	-3.0	0.17	0.83	1.17	2.7	
		Week 28	Tezepelumab	29	24 (82.8)	1.42 (1.24)	-0.5	0.54	1.50	2.13	4.9	0.56 [-0.07, 1.20]
			Placebo	23	17 (73.9)	0.67 (1.45)	-3.0	0.08	0.83	1.17	4.3	
		Week 32	Tezepelumab	29	24 (82.8)	1.71 (1.14)	-0.3	1.04	1.71	2.33	4.6	0.79 [0.14, 1.43]
			Placebo	23	17 (73.9)	0.78 (1.25)	-3.0	0.83	1.08	1.25	2.9	
		Week 36	Tezepelumab	29	24 (82.8)	1.48 (1.08)	-0.9	0.67	1.54	2.13	3.4	0.63 [-0.01, 1.26]
			Placebo	23	17 (73.9)	0.74 (1.32)	-3.0	0.25	1.08	1.67	2.3	
		Week 40	Tezepelumab	29	24 (82.8)	1.57 (1.03)	-0.8	0.88	1.63	2.33	3.3	0.71 [0.07, 1.35]
			Placebo	23	17 (73.9)	0.67 (1.54)	-3.0	0.08	0.83	1.58	4.0	
		Week 44	Tezepelumab	29	24 (82.8)	1.51 (1.05)	-0.8	0.67	1.54	2.13	3.3	0.73 [0.09, 1.37]
			Placebo	23	17 (73.9)	0.60 (1.47)	-3.0	0.00	0.75	1.67	3.4	
		Week 48	Tezepelumab	29	24 (82.8)	1.53 (1.06)	-0.7	0.54	1.54	2.17	3.4	0.82 [0.18, 1.47]
			Placebo	23	17 (73.9)	0.58 (1.26)	-3.0	0.42	0.67	1.33	2.3	
		Week 52	Tezepelumab	29	24 (82.8)	1.55 (1.08)	-0.7	0.63	1.50	2.42	3.4	0.83 [0.18, 1.48]
			Placebo	23	17 (73.9)	0.61 (1.19)	-3.0	0.42	0.67	1.33	2.3	

Note: DITT = Dossier Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_ILMP0: Increase of at least 0.9 points in AQLQ+12 total score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 total score	Week 52	66	57 (86.4)	35 (53.0) [40.3, 65.4]	65	55 (84.6)	22 (33.8) [22.6, 46.6]	1.567 [1.041, 2.358]	2.207 [1.090, 4.468]	19.2 [1.0, 37.4]	0.027 *

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_ILSPK: Increase of at least 0.9 points in AQLQ+12 total score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.736	
Male	19	15 (78.9)	10 (52.6) [28.9, 75.6]	20	17 (85.0)	6 (30.0) [11.9, 54.3]	1.754 [0.793, 3.880]	2.593 [0.697, 9.643]	22.6 [-12.6, 57.9]	0.156	
Female	47	42 (89.4)	25 (53.2) [38.1, 67.9]	45	38 (84.4)	16 (35.6) [21.9, 51.2]	1.496 [0.929, 2.408]	2.060 [0.892, 4.757]	17.6 [-4.5, 39.8]	0.091	
Age										0.168	
< 65 years	57	49 (86.0)	31 (54.4) [40.7, 67.6]	55	48 (87.3)	22 (40.0) [27.0, 54.1]	1.360 [0.910, 2.032]	1.788 [0.845, 3.787]	14.4 [-5.7, 34.5]	0.129	
>= 65 years	9	8 (88.9)	4 (44.4) [13.7, 78.8]	10	7 (70.0)	0 (0.0) [0.0, 30.8]	9.900 + [0.606, 161.735]	17.182 + [0.775, 380.840]	44.4 [1.4, 87.5]	0.033	*
Exacerbations in the year before study										0.842	
<= 2	44	38 (86.4)	22 (50.0) [34.6, 65.4]	45	38 (84.4)	14 (31.1) [18.2, 46.6]	1.607 [0.950, 2.719]	2.214 [0.933, 5.257]	18.9 [-3.4, 41.2]	0.071	
> 2	22	19 (86.4)	13 (59.1) [36.4, 79.3]	20	17 (85.0)	8 (40.0) [19.1, 63.9]	1.477 [0.779, 2.800]	2.167 [0.631, 7.442]	19.1 [-15.4, 53.6]	0.222	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_ILSPK: Increase of at least 0.9 points in AQLQ+12 total score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10	any level							NE
White	60	51 (85.0)	30 (50.0) [36.8, 63.2]	58	48 (82.8)	18 (31.0) [19.5, 44.5]				
Black or African American	2	2 (100.0)	2 (100.0) [15.8, 100.0]	2	2 (100.0)	2 (100.0) [15.8, 100.0]				
Asian	3	3 (100.0)	2 (66.7) [9.4, 99.2]	3	3 (100.0)	0 (0.0) [0.0, 70.8]				
Other	1	1 (100.0)	1 (100.0) [2.5, 100.0]	2	2 (100.0)	2 (100.0) [15.8, 100.0]				
Region		N<10	any level							NE
Europe	40	36 (90.0)	21 (52.5) [36.1, 68.5]	36	31 (86.1)	9 (25.0) [12.1, 42.2]				
America	6	5 (83.3)	4 (66.7) [22.3, 95.7]	4	3 (75.0)	3 (75.0) [19.4, 99.4]				
Asia/Pacific	3	3 (100.0)	2 (66.7) [9.4, 99.2]	3	3 (100.0)	0 (0.0) [0.0, 70.8]				
Rest of the world	17	13 (76.5)	8 (47.1) [23.0, 72.2]	22	18 (81.8)	10 (45.5) [24.4, 67.8]				
BMI										0.394
18.5 - < 25.0 kg/m**2	15	13 (86.7)	10 (66.7) [38.4, 88.2]	21	17 (81.0)	7 (33.3) [14.6, 57.0]	2.000 [0.990, 4.039]	4.000 [0.981, 16.311]	33.3 [-3.6, 70.3]	0.051
25.0 - < 30.0 kg/m**2	24	20 (83.3)	14 (58.3) [36.6, 77.9]	20	18 (90.0)	6 (30.0) [11.9, 54.3]	1.944 [0.918, 4.116]	3.267 [0.932, 11.450]	28.3 [-4.4, 61.1]	0.063
>= 30.0 kg/m**2	27	24 (88.9)	11 (40.7) [22.4, 61.2]	24	20 (83.3)	9 (37.5) [18.8, 59.4]	1.086 [0.546, 2.162]	1.146 [0.371, 3.540]	3.2 [-27.5, 34.0]	0.815

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_ILSPK: Increase of at least 0.9 points in AQLQ+12 total score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.116	
< 150 cells/uL	11	11 (100.0)	8 (72.7) [39.0, 94.0]	14	11 (78.6)	3 (21.4) [4.7, 50.8]	3.394 [1.168, 9.858]	9.778 [1.551, 61.646]	51.3 [9.2, 93.4]	0.017	*
>= 150 cells/uL	54	45 (83.3)	27 (50.0) [36.1, 63.9]	51	44 (86.3)	19 (37.3) [24.1, 51.9]	1.342 [0.860, 2.094]	1.684 [0.773, 3.670]	12.7 [-8.0, 33.5]	0.190	
Baseline eosinophils - High										0.903	
< 300 cells/uL	33	30 (90.9)	19 (57.6) [39.2, 74.5]	34	27 (79.4)	12 (35.3) [19.7, 53.5]	1.631 [0.949, 2.803]	2.488 [0.929, 6.666]	22.3 [-4.0, 48.6]	0.070	
>= 300 cells/uL	32	26 (81.3)	16 (50.0) [31.9, 68.1]	31	28 (90.3)	10 (32.3) [16.7, 51.4]	1.550 [0.837, 2.872]	2.100 [0.755, 5.843]	17.7 [-9.3, 44.8]	0.156	
Baseline FENO										0.376	
< 25 ppb	39	32 (82.1)	17 (43.6) [27.8, 60.4]	30	23 (76.7)	10 (33.3) [17.3, 52.8]	1.308 [0.704, 2.429]	1.545 [0.575, 4.152]	10.3 [-15.6, 36.2]	0.390	
>= 25 ppb	27	25 (92.6)	18 (66.7) [46.0, 83.5]	34	31 (91.2)	12 (35.3) [19.7, 53.5]	1.889 [1.115, 3.201]	3.667 [1.264, 10.640]	31.4 [4.1, 58.7]	0.016	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_ILSPK: Increase of at least 0.9 points in AQLQ+12 total score by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 total score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.241	
All negative	27	23 (85.2)	15 (55.6) [35.3, 74.5]	29	23 (79.3)	7 (24.1) [10.3, 43.5]	2.302 [1.111, 4.767]	3.929 [1.256, 12.284]	31.4 [3.5, 59.4]	0.017	*
Any positive	34	31 (91.2)	18 (52.9) [35.1, 70.2]	33	29 (87.9)	13 (39.4) [22.9, 57.9]	1.344 [0.792, 2.280]	1.731 [0.656, 4.566]	13.5 [-13.1, 40.2]	0.270	
Total serum IgE										0.084	
Low	23	20 (87.0)	11 (47.8) [26.8, 69.4]	14	11 (78.6)	2 (14.3) [1.8, 42.8]	3.348 [0.866, 12.943]	5.500 [0.999, 30.286]	33.5 [0.4, 66.7]	0.074	#
Normal	40	34 (85.0)	21 (52.5) [36.1, 68.5]	44	37 (84.1)	19 (43.2) [28.3, 59.0]	1.216 [0.776, 1.905]	1.454 [0.615, 3.439]	9.3 [-14.4, 33.0]	0.396	
High	3	3 (100.0)	3 (100.0) [29.2, 100.0]	7	7 (100.0)	1 (14.3) [0.4, 57.9]	7.000 [1.140, 42.969]	30.333 + [0.959, 959.665]	85.7 [36.0, 100.0]	0.033	*
OCS at baseline										0.359	
Yes	9	7 (77.8)	4 (44.4) [13.7, 78.8]	13	9 (69.2)	2 (15.4) [1.9, 45.4]	2.889 [0.665, 12.555]	4.400 [0.596, 32.501]	29.1 [-18.3, 76.4]	0.178	#
No	57	50 (87.7)	31 (54.4) [40.7, 67.6]	52	46 (88.5)	20 (38.5) [25.3, 53.0]	1.414 [0.931, 2.148]	1.908 [0.889, 4.096]	15.9 [-4.4, 36.3]	0.098	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_ILSPK: Increase of at least 0.9 points in AQLQ+12 total score by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 total score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline										0.419
Yes	7	6 (85.7)	4 (57.1) [18.4, 90.1]	3	2 (66.7)	0 (0.0) [0.0, 70.8]	4.500 + [0.314, 64.581]	9.000 + [0.340, 238.210]	57.1 [-3.3, 100.0]	0.200 #
No	59	51 (86.4)	31 (52.5) [39.1, 65.7]	62	53 (85.5)	22 (35.5) [23.7, 48.7]	1.481 [0.979, 2.240]	2.013 [0.971, 4.174]	17.1 [-2.0, 36.2]	0.060
Tiotropium use at baseline		N<10	any level							NE
Yes	6	5 (83.3)	4 (66.7) [22.3, 95.7]	2	1 (50.0)	0 (0.0) [0.0, 84.2]				
No	60	52 (86.7)	31 (51.7) [38.4, 64.8]	63	54 (85.7)	22 (34.9) [23.3, 48.0]				
Montelukast/ Cromoglicic acid use at baseline										0.460
Yes	17	14 (82.4)	8 (47.1) [23.0, 72.2]	21	20 (95.2)	8 (38.1) [18.1, 61.6]	1.235 [0.588, 2.596]	1.444 [0.395, 5.285]	9.0 [-27.9, 45.8]	0.583
No	49	43 (87.8)	27 (55.1) [40.2, 69.3]	44	35 (79.5)	14 (31.8) [18.6, 47.6]	1.732 [1.049, 2.858]	2.630 [1.126, 6.141]	23.3 [1.5, 45.0]	0.025 *

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_ILSPP: Increase of at least 0.9 points in AQLQ+12 total score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.822	
White	60	51 (85.0)	30 (50.0) [36.8, 63.2]	58	48 (82.8)	18 (31.0) [19.5, 44.5]	1.611 [1.018, 2.551]	2.222 [1.048, 4.714]	19.0 [-0.1, 38.0]	0.037	*
Non-white	6	6 (100.0)	5 (83.3) [35.9, 99.6]	7	7 (100.0)	4 (57.1) [18.4, 90.1]	1.458 [0.700, 3.040]	3.750 [0.274, 51.373]	26.2 [-36.5, 88.9]	0.559	#
Region (cat. P)										0.182	
North America/Western EU	6	5 (83.3)	4 (66.7) [22.3, 95.7]	4	3 (75.0)	3 (75.0) [19.4, 99.4]	0.889 [0.399, 1.979]	0.667 [0.039, 11.285]	-8.3 [-85.9, 69.3]	1.000	#
Rest of world	60	52 (86.7)	31 (51.7) [38.4, 64.8]	61	52 (85.2)	19 (31.1) [19.9, 44.3]	1.659 [1.062, 2.592]	2.363 [1.126, 4.961]	20.5 [1.7, 39.3]	0.022	*
Baseline eosinophils (cat. P)										0.955	
< 250 cells/uL	30	25 (83.3)	16 (53.3) [34.3, 71.7]	29	25 (86.2)	10 (34.5) [17.9, 54.3]	1.547 [0.846, 2.827]	2.171 [0.760, 6.200]	18.9 [-9.4, 47.1]	0.148	
>= 250 cells/uL	36	32 (88.9)	19 (52.8) [35.5, 69.6]	36	30 (83.3)	12 (33.3) [18.6, 51.0]	1.583 [0.908, 2.760]	2.235 [0.862, 5.798]	19.4 [-5.8, 44.7]	0.098	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_ILSPP: Increase of at least 0.9 points in AQLQ+12 total score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. P)										0.463	
< 24 ppb	38	31 (81.6)	17 (44.7) [28.6, 61.7]	30	23 (76.7)	10 (33.3) [17.3, 52.8]	1.342 [0.724, 2.488]	1.619 [0.600, 4.368]	11.4 [-14.7, 37.5]	0.344	
>= 24 ppb	28	26 (92.9)	18 (64.3) [44.1, 81.4]	34	31 (91.2)	12 (35.3) [19.7, 53.5]	1.821 [1.070, 3.102]	3.300 [1.160, 9.384]	29.0 [1.8, 56.2]	0.024	*
Baseline FENO (cat. M)										0.494	
< 22.0 ppb	32	26 (81.3)	14 (43.8) [26.4, 62.3]	27	21 (77.8)	9 (33.3) [16.5, 54.0]	1.313 [0.677, 2.546]	1.556 [0.538, 4.499]	10.4 [-17.7, 38.6]	0.418	
>= 22.0 ppb	34	31 (91.2)	21 (61.8) [43.6, 77.8]	37	33 (89.2)	13 (35.1) [20.2, 52.5]	1.758 [1.054, 2.932]	2.982 [1.135, 7.839]	26.6 [1.4, 51.9]	0.026	*
Baseline all FEIA status										0.488	
All negative	25	21 (84.0)	14 (56.0) [34.9, 75.6]	22	18 (81.8)	6 (27.3) [10.7, 50.2]	2.053 [0.955, 4.416]	3.394 [0.996, 11.569]	28.7 [-2.5, 59.9]	0.049	*
Any positive	35	32 (91.4)	19 (54.3) [36.6, 71.2]	41	35 (85.4)	15 (36.6) [22.1, 53.1]	1.484 [0.896, 2.458]	2.058 [0.820, 5.164]	17.7 [-7.1, 42.5]	0.124	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_ILSPP: Increase of at least 0.9 points in AQLQ+12 total score by study specific subgroups
DITTL

	Tezepelumab			Placebo							
Increase of at least 0.9 points in AQLQ+12 total score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Th2 status										0.538	
Low	41	35 (85.4)	21 (51.2) [35.1, 67.1]	30	25 (83.3)	8 (26.7) [12.3, 45.9]	1.921 [0.988, 3.732]	2.888 [1.047, 7.966]	24.6 [-0.3, 49.5]	0.039	*
High	25	22 (88.0)	14 (56.0) [34.9, 75.6]	34	29 (85.3)	13 (38.2) [22.2, 56.4]	1.465 [0.844, 2.540]	2.056 [0.720, 5.874]	17.8 [-11.1, 46.6]	0.180	
Baseline Periostin										0.384	
Low (< 20.9 ng/ml)	26	23 (88.5)	13 (50.0) [29.9, 70.1]	31	25 (80.6)	12 (38.7) [21.8, 57.8]	1.292 [0.719, 2.322]	1.583 [0.551, 4.548]	11.3 [-18.0, 40.6]	0.396	
High (>= 20.9 ng/ml)	40	34 (85.0)	22 (55.0) [38.5, 70.7]	34	30 (88.2)	10 (29.4) [15.1, 47.5]	1.870 [1.035, 3.378]	2.933 [1.117, 7.703]	25.6 [1.1, 50.0]	0.028	*
Current post-BD FEV1 reversibility										0.890	
Yes	57	48 (84.2)	29 (50.9) [37.3, 64.4]	60	51 (85.0)	20 (33.3) [21.7, 46.7]	1.526 [0.984, 2.369]	2.071 [0.982, 4.371]	17.5 [-1.8, 36.9]	0.056	
No	9	9 (100.0)	6 (66.7) [29.9, 92.5]	5	4 (80.0)	2 (40.0) [5.3, 85.3]	1.667 [0.518, 5.363]	3.000 [0.312, 28.841]	26.7 [-41.7, 95.1]	0.580	#

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_ILSPP: Increase of at least 0.9 points in AQLQ+12 total score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 total score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Maintenance OCS use at baseline										0.600	
Yes	9	7 (77.8)	4 (44.4) [13.7, 78.8]	14	10 (71.4)	3 (21.4) [4.7, 50.8]	2.074 [0.600, 7.173]	2.933 [0.469, 18.333]	23.0 [-25.0, 71.1]	0.363	#
No	57	50 (87.7)	31 (54.4) [40.7, 67.6]	51	45 (88.2)	19 (37.3) [24.1, 51.9]	1.460 [0.951, 2.240]	2.008 [0.929, 4.340]	17.1 [-3.3, 37.5]	0.076	
No chronic OCS use and current post-BD FEV1 reversibility										0.306	
Yes	51	44 (86.3)	26 (51.0) [36.6, 65.2]	49	43 (87.8)	18 (36.7) [23.4, 51.7]	1.388 [0.880, 2.188]	1.791 [0.805, 3.983]	14.2 [-7.0, 35.5]	0.153	
No	15	13 (86.7)	9 (60.0) [32.3, 83.7]	16	12 (75.0)	4 (25.0) [7.3, 52.4]	2.400 [0.934, 6.168]	4.500 [0.972, 20.827]	35.0 [-4.1, 74.1]	0.052	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_ILMP0: Increase of at least 0.9 points in AQLQ+12 activity limitations score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 activity limitations score	Week 52	66	57 (86.4)	35 (53.0) [40.3, 65.4]	65	55 (84.6)	23 (35.4) [23.9, 48.2]	1.499 [1.005, 2.234]	2.062 [1.022, 4.158]	17.6 [-0.6, 35.9]	0.043 *

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_ILMP0: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 environmental stimuli score	Week 52	66	57 (86.4)	35 (53.0) [40.3, 65.4]	65	55 (84.6)	19 (29.2) [18.6, 41.8]	1.814 [1.167, 2.820]	2.733 [1.330, 5.619]	23.8 [5.9, 41.7]	0.006 *

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_ILSPK: Increase of at least 0.9 points in AQLQ+12 activity limitations score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.536	
Male	19	15 (78.9)	9 (47.4) [24.4, 71.1]	20	17 (85.0)	5 (25.0) [8.7, 49.1]	1.895 [0.774, 4.637]	2.700 [0.697, 10.465]	22.4 [-12.2, 56.9]	0.151	
Female	47	42 (89.4)	26 (55.3) [40.1, 69.8]	45	38 (84.4)	18 (40.0) [25.7, 55.7]	1.383 [0.890, 2.148]	1.857 [0.811, 4.253]	15.3 [-7.0, 37.7]	0.144	
Age										0.255	
< 65 years	57	49 (86.0)	31 (54.4) [40.7, 67.6]	55	48 (87.3)	22 (40.0) [27.0, 54.1]	1.360 [0.910, 2.032]	1.788 [0.845, 3.787]	14.4 [-5.7, 34.5]	0.129	
>= 65 years	9	8 (88.9)	4 (44.4) [13.7, 78.8]	10	7 (70.0)	1 (10.0) [0.3, 44.5]	4.444 [0.603, 32.765]	7.200 [0.622, 83.342]	34.4 [-13.5, 82.4]	0.141	#
Exacerbations in the year before study										0.971	
<= 2	44	38 (86.4)	22 (50.0) [34.6, 65.4]	45	38 (84.4)	15 (33.3) [20.0, 49.0]	1.500 [0.903, 2.493]	2.000 [0.849, 4.709]	16.7 [-5.8, 39.1]	0.113	
> 2	22	19 (86.4)	13 (59.1) [36.4, 79.3]	20	17 (85.0)	8 (40.0) [19.1, 63.9]	1.477 [0.779, 2.800]	2.167 [0.631, 7.442]	19.1 [-15.4, 53.6]	0.222	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_ILSPK: Increase of at least 0.9 points in AQLQ+12 activity limitations score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10	any level							NE
White	60	51 (85.0)	30 (50.0) [36.8, 63.2]	58	48 (82.8)	18 (31.0) [19.5, 44.5]				
Black or African American	2	2 (100.0)	2 (100.0) [15.8, 100.0]	2	2 (100.0)	2 (100.0) [15.8, 100.0]				
Asian	3	3 (100.0)	2 (66.7) [9.4, 99.2]	3	3 (100.0)	1 (33.3) [0.8, 90.6]				
Other	1	1 (100.0)	1 (100.0) [2.5, 100.0]	2	2 (100.0)	2 (100.0) [15.8, 100.0]				
Region		N<10	any level							NE
Europe	40	36 (90.0)	23 (57.5) [40.9, 73.0]	36	31 (86.1)	9 (25.0) [12.1, 42.2]				
America	6	5 (83.3)	3 (50.0) [11.8, 88.2]	4	3 (75.0)	3 (75.0) [19.4, 99.4]				
Asia/Pacific	3	3 (100.0)	2 (66.7) [9.4, 99.2]	3	3 (100.0)	1 (33.3) [0.8, 90.6]				
Rest of the world	17	13 (76.5)	7 (41.2) [18.4, 67.1]	22	18 (81.8)	10 (45.5) [24.4, 67.8]				
BMI										0.313
18.5 - < 25.0 kg/m**2	15	13 (86.7)	9 (60.0) [32.3, 83.7]	21	17 (81.0)	6 (28.6) [11.3, 52.2]	2.100 [0.951, 4.639]	3.750 [0.924, 15.226]	31.4 [-5.7, 68.6]	0.063
25.0 - < 30.0 kg/m**2	24	20 (83.3)	13 (54.2) [32.8, 74.4]	20	18 (90.0)	6 (30.0) [11.9, 54.3]	1.806 [0.841, 3.876]	2.758 [0.791, 9.613]	24.2 [-8.7, 57.0]	0.111
>= 30.0 kg/m**2	27	24 (88.9)	13 (48.1) [28.7, 68.1]	24	20 (83.3)	11 (45.8) [25.6, 67.2]	1.051 [0.585, 1.886]	1.097 [0.365, 3.304]	2.3 [-29.1, 33.7]	0.870

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_ILSPK: Increase of at least 0.9 points in AQLQ+12 activity limitations score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.436	
< 150 cells/uL	11	11 (100.0)	8 (72.7) [39.0, 94.0]	14	11 (78.6)	5 (35.7) [12.8, 64.9]	2.036 [0.924, 4.489]	4.800 [0.860, 26.785]	37.0 [-7.5, 81.5]	0.072	
>= 150 cells/uL	54	45 (83.3)	27 (50.0) [36.1, 63.9]	51	44 (86.3)	18 (35.3) [22.4, 49.9]	1.417 [0.897, 2.238]	1.833 [0.837, 4.015]	14.7 [-5.9, 35.3]	0.130	
Baseline eosinophils - High										0.833	
< 300 cells/uL	33	30 (90.9)	20 (60.6) [42.1, 77.1]	34	27 (79.4)	13 (38.2) [22.2, 56.4]	1.585 [0.954, 2.635]	2.485 [0.930, 6.641]	22.4 [-4.0, 48.7]	0.069	
>= 300 cells/uL	32	26 (81.3)	15 (46.9) [29.1, 65.3]	31	28 (90.3)	10 (32.3) [16.7, 51.4]	1.453 [0.774, 2.727]	1.853 [0.665, 5.161]	14.6 [-12.4, 41.7]	0.240	
Baseline FENO										0.087	
< 25 ppb	39	32 (82.1)	18 (46.2) [30.1, 62.8]	30	23 (76.7)	13 (43.3) [25.5, 62.6]	1.065 [0.626, 1.812]	1.121 [0.430, 2.922]	2.8 [-23.8, 29.4]	0.817	
>= 25 ppb	27	25 (92.6)	17 (63.0) [42.4, 80.6]	34	31 (91.2)	10 (29.4) [15.1, 47.5]	2.141 [1.180, 3.884]	4.080 [1.393, 11.947]	33.6 [6.4, 60.7]	0.009	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_ILSPK: Increase of at least 0.9 points in AQLQ+12 activity limitations score by key subgroups
DITTL

	Tezepelumab			Placebo							
Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.082	
All negative	27	23 (85.2)	16 (59.3) [38.8, 77.6]	29	23 (79.3)	7 (24.1) [10.3, 43.5]	2.455 [1.199, 5.029]	4.571 [1.454, 14.376]	35.1 [7.3, 62.9]	0.008	*
Any positive	34	31 (91.2)	16 (47.1) [29.8, 64.9]	33	29 (87.9)	14 (42.4) [25.5, 60.8]	1.109 [0.650, 1.892]	1.206 [0.460, 3.165]	4.6 [-22.1, 31.4]	0.705	
Total serum IgE										0.033	i
Low	23	20 (87.0)	13 (56.5) [34.5, 76.8]	14	11 (78.6)	2 (14.3) [1.8, 42.8]	3.957 [1.044, 14.993]	7.800 [1.412, 43.080]	42.2 [9.2, 75.3]	0.012	*
Normal	40	34 (85.0)	19 (47.5) [31.5, 63.9]	44	37 (84.1)	20 (45.5) [30.4, 61.2]	1.045 [0.660, 1.654]	1.086 [0.460, 2.562]	2.0 [-21.7, 25.8]	0.852	
High	3	3 (100.0)	3 (100.0) [29.2, 100.0]	7	7 (100.0)	1 (14.3) [0.4, 57.9]	7.000 [1.140, 42.969]	30.333 + [0.959, 959.665]	85.7 [36.0, 100.0]	0.033	*
OCS at baseline										0.367	
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	13	9 (69.2)	3 (23.1) [5.0, 53.8]	2.407 [0.761, 7.616]	4.167 [0.660, 26.290]	32.5 [-16.7, 81.6]	0.187	#
No	57	50 (87.7)	30 (52.6) [39.0, 66.0]	52	46 (88.5)	20 (38.5) [25.3, 53.0]	1.368 [0.897, 2.089]	1.778 [0.829, 3.813]	14.2 [-6.2, 34.5]	0.140	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_ILSPK: Increase of at least 0.9 points in AQLQ+12 activity limitations score by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline										0.400
Yes	7	6 (85.7)	4 (57.1) [18.4, 90.1]	3	2 (66.7)	0 (0.0) [0.0, 70.8]	4.500 + [0.314, 64.581]	9.000 + [0.340, 238.210]	57.1 [-3.3, 100.0]	0.200 #
No	59	51 (86.4)	31 (52.5) [39.1, 65.7]	62	53 (85.5)	23 (37.1) [25.2, 50.3]	1.416 [0.945, 2.123]	1.877 [0.909, 3.879]	15.4 [-3.7, 34.6]	0.089
Tiotropium use at baseline		N<10	any level							NE
Yes	6	5 (83.3)	4 (66.7) [22.3, 95.7]	2	1 (50.0)	0 (0.0) [0.0, 84.2]				
No	60	52 (86.7)	31 (51.7) [38.4, 64.8]	63	54 (85.7)	23 (36.5) [24.7, 49.6]				
Montelukast/ Cromoglicic acid use at baseline										0.852
Yes	17	14 (82.4)	9 (52.9) [27.8, 77.0]	21	20 (95.2)	7 (33.3) [14.6, 57.0]	1.588 [0.748, 3.372]	2.250 [0.604, 8.384]	19.6 [-16.9, 56.1]	0.230
No	49	43 (87.8)	26 (53.1) [38.3, 67.5]	44	35 (79.5)	16 (36.4) [22.4, 52.2]	1.459 [0.911, 2.338]	1.978 [0.861, 4.545]	16.7 [-5.4, 38.8]	0.108

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_ILSPK: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex										0.904	
Male	19	15 (78.9)	9 (47.4) [24.4, 71.1]	20	17 (85.0)	5 (25.0) [8.7, 49.1]	1.895 [0.774, 4.637]	2.700 [0.697, 10.465]	22.4 [-12.2, 56.9]	0.151	
Female	47	42 (89.4)	26 (55.3) [40.1, 69.8]	45	38 (84.4)	14 (31.1) [18.2, 46.6]	1.778 [1.073, 2.946]	2.741 [1.167, 6.439]	24.2 [2.4, 46.0]	0.020	*
Age										0.098	
< 65 years	57	49 (86.0)	28 (49.1) [35.6, 62.7]	55	48 (87.3)	18 (32.7) [20.7, 46.7]	1.501 [0.946, 2.382]	1.985 [0.923, 4.270]	16.4 [-3.3, 36.1]	0.079	
>= 65 years	9	8 (88.9)	7 (77.8) [40.0, 97.2]	10	7 (70.0)	1 (10.0) [0.3, 44.5]	7.778 [1.173, 51.582]	31.500 [2.350, 422.299]	67.8 [24.3, 100.0]	0.005	*
Exacerbations in the year before study										0.992	
<= 2	44	38 (86.4)	23 (52.3) [36.7, 67.5]	45	38 (84.4)	13 (28.9) [16.4, 44.3]	1.809 [1.056, 3.100]	2.696 [1.124, 6.467]	23.4 [1.3, 45.5]	0.025	*
> 2	22	19 (86.4)	12 (54.5) [32.2, 75.6]	20	17 (85.0)	6 (30.0) [11.9, 54.3]	1.818 [0.841, 3.929]	2.800 [0.784, 9.994]	24.5 [-9.1, 58.2]	0.113	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_ILSPK: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race		N<10	any level							NE	
White	60	51 (85.0)	30 (50.0) [36.8, 63.2]	58	48 (82.8)	15 (25.9) [15.3, 39.0]					
Black or African American	2	2 (100.0)	2 (100.0) [15.8, 100.0]	2	2 (100.0)	2 (100.0) [15.8, 100.0]					
Asian	3	3 (100.0)	2 (66.7) [9.4, 99.2]	3	3 (100.0)	1 (33.3) [0.8, 90.6]					
Other	1	1 (100.0)	1 (100.0) [2.5, 100.0]	2	2 (100.0)	1 (50.0) [1.3, 98.7]					
Region		N<10	any level							NE	
Europe	40	36 (90.0)	21 (52.5) [36.1, 68.5]	36	31 (86.1)	8 (22.2) [10.1, 39.2]					
America	6	5 (83.3)	3 (50.0) [11.8, 88.2]	4	3 (75.0)	3 (75.0) [19.4, 99.4]					
Asia/Pacific	3	3 (100.0)	2 (66.7) [9.4, 99.2]	3	3 (100.0)	1 (33.3) [0.8, 90.6]					
Rest of the world	17	13 (76.5)	9 (52.9) [27.8, 77.0]	22	18 (81.8)	7 (31.8) [13.9, 54.9]					
BMI										0.850	
18.5 - < 25.0 kg/m**2	15	13 (86.7)	9 (60.0) [32.3, 83.7]	21	17 (81.0)	8 (38.1) [18.1, 61.6]	1.575 [0.795, 3.122]	2.438 [0.627, 9.473]	21.9 [-16.2, 60.0]	0.201	
25.0 - < 30.0 kg/m**2	24	20 (83.3)	15 (62.5) [40.6, 81.2]	20	18 (90.0)	6 (30.0) [11.9, 54.3]	2.083 [0.996, 4.357]	3.889 [1.099, 13.764]	32.5 [0.0, 65.0]	0.034	*
>= 30.0 kg/m**2	27	24 (88.9)	11 (40.7) [22.4, 61.2]	24	20 (83.3)	5 (20.8) [7.1, 42.2]	1.956 [0.793, 4.824]	2.613 [0.749, 9.109]	19.9 [-8.7, 48.5]	0.130	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_ILSPK: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.081	
< 150 cells/uL	11	11 (100.0)	8 (72.7) [39.0, 94.0]	14	11 (78.6)	2 (14.3) [1.8, 42.8]	5.091 [1.342, 19.310]	16.000 [2.165, 118.270]	58.4 [18.3, 98.6]	0.005	*
>= 150 cells/uL	54	45 (83.3)	26 (48.1) [34.3, 62.2]	51	44 (86.3)	17 (33.3) [20.8, 47.9]	1.444 [0.897, 2.327]	1.857 [0.843, 4.091]	14.8 [-5.7, 35.3]	0.125	
Baseline eosinophils - High										0.672	
< 300 cells/uL	33	30 (90.9)	19 (57.6) [39.2, 74.5]	34	27 (79.4)	10 (29.4) [15.1, 47.5]	1.958 [1.077, 3.558]	3.257 [1.186, 8.946]	28.2 [2.4, 53.9]	0.021	*
>= 300 cells/uL	32	26 (81.3)	15 (46.9) [29.1, 65.3]	31	28 (90.3)	9 (29.0) [14.2, 48.0]	1.615 [0.832, 3.132]	2.157 [0.762, 6.108]	17.8 [-8.9, 44.6]	0.148	
Baseline FENO										0.630	
< 25 ppb	39	32 (82.1)	19 (48.7) [32.4, 65.2]	30	23 (76.7)	9 (30.0) [14.7, 49.4]	1.624 [0.861, 3.063]	2.217 [0.814, 6.038]	18.7 [-6.9, 44.4]	0.119	
>= 25 ppb	27	25 (92.6)	16 (59.3) [38.8, 77.6]	34	31 (91.2)	10 (29.4) [15.1, 47.5]	2.015 [1.098, 3.699]	3.491 [1.204, 10.123]	29.8 [2.5, 57.2]	0.020	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_ILSPK: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.410	
All negative	27	23 (85.2)	16 (59.3) [38.8, 77.6]	29	23 (79.3)	7 (24.1) [10.3, 43.5]	2.455 [1.199, 5.029]	4.571 [1.454, 14.376]	35.1 [7.3, 62.9]	0.008	*
Any positive	34	31 (91.2)	17 (50.0) [32.4, 67.6]	33	29 (87.9)	10 (30.3) [15.6, 48.7]	1.650 [0.890, 3.058]	2.300 [0.845, 6.262]	19.7 [-6.3, 45.7]	0.103	
Total serum IgE										0.262	
Low	23	20 (87.0)	14 (60.9) [38.5, 80.3]	14	11 (78.6)	3 (21.4) [4.7, 50.8]	2.841 [0.989, 8.160]	5.704 [1.239, 26.255]	39.4 [4.4, 74.5]	0.021	*
Normal	40	34 (85.0)	18 (45.0) [29.3, 61.5]	44	37 (84.1)	14 (31.8) [18.6, 47.6]	1.414 [0.815, 2.456]	1.753 [0.721, 4.265]	13.2 [-9.9, 36.2]	0.217	
High	3	3 (100.0)	3 (100.0) [29.2, 100.0]	7	7 (100.0)	2 (28.6) [3.7, 71.0]	3.500 [1.085, 11.292]	15.400 + [0.557, 425.527]	71.4 [14.2, 100.0]	0.167	#
OCS at baseline										0.283	
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	13	9 (69.2)	2 (15.4) [1.9, 45.4]	3.611 [0.888, 14.679]	6.875 [0.931, 50.782]	40.2 [-7.2, 87.5]	0.074	#
No	57	50 (87.7)	30 (52.6) [39.0, 66.0]	52	46 (88.5)	17 (32.7) [20.3, 47.1]	1.610 [1.015, 2.553]	2.288 [1.050, 4.983]	19.9 [-0.1, 40.0]	0.037	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_ILSPK: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
LAMA use at baseline										0.827	
Yes	7	6 (85.7)	2 (28.6) [3.7, 71.0]	3	2 (66.7)	0 (0.0) [0.0, 70.8]	2.500 + [0.154, 40.665]	3.182 + [0.115, 87.919]	28.6 [-28.7, 85.8]	1.000	#
No	59	51 (86.4)	33 (55.9) [42.4, 68.8]	62	53 (85.5)	19 (30.6) [19.6, 43.7]	1.825 [1.178, 2.827]	2.872 [1.363, 6.053]	25.3 [6.5, 44.0]	0.005	*
Tiotropium use at baseline		N<10	any level							NE	
Yes	6	5 (83.3)	2 (33.3) [4.3, 77.7]	2	1 (50.0)	0 (0.0) [0.0, 84.2]					
No	60	52 (86.7)	33 (55.0) [41.6, 67.9]	63	54 (85.7)	19 (30.2) [19.2, 43.0]					
Montelukast/ Cromoglicic acid use at baseline										0.226	
Yes	17	14 (82.4)	8 (47.1) [23.0, 72.2]	21	20 (95.2)	8 (38.1) [18.1, 61.6]	1.235 [0.588, 2.596]	1.444 [0.395, 5.285]	9.0 [-27.9, 45.8]	0.583	
No	49	43 (87.8)	27 (55.1) [40.2, 69.3]	44	35 (79.5)	11 (25.0) [13.2, 40.3]	2.204 [1.245, 3.900]	3.682 [1.520, 8.917]	30.1 [9.0, 51.2]	0.003	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_ILSPP: Increase of at least 0.9 points in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.397	
White	60	51 (85.0)	30 (50.0) [36.8, 63.2]	58	48 (82.8)	18 (31.0) [19.5, 44.5]	1.611 [1.018, 2.551]	2.222 [1.048, 4.714]	19.0 [-0.1, 38.0]	0.037	*
Non-white	6	6 (100.0)	5 (83.3) [35.9, 99.6]	7	7 (100.0)	5 (71.4) [29.0, 96.3]	1.167 [0.647, 2.104]	2.000 [0.134, 29.808]	11.9 [-48.4, 72.2]	1.000	#
Region (cat. P)										0.102	
North America/Western EU	6	5 (83.3)	3 (50.0) [11.8, 88.2]	4	3 (75.0)	3 (75.0) [19.4, 99.4]	0.667 [0.250, 1.776]	0.333 [0.021, 5.329]	-25.0 [-100.0, 54.2]	0.571	#
Rest of world	60	52 (86.7)	32 (53.3) [40.0, 66.3]	61	52 (85.2)	20 (32.8) [21.3, 46.0]	1.627 [1.058, 2.501]	2.343 [1.121, 4.895]	20.5 [1.6, 39.5]	0.023	*
Baseline eosinophils (cat. P)										0.992	
< 250 cells/uL	30	25 (83.3)	17 (56.7) [37.4, 74.5]	29	25 (86.2)	11 (37.9) [20.7, 57.7]	1.494 [0.853, 2.618]	2.140 [0.755, 6.061]	18.7 [-9.7, 47.2]	0.153	
>= 250 cells/uL	36	32 (88.9)	18 (50.0) [32.9, 67.1]	36	30 (83.3)	12 (33.3) [18.6, 51.0]	1.500 [0.852, 2.641]	2.000 [0.772, 5.184]	16.7 [-8.6, 41.9]	0.154	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_ILSPP: Increase of at least 0.9 points in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. P)										0.119	
< 24 ppb	38	31 (81.6)	18 (47.4) [31.0, 64.2]	30	23 (76.7)	13 (43.3) [25.5, 62.6]	1.093 [0.644, 1.855]	1.177 [0.449, 3.082]	4.0 [-22.7, 30.8]	0.742	
>= 24 ppb	28	26 (92.9)	17 (60.7) [40.6, 78.5]	34	31 (91.2)	10 (29.4) [15.1, 47.5]	2.064 [1.133, 3.761]	3.709 [1.288, 10.685]	31.3 [4.3, 58.3]	0.014	*
Baseline FENO (cat. M)										0.069	
< 22.0 ppb	32	26 (81.3)	14 (43.8) [26.4, 62.3]	27	21 (77.8)	12 (44.4) [25.5, 64.7]	0.984 [0.553, 1.752]	0.972 [0.347, 2.727]	-0.7 [-29.5, 28.2]	0.958	
>= 22.0 ppb	34	31 (91.2)	21 (61.8) [43.6, 77.8]	37	33 (89.2)	11 (29.7) [15.9, 47.0]	2.078 [1.185, 3.643]	3.818 [1.422, 10.251]	32.0 [7.2, 56.9]	0.007	*
Baseline all FEIA status										0.101	
All negative	25	21 (84.0)	15 (60.0) [38.7, 78.9]	22	18 (81.8)	5 (22.7) [7.8, 45.4]	2.640 [1.146, 6.081]	5.100 [1.420, 18.315]	37.3 [7.0, 67.5]	0.011	*
Any positive	35	32 (91.4)	17 (48.6) [31.4, 66.0]	41	35 (85.4)	17 (41.5) [26.3, 57.9]	1.171 [0.712, 1.928]	1.333 [0.537, 3.308]	7.1 [-17.9, 32.2]	0.537	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_ILSPP: Increase of at least 0.9 points in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Th2 status										0.182	
Low	41	35 (85.4)	23 (56.1) [39.7, 71.5]	30	25 (83.3)	8 (26.7) [12.3, 45.9]	2.104 [1.096, 4.039]	3.514 [1.270, 9.720]	29.4 [4.6, 54.3]	0.014	*
High	25	22 (88.0)	12 (48.0) [27.8, 68.7]	34	29 (85.3)	14 (41.2) [24.6, 59.3]	1.166 [0.658, 2.067]	1.319 [0.466, 3.732]	6.8 [-22.3, 35.9]	0.605	
Baseline Periostin										0.281	
Low (< 20.9 ng/ml)	26	23 (88.5)	13 (50.0) [29.9, 70.1]	31	25 (80.6)	13 (41.9) [24.5, 60.9]	1.192 [0.678, 2.098]	1.385 [0.485, 3.952]	8.1 [-21.4, 37.5]	0.546	
High (>= 20.9 ng/ml)	40	34 (85.0)	22 (55.0) [38.5, 70.7]	34	30 (88.2)	10 (29.4) [15.1, 47.5]	1.870 [1.035, 3.378]	2.933 [1.117, 7.703]	25.6 [1.1, 50.0]	0.028	*
Current post-BD FEV1 reversibility										0.597	
Yes	57	48 (84.2)	28 (49.1) [35.6, 62.7]	60	51 (85.0)	21 (35.0) [23.1, 48.4]	1.404 [0.909, 2.167]	1.793 [0.854, 3.767]	14.1 [-5.3, 33.6]	0.123	
No	9	9 (100.0)	7 (77.8) [40.0, 97.2]	5	4 (80.0)	2 (40.0) [5.3, 85.3]	1.944 [0.629, 6.013]	5.250 [0.485, 56.801]	37.8 [-28.6, 100.0]	0.266	#

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_ILSPP: Increase of at least 0.9 points in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 activity limitations score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Maintenance OCS use at baseline										0.570	
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	14	10 (71.4)	4 (28.6) [8.4, 58.1]	1.944 [0.706, 5.358]	3.125 [0.541, 18.038]	27.0 [-22.3, 76.3]	0.383	#
No	57	50 (87.7)	30 (52.6) [39.0, 66.0]	51	45 (88.2)	19 (37.3) [24.1, 51.9]	1.413 [0.916, 2.178]	1.871 [0.867, 4.041]	15.4 [-5.0, 35.8]	0.111	
No chronic OCS use and current post-BD FEV1 reversibility										0.324	
Yes	51	44 (86.3)	25 (49.0) [34.8, 63.4]	49	43 (87.8)	18 (36.7) [23.4, 51.7]	1.334 [0.841, 2.118]	1.656 [0.745, 3.683]	12.3 [-9.0, 33.5]	0.217	
No	15	13 (86.7)	10 (66.7) [38.4, 88.2]	16	12 (75.0)	5 (31.3) [11.0, 58.7]	2.133 [0.949, 4.796]	4.400 [0.975, 19.851]	35.4 [-4.0, 74.8]	0.052	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_ILSPP: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.535	
White	60	51 (85.0)	30 (50.0) [36.8, 63.2]	58	48 (82.8)	15 (25.9) [15.3, 39.0]	1.933 [1.168, 3.200]	2.867 [1.320, 6.226]	24.1 [5.5, 42.8]	0.007	*
Non-white	6	6 (100.0)	5 (83.3) [35.9, 99.6]	7	7 (100.0)	4 (57.1) [18.4, 90.1]	1.458 [0.700, 3.040]	3.750 [0.274, 51.373]	26.2 [-36.5, 88.9]	0.559	#
Region (cat. P)										0.045	i
North America/Western EU	6	5 (83.3)	3 (50.0) [11.8, 88.2]	4	3 (75.0)	3 (75.0) [19.4, 99.4]	0.667 [0.250, 1.776]	0.333 [0.021, 5.329]	-25.0 [-100.0, 54.2]	0.571	#
Rest of world	60	52 (86.7)	32 (53.3) [40.0, 66.3]	61	52 (85.2)	16 (26.2) [15.8, 39.1]	2.033 [1.255, 3.295]	3.214 [1.498, 6.896]	27.1 [8.7, 45.5]	0.002	*
Baseline eosinophils (cat. P)										0.228	
< 250 cells/uL	30	25 (83.3)	18 (60.0) [40.6, 77.3]	29	25 (86.2)	7 (24.1) [10.3, 43.5]	2.486 [1.224, 5.047]	4.714 [1.536, 14.465]	35.9 [9.0, 62.7]	0.006	*
>= 250 cells/uL	36	32 (88.9)	17 (47.2) [30.4, 64.5]	36	30 (83.3)	12 (33.3) [18.6, 51.0]	1.417 [0.796, 2.522]	1.789 [0.690, 4.641]	13.9 [-11.3, 39.1]	0.233	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_ILSPP: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. P)										0.733	
< 24 ppb	38	31 (81.6)	19 (50.0) [33.4, 66.6]	30	23 (76.7)	9 (30.0) [14.7, 49.4]	1.667 [0.886, 3.137]	2.333 [0.852, 6.387]	20.0 [-5.8, 45.8]	0.099	
>= 24 ppb	28	26 (92.9)	16 (57.1) [37.2, 75.5]	34	31 (91.2)	10 (29.4) [15.1, 47.5]	1.943 [1.054, 3.581]	3.200 [1.119, 9.153]	27.7 [0.6, 54.9]	0.029	*
Baseline FENO (cat. M)										0.812	
< 22.0 ppb	32	26 (81.3)	16 (50.0) [31.9, 68.1]	27	21 (77.8)	8 (29.6) [13.8, 50.2]	1.688 [0.858, 3.320]	2.375 [0.808, 6.981]	20.4 [-7.5, 48.2]	0.116	
>= 22.0 ppb	34	31 (91.2)	19 (55.9) [37.9, 72.8]	37	33 (89.2)	11 (29.7) [15.9, 47.0]	1.880 [1.054, 3.352]	2.994 [1.127, 7.956]	26.2 [1.1, 51.2]	0.027	*
Baseline all FEIA status										0.417	
All negative	25	21 (84.0)	14 (56.0) [34.9, 75.6]	22	18 (81.8)	5 (22.7) [7.8, 45.4]	2.464 [1.058, 5.737]	4.327 [1.213, 15.439]	33.3 [2.8, 63.7]	0.022	*
Any positive	35	32 (91.4)	18 (51.4) [34.0, 68.6]	41	35 (85.4)	13 (31.7) [18.1, 48.1]	1.622 [0.933, 2.819]	2.281 [0.896, 5.802]	19.7 [-4.8, 44.2]	0.083	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_ILSPP: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Th2 status										0.013	i
Low	41	35 (85.4)	24 (58.5) [42.1, 73.7]	30	25 (83.3)	4 (13.3) [3.8, 30.7]	4.390 [1.701, 11.329]	9.176 [2.703, 31.156]	45.2 [22.9, 67.5]	<0.001	*
High	25	22 (88.0)	11 (44.0) [24.4, 65.1]	34	29 (85.3)	14 (41.2) [24.6, 59.3]	1.069 [0.588, 1.942]	1.122 [0.395, 3.189]	2.8 [-26.2, 31.8]	0.830	
Baseline Periostin										0.365	
Low (< 20.9 ng/ml)	26	23 (88.5)	12 (46.2) [26.6, 66.6]	31	25 (80.6)	10 (32.3) [16.7, 51.4]	1.431 [0.741, 2.762]	1.800 [0.613, 5.289]	13.9 [-14.9, 42.7]	0.287	
High (>= 20.9 ng/ml)	40	34 (85.0)	23 (57.5) [40.9, 73.0]	34	30 (88.2)	9 (26.5) [12.9, 44.4]	2.172 [1.168, 4.039]	3.758 [1.401, 10.080]	31.0 [7.0, 55.1]	0.008	*
Current post-BD FEV1 reversibility										0.636	
Yes	57	48 (84.2)	30 (52.6) [39.0, 66.0]	60	51 (85.0)	18 (30.0) [18.8, 43.2]	1.754 [1.109, 2.774]	2.593 [1.214, 5.535]	22.6 [3.5, 41.7]	0.013	*
No	9	9 (100.0)	5 (55.6) [21.2, 86.3]	5	4 (80.0)	1 (20.0) [0.5, 71.6]	2.778 [0.438, 17.629]	5.000 [0.388, 64.387]	35.6 [-27.8, 98.9]	0.301	#

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_ILSPP: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 environmental stimuli score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Maintenance OCS use at baseline										0.496	
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	14	10 (71.4)	3 (21.4) [4.7, 50.8]	2.593 [0.812, 8.277]	4.583 [0.733, 28.646]	34.1 [-13.9, 82.2]	0.179	#
No	57	50 (87.7)	30 (52.6) [39.0, 66.0]	51	45 (88.2)	16 (31.4) [19.1, 45.9]	1.678 [1.044, 2.697]	2.431 [1.106, 5.342]	21.3 [1.2, 41.3]	0.026	*
No chronic OCS use and current post-BD FEV1 reversibility										0.242	
Yes	51	44 (86.3)	26 (51.0) [36.6, 65.2]	49	43 (87.8)	16 (32.7) [19.9, 47.5]	1.561 [0.962, 2.533]	2.145 [0.953, 4.827]	18.3 [-2.7, 39.3]	0.065	
No	15	13 (86.7)	9 (60.0) [32.3, 83.7]	16	12 (75.0)	3 (18.8) [4.0, 45.6]	3.200 [1.065, 9.618]	6.500 [1.279, 33.034]	41.3 [3.5, 79.0]	0.020	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_ILMP0: Increase of at least 0.9 points in AQLQ+12 emotional function score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 emotional function score	Week 52	66	57 (86.4)	33 (50.0) [37.4, 62.6]	65	55 (84.6)	21 (32.3) [21.2, 45.1]	1.548 [1.010, 2.371]	2.095 [1.031, 4.259]	17.7 [-0.4, 35.8]	0.040 *

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_ILSPK: Increase of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex										0.951
Male	19	15 (78.9)	9 (47.4) [24.4, 71.1]	20	17 (85.0)	6 (30.0) [11.9, 54.3]	1.579 [0.695, 3.586]	2.100 [0.565, 7.811]	17.4 [-17.9, 52.6]	0.271
Female	47	42 (89.4)	24 (51.1) [36.1, 65.9]	45	38 (84.4)	15 (33.3) [20.0, 49.0]	1.532 [0.930, 2.523]	2.087 [0.898, 4.850]	17.7 [-4.3, 39.8]	0.087
Age										0.164
< 65 years	57	49 (86.0)	29 (50.9) [37.3, 64.4]	55	48 (87.3)	21 (38.2) [25.4, 52.3]	1.332 [0.874, 2.032]	1.677 [0.790, 3.557]	12.7 [-7.3, 32.7]	0.179
>= 65 years	9	8 (88.9)	4 (44.4) [13.7, 78.8]	10	7 (70.0)	0 (0.0) [0.0, 30.8]	9.900 + [0.606, 161.735]	17.182 + [0.775, 380.840]	44.4 [1.4, 87.5]	0.033 *
Exacerbations in the year before study										0.160
<= 2	44	38 (86.4)	21 (47.7) [32.5, 63.3]	45	38 (84.4)	17 (37.8) [23.8, 53.5]	1.263 [0.777, 2.054]	1.504 [0.646, 3.499]	9.9 [-12.8, 32.7]	0.345
> 2	22	19 (86.4)	12 (54.5) [32.2, 75.6]	20	17 (85.0)	4 (20.0) [5.7, 43.7]	2.727 [1.049, 7.094]	4.800 [1.207, 19.082]	34.5 [2.6, 66.5]	0.023 *

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_ILSPK: Increase of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10	any level							NE
White	60	51 (85.0)	28 (46.7) [33.7, 60.0]	58	48 (82.8)	18 (31.0) [19.5, 44.5]				
Black or African American	2	2 (100.0)	2 (100.0) [15.8, 100.0]	2	2 (100.0)	2 (100.0) [15.8, 100.0]				
Asian	3	3 (100.0)	2 (66.7) [9.4, 99.2]	3	3 (100.0)	0 (0.0) [0.0, 70.8]				
Other	1	1 (100.0)	1 (100.0) [2.5, 100.0]	2	2 (100.0)	1 (50.0) [1.3, 98.7]				
Region		N<10	any level							NE
Europe	40	36 (90.0)	20 (50.0) [33.8, 66.2]	36	31 (86.1)	10 (27.8) [14.2, 45.2]				
America	6	5 (83.3)	4 (66.7) [22.3, 95.7]	4	3 (75.0)	3 (75.0) [19.4, 99.4]				
Asia/Pacific	3	3 (100.0)	2 (66.7) [9.4, 99.2]	3	3 (100.0)	0 (0.0) [0.0, 70.8]				
Rest of the world	17	13 (76.5)	7 (41.2) [18.4, 67.1]	22	18 (81.8)	8 (36.4) [17.2, 59.3]				
BMI										0.942
18.5 - < 25.0 kg/m**2	15	13 (86.7)	8 (53.3) [26.6, 78.7]	21	17 (81.0)	7 (33.3) [14.6, 57.0]	1.600 [0.742, 3.449]	2.286 [0.586, 8.914]	20.0 [-18.0, 58.0]	0.237
25.0 - < 30.0 kg/m**2	24	20 (83.3)	14 (58.3) [36.6, 77.9]	20	18 (90.0)	7 (35.0) [15.4, 59.2]	1.667 [0.839, 3.311]	2.600 [0.763, 8.859]	23.3 [-10.0, 56.7]	0.127
>= 30.0 kg/m**2	27	24 (88.9)	11 (40.7) [22.4, 61.2]	24	20 (83.3)	7 (29.2) [12.6, 51.1]	1.397 [0.646, 3.022]	1.670 [0.519, 5.368]	11.6 [-18.3, 41.5]	0.393

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_ILSPK: Increase of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.090	
< 150 cells/uL	11	11 (100.0)	7 (63.6) [30.8, 89.1]	14	11 (78.6)	2 (14.3) [1.8, 42.8]	4.455 [1.145, 17.332]	10.500 [1.514, 72.811]	49.4 [7.4, 91.3]	0.017	*
>= 150 cells/uL	54	45 (83.3)	26 (48.1) [34.3, 62.2]	51	44 (86.3)	19 (37.3) [24.1, 51.9]	1.292 [0.823, 2.029]	1.564 [0.717, 3.409]	10.9 [-9.8, 31.6]	0.262	
Baseline eosinophils - High										0.138	
< 300 cells/uL	33	30 (90.9)	19 (57.6) [39.2, 74.5]	34	27 (79.4)	9 (26.5) [12.9, 44.4]	2.175 [1.156, 4.093]	3.770 [1.348, 10.540]	31.1 [5.7, 56.5]	0.010	*
>= 300 cells/uL	32	26 (81.3)	14 (43.8) [26.4, 62.3]	31	28 (90.3)	12 (38.7) [21.8, 57.8]	1.130 [0.625, 2.043]	1.231 [0.451, 3.364]	5.0 [-22.4, 32.5]	0.687	
Baseline FENO										0.542	
< 25 ppb	39	32 (82.1)	16 (41.0) [25.6, 57.9]	30	23 (76.7)	9 (30.0) [14.7, 49.4]	1.368 [0.704, 2.655]	1.623 [0.592, 4.449]	11.0 [-14.4, 36.5]	0.348	
>= 25 ppb	27	25 (92.6)	17 (63.0) [42.4, 80.6]	34	31 (91.2)	12 (35.3) [19.7, 53.5]	1.784 [1.040, 3.059]	3.117 [1.089, 8.916]	27.7 [0.1, 55.3]	0.033	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_ILSPK: Increase of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.123	
All negative	27	23 (85.2)	13 (48.1) [28.7, 68.1]	29	23 (79.3)	5 (17.2) [5.8, 35.8]	2.793 [1.149, 6.789]	4.457 [1.311, 15.158]	30.9 [4.0, 57.8]	0.014	*
Any positive	34	31 (91.2)	18 (52.9) [35.1, 70.2]	33	29 (87.9)	14 (42.4) [25.5, 60.8]	1.248 [0.751, 2.075]	1.527 [0.582, 4.005]	10.5 [-16.3, 37.3]	0.392	
Total serum IgE										0.068	
Low	23	20 (87.0)	11 (47.8) [26.8, 69.4]	14	11 (78.6)	1 (7.1) [0.2, 33.9]	6.696 [0.966, 46.421]	11.917 [1.331, 106.726]	40.7 [10.5, 70.9]	0.013	*
Normal	40	34 (85.0)	19 (47.5) [31.5, 63.9]	44	37 (84.1)	18 (40.9) [26.3, 56.8]	1.161 [0.717, 1.880]	1.307 [0.551, 3.100]	6.6 [-17.0, 30.2]	0.546	
High	3	3 (100.0)	3 (100.0) [29.2, 100.0]	7	7 (100.0)	2 (28.6) [3.7, 71.0]	3.500 [1.085, 11.292]	15.400 + [0.557, 425.527]	71.4 [14.2, 100.0]	0.167	#
OCS at baseline										0.687	
Yes	9	7 (77.8)	4 (44.4) [13.7, 78.8]	13	9 (69.2)	3 (23.1) [5.0, 53.8]	1.926 [0.562, 6.604]	2.667 [0.423, 16.826]	21.4 [-27.8, 70.5]	0.376	#
No	57	50 (87.7)	29 (50.9) [37.3, 64.4]	52	46 (88.5)	18 (34.6) [22.0, 49.1]	1.470 [0.935, 2.310]	1.956 [0.904, 4.234]	16.3 [-3.9, 36.4]	0.088	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_ILSPK: Increase of at least 0.9 points in AQLQ+12 emotional function score by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline										0.545
Yes	7	6 (85.7)	3 (42.9) [9.9, 81.6]	3	2 (66.7)	0 (0.0) [0.0, 70.8]	3.500 + [0.233, 52.562]	5.444 + [0.206, 144.102]	42.9 [-17.6, 100.0]	0.475 #
No	59	51 (86.4)	30 (50.8) [37.5, 64.1]	62	53 (85.5)	21 (33.9) [22.3, 47.0]	1.501 [0.978, 2.305]	2.020 [0.971, 4.203]	17.0 [-2.0, 36.0]	0.060
Tiotropium use at baseline		N<10	any level							NE
Yes	6	5 (83.3)	2 (33.3) [4.3, 77.7]	2	1 (50.0)	0 (0.0) [0.0, 84.2]				
No	60	52 (86.7)	31 (51.7) [38.4, 64.8]	63	54 (85.7)	21 (33.3) [22.0, 46.3]				
Montelukast/ Cromoglicic acid use at baseline										0.848
Yes	17	14 (82.4)	8 (47.1) [23.0, 72.2]	21	20 (95.2)	6 (28.6) [11.3, 52.2]	1.647 [0.709, 3.829]	2.222 [0.580, 8.511]	18.5 [-17.4, 54.4]	0.246
No	49	43 (87.8)	25 (51.0) [36.3, 65.6]	44	35 (79.5)	15 (34.1) [20.5, 49.9]	1.497 [0.913, 2.453]	2.014 [0.871, 4.656]	16.9 [-5.0, 38.9]	0.102

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_ILSPP: Increase of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.628	
White	60	51 (85.0)	28 (46.7) [33.7, 60.0]	58	48 (82.8)	18 (31.0) [19.5, 44.5]	1.504 [0.940, 2.405]	1.944 [0.916, 4.128]	15.6 [-3.4, 34.7]	0.083	
Non-white	6	6 (100.0)	5 (83.3) [35.9, 99.6]	7	7 (100.0)	3 (42.9) [9.9, 81.6]	1.944 [0.769, 4.915]	6.667 [0.487, 91.331]	40.5 [-22.3, 100.0]	0.266	#
Region (cat. P)										0.196	
North America/Western EU	6	5 (83.3)	4 (66.7) [22.3, 95.7]	4	3 (75.0)	3 (75.0) [19.4, 99.4]	0.889 [0.399, 1.979]	0.667 [0.039, 11.285]	-8.3 [-85.9, 69.3]	1.000	#
Rest of world	60	52 (86.7)	29 (48.3) [35.2, 61.6]	61	52 (85.2)	18 (29.5) [18.5, 42.6]	1.638 [1.026, 2.615]	2.235 [1.058, 4.720]	18.8 [0.1, 37.5]	0.034	*
Baseline eosinophils (cat. P)										0.907	
< 250 cells/uL	30	25 (83.3)	14 (46.7) [28.3, 65.7]	29	25 (86.2)	9 (31.0) [15.3, 50.8]	1.504 [0.774, 2.921]	1.944 [0.671, 5.638]	15.6 [-12.3, 43.6]	0.222	
>= 250 cells/uL	36	32 (88.9)	19 (52.8) [35.5, 69.6]	36	30 (83.3)	12 (33.3) [18.6, 51.0]	1.583 [0.908, 2.760]	2.235 [0.862, 5.798]	19.4 [-5.8, 44.7]	0.098	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_ILSPP: Increase of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. P)										0.641
< 24 ppb	38	31 (81.6)	16 (42.1) [26.3, 59.2]	30	23 (76.7)	9 (30.0) [14.7, 49.4]	1.404 [0.724, 2.720]	1.697 [0.617, 4.669]	12.1 [-13.6, 37.8]	0.308
>= 24 ppb	28	26 (92.9)	17 (60.7) [40.6, 78.5]	34	31 (91.2)	12 (35.3) [19.7, 53.5]	1.720 [0.998, 2.964]	2.833 [1.007, 7.971]	25.4 [-2.0, 52.9]	0.048 *
Baseline FENO (cat. M)										0.658
< 22.0 ppb	32	26 (81.3)	13 (40.6) [23.7, 59.4]	27	21 (77.8)	8 (29.6) [13.8, 50.2]	1.371 [0.670, 2.807]	1.625 [0.548, 4.815]	11.0 [-16.6, 38.6]	0.384
>= 22.0 ppb	34	31 (91.2)	20 (58.8) [40.7, 75.4]	37	33 (89.2)	13 (35.1) [20.2, 52.5]	1.674 [0.995, 2.817]	2.637 [1.010, 6.889]	23.7 [-1.7, 49.1]	0.047 *
Baseline all FEIA status										0.492
All negative	25	21 (84.0)	12 (48.0) [27.8, 68.7]	22	18 (81.8)	5 (22.7) [7.8, 45.4]	2.112 [0.883, 5.051]	3.138 [0.882, 11.162]	25.3 [-5.3, 55.8]	0.075
Any positive	35	32 (91.4)	19 (54.3) [36.6, 71.2]	41	35 (85.4)	15 (36.6) [22.1, 53.1]	1.484 [0.896, 2.458]	2.058 [0.820, 5.164]	17.7 [-7.1, 42.5]	0.124

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_ILSPP: Increase of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Th2 status										0.177	
Low	41	35 (85.4)	20 (48.8) [32.9, 64.9]	30	25 (83.3)	6 (20.0) [7.7, 38.6]	2.439 [1.117, 5.328]	3.810 [1.288, 11.264]	28.8 [4.9, 52.6]	0.014	*
High	25	22 (88.0)	13 (52.0) [31.3, 72.2]	34	29 (85.3)	14 (41.2) [24.6, 59.3]	1.263 [0.728, 2.190]	1.548 [0.547, 4.380]	10.8 [-18.3, 39.9]	0.414	
Baseline Periostin										0.768	
Low (< 20.9 ng/ml)	26	23 (88.5)	14 (53.8) [33.4, 73.4]	31	25 (80.6)	10 (32.3) [16.7, 51.4]	1.669 [0.896, 3.109]	2.450 [0.834, 7.198]	21.6 [-7.2, 50.4]	0.103	
High (>= 20.9 ng/ml)	40	34 (85.0)	19 (47.5) [31.5, 63.9]	34	30 (88.2)	11 (32.4) [17.4, 50.5]	1.468 [0.818, 2.636]	1.892 [0.732, 4.889]	15.1 [-9.6, 39.9]	0.189	
Current post-BD FEV1 reversibility										0.513	
Yes	57	48 (84.2)	28 (49.1) [35.6, 62.7]	60	51 (85.0)	20 (33.3) [21.7, 46.7]	1.474 [0.945, 2.299]	1.931 [0.915, 4.075]	15.8 [-3.5, 35.1]	0.084	
No	9	9 (100.0)	5 (55.6) [21.2, 86.3]	5	4 (80.0)	1 (20.0) [0.5, 71.6]	2.778 [0.438, 17.629]	5.000 [0.388, 64.387]	35.6 [-27.8, 98.9]	0.301	#

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_ILSPP: Increase of at least 0.9 points in AQLQ+12 emotional function score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 emotional function score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Maintenance OCS use at baseline										0.589	
Yes	9	7 (77.8)	4 (44.4) [13.7, 78.8]	14	10 (71.4)	3 (21.4) [4.7, 50.8]	2.074 [0.600, 7.173]	2.933 [0.469, 18.333]	23.0 [-25.0, 71.1]	0.363	#
No	57	50 (87.7)	29 (50.9) [37.3, 64.4]	51	45 (88.2)	18 (35.3) [22.4, 49.9]	1.442 [0.918, 2.262]	1.899 [0.875, 4.118]	15.6 [-4.7, 35.9]	0.105	
No chronic OCS use and current post-BD FEV1 reversibility										0.455	
Yes	51	44 (86.3)	25 (49.0) [34.8, 63.4]	49	43 (87.8)	17 (34.7) [21.7, 49.6]	1.413 [0.878, 2.273]	1.810 [0.810, 4.047]	14.3 [-6.8, 35.5]	0.149	
No	15	13 (86.7)	8 (53.3) [26.6, 78.7]	16	12 (75.0)	4 (25.0) [7.3, 52.4]	2.133 [0.807, 5.638]	3.429 [0.750, 15.671]	28.3 [-11.1, 67.8]	0.111	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_ILMP0: Increase of at least 0.9 points in AQLQ+12 symptom score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 symptom score	Week 52	66	57 (86.4)	36 (54.5) [41.8, 66.9]	65	55 (84.6)	25 (38.5) [26.7, 51.4]	1.418 [0.972, 2.070]	1.920 [0.957, 3.851]	16.1 [-2.3, 34.5]	0.066

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_ILSPK: Increase of at least 0.9 points in AQLQ+12 symptom score by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex										0.562
Male	19	15 (78.9)	9 (47.4) [24.4, 71.1]	20	17 (85.0)	8 (40.0) [19.1, 63.9]	1.184 [0.579, 2.423]	1.350 [0.379, 4.804]	7.4 [-28.8, 43.6]	0.647
Female	47	42 (89.4)	27 (57.4) [42.2, 71.7]	45	38 (84.4)	17 (37.8) [23.8, 53.5]	1.521 [0.971, 2.381]	2.224 [0.965, 5.126]	19.7 [-2.5, 41.9]	0.060
Age										0.148
< 65 years	57	49 (86.0)	32 (56.1) [42.4, 69.3]	55	48 (87.3)	25 (45.5) [32.0, 59.4]	1.235 [0.854, 1.787]	1.536 [0.729, 3.236]	10.7 [-9.5, 30.9]	0.260
>= 65 years	9	8 (88.9)	4 (44.4) [13.7, 78.8]	10	7 (70.0)	0 (0.0) [0.0, 30.8]	9.900 + [0.606, 161.735]	17.182 + [0.775, 380.840]	44.4 [1.4, 87.5]	0.033 *
Exacerbations in the year before study										0.646
<= 2	44	38 (86.4)	22 (50.0) [34.6, 65.4]	45	38 (84.4)	17 (37.8) [23.8, 53.5]	1.324 [0.821, 2.133]	1.647 [0.708, 3.831]	12.2 [-10.5, 34.9]	0.248
> 2	22	19 (86.4)	14 (63.6) [40.7, 82.8]	20	17 (85.0)	8 (40.0) [19.1, 63.9]	1.591 [0.853, 2.966]	2.625 [0.754, 9.134]	23.6 [-10.5, 57.8]	0.130

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_ILSPK: Increase of at least 0.9 points in AQLQ+12 symptom score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10	any level							NE
White	60	51 (85.0)	32 (53.3) [40.0, 66.3]	58	48 (82.8)	21 (36.2) [24.0, 49.9]				
Black or African American	2	2 (100.0)	1 (50.0) [1.3, 98.7]	2	2 (100.0)	2 (100.0) [15.8, 100.0]				
Asian	3	3 (100.0)	3 (100.0) [29.2, 100.0]	3	3 (100.0)	0 (0.0) [0.0, 70.8]				
Other	1	1 (100.0)	0 (0.0) [0.0, 97.5]	2	2 (100.0)	2 (100.0) [15.8, 100.0]				
Region		N<10	any level							NE
Europe	40	36 (90.0)	21 (52.5) [36.1, 68.5]	36	31 (86.1)	12 (33.3) [18.6, 51.0]				
America	6	5 (83.3)	3 (50.0) [11.8, 88.2]	4	3 (75.0)	3 (75.0) [19.4, 99.4]				
Asia/Pacific	3	3 (100.0)	3 (100.0) [29.2, 100.0]	3	3 (100.0)	0 (0.0) [0.0, 70.8]				
Rest of the world	17	13 (76.5)	9 (52.9) [27.8, 77.0]	22	18 (81.8)	10 (45.5) [24.4, 67.8]				
BMI										0.355
18.5 - < 25.0 kg/m**2	15	13 (86.7)	10 (66.7) [38.4, 88.2]	21	17 (81.0)	8 (38.1) [18.1, 61.6]	1.750 [0.912, 3.359]	3.250 [0.811, 13.030]	28.6 [-8.8, 65.9]	0.096
25.0 - < 30.0 kg/m**2	24	20 (83.3)	15 (62.5) [40.6, 81.2]	20	18 (90.0)	7 (35.0) [15.4, 59.2]	1.786 [0.911, 3.500]	3.095 [0.899, 10.651]	27.5 [-5.6, 60.6]	0.073
>= 30.0 kg/m**2	27	24 (88.9)	11 (40.7) [22.4, 61.2]	24	20 (83.3)	10 (41.7) [22.1, 63.4]	0.978 [0.507, 1.885]	0.963 [0.315, 2.941]	-0.9 [-31.9, 30.1]	0.947

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_ILSPK: Increase of at least 0.9 points in AQLQ+12 symptom score by key subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low										0.277	
< 150 cells/uL	11	11 (100.0)	7 (63.6) [30.8, 89.1]	14	11 (78.6)	4 (28.6) [8.4, 58.1]	2.227 [0.869, 5.708]	4.375 [0.808, 23.693]	35.1 [-10.0, 80.2]	0.116	#
>= 150 cells/uL	54	45 (83.3)	28 (51.9) [37.8, 65.7]	51	44 (86.3)	21 (41.2) [27.6, 55.8]	1.259 [0.830, 1.910]	1.538 [0.711, 3.329]	10.7 [-10.2, 31.6]	0.275	
Baseline eosinophils - High										0.984	
< 300 cells/uL	33	30 (90.9)	19 (57.6) [39.2, 74.5]	34	27 (79.4)	14 (41.2) [24.6, 59.3]	1.398 [0.850, 2.299]	1.939 [0.734, 5.120]	16.4 [-10.2, 43.0]	0.183	
>= 300 cells/uL	32	26 (81.3)	16 (50.0) [31.9, 68.1]	31	28 (90.3)	11 (35.5) [19.2, 54.6]	1.409 [0.783, 2.536]	1.818 [0.662, 4.995]	14.5 [-12.8, 41.9]	0.248	
Baseline FENO										0.823	
< 25 ppb	39	32 (82.1)	18 (46.2) [30.1, 62.8]	30	23 (76.7)	10 (33.3) [17.3, 52.8]	1.385 [0.753, 2.546]	1.714 [0.639, 4.596]	12.8 [-13.1, 38.8]	0.286	
>= 25 ppb	27	25 (92.6)	18 (66.7) [46.0, 83.5]	34	31 (91.2)	15 (44.1) [27.2, 62.1]	1.511 [0.951, 2.401]	2.533 [0.888, 7.226]	22.5 [-5.2, 50.3]	0.082	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_ILSPK: Increase of at least 0.9 points in AQLQ+12 symptom score by key subgroups
DITTL

	Tezepelumab			Placebo							
Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline specific perennial FEIA status										0.244	
All negative	27	23 (85.2)	15 (55.6) [35.3, 74.5]	29	23 (79.3)	8 (27.6) [12.7, 47.2]	2.014 [1.021, 3.973]	3.281 [1.078, 9.989]	28.0 [-0.4, 56.4]	0.035	*
Any positive	34	31 (91.2)	19 (55.9) [37.9, 72.8]	33	29 (87.9)	15 (45.5) [28.1, 63.6]	1.229 [0.762, 1.984]	1.520 [0.580, 3.983]	10.4 [-16.4, 37.2]	0.397	
Total serum IgE										0.147	
Low	23	20 (87.0)	11 (47.8) [26.8, 69.4]	14	11 (78.6)	2 (14.3) [1.8, 42.8]	3.348 [0.866, 12.943]	5.500 [0.999, 30.286]	33.5 [0.4, 66.7]	0.074	#
Normal	40	34 (85.0)	23 (57.5) [40.9, 73.0]	44	37 (84.1)	22 (50.0) [34.6, 65.4]	1.150 [0.773, 1.712]	1.353 [0.572, 3.202]	7.5 [-16.2, 31.2]	0.494	
High	3	3 (100.0)	2 (66.7) [9.4, 99.2]	7	7 (100.0)	1 (14.3) [0.4, 57.9]	4.667 [0.642, 33.906]	12.000 [0.489, 294.569]	52.4 [-30.7, 100.0]	0.183	#
OCS at baseline										0.147	
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	13	9 (69.2)	2 (15.4) [1.9, 45.4]	3.611 [0.888, 14.679]	6.875 [0.931, 50.782]	40.2 [-7.2, 87.5]	0.074	#
No	57	50 (87.7)	31 (54.4) [40.7, 67.6]	52	46 (88.5)	23 (44.2) [30.5, 58.7]	1.230 [0.835, 1.810]	1.503 [0.706, 3.201]	10.2 [-10.4, 30.7]	0.292	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_ILSPK: Increase of at least 0.9 points in AQLQ+12 symptom score by key subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline										0.289
Yes	7	6 (85.7)	5 (71.4) [29.0, 96.3]	3	2 (66.7)	0 (0.0) [0.0, 70.8]	5.500 + [0.395, 76.653]	15.400 + [0.557, 425.527]	71.4 [14.2, 100.0]	0.167 #
No	59	51 (86.4)	31 (52.5) [39.1, 65.7]	62	53 (85.5)	25 (40.3) [28.1, 53.6]	1.303 [0.884, 1.921]	1.639 [0.797, 3.367]	12.2 [-7.1, 31.5]	0.180
Tiotropium use at baseline		N<10	any level							NE
Yes	6	5 (83.3)	4 (66.7) [22.3, 95.7]	2	1 (50.0)	0 (0.0) [0.0, 84.2]				
No	60	52 (86.7)	32 (53.3) [40.0, 66.3]	63	54 (85.7)	25 (39.7) [27.6, 52.8]				
Montelukast/ Cromoglicic acid use at baseline										0.309
Yes	17	14 (82.4)	10 (58.8) [32.9, 81.6]	21	20 (95.2)	11 (52.4) [29.8, 74.3]	1.123 [0.635, 1.985]	1.299 [0.357, 4.722]	6.4 [-30.6, 43.4]	0.695
No	49	43 (87.8)	26 (53.1) [38.3, 67.5]	44	35 (79.5)	14 (31.8) [18.6, 47.6]	1.668 [1.005, 2.767]	2.422 [1.039, 5.650]	21.2 [-0.5, 43.0]	0.040 *

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_ILSPP: Increase of at least 0.9 points in AQLQ+12 symptom score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race (cat. P)										0.631	
White	60	51 (85.0)	32 (53.3) [40.0, 66.3]	58	48 (82.8)	21 (36.2) [24.0, 49.9]	1.473 [0.972, 2.232]	2.014 [0.963, 4.210]	17.1 [-2.2, 36.5]	0.063	
Non-white	6	6 (100.0)	4 (66.7) [22.3, 95.7]	7	7 (100.0)	4 (57.1) [18.4, 90.1]	1.167 [0.496, 2.744]	1.500 [0.156, 14.420]	9.5 [-58.6, 77.6]	1.000	#
Region (cat. P)										0.126	
North America/Western EU	6	5 (83.3)	3 (50.0) [11.8, 88.2]	4	3 (75.0)	3 (75.0) [19.4, 99.4]	0.667 [0.250, 1.776]	0.333 [0.021, 5.329]	-25.0 [-100.0, 54.2]	0.571	#
Rest of world	60	52 (86.7)	33 (55.0) [41.6, 67.9]	61	52 (85.2)	22 (36.1) [24.2, 49.4]	1.525 [1.017, 2.286]	2.167 [1.045, 4.493]	18.9 [-0.1, 38.0]	0.037	*
Baseline eosinophils (cat. P)										0.363	
< 250 cells/uL	30	25 (83.3)	13 (43.3) [25.5, 62.6]	29	25 (86.2)	11 (37.9) [20.7, 57.7]	1.142 [0.615, 2.123]	1.251 [0.442, 3.545]	5.4 [-23.0, 33.8]	0.675	
>= 250 cells/uL	36	32 (88.9)	23 (63.9) [46.2, 79.2]	36	30 (83.3)	14 (38.9) [23.1, 56.5]	1.643 [1.019, 2.648]	2.780 [1.070, 7.223]	25.0 [-0.1, 50.1]	0.035	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_ILSPP: Increase of at least 0.9 points in AQLQ+12 symptom score by study specific subgroups
DITTL

	Tezepelumab			Placebo						
Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. P)										0.949
< 24 ppb	38	31 (81.6)	18 (47.4) [31.0, 64.2]	30	23 (76.7)	10 (33.3) [17.3, 52.8]	1.421 [0.774, 2.607]	1.800 [0.668, 4.848]	14.0 [-12.1, 40.2]	0.246
>= 24 ppb	28	26 (92.9)	18 (64.3) [44.1, 81.4]	34	31 (91.2)	15 (44.1) [27.2, 62.1]	1.457 [0.912, 2.328]	2.280 [0.816, 6.371]	20.2 [-7.5, 47.8]	0.116
Baseline FENO (cat. M)										0.969
< 22.0 ppb	32	26 (81.3)	15 (46.9) [29.1, 65.3]	27	21 (77.8)	9 (33.3) [16.5, 54.0]	1.406 [0.735, 2.690]	1.765 [0.612, 5.090]	13.5 [-14.7, 41.8]	0.296
>= 22.0 ppb	34	31 (91.2)	21 (61.8) [43.6, 77.8]	37	33 (89.2)	16 (43.2) [27.1, 60.5]	1.428 [0.907, 2.249]	2.120 [0.820, 5.479]	18.5 [-7.1, 44.2]	0.121
Baseline all FEIA status										0.406
All negative	25	21 (84.0)	13 (52.0) [31.3, 72.2]	22	18 (81.8)	6 (27.3) [10.7, 50.2]	1.907 [0.875, 4.157]	2.889 [0.850, 9.816]	24.7 [-6.6, 56.0]	0.088
Any positive	35	32 (91.4)	20 (57.1) [39.4, 73.7]	41	35 (85.4)	18 (43.9) [28.5, 60.3]	1.302 [0.830, 2.040]	1.704 [0.686, 4.234]	13.2 [-11.8, 38.2]	0.253

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_ILSPP: Increase of at least 0.9 points in AQLQ+12 symptom score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Th2 status										0.656	
Low	41	35 (85.4)	19 (46.3) [30.7, 62.6]	30	25 (83.3)	8 (26.7) [12.3, 45.9]	1.738 [0.882, 3.426]	2.375 [0.860, 6.558]	19.7 [-5.2, 44.5]	0.094	
High	25	22 (88.0)	17 (68.0) [46.5, 85.1]	34	29 (85.3)	16 (47.1) [29.8, 64.9]	1.445 [0.925, 2.258]	2.391 [0.814, 7.018]	20.9 [-7.3, 49.2]	0.112	
Baseline Periostin										0.113	
Low (< 20.9 ng/ml)	26	23 (88.5)	13 (50.0) [29.9, 70.1]	31	25 (80.6)	15 (48.4) [30.2, 66.9]	1.033 [0.609, 1.754]	1.067 [0.376, 3.026]	1.6 [-28.0, 31.2]	0.904	
High (>= 20.9 ng/ml)	40	34 (85.0)	23 (57.5) [40.9, 73.0]	34	30 (88.2)	10 (29.4) [15.1, 47.5]	1.955 [1.089, 3.509]	3.247 [1.233, 8.549]	28.1 [3.7, 52.5]	0.016	*
Current post-BD FEV1 reversibility										0.533	
Yes	57	48 (84.2)	29 (50.9) [37.3, 64.4]	60	51 (85.0)	23 (38.3) [26.1, 51.8]	1.327 [0.881, 2.000]	1.666 [0.799, 3.475]	12.5 [-7.0, 32.1]	0.174	
No	9	9 (100.0)	7 (77.8) [40.0, 97.2]	5	4 (80.0)	2 (40.0) [5.3, 85.3]	1.944 [0.629, 6.013]	5.250 [0.485, 56.801]	37.8 [-28.6, 100.0]	0.266	#

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_ILSPP: Increase of at least 0.9 points in AQLQ+12 symptom score by study specific subgroups
DITTL

Increase of at least 0.9 points in AQLQ+12 symptom score / Week 52	Tezepelumab N	Tezepelumab nval (%)	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo nval (%)	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Maintenance OCS use at baseline										0.249	
Yes	9	7 (77.8)	5 (55.6) [21.2, 86.3]	14	10 (71.4)	3 (21.4) [4.7, 50.8]	2.593 [0.812, 8.277]	4.583 [0.733, 28.646]	34.1 [-13.9, 82.2]	0.179	#
No	57	50 (87.7)	31 (54.4) [40.7, 67.6]	51	45 (88.2)	22 (43.1) [29.3, 57.8]	1.261 [0.850, 1.871]	1.572 [0.734, 3.363]	11.2 [-9.4, 31.9]	0.245	
No chronic OCS use and current post-BD FEV1 reversibility										0.118	
Yes	51	44 (86.3)	26 (51.0) [36.6, 65.2]	49	43 (87.8)	21 (42.9) [28.8, 57.8]	1.190 [0.781, 1.812]	1.387 [0.630, 3.050]	8.1 [-13.4, 29.6]	0.418	
No	15	13 (86.7)	10 (66.7) [38.4, 88.2]	16	12 (75.0)	4 (25.0) [7.3, 52.4]	2.667 [1.062, 6.698]	6.000 [1.261, 28.547]	41.7 [3.3, 80.1]	0.022	*

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTD_ILMP0: Decrease of at least 0.9 points in AQLQ+12 total score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 total score	Week 52	66	57 (86.4)	2 (3.0) [0.4, 10.5]	65	55 (84.6)	2 (3.1) [0.4, 10.7]	0.985 [0.143, 6.784]	0.984 [0.134, 7.205]	-0.0 [-7.5, 7.4]	1.000 #

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAD_ILMP0: Decrease of at least 0.9 points in AQLQ+12 activity limitations score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 activity limitations score	Week 52	66	57 (86.4)	0 (0.0) [0.0, 5.4]	65	55 (84.6)	2 (3.1) [0.4, 10.7]	0.197 + [0.010, 4.026]	0.191 + [0.009, 4.056]	-3.1 [-8.8, 2.6]	0.244 #

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_ILMP0: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score	Week 52	66	57 (86.4)	1 (1.5) [0.0, 8.2]	65	55 (84.6)	4 (6.2) [1.7, 15.0]	0.246 [0.028, 2.144]	0.235 [0.026, 2.158]	-4.6 [-12.7, 3.4]	0.208 #

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_ILMP0: Decrease of at least 0.9 points in AQLQ+12 emotional function score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 emotional function score	Week 52	66	57 (86.4)	2 (3.0) [0.4, 10.5]	65	55 (84.6)	5 (7.7) [2.5, 17.0]	0.394 [0.079, 1.958]	0.375 [0.070, 2.006]	-4.7 [-13.9, 4.6]	0.274 #

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMD_ILMP0: Decrease of at least 0.9 points in AQLQ+12 symptom score
DITTL

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 symptom score	Week 52	66	57 (86.4)	2 (3.0) [0.4, 10.5]	65	55 (84.6)	3 (4.6) [1.0, 12.9]	0.657 [0.113, 3.801]	0.646 [0.104, 3.998]	-1.6 [-9.7, 6.5]	0.680 #

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILMH0: Course of AQLQ+12 total score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	66	58 (87.9)	4.08 (0.90)	2.0	3.63	4.06	4.59	6.3	
		Placebo	65	55 (84.6)	4.26 (0.81)	1.8	3.75	4.28	4.72	6.3	
	Week 4	Tezepelumab	66	60 (90.9)	4.82 (1.05)	1.4	4.03	4.97	5.66	6.8	
		Placebo	65	57 (87.7)	4.77 (0.93)	2.4	4.06	4.81	5.28	6.8	
	Week 8	Tezepelumab	66	62 (93.9)	5.10 (1.05)	3.0	4.16	5.14	5.97	6.8	
		Placebo	65	59 (90.8)	4.84 (1.00)	2.4	4.22	4.75	5.53	7.0	
	Week 12	Tezepelumab	66	62 (93.9)	5.30 (1.00)	3.0	4.50	5.16	6.22	7.0	
		Placebo	65	59 (90.8)	4.96 (1.01)	2.8	4.22	4.94	5.56	7.0	
	Week 16	Tezepelumab	66	62 (93.9)	5.26 (1.03)	2.7	4.44	5.23	6.09	7.0	
		Placebo	65	59 (90.8)	4.95 (1.19)	1.2	4.13	4.94	5.72	7.0	
	Week 20	Tezepelumab	66	63 (95.5)	5.22 (1.03)	3.2	4.31	5.22	6.13	7.0	
		Placebo	65	59 (90.8)	4.87 (1.18)	1.2	4.03	4.88	5.88	7.0	
	Week 24	Tezepelumab	66	63 (95.5)	5.25 (1.04)	3.3	4.34	5.16	6.06	7.0	
		Placebo	65	59 (90.8)	4.85 (1.21)	1.2	4.00	4.81	5.75	7.0	
	Week 28	Tezepelumab	66	65 (98.5)	5.23 (1.04)	3.3	4.47	5.19	6.03	7.0	
		Placebo	65	60 (92.3)	4.95 (1.28)	1.2	3.98	4.97	5.94	7.0	
	Week 32	Tezepelumab	66	65 (98.5)	5.29 (1.06)	2.9	4.34	5.28	6.09	7.0	
		Placebo	65	60 (92.3)	5.00 (1.19)	1.2	4.13	5.11	5.91	7.0	
	Week 36	Tezepelumab	66	65 (98.5)	5.34 (1.05)	3.3	4.59	5.38	6.22	7.0	
		Placebo	65	60 (92.3)	4.92 (1.15)	2.2	4.00	4.84	5.83	7.0	
	Week 40	Tezepelumab	66	65 (98.5)	5.28 (1.06)	3.2	4.47	5.25	6.06	7.0	
		Placebo	65	60 (92.3)	5.00 (1.19)	2.3	4.02	5.06	6.00	7.0	
	Week 44	Tezepelumab	66	65 (98.5)	5.30 (1.03)	3.5	4.34	5.19	6.16	7.0	
		Placebo	65	60 (92.3)	5.00 (1.13)	2.8	4.02	5.00	5.89	7.0	
	Week 48	Tezepelumab	66	65 (98.5)	5.34 (1.06)	2.9	4.50	5.34	6.16	7.0	
		Placebo	65	60 (92.3)	4.99 (1.13)	2.1	4.16	4.80	5.98	7.0	
	Week 52	Tezepelumab	66	65 (98.5)	5.34 (1.06)	2.9	4.56	5.28	6.22	7.0	
		Placebo	65	60 (92.3)	5.04 (1.11)	2.9	4.11	4.80	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILMH0: Course of AQLQ+12 total score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	66	55 (83.3)	0.75 (1.03)	-3.7	0.22	0.75	1.44	3.3	0.25 [-0.12, 0.63]
		Placebo	65	54 (83.1)	0.52 (0.80)	-1.2	0.13	0.44	0.94	2.6	
	Week 8	Tezepelumab	66	57 (86.4)	0.96 (1.00)	-1.0	0.31	0.81	1.75	3.8	0.36 [-0.01, 0.73]
		Placebo	65	55 (84.6)	0.62 (0.90)	-1.4	0.09	0.50	1.00	3.1	
	Week 12	Tezepelumab	66	57 (86.4)	1.17 (1.00)	-2.1	0.59	1.22	1.91	4.0	0.45 [0.08, 0.83]
		Placebo	65	55 (84.6)	0.71 (1.02)	-1.7	0.22	0.72	1.22	3.5	
	Week 16	Tezepelumab	66	57 (86.4)	1.14 (1.00)	-2.4	0.53	1.25	1.78	3.4	0.39 [0.02, 0.77]
		Placebo	65	55 (84.6)	0.73 (1.11)	-3.2	0.31	0.72	1.16	3.8	
	Week 20	Tezepelumab	66	57 (86.4)	1.14 (0.99)	-1.2	0.47	1.09	1.78	3.4	0.47 [0.10, 0.85]
		Placebo	65	55 (84.6)	0.65 (1.06)	-3.2	0.19	0.72	1.09	3.2	
	Week 24	Tezepelumab	66	57 (86.4)	1.20 (1.01)	-1.2	0.38	1.34	1.78	3.4	0.51 [0.14, 0.89]
		Placebo	65	55 (84.6)	0.64 (1.15)	-3.2	0.09	0.72	1.22	3.2	
	Week 28	Tezepelumab	66	57 (86.4)	1.15 (1.03)	-1.3	0.34	1.00	1.97	3.4	0.40 [0.02, 0.77]
		Placebo	65	55 (84.6)	0.71 (1.21)	-3.2	0.09	0.84	1.25	4.0	
	Week 32	Tezepelumab	66	57 (86.4)	1.20 (1.05)	-1.2	0.41	1.06	2.19	3.4	0.41 [0.03, 0.78]
		Placebo	65	55 (84.6)	0.77 (1.07)	-3.2	0.25	0.72	1.38	3.2	
	Week 36	Tezepelumab	66	57 (86.4)	1.26 (1.09)	-1.3	0.66	1.03	2.25	3.4	0.56 [0.18, 0.93]
		Placebo	65	55 (84.6)	0.68 (1.00)	-2.0	0.19	0.66	1.19	2.9	
	Week 40	Tezepelumab	66	57 (86.4)	1.21 (1.05)	-1.3	0.63	1.06	2.06	3.4	0.41 [0.04, 0.78]
		Placebo	65	55 (84.6)	0.77 (1.10)	-2.0	0.06	0.78	1.50	3.8	
	Week 44	Tezepelumab	66	57 (86.4)	1.23 (1.06)	-1.1	0.59	0.97	2.06	3.4	0.44 [0.07, 0.82]
		Placebo	65	55 (84.6)	0.75 (1.09)	-2.0	-0.03	0.75	1.31	3.4	
	Week 48	Tezepelumab	66	57 (86.4)	1.27 (1.06)	-1.1	0.50	1.19	2.13	3.4	0.50 [0.13, 0.88]
		Placebo	65	55 (84.6)	0.75 (1.04)	-2.0	0.09	0.72	1.38	3.3	
	Week 52	Tezepelumab	66	57 (86.4)	1.27 (1.06)	-1.2	0.50	1.19	2.13	3.4	0.44 [0.07, 0.82]
		Placebo	65	55 (84.6)	0.80 (1.04)	-2.0	0.19	0.72	1.41	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILMC0: Change from baseline in AQLQ+12 total score - MMRM results
DITTL

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	54 (83.1)					
Week 8	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	55 (84.6)					
Week 12	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	52 (80.0)					
Week 16	Tezepelumab	66	53 (80.3)	NE		NE		
	Placebo	65	50 (76.9)					
Week 20	Tezepelumab	66	51 (77.3)	NE		NE		
	Placebo	65	47 (72.3)					
Week 24	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	45 (69.2)					
Week 28	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 32	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	43 (66.2)					
Week 36	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 40	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	45 (69.2)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILMC0: Change from baseline in AQLQ+12 total score - MMRM results
DITTL

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 48	Tezepelumab	66	46 (69.7)	NE		NE		
	Placebo	65	44 (67.7)					
Week 52	Tezepelumab	66	18 (27.3)	NE		NE		
	Placebo	65	16 (24.6)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QTC_ILMG0: Course of AQLQ+12 total score
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QTC_ILMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	19	16 (84.2)	3.84 (0.71)	2.8	3.28	3.84	4.25	5.3	
			Placebo	20	17 (85.0)	4.01 (0.74)	1.8	3.84	4.13	4.34	5.2	
		Week 4	Tezepelumab	19	17 (89.5)	4.84 (1.09)	3.0	3.84	4.97	5.66	6.8	
			Placebo	20	17 (85.0)	4.53 (1.14)	2.4	3.72	4.88	5.31	6.3	
		Week 8	Tezepelumab	19	17 (89.5)	5.05 (1.12)	3.3	3.91	5.16	5.97	6.8	
			Placebo	20	18 (90.0)	4.48 (0.97)	2.8	3.72	4.31	5.22	6.8	
		Week 12	Tezepelumab	19	17 (89.5)	5.21 (0.98)	3.8	4.59	4.84	5.50	7.0	
			Placebo	20	18 (90.0)	4.70 (1.05)	2.8	3.88	4.86	5.53	6.9	
		Week 16	Tezepelumab	19	17 (89.5)	5.12 (1.07)	3.5	4.44	5.06	5.66	6.9	
			Placebo	20	18 (90.0)	4.45 (1.36)	1.2	3.84	4.45	5.44	6.8	
		Week 20	Tezepelumab	19	17 (89.5)	5.17 (1.13)	3.2	4.34	5.13	5.88	7.0	
			Placebo	20	18 (90.0)	4.52 (1.40)	1.2	3.78	4.66	5.53	6.8	
		Week 24	Tezepelumab	19	17 (89.5)	5.15 (1.18)	3.3	4.38	5.09	6.06	7.0	
			Placebo	20	18 (90.0)	4.42 (1.46)	1.2	3.47	4.39	5.50	6.9	
		Week 28	Tezepelumab	19	18 (94.7)	5.15 (1.13)	3.6	4.25	4.94	6.22	7.0	
			Placebo	20	19 (95.0)	4.53 (1.51)	1.2	3.63	4.38	5.69	6.8	
		Week 32	Tezepelumab	19	18 (94.7)	5.21 (1.11)	3.6	4.06	5.23	5.97	7.0	
			Placebo	20	19 (95.0)	4.72 (1.44)	1.2	3.97	5.09	5.72	6.9	
		Week 36	Tezepelumab	19	18 (94.7)	5.26 (1.21)	3.5	4.03	5.23	6.25	7.0	
			Placebo	20	19 (95.0)	4.69 (1.33)	2.2	3.84	4.81	5.72	6.9	
		Week 40	Tezepelumab	19	18 (94.7)	5.09 (1.17)	3.6	4.09	4.94	6.25	7.0	
			Placebo	20	19 (95.0)	4.77 (1.33)	2.3	3.88	5.06	5.91	6.9	
		Week 44	Tezepelumab	19	18 (94.7)	5.09 (1.21)	3.5	3.97	4.94	6.25	7.0	
			Placebo	20	19 (95.0)	4.81 (1.23)	2.8	3.97	5.00	5.97	6.9	
		Week 48	Tezepelumab	19	18 (94.7)	5.18 (1.15)	3.5	4.16	5.06	6.25	7.0	
			Placebo	20	19 (95.0)	4.78 (1.30)	2.1	3.97	4.75	6.16	6.8	
		Week 52	Tezepelumab	19	18 (94.7)	5.10 (1.10)	3.4	4.16	5.06	5.94	7.0	
			Placebo	20	19 (95.0)	4.82 (1.22)	2.9	3.88	4.75	6.16	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	19	15 (78.9)	0.97 (0.69)	-0.1	0.41	0.88	1.69	2.0	0.46 [-0.25, 1.17]
			Placebo	20	16 (80.0)	0.60 (0.90)	-0.8	0.11	0.47	1.14	2.6	
		Week 8	Tezepelumab	19	15 (78.9)	1.18 (0.78)	-0.0	0.44	1.28	1.78	2.6	0.80 [0.08, 1.53]
			Placebo	20	17 (85.0)	0.51 (0.88)	-0.6	0.03	0.34	0.84	3.1	
		Week 12	Tezepelumab	19	15 (78.9)	1.39 (0.66)	0.5	0.78	1.22	1.88	2.7	0.80 [0.07, 1.52]
			Placebo	20	17 (85.0)	0.74 (0.93)	-1.1	0.31	0.78	0.97	3.3	
		Week 16	Tezepelumab	19	15 (78.9)	1.36 (0.72)	0.5	0.59	1.34	1.84	2.7	0.84 [0.11, 1.57]
			Placebo	20	17 (85.0)	0.45 (1.33)	-3.2	0.09	0.66	0.78	3.2	
		Week 20	Tezepelumab	19	15 (78.9)	1.40 (0.78)	0.2	0.53	1.56	1.78	3.0	0.78 [0.06, 1.51]
			Placebo	20	17 (85.0)	0.55 (1.31)	-3.2	0.19	0.72	1.06	3.2	
		Week 24	Tezepelumab	19	15 (78.9)	1.47 (0.75)	0.3	0.56	1.56	1.66	2.8	0.90 [0.17, 1.63]
			Placebo	20	17 (85.0)	0.42 (1.42)	-3.2	0.09	0.53	1.06	3.2	
		Week 28	Tezepelumab	19	15 (78.9)	1.46 (0.84)	-0.0	0.66	1.56	1.97	2.7	0.89 [0.16, 1.62]
			Placebo	20	17 (85.0)	0.41 (1.42)	-3.2	0.00	0.63	1.19	3.2	
		Week 32	Tezepelumab	19	15 (78.9)	1.51 (0.80)	0.3	0.91	1.47	2.22	2.9	0.83 [0.11, 1.56]
			Placebo	20	17 (85.0)	0.61 (1.28)	-3.2	0.13	0.78	1.38	2.9	
		Week 36	Tezepelumab	19	15 (78.9)	1.56 (0.95)	0.0	0.81	1.63	2.56	2.8	0.97 [0.23, 1.71]
			Placebo	20	17 (85.0)	0.57 (1.08)	-1.7	0.19	0.53	1.06	2.5	
		Week 40	Tezepelumab	19	15 (78.9)	1.45 (0.84)	0.1	0.69	1.34	2.06	2.9	0.76 [0.04, 1.48]
			Placebo	20	17 (85.0)	0.68 (1.14)	-1.6	0.09	0.78	1.50	2.6	
		Week 44	Tezepelumab	19	15 (78.9)	1.41 (0.90)	0.2	0.75	0.91	2.25	2.9	0.76 [0.04, 1.48]
			Placebo	20	17 (85.0)	0.68 (1.01)	-1.0	0.03	0.69	1.31	2.6	
		Week 48	Tezepelumab	19	15 (78.9)	1.50 (0.85)	0.4	0.94	1.34	2.13	2.9	0.88 [0.15, 1.61]
			Placebo	20	17 (85.0)	0.65 (1.05)	-1.8	0.22	0.59	1.25	2.5	
		Week 52	Tezepelumab	19	15 (78.9)	1.40 (0.98)	0.1	0.47	1.22	2.50	3.0	0.72 [0.00, 1.44]
			Placebo	20	17 (85.0)	0.72 (0.92)	-0.9	0.22	0.59	1.25	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	47	42 (89.4)	4.17 (0.96)	2.0	3.66	4.27	4.69	6.3	
			Placebo	45	38 (84.4)	4.37 (0.82)	2.7	3.75	4.33	4.78	6.3	
		Week 4	Tezepelumab	47	43 (91.5)	4.81 (1.04)	1.4	4.13	4.78	5.53	6.6	
			Placebo	45	40 (88.9)	4.87 (0.82)	3.3	4.38	4.78	5.23	6.8	
		Week 8	Tezepelumab	47	45 (95.7)	5.11 (1.04)	3.0	4.19	5.13	5.94	6.8	
			Placebo	45	41 (91.1)	4.99 (0.98)	2.4	4.38	4.81	5.72	7.0	
		Week 12	Tezepelumab	47	45 (95.7)	5.33 (1.02)	3.0	4.38	5.16	6.22	7.0	
			Placebo	45	41 (91.1)	5.07 (0.99)	3.4	4.25	4.94	5.78	7.0	
		Week 16	Tezepelumab	47	45 (95.7)	5.31 (1.02)	2.7	4.38	5.50	6.09	7.0	
			Placebo	45	41 (91.1)	5.18 (1.04)	3.0	4.56	5.00	5.81	7.0	
		Week 20	Tezepelumab	47	46 (97.9)	5.24 (1.00)	3.5	4.31	5.27	6.13	6.9	
			Placebo	45	41 (91.1)	5.02 (1.05)	2.4	4.31	4.88	5.88	7.0	
		Week 24	Tezepelumab	47	46 (97.9)	5.29 (0.99)	3.5	4.34	5.33	6.06	7.0	
			Placebo	45	41 (91.1)	5.05 (1.05)	2.4	4.31	4.84	5.84	7.0	
		Week 28	Tezepelumab	47	47 (100.0)	5.27 (1.02)	3.3	4.50	5.38	6.03	7.0	
			Placebo	45	41 (91.1)	5.14 (1.13)	2.2	4.31	5.06	5.97	7.0	
		Week 32	Tezepelumab	47	47 (100.0)	5.32 (1.05)	2.9	4.41	5.63	6.13	7.0	
			Placebo	45	41 (91.1)	5.12 (1.04)	2.7	4.22	5.19	5.91	7.0	
		Week 36	Tezepelumab	47	47 (100.0)	5.37 (1.00)	3.3	4.63	5.38	6.22	7.0	
			Placebo	45	41 (91.1)	5.02 (1.06)	3.0	4.16	4.84	5.91	7.0	
		Week 40	Tezepelumab	47	47 (100.0)	5.35 (1.02)	3.2	4.63	5.28	6.06	7.0	
			Placebo	45	41 (91.1)	5.11 (1.13)	2.5	4.16	5.06	6.09	7.0	
		Week 44	Tezepelumab	47	47 (100.0)	5.38 (0.95)	3.7	4.47	5.41	6.16	7.0	
			Placebo	45	41 (91.1)	5.09 (1.09)	3.2	4.22	5.00	5.81	7.0	
		Week 48	Tezepelumab	47	47 (100.0)	5.39 (1.03)	2.9	4.56	5.50	6.16	7.0	
			Placebo	45	41 (91.1)	5.09 (1.05)	3.2	4.22	4.81	5.97	7.0	
		Week 52	Tezepelumab	47	47 (100.0)	5.43 (1.04)	2.9	4.63	5.53	6.28	7.0	
			Placebo	45	41 (91.1)	5.14 (1.06)	3.6	4.22	4.94	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	47	40 (85.1)	0.67 (1.13)	-3.7	0.05	0.70	1.39	3.3	0.19 [-0.25, 0.64]
			Placebo	45	38 (84.4)	0.49 (0.77)	-1.2	0.16	0.44	0.81	2.6	
		Week 8	Tezepelumab	47	42 (89.4)	0.89 (1.06)	-1.0	0.03	0.75	1.69	3.8	0.22 [-0.22, 0.66]
			Placebo	45	38 (84.4)	0.67 (0.92)	-1.4	0.16	0.59	1.09	2.7	
		Week 12	Tezepelumab	47	42 (89.4)	1.10 (1.09)	-2.1	0.50	1.02	1.91	4.0	0.36 [-0.08, 0.81]
			Placebo	45	38 (84.4)	0.70 (1.07)	-1.7	0.16	0.64	1.25	3.5	
		Week 16	Tezepelumab	47	42 (89.4)	1.07 (1.08)	-2.4	0.34	1.02	1.78	3.4	0.20 [-0.24, 0.64]
			Placebo	45	38 (84.4)	0.86 (0.99)	-2.0	0.31	0.89	1.41	3.8	
		Week 20	Tezepelumab	47	42 (89.4)	1.04 (1.04)	-1.2	0.28	0.78	1.81	3.4	0.34 [-0.10, 0.78]
			Placebo	45	38 (84.4)	0.70 (0.95)	-2.0	0.31	0.70	1.09	2.5	
		Week 24	Tezepelumab	47	42 (89.4)	1.10 (1.07)	-1.2	0.31	1.00	1.84	3.4	0.34 [-0.10, 0.78]
			Placebo	45	38 (84.4)	0.74 (1.01)	-2.0	0.09	0.75	1.22	2.8	
		Week 28	Tezepelumab	47	42 (89.4)	1.04 (1.07)	-1.3	0.28	0.80	2.03	3.4	0.18 [-0.26, 0.62]
			Placebo	45	38 (84.4)	0.84 (1.10)	-2.0	0.25	0.95	1.41	4.0	
		Week 32	Tezepelumab	47	42 (89.4)	1.09 (1.11)	-1.2	0.31	0.95	2.19	3.4	0.24 [-0.20, 0.68]
			Placebo	45	38 (84.4)	0.84 (0.96)	-2.0	0.44	0.72	1.34	3.2	
		Week 36	Tezepelumab	47	42 (89.4)	1.15 (1.13)	-1.3	0.44	0.97	2.19	3.4	0.40 [-0.04, 0.85]
			Placebo	45	38 (84.4)	0.72 (0.97)	-2.0	0.28	0.69	1.19	2.9	
		Week 40	Tezepelumab	47	42 (89.4)	1.13 (1.11)	-1.3	0.44	1.02	2.09	3.4	0.29 [-0.15, 0.73]
			Placebo	45	38 (84.4)	0.81 (1.10)	-2.0	0.06	0.77	1.44	3.8	
		Week 44	Tezepelumab	47	42 (89.4)	1.17 (1.11)	-1.1	0.44	0.98	2.03	3.4	0.34 [-0.10, 0.78]
			Placebo	45	38 (84.4)	0.79 (1.14)	-2.0	-0.03	0.78	1.22	3.4	
		Week 48	Tezepelumab	47	42 (89.4)	1.19 (1.12)	-1.1	0.44	1.14	2.13	3.4	0.37 [-0.07, 0.81]
			Placebo	45	38 (84.4)	0.79 (1.05)	-2.0	0.06	0.73	1.38	3.3	
		Week 52	Tezepelumab	47	42 (89.4)	1.22 (1.10)	-1.2	0.50	1.17	2.13	3.4	0.35 [-0.10, 0.79]
			Placebo	45	38 (84.4)	0.84 (1.10)	-2.0	0.19	0.73	1.41	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.10 (0.96)	2.0	3.59	4.14	4.69	6.3	
			Placebo	55	48 (87.3)	4.28 (0.85)	1.8	3.73	4.28	4.77	6.3	
		Week 4	Tezepelumab	57	52 (91.2)	4.83 (1.11)	1.4	3.95	4.97	5.66	6.8	
			Placebo	55	49 (89.1)	4.86 (0.94)	2.4	4.38	4.84	5.41	6.8	
		Week 8	Tezepelumab	57	54 (94.7)	5.15 (1.09)	3.0	4.09	5.16	6.00	6.8	
			Placebo	55	51 (92.7)	4.92 (1.02)	2.4	4.25	4.78	5.69	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.38 (1.03)	3.0	4.50	5.22	6.31	7.0	
			Placebo	55	51 (92.7)	5.08 (1.03)	2.8	4.34	5.13	5.78	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.32 (1.06)	2.7	4.44	5.34	6.25	7.0	
			Placebo	55	51 (92.7)	5.07 (1.20)	1.2	4.56	4.97	5.81	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.32 (1.05)	3.2	4.34	5.28	6.19	7.0	
			Placebo	55	51 (92.7)	4.98 (1.19)	1.2	4.22	4.91	5.91	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.32 (1.08)	3.3	4.34	5.38	6.25	7.0	
			Placebo	55	51 (92.7)	4.96 (1.22)	1.2	4.22	4.84	5.84	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.31 (1.08)	3.3	4.41	5.42	6.14	7.0	
			Placebo	55	51 (92.7)	5.05 (1.27)	1.2	4.22	5.13	6.00	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.35 (1.10)	2.9	4.30	5.55	6.19	7.0	
			Placebo	55	51 (92.7)	5.08 (1.16)	1.2	4.22	5.25	5.91	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.38 (1.09)	3.3	4.55	5.48	6.25	7.0	
			Placebo	55	51 (92.7)	4.99 (1.15)	2.2	4.00	5.03	5.94	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.33 (1.10)	3.2	4.42	5.28	6.19	7.0	
			Placebo	55	51 (92.7)	5.11 (1.16)	2.3	4.16	5.22	6.13	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.34 (1.06)	3.5	4.33	5.36	6.20	7.0	
			Placebo	55	51 (92.7)	5.08 (1.14)	2.8	4.03	5.06	6.19	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.35 (1.10)	2.9	4.42	5.36	6.23	7.0	
			Placebo	55	51 (92.7)	5.06 (1.14)	2.1	4.22	4.84	6.00	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.36 (1.10)	2.9	4.45	5.36	6.27	7.0	
			Placebo	55	51 (92.7)	5.12 (1.11)	2.9	4.22	5.06	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	57	47 (82.5)	0.74 (1.09)	-3.7	0.09	0.75	1.50	3.3	0.17 [-0.23, 0.58]
			Placebo	55	47 (85.5)	0.57 (0.82)	-1.2	0.16	0.50	0.97	2.6	
		Week 8	Tezepelumab	57	49 (86.0)	0.98 (1.03)	-1.0	0.31	0.84	1.75	3.8	0.31 [-0.09, 0.71]
			Placebo	55	48 (87.3)	0.68 (0.93)	-1.4	0.16	0.53	1.00	3.1	
		Week 12	Tezepelumab	57	49 (86.0)	1.23 (1.05)	-2.1	0.63	1.34	1.94	4.0	0.40 [-0.00, 0.80]
			Placebo	55	48 (87.3)	0.81 (1.05)	-1.7	0.33	0.75	1.23	3.5	
		Week 16	Tezepelumab	57	49 (86.0)	1.19 (1.04)	-2.4	0.53	1.34	1.78	3.4	0.33 [-0.07, 0.73]
			Placebo	55	48 (87.3)	0.83 (1.14)	-3.2	0.45	0.77	1.41	3.8	
		Week 20	Tezepelumab	57	49 (86.0)	1.22 (1.02)	-1.2	0.50	1.41	1.81	3.4	0.45 [0.05, 0.85]
			Placebo	55	48 (87.3)	0.75 (1.08)	-3.2	0.33	0.78	1.30	3.2	
		Week 24	Tezepelumab	57	49 (86.0)	1.25 (1.04)	-1.2	0.47	1.44	1.84	3.4	0.46 [0.06, 0.87]
			Placebo	55	48 (87.3)	0.73 (1.18)	-3.2	0.11	0.78	1.42	3.2	
		Week 28	Tezepelumab	57	49 (86.0)	1.21 (1.06)	-1.3	0.38	1.41	2.03	3.4	0.34 [-0.06, 0.74]
			Placebo	55	48 (87.3)	0.82 (1.23)	-3.2	0.30	0.97	1.44	4.0	
		Week 32	Tezepelumab	57	49 (86.0)	1.26 (1.09)	-1.2	0.41	1.38	2.19	3.4	0.36 [-0.05, 0.76]
			Placebo	55	48 (87.3)	0.87 (1.07)	-3.2	0.52	0.80	1.39	3.2	
		Week 36	Tezepelumab	57	49 (86.0)	1.30 (1.14)	-1.3	0.66	1.34	2.28	3.4	0.50 [0.09, 0.90]
			Placebo	55	48 (87.3)	0.76 (1.02)	-2.0	0.38	0.77	1.27	2.9	
		Week 40	Tezepelumab	57	49 (86.0)	1.25 (1.08)	-1.3	0.63	1.09	2.09	3.4	0.32 [-0.08, 0.72]
			Placebo	55	48 (87.3)	0.90 (1.11)	-2.0	0.31	0.92	1.61	3.8	
		Week 44	Tezepelumab	57	49 (86.0)	1.27 (1.09)	-1.1	0.59	1.00	2.19	3.4	0.37 [-0.03, 0.78]
			Placebo	55	48 (87.3)	0.85 (1.13)	-2.0	0.13	0.84	1.44	3.4	
		Week 48	Tezepelumab	57	49 (86.0)	1.29 (1.09)	-1.1	0.50	1.22	2.13	3.4	0.41 [0.01, 0.82]
			Placebo	55	48 (87.3)	0.84 (1.08)	-2.0	0.20	0.80	1.45	3.3	
		Week 52	Tezepelumab	57	49 (86.0)	1.29 (1.09)	-1.2	0.50	1.22	2.19	3.4	0.35 [-0.05, 0.76]
			Placebo	55	48 (87.3)	0.91 (1.07)	-2.0	0.20	0.80	1.58	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.93 (0.28)	3.6	3.66	3.91	4.17	4.3	
			Placebo	10	7 (70.0)	4.16 (0.40)	3.7	3.84	4.13	4.69	4.7	
		Week 4	Tezepelumab	9	8 (88.9)	4.76 (0.60)	3.9	4.31	4.70	5.22	5.7	
			Placebo	10	8 (80.0)	4.21 (0.72)	3.4	3.55	4.08	4.92	5.2	
		Week 8	Tezepelumab	9	8 (88.9)	4.76 (0.69)	4.2	4.22	4.45	5.31	6.0	
			Placebo	10	8 (80.0)	4.30 (0.68)	3.3	3.80	4.31	4.78	5.3	
		Week 12	Tezepelumab	9	8 (88.9)	4.73 (0.49)	4.2	4.36	4.64	5.08	5.5	
			Placebo	10	8 (80.0)	4.15 (0.39)	3.7	3.88	4.09	4.31	4.9	
		Week 16	Tezepelumab	9	8 (88.9)	4.81 (0.62)	4.0	4.27	4.81	5.34	5.7	
			Placebo	10	8 (80.0)	4.24 (0.77)	3.3	3.78	4.03	4.64	5.7	
		Week 20	Tezepelumab	9	9 (100.0)	4.65 (0.63)	3.8	4.16	4.63	5.28	5.6	
			Placebo	10	8 (80.0)	4.15 (0.92)	2.4	3.84	4.00	4.80	5.5	
		Week 24	Tezepelumab	9	9 (100.0)	4.86 (0.70)	4.0	4.50	4.63	5.28	6.1	
			Placebo	10	8 (80.0)	4.18 (0.97)	2.4	3.73	4.05	4.91	5.6	
		Week 28	Tezepelumab	9	9 (100.0)	4.74 (0.65)	4.0	4.53	4.63	4.72	6.2	
			Placebo	10	9 (90.0)	4.40 (1.30)	2.2	3.91	4.00	4.72	6.8	
		Week 32	Tezepelumab	9	9 (100.0)	4.93 (0.72)	4.0	4.53	4.66	5.25	6.2	
			Placebo	10	9 (90.0)	4.51 (1.28)	2.7	3.97	4.16	4.75	6.9	
		Week 36	Tezepelumab	9	9 (100.0)	5.08 (0.77)	4.1	4.63	5.00	5.09	6.4	
			Placebo	10	9 (90.0)	4.51 (1.15)	3.0	4.00	4.16	4.75	6.9	
		Week 40	Tezepelumab	9	9 (100.0)	4.98 (0.73)	4.0	4.63	4.97	5.25	6.5	
			Placebo	10	9 (90.0)	4.36 (1.23)	2.5	3.88	4.00	4.63	6.9	
		Week 44	Tezepelumab	9	9 (100.0)	5.05 (0.79)	4.0	4.63	5.03	5.13	6.5	
			Placebo	10	9 (90.0)	4.58 (1.07)	3.2	4.00	4.47	4.81	6.9	
		Week 48	Tezepelumab	9	9 (100.0)	5.23 (0.83)	4.0	4.63	5.16	5.75	6.6	
			Placebo	10	9 (90.0)	4.59 (1.06)	3.2	3.97	4.56	4.81	6.8	
		Week 52	Tezepelumab	9	9 (100.0)	5.20 (0.84)	4.0	4.63	5.13	5.75	6.6	
			Placebo	10	9 (90.0)	4.56 (1.08)	3.7	3.88	4.09	4.94	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	0.83 (0.64)	-0.2	0.53	0.81	1.06	2.0	1.09 [-0.01, 2.18]
			Placebo	10	7 (70.0)	0.16 (0.58)	-0.7	-0.50	0.41	0.50	0.9	
		Week 8	Tezepelumab	9	8 (88.9)	0.83 (0.77)	-0.1	0.20	0.59	1.67	1.8	0.88 [-0.19, 1.94]
			Placebo	10	7 (70.0)	0.22 (0.61)	-0.4	-0.31	0.06	0.63	1.3	
		Week 12	Tezepelumab	9	8 (88.9)	0.80 (0.55)	0.0	0.50	0.73	1.02	1.9	1.62 [0.43, 2.81]
			Placebo	10	7 (70.0)	0.04 (0.36)	-0.4	-0.31	0.16	0.28	0.5	
		Week 16	Tezepelumab	9	8 (88.9)	0.88 (0.70)	0.2	0.31	0.67	1.42	2.0	1.30 [0.17, 2.43]
			Placebo	10	7 (70.0)	0.08 (0.51)	-0.5	-0.38	0.09	0.31	1.0	
		Week 20	Tezepelumab	9	8 (88.9)	0.64 (0.62)	0.2	0.23	0.36	0.89	2.0	0.95 [-0.13, 2.03]
			Placebo	10	7 (70.0)	0.03 (0.66)	-1.3	-0.34	0.16	0.41	0.8	
		Week 24	Tezepelumab	9	8 (88.9)	0.88 (0.75)	0.3	0.34	0.59	1.20	2.4	1.16 [0.05, 2.27]
			Placebo	10	7 (70.0)	0.03 (0.71)	-1.3	-0.25	0.09	0.66	0.9	
		Week 28	Tezepelumab	9	8 (88.9)	0.81 (0.79)	0.0	0.31	0.70	0.94	2.6	1.08 [-0.02, 2.18]
			Placebo	10	7 (70.0)	-0.04 (0.79)	-1.5	-0.50	0.00	0.56	1.0	
		Week 32	Tezepelumab	9	8 (88.9)	0.84 (0.62)	0.3	0.41	0.73	0.97	2.2	1.17 [0.06, 2.28]
			Placebo	10	7 (70.0)	0.05 (0.71)	-1.0	-0.16	0.00	0.13	1.4	
		Week 36	Tezepelumab	9	8 (88.9)	0.99 (0.73)	0.2	0.56	0.78	1.22	2.6	1.44 [0.28, 2.60]
			Placebo	10	7 (70.0)	0.06 (0.53)	-0.7	-0.41	0.06	0.31	1.0	
		Week 40	Tezepelumab	9	8 (88.9)	1.01 (0.86)	0.1	0.47	0.84	1.23	2.9	1.50 [0.33, 2.67]
			Placebo	10	7 (70.0)	-0.10 (0.57)	-1.2	-0.28	0.03	0.09	0.7	
		Week 44	Tezepelumab	9	8 (88.9)	0.99 (0.83)	0.2	0.50	0.78	1.19	2.8	1.42 [0.27, 2.57]
			Placebo	10	7 (70.0)	0.07 (0.33)	-0.5	-0.06	0.09	0.31	0.5	
		Week 48	Tezepelumab	9	8 (88.9)	1.20 (0.92)	0.2	0.50	1.05	1.67	2.9	1.48 [0.32, 2.64]
			Placebo	10	7 (70.0)	0.12 (0.40)	-0.5	-0.16	0.09	0.53	0.7	
		Week 52	Tezepelumab	9	8 (88.9)	1.16 (0.95)	0.2	0.52	0.86	1.67	3.0	1.41 [0.26, 2.56]
			Placebo	10	7 (70.0)	0.10 (0.40)	-0.5	-0.25	0.09	0.41	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	44	39 (88.6)	4.12 (0.84)	2.2	3.66	4.16	4.59	6.3	
			Placebo	45	38 (84.4)	4.28 (0.77)	1.8	3.75	4.28	4.75	6.1	
		Week 4	Tezepelumab	44	40 (90.9)	4.84 (0.91)	3.0	4.08	4.97	5.48	6.8	
			Placebo	45	39 (86.7)	4.87 (0.98)	2.4	4.06	4.84	5.47	6.8	
		Week 8	Tezepelumab	44	41 (93.2)	5.08 (0.99)	3.0	4.25	5.03	5.91	6.8	
			Placebo	45	40 (88.9)	4.95 (0.99)	2.8	4.27	4.77	5.56	7.0	
		Week 12	Tezepelumab	44	41 (93.2)	5.27 (0.93)	3.8	4.63	5.09	6.13	7.0	
			Placebo	45	40 (88.9)	4.99 (1.01)	3.0	4.22	5.08	5.52	7.0	
		Week 16	Tezepelumab	44	41 (93.2)	5.20 (0.96)	3.7	4.44	5.06	5.97	6.9	
			Placebo	45	40 (88.9)	5.02 (1.08)	2.9	4.09	4.91	5.69	7.0	
		Week 20	Tezepelumab	44	42 (95.5)	5.21 (0.98)	3.5	4.31	5.20	6.06	7.0	
			Placebo	45	40 (88.9)	5.00 (1.10)	2.4	4.14	4.97	5.88	7.0	
		Week 24	Tezepelumab	44	42 (95.5)	5.23 (1.03)	3.3	4.38	5.11	6.06	7.0	
			Placebo	45	40 (88.9)	5.00 (1.15)	2.4	4.11	4.97	5.81	7.0	
		Week 28	Tezepelumab	44	43 (97.7)	5.15 (1.03)	3.3	4.34	5.16	5.91	7.0	
			Placebo	45	41 (91.1)	5.08 (1.19)	2.2	4.34	5.13	5.97	7.0	
		Week 32	Tezepelumab	44	43 (97.7)	5.25 (1.07)	2.9	4.25	5.22	6.00	7.0	
			Placebo	45	41 (91.1)	5.11 (1.13)	2.7	4.13	5.19	5.91	7.0	
		Week 36	Tezepelumab	44	43 (97.7)	5.30 (1.07)	3.3	4.50	5.09	6.25	7.0	
			Placebo	45	41 (91.1)	5.15 (1.09)	2.9	4.22	5.13	6.13	7.0	
		Week 40	Tezepelumab	44	43 (97.7)	5.24 (1.08)	3.2	4.38	5.25	6.13	7.0	
			Placebo	45	41 (91.1)	5.13 (1.17)	2.5	4.16	5.13	6.19	7.0	
		Week 44	Tezepelumab	44	43 (97.7)	5.26 (1.03)	3.7	4.31	5.13	6.16	7.0	
			Placebo	45	41 (91.1)	5.16 (1.11)	2.9	4.22	5.06	6.19	7.0	
		Week 48	Tezepelumab	44	43 (97.7)	5.29 (1.08)	2.9	4.34	5.34	6.16	7.0	
			Placebo	45	41 (91.1)	5.17 (1.13)	2.9	4.22	5.09	6.16	7.0	
		Week 52	Tezepelumab	44	43 (97.7)	5.28 (1.07)	2.9	4.34	5.19	6.22	7.0	
			Placebo	45	41 (91.1)	5.18 (1.12)	2.9	4.22	5.06	6.16	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	44	37 (84.1)	0.74 (0.82)	-0.5	0.22	0.72	1.38	3.3	0.18 [-0.27, 0.63]
			Placebo	45	38 (84.4)	0.60 (0.84)	-1.2	0.16	0.50	0.94	2.6	
		Week 8	Tezepelumab	44	38 (86.4)	0.92 (0.91)	-0.6	0.31	0.72	1.72	3.8	0.25 [-0.20, 0.70]
			Placebo	45	38 (84.4)	0.70 (0.87)	-1.0	0.16	0.56	1.00	3.1	
		Week 12	Tezepelumab	44	38 (86.4)	1.14 (0.89)	-0.7	0.56	0.95	1.75	4.0	0.46 [0.00, 0.91]
			Placebo	45	38 (84.4)	0.73 (0.91)	-1.0	0.28	0.72	1.09	3.3	
		Week 16	Tezepelumab	44	38 (86.4)	1.09 (0.86)	-0.5	0.44	0.81	1.69	3.4	0.36 [-0.10, 0.81]
			Placebo	45	38 (84.4)	0.78 (0.86)	-0.5	0.31	0.67	1.06	3.2	
		Week 20	Tezepelumab	44	38 (86.4)	1.13 (0.89)	-0.5	0.47	1.05	1.75	3.4	0.41 [-0.04, 0.87]
			Placebo	45	38 (84.4)	0.77 (0.86)	-1.3	0.31	0.69	1.06	3.2	
		Week 24	Tezepelumab	44	38 (86.4)	1.19 (0.93)	-0.5	0.34	1.45	1.78	3.4	0.46 [0.00, 0.91]
			Placebo	45	38 (84.4)	0.75 (0.98)	-1.3	0.09	0.67	1.28	3.2	
		Week 28	Tezepelumab	44	38 (86.4)	1.11 (0.98)	-0.5	0.31	0.81	1.88	3.4	0.34 [-0.11, 0.79]
			Placebo	45	38 (84.4)	0.78 (0.97)	-1.5	0.16	0.89	1.25	3.2	
		Week 32	Tezepelumab	44	38 (86.4)	1.18 (1.00)	-0.7	0.34	1.08	2.03	3.4	0.38 [-0.07, 0.83]
			Placebo	45	38 (84.4)	0.83 (0.84)	-1.0	0.22	0.72	1.38	2.9	
		Week 36	Tezepelumab	44	38 (86.4)	1.23 (1.05)	-0.5	0.66	0.97	2.19	3.4	0.39 [-0.06, 0.84]
			Placebo	45	38 (84.4)	0.87 (0.80)	-0.7	0.38	0.70	1.19	2.9	
		Week 40	Tezepelumab	44	38 (86.4)	1.22 (1.01)	-0.5	0.63	1.06	2.06	3.4	0.39 [-0.06, 0.85]
			Placebo	45	38 (84.4)	0.85 (0.90)	-1.2	0.25	0.78	1.41	2.8	
		Week 44	Tezepelumab	44	38 (86.4)	1.20 (0.99)	-0.6	0.66	0.91	1.88	3.4	0.37 [-0.09, 0.82]
			Placebo	45	38 (84.4)	0.86 (0.85)	-0.5	0.28	0.72	1.31	2.9	
		Week 48	Tezepelumab	44	38 (86.4)	1.23 (1.00)	-0.7	0.44	1.09	2.13	3.4	0.38 [-0.08, 0.83]
			Placebo	45	38 (84.4)	0.88 (0.85)	-0.5	0.25	0.73	1.41	3.3	
		Week 52	Tezepelumab	44	38 (86.4)	1.23 (1.01)	-0.7	0.50	1.03	2.13	3.4	0.36 [-0.09, 0.81]
			Placebo	45	38 (84.4)	0.89 (0.85)	-0.5	0.25	0.73	1.41	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	22	19 (86.4)	3.99 (1.03)	2.0	3.16	4.03	4.69	6.1	
			Placebo	20	17 (85.0)	4.22 (0.90)	2.7	3.84	4.22	4.47	6.3	
		Week 4	Tezepelumab	22	20 (90.9)	4.78 (1.30)	1.4	3.94	4.61	5.95	6.6	
			Placebo	20	18 (90.0)	4.56 (0.82)	3.0	3.97	4.63	5.09	5.9	
		Week 8	Tezepelumab	22	21 (95.5)	5.12 (1.19)	3.3	4.03	5.19	6.09	6.7	
			Placebo	20	19 (95.0)	4.60 (1.00)	2.4	3.88	4.63	5.50	6.5	
		Week 12	Tezepelumab	22	21 (95.5)	5.35 (1.15)	3.0	4.34	5.16	6.47	6.9	
			Placebo	20	19 (95.0)	4.88 (1.05)	2.8	4.16	4.81	5.78	6.5	
		Week 16	Tezepelumab	22	21 (95.5)	5.37 (1.16)	2.7	4.69	5.59	6.09	7.0	
			Placebo	20	19 (95.0)	4.81 (1.40)	1.2	4.25	4.94	5.75	6.9	
		Week 20	Tezepelumab	22	21 (95.5)	5.24 (1.14)	3.2	4.31	5.31	6.19	7.0	
			Placebo	20	19 (95.0)	4.59 (1.33)	1.2	3.75	4.72	5.75	6.7	
		Week 24	Tezepelumab	22	21 (95.5)	5.31 (1.09)	3.5	4.34	5.38	6.13	7.0	
			Placebo	20	19 (95.0)	4.55 (1.31)	1.2	3.88	4.50	5.75	6.9	
		Week 28	Tezepelumab	22	22 (100.0)	5.39 (1.08)	3.6	4.47	5.56	6.63	6.8	
			Placebo	20	19 (95.0)	4.67 (1.46)	1.2	3.75	4.31	5.91	7.0	
		Week 32	Tezepelumab	22	22 (100.0)	5.37 (1.05)	3.6	4.34	5.52	6.13	7.0	
			Placebo	20	19 (95.0)	4.75 (1.30)	1.2	3.97	4.69	5.91	6.5	
		Week 36	Tezepelumab	22	22 (100.0)	5.43 (1.04)	3.5	4.69	5.70	6.22	6.8	
			Placebo	20	19 (95.0)	4.40 (1.16)	2.2	3.75	4.16	5.34	6.7	
		Week 40	Tezepelumab	22	22 (100.0)	5.36 (1.04)	3.6	4.66	5.23	5.97	7.0	
			Placebo	20	19 (95.0)	4.72 (1.23)	2.3	3.75	4.31	5.84	6.8	
		Week 44	Tezepelumab	22	22 (100.0)	5.40 (1.03)	3.5	4.69	5.36	6.22	7.0	
			Placebo	20	19 (95.0)	4.67 (1.13)	2.8	3.72	4.75	5.63	6.5	
		Week 48	Tezepelumab	22	22 (100.0)	5.43 (1.03)	3.5	4.69	5.52	6.22	6.9	
			Placebo	20	19 (95.0)	4.61 (1.08)	2.1	3.97	4.56	5.16	6.5	
		Week 52	Tezepelumab	22	22 (100.0)	5.45 (1.06)	3.4	4.69	5.52	6.47	7.0	
			Placebo	20	19 (95.0)	4.73 (1.06)	3.3	3.97	4.47	5.75	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	22	18 (81.8)	0.77 (1.40)	-3.7	0.47	1.05	1.56	2.4	0.38 [-0.30, 1.06]
			Placebo	20	16 (80.0)	0.34 (0.71)	-1.1	0.05	0.25	0.77	1.7	
		Week 8	Tezepelumab	22	19 (86.4)	1.04 (1.17)	-1.0	0.28	1.41	1.94	2.7	0.55 [-0.12, 1.22]
			Placebo	20	17 (85.0)	0.44 (0.98)	-1.4	-0.25	0.31	0.97	2.5	
		Week 12	Tezepelumab	22	19 (86.4)	1.23 (1.22)	-2.1	0.88	1.41	2.09	2.7	0.45 [-0.21, 1.11]
			Placebo	20	17 (85.0)	0.67 (1.26)	-1.7	0.13	0.56	1.59	3.5	
		Week 16	Tezepelumab	22	19 (86.4)	1.26 (1.26)	-2.4	0.59	1.63	2.34	2.7	0.45 [-0.21, 1.12]
			Placebo	20	17 (85.0)	0.62 (1.56)	-3.2	0.31	0.94	1.41	3.8	
		Week 20	Tezepelumab	22	19 (86.4)	1.14 (1.19)	-1.2	0.22	1.41	2.31	3.0	0.58 [-0.09, 1.25]
			Placebo	20	17 (85.0)	0.39 (1.40)	-3.2	-0.25	0.91	1.09	2.0	
		Week 24	Tezepelumab	22	19 (86.4)	1.22 (1.17)	-1.2	0.53	1.34	2.28	3.0	0.61 [-0.06, 1.28]
			Placebo	20	17 (85.0)	0.41 (1.47)	-3.2	0.09	0.78	1.13	2.8	
		Week 28	Tezepelumab	22	19 (86.4)	1.24 (1.13)	-1.3	0.63	1.41	2.34	2.7	0.49 [-0.18, 1.15]
			Placebo	20	17 (85.0)	0.55 (1.67)	-3.2	-0.31	0.72	1.41	4.0	
		Week 32	Tezepelumab	22	19 (86.4)	1.24 (1.16)	-1.2	0.53	1.03	2.25	2.9	0.46 [-0.21, 1.12]
			Placebo	20	17 (85.0)	0.63 (1.47)	-3.2	0.56	0.78	1.19	3.2	
		Week 36	Tezepelumab	22	19 (86.4)	1.31 (1.20)	-1.3	0.53	1.41	2.34	2.8	0.86 [0.18, 1.55]
			Placebo	20	17 (85.0)	0.24 (1.27)	-2.0	-0.25	0.38	1.06	2.3	
		Week 40	Tezepelumab	22	19 (86.4)	1.20 (1.15)	-1.3	0.56	1.03	2.31	2.8	0.45 [-0.21, 1.11]
			Placebo	20	17 (85.0)	0.61 (1.47)	-2.0	-0.19	0.72	1.69	3.8	
		Week 44	Tezepelumab	22	19 (86.4)	1.29 (1.21)	-1.1	0.47	1.38	2.34	3.3	0.58 [-0.09, 1.25]
			Placebo	20	17 (85.0)	0.51 (1.51)	-2.0	-0.66	0.81	1.13	3.4	
		Week 48	Tezepelumab	22	19 (86.4)	1.36 (1.18)	-1.1	0.53	1.41	2.34	2.9	0.72 [0.04, 1.39]
			Placebo	20	17 (85.0)	0.45 (1.36)	-2.0	-0.28	0.19	1.09	3.3	
		Week 52	Tezepelumab	22	19 (86.4)	1.35 (1.19)	-1.2	0.47	1.41	2.22	3.0	0.58 [-0.09, 1.25]
			Placebo	20	17 (85.0)	0.61 (1.39)	-2.0	-0.28	0.19	1.25	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	4.09 (0.88)	2.0	3.63	4.03	4.61	6.3	
			Placebo	58	48 (82.8)	4.33 (0.79)	1.8	3.84	4.28	4.77	6.3	
		Week 4	Tezepelumab	60	54 (90.0)	4.74 (1.04)	1.4	3.94	4.88	5.44	6.8	
			Placebo	58	50 (86.2)	4.81 (0.96)	2.4	4.06	4.83	5.41	6.8	
		Week 8	Tezepelumab	60	56 (93.3)	5.03 (1.05)	3.0	4.14	5.08	5.92	6.8	
			Placebo	58	52 (89.7)	4.87 (0.99)	2.8	4.20	4.77	5.56	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.23 (0.99)	3.0	4.44	5.06	6.16	7.0	
			Placebo	58	52 (89.7)	4.94 (1.02)	2.8	4.20	4.84	5.55	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.20 (1.04)	2.7	4.38	5.13	6.09	7.0	
			Placebo	58	52 (89.7)	4.94 (1.19)	1.2	4.19	4.86	5.69	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.15 (1.03)	3.2	4.31	5.16	5.91	7.0	
			Placebo	58	52 (89.7)	4.92 (1.20)	1.2	4.14	4.88	5.88	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.19 (1.04)	3.3	4.34	5.09	6.06	7.0	
			Placebo	58	52 (89.7)	4.86 (1.25)	1.2	4.05	4.80	5.72	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.16 (1.04)	3.3	4.34	5.16	6.00	7.0	
			Placebo	58	53 (91.4)	4.89 (1.29)	1.2	4.00	4.88	5.75	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.24 (1.08)	2.9	4.25	5.22	6.09	7.0	
			Placebo	58	53 (91.4)	4.97 (1.22)	1.2	4.13	5.00	5.75	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.28 (1.06)	3.3	4.41	5.16	6.25	7.0	
			Placebo	58	53 (91.4)	4.95 (1.18)	2.2	4.09	4.84	5.94	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.22 (1.08)	3.2	4.34	5.13	6.13	7.0	
			Placebo	58	53 (91.4)	5.00 (1.21)	2.3	4.03	5.06	6.09	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.25 (1.04)	3.5	4.31	5.16	6.16	7.0	
			Placebo	58	53 (91.4)	4.99 (1.12)	2.8	4.16	5.00	5.81	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.27 (1.08)	2.9	4.34	5.16	6.22	7.0	
			Placebo	58	53 (91.4)	4.98 (1.15)	2.1	4.19	4.75	5.97	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.27 (1.08)	2.9	4.34	5.16	6.25	7.0	
			Placebo	58	53 (91.4)	5.02 (1.11)	2.9	4.13	4.75	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	60	49 (81.7)	0.66 (1.00)	-3.7	0.09	0.72	1.38	2.4	0.18 [-0.23, 0.58]
			Placebo	58	47 (81.0)	0.50 (0.83)	-1.2	0.09	0.47	0.88	2.6	
		Week 8	Tezepelumab	60	51 (85.0)	0.88 (0.92)	-1.0	0.28	0.81	1.69	2.7	0.32 [-0.08, 0.71]
			Placebo	58	48 (82.8)	0.59 (0.90)	-1.4	0.13	0.52	0.97	3.1	
		Week 12	Tezepelumab	60	51 (85.0)	1.08 (0.93)	-2.1	0.56	1.13	1.84	2.7	0.48 [0.08, 0.88]
			Placebo	58	48 (82.8)	0.63 (0.99)	-1.7	0.14	0.55	1.06	3.3	
		Week 16	Tezepelumab	60	51 (85.0)	1.07 (0.97)	-2.4	0.50	1.25	1.78	2.8	0.42 [0.02, 0.82]
			Placebo	58	48 (82.8)	0.65 (1.07)	-3.2	0.27	0.72	1.05	3.2	
		Week 20	Tezepelumab	60	51 (85.0)	1.05 (0.95)	-1.2	0.31	1.00	1.75	3.0	0.39 [-0.01, 0.79]
			Placebo	58	48 (82.8)	0.65 (1.08)	-3.2	0.25	0.70	1.08	3.2	
		Week 24	Tezepelumab	60	51 (85.0)	1.12 (0.96)	-1.2	0.34	1.34	1.78	3.0	0.51 [0.10, 0.91]
			Placebo	58	48 (82.8)	0.59 (1.16)	-3.2	0.06	0.67	1.22	3.2	
		Week 28	Tezepelumab	60	51 (85.0)	1.06 (0.97)	-1.3	0.31	0.91	1.88	3.0	0.45 [0.05, 0.85]
			Placebo	58	48 (82.8)	0.58 (1.17)	-3.2	0.02	0.70	1.22	3.2	
		Week 32	Tezepelumab	60	51 (85.0)	1.13 (1.02)	-1.2	0.34	1.06	2.06	2.9	0.44 [0.04, 0.84]
			Placebo	58	48 (82.8)	0.67 (1.07)	-3.2	0.17	0.72	1.27	2.9	
		Week 36	Tezepelumab	60	51 (85.0)	1.17 (1.07)	-1.3	0.44	1.03	2.19	3.3	0.51 [0.11, 0.91]
			Placebo	58	48 (82.8)	0.64 (0.99)	-2.0	0.14	0.61	1.14	2.9	
		Week 40	Tezepelumab	60	51 (85.0)	1.14 (1.02)	-1.3	0.53	1.03	2.03	2.9	0.42 [0.02, 0.81]
			Placebo	58	48 (82.8)	0.70 (1.08)	-2.0	0.05	0.77	1.47	2.8	
		Week 44	Tezepelumab	60	51 (85.0)	1.16 (1.01)	-1.1	0.59	0.97	2.03	2.9	0.49 [0.09, 0.89]
			Placebo	58	48 (82.8)	0.67 (0.98)	-2.0	0.00	0.72	1.22	2.9	
		Week 48	Tezepelumab	60	51 (85.0)	1.19 (1.03)	-1.1	0.44	1.13	2.09	2.9	0.52 [0.12, 0.92]
			Placebo	58	48 (82.8)	0.67 (1.00)	-2.0	0.08	0.56	1.23	3.3	
		Week 52	Tezepelumab	60	51 (85.0)	1.19 (1.03)	-1.2	0.44	1.06	2.09	3.0	0.46 [0.06, 0.86]
			Placebo	58	48 (82.8)	0.72 (0.98)	-2.0	0.14	0.61	1.31	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	3.39 (1.66)	2.2	2.22	3.39	4.56	4.6	
			Placebo	2	2 (100.0)	3.73 (0.69)	3.3	3.25	3.73	4.22	4.2	
		Week 4	Tezepelumab	2	2 (100.0)	6.06 (0.75)	5.5	5.53	6.06	6.59	6.6	
			Placebo	2	2 (100.0)	4.67 (0.42)	4.4	4.38	4.67	4.97	5.0	
		Week 8	Tezepelumab	2	2 (100.0)	6.31 (0.49)	6.0	5.97	6.31	6.66	6.7	
			Placebo	2	2 (100.0)	5.17 (0.77)	4.6	4.63	5.17	5.72	5.7	
		Week 12	Tezepelumab	2	2 (100.0)	6.34 (0.18)	6.2	6.22	6.34	6.47	6.5	
			Placebo	2	2 (100.0)	4.69 (1.72)	3.5	3.47	4.69	5.91	5.9	
		Week 16	Tezepelumab	2	2 (100.0)	5.69 (0.13)	5.6	5.59	5.69	5.78	5.8	
			Placebo	2	2 (100.0)	4.45 (2.06)	3.0	3.00	4.45	5.91	5.9	
		Week 20	Tezepelumab	2	2 (100.0)	5.91 (0.40)	5.6	5.63	5.91	6.19	6.2	
			Placebo	2	2 (100.0)	4.45 (2.06)	3.0	3.00	4.45	5.91	5.9	
		Week 24	Tezepelumab	2	2 (100.0)	5.88 (0.35)	5.6	5.63	5.88	6.13	6.1	
			Placebo	2	2 (100.0)	4.94 (1.37)	4.0	3.97	4.94	5.91	5.9	
		Week 28	Tezepelumab	2	2 (100.0)	6.17 (0.77)	5.6	5.63	6.17	6.72	6.7	
			Placebo	2	2 (100.0)	4.94 (1.37)	4.0	3.97	4.94	5.91	5.9	
		Week 32	Tezepelumab	2	2 (100.0)	5.48 (0.20)	5.3	5.34	5.48	5.63	5.6	
			Placebo	2	2 (100.0)	4.94 (1.37)	4.0	3.97	4.94	5.91	5.9	
		Week 36	Tezepelumab	2	2 (100.0)	5.91 (0.40)	5.6	5.63	5.91	6.19	6.2	
			Placebo	2	2 (100.0)	4.94 (1.37)	4.0	3.97	4.94	5.91	5.9	
		Week 40	Tezepelumab	2	2 (100.0)	5.47 (0.22)	5.3	5.31	5.47	5.63	5.6	
			Placebo	2	2 (100.0)	4.94 (1.37)	4.0	3.97	4.94	5.91	5.9	
		Week 44	Tezepelumab	2	2 (100.0)	5.47 (0.22)	5.3	5.31	5.47	5.63	5.6	
			Placebo	2	2 (100.0)	6.39 (0.15)	6.3	6.28	6.39	6.50	6.5	
		Week 48	Tezepelumab	2	2 (100.0)	5.69 (0.09)	5.6	5.63	5.69	5.75	5.8	
			Placebo	2	2 (100.0)	6.47 (0.04)	6.4	6.44	6.47	6.50	6.5	
		Week 52	Tezepelumab	2	2 (100.0)	5.69 (0.09)	5.6	5.63	5.69	5.75	5.8	
			Placebo	2	2 (100.0)	6.72 (0.40)	6.4	6.44	6.72	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	2	2 (100.0)	2.67 (0.91)	2.0	2.03	2.67	3.31	3.3	1.72 [-0.87, 4.30]
			Placebo	2	2 (100.0)	0.94 (1.10)	0.2	0.16	0.94	1.72	1.7	
		Week 8	Tezepelumab	2	2 (100.0)	2.92 (1.17)	2.1	2.09	2.92	3.75	3.8	1.79 [-0.84, 4.42]
			Placebo	2	2 (100.0)	1.44 (0.09)	1.4	1.38	1.44	1.50	1.5	
		Week 12	Tezepelumab	2	2 (100.0)	2.95 (1.48)	1.9	1.91	2.95	4.00	4.0	1.56 [-0.92, 4.05]
			Placebo	2	2 (100.0)	0.95 (1.04)	0.2	0.22	0.95	1.69	1.7	
		Week 16	Tezepelumab	2	2 (100.0)	2.30 (1.52)	1.2	1.22	2.30	3.38	3.4	1.09 [-1.14, 3.32]
			Placebo	2	2 (100.0)	0.72 (1.37)	-0.3	-0.25	0.72	1.69	1.7	
		Week 20	Tezepelumab	2	2 (100.0)	2.52 (1.26)	1.6	1.63	2.52	3.41	3.4	1.37 [-1.01, 3.74]
			Placebo	2	2 (100.0)	0.72 (1.37)	-0.3	-0.25	0.72	1.69	1.7	
		Week 24	Tezepelumab	2	2 (100.0)	2.48 (1.30)	1.6	1.56	2.48	3.41	3.4	1.23 [-1.07, 3.53]
			Placebo	2	2 (100.0)	1.20 (0.69)	0.7	0.72	1.20	1.69	1.7	
		Week 28	Tezepelumab	2	2 (100.0)	2.78 (0.88)	2.2	2.16	2.78	3.41	3.4	2.00 [-0.77, 4.76]
			Placebo	2	2 (100.0)	1.20 (0.69)	0.7	0.72	1.20	1.69	1.7	
		Week 32	Tezepelumab	2	2 (100.0)	2.09 (1.86)	0.8	0.78	2.09	3.41	3.4	0.64 [-1.42, 2.69]
			Placebo	2	2 (100.0)	1.20 (0.69)	0.7	0.72	1.20	1.69	1.7	
		Week 36	Tezepelumab	2	2 (100.0)	2.52 (1.26)	1.6	1.63	2.52	3.41	3.4	1.29 [-1.04, 3.63]
			Placebo	2	2 (100.0)	1.20 (0.69)	0.7	0.72	1.20	1.69	1.7	
		Week 40	Tezepelumab	2	2 (100.0)	2.08 (1.88)	0.8	0.75	2.08	3.41	3.4	0.62 [-1.43, 2.67]
			Placebo	2	2 (100.0)	1.20 (0.69)	0.7	0.72	1.20	1.69	1.7	
		Week 44	Tezepelumab	2	2 (100.0)	2.08 (1.88)	0.8	0.75	2.08	3.41	3.4	-0.40 [-2.40, 1.60]
			Placebo	2	2 (100.0)	2.66 (0.84)	2.1	2.06	2.66	3.25	3.3	
		Week 48	Tezepelumab	2	2 (100.0)	2.30 (1.57)	1.2	1.19	2.30	3.41	3.4	-0.36 [-2.35, 1.63]
			Placebo	2	2 (100.0)	2.73 (0.73)	2.2	2.22	2.73	3.25	3.3	
		Week 52	Tezepelumab	2	2 (100.0)	2.30 (1.57)	1.2	1.19	2.30	3.41	3.4	-0.51 [-2.53, 1.51]
			Placebo	2	2 (100.0)	2.98 (1.08)	2.2	2.22	2.98	3.75	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	4.33 (1.13)	3.2	3.16	4.44	5.41	5.4	
			Placebo	3	3 (100.0)	4.45 (0.16)	4.3	4.28	4.47	4.59	4.6	
		Week 4	Tezepelumab	3	3 (100.0)	5.54 (0.96)	4.4	4.44	6.06	6.13	6.1	
			Placebo	3	3 (100.0)	4.92 (0.38)	4.5	4.50	5.00	5.25	5.3	
		Week 8	Tezepelumab	3	3 (100.0)	5.82 (0.69)	5.1	5.09	5.91	6.47	6.5	
			Placebo	3	3 (100.0)	4.68 (0.33)	4.3	4.31	4.75	4.97	5.0	
		Week 12	Tezepelumab	3	3 (100.0)	6.22 (0.87)	5.3	5.25	6.47	6.94	6.9	
			Placebo	3	3 (100.0)	5.22 (0.09)	5.1	5.13	5.22	5.31	5.3	
		Week 16	Tezepelumab	3	3 (100.0)	6.19 (0.69)	5.6	5.59	6.03	6.94	6.9	
			Placebo	3	3 (100.0)	5.31 (0.49)	5.0	4.97	5.09	5.88	5.9	
		Week 20	Tezepelumab	3	3 (100.0)	6.25 (0.69)	5.6	5.59	6.19	6.97	7.0	
			Placebo	3	3 (100.0)	4.56 (0.78)	3.7	3.66	5.00	5.03	5.0	
		Week 24	Tezepelumab	3	3 (100.0)	6.29 (0.56)	5.9	5.91	6.03	6.94	6.9	
			Placebo	3	3 (100.0)	4.74 (0.83)	3.9	3.88	4.81	5.53	5.5	
		Week 28	Tezepelumab	3	3 (100.0)	6.30 (0.61)	5.9	5.88	6.03	7.00	7.0	
			Placebo	3	3 (100.0)	5.74 (0.88)	4.9	4.91	5.66	6.66	6.7	
		Week 32	Tezepelumab	3	3 (100.0)	6.29 (0.61)	5.8	5.78	6.13	6.97	7.0	
			Placebo	3	3 (100.0)	5.55 (0.47)	5.3	5.25	5.31	6.09	6.1	
		Week 36	Tezepelumab	3	3 (100.0)	6.39 (0.55)	5.9	5.94	6.22	7.00	7.0	
			Placebo	3	3 (100.0)	4.57 (1.16)	3.3	3.31	4.81	5.59	5.6	
		Week 40	Tezepelumab	3	3 (100.0)	6.30 (0.60)	5.9	5.94	5.97	7.00	7.0	
			Placebo	3	3 (100.0)	4.96 (0.63)	4.3	4.28	5.06	5.53	5.5	
		Week 44	Tezepelumab	3	3 (100.0)	6.42 (0.58)	5.8	5.84	6.41	7.00	7.0	
			Placebo	3	3 (100.0)	4.20 (0.85)	3.5	3.47	4.00	5.13	5.1	
		Week 48	Tezepelumab	3	3 (100.0)	6.38 (0.51)	6.1	6.06	6.09	6.97	7.0	
			Placebo	3	3 (100.0)	4.70 (0.69)	4.0	3.97	4.78	5.34	5.3	
		Week 52	Tezepelumab	3	3 (100.0)	6.38 (0.51)	6.1	6.06	6.09	6.97	7.0	
			Placebo	3	3 (100.0)	4.70 (0.69)	4.0	3.97	4.78	5.34	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.21 (0.52)	0.7	0.66	1.28	1.69	1.7	1.49 [-0.41, 3.39]
			Placebo	3	3 (100.0)	0.47 (0.47)	0.0	0.03	0.41	0.97	1.0	
		Week 8	Tezepelumab	3	3 (100.0)	1.49 (0.86)	0.5	0.50	1.94	2.03	2.0	2.00 [-0.12, 4.11]
			Placebo	3	3 (100.0)	0.23 (0.24)	0.0	0.03	0.16	0.50	0.5	
		Week 12	Tezepelumab	3	3 (100.0)	1.89 (0.74)	1.1	1.06	2.09	2.50	2.5	2.12 [-0.05, 4.29]
			Placebo	3	3 (100.0)	0.77 (0.07)	0.7	0.72	0.75	0.84	0.8	
		Week 16	Tezepelumab	3	3 (100.0)	1.85 (1.06)	0.6	0.63	2.44	2.50	2.5	1.20 [-0.60, 3.00]
			Placebo	3	3 (100.0)	0.86 (0.48)	0.5	0.50	0.69	1.41	1.4	
		Week 20	Tezepelumab	3	3 (100.0)	1.92 (0.98)	0.8	0.78	2.44	2.53	2.5	1.99 [-0.12, 4.10]
			Placebo	3	3 (100.0)	0.11 (0.82)	-0.8	-0.81	0.41	0.75	0.8	
		Week 24	Tezepelumab	3	3 (100.0)	1.96 (1.16)	0.6	0.63	2.50	2.75	2.8	1.68 [-0.30, 3.65]
			Placebo	3	3 (100.0)	0.29 (0.79)	-0.6	-0.59	0.53	0.94	0.9	
		Week 28	Tezepelumab	3	3 (100.0)	1.97 (1.17)	0.6	0.63	2.56	2.72	2.7	0.68 [-0.99, 2.34]
			Placebo	3	3 (100.0)	1.29 (0.81)	0.6	0.63	1.06	2.19	2.2	
		Week 32	Tezepelumab	3	3 (100.0)	1.96 (1.07)	0.7	0.72	2.53	2.63	2.6	1.03 [-0.72, 2.78]
			Placebo	3	3 (100.0)	1.10 (0.47)	0.7	0.72	0.97	1.63	1.6	
		Week 36	Tezepelumab	3	3 (100.0)	2.05 (1.08)	0.8	0.81	2.56	2.78	2.8	1.74 [-0.26, 3.75]
			Placebo	3	3 (100.0)	0.13 (1.13)	-1.2	-1.16	0.53	1.00	1.0	
		Week 40	Tezepelumab	3	3 (100.0)	1.97 (1.22)	0.6	0.56	2.56	2.78	2.8	1.51 [-0.40, 3.42]
			Placebo	3	3 (100.0)	0.51 (0.61)	-0.2	-0.19	0.78	0.94	0.9	
		Week 44	Tezepelumab	3	3 (100.0)	2.08 (1.47)	0.4	0.44	2.56	3.25	3.3	1.99 [-0.12, 4.11]
			Placebo	3	3 (100.0)	-0.25 (0.77)	-1.0	-1.00	-0.28	0.53	0.5	
		Week 48	Tezepelumab	3	3 (100.0)	2.04 (1.19)	0.7	0.69	2.53	2.91	2.9	1.86 [-0.19, 3.92]
			Placebo	3	3 (100.0)	0.25 (0.66)	-0.5	-0.50	0.50	0.75	0.8	
		Week 52	Tezepelumab	3	3 (100.0)	2.04 (1.19)	0.7	0.69	2.53	2.91	2.9	1.86 [-0.19, 3.92]
			Placebo	3	3 (100.0)	0.25 (0.66)	-0.5	-0.50	0.50	0.75	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	4.19	4.2	4.19	4.19	4.19	4.2	
			Placebo	2	2 (100.0)	2.83 (0.24)	2.7	2.66	2.83	3.00	3.0	
		Week 4	Tezepelumab	1	1 (100.0)	4.41	4.4	4.41	4.41	4.41	4.4	
			Placebo	2	2 (100.0)	3.55 (0.42)	3.3	3.25	3.55	3.84	3.8	
		Week 8	Tezepelumab	1	1 (100.0)	3.94	3.9	3.94	3.94	3.94	3.9	
			Placebo	2	2 (100.0)	3.95 (2.19)	2.4	2.41	3.95	5.50	5.5	
		Week 12	Tezepelumab	1	1 (100.0)	4.31	4.3	4.31	4.31	4.31	4.3	
			Placebo	2	2 (100.0)	5.38 (1.59)	4.3	4.25	5.38	6.50	6.5	
		Week 16	Tezepelumab	1	1 (100.0)	4.63	4.6	4.63	4.63	4.63	4.6	
			Placebo	2	2 (100.0)	5.41 (1.90)	4.1	4.06	5.41	6.75	6.8	
		Week 20	Tezepelumab	1	1 (100.0)	4.72	4.7	4.72	4.72	4.72	4.7	
			Placebo	2	2 (100.0)	4.27 (0.73)	3.8	3.75	4.27	4.78	4.8	
		Week 24	Tezepelumab	1	1 (100.0)	4.28	4.3	4.28	4.28	4.28	4.3	
			Placebo	2	2 (100.0)	4.80 (1.48)	3.8	3.75	4.80	5.84	5.8	
		Week 28	Tezepelumab	1	1 (100.0)	4.50	4.5	4.50	4.50	4.50	4.5	
			Placebo	2	2 (100.0)	5.38 (2.30)	3.8	3.75	5.38	7.00	7.0	
		Week 32	Tezepelumab	1	1 (100.0)	4.59	4.6	4.59	4.59	4.59	4.6	
			Placebo	2	2 (100.0)	4.95 (1.70)	3.8	3.75	4.95	6.16	6.2	
		Week 36	Tezepelumab	1	1 (100.0)	4.94	4.9	4.94	4.94	4.94	4.9	
			Placebo	2	2 (100.0)	4.55 (1.13)	3.8	3.75	4.55	5.34	5.3	
		Week 40	Tezepelumab	1	1 (100.0)	5.28	5.3	5.28	5.28	5.28	5.3	
			Placebo	2	2 (100.0)	5.25 (2.12)	3.8	3.75	5.25	6.75	6.8	
		Week 44	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	2	2 (100.0)	5.08 (1.88)	3.8	3.75	5.08	6.41	6.4	
		Week 48	Tezepelumab	1	1 (100.0)	5.34	5.3	5.34	5.34	5.34	5.3	
			Placebo	2	2 (100.0)	4.28 (0.75)	3.8	3.75	4.28	4.81	4.8	
		Week 52	Tezepelumab	1	1 (100.0)	5.34	5.3	5.34	5.34	5.34	5.3	
			Placebo	2	2 (100.0)	4.28 (0.75)	3.8	3.75	4.28	4.81	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	0.22	0.2	0.22	0.22	0.22	0.2	NE
			Placebo	2	2 (100.0)	0.72 (0.66)	0.3	0.25	0.72	1.19	1.2	
		Week 8	Tezepelumab	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	NE
			Placebo	2	2 (100.0)	1.13 (1.94)	-0.3	-0.25	1.13	2.50	2.5	
		Week 12	Tezepelumab	1	1 (100.0)	0.13	0.1	0.13	0.13	0.13	0.1	NE
			Placebo	2	2 (100.0)	2.55 (1.35)	1.6	1.59	2.55	3.50	3.5	
		Week 16	Tezepelumab	1	1 (100.0)	0.44	0.4	0.44	0.44	0.44	0.4	NE
			Placebo	2	2 (100.0)	2.58 (1.66)	1.4	1.41	2.58	3.75	3.8	
		Week 20	Tezepelumab	1	1 (100.0)	0.53	0.5	0.53	0.53	0.53	0.5	NE
			Placebo	2	2 (100.0)	1.44 (0.49)	1.1	1.09	1.44	1.78	1.8	
		Week 24	Tezepelumab	1	1 (100.0)	0.09	0.1	0.09	0.09	0.09	0.1	NE
			Placebo	2	2 (100.0)	1.97 (1.24)	1.1	1.09	1.97	2.84	2.8	
		Week 28	Tezepelumab	1	1 (100.0)	0.31	0.3	0.31	0.31	0.31	0.3	NE
			Placebo	2	2 (100.0)	2.55 (2.06)	1.1	1.09	2.55	4.00	4.0	
		Week 32	Tezepelumab	1	1 (100.0)	0.41	0.4	0.41	0.41	0.41	0.4	NE
			Placebo	2	2 (100.0)	2.13 (1.46)	1.1	1.09	2.13	3.16	3.2	
		Week 36	Tezepelumab	1	1 (100.0)	0.75	0.8	0.75	0.75	0.75	0.8	NE
			Placebo	2	2 (100.0)	1.72 (0.88)	1.1	1.09	1.72	2.34	2.3	
		Week 40	Tezepelumab	1	1 (100.0)	1.09	1.1	1.09	1.09	1.09	1.1	NE
			Placebo	2	2 (100.0)	2.42 (1.88)	1.1	1.09	2.42	3.75	3.8	
		Week 44	Tezepelumab	1	1 (100.0)	0.81	0.8	0.81	0.81	0.81	0.8	NE
			Placebo	2	2 (100.0)	2.25 (1.64)	1.1	1.09	2.25	3.41	3.4	
		Week 48	Tezepelumab	1	1 (100.0)	1.16	1.2	1.16	1.16	1.16	1.2	NE
			Placebo	2	2 (100.0)	1.45 (0.51)	1.1	1.09	1.45	1.81	1.8	
		Week 52	Tezepelumab	1	1 (100.0)	1.16	1.2	1.16	1.16	1.16	1.2	NE
			Placebo	2	2 (100.0)	1.45 (0.51)	1.1	1.09	1.45	1.81	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	40	36 (90.0)	4.14 (0.90)	2.3	3.61	4.17	4.66	6.3	
			Placebo	36	31 (86.1)	4.43 (0.74)	3.3	3.84	4.34	4.94	6.1	
		Week 4	Tezepelumab	40	37 (92.5)	4.69 (1.11)	1.4	3.88	4.69	5.66	6.8	
			Placebo	36	31 (86.1)	4.79 (0.92)	3.0	4.00	4.75	5.41	6.8	
		Week 8	Tezepelumab	40	38 (95.0)	5.04 (1.08)	3.0	4.09	5.08	5.94	6.8	
			Placebo	36	32 (88.9)	4.85 (0.99)	3.3	4.11	4.70	5.61	7.0	
		Week 12	Tezepelumab	40	38 (95.0)	5.23 (1.02)	3.0	4.38	5.13	6.19	7.0	
			Placebo	36	32 (88.9)	5.01 (1.01)	2.8	4.28	4.97	5.55	7.0	
		Week 16	Tezepelumab	40	38 (95.0)	5.15 (1.08)	2.7	4.25	5.08	6.25	6.9	
			Placebo	36	32 (88.9)	4.93 (1.27)	1.2	4.19	4.89	5.66	7.0	
		Week 20	Tezepelumab	40	39 (97.5)	5.17 (1.05)	3.2	4.31	5.19	6.13	7.0	
			Placebo	36	32 (88.9)	4.95 (1.22)	1.2	4.30	4.91	5.88	7.0	
		Week 24	Tezepelumab	40	39 (97.5)	5.24 (1.08)	3.5	4.28	5.13	6.25	7.0	
			Placebo	36	32 (88.9)	4.82 (1.29)	1.2	3.98	4.75	5.59	7.0	
		Week 28	Tezepelumab	40	40 (100.0)	5.14 (1.08)	3.3	4.20	5.16	6.02	7.0	
			Placebo	36	33 (91.7)	4.89 (1.35)	1.2	3.97	5.06	5.97	7.0	
		Week 32	Tezepelumab	40	40 (100.0)	5.21 (1.12)	2.9	4.17	5.19	6.11	7.0	
			Placebo	36	33 (91.7)	5.01 (1.25)	1.2	4.19	5.09	5.69	7.0	
		Week 36	Tezepelumab	40	40 (100.0)	5.28 (1.10)	3.3	4.45	5.08	6.22	7.0	
			Placebo	36	33 (91.7)	5.01 (1.21)	2.2	4.16	4.84	5.94	7.0	
		Week 40	Tezepelumab	40	40 (100.0)	5.32 (1.07)	3.5	4.50	5.25	6.19	7.0	
			Placebo	36	33 (91.7)	5.05 (1.24)	2.3	4.03	5.13	6.09	7.0	
		Week 44	Tezepelumab	40	40 (100.0)	5.29 (1.07)	3.5	4.17	5.19	6.13	7.0	
			Placebo	36	33 (91.7)	5.08 (1.15)	2.8	4.03	5.03	5.81	7.0	
		Week 48	Tezepelumab	40	40 (100.0)	5.25 (1.12)	2.9	4.42	5.16	6.16	7.0	
			Placebo	36	33 (91.7)	5.05 (1.20)	2.1	4.13	4.81	6.00	7.0	
		Week 52	Tezepelumab	40	40 (100.0)	5.24 (1.10)	2.9	4.45	5.17	6.19	7.0	
			Placebo	36	33 (91.7)	5.09 (1.14)	3.3	4.13	4.94	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	40	35 (87.5)	0.61 (1.11)	-3.7	0.00	0.72	1.44	2.4	0.23 [-0.26, 0.72]
			Placebo	36	30 (83.3)	0.40 (0.73)	-1.2	0.06	0.39	0.78	2.3	
		Week 8	Tezepelumab	40	36 (90.0)	0.85 (1.01)	-1.0	0.02	0.92	1.73	2.7	0.44 [-0.05, 0.92]
			Placebo	36	31 (86.1)	0.46 (0.77)	-1.0	-0.03	0.34	0.94	2.6	
		Week 12	Tezepelumab	40	36 (90.0)	1.05 (1.03)	-2.1	0.39	1.31	1.86	2.7	0.46 [-0.03, 0.95]
			Placebo	36	31 (86.1)	0.61 (0.84)	-1.1	0.13	0.56	1.03	2.8	
		Week 16	Tezepelumab	40	36 (90.0)	0.99 (1.05)	-2.4	0.36	1.14	1.75	2.8	0.46 [-0.03, 0.94]
			Placebo	36	31 (86.1)	0.52 (1.01)	-3.2	0.22	0.69	0.94	2.8	
		Week 20	Tezepelumab	40	36 (90.0)	1.00 (0.98)	-1.2	0.25	1.22	1.67	2.7	0.47 [-0.02, 0.95]
			Placebo	36	31 (86.1)	0.55 (0.97)	-3.2	0.19	0.63	0.91	2.5	
		Week 24	Tezepelumab	40	36 (90.0)	1.09 (1.03)	-1.2	0.34	1.38	1.78	3.0	0.65 [0.16, 1.14]
			Placebo	36	31 (86.1)	0.41 (1.07)	-3.2	-0.03	0.31	1.13	2.7	
		Week 28	Tezepelumab	40	36 (90.0)	1.02 (1.03)	-1.3	0.31	0.89	1.88	3.0	0.56 [0.07, 1.05]
			Placebo	36	31 (86.1)	0.43 (1.09)	-3.2	-0.03	0.44	1.03	2.4	
		Week 32	Tezepelumab	40	36 (90.0)	1.06 (1.06)	-1.2	0.31	1.22	2.03	2.8	0.51 [0.02, 1.00]
			Placebo	36	31 (86.1)	0.54 (0.96)	-3.2	0.22	0.56	0.84	2.7	
		Week 36	Tezepelumab	40	36 (90.0)	1.12 (1.09)	-1.3	0.42	0.97	2.03	3.3	0.58 [0.09, 1.07]
			Placebo	36	31 (86.1)	0.55 (0.88)	-1.7	0.28	0.53	0.81	2.9	
		Week 40	Tezepelumab	40	36 (90.0)	1.21 (1.04)	-1.3	0.58	1.20	2.05	2.9	0.61 [0.12, 1.10]
			Placebo	36	31 (86.1)	0.60 (0.97)	-1.6	0.03	0.50	1.25	2.8	
		Week 44	Tezepelumab	40	36 (90.0)	1.16 (1.07)	-1.1	0.53	1.13	1.95	2.8	0.58 [0.09, 1.07]
			Placebo	36	31 (86.1)	0.59 (0.86)	-1.0	-0.03	0.63	1.13	2.9	
		Week 48	Tezepelumab	40	36 (90.0)	1.13 (1.08)	-1.1	0.44	1.11	2.09	2.9	0.56 [0.07, 1.05]
			Placebo	36	31 (86.1)	0.57 (0.90)	-1.8	0.06	0.41	1.06	3.3	
		Week 52	Tezepelumab	40	36 (90.0)	1.12 (1.09)	-1.2	0.44	1.11	2.09	3.0	0.51 [0.02, 1.00]
			Placebo	36	31 (86.1)	0.63 (0.83)	-0.9	0.19	0.41	1.19	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	3.95 (1.73)	2.0	2.22	4.56	5.28	5.7	
			Placebo	4	3 (75.0)	3.71 (0.49)	3.3	3.25	3.66	4.22	4.2	
		Week 4	Tezepelumab	6	4 (66.7)	5.82 (0.61)	5.2	5.36	5.75	6.28	6.6	
			Placebo	4	3 (75.0)	5.20 (0.96)	4.4	4.38	4.97	6.25	6.3	
		Week 8	Tezepelumab	6	5 (83.3)	5.63 (1.17)	3.6	5.81	5.97	6.09	6.7	
			Placebo	4	3 (75.0)	5.70 (1.06)	4.6	4.63	5.72	6.75	6.8	
		Week 12	Tezepelumab	6	5 (83.3)	5.86 (0.86)	4.3	6.03	6.22	6.22	6.5	
			Placebo	4	3 (75.0)	5.43 (1.77)	3.5	3.47	5.91	6.91	6.9	
		Week 16	Tezepelumab	6	5 (83.3)	5.54 (0.70)	4.3	5.59	5.78	5.91	6.1	
			Placebo	4	3 (75.0)	5.24 (1.99)	3.0	3.00	5.91	6.81	6.8	
		Week 20	Tezepelumab	6	5 (83.3)	5.58 (0.73)	4.3	5.63	5.69	6.06	6.2	
			Placebo	4	3 (75.0)	5.25 (2.00)	3.0	3.00	5.91	6.84	6.8	
		Week 24	Tezepelumab	6	5 (83.3)	5.48 (0.67)	4.3	5.50	5.63	5.78	6.1	
			Placebo	4	3 (75.0)	5.58 (1.48)	4.0	3.97	5.91	6.88	6.9	
		Week 28	Tezepelumab	6	6 (100.0)	5.78 (0.87)	4.3	5.47	5.77	6.63	6.7	
			Placebo	4	3 (75.0)	5.57 (1.47)	4.0	3.97	5.91	6.84	6.8	
		Week 32	Tezepelumab	6	6 (100.0)	5.58 (0.76)	4.3	5.34	5.63	5.88	6.7	
			Placebo	4	3 (75.0)	5.47 (1.34)	4.0	3.97	5.91	6.53	6.5	
		Week 36	Tezepelumab	6	6 (100.0)	5.55 (0.74)	4.3	5.34	5.50	6.19	6.4	
			Placebo	4	3 (75.0)	5.33 (1.19)	4.0	3.97	5.91	6.13	6.1	
		Week 40	Tezepelumab	6	6 (100.0)	5.54 (0.78)	4.3	5.28	5.47	6.06	6.6	
			Placebo	4	3 (75.0)	5.39 (1.24)	4.0	3.97	5.91	6.28	6.3	
		Week 44	Tezepelumab	6	6 (100.0)	5.53 (0.68)	4.3	5.31	5.58	6.16	6.2	
			Placebo	4	3 (75.0)	6.35 (0.13)	6.3	6.28	6.28	6.50	6.5	
		Week 48	Tezepelumab	6	6 (100.0)	5.65 (0.70)	4.3	5.63	5.72	6.22	6.3	
			Placebo	4	3 (75.0)	6.36 (0.18)	6.2	6.16	6.44	6.50	6.5	
		Week 52	Tezepelumab	6	6 (100.0)	5.78 (0.82)	4.3	5.63	5.83	6.28	6.8	
			Placebo	4	3 (75.0)	6.53 (0.43)	6.2	6.16	6.44	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	6	4 (66.7)	1.38 (1.65)	-0.5	0.09	1.36	2.67	3.3	-0.07 [-1.57, 1.43]
			Placebo	4	3 (75.0)	1.49 (1.23)	0.2	0.16	1.72	2.59	2.6	
		Week 8	Tezepelumab	6	5 (83.3)	1.68 (1.38)	0.1	0.81	1.63	2.09	3.8	-0.25 [-1.68, 1.19]
			Placebo	4	3 (75.0)	1.99 (0.96)	1.4	1.38	1.50	3.09	3.1	
		Week 12	Tezepelumab	6	5 (83.3)	1.91 (1.41)	0.3	0.94	1.91	2.34	4.0	0.13 [-1.30, 1.56]
			Placebo	4	3 (75.0)	1.72 (1.52)	0.2	0.22	1.69	3.25	3.3	
		Week 16	Tezepelumab	6	5 (83.3)	1.59 (1.26)	0.2	0.81	1.22	2.34	3.4	0.04 [-1.39, 1.48]
			Placebo	4	3 (75.0)	1.53 (1.71)	-0.3	-0.25	1.69	3.16	3.2	
		Week 20	Tezepelumab	6	5 (83.3)	1.63 (1.33)	0.0	0.78	1.63	2.34	3.4	0.06 [-1.37, 1.49]
			Placebo	4	3 (75.0)	1.54 (1.72)	-0.3	-0.25	1.69	3.19	3.2	
		Week 24	Tezepelumab	6	5 (83.3)	1.53 (1.41)	0.1	0.22	1.56	2.34	3.4	-0.26 [-1.70, 1.18]
			Placebo	4	3 (75.0)	1.88 (1.26)	0.7	0.72	1.69	3.22	3.2	
		Week 28	Tezepelumab	6	5 (83.3)	1.66 (1.41)	0.2	0.22	2.16	2.34	3.4	-0.15 [-1.58, 1.29]
			Placebo	4	3 (75.0)	1.86 (1.24)	0.7	0.72	1.69	3.19	3.2	
		Week 32	Tezepelumab	6	5 (83.3)	1.41 (1.40)	0.2	0.34	0.78	2.34	3.4	-0.27 [-1.71, 1.17]
			Placebo	4	3 (75.0)	1.76 (1.08)	0.7	0.72	1.69	2.88	2.9	
		Week 36	Tezepelumab	6	5 (83.3)	1.43 (1.56)	-0.3	0.09	1.63	2.34	3.4	-0.15 [-1.58, 1.29]
			Placebo	4	3 (75.0)	1.63 (0.88)	0.7	0.72	1.69	2.47	2.5	
		Week 40	Tezepelumab	6	5 (83.3)	1.38 (1.50)	-0.4	0.75	0.78	2.34	3.4	-0.23 [-1.66, 1.21]
			Placebo	4	3 (75.0)	1.68 (0.95)	0.7	0.72	1.69	2.63	2.6	
		Week 44	Tezepelumab	6	5 (83.3)	1.44 (1.42)	-0.2	0.75	0.88	2.34	3.4	-1.00 [-2.53, 0.54]
			Placebo	4	3 (75.0)	2.65 (0.59)	2.1	2.06	2.63	3.25	3.3	
		Week 48	Tezepelumab	6	5 (83.3)	1.59 (1.31)	0.0	1.00	1.19	2.34	3.4	-0.96 [-2.49, 0.57]
			Placebo	4	3 (75.0)	2.66 (0.53)	2.2	2.22	2.50	3.25	3.3	
		Week 52	Tezepelumab	6	5 (83.3)	1.63 (1.25)	0.2	1.00	1.19	2.34	3.4	-1.06 [-2.61, 0.49]
			Placebo	4	3 (75.0)	2.82 (0.82)	2.2	2.22	2.50	3.75	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	4.33 (1.13)	3.2	3.16	4.44	5.41	5.4	
			Placebo	3	3 (100.0)	4.45 (0.16)	4.3	4.28	4.47	4.59	4.6	
		Week 4	Tezepelumab	3	3 (100.0)	5.54 (0.96)	4.4	4.44	6.06	6.13	6.1	
			Placebo	3	3 (100.0)	4.92 (0.38)	4.5	4.50	5.00	5.25	5.3	
		Week 8	Tezepelumab	3	3 (100.0)	5.82 (0.69)	5.1	5.09	5.91	6.47	6.5	
			Placebo	3	3 (100.0)	4.68 (0.33)	4.3	4.31	4.75	4.97	5.0	
		Week 12	Tezepelumab	3	3 (100.0)	6.22 (0.87)	5.3	5.25	6.47	6.94	6.9	
			Placebo	3	3 (100.0)	5.22 (0.09)	5.1	5.13	5.22	5.31	5.3	
		Week 16	Tezepelumab	3	3 (100.0)	6.19 (0.69)	5.6	5.59	6.03	6.94	6.9	
			Placebo	3	3 (100.0)	5.31 (0.49)	5.0	4.97	5.09	5.88	5.9	
		Week 20	Tezepelumab	3	3 (100.0)	6.25 (0.69)	5.6	5.59	6.19	6.97	7.0	
			Placebo	3	3 (100.0)	4.56 (0.78)	3.7	3.66	5.00	5.03	5.0	
		Week 24	Tezepelumab	3	3 (100.0)	6.29 (0.56)	5.9	5.91	6.03	6.94	6.9	
			Placebo	3	3 (100.0)	4.74 (0.83)	3.9	3.88	4.81	5.53	5.5	
		Week 28	Tezepelumab	3	3 (100.0)	6.30 (0.61)	5.9	5.88	6.03	7.00	7.0	
			Placebo	3	3 (100.0)	5.74 (0.88)	4.9	4.91	5.66	6.66	6.7	
		Week 32	Tezepelumab	3	3 (100.0)	6.29 (0.61)	5.8	5.78	6.13	6.97	7.0	
			Placebo	3	3 (100.0)	5.55 (0.47)	5.3	5.25	5.31	6.09	6.1	
		Week 36	Tezepelumab	3	3 (100.0)	6.39 (0.55)	5.9	5.94	6.22	7.00	7.0	
			Placebo	3	3 (100.0)	4.57 (1.16)	3.3	3.31	4.81	5.59	5.6	
		Week 40	Tezepelumab	3	3 (100.0)	6.30 (0.60)	5.9	5.94	5.97	7.00	7.0	
			Placebo	3	3 (100.0)	4.96 (0.63)	4.3	4.28	5.06	5.53	5.5	
		Week 44	Tezepelumab	3	3 (100.0)	6.42 (0.58)	5.8	5.84	6.41	7.00	7.0	
			Placebo	3	3 (100.0)	4.20 (0.85)	3.5	3.47	4.00	5.13	5.1	
		Week 48	Tezepelumab	3	3 (100.0)	6.38 (0.51)	6.1	6.06	6.09	6.97	7.0	
			Placebo	3	3 (100.0)	4.70 (0.69)	4.0	3.97	4.78	5.34	5.3	
		Week 52	Tezepelumab	3	3 (100.0)	6.38 (0.51)	6.1	6.06	6.09	6.97	7.0	
			Placebo	3	3 (100.0)	4.70 (0.69)	4.0	3.97	4.78	5.34	5.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.21 (0.52)	0.7	0.66	1.28	1.69	1.7	1.49 [-0.41, 3.39]
			Placebo	3	3 (100.0)	0.47 (0.47)	0.0	0.03	0.41	0.97	1.0	
		Week 8	Tezepelumab	3	3 (100.0)	1.49 (0.86)	0.5	0.50	1.94	2.03	2.0	2.00 [-0.12, 4.11]
			Placebo	3	3 (100.0)	0.23 (0.24)	0.0	0.03	0.16	0.50	0.5	
		Week 12	Tezepelumab	3	3 (100.0)	1.89 (0.74)	1.1	1.06	2.09	2.50	2.5	2.12 [-0.05, 4.29]
			Placebo	3	3 (100.0)	0.77 (0.07)	0.7	0.72	0.75	0.84	0.8	
		Week 16	Tezepelumab	3	3 (100.0)	1.85 (1.06)	0.6	0.63	2.44	2.50	2.5	1.20 [-0.60, 3.00]
			Placebo	3	3 (100.0)	0.86 (0.48)	0.5	0.50	0.69	1.41	1.4	
		Week 20	Tezepelumab	3	3 (100.0)	1.92 (0.98)	0.8	0.78	2.44	2.53	2.5	1.99 [-0.12, 4.10]
			Placebo	3	3 (100.0)	0.11 (0.82)	-0.8	-0.81	0.41	0.75	0.8	
		Week 24	Tezepelumab	3	3 (100.0)	1.96 (1.16)	0.6	0.63	2.50	2.75	2.8	1.68 [-0.30, 3.65]
			Placebo	3	3 (100.0)	0.29 (0.79)	-0.6	-0.59	0.53	0.94	0.9	
		Week 28	Tezepelumab	3	3 (100.0)	1.97 (1.17)	0.6	0.63	2.56	2.72	2.7	0.68 [-0.99, 2.34]
			Placebo	3	3 (100.0)	1.29 (0.81)	0.6	0.63	1.06	2.19	2.2	
		Week 32	Tezepelumab	3	3 (100.0)	1.96 (1.07)	0.7	0.72	2.53	2.63	2.6	1.03 [-0.72, 2.78]
			Placebo	3	3 (100.0)	1.10 (0.47)	0.7	0.72	0.97	1.63	1.6	
		Week 36	Tezepelumab	3	3 (100.0)	2.05 (1.08)	0.8	0.81	2.56	2.78	2.8	1.74 [-0.26, 3.75]
			Placebo	3	3 (100.0)	0.13 (1.13)	-1.2	-1.16	0.53	1.00	1.0	
		Week 40	Tezepelumab	3	3 (100.0)	1.97 (1.22)	0.6	0.56	2.56	2.78	2.8	1.51 [-0.40, 3.42]
			Placebo	3	3 (100.0)	0.51 (0.61)	-0.2	-0.19	0.78	0.94	0.9	
		Week 44	Tezepelumab	3	3 (100.0)	2.08 (1.47)	0.4	0.44	2.56	3.25	3.3	1.99 [-0.12, 4.11]
			Placebo	3	3 (100.0)	-0.25 (0.77)	-1.0	-1.00	-0.28	0.53	0.5	
		Week 48	Tezepelumab	3	3 (100.0)	2.04 (1.19)	0.7	0.69	2.53	2.91	2.9	1.86 [-0.19, 3.92]
			Placebo	3	3 (100.0)	0.25 (0.66)	-0.5	-0.50	0.50	0.75	0.8	
		Week 52	Tezepelumab	3	3 (100.0)	2.04 (1.19)	0.7	0.69	2.53	2.91	2.9	1.86 [-0.19, 3.92]
			Placebo	3	3 (100.0)	0.25 (0.66)	-0.5	-0.50	0.50	0.75	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	17	14 (82.4)	3.91 (0.47)	3.0	3.66	3.98	4.31	4.7	
			Placebo	22	18 (81.8)	4.03 (0.94)	1.8	3.69	4.08	4.47	6.3	
		Week 4	Tezepelumab	17	16 (94.1)	4.72 (0.86)	3.3	4.03	4.88	5.14	6.5	
			Placebo	22	20 (90.9)	4.65 (1.04)	2.4	3.92	4.75	5.23	6.8	
		Week 8	Tezepelumab	17	16 (94.1)	4.93 (0.99)	3.3	4.22	4.58	5.81	6.6	
			Placebo	22	21 (95.5)	4.71 (1.05)	2.4	4.25	4.81	5.50	6.9	
		Week 12	Tezepelumab	17	16 (94.1)	5.12 (0.95)	3.8	4.44	4.84	5.84	6.8	
			Placebo	22	21 (95.5)	4.77 (1.00)	3.0	4.19	4.59	5.53	6.8	
		Week 16	Tezepelumab	17	16 (94.1)	5.24 (0.98)	3.7	4.50	5.17	5.89	7.0	
			Placebo	22	21 (95.5)	4.90 (1.06)	2.9	4.06	4.78	5.69	6.8	
		Week 20	Tezepelumab	17	16 (94.1)	5.04 (1.02)	3.8	4.22	4.66	5.86	7.0	
			Placebo	22	21 (95.5)	4.73 (1.10)	2.4	4.03	4.78	5.53	6.7	
		Week 24	Tezepelumab	17	16 (94.1)	5.01 (1.03)	3.3	4.36	4.72	5.69	6.8	
			Placebo	22	21 (95.5)	4.83 (1.15)	2.4	4.00	4.81	5.75	6.7	
		Week 28	Tezepelumab	17	16 (94.1)	5.06 (0.96)	3.7	4.50	4.63	5.77	6.8	
			Placebo	22	21 (95.5)	4.83 (1.21)	2.2	4.22	4.72	5.72	7.0	
		Week 32	Tezepelumab	17	16 (94.1)	5.17 (1.00)	4.0	4.36	4.80	6.03	7.0	
			Placebo	22	21 (95.5)	4.82 (1.16)	2.7	4.09	4.78	5.75	6.8	
		Week 36	Tezepelumab	17	16 (94.1)	5.23 (1.04)	3.8	4.36	5.05	6.13	6.8	
			Placebo	22	21 (95.5)	4.75 (1.11)	2.9	4.00	4.69	5.69	6.5	
		Week 40	Tezepelumab	17	16 (94.1)	4.90 (1.09)	3.2	4.03	4.72	5.39	6.8	
			Placebo	22	21 (95.5)	4.87 (1.23)	2.5	4.00	4.97	5.75	6.8	
		Week 44	Tezepelumab	17	16 (94.1)	5.05 (0.99)	3.9	4.39	4.81	5.53	6.9	
			Placebo	22	21 (95.5)	4.81 (1.08)	2.9	4.19	4.53	5.75	6.8	
		Week 48	Tezepelumab	17	16 (94.1)	5.24 (1.03)	4.0	4.31	5.06	6.11	7.0	
			Placebo	22	21 (95.5)	4.75 (1.03)	2.9	4.19	4.69	5.41	6.7	
		Week 52	Tezepelumab	17	16 (94.1)	5.22 (1.03)	4.0	4.31	5.06	6.11	7.0	
			Placebo	22	21 (95.5)	4.79 (1.05)	2.9	4.09	4.63	5.41	6.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	17	13 (76.5)	0.84 (0.61)	-0.4	0.69	0.75	0.97	2.0	0.35 [-0.37, 1.07]
			Placebo	22	18 (81.8)	0.57 (0.84)	-1.1	0.16	0.50	1.16	2.6	
		Week 8	Tezepelumab	17	13 (76.5)	0.87 (0.76)	-0.1	0.44	0.69	1.41	2.6	0.14 [-0.57, 0.85]
			Placebo	22	18 (81.8)	0.74 (1.00)	-1.4	0.16	0.73	0.97	2.7	
		Week 12	Tezepelumab	17	13 (76.5)	1.07 (0.65)	0.5	0.69	0.84	1.22	2.7	0.34 [-0.38, 1.06]
			Placebo	22	18 (81.8)	0.71 (1.26)	-1.7	0.25	0.69	1.22	3.5	
		Week 16	Tezepelumab	17	13 (76.5)	1.25 (0.68)	0.3	0.69	1.25	1.66	2.7	0.29 [-0.43, 1.01]
			Placebo	22	18 (81.8)	0.94 (1.22)	-2.0	0.41	0.98	1.66	3.8	
		Week 20	Tezepelumab	17	13 (76.5)	1.13 (0.85)	0.2	0.47	0.75	1.78	3.0	0.35 [-0.37, 1.07]
			Placebo	22	18 (81.8)	0.78 (1.12)	-2.0	0.34	0.89	1.59	2.5	
		Week 24	Tezepelumab	17	13 (76.5)	1.20 (0.73)	0.3	0.69	1.03	1.56	2.8	0.29 [-0.43, 1.00]
			Placebo	22	18 (81.8)	0.90 (1.20)	-2.0	0.63	1.02	1.72	2.8	
		Week 28	Tezepelumab	17	13 (76.5)	1.13 (0.79)	-0.0	0.56	1.03	1.56	2.7	0.20 [-0.52, 0.91]
			Placebo	22	18 (81.8)	0.90 (1.36)	-2.0	0.28	1.02	1.47	4.0	
		Week 32	Tezepelumab	17	13 (76.5)	1.32 (0.87)	0.3	0.69	1.03	2.06	2.9	0.35 [-0.37, 1.07]
			Placebo	22	18 (81.8)	0.93 (1.23)	-2.0	0.13	1.08	1.50	3.2	
		Week 36	Tezepelumab	17	13 (76.5)	1.38 (0.94)	0.0	0.75	1.03	2.34	2.8	0.52 [-0.21, 1.25]
			Placebo	22	18 (81.8)	0.83 (1.14)	-2.0	0.06	1.08	1.69	2.3	
		Week 40	Tezepelumab	17	13 (76.5)	1.00 (0.89)	-0.5	0.63	0.97	1.09	2.7	0.02 [-0.69, 0.73]
			Placebo	22	18 (81.8)	0.97 (1.34)	-2.0	0.09	1.08	1.72	3.8	
		Week 44	Tezepelumab	17	13 (76.5)	1.15 (0.80)	0.2	0.72	0.78	1.38	2.9	0.25 [-0.46, 0.97]
			Placebo	22	18 (81.8)	0.88 (1.23)	-2.0	0.09	1.02	1.72	3.4	
		Week 48	Tezepelumab	17	13 (76.5)	1.38 (0.85)	0.3	0.69	1.22	2.06	2.9	0.56 [-0.17, 1.29]
			Placebo	22	18 (81.8)	0.82 (1.09)	-2.0	0.09	1.02	1.66	2.5	
		Week 52	Tezepelumab	17	13 (76.5)	1.35 (0.87)	0.3	0.69	1.22	2.06	3.0	0.47 [-0.25, 1.20]
			Placebo	22	18 (81.8)	0.86 (1.13)	-2.0	0.09	1.02	1.72	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	4.16 (1.14)	2.2	3.22	3.95	5.28	6.3	
			Placebo	21	17 (81.0)	4.29 (0.99)	1.8	3.69	4.47	4.94	5.8	
		Week 4	Tezepelumab	15	13 (86.7)	5.30 (0.96)	3.7	4.44	5.53	5.97	6.8	
			Placebo	21	19 (90.5)	4.73 (0.98)	2.4	4.16	4.75	5.47	6.3	
		Week 8	Tezepelumab	15	14 (93.3)	5.69 (0.93)	3.3	5.19	5.95	6.09	6.8	
			Placebo	21	19 (90.5)	4.88 (1.13)	2.8	4.19	4.75	5.97	7.0	
		Week 12	Tezepelumab	15	14 (93.3)	5.94 (0.81)	4.3	5.25	6.22	6.59	7.0	
			Placebo	21	19 (90.5)	5.11 (1.10)	3.0	4.22	5.22	6.00	7.0	
		Week 16	Tezepelumab	15	14 (93.3)	5.94 (0.69)	4.7	5.59	5.84	6.53	7.0	
			Placebo	21	19 (90.5)	5.20 (1.17)	2.9	4.25	5.19	5.88	7.0	
		Week 20	Tezepelumab	15	14 (93.3)	5.86 (0.76)	4.3	5.59	5.89	6.41	7.0	
			Placebo	21	19 (90.5)	5.04 (1.35)	2.4	3.91	5.00	5.97	7.0	
		Week 24	Tezepelumab	15	14 (93.3)	5.92 (0.81)	4.3	5.63	5.97	6.66	7.0	
			Placebo	21	19 (90.5)	5.00 (1.37)	2.4	3.81	5.50	6.03	7.0	
		Week 28	Tezepelumab	15	14 (93.3)	5.92 (0.76)	4.5	5.63	5.84	6.66	7.0	
			Placebo	21	20 (95.2)	5.22 (1.35)	2.2	4.19	5.63	6.20	7.0	
		Week 32	Tezepelumab	15	14 (93.3)	5.91 (0.68)	4.3	5.63	5.81	6.34	7.0	
			Placebo	21	20 (95.2)	5.18 (1.29)	2.7	4.16	5.45	6.05	7.0	
		Week 36	Tezepelumab	15	14 (93.3)	6.10 (0.69)	4.7	5.63	6.06	6.69	7.0	
			Placebo	21	20 (95.2)	5.04 (1.40)	2.9	3.80	4.91	6.25	7.0	
		Week 40	Tezepelumab	15	14 (93.3)	5.96 (0.75)	4.8	5.63	5.95	6.50	7.0	
			Placebo	21	20 (95.2)	5.14 (1.36)	2.5	4.09	5.22	6.27	7.0	
		Week 44	Tezepelumab	15	14 (93.3)	6.03 (0.69)	4.8	5.63	6.11	6.47	7.0	
			Placebo	21	20 (95.2)	5.00 (1.28)	2.9	3.84	5.11	5.89	7.0	
		Week 48	Tezepelumab	15	14 (93.3)	6.10 (0.70)	4.9	5.63	6.22	6.56	7.0	
			Placebo	21	20 (95.2)	4.99 (1.24)	2.9	3.97	4.73	5.98	7.0	
		Week 52	Tezepelumab	15	14 (93.3)	5.99 (0.67)	4.9	5.41	6.13	6.53	7.0	
			Placebo	21	20 (95.2)	5.08 (1.25)	2.9	4.03	4.73	6.16	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	15	12 (80.0)	1.44 (0.85)	0.5	0.69	1.39	1.91	3.3	1.48 [0.64, 2.32]
			Placebo	21	17 (81.0)	0.45 (0.51)	-0.7	0.06	0.41	0.66	1.3	
		Week 8	Tezepelumab	15	13 (86.7)	1.51 (1.02)	0.3	0.50	1.53	1.94	3.8	1.02 [0.25, 1.79]
			Placebo	21	17 (81.0)	0.68 (0.61)	-0.4	0.22	0.72	0.97	2.1	
		Week 12	Tezepelumab	15	13 (86.7)	1.73 (0.98)	0.3	1.06	1.66	2.09	4.0	1.03 [0.26, 1.80]
			Placebo	21	17 (81.0)	0.85 (0.75)	-0.8	0.53	0.88	1.22	2.1	
		Week 16	Tezepelumab	15	13 (86.7)	1.72 (0.90)	0.3	1.25	1.66	2.44	3.4	1.00 [0.23, 1.76]
			Placebo	21	17 (81.0)	0.98 (0.58)	-0.4	0.66	0.94	1.41	2.1	
		Week 20	Tezepelumab	15	13 (86.7)	1.65 (0.97)	0.5	0.78	1.66	2.44	3.4	0.88 [0.13, 1.64]
			Placebo	21	17 (81.0)	0.83 (0.90)	-1.3	0.41	0.91	1.50	2.1	
		Week 24	Tezepelumab	15	13 (86.7)	1.72 (1.10)	0.2	0.66	1.63	2.75	3.4	0.86 [0.11, 1.62]
			Placebo	21	17 (81.0)	0.84 (0.95)	-1.3	0.09	1.13	1.59	2.1	
		Week 28	Tezepelumab	15	13 (86.7)	1.72 (1.03)	0.2	0.88	1.69	2.59	3.4	0.75 [0.00, 1.50]
			Placebo	21	17 (81.0)	0.99 (0.93)	-1.5	0.63	1.03	1.66	2.2	
		Week 32	Tezepelumab	15	13 (86.7)	1.73 (0.99)	0.3	0.72	1.88	2.47	3.4	0.91 [0.15, 1.67]
			Placebo	21	17 (81.0)	0.94 (0.79)	-1.0	0.72	1.03	1.50	2.1	
		Week 36	Tezepelumab	15	13 (86.7)	1.92 (1.14)	0.1	0.81	2.56	2.72	3.4	1.13 [0.35, 1.91]
			Placebo	21	17 (81.0)	0.76 (0.93)	-1.2	0.28	0.88	1.63	2.1	
		Week 40	Tezepelumab	15	13 (86.7)	1.75 (1.04)	0.6	0.78	1.69	2.78	3.4	0.90 [0.14, 1.66]
			Placebo	21	17 (81.0)	0.90 (0.87)	-1.2	0.34	0.94	1.56	2.1	
		Week 44	Tezepelumab	15	13 (86.7)	1.83 (1.07)	0.4	0.88	1.69	2.84	3.4	1.20 [0.41, 1.99]
			Placebo	21	17 (81.0)	0.68 (0.87)	-1.0	-0.03	0.81	1.22	2.1	
		Week 48	Tezepelumab	15	13 (86.7)	1.91 (0.99)	0.7	1.00	1.78	2.91	3.4	1.37 [0.56, 2.17]
			Placebo	21	17 (81.0)	0.69 (0.82)	-0.5	0.06	0.59	1.06	2.2	
		Week 52	Tezepelumab	15	13 (86.7)	1.80 (1.12)	0.1	0.94	1.78	2.91	3.4	1.01 [0.24, 1.78]
			Placebo	21	17 (81.0)	0.81 (0.85)	-0.5	0.19	0.59	1.38	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	24	20 (83.3)	4.25 (0.92)	2.3	3.73	4.36	4.75	6.1	
			Placebo	20	18 (90.0)	4.24 (0.67)	3.3	3.91	4.14	4.34	6.3	
		Week 4	Tezepelumab	24	23 (95.8)	5.10 (0.82)	3.5	4.59	5.16	5.81	6.5	
			Placebo	20	17 (85.0)	4.69 (0.90)	3.0	4.00	4.84	5.25	6.3	
		Week 8	Tezepelumab	24	23 (95.8)	5.29 (0.95)	3.8	4.28	5.16	5.84	6.8	
			Placebo	20	18 (90.0)	4.76 (0.85)	3.3	4.22	4.70	5.34	6.8	
		Week 12	Tezepelumab	24	23 (95.8)	5.48 (1.00)	3.8	4.66	5.38	6.28	7.0	
			Placebo	20	18 (90.0)	4.77 (1.01)	2.8	4.19	4.83	5.53	6.9	
		Week 16	Tezepelumab	24	23 (95.8)	5.43 (1.03)	3.7	4.25	5.34	6.34	6.9	
			Placebo	20	18 (90.0)	4.54 (1.36)	1.2	3.97	4.61	5.59	6.8	
		Week 20	Tezepelumab	24	23 (95.8)	5.43 (1.04)	4.1	4.22	5.22	6.47	7.0	
			Placebo	20	18 (90.0)	4.61 (1.36)	1.2	4.00	4.69	5.53	6.8	
		Week 24	Tezepelumab	24	23 (95.8)	5.44 (1.03)	4.1	4.63	5.16	6.59	7.0	
			Placebo	20	18 (90.0)	4.61 (1.30)	1.2	4.00	4.69	5.34	6.9	
		Week 28	Tezepelumab	24	24 (100.0)	5.50 (0.96)	4.1	4.63	5.42	6.45	7.0	
			Placebo	20	18 (90.0)	4.57 (1.30)	1.2	3.97	4.78	5.19	6.8	
		Week 32	Tezepelumab	24	24 (100.0)	5.58 (1.07)	4.0	4.67	5.59	6.70	7.0	
			Placebo	20	18 (90.0)	4.65 (1.26)	1.2	3.97	4.91	5.34	6.5	
		Week 36	Tezepelumab	24	24 (100.0)	5.54 (0.98)	4.0	4.80	5.53	6.34	7.0	
			Placebo	20	18 (90.0)	4.59 (1.11)	2.2	4.00	4.59	5.19	6.4	
		Week 40	Tezepelumab	24	24 (100.0)	5.62 (1.02)	4.1	4.84	5.39	6.67	7.0	
			Placebo	20	18 (90.0)	4.76 (1.09)	2.3	4.00	5.06	5.44	6.4	
		Week 44	Tezepelumab	24	24 (100.0)	5.54 (1.01)	3.9	4.84	5.47	6.28	7.0	
			Placebo	20	18 (90.0)	4.85 (1.08)	2.8	4.03	4.89	5.81	6.5	
		Week 48	Tezepelumab	24	24 (100.0)	5.54 (0.97)	4.1	4.67	5.48	6.34	7.0	
			Placebo	20	18 (90.0)	4.86 (1.15)	2.1	4.00	4.81	5.53	6.5	
		Week 52	Tezepelumab	24	24 (100.0)	5.63 (1.00)	4.1	4.84	5.64	6.53	7.0	
			Placebo	20	18 (90.0)	4.90 (1.11)	3.3	4.00	4.92	5.53	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	24	20 (83.3)	0.89 (0.80)	-0.9	0.36	0.95	1.55	2.0	0.48 [-0.18, 1.14]
			Placebo	20	17 (85.0)	0.46 (1.02)	-1.1	-0.47	0.41	0.97	2.6	
		Week 8	Tezepelumab	24	20 (83.3)	0.97 (0.93)	-0.9	0.25	1.20	1.70	2.6	0.46 [-0.19, 1.10]
			Placebo	20	18 (90.0)	0.52 (1.06)	-1.4	-0.03	0.25	1.38	3.1	
		Week 12	Tezepelumab	24	20 (83.3)	1.20 (0.95)	-0.9	0.66	1.34	1.95	2.7	0.65 [-0.00, 1.31]
			Placebo	20	18 (90.0)	0.53 (1.11)	-1.7	0.06	0.38	0.84	3.3	
		Week 16	Tezepelumab	24	20 (83.3)	1.15 (0.96)	-0.9	0.59	1.47	1.86	2.7	0.70 [0.05, 1.36]
			Placebo	20	18 (90.0)	0.30 (1.43)	-3.2	-0.25	0.50	0.78	3.2	
		Week 20	Tezepelumab	24	20 (83.3)	1.24 (1.02)	-0.9	0.55	1.52	1.98	3.0	0.71 [0.05, 1.37]
			Placebo	20	18 (90.0)	0.37 (1.42)	-3.2	-0.25	0.66	0.78	3.2	
		Week 24	Tezepelumab	24	20 (83.3)	1.25 (1.02)	-0.9	0.42	1.61	1.91	2.8	0.71 [0.05, 1.37]
			Placebo	20	18 (90.0)	0.38 (1.44)	-3.2	-0.03	0.67	0.78	3.2	
		Week 28	Tezepelumab	24	20 (83.3)	1.24 (1.04)	-0.9	0.33	1.55	2.05	2.7	0.74 [0.08, 1.40]
			Placebo	20	18 (90.0)	0.33 (1.41)	-3.2	0.00	0.50	0.84	3.2	
		Week 32	Tezepelumab	24	20 (83.3)	1.37 (1.10)	-0.9	0.59	1.67	2.23	2.9	0.78 [0.11, 1.44]
			Placebo	20	18 (90.0)	0.41 (1.37)	-3.2	0.00	0.64	1.19	2.9	
		Week 36	Tezepelumab	24	20 (83.3)	1.31 (1.13)	-0.9	0.72	1.50	2.27	2.8	0.83 [0.16, 1.49]
			Placebo	20	18 (90.0)	0.35 (1.19)	-2.0	0.06	0.53	1.09	2.5	
		Week 40	Tezepelumab	24	20 (83.3)	1.39 (1.13)	-0.9	0.66	1.67	2.31	2.7	0.74 [0.08, 1.40]
			Placebo	20	18 (90.0)	0.52 (1.21)	-2.0	0.03	0.75	1.50	2.6	
		Week 44	Tezepelumab	24	20 (83.3)	1.34 (1.18)	-0.9	0.70	1.63	2.28	2.9	0.57 [-0.08, 1.23]
			Placebo	20	18 (90.0)	0.61 (1.34)	-2.0	-0.19	0.39	1.72	3.3	
		Week 48	Tezepelumab	24	20 (83.3)	1.36 (1.13)	-0.9	0.56	1.52	2.30	2.9	0.59 [-0.06, 1.25]
			Placebo	20	18 (90.0)	0.62 (1.36)	-2.0	0.09	0.52	1.41	3.3	
		Week 52	Tezepelumab	24	20 (83.3)	1.44 (1.10)	-0.9	0.72	1.52	2.45	3.0	0.63 [-0.02, 1.29]
			Placebo	20	18 (90.0)	0.66 (1.36)	-2.0	-0.25	0.56	1.41	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	27	24 (88.9)	3.90 (0.72)	2.0	3.64	3.98	4.44	5.1	
			Placebo	24	20 (83.3)	4.26 (0.79)	2.7	3.70	4.33	4.77	6.1	
		Week 4	Tezepelumab	27	24 (88.9)	4.29 (1.09)	1.4	3.73	4.14	4.98	6.6	
			Placebo	24	21 (87.5)	4.87 (0.96)	3.3	4.06	4.72	5.28	6.8	
		Week 8	Tezepelumab	27	25 (92.6)	4.58 (1.00)	3.0	3.91	4.25	5.22	6.7	
			Placebo	24	22 (91.7)	4.86 (1.03)	2.4	4.22	4.77	5.50	6.9	
		Week 12	Tezepelumab	27	25 (92.6)	4.77 (0.85)	3.0	4.31	4.59	5.03	6.6	
			Placebo	24	22 (91.7)	4.98 (0.97)	3.4	4.22	4.83	5.53	6.8	
		Week 16	Tezepelumab	27	25 (92.6)	4.71 (0.91)	2.7	4.34	4.47	5.19	6.9	
			Placebo	24	22 (91.7)	5.08 (0.99)	3.4	4.56	4.86	5.75	6.8	
		Week 20	Tezepelumab	27	26 (96.3)	4.69 (0.89)	3.2	4.09	4.47	5.28	6.8	
			Placebo	24	22 (91.7)	4.92 (0.85)	3.8	4.06	4.83	5.56	6.7	
		Week 24	Tezepelumab	27	26 (96.3)	4.72 (0.91)	3.3	4.06	4.50	5.38	6.8	
			Placebo	24	22 (91.7)	4.92 (0.99)	3.2	4.22	4.78	5.75	6.7	
		Week 28	Tezepelumab	27	27 (100.0)	4.64 (0.93)	3.3	3.84	4.50	5.19	6.8	
			Placebo	24	22 (91.7)	5.02 (1.19)	2.9	3.97	4.86	6.03	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	4.70 (0.93)	2.9	3.97	4.53	5.34	6.7	
			Placebo	24	22 (91.7)	5.11 (1.01)	3.8	4.22	4.77	6.09	6.9	
		Week 36	Tezepelumab	27	27 (100.0)	4.78 (0.97)	3.3	3.91	4.69	5.50	6.8	
			Placebo	24	22 (91.7)	5.07 (0.91)	3.8	4.22	5.09	5.69	6.7	
		Week 40	Tezepelumab	27	27 (100.0)	4.63 (0.88)	3.2	3.81	4.63	5.25	6.8	
			Placebo	24	22 (91.7)	5.07 (1.14)	3.3	4.13	5.19	5.91	6.8	
		Week 44	Tezepelumab	27	27 (100.0)	4.71 (0.86)	3.5	4.00	4.47	5.31	6.8	
			Placebo	24	22 (91.7)	5.13 (1.07)	3.5	4.22	5.03	6.19	6.8	
		Week 48	Tezepelumab	27	27 (100.0)	4.75 (0.99)	2.9	4.03	4.69	5.53	6.8	
			Placebo	24	22 (91.7)	5.10 (1.05)	3.4	4.22	4.81	6.00	7.0	
		Week 52	Tezepelumab	27	27 (100.0)	4.74 (0.98)	2.9	4.06	4.66	5.53	6.7	
			Placebo	24	22 (91.7)	5.11 (1.02)	3.6	4.22	4.88	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	0.28 (1.09)	-3.7	-0.22	0.25	0.97	2.0	-0.37 [-0.97, 0.24]
			Placebo	24	20 (83.3)	0.64 (0.83)	-1.2	0.25	0.50	0.83	2.6	
		Week 8	Tezepelumab	27	24 (88.9)	0.66 (0.94)	-1.0	0.00	0.59	1.59	2.1	-0.00 [-0.60, 0.59]
			Placebo	24	20 (83.3)	0.66 (0.99)	-1.0	-0.02	0.52	1.03	2.7	
		Week 12	Tezepelumab	27	24 (88.9)	0.85 (0.96)	-2.1	0.30	0.86	1.50	2.3	0.08 [-0.51, 0.67]
			Placebo	24	20 (83.3)	0.77 (1.15)	-1.0	0.20	0.59	1.03	3.5	
		Week 16	Tezepelumab	27	24 (88.9)	0.83 (0.99)	-2.4	0.39	0.66	1.61	2.4	-0.07 [-0.67, 0.52]
			Placebo	24	20 (83.3)	0.90 (1.05)	-0.5	0.27	0.80	1.06	3.8	
		Week 20	Tezepelumab	27	24 (88.9)	0.77 (0.86)	-1.2	0.22	0.53	1.55	2.3	0.01 [-0.58, 0.61]
			Placebo	24	20 (83.3)	0.76 (0.77)	-0.2	0.25	0.55	1.09	2.5	
		Week 24	Tezepelumab	27	24 (88.9)	0.86 (0.84)	-1.2	0.31	0.70	1.56	2.3	0.16 [-0.43, 0.76]
			Placebo	24	20 (83.3)	0.72 (1.02)	-1.2	0.08	0.50	1.03	2.8	
		Week 28	Tezepelumab	27	24 (88.9)	0.78 (0.88)	-1.3	0.30	0.56	1.38	2.3	-0.03 [-0.63, 0.56]
			Placebo	24	20 (83.3)	0.81 (1.21)	-1.5	0.00	0.95	1.22	4.0	
		Week 32	Tezepelumab	27	24 (88.9)	0.77 (0.89)	-1.2	0.30	0.83	1.36	2.3	-0.20 [-0.80, 0.39]
			Placebo	24	20 (83.3)	0.95 (0.91)	-0.2	0.36	0.75	1.23	3.2	
		Week 36	Tezepelumab	27	24 (88.9)	0.86 (0.88)	-1.3	0.30	0.80	1.48	2.3	-0.04 [-0.63, 0.56]
			Placebo	24	20 (83.3)	0.89 (0.83)	-0.3	0.38	0.77	1.08	2.9	
		Week 40	Tezepelumab	27	24 (88.9)	0.78 (0.83)	-1.3	0.30	0.86	1.09	2.3	-0.11 [-0.71, 0.48]
			Placebo	24	20 (83.3)	0.89 (1.19)	-1.0	-0.03	0.73	1.34	3.8	
		Week 44	Tezepelumab	27	24 (88.9)	0.82 (0.76)	-1.1	0.30	0.78	1.23	2.4	-0.14 [-0.73, 0.46]
			Placebo	24	20 (83.3)	0.94 (1.05)	-0.7	0.31	0.84	1.25	3.4	
		Week 48	Tezepelumab	27	24 (88.9)	0.86 (0.86)	-1.1	0.42	0.80	1.30	2.3	-0.06 [-0.66, 0.53]
			Placebo	24	20 (83.3)	0.91 (0.91)	-0.2	0.14	0.86	1.36	3.3	
		Week 52	Tezepelumab	27	24 (88.9)	0.84 (0.85)	-1.2	0.42	0.67	1.30	2.3	-0.09 [-0.68, 0.50]
			Placebo	24	20 (83.3)	0.92 (0.89)	-0.2	0.20	0.78	1.36	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	3.60 (0.80)	2.2	2.78	3.75	4.41	4.5	
			Placebo	14	11 (78.6)	4.31 (0.82)	3.0	3.75	4.16	4.69	6.1	
		Week 4	Tezepelumab	11	11 (100.0)	4.53 (0.90)	3.0	3.72	4.50	5.44	5.8	
			Placebo	14	12 (85.7)	4.63 (1.11)	3.3	3.66	4.55	5.09	6.8	
		Week 8	Tezepelumab	11	11 (100.0)	4.82 (1.12)	3.3	3.88	4.56	5.97	6.6	
			Placebo	14	12 (85.7)	5.02 (0.81)	3.7	4.41	4.94	5.42	6.5	
		Week 12	Tezepelumab	11	11 (100.0)	5.01 (0.88)	4.1	4.25	4.78	5.88	6.6	
			Placebo	14	12 (85.7)	4.99 (1.12)	3.4	3.95	4.91	5.89	6.8	
		Week 16	Tezepelumab	11	11 (100.0)	5.02 (0.83)	4.1	4.47	5.00	5.59	6.9	
			Placebo	14	12 (85.7)	5.20 (1.06)	4.0	4.34	4.89	6.22	6.8	
		Week 20	Tezepelumab	11	11 (100.0)	4.95 (0.84)	4.1	4.22	4.69	5.59	6.8	
			Placebo	14	12 (85.7)	4.82 (0.89)	3.9	4.13	4.58	5.25	6.8	
		Week 24	Tezepelumab	11	11 (100.0)	5.03 (0.93)	4.1	4.09	4.69	5.75	6.8	
			Placebo	14	12 (85.7)	4.99 (0.96)	3.6	4.27	4.67	5.72	6.8	
		Week 28	Tezepelumab	11	11 (100.0)	4.96 (0.90)	3.7	4.16	4.69	5.63	6.8	
			Placebo	14	12 (85.7)	5.11 (1.27)	3.6	4.00	4.70	6.25	7.0	
		Week 32	Tezepelumab	11	11 (100.0)	5.04 (0.89)	3.9	4.09	5.25	5.72	6.7	
			Placebo	14	12 (85.7)	5.09 (1.12)	3.8	4.17	4.73	6.13	6.9	
		Week 36	Tezepelumab	11	11 (100.0)	5.07 (0.99)	3.8	4.09	5.00	5.72	6.8	
			Placebo	14	12 (85.7)	4.97 (1.06)	3.8	4.16	4.70	5.64	6.8	
		Week 40	Tezepelumab	11	11 (100.0)	5.00 (0.89)	3.9	4.13	4.88	5.63	6.8	
			Placebo	14	12 (85.7)	4.96 (1.25)	3.5	3.89	4.59	6.13	6.8	
		Week 44	Tezepelumab	11	11 (100.0)	4.95 (0.97)	3.7	4.06	5.03	5.63	6.8	
			Placebo	14	12 (85.7)	5.01 (1.14)	3.5	4.13	4.88	5.81	6.8	
		Week 48	Tezepelumab	11	11 (100.0)	5.04 (0.92)	4.0	4.13	5.09	5.63	6.8	
			Placebo	14	12 (85.7)	4.99 (1.00)	3.8	4.17	4.75	5.38	6.8	
		Week 52	Tezepelumab	11	11 (100.0)	5.03 (0.90)	4.1	4.13	5.09	5.63	6.7	
			Placebo	14	12 (85.7)	4.84 (1.01)	3.7	4.06	4.52	5.38	6.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	11	11 (100.0)	0.93 (0.98)	-0.3	0.22	0.75	1.41	3.3	0.65 [-0.21, 1.51]
			Placebo	14	11 (78.6)	0.42 (0.49)	-0.7	0.25	0.41	0.78	1.2	
		Week 8	Tezepelumab	11	11 (100.0)	1.21 (1.26)	-1.0	0.31	1.41	1.88	3.8	0.38 [-0.47, 1.22]
			Placebo	14	11 (78.6)	0.82 (0.73)	0.1	0.19	0.63	1.25	2.5	
		Week 12	Tezepelumab	11	11 (100.0)	1.41 (1.09)	-0.1	0.56	1.22	2.00	4.0	0.56 [-0.30, 1.41]
			Placebo	14	11 (78.6)	0.78 (1.16)	-1.0	0.16	0.72	1.31	3.5	
		Week 16	Tezepelumab	11	11 (100.0)	1.42 (0.90)	0.5	0.59	1.41	1.69	3.4	0.46 [-0.39, 1.30]
			Placebo	14	11 (78.6)	0.97 (1.04)	-0.2	0.41	0.72	1.09	3.8	
		Week 20	Tezepelumab	11	11 (100.0)	1.35 (0.94)	0.1	0.50	1.41	1.66	3.4	0.95 [0.06, 1.84]
			Placebo	14	11 (78.6)	0.59 (0.62)	-0.2	0.16	0.41	0.81	1.8	
		Week 24	Tezepelumab	11	11 (100.0)	1.43 (0.93)	0.3	0.47	1.44	1.97	3.4	0.74 [-0.13, 1.60]
			Placebo	14	11 (78.6)	0.76 (0.88)	-0.3	0.03	0.66	0.94	2.8	
		Week 28	Tezepelumab	11	11 (100.0)	1.36 (0.98)	-0.0	0.56	1.41	1.88	3.4	0.41 [-0.43, 1.26]
			Placebo	14	11 (78.6)	0.90 (1.20)	-0.5	0.09	0.94	1.06	4.0	
		Week 32	Tezepelumab	11	11 (100.0)	1.43 (0.95)	0.3	0.34	1.41	2.19	3.4	0.60 [-0.26, 1.45]
			Placebo	14	11 (78.6)	0.86 (0.96)	-0.2	0.00	0.72	1.41	3.2	
		Week 36	Tezepelumab	11	11 (100.0)	1.46 (1.10)	0.0	0.31	1.41	2.28	3.4	0.74 [-0.13, 1.60]
			Placebo	14	11 (78.6)	0.74 (0.85)	-0.4	-0.16	0.66	1.34	2.3	
		Week 40	Tezepelumab	11	11 (100.0)	1.39 (0.96)	0.1	0.53	1.41	1.84	3.4	0.59 [-0.26, 1.45]
			Placebo	14	11 (78.6)	0.75 (1.21)	-0.7	-0.16	0.66	1.28	3.8	
		Week 44	Tezepelumab	11	11 (100.0)	1.35 (0.99)	0.2	0.47	0.97	2.06	3.4	0.60 [-0.26, 1.45]
			Placebo	14	11 (78.6)	0.72 (1.10)	-0.7	-0.06	0.53	1.31	3.4	
		Week 48	Tezepelumab	11	11 (100.0)	1.43 (0.96)	0.3	0.44	1.34	2.06	3.4	0.84 [-0.03, 1.72]
			Placebo	14	11 (78.6)	0.72 (0.71)	-0.2	0.00	0.72	1.66	1.8	
		Week 52	Tezepelumab	11	11 (100.0)	1.43 (0.95)	0.3	0.47	1.34	2.06	3.4	0.98 [0.09, 1.87]
			Placebo	14	11 (78.6)	0.59 (0.75)	-0.5	0.00	0.72	1.19	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	54	46 (85.2)	4.19 (0.90)	2.0	3.66	4.13	4.69	6.3	
			Placebo	51	44 (86.3)	4.25 (0.81)	1.8	3.78	4.28	4.73	6.3	
		Week 4	Tezepelumab	54	48 (88.9)	4.87 (1.09)	1.4	4.03	4.97	5.66	6.8	
			Placebo	51	45 (88.2)	4.81 (0.89)	2.4	4.16	4.84	5.31	6.8	
		Week 8	Tezepelumab	54	50 (92.6)	5.17 (1.04)	3.0	4.19	5.17	6.00	6.8	
			Placebo	51	47 (92.2)	4.79 (1.04)	2.4	4.16	4.66	5.59	7.0	
		Week 12	Tezepelumab	54	50 (92.6)	5.37 (1.03)	3.0	4.56	5.22	6.31	7.0	
			Placebo	51	47 (92.2)	4.95 (1.00)	2.8	4.22	5.09	5.56	7.0	
		Week 16	Tezepelumab	54	50 (92.6)	5.32 (1.07)	2.7	4.38	5.42	6.25	7.0	
			Placebo	51	47 (92.2)	4.89 (1.22)	1.2	4.06	4.94	5.72	7.0	
		Week 20	Tezepelumab	54	51 (94.4)	5.29 (1.07)	3.2	4.31	5.28	6.19	7.0	
			Placebo	51	47 (92.2)	4.88 (1.25)	1.2	4.00	4.91	5.88	7.0	
		Week 24	Tezepelumab	54	51 (94.4)	5.31 (1.07)	3.3	4.34	5.28	6.25	7.0	
			Placebo	51	47 (92.2)	4.82 (1.28)	1.2	3.88	4.81	5.75	7.0	
		Week 28	Tezepelumab	54	53 (98.1)	5.30 (1.07)	3.3	4.50	5.41	6.22	7.0	
			Placebo	51	48 (94.1)	4.91 (1.30)	1.2	3.97	5.05	5.94	7.0	
		Week 32	Tezepelumab	54	53 (98.1)	5.35 (1.10)	2.9	4.41	5.47	6.22	7.0	
			Placebo	51	48 (94.1)	4.97 (1.21)	1.2	4.11	5.16	5.83	7.0	
		Week 36	Tezepelumab	54	53 (98.1)	5.40 (1.07)	3.3	4.63	5.44	6.25	7.0	
			Placebo	51	48 (94.1)	4.90 (1.19)	2.2	4.00	4.84	5.92	7.0	
		Week 40	Tezepelumab	54	53 (98.1)	5.35 (1.10)	3.2	4.63	5.28	6.25	7.0	
			Placebo	51	48 (94.1)	5.01 (1.19)	2.3	4.14	5.09	6.00	7.0	
		Week 44	Tezepelumab	54	53 (98.1)	5.38 (1.04)	3.5	4.47	5.31	6.22	7.0	
			Placebo	51	48 (94.1)	5.00 (1.14)	2.8	4.00	5.02	5.89	7.0	
		Week 48	Tezepelumab	54	53 (98.1)	5.39 (1.09)	2.9	4.56	5.38	6.25	7.0	
			Placebo	51	48 (94.1)	4.99 (1.17)	2.1	4.09	4.80	6.00	7.0	
		Week 52	Tezepelumab	54	53 (98.1)	5.41 (1.10)	2.9	4.63	5.38	6.28	7.0	
			Placebo	51	48 (94.1)	5.09 (1.14)	2.9	4.14	4.86	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	54	43 (79.6)	0.71 (1.07)	-3.7	0.09	0.72	1.53	2.4	0.17 [-0.26, 0.59]
			Placebo	51	43 (84.3)	0.55 (0.87)	-1.2	0.06	0.47	0.97	2.6	
		Week 8	Tezepelumab	54	45 (83.3)	0.93 (0.93)	-1.0	0.31	0.81	1.69	2.7	0.38 [-0.04, 0.80]
			Placebo	51	44 (86.3)	0.57 (0.94)	-1.4	0.00	0.38	0.97	3.1	
		Week 12	Tezepelumab	54	45 (83.3)	1.13 (0.99)	-2.1	0.63	1.22	1.91	2.7	0.44 [0.02, 0.86]
			Placebo	51	44 (86.3)	0.70 (0.99)	-1.7	0.25	0.69	1.13	3.3	
		Week 16	Tezepelumab	54	45 (83.3)	1.09 (1.03)	-2.4	0.44	1.25	1.84	2.8	0.39 [-0.03, 0.81]
			Placebo	51	44 (86.3)	0.67 (1.13)	-3.2	0.20	0.72	1.28	3.2	
		Week 20	Tezepelumab	54	45 (83.3)	1.10 (1.01)	-1.2	0.31	1.00	1.81	3.0	0.40 [-0.02, 0.82]
			Placebo	51	44 (86.3)	0.67 (1.15)	-3.2	0.25	0.78	1.09	3.2	
		Week 24	Tezepelumab	54	45 (83.3)	1.15 (1.03)	-1.2	0.34	1.34	1.78	3.0	0.48 [0.06, 0.90]
			Placebo	51	44 (86.3)	0.61 (1.21)	-3.2	0.09	0.73	1.25	3.2	
		Week 28	Tezepelumab	54	45 (83.3)	1.12 (1.05)	-1.3	0.34	0.88	2.03	3.0	0.41 [-0.01, 0.83]
			Placebo	51	44 (86.3)	0.66 (1.23)	-3.2	0.09	0.81	1.33	3.2	
		Week 32	Tezepelumab	54	45 (83.3)	1.16 (1.08)	-1.2	0.41	1.03	2.19	2.9	0.38 [-0.04, 0.80]
			Placebo	51	44 (86.3)	0.75 (1.10)	-3.2	0.28	0.75	1.36	2.9	
		Week 36	Tezepelumab	54	45 (83.3)	1.22 (1.11)	-1.3	0.66	1.03	2.19	3.3	0.52 [0.10, 0.94]
			Placebo	51	44 (86.3)	0.66 (1.04)	-2.0	0.23	0.66	1.14	2.9	
		Week 40	Tezepelumab	54	45 (83.3)	1.18 (1.09)	-1.3	0.63	1.03	2.09	2.9	0.37 [-0.05, 0.79]
			Placebo	51	44 (86.3)	0.78 (1.09)	-2.0	0.17	0.78	1.53	2.8	
		Week 44	Tezepelumab	54	45 (83.3)	1.21 (1.09)	-1.1	0.59	1.00	2.19	3.3	0.41 [-0.01, 0.83]
			Placebo	51	44 (86.3)	0.76 (1.10)	-2.0	0.00	0.81	1.27	3.3	
		Week 48	Tezepelumab	54	45 (83.3)	1.24 (1.10)	-1.1	0.50	1.19	2.13	2.9	0.44 [0.02, 0.86]
			Placebo	51	44 (86.3)	0.75 (1.12)	-2.0	0.09	0.69	1.31	3.3	
		Week 52	Tezepelumab	54	45 (83.3)	1.24 (1.10)	-1.2	0.50	1.19	2.19	3.0	0.35 [-0.07, 0.77]
			Placebo	51	44 (86.3)	0.86 (1.10)	-2.0	0.19	0.70	1.45	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	33	31 (93.9)	3.95 (0.79)	2.0	3.59	4.16	4.47	5.1	
			Placebo	34	27 (79.4)	4.23 (0.80)	1.8	3.72	4.28	4.69	6.1	
		Week 4	Tezepelumab	33	29 (87.9)	4.66 (1.19)	1.4	3.88	4.50	5.53	6.6	
			Placebo	34	27 (79.4)	4.73 (1.08)	2.4	3.97	4.69	5.31	6.8	
		Week 8	Tezepelumab	33	30 (90.9)	4.91 (1.09)	3.3	4.09	4.58	5.97	6.7	
			Placebo	34	29 (85.3)	4.92 (0.99)	2.8	4.22	4.91	5.53	6.9	
		Week 12	Tezepelumab	33	30 (90.9)	5.16 (1.05)	3.0	4.34	4.75	6.22	6.9	
			Placebo	34	29 (85.3)	5.03 (1.06)	3.0	4.16	4.94	5.75	6.8	
		Week 16	Tezepelumab	33	30 (90.9)	5.09 (1.08)	2.7	4.38	4.92	5.78	6.9	
			Placebo	34	29 (85.3)	5.05 (1.30)	1.2	4.25	5.19	5.75	6.8	
		Week 20	Tezepelumab	33	31 (93.9)	5.09 (1.07)	3.2	4.31	4.81	5.63	7.0	
			Placebo	34	29 (85.3)	4.91 (1.31)	1.2	4.22	4.78	5.91	6.8	
		Week 24	Tezepelumab	33	31 (93.9)	5.13 (1.03)	3.5	4.28	4.75	6.00	7.0	
			Placebo	34	29 (85.3)	4.93 (1.33)	1.2	4.22	5.34	5.84	6.8	
		Week 28	Tezepelumab	33	32 (97.0)	5.07 (1.09)	3.6	4.20	4.70	5.73	7.0	
			Placebo	34	30 (88.2)	5.07 (1.43)	1.2	4.22	5.33	6.06	7.0	
		Week 32	Tezepelumab	33	32 (97.0)	5.15 (1.07)	3.6	4.17	4.86	5.78	7.0	
			Placebo	34	30 (88.2)	5.07 (1.38)	1.2	4.16	5.36	6.16	6.9	
		Week 36	Tezepelumab	33	32 (97.0)	5.20 (1.06)	3.5	4.39	4.95	6.22	7.0	
			Placebo	34	30 (88.2)	5.09 (1.23)	2.6	4.16	5.19	6.16	6.9	
		Week 40	Tezepelumab	33	32 (97.0)	5.12 (1.06)	3.2	4.31	5.14	5.64	7.0	
			Placebo	34	30 (88.2)	5.16 (1.30)	2.5	4.03	5.42	6.41	6.9	
		Week 44	Tezepelumab	33	32 (97.0)	5.13 (1.07)	3.5	4.11	5.06	5.80	7.0	
			Placebo	34	30 (88.2)	5.13 (1.23)	2.9	4.19	5.05	6.41	6.9	
		Week 48	Tezepelumab	33	32 (97.0)	5.21 (1.06)	3.5	4.28	5.11	6.08	7.0	
			Placebo	34	30 (88.2)	5.09 (1.20)	2.9	4.19	4.78	6.38	7.0	
		Week 52	Tezepelumab	33	32 (97.0)	5.23 (1.07)	3.4	4.28	5.14	6.08	7.0	
			Placebo	34	30 (88.2)	5.09 (1.22)	2.9	4.13	4.78	6.38	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High											
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	33	29 (87.9)	0.66 (1.24)	-3.7	0.00	0.72	1.44	3.3	0.11 [-0.42, 0.64]
			Placebo	34	26 (76.5)	0.55 (0.69)	-0.7	0.16	0.39	0.66	2.6	
		Week 8	Tezepelumab	33	30 (90.9)	0.98 (1.08)	-1.0	0.28	0.78	1.78	3.8	0.21 [-0.31, 0.73]
			Placebo	34	27 (79.4)	0.77 (0.83)	-0.6	0.19	0.63	1.00	2.7	
		Week 12	Tezepelumab	33	30 (90.9)	1.22 (1.11)	-2.1	0.59	1.22	1.97	4.0	0.32 [-0.20, 0.85]
			Placebo	34	27 (79.4)	0.88 (1.00)	-1.0	0.25	0.75	1.25	3.5	
		Week 16	Tezepelumab	33	30 (90.9)	1.15 (1.09)	-2.4	0.50	1.11	1.78	3.4	0.23 [-0.29, 0.75]
			Placebo	34	27 (79.4)	0.89 (1.19)	-3.2	0.50	0.91	1.09	3.8	
		Week 20	Tezepelumab	33	30 (90.9)	1.15 (1.04)	-1.2	0.47	0.94	1.75	3.4	0.37 [-0.15, 0.90]
			Placebo	34	27 (79.4)	0.74 (1.12)	-3.2	0.41	0.81	1.50	2.5	
		Week 24	Tezepelumab	33	30 (90.9)	1.19 (1.00)	-1.2	0.34	1.22	1.97	3.4	0.39 [-0.14, 0.91]
			Placebo	34	27 (79.4)	0.77 (1.20)	-3.2	0.16	0.91	1.28	2.8	
		Week 28	Tezepelumab	33	30 (90.9)	1.18 (1.06)	-1.3	0.31	1.02	2.06	3.4	0.29 [-0.23, 0.82]
			Placebo	34	27 (79.4)	0.84 (1.30)	-3.2	0.25	1.00	1.41	4.0	
		Week 32	Tezepelumab	33	30 (90.9)	1.21 (1.07)	-1.2	0.34	1.05	2.19	3.4	0.34 [-0.19, 0.86]
			Placebo	34	27 (79.4)	0.83 (1.20)	-3.2	0.25	0.84	1.41	3.2	
		Week 36	Tezepelumab	33	30 (90.9)	1.27 (1.07)	-1.3	0.53	1.06	2.19	3.4	0.42 [-0.11, 0.95]
			Placebo	34	27 (79.4)	0.83 (1.01)	-1.7	0.31	0.97	1.66	2.9	
		Week 40	Tezepelumab	33	30 (90.9)	1.23 (1.04)	-1.3	0.53	1.08	2.06	3.4	0.26 [-0.26, 0.78]
			Placebo	34	27 (79.4)	0.94 (1.15)	-1.2	0.06	0.94	1.69	3.8	
		Week 44	Tezepelumab	33	30 (90.9)	1.20 (1.04)	-1.1	0.59	0.94	2.06	3.4	0.32 [-0.21, 0.84]
			Placebo	34	27 (79.4)	0.87 (1.08)	-0.9	-0.06	0.81	1.56	3.4	
		Week 48	Tezepelumab	33	30 (90.9)	1.30 (1.00)	-1.1	0.50	1.22	2.13	3.4	0.46 [-0.07, 0.99]
			Placebo	34	27 (79.4)	0.85 (0.97)	-0.9	0.03	0.75	1.66	3.3	
		Week 52	Tezepelumab	33	30 (90.9)	1.32 (1.00)	-1.2	0.50	1.22	2.13	3.4	0.47 [-0.06, 1.00]
			Placebo	34	27 (79.4)	0.85 (0.98)	-0.9	0.03	0.75	1.66	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	4.23 (1.03)	2.3	3.63	3.98	5.06	6.3	
			Placebo	31	28 (90.3)	4.29 (0.82)	2.7	3.88	4.25	4.73	6.3	
		Week 4	Tezepelumab	32	30 (93.8)	4.96 (0.90)	3.3	4.28	5.05	5.66	6.8	
			Placebo	31	30 (96.8)	4.81 (0.80)	3.0	4.06	4.86	5.25	6.3	
		Week 8	Tezepelumab	32	31 (96.9)	5.30 (1.00)	3.0	4.53	5.41	6.00	6.8	
			Placebo	31	30 (96.8)	4.75 (1.01)	2.4	4.22	4.58	5.16	7.0	
		Week 12	Tezepelumab	32	31 (96.9)	5.44 (0.97)	3.8	4.63	5.38	6.28	7.0	
			Placebo	31	30 (96.8)	4.88 (0.98)	2.8	4.25	4.91	5.47	7.0	
		Week 16	Tezepelumab	32	31 (96.9)	5.43 (0.98)	3.7	4.44	5.66	6.09	7.0	
			Placebo	31	30 (96.8)	4.87 (1.08)	2.9	4.06	4.80	5.59	7.0	
		Week 20	Tezepelumab	32	31 (96.9)	5.37 (0.99)	3.8	4.31	5.59	6.19	7.0	
			Placebo	31	30 (96.8)	4.83 (1.07)	2.9	3.94	4.88	5.13	7.0	
		Week 24	Tezepelumab	32	31 (96.9)	5.38 (1.07)	3.3	4.44	5.50	6.25	7.0	
			Placebo	31	30 (96.8)	4.78 (1.10)	2.7	3.88	4.70	5.50	7.0	
		Week 28	Tezepelumab	32	32 (100.0)	5.42 (0.99)	3.3	4.63	5.47	6.13	7.0	
			Placebo	31	30 (96.8)	4.83 (1.14)	2.8	3.91	4.86	5.66	7.0	
		Week 32	Tezepelumab	32	32 (100.0)	5.45 (1.06)	2.9	4.58	5.75	6.19	7.0	
			Placebo	31	30 (96.8)	4.93 (0.97)	3.2	4.03	4.91	5.69	7.0	
		Week 36	Tezepelumab	32	32 (100.0)	5.49 (1.05)	3.3	4.70	5.70	6.23	7.0	
			Placebo	31	30 (96.8)	4.75 (1.07)	2.2	4.00	4.78	5.19	7.0	
		Week 40	Tezepelumab	32	32 (100.0)	5.45 (1.07)	3.5	4.64	5.55	6.38	7.0	
			Placebo	31	30 (96.8)	4.85 (1.07)	2.3	4.00	4.84	5.66	7.0	
		Week 44	Tezepelumab	32	32 (100.0)	5.49 (0.98)	3.7	4.70	5.47	6.30	7.0	
			Placebo	31	30 (96.8)	4.88 (1.03)	2.8	4.00	4.89	5.72	7.0	
		Week 48	Tezepelumab	32	32 (100.0)	5.46 (1.08)	2.9	4.70	5.59	6.23	7.0	
			Placebo	31	30 (96.8)	4.89 (1.07)	2.1	4.00	4.80	5.91	7.0	
		Week 52	Tezepelumab	32	32 (100.0)	5.46 (1.07)	2.9	4.70	5.58	6.27	7.0	
			Placebo	31	30 (96.8)	4.99 (1.02)	3.3	4.00	4.86	5.97	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	32	25 (78.1)	0.86 (0.77)	-0.9	0.47	0.75	1.38	2.4	0.43 [-0.11, 0.98]
			Placebo	31	28 (90.3)	0.50 (0.91)	-1.2	-0.08	0.59	1.06	2.6	
		Week 8	Tezepelumab	32	26 (81.3)	0.98 (0.91)	-0.9	0.47	1.06	1.69	2.7	0.55 [0.00, 1.09]
			Placebo	31	28 (90.3)	0.47 (0.96)	-1.4	-0.23	0.36	0.94	3.1	
		Week 12	Tezepelumab	32	26 (81.3)	1.14 (0.89)	-0.9	0.69	1.20	1.75	2.7	0.61 [0.06, 1.15]
			Placebo	31	28 (90.3)	0.55 (1.03)	-1.7	0.09	0.53	0.92	3.3	
		Week 16	Tezepelumab	32	26 (81.3)	1.16 (0.92)	-0.9	0.53	1.31	1.84	2.8	0.59 [0.04, 1.14]
			Placebo	31	28 (90.3)	0.58 (1.02)	-2.0	-0.03	0.59	1.28	3.2	
		Week 20	Tezepelumab	32	26 (81.3)	1.16 (0.95)	-0.9	0.47	1.38	1.81	2.7	0.59 [0.05, 1.14]
			Placebo	31	28 (90.3)	0.57 (1.01)	-2.0	0.14	0.64	0.86	3.2	
		Week 24	Tezepelumab	32	26 (81.3)	1.23 (1.04)	-0.9	0.53	1.45	1.78	3.0	0.65 [0.10, 1.20]
			Placebo	31	28 (90.3)	0.52 (1.11)	-2.0	-0.03	0.42	1.17	3.2	
		Week 28	Tezepelumab	32	26 (81.3)	1.15 (1.01)	-0.9	0.38	1.11	1.88	3.0	0.53 [-0.02, 1.07]
			Placebo	31	28 (90.3)	0.58 (1.13)	-2.0	-0.02	0.55	1.25	3.2	
		Week 32	Tezepelumab	32	26 (81.3)	1.21 (1.05)	-0.9	0.53	1.22	2.22	2.8	0.51 [-0.04, 1.05]
			Placebo	31	28 (90.3)	0.71 (0.94)	-2.0	0.20	0.72	1.27	2.9	
		Week 36	Tezepelumab	32	26 (81.3)	1.26 (1.16)	-0.9	0.66	1.13	2.38	3.3	0.69 [0.14, 1.24]
			Placebo	31	28 (90.3)	0.52 (0.99)	-2.0	0.14	0.47	0.98	2.5	
		Week 40	Tezepelumab	32	26 (81.3)	1.23 (1.10)	-0.9	0.66	1.03	2.44	2.9	0.57 [0.03, 1.12]
			Placebo	31	28 (90.3)	0.61 (1.05)	-2.0	0.06	0.73	1.33	2.6	
		Week 44	Tezepelumab	32	26 (81.3)	1.28 (1.11)	-0.9	0.66	1.23	2.31	3.3	0.57 [0.03, 1.12]
			Placebo	31	28 (90.3)	0.64 (1.12)	-2.0	0.00	0.66	1.20	3.3	
		Week 48	Tezepelumab	32	26 (81.3)	1.25 (1.16)	-0.9	0.44	1.14	2.41	2.9	0.53 [-0.02, 1.07]
			Placebo	31	28 (90.3)	0.65 (1.12)	-2.0	0.09	0.55	1.23	3.3	
		Week 52	Tezepelumab	32	26 (81.3)	1.23 (1.16)	-0.9	0.44	1.14	2.41	3.0	0.42 [-0.12, 0.96]
			Placebo	31	28 (90.3)	0.75 (1.11)	-2.0	0.19	0.61	1.31	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	39	32 (82.1)	4.06 (0.80)	2.2	3.64	4.06	4.58	5.7	
			Placebo	30	23 (76.7)	4.15 (0.49)	3.4	3.69	4.13	4.59	5.2	
		Week 4	Tezepelumab	39	36 (92.3)	4.63 (1.07)	1.4	3.89	4.66	5.36	6.6	
			Placebo	30	25 (83.3)	4.63 (0.87)	3.4	4.00	4.41	5.19	6.8	
		Week 8	Tezepelumab	39	36 (92.3)	4.98 (0.99)	3.0	4.22	4.70	5.88	6.7	
			Placebo	30	25 (83.3)	4.86 (0.94)	3.3	4.22	4.75	5.31	6.9	
		Week 12	Tezepelumab	39	36 (92.3)	5.17 (0.97)	3.0	4.42	4.97	6.16	6.9	
			Placebo	30	25 (83.3)	4.87 (0.96)	3.7	4.16	4.78	5.50	6.9	
		Week 16	Tezepelumab	39	36 (92.3)	5.08 (1.00)	2.7	4.41	5.03	5.86	6.9	
			Placebo	30	25 (83.3)	4.93 (0.98)	3.3	4.13	4.94	5.69	6.8	
		Week 20	Tezepelumab	39	37 (94.9)	5.07 (1.00)	3.2	4.22	5.13	5.88	6.9	
			Placebo	30	25 (83.3)	4.90 (1.06)	2.4	4.00	4.78	5.75	6.8	
		Week 24	Tezepelumab	39	37 (94.9)	5.07 (1.03)	3.3	4.22	4.97	5.81	7.0	
			Placebo	30	25 (83.3)	4.95 (1.08)	2.4	4.09	4.81	5.69	6.9	
		Week 28	Tezepelumab	39	39 (100.0)	5.11 (1.05)	3.6	4.16	4.78	6.00	7.0	
			Placebo	30	26 (86.7)	5.00 (1.16)	2.2	4.00	4.88	5.91	6.8	
		Week 32	Tezepelumab	39	39 (100.0)	5.12 (1.06)	2.9	4.09	5.22	5.97	7.0	
			Placebo	30	26 (86.7)	5.07 (1.10)	2.7	4.13	5.03	5.91	6.9	
		Week 36	Tezepelumab	39	39 (100.0)	5.20 (1.08)	3.3	4.38	5.00	6.25	7.0	
			Placebo	30	26 (86.7)	5.03 (1.07)	3.0	4.00	5.11	5.91	6.9	
		Week 40	Tezepelumab	39	39 (100.0)	5.04 (1.04)	3.2	4.13	5.03	5.84	7.0	
			Placebo	30	26 (86.7)	5.09 (1.16)	2.5	4.00	5.23	5.91	6.9	
		Week 44	Tezepelumab	39	39 (100.0)	5.05 (0.99)	3.5	4.09	5.09	5.84	7.0	
			Placebo	30	26 (86.7)	5.01 (1.10)	3.2	4.00	4.81	6.19	6.9	
		Week 48	Tezepelumab	39	39 (100.0)	5.09 (1.02)	2.9	4.22	5.03	6.06	7.0	
			Placebo	30	26 (86.7)	5.11 (1.12)	3.2	4.13	5.06	6.16	7.0	
		Week 52	Tezepelumab	39	39 (100.0)	5.13 (1.04)	2.9	4.22	5.09	6.06	7.0	
			Placebo	30	26 (86.7)	5.09 (1.11)	3.6	4.09	5.06	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	39	32 (82.1)	0.54 (1.15)	-3.7	-0.05	0.69	1.19	3.3	0.00 [-0.53, 0.54]
			Placebo	30	23 (76.7)	0.54 (0.92)	-1.2	0.16	0.41	0.81	2.6	
		Week 8	Tezepelumab	39	32 (82.1)	0.84 (1.01)	-1.0	0.30	0.69	1.67	3.8	0.08 [-0.46, 0.62]
			Placebo	30	23 (76.7)	0.76 (0.98)	-1.0	0.16	0.63	1.09	3.1	
		Week 12	Tezepelumab	39	32 (82.1)	1.06 (1.04)	-2.1	0.53	1.02	1.70	4.0	0.29 [-0.25, 0.83]
			Placebo	30	23 (76.7)	0.76 (1.04)	-1.0	0.25	0.66	1.09	3.3	
		Week 16	Tezepelumab	39	32 (82.1)	0.99 (1.03)	-2.4	0.42	0.77	1.67	3.4	0.17 [-0.37, 0.70]
			Placebo	30	23 (76.7)	0.82 (0.96)	-0.5	0.09	0.72	1.03	3.2	
		Week 20	Tezepelumab	39	32 (82.1)	1.02 (0.98)	-1.2	0.25	0.78	1.67	3.4	0.19 [-0.34, 0.73]
			Placebo	30	23 (76.7)	0.83 (0.98)	-1.3	0.34	0.78	1.09	3.2	
		Week 24	Tezepelumab	39	32 (82.1)	1.07 (0.97)	-1.2	0.33	1.03	1.64	3.4	0.23 [-0.30, 0.77]
			Placebo	30	23 (76.7)	0.84 (0.99)	-1.3	0.31	0.69	1.22	3.2	
		Week 28	Tezepelumab	39	32 (82.1)	1.07 (1.02)	-1.3	0.31	0.81	1.83	3.4	0.23 [-0.31, 0.77]
			Placebo	30	23 (76.7)	0.83 (1.04)	-1.5	0.09	0.97	1.25	3.2	
		Week 32	Tezepelumab	39	32 (82.1)	1.04 (1.05)	-1.2	0.30	0.91	1.95	3.4	0.12 [-0.41, 0.66]
			Placebo	30	23 (76.7)	0.92 (0.92)	-1.0	0.47	0.78	1.38	2.9	
		Week 36	Tezepelumab	39	32 (82.1)	1.14 (1.12)	-1.3	0.30	1.03	2.03	3.4	0.25 [-0.29, 0.79]
			Placebo	30	23 (76.7)	0.88 (0.91)	-0.7	0.31	0.78	1.34	2.9	
		Week 40	Tezepelumab	39	32 (82.1)	1.00 (1.03)	-1.3	0.30	0.72	1.83	3.4	0.06 [-0.48, 0.59]
			Placebo	30	23 (76.7)	0.94 (1.03)	-1.2	0.09	0.94	1.69	2.8	
		Week 44	Tezepelumab	39	32 (82.1)	0.99 (1.00)	-1.1	0.30	0.75	1.86	3.4	0.18 [-0.36, 0.72]
			Placebo	30	23 (76.7)	0.81 (1.00)	-0.7	0.03	0.56	1.31	2.9	
		Week 48	Tezepelumab	39	32 (82.1)	1.04 (1.01)	-1.1	0.42	0.95	1.84	3.4	0.11 [-0.43, 0.65]
			Placebo	30	23 (76.7)	0.93 (1.00)	-0.5	0.00	0.75	1.50	3.3	
		Week 52	Tezepelumab	39	32 (82.1)	1.07 (0.99)	-1.2	0.42	0.95	1.84	3.4	0.15 [-0.38, 0.69]
			Placebo	30	23 (76.7)	0.92 (1.00)	-0.5	0.09	0.75	1.50	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	27	26 (96.3)	4.11 (1.03)	2.0	3.59	4.11	4.63	6.3	
			Placebo	34	31 (91.2)	4.34 (0.99)	1.8	3.84	4.38	4.94	6.3	
		Week 4	Tezepelumab	27	24 (88.9)	5.09 (0.98)	3.3	4.34	5.13	5.95	6.8	
			Placebo	34	32 (94.1)	4.88 (0.98)	2.4	4.45	4.88	5.50	6.8	
		Week 8	Tezepelumab	27	26 (96.3)	5.26 (1.13)	3.6	4.03	5.20	6.25	6.8	
			Placebo	34	33 (97.1)	4.85 (1.05)	2.4	4.31	4.78	5.53	7.0	
		Week 12	Tezepelumab	27	26 (96.3)	5.47 (1.04)	3.8	4.56	5.20	6.59	7.0	
			Placebo	34	33 (97.1)	5.04 (1.07)	2.8	4.34	5.13	5.78	7.0	
		Week 16	Tezepelumab	27	26 (96.3)	5.50 (1.03)	3.7	4.44	5.63	6.47	7.0	
			Placebo	34	33 (97.1)	5.09 (1.16)	2.9	4.44	4.94	5.72	7.0	
		Week 20	Tezepelumab	27	26 (96.3)	5.44 (1.05)	3.8	4.34	5.45	6.47	7.0	
			Placebo	34	33 (97.1)	4.96 (1.12)	2.9	4.31	4.88	5.88	7.0	
		Week 24	Tezepelumab	27	26 (96.3)	5.51 (1.02)	4.1	4.50	5.44	6.59	7.0	
			Placebo	34	33 (97.1)	4.90 (1.16)	2.7	4.00	4.78	5.84	7.0	
		Week 28	Tezepelumab	27	26 (96.3)	5.41 (1.03)	3.3	4.53	5.45	6.22	7.0	
			Placebo	34	33 (97.1)	5.02 (1.24)	2.8	4.00	5.13	5.97	7.0	
		Week 32	Tezepelumab	27	26 (96.3)	5.54 (1.03)	3.9	4.59	5.70	6.34	7.0	
			Placebo	34	33 (97.1)	5.06 (1.09)	2.9	4.22	5.13	5.72	7.0	
		Week 36	Tezepelumab	27	26 (96.3)	5.55 (0.98)	3.5	4.94	5.56	6.19	7.0	
			Placebo	34	33 (97.1)	4.90 (1.18)	2.2	4.09	4.84	5.72	7.0	
		Week 40	Tezepelumab	27	26 (96.3)	5.64 (1.02)	3.8	4.91	5.73	6.72	7.0	
			Placebo	34	33 (97.1)	4.98 (1.22)	2.3	4.13	5.06	6.09	7.0	
		Week 44	Tezepelumab	27	26 (96.3)	5.68 (0.98)	3.9	5.00	5.86	6.47	7.0	
			Placebo	34	33 (97.1)	5.05 (1.15)	2.8	4.22	5.06	5.81	7.0	
		Week 48	Tezepelumab	27	26 (96.3)	5.71 (1.03)	3.2	5.00	5.91	6.56	7.0	
			Placebo	34	33 (97.1)	4.95 (1.14)	2.1	4.22	4.81	5.91	7.0	
		Week 52	Tezepelumab	27	26 (96.3)	5.65 (1.03)	3.2	4.88	5.91	6.47	7.0	
			Placebo	34	33 (97.1)	5.05 (1.11)	2.9	4.22	4.81	5.97	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	1.04 (0.78)	-0.9	0.47	1.13	1.69	2.4	0.72 [0.17, 1.28]
			Placebo	34	31 (91.2)	0.51 (0.72)	-1.1	0.06	0.50	1.16	1.7	
		Week 8	Tezepelumab	27	25 (92.6)	1.12 (0.97)	-0.9	0.47	1.53	1.78	2.7	0.63 [0.09, 1.17]
			Placebo	34	31 (91.2)	0.56 (0.83)	-1.4	0.09	0.38	1.00	2.5	
		Week 12	Tezepelumab	27	25 (92.6)	1.32 (0.95)	-0.9	0.78	1.50	1.94	2.7	0.62 [0.08, 1.16]
			Placebo	34	31 (91.2)	0.70 (1.03)	-1.7	0.22	0.75	1.25	3.5	
		Week 16	Tezepelumab	27	25 (92.6)	1.34 (0.95)	-0.9	0.66	1.59	1.88	2.7	0.56 [0.03, 1.10]
			Placebo	34	31 (91.2)	0.79 (1.01)	-2.0	0.31	0.72	1.41	3.8	
		Week 20	Tezepelumab	27	25 (92.6)	1.29 (1.01)	-0.9	0.53	1.53	1.97	3.0	0.68 [0.13, 1.22]
			Placebo	34	31 (91.2)	0.65 (0.90)	-2.0	0.19	0.69	1.09	2.1	
		Week 24	Tezepelumab	27	25 (92.6)	1.36 (1.04)	-0.9	0.56	1.56	2.22	3.0	0.70 [0.16, 1.24]
			Placebo	34	31 (91.2)	0.62 (1.07)	-2.0	-0.03	0.78	1.56	2.8	
		Week 28	Tezepelumab	27	25 (92.6)	1.27 (1.05)	-0.9	0.38	1.41	2.13	2.7	0.47 [-0.07, 1.00]
			Placebo	34	31 (91.2)	0.74 (1.16)	-2.0	0.16	0.78	1.47	4.0	
		Week 32	Tezepelumab	27	25 (92.6)	1.40 (1.03)	-0.9	0.66	1.50	2.34	2.9	0.63 [0.09, 1.17]
			Placebo	34	31 (91.2)	0.79 (0.95)	-2.0	0.25	0.72	1.41	3.2	
		Week 36	Tezepelumab	27	25 (92.6)	1.41 (1.06)	-0.9	0.75	1.34	2.38	2.8	0.80 [0.25, 1.35]
			Placebo	34	31 (91.2)	0.60 (0.99)	-2.0	0.19	0.63	1.09	2.3	
		Week 40	Tezepelumab	27	25 (92.6)	1.49 (1.03)	-0.9	0.97	1.09	2.53	2.9	0.72 [0.18, 1.27]
			Placebo	34	31 (91.2)	0.71 (1.13)	-2.0	0.06	0.75	1.50	3.8	
		Week 44	Tezepelumab	27	25 (92.6)	1.54 (1.07)	-0.9	0.88	1.38	2.47	3.3	0.69 [0.15, 1.23]
			Placebo	34	31 (91.2)	0.76 (1.15)	-2.0	-0.03	0.78	1.56	3.4	
		Week 48	Tezepelumab	27	25 (92.6)	1.57 (1.07)	-0.9	1.06	1.66	2.53	2.9	0.86 [0.31, 1.41]
			Placebo	34	31 (91.2)	0.67 (1.05)	-2.0	0.19	0.59	1.25	3.3	
		Week 52	Tezepelumab	27	25 (92.6)	1.52 (1.11)	-0.9	0.75	1.25	2.53	3.0	0.69 [0.15, 1.23]
			Placebo	34	31 (91.2)	0.77 (1.05)	-2.0	0.19	0.63	1.38	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	27	23 (85.2)	3.99 (0.61)	2.7	3.72	4.03	4.41	5.0	
			Placebo	29	23 (79.3)	4.25 (0.93)	1.8	3.75	4.19	4.59	6.3	
		Week 4	Tezepelumab	27	26 (96.3)	4.73 (0.85)	3.0	4.13	4.70	5.25	6.5	
			Placebo	29	25 (86.2)	4.66 (1.04)	2.4	4.06	4.72	5.19	6.8	
		Week 8	Tezepelumab	27	26 (96.3)	4.98 (0.93)	3.4	4.25	4.70	5.84	6.6	
			Placebo	29	27 (93.1)	4.65 (1.02)	2.8	3.81	4.75	5.16	6.9	
		Week 12	Tezepelumab	27	26 (96.3)	5.25 (0.90)	3.9	4.63	4.97	6.09	6.9	
			Placebo	29	27 (93.1)	4.78 (1.06)	2.8	3.91	4.81	5.47	6.8	
		Week 16	Tezepelumab	27	26 (96.3)	5.31 (0.94)	3.9	4.47	5.27	6.09	7.0	
			Placebo	29	27 (93.1)	4.61 (1.34)	1.2	3.84	4.56	5.63	6.9	
		Week 20	Tezepelumab	27	26 (96.3)	5.15 (1.08)	3.5	4.22	5.00	5.88	7.0	
			Placebo	29	27 (93.1)	4.55 (1.38)	1.2	3.91	4.56	5.66	6.8	
		Week 24	Tezepelumab	27	26 (96.3)	5.22 (1.01)	4.0	4.34	4.80	6.00	7.0	
			Placebo	29	27 (93.1)	4.45 (1.40)	1.2	3.59	4.53	5.53	6.9	
		Week 28	Tezepelumab	27	27 (100.0)	5.14 (1.06)	3.3	4.53	4.69	6.00	7.0	
			Placebo	29	27 (93.1)	4.52 (1.44)	1.2	3.72	4.34	5.66	6.8	
		Week 32	Tezepelumab	27	27 (100.0)	5.18 (1.07)	3.9	4.19	4.69	6.09	7.0	
			Placebo	29	27 (93.1)	4.57 (1.34)	1.2	3.84	4.31	5.69	6.8	
		Week 36	Tezepelumab	27	27 (100.0)	5.25 (1.08)	3.5	4.41	5.00	6.28	7.0	
			Placebo	29	27 (93.1)	4.50 (1.28)	2.2	3.75	4.16	5.59	6.8	
		Week 40	Tezepelumab	27	27 (100.0)	5.17 (1.01)	3.7	4.47	4.84	5.88	7.0	
			Placebo	29	27 (93.1)	4.59 (1.30)	2.3	3.81	4.28	5.84	6.8	
		Week 44	Tezepelumab	27	27 (100.0)	5.12 (1.03)	3.7	4.13	5.03	5.91	7.0	
			Placebo	29	27 (93.1)	4.56 (1.07)	2.8	3.72	4.47	5.16	6.8	
		Week 48	Tezepelumab	27	27 (100.0)	5.16 (1.06)	3.2	4.28	5.03	6.09	7.0	
			Placebo	29	27 (93.1)	4.53 (1.14)	2.1	3.84	4.53	5.16	6.8	
		Week 52	Tezepelumab	27	27 (100.0)	5.16 (1.05)	3.2	4.28	5.03	6.09	7.0	
			Placebo	29	27 (93.1)	4.58 (1.05)	2.9	3.88	4.22	5.34	6.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	0.79 (0.60)	-0.3	0.25	0.88	1.31	2.0	0.49 [-0.10, 1.09]
			Placebo	29	22 (75.9)	0.43 (0.85)	-1.1	0.03	0.44	0.88	2.6	
		Week 8	Tezepelumab	27	23 (85.2)	0.86 (0.92)	-1.0	0.31	0.69	1.63	2.6	0.43 [-0.16, 1.01]
			Placebo	29	23 (79.3)	0.48 (0.87)	-1.4	0.16	0.31	0.97	2.7	
		Week 12	Tezepelumab	27	23 (85.2)	1.13 (0.81)	-0.7	0.63	0.97	1.84	2.7	0.64 [0.05, 1.23]
			Placebo	29	23 (79.3)	0.55 (1.01)	-1.7	0.06	0.53	1.22	2.6	
		Week 16	Tezepelumab	27	23 (85.2)	1.19 (0.82)	-0.5	0.59	1.28	1.69	2.8	0.76 [0.16, 1.36]
			Placebo	29	23 (79.3)	0.39 (1.23)	-3.2	-0.19	0.66	1.06	2.5	
		Week 20	Tezepelumab	27	23 (85.2)	1.10 (0.95)	-0.5	0.31	1.09	1.78	3.0	0.65 [0.06, 1.25]
			Placebo	29	23 (79.3)	0.37 (1.28)	-3.2	0.16	0.63	1.06	2.5	
		Week 24	Tezepelumab	27	23 (85.2)	1.18 (0.90)	-0.5	0.34	1.34	1.84	3.0	0.80 [0.20, 1.40]
			Placebo	29	23 (79.3)	0.26 (1.36)	-3.2	-0.59	0.66	1.13	2.5	
		Week 28	Tezepelumab	27	23 (85.2)	1.12 (0.91)	-0.5	0.34	0.91	1.78	3.0	0.67 [0.07, 1.26]
			Placebo	29	23 (79.3)	0.33 (1.41)	-3.2	-0.25	0.41	1.41	2.5	
		Week 32	Tezepelumab	27	23 (85.2)	1.20 (0.92)	-0.5	0.50	1.09	2.03	2.9	0.70 [0.11, 1.30]
			Placebo	29	23 (79.3)	0.42 (1.28)	-3.2	0.00	0.72	1.19	2.6	
		Week 36	Tezepelumab	27	23 (85.2)	1.29 (0.94)	-0.5	0.72	1.09	1.91	3.3	0.93 [0.32, 1.54]
			Placebo	29	23 (79.3)	0.31 (1.18)	-2.0	-0.41	0.38	1.06	2.3	
		Week 40	Tezepelumab	27	23 (85.2)	1.18 (0.82)	-0.5	0.69	1.03	1.81	2.8	0.69 [0.10, 1.29]
			Placebo	29	23 (79.3)	0.44 (1.26)	-2.0	-0.28	0.34	1.66	2.6	
		Week 44	Tezepelumab	27	23 (85.2)	1.13 (0.89)	-0.6	0.69	1.13	1.84	2.9	0.80 [0.20, 1.40]
			Placebo	29	23 (79.3)	0.35 (1.05)	-2.0	-0.28	0.34	1.13	2.6	
		Week 48	Tezepelumab	27	23 (85.2)	1.21 (0.88)	-0.5	0.63	1.13	2.06	2.9	0.89 [0.29, 1.50]
			Placebo	29	23 (79.3)	0.32 (1.09)	-2.0	-0.28	0.22	1.06	2.5	
		Week 52	Tezepelumab	27	23 (85.2)	1.22 (0.86)	-0.5	0.63	1.06	2.06	3.0	0.86 [0.25, 1.46]
			Placebo	29	23 (79.3)	0.40 (1.04)	-2.0	-0.28	0.22	1.06	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	4.17 (1.04)	2.0	3.52	4.17	4.98	6.3	
			Placebo	33	29 (87.9)	4.23 (0.73)	2.7	3.72	4.28	4.75	6.1	
		Week 4	Tezepelumab	34	30 (88.2)	4.84 (1.22)	1.4	3.84	5.13	5.66	6.8	
			Placebo	33	29 (87.9)	4.83 (0.86)	3.3	4.00	4.84	5.31	6.8	
		Week 8	Tezepelumab	34	32 (94.1)	5.14 (1.18)	3.0	3.97	5.16	6.14	6.8	
			Placebo	33	29 (87.9)	4.92 (0.92)	2.4	4.31	4.78	5.53	6.8	
		Week 12	Tezepelumab	34	32 (94.1)	5.30 (1.12)	3.0	4.33	5.20	6.41	7.0	
			Placebo	33	29 (87.9)	5.03 (0.92)	3.4	4.34	4.94	5.53	6.9	
		Week 16	Tezepelumab	34	32 (94.1)	5.21 (1.13)	2.7	4.36	5.22	6.06	6.9	
			Placebo	33	29 (87.9)	5.17 (0.95)	3.0	4.75	5.00	5.69	6.8	
		Week 20	Tezepelumab	34	32 (94.1)	5.27 (1.05)	3.2	4.33	5.20	6.19	7.0	
			Placebo	33	29 (87.9)	5.04 (0.90)	3.0	4.59	5.03	5.75	6.8	
		Week 24	Tezepelumab	34	32 (94.1)	5.31 (1.08)	3.5	4.41	5.27	6.19	7.0	
			Placebo	33	29 (87.9)	5.11 (0.89)	3.8	4.41	5.13	5.75	6.9	
		Week 28	Tezepelumab	34	33 (97.1)	5.31 (1.10)	3.6	4.34	5.44	6.22	7.0	
			Placebo	33	30 (90.9)	5.24 (1.03)	3.6	4.38	5.17	6.03	7.0	
		Week 32	Tezepelumab	34	33 (97.1)	5.38 (1.09)	2.9	4.59	5.47	6.13	7.0	
			Placebo	33	30 (90.9)	5.29 (0.91)	3.8	4.69	5.28	6.09	6.9	
		Week 36	Tezepelumab	34	33 (97.1)	5.40 (1.08)	3.3	4.75	5.47	6.19	7.0	
			Placebo	33	30 (90.9)	5.20 (0.90)	3.8	4.66	5.14	5.75	6.9	
		Week 40	Tezepelumab	34	33 (97.1)	5.40 (1.15)	3.2	4.34	5.31	6.25	7.0	
			Placebo	33	30 (90.9)	5.28 (0.99)	3.5	4.31	5.31	6.19	6.9	
		Week 44	Tezepelumab	34	33 (97.1)	5.42 (1.05)	3.5	4.47	5.53	6.22	7.0	
			Placebo	33	30 (90.9)	5.30 (1.05)	3.5	4.22	5.17	6.38	6.9	
		Week 48	Tezepelumab	34	33 (97.1)	5.45 (1.11)	2.9	4.34	5.56	6.25	7.0	
			Placebo	33	30 (90.9)	5.30 (0.97)	3.8	4.72	5.23	6.16	7.0	
		Week 52	Tezepelumab	34	33 (97.1)	5.45 (1.12)	2.9	4.34	5.75	6.28	7.0	
			Placebo	33	30 (90.9)	5.34 (1.03)	3.8	4.72	5.23	6.16	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status											
Any positive	Change from baseline	Week 4	Tezepelumab	34	29 (85.3)	0.65 (1.20)	-3.7	0.03	0.72	1.50	2.4	0.05 [-0.46, 0.57]
			Placebo	33	29 (87.9)	0.59 (0.81)	-1.2	0.16	0.50	0.97	2.6	
		Week 8	Tezepelumab	34	31 (91.2)	0.96 (0.96)	-1.0	0.28	0.81	1.78	2.7	0.29 [-0.22, 0.80]
			Placebo	33	29 (87.9)	0.69 (0.91)	-1.0	0.09	0.56	0.97	3.1	
		Week 12	Tezepelumab	34	31 (91.2)	1.13 (1.04)	-2.1	0.47	1.22	1.91	2.6	0.32 [-0.19, 0.83]
			Placebo	33	29 (87.9)	0.80 (1.02)	-1.0	0.31	0.75	1.03	3.5	
		Week 16	Tezepelumab	34	31 (91.2)	1.04 (1.08)	-2.4	0.50	0.81	1.84	2.5	0.11 [-0.40, 0.61]
			Placebo	33	29 (87.9)	0.94 (0.97)	-0.5	0.41	0.72	1.09	3.8	
		Week 20	Tezepelumab	34	31 (91.2)	1.10 (0.98)	-1.2	0.47	1.00	1.88	2.7	0.33 [-0.18, 0.84]
			Placebo	33	29 (87.9)	0.81 (0.82)	-0.3	0.31	0.78	1.09	3.2	
		Week 24	Tezepelumab	34	31 (91.2)	1.15 (1.05)	-1.2	0.34	1.34	1.78	3.0	0.28 [-0.23, 0.79]
			Placebo	33	29 (87.9)	0.88 (0.89)	-0.3	0.16	0.72	1.22	3.2	
		Week 28	Tezepelumab	34	31 (91.2)	1.11 (1.08)	-1.3	0.31	1.03	2.13	2.7	0.15 [-0.36, 0.66]
			Placebo	33	29 (87.9)	0.95 (0.99)	-0.5	0.44	0.97	1.19	4.0	
		Week 32	Tezepelumab	34	31 (91.2)	1.17 (1.07)	-1.2	0.34	1.03	2.22	2.6	0.19 [-0.32, 0.69]
			Placebo	33	29 (87.9)	1.00 (0.80)	-0.2	0.56	0.81	1.34	3.2	
		Week 36	Tezepelumab	34	31 (91.2)	1.19 (1.17)	-1.3	0.31	0.91	2.34	2.8	0.29 [-0.21, 0.80]
			Placebo	33	29 (87.9)	0.90 (0.75)	-0.3	0.44	0.75	1.19	2.9	
		Week 40	Tezepelumab	34	31 (91.2)	1.20 (1.18)	-1.3	0.53	1.06	2.34	2.9	0.19 [-0.32, 0.70]
			Placebo	33	29 (87.9)	0.99 (0.92)	-0.7	0.66	0.78	1.28	3.8	
		Week 44	Tezepelumab	34	31 (91.2)	1.24 (1.14)	-1.1	0.47	0.91	2.34	3.3	0.21 [-0.30, 0.72]
			Placebo	33	29 (87.9)	1.01 (1.05)	-0.7	0.47	0.88	1.31	3.4	
		Week 48	Tezepelumab	34	31 (91.2)	1.27 (1.15)	-1.1	0.44	1.19	2.34	2.9	0.25 [-0.26, 0.76]
			Placebo	33	29 (87.9)	1.01 (0.89)	-0.2	0.41	0.81	1.41	3.3	
		Week 52	Tezepelumab	34	31 (91.2)	1.25 (1.17)	-1.2	0.44	1.19	2.41	3.0	0.18 [-0.33, 0.69]
			Placebo	33	29 (87.9)	1.05 (0.95)	-0.3	0.41	0.81	1.50	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	4.03 (0.76)	2.2	3.66	4.19	4.61	5.0	
			Placebo	14	11 (78.6)	4.44 (0.86)	3.6	3.84	4.31	4.47	6.3	
		Week 4	Tezepelumab	23	21 (91.3)	5.01 (1.01)	3.3	4.13	5.00	5.81	6.6	
			Placebo	14	10 (71.4)	4.66 (0.91)	3.0	4.16	4.59	5.19	6.0	
		Week 8	Tezepelumab	23	21 (91.3)	5.05 (1.07)	3.4	4.09	4.63	5.97	6.7	
			Placebo	14	11 (78.6)	4.58 (0.99)	3.3	3.72	4.63	5.09	6.5	
		Week 12	Tezepelumab	23	21 (91.3)	5.28 (1.01)	3.9	4.34	4.91	6.22	6.9	
			Placebo	14	11 (78.6)	4.44 (1.07)	2.8	3.72	4.22	5.34	6.3	
		Week 16	Tezepelumab	23	21 (91.3)	5.35 (0.90)	4.0	4.63	5.50	6.09	6.8	
			Placebo	14	11 (78.6)	4.29 (1.55)	1.2	3.31	4.31	5.41	6.9	
		Week 20	Tezepelumab	23	22 (95.7)	5.19 (0.94)	3.8	4.31	5.30	5.88	6.9	
			Placebo	14	11 (78.6)	4.28 (1.63)	1.2	2.94	4.31	5.91	6.7	
		Week 24	Tezepelumab	23	22 (95.7)	5.24 (0.93)	4.0	4.50	5.13	6.00	7.0	
			Placebo	14	11 (78.6)	4.05 (1.69)	1.2	2.66	4.22	5.69	6.9	
		Week 28	Tezepelumab	23	23 (100.0)	5.14 (1.05)	3.3	4.16	4.78	6.00	7.0	
			Placebo	14	11 (78.6)	3.97 (1.59)	1.2	2.78	4.22	5.03	6.4	
		Week 32	Tezepelumab	23	23 (100.0)	5.14 (1.03)	3.9	4.09	4.84	6.00	7.0	
			Placebo	14	11 (78.6)	4.19 (1.51)	1.2	3.16	4.31	5.50	6.5	
		Week 36	Tezepelumab	23	23 (100.0)	5.23 (1.08)	3.5	4.09	5.09	6.19	7.0	
			Placebo	14	11 (78.6)	4.47 (1.45)	2.2	3.03	4.31	5.91	6.7	
		Week 40	Tezepelumab	23	23 (100.0)	5.11 (0.95)	3.7	4.13	5.03	5.81	7.0	
			Placebo	14	11 (78.6)	4.35 (1.46)	2.3	3.34	4.22	5.91	6.3	
		Week 44	Tezepelumab	23	23 (100.0)	5.16 (0.98)	3.8	4.09	5.19	5.91	7.0	
			Placebo	14	11 (78.6)	4.32 (1.05)	2.8	3.38	4.22	5.06	6.3	
		Week 48	Tezepelumab	23	23 (100.0)	5.20 (1.07)	3.2	4.09	5.28	6.09	7.0	
			Placebo	14	11 (78.6)	4.27 (1.21)	2.1	3.38	4.22	4.69	6.4	
		Week 52	Tezepelumab	23	23 (100.0)	5.22 (1.05)	3.2	4.09	5.19	6.09	7.0	
			Placebo	14	11 (78.6)	4.45 (0.98)	3.3	3.88	4.22	4.69	6.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	1.05 (0.89)	-0.5	0.44	1.06	1.56	3.3	0.99 [0.19, 1.79]
			Placebo	14	10 (71.4)	0.20 (0.79)	-1.1	0.03	0.23	0.47	1.7	
		Week 8	Tezepelumab	23	20 (87.0)	0.99 (1.14)	-1.0	0.00	0.92	1.77	3.8	0.81 [0.05, 1.58]
			Placebo	14	11 (78.6)	0.14 (0.86)	-1.4	-0.56	0.19	0.72	1.5	
		Week 12	Tezepelumab	23	20 (87.0)	1.20 (1.05)	-0.7	0.50	1.09	1.88	4.0	1.16 [0.36, 1.95]
			Placebo	14	11 (78.6)	-0.00 (1.02)	-1.7	-0.97	0.16	0.56	1.7	
		Week 16	Tezepelumab	23	20 (87.0)	1.28 (0.91)	-0.5	0.63	1.47	1.78	3.4	1.27 [0.46, 2.07]
			Placebo	14	11 (78.6)	-0.15 (1.46)	-3.2	-0.97	0.22	0.94	1.7	
		Week 20	Tezepelumab	23	20 (87.0)	1.13 (0.98)	-0.5	0.36	1.05	1.66	3.4	1.08 [0.30, 1.87]
			Placebo	14	11 (78.6)	-0.16 (1.53)	-3.2	-1.25	0.16	1.09	1.7	
		Week 24	Tezepelumab	23	20 (87.0)	1.19 (0.99)	-0.5	0.42	1.16	1.75	3.4	1.31 [0.51, 2.12]
			Placebo	14	11 (78.6)	-0.39 (1.53)	-3.2	-1.25	-0.25	1.13	1.7	
		Week 28	Tezepelumab	23	20 (87.0)	1.16 (1.00)	-0.5	0.44	0.95	1.75	3.4	1.37 [0.56, 2.19]
			Placebo	14	11 (78.6)	-0.47 (1.49)	-3.2	-1.47	-0.16	0.63	1.7	
		Week 32	Tezepelumab	23	20 (87.0)	1.09 (1.05)	-0.6	0.33	0.95	1.86	3.4	1.13 [0.34, 1.92]
			Placebo	14	11 (78.6)	-0.25 (1.41)	-3.2	-1.03	0.00	0.78	1.7	
		Week 36	Tezepelumab	23	20 (87.0)	1.19 (1.07)	-0.5	0.38	1.05	1.75	3.4	0.99 [0.21, 1.77]
			Placebo	14	11 (78.6)	0.03 (1.35)	-2.0	-1.63	0.31	1.06	1.7	
		Week 40	Tezepelumab	23	20 (87.0)	1.11 (0.95)	-0.5	0.48	0.98	1.61	3.4	1.06 [0.27, 1.84]
			Placebo	14	11 (78.6)	-0.09 (1.43)	-2.0	-1.19	-0.16	1.69	2.0	
		Week 44	Tezepelumab	23	20 (87.0)	1.15 (1.01)	-0.6	0.53	1.05	1.86	3.4	1.22 [0.42, 2.01]
			Placebo	14	11 (78.6)	-0.12 (1.10)	-2.0	-0.94	-0.16	0.69	2.1	
		Week 48	Tezepelumab	23	20 (87.0)	1.23 (1.01)	-0.5	0.44	1.22	1.92	3.4	1.30 [0.49, 2.11]
			Placebo	14	11 (78.6)	-0.17 (1.19)	-2.0	-0.94	-0.16	0.22	2.2	
		Week 52	Tezepelumab	23	20 (87.0)	1.24 (0.98)	-0.5	0.45	1.22	1.92	3.4	1.21 [0.41, 2.01]
			Placebo	14	11 (78.6)	0.01 (1.08)	-2.0	-0.59	0.03	0.41	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	4.13 (0.96)	2.0	3.59	4.03	4.47	6.3	
			Placebo	44	37 (84.1)	4.24 (0.85)	1.8	3.75	4.22	4.78	6.1	
		Week 4	Tezepelumab	40	36 (90.0)	4.72 (1.09)	1.4	3.91	4.97	5.52	6.8	
			Placebo	44	40 (90.9)	4.79 (0.97)	2.4	4.03	4.86	5.30	6.8	
		Week 8	Tezepelumab	40	38 (95.0)	5.15 (1.05)	3.0	4.25	5.16	5.94	6.8	
			Placebo	44	41 (93.2)	4.92 (1.02)	2.4	4.25	4.81	5.53	7.0	
		Week 12	Tezepelumab	40	38 (95.0)	5.33 (1.01)	3.0	4.66	5.17	6.22	7.0	
			Placebo	44	41 (93.2)	5.09 (1.02)	3.0	4.25	5.09	5.75	7.0	
		Week 16	Tezepelumab	40	38 (95.0)	5.23 (1.11)	2.7	4.44	5.17	6.03	7.0	
			Placebo	44	41 (93.2)	5.11 (1.09)	2.9	4.44	5.00	5.75	7.0	
		Week 20	Tezepelumab	40	38 (95.0)	5.25 (1.09)	3.2	4.31	5.20	6.19	7.0	
			Placebo	44	41 (93.2)	4.98 (1.08)	2.9	4.03	4.88	5.88	7.0	
		Week 24	Tezepelumab	40	38 (95.0)	5.29 (1.11)	3.3	4.34	5.27	6.25	7.0	
			Placebo	44	41 (93.2)	5.05 (1.05)	2.9	4.09	4.94	5.84	7.0	
		Week 28	Tezepelumab	40	39 (97.5)	5.30 (1.06)	3.6	4.47	5.38	6.22	7.0	
			Placebo	44	42 (95.5)	5.20 (1.17)	2.9	4.00	5.33	6.03	7.0	
		Week 32	Tezepelumab	40	39 (97.5)	5.38 (1.10)	2.9	4.34	5.47	6.34	7.0	
			Placebo	44	42 (95.5)	5.18 (1.09)	2.9	4.13	5.31	6.09	7.0	
		Week 36	Tezepelumab	40	39 (97.5)	5.40 (1.07)	3.3	4.69	5.47	6.25	7.0	
			Placebo	44	42 (95.5)	5.01 (1.11)	2.9	4.00	4.91	5.94	7.0	
		Week 40	Tezepelumab	40	39 (97.5)	5.37 (1.15)	3.2	4.38	5.28	6.50	7.0	
			Placebo	44	42 (95.5)	5.15 (1.14)	2.9	4.03	5.14	6.19	7.0	
		Week 44	Tezepelumab	40	39 (97.5)	5.38 (1.08)	3.5	4.34	5.28	6.22	7.0	
			Placebo	44	42 (95.5)	5.19 (1.12)	2.9	4.44	5.06	6.28	7.0	
		Week 48	Tezepelumab	40	39 (97.5)	5.41 (1.09)	2.9	4.34	5.38	6.28	7.0	
			Placebo	44	42 (95.5)	5.18 (1.08)	2.9	4.22	5.08	6.16	7.0	
		Week 52	Tezepelumab	40	39 (97.5)	5.40 (1.10)	2.9	4.34	5.38	6.28	7.0	
			Placebo	44	42 (95.5)	5.20 (1.14)	2.9	4.13	5.25	6.16	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	40	32 (80.0)	0.56 (1.12)	-3.7	0.02	0.69	1.33	2.4	-0.00 [-0.48, 0.47]
			Placebo	44	37 (84.1)	0.57 (0.77)	-1.2	0.16	0.50	0.94	2.6	
		Week 8	Tezepelumab	40	34 (85.0)	0.95 (0.93)	-1.0	0.31	0.78	1.78	2.7	0.21 [-0.25, 0.68]
			Placebo	44	37 (84.1)	0.76 (0.85)	-1.0	0.22	0.63	1.00	3.1	
		Week 12	Tezepelumab	40	34 (85.0)	1.15 (1.00)	-2.1	0.72	1.17	1.94	2.7	0.26 [-0.20, 0.73]
			Placebo	44	37 (84.1)	0.89 (0.96)	-1.0	0.34	0.75	1.25	3.5	
		Week 16	Tezepelumab	40	34 (85.0)	1.06 (1.08)	-2.4	0.50	0.91	1.84	2.7	0.11 [-0.35, 0.58]
			Placebo	44	37 (84.1)	0.94 (0.90)	-0.5	0.47	0.75	1.41	3.8	
		Week 20	Tezepelumab	40	34 (85.0)	1.13 (1.04)	-1.2	0.47	1.05	1.97	3.0	0.33 [-0.14, 0.80]
			Placebo	44	37 (84.1)	0.83 (0.82)	-0.8	0.34	0.72	1.09	3.2	
		Week 24	Tezepelumab	40	34 (85.0)	1.21 (1.05)	-1.2	0.34	1.50	1.97	3.0	0.31 [-0.15, 0.78]
			Placebo	44	37 (84.1)	0.91 (0.88)	-0.6	0.28	0.78	1.28	3.2	
		Week 28	Tezepelumab	40	34 (85.0)	1.14 (1.08)	-1.3	0.31	0.95	2.06	2.7	0.10 [-0.36, 0.57]
			Placebo	44	37 (84.1)	1.03 (0.97)	-0.5	0.41	1.00	1.47	4.0	
		Week 32	Tezepelumab	40	34 (85.0)	1.25 (1.07)	-1.2	0.53	1.22	2.22	2.9	0.24 [-0.23, 0.71]
			Placebo	44	37 (84.1)	1.02 (0.80)	-0.2	0.56	0.84	1.41	3.2	
		Week 36	Tezepelumab	40	34 (85.0)	1.27 (1.14)	-1.3	0.66	1.03	2.34	2.8	0.45 [-0.02, 0.93]
			Placebo	44	37 (84.1)	0.82 (0.83)	-1.2	0.28	0.72	1.19	2.5	
		Week 40	Tezepelumab	40	34 (85.0)	1.24 (1.14)	-1.3	0.63	1.06	2.31	2.9	0.25 [-0.21, 0.72]
			Placebo	44	37 (84.1)	0.98 (0.91)	-0.7	0.28	0.94	1.44	3.8	
		Week 44	Tezepelumab	40	34 (85.0)	1.24 (1.11)	-1.1	0.59	0.94	2.31	3.3	0.24 [-0.22, 0.71]
			Placebo	44	37 (84.1)	0.99 (0.97)	-1.0	0.34	0.94	1.31	3.4	
		Week 48	Tezepelumab	40	34 (85.0)	1.27 (1.13)	-1.1	0.53	1.06	2.34	2.9	0.28 [-0.19, 0.75]
			Placebo	44	37 (84.1)	0.99 (0.85)	-0.5	0.34	1.00	1.50	3.3	
		Week 52	Tezepelumab	40	34 (85.0)	1.25 (1.15)	-1.2	0.50	1.06	2.34	3.0	0.22 [-0.24, 0.69]
			Placebo	44	37 (84.1)	1.02 (0.94)	-0.5	0.25	0.97	1.66	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.80 (1.34)	2.3	2.31	4.19	4.91	4.9	
			Placebo	7	7 (100.0)	4.10 (0.45)	3.4	3.72	4.28	4.34	4.8	
		Week 4	Tezepelumab	3	3 (100.0)	4.64 (0.93)	3.8	3.84	4.41	5.66	5.7	
			Placebo	7	7 (100.0)	4.84 (0.84)	3.8	3.88	4.84	5.53	6.0	
		Week 8	Tezepelumab	3	3 (100.0)	4.71 (1.28)	3.9	3.94	4.00	6.19	6.2	
			Placebo	7	7 (100.0)	4.73 (0.88)	3.9	4.19	4.31	5.59	6.3	
		Week 12	Tezepelumab	3	3 (100.0)	5.01 (1.16)	4.3	4.31	4.38	6.34	6.3	
			Placebo	7	7 (100.0)	5.00 (0.74)	4.3	4.59	4.72	5.13	6.5	
		Week 16	Tezepelumab	3	3 (100.0)	5.02 (1.09)	4.2	4.19	4.63	6.25	6.3	
			Placebo	7	7 (100.0)	5.09 (0.77)	4.1	4.59	4.97	5.59	6.5	
		Week 20	Tezepelumab	3	3 (100.0)	5.05 (1.07)	4.2	4.19	4.72	6.25	6.3	
			Placebo	7	7 (100.0)	5.14 (0.63)	4.2	4.88	5.03	5.53	6.3	
		Week 24	Tezepelumab	3	3 (100.0)	4.88 (1.19)	4.1	4.09	4.28	6.25	6.3	
			Placebo	7	7 (100.0)	4.97 (0.83)	3.8	4.41	4.81	5.50	6.4	
		Week 28	Tezepelumab	3	3 (100.0)	5.03 (1.06)	4.3	4.34	4.50	6.25	6.3	
			Placebo	7	7 (100.0)	4.96 (0.67)	4.0	4.38	5.06	5.19	6.1	
		Week 32	Tezepelumab	3	3 (100.0)	5.19 (0.92)	4.6	4.59	4.72	6.25	6.3	
			Placebo	7	7 (100.0)	5.14 (0.70)	4.1	4.56	5.19	5.34	6.4	
		Week 36	Tezepelumab	3	3 (100.0)	5.39 (0.75)	4.9	4.94	4.97	6.25	6.3	
			Placebo	7	7 (100.0)	5.04 (0.83)	3.8	4.66	5.03	5.16	6.6	
		Week 40	Tezepelumab	3	3 (100.0)	5.48 (0.69)	4.9	4.91	5.28	6.25	6.3	
			Placebo	7	7 (100.0)	5.16 (0.80)	4.1	4.31	5.13	5.50	6.5	
		Week 44	Tezepelumab	3	3 (100.0)	5.44 (0.70)	5.0	5.00	5.06	6.25	6.3	
			Placebo	7	7 (100.0)	4.97 (1.06)	3.9	3.97	5.13	5.81	6.6	
		Week 48	Tezepelumab	3	3 (100.0)	5.44 (0.77)	4.7	4.72	5.34	6.25	6.3	
			Placebo	7	7 (100.0)	5.00 (0.97)	3.8	4.47	4.78	5.13	7.0	
		Week 52	Tezepelumab	3	3 (100.0)	5.44 (0.77)	4.7	4.72	5.34	6.25	6.3	
			Placebo	7	7 (100.0)	5.00 (0.97)	3.8	4.47	4.78	5.13	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	0.83 (0.66)	0.2	0.22	0.75	1.53	1.5	0.11 [-1.25, 1.46]
			Placebo	7	7 (100.0)	0.74 (0.98)	-0.5	-0.19	0.56	1.59	2.3	
		Week 8	Tezepelumab	3	3 (100.0)	0.91 (1.02)	-0.3	-0.25	1.28	1.69	1.7	0.25 [-1.11, 1.61]
			Placebo	7	7 (100.0)	0.63 (1.12)	-0.4	-0.22	0.03	1.66	2.6	
		Week 12	Tezepelumab	3	3 (100.0)	1.21 (0.99)	0.1	0.13	1.44	2.06	2.1	0.33 [-1.03, 1.69]
			Placebo	7	7 (100.0)	0.89 (0.94)	-0.0	0.31	0.78	1.22	2.8	
		Week 16	Tezepelumab	3	3 (100.0)	1.22 (0.73)	0.4	0.44	1.34	1.88	1.9	0.26 [-1.10, 1.61]
			Placebo	7	7 (100.0)	0.99 (0.94)	0.0	0.31	0.72	1.66	2.8	
		Week 20	Tezepelumab	3	3 (100.0)	1.25 (0.68)	0.5	0.53	1.34	1.88	1.9	0.28 [-1.08, 1.64]
			Placebo	7	7 (100.0)	1.04 (0.78)	0.2	0.59	0.78	1.59	2.5	
		Week 24	Tezepelumab	3	3 (100.0)	1.07 (0.88)	0.1	0.09	1.34	1.78	1.8	0.22 [-1.14, 1.58]
			Placebo	7	7 (100.0)	0.87 (0.96)	-0.0	0.13	0.53	1.56	2.7	
		Week 28	Tezepelumab	3	3 (100.0)	1.23 (0.87)	0.3	0.31	1.34	2.03	2.0	0.44 [-0.93, 1.81]
			Placebo	7	7 (100.0)	0.86 (0.84)	-0.3	0.31	0.78	1.25	2.4	
		Week 32	Tezepelumab	3	3 (100.0)	1.39 (1.00)	0.4	0.41	1.34	2.41	2.4	0.41 [-0.96, 1.78]
			Placebo	7	7 (100.0)	1.04 (0.80)	0.3	0.44	0.78	1.41	2.7	
		Week 36	Tezepelumab	3	3 (100.0)	1.58 (0.98)	0.8	0.75	1.34	2.66	2.7	0.70 [-0.69, 2.10]
			Placebo	7	7 (100.0)	0.93 (0.91)	0.4	0.41	0.53	1.09	2.9	
		Week 40	Tezepelumab	3	3 (100.0)	1.68 (0.80)	1.1	1.09	1.34	2.59	2.6	0.70 [-0.69, 2.10]
			Placebo	7	7 (100.0)	1.05 (0.91)	-0.2	0.75	0.78	1.50	2.8	
		Week 44	Tezepelumab	3	3 (100.0)	1.64 (1.00)	0.8	0.81	1.34	2.75	2.8	0.68 [-0.71, 2.07]
			Placebo	7	7 (100.0)	0.87 (1.17)	-0.4	-0.28	0.63	1.88	2.9	
		Week 48	Tezepelumab	3	3 (100.0)	1.64 (0.67)	1.2	1.16	1.34	2.41	2.4	0.75 [-0.65, 2.16]
			Placebo	7	7 (100.0)	0.90 (1.06)	0.2	0.34	0.50	0.81	3.3	
		Week 52	Tezepelumab	3	3 (100.0)	1.64 (0.67)	1.2	1.16	1.34	2.41	2.4	0.76 [-0.65, 2.16]
			Placebo	7	7 (100.0)	0.89 (1.06)	0.2	0.31	0.50	0.81	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.10 (0.90)	2.8	3.41	4.13	4.77	5.4	
			Placebo	13	9 (69.2)	4.52 (0.73)	3.8	4.22	4.34	4.69	6.3	
		Week 4	Tezepelumab	9	8 (88.9)	4.95 (0.88)	3.3	4.53	4.98	5.61	6.1	
			Placebo	13	11 (84.6)	4.77 (0.96)	3.0	3.88	4.88	5.53	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.46 (1.05)	3.6	4.86	5.53	6.23	6.8	
			Placebo	13	12 (92.3)	4.53 (0.77)	3.3	3.84	4.47	5.23	5.6	
		Week 12	Tezepelumab	9	8 (88.9)	5.54 (1.05)	4.2	4.59	5.41	6.53	7.0	
			Placebo	13	12 (92.3)	4.49 (0.89)	2.8	3.91	4.59	5.11	5.8	
		Week 16	Tezepelumab	9	8 (88.9)	5.70 (0.90)	4.4	5.06	5.70	6.41	6.9	
			Placebo	13	12 (92.3)	4.77 (0.93)	2.9	4.28	4.83	5.36	6.4	
		Week 20	Tezepelumab	9	8 (88.9)	5.25 (1.14)	3.8	4.27	5.11	6.33	6.8	
			Placebo	13	12 (92.3)	4.72 (0.91)	2.9	4.14	4.88	5.31	6.4	
		Week 24	Tezepelumab	9	8 (88.9)	5.41 (1.07)	4.3	4.47	5.27	6.39	6.8	
			Placebo	13	12 (92.3)	4.67 (1.08)	2.7	4.05	4.36	5.55	6.4	
		Week 28	Tezepelumab	9	8 (88.9)	5.16 (1.10)	3.3	4.58	5.03	5.95	6.8	
			Placebo	13	13 (100.0)	4.79 (1.14)	2.8	4.00	4.34	5.69	6.8	
		Week 32	Tezepelumab	9	8 (88.9)	5.34 (1.17)	3.9	4.36	5.20	6.39	6.9	
			Placebo	13	13 (100.0)	4.91 (1.13)	3.2	4.19	4.56	5.72	6.9	
		Week 36	Tezepelumab	9	8 (88.9)	5.25 (1.13)	3.5	4.36	5.45	6.08	6.8	
			Placebo	13	13 (100.0)	4.88 (1.26)	2.2	4.22	4.69	5.69	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.41 (1.17)	3.8	4.55	5.30	6.38	7.0	
			Placebo	13	13 (100.0)	4.78 (1.29)	2.3	4.13	4.31	5.44	6.9	
		Week 44	Tezepelumab	9	8 (88.9)	5.41 (1.00)	4.2	4.55	5.31	6.23	6.8	
			Placebo	13	13 (100.0)	4.89 (1.16)	2.8	4.22	4.75	5.81	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.29 (1.17)	3.2	4.45	5.63	6.08	6.8	
			Placebo	13	13 (100.0)	4.81 (1.27)	2.1	4.22	4.56	5.41	6.8	
		Week 52	Tezepelumab	9	8 (88.9)	5.38 (1.20)	3.2	4.45	5.91	6.19	6.7	
			Placebo	13	13 (100.0)	4.88 (1.13)	3.3	4.22	4.47	5.41	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.85 (0.41)	0.3	0.50	0.69	1.28	1.4	0.76 [-0.27, 1.79]
			Placebo	13	9 (69.2)	0.28 (0.93)	-1.1	-0.47	0.50	0.66	1.6	
		Week 8	Tezepelumab	9	7 (77.8)	1.34 (0.65)	0.5	0.69	1.56	1.94	2.1	1.39 [0.27, 2.50]
			Placebo	13	9 (69.2)	0.20 (0.93)	-1.4	-0.41	0.19	0.84	1.7	
		Week 12	Tezepelumab	9	7 (77.8)	1.46 (0.60)	0.7	0.91	1.44	2.09	2.1	1.83 [0.63, 3.03]
			Placebo	13	9 (69.2)	-0.05 (0.96)	-1.7	-0.97	0.31	0.78	0.9	
		Week 16	Tezepelumab	9	7 (77.8)	1.62 (0.74)	0.6	0.69	1.72	2.44	2.4	1.19 [0.11, 2.27]
			Placebo	13	9 (69.2)	0.40 (1.20)	-2.0	0.31	0.66	1.00	1.7	
		Week 20	Tezepelumab	9	7 (77.8)	1.33 (0.84)	0.2	0.69	1.41	2.31	2.4	0.94 [-0.11, 1.98]
			Placebo	13	9 (69.2)	0.35 (1.19)	-2.0	-0.16	0.69	0.81	1.7	
		Week 24	Tezepelumab	9	7 (77.8)	1.51 (0.83)	0.6	0.69	1.66	2.28	2.8	0.97 [-0.08, 2.03]
			Placebo	13	9 (69.2)	0.40 (1.33)	-2.0	-0.16	0.78	1.56	1.8	
		Week 28	Tezepelumab	9	7 (77.8)	1.17 (0.95)	0.4	0.53	0.69	2.34	2.7	0.76 [-0.27, 1.78]
			Placebo	13	9 (69.2)	0.30 (1.26)	-2.0	-0.31	0.78	1.25	1.7	
		Week 32	Tezepelumab	9	7 (77.8)	1.43 (0.78)	0.7	0.72	1.09	2.19	2.6	0.90 [-0.14, 1.94]
			Placebo	13	9 (69.2)	0.47 (1.24)	-2.0	-0.16	0.78	1.41	1.7	
		Week 36	Tezepelumab	9	7 (77.8)	1.35 (0.85)	0.7	0.72	0.84	2.28	2.8	0.82 [-0.21, 1.85]
			Placebo	13	9 (69.2)	0.37 (1.41)	-2.0	-0.16	0.78	1.09	2.1	
		Week 40	Tezepelumab	9	7 (77.8)	1.47 (0.87)	0.6	0.69	1.03	2.31	2.8	0.96 [-0.09, 2.01]
			Placebo	13	9 (69.2)	0.31 (1.41)	-2.0	-0.16	0.72	1.50	2.0	
		Week 44	Tezepelumab	9	7 (77.8)	1.47 (1.00)	0.4	0.69	1.13	2.38	3.3	0.93 [-0.11, 1.98]
			Placebo	13	9 (69.2)	0.34 (1.35)	-2.0	-0.41	0.53	1.72	1.9	
		Week 48	Tezepelumab	9	7 (77.8)	1.37 (1.04)	0.4	0.44	0.69	2.34	2.9	0.87 [-0.17, 1.91]
			Placebo	13	9 (69.2)	0.27 (1.41)	-2.0	-0.16	0.72	0.81	2.2	
		Week 52	Tezepelumab	9	7 (77.8)	1.46 (0.95)	0.4	0.69	1.22	2.22	2.9	0.94 [-0.10, 1.99]
			Placebo	13	9 (69.2)	0.40 (1.24)	-2.0	-0.16	0.72	0.81	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.08 (0.91)	2.0	3.63	4.06	4.59	6.3	
			Placebo	52	46 (88.5)	4.21 (0.82)	1.8	3.69	4.20	4.75	6.1	
		Week 4	Tezepelumab	57	52 (91.2)	4.80 (1.08)	1.4	3.98	4.97	5.66	6.8	
			Placebo	52	46 (88.5)	4.77 (0.94)	2.4	4.06	4.73	5.28	6.8	
		Week 8	Tezepelumab	57	54 (94.7)	5.04 (1.05)	3.0	4.13	5.08	5.97	6.8	
			Placebo	52	47 (90.4)	4.91 (1.04)	2.4	4.22	4.78	5.72	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.26 (1.00)	3.0	4.38	5.13	6.22	7.0	
			Placebo	52	47 (90.4)	5.08 (1.02)	3.0	4.22	5.09	5.78	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.19 (1.03)	2.7	4.38	5.13	6.09	7.0	
			Placebo	52	47 (90.4)	5.00 (1.25)	1.2	4.06	4.97	5.81	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.22 (1.02)	3.2	4.31	5.22	6.06	7.0	
			Placebo	52	47 (90.4)	4.90 (1.25)	1.2	4.00	4.78	5.91	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.23 (1.04)	3.3	4.34	5.16	6.06	7.0	
			Placebo	52	47 (90.4)	4.90 (1.25)	1.2	3.97	4.81	5.84	7.0	
		Week 28	Tezepelumab	57	57 (100.0)	5.25 (1.04)	3.6	4.34	5.19	6.03	7.0	
			Placebo	52	47 (90.4)	4.99 (1.33)	1.2	3.97	5.03	6.00	7.0	
		Week 32	Tezepelumab	57	57 (100.0)	5.28 (1.05)	2.9	4.34	5.28	6.00	7.0	
			Placebo	52	47 (90.4)	5.02 (1.21)	1.2	4.13	5.19	5.91	7.0	
		Week 36	Tezepelumab	57	57 (100.0)	5.35 (1.05)	3.3	4.59	5.38	6.25	7.0	
			Placebo	52	47 (90.4)	4.93 (1.14)	2.6	4.00	4.84	5.91	7.0	
		Week 40	Tezepelumab	57	57 (100.0)	5.26 (1.06)	3.2	4.38	5.25	6.06	7.0	
			Placebo	52	47 (90.4)	5.06 (1.17)	2.5	4.00	5.06	6.09	7.0	
		Week 44	Tezepelumab	57	57 (100.0)	5.29 (1.04)	3.5	4.31	5.19	6.16	7.0	
			Placebo	52	47 (90.4)	5.03 (1.13)	2.9	4.00	5.00	6.19	7.0	
		Week 48	Tezepelumab	57	57 (100.0)	5.34 (1.05)	2.9	4.50	5.28	6.22	7.0	
			Placebo	52	47 (90.4)	5.04 (1.10)	2.9	4.00	4.81	6.00	7.0	
		Week 52	Tezepelumab	57	57 (100.0)	5.33 (1.05)	2.9	4.56	5.19	6.22	7.0	
			Placebo	52	47 (90.4)	5.08 (1.12)	2.9	4.00	4.94	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	0.74 (1.10)	-3.7	0.06	0.75	1.52	3.3	0.18 [-0.23, 0.59]
			Placebo	52	45 (86.5)	0.57 (0.78)	-1.2	0.16	0.41	0.94	2.6	
		Week 8	Tezepelumab	57	50 (87.7)	0.91 (1.03)	-1.0	0.13	0.78	1.72	3.8	0.21 [-0.19, 0.62]
			Placebo	52	46 (88.5)	0.70 (0.88)	-1.0	0.16	0.53	1.00	3.1	
		Week 12	Tezepelumab	57	50 (87.7)	1.13 (1.04)	-2.1	0.50	1.17	1.88	4.0	0.27 [-0.14, 0.67]
			Placebo	52	46 (88.5)	0.86 (0.97)	-1.0	0.28	0.73	1.25	3.5	
		Week 16	Tezepelumab	57	50 (87.7)	1.08 (1.02)	-2.4	0.50	1.11	1.78	3.4	0.27 [-0.14, 0.67]
			Placebo	52	46 (88.5)	0.80 (1.09)	-3.2	0.31	0.72	1.16	3.8	
		Week 20	Tezepelumab	57	50 (87.7)	1.11 (1.01)	-1.2	0.41	1.05	1.78	3.4	0.39 [-0.02, 0.79]
			Placebo	52	46 (88.5)	0.71 (1.04)	-3.2	0.31	0.73	1.09	3.2	
		Week 24	Tezepelumab	57	50 (87.7)	1.15 (1.03)	-1.2	0.34	1.34	1.78	3.4	0.43 [0.02, 0.83]
			Placebo	52	46 (88.5)	0.69 (1.12)	-3.2	0.09	0.70	1.22	3.2	
		Week 28	Tezepelumab	57	50 (87.7)	1.15 (1.04)	-1.3	0.31	1.19	1.97	3.4	0.32 [-0.08, 0.73]
			Placebo	52	46 (88.5)	0.79 (1.20)	-3.2	0.25	0.89	1.25	4.0	
		Week 32	Tezepelumab	57	50 (87.7)	1.17 (1.08)	-1.2	0.34	1.05	2.19	3.4	0.32 [-0.08, 0.72]
			Placebo	52	46 (88.5)	0.83 (1.03)	-3.2	0.28	0.72	1.19	3.2	
		Week 36	Tezepelumab	57	50 (87.7)	1.24 (1.13)	-1.3	0.44	1.06	2.25	3.4	0.49 [0.09, 0.90]
			Placebo	52	46 (88.5)	0.74 (0.91)	-1.7	0.28	0.64	1.19	2.9	
		Week 40	Tezepelumab	57	50 (87.7)	1.18 (1.08)	-1.3	0.53	1.06	2.06	3.4	0.30 [-0.10, 0.70]
			Placebo	52	46 (88.5)	0.86 (1.02)	-1.2	0.25	0.78	1.44	3.8	
		Week 44	Tezepelumab	57	50 (87.7)	1.20 (1.07)	-1.1	0.59	0.94	2.06	3.4	0.34 [-0.06, 0.75]
			Placebo	52	46 (88.5)	0.83 (1.03)	-1.0	0.09	0.78	1.22	3.4	
		Week 48	Tezepelumab	57	50 (87.7)	1.26 (1.07)	-1.1	0.50	1.20	2.13	3.4	0.41 [0.01, 0.82]
			Placebo	52	46 (88.5)	0.84 (0.95)	-0.9	0.09	0.67	1.38	3.3	
		Week 52	Tezepelumab	57	50 (87.7)	1.24 (1.08)	-1.2	0.47	1.17	2.13	3.4	0.35 [-0.06, 0.75]
			Placebo	52	46 (88.5)	0.88 (0.99)	-0.9	0.19	0.69	1.41	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	4.42 (0.58)	3.8	3.94	4.33	4.69	5.4	
			Placebo	3	2 (66.7)	3.84 (0.00)	3.8	3.84	3.84	3.84	3.8	
		Week 4	Tezepelumab	7	7 (100.0)	4.90 (1.06)	3.8	3.84	4.72	6.06	6.5	
			Placebo	3	3 (100.0)	3.73 (0.89)	3.0	3.00	3.47	4.72	4.7	
		Week 8	Tezepelumab	7	7 (100.0)	5.49 (0.78)	4.3	4.78	5.84	5.97	6.5	
			Placebo	3	3 (100.0)	4.03 (0.95)	3.3	3.28	3.72	5.09	5.1	
		Week 12	Tezepelumab	7	7 (100.0)	5.68 (0.74)	4.9	5.03	5.31	6.47	6.6	
			Placebo	3	3 (100.0)	3.53 (0.68)	2.8	2.75	3.84	4.00	4.0	
		Week 16	Tezepelumab	7	7 (100.0)	5.40 (0.86)	3.9	5.00	5.19	6.09	6.5	
			Placebo	3	3 (100.0)	3.73 (0.75)	2.9	2.88	4.06	4.25	4.3	
		Week 20	Tezepelumab	7	7 (100.0)	5.10 (0.92)	3.5	4.31	5.28	5.88	6.2	
			Placebo	3	3 (100.0)	3.61 (0.59)	2.9	2.94	3.91	4.00	4.0	
		Week 24	Tezepelumab	7	7 (100.0)	5.33 (0.74)	4.2	4.34	5.66	5.81	6.0	
			Placebo	3	3 (100.0)	3.45 (0.73)	2.7	2.66	3.59	4.09	4.1	
		Week 28	Tezepelumab	7	7 (100.0)	5.26 (0.79)	3.8	4.69	5.38	6.00	6.0	
			Placebo	3	3 (100.0)	3.57 (0.69)	2.8	2.78	3.94	4.00	4.0	
		Week 32	Tezepelumab	7	7 (100.0)	5.29 (0.81)	4.0	4.34	5.72	5.84	6.1	
			Placebo	3	3 (100.0)	3.73 (0.53)	3.2	3.16	3.84	4.19	4.2	
		Week 36	Tezepelumab	7	7 (100.0)	5.33 (0.55)	4.7	4.72	5.44	5.72	6.2	
			Placebo	3	3 (100.0)	3.51 (1.12)	2.2	2.22	4.16	4.16	4.2	
		Week 40	Tezepelumab	7	7 (100.0)	5.38 (0.51)	4.6	4.84	5.44	5.88	6.0	
			Placebo	3	3 (100.0)	3.34 (0.95)	2.3	2.25	3.88	3.91	3.9	
		Week 44	Tezepelumab	7	7 (100.0)	5.24 (0.56)	4.1	5.03	5.41	5.66	5.8	
			Placebo	3	3 (100.0)	3.78 (0.97)	2.8	2.81	3.78	4.75	4.8	
		Week 48	Tezepelumab	7	7 (100.0)	5.38 (0.69)	4.6	4.88	5.16	6.09	6.5	
			Placebo	3	3 (100.0)	3.50 (1.27)	2.1	2.09	3.84	4.56	4.6	
		Week 52	Tezepelumab	7	7 (100.0)	5.38 (0.69)	4.6	4.88	5.16	6.09	6.5	
			Placebo	3	3 (100.0)	3.76 (0.46)	3.3	3.25	3.88	4.16	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	0.68 (0.65)	-0.1	0.25	0.56	1.00	1.8	0.85 [-0.82, 2.52]
			Placebo	3	2 (66.7)	0.02 (1.22)	-0.8	-0.84	0.02	0.88	0.9	
		Week 8	Tezepelumab	7	6 (85.7)	1.01 (0.71)	0.3	0.31	0.94	1.78	1.8	0.80 [-0.87, 2.46]
			Placebo	3	2 (66.7)	0.34 (1.28)	-0.6	-0.56	0.34	1.25	1.3	
		Week 12	Tezepelumab	7	6 (85.7)	1.16 (0.45)	0.6	0.97	1.09	1.34	1.9	3.00 [0.66, 5.33]
			Placebo	3	2 (66.7)	-0.47 (0.88)	-1.1	-1.09	-0.47	0.16	0.2	
		Week 16	Tezepelumab	7	6 (85.7)	0.87 (0.62)	0.0	0.53	0.81	1.28	1.8	1.87 [-0.05, 3.79]
			Placebo	3	2 (66.7)	-0.38 (0.84)	-1.0	-0.97	-0.38	0.22	0.2	
		Week 20	Tezepelumab	7	6 (85.7)	0.56 (0.53)	-0.4	0.50	0.70	0.78	1.1	1.64 [-0.21, 3.48]
			Placebo	3	2 (66.7)	-0.38 (0.75)	-0.9	-0.91	-0.38	0.16	0.2	
		Week 24	Tezepelumab	7	6 (85.7)	0.83 (0.46)	0.3	0.53	0.80	1.03	1.6	3.09 [0.72, 5.46]
			Placebo	3	2 (66.7)	-0.72 (0.66)	-1.2	-1.19	-0.72	-0.25	-0.3	
		Week 28	Tezepelumab	7	6 (85.7)	0.72 (0.43)	-0.1	0.63	0.89	1.00	1.0	2.36 [0.28, 4.44]
			Placebo	3	2 (66.7)	-0.48 (0.82)	-1.1	-1.06	-0.48	0.09	0.1	
		Week 32	Tezepelumab	7	6 (85.7)	0.80 (0.46)	0.1	0.53	0.88	1.06	1.4	2.44 [0.33, 4.55]
			Placebo	3	2 (66.7)	-0.34 (0.49)	-0.7	-0.69	-0.34	0.00	0.0	
		Week 36	Tezepelumab	7	6 (85.7)	0.85 (0.10)	0.8	0.78	0.81	0.91	1.0	2.65 [0.46, 4.85]
			Placebo	3	2 (66.7)	-0.66 (1.37)	-1.6	-1.63	-0.66	0.31	0.3	
		Week 40	Tezepelumab	7	6 (85.7)	0.88 (0.20)	0.6	0.69	0.97	1.03	1.1	3.29 [0.84, 5.74]
			Placebo	3	2 (66.7)	-0.78 (1.15)	-1.6	-1.59	-0.78	0.03	0.0	
		Week 44	Tezepelumab	7	6 (85.7)	0.80 (0.42)	0.2	0.44	0.91	0.97	1.4	2.82 [0.56, 5.08]
			Placebo	3	2 (66.7)	-0.55 (0.69)	-1.0	-1.03	-0.55	-0.06	-0.1	
		Week 48	Tezepelumab	7	6 (85.7)	1.03 (0.41)	0.6	0.69	1.02	1.06	1.8	3.02 [0.68, 5.37]
			Placebo	3	2 (66.7)	-0.88 (1.24)	-1.8	-1.75	-0.88	0.00	0.0	
		Week 52	Tezepelumab	7	6 (85.7)	1.03 (0.41)	0.6	0.69	1.02	1.06	1.8	3.14 [0.75, 5.53]
			Placebo	3	2 (66.7)	-0.28 (0.44)	-0.6	-0.59	-0.28	0.03	0.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	59	52 (88.1)	4.04 (0.93)	2.0	3.59	4.03	4.58	6.3	
			Placebo	62	53 (85.5)	4.28 (0.82)	1.8	3.75	4.28	4.72	6.3	
		Week 4	Tezepelumab	59	53 (89.8)	4.81 (1.06)	1.4	4.03	4.97	5.66	6.8	
			Placebo	62	54 (87.1)	4.83 (0.91)	2.4	4.16	4.84	5.31	6.8	
		Week 8	Tezepelumab	59	55 (93.2)	5.05 (1.08)	3.0	4.09	5.09	5.97	6.8	
			Placebo	62	56 (90.3)	4.88 (0.99)	2.4	4.23	4.77	5.56	7.0	
		Week 12	Tezepelumab	59	55 (93.2)	5.25 (1.03)	3.0	4.34	5.09	6.22	7.0	
			Placebo	62	56 (90.3)	5.03 (0.98)	3.0	4.25	5.08	5.66	7.0	
		Week 16	Tezepelumab	59	55 (93.2)	5.24 (1.05)	2.7	4.38	5.28	6.09	7.0	
			Placebo	62	56 (90.3)	5.02 (1.17)	1.2	4.38	4.95	5.73	7.0	
		Week 20	Tezepelumab	59	56 (94.9)	5.24 (1.05)	3.2	4.31	5.17	6.16	7.0	
			Placebo	62	56 (90.3)	4.93 (1.17)	1.2	4.22	4.89	5.88	7.0	
		Week 24	Tezepelumab	59	56 (94.9)	5.24 (1.08)	3.3	4.36	5.11	6.19	7.0	
			Placebo	62	56 (90.3)	4.93 (1.19)	1.2	4.11	4.83	5.80	7.0	
		Week 28	Tezepelumab	59	58 (98.3)	5.23 (1.07)	3.3	4.34	5.16	6.22	7.0	
			Placebo	62	57 (91.9)	5.02 (1.27)	1.2	4.22	5.06	5.97	7.0	
		Week 32	Tezepelumab	59	58 (98.3)	5.29 (1.09)	2.9	4.34	5.25	6.22	7.0	
			Placebo	62	57 (91.9)	5.06 (1.18)	1.2	4.16	5.19	5.91	7.0	
		Week 36	Tezepelumab	59	58 (98.3)	5.34 (1.10)	3.3	4.41	5.36	6.25	7.0	
			Placebo	62	57 (91.9)	4.99 (1.12)	2.6	4.00	4.97	5.91	7.0	
		Week 40	Tezepelumab	59	58 (98.3)	5.27 (1.11)	3.2	4.34	5.20	6.25	7.0	
			Placebo	62	57 (91.9)	5.09 (1.15)	2.5	4.16	5.13	6.09	7.0	
		Week 44	Tezepelumab	59	58 (98.3)	5.31 (1.07)	3.5	4.31	5.17	6.22	7.0	
			Placebo	62	57 (91.9)	5.07 (1.11)	2.9	4.16	5.03	5.97	7.0	
		Week 48	Tezepelumab	59	58 (98.3)	5.33 (1.10)	2.9	4.34	5.36	6.22	7.0	
			Placebo	62	57 (91.9)	5.07 (1.08)	2.9	4.22	4.81	6.00	7.0	
		Week 52	Tezepelumab	59	58 (98.3)	5.33 (1.10)	2.9	4.34	5.31	6.25	7.0	
			Placebo	62	57 (91.9)	5.11 (1.10)	2.9	4.19	4.94	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	59	49 (83.1)	0.76 (1.08)	-3.7	0.22	0.75	1.44	3.3	0.24 [-0.15, 0.63]
			Placebo	62	52 (83.9)	0.54 (0.79)	-1.2	0.14	0.44	0.95	2.6	
		Week 8	Tezepelumab	59	51 (86.4)	0.96 (1.03)	-1.0	0.13	0.81	1.75	3.8	0.34 [-0.05, 0.72]
			Placebo	62	53 (85.5)	0.63 (0.90)	-1.4	0.16	0.50	0.97	3.1	
		Week 12	Tezepelumab	59	51 (86.4)	1.17 (1.05)	-2.1	0.50	1.22	1.94	4.0	0.40 [0.02, 0.79]
			Placebo	62	53 (85.5)	0.76 (1.00)	-1.7	0.28	0.72	1.22	3.5	
		Week 16	Tezepelumab	59	51 (86.4)	1.18 (1.04)	-2.4	0.50	1.34	1.84	3.4	0.38 [-0.01, 0.77]
			Placebo	62	53 (85.5)	0.77 (1.10)	-3.2	0.31	0.72	1.16	3.8	
		Week 20	Tezepelumab	59	51 (86.4)	1.21 (1.01)	-1.2	0.41	1.41	1.88	3.4	0.50 [0.11, 0.89]
			Placebo	62	53 (85.5)	0.69 (1.06)	-3.2	0.31	0.75	1.09	3.2	
		Week 24	Tezepelumab	59	51 (86.4)	1.24 (1.04)	-1.2	0.34	1.44	1.97	3.4	0.50 [0.11, 0.89]
			Placebo	62	53 (85.5)	0.69 (1.14)	-3.2	0.09	0.75	1.22	3.2	
		Week 28	Tezepelumab	59	51 (86.4)	1.20 (1.07)	-1.3	0.31	1.41	2.06	3.4	0.39 [0.01, 0.78]
			Placebo	62	53 (85.5)	0.75 (1.21)	-3.2	0.25	0.94	1.25	4.0	
		Week 32	Tezepelumab	59	51 (86.4)	1.25 (1.09)	-1.2	0.34	1.34	2.22	3.4	0.41 [0.02, 0.79]
			Placebo	62	53 (85.5)	0.81 (1.06)	-3.2	0.28	0.78	1.38	3.2	
		Week 36	Tezepelumab	59	51 (86.4)	1.31 (1.15)	-1.3	0.44	1.34	2.34	3.4	0.55 [0.16, 0.94]
			Placebo	62	53 (85.5)	0.73 (0.97)	-2.0	0.28	0.72	1.19	2.9	
		Week 40	Tezepelumab	59	51 (86.4)	1.25 (1.10)	-1.3	0.53	1.09	2.19	3.4	0.39 [0.00, 0.78]
			Placebo	62	53 (85.5)	0.83 (1.07)	-2.0	0.25	0.78	1.50	3.8	
		Week 44	Tezepelumab	59	51 (86.4)	1.28 (1.10)	-1.1	0.59	1.13	2.25	3.4	0.44 [0.05, 0.83]
			Placebo	62	53 (85.5)	0.80 (1.08)	-2.0	0.09	0.78	1.31	3.4	
		Week 48	Tezepelumab	59	51 (86.4)	1.30 (1.11)	-1.1	0.44	1.25	2.19	3.4	0.47 [0.08, 0.86]
			Placebo	62	53 (85.5)	0.81 (1.00)	-2.0	0.19	0.75	1.38	3.3	
		Week 52	Tezepelumab	59	51 (86.4)	1.30 (1.11)	-1.2	0.44	1.22	2.22	3.4	0.42 [0.03, 0.81]
			Placebo	62	53 (85.5)	0.84 (1.04)	-2.0	0.19	0.75	1.41	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	4.51 (0.60)	3.8	4.19	4.47	4.69	5.4	
			Placebo	2	1 (50.0)	3.84	3.8	3.84	3.84	3.84	3.8	
		Week 4	Tezepelumab	6	6 (100.0)	5.08 (1.04)	3.8	4.28	4.95	6.06	6.5	
			Placebo	2	2 (100.0)	4.09 (0.88)	3.5	3.47	4.09	4.72	4.7	
		Week 8	Tezepelumab	6	6 (100.0)	5.69 (0.61)	4.8	5.19	5.88	5.97	6.5	
			Placebo	2	2 (100.0)	4.41 (0.97)	3.7	3.72	4.41	5.09	5.1	
		Week 12	Tezepelumab	6	6 (100.0)	5.81 (0.71)	5.0	5.16	5.80	6.47	6.6	
			Placebo	2	2 (100.0)	3.92 (0.11)	3.8	3.84	3.92	4.00	4.0	
		Week 16	Tezepelumab	6	6 (100.0)	5.65 (0.63)	5.0	5.09	5.61	6.09	6.5	
			Placebo	2	2 (100.0)	4.16 (0.13)	4.1	4.06	4.16	4.25	4.3	
		Week 20	Tezepelumab	6	6 (100.0)	5.37 (0.64)	4.3	5.25	5.30	5.88	6.2	
			Placebo	2	2 (100.0)	3.95 (0.07)	3.9	3.91	3.95	4.00	4.0	
		Week 24	Tezepelumab	6	6 (100.0)	5.52 (0.60)	4.3	5.50	5.70	5.81	6.0	
			Placebo	2	2 (100.0)	3.84 (0.35)	3.6	3.59	3.84	4.09	4.1	
		Week 28	Tezepelumab	6	6 (100.0)	5.50 (0.52)	4.7	5.19	5.55	6.00	6.0	
			Placebo	2	2 (100.0)	3.97 (0.04)	3.9	3.94	3.97	4.00	4.0	
		Week 32	Tezepelumab	6	6 (100.0)	5.50 (0.63)	4.3	5.25	5.72	5.84	6.1	
			Placebo	2	2 (100.0)	4.02 (0.24)	3.8	3.84	4.02	4.19	4.2	
		Week 36	Tezepelumab	6	6 (100.0)	5.43 (0.53)	4.7	5.00	5.47	5.72	6.2	
			Placebo	2	2 (100.0)	4.16 (0.00)	4.2	4.16	4.16	4.16	4.2	
		Week 40	Tezepelumab	6	6 (100.0)	5.51 (0.42)	4.8	5.25	5.55	5.88	6.0	
			Placebo	2	2 (100.0)	3.89 (0.02)	3.9	3.88	3.89	3.91	3.9	
		Week 44	Tezepelumab	6	6 (100.0)	5.43 (0.30)	5.0	5.19	5.42	5.66	5.8	
			Placebo	2	2 (100.0)	4.27 (0.69)	3.8	3.78	4.27	4.75	4.8	
		Week 48	Tezepelumab	6	6 (100.0)	5.52 (0.64)	4.9	5.00	5.34	6.09	6.5	
			Placebo	2	2 (100.0)	4.20 (0.51)	3.8	3.84	4.20	4.56	4.6	
		Week 52	Tezepelumab	6	6 (100.0)	5.52 (0.64)	4.9	5.00	5.34	6.09	6.5	
			Placebo	2	2 (100.0)	4.02 (0.20)	3.9	3.88	4.02	4.16	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	6	5 (83.3)	0.83 (0.60)	0.3	0.47	0.66	1.00	1.8	NE
			Placebo	2	1 (50.0)	0.88	0.9	0.88	0.88	0.88	0.9	
		Week 8	Tezepelumab	6	5 (83.3)	1.15 (0.70)	0.3	0.50	1.38	1.78	1.8	NE
			Placebo	2	1 (50.0)	1.25	1.3	1.25	1.25	1.25	1.3	
		Week 12	Tezepelumab	6	5 (83.3)	1.20 (0.49)	0.6	1.06	1.13	1.34	1.9	NE
			Placebo	2	1 (50.0)	0.16	0.2	0.16	0.16	0.16	0.2	
		Week 16	Tezepelumab	6	5 (83.3)	1.04 (0.51)	0.5	0.63	1.00	1.28	1.8	NE
			Placebo	2	1 (50.0)	0.22	0.2	0.22	0.22	0.22	0.2	
		Week 20	Tezepelumab	6	5 (83.3)	0.76 (0.22)	0.5	0.63	0.78	0.78	1.1	NE
			Placebo	2	1 (50.0)	0.16	0.2	0.16	0.16	0.16	0.2	
		Week 24	Tezepelumab	6	5 (83.3)	0.94 (0.41)	0.5	0.63	0.97	1.03	1.6	NE
			Placebo	2	1 (50.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	
		Week 28	Tezepelumab	6	5 (83.3)	0.89 (0.16)	0.6	0.88	0.91	1.00	1.0	NE
			Placebo	2	1 (50.0)	0.09	0.1	0.09	0.09	0.09	0.1	
		Week 32	Tezepelumab	6	5 (83.3)	0.94 (0.33)	0.5	0.72	1.03	1.06	1.4	NE
			Placebo	2	1 (50.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 36	Tezepelumab	6	5 (83.3)	0.86 (0.11)	0.8	0.81	0.81	0.91	1.0	NE
			Placebo	2	1 (50.0)	0.31	0.3	0.31	0.31	0.31	0.3	
		Week 40	Tezepelumab	6	5 (83.3)	0.92 (0.20)	0.6	0.97	0.97	1.03	1.1	NE
			Placebo	2	1 (50.0)	0.03	0.0	0.03	0.03	0.03	0.0	
		Week 44	Tezepelumab	6	5 (83.3)	0.92 (0.34)	0.4	0.84	0.97	0.97	1.4	NE
			Placebo	2	1 (50.0)	-0.06	-0.1	-0.06	-0.06	-0.06	-0.1	
		Week 48	Tezepelumab	6	5 (83.3)	1.11 (0.40)	0.7	0.97	1.06	1.06	1.8	NE
			Placebo	2	1 (50.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 52	Tezepelumab	6	5 (83.3)	1.11 (0.40)	0.7	0.97	1.06	1.06	1.8	NE
			Placebo	2	1 (50.0)	0.03	0.0	0.03	0.03	0.03	0.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	4.04 (0.92)	2.0	3.59	4.03	4.56	6.3	
			Placebo	63	54 (85.7)	4.27 (0.81)	1.8	3.75	4.28	4.72	6.3	
		Week 4	Tezepelumab	60	54 (90.0)	4.79 (1.05)	1.4	4.03	4.97	5.66	6.8	
			Placebo	63	55 (87.3)	4.79 (0.93)	2.4	4.06	4.84	5.31	6.8	
		Week 8	Tezepelumab	60	56 (93.3)	5.03 (1.07)	3.0	4.11	5.06	5.95	6.8	
			Placebo	63	57 (90.5)	4.85 (1.00)	2.4	4.22	4.75	5.53	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.24 (1.02)	3.0	4.36	5.00	6.20	7.0	
			Placebo	63	57 (90.5)	4.99 (1.01)	2.8	4.25	5.06	5.56	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.22 (1.06)	2.7	4.38	5.22	6.03	7.0	
			Placebo	63	57 (90.5)	4.98 (1.20)	1.2	4.31	4.94	5.72	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.21 (1.06)	3.2	4.31	5.16	6.13	7.0	
			Placebo	63	57 (90.5)	4.90 (1.19)	1.2	4.22	4.88	5.88	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.22 (1.07)	3.3	4.34	5.09	6.13	7.0	
			Placebo	63	57 (90.5)	4.89 (1.22)	1.2	4.00	4.81	5.75	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.21 (1.08)	3.3	4.34	5.16	6.22	7.0	
			Placebo	63	58 (92.1)	4.98 (1.29)	1.2	4.00	5.05	5.97	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.27 (1.10)	2.9	4.25	5.22	6.22	7.0	
			Placebo	63	58 (92.1)	5.03 (1.19)	1.2	4.13	5.16	5.91	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.33 (1.09)	3.3	4.41	5.34	6.25	7.0	
			Placebo	63	58 (92.1)	4.94 (1.17)	2.2	4.00	4.91	5.91	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.26 (1.11)	3.2	4.34	5.16	6.25	7.0	
			Placebo	63	58 (92.1)	5.04 (1.20)	2.3	4.13	5.09	6.09	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.29 (1.07)	3.5	4.31	5.16	6.22	7.0	
			Placebo	63	58 (92.1)	5.03 (1.14)	2.8	4.03	5.02	5.97	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.32 (1.10)	2.9	4.34	5.34	6.22	7.0	
			Placebo	63	58 (92.1)	5.02 (1.14)	2.1	4.19	4.81	6.00	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.32 (1.09)	2.9	4.34	5.28	6.25	7.0	
			Placebo	63	58 (92.1)	5.07 (1.12)	2.9	4.13	4.88	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	60	50 (83.3)	0.75 (1.07)	-3.7	0.09	0.75	1.44	3.3	0.25 [-0.14, 0.63]
			Placebo	63	53 (84.1)	0.51 (0.81)	-1.2	0.13	0.41	0.94	2.6	
		Week 8	Tezepelumab	60	52 (86.7)	0.95 (1.02)	-1.0	0.20	0.81	1.73	3.8	0.35 [-0.04, 0.73]
			Placebo	63	54 (85.7)	0.61 (0.91)	-1.4	0.09	0.48	0.97	3.1	
		Week 12	Tezepelumab	60	52 (86.7)	1.17 (1.04)	-2.1	0.55	1.22	1.92	4.0	0.43 [0.05, 0.82]
			Placebo	63	54 (85.7)	0.73 (1.03)	-1.7	0.25	0.72	1.22	3.5	
		Week 16	Tezepelumab	60	52 (86.7)	1.15 (1.04)	-2.4	0.50	1.30	1.84	3.4	0.38 [-0.00, 0.77]
			Placebo	63	54 (85.7)	0.74 (1.12)	-3.2	0.31	0.72	1.16	3.8	
		Week 20	Tezepelumab	60	52 (86.7)	1.17 (1.03)	-1.2	0.36	1.41	1.84	3.4	0.49 [0.10, 0.87]
			Placebo	63	54 (85.7)	0.66 (1.07)	-3.2	0.31	0.73	1.09	3.2	
		Week 24	Tezepelumab	60	52 (86.7)	1.22 (1.04)	-1.2	0.34	1.42	1.91	3.4	0.51 [0.12, 0.90]
			Placebo	63	54 (85.7)	0.66 (1.15)	-3.2	0.09	0.73	1.22	3.2	
		Week 28	Tezepelumab	60	52 (86.7)	1.18 (1.07)	-1.3	0.31	1.38	2.05	3.4	0.40 [0.01, 0.78]
			Placebo	63	54 (85.7)	0.72 (1.22)	-3.2	0.16	0.89	1.25	4.0	
		Week 32	Tezepelumab	60	52 (86.7)	1.22 (1.09)	-1.2	0.34	1.22	2.20	3.4	0.41 [0.02, 0.79]
			Placebo	63	54 (85.7)	0.78 (1.07)	-3.2	0.28	0.75	1.38	3.2	
		Week 36	Tezepelumab	60	52 (86.7)	1.30 (1.14)	-1.3	0.48	1.34	2.31	3.4	0.57 [0.18, 0.96]
			Placebo	63	54 (85.7)	0.68 (1.01)	-2.0	0.19	0.69	1.19	2.9	
		Week 40	Tezepelumab	60	52 (86.7)	1.24 (1.10)	-1.3	0.58	1.09	2.14	3.4	0.41 [0.03, 0.80]
			Placebo	63	54 (85.7)	0.79 (1.11)	-2.0	0.09	0.78	1.50	3.8	
		Week 44	Tezepelumab	60	52 (86.7)	1.26 (1.10)	-1.1	0.59	1.06	2.22	3.4	0.45 [0.06, 0.83]
			Placebo	63	54 (85.7)	0.77 (1.10)	-2.0	0.03	0.77	1.31	3.4	
		Week 48	Tezepelumab	60	52 (86.7)	1.29 (1.10)	-1.1	0.44	1.23	2.16	3.4	0.49 [0.11, 0.88]
			Placebo	63	54 (85.7)	0.76 (1.05)	-2.0	0.09	0.73	1.38	3.3	
		Week 52	Tezepelumab	60	52 (86.7)	1.28 (1.10)	-1.2	0.45	1.22	2.20	3.4	0.43 [0.05, 0.82]
			Placebo	63	54 (85.7)	0.82 (1.05)	-2.0	0.19	0.73	1.41	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	17	15 (88.2)	3.80 (1.17)	2.0	2.94	3.63	4.91	6.1	
			Placebo	21	20 (95.2)	4.27 (0.71)	3.0	3.88	4.30	4.69	6.1	
		Week 4	Tezepelumab	17	15 (88.2)	4.61 (0.95)	3.3	3.84	4.44	5.66	6.1	
			Placebo	21	20 (95.2)	4.77 (1.02)	3.0	3.92	4.81	5.42	6.8	
		Week 8	Tezepelumab	17	16 (94.1)	4.99 (1.14)	3.0	3.88	5.16	5.92	6.8	
			Placebo	21	21 (100.0)	4.81 (0.97)	3.3	4.06	4.78	5.50	7.0	
		Week 12	Tezepelumab	17	16 (94.1)	5.29 (1.05)	3.8	4.36	5.20	6.31	7.0	
			Placebo	21	21 (100.0)	5.07 (1.02)	2.8	4.34	5.13	5.56	7.0	
		Week 16	Tezepelumab	17	16 (94.1)	5.25 (1.07)	3.5	4.36	5.44	6.06	7.0	
			Placebo	21	21 (100.0)	5.05 (1.37)	1.2	4.56	5.13	5.72	7.0	
		Week 20	Tezepelumab	17	16 (94.1)	5.19 (1.05)	3.2	4.31	5.39	6.05	6.7	
			Placebo	21	21 (100.0)	4.87 (1.32)	1.2	4.59	5.03	5.88	7.0	
		Week 24	Tezepelumab	17	16 (94.1)	5.27 (1.10)	3.5	4.39	5.48	6.16	6.8	
			Placebo	21	21 (100.0)	4.74 (1.35)	1.2	4.09	4.81	5.63	7.0	
		Week 28	Tezepelumab	17	16 (94.1)	5.13 (1.08)	3.3	4.25	5.42	6.02	6.7	
			Placebo	21	21 (100.0)	5.00 (1.56)	1.2	4.00	5.16	6.06	7.0	
		Week 32	Tezepelumab	17	16 (94.1)	5.20 (1.11)	2.9	4.38	5.58	5.98	6.9	
			Placebo	21	21 (100.0)	5.09 (1.35)	1.2	4.44	5.25	6.09	7.0	
		Week 36	Tezepelumab	17	16 (94.1)	5.21 (1.10)	3.3	4.36	5.66	6.06	6.5	
			Placebo	21	21 (100.0)	4.72 (1.23)	2.2	4.00	4.81	5.34	7.0	
		Week 40	Tezepelumab	17	16 (94.1)	5.33 (1.14)	3.5	4.31	5.69	6.11	7.0	
			Placebo	21	21 (100.0)	4.98 (1.28)	2.3	3.91	5.13	5.84	7.0	
		Week 44	Tezepelumab	17	16 (94.1)	5.33 (1.03)	3.5	4.33	5.55	6.16	6.7	
			Placebo	21	21 (100.0)	4.97 (1.20)	2.8	4.00	5.03	5.81	7.0	
		Week 48	Tezepelumab	17	16 (94.1)	5.12 (1.20)	2.9	4.34	5.33	6.13	6.6	
			Placebo	21	21 (100.0)	4.88 (1.14)	2.1	4.56	4.75	5.16	7.0	
		Week 52	Tezepelumab	17	16 (94.1)	5.19 (1.25)	2.9	4.34	5.55	6.20	6.6	
			Placebo	21	21 (100.0)	4.97 (1.06)	3.3	4.16	4.75	5.53	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	17	13 (76.5)	0.82 (0.97)	-0.9	0.31	0.75	1.53	2.4	0.30 [-0.41, 1.01]
			Placebo	21	19 (90.5)	0.58 (0.69)	-0.8	0.13	0.34	1.16	1.7	
		Week 8	Tezepelumab	17	14 (82.4)	1.09 (1.03)	-0.9	0.50	1.45	1.78	2.7	0.54 [-0.16, 1.23]
			Placebo	21	20 (95.2)	0.60 (0.82)	-0.6	0.13	0.36	0.89	2.5	
		Week 12	Tezepelumab	17	14 (82.4)	1.35 (0.99)	-0.9	1.06	1.50	2.06	2.6	0.50 [-0.19, 1.19]
			Placebo	21	20 (95.2)	0.87 (0.94)	-1.1	0.39	0.75	0.98	3.5	
		Week 16	Tezepelumab	17	14 (82.4)	1.30 (1.02)	-0.9	0.59	1.66	2.03	2.4	0.39 [-0.30, 1.08]
			Placebo	21	20 (95.2)	0.82 (1.35)	-3.2	0.52	0.83	1.58	3.8	
		Week 20	Tezepelumab	17	14 (82.4)	1.27 (1.04)	-0.9	0.22	1.47	1.97	2.7	0.53 [-0.16, 1.23]
			Placebo	21	20 (95.2)	0.65 (1.23)	-3.2	0.25	0.77	1.66	2.1	
		Week 24	Tezepelumab	17	14 (82.4)	1.37 (1.14)	-0.9	0.53	1.66	2.34	3.0	0.68 [-0.02, 1.38]
			Placebo	21	20 (95.2)	0.50 (1.36)	-3.2	0.06	0.64	1.58	2.8	
		Week 28	Tezepelumab	17	14 (82.4)	1.19 (1.16)	-0.9	0.38	1.00	2.34	2.7	0.29 [-0.40, 0.98]
			Placebo	21	20 (95.2)	0.79 (1.53)	-3.2	0.27	0.95	1.77	4.0	
		Week 32	Tezepelumab	17	14 (82.4)	1.31 (1.17)	-0.9	0.66	1.59	2.34	2.6	0.36 [-0.32, 1.05]
			Placebo	21	20 (95.2)	0.87 (1.26)	-3.2	0.42	0.91	1.52	3.2	
		Week 36	Tezepelumab	17	14 (82.4)	1.31 (1.23)	-0.9	0.53	1.09	2.56	2.8	0.72 [0.01, 1.42]
			Placebo	21	20 (95.2)	0.49 (1.10)	-1.7	-0.06	0.59	1.08	2.3	
		Week 40	Tezepelumab	17	14 (82.4)	1.43 (1.22)	-0.9	0.56	1.64	2.59	2.9	0.53 [-0.17, 1.22]
			Placebo	21	20 (95.2)	0.77 (1.28)	-1.6	-0.06	0.78	1.61	3.8	
		Week 44	Tezepelumab	17	14 (82.4)	1.46 (1.28)	-0.9	0.44	1.39	2.75	3.3	0.62 [-0.08, 1.32]
			Placebo	21	20 (95.2)	0.72 (1.15)	-1.0	-0.23	0.80	1.27	3.4	
		Week 48	Tezepelumab	17	14 (82.4)	1.26 (1.35)	-0.9	0.44	1.02	2.41	2.9	0.56 [-0.14, 1.25]
			Placebo	21	20 (95.2)	0.63 (0.95)	-1.8	0.13	0.77	1.31	2.1	
		Week 52	Tezepelumab	17	14 (82.4)	1.34 (1.36)	-0.9	0.44	1.28	2.50	3.0	0.55 [-0.15, 1.24]
			Placebo	21	20 (95.2)	0.74 (0.88)	-0.9	0.13	0.77	1.44	2.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	49	43 (87.8)	4.18 (0.78)	2.2	3.72	4.19	4.59	6.3	
			Placebo	44	35 (79.5)	4.26 (0.87)	1.8	3.72	4.22	4.75	6.3	
		Week 4	Tezepelumab	49	45 (91.8)	4.89 (1.08)	1.4	4.16	4.97	5.66	6.8	
			Placebo	44	37 (84.1)	4.77 (0.90)	2.4	4.16	4.81	5.19	6.8	
		Week 8	Tezepelumab	49	46 (93.9)	5.13 (1.03)	3.3	4.25	5.08	5.97	6.8	
			Placebo	44	38 (86.4)	4.85 (1.02)	2.4	4.22	4.70	5.72	6.9	
		Week 12	Tezepelumab	49	46 (93.9)	5.30 (1.00)	3.0	4.59	5.13	6.22	7.0	
			Placebo	44	38 (86.4)	4.89 (1.02)	3.0	4.19	4.75	5.50	6.9	
		Week 16	Tezepelumab	49	46 (93.9)	5.26 (1.02)	2.7	4.47	5.14	6.09	6.9	
			Placebo	44	38 (86.4)	4.90 (1.09)	2.9	4.06	4.78	5.69	6.9	
		Week 20	Tezepelumab	49	47 (95.9)	5.23 (1.03)	3.5	4.31	5.22	6.13	7.0	
			Placebo	44	38 (86.4)	4.86 (1.12)	2.4	4.03	4.83	5.75	6.8	
		Week 24	Tezepelumab	49	47 (95.9)	5.25 (1.03)	3.3	4.34	5.13	6.06	7.0	
			Placebo	44	38 (86.4)	4.92 (1.14)	2.4	4.00	4.77	5.75	6.9	
		Week 28	Tezepelumab	49	49 (100.0)	5.27 (1.04)	3.7	4.53	5.16	6.03	7.0	
			Placebo	44	39 (88.6)	4.92 (1.13)	2.2	3.97	4.75	5.75	6.8	
		Week 32	Tezepelumab	49	49 (100.0)	5.32 (1.05)	3.9	4.34	5.25	6.09	7.0	
			Placebo	44	39 (88.6)	4.95 (1.10)	2.7	4.03	4.81	5.75	6.9	
		Week 36	Tezepelumab	49	49 (100.0)	5.39 (1.04)	3.8	4.63	5.34	6.28	7.0	
			Placebo	44	39 (88.6)	5.02 (1.11)	2.9	4.00	4.84	6.13	6.9	
		Week 40	Tezepelumab	49	49 (100.0)	5.27 (1.05)	3.2	4.63	5.25	6.06	7.0	
			Placebo	44	39 (88.6)	5.01 (1.16)	2.5	4.03	5.06	6.13	6.9	
		Week 44	Tezepelumab	49	49 (100.0)	5.30 (1.04)	3.7	4.47	5.19	6.16	7.0	
			Placebo	44	39 (88.6)	5.02 (1.11)	2.9	4.03	4.91	5.97	6.9	
		Week 48	Tezepelumab	49	49 (100.0)	5.40 (1.01)	3.6	4.56	5.34	6.22	7.0	
			Placebo	44	39 (88.6)	5.05 (1.14)	2.9	4.00	4.84	6.00	7.0	
		Week 52	Tezepelumab	49	49 (100.0)	5.39 (1.00)	3.6	4.63	5.28	6.22	7.0	
			Placebo	44	39 (88.6)	5.08 (1.16)	2.9	4.00	5.06	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHK: Change from baseline in AQLQ+12 total score by key subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	49	42 (85.7)	0.73 (1.06)	-3.7	0.22	0.73	1.41	3.3	0.25 [-0.20, 0.70]
			Placebo	44	35 (79.5)	0.49 (0.87)	-1.2	0.09	0.47	0.66	2.6	
		Week 8	Tezepelumab	49	43 (87.8)	0.92 (0.99)	-1.0	0.28	0.69	1.75	3.8	0.30 [-0.15, 0.74]
			Placebo	44	35 (79.5)	0.63 (0.96)	-1.4	0.06	0.63	1.00	3.1	
		Week 12	Tezepelumab	49	43 (87.8)	1.12 (1.01)	-2.1	0.56	0.94	1.84	4.0	0.47 [0.02, 0.92]
			Placebo	44	35 (79.5)	0.63 (1.06)	-1.7	-0.03	0.56	1.22	3.3	
		Week 16	Tezepelumab	49	43 (87.8)	1.09 (1.00)	-2.4	0.50	1.00	1.69	3.4	0.42 [-0.03, 0.87]
			Placebo	44	35 (79.5)	0.68 (0.96)	-2.0	0.09	0.66	1.06	3.2	
		Week 20	Tezepelumab	49	43 (87.8)	1.09 (0.98)	-1.2	0.47	0.78	1.69	3.4	0.45 [-0.00, 0.90]
			Placebo	44	35 (79.5)	0.65 (0.97)	-2.0	0.19	0.63	0.97	3.2	
		Week 24	Tezepelumab	49	43 (87.8)	1.14 (0.96)	-1.2	0.34	1.03	1.78	3.4	0.42 [-0.03, 0.87]
			Placebo	44	35 (79.5)	0.72 (1.02)	-2.0	0.09	0.72	1.22	3.2	
		Week 28	Tezepelumab	49	43 (87.8)	1.14 (0.99)	-1.3	0.31	1.00	1.88	3.4	0.48 [0.02, 0.93]
			Placebo	44	35 (79.5)	0.67 (1.01)	-2.0	0.03	0.72	1.06	3.2	
		Week 32	Tezepelumab	49	43 (87.8)	1.16 (1.02)	-1.2	0.34	1.03	2.06	3.4	0.45 [0.00, 0.91]
			Placebo	44	35 (79.5)	0.71 (0.95)	-2.0	0.13	0.72	1.09	2.9	
		Week 36	Tezepelumab	49	43 (87.8)	1.24 (1.06)	-1.3	0.66	1.03	2.19	3.4	0.45 [0.00, 0.90]
			Placebo	44	35 (79.5)	0.78 (0.94)	-2.0	0.31	0.72	1.19	2.9	
		Week 40	Tezepelumab	49	43 (87.8)	1.15 (0.99)	-1.3	0.63	1.03	1.84	3.4	0.37 [-0.08, 0.82]
			Placebo	44	35 (79.5)	0.78 (1.00)	-2.0	0.09	0.78	1.41	2.8	
		Week 44	Tezepelumab	49	43 (87.8)	1.16 (0.98)	-1.1	0.66	0.91	1.88	3.4	0.37 [-0.08, 0.82]
			Placebo	44	35 (79.5)	0.77 (1.07)	-2.0	0.03	0.56	1.31	3.3	
		Week 48	Tezepelumab	49	43 (87.8)	1.28 (0.96)	-1.1	0.63	1.19	2.06	3.4	0.45 [0.00, 0.91]
			Placebo	44	35 (79.5)	0.81 (1.10)	-2.0	0.09	0.53	1.41	3.3	
		Week 52	Tezepelumab	49	43 (87.8)	1.25 (0.96)	-1.2	0.59	1.16	2.06	3.4	0.39 [-0.06, 0.84]
			Placebo	44	35 (79.5)	0.84 (1.14)	-2.0	0.19	0.63	1.41	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	4.09 (0.88)	2.0	3.63	4.03	4.61	6.3	
			Placebo	58	48 (82.8)	4.33 (0.79)	1.8	3.84	4.28	4.77	6.3	
		Week 4	Tezepelumab	60	54 (90.0)	4.74 (1.04)	1.4	3.94	4.88	5.44	6.8	
			Placebo	58	50 (86.2)	4.81 (0.96)	2.4	4.06	4.83	5.41	6.8	
		Week 8	Tezepelumab	60	56 (93.3)	5.03 (1.05)	3.0	4.14	5.08	5.92	6.8	
			Placebo	58	52 (89.7)	4.87 (0.99)	2.8	4.20	4.77	5.56	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.23 (0.99)	3.0	4.44	5.06	6.16	7.0	
			Placebo	58	52 (89.7)	4.94 (1.02)	2.8	4.20	4.84	5.55	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.20 (1.04)	2.7	4.38	5.13	6.09	7.0	
			Placebo	58	52 (89.7)	4.94 (1.19)	1.2	4.19	4.86	5.69	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.15 (1.03)	3.2	4.31	5.16	5.91	7.0	
			Placebo	58	52 (89.7)	4.92 (1.20)	1.2	4.14	4.88	5.88	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.19 (1.04)	3.3	4.34	5.09	6.06	7.0	
			Placebo	58	52 (89.7)	4.86 (1.25)	1.2	4.05	4.80	5.72	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.16 (1.04)	3.3	4.34	5.16	6.00	7.0	
			Placebo	58	53 (91.4)	4.89 (1.29)	1.2	4.00	4.88	5.75	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.24 (1.08)	2.9	4.25	5.22	6.09	7.0	
			Placebo	58	53 (91.4)	4.97 (1.22)	1.2	4.13	5.00	5.75	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.28 (1.06)	3.3	4.41	5.16	6.25	7.0	
			Placebo	58	53 (91.4)	4.95 (1.18)	2.2	4.09	4.84	5.94	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.22 (1.08)	3.2	4.34	5.13	6.13	7.0	
			Placebo	58	53 (91.4)	5.00 (1.21)	2.3	4.03	5.06	6.09	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.25 (1.04)	3.5	4.31	5.16	6.16	7.0	
			Placebo	58	53 (91.4)	4.99 (1.12)	2.8	4.16	5.00	5.81	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.27 (1.08)	2.9	4.34	5.16	6.22	7.0	
			Placebo	58	53 (91.4)	4.98 (1.15)	2.1	4.19	4.75	5.97	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.27 (1.08)	2.9	4.34	5.16	6.25	7.0	
			Placebo	58	53 (91.4)	5.02 (1.11)	2.9	4.13	4.75	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	60	49 (81.7)	0.66 (1.00)	-3.7	0.09	0.72	1.38	2.4	0.18 [-0.23, 0.58]
			Placebo	58	47 (81.0)	0.50 (0.83)	-1.2	0.09	0.47	0.88	2.6	
		Week 8	Tezepelumab	60	51 (85.0)	0.88 (0.92)	-1.0	0.28	0.81	1.69	2.7	0.32 [-0.08, 0.71]
			Placebo	58	48 (82.8)	0.59 (0.90)	-1.4	0.13	0.52	0.97	3.1	
		Week 12	Tezepelumab	60	51 (85.0)	1.08 (0.93)	-2.1	0.56	1.13	1.84	2.7	0.48 [0.08, 0.88]
			Placebo	58	48 (82.8)	0.63 (0.99)	-1.7	0.14	0.55	1.06	3.3	
		Week 16	Tezepelumab	60	51 (85.0)	1.07 (0.97)	-2.4	0.50	1.25	1.78	2.8	0.42 [0.02, 0.82]
			Placebo	58	48 (82.8)	0.65 (1.07)	-3.2	0.27	0.72	1.05	3.2	
		Week 20	Tezepelumab	60	51 (85.0)	1.05 (0.95)	-1.2	0.31	1.00	1.75	3.0	0.39 [-0.01, 0.79]
			Placebo	58	48 (82.8)	0.65 (1.08)	-3.2	0.25	0.70	1.08	3.2	
		Week 24	Tezepelumab	60	51 (85.0)	1.12 (0.96)	-1.2	0.34	1.34	1.78	3.0	0.51 [0.10, 0.91]
			Placebo	58	48 (82.8)	0.59 (1.16)	-3.2	0.06	0.67	1.22	3.2	
		Week 28	Tezepelumab	60	51 (85.0)	1.06 (0.97)	-1.3	0.31	0.91	1.88	3.0	0.45 [0.05, 0.85]
			Placebo	58	48 (82.8)	0.58 (1.17)	-3.2	0.02	0.70	1.22	3.2	
		Week 32	Tezepelumab	60	51 (85.0)	1.13 (1.02)	-1.2	0.34	1.06	2.06	2.9	0.44 [0.04, 0.84]
			Placebo	58	48 (82.8)	0.67 (1.07)	-3.2	0.17	0.72	1.27	2.9	
		Week 36	Tezepelumab	60	51 (85.0)	1.17 (1.07)	-1.3	0.44	1.03	2.19	3.3	0.51 [0.11, 0.91]
			Placebo	58	48 (82.8)	0.64 (0.99)	-2.0	0.14	0.61	1.14	2.9	
		Week 40	Tezepelumab	60	51 (85.0)	1.14 (1.02)	-1.3	0.53	1.03	2.03	2.9	0.42 [0.02, 0.81]
			Placebo	58	48 (82.8)	0.70 (1.08)	-2.0	0.05	0.77	1.47	2.8	
		Week 44	Tezepelumab	60	51 (85.0)	1.16 (1.01)	-1.1	0.59	0.97	2.03	2.9	0.49 [0.09, 0.89]
			Placebo	58	48 (82.8)	0.67 (0.98)	-2.0	0.00	0.72	1.22	2.9	
		Week 48	Tezepelumab	60	51 (85.0)	1.19 (1.03)	-1.1	0.44	1.13	2.09	2.9	0.52 [0.12, 0.92]
			Placebo	58	48 (82.8)	0.67 (1.00)	-2.0	0.08	0.56	1.23	3.3	
		Week 52	Tezepelumab	60	51 (85.0)	1.19 (1.03)	-1.2	0.44	1.06	2.09	3.0	0.46 [0.06, 0.86]
			Placebo	58	48 (82.8)	0.72 (0.98)	-2.0	0.14	0.61	1.31	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	3.99 (1.13)	2.2	3.16	4.31	4.56	5.4	
			Placebo	7	7 (100.0)	3.78 (0.79)	2.7	3.00	4.22	4.47	4.6	
		Week 4	Tezepelumab	6	6 (100.0)	5.53 (0.92)	4.4	4.44	5.80	6.13	6.6	
			Placebo	7	7 (100.0)	4.46 (0.71)	3.3	3.84	4.50	5.00	5.3	
		Week 8	Tezepelumab	6	6 (100.0)	5.67 (1.01)	3.9	5.09	5.94	6.47	6.7	
			Placebo	7	7 (100.0)	4.61 (1.09)	2.4	4.31	4.75	5.50	5.7	
		Week 12	Tezepelumab	6	6 (100.0)	5.94 (0.98)	4.3	5.25	6.34	6.47	6.9	
			Placebo	7	7 (100.0)	5.11 (1.00)	3.5	4.25	5.22	5.91	6.5	
		Week 16	Tezepelumab	6	6 (100.0)	5.76 (0.75)	4.6	5.59	5.69	6.03	6.9	
			Placebo	7	7 (100.0)	5.09 (1.26)	3.0	4.06	5.09	5.91	6.8	
		Week 20	Tezepelumab	6	6 (100.0)	5.88 (0.76)	4.7	5.59	5.91	6.19	7.0	
			Placebo	7	7 (100.0)	4.45 (1.01)	3.0	3.66	4.78	5.03	5.9	
		Week 24	Tezepelumab	6	6 (100.0)	5.82 (0.87)	4.3	5.63	5.97	6.13	6.9	
			Placebo	7	7 (100.0)	4.81 (0.96)	3.8	3.88	4.81	5.84	5.9	
		Week 28	Tezepelumab	6	6 (100.0)	5.96 (0.88)	4.5	5.63	5.95	6.72	7.0	
			Placebo	7	7 (100.0)	5.41 (1.26)	3.8	3.97	5.66	6.66	7.0	
		Week 32	Tezepelumab	6	6 (100.0)	5.74 (0.79)	4.6	5.34	5.70	6.13	7.0	
			Placebo	7	7 (100.0)	5.21 (0.99)	3.8	3.97	5.31	6.09	6.2	
		Week 36	Tezepelumab	6	6 (100.0)	5.98 (0.69)	4.9	5.63	6.06	6.22	7.0	
			Placebo	7	7 (100.0)	4.67 (1.00)	3.3	3.75	4.81	5.59	5.9	
		Week 40	Tezepelumab	6	6 (100.0)	5.85 (0.63)	5.3	5.31	5.78	5.97	7.0	
			Placebo	7	7 (100.0)	5.04 (1.10)	3.8	3.97	5.06	5.91	6.8	
		Week 44	Tezepelumab	6	6 (100.0)	5.86 (0.73)	5.0	5.31	5.73	6.41	7.0	
			Placebo	7	7 (100.0)	5.08 (1.34)	3.5	3.75	5.13	6.41	6.5	
		Week 48	Tezepelumab	6	6 (100.0)	5.97 (0.56)	5.3	5.63	5.91	6.09	7.0	
			Placebo	7	7 (100.0)	5.08 (1.09)	3.8	3.97	4.81	6.44	6.5	
		Week 52	Tezepelumab	6	6 (100.0)	5.97 (0.56)	5.3	5.63	5.91	6.09	7.0	
			Placebo	7	7 (100.0)	5.16 (1.21)	3.8	3.97	4.81	6.44	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	6	6 (100.0)	1.53 (1.10)	0.2	0.66	1.48	2.03	3.3	0.98 [-0.18, 2.15]
			Placebo	7	7 (100.0)	0.67 (0.63)	0.0	0.16	0.41	1.19	1.7	
		Week 8	Tezepelumab	6	6 (100.0)	1.68 (1.40)	-0.3	0.50	1.98	2.09	3.8	0.71 [-0.42, 1.84]
			Placebo	7	7 (100.0)	0.83 (0.99)	-0.3	0.03	0.50	1.50	2.5	
		Week 12	Tezepelumab	6	6 (100.0)	1.95 (1.31)	0.1	1.06	2.00	2.50	4.0	0.52 [-0.60, 1.63]
			Placebo	7	7 (100.0)	1.33 (1.09)	0.2	0.72	0.84	1.69	3.5	
		Week 16	Tezepelumab	6	6 (100.0)	1.77 (1.18)	0.4	0.63	1.83	2.50	3.4	0.37 [-0.73, 1.47]
			Placebo	7	7 (100.0)	1.31 (1.26)	-0.3	0.50	1.41	1.69	3.8	
		Week 20	Tezepelumab	6	6 (100.0)	1.89 (1.11)	0.5	0.78	2.03	2.53	3.4	1.18 [-0.02, 2.38]
			Placebo	7	7 (100.0)	0.67 (0.96)	-0.8	-0.25	0.75	1.69	1.8	
		Week 24	Tezepelumab	6	6 (100.0)	1.82 (1.29)	0.1	0.63	2.03	2.75	3.4	0.68 [-0.45, 1.80]
			Placebo	7	7 (100.0)	1.03 (1.06)	-0.6	0.53	0.94	1.69	2.8	
		Week 28	Tezepelumab	6	6 (100.0)	1.96 (1.23)	0.3	0.63	2.36	2.72	3.4	0.28 [-0.82, 1.38]
			Placebo	7	7 (100.0)	1.63 (1.18)	0.6	0.72	1.09	2.19	4.0	
		Week 32	Tezepelumab	6	6 (100.0)	1.74 (1.26)	0.4	0.72	1.66	2.63	3.4	0.30 [-0.80, 1.40]
			Placebo	7	7 (100.0)	1.42 (0.86)	0.7	0.72	1.09	1.69	3.2	
		Week 36	Tezepelumab	6	6 (100.0)	1.99 (1.10)	0.8	0.81	2.09	2.78	3.4	1.01 [-0.16, 2.18]
			Placebo	7	7 (100.0)	0.89 (1.09)	-1.2	0.53	1.00	1.69	2.3	
		Week 40	Tezepelumab	6	6 (100.0)	1.86 (1.20)	0.6	0.75	1.83	2.78	3.4	0.50 [-0.61, 1.61]
			Placebo	7	7 (100.0)	1.25 (1.23)	-0.2	0.72	0.94	1.69	3.8	
		Week 44	Tezepelumab	6	6 (100.0)	1.87 (1.35)	0.4	0.75	1.69	3.25	3.4	0.37 [-0.73, 1.47]
			Placebo	7	7 (100.0)	1.29 (1.70)	-1.0	-0.28	1.09	3.25	3.4	
		Week 48	Tezepelumab	6	6 (100.0)	1.98 (1.11)	0.7	1.16	1.86	2.91	3.4	0.57 [-0.54, 1.69]
			Placebo	7	7 (100.0)	1.30 (1.23)	-0.5	0.50	1.09	2.22	3.3	
		Week 52	Tezepelumab	6	6 (100.0)	1.98 (1.11)	0.7	1.16	1.86	2.91	3.4	0.48 [-0.63, 1.59]
			Placebo	7	7 (100.0)	1.38 (1.37)	-0.5	0.50	1.09	2.22	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	3.95 (1.73)	2.0	2.22	4.56	5.28	5.7	
			Placebo	4	3 (75.0)	3.71 (0.49)	3.3	3.25	3.66	4.22	4.2	
		Week 4	Tezepelumab	6	4 (66.7)	5.82 (0.61)	5.2	5.36	5.75	6.28	6.6	
			Placebo	4	3 (75.0)	5.20 (0.96)	4.4	4.38	4.97	6.25	6.3	
		Week 8	Tezepelumab	6	5 (83.3)	5.63 (1.17)	3.6	5.81	5.97	6.09	6.7	
			Placebo	4	3 (75.0)	5.70 (1.06)	4.6	4.63	5.72	6.75	6.8	
		Week 12	Tezepelumab	6	5 (83.3)	5.86 (0.86)	4.3	6.03	6.22	6.22	6.5	
			Placebo	4	3 (75.0)	5.43 (1.77)	3.5	3.47	5.91	6.91	6.9	
		Week 16	Tezepelumab	6	5 (83.3)	5.54 (0.70)	4.3	5.59	5.78	5.91	6.1	
			Placebo	4	3 (75.0)	5.24 (1.99)	3.0	3.00	5.91	6.81	6.8	
		Week 20	Tezepelumab	6	5 (83.3)	5.58 (0.73)	4.3	5.63	5.69	6.06	6.2	
			Placebo	4	3 (75.0)	5.25 (2.00)	3.0	3.00	5.91	6.84	6.8	
		Week 24	Tezepelumab	6	5 (83.3)	5.48 (0.67)	4.3	5.50	5.63	5.78	6.1	
			Placebo	4	3 (75.0)	5.58 (1.48)	4.0	3.97	5.91	6.88	6.9	
		Week 28	Tezepelumab	6	6 (100.0)	5.78 (0.87)	4.3	5.47	5.77	6.63	6.7	
			Placebo	4	3 (75.0)	5.57 (1.47)	4.0	3.97	5.91	6.84	6.8	
		Week 32	Tezepelumab	6	6 (100.0)	5.58 (0.76)	4.3	5.34	5.63	5.88	6.7	
			Placebo	4	3 (75.0)	5.47 (1.34)	4.0	3.97	5.91	6.53	6.5	
		Week 36	Tezepelumab	6	6 (100.0)	5.55 (0.74)	4.3	5.34	5.50	6.19	6.4	
			Placebo	4	3 (75.0)	5.33 (1.19)	4.0	3.97	5.91	6.13	6.1	
		Week 40	Tezepelumab	6	6 (100.0)	5.54 (0.78)	4.3	5.28	5.47	6.06	6.6	
			Placebo	4	3 (75.0)	5.39 (1.24)	4.0	3.97	5.91	6.28	6.3	
		Week 44	Tezepelumab	6	6 (100.0)	5.53 (0.68)	4.3	5.31	5.58	6.16	6.2	
			Placebo	4	3 (75.0)	6.35 (0.13)	6.3	6.28	6.28	6.50	6.5	
		Week 48	Tezepelumab	6	6 (100.0)	5.65 (0.70)	4.3	5.63	5.72	6.22	6.3	
			Placebo	4	3 (75.0)	6.36 (0.18)	6.2	6.16	6.44	6.50	6.5	
		Week 52	Tezepelumab	6	6 (100.0)	5.78 (0.82)	4.3	5.63	5.83	6.28	6.8	
			Placebo	4	3 (75.0)	6.53 (0.43)	6.2	6.16	6.44	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	6	4 (66.7)	1.38 (1.65)	-0.5	0.09	1.36	2.67	3.3	-0.07 [-1.57, 1.43]
			Placebo	4	3 (75.0)	1.49 (1.23)	0.2	0.16	1.72	2.59	2.6	
		Week 8	Tezepelumab	6	5 (83.3)	1.68 (1.38)	0.1	0.81	1.63	2.09	3.8	-0.25 [-1.68, 1.19]
			Placebo	4	3 (75.0)	1.99 (0.96)	1.4	1.38	1.50	3.09	3.1	
		Week 12	Tezepelumab	6	5 (83.3)	1.91 (1.41)	0.3	0.94	1.91	2.34	4.0	0.13 [-1.30, 1.56]
			Placebo	4	3 (75.0)	1.72 (1.52)	0.2	0.22	1.69	3.25	3.3	
		Week 16	Tezepelumab	6	5 (83.3)	1.59 (1.26)	0.2	0.81	1.22	2.34	3.4	0.04 [-1.39, 1.48]
			Placebo	4	3 (75.0)	1.53 (1.71)	-0.3	-0.25	1.69	3.16	3.2	
		Week 20	Tezepelumab	6	5 (83.3)	1.63 (1.33)	0.0	0.78	1.63	2.34	3.4	0.06 [-1.37, 1.49]
			Placebo	4	3 (75.0)	1.54 (1.72)	-0.3	-0.25	1.69	3.19	3.2	
		Week 24	Tezepelumab	6	5 (83.3)	1.53 (1.41)	0.1	0.22	1.56	2.34	3.4	-0.26 [-1.70, 1.18]
			Placebo	4	3 (75.0)	1.88 (1.26)	0.7	0.72	1.69	3.22	3.2	
		Week 28	Tezepelumab	6	5 (83.3)	1.66 (1.41)	0.2	0.22	2.16	2.34	3.4	-0.15 [-1.58, 1.29]
			Placebo	4	3 (75.0)	1.86 (1.24)	0.7	0.72	1.69	3.19	3.2	
		Week 32	Tezepelumab	6	5 (83.3)	1.41 (1.40)	0.2	0.34	0.78	2.34	3.4	-0.27 [-1.71, 1.17]
			Placebo	4	3 (75.0)	1.76 (1.08)	0.7	0.72	1.69	2.88	2.9	
		Week 36	Tezepelumab	6	5 (83.3)	1.43 (1.56)	-0.3	0.09	1.63	2.34	3.4	-0.15 [-1.58, 1.29]
			Placebo	4	3 (75.0)	1.63 (0.88)	0.7	0.72	1.69	2.47	2.5	
		Week 40	Tezepelumab	6	5 (83.3)	1.38 (1.50)	-0.4	0.75	0.78	2.34	3.4	-0.23 [-1.66, 1.21]
			Placebo	4	3 (75.0)	1.68 (0.95)	0.7	0.72	1.69	2.63	2.6	
		Week 44	Tezepelumab	6	5 (83.3)	1.44 (1.42)	-0.2	0.75	0.88	2.34	3.4	-1.00 [-2.53, 0.54]
			Placebo	4	3 (75.0)	2.65 (0.59)	2.1	2.06	2.63	3.25	3.3	
		Week 48	Tezepelumab	6	5 (83.3)	1.59 (1.31)	0.0	1.00	1.19	2.34	3.4	-0.96 [-2.49, 0.57]
			Placebo	4	3 (75.0)	2.66 (0.53)	2.2	2.22	2.50	3.25	3.3	
		Week 52	Tezepelumab	6	5 (83.3)	1.63 (1.25)	0.2	1.00	1.19	2.34	3.4	-1.06 [-2.61, 0.49]
			Placebo	4	3 (75.0)	2.82 (0.82)	2.2	2.22	2.50	3.75	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	4.09 (0.81)	2.3	3.63	4.03	4.50	6.3	
			Placebo	61	52 (85.2)	4.29 (0.81)	1.8	3.84	4.28	4.73	6.3	
		Week 4	Tezepelumab	60	56 (93.3)	4.75 (1.04)	1.4	3.98	4.75	5.55	6.8	
			Placebo	61	54 (88.5)	4.75 (0.94)	2.4	4.00	4.78	5.28	6.8	
		Week 8	Tezepelumab	60	57 (95.0)	5.05 (1.04)	3.0	4.16	5.09	5.91	6.8	
			Placebo	61	56 (91.8)	4.79 (0.98)	2.4	4.20	4.75	5.42	7.0	
		Week 12	Tezepelumab	60	57 (95.0)	5.25 (1.01)	3.0	4.50	5.09	6.19	7.0	
			Placebo	61	56 (91.8)	4.93 (0.98)	2.8	4.22	4.91	5.53	7.0	
		Week 16	Tezepelumab	60	57 (95.0)	5.23 (1.05)	2.7	4.44	5.16	6.09	7.0	
			Placebo	61	56 (91.8)	4.94 (1.15)	1.2	4.19	4.91	5.69	7.0	
		Week 20	Tezepelumab	60	58 (96.7)	5.19 (1.05)	3.2	4.31	5.17	6.13	7.0	
			Placebo	61	56 (91.8)	4.85 (1.15)	1.2	4.05	4.83	5.70	7.0	
		Week 24	Tezepelumab	60	58 (96.7)	5.23 (1.07)	3.3	4.34	5.11	6.06	7.0	
			Placebo	61	56 (91.8)	4.82 (1.20)	1.2	4.00	4.80	5.66	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.18 (1.05)	3.3	4.34	5.16	6.03	7.0	
			Placebo	61	57 (93.4)	4.92 (1.28)	1.2	4.00	4.91	5.75	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.26 (1.09)	2.9	4.25	5.22	6.13	7.0	
			Placebo	61	57 (93.4)	4.97 (1.19)	1.2	4.13	5.09	5.75	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.32 (1.08)	3.3	4.50	5.16	6.25	7.0	
			Placebo	61	57 (93.4)	4.89 (1.16)	2.2	4.00	4.84	5.72	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.25 (1.09)	3.2	4.38	5.16	6.13	7.0	
			Placebo	61	57 (93.4)	4.98 (1.20)	2.3	4.03	5.06	5.91	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.28 (1.06)	3.5	4.31	5.16	6.19	7.0	
			Placebo	61	57 (93.4)	4.93 (1.12)	2.8	4.00	4.91	5.75	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.30 (1.09)	2.9	4.34	5.16	6.16	7.0	
			Placebo	61	57 (93.4)	4.92 (1.12)	2.1	4.13	4.75	5.75	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.29 (1.08)	2.9	4.34	5.16	6.22	7.0	
			Placebo	61	57 (93.4)	4.96 (1.08)	2.9	4.09	4.75	5.91	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	60	51 (85.0)	0.70 (0.98)	-3.7	0.22	0.75	1.41	2.4	0.28 [-0.11, 0.67]
			Placebo	61	51 (83.6)	0.46 (0.75)	-1.2	0.09	0.41	0.88	2.6	
		Week 8	Tezepelumab	60	52 (86.7)	0.89 (0.94)	-1.0	0.30	0.78	1.73	2.7	0.39 [0.01, 0.78]
			Placebo	61	52 (85.2)	0.54 (0.84)	-1.4	0.08	0.42	0.95	2.7	
		Week 12	Tezepelumab	60	52 (86.7)	1.10 (0.94)	-2.1	0.58	1.17	1.86	2.7	0.47 [0.08, 0.86]
			Placebo	61	52 (85.2)	0.66 (0.97)	-1.7	0.20	0.69	1.06	3.5	
		Week 16	Tezepelumab	60	52 (86.7)	1.10 (0.98)	-2.4	0.52	1.27	1.78	2.8	0.41 [0.02, 0.79]
			Placebo	61	52 (85.2)	0.69 (1.07)	-3.2	0.31	0.72	1.08	3.8	
		Week 20	Tezepelumab	60	52 (86.7)	1.09 (0.95)	-1.2	0.44	1.05	1.77	3.0	0.49 [0.10, 0.89]
			Placebo	61	52 (85.2)	0.60 (1.01)	-3.2	0.25	0.70	1.08	2.5	
		Week 24	Tezepelumab	60	52 (86.7)	1.16 (0.97)	-1.2	0.42	1.34	1.78	3.0	0.57 [0.17, 0.96]
			Placebo	61	52 (85.2)	0.57 (1.11)	-3.2	0.06	0.67	1.22	2.8	
		Week 28	Tezepelumab	60	52 (86.7)	1.10 (0.99)	-1.3	0.36	0.95	1.88	3.0	0.42 [0.03, 0.81]
			Placebo	61	52 (85.2)	0.64 (1.19)	-3.2	0.06	0.81	1.22	4.0	
		Week 32	Tezepelumab	60	52 (86.7)	1.18 (1.02)	-1.2	0.45	1.08	2.13	2.9	0.45 [0.06, 0.84]
			Placebo	61	52 (85.2)	0.71 (1.05)	-3.2	0.23	0.72	1.27	3.2	
		Week 36	Tezepelumab	60	52 (86.7)	1.24 (1.06)	-1.3	0.67	1.03	2.22	3.3	0.61 [0.21, 1.00]
			Placebo	61	52 (85.2)	0.62 (0.99)	-2.0	0.14	0.61	1.09	2.9	
		Week 40	Tezepelumab	60	52 (86.7)	1.20 (1.02)	-1.3	0.59	1.06	2.05	2.9	0.45 [0.06, 0.84]
			Placebo	61	52 (85.2)	0.72 (1.09)	-2.0	0.05	0.78	1.42	3.8	
		Week 44	Tezepelumab	60	52 (86.7)	1.21 (1.03)	-1.1	0.59	0.98	2.05	3.3	0.55 [0.16, 0.95]
			Placebo	61	52 (85.2)	0.64 (1.01)	-2.0	-0.05	0.66	1.20	3.4	
		Week 48	Tezepelumab	60	52 (86.7)	1.24 (1.04)	-1.1	0.47	1.19	2.11	2.9	0.61 [0.21, 1.00]
			Placebo	61	52 (85.2)	0.64 (0.96)	-2.0	0.08	0.56	1.16	3.3	
		Week 52	Tezepelumab	60	52 (86.7)	1.23 (1.05)	-1.2	0.48	1.19	2.11	3.0	0.55 [0.16, 0.94]
			Placebo	61	52 (85.2)	0.69 (0.93)	-2.0	0.14	0.61	1.23	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	30	26 (86.7)	4.08 (0.87)	2.2	3.66	4.17	4.59	6.3	
			Placebo	29	25 (86.2)	4.18 (0.80)	1.8	3.91	4.22	4.59	6.1	
		Week 4	Tezepelumab	30	26 (86.7)	4.71 (1.13)	1.4	4.13	4.70	5.44	6.6	
			Placebo	29	25 (86.2)	4.85 (1.10)	2.4	4.00	4.72	5.53	6.8	
		Week 8	Tezepelumab	30	27 (90.0)	5.01 (0.98)	3.3	4.19	4.63	5.91	6.8	
			Placebo	29	26 (89.7)	4.88 (1.07)	2.4	4.25	4.75	5.72	6.9	
		Week 12	Tezepelumab	30	27 (90.0)	5.09 (0.95)	3.0	4.31	4.84	5.88	6.9	
			Placebo	29	26 (89.7)	4.96 (1.06)	3.0	4.19	4.91	5.75	6.8	
		Week 16	Tezepelumab	30	27 (90.0)	5.05 (0.92)	2.7	4.44	5.00	5.59	6.8	
			Placebo	29	26 (89.7)	4.92 (1.29)	1.2	4.06	5.05	5.75	6.8	
		Week 20	Tezepelumab	30	28 (93.3)	5.05 (0.89)	3.8	4.27	4.97	5.59	6.9	
			Placebo	29	26 (89.7)	4.86 (1.25)	1.2	4.03	4.78	5.91	6.8	
		Week 24	Tezepelumab	30	28 (93.3)	5.06 (0.98)	3.3	4.25	4.91	5.73	7.0	
			Placebo	29	26 (89.7)	4.81 (1.35)	1.2	3.81	5.16	5.75	6.8	
		Week 28	Tezepelumab	30	29 (96.7)	5.05 (0.97)	3.7	4.47	4.72	5.72	7.0	
			Placebo	29	26 (89.7)	4.79 (1.40)	1.2	3.75	4.73	5.91	7.0	
		Week 32	Tezepelumab	30	29 (96.7)	5.09 (0.96)	3.9	4.25	4.84	5.72	7.0	
			Placebo	29	26 (89.7)	4.91 (1.34)	1.2	4.03	5.05	5.91	6.9	
		Week 36	Tezepelumab	30	29 (96.7)	5.21 (1.01)	3.8	4.41	5.00	5.94	7.0	
			Placebo	29	26 (89.7)	4.92 (1.19)	2.6	3.88	5.03	5.75	6.8	
		Week 40	Tezepelumab	30	29 (96.7)	5.04 (0.94)	3.7	4.28	5.03	5.44	7.0	
			Placebo	29	26 (89.7)	4.93 (1.24)	2.9	3.88	5.02	5.91	6.8	
		Week 44	Tezepelumab	30	29 (96.7)	5.07 (0.98)	3.7	4.09	5.06	5.63	7.0	
			Placebo	29	26 (89.7)	4.93 (1.19)	2.9	3.97	5.03	5.81	6.8	
		Week 48	Tezepelumab	30	29 (96.7)	5.21 (0.95)	3.6	4.34	5.16	5.75	7.0	
			Placebo	29	26 (89.7)	4.95 (1.21)	2.9	3.97	4.72	6.00	7.0	
		Week 52	Tezepelumab	30	29 (96.7)	5.22 (0.94)	3.6	4.34	5.16	5.75	7.0	
			Placebo	29	26 (89.7)	4.89 (1.21)	2.9	3.88	4.67	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	30	24 (80.0)	0.69 (1.25)	-3.7	0.22	0.81	1.34	3.3	0.06 [-0.51, 0.62]
			Placebo	29	24 (82.8)	0.63 (0.79)	-0.7	0.16	0.45	1.03	2.6	
		Week 8	Tezepelumab	30	25 (83.3)	0.91 (1.03)	-1.0	0.28	0.50	1.78	3.8	0.21 [-0.35, 0.76]
			Placebo	29	25 (86.2)	0.72 (0.79)	-0.6	0.19	0.56	1.00	2.7	
		Week 12	Tezepelumab	30	25 (83.3)	1.00 (1.10)	-2.1	0.50	0.84	1.84	4.0	0.25 [-0.31, 0.81]
			Placebo	29	25 (86.2)	0.75 (0.91)	-1.0	0.25	0.72	1.22	2.8	
		Week 16	Tezepelumab	30	25 (83.3)	1.00 (1.06)	-2.4	0.44	1.00	1.69	3.4	0.24 [-0.31, 0.80]
			Placebo	29	25 (86.2)	0.74 (1.13)	-3.2	0.41	0.91	1.09	2.8	
		Week 20	Tezepelumab	30	25 (83.3)	0.99 (0.94)	-1.2	0.41	0.69	1.63	3.4	0.30 [-0.25, 0.86]
			Placebo	29	25 (86.2)	0.68 (1.10)	-3.2	0.31	0.78	1.09	2.5	
		Week 24	Tezepelumab	30	25 (83.3)	1.05 (0.97)	-1.2	0.34	0.97	1.59	3.4	0.36 [-0.20, 0.91]
			Placebo	29	25 (86.2)	0.67 (1.18)	-3.2	0.09	0.91	1.22	2.7	
		Week 28	Tezepelumab	30	25 (83.3)	1.06 (1.01)	-1.3	0.34	0.91	1.72	3.4	0.37 [-0.19, 0.93]
			Placebo	29	25 (86.2)	0.65 (1.19)	-3.2	0.09	1.00	1.19	2.5	
		Week 32	Tezepelumab	30	25 (83.3)	1.03 (1.03)	-1.2	0.34	0.88	1.69	3.4	0.24 [-0.31, 0.80]
			Placebo	29	25 (86.2)	0.77 (1.11)	-3.2	0.13	0.97	1.38	2.7	
		Week 36	Tezepelumab	30	25 (83.3)	1.16 (1.09)	-1.3	0.44	1.03	1.84	3.4	0.37 [-0.19, 0.93]
			Placebo	29	25 (86.2)	0.79 (0.93)	-1.7	0.31	0.81	1.09	2.9	
		Week 40	Tezepelumab	30	25 (83.3)	1.06 (0.97)	-1.3	0.53	0.97	1.59	3.4	0.27 [-0.29, 0.83]
			Placebo	29	25 (86.2)	0.80 (0.99)	-1.0	0.03	0.94	1.41	2.8	
		Week 44	Tezepelumab	30	25 (83.3)	1.04 (1.03)	-1.1	0.59	0.84	1.41	3.4	0.24 [-0.31, 0.80]
			Placebo	29	25 (86.2)	0.80 (0.94)	-0.9	0.09	0.75	1.31	2.9	
		Week 48	Tezepelumab	30	25 (83.3)	1.19 (0.98)	-1.1	0.44	1.16	1.78	3.4	0.39 [-0.17, 0.95]
			Placebo	29	25 (86.2)	0.82 (0.95)	-0.9	0.09	0.75	1.22	3.3	
		Week 52	Tezepelumab	30	25 (83.3)	1.20 (0.96)	-1.2	0.59	1.16	1.78	3.4	0.46 [-0.10, 1.02]
			Placebo	29	25 (86.2)	0.75 (0.98)	-0.9	0.03	0.75	1.19	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	36	32 (88.9)	4.08 (0.94)	2.0	3.61	3.98	4.56	6.1	
			Placebo	36	30 (83.3)	4.33 (0.81)	3.0	3.69	4.28	4.75	6.3	
		Week 4	Tezepelumab	36	34 (94.4)	4.90 (0.99)	3.3	3.88	5.13	5.66	6.8	
			Placebo	36	32 (88.9)	4.71 (0.79)	3.0	4.11	4.83	5.19	6.3	
		Week 8	Tezepelumab	36	35 (97.2)	5.16 (1.12)	3.0	4.03	5.19	6.09	6.8	
			Placebo	36	33 (91.7)	4.80 (0.95)	3.3	4.16	4.78	5.34	7.0	
		Week 12	Tezepelumab	36	35 (97.2)	5.46 (1.02)	3.8	4.50	5.50	6.34	7.0	
			Placebo	36	33 (91.7)	4.95 (1.00)	2.8	4.22	5.06	5.53	7.0	
		Week 16	Tezepelumab	36	35 (97.2)	5.42 (1.08)	3.5	4.38	5.66	6.31	7.0	
			Placebo	36	33 (91.7)	4.98 (1.12)	2.9	4.44	4.84	5.69	7.0	
		Week 20	Tezepelumab	36	35 (97.2)	5.36 (1.12)	3.2	4.31	5.59	6.41	7.0	
			Placebo	36	33 (91.7)	4.87 (1.14)	2.4	4.06	4.88	5.66	7.0	
		Week 24	Tezepelumab	36	35 (97.2)	5.41 (1.07)	3.5	4.44	5.38	6.31	7.0	
			Placebo	36	33 (91.7)	4.89 (1.11)	2.4	4.31	4.78	5.50	7.0	
		Week 28	Tezepelumab	36	36 (100.0)	5.39 (1.09)	3.3	4.48	5.45	6.33	7.0	
			Placebo	36	34 (94.4)	5.07 (1.20)	2.2	4.31	5.05	5.97	7.0	
		Week 32	Tezepelumab	36	36 (100.0)	5.45 (1.12)	2.9	4.48	5.70	6.41	7.0	
			Placebo	36	34 (94.4)	5.07 (1.07)	2.7	4.19	5.11	5.91	7.0	
		Week 36	Tezepelumab	36	36 (100.0)	5.45 (1.09)	3.3	4.70	5.64	6.25	7.0	
			Placebo	36	34 (94.4)	4.92 (1.14)	2.2	4.09	4.78	5.94	7.0	
		Week 40	Tezepelumab	36	36 (100.0)	5.47 (1.13)	3.2	4.63	5.66	6.50	7.0	
			Placebo	36	34 (94.4)	5.05 (1.18)	2.3	4.16	5.09	6.09	7.0	
		Week 44	Tezepelumab	36	36 (100.0)	5.49 (1.04)	3.5	4.55	5.61	6.30	7.0	
			Placebo	36	34 (94.4)	5.06 (1.10)	2.8	4.31	4.95	5.97	7.0	
		Week 48	Tezepelumab	36	36 (100.0)	5.44 (1.14)	2.9	4.59	5.53	6.38	7.0	
			Placebo	36	34 (94.4)	5.02 (1.09)	2.1	4.47	4.83	5.97	7.0	
		Week 52	Tezepelumab	36	36 (100.0)	5.43 (1.15)	2.9	4.59	5.66	6.38	7.0	
			Placebo	36	34 (94.4)	5.16 (1.03)	3.3	4.31	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	36	31 (86.1)	0.80 (0.85)	-0.9	0.09	0.72	1.53	2.4	0.45 [-0.06, 0.95]
			Placebo	36	30 (83.3)	0.43 (0.81)	-1.2	0.06	0.44	0.94	2.6	
		Week 8	Tezepelumab	36	32 (88.9)	1.01 (0.99)	-1.0	0.41	1.06	1.73	2.7	0.47 [-0.03, 0.98]
			Placebo	36	30 (83.3)	0.54 (0.99)	-1.4	-0.03	0.33	0.94	3.1	
		Week 12	Tezepelumab	36	32 (88.9)	1.31 (0.92)	-0.9	0.75	1.44	1.95	2.7	0.61 [0.10, 1.12]
			Placebo	36	30 (83.3)	0.68 (1.11)	-1.7	0.22	0.55	1.00	3.5	
		Week 16	Tezepelumab	36	32 (88.9)	1.26 (0.96)	-0.9	0.59	1.45	1.92	2.8	0.51 [0.01, 1.02]
			Placebo	36	30 (83.3)	0.73 (1.11)	-2.0	0.31	0.67	1.16	3.8	
		Week 20	Tezepelumab	36	32 (88.9)	1.25 (1.02)	-0.9	0.52	1.47	2.03	3.0	0.60 [0.09, 1.11]
			Placebo	36	30 (83.3)	0.63 (1.05)	-2.0	0.19	0.70	0.97	3.2	
		Week 24	Tezepelumab	36	32 (88.9)	1.31 (1.03)	-0.9	0.53	1.56	2.09	3.0	0.63 [0.12, 1.14]
			Placebo	36	30 (83.3)	0.62 (1.14)	-2.0	0.09	0.61	1.22	3.2	
		Week 28	Tezepelumab	36	32 (88.9)	1.23 (1.05)	-0.9	0.34	1.38	2.09	3.0	0.41 [-0.10, 0.91]
			Placebo	36	30 (83.3)	0.76 (1.25)	-2.0	0.16	0.63	1.47	4.0	
		Week 32	Tezepelumab	36	32 (88.9)	1.33 (1.06)	-0.9	0.59	1.42	2.23	2.9	0.53 [0.03, 1.04]
			Placebo	36	30 (83.3)	0.77 (1.05)	-2.0	0.28	0.72	1.34	3.2	
		Week 36	Tezepelumab	36	32 (88.9)	1.33 (1.10)	-0.9	0.70	1.19	2.34	3.3	0.69 [0.18, 1.21]
			Placebo	36	30 (83.3)	0.58 (1.06)	-2.0	0.19	0.53	1.19	2.5	
		Week 40	Tezepelumab	36	32 (88.9)	1.33 (1.11)	-0.9	0.66	1.20	2.39	2.9	0.50 [-0.00, 1.01]
			Placebo	36	30 (83.3)	0.75 (1.20)	-2.0	0.25	0.73	1.56	3.8	
		Week 44	Tezepelumab	36	32 (88.9)	1.38 (1.07)	-0.9	0.64	1.38	2.36	2.9	0.58 [0.07, 1.09]
			Placebo	36	30 (83.3)	0.72 (1.22)	-2.0	-0.16	0.70	1.22	3.4	
		Week 48	Tezepelumab	36	32 (88.9)	1.34 (1.12)	-0.9	0.52	1.23	2.38	2.9	0.58 [0.07, 1.09]
			Placebo	36	30 (83.3)	0.69 (1.12)	-2.0	0.09	0.55	1.38	3.3	
		Week 52	Tezepelumab	36	32 (88.9)	1.32 (1.15)	-0.9	0.47	1.22	2.45	3.0	0.42 [-0.08, 0.93]
			Placebo	36	30 (83.3)	0.85 (1.11)	-2.0	0.19	0.61	1.72	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	38	31 (81.6)	4.00 (0.75)	2.2	3.63	4.03	4.56	5.4	
			Placebo	30	23 (76.7)	4.15 (0.49)	3.4	3.69	4.13	4.59	5.2	
		Week 4	Tezepelumab	38	35 (92.1)	4.62 (1.08)	1.4	3.84	4.63	5.44	6.6	
			Placebo	30	25 (83.3)	4.63 (0.87)	3.4	4.00	4.41	5.19	6.8	
		Week 8	Tezepelumab	38	35 (92.1)	4.96 (1.00)	3.0	4.19	4.63	5.91	6.7	
			Placebo	30	25 (83.3)	4.86 (0.94)	3.3	4.22	4.75	5.31	6.9	
		Week 12	Tezepelumab	38	35 (92.1)	5.15 (0.97)	3.0	4.34	4.91	6.22	6.9	
			Placebo	30	25 (83.3)	4.87 (0.96)	3.7	4.16	4.78	5.50	6.9	
		Week 16	Tezepelumab	38	35 (92.1)	5.06 (1.00)	2.7	4.38	5.00	5.81	6.9	
			Placebo	30	25 (83.3)	4.93 (0.98)	3.3	4.13	4.94	5.69	6.8	
		Week 20	Tezepelumab	38	36 (94.7)	5.05 (1.01)	3.2	4.22	4.97	5.88	6.9	
			Placebo	30	25 (83.3)	4.90 (1.06)	2.4	4.00	4.78	5.75	6.8	
		Week 24	Tezepelumab	38	36 (94.7)	5.05 (1.03)	3.3	4.20	4.86	5.91	7.0	
			Placebo	30	25 (83.3)	4.95 (1.08)	2.4	4.09	4.81	5.69	6.9	
		Week 28	Tezepelumab	38	38 (100.0)	5.09 (1.05)	3.6	4.16	4.75	6.00	7.0	
			Placebo	30	26 (86.7)	5.00 (1.16)	2.2	4.00	4.88	5.91	6.8	
		Week 32	Tezepelumab	38	38 (100.0)	5.10 (1.07)	2.9	4.09	4.98	5.97	7.0	
			Placebo	30	26 (86.7)	5.07 (1.10)	2.7	4.13	5.03	5.91	6.9	
		Week 36	Tezepelumab	38	38 (100.0)	5.20 (1.10)	3.3	4.38	4.98	6.25	7.0	
			Placebo	30	26 (86.7)	5.03 (1.07)	3.0	4.00	5.11	5.91	6.9	
		Week 40	Tezepelumab	38	38 (100.0)	5.04 (1.05)	3.2	4.13	4.95	5.84	7.0	
			Placebo	30	26 (86.7)	5.09 (1.16)	2.5	4.00	5.23	5.91	6.9	
		Week 44	Tezepelumab	38	38 (100.0)	5.04 (1.00)	3.5	4.09	5.06	5.84	7.0	
			Placebo	30	26 (86.7)	5.01 (1.10)	3.2	4.00	4.81	6.19	6.9	
		Week 48	Tezepelumab	38	38 (100.0)	5.07 (1.03)	2.9	4.22	5.03	6.06	7.0	
			Placebo	30	26 (86.7)	5.11 (1.12)	3.2	4.13	5.06	6.16	7.0	
		Week 52	Tezepelumab	38	38 (100.0)	5.11 (1.05)	2.9	4.22	5.06	6.06	7.0	
			Placebo	30	26 (86.7)	5.09 (1.11)	3.6	4.09	5.06	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	38	31 (81.6)	0.58 (1.15)	-3.7	0.00	0.69	1.38	3.3	0.04 [-0.50, 0.58]
			Placebo	30	23 (76.7)	0.54 (0.92)	-1.2	0.16	0.41	0.81	2.6	
		Week 8	Tezepelumab	38	31 (81.6)	0.86 (1.02)	-1.0	0.31	0.69	1.72	3.8	0.10 [-0.44, 0.64]
			Placebo	30	23 (76.7)	0.76 (0.98)	-1.0	0.16	0.63	1.09	3.1	
		Week 12	Tezepelumab	38	31 (81.6)	1.08 (1.05)	-2.1	0.56	1.06	1.84	4.0	0.31 [-0.23, 0.86]
			Placebo	30	23 (76.7)	0.76 (1.04)	-1.0	0.25	0.66	1.09	3.3	
		Week 16	Tezepelumab	38	31 (81.6)	1.01 (1.04)	-2.4	0.50	0.81	1.69	3.4	0.19 [-0.35, 0.73]
			Placebo	30	23 (76.7)	0.82 (0.96)	-0.5	0.09	0.72	1.03	3.2	
		Week 20	Tezepelumab	38	31 (81.6)	1.05 (0.97)	-1.2	0.28	0.78	1.69	3.4	0.23 [-0.31, 0.77]
			Placebo	30	23 (76.7)	0.83 (0.98)	-1.3	0.34	0.78	1.09	3.2	
		Week 24	Tezepelumab	38	31 (81.6)	1.10 (0.97)	-1.2	0.34	1.03	1.66	3.4	0.27 [-0.28, 0.81]
			Placebo	30	23 (76.7)	0.84 (0.99)	-1.3	0.31	0.69	1.22	3.2	
		Week 28	Tezepelumab	38	31 (81.6)	1.09 (1.02)	-1.3	0.34	0.91	1.88	3.4	0.26 [-0.29, 0.80]
			Placebo	30	23 (76.7)	0.83 (1.04)	-1.5	0.09	0.97	1.25	3.2	
		Week 32	Tezepelumab	38	31 (81.6)	1.07 (1.06)	-1.2	0.31	1.03	2.03	3.4	0.15 [-0.39, 0.69]
			Placebo	30	23 (76.7)	0.92 (0.92)	-1.0	0.47	0.78	1.38	2.9	
		Week 36	Tezepelumab	38	31 (81.6)	1.19 (1.11)	-1.3	0.31	1.03	2.16	3.4	0.30 [-0.25, 0.84]
			Placebo	30	23 (76.7)	0.88 (0.91)	-0.7	0.31	0.78	1.34	2.9	
		Week 40	Tezepelumab	38	31 (81.6)	1.04 (1.02)	-1.3	0.31	0.75	1.84	3.4	0.10 [-0.44, 0.64]
			Placebo	30	23 (76.7)	0.94 (1.03)	-1.2	0.09	0.94	1.69	2.8	
		Week 44	Tezepelumab	38	31 (81.6)	1.03 (0.99)	-1.1	0.31	0.75	1.88	3.4	0.22 [-0.32, 0.76]
			Placebo	30	23 (76.7)	0.81 (1.00)	-0.7	0.03	0.56	1.31	2.9	
		Week 48	Tezepelumab	38	31 (81.6)	1.08 (1.00)	-1.1	0.44	0.97	2.06	3.4	0.14 [-0.40, 0.68]
			Placebo	30	23 (76.7)	0.93 (1.00)	-0.5	0.00	0.75	1.50	3.3	
		Week 52	Tezepelumab	38	31 (81.6)	1.10 (1.00)	-1.2	0.44	0.97	2.06	3.4	0.18 [-0.36, 0.72]
			Placebo	30	23 (76.7)	0.92 (1.00)	-0.5	0.09	0.75	1.50	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	28	27 (96.4)	4.17 (1.05)	2.0	3.59	4.19	4.69	6.3	
			Placebo	34	31 (91.2)	4.34 (0.99)	1.8	3.84	4.38	4.94	6.3	
		Week 4	Tezepelumab	28	25 (89.3)	5.10 (0.96)	3.3	4.41	5.16	5.94	6.8	
			Placebo	34	32 (94.1)	4.88 (0.98)	2.4	4.45	4.88	5.50	6.8	
		Week 8	Tezepelumab	28	27 (96.4)	5.28 (1.11)	3.6	4.03	5.22	6.25	6.8	
			Placebo	34	33 (97.1)	4.85 (1.05)	2.4	4.31	4.78	5.53	7.0	
		Week 12	Tezepelumab	28	27 (96.4)	5.49 (1.03)	3.8	4.56	5.25	6.59	7.0	
			Placebo	34	33 (97.1)	5.04 (1.07)	2.8	4.34	5.13	5.78	7.0	
		Week 16	Tezepelumab	28	27 (96.4)	5.52 (1.01)	3.7	4.44	5.66	6.47	7.0	
			Placebo	34	33 (97.1)	5.09 (1.16)	2.9	4.44	4.94	5.72	7.0	
		Week 20	Tezepelumab	28	27 (96.4)	5.45 (1.03)	3.8	4.34	5.59	6.47	7.0	
			Placebo	34	33 (97.1)	4.96 (1.12)	2.9	4.31	4.88	5.88	7.0	
		Week 24	Tezepelumab	28	27 (96.4)	5.52 (1.00)	4.1	4.50	5.50	6.59	7.0	
			Placebo	34	33 (97.1)	4.90 (1.16)	2.7	4.00	4.78	5.84	7.0	
		Week 28	Tezepelumab	28	27 (96.4)	5.43 (1.02)	3.3	4.53	5.47	6.22	7.0	
			Placebo	34	33 (97.1)	5.02 (1.24)	2.8	4.00	5.13	5.97	7.0	
		Week 32	Tezepelumab	28	27 (96.4)	5.55 (1.01)	3.9	4.59	5.72	6.34	7.0	
			Placebo	34	33 (97.1)	5.06 (1.09)	2.9	4.22	5.13	5.72	7.0	
		Week 36	Tezepelumab	28	27 (96.4)	5.54 (0.97)	3.5	4.94	5.44	6.19	7.0	
			Placebo	34	33 (97.1)	4.90 (1.18)	2.2	4.09	4.84	5.72	7.0	
		Week 40	Tezepelumab	28	27 (96.4)	5.62 (1.00)	3.8	4.91	5.66	6.72	7.0	
			Placebo	34	33 (97.1)	4.98 (1.22)	2.3	4.13	5.06	6.09	7.0	
		Week 44	Tezepelumab	28	27 (96.4)	5.67 (0.96)	3.9	5.00	5.66	6.47	7.0	
			Placebo	34	33 (97.1)	5.05 (1.15)	2.8	4.22	5.06	5.81	7.0	
		Week 48	Tezepelumab	28	27 (96.4)	5.71 (1.01)	3.2	5.00	5.75	6.56	7.0	
			Placebo	34	33 (97.1)	4.95 (1.14)	2.1	4.22	4.81	5.91	7.0	
		Week 52	Tezepelumab	28	27 (96.4)	5.66 (1.01)	3.2	4.88	5.91	6.47	7.0	
			Placebo	34	33 (97.1)	5.05 (1.11)	2.9	4.22	4.81	5.97	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	28	24 (85.7)	0.98 (0.83)	-0.9	0.44	1.05	1.61	2.4	0.62 [0.07, 1.16]
			Placebo	34	31 (91.2)	0.51 (0.72)	-1.1	0.06	0.50	1.16	1.7	
		Week 8	Tezepelumab	28	26 (92.9)	1.08 (0.97)	-0.9	0.13	1.47	1.78	2.7	0.59 [0.05, 1.12]
			Placebo	34	31 (91.2)	0.56 (0.83)	-1.4	0.09	0.38	1.00	2.5	
		Week 12	Tezepelumab	28	26 (92.9)	1.28 (0.95)	-0.9	0.72	1.47	1.94	2.7	0.58 [0.05, 1.11]
			Placebo	34	31 (91.2)	0.70 (1.03)	-1.7	0.22	0.75	1.25	3.5	
		Week 16	Tezepelumab	28	26 (92.9)	1.30 (0.96)	-0.9	0.53	1.59	1.88	2.7	0.52 [-0.01, 1.05]
			Placebo	34	31 (91.2)	0.79 (1.01)	-2.0	0.31	0.72	1.41	3.8	
		Week 20	Tezepelumab	28	26 (92.9)	1.24 (1.02)	-0.9	0.50	1.47	1.97	3.0	0.62 [0.08, 1.15]
			Placebo	34	31 (91.2)	0.65 (0.90)	-2.0	0.19	0.69	1.09	2.1	
		Week 24	Tezepelumab	28	26 (92.9)	1.31 (1.05)	-0.9	0.53	1.56	2.22	3.0	0.65 [0.12, 1.19]
			Placebo	34	31 (91.2)	0.62 (1.07)	-2.0	-0.03	0.78	1.56	2.8	
		Week 28	Tezepelumab	28	26 (92.9)	1.22 (1.05)	-0.9	0.31	1.22	2.13	2.7	0.43 [-0.10, 0.96]
			Placebo	34	31 (91.2)	0.74 (1.16)	-2.0	0.16	0.78	1.47	4.0	
		Week 32	Tezepelumab	28	26 (92.9)	1.36 (1.03)	-0.9	0.53	1.30	2.34	2.9	0.58 [0.05, 1.11]
			Placebo	34	31 (91.2)	0.79 (0.95)	-2.0	0.25	0.72	1.41	3.2	
		Week 36	Tezepelumab	28	26 (92.9)	1.34 (1.09)	-0.9	0.75	1.13	2.38	2.8	0.72 [0.18, 1.26]
			Placebo	34	31 (91.2)	0.60 (0.99)	-2.0	0.19	0.63	1.09	2.3	
		Week 40	Tezepelumab	28	26 (92.9)	1.42 (1.07)	-0.9	0.97	1.09	2.53	2.9	0.65 [0.11, 1.18]
			Placebo	34	31 (91.2)	0.71 (1.13)	-2.0	0.06	0.75	1.50	3.8	
		Week 44	Tezepelumab	28	26 (92.9)	1.47 (1.10)	-0.9	0.81	1.38	2.47	3.3	0.63 [0.09, 1.16]
			Placebo	34	31 (91.2)	0.76 (1.15)	-2.0	-0.03	0.78	1.56	3.4	
		Week 48	Tezepelumab	28	26 (92.9)	1.51 (1.09)	-0.9	1.00	1.45	2.53	2.9	0.79 [0.25, 1.33]
			Placebo	34	31 (91.2)	0.67 (1.05)	-2.0	0.19	0.59	1.25	3.3	
		Week 52	Tezepelumab	28	26 (92.9)	1.47 (1.12)	-0.9	0.72	1.23	2.53	3.0	0.64 [0.11, 1.18]
			Placebo	34	31 (91.2)	0.77 (1.05)	-2.0	0.19	0.63	1.38	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	3.99 (0.77)	2.2	3.66	3.98	4.47	5.4	
			Placebo	27	21 (77.8)	4.21 (0.47)	3.4	3.84	4.16	4.59	5.2	
		Week 4	Tezepelumab	32	30 (93.8)	4.67 (1.10)	1.4	3.94	4.70	5.44	6.6	
			Placebo	27	23 (85.2)	4.60 (0.83)	3.4	4.00	4.41	5.19	6.8	
		Week 8	Tezepelumab	32	30 (93.8)	5.06 (0.95)	3.4	4.25	4.70	5.91	6.7	
			Placebo	27	23 (85.2)	4.80 (0.88)	3.3	4.22	4.75	5.31	6.9	
		Week 12	Tezepelumab	32	30 (93.8)	5.17 (0.96)	3.0	4.50	4.97	6.22	6.9	
			Placebo	27	23 (85.2)	4.79 (0.90)	3.7	4.00	4.78	5.50	6.8	
		Week 16	Tezepelumab	32	30 (93.8)	5.04 (1.00)	2.7	4.38	5.03	5.78	6.9	
			Placebo	27	23 (85.2)	4.89 (0.93)	3.3	4.06	4.94	5.69	6.7	
		Week 20	Tezepelumab	32	31 (96.9)	5.00 (0.97)	3.2	4.22	5.13	5.88	6.8	
			Placebo	27	23 (85.2)	4.84 (1.01)	2.4	4.00	4.78	5.75	6.7	
		Week 24	Tezepelumab	32	31 (96.9)	5.03 (1.01)	3.3	4.19	4.75	5.81	7.0	
			Placebo	27	23 (85.2)	4.91 (1.03)	2.4	4.09	4.81	5.69	6.7	
		Week 28	Tezepelumab	32	32 (100.0)	5.01 (0.99)	3.6	4.16	4.70	5.78	6.8	
			Placebo	27	24 (88.9)	4.95 (1.14)	2.2	3.97	4.88	5.83	6.8	
		Week 32	Tezepelumab	32	32 (100.0)	5.05 (0.95)	3.6	4.14	4.72	5.78	7.0	
			Placebo	27	24 (88.9)	5.05 (1.08)	2.7	4.14	5.03	5.91	6.9	
		Week 36	Tezepelumab	32	32 (100.0)	5.14 (1.05)	3.5	4.23	4.86	6.20	7.0	
			Placebo	27	24 (88.9)	5.03 (1.06)	3.0	4.08	5.11	5.83	6.9	
		Week 40	Tezepelumab	32	32 (100.0)	4.94 (0.98)	3.2	4.11	4.78	5.56	7.0	
			Placebo	27	24 (88.9)	5.07 (1.17)	2.5	3.95	5.23	5.91	6.9	
		Week 44	Tezepelumab	32	32 (100.0)	4.94 (0.96)	3.5	4.08	4.77	5.66	7.0	
			Placebo	27	24 (88.9)	5.00 (1.10)	3.2	4.08	4.81	5.97	6.9	
		Week 48	Tezepelumab	32	32 (100.0)	5.00 (0.93)	3.5	4.19	4.84	5.69	6.8	
			Placebo	27	24 (88.9)	5.12 (1.11)	3.2	4.16	5.06	6.09	7.0	
		Week 52	Tezepelumab	32	32 (100.0)	5.02 (0.94)	3.4	4.19	4.98	5.84	6.7	
			Placebo	27	24 (88.9)	5.10 (1.11)	3.6	4.11	5.06	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	32	26 (81.3)	0.65 (1.22)	-3.7	0.03	0.73	1.41	3.3	0.19 [-0.39, 0.76]
			Placebo	27	21 (77.8)	0.45 (0.84)	-1.2	0.16	0.41	0.63	2.6	
		Week 8	Tezepelumab	32	26 (81.3)	0.97 (1.05)	-1.0	0.31	0.72	1.78	3.8	0.33 [-0.25, 0.91]
			Placebo	27	21 (77.8)	0.65 (0.88)	-1.0	0.16	0.56	0.97	2.7	
		Week 12	Tezepelumab	32	26 (81.3)	1.11 (1.10)	-2.1	0.59	1.02	1.84	4.0	0.48 [-0.10, 1.07]
			Placebo	27	21 (77.8)	0.62 (0.92)	-1.0	0.25	0.53	0.84	2.8	
		Week 16	Tezepelumab	32	26 (81.3)	1.00 (1.08)	-2.4	0.53	0.77	1.69	3.4	0.29 [-0.29, 0.87]
			Placebo	27	21 (77.8)	0.71 (0.86)	-0.5	0.09	0.69	1.00	2.8	
		Week 20	Tezepelumab	32	26 (81.3)	1.01 (0.98)	-1.2	0.31	0.78	1.63	3.4	0.31 [-0.27, 0.89]
			Placebo	27	21 (77.8)	0.72 (0.87)	-1.3	0.34	0.75	1.09	2.5	
		Week 24	Tezepelumab	32	26 (81.3)	1.10 (0.99)	-1.2	0.34	1.03	1.63	3.4	0.37 [-0.21, 0.95]
			Placebo	27	21 (77.8)	0.75 (0.88)	-1.3	0.31	0.69	0.97	2.7	
		Week 28	Tezepelumab	32	26 (81.3)	1.06 (1.05)	-1.3	0.34	0.81	1.78	3.4	0.35 [-0.23, 0.93]
			Placebo	27	21 (77.8)	0.71 (0.94)	-1.5	0.09	0.84	1.19	2.5	
		Week 32	Tezepelumab	32	26 (81.3)	1.06 (0.97)	-1.2	0.31	0.91	1.69	3.4	0.25 [-0.32, 0.83]
			Placebo	27	21 (77.8)	0.83 (0.85)	-1.0	0.47	0.78	1.09	2.7	
		Week 36	Tezepelumab	32	26 (81.3)	1.17 (1.07)	-1.3	0.44	1.03	1.84	3.4	0.35 [-0.23, 0.93]
			Placebo	27	21 (77.8)	0.83 (0.87)	-0.7	0.31	0.78	1.19	2.9	
		Week 40	Tezepelumab	32	26 (81.3)	0.99 (1.02)	-1.3	0.31	0.72	1.59	3.4	0.13 [-0.44, 0.71]
			Placebo	27	21 (77.8)	0.86 (1.01)	-1.2	0.09	0.94	1.41	2.8	
		Week 44	Tezepelumab	32	26 (81.3)	0.97 (1.01)	-1.1	0.31	0.75	1.41	3.4	0.23 [-0.34, 0.81]
			Placebo	27	21 (77.8)	0.74 (0.96)	-0.7	0.03	0.56	1.19	2.9	
		Week 48	Tezepelumab	32	26 (81.3)	1.05 (0.96)	-1.1	0.44	0.95	1.41	3.4	0.17 [-0.40, 0.75]
			Placebo	27	21 (77.8)	0.88 (0.98)	-0.5	0.00	0.75	1.41	3.3	
		Week 52	Tezepelumab	32	26 (81.3)	1.07 (0.96)	-1.2	0.44	0.95	1.41	3.4	0.21 [-0.37, 0.79]
			Placebo	27	21 (77.8)	0.87 (0.98)	-0.5	0.09	0.75	1.41	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	4.15 (1.00)	2.0	3.61	4.25	4.66	6.3	
			Placebo	37	33 (89.2)	4.29 (0.97)	1.8	3.75	4.34	4.75	6.3	
		Week 4	Tezepelumab	34	30 (88.2)	4.96 (0.99)	3.3	4.13	5.05	5.81	6.8	
			Placebo	37	34 (91.9)	4.89 (0.99)	2.4	4.41	4.88	5.53	6.8	
		Week 8	Tezepelumab	34	32 (94.1)	5.13 (1.15)	3.0	4.02	5.17	6.09	6.8	
			Placebo	37	35 (94.6)	4.89 (1.08)	2.4	4.28	4.78	5.59	7.0	
		Week 12	Tezepelumab	34	32 (94.1)	5.42 (1.04)	3.8	4.47	5.20	6.27	7.0	
			Placebo	37	35 (94.6)	5.08 (1.09)	2.8	4.34	5.13	5.78	7.0	
		Week 16	Tezepelumab	34	32 (94.1)	5.46 (1.02)	3.7	4.53	5.63	6.36	7.0	
			Placebo	37	35 (94.6)	5.11 (1.18)	2.9	4.31	4.94	5.88	7.0	
		Week 20	Tezepelumab	34	32 (94.1)	5.43 (1.05)	3.8	4.41	5.45	6.47	7.0	
			Placebo	37	35 (94.6)	4.99 (1.14)	2.9	4.22	4.88	5.88	7.0	
		Week 24	Tezepelumab	34	32 (94.1)	5.46 (1.04)	3.5	4.48	5.44	6.45	7.0	
			Placebo	37	35 (94.6)	4.92 (1.19)	2.7	3.97	4.78	5.84	7.0	
		Week 28	Tezepelumab	34	33 (97.1)	5.45 (1.06)	3.3	4.53	5.47	6.41	7.0	
			Placebo	37	35 (94.6)	5.06 (1.25)	2.8	4.00	5.13	6.00	7.0	
		Week 32	Tezepelumab	34	33 (97.1)	5.52 (1.12)	2.9	4.59	5.72	6.59	7.0	
			Placebo	37	35 (94.6)	5.07 (1.10)	2.9	4.13	5.13	6.00	7.0	
		Week 36	Tezepelumab	34	33 (97.1)	5.54 (1.03)	3.3	4.94	5.69	6.25	7.0	
			Placebo	37	35 (94.6)	4.90 (1.18)	2.2	4.00	4.84	6.13	7.0	
		Week 40	Tezepelumab	34	33 (97.1)	5.62 (1.04)	3.5	4.91	5.66	6.63	7.0	
			Placebo	37	35 (94.6)	5.00 (1.21)	2.3	4.13	5.06	6.13	7.0	
		Week 44	Tezepelumab	34	33 (97.1)	5.65 (0.98)	3.7	5.06	5.66	6.41	7.0	
			Placebo	37	35 (94.6)	5.05 (1.15)	2.8	4.03	5.06	5.97	7.0	
		Week 48	Tezepelumab	34	33 (97.1)	5.66 (1.09)	2.9	5.03	5.75	6.47	7.0	
			Placebo	37	35 (94.6)	4.95 (1.14)	2.1	4.22	4.81	5.97	7.0	
		Week 52	Tezepelumab	34	33 (97.1)	5.65 (1.09)	2.9	5.09	5.91	6.47	7.0	
			Placebo	37	35 (94.6)	5.04 (1.11)	2.9	4.22	4.81	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	34	29 (85.3)	0.85 (0.84)	-0.9	0.31	0.91	1.50	2.4	0.35 [-0.16, 0.85]
			Placebo	37	33 (89.2)	0.56 (0.79)	-1.1	0.13	0.50	1.16	2.6	
		Week 8	Tezepelumab	34	31 (91.2)	0.95 (0.96)	-0.9	0.00	1.00	1.75	2.7	0.33 [-0.16, 0.83]
			Placebo	37	33 (89.2)	0.64 (0.92)	-1.4	0.16	0.47	1.00	3.1	
		Week 12	Tezepelumab	34	31 (91.2)	1.22 (0.93)	-0.9	0.50	1.34	1.94	2.7	0.42 [-0.07, 0.92]
			Placebo	37	33 (89.2)	0.80 (1.09)	-1.7	0.31	0.78	1.25	3.5	
		Week 16	Tezepelumab	34	31 (91.2)	1.27 (0.93)	-0.9	0.50	1.59	1.88	2.7	0.41 [-0.09, 0.90]
			Placebo	37	33 (89.2)	0.86 (1.06)	-2.0	0.41	0.72	1.41	3.8	
		Week 20	Tezepelumab	34	31 (91.2)	1.24 (1.00)	-0.9	0.47	1.53	2.09	3.0	0.52 [0.02, 1.02]
			Placebo	37	33 (89.2)	0.73 (0.98)	-2.0	0.31	0.72	1.09	3.2	
		Week 24	Tezepelumab	34	31 (91.2)	1.28 (1.02)	-0.9	0.50	1.56	1.97	3.0	0.54 [0.04, 1.04]
			Placebo	37	33 (89.2)	0.69 (1.14)	-2.0	0.03	0.78	1.56	3.2	
		Week 28	Tezepelumab	34	31 (91.2)	1.23 (1.02)	-0.9	0.31	1.41	2.13	2.7	0.36 [-0.13, 0.85]
			Placebo	37	33 (89.2)	0.83 (1.21)	-2.0	0.25	0.94	1.47	4.0	
		Week 32	Tezepelumab	34	31 (91.2)	1.31 (1.11)	-0.9	0.50	1.50	2.25	2.9	0.44 [-0.05, 0.94]
			Placebo	37	33 (89.2)	0.85 (0.99)	-2.0	0.28	0.72	1.41	3.2	
		Week 36	Tezepelumab	34	31 (91.2)	1.33 (1.12)	-0.9	0.72	1.34	2.38	2.8	0.64 [0.14, 1.14]
			Placebo	37	33 (89.2)	0.65 (1.01)	-2.0	0.28	0.63	1.09	2.5	
		Week 40	Tezepelumab	34	31 (91.2)	1.40 (1.05)	-0.9	0.78	1.09	2.44	2.9	0.57 [0.07, 1.07]
			Placebo	37	33 (89.2)	0.77 (1.15)	-2.0	0.25	0.78	1.50	3.8	
		Week 44	Tezepelumab	34	31 (91.2)	1.45 (1.06)	-0.9	0.78	1.38	2.34	3.3	0.57 [0.07, 1.07]
			Placebo	37	33 (89.2)	0.81 (1.16)	-2.0	0.09	0.78	1.56	3.4	
		Week 48	Tezepelumab	34	31 (91.2)	1.46 (1.11)	-0.9	0.66	1.66	2.41	2.9	0.69 [0.18, 1.20]
			Placebo	37	33 (89.2)	0.71 (1.07)	-2.0	0.19	0.59	1.25	3.3	
		Week 52	Tezepelumab	34	31 (91.2)	1.43 (1.13)	-0.9	0.66	1.25	2.41	3.0	0.57 [0.07, 1.07]
			Placebo	37	33 (89.2)	0.81 (1.07)	-2.0	0.22	0.63	1.38	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	25	21 (84.0)	3.94 (0.61)	2.7	3.72	4.03	4.34	5.0	
			Placebo	22	18 (81.8)	4.29 (1.03)	1.8	3.75	4.20	4.69	6.3	
		Week 4	Tezepelumab	25	24 (96.0)	4.66 (0.85)	3.0	4.08	4.66	5.19	6.5	
			Placebo	22	18 (81.8)	4.71 (1.14)	2.4	4.06	4.73	5.19	6.8	
		Week 8	Tezepelumab	25	24 (96.0)	4.97 (0.94)	3.4	4.20	4.70	5.88	6.6	
			Placebo	22	20 (90.9)	4.73 (1.14)	2.8	3.77	4.81	5.52	6.9	
		Week 12	Tezepelumab	25	24 (96.0)	5.23 (0.91)	3.9	4.59	4.97	6.08	6.9	
			Placebo	22	20 (90.9)	4.71 (1.15)	2.8	3.91	4.48	5.41	6.8	
		Week 16	Tezepelumab	25	24 (96.0)	5.28 (0.95)	3.9	4.42	5.27	5.95	7.0	
			Placebo	22	20 (90.9)	4.57 (1.51)	1.2	3.58	4.38	5.67	6.9	
		Week 20	Tezepelumab	25	24 (96.0)	5.10 (1.06)	3.5	4.19	4.94	5.88	7.0	
			Placebo	22	20 (90.9)	4.64 (1.57)	1.2	3.92	4.53	5.97	6.8	
		Week 24	Tezepelumab	25	24 (96.0)	5.17 (1.01)	4.0	4.30	4.72	5.91	7.0	
			Placebo	22	20 (90.9)	4.47 (1.58)	1.2	3.38	4.42	5.77	6.9	
		Week 28	Tezepelumab	25	25 (100.0)	5.09 (1.03)	3.3	4.53	4.69	5.81	6.8	
			Placebo	22	20 (90.9)	4.43 (1.57)	1.2	3.19	4.33	5.67	6.8	
		Week 32	Tezepelumab	25	25 (100.0)	5.12 (1.04)	3.9	4.19	4.69	5.97	7.0	
			Placebo	22	20 (90.9)	4.57 (1.48)	1.2	3.88	4.36	5.70	6.8	
		Week 36	Tezepelumab	25	25 (100.0)	5.19 (1.06)	3.5	4.41	4.97	6.25	7.0	
			Placebo	22	20 (90.9)	4.66 (1.40)	2.2	3.91	4.44	6.14	6.8	
		Week 40	Tezepelumab	25	25 (100.0)	5.11 (0.97)	3.7	4.47	4.78	5.84	7.0	
			Placebo	22	20 (90.9)	4.62 (1.44)	2.3	3.59	4.23	6.11	6.8	
		Week 44	Tezepelumab	25	25 (100.0)	5.05 (1.00)	3.7	4.13	4.84	5.44	7.0	
			Placebo	22	20 (90.9)	4.66 (1.18)	2.8	3.89	4.59	5.56	6.8	
		Week 48	Tezepelumab	25	25 (100.0)	5.07 (1.03)	3.2	4.28	5.00	5.75	6.9	
			Placebo	22	20 (90.9)	4.54 (1.29)	2.1	3.64	4.44	5.45	6.8	
		Week 52	Tezepelumab	25	25 (100.0)	5.09 (1.02)	3.2	4.28	5.00	5.75	7.0	
			Placebo	22	20 (90.9)	4.66 (1.15)	2.9	3.94	4.27	5.94	6.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	25	21 (84.0)	0.77 (0.63)	-0.3	0.25	0.72	1.31	2.0	0.36 [-0.28, 1.01]
			Placebo	22	17 (77.3)	0.49 (0.91)	-1.1	0.06	0.56	0.88	2.6	
		Week 8	Tezepelumab	25	21 (84.0)	0.90 (0.94)	-1.0	0.31	0.69	1.63	2.6	0.37 [-0.27, 1.00]
			Placebo	22	18 (81.8)	0.55 (0.97)	-1.4	0.16	0.55	1.00	2.7	
		Week 12	Tezepelumab	25	21 (84.0)	1.16 (0.83)	-0.7	0.69	0.97	1.84	2.7	0.68 [0.04, 1.33]
			Placebo	22	18 (81.8)	0.50 (1.08)	-1.7	0.06	0.53	1.22	2.6	
		Week 16	Tezepelumab	25	21 (84.0)	1.20 (0.85)	-0.5	0.59	1.28	1.69	2.8	0.77 [0.12, 1.42]
			Placebo	22	18 (81.8)	0.34 (1.36)	-3.2	-0.38	0.67	1.06	2.5	
		Week 20	Tezepelumab	25	21 (84.0)	1.08 (0.95)	-0.5	0.31	1.09	1.69	3.0	0.56 [-0.08, 1.20]
			Placebo	22	18 (81.8)	0.42 (1.43)	-3.2	0.16	0.75	1.09	2.5	
		Week 24	Tezepelumab	25	21 (84.0)	1.18 (0.92)	-0.5	0.34	1.34	1.66	3.0	0.78 [0.12, 1.43]
			Placebo	22	18 (81.8)	0.22 (1.52)	-3.2	-1.19	0.55	1.22	2.5	
		Week 28	Tezepelumab	25	21 (84.0)	1.11 (0.90)	-0.5	0.53	0.91	1.72	3.0	0.77 [0.12, 1.43]
			Placebo	22	18 (81.8)	0.17 (1.52)	-3.2	-1.06	0.27	1.41	2.5	
		Week 32	Tezepelumab	25	21 (84.0)	1.19 (0.93)	-0.5	0.53	1.09	1.88	2.9	0.74 [0.09, 1.39]
			Placebo	22	18 (81.8)	0.32 (1.41)	-3.2	-0.16	0.59	1.06	2.6	
		Week 36	Tezepelumab	25	21 (84.0)	1.28 (0.95)	-0.5	0.72	1.09	1.84	3.3	0.80 [0.14, 1.45]
			Placebo	22	18 (81.8)	0.40 (1.26)	-2.0	-0.19	0.50	1.06	2.3	
		Week 40	Tezepelumab	25	21 (84.0)	1.15 (0.82)	-0.5	0.69	1.03	1.59	2.8	0.69 [0.04, 1.33]
			Placebo	22	18 (81.8)	0.40 (1.36)	-2.0	-0.94	0.31	1.66	2.6	
		Week 44	Tezepelumab	25	21 (84.0)	1.10 (0.90)	-0.6	0.69	1.13	1.44	2.9	0.72 [0.07, 1.37]
			Placebo	22	18 (81.8)	0.37 (1.13)	-2.0	-0.28	0.42	1.13	2.6	
		Week 48	Tezepelumab	25	21 (84.0)	1.17 (0.90)	-0.5	0.63	1.06	1.63	2.9	0.86 [0.20, 1.52]
			Placebo	22	18 (81.8)	0.27 (1.19)	-2.0	-0.28	0.13	1.06	2.5	
		Week 52	Tezepelumab	25	21 (84.0)	1.20 (0.87)	-0.5	0.63	1.06	1.63	3.0	0.78 [0.12, 1.43]
			Placebo	22	18 (81.8)	0.42 (1.12)	-2.0	0.03	0.20	1.06	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	35	33 (94.3)	4.19 (1.03)	2.0	3.59	4.19	4.91	6.3	
			Placebo	41	35 (85.4)	4.23 (0.70)	2.7	3.72	4.28	4.75	6.1	
		Week 4	Tezepelumab	35	31 (88.6)	4.87 (1.22)	1.4	3.84	5.16	5.81	6.8	
			Placebo	41	37 (90.2)	4.80 (0.86)	3.3	4.00	4.84	5.31	6.8	
		Week 8	Tezepelumab	35	33 (94.3)	5.16 (1.17)	3.0	4.00	5.16	6.09	6.8	
			Placebo	41	37 (90.2)	4.88 (0.93)	2.4	4.28	4.75	5.50	7.0	
		Week 12	Tezepelumab	35	33 (94.3)	5.32 (1.12)	3.0	4.34	5.25	6.34	7.0	
			Placebo	41	37 (90.2)	5.08 (0.94)	3.4	4.34	5.13	5.56	7.0	
		Week 16	Tezepelumab	35	33 (94.3)	5.24 (1.13)	2.7	4.38	5.28	6.09	6.9	
			Placebo	41	37 (90.2)	5.14 (0.95)	3.0	4.66	4.97	5.69	7.0	
		Week 20	Tezepelumab	35	33 (94.3)	5.32 (1.08)	3.2	4.34	5.22	6.19	7.0	
			Placebo	41	37 (90.2)	4.96 (0.94)	3.0	4.22	4.88	5.56	7.0	
		Week 24	Tezepelumab	35	33 (94.3)	5.35 (1.09)	3.5	4.47	5.38	6.25	7.0	
			Placebo	41	37 (90.2)	5.03 (0.95)	3.5	4.31	4.84	5.63	7.0	
		Week 28	Tezepelumab	35	34 (97.1)	5.36 (1.12)	3.6	4.34	5.45	6.25	7.0	
			Placebo	41	38 (92.7)	5.20 (1.06)	3.6	4.31	5.14	6.03	7.0	
		Week 32	Tezepelumab	35	34 (97.1)	5.42 (1.11)	2.9	4.59	5.55	6.25	7.0	
			Placebo	41	38 (92.7)	5.20 (0.98)	3.7	4.22	5.22	6.09	7.0	
		Week 36	Tezepelumab	35	34 (97.1)	5.44 (1.10)	3.3	4.75	5.53	6.22	7.0	
			Placebo	41	38 (92.7)	5.03 (1.02)	3.3	4.00	5.03	5.72	7.0	
		Week 40	Tezepelumab	35	34 (97.1)	5.44 (1.17)	3.2	4.34	5.41	6.50	7.0	
			Placebo	41	38 (92.7)	5.19 (1.03)	3.5	4.22	5.17	5.91	7.0	
		Week 44	Tezepelumab	35	34 (97.1)	5.47 (1.07)	3.5	4.47	5.59	6.25	7.0	
			Placebo	41	38 (92.7)	5.16 (1.09)	3.5	4.16	5.06	6.28	7.0	
		Week 48	Tezepelumab	35	34 (97.1)	5.50 (1.13)	2.9	4.34	5.63	6.28	7.0	
			Placebo	41	38 (92.7)	5.19 (0.99)	3.7	4.47	5.11	6.00	7.0	
		Week 52	Tezepelumab	35	34 (97.1)	5.50 (1.14)	2.9	4.34	5.83	6.28	7.0	
			Placebo	41	38 (92.7)	5.20 (1.07)	3.7	4.22	5.09	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	35	30 (85.7)	0.66 (1.18)	-3.7	0.03	0.73	1.50	2.4	0.11 [-0.37, 0.60]
			Placebo	41	35 (85.4)	0.55 (0.78)	-1.2	0.13	0.41	0.97	2.6	
		Week 8	Tezepelumab	35	32 (91.4)	0.96 (0.94)	-1.0	0.30	0.91	1.75	2.7	0.33 [-0.16, 0.81]
			Placebo	41	35 (85.4)	0.66 (0.88)	-1.0	0.09	0.50	0.97	3.1	
		Week 12	Tezepelumab	35	32 (91.4)	1.13 (1.02)	-2.1	0.53	1.25	1.91	2.6	0.31 [-0.17, 0.79]
			Placebo	41	35 (85.4)	0.83 (0.98)	-1.0	0.31	0.75	1.09	3.5	
		Week 16	Tezepelumab	35	32 (91.4)	1.06 (1.06)	-2.4	0.50	1.02	1.81	2.5	0.14 [-0.34, 0.62]
			Placebo	41	35 (85.4)	0.92 (0.93)	-0.5	0.41	0.72	1.41	3.8	
		Week 20	Tezepelumab	35	32 (91.4)	1.14 (0.98)	-1.2	0.48	1.17	1.92	2.7	0.42 [-0.06, 0.90]
			Placebo	41	35 (85.4)	0.76 (0.83)	-0.8	0.19	0.72	1.09	3.2	
		Week 24	Tezepelumab	35	32 (91.4)	1.17 (1.04)	-1.2	0.41	1.39	1.81	3.0	0.35 [-0.13, 0.83]
			Placebo	41	35 (85.4)	0.84 (0.88)	-0.6	0.13	0.72	1.22	3.2	
		Week 28	Tezepelumab	35	32 (91.4)	1.14 (1.08)	-1.3	0.31	1.19	2.14	2.7	0.16 [-0.32, 0.64]
			Placebo	41	35 (85.4)	0.98 (0.96)	-0.5	0.41	0.97	1.25	4.0	
		Week 32	Tezepelumab	35	32 (91.4)	1.21 (1.07)	-1.2	0.38	1.03	2.22	2.6	0.23 [-0.25, 0.71]
			Placebo	41	35 (85.4)	0.99 (0.79)	-0.2	0.56	0.81	1.38	3.2	
		Week 36	Tezepelumab	35	32 (91.4)	1.23 (1.16)	-1.3	0.42	0.97	2.34	2.8	0.42 [-0.07, 0.90]
			Placebo	41	35 (85.4)	0.81 (0.83)	-1.2	0.38	0.72	1.19	2.9	
		Week 40	Tezepelumab	35	32 (91.4)	1.23 (1.17)	-1.3	0.55	1.08	2.33	2.9	0.25 [-0.23, 0.73]
			Placebo	41	35 (85.4)	0.97 (0.92)	-0.7	0.47	0.78	1.41	3.8	
		Week 44	Tezepelumab	35	32 (91.4)	1.27 (1.14)	-1.1	0.53	0.94	2.33	3.3	0.31 [-0.17, 0.79]
			Placebo	41	35 (85.4)	0.93 (1.04)	-1.0	0.31	0.81	1.31	3.4	
		Week 48	Tezepelumab	35	32 (91.4)	1.29 (1.15)	-1.1	0.47	1.20	2.34	2.9	0.32 [-0.16, 0.80]
			Placebo	41	35 (85.4)	0.97 (0.87)	-0.5	0.41	0.78	1.41	3.3	
		Week 52	Tezepelumab	35	32 (91.4)	1.28 (1.17)	-1.2	0.45	1.20	2.38	3.0	0.28 [-0.20, 0.76]
			Placebo	41	35 (85.4)	0.98 (0.96)	-0.5	0.34	0.78	1.50	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	41	36 (87.8)	4.15 (0.79)	2.2	3.69	4.19	4.53	6.3	
			Placebo	30	25 (83.3)	4.24 (0.98)	1.8	3.75	4.31	4.69	6.3	
		Week 4	Tezepelumab	41	37 (90.2)	4.94 (0.90)	3.3	4.16	4.97	5.53	6.6	
			Placebo	30	24 (80.0)	4.54 (0.97)	2.4	3.91	4.59	5.19	6.3	
		Week 8	Tezepelumab	41	38 (92.7)	5.16 (1.05)	3.0	4.25	5.14	5.97	6.8	
			Placebo	30	26 (86.7)	4.70 (1.06)	2.4	3.94	4.78	5.50	6.5	
		Week 12	Tezepelumab	41	38 (92.7)	5.38 (0.96)	3.8	4.59	5.23	6.28	6.9	
			Placebo	30	26 (86.7)	4.75 (1.03)	2.8	4.00	4.72	5.47	6.8	
		Week 16	Tezepelumab	41	38 (92.7)	5.39 (0.96)	3.7	4.63	5.42	6.31	7.0	
			Placebo	30	26 (86.7)	4.73 (1.38)	1.2	3.97	4.66	5.75	6.9	
		Week 20	Tezepelumab	41	39 (95.1)	5.33 (1.02)	3.5	4.31	5.28	6.19	7.0	
			Placebo	30	26 (86.7)	4.65 (1.34)	1.2	4.06	4.64	5.66	6.8	
		Week 24	Tezepelumab	41	39 (95.1)	5.37 (1.02)	3.5	4.44	5.38	6.25	7.0	
			Placebo	30	26 (86.7)	4.52 (1.38)	1.2	3.75	4.52	5.69	6.9	
		Week 28	Tezepelumab	41	40 (97.6)	5.29 (1.09)	3.3	4.52	5.28	6.22	7.0	
			Placebo	30	26 (86.7)	4.57 (1.44)	1.2	3.75	4.55	5.72	7.0	
		Week 32	Tezepelumab	41	40 (97.6)	5.30 (1.11)	2.9	4.14	5.48	6.16	7.0	
			Placebo	30	26 (86.7)	4.62 (1.31)	1.2	3.97	4.42	5.69	6.8	
		Week 36	Tezepelumab	41	40 (97.6)	5.38 (1.12)	3.3	4.55	5.47	6.34	7.0	
			Placebo	30	26 (86.7)	4.64 (1.22)	2.2	3.84	4.59	5.69	6.8	
		Week 40	Tezepelumab	41	40 (97.6)	5.31 (1.03)	3.5	4.63	5.25	6.03	7.0	
			Placebo	30	26 (86.7)	4.66 (1.33)	2.3	3.75	4.31	5.91	6.8	
		Week 44	Tezepelumab	41	40 (97.6)	5.32 (1.04)	3.7	4.34	5.25	6.13	7.0	
			Placebo	30	26 (86.7)	4.64 (1.11)	2.8	3.78	4.45	5.63	6.8	
		Week 48	Tezepelumab	41	40 (97.6)	5.37 (1.12)	2.9	4.53	5.41	6.31	7.0	
			Placebo	30	26 (86.7)	4.56 (1.12)	2.1	3.84	4.45	5.41	6.8	
		Week 52	Tezepelumab	41	40 (97.6)	5.38 (1.11)	2.9	4.59	5.31	6.34	7.0	
			Placebo	30	26 (86.7)	4.59 (0.99)	2.9	3.88	4.27	5.41	6.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	41	34 (82.9)	0.91 (0.90)	-0.9	0.22	0.94	1.44	3.3	0.75 [0.21, 1.29]
			Placebo	30	24 (80.0)	0.30 (0.65)	-1.1	0.11	0.36	0.59	1.7	
		Week 8	Tezepelumab	41	35 (85.4)	0.95 (1.11)	-1.0	0.00	0.75	1.78	3.8	0.46 [-0.06, 0.98]
			Placebo	30	25 (83.3)	0.49 (0.82)	-1.4	0.16	0.38	0.97	2.5	
		Week 12	Tezepelumab	41	35 (85.4)	1.16 (1.02)	-0.9	0.50	0.97	1.91	4.0	0.59 [0.07, 1.12]
			Placebo	30	25 (83.3)	0.54 (1.08)	-1.7	0.06	0.56	1.22	3.5	
		Week 16	Tezepelumab	41	35 (85.4)	1.17 (0.96)	-0.9	0.50	1.22	1.78	3.4	0.57 [0.05, 1.10]
			Placebo	30	25 (83.3)	0.53 (1.30)	-3.2	0.22	0.88	1.03	3.8	
		Week 20	Tezepelumab	41	35 (85.4)	1.16 (1.04)	-0.9	0.41	1.09	1.81	3.4	0.66 [0.14, 1.19]
			Placebo	30	25 (83.3)	0.43 (1.16)	-3.2	0.31	0.81	1.06	1.8	
		Week 24	Tezepelumab	41	35 (85.4)	1.21 (1.05)	-0.9	0.31	1.34	1.97	3.4	0.79 [0.25, 1.32]
			Placebo	30	25 (83.3)	0.30 (1.30)	-3.2	-0.25	0.66	1.09	2.8	
		Week 28	Tezepelumab	41	35 (85.4)	1.15 (1.04)	-0.9	0.31	1.00	2.06	3.4	0.68 [0.15, 1.20]
			Placebo	30	25 (83.3)	0.33 (1.43)	-3.2	-0.25	0.56	1.06	4.0	
		Week 32	Tezepelumab	41	35 (85.4)	1.15 (1.11)	-0.9	0.31	1.06	2.19	3.4	0.65 [0.12, 1.18]
			Placebo	30	25 (83.3)	0.40 (1.24)	-3.2	0.00	0.72	1.03	3.2	
		Week 36	Tezepelumab	41	35 (85.4)	1.24 (1.11)	-0.9	0.44	1.03	2.25	3.4	0.77 [0.24, 1.30]
			Placebo	30	25 (83.3)	0.40 (1.09)	-2.0	-0.19	0.59	1.06	2.3	
		Week 40	Tezepelumab	41	35 (85.4)	1.18 (1.02)	-0.9	0.53	1.00	2.09	3.4	0.65 [0.12, 1.17]
			Placebo	30	25 (83.3)	0.44 (1.29)	-2.0	-0.28	0.34	1.09	3.8	
		Week 44	Tezepelumab	41	35 (85.4)	1.18 (1.06)	-0.9	0.47	0.97	2.03	3.4	0.72 [0.19, 1.25]
			Placebo	30	25 (83.3)	0.41 (1.10)	-2.0	-0.16	0.47	0.97	3.4	
		Week 48	Tezepelumab	41	35 (85.4)	1.26 (1.09)	-0.9	0.44	1.16	2.13	3.4	0.88 [0.34, 1.42]
			Placebo	30	25 (83.3)	0.33 (0.99)	-2.0	0.00	0.25	1.06	2.2	
		Week 52	Tezepelumab	41	35 (85.4)	1.27 (1.08)	-0.9	0.47	1.16	2.13	3.4	0.90 [0.36, 1.44]
			Placebo	30	25 (83.3)	0.36 (0.89)	-2.0	0.00	0.25	1.06	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	25	22 (88.0)	3.96 (1.07)	2.0	3.13	3.84	5.06	5.7	
			Placebo	34	29 (85.3)	4.28 (0.65)	3.3	3.91	4.28	4.72	6.1	
		Week 4	Tezepelumab	25	23 (92.0)	4.63 (1.25)	1.4	3.84	4.59	5.66	6.8	
			Placebo	34	32 (94.1)	4.88 (0.83)	3.5	4.20	4.88	5.39	6.8	
		Week 8	Tezepelumab	25	24 (96.0)	4.99 (1.07)	3.3	4.06	5.13	5.86	6.8	
			Placebo	34	32 (94.1)	4.88 (0.89)	3.6	4.27	4.64	5.41	7.0	
		Week 12	Tezepelumab	25	24 (96.0)	5.17 (1.07)	3.0	4.36	4.97	6.13	7.0	
			Placebo	34	32 (94.1)	5.07 (0.95)	3.5	4.30	5.11	5.67	7.0	
		Week 16	Tezepelumab	25	24 (96.0)	5.04 (1.12)	2.7	4.36	4.88	5.97	6.9	
			Placebo	34	32 (94.1)	5.08 (0.97)	3.0	4.63	4.95	5.66	7.0	
		Week 20	Tezepelumab	25	24 (96.0)	5.05 (1.03)	3.2	4.31	4.66	5.88	7.0	
			Placebo	34	32 (94.1)	4.99 (1.00)	3.0	4.02	4.97	5.88	7.0	
		Week 24	Tezepelumab	25	24 (96.0)	5.06 (1.07)	3.3	4.34	4.72	5.97	7.0	
			Placebo	34	32 (94.1)	5.07 (0.97)	3.5	4.20	4.97	5.73	7.0	
		Week 28	Tezepelumab	25	25 (100.0)	5.15 (0.99)	3.6	4.34	4.69	5.91	7.0	
			Placebo	34	33 (97.1)	5.20 (1.07)	3.5	4.31	5.16	6.00	7.0	
		Week 32	Tezepelumab	25	25 (100.0)	5.27 (1.00)	3.6	4.41	5.22	5.88	7.0	
			Placebo	34	33 (97.1)	5.24 (0.99)	3.7	4.56	5.25	6.00	7.0	
		Week 36	Tezepelumab	25	25 (100.0)	5.27 (0.95)	3.5	4.69	5.34	5.94	7.0	
			Placebo	34	33 (97.1)	5.08 (1.05)	3.3	4.09	5.03	5.94	7.0	
		Week 40	Tezepelumab	25	25 (100.0)	5.23 (1.13)	3.2	4.34	5.25	6.06	7.0	
			Placebo	34	33 (97.1)	5.21 (1.00)	3.7	4.28	5.13	5.91	7.0	
		Week 44	Tezepelumab	25	25 (100.0)	5.27 (1.02)	3.5	4.34	5.19	6.16	7.0	
			Placebo	34	33 (97.1)	5.24 (1.06)	3.5	4.53	5.09	6.28	7.0	
		Week 48	Tezepelumab	25	25 (100.0)	5.28 (0.97)	3.5	4.34	5.13	6.09	7.0	
			Placebo	34	33 (97.1)	5.27 (1.03)	3.4	4.56	5.13	6.19	7.0	
		Week 52	Tezepelumab	25	25 (100.0)	5.27 (0.99)	3.4	4.34	5.13	6.09	7.0	
			Placebo	34	33 (97.1)	5.34 (1.09)	3.6	4.63	5.16	6.38	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	25	21 (84.0)	0.51 (1.20)	-3.7	0.22	0.69	1.28	2.0	-0.12 [-0.69, 0.44]
			Placebo	34	29 (85.3)	0.63 (0.82)	-1.2	0.13	0.56	0.97	2.6	
		Week 8	Tezepelumab	25	22 (88.0)	0.99 (0.81)	-1.0	0.38	1.05	1.72	2.0	0.38 [-0.18, 0.94]
			Placebo	34	29 (85.3)	0.66 (0.91)	-1.0	0.09	0.50	0.94	3.1	
		Week 12	Tezepelumab	25	22 (88.0)	1.20 (1.00)	-2.1	0.78	1.28	1.94	2.5	0.41 [-0.15, 0.98]
			Placebo	34	29 (85.3)	0.80 (0.91)	-1.0	0.31	0.72	1.03	3.3	
		Week 16	Tezepelumab	25	22 (88.0)	1.11 (1.09)	-2.4	0.53	1.31	1.84	2.5	0.27 [-0.28, 0.83]
			Placebo	34	29 (85.3)	0.85 (0.87)	-0.5	0.31	0.69	1.41	3.2	
		Week 20	Tezepelumab	25	22 (88.0)	1.11 (0.92)	-1.2	0.50	1.17	1.75	2.5	0.35 [-0.21, 0.91]
			Placebo	34	29 (85.3)	0.78 (0.91)	-0.8	0.19	0.69	1.09	3.2	
		Week 24	Tezepelumab	25	22 (88.0)	1.18 (0.96)	-1.2	0.53	1.39	1.72	2.8	0.32 [-0.23, 0.88]
			Placebo	34	29 (85.3)	0.88 (0.90)	-0.6	0.16	0.72	1.56	3.2	
		Week 28	Tezepelumab	25	22 (88.0)	1.15 (1.03)	-1.3	0.38	1.11	1.97	2.7	0.19 [-0.37, 0.75]
			Placebo	34	29 (85.3)	0.97 (0.87)	-0.5	0.38	0.94	1.47	3.2	
		Week 32	Tezepelumab	25	22 (88.0)	1.27 (0.96)	-1.2	0.66	1.19	2.22	2.6	0.29 [-0.27, 0.85]
			Placebo	34	29 (85.3)	1.03 (0.75)	-0.2	0.47	0.84	1.41	2.9	
		Week 36	Tezepelumab	25	22 (88.0)	1.28 (1.09)	-1.3	0.81	1.06	2.34	2.8	0.44 [-0.12, 1.00]
			Placebo	34	29 (85.3)	0.86 (0.85)	-1.2	0.38	0.72	1.19	2.9	
		Week 40	Tezepelumab	25	22 (88.0)	1.27 (1.12)	-1.3	0.63	1.38	2.06	2.9	0.29 [-0.27, 0.84]
			Placebo	34	29 (85.3)	1.00 (0.80)	-0.2	0.47	0.78	1.50	2.8	
		Week 44	Tezepelumab	25	22 (88.0)	1.31 (1.08)	-1.1	0.75	1.13	2.25	3.3	0.31 [-0.25, 0.87]
			Placebo	34	29 (85.3)	0.99 (0.99)	-1.0	0.34	0.88	1.56	3.3	
		Week 48	Tezepelumab	25	22 (88.0)	1.29 (1.02)	-1.1	0.53	1.23	2.13	2.9	0.26 [-0.30, 0.81]
			Placebo	34	29 (85.3)	1.04 (0.95)	-0.5	0.34	0.81	1.50	3.3	
		Week 52	Tezepelumab	25	22 (88.0)	1.27 (1.06)	-1.2	0.50	1.22	2.34	3.0	0.14 [-0.42, 0.69]
			Placebo	34	29 (85.3)	1.12 (1.01)	-0.5	0.34	0.81	1.72	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	26	23 (88.5)	3.96 (0.66)	2.7	3.59	3.94	4.56	5.1	
			Placebo	31	25 (80.6)	4.26 (0.87)	1.8	3.75	4.31	4.78	6.1	
		Week 4	Tezepelumab	26	23 (88.5)	4.46 (1.19)	1.4	3.84	4.41	5.19	6.6	
			Placebo	31	25 (80.6)	4.72 (1.14)	2.4	4.00	4.56	5.31	6.8	
		Week 8	Tezepelumab	26	23 (88.5)	4.73 (1.01)	3.4	3.94	4.41	5.91	6.7	
			Placebo	31	27 (87.1)	4.88 (1.04)	2.8	3.94	4.75	5.72	6.9	
		Week 12	Tezepelumab	26	23 (88.5)	4.94 (0.96)	3.0	4.31	4.72	5.31	6.9	
			Placebo	31	27 (87.1)	4.95 (1.21)	2.8	3.88	5.06	5.91	6.8	
		Week 16	Tezepelumab	26	23 (88.5)	4.79 (1.02)	2.7	4.09	4.53	5.66	6.8	
			Placebo	31	27 (87.1)	4.97 (1.40)	1.2	4.25	5.09	5.91	6.8	
		Week 20	Tezepelumab	26	24 (92.3)	4.82 (0.90)	3.2	4.14	4.59	5.34	6.7	
			Placebo	31	27 (87.1)	4.86 (1.36)	1.2	4.06	4.94	5.97	6.8	
		Week 24	Tezepelumab	26	24 (92.3)	4.93 (0.92)	3.5	4.20	4.72	5.52	7.0	
			Placebo	31	27 (87.1)	4.97 (1.36)	1.2	4.09	5.50	5.91	6.8	
		Week 28	Tezepelumab	26	26 (100.0)	4.91 (0.98)	3.6	4.16	4.69	5.47	6.8	
			Placebo	31	28 (90.3)	5.07 (1.45)	1.2	4.00	5.33	6.08	7.0	
		Week 32	Tezepelumab	26	26 (100.0)	4.95 (0.99)	3.6	4.03	4.69	5.72	7.0	
			Placebo	31	28 (90.3)	5.10 (1.39)	1.2	4.14	5.38	6.20	6.9	
		Week 36	Tezepelumab	26	26 (100.0)	5.02 (1.03)	3.5	4.09	4.80	5.97	7.0	
			Placebo	31	28 (90.3)	5.13 (1.31)	2.2	4.19	5.47	6.16	6.9	
		Week 40	Tezepelumab	26	26 (100.0)	4.93 (0.98)	3.2	4.09	5.02	5.31	7.0	
			Placebo	31	28 (90.3)	5.22 (1.36)	2.3	4.00	5.58	6.47	6.9	
		Week 44	Tezepelumab	26	26 (100.0)	4.91 (0.97)	3.5	4.06	4.92	5.66	7.0	
			Placebo	31	28 (90.3)	5.27 (1.31)	2.8	4.20	5.25	6.45	6.9	
		Week 48	Tezepelumab	26	26 (100.0)	5.02 (0.96)	3.5	4.16	5.02	6.06	6.6	
			Placebo	31	28 (90.3)	5.20 (1.33)	2.1	4.20	5.22	6.42	7.0	
		Week 52	Tezepelumab	26	26 (100.0)	5.06 (1.00)	3.4	4.16	5.05	6.06	6.8	
			Placebo	31	28 (90.3)	5.25 (1.29)	2.9	4.17	5.20	6.42	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	26	23 (88.5)	0.49 (1.18)	-3.7	-0.06	0.72	1.41	2.0	-0.02 [-0.59, 0.55]
			Placebo	31	24 (77.4)	0.51 (0.85)	-1.2	0.14	0.34	0.72	2.6	
		Week 8	Tezepelumab	26	23 (88.5)	0.77 (0.97)	-1.0	0.00	0.69	1.78	2.3	0.06 [-0.50, 0.63]
			Placebo	31	25 (80.6)	0.71 (0.95)	-1.0	0.16	0.47	1.00	2.7	
		Week 12	Tezepelumab	26	23 (88.5)	0.98 (0.98)	-2.1	0.59	0.88	1.84	2.7	0.20 [-0.37, 0.76]
			Placebo	31	25 (80.6)	0.77 (1.14)	-1.1	0.22	0.72	1.25	3.5	
		Week 16	Tezepelumab	26	23 (88.5)	0.83 (0.98)	-2.4	0.50	0.66	1.63	2.8	0.04 [-0.53, 0.61]
			Placebo	31	25 (80.6)	0.79 (1.29)	-3.2	0.44	0.72	1.06	3.8	
		Week 20	Tezepelumab	26	23 (88.5)	0.84 (0.85)	-1.2	0.28	0.69	1.56	2.7	0.16 [-0.40, 0.73]
			Placebo	31	25 (80.6)	0.67 (1.17)	-3.2	0.19	0.69	1.50	2.5	
		Week 24	Tezepelumab	26	23 (88.5)	0.95 (0.90)	-1.2	0.31	0.97	1.56	3.0	0.16 [-0.40, 0.73]
			Placebo	31	25 (80.6)	0.78 (1.24)	-3.2	0.16	0.91	1.28	2.8	
		Week 28	Tezepelumab	26	23 (88.5)	0.93 (0.93)	-1.3	0.31	0.72	1.72	3.0	0.10 [-0.46, 0.67]
			Placebo	31	25 (80.6)	0.81 (1.32)	-3.2	0.28	0.97	1.41	4.0	
		Week 32	Tezepelumab	26	23 (88.5)	0.89 (0.92)	-1.2	0.31	0.91	1.47	2.8	0.05 [-0.52, 0.62]
			Placebo	31	25 (80.6)	0.84 (1.21)	-3.2	0.44	0.78	1.38	3.2	
		Week 36	Tezepelumab	26	23 (88.5)	0.99 (0.97)	-1.3	0.31	0.91	1.63	3.3	0.13 [-0.43, 0.70]
			Placebo	31	25 (80.6)	0.85 (1.07)	-1.7	0.53	0.78	1.66	2.9	
		Week 40	Tezepelumab	26	23 (88.5)	0.94 (0.91)	-1.3	0.44	0.97	1.41	2.8	-0.05 [-0.61, 0.52]
			Placebo	31	25 (80.6)	0.99 (1.18)	-1.6	0.47	0.94	1.69	3.8	
		Week 44	Tezepelumab	26	23 (88.5)	0.89 (0.87)	-1.1	0.47	0.81	1.38	2.7	-0.10 [-0.67, 0.46]
			Placebo	31	25 (80.6)	1.00 (1.22)	-1.0	0.28	0.97	1.66	3.4	
		Week 48	Tezepelumab	26	23 (88.5)	1.03 (0.87)	-1.1	0.44	1.16	1.41	2.8	0.09 [-0.48, 0.65]
			Placebo	31	25 (80.6)	0.94 (1.17)	-1.8	0.34	0.97	1.66	3.3	
		Week 52	Tezepelumab	26	23 (88.5)	1.04 (0.85)	-1.2	0.47	1.16	1.41	2.8	0.03 [-0.54, 0.60]
			Placebo	31	25 (80.6)	1.01 (1.14)	-0.9	0.31	0.81	1.72	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	4.16 (1.03)	2.0	3.63	4.31	4.81	6.3	
			Placebo	34	30 (88.2)	4.26 (0.77)	2.7	3.84	4.19	4.69	6.3	
		Week 4	Tezepelumab	40	37 (92.5)	5.04 (0.89)	3.3	4.44	5.16	5.66	6.8	
			Placebo	34	32 (94.1)	4.81 (0.76)	3.4	4.11	4.84	5.22	6.3	
		Week 8	Tezepelumab	40	39 (97.5)	5.31 (1.03)	3.0	4.53	5.41	6.09	6.8	
			Placebo	34	32 (94.1)	4.80 (0.97)	2.4	4.23	4.77	5.23	7.0	
		Week 12	Tezepelumab	40	39 (97.5)	5.50 (0.98)	3.8	4.63	5.50	6.31	7.0	
			Placebo	34	32 (94.1)	4.96 (0.84)	3.7	4.30	4.88	5.41	7.0	
		Week 16	Tezepelumab	40	39 (97.5)	5.53 (0.94)	3.7	4.69	5.59	6.31	7.0	
			Placebo	34	32 (94.1)	4.94 (0.99)	3.3	4.09	4.81	5.66	7.0	
		Week 20	Tezepelumab	40	39 (97.5)	5.47 (1.03)	3.8	4.34	5.59	6.47	7.0	
			Placebo	34	32 (94.1)	4.87 (1.03)	2.4	4.02	4.83	5.52	7.0	
		Week 24	Tezepelumab	40	39 (97.5)	5.45 (1.07)	3.3	4.47	5.63	6.31	7.0	
			Placebo	34	32 (94.1)	4.76 (1.09)	2.4	3.88	4.73	5.50	7.0	
		Week 28	Tezepelumab	40	39 (97.5)	5.45 (1.04)	3.3	4.53	5.47	6.25	7.0	
			Placebo	34	32 (94.1)	4.84 (1.14)	2.2	3.95	4.78	5.67	7.0	
		Week 32	Tezepelumab	40	39 (97.5)	5.52 (1.06)	2.9	4.63	5.69	6.34	7.0	
			Placebo	34	32 (94.1)	4.91 (0.98)	2.7	4.13	4.80	5.59	7.0	
		Week 36	Tezepelumab	40	39 (97.5)	5.55 (1.02)	3.3	4.72	5.63	6.25	7.0	
			Placebo	34	32 (94.1)	4.73 (0.98)	3.0	4.00	4.70	5.19	7.0	
		Week 40	Tezepelumab	40	39 (97.5)	5.51 (1.06)	3.5	4.66	5.50	6.50	7.0	
			Placebo	34	32 (94.1)	4.81 (1.01)	2.5	4.06	4.69	5.42	7.0	
		Week 44	Tezepelumab	40	39 (97.5)	5.57 (0.99)	3.7	4.78	5.53	6.41	7.0	
			Placebo	34	32 (94.1)	4.77 (0.90)	3.2	4.00	4.84	5.36	7.0	
		Week 48	Tezepelumab	40	39 (97.5)	5.54 (1.08)	2.9	4.72	5.56	6.47	7.0	
			Placebo	34	32 (94.1)	4.81 (0.91)	3.2	3.98	4.73	5.38	7.0	
		Week 52	Tezepelumab	40	39 (97.5)	5.53 (1.07)	2.9	4.72	5.63	6.28	7.0	
			Placebo	34	32 (94.1)	4.85 (0.91)	3.6	3.98	4.73	5.41	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	40	32 (80.0)	0.94 (0.88)	-0.9	0.42	0.81	1.52	3.3	0.50 [-0.01, 1.00]
			Placebo	34	30 (88.2)	0.53 (0.78)	-1.1	0.09	0.53	0.97	2.6	
		Week 8	Tezepelumab	40	34 (85.0)	1.10 (1.01)	-0.9	0.44	1.14	1.75	3.8	0.58 [0.08, 1.08]
			Placebo	34	30 (88.2)	0.55 (0.87)	-1.4	0.03	0.53	0.94	3.1	
		Week 12	Tezepelumab	40	34 (85.0)	1.30 (1.01)	-0.9	0.56	1.31	1.97	4.0	0.65 [0.15, 1.16]
			Placebo	34	30 (88.2)	0.67 (0.92)	-1.7	0.25	0.64	1.00	3.3	
		Week 16	Tezepelumab	40	34 (85.0)	1.36 (0.98)	-0.9	0.63	1.58	1.97	3.4	0.70 [0.19, 1.20]
			Placebo	34	30 (88.2)	0.69 (0.95)	-2.0	0.22	0.70	1.16	3.2	
		Week 20	Tezepelumab	40	34 (85.0)	1.34 (1.04)	-0.9	0.47	1.58	2.13	3.4	0.69 [0.19, 1.20]
			Placebo	34	30 (88.2)	0.64 (0.98)	-2.0	0.31	0.73	0.91	3.2	
		Week 24	Tezepelumab	40	34 (85.0)	1.36 (1.05)	-0.9	0.53	1.59	2.22	3.4	0.78 [0.27, 1.29]
			Placebo	34	30 (88.2)	0.53 (1.08)	-2.0	-0.03	0.58	1.13	3.2	
		Week 28	Tezepelumab	40	34 (85.0)	1.30 (1.07)	-0.9	0.38	1.39	2.19	3.4	0.62 [0.12, 1.12]
			Placebo	34	30 (88.2)	0.62 (1.13)	-2.0	0.00	0.70	1.25	3.2	
		Week 32	Tezepelumab	40	34 (85.0)	1.41 (1.09)	-0.9	0.53	1.58	2.25	3.4	0.68 [0.17, 1.18]
			Placebo	34	30 (88.2)	0.71 (0.95)	-2.0	0.06	0.72	1.34	2.9	
		Week 36	Tezepelumab	40	34 (85.0)	1.44 (1.15)	-0.9	0.69	1.47	2.56	3.4	0.87 [0.35, 1.38]
			Placebo	34	30 (88.2)	0.53 (0.93)	-2.0	0.06	0.42	1.09	2.5	
		Week 40	Tezepelumab	40	34 (85.0)	1.40 (1.11)	-0.9	0.66	1.33	2.34	3.4	0.76 [0.25, 1.27]
			Placebo	34	30 (88.2)	0.59 (1.02)	-2.0	0.03	0.75	1.28	2.6	
		Week 44	Tezepelumab	40	34 (85.0)	1.46 (1.12)	-0.9	0.69	1.41	2.34	3.4	0.88 [0.36, 1.39]
			Placebo	34	30 (88.2)	0.55 (0.95)	-2.0	-0.03	0.56	1.13	2.6	
		Week 48	Tezepelumab	40	34 (85.0)	1.44 (1.15)	-0.9	0.66	1.50	2.34	3.4	0.81 [0.30, 1.33]
			Placebo	34	30 (88.2)	0.59 (0.91)	-2.0	0.06	0.45	1.22	2.5	
		Week 52	Tezepelumab	40	34 (85.0)	1.43 (1.17)	-0.9	0.66	1.28	2.41	3.4	0.74 [0.23, 1.25]
			Placebo	34	30 (88.2)	0.63 (0.94)	-2.0	0.09	0.45	1.25	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	57	49 (86.0)	4.00 (0.90)	2.0	3.59	4.03	4.47	6.3	
			Placebo	60	51 (85.0)	4.28 (0.73)	1.8	3.84	4.28	4.72	6.1	
		Week 4	Tezepelumab	57	51 (89.5)	4.68 (0.99)	1.4	3.94	4.69	5.44	6.6	
			Placebo	60	52 (86.7)	4.84 (0.92)	2.4	4.25	4.84	5.36	6.8	
		Week 8	Tezepelumab	57	53 (93.0)	4.96 (0.99)	3.0	4.13	5.03	5.84	6.8	
			Placebo	60	54 (90.0)	4.89 (0.97)	2.8	4.22	4.75	5.59	7.0	
		Week 12	Tezepelumab	57	53 (93.0)	5.14 (0.92)	3.0	4.38	4.91	6.03	6.8	
			Placebo	60	54 (90.0)	4.97 (1.02)	2.8	4.22	5.08	5.56	7.0	
		Week 16	Tezepelumab	57	53 (93.0)	5.10 (0.97)	2.7	4.38	5.09	5.78	7.0	
			Placebo	60	54 (90.0)	4.96 (1.20)	1.2	4.13	4.94	5.72	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.07 (0.97)	3.2	4.22	4.97	5.84	7.0	
			Placebo	60	54 (90.0)	4.92 (1.22)	1.2	4.06	4.92	5.88	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.08 (0.97)	3.3	4.28	4.91	5.81	7.0	
			Placebo	60	54 (90.0)	4.89 (1.24)	1.2	4.00	4.83	5.75	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.12 (0.98)	3.6	4.34	4.75	5.84	7.0	
			Placebo	60	55 (91.7)	4.99 (1.28)	1.2	4.00	5.06	5.97	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.14 (1.00)	2.9	4.30	5.06	5.83	7.0	
			Placebo	60	55 (91.7)	5.03 (1.21)	1.2	4.13	5.19	5.91	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.22 (0.99)	3.3	4.45	5.05	6.08	7.0	
			Placebo	60	55 (91.7)	4.97 (1.18)	2.2	4.00	4.97	5.94	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.14 (1.00)	3.2	4.36	5.08	5.91	7.0	
			Placebo	60	55 (91.7)	5.05 (1.18)	2.3	4.13	5.13	6.09	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.17 (0.99)	3.5	4.31	5.11	6.06	7.0	
			Placebo	60	55 (91.7)	5.05 (1.13)	2.8	4.03	5.03	5.97	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.24 (1.02)	2.9	4.34	5.14	6.13	7.0	
			Placebo	60	55 (91.7)	5.05 (1.16)	2.1	4.19	4.84	6.00	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.25 (1.04)	2.9	4.34	5.14	6.13	7.0	
			Placebo	60	55 (91.7)	5.11 (1.13)	2.9	4.09	5.06	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	57	46 (80.7)	0.69 (1.09)	-3.7	0.03	0.73	1.38	3.3	0.15 [-0.25, 0.55]
			Placebo	60	50 (83.3)	0.55 (0.79)	-1.2	0.13	0.48	0.94	2.6	
		Week 8	Tezepelumab	57	48 (84.2)	0.88 (1.03)	-1.0	0.08	0.72	1.70	3.8	0.26 [-0.14, 0.65]
			Placebo	60	51 (85.0)	0.64 (0.84)	-1.0	0.16	0.50	1.00	3.1	
		Week 12	Tezepelumab	57	48 (84.2)	1.07 (1.03)	-2.1	0.50	0.95	1.86	4.0	0.39 [-0.00, 0.79]
			Placebo	60	51 (85.0)	0.69 (0.91)	-1.1	0.22	0.66	1.09	3.3	
		Week 16	Tezepelumab	57	48 (84.2)	1.05 (1.02)	-2.4	0.47	0.91	1.73	3.4	0.34 [-0.06, 0.73]
			Placebo	60	51 (85.0)	0.71 (0.99)	-3.2	0.31	0.72	1.09	3.2	
		Week 20	Tezepelumab	57	48 (84.2)	1.04 (1.02)	-1.2	0.30	0.77	1.80	3.4	0.36 [-0.04, 0.76]
			Placebo	60	51 (85.0)	0.68 (1.02)	-3.2	0.19	0.72	1.09	3.2	
		Week 24	Tezepelumab	57	48 (84.2)	1.09 (1.02)	-1.2	0.33	1.00	1.78	3.4	0.42 [0.02, 0.82]
			Placebo	60	51 (85.0)	0.65 (1.09)	-3.2	0.09	0.72	1.22	3.2	
		Week 28	Tezepelumab	57	48 (84.2)	1.10 (1.05)	-1.3	0.30	0.94	2.00	3.4	0.36 [-0.04, 0.76]
			Placebo	60	51 (85.0)	0.71 (1.09)	-3.2	0.16	0.84	1.25	3.2	
		Week 32	Tezepelumab	57	48 (84.2)	1.10 (1.08)	-1.2	0.33	0.97	2.19	3.4	0.32 [-0.08, 0.71]
			Placebo	60	51 (85.0)	0.77 (0.98)	-3.2	0.25	0.72	1.38	2.9	
		Week 36	Tezepelumab	57	48 (84.2)	1.19 (1.13)	-1.3	0.38	0.97	2.27	3.4	0.48 [0.08, 0.88]
			Placebo	60	51 (85.0)	0.70 (0.93)	-1.7	0.28	0.66	1.19	2.9	
		Week 40	Tezepelumab	57	48 (84.2)	1.13 (1.08)	-1.3	0.48	1.02	2.08	3.4	0.33 [-0.06, 0.73]
			Placebo	60	51 (85.0)	0.79 (0.97)	-1.6	0.09	0.78	1.50	2.8	
		Week 44	Tezepelumab	57	48 (84.2)	1.16 (1.09)	-1.1	0.53	0.89	2.13	3.4	0.37 [-0.03, 0.76]
			Placebo	60	51 (85.0)	0.78 (0.98)	-1.0	0.03	0.75	1.31	3.3	
		Week 48	Tezepelumab	57	48 (84.2)	1.24 (1.09)	-1.1	0.47	1.17	2.13	3.4	0.44 [0.04, 0.84]
			Placebo	60	51 (85.0)	0.79 (0.99)	-1.8	0.09	0.72	1.38	3.3	
		Week 52	Tezepelumab	57	48 (84.2)	1.25 (1.09)	-1.2	0.48	1.17	2.16	3.4	0.39 [-0.01, 0.79]
			Placebo	60	51 (85.0)	0.85 (0.99)	-0.9	0.19	0.72	1.41	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	4.52 (0.84)	2.8	4.44	4.50	5.06	5.4	
			Placebo	5	4 (80.0)	4.02 (1.65)	2.7	2.83	3.56	5.22	6.3	
		Week 4	Tezepelumab	9	9 (100.0)	5.60 (1.09)	3.3	5.28	6.06	6.22	6.8	
			Placebo	5	5 (100.0)	4.03 (0.78)	3.3	3.47	3.84	4.38	5.2	
		Week 8	Tezepelumab	9	9 (100.0)	5.92 (1.07)	3.6	5.91	6.25	6.59	6.8	
			Placebo	5	5 (100.0)	4.26 (1.22)	2.4	3.72	4.78	4.88	5.5	
		Week 12	Tezepelumab	9	9 (100.0)	6.24 (0.98)	4.2	6.19	6.47	6.94	7.0	
			Placebo	5	5 (100.0)	4.81 (1.02)	3.8	4.25	4.59	4.88	6.5	
		Week 16	Tezepelumab	9	9 (100.0)	6.18 (0.91)	4.4	6.03	6.53	6.78	6.9	
			Placebo	5	5 (100.0)	4.88 (1.11)	4.1	4.25	4.31	5.00	6.8	
		Week 20	Tezepelumab	9	9 (100.0)	6.15 (0.86)	4.3	6.13	6.41	6.66	7.0	
			Placebo	5	5 (100.0)	4.27 (0.44)	3.8	3.91	4.31	4.59	4.8	
		Week 24	Tezepelumab	9	9 (100.0)	6.27 (0.87)	4.4	6.03	6.75	6.94	7.0	
			Placebo	5	5 (100.0)	4.50 (0.80)	3.8	4.09	4.31	4.50	5.8	
		Week 28	Tezepelumab	9	9 (100.0)	5.96 (1.17)	3.3	5.44	6.03	6.75	7.0	
			Placebo	5	5 (100.0)	4.54 (1.40)	3.6	3.75	4.00	4.31	7.0	
		Week 32	Tezepelumab	9	9 (100.0)	6.24 (1.00)	3.9	6.00	6.47	6.97	7.0	
			Placebo	5	5 (100.0)	4.62 (0.92)	3.8	4.19	4.31	4.69	6.2	
		Week 36	Tezepelumab	9	9 (100.0)	6.11 (1.12)	3.5	5.91	6.22	7.00	7.0	
			Placebo	5	5 (100.0)	4.29 (0.63)	3.8	3.88	4.16	4.31	5.3	
		Week 40	Tezepelumab	9	9 (100.0)	6.17 (1.07)	3.8	5.81	6.50	7.00	7.0	
			Placebo	5	5 (100.0)	4.44 (1.33)	3.5	3.75	3.91	4.31	6.8	
		Week 44	Tezepelumab	9	9 (100.0)	6.14 (0.91)	4.2	5.84	6.34	7.00	7.0	
			Placebo	5	5 (100.0)	4.54 (1.16)	3.5	3.75	4.31	4.75	6.4	
		Week 48	Tezepelumab	9	9 (100.0)	5.95 (1.16)	3.2	5.53	6.16	6.59	7.0	
			Placebo	5	5 (100.0)	4.31 (0.41)	3.8	4.13	4.31	4.56	4.8	
		Week 52	Tezepelumab	9	9 (100.0)	5.87 (1.11)	3.2	5.53	6.16	6.56	7.0	
			Placebo	5	5 (100.0)	4.23 (0.39)	3.8	4.13	4.16	4.31	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	1.08 (0.63)	0.3	0.50	1.50	1.56	1.7	1.28 [-0.01, 2.58]
			Placebo	5	4 (80.0)	0.14 (0.95)	-1.1	-0.44	0.25	0.72	1.2	
		Week 8	Tezepelumab	9	9 (100.0)	1.41 (0.69)	0.3	0.84	1.63	1.78	2.3	0.99 [-0.26, 2.24]
			Placebo	5	4 (80.0)	0.37 (1.66)	-1.4	-0.84	0.20	1.58	2.5	
		Week 12	Tezepelumab	9	9 (100.0)	1.72 (0.66)	0.6	1.44	1.69	1.97	2.7	0.55 [-0.65, 1.74]
			Placebo	5	4 (80.0)	1.03 (2.16)	-1.7	-0.48	1.17	2.55	3.5	
		Week 16	Tezepelumab	9	9 (100.0)	1.67 (0.75)	0.5	1.56	1.72	1.88	2.8	0.47 [-0.72, 1.67]
			Placebo	5	4 (80.0)	1.01 (2.36)	-2.0	-0.56	1.14	2.58	3.8	
		Week 20	Tezepelumab	9	9 (100.0)	1.63 (0.66)	0.8	1.41	1.63	1.69	2.7	1.26 [-0.03, 2.55]
			Placebo	5	4 (80.0)	0.34 (1.65)	-2.0	-0.77	0.78	1.44	1.8	
		Week 24	Tezepelumab	9	9 (100.0)	1.76 (0.72)	0.6	1.56	1.66	2.03	3.0	0.97 [-0.27, 2.22]
			Placebo	5	4 (80.0)	0.58 (2.01)	-2.0	-0.81	0.73	1.97	2.8	
		Week 28	Tezepelumab	9	9 (100.0)	1.44 (0.91)	0.4	0.63	1.53	1.78	3.0	0.51 [-0.69, 1.71]
			Placebo	5	4 (80.0)	0.65 (2.57)	-2.0	-1.25	0.30	2.55	4.0	
		Week 32	Tezepelumab	9	9 (100.0)	1.72 (0.65)	0.7	1.38	1.66	2.03	2.8	0.82 [-0.40, 2.05]
			Placebo	5	4 (80.0)	0.70 (2.12)	-2.0	-0.72	0.83	2.13	3.2	
		Week 36	Tezepelumab	9	9 (100.0)	1.60 (0.87)	0.7	0.84	1.59	1.84	3.3	1.06 [-0.20, 2.32]
			Placebo	5	4 (80.0)	0.30 (1.86)	-2.0	-1.13	0.42	1.72	2.3	
		Week 40	Tezepelumab	9	9 (100.0)	1.65 (0.75)	0.6	1.03	1.69	2.03	2.8	0.77 [-0.46, 1.99]
			Placebo	5	4 (80.0)	0.55 (2.48)	-2.0	-1.33	0.22	2.42	3.8	
		Week 44	Tezepelumab	9	9 (100.0)	1.63 (0.74)	0.4	1.00	1.69	2.03	2.7	0.85 [-0.38, 2.08]
			Placebo	5	4 (80.0)	0.46 (2.34)	-2.0	-1.33	0.22	2.25	3.4	
		Week 48	Tezepelumab	9	9 (100.0)	1.44 (0.87)	0.4	0.69	1.63	1.66	2.8	1.06 [-0.20, 2.32]
			Placebo	5	4 (80.0)	0.23 (1.66)	-2.0	-1.00	0.55	1.45	1.8	
		Week 52	Tezepelumab	9	9 (100.0)	1.35 (0.92)	0.1	0.69	1.22	1.66	2.8	0.96 [-0.28, 2.21]
			Placebo	5	4 (80.0)	0.23 (1.66)	-2.0	-1.00	0.55	1.45	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.10 (0.90)	2.8	3.41	4.13	4.77	5.4	
			Placebo	14	10 (71.4)	4.37 (0.84)	3.0	3.94	4.31	4.69	6.3	
		Week 4	Tezepelumab	9	8 (88.9)	4.95 (0.88)	3.3	4.53	4.98	5.61	6.1	
			Placebo	14	12 (85.7)	4.65 (1.02)	3.0	3.67	4.86	5.36	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.46 (1.05)	3.6	4.86	5.53	6.23	6.8	
			Placebo	14	13 (92.9)	4.61 (0.78)	3.3	3.88	4.56	5.31	5.6	
		Week 12	Tezepelumab	9	8 (88.9)	5.54 (1.05)	4.2	4.59	5.41	6.53	7.0	
			Placebo	14	13 (92.9)	4.64 (1.02)	2.8	3.97	4.59	5.13	6.5	
		Week 16	Tezepelumab	9	8 (88.9)	5.70 (0.90)	4.4	5.06	5.70	6.41	6.9	
			Placebo	14	13 (92.9)	4.92 (1.04)	2.9	4.31	4.88	5.59	6.8	
		Week 20	Tezepelumab	9	8 (88.9)	5.25 (1.14)	3.8	4.27	5.11	6.33	6.8	
			Placebo	14	13 (92.9)	4.73 (0.87)	2.9	4.22	4.88	5.13	6.4	
		Week 24	Tezepelumab	9	8 (88.9)	5.41 (1.07)	4.3	4.47	5.27	6.39	6.8	
			Placebo	14	13 (92.9)	4.76 (1.08)	2.7	4.09	4.41	5.59	6.4	
		Week 28	Tezepelumab	9	8 (88.9)	5.16 (1.10)	3.3	4.58	5.03	5.95	6.8	
			Placebo	14	14 (100.0)	4.94 (1.25)	2.8	4.00	4.73	5.72	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.34 (1.17)	3.9	4.36	5.20	6.39	6.9	
			Placebo	14	14 (100.0)	5.00 (1.13)	3.2	4.19	4.84	6.09	6.9	
		Week 36	Tezepelumab	9	8 (88.9)	5.25 (1.13)	3.5	4.36	5.45	6.08	6.8	
			Placebo	14	14 (100.0)	4.92 (1.22)	2.2	4.22	4.86	5.69	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.41 (1.17)	3.8	4.55	5.30	6.38	7.0	
			Placebo	14	14 (100.0)	4.92 (1.34)	2.3	4.13	4.72	6.19	6.9	
		Week 44	Tezepelumab	9	8 (88.9)	5.41 (1.00)	4.2	4.55	5.31	6.23	6.8	
			Placebo	14	14 (100.0)	5.00 (1.19)	2.8	4.22	4.94	5.97	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.29 (1.17)	3.2	4.45	5.63	6.08	6.8	
			Placebo	14	14 (100.0)	4.81 (1.22)	2.1	4.22	4.66	5.41	6.8	
		Week 52	Tezepelumab	9	8 (88.9)	5.38 (1.20)	3.2	4.45	5.91	6.19	6.7	
			Placebo	14	14 (100.0)	4.87 (1.09)	3.3	4.22	4.61	5.41	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.85 (0.41)	0.3	0.50	0.69	1.28	1.4	0.79 [-0.22, 1.80]
			Placebo	14	10 (71.4)	0.28 (0.87)	-1.1	-0.47	0.41	0.66	1.6	
		Week 8	Tezepelumab	9	7 (77.8)	1.34 (0.65)	0.5	0.69	1.56	1.94	2.1	0.94 [-0.09, 1.96]
			Placebo	14	10 (71.4)	0.43 (1.14)	-1.4	-0.41	0.41	0.94	2.5	
		Week 12	Tezepelumab	9	7 (77.8)	1.46 (0.60)	0.7	0.91	1.44	2.09	2.1	0.98 [-0.05, 2.01]
			Placebo	14	10 (71.4)	0.31 (1.44)	-1.7	-0.97	0.31	0.84	3.5	
		Week 16	Tezepelumab	9	7 (77.8)	1.62 (0.74)	0.6	0.69	1.72	2.44	2.4	0.69 [-0.31, 1.69]
			Placebo	14	10 (71.4)	0.73 (1.55)	-2.0	0.31	0.72	1.66	3.8	
		Week 20	Tezepelumab	9	7 (77.8)	1.33 (0.84)	0.2	0.69	1.41	2.31	2.4	0.78 [-0.22, 1.79]
			Placebo	14	10 (71.4)	0.49 (1.21)	-2.0	-0.16	0.73	1.59	1.8	
		Week 24	Tezepelumab	9	7 (77.8)	1.51 (0.83)	0.6	0.69	1.66	2.28	2.8	0.69 [-0.31, 1.69]
			Placebo	14	10 (71.4)	0.64 (1.47)	-2.0	-0.16	0.84	1.72	2.8	
		Week 28	Tezepelumab	9	7 (77.8)	1.17 (0.95)	0.4	0.53	0.69	2.34	2.7	0.35 [-0.63, 1.32]
			Placebo	14	10 (71.4)	0.67 (1.67)	-2.0	-0.31	0.91	1.47	4.0	
		Week 32	Tezepelumab	9	7 (77.8)	1.43 (0.78)	0.7	0.72	1.09	2.19	2.6	0.57 [-0.42, 1.55]
			Placebo	14	10 (71.4)	0.74 (1.45)	-2.0	-0.16	1.09	1.50	3.2	
		Week 36	Tezepelumab	9	7 (77.8)	1.35 (0.85)	0.7	0.72	0.84	2.28	2.8	0.63 [-0.37, 1.62]
			Placebo	14	10 (71.4)	0.57 (1.47)	-2.0	-0.16	0.89	1.72	2.3	
		Week 40	Tezepelumab	9	7 (77.8)	1.47 (0.87)	0.6	0.69	1.03	2.31	2.8	0.57 [-0.42, 1.56]
			Placebo	14	10 (71.4)	0.65 (1.72)	-2.0	-0.16	0.75	1.72	3.8	
		Week 44	Tezepelumab	9	7 (77.8)	1.47 (1.00)	0.4	0.69	1.13	2.38	3.3	0.59 [-0.40, 1.58]
			Placebo	14	10 (71.4)	0.65 (1.60)	-2.0	-0.41	0.66	1.75	3.4	
		Week 48	Tezepelumab	9	7 (77.8)	1.37 (1.04)	0.4	0.44	0.69	2.34	2.9	0.74 [-0.26, 1.74]
			Placebo	14	10 (71.4)	0.43 (1.41)	-2.0	-0.16	0.75	1.72	2.2	
		Week 52	Tezepelumab	9	7 (77.8)	1.46 (0.95)	0.4	0.69	1.22	2.22	2.9	0.81 [-0.20, 1.82]
			Placebo	14	10 (71.4)	0.54 (1.25)	-2.0	-0.16	0.75	1.72	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.08 (0.91)	2.0	3.63	4.06	4.59	6.3	
			Placebo	51	45 (88.2)	4.24 (0.81)	1.8	3.72	4.22	4.75	6.1	
		Week 4	Tezepelumab	57	52 (91.2)	4.80 (1.08)	1.4	3.98	4.97	5.66	6.8	
			Placebo	51	45 (88.2)	4.80 (0.92)	2.4	4.16	4.75	5.28	6.8	
		Week 8	Tezepelumab	57	54 (94.7)	5.04 (1.05)	3.0	4.13	5.08	5.97	6.8	
			Placebo	51	46 (90.2)	4.90 (1.05)	2.4	4.22	4.77	5.72	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.26 (1.00)	3.0	4.38	5.13	6.22	7.0	
			Placebo	51	46 (90.2)	5.04 (1.01)	3.0	4.22	5.08	5.75	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.19 (1.03)	2.7	4.38	5.13	6.09	7.0	
			Placebo	51	46 (90.2)	4.96 (1.23)	1.2	4.06	4.95	5.75	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.22 (1.02)	3.2	4.31	5.22	6.06	7.0	
			Placebo	51	46 (90.2)	4.91 (1.26)	1.2	4.00	4.86	5.91	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.23 (1.04)	3.3	4.34	5.16	6.06	7.0	
			Placebo	51	46 (90.2)	4.88 (1.26)	1.2	3.97	4.81	5.75	7.0	
		Week 28	Tezepelumab	57	57 (100.0)	5.25 (1.04)	3.6	4.34	5.19	6.03	7.0	
			Placebo	51	46 (90.2)	4.95 (1.31)	1.2	3.97	4.97	5.97	7.0	
		Week 32	Tezepelumab	57	57 (100.0)	5.28 (1.05)	2.9	4.34	5.28	6.00	7.0	
			Placebo	51	46 (90.2)	4.99 (1.21)	1.2	4.13	5.14	5.91	7.0	
		Week 36	Tezepelumab	57	57 (100.0)	5.35 (1.05)	3.3	4.59	5.38	6.25	7.0	
			Placebo	51	46 (90.2)	4.92 (1.15)	2.6	4.00	4.84	5.91	7.0	
		Week 40	Tezepelumab	57	57 (100.0)	5.26 (1.06)	3.2	4.38	5.25	6.06	7.0	
			Placebo	51	46 (90.2)	5.03 (1.16)	2.5	4.00	5.06	5.91	7.0	
		Week 44	Tezepelumab	57	57 (100.0)	5.29 (1.04)	3.5	4.31	5.19	6.16	7.0	
			Placebo	51	46 (90.2)	5.00 (1.13)	2.9	4.00	5.00	5.81	7.0	
		Week 48	Tezepelumab	57	57 (100.0)	5.34 (1.05)	2.9	4.50	5.28	6.22	7.0	
			Placebo	51	46 (90.2)	5.05 (1.11)	2.9	4.00	4.83	6.00	7.0	
		Week 52	Tezepelumab	57	57 (100.0)	5.33 (1.05)	2.9	4.56	5.19	6.22	7.0	
			Placebo	51	46 (90.2)	5.09 (1.13)	2.9	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	0.74 (1.10)	-3.7	0.06	0.75	1.52	3.3	0.17 [-0.24, 0.58]
			Placebo	51	44 (86.3)	0.58 (0.79)	-1.2	0.14	0.44	0.95	2.6	
		Week 8	Tezepelumab	57	50 (87.7)	0.91 (1.03)	-1.0	0.13	0.78	1.72	3.8	0.26 [-0.14, 0.66]
			Placebo	51	45 (88.2)	0.66 (0.85)	-1.0	0.16	0.50	1.00	3.1	
		Week 12	Tezepelumab	57	50 (87.7)	1.13 (1.04)	-2.1	0.50	1.17	1.88	4.0	0.34 [-0.07, 0.74]
			Placebo	51	45 (88.2)	0.80 (0.90)	-1.0	0.28	0.72	1.22	3.3	
		Week 16	Tezepelumab	57	50 (87.7)	1.08 (1.02)	-2.4	0.50	1.11	1.78	3.4	0.34 [-0.06, 0.75]
			Placebo	51	45 (88.2)	0.73 (1.01)	-3.2	0.31	0.72	1.09	3.2	
		Week 20	Tezepelumab	57	50 (87.7)	1.11 (1.01)	-1.2	0.41	1.05	1.78	3.4	0.41 [0.00, 0.82]
			Placebo	51	45 (88.2)	0.69 (1.04)	-3.2	0.31	0.72	1.09	3.2	
		Week 24	Tezepelumab	57	50 (87.7)	1.15 (1.03)	-1.2	0.34	1.34	1.78	3.4	0.48 [0.07, 0.89]
			Placebo	51	45 (88.2)	0.64 (1.09)	-3.2	0.09	0.69	1.22	3.2	
		Week 28	Tezepelumab	57	50 (87.7)	1.15 (1.04)	-1.3	0.31	1.19	1.97	3.4	0.40 [-0.00, 0.81]
			Placebo	51	45 (88.2)	0.72 (1.11)	-3.2	0.25	0.84	1.19	3.2	
		Week 32	Tezepelumab	57	50 (87.7)	1.17 (1.08)	-1.2	0.34	1.05	2.19	3.4	0.38 [-0.03, 0.78]
			Placebo	51	45 (88.2)	0.78 (0.98)	-3.2	0.28	0.72	1.09	2.9	
		Week 36	Tezepelumab	57	50 (87.7)	1.24 (1.13)	-1.3	0.44	1.06	2.25	3.4	0.53 [0.12, 0.94]
			Placebo	51	45 (88.2)	0.70 (0.88)	-1.7	0.28	0.63	1.09	2.9	
		Week 40	Tezepelumab	57	50 (87.7)	1.18 (1.08)	-1.3	0.53	1.06	2.06	3.4	0.37 [-0.03, 0.78]
			Placebo	51	45 (88.2)	0.80 (0.94)	-1.2	0.25	0.78	1.41	2.8	
		Week 44	Tezepelumab	57	50 (87.7)	1.20 (1.07)	-1.1	0.59	0.94	2.06	3.4	0.41 [0.00, 0.82]
			Placebo	51	45 (88.2)	0.78 (0.97)	-1.0	0.09	0.75	1.22	3.3	
		Week 48	Tezepelumab	57	50 (87.7)	1.26 (1.07)	-1.1	0.50	1.20	2.13	3.4	0.44 [0.03, 0.84]
			Placebo	51	45 (88.2)	0.82 (0.95)	-0.9	0.09	0.59	1.25	3.3	
		Week 52	Tezepelumab	57	50 (87.7)	1.24 (1.08)	-1.2	0.47	1.17	2.13	3.4	0.37 [-0.04, 0.77]
			Placebo	51	45 (88.2)	0.86 (1.00)	-0.9	0.19	0.63	1.38	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	51	44 (86.3)	4.01 (0.93)	2.0	3.59	4.03	4.58	6.3	
			Placebo	49	43 (87.8)	4.28 (0.79)	1.8	3.72	4.28	4.78	6.1	
		Week 4	Tezepelumab	51	46 (90.2)	4.65 (1.02)	1.4	3.88	4.64	5.44	6.6	
			Placebo	49	43 (87.8)	4.84 (0.93)	2.4	4.16	4.81	5.31	6.8	
		Week 8	Tezepelumab	51	48 (94.1)	4.90 (1.01)	3.0	4.09	4.61	5.83	6.8	
			Placebo	49	44 (89.8)	4.96 (1.00)	2.8	4.23	4.77	5.73	7.0	
		Week 12	Tezepelumab	51	48 (94.1)	5.12 (0.94)	3.0	4.34	4.91	6.06	6.8	
			Placebo	49	44 (89.8)	5.07 (1.02)	3.0	4.22	5.11	5.77	7.0	
		Week 16	Tezepelumab	51	48 (94.1)	5.04 (0.97)	2.7	4.30	5.03	5.75	7.0	
			Placebo	49	44 (89.8)	4.98 (1.25)	1.2	4.09	4.95	5.78	7.0	
		Week 20	Tezepelumab	51	49 (96.1)	5.07 (0.97)	3.2	4.31	5.13	5.84	7.0	
			Placebo	49	44 (89.8)	4.94 (1.28)	1.2	4.02	4.97	5.94	7.0	
		Week 24	Tezepelumab	51	49 (96.1)	5.07 (0.97)	3.3	4.28	4.97	5.78	7.0	
			Placebo	49	44 (89.8)	4.91 (1.27)	1.2	3.98	4.83	5.80	7.0	
		Week 28	Tezepelumab	51	51 (100.0)	5.10 (0.99)	3.6	4.28	4.78	5.81	7.0	
			Placebo	49	44 (89.8)	5.01 (1.31)	1.2	4.16	5.05	5.98	7.0	
		Week 32	Tezepelumab	51	51 (100.0)	5.13 (1.00)	2.9	4.25	5.16	5.84	7.0	
			Placebo	49	44 (89.8)	5.03 (1.23)	1.2	4.13	5.22	5.91	7.0	
		Week 36	Tezepelumab	51	51 (100.0)	5.21 (1.00)	3.3	4.41	5.09	6.19	7.0	
			Placebo	49	44 (89.8)	4.97 (1.15)	2.6	4.00	4.91	5.92	7.0	
		Week 40	Tezepelumab	51	51 (100.0)	5.12 (1.00)	3.2	4.28	5.13	5.88	7.0	
			Placebo	49	44 (89.8)	5.09 (1.14)	2.5	4.09	5.14	6.00	7.0	
		Week 44	Tezepelumab	51	51 (100.0)	5.14 (0.98)	3.5	4.13	5.13	6.06	7.0	
			Placebo	49	44 (89.8)	5.07 (1.11)	2.9	4.09	5.02	6.00	7.0	
		Week 48	Tezepelumab	51	51 (100.0)	5.21 (1.02)	2.9	4.34	5.13	6.16	7.0	
			Placebo	49	44 (89.8)	5.10 (1.11)	2.9	4.09	4.92	6.00	7.0	
		Week 52	Tezepelumab	51	51 (100.0)	5.23 (1.05)	2.9	4.34	5.13	6.16	7.0	
			Placebo	49	44 (89.8)	5.14 (1.13)	2.9	4.05	5.06	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	51	42 (82.4)	0.65 (1.13)	-3.7	0.00	0.72	1.38	3.3	0.08 [-0.35, 0.51]
			Placebo	49	42 (85.7)	0.57 (0.80)	-1.2	0.13	0.44	0.94	2.6	
		Week 8	Tezepelumab	51	44 (86.3)	0.82 (1.04)	-1.0	0.02	0.69	1.66	3.8	0.14 [-0.28, 0.56]
			Placebo	49	43 (87.8)	0.68 (0.86)	-1.0	0.16	0.50	1.00	3.1	
		Week 12	Tezepelumab	51	44 (86.3)	1.04 (1.05)	-2.1	0.48	0.95	1.80	4.0	0.25 [-0.17, 0.68]
			Placebo	49	43 (87.8)	0.79 (0.91)	-1.0	0.22	0.72	1.22	3.3	
		Week 16	Tezepelumab	51	44 (86.3)	0.97 (1.01)	-2.4	0.39	0.81	1.67	3.4	0.26 [-0.17, 0.68]
			Placebo	49	43 (87.8)	0.71 (1.02)	-3.2	0.22	0.72	1.09	3.2	
		Week 20	Tezepelumab	51	44 (86.3)	1.01 (1.01)	-1.2	0.30	0.77	1.77	3.4	0.31 [-0.11, 0.74]
			Placebo	49	43 (87.8)	0.69 (1.06)	-3.2	0.19	0.72	1.09	3.2	
		Week 24	Tezepelumab	51	44 (86.3)	1.04 (1.02)	-1.2	0.31	1.00	1.72	3.4	0.38 [-0.05, 0.80]
			Placebo	49	43 (87.8)	0.64 (1.11)	-3.2	0.09	0.69	1.22	3.2	
		Week 28	Tezepelumab	51	44 (86.3)	1.05 (1.04)	-1.3	0.28	0.94	1.92	3.4	0.29 [-0.14, 0.71]
			Placebo	49	43 (87.8)	0.74 (1.12)	-3.2	0.25	0.84	1.25	3.2	
		Week 32	Tezepelumab	51	44 (86.3)	1.06 (1.09)	-1.2	0.31	0.97	2.13	3.4	0.27 [-0.15, 0.69]
			Placebo	49	43 (87.8)	0.77 (1.00)	-3.2	0.25	0.72	1.19	2.9	
		Week 36	Tezepelumab	51	44 (86.3)	1.14 (1.13)	-1.3	0.30	0.91	2.22	3.4	0.42 [-0.01, 0.84]
			Placebo	49	43 (87.8)	0.71 (0.89)	-1.7	0.28	0.63	1.19	2.9	
		Week 40	Tezepelumab	51	44 (86.3)	1.08 (1.09)	-1.3	0.38	1.00	1.95	3.4	0.25 [-0.17, 0.67]
			Placebo	49	43 (87.8)	0.83 (0.93)	-1.2	0.25	0.78	1.44	2.8	
		Week 44	Tezepelumab	51	44 (86.3)	1.09 (1.08)	-1.1	0.39	0.86	1.97	3.4	0.28 [-0.14, 0.71]
			Placebo	49	43 (87.8)	0.80 (0.96)	-1.0	0.09	0.75	1.22	3.3	
		Week 48	Tezepelumab	51	44 (86.3)	1.17 (1.09)	-1.1	0.44	1.14	2.09	3.4	0.33 [-0.09, 0.76]
			Placebo	49	43 (87.8)	0.83 (0.96)	-0.9	0.09	0.59	1.38	3.3	
		Week 52	Tezepelumab	51	44 (86.3)	1.19 (1.09)	-1.2	0.45	1.11	2.09	3.4	0.30 [-0.13, 0.72]
			Placebo	49	43 (87.8)	0.88 (1.01)	-0.9	0.19	0.63	1.41	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	4.30 (0.78)	2.8	3.72	4.45	4.97	5.4	
			Placebo	16	12 (75.0)	4.21 (0.91)	2.7	3.89	4.25	4.53	6.3	
		Week 4	Tezepelumab	15	14 (93.3)	5.38 (0.96)	3.3	4.72	5.33	6.13	6.8	
			Placebo	16	14 (87.5)	4.57 (0.96)	3.0	3.84	4.77	5.19	6.0	
		Week 8	Tezepelumab	15	14 (93.3)	5.76 (0.96)	3.6	5.09	5.95	6.56	6.8	
			Placebo	16	15 (93.8)	4.47 (0.92)	2.4	3.81	4.56	5.31	5.6	
		Week 12	Tezepelumab	15	14 (93.3)	5.91 (1.01)	4.2	5.03	6.28	6.94	7.0	
			Placebo	16	15 (93.8)	4.63 (0.95)	2.8	3.97	4.59	5.13	6.5	
		Week 16	Tezepelumab	15	14 (93.3)	6.01 (0.88)	4.4	5.50	6.20	6.78	6.9	
			Placebo	16	15 (93.8)	4.87 (0.99)	2.9	4.25	4.88	5.59	6.8	
		Week 20	Tezepelumab	15	14 (93.3)	5.74 (1.10)	3.8	4.63	6.16	6.66	7.0	
			Placebo	16	15 (93.8)	4.65 (0.84)	2.9	4.06	4.78	5.13	6.4	
		Week 24	Tezepelumab	15	14 (93.3)	5.89 (1.05)	4.3	4.63	6.05	6.78	7.0	
			Placebo	16	15 (93.8)	4.68 (1.04)	2.7	4.00	4.41	5.59	6.4	
		Week 28	Tezepelumab	15	14 (93.3)	5.72 (1.13)	3.3	4.63	5.95	6.75	7.0	
			Placebo	16	16 (100.0)	4.79 (1.24)	2.8	3.86	4.33	5.70	7.0	
		Week 32	Tezepelumab	15	14 (93.3)	5.85 (1.11)	3.9	4.63	6.06	6.91	7.0	
			Placebo	16	16 (100.0)	4.90 (1.10)	3.2	4.14	4.63	5.91	6.9	
		Week 36	Tezepelumab	15	14 (93.3)	5.82 (1.14)	3.5	5.00	6.02	6.81	7.0	
			Placebo	16	16 (100.0)	4.78 (1.20)	2.2	4.02	4.67	5.52	6.9	
		Week 40	Tezepelumab	15	14 (93.3)	5.86 (1.10)	3.8	4.66	5.95	7.00	7.0	
			Placebo	16	16 (100.0)	4.76 (1.33)	2.3	3.83	4.27	5.81	6.9	
		Week 44	Tezepelumab	15	14 (93.3)	5.89 (1.01)	4.2	4.78	6.20	6.84	7.0	
			Placebo	16	16 (100.0)	4.82 (1.21)	2.8	3.81	4.59	5.89	6.9	
		Week 48	Tezepelumab	15	14 (93.3)	5.79 (1.10)	3.2	5.50	6.08	6.59	7.0	
			Placebo	16	16 (100.0)	4.70 (1.17)	2.1	4.17	4.52	5.27	6.8	
		Week 52	Tezepelumab	15	14 (93.3)	5.73 (1.05)	3.2	5.41	6.08	6.56	7.0	
			Placebo	16	16 (100.0)	4.76 (1.06)	3.3	4.14	4.39	5.27	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_ILSHP: Change from baseline in AQLQ+12 total score by study specific subgroups
DITTL

Subgroup	AQLQ+12 total score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	15	13 (86.7)	1.09 (0.54)	0.3	0.66	1.28	1.56	1.7	1.07 [0.23, 1.91]
			Placebo	16	12 (75.0)	0.35 (0.83)	-1.1	-0.11	0.41	0.92	1.6	
		Week 8	Tezepelumab	15	13 (86.7)	1.46 (0.65)	0.3	0.84	1.63	1.94	2.3	1.23 [0.37, 2.09]
			Placebo	16	12 (75.0)	0.39 (1.05)	-1.4	-0.33	0.41	0.89	2.5	
		Week 12	Tezepelumab	15	13 (86.7)	1.64 (0.67)	0.6	1.06	1.69	2.09	2.7	1.12 [0.27, 1.97]
			Placebo	16	12 (75.0)	0.45 (1.36)	-1.7	-0.36	0.53	0.86	3.5	
		Week 16	Tezepelumab	15	13 (86.7)	1.72 (0.74)	0.5	1.56	1.78	2.44	2.8	0.83 [0.01, 1.65]
			Placebo	16	12 (75.0)	0.80 (1.42)	-2.0	0.36	0.83	1.53	3.8	
		Week 20	Tezepelumab	15	13 (86.7)	1.56 (0.79)	0.2	0.78	1.63	2.31	2.7	1.07 [0.23, 1.91]
			Placebo	16	12 (75.0)	0.54 (1.11)	-2.0	0.16	0.73	1.34	1.8	
		Week 24	Tezepelumab	15	13 (86.7)	1.72 (0.78)	0.6	1.03	1.66	2.28	3.0	0.98 [0.15, 1.81]
			Placebo	16	12 (75.0)	0.66 (1.34)	-2.0	-0.02	0.84	1.64	2.8	
		Week 28	Tezepelumab	15	13 (86.7)	1.51 (0.91)	0.4	0.69	1.53	2.34	3.0	0.71 [-0.10, 1.52]
			Placebo	16	12 (75.0)	0.61 (1.55)	-2.0	-0.41	0.91	1.36	4.0	
		Week 32	Tezepelumab	15	13 (86.7)	1.68 (0.72)	0.7	1.09	1.66	2.19	2.8	0.89 [0.06, 1.71]
			Placebo	16	12 (75.0)	0.76 (1.31)	-2.0	0.06	0.94	1.45	3.2	
		Week 36	Tezepelumab	15	13 (86.7)	1.65 (0.86)	0.7	0.84	1.59	2.28	3.3	0.99 [0.15, 1.82]
			Placebo	16	12 (75.0)	0.54 (1.36)	-2.0	-0.20	0.89	1.41	2.3	
		Week 40	Tezepelumab	15	13 (86.7)	1.67 (0.79)	0.6	1.00	1.69	2.31	2.8	0.87 [0.04, 1.69]
			Placebo	16	12 (75.0)	0.58 (1.61)	-2.0	-0.41	0.75	1.61	3.8	
		Week 44	Tezepelumab	15	13 (86.7)	1.70 (0.85)	0.4	1.00	1.69	2.38	3.3	0.93 [0.10, 1.76]
			Placebo	16	12 (75.0)	0.58 (1.51)	-2.0	-0.53	0.66	1.73	3.4	
		Week 48	Tezepelumab	15	13 (86.7)	1.61 (0.89)	0.4	0.69	1.66	2.34	2.9	1.05 [0.21, 1.89]
			Placebo	16	12 (75.0)	0.45 (1.30)	-2.0	-0.08	0.75	1.41	2.2	
		Week 52	Tezepelumab	15	13 (86.7)	1.54 (0.93)	0.1	0.69	1.63	2.22	2.9	0.96 [0.12, 1.79]
			Placebo	16	12 (75.0)	0.54 (1.16)	-2.0	-0.08	0.75	1.41	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILMH0: Course of AQLQ+12 activity limitations score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	66	58 (87.9)	4.13 (0.89)	2.1	3.64	4.09	4.55	6.3	
		Placebo	65	55 (84.6)	4.31 (0.78)	2.3	3.82	4.27	4.64	6.2	
	Week 4	Tezepelumab	66	60 (90.9)	4.87 (1.06)	1.6	4.14	4.95	5.73	6.9	
		Placebo	65	57 (87.7)	4.75 (1.03)	2.5	4.00	4.55	5.45	7.0	
	Week 8	Tezepelumab	66	62 (93.9)	5.15 (1.08)	2.9	4.18	5.27	6.09	6.9	
		Placebo	65	59 (90.8)	4.85 (1.07)	2.3	4.09	4.73	5.64	7.0	
	Week 12	Tezepelumab	66	62 (93.9)	5.37 (1.04)	3.0	4.64	5.18	6.36	7.0	
		Placebo	65	59 (90.8)	4.98 (1.11)	2.8	4.09	4.91	6.00	7.0	
	Week 16	Tezepelumab	66	62 (93.9)	5.31 (1.06)	2.8	4.36	5.27	6.18	7.0	
		Placebo	65	59 (90.8)	5.03 (1.25)	1.1	4.09	4.91	6.00	7.0	
	Week 20	Tezepelumab	66	63 (95.5)	5.25 (1.11)	2.8	4.27	5.18	6.27	7.0	
		Placebo	65	59 (90.8)	4.92 (1.25)	1.1	4.09	4.82	5.91	7.0	
	Week 24	Tezepelumab	66	63 (95.5)	5.31 (1.09)	2.9	4.27	5.18	6.27	7.0	
		Placebo	65	59 (90.8)	4.94 (1.27)	1.1	4.09	5.00	5.82	7.0	
	Week 28	Tezepelumab	66	65 (98.5)	5.28 (1.08)	2.9	4.45	5.27	6.27	7.0	
		Placebo	65	60 (92.3)	4.99 (1.36)	1.1	3.91	5.09	6.00	7.0	
	Week 32	Tezepelumab	66	65 (98.5)	5.34 (1.09)	2.9	4.36	5.27	6.18	7.0	
		Placebo	65	60 (92.3)	5.05 (1.26)	1.1	4.09	5.09	6.00	7.0	
	Week 36	Tezepelumab	66	65 (98.5)	5.37 (1.07)	3.0	4.45	5.45	6.18	7.0	
		Placebo	65	60 (92.3)	4.98 (1.22)	2.4	4.05	4.95	6.00	7.0	
	Week 40	Tezepelumab	66	65 (98.5)	5.34 (1.06)	3.3	4.36	5.18	6.18	7.0	
		Placebo	65	60 (92.3)	5.05 (1.28)	2.0	4.09	5.09	6.14	7.0	
	Week 44	Tezepelumab	66	65 (98.5)	5.34 (1.07)	3.0	4.45	5.36	6.27	7.0	
		Placebo	65	60 (92.3)	5.07 (1.20)	2.5	4.05	5.14	5.95	7.0	
	Week 48	Tezepelumab	66	65 (98.5)	5.39 (1.09)	2.6	4.36	5.45	6.36	7.0	
		Placebo	65	60 (92.3)	5.02 (1.21)	2.3	4.05	4.95	6.05	7.0	
	Week 52	Tezepelumab	66	65 (98.5)	5.39 (1.09)	2.6	4.45	5.36	6.36	7.0	
		Placebo	65	60 (92.3)	5.08 (1.17)	2.9	4.05	5.00	6.05	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILMH0: Course of AQLQ+12 activity limitations score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	66	55 (83.3)	0.76 (0.99)	-2.8	0.00	0.82	1.45	3.1	0.34 [-0.04, 0.72]
		Placebo	65	54 (83.1)	0.44 (0.86)	-1.5	0.00	0.36	0.82	2.5	
	Week 8	Tezepelumab	66	57 (86.4)	0.97 (0.98)	-1.3	0.27	0.91	1.55	3.7	0.42 [0.04, 0.79]
		Placebo	65	55 (84.6)	0.58 (0.89)	-1.3	-0.09	0.55	1.00	2.6	
	Week 12	Tezepelumab	66	57 (86.4)	1.20 (1.01)	-1.5	0.64	1.09	1.73	4.2	0.53 [0.15, 0.90]
		Placebo	65	55 (84.6)	0.68 (0.97)	-1.3	0.09	0.73	1.18	3.3	
	Week 16	Tezepelumab	66	57 (86.4)	1.15 (1.00)	-1.6	0.36	1.09	1.82	3.5	0.37 [-0.00, 0.75]
		Placebo	65	55 (84.6)	0.76 (1.08)	-3.2	0.27	0.82	1.55	3.5	
	Week 20	Tezepelumab	66	57 (86.4)	1.11 (1.07)	-0.9	0.36	1.00	1.91	3.5	0.42 [0.04, 0.79]
		Placebo	65	55 (84.6)	0.67 (1.04)	-3.2	0.18	0.64	1.27	2.5	
	Week 24	Tezepelumab	66	57 (86.4)	1.22 (1.03)	-0.7	0.45	1.09	1.91	3.5	0.50 [0.12, 0.88]
		Placebo	65	55 (84.6)	0.68 (1.13)	-3.2	0.09	0.64	1.45	2.9	
	Week 28	Tezepelumab	66	57 (86.4)	1.18 (1.04)	-0.8	0.45	1.09	2.00	3.5	0.43 [0.05, 0.80]
		Placebo	65	55 (84.6)	0.70 (1.20)	-3.2	0.09	0.82	1.36	3.7	
	Week 32	Tezepelumab	66	57 (86.4)	1.19 (1.05)	-0.7	0.45	1.00	1.91	3.5	0.41 [0.03, 0.78]
		Placebo	65	55 (84.6)	0.76 (1.11)	-3.2	0.27	0.82	1.55	3.3	
	Week 36	Tezepelumab	66	57 (86.4)	1.25 (1.06)	-0.7	0.64	1.09	1.91	3.5	0.53 [0.15, 0.91]
		Placebo	65	55 (84.6)	0.69 (1.02)	-1.8	0.09	0.73	1.27	2.7	
	Week 40	Tezepelumab	66	57 (86.4)	1.22 (1.02)	-0.9	0.45	1.09	1.91	3.5	0.42 [0.05, 0.80]
		Placebo	65	55 (84.6)	0.77 (1.10)	-1.6	0.18	0.73	1.64	3.5	
	Week 44	Tezepelumab	66	57 (86.4)	1.23 (1.05)	-0.7	0.45	1.09	1.91	3.5	0.43 [0.06, 0.80]
		Placebo	65	55 (84.6)	0.77 (1.11)	-1.6	0.09	0.73	1.55	3.4	
	Week 48	Tezepelumab	66	57 (86.4)	1.30 (1.03)	-0.7	0.45	1.18	2.00	3.5	0.56 [0.18, 0.93]
		Placebo	65	55 (84.6)	0.71 (1.06)	-1.6	0.09	0.82	1.27	3.2	
	Week 52	Tezepelumab	66	57 (86.4)	1.28 (1.03)	-0.7	0.55	1.18	1.91	3.5	0.46 [0.09, 0.84]
		Placebo	65	55 (84.6)	0.80 (1.04)	-1.6	0.09	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
DITTL

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	55 (83.3)	0.73 (0.12)	(0.49, 0.97)	0.29 (0.17)	(-0.05, 0.63)	0.097
	Placebo	65	54 (83.1)	0.45 (0.12)	(0.20, 0.69)			
Week 8	Tezepelumab	66	55 (83.3)	0.95 (0.12)	(0.71, 1.19)	0.35 (0.17)	(0.00, 0.69)	0.049 *
	Placebo	65	55 (84.6)	0.60 (0.12)	(0.36, 0.85)			
Week 12	Tezepelumab	66	54 (81.8)	1.20 (0.13)	(0.95, 1.45)	0.47 (0.18)	(0.10, 0.83)	0.012 *
	Placebo	65	52 (80.0)	0.73 (0.13)	(0.48, 0.99)			
Week 16	Tezepelumab	66	53 (80.3)	1.14 (0.14)	(0.86, 1.41)	0.36 (0.20)	(-0.03, 0.75)	0.068
	Placebo	65	50 (76.9)	0.77 (0.14)	(0.50, 1.05)			
Week 20	Tezepelumab	66	51 (77.3)	1.09 (0.13)	(0.82, 1.36)	0.37 (0.19)	(-0.01, 0.75)	0.056
	Placebo	65	47 (72.3)	0.72 (0.14)	(0.45, 0.99)			
Week 24	Tezepelumab	66	50 (75.8)	1.21 (0.14)	(0.94, 1.49)	0.49 (0.20)	(0.10, 0.89)	0.014 *
	Placebo	65	45 (69.2)	0.72 (0.14)	(0.44, 1.00)			
Week 28	Tezepelumab	66	47 (71.2)	1.15 (0.15)	(0.86, 1.45)	0.40 (0.21)	(-0.02, 0.82)	0.061
	Placebo	65	44 (67.7)	0.75 (0.15)	(0.45, 1.05)			
Week 32	Tezepelumab	66	48 (72.7)	1.20 (0.14)	(0.92, 1.47)	0.37 (0.20)	(-0.03, 0.76)	0.068
	Placebo	65	43 (66.2)	0.83 (0.14)	(0.55, 1.11)			
Week 36	Tezepelumab	66	49 (74.2)	1.26 (0.14)	(0.98, 1.53)	0.50 (0.20)	(0.11, 0.90)	0.014 *
	Placebo	65	44 (67.7)	0.75 (0.14)	(0.47, 1.04)			
Week 40	Tezepelumab	66	48 (72.7)	1.22 (0.14)	(0.93, 1.50)	0.38 (0.21)	(-0.02, 0.79)	0.065
	Placebo	65	45 (69.2)	0.83 (0.15)	(0.54, 1.12)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
DITTL

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	66	47 (71.2)	1.25 (0.14)	(0.97, 1.53)	0.45 (0.20)	(0.05, 0.86)	0.029 *
	Placebo	65	44 (67.7)	0.80 (0.15)	(0.51, 1.09)			
Week 48	Tezepelumab	66	46 (69.7)	1.31 (0.14)	(1.04, 1.59)	0.58 (0.20)	(0.19, 0.97)	0.004 *
	Placebo	65	44 (67.7)	0.73 (0.14)	(0.45, 1.01)			
Week 52	Tezepelumab	66	18 (27.3)	1.09 (0.23)	(0.63, 1.55)	0.24 (0.33)	(-0.44, 0.91)	0.482
	Placebo	65	16 (24.6)	0.85 (0.24)	(0.36, 1.34)			

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QAC_ILMG0: Course of AQLQ+12 activity limitations score
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QAC_ILMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	19	16 (84.2)	3.97 (0.54)	3.3	3.59	3.91	4.32	5.3	
			Placebo	20	17 (85.0)	4.10 (0.79)	2.3	3.82	4.00	4.27	6.2	
		Week 4	Tezepelumab	19	17 (89.5)	4.98 (1.05)	3.1	4.18	5.18	5.73	6.8	
			Placebo	20	17 (85.0)	4.65 (1.17)	2.5	3.82	4.64	5.45	6.7	
		Week 8	Tezepelumab	19	17 (89.5)	5.15 (1.12)	3.3	3.91	5.27	6.18	6.9	
			Placebo	20	18 (90.0)	4.60 (0.98)	3.3	3.91	4.18	5.00	7.0	
		Week 12	Tezepelumab	19	17 (89.5)	5.34 (0.97)	3.9	4.64	5.09	5.73	7.0	
			Placebo	20	18 (90.0)	4.78 (1.12)	2.8	4.00	4.86	5.45	7.0	
		Week 16	Tezepelumab	19	17 (89.5)	5.32 (1.06)	3.9	4.64	5.09	6.45	7.0	
			Placebo	20	18 (90.0)	4.59 (1.44)	1.1	3.91	4.73	5.55	6.9	
		Week 20	Tezepelumab	19	17 (89.5)	5.26 (1.17)	3.6	4.27	5.00	6.55	7.0	
			Placebo	20	18 (90.0)	4.61 (1.43)	1.1	3.91	4.73	5.64	6.9	
		Week 24	Tezepelumab	19	17 (89.5)	5.32 (1.18)	3.5	4.45	4.91	6.55	7.0	
			Placebo	20	18 (90.0)	4.56 (1.48)	1.1	3.91	4.59	5.55	6.9	
		Week 28	Tezepelumab	19	18 (94.7)	5.26 (1.11)	3.6	4.36	5.09	6.27	7.0	
			Placebo	20	19 (95.0)	4.58 (1.57)	1.1	3.27	4.64	5.73	6.9	
		Week 32	Tezepelumab	19	18 (94.7)	5.30 (1.09)	3.9	4.27	5.23	6.45	7.0	
			Placebo	20	19 (95.0)	4.82 (1.46)	1.1	4.00	5.09	5.91	7.0	
		Week 36	Tezepelumab	19	18 (94.7)	5.27 (1.18)	3.8	4.09	5.41	6.55	7.0	
			Placebo	20	19 (95.0)	4.77 (1.32)	2.4	3.91	4.64	6.00	6.9	
		Week 40	Tezepelumab	19	18 (94.7)	5.18 (1.14)	3.7	4.18	5.05	6.45	7.0	
			Placebo	20	19 (95.0)	4.83 (1.37)	2.5	3.91	5.09	6.09	6.9	
		Week 44	Tezepelumab	19	18 (94.7)	5.17 (1.18)	3.8	4.00	4.95	6.36	7.0	
			Placebo	20	19 (95.0)	4.92 (1.28)	2.9	4.00	5.09	5.91	6.9	
		Week 48	Tezepelumab	19	18 (94.7)	5.24 (1.14)	3.8	4.18	5.18	6.55	7.0	
			Placebo	20	19 (95.0)	4.76 (1.30)	2.4	3.91	4.73	5.73	6.8	
		Week 52	Tezepelumab	19	18 (94.7)	5.11 (1.11)	3.5	4.18	4.91	6.00	7.0	
			Placebo	20	19 (95.0)	4.85 (1.19)	2.9	3.91	4.73	5.73	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	19	15 (78.9)	1.00 (0.86)	-0.3	0.45	0.82	1.73	2.7	0.43 [-0.29, 1.14]
			Placebo	20	16 (80.0)	0.62 (0.93)	-0.7	0.00	0.36	1.64	2.1	
		Week 8	Tezepelumab	19	15 (78.9)	1.16 (0.91)	-0.4	0.45	1.18	1.82	2.9	0.72 [0.00, 1.44]
			Placebo	20	17 (85.0)	0.54 (0.82)	-0.5	-0.18	0.36	1.00	2.4	
		Week 12	Tezepelumab	19	15 (78.9)	1.42 (0.76)	0.3	0.91	1.18	1.73	3.0	0.88 [0.15, 1.60]
			Placebo	20	17 (85.0)	0.73 (0.82)	-1.0	0.18	0.73	1.18	2.4	
		Week 16	Tezepelumab	19	15 (78.9)	1.48 (0.81)	0.5	0.73	1.27	2.36	3.0	0.91 [0.18, 1.64]
			Placebo	20	17 (85.0)	0.49 (1.30)	-3.2	0.09	0.55	0.91	2.4	
		Week 20	Tezepelumab	19	15 (78.9)	1.39 (0.95)	0.3	0.73	1.00	2.36	3.3	0.75 [0.03, 1.47]
			Placebo	20	17 (85.0)	0.55 (1.24)	-3.2	0.18	0.73	0.82	2.4	
		Week 24	Tezepelumab	19	15 (78.9)	1.56 (0.88)	0.3	0.73	1.27	2.36	3.0	0.91 [0.18, 1.64]
			Placebo	20	17 (85.0)	0.48 (1.41)	-3.2	0.00	0.55	1.45	2.4	
		Week 28	Tezepelumab	19	15 (78.9)	1.53 (0.86)	0.0	0.73	1.27	2.27	3.0	0.96 [0.22, 1.69]
			Placebo	20	17 (85.0)	0.39 (1.41)	-3.2	-0.27	0.82	1.18	2.4	
		Week 32	Tezepelumab	19	15 (78.9)	1.50 (0.87)	0.3	0.91	1.27	2.36	3.2	0.81 [0.09, 1.54]
			Placebo	20	17 (85.0)	0.60 (1.27)	-3.2	0.00	0.82	1.55	2.4	
		Week 36	Tezepelumab	19	15 (78.9)	1.48 (0.97)	-0.1	0.73	1.27	2.36	3.0	0.90 [0.17, 1.63]
			Placebo	20	17 (85.0)	0.56 (1.06)	-1.8	0.18	0.73	1.00	2.4	
		Week 40	Tezepelumab	19	15 (78.9)	1.39 (0.90)	-0.2	0.91	1.18	2.36	3.0	0.70 [-0.01, 1.42]
			Placebo	20	17 (85.0)	0.66 (1.15)	-1.4	0.00	0.73	1.64	2.4	
		Week 44	Tezepelumab	19	15 (78.9)	1.38 (0.97)	0.2	0.55	1.09	2.36	3.2	0.67 [-0.05, 1.38]
			Placebo	20	17 (85.0)	0.70 (1.06)	-1.4	0.00	0.82	1.64	2.4	
		Week 48	Tezepelumab	19	15 (78.9)	1.47 (0.88)	0.4	0.82	1.18	2.36	3.2	0.94 [0.20, 1.67]
			Placebo	20	17 (85.0)	0.54 (1.07)	-1.5	0.09	0.55	1.18	2.4	
		Week 52	Tezepelumab	19	15 (78.9)	1.31 (0.99)	0.0	0.55	1.09	2.45	3.3	0.68 [-0.03, 1.40]
			Placebo	20	17 (85.0)	0.65 (0.95)	-1.4	0.09	0.55	1.18	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	47	42 (89.4)	4.20 (0.99)	2.1	3.73	4.18	4.64	6.3	
			Placebo	45	38 (84.4)	4.41 (0.77)	3.2	3.91	4.36	4.82	6.2	
		Week 4	Tezepelumab	47	43 (91.5)	4.83 (1.07)	1.6	4.09	4.91	5.73	6.9	
			Placebo	45	40 (88.9)	4.79 (0.97)	3.2	4.09	4.55	5.41	7.0	
		Week 8	Tezepelumab	47	45 (95.7)	5.15 (1.07)	2.9	4.27	5.27	6.09	6.8	
			Placebo	45	41 (91.1)	4.96 (1.11)	2.3	4.18	4.82	5.64	7.0	
		Week 12	Tezepelumab	47	45 (95.7)	5.38 (1.08)	3.0	4.73	5.27	6.36	7.0	
			Placebo	45	41 (91.1)	5.07 (1.10)	3.2	4.27	4.91	6.00	7.0	
		Week 16	Tezepelumab	47	45 (95.7)	5.30 (1.07)	2.8	4.36	5.27	6.18	7.0	
			Placebo	45	41 (91.1)	5.23 (1.12)	2.9	4.45	5.09	6.09	7.0	
		Week 20	Tezepelumab	47	46 (97.9)	5.25 (1.10)	2.8	4.27	5.27	6.27	7.0	
			Placebo	45	41 (91.1)	5.06 (1.15)	2.1	4.27	4.91	6.09	7.0	
		Week 24	Tezepelumab	47	46 (97.9)	5.31 (1.06)	2.9	4.27	5.32	6.18	7.0	
			Placebo	45	41 (91.1)	5.11 (1.14)	2.0	4.27	5.18	6.00	7.0	
		Week 28	Tezepelumab	47	47 (100.0)	5.29 (1.08)	2.9	4.45	5.27	6.27	7.0	
			Placebo	45	41 (91.1)	5.18 (1.22)	2.0	4.36	5.09	6.00	7.0	
		Week 32	Tezepelumab	47	47 (100.0)	5.35 (1.10)	2.9	4.45	5.64	6.18	7.0	
			Placebo	45	41 (91.1)	5.15 (1.17)	1.7	4.27	5.09	6.09	7.0	
		Week 36	Tezepelumab	47	47 (100.0)	5.41 (1.03)	3.0	4.55	5.45	6.18	7.0	
			Placebo	45	41 (91.1)	5.08 (1.17)	2.5	4.09	5.00	6.00	7.0	
		Week 40	Tezepelumab	47	47 (100.0)	5.41 (1.03)	3.3	4.64	5.18	6.18	7.0	
			Placebo	45	41 (91.1)	5.14 (1.24)	2.0	4.09	5.18	6.18	7.0	
		Week 44	Tezepelumab	47	47 (100.0)	5.41 (1.03)	3.0	4.55	5.45	6.27	7.0	
			Placebo	45	41 (91.1)	5.14 (1.18)	2.5	4.27	5.18	6.27	7.0	
		Week 48	Tezepelumab	47	47 (100.0)	5.45 (1.08)	2.6	4.73	5.64	6.36	7.0	
			Placebo	45	41 (91.1)	5.14 (1.17)	2.3	4.27	5.00	6.09	7.0	
		Week 52	Tezepelumab	47	47 (100.0)	5.50 (1.08)	2.6	4.73	5.64	6.45	7.0	
			Placebo	45	41 (91.1)	5.19 (1.15)	3.5	4.18	5.00	6.09	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	47	40 (85.1)	0.67 (1.04)	-2.8	0.00	0.59	1.41	3.1	0.32 [-0.12, 0.77]
			Placebo	45	38 (84.4)	0.37 (0.83)	-1.5	0.00	0.36	0.64	2.5	
		Week 8	Tezepelumab	47	42 (89.4)	0.90 (1.01)	-1.3	0.18	0.86	1.55	3.7	0.31 [-0.13, 0.75]
			Placebo	45	38 (84.4)	0.60 (0.93)	-1.3	0.00	0.55	1.27	2.6	
		Week 12	Tezepelumab	47	42 (89.4)	1.12 (1.08)	-1.5	0.36	1.05	1.73	4.2	0.44 [-0.01, 0.88]
			Placebo	45	38 (84.4)	0.66 (1.04)	-1.3	0.00	0.73	1.27	3.3	
		Week 16	Tezepelumab	47	42 (89.4)	1.03 (1.05)	-1.6	0.36	0.86	1.64	3.5	0.14 [-0.30, 0.58]
			Placebo	45	38 (84.4)	0.89 (0.96)	-1.6	0.36	0.91	1.55	3.5	
		Week 20	Tezepelumab	47	42 (89.4)	1.01 (1.10)	-0.9	0.18	0.91	1.91	3.5	0.28 [-0.16, 0.72]
			Placebo	45	38 (84.4)	0.72 (0.94)	-1.6	0.18	0.64	1.45	2.5	
		Week 24	Tezepelumab	47	42 (89.4)	1.09 (1.06)	-0.7	0.27	0.77	1.82	3.5	0.32 [-0.12, 0.76]
			Placebo	45	38 (84.4)	0.77 (0.99)	-1.6	0.09	0.82	1.36	2.9	
		Week 28	Tezepelumab	47	42 (89.4)	1.05 (1.08)	-0.8	0.09	0.82	2.00	3.5	0.20 [-0.24, 0.64]
			Placebo	45	38 (84.4)	0.83 (1.09)	-1.6	0.27	0.86	1.36	3.7	
		Week 32	Tezepelumab	47	42 (89.4)	1.09 (1.09)	-0.7	0.27	0.82	1.91	3.5	0.24 [-0.20, 0.68]
			Placebo	45	38 (84.4)	0.83 (1.05)	-1.8	0.36	0.82	1.45	3.3	
		Week 36	Tezepelumab	47	42 (89.4)	1.16 (1.09)	-0.7	0.36	0.91	1.73	3.5	0.39 [-0.05, 0.83]
			Placebo	45	38 (84.4)	0.75 (1.01)	-1.6	0.09	0.82	1.36	2.7	
		Week 40	Tezepelumab	47	42 (89.4)	1.16 (1.07)	-0.9	0.36	1.05	1.91	3.5	0.32 [-0.12, 0.76]
			Placebo	45	38 (84.4)	0.82 (1.10)	-1.6	0.18	0.77	1.45	3.5	
		Week 44	Tezepelumab	47	42 (89.4)	1.18 (1.09)	-0.7	0.27	1.05	1.91	3.5	0.34 [-0.10, 0.79]
			Placebo	45	38 (84.4)	0.79 (1.15)	-1.6	0.27	0.68	1.45	3.4	
		Week 48	Tezepelumab	47	42 (89.4)	1.24 (1.09)	-0.7	0.36	1.23	2.00	3.5	0.42 [-0.03, 0.86]
			Placebo	45	38 (84.4)	0.79 (1.06)	-1.6	0.09	0.82	1.27	3.2	
		Week 52	Tezepelumab	47	42 (89.4)	1.26 (1.06)	-0.7	0.55	1.23	1.91	3.5	0.37 [-0.07, 0.82]
			Placebo	45	38 (84.4)	0.87 (1.08)	-1.6	0.09	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.14 (0.96)	2.1	3.64	4.14	4.64	6.3	
			Placebo	55	48 (87.3)	4.36 (0.80)	2.3	3.91	4.27	4.77	6.2	
		Week 4	Tezepelumab	57	52 (91.2)	4.89 (1.11)	1.6	4.14	5.05	5.77	6.9	
			Placebo	55	49 (89.1)	4.88 (1.02)	2.5	4.09	4.64	5.64	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.20 (1.11)	2.9	4.27	5.36	6.09	6.9	
			Placebo	55	51 (92.7)	4.95 (1.09)	2.3	4.09	4.82	5.82	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.47 (1.06)	3.0	4.73	5.27	6.45	7.0	
			Placebo	55	51 (92.7)	5.15 (1.08)	2.8	4.27	5.18	6.00	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.38 (1.09)	2.8	4.55	5.45	6.45	7.0	
			Placebo	55	51 (92.7)	5.15 (1.26)	1.1	4.36	5.09	6.27	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.36 (1.12)	2.8	4.55	5.27	6.36	7.0	
			Placebo	55	51 (92.7)	5.06 (1.24)	1.1	4.18	5.00	6.18	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.37 (1.12)	2.9	4.27	5.36	6.27	7.0	
			Placebo	55	51 (92.7)	5.07 (1.25)	1.1	4.18	5.18	6.00	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.36 (1.12)	2.9	4.41	5.41	6.36	7.0	
			Placebo	55	51 (92.7)	5.11 (1.33)	1.1	4.09	5.09	6.00	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.40 (1.13)	2.9	4.36	5.55	6.41	7.0	
			Placebo	55	51 (92.7)	5.15 (1.21)	1.1	4.27	5.36	6.00	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.42 (1.11)	3.0	4.41	5.55	6.45	7.0	
			Placebo	55	51 (92.7)	5.07 (1.19)	2.4	4.09	5.09	6.09	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.39 (1.10)	3.3	4.36	5.27	6.27	7.0	
			Placebo	55	51 (92.7)	5.18 (1.23)	2.5	4.09	5.18	6.18	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.38 (1.11)	3.0	4.45	5.41	6.36	7.0	
			Placebo	55	51 (92.7)	5.18 (1.18)	2.9	4.09	5.27	6.27	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.42 (1.14)	2.6	4.32	5.45	6.45	7.0	
			Placebo	55	51 (92.7)	5.12 (1.19)	2.4	4.18	5.09	6.09	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.41 (1.14)	2.6	4.41	5.41	6.45	7.0	
			Placebo	55	51 (92.7)	5.18 (1.16)	2.9	4.18	5.09	6.09	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	57	47 (82.5)	0.78 (1.06)	-2.8	0.00	0.82	1.55	3.1	0.28 [-0.13, 0.68]
			Placebo	55	47 (85.5)	0.51 (0.89)	-1.5	0.09	0.36	1.09	2.5	
		Week 8	Tezepelumab	57	49 (86.0)	1.01 (1.02)	-1.3	0.36	0.91	1.64	3.7	0.40 [-0.01, 0.80]
			Placebo	55	48 (87.3)	0.62 (0.93)	-1.3	-0.09	0.59	1.23	2.6	
		Week 12	Tezepelumab	57	49 (86.0)	1.31 (1.04)	-1.5	0.82	1.27	1.82	4.2	0.51 [0.10, 0.91]
			Placebo	55	48 (87.3)	0.80 (0.98)	-1.3	0.18	0.91	1.27	3.3	
		Week 16	Tezepelumab	57	49 (86.0)	1.23 (1.05)	-1.6	0.45	1.27	1.91	3.5	0.35 [-0.05, 0.76]
			Placebo	55	48 (87.3)	0.85 (1.10)	-3.2	0.32	0.86	1.64	3.5	
		Week 20	Tezepelumab	57	49 (86.0)	1.23 (1.07)	-0.9	0.55	1.18	2.00	3.5	0.45 [0.05, 0.86]
			Placebo	55	48 (87.3)	0.75 (1.05)	-3.2	0.23	0.73	1.45	2.5	
		Week 24	Tezepelumab	57	49 (86.0)	1.28 (1.06)	-0.7	0.55	1.27	2.00	3.5	0.47 [0.07, 0.87]
			Placebo	55	48 (87.3)	0.76 (1.15)	-3.2	0.14	0.82	1.50	2.9	
		Week 28	Tezepelumab	57	49 (86.0)	1.26 (1.07)	-0.8	0.55	1.27	2.00	3.5	0.40 [-0.00, 0.80]
			Placebo	55	48 (87.3)	0.80 (1.22)	-3.2	0.27	0.86	1.50	3.7	
		Week 32	Tezepelumab	57	49 (86.0)	1.28 (1.09)	-0.7	0.45	1.09	2.27	3.5	0.39 [-0.02, 0.79]
			Placebo	55	48 (87.3)	0.86 (1.10)	-3.2	0.41	0.86	1.55	3.3	
		Week 36	Tezepelumab	57	49 (86.0)	1.32 (1.12)	-0.7	0.64	1.27	2.36	3.5	0.51 [0.10, 0.91]
			Placebo	55	48 (87.3)	0.77 (1.02)	-1.8	0.23	0.82	1.45	2.7	
		Week 40	Tezepelumab	57	49 (86.0)	1.27 (1.06)	-0.9	0.55	1.18	2.00	3.5	0.35 [-0.05, 0.76]
			Placebo	55	48 (87.3)	0.89 (1.09)	-1.6	0.27	0.82	1.68	3.5	
		Week 44	Tezepelumab	57	49 (86.0)	1.29 (1.10)	-0.7	0.45	1.27	2.36	3.5	0.38 [-0.03, 0.78]
			Placebo	55	48 (87.3)	0.87 (1.13)	-1.6	0.27	0.86	1.68	3.4	
		Week 48	Tezepelumab	57	49 (86.0)	1.33 (1.08)	-0.7	0.45	1.27	2.36	3.5	0.49 [0.08, 0.89]
			Placebo	55	48 (87.3)	0.81 (1.08)	-1.6	0.14	0.82	1.41	3.2	
		Week 52	Tezepelumab	57	49 (86.0)	1.31 (1.08)	-0.7	0.55	1.27	2.36	3.5	0.40 [-0.00, 0.80]
			Placebo	55	48 (87.3)	0.88 (1.06)	-1.6	0.14	0.82	1.59	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.11 (0.29)	3.5	4.05	4.09	4.27	4.5	
			Placebo	10	7 (70.0)	4.01 (0.57)	3.4	3.45	4.00	4.64	4.6	
		Week 4	Tezepelumab	9	8 (88.9)	4.78 (0.67)	3.8	4.23	4.86	5.27	5.7	
			Placebo	10	8 (80.0)	3.97 (0.72)	3.3	3.41	3.77	4.45	5.2	
		Week 8	Tezepelumab	9	8 (88.9)	4.81 (0.77)	4.0	4.05	4.82	5.27	6.2	
			Placebo	10	8 (80.0)	4.23 (0.78)	2.8	3.91	4.14	4.77	5.4	
		Week 12	Tezepelumab	9	8 (88.9)	4.66 (0.56)	3.9	4.18	4.73	5.00	5.5	
			Placebo	10	8 (80.0)	3.89 (0.53)	3.4	3.45	3.73	4.27	4.8	
		Week 16	Tezepelumab	9	8 (88.9)	4.80 (0.65)	3.9	4.14	5.00	5.36	5.5	
			Placebo	10	8 (80.0)	4.25 (0.88)	2.9	3.82	4.00	4.86	5.7	
		Week 20	Tezepelumab	9	9 (100.0)	4.58 (0.82)	3.5	3.91	4.45	5.09	5.8	
			Placebo	10	8 (80.0)	4.08 (1.01)	2.1	3.77	4.05	4.77	5.4	
		Week 24	Tezepelumab	9	9 (100.0)	4.99 (0.83)	3.9	4.36	4.91	5.55	6.4	
			Placebo	10	8 (80.0)	4.13 (1.11)	2.0	3.68	4.14	4.82	5.7	
		Week 28	Tezepelumab	9	9 (100.0)	4.79 (0.63)	4.0	4.45	4.73	4.91	6.0	
			Placebo	10	9 (90.0)	4.29 (1.41)	2.0	3.73	3.91	4.64	6.7	
		Week 32	Tezepelumab	9	9 (100.0)	4.94 (0.70)	3.9	4.55	4.82	5.45	6.2	
			Placebo	10	9 (90.0)	4.45 (1.49)	1.7	4.00	4.09	4.55	7.0	
		Week 36	Tezepelumab	9	9 (100.0)	5.04 (0.63)	4.2	4.73	4.91	5.45	6.1	
			Placebo	10	9 (90.0)	4.49 (1.28)	2.5	3.82	4.45	4.55	6.9	
		Week 40	Tezepelumab	9	9 (100.0)	5.03 (0.72)	3.9	4.91	5.00	5.09	6.5	
			Placebo	10	9 (90.0)	4.27 (1.33)	2.0	3.91	4.09	4.64	6.9	
		Week 44	Tezepelumab	9	9 (100.0)	5.11 (0.76)	3.9	4.82	4.91	5.45	6.4	
			Placebo	10	9 (90.0)	4.47 (1.25)	2.5	3.91	4.09	4.91	6.9	
		Week 48	Tezepelumab	9	9 (100.0)	5.25 (0.78)	3.9	4.91	5.45	5.73	6.5	
			Placebo	10	9 (90.0)	4.45 (1.30)	2.3	3.82	4.27	4.82	6.8	
		Week 52	Tezepelumab	9	9 (100.0)	5.23 (0.76)	4.0	4.91	5.18	5.73	6.5	
			Placebo	10	9 (90.0)	4.55 (1.11)	3.6	3.91	4.09	4.45	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	0.67 (0.47)	-0.2	0.41	0.73	1.00	1.3	1.35 [0.21, 2.49]
			Placebo	10	7 (70.0)	-0.00 (0.52)	-1.0	-0.27	0.00	0.45	0.5	
		Week 8	Tezepelumab	9	8 (88.9)	0.69 (0.65)	-0.1	0.14	0.64	1.14	1.8	0.74 [-0.32, 1.79]
			Placebo	10	7 (70.0)	0.26 (0.50)	-0.7	0.00	0.45	0.64	0.7	
		Week 12	Tezepelumab	9	8 (88.9)	0.55 (0.42)	-0.1	0.36	0.36	0.91	1.2	1.67 [0.47, 2.88]
			Placebo	10	7 (70.0)	-0.13 (0.39)	-0.9	-0.27	0.00	0.18	0.2	
		Week 16	Tezepelumab	9	8 (88.9)	0.68 (0.49)	-0.1	0.32	0.68	1.09	1.4	0.83 [-0.23, 1.89]
			Placebo	10	7 (70.0)	0.19 (0.68)	-0.7	-0.64	0.45	0.64	1.1	
		Week 20	Tezepelumab	9	8 (88.9)	0.34 (0.71)	-0.6	-0.23	0.27	0.91	1.5	0.34 [-0.68, 1.36]
			Placebo	10	7 (70.0)	0.09 (0.76)	-1.5	-0.09	0.18	0.73	0.7	
		Week 24	Tezepelumab	9	8 (88.9)	0.81 (0.70)	0.0	0.32	0.64	1.27	2.0	0.95 [-0.13, 2.03]
			Placebo	10	7 (70.0)	0.09 (0.80)	-1.5	0.00	0.27	0.45	1.1	
		Week 28	Tezepelumab	9	8 (88.9)	0.68 (0.63)	-0.1	0.23	0.64	0.95	1.9	0.91 [-0.16, 1.99]
			Placebo	10	7 (70.0)	-0.01 (0.89)	-1.5	-0.27	-0.18	0.55	1.4	
		Week 32	Tezepelumab	9	8 (88.9)	0.67 (0.46)	0.1	0.32	0.59	1.05	1.4	0.77 [-0.28, 1.83]
			Placebo	10	7 (70.0)	0.06 (1.04)	-1.8	-0.36	0.00	0.64	1.5	
		Week 36	Tezepelumab	9	8 (88.9)	0.80 (0.47)	0.2	0.50	0.77	0.95	1.7	0.96 [-0.12, 2.04]
			Placebo	10	7 (70.0)	0.14 (0.86)	-1.0	-0.73	0.00	1.00	1.4	
		Week 40	Tezepelumab	9	8 (88.9)	0.91 (0.68)	0.3	0.36	0.82	1.14	2.4	1.23 [0.11, 2.35]
			Placebo	10	7 (70.0)	-0.06 (0.90)	-1.5	-1.00	0.00	0.73	0.7	
		Week 44	Tezepelumab	9	8 (88.9)	0.89 (0.66)	0.3	0.32	0.86	1.09	2.3	1.22 [0.11, 2.34]
			Placebo	10	7 (70.0)	0.05 (0.71)	-1.1	-0.73	0.27	0.64	0.7	
		Week 48	Tezepelumab	9	8 (88.9)	1.08 (0.69)	0.3	0.59	1.00	1.36	2.5	1.44 [0.28, 2.59]
			Placebo	10	7 (70.0)	0.06 (0.72)	-1.3	-0.18	0.18	0.45	1.1	
		Week 52	Tezepelumab	9	8 (88.9)	1.06 (0.70)	0.3	0.55	0.95	1.36	2.5	1.29 [0.16, 2.42]
			Placebo	10	7 (70.0)	0.21 (0.61)	-0.8	-0.18	0.36	0.55	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	44	39 (88.6)	4.14 (0.88)	2.1	3.73	4.09	4.55	6.3	
			Placebo	45	38 (84.4)	4.36 (0.79)	2.3	3.91	4.32	4.73	6.2	
		Week 4	Tezepelumab	44	40 (90.9)	4.89 (0.96)	3.1	4.14	5.05	5.68	6.8	
			Placebo	45	39 (86.7)	4.86 (1.10)	2.5	3.91	4.82	5.64	7.0	
		Week 8	Tezepelumab	44	41 (93.2)	5.15 (1.06)	2.9	4.27	5.18	6.00	6.9	
			Placebo	45	40 (88.9)	4.97 (1.06)	2.8	4.09	4.73	5.77	7.0	
		Week 12	Tezepelumab	44	41 (93.2)	5.33 (1.02)	3.4	4.73	5.09	6.27	7.0	
			Placebo	45	40 (88.9)	5.00 (1.12)	3.2	4.14	5.05	5.73	7.0	
		Week 16	Tezepelumab	44	41 (93.2)	5.24 (1.07)	3.4	4.36	5.09	6.27	7.0	
			Placebo	45	40 (88.9)	5.08 (1.16)	2.9	4.00	4.91	6.18	7.0	
		Week 20	Tezepelumab	44	42 (95.5)	5.19 (1.11)	2.8	4.27	5.05	6.18	7.0	
			Placebo	45	40 (88.9)	5.07 (1.18)	2.1	4.14	4.95	6.23	7.0	
		Week 24	Tezepelumab	44	42 (95.5)	5.29 (1.12)	2.9	4.27	5.23	6.27	7.0	
			Placebo	45	40 (88.9)	5.09 (1.22)	2.0	4.09	5.18	6.00	7.0	
		Week 28	Tezepelumab	44	43 (97.7)	5.18 (1.12)	2.9	4.27	5.18	6.00	7.0	
			Placebo	45	41 (91.1)	5.12 (1.26)	2.0	4.27	5.09	6.00	7.0	
		Week 32	Tezepelumab	44	43 (97.7)	5.27 (1.14)	2.9	4.36	5.18	6.18	7.0	
			Placebo	45	41 (91.1)	5.17 (1.22)	1.7	4.27	5.27	6.00	7.0	
		Week 36	Tezepelumab	44	43 (97.7)	5.31 (1.10)	3.0	4.36	5.45	6.18	7.0	
			Placebo	45	41 (91.1)	5.19 (1.17)	2.5	4.18	5.18	6.09	7.0	
		Week 40	Tezepelumab	44	43 (97.7)	5.30 (1.08)	3.3	4.36	5.09	6.27	7.0	
			Placebo	45	41 (91.1)	5.18 (1.26)	2.0	4.18	5.18	6.18	7.0	
		Week 44	Tezepelumab	44	43 (97.7)	5.28 (1.11)	3.0	4.36	5.36	6.36	7.0	
			Placebo	45	41 (91.1)	5.21 (1.20)	2.5	4.09	5.27	6.00	7.0	
		Week 48	Tezepelumab	44	43 (97.7)	5.32 (1.15)	2.6	4.27	5.36	6.36	7.0	
			Placebo	45	41 (91.1)	5.16 (1.22)	2.3	4.27	5.09	6.09	7.0	
		Week 52	Tezepelumab	44	43 (97.7)	5.30 (1.12)	2.6	4.36	5.18	6.27	7.0	
			Placebo	45	41 (91.1)	5.19 (1.18)	3.1	4.09	5.00	6.09	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	44	37 (84.1)	0.77 (0.83)	-0.7	0.00	0.55	1.36	3.1	0.30 [-0.15, 0.76]
			Placebo	45	38 (84.4)	0.50 (0.91)	-1.2	0.00	0.36	1.09	2.5	
		Week 8	Tezepelumab	44	38 (86.4)	0.97 (0.90)	-0.5	0.36	0.86	1.55	3.7	0.39 [-0.06, 0.85]
			Placebo	45	38 (84.4)	0.63 (0.85)	-0.7	0.00	0.55	1.00	2.6	
		Week 12	Tezepelumab	44	38 (86.4)	1.19 (0.92)	-0.5	0.64	1.00	1.55	4.2	0.61 [0.15, 1.07]
			Placebo	45	38 (84.4)	0.65 (0.87)	-1.2	0.09	0.68	1.18	2.5	
		Week 16	Tezepelumab	44	38 (86.4)	1.12 (0.93)	-0.3	0.36	0.91	1.82	3.5	0.41 [-0.04, 0.87]
			Placebo	45	38 (84.4)	0.77 (0.82)	-0.7	0.27	0.59	1.18	2.5	
		Week 20	Tezepelumab	44	38 (86.4)	1.10 (1.01)	-0.9	0.55	0.95	1.73	3.5	0.35 [-0.10, 0.80]
			Placebo	45	38 (84.4)	0.77 (0.85)	-1.5	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	44	38 (86.4)	1.25 (0.97)	-0.4	0.55	1.18	1.91	3.5	0.50 [0.05, 0.96]
			Placebo	45	38 (84.4)	0.76 (0.99)	-1.5	0.09	0.64	1.36	2.5	
		Week 28	Tezepelumab	44	38 (86.4)	1.15 (1.01)	-0.3	0.36	0.86	2.00	3.5	0.41 [-0.04, 0.87]
			Placebo	45	38 (84.4)	0.74 (0.98)	-1.5	0.09	0.82	1.36	2.5	
		Week 32	Tezepelumab	44	38 (86.4)	1.18 (1.03)	-0.5	0.36	1.00	1.91	3.5	0.39 [-0.07, 0.84]
			Placebo	45	38 (84.4)	0.80 (0.93)	-1.8	0.27	0.82	1.45	2.6	
		Week 36	Tezepelumab	44	38 (86.4)	1.23 (1.05)	-0.3	0.64	1.00	1.91	3.5	0.41 [-0.04, 0.87]
			Placebo	45	38 (84.4)	0.83 (0.87)	-1.0	0.27	0.82	1.36	2.6	
		Week 40	Tezepelumab	44	38 (86.4)	1.26 (0.95)	-0.3	0.64	1.09	1.91	3.5	0.46 [0.00, 0.92]
			Placebo	45	38 (84.4)	0.82 (0.96)	-1.5	0.27	0.77	1.45	2.6	
		Week 44	Tezepelumab	44	38 (86.4)	1.21 (1.00)	-0.3	0.55	1.00	1.91	3.5	0.40 [-0.05, 0.86]
			Placebo	45	38 (84.4)	0.82 (0.93)	-1.1	0.27	0.68	1.55	2.7	
		Week 48	Tezepelumab	44	38 (86.4)	1.26 (0.99)	-0.6	0.64	1.05	2.00	3.5	0.50 [0.05, 0.96]
			Placebo	45	38 (84.4)	0.78 (0.92)	-1.3	0.18	0.82	1.27	2.8	
		Week 52	Tezepelumab	44	38 (86.4)	1.24 (0.98)	-0.6	0.64	1.00	1.91	3.5	0.44 [-0.02, 0.89]
			Placebo	45	38 (84.4)	0.83 (0.88)	-0.8	0.27	0.82	1.27	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	22	19 (86.4)	4.11 (0.94)	2.4	3.64	4.09	4.64	5.9	
			Placebo	20	17 (85.0)	4.21 (0.76)	3.2	3.82	4.00	4.45	6.0	
		Week 4	Tezepelumab	22	20 (90.9)	4.85 (1.28)	1.6	4.09	4.68	5.82	6.9	
			Placebo	20	18 (90.0)	4.51 (0.82)	3.2	4.00	4.50	5.36	5.8	
		Week 8	Tezepelumab	22	21 (95.5)	5.16 (1.13)	3.3	4.09	5.27	6.09	6.6	
			Placebo	20	19 (95.0)	4.61 (1.10)	2.3	3.91	4.73	5.45	6.7	
		Week 12	Tezepelumab	22	21 (95.5)	5.44 (1.11)	3.0	4.64	5.27	6.45	7.0	
			Placebo	20	19 (95.0)	4.94 (1.11)	2.8	3.91	4.73	6.00	6.5	
		Week 16	Tezepelumab	22	21 (95.5)	5.44 (1.05)	2.8	5.00	5.55	6.18	7.0	
			Placebo	20	19 (95.0)	4.92 (1.44)	1.1	4.36	5.27	6.00	7.0	
		Week 20	Tezepelumab	22	21 (95.5)	5.35 (1.12)	3.5	4.27	5.27	6.27	7.0	
			Placebo	20	19 (95.0)	4.61 (1.35)	1.1	3.91	4.45	5.82	6.7	
		Week 24	Tezepelumab	22	21 (95.5)	5.35 (1.05)	3.8	4.45	5.18	6.09	7.0	
			Placebo	20	19 (95.0)	4.62 (1.34)	1.1	4.09	4.45	5.55	6.9	
		Week 28	Tezepelumab	22	22 (100.0)	5.47 (1.00)	3.6	4.82	5.36	6.36	7.0	
			Placebo	20	19 (95.0)	4.70 (1.54)	1.1	3.64	5.09	6.00	7.0	
		Week 32	Tezepelumab	22	22 (100.0)	5.48 (0.99)	3.9	4.82	5.55	6.36	7.0	
			Placebo	20	19 (95.0)	4.78 (1.35)	1.1	4.09	4.82	6.00	6.5	
		Week 36	Tezepelumab	22	22 (100.0)	5.50 (1.00)	3.7	4.91	5.55	6.36	6.8	
			Placebo	20	19 (95.0)	4.55 (1.22)	2.4	3.91	4.45	5.82	6.5	
		Week 40	Tezepelumab	22	22 (100.0)	5.43 (1.03)	3.5	4.82	5.27	6.18	7.0	
			Placebo	20	19 (95.0)	4.76 (1.30)	2.5	3.91	4.36	6.00	6.8	
		Week 44	Tezepelumab	22	22 (100.0)	5.46 (0.99)	3.8	4.91	5.36	6.27	7.0	
			Placebo	20	19 (95.0)	4.78 (1.19)	2.9	3.55	4.91	5.64	6.6	
		Week 48	Tezepelumab	22	22 (100.0)	5.54 (0.99)	3.8	4.91	5.73	6.45	6.9	
			Placebo	20	19 (95.0)	4.71 (1.18)	2.4	3.82	4.55	5.64	6.6	
		Week 52	Tezepelumab	22	22 (100.0)	5.56 (1.03)	3.5	4.91	5.73	6.45	7.0	
			Placebo	20	19 (95.0)	4.84 (1.13)	2.9	3.91	4.55	5.91	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	22	18 (81.8)	0.75 (1.29)	-2.8	0.00	0.86	1.55	2.7	0.42 [-0.26, 1.10]
			Placebo	20	16 (80.0)	0.30 (0.75)	-1.5	-0.00	0.32	0.59	1.7	
		Week 8	Tezepelumab	22	19 (86.4)	0.97 (1.16)	-1.3	0.09	1.36	1.64	2.9	0.46 [-0.21, 1.12]
			Placebo	20	17 (85.0)	0.47 (0.99)	-1.3	-0.18	0.73	1.00	2.2	
		Week 12	Tezepelumab	22	19 (86.4)	1.22 (1.19)	-1.5	0.36	1.45	1.82	3.0	0.39 [-0.27, 1.05]
			Placebo	20	17 (85.0)	0.75 (1.20)	-1.3	0.00	0.91	1.27	3.3	
		Week 16	Tezepelumab	22	19 (86.4)	1.21 (1.17)	-1.6	0.55	1.45	1.91	3.0	0.33 [-0.33, 0.99]
			Placebo	20	17 (85.0)	0.76 (1.54)	-3.2	0.64	1.00	1.73	3.5	
		Week 20	Tezepelumab	22	19 (86.4)	1.13 (1.22)	-0.7	0.27	1.27	2.18	3.3	0.54 [-0.13, 1.21]
			Placebo	20	17 (85.0)	0.43 (1.36)	-3.2	-0.45	0.91	1.27	2.1	
		Week 24	Tezepelumab	22	19 (86.4)	1.15 (1.16)	-0.7	0.27	1.09	2.36	3.0	0.51 [-0.16, 1.17]
			Placebo	20	17 (85.0)	0.49 (1.42)	-3.2	0.09	0.82	1.45	2.9	
		Week 28	Tezepelumab	22	19 (86.4)	1.23 (1.12)	-0.8	0.64	1.27	2.36	3.0	0.46 [-0.20, 1.12]
			Placebo	20	17 (85.0)	0.60 (1.63)	-3.2	-0.18	0.91	1.18	3.7	
		Week 32	Tezepelumab	22	19 (86.4)	1.22 (1.12)	-0.7	0.55	1.00	2.27	3.2	0.44 [-0.23, 1.10]
			Placebo	20	17 (85.0)	0.66 (1.47)	-3.2	0.55	0.91	1.55	3.3	
		Week 36	Tezepelumab	22	19 (86.4)	1.29 (1.13)	-0.7	0.45	1.64	2.36	3.0	0.75 [0.07, 1.42]
			Placebo	20	17 (85.0)	0.40 (1.27)	-1.8	0.00	0.73	1.09	2.7	
		Week 40	Tezepelumab	22	19 (86.4)	1.15 (1.17)	-0.9	0.36	1.09	2.45	3.0	0.38 [-0.28, 1.04]
			Placebo	20	17 (85.0)	0.66 (1.41)	-1.6	-0.18	0.64	1.64	3.5	
		Week 44	Tezepelumab	22	19 (86.4)	1.27 (1.19)	-0.7	0.36	1.27	2.55	3.2	0.48 [-0.19, 1.14]
			Placebo	20	17 (85.0)	0.64 (1.47)	-1.6	-0.45	0.82	1.27	3.4	
		Week 48	Tezepelumab	22	19 (86.4)	1.37 (1.14)	-0.7	0.45	1.55	2.36	3.2	0.65 [-0.03, 1.32]
			Placebo	20	17 (85.0)	0.56 (1.36)	-1.6	0.00	0.45	1.27	3.2	
		Week 52	Tezepelumab	22	19 (86.4)	1.35 (1.15)	-0.7	0.36	1.55	2.36	3.3	0.50 [-0.17, 1.16]
			Placebo	20	17 (85.0)	0.73 (1.35)	-1.6	0.09	0.45	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	4.14 (0.86)	2.1	3.64	4.09	4.55	6.3	
			Placebo	58	48 (82.8)	4.36 (0.78)	2.3	3.91	4.27	4.68	6.2	
		Week 4	Tezepelumab	60	54 (90.0)	4.81 (1.06)	1.6	4.00	4.91	5.64	6.8	
			Placebo	58	50 (86.2)	4.79 (1.06)	2.5	4.00	4.59	5.64	7.0	
		Week 8	Tezepelumab	60	56 (93.3)	5.09 (1.09)	2.9	4.14	5.18	6.09	6.9	
			Placebo	58	52 (89.7)	4.88 (1.06)	2.8	4.09	4.68	5.64	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.30 (1.03)	3.0	4.64	5.09	6.27	7.0	
			Placebo	58	52 (89.7)	4.94 (1.11)	2.8	4.09	4.86	5.77	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.27 (1.07)	2.8	4.36	5.14	6.23	7.0	
			Placebo	58	52 (89.7)	5.00 (1.25)	1.1	4.09	4.91	6.00	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.18 (1.12)	2.8	4.27	5.09	6.18	7.0	
			Placebo	58	52 (89.7)	4.96 (1.27)	1.1	4.09	4.82	6.14	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.25 (1.10)	2.9	4.27	5.18	6.27	7.0	
			Placebo	58	52 (89.7)	4.93 (1.31)	1.1	4.09	5.05	5.77	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.20 (1.06)	2.9	4.36	5.18	6.00	7.0	
			Placebo	58	53 (91.4)	4.92 (1.37)	1.1	3.91	5.09	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.29 (1.10)	2.9	4.36	5.18	6.18	7.0	
			Placebo	58	53 (91.4)	4.99 (1.30)	1.1	4.09	5.00	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.31 (1.07)	3.0	4.36	5.45	6.09	7.0	
			Placebo	58	53 (91.4)	5.00 (1.24)	2.4	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.29 (1.08)	3.3	4.36	5.09	6.27	7.0	
			Placebo	58	53 (91.4)	5.03 (1.30)	2.0	4.00	5.09	6.09	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.30 (1.08)	3.0	4.36	5.27	6.27	7.0	
			Placebo	58	53 (91.4)	5.05 (1.19)	2.5	4.09	5.09	5.91	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.34 (1.11)	2.6	4.27	5.18	6.45	7.0	
			Placebo	58	53 (91.4)	4.97 (1.23)	2.3	4.00	4.91	6.00	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.33 (1.11)	2.6	4.36	5.18	6.45	7.0	
			Placebo	58	53 (91.4)	5.04 (1.16)	2.9	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	60	49 (81.7)	0.69 (0.96)	-2.8	0.00	0.64	1.36	2.7	0.27 [-0.13, 0.67]
			Placebo	58	47 (81.0)	0.44 (0.91)	-1.5	0.00	0.36	0.91	2.5	
		Week 8	Tezepelumab	60	51 (85.0)	0.90 (0.93)	-1.3	0.27	0.91	1.55	2.9	0.36 [-0.04, 0.76]
			Placebo	58	48 (82.8)	0.57 (0.88)	-1.3	-0.05	0.50	1.00	2.6	
		Week 12	Tezepelumab	60	51 (85.0)	1.13 (0.94)	-1.5	0.45	1.09	1.73	3.0	0.57 [0.17, 0.97]
			Placebo	58	48 (82.8)	0.59 (0.94)	-1.3	0.05	0.50	1.18	2.5	
		Week 16	Tezepelumab	60	51 (85.0)	1.10 (0.96)	-1.6	0.36	1.09	1.64	3.0	0.41 [0.01, 0.81]
			Placebo	58	48 (82.8)	0.69 (1.05)	-3.2	0.23	0.68	1.36	2.5	
		Week 20	Tezepelumab	60	51 (85.0)	1.02 (1.04)	-0.9	0.36	0.91	1.73	3.3	0.34 [-0.05, 0.74]
			Placebo	58	48 (82.8)	0.66 (1.06)	-3.2	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	60	51 (85.0)	1.15 (0.99)	-0.7	0.36	1.09	1.82	3.0	0.49 [0.09, 0.89]
			Placebo	58	48 (82.8)	0.62 (1.15)	-3.2	0.09	0.64	1.41	2.5	
		Week 28	Tezepelumab	60	51 (85.0)	1.09 (0.99)	-0.8	0.36	0.91	1.91	3.0	0.47 [0.07, 0.87]
			Placebo	58	48 (82.8)	0.58 (1.17)	-3.2	-0.18	0.82	1.27	2.5	
		Week 32	Tezepelumab	60	51 (85.0)	1.13 (1.01)	-0.7	0.36	1.00	1.91	3.2	0.45 [0.05, 0.85]
			Placebo	58	48 (82.8)	0.65 (1.11)	-3.2	0.05	0.73	1.41	2.6	
		Week 36	Tezepelumab	60	51 (85.0)	1.17 (1.04)	-0.7	0.36	1.00	1.91	3.2	0.49 [0.09, 0.89]
			Placebo	58	48 (82.8)	0.67 (1.01)	-1.8	0.09	0.73	1.23	2.6	
		Week 40	Tezepelumab	60	51 (85.0)	1.16 (0.98)	-0.9	0.36	1.09	1.91	3.0	0.44 [0.04, 0.84]
			Placebo	58	48 (82.8)	0.70 (1.09)	-1.6	0.09	0.73	1.55	2.6	
		Week 44	Tezepelumab	60	51 (85.0)	1.17 (1.01)	-0.7	0.36	1.09	1.91	3.2	0.48 [0.08, 0.88]
			Placebo	58	48 (82.8)	0.70 (1.01)	-1.6	0.18	0.68	1.36	2.7	
		Week 48	Tezepelumab	60	51 (85.0)	1.23 (1.01)	-0.7	0.45	1.18	2.00	3.2	0.61 [0.21, 1.02]
			Placebo	58	48 (82.8)	0.61 (1.01)	-1.6	0.09	0.64	1.23	2.8	
		Week 52	Tezepelumab	60	51 (85.0)	1.21 (1.00)	-0.7	0.55	1.18	1.91	3.3	0.51 [0.11, 0.91]
			Placebo	58	48 (82.8)	0.70 (0.96)	-1.6	0.09	0.68	1.27	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	3.59 (1.99)	2.2	2.18	3.59	5.00	5.0	
			Placebo	2	2 (100.0)	3.82 (0.51)	3.5	3.45	3.82	4.18	4.2	
		Week 4	Tezepelumab	2	2 (100.0)	6.09 (1.16)	5.3	5.27	6.09	6.91	6.9	
			Placebo	2	2 (100.0)	4.45 (0.26)	4.3	4.27	4.45	4.64	4.6	
		Week 8	Tezepelumab	2	2 (100.0)	6.18 (0.39)	5.9	5.91	6.18	6.45	6.5	
			Placebo	2	2 (100.0)	4.91 (1.03)	4.2	4.18	4.91	5.64	5.6	
		Week 12	Tezepelumab	2	2 (100.0)	6.41 (0.06)	6.4	6.36	6.41	6.45	6.5	
			Placebo	2	2 (100.0)	4.73 (1.80)	3.5	3.45	4.73	6.00	6.0	
		Week 16	Tezepelumab	2	2 (100.0)	5.59 (0.06)	5.5	5.55	5.59	5.64	5.6	
			Placebo	2	2 (100.0)	4.50 (2.12)	3.0	3.00	4.50	6.00	6.0	
		Week 20	Tezepelumab	2	2 (100.0)	5.95 (0.45)	5.6	5.64	5.95	6.27	6.3	
			Placebo	2	2 (100.0)	4.41 (1.99)	3.0	3.00	4.41	5.82	5.8	
		Week 24	Tezepelumab	2	2 (100.0)	5.86 (0.32)	5.6	5.64	5.86	6.09	6.1	
			Placebo	2	2 (100.0)	4.95 (1.22)	4.1	4.09	4.95	5.82	5.8	
		Week 28	Tezepelumab	2	2 (100.0)	6.32 (0.96)	5.6	5.64	6.32	7.00	7.0	
			Placebo	2	2 (100.0)	4.95 (1.22)	4.1	4.09	4.95	5.82	5.8	
		Week 32	Tezepelumab	2	2 (100.0)	5.73 (0.13)	5.6	5.64	5.73	5.82	5.8	
			Placebo	2	2 (100.0)	4.95 (1.22)	4.1	4.09	4.95	5.82	5.8	
		Week 36	Tezepelumab	2	2 (100.0)	6.00 (0.51)	5.6	5.64	6.00	6.36	6.4	
			Placebo	2	2 (100.0)	4.95 (1.22)	4.1	4.09	4.95	5.82	5.8	
		Week 40	Tezepelumab	2	2 (100.0)	5.55 (0.13)	5.5	5.45	5.55	5.64	5.6	
			Placebo	2	2 (100.0)	4.95 (1.22)	4.1	4.09	4.95	5.82	5.8	
		Week 44	Tezepelumab	2	2 (100.0)	5.55 (0.13)	5.5	5.45	5.55	5.64	5.6	
			Placebo	2	2 (100.0)	6.50 (0.19)	6.4	6.36	6.50	6.64	6.6	
		Week 48	Tezepelumab	2	2 (100.0)	5.95 (0.45)	5.6	5.64	5.95	6.27	6.3	
			Placebo	2	2 (100.0)	6.55 (0.13)	6.5	6.45	6.55	6.64	6.6	
		Week 52	Tezepelumab	2	2 (100.0)	5.95 (0.45)	5.6	5.64	5.95	6.27	6.3	
			Placebo	2	2 (100.0)	6.73 (0.39)	6.5	6.45	6.73	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	2	2 (100.0)	2.50 (0.84)	1.9	1.91	2.50	3.09	3.1	3.01 [-0.53, 6.56]
			Placebo	2	2 (100.0)	0.64 (0.26)	0.5	0.45	0.64	0.82	0.8	
		Week 8	Tezepelumab	2	2 (100.0)	2.59 (1.61)	1.5	1.45	2.59	3.73	3.7	1.26 [-1.06, 3.57]
			Placebo	2	2 (100.0)	1.09 (0.51)	0.7	0.73	1.09	1.45	1.5	
		Week 12	Tezepelumab	2	2 (100.0)	2.82 (1.93)	1.5	1.45	2.82	4.18	4.2	1.16 [-1.10, 3.43]
			Placebo	2	2 (100.0)	0.91 (1.29)	0.0	0.00	0.91	1.82	1.8	
		Week 16	Tezepelumab	2	2 (100.0)	2.00 (2.06)	0.5	0.55	2.00	3.45	3.5	0.71 [-1.37, 2.80]
			Placebo	2	2 (100.0)	0.68 (1.61)	-0.5	-0.45	0.68	1.82	1.8	
		Week 20	Tezepelumab	2	2 (100.0)	2.36 (1.54)	1.3	1.27	2.36	3.45	3.5	1.17 [-1.10, 3.45]
			Placebo	2	2 (100.0)	0.59 (1.48)	-0.5	-0.45	0.59	1.64	1.6	
		Week 24	Tezepelumab	2	2 (100.0)	2.27 (1.67)	1.1	1.09	2.27	3.45	3.5	0.89 [-1.26, 3.03]
			Placebo	2	2 (100.0)	1.14 (0.71)	0.6	0.64	1.14	1.64	1.6	
		Week 28	Tezepelumab	2	2 (100.0)	2.73 (1.03)	2.0	2.00	2.73	3.45	3.5	1.80 [-0.84, 4.44]
			Placebo	2	2 (100.0)	1.14 (0.71)	0.6	0.64	1.14	1.64	1.6	
		Week 32	Tezepelumab	2	2 (100.0)	2.14 (1.86)	0.8	0.82	2.14	3.45	3.5	0.71 [-1.37, 2.79]
			Placebo	2	2 (100.0)	1.14 (0.71)	0.6	0.64	1.14	1.64	1.6	
		Week 36	Tezepelumab	2	2 (100.0)	2.41 (1.48)	1.4	1.36	2.41	3.45	3.5	1.10 [-1.14, 3.33]
			Placebo	2	2 (100.0)	1.14 (0.71)	0.6	0.64	1.14	1.64	1.6	
		Week 40	Tezepelumab	2	2 (100.0)	1.95 (2.12)	0.5	0.45	1.95	3.45	3.5	0.52 [-1.51, 2.54]
			Placebo	2	2 (100.0)	1.14 (0.71)	0.6	0.64	1.14	1.64	1.6	
		Week 44	Tezepelumab	2	2 (100.0)	1.95 (2.12)	0.5	0.45	1.95	3.45	3.5	-0.46 [-2.47, 1.55]
			Placebo	2	2 (100.0)	2.68 (0.71)	2.2	2.18	2.68	3.18	3.2	
		Week 48	Tezepelumab	2	2 (100.0)	2.36 (1.54)	1.3	1.27	2.36	3.45	3.5	-0.31 [-2.29, 1.68]
			Placebo	2	2 (100.0)	2.73 (0.64)	2.3	2.27	2.73	3.18	3.2	
		Week 52	Tezepelumab	2	2 (100.0)	2.36 (1.54)	1.3	1.27	2.36	3.45	3.5	-0.43 [-2.44, 1.57]
			Placebo	2	2 (100.0)	2.91 (0.90)	2.3	2.27	2.91	3.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	4.58 (1.12)	3.6	3.64	4.27	5.82	5.8	
			Placebo	3	3 (100.0)	4.58 (0.45)	4.3	4.27	4.36	5.09	5.1	
		Week 4	Tezepelumab	3	3 (100.0)	5.48 (0.82)	4.5	4.55	5.82	6.09	6.1	
			Placebo	3	3 (100.0)	5.09 (0.48)	4.5	4.55	5.27	5.45	5.5	
		Week 8	Tezepelumab	3	3 (100.0)	5.85 (0.55)	5.3	5.27	5.91	6.36	6.4	
			Placebo	3	3 (100.0)	4.94 (0.73)	4.2	4.18	5.00	5.64	5.6	
		Week 12	Tezepelumab	3	3 (100.0)	6.27 (0.96)	5.2	5.18	6.64	7.00	7.0	
			Placebo	3	3 (100.0)	5.58 (0.32)	5.3	5.27	5.55	5.91	5.9	
		Week 16	Tezepelumab	3	3 (100.0)	6.24 (0.73)	5.5	5.55	6.18	7.00	7.0	
			Placebo	3	3 (100.0)	5.61 (0.61)	4.9	4.91	5.91	6.00	6.0	
		Week 20	Tezepelumab	3	3 (100.0)	6.33 (0.68)	5.6	5.64	6.36	7.00	7.0	
			Placebo	3	3 (100.0)	4.88 (0.97)	3.8	3.82	5.09	5.73	5.7	
		Week 24	Tezepelumab	3	3 (100.0)	6.36 (0.55)	6.0	6.00	6.09	7.00	7.0	
			Placebo	3	3 (100.0)	5.00 (0.96)	4.1	4.09	4.91	6.00	6.0	
		Week 28	Tezepelumab	3	3 (100.0)	6.45 (0.51)	6.0	6.00	6.36	7.00	7.0	
			Placebo	3	3 (100.0)	5.76 (1.05)	4.6	4.64	5.91	6.73	6.7	
		Week 32	Tezepelumab	3	3 (100.0)	6.42 (0.55)	5.9	5.91	6.36	7.00	7.0	
			Placebo	3	3 (100.0)	5.85 (0.37)	5.5	5.45	5.91	6.18	6.2	
		Week 36	Tezepelumab	3	3 (100.0)	6.52 (0.50)	6.0	6.00	6.55	7.00	7.0	
			Placebo	3	3 (100.0)	4.67 (1.41)	3.3	3.27	4.64	6.09	6.1	
		Week 40	Tezepelumab	3	3 (100.0)	6.36 (0.55)	6.0	6.00	6.09	7.00	7.0	
			Placebo	3	3 (100.0)	5.18 (1.14)	4.1	4.09	5.09	6.36	6.4	
		Week 44	Tezepelumab	3	3 (100.0)	6.45 (0.51)	6.0	6.00	6.36	7.00	7.0	
			Placebo	3	3 (100.0)	4.27 (1.07)	3.4	3.36	4.00	5.45	5.5	
		Week 48	Tezepelumab	3	3 (100.0)	6.39 (0.53)	6.0	6.00	6.18	7.00	7.0	
			Placebo	3	3 (100.0)	4.94 (1.19)	3.8	3.82	4.82	6.18	6.2	
		Week 52	Tezepelumab	3	3 (100.0)	6.39 (0.53)	6.0	6.00	6.18	7.00	7.0	
			Placebo	3	3 (100.0)	4.94 (1.19)	3.8	3.82	4.82	6.18	6.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	0.91 (0.91)	0.0	0.00	0.91	1.82	1.8	0.54 [-1.11, 2.18]
			Placebo	3	3 (100.0)	0.52 (0.50)	0.2	0.18	0.27	1.09	1.1	
		Week 8	Tezepelumab	3	3 (100.0)	1.27 (1.05)	0.1	0.09	1.64	2.09	2.1	1.11 [-0.66, 2.89]
			Placebo	3	3 (100.0)	0.36 (0.48)	-0.2	-0.18	0.55	0.73	0.7	
		Week 12	Tezepelumab	3	3 (100.0)	1.70 (0.96)	0.8	0.82	1.55	2.73	2.7	0.99 [-0.75, 2.73]
			Placebo	3	3 (100.0)	1.00 (0.24)	0.8	0.82	0.91	1.27	1.3	
		Week 16	Tezepelumab	3	3 (100.0)	1.67 (1.20)	0.4	0.36	1.91	2.73	2.7	0.67 [-1.00, 2.33]
			Placebo	3	3 (100.0)	1.03 (0.62)	0.5	0.55	0.82	1.73	1.7	
		Week 20	Tezepelumab	3	3 (100.0)	1.76 (1.11)	0.5	0.55	2.00	2.73	2.7	1.59 [-0.35, 3.54]
			Placebo	3	3 (100.0)	0.30 (0.66)	-0.5	-0.45	0.64	0.73	0.7	
		Week 24	Tezepelumab	3	3 (100.0)	1.79 (1.32)	0.3	0.27	2.36	2.73	2.7	1.34 [-0.51, 3.19]
			Placebo	3	3 (100.0)	0.42 (0.56)	-0.2	-0.18	0.55	0.91	0.9	
		Week 28	Tezepelumab	3	3 (100.0)	1.88 (1.17)	0.5	0.55	2.36	2.73	2.7	0.60 [-1.05, 2.26]
			Placebo	3	3 (100.0)	1.18 (1.14)	0.3	0.27	0.82	2.45	2.5	
		Week 32	Tezepelumab	3	3 (100.0)	1.85 (1.15)	0.5	0.55	2.27	2.73	2.7	0.63 [-1.03, 2.29]
			Placebo	3	3 (100.0)	1.27 (0.57)	0.8	0.82	1.09	1.91	1.9	
		Week 36	Tezepelumab	3	3 (100.0)	1.94 (1.07)	0.7	0.73	2.36	2.73	2.7	1.78 [-0.24, 3.80]
			Placebo	3	3 (100.0)	0.09 (1.01)	-1.0	-1.00	0.27	1.00	1.0	
		Week 40	Tezepelumab	3	3 (100.0)	1.79 (1.40)	0.2	0.18	2.45	2.73	2.7	1.06 [-0.70, 2.82]
			Placebo	3	3 (100.0)	0.61 (0.73)	-0.2	-0.18	0.73	1.27	1.3	
		Week 44	Tezepelumab	3	3 (100.0)	1.88 (1.47)	0.2	0.18	2.73	2.73	2.7	1.93 [-0.16, 4.01]
			Placebo	3	3 (100.0)	-0.30 (0.64)	-0.9	-0.91	-0.36	0.36	0.4	
		Week 48	Tezepelumab	3	3 (100.0)	1.82 (1.27)	0.4	0.36	2.36	2.73	2.7	1.38 [-0.48, 3.24]
			Placebo	3	3 (100.0)	0.36 (0.78)	-0.5	-0.45	0.45	1.09	1.1	
		Week 52	Tezepelumab	3	3 (100.0)	1.82 (1.27)	0.4	0.36	2.36	2.73	2.7	1.38 [-0.48, 3.24]
			Placebo	3	3 (100.0)	0.36 (0.78)	-0.5	-0.45	0.45	1.09	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	3.73	3.7	3.73	3.73	3.73	3.7	
			Placebo	2	2 (100.0)	3.23 (0.06)	3.2	3.18	3.23	3.27	3.3	
		Week 4	Tezepelumab	1	1 (100.0)	4.18	4.2	4.18	4.18	4.18	4.2	
			Placebo	2	2 (100.0)	3.50 (0.45)	3.2	3.18	3.50	3.82	3.8	
		Week 8	Tezepelumab	1	1 (100.0)	4.18	4.2	4.18	4.18	4.18	4.2	
			Placebo	2	2 (100.0)	3.86 (2.25)	2.3	2.27	3.86	5.45	5.5	
		Week 12	Tezepelumab	1	1 (100.0)	4.09	4.1	4.09	4.09	4.09	4.1	
			Placebo	2	2 (100.0)	5.41 (1.61)	4.3	4.27	5.41	6.55	6.5	
		Week 16	Tezepelumab	1	1 (100.0)	4.09	4.1	4.09	4.09	4.09	4.1	
			Placebo	2	2 (100.0)	5.41 (1.86)	4.1	4.09	5.41	6.73	6.7	
		Week 20	Tezepelumab	1	1 (100.0)	4.73	4.7	4.73	4.73	4.73	4.7	
			Placebo	2	2 (100.0)	4.64 (0.77)	4.1	4.09	4.64	5.18	5.2	
		Week 24	Tezepelumab	1	1 (100.0)	4.45	4.5	4.45	4.45	4.45	4.5	
			Placebo	2	2 (100.0)	5.14 (1.48)	4.1	4.09	5.14	6.18	6.2	
		Week 28	Tezepelumab	1	1 (100.0)	4.27	4.3	4.27	4.27	4.27	4.3	
			Placebo	2	2 (100.0)	5.55 (2.06)	4.1	4.09	5.55	7.00	7.0	
		Week 32	Tezepelumab	1	1 (100.0)	4.18	4.2	4.18	4.18	4.18	4.2	
			Placebo	2	2 (100.0)	5.32 (1.74)	4.1	4.09	5.32	6.55	6.5	
		Week 36	Tezepelumab	1	1 (100.0)	4.45	4.5	4.45	4.45	4.45	4.5	
			Placebo	2	2 (100.0)	5.05 (1.35)	4.1	4.09	5.05	6.00	6.0	
		Week 40	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	2	2 (100.0)	5.45 (1.93)	4.1	4.09	5.45	6.82	6.8	
		Week 44	Tezepelumab	1	1 (100.0)	4.45	4.5	4.45	4.45	4.45	4.5	
			Placebo	2	2 (100.0)	5.36 (1.80)	4.1	4.09	5.36	6.64	6.6	
		Week 48	Tezepelumab	1	1 (100.0)	4.73	4.7	4.73	4.73	4.73	4.7	
			Placebo	2	2 (100.0)	4.86 (1.09)	4.1	4.09	4.86	5.64	5.6	
		Week 52	Tezepelumab	1	1 (100.0)	4.73	4.7	4.73	4.73	4.73	4.7	
			Placebo	2	2 (100.0)	4.86 (1.09)	4.1	4.09	4.86	5.64	5.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	0.45	0.5	0.45	0.45	0.45	0.5	NE
			Placebo	2	2 (100.0)	0.27 (0.51)	-0.1	-0.09	0.27	0.64	0.6	
		Week 8	Tezepelumab	1	1 (100.0)	0.45	0.5	0.45	0.45	0.45	0.5	NE
			Placebo	2	2 (100.0)	0.64 (2.19)	-0.9	-0.91	0.64	2.18	2.2	
		Week 12	Tezepelumab	1	1 (100.0)	0.36	0.4	0.36	0.36	0.36	0.4	NE
			Placebo	2	2 (100.0)	2.18 (1.54)	1.1	1.09	2.18	3.27	3.3	
		Week 16	Tezepelumab	1	1 (100.0)	0.36	0.4	0.36	0.36	0.36	0.4	NE
			Placebo	2	2 (100.0)	2.18 (1.80)	0.9	0.91	2.18	3.45	3.5	
		Week 20	Tezepelumab	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	NE
			Placebo	2	2 (100.0)	1.41 (0.71)	0.9	0.91	1.41	1.91	1.9	
		Week 24	Tezepelumab	1	1 (100.0)	0.73	0.7	0.73	0.73	0.73	0.7	NE
			Placebo	2	2 (100.0)	1.91 (1.41)	0.9	0.91	1.91	2.91	2.9	
		Week 28	Tezepelumab	1	1 (100.0)	0.55	0.5	0.55	0.55	0.55	0.5	NE
			Placebo	2	2 (100.0)	2.32 (1.99)	0.9	0.91	2.32	3.73	3.7	
		Week 32	Tezepelumab	1	1 (100.0)	0.45	0.5	0.45	0.45	0.45	0.5	NE
			Placebo	2	2 (100.0)	2.09 (1.67)	0.9	0.91	2.09	3.27	3.3	
		Week 36	Tezepelumab	1	1 (100.0)	0.73	0.7	0.73	0.73	0.73	0.7	NE
			Placebo	2	2 (100.0)	1.82 (1.29)	0.9	0.91	1.82	2.73	2.7	
		Week 40	Tezepelumab	1	1 (100.0)	1.27	1.3	1.27	1.27	1.27	1.3	NE
			Placebo	2	2 (100.0)	2.23 (1.86)	0.9	0.91	2.23	3.55	3.5	
		Week 44	Tezepelumab	1	1 (100.0)	0.73	0.7	0.73	0.73	0.73	0.7	NE
			Placebo	2	2 (100.0)	2.14 (1.74)	0.9	0.91	2.14	3.36	3.4	
		Week 48	Tezepelumab	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	NE
			Placebo	2	2 (100.0)	1.64 (1.03)	0.9	0.91	1.64	2.36	2.4	
		Week 52	Tezepelumab	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	NE
			Placebo	2	2 (100.0)	1.64 (1.03)	0.9	0.91	1.64	2.36	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	40	36 (90.0)	4.13 (0.89)	2.1	3.59	4.14	4.50	6.3	
			Placebo	36	31 (86.1)	4.43 (0.80)	3.4	3.82	4.27	4.91	6.2	
		Week 4	Tezepelumab	40	37 (92.5)	4.71 (1.12)	1.6	4.00	4.55	5.36	6.8	
			Placebo	36	31 (86.1)	4.78 (1.03)	3.2	3.91	4.55	5.64	7.0	
		Week 8	Tezepelumab	40	38 (95.0)	5.06 (1.15)	2.9	4.09	5.00	6.09	6.9	
			Placebo	36	32 (88.9)	4.86 (1.06)	3.1	4.05	4.73	5.68	7.0	
		Week 12	Tezepelumab	40	38 (95.0)	5.25 (1.11)	3.0	4.36	5.09	6.27	7.0	
			Placebo	36	32 (88.9)	5.03 (1.09)	2.8	4.23	4.91	6.09	7.0	
		Week 16	Tezepelumab	40	38 (95.0)	5.17 (1.14)	2.8	4.27	5.05	6.27	7.0	
			Placebo	36	32 (88.9)	5.03 (1.32)	1.1	4.09	4.95	6.18	7.0	
		Week 20	Tezepelumab	40	39 (97.5)	5.16 (1.14)	2.8	4.27	5.18	6.09	7.0	
			Placebo	36	32 (88.9)	4.99 (1.29)	1.1	4.09	4.95	6.23	7.0	
		Week 24	Tezepelumab	40	39 (97.5)	5.23 (1.16)	2.9	4.27	5.00	6.27	7.0	
			Placebo	36	32 (88.9)	4.89 (1.33)	1.1	4.05	4.95	5.59	7.0	
		Week 28	Tezepelumab	40	40 (100.0)	5.18 (1.12)	2.9	4.32	5.05	6.00	7.0	
			Placebo	36	33 (91.7)	4.89 (1.42)	1.1	3.91	5.09	5.91	7.0	
		Week 32	Tezepelumab	40	40 (100.0)	5.23 (1.18)	2.9	4.27	5.18	6.18	7.0	
			Placebo	36	33 (91.7)	5.03 (1.27)	1.1	4.27	5.00	6.00	7.0	
		Week 36	Tezepelumab	40	40 (100.0)	5.29 (1.16)	3.0	4.32	5.45	6.14	7.0	
			Placebo	36	33 (91.7)	5.07 (1.23)	2.4	4.45	5.09	6.00	7.0	
		Week 40	Tezepelumab	40	40 (100.0)	5.34 (1.10)	3.3	4.36	5.18	6.23	7.0	
			Placebo	36	33 (91.7)	5.08 (1.28)	2.5	4.09	5.09	6.09	7.0	
		Week 44	Tezepelumab	40	40 (100.0)	5.33 (1.14)	3.0	4.32	5.36	6.32	7.0	
			Placebo	36	33 (91.7)	5.13 (1.16)	2.9	4.09	5.09	5.91	7.0	
		Week 48	Tezepelumab	40	40 (100.0)	5.29 (1.16)	2.6	4.32	5.18	6.41	7.0	
			Placebo	36	33 (91.7)	5.01 (1.23)	2.4	4.00	4.91	6.00	7.0	
		Week 52	Tezepelumab	40	40 (100.0)	5.26 (1.13)	2.6	4.36	5.18	6.32	7.0	
			Placebo	36	33 (91.7)	5.06 (1.18)	2.9	4.00	5.00	5.91	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	40	35 (87.5)	0.64 (1.01)	-2.8	0.00	0.55	1.45	2.5	0.28 [-0.21, 0.77]
			Placebo	36	30 (83.3)	0.38 (0.83)	-1.2	0.00	0.32	0.82	1.9	
		Week 8	Tezepelumab	40	36 (90.0)	0.90 (1.00)	-1.3	0.05	0.91	1.59	2.7	0.49 [0.00, 0.98]
			Placebo	36	31 (86.1)	0.46 (0.77)	-0.8	-0.18	0.36	1.00	2.3	
		Week 12	Tezepelumab	40	36 (90.0)	1.09 (1.01)	-1.5	0.41	1.14	1.73	2.8	0.49 [0.01, 0.98]
			Placebo	36	31 (86.1)	0.64 (0.80)	-1.0	0.09	0.55	1.18	2.4	
		Week 16	Tezepelumab	40	36 (90.0)	1.03 (1.02)	-1.6	0.32	1.05	1.73	2.8	0.41 [-0.07, 0.90]
			Placebo	36	31 (86.1)	0.61 (1.01)	-3.2	0.18	0.64	1.36	2.5	
		Week 20	Tezepelumab	40	36 (90.0)	1.02 (1.01)	-0.9	0.32	1.00	1.68	2.6	0.43 [-0.06, 0.92]
			Placebo	36	31 (86.1)	0.60 (0.96)	-3.2	0.18	0.55	1.27	2.5	
		Week 24	Tezepelumab	40	36 (90.0)	1.10 (1.02)	-0.7	0.27	1.18	1.77	3.0	0.59 [0.10, 1.08]
			Placebo	36	31 (86.1)	0.49 (1.08)	-3.2	0.09	0.45	1.36	2.5	
		Week 28	Tezepelumab	40	36 (90.0)	1.08 (1.00)	-0.8	0.50	1.00	1.86	2.9	0.61 [0.12, 1.10]
			Placebo	36	31 (86.1)	0.44 (1.10)	-3.2	-0.18	0.82	1.18	2.5	
		Week 32	Tezepelumab	40	36 (90.0)	1.09 (1.05)	-0.7	0.27	1.09	1.86	2.8	0.52 [0.03, 1.01]
			Placebo	36	31 (86.1)	0.56 (0.99)	-3.2	0.09	0.64	1.27	2.4	
		Week 36	Tezepelumab	40	36 (90.0)	1.17 (1.06)	-0.7	0.41	1.09	1.82	3.2	0.58 [0.09, 1.07]
			Placebo	36	31 (86.1)	0.60 (0.88)	-1.8	0.18	0.64	1.09	2.6	
		Week 40	Tezepelumab	40	36 (90.0)	1.24 (1.01)	-0.9	0.59	1.27	1.95	2.9	0.62 [0.13, 1.11]
			Placebo	36	31 (86.1)	0.63 (0.94)	-1.4	0.18	0.73	1.45	2.6	
		Week 44	Tezepelumab	40	36 (90.0)	1.22 (1.06)	-0.7	0.41	1.23	2.09	2.9	0.58 [0.09, 1.07]
			Placebo	36	31 (86.1)	0.66 (0.86)	-1.4	0.27	0.64	1.27	2.7	
		Week 48	Tezepelumab	40	36 (90.0)	1.20 (1.06)	-0.7	0.45	1.14	2.00	3.1	0.69 [0.19, 1.18]
			Placebo	36	31 (86.1)	0.53 (0.88)	-1.5	0.09	0.45	1.18	2.8	
		Week 52	Tezepelumab	40	36 (90.0)	1.17 (1.05)	-0.7	0.45	1.14	1.86	3.1	0.60 [0.11, 1.10]
			Placebo	36	31 (86.1)	0.60 (0.81)	-1.4	0.09	0.45	1.18	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	4.16 (1.75)	2.2	2.36	5.00	5.64	5.6	
			Placebo	4	3 (75.0)	4.09 (0.60)	3.5	3.45	4.18	4.64	4.6	
		Week 4	Tezepelumab	6	4 (66.7)	5.86 (0.75)	5.3	5.32	5.64	6.41	6.9	
			Placebo	4	3 (75.0)	5.21 (1.32)	4.3	4.27	4.64	6.73	6.7	
		Week 8	Tezepelumab	6	5 (83.3)	5.75 (1.11)	3.8	5.91	6.00	6.45	6.5	
			Placebo	4	3 (75.0)	5.61 (1.41)	4.2	4.18	5.64	7.00	7.0	
		Week 12	Tezepelumab	6	5 (83.3)	6.11 (0.68)	4.9	6.27	6.36	6.45	6.5	
			Placebo	4	3 (75.0)	5.48 (1.83)	3.5	3.45	6.00	7.00	7.0	
		Week 16	Tezepelumab	6	5 (83.3)	5.73 (0.60)	4.9	5.55	5.64	6.00	6.5	
			Placebo	4	3 (75.0)	5.30 (2.05)	3.0	3.00	6.00	6.91	6.9	
		Week 20	Tezepelumab	6	5 (83.3)	5.69 (0.56)	4.9	5.45	5.64	6.18	6.3	
			Placebo	4	3 (75.0)	5.24 (2.02)	3.0	3.00	5.82	6.91	6.9	
		Week 24	Tezepelumab	6	5 (83.3)	5.71 (0.50)	4.9	5.64	5.73	6.09	6.2	
			Placebo	4	3 (75.0)	5.61 (1.42)	4.1	4.09	5.82	6.91	6.9	
		Week 28	Tezepelumab	6	6 (100.0)	5.91 (0.70)	4.9	5.64	5.82	6.27	7.0	
			Placebo	4	3 (75.0)	5.61 (1.42)	4.1	4.09	5.82	6.91	6.9	
		Week 32	Tezepelumab	6	6 (100.0)	5.83 (0.57)	4.9	5.64	5.86	6.09	6.6	
			Placebo	4	3 (75.0)	5.52 (1.30)	4.1	4.09	5.82	6.64	6.6	
		Week 36	Tezepelumab	6	6 (100.0)	5.68 (0.50)	4.9	5.55	5.59	6.09	6.4	
			Placebo	4	3 (75.0)	5.42 (1.19)	4.1	4.09	5.82	6.36	6.4	
		Week 40	Tezepelumab	6	6 (100.0)	5.82 (0.64)	4.9	5.45	5.77	6.27	6.7	
			Placebo	4	3 (75.0)	5.55 (1.34)	4.1	4.09	5.82	6.73	6.7	
		Week 44	Tezepelumab	6	6 (100.0)	5.64 (0.47)	4.9	5.45	5.64	5.82	6.4	
			Placebo	4	3 (75.0)	6.58 (0.19)	6.4	6.36	6.64	6.73	6.7	
		Week 48	Tezepelumab	6	6 (100.0)	5.85 (0.55)	4.9	5.64	5.91	6.27	6.5	
			Placebo	4	3 (75.0)	6.58 (0.10)	6.5	6.45	6.64	6.64	6.6	
		Week 52	Tezepelumab	6	6 (100.0)	6.05 (0.68)	4.9	5.64	6.23	6.45	6.8	
			Placebo	4	3 (75.0)	6.70 (0.28)	6.5	6.45	6.64	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	6	4 (66.7)	1.25 (1.54)	-0.3	-0.00	1.09	2.50	3.1	0.10 [-1.40, 1.60]
			Placebo	4	3 (75.0)	1.12 (0.86)	0.5	0.45	0.82	2.09	2.1	
		Week 8	Tezepelumab	6	5 (83.3)	1.58 (1.28)	0.4	0.91	1.45	1.45	3.7	0.06 [-1.37, 1.49]
			Placebo	4	3 (75.0)	1.52 (0.82)	0.7	0.73	1.45	2.36	2.4	
		Week 12	Tezepelumab	6	5 (83.3)	1.95 (1.45)	0.6	0.91	1.45	2.55	4.2	0.40 [-1.05, 1.85]
			Placebo	4	3 (75.0)	1.39 (1.24)	0.0	0.00	1.82	2.36	2.4	
		Week 16	Tezepelumab	6	5 (83.3)	1.56 (1.36)	0.4	0.55	0.91	2.55	3.5	0.25 [-1.19, 1.69]
			Placebo	4	3 (75.0)	1.21 (1.46)	-0.5	-0.45	1.82	2.27	2.3	
		Week 20	Tezepelumab	6	5 (83.3)	1.53 (1.47)	-0.2	0.55	1.27	2.55	3.5	0.26 [-1.18, 1.70]
			Placebo	4	3 (75.0)	1.15 (1.43)	-0.5	-0.45	1.64	2.27	2.3	
		Week 24	Tezepelumab	6	5 (83.3)	1.55 (1.41)	0.1	0.55	1.09	2.55	3.5	0.02 [-1.41, 1.46]
			Placebo	4	3 (75.0)	1.52 (0.82)	0.6	0.64	1.64	2.27	2.3	
		Week 28	Tezepelumab	6	5 (83.3)	1.67 (1.46)	0.0	0.36	2.00	2.55	3.5	0.12 [-1.31, 1.56]
			Placebo	4	3 (75.0)	1.52 (0.82)	0.6	0.64	1.64	2.27	2.3	
		Week 32	Tezepelumab	6	5 (83.3)	1.51 (1.41)	0.3	0.45	0.82	2.55	3.5	0.07 [-1.36, 1.50]
			Placebo	4	3 (75.0)	1.42 (0.71)	0.6	0.64	1.64	2.00	2.0	
		Week 36	Tezepelumab	6	5 (83.3)	1.44 (1.58)	-0.1	-0.09	1.36	2.55	3.5	0.08 [-1.35, 1.51]
			Placebo	4	3 (75.0)	1.33 (0.61)	0.6	0.64	1.64	1.73	1.7	
		Week 40	Tezepelumab	6	5 (83.3)	1.47 (1.44)	0.3	0.45	0.64	2.55	3.5	0.01 [-1.42, 1.45]
			Placebo	4	3 (75.0)	1.45 (0.74)	0.6	0.64	1.64	2.09	2.1	
		Week 44	Tezepelumab	6	5 (83.3)	1.44 (1.49)	0.0	0.45	0.73	2.55	3.5	-0.83 [-2.34, 0.68]
			Placebo	4	3 (75.0)	2.48 (0.61)	2.1	2.09	2.18	3.18	3.2	
		Week 48	Tezepelumab	6	5 (83.3)	1.69 (1.28)	0.4	0.82	1.27	2.55	3.5	-0.72 [-2.21, 0.77]
			Placebo	4	3 (75.0)	2.48 (0.62)	2.0	2.00	2.27	3.18	3.2	
		Week 52	Tezepelumab	6	5 (83.3)	1.73 (1.23)	0.5	0.82	1.27	2.55	3.5	-0.79 [-2.29, 0.71]
			Placebo	4	3 (75.0)	2.61 (0.82)	2.0	2.00	2.27	3.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	4.58 (1.12)	3.6	3.64	4.27	5.82	5.8	
			Placebo	3	3 (100.0)	4.58 (0.45)	4.3	4.27	4.36	5.09	5.1	
		Week 4	Tezepelumab	3	3 (100.0)	5.48 (0.82)	4.5	4.55	5.82	6.09	6.1	
			Placebo	3	3 (100.0)	5.09 (0.48)	4.5	4.55	5.27	5.45	5.5	
		Week 8	Tezepelumab	3	3 (100.0)	5.85 (0.55)	5.3	5.27	5.91	6.36	6.4	
			Placebo	3	3 (100.0)	4.94 (0.73)	4.2	4.18	5.00	5.64	5.6	
		Week 12	Tezepelumab	3	3 (100.0)	6.27 (0.96)	5.2	5.18	6.64	7.00	7.0	
			Placebo	3	3 (100.0)	5.58 (0.32)	5.3	5.27	5.55	5.91	5.9	
		Week 16	Tezepelumab	3	3 (100.0)	6.24 (0.73)	5.5	5.55	6.18	7.00	7.0	
			Placebo	3	3 (100.0)	5.61 (0.61)	4.9	4.91	5.91	6.00	6.0	
		Week 20	Tezepelumab	3	3 (100.0)	6.33 (0.68)	5.6	5.64	6.36	7.00	7.0	
			Placebo	3	3 (100.0)	4.88 (0.97)	3.8	3.82	5.09	5.73	5.7	
		Week 24	Tezepelumab	3	3 (100.0)	6.36 (0.55)	6.0	6.00	6.09	7.00	7.0	
			Placebo	3	3 (100.0)	5.00 (0.96)	4.1	4.09	4.91	6.00	6.0	
		Week 28	Tezepelumab	3	3 (100.0)	6.45 (0.51)	6.0	6.00	6.36	7.00	7.0	
			Placebo	3	3 (100.0)	5.76 (1.05)	4.6	4.64	5.91	6.73	6.7	
		Week 32	Tezepelumab	3	3 (100.0)	6.42 (0.55)	5.9	5.91	6.36	7.00	7.0	
			Placebo	3	3 (100.0)	5.85 (0.37)	5.5	5.45	5.91	6.18	6.2	
		Week 36	Tezepelumab	3	3 (100.0)	6.52 (0.50)	6.0	6.00	6.55	7.00	7.0	
			Placebo	3	3 (100.0)	4.67 (1.41)	3.3	3.27	4.64	6.09	6.1	
		Week 40	Tezepelumab	3	3 (100.0)	6.36 (0.55)	6.0	6.00	6.09	7.00	7.0	
			Placebo	3	3 (100.0)	5.18 (1.14)	4.1	4.09	5.09	6.36	6.4	
		Week 44	Tezepelumab	3	3 (100.0)	6.45 (0.51)	6.0	6.00	6.36	7.00	7.0	
			Placebo	3	3 (100.0)	4.27 (1.07)	3.4	3.36	4.00	5.45	5.5	
		Week 48	Tezepelumab	3	3 (100.0)	6.39 (0.53)	6.0	6.00	6.18	7.00	7.0	
			Placebo	3	3 (100.0)	4.94 (1.19)	3.8	3.82	4.82	6.18	6.2	
		Week 52	Tezepelumab	3	3 (100.0)	6.39 (0.53)	6.0	6.00	6.18	7.00	7.0	
			Placebo	3	3 (100.0)	4.94 (1.19)	3.8	3.82	4.82	6.18	6.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	0.91 (0.91)	0.0	0.00	0.91	1.82	1.8	0.54 [-1.11, 2.18]
			Placebo	3	3 (100.0)	0.52 (0.50)	0.2	0.18	0.27	1.09	1.1	
		Week 8	Tezepelumab	3	3 (100.0)	1.27 (1.05)	0.1	0.09	1.64	2.09	2.1	1.11 [-0.66, 2.89]
			Placebo	3	3 (100.0)	0.36 (0.48)	-0.2	-0.18	0.55	0.73	0.7	
		Week 12	Tezepelumab	3	3 (100.0)	1.70 (0.96)	0.8	0.82	1.55	2.73	2.7	0.99 [-0.75, 2.73]
			Placebo	3	3 (100.0)	1.00 (0.24)	0.8	0.82	0.91	1.27	1.3	
		Week 16	Tezepelumab	3	3 (100.0)	1.67 (1.20)	0.4	0.36	1.91	2.73	2.7	0.67 [-1.00, 2.33]
			Placebo	3	3 (100.0)	1.03 (0.62)	0.5	0.55	0.82	1.73	1.7	
		Week 20	Tezepelumab	3	3 (100.0)	1.76 (1.11)	0.5	0.55	2.00	2.73	2.7	1.59 [-0.35, 3.54]
			Placebo	3	3 (100.0)	0.30 (0.66)	-0.5	-0.45	0.64	0.73	0.7	
		Week 24	Tezepelumab	3	3 (100.0)	1.79 (1.32)	0.3	0.27	2.36	2.73	2.7	1.34 [-0.51, 3.19]
			Placebo	3	3 (100.0)	0.42 (0.56)	-0.2	-0.18	0.55	0.91	0.9	
		Week 28	Tezepelumab	3	3 (100.0)	1.88 (1.17)	0.5	0.55	2.36	2.73	2.7	0.60 [-1.05, 2.26]
			Placebo	3	3 (100.0)	1.18 (1.14)	0.3	0.27	0.82	2.45	2.5	
		Week 32	Tezepelumab	3	3 (100.0)	1.85 (1.15)	0.5	0.55	2.27	2.73	2.7	0.63 [-1.03, 2.29]
			Placebo	3	3 (100.0)	1.27 (0.57)	0.8	0.82	1.09	1.91	1.9	
		Week 36	Tezepelumab	3	3 (100.0)	1.94 (1.07)	0.7	0.73	2.36	2.73	2.7	1.78 [-0.24, 3.80]
			Placebo	3	3 (100.0)	0.09 (1.01)	-1.0	-1.00	0.27	1.00	1.0	
		Week 40	Tezepelumab	3	3 (100.0)	1.79 (1.40)	0.2	0.18	2.45	2.73	2.7	1.06 [-0.70, 2.82]
			Placebo	3	3 (100.0)	0.61 (0.73)	-0.2	-0.18	0.73	1.27	1.3	
		Week 44	Tezepelumab	3	3 (100.0)	1.88 (1.47)	0.2	0.18	2.73	2.73	2.7	1.93 [-0.16, 4.01]
			Placebo	3	3 (100.0)	-0.30 (0.64)	-0.9	-0.91	-0.36	0.36	0.4	
		Week 48	Tezepelumab	3	3 (100.0)	1.82 (1.27)	0.4	0.36	2.36	2.73	2.7	1.38 [-0.48, 3.24]
			Placebo	3	3 (100.0)	0.36 (0.78)	-0.5	-0.45	0.45	1.09	1.1	
		Week 52	Tezepelumab	3	3 (100.0)	1.82 (1.27)	0.4	0.36	2.36	2.73	2.7	1.38 [-0.48, 3.24]
			Placebo	3	3 (100.0)	0.36 (0.78)	-0.5	-0.45	0.45	1.09	1.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	17	14 (82.4)	4.05 (0.42)	3.3	3.73	4.05	4.55	4.6	
			Placebo	22	18 (81.8)	4.11 (0.80)	2.3	3.91	4.00	4.45	6.0	
		Week 4	Tezepelumab	17	16 (94.1)	4.90 (0.92)	3.3	4.09	4.91	5.55	6.5	
			Placebo	22	20 (90.9)	4.58 (1.08)	2.5	3.91	4.55	5.41	6.9	
		Week 8	Tezepelumab	17	16 (94.1)	5.05 (0.91)	3.3	4.59	5.05	5.68	6.6	
			Placebo	22	21 (95.5)	4.72 (1.12)	2.3	4.18	4.64	5.45	7.0	
		Week 12	Tezepelumab	17	16 (94.1)	5.25 (0.86)	3.9	4.68	5.00	5.86	6.7	
			Placebo	22	21 (95.5)	4.75 (1.10)	3.2	4.00	4.73	5.45	6.8	
		Week 16	Tezepelumab	17	16 (94.1)	5.34 (0.94)	3.9	4.82	5.18	5.95	7.0	
			Placebo	22	21 (95.5)	4.92 (1.13)	2.9	4.09	4.91	5.73	6.7	
		Week 20	Tezepelumab	17	16 (94.1)	5.11 (1.13)	3.5	4.27	4.73	6.32	7.0	
			Placebo	22	21 (95.5)	4.79 (1.18)	2.1	4.09	4.73	5.73	6.7	
		Week 24	Tezepelumab	17	16 (94.1)	5.20 (1.04)	3.5	4.50	5.05	6.05	6.9	
			Placebo	22	21 (95.5)	4.91 (1.25)	2.0	4.09	5.18	5.82	6.9	
		Week 28	Tezepelumab	17	16 (94.1)	5.09 (1.00)	3.6	4.27	4.91	5.86	6.7	
			Placebo	22	21 (95.5)	4.94 (1.31)	2.0	4.09	4.91	6.00	7.0	
		Week 32	Tezepelumab	17	16 (94.1)	5.21 (0.98)	3.9	4.41	4.86	6.23	6.9	
			Placebo	22	21 (95.5)	4.89 (1.33)	1.7	4.09	4.64	6.00	7.0	
		Week 36	Tezepelumab	17	16 (94.1)	5.24 (0.96)	3.8	4.50	4.95	6.05	6.7	
			Placebo	22	21 (95.5)	4.84 (1.24)	2.5	4.00	4.64	6.00	6.7	
		Week 40	Tezepelumab	17	16 (94.1)	4.98 (1.01)	3.7	4.09	4.91	5.27	6.9	
			Placebo	22	21 (95.5)	4.90 (1.35)	2.0	4.00	4.91	5.73	6.9	
		Week 44	Tezepelumab	17	16 (94.1)	5.07 (1.00)	3.8	4.32	4.86	5.45	6.9	
			Placebo	22	21 (95.5)	4.87 (1.23)	2.5	4.00	4.64	5.82	6.8	
		Week 48	Tezepelumab	17	16 (94.1)	5.29 (1.07)	3.9	4.23	5.18	6.09	7.0	
			Placebo	22	21 (95.5)	4.82 (1.18)	2.3	4.09	4.73	5.73	6.8	
		Week 52	Tezepelumab	17	16 (94.1)	5.27 (1.05)	4.0	4.23	5.18	6.09	7.0	
			Placebo	22	21 (95.5)	4.90 (1.11)	3.1	4.09	4.73	5.73	6.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	17	13 (76.5)	0.90 (0.83)	-0.7	0.45	0.82	1.27	2.7	0.53 [-0.20, 1.25]
			Placebo	22	18 (81.8)	0.42 (0.97)	-1.5	-0.09	0.41	0.64	2.5	
		Week 8	Tezepelumab	17	13 (76.5)	0.85 (0.78)	-0.4	0.45	0.73	1.09	2.9	0.19 [-0.52, 0.91]
			Placebo	22	18 (81.8)	0.67 (1.08)	-1.3	0.00	0.68	1.18	2.6	
		Week 12	Tezepelumab	17	13 (76.5)	1.11 (0.74)	0.4	0.73	0.91	1.36	3.0	0.49 [-0.23, 1.22]
			Placebo	22	18 (81.8)	0.59 (1.25)	-1.3	-0.18	0.59	1.18	3.3	
		Week 16	Tezepelumab	17	13 (76.5)	1.20 (0.80)	0.2	0.64	1.09	1.45	3.0	0.28 [-0.44, 1.00]
			Placebo	22	18 (81.8)	0.90 (1.21)	-1.6	0.27	0.95	1.64	3.5	
		Week 20	Tezepelumab	17	13 (76.5)	1.04 (1.11)	-0.6	0.36	0.82	1.73	3.3	0.23 [-0.48, 0.95]
			Placebo	22	18 (81.8)	0.77 (1.18)	-1.6	0.00	0.86	1.82	2.4	
		Week 24	Tezepelumab	17	13 (76.5)	1.27 (0.87)	0.4	0.64	0.82	1.91	3.0	0.32 [-0.40, 1.04]
			Placebo	22	18 (81.8)	0.90 (1.28)	-1.6	0.27	0.95	1.82	2.9	
		Week 28	Tezepelumab	17	13 (76.5)	1.10 (0.95)	-0.1	0.45	0.82	1.82	3.0	0.14 [-0.57, 0.86]
			Placebo	22	18 (81.8)	0.93 (1.38)	-1.6	0.18	0.95	1.82	3.7	
		Week 32	Tezepelumab	17	13 (76.5)	1.22 (0.92)	0.1	0.64	0.82	1.91	3.2	0.26 [-0.46, 0.98]
			Placebo	22	18 (81.8)	0.90 (1.37)	-1.8	0.00	1.05	1.55	3.3	
		Week 36	Tezepelumab	17	13 (76.5)	1.23 (0.92)	-0.1	0.73	0.91	1.73	3.0	0.34 [-0.38, 1.06]
			Placebo	22	18 (81.8)	0.85 (1.26)	-1.6	0.00	0.95	1.82	2.7	
		Week 40	Tezepelumab	17	13 (76.5)	0.94 (0.82)	-0.2	0.36	0.82	1.09	3.0	0.02 [-0.69, 0.73]
			Placebo	22	18 (81.8)	0.91 (1.42)	-1.6	0.00	0.95	1.73	3.5	
		Week 44	Tezepelumab	17	13 (76.5)	1.04 (0.82)	0.2	0.55	0.82	1.27	3.2	0.17 [-0.54, 0.89]
			Placebo	22	18 (81.8)	0.84 (1.33)	-1.6	0.00	0.86	1.91	3.4	
		Week 48	Tezepelumab	17	13 (76.5)	1.29 (0.87)	0.1	0.82	1.18	1.64	3.2	0.46 [-0.27, 1.18]
			Placebo	22	18 (81.8)	0.79 (1.21)	-1.6	0.00	0.95	1.73	2.5	
		Week 52	Tezepelumab	17	13 (76.5)	1.28 (0.89)	0.1	0.64	1.18	1.64	3.3	0.34 [-0.38, 1.06]
			Placebo	22	18 (81.8)	0.92 (1.18)	-1.6	0.09	0.95	2.00	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	4.29 (1.07)	2.2	3.64	4.05	4.64	6.3	
			Placebo	21	17 (81.0)	4.35 (0.93)	2.3	3.73	4.27	5.09	5.9	
		Week 4	Tezepelumab	15	13 (86.7)	5.27 (0.89)	4.0	4.55	5.36	5.82	6.8	
			Placebo	21	19 (90.5)	4.68 (1.08)	2.5	3.82	4.64	5.45	7.0	
		Week 8	Tezepelumab	15	14 (93.3)	5.78 (0.91)	3.3	5.27	6.00	6.18	6.9	
			Placebo	21	19 (90.5)	4.88 (1.20)	2.8	4.00	4.82	5.82	7.0	
		Week 12	Tezepelumab	15	14 (93.3)	6.06 (0.74)	4.6	5.27	6.36	6.64	7.0	
			Placebo	21	19 (90.5)	5.11 (1.16)	3.3	4.09	5.27	6.00	7.0	
		Week 16	Tezepelumab	15	14 (93.3)	6.11 (0.65)	5.1	5.55	6.09	6.73	7.0	
			Placebo	21	19 (90.5)	5.27 (1.24)	2.9	4.45	5.45	6.27	7.0	
		Week 20	Tezepelumab	15	14 (93.3)	5.97 (0.77)	4.5	5.27	6.09	6.64	7.0	
			Placebo	21	19 (90.5)	5.11 (1.39)	2.1	3.91	5.36	6.36	7.0	
		Week 24	Tezepelumab	15	14 (93.3)	6.01 (0.87)	4.1	5.64	6.05	6.91	7.0	
			Placebo	21	19 (90.5)	5.02 (1.40)	2.0	3.91	5.27	6.00	7.0	
		Week 28	Tezepelumab	15	14 (93.3)	6.03 (0.70)	4.9	5.64	6.00	6.64	7.0	
			Placebo	21	20 (95.2)	5.22 (1.41)	2.0	4.09	5.41	6.45	7.0	
		Week 32	Tezepelumab	15	14 (93.3)	6.01 (0.68)	4.8	5.45	5.91	6.55	7.0	
			Placebo	21	20 (95.2)	5.17 (1.37)	1.7	4.41	5.55	6.05	7.0	
		Week 36	Tezepelumab	15	14 (93.3)	6.17 (0.62)	5.5	5.55	6.00	6.73	7.0	
			Placebo	21	20 (95.2)	5.07 (1.43)	2.5	3.86	5.23	6.41	7.0	
		Week 40	Tezepelumab	15	14 (93.3)	6.05 (0.73)	4.8	5.36	6.14	6.64	7.0	
			Placebo	21	20 (95.2)	5.17 (1.44)	2.0	4.05	5.27	6.55	7.0	
		Week 44	Tezepelumab	15	14 (93.3)	6.10 (0.69)	4.8	5.55	6.32	6.55	7.0	
			Placebo	21	20 (95.2)	4.94 (1.31)	2.5	3.91	4.95	5.55	7.0	
		Week 48	Tezepelumab	15	14 (93.3)	6.21 (0.67)	5.2	5.64	6.45	6.82	7.0	
			Placebo	21	20 (95.2)	4.95 (1.31)	2.3	3.95	4.86	5.95	7.0	
		Week 52	Tezepelumab	15	14 (93.3)	6.03 (0.73)	4.6	5.18	6.32	6.55	7.0	
			Placebo	21	20 (95.2)	5.11 (1.25)	3.1	4.05	4.77	6.09	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	15	12 (80.0)	1.27 (0.97)	0.0	0.41	1.23	1.95	3.1	1.07 [0.28, 1.86]
			Placebo	21	17 (81.0)	0.36 (0.77)	-1.2	0.09	0.27	0.64	1.9	
		Week 8	Tezepelumab	15	13 (86.7)	1.48 (1.10)	-0.4	0.91	1.55	2.18	3.7	0.94 [0.18, 1.70]
			Placebo	21	17 (81.0)	0.64 (0.72)	-0.7	0.09	0.64	1.00	1.8	
		Week 12	Tezepelumab	15	13 (86.7)	1.75 (1.03)	0.5	1.00	1.55	2.36	4.2	1.03 [0.26, 1.81]
			Placebo	21	17 (81.0)	0.81 (0.80)	-0.7	0.36	1.00	1.27	2.0	
		Week 16	Tezepelumab	15	13 (86.7)	1.77 (0.93)	0.4	1.36	1.45	2.45	3.5	0.95 [0.19, 1.72]
			Placebo	21	17 (81.0)	1.01 (0.68)	-0.6	0.64	1.00	1.64	1.9	
		Week 20	Tezepelumab	15	13 (86.7)	1.63 (1.02)	0.5	0.55	1.45	2.55	3.5	0.81 [0.06, 1.56]
			Placebo	21	17 (81.0)	0.85 (0.91)	-1.5	0.45	0.82	1.45	2.1	
		Week 24	Tezepelumab	15	13 (86.7)	1.67 (1.19)	0.1	0.64	1.73	2.64	3.5	0.81 [0.06, 1.56]
			Placebo	21	17 (81.0)	0.81 (0.97)	-1.5	0.18	0.91	1.55	1.8	
		Week 28	Tezepelumab	15	13 (86.7)	1.71 (1.05)	0.0	0.73	1.91	2.36	3.5	0.74 [-0.00, 1.49]
			Placebo	21	17 (81.0)	0.96 (0.97)	-1.5	0.82	1.00	1.64	2.5	
		Week 32	Tezepelumab	15	13 (86.7)	1.70 (1.00)	0.3	0.73	1.64	2.45	3.5	0.85 [0.10, 1.61]
			Placebo	21	17 (81.0)	0.85 (0.99)	-1.8	0.55	0.82	1.55	2.0	
		Week 36	Tezepelumab	15	13 (86.7)	1.86 (1.05)	-0.1	0.91	1.91	2.64	3.5	1.11 [0.33, 1.89]
			Placebo	21	17 (81.0)	0.74 (0.98)	-1.0	0.09	1.00	1.73	2.0	
		Week 40	Tezepelumab	15	13 (86.7)	1.71 (1.03)	0.2	0.82	1.36	2.45	3.5	0.83 [0.08, 1.59]
			Placebo	21	17 (81.0)	0.89 (0.95)	-1.5	0.27	0.82	1.73	2.3	
		Week 44	Tezepelumab	15	13 (86.7)	1.76 (1.03)	0.2	0.82	1.55	2.64	3.5	1.24 [0.45, 2.03]
			Placebo	21	17 (81.0)	0.56 (0.92)	-1.1	0.09	0.64	1.27	1.8	
		Week 48	Tezepelumab	15	13 (86.7)	1.89 (0.98)	0.4	1.18	1.91	2.45	3.5	1.47 [0.65, 2.29]
			Placebo	21	17 (81.0)	0.58 (0.82)	-1.3	0.09	0.73	1.00	1.8	
		Week 52	Tezepelumab	15	13 (86.7)	1.71 (1.09)	0.0	0.82	1.55	2.45	3.5	1.01 [0.24, 1.78]
			Placebo	21	17 (81.0)	0.79 (0.74)	-0.5	0.18	0.82	1.55	2.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	24	20 (83.3)	4.34 (0.92)	2.6	3.86	4.32	4.77	5.9	
			Placebo	20	18 (90.0)	4.29 (0.74)	3.5	3.91	4.23	4.45	6.2	
		Week 4	Tezepelumab	24	23 (95.8)	5.23 (0.89)	3.6	4.27	5.27	6.00	6.6	
			Placebo	20	17 (85.0)	4.74 (0.94)	3.2	4.00	4.55	5.45	6.7	
		Week 8	Tezepelumab	24	23 (95.8)	5.36 (0.94)	3.9	4.27	5.36	6.00	6.8	
			Placebo	20	18 (90.0)	4.84 (0.90)	3.6	4.18	4.68	5.45	7.0	
		Week 12	Tezepelumab	24	23 (95.8)	5.57 (0.96)	4.1	4.91	5.45	6.36	7.0	
			Placebo	20	18 (90.0)	4.79 (1.13)	2.8	4.00	4.82	5.45	7.0	
		Week 16	Tezepelumab	24	23 (95.8)	5.47 (1.02)	3.9	4.36	5.36	6.45	7.0	
			Placebo	20	18 (90.0)	4.62 (1.45)	1.1	3.91	4.50	5.64	6.9	
		Week 20	Tezepelumab	24	23 (95.8)	5.42 (1.06)	3.6	4.45	5.27	6.36	7.0	
			Placebo	20	18 (90.0)	4.66 (1.43)	1.1	4.00	4.59	5.73	6.9	
		Week 24	Tezepelumab	24	23 (95.8)	5.46 (1.04)	4.0	4.27	5.27	6.55	7.0	
			Placebo	20	18 (90.0)	4.69 (1.37)	1.1	4.09	4.64	5.55	6.9	
		Week 28	Tezepelumab	24	24 (100.0)	5.54 (0.91)	4.3	4.64	5.50	6.36	7.0	
			Placebo	20	18 (90.0)	4.60 (1.41)	1.1	3.91	4.68	5.73	6.9	
		Week 32	Tezepelumab	24	24 (100.0)	5.61 (1.02)	4.2	4.59	5.64	6.59	7.0	
			Placebo	20	18 (90.0)	4.70 (1.32)	1.1	4.00	4.64	5.45	6.6	
		Week 36	Tezepelumab	24	24 (100.0)	5.58 (0.93)	4.3	4.73	5.55	6.23	7.0	
			Placebo	20	18 (90.0)	4.65 (1.17)	2.4	4.09	4.64	5.09	6.6	
		Week 40	Tezepelumab	24	24 (100.0)	5.66 (0.98)	4.2	4.91	5.64	6.64	7.0	
			Placebo	20	18 (90.0)	4.80 (1.22)	2.5	4.00	4.91	5.82	6.7	
		Week 44	Tezepelumab	24	24 (100.0)	5.57 (1.02)	3.8	4.86	5.50	6.55	7.0	
			Placebo	20	18 (90.0)	4.91 (1.24)	2.9	4.00	4.77	5.91	6.7	
		Week 48	Tezepelumab	24	24 (100.0)	5.62 (0.95)	4.1	4.95	5.50	6.41	7.0	
			Placebo	20	18 (90.0)	4.85 (1.25)	2.4	4.00	4.86	5.45	6.6	
		Week 52	Tezepelumab	24	24 (100.0)	5.71 (0.97)	4.1	4.95	5.68	6.68	7.0	
			Placebo	20	18 (90.0)	4.94 (1.17)	2.9	3.91	4.91	5.45	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	24	20 (83.3)	0.92 (0.87)	-0.7	0.18	1.14	1.55	2.7	0.50 [-0.15, 1.16]
			Placebo	20	17 (85.0)	0.44 (1.03)	-1.5	-0.36	0.45	1.09	2.1	
		Week 8	Tezepelumab	24	20 (83.3)	0.95 (0.91)	-0.7	0.27	0.86	1.59	2.9	0.43 [-0.21, 1.08]
			Placebo	20	18 (90.0)	0.55 (0.97)	-1.3	-0.18	0.50	1.18	2.4	
		Week 12	Tezepelumab	24	20 (83.3)	1.21 (0.95)	-0.7	0.73	1.18	1.77	3.0	0.72 [0.06, 1.38]
			Placebo	20	18 (90.0)	0.49 (1.03)	-1.3	0.00	0.27	1.18	2.4	
		Week 16	Tezepelumab	24	20 (83.3)	1.14 (0.99)	-0.7	0.45	1.14	1.86	3.0	0.67 [0.01, 1.33]
			Placebo	20	18 (90.0)	0.33 (1.41)	-3.2	-0.45	0.36	1.64	2.4	
		Week 20	Tezepelumab	24	20 (83.3)	1.16 (1.09)	-0.7	0.36	1.18	1.82	3.3	0.65 [-0.01, 1.30]
			Placebo	20	18 (90.0)	0.37 (1.36)	-3.2	-0.09	0.36	1.27	2.4	
		Week 24	Tezepelumab	24	20 (83.3)	1.24 (0.99)	-0.7	0.59	1.36	1.86	3.0	0.69 [0.04, 1.35]
			Placebo	20	18 (90.0)	0.40 (1.41)	-3.2	0.00	0.50	1.45	2.4	
		Week 28	Tezepelumab	24	20 (83.3)	1.23 (1.05)	-0.7	0.41	1.45	2.00	3.0	0.75 [0.09, 1.41]
			Placebo	20	18 (90.0)	0.31 (1.39)	-3.2	-0.27	0.32	1.18	2.4	
		Week 32	Tezepelumab	24	20 (83.3)	1.29 (1.07)	-0.7	0.50	1.36	1.95	3.2	0.73 [0.08, 1.39]
			Placebo	20	18 (90.0)	0.40 (1.34)	-3.2	-0.27	0.50	1.55	2.4	
		Week 36	Tezepelumab	24	20 (83.3)	1.28 (1.09)	-0.7	0.45	1.45	2.00	3.0	0.82 [0.16, 1.48]
			Placebo	20	18 (90.0)	0.36 (1.15)	-1.8	0.00	0.55	1.00	2.4	
		Week 40	Tezepelumab	24	20 (83.3)	1.34 (1.04)	-0.7	0.59	1.45	1.95	3.0	0.73 [0.07, 1.39]
			Placebo	20	18 (90.0)	0.51 (1.23)	-1.6	0.00	0.68	1.64	2.4	
		Week 44	Tezepelumab	24	20 (83.3)	1.31 (1.13)	-0.7	0.41	1.59	2.14	3.2	0.55 [-0.10, 1.20]
			Placebo	20	18 (90.0)	0.62 (1.39)	-1.6	-0.45	0.55	2.00	3.2	
		Week 48	Tezepelumab	24	20 (83.3)	1.36 (1.05)	-0.7	0.73	1.36	2.18	3.2	0.66 [0.00, 1.31]
			Placebo	20	18 (90.0)	0.56 (1.37)	-1.6	-0.18	0.45	1.55	3.2	
		Week 52	Tezepelumab	24	20 (83.3)	1.42 (1.04)	-0.7	0.73	1.36	2.41	3.3	0.64 [-0.01, 1.30]
			Placebo	20	18 (90.0)	0.65 (1.35)	-1.6	0.00	0.50	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	27	24 (88.9)	3.88 (0.71)	2.1	3.45	3.95	4.23	5.3	
			Placebo	24	20 (83.3)	4.30 (0.72)	3.2	3.86	4.32	4.68	6.2	
		Week 4	Tezepelumab	27	24 (88.9)	4.32 (1.09)	1.6	3.64	4.27	5.05	6.9	
			Placebo	24	21 (87.5)	4.81 (1.09)	3.2	4.00	4.45	5.82	7.0	
		Week 8	Tezepelumab	27	25 (92.6)	4.61 (1.05)	2.9	3.91	4.45	5.27	6.5	
			Placebo	24	22 (91.7)	4.84 (1.14)	2.3	4.09	4.73	5.45	7.0	
		Week 12	Tezepelumab	27	25 (92.6)	4.79 (0.97)	3.0	4.09	4.73	5.09	6.6	
			Placebo	24	22 (91.7)	5.02 (1.07)	3.2	4.27	4.86	6.00	6.8	
		Week 16	Tezepelumab	27	25 (92.6)	4.71 (0.95)	2.8	4.09	4.64	5.27	6.9	
			Placebo	24	22 (91.7)	5.16 (1.02)	3.6	4.45	4.95	6.09	6.9	
		Week 20	Tezepelumab	27	26 (96.3)	4.71 (1.06)	2.8	4.00	4.59	5.55	6.8	
			Placebo	24	22 (91.7)	4.98 (0.95)	3.8	4.09	4.86	5.64	6.7	
		Week 24	Tezepelumab	27	26 (96.3)	4.80 (1.00)	2.9	4.00	4.55	5.55	6.7	
			Placebo	24	22 (91.7)	5.07 (1.09)	3.4	4.18	5.09	6.00	6.9	
		Week 28	Tezepelumab	27	27 (100.0)	4.67 (1.06)	2.9	4.00	4.45	5.45	7.0	
			Placebo	24	22 (91.7)	5.09 (1.26)	3.2	3.91	5.00	6.00	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	4.75 (1.05)	2.9	3.91	4.36	5.82	6.7	
			Placebo	24	22 (91.7)	5.22 (1.11)	3.6	4.27	4.95	6.18	7.0	
		Week 36	Tezepelumab	27	27 (100.0)	4.77 (1.04)	3.0	4.00	4.45	5.45	6.7	
			Placebo	24	22 (91.7)	5.18 (1.02)	3.8	4.18	5.14	6.00	6.9	
		Week 40	Tezepelumab	27	27 (100.0)	4.70 (0.93)	3.3	3.91	4.45	5.18	6.7	
			Placebo	24	22 (91.7)	5.13 (1.20)	3.3	4.09	5.23	6.18	7.0	
		Week 44	Tezepelumab	27	27 (100.0)	4.75 (0.96)	3.0	3.91	4.45	5.45	6.9	
			Placebo	24	22 (91.7)	5.33 (1.08)	3.5	4.27	5.32	6.27	6.9	
		Week 48	Tezepelumab	27	27 (100.0)	4.77 (1.06)	2.6	4.09	4.45	5.73	6.8	
			Placebo	24	22 (91.7)	5.21 (1.12)	3.5	4.18	5.18	6.09	7.0	
		Week 52	Tezepelumab	27	27 (100.0)	4.77 (1.06)	2.6	4.09	4.45	5.73	6.6	
			Placebo	24	22 (91.7)	5.17 (1.13)	3.6	4.18	5.09	6.09	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	0.36 (0.98)	-2.8	-0.09	0.45	1.00	2.0	-0.17 [-0.77, 0.43]
			Placebo	24	20 (83.3)	0.51 (0.81)	-0.9	0.05	0.41	0.73	2.5	
		Week 8	Tezepelumab	27	24 (88.9)	0.70 (0.90)	-1.3	0.14	0.55	1.23	2.7	0.15 [-0.44, 0.75]
			Placebo	24	20 (83.3)	0.56 (0.99)	-0.9	-0.05	0.41	1.00	2.6	
		Week 12	Tezepelumab	27	24 (88.9)	0.90 (0.96)	-1.5	0.36	0.91	1.36	2.8	0.16 [-0.43, 0.76]
			Placebo	24	20 (83.3)	0.74 (1.07)	-1.2	0.05	0.50	1.14	3.3	
		Week 16	Tezepelumab	27	24 (88.9)	0.83 (0.93)	-1.6	0.32	0.59	1.27	2.7	-0.12 [-0.72, 0.47]
			Placebo	24	20 (83.3)	0.95 (0.94)	-0.6	0.55	0.82	1.23	3.5	
		Week 20	Tezepelumab	27	24 (88.9)	0.78 (1.00)	-0.9	0.23	0.59	1.36	2.6	0.00 [-0.59, 0.60]
			Placebo	24	20 (83.3)	0.78 (0.76)	-0.5	0.27	0.68	0.95	2.5	
		Week 24	Tezepelumab	27	24 (88.9)	0.95 (0.91)	-0.6	0.36	0.73	1.41	2.9	0.15 [-0.45, 0.74]
			Placebo	24	20 (83.3)	0.81 (0.98)	-0.9	0.18	0.73	1.18	2.9	
		Week 28	Tezepelumab	27	24 (88.9)	0.85 (0.93)	-0.8	0.05	0.68	1.32	2.6	0.02 [-0.57, 0.62]
			Placebo	24	20 (83.3)	0.83 (1.17)	-1.1	-0.05	0.91	1.23	3.7	
		Week 32	Tezepelumab	27	24 (88.9)	0.84 (0.96)	-0.5	0.27	0.77	1.27	2.8	-0.16 [-0.75, 0.44]
			Placebo	24	20 (83.3)	1.00 (0.96)	-0.5	0.41	0.95	1.36	3.3	
		Week 36	Tezepelumab	27	24 (88.9)	0.89 (0.93)	-0.7	0.32	0.73	1.27	3.2	-0.08 [-0.67, 0.52]
			Placebo	24	20 (83.3)	0.96 (0.88)	-0.5	0.45	0.82	1.27	2.7	
		Week 40	Tezepelumab	27	24 (88.9)	0.86 (0.91)	-0.9	0.32	0.77	1.27	2.9	-0.04 [-0.63, 0.55]
			Placebo	24	20 (83.3)	0.90 (1.12)	-1.0	0.18	0.77	1.45	3.5	
		Week 44	Tezepelumab	27	24 (88.9)	0.87 (0.89)	-0.5	0.32	0.64	1.27	2.8	-0.21 [-0.81, 0.38]
			Placebo	24	20 (83.3)	1.07 (0.96)	-0.5	0.45	0.95	1.41	3.4	
		Week 48	Tezepelumab	27	24 (88.9)	0.92 (0.92)	-0.6	0.36	1.00	1.32	3.0	-0.04 [-0.63, 0.56]
			Placebo	24	20 (83.3)	0.96 (0.93)	-0.5	0.23	0.95	1.27	2.8	
		Week 52	Tezepelumab	27	24 (88.9)	0.92 (0.91)	-0.6	0.32	1.00	1.32	3.0	-0.02 [-0.62, 0.57]
			Placebo	24	20 (83.3)	0.94 (0.95)	-0.5	0.18	0.95	1.27	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	3.64 (0.74)	2.2	3.36	3.64	4.18	4.6	
			Placebo	14	11 (78.6)	4.35 (0.88)	3.3	3.64	4.36	5.09	6.2	
		Week 4	Tezepelumab	11	11 (100.0)	4.57 (0.75)	3.1	4.18	4.73	5.27	5.4	
			Placebo	14	12 (85.7)	4.60 (1.31)	3.2	3.55	4.27	5.23	7.0	
		Week 8	Tezepelumab	11	11 (100.0)	4.85 (1.16)	3.3	3.91	4.64	6.09	6.5	
			Placebo	14	12 (85.7)	5.03 (0.85)	3.9	4.36	4.95	5.55	6.5	
		Week 12	Tezepelumab	11	11 (100.0)	5.11 (0.94)	3.9	4.27	4.82	6.18	6.6	
			Placebo	14	12 (85.7)	4.95 (1.29)	3.2	3.73	4.91	6.18	6.9	
		Week 16	Tezepelumab	11	11 (100.0)	5.15 (0.79)	4.2	4.64	5.00	5.64	6.9	
			Placebo	14	12 (85.7)	5.27 (1.14)	3.7	4.36	4.95	6.32	6.9	
		Week 20	Tezepelumab	11	11 (100.0)	4.96 (0.93)	4.0	4.27	4.55	5.82	6.8	
			Placebo	14	12 (85.7)	4.93 (0.98)	3.8	4.18	4.64	5.55	6.9	
		Week 24	Tezepelumab	11	11 (100.0)	5.17 (0.99)	3.9	4.27	4.91	6.27	6.7	
			Placebo	14	12 (85.7)	5.14 (1.13)	3.5	4.27	5.00	6.09	6.9	
		Week 28	Tezepelumab	11	11 (100.0)	5.10 (0.89)	3.9	4.36	4.91	5.73	6.8	
			Placebo	14	12 (85.7)	5.13 (1.36)	3.6	3.91	4.77	6.45	7.0	
		Week 32	Tezepelumab	11	11 (100.0)	5.15 (0.95)	3.9	4.27	5.27	6.00	6.7	
			Placebo	14	12 (85.7)	5.26 (1.22)	3.8	4.05	5.09	6.36	7.0	
		Week 36	Tezepelumab	11	11 (100.0)	5.07 (1.04)	3.8	4.09	5.45	5.64	6.7	
			Placebo	14	12 (85.7)	5.12 (1.26)	3.7	3.86	5.09	6.05	6.9	
		Week 40	Tezepelumab	11	11 (100.0)	5.04 (0.98)	3.7	4.27	4.82	5.64	6.7	
			Placebo	14	12 (85.7)	5.02 (1.45)	3.3	3.86	4.68	6.59	7.0	
		Week 44	Tezepelumab	11	11 (100.0)	5.05 (0.99)	3.9	4.09	5.18	5.64	6.9	
			Placebo	14	12 (85.7)	5.07 (1.28)	3.5	3.86	5.14	6.23	6.9	
		Week 48	Tezepelumab	11	11 (100.0)	5.13 (0.92)	4.1	4.27	5.18	5.64	6.8	
			Placebo	14	12 (85.7)	5.16 (1.24)	3.8	3.86	5.18	6.14	7.0	
		Week 52	Tezepelumab	11	11 (100.0)	5.12 (0.88)	4.2	4.27	5.18	5.64	6.6	
			Placebo	14	12 (85.7)	5.05 (1.28)	3.6	3.82	5.00	6.14	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	11	11 (100.0)	0.93 (1.02)	-0.3	0.00	0.82	1.55	3.1	0.66 [-0.20, 1.52]
			Placebo	14	11 (78.6)	0.34 (0.73)	-1.0	0.00	0.18	0.82	1.9	
		Week 8	Tezepelumab	11	11 (100.0)	1.21 (1.46)	-1.3	0.27	1.36	2.36	3.7	0.36 [-0.48, 1.21]
			Placebo	14	11 (78.6)	0.79 (0.76)	-0.1	0.00	0.55	1.45	2.2	
		Week 12	Tezepelumab	11	11 (100.0)	1.46 (1.28)	-0.5	0.82	1.18	2.45	4.2	0.60 [-0.25, 1.46]
			Placebo	14	11 (78.6)	0.70 (1.25)	-1.2	0.00	0.82	1.27	3.3	
		Week 16	Tezepelumab	11	11 (100.0)	1.50 (1.01)	0.4	0.55	1.27	2.55	3.5	0.51 [-0.34, 1.36]
			Placebo	14	11 (78.6)	0.99 (1.02)	-0.7	0.55	0.82	1.09	3.5	
		Week 20	Tezepelumab	11	11 (100.0)	1.31 (1.16)	-0.4	0.36	0.91	2.55	3.5	0.66 [-0.20, 1.52]
			Placebo	14	11 (78.6)	0.68 (0.73)	-0.5	0.09	0.64	0.91	1.9	
		Week 24	Tezepelumab	11	11 (100.0)	1.52 (1.14)	-0.2	0.36	1.36	2.55	3.5	0.63 [-0.23, 1.48]
			Placebo	14	11 (78.6)	0.87 (0.93)	-0.5	0.27	0.64	1.36	2.9	
		Week 28	Tezepelumab	11	11 (100.0)	1.45 (1.11)	-0.2	0.73	1.27	2.64	3.5	0.50 [-0.35, 1.34]
			Placebo	14	11 (78.6)	0.89 (1.16)	-0.5	0.18	0.82	1.36	3.7	
		Week 32	Tezepelumab	11	11 (100.0)	1.50 (1.13)	-0.2	0.36	1.64	2.55	3.5	0.48 [-0.37, 1.33]
			Placebo	14	11 (78.6)	0.98 (1.06)	-0.5	0.27	0.82	1.55	3.3	
		Week 36	Tezepelumab	11	11 (100.0)	1.43 (1.26)	-0.2	0.18	1.27	2.55	3.5	0.51 [-0.34, 1.36]
			Placebo	14	11 (78.6)	0.83 (1.05)	-0.7	0.09	0.73	1.82	2.7	
		Week 40	Tezepelumab	11	11 (100.0)	1.40 (1.19)	-0.2	0.36	1.27	2.55	3.5	0.51 [-0.34, 1.36]
			Placebo	14	11 (78.6)	0.77 (1.28)	-1.0	-0.55	0.73	1.45	3.5	
		Week 44	Tezepelumab	11	11 (100.0)	1.40 (1.18)	-0.2	0.36	1.27	2.73	3.5	0.56 [-0.29, 1.41]
			Placebo	14	11 (78.6)	0.74 (1.21)	-0.7	-0.27	0.55	1.82	3.4	
		Week 48	Tezepelumab	11	11 (100.0)	1.49 (1.14)	-0.2	0.45	1.36	2.64	3.5	0.60 [-0.25, 1.46]
			Placebo	14	11 (78.6)	0.85 (0.97)	-0.5	0.00	0.82	1.82	2.4	
		Week 52	Tezepelumab	11	11 (100.0)	1.48 (1.12)	-0.2	0.55	1.36	2.45	3.5	0.67 [-0.19, 1.53]
			Placebo	14	11 (78.6)	0.76 (1.03)	-0.8	0.00	0.82	1.55	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	54	46 (85.2)	4.24 (0.90)	2.1	3.73	4.14	4.64	6.3	
			Placebo	51	44 (86.3)	4.30 (0.76)	2.3	3.91	4.27	4.64	6.2	
		Week 4	Tezepelumab	54	48 (88.9)	4.93 (1.12)	1.6	4.05	5.05	5.82	6.9	
			Placebo	51	45 (88.2)	4.79 (0.95)	2.5	4.00	4.64	5.45	6.9	
		Week 8	Tezepelumab	54	50 (92.6)	5.23 (1.07)	2.9	4.18	5.32	6.09	6.9	
			Placebo	51	47 (92.2)	4.80 (1.13)	2.3	4.09	4.64	5.64	7.0	
		Week 12	Tezepelumab	54	50 (92.6)	5.43 (1.07)	3.0	4.73	5.27	6.45	7.0	
			Placebo	51	47 (92.2)	4.99 (1.07)	2.8	4.18	5.09	6.00	7.0	
		Week 16	Tezepelumab	54	50 (92.6)	5.35 (1.12)	2.8	4.36	5.41	6.45	7.0	
			Placebo	51	47 (92.2)	4.97 (1.28)	1.1	4.00	4.91	6.00	7.0	
		Week 20	Tezepelumab	54	51 (94.4)	5.33 (1.14)	2.8	4.55	5.27	6.36	7.0	
			Placebo	51	47 (92.2)	4.92 (1.31)	1.1	4.09	4.91	6.09	7.0	
		Week 24	Tezepelumab	54	51 (94.4)	5.35 (1.12)	2.9	4.27	5.27	6.27	7.0	
			Placebo	51	47 (92.2)	4.89 (1.31)	1.1	4.09	5.00	5.82	7.0	
		Week 28	Tezepelumab	54	53 (98.1)	5.33 (1.12)	2.9	4.55	5.27	6.36	7.0	
			Placebo	51	48 (94.1)	4.95 (1.37)	1.1	4.09	5.09	5.95	7.0	
		Week 32	Tezepelumab	54	53 (98.1)	5.39 (1.13)	2.9	4.36	5.45	6.36	7.0	
			Placebo	51	48 (94.1)	4.99 (1.28)	1.1	4.18	5.09	6.00	7.0	
		Week 36	Tezepelumab	54	53 (98.1)	5.44 (1.08)	3.0	4.55	5.55	6.27	7.0	
			Placebo	51	48 (94.1)	4.95 (1.21)	2.4	4.09	4.95	6.00	7.0	
		Week 40	Tezepelumab	54	53 (98.1)	5.41 (1.08)	3.3	4.64	5.18	6.27	7.0	
			Placebo	51	48 (94.1)	5.05 (1.25)	2.0	4.09	5.09	6.05	7.0	
		Week 44	Tezepelumab	54	53 (98.1)	5.42 (1.09)	3.0	4.55	5.36	6.36	7.0	
			Placebo	51	48 (94.1)	5.07 (1.20)	2.5	4.09	5.14	5.95	7.0	
		Week 48	Tezepelumab	54	53 (98.1)	5.45 (1.13)	2.6	4.73	5.55	6.45	7.0	
			Placebo	51	48 (94.1)	4.98 (1.22)	2.3	4.14	4.95	6.00	7.0	
		Week 52	Tezepelumab	54	53 (98.1)	5.45 (1.14)	2.6	4.64	5.45	6.45	7.0	
			Placebo	51	48 (94.1)	5.09 (1.15)	2.9	4.14	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	54	43 (79.6)	0.71 (1.00)	-2.8	0.00	0.64	1.45	2.7	0.25 [-0.17, 0.68]
			Placebo	51	43 (84.3)	0.47 (0.90)	-1.5	0.00	0.36	1.09	2.5	
		Week 8	Tezepelumab	54	45 (83.3)	0.93 (0.85)	-0.7	0.45	0.91	1.55	2.9	0.45 [0.03, 0.87]
			Placebo	51	44 (86.3)	0.53 (0.92)	-1.3	-0.18	0.45	1.00	2.6	
		Week 12	Tezepelumab	54	45 (83.3)	1.16 (0.94)	-1.5	0.64	1.09	1.73	3.0	0.52 [0.10, 0.94]
			Placebo	51	44 (86.3)	0.68 (0.91)	-1.3	0.09	0.68	1.18	2.5	
		Week 16	Tezepelumab	54	45 (83.3)	1.08 (1.00)	-1.6	0.36	1.00	1.82	3.0	0.35 [-0.06, 0.77]
			Placebo	51	44 (86.3)	0.71 (1.10)	-3.2	0.14	0.73	1.59	2.5	
		Week 20	Tezepelumab	54	45 (83.3)	1.08 (1.05)	-0.9	0.55	1.00	1.91	3.3	0.39 [-0.03, 0.81]
			Placebo	51	44 (86.3)	0.67 (1.11)	-3.2	0.18	0.68	1.36	2.5	
		Week 24	Tezepelumab	54	45 (83.3)	1.15 (1.01)	-0.7	0.45	1.00	1.82	3.0	0.48 [0.06, 0.90]
			Placebo	51	44 (86.3)	0.63 (1.18)	-3.2	0.09	0.73	1.45	2.5	
		Week 28	Tezepelumab	54	45 (83.3)	1.14 (1.02)	-0.8	0.45	0.82	2.00	3.0	0.44 [0.02, 0.86]
			Placebo	51	44 (86.3)	0.65 (1.22)	-3.2	-0.05	0.82	1.32	2.5	
		Week 32	Tezepelumab	54	45 (83.3)	1.14 (1.02)	-0.7	0.45	0.91	1.91	3.2	0.41 [-0.01, 0.83]
			Placebo	51	44 (86.3)	0.70 (1.13)	-3.2	0.18	0.82	1.45	2.6	
		Week 36	Tezepelumab	54	45 (83.3)	1.23 (1.02)	-0.7	0.64	1.00	1.91	3.1	0.55 [0.13, 0.98]
			Placebo	51	44 (86.3)	0.66 (1.02)	-1.8	0.14	0.77	1.18	2.6	
		Week 40	Tezepelumab	54	45 (83.3)	1.20 (0.99)	-0.9	0.55	1.09	1.91	3.0	0.41 [-0.01, 0.83]
			Placebo	51	44 (86.3)	0.77 (1.07)	-1.6	0.18	0.77	1.64	2.6	
		Week 44	Tezepelumab	54	45 (83.3)	1.21 (1.03)	-0.7	0.45	1.00	1.91	3.2	0.41 [-0.01, 0.83]
			Placebo	51	44 (86.3)	0.77 (1.10)	-1.6	0.18	0.82	1.50	3.2	
		Week 48	Tezepelumab	54	45 (83.3)	1.26 (1.03)	-0.7	0.45	1.18	2.00	3.2	0.55 [0.12, 0.97]
			Placebo	51	44 (86.3)	0.68 (1.09)	-1.6	0.09	0.77	1.27	3.2	
		Week 52	Tezepelumab	54	45 (83.3)	1.24 (1.02)	-0.7	0.55	1.18	1.91	3.3	0.42 [-0.00, 0.84]
			Placebo	51	44 (86.3)	0.81 (1.05)	-1.6	0.09	0.82	1.41	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	33	31 (93.9)	3.93 (0.68)	2.2	3.64	4.00	4.36	5.2	
			Placebo	34	27 (79.4)	4.33 (0.86)	2.3	3.82	4.27	4.91	6.2	
		Week 4	Tezepelumab	33	29 (87.9)	4.69 (1.18)	1.6	4.18	4.36	5.36	6.9	
			Placebo	34	27 (79.4)	4.70 (1.22)	2.5	3.64	4.55	5.64	7.0	
		Week 8	Tezepelumab	33	30 (90.9)	4.91 (1.07)	3.3	4.09	4.64	6.09	6.6	
			Placebo	34	29 (85.3)	4.95 (1.06)	2.8	4.09	4.82	5.64	7.0	
		Week 12	Tezepelumab	33	30 (90.9)	5.21 (1.05)	3.0	4.64	4.86	6.36	7.0	
			Placebo	34	29 (85.3)	5.05 (1.19)	3.2	4.18	4.91	6.27	6.9	
		Week 16	Tezepelumab	33	30 (90.9)	5.11 (1.05)	2.8	4.27	4.95	5.91	7.0	
			Placebo	34	29 (85.3)	5.16 (1.41)	1.1	4.18	5.45	6.27	6.9	
		Week 20	Tezepelumab	33	31 (93.9)	5.09 (1.11)	2.8	4.27	4.82	5.91	7.0	
			Placebo	34	29 (85.3)	4.97 (1.43)	1.1	4.09	5.18	6.27	6.9	
		Week 24	Tezepelumab	33	31 (93.9)	5.17 (1.02)	3.8	4.27	4.91	6.09	7.0	
			Placebo	34	29 (85.3)	5.04 (1.45)	1.1	4.27	5.27	6.18	6.9	
		Week 28	Tezepelumab	33	32 (97.0)	5.11 (1.08)	3.5	4.27	4.82	5.86	7.0	
			Placebo	34	30 (88.2)	5.15 (1.52)	1.1	3.91	5.41	6.45	7.0	
		Week 32	Tezepelumab	33	32 (97.0)	5.17 (1.09)	3.3	4.27	4.95	6.09	7.0	
			Placebo	34	30 (88.2)	5.17 (1.50)	1.1	4.27	5.55	6.27	7.0	
		Week 36	Tezepelumab	33	32 (97.0)	5.18 (1.06)	3.7	4.32	4.91	6.09	7.0	
			Placebo	34	30 (88.2)	5.22 (1.38)	2.5	3.91	5.55	6.27	6.9	
		Week 40	Tezepelumab	33	32 (97.0)	5.14 (1.01)	3.5	4.36	5.00	5.64	7.0	
			Placebo	34	30 (88.2)	5.22 (1.48)	2.0	3.91	5.50	6.73	7.0	
		Week 44	Tezepelumab	33	32 (97.0)	5.18 (1.05)	3.7	4.32	5.05	5.91	7.0	
			Placebo	34	30 (88.2)	5.19 (1.38)	2.5	3.91	5.32	6.64	6.9	
		Week 48	Tezepelumab	33	32 (97.0)	5.23 (1.04)	3.8	4.27	5.09	6.23	7.0	
			Placebo	34	30 (88.2)	5.18 (1.35)	2.3	4.00	5.32	6.27	7.0	
		Week 52	Tezepelumab	33	32 (97.0)	5.26 (1.05)	3.5	4.32	5.18	6.23	7.0	
			Placebo	34	30 (88.2)	5.23 (1.32)	2.9	4.00	5.32	6.45	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	33	29 (87.9)	0.73 (1.18)	-2.8	0.00	0.55	1.55	3.1	0.31 [-0.22, 0.84]
			Placebo	34	26 (76.5)	0.41 (0.81)	-1.0	0.00	0.18	0.55	2.5	
		Week 8	Tezepelumab	33	30 (90.9)	1.00 (1.12)	-1.3	0.09	0.82	1.64	3.7	0.31 [-0.21, 0.83]
			Placebo	34	27 (79.4)	0.69 (0.87)	-0.7	0.00	0.55	1.18	2.6	
		Week 12	Tezepelumab	33	30 (90.9)	1.30 (1.13)	-1.5	0.73	1.14	1.82	4.2	0.47 [-0.06, 1.00]
			Placebo	34	27 (79.4)	0.79 (1.02)	-1.2	0.18	0.82	1.18	3.3	
		Week 16	Tezepelumab	33	30 (90.9)	1.19 (1.11)	-1.6	0.36	1.00	1.91	3.5	0.26 [-0.26, 0.78]
			Placebo	34	27 (79.4)	0.89 (1.21)	-3.2	0.55	0.91	1.36	3.5	
		Week 20	Tezepelumab	33	30 (90.9)	1.17 (1.14)	-0.9	0.36	0.95	2.00	3.5	0.40 [-0.13, 0.92]
			Placebo	34	27 (79.4)	0.71 (1.18)	-3.2	0.18	0.73	1.45	2.5	
		Week 24	Tezepelumab	33	30 (90.9)	1.25 (1.06)	-0.6	0.45	1.09	2.00	3.5	0.41 [-0.12, 0.93]
			Placebo	34	27 (79.4)	0.77 (1.28)	-3.2	0.27	0.82	1.36	2.9	
		Week 28	Tezepelumab	33	30 (90.9)	1.25 (1.11)	-0.8	0.55	1.14	2.00	3.5	0.34 [-0.19, 0.86]
			Placebo	34	27 (79.4)	0.84 (1.33)	-3.2	0.27	0.82	1.36	3.7	
		Week 32	Tezepelumab	33	30 (90.9)	1.25 (1.13)	-0.5	0.36	1.00	2.00	3.5	0.35 [-0.18, 0.87]
			Placebo	34	27 (79.4)	0.82 (1.32)	-3.2	0.45	0.82	1.55	3.3	
		Week 36	Tezepelumab	33	30 (90.9)	1.28 (1.10)	-0.7	0.45	1.05	2.09	3.5	0.37 [-0.15, 0.90]
			Placebo	34	27 (79.4)	0.87 (1.12)	-1.8	0.09	1.00	1.82	2.7	
		Week 40	Tezepelumab	33	30 (90.9)	1.26 (1.09)	-0.9	0.45	1.14	1.91	3.5	0.30 [-0.22, 0.82]
			Placebo	34	27 (79.4)	0.91 (1.24)	-1.5	0.27	0.82	1.73	3.5	
		Week 44	Tezepelumab	33	30 (90.9)	1.27 (1.10)	-0.5	0.45	1.05	2.36	3.5	0.38 [-0.14, 0.91]
			Placebo	34	27 (79.4)	0.83 (1.19)	-1.4	0.09	0.73	1.82	3.4	
		Week 48	Tezepelumab	33	30 (90.9)	1.35 (1.06)	-0.5	0.45	1.23	2.00	3.5	0.47 [-0.06, 1.00]
			Placebo	34	27 (79.4)	0.83 (1.14)	-1.4	0.09	0.82	1.82	2.8	
		Week 52	Tezepelumab	33	30 (90.9)	1.38 (1.05)	-0.5	0.55	1.23	2.45	3.5	0.45 [-0.08, 0.97]
			Placebo	34	27 (79.4)	0.90 (1.10)	-1.4	0.09	0.82	1.64	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	4.36 (1.07)	2.1	3.64	4.14	5.27	6.3	
			Placebo	31	28 (90.3)	4.29 (0.71)	3.2	3.86	4.14	4.64	6.0	
		Week 4	Tezepelumab	32	30 (93.8)	5.02 (0.94)	3.2	4.09	5.23	5.73	6.8	
			Placebo	31	30 (96.8)	4.79 (0.84)	3.2	4.00	4.68	5.45	6.7	
		Week 8	Tezepelumab	32	31 (96.9)	5.40 (1.05)	2.9	4.91	5.36	6.09	6.9	
			Placebo	31	30 (96.8)	4.75 (1.10)	2.3	4.09	4.64	5.36	7.0	
		Week 12	Tezepelumab	32	31 (96.9)	5.53 (1.04)	3.4	5.00	5.45	6.55	7.0	
			Placebo	31	30 (96.8)	4.91 (1.03)	2.8	4.09	4.91	5.55	7.0	
		Week 16	Tezepelumab	32	31 (96.9)	5.51 (1.07)	3.4	4.73	5.55	6.45	7.0	
			Placebo	31	30 (96.8)	4.91 (1.08)	3.0	4.09	4.77	5.64	7.0	
		Week 20	Tezepelumab	32	31 (96.9)	5.43 (1.10)	3.2	4.55	5.45	6.36	7.0	
			Placebo	31	30 (96.8)	4.88 (1.07)	3.0	4.00	4.77	5.45	7.0	
		Week 24	Tezepelumab	32	31 (96.9)	5.46 (1.16)	2.9	4.27	5.55	6.55	7.0	
			Placebo	31	30 (96.8)	4.84 (1.08)	2.7	4.09	4.77	5.55	7.0	
		Week 28	Tezepelumab	32	32 (100.0)	5.47 (1.07)	2.9	4.86	5.68	6.32	7.0	
			Placebo	31	30 (96.8)	4.82 (1.18)	2.5	3.82	4.77	5.73	7.0	
		Week 32	Tezepelumab	32	32 (100.0)	5.53 (1.09)	2.9	4.82	5.82	6.50	7.0	
			Placebo	31	30 (96.8)	4.92 (0.98)	3.3	4.09	4.82	5.55	7.0	
		Week 36	Tezepelumab	32	32 (100.0)	5.58 (1.06)	3.0	4.95	5.68	6.41	7.0	
			Placebo	31	30 (96.8)	4.75 (1.00)	2.4	4.09	4.64	5.27	7.0	
		Week 40	Tezepelumab	32	32 (100.0)	5.56 (1.10)	3.3	4.95	5.86	6.50	7.0	
			Placebo	31	30 (96.8)	4.87 (1.04)	2.5	4.09	4.91	5.73	7.0	
		Week 44	Tezepelumab	32	32 (100.0)	5.52 (1.09)	3.0	4.86	5.50	6.45	7.0	
			Placebo	31	30 (96.8)	4.95 (1.01)	3.1	4.09	4.95	5.64	7.0	
		Week 48	Tezepelumab	32	32 (100.0)	5.56 (1.15)	2.6	4.95	5.77	6.50	7.0	
			Placebo	31	30 (96.8)	4.85 (1.06)	2.4	4.09	4.82	5.64	7.0	
		Week 52	Tezepelumab	32	32 (100.0)	5.53 (1.15)	2.6	4.82	5.73	6.50	7.0	
			Placebo	31	30 (96.8)	4.94 (0.99)	3.5	4.09	4.77	5.73	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	32	25 (78.1)	0.79 (0.77)	-0.7	0.27	0.82	1.27	2.5	0.37 [-0.18, 0.91]
			Placebo	31	28 (90.3)	0.47 (0.92)	-1.5	0.05	0.45	1.14	2.1	
		Week 8	Tezepelumab	32	26 (81.3)	0.96 (0.83)	-0.7	0.45	0.91	1.55	2.7	0.56 [0.01, 1.10]
			Placebo	31	28 (90.3)	0.47 (0.92)	-1.3	-0.18	0.45	1.00	2.4	
		Week 12	Tezepelumab	32	26 (81.3)	1.12 (0.86)	-0.7	0.64	1.14	1.55	2.7	0.61 [0.06, 1.16]
			Placebo	31	28 (90.3)	0.57 (0.93)	-1.3	0.00	0.50	1.23	2.4	
		Week 16	Tezepelumab	32	26 (81.3)	1.13 (0.91)	-0.7	0.36	1.18	1.55	2.8	0.53 [-0.02, 1.07]
			Placebo	31	28 (90.3)	0.64 (0.94)	-1.6	0.05	0.55	1.59	2.3	
		Week 20	Tezepelumab	32	26 (81.3)	1.09 (1.00)	-0.7	0.55	1.09	1.91	2.6	0.48 [-0.06, 1.03]
			Placebo	31	28 (90.3)	0.63 (0.90)	-1.6	0.18	0.45	1.27	2.3	
		Week 24	Tezepelumab	32	26 (81.3)	1.20 (1.02)	-0.7	0.36	1.32	1.91	3.0	0.61 [0.07, 1.16]
			Placebo	31	28 (90.3)	0.58 (0.98)	-1.6	0.05	0.50	1.45	2.3	
		Week 28	Tezepelumab	32	26 (81.3)	1.15 (0.96)	-0.7	0.45	0.95	2.00	2.9	0.57 [0.03, 1.12]
			Placebo	31	28 (90.3)	0.56 (1.07)	-1.6	-0.18	0.68	1.27	2.5	
		Week 32	Tezepelumab	32	26 (81.3)	1.17 (0.96)	-0.7	0.55	1.05	1.91	2.8	0.52 [-0.02, 1.07]
			Placebo	31	28 (90.3)	0.69 (0.89)	-1.6	0.05	0.64	1.45	2.0	
		Week 36	Tezepelumab	32	26 (81.3)	1.25 (1.04)	-0.7	0.73	1.18	1.91	3.1	0.74 [0.19, 1.30]
			Placebo	31	28 (90.3)	0.53 (0.90)	-1.6	0.09	0.68	1.05	2.0	
		Week 40	Tezepelumab	32	26 (81.3)	1.21 (0.96)	-0.7	0.64	1.09	2.00	2.8	0.60 [0.06, 1.15]
			Placebo	31	28 (90.3)	0.63 (0.95)	-1.6	0.09	0.68	1.41	2.2	
		Week 44	Tezepelumab	32	26 (81.3)	1.23 (1.02)	-0.7	0.55	1.18	1.91	2.9	0.51 [-0.04, 1.05]
			Placebo	31	28 (90.3)	0.70 (1.05)	-1.6	0.14	0.73	1.41	3.2	
		Week 48	Tezepelumab	32	26 (81.3)	1.26 (1.04)	-0.7	0.64	1.23	2.36	3.1	0.65 [0.10, 1.20]
			Placebo	31	28 (90.3)	0.60 (1.00)	-1.6	0.14	0.45	1.18	3.2	
		Week 52	Tezepelumab	32	26 (81.3)	1.18 (1.03)	-0.7	0.55	1.09	1.91	3.1	0.48 [-0.06, 1.02]
			Placebo	31	28 (90.3)	0.70 (0.98)	-1.6	0.09	0.50	1.18	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	39	32 (82.1)	4.07 (0.78)	2.2	3.59	4.05	4.41	5.8	
			Placebo	30	23 (76.7)	4.23 (0.54)	3.4	3.82	4.18	4.64	5.3	
		Week 4	Tezepelumab	39	36 (92.3)	4.68 (1.07)	1.6	4.05	4.82	5.36	6.9	
			Placebo	30	25 (83.3)	4.64 (1.03)	3.3	3.91	4.45	5.27	6.9	
		Week 8	Tezepelumab	39	36 (92.3)	5.01 (1.03)	2.9	4.18	4.86	5.95	6.5	
			Placebo	30	25 (83.3)	4.88 (1.06)	2.8	4.09	4.64	5.64	7.0	
		Week 12	Tezepelumab	39	36 (92.3)	5.24 (1.04)	3.0	4.64	5.09	6.27	7.0	
			Placebo	30	25 (83.3)	4.88 (1.14)	3.4	4.00	4.82	5.91	7.0	
		Week 16	Tezepelumab	39	36 (92.3)	5.14 (1.05)	2.8	4.32	5.05	6.09	6.9	
			Placebo	30	25 (83.3)	5.03 (1.07)	2.9	4.00	4.91	5.91	6.9	
		Week 20	Tezepelumab	39	37 (94.9)	5.08 (1.11)	2.8	4.27	4.91	6.00	7.0	
			Placebo	30	25 (83.3)	4.92 (1.18)	2.1	4.09	4.82	5.82	6.9	
		Week 24	Tezepelumab	39	37 (94.9)	5.12 (1.11)	2.9	4.27	4.91	6.09	7.0	
			Placebo	30	25 (83.3)	5.04 (1.18)	2.0	4.27	5.18	5.82	6.9	
		Week 28	Tezepelumab	39	39 (100.0)	5.14 (1.11)	3.2	4.18	4.91	6.27	7.0	
			Placebo	30	26 (86.7)	5.06 (1.26)	2.0	3.91	5.09	6.00	6.9	
		Week 32	Tezepelumab	39	39 (100.0)	5.19 (1.12)	2.9	4.27	5.18	6.18	7.0	
			Placebo	30	26 (86.7)	5.19 (1.22)	1.7	4.27	5.41	6.09	7.0	
		Week 36	Tezepelumab	39	39 (100.0)	5.20 (1.10)	3.0	4.27	5.36	6.09	7.0	
			Placebo	30	26 (86.7)	5.12 (1.18)	2.5	4.00	5.23	6.09	6.9	
		Week 40	Tezepelumab	39	39 (100.0)	5.10 (1.04)	3.3	4.36	5.00	5.91	7.0	
			Placebo	30	26 (86.7)	5.15 (1.31)	2.0	4.09	5.32	6.27	6.9	
		Week 44	Tezepelumab	39	39 (100.0)	5.08 (1.03)	3.0	4.09	5.00	5.91	7.0	
			Placebo	30	26 (86.7)	5.12 (1.24)	2.5	4.00	5.23	6.27	6.9	
		Week 48	Tezepelumab	39	39 (100.0)	5.12 (1.04)	2.6	4.27	5.18	6.00	7.0	
			Placebo	30	26 (86.7)	5.20 (1.26)	2.3	4.00	5.18	6.18	7.0	
		Week 52	Tezepelumab	39	39 (100.0)	5.18 (1.07)	2.6	4.27	5.18	6.18	7.0	
			Placebo	30	26 (86.7)	5.22 (1.17)	3.6	4.00	5.14	6.18	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	39	32 (82.1)	0.57 (1.05)	-2.8	-0.05	0.55	1.32	3.1	0.12 [-0.41, 0.66]
			Placebo	30	23 (76.7)	0.45 (0.85)	-1.0	0.00	0.45	0.55	2.5	
		Week 8	Tezepelumab	39	32 (82.1)	0.85 (1.04)	-1.3	0.09	0.68	1.45	3.7	0.18 [-0.36, 0.71]
			Placebo	30	23 (76.7)	0.68 (0.88)	-0.7	0.09	0.55	1.00	2.6	
		Week 12	Tezepelumab	39	32 (82.1)	1.13 (1.05)	-1.5	0.55	1.00	1.73	4.2	0.46 [-0.08, 1.00]
			Placebo	30	23 (76.7)	0.67 (0.95)	-0.9	0.00	0.55	1.09	2.5	
		Week 16	Tezepelumab	39	32 (82.1)	1.05 (1.05)	-1.6	0.36	0.82	1.73	3.5	0.22 [-0.31, 0.76]
			Placebo	30	23 (76.7)	0.83 (0.85)	-0.7	0.27	0.82	1.36	2.5	
		Week 20	Tezepelumab	39	32 (82.1)	1.00 (1.08)	-0.9	0.32	0.82	1.68	3.5	0.22 [-0.32, 0.76]
			Placebo	30	23 (76.7)	0.78 (0.88)	-1.5	0.18	0.73	1.45	2.5	
		Week 24	Tezepelumab	39	32 (82.1)	1.11 (1.05)	-0.6	0.32	0.95	1.77	3.5	0.28 [-0.26, 0.82]
			Placebo	30	23 (76.7)	0.83 (0.89)	-1.5	0.45	0.82	1.27	2.5	
		Week 28	Tezepelumab	39	32 (82.1)	1.12 (1.06)	-0.8	0.23	1.00	1.91	3.5	0.30 [-0.24, 0.84]
			Placebo	30	23 (76.7)	0.81 (0.94)	-1.5	0.18	0.82	1.27	2.5	
		Week 32	Tezepelumab	39	32 (82.1)	1.10 (1.09)	-0.5	0.32	0.82	1.86	3.5	0.16 [-0.38, 0.70]
			Placebo	30	23 (76.7)	0.93 (0.92)	-1.8	0.55	1.00	1.45	2.6	
		Week 36	Tezepelumab	39	32 (82.1)	1.14 (1.10)	-0.7	0.32	0.77	1.82	3.5	0.25 [-0.29, 0.79]
			Placebo	30	23 (76.7)	0.89 (0.90)	-1.0	0.27	1.00	1.64	2.6	
		Week 40	Tezepelumab	39	32 (82.1)	1.03 (1.03)	-0.9	0.27	0.91	1.73	3.5	0.10 [-0.44, 0.63]
			Placebo	30	23 (76.7)	0.93 (1.05)	-1.5	0.64	0.91	1.64	2.6	
		Week 44	Tezepelumab	39	32 (82.1)	1.02 (1.04)	-0.5	0.23	0.82	1.59	3.5	0.20 [-0.34, 0.74]
			Placebo	30	23 (76.7)	0.81 (1.01)	-1.1	0.09	0.64	1.55	2.7	
		Week 48	Tezepelumab	39	32 (82.1)	1.08 (1.03)	-0.6	0.36	1.05	1.59	3.5	0.16 [-0.38, 0.70]
			Placebo	30	23 (76.7)	0.92 (1.00)	-1.3	0.09	1.09	1.27	2.8	
		Week 52	Tezepelumab	39	32 (82.1)	1.13 (1.02)	-0.6	0.36	1.14	1.59	3.5	0.16 [-0.38, 0.70]
			Placebo	30	23 (76.7)	0.97 (0.92)	-0.8	0.36	1.00	1.27	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	27	26 (96.3)	4.21 (1.03)	2.1	3.73	4.18	4.64	6.3	
			Placebo	34	31 (91.2)	4.38 (0.93)	2.3	3.82	4.27	5.09	6.2	
		Week 4	Tezepelumab	27	24 (88.9)	5.16 (1.01)	3.2	4.14	5.32	6.00	6.8	
			Placebo	34	32 (94.1)	4.83 (1.04)	2.5	4.14	4.68	5.55	7.0	
		Week 8	Tezepelumab	27	26 (96.3)	5.34 (1.13)	3.0	4.18	5.32	6.36	6.9	
			Placebo	34	33 (97.1)	4.86 (1.10)	2.3	4.09	4.82	5.45	7.0	
		Week 12	Tezepelumab	27	26 (96.3)	5.53 (1.05)	3.5	4.91	5.27	6.55	7.0	
			Placebo	34	33 (97.1)	5.06 (1.11)	2.8	4.27	5.09	6.00	7.0	
		Week 16	Tezepelumab	27	26 (96.3)	5.54 (1.05)	3.6	4.73	5.50	6.55	7.0	
			Placebo	34	33 (97.1)	5.15 (1.21)	3.0	4.36	5.09	6.27	7.0	
		Week 20	Tezepelumab	27	26 (96.3)	5.49 (1.08)	3.5	4.64	5.32	6.36	7.0	
			Placebo	34	33 (97.1)	5.04 (1.14)	3.0	4.27	4.91	6.09	7.0	
		Week 24	Tezepelumab	27	26 (96.3)	5.59 (1.00)	3.9	4.82	5.55	6.55	7.0	
			Placebo	34	33 (97.1)	4.99 (1.18)	2.7	4.09	4.91	5.82	7.0	
		Week 28	Tezepelumab	27	26 (96.3)	5.50 (1.02)	2.9	4.82	5.55	6.36	7.0	
			Placebo	34	33 (97.1)	5.04 (1.29)	2.5	4.09	5.09	6.00	7.0	
		Week 32	Tezepelumab	27	26 (96.3)	5.56 (1.02)	3.4	4.82	5.64	6.55	7.0	
			Placebo	34	33 (97.1)	5.06 (1.13)	3.1	4.09	5.09	5.91	7.0	
		Week 36	Tezepelumab	27	26 (96.3)	5.62 (0.98)	3.2	4.91	5.68	6.27	7.0	
			Placebo	34	33 (97.1)	4.95 (1.19)	2.4	4.09	4.82	6.00	7.0	
		Week 40	Tezepelumab	27	26 (96.3)	5.71 (1.00)	3.5	5.00	5.73	6.55	7.0	
			Placebo	34	33 (97.1)	5.02 (1.23)	2.5	4.09	4.91	6.00	7.0	
		Week 44	Tezepelumab	27	26 (96.3)	5.74 (1.02)	3.8	4.91	5.82	6.55	7.0	
			Placebo	34	33 (97.1)	5.10 (1.15)	3.1	4.27	5.09	5.73	7.0	
		Week 48	Tezepelumab	27	26 (96.3)	5.81 (1.05)	3.1	5.09	6.09	6.55	7.0	
			Placebo	34	33 (97.1)	4.94 (1.14)	2.4	4.18	4.82	5.64	7.0	
		Week 52	Tezepelumab	27	26 (96.3)	5.70 (1.06)	3.1	4.91	5.86	6.55	7.0	
			Placebo	34	33 (97.1)	5.04 (1.13)	3.1	4.18	5.00	5.73	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	1.03 (0.85)	-0.7	0.36	1.09	1.55	2.7	0.68 [0.12, 1.23]
			Placebo	34	31 (91.2)	0.44 (0.89)	-1.5	-0.09	0.36	0.91	1.9	
		Week 8	Tezepelumab	27	25 (92.6)	1.12 (0.90)	-0.7	0.55	1.09	1.64	2.9	0.64 [0.10, 1.18]
			Placebo	34	31 (91.2)	0.54 (0.90)	-1.3	-0.18	0.55	1.18	2.2	
		Week 12	Tezepelumab	27	25 (92.6)	1.29 (0.97)	-0.7	0.82	1.27	1.82	3.0	0.60 [0.06, 1.13]
			Placebo	34	31 (91.2)	0.70 (1.02)	-1.3	0.09	0.91	1.27	3.3	
		Week 16	Tezepelumab	27	25 (92.6)	1.28 (0.95)	-0.7	0.64	1.36	1.91	3.0	0.45 [-0.09, 0.98]
			Placebo	34	31 (91.2)	0.84 (1.02)	-1.6	0.27	0.82	1.64	3.5	
		Week 20	Tezepelumab	27	25 (92.6)	1.24 (1.06)	-0.7	0.55	1.18	2.00	3.3	0.54 [0.01, 1.08]
			Placebo	34	31 (91.2)	0.71 (0.92)	-1.6	0.18	0.64	1.27	2.4	
		Week 24	Tezepelumab	27	25 (92.6)	1.35 (1.00)	-0.7	0.64	1.36	2.00	3.0	0.63 [0.09, 1.17]
			Placebo	34	31 (91.2)	0.68 (1.10)	-1.6	0.09	0.64	1.55	2.9	
		Week 28	Tezepelumab	27	25 (92.6)	1.26 (1.03)	-0.7	0.64	1.09	2.00	3.0	0.46 [-0.07, 0.99]
			Placebo	34	31 (91.2)	0.74 (1.20)	-1.6	-0.18	0.82	1.64	3.7	
		Week 32	Tezepelumab	27	25 (92.6)	1.32 (1.00)	-0.7	0.73	1.09	2.27	3.2	0.56 [0.02, 1.09]
			Placebo	34	31 (91.2)	0.75 (1.03)	-1.6	0.00	0.64	1.55	3.3	
		Week 36	Tezepelumab	27	25 (92.6)	1.39 (1.02)	-0.7	0.82	1.27	2.36	3.0	0.74 [0.19, 1.28]
			Placebo	34	31 (91.2)	0.63 (1.02)	-1.6	0.09	0.73	1.09	2.7	
		Week 40	Tezepelumab	27	25 (92.6)	1.46 (0.98)	-0.7	0.82	1.27	2.36	3.0	0.71 [0.16, 1.25]
			Placebo	34	31 (91.2)	0.72 (1.10)	-1.6	0.00	0.64	1.64	3.5	
		Week 44	Tezepelumab	27	25 (92.6)	1.50 (1.03)	-0.7	0.73	1.55	2.36	3.2	0.64 [0.10, 1.18]
			Placebo	34	31 (91.2)	0.80 (1.15)	-1.6	0.27	0.82	1.64	3.4	
		Week 48	Tezepelumab	27	25 (92.6)	1.57 (0.99)	-0.7	0.91	1.55	2.36	3.2	0.92 [0.36, 1.47]
			Placebo	34	31 (91.2)	0.63 (1.06)	-1.6	0.09	0.73	1.00	3.2	
		Week 52	Tezepelumab	27	25 (92.6)	1.47 (1.04)	-0.7	0.82	1.36	2.36	3.3	0.69 [0.15, 1.23]
			Placebo	34	31 (91.2)	0.74 (1.06)	-1.6	0.09	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	27	23 (85.2)	3.96 (0.66)	2.1	3.73	4.09	4.36	5.2	
			Placebo	29	23 (79.3)	4.26 (0.84)	2.3	3.73	4.27	4.45	6.0	
		Week 4	Tezepelumab	27	26 (96.3)	4.79 (0.98)	3.1	4.00	4.77	5.45	6.6	
			Placebo	29	25 (86.2)	4.63 (1.12)	2.5	3.82	4.55	5.36	7.0	
		Week 8	Tezepelumab	27	26 (96.3)	5.04 (0.98)	3.0	4.27	4.86	6.00	6.6	
			Placebo	29	27 (93.1)	4.71 (1.04)	2.8	3.91	4.64	5.45	7.0	
		Week 12	Tezepelumab	27	26 (96.3)	5.29 (0.98)	3.5	4.55	5.18	6.18	7.0	
			Placebo	29	27 (93.1)	4.83 (1.13)	2.8	3.91	4.73	5.55	6.9	
		Week 16	Tezepelumab	27	26 (96.3)	5.35 (1.02)	3.6	4.64	5.27	6.27	7.0	
			Placebo	29	27 (93.1)	4.70 (1.39)	1.1	3.82	4.55	5.91	7.0	
		Week 20	Tezepelumab	27	26 (96.3)	5.17 (1.25)	2.8	4.27	5.09	6.36	7.0	
			Placebo	29	27 (93.1)	4.57 (1.39)	1.1	3.91	4.36	5.73	6.9	
		Week 24	Tezepelumab	27	26 (96.3)	5.27 (1.12)	3.9	4.27	5.05	6.36	7.0	
			Placebo	29	27 (93.1)	4.50 (1.43)	1.1	3.55	4.36	5.36	6.9	
		Week 28	Tezepelumab	27	27 (100.0)	5.18 (1.10)	2.9	4.36	4.91	6.27	7.0	
			Placebo	29	27 (93.1)	4.58 (1.48)	1.1	3.82	4.64	5.64	6.9	
		Week 32	Tezepelumab	27	27 (100.0)	5.24 (1.15)	3.3	4.36	4.82	6.36	7.0	
			Placebo	29	27 (93.1)	4.60 (1.40)	1.1	3.91	4.55	5.55	7.0	
		Week 36	Tezepelumab	27	27 (100.0)	5.27 (1.10)	3.2	4.27	5.00	6.55	7.0	
			Placebo	29	27 (93.1)	4.51 (1.30)	2.4	3.73	4.36	5.45	6.9	
		Week 40	Tezepelumab	27	27 (100.0)	5.24 (1.02)	3.5	4.36	5.00	6.18	7.0	
			Placebo	29	27 (93.1)	4.61 (1.38)	2.0	3.55	4.36	5.91	6.9	
		Week 44	Tezepelumab	27	27 (100.0)	5.16 (1.04)	3.7	4.27	4.91	5.91	7.0	
			Placebo	29	27 (93.1)	4.57 (1.13)	2.5	3.73	4.55	5.27	6.9	
		Week 48	Tezepelumab	27	27 (100.0)	5.23 (1.07)	3.1	4.27	5.18	6.18	7.0	
			Placebo	29	27 (93.1)	4.53 (1.22)	2.3	3.82	4.36	5.45	6.9	
		Week 52	Tezepelumab	27	27 (100.0)	5.25 (1.05)	3.1	4.36	5.18	6.18	7.0	
			Placebo	29	27 (93.1)	4.63 (1.08)	2.9	3.82	4.36	5.64	6.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	0.87 (0.78)	-0.3	0.18	0.82	1.45	2.7	0.54 [-0.05, 1.14]
			Placebo	29	22 (75.9)	0.38 (1.04)	-1.5	-0.27	0.27	0.91	2.5	
		Week 8	Tezepelumab	27	23 (85.2)	0.96 (0.98)	-1.3	0.27	0.91	1.55	2.9	0.46 [-0.12, 1.05]
			Placebo	29	23 (79.3)	0.52 (0.91)	-1.3	0.00	0.36	1.00	2.6	
		Week 12	Tezepelumab	27	23 (85.2)	1.21 (0.92)	-0.5	0.36	1.18	1.73	3.0	0.64 [0.04, 1.23]
			Placebo	29	23 (79.3)	0.58 (1.06)	-1.3	-0.18	0.45	1.27	2.5	
		Week 16	Tezepelumab	27	23 (85.2)	1.26 (0.91)	-0.3	0.55	1.27	1.91	3.0	0.70 [0.10, 1.29]
			Placebo	29	23 (79.3)	0.49 (1.29)	-3.2	-0.64	0.82	1.55	2.3	
		Week 20	Tezepelumab	27	23 (85.2)	1.14 (1.20)	-0.9	-0.09	1.36	2.18	3.3	0.62 [0.03, 1.21]
			Placebo	29	23 (79.3)	0.38 (1.26)	-3.2	-0.09	0.64	1.27	2.4	
		Week 24	Tezepelumab	27	23 (85.2)	1.28 (1.05)	-0.3	0.36	1.36	2.00	3.0	0.84 [0.23, 1.44]
			Placebo	29	23 (79.3)	0.27 (1.34)	-3.2	-0.64	0.27	1.45	2.5	
		Week 28	Tezepelumab	27	23 (85.2)	1.19 (1.01)	-0.3	0.45	1.09	2.00	3.0	0.66 [0.07, 1.25]
			Placebo	29	23 (79.3)	0.38 (1.42)	-3.2	-0.64	0.64	1.18	2.5	
		Week 32	Tezepelumab	27	23 (85.2)	1.26 (1.08)	-0.5	0.36	1.27	2.00	3.2	0.71 [0.11, 1.31]
			Placebo	29	23 (79.3)	0.40 (1.35)	-3.2	-0.36	0.64	1.55	2.6	
		Week 36	Tezepelumab	27	23 (85.2)	1.32 (1.04)	-0.3	0.64	1.09	1.73	3.2	0.92 [0.31, 1.52]
			Placebo	29	23 (79.3)	0.30 (1.19)	-1.8	-0.73	0.45	1.09	2.4	
		Week 40	Tezepelumab	27	23 (85.2)	1.25 (0.92)	-0.3	0.64	1.09	1.82	3.0	0.72 [0.12, 1.32]
			Placebo	29	23 (79.3)	0.43 (1.30)	-1.6	-1.00	0.27	1.73	2.5	
		Week 44	Tezepelumab	27	23 (85.2)	1.18 (0.99)	-0.3	0.36	1.09	1.73	3.2	0.82 [0.22, 1.43]
			Placebo	29	23 (79.3)	0.32 (1.11)	-1.6	-0.73	0.36	1.27	2.5	
		Week 48	Tezepelumab	27	23 (85.2)	1.30 (0.95)	-0.3	0.82	1.18	1.64	3.2	0.99 [0.37, 1.60]
			Placebo	29	23 (79.3)	0.28 (1.10)	-1.6	-0.27	0.18	1.09	2.5	
		Week 52	Tezepelumab	27	23 (85.2)	1.32 (0.93)	-0.3	0.64	1.18	1.64	3.3	0.90 [0.29, 1.50]
			Placebo	29	23 (79.3)	0.44 (1.03)	-1.6	-0.09	0.27	1.27	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	4.29 (0.98)	2.4	3.64	4.14	4.82	6.3	
			Placebo	33	29 (87.9)	4.31 (0.76)	3.2	3.91	4.27	4.64	6.2	
		Week 4	Tezepelumab	34	30 (88.2)	4.91 (1.18)	1.6	4.09	5.23	5.82	6.9	
			Placebo	33	29 (87.9)	4.81 (0.98)	3.2	4.00	4.55	5.45	7.0	
		Week 8	Tezepelumab	34	32 (94.1)	5.19 (1.17)	2.9	4.05	5.32	6.27	6.9	
			Placebo	33	29 (87.9)	4.86 (1.08)	2.3	4.18	4.64	5.91	7.0	
		Week 12	Tezepelumab	34	32 (94.1)	5.39 (1.13)	3.0	4.68	5.18	6.50	7.0	
			Placebo	33	29 (87.9)	5.03 (1.06)	3.2	4.18	5.00	6.00	7.0	
		Week 16	Tezepelumab	34	32 (94.1)	5.26 (1.14)	2.8	4.32	5.27	6.09	7.0	
			Placebo	33	29 (87.9)	5.24 (1.05)	3.0	4.55	5.00	6.27	6.9	
		Week 20	Tezepelumab	34	32 (94.1)	5.29 (1.08)	3.2	4.55	5.14	6.32	7.0	
			Placebo	33	29 (87.9)	5.14 (1.03)	3.0	4.45	5.09	6.18	6.9	
		Week 24	Tezepelumab	34	32 (94.1)	5.36 (1.10)	2.9	4.50	5.23	6.23	7.0	
			Placebo	33	29 (87.9)	5.25 (0.99)	3.8	4.45	5.27	6.00	6.9	
		Week 28	Tezepelumab	34	33 (97.1)	5.41 (1.10)	3.2	4.55	5.36	6.36	7.0	
			Placebo	33	30 (90.9)	5.28 (1.18)	3.2	4.27	5.32	6.27	7.0	
		Week 32	Tezepelumab	34	33 (97.1)	5.44 (1.08)	2.9	4.82	5.45	6.36	7.0	
			Placebo	33	30 (90.9)	5.38 (1.02)	3.6	4.45	5.45	6.18	7.0	
		Week 36	Tezepelumab	34	33 (97.1)	5.45 (1.09)	3.0	4.73	5.55	6.27	7.0	
			Placebo	33	30 (90.9)	5.33 (0.99)	3.8	4.64	5.23	6.27	6.9	
		Week 40	Tezepelumab	34	33 (97.1)	5.46 (1.13)	3.3	4.82	5.45	6.45	7.0	
			Placebo	33	30 (90.9)	5.36 (1.08)	3.3	4.27	5.23	6.27	7.0	
		Week 44	Tezepelumab	34	33 (97.1)	5.47 (1.11)	3.0	4.55	5.55	6.36	7.0	
			Placebo	33	30 (90.9)	5.42 (1.12)	3.5	4.27	5.59	6.64	6.9	
		Week 48	Tezepelumab	34	33 (97.1)	5.53 (1.15)	2.6	4.73	5.82	6.45	7.0	
			Placebo	33	30 (90.9)	5.35 (1.07)	3.6	4.27	5.27	6.09	7.0	
		Week 52	Tezepelumab	34	33 (97.1)	5.50 (1.18)	2.6	4.64	6.00	6.45	7.0	
			Placebo	33	30 (90.9)	5.40 (1.10)	3.8	4.27	5.27	6.27	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	34	29 (85.3)	0.60 (1.08)	-2.8	0.00	0.45	1.27	2.5	0.11 [-0.40, 0.63]
			Placebo	33	29 (87.9)	0.49 (0.77)	-0.9	0.00	0.36	0.82	2.1	
		Week 8	Tezepelumab	34	31 (91.2)	0.89 (0.89)	-0.7	0.27	0.73	1.55	2.7	0.39 [-0.13, 0.90]
			Placebo	33	29 (87.9)	0.55 (0.89)	-0.9	-0.09	0.55	1.00	2.4	
		Week 12	Tezepelumab	34	31 (91.2)	1.11 (0.97)	-1.5	0.64	1.00	1.73	2.7	0.42 [-0.09, 0.93]
			Placebo	33	29 (87.9)	0.72 (0.90)	-1.2	0.09	0.73	1.09	3.3	
		Week 16	Tezepelumab	34	31 (91.2)	1.01 (1.02)	-1.6	0.36	0.91	1.82	2.7	0.09 [-0.41, 0.60]
			Placebo	33	29 (87.9)	0.92 (0.87)	-0.5	0.45	0.73	1.18	3.5	
		Week 20	Tezepelumab	34	31 (91.2)	1.03 (0.94)	-0.7	0.36	0.91	1.73	2.7	0.22 [-0.29, 0.73]
			Placebo	33	29 (87.9)	0.83 (0.81)	-0.5	0.27	0.73	1.27	2.5	
		Week 24	Tezepelumab	34	31 (91.2)	1.11 (0.98)	-0.7	0.36	1.00	1.91	2.9	0.18 [-0.33, 0.68]
			Placebo	33	29 (87.9)	0.94 (0.88)	-0.6	0.45	0.82	1.36	2.9	
		Week 28	Tezepelumab	34	31 (91.2)	1.11 (1.04)	-0.8	0.36	0.73	2.00	2.7	0.20 [-0.31, 0.71]
			Placebo	33	29 (87.9)	0.91 (1.00)	-0.7	0.36	0.91	1.27	3.7	
		Week 32	Tezepelumab	34	31 (91.2)	1.13 (0.97)	-0.7	0.45	0.91	1.91	2.7	0.13 [-0.37, 0.64]
			Placebo	33	29 (87.9)	1.01 (0.83)	-0.5	0.55	1.00	1.36	3.3	
		Week 36	Tezepelumab	34	31 (91.2)	1.15 (1.06)	-0.7	0.36	1.00	2.09	2.8	0.20 [-0.31, 0.71]
			Placebo	33	29 (87.9)	0.96 (0.78)	-0.5	0.45	0.91	1.27	2.7	
		Week 40	Tezepelumab	34	31 (91.2)	1.14 (1.07)	-0.9	0.27	1.09	2.36	2.8	0.15 [-0.36, 0.66]
			Placebo	33	29 (87.9)	1.00 (0.89)	-0.5	0.64	0.82	1.45	3.5	
		Week 44	Tezepelumab	34	31 (91.2)	1.18 (1.09)	-0.7	0.36	1.00	2.36	2.9	0.12 [-0.39, 0.63]
			Placebo	33	29 (87.9)	1.06 (1.03)	-0.5	0.45	0.91	1.55	3.4	
		Week 48	Tezepelumab	34	31 (91.2)	1.25 (1.08)	-0.7	0.36	1.09	2.36	3.1	0.26 [-0.25, 0.77]
			Placebo	33	29 (87.9)	0.98 (0.94)	-0.7	0.45	0.82	1.27	3.2	
		Week 52	Tezepelumab	34	31 (91.2)	1.17 (1.09)	-0.7	0.36	0.91	2.36	3.1	0.13 [-0.37, 0.64]
			Placebo	33	29 (87.9)	1.03 (0.96)	-0.7	0.45	0.82	1.27	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	4.00 (0.87)	2.1	3.59	4.23	4.55	5.2	
			Placebo	14	11 (78.6)	4.33 (0.78)	3.4	3.82	4.27	4.45	6.0	
		Week 4	Tezepelumab	23	21 (91.3)	5.06 (1.07)	3.2	4.27	5.09	6.00	6.9	
			Placebo	14	10 (71.4)	4.38 (0.98)	3.2	3.36	4.45	4.64	6.1	
		Week 8	Tezepelumab	23	21 (91.3)	5.06 (1.11)	3.0	4.27	4.91	6.09	6.6	
			Placebo	14	11 (78.6)	4.42 (1.05)	2.8	3.73	4.27	4.73	6.7	
		Week 12	Tezepelumab	23	21 (91.3)	5.30 (1.11)	3.5	4.27	5.09	6.36	7.0	
			Placebo	14	11 (78.6)	4.36 (1.19)	2.8	3.36	4.36	5.45	6.4	
		Week 16	Tezepelumab	23	21 (91.3)	5.30 (0.94)	3.6	4.55	5.27	6.00	6.7	
			Placebo	14	11 (78.6)	4.33 (1.65)	1.1	3.00	4.36	5.45	7.0	
		Week 20	Tezepelumab	23	22 (95.7)	5.19 (1.04)	3.5	4.27	5.18	6.09	7.0	
			Placebo	14	11 (78.6)	4.17 (1.66)	1.1	3.18	4.09	5.82	6.7	
		Week 24	Tezepelumab	23	22 (95.7)	5.25 (0.99)	3.9	4.27	5.18	6.09	7.0	
			Placebo	14	11 (78.6)	3.98 (1.71)	1.1	2.73	3.82	5.27	6.9	
		Week 28	Tezepelumab	23	23 (100.0)	5.14 (1.07)	2.9	4.36	4.91	5.82	7.0	
			Placebo	14	11 (78.6)	3.94 (1.65)	1.1	2.55	3.91	5.09	6.5	
		Week 32	Tezepelumab	23	23 (100.0)	5.16 (1.07)	3.4	4.27	4.91	6.00	7.0	
			Placebo	14	11 (78.6)	4.06 (1.57)	1.1	3.27	4.36	5.55	6.1	
		Week 36	Tezepelumab	23	23 (100.0)	5.22 (1.11)	3.2	4.27	5.00	6.18	7.0	
			Placebo	14	11 (78.6)	4.39 (1.53)	2.4	2.55	4.36	5.82	6.5	
		Week 40	Tezepelumab	23	23 (100.0)	5.15 (0.99)	3.5	4.36	5.00	5.82	7.0	
			Placebo	14	11 (78.6)	4.29 (1.57)	2.0	2.91	4.09	5.82	6.7	
		Week 44	Tezepelumab	23	23 (100.0)	5.22 (0.99)	3.8	4.27	5.27	6.00	7.0	
			Placebo	14	11 (78.6)	4.26 (1.17)	2.5	3.09	4.36	5.18	6.4	
		Week 48	Tezepelumab	23	23 (100.0)	5.26 (1.10)	3.1	4.27	5.45	6.27	7.0	
			Placebo	14	11 (78.6)	4.18 (1.35)	2.3	2.91	4.36	5.18	6.5	
		Week 52	Tezepelumab	23	23 (100.0)	5.31 (1.07)	3.1	4.27	5.45	6.27	7.0	
			Placebo	14	11 (78.6)	4.48 (1.02)	2.9	3.82	4.36	5.18	6.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	1.12 (0.83)	-0.3	0.45	1.23	1.55	3.1	1.29 [0.46, 2.12]
			Placebo	14	10 (71.4)	0.05 (0.86)	-1.5	-0.36	0.05	0.45	1.8	
		Week 8	Tezepelumab	23	20 (87.0)	1.02 (1.14)	-1.3	0.23	1.00	1.64	3.7	0.89 [0.12, 1.66]
			Placebo	14	11 (78.6)	0.09 (0.81)	-1.3	-0.55	0.09	0.55	1.5	
		Week 12	Tezepelumab	23	20 (87.0)	1.25 (1.14)	-0.5	0.36	1.27	1.82	4.2	1.10 [0.32, 1.89]
			Placebo	14	11 (78.6)	0.03 (1.02)	-1.3	-1.00	0.00	0.91	1.8	
		Week 16	Tezepelumab	23	20 (87.0)	1.25 (0.94)	-0.3	0.55	1.27	1.59	3.5	1.06 [0.28, 1.85]
			Placebo	14	11 (78.6)	0.00 (1.53)	-3.2	-0.82	0.55	1.36	1.8	
		Week 20	Tezepelumab	23	20 (87.0)	1.13 (1.12)	-0.6	0.36	1.09	1.91	3.5	1.02 [0.24, 1.81]
			Placebo	14	11 (78.6)	-0.17 (1.50)	-3.2	-1.45	0.18	1.27	1.6	
		Week 24	Tezepelumab	23	20 (87.0)	1.22 (1.07)	-0.3	0.50	0.95	1.82	3.5	1.26 [0.46, 2.07]
			Placebo	14	11 (78.6)	-0.35 (1.51)	-3.2	-1.55	-0.55	1.09	1.6	
		Week 28	Tezepelumab	23	20 (87.0)	1.17 (1.07)	-0.3	0.55	0.82	1.82	3.5	1.27 [0.46, 2.07]
			Placebo	14	11 (78.6)	-0.39 (1.50)	-3.2	-1.55	-0.55	1.00	1.6	
		Week 32	Tezepelumab	23	20 (87.0)	1.11 (1.14)	-0.4	0.18	0.82	1.86	3.5	1.10 [0.31, 1.89]
			Placebo	14	11 (78.6)	-0.27 (1.45)	-3.2	-1.64	0.09	0.64	1.6	
		Week 36	Tezepelumab	23	20 (87.0)	1.22 (1.13)	-0.3	0.23	1.00	1.68	3.5	0.95 [0.18, 1.73]
			Placebo	14	11 (78.6)	0.06 (1.38)	-1.8	-1.45	0.45	1.18	1.8	
		Week 40	Tezepelumab	23	20 (87.0)	1.16 (1.06)	-0.3	0.36	0.82	1.73	3.5	0.99 [0.21, 1.77]
			Placebo	14	11 (78.6)	-0.04 (1.47)	-1.6	-1.36	-0.55	1.64	2.3	
		Week 44	Tezepelumab	23	20 (87.0)	1.22 (1.07)	-0.3	0.36	1.14	1.77	3.5	1.15 [0.36, 1.94]
			Placebo	14	11 (78.6)	-0.07 (1.20)	-1.6	-1.09	-0.45	1.00	2.2	
		Week 48	Tezepelumab	23	20 (87.0)	1.32 (1.06)	-0.3	0.55	1.32	1.77	3.5	1.30 [0.49, 2.11]
			Placebo	14	11 (78.6)	-0.15 (1.25)	-1.6	-1.36	0.09	0.45	2.3	
		Week 52	Tezepelumab	23	20 (87.0)	1.37 (1.01)	-0.3	0.64	1.32	1.77	3.5	1.18 [0.38, 1.97]
			Placebo	14	11 (78.6)	0.15 (1.10)	-1.6	-0.55	0.09	0.55	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	4.23 (0.89)	2.4	3.64	4.09	4.55	6.3	
			Placebo	44	37 (84.1)	4.35 (0.84)	2.3	3.82	4.27	4.82	6.2	
		Week 4	Tezepelumab	40	36 (90.0)	4.79 (1.08)	1.6	4.00	4.95	5.55	6.8	
			Placebo	44	40 (90.9)	4.86 (1.06)	2.5	4.00	4.77	5.55	7.0	
		Week 8	Tezepelumab	40	38 (95.0)	5.22 (1.07)	2.9	4.45	5.32	6.09	6.9	
			Placebo	44	41 (93.2)	5.01 (1.05)	2.3	4.18	4.91	5.64	7.0	
		Week 12	Tezepelumab	40	38 (95.0)	5.41 (1.02)	3.0	4.73	5.23	6.27	7.0	
			Placebo	44	41 (93.2)	5.18 (1.07)	3.3	4.27	5.18	6.00	7.0	
		Week 16	Tezepelumab	40	38 (95.0)	5.33 (1.13)	2.8	4.36	5.32	6.27	7.0	
			Placebo	44	41 (93.2)	5.22 (1.13)	3.0	4.27	5.09	6.27	7.0	
		Week 20	Tezepelumab	40	38 (95.0)	5.28 (1.17)	2.8	4.27	5.23	6.36	7.0	
			Placebo	44	41 (93.2)	5.09 (1.12)	3.0	4.18	5.00	6.18	7.0	
		Week 24	Tezepelumab	40	38 (95.0)	5.37 (1.15)	2.9	4.36	5.41	6.36	7.0	
			Placebo	44	41 (93.2)	5.18 (1.07)	3.1	4.27	5.27	6.00	7.0	
		Week 28	Tezepelumab	40	39 (97.5)	5.37 (1.10)	3.2	4.55	5.45	6.36	7.0	
			Placebo	44	42 (95.5)	5.27 (1.20)	3.1	4.09	5.27	6.27	7.0	
		Week 32	Tezepelumab	40	39 (97.5)	5.45 (1.11)	2.9	4.45	5.45	6.45	7.0	
			Placebo	44	42 (95.5)	5.30 (1.11)	3.1	4.27	5.41	6.18	7.0	
		Week 36	Tezepelumab	40	39 (97.5)	5.45 (1.06)	3.0	4.64	5.55	6.27	7.0	
			Placebo	44	42 (95.5)	5.14 (1.15)	3.1	4.09	5.05	6.09	7.0	
		Week 40	Tezepelumab	40	39 (97.5)	5.44 (1.12)	3.3	4.36	5.45	6.45	7.0	
			Placebo	44	42 (95.5)	5.23 (1.21)	3.1	4.09	5.23	6.27	7.0	
		Week 44	Tezepelumab	40	39 (97.5)	5.41 (1.13)	3.0	4.55	5.45	6.36	7.0	
			Placebo	44	42 (95.5)	5.29 (1.16)	3.1	4.09	5.32	6.36	7.0	
		Week 48	Tezepelumab	40	39 (97.5)	5.47 (1.11)	2.6	4.36	5.45	6.45	7.0	
			Placebo	44	42 (95.5)	5.25 (1.14)	3.1	4.27	5.32	6.09	7.0	
		Week 52	Tezepelumab	40	39 (97.5)	5.43 (1.14)	2.6	4.36	5.36	6.45	7.0	
			Placebo	44	42 (95.5)	5.26 (1.20)	3.1	4.09	5.45	6.18	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	40	32 (80.0)	0.53 (1.07)	-2.8	-0.09	0.50	1.14	2.7	0.01 [-0.47, 0.48]
			Placebo	44	37 (84.1)	0.53 (0.85)	-1.2	0.09	0.45	0.82	2.5	
		Week 8	Tezepelumab	40	34 (85.0)	0.93 (0.93)	-0.7	0.27	0.82	1.55	2.9	0.23 [-0.24, 0.69]
			Placebo	44	37 (84.1)	0.74 (0.81)	-0.9	0.18	0.73	1.00	2.6	
		Week 12	Tezepelumab	40	34 (85.0)	1.16 (0.95)	-1.5	0.82	1.05	1.73	3.0	0.31 [-0.16, 0.78]
			Placebo	44	37 (84.1)	0.87 (0.92)	-0.9	0.18	1.00	1.27	3.3	
		Week 16	Tezepelumab	40	34 (85.0)	1.08 (1.07)	-1.6	0.36	0.95	1.91	3.0	0.13 [-0.34, 0.59]
			Placebo	44	37 (84.1)	0.96 (0.86)	-0.7	0.36	0.91	1.64	3.5	
		Week 20	Tezepelumab	40	34 (85.0)	1.07 (1.10)	-0.9	0.36	0.86	2.00	3.3	0.24 [-0.23, 0.71]
			Placebo	44	37 (84.1)	0.85 (0.78)	-0.5	0.18	0.73	1.27	2.4	
		Week 24	Tezepelumab	40	34 (85.0)	1.21 (1.06)	-0.7	0.36	1.18	2.00	3.0	0.30 [-0.17, 0.77]
			Placebo	44	37 (84.1)	0.93 (0.86)	-0.6	0.27	0.82	1.45	2.9	
		Week 28	Tezepelumab	40	34 (85.0)	1.17 (1.07)	-0.8	0.36	1.14	2.00	3.0	0.18 [-0.29, 0.65]
			Placebo	44	37 (84.1)	0.99 (0.95)	-0.6	0.27	0.91	1.36	3.7	
		Week 32	Tezepelumab	40	34 (85.0)	1.23 (1.02)	-0.7	0.55	1.09	2.00	3.2	0.22 [-0.25, 0.69]
			Placebo	44	37 (84.1)	1.02 (0.87)	-0.6	0.45	1.00	1.55	3.3	
		Week 36	Tezepelumab	40	34 (85.0)	1.23 (1.05)	-0.7	0.64	1.05	2.09	3.0	0.40 [-0.07, 0.87]
			Placebo	44	37 (84.1)	0.84 (0.88)	-1.0	0.18	0.82	1.36	2.7	
		Week 40	Tezepelumab	40	34 (85.0)	1.21 (1.04)	-0.9	0.55	1.09	2.00	3.0	0.27 [-0.20, 0.73]
			Placebo	44	37 (84.1)	0.95 (0.93)	-1.0	0.27	0.82	1.45	3.5	
		Week 44	Tezepelumab	40	34 (85.0)	1.21 (1.07)	-0.7	0.45	1.00	2.27	3.2	0.23 [-0.24, 0.69]
			Placebo	44	37 (84.1)	0.97 (1.00)	-0.9	0.36	0.82	1.64	3.4	
		Week 48	Tezepelumab	40	34 (85.0)	1.26 (1.06)	-0.7	0.36	1.14	2.36	3.2	0.32 [-0.15, 0.79]
			Placebo	44	37 (84.1)	0.94 (0.92)	-0.7	0.18	0.91	1.55	3.2	
		Week 52	Tezepelumab	40	34 (85.0)	1.19 (1.08)	-0.7	0.36	1.05	2.36	3.3	0.21 [-0.26, 0.68]
			Placebo	44	37 (84.1)	0.98 (0.99)	-0.8	0.18	1.00	1.64	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.88 (1.32)	2.6	2.64	3.73	5.27	5.3	
			Placebo	7	7 (100.0)	4.09 (0.36)	3.5	3.91	4.18	4.36	4.5	
		Week 4	Tezepelumab	3	3 (100.0)	4.67 (0.92)	4.1	4.09	4.18	5.73	5.7	
			Placebo	7	7 (100.0)	4.65 (0.93)	3.6	3.91	4.27	5.45	5.9	
		Week 8	Tezepelumab	3	3 (100.0)	4.91 (1.26)	4.2	4.18	4.18	6.36	6.4	
			Placebo	7	7 (100.0)	4.60 (1.19)	3.1	4.09	4.18	6.00	6.5	
		Week 12	Tezepelumab	3	3 (100.0)	5.24 (1.29)	4.1	4.09	5.00	6.64	6.6	
			Placebo	7	7 (100.0)	4.81 (0.93)	3.9	4.00	4.64	5.27	6.5	
		Week 16	Tezepelumab	3	3 (100.0)	5.12 (1.27)	4.1	4.09	4.73	6.55	6.5	
			Placebo	7	7 (100.0)	5.01 (0.88)	3.9	4.45	4.91	5.55	6.6	
		Week 20	Tezepelumab	3	3 (100.0)	5.27 (1.11)	4.5	4.55	4.73	6.55	6.5	
			Placebo	7	7 (100.0)	5.13 (0.85)	4.1	4.36	5.09	5.73	6.6	
		Week 24	Tezepelumab	3	3 (100.0)	5.09 (1.26)	4.3	4.27	4.45	6.55	6.5	
			Placebo	7	7 (100.0)	5.05 (0.97)	3.9	4.18	4.91	6.00	6.6	
		Week 28	Tezepelumab	3	3 (100.0)	5.15 (1.22)	4.3	4.27	4.64	6.55	6.5	
			Placebo	7	7 (100.0)	4.94 (1.12)	3.2	4.27	4.91	5.73	6.7	
		Week 32	Tezepelumab	3	3 (100.0)	5.27 (1.19)	4.2	4.18	5.09	6.55	6.5	
			Placebo	7	7 (100.0)	5.08 (0.93)	3.6	4.27	5.09	5.45	6.5	
		Week 36	Tezepelumab	3	3 (100.0)	5.48 (1.05)	4.5	4.45	5.45	6.55	6.5	
			Placebo	7	7 (100.0)	5.00 (0.91)	3.8	4.64	5.00	5.09	6.8	
		Week 40	Tezepelumab	3	3 (100.0)	5.58 (0.84)	5.0	5.00	5.18	6.55	6.5	
			Placebo	7	7 (100.0)	5.16 (0.90)	4.1	4.27	5.09	5.55	6.8	
		Week 44	Tezepelumab	3	3 (100.0)	5.45 (1.05)	4.5	4.45	5.36	6.55	6.5	
			Placebo	7	7 (100.0)	5.06 (1.12)	3.8	4.00	5.09	5.91	6.9	
		Week 48	Tezepelumab	3	3 (100.0)	5.45 (0.96)	4.7	4.73	5.09	6.55	6.5	
			Placebo	7	7 (100.0)	4.95 (0.98)	4.0	4.18	4.82	5.09	7.0	
		Week 52	Tezepelumab	3	3 (100.0)	5.45 (0.96)	4.7	4.73	5.09	6.55	6.5	
			Placebo	7	7 (100.0)	4.97 (0.98)	4.0	4.18	4.82	5.09	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	0.79 (0.58)	0.5	0.45	0.45	1.45	1.5	0.27 [-1.09, 1.63]
			Placebo	7	7 (100.0)	0.56 (0.92)	-0.6	-0.36	0.36	1.55	1.7	
		Week 8	Tezepelumab	3	3 (100.0)	1.03 (0.55)	0.5	0.45	1.09	1.55	1.5	0.48 [-0.89, 1.85]
			Placebo	7	7 (100.0)	0.51 (1.22)	-0.8	-0.27	-0.18	2.09	2.3	
		Week 12	Tezepelumab	3	3 (100.0)	1.36 (1.00)	0.4	0.36	1.36	2.36	2.4	0.75 [-0.65, 2.15]
			Placebo	7	7 (100.0)	0.71 (0.82)	0.0	0.09	0.73	0.91	2.4	
		Week 16	Tezepelumab	3	3 (100.0)	1.24 (0.86)	0.4	0.36	1.27	2.09	2.1	0.38 [-0.99, 1.74]
			Placebo	7	7 (100.0)	0.92 (0.85)	-0.1	0.45	0.64	1.64	2.5	
		Week 20	Tezepelumab	3	3 (100.0)	1.39 (0.47)	1.0	1.00	1.27	1.91	1.9	0.49 [-0.88, 1.87]
			Placebo	7	7 (100.0)	1.04 (0.79)	0.4	0.45	0.73	1.82	2.5	
		Week 24	Tezepelumab	3	3 (100.0)	1.21 (0.46)	0.7	0.73	1.27	1.64	1.6	0.30 [-1.06, 1.66]
			Placebo	7	7 (100.0)	0.96 (0.93)	0.1	0.27	0.55	2.09	2.5	
		Week 28	Tezepelumab	3	3 (100.0)	1.27 (0.73)	0.5	0.55	1.27	2.00	2.0	0.43 [-0.94, 1.80]
			Placebo	7	7 (100.0)	0.84 (1.07)	-0.7	0.27	0.82	1.82	2.5	
		Week 32	Tezepelumab	3	3 (100.0)	1.39 (1.01)	0.5	0.45	1.27	2.45	2.5	0.47 [-0.90, 1.84]
			Placebo	7	7 (100.0)	0.99 (0.82)	-0.3	0.55	0.82	1.55	2.4	
		Week 36	Tezepelumab	3	3 (100.0)	1.61 (1.08)	0.7	0.73	1.27	2.82	2.8	0.78 [-0.62, 2.19]
			Placebo	7	7 (100.0)	0.91 (0.81)	0.3	0.36	0.73	1.09	2.6	
		Week 40	Tezepelumab	3	3 (100.0)	1.70 (0.73)	1.3	1.27	1.27	2.55	2.5	0.79 [-0.61, 2.20]
			Placebo	7	7 (100.0)	1.06 (0.82)	0.2	0.64	0.82	1.64	2.6	
		Week 44	Tezepelumab	3	3 (100.0)	1.58 (1.03)	0.7	0.73	1.27	2.73	2.7	0.57 [-0.81, 1.95]
			Placebo	7	7 (100.0)	0.97 (1.06)	-0.4	0.36	0.82	2.00	2.7	
		Week 48	Tezepelumab	3	3 (100.0)	1.58 (0.77)	1.0	1.00	1.27	2.45	2.5	0.83 [-0.58, 2.24]
			Placebo	7	7 (100.0)	0.86 (0.89)	0.3	0.27	0.55	0.82	2.8	
		Week 52	Tezepelumab	3	3 (100.0)	1.58 (0.77)	1.0	1.00	1.27	2.45	2.5	0.81 [-0.60, 2.22]
			Placebo	7	7 (100.0)	0.88 (0.88)	0.3	0.45	0.55	0.82	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.31 (1.22)	2.1	3.86	4.18	5.18	5.9	
			Placebo	13	9 (69.2)	4.35 (0.67)	3.8	3.91	4.27	4.36	6.0	
		Week 4	Tezepelumab	9	8 (88.9)	5.01 (0.88)	3.2	4.68	5.14	5.73	5.8	
			Placebo	13	11 (84.6)	4.60 (0.85)	3.2	3.91	4.55	5.36	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.47 (1.19)	3.0	5.09	5.59	6.27	6.8	
			Placebo	13	12 (92.3)	4.45 (0.83)	3.1	3.95	4.18	5.05	6.0	
		Week 12	Tezepelumab	9	8 (88.9)	5.50 (1.22)	3.5	4.73	5.41	6.64	7.0	
			Placebo	13	12 (92.3)	4.41 (0.87)	2.8	3.91	4.50	5.18	5.5	
		Week 16	Tezepelumab	9	8 (88.9)	5.65 (1.08)	3.6	5.09	5.68	6.55	6.9	
			Placebo	13	12 (92.3)	4.80 (0.92)	3.0	4.41	4.73	5.32	6.6	
		Week 20	Tezepelumab	9	8 (88.9)	5.24 (1.34)	3.5	3.95	5.27	6.55	6.8	
			Placebo	13	12 (92.3)	4.68 (0.93)	3.2	4.05	4.55	5.23	6.6	
		Week 24	Tezepelumab	9	8 (88.9)	5.44 (1.14)	3.9	4.50	5.45	6.41	6.9	
			Placebo	13	12 (92.3)	4.70 (1.16)	2.7	4.00	4.32	5.77	6.6	
		Week 28	Tezepelumab	9	8 (88.9)	5.35 (1.29)	2.9	4.73	5.45	6.36	6.8	
			Placebo	13	13 (100.0)	4.73 (1.34)	2.5	3.82	4.36	5.73	6.7	
		Week 32	Tezepelumab	9	8 (88.9)	5.44 (1.26)	3.4	4.64	5.41	6.55	7.0	
			Placebo	13	13 (100.0)	4.87 (1.22)	3.3	3.82	4.55	5.55	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.48 (1.27)	3.2	4.77	5.50	6.64	6.8	
			Placebo	13	13 (100.0)	4.88 (1.28)	2.4	4.36	4.64	6.00	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.48 (1.19)	3.5	4.77	5.50	6.41	7.0	
			Placebo	13	13 (100.0)	4.76 (1.25)	2.5	3.91	4.36	5.55	6.9	
		Week 44	Tezepelumab	9	8 (88.9)	5.60 (1.12)	3.8	4.77	5.64	6.64	6.9	
			Placebo	13	13 (100.0)	4.92 (1.16)	3.1	4.27	4.91	5.64	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.50 (1.22)	3.1	4.82	5.86	6.36	6.8	
			Placebo	13	13 (100.0)	4.78 (1.24)	2.4	4.18	4.73	5.73	6.8	
		Week 52	Tezepelumab	9	8 (88.9)	5.51 (1.23)	3.1	4.82	5.86	6.41	6.8	
			Placebo	13	13 (100.0)	4.87 (1.10)	3.5	4.18	4.36	5.73	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.65 (0.51)	-0.1	0.00	0.82	1.09	1.2	0.45 [-0.55, 1.45]
			Placebo	13	9 (69.2)	0.27 (1.01)	-1.5	-0.36	0.36	0.64	1.7	
		Week 8	Tezepelumab	9	7 (77.8)	1.12 (0.71)	0.1	0.82	0.91	1.64	2.4	0.95 [-0.10, 2.00]
			Placebo	13	9 (69.2)	0.24 (1.05)	-1.3	-0.18	-0.09	1.00	2.1	
		Week 12	Tezepelumab	9	7 (77.8)	1.21 (0.67)	0.4	0.82	1.09	1.55	2.5	1.39 [0.27, 2.50]
			Placebo	13	9 (69.2)	0.01 (0.98)	-1.3	-1.00	0.09	0.82	1.3	
		Week 16	Tezepelumab	9	7 (77.8)	1.35 (0.78)	0.4	0.82	1.09	1.91	2.7	0.70 [-0.32, 1.72]
			Placebo	13	9 (69.2)	0.62 (1.20)	-1.6	0.55	0.82	1.09	2.4	
		Week 20	Tezepelumab	9	7 (77.8)	1.10 (1.07)	-0.6	0.55	0.82	2.00	2.6	0.55 [-0.46, 1.55]
			Placebo	13	9 (69.2)	0.46 (1.25)	-1.6	-0.55	0.73	0.82	2.4	
		Week 24	Tezepelumab	9	7 (77.8)	1.35 (0.89)	0.3	0.64	1.00	2.36	2.5	0.63 [-0.38, 1.65]
			Placebo	13	9 (69.2)	0.58 (1.43)	-1.6	-0.55	0.82	1.82	2.4	
		Week 28	Tezepelumab	9	7 (77.8)	1.18 (0.91)	0.5	0.55	0.82	2.36	2.6	0.60 [-0.42, 1.61]
			Placebo	13	9 (69.2)	0.42 (1.48)	-1.6	-0.73	0.82	1.64	2.4	
		Week 32	Tezepelumab	9	7 (77.8)	1.31 (0.79)	0.5	0.64	1.09	2.27	2.5	0.69 [-0.33, 1.71]
			Placebo	13	9 (69.2)	0.54 (1.33)	-1.6	-0.55	0.82	1.55	2.4	
		Week 36	Tezepelumab	9	7 (77.8)	1.32 (0.78)	0.7	0.82	0.91	2.36	2.5	0.67 [-0.35, 1.69]
			Placebo	13	9 (69.2)	0.53 (1.43)	-1.6	-0.55	0.82	1.36	2.4	
		Week 40	Tezepelumab	9	7 (77.8)	1.32 (0.88)	0.2	0.82	1.09	2.45	2.5	0.75 [-0.28, 1.77]
			Placebo	13	9 (69.2)	0.43 (1.38)	-1.6	-0.55	0.64	1.64	2.4	
		Week 44	Tezepelumab	9	7 (77.8)	1.47 (0.97)	0.2	0.82	1.09	2.73	2.7	0.76 [-0.26, 1.79]
			Placebo	13	9 (69.2)	0.56 (1.34)	-1.6	-0.55	0.73	1.64	2.4	
		Week 48	Tezepelumab	9	7 (77.8)	1.34 (0.88)	0.4	0.64	1.00	2.36	2.6	0.81 [-0.22, 1.84]
			Placebo	13	9 (69.2)	0.38 (1.37)	-1.6	-0.55	0.82	1.09	2.4	
		Week 52	Tezepelumab	9	7 (77.8)	1.35 (0.80)	0.4	0.82	1.00	2.36	2.5	0.76 [-0.27, 1.79]
			Placebo	13	9 (69.2)	0.56 (1.19)	-1.6	0.09	0.82	1.09	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.11 (0.84)	2.2	3.64	4.09	4.55	6.3	
			Placebo	52	46 (88.5)	4.30 (0.80)	2.3	3.73	4.27	4.73	6.2	
		Week 4	Tezepelumab	57	52 (91.2)	4.85 (1.09)	1.6	4.05	4.95	5.73	6.9	
			Placebo	52	46 (88.5)	4.78 (1.07)	2.5	4.00	4.59	5.64	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.10 (1.06)	2.9	4.18	5.18	6.09	6.9	
			Placebo	52	47 (90.4)	4.95 (1.11)	2.3	4.09	4.82	5.82	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.35 (1.03)	3.0	4.64	5.14	6.36	7.0	
			Placebo	52	47 (90.4)	5.13 (1.12)	3.3	4.18	5.09	6.18	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.26 (1.06)	2.8	4.36	5.14	6.18	7.0	
			Placebo	52	47 (90.4)	5.09 (1.32)	1.1	4.00	5.09	6.27	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.25 (1.08)	2.8	4.27	5.18	6.27	7.0	
			Placebo	52	47 (90.4)	4.99 (1.31)	1.1	4.09	5.00	6.18	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.29 (1.09)	2.9	4.27	5.18	6.27	7.0	
			Placebo	52	47 (90.4)	5.00 (1.30)	1.1	4.09	5.18	6.00	7.0	
		Week 28	Tezepelumab	57	57 (100.0)	5.27 (1.06)	3.2	4.36	5.27	6.00	7.0	
			Placebo	52	47 (90.4)	5.06 (1.37)	1.1	4.09	5.09	6.00	7.0	
		Week 32	Tezepelumab	57	57 (100.0)	5.32 (1.08)	2.9	4.36	5.27	6.18	7.0	
			Placebo	52	47 (90.4)	5.09 (1.28)	1.1	4.09	5.27	6.00	7.0	
		Week 36	Tezepelumab	57	57 (100.0)	5.36 (1.05)	3.0	4.45	5.45	6.09	7.0	
			Placebo	52	47 (90.4)	5.01 (1.21)	2.5	4.00	5.00	6.09	7.0	
		Week 40	Tezepelumab	57	57 (100.0)	5.32 (1.05)	3.3	4.36	5.18	6.18	7.0	
			Placebo	52	47 (90.4)	5.13 (1.29)	2.0	4.09	5.18	6.18	7.0	
		Week 44	Tezepelumab	57	57 (100.0)	5.31 (1.07)	3.0	4.45	5.36	6.18	7.0	
			Placebo	52	47 (90.4)	5.11 (1.22)	2.5	4.00	5.27	6.27	7.0	
		Week 48	Tezepelumab	57	57 (100.0)	5.38 (1.08)	2.6	4.36	5.36	6.36	7.0	
			Placebo	52	47 (90.4)	5.08 (1.21)	2.3	4.00	5.00	6.09	7.0	
		Week 52	Tezepelumab	57	57 (100.0)	5.37 (1.08)	2.6	4.36	5.18	6.36	7.0	
			Placebo	52	47 (90.4)	5.14 (1.19)	2.9	4.00	5.00	6.09	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	0.78 (1.05)	-2.8	0.00	0.68	1.50	3.1	0.32 [-0.09, 0.73]
			Placebo	52	45 (86.5)	0.48 (0.84)	-1.2	0.00	0.36	0.82	2.5	
		Week 8	Tezepelumab	57	50 (87.7)	0.95 (1.02)	-1.3	0.27	0.82	1.55	3.7	0.32 [-0.08, 0.72]
			Placebo	52	46 (88.5)	0.64 (0.85)	-0.9	0.00	0.59	1.00	2.6	
		Week 12	Tezepelumab	57	50 (87.7)	1.20 (1.05)	-1.5	0.45	1.14	1.73	4.2	0.39 [-0.01, 0.80]
			Placebo	52	46 (88.5)	0.81 (0.92)	-0.9	0.09	0.86	1.27	3.3	
		Week 16	Tezepelumab	57	50 (87.7)	1.12 (1.04)	-1.6	0.36	1.00	1.82	3.5	0.32 [-0.09, 0.72]
			Placebo	52	46 (88.5)	0.79 (1.06)	-3.2	0.27	0.77	1.55	3.5	
		Week 20	Tezepelumab	57	50 (87.7)	1.11 (1.08)	-0.9	0.36	1.00	1.91	3.5	0.38 [-0.02, 0.79]
			Placebo	52	46 (88.5)	0.71 (1.00)	-3.2	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	57	50 (87.7)	1.20 (1.05)	-0.7	0.36	1.18	1.91	3.5	0.47 [0.06, 0.88]
			Placebo	52	46 (88.5)	0.70 (1.08)	-3.2	0.09	0.64	1.36	2.9	
		Week 28	Tezepelumab	57	50 (87.7)	1.18 (1.06)	-0.8	0.36	1.14	2.00	3.5	0.39 [-0.02, 0.79]
			Placebo	52	46 (88.5)	0.75 (1.15)	-3.2	0.18	0.82	1.27	3.7	
		Week 32	Tezepelumab	57	50 (87.7)	1.18 (1.08)	-0.7	0.36	0.95	1.91	3.5	0.35 [-0.05, 0.75]
			Placebo	52	46 (88.5)	0.80 (1.08)	-3.2	0.36	0.82	1.36	3.3	
		Week 36	Tezepelumab	57	50 (87.7)	1.24 (1.10)	-0.7	0.36	1.18	1.91	3.5	0.50 [0.09, 0.90]
			Placebo	52	46 (88.5)	0.73 (0.94)	-1.8	0.18	0.73	1.18	2.7	
		Week 40	Tezepelumab	57	50 (87.7)	1.21 (1.05)	-0.9	0.36	1.09	1.91	3.5	0.35 [-0.05, 0.76]
			Placebo	52	46 (88.5)	0.83 (1.05)	-1.5	0.27	0.77	1.45	3.5	
		Week 44	Tezepelumab	57	50 (87.7)	1.20 (1.07)	-0.7	0.36	1.05	1.91	3.5	0.37 [-0.04, 0.77]
			Placebo	52	46 (88.5)	0.81 (1.08)	-1.4	0.27	0.73	1.45	3.4	
		Week 48	Tezepelumab	57	50 (87.7)	1.29 (1.06)	-0.7	0.45	1.23	2.00	3.5	0.50 [0.09, 0.90]
			Placebo	52	46 (88.5)	0.78 (1.00)	-1.4	0.09	0.77	1.27	3.2	
		Week 52	Tezepelumab	57	50 (87.7)	1.27 (1.07)	-0.7	0.55	1.18	1.91	3.5	0.40 [-0.00, 0.81]
			Placebo	52	46 (88.5)	0.85 (1.01)	-1.4	0.09	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	4.41 (0.76)	3.7	3.82	4.27	4.55	5.8	
			Placebo	3	2 (66.7)	3.59 (0.32)	3.4	3.36	3.59	3.82	3.8	
		Week 4	Tezepelumab	7	7 (100.0)	4.75 (1.06)	3.6	3.64	4.73	5.82	6.3	
			Placebo	3	3 (100.0)	3.39 (0.23)	3.2	3.18	3.36	3.64	3.6	
		Week 8	Tezepelumab	7	7 (100.0)	5.49 (0.71)	4.5	4.64	5.73	6.18	6.2	
			Placebo	3	3 (100.0)	3.82 (0.16)	3.6	3.64	3.91	3.91	3.9	
		Week 12	Tezepelumab	7	7 (100.0)	5.69 (0.74)	4.7	5.00	5.55	6.36	6.6	
			Placebo	3	3 (100.0)	3.36 (0.55)	2.8	2.82	3.36	3.91	3.9	
		Week 16	Tezepelumab	7	7 (100.0)	5.39 (0.84)	3.9	4.73	5.45	6.18	6.2	
			Placebo	3	3 (100.0)	3.85 (0.78)	3.0	3.00	4.00	4.55	4.5	
		Week 20	Tezepelumab	7	7 (100.0)	5.17 (1.17)	2.8	4.82	5.27	6.00	6.4	
			Placebo	3	3 (100.0)	3.73 (0.48)	3.2	3.18	3.91	4.09	4.1	
		Week 24	Tezepelumab	7	7 (100.0)	5.27 (0.87)	4.1	4.18	5.45	6.09	6.4	
			Placebo	3	3 (100.0)	3.48 (0.77)	2.7	2.73	3.45	4.27	4.3	
		Week 28	Tezepelumab	7	7 (100.0)	5.30 (0.90)	3.5	4.91	5.45	5.82	6.4	
			Placebo	3	3 (100.0)	3.45 (0.79)	2.5	2.55	3.91	3.91	3.9	
		Week 32	Tezepelumab	7	7 (100.0)	5.31 (1.03)	3.3	4.82	5.64	6.00	6.4	
			Placebo	3	3 (100.0)	3.94 (0.64)	3.3	3.27	4.00	4.55	4.5	
		Week 36	Tezepelumab	7	7 (100.0)	5.47 (0.63)	4.4	5.45	5.45	5.55	6.5	
			Placebo	3	3 (100.0)	3.55 (1.07)	2.4	2.36	3.82	4.45	4.5	
		Week 40	Tezepelumab	7	7 (100.0)	5.42 (0.54)	4.4	5.18	5.55	5.82	6.0	
			Placebo	3	3 (100.0)	3.52 (0.84)	2.5	2.55	3.91	4.09	4.1	
		Week 44	Tezepelumab	7	7 (100.0)	5.25 (0.72)	3.7	5.18	5.45	5.55	6.0	
			Placebo	3	3 (100.0)	3.97 (0.91)	3.1	3.09	3.91	4.91	4.9	
		Week 48	Tezepelumab	7	7 (100.0)	5.42 (0.78)	4.1	5.00	5.45	6.18	6.5	
			Placebo	3	3 (100.0)	3.64 (1.19)	2.4	2.36	3.82	4.73	4.7	
		Week 52	Tezepelumab	7	7 (100.0)	5.42 (0.78)	4.1	5.00	5.45	6.18	6.5	
			Placebo	3	3 (100.0)	4.00 (0.33)	3.7	3.73	3.91	4.36	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	0.53 (0.68)	-0.1	0.00	0.36	0.82	1.7	1.31 [-0.45, 3.08]
			Placebo	3	2 (66.7)	-0.32 (0.45)	-0.6	-0.64	-0.32	0.00	0.0	
		Week 8	Tezepelumab	7	6 (85.7)	1.05 (0.74)	0.1	0.27	1.23	1.64	1.8	1.22 [-0.52, 2.97]
			Placebo	3	2 (66.7)	0.18 (0.51)	-0.2	-0.18	0.18	0.55	0.5	
		Week 12	Tezepelumab	7	6 (85.7)	1.18 (0.39)	0.8	0.82	1.09	1.45	1.8	3.65 [1.04, 6.26]
			Placebo	3	2 (66.7)	-0.50 (0.71)	-1.0	-1.00	-0.50	0.00	0.0	
		Week 16	Tezepelumab	7	6 (85.7)	0.85 (0.56)	0.2	0.36	0.82	1.45	1.5	1.42 [-0.37, 3.21]
			Placebo	3	2 (66.7)	-0.09 (1.03)	-0.8	-0.82	-0.09	0.64	0.6	
		Week 20	Tezepelumab	7	6 (85.7)	0.62 (0.87)	-0.9	0.55	0.59	1.45	1.5	0.65 [-0.99, 2.29]
			Placebo	3	2 (66.7)	0.05 (0.96)	-0.6	-0.64	0.05	0.73	0.7	
		Week 24	Tezepelumab	7	6 (85.7)	0.83 (0.70)	0.3	0.27	0.55	1.36	2.0	1.84 [-0.07, 3.75]
			Placebo	3	2 (66.7)	-0.50 (0.84)	-1.1	-1.09	-0.50	0.09	0.1	
		Week 28	Tezepelumab	7	6 (85.7)	0.80 (0.59)	-0.2	0.55	0.91	1.09	1.5	1.55 [-0.28, 3.37]
			Placebo	3	2 (66.7)	-0.36 (1.29)	-1.3	-1.27	-0.36	0.55	0.5	
		Week 32	Tezepelumab	7	6 (85.7)	0.82 (0.77)	-0.5	0.55	0.86	1.27	1.8	0.99 [-0.70, 2.69]
			Placebo	3	2 (66.7)	0.05 (0.84)	-0.5	-0.55	0.05	0.64	0.6	
		Week 36	Tezepelumab	7	6 (85.7)	1.05 (0.37)	0.6	0.73	1.00	1.27	1.6	2.39 [0.29, 4.48]
			Placebo	3	2 (66.7)	-0.50 (1.35)	-1.5	-1.45	-0.50	0.45	0.5	
		Week 40	Tezepelumab	7	6 (85.7)	0.94 (0.48)	0.2	0.64	1.05	1.36	1.4	1.67 [-0.19, 3.53]
			Placebo	3	2 (66.7)	-0.27 (1.41)	-1.3	-1.27	-0.27	0.73	0.7	
		Week 44	Tezepelumab	7	6 (85.7)	0.85 (0.62)	0.0	0.18	1.05	1.27	1.5	1.39 [-0.39, 3.18]
			Placebo	3	2 (66.7)	-0.09 (0.90)	-0.7	-0.73	-0.09	0.55	0.5	
		Week 48	Tezepelumab	7	6 (85.7)	1.08 (0.61)	0.4	0.36	1.23	1.36	1.9	2.01 [0.05, 3.97]
			Placebo	3	2 (66.7)	-0.50 (1.35)	-1.5	-1.45	-0.50	0.45	0.5	
		Week 52	Tezepelumab	7	6 (85.7)	1.08 (0.61)	0.4	0.36	1.23	1.36	1.9	1.50 [-0.31, 3.32]
			Placebo	3	2 (66.7)	0.23 (0.19)	0.1	0.09	0.23	0.36	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	59	52 (88.1)	4.10 (0.91)	2.1	3.59	4.09	4.55	6.3	
			Placebo	62	53 (85.5)	4.34 (0.78)	2.3	3.91	4.27	4.64	6.2	
		Week 4	Tezepelumab	59	53 (89.8)	4.89 (1.07)	1.6	4.18	5.00	5.73	6.9	
			Placebo	62	54 (87.1)	4.82 (1.00)	2.5	4.00	4.64	5.45	7.0	
		Week 8	Tezepelumab	59	55 (93.2)	5.11 (1.11)	2.9	4.09	5.18	6.09	6.9	
			Placebo	62	56 (90.3)	4.91 (1.07)	2.3	4.09	4.82	5.64	7.0	
		Week 12	Tezepelumab	59	55 (93.2)	5.33 (1.07)	3.0	4.64	5.09	6.36	7.0	
			Placebo	62	56 (90.3)	5.07 (1.06)	3.2	4.23	5.05	6.00	7.0	
		Week 16	Tezepelumab	59	55 (93.2)	5.30 (1.09)	2.8	4.36	5.18	6.45	7.0	
			Placebo	62	56 (90.3)	5.09 (1.24)	1.1	4.23	5.05	6.05	7.0	
		Week 20	Tezepelumab	59	56 (94.9)	5.26 (1.11)	3.2	4.27	5.14	6.32	7.0	
			Placebo	62	56 (90.3)	4.99 (1.24)	1.1	4.14	4.95	6.00	7.0	
		Week 24	Tezepelumab	59	56 (94.9)	5.32 (1.12)	2.9	4.32	5.18	6.27	7.0	
			Placebo	62	56 (90.3)	5.02 (1.25)	1.1	4.14	5.14	5.91	7.0	
		Week 28	Tezepelumab	59	58 (98.3)	5.28 (1.11)	2.9	4.36	5.18	6.27	7.0	
			Placebo	62	57 (91.9)	5.07 (1.34)	1.1	4.09	5.09	6.00	7.0	
		Week 32	Tezepelumab	59	58 (98.3)	5.34 (1.11)	2.9	4.36	5.23	6.36	7.0	
			Placebo	62	57 (91.9)	5.11 (1.27)	1.1	4.27	5.27	6.00	7.0	
		Week 36	Tezepelumab	59	58 (98.3)	5.36 (1.11)	3.0	4.45	5.50	6.27	7.0	
			Placebo	62	57 (91.9)	5.06 (1.18)	2.5	4.09	5.00	6.00	7.0	
		Week 40	Tezepelumab	59	58 (98.3)	5.33 (1.11)	3.3	4.36	5.09	6.27	7.0	
			Placebo	62	57 (91.9)	5.13 (1.25)	2.0	4.09	5.18	6.18	7.0	
		Week 44	Tezepelumab	59	58 (98.3)	5.36 (1.11)	3.0	4.45	5.32	6.36	7.0	
			Placebo	62	57 (91.9)	5.13 (1.19)	2.5	4.09	5.27	6.00	7.0	
		Week 48	Tezepelumab	59	58 (98.3)	5.39 (1.13)	2.6	4.36	5.41	6.45	7.0	
			Placebo	62	57 (91.9)	5.09 (1.18)	2.3	4.18	5.00	6.09	7.0	
		Week 52	Tezepelumab	59	58 (98.3)	5.39 (1.13)	2.6	4.36	5.27	6.45	7.0	
			Placebo	62	57 (91.9)	5.14 (1.17)	2.9	4.09	5.00	6.09	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	59	49 (83.1)	0.79 (1.03)	-2.8	0.00	0.82	1.45	3.1	0.34 [-0.06, 0.73]
			Placebo	62	52 (83.9)	0.47 (0.86)	-1.5	0.05	0.36	0.86	2.5	
		Week 8	Tezepelumab	59	51 (86.4)	0.96 (1.01)	-1.3	0.27	0.91	1.55	3.7	0.38 [-0.01, 0.77]
			Placebo	62	53 (85.5)	0.59 (0.90)	-1.3	0.00	0.55	1.00	2.6	
		Week 12	Tezepelumab	59	51 (86.4)	1.20 (1.06)	-1.5	0.45	1.09	1.73	4.2	0.48 [0.09, 0.87]
			Placebo	62	53 (85.5)	0.73 (0.96)	-1.3	0.09	0.82	1.18	3.3	
		Week 16	Tezepelumab	59	51 (86.4)	1.19 (1.04)	-1.6	0.36	1.09	1.91	3.5	0.37 [-0.02, 0.76]
			Placebo	62	53 (85.5)	0.80 (1.08)	-3.2	0.27	0.82	1.55	3.5	
		Week 20	Tezepelumab	59	51 (86.4)	1.17 (1.09)	-0.7	0.36	1.00	2.00	3.5	0.45 [0.06, 0.84]
			Placebo	62	53 (85.5)	0.69 (1.04)	-3.2	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	59	51 (86.4)	1.26 (1.05)	-0.7	0.55	1.27	2.00	3.5	0.50 [0.11, 0.89]
			Placebo	62	53 (85.5)	0.72 (1.12)	-3.2	0.18	0.82	1.45	2.9	
		Week 28	Tezepelumab	59	51 (86.4)	1.22 (1.07)	-0.8	0.45	1.18	2.00	3.5	0.43 [0.04, 0.82]
			Placebo	62	53 (85.5)	0.74 (1.20)	-3.2	0.09	0.82	1.36	3.7	
		Week 32	Tezepelumab	59	51 (86.4)	1.24 (1.07)	-0.7	0.36	1.09	2.27	3.5	0.41 [0.03, 0.80]
			Placebo	62	53 (85.5)	0.78 (1.12)	-3.2	0.27	0.82	1.55	3.3	
		Week 36	Tezepelumab	59	51 (86.4)	1.27 (1.12)	-0.7	0.36	1.09	2.36	3.5	0.50 [0.11, 0.89]
			Placebo	62	53 (85.5)	0.74 (0.99)	-1.8	0.18	0.82	1.27	2.7	
		Week 40	Tezepelumab	59	51 (86.4)	1.25 (1.07)	-0.9	0.36	1.09	2.36	3.5	0.41 [0.02, 0.80]
			Placebo	62	53 (85.5)	0.81 (1.09)	-1.6	0.18	0.82	1.64	3.5	
		Week 44	Tezepelumab	59	51 (86.4)	1.28 (1.09)	-0.7	0.45	1.09	2.36	3.5	0.43 [0.05, 0.82]
			Placebo	62	53 (85.5)	0.80 (1.11)	-1.6	0.27	0.82	1.55	3.4	
		Week 48	Tezepelumab	59	51 (86.4)	1.32 (1.07)	-0.7	0.45	1.18	2.36	3.5	0.53 [0.14, 0.93]
			Placebo	62	53 (85.5)	0.76 (1.04)	-1.6	0.09	0.82	1.27	3.2	
		Week 52	Tezepelumab	59	51 (86.4)	1.30 (1.07)	-0.7	0.55	1.18	2.36	3.5	0.45 [0.06, 0.84]
			Placebo	62	53 (85.5)	0.82 (1.05)	-1.6	0.09	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	4.55 (0.76)	3.8	4.18	4.36	4.55	5.8	
			Placebo	2	1 (50.0)	3.36	3.4	3.36	3.36	3.36	3.4	
		Week 4	Tezepelumab	6	6 (100.0)	4.94 (1.02)	3.6	4.00	4.95	5.82	6.3	
			Placebo	2	2 (100.0)	3.50 (0.19)	3.4	3.36	3.50	3.64	3.6	
		Week 8	Tezepelumab	6	6 (100.0)	5.64 (0.66)	4.5	5.36	5.82	6.18	6.2	
			Placebo	2	2 (100.0)	3.91 (0.00)	3.9	3.91	3.91	3.91	3.9	
		Week 12	Tezepelumab	6	6 (100.0)	5.85 (0.66)	5.0	5.27	5.91	6.36	6.6	
			Placebo	2	2 (100.0)	3.64 (0.39)	3.4	3.36	3.64	3.91	3.9	
		Week 16	Tezepelumab	6	6 (100.0)	5.64 (0.59)	4.7	5.27	5.73	6.18	6.2	
			Placebo	2	2 (100.0)	4.27 (0.39)	4.0	4.00	4.27	4.55	4.5	
		Week 20	Tezepelumab	6	6 (100.0)	5.56 (0.59)	4.8	5.09	5.55	6.00	6.4	
			Placebo	2	2 (100.0)	4.00 (0.13)	3.9	3.91	4.00	4.09	4.1	
		Week 24	Tezepelumab	6	6 (100.0)	5.45 (0.80)	4.1	5.18	5.50	6.09	6.4	
			Placebo	2	2 (100.0)	3.86 (0.58)	3.5	3.45	3.86	4.27	4.3	
		Week 28	Tezepelumab	6	6 (100.0)	5.59 (0.50)	4.9	5.27	5.59	5.82	6.4	
			Placebo	2	2 (100.0)	3.91 (0.00)	3.9	3.91	3.91	3.91	3.9	
		Week 32	Tezepelumab	6	6 (100.0)	5.65 (0.55)	4.8	5.27	5.73	6.00	6.4	
			Placebo	2	2 (100.0)	4.27 (0.39)	4.0	4.00	4.27	4.55	4.5	
		Week 36	Tezepelumab	6	6 (100.0)	5.65 (0.44)	5.5	5.45	5.45	5.55	6.5	
			Placebo	2	2 (100.0)	4.14 (0.45)	3.8	3.82	4.14	4.45	4.5	
		Week 40	Tezepelumab	6	6 (100.0)	5.59 (0.30)	5.2	5.36	5.59	5.82	6.0	
			Placebo	2	2 (100.0)	4.00 (0.13)	3.9	3.91	4.00	4.09	4.1	
		Week 44	Tezepelumab	6	6 (100.0)	5.50 (0.27)	5.2	5.36	5.45	5.55	6.0	
			Placebo	2	2 (100.0)	4.41 (0.71)	3.9	3.91	4.41	4.91	4.9	
		Week 48	Tezepelumab	6	6 (100.0)	5.64 (0.57)	5.0	5.18	5.50	6.18	6.5	
			Placebo	2	2 (100.0)	4.27 (0.64)	3.8	3.82	4.27	4.73	4.7	
		Week 52	Tezepelumab	6	6 (100.0)	5.64 (0.57)	5.0	5.18	5.50	6.18	6.5	
			Placebo	2	2 (100.0)	4.05 (0.45)	3.7	3.73	4.05	4.36	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	6	5 (83.3)	0.65 (0.68)	0.0	0.18	0.55	0.82	1.7	NE
			Placebo	2	1 (50.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 8	Tezepelumab	6	5 (83.3)	1.07 (0.82)	0.1	0.27	1.55	1.64	1.8	NE
			Placebo	2	1 (50.0)	0.55	0.5	0.55	0.55	0.55	0.5	
		Week 12	Tezepelumab	6	5 (83.3)	1.22 (0.43)	0.8	0.82	1.18	1.45	1.8	NE
			Placebo	2	1 (50.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 16	Tezepelumab	6	5 (83.3)	0.98 (0.51)	0.4	0.55	1.09	1.45	1.5	NE
			Placebo	2	1 (50.0)	0.64	0.6	0.64	0.64	0.64	0.6	
		Week 20	Tezepelumab	6	5 (83.3)	0.93 (0.48)	0.5	0.55	0.64	1.45	1.5	NE
			Placebo	2	1 (50.0)	0.73	0.7	0.73	0.73	0.73	0.7	
		Week 24	Tezepelumab	6	5 (83.3)	0.91 (0.76)	0.3	0.27	0.64	1.36	2.0	NE
			Placebo	2	1 (50.0)	0.09	0.1	0.09	0.09	0.09	0.1	
		Week 28	Tezepelumab	6	5 (83.3)	1.00 (0.39)	0.5	0.73	1.09	1.09	1.5	NE
			Placebo	2	1 (50.0)	0.55	0.5	0.55	0.55	0.55	0.5	
		Week 32	Tezepelumab	6	5 (83.3)	1.07 (0.50)	0.5	0.73	1.00	1.27	1.8	NE
			Placebo	2	1 (50.0)	0.64	0.6	0.64	0.64	0.64	0.6	
		Week 36	Tezepelumab	6	5 (83.3)	1.13 (0.35)	0.7	0.91	1.09	1.27	1.6	NE
			Placebo	2	1 (50.0)	0.45	0.5	0.45	0.45	0.45	0.5	
		Week 40	Tezepelumab	6	5 (83.3)	1.00 (0.51)	0.2	0.82	1.27	1.36	1.4	NE
			Placebo	2	1 (50.0)	0.73	0.7	0.73	0.73	0.73	0.7	
		Week 44	Tezepelumab	6	5 (83.3)	1.02 (0.51)	0.2	1.00	1.09	1.27	1.5	NE
			Placebo	2	1 (50.0)	0.55	0.5	0.55	0.55	0.55	0.5	
		Week 48	Tezepelumab	6	5 (83.3)	1.22 (0.56)	0.4	1.09	1.36	1.36	1.9	NE
			Placebo	2	1 (50.0)	0.45	0.5	0.45	0.45	0.45	0.5	
		Week 52	Tezepelumab	6	5 (83.3)	1.22 (0.56)	0.4	1.09	1.36	1.36	1.9	NE
			Placebo	2	1 (50.0)	0.36	0.4	0.36	0.36	0.36	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	4.10 (0.90)	2.1	3.64	4.09	4.55	6.3	
			Placebo	63	54 (85.7)	4.33 (0.78)	2.3	3.91	4.27	4.64	6.2	
		Week 4	Tezepelumab	60	54 (90.0)	4.87 (1.08)	1.6	4.18	4.95	5.73	6.9	
			Placebo	63	55 (87.3)	4.79 (1.02)	2.5	4.00	4.64	5.45	7.0	
		Week 8	Tezepelumab	60	56 (93.3)	5.10 (1.10)	2.9	4.14	5.18	6.09	6.9	
			Placebo	63	57 (90.5)	4.88 (1.08)	2.3	4.09	4.82	5.64	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.31 (1.07)	3.0	4.64	5.09	6.36	7.0	
			Placebo	63	57 (90.5)	5.03 (1.09)	2.8	4.18	5.00	6.00	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.27 (1.10)	2.8	4.32	5.14	6.36	7.0	
			Placebo	63	57 (90.5)	5.06 (1.26)	1.1	4.18	5.00	6.00	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.22 (1.15)	2.8	4.27	5.09	6.27	7.0	
			Placebo	63	57 (90.5)	4.96 (1.26)	1.1	4.09	4.91	5.91	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.30 (1.12)	2.9	4.27	5.18	6.27	7.0	
			Placebo	63	57 (90.5)	4.98 (1.27)	1.1	4.09	5.09	5.82	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.25 (1.12)	2.9	4.36	5.18	6.27	7.0	
			Placebo	63	58 (92.1)	5.02 (1.37)	1.1	4.09	5.09	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.31 (1.13)	2.9	4.36	5.18	6.36	7.0	
			Placebo	63	58 (92.1)	5.07 (1.28)	1.1	4.09	5.18	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.34 (1.11)	3.0	4.36	5.45	6.27	7.0	
			Placebo	63	58 (92.1)	5.01 (1.22)	2.4	4.09	5.00	6.00	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.32 (1.11)	3.3	4.36	5.09	6.27	7.0	
			Placebo	63	58 (92.1)	5.08 (1.29)	2.0	4.09	5.14	6.18	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.33 (1.12)	3.0	4.36	5.27	6.36	7.0	
			Placebo	63	58 (92.1)	5.10 (1.21)	2.5	4.09	5.23	6.00	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.37 (1.13)	2.6	4.27	5.36	6.45	7.0	
			Placebo	63	58 (92.1)	5.04 (1.22)	2.3	4.09	5.00	6.09	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.36 (1.13)	2.6	4.36	5.18	6.45	7.0	
			Placebo	63	58 (92.1)	5.12 (1.17)	2.9	4.09	5.00	6.09	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	60	50 (83.3)	0.77 (1.02)	-2.8	0.00	0.82	1.45	3.1	0.34 [-0.05, 0.73]
			Placebo	63	53 (84.1)	0.45 (0.87)	-1.5	0.00	0.36	0.82	2.5	
		Week 8	Tezepelumab	60	52 (86.7)	0.96 (1.00)	-1.3	0.32	0.91	1.55	3.7	0.40 [0.01, 0.78]
			Placebo	63	54 (85.7)	0.58 (0.90)	-1.3	-0.09	0.55	1.00	2.6	
		Week 12	Tezepelumab	60	52 (86.7)	1.20 (1.05)	-1.5	0.45	1.09	1.73	4.2	0.50 [0.11, 0.89]
			Placebo	63	54 (85.7)	0.69 (0.98)	-1.3	0.09	0.77	1.18	3.3	
		Week 16	Tezepelumab	60	52 (86.7)	1.17 (1.04)	-1.6	0.36	1.05	1.91	3.5	0.38 [-0.01, 0.76]
			Placebo	63	54 (85.7)	0.77 (1.09)	-3.2	0.27	0.82	1.55	3.5	
		Week 20	Tezepelumab	60	52 (86.7)	1.13 (1.11)	-0.9	0.36	1.00	2.00	3.5	0.43 [0.04, 0.81]
			Placebo	63	54 (85.7)	0.67 (1.05)	-3.2	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	60	52 (86.7)	1.24 (1.05)	-0.7	0.50	1.18	1.95	3.5	0.51 [0.12, 0.90]
			Placebo	63	54 (85.7)	0.69 (1.14)	-3.2	0.09	0.73	1.45	2.9	
		Week 28	Tezepelumab	60	52 (86.7)	1.20 (1.08)	-0.8	0.41	1.05	2.00	3.5	0.43 [0.05, 0.82]
			Placebo	63	54 (85.7)	0.70 (1.22)	-3.2	0.09	0.82	1.36	3.7	
		Week 32	Tezepelumab	60	52 (86.7)	1.21 (1.09)	-0.7	0.36	1.00	2.14	3.5	0.40 [0.02, 0.79]
			Placebo	63	54 (85.7)	0.76 (1.12)	-3.2	0.27	0.82	1.55	3.3	
		Week 36	Tezepelumab	60	52 (86.7)	1.26 (1.11)	-0.7	0.41	1.05	2.23	3.5	0.52 [0.14, 0.91]
			Placebo	63	54 (85.7)	0.70 (1.03)	-1.8	0.09	0.77	1.27	2.7	
		Week 40	Tezepelumab	60	52 (86.7)	1.24 (1.06)	-0.9	0.41	1.09	2.18	3.5	0.43 [0.05, 0.82]
			Placebo	63	54 (85.7)	0.77 (1.11)	-1.6	0.18	0.77	1.64	3.5	
		Week 44	Tezepelumab	60	52 (86.7)	1.25 (1.09)	-0.7	0.41	1.05	2.32	3.5	0.44 [0.05, 0.82]
			Placebo	63	54 (85.7)	0.77 (1.12)	-1.6	0.09	0.77	1.55	3.4	
		Week 48	Tezepelumab	60	52 (86.7)	1.30 (1.07)	-0.7	0.45	1.18	2.36	3.5	0.55 [0.16, 0.94]
			Placebo	63	54 (85.7)	0.72 (1.07)	-1.6	0.09	0.82	1.27	3.2	
		Week 52	Tezepelumab	60	52 (86.7)	1.28 (1.07)	-0.7	0.55	1.18	2.36	3.5	0.45 [0.06, 0.84]
			Placebo	63	54 (85.7)	0.81 (1.04)	-1.6	0.09	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	17	15 (88.2)	3.99 (1.26)	2.1	3.27	3.64	5.27	5.9	
			Placebo	21	20 (95.2)	4.33 (0.78)	3.3	3.86	4.27	4.41	6.2	
		Week 4	Tezepelumab	17	15 (88.2)	4.65 (0.96)	3.2	3.91	4.55	5.73	5.8	
			Placebo	21	20 (95.2)	4.89 (1.05)	3.2	3.95	5.05	5.55	7.0	
		Week 8	Tezepelumab	17	16 (94.1)	4.99 (1.21)	2.9	3.91	5.27	6.00	6.8	
			Placebo	21	21 (100.0)	4.87 (0.94)	3.6	4.00	4.82	5.45	7.0	
		Week 12	Tezepelumab	17	16 (94.1)	5.32 (1.14)	3.4	4.77	5.14	6.45	7.0	
			Placebo	21	21 (100.0)	5.17 (1.04)	2.8	4.45	5.27	6.00	7.0	
		Week 16	Tezepelumab	17	16 (94.1)	5.33 (1.11)	3.4	4.55	5.41	6.18	7.0	
			Placebo	21	21 (100.0)	5.19 (1.41)	1.1	4.73	5.45	6.00	7.0	
		Week 20	Tezepelumab	17	16 (94.1)	5.24 (1.15)	3.2	4.41	5.23	6.18	6.8	
			Placebo	21	21 (100.0)	4.96 (1.35)	1.1	4.09	5.18	5.73	7.0	
		Week 24	Tezepelumab	17	16 (94.1)	5.27 (1.18)	2.9	4.32	5.32	6.18	6.9	
			Placebo	21	21 (100.0)	4.90 (1.39)	1.1	4.27	5.09	5.55	7.0	
		Week 28	Tezepelumab	17	16 (94.1)	5.24 (1.19)	2.9	4.36	5.59	6.18	6.6	
			Placebo	21	21 (100.0)	5.04 (1.58)	1.1	3.91	5.09	6.00	7.0	
		Week 32	Tezepelumab	17	16 (94.1)	5.30 (1.16)	2.9	4.64	5.45	6.14	7.0	
			Placebo	21	21 (100.0)	5.19 (1.38)	1.1	4.55	5.45	6.00	7.0	
		Week 36	Tezepelumab	17	16 (94.1)	5.35 (1.20)	3.0	4.68	5.59	6.27	6.8	
			Placebo	21	21 (100.0)	4.86 (1.29)	2.4	4.00	5.00	5.36	7.0	
		Week 40	Tezepelumab	17	16 (94.1)	5.42 (1.18)	3.3	4.64	5.64	6.32	7.0	
			Placebo	21	21 (100.0)	5.05 (1.37)	2.5	4.00	5.18	6.09	7.0	
		Week 44	Tezepelumab	17	16 (94.1)	5.43 (1.19)	3.0	4.64	5.64	6.36	6.9	
			Placebo	21	21 (100.0)	5.10 (1.23)	2.9	4.00	5.27	5.91	7.0	
		Week 48	Tezepelumab	17	16 (94.1)	5.30 (1.29)	2.6	4.64	5.36	6.50	6.8	
			Placebo	21	21 (100.0)	4.90 (1.21)	2.4	4.27	4.82	5.45	7.0	
		Week 52	Tezepelumab	17	16 (94.1)	5.31 (1.33)	2.6	4.64	5.59	6.50	6.8	
			Placebo	21	21 (100.0)	5.00 (1.12)	2.9	4.27	4.82	5.64	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	17	13 (76.5)	0.71 (0.90)	-0.7	0.00	0.82	1.27	2.5	0.09 [-0.61, 0.80]
			Placebo	21	19 (90.5)	0.63 (0.85)	-0.7	0.00	0.55	1.55	1.8	
		Week 8	Tezepelumab	17	14 (82.4)	0.90 (0.95)	-0.7	0.09	1.00	1.55	2.7	0.35 [-0.34, 1.04]
			Placebo	21	20 (95.2)	0.59 (0.84)	-0.5	-0.09	0.36	1.09	2.2	
		Week 12	Tezepelumab	17	14 (82.4)	1.21 (0.99)	-0.7	0.82	1.23	1.73	2.7	0.31 [-0.37, 1.00]
			Placebo	21	20 (95.2)	0.91 (0.93)	-1.0	0.32	0.86	1.23	3.3	
		Week 16	Tezepelumab	17	14 (82.4)	1.19 (0.97)	-0.7	0.36	1.32	1.91	2.5	0.25 [-0.44, 0.93]
			Placebo	21	20 (95.2)	0.89 (1.38)	-3.2	0.41	0.95	1.73	3.5	
		Week 20	Tezepelumab	17	14 (82.4)	1.12 (1.01)	-0.7	0.27	1.14	1.91	2.6	0.37 [-0.32, 1.06]
			Placebo	21	20 (95.2)	0.69 (1.26)	-3.2	0.18	0.73	1.77	2.4	
		Week 24	Tezepelumab	17	14 (82.4)	1.19 (1.08)	-0.7	0.27	1.27	1.82	2.9	0.45 [-0.24, 1.14]
			Placebo	21	20 (95.2)	0.61 (1.40)	-3.2	-0.05	0.64	1.64	2.9	
		Week 28	Tezepelumab	17	14 (82.4)	1.15 (1.06)	-0.7	0.45	1.05	2.00	2.5	0.28 [-0.41, 0.97]
			Placebo	21	20 (95.2)	0.77 (1.53)	-3.2	-0.05	0.91	1.77	3.7	
		Week 32	Tezepelumab	17	14 (82.4)	1.22 (1.05)	-0.7	0.55	1.27	2.27	2.5	0.27 [-0.42, 0.96]
			Placebo	21	20 (95.2)	0.89 (1.33)	-3.2	0.32	1.05	1.64	3.3	
		Week 36	Tezepelumab	17	14 (82.4)	1.29 (1.12)	-0.7	0.45	1.18	2.36	2.8	0.65 [-0.05, 1.35]
			Placebo	21	20 (95.2)	0.55 (1.15)	-1.8	0.09	0.59	1.14	2.7	
		Week 40	Tezepelumab	17	14 (82.4)	1.33 (1.14)	-0.7	0.27	1.32	2.45	2.8	0.45 [-0.24, 1.14]
			Placebo	21	20 (95.2)	0.78 (1.29)	-1.4	-0.09	0.77	1.73	3.5	
		Week 44	Tezepelumab	17	14 (82.4)	1.39 (1.24)	-0.7	0.27	1.50	2.55	2.9	0.50 [-0.19, 1.20]
			Placebo	21	20 (95.2)	0.78 (1.20)	-1.4	-0.32	0.91	1.50	3.4	
		Week 48	Tezepelumab	17	14 (82.4)	1.25 (1.24)	-0.7	0.36	1.14	2.45	3.1	0.59 [-0.11, 1.29]
			Placebo	21	20 (95.2)	0.58 (1.06)	-1.5	0.05	0.82	1.23	2.4	
		Week 52	Tezepelumab	17	14 (82.4)	1.29 (1.28)	-0.7	0.27	1.14	2.45	3.1	0.52 [-0.18, 1.21]
			Placebo	21	20 (95.2)	0.70 (1.00)	-1.4	0.09	0.82	1.41	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	49	43 (87.8)	4.18 (0.74)	2.2	3.73	4.18	4.55	6.3	
			Placebo	44	35 (79.5)	4.30 (0.79)	2.3	3.73	4.36	4.73	6.0	
		Week 4	Tezepelumab	49	45 (91.8)	4.95 (1.09)	1.6	4.18	5.00	5.73	6.9	
			Placebo	44	37 (84.1)	4.67 (1.02)	2.5	4.00	4.55	5.27	7.0	
		Week 8	Tezepelumab	49	46 (93.9)	5.21 (1.03)	3.3	4.27	5.23	6.09	6.9	
			Placebo	44	38 (86.4)	4.84 (1.15)	2.3	4.09	4.64	5.64	7.0	
		Week 12	Tezepelumab	49	46 (93.9)	5.38 (1.02)	3.0	4.64	5.27	6.36	7.0	
			Placebo	44	38 (86.4)	4.87 (1.14)	3.2	4.00	4.77	5.91	7.0	
		Week 16	Tezepelumab	49	46 (93.9)	5.30 (1.05)	2.8	4.36	5.18	6.27	7.0	
			Placebo	44	38 (86.4)	4.94 (1.16)	2.9	4.00	4.77	6.00	7.0	
		Week 20	Tezepelumab	49	47 (95.9)	5.25 (1.11)	2.8	4.27	5.09	6.27	7.0	
			Placebo	44	38 (86.4)	4.90 (1.20)	2.1	4.09	4.73	5.91	6.9	
		Week 24	Tezepelumab	49	47 (95.9)	5.33 (1.07)	3.5	4.27	5.18	6.27	7.0	
			Placebo	44	38 (86.4)	4.96 (1.22)	2.0	4.09	4.82	5.82	6.9	
		Week 28	Tezepelumab	49	49 (100.0)	5.29 (1.06)	3.5	4.45	5.18	6.27	7.0	
			Placebo	44	39 (88.6)	4.96 (1.24)	2.0	3.91	4.91	6.00	6.9	
		Week 32	Tezepelumab	49	49 (100.0)	5.35 (1.08)	3.3	4.36	5.27	6.18	7.0	
			Placebo	44	39 (88.6)	4.97 (1.21)	1.7	4.00	4.82	6.00	7.0	
		Week 36	Tezepelumab	49	49 (100.0)	5.38 (1.03)	3.7	4.45	5.45	6.18	7.0	
			Placebo	44	39 (88.6)	5.05 (1.18)	2.5	4.09	4.91	6.09	6.9	
		Week 40	Tezepelumab	49	49 (100.0)	5.32 (1.03)	3.5	4.36	5.09	6.18	7.0	
			Placebo	44	39 (88.6)	5.04 (1.25)	2.0	4.09	4.91	6.18	6.9	
		Week 44	Tezepelumab	49	49 (100.0)	5.32 (1.04)	3.7	4.45	5.36	6.09	7.0	
			Placebo	44	39 (88.6)	5.06 (1.20)	2.5	4.09	4.91	6.27	6.9	
		Week 48	Tezepelumab	49	49 (100.0)	5.43 (1.03)	3.8	4.36	5.45	6.27	7.0	
			Placebo	44	39 (88.6)	5.08 (1.23)	2.3	4.00	5.00	6.09	7.0	
		Week 52	Tezepelumab	49	49 (100.0)	5.41 (1.02)	3.8	4.45	5.36	6.27	7.0	
			Placebo	44	39 (88.6)	5.13 (1.20)	3.1	4.00	5.00	6.18	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHK: Change from baseline in AQLQ+12 activity limitations score by key subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	49	42 (85.7)	0.78 (1.03)	-2.8	0.09	0.73	1.45	3.1	0.46 [0.00, 0.91]
			Placebo	44	35 (79.5)	0.34 (0.86)	-1.5	0.00	0.36	0.64	2.5	
		Week 8	Tezepelumab	49	43 (87.8)	0.99 (1.00)	-1.3	0.27	0.82	1.64	3.7	0.43 [-0.02, 0.88]
			Placebo	44	35 (79.5)	0.57 (0.93)	-1.3	-0.09	0.64	1.00	2.6	
		Week 12	Tezepelumab	49	43 (87.8)	1.20 (1.02)	-1.5	0.45	1.00	1.73	4.2	0.65 [0.19, 1.10]
			Placebo	44	35 (79.5)	0.55 (0.98)	-1.3	0.00	0.64	1.18	2.5	
		Week 16	Tezepelumab	49	43 (87.8)	1.14 (1.03)	-1.6	0.36	0.91	1.64	3.5	0.47 [0.01, 0.92]
			Placebo	44	35 (79.5)	0.69 (0.87)	-1.6	0.18	0.64	1.09	2.5	
		Week 20	Tezepelumab	49	43 (87.8)	1.11 (1.10)	-0.9	0.36	0.91	2.00	3.5	0.44 [-0.01, 0.89]
			Placebo	44	35 (79.5)	0.66 (0.91)	-1.6	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	49	43 (87.8)	1.22 (1.02)	-0.6	0.45	1.09	2.00	3.5	0.51 [0.06, 0.96]
			Placebo	44	35 (79.5)	0.71 (0.97)	-1.6	0.09	0.82	1.36	2.5	
		Week 28	Tezepelumab	49	43 (87.8)	1.19 (1.04)	-0.8	0.45	1.09	2.00	3.5	0.52 [0.07, 0.97]
			Placebo	44	35 (79.5)	0.66 (0.99)	-1.6	0.09	0.82	1.27	2.5	
		Week 32	Tezepelumab	49	43 (87.8)	1.19 (1.06)	-0.5	0.36	0.91	1.91	3.5	0.49 [0.04, 0.95]
			Placebo	44	35 (79.5)	0.68 (0.98)	-1.8	0.27	0.64	1.36	2.6	
		Week 36	Tezepelumab	49	43 (87.8)	1.23 (1.06)	-0.7	0.64	1.00	1.91	3.5	0.45 [0.00, 0.91]
			Placebo	44	35 (79.5)	0.78 (0.95)	-1.6	0.36	0.91	1.36	2.6	
		Week 40	Tezepelumab	49	43 (87.8)	1.18 (0.99)	-0.9	0.45	1.09	1.82	3.5	0.42 [-0.03, 0.87]
			Placebo	44	35 (79.5)	0.76 (1.00)	-1.6	0.18	0.73	1.45	2.6	
		Week 44	Tezepelumab	49	43 (87.8)	1.18 (1.00)	-0.5	0.45	1.00	1.82	3.5	0.41 [-0.04, 0.86]
			Placebo	44	35 (79.5)	0.76 (1.08)	-1.6	0.27	0.64	1.55	3.2	
		Week 48	Tezepelumab	49	43 (87.8)	1.31 (0.97)	-0.5	0.64	1.18	1.91	3.5	0.51 [0.06, 0.97]
			Placebo	44	35 (79.5)	0.79 (1.07)	-1.6	0.18	0.73	1.27	3.2	
		Week 52	Tezepelumab	49	43 (87.8)	1.27 (0.96)	-0.5	0.64	1.18	1.82	3.5	0.42 [-0.03, 0.87]
			Placebo	44	35 (79.5)	0.85 (1.06)	-1.6	0.27	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	4.14 (0.86)	2.1	3.64	4.09	4.55	6.3	
			Placebo	58	48 (82.8)	4.36 (0.78)	2.3	3.91	4.27	4.68	6.2	
		Week 4	Tezepelumab	60	54 (90.0)	4.81 (1.06)	1.6	4.00	4.91	5.64	6.8	
			Placebo	58	50 (86.2)	4.79 (1.06)	2.5	4.00	4.59	5.64	7.0	
		Week 8	Tezepelumab	60	56 (93.3)	5.09 (1.09)	2.9	4.14	5.18	6.09	6.9	
			Placebo	58	52 (89.7)	4.88 (1.06)	2.8	4.09	4.68	5.64	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.30 (1.03)	3.0	4.64	5.09	6.27	7.0	
			Placebo	58	52 (89.7)	4.94 (1.11)	2.8	4.09	4.86	5.77	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.27 (1.07)	2.8	4.36	5.14	6.23	7.0	
			Placebo	58	52 (89.7)	5.00 (1.25)	1.1	4.09	4.91	6.00	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.18 (1.12)	2.8	4.27	5.09	6.18	7.0	
			Placebo	58	52 (89.7)	4.96 (1.27)	1.1	4.09	4.82	6.14	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.25 (1.10)	2.9	4.27	5.18	6.27	7.0	
			Placebo	58	52 (89.7)	4.93 (1.31)	1.1	4.09	5.05	5.77	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.20 (1.06)	2.9	4.36	5.18	6.00	7.0	
			Placebo	58	53 (91.4)	4.92 (1.37)	1.1	3.91	5.09	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.29 (1.10)	2.9	4.36	5.18	6.18	7.0	
			Placebo	58	53 (91.4)	4.99 (1.30)	1.1	4.09	5.00	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.31 (1.07)	3.0	4.36	5.45	6.09	7.0	
			Placebo	58	53 (91.4)	5.00 (1.24)	2.4	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.29 (1.08)	3.3	4.36	5.09	6.27	7.0	
			Placebo	58	53 (91.4)	5.03 (1.30)	2.0	4.00	5.09	6.09	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.30 (1.08)	3.0	4.36	5.27	6.27	7.0	
			Placebo	58	53 (91.4)	5.05 (1.19)	2.5	4.09	5.09	5.91	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.34 (1.11)	2.6	4.27	5.18	6.45	7.0	
			Placebo	58	53 (91.4)	4.97 (1.23)	2.3	4.00	4.91	6.00	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.33 (1.11)	2.6	4.36	5.18	6.45	7.0	
			Placebo	58	53 (91.4)	5.04 (1.16)	2.9	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	60	49 (81.7)	0.69 (0.96)	-2.8	0.00	0.64	1.36	2.7	0.27 [-0.13, 0.67]
			Placebo	58	47 (81.0)	0.44 (0.91)	-1.5	0.00	0.36	0.91	2.5	
		Week 8	Tezepelumab	60	51 (85.0)	0.90 (0.93)	-1.3	0.27	0.91	1.55	2.9	0.36 [-0.04, 0.76]
			Placebo	58	48 (82.8)	0.57 (0.88)	-1.3	-0.05	0.50	1.00	2.6	
		Week 12	Tezepelumab	60	51 (85.0)	1.13 (0.94)	-1.5	0.45	1.09	1.73	3.0	0.57 [0.17, 0.97]
			Placebo	58	48 (82.8)	0.59 (0.94)	-1.3	0.05	0.50	1.18	2.5	
		Week 16	Tezepelumab	60	51 (85.0)	1.10 (0.96)	-1.6	0.36	1.09	1.64	3.0	0.41 [0.01, 0.81]
			Placebo	58	48 (82.8)	0.69 (1.05)	-3.2	0.23	0.68	1.36	2.5	
		Week 20	Tezepelumab	60	51 (85.0)	1.02 (1.04)	-0.9	0.36	0.91	1.73	3.3	0.34 [-0.05, 0.74]
			Placebo	58	48 (82.8)	0.66 (1.06)	-3.2	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	60	51 (85.0)	1.15 (0.99)	-0.7	0.36	1.09	1.82	3.0	0.49 [0.09, 0.89]
			Placebo	58	48 (82.8)	0.62 (1.15)	-3.2	0.09	0.64	1.41	2.5	
		Week 28	Tezepelumab	60	51 (85.0)	1.09 (0.99)	-0.8	0.36	0.91	1.91	3.0	0.47 [0.07, 0.87]
			Placebo	58	48 (82.8)	0.58 (1.17)	-3.2	-0.18	0.82	1.27	2.5	
		Week 32	Tezepelumab	60	51 (85.0)	1.13 (1.01)	-0.7	0.36	1.00	1.91	3.2	0.45 [0.05, 0.85]
			Placebo	58	48 (82.8)	0.65 (1.11)	-3.2	0.05	0.73	1.41	2.6	
		Week 36	Tezepelumab	60	51 (85.0)	1.17 (1.04)	-0.7	0.36	1.00	1.91	3.2	0.49 [0.09, 0.89]
			Placebo	58	48 (82.8)	0.67 (1.01)	-1.8	0.09	0.73	1.23	2.6	
		Week 40	Tezepelumab	60	51 (85.0)	1.16 (0.98)	-0.9	0.36	1.09	1.91	3.0	0.44 [0.04, 0.84]
			Placebo	58	48 (82.8)	0.70 (1.09)	-1.6	0.09	0.73	1.55	2.6	
		Week 44	Tezepelumab	60	51 (85.0)	1.17 (1.01)	-0.7	0.36	1.09	1.91	3.2	0.48 [0.08, 0.88]
			Placebo	58	48 (82.8)	0.70 (1.01)	-1.6	0.18	0.68	1.36	2.7	
		Week 48	Tezepelumab	60	51 (85.0)	1.23 (1.01)	-0.7	0.45	1.18	2.00	3.2	0.61 [0.21, 1.02]
			Placebo	58	48 (82.8)	0.61 (1.01)	-1.6	0.09	0.64	1.23	2.8	
		Week 52	Tezepelumab	60	51 (85.0)	1.21 (1.00)	-0.7	0.55	1.18	1.91	3.3	0.51 [0.11, 0.91]
			Placebo	58	48 (82.8)	0.70 (0.96)	-1.6	0.09	0.68	1.27	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	4.11 (1.25)	2.2	3.64	4.00	5.00	5.8	
			Placebo	7	7 (100.0)	3.97 (0.70)	3.2	3.27	4.18	4.36	5.1	
		Week 4	Tezepelumab	6	6 (100.0)	5.47 (1.01)	4.2	4.55	5.55	6.09	6.9	
			Placebo	7	7 (100.0)	4.45 (0.79)	3.2	3.82	4.55	5.27	5.5	
		Week 8	Tezepelumab	6	6 (100.0)	5.68 (0.85)	4.2	5.27	5.91	6.36	6.5	
			Placebo	7	7 (100.0)	4.62 (1.21)	2.3	4.18	5.00	5.64	5.6	
		Week 12	Tezepelumab	6	6 (100.0)	5.95 (1.10)	4.1	5.18	6.41	6.64	7.0	
			Placebo	7	7 (100.0)	5.29 (1.07)	3.5	4.27	5.55	6.00	6.5	
		Week 16	Tezepelumab	6	6 (100.0)	5.67 (0.95)	4.1	5.55	5.59	6.18	7.0	
			Placebo	7	7 (100.0)	5.23 (1.31)	3.0	4.09	5.91	6.00	6.7	
		Week 20	Tezepelumab	6	6 (100.0)	5.94 (0.78)	4.7	5.64	5.95	6.36	7.0	
			Placebo	7	7 (100.0)	4.68 (1.06)	3.0	3.82	5.09	5.73	5.8	
		Week 24	Tezepelumab	6	6 (100.0)	5.88 (0.83)	4.5	5.64	6.05	6.09	7.0	
			Placebo	7	7 (100.0)	5.03 (0.96)	4.1	4.09	4.91	6.00	6.2	
		Week 28	Tezepelumab	6	6 (100.0)	6.05 (1.02)	4.3	5.64	6.18	7.00	7.0	
			Placebo	7	7 (100.0)	5.47 (1.21)	4.1	4.09	5.82	6.73	7.0	
		Week 32	Tezepelumab	6	6 (100.0)	5.82 (0.94)	4.2	5.64	5.86	6.36	7.0	
			Placebo	7	7 (100.0)	5.44 (0.98)	4.1	4.09	5.82	6.18	6.5	
		Week 36	Tezepelumab	6	6 (100.0)	6.00 (0.89)	4.5	5.64	6.18	6.55	7.0	
			Placebo	7	7 (100.0)	4.86 (1.12)	3.3	4.09	4.64	6.00	6.1	
		Week 40	Tezepelumab	6	6 (100.0)	5.86 (0.68)	5.0	5.45	5.82	6.09	7.0	
			Placebo	7	7 (100.0)	5.19 (1.16)	4.1	4.09	5.09	6.36	6.8	
		Week 44	Tezepelumab	6	6 (100.0)	5.82 (0.87)	4.5	5.45	5.82	6.36	7.0	
			Placebo	7	7 (100.0)	5.22 (1.39)	3.4	4.00	5.45	6.64	6.6	
		Week 48	Tezepelumab	6	6 (100.0)	5.97 (0.76)	4.7	5.64	6.09	6.27	7.0	
			Placebo	7	7 (100.0)	5.38 (1.14)	3.8	4.09	5.64	6.45	6.6	
		Week 52	Tezepelumab	6	6 (100.0)	5.97 (0.76)	4.7	5.64	6.09	6.27	7.0	
			Placebo	7	7 (100.0)	5.43 (1.22)	3.8	4.09	5.64	6.45	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	6	6 (100.0)	1.36 (1.13)	0.0	0.45	1.36	1.91	3.1	1.08 [-0.10, 2.26]
			Placebo	7	7 (100.0)	0.48 (0.40)	-0.1	0.18	0.45	0.82	1.1	
		Week 8	Tezepelumab	6	6 (100.0)	1.58 (1.29)	0.1	0.45	1.55	2.09	3.7	0.81 [-0.33, 1.95]
			Placebo	7	7 (100.0)	0.65 (1.01)	-0.9	-0.18	0.73	1.45	2.2	
		Week 12	Tezepelumab	6	6 (100.0)	1.85 (1.39)	0.4	0.82	1.50	2.73	4.2	0.44 [-0.66, 1.55]
			Placebo	7	7 (100.0)	1.31 (1.02)	0.0	0.82	1.09	1.82	3.3	
		Week 16	Tezepelumab	6	6 (100.0)	1.56 (1.34)	0.4	0.36	1.23	2.73	3.5	0.23 [-0.86, 1.33]
			Placebo	7	7 (100.0)	1.26 (1.23)	-0.5	0.55	0.91	1.82	3.5	
		Week 20	Tezepelumab	6	6 (100.0)	1.83 (1.11)	0.5	1.00	1.64	2.73	3.5	1.12 [-0.06, 2.31]
			Placebo	7	7 (100.0)	0.70 (0.92)	-0.5	-0.45	0.73	1.64	1.9	
		Week 24	Tezepelumab	6	6 (100.0)	1.77 (1.26)	0.3	0.73	1.73	2.73	3.5	0.65 [-0.48, 1.77]
			Placebo	7	7 (100.0)	1.05 (0.98)	-0.2	0.55	0.91	1.64	2.9	
		Week 28	Tezepelumab	6	6 (100.0)	1.94 (1.18)	0.5	0.55	2.18	2.73	3.5	0.37 [-0.73, 1.47]
			Placebo	7	7 (100.0)	1.49 (1.22)	0.3	0.64	0.91	2.45	3.7	
		Week 32	Tezepelumab	6	6 (100.0)	1.71 (1.27)	0.5	0.55	1.55	2.73	3.5	0.22 [-0.87, 1.32]
			Placebo	7	7 (100.0)	1.47 (0.92)	0.6	0.82	1.09	1.91	3.3	
		Week 36	Tezepelumab	6	6 (100.0)	1.89 (1.13)	0.7	0.73	1.86	2.73	3.5	0.89 [-0.27, 2.04]
			Placebo	7	7 (100.0)	0.88 (1.15)	-1.0	0.27	0.91	1.64	2.7	
		Week 40	Tezepelumab	6	6 (100.0)	1.76 (1.32)	0.2	0.45	1.86	2.73	3.5	0.43 [-0.67, 1.54]
			Placebo	7	7 (100.0)	1.22 (1.17)	-0.2	0.64	0.91	1.64	3.5	
		Week 44	Tezepelumab	6	6 (100.0)	1.71 (1.41)	0.2	0.45	1.73	2.73	3.5	0.30 [-0.80, 1.39]
			Placebo	7	7 (100.0)	1.25 (1.69)	-0.9	-0.36	0.91	3.18	3.4	
		Week 48	Tezepelumab	6	6 (100.0)	1.86 (1.17)	0.4	1.00	1.82	2.73	3.5	0.38 [-0.72, 1.48]
			Placebo	7	7 (100.0)	1.40 (1.26)	-0.5	0.45	1.09	2.36	3.2	
		Week 52	Tezepelumab	6	6 (100.0)	1.86 (1.17)	0.4	1.00	1.82	2.73	3.5	0.32 [-0.78, 1.42]
			Placebo	7	7 (100.0)	1.45 (1.35)	-0.5	0.45	1.09	2.36	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	4.16 (1.75)	2.2	2.36	5.00	5.64	5.6	
			Placebo	4	3 (75.0)	4.09 (0.60)	3.5	3.45	4.18	4.64	4.6	
		Week 4	Tezepelumab	6	4 (66.7)	5.86 (0.75)	5.3	5.32	5.64	6.41	6.9	
			Placebo	4	3 (75.0)	5.21 (1.32)	4.3	4.27	4.64	6.73	6.7	
		Week 8	Tezepelumab	6	5 (83.3)	5.75 (1.11)	3.8	5.91	6.00	6.45	6.5	
			Placebo	4	3 (75.0)	5.61 (1.41)	4.2	4.18	5.64	7.00	7.0	
		Week 12	Tezepelumab	6	5 (83.3)	6.11 (0.68)	4.9	6.27	6.36	6.45	6.5	
			Placebo	4	3 (75.0)	5.48 (1.83)	3.5	3.45	6.00	7.00	7.0	
		Week 16	Tezepelumab	6	5 (83.3)	5.73 (0.60)	4.9	5.55	5.64	6.00	6.5	
			Placebo	4	3 (75.0)	5.30 (2.05)	3.0	3.00	6.00	6.91	6.9	
		Week 20	Tezepelumab	6	5 (83.3)	5.69 (0.56)	4.9	5.45	5.64	6.18	6.3	
			Placebo	4	3 (75.0)	5.24 (2.02)	3.0	3.00	5.82	6.91	6.9	
		Week 24	Tezepelumab	6	5 (83.3)	5.71 (0.50)	4.9	5.64	5.73	6.09	6.2	
			Placebo	4	3 (75.0)	5.61 (1.42)	4.1	4.09	5.82	6.91	6.9	
		Week 28	Tezepelumab	6	6 (100.0)	5.91 (0.70)	4.9	5.64	5.82	6.27	7.0	
			Placebo	4	3 (75.0)	5.61 (1.42)	4.1	4.09	5.82	6.91	6.9	
		Week 32	Tezepelumab	6	6 (100.0)	5.83 (0.57)	4.9	5.64	5.86	6.09	6.6	
			Placebo	4	3 (75.0)	5.52 (1.30)	4.1	4.09	5.82	6.64	6.6	
		Week 36	Tezepelumab	6	6 (100.0)	5.68 (0.50)	4.9	5.55	5.59	6.09	6.4	
			Placebo	4	3 (75.0)	5.42 (1.19)	4.1	4.09	5.82	6.36	6.4	
		Week 40	Tezepelumab	6	6 (100.0)	5.82 (0.64)	4.9	5.45	5.77	6.27	6.7	
			Placebo	4	3 (75.0)	5.55 (1.34)	4.1	4.09	5.82	6.73	6.7	
		Week 44	Tezepelumab	6	6 (100.0)	5.64 (0.47)	4.9	5.45	5.64	5.82	6.4	
			Placebo	4	3 (75.0)	6.58 (0.19)	6.4	6.36	6.64	6.73	6.7	
		Week 48	Tezepelumab	6	6 (100.0)	5.85 (0.55)	4.9	5.64	5.91	6.27	6.5	
			Placebo	4	3 (75.0)	6.58 (0.10)	6.5	6.45	6.64	6.64	6.6	
		Week 52	Tezepelumab	6	6 (100.0)	6.05 (0.68)	4.9	5.64	6.23	6.45	6.8	
			Placebo	4	3 (75.0)	6.70 (0.28)	6.5	6.45	6.64	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	6	4 (66.7)	1.25 (1.54)	-0.3	-0.00	1.09	2.50	3.1	0.10 [-1.40, 1.60]
			Placebo	4	3 (75.0)	1.12 (0.86)	0.5	0.45	0.82	2.09	2.1	
		Week 8	Tezepelumab	6	5 (83.3)	1.58 (1.28)	0.4	0.91	1.45	1.45	3.7	0.06 [-1.37, 1.49]
			Placebo	4	3 (75.0)	1.52 (0.82)	0.7	0.73	1.45	2.36	2.4	
		Week 12	Tezepelumab	6	5 (83.3)	1.95 (1.45)	0.6	0.91	1.45	2.55	4.2	0.40 [-1.05, 1.85]
			Placebo	4	3 (75.0)	1.39 (1.24)	0.0	0.00	1.82	2.36	2.4	
		Week 16	Tezepelumab	6	5 (83.3)	1.56 (1.36)	0.4	0.55	0.91	2.55	3.5	0.25 [-1.19, 1.69]
			Placebo	4	3 (75.0)	1.21 (1.46)	-0.5	-0.45	1.82	2.27	2.3	
		Week 20	Tezepelumab	6	5 (83.3)	1.53 (1.47)	-0.2	0.55	1.27	2.55	3.5	0.26 [-1.18, 1.70]
			Placebo	4	3 (75.0)	1.15 (1.43)	-0.5	-0.45	1.64	2.27	2.3	
		Week 24	Tezepelumab	6	5 (83.3)	1.55 (1.41)	0.1	0.55	1.09	2.55	3.5	0.02 [-1.41, 1.46]
			Placebo	4	3 (75.0)	1.52 (0.82)	0.6	0.64	1.64	2.27	2.3	
		Week 28	Tezepelumab	6	5 (83.3)	1.67 (1.46)	0.0	0.36	2.00	2.55	3.5	0.12 [-1.31, 1.56]
			Placebo	4	3 (75.0)	1.52 (0.82)	0.6	0.64	1.64	2.27	2.3	
		Week 32	Tezepelumab	6	5 (83.3)	1.51 (1.41)	0.3	0.45	0.82	2.55	3.5	0.07 [-1.36, 1.50]
			Placebo	4	3 (75.0)	1.42 (0.71)	0.6	0.64	1.64	2.00	2.0	
		Week 36	Tezepelumab	6	5 (83.3)	1.44 (1.58)	-0.1	-0.09	1.36	2.55	3.5	0.08 [-1.35, 1.51]
			Placebo	4	3 (75.0)	1.33 (0.61)	0.6	0.64	1.64	1.73	1.7	
		Week 40	Tezepelumab	6	5 (83.3)	1.47 (1.44)	0.3	0.45	0.64	2.55	3.5	0.01 [-1.42, 1.45]
			Placebo	4	3 (75.0)	1.45 (0.74)	0.6	0.64	1.64	2.09	2.1	
		Week 44	Tezepelumab	6	5 (83.3)	1.44 (1.49)	0.0	0.45	0.73	2.55	3.5	-0.83 [-2.34, 0.68]
			Placebo	4	3 (75.0)	2.48 (0.61)	2.1	2.09	2.18	3.18	3.2	
		Week 48	Tezepelumab	6	5 (83.3)	1.69 (1.28)	0.4	0.82	1.27	2.55	3.5	-0.72 [-2.21, 0.77]
			Placebo	4	3 (75.0)	2.48 (0.62)	2.0	2.00	2.27	3.18	3.2	
		Week 52	Tezepelumab	6	5 (83.3)	1.73 (1.23)	0.5	0.82	1.27	2.55	3.5	-0.79 [-2.29, 0.71]
			Placebo	4	3 (75.0)	2.61 (0.82)	2.0	2.00	2.27	3.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	4.13 (0.80)	2.1	3.64	4.09	4.55	6.3	
			Placebo	61	52 (85.2)	4.33 (0.79)	2.3	3.86	4.27	4.68	6.2	
		Week 4	Tezepelumab	60	56 (93.3)	4.80 (1.05)	1.6	4.05	4.91	5.68	6.8	
			Placebo	61	54 (88.5)	4.72 (1.02)	2.5	3.91	4.55	5.45	7.0	
		Week 8	Tezepelumab	60	57 (95.0)	5.10 (1.07)	2.9	4.18	5.18	6.09	6.9	
			Placebo	61	56 (91.8)	4.81 (1.05)	2.3	4.09	4.68	5.45	7.0	
		Week 12	Tezepelumab	60	57 (95.0)	5.30 (1.05)	3.0	4.64	5.09	6.27	7.0	
			Placebo	61	56 (91.8)	4.95 (1.07)	2.8	4.14	4.91	5.73	7.0	
		Week 16	Tezepelumab	60	57 (95.0)	5.27 (1.09)	2.8	4.36	5.18	6.18	7.0	
			Placebo	61	56 (91.8)	5.02 (1.22)	1.1	4.14	4.91	5.95	7.0	
		Week 20	Tezepelumab	60	58 (96.7)	5.21 (1.14)	2.8	4.27	5.09	6.36	7.0	
			Placebo	61	56 (91.8)	4.91 (1.22)	1.1	4.09	4.82	5.82	7.0	
		Week 24	Tezepelumab	60	58 (96.7)	5.28 (1.12)	2.9	4.27	5.18	6.27	7.0	
			Placebo	61	56 (91.8)	4.91 (1.26)	1.1	4.09	4.95	5.77	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.22 (1.10)	2.9	4.36	5.18	6.27	7.0	
			Placebo	61	57 (93.4)	4.95 (1.36)	1.1	3.91	5.09	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.29 (1.12)	2.9	4.36	5.18	6.36	7.0	
			Placebo	61	57 (93.4)	5.02 (1.27)	1.1	4.09	5.09	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.34 (1.10)	3.0	4.36	5.45	6.27	7.0	
			Placebo	61	57 (93.4)	4.96 (1.22)	2.4	4.00	4.91	6.00	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.29 (1.09)	3.3	4.36	5.09	6.18	7.0	
			Placebo	61	57 (93.4)	5.02 (1.28)	2.0	4.09	5.09	6.09	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.31 (1.11)	3.0	4.36	5.27	6.36	7.0	
			Placebo	61	57 (93.4)	4.99 (1.18)	2.5	4.00	5.00	5.82	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.35 (1.12)	2.6	4.27	5.18	6.45	7.0	
			Placebo	61	57 (93.4)	4.93 (1.19)	2.3	4.00	4.82	5.91	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.32 (1.11)	2.6	4.36	5.18	6.36	7.0	
			Placebo	61	57 (93.4)	5.00 (1.13)	2.9	4.00	4.82	5.91	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	60	51 (85.0)	0.72 (0.95)	-2.8	0.00	0.82	1.45	2.7	0.36 [-0.04, 0.75]
			Placebo	61	51 (83.6)	0.40 (0.85)	-1.5	0.00	0.27	0.82	2.5	
		Week 8	Tezepelumab	60	52 (86.7)	0.91 (0.94)	-1.3	0.23	0.86	1.59	2.9	0.42 [0.04, 0.81]
			Placebo	61	52 (85.2)	0.52 (0.87)	-1.3	-0.09	0.50	1.00	2.6	
		Week 12	Tezepelumab	60	52 (86.7)	1.13 (0.94)	-1.5	0.45	1.09	1.73	3.0	0.52 [0.13, 0.91]
			Placebo	61	52 (85.2)	0.64 (0.95)	-1.3	0.09	0.68	1.18	3.3	
		Week 16	Tezepelumab	60	52 (86.7)	1.11 (0.97)	-1.6	0.36	1.09	1.73	3.0	0.37 [-0.02, 0.75]
			Placebo	61	52 (85.2)	0.74 (1.06)	-3.2	0.27	0.77	1.36	3.5	
		Week 20	Tezepelumab	60	52 (86.7)	1.07 (1.03)	-0.9	0.36	0.95	1.82	3.3	0.42 [0.03, 0.81]
			Placebo	61	52 (85.2)	0.64 (1.02)	-3.2	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	60	52 (86.7)	1.18 (0.99)	-0.7	0.41	1.18	1.86	3.0	0.52 [0.13, 0.91]
			Placebo	61	52 (85.2)	0.63 (1.13)	-3.2	0.09	0.64	1.36	2.9	
		Week 28	Tezepelumab	60	52 (86.7)	1.13 (0.99)	-0.8	0.50	1.00	1.95	3.0	0.43 [0.04, 0.82]
			Placebo	61	52 (85.2)	0.65 (1.21)	-3.2	-0.05	0.82	1.27	3.7	
		Week 32	Tezepelumab	60	52 (86.7)	1.16 (1.02)	-0.7	0.41	1.05	1.91	3.2	0.42 [0.03, 0.80]
			Placebo	61	52 (85.2)	0.72 (1.12)	-3.2	0.18	0.82	1.41	3.3	
		Week 36	Tezepelumab	60	52 (86.7)	1.23 (1.02)	-0.7	0.64	1.05	1.91	3.2	0.56 [0.17, 0.95]
			Placebo	61	52 (85.2)	0.66 (1.03)	-1.8	0.09	0.73	1.18	2.7	
		Week 40	Tezepelumab	60	52 (86.7)	1.20 (0.99)	-0.9	0.45	1.09	1.91	3.0	0.44 [0.05, 0.83]
			Placebo	61	52 (85.2)	0.73 (1.11)	-1.6	0.09	0.73	1.45	3.5	
		Week 44	Tezepelumab	60	52 (86.7)	1.21 (1.02)	-0.7	0.41	1.09	1.91	3.2	0.53 [0.13, 0.92]
			Placebo	61	52 (85.2)	0.67 (1.05)	-1.6	0.05	0.64	1.27	3.4	
		Week 48	Tezepelumab	60	52 (86.7)	1.26 (1.01)	-0.7	0.45	1.18	2.00	3.2	0.65 [0.25, 1.04]
			Placebo	61	52 (85.2)	0.61 (0.99)	-1.6	0.09	0.64	1.14	2.8	
		Week 52	Tezepelumab	60	52 (86.7)	1.23 (1.01)	-0.7	0.50	1.18	1.91	3.3	0.55 [0.16, 0.94]
			Placebo	61	52 (85.2)	0.69 (0.95)	-1.6	0.09	0.68	1.23	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	30	26 (86.7)	4.08 (0.79)	2.2	3.64	4.14	4.45	6.3	
			Placebo	29	25 (86.2)	4.24 (0.78)	2.3	3.91	4.27	4.64	6.2	
		Week 4	Tezepelumab	30	26 (86.7)	4.78 (1.13)	1.6	4.18	4.77	5.45	6.9	
			Placebo	29	25 (86.2)	4.83 (1.22)	2.5	4.00	4.64	5.82	7.0	
		Week 8	Tezepelumab	30	27 (90.0)	5.03 (0.98)	3.3	4.18	4.73	5.91	6.8	
			Placebo	29	26 (89.7)	4.88 (1.15)	2.3	4.09	4.64	6.00	7.0	
		Week 12	Tezepelumab	30	27 (90.0)	5.12 (1.01)	3.0	4.36	5.00	6.18	7.0	
			Placebo	29	26 (89.7)	4.97 (1.17)	3.2	4.00	4.95	6.00	6.9	
		Week 16	Tezepelumab	30	27 (90.0)	5.05 (0.95)	2.8	4.36	5.09	5.64	6.7	
			Placebo	29	26 (89.7)	4.96 (1.36)	1.1	4.00	4.95	6.00	6.9	
		Week 20	Tezepelumab	30	28 (93.3)	5.04 (1.00)	3.5	4.27	4.82	5.73	7.0	
			Placebo	29	26 (89.7)	4.94 (1.32)	1.1	4.09	4.77	5.91	6.9	
		Week 24	Tezepelumab	30	28 (93.3)	5.13 (1.05)	3.5	4.27	4.95	6.05	7.0	
			Placebo	29	26 (89.7)	4.92 (1.43)	1.1	3.91	5.27	6.00	6.9	
		Week 28	Tezepelumab	30	29 (96.7)	5.07 (1.03)	3.6	4.27	4.82	5.73	7.0	
			Placebo	29	26 (89.7)	4.88 (1.49)	1.1	3.73	5.00	6.00	7.0	
		Week 32	Tezepelumab	30	29 (96.7)	5.13 (1.02)	3.9	4.27	4.82	5.91	7.0	
			Placebo	29	26 (89.7)	5.03 (1.41)	1.1	4.00	5.41	6.00	7.0	
		Week 36	Tezepelumab	30	29 (96.7)	5.17 (1.05)	3.7	4.27	5.00	6.00	7.0	
			Placebo	29	26 (89.7)	5.01 (1.29)	2.5	3.82	5.18	6.09	6.9	
		Week 40	Tezepelumab	30	29 (96.7)	5.06 (0.96)	3.5	4.36	5.00	5.55	7.0	
			Placebo	29	26 (89.7)	4.99 (1.38)	2.9	3.82	5.09	6.27	7.0	
		Week 44	Tezepelumab	30	29 (96.7)	5.10 (0.97)	3.9	4.27	5.00	5.55	7.0	
			Placebo	29	26 (89.7)	4.99 (1.29)	2.9	3.82	5.05	6.00	6.9	
		Week 48	Tezepelumab	30	29 (96.7)	5.22 (0.96)	3.8	4.27	5.18	5.73	7.0	
			Placebo	29	26 (89.7)	5.01 (1.33)	2.9	3.82	4.64	6.18	7.0	
		Week 52	Tezepelumab	30	29 (96.7)	5.25 (0.93)	3.8	4.36	5.18	5.73	7.0	
			Placebo	29	26 (89.7)	4.98 (1.33)	2.9	3.82	4.64	6.18	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	30	24 (80.0)	0.77 (1.11)	-2.8	0.18	0.73	1.50	3.1	0.20 [-0.37, 0.77]
			Placebo	29	24 (82.8)	0.57 (0.83)	-1.0	0.05	0.36	1.00	2.5	
		Week 8	Tezepelumab	30	25 (83.3)	0.93 (0.98)	-0.4	0.18	0.73	1.45	3.7	0.28 [-0.28, 0.83]
			Placebo	29	25 (86.2)	0.68 (0.86)	-0.9	0.00	0.55	1.00	2.6	
		Week 12	Tezepelumab	30	25 (83.3)	1.05 (1.07)	-1.5	0.36	0.91	1.64	4.2	0.34 [-0.22, 0.90]
			Placebo	29	25 (86.2)	0.71 (0.91)	-1.2	0.18	0.82	1.18	2.5	
		Week 16	Tezepelumab	30	25 (83.3)	1.03 (1.01)	-1.6	0.45	0.91	1.55	3.5	0.28 [-0.28, 0.83]
			Placebo	29	25 (86.2)	0.74 (1.11)	-3.2	0.55	0.82	1.09	2.5	
		Week 20	Tezepelumab	30	25 (83.3)	0.99 (1.04)	-0.6	0.36	0.82	1.45	3.5	0.25 [-0.30, 0.81]
			Placebo	29	25 (86.2)	0.71 (1.10)	-3.2	0.27	0.73	1.45	2.5	
		Week 24	Tezepelumab	30	25 (83.3)	1.15 (1.02)	-0.6	0.36	0.73	1.82	3.5	0.38 [-0.18, 0.94]
			Placebo	29	25 (86.2)	0.73 (1.17)	-3.2	0.36	0.82	1.36	2.5	
		Week 28	Tezepelumab	30	25 (83.3)	1.12 (1.01)	-0.8	0.55	0.91	1.64	3.5	0.38 [-0.18, 0.94]
			Placebo	29	25 (86.2)	0.70 (1.20)	-3.2	0.18	0.82	1.36	2.5	
		Week 32	Tezepelumab	30	25 (83.3)	1.08 (1.04)	-0.5	0.36	0.73	1.82	3.5	0.22 [-0.34, 0.77]
			Placebo	29	25 (86.2)	0.85 (1.12)	-3.2	0.64	1.00	1.45	2.6	
		Week 36	Tezepelumab	30	25 (83.3)	1.15 (1.07)	-0.7	0.36	0.82	1.64	3.5	0.31 [-0.25, 0.86]
			Placebo	29	25 (86.2)	0.83 (0.97)	-1.8	0.45	0.91	1.36	2.6	
		Week 40	Tezepelumab	30	25 (83.3)	1.08 (0.99)	-0.9	0.36	1.00	1.36	3.5	0.26 [-0.30, 0.82]
			Placebo	29	25 (86.2)	0.81 (1.07)	-1.4	0.64	0.82	1.45	2.6	
		Week 44	Tezepelumab	30	25 (83.3)	1.08 (0.98)	-0.5	0.36	0.91	1.55	3.5	0.28 [-0.28, 0.84]
			Placebo	29	25 (86.2)	0.81 (1.00)	-1.4	0.36	0.73	1.18	2.7	
		Week 48	Tezepelumab	30	25 (83.3)	1.23 (0.92)	-0.5	0.64	1.18	1.55	3.5	0.43 [-0.13, 0.99]
			Placebo	29	25 (86.2)	0.83 (0.97)	-1.4	0.09	0.82	1.18	2.8	
		Week 52	Tezepelumab	30	25 (83.3)	1.27 (0.88)	-0.5	0.64	1.18	1.55	3.5	0.50 [-0.06, 1.06]
			Placebo	29	25 (86.2)	0.80 (1.00)	-1.4	0.09	0.82	1.18	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	36	32 (88.9)	4.18 (0.98)	2.1	3.64	4.09	4.64	5.9	
			Placebo	36	30 (83.3)	4.37 (0.78)	3.3	3.82	4.27	4.64	6.2	
		Week 4	Tezepelumab	36	34 (94.4)	4.95 (1.02)	3.2	4.00	5.23	5.82	6.8	
			Placebo	36	32 (88.9)	4.68 (0.87)	3.2	4.05	4.55	5.45	6.7	
		Week 8	Tezepelumab	36	35 (97.2)	5.24 (1.15)	2.9	4.18	5.36	6.09	6.9	
			Placebo	36	33 (91.7)	4.83 (1.03)	2.8	4.09	4.82	5.45	7.0	
		Week 12	Tezepelumab	36	35 (97.2)	5.56 (1.04)	3.4	4.82	5.45	6.64	7.0	
			Placebo	36	33 (91.7)	4.99 (1.07)	2.8	4.27	4.91	5.55	7.0	
		Week 16	Tezepelumab	36	35 (97.2)	5.50 (1.11)	3.4	4.64	5.55	6.55	7.0	
			Placebo	36	33 (91.7)	5.09 (1.17)	2.9	4.36	4.91	6.00	7.0	
		Week 20	Tezepelumab	36	35 (97.2)	5.41 (1.18)	2.8	4.55	5.36	6.36	7.0	
			Placebo	36	33 (91.7)	4.91 (1.20)	2.1	4.09	4.91	5.45	7.0	
		Week 24	Tezepelumab	36	35 (97.2)	5.46 (1.11)	2.9	4.45	5.55	6.55	7.0	
			Placebo	36	33 (91.7)	4.96 (1.15)	2.0	4.27	4.91	5.55	7.0	
		Week 28	Tezepelumab	36	36 (100.0)	5.45 (1.11)	2.9	4.64	5.64	6.36	7.0	
			Placebo	36	34 (94.4)	5.06 (1.26)	2.0	4.36	5.09	6.00	7.0	
		Week 32	Tezepelumab	36	36 (100.0)	5.51 (1.13)	2.9	4.82	5.82	6.55	7.0	
			Placebo	36	34 (94.4)	5.06 (1.17)	1.7	4.36	5.05	6.00	7.0	
		Week 36	Tezepelumab	36	36 (100.0)	5.53 (1.07)	3.0	4.82	5.59	6.41	7.0	
			Placebo	36	34 (94.4)	4.96 (1.17)	2.4	4.18	4.73	6.00	7.0	
		Week 40	Tezepelumab	36	36 (100.0)	5.57 (1.10)	3.3	4.77	5.86	6.55	7.0	
			Placebo	36	34 (94.4)	5.09 (1.22)	2.0	4.09	5.09	6.00	7.0	
		Week 44	Tezepelumab	36	36 (100.0)	5.54 (1.11)	3.0	4.77	5.73	6.55	7.0	
			Placebo	36	34 (94.4)	5.14 (1.14)	2.5	4.36	5.14	5.73	7.0	
		Week 48	Tezepelumab	36	36 (100.0)	5.54 (1.18)	2.6	4.82	5.77	6.55	7.0	
			Placebo	36	34 (94.4)	5.02 (1.14)	2.3	4.36	5.05	5.73	7.0	
		Week 52	Tezepelumab	36	36 (100.0)	5.50 (1.21)	2.6	4.64	5.86	6.55	7.0	
			Placebo	36	34 (94.4)	5.16 (1.04)	3.6	4.27	5.05	5.82	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	36	31 (86.1)	0.76 (0.91)	-0.7	0.00	0.82	1.36	2.7	0.46 [-0.04, 0.97]
			Placebo	36	30 (83.3)	0.34 (0.89)	-1.5	-0.27	0.36	0.82	2.1	
		Week 8	Tezepelumab	36	32 (88.9)	1.00 (0.99)	-1.3	0.45	0.91	1.64	2.9	0.52 [0.01, 1.03]
			Placebo	36	30 (83.3)	0.50 (0.92)	-1.3	-0.18	0.45	1.00	2.4	
		Week 12	Tezepelumab	36	32 (88.9)	1.32 (0.96)	-0.7	0.82	1.23	2.05	3.0	0.67 [0.16, 1.18]
			Placebo	36	30 (83.3)	0.65 (1.03)	-1.3	0.00	0.55	1.27	3.3	
		Week 16	Tezepelumab	36	32 (88.9)	1.24 (1.00)	-0.7	0.36	1.27	2.00	3.0	0.44 [-0.06, 0.95]
			Placebo	36	30 (83.3)	0.78 (1.07)	-1.6	0.09	0.59	1.64	3.5	
		Week 20	Tezepelumab	36	32 (88.9)	1.20 (1.10)	-0.9	0.55	1.18	2.09	3.3	0.55 [0.04, 1.05]
			Placebo	36	30 (83.3)	0.63 (0.99)	-1.6	0.18	0.50	1.27	2.4	
		Week 24	Tezepelumab	36	32 (88.9)	1.27 (1.05)	-0.7	0.50	1.32	1.95	3.0	0.59 [0.08, 1.10]
			Placebo	36	30 (83.3)	0.63 (1.12)	-1.6	0.09	0.59	1.45	2.9	
		Week 28	Tezepelumab	36	32 (88.9)	1.22 (1.07)	-0.7	0.41	1.18	2.00	3.0	0.46 [-0.05, 0.96]
			Placebo	36	30 (83.3)	0.70 (1.23)	-1.6	0.09	0.77	1.27	3.7	
		Week 32	Tezepelumab	36	32 (88.9)	1.28 (1.06)	-0.7	0.64	1.18	2.18	3.2	0.55 [0.04, 1.06]
			Placebo	36	30 (83.3)	0.68 (1.12)	-1.8	0.00	0.59	1.55	3.3	
		Week 36	Tezepelumab	36	32 (88.9)	1.33 (1.07)	-0.7	0.68	1.27	2.23	3.1	0.70 [0.19, 1.21]
			Placebo	36	30 (83.3)	0.58 (1.06)	-1.6	0.09	0.55	1.18	2.7	
		Week 40	Tezepelumab	36	32 (88.9)	1.33 (1.05)	-0.7	0.59	1.27	2.36	3.0	0.54 [0.04, 1.05]
			Placebo	36	30 (83.3)	0.74 (1.15)	-1.6	0.18	0.64	1.73	3.5	
		Week 44	Tezepelumab	36	32 (88.9)	1.35 (1.11)	-0.7	0.50	1.41	2.36	3.2	0.53 [0.02, 1.04]
			Placebo	36	30 (83.3)	0.73 (1.21)	-1.6	-0.36	0.73	1.55	3.4	
		Week 48	Tezepelumab	36	32 (88.9)	1.35 (1.13)	-0.7	0.41	1.32	2.41	3.2	0.64 [0.13, 1.16]
			Placebo	36	30 (83.3)	0.62 (1.14)	-1.6	0.09	0.45	1.27	3.2	
		Week 52	Tezepelumab	36	32 (88.9)	1.28 (1.15)	-0.7	0.36	1.14	2.45	3.3	0.43 [-0.07, 0.94]
			Placebo	36	30 (83.3)	0.80 (1.08)	-1.6	0.09	0.55	1.64	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	38	31 (81.6)	4.02 (0.74)	2.2	3.55	4.00	4.36	5.8	
			Placebo	30	23 (76.7)	4.23 (0.54)	3.4	3.82	4.18	4.64	5.3	
		Week 4	Tezepelumab	38	35 (92.1)	4.66 (1.08)	1.6	3.91	4.73	5.36	6.9	
			Placebo	30	25 (83.3)	4.64 (1.03)	3.3	3.91	4.45	5.27	6.9	
		Week 8	Tezepelumab	38	35 (92.1)	4.98 (1.03)	2.9	4.09	4.82	5.91	6.5	
			Placebo	30	25 (83.3)	4.88 (1.06)	2.8	4.09	4.64	5.64	7.0	
		Week 12	Tezepelumab	38	35 (92.1)	5.22 (1.04)	3.0	4.64	5.09	6.27	7.0	
			Placebo	30	25 (83.3)	4.88 (1.14)	3.4	4.00	4.82	5.91	7.0	
		Week 16	Tezepelumab	38	35 (92.1)	5.12 (1.06)	2.8	4.27	5.00	6.18	6.9	
			Placebo	30	25 (83.3)	5.03 (1.07)	2.9	4.00	4.91	5.91	6.9	
		Week 20	Tezepelumab	38	36 (94.7)	5.07 (1.13)	2.8	4.27	4.86	6.14	7.0	
			Placebo	30	25 (83.3)	4.92 (1.18)	2.1	4.09	4.82	5.82	6.9	
		Week 24	Tezepelumab	38	36 (94.7)	5.09 (1.11)	2.9	4.23	4.86	6.09	7.0	
			Placebo	30	25 (83.3)	5.04 (1.18)	2.0	4.27	5.18	5.82	6.9	
		Week 28	Tezepelumab	38	38 (100.0)	5.11 (1.11)	3.2	4.18	4.91	6.27	7.0	
			Placebo	30	26 (86.7)	5.06 (1.26)	2.0	3.91	5.09	6.00	6.9	
		Week 32	Tezepelumab	38	38 (100.0)	5.17 (1.13)	2.9	4.27	5.05	6.18	7.0	
			Placebo	30	26 (86.7)	5.19 (1.22)	1.7	4.27	5.41	6.09	7.0	
		Week 36	Tezepelumab	38	38 (100.0)	5.19 (1.11)	3.0	4.27	5.14	6.09	7.0	
			Placebo	30	26 (86.7)	5.12 (1.18)	2.5	4.00	5.23	6.09	6.9	
		Week 40	Tezepelumab	38	38 (100.0)	5.08 (1.05)	3.3	4.36	5.00	5.82	7.0	
			Placebo	30	26 (86.7)	5.15 (1.31)	2.0	4.09	5.32	6.27	6.9	
		Week 44	Tezepelumab	38	38 (100.0)	5.06 (1.03)	3.0	4.09	4.95	5.91	7.0	
			Placebo	30	26 (86.7)	5.12 (1.24)	2.5	4.00	5.23	6.27	6.9	
		Week 48	Tezepelumab	38	38 (100.0)	5.09 (1.05)	2.6	4.27	5.09	5.82	7.0	
			Placebo	30	26 (86.7)	5.20 (1.26)	2.3	4.00	5.18	6.18	7.0	
		Week 52	Tezepelumab	38	38 (100.0)	5.16 (1.07)	2.6	4.27	5.18	6.18	7.0	
			Placebo	30	26 (86.7)	5.22 (1.17)	3.6	4.00	5.14	6.18	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	38	31 (81.6)	0.60 (1.06)	-2.8	0.00	0.55	1.45	3.1	0.15 [-0.39, 0.69]
			Placebo	30	23 (76.7)	0.45 (0.85)	-1.0	0.00	0.45	0.55	2.5	
		Week 8	Tezepelumab	38	31 (81.6)	0.87 (1.05)	-1.3	0.09	0.73	1.45	3.7	0.19 [-0.35, 0.73]
			Placebo	30	23 (76.7)	0.68 (0.88)	-0.7	0.09	0.55	1.00	2.6	
		Week 12	Tezepelumab	38	31 (81.6)	1.15 (1.06)	-1.5	0.45	1.00	1.73	4.2	0.47 [-0.07, 1.02]
			Placebo	30	23 (76.7)	0.67 (0.95)	-0.9	0.00	0.55	1.09	2.5	
		Week 16	Tezepelumab	38	31 (81.6)	1.07 (1.06)	-1.6	0.36	0.82	1.82	3.5	0.25 [-0.30, 0.79]
			Placebo	30	23 (76.7)	0.83 (0.85)	-0.7	0.27	0.82	1.36	2.5	
		Week 20	Tezepelumab	38	31 (81.6)	1.04 (1.08)	-0.9	0.36	0.82	1.73	3.5	0.26 [-0.28, 0.80]
			Placebo	30	23 (76.7)	0.78 (0.88)	-1.5	0.18	0.73	1.45	2.5	
		Week 24	Tezepelumab	38	31 (81.6)	1.13 (1.06)	-0.6	0.27	1.09	1.82	3.5	0.30 [-0.24, 0.84]
			Placebo	30	23 (76.7)	0.83 (0.89)	-1.5	0.45	0.82	1.27	2.5	
		Week 28	Tezepelumab	38	31 (81.6)	1.14 (1.06)	-0.8	0.09	1.09	2.00	3.5	0.33 [-0.22, 0.87]
			Placebo	30	23 (76.7)	0.81 (0.94)	-1.5	0.18	0.82	1.27	2.5	
		Week 32	Tezepelumab	38	31 (81.6)	1.12 (1.10)	-0.5	0.27	0.82	1.91	3.5	0.18 [-0.36, 0.72]
			Placebo	30	23 (76.7)	0.93 (0.92)	-1.8	0.55	1.00	1.45	2.6	
		Week 36	Tezepelumab	38	31 (81.6)	1.18 (1.10)	-0.7	0.36	0.82	1.91	3.5	0.29 [-0.25, 0.83]
			Placebo	30	23 (76.7)	0.89 (0.90)	-1.0	0.27	1.00	1.64	2.6	
		Week 40	Tezepelumab	38	31 (81.6)	1.06 (1.04)	-0.9	0.27	1.00	1.82	3.5	0.12 [-0.42, 0.66]
			Placebo	30	23 (76.7)	0.93 (1.05)	-1.5	0.64	0.91	1.64	2.6	
		Week 44	Tezepelumab	38	31 (81.6)	1.05 (1.04)	-0.5	0.27	0.82	1.64	3.5	0.23 [-0.31, 0.77]
			Placebo	30	23 (76.7)	0.81 (1.01)	-1.1	0.09	0.64	1.55	2.7	
		Week 48	Tezepelumab	38	31 (81.6)	1.10 (1.04)	-0.6	0.36	1.09	1.64	3.5	0.18 [-0.36, 0.72]
			Placebo	30	23 (76.7)	0.92 (1.00)	-1.3	0.09	1.09	1.27	2.8	
		Week 52	Tezepelumab	38	31 (81.6)	1.15 (1.03)	-0.6	0.36	1.18	1.64	3.5	0.18 [-0.36, 0.72]
			Placebo	30	23 (76.7)	0.97 (0.92)	-0.8	0.36	1.00	1.27	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	28	27 (96.4)	4.26 (1.04)	2.1	3.73	4.18	4.64	6.3	
			Placebo	34	31 (91.2)	4.38 (0.93)	2.3	3.82	4.27	5.09	6.2	
		Week 4	Tezepelumab	28	25 (89.3)	5.17 (0.99)	3.2	4.18	5.36	5.91	6.8	
			Placebo	34	32 (94.1)	4.83 (1.04)	2.5	4.14	4.68	5.55	7.0	
		Week 8	Tezepelumab	28	27 (96.4)	5.37 (1.11)	3.0	4.18	5.36	6.36	6.9	
			Placebo	34	33 (97.1)	4.86 (1.10)	2.3	4.09	4.82	5.45	7.0	
		Week 12	Tezepelumab	28	27 (96.4)	5.56 (1.03)	3.5	4.91	5.27	6.55	7.0	
			Placebo	34	33 (97.1)	5.06 (1.11)	2.8	4.27	5.09	6.00	7.0	
		Week 16	Tezepelumab	28	27 (96.4)	5.56 (1.03)	3.6	4.73	5.55	6.55	7.0	
			Placebo	34	33 (97.1)	5.15 (1.21)	3.0	4.36	5.09	6.27	7.0	
		Week 20	Tezepelumab	28	27 (96.4)	5.49 (1.05)	3.5	4.64	5.36	6.36	7.0	
			Placebo	34	33 (97.1)	5.04 (1.14)	3.0	4.27	4.91	6.09	7.0	
		Week 24	Tezepelumab	28	27 (96.4)	5.62 (0.99)	3.9	4.82	5.55	6.55	7.0	
			Placebo	34	33 (97.1)	4.99 (1.18)	2.7	4.09	4.91	5.82	7.0	
		Week 28	Tezepelumab	28	27 (96.4)	5.52 (1.00)	2.9	4.82	5.64	6.36	7.0	
			Placebo	34	33 (97.1)	5.04 (1.29)	2.5	4.09	5.09	6.00	7.0	
		Week 32	Tezepelumab	28	27 (96.4)	5.58 (1.01)	3.4	4.82	5.82	6.55	7.0	
			Placebo	34	33 (97.1)	5.06 (1.13)	3.1	4.09	5.09	5.91	7.0	
		Week 36	Tezepelumab	28	27 (96.4)	5.62 (0.96)	3.2	4.91	5.55	6.27	7.0	
			Placebo	34	33 (97.1)	4.95 (1.19)	2.4	4.09	4.82	6.00	7.0	
		Week 40	Tezepelumab	28	27 (96.4)	5.71 (0.98)	3.5	5.00	5.91	6.55	7.0	
			Placebo	34	33 (97.1)	5.02 (1.23)	2.5	4.09	4.91	6.00	7.0	
		Week 44	Tezepelumab	28	27 (96.4)	5.74 (1.00)	3.8	4.91	5.64	6.55	7.0	
			Placebo	34	33 (97.1)	5.10 (1.15)	3.1	4.27	5.09	5.73	7.0	
		Week 48	Tezepelumab	28	27 (96.4)	5.82 (1.03)	3.1	5.09	6.00	6.55	7.0	
			Placebo	34	33 (97.1)	4.94 (1.14)	2.4	4.18	4.82	5.64	7.0	
		Week 52	Tezepelumab	28	27 (96.4)	5.72 (1.05)	3.1	4.91	6.00	6.55	7.0	
			Placebo	34	33 (97.1)	5.04 (1.13)	3.1	4.18	5.00	5.73	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	28	24 (85.7)	0.97 (0.88)	-0.7	0.32	1.09	1.50	2.7	0.61 [0.06, 1.15]
			Placebo	34	31 (91.2)	0.44 (0.89)	-1.5	-0.09	0.36	0.91	1.9	
		Week 8	Tezepelumab	28	26 (92.9)	1.09 (0.89)	-0.7	0.45	1.00	1.64	2.9	0.61 [0.08, 1.14]
			Placebo	34	31 (91.2)	0.54 (0.90)	-1.3	-0.18	0.55	1.18	2.2	
		Week 12	Tezepelumab	28	26 (92.9)	1.27 (0.96)	-0.7	0.64	1.23	1.82	3.0	0.57 [0.04, 1.11]
			Placebo	34	31 (91.2)	0.70 (1.02)	-1.3	0.09	0.91	1.27	3.3	
		Week 16	Tezepelumab	28	26 (92.9)	1.25 (0.95)	-0.7	0.55	1.32	1.91	3.0	0.41 [-0.11, 0.94]
			Placebo	34	31 (91.2)	0.84 (1.02)	-1.6	0.27	0.82	1.64	3.5	
		Week 20	Tezepelumab	28	26 (92.9)	1.19 (1.08)	-0.7	0.55	1.09	2.00	3.3	0.48 [-0.05, 1.01]
			Placebo	34	31 (91.2)	0.71 (0.92)	-1.6	0.18	0.64	1.27	2.4	
		Week 24	Tezepelumab	28	26 (92.9)	1.31 (1.00)	-0.7	0.64	1.36	2.00	3.0	0.60 [0.07, 1.13]
			Placebo	34	31 (91.2)	0.68 (1.10)	-1.6	0.09	0.64	1.55	2.9	
		Week 28	Tezepelumab	28	26 (92.9)	1.22 (1.02)	-0.7	0.55	0.95	2.00	3.0	0.43 [-0.10, 0.96]
			Placebo	34	31 (91.2)	0.74 (1.20)	-1.6	-0.18	0.82	1.64	3.7	
		Week 32	Tezepelumab	28	26 (92.9)	1.29 (1.00)	-0.7	0.64	1.09	2.27	3.2	0.52 [-0.01, 1.05]
			Placebo	34	31 (91.2)	0.75 (1.03)	-1.6	0.00	0.64	1.55	3.3	
		Week 36	Tezepelumab	28	26 (92.9)	1.33 (1.04)	-0.7	0.73	1.18	2.36	3.0	0.68 [0.14, 1.21]
			Placebo	34	31 (91.2)	0.63 (1.02)	-1.6	0.09	0.73	1.09	2.7	
		Week 40	Tezepelumab	28	26 (92.9)	1.42 (0.99)	-0.7	0.82	1.27	2.36	3.0	0.66 [0.13, 1.20]
			Placebo	34	31 (91.2)	0.72 (1.10)	-1.6	0.00	0.64	1.64	3.5	
		Week 44	Tezepelumab	28	26 (92.9)	1.44 (1.05)	-0.7	0.73	1.41	2.36	3.2	0.58 [0.05, 1.12]
			Placebo	34	31 (91.2)	0.80 (1.15)	-1.6	0.27	0.82	1.64	3.4	
		Week 48	Tezepelumab	28	26 (92.9)	1.53 (1.00)	-0.7	0.82	1.45	2.36	3.2	0.87 [0.32, 1.42]
			Placebo	34	31 (91.2)	0.63 (1.06)	-1.6	0.09	0.73	1.00	3.2	
		Week 52	Tezepelumab	28	26 (92.9)	1.43 (1.04)	-0.7	0.73	1.36	2.36	3.3	0.66 [0.12, 1.19]
			Placebo	34	31 (91.2)	0.74 (1.06)	-1.6	0.09	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	4.03 (0.78)	2.2	3.55	4.00	4.36	5.8	
			Placebo	27	21 (77.8)	4.25 (0.54)	3.4	3.91	4.18	4.64	5.3	
		Week 4	Tezepelumab	32	30 (93.8)	4.70 (1.10)	1.6	3.91	4.91	5.36	6.9	
			Placebo	27	23 (85.2)	4.60 (0.95)	3.3	3.91	4.45	5.27	6.9	
		Week 8	Tezepelumab	32	30 (93.8)	5.11 (0.96)	3.4	4.27	5.05	6.00	6.5	
			Placebo	27	23 (85.2)	4.82 (0.99)	2.8	4.09	4.64	5.64	7.0	
		Week 12	Tezepelumab	32	30 (93.8)	5.25 (1.03)	3.0	4.64	5.09	6.27	7.0	
			Placebo	27	23 (85.2)	4.82 (1.08)	3.4	3.91	4.82	5.91	6.8	
		Week 16	Tezepelumab	32	30 (93.8)	5.11 (1.04)	2.8	4.27	4.95	5.91	6.9	
			Placebo	27	23 (85.2)	4.99 (1.01)	2.9	4.00	4.91	5.91	6.6	
		Week 20	Tezepelumab	32	31 (96.9)	5.05 (1.08)	2.8	4.27	4.91	6.00	6.8	
			Placebo	27	23 (85.2)	4.87 (1.14)	2.1	4.00	4.82	5.82	6.7	
		Week 24	Tezepelumab	32	31 (96.9)	5.08 (1.08)	3.5	4.18	4.73	6.09	7.0	
			Placebo	27	23 (85.2)	5.00 (1.14)	2.0	4.27	5.18	5.82	6.9	
		Week 28	Tezepelumab	32	32 (100.0)	5.04 (1.07)	3.5	4.14	4.68	5.91	7.0	
			Placebo	27	24 (88.9)	5.02 (1.25)	2.0	3.91	5.09	5.95	6.9	
		Week 32	Tezepelumab	32	32 (100.0)	5.13 (1.04)	3.3	4.32	4.86	6.09	7.0	
			Placebo	27	24 (88.9)	5.17 (1.22)	1.7	4.27	5.41	6.05	7.0	
		Week 36	Tezepelumab	32	32 (100.0)	5.16 (1.07)	3.7	4.27	4.82	6.23	7.0	
			Placebo	27	24 (88.9)	5.12 (1.17)	2.5	4.09	5.23	6.05	6.9	
		Week 40	Tezepelumab	32	32 (100.0)	5.00 (0.97)	3.5	4.32	4.95	5.64	7.0	
			Placebo	27	24 (88.9)	5.13 (1.31)	2.0	4.05	5.32	6.23	6.9	
		Week 44	Tezepelumab	32	32 (100.0)	5.00 (0.98)	3.7	4.05	4.86	5.77	7.0	
			Placebo	27	24 (88.9)	5.11 (1.22)	2.5	4.05	5.23	6.14	6.9	
		Week 48	Tezepelumab	32	32 (100.0)	5.06 (0.97)	3.8	4.23	4.95	5.68	6.8	
			Placebo	27	24 (88.9)	5.19 (1.25)	2.3	4.14	5.18	6.14	7.0	
		Week 52	Tezepelumab	32	32 (100.0)	5.08 (0.96)	3.5	4.23	4.95	5.86	6.8	
			Placebo	27	24 (88.9)	5.21 (1.16)	3.6	4.05	5.14	6.14	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	32	26 (81.3)	0.63 (1.13)	-2.8	0.00	0.68	1.45	3.1	0.25 [-0.33, 0.83]
			Placebo	27	21 (77.8)	0.39 (0.80)	-1.0	0.00	0.45	0.55	2.5	
		Week 8	Tezepelumab	32	26 (81.3)	0.99 (1.07)	-1.3	0.27	0.86	1.64	3.7	0.40 [-0.18, 0.98]
			Placebo	27	21 (77.8)	0.60 (0.83)	-0.7	0.09	0.55	1.00	2.6	
		Week 12	Tezepelumab	32	26 (81.3)	1.17 (1.12)	-1.5	0.73	1.05	1.73	4.2	0.57 [-0.02, 1.15]
			Placebo	27	21 (77.8)	0.58 (0.91)	-0.9	0.00	0.45	1.09	2.5	
		Week 16	Tezepelumab	32	26 (81.3)	1.06 (1.10)	-1.6	0.36	0.82	1.64	3.5	0.28 [-0.30, 0.86]
			Placebo	27	21 (77.8)	0.78 (0.82)	-0.7	0.27	0.82	1.09	2.5	
		Week 20	Tezepelumab	32	26 (81.3)	1.01 (1.10)	-0.9	0.36	0.82	1.64	3.5	0.30 [-0.28, 0.87]
			Placebo	27	21 (77.8)	0.72 (0.86)	-1.5	0.18	0.73	1.00	2.5	
		Week 24	Tezepelumab	32	26 (81.3)	1.13 (1.09)	-0.6	0.27	0.95	1.82	3.5	0.35 [-0.23, 0.93]
			Placebo	27	21 (77.8)	0.78 (0.88)	-1.5	0.45	0.82	1.09	2.5	
		Week 28	Tezepelumab	32	26 (81.3)	1.10 (1.09)	-0.8	0.09	0.95	1.82	3.5	0.36 [-0.22, 0.94]
			Placebo	27	21 (77.8)	0.74 (0.93)	-1.5	0.18	0.82	1.18	2.5	
		Week 32	Tezepelumab	32	26 (81.3)	1.12 (1.07)	-0.5	0.36	0.82	1.82	3.5	0.23 [-0.35, 0.81]
			Placebo	27	21 (77.8)	0.89 (0.94)	-1.8	0.55	1.00	1.27	2.6	
		Week 36	Tezepelumab	32	26 (81.3)	1.17 (1.11)	-0.7	0.45	0.77	1.64	3.5	0.29 [-0.29, 0.87]
			Placebo	27	21 (77.8)	0.87 (0.92)	-1.0	0.27	1.00	1.36	2.6	
		Week 40	Tezepelumab	32	26 (81.3)	1.02 (1.06)	-0.9	0.27	0.91	1.64	3.5	0.13 [-0.45, 0.71]
			Placebo	27	21 (77.8)	0.88 (1.07)	-1.5	0.64	0.91	1.45	2.6	
		Week 44	Tezepelumab	32	26 (81.3)	1.00 (1.06)	-0.5	0.27	0.68	1.64	3.5	0.22 [-0.36, 0.80]
			Placebo	27	21 (77.8)	0.77 (1.02)	-1.1	0.09	0.64	1.27	2.7	
		Week 48	Tezepelumab	32	26 (81.3)	1.09 (1.02)	-0.5	0.36	1.05	1.36	3.5	0.20 [-0.38, 0.78]
			Placebo	27	21 (77.8)	0.88 (1.01)	-1.3	0.09	1.09	1.27	2.8	
		Week 52	Tezepelumab	32	26 (81.3)	1.12 (1.02)	-0.5	0.36	1.05	1.36	3.5	0.18 [-0.40, 0.75]
			Placebo	27	21 (77.8)	0.94 (0.93)	-0.8	0.36	1.00	1.27	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	4.22 (0.98)	2.1	3.68	4.23	4.59	6.3	
			Placebo	37	33 (89.2)	4.36 (0.92)	2.3	3.82	4.27	4.64	6.2	
		Week 4	Tezepelumab	34	30 (88.2)	5.05 (1.01)	3.2	4.18	5.23	5.91	6.8	
			Placebo	37	34 (91.9)	4.85 (1.08)	2.5	4.00	4.68	5.64	7.0	
		Week 8	Tezepelumab	34	32 (94.1)	5.19 (1.18)	2.9	4.18	5.27	6.14	6.9	
			Placebo	37	35 (94.6)	4.90 (1.13)	2.3	4.09	4.82	5.82	7.0	
		Week 12	Tezepelumab	34	32 (94.1)	5.48 (1.06)	3.4	4.77	5.27	6.41	7.0	
			Placebo	37	35 (94.6)	5.09 (1.14)	2.8	4.27	5.09	6.18	7.0	
		Week 16	Tezepelumab	34	32 (94.1)	5.49 (1.06)	3.4	4.68	5.50	6.45	7.0	
			Placebo	37	35 (94.6)	5.17 (1.23)	3.0	4.18	5.09	6.27	7.0	
		Week 20	Tezepelumab	34	32 (94.1)	5.44 (1.12)	3.2	4.59	5.32	6.36	7.0	
			Placebo	37	35 (94.6)	5.07 (1.16)	3.0	4.18	4.91	6.27	7.0	
		Week 24	Tezepelumab	34	32 (94.1)	5.54 (1.06)	2.9	4.86	5.55	6.41	7.0	
			Placebo	37	35 (94.6)	5.01 (1.21)	2.7	4.09	4.91	6.00	7.0	
		Week 28	Tezepelumab	34	33 (97.1)	5.51 (1.05)	2.9	4.91	5.64	6.36	7.0	
			Placebo	37	35 (94.6)	5.08 (1.30)	2.5	4.09	5.09	6.45	7.0	
		Week 32	Tezepelumab	34	33 (97.1)	5.53 (1.12)	2.9	4.82	5.82	6.55	7.0	
			Placebo	37	35 (94.6)	5.08 (1.14)	3.1	4.09	5.09	6.00	7.0	
		Week 36	Tezepelumab	34	33 (97.1)	5.58 (1.04)	3.0	4.91	5.55	6.18	7.0	
			Placebo	37	35 (94.6)	4.96 (1.20)	2.4	4.09	4.82	6.00	7.0	
		Week 40	Tezepelumab	34	33 (97.1)	5.67 (1.05)	3.3	5.00	5.91	6.55	7.0	
			Placebo	37	35 (94.6)	5.05 (1.24)	2.5	4.09	4.91	6.09	7.0	
		Week 44	Tezepelumab	34	33 (97.1)	5.68 (1.05)	3.0	5.18	5.64	6.55	7.0	
			Placebo	37	35 (94.6)	5.11 (1.17)	3.1	4.09	5.09	5.91	7.0	
		Week 48	Tezepelumab	34	33 (97.1)	5.72 (1.12)	2.6	5.09	6.00	6.55	7.0	
			Placebo	37	35 (94.6)	4.96 (1.16)	2.4	4.09	4.82	5.73	7.0	
		Week 52	Tezepelumab	34	33 (97.1)	5.69 (1.14)	2.6	5.09	6.00	6.55	7.0	
			Placebo	37	35 (94.6)	5.05 (1.14)	3.1	4.09	5.00	5.91	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	34	29 (85.3)	0.88 (0.86)	-0.7	0.18	0.91	1.45	2.7	0.45 [-0.06, 0.95]
			Placebo	37	33 (89.2)	0.48 (0.91)	-1.5	0.09	0.36	0.91	2.1	
		Week 8	Tezepelumab	34	31 (91.2)	0.95 (0.92)	-0.7	0.36	0.91	1.55	2.9	0.38 [-0.11, 0.88]
			Placebo	37	33 (89.2)	0.60 (0.93)	-1.3	-0.09	0.64	1.18	2.4	
		Week 12	Tezepelumab	34	31 (91.2)	1.23 (0.92)	-0.7	0.45	1.18	1.82	3.0	0.49 [-0.01, 0.99]
			Placebo	37	33 (89.2)	0.75 (1.03)	-1.3	0.09	0.91	1.27	3.3	
		Week 16	Tezepelumab	34	31 (91.2)	1.23 (0.93)	-0.7	0.45	1.36	1.91	3.0	0.37 [-0.13, 0.86]
			Placebo	37	33 (89.2)	0.87 (1.02)	-1.6	0.36	0.82	1.64	3.5	
		Week 20	Tezepelumab	34	31 (91.2)	1.19 (1.06)	-0.7	0.55	1.00	2.00	3.3	0.44 [-0.06, 0.93]
			Placebo	37	33 (89.2)	0.75 (0.94)	-1.6	0.27	0.64	1.27	2.4	
		Week 24	Tezepelumab	34	31 (91.2)	1.28 (0.98)	-0.7	0.64	1.36	2.00	3.0	0.54 [0.04, 1.04]
			Placebo	37	33 (89.2)	0.72 (1.10)	-1.6	0.09	0.64	1.55	2.9	
		Week 28	Tezepelumab	34	31 (91.2)	1.24 (1.01)	-0.7	0.55	1.09	2.00	3.0	0.41 [-0.09, 0.90]
			Placebo	37	33 (89.2)	0.79 (1.19)	-1.6	0.09	0.82	1.64	3.7	
		Week 32	Tezepelumab	34	31 (91.2)	1.26 (1.04)	-0.7	0.45	1.09	2.27	3.2	0.45 [-0.05, 0.94]
			Placebo	37	33 (89.2)	0.79 (1.02)	-1.6	0.09	0.82	1.55	3.3	
		Week 36	Tezepelumab	34	31 (91.2)	1.31 (1.04)	-0.7	0.73	1.27	2.36	3.0	0.64 [0.14, 1.14]
			Placebo	37	33 (89.2)	0.66 (1.00)	-1.6	0.09	0.73	1.09	2.7	
		Week 40	Tezepelumab	34	31 (91.2)	1.39 (0.97)	-0.7	0.73	1.27	2.36	3.0	0.60 [0.10, 1.11]
			Placebo	37	33 (89.2)	0.76 (1.09)	-1.6	0.18	0.73	1.64	3.5	
		Week 44	Tezepelumab	34	31 (91.2)	1.42 (1.03)	-0.7	0.73	1.55	2.36	3.2	0.55 [0.05, 1.05]
			Placebo	37	33 (89.2)	0.82 (1.14)	-1.6	0.27	0.82	1.64	3.4	
		Week 48	Tezepelumab	34	31 (91.2)	1.47 (1.03)	-0.7	0.82	1.55	2.36	3.2	0.77 [0.26, 1.28]
			Placebo	37	33 (89.2)	0.67 (1.05)	-1.6	0.18	0.73	1.00	3.2	
		Week 52	Tezepelumab	34	31 (91.2)	1.41 (1.04)	-0.7	0.73	1.36	2.36	3.3	0.61 [0.11, 1.11]
			Placebo	37	33 (89.2)	0.77 (1.05)	-1.6	0.09	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	25	21 (84.0)	3.91 (0.67)	2.1	3.73	4.00	4.27	5.2	
			Placebo	22	18 (81.8)	4.25 (0.92)	2.3	3.73	4.14	4.45	6.0	
		Week 4	Tezepelumab	25	24 (96.0)	4.70 (0.96)	3.1	4.00	4.64	5.36	6.6	
			Placebo	22	18 (81.8)	4.61 (1.24)	2.5	3.64	4.55	5.45	7.0	
		Week 8	Tezepelumab	25	24 (96.0)	5.02 (1.00)	3.0	4.27	4.86	6.05	6.6	
			Placebo	22	20 (90.9)	4.71 (1.16)	2.8	3.91	4.59	5.45	7.0	
		Week 12	Tezepelumab	25	24 (96.0)	5.26 (1.00)	3.5	4.45	5.18	6.14	7.0	
			Placebo	22	20 (90.9)	4.71 (1.18)	2.8	3.82	4.68	5.36	6.9	
		Week 16	Tezepelumab	25	24 (96.0)	5.32 (1.03)	3.6	4.45	5.27	6.23	7.0	
			Placebo	22	20 (90.9)	4.62 (1.53)	1.1	3.73	4.45	5.68	7.0	
		Week 20	Tezepelumab	25	24 (96.0)	5.12 (1.23)	2.8	4.23	5.09	6.32	7.0	
			Placebo	22	20 (90.9)	4.59 (1.57)	1.1	3.91	4.32	6.00	6.9	
		Week 24	Tezepelumab	25	24 (96.0)	5.22 (1.12)	3.9	4.23	4.86	6.32	7.0	
			Placebo	22	20 (90.9)	4.43 (1.59)	1.1	3.41	4.32	5.41	6.9	
		Week 28	Tezepelumab	25	25 (100.0)	5.13 (1.07)	2.9	4.36	4.91	6.00	6.8	
			Placebo	22	20 (90.9)	4.44 (1.59)	1.1	3.50	4.36	5.45	6.9	
		Week 32	Tezepelumab	25	25 (100.0)	5.19 (1.13)	3.3	4.36	4.82	6.18	7.0	
			Placebo	22	20 (90.9)	4.53 (1.51)	1.1	3.95	4.45	5.55	7.0	
		Week 36	Tezepelumab	25	25 (100.0)	5.23 (1.08)	3.2	4.27	5.00	6.09	7.0	
			Placebo	22	20 (90.9)	4.62 (1.41)	2.4	3.86	4.50	5.73	6.9	
		Week 40	Tezepelumab	25	25 (100.0)	5.18 (0.99)	3.5	4.36	5.00	5.82	7.0	
			Placebo	22	20 (90.9)	4.61 (1.48)	2.0	3.59	4.36	5.82	6.9	
		Week 44	Tezepelumab	25	25 (100.0)	5.11 (1.01)	3.7	4.27	4.91	5.45	7.0	
			Placebo	22	20 (90.9)	4.62 (1.20)	2.5	3.91	4.73	5.27	6.9	
		Week 48	Tezepelumab	25	25 (100.0)	5.15 (1.05)	3.1	4.27	5.18	5.73	6.9	
			Placebo	22	20 (90.9)	4.50 (1.31)	2.3	3.68	4.45	5.41	6.9	
		Week 52	Tezepelumab	25	25 (100.0)	5.18 (1.02)	3.1	4.36	5.18	5.73	7.0	
			Placebo	22	20 (90.9)	4.68 (1.13)	2.9	3.91	4.36	5.68	6.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	25	21 (84.0)	0.83 (0.80)	-0.3	0.18	0.82	1.45	2.7	0.44 [-0.20, 1.09]
			Placebo	22	17 (77.3)	0.41 (1.08)	-1.5	-0.27	0.27	0.91	2.5	
		Week 8	Tezepelumab	25	21 (84.0)	0.97 (1.01)	-1.3	0.45	0.91	1.55	2.9	0.43 [-0.20, 1.07]
			Placebo	22	18 (81.8)	0.54 (1.02)	-1.3	-0.18	0.36	1.27	2.6	
		Week 12	Tezepelumab	25	21 (84.0)	1.22 (0.93)	-0.5	0.82	1.18	1.73	3.0	0.70 [0.05, 1.34]
			Placebo	22	18 (81.8)	0.53 (1.06)	-1.3	-0.18	0.41	1.27	2.5	
		Week 16	Tezepelumab	25	21 (84.0)	1.26 (0.93)	-0.3	0.55	1.27	1.64	3.0	0.74 [0.09, 1.39]
			Placebo	22	18 (81.8)	0.41 (1.37)	-3.2	-0.64	0.73	1.36	2.3	
		Week 20	Tezepelumab	25	21 (84.0)	1.13 (1.19)	-0.9	0.36	1.36	2.00	3.3	0.57 [-0.07, 1.21]
			Placebo	22	18 (81.8)	0.40 (1.39)	-3.2	0.18	0.68	1.27	2.4	
		Week 24	Tezepelumab	25	21 (84.0)	1.26 (1.07)	-0.3	0.36	1.36	1.82	3.0	0.83 [0.17, 1.49]
			Placebo	22	18 (81.8)	0.20 (1.48)	-3.2	-0.91	0.36	1.45	2.5	
		Week 28	Tezepelumab	25	21 (84.0)	1.19 (0.98)	-0.3	0.64	1.09	1.64	3.0	0.78 [0.12, 1.43]
			Placebo	22	18 (81.8)	0.22 (1.50)	-3.2	-1.09	0.59	1.18	2.5	
		Week 32	Tezepelumab	25	21 (84.0)	1.26 (1.06)	-0.5	0.55	1.27	1.91	3.2	0.78 [0.12, 1.43]
			Placebo	22	18 (81.8)	0.29 (1.44)	-3.2	-0.55	0.59	1.09	2.6	
		Week 36	Tezepelumab	25	21 (84.0)	1.32 (1.02)	-0.3	0.73	1.09	1.73	3.2	0.82 [0.17, 1.48]
			Placebo	22	18 (81.8)	0.38 (1.27)	-1.8	-0.45	0.45	1.18	2.4	
		Week 40	Tezepelumab	25	21 (84.0)	1.23 (0.90)	-0.3	0.82	1.09	1.64	3.0	0.72 [0.07, 1.37]
			Placebo	22	18 (81.8)	0.41 (1.35)	-1.6	-1.00	0.41	1.73	2.5	
		Week 44	Tezepelumab	25	21 (84.0)	1.16 (0.97)	-0.3	0.55	1.09	1.64	3.2	0.75 [0.10, 1.41]
			Placebo	22	18 (81.8)	0.36 (1.15)	-1.6	-0.55	0.45	1.27	2.5	
		Week 48	Tezepelumab	25	21 (84.0)	1.26 (0.95)	-0.3	0.82	1.18	1.64	3.2	0.96 [0.29, 1.62]
			Placebo	22	18 (81.8)	0.24 (1.17)	-1.6	-0.27	0.18	1.00	2.5	
		Week 52	Tezepelumab	25	21 (84.0)	1.29 (0.93)	-0.3	0.82	1.18	1.64	3.3	0.82 [0.17, 1.48]
			Placebo	22	18 (81.8)	0.47 (1.07)	-1.6	0.09	0.32	1.27	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	35	33 (94.3)	4.30 (0.97)	2.4	3.64	4.18	4.64	6.3	
			Placebo	41	35 (85.4)	4.34 (0.73)	3.2	3.91	4.27	4.73	6.2	
		Week 4	Tezepelumab	35	31 (88.6)	4.94 (1.17)	1.6	4.09	5.27	5.82	6.9	
			Placebo	41	37 (90.2)	4.82 (0.95)	3.2	4.00	4.82	5.45	7.0	
		Week 8	Tezepelumab	35	33 (94.3)	5.21 (1.16)	2.9	4.09	5.36	6.18	6.9	
			Placebo	41	37 (90.2)	4.89 (1.05)	2.3	4.18	4.82	5.64	7.0	
		Week 12	Tezepelumab	35	33 (94.3)	5.42 (1.12)	3.0	4.73	5.18	6.45	7.0	
			Placebo	41	37 (90.2)	5.12 (1.07)	3.2	4.18	5.09	6.00	7.0	
		Week 16	Tezepelumab	35	33 (94.3)	5.30 (1.14)	2.8	4.36	5.36	6.18	7.0	
			Placebo	41	37 (90.2)	5.22 (1.06)	3.0	4.45	5.00	6.09	7.0	
		Week 20	Tezepelumab	35	33 (94.3)	5.34 (1.10)	3.2	4.55	5.18	6.36	7.0	
			Placebo	41	37 (90.2)	5.07 (1.05)	3.0	4.36	5.00	5.73	7.0	
		Week 24	Tezepelumab	35	33 (94.3)	5.40 (1.11)	2.9	4.55	5.27	6.27	7.0	
			Placebo	41	37 (90.2)	5.19 (1.01)	3.5	4.18	5.18	6.00	7.0	
		Week 28	Tezepelumab	35	34 (97.1)	5.46 (1.12)	3.2	4.55	5.50	6.36	7.0	
			Placebo	41	38 (92.7)	5.27 (1.18)	3.2	4.27	5.09	6.27	7.0	
		Week 32	Tezepelumab	35	34 (97.1)	5.49 (1.09)	2.9	4.82	5.45	6.55	7.0	
			Placebo	41	38 (92.7)	5.31 (1.06)	3.5	4.27	5.45	6.18	7.0	
		Week 36	Tezepelumab	35	34 (97.1)	5.50 (1.10)	3.0	4.73	5.55	6.36	7.0	
			Placebo	41	38 (92.7)	5.17 (1.10)	3.3	4.09	5.05	6.09	7.0	
		Week 40	Tezepelumab	35	34 (97.1)	5.50 (1.15)	3.3	4.82	5.45	6.55	7.0	
			Placebo	41	38 (92.7)	5.26 (1.15)	3.3	4.09	5.18	6.27	7.0	
		Week 44	Tezepelumab	35	34 (97.1)	5.51 (1.12)	3.0	4.55	5.59	6.36	7.0	
			Placebo	41	38 (92.7)	5.28 (1.17)	3.4	4.09	5.41	6.36	7.0	
		Week 48	Tezepelumab	35	34 (97.1)	5.58 (1.16)	2.6	4.73	5.91	6.55	7.0	
			Placebo	41	38 (92.7)	5.26 (1.10)	3.5	4.18	5.14	6.09	7.0	
		Week 52	Tezepelumab	35	34 (97.1)	5.54 (1.19)	2.6	4.64	6.00	6.55	7.0	
			Placebo	41	38 (92.7)	5.27 (1.15)	3.5	4.09	5.09	6.18	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	35	30 (85.7)	0.63 (1.07)	-2.8	0.00	0.50	1.45	2.5	0.18 [-0.31, 0.67]
			Placebo	41	35 (85.4)	0.46 (0.78)	-1.0	0.00	0.36	0.82	2.1	
		Week 8	Tezepelumab	35	32 (91.4)	0.91 (0.88)	-0.7	0.32	0.82	1.55	2.7	0.39 [-0.09, 0.88]
			Placebo	41	35 (85.4)	0.57 (0.85)	-0.9	-0.09	0.55	1.00	2.4	
		Week 12	Tezepelumab	35	32 (91.4)	1.14 (0.97)	-1.5	0.68	1.05	1.77	2.7	0.41 [-0.08, 0.89]
			Placebo	41	35 (85.4)	0.76 (0.92)	-1.2	0.09	0.82	1.18	3.3	
		Week 16	Tezepelumab	35	32 (91.4)	1.04 (1.02)	-1.6	0.36	0.91	1.86	2.7	0.12 [-0.36, 0.60]
			Placebo	41	35 (85.4)	0.92 (0.88)	-0.7	0.27	0.82	1.64	3.5	
		Week 20	Tezepelumab	35	32 (91.4)	1.07 (0.96)	-0.7	0.45	0.91	1.82	2.7	0.33 [-0.15, 0.81]
			Placebo	41	35 (85.4)	0.78 (0.81)	-0.5	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	35	32 (91.4)	1.14 (0.99)	-0.7	0.45	1.05	1.95	2.9	0.26 [-0.22, 0.74]
			Placebo	41	35 (85.4)	0.90 (0.85)	-0.6	0.27	0.82	1.36	2.9	
		Week 28	Tezepelumab	35	32 (91.4)	1.16 (1.05)	-0.8	0.41	1.00	2.00	2.7	0.22 [-0.26, 0.70]
			Placebo	41	35 (85.4)	0.94 (0.97)	-0.7	0.27	0.91	1.36	3.7	
		Week 32	Tezepelumab	35	32 (91.4)	1.17 (0.98)	-0.7	0.45	1.00	2.09	2.7	0.19 [-0.29, 0.67]
			Placebo	41	35 (85.4)	1.00 (0.84)	-0.5	0.45	1.00	1.55	3.3	
		Week 36	Tezepelumab	35	32 (91.4)	1.19 (1.07)	-0.7	0.41	1.00	2.23	2.8	0.36 [-0.13, 0.84]
			Placebo	41	35 (85.4)	0.85 (0.85)	-1.0	0.36	0.82	1.27	2.7	
		Week 40	Tezepelumab	35	32 (91.4)	1.19 (1.08)	-0.9	0.32	1.09	2.36	2.8	0.24 [-0.24, 0.72]
			Placebo	41	35 (85.4)	0.95 (0.94)	-1.0	0.45	0.82	1.45	3.5	
		Week 44	Tezepelumab	35	32 (91.4)	1.23 (1.10)	-0.7	0.41	1.00	2.36	2.9	0.26 [-0.22, 0.74]
			Placebo	41	35 (85.4)	0.95 (1.06)	-0.9	0.36	0.82	1.73	3.4	
		Week 48	Tezepelumab	35	32 (91.4)	1.29 (1.08)	-0.7	0.41	1.18	2.36	3.1	0.36 [-0.12, 0.84]
			Placebo	41	35 (85.4)	0.92 (0.93)	-0.7	0.27	0.82	1.27	3.2	
		Week 52	Tezepelumab	35	32 (91.4)	1.22 (1.09)	-0.7	0.36	0.95	2.41	3.1	0.26 [-0.23, 0.74]
			Placebo	41	35 (85.4)	0.95 (0.98)	-0.8	0.45	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	41	36 (87.8)	4.12 (0.84)	2.1	3.73	4.18	4.55	6.3	
			Placebo	30	25 (83.3)	4.25 (0.87)	2.3	3.64	4.27	4.64	6.0	
		Week 4	Tezepelumab	41	37 (90.2)	4.99 (0.97)	3.2	4.27	5.09	5.64	6.9	
			Placebo	30	24 (80.0)	4.46 (1.09)	2.5	3.55	4.50	5.00	7.0	
		Week 8	Tezepelumab	41	38 (92.7)	5.20 (1.08)	2.9	4.27	5.23	6.09	6.8	
			Placebo	30	26 (86.7)	4.68 (1.11)	2.3	4.00	4.68	5.45	6.7	
		Week 12	Tezepelumab	41	38 (92.7)	5.42 (1.04)	3.4	4.73	5.50	6.36	7.0	
			Placebo	30	26 (86.7)	4.73 (1.14)	2.8	3.73	4.73	5.45	6.9	
		Week 16	Tezepelumab	41	38 (92.7)	5.39 (1.03)	3.4	4.55	5.50	6.27	7.0	
			Placebo	30	26 (86.7)	4.74 (1.44)	1.1	3.91	4.68	6.00	7.0	
		Week 20	Tezepelumab	41	39 (95.1)	5.32 (1.16)	2.8	4.27	5.36	6.36	7.0	
			Placebo	30	26 (86.7)	4.64 (1.38)	1.1	4.09	4.41	5.82	6.9	
		Week 24	Tezepelumab	41	39 (95.1)	5.41 (1.10)	2.9	4.27	5.55	6.36	7.0	
			Placebo	30	26 (86.7)	4.54 (1.43)	1.1	3.82	4.50	5.73	6.9	
		Week 28	Tezepelumab	41	40 (97.6)	5.30 (1.13)	2.9	4.36	5.36	6.32	7.0	
			Placebo	30	26 (86.7)	4.57 (1.48)	1.1	3.82	4.50	5.82	7.0	
		Week 32	Tezepelumab	41	40 (97.6)	5.32 (1.16)	2.9	4.32	5.64	6.27	7.0	
			Placebo	30	26 (86.7)	4.62 (1.39)	1.1	4.00	4.45	5.82	6.9	
		Week 36	Tezepelumab	41	40 (97.6)	5.37 (1.13)	3.0	4.41	5.45	6.32	7.0	
			Placebo	30	26 (86.7)	4.65 (1.29)	2.4	3.82	4.59	5.82	6.9	
		Week 40	Tezepelumab	41	40 (97.6)	5.34 (1.06)	3.3	4.41	5.18	6.18	7.0	
			Placebo	30	26 (86.7)	4.64 (1.41)	2.0	3.45	4.36	5.91	6.9	
		Week 44	Tezepelumab	41	40 (97.6)	5.34 (1.09)	3.0	4.45	5.41	6.23	7.0	
			Placebo	30	26 (86.7)	4.62 (1.20)	2.5	3.82	4.50	5.36	6.9	
		Week 48	Tezepelumab	41	40 (97.6)	5.40 (1.16)	2.6	4.36	5.50	6.41	7.0	
			Placebo	30	26 (86.7)	4.58 (1.23)	2.3	3.82	4.36	5.64	6.9	
		Week 52	Tezepelumab	41	40 (97.6)	5.42 (1.13)	2.6	4.59	5.50	6.41	7.0	
			Placebo	30	26 (86.7)	4.67 (1.06)	2.9	3.91	4.36	5.64	6.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	41	34 (82.9)	0.99 (0.89)	-0.7	0.27	1.09	1.55	3.1	0.91 [0.36, 1.46]
			Placebo	30	24 (80.0)	0.21 (0.81)	-1.5	-0.18	0.23	0.55	1.9	
		Week 8	Tezepelumab	41	35 (85.4)	1.03 (1.09)	-1.3	0.27	0.91	1.64	3.7	0.56 [0.04, 1.09]
			Placebo	30	25 (83.3)	0.45 (0.88)	-1.3	-0.09	0.36	1.00	2.2	
		Week 12	Tezepelumab	41	35 (85.4)	1.24 (1.07)	-0.7	0.36	1.18	1.82	4.2	0.69 [0.16, 1.22]
			Placebo	30	25 (83.3)	0.49 (1.09)	-1.3	-0.18	0.64	1.09	3.3	
		Week 16	Tezepelumab	41	35 (85.4)	1.20 (1.02)	-0.7	0.36	1.09	1.91	3.5	0.59 [0.06, 1.11]
			Placebo	30	25 (83.3)	0.53 (1.30)	-3.2	0.18	0.82	1.09	3.5	
		Week 20	Tezepelumab	41	35 (85.4)	1.17 (1.17)	-0.9	0.36	1.18	2.18	3.5	0.65 [0.12, 1.17]
			Placebo	30	25 (83.3)	0.41 (1.17)	-3.2	0.18	0.64	1.00	1.9	
		Week 24	Tezepelumab	41	35 (85.4)	1.29 (1.10)	-0.7	0.45	1.36	2.00	3.5	0.83 [0.30, 1.37]
			Placebo	30	25 (83.3)	0.30 (1.30)	-3.2	-0.55	0.64	1.09	2.9	
		Week 28	Tezepelumab	41	35 (85.4)	1.20 (1.09)	-0.7	0.45	0.91	2.00	3.5	0.71 [0.18, 1.24]
			Placebo	30	25 (83.3)	0.33 (1.39)	-3.2	-0.55	0.64	1.00	3.7	
		Week 32	Tezepelumab	41	35 (85.4)	1.18 (1.16)	-0.7	0.27	0.91	2.00	3.5	0.65 [0.13, 1.18]
			Placebo	30	25 (83.3)	0.39 (1.31)	-3.2	-0.36	0.64	1.00	3.3	
		Week 36	Tezepelumab	41	35 (85.4)	1.25 (1.12)	-0.7	0.27	1.09	1.91	3.5	0.75 [0.22, 1.28]
			Placebo	30	25 (83.3)	0.40 (1.15)	-1.8	-0.45	0.45	1.09	2.7	
		Week 40	Tezepelumab	41	35 (85.4)	1.22 (1.06)	-0.7	0.36	1.09	1.91	3.5	0.70 [0.17, 1.23]
			Placebo	30	25 (83.3)	0.40 (1.30)	-1.6	-0.55	0.55	1.00	3.5	
		Week 44	Tezepelumab	41	35 (85.4)	1.21 (1.10)	-0.7	0.36	1.09	1.91	3.5	0.74 [0.21, 1.27]
			Placebo	30	25 (83.3)	0.38 (1.15)	-1.6	-0.55	0.45	1.00	3.4	
		Week 48	Tezepelumab	41	35 (85.4)	1.32 (1.11)	-0.7	0.45	1.27	2.00	3.5	0.89 [0.35, 1.43]
			Placebo	30	25 (83.3)	0.34 (1.08)	-1.6	-0.18	0.45	1.00	2.4	
		Week 52	Tezepelumab	41	35 (85.4)	1.35 (1.08)	-0.7	0.64	1.27	1.91	3.5	0.88 [0.34, 1.41]
			Placebo	30	25 (83.3)	0.44 (0.96)	-1.6	0.09	0.45	1.00	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	25	22 (88.0)	4.15 (0.99)	2.4	3.55	4.00	4.64	5.9	
			Placebo	34	29 (85.3)	4.36 (0.71)	3.5	3.91	4.18	4.64	6.2	
		Week 4	Tezepelumab	25	23 (92.0)	4.69 (1.19)	1.6	3.91	4.55	5.73	6.8	
			Placebo	34	32 (94.1)	4.90 (0.89)	3.6	4.05	4.86	5.45	7.0	
		Week 8	Tezepelumab	25	24 (96.0)	5.07 (1.09)	3.3	4.05	5.27	5.95	6.9	
			Placebo	34	32 (94.1)	4.92 (0.99)	3.1	4.09	4.77	5.73	7.0	
		Week 12	Tezepelumab	25	24 (96.0)	5.29 (1.07)	3.0	4.64	5.09	6.41	7.0	
			Placebo	34	32 (94.1)	5.13 (1.03)	3.5	4.14	5.27	5.95	7.0	
		Week 16	Tezepelumab	25	24 (96.0)	5.17 (1.12)	2.8	4.36	5.00	6.09	7.0	
			Placebo	34	32 (94.1)	5.21 (1.03)	3.0	4.50	5.05	5.95	7.0	
		Week 20	Tezepelumab	25	24 (96.0)	5.13 (1.03)	3.6	4.41	4.95	5.91	7.0	
			Placebo	34	32 (94.1)	5.10 (1.08)	3.0	4.18	5.05	5.91	7.0	
		Week 24	Tezepelumab	25	24 (96.0)	5.15 (1.07)	3.5	4.32	4.86	6.05	7.0	
			Placebo	34	32 (94.1)	5.21 (1.01)	3.5	4.23	5.23	5.91	7.0	
		Week 28	Tezepelumab	25	25 (100.0)	5.25 (1.02)	3.6	4.55	4.91	6.00	7.0	
			Placebo	34	33 (97.1)	5.25 (1.17)	3.2	4.45	5.09	6.00	7.0	
		Week 32	Tezepelumab	25	25 (100.0)	5.37 (0.98)	3.9	4.55	5.18	6.09	7.0	
			Placebo	34	33 (97.1)	5.32 (1.04)	3.5	4.55	5.45	6.00	7.0	
		Week 36	Tezepelumab	25	25 (100.0)	5.37 (0.97)	3.7	4.73	5.45	6.00	7.0	
			Placebo	34	33 (97.1)	5.19 (1.09)	3.3	4.45	5.00	6.09	7.0	
		Week 40	Tezepelumab	25	25 (100.0)	5.35 (1.09)	3.5	4.36	5.18	6.27	7.0	
			Placebo	34	33 (97.1)	5.31 (1.08)	3.5	4.18	5.18	6.18	7.0	
		Week 44	Tezepelumab	25	25 (100.0)	5.36 (1.05)	3.8	4.55	5.36	6.36	7.0	
			Placebo	34	33 (97.1)	5.37 (1.09)	3.4	4.64	5.45	6.36	7.0	
		Week 48	Tezepelumab	25	25 (100.0)	5.38 (1.00)	3.8	4.36	5.18	6.18	7.0	
			Placebo	34	33 (97.1)	5.30 (1.10)	3.5	4.73	5.09	6.09	7.0	
		Week 52	Tezepelumab	25	25 (100.0)	5.33 (1.05)	3.5	4.36	5.18	6.18	7.0	
			Placebo	34	33 (97.1)	5.35 (1.15)	3.5	4.36	5.09	6.18	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	25	21 (84.0)	0.39 (1.07)	-2.8	-0.09	0.45	0.91	2.2	-0.18 [-0.75, 0.38]
			Placebo	34	29 (85.3)	0.56 (0.80)	-0.9	0.09	0.45	1.09	2.1	
		Week 8	Tezepelumab	25	22 (88.0)	0.88 (0.79)	-0.4	0.09	0.91	1.55	2.3	0.32 [-0.24, 0.88]
			Placebo	34	29 (85.3)	0.61 (0.83)	-0.8	0.00	0.64	1.00	2.4	
		Week 12	Tezepelumab	25	22 (88.0)	1.14 (0.92)	-1.5	0.82	1.05	1.55	2.7	0.42 [-0.14, 0.98]
			Placebo	34	29 (85.3)	0.78 (0.81)	-0.5	0.09	0.82	1.18	2.4	
		Week 16	Tezepelumab	25	22 (88.0)	1.07 (1.00)	-1.6	0.36	1.14	1.82	2.7	0.18 [-0.38, 0.73]
			Placebo	34	29 (85.3)	0.92 (0.80)	-0.5	0.27	0.73	1.64	2.5	
		Week 20	Tezepelumab	25	22 (88.0)	1.01 (0.91)	-0.5	0.55	0.86	1.73	2.7	0.21 [-0.35, 0.76]
			Placebo	34	29 (85.3)	0.83 (0.84)	-0.5	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	25	22 (88.0)	1.10 (0.92)	-0.6	0.27	1.05	1.73	2.7	0.19 [-0.37, 0.74]
			Placebo	34	29 (85.3)	0.93 (0.84)	-0.6	0.27	0.82	1.55	2.5	
		Week 28	Tezepelumab	25	22 (88.0)	1.14 (0.97)	-0.8	0.45	1.14	2.00	2.7	0.20 [-0.35, 0.76]
			Placebo	34	29 (85.3)	0.95 (0.91)	-0.7	0.27	0.91	1.64	2.5	
		Week 32	Tezepelumab	25	22 (88.0)	1.21 (0.87)	-0.5	0.55	1.05	1.91	2.7	0.24 [-0.31, 0.80]
			Placebo	34	29 (85.3)	1.01 (0.77)	-0.3	0.45	1.09	1.55	2.4	
		Week 36	Tezepelumab	25	22 (88.0)	1.24 (0.99)	-0.7	0.73	1.00	2.09	2.8	0.39 [-0.17, 0.95]
			Placebo	34	29 (85.3)	0.89 (0.81)	-1.0	0.27	0.82	1.27	2.6	
		Week 40	Tezepelumab	25	22 (88.0)	1.22 (0.98)	-0.9	0.55	1.09	2.36	2.7	0.22 [-0.33, 0.78]
			Placebo	34	29 (85.3)	1.03 (0.77)	-0.2	0.64	0.82	1.64	2.6	
		Week 44	Tezepelumab	25	22 (88.0)	1.26 (1.00)	-0.5	0.55	1.00	2.36	2.7	0.23 [-0.33, 0.78]
			Placebo	34	29 (85.3)	1.04 (0.97)	-0.9	0.36	0.91	1.73	3.2	
		Week 48	Tezepelumab	25	22 (88.0)	1.26 (0.93)	-0.5	0.45	1.14	2.36	2.7	0.31 [-0.25, 0.87]
			Placebo	34	29 (85.3)	0.97 (0.94)	-0.7	0.27	0.82	1.55	3.2	
		Week 52	Tezepelumab	25	22 (88.0)	1.17 (0.96)	-0.5	0.36	0.95	2.36	2.7	0.12 [-0.43, 0.68]
			Placebo	34	29 (85.3)	1.05 (1.00)	-0.7	0.45	0.82	1.73	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	26	23 (88.5)	3.99 (0.59)	2.6	3.64	4.00	4.36	5.2	
			Placebo	31	25 (80.6)	4.38 (0.87)	2.3	3.82	4.27	4.91	6.2	
		Week 4	Tezepelumab	26	23 (88.5)	4.52 (1.19)	1.6	3.73	4.36	5.27	6.9	
			Placebo	31	25 (80.6)	4.74 (1.22)	2.5	3.91	4.45	5.64	7.0	
		Week 8	Tezepelumab	26	23 (88.5)	4.81 (0.99)	3.4	4.09	4.55	6.09	6.5	
			Placebo	31	27 (87.1)	4.96 (1.06)	3.3	4.09	4.82	5.91	7.0	
		Week 12	Tezepelumab	26	23 (88.5)	5.02 (0.99)	3.0	4.27	4.82	5.55	7.0	
			Placebo	31	27 (87.1)	5.07 (1.24)	2.8	4.09	4.91	6.27	6.9	
		Week 16	Tezepelumab	26	23 (88.5)	4.79 (0.97)	2.8	4.09	4.64	5.55	6.7	
			Placebo	31	27 (87.1)	5.11 (1.47)	1.1	4.18	5.27	6.45	6.9	
		Week 20	Tezepelumab	26	24 (92.3)	4.86 (1.00)	2.8	4.18	4.68	5.68	6.5	
			Placebo	31	27 (87.1)	4.96 (1.45)	1.1	3.91	5.00	6.27	6.9	
		Week 24	Tezepelumab	26	24 (92.3)	5.01 (0.96)	3.8	4.27	4.68	5.55	7.0	
			Placebo	31	27 (87.1)	5.10 (1.43)	1.1	4.18	5.55	6.27	6.9	
		Week 28	Tezepelumab	26	26 (100.0)	4.94 (0.98)	3.5	4.27	4.59	5.45	7.0	
			Placebo	31	28 (90.3)	5.17 (1.54)	1.1	3.91	5.64	6.55	7.0	
		Week 32	Tezepelumab	26	26 (100.0)	4.97 (1.04)	3.3	4.18	4.50	5.82	7.0	
			Placebo	31	28 (90.3)	5.24 (1.45)	1.1	4.18	5.64	6.41	7.0	
		Week 36	Tezepelumab	26	26 (100.0)	5.00 (1.04)	3.7	4.27	4.64	6.09	7.0	
			Placebo	31	28 (90.3)	5.27 (1.39)	2.4	4.09	5.59	6.41	6.9	
		Week 40	Tezepelumab	26	26 (100.0)	4.97 (0.97)	3.5	4.27	5.00	5.45	7.0	
			Placebo	31	28 (90.3)	5.32 (1.46)	2.5	3.95	5.68	6.73	7.0	
		Week 44	Tezepelumab	26	26 (100.0)	4.93 (0.95)	3.7	4.00	4.73	5.55	7.0	
			Placebo	31	28 (90.3)	5.39 (1.35)	2.9	4.23	5.59	6.64	6.9	
		Week 48	Tezepelumab	26	26 (100.0)	5.03 (0.98)	3.8	4.09	4.82	5.82	6.8	
			Placebo	31	28 (90.3)	5.30 (1.38)	2.4	4.14	5.55	6.55	7.0	
		Week 52	Tezepelumab	26	26 (100.0)	5.09 (1.03)	3.5	4.18	4.82	6.09	6.8	
			Placebo	31	28 (90.3)	5.38 (1.33)	2.9	4.05	5.55	6.64	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	26	23 (88.5)	0.53 (1.06)	-2.8	0.00	0.55	1.27	2.0	0.13 [-0.44, 0.70]
			Placebo	31	24 (77.4)	0.40 (0.88)	-0.9	-0.14	0.23	0.82	2.5	
		Week 8	Tezepelumab	26	23 (88.5)	0.81 (0.92)	-1.3	0.09	0.64	1.55	2.7	0.17 [-0.39, 0.74]
			Placebo	31	25 (80.6)	0.65 (0.92)	-0.5	-0.09	0.55	1.18	2.6	
		Week 12	Tezepelumab	26	23 (88.5)	1.03 (0.93)	-1.5	0.45	1.00	1.64	2.8	0.26 [-0.31, 0.83]
			Placebo	31	25 (80.6)	0.76 (1.08)	-1.2	0.09	0.82	1.18	3.3	
		Week 16	Tezepelumab	26	23 (88.5)	0.80 (0.91)	-1.6	0.27	0.64	1.45	2.8	-0.00 [-0.57, 0.56]
			Placebo	31	25 (80.6)	0.80 (1.28)	-3.2	0.27	0.82	1.36	3.5	
		Week 20	Tezepelumab	26	23 (88.5)	0.83 (0.90)	-0.9	0.36	0.82	1.36	2.5	0.17 [-0.40, 0.74]
			Placebo	31	25 (80.6)	0.65 (1.20)	-3.2	0.18	0.64	1.45	2.5	
		Week 24	Tezepelumab	26	23 (88.5)	0.99 (0.93)	-0.6	0.36	0.73	1.64	3.0	0.18 [-0.38, 0.75]
			Placebo	31	25 (80.6)	0.79 (1.29)	-3.2	0.36	0.82	1.36	2.9	
		Week 28	Tezepelumab	26	23 (88.5)	0.94 (0.92)	-0.8	0.09	0.73	1.45	2.9	0.11 [-0.45, 0.68]
			Placebo	31	25 (80.6)	0.80 (1.37)	-3.2	0.27	0.82	1.36	3.7	
		Week 32	Tezepelumab	26	23 (88.5)	0.87 (0.93)	-0.5	0.27	0.82	1.64	2.8	0.02 [-0.55, 0.58]
			Placebo	31	25 (80.6)	0.85 (1.27)	-3.2	0.45	0.82	1.36	3.3	
		Week 36	Tezepelumab	26	23 (88.5)	0.96 (0.95)	-0.7	0.27	0.73	1.64	3.2	0.07 [-0.50, 0.64]
			Placebo	31	25 (80.6)	0.88 (1.13)	-1.8	0.45	1.00	1.64	2.7	
		Week 40	Tezepelumab	26	23 (88.5)	0.92 (0.91)	-0.9	0.36	0.91	1.27	2.9	-0.05 [-0.62, 0.51]
			Placebo	31	25 (80.6)	0.97 (1.21)	-1.4	0.27	0.82	1.73	3.5	
		Week 44	Tezepelumab	26	23 (88.5)	0.88 (0.86)	-0.5	0.36	0.73	1.27	2.8	-0.12 [-0.68, 0.45]
			Placebo	31	25 (80.6)	1.00 (1.25)	-1.4	0.27	0.91	1.82	3.4	
		Week 48	Tezepelumab	26	23 (88.5)	1.03 (0.89)	-0.5	0.36	1.00	1.64	3.0	0.10 [-0.47, 0.67]
			Placebo	31	25 (80.6)	0.92 (1.24)	-1.5	0.18	0.82	1.82	3.2	
		Week 52	Tezepelumab	26	23 (88.5)	1.05 (0.87)	-0.5	0.36	1.00	1.64	3.0	0.03 [-0.54, 0.59]
			Placebo	31	25 (80.6)	1.02 (1.18)	-1.4	0.18	1.00	1.64	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	4.23 (1.05)	2.1	3.64	4.18	4.64	6.3	
			Placebo	34	30 (88.2)	4.25 (0.71)	3.2	3.91	4.14	4.64	6.0	
		Week 4	Tezepelumab	40	37 (92.5)	5.09 (0.92)	3.2	4.27	5.27	5.82	6.8	
			Placebo	34	32 (94.1)	4.75 (0.87)	3.3	4.05	4.68	5.45	6.7	
		Week 8	Tezepelumab	40	39 (97.5)	5.35 (1.08)	2.9	4.73	5.36	6.09	6.9	
			Placebo	34	32 (94.1)	4.76 (1.09)	2.3	4.09	4.68	5.27	7.0	
		Week 12	Tezepelumab	40	39 (97.5)	5.57 (1.03)	3.4	4.91	5.64	6.55	7.0	
			Placebo	34	32 (94.1)	4.91 (0.99)	3.4	4.14	4.91	5.50	7.0	
		Week 16	Tezepelumab	40	39 (97.5)	5.61 (1.00)	3.4	4.91	5.64	6.45	7.0	
			Placebo	34	32 (94.1)	4.96 (1.04)	2.9	4.05	4.91	5.68	7.0	
		Week 20	Tezepelumab	40	39 (97.5)	5.49 (1.11)	3.2	4.55	5.45	6.55	7.0	
			Placebo	34	32 (94.1)	4.89 (1.07)	2.1	4.09	4.77	5.41	7.0	
		Week 24	Tezepelumab	40	39 (97.5)	5.50 (1.13)	2.9	4.55	5.64	6.55	7.0	
			Placebo	34	32 (94.1)	4.81 (1.12)	2.0	4.05	4.82	5.45	7.0	
		Week 28	Tezepelumab	40	39 (97.5)	5.51 (1.10)	2.9	4.82	5.73	6.36	7.0	
			Placebo	34	32 (94.1)	4.83 (1.18)	2.0	4.00	4.77	5.68	7.0	
		Week 32	Tezepelumab	40	39 (97.5)	5.59 (1.07)	2.9	4.82	5.82	6.55	7.0	
			Placebo	34	32 (94.1)	4.88 (1.07)	1.7	4.09	4.82	5.50	7.0	
		Week 36	Tezepelumab	40	39 (97.5)	5.62 (1.02)	3.0	4.91	5.55	6.55	7.0	
			Placebo	34	32 (94.1)	4.73 (1.00)	2.5	4.00	4.64	5.32	7.0	
		Week 40	Tezepelumab	40	39 (97.5)	5.59 (1.06)	3.3	4.91	5.64	6.55	7.0	
			Placebo	34	32 (94.1)	4.80 (1.07)	2.0	4.09	4.82	5.45	7.0	
		Week 44	Tezepelumab	40	39 (97.5)	5.62 (1.06)	3.0	4.91	5.64	6.55	7.0	
			Placebo	34	32 (94.1)	4.80 (0.99)	2.5	4.05	4.91	5.36	7.0	
		Week 48	Tezepelumab	40	39 (97.5)	5.64 (1.10)	2.6	5.00	5.64	6.55	7.0	
			Placebo	34	32 (94.1)	4.77 (1.01)	2.3	4.05	4.77	5.55	7.0	
		Week 52	Tezepelumab	40	39 (97.5)	5.59 (1.10)	2.6	4.91	5.64	6.55	7.0	
			Placebo	34	32 (94.1)	4.82 (0.95)	3.5	4.05	4.64	5.68	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	40	32 (80.0)	0.93 (0.93)	-0.7	0.23	0.86	1.50	3.1	0.51 [0.00, 1.01]
			Placebo	34	30 (88.2)	0.48 (0.86)	-1.5	0.09	0.41	1.09	2.1	
		Week 8	Tezepelumab	40	34 (85.0)	1.07 (1.02)	-0.7	0.36	1.00	1.64	3.7	0.58 [0.08, 1.08]
			Placebo	34	30 (88.2)	0.52 (0.87)	-1.3	0.00	0.55	1.00	2.4	
		Week 12	Tezepelumab	40	34 (85.0)	1.32 (1.06)	-0.7	0.64	1.23	1.91	4.2	0.72 [0.22, 1.23]
			Placebo	34	30 (88.2)	0.61 (0.89)	-1.3	0.00	0.68	1.18	2.4	
		Week 16	Tezepelumab	40	34 (85.0)	1.39 (1.00)	-0.7	0.55	1.41	2.09	3.5	0.69 [0.19, 1.20]
			Placebo	34	30 (88.2)	0.73 (0.89)	-1.6	0.27	0.73	1.55	2.3	
		Week 20	Tezepelumab	40	34 (85.0)	1.29 (1.15)	-0.7	0.55	1.23	2.36	3.5	0.59 [0.09, 1.10]
			Placebo	34	30 (88.2)	0.68 (0.90)	-1.6	0.27	0.73	1.27	2.3	
		Week 24	Tezepelumab	40	34 (85.0)	1.37 (1.08)	-0.7	0.55	1.32	2.36	3.5	0.75 [0.24, 1.26]
			Placebo	34	30 (88.2)	0.58 (1.00)	-1.6	0.09	0.45	1.45	2.3	
		Week 28	Tezepelumab	40	34 (85.0)	1.34 (1.09)	-0.7	0.45	1.27	2.36	3.5	0.68 [0.17, 1.19]
			Placebo	34	30 (88.2)	0.61 (1.06)	-1.6	-0.18	0.82	1.27	2.5	
		Week 32	Tezepelumab	40	34 (85.0)	1.41 (1.08)	-0.7	0.55	1.32	2.45	3.5	0.71 [0.20, 1.22]
			Placebo	34	30 (88.2)	0.68 (0.98)	-1.8	0.09	0.73	1.55	2.0	
		Week 36	Tezepelumab	40	34 (85.0)	1.44 (1.11)	-0.7	0.73	1.45	2.55	3.5	0.89 [0.38, 1.41]
			Placebo	34	30 (88.2)	0.54 (0.91)	-1.6	0.00	0.68	1.09	2.0	
		Week 40	Tezepelumab	40	34 (85.0)	1.43 (1.06)	-0.7	0.64	1.32	2.45	3.5	0.80 [0.29, 1.31]
			Placebo	34	30 (88.2)	0.60 (1.00)	-1.6	0.00	0.73	1.45	2.2	
		Week 44	Tezepelumab	40	34 (85.0)	1.47 (1.12)	-0.7	0.73	1.55	2.55	3.5	0.86 [0.35, 1.37]
			Placebo	34	30 (88.2)	0.57 (0.96)	-1.6	0.00	0.64	1.27	2.1	
		Week 48	Tezepelumab	40	34 (85.0)	1.48 (1.10)	-0.7	0.73	1.36	2.45	3.5	0.94 [0.42, 1.46]
			Placebo	34	30 (88.2)	0.54 (0.87)	-1.6	0.09	0.45	1.09	2.2	
		Week 52	Tezepelumab	40	34 (85.0)	1.43 (1.12)	-0.7	0.64	1.36	2.45	3.5	0.81 [0.30, 1.32]
			Placebo	34	30 (88.2)	0.61 (0.87)	-1.6	0.09	0.55	1.09	2.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	57	49 (86.0)	4.06 (0.83)	2.2	3.64	4.09	4.45	6.3	
			Placebo	60	51 (85.0)	4.33 (0.74)	2.3	3.91	4.27	4.64	6.2	
		Week 4	Tezepelumab	57	51 (89.5)	4.75 (1.01)	1.6	4.00	4.91	5.36	6.9	
			Placebo	60	52 (86.7)	4.84 (1.03)	2.5	4.05	4.68	5.55	7.0	
		Week 8	Tezepelumab	57	53 (93.0)	5.03 (1.00)	2.9	4.18	5.18	5.91	6.8	
			Placebo	60	54 (90.0)	4.91 (1.05)	2.8	4.09	4.73	5.64	7.0	
		Week 12	Tezepelumab	57	53 (93.0)	5.22 (0.94)	3.0	4.64	5.09	6.09	6.7	
			Placebo	60	54 (90.0)	4.99 (1.12)	2.8	4.09	5.05	6.00	7.0	
		Week 16	Tezepelumab	57	53 (93.0)	5.16 (0.98)	2.8	4.36	5.09	5.91	7.0	
			Placebo	60	54 (90.0)	5.04 (1.27)	1.1	4.00	5.05	6.00	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.11 (1.05)	2.8	4.27	5.05	6.00	7.0	
			Placebo	60	54 (90.0)	4.97 (1.29)	1.1	4.09	4.95	6.09	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.15 (1.01)	2.9	4.27	4.95	6.09	7.0	
			Placebo	60	54 (90.0)	4.97 (1.30)	1.1	4.09	5.14	5.82	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.16 (1.00)	3.2	4.36	4.91	6.00	7.0	
			Placebo	60	55 (91.7)	5.02 (1.36)	1.1	3.91	5.09	6.00	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.19 (1.01)	2.9	4.36	5.14	5.95	7.0	
			Placebo	60	55 (91.7)	5.06 (1.29)	1.1	4.09	5.27	6.00	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.23 (0.98)	3.0	4.41	5.41	6.05	7.0	
			Placebo	60	55 (91.7)	5.02 (1.24)	2.4	4.00	5.00	6.09	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.20 (0.99)	3.3	4.36	5.09	6.14	7.0	
			Placebo	60	55 (91.7)	5.10 (1.27)	2.0	4.09	5.18	6.18	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.20 (1.00)	3.0	4.41	5.18	5.95	7.0	
			Placebo	60	55 (91.7)	5.11 (1.21)	2.5	4.00	5.27	6.00	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.28 (1.03)	2.6	4.32	5.18	6.18	7.0	
			Placebo	60	55 (91.7)	5.06 (1.25)	2.3	4.00	5.00	6.09	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.31 (1.05)	2.6	4.36	5.18	6.23	7.0	
			Placebo	60	55 (91.7)	5.14 (1.19)	2.9	4.00	5.00	6.09	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	57	46 (80.7)	0.70 (1.03)	-2.8	0.00	0.59	1.45	3.1	0.22 [-0.18, 0.63]
			Placebo	60	50 (83.3)	0.49 (0.85)	-1.2	0.00	0.36	0.91	2.5	
		Week 8	Tezepelumab	57	48 (84.2)	0.90 (1.00)	-1.3	0.23	0.77	1.55	3.7	0.33 [-0.07, 0.72]
			Placebo	60	51 (85.0)	0.60 (0.83)	-0.8	0.00	0.55	1.00	2.6	
		Week 12	Tezepelumab	57	48 (84.2)	1.11 (1.03)	-1.5	0.41	1.00	1.68	4.2	0.48 [0.08, 0.88]
			Placebo	60	51 (85.0)	0.65 (0.90)	-1.2	0.09	0.64	1.18	2.5	
		Week 16	Tezepelumab	57	48 (84.2)	1.07 (1.01)	-1.6	0.36	0.91	1.73	3.5	0.31 [-0.08, 0.71]
			Placebo	60	51 (85.0)	0.75 (1.00)	-3.2	0.27	0.73	1.55	2.5	
		Week 20	Tezepelumab	57	48 (84.2)	1.03 (1.10)	-0.9	0.32	0.91	1.82	3.5	0.33 [-0.07, 0.72]
			Placebo	60	51 (85.0)	0.68 (1.01)	-3.2	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	57	48 (84.2)	1.12 (1.03)	-0.7	0.36	0.77	1.82	3.5	0.42 [0.02, 0.82]
			Placebo	60	51 (85.0)	0.67 (1.08)	-3.2	0.09	0.64	1.45	2.5	
		Week 28	Tezepelumab	57	48 (84.2)	1.12 (1.05)	-0.8	0.23	1.00	2.00	3.5	0.38 [-0.01, 0.78]
			Placebo	60	51 (85.0)	0.70 (1.12)	-3.2	0.09	0.82	1.36	2.5	
		Week 32	Tezepelumab	57	48 (84.2)	1.10 (1.06)	-0.7	0.32	0.86	1.91	3.5	0.33 [-0.06, 0.73]
			Placebo	60	51 (85.0)	0.75 (1.05)	-3.2	0.27	0.82	1.55	2.6	
		Week 36	Tezepelumab	57	48 (84.2)	1.17 (1.09)	-0.7	0.32	0.95	1.91	3.5	0.45 [0.05, 0.85]
			Placebo	60	51 (85.0)	0.71 (0.96)	-1.8	0.18	0.73	1.27	2.6	
		Week 40	Tezepelumab	57	48 (84.2)	1.14 (1.04)	-0.9	0.36	1.00	1.91	3.5	0.35 [-0.05, 0.74]
			Placebo	60	51 (85.0)	0.78 (1.01)	-1.5	0.18	0.73	1.64	2.6	
		Week 44	Tezepelumab	57	48 (84.2)	1.14 (1.08)	-0.7	0.36	0.95	1.91	3.5	0.34 [-0.05, 0.74]
			Placebo	60	51 (85.0)	0.78 (1.03)	-1.4	0.27	0.73	1.55	3.2	
		Week 48	Tezepelumab	57	48 (84.2)	1.25 (1.06)	-0.7	0.41	1.14	2.00	3.5	0.49 [0.09, 0.89]
			Placebo	60	51 (85.0)	0.74 (1.02)	-1.5	0.09	0.82	1.27	3.2	
		Week 52	Tezepelumab	57	48 (84.2)	1.27 (1.05)	-0.7	0.55	1.18	2.14	3.5	0.43 [0.03, 0.83]
			Placebo	60	51 (85.0)	0.83 (0.99)	-1.4	0.09	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	4.55 (1.15)	2.1	4.18	4.64	5.18	5.9	
			Placebo	5	4 (80.0)	4.07 (1.32)	3.2	3.23	3.55	4.91	6.0	
		Week 4	Tezepelumab	9	9 (100.0)	5.61 (1.13)	3.2	5.09	5.82	6.27	6.8	
			Placebo	5	5 (100.0)	3.84 (0.50)	3.2	3.64	3.82	4.00	4.5	
		Week 8	Tezepelumab	9	9 (100.0)	5.86 (1.30)	3.0	5.91	6.36	6.64	6.9	
			Placebo	5	5 (100.0)	4.24 (1.23)	2.3	3.91	4.73	4.82	5.5	
		Week 12	Tezepelumab	9	9 (100.0)	6.24 (1.22)	3.5	6.45	6.64	7.00	7.0	
			Placebo	5	5 (100.0)	4.87 (1.01)	3.9	4.27	4.73	4.91	6.5	
		Week 16	Tezepelumab	9	9 (100.0)	6.15 (1.18)	3.6	6.18	6.73	6.91	7.0	
			Placebo	5	5 (100.0)	4.89 (1.05)	4.1	4.36	4.55	4.73	6.7	
		Week 20	Tezepelumab	9	9 (100.0)	6.07 (1.12)	3.6	6.09	6.45	6.73	7.0	
			Placebo	5	5 (100.0)	4.40 (0.49)	3.9	4.09	4.36	4.45	5.2	
		Week 24	Tezepelumab	9	9 (100.0)	6.29 (1.03)	3.9	6.09	6.91	7.00	7.0	
			Placebo	5	5 (100.0)	4.67 (0.85)	4.1	4.27	4.36	4.45	6.2	
		Week 28	Tezepelumab	9	9 (100.0)	6.06 (1.28)	2.9	5.73	6.36	6.82	7.0	
			Placebo	5	5 (100.0)	4.60 (1.37)	3.6	3.91	4.09	4.36	7.0	
		Week 32	Tezepelumab	9	9 (100.0)	6.25 (1.18)	3.4	6.00	6.73	7.00	7.0	
			Placebo	5	5 (100.0)	4.87 (0.97)	4.1	4.36	4.55	4.82	6.5	
		Week 36	Tezepelumab	9	9 (100.0)	6.22 (1.25)	3.2	6.18	6.82	7.00	7.0	
			Placebo	5	5 (100.0)	4.56 (0.83)	3.9	4.09	4.36	4.45	6.0	
		Week 40	Tezepelumab	9	9 (100.0)	6.20 (1.16)	3.5	6.00	6.64	7.00	7.0	
			Placebo	5	5 (100.0)	4.49 (1.36)	3.3	3.91	4.09	4.36	6.8	
		Week 44	Tezepelumab	9	9 (100.0)	6.25 (1.06)	3.8	6.00	6.55	7.00	7.0	
			Placebo	5	5 (100.0)	4.71 (1.18)	3.5	4.09	4.36	4.91	6.6	
		Week 48	Tezepelumab	9	9 (100.0)	6.11 (1.22)	3.1	6.18	6.55	6.82	7.0	
			Placebo	5	5 (100.0)	4.53 (0.71)	3.8	4.09	4.36	4.73	5.6	
		Week 52	Tezepelumab	9	9 (100.0)	5.88 (1.28)	3.1	5.55	6.27	6.82	7.0	
			Placebo	5	5 (100.0)	4.45 (0.70)	3.8	4.09	4.36	4.36	5.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	1.06 (0.78)	-0.1	0.55	1.18	1.45	2.2	1.53 [0.19, 2.87]
			Placebo	5	4 (80.0)	-0.18 (0.90)	-1.5	-0.77	0.05	0.41	0.6	
		Week 8	Tezepelumab	9	9 (100.0)	1.31 (0.82)	0.1	0.91	1.36	2.09	2.3	0.97 [-0.28, 2.21]
			Placebo	5	4 (80.0)	0.25 (1.63)	-1.3	-1.09	0.05	1.59	2.2	
		Week 12	Tezepelumab	9	9 (100.0)	1.70 (0.76)	0.8	1.09	1.55	2.36	2.7	0.56 [-0.64, 1.76]
			Placebo	5	4 (80.0)	1.05 (1.86)	-1.3	-0.09	1.09	2.18	3.3	
		Week 16	Tezepelumab	9	9 (100.0)	1.61 (0.89)	0.4	1.00	1.55	2.36	2.8	0.53 [-0.67, 1.72]
			Placebo	5	4 (80.0)	0.91 (2.08)	-1.6	-0.36	0.91	2.18	3.5	
		Week 20	Tezepelumab	9	9 (100.0)	1.53 (0.84)	0.5	0.82	1.36	2.36	2.7	1.01 [-0.24, 2.26]
			Placebo	5	4 (80.0)	0.45 (1.50)	-1.6	-0.50	0.77	1.41	1.9	
		Week 24	Tezepelumab	9	9 (100.0)	1.75 (0.86)	0.3	1.36	1.82	2.36	3.0	0.86 [-0.38, 2.09]
			Placebo	5	4 (80.0)	0.70 (1.86)	-1.6	-0.50	0.77	1.91	2.9	
		Week 28	Tezepelumab	9	9 (100.0)	1.52 (0.95)	0.5	0.82	1.45	2.36	2.9	0.57 [-0.64, 1.77]
			Placebo	5	4 (80.0)	0.70 (2.27)	-1.6	-0.91	0.36	2.32	3.7	
		Week 32	Tezepelumab	9	9 (100.0)	1.71 (0.81)	0.5	1.09	1.82	2.36	2.8	0.65 [-0.56, 1.86]
			Placebo	5	4 (80.0)	0.89 (2.01)	-1.6	-0.36	0.95	2.14	3.3	
		Week 36	Tezepelumab	9	9 (100.0)	1.68 (0.85)	0.7	1.09	1.27	2.36	3.1	0.97 [-0.28, 2.21]
			Placebo	5	4 (80.0)	0.52 (1.81)	-1.6	-0.77	0.50	1.82	2.7	
		Week 40	Tezepelumab	9	9 (100.0)	1.66 (0.84)	0.2	1.27	1.36	2.36	2.7	0.79 [-0.43, 2.02]
			Placebo	5	4 (80.0)	0.57 (2.24)	-1.6	-1.09	0.18	2.23	3.5	
		Week 44	Tezepelumab	9	9 (100.0)	1.71 (0.82)	0.2	1.27	1.73	2.36	2.7	0.85 [-0.38, 2.08]
			Placebo	5	4 (80.0)	0.59 (2.12)	-1.6	-0.95	0.32	2.14	3.4	
		Week 48	Tezepelumab	9	9 (100.0)	1.57 (0.90)	0.4	1.00	1.36	2.36	2.9	0.99 [-0.26, 2.24]
			Placebo	5	4 (80.0)	0.41 (1.68)	-1.6	-0.82	0.45	1.64	2.4	
		Week 52	Tezepelumab	9	9 (100.0)	1.33 (0.96)	0.0	0.91	1.36	1.36	2.9	0.77 [-0.45, 1.99]
			Placebo	5	4 (80.0)	0.41 (1.68)	-1.6	-0.82	0.45	1.64	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.31 (1.22)	2.1	3.86	4.18	5.18	5.9	
			Placebo	14	10 (71.4)	4.25 (0.72)	3.3	3.91	4.14	4.36	6.0	
		Week 4	Tezepelumab	9	8 (88.9)	5.01 (0.88)	3.2	4.68	5.14	5.73	5.8	
			Placebo	14	12 (85.7)	4.48 (0.91)	3.2	3.77	4.50	5.27	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.47 (1.19)	3.0	5.09	5.59	6.27	6.8	
			Placebo	14	13 (92.9)	4.52 (0.84)	3.1	4.00	4.27	5.09	6.0	
		Week 12	Tezepelumab	9	8 (88.9)	5.50 (1.22)	3.5	4.73	5.41	6.64	7.0	
			Placebo	14	13 (92.9)	4.57 (1.02)	2.8	3.91	4.73	5.27	6.5	
		Week 16	Tezepelumab	9	8 (88.9)	5.65 (1.08)	3.6	5.09	5.68	6.55	6.9	
			Placebo	14	13 (92.9)	4.95 (1.03)	3.0	4.45	4.91	5.55	6.7	
		Week 20	Tezepelumab	9	8 (88.9)	5.24 (1.34)	3.5	3.95	5.27	6.55	6.8	
			Placebo	14	13 (92.9)	4.72 (0.91)	3.2	4.18	4.73	5.18	6.6	
		Week 24	Tezepelumab	9	8 (88.9)	5.44 (1.14)	3.9	4.50	5.45	6.41	6.9	
			Placebo	14	13 (92.9)	4.81 (1.18)	2.7	4.18	4.36	5.82	6.6	
		Week 28	Tezepelumab	9	8 (88.9)	5.35 (1.29)	2.9	4.73	5.45	6.36	6.8	
			Placebo	14	14 (100.0)	4.90 (1.42)	2.5	3.82	4.73	6.00	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.44 (1.26)	3.4	4.64	5.41	6.55	7.0	
			Placebo	14	14 (100.0)	4.99 (1.25)	3.3	3.82	4.82	6.18	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.48 (1.27)	3.2	4.77	5.50	6.64	6.8	
			Placebo	14	14 (100.0)	4.96 (1.26)	2.4	4.36	4.82	6.00	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.48 (1.19)	3.5	4.77	5.50	6.41	7.0	
			Placebo	14	14 (100.0)	4.90 (1.32)	2.5	3.91	4.73	5.73	6.9	
		Week 44	Tezepelumab	9	8 (88.9)	5.60 (1.12)	3.8	4.77	5.64	6.64	6.9	
			Placebo	14	14 (100.0)	5.05 (1.20)	3.1	4.27	5.00	5.91	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.50 (1.22)	3.1	4.82	5.86	6.36	6.8	
			Placebo	14	14 (100.0)	4.84 (1.21)	2.4	4.18	4.73	5.73	6.8	
		Week 52	Tezepelumab	9	8 (88.9)	5.51 (1.23)	3.1	4.82	5.86	6.41	6.8	
			Placebo	14	14 (100.0)	4.92 (1.07)	3.5	4.18	4.55	5.73	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.65 (0.51)	-0.1	0.00	0.82	1.09	1.2	0.51 [-0.47, 1.49]
			Placebo	14	10 (71.4)	0.24 (0.96)	-1.5	-0.36	0.23	0.64	1.7	
		Week 8	Tezepelumab	9	7 (77.8)	1.12 (0.71)	0.1	0.82	0.91	1.64	2.4	0.67 [-0.32, 1.67]
			Placebo	14	10 (71.4)	0.44 (1.16)	-1.3	-0.18	0.18	1.18	2.2	
		Week 12	Tezepelumab	9	7 (77.8)	1.21 (0.67)	0.4	0.82	1.09	1.55	2.5	0.75 [-0.25, 1.76]
			Placebo	14	10 (71.4)	0.34 (1.39)	-1.3	-1.00	0.14	1.18	3.3	
		Week 16	Tezepelumab	9	7 (77.8)	1.35 (0.78)	0.4	0.82	1.09	1.91	2.7	0.37 [-0.61, 1.34]
			Placebo	14	10 (71.4)	0.90 (1.45)	-1.6	0.55	0.86	1.64	3.5	
		Week 20	Tezepelumab	9	7 (77.8)	1.10 (1.07)	-0.6	0.55	0.82	2.00	2.6	0.42 [-0.56, 1.39]
			Placebo	14	10 (71.4)	0.61 (1.26)	-1.6	-0.55	0.77	1.82	2.4	
		Week 24	Tezepelumab	9	7 (77.8)	1.35 (0.89)	0.3	0.64	1.00	2.36	2.5	0.41 [-0.57, 1.39]
			Placebo	14	10 (71.4)	0.81 (1.54)	-1.6	-0.55	0.95	2.09	2.9	
		Week 28	Tezepelumab	9	7 (77.8)	1.18 (0.91)	0.5	0.55	0.82	2.36	2.6	0.29 [-0.68, 1.26]
			Placebo	14	10 (71.4)	0.75 (1.75)	-1.6	-0.73	1.09	1.82	3.7	
		Week 32	Tezepelumab	9	7 (77.8)	1.31 (0.79)	0.5	0.64	1.09	2.27	2.5	0.39 [-0.58, 1.37]
			Placebo	14	10 (71.4)	0.81 (1.53)	-1.6	-0.55	1.18	1.55	3.3	
		Week 36	Tezepelumab	9	7 (77.8)	1.32 (0.78)	0.7	0.82	0.91	2.36	2.5	0.45 [-0.53, 1.43]
			Placebo	14	10 (71.4)	0.75 (1.52)	-1.6	-0.55	0.95	2.00	2.7	
		Week 40	Tezepelumab	9	7 (77.8)	1.32 (0.88)	0.2	0.82	1.09	2.45	2.5	0.42 [-0.56, 1.40]
			Placebo	14	10 (71.4)	0.75 (1.63)	-1.6	-0.55	0.73	1.73	3.5	
		Week 44	Tezepelumab	9	7 (77.8)	1.47 (0.97)	0.2	0.82	1.09	2.73	2.7	0.47 [-0.51, 1.45]
			Placebo	14	10 (71.4)	0.84 (1.54)	-1.6	-0.55	0.77	2.00	3.4	
		Week 48	Tezepelumab	9	7 (77.8)	1.34 (0.88)	0.4	0.64	1.00	2.36	2.6	0.61 [-0.38, 1.60]
			Placebo	14	10 (71.4)	0.58 (1.43)	-1.6	-0.55	0.82	1.73	2.4	
		Week 52	Tezepelumab	9	7 (77.8)	1.35 (0.80)	0.4	0.82	1.00	2.36	2.5	0.56 [-0.43, 1.54]
			Placebo	14	10 (71.4)	0.74 (1.26)	-1.6	0.09	0.82	1.73	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.11 (0.84)	2.2	3.64	4.09	4.55	6.3	
			Placebo	51	45 (88.2)	4.33 (0.80)	2.3	3.82	4.27	4.73	6.2	
		Week 4	Tezepelumab	57	52 (91.2)	4.85 (1.09)	1.6	4.05	4.95	5.73	6.9	
			Placebo	51	45 (88.2)	4.82 (1.06)	2.5	4.00	4.64	5.64	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.10 (1.06)	2.9	4.18	5.18	6.09	6.9	
			Placebo	51	46 (90.2)	4.94 (1.12)	2.3	4.09	4.82	5.82	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.35 (1.03)	3.0	4.64	5.14	6.36	7.0	
			Placebo	51	46 (90.2)	5.09 (1.11)	3.3	4.18	5.05	6.00	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.26 (1.06)	2.8	4.36	5.14	6.18	7.0	
			Placebo	51	46 (90.2)	5.05 (1.31)	1.1	4.00	5.05	6.09	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.25 (1.08)	2.8	4.27	5.18	6.27	7.0	
			Placebo	51	46 (90.2)	4.98 (1.33)	1.1	4.09	4.95	6.18	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.29 (1.09)	2.9	4.27	5.18	6.27	7.0	
			Placebo	51	46 (90.2)	4.98 (1.30)	1.1	4.09	5.09	5.82	7.0	
		Week 28	Tezepelumab	57	57 (100.0)	5.27 (1.06)	3.2	4.36	5.27	6.00	7.0	
			Placebo	51	46 (90.2)	5.01 (1.35)	1.1	4.09	5.09	6.00	7.0	
		Week 32	Tezepelumab	57	57 (100.0)	5.32 (1.08)	2.9	4.36	5.27	6.18	7.0	
			Placebo	51	46 (90.2)	5.06 (1.28)	1.1	4.09	5.18	6.00	7.0	
		Week 36	Tezepelumab	57	57 (100.0)	5.36 (1.05)	3.0	4.45	5.45	6.09	7.0	
			Placebo	51	46 (90.2)	4.99 (1.21)	2.5	4.00	4.95	6.09	7.0	
		Week 40	Tezepelumab	57	57 (100.0)	5.32 (1.05)	3.3	4.36	5.18	6.18	7.0	
			Placebo	51	46 (90.2)	5.09 (1.28)	2.0	4.09	5.14	6.18	7.0	
		Week 44	Tezepelumab	57	57 (100.0)	5.31 (1.07)	3.0	4.45	5.36	6.18	7.0	
			Placebo	51	46 (90.2)	5.08 (1.22)	2.5	4.00	5.23	6.00	7.0	
		Week 48	Tezepelumab	57	57 (100.0)	5.38 (1.08)	2.6	4.36	5.36	6.36	7.0	
			Placebo	51	46 (90.2)	5.07 (1.22)	2.3	4.00	5.00	6.09	7.0	
		Week 52	Tezepelumab	57	57 (100.0)	5.37 (1.08)	2.6	4.36	5.18	6.36	7.0	
			Placebo	51	46 (90.2)	5.13 (1.20)	2.9	4.00	5.00	6.09	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	0.78 (1.05)	-2.8	0.00	0.68	1.50	3.1	0.30 [-0.11, 0.71]
			Placebo	51	44 (86.3)	0.49 (0.84)	-1.2	0.05	0.36	0.86	2.5	
		Week 8	Tezepelumab	57	50 (87.7)	0.95 (1.02)	-1.3	0.27	0.82	1.55	3.7	0.36 [-0.05, 0.77]
			Placebo	51	45 (88.2)	0.61 (0.83)	-0.9	0.00	0.55	1.00	2.6	
		Week 12	Tezepelumab	57	50 (87.7)	1.20 (1.05)	-1.5	0.45	1.14	1.73	4.2	0.46 [0.05, 0.87]
			Placebo	51	45 (88.2)	0.76 (0.86)	-0.9	0.09	0.82	1.18	2.5	
		Week 16	Tezepelumab	57	50 (87.7)	1.12 (1.04)	-1.6	0.36	1.00	1.82	3.5	0.38 [-0.02, 0.79]
			Placebo	51	45 (88.2)	0.73 (1.00)	-3.2	0.27	0.73	1.36	2.5	
		Week 20	Tezepelumab	57	50 (87.7)	1.11 (1.08)	-0.9	0.36	1.00	1.91	3.5	0.41 [0.00, 0.82]
			Placebo	51	45 (88.2)	0.68 (1.00)	-3.2	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	57	50 (87.7)	1.20 (1.05)	-0.7	0.36	1.18	1.91	3.5	0.53 [0.12, 0.94]
			Placebo	51	45 (88.2)	0.65 (1.04)	-3.2	0.09	0.64	1.36	2.5	
		Week 28	Tezepelumab	57	50 (87.7)	1.18 (1.06)	-0.8	0.36	1.14	2.00	3.5	0.46 [0.05, 0.87]
			Placebo	51	45 (88.2)	0.68 (1.08)	-3.2	0.18	0.82	1.18	2.5	
		Week 32	Tezepelumab	57	50 (87.7)	1.18 (1.08)	-0.7	0.36	0.95	1.91	3.5	0.41 [0.00, 0.82]
			Placebo	51	45 (88.2)	0.75 (1.02)	-3.2	0.36	0.82	1.36	2.6	
		Week 36	Tezepelumab	57	50 (87.7)	1.24 (1.10)	-0.7	0.36	1.18	1.91	3.5	0.55 [0.14, 0.96]
			Placebo	51	45 (88.2)	0.68 (0.90)	-1.8	0.18	0.73	1.18	2.6	
		Week 40	Tezepelumab	57	50 (87.7)	1.21 (1.05)	-0.9	0.36	1.09	1.91	3.5	0.43 [0.02, 0.83]
			Placebo	51	45 (88.2)	0.77 (0.98)	-1.5	0.27	0.73	1.45	2.6	
		Week 44	Tezepelumab	57	50 (87.7)	1.20 (1.07)	-0.7	0.36	1.05	1.91	3.5	0.43 [0.02, 0.84]
			Placebo	51	45 (88.2)	0.75 (1.02)	-1.4	0.27	0.64	1.27	3.2	
		Week 48	Tezepelumab	57	50 (87.7)	1.29 (1.06)	-0.7	0.45	1.23	2.00	3.5	0.54 [0.13, 0.95]
			Placebo	51	45 (88.2)	0.74 (0.98)	-1.4	0.09	0.73	1.27	3.2	
		Week 52	Tezepelumab	57	50 (87.7)	1.27 (1.07)	-0.7	0.55	1.18	1.91	3.5	0.44 [0.03, 0.85]
			Placebo	51	45 (88.2)	0.81 (0.99)	-1.4	0.09	0.82	1.27	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	51	44 (86.3)	4.05 (0.87)	2.2	3.55	4.00	4.50	6.3	
			Placebo	49	43 (87.8)	4.37 (0.79)	2.3	3.91	4.27	4.82	6.2	
		Week 4	Tezepelumab	51	46 (90.2)	4.71 (1.05)	1.6	4.00	4.73	5.36	6.9	
			Placebo	49	43 (87.8)	4.86 (1.06)	2.5	4.00	4.73	5.64	7.0	
		Week 8	Tezepelumab	51	48 (94.1)	4.97 (1.01)	2.9	4.09	4.77	5.91	6.8	
			Placebo	49	44 (89.8)	5.01 (1.07)	2.8	4.14	4.82	5.86	7.0	
		Week 12	Tezepelumab	51	48 (94.1)	5.20 (0.96)	3.0	4.64	5.09	6.14	6.7	
			Placebo	49	44 (89.8)	5.12 (1.13)	3.3	4.18	5.14	6.09	7.0	
		Week 16	Tezepelumab	51	48 (94.1)	5.11 (0.99)	2.8	4.27	5.09	5.91	7.0	
			Placebo	49	44 (89.8)	5.08 (1.33)	1.1	4.00	5.14	6.18	7.0	
		Week 20	Tezepelumab	51	49 (96.1)	5.12 (1.05)	2.8	4.27	5.09	6.00	7.0	
			Placebo	49	44 (89.8)	5.01 (1.35)	1.1	4.09	5.05	6.23	7.0	
		Week 24	Tezepelumab	51	49 (96.1)	5.13 (1.02)	2.9	4.27	5.00	6.09	7.0	
			Placebo	49	44 (89.8)	5.01 (1.32)	1.1	4.09	5.18	5.91	7.0	
		Week 28	Tezepelumab	51	51 (100.0)	5.13 (1.01)	3.2	4.27	4.91	6.00	7.0	
			Placebo	49	44 (89.8)	5.07 (1.36)	1.1	4.18	5.09	6.00	7.0	
		Week 32	Tezepelumab	51	51 (100.0)	5.17 (1.03)	2.9	4.27	5.18	6.00	7.0	
			Placebo	49	44 (89.8)	5.09 (1.30)	1.1	4.18	5.32	6.00	7.0	
		Week 36	Tezepelumab	51	51 (100.0)	5.21 (0.99)	3.0	4.36	5.45	6.09	7.0	
			Placebo	49	44 (89.8)	5.04 (1.22)	2.5	4.05	5.05	6.18	7.0	
		Week 40	Tezepelumab	51	51 (100.0)	5.18 (1.00)	3.3	4.36	5.09	6.18	7.0	
			Placebo	49	44 (89.8)	5.15 (1.27)	2.0	4.09	5.18	6.18	7.0	
		Week 44	Tezepelumab	51	51 (100.0)	5.16 (1.01)	3.0	4.27	5.18	5.91	7.0	
			Placebo	49	44 (89.8)	5.14 (1.21)	2.5	4.05	5.27	6.14	7.0	
		Week 48	Tezepelumab	51	51 (100.0)	5.24 (1.05)	2.6	4.27	5.18	6.18	7.0	
			Placebo	49	44 (89.8)	5.12 (1.23)	2.3	4.14	5.05	6.09	7.0	
		Week 52	Tezepelumab	51	51 (100.0)	5.28 (1.07)	2.6	4.27	5.18	6.27	7.0	
			Placebo	49	44 (89.8)	5.18 (1.20)	2.9	4.05	5.05	6.14	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	51	42 (82.4)	0.69 (1.07)	-2.8	0.00	0.50	1.45	3.1	0.20 [-0.23, 0.63]
			Placebo	49	42 (85.7)	0.49 (0.86)	-1.2	0.00	0.36	0.91	2.5	
		Week 8	Tezepelumab	51	44 (86.3)	0.85 (1.02)	-1.3	0.14	0.68	1.50	3.7	0.23 [-0.19, 0.65]
			Placebo	49	43 (87.8)	0.64 (0.81)	-0.7	0.00	0.55	1.00	2.6	
		Week 12	Tezepelumab	51	44 (86.3)	1.09 (1.05)	-1.5	0.41	1.00	1.68	4.2	0.36 [-0.06, 0.79]
			Placebo	49	43 (87.8)	0.74 (0.87)	-0.9	0.09	0.73	1.27	2.5	
		Week 16	Tezepelumab	51	44 (86.3)	1.01 (1.01)	-1.6	0.36	0.86	1.55	3.5	0.28 [-0.14, 0.71]
			Placebo	49	43 (87.8)	0.73 (1.02)	-3.2	0.18	0.64	1.55	2.5	
		Week 20	Tezepelumab	51	44 (86.3)	1.01 (1.08)	-0.9	0.32	0.91	1.73	3.5	0.32 [-0.10, 0.74]
			Placebo	49	43 (87.8)	0.68 (1.02)	-3.2	0.18	0.64	1.27	2.5	
		Week 24	Tezepelumab	51	44 (86.3)	1.07 (1.04)	-0.7	0.32	0.73	1.73	3.5	0.41 [-0.01, 0.84]
			Placebo	49	43 (87.8)	0.64 (1.06)	-3.2	0.09	0.64	1.36	2.5	
		Week 28	Tezepelumab	51	44 (86.3)	1.07 (1.05)	-0.8	0.09	1.00	1.95	3.5	0.35 [-0.08, 0.77]
			Placebo	49	43 (87.8)	0.70 (1.09)	-3.2	0.18	0.82	1.27	2.5	
		Week 32	Tezepelumab	51	44 (86.3)	1.06 (1.07)	-0.7	0.27	0.86	1.91	3.5	0.30 [-0.12, 0.73]
			Placebo	49	43 (87.8)	0.74 (1.04)	-3.2	0.27	0.82	1.36	2.6	
		Week 36	Tezepelumab	51	44 (86.3)	1.12 (1.10)	-0.7	0.23	0.95	1.82	3.5	0.43 [0.00, 0.85]
			Placebo	49	43 (87.8)	0.69 (0.91)	-1.8	0.18	0.73	1.18	2.6	
		Week 40	Tezepelumab	51	44 (86.3)	1.09 (1.04)	-0.9	0.36	1.00	1.86	3.5	0.29 [-0.14, 0.71]
			Placebo	49	43 (87.8)	0.80 (0.98)	-1.5	0.27	0.73	1.45	2.6	
		Week 44	Tezepelumab	51	44 (86.3)	1.08 (1.07)	-0.7	0.32	0.86	1.77	3.5	0.29 [-0.13, 0.72]
			Placebo	49	43 (87.8)	0.77 (1.03)	-1.4	0.27	0.64	1.45	3.2	
		Week 48	Tezepelumab	51	44 (86.3)	1.19 (1.07)	-0.7	0.36	1.09	1.95	3.5	0.42 [-0.00, 0.85]
			Placebo	49	43 (87.8)	0.75 (1.00)	-1.4	0.09	0.73	1.27	3.2	
		Week 52	Tezepelumab	51	44 (86.3)	1.22 (1.07)	-0.7	0.50	1.14	1.91	3.5	0.37 [-0.05, 0.80]
			Placebo	49	43 (87.8)	0.83 (1.01)	-1.4	0.09	0.82	1.55	3.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	4.40 (0.95)	2.1	4.09	4.23	4.91	5.9	
			Placebo	16	12 (75.0)	4.12 (0.73)	3.2	3.82	3.95	4.32	6.0	
		Week 4	Tezepelumab	15	14 (93.3)	5.41 (0.96)	3.2	4.82	5.50	6.09	6.8	
			Placebo	16	14 (87.5)	4.40 (0.86)	3.2	3.82	4.36	5.18	6.0	
		Week 8	Tezepelumab	15	14 (93.3)	5.77 (1.09)	3.0	5.27	6.05	6.55	6.9	
			Placebo	16	15 (93.8)	4.39 (0.98)	2.3	3.91	4.27	5.09	6.0	
		Week 12	Tezepelumab	15	14 (93.3)	5.94 (1.14)	3.5	5.00	6.55	7.00	7.0	
			Placebo	16	15 (93.8)	4.58 (0.96)	2.8	3.91	4.73	5.27	6.5	
		Week 16	Tezepelumab	15	14 (93.3)	5.99 (1.04)	3.6	5.27	6.32	6.91	7.0	
			Placebo	16	15 (93.8)	4.88 (0.98)	3.0	4.36	4.73	5.55	6.7	
		Week 20	Tezepelumab	15	14 (93.3)	5.70 (1.24)	3.5	4.82	6.23	6.73	7.0	
			Placebo	16	15 (93.8)	4.66 (0.86)	3.2	4.09	4.45	5.18	6.6	
		Week 24	Tezepelumab	15	14 (93.3)	5.95 (1.10)	3.9	4.91	6.18	6.91	7.0	
			Placebo	16	15 (93.8)	4.74 (1.11)	2.7	4.09	4.36	5.82	6.6	
		Week 28	Tezepelumab	15	14 (93.3)	5.84 (1.17)	2.9	4.91	6.18	6.82	7.0	
			Placebo	16	16 (100.0)	4.77 (1.37)	2.5	3.73	4.36	5.86	7.0	
		Week 32	Tezepelumab	15	14 (93.3)	5.94 (1.15)	3.4	4.91	6.18	7.00	7.0	
			Placebo	16	16 (100.0)	4.93 (1.19)	3.3	3.95	4.68	5.86	7.0	
		Week 36	Tezepelumab	15	14 (93.3)	5.95 (1.16)	3.2	5.00	6.36	6.82	7.0	
			Placebo	16	16 (100.0)	4.84 (1.22)	2.4	4.00	4.64	6.00	6.9	
		Week 40	Tezepelumab	15	14 (93.3)	5.94 (1.10)	3.5	5.00	6.14	7.00	7.0	
			Placebo	16	16 (100.0)	4.75 (1.31)	2.5	3.86	4.36	5.64	6.9	
		Week 44	Tezepelumab	15	14 (93.3)	6.03 (1.04)	3.8	5.27	6.45	6.91	7.0	
			Placebo	16	16 (100.0)	4.89 (1.20)	3.1	3.95	4.68	5.77	6.9	
		Week 48	Tezepelumab	15	14 (93.3)	5.94 (1.09)	3.1	5.55	6.23	6.82	7.0	
			Placebo	16	16 (100.0)	4.73 (1.17)	2.4	3.95	4.55	5.68	6.8	
		Week 52	Tezepelumab	15	14 (93.3)	5.78 (1.11)	3.1	4.91	6.09	6.64	7.0	
			Placebo	16	16 (100.0)	4.80 (1.05)	3.5	4.00	4.36	5.68	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_ILSHP: Change from baseline in AQLQ+12 activity limitations score by study specific subgroups
DITTL

Subgroup	AQLQ+12 activity limitations score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	15	13 (86.7)	1.01 (0.65)	-0.1	0.64	1.09	1.36	2.2	0.97 [0.13, 1.80]
			Placebo	16	12 (75.0)	0.27 (0.88)	-1.5	-0.23	0.27	0.64	1.7	
		Week 8	Tezepelumab	15	13 (86.7)	1.36 (0.75)	0.1	0.91	1.36	2.09	2.4	1.04 [0.20, 1.88]
			Placebo	16	12 (75.0)	0.37 (1.14)	-1.3	-0.50	0.18	1.09	2.2	
		Week 12	Tezepelumab	15	13 (86.7)	1.57 (0.79)	0.4	0.82	1.55	2.36	2.7	1.05 [0.21, 1.89]
			Placebo	16	12 (75.0)	0.46 (1.29)	-1.3	-0.50	0.50	1.14	3.3	
		Week 16	Tezepelumab	15	13 (86.7)	1.62 (0.85)	0.4	1.00	1.55	2.36	2.8	0.65 [-0.15, 1.46]
			Placebo	16	12 (75.0)	0.90 (1.31)	-1.6	0.59	0.91	1.36	3.5	
		Week 20	Tezepelumab	15	13 (86.7)	1.43 (1.00)	-0.6	0.82	1.36	2.36	2.7	0.74 [-0.08, 1.55]
			Placebo	16	12 (75.0)	0.64 (1.14)	-1.6	-0.05	0.77	1.36	2.4	
		Week 24	Tezepelumab	15	13 (86.7)	1.70 (0.87)	0.3	1.00	1.82	2.36	3.0	0.78 [-0.04, 1.60]
			Placebo	16	12 (75.0)	0.80 (1.39)	-1.6	-0.14	0.86	1.95	2.9	
		Week 28	Tezepelumab	15	13 (86.7)	1.55 (0.93)	0.5	0.82	1.45	2.36	2.9	0.66 [-0.15, 1.47]
			Placebo	16	12 (75.0)	0.69 (1.60)	-1.6	-0.64	0.86	1.73	3.7	
		Week 32	Tezepelumab	15	13 (86.7)	1.66 (0.83)	0.5	0.91	1.82	2.36	2.8	0.74 [-0.08, 1.55]
			Placebo	16	12 (75.0)	0.83 (1.38)	-1.6	-0.41	0.95	1.55	3.3	
		Week 36	Tezepelumab	15	13 (86.7)	1.66 (0.84)	0.7	0.91	1.27	2.36	3.1	0.84 [0.02, 1.67]
			Placebo	16	12 (75.0)	0.70 (1.39)	-1.6	-0.23	0.86	1.68	2.7	
		Week 40	Tezepelumab	15	13 (86.7)	1.66 (0.84)	0.2	1.09	1.36	2.45	2.7	0.83 [0.01, 1.65]
			Placebo	16	12 (75.0)	0.65 (1.52)	-1.6	-0.55	0.73	1.68	3.5	
		Week 44	Tezepelumab	15	13 (86.7)	1.75 (0.85)	0.2	1.09	1.73	2.64	2.7	0.86 [0.03, 1.68]
			Placebo	16	12 (75.0)	0.75 (1.43)	-1.6	-0.41	0.77	1.82	3.4	
		Week 48	Tezepelumab	15	13 (86.7)	1.65 (0.86)	0.4	1.00	1.36	2.36	2.9	0.99 [0.16, 1.83]
			Placebo	16	12 (75.0)	0.56 (1.31)	-1.6	-0.27	0.82	1.41	2.4	
		Week 52	Tezepelumab	15	13 (86.7)	1.48 (0.90)	0.0	0.91	1.36	2.36	2.9	0.76 [-0.06, 1.57]
			Placebo	16	12 (75.0)	0.69 (1.16)	-1.6	0.05	0.82	1.41	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILMH0: Course of AQLQ+12 environmental stimuli score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli score	Baseline	Tezepelumab	66	58 (87.9)	3.99 (1.06)	1.8	3.25	4.00	4.75	6.8	
		Placebo	65	55 (84.6)	4.38 (1.22)	1.5	3.50	4.25	5.50	7.0	
	Week 4	Tezepelumab	66	60 (90.9)	4.80 (1.12)	1.3	4.00	5.00	5.75	7.0	
		Placebo	65	57 (87.7)	4.84 (1.21)	2.0	4.25	5.00	5.50	7.0	
	Week 8	Tezepelumab	66	62 (93.9)	5.15 (1.15)	1.0	4.25	5.38	6.00	7.0	
		Placebo	65	59 (90.8)	4.91 (1.29)	1.5	4.00	5.00	5.75	7.0	
	Week 12	Tezepelumab	66	62 (93.9)	5.27 (1.14)	1.0	4.50	5.50	6.25	7.0	
		Placebo	65	59 (90.8)	4.92 (1.16)	2.0	4.00	5.00	5.75	7.0	
	Week 16	Tezepelumab	66	62 (93.9)	5.16 (1.19)	1.0	4.50	5.25	6.00	7.0	
		Placebo	65	59 (90.8)	4.88 (1.38)	1.3	4.00	5.00	5.75	7.0	
	Week 20	Tezepelumab	66	63 (95.5)	5.13 (1.24)	1.0	4.50	5.00	6.00	7.0	
		Placebo	65	59 (90.8)	4.84 (1.41)	1.3	4.00	5.00	5.75	7.0	
	Week 24	Tezepelumab	66	63 (95.5)	5.23 (1.26)	1.0	4.50	5.00	6.25	7.0	
		Placebo	65	59 (90.8)	4.80 (1.50)	1.0	4.25	5.00	5.75	7.0	
	Week 28	Tezepelumab	66	65 (98.5)	5.20 (1.25)	1.0	4.50	5.00	6.25	7.0	
		Placebo	65	60 (92.3)	5.00 (1.49)	1.3	4.13	5.25	6.00	7.0	
	Week 32	Tezepelumab	66	65 (98.5)	5.28 (1.27)	1.0	4.50	5.25	6.00	7.0	
		Placebo	65	60 (92.3)	5.04 (1.47)	1.3	4.00	5.25	6.00	7.0	
	Week 36	Tezepelumab	66	65 (98.5)	5.30 (1.23)	1.0	4.50	5.25	6.25	7.0	
		Placebo	65	60 (92.3)	4.87 (1.49)	1.0	4.00	5.00	6.00	7.0	
	Week 40	Tezepelumab	66	65 (98.5)	5.32 (1.14)	2.0	4.50	5.25	6.00	7.0	
		Placebo	65	60 (92.3)	5.04 (1.48)	1.0	4.00	5.25	6.13	7.0	
	Week 44	Tezepelumab	66	65 (98.5)	5.32 (1.19)	1.3	4.50	5.25	6.25	7.0	
		Placebo	65	60 (92.3)	5.03 (1.41)	1.3	4.00	5.13	6.13	7.0	
	Week 48	Tezepelumab	66	65 (98.5)	5.35 (1.21)	1.0	4.50	5.25	6.25	7.0	
		Placebo	65	60 (92.3)	5.00 (1.37)	1.0	4.00	5.00	6.00	7.0	
	Week 52	Tezepelumab	66	65 (98.5)	5.35 (1.20)	1.0	4.50	5.50	6.25	7.0	
		Placebo	65	60 (92.3)	5.07 (1.32)	1.8	4.25	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILMH0: Course of AQLQ+12 environmental stimuli score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	66	55 (83.3)	0.83 (1.24)	-4.0	0.00	0.75	1.75	4.0	0.33 [-0.05, 0.71]
		Placebo	65	54 (83.1)	0.45 (1.04)	-2.0	-0.25	0.38	1.00	3.0	
	Week 8	Tezepelumab	66	57 (86.4)	1.14 (1.21)	-1.3	0.25	1.25	2.00	4.3	0.45 [0.08, 0.83]
		Placebo	65	55 (84.6)	0.60 (1.17)	-1.8	-0.25	0.50	1.25	3.3	
	Week 12	Tezepelumab	66	57 (86.4)	1.26 (1.17)	-2.3	0.50	1.25	2.25	4.8	0.62 [0.24, 1.00]
		Placebo	65	55 (84.6)	0.57 (1.05)	-1.8	-0.25	0.75	1.25	3.0	
	Week 16	Tezepelumab	66	57 (86.4)	1.17 (1.24)	-2.8	0.25	1.25	2.25	3.3	0.56 [0.18, 0.94]
		Placebo	65	55 (84.6)	0.53 (1.04)	-1.8	0.00	0.50	1.00	3.0	
	Week 20	Tezepelumab	66	57 (86.4)	1.15 (1.22)	-1.8	0.25	1.25	2.25	3.5	0.55 [0.18, 0.93]
		Placebo	65	55 (84.6)	0.51 (1.07)	-2.3	0.00	0.50	1.25	3.0	
	Week 24	Tezepelumab	66	57 (86.4)	1.26 (1.22)	-1.5	0.25	1.50	2.25	3.5	0.64 [0.26, 1.02]
		Placebo	65	55 (84.6)	0.48 (1.21)	-2.8	-0.25	0.50	1.25	3.8	
	Week 28	Tezepelumab	66	57 (86.4)	1.24 (1.24)	-1.5	0.25	1.50	2.25	3.3	0.46 [0.09, 0.84]
		Placebo	65	55 (84.6)	0.66 (1.27)	-2.8	0.00	0.75	1.25	3.8	
	Week 32	Tezepelumab	66	57 (86.4)	1.31 (1.27)	-1.3	0.25	1.50	2.25	3.5	0.51 [0.13, 0.88]
		Placebo	65	55 (84.6)	0.72 (1.07)	-1.8	0.00	0.75	1.25	3.8	
	Week 36	Tezepelumab	66	57 (86.4)	1.33 (1.25)	-1.3	0.25	1.50	2.25	3.5	0.65 [0.27, 1.03]
		Placebo	65	55 (84.6)	0.54 (1.20)	-2.8	0.00	0.25	1.25	3.8	
	Week 40	Tezepelumab	66	57 (86.4)	1.36 (1.16)	-1.3	0.25	1.50	2.25	3.3	0.56 [0.18, 0.94]
		Placebo	65	55 (84.6)	0.70 (1.22)	-2.5	0.00	0.75	1.25	3.8	
	Week 44	Tezepelumab	66	57 (86.4)	1.39 (1.24)	-1.5	0.50	1.50	2.25	3.8	0.56 [0.19, 0.94]
		Placebo	65	55 (84.6)	0.69 (1.22)	-1.5	0.00	0.50	1.25	3.8	
	Week 48	Tezepelumab	66	57 (86.4)	1.40 (1.25)	-1.3	0.50	1.50	2.25	3.8	0.58 [0.21, 0.96]
		Placebo	65	55 (84.6)	0.66 (1.30)	-2.8	0.00	0.50	1.25	3.8	
	Week 52	Tezepelumab	66	57 (86.4)	1.41 (1.22)	-1.3	0.50	1.50	2.25	3.8	0.56 [0.18, 0.94]
		Placebo	65	55 (84.6)	0.72 (1.23)	-1.3	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
DITTL

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	54 (83.1)					
Week 8	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	55 (84.6)					
Week 12	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	52 (80.0)					
Week 16	Tezepelumab	66	53 (80.3)	NE		NE		
	Placebo	65	50 (76.9)					
Week 20	Tezepelumab	66	51 (77.3)	NE		NE		
	Placebo	65	47 (72.3)					
Week 24	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	45 (69.2)					
Week 28	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 32	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	43 (66.2)					
Week 36	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 40	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	45 (69.2)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
DITTL

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 48	Tezepelumab	66	46 (69.7)	NE		NE		
	Placebo	65	44 (67.7)					
Week 52	Tezepelumab	66	18 (27.3)	NE		NE		
	Placebo	65	16 (24.6)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QEC_ILMG0: Course of AQLQ+12 environmental stimuli score
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QEC_ILMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	19	16 (84.2)	4.02 (0.97)	2.5	3.63	4.00	4.25	6.8	
			Placebo	20	17 (85.0)	4.07 (1.30)	2.0	3.25	3.75	4.75	7.0	
		Week 4	Tezepelumab	19	17 (89.5)	4.94 (1.06)	3.3	4.00	5.00	6.00	6.8	
			Placebo	20	17 (85.0)	4.47 (1.49)	2.0	3.50	4.25	5.50	7.0	
		Week 8	Tezepelumab	19	17 (89.5)	5.29 (1.10)	3.5	4.50	5.00	6.00	7.0	
			Placebo	20	18 (90.0)	4.38 (1.22)	2.3	3.50	4.38	5.25	7.0	
		Week 12	Tezepelumab	19	17 (89.5)	5.25 (1.09)	3.0	4.50	5.25	5.75	7.0	
			Placebo	20	18 (90.0)	4.81 (1.08)	2.5	4.25	5.00	5.50	7.0	
		Week 16	Tezepelumab	19	17 (89.5)	5.26 (1.08)	4.0	4.25	5.00	6.00	7.0	
			Placebo	20	18 (90.0)	4.43 (1.62)	1.3	3.50	4.00	5.75	7.0	
		Week 20	Tezepelumab	19	17 (89.5)	5.38 (1.16)	4.0	4.50	5.00	6.50	7.0	
			Placebo	20	18 (90.0)	4.40 (1.72)	1.3	3.50	3.88	5.75	7.0	
		Week 24	Tezepelumab	19	17 (89.5)	5.32 (1.20)	3.8	4.25	5.00	6.50	7.0	
			Placebo	20	18 (90.0)	4.26 (1.77)	1.3	2.75	4.50	5.75	7.0	
		Week 28	Tezepelumab	19	18 (94.7)	5.28 (1.17)	3.8	4.25	5.00	6.25	7.0	
			Placebo	20	19 (95.0)	4.61 (1.72)	1.3	3.50	4.50	5.75	7.0	
		Week 32	Tezepelumab	19	18 (94.7)	5.32 (1.23)	3.5	4.25	5.00	7.00	7.0	
			Placebo	20	19 (95.0)	4.71 (1.68)	1.3	3.25	4.75	6.00	7.0	
		Week 36	Tezepelumab	19	18 (94.7)	5.36 (1.16)	3.8	4.50	4.88	6.75	7.0	
			Placebo	20	19 (95.0)	4.57 (1.70)	1.8	3.00	4.25	6.00	7.0	
		Week 40	Tezepelumab	19	18 (94.7)	5.24 (1.10)	3.8	4.50	5.00	6.00	7.0	
			Placebo	20	19 (95.0)	4.70 (1.65)	1.8	3.50	5.00	6.25	7.0	
		Week 44	Tezepelumab	19	18 (94.7)	5.19 (1.13)	3.8	4.25	5.00	6.50	7.0	
			Placebo	20	19 (95.0)	4.79 (1.53)	2.0	3.75	4.25	6.00	7.0	
		Week 48	Tezepelumab	19	18 (94.7)	5.42 (1.13)	4.0	4.50	5.00	7.00	7.0	
			Placebo	20	19 (95.0)	4.64 (1.54)	2.0	3.75	4.50	6.00	7.0	
		Week 52	Tezepelumab	19	18 (94.7)	5.36 (1.10)	4.0	4.50	5.00	6.25	7.0	
			Placebo	20	19 (95.0)	4.78 (1.46)	1.8	4.00	4.50	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	19	15 (78.9)	0.85 (0.78)	-0.3	0.00	0.75	1.75	2.3	0.50 [-0.22, 1.21]
			Placebo	20	16 (80.0)	0.39 (1.04)	-2.0	0.00	0.25	0.88	2.0	
		Week 8	Tezepelumab	19	15 (78.9)	1.25 (0.94)	0.0	0.25	1.25	2.25	2.5	0.91 [0.18, 1.64]
			Placebo	20	17 (85.0)	0.35 (1.02)	-1.8	-0.25	0.25	1.00	2.5	
		Week 12	Tezepelumab	19	15 (78.9)	1.27 (0.82)	0.3	0.25	1.25	2.00	2.5	0.54 [-0.16, 1.25]
			Placebo	20	17 (85.0)	0.79 (0.91)	-1.8	0.50	1.00	1.25	2.5	
		Week 16	Tezepelumab	19	15 (78.9)	1.33 (1.00)	0.0	0.25	1.50	2.25	2.8	0.92 [0.19, 1.66]
			Placebo	20	17 (85.0)	0.38 (1.05)	-1.8	0.00	0.25	1.00	2.5	
		Week 20	Tezepelumab	19	15 (78.9)	1.45 (1.06)	0.3	0.25	1.25	2.25	3.5	0.95 [0.22, 1.69]
			Placebo	20	17 (85.0)	0.38 (1.18)	-2.3	0.00	0.25	1.00	2.5	
		Week 24	Tezepelumab	19	15 (78.9)	1.43 (1.10)	-0.5	0.25	1.75	2.25	3.3	1.04 [0.30, 1.79]
			Placebo	20	17 (85.0)	0.19 (1.26)	-2.8	0.00	0.25	1.00	2.5	
		Week 28	Tezepelumab	19	15 (78.9)	1.43 (1.11)	0.0	0.25	1.75	2.25	3.0	0.83 [0.10, 1.55]
			Placebo	20	17 (85.0)	0.46 (1.24)	-1.8	0.00	0.50	1.00	2.5	
		Week 32	Tezepelumab	19	15 (78.9)	1.48 (1.22)	-0.5	0.25	1.50	2.50	3.5	0.89 [0.16, 1.62]
			Placebo	20	17 (85.0)	0.51 (0.97)	-1.8	0.00	0.25	1.00	2.5	
		Week 36	Tezepelumab	19	15 (78.9)	1.47 (1.16)	-0.3	0.25	1.75	2.25	3.3	0.90 [0.17, 1.63]
			Placebo	20	17 (85.0)	0.41 (1.18)	-2.8	0.00	0.25	0.75	2.5	
		Week 40	Tezepelumab	19	15 (78.9)	1.38 (1.02)	0.0	0.25	1.25	2.25	3.3	0.75 [0.03, 1.47]
			Placebo	20	17 (85.0)	0.54 (1.21)	-2.5	0.00	0.25	1.25	2.5	
		Week 44	Tezepelumab	19	15 (78.9)	1.37 (1.03)	-0.3	0.25	1.00	2.25	3.0	0.75 [0.03, 1.47]
			Placebo	20	17 (85.0)	0.57 (1.07)	-1.5	0.00	0.25	1.00	2.5	
		Week 48	Tezepelumab	19	15 (78.9)	1.55 (1.09)	0.0	0.50	1.50	2.25	3.5	1.01 [0.27, 1.75]
			Placebo	20	17 (85.0)	0.46 (1.08)	-2.8	0.00	0.75	1.00	2.5	
		Week 52	Tezepelumab	19	15 (78.9)	1.48 (1.06)	0.0	0.50	1.50	2.25	3.5	0.99 [0.25, 1.73]
			Placebo	20	17 (85.0)	0.59 (0.74)	-0.3	0.00	0.75	1.00	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	47	42 (89.4)	3.98 (1.10)	1.8	3.00	4.00	4.75	6.0	
			Placebo	45	38 (84.4)	4.52 (1.17)	1.5	3.75	4.38	5.50	6.5	
		Week 4	Tezepelumab	47	43 (91.5)	4.74 (1.16)	1.3	4.00	5.00	5.75	7.0	
			Placebo	45	40 (88.9)	5.00 (1.04)	2.3	4.63	5.25	5.50	7.0	
		Week 8	Tezepelumab	47	45 (95.7)	5.10 (1.18)	1.0	4.25	5.50	5.75	7.0	
			Placebo	45	41 (91.1)	5.15 (1.26)	1.5	4.75	5.25	6.00	7.0	
		Week 12	Tezepelumab	47	45 (95.7)	5.28 (1.17)	1.0	4.75	5.50	6.25	7.0	
			Placebo	45	41 (91.1)	4.97 (1.20)	2.0	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	47	45 (95.7)	5.12 (1.24)	1.0	4.50	5.25	5.75	7.0	
			Placebo	45	41 (91.1)	5.08 (1.24)	1.5	4.50	5.25	6.00	7.0	
		Week 20	Tezepelumab	47	46 (97.9)	5.04 (1.26)	1.0	4.50	5.00	5.75	7.0	
			Placebo	45	41 (91.1)	5.04 (1.23)	1.5	4.50	5.00	5.75	7.0	
		Week 24	Tezepelumab	47	46 (97.9)	5.20 (1.29)	1.0	4.50	5.13	6.00	7.0	
			Placebo	45	41 (91.1)	5.03 (1.32)	1.0	4.50	5.00	5.75	7.0	
		Week 28	Tezepelumab	47	47 (100.0)	5.18 (1.29)	1.0	4.50	5.25	6.00	7.0	
			Placebo	45	41 (91.1)	5.18 (1.36)	1.3	4.50	5.25	6.00	7.0	
		Week 32	Tezepelumab	47	47 (100.0)	5.27 (1.30)	1.0	4.50	5.50	6.00	7.0	
			Placebo	45	41 (91.1)	5.20 (1.35)	1.3	4.50	5.25	6.00	7.0	
		Week 36	Tezepelumab	47	47 (100.0)	5.28 (1.26)	1.0	4.50	5.50	6.25	7.0	
			Placebo	45	41 (91.1)	5.01 (1.39)	1.0	4.25	5.25	6.00	7.0	
		Week 40	Tezepelumab	47	47 (100.0)	5.35 (1.16)	2.0	4.50	5.50	6.25	7.0	
			Placebo	45	41 (91.1)	5.20 (1.38)	1.0	4.75	5.50	6.00	7.0	
		Week 44	Tezepelumab	47	47 (100.0)	5.37 (1.22)	1.3	4.75	5.25	6.25	7.0	
			Placebo	45	41 (91.1)	5.15 (1.35)	1.3	4.25	5.25	6.25	7.0	
		Week 48	Tezepelumab	47	47 (100.0)	5.32 (1.24)	1.0	4.50	5.75	6.25	7.0	
			Placebo	45	41 (91.1)	5.16 (1.28)	1.0	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	47	47 (100.0)	5.35 (1.24)	1.0	4.50	5.50	6.25	7.0	
			Placebo	45	41 (91.1)	5.21 (1.24)	2.0	4.25	5.25	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	47	40 (85.1)	0.82 (1.39)	-4.0	0.00	0.88	1.75	4.0	0.28 [-0.17, 0.73]
			Placebo	45	38 (84.4)	0.47 (1.05)	-1.8	-0.25	0.50	1.00	3.0	
		Week 8	Tezepelumab	47	42 (89.4)	1.10 (1.30)	-1.3	0.00	1.13	2.00	4.3	0.31 [-0.13, 0.75]
			Placebo	45	38 (84.4)	0.71 (1.23)	-1.5	0.00	0.50	1.50	3.3	
		Week 12	Tezepelumab	47	42 (89.4)	1.26 (1.28)	-2.3	0.50	1.25	2.25	4.8	0.66 [0.21, 1.11]
			Placebo	45	38 (84.4)	0.47 (1.10)	-1.3	-0.50	0.50	1.00	3.0	
		Week 16	Tezepelumab	47	42 (89.4)	1.11 (1.32)	-2.8	0.00	1.13	2.00	3.3	0.43 [-0.01, 0.87]
			Placebo	45	38 (84.4)	0.59 (1.05)	-1.3	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	47	42 (89.4)	1.04 (1.26)	-1.8	0.00	1.13	2.00	3.3	0.41 [-0.04, 0.85]
			Placebo	45	38 (84.4)	0.57 (1.03)	-1.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	47	42 (89.4)	1.20 (1.27)	-1.5	0.25	1.50	2.25	3.5	0.48 [0.03, 0.92]
			Placebo	45	38 (84.4)	0.61 (1.18)	-1.5	-0.25	0.50	1.25	3.8	
		Week 28	Tezepelumab	47	42 (89.4)	1.17 (1.29)	-1.5	0.25	1.38	2.25	3.3	0.32 [-0.12, 0.77]
			Placebo	45	38 (84.4)	0.75 (1.28)	-2.8	0.00	0.75	1.50	3.8	
		Week 32	Tezepelumab	47	42 (89.4)	1.25 (1.29)	-1.3	0.25	1.50	2.25	3.5	0.36 [-0.08, 0.81]
			Placebo	45	38 (84.4)	0.81 (1.11)	-1.5	0.25	0.75	1.50	3.8	
		Week 36	Tezepelumab	47	42 (89.4)	1.29 (1.29)	-1.3	0.25	1.50	2.25	3.5	0.55 [0.10, 1.00]
			Placebo	45	38 (84.4)	0.59 (1.22)	-2.3	0.00	0.38	1.25	3.8	
		Week 40	Tezepelumab	47	42 (89.4)	1.36 (1.21)	-1.3	0.25	1.50	2.25	3.3	0.48 [0.03, 0.93]
			Placebo	45	38 (84.4)	0.77 (1.23)	-1.5	0.00	0.75	1.25	3.8	
		Week 44	Tezepelumab	47	42 (89.4)	1.39 (1.32)	-1.5	0.50	1.50	2.25	3.8	0.50 [0.05, 0.94]
			Placebo	45	38 (84.4)	0.74 (1.29)	-1.3	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	47	42 (89.4)	1.35 (1.32)	-1.3	0.50	1.50	2.25	3.8	0.44 [0.00, 0.89]
			Placebo	45	38 (84.4)	0.75 (1.39)	-1.5	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	47	42 (89.4)	1.38 (1.29)	-1.3	0.50	1.50	2.25	3.8	0.45 [0.00, 0.89]
			Placebo	45	38 (84.4)	0.78 (1.40)	-1.3	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.03 (1.11)	1.8	3.25	4.00	4.75	6.8	
			Placebo	55	48 (87.3)	4.51 (1.15)	2.0	3.63	4.38	5.50	7.0	
		Week 4	Tezepelumab	57	52 (91.2)	4.77 (1.17)	1.3	4.00	5.00	5.75	7.0	
			Placebo	55	49 (89.1)	4.99 (1.12)	2.0	4.50	5.25	5.50	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.18 (1.20)	1.0	4.50	5.38	6.00	7.0	
			Placebo	55	51 (92.7)	5.06 (1.14)	2.3	4.50	5.25	5.75	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.31 (1.19)	1.0	4.50	5.50	6.25	7.0	
			Placebo	55	51 (92.7)	5.11 (1.07)	2.0	4.50	5.25	5.75	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.19 (1.22)	1.0	4.50	5.25	6.00	7.0	
			Placebo	55	51 (92.7)	5.03 (1.31)	1.3	4.25	5.25	6.00	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.19 (1.28)	1.0	4.50	5.00	6.00	7.0	
			Placebo	55	51 (92.7)	4.99 (1.34)	1.3	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.25 (1.32)	1.0	4.50	5.00	6.25	7.0	
			Placebo	55	51 (92.7)	4.93 (1.42)	1.3	4.25	5.00	5.75	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.21 (1.30)	1.0	4.50	5.13	6.25	7.0	
			Placebo	55	51 (92.7)	5.16 (1.45)	1.3	4.50	5.25	6.25	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.32 (1.34)	1.0	4.38	5.50	6.38	7.0	
			Placebo	55	51 (92.7)	5.20 (1.34)	1.3	4.50	5.25	6.00	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.32 (1.29)	1.0	4.50	5.13	6.50	7.0	
			Placebo	55	51 (92.7)	5.03 (1.38)	1.5	4.25	5.25	6.00	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.35 (1.19)	2.0	4.50	5.25	6.50	7.0	
			Placebo	55	51 (92.7)	5.24 (1.33)	1.5	4.50	5.50	6.25	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.35 (1.24)	1.3	4.50	5.25	6.25	7.0	
			Placebo	55	51 (92.7)	5.18 (1.28)	2.3	4.00	5.25	6.25	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.33 (1.25)	1.0	4.50	5.38	6.25	7.0	
			Placebo	55	51 (92.7)	5.10 (1.37)	1.0	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.37 (1.26)	1.0	4.50	5.50	6.50	7.0	
			Placebo	55	51 (92.7)	5.21 (1.25)	2.0	4.25	5.25	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	57	47 (82.5)	0.75 (1.29)	-4.0	0.00	0.75	1.75	4.0	0.26 [-0.15, 0.66]
			Placebo	55	47 (85.5)	0.45 (1.08)	-2.0	-0.25	0.50	1.00	3.0	
		Week 8	Tezepelumab	57	49 (86.0)	1.12 (1.27)	-1.3	0.00	1.00	2.00	4.3	0.42 [0.01, 0.82]
			Placebo	55	48 (87.3)	0.61 (1.15)	-1.8	-0.13	0.50	1.25	3.3	
		Week 12	Tezepelumab	57	49 (86.0)	1.27 (1.24)	-2.3	0.25	1.25	2.25	4.8	0.54 [0.14, 0.95]
			Placebo	55	48 (87.3)	0.63 (1.09)	-1.8	-0.13	0.75	1.25	3.0	
		Week 16	Tezepelumab	57	49 (86.0)	1.15 (1.28)	-2.8	0.25	1.25	2.25	3.0	0.50 [0.10, 0.91]
			Placebo	55	48 (87.3)	0.55 (1.10)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	57	49 (86.0)	1.17 (1.28)	-1.8	0.25	1.25	2.25	3.5	0.54 [0.13, 0.94]
			Placebo	55	48 (87.3)	0.53 (1.13)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	57	49 (86.0)	1.24 (1.28)	-1.5	0.25	1.50	2.25	3.5	0.59 [0.18, 0.99]
			Placebo	55	48 (87.3)	0.49 (1.27)	-2.8	-0.25	0.50	1.25	3.8	
		Week 28	Tezepelumab	57	49 (86.0)	1.20 (1.29)	-1.5	0.25	1.50	2.25	3.3	0.37 [-0.03, 0.77]
			Placebo	55	48 (87.3)	0.72 (1.33)	-2.8	0.00	0.75	1.50	3.8	
		Week 32	Tezepelumab	57	49 (86.0)	1.33 (1.35)	-1.3	0.25	1.50	2.25	3.5	0.43 [0.03, 0.83]
			Placebo	55	48 (87.3)	0.80 (1.09)	-1.8	0.00	0.75	1.38	3.8	
		Week 36	Tezepelumab	57	49 (86.0)	1.33 (1.33)	-1.3	0.25	1.50	2.25	3.5	0.56 [0.15, 0.96]
			Placebo	55	48 (87.3)	0.60 (1.26)	-2.8	0.00	0.38	1.25	3.8	
		Week 40	Tezepelumab	57	49 (86.0)	1.35 (1.22)	-1.3	0.25	1.50	2.25	3.3	0.44 [0.03, 0.84]
			Placebo	55	48 (87.3)	0.81 (1.26)	-2.5	0.00	0.75	1.63	3.8	
		Week 44	Tezepelumab	57	49 (86.0)	1.38 (1.30)	-1.5	0.50	1.50	2.25	3.8	0.47 [0.07, 0.87]
			Placebo	55	48 (87.3)	0.77 (1.28)	-1.5	0.00	0.50	1.38	3.8	
		Week 48	Tezepelumab	57	49 (86.0)	1.35 (1.30)	-1.3	0.25	1.50	2.25	3.8	0.51 [0.10, 0.91]
			Placebo	55	48 (87.3)	0.67 (1.35)	-2.8	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	57	49 (86.0)	1.38 (1.29)	-1.3	0.25	1.50	2.25	3.8	0.48 [0.07, 0.88]
			Placebo	55	48 (87.3)	0.78 (1.25)	-1.3	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.72 (0.57)	2.5	3.50	4.00	4.00	4.3	
			Placebo	10	7 (70.0)	3.54 (1.40)	1.5	2.00	3.75	5.00	5.3	
		Week 4	Tezepelumab	9	8 (88.9)	5.00 (0.76)	4.0	4.50	4.75	5.63	6.3	
			Placebo	10	8 (80.0)	3.94 (1.37)	2.3	2.75	3.75	5.25	5.8	
		Week 8	Tezepelumab	9	8 (88.9)	5.00 (0.87)	4.0	4.13	5.13	5.63	6.3	
			Placebo	10	8 (80.0)	3.97 (1.83)	1.5	2.75	3.50	5.63	6.5	
		Week 12	Tezepelumab	9	8 (88.9)	4.97 (0.67)	4.0	4.38	5.13	5.50	5.8	
			Placebo	10	8 (80.0)	3.72 (1.02)	2.3	3.00	3.88	4.13	5.5	
		Week 16	Tezepelumab	9	8 (88.9)	4.97 (0.96)	3.8	4.25	4.75	5.75	6.5	
			Placebo	10	8 (80.0)	3.91 (1.53)	1.5	3.00	4.13	4.63	6.3	
		Week 20	Tezepelumab	9	9 (100.0)	4.83 (0.95)	3.8	4.00	4.75	5.50	6.5	
			Placebo	10	8 (80.0)	3.91 (1.56)	1.5	2.88	4.00	4.75	6.5	
		Week 24	Tezepelumab	9	9 (100.0)	5.14 (0.88)	4.0	4.50	5.25	5.75	6.5	
			Placebo	10	8 (80.0)	3.97 (1.80)	1.0	2.88	4.13	5.00	6.8	
		Week 28	Tezepelumab	9	9 (100.0)	5.14 (0.93)	4.0	4.50	5.00	5.50	7.0	
			Placebo	10	9 (90.0)	4.11 (1.53)	1.8	3.75	4.25	4.50	6.3	
		Week 32	Tezepelumab	9	9 (100.0)	5.06 (0.73)	4.0	4.75	4.75	5.50	6.3	
			Placebo	10	9 (90.0)	4.17 (1.91)	1.3	3.00	4.00	5.00	7.0	
		Week 36	Tezepelumab	9	9 (100.0)	5.22 (0.79)	4.0	4.50	5.50	5.50	6.3	
			Placebo	10	9 (90.0)	3.97 (1.88)	1.0	3.25	4.00	5.00	6.8	
		Week 40	Tezepelumab	9	9 (100.0)	5.11 (0.73)	4.0	4.50	5.25	5.50	6.0	
			Placebo	10	9 (90.0)	3.92 (1.84)	1.0	3.00	4.00	4.75	6.8	
		Week 44	Tezepelumab	9	9 (100.0)	5.17 (0.82)	4.0	5.00	5.25	5.50	6.5	
			Placebo	10	9 (90.0)	4.19 (1.85)	1.3	3.50	4.00	5.25	6.8	
		Week 48	Tezepelumab	9	9 (100.0)	5.44 (0.93)	4.0	5.00	5.25	6.25	7.0	
			Placebo	10	9 (90.0)	4.44 (1.30)	2.0	4.00	4.00	4.75	6.5	
		Week 52	Tezepelumab	9	9 (100.0)	5.28 (0.73)	4.0	5.00	5.25	5.50	6.3	
			Placebo	10	9 (90.0)	4.31 (1.53)	1.8	4.00	4.00	4.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	1.28 (0.88)	0.0	0.75	1.00	2.13	2.5	0.98 [-0.11, 2.06]
			Placebo	10	7 (70.0)	0.46 (0.78)	-0.5	0.00	0.25	0.75	2.0	
		Week 8	Tezepelumab	9	8 (88.9)	1.28 (0.81)	0.3	0.50	1.38	2.00	2.3	0.68 [-0.36, 1.73]
			Placebo	10	7 (70.0)	0.50 (1.44)	-1.5	-0.50	0.25	1.25	3.0	
		Week 12	Tezepelumab	9	8 (88.9)	1.25 (0.67)	0.0	1.00	1.25	1.63	2.3	1.67 [0.47, 2.87]
			Placebo	10	7 (70.0)	0.18 (0.61)	-1.0	-0.25	0.50	0.50	0.8	
		Week 16	Tezepelumab	9	8 (88.9)	1.25 (1.02)	0.0	0.63	1.00	1.75	3.3	1.12 [0.02, 2.22]
			Placebo	10	7 (70.0)	0.36 (0.40)	0.0	0.00	0.25	0.75	1.0	
		Week 20	Tezepelumab	9	8 (88.9)	1.00 (0.77)	0.0	0.50	0.88	1.38	2.5	0.89 [-0.18, 1.96]
			Placebo	10	7 (70.0)	0.43 (0.45)	0.0	0.00	0.25	0.75	1.3	
		Week 24	Tezepelumab	9	8 (88.9)	1.34 (0.80)	0.3	0.63	1.38	2.00	2.5	1.24 [0.12, 2.37]
			Placebo	10	7 (70.0)	0.39 (0.72)	-0.5	0.00	0.25	1.25	1.5	
		Week 28	Tezepelumab	9	8 (88.9)	1.44 (0.96)	0.3	0.88	1.13	2.13	3.0	1.53 [0.36, 2.70]
			Placebo	10	7 (70.0)	0.25 (0.48)	-0.5	-0.25	0.25	0.75	0.8	
		Week 32	Tezepelumab	9	8 (88.9)	1.22 (0.53)	0.8	0.75	1.13	1.50	2.3	1.72 [0.51, 2.93]
			Placebo	10	7 (70.0)	0.18 (0.69)	-0.8	-0.25	0.25	0.25	1.5	
		Week 36	Tezepelumab	9	8 (88.9)	1.38 (0.67)	0.5	0.88	1.38	1.88	2.3	2.11 [0.81, 3.41]
			Placebo	10	7 (70.0)	0.07 (0.55)	-0.5	-0.50	0.00	0.50	1.0	
		Week 40	Tezepelumab	9	8 (88.9)	1.47 (0.73)	0.3	1.13	1.50	1.75	2.8	2.32 [0.97, 3.67]
			Placebo	10	7 (70.0)	-0.04 (0.55)	-0.8	-0.50	-0.25	0.50	0.8	
		Week 44	Tezepelumab	9	8 (88.9)	1.44 (0.87)	0.0	1.00	1.38	2.00	2.8	1.77 [0.55, 2.99]
			Placebo	10	7 (70.0)	0.14 (0.52)	-0.3	-0.25	0.00	0.25	1.3	
		Week 48	Tezepelumab	9	8 (88.9)	1.75 (0.92)	0.5	1.13	1.50	2.63	3.0	1.29 [0.16, 2.42]
			Placebo	10	7 (70.0)	0.57 (0.91)	-0.3	0.00	0.25	0.75	2.5	
		Week 52	Tezepelumab	9	8 (88.9)	1.56 (0.76)	0.5	1.13	1.50	1.88	3.0	1.30 [0.17, 2.43]
			Placebo	10	7 (70.0)	0.36 (1.09)	-0.8	-0.50	0.25	0.75	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	44	39 (88.6)	3.99 (1.09)	1.8	3.50	4.00	4.75	6.8	
			Placebo	45	38 (84.4)	4.29 (1.27)	1.5	3.50	4.00	5.50	7.0	
		Week 4	Tezepelumab	44	40 (90.9)	4.89 (0.99)	2.0	4.50	5.00	5.75	6.8	
			Placebo	45	39 (86.7)	4.81 (1.39)	2.0	4.00	5.00	5.75	7.0	
		Week 8	Tezepelumab	44	41 (93.2)	5.12 (1.27)	1.0	4.25	5.25	6.00	7.0	
			Placebo	45	40 (88.9)	4.86 (1.43)	1.5	3.75	5.00	5.88	7.0	
		Week 12	Tezepelumab	44	41 (93.2)	5.25 (1.14)	1.0	4.75	5.50	6.00	7.0	
			Placebo	45	40 (88.9)	4.85 (1.28)	2.0	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	44	41 (93.2)	5.12 (1.23)	1.0	4.50	5.25	6.00	7.0	
			Placebo	45	40 (88.9)	4.93 (1.44)	1.5	4.13	5.00	6.00	7.0	
		Week 20	Tezepelumab	44	42 (95.5)	5.15 (1.34)	1.0	4.50	5.00	6.25	7.0	
			Placebo	45	40 (88.9)	4.95 (1.45)	1.5	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	44	42 (95.5)	5.18 (1.36)	1.0	4.25	5.00	6.25	7.0	
			Placebo	45	40 (88.9)	4.88 (1.54)	1.0	3.88	5.00	5.88	7.0	
		Week 28	Tezepelumab	44	43 (97.7)	5.12 (1.35)	1.0	4.25	5.00	6.25	7.0	
			Placebo	45	41 (91.1)	5.11 (1.54)	1.3	4.50	5.25	6.25	7.0	
		Week 32	Tezepelumab	44	43 (97.7)	5.22 (1.39)	1.0	4.25	5.00	6.25	7.0	
			Placebo	45	41 (91.1)	5.06 (1.55)	1.3	4.00	5.25	6.25	7.0	
		Week 36	Tezepelumab	44	43 (97.7)	5.27 (1.35)	1.0	4.50	5.00	6.25	7.0	
			Placebo	45	41 (91.1)	5.01 (1.60)	1.0	4.00	5.25	6.25	7.0	
		Week 40	Tezepelumab	44	43 (97.7)	5.27 (1.20)	2.0	4.50	5.25	6.00	7.0	
			Placebo	45	41 (91.1)	5.05 (1.62)	1.0	4.00	5.25	6.50	7.0	
		Week 44	Tezepelumab	44	43 (97.7)	5.26 (1.28)	1.3	4.50	5.25	6.25	7.0	
			Placebo	45	41 (91.1)	5.04 (1.56)	1.3	4.00	5.50	6.50	7.0	
		Week 48	Tezepelumab	44	43 (97.7)	5.34 (1.29)	1.0	4.50	5.25	6.25	7.0	
			Placebo	45	41 (91.1)	5.09 (1.45)	1.0	4.00	5.00	6.25	7.0	
		Week 52	Tezepelumab	44	43 (97.7)	5.35 (1.28)	1.0	4.50	5.25	6.50	7.0	
			Placebo	45	41 (91.1)	5.11 (1.43)	1.8	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	44	37 (84.1)	0.91 (1.09)	-1.3	0.25	1.00	1.75	4.0	0.35 [-0.11, 0.81]
			Placebo	45	38 (84.4)	0.53 (1.08)	-2.0	-0.25	0.50	1.25	3.0	
		Week 8	Tezepelumab	44	38 (86.4)	1.10 (1.25)	-1.0	0.00	1.13	2.00	4.3	0.38 [-0.07, 0.84]
			Placebo	45	38 (84.4)	0.64 (1.15)	-1.8	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	44	38 (86.4)	1.27 (1.16)	-1.0	0.25	1.25	2.00	4.8	0.60 [0.14, 1.06]
			Placebo	45	38 (84.4)	0.60 (1.08)	-1.8	-0.25	0.63	1.25	3.0	
		Week 16	Tezepelumab	44	38 (86.4)	1.16 (1.11)	-0.8	0.25	0.88	2.00	3.0	0.48 [0.02, 0.93]
			Placebo	45	38 (84.4)	0.67 (0.92)	-1.0	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	44	38 (86.4)	1.20 (1.21)	-1.8	0.25	1.25	2.25	3.3	0.47 [0.01, 0.93]
			Placebo	45	38 (84.4)	0.70 (0.89)	-0.8	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	44	38 (86.4)	1.25 (1.20)	-1.5	0.25	1.50	2.25	3.3	0.57 [0.11, 1.03]
			Placebo	45	38 (84.4)	0.63 (0.99)	-1.0	0.00	0.38	1.25	3.0	
		Week 28	Tezepelumab	44	38 (86.4)	1.21 (1.23)	-1.3	0.25	1.38	2.25	3.3	0.34 [-0.11, 0.80]
			Placebo	45	38 (84.4)	0.82 (1.06)	-1.5	0.25	0.75	1.25	3.0	
		Week 32	Tezepelumab	44	38 (86.4)	1.30 (1.29)	-1.3	0.25	1.50	2.25	3.5	0.46 [0.00, 0.91]
			Placebo	45	38 (84.4)	0.79 (0.92)	-0.8	0.00	0.50	1.50	3.0	
		Week 36	Tezepelumab	44	38 (86.4)	1.34 (1.28)	-1.0	0.50	1.50	2.25	3.5	0.54 [0.08, 0.99]
			Placebo	45	38 (84.4)	0.72 (1.01)	-1.0	0.00	0.25	1.25	3.0	
		Week 40	Tezepelumab	44	38 (86.4)	1.39 (1.12)	-0.5	0.25	1.50	2.25	3.3	0.58 [0.13, 1.04]
			Placebo	45	38 (84.4)	0.75 (1.07)	-1.0	0.00	0.63	1.25	3.3	
		Week 44	Tezepelumab	44	38 (86.4)	1.36 (1.22)	-1.5	0.50	1.50	2.25	3.8	0.52 [0.07, 0.98]
			Placebo	45	38 (84.4)	0.76 (1.09)	-1.5	0.00	0.38	1.25	3.3	
		Week 48	Tezepelumab	44	38 (86.4)	1.43 (1.23)	-1.0	0.50	1.50	2.25	3.8	0.54 [0.08, 1.00]
			Placebo	45	38 (84.4)	0.81 (1.07)	-1.5	0.25	0.50	1.25	3.8	
		Week 52	Tezepelumab	44	38 (86.4)	1.45 (1.19)	-0.8	0.50	1.50	2.25	3.8	0.57 [0.11, 1.03]
			Placebo	45	38 (84.4)	0.80 (1.06)	-0.8	0.25	0.50	1.00	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	22	19 (86.4)	3.99 (1.02)	2.5	3.00	3.75	4.75	6.0	
			Placebo	20	17 (85.0)	4.59 (1.09)	3.0	3.75	4.75	5.25	6.5	
		Week 4	Tezepelumab	22	20 (90.9)	4.61 (1.36)	1.3	3.63	4.63	5.75	7.0	
			Placebo	20	18 (90.0)	4.92 (0.70)	3.5	4.50	5.13	5.50	6.0	
		Week 8	Tezepelumab	22	21 (95.5)	5.21 (0.90)	3.5	4.50	5.50	5.75	6.8	
			Placebo	20	19 (95.0)	5.01 (0.96)	2.8	4.75	5.25	5.75	6.5	
		Week 12	Tezepelumab	22	21 (95.5)	5.31 (1.16)	3.0	4.50	5.50	6.25	7.0	
			Placebo	20	19 (95.0)	5.07 (0.84)	3.3	4.25	5.25	5.75	6.3	
		Week 16	Tezepelumab	22	21 (95.5)	5.24 (1.12)	2.5	4.50	5.25	6.00	7.0	
			Placebo	20	19 (95.0)	4.79 (1.30)	1.3	4.00	5.00	5.75	6.5	
		Week 20	Tezepelumab	22	21 (95.5)	5.10 (1.01)	3.5	4.50	5.00	5.75	7.0	
			Placebo	20	19 (95.0)	4.62 (1.33)	1.3	3.75	5.00	5.25	6.5	
		Week 24	Tezepelumab	22	21 (95.5)	5.32 (1.05)	3.8	4.50	5.25	6.00	7.0	
			Placebo	20	19 (95.0)	4.63 (1.44)	1.3	4.25	4.75	5.25	7.0	
		Week 28	Tezepelumab	22	22 (100.0)	5.36 (1.02)	3.8	4.50	5.50	6.00	7.0	
			Placebo	20	19 (95.0)	4.76 (1.41)	1.3	4.00	4.75	6.00	7.0	
		Week 32	Tezepelumab	22	22 (100.0)	5.40 (1.03)	4.0	4.50	5.50	6.00	7.0	
			Placebo	20	19 (95.0)	5.00 (1.31)	1.3	4.50	5.25	6.00	7.0	
		Week 36	Tezepelumab	22	22 (100.0)	5.36 (0.97)	4.0	4.50	5.38	6.50	6.8	
			Placebo	20	19 (95.0)	4.57 (1.22)	2.0	3.75	4.75	5.25	7.0	
		Week 40	Tezepelumab	22	22 (100.0)	5.40 (1.03)	4.0	4.50	5.25	6.50	7.0	
			Placebo	20	19 (95.0)	5.00 (1.14)	2.3	4.50	5.25	5.50	7.0	
		Week 44	Tezepelumab	22	22 (100.0)	5.45 (1.01)	4.0	4.50	5.25	6.50	7.0	
			Placebo	20	19 (95.0)	5.03 (1.04)	3.0	4.25	5.00	5.75	7.0	
		Week 48	Tezepelumab	22	22 (100.0)	5.36 (1.05)	3.8	4.50	5.75	6.25	7.0	
			Placebo	20	19 (95.0)	4.80 (1.21)	2.0	4.25	5.00	5.25	7.0	
		Week 52	Tezepelumab	22	22 (100.0)	5.35 (1.03)	3.8	4.50	5.75	6.00	7.0	
			Placebo	20	19 (95.0)	4.99 (1.06)	3.0	4.25	5.00	5.75	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	22	18 (81.8)	0.65 (1.53)	-4.0	0.00	0.63	1.75	2.8	0.31 [-0.36, 0.99]
			Placebo	20	16 (80.0)	0.25 (0.94)	-1.3	-0.38	0.25	0.75	2.5	
		Week 8	Tezepelumab	22	19 (86.4)	1.22 (1.16)	-1.3	0.25	1.25	2.25	3.3	0.59 [-0.08, 1.26]
			Placebo	20	17 (85.0)	0.51 (1.26)	-1.3	-0.25	0.25	1.25	3.3	
		Week 12	Tezepelumab	22	19 (86.4)	1.25 (1.22)	-2.3	0.50	1.50	2.25	3.0	0.66 [-0.02, 1.33]
			Placebo	20	17 (85.0)	0.51 (0.99)	-1.3	0.00	0.75	1.00	2.5	
		Week 16	Tezepelumab	22	19 (86.4)	1.18 (1.49)	-2.8	0.00	1.50	2.50	3.3	0.71 [0.03, 1.39]
			Placebo	20	17 (85.0)	0.21 (1.24)	-1.8	-1.00	0.50	0.75	3.0	
		Week 20	Tezepelumab	22	19 (86.4)	1.04 (1.25)	-1.3	0.00	1.00	1.75	3.5	0.74 [0.06, 1.42]
			Placebo	20	17 (85.0)	0.09 (1.32)	-2.3	-1.25	0.25	1.00	2.0	
		Week 24	Tezepelumab	22	19 (86.4)	1.28 (1.30)	-1.3	0.25	1.50	2.25	3.5	0.77 [0.09, 1.45]
			Placebo	20	17 (85.0)	0.16 (1.59)	-2.8	-1.00	0.50	1.00	3.8	
		Week 28	Tezepelumab	22	19 (86.4)	1.29 (1.29)	-1.5	0.00	1.50	2.50	3.0	0.68 [0.00, 1.35]
			Placebo	20	17 (85.0)	0.31 (1.62)	-2.8	-0.75	0.50	1.25	3.8	
		Week 32	Tezepelumab	22	19 (86.4)	1.33 (1.26)	-1.3	0.25	1.50	2.25	3.5	0.59 [-0.08, 1.26]
			Placebo	20	17 (85.0)	0.56 (1.35)	-1.8	-0.25	0.75	1.00	3.8	
		Week 36	Tezepelumab	22	19 (86.4)	1.32 (1.22)	-1.3	0.25	1.50	2.25	3.3	0.88 [0.19, 1.57]
			Placebo	20	17 (85.0)	0.12 (1.50)	-2.8	-0.75	0.25	0.75	3.8	
		Week 40	Tezepelumab	22	19 (86.4)	1.32 (1.27)	-1.3	0.25	1.50	2.25	3.3	0.52 [-0.15, 1.19]
			Placebo	20	17 (85.0)	0.59 (1.54)	-2.5	-0.25	0.75	1.25	3.8	
		Week 44	Tezepelumab	22	19 (86.4)	1.43 (1.31)	-1.3	0.25	1.50	2.25	3.8	0.63 [-0.04, 1.30]
			Placebo	20	17 (85.0)	0.54 (1.51)	-1.3	-0.75	0.50	1.25	3.8	
		Week 48	Tezepelumab	22	19 (86.4)	1.36 (1.34)	-1.3	0.25	1.50	2.50	3.5	0.68 [0.01, 1.35]
			Placebo	20	17 (85.0)	0.32 (1.69)	-2.8	-1.00	0.25	1.00	3.8	
		Week 52	Tezepelumab	22	19 (86.4)	1.33 (1.32)	-1.3	0.25	1.50	2.25	3.5	0.54 [-0.12, 1.21]
			Placebo	20	17 (85.0)	0.54 (1.57)	-1.3	-0.75	0.25	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	4.02 (1.00)	1.8	3.50	4.00	4.63	6.8	
			Placebo	58	48 (82.8)	4.42 (1.25)	1.5	3.50	4.38	5.50	7.0	
		Week 4	Tezepelumab	60	54 (90.0)	4.72 (1.11)	1.3	4.00	5.00	5.50	6.8	
			Placebo	58	50 (86.2)	4.82 (1.27)	2.0	4.00	5.13	5.50	7.0	
		Week 8	Tezepelumab	60	56 (93.3)	5.09 (1.17)	1.0	4.25	5.13	5.88	7.0	
			Placebo	58	52 (89.7)	4.86 (1.33)	1.5	3.88	5.00	5.75	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.19 (1.14)	1.0	4.50	5.38	5.88	7.0	
			Placebo	58	52 (89.7)	4.91 (1.22)	2.0	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.15 (1.22)	1.0	4.50	5.25	6.00	7.0	
			Placebo	58	52 (89.7)	4.87 (1.43)	1.3	4.00	5.00	5.88	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.12 (1.26)	1.0	4.50	5.00	6.00	7.0	
			Placebo	58	52 (89.7)	4.87 (1.48)	1.3	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.19 (1.28)	1.0	4.50	5.00	6.25	7.0	
			Placebo	58	52 (89.7)	4.75 (1.56)	1.0	3.88	5.00	5.75	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.14 (1.25)	1.0	4.50	5.00	6.25	7.0	
			Placebo	58	53 (91.4)	4.92 (1.54)	1.3	4.00	5.25	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.25 (1.30)	1.0	4.50	5.00	6.25	7.0	
			Placebo	58	53 (91.4)	4.98 (1.53)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.25 (1.25)	1.0	4.50	5.00	6.25	7.0	
			Placebo	58	53 (91.4)	4.82 (1.56)	1.0	3.75	5.00	6.00	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.25 (1.15)	2.0	4.50	5.00	6.00	7.0	
			Placebo	58	53 (91.4)	4.99 (1.54)	1.0	4.00	5.25	6.25	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.24 (1.19)	1.3	4.50	5.25	6.25	7.0	
			Placebo	58	53 (91.4)	4.97 (1.44)	1.3	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.27 (1.22)	1.0	4.50	5.25	6.25	7.0	
			Placebo	58	53 (91.4)	4.94 (1.41)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.28 (1.21)	1.0	4.50	5.25	6.25	7.0	
			Placebo	58	53 (91.4)	5.02 (1.34)	1.8	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	60	49 (81.7)	0.70 (1.19)	-4.0	0.00	0.75	1.50	3.0	0.29 [-0.11, 0.69]
			Placebo	58	47 (81.0)	0.38 (1.03)	-2.0	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	60	51 (85.0)	1.03 (1.16)	-1.3	0.25	1.00	2.00	3.3	0.46 [0.06, 0.86]
			Placebo	58	48 (82.8)	0.52 (1.11)	-1.8	-0.25	0.38	1.25	3.0	
		Week 12	Tezepelumab	60	51 (85.0)	1.14 (1.09)	-2.3	0.25	1.25	2.00	3.0	0.57 [0.17, 0.98]
			Placebo	58	48 (82.8)	0.53 (1.05)	-1.8	-0.25	0.50	1.13	3.0	
		Week 16	Tezepelumab	60	51 (85.0)	1.12 (1.21)	-2.8	0.25	1.00	2.00	3.3	0.58 [0.17, 0.98]
			Placebo	58	48 (82.8)	0.47 (1.00)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	60	51 (85.0)	1.10 (1.19)	-1.8	0.25	1.00	2.00	3.5	0.52 [0.12, 0.92]
			Placebo	58	48 (82.8)	0.51 (1.07)	-2.3	0.00	0.38	1.25	3.0	
		Week 24	Tezepelumab	60	51 (85.0)	1.18 (1.23)	-1.5	0.25	1.50	2.25	3.5	0.66 [0.25, 1.06]
			Placebo	58	48 (82.8)	0.40 (1.14)	-2.8	-0.25	0.25	1.13	3.0	
		Week 28	Tezepelumab	60	51 (85.0)	1.13 (1.21)	-1.5	0.25	1.25	2.25	3.3	0.49 [0.09, 0.89]
			Placebo	58	48 (82.8)	0.54 (1.22)	-2.8	0.00	0.50	1.25	3.0	
		Week 32	Tezepelumab	60	51 (85.0)	1.25 (1.28)	-1.3	0.25	1.50	2.25	3.5	0.54 [0.14, 0.95]
			Placebo	58	48 (82.8)	0.62 (1.00)	-1.8	0.00	0.50	1.13	3.0	
		Week 36	Tezepelumab	60	51 (85.0)	1.24 (1.24)	-1.3	0.25	1.25	2.25	3.5	0.67 [0.26, 1.07]
			Placebo	58	48 (82.8)	0.45 (1.12)	-2.8	0.00	0.25	1.00	3.0	
		Week 40	Tezepelumab	60	51 (85.0)	1.25 (1.12)	-1.3	0.25	1.25	2.00	3.3	0.56 [0.16, 0.96]
			Placebo	58	48 (82.8)	0.61 (1.16)	-2.5	0.00	0.50	1.25	3.3	
		Week 44	Tezepelumab	60	51 (85.0)	1.26 (1.19)	-1.5	0.50	1.25	2.25	3.8	0.60 [0.19, 1.00]
			Placebo	58	48 (82.8)	0.59 (1.08)	-1.5	0.00	0.38	1.13	3.3	
		Week 48	Tezepelumab	60	51 (85.0)	1.28 (1.21)	-1.3	0.50	1.50	2.25	3.5	0.60 [0.20, 1.01]
			Placebo	58	48 (82.8)	0.56 (1.18)	-2.8	0.00	0.50	1.00	3.8	
		Week 52	Tezepelumab	60	51 (85.0)	1.29 (1.18)	-1.3	0.50	1.50	2.25	3.5	0.58 [0.18, 0.98]
			Placebo	58	48 (82.8)	0.63 (1.09)	-1.3	0.00	0.50	1.00	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	3.38 (2.30)	1.8	1.75	3.38	5.00	5.0	
			Placebo	2	2 (100.0)	3.63 (0.88)	3.0	3.00	3.63	4.25	4.3	
		Week 4	Tezepelumab	2	2 (100.0)	6.38 (0.88)	5.8	5.75	6.38	7.00	7.0	
			Placebo	2	2 (100.0)	4.88 (0.88)	4.3	4.25	4.88	5.50	5.5	
		Week 8	Tezepelumab	2	2 (100.0)	6.38 (0.53)	6.0	6.00	6.38	6.75	6.8	
			Placebo	2	2 (100.0)	5.63 (0.18)	5.5	5.50	5.63	5.75	5.8	
		Week 12	Tezepelumab	2	2 (100.0)	6.63 (0.18)	6.5	6.50	6.63	6.75	6.8	
			Placebo	2	2 (100.0)	4.63 (0.88)	4.0	4.00	4.63	5.25	5.3	
		Week 16	Tezepelumab	2	2 (100.0)	4.75 (0.00)	4.8	4.75	4.75	4.75	4.8	
			Placebo	2	2 (100.0)	4.25 (1.41)	3.3	3.25	4.25	5.25	5.3	
		Week 20	Tezepelumab	2	2 (100.0)	4.88 (0.18)	4.8	4.75	4.88	5.00	5.0	
			Placebo	2	2 (100.0)	4.25 (1.41)	3.3	3.25	4.25	5.25	5.3	
		Week 24	Tezepelumab	2	2 (100.0)	5.75 (1.06)	5.0	5.00	5.75	6.50	6.5	
			Placebo	2	2 (100.0)	5.00 (0.35)	4.8	4.75	5.00	5.25	5.3	
		Week 28	Tezepelumab	2	2 (100.0)	6.00 (1.41)	5.0	5.00	6.00	7.00	7.0	
			Placebo	2	2 (100.0)	5.00 (0.35)	4.8	4.75	5.00	5.25	5.3	
		Week 32	Tezepelumab	2	2 (100.0)	5.50 (0.71)	5.0	5.00	5.50	6.00	6.0	
			Placebo	2	2 (100.0)	5.00 (0.35)	4.8	4.75	5.00	5.25	5.3	
		Week 36	Tezepelumab	2	2 (100.0)	5.75 (1.06)	5.0	5.00	5.75	6.50	6.5	
			Placebo	2	2 (100.0)	5.00 (0.35)	4.8	4.75	5.00	5.25	5.3	
		Week 40	Tezepelumab	2	2 (100.0)	6.00 (1.41)	5.0	5.00	6.00	7.00	7.0	
			Placebo	2	2 (100.0)	5.00 (0.35)	4.8	4.75	5.00	5.25	5.3	
		Week 44	Tezepelumab	2	2 (100.0)	6.00 (1.41)	5.0	5.00	6.00	7.00	7.0	
			Placebo	2	2 (100.0)	6.25 (0.71)	5.8	5.75	6.25	6.75	6.8	
		Week 48	Tezepelumab	2	2 (100.0)	5.88 (1.24)	5.0	5.00	5.88	6.75	6.8	
			Placebo	2	2 (100.0)	6.25 (0.71)	5.8	5.75	6.25	6.75	6.8	
		Week 52	Tezepelumab	2	2 (100.0)	5.88 (1.24)	5.0	5.00	5.88	6.75	6.8	
			Placebo	2	2 (100.0)	6.38 (0.88)	5.8	5.75	6.38	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	2	2 (100.0)	3.00 (1.41)	2.0	2.00	3.00	4.00	4.0	1.09 [-1.14, 3.33]
			Placebo	2	2 (100.0)	1.25 (1.77)	0.0	0.00	1.25	2.50	2.5	
		Week 8	Tezepelumab	2	2 (100.0)	3.00 (1.77)	1.8	1.75	3.00	4.25	4.3	0.74 [-1.35, 2.83]
			Placebo	2	2 (100.0)	2.00 (0.71)	1.5	1.50	2.00	2.50	2.5	
		Week 12	Tezepelumab	2	2 (100.0)	3.25 (2.12)	1.8	1.75	3.25	4.75	4.8	1.50 [-0.95, 3.95]
			Placebo	2	2 (100.0)	1.00 (0.00)	1.0	1.00	1.00	1.00	1.0	
		Week 16	Tezepelumab	2	2 (100.0)	1.38 (2.30)	-0.3	-0.25	1.38	3.00	3.0	0.45 [-1.56, 2.46]
			Placebo	2	2 (100.0)	0.63 (0.53)	0.3	0.25	0.63	1.00	1.0	
		Week 20	Tezepelumab	2	2 (100.0)	1.50 (2.47)	-0.3	-0.25	1.50	3.25	3.3	0.49 [-1.53, 2.51]
			Placebo	2	2 (100.0)	0.63 (0.53)	0.3	0.25	0.63	1.00	1.0	
		Week 24	Tezepelumab	2	2 (100.0)	2.38 (1.24)	1.5	1.50	2.38	3.25	3.3	1.05 [-1.16, 3.26]
			Placebo	2	2 (100.0)	1.38 (0.53)	1.0	1.00	1.38	1.75	1.8	
		Week 28	Tezepelumab	2	2 (100.0)	2.63 (0.88)	2.0	2.00	2.63	3.25	3.3	1.71 [-0.87, 4.30]
			Placebo	2	2 (100.0)	1.38 (0.53)	1.0	1.00	1.38	1.75	1.8	
		Week 32	Tezepelumab	2	2 (100.0)	2.13 (1.59)	1.0	1.00	2.13	3.25	3.3	0.63 [-1.42, 2.69]
			Placebo	2	2 (100.0)	1.38 (0.53)	1.0	1.00	1.38	1.75	1.8	
		Week 36	Tezepelumab	2	2 (100.0)	2.38 (1.24)	1.5	1.50	2.38	3.25	3.3	1.05 [-1.16, 3.26]
			Placebo	2	2 (100.0)	1.38 (0.53)	1.0	1.00	1.38	1.75	1.8	
		Week 40	Tezepelumab	2	2 (100.0)	2.63 (0.88)	2.0	2.00	2.63	3.25	3.3	1.71 [-0.87, 4.30]
			Placebo	2	2 (100.0)	1.38 (0.53)	1.0	1.00	1.38	1.75	1.8	
		Week 44	Tezepelumab	2	2 (100.0)	2.63 (0.88)	2.0	2.00	2.63	3.25	3.3	0.00 [-1.96, 1.96]
			Placebo	2	2 (100.0)	2.63 (1.59)	1.5	1.50	2.63	3.75	3.8	
		Week 48	Tezepelumab	2	2 (100.0)	2.50 (1.06)	1.8	1.75	2.50	3.25	3.3	-0.09 [-2.05, 1.87]
			Placebo	2	2 (100.0)	2.63 (1.59)	1.5	1.50	2.63	3.75	3.8	
		Week 52	Tezepelumab	2	2 (100.0)	2.50 (1.06)	1.8	1.75	2.50	3.25	3.3	-0.17 [-2.14, 1.80]
			Placebo	2	2 (100.0)	2.75 (1.77)	1.5	1.50	2.75	4.00	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	4.33 (1.38)	3.0	3.00	4.25	5.75	5.8	
			Placebo	3	3 (100.0)	4.25 (0.87)	3.8	3.75	3.75	5.25	5.3	
		Week 4	Tezepelumab	3	3 (100.0)	5.33 (0.95)	4.3	4.25	5.75	6.00	6.0	
			Placebo	3	3 (100.0)	5.00 (0.43)	4.8	4.75	4.75	5.50	5.5	
		Week 8	Tezepelumab	3	3 (100.0)	5.75 (0.50)	5.3	5.25	5.75	6.25	6.3	
			Placebo	3	3 (100.0)	4.83 (0.95)	3.8	3.75	5.25	5.50	5.5	
		Week 12	Tezepelumab	3	3 (100.0)	6.08 (0.76)	5.3	5.25	6.25	6.75	6.8	
			Placebo	3	3 (100.0)	5.08 (0.29)	4.8	4.75	5.25	5.25	5.3	
		Week 16	Tezepelumab	3	3 (100.0)	6.00 (0.87)	5.5	5.50	5.50	7.00	7.0	
			Placebo	3	3 (100.0)	5.33 (0.38)	5.0	5.00	5.25	5.75	5.8	
		Week 20	Tezepelumab	3	3 (100.0)	6.08 (0.80)	5.5	5.50	5.75	7.00	7.0	
			Placebo	3	3 (100.0)	4.67 (0.58)	4.0	4.00	5.00	5.00	5.0	
		Week 24	Tezepelumab	3	3 (100.0)	6.08 (0.63)	5.5	5.50	6.00	6.75	6.8	
			Placebo	3	3 (100.0)	4.75 (0.50)	4.3	4.25	4.75	5.25	5.3	
		Week 28	Tezepelumab	3	3 (100.0)	6.25 (0.66)	5.8	5.75	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	5.83 (0.76)	5.0	5.00	6.00	6.50	6.5	
		Week 32	Tezepelumab	3	3 (100.0)	6.17 (0.76)	5.5	5.50	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	5.58 (0.63)	5.0	5.00	5.50	6.25	6.3	
		Week 36	Tezepelumab	3	3 (100.0)	6.25 (0.66)	5.8	5.75	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	5.00 (0.66)	4.3	4.25	5.25	5.50	5.5	
		Week 40	Tezepelumab	3	3 (100.0)	6.17 (0.72)	5.8	5.75	5.75	7.00	7.0	
			Placebo	3	3 (100.0)	5.33 (0.58)	5.0	5.00	5.00	6.00	6.0	
		Week 44	Tezepelumab	3	3 (100.0)	6.50 (0.66)	5.8	5.75	6.75	7.00	7.0	
			Placebo	3	3 (100.0)	4.75 (0.90)	4.0	4.00	4.50	5.75	5.8	
		Week 48	Tezepelumab	3	3 (100.0)	6.25 (0.66)	5.8	5.75	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.58 (0.38)	4.3	4.25	4.50	5.00	5.0	
		Week 52	Tezepelumab	3	3 (100.0)	6.25 (0.66)	5.8	5.75	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.58 (0.38)	4.3	4.25	4.50	5.00	5.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.00 (0.90)	0.0	0.00	1.25	1.75	1.8	0.24 [-1.37, 1.85]
			Placebo	3	3 (100.0)	0.75 (1.15)	-0.5	-0.50	1.00	1.75	1.8	
		Week 8	Tezepelumab	3	3 (100.0)	1.42 (1.23)	0.0	0.00	2.00	2.25	2.3	0.74 [-0.94, 2.42]
			Placebo	3	3 (100.0)	0.58 (1.01)	0.0	0.00	0.00	1.75	1.8	
		Week 12	Tezepelumab	3	3 (100.0)	1.75 (1.09)	0.5	0.50	2.25	2.50	2.5	0.97 [-0.76, 2.71]
			Placebo	3	3 (100.0)	0.83 (0.76)	0.0	0.00	1.00	1.50	1.5	
		Week 16	Tezepelumab	3	3 (100.0)	1.67 (1.66)	-0.3	-0.25	2.50	2.75	2.8	0.47 [-1.16, 2.11]
			Placebo	3	3 (100.0)	1.08 (0.52)	0.5	0.50	1.25	1.50	1.5	
		Week 20	Tezepelumab	3	3 (100.0)	1.75 (1.52)	0.0	0.00	2.50	2.75	2.8	0.90 [-0.82, 2.62]
			Placebo	3	3 (100.0)	0.42 (1.44)	-1.3	-1.25	1.25	1.25	1.3	
		Week 24	Tezepelumab	3	3 (100.0)	1.75 (1.30)	0.3	0.25	2.50	2.50	2.5	0.95 [-0.78, 2.68]
			Placebo	3	3 (100.0)	0.50 (1.32)	-1.0	-1.00	1.00	1.50	1.5	
		Week 28	Tezepelumab	3	3 (100.0)	1.92 (1.66)	0.0	0.00	2.75	3.00	3.0	0.27 [-1.34, 1.88]
			Placebo	3	3 (100.0)	1.58 (0.58)	1.3	1.25	1.25	2.25	2.3	
		Week 32	Tezepelumab	3	3 (100.0)	1.83 (1.38)	0.3	0.25	2.50	2.75	2.8	0.49 [-1.14, 2.13]
			Placebo	3	3 (100.0)	1.33 (0.38)	1.0	1.00	1.25	1.75	1.8	
		Week 36	Tezepelumab	3	3 (100.0)	1.92 (1.44)	0.3	0.25	2.75	2.75	2.8	0.79 [-0.90, 2.48]
			Placebo	3	3 (100.0)	0.75 (1.52)	-1.0	-1.00	1.50	1.75	1.8	
		Week 40	Tezepelumab	3	3 (100.0)	1.83 (1.59)	0.0	0.00	2.75	2.75	2.8	0.52 [-1.12, 2.16]
			Placebo	3	3 (100.0)	1.08 (1.26)	-0.3	-0.25	1.25	2.25	2.3	
		Week 44	Tezepelumab	3	3 (100.0)	2.17 (1.94)	0.0	0.00	2.75	3.75	3.8	0.99 [-0.75, 2.73]
			Placebo	3	3 (100.0)	0.50 (1.39)	-0.8	-0.75	0.25	2.00	2.0	
		Week 48	Tezepelumab	3	3 (100.0)	1.92 (1.44)	0.3	0.25	2.75	2.75	2.8	1.20 [-0.60, 3.00]
			Placebo	3	3 (100.0)	0.33 (1.18)	-1.0	-1.00	0.75	1.25	1.3	
		Week 52	Tezepelumab	3	3 (100.0)	1.92 (1.44)	0.3	0.25	2.75	2.75	2.8	1.20 [-0.60, 3.00]
			Placebo	3	3 (100.0)	0.33 (1.18)	-1.0	-1.00	0.75	1.25	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	
			Placebo	2	2 (100.0)	4.38 (1.59)	3.3	3.25	4.38	5.50	5.5	
		Week 4	Tezepelumab	1	1 (100.0)	4.50	4.5	4.50	4.50	4.50	4.5	
			Placebo	2	2 (100.0)	5.13 (0.88)	4.5	4.50	5.13	5.75	5.8	
		Week 8	Tezepelumab	1	1 (100.0)	4.50	4.5	4.50	4.50	4.50	4.5	
			Placebo	2	2 (100.0)	5.63 (1.24)	4.8	4.75	5.63	6.50	6.5	
		Week 12	Tezepelumab	1	1 (100.0)	4.50	4.5	4.50	4.50	4.50	4.5	
			Placebo	2	2 (100.0)	5.25 (0.71)	4.8	4.75	5.25	5.75	5.8	
		Week 16	Tezepelumab	1	1 (100.0)	4.25	4.3	4.25	4.25	4.25	4.3	
			Placebo	2	2 (100.0)	5.25 (1.41)	4.3	4.25	5.25	6.25	6.3	
		Week 20	Tezepelumab	1	1 (100.0)	3.75	3.8	3.75	3.75	3.75	3.8	
			Placebo	2	2 (100.0)	5.00 (0.35)	4.8	4.75	5.00	5.25	5.3	
		Week 24	Tezepelumab	1	1 (100.0)	4.00	4.0	4.00	4.00	4.00	4.0	
			Placebo	2	2 (100.0)	5.88 (1.59)	4.8	4.75	5.88	7.00	7.0	
		Week 28	Tezepelumab	1	1 (100.0)	4.25	4.3	4.25	4.25	4.25	4.3	
			Placebo	2	2 (100.0)	5.88 (1.59)	4.8	4.75	5.88	7.00	7.0	
		Week 32	Tezepelumab	1	1 (100.0)	4.00	4.0	4.00	4.00	4.00	4.0	
			Placebo	2	2 (100.0)	5.88 (1.59)	4.8	4.75	5.88	7.00	7.0	
		Week 36	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	2	2 (100.0)	5.88 (1.59)	4.8	4.75	5.88	7.00	7.0	
		Week 40	Tezepelumab	1	1 (100.0)	5.50	5.5	5.50	5.50	5.50	5.5	
			Placebo	2	2 (100.0)	5.88 (1.59)	4.8	4.75	5.88	7.00	7.0	
		Week 44	Tezepelumab	1	1 (100.0)	5.25	5.3	5.25	5.25	5.25	5.3	
			Placebo	2	2 (100.0)	5.88 (1.59)	4.8	4.75	5.88	7.00	7.0	
		Week 48	Tezepelumab	1	1 (100.0)	6.25	6.3	6.25	6.25	6.25	6.3	
			Placebo	2	2 (100.0)	5.88 (1.59)	4.8	4.75	5.88	7.00	7.0	
		Week 52	Tezepelumab	1	1 (100.0)	6.25	6.3	6.25	6.25	6.25	6.3	
			Placebo	2	2 (100.0)	5.88 (1.59)	4.8	4.75	5.88	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	NE
			Placebo	2	2 (100.0)	0.75 (0.71)	0.3	0.25	0.75	1.25	1.3	
		Week 8	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	NE
			Placebo	2	2 (100.0)	1.25 (2.83)	-0.8	-0.75	1.25	3.25	3.3	
		Week 12	Tezepelumab	1	1 (100.0)	2.00	2.0	2.00	2.00	2.00	2.0	NE
			Placebo	2	2 (100.0)	0.88 (2.30)	-0.8	-0.75	0.88	2.50	2.5	
		Week 16	Tezepelumab	1	1 (100.0)	1.75	1.8	1.75	1.75	1.75	1.8	NE
			Placebo	2	2 (100.0)	0.88 (3.01)	-1.3	-1.25	0.88	3.00	3.0	
		Week 20	Tezepelumab	1	1 (100.0)	1.25	1.3	1.25	1.25	1.25	1.3	NE
			Placebo	2	2 (100.0)	0.63 (1.94)	-0.8	-0.75	0.63	2.00	2.0	
		Week 24	Tezepelumab	1	1 (100.0)	1.50	1.5	1.50	1.50	1.50	1.5	NE
			Placebo	2	2 (100.0)	1.50 (3.18)	-0.8	-0.75	1.50	3.75	3.8	
		Week 28	Tezepelumab	1	1 (100.0)	1.75	1.8	1.75	1.75	1.75	1.8	NE
			Placebo	2	2 (100.0)	1.50 (3.18)	-0.8	-0.75	1.50	3.75	3.8	
		Week 32	Tezepelumab	1	1 (100.0)	1.50	1.5	1.50	1.50	1.50	1.5	NE
			Placebo	2	2 (100.0)	1.50 (3.18)	-0.8	-0.75	1.50	3.75	3.8	
		Week 36	Tezepelumab	1	1 (100.0)	2.50	2.5	2.50	2.50	2.50	2.5	NE
			Placebo	2	2 (100.0)	1.50 (3.18)	-0.8	-0.75	1.50	3.75	3.8	
		Week 40	Tezepelumab	1	1 (100.0)	3.00	3.0	3.00	3.00	3.00	3.0	NE
			Placebo	2	2 (100.0)	1.50 (3.18)	-0.8	-0.75	1.50	3.75	3.8	
		Week 44	Tezepelumab	1	1 (100.0)	2.75	2.8	2.75	2.75	2.75	2.8	NE
			Placebo	2	2 (100.0)	1.50 (3.18)	-0.8	-0.75	1.50	3.75	3.8	
		Week 48	Tezepelumab	1	1 (100.0)	3.75	3.8	3.75	3.75	3.75	3.8	NE
			Placebo	2	2 (100.0)	1.50 (3.18)	-0.8	-0.75	1.50	3.75	3.8	
		Week 52	Tezepelumab	1	1 (100.0)	3.75	3.8	3.75	3.75	3.75	3.8	NE
			Placebo	2	2 (100.0)	1.50 (3.18)	-0.8	-0.75	1.50	3.75	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	40	36 (90.0)	4.00 (1.07)	1.8	3.13	4.00	4.75	6.8	
			Placebo	36	31 (86.1)	4.54 (1.21)	2.0	3.25	4.75	5.75	6.3	
		Week 4	Tezepelumab	40	37 (92.5)	4.57 (1.21)	1.3	3.75	4.50	5.75	6.8	
			Placebo	36	31 (86.1)	4.80 (1.19)	2.3	4.00	5.00	5.50	6.8	
		Week 8	Tezepelumab	40	38 (95.0)	5.03 (1.31)	1.0	4.25	5.00	6.00	7.0	
			Placebo	36	32 (88.9)	4.88 (1.29)	2.3	3.88	5.00	5.88	7.0	
		Week 12	Tezepelumab	40	38 (95.0)	5.13 (1.22)	1.0	4.50	5.25	5.75	7.0	
			Placebo	36	32 (88.9)	5.05 (1.16)	2.0	4.25	5.00	5.88	7.0	
		Week 16	Tezepelumab	40	38 (95.0)	5.02 (1.33)	1.0	4.50	5.00	6.00	7.0	
			Placebo	36	32 (88.9)	4.84 (1.47)	1.3	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	40	39 (97.5)	5.07 (1.39)	1.0	4.25	5.00	6.00	7.0	
			Placebo	36	32 (88.9)	4.83 (1.51)	1.3	3.75	5.00	5.88	7.0	
		Week 24	Tezepelumab	40	39 (97.5)	5.15 (1.44)	1.0	4.25	5.00	6.25	7.0	
			Placebo	36	32 (88.9)	4.72 (1.57)	1.3	4.00	5.00	5.75	7.0	
		Week 28	Tezepelumab	40	40 (100.0)	5.04 (1.38)	1.0	4.25	5.00	6.00	7.0	
			Placebo	36	33 (91.7)	4.95 (1.63)	1.3	4.00	5.25	6.00	7.0	
		Week 32	Tezepelumab	40	40 (100.0)	5.16 (1.39)	1.0	4.25	5.00	6.13	7.0	
			Placebo	36	33 (91.7)	5.11 (1.49)	1.3	4.25	5.50	6.00	7.0	
		Week 36	Tezepelumab	40	40 (100.0)	5.18 (1.35)	1.0	4.38	5.00	6.25	7.0	
			Placebo	36	33 (91.7)	4.89 (1.52)	1.5	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	40	40 (100.0)	5.23 (1.24)	2.0	4.50	5.13	6.00	7.0	
			Placebo	36	33 (91.7)	5.09 (1.53)	1.5	4.00	5.50	6.25	7.0	
		Week 44	Tezepelumab	40	40 (100.0)	5.23 (1.31)	1.3	4.38	5.25	6.25	7.0	
			Placebo	36	33 (91.7)	5.08 (1.33)	2.0	4.00	5.25	6.00	7.0	
		Week 48	Tezepelumab	40	40 (100.0)	5.21 (1.35)	1.0	4.25	5.13	6.13	7.0	
			Placebo	36	33 (91.7)	5.02 (1.50)	1.0	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	40	40 (100.0)	5.22 (1.32)	1.0	4.38	5.13	6.25	7.0	
			Placebo	36	33 (91.7)	5.13 (1.35)	1.8	4.25	5.25	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	40	35 (87.5)	0.61 (1.29)	-4.0	0.00	0.75	1.25	3.0	0.31 [-0.18, 0.80]
			Placebo	36	30 (83.3)	0.25 (1.03)	-2.0	-0.25	0.25	0.75	2.3	
		Week 8	Tezepelumab	40	36 (90.0)	1.01 (1.27)	-1.3	0.13	0.88	2.13	3.3	0.53 [0.04, 1.02]
			Placebo	36	31 (86.1)	0.39 (1.04)	-1.5	-0.25	0.25	0.75	3.0	
		Week 12	Tezepelumab	40	36 (90.0)	1.11 (1.17)	-2.3	0.25	1.25	2.00	3.0	0.53 [0.04, 1.02]
			Placebo	36	31 (86.1)	0.55 (0.93)	-1.3	0.00	0.50	1.25	3.0	
		Week 16	Tezepelumab	40	36 (90.0)	1.03 (1.30)	-2.8	0.25	0.75	2.00	3.0	0.61 [0.11, 1.10]
			Placebo	36	31 (86.1)	0.32 (0.99)	-1.8	0.00	0.25	0.75	3.0	
		Week 20	Tezepelumab	40	36 (90.0)	1.05 (1.22)	-1.8	0.13	1.13	2.13	3.0	0.63 [0.14, 1.13]
			Placebo	36	31 (86.1)	0.33 (1.03)	-2.3	0.00	0.25	1.00	2.5	
		Week 24	Tezepelumab	40	36 (90.0)	1.13 (1.29)	-1.5	0.25	1.50	2.25	3.5	0.77 [0.27, 1.26]
			Placebo	36	31 (86.1)	0.19 (1.12)	-2.8	-0.25	0.00	1.00	3.0	
		Week 28	Tezepelumab	40	36 (90.0)	1.08 (1.27)	-1.5	0.13	1.50	2.25	3.0	0.53 [0.04, 1.02]
			Placebo	36	31 (86.1)	0.40 (1.30)	-2.8	-0.25	0.25	1.25	3.0	
		Week 32	Tezepelumab	40	36 (90.0)	1.17 (1.30)	-1.3	0.00	1.50	2.25	3.5	0.56 [0.07, 1.05]
			Placebo	36	31 (86.1)	0.52 (0.94)	-1.8	0.00	0.25	1.00	2.8	
		Week 36	Tezepelumab	40	36 (90.0)	1.17 (1.30)	-1.3	0.13	1.38	2.25	3.5	0.70 [0.21, 1.20]
			Placebo	36	31 (86.1)	0.32 (1.10)	-2.8	0.00	0.25	0.75	3.0	
		Week 40	Tezepelumab	40	36 (90.0)	1.28 (1.17)	-1.3	0.25	1.50	2.25	3.3	0.64 [0.15, 1.13]
			Placebo	36	31 (86.1)	0.53 (1.20)	-2.5	0.00	0.50	1.00	3.3	
		Week 44	Tezepelumab	40	36 (90.0)	1.28 (1.28)	-1.5	0.25	1.50	2.25	3.8	0.69 [0.19, 1.18]
			Placebo	36	31 (86.1)	0.48 (1.00)	-1.5	0.00	0.25	1.00	3.3	
		Week 48	Tezepelumab	40	36 (90.0)	1.25 (1.33)	-1.3	0.13	1.50	2.13	3.8	0.63 [0.14, 1.13]
			Placebo	36	31 (86.1)	0.44 (1.21)	-2.8	0.00	0.25	1.00	3.8	
		Week 52	Tezepelumab	40	36 (90.0)	1.26 (1.29)	-1.3	0.13	1.50	2.25	3.8	0.61 [0.12, 1.10]
			Placebo	36	31 (86.1)	0.55 (1.03)	-1.3	0.00	0.25	1.00	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	4.40 (1.77)	1.8	3.50	5.00	5.75	6.0	
			Placebo	4	3 (75.0)	3.92 (0.80)	3.0	3.00	4.25	4.50	4.5	
		Week 4	Tezepelumab	6	4 (66.7)	5.94 (0.72)	5.5	5.50	5.63	6.38	7.0	
			Placebo	4	3 (75.0)	5.42 (1.13)	4.3	4.25	5.50	6.50	6.5	
		Week 8	Tezepelumab	6	5 (83.3)	5.70 (1.02)	4.0	5.75	6.00	6.00	6.8	
			Placebo	4	3 (75.0)	6.08 (0.80)	5.5	5.50	5.75	7.00	7.0	
		Week 12	Tezepelumab	6	5 (83.3)	5.95 (0.89)	4.5	5.75	6.25	6.50	6.8	
			Placebo	4	3 (75.0)	5.42 (1.51)	4.0	4.00	5.25	7.00	7.0	
		Week 16	Tezepelumab	6	5 (83.3)	5.15 (0.68)	4.5	4.75	4.75	5.75	6.0	
			Placebo	4	3 (75.0)	5.17 (1.88)	3.3	3.25	5.25	7.00	7.0	
		Week 20	Tezepelumab	6	5 (83.3)	5.00 (0.40)	4.5	4.75	5.00	5.25	5.5	
			Placebo	4	3 (75.0)	5.17 (1.88)	3.3	3.25	5.25	7.00	7.0	
		Week 24	Tezepelumab	6	5 (83.3)	5.40 (0.74)	4.5	5.00	5.50	5.50	6.5	
			Placebo	4	3 (75.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 28	Tezepelumab	6	6 (100.0)	5.83 (1.07)	4.5	5.00	5.75	7.00	7.0	
			Placebo	4	3 (75.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 32	Tezepelumab	6	6 (100.0)	5.71 (0.87)	4.5	5.00	5.88	6.00	7.0	
			Placebo	4	3 (75.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 36	Tezepelumab	6	6 (100.0)	5.71 (0.84)	4.5	5.00	5.88	6.50	6.5	
			Placebo	4	3 (75.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 40	Tezepelumab	6	6 (100.0)	5.79 (0.95)	4.5	5.00	5.88	6.50	7.0	
			Placebo	4	3 (75.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 44	Tezepelumab	6	6 (100.0)	5.83 (0.92)	4.5	5.00	6.13	6.25	7.0	
			Placebo	4	3 (75.0)	6.50 (0.66)	5.8	5.75	6.75	7.00	7.0	
		Week 48	Tezepelumab	6	6 (100.0)	5.79 (0.89)	4.5	5.00	6.00	6.50	6.8	
			Placebo	4	3 (75.0)	6.17 (0.52)	5.8	5.75	6.00	6.75	6.8	
		Week 52	Tezepelumab	6	6 (100.0)	5.92 (0.96)	4.5	5.00	6.25	6.75	6.8	
			Placebo	4	3 (75.0)	6.25 (0.66)	5.8	5.75	6.00	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	6	4 (66.7)	1.31 (2.12)	-0.5	-0.38	0.88	3.00	4.0	-0.10 [-1.60, 1.40]
			Placebo	4	3 (75.0)	1.50 (1.32)	0.0	0.00	2.00	2.50	2.5	
		Week 8	Tezepelumab	6	5 (83.3)	1.30 (1.80)	0.0	0.00	0.50	1.75	4.3	-0.58 [-2.04, 0.89]
			Placebo	4	3 (75.0)	2.17 (0.58)	1.5	1.50	2.50	2.50	2.5	
		Week 12	Tezepelumab	6	5 (83.3)	1.55 (1.92)	0.0	0.25	1.00	1.75	4.8	0.03 [-1.40, 1.46]
			Placebo	4	3 (75.0)	1.50 (0.87)	1.0	1.00	1.00	2.50	2.5	
		Week 16	Tezepelumab	6	5 (83.3)	0.75 (1.35)	-0.3	0.00	0.00	1.00	3.0	-0.39 [-1.84, 1.06]
			Placebo	4	3 (75.0)	1.25 (1.15)	0.3	0.25	1.00	2.50	2.5	
		Week 20	Tezepelumab	6	5 (83.3)	0.60 (1.61)	-0.5	-0.50	-0.25	1.00	3.3	-0.44 [-1.90, 1.01]
			Placebo	4	3 (75.0)	1.25 (1.15)	0.3	0.25	1.00	2.50	2.5	
		Week 24	Tezepelumab	6	5 (83.3)	1.00 (1.51)	-0.5	-0.25	1.00	1.50	3.3	-0.57 [-2.04, 0.89]
			Placebo	4	3 (75.0)	1.75 (0.75)	1.0	1.00	1.75	2.50	2.5	
		Week 28	Tezepelumab	6	5 (83.3)	1.20 (1.47)	-0.5	0.25	1.00	2.00	3.3	-0.43 [-1.88, 1.02]
			Placebo	4	3 (75.0)	1.75 (0.75)	1.0	1.00	1.75	2.50	2.5	
		Week 32	Tezepelumab	6	5 (83.3)	1.05 (1.34)	-0.3	0.25	1.00	1.00	3.3	-0.60 [-2.07, 0.88]
			Placebo	4	3 (75.0)	1.75 (0.75)	1.0	1.00	1.75	2.50	2.5	
		Week 36	Tezepelumab	6	5 (83.3)	1.15 (1.39)	-0.5	0.50	1.00	1.50	3.3	-0.49 [-1.95, 0.96]
			Placebo	4	3 (75.0)	1.75 (0.75)	1.0	1.00	1.75	2.50	2.5	
		Week 40	Tezepelumab	6	5 (83.3)	1.25 (1.44)	-0.5	0.50	1.00	2.00	3.3	-0.40 [-1.85, 1.05]
			Placebo	4	3 (75.0)	1.75 (0.75)	1.0	1.00	1.75	2.50	2.5	
		Week 44	Tezepelumab	6	5 (83.3)	1.35 (1.29)	0.0	0.50	1.00	2.00	3.3	-0.99 [-2.53, 0.54]
			Placebo	4	3 (75.0)	2.58 (1.13)	1.5	1.50	2.50	3.75	3.8	
		Week 48	Tezepelumab	6	5 (83.3)	1.30 (1.30)	-0.3	0.75	1.00	1.75	3.3	-0.73 [-2.22, 0.76]
			Placebo	4	3 (75.0)	2.25 (1.30)	1.5	1.50	1.50	3.75	3.8	
		Week 52	Tezepelumab	6	5 (83.3)	1.35 (1.23)	0.0	0.75	1.00	1.75	3.3	-0.75 [-2.25, 0.74]
			Placebo	4	3 (75.0)	2.33 (1.44)	1.5	1.50	1.50	4.00	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	4.33 (1.38)	3.0	3.00	4.25	5.75	5.8	
			Placebo	3	3 (100.0)	4.25 (0.87)	3.8	3.75	3.75	5.25	5.3	
		Week 4	Tezepelumab	3	3 (100.0)	5.33 (0.95)	4.3	4.25	5.75	6.00	6.0	
			Placebo	3	3 (100.0)	5.00 (0.43)	4.8	4.75	4.75	5.50	5.5	
		Week 8	Tezepelumab	3	3 (100.0)	5.75 (0.50)	5.3	5.25	5.75	6.25	6.3	
			Placebo	3	3 (100.0)	4.83 (0.95)	3.8	3.75	5.25	5.50	5.5	
		Week 12	Tezepelumab	3	3 (100.0)	6.08 (0.76)	5.3	5.25	6.25	6.75	6.8	
			Placebo	3	3 (100.0)	5.08 (0.29)	4.8	4.75	5.25	5.25	5.3	
		Week 16	Tezepelumab	3	3 (100.0)	6.00 (0.87)	5.5	5.50	5.50	7.00	7.0	
			Placebo	3	3 (100.0)	5.33 (0.38)	5.0	5.00	5.25	5.75	5.8	
		Week 20	Tezepelumab	3	3 (100.0)	6.08 (0.80)	5.5	5.50	5.75	7.00	7.0	
			Placebo	3	3 (100.0)	4.67 (0.58)	4.0	4.00	5.00	5.00	5.0	
		Week 24	Tezepelumab	3	3 (100.0)	6.08 (0.63)	5.5	5.50	6.00	6.75	6.8	
			Placebo	3	3 (100.0)	4.75 (0.50)	4.3	4.25	4.75	5.25	5.3	
		Week 28	Tezepelumab	3	3 (100.0)	6.25 (0.66)	5.8	5.75	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	5.83 (0.76)	5.0	5.00	6.00	6.50	6.5	
		Week 32	Tezepelumab	3	3 (100.0)	6.17 (0.76)	5.5	5.50	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	5.58 (0.63)	5.0	5.00	5.50	6.25	6.3	
		Week 36	Tezepelumab	3	3 (100.0)	6.25 (0.66)	5.8	5.75	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	5.00 (0.66)	4.3	4.25	5.25	5.50	5.5	
		Week 40	Tezepelumab	3	3 (100.0)	6.17 (0.72)	5.8	5.75	5.75	7.00	7.0	
			Placebo	3	3 (100.0)	5.33 (0.58)	5.0	5.00	5.00	6.00	6.0	
		Week 44	Tezepelumab	3	3 (100.0)	6.50 (0.66)	5.8	5.75	6.75	7.00	7.0	
			Placebo	3	3 (100.0)	4.75 (0.90)	4.0	4.00	4.50	5.75	5.8	
		Week 48	Tezepelumab	3	3 (100.0)	6.25 (0.66)	5.8	5.75	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.58 (0.38)	4.3	4.25	4.50	5.00	5.0	
		Week 52	Tezepelumab	3	3 (100.0)	6.25 (0.66)	5.8	5.75	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.58 (0.38)	4.3	4.25	4.50	5.00	5.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.00 (0.90)	0.0	0.00	1.25	1.75	1.8	0.24 [-1.37, 1.85]
			Placebo	3	3 (100.0)	0.75 (1.15)	-0.5	-0.50	1.00	1.75	1.8	
		Week 8	Tezepelumab	3	3 (100.0)	1.42 (1.23)	0.0	0.00	2.00	2.25	2.3	0.74 [-0.94, 2.42]
			Placebo	3	3 (100.0)	0.58 (1.01)	0.0	0.00	0.00	1.75	1.8	
		Week 12	Tezepelumab	3	3 (100.0)	1.75 (1.09)	0.5	0.50	2.25	2.50	2.5	0.97 [-0.76, 2.71]
			Placebo	3	3 (100.0)	0.83 (0.76)	0.0	0.00	1.00	1.50	1.5	
		Week 16	Tezepelumab	3	3 (100.0)	1.67 (1.66)	-0.3	-0.25	2.50	2.75	2.8	0.47 [-1.16, 2.11]
			Placebo	3	3 (100.0)	1.08 (0.52)	0.5	0.50	1.25	1.50	1.5	
		Week 20	Tezepelumab	3	3 (100.0)	1.75 (1.52)	0.0	0.00	2.50	2.75	2.8	0.90 [-0.82, 2.62]
			Placebo	3	3 (100.0)	0.42 (1.44)	-1.3	-1.25	1.25	1.25	1.3	
		Week 24	Tezepelumab	3	3 (100.0)	1.75 (1.30)	0.3	0.25	2.50	2.50	2.5	0.95 [-0.78, 2.68]
			Placebo	3	3 (100.0)	0.50 (1.32)	-1.0	-1.00	1.00	1.50	1.5	
		Week 28	Tezepelumab	3	3 (100.0)	1.92 (1.66)	0.0	0.00	2.75	3.00	3.0	0.27 [-1.34, 1.88]
			Placebo	3	3 (100.0)	1.58 (0.58)	1.3	1.25	1.25	2.25	2.3	
		Week 32	Tezepelumab	3	3 (100.0)	1.83 (1.38)	0.3	0.25	2.50	2.75	2.8	0.49 [-1.14, 2.13]
			Placebo	3	3 (100.0)	1.33 (0.38)	1.0	1.00	1.25	1.75	1.8	
		Week 36	Tezepelumab	3	3 (100.0)	1.92 (1.44)	0.3	0.25	2.75	2.75	2.8	0.79 [-0.90, 2.48]
			Placebo	3	3 (100.0)	0.75 (1.52)	-1.0	-1.00	1.50	1.75	1.8	
		Week 40	Tezepelumab	3	3 (100.0)	1.83 (1.59)	0.0	0.00	2.75	2.75	2.8	0.52 [-1.12, 2.16]
			Placebo	3	3 (100.0)	1.08 (1.26)	-0.3	-0.25	1.25	2.25	2.3	
		Week 44	Tezepelumab	3	3 (100.0)	2.17 (1.94)	0.0	0.00	2.75	3.75	3.8	0.99 [-0.75, 2.73]
			Placebo	3	3 (100.0)	0.50 (1.39)	-0.8	-0.75	0.25	2.00	2.0	
		Week 48	Tezepelumab	3	3 (100.0)	1.92 (1.44)	0.3	0.25	2.75	2.75	2.8	1.20 [-0.60, 3.00]
			Placebo	3	3 (100.0)	0.33 (1.18)	-1.0	-1.00	0.75	1.25	1.3	
		Week 52	Tezepelumab	3	3 (100.0)	1.92 (1.44)	0.3	0.25	2.75	2.75	2.8	1.20 [-0.60, 3.00]
			Placebo	3	3 (100.0)	0.33 (1.18)	-1.0	-1.00	0.75	1.25	1.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	17	14 (82.4)	3.73 (0.63)	2.5	3.50	3.75	4.00	5.0	
			Placebo	22	18 (81.8)	4.21 (1.35)	1.5	3.50	4.13	4.75	7.0	
		Week 4	Tezepelumab	17	16 (94.1)	4.94 (0.81)	3.3	4.50	5.00	5.50	6.3	
			Placebo	22	20 (90.9)	4.80 (1.35)	2.0	4.13	5.25	5.63	7.0	
		Week 8	Tezepelumab	17	16 (94.1)	5.16 (0.83)	3.5	4.63	5.50	5.75	6.3	
			Placebo	22	21 (95.5)	4.80 (1.36)	1.5	4.25	5.00	5.75	7.0	
		Week 12	Tezepelumab	17	16 (94.1)	5.25 (0.99)	3.0	4.75	5.50	6.00	6.8	
			Placebo	22	21 (95.5)	4.63 (1.18)	2.3	3.50	4.75	5.50	6.8	
		Week 16	Tezepelumab	17	16 (94.1)	5.34 (0.95)	4.0	4.63	5.25	6.13	7.0	
			Placebo	22	21 (95.5)	4.85 (1.34)	1.5	4.25	5.00	5.75	7.0	
		Week 20	Tezepelumab	17	16 (94.1)	5.16 (1.04)	3.8	4.13	5.13	6.00	7.0	
			Placebo	22	21 (95.5)	4.85 (1.35)	1.5	4.25	4.75	5.50	7.0	
		Week 24	Tezepelumab	17	16 (94.1)	5.22 (0.96)	4.0	4.38	5.00	6.00	6.8	
			Placebo	22	21 (95.5)	4.80 (1.55)	1.0	4.00	4.75	6.00	7.0	
		Week 28	Tezepelumab	17	16 (94.1)	5.17 (0.89)	3.8	4.50	5.00	6.00	6.8	
			Placebo	22	21 (95.5)	4.86 (1.39)	2.0	4.00	4.75	6.00	7.0	
		Week 32	Tezepelumab	17	16 (94.1)	5.27 (1.12)	3.5	4.38	5.00	6.13	7.0	
			Placebo	22	21 (95.5)	4.77 (1.57)	1.3	4.00	4.75	6.00	7.0	
		Week 36	Tezepelumab	17	16 (94.1)	5.30 (1.04)	3.8	4.63	5.25	6.00	7.0	
			Placebo	22	21 (95.5)	4.71 (1.60)	1.0	3.75	4.75	5.25	7.0	
		Week 40	Tezepelumab	17	16 (94.1)	5.19 (0.93)	4.0	4.38	5.00	5.75	6.8	
			Placebo	22	21 (95.5)	4.82 (1.54)	1.0	4.00	4.75	5.75	7.0	
		Week 44	Tezepelumab	17	16 (94.1)	5.16 (0.89)	3.8	4.63	5.00	5.75	6.8	
			Placebo	22	21 (95.5)	4.79 (1.57)	1.3	4.00	4.75	5.75	7.0	
		Week 48	Tezepelumab	17	16 (94.1)	5.36 (0.94)	4.0	4.50	5.25	6.25	7.0	
			Placebo	22	21 (95.5)	4.86 (1.30)	2.8	4.00	4.50	5.25	7.0	
		Week 52	Tezepelumab	17	16 (94.1)	5.31 (0.92)	4.0	4.50	5.25	5.88	7.0	
			Placebo	22	21 (95.5)	4.88 (1.37)	2.8	4.00	4.75	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	17	13 (76.5)	1.21 (0.80)	-0.3	0.75	1.25	1.75	2.5	0.74 [0.00, 1.48]
			Placebo	22	18 (81.8)	0.56 (0.95)	-1.3	0.00	0.50	1.00	3.0	
		Week 8	Tezepelumab	17	13 (76.5)	1.38 (0.77)	0.0	0.75	1.25	2.00	2.5	0.60 [-0.13, 1.33]
			Placebo	22	18 (81.8)	0.71 (1.33)	-1.8	-0.25	0.88	1.25	3.3	
		Week 12	Tezepelumab	17	13 (76.5)	1.46 (0.85)	0.3	1.00	1.25	2.25	2.8	0.94 [0.18, 1.69]
			Placebo	22	18 (81.8)	0.42 (1.27)	-1.8	-0.75	0.50	1.00	2.8	
		Week 16	Tezepelumab	17	13 (76.5)	1.60 (0.89)	0.0	1.00	1.50	2.25	3.3	0.89 [0.14, 1.64]
			Placebo	22	18 (81.8)	0.67 (1.14)	-1.3	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	17	13 (76.5)	1.50 (0.98)	0.3	0.75	1.25	2.00	3.5	0.75 [0.01, 1.49]
			Placebo	22	18 (81.8)	0.72 (1.07)	-1.3	0.00	0.50	1.50	3.0	
		Week 24	Tezepelumab	17	13 (76.5)	1.62 (0.91)	0.3	1.00	1.50	2.00	3.3	0.74 [0.01, 1.48]
			Placebo	22	18 (81.8)	0.76 (1.28)	-1.3	-0.25	0.63	1.50	3.8	
		Week 28	Tezepelumab	17	13 (76.5)	1.54 (0.99)	0.0	0.75	1.25	2.25	3.3	0.67 [-0.06, 1.40]
			Placebo	22	18 (81.8)	0.78 (1.23)	-1.3	0.25	0.63	1.00	3.8	
		Week 32	Tezepelumab	17	13 (76.5)	1.69 (1.17)	-0.5	1.25	1.50	2.50	3.5	0.74 [0.00, 1.48]
			Placebo	22	18 (81.8)	0.78 (1.28)	-1.3	0.00	0.63	1.50	3.8	
		Week 36	Tezepelumab	17	13 (76.5)	1.71 (1.02)	-0.3	1.25	1.50	2.25	3.3	0.87 [0.12, 1.62]
			Placebo	22	18 (81.8)	0.67 (1.31)	-1.3	-0.25	0.38	1.25	3.8	
		Week 40	Tezepelumab	17	13 (76.5)	1.52 (1.04)	0.0	0.75	1.50	1.75	3.3	0.64 [-0.09, 1.38]
			Placebo	22	18 (81.8)	0.75 (1.29)	-1.3	0.00	0.63	1.25	3.8	
		Week 44	Tezepelumab	17	13 (76.5)	1.52 (1.03)	-0.3	1.00	1.25	2.25	3.3	0.61 [-0.12, 1.34]
			Placebo	22	18 (81.8)	0.76 (1.37)	-1.3	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	17	13 (76.5)	1.75 (1.02)	0.5	0.75	1.50	2.25	3.5	0.76 [0.02, 1.50]
			Placebo	22	18 (81.8)	0.82 (1.35)	-1.3	0.25	0.63	1.00	3.8	
		Week 52	Tezepelumab	17	13 (76.5)	1.71 (1.04)	0.5	0.75	1.50	2.25	3.5	0.70 [-0.03, 1.44]
			Placebo	22	18 (81.8)	0.82 (1.41)	-1.3	0.00	0.63	1.75	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	4.23 (1.42)	1.8	3.00	4.13	5.50	6.8	
			Placebo	21	17 (81.0)	4.26 (1.34)	1.5	3.25	4.25	5.25	6.3	
		Week 4	Tezepelumab	15	13 (86.7)	5.17 (1.08)	3.3	5.00	5.25	5.75	6.8	
			Placebo	21	19 (90.5)	4.71 (1.33)	2.0	3.50	5.25	5.50	6.8	
		Week 8	Tezepelumab	15	14 (93.3)	5.63 (0.97)	3.5	5.25	5.75	6.25	7.0	
			Placebo	21	19 (90.5)	5.03 (1.38)	1.5	4.00	5.50	6.00	7.0	
		Week 12	Tezepelumab	15	14 (93.3)	5.77 (1.04)	3.0	5.25	6.00	6.50	7.0	
			Placebo	21	19 (90.5)	5.04 (1.33)	2.3	4.00	5.25	6.00	7.0	
		Week 16	Tezepelumab	15	14 (93.3)	5.86 (0.92)	4.3	5.50	5.88	6.75	7.0	
			Placebo	21	19 (90.5)	5.14 (1.45)	1.5	4.00	5.50	6.25	7.0	
		Week 20	Tezepelumab	15	14 (93.3)	5.66 (1.06)	3.5	5.00	5.63	6.50	7.0	
			Placebo	21	19 (90.5)	5.03 (1.57)	1.5	3.50	5.00	6.50	7.0	
		Week 24	Tezepelumab	15	14 (93.3)	5.89 (0.96)	3.8	5.50	6.00	6.75	7.0	
			Placebo	21	19 (90.5)	4.78 (1.69)	1.0	3.25	5.25	6.00	7.0	
		Week 28	Tezepelumab	15	14 (93.3)	5.86 (0.94)	4.0	5.25	5.88	7.00	7.0	
			Placebo	21	20 (95.2)	5.36 (1.50)	2.0	4.13	6.00	6.50	7.0	
		Week 32	Tezepelumab	15	14 (93.3)	5.88 (0.93)	4.0	5.50	6.00	6.75	7.0	
			Placebo	21	20 (95.2)	5.20 (1.65)	1.3	3.88	5.88	6.25	7.0	
		Week 36	Tezepelumab	15	14 (93.3)	5.96 (0.94)	4.0	5.25	6.13	7.00	7.0	
			Placebo	21	20 (95.2)	4.96 (1.74)	1.0	3.63	5.38	6.75	7.0	
		Week 40	Tezepelumab	15	14 (93.3)	5.75 (0.93)	4.3	5.00	5.75	6.50	7.0	
			Placebo	21	20 (95.2)	5.10 (1.66)	1.0	3.75	5.63	6.50	7.0	
		Week 44	Tezepelumab	15	14 (93.3)	5.91 (0.90)	4.8	5.00	6.00	6.75	7.0	
			Placebo	21	20 (95.2)	5.05 (1.66)	1.3	3.50	5.63	6.25	7.0	
		Week 48	Tezepelumab	15	14 (93.3)	5.95 (0.95)	3.8	5.50	5.88	7.00	7.0	
			Placebo	21	20 (95.2)	5.08 (1.40)	2.8	4.00	5.00	6.25	7.0	
		Week 52	Tezepelumab	15	14 (93.3)	5.88 (0.90)	3.8	5.50	5.88	6.50	7.0	
			Placebo	21	20 (95.2)	5.11 (1.42)	2.8	4.00	5.13	6.25	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	15	12 (80.0)	1.13 (1.40)	-0.8	0.00	0.88	2.13	4.0	0.63 [-0.13, 1.38]
			Placebo	21	17 (81.0)	0.44 (0.82)	-0.8	-0.25	0.75	1.00	1.8	
		Week 8	Tezepelumab	15	13 (86.7)	1.46 (1.35)	0.0	0.25	1.00	2.25	4.3	0.60 [-0.14, 1.34]
			Placebo	21	17 (81.0)	0.85 (0.66)	0.0	0.25	0.75	1.25	2.0	
		Week 12	Tezepelumab	15	13 (86.7)	1.52 (1.36)	0.0	0.50	1.00	2.25	4.8	0.65 [-0.09, 1.40]
			Placebo	21	17 (81.0)	0.81 (0.82)	-1.3	0.25	1.00	1.25	2.0	
		Week 16	Tezepelumab	15	13 (86.7)	1.60 (1.20)	-0.3	0.50	2.00	2.50	3.0	0.74 [-0.01, 1.48]
			Placebo	21	17 (81.0)	0.93 (0.61)	0.0	0.50	0.75	1.25	2.3	
		Week 20	Tezepelumab	15	13 (86.7)	1.42 (1.36)	-0.5	0.25	1.25	2.50	3.3	0.51 [-0.23, 1.24]
			Placebo	21	17 (81.0)	0.87 (0.86)	-1.3	0.50	0.75	1.25	2.5	
		Week 24	Tezepelumab	15	13 (86.7)	1.65 (1.31)	-0.3	0.25	2.00	2.50	3.5	0.91 [0.15, 1.67]
			Placebo	21	17 (81.0)	0.65 (0.94)	-1.0	-0.25	0.75	1.50	2.0	
		Week 28	Tezepelumab	15	13 (86.7)	1.67 (1.35)	-0.5	0.25	2.00	3.00	3.3	0.38 [-0.35, 1.11]
			Placebo	21	17 (81.0)	1.25 (0.91)	-0.5	0.75	1.25	1.75	3.0	
		Week 32	Tezepelumab	15	13 (86.7)	1.69 (1.21)	0.0	0.25	1.75	2.50	3.3	0.71 [-0.04, 1.45]
			Placebo	21	17 (81.0)	1.00 (0.77)	-0.3	0.75	1.00	1.50	2.5	
		Week 36	Tezepelumab	15	13 (86.7)	1.75 (1.23)	0.0	0.50	2.00	2.75	3.3	0.88 [0.12, 1.64]
			Placebo	21	17 (81.0)	0.78 (1.00)	-1.0	0.25	0.75	1.50	2.5	
		Week 40	Tezepelumab	15	13 (86.7)	1.52 (1.15)	0.0	0.50	1.50	2.75	3.3	0.56 [-0.18, 1.30]
			Placebo	21	17 (81.0)	0.93 (0.98)	-0.5	0.25	1.00	1.50	2.5	
		Week 44	Tezepelumab	15	13 (86.7)	1.69 (1.28)	0.0	0.50	1.50	2.75	3.8	0.75 [0.00, 1.50]
			Placebo	21	17 (81.0)	0.79 (1.13)	-1.0	0.00	0.75	1.50	2.5	
		Week 48	Tezepelumab	15	13 (86.7)	1.75 (1.22)	-0.3	0.75	1.50	2.75	3.3	0.72 [-0.02, 1.47]
			Placebo	21	17 (81.0)	0.87 (1.21)	-1.0	0.00	0.75	1.50	3.3	
		Week 52	Tezepelumab	15	13 (86.7)	1.69 (1.18)	-0.3	0.75	1.50	2.75	3.3	0.65 [-0.09, 1.39]
			Placebo	21	17 (81.0)	0.90 (1.25)	-1.0	0.00	0.75	1.75	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	24	20 (83.3)	4.14 (0.94)	2.5	3.50	4.00	4.75	6.0	
			Placebo	20	18 (90.0)	4.36 (1.32)	2.0	3.75	3.88	5.50	7.0	
		Week 4	Tezepelumab	24	23 (95.8)	5.09 (0.79)	3.3	4.50	5.25	5.75	6.0	
			Placebo	20	17 (85.0)	4.88 (1.25)	2.3	4.00	4.75	5.50	7.0	
		Week 8	Tezepelumab	24	23 (95.8)	5.30 (0.87)	4.0	4.50	5.50	6.00	7.0	
			Placebo	20	18 (90.0)	4.82 (1.26)	2.3	3.75	5.13	5.50	7.0	
		Week 12	Tezepelumab	24	23 (95.8)	5.53 (0.84)	3.8	5.00	5.50	6.25	7.0	
			Placebo	20	18 (90.0)	5.03 (1.06)	2.5	4.25	5.25	5.75	7.0	
		Week 16	Tezepelumab	24	23 (95.8)	5.36 (0.86)	3.8	4.75	5.50	6.00	7.0	
			Placebo	20	18 (90.0)	4.64 (1.57)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	24	23 (95.8)	5.43 (0.99)	3.8	4.75	5.25	6.25	7.0	
			Placebo	20	18 (90.0)	4.64 (1.63)	1.3	3.75	4.75	5.75	7.0	
		Week 24	Tezepelumab	24	23 (95.8)	5.49 (0.98)	4.0	4.50	5.50	6.50	7.0	
			Placebo	20	18 (90.0)	4.69 (1.57)	1.3	4.50	4.88	5.75	7.0	
		Week 28	Tezepelumab	24	24 (100.0)	5.56 (0.91)	4.3	4.75	5.38	6.25	7.0	
			Placebo	20	18 (90.0)	4.74 (1.58)	1.3	4.00	4.88	5.75	7.0	
		Week 32	Tezepelumab	24	24 (100.0)	5.63 (1.12)	3.5	4.75	5.63	7.00	7.0	
			Placebo	20	18 (90.0)	4.81 (1.53)	1.3	4.00	4.88	5.75	7.0	
		Week 36	Tezepelumab	24	24 (100.0)	5.55 (1.05)	3.8	4.75	5.63	6.50	7.0	
			Placebo	20	18 (90.0)	4.71 (1.52)	1.8	4.00	5.00	5.75	7.0	
		Week 40	Tezepelumab	24	24 (100.0)	5.68 (0.98)	4.0	5.00	5.63	6.63	7.0	
			Placebo	20	18 (90.0)	4.88 (1.56)	1.8	3.75	5.13	6.00	7.0	
		Week 44	Tezepelumab	24	24 (100.0)	5.61 (0.98)	3.8	4.88	5.75	6.25	7.0	
			Placebo	20	18 (90.0)	4.94 (1.35)	2.0	4.00	4.88	5.75	7.0	
		Week 48	Tezepelumab	24	24 (100.0)	5.64 (0.96)	4.0	4.75	5.88	6.25	7.0	
			Placebo	20	18 (90.0)	4.83 (1.41)	2.0	4.00	5.00	5.75	7.0	
		Week 52	Tezepelumab	24	24 (100.0)	5.74 (0.96)	4.0	4.88	5.88	6.63	7.0	
			Placebo	20	18 (90.0)	4.94 (1.38)	1.8	4.00	5.00	5.75	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	24	20 (83.3)	1.00 (1.00)	-1.0	0.25	1.25	1.75	3.0	0.53 [-0.13, 1.19]
			Placebo	20	17 (85.0)	0.44 (1.12)	-2.0	0.00	0.25	1.00	2.5	
		Week 8	Tezepelumab	24	20 (83.3)	1.13 (1.20)	-0.8	0.00	1.25	2.13	3.0	0.55 [-0.10, 1.20]
			Placebo	20	18 (90.0)	0.46 (1.21)	-1.8	-0.25	0.50	1.25	2.5	
		Week 12	Tezepelumab	24	20 (83.3)	1.41 (1.15)	-1.0	0.50	1.50	2.50	3.0	0.69 [0.04, 1.35]
			Placebo	20	18 (90.0)	0.67 (0.99)	-1.8	0.25	0.88	1.25	2.5	
		Week 16	Tezepelumab	24	20 (83.3)	1.28 (1.18)	-0.5	0.00	1.25	2.25	3.0	0.88 [0.21, 1.55]
			Placebo	20	18 (90.0)	0.28 (1.07)	-1.8	0.00	0.25	1.00	2.5	
		Week 20	Tezepelumab	24	20 (83.3)	1.40 (1.24)	-0.5	0.13	1.50	2.38	3.5	0.93 [0.26, 1.60]
			Placebo	20	18 (90.0)	0.28 (1.17)	-2.3	0.00	0.25	1.00	2.5	
		Week 24	Tezepelumab	24	20 (83.3)	1.44 (1.24)	-0.5	0.38	1.63	2.38	3.3	0.88 [0.21, 1.55]
			Placebo	20	18 (90.0)	0.33 (1.27)	-2.8	0.00	0.50	1.00	2.5	
		Week 28	Tezepelumab	24	20 (83.3)	1.46 (1.12)	-0.5	0.75	1.50	2.38	3.3	0.99 [0.31, 1.67]
			Placebo	20	18 (90.0)	0.38 (1.07)	-1.8	0.00	0.38	1.00	2.5	
		Week 32	Tezepelumab	24	20 (83.3)	1.54 (1.38)	-0.5	0.25	1.63	2.50	3.5	0.88 [0.21, 1.55]
			Placebo	20	18 (90.0)	0.44 (1.06)	-1.8	0.00	0.38	1.00	2.5	
		Week 36	Tezepelumab	24	20 (83.3)	1.51 (1.35)	-0.8	0.50	1.63	2.50	3.5	0.91 [0.24, 1.59]
			Placebo	20	18 (90.0)	0.35 (1.18)	-2.8	0.00	0.25	1.25	2.5	
		Week 40	Tezepelumab	24	20 (83.3)	1.58 (1.26)	-0.5	0.63	1.63	2.50	3.3	0.85 [0.18, 1.51]
			Placebo	20	18 (90.0)	0.51 (1.25)	-2.5	0.00	0.75	1.25	2.5	
		Week 44	Tezepelumab	24	20 (83.3)	1.56 (1.36)	-1.0	0.50	1.75	2.50	3.8	0.74 [0.08, 1.39]
			Placebo	20	18 (90.0)	0.58 (1.29)	-1.5	0.00	0.25	1.25	3.8	
		Week 48	Tezepelumab	24	20 (83.3)	1.59 (1.30)	-1.0	1.00	1.88	2.25	3.5	0.86 [0.19, 1.53]
			Placebo	20	18 (90.0)	0.47 (1.30)	-2.8	0.00	0.25	1.00	3.8	
		Week 52	Tezepelumab	24	20 (83.3)	1.69 (1.24)	-0.5	1.00	1.63	2.63	3.5	0.93 [0.25, 1.60]
			Placebo	20	18 (90.0)	0.58 (1.14)	-1.3	0.00	0.50	1.00	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	27	24 (88.9)	3.72 (0.87)	1.8	3.13	3.75	4.25	5.3	
			Placebo	24	20 (83.3)	4.50 (1.05)	2.5	3.50	4.75	5.38	6.0	
		Week 4	Tezepelumab	27	24 (88.9)	4.32 (1.28)	1.3	3.75	4.38	5.25	7.0	
			Placebo	24	21 (87.5)	4.93 (1.10)	2.3	4.25	5.00	5.50	7.0	
		Week 8	Tezepelumab	27	25 (92.6)	4.75 (1.37)	1.0	4.00	4.75	5.75	7.0	
			Placebo	24	22 (91.7)	4.89 (1.29)	2.3	4.00	4.75	6.25	7.0	
		Week 12	Tezepelumab	27	25 (92.6)	4.75 (1.25)	1.0	4.25	4.75	5.50	7.0	
			Placebo	24	22 (91.7)	4.73 (1.09)	2.0	4.00	4.75	5.50	6.8	
		Week 16	Tezepelumab	27	25 (92.6)	4.59 (1.33)	1.0	4.25	4.75	5.25	7.0	
			Placebo	24	22 (91.7)	4.85 (1.17)	1.8	4.25	5.00	5.50	6.8	
		Week 20	Tezepelumab	27	26 (96.3)	4.59 (1.34)	1.0	4.00	4.50	5.25	7.0	
			Placebo	24	22 (91.7)	4.85 (1.08)	2.0	4.25	5.00	5.25	7.0	
		Week 24	Tezepelumab	27	26 (96.3)	4.64 (1.39)	1.0	4.00	4.63	5.75	7.0	
			Placebo	24	22 (91.7)	4.90 (1.33)	1.8	4.25	4.88	5.75	7.0	
		Week 28	Tezepelumab	27	27 (100.0)	4.55 (1.36)	1.0	4.00	4.50	5.00	7.0	
			Placebo	24	22 (91.7)	4.89 (1.42)	1.3	4.50	5.00	6.00	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	4.67 (1.33)	1.0	4.00	4.75	5.50	7.0	
			Placebo	24	22 (91.7)	5.09 (1.26)	2.5	4.00	5.13	6.00	7.0	
		Week 36	Tezepelumab	27	27 (100.0)	4.74 (1.29)	1.0	4.25	4.50	5.25	7.0	
			Placebo	24	22 (91.7)	4.92 (1.28)	1.5	4.25	5.00	6.00	7.0	
		Week 40	Tezepelumab	27	27 (100.0)	4.77 (1.17)	2.0	4.25	4.75	5.50	7.0	
			Placebo	24	22 (91.7)	5.11 (1.28)	1.5	4.50	5.13	6.00	7.0	
		Week 44	Tezepelumab	27	27 (100.0)	4.76 (1.27)	1.3	4.00	5.00	5.25	7.0	
			Placebo	24	22 (91.7)	5.09 (1.26)	2.3	4.00	4.88	6.25	7.0	
		Week 48	Tezepelumab	27	27 (100.0)	4.78 (1.31)	1.0	4.25	4.50	5.25	7.0	
			Placebo	24	22 (91.7)	5.07 (1.37)	1.0	4.25	4.75	6.00	7.0	
		Week 52	Tezepelumab	27	27 (100.0)	4.74 (1.28)	1.0	4.25	4.50	5.25	7.0	
			Placebo	24	22 (91.7)	5.14 (1.22)	2.0	4.25	4.88	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	0.52 (1.34)	-4.0	0.00	0.50	1.25	2.5	0.05 [-0.55, 0.65]
			Placebo	24	20 (83.3)	0.46 (1.18)	-1.8	-0.25	0.38	1.13	3.0	
		Week 8	Tezepelumab	27	24 (88.9)	0.98 (1.15)	-1.3	0.25	1.13	1.88	2.8	0.36 [-0.24, 0.96]
			Placebo	24	20 (83.3)	0.51 (1.46)	-1.5	-0.25	0.13	1.00	3.3	
		Week 12	Tezepelumab	27	24 (88.9)	1.00 (1.07)	-2.3	0.38	1.13	1.88	2.3	0.62 [0.01, 1.23]
			Placebo	24	20 (83.3)	0.29 (1.23)	-1.3	-0.63	0.00	0.75	3.0	
		Week 16	Tezepelumab	27	24 (88.9)	0.84 (1.27)	-2.8	0.25	0.75	1.63	3.3	0.34 [-0.25, 0.94]
			Placebo	24	20 (83.3)	0.41 (1.24)	-1.3	-0.25	0.13	0.75	3.0	
		Week 20	Tezepelumab	27	24 (88.9)	0.79 (1.06)	-1.8	0.25	0.75	1.63	2.5	0.34 [-0.26, 0.94]
			Placebo	24	20 (83.3)	0.43 (1.11)	-1.3	-0.25	0.13	1.00	3.0	
		Week 24	Tezepelumab	27	24 (88.9)	0.90 (1.11)	-1.5	0.25	1.00	2.00	2.3	0.34 [-0.26, 0.94]
			Placebo	24	20 (83.3)	0.48 (1.39)	-1.5	-0.38	0.13	0.88	3.8	
		Week 28	Tezepelumab	27	24 (88.9)	0.81 (1.19)	-1.5	0.13	0.75	1.88	2.8	0.29 [-0.30, 0.89]
			Placebo	24	20 (83.3)	0.41 (1.54)	-2.8	-0.50	0.25	0.88	3.8	
		Week 32	Tezepelumab	27	24 (88.9)	0.92 (1.14)	-1.3	0.13	1.13	1.63	2.5	0.16 [-0.43, 0.76]
			Placebo	24	20 (83.3)	0.73 (1.26)	-1.5	0.00	0.38	1.00	3.8	
		Week 36	Tezepelumab	27	24 (88.9)	0.96 (1.11)	-1.3	0.25	0.88	2.13	2.5	0.37 [-0.23, 0.97]
			Placebo	24	20 (83.3)	0.50 (1.39)	-2.3	0.00	0.25	0.75	3.8	
		Week 40	Tezepelumab	27	24 (88.9)	1.10 (1.07)	-1.3	0.25	1.00	2.00	3.0	0.35 [-0.25, 0.95]
			Placebo	24	20 (83.3)	0.68 (1.40)	-1.5	-0.13	0.50	0.75	3.8	
		Week 44	Tezepelumab	27	24 (88.9)	1.07 (1.09)	-1.5	0.38	1.00	2.00	2.8	0.32 [-0.28, 0.91]
			Placebo	24	20 (83.3)	0.70 (1.28)	-1.3	0.00	0.50	1.00	3.8	
		Week 48	Tezepelumab	27	24 (88.9)	1.06 (1.20)	-1.3	0.38	0.88	2.00	3.8	0.32 [-0.28, 0.92]
			Placebo	24	20 (83.3)	0.65 (1.40)	-1.5	0.00	0.50	0.88	3.8	
		Week 52	Tezepelumab	27	24 (88.9)	1.02 (1.18)	-1.3	0.38	0.75	2.00	3.8	0.26 [-0.34, 0.85]
			Placebo	24	20 (83.3)	0.70 (1.34)	-1.3	0.25	0.50	0.88	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	3.39 (0.85)	1.8	2.75	3.75	4.00	4.5	
			Placebo	14	11 (78.6)	4.41 (1.06)	3.3	3.50	3.75	5.50	6.0	
		Week 4	Tezepelumab	11	11 (100.0)	4.41 (0.80)	3.3	3.75	4.50	5.25	5.8	
			Placebo	14	12 (85.7)	4.96 (1.21)	3.3	4.00	5.00	5.63	6.8	
		Week 8	Tezepelumab	11	11 (100.0)	5.09 (0.89)	3.5	4.50	5.00	5.75	6.3	
			Placebo	14	12 (85.7)	5.17 (1.27)	3.3	4.13	5.25	6.38	6.5	
		Week 12	Tezepelumab	11	11 (100.0)	4.86 (1.04)	3.0	4.25	4.75	5.50	6.5	
			Placebo	14	12 (85.7)	4.79 (1.20)	3.3	3.63	4.88	5.63	7.0	
		Week 16	Tezepelumab	11	11 (100.0)	4.89 (0.80)	4.0	4.50	4.75	5.00	7.0	
			Placebo	14	12 (85.7)	5.06 (1.18)	3.3	4.25	4.75	6.25	7.0	
		Week 20	Tezepelumab	11	11 (100.0)	4.89 (0.86)	4.0	4.50	4.50	5.00	7.0	
			Placebo	14	12 (85.7)	4.85 (1.17)	3.3	4.00	4.63	5.63	7.0	
		Week 24	Tezepelumab	11	11 (100.0)	5.00 (0.92)	4.0	4.00	5.00	6.00	6.8	
			Placebo	14	12 (85.7)	5.10 (1.25)	3.3	4.38	4.75	6.13	7.0	
		Week 28	Tezepelumab	11	11 (100.0)	4.93 (0.84)	3.8	4.50	5.00	5.00	7.0	
			Placebo	14	12 (85.7)	5.06 (1.44)	3.3	3.75	4.50	6.50	7.0	
		Week 32	Tezepelumab	11	11 (100.0)	5.02 (0.77)	4.0	4.50	5.00	5.50	6.8	
			Placebo	14	12 (85.7)	5.13 (1.46)	3.0	4.00	4.50	6.88	7.0	
		Week 36	Tezepelumab	11	11 (100.0)	5.00 (0.81)	4.0	4.50	4.75	5.00	6.8	
			Placebo	14	12 (85.7)	4.92 (1.39)	3.3	3.75	4.25	6.25	7.0	
		Week 40	Tezepelumab	11	11 (100.0)	4.98 (0.76)	4.0	4.50	5.00	5.25	6.8	
			Placebo	14	12 (85.7)	5.02 (1.39)	3.0	4.00	4.50	6.25	7.0	
		Week 44	Tezepelumab	11	11 (100.0)	4.98 (0.81)	4.0	4.50	5.00	5.00	6.8	
			Placebo	14	12 (85.7)	5.23 (1.33)	3.5	4.00	5.00	6.63	7.0	
		Week 48	Tezepelumab	11	11 (100.0)	5.02 (0.84)	4.0	4.50	5.00	5.00	7.0	
			Placebo	14	12 (85.7)	5.13 (1.18)	4.0	4.00	4.75	6.25	7.0	
		Week 52	Tezepelumab	11	11 (100.0)	4.98 (0.73)	4.0	4.50	5.00	5.00	6.5	
			Placebo	14	12 (85.7)	4.94 (1.20)	3.0	4.00	4.63	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	11	11 (100.0)	1.02 (1.07)	0.0	0.50	0.75	1.25	4.0	0.33 [-0.51, 1.17]
			Placebo	14	11 (78.6)	0.68 (0.99)	-1.3	-0.25	1.00	1.25	2.0	
		Week 8	Tezepelumab	11	11 (100.0)	1.70 (1.17)	0.3	0.75	1.75	2.50	4.3	0.63 [-0.23, 1.49]
			Placebo	14	11 (78.6)	0.91 (1.36)	-1.0	-0.25	0.50	1.75	3.3	
		Week 12	Tezepelumab	11	11 (100.0)	1.48 (1.25)	0.3	0.50	1.25	2.00	4.8	0.89 [0.01, 1.77]
			Placebo	14	11 (78.6)	0.48 (0.99)	-0.8	-0.25	0.25	1.25	2.5	
		Week 16	Tezepelumab	11	11 (100.0)	1.50 (0.88)	0.3	0.75	1.50	2.25	3.0	0.78 [-0.09, 1.65]
			Placebo	14	11 (78.6)	0.75 (1.04)	-1.0	0.25	0.50	1.50	3.0	
		Week 20	Tezepelumab	11	11 (100.0)	1.50 (0.86)	0.3	0.75	1.50	2.00	3.3	1.05 [0.15, 1.95]
			Placebo	14	11 (78.6)	0.57 (0.92)	-1.3	0.00	0.50	1.25	2.0	
		Week 24	Tezepelumab	11	11 (100.0)	1.61 (0.90)	0.3	0.75	2.00	2.00	3.3	0.72 [-0.14, 1.59]
			Placebo	14	11 (78.6)	0.77 (1.38)	-1.5	-0.25	0.75	1.50	3.8	
		Week 28	Tezepelumab	11	11 (100.0)	1.55 (0.99)	0.0	0.75	1.50	2.25	3.3	0.62 [-0.24, 1.47]
			Placebo	14	11 (78.6)	0.73 (1.59)	-2.8	0.25	0.75	1.50	3.8	
		Week 32	Tezepelumab	11	11 (100.0)	1.64 (0.88)	0.3	1.00	1.75	2.25	3.3	0.74 [-0.12, 1.61]
			Placebo	14	11 (78.6)	0.77 (1.39)	-1.5	0.25	0.50	1.50	3.8	
		Week 36	Tezepelumab	11	11 (100.0)	1.61 (0.94)	0.3	0.75	2.00	2.25	3.3	0.81 [-0.07, 1.68]
			Placebo	14	11 (78.6)	0.61 (1.48)	-2.3	0.25	0.25	1.50	3.8	
		Week 40	Tezepelumab	11	11 (100.0)	1.59 (0.87)	0.3	1.00	1.75	2.25	3.3	0.75 [-0.11, 1.62]
			Placebo	14	11 (78.6)	0.70 (1.42)	-1.5	0.00	0.50	1.50	3.8	
		Week 44	Tezepelumab	11	11 (100.0)	1.59 (0.87)	0.3	0.75	1.50	2.25	3.3	0.70 [-0.17, 1.56]
			Placebo	14	11 (78.6)	0.82 (1.30)	-1.3	0.00	0.50	1.50	3.8	
		Week 48	Tezepelumab	11	11 (100.0)	1.64 (0.92)	0.3	0.75	2.00	2.25	3.3	0.82 [-0.05, 1.69]
			Placebo	14	11 (78.6)	0.75 (1.21)	-1.3	0.25	0.50	1.25	3.8	
		Week 52	Tezepelumab	11	11 (100.0)	1.59 (0.89)	0.3	0.75	2.00	2.00	3.3	0.94 [0.05, 1.82]
			Placebo	14	11 (78.6)	0.57 (1.26)	-1.3	0.25	0.50	0.75	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	54	46 (85.2)	4.13 (1.07)	1.8	3.50	4.00	4.75	6.8	
			Placebo	51	44 (86.3)	4.38 (1.26)	1.5	3.38	4.38	5.38	7.0	
		Week 4	Tezepelumab	54	48 (88.9)	4.89 (1.18)	1.3	4.13	5.00	5.75	7.0	
			Placebo	51	45 (88.2)	4.81 (1.22)	2.0	4.25	5.00	5.50	7.0	
		Week 8	Tezepelumab	54	50 (92.6)	5.18 (1.22)	1.0	4.25	5.50	6.00	7.0	
			Placebo	51	47 (92.2)	4.85 (1.30)	1.5	4.00	5.00	5.75	7.0	
		Week 12	Tezepelumab	54	50 (92.6)	5.37 (1.16)	1.0	4.75	5.50	6.25	7.0	
			Placebo	51	47 (92.2)	4.95 (1.16)	2.0	4.25	5.00	5.75	7.0	
		Week 16	Tezepelumab	54	50 (92.6)	5.23 (1.26)	1.0	4.50	5.38	6.00	7.0	
			Placebo	51	47 (92.2)	4.84 (1.44)	1.3	4.00	5.00	5.75	7.0	
		Week 20	Tezepelumab	54	51 (94.4)	5.20 (1.31)	1.0	4.25	5.25	6.25	7.0	
			Placebo	51	47 (92.2)	4.84 (1.48)	1.3	4.00	5.00	5.75	7.0	
		Week 24	Tezepelumab	54	51 (94.4)	5.29 (1.33)	1.0	4.50	5.50	6.50	7.0	
			Placebo	51	47 (92.2)	4.72 (1.56)	1.0	4.00	5.00	5.75	7.0	
		Week 28	Tezepelumab	54	53 (98.1)	5.26 (1.32)	1.0	4.50	5.25	6.25	7.0	
			Placebo	51	48 (94.1)	4.98 (1.52)	1.3	4.38	5.25	6.00	7.0	
		Week 32	Tezepelumab	54	53 (98.1)	5.34 (1.36)	1.0	4.50	5.50	6.25	7.0	
			Placebo	51	48 (94.1)	5.02 (1.48)	1.3	4.13	5.25	6.00	7.0	
		Week 36	Tezepelumab	54	53 (98.1)	5.36 (1.31)	1.0	4.50	5.50	6.50	7.0	
			Placebo	51	48 (94.1)	4.86 (1.53)	1.0	4.13	5.00	5.88	7.0	
		Week 40	Tezepelumab	54	53 (98.1)	5.38 (1.20)	2.0	4.50	5.50	6.50	7.0	
			Placebo	51	48 (94.1)	5.04 (1.51)	1.0	4.50	5.25	6.13	7.0	
		Week 44	Tezepelumab	54	53 (98.1)	5.40 (1.26)	1.3	4.75	5.50	6.25	7.0	
			Placebo	51	48 (94.1)	4.98 (1.44)	1.3	4.00	5.13	6.00	7.0	
		Week 48	Tezepelumab	54	53 (98.1)	5.40 (1.27)	1.0	4.50	5.75	6.25	7.0	
			Placebo	51	48 (94.1)	4.97 (1.43)	1.0	4.13	5.00	6.00	7.0	
		Week 52	Tezepelumab	54	53 (98.1)	5.43 (1.27)	1.0	4.50	5.75	6.50	7.0	
			Placebo	51	48 (94.1)	5.10 (1.36)	1.8	4.25	5.13	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	54	43 (79.6)	0.78 (1.30)	-4.0	0.00	1.00	1.75	3.0	0.33 [-0.10, 0.75]
			Placebo	51	43 (84.3)	0.39 (1.06)	-2.0	-0.25	0.25	0.75	3.0	
		Week 8	Tezepelumab	54	45 (83.3)	1.01 (1.20)	-1.3	0.00	1.00	2.00	3.3	0.42 [-0.00, 0.84]
			Placebo	51	44 (86.3)	0.52 (1.12)	-1.8	-0.13	0.25	1.25	3.0	
		Week 12	Tezepelumab	54	45 (83.3)	1.22 (1.17)	-2.3	0.25	1.25	2.25	3.0	0.56 [0.13, 0.98]
			Placebo	51	44 (86.3)	0.60 (1.07)	-1.8	0.00	0.75	1.13	3.0	
		Week 16	Tezepelumab	54	45 (83.3)	1.09 (1.32)	-2.8	0.00	1.00	2.25	3.3	0.52 [0.10, 0.95]
			Placebo	51	44 (86.3)	0.47 (1.05)	-1.8	0.00	0.38	1.00	3.0	
		Week 20	Tezepelumab	54	45 (83.3)	1.07 (1.29)	-1.8	0.00	1.00	2.25	3.5	0.47 [0.05, 0.90]
			Placebo	51	44 (86.3)	0.50 (1.11)	-2.3	0.00	0.38	1.25	3.0	
		Week 24	Tezepelumab	54	45 (83.3)	1.19 (1.29)	-1.5	0.25	1.50	2.25	3.5	0.63 [0.21, 1.06]
			Placebo	51	44 (86.3)	0.41 (1.17)	-2.8	-0.25	0.38	1.00	3.0	
		Week 28	Tezepelumab	54	45 (83.3)	1.17 (1.31)	-1.5	0.25	1.25	2.25	3.3	0.42 [-0.00, 0.84]
			Placebo	51	44 (86.3)	0.64 (1.19)	-1.8	-0.13	0.63	1.25	3.0	
		Week 32	Tezepelumab	54	45 (83.3)	1.24 (1.35)	-1.3	0.00	1.50	2.25	3.5	0.45 [0.03, 0.88]
			Placebo	51	44 (86.3)	0.70 (0.99)	-1.8	0.00	0.75	1.25	3.0	
		Week 36	Tezepelumab	54	45 (83.3)	1.26 (1.33)	-1.3	0.25	1.25	2.25	3.5	0.60 [0.18, 1.03]
			Placebo	51	44 (86.3)	0.52 (1.14)	-2.8	0.00	0.25	1.25	3.0	
		Week 40	Tezepelumab	54	45 (83.3)	1.31 (1.23)	-1.3	0.25	1.25	2.25	3.3	0.50 [0.08, 0.92]
			Placebo	51	44 (86.3)	0.70 (1.18)	-2.5	0.00	0.75	1.25	3.3	
		Week 44	Tezepelumab	54	45 (83.3)	1.34 (1.33)	-1.5	0.25	1.50	2.25	3.8	0.54 [0.11, 0.96]
			Placebo	51	44 (86.3)	0.66 (1.21)	-1.5	0.00	0.38	1.25	3.8	
		Week 48	Tezepelumab	54	45 (83.3)	1.33 (1.33)	-1.3	0.25	1.50	2.25	3.8	0.52 [0.10, 0.94]
			Placebo	51	44 (86.3)	0.64 (1.33)	-2.8	0.00	0.50	1.13	3.8	
		Week 52	Tezepelumab	54	45 (83.3)	1.36 (1.31)	-1.3	0.25	1.50	2.25	3.8	0.47 [0.05, 0.89]
			Placebo	51	44 (86.3)	0.76 (1.24)	-1.3	0.00	0.63	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	33	31 (93.9)	3.86 (0.87)	1.8	3.25	4.00	4.50	5.3	
			Placebo	34	27 (79.4)	4.19 (1.24)	1.5	3.25	4.00	5.25	7.0	
		Week 4	Tezepelumab	33	29 (87.9)	4.59 (1.16)	1.3	4.00	4.50	5.25	7.0	
			Placebo	34	27 (79.4)	4.80 (1.40)	2.0	3.75	4.75	5.50	7.0	
		Week 8	Tezepelumab	33	30 (90.9)	4.93 (1.07)	1.8	4.25	5.00	5.75	6.8	
			Placebo	34	29 (85.3)	4.88 (1.38)	1.5	4.00	5.25	5.75	7.0	
		Week 12	Tezepelumab	33	30 (90.9)	5.13 (1.11)	3.0	4.50	4.88	6.00	7.0	
			Placebo	34	29 (85.3)	4.78 (1.20)	2.3	3.75	5.00	5.50	7.0	
		Week 16	Tezepelumab	33	30 (90.9)	4.89 (1.13)	2.0	4.25	4.75	5.50	7.0	
			Placebo	34	29 (85.3)	4.88 (1.49)	1.3	4.00	5.00	6.25	7.0	
		Week 20	Tezepelumab	33	31 (93.9)	4.96 (1.22)	1.0	4.50	5.00	5.75	7.0	
			Placebo	34	29 (85.3)	4.84 (1.50)	1.3	4.00	5.00	5.75	7.0	
		Week 24	Tezepelumab	33	31 (93.9)	5.06 (1.26)	1.3	4.00	5.00	6.00	7.0	
			Placebo	34	29 (85.3)	4.80 (1.60)	1.0	4.25	5.00	5.75	7.0	
		Week 28	Tezepelumab	33	32 (97.0)	4.95 (1.19)	1.5	4.25	4.88	5.50	7.0	
			Placebo	34	30 (88.2)	5.06 (1.51)	1.3	4.00	5.25	6.00	7.0	
		Week 32	Tezepelumab	33	32 (97.0)	5.08 (1.19)	1.5	4.38	5.00	5.88	7.0	
			Placebo	34	30 (88.2)	5.02 (1.65)	1.3	4.00	5.25	6.25	7.0	
		Week 36	Tezepelumab	33	32 (97.0)	5.10 (1.11)	1.8	4.50	5.00	6.13	7.0	
			Placebo	34	30 (88.2)	4.93 (1.50)	1.0	3.75	5.13	6.25	7.0	
		Week 40	Tezepelumab	33	32 (97.0)	5.16 (1.11)	2.3	4.50	5.00	5.63	7.0	
			Placebo	34	30 (88.2)	5.10 (1.50)	1.0	4.00	5.25	6.50	7.0	
		Week 44	Tezepelumab	33	32 (97.0)	5.08 (1.21)	1.3	4.50	5.00	5.63	7.0	
			Placebo	34	30 (88.2)	5.04 (1.52)	1.3	4.00	5.13	6.50	7.0	
		Week 48	Tezepelumab	33	32 (97.0)	5.16 (1.12)	2.3	4.50	5.00	6.00	7.0	
			Placebo	34	30 (88.2)	5.12 (1.27)	2.8	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	33	32 (97.0)	5.17 (1.08)	2.3	4.50	5.00	6.00	7.0	
			Placebo	34	30 (88.2)	5.07 (1.32)	2.8	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	33	29 (87.9)	0.76 (1.35)	-4.0	0.25	0.75	1.75	4.0	0.13 [-0.40, 0.66]
			Placebo	34	26 (76.5)	0.61 (0.99)	-1.3	0.00	0.75	1.25	3.0	
		Week 8	Tezepelumab	33	30 (90.9)	1.11 (1.22)	-1.3	0.25	1.25	2.00	4.3	0.25 [-0.28, 0.77]
			Placebo	34	27 (79.4)	0.81 (1.24)	-1.8	0.00	0.50	1.50	3.3	
		Week 12	Tezepelumab	33	30 (90.9)	1.30 (1.18)	-2.3	0.75	1.38	2.00	4.8	0.56 [0.03, 1.09]
			Placebo	34	27 (79.4)	0.66 (1.12)	-1.8	0.00	0.75	1.25	3.0	
		Week 16	Tezepelumab	33	30 (90.9)	1.07 (1.21)	-2.8	0.50	1.13	2.00	3.0	0.28 [-0.24, 0.80]
			Placebo	34	27 (79.4)	0.75 (1.04)	-1.8	0.25	0.75	1.00	3.0	
		Week 20	Tezepelumab	33	30 (90.9)	1.11 (1.17)	-1.8	0.50	1.13	1.75	3.5	0.35 [-0.17, 0.88]
			Placebo	34	27 (79.4)	0.72 (0.99)	-1.8	0.25	0.75	1.25	3.0	
		Week 24	Tezepelumab	33	30 (90.9)	1.22 (1.19)	-1.5	0.25	1.50	2.00	3.3	0.45 [-0.08, 0.98]
			Placebo	34	27 (79.4)	0.67 (1.26)	-1.8	-0.25	0.75	1.25	3.8	
		Week 28	Tezepelumab	33	30 (90.9)	1.16 (1.16)	-1.5	0.25	1.38	2.00	3.3	0.24 [-0.28, 0.76]
			Placebo	34	27 (79.4)	0.86 (1.34)	-2.8	0.25	0.75	1.50	3.8	
		Week 32	Tezepelumab	33	30 (90.9)	1.26 (1.16)	-1.3	0.75	1.38	2.00	3.5	0.38 [-0.14, 0.91]
			Placebo	34	27 (79.4)	0.81 (1.21)	-1.8	0.25	0.75	1.50	3.8	
		Week 36	Tezepelumab	33	30 (90.9)	1.26 (1.16)	-1.3	0.50	1.38	2.25	3.3	0.46 [-0.07, 0.99]
			Placebo	34	27 (79.4)	0.71 (1.21)	-2.3	0.00	0.50	1.25	3.8	
		Week 40	Tezepelumab	33	30 (90.9)	1.40 (1.10)	-1.3	0.50	1.63	2.25	3.3	0.43 [-0.10, 0.96]
			Placebo	34	27 (79.4)	0.90 (1.23)	-1.5	0.00	0.75	1.50	3.8	
		Week 44	Tezepelumab	33	30 (90.9)	1.28 (1.21)	-1.5	0.50	1.50	2.25	3.3	0.38 [-0.15, 0.90]
			Placebo	34	27 (79.4)	0.81 (1.26)	-1.5	0.00	0.75	1.50	3.8	
		Week 48	Tezepelumab	33	30 (90.9)	1.38 (1.22)	-1.3	0.50	1.50	2.00	3.8	0.38 [-0.14, 0.91]
			Placebo	34	27 (79.4)	0.91 (1.22)	-1.3	0.25	0.75	1.50	3.8	
		Week 52	Tezepelumab	33	30 (90.9)	1.38 (1.16)	-1.3	0.50	1.50	2.00	3.8	0.44 [-0.09, 0.96]
			Placebo	34	27 (79.4)	0.85 (1.27)	-1.3	0.00	0.50	1.25	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	4.13 (1.27)	1.8	3.25	4.00	4.75	6.8	
			Placebo	31	28 (90.3)	4.56 (1.19)	2.0	3.75	4.63	5.63	6.5	
		Week 4	Tezepelumab	32	30 (93.8)	5.00 (1.09)	2.0	4.50	5.38	5.75	6.8	
			Placebo	31	30 (96.8)	4.88 (1.03)	2.3	4.25	5.25	5.50	6.5	
		Week 8	Tezepelumab	32	31 (96.9)	5.38 (1.22)	1.0	4.50	5.75	6.00	7.0	
			Placebo	31	30 (96.8)	4.94 (1.22)	2.3	4.25	5.00	5.75	7.0	
		Week 12	Tezepelumab	32	31 (96.9)	5.43 (1.18)	1.0	5.00	5.50	6.25	7.0	
			Placebo	31	30 (96.8)	5.06 (1.12)	2.0	4.50	5.13	5.75	7.0	
		Week 16	Tezepelumab	32	31 (96.9)	5.44 (1.21)	1.0	4.75	5.50	6.25	7.0	
			Placebo	31	30 (96.8)	4.88 (1.30)	1.8	4.00	5.00	5.75	7.0	
		Week 20	Tezepelumab	32	31 (96.9)	5.32 (1.26)	1.3	4.25	5.50	6.50	7.0	
			Placebo	31	30 (96.8)	4.85 (1.34)	2.0	4.00	5.00	5.75	7.0	
		Week 24	Tezepelumab	32	31 (96.9)	5.42 (1.28)	1.0	4.75	5.50	6.50	7.0	
			Placebo	31	30 (96.8)	4.79 (1.42)	1.8	4.25	4.88	5.75	7.0	
		Week 28	Tezepelumab	32	32 (100.0)	5.46 (1.29)	1.0	4.75	5.50	6.25	7.0	
			Placebo	31	30 (96.8)	4.94 (1.50)	1.3	4.25	5.00	6.00	7.0	
		Week 32	Tezepelumab	32	32 (100.0)	5.50 (1.35)	1.0	4.75	5.75	6.50	7.0	
			Placebo	31	30 (96.8)	5.07 (1.28)	2.3	4.50	5.25	6.00	7.0	
		Week 36	Tezepelumab	32	32 (100.0)	5.50 (1.34)	1.0	4.63	5.75	6.50	7.0	
			Placebo	31	30 (96.8)	4.81 (1.51)	1.5	4.00	5.00	5.75	7.0	
		Week 40	Tezepelumab	32	32 (100.0)	5.47 (1.17)	2.0	4.63	5.75	6.38	7.0	
			Placebo	31	30 (96.8)	4.98 (1.48)	1.5	4.25	5.25	5.75	7.0	
		Week 44	Tezepelumab	32	32 (100.0)	5.58 (1.15)	2.0	4.88	5.75	6.38	7.0	
			Placebo	31	30 (96.8)	5.03 (1.31)	2.0	4.00	5.13	5.75	7.0	
		Week 48	Tezepelumab	32	32 (100.0)	5.50 (1.29)	1.0	4.63	5.75	6.25	7.0	
			Placebo	31	30 (96.8)	4.88 (1.48)	1.0	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	32	32 (100.0)	5.53 (1.31)	1.0	4.63	5.88	6.50	7.0	
			Placebo	31	30 (96.8)	5.08 (1.33)	1.8	4.50	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	32	25 (78.1)	0.91 (1.16)	-1.3	0.00	1.00	1.75	3.0	0.54 [-0.01, 1.09]
			Placebo	31	28 (90.3)	0.30 (1.08)	-2.0	-0.25	0.25	0.88	2.5	
		Week 8	Tezepelumab	32	26 (81.3)	1.19 (1.24)	-0.8	0.00	1.13	2.25	3.3	0.68 [0.13, 1.23]
			Placebo	31	28 (90.3)	0.40 (1.09)	-1.5	-0.25	0.25	1.13	2.5	
		Week 12	Tezepelumab	32	26 (81.3)	1.24 (1.20)	-1.0	0.25	1.13	2.25	3.0	0.69 [0.14, 1.24]
			Placebo	31	28 (90.3)	0.49 (0.98)	-1.3	-0.38	0.63	1.13	2.5	
		Week 16	Tezepelumab	32	26 (81.3)	1.30 (1.31)	-0.8	0.00	1.38	2.50	3.3	0.85 [0.29, 1.40]
			Placebo	31	28 (90.3)	0.31 (1.01)	-1.5	-0.13	0.25	0.88	2.5	
		Week 20	Tezepelumab	32	26 (81.3)	1.21 (1.30)	-0.5	0.00	1.38	2.50	3.0	0.74 [0.19, 1.29]
			Placebo	31	28 (90.3)	0.31 (1.12)	-2.3	-0.25	0.25	0.88	2.5	
		Week 24	Tezepelumab	32	26 (81.3)	1.34 (1.30)	-0.8	0.25	1.50	2.50	3.5	0.84 [0.28, 1.40]
			Placebo	31	28 (90.3)	0.30 (1.16)	-2.8	-0.25	0.00	1.13	2.5	
		Week 28	Tezepelumab	32	26 (81.3)	1.34 (1.36)	-0.8	0.00	1.50	2.75	3.3	0.69 [0.14, 1.24]
			Placebo	31	28 (90.3)	0.46 (1.18)	-1.5	-0.38	0.38	1.25	3.0	
		Week 32	Tezepelumab	32	26 (81.3)	1.39 (1.42)	-0.8	0.00	1.50	2.50	3.5	0.64 [0.09, 1.19]
			Placebo	31	28 (90.3)	0.63 (0.92)	-1.3	0.00	0.38	1.25	2.5	
		Week 36	Tezepelumab	32	26 (81.3)	1.41 (1.39)	-0.8	0.00	1.50	2.75	3.5	0.81 [0.26, 1.37]
			Placebo	31	28 (90.3)	0.37 (1.19)	-2.8	-0.25	0.25	1.25	2.5	
		Week 40	Tezepelumab	32	26 (81.3)	1.32 (1.26)	-0.5	0.25	1.25	2.75	3.3	0.66 [0.11, 1.21]
			Placebo	31	28 (90.3)	0.51 (1.20)	-2.5	-0.25	0.63	1.25	2.5	
		Week 44	Tezepelumab	32	26 (81.3)	1.52 (1.31)	-0.5	0.25	1.38	2.75	3.8	0.76 [0.21, 1.31]
			Placebo	31	28 (90.3)	0.57 (1.19)	-1.3	-0.13	0.25	1.25	3.8	
		Week 48	Tezepelumab	32	26 (81.3)	1.40 (1.33)	-0.8	0.25	1.50	2.75	3.5	0.73 [0.18, 1.29]
			Placebo	31	28 (90.3)	0.42 (1.35)	-2.8	-0.25	0.25	1.00	3.8	
		Week 52	Tezepelumab	32	26 (81.3)	1.43 (1.34)	-0.8	0.25	1.50	2.75	3.5	0.66 [0.11, 1.20]
			Placebo	31	28 (90.3)	0.60 (1.21)	-1.3	-0.25	0.25	1.13	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	39	32 (82.1)	4.02 (0.97)	1.8	3.50	4.13	4.75	6.0	
			Placebo	30	23 (76.7)	3.97 (1.13)	1.5	3.25	3.75	4.75	6.0	
		Week 4	Tezepelumab	39	36 (92.3)	4.65 (1.14)	1.3	3.88	4.75	5.50	7.0	
			Placebo	30	25 (83.3)	4.35 (1.29)	2.3	3.50	4.25	5.25	7.0	
		Week 8	Tezepelumab	39	36 (92.3)	5.09 (1.06)	1.8	4.38	5.00	5.88	7.0	
			Placebo	30	25 (83.3)	4.68 (1.50)	1.5	3.75	4.75	5.75	7.0	
		Week 12	Tezepelumab	39	36 (92.3)	5.21 (1.06)	3.0	4.50	5.25	6.13	7.0	
			Placebo	30	25 (83.3)	4.48 (1.28)	2.0	3.75	4.50	5.25	7.0	
		Week 16	Tezepelumab	39	36 (92.3)	5.00 (1.08)	2.0	4.50	4.88	5.50	7.0	
			Placebo	30	25 (83.3)	4.57 (1.39)	1.5	4.00	4.75	5.25	7.0	
		Week 20	Tezepelumab	39	37 (94.9)	5.06 (1.15)	1.0	4.50	5.00	5.75	7.0	
			Placebo	30	25 (83.3)	4.58 (1.39)	1.5	4.00	5.00	5.25	7.0	
		Week 24	Tezepelumab	39	37 (94.9)	5.14 (1.21)	1.3	4.25	5.00	6.00	7.0	
			Placebo	30	25 (83.3)	4.59 (1.59)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	39	39 (100.0)	5.10 (1.21)	1.5	4.25	5.00	6.25	7.0	
			Placebo	30	26 (86.7)	4.74 (1.48)	1.3	4.00	5.13	6.00	7.0	
		Week 32	Tezepelumab	39	39 (100.0)	5.17 (1.19)	1.5	4.25	5.00	6.00	7.0	
			Placebo	30	26 (86.7)	4.73 (1.53)	1.3	3.75	4.88	6.00	7.0	
		Week 36	Tezepelumab	39	39 (100.0)	5.17 (1.15)	1.8	4.50	5.00	6.25	7.0	
			Placebo	30	26 (86.7)	4.55 (1.63)	1.0	3.75	5.00	5.50	7.0	
		Week 40	Tezepelumab	39	39 (100.0)	5.19 (1.07)	2.3	4.50	5.00	5.75	7.0	
			Placebo	30	26 (86.7)	4.73 (1.64)	1.0	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	39	39 (100.0)	5.13 (1.17)	1.3	4.25	5.00	6.00	7.0	
			Placebo	30	26 (86.7)	4.72 (1.58)	1.3	3.75	4.75	6.00	7.0	
		Week 48	Tezepelumab	39	39 (100.0)	5.14 (1.07)	2.3	4.25	5.00	6.00	7.0	
			Placebo	30	26 (86.7)	4.75 (1.46)	1.0	4.00	4.75	6.00	7.0	
		Week 52	Tezepelumab	39	39 (100.0)	5.18 (1.06)	2.3	4.50	5.00	6.00	7.0	
			Placebo	30	26 (86.7)	4.77 (1.43)	1.8	4.00	4.75	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	39	32 (82.1)	0.58 (1.31)	-4.0	0.00	0.75	1.25	4.0	0.12 [-0.41, 0.66]
			Placebo	30	23 (76.7)	0.42 (1.17)	-1.8	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	39	32 (82.1)	0.99 (1.19)	-1.3	0.25	1.00	1.75	4.3	0.17 [-0.36, 0.71]
			Placebo	30	23 (76.7)	0.78 (1.24)	-1.3	-0.25	0.75	1.50	3.0	
		Week 12	Tezepelumab	39	32 (82.1)	1.16 (1.14)	-2.3	0.38	1.25	1.63	4.8	0.54 [-0.01, 1.08]
			Placebo	30	23 (76.7)	0.54 (1.13)	-1.3	-0.25	0.50	1.00	3.0	
		Week 16	Tezepelumab	39	32 (82.1)	0.97 (1.18)	-2.8	0.13	1.13	1.75	3.0	0.30 [-0.24, 0.84]
			Placebo	30	23 (76.7)	0.63 (1.06)	-1.0	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	39	32 (82.1)	1.04 (1.15)	-1.8	0.13	1.25	1.88	3.3	0.33 [-0.21, 0.87]
			Placebo	30	23 (76.7)	0.67 (1.03)	-1.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	39	32 (82.1)	1.14 (1.19)	-1.5	0.25	1.50	2.00	3.3	0.43 [-0.12, 0.97]
			Placebo	30	23 (76.7)	0.64 (1.16)	-1.5	-0.25	0.50	1.25	3.0	
		Week 28	Tezepelumab	39	32 (82.1)	1.08 (1.19)	-1.5	0.25	1.38	2.00	3.3	0.27 [-0.27, 0.81]
			Placebo	30	23 (76.7)	0.74 (1.33)	-2.8	0.25	0.75	2.00	2.8	
		Week 32	Tezepelumab	39	32 (82.1)	1.14 (1.18)	-1.3	0.25	1.38	2.13	3.3	0.36 [-0.18, 0.90]
			Placebo	30	23 (76.7)	0.73 (1.07)	-1.5	0.00	0.50	1.25	3.0	
		Week 36	Tezepelumab	39	32 (82.1)	1.16 (1.17)	-1.3	0.25	1.38	2.13	3.3	0.48 [-0.06, 1.03]
			Placebo	30	23 (76.7)	0.58 (1.25)	-2.3	-0.25	0.50	1.25	3.0	
		Week 40	Tezepelumab	39	32 (82.1)	1.20 (1.07)	-1.3	0.25	1.50	2.00	3.3	0.41 [-0.13, 0.96]
			Placebo	30	23 (76.7)	0.73 (1.25)	-1.5	0.00	0.50	1.25	3.3	
		Week 44	Tezepelumab	39	32 (82.1)	1.16 (1.14)	-1.5	0.38	1.50	2.00	3.3	0.43 [-0.11, 0.97]
			Placebo	30	23 (76.7)	0.67 (1.15)	-1.3	0.00	0.50	1.25	3.3	
		Week 48	Tezepelumab	39	32 (82.1)	1.15 (1.10)	-1.3	0.38	1.38	2.00	3.3	0.35 [-0.19, 0.89]
			Placebo	30	23 (76.7)	0.74 (1.23)	-1.5	0.25	0.50	1.25	3.8	
		Week 52	Tezepelumab	39	32 (82.1)	1.18 (1.03)	-1.3	0.38	1.38	2.00	3.3	0.42 [-0.12, 0.96]
			Placebo	30	23 (76.7)	0.72 (1.21)	-1.3	-0.25	0.50	1.25	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	27	26 (96.3)	3.94 (1.17)	1.8	3.25	4.00	4.25	6.8	
			Placebo	34	31 (91.2)	4.73 (1.19)	2.0	3.75	4.75	5.75	7.0	
		Week 4	Tezepelumab	27	24 (88.9)	5.02 (1.09)	2.0	4.38	5.25	5.75	6.8	
			Placebo	34	32 (94.1)	5.23 (0.99)	2.0	4.75	5.25	5.75	7.0	
		Week 8	Tezepelumab	27	26 (96.3)	5.24 (1.29)	1.0	4.25	5.63	6.25	7.0	
			Placebo	34	33 (97.1)	5.15 (1.04)	3.0	4.75	5.25	5.75	7.0	
		Week 12	Tezepelumab	27	26 (96.3)	5.36 (1.26)	1.0	4.75	5.50	6.25	7.0	
			Placebo	34	33 (97.1)	5.27 (0.95)	3.0	5.00	5.50	5.75	7.0	
		Week 16	Tezepelumab	27	26 (96.3)	5.38 (1.32)	1.0	4.50	5.50	6.25	7.0	
			Placebo	34	33 (97.1)	5.23 (1.18)	2.8	4.25	5.25	6.25	7.0	
		Week 20	Tezepelumab	27	26 (96.3)	5.24 (1.37)	1.3	4.25	5.38	6.50	7.0	
			Placebo	34	33 (97.1)	5.15 (1.26)	2.5	4.00	5.25	6.25	7.0	
		Week 24	Tezepelumab	27	26 (96.3)	5.37 (1.35)	1.0	4.50	5.50	6.50	7.0	
			Placebo	34	33 (97.1)	5.06 (1.30)	2.0	4.50	5.00	5.75	7.0	
		Week 28	Tezepelumab	27	26 (96.3)	5.37 (1.31)	1.0	4.50	5.50	6.25	7.0	
			Placebo	34	33 (97.1)	5.32 (1.34)	2.5	4.50	5.25	6.50	7.0	
		Week 32	Tezepelumab	27	26 (96.3)	5.45 (1.39)	1.0	4.75	5.75	6.25	7.0	
			Placebo	34	33 (97.1)	5.40 (1.21)	2.8	4.75	5.75	6.25	7.0	
		Week 36	Tezepelumab	27	26 (96.3)	5.50 (1.34)	1.0	5.00	5.75	6.50	7.0	
			Placebo	34	33 (97.1)	5.18 (1.32)	2.0	4.25	5.00	6.25	7.0	
		Week 40	Tezepelumab	27	26 (96.3)	5.51 (1.23)	2.0	4.50	5.75	6.50	7.0	
			Placebo	34	33 (97.1)	5.32 (1.31)	2.3	4.75	5.50	6.50	7.0	
		Week 44	Tezepelumab	27	26 (96.3)	5.61 (1.18)	2.0	4.75	5.88	6.50	7.0	
			Placebo	34	33 (97.1)	5.32 (1.22)	2.8	4.50	5.50	6.25	7.0	
		Week 48	Tezepelumab	27	26 (96.3)	5.65 (1.34)	1.0	4.75	6.00	6.50	7.0	
			Placebo	34	33 (97.1)	5.23 (1.29)	2.0	4.50	5.00	6.25	7.0	
		Week 52	Tezepelumab	27	26 (96.3)	5.62 (1.36)	1.0	4.75	5.88	6.50	7.0	
			Placebo	34	33 (97.1)	5.35 (1.18)	2.8	4.50	5.25	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	1.17 (1.09)	-0.8	0.25	1.50	2.00	3.0	0.70 [0.14, 1.26]
			Placebo	34	31 (91.2)	0.47 (0.95)	-2.0	-0.25	0.50	1.00	2.5	
		Week 8	Tezepelumab	27	25 (92.6)	1.33 (1.22)	-0.8	0.25	1.75	2.25	3.3	0.71 [0.17, 1.26]
			Placebo	34	31 (91.2)	0.49 (1.13)	-1.8	0.00	0.25	1.25	3.3	
		Week 12	Tezepelumab	27	25 (92.6)	1.40 (1.22)	-1.0	0.75	1.75	2.50	3.0	0.75 [0.20, 1.30]
			Placebo	34	31 (91.2)	0.57 (1.00)	-1.8	0.00	0.75	1.25	2.5	
		Week 16	Tezepelumab	27	25 (92.6)	1.42 (1.28)	-0.8	0.50	1.50	2.50	3.3	0.80 [0.25, 1.35]
			Placebo	34	31 (91.2)	0.52 (0.97)	-1.5	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	27	25 (92.6)	1.29 (1.30)	-0.5	0.25	1.00	2.50	3.5	0.71 [0.16, 1.25]
			Placebo	34	31 (91.2)	0.47 (1.04)	-2.3	0.00	0.25	1.25	2.5	
		Week 24	Tezepelumab	27	25 (92.6)	1.41 (1.27)	-0.8	0.50	1.50	2.50	3.5	0.78 [0.24, 1.33]
			Placebo	34	31 (91.2)	0.44 (1.22)	-2.8	-0.25	0.25	1.25	3.8	
		Week 28	Tezepelumab	27	25 (92.6)	1.44 (1.30)	-0.8	0.25	1.50	2.75	3.3	0.62 [0.08, 1.16]
			Placebo	34	31 (91.2)	0.68 (1.18)	-1.5	0.00	0.75	1.25	3.8	
		Week 32	Tezepelumab	27	25 (92.6)	1.53 (1.36)	-0.8	0.25	1.50	2.50	3.5	0.63 [0.09, 1.17]
			Placebo	34	31 (91.2)	0.79 (1.00)	-1.3	0.00	0.75	1.50	3.8	
		Week 36	Tezepelumab	27	25 (92.6)	1.56 (1.33)	-0.8	0.50	1.50	2.75	3.5	0.82 [0.27, 1.37]
			Placebo	34	31 (91.2)	0.52 (1.20)	-2.8	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	27	25 (92.6)	1.57 (1.26)	-0.5	0.50	1.50	2.75	3.3	0.72 [0.17, 1.26]
			Placebo	34	31 (91.2)	0.68 (1.23)	-2.5	0.00	0.75	1.50	3.8	
		Week 44	Tezepelumab	27	25 (92.6)	1.67 (1.33)	-0.5	0.50	1.50	2.75	3.8	0.74 [0.19, 1.28]
			Placebo	34	31 (91.2)	0.70 (1.31)	-1.5	0.00	0.25	1.25	3.8	
		Week 48	Tezepelumab	27	25 (92.6)	1.73 (1.38)	-0.8	0.75	2.00	3.00	3.8	0.82 [0.27, 1.37]
			Placebo	34	31 (91.2)	0.60 (1.38)	-2.8	0.00	0.25	1.25	3.8	
		Week 52	Tezepelumab	27	25 (92.6)	1.70 (1.40)	-0.8	0.75	1.50	2.75	3.8	0.73 [0.18, 1.27]
			Placebo	34	31 (91.2)	0.73 (1.29)	-1.3	0.00	0.25	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	27	23 (85.2)	3.76 (0.86)	1.8	3.00	4.00	4.25	5.0	
			Placebo	29	23 (79.3)	4.12 (1.29)	1.5	3.25	4.00	5.25	6.5	
		Week 4	Tezepelumab	27	26 (96.3)	4.53 (0.99)	2.0	3.75	4.75	5.25	6.0	
			Placebo	29	25 (86.2)	4.69 (1.34)	2.0	3.75	5.25	5.50	7.0	
		Week 8	Tezepelumab	27	26 (96.3)	4.78 (1.22)	1.0	4.25	4.88	5.75	6.5	
			Placebo	29	27 (93.1)	4.61 (1.45)	1.5	3.50	5.00	5.75	7.0	
		Week 12	Tezepelumab	27	26 (96.3)	5.01 (1.19)	1.0	4.50	5.00	5.50	7.0	
			Placebo	29	27 (93.1)	4.71 (1.29)	2.0	3.75	5.00	5.75	7.0	
		Week 16	Tezepelumab	27	26 (96.3)	5.01 (1.36)	1.0	4.50	5.00	6.00	7.0	
			Placebo	29	27 (93.1)	4.54 (1.58)	1.3	3.75	4.25	5.75	7.0	
		Week 20	Tezepelumab	27	26 (96.3)	4.87 (1.52)	1.0	4.00	5.00	6.00	7.0	
			Placebo	29	27 (93.1)	4.45 (1.63)	1.3	3.50	4.25	6.00	7.0	
		Week 24	Tezepelumab	27	26 (96.3)	4.98 (1.55)	1.0	4.25	5.00	6.25	7.0	
			Placebo	29	27 (93.1)	4.31 (1.70)	1.0	3.00	4.25	5.75	7.0	
		Week 28	Tezepelumab	27	27 (100.0)	4.93 (1.39)	1.0	4.50	5.00	6.00	7.0	
			Placebo	29	27 (93.1)	4.54 (1.71)	1.3	3.50	4.50	6.00	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	5.05 (1.49)	1.0	4.25	5.00	6.25	7.0	
			Placebo	29	27 (93.1)	4.49 (1.64)	1.3	3.25	4.50	6.00	7.0	
		Week 36	Tezepelumab	27	27 (100.0)	5.00 (1.46)	1.0	4.25	5.00	6.25	7.0	
			Placebo	29	27 (93.1)	4.32 (1.66)	1.0	3.25	4.25	5.50	7.0	
		Week 40	Tezepelumab	27	27 (100.0)	5.10 (1.28)	2.0	4.25	5.00	6.00	7.0	
			Placebo	29	27 (93.1)	4.53 (1.64)	1.0	3.50	4.75	5.75	7.0	
		Week 44	Tezepelumab	27	27 (100.0)	4.99 (1.37)	1.3	4.25	5.00	6.00	7.0	
			Placebo	29	27 (93.1)	4.51 (1.45)	1.3	3.50	4.25	5.75	7.0	
		Week 48	Tezepelumab	27	27 (100.0)	4.99 (1.42)	1.0	4.00	5.00	6.25	7.0	
			Placebo	29	27 (93.1)	4.46 (1.42)	1.0	4.00	4.25	5.25	7.0	
		Week 52	Tezepelumab	27	27 (100.0)	4.99 (1.38)	1.0	4.25	5.00	6.00	7.0	
			Placebo	29	27 (93.1)	4.56 (1.24)	2.0	4.00	4.25	5.25	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	0.78 (0.81)	-1.0	0.25	0.75	1.25	2.5	0.27 [-0.32, 0.86]
			Placebo	29	22 (75.9)	0.53 (1.01)	-1.3	-0.25	0.50	1.00	3.0	
		Week 8	Tezepelumab	27	23 (85.2)	0.93 (1.14)	-1.0	0.25	1.00	1.75	2.8	0.29 [-0.29, 0.87]
			Placebo	29	23 (79.3)	0.61 (1.09)	-1.3	-0.25	0.25	1.25	3.0	
		Week 12	Tezepelumab	27	23 (85.2)	1.14 (0.88)	-1.0	0.75	1.25	1.50	2.5	0.56 [-0.03, 1.15]
			Placebo	29	23 (79.3)	0.64 (0.91)	-1.3	0.00	0.75	1.25	2.8	
		Week 16	Tezepelumab	27	23 (85.2)	1.16 (1.09)	-0.8	0.50	1.25	2.00	3.3	0.69 [0.09, 1.29]
			Placebo	29	23 (79.3)	0.42 (1.05)	-1.8	0.00	0.50	1.00	2.8	
		Week 20	Tezepelumab	27	23 (85.2)	1.07 (1.21)	-1.8	0.00	1.25	1.75	3.5	0.55 [-0.04, 1.14]
			Placebo	29	23 (79.3)	0.39 (1.24)	-2.3	-0.25	0.50	1.25	3.0	
		Week 24	Tezepelumab	27	23 (85.2)	1.17 (1.23)	-1.5	0.25	1.50	2.00	3.3	0.71 [0.11, 1.30]
			Placebo	29	23 (79.3)	0.27 (1.32)	-2.8	-0.75	0.50	1.25	3.0	
		Week 28	Tezepelumab	27	23 (85.2)	1.18 (1.16)	-1.3	0.75	1.50	2.25	2.8	0.56 [-0.02, 1.15]
			Placebo	29	23 (79.3)	0.49 (1.30)	-1.8	-0.50	0.50	1.50	2.8	
		Week 32	Tezepelumab	27	23 (85.2)	1.34 (1.24)	-1.3	0.75	1.50	2.25	3.5	0.73 [0.13, 1.33]
			Placebo	29	23 (79.3)	0.50 (1.06)	-1.8	-0.25	0.75	1.00	3.0	
		Week 36	Tezepelumab	27	23 (85.2)	1.28 (1.22)	-1.0	0.50	1.50	2.25	3.3	0.80 [0.20, 1.40]
			Placebo	29	23 (79.3)	0.30 (1.23)	-2.8	-0.50	0.25	0.75	3.0	
		Week 40	Tezepelumab	27	23 (85.2)	1.36 (1.02)	-0.5	0.50	1.50	2.25	3.3	0.72 [0.12, 1.32]
			Placebo	29	23 (79.3)	0.50 (1.34)	-2.5	-0.50	0.50	1.50	3.0	
		Week 44	Tezepelumab	27	23 (85.2)	1.25 (1.14)	-1.5	0.75	1.50	2.00	3.0	0.70 [0.11, 1.30]
			Placebo	29	23 (79.3)	0.47 (1.09)	-1.3	-0.25	0.25	1.25	3.0	
		Week 48	Tezepelumab	27	23 (85.2)	1.28 (1.22)	-1.0	0.75	1.50	2.00	3.5	0.68 [0.08, 1.27]
			Placebo	29	23 (79.3)	0.41 (1.35)	-2.8	-0.25	0.50	1.25	3.0	
		Week 52	Tezepelumab	27	23 (85.2)	1.29 (1.13)	-0.8	0.75	1.50	2.00	3.5	0.68 [0.08, 1.27]
			Placebo	29	23 (79.3)	0.52 (1.15)	-1.3	-0.25	0.50	1.25	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	4.24 (1.10)	2.5	3.63	4.00	5.00	6.8	
			Placebo	33	29 (87.9)	4.53 (1.18)	2.0	3.50	4.50	5.50	7.0	
		Week 4	Tezepelumab	34	30 (88.2)	4.96 (1.23)	1.3	4.25	5.25	5.75	7.0	
			Placebo	33	29 (87.9)	4.97 (1.15)	2.3	4.50	5.00	5.50	7.0	
		Week 8	Tezepelumab	34	32 (94.1)	5.40 (1.08)	3.5	4.25	5.75	6.25	7.0	
			Placebo	33	29 (87.9)	5.14 (1.04)	2.3	4.75	5.25	5.75	7.0	
		Week 12	Tezepelumab	34	32 (94.1)	5.45 (1.12)	3.0	4.50	5.75	6.25	7.0	
			Placebo	33	29 (87.9)	5.06 (0.99)	2.5	4.50	5.25	5.75	7.0	
		Week 16	Tezepelumab	34	32 (94.1)	5.27 (1.12)	2.5	4.50	5.38	6.00	7.0	
			Placebo	33	29 (87.9)	5.11 (1.15)	2.0	4.50	5.00	5.75	7.0	
		Week 20	Tezepelumab	34	32 (94.1)	5.34 (1.03)	3.8	4.50	5.25	6.25	7.0	
			Placebo	33	29 (87.9)	5.11 (1.12)	2.3	4.75	5.25	5.75	7.0	
		Week 24	Tezepelumab	34	32 (94.1)	5.48 (1.04)	3.8	4.63	5.50	6.50	7.0	
			Placebo	33	29 (87.9)	5.15 (1.21)	2.0	4.75	5.25	5.75	7.0	
		Week 28	Tezepelumab	34	33 (97.1)	5.45 (1.18)	3.5	4.25	5.50	6.75	7.0	
			Placebo	33	30 (90.9)	5.36 (1.20)	1.8	4.75	5.38	6.00	7.0	
		Week 32	Tezepelumab	34	33 (97.1)	5.52 (1.11)	3.5	4.50	5.75	6.25	7.0	
			Placebo	33	30 (90.9)	5.47 (1.17)	2.3	4.75	5.63	6.25	7.0	
		Week 36	Tezepelumab	34	33 (97.1)	5.58 (1.02)	3.8	4.50	5.75	6.50	7.0	
			Placebo	33	30 (90.9)	5.28 (1.21)	1.8	4.75	5.25	6.25	7.0	
		Week 40	Tezepelumab	34	33 (97.1)	5.60 (1.02)	4.0	4.50	5.75	6.50	7.0	
			Placebo	33	30 (90.9)	5.43 (1.22)	1.8	4.75	5.63	6.50	7.0	
		Week 44	Tezepelumab	34	33 (97.1)	5.64 (1.03)	3.8	4.75	5.75	6.50	7.0	
			Placebo	33	30 (90.9)	5.43 (1.25)	2.0	4.75	5.63	6.50	7.0	
		Week 48	Tezepelumab	34	33 (97.1)	5.69 (1.01)	4.0	4.75	5.75	6.50	7.0	
			Placebo	33	30 (90.9)	5.40 (1.20)	2.0	4.75	5.63	6.25	7.0	
		Week 52	Tezepelumab	34	33 (97.1)	5.70 (1.03)	4.0	4.50	6.00	6.50	7.0	
			Placebo	33	30 (90.9)	5.46 (1.27)	1.8	4.75	5.63	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	34	29 (85.3)	0.72 (1.36)	-4.0	0.00	0.75	1.75	2.8	0.23 [-0.29, 0.74]
			Placebo	33	29 (87.9)	0.44 (1.12)	-2.0	-0.25	0.50	1.00	2.5	
		Week 8	Tezepelumab	34	31 (91.2)	1.16 (1.13)	-1.3	0.00	1.25	2.00	3.3	0.47 [-0.05, 0.98]
			Placebo	33	29 (87.9)	0.61 (1.23)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	34	31 (91.2)	1.23 (1.20)	-2.3	0.25	1.50	2.25	3.0	0.58 [0.07, 1.10]
			Placebo	33	29 (87.9)	0.53 (1.16)	-1.8	-0.25	0.50	1.00	3.0	
		Week 16	Tezepelumab	34	31 (91.2)	1.06 (1.32)	-2.8	0.00	0.75	2.25	3.0	0.39 [-0.12, 0.91]
			Placebo	33	29 (87.9)	0.59 (1.09)	-1.3	0.00	0.25	1.00	3.0	
		Week 20	Tezepelumab	34	31 (91.2)	1.13 (1.21)	-1.3	0.25	1.00	2.50	3.0	0.49 [-0.02, 1.01]
			Placebo	33	29 (87.9)	0.59 (0.97)	-1.3	0.00	0.25	1.25	2.5	
		Week 24	Tezepelumab	34	31 (91.2)	1.26 (1.21)	-1.3	0.25	1.50	2.25	3.5	0.53 [0.02, 1.05]
			Placebo	33	29 (87.9)	0.62 (1.17)	-1.5	0.00	0.25	1.25	3.8	
		Week 28	Tezepelumab	34	31 (91.2)	1.19 (1.30)	-1.5	0.25	1.25	2.25	3.3	0.30 [-0.21, 0.81]
			Placebo	33	29 (87.9)	0.80 (1.28)	-2.8	0.25	0.75	1.25	3.8	
		Week 32	Tezepelumab	34	31 (91.2)	1.26 (1.27)	-1.3	0.25	1.25	2.25	3.5	0.31 [-0.20, 0.82]
			Placebo	33	29 (87.9)	0.89 (1.10)	-1.5	0.25	0.75	1.50	3.8	
		Week 36	Tezepelumab	34	31 (91.2)	1.33 (1.26)	-1.3	0.25	1.50	2.25	3.5	0.51 [-0.00, 1.03]
			Placebo	33	29 (87.9)	0.70 (1.22)	-2.3	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	34	31 (91.2)	1.35 (1.26)	-1.3	0.25	1.50	2.25	3.3	0.40 [-0.11, 0.91]
			Placebo	33	29 (87.9)	0.86 (1.16)	-1.5	0.00	0.75	1.25	3.8	
		Week 44	Tezepelumab	34	31 (91.2)	1.40 (1.30)	-1.3	0.25	1.50	2.25	3.8	0.42 [-0.10, 0.93]
			Placebo	33	29 (87.9)	0.85 (1.34)	-1.5	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	34	31 (91.2)	1.44 (1.30)	-1.3	0.25	1.50	2.50	3.8	0.47 [-0.04, 0.98]
			Placebo	33	29 (87.9)	0.84 (1.29)	-1.3	0.00	0.50	1.00	3.8	
		Week 52	Tezepelumab	34	31 (91.2)	1.44 (1.30)	-1.3	0.25	1.50	2.50	3.8	0.43 [-0.08, 0.94]
			Placebo	33	29 (87.9)	0.88 (1.32)	-1.3	0.25	0.50	1.00	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	3.75 (1.01)	1.8	3.00	4.00	4.63	5.0	
			Placebo	14	11 (78.6)	4.14 (1.38)	1.5	3.25	4.25	4.75	6.5	
		Week 4	Tezepelumab	23	21 (91.3)	4.88 (1.19)	2.0	4.00	5.00	5.75	7.0	
			Placebo	14	10 (71.4)	4.80 (1.09)	2.3	4.25	5.25	5.50	5.8	
		Week 8	Tezepelumab	23	21 (91.3)	5.06 (1.24)	1.0	4.50	5.25	5.75	6.8	
			Placebo	14	11 (78.6)	4.55 (1.56)	1.5	3.75	4.75	5.75	6.5	
		Week 12	Tezepelumab	23	21 (91.3)	5.10 (1.34)	1.0	4.50	5.25	5.75	7.0	
			Placebo	14	11 (78.6)	4.45 (1.21)	2.3	3.50	4.25	5.50	6.3	
		Week 16	Tezepelumab	23	21 (91.3)	5.07 (1.27)	1.0	4.75	5.00	5.75	7.0	
			Placebo	14	11 (78.6)	4.05 (1.58)	1.3	3.25	4.25	5.25	6.5	
		Week 20	Tezepelumab	23	22 (95.7)	4.92 (1.18)	1.3	4.50	5.00	5.50	7.0	
			Placebo	14	11 (78.6)	4.05 (1.67)	1.3	2.50	4.50	5.25	6.5	
		Week 24	Tezepelumab	23	22 (95.7)	5.08 (1.30)	1.0	4.50	5.00	5.75	7.0	
			Placebo	14	11 (78.6)	3.77 (1.83)	1.0	2.00	4.25	5.25	7.0	
		Week 28	Tezepelumab	23	23 (100.0)	5.02 (1.27)	1.0	4.50	5.00	5.50	7.0	
			Placebo	14	11 (78.6)	3.93 (1.52)	1.3	2.50	4.00	5.25	6.0	
		Week 32	Tezepelumab	23	23 (100.0)	5.02 (1.29)	1.0	4.25	5.00	6.00	7.0	
			Placebo	14	11 (78.6)	4.16 (1.67)	1.3	3.75	4.50	5.25	6.8	
		Week 36	Tezepelumab	23	23 (100.0)	5.05 (1.30)	1.0	4.25	5.00	6.25	7.0	
			Placebo	14	11 (78.6)	4.11 (1.61)	1.0	3.00	4.25	5.25	6.8	
		Week 40	Tezepelumab	23	23 (100.0)	5.03 (1.23)	2.0	4.25	5.00	5.75	7.0	
			Placebo	14	11 (78.6)	4.30 (1.62)	1.0	3.50	4.50	5.50	6.5	
		Week 44	Tezepelumab	23	23 (100.0)	5.10 (1.23)	2.0	4.25	5.00	6.00	7.0	
			Placebo	14	11 (78.6)	4.18 (1.29)	1.3	3.50	4.25	5.25	6.0	
		Week 48	Tezepelumab	23	23 (100.0)	5.03 (1.33)	1.0	4.00	5.00	6.00	7.0	
			Placebo	14	11 (78.6)	4.30 (1.11)	2.0	3.75	4.25	5.25	6.0	
		Week 52	Tezepelumab	23	23 (100.0)	5.04 (1.29)	1.0	4.25	5.00	6.00	7.0	
			Placebo	14	11 (78.6)	4.52 (0.81)	3.5	4.00	4.25	5.25	6.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	1.21 (1.12)	-0.5	0.38	1.13	2.00	4.0	0.62 [-0.16, 1.39]
			Placebo	14	10 (71.4)	0.55 (0.97)	-1.3	0.00	0.63	1.00	2.0	
		Week 8	Tezepelumab	23	20 (87.0)	1.31 (1.28)	-0.8	0.38	1.38	2.13	4.3	0.72 [-0.04, 1.48]
			Placebo	14	11 (78.6)	0.41 (1.21)	-1.3	-0.25	0.25	1.25	3.0	
		Week 12	Tezepelumab	23	20 (87.0)	1.34 (1.29)	-1.0	0.50	1.38	2.25	4.8	0.87 [0.10, 1.64]
			Placebo	14	11 (78.6)	0.32 (0.90)	-1.3	-0.75	0.75	1.00	1.3	
		Week 16	Tezepelumab	23	20 (87.0)	1.34 (1.19)	-0.8	0.50	1.50	2.25	3.3	1.27 [0.47, 2.08]
			Placebo	14	11 (78.6)	-0.09 (0.98)	-1.8	-1.25	0.25	0.75	1.0	
		Week 20	Tezepelumab	23	20 (87.0)	1.13 (1.06)	-0.5	0.38	1.25	1.75	3.3	1.10 [0.31, 1.88]
			Placebo	14	11 (78.6)	-0.09 (1.21)	-2.3	-1.25	0.25	0.50	1.8	
		Week 24	Tezepelumab	23	20 (87.0)	1.30 (1.12)	-0.8	0.38	1.50	2.13	3.3	1.43 [0.61, 2.26]
			Placebo	14	11 (78.6)	-0.36 (1.23)	-2.8	-1.25	-0.25	1.00	1.0	
		Week 28	Tezepelumab	23	20 (87.0)	1.34 (1.13)	-0.8	0.63	1.50	2.13	3.3	1.35 [0.54, 2.16]
			Placebo	14	11 (78.6)	-0.20 (1.17)	-1.8	-1.25	0.00	0.50	2.0	
		Week 32	Tezepelumab	23	20 (87.0)	1.29 (1.14)	-0.8	0.50	1.50	2.25	3.3	1.19 [0.39, 1.99]
			Placebo	14	11 (78.6)	0.02 (0.90)	-1.8	-0.25	0.25	0.75	1.0	
		Week 36	Tezepelumab	23	20 (87.0)	1.31 (1.16)	-0.8	0.63	1.50	2.25	3.3	1.16 [0.37, 1.96]
			Placebo	14	11 (78.6)	-0.02 (1.12)	-2.8	-0.50	0.25	0.75	1.0	
		Week 40	Tezepelumab	23	20 (87.0)	1.38 (1.03)	-0.5	0.38	1.50	2.13	3.3	1.08 [0.29, 1.86]
			Placebo	14	11 (78.6)	0.16 (1.30)	-2.5	-0.50	0.50	1.00	2.3	
		Week 44	Tezepelumab	23	20 (87.0)	1.44 (1.17)	-1.0	0.50	1.50	2.25	3.3	1.31 [0.50, 2.12]
			Placebo	14	11 (78.6)	0.05 (0.82)	-1.3	-0.50	0.00	0.75	1.5	
		Week 48	Tezepelumab	23	20 (87.0)	1.38 (1.19)	-1.0	0.63	1.50	2.13	3.3	0.95 [0.18, 1.73]
			Placebo	14	11 (78.6)	0.16 (1.42)	-2.8	-1.00	0.25	1.00	2.5	
		Week 52	Tezepelumab	23	20 (87.0)	1.39 (1.09)	-0.8	0.63	1.50	2.00	3.3	0.92 [0.15, 1.70]
			Placebo	14	11 (78.6)	0.39 (1.07)	-1.3	-0.25	0.25	1.00	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	4.19 (1.04)	2.5	3.50	4.00	4.75	6.8	
			Placebo	44	37 (84.1)	4.49 (1.22)	2.0	3.75	4.50	5.50	7.0	
		Week 4	Tezepelumab	40	36 (90.0)	4.74 (1.13)	1.3	4.00	5.00	5.50	6.8	
			Placebo	44	40 (90.9)	4.89 (1.27)	2.0	4.13	5.00	5.75	7.0	
		Week 8	Tezepelumab	40	38 (95.0)	5.20 (1.11)	1.8	4.25	5.63	6.00	7.0	
			Placebo	44	41 (93.2)	5.01 (1.28)	2.3	4.50	5.25	5.75	7.0	
		Week 12	Tezepelumab	40	38 (95.0)	5.34 (1.03)	3.0	4.75	5.50	6.25	7.0	
			Placebo	44	41 (93.2)	4.99 (1.19)	2.0	4.25	5.00	5.75	7.0	
		Week 16	Tezepelumab	40	38 (95.0)	5.18 (1.16)	2.0	4.50	5.25	6.00	7.0	
			Placebo	44	41 (93.2)	5.05 (1.35)	1.8	4.25	5.25	6.25	7.0	
		Week 20	Tezepelumab	40	38 (95.0)	5.25 (1.26)	1.0	4.50	5.25	6.25	7.0	
			Placebo	44	41 (93.2)	5.02 (1.37)	2.0	4.00	5.00	6.25	7.0	
		Week 24	Tezepelumab	40	38 (95.0)	5.31 (1.25)	1.3	4.25	5.50	6.25	7.0	
			Placebo	44	41 (93.2)	5.07 (1.36)	1.8	4.50	5.25	6.00	7.0	
		Week 28	Tezepelumab	40	39 (97.5)	5.29 (1.24)	1.5	4.50	5.25	6.25	7.0	
			Placebo	44	42 (95.5)	5.24 (1.49)	1.3	4.25	5.50	6.50	7.0	
		Week 32	Tezepelumab	40	39 (97.5)	5.40 (1.25)	1.5	4.50	5.50	6.50	7.0	
			Placebo	44	42 (95.5)	5.25 (1.43)	2.3	4.00	5.50	6.25	7.0	
		Week 36	Tezepelumab	40	39 (97.5)	5.40 (1.19)	1.8	4.50	5.50	6.50	7.0	
			Placebo	44	42 (95.5)	5.05 (1.50)	1.5	4.00	5.25	6.25	7.0	
		Week 40	Tezepelumab	40	39 (97.5)	5.42 (1.08)	2.3	4.50	5.50	6.50	7.0	
			Placebo	44	42 (95.5)	5.19 (1.47)	1.5	4.25	5.38	6.50	7.0	
		Week 44	Tezepelumab	40	39 (97.5)	5.39 (1.17)	1.3	4.75	5.25	6.25	7.0	
			Placebo	44	42 (95.5)	5.24 (1.42)	2.0	4.00	5.38	6.50	7.0	
		Week 48	Tezepelumab	40	39 (97.5)	5.45 (1.11)	2.3	4.50	5.50	6.25	7.0	
			Placebo	44	42 (95.5)	5.20 (1.42)	1.0	4.25	5.13	6.25	7.0	
		Week 52	Tezepelumab	40	39 (97.5)	5.46 (1.13)	2.3	4.50	5.50	6.50	7.0	
			Placebo	44	42 (95.5)	5.23 (1.42)	1.8	4.25	5.25	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	40	32 (80.0)	0.51 (1.28)	-4.0	-0.13	0.63	1.50	2.8	0.07 [-0.40, 0.55]
			Placebo	44	37 (84.1)	0.43 (0.98)	-1.8	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	40	34 (85.0)	0.96 (1.19)	-1.3	0.00	0.63	2.00	3.3	0.28 [-0.18, 0.75]
			Placebo	44	37 (84.1)	0.63 (1.18)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	40	34 (85.0)	1.13 (1.10)	-2.3	0.25	1.00	2.00	3.0	0.53 [0.05, 1.00]
			Placebo	44	37 (84.1)	0.55 (1.06)	-1.8	-0.25	0.50	1.25	2.8	
		Week 16	Tezepelumab	40	34 (85.0)	0.96 (1.26)	-2.8	0.00	0.75	2.00	3.0	0.30 [-0.17, 0.77]
			Placebo	44	37 (84.1)	0.62 (1.00)	-1.3	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	40	34 (85.0)	1.09 (1.33)	-1.8	0.00	1.00	2.25	3.5	0.39 [-0.08, 0.86]
			Placebo	44	37 (84.1)	0.63 (1.00)	-1.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	40	34 (85.0)	1.16 (1.31)	-1.5	0.25	1.25	2.25	3.5	0.38 [-0.09, 0.85]
			Placebo	44	37 (84.1)	0.70 (1.11)	-1.5	0.00	0.75	1.50	3.8	
		Week 28	Tezepelumab	40	34 (85.0)	1.09 (1.32)	-1.5	0.00	0.88	2.25	3.3	0.19 [-0.28, 0.66]
			Placebo	44	37 (84.1)	0.84 (1.23)	-2.8	0.25	0.75	1.50	3.8	
		Week 32	Tezepelumab	40	34 (85.0)	1.23 (1.34)	-1.3	0.25	1.25	2.25	3.5	0.30 [-0.17, 0.76]
			Placebo	44	37 (84.1)	0.87 (1.06)	-1.5	0.25	0.75	1.50	3.8	
		Week 36	Tezepelumab	40	34 (85.0)	1.22 (1.29)	-1.3	0.25	1.13	2.25	3.3	0.46 [-0.01, 0.93]
			Placebo	44	37 (84.1)	0.65 (1.21)	-2.3	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	40	34 (85.0)	1.23 (1.20)	-1.3	0.25	1.13	2.00	3.3	0.37 [-0.10, 0.84]
			Placebo	44	37 (84.1)	0.78 (1.19)	-1.5	0.00	0.75	1.50	3.8	
		Week 44	Tezepelumab	40	34 (85.0)	1.22 (1.25)	-1.5	0.25	1.00	2.25	3.8	0.30 [-0.16, 0.77]
			Placebo	44	37 (84.1)	0.84 (1.27)	-1.5	0.00	0.75	1.25	3.8	
		Week 48	Tezepelumab	40	34 (85.0)	1.26 (1.23)	-1.3	0.25	1.13	2.25	3.5	0.38 [-0.09, 0.85]
			Placebo	44	37 (84.1)	0.79 (1.24)	-1.5	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	40	34 (85.0)	1.26 (1.23)	-1.3	0.25	1.00	2.25	3.5	0.37 [-0.10, 0.84]
			Placebo	44	37 (84.1)	0.80 (1.27)	-1.3	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.25 (1.30)	2.5	2.50	2.50	4.75	4.8	
			Placebo	7	7 (100.0)	4.18 (0.99)	3.3	3.25	3.75	5.00	5.8	
		Week 4	Tezepelumab	3	3 (100.0)	4.92 (0.72)	4.5	4.50	4.50	5.75	5.8	
			Placebo	7	7 (100.0)	4.61 (1.13)	2.5	3.75	4.75	5.50	5.5	
		Week 8	Tezepelumab	3	3 (100.0)	5.25 (1.52)	4.3	4.25	4.50	7.00	7.0	
			Placebo	7	7 (100.0)	4.93 (0.86)	3.8	4.00	5.00	5.50	6.3	
		Week 12	Tezepelumab	3	3 (100.0)	5.58 (1.28)	4.5	4.50	5.25	7.00	7.0	
			Placebo	7	7 (100.0)	5.25 (0.69)	4.3	4.50	5.25	5.75	6.3	
		Week 16	Tezepelumab	3	3 (100.0)	5.58 (1.38)	4.3	4.25	5.50	7.00	7.0	
			Placebo	7	7 (100.0)	5.18 (0.70)	4.0	5.00	5.00	5.75	6.3	
		Week 20	Tezepelumab	3	3 (100.0)	5.25 (1.64)	3.8	3.75	5.00	7.00	7.0	
			Placebo	7	7 (100.0)	5.04 (0.74)	3.5	5.00	5.00	5.50	5.8	
		Week 24	Tezepelumab	3	3 (100.0)	5.33 (1.53)	4.0	4.00	5.00	7.00	7.0	
			Placebo	7	7 (100.0)	4.82 (1.19)	2.5	4.50	5.00	5.75	6.3	
		Week 28	Tezepelumab	3	3 (100.0)	5.50 (1.39)	4.3	4.25	5.25	7.00	7.0	
			Placebo	7	7 (100.0)	5.21 (0.59)	4.5	4.50	5.25	5.75	6.0	
		Week 32	Tezepelumab	3	3 (100.0)	5.67 (1.53)	4.0	4.00	6.00	7.00	7.0	
			Placebo	7	7 (100.0)	5.18 (0.92)	3.3	5.00	5.25	5.75	6.0	
		Week 36	Tezepelumab	3	3 (100.0)	6.00 (1.00)	5.0	5.00	6.00	7.00	7.0	
			Placebo	7	7 (100.0)	5.00 (1.02)	3.0	4.75	5.00	5.75	6.3	
		Week 40	Tezepelumab	3	3 (100.0)	6.08 (0.80)	5.5	5.50	5.75	7.00	7.0	
			Placebo	7	7 (100.0)	5.29 (1.01)	3.3	5.00	5.50	5.75	6.5	
		Week 44	Tezepelumab	3	3 (100.0)	6.17 (0.88)	5.3	5.25	6.25	7.00	7.0	
			Placebo	7	7 (100.0)	5.11 (1.13)	3.3	4.00	5.50	5.75	6.5	
		Week 48	Tezepelumab	3	3 (100.0)	6.42 (0.52)	6.0	6.00	6.25	7.00	7.0	
			Placebo	7	7 (100.0)	4.93 (1.23)	3.0	4.50	4.75	5.75	7.0	
		Week 52	Tezepelumab	3	3 (100.0)	6.42 (0.52)	6.0	6.00	6.25	7.00	7.0	
			Placebo	7	7 (100.0)	5.00 (1.23)	3.0	4.50	5.00	5.75	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.67 (0.58)	1.0	1.00	2.00	2.00	2.0	0.92 [-0.51, 2.34]
			Placebo	7	7 (100.0)	0.43 (1.53)	-2.0	-0.75	0.75	2.00	2.3	
		Week 8	Tezepelumab	3	3 (100.0)	2.00 (0.25)	1.8	1.75	2.00	2.25	2.3	1.19 [-0.29, 2.66]
			Placebo	7	7 (100.0)	0.75 (1.21)	-0.3	0.00	0.00	1.75	3.0	
		Week 12	Tezepelumab	3	3 (100.0)	2.33 (0.38)	2.0	2.00	2.25	2.75	2.8	1.23 [-0.25, 2.71]
			Placebo	7	7 (100.0)	1.07 (1.16)	-0.5	0.00	1.00	1.75	3.0	
		Week 16	Tezepelumab	3	3 (100.0)	2.33 (0.63)	1.8	1.75	2.25	3.00	3.0	1.33 [-0.17, 2.83]
			Placebo	7	7 (100.0)	1.00 (1.10)	0.0	0.00	0.75	1.75	3.0	
		Week 20	Tezepelumab	3	3 (100.0)	2.00 (0.66)	1.3	1.25	2.25	2.50	2.5	1.27 [-0.22, 2.76]
			Placebo	7	7 (100.0)	0.86 (0.97)	0.0	0.00	0.25	2.00	2.3	
		Week 24	Tezepelumab	3	3 (100.0)	2.08 (0.52)	1.5	1.50	2.25	2.50	2.5	1.26 [-0.23, 2.74]
			Placebo	7	7 (100.0)	0.64 (1.29)	-0.8	-0.25	0.00	1.50	3.0	
		Week 28	Tezepelumab	3	3 (100.0)	2.25 (0.50)	1.8	1.75	2.25	2.75	2.8	1.19 [-0.28, 2.67]
			Placebo	7	7 (100.0)	1.04 (1.14)	-0.3	0.00	1.00	2.25	2.8	
		Week 32	Tezepelumab	3	3 (100.0)	2.42 (1.01)	1.5	1.50	2.25	3.50	3.5	1.39 [-0.12, 2.91]
			Placebo	7	7 (100.0)	1.00 (1.02)	0.0	0.00	1.00	1.75	2.8	
		Week 36	Tezepelumab	3	3 (100.0)	2.75 (0.66)	2.3	2.25	2.50	3.50	3.5	1.81 [0.19, 3.43]
			Placebo	7	7 (100.0)	0.82 (1.17)	-0.3	0.00	0.25	1.50	3.0	
		Week 40	Tezepelumab	3	3 (100.0)	2.83 (0.52)	2.3	2.25	3.00	3.25	3.3	1.70 [0.11, 3.29]
			Placebo	7	7 (100.0)	1.11 (1.14)	0.0	0.00	0.75	1.75	3.3	
		Week 44	Tezepelumab	3	3 (100.0)	2.92 (0.76)	2.3	2.25	2.75	3.75	3.8	1.69 [0.10, 3.27]
			Placebo	7	7 (100.0)	0.93 (1.29)	0.0	0.00	0.25	2.25	3.3	
		Week 48	Tezepelumab	3	3 (100.0)	3.17 (0.80)	2.3	2.25	3.50	3.75	3.8	1.88 [0.25, 3.52]
			Placebo	7	7 (100.0)	0.75 (1.41)	-0.3	-0.25	0.25	1.00	3.8	
		Week 52	Tezepelumab	3	3 (100.0)	3.17 (0.80)	2.3	2.25	3.50	3.75	3.8	1.89 [0.25, 3.52]
			Placebo	7	7 (100.0)	0.82 (1.36)	-0.3	0.00	0.25	1.00	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.94 (1.25)	1.8	3.13	4.13	4.75	5.8	
			Placebo	13	9 (69.2)	5.14 (1.11)	3.5	4.50	4.75	5.75	7.0	
		Week 4	Tezepelumab	9	8 (88.9)	4.88 (1.26)	2.0	4.63	5.38	5.63	5.8	
			Placebo	13	11 (84.6)	5.27 (0.96)	3.5	5.25	5.25	5.75	7.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.25 (1.80)	1.0	5.38	5.63	6.00	7.0	
			Placebo	13	12 (92.3)	4.85 (1.00)	3.0	4.25	5.13	5.38	6.5	
		Week 12	Tezepelumab	9	8 (88.9)	5.31 (1.85)	1.0	5.38	5.50	6.38	7.0	
			Placebo	13	12 (92.3)	5.06 (0.86)	3.5	4.50	5.50	5.63	5.8	
		Week 16	Tezepelumab	9	8 (88.9)	5.41 (1.92)	1.0	5.38	5.50	6.75	7.0	
			Placebo	13	12 (92.3)	5.13 (1.05)	3.3	4.25	5.25	5.75	7.0	
		Week 20	Tezepelumab	9	8 (88.9)	4.94 (1.88)	1.3	3.88	5.50	6.25	7.0	
			Placebo	13	12 (92.3)	5.02 (1.28)	2.5	4.25	5.13	5.88	7.0	
		Week 24	Tezepelumab	9	8 (88.9)	5.13 (1.86)	1.0	4.75	5.50	6.38	6.8	
			Placebo	13	12 (92.3)	4.81 (1.47)	2.0	4.00	4.75	5.88	7.0	
		Week 28	Tezepelumab	9	8 (88.9)	5.25 (1.86)	1.0	5.00	5.88	6.13	7.0	
			Placebo	13	13 (100.0)	5.08 (1.22)	3.0	4.50	4.75	6.00	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.09 (1.89)	1.0	4.50	5.50	6.38	7.0	
			Placebo	13	13 (100.0)	5.33 (1.21)	3.0	4.50	5.25	6.00	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.16 (1.95)	1.0	4.63	5.63	6.38	7.0	
			Placebo	13	13 (100.0)	5.08 (1.53)	2.0	4.50	5.00	6.25	7.0	
		Week 40	Tezepelumab	9	8 (88.9)	5.44 (1.56)	2.0	5.13	5.75	6.38	7.0	
			Placebo	13	13 (100.0)	5.12 (1.41)	2.3	4.50	5.25	6.00	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.44 (1.53)	2.0	5.13	5.88	6.38	6.8	
			Placebo	13	13 (100.0)	5.38 (1.24)	3.0	4.50	5.25	6.50	7.0	
		Week 48	Tezepelumab	9	8 (88.9)	5.25 (1.86)	1.0	5.00	5.88	6.13	7.0	
			Placebo	13	13 (100.0)	5.06 (1.46)	2.0	4.50	5.00	6.00	7.0	
		Week 52	Tezepelumab	9	8 (88.9)	5.25 (1.84)	1.0	5.00	5.88	6.38	6.5	
			Placebo	13	13 (100.0)	5.25 (1.24)	3.0	4.50	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	1.07 (0.84)	0.0	0.25	1.25	1.50	2.5	0.77 [-0.26, 1.80]
			Placebo	13	9 (69.2)	0.25 (1.21)	-2.0	0.00	0.50	0.75	2.0	
		Week 8	Tezepelumab	9	7 (77.8)	1.39 (1.34)	-0.8	0.00	1.75	2.25	3.0	1.05 [-0.01, 2.11]
			Placebo	13	9 (69.2)	0.06 (1.23)	-1.8	-1.00	0.00	1.25	1.8	
		Week 12	Tezepelumab	9	7 (77.8)	1.50 (1.27)	-0.8	0.50	2.00	2.25	3.0	1.14 [0.07, 2.22]
			Placebo	13	9 (69.2)	0.14 (1.13)	-1.8	-0.75	0.25	1.00	1.8	
		Week 16	Tezepelumab	9	7 (77.8)	1.64 (1.60)	-0.8	-0.25	2.50	3.00	3.3	1.09 [0.03, 2.16]
			Placebo	13	9 (69.2)	0.19 (1.07)	-1.5	0.00	0.25	1.00	1.8	
		Week 20	Tezepelumab	9	7 (77.8)	1.29 (1.33)	-0.5	0.00	1.25	2.50	2.8	0.82 [-0.21, 1.85]
			Placebo	13	9 (69.2)	0.19 (1.33)	-2.3	0.00	0.25	1.25	2.0	
		Week 24	Tezepelumab	9	7 (77.8)	1.46 (1.29)	-0.8	0.25	2.00	2.50	2.8	1.03 [-0.03, 2.09]
			Placebo	13	9 (69.2)	0.06 (1.41)	-2.8	-0.25	0.00	1.50	1.5	
		Week 28	Tezepelumab	9	7 (77.8)	1.57 (1.46)	-0.8	0.00	2.25	2.75	3.0	1.11 [0.04, 2.18]
			Placebo	13	9 (69.2)	0.17 (1.10)	-1.3	-0.25	0.00	0.75	2.3	
		Week 32	Tezepelumab	9	7 (77.8)	1.43 (1.32)	-0.8	0.25	1.50	2.50	3.0	0.81 [-0.22, 1.84]
			Placebo	13	9 (69.2)	0.50 (1.00)	-1.3	0.00	0.25	1.50	1.8	
		Week 36	Tezepelumab	9	7 (77.8)	1.57 (1.39)	-0.8	0.25	2.25	2.75	3.0	0.99 [-0.07, 2.04]
			Placebo	13	9 (69.2)	0.14 (1.50)	-2.8	0.00	0.25	1.00	2.5	
		Week 40	Tezepelumab	9	7 (77.8)	1.75 (1.25)	0.0	0.25	2.25	2.75	3.0	1.16 [0.08, 2.24]
			Placebo	13	9 (69.2)	0.19 (1.40)	-2.5	0.00	0.25	0.75	2.0	
		Week 44	Tezepelumab	9	7 (77.8)	1.75 (1.35)	0.0	0.25	2.00	2.75	3.8	0.95 [-0.10, 2.00]
			Placebo	13	9 (69.2)	0.53 (1.24)	-1.3	0.00	0.25	1.25	2.5	
		Week 48	Tezepelumab	9	7 (77.8)	1.57 (1.40)	-0.8	0.25	2.00	2.75	3.0	1.04 [-0.02, 2.10]
			Placebo	13	9 (69.2)	0.08 (1.46)	-2.8	0.00	0.25	0.75	2.5	
		Week 52	Tezepelumab	9	7 (77.8)	1.57 (1.40)	-0.8	0.25	2.00	2.75	3.0	1.01 [-0.05, 2.07]
			Placebo	13	9 (69.2)	0.36 (1.02)	-1.3	0.00	0.25	0.75	2.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.00 (1.04)	1.8	3.50	4.00	4.75	6.8	
			Placebo	52	46 (88.5)	4.23 (1.19)	1.5	3.25	4.00	5.25	6.3	
		Week 4	Tezepelumab	57	52 (91.2)	4.79 (1.11)	1.3	4.00	4.88	5.75	7.0	
			Placebo	52	46 (88.5)	4.74 (1.24)	2.0	4.00	4.75	5.50	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.14 (1.05)	1.8	4.25	5.00	6.00	7.0	
			Placebo	52	47 (90.4)	4.93 (1.36)	1.5	4.00	5.00	6.00	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.26 (1.02)	3.0	4.50	5.25	6.00	7.0	
			Placebo	52	47 (90.4)	4.88 (1.23)	2.0	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.13 (1.06)	2.0	4.50	5.00	6.00	7.0	
			Placebo	52	47 (90.4)	4.82 (1.46)	1.3	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.16 (1.13)	1.0	4.50	5.00	6.00	7.0	
			Placebo	52	47 (90.4)	4.80 (1.45)	1.3	4.00	5.00	5.75	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.25 (1.17)	1.3	4.50	5.00	6.25	7.0	
			Placebo	52	47 (90.4)	4.79 (1.52)	1.0	4.25	5.00	5.75	7.0	
		Week 28	Tezepelumab	57	57 (100.0)	5.20 (1.16)	1.5	4.50	5.00	6.25	7.0	
			Placebo	52	47 (90.4)	4.98 (1.57)	1.3	4.00	5.25	6.00	7.0	
		Week 32	Tezepelumab	57	57 (100.0)	5.31 (1.18)	1.5	4.50	5.00	6.00	7.0	
			Placebo	52	47 (90.4)	4.96 (1.53)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	57	57 (100.0)	5.32 (1.12)	1.8	4.50	5.00	6.25	7.0	
			Placebo	52	47 (90.4)	4.81 (1.50)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	57	57 (100.0)	5.30 (1.08)	2.3	4.50	5.00	6.00	7.0	
			Placebo	52	47 (90.4)	5.02 (1.51)	1.0	4.00	5.25	6.25	7.0	
		Week 44	Tezepelumab	57	57 (100.0)	5.31 (1.15)	1.3	4.50	5.25	6.25	7.0	
			Placebo	52	47 (90.4)	4.94 (1.45)	1.3	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	57	57 (100.0)	5.36 (1.11)	2.3	4.50	5.25	6.25	7.0	
			Placebo	52	47 (90.4)	4.98 (1.36)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	57	57 (100.0)	5.37 (1.10)	2.3	4.50	5.25	6.25	7.0	
			Placebo	52	47 (90.4)	5.02 (1.35)	1.8	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	0.79 (1.29)	-4.0	0.00	0.75	1.75	4.0	0.26 [-0.15, 0.67]
			Placebo	52	45 (86.5)	0.49 (1.01)	-1.8	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	57	50 (87.7)	1.11 (1.20)	-1.3	0.25	1.00	2.00	4.3	0.34 [-0.06, 0.74]
			Placebo	52	46 (88.5)	0.71 (1.14)	-1.5	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	57	50 (87.7)	1.23 (1.16)	-2.3	0.25	1.25	2.00	4.8	0.52 [0.11, 0.93]
			Placebo	52	46 (88.5)	0.66 (1.02)	-1.3	0.00	0.75	1.25	3.0	
		Week 16	Tezepelumab	57	50 (87.7)	1.10 (1.18)	-2.8	0.25	1.00	2.00	3.0	0.46 [0.05, 0.86]
			Placebo	52	46 (88.5)	0.59 (1.03)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	57	50 (87.7)	1.13 (1.21)	-1.8	0.25	1.13	2.00	3.5	0.49 [0.09, 0.90]
			Placebo	52	46 (88.5)	0.58 (1.01)	-1.8	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	57	50 (87.7)	1.23 (1.22)	-1.5	0.25	1.50	2.25	3.5	0.56 [0.15, 0.96]
			Placebo	52	46 (88.5)	0.57 (1.17)	-1.8	-0.25	0.50	1.25	3.8	
		Week 28	Tezepelumab	57	50 (87.7)	1.19 (1.22)	-1.5	0.25	1.38	2.25	3.3	0.35 [-0.06, 0.75]
			Placebo	52	46 (88.5)	0.76 (1.28)	-2.8	0.25	0.75	1.50	3.8	
		Week 32	Tezepelumab	57	50 (87.7)	1.30 (1.27)	-1.3	0.25	1.50	2.25	3.5	0.45 [0.04, 0.86]
			Placebo	52	46 (88.5)	0.76 (1.08)	-1.8	0.00	0.75	1.25	3.8	
		Week 36	Tezepelumab	57	50 (87.7)	1.30 (1.24)	-1.3	0.25	1.50	2.25	3.5	0.57 [0.17, 0.98]
			Placebo	52	46 (88.5)	0.61 (1.14)	-2.3	0.00	0.38	1.25	3.8	
		Week 40	Tezepelumab	57	50 (87.7)	1.31 (1.15)	-1.3	0.25	1.50	2.00	3.3	0.44 [0.04, 0.85]
			Placebo	52	46 (88.5)	0.80 (1.17)	-1.5	0.00	0.75	1.25	3.8	
		Week 44	Tezepelumab	57	50 (87.7)	1.34 (1.23)	-1.5	0.50	1.50	2.25	3.8	0.50 [0.09, 0.90]
			Placebo	52	46 (88.5)	0.72 (1.23)	-1.5	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	57	50 (87.7)	1.38 (1.25)	-1.3	0.50	1.50	2.25	3.8	0.49 [0.08, 0.89]
			Placebo	52	46 (88.5)	0.77 (1.25)	-1.5	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	57	50 (87.7)	1.39 (1.21)	-1.3	0.50	1.50	2.25	3.8	0.48 [0.07, 0.88]
			Placebo	52	46 (88.5)	0.79 (1.27)	-1.3	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	4.17 (0.96)	2.8	4.00	4.13	4.25	5.8	
			Placebo	3	2 (66.7)	4.13 (0.88)	3.5	3.50	4.13	4.75	4.8	
		Week 4	Tezepelumab	7	7 (100.0)	4.39 (1.29)	3.0	3.25	4.50	5.75	6.3	
			Placebo	3	3 (100.0)	4.75 (1.09)	3.5	3.50	5.25	5.50	5.5	
		Week 8	Tezepelumab	7	7 (100.0)	4.75 (1.51)	1.8	4.25	5.00	5.75	6.3	
			Placebo	3	3 (100.0)	4.58 (1.66)	3.5	3.50	3.75	6.50	6.5	
		Week 12	Tezepelumab	7	7 (100.0)	5.18 (1.01)	3.5	4.75	5.25	6.25	6.5	
			Placebo	3	3 (100.0)	4.50 (1.09)	3.8	3.75	4.00	5.75	5.8	
		Week 16	Tezepelumab	7	7 (100.0)	4.71 (1.42)	2.0	4.50	4.75	5.50	6.8	
			Placebo	3	3 (100.0)	3.83 (0.52)	3.3	3.25	4.00	4.25	4.3	
		Week 20	Tezepelumab	7	7 (100.0)	4.32 (1.61)	1.0	3.50	5.00	5.00	5.8	
			Placebo	3	3 (100.0)	3.33 (0.76)	2.5	2.50	3.50	4.00	4.0	
		Week 24	Tezepelumab	7	7 (100.0)	4.64 (1.68)	1.3	3.75	5.00	6.00	6.0	
			Placebo	3	3 (100.0)	3.33 (1.18)	2.0	2.00	3.75	4.25	4.3	
		Week 28	Tezepelumab	7	7 (100.0)	4.50 (1.44)	1.5	4.00	5.00	5.50	5.8	
			Placebo	3	3 (100.0)	3.83 (0.38)	3.5	3.50	3.75	4.25	4.3	
		Week 32	Tezepelumab	7	7 (100.0)	4.61 (1.51)	1.5	4.00	5.00	5.50	6.0	
			Placebo	3	3 (100.0)	4.25 (0.43)	3.8	3.75	4.50	4.50	4.5	
		Week 36	Tezepelumab	7	7 (100.0)	4.39 (1.35)	1.8	4.00	4.50	5.25	6.0	
			Placebo	3	3 (100.0)	3.25 (1.09)	2.0	2.00	3.75	4.00	4.0	
		Week 40	Tezepelumab	7	7 (100.0)	4.64 (1.14)	2.3	4.25	5.00	5.25	5.8	
			Placebo	3	3 (100.0)	3.42 (1.01)	2.3	2.25	4.00	4.00	4.0	
		Week 44	Tezepelumab	7	7 (100.0)	4.39 (1.46)	1.3	4.25	4.75	5.00	5.8	
			Placebo	3	3 (100.0)	4.33 (0.88)	3.5	3.50	4.25	5.25	5.3	
		Week 48	Tezepelumab	7	7 (100.0)	4.54 (1.30)	2.3	3.75	5.00	5.75	6.0	
			Placebo	3	3 (100.0)	3.58 (1.42)	2.0	2.00	4.00	4.75	4.8	
		Week 52	Tezepelumab	7	7 (100.0)	4.54 (1.30)	2.3	3.75	5.00	5.75	6.0	
			Placebo	3	3 (100.0)	4.33 (0.29)	4.0	4.00	4.50	4.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	0.42 (0.92)	-0.8	0.00	0.25	0.75	2.0	-0.88 [-2.56, 0.79]
			Placebo	3	2 (66.7)	1.25 (1.06)	0.5	0.50	1.25	2.00	2.0	
		Week 8	Tezepelumab	7	6 (85.7)	0.54 (1.13)	-1.0	0.00	0.25	1.75	2.0	-0.30 [-1.90, 1.31]
			Placebo	3	2 (66.7)	1.00 (2.83)	-1.0	-1.00	1.00	3.00	3.0	
		Week 12	Tezepelumab	7	6 (85.7)	1.00 (0.67)	0.5	0.50	0.75	1.25	2.3	0.40 [-1.22, 2.01]
			Placebo	3	2 (66.7)	0.75 (0.35)	0.5	0.50	0.75	1.00	1.0	
		Week 16	Tezepelumab	7	6 (85.7)	0.54 (1.11)	-0.8	-0.25	0.50	0.75	2.5	0.76 [-0.90, 2.42]
			Placebo	3	2 (66.7)	-0.38 (1.59)	-1.5	-1.50	-0.38	0.75	0.8	
		Week 20	Tezepelumab	7	6 (85.7)	0.04 (1.04)	-1.8	-0.50	0.38	0.75	1.0	0.74 [-0.91, 2.39]
			Placebo	3	2 (66.7)	-0.88 (1.94)	-2.3	-2.25	-0.88	0.50	0.5	
		Week 24	Tezepelumab	7	6 (85.7)	0.42 (1.22)	-1.5	-0.25	0.50	1.25	2.0	1.18 [-0.55, 2.91]
			Placebo	3	2 (66.7)	-1.25 (2.12)	-2.8	-2.75	-1.25	0.25	0.3	
		Week 28	Tezepelumab	7	6 (85.7)	0.29 (0.91)	-1.3	0.00	0.38	1.00	1.3	0.84 [-0.83, 2.51]
			Placebo	3	2 (66.7)	-0.50 (1.06)	-1.3	-1.25	-0.50	0.25	0.3	
		Week 32	Tezepelumab	7	6 (85.7)	0.42 (0.97)	-1.3	0.00	0.63	1.25	1.3	0.46 [-1.16, 2.09]
			Placebo	3	2 (66.7)	0.00 (0.35)	-0.3	-0.25	0.00	0.25	0.3	
		Week 36	Tezepelumab	7	6 (85.7)	0.25 (0.71)	-1.0	0.00	0.38	0.75	1.0	1.21 [-0.53, 2.95]
			Placebo	3	2 (66.7)	-1.13 (2.30)	-2.8	-2.75	-1.13	0.50	0.5	
		Week 40	Tezepelumab	7	6 (85.7)	0.42 (0.61)	-0.5	0.00	0.50	1.00	1.0	1.38 [-0.40, 3.16]
			Placebo	3	2 (66.7)	-1.00 (2.12)	-2.5	-2.50	-1.00	0.50	0.5	
		Week 44	Tezepelumab	7	6 (85.7)	0.25 (0.92)	-1.5	0.00	0.63	0.75	1.0	0.59 [-1.05, 2.22]
			Placebo	3	2 (66.7)	-0.25 (0.35)	-0.5	-0.50	-0.25	0.00	0.0	
		Week 48	Tezepelumab	7	6 (85.7)	0.46 (0.77)	-0.5	-0.25	0.50	1.00	1.5	1.35 [-0.42, 3.13]
			Placebo	3	2 (66.7)	-1.13 (2.30)	-2.8	-2.75	-1.13	0.50	0.5	
		Week 52	Tezepelumab	7	6 (85.7)	0.46 (0.77)	-0.5	-0.25	0.50	1.00	1.5	0.46 [-1.17, 2.08]
			Placebo	3	2 (66.7)	0.13 (0.53)	-0.3	-0.25	0.13	0.50	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	59	52 (88.1)	3.97 (1.07)	1.8	3.25	4.00	4.75	6.8	
			Placebo	62	53 (85.5)	4.39 (1.23)	1.5	3.50	4.25	5.50	7.0	
		Week 4	Tezepelumab	59	53 (89.8)	4.85 (1.10)	1.3	4.25	5.00	5.75	7.0	
			Placebo	62	54 (87.1)	4.85 (1.22)	2.0	4.25	5.00	5.50	7.0	
		Week 8	Tezepelumab	59	55 (93.2)	5.20 (1.11)	1.0	4.25	5.50	6.00	7.0	
			Placebo	62	56 (90.3)	4.93 (1.28)	1.5	4.13	5.13	5.75	7.0	
		Week 12	Tezepelumab	59	55 (93.2)	5.28 (1.16)	1.0	4.50	5.50	6.25	7.0	
			Placebo	62	56 (90.3)	4.94 (1.16)	2.0	4.25	5.00	5.75	7.0	
		Week 16	Tezepelumab	59	55 (93.2)	5.22 (1.16)	1.0	4.50	5.25	6.00	7.0	
			Placebo	62	56 (90.3)	4.94 (1.39)	1.3	4.13	5.00	5.88	7.0	
		Week 20	Tezepelumab	59	56 (94.9)	5.24 (1.16)	1.3	4.50	5.13	6.13	7.0	
			Placebo	62	56 (90.3)	4.92 (1.39)	1.3	4.00	5.00	5.88	7.0	
		Week 24	Tezepelumab	59	56 (94.9)	5.30 (1.20)	1.0	4.50	5.13	6.38	7.0	
			Placebo	62	56 (90.3)	4.88 (1.48)	1.0	4.25	5.00	5.75	7.0	
		Week 28	Tezepelumab	59	58 (98.3)	5.29 (1.21)	1.0	4.50	5.13	6.25	7.0	
			Placebo	62	57 (91.9)	5.06 (1.51)	1.3	4.50	5.25	6.00	7.0	
		Week 32	Tezepelumab	59	58 (98.3)	5.36 (1.23)	1.0	4.50	5.38	6.25	7.0	
			Placebo	62	57 (91.9)	5.08 (1.49)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	59	58 (98.3)	5.41 (1.18)	1.0	4.50	5.50	6.50	7.0	
			Placebo	62	57 (91.9)	4.96 (1.47)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	59	58 (98.3)	5.40 (1.12)	2.0	4.50	5.50	6.50	7.0	
			Placebo	62	57 (91.9)	5.12 (1.45)	1.0	4.50	5.25	6.25	7.0	
		Week 44	Tezepelumab	59	58 (98.3)	5.44 (1.11)	2.0	4.50	5.25	6.25	7.0	
			Placebo	62	57 (91.9)	5.07 (1.43)	1.3	4.00	5.25	6.25	7.0	
		Week 48	Tezepelumab	59	58 (98.3)	5.44 (1.17)	1.0	4.50	5.50	6.25	7.0	
			Placebo	62	57 (91.9)	5.07 (1.34)	1.0	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	59	58 (98.3)	5.45 (1.16)	1.0	4.50	5.50	6.50	7.0	
			Placebo	62	57 (91.9)	5.11 (1.34)	1.8	4.25	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	59	49 (83.1)	0.88 (1.28)	-4.0	0.00	1.00	1.75	4.0	0.40 [0.00, 0.79]
			Placebo	62	52 (83.9)	0.42 (1.04)	-2.0	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	59	51 (86.4)	1.21 (1.21)	-1.3	0.25	1.25	2.25	4.3	0.54 [0.15, 0.93]
			Placebo	62	53 (85.5)	0.58 (1.12)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	59	51 (86.4)	1.29 (1.22)	-2.3	0.25	1.50	2.25	4.8	0.64 [0.24, 1.03]
			Placebo	62	53 (85.5)	0.57 (1.06)	-1.8	-0.25	0.75	1.25	3.0	
		Week 16	Tezepelumab	59	51 (86.4)	1.24 (1.24)	-2.8	0.25	1.25	2.25	3.3	0.60 [0.20, 0.99]
			Placebo	62	53 (85.5)	0.56 (1.02)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	59	51 (86.4)	1.28 (1.18)	-1.3	0.25	1.25	2.25	3.5	0.65 [0.26, 1.04]
			Placebo	62	53 (85.5)	0.57 (1.02)	-1.8	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	59	51 (86.4)	1.36 (1.20)	-1.3	0.25	1.50	2.25	3.5	0.69 [0.30, 1.09]
			Placebo	62	53 (85.5)	0.55 (1.15)	-1.8	-0.25	0.50	1.25	3.8	
		Week 28	Tezepelumab	59	51 (86.4)	1.35 (1.23)	-1.5	0.25	1.50	2.25	3.3	0.52 [0.13, 0.91]
			Placebo	62	53 (85.5)	0.70 (1.26)	-2.8	0.00	0.75	1.25	3.8	
		Week 32	Tezepelumab	59	51 (86.4)	1.42 (1.26)	-1.3	0.25	1.50	2.25	3.5	0.57 [0.18, 0.97]
			Placebo	62	53 (85.5)	0.75 (1.07)	-1.8	0.00	0.75	1.25	3.8	
		Week 36	Tezepelumab	59	51 (86.4)	1.46 (1.24)	-1.3	0.50	1.50	2.25	3.5	0.73 [0.33, 1.12]
			Placebo	62	53 (85.5)	0.60 (1.13)	-2.3	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	59	51 (86.4)	1.48 (1.16)	-1.3	0.25	1.50	2.25	3.3	0.61 [0.22, 1.01]
			Placebo	62	53 (85.5)	0.76 (1.16)	-1.5	0.00	0.75	1.25	3.8	
		Week 44	Tezepelumab	59	51 (86.4)	1.52 (1.21)	-1.3	0.50	1.50	2.25	3.8	0.65 [0.26, 1.04]
			Placebo	62	53 (85.5)	0.73 (1.23)	-1.5	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	59	51 (86.4)	1.51 (1.26)	-1.3	0.50	1.50	2.25	3.8	0.63 [0.24, 1.03]
			Placebo	62	53 (85.5)	0.73 (1.23)	-1.5	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	59	51 (86.4)	1.52 (1.22)	-1.3	0.50	1.50	2.25	3.8	0.63 [0.23, 1.02]
			Placebo	62	53 (85.5)	0.75 (1.25)	-1.3	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	4.45 (0.74)	4.0	4.00	4.25	4.25	5.8	
			Placebo	2	1 (50.0)	3.50	3.5	3.50	3.50	3.50	3.5	
		Week 4	Tezepelumab	6	6 (100.0)	4.63 (1.24)	3.3	3.25	4.63	5.75	6.3	
			Placebo	2	2 (100.0)	4.50 (1.41)	3.5	3.50	4.50	5.50	5.5	
		Week 8	Tezepelumab	6	6 (100.0)	5.25 (0.79)	4.3	4.50	5.38	5.75	6.3	
			Placebo	2	2 (100.0)	5.00 (2.12)	3.5	3.50	5.00	6.50	6.5	
		Week 12	Tezepelumab	6	6 (100.0)	5.46 (0.75)	4.8	4.75	5.25	6.25	6.5	
			Placebo	2	2 (100.0)	3.88 (0.18)	3.8	3.75	3.88	4.00	4.0	
		Week 16	Tezepelumab	6	6 (100.0)	5.17 (0.85)	4.5	4.75	4.75	5.50	6.8	
			Placebo	2	2 (100.0)	4.13 (0.18)	4.0	4.00	4.13	4.25	4.3	
		Week 20	Tezepelumab	6	6 (100.0)	4.88 (0.74)	3.5	5.00	5.00	5.00	5.8	
			Placebo	2	2 (100.0)	3.75 (0.35)	3.5	3.50	3.75	4.00	4.0	
		Week 24	Tezepelumab	6	6 (100.0)	5.21 (0.84)	3.8	5.00	5.25	6.00	6.0	
			Placebo	2	2 (100.0)	4.00 (0.35)	3.8	3.75	4.00	4.25	4.3	
		Week 28	Tezepelumab	6	6 (100.0)	5.00 (0.61)	4.0	4.75	5.00	5.50	5.8	
			Placebo	2	2 (100.0)	4.00 (0.35)	3.8	3.75	4.00	4.25	4.3	
		Week 32	Tezepelumab	6	6 (100.0)	5.13 (0.70)	4.0	4.75	5.25	5.50	6.0	
			Placebo	2	2 (100.0)	4.13 (0.53)	3.8	3.75	4.13	4.50	4.5	
		Week 36	Tezepelumab	6	6 (100.0)	4.83 (0.74)	4.0	4.25	4.75	5.25	6.0	
			Placebo	2	2 (100.0)	3.88 (0.18)	3.8	3.75	3.88	4.00	4.0	
		Week 40	Tezepelumab	6	6 (100.0)	5.04 (0.49)	4.3	5.00	5.00	5.25	5.8	
			Placebo	2	2 (100.0)	4.00 (0.00)	4.0	4.00	4.00	4.00	4.0	
		Week 44	Tezepelumab	6	6 (100.0)	4.92 (0.49)	4.3	4.75	4.88	5.00	5.8	
			Placebo	2	2 (100.0)	4.38 (1.24)	3.5	3.50	4.38	5.25	5.3	
		Week 48	Tezepelumab	6	6 (100.0)	4.92 (0.90)	3.8	4.00	5.00	5.75	6.0	
			Placebo	2	2 (100.0)	4.38 (0.53)	4.0	4.00	4.38	4.75	4.8	
		Week 52	Tezepelumab	6	6 (100.0)	4.92 (0.90)	3.8	4.00	5.00	5.75	6.0	
			Placebo	2	2 (100.0)	4.25 (0.35)	4.0	4.00	4.25	4.50	4.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	6	5 (83.3)	0.45 (1.02)	-0.8	0.00	0.25	0.75	2.0	NE
			Placebo	2	1 (50.0)	2.00	2.0	2.00	2.00	2.00	2.0	
		Week 8	Tezepelumab	6	5 (83.3)	0.85 (0.95)	0.0	0.25	0.25	1.75	2.0	NE
			Placebo	2	1 (50.0)	3.00	3.0	3.00	3.00	3.00	3.0	
		Week 12	Tezepelumab	6	5 (83.3)	1.05 (0.74)	0.5	0.50	0.75	1.25	2.3	NE
			Placebo	2	1 (50.0)	0.50	0.5	0.50	0.50	0.50	0.5	
		Week 16	Tezepelumab	6	5 (83.3)	0.80 (1.02)	-0.3	0.50	0.50	0.75	2.5	NE
			Placebo	2	1 (50.0)	0.75	0.8	0.75	0.75	0.75	0.8	
		Week 20	Tezepelumab	6	5 (83.3)	0.40 (0.63)	-0.5	0.00	0.75	0.75	1.0	NE
			Placebo	2	1 (50.0)	0.50	0.5	0.50	0.50	0.50	0.5	
		Week 24	Tezepelumab	6	5 (83.3)	0.80 (0.87)	-0.3	0.25	0.75	1.25	2.0	NE
			Placebo	2	1 (50.0)	0.25	0.3	0.25	0.25	0.25	0.3	
		Week 28	Tezepelumab	6	5 (83.3)	0.60 (0.58)	0.0	0.00	0.75	1.00	1.3	NE
			Placebo	2	1 (50.0)	0.25	0.3	0.25	0.25	0.25	0.3	
		Week 32	Tezepelumab	6	5 (83.3)	0.75 (0.59)	0.0	0.25	1.00	1.25	1.3	NE
			Placebo	2	1 (50.0)	0.25	0.3	0.25	0.25	0.25	0.3	
		Week 36	Tezepelumab	6	5 (83.3)	0.50 (0.40)	0.0	0.25	0.50	0.75	1.0	NE
			Placebo	2	1 (50.0)	0.50	0.5	0.50	0.50	0.50	0.5	
		Week 40	Tezepelumab	6	5 (83.3)	0.60 (0.45)	0.0	0.25	0.75	1.00	1.0	NE
			Placebo	2	1 (50.0)	0.50	0.5	0.50	0.50	0.50	0.5	
		Week 44	Tezepelumab	6	5 (83.3)	0.60 (0.38)	0.0	0.50	0.75	0.75	1.0	NE
			Placebo	2	1 (50.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 48	Tezepelumab	6	5 (83.3)	0.65 (0.68)	-0.3	0.25	0.75	1.00	1.5	NE
			Placebo	2	1 (50.0)	0.50	0.5	0.50	0.50	0.50	0.5	
		Week 52	Tezepelumab	6	5 (83.3)	0.65 (0.68)	-0.3	0.25	0.75	1.00	1.5	NE
			Placebo	2	1 (50.0)	0.50	0.5	0.50	0.50	0.50	0.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	3.94 (1.08)	1.8	3.25	4.00	4.75	6.8	
			Placebo	63	54 (85.7)	4.40 (1.22)	1.5	3.50	4.25	5.50	7.0	
		Week 4	Tezepelumab	60	54 (90.0)	4.82 (1.12)	1.3	4.00	5.00	5.75	7.0	
			Placebo	63	55 (87.3)	4.85 (1.21)	2.0	4.25	5.00	5.50	7.0	
		Week 8	Tezepelumab	60	56 (93.3)	5.14 (1.19)	1.0	4.25	5.38	6.00	7.0	
			Placebo	63	57 (90.5)	4.91 (1.28)	1.5	4.00	5.00	5.75	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.25 (1.18)	1.0	4.50	5.50	6.13	7.0	
			Placebo	63	57 (90.5)	4.96 (1.16)	2.0	4.25	5.00	5.75	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.16 (1.22)	1.0	4.50	5.25	6.00	7.0	
			Placebo	63	57 (90.5)	4.91 (1.40)	1.3	4.00	5.00	5.75	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.16 (1.28)	1.0	4.50	5.00	6.00	7.0	
			Placebo	63	57 (90.5)	4.88 (1.42)	1.3	4.00	5.00	5.75	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.23 (1.30)	1.0	4.50	5.00	6.25	7.0	
			Placebo	63	57 (90.5)	4.82 (1.52)	1.0	4.25	5.00	5.75	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.22 (1.29)	1.0	4.50	5.00	6.25	7.0	
			Placebo	63	58 (92.1)	5.03 (1.51)	1.3	4.25	5.25	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.30 (1.32)	1.0	4.50	5.25	6.25	7.0	
			Placebo	63	58 (92.1)	5.07 (1.48)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.35 (1.26)	1.0	4.50	5.50	6.50	7.0	
			Placebo	63	58 (92.1)	4.91 (1.51)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.34 (1.18)	2.0	4.50	5.50	6.50	7.0	
			Placebo	63	58 (92.1)	5.07 (1.49)	1.0	4.25	5.25	6.25	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.36 (1.23)	1.3	4.50	5.25	6.25	7.0	
			Placebo	63	58 (92.1)	5.06 (1.42)	1.3	4.00	5.13	6.25	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.39 (1.23)	1.0	4.50	5.50	6.25	7.0	
			Placebo	63	58 (92.1)	5.02 (1.39)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.40 (1.22)	1.0	4.50	5.50	6.50	7.0	
			Placebo	63	58 (92.1)	5.10 (1.33)	1.8	4.25	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	60	50 (83.3)	0.87 (1.27)	-4.0	0.00	1.00	1.75	4.0	0.39 [-0.00, 0.78]
			Placebo	63	53 (84.1)	0.42 (1.03)	-2.0	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	60	52 (86.7)	1.17 (1.23)	-1.3	0.25	1.25	2.25	4.3	0.52 [0.13, 0.90]
			Placebo	63	54 (85.7)	0.56 (1.13)	-1.8	-0.25	0.38	1.25	3.3	
		Week 12	Tezepelumab	60	52 (86.7)	1.28 (1.21)	-2.3	0.25	1.38	2.25	4.8	0.63 [0.24, 1.02]
			Placebo	63	54 (85.7)	0.57 (1.06)	-1.8	-0.25	0.75	1.25	3.0	
		Week 16	Tezepelumab	60	52 (86.7)	1.20 (1.26)	-2.8	0.25	1.25	2.25	3.3	0.59 [0.20, 0.98]
			Placebo	63	54 (85.7)	0.52 (1.05)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	60	52 (86.7)	1.22 (1.24)	-1.8	0.25	1.25	2.25	3.5	0.61 [0.22, 1.00]
			Placebo	63	54 (85.7)	0.51 (1.08)	-2.3	0.00	0.38	1.25	3.0	
		Week 24	Tezepelumab	60	52 (86.7)	1.30 (1.25)	-1.5	0.25	1.50	2.25	3.5	0.66 [0.27, 1.05]
			Placebo	63	54 (85.7)	0.49 (1.22)	-2.8	-0.25	0.50	1.25	3.8	
		Week 28	Tezepelumab	60	52 (86.7)	1.30 (1.27)	-1.5	0.25	1.50	2.25	3.3	0.50 [0.11, 0.88]
			Placebo	63	54 (85.7)	0.67 (1.28)	-2.8	0.00	0.75	1.25	3.8	
		Week 32	Tezepelumab	60	52 (86.7)	1.37 (1.31)	-1.3	0.25	1.50	2.25	3.5	0.54 [0.15, 0.92]
			Placebo	63	54 (85.7)	0.73 (1.07)	-1.8	0.00	0.75	1.25	3.8	
		Week 36	Tezepelumab	60	52 (86.7)	1.41 (1.28)	-1.3	0.38	1.50	2.25	3.5	0.70 [0.31, 1.10]
			Placebo	63	54 (85.7)	0.54 (1.21)	-2.8	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	60	52 (86.7)	1.44 (1.18)	-1.3	0.25	1.50	2.25	3.3	0.61 [0.22, 1.00]
			Placebo	63	54 (85.7)	0.70 (1.23)	-2.5	0.00	0.75	1.25	3.8	
		Week 44	Tezepelumab	60	52 (86.7)	1.46 (1.27)	-1.5	0.50	1.50	2.25	3.8	0.61 [0.22, 1.00]
			Placebo	63	54 (85.7)	0.70 (1.23)	-1.5	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	60	52 (86.7)	1.48 (1.28)	-1.3	0.50	1.50	2.25	3.8	0.63 [0.24, 1.02]
			Placebo	63	54 (85.7)	0.66 (1.31)	-2.8	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	60	52 (86.7)	1.48 (1.24)	-1.3	0.50	1.50	2.25	3.8	0.61 [0.22, 1.00]
			Placebo	63	54 (85.7)	0.73 (1.24)	-1.3	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	17	15 (88.2)	3.90 (1.19)	1.8	3.00	4.00	4.75	6.0	
			Placebo	21	20 (95.2)	4.58 (1.20)	3.0	3.38	4.50	5.63	7.0	
		Week 4	Tezepelumab	17	15 (88.2)	4.63 (1.19)	2.0	4.00	5.00	5.75	6.3	
			Placebo	21	20 (95.2)	4.94 (1.01)	3.5	4.13	4.88	5.50	7.0	
		Week 8	Tezepelumab	17	16 (94.1)	5.05 (1.43)	1.0	4.25	5.13	5.75	7.0	
			Placebo	21	21 (100.0)	4.89 (1.12)	2.8	3.75	5.25	5.50	7.0	
		Week 12	Tezepelumab	17	16 (94.1)	5.25 (1.45)	1.0	4.63	5.38	6.00	7.0	
			Placebo	21	21 (100.0)	5.24 (0.77)	3.8	5.00	5.25	5.75	7.0	
		Week 16	Tezepelumab	17	16 (94.1)	5.22 (1.44)	1.0	4.50	5.50	5.88	7.0	
			Placebo	21	21 (100.0)	5.07 (1.45)	1.3	4.00	5.25	6.25	7.0	
		Week 20	Tezepelumab	17	16 (94.1)	5.23 (1.35)	1.3	4.75	5.25	6.13	7.0	
			Placebo	21	21 (100.0)	4.96 (1.52)	1.3	3.75	5.25	6.00	7.0	
		Week 24	Tezepelumab	17	16 (94.1)	5.23 (1.47)	1.0	4.63	5.25	6.25	7.0	
			Placebo	21	21 (100.0)	4.86 (1.54)	1.3	4.25	5.00	5.75	7.0	
		Week 28	Tezepelumab	17	16 (94.1)	5.11 (1.47)	1.0	4.38	5.38	6.00	7.0	
			Placebo	21	21 (100.0)	5.15 (1.62)	1.3	4.25	5.75	6.50	7.0	
		Week 32	Tezepelumab	17	16 (94.1)	5.19 (1.46)	1.0	4.63	5.63	6.00	7.0	
			Placebo	21	21 (100.0)	5.29 (1.44)	1.3	4.50	5.75	6.25	7.0	
		Week 36	Tezepelumab	17	16 (94.1)	5.25 (1.47)	1.0	4.50	5.75	6.13	7.0	
			Placebo	21	21 (100.0)	4.87 (1.37)	2.0	4.00	4.75	5.75	7.0	
		Week 40	Tezepelumab	17	16 (94.1)	5.31 (1.23)	2.0	4.50	5.63	5.88	7.0	
			Placebo	21	21 (100.0)	5.21 (1.28)	2.3	4.50	5.50	6.00	7.0	
		Week 44	Tezepelumab	17	16 (94.1)	5.36 (1.28)	2.0	4.50	5.63	6.38	7.0	
			Placebo	21	21 (100.0)	5.23 (1.15)	3.5	4.25	5.25	6.00	7.0	
		Week 48	Tezepelumab	17	16 (94.1)	5.20 (1.47)	1.0	4.38	5.75	6.00	7.0	
			Placebo	21	21 (100.0)	5.12 (1.26)	2.0	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	17	16 (94.1)	5.19 (1.43)	1.0	4.38	5.75	6.00	7.0	
			Placebo	21	21 (100.0)	5.27 (1.08)	3.8	4.50	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	17	13 (76.5)	0.87 (1.17)	-1.3	0.00	1.00	1.75	2.8	0.47 [-0.25, 1.18]
			Placebo	21	19 (90.5)	0.36 (1.04)	-2.0	-0.25	0.50	1.00	2.0	
		Week 8	Tezepelumab	17	14 (82.4)	1.20 (1.31)	-0.8	0.00	1.25	2.25	3.3	0.66 [-0.05, 1.36]
			Placebo	21	20 (95.2)	0.39 (1.18)	-1.8	-0.25	0.13	1.13	3.3	
		Week 12	Tezepelumab	17	14 (82.4)	1.32 (1.26)	-0.8	0.00	1.50	2.25	3.0	0.53 [-0.16, 1.23]
			Placebo	21	20 (95.2)	0.74 (0.97)	-1.8	0.00	0.88	1.38	2.5	
		Week 16	Tezepelumab	17	14 (82.4)	1.30 (1.37)	-0.8	0.00	1.50	2.50	3.0	0.59 [-0.10, 1.29]
			Placebo	21	20 (95.2)	0.55 (1.19)	-1.8	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	17	14 (82.4)	1.34 (1.25)	-0.5	0.00	1.38	2.50	3.0	0.67 [-0.03, 1.37]
			Placebo	21	20 (95.2)	0.46 (1.35)	-2.3	-0.13	0.50	1.50	2.5	
		Week 24	Tezepelumab	17	14 (82.4)	1.32 (1.38)	-0.8	0.25	1.38	2.50	3.5	0.70 [-0.01, 1.40]
			Placebo	21	20 (95.2)	0.31 (1.49)	-2.8	-0.75	0.38	1.13	3.8	
		Week 28	Tezepelumab	17	14 (82.4)	1.25 (1.47)	-0.8	0.00	1.38	2.75	3.0	0.41 [-0.28, 1.10]
			Placebo	21	20 (95.2)	0.63 (1.56)	-2.8	0.00	0.88	1.25	3.8	
		Week 32	Tezepelumab	17	14 (82.4)	1.34 (1.46)	-0.8	0.00	1.25	2.50	3.5	0.44 [-0.25, 1.13]
			Placebo	21	20 (95.2)	0.75 (1.25)	-1.8	0.00	1.00	1.25	3.8	
		Week 36	Tezepelumab	17	14 (82.4)	1.41 (1.43)	-0.8	0.25	1.38	2.75	3.5	0.74 [0.04, 1.45]
			Placebo	21	20 (95.2)	0.35 (1.43)	-2.8	0.00	0.25	1.13	3.8	
		Week 40	Tezepelumab	17	14 (82.4)	1.43 (1.30)	-0.3	0.25	1.50	2.75	3.3	0.53 [-0.17, 1.22]
			Placebo	21	20 (95.2)	0.70 (1.43)	-2.5	0.00	0.63	1.50	3.8	
		Week 44	Tezepelumab	17	14 (82.4)	1.54 (1.40)	-0.3	0.25	1.50	2.50	3.8	0.67 [-0.03, 1.37]
			Placebo	21	20 (95.2)	0.65 (1.26)	-1.5	0.00	0.75	1.25	3.8	
		Week 48	Tezepelumab	17	14 (82.4)	1.39 (1.45)	-0.8	0.00	1.50	2.75	3.5	0.59 [-0.11, 1.28]
			Placebo	21	20 (95.2)	0.56 (1.40)	-2.8	0.00	0.75	1.00	3.8	
		Week 52	Tezepelumab	17	14 (82.4)	1.39 (1.43)	-0.8	0.00	1.63	2.50	3.5	0.50 [-0.19, 1.20]
			Placebo	21	20 (95.2)	0.74 (1.20)	-1.3	0.00	0.75	1.13	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	49	43 (87.8)	4.02 (1.02)	1.8	3.50	4.00	4.75	6.8	
			Placebo	44	35 (79.5)	4.27 (1.23)	1.5	3.50	4.25	5.25	6.5	
		Week 4	Tezepelumab	49	45 (91.8)	4.86 (1.11)	1.3	4.00	5.00	5.75	7.0	
			Placebo	44	37 (84.1)	4.79 (1.31)	2.0	4.25	5.25	5.50	7.0	
		Week 8	Tezepelumab	49	46 (93.9)	5.19 (1.06)	1.8	4.50	5.50	6.00	7.0	
			Placebo	44	38 (86.4)	4.92 (1.39)	1.5	4.25	5.00	5.75	7.0	
		Week 12	Tezepelumab	49	46 (93.9)	5.28 (1.03)	3.0	4.50	5.50	6.25	7.0	
			Placebo	44	38 (86.4)	4.74 (1.30)	2.0	4.00	4.75	5.50	7.0	
		Week 16	Tezepelumab	49	46 (93.9)	5.14 (1.10)	2.0	4.50	5.00	6.00	7.0	
			Placebo	44	38 (86.4)	4.78 (1.35)	1.5	4.25	5.00	5.50	7.0	
		Week 20	Tezepelumab	49	47 (95.9)	5.10 (1.21)	1.0	4.25	5.00	6.00	7.0	
			Placebo	44	38 (86.4)	4.78 (1.36)	1.5	4.00	5.00	5.50	7.0	
		Week 24	Tezepelumab	49	47 (95.9)	5.23 (1.20)	1.3	4.25	5.00	6.25	7.0	
			Placebo	44	38 (86.4)	4.76 (1.50)	1.0	4.00	4.88	5.75	7.0	
		Week 28	Tezepelumab	49	49 (100.0)	5.23 (1.18)	1.5	4.50	5.00	6.25	7.0	
			Placebo	44	39 (88.6)	4.92 (1.44)	1.3	4.00	5.25	6.00	7.0	
		Week 32	Tezepelumab	49	49 (100.0)	5.31 (1.22)	1.5	4.50	5.00	6.25	7.0	
			Placebo	44	39 (88.6)	4.91 (1.48)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	49	49 (100.0)	5.32 (1.15)	1.8	4.50	5.00	6.25	7.0	
			Placebo	44	39 (88.6)	4.87 (1.58)	1.0	4.00	5.00	6.25	7.0	
		Week 40	Tezepelumab	49	49 (100.0)	5.32 (1.12)	2.3	4.50	5.00	6.25	7.0	
			Placebo	44	39 (88.6)	4.94 (1.58)	1.0	4.00	5.25	6.25	7.0	
		Week 44	Tezepelumab	49	49 (100.0)	5.31 (1.17)	1.3	4.75	5.00	6.25	7.0	
			Placebo	44	39 (88.6)	4.93 (1.53)	1.3	4.00	5.00	6.25	7.0	
		Week 48	Tezepelumab	49	49 (100.0)	5.39 (1.12)	2.3	4.50	5.25	6.25	7.0	
			Placebo	44	39 (88.6)	4.94 (1.44)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	49	49 (100.0)	5.41 (1.12)	2.3	4.50	5.25	6.50	7.0	
			Placebo	44	39 (88.6)	4.96 (1.43)	1.8	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHK: Change from baseline in AQLQ+12 environmental stimuli score by key subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	49	42 (85.7)	0.82 (1.28)	-4.0	0.25	0.75	1.75	4.0	0.27 [-0.18, 0.72]
			Placebo	44	35 (79.5)	0.50 (1.05)	-1.8	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	49	43 (87.8)	1.12 (1.19)	-1.3	0.25	1.25	2.00	4.3	0.34 [-0.11, 0.79]
			Placebo	44	35 (79.5)	0.72 (1.17)	-1.5	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	49	43 (87.8)	1.24 (1.15)	-2.3	0.50	1.25	2.00	4.8	0.68 [0.22, 1.14]
			Placebo	44	35 (79.5)	0.48 (1.09)	-1.3	-0.50	0.50	1.00	3.0	
		Week 16	Tezepelumab	49	43 (87.8)	1.12 (1.21)	-2.8	0.25	1.25	2.00	3.3	0.55 [0.10, 1.00]
			Placebo	44	35 (79.5)	0.51 (0.97)	-1.3	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	49	43 (87.8)	1.09 (1.21)	-1.8	0.25	1.25	2.00	3.5	0.50 [0.05, 0.96]
			Placebo	44	35 (79.5)	0.54 (0.89)	-1.3	0.00	0.50	1.00	3.0	
		Week 24	Tezepelumab	49	43 (87.8)	1.24 (1.18)	-1.5	0.25	1.50	2.25	3.3	0.59 [0.13, 1.05]
			Placebo	44	35 (79.5)	0.58 (1.04)	-1.3	-0.25	0.50	1.25	3.0	
		Week 28	Tezepelumab	49	43 (87.8)	1.23 (1.18)	-1.5	0.25	1.50	2.25	3.3	0.49 [0.03, 0.94]
			Placebo	44	35 (79.5)	0.68 (1.08)	-1.3	0.00	0.50	1.50	2.8	
		Week 32	Tezepelumab	49	43 (87.8)	1.30 (1.22)	-1.3	0.25	1.50	2.25	3.5	0.54 [0.09, 1.00]
			Placebo	44	35 (79.5)	0.70 (0.96)	-1.3	0.00	0.50	1.50	3.0	
		Week 36	Tezepelumab	49	43 (87.8)	1.31 (1.20)	-1.3	0.50	1.50	2.25	3.3	0.58 [0.13, 1.04]
			Placebo	44	35 (79.5)	0.64 (1.06)	-1.3	0.00	0.50	1.25	3.0	
		Week 40	Tezepelumab	49	43 (87.8)	1.34 (1.12)	-1.3	0.50	1.50	2.25	3.3	0.58 [0.12, 1.03]
			Placebo	44	35 (79.5)	0.70 (1.10)	-1.3	0.00	0.75	1.25	3.3	
		Week 44	Tezepelumab	49	43 (87.8)	1.34 (1.20)	-1.5	0.50	1.50	2.25	3.3	0.52 [0.06, 0.97]
			Placebo	44	35 (79.5)	0.71 (1.22)	-1.3	0.00	0.25	1.50	3.8	
		Week 48	Tezepelumab	49	43 (87.8)	1.41 (1.20)	-1.3	0.75	1.50	2.25	3.8	0.56 [0.11, 1.02]
			Placebo	44	35 (79.5)	0.71 (1.25)	-1.5	0.00	0.50	1.50	3.8	
		Week 52	Tezepelumab	49	43 (87.8)	1.41 (1.17)	-1.3	0.75	1.50	2.00	3.8	0.58 [0.12, 1.03]
			Placebo	44	35 (79.5)	0.71 (1.27)	-1.3	-0.25	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	4.02 (1.00)	1.8	3.50	4.00	4.63	6.8	
			Placebo	58	48 (82.8)	4.42 (1.25)	1.5	3.50	4.38	5.50	7.0	
		Week 4	Tezepelumab	60	54 (90.0)	4.72 (1.11)	1.3	4.00	5.00	5.50	6.8	
			Placebo	58	50 (86.2)	4.82 (1.27)	2.0	4.00	5.13	5.50	7.0	
		Week 8	Tezepelumab	60	56 (93.3)	5.09 (1.17)	1.0	4.25	5.13	5.88	7.0	
			Placebo	58	52 (89.7)	4.86 (1.33)	1.5	3.88	5.00	5.75	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.19 (1.14)	1.0	4.50	5.38	5.88	7.0	
			Placebo	58	52 (89.7)	4.91 (1.22)	2.0	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.15 (1.22)	1.0	4.50	5.25	6.00	7.0	
			Placebo	58	52 (89.7)	4.87 (1.43)	1.3	4.00	5.00	5.88	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.12 (1.26)	1.0	4.50	5.00	6.00	7.0	
			Placebo	58	52 (89.7)	4.87 (1.48)	1.3	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.19 (1.28)	1.0	4.50	5.00	6.25	7.0	
			Placebo	58	52 (89.7)	4.75 (1.56)	1.0	3.88	5.00	5.75	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.14 (1.25)	1.0	4.50	5.00	6.25	7.0	
			Placebo	58	53 (91.4)	4.92 (1.54)	1.3	4.00	5.25	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.25 (1.30)	1.0	4.50	5.00	6.25	7.0	
			Placebo	58	53 (91.4)	4.98 (1.53)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.25 (1.25)	1.0	4.50	5.00	6.25	7.0	
			Placebo	58	53 (91.4)	4.82 (1.56)	1.0	3.75	5.00	6.00	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.25 (1.15)	2.0	4.50	5.00	6.00	7.0	
			Placebo	58	53 (91.4)	4.99 (1.54)	1.0	4.00	5.25	6.25	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.24 (1.19)	1.3	4.50	5.25	6.25	7.0	
			Placebo	58	53 (91.4)	4.97 (1.44)	1.3	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.27 (1.22)	1.0	4.50	5.25	6.25	7.0	
			Placebo	58	53 (91.4)	4.94 (1.41)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.28 (1.21)	1.0	4.50	5.25	6.25	7.0	
			Placebo	58	53 (91.4)	5.02 (1.34)	1.8	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	60	49 (81.7)	0.70 (1.19)	-4.0	0.00	0.75	1.50	3.0	0.29 [-0.11, 0.69]
			Placebo	58	47 (81.0)	0.38 (1.03)	-2.0	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	60	51 (85.0)	1.03 (1.16)	-1.3	0.25	1.00	2.00	3.3	0.46 [0.06, 0.86]
			Placebo	58	48 (82.8)	0.52 (1.11)	-1.8	-0.25	0.38	1.25	3.0	
		Week 12	Tezepelumab	60	51 (85.0)	1.14 (1.09)	-2.3	0.25	1.25	2.00	3.0	0.57 [0.17, 0.98]
			Placebo	58	48 (82.8)	0.53 (1.05)	-1.8	-0.25	0.50	1.13	3.0	
		Week 16	Tezepelumab	60	51 (85.0)	1.12 (1.21)	-2.8	0.25	1.00	2.00	3.3	0.58 [0.17, 0.98]
			Placebo	58	48 (82.8)	0.47 (1.00)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	60	51 (85.0)	1.10 (1.19)	-1.8	0.25	1.00	2.00	3.5	0.52 [0.12, 0.92]
			Placebo	58	48 (82.8)	0.51 (1.07)	-2.3	0.00	0.38	1.25	3.0	
		Week 24	Tezepelumab	60	51 (85.0)	1.18 (1.23)	-1.5	0.25	1.50	2.25	3.5	0.66 [0.25, 1.06]
			Placebo	58	48 (82.8)	0.40 (1.14)	-2.8	-0.25	0.25	1.13	3.0	
		Week 28	Tezepelumab	60	51 (85.0)	1.13 (1.21)	-1.5	0.25	1.25	2.25	3.3	0.49 [0.09, 0.89]
			Placebo	58	48 (82.8)	0.54 (1.22)	-2.8	0.00	0.50	1.25	3.0	
		Week 32	Tezepelumab	60	51 (85.0)	1.25 (1.28)	-1.3	0.25	1.50	2.25	3.5	0.54 [0.14, 0.95]
			Placebo	58	48 (82.8)	0.62 (1.00)	-1.8	0.00	0.50	1.13	3.0	
		Week 36	Tezepelumab	60	51 (85.0)	1.24 (1.24)	-1.3	0.25	1.25	2.25	3.5	0.67 [0.26, 1.07]
			Placebo	58	48 (82.8)	0.45 (1.12)	-2.8	0.00	0.25	1.00	3.0	
		Week 40	Tezepelumab	60	51 (85.0)	1.25 (1.12)	-1.3	0.25	1.25	2.00	3.3	0.56 [0.16, 0.96]
			Placebo	58	48 (82.8)	0.61 (1.16)	-2.5	0.00	0.50	1.25	3.3	
		Week 44	Tezepelumab	60	51 (85.0)	1.26 (1.19)	-1.5	0.50	1.25	2.25	3.8	0.60 [0.19, 1.00]
			Placebo	58	48 (82.8)	0.59 (1.08)	-1.5	0.00	0.38	1.13	3.3	
		Week 48	Tezepelumab	60	51 (85.0)	1.28 (1.21)	-1.3	0.50	1.50	2.25	3.5	0.60 [0.20, 1.01]
			Placebo	58	48 (82.8)	0.56 (1.18)	-2.8	0.00	0.50	1.00	3.8	
		Week 52	Tezepelumab	60	51 (85.0)	1.29 (1.18)	-1.3	0.50	1.50	2.25	3.5	0.58 [0.18, 0.98]
			Placebo	58	48 (82.8)	0.63 (1.09)	-1.3	0.00	0.50	1.00	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	3.71 (1.54)	1.8	2.50	3.63	5.00	5.8	
			Placebo	7	7 (100.0)	4.11 (0.96)	3.0	3.25	3.75	5.25	5.5	
		Week 4	Tezepelumab	6	6 (100.0)	5.54 (1.02)	4.3	4.50	5.75	6.00	7.0	
			Placebo	7	7 (100.0)	5.00 (0.58)	4.3	4.50	4.75	5.50	5.8	
		Week 8	Tezepelumab	6	6 (100.0)	5.75 (0.79)	4.5	5.25	5.88	6.25	6.8	
			Placebo	7	7 (100.0)	5.29 (0.86)	3.8	4.75	5.50	5.75	6.5	
		Week 12	Tezepelumab	6	6 (100.0)	6.00 (0.92)	4.5	5.25	6.38	6.75	6.8	
			Placebo	7	7 (100.0)	5.00 (0.56)	4.0	4.75	5.25	5.25	5.8	
		Week 16	Tezepelumab	6	6 (100.0)	5.29 (0.97)	4.3	4.75	5.13	5.50	7.0	
			Placebo	7	7 (100.0)	5.00 (0.99)	3.3	4.25	5.25	5.75	6.3	
		Week 20	Tezepelumab	6	6 (100.0)	5.29 (1.09)	3.8	4.75	5.25	5.75	7.0	
			Placebo	7	7 (100.0)	4.64 (0.75)	3.3	4.00	5.00	5.25	5.3	
		Week 24	Tezepelumab	6	6 (100.0)	5.63 (1.02)	4.0	5.00	5.75	6.50	6.8	
			Placebo	7	7 (100.0)	5.14 (0.89)	4.3	4.75	4.75	5.25	7.0	
		Week 28	Tezepelumab	6	6 (100.0)	5.83 (1.09)	4.3	5.00	5.88	7.00	7.0	
			Placebo	7	7 (100.0)	5.61 (0.90)	4.8	4.75	5.25	6.50	7.0	
		Week 32	Tezepelumab	6	6 (100.0)	5.58 (1.02)	4.0	5.00	5.75	6.00	7.0	
			Placebo	7	7 (100.0)	5.50 (0.84)	4.8	4.75	5.25	6.25	7.0	
		Week 36	Tezepelumab	6	6 (100.0)	5.88 (0.80)	5.0	5.00	5.88	6.50	7.0	
			Placebo	7	7 (100.0)	5.25 (0.88)	4.3	4.75	5.25	5.50	7.0	
		Week 40	Tezepelumab	6	6 (100.0)	6.00 (0.82)	5.0	5.50	5.75	7.00	7.0	
			Placebo	7	7 (100.0)	5.39 (0.83)	4.8	4.75	5.00	6.00	7.0	
		Week 44	Tezepelumab	6	6 (100.0)	6.13 (0.90)	5.0	5.25	6.25	7.00	7.0	
			Placebo	7	7 (100.0)	5.50 (1.14)	4.0	4.50	5.75	6.75	7.0	
		Week 48	Tezepelumab	6	6 (100.0)	6.13 (0.72)	5.0	5.75	6.13	6.75	7.0	
			Placebo	7	7 (100.0)	5.43 (1.10)	4.3	4.50	5.00	6.75	7.0	
		Week 52	Tezepelumab	6	6 (100.0)	6.13 (0.72)	5.0	5.75	6.13	6.75	7.0	
			Placebo	7	7 (100.0)	5.46 (1.15)	4.3	4.50	5.00	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	6	6 (100.0)	1.83 (1.30)	0.0	1.25	1.88	2.00	4.0	0.80 [-0.34, 1.94]
			Placebo	7	7 (100.0)	0.89 (1.05)	-0.5	0.00	1.00	1.75	2.5	
		Week 8	Tezepelumab	6	6 (100.0)	2.04 (1.35)	0.0	1.75	2.00	2.25	4.3	0.61 [-0.51, 1.73]
			Placebo	7	7 (100.0)	1.18 (1.47)	-0.8	0.00	1.50	2.50	3.3	
		Week 12	Tezepelumab	6	6 (100.0)	2.29 (1.39)	0.5	1.75	2.13	2.50	4.8	1.15 [-0.04, 2.35]
			Placebo	7	7 (100.0)	0.89 (1.04)	-0.8	0.00	1.00	1.50	2.5	
		Week 16	Tezepelumab	6	6 (100.0)	1.58 (1.48)	-0.3	-0.25	2.13	2.75	3.0	0.50 [-0.61, 1.61]
			Placebo	7	7 (100.0)	0.89 (1.30)	-1.3	0.25	1.00	1.50	3.0	
		Week 20	Tezepelumab	6	6 (100.0)	1.58 (1.48)	-0.3	0.00	1.88	2.75	3.3	0.79 [-0.35, 1.93]
			Placebo	7	7 (100.0)	0.54 (1.18)	-1.3	-0.75	1.00	1.25	2.0	
		Week 24	Tezepelumab	6	6 (100.0)	1.92 (1.06)	0.3	1.50	2.00	2.50	3.3	0.64 [-0.49, 1.76]
			Placebo	7	7 (100.0)	1.04 (1.60)	-1.0	-0.75	1.00	1.75	3.8	
		Week 28	Tezepelumab	6	6 (100.0)	2.13 (1.19)	0.0	1.75	2.38	3.00	3.3	0.49 [-0.62, 1.59]
			Placebo	7	7 (100.0)	1.50 (1.36)	-0.8	1.00	1.25	2.25	3.8	
		Week 32	Tezepelumab	6	6 (100.0)	1.88 (1.15)	0.3	1.00	2.00	2.75	3.3	0.38 [-0.72, 1.49]
			Placebo	7	7 (100.0)	1.39 (1.34)	-0.8	1.00	1.25	1.75	3.8	
		Week 36	Tezepelumab	6	6 (100.0)	2.17 (1.10)	0.3	1.50	2.63	2.75	3.3	0.72 [-0.41, 1.86]
			Placebo	7	7 (100.0)	1.14 (1.63)	-1.0	-0.75	1.50	1.75	3.8	
		Week 40	Tezepelumab	6	6 (100.0)	2.29 (1.20)	0.0	2.00	2.75	3.00	3.3	0.73 [-0.40, 1.86]
			Placebo	7	7 (100.0)	1.29 (1.52)	-0.8	-0.25	1.25	2.25	3.8	
		Week 44	Tezepelumab	6	6 (100.0)	2.42 (1.32)	0.0	2.00	2.75	3.25	3.8	0.61 [-0.51, 1.73]
			Placebo	7	7 (100.0)	1.39 (1.91)	-0.8	-0.75	1.50	3.75	3.8	
		Week 48	Tezepelumab	6	6 (100.0)	2.42 (1.25)	0.3	1.75	2.75	3.25	3.8	0.67 [-0.46, 1.79]
			Placebo	7	7 (100.0)	1.32 (1.91)	-1.0	-0.75	1.25	3.75	3.8	
		Week 52	Tezepelumab	6	6 (100.0)	2.42 (1.25)	0.3	1.75	2.75	3.25	3.8	0.63 [-0.49, 1.75]
			Placebo	7	7 (100.0)	1.36 (1.96)	-1.0	-0.75	1.25	3.75	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	4.40 (1.77)	1.8	3.50	5.00	5.75	6.0	
			Placebo	4	3 (75.0)	3.92 (0.80)	3.0	3.00	4.25	4.50	4.5	
		Week 4	Tezepelumab	6	4 (66.7)	5.94 (0.72)	5.5	5.50	5.63	6.38	7.0	
			Placebo	4	3 (75.0)	5.42 (1.13)	4.3	4.25	5.50	6.50	6.5	
		Week 8	Tezepelumab	6	5 (83.3)	5.70 (1.02)	4.0	5.75	6.00	6.00	6.8	
			Placebo	4	3 (75.0)	6.08 (0.80)	5.5	5.50	5.75	7.00	7.0	
		Week 12	Tezepelumab	6	5 (83.3)	5.95 (0.89)	4.5	5.75	6.25	6.50	6.8	
			Placebo	4	3 (75.0)	5.42 (1.51)	4.0	4.00	5.25	7.00	7.0	
		Week 16	Tezepelumab	6	5 (83.3)	5.15 (0.68)	4.5	4.75	4.75	5.75	6.0	
			Placebo	4	3 (75.0)	5.17 (1.88)	3.3	3.25	5.25	7.00	7.0	
		Week 20	Tezepelumab	6	5 (83.3)	5.00 (0.40)	4.5	4.75	5.00	5.25	5.5	
			Placebo	4	3 (75.0)	5.17 (1.88)	3.3	3.25	5.25	7.00	7.0	
		Week 24	Tezepelumab	6	5 (83.3)	5.40 (0.74)	4.5	5.00	5.50	5.50	6.5	
			Placebo	4	3 (75.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 28	Tezepelumab	6	6 (100.0)	5.83 (1.07)	4.5	5.00	5.75	7.00	7.0	
			Placebo	4	3 (75.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 32	Tezepelumab	6	6 (100.0)	5.71 (0.87)	4.5	5.00	5.88	6.00	7.0	
			Placebo	4	3 (75.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 36	Tezepelumab	6	6 (100.0)	5.71 (0.84)	4.5	5.00	5.88	6.50	6.5	
			Placebo	4	3 (75.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 40	Tezepelumab	6	6 (100.0)	5.79 (0.95)	4.5	5.00	5.88	6.50	7.0	
			Placebo	4	3 (75.0)	5.67 (1.18)	4.8	4.75	5.25	7.00	7.0	
		Week 44	Tezepelumab	6	6 (100.0)	5.83 (0.92)	4.5	5.00	6.13	6.25	7.0	
			Placebo	4	3 (75.0)	6.50 (0.66)	5.8	5.75	6.75	7.00	7.0	
		Week 48	Tezepelumab	6	6 (100.0)	5.79 (0.89)	4.5	5.00	6.00	6.50	6.8	
			Placebo	4	3 (75.0)	6.17 (0.52)	5.8	5.75	6.00	6.75	6.8	
		Week 52	Tezepelumab	6	6 (100.0)	5.92 (0.96)	4.5	5.00	6.25	6.75	6.8	
			Placebo	4	3 (75.0)	6.25 (0.66)	5.8	5.75	6.00	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	6	4 (66.7)	1.31 (2.12)	-0.5	-0.38	0.88	3.00	4.0	-0.10 [-1.60, 1.40]
			Placebo	4	3 (75.0)	1.50 (1.32)	0.0	0.00	2.00	2.50	2.5	
		Week 8	Tezepelumab	6	5 (83.3)	1.30 (1.80)	0.0	0.00	0.50	1.75	4.3	-0.58 [-2.04, 0.89]
			Placebo	4	3 (75.0)	2.17 (0.58)	1.5	1.50	2.50	2.50	2.5	
		Week 12	Tezepelumab	6	5 (83.3)	1.55 (1.92)	0.0	0.25	1.00	1.75	4.8	0.03 [-1.40, 1.46]
			Placebo	4	3 (75.0)	1.50 (0.87)	1.0	1.00	1.00	2.50	2.5	
		Week 16	Tezepelumab	6	5 (83.3)	0.75 (1.35)	-0.3	0.00	0.00	1.00	3.0	-0.39 [-1.84, 1.06]
			Placebo	4	3 (75.0)	1.25 (1.15)	0.3	0.25	1.00	2.50	2.5	
		Week 20	Tezepelumab	6	5 (83.3)	0.60 (1.61)	-0.5	-0.50	-0.25	1.00	3.3	-0.44 [-1.90, 1.01]
			Placebo	4	3 (75.0)	1.25 (1.15)	0.3	0.25	1.00	2.50	2.5	
		Week 24	Tezepelumab	6	5 (83.3)	1.00 (1.51)	-0.5	-0.25	1.00	1.50	3.3	-0.57 [-2.04, 0.89]
			Placebo	4	3 (75.0)	1.75 (0.75)	1.0	1.00	1.75	2.50	2.5	
		Week 28	Tezepelumab	6	5 (83.3)	1.20 (1.47)	-0.5	0.25	1.00	2.00	3.3	-0.43 [-1.88, 1.02]
			Placebo	4	3 (75.0)	1.75 (0.75)	1.0	1.00	1.75	2.50	2.5	
		Week 32	Tezepelumab	6	5 (83.3)	1.05 (1.34)	-0.3	0.25	1.00	1.00	3.3	-0.60 [-2.07, 0.88]
			Placebo	4	3 (75.0)	1.75 (0.75)	1.0	1.00	1.75	2.50	2.5	
		Week 36	Tezepelumab	6	5 (83.3)	1.15 (1.39)	-0.5	0.50	1.00	1.50	3.3	-0.49 [-1.95, 0.96]
			Placebo	4	3 (75.0)	1.75 (0.75)	1.0	1.00	1.75	2.50	2.5	
		Week 40	Tezepelumab	6	5 (83.3)	1.25 (1.44)	-0.5	0.50	1.00	2.00	3.3	-0.40 [-1.85, 1.05]
			Placebo	4	3 (75.0)	1.75 (0.75)	1.0	1.00	1.75	2.50	2.5	
		Week 44	Tezepelumab	6	5 (83.3)	1.35 (1.29)	0.0	0.50	1.00	2.00	3.3	-0.99 [-2.53, 0.54]
			Placebo	4	3 (75.0)	2.58 (1.13)	1.5	1.50	2.50	3.75	3.8	
		Week 48	Tezepelumab	6	5 (83.3)	1.30 (1.30)	-0.3	0.75	1.00	1.75	3.3	-0.73 [-2.22, 0.76]
			Placebo	4	3 (75.0)	2.25 (1.30)	1.5	1.50	1.50	3.75	3.8	
		Week 52	Tezepelumab	6	5 (83.3)	1.35 (1.23)	0.0	0.75	1.00	1.75	3.3	-0.75 [-2.25, 0.74]
			Placebo	4	3 (75.0)	2.33 (1.44)	1.5	1.50	1.50	4.00	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	3.95 (0.98)	1.8	3.25	4.00	4.50	6.8	
			Placebo	61	52 (85.2)	4.41 (1.24)	1.5	3.50	4.25	5.50	7.0	
		Week 4	Tezepelumab	60	56 (93.3)	4.72 (1.11)	1.3	4.00	4.88	5.75	6.8	
			Placebo	61	54 (88.5)	4.81 (1.21)	2.0	4.00	5.00	5.50	7.0	
		Week 8	Tezepelumab	60	57 (95.0)	5.11 (1.16)	1.0	4.25	5.25	5.75	7.0	
			Placebo	61	56 (91.8)	4.85 (1.28)	1.5	3.88	5.00	5.75	7.0	
		Week 12	Tezepelumab	60	57 (95.0)	5.21 (1.15)	1.0	4.50	5.25	6.00	7.0	
			Placebo	61	56 (91.8)	4.89 (1.15)	2.0	4.13	5.00	5.75	7.0	
		Week 16	Tezepelumab	60	57 (95.0)	5.16 (1.23)	1.0	4.50	5.25	6.00	7.0	
			Placebo	61	56 (91.8)	4.87 (1.37)	1.3	4.00	5.00	5.75	7.0	
		Week 20	Tezepelumab	60	58 (96.7)	5.15 (1.28)	1.0	4.25	5.00	6.00	7.0	
			Placebo	61	56 (91.8)	4.83 (1.40)	1.3	4.00	5.00	5.75	7.0	
		Week 24	Tezepelumab	60	58 (96.7)	5.22 (1.30)	1.0	4.25	5.00	6.25	7.0	
			Placebo	61	56 (91.8)	4.75 (1.51)	1.0	4.13	4.88	5.75	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.14 (1.25)	1.0	4.25	5.00	6.00	7.0	
			Placebo	61	57 (93.4)	4.96 (1.51)	1.3	4.00	5.25	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.24 (1.30)	1.0	4.25	5.00	6.25	7.0	
			Placebo	61	57 (93.4)	5.01 (1.48)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.26 (1.26)	1.0	4.50	5.00	6.25	7.0	
			Placebo	61	57 (93.4)	4.83 (1.51)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.27 (1.15)	2.0	4.50	5.25	6.00	7.0	
			Placebo	61	57 (93.4)	5.00 (1.49)	1.0	4.00	5.25	6.00	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.27 (1.21)	1.3	4.50	5.25	6.25	7.0	
			Placebo	61	57 (93.4)	4.96 (1.40)	1.3	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.30 (1.23)	1.0	4.50	5.25	6.25	7.0	
			Placebo	61	57 (93.4)	4.94 (1.38)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.30 (1.21)	1.0	4.50	5.25	6.25	7.0	
			Placebo	61	57 (93.4)	5.01 (1.32)	1.8	4.25	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	60	51 (85.0)	0.79 (1.18)	-4.0	0.00	0.75	1.75	3.0	0.37 [-0.02, 0.76]
			Placebo	61	51 (83.6)	0.39 (1.00)	-2.0	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	60	52 (86.7)	1.13 (1.16)	-1.3	0.25	1.25	2.13	3.3	0.54 [0.14, 0.93]
			Placebo	61	52 (85.2)	0.51 (1.13)	-1.8	-0.25	0.25	1.25	3.3	
		Week 12	Tezepelumab	60	52 (86.7)	1.24 (1.10)	-2.3	0.50	1.25	2.25	3.0	0.67 [0.28, 1.07]
			Placebo	61	52 (85.2)	0.52 (1.04)	-1.8	-0.25	0.50	1.13	3.0	
		Week 16	Tezepelumab	60	52 (86.7)	1.21 (1.23)	-2.8	0.38	1.25	2.25	3.3	0.63 [0.24, 1.03]
			Placebo	61	52 (85.2)	0.49 (1.03)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	60	52 (86.7)	1.20 (1.18)	-1.8	0.25	1.25	2.25	3.5	0.65 [0.26, 1.05]
			Placebo	61	52 (85.2)	0.47 (1.06)	-2.3	0.00	0.38	1.25	3.0	
		Week 24	Tezepelumab	60	52 (86.7)	1.28 (1.21)	-1.5	0.25	1.50	2.25	3.5	0.73 [0.33, 1.13]
			Placebo	61	52 (85.2)	0.41 (1.20)	-2.8	-0.25	0.25	1.13	3.8	
		Week 28	Tezepelumab	60	52 (86.7)	1.24 (1.23)	-1.5	0.25	1.50	2.25	3.3	0.52 [0.13, 0.91]
			Placebo	61	52 (85.2)	0.60 (1.26)	-2.8	0.00	0.50	1.25	3.8	
		Week 32	Tezepelumab	60	52 (86.7)	1.34 (1.27)	-1.3	0.25	1.50	2.25	3.5	0.58 [0.19, 0.97]
			Placebo	61	52 (85.2)	0.66 (1.05)	-1.8	0.00	0.63	1.25	3.8	
		Week 36	Tezepelumab	60	52 (86.7)	1.35 (1.25)	-1.3	0.25	1.50	2.25	3.5	0.73 [0.33, 1.12]
			Placebo	61	52 (85.2)	0.47 (1.19)	-2.8	0.00	0.25	1.13	3.8	
		Week 40	Tezepelumab	60	52 (86.7)	1.38 (1.14)	-1.3	0.25	1.50	2.25	3.3	0.62 [0.23, 1.02]
			Placebo	61	52 (85.2)	0.64 (1.22)	-2.5	0.00	0.50	1.25	3.8	
		Week 44	Tezepelumab	60	52 (86.7)	1.39 (1.25)	-1.5	0.50	1.50	2.25	3.8	0.67 [0.28, 1.07]
			Placebo	61	52 (85.2)	0.58 (1.14)	-1.5	0.00	0.25	1.13	3.8	
		Week 48	Tezepelumab	60	52 (86.7)	1.41 (1.26)	-1.3	0.50	1.50	2.25	3.8	0.67 [0.28, 1.07]
			Placebo	61	52 (85.2)	0.57 (1.25)	-2.8	0.00	0.50	1.00	3.8	
		Week 52	Tezepelumab	60	52 (86.7)	1.41 (1.23)	-1.3	0.50	1.50	2.25	3.8	0.65 [0.26, 1.05]
			Placebo	61	52 (85.2)	0.63 (1.17)	-1.3	0.00	0.50	1.00	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	30	26 (86.7)	3.88 (0.98)	1.8	3.00	4.00	4.75	5.5	
			Placebo	29	25 (86.2)	4.15 (1.09)	2.0	3.50	4.00	5.00	6.0	
		Week 4	Tezepelumab	30	26 (86.7)	4.77 (1.16)	1.3	4.25	4.63	5.75	7.0	
			Placebo	29	25 (86.2)	4.86 (1.37)	2.0	4.25	5.25	5.75	7.0	
		Week 8	Tezepelumab	30	27 (90.0)	5.06 (0.89)	3.5	4.25	5.00	6.00	6.8	
			Placebo	29	26 (89.7)	4.90 (1.27)	2.3	4.00	5.00	5.75	7.0	
		Week 12	Tezepelumab	30	27 (90.0)	5.06 (1.01)	3.0	4.50	5.00	5.50	7.0	
			Placebo	29	26 (89.7)	4.75 (1.15)	2.5	4.00	4.88	5.50	7.0	
		Week 16	Tezepelumab	30	27 (90.0)	4.97 (0.95)	2.5	4.50	4.75	5.50	6.8	
			Placebo	29	26 (89.7)	4.74 (1.39)	1.3	4.00	5.00	5.50	7.0	
		Week 20	Tezepelumab	30	28 (93.3)	4.93 (0.86)	3.8	4.25	5.00	5.38	7.0	
			Placebo	29	26 (89.7)	4.68 (1.36)	1.3	4.00	4.75	5.50	7.0	
		Week 24	Tezepelumab	30	28 (93.3)	5.12 (1.01)	4.0	4.13	4.88	5.88	7.0	
			Placebo	29	26 (89.7)	4.55 (1.53)	1.3	3.25	4.75	5.50	7.0	
		Week 28	Tezepelumab	30	29 (96.7)	5.09 (0.96)	3.8	4.50	5.00	5.50	7.0	
			Placebo	29	26 (89.7)	4.62 (1.56)	1.3	3.75	4.63	6.00	7.0	
		Week 32	Tezepelumab	30	29 (96.7)	5.11 (0.98)	4.0	4.50	4.75	5.50	7.0	
			Placebo	29	26 (89.7)	4.68 (1.53)	1.3	3.75	5.00	5.50	7.0	
		Week 36	Tezepelumab	30	29 (96.7)	5.23 (0.95)	4.0	4.50	5.00	5.75	7.0	
			Placebo	29	26 (89.7)	4.61 (1.35)	1.8	3.75	4.75	5.25	7.0	
		Week 40	Tezepelumab	30	29 (96.7)	5.16 (0.95)	3.8	4.50	5.00	5.75	7.0	
			Placebo	29	26 (89.7)	4.75 (1.40)	1.8	3.75	4.88	6.00	7.0	
		Week 44	Tezepelumab	30	29 (96.7)	5.14 (1.02)	4.0	4.25	5.00	5.50	7.0	
			Placebo	29	26 (89.7)	4.78 (1.41)	2.0	3.75	4.75	5.75	7.0	
		Week 48	Tezepelumab	30	29 (96.7)	5.27 (0.94)	4.0	4.50	5.00	6.00	7.0	
			Placebo	29	26 (89.7)	4.74 (1.37)	2.0	4.00	4.63	6.00	7.0	
		Week 52	Tezepelumab	30	29 (96.7)	5.28 (0.89)	4.0	4.50	5.00	6.00	7.0	
			Placebo	29	26 (89.7)	4.65 (1.38)	1.8	3.75	4.63	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	30	24 (80.0)	0.91 (1.43)	-4.0	0.38	1.00	1.63	4.0	0.23 [-0.34, 0.80]
			Placebo	29	24 (82.8)	0.61 (1.08)	-1.3	-0.13	0.38	1.50	3.0	
		Week 8	Tezepelumab	30	25 (83.3)	1.15 (1.14)	-1.3	0.25	1.25	1.75	4.3	0.35 [-0.21, 0.91]
			Placebo	29	25 (86.2)	0.75 (1.12)	-1.0	-0.25	0.50	1.25	3.0	
		Week 12	Tezepelumab	30	25 (83.3)	1.20 (1.25)	-2.3	0.50	1.25	2.00	4.8	0.56 [-0.01, 1.12]
			Placebo	29	25 (86.2)	0.56 (1.05)	-1.3	-0.25	0.50	1.00	3.0	
		Week 16	Tezepelumab	30	25 (83.3)	1.13 (1.24)	-2.8	0.50	1.25	1.75	3.3	0.49 [-0.08, 1.05]
			Placebo	29	25 (86.2)	0.56 (1.09)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	30	25 (83.3)	1.04 (0.98)	-1.3	0.50	1.00	1.50	3.3	0.51 [-0.06, 1.07]
			Placebo	29	25 (86.2)	0.53 (1.04)	-1.8	0.00	0.50	1.00	3.0	
		Week 24	Tezepelumab	30	25 (83.3)	1.28 (1.03)	-1.3	0.50	1.50	2.00	3.3	0.73 [0.16, 1.31]
			Placebo	29	25 (86.2)	0.46 (1.20)	-1.8	-0.25	0.50	1.25	3.0	
		Week 28	Tezepelumab	30	25 (83.3)	1.31 (1.10)	-1.5	0.75	1.50	2.00	3.3	0.64 [0.07, 1.21]
			Placebo	29	25 (86.2)	0.53 (1.32)	-2.8	0.25	0.75	1.00	2.8	
		Week 32	Tezepelumab	30	25 (83.3)	1.29 (1.06)	-1.3	0.75	1.50	1.75	3.3	0.63 [0.06, 1.20]
			Placebo	29	25 (86.2)	0.60 (1.14)	-1.8	0.00	0.50	1.25	3.0	
		Week 36	Tezepelumab	30	25 (83.3)	1.38 (1.13)	-1.3	0.75	1.50	2.25	3.3	0.77 [0.19, 1.34]
			Placebo	29	25 (86.2)	0.52 (1.11)	-2.3	0.00	0.25	1.00	3.0	
		Week 40	Tezepelumab	30	25 (83.3)	1.41 (1.06)	-1.3	0.75	1.50	2.25	3.3	0.68 [0.11, 1.25]
			Placebo	29	25 (86.2)	0.67 (1.11)	-1.5	0.00	0.50	1.00	3.3	
		Week 44	Tezepelumab	30	25 (83.3)	1.37 (1.20)	-1.3	0.75	1.50	2.25	3.8	0.58 [0.01, 1.14]
			Placebo	29	25 (86.2)	0.70 (1.12)	-1.3	0.00	0.50	1.25	3.3	
		Week 48	Tezepelumab	30	25 (83.3)	1.47 (1.18)	-1.3	0.75	1.50	2.25	3.8	0.72 [0.15, 1.29]
			Placebo	29	25 (86.2)	0.66 (1.07)	-1.3	0.25	0.50	1.00	3.8	
		Week 52	Tezepelumab	30	25 (83.3)	1.48 (1.10)	-1.3	0.75	1.50	2.00	3.8	0.83 [0.25, 1.41]
			Placebo	29	25 (86.2)	0.57 (1.10)	-1.3	0.25	0.50	1.00	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	36	32 (88.9)	4.08 (1.12)	1.8	3.50	4.00	4.63	6.8	
			Placebo	36	30 (83.3)	4.58 (1.30)	1.5	3.75	4.63	5.75	7.0	
		Week 4	Tezepelumab	36	34 (94.4)	4.82 (1.11)	2.0	4.00	5.13	5.75	6.8	
			Placebo	36	32 (88.9)	4.83 (1.09)	2.3	4.13	5.00	5.50	7.0	
		Week 8	Tezepelumab	36	35 (97.2)	5.23 (1.33)	1.0	4.25	5.75	6.00	7.0	
			Placebo	36	33 (91.7)	4.92 (1.32)	1.5	4.00	5.25	5.75	7.0	
		Week 12	Tezepelumab	36	35 (97.2)	5.43 (1.22)	1.0	4.75	5.75	6.25	7.0	
			Placebo	36	33 (91.7)	5.05 (1.16)	2.0	4.50	5.25	5.75	7.0	
		Week 16	Tezepelumab	36	35 (97.2)	5.31 (1.34)	1.0	4.50	5.50	6.00	7.0	
			Placebo	36	33 (91.7)	4.99 (1.39)	1.5	4.00	5.00	6.00	7.0	
		Week 20	Tezepelumab	36	35 (97.2)	5.30 (1.46)	1.0	4.50	5.50	6.50	7.0	
			Placebo	36	33 (91.7)	4.97 (1.46)	1.5	4.00	5.00	6.25	7.0	
		Week 24	Tezepelumab	36	35 (97.2)	5.32 (1.44)	1.0	4.50	5.50	6.50	7.0	
			Placebo	36	33 (91.7)	4.99 (1.47)	1.0	4.50	5.00	5.75	7.0	
		Week 28	Tezepelumab	36	36 (100.0)	5.29 (1.44)	1.0	4.50	5.38	6.38	7.0	
			Placebo	36	34 (94.4)	5.29 (1.39)	1.3	4.50	5.25	6.50	7.0	
		Week 32	Tezepelumab	36	36 (100.0)	5.42 (1.47)	1.0	4.63	5.75	6.63	7.0	
			Placebo	36	34 (94.4)	5.32 (1.37)	1.3	4.50	5.75	6.25	7.0	
		Week 36	Tezepelumab	36	36 (100.0)	5.36 (1.42)	1.0	4.50	5.63	6.50	7.0	
			Placebo	36	34 (94.4)	5.07 (1.58)	1.0	4.25	5.25	6.25	7.0	
		Week 40	Tezepelumab	36	36 (100.0)	5.44 (1.27)	2.0	4.50	5.50	6.50	7.0	
			Placebo	36	34 (94.4)	5.26 (1.51)	1.0	4.75	5.50	6.50	7.0	
		Week 44	Tezepelumab	36	36 (100.0)	5.47 (1.30)	1.3	4.75	5.75	6.38	7.0	
			Placebo	36	34 (94.4)	5.23 (1.40)	1.3	4.25	5.38	6.25	7.0	
		Week 48	Tezepelumab	36	36 (100.0)	5.41 (1.40)	1.0	4.50	5.75	6.50	7.0	
			Placebo	36	34 (94.4)	5.20 (1.36)	1.0	4.50	5.13	6.25	7.0	
		Week 52	Tezepelumab	36	36 (100.0)	5.42 (1.41)	1.0	4.50	5.75	6.50	7.0	
			Placebo	36	34 (94.4)	5.39 (1.20)	2.0	4.50	5.25	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	36	31 (86.1)	0.77 (1.10)	-1.3	0.00	0.75	1.75	3.0	0.43 [-0.08, 0.94]
			Placebo	36	30 (83.3)	0.32 (1.00)	-2.0	-0.25	0.38	1.00	2.5	
		Week 8	Tezepelumab	36	32 (88.9)	1.13 (1.28)	-1.0	0.00	1.13	2.25	3.3	0.53 [0.02, 1.03]
			Placebo	36	30 (83.3)	0.48 (1.21)	-1.8	0.00	0.25	1.25	3.3	
		Week 12	Tezepelumab	36	32 (88.9)	1.31 (1.12)	-1.0	0.38	1.38	2.25	3.0	0.67 [0.15, 1.18]
			Placebo	36	30 (83.3)	0.58 (1.06)	-1.8	0.00	0.75	1.25	2.5	
		Week 16	Tezepelumab	36	32 (88.9)	1.20 (1.25)	-0.8	0.00	1.13	2.38	3.0	0.61 [0.10, 1.12]
			Placebo	36	30 (83.3)	0.50 (1.02)	-1.5	0.00	0.38	1.00	3.0	
		Week 20	Tezepelumab	36	32 (88.9)	1.23 (1.38)	-1.8	0.00	1.50	2.50	3.5	0.58 [0.07, 1.09]
			Placebo	36	30 (83.3)	0.50 (1.11)	-2.3	0.00	0.25	1.25	2.5	
		Week 24	Tezepelumab	36	32 (88.9)	1.24 (1.37)	-1.5	0.00	1.38	2.38	3.5	0.57 [0.06, 1.07]
			Placebo	36	30 (83.3)	0.50 (1.24)	-2.8	-0.25	0.38	1.25	3.8	
		Week 28	Tezepelumab	36	32 (88.9)	1.18 (1.35)	-1.3	0.00	1.13	2.50	3.3	0.32 [-0.18, 0.82]
			Placebo	36	30 (83.3)	0.77 (1.23)	-1.3	0.00	0.63	1.50	3.8	
		Week 32	Tezepelumab	36	32 (88.9)	1.33 (1.43)	-1.3	0.00	1.50	2.38	3.5	0.41 [-0.09, 0.92]
			Placebo	36	30 (83.3)	0.82 (1.01)	-1.3	0.00	0.75	1.25	3.8	
		Week 36	Tezepelumab	36	32 (88.9)	1.30 (1.35)	-1.0	0.13	1.25	2.25	3.5	0.56 [0.06, 1.07]
			Placebo	36	30 (83.3)	0.55 (1.29)	-2.8	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	36	32 (88.9)	1.33 (1.24)	-0.5	0.25	1.25	2.25	3.3	0.47 [-0.03, 0.98]
			Placebo	36	30 (83.3)	0.73 (1.32)	-2.5	0.00	0.75	1.75	3.8	
		Week 44	Tezepelumab	36	32 (88.9)	1.40 (1.29)	-1.5	0.25	1.38	2.38	3.8	0.55 [0.04, 1.05]
			Placebo	36	30 (83.3)	0.68 (1.32)	-1.5	-0.25	0.25	1.25	3.8	
		Week 48	Tezepelumab	36	32 (88.9)	1.35 (1.33)	-0.8	0.13	1.25	2.38	3.5	0.49 [-0.01, 1.00]
			Placebo	36	30 (83.3)	0.66 (1.48)	-2.8	0.00	0.38	1.25	3.8	
		Week 52	Tezepelumab	36	32 (88.9)	1.35 (1.33)	-0.8	0.13	1.13	2.38	3.5	0.38 [-0.13, 0.88]
			Placebo	36	30 (83.3)	0.85 (1.34)	-1.3	0.00	0.50	1.50	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	38	31 (81.6)	3.96 (0.92)	1.8	3.25	4.00	4.75	5.8	
			Placebo	30	23 (76.7)	3.97 (1.13)	1.5	3.25	3.75	4.75	6.0	
		Week 4	Tezepelumab	38	35 (92.1)	4.63 (1.14)	1.3	3.75	4.75	5.50	7.0	
			Placebo	30	25 (83.3)	4.35 (1.29)	2.3	3.50	4.25	5.25	7.0	
		Week 8	Tezepelumab	38	35 (92.1)	5.06 (1.06)	1.8	4.25	5.00	5.75	7.0	
			Placebo	30	25 (83.3)	4.68 (1.50)	1.5	3.75	4.75	5.75	7.0	
		Week 12	Tezepelumab	38	35 (92.1)	5.18 (1.06)	3.0	4.50	5.25	6.00	7.0	
			Placebo	30	25 (83.3)	4.48 (1.28)	2.0	3.75	4.50	5.25	7.0	
		Week 16	Tezepelumab	38	35 (92.1)	4.97 (1.08)	2.0	4.50	4.75	5.50	7.0	
			Placebo	30	25 (83.3)	4.57 (1.39)	1.5	4.00	4.75	5.25	7.0	
		Week 20	Tezepelumab	38	36 (94.7)	5.05 (1.16)	1.0	4.50	5.00	5.75	7.0	
			Placebo	30	25 (83.3)	4.58 (1.39)	1.5	4.00	5.00	5.25	7.0	
		Week 24	Tezepelumab	38	36 (94.7)	5.13 (1.22)	1.3	4.25	5.00	6.00	7.0	
			Placebo	30	25 (83.3)	4.59 (1.59)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	38	38 (100.0)	5.07 (1.21)	1.5	4.25	5.00	5.75	7.0	
			Placebo	30	26 (86.7)	4.74 (1.48)	1.3	4.00	5.13	6.00	7.0	
		Week 32	Tezepelumab	38	38 (100.0)	5.15 (1.20)	1.5	4.25	5.00	6.00	7.0	
			Placebo	30	26 (86.7)	4.73 (1.53)	1.3	3.75	4.88	6.00	7.0	
		Week 36	Tezepelumab	38	38 (100.0)	5.16 (1.16)	1.8	4.50	5.00	6.25	7.0	
			Placebo	30	26 (86.7)	4.55 (1.63)	1.0	3.75	5.00	5.50	7.0	
		Week 40	Tezepelumab	38	38 (100.0)	5.18 (1.08)	2.3	4.50	5.00	5.75	7.0	
			Placebo	30	26 (86.7)	4.73 (1.64)	1.0	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	38	38 (100.0)	5.11 (1.18)	1.3	4.25	5.00	5.75	7.0	
			Placebo	30	26 (86.7)	4.72 (1.58)	1.3	3.75	4.75	6.00	7.0	
		Week 48	Tezepelumab	38	38 (100.0)	5.13 (1.08)	2.3	4.25	5.00	6.00	7.0	
			Placebo	30	26 (86.7)	4.75 (1.46)	1.0	4.00	4.75	6.00	7.0	
		Week 52	Tezepelumab	38	38 (100.0)	5.16 (1.07)	2.3	4.50	5.00	6.00	7.0	
			Placebo	30	26 (86.7)	4.77 (1.43)	1.8	4.00	4.75	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	38	31 (81.6)	0.61 (1.31)	-4.0	0.00	0.75	1.25	4.0	0.15 [-0.39, 0.69]
			Placebo	30	23 (76.7)	0.42 (1.17)	-1.8	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	38	31 (81.6)	1.02 (1.20)	-1.3	0.25	1.25	1.75	4.3	0.20 [-0.34, 0.74]
			Placebo	30	23 (76.7)	0.78 (1.24)	-1.3	-0.25	0.75	1.50	3.0	
		Week 12	Tezepelumab	38	31 (81.6)	1.19 (1.15)	-2.3	0.50	1.25	1.75	4.8	0.56 [0.01, 1.11]
			Placebo	30	23 (76.7)	0.54 (1.13)	-1.3	-0.25	0.50	1.00	3.0	
		Week 16	Tezepelumab	38	31 (81.6)	1.00 (1.19)	-2.8	0.25	1.25	2.00	3.0	0.32 [-0.22, 0.87]
			Placebo	30	23 (76.7)	0.63 (1.06)	-1.0	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	38	31 (81.6)	1.09 (1.13)	-1.8	0.25	1.25	2.00	3.3	0.38 [-0.16, 0.92]
			Placebo	30	23 (76.7)	0.67 (1.03)	-1.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	38	31 (81.6)	1.19 (1.17)	-1.5	0.25	1.50	2.00	3.3	0.47 [-0.07, 1.02]
			Placebo	30	23 (76.7)	0.64 (1.16)	-1.5	-0.25	0.50	1.25	3.0	
		Week 28	Tezepelumab	38	31 (81.6)	1.10 (1.20)	-1.5	0.25	1.50	2.00	3.3	0.29 [-0.25, 0.83]
			Placebo	30	23 (76.7)	0.74 (1.33)	-2.8	0.25	0.75	2.00	2.8	
		Week 32	Tezepelumab	38	31 (81.6)	1.19 (1.17)	-1.3	0.25	1.50	2.25	3.3	0.40 [-0.14, 0.95]
			Placebo	30	23 (76.7)	0.73 (1.07)	-1.5	0.00	0.50	1.25	3.0	
		Week 36	Tezepelumab	38	31 (81.6)	1.21 (1.15)	-1.3	0.25	1.50	2.25	3.3	0.53 [-0.02, 1.08]
			Placebo	30	23 (76.7)	0.58 (1.25)	-2.3	-0.25	0.50	1.25	3.0	
		Week 40	Tezepelumab	38	31 (81.6)	1.26 (1.04)	-1.3	0.25	1.50	2.00	3.3	0.47 [-0.08, 1.01]
			Placebo	30	23 (76.7)	0.73 (1.25)	-1.5	0.00	0.50	1.25	3.3	
		Week 44	Tezepelumab	38	31 (81.6)	1.20 (1.14)	-1.5	0.50	1.50	2.00	3.3	0.46 [-0.09, 1.01]
			Placebo	30	23 (76.7)	0.67 (1.15)	-1.3	0.00	0.50	1.25	3.3	
		Week 48	Tezepelumab	38	31 (81.6)	1.19 (1.09)	-1.3	0.50	1.50	2.00	3.3	0.40 [-0.15, 0.94]
			Placebo	30	23 (76.7)	0.74 (1.23)	-1.5	0.25	0.50	1.25	3.8	
		Week 52	Tezepelumab	38	31 (81.6)	1.22 (1.02)	-1.3	0.50	1.50	2.00	3.3	0.45 [-0.09, 1.00]
			Placebo	30	23 (76.7)	0.72 (1.21)	-1.3	-0.25	0.50	1.25	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	28	27 (96.4)	4.02 (1.21)	1.8	3.25	4.00	4.75	6.8	
			Placebo	34	31 (91.2)	4.73 (1.19)	2.0	3.75	4.75	5.75	7.0	
		Week 4	Tezepelumab	28	25 (89.3)	5.04 (1.07)	2.0	4.50	5.25	5.75	6.8	
			Placebo	34	32 (94.1)	5.23 (0.99)	2.0	4.75	5.25	5.75	7.0	
		Week 8	Tezepelumab	28	27 (96.4)	5.27 (1.27)	1.0	4.25	5.75	6.25	7.0	
			Placebo	34	33 (97.1)	5.15 (1.04)	3.0	4.75	5.25	5.75	7.0	
		Week 12	Tezepelumab	28	27 (96.4)	5.39 (1.24)	1.0	4.75	5.50	6.25	7.0	
			Placebo	34	33 (97.1)	5.27 (0.95)	3.0	5.00	5.50	5.75	7.0	
		Week 16	Tezepelumab	28	27 (96.4)	5.41 (1.30)	1.0	4.50	5.50	6.25	7.0	
			Placebo	34	33 (97.1)	5.23 (1.18)	2.8	4.25	5.25	6.25	7.0	
		Week 20	Tezepelumab	28	27 (96.4)	5.25 (1.34)	1.3	4.25	5.50	6.50	7.0	
			Placebo	34	33 (97.1)	5.15 (1.26)	2.5	4.00	5.25	6.25	7.0	
		Week 24	Tezepelumab	28	27 (96.4)	5.37 (1.32)	1.0	4.50	5.50	6.50	7.0	
			Placebo	34	33 (97.1)	5.06 (1.30)	2.0	4.50	5.00	5.75	7.0	
		Week 28	Tezepelumab	28	27 (96.4)	5.40 (1.30)	1.0	4.50	5.50	6.25	7.0	
			Placebo	34	33 (97.1)	5.32 (1.34)	2.5	4.50	5.25	6.50	7.0	
		Week 32	Tezepelumab	28	27 (96.4)	5.46 (1.37)	1.0	4.75	5.75	6.25	7.0	
			Placebo	34	33 (97.1)	5.40 (1.21)	2.8	4.75	5.75	6.25	7.0	
		Week 36	Tezepelumab	28	27 (96.4)	5.50 (1.31)	1.0	5.00	5.75	6.50	7.0	
			Placebo	34	33 (97.1)	5.18 (1.32)	2.0	4.25	5.00	6.25	7.0	
		Week 40	Tezepelumab	28	27 (96.4)	5.51 (1.20)	2.0	4.50	5.75	6.50	7.0	
			Placebo	34	33 (97.1)	5.32 (1.31)	2.3	4.75	5.50	6.50	7.0	
		Week 44	Tezepelumab	28	27 (96.4)	5.62 (1.16)	2.0	4.75	6.00	6.50	7.0	
			Placebo	34	33 (97.1)	5.32 (1.22)	2.8	4.50	5.50	6.25	7.0	
		Week 48	Tezepelumab	28	27 (96.4)	5.66 (1.32)	1.0	4.75	6.00	6.50	7.0	
			Placebo	34	33 (97.1)	5.23 (1.29)	2.0	4.50	5.00	6.25	7.0	
		Week 52	Tezepelumab	28	27 (96.4)	5.63 (1.33)	1.0	4.75	6.00	6.50	7.0	
			Placebo	34	33 (97.1)	5.35 (1.18)	2.8	4.50	5.25	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	28	24 (85.7)	1.10 (1.12)	-0.8	0.13	1.38	2.00	3.0	0.62 [0.07, 1.17]
			Placebo	34	31 (91.2)	0.47 (0.95)	-2.0	-0.25	0.50	1.00	2.5	
		Week 8	Tezepelumab	28	26 (92.9)	1.28 (1.23)	-0.8	0.00	1.38	2.25	3.3	0.67 [0.13, 1.20]
			Placebo	34	31 (91.2)	0.49 (1.13)	-1.8	0.00	0.25	1.25	3.3	
		Week 12	Tezepelumab	28	26 (92.9)	1.36 (1.21)	-1.0	0.25	1.38	2.50	3.0	0.71 [0.17, 1.25]
			Placebo	34	31 (91.2)	0.57 (1.00)	-1.8	0.00	0.75	1.25	2.5	
		Week 16	Tezepelumab	28	26 (92.9)	1.37 (1.29)	-0.8	0.25	1.25	2.50	3.3	0.75 [0.21, 1.29]
			Placebo	34	31 (91.2)	0.52 (0.97)	-1.5	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	28	26 (92.9)	1.22 (1.33)	-0.5	0.25	1.00	2.50	3.5	0.64 [0.10, 1.17]
			Placebo	34	31 (91.2)	0.47 (1.04)	-2.3	0.00	0.25	1.25	2.5	
		Week 24	Tezepelumab	28	26 (92.9)	1.34 (1.30)	-0.8	0.25	1.38	2.50	3.5	0.72 [0.18, 1.26]
			Placebo	34	31 (91.2)	0.44 (1.22)	-2.8	-0.25	0.25	1.25	3.8	
		Week 28	Tezepelumab	28	26 (92.9)	1.39 (1.30)	-0.8	0.25	1.38	2.75	3.3	0.58 [0.05, 1.11]
			Placebo	34	31 (91.2)	0.68 (1.18)	-1.5	0.00	0.75	1.25	3.8	
		Week 32	Tezepelumab	28	26 (92.9)	1.46 (1.38)	-0.8	0.25	1.50	2.50	3.5	0.57 [0.03, 1.10]
			Placebo	34	31 (91.2)	0.79 (1.00)	-1.3	0.00	0.75	1.50	3.8	
		Week 36	Tezepelumab	28	26 (92.9)	1.48 (1.37)	-0.8	0.25	1.50	2.75	3.5	0.75 [0.21, 1.29]
			Placebo	34	31 (91.2)	0.52 (1.20)	-2.8	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	28	26 (92.9)	1.49 (1.30)	-0.5	0.25	1.38	2.75	3.3	0.64 [0.11, 1.18]
			Placebo	34	31 (91.2)	0.68 (1.23)	-2.5	0.00	0.75	1.50	3.8	
		Week 44	Tezepelumab	28	26 (92.9)	1.61 (1.34)	-0.5	0.50	1.38	2.75	3.8	0.68 [0.15, 1.22]
			Placebo	34	31 (91.2)	0.70 (1.31)	-1.5	0.00	0.25	1.25	3.8	
		Week 48	Tezepelumab	28	26 (92.9)	1.65 (1.41)	-0.8	0.75	1.75	3.00	3.8	0.76 [0.22, 1.30]
			Placebo	34	31 (91.2)	0.60 (1.38)	-2.8	0.00	0.25	1.25	3.8	
		Week 52	Tezepelumab	28	26 (92.9)	1.63 (1.41)	-0.8	0.75	1.50	2.75	3.8	0.68 [0.14, 1.21]
			Placebo	34	31 (91.2)	0.73 (1.29)	-1.3	0.00	0.25	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	3.91 (0.94)	1.8	3.25	4.00	4.50	5.8	
			Placebo	27	21 (77.8)	3.98 (1.16)	1.5	3.50	3.75	4.75	6.0	
		Week 4	Tezepelumab	32	30 (93.8)	4.74 (1.13)	1.3	4.25	4.88	5.50	7.0	
			Placebo	27	23 (85.2)	4.34 (1.21)	2.3	3.50	4.25	5.25	7.0	
		Week 8	Tezepelumab	32	30 (93.8)	5.18 (1.08)	1.8	4.50	5.25	6.00	7.0	
			Placebo	27	23 (85.2)	4.61 (1.47)	1.5	3.50	4.75	5.75	7.0	
		Week 12	Tezepelumab	32	30 (93.8)	5.24 (1.03)	3.0	4.50	5.25	6.00	7.0	
			Placebo	27	23 (85.2)	4.38 (1.22)	2.0	3.50	4.50	5.25	6.8	
		Week 16	Tezepelumab	32	30 (93.8)	4.93 (1.12)	2.0	4.50	4.75	5.50	7.0	
			Placebo	27	23 (85.2)	4.49 (1.35)	1.5	4.00	4.75	5.25	6.8	
		Week 20	Tezepelumab	32	31 (96.9)	5.01 (1.16)	1.0	4.50	5.00	5.75	7.0	
			Placebo	27	23 (85.2)	4.52 (1.34)	1.5	4.00	5.00	5.25	7.0	
		Week 24	Tezepelumab	32	31 (96.9)	5.07 (1.25)	1.3	4.00	5.00	6.00	7.0	
			Placebo	27	23 (85.2)	4.58 (1.51)	1.0	4.00	4.75	5.75	7.0	
		Week 28	Tezepelumab	32	32 (100.0)	4.96 (1.16)	1.5	4.25	5.00	5.50	7.0	
			Placebo	27	24 (88.9)	4.61 (1.46)	1.3	3.88	5.00	5.88	6.8	
		Week 32	Tezepelumab	32	32 (100.0)	5.09 (1.15)	1.5	4.38	5.00	5.88	7.0	
			Placebo	27	24 (88.9)	4.70 (1.49)	1.3	3.88	4.88	5.75	7.0	
		Week 36	Tezepelumab	32	32 (100.0)	5.11 (1.16)	1.8	4.50	5.00	6.13	7.0	
			Placebo	27	24 (88.9)	4.51 (1.59)	1.0	3.75	5.00	5.38	7.0	
		Week 40	Tezepelumab	32	32 (100.0)	5.09 (1.07)	2.3	4.50	5.00	5.63	7.0	
			Placebo	27	24 (88.9)	4.70 (1.61)	1.0	4.00	5.00	5.88	7.0	
		Week 44	Tezepelumab	32	32 (100.0)	4.98 (1.20)	1.3	4.13	5.00	5.50	7.0	
			Placebo	27	24 (88.9)	4.69 (1.54)	1.3	3.88	4.75	5.88	7.0	
		Week 48	Tezepelumab	32	32 (100.0)	5.02 (1.07)	2.3	4.25	5.00	5.75	7.0	
			Placebo	27	24 (88.9)	4.77 (1.45)	1.0	4.00	4.75	6.00	7.0	
		Week 52	Tezepelumab	32	32 (100.0)	5.05 (1.03)	2.3	4.38	5.00	5.75	7.0	
			Placebo	27	24 (88.9)	4.79 (1.42)	1.8	4.00	4.75	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	32	26 (81.3)	0.78 (1.32)	-4.0	0.25	0.75	1.25	4.0	0.30 [-0.28, 0.88]
			Placebo	27	21 (77.8)	0.40 (1.15)	-1.8	-0.25	0.25	0.75	3.0	
		Week 8	Tezepelumab	32	26 (81.3)	1.18 (1.24)	-1.3	0.25	1.38	1.75	4.3	0.39 [-0.19, 0.97]
			Placebo	27	21 (77.8)	0.70 (1.24)	-1.3	-0.25	0.50	1.25	3.0	
		Week 12	Tezepelumab	32	26 (81.3)	1.30 (1.20)	-2.3	0.75	1.38	2.00	4.8	0.75 [0.16, 1.35]
			Placebo	27	21 (77.8)	0.43 (1.10)	-1.3	-0.25	0.50	0.75	3.0	
		Week 16	Tezepelumab	32	26 (81.3)	1.00 (1.29)	-2.8	0.00	1.13	2.00	3.0	0.39 [-0.19, 0.97]
			Placebo	27	21 (77.8)	0.54 (1.03)	-1.0	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	32	26 (81.3)	1.09 (1.19)	-1.8	0.25	1.25	2.00	3.3	0.43 [-0.15, 1.01]
			Placebo	27	21 (77.8)	0.61 (1.00)	-1.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	32	26 (81.3)	1.18 (1.22)	-1.5	0.25	1.50	2.00	3.3	0.48 [-0.10, 1.07]
			Placebo	27	21 (77.8)	0.62 (1.09)	-1.5	0.00	0.50	1.00	3.0	
		Week 28	Tezepelumab	32	26 (81.3)	1.10 (1.21)	-1.5	0.25	1.38	2.00	3.3	0.41 [-0.17, 0.99]
			Placebo	27	21 (77.8)	0.58 (1.28)	-2.8	0.25	0.50	1.00	2.8	
		Week 32	Tezepelumab	32	26 (81.3)	1.23 (1.16)	-1.3	0.50	1.38	2.25	3.3	0.50 [-0.09, 1.08]
			Placebo	27	21 (77.8)	0.68 (1.04)	-1.5	0.25	0.50	1.00	3.0	
		Week 36	Tezepelumab	32	26 (81.3)	1.24 (1.18)	-1.3	0.50	1.50	2.25	3.3	0.60 [0.01, 1.19]
			Placebo	27	21 (77.8)	0.52 (1.22)	-2.3	-0.25	0.50	1.00	3.0	
		Week 40	Tezepelumab	32	26 (81.3)	1.26 (1.07)	-1.3	0.25	1.50	2.00	3.3	0.50 [-0.08, 1.09]
			Placebo	27	21 (77.8)	0.68 (1.24)	-1.5	0.00	0.50	1.25	3.3	
		Week 44	Tezepelumab	32	26 (81.3)	1.14 (1.20)	-1.5	0.25	1.50	2.00	3.3	0.45 [-0.13, 1.03]
			Placebo	27	21 (77.8)	0.62 (1.13)	-1.3	0.00	0.50	1.00	3.3	
		Week 48	Tezepelumab	32	26 (81.3)	1.16 (1.11)	-1.3	0.50	1.38	2.00	3.3	0.35 [-0.23, 0.93]
			Placebo	27	21 (77.8)	0.75 (1.26)	-1.5	0.25	0.50	1.00	3.8	
		Week 52	Tezepelumab	32	26 (81.3)	1.19 (1.04)	-1.3	0.50	1.38	2.00	3.3	0.41 [-0.17, 0.99]
			Placebo	27	21 (77.8)	0.73 (1.24)	-1.3	0.25	0.50	1.00	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	4.05 (1.15)	1.8	3.38	4.00	4.75	6.8	
			Placebo	37	33 (89.2)	4.68 (1.18)	2.0	3.75	4.75	5.50	7.0	
		Week 4	Tezepelumab	34	30 (88.2)	4.86 (1.13)	2.0	4.00	5.13	5.75	6.8	
			Placebo	37	34 (91.9)	5.18 (1.09)	2.0	4.75	5.25	5.75	7.0	
		Week 8	Tezepelumab	34	32 (94.1)	5.13 (1.23)	1.0	4.25	5.38	6.00	7.0	
			Placebo	37	35 (94.6)	5.17 (1.07)	3.0	4.75	5.25	6.00	7.0	
		Week 12	Tezepelumab	34	32 (94.1)	5.30 (1.25)	1.0	4.63	5.50	6.25	7.0	
			Placebo	37	35 (94.6)	5.29 (0.99)	3.0	4.75	5.50	6.00	7.0	
		Week 16	Tezepelumab	34	32 (94.1)	5.38 (1.22)	1.0	4.50	5.50	6.00	7.0	
			Placebo	37	35 (94.6)	5.24 (1.21)	2.8	4.25	5.25	6.25	7.0	
		Week 20	Tezepelumab	34	32 (94.1)	5.26 (1.31)	1.3	4.25	5.38	6.50	7.0	
			Placebo	37	35 (94.6)	5.16 (1.30)	2.5	4.00	5.25	6.25	7.0	
		Week 24	Tezepelumab	34	32 (94.1)	5.38 (1.28)	1.0	4.63	5.50	6.50	7.0	
			Placebo	37	35 (94.6)	5.04 (1.38)	2.0	4.50	5.00	6.00	7.0	
		Week 28	Tezepelumab	34	33 (97.1)	5.44 (1.30)	1.0	4.75	5.50	6.25	7.0	
			Placebo	37	35 (94.6)	5.37 (1.33)	2.5	4.50	5.50	6.50	7.0	
		Week 32	Tezepelumab	34	33 (97.1)	5.46 (1.38)	1.0	4.50	5.75	6.50	7.0	
			Placebo	37	35 (94.6)	5.39 (1.26)	2.8	4.50	5.75	6.25	7.0	
		Week 36	Tezepelumab	34	33 (97.1)	5.49 (1.28)	1.0	4.75	5.75	6.50	7.0	
			Placebo	37	35 (94.6)	5.17 (1.37)	2.0	4.25	5.00	6.25	7.0	
		Week 40	Tezepelumab	34	33 (97.1)	5.53 (1.18)	2.0	4.50	5.75	6.50	7.0	
			Placebo	37	35 (94.6)	5.31 (1.35)	2.3	4.75	5.50	6.50	7.0	
		Week 44	Tezepelumab	34	33 (97.1)	5.65 (1.10)	2.0	5.00	6.00	6.50	7.0	
			Placebo	37	35 (94.6)	5.31 (1.27)	2.8	4.25	5.50	6.50	7.0	
		Week 48	Tezepelumab	34	33 (97.1)	5.66 (1.26)	1.0	5.00	6.00	6.50	7.0	
			Placebo	37	35 (94.6)	5.19 (1.32)	2.0	4.50	5.00	6.25	7.0	
		Week 52	Tezepelumab	34	33 (97.1)	5.65 (1.28)	1.0	4.75	6.00	6.50	7.0	
			Placebo	37	35 (94.6)	5.30 (1.22)	2.8	4.50	5.25	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	34	29 (85.3)	0.87 (1.19)	-1.3	-0.25	1.00	1.75	3.0	0.36 [-0.14, 0.87]
			Placebo	37	33 (89.2)	0.48 (0.98)	-2.0	-0.25	0.50	1.00	2.5	
		Week 8	Tezepelumab	34	31 (91.2)	1.10 (1.20)	-0.8	0.00	0.75	2.25	3.3	0.46 [-0.03, 0.96]
			Placebo	37	33 (89.2)	0.56 (1.15)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	34	31 (91.2)	1.23 (1.17)	-1.0	0.25	1.00	2.25	3.0	0.54 [0.04, 1.04]
			Placebo	37	33 (89.2)	0.64 (1.03)	-1.8	0.00	1.00	1.25	2.5	
		Week 16	Tezepelumab	34	31 (91.2)	1.31 (1.20)	-0.8	0.25	1.25	2.50	3.3	0.65 [0.15, 1.15]
			Placebo	37	33 (89.2)	0.59 (1.00)	-1.5	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	34	31 (91.2)	1.20 (1.25)	-0.5	0.25	1.00	2.50	3.5	0.58 [0.08, 1.09]
			Placebo	37	33 (89.2)	0.52 (1.07)	-2.3	0.00	0.25	1.25	2.5	
		Week 24	Tezepelumab	34	31 (91.2)	1.32 (1.24)	-0.8	0.25	1.50	2.50	3.5	0.69 [0.19, 1.20]
			Placebo	37	33 (89.2)	0.46 (1.25)	-2.8	-0.25	0.25	1.25	3.8	
		Week 28	Tezepelumab	34	31 (91.2)	1.35 (1.27)	-0.8	0.25	1.50	2.75	3.3	0.46 [-0.03, 0.96]
			Placebo	37	33 (89.2)	0.78 (1.21)	-1.5	0.00	0.75	1.50	3.8	
		Week 32	Tezepelumab	34	31 (91.2)	1.38 (1.37)	-0.8	0.00	1.50	2.50	3.5	0.47 [-0.03, 0.96]
			Placebo	37	33 (89.2)	0.82 (1.02)	-1.3	0.00	0.75	1.50	3.8	
		Week 36	Tezepelumab	34	31 (91.2)	1.41 (1.32)	-0.8	0.00	1.50	2.50	3.5	0.67 [0.16, 1.17]
			Placebo	37	33 (89.2)	0.56 (1.22)	-2.8	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	34	31 (91.2)	1.45 (1.24)	-0.5	0.25	1.50	2.75	3.3	0.60 [0.10, 1.10]
			Placebo	37	33 (89.2)	0.71 (1.24)	-2.5	0.00	0.75	1.50	3.8	
		Week 44	Tezepelumab	34	31 (91.2)	1.59 (1.26)	-0.5	0.50	1.50	2.75	3.8	0.66 [0.16, 1.17]
			Placebo	37	33 (89.2)	0.73 (1.31)	-1.5	0.00	0.25	1.25	3.8	
		Week 48	Tezepelumab	34	31 (91.2)	1.60 (1.35)	-0.8	0.50	1.75	2.75	3.8	0.74 [0.24, 1.25]
			Placebo	37	33 (89.2)	0.60 (1.36)	-2.8	0.00	0.25	1.25	3.8	
		Week 52	Tezepelumab	34	31 (91.2)	1.59 (1.35)	-0.8	0.50	1.50	2.75	3.8	0.66 [0.16, 1.17]
			Placebo	37	33 (89.2)	0.72 (1.27)	-1.3	0.00	0.25	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	25	21 (84.0)	3.70 (0.87)	1.8	3.00	4.00	4.25	5.0	
			Placebo	22	18 (81.8)	4.17 (1.42)	1.5	3.25	4.13	5.25	6.5	
		Week 4	Tezepelumab	25	24 (96.0)	4.47 (0.99)	2.0	3.75	4.63	5.13	6.0	
			Placebo	22	18 (81.8)	4.78 (1.46)	2.0	3.75	5.25	5.50	7.0	
		Week 8	Tezepelumab	25	24 (96.0)	4.76 (1.27)	1.0	4.25	4.88	5.75	6.5	
			Placebo	22	20 (90.9)	4.65 (1.63)	1.5	3.25	5.13	6.00	7.0	
		Week 12	Tezepelumab	25	24 (96.0)	4.99 (1.23)	1.0	4.50	5.00	5.50	7.0	
			Placebo	22	20 (90.9)	4.73 (1.45)	2.0	3.75	5.00	5.88	7.0	
		Week 16	Tezepelumab	25	24 (96.0)	4.98 (1.40)	1.0	4.50	5.00	6.00	7.0	
			Placebo	22	20 (90.9)	4.49 (1.78)	1.3	3.50	4.25	6.13	7.0	
		Week 20	Tezepelumab	25	24 (96.0)	4.78 (1.52)	1.0	4.00	5.00	5.88	7.0	
			Placebo	22	20 (90.9)	4.53 (1.88)	1.3	3.13	4.50	6.38	7.0	
		Week 24	Tezepelumab	25	24 (96.0)	4.92 (1.56)	1.0	4.13	5.00	6.13	7.0	
			Placebo	22	20 (90.9)	4.33 (1.92)	1.0	2.88	4.25	6.00	7.0	
		Week 28	Tezepelumab	25	25 (100.0)	4.84 (1.38)	1.0	4.50	4.75	6.00	7.0	
			Placebo	22	20 (90.9)	4.49 (1.88)	1.3	3.13	4.50	6.25	7.0	
		Week 32	Tezepelumab	25	25 (100.0)	4.98 (1.50)	1.0	4.25	5.00	6.00	7.0	
			Placebo	22	20 (90.9)	4.60 (1.75)	1.3	3.75	4.50	6.00	7.0	
		Week 36	Tezepelumab	25	25 (100.0)	4.90 (1.46)	1.0	4.25	5.00	6.00	7.0	
			Placebo	22	20 (90.9)	4.49 (1.85)	1.0	3.38	4.25	6.13	7.0	
		Week 40	Tezepelumab	25	25 (100.0)	5.01 (1.27)	2.0	4.25	5.00	5.75	7.0	
			Placebo	22	20 (90.9)	4.58 (1.76)	1.0	3.63	5.00	5.75	7.0	
		Week 44	Tezepelumab	25	25 (100.0)	4.91 (1.37)	1.3	4.25	5.00	6.00	7.0	
			Placebo	22	20 (90.9)	4.61 (1.60)	1.3	3.63	4.25	5.88	7.0	
		Week 48	Tezepelumab	25	25 (100.0)	4.86 (1.39)	1.0	4.00	5.00	6.00	7.0	
			Placebo	22	20 (90.9)	4.56 (1.60)	1.0	3.88	4.38	5.63	7.0	
		Week 52	Tezepelumab	25	25 (100.0)	4.89 (1.37)	1.0	4.25	5.00	6.00	7.0	
			Placebo	22	20 (90.9)	4.71 (1.33)	2.0	4.00	4.38	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	25	21 (84.0)	0.77 (0.85)	-1.0	0.25	0.75	1.25	2.5	0.17 [-0.47, 0.81]
			Placebo	22	17 (77.3)	0.62 (1.05)	-1.3	-0.25	0.75	1.00	3.0	
		Week 8	Tezepelumab	25	21 (84.0)	0.96 (1.19)	-1.0	0.25	1.25	1.75	2.8	0.28 [-0.36, 0.91]
			Placebo	22	18 (81.8)	0.64 (1.17)	-1.3	-0.25	0.38	1.25	3.0	
		Week 12	Tezepelumab	25	21 (84.0)	1.17 (0.92)	-1.0	0.75	1.25	1.50	2.5	0.53 [-0.11, 1.17]
			Placebo	22	18 (81.8)	0.67 (0.98)	-1.3	0.25	0.88	1.25	2.8	
		Week 16	Tezepelumab	25	21 (84.0)	1.18 (1.14)	-0.8	0.50	1.50	2.00	3.3	0.70 [0.05, 1.35]
			Placebo	22	18 (81.8)	0.38 (1.16)	-1.8	-0.25	0.50	1.00	2.8	
		Week 20	Tezepelumab	25	21 (84.0)	1.02 (1.24)	-1.8	0.00	1.25	1.75	3.5	0.45 [-0.19, 1.09]
			Placebo	22	18 (81.8)	0.44 (1.33)	-2.3	-0.25	0.50	1.50	3.0	
		Week 24	Tezepelumab	25	21 (84.0)	1.15 (1.26)	-1.5	0.25	1.50	2.00	3.3	0.72 [0.07, 1.37]
			Placebo	22	18 (81.8)	0.19 (1.40)	-2.8	-0.75	0.38	1.00	3.0	
		Week 28	Tezepelumab	25	21 (84.0)	1.14 (1.19)	-1.3	0.75	1.50	2.00	2.8	0.64 [-0.01, 1.29]
			Placebo	22	18 (81.8)	0.32 (1.39)	-1.8	-1.25	0.25	1.50	2.8	
		Week 32	Tezepelumab	25	21 (84.0)	1.32 (1.27)	-1.3	0.75	1.50	2.25	3.5	0.71 [0.06, 1.36]
			Placebo	22	18 (81.8)	0.47 (1.10)	-1.8	-0.25	0.50	1.00	3.0	
		Week 36	Tezepelumab	25	21 (84.0)	1.23 (1.26)	-1.0	0.50	1.25	2.25	3.3	0.70 [0.05, 1.35]
			Placebo	22	18 (81.8)	0.33 (1.31)	-2.8	-0.25	0.38	0.75	3.0	
		Week 40	Tezepelumab	25	21 (84.0)	1.31 (1.05)	-0.5	0.50	1.50	2.00	3.3	0.73 [0.08, 1.38]
			Placebo	22	18 (81.8)	0.43 (1.36)	-2.5	-0.50	0.50	1.25	3.0	
		Week 44	Tezepelumab	25	21 (84.0)	1.21 (1.17)	-1.5	0.75	1.50	2.00	3.0	0.67 [0.02, 1.32]
			Placebo	22	18 (81.8)	0.44 (1.12)	-1.3	-0.25	0.13	1.00	3.0	
		Week 48	Tezepelumab	25	21 (84.0)	1.19 (1.23)	-1.0	0.75	1.50	2.00	3.5	0.60 [-0.05, 1.24]
			Placebo	22	18 (81.8)	0.39 (1.47)	-2.8	-0.25	0.38	1.00	3.0	
		Week 52	Tezepelumab	25	21 (84.0)	1.24 (1.16)	-0.8	0.75	1.50	2.00	3.5	0.56 [-0.09, 1.20]
			Placebo	22	18 (81.8)	0.58 (1.19)	-1.3	-0.25	0.38	1.00	3.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	35	33 (94.3)	4.26 (1.08)	2.5	3.75	4.00	5.00	6.8	
			Placebo	41	35 (85.4)	4.48 (1.14)	2.0	3.50	4.25	5.50	7.0	
		Week 4	Tezepelumab	35	31 (88.6)	4.98 (1.21)	1.3	4.25	5.25	5.75	7.0	
			Placebo	41	37 (90.2)	4.89 (1.11)	2.3	4.25	4.75	5.50	7.0	
		Week 8	Tezepelumab	35	33 (94.3)	5.39 (1.07)	3.5	4.25	5.75	6.25	7.0	
			Placebo	41	37 (90.2)	5.07 (1.07)	2.3	4.75	5.00	5.50	7.0	
		Week 12	Tezepelumab	35	33 (94.3)	5.45 (1.10)	3.0	4.50	5.75	6.25	7.0	
			Placebo	41	37 (90.2)	5.04 (0.99)	2.5	4.50	5.00	5.75	7.0	
		Week 16	Tezepelumab	35	33 (94.3)	5.30 (1.10)	2.5	4.50	5.50	6.00	7.0	
			Placebo	41	37 (90.2)	5.08 (1.13)	2.0	4.50	5.00	5.75	7.0	
		Week 20	Tezepelumab	35	33 (94.3)	5.39 (1.06)	3.8	4.50	5.25	6.50	7.0	
			Placebo	41	37 (90.2)	5.00 (1.12)	2.3	4.50	5.00	5.75	7.0	
		Week 24	Tezepelumab	35	33 (94.3)	5.52 (1.06)	3.8	4.75	5.50	6.50	7.0	
			Placebo	41	37 (90.2)	5.03 (1.22)	2.0	4.50	5.00	5.75	7.0	
		Week 28	Tezepelumab	35	34 (97.1)	5.50 (1.19)	3.5	4.25	5.50	7.00	7.0	
			Placebo	41	38 (92.7)	5.28 (1.23)	1.8	4.50	5.25	6.00	7.0	
		Week 32	Tezepelumab	35	34 (97.1)	5.57 (1.13)	3.5	4.50	5.75	6.75	7.0	
			Placebo	41	38 (92.7)	5.27 (1.30)	2.3	4.50	5.38	6.25	7.0	
		Week 36	Tezepelumab	35	34 (97.1)	5.63 (1.04)	3.8	4.50	5.75	6.50	7.0	
			Placebo	41	38 (92.7)	5.06 (1.30)	1.8	4.25	5.25	6.00	7.0	
		Week 40	Tezepelumab	35	34 (97.1)	5.64 (1.03)	4.0	4.50	5.75	6.75	7.0	
			Placebo	41	38 (92.7)	5.28 (1.30)	1.8	4.50	5.38	6.25	7.0	
		Week 44	Tezepelumab	35	34 (97.1)	5.68 (1.04)	3.8	4.75	5.75	6.75	7.0	
			Placebo	41	38 (92.7)	5.24 (1.30)	2.0	4.00	5.38	6.50	7.0	
		Week 48	Tezepelumab	35	34 (97.1)	5.73 (1.02)	4.0	4.75	5.88	6.75	7.0	
			Placebo	41	38 (92.7)	5.22 (1.24)	2.0	4.50	5.00	6.25	7.0	
		Week 52	Tezepelumab	35	34 (97.1)	5.74 (1.04)	4.0	4.50	6.00	6.75	7.0	
			Placebo	41	38 (92.7)	5.26 (1.32)	1.8	4.50	5.13	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	35	30 (85.7)	0.73 (1.34)	-4.0	0.00	0.88	1.75	2.8	0.28 [-0.21, 0.77]
			Placebo	41	35 (85.4)	0.39 (1.07)	-2.0	-0.25	0.25	1.00	2.5	
		Week 8	Tezepelumab	35	32 (91.4)	1.14 (1.12)	-1.3	0.13	1.13	2.00	3.3	0.46 [-0.02, 0.95]
			Placebo	41	35 (85.4)	0.61 (1.16)	-1.8	0.00	0.50	1.25	3.3	
		Week 12	Tezepelumab	35	32 (91.4)	1.22 (1.19)	-2.3	0.25	1.25	2.25	3.0	0.58 [0.09, 1.07]
			Placebo	41	35 (85.4)	0.56 (1.08)	-1.8	-0.25	0.50	1.25	3.0	
		Week 16	Tezepelumab	35	32 (91.4)	1.07 (1.30)	-2.8	0.13	0.88	2.13	3.0	0.40 [-0.08, 0.88]
			Placebo	41	35 (85.4)	0.61 (1.01)	-1.3	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	35	32 (91.4)	1.16 (1.21)	-1.3	0.25	1.00	2.38	3.0	0.57 [0.08, 1.06]
			Placebo	41	35 (85.4)	0.55 (0.95)	-1.3	0.00	0.25	1.25	2.5	
		Week 24	Tezepelumab	35	32 (91.4)	1.29 (1.21)	-1.3	0.25	1.50	2.25	3.5	0.57 [0.08, 1.06]
			Placebo	41	35 (85.4)	0.63 (1.13)	-1.5	0.00	0.50	1.25	3.8	
		Week 28	Tezepelumab	35	32 (91.4)	1.23 (1.29)	-1.5	0.25	1.38	2.25	3.3	0.30 [-0.18, 0.78]
			Placebo	41	35 (85.4)	0.86 (1.20)	-2.8	0.25	0.75	1.25	3.8	
		Week 32	Tezepelumab	35	32 (91.4)	1.29 (1.26)	-1.3	0.25	1.38	2.25	3.5	0.37 [-0.11, 0.86]
			Placebo	41	35 (85.4)	0.86 (1.06)	-1.5	0.25	0.75	1.50	3.8	
		Week 36	Tezepelumab	35	32 (91.4)	1.36 (1.25)	-1.3	0.25	1.50	2.25	3.5	0.59 [0.10, 1.08]
			Placebo	41	35 (85.4)	0.64 (1.18)	-2.3	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	35	32 (91.4)	1.38 (1.25)	-1.3	0.25	1.63	2.25	3.3	0.43 [-0.05, 0.92]
			Placebo	41	35 (85.4)	0.86 (1.16)	-1.5	0.00	0.75	1.75	3.8	
		Week 44	Tezepelumab	35	32 (91.4)	1.43 (1.29)	-1.3	0.25	1.50	2.25	3.8	0.47 [-0.01, 0.96]
			Placebo	41	35 (85.4)	0.82 (1.28)	-1.5	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	35	32 (91.4)	1.47 (1.29)	-1.3	0.38	1.50	2.38	3.8	0.53 [0.05, 1.02]
			Placebo	41	35 (85.4)	0.80 (1.22)	-1.3	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	35	32 (91.4)	1.47 (1.29)	-1.3	0.38	1.50	2.38	3.8	0.52 [0.03, 1.00]
			Placebo	41	35 (85.4)	0.81 (1.27)	-1.3	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	41	36 (87.8)	3.88 (1.00)	1.8	3.13	4.00	4.63	6.0	
			Placebo	30	25 (83.3)	4.46 (1.33)	1.5	3.50	4.50	5.50	6.5	
		Week 4	Tezepelumab	41	37 (90.2)	4.80 (1.04)	2.0	4.25	5.00	5.75	7.0	
			Placebo	30	24 (80.0)	4.79 (1.24)	2.0	4.38	5.25	5.63	6.8	
		Week 8	Tezepelumab	41	38 (92.7)	5.12 (1.20)	1.0	4.50	5.50	5.75	6.8	
			Placebo	30	26 (86.7)	4.88 (1.41)	1.5	3.75	5.13	6.00	6.8	
		Week 12	Tezepelumab	41	38 (92.7)	5.25 (1.16)	1.0	4.75	5.50	6.25	7.0	
			Placebo	30	26 (86.7)	4.81 (1.17)	2.3	4.00	5.00	5.50	7.0	
		Week 16	Tezepelumab	41	38 (92.7)	5.16 (1.23)	1.0	4.50	5.25	6.00	7.0	
			Placebo	30	26 (86.7)	4.68 (1.46)	1.3	4.00	4.75	5.75	7.0	
		Week 20	Tezepelumab	41	39 (95.1)	5.10 (1.34)	1.0	4.50	5.00	6.00	7.0	
			Placebo	30	26 (86.7)	4.67 (1.52)	1.3	4.00	4.88	5.25	7.0	
		Week 24	Tezepelumab	41	39 (95.1)	5.26 (1.38)	1.0	4.50	5.25	6.25	7.0	
			Placebo	30	26 (86.7)	4.57 (1.71)	1.0	3.75	4.63	5.75	7.0	
		Week 28	Tezepelumab	41	40 (97.6)	5.14 (1.34)	1.0	4.50	5.00	6.13	7.0	
			Placebo	30	26 (86.7)	4.76 (1.59)	1.3	3.75	5.00	6.00	7.0	
		Week 32	Tezepelumab	41	40 (97.6)	5.21 (1.39)	1.0	4.25	5.25	6.13	7.0	
			Placebo	30	26 (86.7)	4.70 (1.60)	1.3	3.75	4.63	6.00	7.0	
		Week 36	Tezepelumab	41	40 (97.6)	5.23 (1.35)	1.0	4.38	5.13	6.38	7.0	
			Placebo	30	26 (86.7)	4.65 (1.56)	1.0	3.75	4.88	5.50	7.0	
		Week 40	Tezepelumab	41	40 (97.6)	5.24 (1.23)	2.0	4.50	5.00	6.25	7.0	
			Placebo	30	26 (86.7)	4.76 (1.55)	1.0	3.75	5.00	5.75	7.0	
		Week 44	Tezepelumab	41	40 (97.6)	5.26 (1.28)	1.3	4.63	5.13	6.25	7.0	
			Placebo	30	26 (86.7)	4.71 (1.38)	1.3	3.75	4.63	5.75	7.0	
		Week 48	Tezepelumab	41	40 (97.6)	5.28 (1.33)	1.0	4.38	5.38	6.25	7.0	
			Placebo	30	26 (86.7)	4.76 (1.27)	2.0	4.00	4.63	6.00	7.0	
		Week 52	Tezepelumab	41	40 (97.6)	5.28 (1.30)	1.0	4.50	5.38	6.25	7.0	
			Placebo	30	26 (86.7)	4.79 (1.16)	2.8	4.00	4.63	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	41	34 (82.9)	1.04 (1.13)	-1.3	0.25	1.00	1.75	4.0	0.75 [0.20, 1.29]
			Placebo	30	24 (80.0)	0.27 (0.86)	-1.3	-0.38	0.25	0.88	2.0	
		Week 8	Tezepelumab	41	35 (85.4)	1.24 (1.26)	-1.0	0.25	1.25	2.25	4.3	0.63 [0.10, 1.16]
			Placebo	30	25 (83.3)	0.49 (1.09)	-1.3	-0.25	0.50	1.00	3.3	
		Week 12	Tezepelumab	41	35 (85.4)	1.35 (1.15)	-1.0	0.75	1.25	2.25	4.8	0.91 [0.37, 1.45]
			Placebo	30	25 (83.3)	0.39 (0.90)	-1.3	-0.25	0.50	1.00	2.5	
		Week 16	Tezepelumab	41	35 (85.4)	1.27 (1.14)	-0.8	0.50	1.25	2.25	3.3	0.93 [0.39, 1.47]
			Placebo	30	25 (83.3)	0.25 (1.04)	-1.8	-0.25	0.50	0.75	3.0	
		Week 20	Tezepelumab	41	35 (85.4)	1.23 (1.20)	-1.8	0.50	1.25	2.25	3.5	0.86 [0.33, 1.40]
			Placebo	30	25 (83.3)	0.24 (1.05)	-2.3	-0.25	0.50	0.75	2.0	
		Week 24	Tezepelumab	41	35 (85.4)	1.39 (1.23)	-1.5	0.25	1.50	2.25	3.5	0.98 [0.44, 1.53]
			Placebo	30	25 (83.3)	0.14 (1.32)	-2.8	-0.75	0.25	1.00	3.8	
		Week 28	Tezepelumab	41	35 (85.4)	1.33 (1.23)	-1.3	0.50	1.50	2.25	3.3	0.79 [0.26, 1.33]
			Placebo	30	25 (83.3)	0.30 (1.39)	-2.8	-0.50	0.50	1.00	3.8	
		Week 32	Tezepelumab	41	35 (85.4)	1.39 (1.28)	-1.3	0.50	1.50	2.25	3.5	0.93 [0.39, 1.47]
			Placebo	30	25 (83.3)	0.27 (1.12)	-1.8	-0.25	0.25	0.75	3.8	
		Week 36	Tezepelumab	41	35 (85.4)	1.41 (1.25)	-1.0	0.50	1.50	2.25	3.3	0.99 [0.44, 1.53]
			Placebo	30	25 (83.3)	0.18 (1.23)	-2.8	-0.25	0.25	0.75	3.8	
		Week 40	Tezepelumab	41	35 (85.4)	1.44 (1.11)	-0.5	0.50	1.50	2.25	3.3	0.97 [0.43, 1.52]
			Placebo	30	25 (83.3)	0.30 (1.25)	-2.5	-0.50	0.50	0.75	3.8	
		Week 44	Tezepelumab	41	35 (85.4)	1.46 (1.21)	-1.5	0.75	1.50	2.25	3.3	1.02 [0.48, 1.57]
			Placebo	30	25 (83.3)	0.28 (1.05)	-1.3	-0.25	0.00	0.75	3.8	
		Week 48	Tezepelumab	41	35 (85.4)	1.49 (1.28)	-1.0	0.50	1.50	2.25	3.8	0.93 [0.39, 1.47]
			Placebo	30	25 (83.3)	0.31 (1.27)	-2.8	-0.25	0.25	0.75	3.8	
		Week 52	Tezepelumab	41	35 (85.4)	1.51 (1.24)	-0.8	0.50	1.50	2.25	3.8	0.98 [0.43, 1.52]
			Placebo	30	25 (83.3)	0.35 (1.11)	-1.3	-0.25	0.25	0.75	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	25	22 (88.0)	4.16 (1.14)	2.5	3.50	4.00	4.75	6.8	
			Placebo	34	29 (85.3)	4.33 (1.15)	2.0	3.50	4.25	5.00	7.0	
		Week 4	Tezepelumab	25	23 (92.0)	4.79 (1.27)	1.3	4.00	5.00	5.75	6.8	
			Placebo	34	32 (94.1)	4.81 (1.16)	2.3	4.00	4.88	5.50	7.0	
		Week 8	Tezepelumab	25	24 (96.0)	5.21 (1.11)	3.5	4.13	5.13	6.00	7.0	
			Placebo	34	32 (94.1)	4.88 (1.16)	2.3	4.38	5.00	5.50	7.0	
		Week 12	Tezepelumab	25	24 (96.0)	5.30 (1.14)	3.0	4.50	5.38	6.13	7.0	
			Placebo	34	32 (94.1)	4.95 (1.13)	2.0	4.38	5.00	5.75	7.0	
		Week 16	Tezepelumab	25	24 (96.0)	5.16 (1.15)	2.5	4.38	5.13	5.88	7.0	
			Placebo	34	32 (94.1)	4.98 (1.31)	1.8	4.25	5.00	5.75	7.0	
		Week 20	Tezepelumab	25	24 (96.0)	5.19 (1.07)	3.5	4.38	5.13	5.75	7.0	
			Placebo	34	32 (94.1)	4.91 (1.29)	2.0	4.00	5.00	5.75	7.0	
		Week 24	Tezepelumab	25	24 (96.0)	5.19 (1.06)	3.8	4.25	5.00	5.88	7.0	
			Placebo	34	32 (94.1)	4.91 (1.28)	1.8	4.38	5.00	5.75	7.0	
		Week 28	Tezepelumab	25	25 (100.0)	5.31 (1.09)	3.8	4.50	5.00	6.25	7.0	
			Placebo	34	33 (97.1)	5.14 (1.41)	1.3	4.50	5.25	6.00	7.0	
		Week 32	Tezepelumab	25	25 (100.0)	5.39 (1.07)	3.5	4.50	5.25	6.00	7.0	
			Placebo	34	33 (97.1)	5.25 (1.31)	2.3	4.75	5.50	6.00	7.0	
		Week 36	Tezepelumab	25	25 (100.0)	5.42 (1.02)	3.8	4.50	5.25	6.25	7.0	
			Placebo	34	33 (97.1)	4.98 (1.42)	1.5	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	25	25 (100.0)	5.43 (0.98)	4.0	4.50	5.50	6.00	7.0	
			Placebo	34	33 (97.1)	5.20 (1.39)	1.5	4.75	5.50	6.25	7.0	
		Week 44	Tezepelumab	25	25 (100.0)	5.42 (1.05)	3.8	4.50	5.25	6.25	7.0	
			Placebo	34	33 (97.1)	5.23 (1.39)	2.0	4.00	5.50	6.50	7.0	
		Week 48	Tezepelumab	25	25 (100.0)	5.46 (1.00)	3.8	4.50	5.25	6.00	7.0	
			Placebo	34	33 (97.1)	5.13 (1.42)	1.0	4.50	5.00	6.25	7.0	
		Week 52	Tezepelumab	25	25 (100.0)	5.47 (1.02)	3.8	4.50	5.50	6.25	7.0	
			Placebo	34	33 (97.1)	5.23 (1.39)	1.8	4.50	5.00	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	25	21 (84.0)	0.49 (1.37)	-4.0	0.00	0.50	1.50	2.3	-0.02 [-0.58, 0.54]
			Placebo	34	29 (85.3)	0.51 (1.08)	-2.0	-0.25	0.50	1.00	2.5	
		Week 8	Tezepelumab	25	22 (88.0)	0.98 (1.13)	-1.3	0.00	0.63	2.00	3.0	0.31 [-0.24, 0.87]
			Placebo	34	29 (85.3)	0.61 (1.19)	-1.8	0.00	0.25	1.50	3.0	
		Week 12	Tezepelumab	25	22 (88.0)	1.13 (1.21)	-2.3	0.25	1.13	2.25	3.0	0.41 [-0.15, 0.97]
			Placebo	34	29 (85.3)	0.66 (1.10)	-1.8	0.00	0.75	1.25	3.0	
		Week 16	Tezepelumab	25	22 (88.0)	1.00 (1.39)	-2.8	0.00	0.75	2.25	3.0	0.27 [-0.29, 0.82]
			Placebo	34	29 (85.3)	0.69 (0.95)	-1.0	0.00	0.50	1.25	3.0	
		Week 20	Tezepelumab	25	22 (88.0)	1.02 (1.25)	-1.3	0.00	0.88	2.25	2.8	0.33 [-0.23, 0.88]
			Placebo	34	29 (85.3)	0.66 (0.97)	-1.3	0.00	0.25	1.25	2.5	
		Week 24	Tezepelumab	25	22 (88.0)	1.06 (1.22)	-1.3	0.25	0.88	2.25	2.8	0.34 [-0.22, 0.89]
			Placebo	34	29 (85.3)	0.69 (0.99)	-1.0	0.00	0.75	1.50	3.0	
		Week 28	Tezepelumab	25	22 (88.0)	1.09 (1.28)	-1.5	0.25	0.75	2.25	3.0	0.17 [-0.39, 0.72]
			Placebo	34	29 (85.3)	0.90 (1.05)	-1.3	0.25	1.00	1.50	3.0	
		Week 32	Tezepelumab	25	22 (88.0)	1.18 (1.27)	-1.3	0.25	1.13	2.25	3.5	0.15 [-0.40, 0.71]
			Placebo	34	29 (85.3)	1.03 (0.81)	0.0	0.25	1.00	1.75	2.8	
		Week 36	Tezepelumab	25	22 (88.0)	1.22 (1.27)	-1.3	0.25	1.13	2.25	3.5	0.40 [-0.16, 0.96]
			Placebo	34	29 (85.3)	0.76 (1.05)	-1.0	0.00	0.25	1.50	3.0	
		Week 40	Tezepelumab	25	22 (88.0)	1.24 (1.24)	-1.3	0.25	1.38	2.25	3.3	0.24 [-0.32, 0.80]
			Placebo	34	29 (85.3)	0.97 (1.05)	-1.0	0.00	0.75	1.75	3.3	
		Week 44	Tezepelumab	25	22 (88.0)	1.27 (1.30)	-1.3	0.25	1.25	2.25	3.8	0.24 [-0.31, 0.80]
			Placebo	34	29 (85.3)	0.97 (1.23)	-1.5	0.25	0.75	2.00	3.8	
		Week 48	Tezepelumab	25	22 (88.0)	1.26 (1.24)	-1.3	0.25	1.13	2.25	3.5	0.31 [-0.25, 0.87]
			Placebo	34	29 (85.3)	0.88 (1.23)	-1.5	0.00	0.75	1.25	3.8	
		Week 52	Tezepelumab	25	22 (88.0)	1.25 (1.21)	-1.3	0.25	0.88	2.25	3.5	0.23 [-0.32, 0.79]
			Placebo	34	29 (85.3)	0.97 (1.23)	-1.0	0.25	0.75	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	26	23 (88.5)	3.89 (0.76)	2.5	3.75	4.00	4.25	5.3	
			Placebo	31	25 (80.6)	4.36 (1.18)	2.0	3.25	4.25	5.00	7.0	
		Week 4	Tezepelumab	26	23 (88.5)	4.49 (1.20)	1.3	3.75	4.50	5.25	7.0	
			Placebo	31	25 (80.6)	5.00 (1.20)	2.0	4.25	4.75	5.50	7.0	
		Week 8	Tezepelumab	26	23 (88.5)	4.97 (1.16)	1.8	4.00	5.00	5.75	6.8	
			Placebo	31	27 (87.1)	4.94 (1.14)	2.8	4.00	5.00	5.75	7.0	
		Week 12	Tezepelumab	26	23 (88.5)	5.05 (1.03)	3.0	4.50	4.75	5.75	7.0	
			Placebo	31	27 (87.1)	4.93 (1.07)	3.0	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	26	23 (88.5)	4.67 (1.13)	2.0	4.25	4.75	5.25	7.0	
			Placebo	31	27 (87.1)	4.87 (1.39)	1.3	4.00	5.00	6.25	7.0	
		Week 20	Tezepelumab	26	24 (92.3)	4.76 (1.15)	1.0	4.13	4.88	5.63	7.0	
			Placebo	31	27 (87.1)	4.81 (1.40)	1.3	4.00	5.00	5.50	7.0	
		Week 24	Tezepelumab	26	24 (92.3)	4.89 (1.28)	1.3	4.00	4.75	5.88	7.0	
			Placebo	31	27 (87.1)	4.89 (1.45)	1.3	4.25	5.00	5.75	7.0	
		Week 28	Tezepelumab	26	26 (100.0)	4.81 (1.18)	1.5	4.25	4.63	5.50	7.0	
			Placebo	31	28 (90.3)	5.09 (1.41)	1.3	4.13	5.25	6.00	7.0	
		Week 32	Tezepelumab	26	26 (100.0)	4.95 (1.23)	1.5	4.00	5.00	6.00	7.0	
			Placebo	31	28 (90.3)	5.22 (1.42)	1.3	4.50	5.25	6.13	7.0	
		Week 36	Tezepelumab	26	26 (100.0)	4.97 (1.13)	1.8	4.50	4.88	6.00	7.0	
			Placebo	31	28 (90.3)	5.09 (1.36)	2.0	4.13	5.13	6.13	7.0	
		Week 40	Tezepelumab	26	26 (100.0)	5.00 (1.10)	2.3	4.25	5.00	5.50	7.0	
			Placebo	31	28 (90.3)	5.29 (1.33)	2.3	4.50	5.38	6.50	7.0	
		Week 44	Tezepelumab	26	26 (100.0)	4.94 (1.23)	1.3	4.00	5.00	5.25	7.0	
			Placebo	31	28 (90.3)	5.33 (1.31)	2.8	4.13	5.38	6.63	7.0	
		Week 48	Tezepelumab	26	26 (100.0)	5.01 (1.06)	2.3	4.25	5.00	6.00	7.0	
			Placebo	31	28 (90.3)	5.25 (1.38)	2.0	4.38	5.13	6.50	7.0	
		Week 52	Tezepelumab	26	26 (100.0)	5.07 (1.10)	2.3	4.50	5.00	6.00	7.0	
			Placebo	31	28 (90.3)	5.34 (1.25)	2.8	4.38	5.25	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	26	23 (88.5)	0.60 (1.27)	-4.0	0.00	0.75	1.25	2.0	-0.04 [-0.61, 0.53]
			Placebo	31	24 (77.4)	0.65 (1.11)	-1.8	0.00	0.75	1.25	3.0	
		Week 8	Tezepelumab	26	23 (88.5)	1.08 (1.17)	-1.3	0.25	1.25	2.00	2.8	0.29 [-0.28, 0.86]
			Placebo	31	25 (80.6)	0.71 (1.33)	-1.8	0.00	0.50	1.50	3.3	
		Week 12	Tezepelumab	26	23 (88.5)	1.16 (1.02)	-2.3	0.75	1.25	2.00	2.3	0.44 [-0.13, 1.02]
			Placebo	31	25 (80.6)	0.66 (1.22)	-1.8	0.00	1.00	1.25	3.0	
		Week 16	Tezepelumab	26	23 (88.5)	0.78 (1.21)	-2.8	0.00	0.75	1.50	2.8	0.17 [-0.40, 0.73]
			Placebo	31	25 (80.6)	0.58 (1.21)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	26	23 (88.5)	0.83 (1.08)	-1.8	0.25	0.75	1.75	2.8	0.26 [-0.31, 0.83]
			Placebo	31	25 (80.6)	0.53 (1.19)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	26	23 (88.5)	0.96 (1.16)	-1.5	0.25	1.25	2.00	2.8	0.27 [-0.30, 0.84]
			Placebo	31	25 (80.6)	0.60 (1.44)	-2.8	0.00	0.75	1.25	3.8	
		Week 28	Tezepelumab	26	23 (88.5)	0.85 (1.07)	-1.5	0.25	0.75	1.50	2.8	0.09 [-0.47, 0.66]
			Placebo	31	25 (80.6)	0.73 (1.46)	-2.8	0.00	0.75	1.50	3.8	
		Week 32	Tezepelumab	26	23 (88.5)	0.97 (1.16)	-1.3	0.00	1.25	2.00	2.5	0.08 [-0.49, 0.65]
			Placebo	31	25 (80.6)	0.87 (1.23)	-1.8	0.25	0.75	1.50	3.8	
		Week 36	Tezepelumab	26	23 (88.5)	0.98 (1.14)	-1.3	0.25	1.25	2.00	2.8	0.20 [-0.37, 0.77]
			Placebo	31	25 (80.6)	0.72 (1.41)	-2.8	0.25	0.50	1.50	3.8	
		Week 40	Tezepelumab	26	23 (88.5)	1.12 (1.09)	-1.3	0.25	1.25	2.00	3.0	0.13 [-0.43, 0.70]
			Placebo	31	25 (80.6)	0.95 (1.39)	-2.5	0.25	0.75	1.75	3.8	
		Week 44	Tezepelumab	26	23 (88.5)	1.02 (1.20)	-1.5	0.25	1.25	2.00	2.8	0.04 [-0.53, 0.61]
			Placebo	31	25 (80.6)	0.97 (1.42)	-1.5	0.25	0.75	1.50	3.8	
		Week 48	Tezepelumab	26	23 (88.5)	1.10 (1.17)	-1.3	0.50	1.25	2.00	3.8	0.15 [-0.42, 0.72]
			Placebo	31	25 (80.6)	0.89 (1.53)	-2.8	0.25	0.75	1.50	3.8	
		Week 52	Tezepelumab	26	23 (88.5)	1.14 (1.13)	-1.3	0.50	1.00	2.00	3.8	0.12 [-0.45, 0.69]
			Placebo	31	25 (80.6)	0.99 (1.38)	-1.3	0.25	0.75	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	4.05 (1.22)	1.8	3.25	4.00	4.75	6.8	
			Placebo	34	30 (88.2)	4.40 (1.27)	1.5	3.50	4.38	5.50	6.5	
		Week 4	Tezepelumab	40	37 (92.5)	4.99 (1.05)	2.0	4.50	5.25	5.75	6.8	
			Placebo	34	32 (94.1)	4.72 (1.21)	2.3	4.00	5.13	5.50	6.5	
		Week 8	Tezepelumab	40	39 (97.5)	5.26 (1.15)	1.0	4.50	5.50	6.00	7.0	
			Placebo	34	32 (94.1)	4.89 (1.42)	1.5	3.88	5.13	5.88	7.0	
		Week 12	Tezepelumab	40	39 (97.5)	5.40 (1.19)	1.0	4.75	5.50	6.25	7.0	
			Placebo	34	32 (94.1)	4.91 (1.24)	2.0	4.25	5.13	5.63	7.0	
		Week 16	Tezepelumab	40	39 (97.5)	5.45 (1.14)	1.0	4.75	5.50	6.00	7.0	
			Placebo	34	32 (94.1)	4.89 (1.40)	1.5	4.13	5.13	5.75	7.0	
		Week 20	Tezepelumab	40	39 (97.5)	5.37 (1.24)	1.3	4.50	5.25	6.50	7.0	
			Placebo	34	32 (94.1)	4.88 (1.44)	1.5	4.00	5.00	6.13	7.0	
		Week 24	Tezepelumab	40	39 (97.5)	5.44 (1.22)	1.0	4.75	5.50	6.50	7.0	
			Placebo	34	32 (94.1)	4.72 (1.56)	1.0	3.88	4.88	5.88	7.0	
		Week 28	Tezepelumab	40	39 (97.5)	5.47 (1.23)	1.0	4.75	5.50	6.25	7.0	
			Placebo	34	32 (94.1)	4.92 (1.59)	1.3	4.13	5.00	6.13	7.0	
		Week 32	Tezepelumab	40	39 (97.5)	5.50 (1.27)	1.0	4.75	5.50	6.75	7.0	
			Placebo	34	32 (94.1)	4.88 (1.51)	1.3	3.75	5.13	6.00	7.0	
		Week 36	Tezepelumab	40	39 (97.5)	5.53 (1.25)	1.0	4.75	5.75	6.75	7.0	
			Placebo	34	32 (94.1)	4.68 (1.60)	1.0	3.88	4.88	5.75	7.0	
		Week 40	Tezepelumab	40	39 (97.5)	5.53 (1.12)	2.0	4.75	5.50	6.50	7.0	
			Placebo	34	32 (94.1)	4.81 (1.58)	1.0	4.00	5.13	5.88	7.0	
		Week 44	Tezepelumab	40	39 (97.5)	5.58 (1.10)	2.0	5.00	5.75	6.50	7.0	
			Placebo	34	32 (94.1)	4.77 (1.46)	1.3	4.00	4.88	5.75	7.0	
		Week 48	Tezepelumab	40	39 (97.5)	5.57 (1.26)	1.0	4.75	5.75	6.50	7.0	
			Placebo	34	32 (94.1)	4.78 (1.35)	1.0	4.00	4.88	6.00	7.0	
		Week 52	Tezepelumab	40	39 (97.5)	5.54 (1.23)	1.0	4.75	5.75	6.50	7.0	
			Placebo	34	32 (94.1)	4.84 (1.35)	1.8	4.00	4.88	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	40	32 (80.0)	0.99 (1.22)	-1.3	0.00	1.00	1.75	4.0	0.63 [0.12, 1.14]
			Placebo	34	30 (88.2)	0.29 (0.97)	-2.0	-0.25	0.25	0.75	2.0	
		Week 8	Tezepelumab	40	34 (85.0)	1.18 (1.25)	-0.8	0.25	0.88	2.25	4.3	0.58 [0.08, 1.09]
			Placebo	34	30 (88.2)	0.51 (1.04)	-1.5	-0.25	0.25	1.25	3.0	
		Week 12	Tezepelumab	40	34 (85.0)	1.33 (1.27)	-1.0	0.25	1.13	2.25	4.8	0.75 [0.24, 1.26]
			Placebo	34	30 (88.2)	0.50 (0.89)	-1.0	-0.25	0.50	1.00	2.5	
		Week 16	Tezepelumab	40	34 (85.0)	1.43 (1.21)	-0.8	0.50	1.38	2.50	3.3	0.88 [0.36, 1.39]
			Placebo	34	30 (88.2)	0.48 (0.90)	-1.3	0.00	0.38	1.00	2.5	
		Week 20	Tezepelumab	40	34 (85.0)	1.37 (1.27)	-0.5	0.25	1.38	2.50	3.5	0.76 [0.25, 1.27]
			Placebo	34	30 (88.2)	0.50 (0.97)	-1.3	0.00	0.25	1.25	2.5	
		Week 24	Tezepelumab	40	34 (85.0)	1.46 (1.24)	-0.8	0.25	1.63	2.50	3.5	0.95 [0.44, 1.47]
			Placebo	34	30 (88.2)	0.38 (1.00)	-1.3	-0.25	0.25	1.25	2.5	
		Week 28	Tezepelumab	40	34 (85.0)	1.50 (1.29)	-0.8	0.25	1.75	2.75	3.3	0.74 [0.24, 1.25]
			Placebo	34	30 (88.2)	0.60 (1.10)	-1.5	0.00	0.50	1.25	3.0	
		Week 32	Tezepelumab	40	34 (85.0)	1.54 (1.30)	-0.8	0.25	1.50	2.50	3.5	0.84 [0.33, 1.35]
			Placebo	34	30 (88.2)	0.59 (0.91)	-1.3	0.00	0.50	1.25	2.5	
		Week 36	Tezepelumab	40	34 (85.0)	1.57 (1.28)	-0.8	0.50	1.63	2.75	3.5	1.03 [0.51, 1.55]
			Placebo	34	30 (88.2)	0.38 (1.00)	-1.3	-0.25	0.25	1.00	2.5	
		Week 40	Tezepelumab	40	34 (85.0)	1.53 (1.19)	-0.5	0.25	1.50	2.75	3.3	0.93 [0.41, 1.45]
			Placebo	34	30 (88.2)	0.49 (1.03)	-1.3	-0.25	0.50	1.25	2.5	
		Week 44	Tezepelumab	40	34 (85.0)	1.63 (1.22)	-0.5	0.75	1.50	2.75	3.8	1.05 [0.52, 1.57]
			Placebo	34	30 (88.2)	0.46 (0.99)	-1.3	0.00	0.13	1.25	2.5	
		Week 48	Tezepelumab	40	34 (85.0)	1.61 (1.29)	-0.8	0.50	1.88	2.75	3.5	0.97 [0.45, 1.49]
			Placebo	34	30 (88.2)	0.47 (1.05)	-1.5	0.00	0.25	1.00	3.3	
		Week 52	Tezepelumab	40	34 (85.0)	1.59 (1.27)	-0.8	0.50	1.63	2.50	3.5	0.92 [0.41, 1.44]
			Placebo	34	30 (88.2)	0.50 (1.07)	-1.3	-0.25	0.38	1.00	3.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	57	49 (86.0)	3.93 (0.97)	1.8	3.25	4.00	4.50	6.0	
			Placebo	60	51 (85.0)	4.31 (1.18)	1.5	3.50	4.25	5.25	7.0	
		Week 4	Tezepelumab	57	51 (89.5)	4.72 (1.07)	1.3	4.00	4.75	5.50	7.0	
			Placebo	60	52 (86.7)	4.85 (1.24)	2.0	4.13	5.13	5.50	7.0	
		Week 8	Tezepelumab	57	53 (93.0)	5.09 (1.00)	1.8	4.25	5.00	5.75	7.0	
			Placebo	60	54 (90.0)	4.90 (1.31)	1.5	4.00	5.13	5.75	7.0	
		Week 12	Tezepelumab	57	53 (93.0)	5.19 (0.95)	3.0	4.50	5.25	5.75	7.0	
			Placebo	60	54 (90.0)	4.91 (1.19)	2.0	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	57	53 (93.0)	5.07 (1.01)	2.0	4.50	5.00	5.75	7.0	
			Placebo	60	54 (90.0)	4.88 (1.43)	1.3	4.00	5.00	5.75	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.05 (1.11)	1.0	4.25	5.00	5.75	7.0	
			Placebo	60	54 (90.0)	4.86 (1.46)	1.3	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.15 (1.11)	1.3	4.25	5.00	6.00	7.0	
			Placebo	60	54 (90.0)	4.76 (1.54)	1.0	4.00	5.00	5.75	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.14 (1.12)	1.5	4.38	5.00	6.00	7.0	
			Placebo	60	55 (91.7)	5.01 (1.52)	1.3	4.00	5.25	6.00	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.20 (1.13)	1.5	4.38	5.00	6.00	7.0	
			Placebo	60	55 (91.7)	5.03 (1.51)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.24 (1.08)	1.8	4.50	5.00	6.13	7.0	
			Placebo	60	55 (91.7)	4.87 (1.52)	1.0	4.00	5.00	6.00	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.24 (1.00)	2.3	4.50	5.00	5.88	7.0	
			Placebo	60	55 (91.7)	5.03 (1.51)	1.0	4.00	5.25	6.25	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.24 (1.10)	1.3	4.50	5.13	6.25	7.0	
			Placebo	60	55 (91.7)	5.00 (1.44)	1.3	4.00	5.00	6.25	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.32 (1.08)	2.3	4.50	5.25	6.25	7.0	
			Placebo	60	55 (91.7)	4.97 (1.41)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.32 (1.06)	2.3	4.50	5.25	6.13	7.0	
			Placebo	60	55 (91.7)	5.05 (1.35)	1.8	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	57	46 (80.7)	0.80 (1.29)	-4.0	0.00	0.88	1.75	4.0	0.25 [-0.15, 0.66]
			Placebo	60	50 (83.3)	0.51 (1.02)	-2.0	-0.25	0.50	1.00	3.0	
		Week 8	Tezepelumab	57	48 (84.2)	1.12 (1.19)	-1.3	0.25	1.13	2.00	4.3	0.42 [0.02, 0.82]
			Placebo	60	51 (85.0)	0.64 (1.09)	-1.8	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	57	48 (84.2)	1.22 (1.14)	-2.3	0.50	1.25	2.00	4.8	0.57 [0.17, 0.97]
			Placebo	60	51 (85.0)	0.61 (1.00)	-1.8	0.00	0.75	1.25	3.0	
		Week 16	Tezepelumab	57	48 (84.2)	1.12 (1.19)	-2.8	0.25	1.13	2.00	3.3	0.51 [0.11, 0.91]
			Placebo	60	51 (85.0)	0.58 (0.93)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	57	48 (84.2)	1.11 (1.21)	-1.8	0.25	1.13	2.00	3.5	0.48 [0.08, 0.88]
			Placebo	60	51 (85.0)	0.58 (1.01)	-2.3	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	57	48 (84.2)	1.22 (1.22)	-1.5	0.25	1.50	2.13	3.5	0.61 [0.21, 1.02]
			Placebo	60	51 (85.0)	0.51 (1.10)	-2.8	-0.25	0.50	1.25	3.0	
		Week 28	Tezepelumab	57	48 (84.2)	1.22 (1.24)	-1.5	0.25	1.38	2.25	3.3	0.42 [0.02, 0.82]
			Placebo	60	51 (85.0)	0.73 (1.09)	-1.8	0.00	0.75	1.25	3.0	
		Week 32	Tezepelumab	57	48 (84.2)	1.27 (1.27)	-1.3	0.25	1.50	2.25	3.5	0.46 [0.06, 0.86]
			Placebo	60	51 (85.0)	0.77 (0.91)	-1.8	0.00	0.75	1.25	3.0	
		Week 36	Tezepelumab	57	48 (84.2)	1.31 (1.24)	-1.3	0.38	1.50	2.25	3.5	0.63 [0.23, 1.04]
			Placebo	60	51 (85.0)	0.59 (1.05)	-2.8	0.00	0.25	1.25	3.0	
		Week 40	Tezepelumab	57	48 (84.2)	1.34 (1.16)	-1.3	0.25	1.50	2.13	3.3	0.52 [0.12, 0.92]
			Placebo	60	51 (85.0)	0.75 (1.10)	-2.5	0.00	0.75	1.25	3.3	
		Week 44	Tezepelumab	57	48 (84.2)	1.35 (1.25)	-1.5	0.50	1.50	2.25	3.8	0.52 [0.12, 0.92]
			Placebo	60	51 (85.0)	0.74 (1.11)	-1.5	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	57	48 (84.2)	1.43 (1.27)	-1.3	0.50	1.50	2.25	3.8	0.59 [0.19, 0.99]
			Placebo	60	51 (85.0)	0.70 (1.20)	-2.8	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	57	48 (84.2)	1.43 (1.23)	-1.3	0.50	1.50	2.25	3.8	0.56 [0.16, 0.96]
			Placebo	60	51 (85.0)	0.77 (1.12)	-1.0	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	4.28 (1.47)	1.8	4.00	4.25	4.75	6.8	
			Placebo	5	4 (80.0)	5.31 (1.43)	3.3	4.38	5.75	6.25	6.5	
		Week 4	Tezepelumab	9	9 (100.0)	5.25 (1.38)	2.0	5.00	5.75	6.00	6.8	
			Placebo	5	5 (100.0)	4.75 (0.85)	3.5	4.50	4.75	5.25	5.8	
		Week 8	Tezepelumab	9	9 (100.0)	5.53 (1.86)	1.0	5.75	6.00	6.50	7.0	
			Placebo	5	5 (100.0)	5.00 (1.08)	3.5	4.75	5.00	5.25	6.5	
		Week 12	Tezepelumab	9	9 (100.0)	5.75 (1.94)	1.0	5.50	6.50	7.00	7.0	
			Placebo	5	5 (100.0)	5.05 (0.82)	3.8	4.75	5.50	5.50	5.8	
		Week 16	Tezepelumab	9	9 (100.0)	5.69 (1.94)	1.0	5.50	6.25	7.00	7.0	
			Placebo	5	5 (100.0)	4.95 (0.89)	4.0	4.25	5.00	5.25	6.3	
		Week 20	Tezepelumab	9	9 (100.0)	5.64 (1.84)	1.3	5.00	6.00	7.00	7.0	
			Placebo	5	5 (100.0)	4.70 (0.72)	3.5	4.75	4.75	5.25	5.3	
		Week 24	Tezepelumab	9	9 (100.0)	5.72 (1.95)	1.0	5.00	6.75	7.00	7.0	
			Placebo	5	5 (100.0)	5.15 (1.10)	4.3	4.50	4.75	5.25	7.0	
		Week 28	Tezepelumab	9	9 (100.0)	5.61 (1.88)	1.0	5.25	6.25	7.00	7.0	
			Placebo	5	5 (100.0)	4.90 (1.39)	3.3	4.25	4.75	5.25	7.0	
		Week 32	Tezepelumab	9	9 (100.0)	5.81 (1.95)	1.0	5.50	6.75	7.00	7.0	
			Placebo	5	5 (100.0)	5.20 (1.05)	4.5	4.50	4.75	5.25	7.0	
		Week 36	Tezepelumab	9	9 (100.0)	5.72 (1.95)	1.0	5.00	6.50	7.00	7.0	
			Placebo	5	5 (100.0)	4.90 (1.34)	3.8	3.75	4.75	5.25	7.0	
		Week 40	Tezepelumab	9	9 (100.0)	5.78 (1.77)	2.0	5.25	7.00	7.00	7.0	
			Placebo	5	5 (100.0)	5.10 (1.15)	4.0	4.50	4.75	5.25	7.0	
		Week 44	Tezepelumab	9	9 (100.0)	5.83 (1.62)	2.0	5.75	6.00	7.00	7.0	
			Placebo	5	5 (100.0)	5.40 (0.93)	4.8	4.75	5.25	5.25	7.0	
		Week 48	Tezepelumab	9	9 (100.0)	5.53 (1.89)	1.0	5.00	6.00	7.00	7.0	
			Placebo	5	5 (100.0)	5.30 (0.97)	4.8	4.75	4.75	5.25	7.0	
		Week 52	Tezepelumab	9	9 (100.0)	5.58 (1.91)	1.0	5.00	6.00	7.00	7.0	
			Placebo	5	5 (100.0)	5.25 (1.02)	4.5	4.75	4.75	5.25	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	0.97 (1.00)	0.0	0.25	0.75	1.50	3.0	1.14 [-0.13, 2.42]
			Placebo	5	4 (80.0)	-0.25 (1.22)	-1.3	-1.25	-0.50	0.75	1.3	
		Week 8	Tezepelumab	9	9 (100.0)	1.25 (1.38)	-0.8	0.25	1.25	2.25	3.0	0.73 [-0.48, 1.95]
			Placebo	5	4 (80.0)	0.06 (2.13)	-1.3	-1.13	-0.88	1.25	3.3	
		Week 12	Tezepelumab	9	9 (100.0)	1.47 (1.35)	-0.8	0.50	2.25	2.50	3.0	0.98 [-0.26, 2.23]
			Placebo	5	4 (80.0)	0.06 (1.64)	-1.0	-0.88	-0.63	1.00	2.5	
		Week 16	Tezepelumab	9	9 (100.0)	1.42 (1.51)	-0.8	0.25	1.50	2.75	3.0	0.91 [-0.32, 2.15]
			Placebo	5	4 (80.0)	-0.13 (2.09)	-1.3	-1.25	-1.13	1.00	3.0	
		Week 20	Tezepelumab	9	9 (100.0)	1.36 (1.30)	-0.5	0.25	1.25	2.75	2.8	1.22 [-0.07, 2.50]
			Placebo	5	4 (80.0)	-0.31 (1.56)	-1.3	-1.25	-1.00	0.63	2.0	
		Week 24	Tezepelumab	9	9 (100.0)	1.44 (1.32)	-0.8	0.25	2.25	2.50	2.8	0.81 [-0.42, 2.03]
			Placebo	5	4 (80.0)	0.06 (2.48)	-1.5	-1.38	-1.00	1.50	3.8	
		Week 28	Tezepelumab	9	9 (100.0)	1.33 (1.32)	-0.8	0.25	1.50	2.50	2.8	0.86 [-0.37, 2.09]
			Placebo	5	4 (80.0)	-0.25 (2.80)	-2.8	-2.00	-1.00	1.50	3.8	
		Week 32	Tezepelumab	9	9 (100.0)	1.53 (1.33)	-0.8	0.25	2.25	2.50	3.0	0.85 [-0.38, 2.08]
			Placebo	5	4 (80.0)	0.06 (2.48)	-1.5	-1.38	-1.00	1.50	3.8	
		Week 36	Tezepelumab	9	9 (100.0)	1.44 (1.36)	-0.8	0.25	1.75	2.75	3.0	0.87 [-0.36, 2.10]
			Placebo	5	4 (80.0)	-0.13 (2.66)	-2.3	-1.75	-1.00	1.50	3.8	
		Week 40	Tezepelumab	9	9 (100.0)	1.50 (1.21)	0.0	0.25	1.25	2.75	3.0	0.87 [-0.36, 2.10]
			Placebo	5	4 (80.0)	0.06 (2.48)	-1.5	-1.38	-1.00	1.50	3.8	
		Week 44	Tezepelumab	9	9 (100.0)	1.56 (1.23)	0.0	0.25	2.00	2.75	3.0	0.87 [-0.36, 2.10]
			Placebo	5	4 (80.0)	0.13 (2.43)	-1.3	-1.25	-1.00	1.50	3.8	
		Week 48	Tezepelumab	9	9 (100.0)	1.25 (1.22)	-0.8	0.25	1.25	2.00	2.8	0.69 [-0.53, 1.90]
			Placebo	5	4 (80.0)	0.13 (2.43)	-1.3	-1.25	-1.00	1.50	3.8	
		Week 52	Tezepelumab	9	9 (100.0)	1.31 (1.27)	-0.8	0.25	1.25	2.50	2.8	0.71 [-0.51, 1.92]
			Placebo	5	4 (80.0)	0.13 (2.43)	-1.3	-1.25	-1.00	1.50	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.94 (1.25)	1.8	3.13	4.13	4.75	5.8	
			Placebo	14	10 (71.4)	4.95 (1.21)	3.3	4.25	4.75	5.75	7.0	
		Week 4	Tezepelumab	9	8 (88.9)	4.88 (1.26)	2.0	4.63	5.38	5.63	5.8	
			Placebo	14	12 (85.7)	5.21 (0.95)	3.5	4.88	5.25	5.63	7.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.25 (1.80)	1.0	5.38	5.63	6.00	7.0	
			Placebo	14	13 (92.9)	4.98 (1.06)	3.0	4.75	5.25	5.50	6.5	
		Week 12	Tezepelumab	9	8 (88.9)	5.31 (1.85)	1.0	5.38	5.50	6.38	7.0	
			Placebo	14	13 (92.9)	5.12 (0.85)	3.5	5.25	5.50	5.75	5.8	
		Week 16	Tezepelumab	9	8 (88.9)	5.41 (1.92)	1.0	5.38	5.50	6.75	7.0	
			Placebo	14	13 (92.9)	5.21 (1.05)	3.3	4.50	5.25	5.75	7.0	
		Week 20	Tezepelumab	9	8 (88.9)	4.94 (1.88)	1.3	3.88	5.50	6.25	7.0	
			Placebo	14	13 (92.9)	5.04 (1.22)	2.5	4.50	5.25	5.75	7.0	
		Week 24	Tezepelumab	9	8 (88.9)	5.13 (1.86)	1.0	4.75	5.50	6.38	6.8	
			Placebo	14	13 (92.9)	4.98 (1.54)	2.0	4.25	5.00	6.00	7.0	
		Week 28	Tezepelumab	9	8 (88.9)	5.25 (1.86)	1.0	5.00	5.88	6.13	7.0	
			Placebo	14	14 (100.0)	5.21 (1.28)	3.0	4.50	5.00	6.25	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.09 (1.89)	1.0	4.50	5.50	6.38	7.0	
			Placebo	14	14 (100.0)	5.45 (1.25)	3.0	4.50	5.50	6.75	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.16 (1.95)	1.0	4.63	5.63	6.38	7.0	
			Placebo	14	14 (100.0)	5.21 (1.56)	2.0	4.50	5.13	6.75	7.0	
		Week 40	Tezepelumab	9	8 (88.9)	5.44 (1.56)	2.0	5.13	5.75	6.38	7.0	
			Placebo	14	14 (100.0)	5.25 (1.45)	2.3	4.50	5.38	6.50	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.44 (1.53)	2.0	5.13	5.88	6.38	6.8	
			Placebo	14	14 (100.0)	5.50 (1.27)	3.0	4.50	5.50	6.75	7.0	
		Week 48	Tezepelumab	9	8 (88.9)	5.25 (1.86)	1.0	5.00	5.88	6.13	7.0	
			Placebo	14	14 (100.0)	5.20 (1.50)	2.0	4.50	5.13	6.50	7.0	
		Week 52	Tezepelumab	9	8 (88.9)	5.25 (1.84)	1.0	5.00	5.88	6.38	6.5	
			Placebo	14	14 (100.0)	5.38 (1.28)	3.0	4.50	5.13	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	1.07 (0.84)	0.0	0.25	1.25	1.50	2.5	0.68 [-0.31, 1.68]
			Placebo	14	10 (71.4)	0.35 (1.18)	-2.0	0.00	0.63	1.00	2.0	
		Week 8	Tezepelumab	9	7 (77.8)	1.39 (1.34)	-0.8	0.00	1.75	2.25	3.0	0.70 [-0.30, 1.69]
			Placebo	14	10 (71.4)	0.38 (1.54)	-1.8	-1.00	0.25	1.25	3.3	
		Week 12	Tezepelumab	9	7 (77.8)	1.50 (1.27)	-0.8	0.50	2.00	2.25	3.0	0.87 [-0.14, 1.89]
			Placebo	14	10 (71.4)	0.38 (1.30)	-1.8	-0.75	0.50	1.00	2.5	
		Week 16	Tezepelumab	9	7 (77.8)	1.64 (1.60)	-0.8	-0.25	2.50	3.00	3.3	0.80 [-0.20, 1.81]
			Placebo	14	10 (71.4)	0.48 (1.35)	-1.5	0.00	0.25	1.25	3.0	
		Week 20	Tezepelumab	9	7 (77.8)	1.29 (1.33)	-0.5	0.00	1.25	2.50	2.8	0.67 [-0.33, 1.67]
			Placebo	14	10 (71.4)	0.38 (1.38)	-2.3	0.00	0.25	1.50	2.0	
		Week 24	Tezepelumab	9	7 (77.8)	1.46 (1.29)	-0.8	0.25	2.00	2.50	2.8	0.65 [-0.34, 1.64]
			Placebo	14	10 (71.4)	0.43 (1.77)	-2.8	-0.25	0.13	1.50	3.8	
		Week 28	Tezepelumab	9	7 (77.8)	1.57 (1.46)	-0.8	0.00	2.25	2.75	3.0	0.70 [-0.30, 1.69]
			Placebo	14	10 (71.4)	0.53 (1.53)	-1.3	-0.25	0.13	1.00	3.8	
		Week 32	Tezepelumab	9	7 (77.8)	1.43 (1.32)	-0.8	0.25	1.50	2.50	3.0	0.44 [-0.54, 1.42]
			Placebo	14	10 (71.4)	0.83 (1.39)	-1.3	0.00	0.63	1.50	3.8	
		Week 36	Tezepelumab	9	7 (77.8)	1.57 (1.39)	-0.8	0.25	2.25	2.75	3.0	0.65 [-0.35, 1.64]
			Placebo	14	10 (71.4)	0.50 (1.81)	-2.8	0.00	0.25	1.25	3.8	
		Week 40	Tezepelumab	9	7 (77.8)	1.75 (1.25)	0.0	0.25	2.25	2.75	3.0	0.77 [-0.23, 1.77]
			Placebo	14	10 (71.4)	0.55 (1.74)	-2.5	0.00	0.50	1.75	3.8	
		Week 44	Tezepelumab	9	7 (77.8)	1.75 (1.35)	0.0	0.25	2.00	2.75	3.8	0.61 [-0.38, 1.60]
			Placebo	14	10 (71.4)	0.85 (1.55)	-1.3	0.00	0.25	2.25	3.8	
		Week 48	Tezepelumab	9	7 (77.8)	1.57 (1.40)	-0.8	0.25	2.00	2.75	3.0	0.68 [-0.32, 1.68]
			Placebo	14	10 (71.4)	0.45 (1.80)	-2.8	0.00	0.25	1.00	3.8	
		Week 52	Tezepelumab	9	7 (77.8)	1.57 (1.40)	-0.8	0.25	2.00	2.75	3.0	0.61 [-0.38, 1.60]
			Placebo	14	10 (71.4)	0.70 (1.44)	-1.3	0.00	0.25	1.00	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.00 (1.04)	1.8	3.50	4.00	4.75	6.8	
			Placebo	51	45 (88.2)	4.26 (1.19)	1.5	3.50	4.00	5.25	6.3	
		Week 4	Tezepelumab	57	52 (91.2)	4.79 (1.11)	1.3	4.00	4.88	5.75	7.0	
			Placebo	51	45 (88.2)	4.74 (1.26)	2.0	4.00	4.75	5.50	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.14 (1.05)	1.8	4.25	5.00	6.00	7.0	
			Placebo	51	46 (90.2)	4.89 (1.36)	1.5	4.00	5.00	5.75	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.26 (1.02)	3.0	4.50	5.25	6.00	7.0	
			Placebo	51	46 (90.2)	4.86 (1.23)	2.0	4.00	5.00	5.75	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.13 (1.06)	2.0	4.50	5.00	6.00	7.0	
			Placebo	51	46 (90.2)	4.79 (1.46)	1.3	4.00	5.00	5.75	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.16 (1.13)	1.0	4.50	5.00	6.00	7.0	
			Placebo	51	46 (90.2)	4.79 (1.47)	1.3	4.00	5.00	5.75	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.25 (1.17)	1.3	4.50	5.00	6.25	7.0	
			Placebo	51	46 (90.2)	4.74 (1.50)	1.0	4.25	4.88	5.75	7.0	
		Week 28	Tezepelumab	57	57 (100.0)	5.20 (1.16)	1.5	4.50	5.00	6.25	7.0	
			Placebo	51	46 (90.2)	4.93 (1.56)	1.3	4.00	5.25	6.00	7.0	
		Week 32	Tezepelumab	57	57 (100.0)	5.31 (1.18)	1.5	4.50	5.00	6.00	7.0	
			Placebo	51	46 (90.2)	4.92 (1.52)	1.3	4.00	5.25	6.00	7.0	
		Week 36	Tezepelumab	57	57 (100.0)	5.32 (1.12)	1.8	4.50	5.00	6.25	7.0	
			Placebo	51	46 (90.2)	4.77 (1.48)	1.0	4.00	5.00	5.75	7.0	
		Week 40	Tezepelumab	57	57 (100.0)	5.30 (1.08)	2.3	4.50	5.00	6.00	7.0	
			Placebo	51	46 (90.2)	4.97 (1.49)	1.0	4.00	5.13	6.00	7.0	
		Week 44	Tezepelumab	57	57 (100.0)	5.31 (1.15)	1.3	4.50	5.25	6.25	7.0	
			Placebo	51	46 (90.2)	4.89 (1.43)	1.3	4.00	4.88	6.00	7.0	
		Week 48	Tezepelumab	57	57 (100.0)	5.36 (1.11)	2.3	4.50	5.25	6.25	7.0	
			Placebo	51	46 (90.2)	4.94 (1.35)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	57	57 (100.0)	5.37 (1.10)	2.3	4.50	5.25	6.25	7.0	
			Placebo	51	46 (90.2)	4.98 (1.33)	1.8	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	0.79 (1.29)	-4.0	0.00	0.75	1.75	4.0	0.27 [-0.14, 0.68]
			Placebo	51	44 (86.3)	0.47 (1.02)	-1.8	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	57	50 (87.7)	1.11 (1.20)	-1.3	0.25	1.00	2.00	4.3	0.40 [-0.01, 0.80]
			Placebo	51	45 (88.2)	0.65 (1.09)	-1.5	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	57	50 (87.7)	1.23 (1.16)	-2.3	0.25	1.25	2.00	4.8	0.56 [0.15, 0.98]
			Placebo	51	45 (88.2)	0.62 (0.99)	-1.3	0.00	0.75	1.25	3.0	
		Week 16	Tezepelumab	57	50 (87.7)	1.10 (1.18)	-2.8	0.25	1.00	2.00	3.0	0.51 [0.10, 0.92]
			Placebo	51	45 (88.2)	0.54 (0.98)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	57	50 (87.7)	1.13 (1.21)	-1.8	0.25	1.13	2.00	3.5	0.52 [0.11, 0.93]
			Placebo	51	45 (88.2)	0.54 (1.00)	-1.8	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	57	50 (87.7)	1.23 (1.22)	-1.5	0.25	1.50	2.25	3.5	0.64 [0.22, 1.05]
			Placebo	51	45 (88.2)	0.49 (1.08)	-1.8	-0.25	0.50	1.00	3.0	
		Week 28	Tezepelumab	57	50 (87.7)	1.19 (1.22)	-1.5	0.25	1.38	2.25	3.3	0.41 [0.00, 0.82]
			Placebo	51	45 (88.2)	0.69 (1.22)	-2.8	0.25	0.75	1.25	3.0	
		Week 32	Tezepelumab	57	50 (87.7)	1.30 (1.27)	-1.3	0.25	1.50	2.25	3.5	0.52 [0.11, 0.93]
			Placebo	51	45 (88.2)	0.69 (1.00)	-1.8	0.00	0.75	1.25	3.0	
		Week 36	Tezepelumab	57	50 (87.7)	1.30 (1.24)	-1.3	0.25	1.50	2.25	3.5	0.65 [0.24, 1.07]
			Placebo	51	45 (88.2)	0.54 (1.05)	-2.3	0.00	0.25	1.25	3.0	
		Week 40	Tezepelumab	57	50 (87.7)	1.31 (1.15)	-1.3	0.25	1.50	2.00	3.3	0.51 [0.10, 0.92]
			Placebo	51	45 (88.2)	0.73 (1.10)	-1.5	0.00	0.75	1.25	3.3	
		Week 44	Tezepelumab	57	50 (87.7)	1.34 (1.23)	-1.5	0.50	1.50	2.25	3.8	0.57 [0.16, 0.98]
			Placebo	51	45 (88.2)	0.66 (1.15)	-1.5	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	57	50 (87.7)	1.38 (1.25)	-1.3	0.50	1.50	2.25	3.8	0.55 [0.14, 0.97]
			Placebo	51	45 (88.2)	0.71 (1.18)	-1.5	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	57	50 (87.7)	1.39 (1.21)	-1.3	0.50	1.50	2.25	3.8	0.54 [0.13, 0.96]
			Placebo	51	45 (88.2)	0.73 (1.20)	-1.3	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	51	44 (86.3)	3.93 (0.99)	1.8	3.38	4.00	4.63	6.0	
			Placebo	49	43 (87.8)	4.19 (1.18)	1.5	3.25	4.00	5.25	6.3	
		Week 4	Tezepelumab	51	46 (90.2)	4.67 (1.10)	1.3	4.00	4.75	5.50	7.0	
			Placebo	49	43 (87.8)	4.72 (1.28)	2.0	4.00	4.75	5.50	7.0	
		Week 8	Tezepelumab	51	48 (94.1)	5.03 (1.03)	1.8	4.25	5.00	5.75	7.0	
			Placebo	49	44 (89.8)	4.89 (1.39)	1.5	3.88	5.13	5.88	7.0	
		Week 12	Tezepelumab	51	48 (94.1)	5.14 (0.97)	3.0	4.50	5.13	5.75	7.0	
			Placebo	49	44 (89.8)	4.85 (1.26)	2.0	4.00	5.00	5.88	7.0	
		Week 16	Tezepelumab	51	48 (94.1)	4.98 (0.99)	2.0	4.50	4.75	5.63	7.0	
			Placebo	49	44 (89.8)	4.80 (1.49)	1.3	4.00	5.00	5.88	7.0	
		Week 20	Tezepelumab	51	49 (96.1)	5.04 (1.10)	1.0	4.50	5.00	5.75	7.0	
			Placebo	49	44 (89.8)	4.79 (1.50)	1.3	3.88	5.00	5.88	7.0	
		Week 24	Tezepelumab	51	49 (96.1)	5.12 (1.14)	1.3	4.25	5.00	6.00	7.0	
			Placebo	49	44 (89.8)	4.75 (1.54)	1.0	4.13	5.00	5.75	7.0	
		Week 28	Tezepelumab	51	51 (100.0)	5.07 (1.13)	1.5	4.25	5.00	5.75	7.0	
			Placebo	49	44 (89.8)	4.98 (1.58)	1.3	4.00	5.25	6.00	7.0	
		Week 32	Tezepelumab	51	51 (100.0)	5.18 (1.15)	1.5	4.25	5.00	6.00	7.0	
			Placebo	49	44 (89.8)	4.93 (1.55)	1.3	3.88	5.25	6.00	7.0	
		Week 36	Tezepelumab	51	51 (100.0)	5.22 (1.09)	1.8	4.50	5.00	6.25	7.0	
			Placebo	49	44 (89.8)	4.79 (1.50)	1.0	4.00	5.00	5.88	7.0	
		Week 40	Tezepelumab	51	51 (100.0)	5.19 (1.02)	2.3	4.50	5.00	5.75	7.0	
			Placebo	49	44 (89.8)	4.99 (1.53)	1.0	4.00	5.25	6.13	7.0	
		Week 44	Tezepelumab	51	51 (100.0)	5.17 (1.11)	1.3	4.50	5.00	6.25	7.0	
			Placebo	49	44 (89.8)	4.90 (1.46)	1.3	4.00	5.00	6.00	7.0	
		Week 48	Tezepelumab	51	51 (100.0)	5.27 (1.09)	2.3	4.50	5.00	6.25	7.0	
			Placebo	49	44 (89.8)	4.95 (1.38)	1.0	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	51	51 (100.0)	5.28 (1.08)	2.3	4.50	5.00	6.00	7.0	
			Placebo	49	44 (89.8)	4.99 (1.36)	1.8	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	51	42 (82.4)	0.74 (1.32)	-4.0	0.00	0.75	1.75	4.0	0.19 [-0.24, 0.62]
			Placebo	49	42 (85.7)	0.52 (1.01)	-1.8	-0.25	0.25	1.00	3.0	
		Week 8	Tezepelumab	51	44 (86.3)	1.05 (1.21)	-1.3	0.13	0.88	2.00	4.3	0.29 [-0.13, 0.71]
			Placebo	49	43 (87.8)	0.72 (1.06)	-1.5	0.00	0.50	1.25	3.0	
		Week 12	Tezepelumab	51	44 (86.3)	1.16 (1.17)	-2.3	0.25	1.13	1.75	4.8	0.45 [0.02, 0.88]
			Placebo	49	43 (87.8)	0.67 (0.98)	-1.3	0.00	0.75	1.25	3.0	
		Week 16	Tezepelumab	51	44 (86.3)	1.01 (1.16)	-2.8	0.13	0.88	2.00	3.0	0.37 [-0.05, 0.79]
			Placebo	49	43 (87.8)	0.62 (0.93)	-1.8	0.00	0.50	1.00	3.0	
		Week 20	Tezepelumab	51	44 (86.3)	1.06 (1.22)	-1.8	0.13	1.00	2.00	3.5	0.40 [-0.03, 0.82]
			Placebo	49	43 (87.8)	0.62 (0.97)	-1.8	0.00	0.50	1.25	3.0	
		Week 24	Tezepelumab	51	44 (86.3)	1.15 (1.24)	-1.5	0.25	1.50	2.00	3.5	0.51 [0.08, 0.94]
			Placebo	49	43 (87.8)	0.57 (1.04)	-1.8	-0.25	0.50	1.25	3.0	
		Week 28	Tezepelumab	51	44 (86.3)	1.11 (1.23)	-1.5	0.25	1.13	2.00	3.3	0.27 [-0.15, 0.69]
			Placebo	49	43 (87.8)	0.80 (1.10)	-1.8	0.25	0.75	1.50	3.0	
		Week 32	Tezepelumab	51	44 (86.3)	1.22 (1.30)	-1.3	0.13	1.38	2.13	3.5	0.39 [-0.04, 0.81]
			Placebo	49	43 (87.8)	0.78 (0.93)	-1.8	0.25	0.75	1.25	3.0	
		Week 36	Tezepelumab	51	44 (86.3)	1.24 (1.26)	-1.3	0.25	1.38	2.25	3.5	0.53 [0.11, 0.96]
			Placebo	49	43 (87.8)	0.64 (0.96)	-1.0	0.00	0.50	1.25	3.0	
		Week 40	Tezepelumab	51	44 (86.3)	1.26 (1.16)	-1.3	0.25	1.50	2.00	3.3	0.40 [-0.03, 0.82]
			Placebo	49	43 (87.8)	0.82 (1.04)	-1.0	0.00	0.75	1.25	3.3	
		Week 44	Tezepelumab	51	44 (86.3)	1.25 (1.23)	-1.5	0.50	1.38	2.13	3.8	0.44 [0.01, 0.87]
			Placebo	49	43 (87.8)	0.73 (1.12)	-1.5	0.00	0.50	1.25	3.8	
		Week 48	Tezepelumab	51	44 (86.3)	1.35 (1.28)	-1.3	0.50	1.50	2.25	3.8	0.46 [0.04, 0.89]
			Placebo	49	43 (87.8)	0.78 (1.15)	-1.5	0.00	0.50	1.25	3.8	
		Week 52	Tezepelumab	51	44 (86.3)	1.35 (1.24)	-1.3	0.50	1.50	2.25	3.8	0.45 [0.03, 0.88]
			Placebo	49	43 (87.8)	0.81 (1.16)	-1.0	0.00	0.50	1.25	4.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	4.18 (1.25)	1.8	3.25	4.25	4.75	6.8	
			Placebo	16	12 (75.0)	5.08 (1.14)	3.3	4.38	5.00	5.88	7.0	
		Week 4	Tezepelumab	15	14 (93.3)	5.21 (1.13)	2.0	5.00	5.50	5.75	6.8	
			Placebo	16	14 (87.5)	5.21 (0.89)	3.5	4.75	5.25	5.75	7.0	
		Week 8	Tezepelumab	15	14 (93.3)	5.57 (1.48)	1.0	5.50	5.75	6.25	7.0	
			Placebo	16	15 (93.8)	4.97 (0.98)	3.0	4.75	5.00	5.50	6.5	
		Week 12	Tezepelumab	15	14 (93.3)	5.71 (1.55)	1.0	5.50	5.88	6.75	7.0	
			Placebo	16	15 (93.8)	5.12 (0.80)	3.5	4.75	5.50	5.75	5.8	
		Week 16	Tezepelumab	15	14 (93.3)	5.79 (1.58)	1.0	5.50	6.00	7.00	7.0	
			Placebo	16	15 (93.8)	5.13 (1.01)	3.3	4.25	5.25	5.75	7.0	
		Week 20	Tezepelumab	15	14 (93.3)	5.46 (1.63)	1.3	5.00	5.63	7.00	7.0	
			Placebo	16	15 (93.8)	5.00 (1.14)	2.5	4.50	5.00	5.75	7.0	
		Week 24	Tezepelumab	15	14 (93.3)	5.63 (1.61)	1.0	5.00	5.75	6.75	7.0	
			Placebo	16	15 (93.8)	4.93 (1.43)	2.0	4.25	4.75	6.00	7.0	
		Week 28	Tezepelumab	15	14 (93.3)	5.68 (1.56)	1.0	5.25	6.00	7.00	7.0	
			Placebo	16	16 (100.0)	5.06 (1.29)	3.0	4.38	4.75	6.13	7.0	
		Week 32	Tezepelumab	15	14 (93.3)	5.64 (1.63)	1.0	5.00	5.75	7.00	7.0	
			Placebo	16	16 (100.0)	5.34 (1.20)	3.0	4.50	5.25	6.38	7.0	
		Week 36	Tezepelumab	15	14 (93.3)	5.63 (1.65)	1.0	5.00	5.88	7.00	7.0	
			Placebo	16	16 (100.0)	5.09 (1.50)	2.0	4.13	5.00	6.50	7.0	
		Week 40	Tezepelumab	15	14 (93.3)	5.77 (1.45)	2.0	5.25	5.88	7.00	7.0	
			Placebo	16	16 (100.0)	5.17 (1.37)	2.3	4.50	5.25	6.25	7.0	
		Week 44	Tezepelumab	15	14 (93.3)	5.88 (1.35)	2.0	5.50	6.00	7.00	7.0	
			Placebo	16	16 (100.0)	5.41 (1.21)	3.0	4.63	5.25	6.63	7.0	
		Week 48	Tezepelumab	15	14 (93.3)	5.63 (1.57)	1.0	5.00	6.00	7.00	7.0	
			Placebo	16	16 (100.0)	5.14 (1.40)	2.0	4.50	4.88	6.25	7.0	
		Week 52	Tezepelumab	15	14 (93.3)	5.63 (1.56)	1.0	5.00	6.00	6.50	7.0	
			Placebo	16	16 (100.0)	5.30 (1.21)	3.0	4.50	4.88	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_ILSHP: Change from baseline in AQLQ+12 environmental stimuli score by study specific subgroups
DITTL

Subgroup	AQLQ+12 environmental stimuli score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	15	13 (86.7)	1.12 (0.93)	0.0	0.25	1.25	1.50	3.0	0.87 [0.04, 1.69]
			Placebo	16	12 (75.0)	0.21 (1.16)	-2.0	-0.63	0.50	0.88	2.0	
		Week 8	Tezepelumab	15	13 (86.7)	1.44 (1.19)	-0.8	0.25	1.75	2.25	3.0	0.96 [0.12, 1.79]
			Placebo	16	12 (75.0)	0.17 (1.47)	-1.8	-1.00	-0.13	1.25	3.3	
		Week 12	Tezepelumab	15	13 (86.7)	1.62 (1.15)	-0.8	0.50	2.25	2.25	3.0	1.18 [0.32, 2.04]
			Placebo	16	12 (75.0)	0.21 (1.24)	-1.8	-0.75	0.13	1.00	2.5	
		Week 16	Tezepelumab	15	13 (86.7)	1.71 (1.38)	-0.8	0.50	2.50	2.75	3.3	1.09 [0.25, 1.94]
			Placebo	16	12 (75.0)	0.21 (1.37)	-1.5	-1.13	0.13	1.13	3.0	
		Week 20	Tezepelumab	15	13 (86.7)	1.46 (1.18)	-0.5	0.50	1.25	2.50	2.8	1.04 [0.20, 1.87]
			Placebo	16	12 (75.0)	0.15 (1.36)	-2.3	-1.00	0.13	1.38	2.0	
		Week 24	Tezepelumab	15	13 (86.7)	1.62 (1.14)	-0.8	0.75	2.25	2.50	2.8	1.00 [0.16, 1.84]
			Placebo	16	12 (75.0)	0.17 (1.72)	-2.8	-1.00	0.00	1.50	3.8	
		Week 28	Tezepelumab	15	13 (86.7)	1.65 (1.25)	-0.8	0.75	2.25	2.75	3.0	1.02 [0.18, 1.86]
			Placebo	16	12 (75.0)	0.15 (1.70)	-2.8	-1.00	0.00	0.88	3.8	
		Week 32	Tezepelumab	15	13 (86.7)	1.63 (1.14)	-0.8	1.25	2.25	2.50	3.0	0.86 [0.04, 1.69]
			Placebo	16	12 (75.0)	0.50 (1.48)	-1.5	-0.50	0.13	1.50	3.8	
		Week 36	Tezepelumab	15	13 (86.7)	1.65 (1.20)	-0.8	0.75	2.25	2.75	3.0	0.97 [0.13, 1.80]
			Placebo	16	12 (75.0)	0.17 (1.84)	-2.8	-1.00	0.13	1.13	3.8	
		Week 40	Tezepelumab	15	13 (86.7)	1.73 (1.11)	0.0	1.00	2.25	2.75	3.0	1.02 [0.19, 1.86]
			Placebo	16	12 (75.0)	0.27 (1.71)	-2.5	-1.00	0.13	1.25	3.8	
		Week 44	Tezepelumab	15	13 (86.7)	1.85 (1.22)	0.0	0.75	2.25	2.75	3.8	0.93 [0.10, 1.76]
			Placebo	16	12 (75.0)	0.54 (1.58)	-1.3	-0.63	0.13	1.75	3.8	
		Week 48	Tezepelumab	15	13 (86.7)	1.60 (1.20)	-0.8	0.75	2.00	2.75	3.0	0.94 [0.11, 1.77]
			Placebo	16	12 (75.0)	0.21 (1.72)	-2.8	-1.00	0.13	0.88	3.8	
		Week 52	Tezepelumab	15	13 (86.7)	1.60 (1.20)	-0.8	0.75	2.00	2.75	3.0	0.88 [0.06, 1.71]
			Placebo	16	12 (75.0)	0.42 (1.47)	-1.3	-0.50	0.13	0.88	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILMH0: Course of AQLQ+12 emotional function score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	66	58 (87.9)	4.26 (1.16)	1.4	3.60	4.20	5.00	6.4	
		Placebo	65	55 (84.6)	4.39 (1.16)	1.0	3.80	4.20	5.20	7.0	
	Week 4	Tezepelumab	66	60 (90.9)	4.88 (1.17)	1.2	4.00	4.80	5.90	7.0	
		Placebo	65	57 (87.7)	4.90 (1.29)	1.6	4.20	4.80	5.80	7.0	
	Week 8	Tezepelumab	66	62 (93.9)	5.16 (1.20)	2.8	4.20	5.10	6.20	7.0	
		Placebo	65	59 (90.8)	4.97 (1.15)	2.0	4.20	5.00	5.80	7.0	
	Week 12	Tezepelumab	66	62 (93.9)	5.37 (1.17)	2.8	4.40	5.40	6.40	7.0	
		Placebo	65	59 (90.8)	5.11 (1.22)	1.8	4.20	5.20	6.20	7.0	
	Week 16	Tezepelumab	66	62 (93.9)	5.31 (1.21)	2.6	4.40	5.60	6.20	7.0	
		Placebo	65	59 (90.8)	5.08 (1.29)	1.0	4.40	5.00	6.00	7.0	
	Week 20	Tezepelumab	66	63 (95.5)	5.38 (1.16)	2.4	4.40	5.60	6.40	7.0	
		Placebo	65	59 (90.8)	5.03 (1.25)	1.0	4.20	5.00	6.00	7.0	
	Week 24	Tezepelumab	66	63 (95.5)	5.28 (1.23)	2.0	4.20	5.40	6.40	7.0	
		Placebo	65	59 (90.8)	4.99 (1.29)	1.0	4.40	5.00	6.00	7.0	
	Week 28	Tezepelumab	66	65 (98.5)	5.37 (1.12)	2.8	4.40	5.40	6.40	7.0	
		Placebo	65	60 (92.3)	5.08 (1.33)	1.0	4.20	5.20	6.00	7.0	
	Week 32	Tezepelumab	66	65 (98.5)	5.35 (1.17)	2.6	4.40	5.60	6.40	7.0	
		Placebo	65	60 (92.3)	5.09 (1.33)	1.0	4.10	5.20	6.00	7.0	
	Week 36	Tezepelumab	66	65 (98.5)	5.49 (1.22)	2.8	4.60	5.60	6.60	7.0	
		Placebo	65	60 (92.3)	5.06 (1.28)	1.6	4.40	5.00	6.00	7.0	
	Week 40	Tezepelumab	66	65 (98.5)	5.29 (1.30)	1.8	4.20	5.40	6.40	7.0	
		Placebo	65	60 (92.3)	5.09 (1.30)	1.6	4.30	5.00	6.30	7.0	
	Week 44	Tezepelumab	66	65 (98.5)	5.41 (1.16)	2.8	4.40	5.40	6.40	7.0	
		Placebo	65	60 (92.3)	5.07 (1.32)	1.8	4.00	5.10	6.20	7.0	
	Week 48	Tezepelumab	66	65 (98.5)	5.40 (1.17)	2.6	4.60	5.40	6.40	7.0	
		Placebo	65	60 (92.3)	5.06 (1.32)	1.4	4.00	5.00	6.10	7.0	
	Week 52	Tezepelumab	66	65 (98.5)	5.42 (1.17)	2.6	4.60	5.40	6.40	7.0	
		Placebo	65	60 (92.3)	5.03 (1.35)	2.0	4.00	4.80	6.10	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILMH0: Course of AQLQ+12 emotional function score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	66	55 (83.3)	0.62 (1.34)	-4.2	-0.20	0.60	1.60	3.8	0.08 [-0.30, 0.45]
		Placebo	65	54 (83.1)	0.53 (1.04)	-2.2	0.00	0.40	1.20	3.0	
	Week 8	Tezepelumab	66	57 (86.4)	0.84 (1.31)	-2.2	-0.20	1.00	1.60	4.4	0.17 [-0.20, 0.55]
		Placebo	65	55 (84.6)	0.62 (1.17)	-1.6	0.00	0.60	1.20	4.0	
	Week 12	Tezepelumab	66	57 (86.4)	1.05 (1.24)	-2.4	0.20	1.00	1.80	3.8	0.25 [-0.12, 0.62]
		Placebo	65	55 (84.6)	0.74 (1.24)	-1.8	0.00	0.80	1.60	4.4	
	Week 16	Tezepelumab	66	57 (86.4)	0.99 (1.26)	-2.8	0.20	1.00	1.80	4.0	0.21 [-0.16, 0.58]
		Placebo	65	55 (84.6)	0.72 (1.31)	-3.4	0.20	0.60	1.40	4.4	
	Week 20	Tezepelumab	66	57 (86.4)	1.14 (1.19)	-1.4	0.40	1.20	2.00	4.6	0.38 [0.00, 0.75]
		Placebo	65	55 (84.6)	0.68 (1.25)	-3.4	0.00	0.80	1.60	4.2	
	Week 24	Tezepelumab	66	57 (86.4)	1.02 (1.29)	-1.4	0.00	1.00	1.80	4.6	0.29 [-0.08, 0.66]
		Placebo	65	55 (84.6)	0.64 (1.30)	-3.4	0.00	0.40	1.60	4.2	
	Week 28	Tezepelumab	66	57 (86.4)	1.07 (1.24)	-1.4	0.00	0.80	1.80	4.6	0.26 [-0.11, 0.64]
		Placebo	65	55 (84.6)	0.72 (1.42)	-3.4	0.00	0.80	1.60	4.4	
	Week 32	Tezepelumab	66	57 (86.4)	1.04 (1.29)	-1.6	0.20	1.00	2.00	4.6	0.24 [-0.13, 0.62]
		Placebo	65	55 (84.6)	0.73 (1.26)	-3.4	-0.20	0.80	1.40	4.2	
	Week 36	Tezepelumab	66	57 (86.4)	1.22 (1.39)	-1.6	0.40	1.20	2.00	4.6	0.44 [0.06, 0.81]
		Placebo	65	55 (84.6)	0.67 (1.11)	-2.0	0.00	0.60	1.40	3.8	
	Week 40	Tezepelumab	66	57 (86.4)	1.03 (1.37)	-2.4	0.00	1.00	2.00	4.6	0.22 [-0.15, 0.60]
		Placebo	65	55 (84.6)	0.73 (1.27)	-2.0	-0.40	0.80	1.60	3.6	
	Week 44	Tezepelumab	66	57 (86.4)	1.10 (1.30)	-1.4	0.00	1.20	1.60	4.6	0.32 [-0.05, 0.70]
		Placebo	65	55 (84.6)	0.68 (1.26)	-1.8	-0.40	0.60	1.20	4.2	
	Week 48	Tezepelumab	66	57 (86.4)	1.11 (1.29)	-1.4	0.20	1.20	1.80	4.6	0.33 [-0.05, 0.70]
		Placebo	65	55 (84.6)	0.70 (1.23)	-2.2	-0.20	0.60	1.40	4.2	
	Week 52	Tezepelumab	66	57 (86.4)	1.12 (1.31)	-1.6	0.20	1.20	1.80	4.6	0.34 [-0.03, 0.71]
		Placebo	65	55 (84.6)	0.67 (1.34)	-2.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
DITTL

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	54 (83.1)					
Week 8	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	55 (84.6)					
Week 12	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	52 (80.0)					
Week 16	Tezepelumab	66	53 (80.3)	NE		NE		
	Placebo	65	50 (76.9)					
Week 20	Tezepelumab	66	51 (77.3)	NE		NE		
	Placebo	65	47 (72.3)					
Week 24	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	45 (69.2)					
Week 28	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 32	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	43 (66.2)					
Week 36	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 40	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	45 (69.2)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
DITTL

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 48	Tezepelumab	66	46 (69.7)	NE		NE		
	Placebo	65	44 (67.7)					
Week 52	Tezepelumab	66	18 (27.3)	NE		NE		
	Placebo	65	16 (24.6)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QGC_ILMG0: Course of AQLQ+12 emotional function score
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QGC_ILMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	19	16 (84.2)	3.99 (0.81)	2.8	3.40	4.00	4.30	6.4	
			Placebo	20	17 (85.0)	4.07 (1.28)	1.0	3.40	4.20	4.60	6.2	
		Week 4	Tezepelumab	19	17 (89.5)	4.89 (1.12)	3.2	4.00	4.80	5.80	7.0	
			Placebo	20	17 (85.0)	4.68 (1.58)	1.6	3.80	5.20	6.00	7.0	
		Week 8	Tezepelumab	19	17 (89.5)	5.06 (1.21)	3.2	4.00	4.80	5.80	7.0	
			Placebo	20	18 (90.0)	4.74 (1.19)	3.0	4.00	4.60	5.80	7.0	
		Week 12	Tezepelumab	19	17 (89.5)	5.16 (1.21)	3.6	4.20	5.00	6.00	7.0	
			Placebo	20	18 (90.0)	4.87 (1.36)	1.8	4.20	4.60	6.00	7.0	
		Week 16	Tezepelumab	19	17 (89.5)	5.01 (1.29)	3.2	4.00	4.80	6.00	7.0	
			Placebo	20	18 (90.0)	4.54 (1.56)	1.0	3.60	4.60	5.80	7.0	
		Week 20	Tezepelumab	19	17 (89.5)	5.15 (1.36)	2.4	4.20	5.40	6.00	7.0	
			Placebo	20	18 (90.0)	4.70 (1.59)	1.0	3.80	4.80	6.00	7.0	
		Week 24	Tezepelumab	19	17 (89.5)	5.08 (1.39)	2.0	4.20	5.40	6.00	7.0	
			Placebo	20	18 (90.0)	4.51 (1.71)	1.0	2.80	4.90	5.60	7.0	
		Week 28	Tezepelumab	19	18 (94.7)	5.17 (1.16)	3.2	4.00	5.00	6.20	7.0	
			Placebo	20	19 (95.0)	4.66 (1.70)	1.0	3.60	4.60	6.20	7.0	
		Week 32	Tezepelumab	19	18 (94.7)	5.23 (1.18)	3.6	4.40	5.20	6.00	7.0	
			Placebo	20	19 (95.0)	4.69 (1.71)	1.0	3.80	5.00	6.20	7.0	
		Week 36	Tezepelumab	19	18 (94.7)	5.32 (1.40)	3.2	4.20	5.20	6.60	7.0	
			Placebo	20	19 (95.0)	4.78 (1.60)	1.6	4.00	4.80	6.00	7.0	
		Week 40	Tezepelumab	19	18 (94.7)	5.01 (1.39)	2.0	4.00	5.00	6.20	7.0	
			Placebo	20	19 (95.0)	4.81 (1.52)	1.6	4.00	5.00	6.00	7.0	
		Week 44	Tezepelumab	19	18 (94.7)	5.20 (1.30)	3.2	4.00	5.10	6.60	7.0	
			Placebo	20	19 (95.0)	4.89 (1.47)	1.8	4.00	5.20	6.00	7.0	
		Week 48	Tezepelumab	19	18 (94.7)	5.21 (1.24)	2.6	4.40	5.00	6.20	7.0	
			Placebo	20	19 (95.0)	4.89 (1.61)	1.4	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	19	18 (94.7)	5.20 (1.11)	3.2	4.40	4.90	6.00	7.0	
			Placebo	20	19 (95.0)	4.89 (1.53)	2.0	4.00	4.80	6.40	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	19	15 (78.9)	0.88 (0.89)	-0.4	0.20	0.80	1.60	2.6	0.18 [-0.53, 0.89]
			Placebo	20	16 (80.0)	0.69 (1.21)	-2.0	0.40	0.60	1.50	3.0	
		Week 8	Tezepelumab	19	15 (78.9)	1.05 (1.04)	-0.4	-0.20	1.20	2.20	2.4	0.28 [-0.42, 0.98]
			Placebo	20	17 (85.0)	0.72 (1.32)	-1.6	0.20	0.40	1.40	4.0	
		Week 12	Tezepelumab	19	15 (78.9)	1.19 (1.05)	-0.6	0.40	1.00	1.80	3.0	0.30 [-0.40, 1.00]
			Placebo	20	17 (85.0)	0.81 (1.42)	-1.8	0.20	0.60	1.60	4.4	
		Week 16	Tezepelumab	19	15 (78.9)	1.08 (0.97)	-0.2	0.20	1.00	2.20	2.6	0.44 [-0.27, 1.14]
			Placebo	20	17 (85.0)	0.47 (1.68)	-3.4	0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	19	15 (78.9)	1.31 (0.96)	-0.6	0.60	1.20	2.40	2.6	0.51 [-0.19, 1.22]
			Placebo	20	17 (85.0)	0.62 (1.59)	-3.4	0.00	0.80	1.60	4.2	
		Week 24	Tezepelumab	19	15 (78.9)	1.25 (0.91)	-0.4	0.60	1.20	2.00	2.8	0.58 [-0.13, 1.29]
			Placebo	20	17 (85.0)	0.42 (1.74)	-3.4	-0.20	0.40	1.40	4.2	
		Week 28	Tezepelumab	19	15 (78.9)	1.21 (0.98)	-0.2	0.60	1.20	2.20	2.8	0.51 [-0.19, 1.22]
			Placebo	20	17 (85.0)	0.47 (1.77)	-3.4	0.00	0.80	1.20	4.4	
		Week 32	Tezepelumab	19	15 (78.9)	1.32 (0.99)	-0.4	0.60	1.20	2.40	2.8	0.60 [-0.11, 1.31]
			Placebo	20	17 (85.0)	0.51 (1.62)	-3.4	-0.20	0.60	1.40	4.2	
		Week 36	Tezepelumab	19	15 (78.9)	1.48 (1.24)	-0.4	0.60	1.40	2.60	3.4	0.68 [-0.03, 1.40]
			Placebo	20	17 (85.0)	0.58 (1.39)	-2.0	0.00	0.40	1.20	3.8	
		Week 40	Tezepelumab	19	15 (78.9)	1.24 (1.09)	-0.2	0.60	1.00	2.00	3.4	0.47 [-0.24, 1.17]
			Placebo	20	17 (85.0)	0.65 (1.42)	-2.0	-0.60	0.80	1.60	3.4	
		Week 44	Tezepelumab	19	15 (78.9)	1.27 (1.11)	-0.2	0.60	0.80	2.40	3.2	0.50 [-0.21, 1.21]
			Placebo	20	17 (85.0)	0.67 (1.25)	-1.8	-0.20	0.60	1.60	3.4	
		Week 48	Tezepelumab	19	15 (78.9)	1.29 (1.15)	-0.8	0.60	1.00	2.20	3.4	0.49 [-0.22, 1.19]
			Placebo	20	17 (85.0)	0.67 (1.39)	-2.2	0.00	0.60	1.20	3.8	
		Week 52	Tezepelumab	19	15 (78.9)	1.28 (1.19)	-0.6	0.40	1.00	2.40	3.4	0.46 [-0.25, 1.16]
			Placebo	20	17 (85.0)	0.71 (1.31)	-1.6	0.00	0.60	1.20	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	47	42 (89.4)	4.37 (1.26)	1.4	3.60	4.50	5.20	6.4	
			Placebo	45	38 (84.4)	4.53 (1.10)	2.0	3.80	4.40	5.20	7.0	
		Week 4	Tezepelumab	47	43 (91.5)	4.87 (1.20)	1.2	4.00	4.80	6.00	7.0	
			Placebo	45	40 (88.9)	5.00 (1.15)	1.6	4.30	4.80	5.60	7.0	
		Week 8	Tezepelumab	47	45 (95.7)	5.20 (1.21)	2.8	4.40	5.20	6.20	7.0	
			Placebo	45	41 (91.1)	5.07 (1.14)	2.0	4.60	5.20	5.80	7.0	
		Week 12	Tezepelumab	47	45 (95.7)	5.45 (1.16)	2.8	4.60	5.60	6.40	7.0	
			Placebo	45	41 (91.1)	5.21 (1.16)	2.6	4.20	5.20	6.20	7.0	
		Week 16	Tezepelumab	47	45 (95.7)	5.43 (1.17)	2.6	4.40	5.60	6.20	7.0	
			Placebo	45	41 (91.1)	5.32 (1.09)	2.8	4.60	5.20	6.00	7.0	
		Week 20	Tezepelumab	47	46 (97.9)	5.47 (1.08)	2.8	4.60	5.60	6.40	7.0	
			Placebo	45	41 (91.1)	5.17 (1.06)	3.0	4.40	5.00	6.00	7.0	
		Week 24	Tezepelumab	47	46 (97.9)	5.36 (1.18)	2.8	4.20	5.60	6.40	7.0	
			Placebo	45	41 (91.1)	5.20 (1.00)	3.4	4.40	5.00	6.00	7.0	
		Week 28	Tezepelumab	47	47 (100.0)	5.45 (1.11)	2.8	4.40	5.60	6.40	7.0	
			Placebo	45	41 (91.1)	5.27 (1.09)	3.4	4.40	5.20	6.00	7.0	
		Week 32	Tezepelumab	47	47 (100.0)	5.39 (1.18)	2.6	4.40	5.60	6.40	7.0	
			Placebo	45	41 (91.1)	5.27 (1.09)	3.0	4.40	5.20	6.00	7.0	
		Week 36	Tezepelumab	47	47 (100.0)	5.56 (1.16)	2.8	4.60	6.00	6.40	7.0	
			Placebo	45	41 (91.1)	5.19 (1.09)	3.0	4.40	5.20	6.00	7.0	
		Week 40	Tezepelumab	47	47 (100.0)	5.39 (1.26)	1.8	4.60	5.40	6.40	7.0	
			Placebo	45	41 (91.1)	5.21 (1.19)	2.8	4.40	5.00	6.40	7.0	
		Week 44	Tezepelumab	47	47 (100.0)	5.49 (1.11)	2.8	4.60	5.60	6.40	7.0	
			Placebo	45	41 (91.1)	5.15 (1.26)	2.6	4.40	5.00	6.40	7.0	
		Week 48	Tezepelumab	47	47 (100.0)	5.48 (1.14)	2.6	4.60	5.60	6.40	7.0	
			Placebo	45	41 (91.1)	5.14 (1.18)	3.6	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	47	47 (100.0)	5.51 (1.19)	2.6	4.60	5.60	6.80	7.0	
			Placebo	45	41 (91.1)	5.10 (1.27)	2.2	4.00	4.80	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	47	40 (85.1)	0.53 (1.47)	-4.2	-0.50	0.40	1.70	3.8	0.05 [-0.39, 0.49]
			Placebo	45	38 (84.4)	0.46 (0.98)	-2.2	0.00	0.40	1.00	3.0	
		Week 8	Tezepelumab	47	42 (89.4)	0.76 (1.40)	-2.2	-0.40	0.90	1.60	4.4	0.14 [-0.30, 0.58]
			Placebo	45	38 (84.4)	0.58 (1.11)	-1.6	-0.20	0.60	1.20	3.0	
		Week 12	Tezepelumab	47	42 (89.4)	1.00 (1.31)	-2.4	0.00	1.10	1.60	3.8	0.23 [-0.21, 0.67]
			Placebo	45	38 (84.4)	0.71 (1.17)	-1.6	0.00	0.80	1.20	3.6	
		Week 16	Tezepelumab	47	42 (89.4)	0.96 (1.36)	-2.8	0.00	1.00	1.80	4.0	0.10 [-0.33, 0.54]
			Placebo	45	38 (84.4)	0.83 (1.11)	-1.0	0.20	0.60	1.40	4.0	
		Week 20	Tezepelumab	47	42 (89.4)	1.08 (1.27)	-1.4	0.20	1.00	1.80	4.6	0.32 [-0.12, 0.76]
			Placebo	45	38 (84.4)	0.70 (1.08)	-2.2	0.00	0.80	1.40	2.6	
		Week 24	Tezepelumab	47	42 (89.4)	0.93 (1.40)	-1.4	-0.20	0.70	1.80	4.6	0.16 [-0.28, 0.60]
			Placebo	45	38 (84.4)	0.74 (1.05)	-1.0	0.00	0.50	1.60	2.8	
		Week 28	Tezepelumab	47	42 (89.4)	1.01 (1.33)	-1.4	0.00	0.80	1.80	4.6	0.15 [-0.29, 0.58]
			Placebo	45	38 (84.4)	0.83 (1.24)	-2.2	0.00	0.80	1.80	4.0	
		Week 32	Tezepelumab	47	42 (89.4)	0.94 (1.38)	-1.6	0.00	0.80	1.60	4.6	0.09 [-0.35, 0.53]
			Placebo	45	38 (84.4)	0.83 (1.07)	-1.0	0.00	0.80	1.40	3.0	
		Week 36	Tezepelumab	47	42 (89.4)	1.13 (1.44)	-1.6	0.00	1.10	1.80	4.6	0.33 [-0.11, 0.77]
			Placebo	45	38 (84.4)	0.72 (0.97)	-1.4	0.20	0.60	1.40	2.6	
		Week 40	Tezepelumab	47	42 (89.4)	0.95 (1.47)	-2.4	0.00	1.00	1.60	4.6	0.14 [-0.30, 0.57]
			Placebo	45	38 (84.4)	0.77 (1.23)	-1.4	-0.20	0.80	1.80	3.6	
		Week 44	Tezepelumab	47	42 (89.4)	1.04 (1.37)	-1.4	0.00	1.30	1.60	4.6	0.26 [-0.18, 0.70]
			Placebo	45	38 (84.4)	0.69 (1.28)	-1.6	-0.40	0.70	1.20	4.2	
		Week 48	Tezepelumab	47	42 (89.4)	1.04 (1.35)	-1.4	0.00	1.20	1.60	4.6	0.26 [-0.18, 0.70]
			Placebo	45	38 (84.4)	0.71 (1.18)	-1.0	-0.20	0.60	1.40	4.2	
		Week 52	Tezepelumab	47	42 (89.4)	1.06 (1.35)	-1.6	0.00	1.20	1.60	4.6	0.30 [-0.14, 0.74]
			Placebo	45	38 (84.4)	0.65 (1.37)	-2.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.29 (1.23)	1.4	3.60	4.30	5.20	6.4	
			Placebo	55	48 (87.3)	4.33 (1.17)	1.0	3.70	4.30	4.90	7.0	
		Week 4	Tezepelumab	57	52 (91.2)	4.92 (1.23)	1.2	4.00	5.00	6.00	7.0	
			Placebo	55	49 (89.1)	4.95 (1.25)	1.6	4.20	4.80	5.80	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.22 (1.24)	2.8	4.20	5.40	6.20	7.0	
			Placebo	55	51 (92.7)	5.00 (1.17)	2.0	4.20	5.00	5.80	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.47 (1.19)	2.8	4.60	5.60	6.40	7.0	
			Placebo	55	51 (92.7)	5.17 (1.22)	1.8	4.20	5.20	6.20	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.39 (1.25)	2.6	4.40	5.60	6.40	7.0	
			Placebo	55	51 (92.7)	5.19 (1.32)	1.0	4.60	5.00	6.00	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.49 (1.20)	2.4	4.60	5.80	6.40	7.0	
			Placebo	55	51 (92.7)	5.13 (1.29)	1.0	4.40	5.00	6.20	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.38 (1.26)	2.0	4.40	5.60	6.40	7.0	
			Placebo	55	51 (92.7)	5.04 (1.36)	1.0	4.40	5.00	6.20	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.49 (1.14)	2.8	4.50	5.60	6.40	7.0	
			Placebo	55	51 (92.7)	5.15 (1.37)	1.0	4.40	5.20	6.20	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.43 (1.19)	2.6	4.60	5.70	6.40	7.0	
			Placebo	55	51 (92.7)	5.12 (1.35)	1.0	4.20	5.20	6.20	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.54 (1.25)	2.8	4.60	6.00	6.60	7.0	
			Placebo	55	51 (92.7)	5.05 (1.30)	1.6	4.40	5.00	6.00	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.38 (1.32)	1.8	4.50	5.40	6.50	7.0	
			Placebo	55	51 (92.7)	5.16 (1.31)	1.6	4.40	5.20	6.40	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.48 (1.17)	2.8	4.60	5.70	6.50	7.0	
			Placebo	55	51 (92.7)	5.10 (1.33)	1.8	4.40	5.20	6.20	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.45 (1.19)	2.6	4.60	5.60	6.40	7.0	
			Placebo	55	51 (92.7)	5.05 (1.36)	1.4	4.00	5.00	6.20	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.48 (1.19)	2.6	4.60	5.70	6.40	7.0	
			Placebo	55	51 (92.7)	5.12 (1.34)	2.0	4.00	5.00	6.40	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	57	47 (82.5)	0.64 (1.39)	-4.2	-0.20	0.60	1.80	3.8	0.02 [-0.39, 0.42]
			Placebo	55	47 (85.5)	0.62 (0.97)	-2.0	0.00	0.40	1.20	3.0	
		Week 8	Tezepelumab	57	49 (86.0)	0.87 (1.33)	-2.2	-0.20	1.00	1.60	4.4	0.14 [-0.26, 0.54]
			Placebo	55	48 (87.3)	0.70 (1.15)	-1.6	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	57	49 (86.0)	1.12 (1.25)	-2.4	0.40	1.20	1.80	3.8	0.21 [-0.19, 0.61]
			Placebo	55	48 (87.3)	0.86 (1.24)	-1.8	0.00	0.80	1.70	4.4	
		Week 16	Tezepelumab	57	49 (86.0)	1.04 (1.30)	-2.8	0.20	1.00	2.00	4.0	0.13 [-0.27, 0.53]
			Placebo	55	48 (87.3)	0.88 (1.30)	-3.4	0.20	0.80	1.50	4.4	
		Week 20	Tezepelumab	57	49 (86.0)	1.24 (1.21)	-1.4	0.40	1.20	2.00	4.6	0.33 [-0.07, 0.73]
			Placebo	55	48 (87.3)	0.85 (1.19)	-3.4	0.20	0.80	1.60	4.2	
		Week 24	Tezepelumab	57	49 (86.0)	1.11 (1.29)	-1.4	0.40	1.20	2.00	4.6	0.27 [-0.13, 0.67]
			Placebo	55	48 (87.3)	0.75 (1.33)	-3.4	0.00	0.80	1.70	4.2	
		Week 28	Tezepelumab	57	49 (86.0)	1.16 (1.24)	-1.4	0.40	1.20	2.00	4.6	0.22 [-0.18, 0.62]
			Placebo	55	48 (87.3)	0.87 (1.40)	-3.4	0.00	0.80	1.80	4.4	
		Week 32	Tezepelumab	57	49 (86.0)	1.13 (1.32)	-1.6	0.20	1.20	2.00	4.6	0.21 [-0.19, 0.61]
			Placebo	55	48 (87.3)	0.85 (1.26)	-3.4	0.00	0.80	1.50	4.2	
		Week 36	Tezepelumab	57	49 (86.0)	1.28 (1.43)	-1.6	0.40	1.20	2.20	4.6	0.40 [-0.00, 0.80]
			Placebo	55	48 (87.3)	0.76 (1.14)	-2.0	0.20	0.60	1.60	3.8	
		Week 40	Tezepelumab	57	49 (86.0)	1.11 (1.36)	-2.4	0.60	1.40	2.00	4.6	0.17 [-0.23, 0.57]
			Placebo	55	48 (87.3)	0.90 (1.26)	-2.0	0.00	1.10	1.80	3.6	
		Week 44	Tezepelumab	57	49 (86.0)	1.17 (1.31)	-1.4	0.60	1.40	1.80	4.6	0.27 [-0.13, 0.67]
			Placebo	55	48 (87.3)	0.82 (1.29)	-1.8	-0.10	0.80	1.60	4.2	
		Week 48	Tezepelumab	57	49 (86.0)	1.16 (1.31)	-1.4	0.40	1.20	2.00	4.6	0.28 [-0.12, 0.68]
			Placebo	55	48 (87.3)	0.80 (1.28)	-2.2	-0.20	0.60	1.60	4.2	
		Week 52	Tezepelumab	57	49 (86.0)	1.18 (1.31)	-1.6	0.40	1.40	2.00	4.6	0.25 [-0.15, 0.65]
			Placebo	55	48 (87.3)	0.85 (1.27)	-1.6	-0.10	0.80	1.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.10 (0.55)	3.4	3.80	4.00	4.40	5.0	
			Placebo	10	7 (70.0)	4.77 (1.13)	3.6	3.80	4.20	6.20	6.2	
		Week 4	Tezepelumab	9	8 (88.9)	4.63 (0.67)	4.0	4.00	4.70	4.80	6.0	
			Placebo	10	8 (80.0)	4.60 (1.57)	1.6	3.90	4.60	5.70	6.8	
		Week 8	Tezepelumab	9	8 (88.9)	4.75 (0.88)	3.8	4.10	4.50	5.30	6.4	
			Placebo	10	8 (80.0)	4.78 (1.08)	2.6	4.30	5.00	5.50	6.0	
		Week 12	Tezepelumab	9	8 (88.9)	4.70 (0.78)	4.0	4.20	4.40	5.00	6.4	
			Placebo	10	8 (80.0)	4.70 (1.20)	2.6	4.20	4.60	5.30	6.8	
		Week 16	Tezepelumab	9	8 (88.9)	4.78 (0.70)	4.0	4.30	4.50	5.30	6.0	
			Placebo	10	8 (80.0)	4.43 (0.89)	2.8	4.00	4.50	4.90	5.8	
		Week 20	Tezepelumab	9	9 (100.0)	4.73 (0.64)	4.0	4.40	4.60	5.00	5.8	
			Placebo	10	8 (80.0)	4.35 (0.75)	3.0	4.00	4.40	4.80	5.4	
		Week 24	Tezepelumab	9	9 (100.0)	4.69 (0.94)	3.6	4.00	4.40	5.60	6.2	
			Placebo	10	8 (80.0)	4.68 (0.60)	3.8	4.10	4.80	5.20	5.4	
		Week 28	Tezepelumab	9	9 (100.0)	4.67 (0.75)	4.0	4.00	4.60	5.00	6.2	
			Placebo	10	9 (90.0)	4.71 (1.03)	3.8	4.00	4.40	5.20	7.0	
		Week 32	Tezepelumab	9	9 (100.0)	4.84 (0.94)	4.0	4.40	4.40	5.00	6.6	
			Placebo	10	9 (90.0)	4.91 (1.23)	3.0	4.00	5.20	5.60	7.0	
		Week 36	Tezepelumab	9	9 (100.0)	5.18 (1.02)	4.0	4.40	5.20	5.60	6.8	
			Placebo	10	9 (90.0)	5.07 (1.21)	3.0	4.40	5.20	5.60	7.0	
		Week 40	Tezepelumab	9	9 (100.0)	4.73 (1.05)	3.8	4.00	4.20	5.20	6.8	
			Placebo	10	9 (90.0)	4.64 (1.21)	2.8	4.00	4.80	5.00	7.0	
		Week 44	Tezepelumab	9	9 (100.0)	4.98 (1.09)	4.0	4.20	4.40	5.60	6.8	
			Placebo	10	9 (90.0)	4.89 (1.32)	3.4	3.60	5.00	5.60	7.0	
		Week 48	Tezepelumab	9	9 (100.0)	5.13 (1.05)	4.0	4.40	5.00	5.40	6.8	
			Placebo	10	9 (90.0)	5.11 (1.13)	3.8	4.00	5.00	5.40	7.0	
		Week 52	Tezepelumab	9	9 (100.0)	5.09 (1.08)	4.0	4.40	5.00	5.40	6.8	
			Placebo	10	9 (90.0)	4.56 (1.40)	2.2	3.60	4.80	5.40	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	0.53 (1.00)	-0.8	-0.10	0.50	0.80	2.6	0.49 [-0.54, 1.52]
			Placebo	10	7 (70.0)	-0.06 (1.37)	-2.2	-1.60	0.40	0.60	1.8	
		Week 8	Tezepelumab	9	8 (88.9)	0.65 (1.22)	-1.2	-0.10	0.50	1.60	2.4	0.43 [-0.59, 1.46]
			Placebo	10	7 (70.0)	0.11 (1.25)	-1.6	-1.20	-0.20	1.20	1.6	
		Week 12	Tezepelumab	9	8 (88.9)	0.60 (1.15)	-0.8	-0.10	0.40	1.00	3.0	0.61 [-0.43, 1.65]
			Placebo	10	7 (70.0)	-0.06 (1.00)	-1.6	-1.20	0.20	0.60	1.2	
		Week 16	Tezepelumab	9	8 (88.9)	0.68 (1.05)	-0.6	-0.10	0.50	1.30	2.6	1.10 [0.00, 2.20]
			Placebo	10	7 (70.0)	-0.37 (0.81)	-1.6	-1.00	0.00	0.40	0.4	
		Week 20	Tezepelumab	9	8 (88.9)	0.53 (0.94)	-0.6	-0.20	0.50	0.90	2.4	1.03 [-0.06, 2.12]
			Placebo	10	7 (70.0)	-0.49 (1.03)	-2.2	-1.40	0.00	0.40	0.6	
		Week 24	Tezepelumab	9	8 (88.9)	0.48 (1.29)	-1.4	-0.10	0.20	1.10	2.8	0.56 [-0.47, 1.60]
			Placebo	10	7 (70.0)	-0.11 (0.66)	-1.0	-1.00	0.00	0.40	0.6	
		Week 28	Tezepelumab	9	8 (88.9)	0.48 (1.15)	-1.0	-0.30	0.50	0.80	2.8	0.71 [-0.34, 1.77]
			Placebo	10	7 (70.0)	-0.34 (1.14)	-2.2	-1.60	0.00	0.40	1.0	
		Week 32	Tezepelumab	9	8 (88.9)	0.53 (1.03)	-0.4	-0.20	0.40	0.70	2.8	0.61 [-0.43, 1.66]
			Placebo	10	7 (70.0)	-0.09 (0.95)	-1.0	-0.80	-0.20	0.40	1.8	
		Week 36	Tezepelumab	9	8 (88.9)	0.88 (1.09)	-0.4	0.20	0.70	1.20	3.2	0.90 [-0.17, 1.97]
			Placebo	10	7 (70.0)	0.06 (0.63)	-0.8	-0.60	0.20	0.40	1.0	
		Week 40	Tezepelumab	9	8 (88.9)	0.50 (1.41)	-1.2	-0.40	0.20	1.10	3.4	0.79 [-0.27, 1.84]
			Placebo	10	7 (70.0)	-0.40 (0.71)	-1.4	-1.00	-0.40	0.40	0.6	
		Week 44	Tezepelumab	9	8 (88.9)	0.65 (1.24)	-0.6	-0.20	0.30	1.20	3.2	0.96 [-0.12, 2.03]
			Placebo	10	7 (70.0)	-0.26 (0.40)	-0.6	-0.60	-0.40	0.20	0.4	
		Week 48	Tezepelumab	9	8 (88.9)	0.83 (1.22)	-0.4	-0.10	0.70	1.20	3.4	0.83 [-0.23, 1.90]
			Placebo	10	7 (70.0)	0.03 (0.50)	-0.8	-0.40	0.00	0.40	0.6	
		Week 52	Tezepelumab	9	8 (88.9)	0.78 (1.28)	-0.6	-0.20	0.70	1.20	3.4	1.12 [0.02, 2.22]
			Placebo	10	7 (70.0)	-0.60 (1.17)	-2.6	-1.60	-0.40	0.40	0.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	44	39 (88.6)	4.36 (1.08)	1.6	3.60	4.40	5.00	6.4	
			Placebo	45	38 (84.4)	4.47 (1.13)	1.0	3.80	4.40	5.40	6.6	
		Week 4	Tezepelumab	44	40 (90.9)	4.89 (1.06)	3.0	4.00	4.90	5.80	7.0	
			Placebo	45	39 (86.7)	5.08 (1.28)	1.6	4.40	5.40	6.00	7.0	
		Week 8	Tezepelumab	44	41 (93.2)	5.14 (1.14)	2.8	4.20	5.20	6.00	7.0	
			Placebo	45	40 (88.9)	5.18 (1.12)	2.6	4.60	5.20	6.00	7.0	
		Week 12	Tezepelumab	44	41 (93.2)	5.32 (1.07)	3.2	4.40	5.20	6.20	7.0	
			Placebo	45	40 (88.9)	5.22 (1.20)	2.6	4.30	5.20	6.20	7.0	
		Week 16	Tezepelumab	44	41 (93.2)	5.27 (1.12)	3.2	4.40	5.00	6.20	7.0	
			Placebo	45	40 (88.9)	5.18 (1.22)	2.6	4.40	5.10	5.90	7.0	
		Week 20	Tezepelumab	44	42 (95.5)	5.36 (1.10)	2.4	4.40	5.50	6.40	7.0	
			Placebo	45	40 (88.9)	5.12 (1.20)	2.6	4.10	5.00	6.30	7.0	
		Week 24	Tezepelumab	44	42 (95.5)	5.26 (1.21)	2.0	4.20	5.30	6.20	7.0	
			Placebo	45	40 (88.9)	5.16 (1.24)	2.4	4.40	5.10	6.20	7.0	
		Week 28	Tezepelumab	44	43 (97.7)	5.30 (1.05)	3.4	4.20	5.40	6.20	7.0	
			Placebo	45	41 (91.1)	5.19 (1.22)	2.6	4.20	5.20	6.00	7.0	
		Week 32	Tezepelumab	44	43 (97.7)	5.32 (1.16)	2.6	4.40	5.20	6.40	7.0	
			Placebo	45	41 (91.1)	5.26 (1.26)	2.6	4.00	5.40	6.20	7.0	
		Week 36	Tezepelumab	44	43 (97.7)	5.48 (1.22)	3.0	4.40	5.60	6.80	7.0	
			Placebo	45	41 (91.1)	5.37 (1.21)	2.2	4.60	5.40	6.40	7.0	
		Week 40	Tezepelumab	44	43 (97.7)	5.22 (1.34)	1.8	4.20	5.20	6.40	7.0	
			Placebo	45	41 (91.1)	5.27 (1.28)	2.6	4.40	5.20	6.40	7.0	
		Week 44	Tezepelumab	44	43 (97.7)	5.38 (1.14)	3.4	4.40	5.20	6.60	7.0	
			Placebo	45	41 (91.1)	5.28 (1.25)	2.6	4.40	5.40	6.60	7.0	
		Week 48	Tezepelumab	44	43 (97.7)	5.38 (1.12)	2.6	4.60	5.20	6.40	7.0	
			Placebo	45	41 (91.1)	5.29 (1.28)	2.6	4.20	5.20	6.60	7.0	
		Week 52	Tezepelumab	44	43 (97.7)	5.38 (1.13)	2.6	4.40	5.00	6.40	7.0	
			Placebo	45	41 (91.1)	5.22 (1.36)	2.2	4.20	5.20	6.60	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	44	37 (84.1)	0.55 (1.17)	-1.8	-0.20	0.40	1.20	3.8	-0.09 [-0.54, 0.37]
			Placebo	45	38 (84.4)	0.64 (1.03)	-2.2	0.20	0.50	1.20	3.0	
		Week 8	Tezepelumab	44	38 (86.4)	0.74 (1.26)	-2.2	-0.20	0.70	1.40	4.4	-0.01 [-0.46, 0.44]
			Placebo	45	38 (84.4)	0.75 (1.15)	-1.6	0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	44	38 (86.4)	0.94 (1.12)	-1.0	0.40	0.90	1.60	3.8	0.13 [-0.32, 0.58]
			Placebo	45	38 (84.4)	0.79 (1.19)	-1.6	0.20	0.70	1.40	4.4	
		Week 16	Tezepelumab	44	38 (86.4)	0.89 (1.07)	-0.6	0.20	0.80	1.40	4.0	0.12 [-0.33, 0.57]
			Placebo	45	38 (84.4)	0.75 (1.18)	-1.6	0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	44	38 (86.4)	1.07 (1.07)	-0.6	0.40	1.10	1.40	4.6	0.31 [-0.14, 0.76]
			Placebo	45	38 (84.4)	0.72 (1.16)	-2.2	0.00	0.70	1.60	4.2	
		Week 24	Tezepelumab	44	38 (86.4)	0.96 (1.24)	-1.4	0.40	0.80	1.80	4.6	0.20 [-0.25, 0.65]
			Placebo	45	38 (84.4)	0.72 (1.22)	-2.2	0.00	0.40	1.40	4.2	
		Week 28	Tezepelumab	44	38 (86.4)	0.96 (1.18)	-1.0	0.00	0.70	1.60	4.6	0.20 [-0.25, 0.65]
			Placebo	45	38 (84.4)	0.72 (1.28)	-2.2	0.00	0.70	1.20	4.4	
		Week 32	Tezepelumab	44	38 (86.4)	0.96 (1.28)	-1.6	0.20	0.80	1.40	4.6	0.13 [-0.32, 0.58]
			Placebo	45	38 (84.4)	0.81 (1.12)	-1.0	-0.20	0.70	1.40	4.2	
		Week 36	Tezepelumab	44	38 (86.4)	1.18 (1.37)	-1.0	0.40	1.00	1.80	4.6	0.23 [-0.22, 0.68]
			Placebo	45	38 (84.4)	0.90 (0.99)	-0.8	0.40	0.60	1.60	3.8	
		Week 40	Tezepelumab	44	38 (86.4)	0.94 (1.40)	-2.4	0.40	0.80	1.40	4.6	0.10 [-0.35, 0.55]
			Placebo	45	38 (84.4)	0.82 (1.18)	-1.6	0.00	0.80	1.60	3.4	
		Week 44	Tezepelumab	44	38 (86.4)	1.02 (1.27)	-1.0	0.00	0.80	1.60	4.6	0.18 [-0.27, 0.63]
			Placebo	45	38 (84.4)	0.82 (1.00)	-0.6	0.00	0.70	1.20	3.4	
		Week 48	Tezepelumab	44	38 (86.4)	1.03 (1.23)	-1.4	0.20	1.00	1.60	4.6	0.15 [-0.30, 0.60]
			Placebo	45	38 (84.4)	0.86 (1.06)	-0.8	0.00	0.60	1.60	3.8	
		Week 52	Tezepelumab	44	38 (86.4)	1.03 (1.27)	-1.4	0.20	1.00	1.60	4.6	0.20 [-0.25, 0.65]
			Placebo	45	38 (84.4)	0.77 (1.23)	-2.6	0.00	0.70	1.40	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	22	19 (86.4)	4.05 (1.31)	1.4	3.40	4.00	5.20	6.2	
			Placebo	20	17 (85.0)	4.19 (1.26)	2.0	3.60	4.20	4.40	7.0	
		Week 4	Tezepelumab	22	20 (90.9)	4.86 (1.39)	1.2	4.00	4.70	6.00	7.0	
			Placebo	20	18 (90.0)	4.51 (1.24)	1.6	3.80	4.50	5.20	6.6	
		Week 8	Tezepelumab	22	21 (95.5)	5.20 (1.34)	3.0	4.20	5.00	6.20	7.0	
			Placebo	20	19 (95.0)	4.53 (1.13)	2.0	3.80	4.80	5.20	6.4	
		Week 12	Tezepelumab	22	21 (95.5)	5.47 (1.37)	2.8	4.60	5.60	6.80	7.0	
			Placebo	20	19 (95.0)	4.87 (1.25)	1.8	4.00	5.00	6.00	6.6	
		Week 16	Tezepelumab	22	21 (95.5)	5.40 (1.38)	2.6	4.60	5.60	6.60	7.0	
			Placebo	20	19 (95.0)	4.88 (1.44)	1.0	4.20	4.60	6.00	7.0	
		Week 20	Tezepelumab	22	21 (95.5)	5.44 (1.29)	2.8	4.60	5.80	6.20	7.0	
			Placebo	20	19 (95.0)	4.82 (1.36)	1.0	4.40	5.00	5.80	6.8	
		Week 24	Tezepelumab	22	21 (95.5)	5.32 (1.32)	2.8	4.20	5.80	6.40	7.0	
			Placebo	20	19 (95.0)	4.65 (1.36)	1.0	4.20	4.60	5.40	7.0	
		Week 28	Tezepelumab	22	22 (100.0)	5.51 (1.28)	2.8	4.60	5.70	6.60	7.0	
			Placebo	20	19 (95.0)	4.84 (1.54)	1.0	3.80	4.60	6.00	7.0	
		Week 32	Tezepelumab	22	22 (100.0)	5.40 (1.22)	2.8	4.40	5.80	6.40	7.0	
			Placebo	20	19 (95.0)	4.72 (1.43)	1.0	4.20	4.60	6.00	6.8	
		Week 36	Tezepelumab	22	22 (100.0)	5.51 (1.25)	2.8	4.60	6.00	6.40	7.0	
			Placebo	20	19 (95.0)	4.38 (1.18)	1.6	3.60	4.40	4.80	6.6	
		Week 40	Tezepelumab	22	22 (100.0)	5.42 (1.25)	2.8	4.60	5.80	6.40	7.0	
			Placebo	20	19 (95.0)	4.68 (1.30)	1.6	3.60	4.60	5.60	6.6	
		Week 44	Tezepelumab	22	22 (100.0)	5.46 (1.22)	2.8	4.60	5.90	6.40	7.0	
			Placebo	20	19 (95.0)	4.61 (1.39)	1.8	3.60	4.60	6.00	6.8	
		Week 48	Tezepelumab	22	22 (100.0)	5.45 (1.28)	2.6	4.60	5.90	6.40	7.0	
			Placebo	20	19 (95.0)	4.56 (1.29)	1.4	3.80	4.40	5.40	6.8	
		Week 52	Tezepelumab	22	22 (100.0)	5.52 (1.27)	2.8	4.60	5.90	6.40	7.0	
			Placebo	20	19 (95.0)	4.62 (1.26)	2.0	3.80	4.40	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Change from baseline	Week 4	Tezepelumab	22	18 (81.8)	0.78 (1.65)	-4.2	0.20	1.10	1.80	3.0	0.37 [-0.31, 1.05]
			Placebo	20	16 (80.0)	0.26 (1.07)	-2.0	-0.20	0.00	0.70	3.0	
		Week 8	Tezepelumab	22	19 (86.4)	1.04 (1.41)	-1.2	-0.20	1.00	2.20	3.4	0.54 [-0.13, 1.20]
			Placebo	20	17 (85.0)	0.34 (1.18)	-1.2	-0.40	0.00	0.80	3.0	
		Week 12	Tezepelumab	22	19 (86.4)	1.26 (1.45)	-2.4	0.20	1.40	2.20	3.6	0.44 [-0.22, 1.11]
			Placebo	20	17 (85.0)	0.64 (1.37)	-1.8	-0.40	0.80	1.60	3.6	
		Week 16	Tezepelumab	22	19 (86.4)	1.20 (1.60)	-2.8	-0.20	1.60	2.20	3.4	0.34 [-0.31, 1.00]
			Placebo	20	17 (85.0)	0.65 (1.61)	-3.4	0.20	0.80	1.40	4.0	
		Week 20	Tezepelumab	22	19 (86.4)	1.27 (1.42)	-1.4	0.00	1.40	2.40	3.4	0.49 [-0.18, 1.15]
			Placebo	20	17 (85.0)	0.58 (1.45)	-3.4	0.00	0.80	1.40	2.4	
		Week 24	Tezepelumab	22	19 (86.4)	1.14 (1.42)	-1.4	0.00	1.40	2.00	3.8	0.46 [-0.20, 1.12]
			Placebo	20	17 (85.0)	0.47 (1.48)	-3.4	0.00	0.60	1.60	2.4	
		Week 28	Tezepelumab	22	19 (86.4)	1.27 (1.36)	-1.4	0.00	1.40	2.40	3.6	0.37 [-0.29, 1.03]
			Placebo	20	17 (85.0)	0.71 (1.73)	-3.4	-0.40	1.00	1.80	4.0	
		Week 32	Tezepelumab	22	19 (86.4)	1.20 (1.35)	-1.4	0.00	1.40	2.20	3.6	0.44 [-0.22, 1.10]
			Placebo	20	17 (85.0)	0.56 (1.55)	-3.4	0.00	0.80	1.60	3.0	
		Week 36	Tezepelumab	22	19 (86.4)	1.31 (1.46)	-1.6	0.00	1.40	2.20	3.8	0.85 [0.16, 1.53]
			Placebo	20	17 (85.0)	0.16 (1.21)	-2.0	-0.60	0.20	1.00	2.0	
		Week 40	Tezepelumab	22	19 (86.4)	1.20 (1.33)	-1.4	-0.20	1.40	2.00	3.4	0.47 [-0.20, 1.13]
			Placebo	20	17 (85.0)	0.54 (1.48)	-2.0	-0.80	0.80	1.80	3.6	
		Week 44	Tezepelumab	22	19 (86.4)	1.25 (1.39)	-1.4	0.00	1.40	2.40	3.8	0.56 [-0.11, 1.22]
			Placebo	20	17 (85.0)	0.39 (1.72)	-1.8	-1.00	0.40	1.00	4.2	
		Week 48	Tezepelumab	22	19 (86.4)	1.26 (1.42)	-1.4	0.00	1.40	2.20	3.8	0.63 [-0.04, 1.31]
			Placebo	20	17 (85.0)	0.33 (1.52)	-2.2	-0.60	-0.20	0.80	4.2	
		Week 52	Tezepelumab	22	19 (86.4)	1.31 (1.40)	-1.6	0.00	1.40	2.20	3.8	0.59 [-0.08, 1.26]
			Placebo	20	17 (85.0)	0.44 (1.56)	-1.6	-0.60	-0.20	0.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	4.32 (1.13)	1.4	3.60	4.20	5.10	6.4	
			Placebo	58	48 (82.8)	4.51 (1.14)	1.0	3.80	4.40	5.30	7.0	
		Week 4	Tezepelumab	60	54 (90.0)	4.81 (1.18)	1.2	4.00	4.80	5.80	7.0	
			Placebo	58	50 (86.2)	4.99 (1.32)	1.6	4.20	4.90	6.00	7.0	
		Week 8	Tezepelumab	60	56 (93.3)	5.12 (1.16)	3.0	4.20	5.00	6.00	7.0	
			Placebo	58	52 (89.7)	5.03 (1.12)	2.6	4.20	5.00	5.90	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.30 (1.19)	2.8	4.40	5.30	6.40	7.0	
			Placebo	58	52 (89.7)	5.13 (1.24)	1.8	4.20	5.20	6.10	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.24 (1.23)	2.6	4.30	5.20	6.20	7.0	
			Placebo	58	52 (89.7)	5.05 (1.32)	1.0	4.30	5.00	5.90	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.29 (1.16)	2.4	4.40	5.60	6.20	7.0	
			Placebo	58	52 (89.7)	5.10 (1.27)	1.0	4.50	5.00	6.00	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.22 (1.25)	2.0	4.20	5.20	6.20	7.0	
			Placebo	58	52 (89.7)	5.03 (1.33)	1.0	4.40	5.00	6.00	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.29 (1.12)	2.8	4.20	5.40	6.20	7.0	
			Placebo	58	53 (91.4)	5.03 (1.34)	1.0	4.20	5.20	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.28 (1.20)	2.6	4.40	5.40	6.40	7.0	
			Placebo	58	53 (91.4)	5.08 (1.38)	1.0	4.00	5.20	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.41 (1.25)	2.8	4.40	5.60	6.60	7.0	
			Placebo	58	53 (91.4)	5.13 (1.29)	1.6	4.40	5.20	6.00	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.20 (1.33)	1.8	4.20	5.20	6.40	7.0	
			Placebo	58	53 (91.4)	5.11 (1.34)	1.6	4.20	5.20	6.40	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.34 (1.18)	2.8	4.40	5.20	6.60	7.0	
			Placebo	58	53 (91.4)	5.07 (1.32)	1.8	4.40	5.20	6.00	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.32 (1.19)	2.6	4.40	5.20	6.40	7.0	
			Placebo	58	53 (91.4)	5.09 (1.32)	1.4	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.35 (1.19)	2.6	4.40	5.40	6.40	7.0	
			Placebo	58	53 (91.4)	5.06 (1.35)	2.0	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	60	49 (81.7)	0.49 (1.27)	-4.2	-0.20	0.60	1.40	3.0	-0.01 [-0.41, 0.39]
			Placebo	58	47 (81.0)	0.50 (1.03)	-2.2	0.20	0.40	1.20	3.0	
		Week 8	Tezepelumab	60	51 (85.0)	0.72 (1.13)	-1.2	-0.20	0.80	1.40	3.4	0.14 [-0.26, 0.53]
			Placebo	58	48 (82.8)	0.57 (1.14)	-1.6	-0.10	0.60	1.20	4.0	
		Week 12	Tezepelumab	60	51 (85.0)	0.91 (1.15)	-2.4	0.20	1.00	1.60	3.6	0.22 [-0.17, 0.62]
			Placebo	58	48 (82.8)	0.64 (1.22)	-1.8	0.00	0.60	1.30	4.4	
		Week 16	Tezepelumab	60	51 (85.0)	0.84 (1.16)	-2.8	0.00	1.00	1.60	3.4	0.23 [-0.16, 0.63]
			Placebo	58	48 (82.8)	0.56 (1.25)	-3.4	0.10	0.40	1.30	4.4	
		Week 20	Tezepelumab	60	51 (85.0)	0.97 (1.05)	-1.4	0.20	1.00	1.80	3.4	0.29 [-0.11, 0.69]
			Placebo	58	48 (82.8)	0.63 (1.25)	-3.4	0.00	0.80	1.30	4.2	
		Week 24	Tezepelumab	60	51 (85.0)	0.89 (1.14)	-1.4	0.00	1.00	1.60	3.8	0.27 [-0.13, 0.66]
			Placebo	58	48 (82.8)	0.56 (1.31)	-3.4	-0.10	0.40	1.20	4.2	
		Week 28	Tezepelumab	60	51 (85.0)	0.90 (1.08)	-1.4	0.00	0.80	1.60	3.0	0.29 [-0.10, 0.69]
			Placebo	58	48 (82.8)	0.54 (1.38)	-3.4	-0.20	0.50	1.20	4.4	
		Week 32	Tezepelumab	60	51 (85.0)	0.90 (1.19)	-1.6	0.00	0.80	1.60	3.2	0.24 [-0.15, 0.64]
			Placebo	58	48 (82.8)	0.60 (1.27)	-3.4	-0.20	0.60	1.30	4.2	
		Week 36	Tezepelumab	60	51 (85.0)	1.07 (1.31)	-1.6	0.00	1.20	1.80	3.8	0.36 [-0.04, 0.75]
			Placebo	58	48 (82.8)	0.63 (1.10)	-2.0	-0.10	0.50	1.30	3.8	
		Week 40	Tezepelumab	60	51 (85.0)	0.87 (1.30)	-2.4	0.00	0.80	1.60	3.4	0.19 [-0.21, 0.58]
			Placebo	58	48 (82.8)	0.63 (1.26)	-2.0	-0.40	0.80	1.50	3.4	
		Week 44	Tezepelumab	60	51 (85.0)	0.95 (1.20)	-1.4	0.00	0.80	1.60	3.6	0.33 [-0.07, 0.73]
			Placebo	58	48 (82.8)	0.56 (1.13)	-1.8	-0.40	0.60	1.20	3.4	
		Week 48	Tezepelumab	60	51 (85.0)	0.95 (1.18)	-1.4	0.00	1.00	1.80	3.6	0.28 [-0.11, 0.68]
			Placebo	58	48 (82.8)	0.62 (1.16)	-2.2	-0.20	0.60	1.30	3.8	
		Week 52	Tezepelumab	60	51 (85.0)	0.96 (1.20)	-1.6	0.00	1.00	1.80	3.6	0.31 [-0.09, 0.71]
			Placebo	58	48 (82.8)	0.58 (1.27)	-2.6	-0.20	0.60	1.40	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	2.80 (1.41)	1.8	1.80	2.80	3.80	3.8	
			Placebo	2	2 (100.0)	3.40 (1.13)	2.6	2.60	3.40	4.20	4.2	
		Week 4	Tezepelumab	2	2 (100.0)	5.90 (0.42)	5.6	5.60	5.90	6.20	6.2	
			Placebo	2	2 (100.0)	4.90 (0.99)	4.2	4.20	4.90	5.60	5.6	
		Week 8	Tezepelumab	2	2 (100.0)	6.60 (0.57)	6.2	6.20	6.60	7.00	7.0	
			Placebo	2	2 (100.0)	5.70 (0.14)	5.6	5.60	5.70	5.80	5.8	
		Week 12	Tezepelumab	2	2 (100.0)	6.20 (0.85)	5.6	5.60	6.20	6.80	6.8	
			Placebo	2	2 (100.0)	4.90 (1.84)	3.6	3.60	4.90	6.20	6.2	
		Week 16	Tezepelumab	2	2 (100.0)	6.10 (0.42)	5.8	5.80	6.10	6.40	6.4	
			Placebo	2	2 (100.0)	5.60 (0.85)	5.0	5.00	5.60	6.20	6.2	
		Week 20	Tezepelumab	2	2 (100.0)	6.70 (0.42)	6.4	6.40	6.70	7.00	7.0	
			Placebo	2	2 (100.0)	5.60 (0.85)	5.0	5.00	5.60	6.20	6.2	
		Week 24	Tezepelumab	2	2 (100.0)	6.10 (0.42)	5.8	5.80	6.10	6.40	6.4	
			Placebo	2	2 (100.0)	5.30 (1.27)	4.4	4.40	5.30	6.20	6.2	
		Week 28	Tezepelumab	2	2 (100.0)	6.70 (0.42)	6.4	6.40	6.70	7.00	7.0	
			Placebo	2	2 (100.0)	5.30 (1.27)	4.4	4.40	5.30	6.20	6.2	
		Week 32	Tezepelumab	2	2 (100.0)	5.70 (0.99)	5.0	5.00	5.70	6.40	6.4	
			Placebo	2	2 (100.0)	5.30 (1.27)	4.4	4.40	5.30	6.20	6.2	
		Week 36	Tezepelumab	2	2 (100.0)	6.30 (0.14)	6.2	6.20	6.30	6.40	6.4	
			Placebo	2	2 (100.0)	5.30 (1.27)	4.4	4.40	5.30	6.20	6.2	
		Week 40	Tezepelumab	2	2 (100.0)	5.90 (0.71)	5.4	5.40	5.90	6.40	6.4	
			Placebo	2	2 (100.0)	5.30 (1.27)	4.4	4.40	5.30	6.20	6.2	
		Week 44	Tezepelumab	2	2 (100.0)	5.90 (0.71)	5.4	5.40	5.90	6.40	6.4	
			Placebo	2	2 (100.0)	6.70 (0.14)	6.6	6.60	6.70	6.80	6.8	
		Week 48	Tezepelumab	2	2 (100.0)	5.90 (0.71)	5.4	5.40	5.90	6.40	6.4	
			Placebo	2	2 (100.0)	6.80 (0.00)	6.8	6.80	6.80	6.80	6.8	
		Week 52	Tezepelumab	2	2 (100.0)	5.90 (0.71)	5.4	5.40	5.90	6.40	6.4	
			Placebo	2	2 (100.0)	6.90 (0.14)	6.8	6.80	6.90	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	2	2 (100.0)	3.10 (0.99)	2.4	2.40	3.10	3.80	3.8	0.97 [-1.21, 3.14]
			Placebo	2	2 (100.0)	1.50 (2.12)	0.0	0.00	1.50	3.00	3.0	
		Week 8	Tezepelumab	2	2 (100.0)	3.80 (0.85)	3.2	3.20	3.80	4.40	4.4	1.63 [-0.90, 4.15]
			Placebo	2	2 (100.0)	2.30 (0.99)	1.6	1.60	2.30	3.00	3.0	
		Week 12	Tezepelumab	2	2 (100.0)	3.40 (0.57)	3.0	3.00	3.40	3.80	3.8	2.97 [-0.54, 6.47]
			Placebo	2	2 (100.0)	1.50 (0.71)	1.0	1.00	1.50	2.00	2.0	
		Week 16	Tezepelumab	2	2 (100.0)	3.30 (0.99)	2.6	2.60	3.30	4.00	4.0	1.51 [-0.95, 3.97]
			Placebo	2	2 (100.0)	2.20 (0.28)	2.0	2.00	2.20	2.40	2.4	
		Week 20	Tezepelumab	2	2 (100.0)	3.90 (0.99)	3.2	3.20	3.90	4.60	4.6	2.34 [-0.68, 5.35]
			Placebo	2	2 (100.0)	2.20 (0.28)	2.0	2.00	2.20	2.40	2.4	
		Week 24	Tezepelumab	2	2 (100.0)	3.30 (1.84)	2.0	2.00	3.30	4.60	4.6	1.07 [-1.15, 3.30]
			Placebo	2	2 (100.0)	1.90 (0.14)	1.8	1.80	1.90	2.00	2.0	
		Week 28	Tezepelumab	2	2 (100.0)	3.90 (0.99)	3.2	3.20	3.90	4.60	4.6	2.83 [-0.57, 6.22]
			Placebo	2	2 (100.0)	1.90 (0.14)	1.8	1.80	1.90	2.00	2.0	
		Week 32	Tezepelumab	2	2 (100.0)	2.90 (2.40)	1.2	1.20	2.90	4.60	4.6	0.59 [-1.46, 2.63]
			Placebo	2	2 (100.0)	1.90 (0.14)	1.8	1.80	1.90	2.00	2.0	
		Week 36	Tezepelumab	2	2 (100.0)	3.50 (1.56)	2.4	2.40	3.50	4.60	4.6	1.45 [-0.97, 3.87]
			Placebo	2	2 (100.0)	1.90 (0.14)	1.8	1.80	1.90	2.00	2.0	
		Week 40	Tezepelumab	2	2 (100.0)	3.10 (2.12)	1.6	1.60	3.10	4.60	4.6	0.80 [-1.31, 2.91]
			Placebo	2	2 (100.0)	1.90 (0.14)	1.8	1.80	1.90	2.00	2.0	
		Week 44	Tezepelumab	2	2 (100.0)	3.10 (2.12)	1.6	1.60	3.10	4.60	4.6	-0.11 [-2.08, 1.85]
			Placebo	2	2 (100.0)	3.30 (1.27)	2.4	2.40	3.30	4.20	4.2	
		Week 48	Tezepelumab	2	2 (100.0)	3.10 (2.12)	1.6	1.60	3.10	4.60	4.6	-0.18 [-2.14, 1.79]
			Placebo	2	2 (100.0)	3.40 (1.13)	2.6	2.60	3.40	4.20	4.2	
		Week 52	Tezepelumab	2	2 (100.0)	3.10 (2.12)	1.6	1.60	3.10	4.60	4.6	-0.23 [-2.20, 1.74]
			Placebo	2	2 (100.0)	3.50 (1.27)	2.6	2.60	3.50	4.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.93 (1.55)	2.2	2.20	4.40	5.20	5.2	
			Placebo	3	3 (100.0)	4.33 (0.12)	4.2	4.20	4.40	4.40	4.4	
		Week 4	Tezepelumab	3	3 (100.0)	5.53 (1.15)	4.2	4.20	6.20	6.20	6.2	
			Placebo	3	3 (100.0)	4.60 (0.53)	4.2	4.20	4.40	5.20	5.2	
		Week 8	Tezepelumab	3	3 (100.0)	5.80 (1.06)	4.6	4.60	6.20	6.60	6.6	
			Placebo	3	3 (100.0)	4.40 (0.92)	3.4	3.40	4.60	5.20	5.2	
		Week 12	Tezepelumab	3	3 (100.0)	6.20 (0.92)	5.2	5.20	6.40	7.00	7.0	
			Placebo	3	3 (100.0)	4.80 (0.53)	4.2	4.20	5.00	5.20	5.2	
		Week 16	Tezepelumab	3	3 (100.0)	6.27 (0.70)	5.6	5.60	6.20	7.00	7.0	
			Placebo	3	3 (100.0)	5.07 (0.70)	4.4	4.40	5.00	5.80	5.8	
		Week 20	Tezepelumab	3	3 (100.0)	6.20 (0.80)	5.4	5.40	6.20	7.00	7.0	
			Placebo	3	3 (100.0)	4.13 (0.90)	3.2	3.20	4.20	5.00	5.0	
		Week 24	Tezepelumab	3	3 (100.0)	6.33 (0.58)	6.0	6.00	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.53 (0.99)	3.4	3.40	5.00	5.20	5.2	
		Week 28	Tezepelumab	3	3 (100.0)	6.27 (0.64)	5.8	5.80	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	5.67 (0.99)	5.0	5.00	5.20	6.80	6.8	
		Week 32	Tezepelumab	3	3 (100.0)	6.27 (0.64)	5.8	5.80	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	5.27 (0.46)	5.0	5.00	5.00	5.80	5.8	
		Week 36	Tezepelumab	3	3 (100.0)	6.33 (0.58)	6.0	6.00	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.27 (1.10)	3.0	3.00	4.80	5.00	5.0	
		Week 40	Tezepelumab	3	3 (100.0)	6.13 (0.81)	5.4	5.40	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.60 (0.35)	4.4	4.40	4.40	5.00	5.0	
		Week 44	Tezepelumab	3	3 (100.0)	6.27 (0.64)	5.8	5.80	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.07 (0.50)	3.6	3.60	4.00	4.60	4.6	
		Week 48	Tezepelumab	3	3 (100.0)	6.33 (0.58)	6.0	6.00	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.27 (0.31)	4.0	4.00	4.20	4.60	4.6	
		Week 52	Tezepelumab	3	3 (100.0)	6.33 (0.58)	6.0	6.00	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.27 (0.31)	4.0	4.00	4.20	4.60	4.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.60 (0.53)	1.0	1.00	1.80	2.00	2.0	2.26 [0.02, 4.51]
			Placebo	3	3 (100.0)	0.27 (0.64)	-0.2	-0.20	0.00	1.00	1.0	
		Week 8	Tezepelumab	3	3 (100.0)	1.87 (0.76)	1.0	1.00	2.20	2.40	2.4	2.10 [-0.06, 4.27]
			Placebo	3	3 (100.0)	0.07 (0.95)	-1.0	-1.00	0.40	0.80	0.8	
		Week 12	Tezepelumab	3	3 (100.0)	2.27 (0.95)	1.2	1.20	2.60	3.00	3.0	2.30 [0.04, 4.56]
			Placebo	3	3 (100.0)	0.47 (0.58)	-0.2	-0.20	0.80	0.80	0.8	
		Week 16	Tezepelumab	3	3 (100.0)	2.33 (1.22)	1.0	1.00	2.60	3.40	3.4	1.61 [-0.34, 3.55]
			Placebo	3	3 (100.0)	0.73 (0.70)	0.0	0.00	0.80	1.40	1.4	
		Week 20	Tezepelumab	3	3 (100.0)	2.27 (1.14)	1.0	1.00	2.60	3.20	3.2	2.30 [0.04, 4.56]
			Placebo	3	3 (100.0)	-0.20 (1.00)	-1.2	-1.20	-0.20	0.80	0.8	
		Week 24	Tezepelumab	3	3 (100.0)	2.40 (1.51)	0.8	0.80	2.60	3.80	3.8	1.70 [-0.29, 3.68]
			Placebo	3	3 (100.0)	0.20 (1.04)	-1.0	-1.00	0.80	0.80	0.8	
		Week 28	Tezepelumab	3	3 (100.0)	2.33 (1.42)	0.8	0.80	2.60	3.60	3.6	0.84 [-0.87, 2.54]
			Placebo	3	3 (100.0)	1.33 (0.92)	0.8	0.80	0.80	2.40	2.4	
		Week 32	Tezepelumab	3	3 (100.0)	2.33 (1.42)	0.8	0.80	2.60	3.60	3.6	1.34 [-0.51, 3.19]
			Placebo	3	3 (100.0)	0.93 (0.42)	0.6	0.60	0.80	1.40	1.4	
		Week 36	Tezepelumab	3	3 (100.0)	2.40 (1.51)	0.8	0.80	2.60	3.80	3.8	1.84 [-0.21, 3.88]
			Placebo	3	3 (100.0)	-0.07 (1.15)	-1.4	-1.40	0.60	0.60	0.6	
		Week 40	Tezepelumab	3	3 (100.0)	2.20 (1.25)	0.8	0.80	2.60	3.20	3.2	2.05 [-0.09, 4.19]
			Placebo	3	3 (100.0)	0.27 (0.46)	0.0	0.00	0.00	0.80	0.8	
		Week 44	Tezepelumab	3	3 (100.0)	2.33 (1.62)	0.6	0.60	2.60	3.80	3.8	2.17 [-0.03, 4.37]
			Placebo	3	3 (100.0)	-0.27 (0.50)	-0.8	-0.80	-0.20	0.20	0.2	
		Week 48	Tezepelumab	3	3 (100.0)	2.40 (1.51)	0.8	0.80	2.60	3.80	3.8	2.23 [0.00, 4.45]
			Placebo	3	3 (100.0)	-0.07 (0.42)	-0.4	-0.40	-0.20	0.40	0.4	
		Week 52	Tezepelumab	3	3 (100.0)	2.40 (1.51)	0.8	0.80	2.60	3.80	3.8	2.23 [0.00, 4.45]
			Placebo	3	3 (100.0)	-0.07 (0.42)	-0.4	-0.40	-0.20	0.40	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	2	2 (100.0)	2.50 (0.71)	2.0	2.00	2.50	3.00	3.0	
		Week 4	Tezepelumab	1	1 (100.0)	4.40	4.4	4.40	4.40	4.40	4.4	
			Placebo	2	2 (100.0)	3.20 (0.28)	3.0	3.00	3.20	3.40	3.4	
		Week 8	Tezepelumab	1	1 (100.0)	2.80	2.8	2.80	2.80	2.80	2.8	
			Placebo	2	2 (100.0)	3.60 (2.26)	2.0	2.00	3.60	5.20	5.2	
		Week 12	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	2	2 (100.0)	5.30 (1.84)	4.0	4.00	5.30	6.60	6.6	
		Week 16	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	2	2 (100.0)	5.50 (2.12)	4.0	4.00	5.50	7.00	7.0	
		Week 20	Tezepelumab	1	1 (100.0)	5.80	5.8	5.80	5.80	5.80	5.8	
			Placebo	2	2 (100.0)	4.00 (0.57)	3.6	3.60	4.00	4.40	4.4	
		Week 24	Tezepelumab	1	1 (100.0)	4.00	4.0	4.00	4.00	4.00	4.0	
			Placebo	2	2 (100.0)	4.50 (1.27)	3.6	3.60	4.50	5.40	5.4	
		Week 28	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	2	2 (100.0)	5.30 (2.40)	3.6	3.60	5.30	7.00	7.0	
		Week 32	Tezepelumab	1	1 (100.0)	5.60	5.6	5.60	5.60	5.60	5.6	
			Placebo	2	2 (100.0)	4.80 (1.70)	3.6	3.60	4.80	6.00	6.0	
		Week 36	Tezepelumab	1	1 (100.0)	6.00	6.0	6.00	6.00	6.00	6.0	
			Placebo	2	2 (100.0)	4.00 (0.57)	3.6	3.60	4.00	4.40	4.4	
		Week 40	Tezepelumab	1	1 (100.0)	6.40	6.4	6.40	6.40	6.40	6.4	
			Placebo	2	2 (100.0)	5.10 (2.12)	3.6	3.60	5.10	6.60	6.6	
		Week 44	Tezepelumab	1	1 (100.0)	6.20	6.2	6.20	6.20	6.20	6.2	
			Placebo	2	2 (100.0)	4.90 (1.84)	3.6	3.60	4.90	6.20	6.2	
		Week 48	Tezepelumab	1	1 (100.0)	6.40	6.4	6.40	6.40	6.40	6.4	
			Placebo	2	2 (100.0)	3.60 (0.00)	3.6	3.60	3.60	3.60	3.6	
		Week 52	Tezepelumab	1	1 (100.0)	6.40	6.4	6.40	6.40	6.40	6.4	
			Placebo	2	2 (100.0)	3.60 (0.00)	3.6	3.60	3.60	3.60	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	-0.60	-0.6	-0.60	-0.60	-0.60	-0.6	NE
			Placebo	2	2 (100.0)	0.70 (0.99)	0.0	0.00	0.70	1.40	1.4	
		Week 8	Tezepelumab	1	1 (100.0)	-2.20	-2.2	-2.20	-2.20	-2.20	-2.2	NE
			Placebo	2	2 (100.0)	1.10 (1.56)	0.0	0.00	1.10	2.20	2.2	
		Week 12	Tezepelumab	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	NE
			Placebo	2	2 (100.0)	2.80 (1.13)	2.0	2.00	2.80	3.60	3.6	
		Week 16	Tezepelumab	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	NE
			Placebo	2	2 (100.0)	3.00 (1.41)	2.0	2.00	3.00	4.00	4.0	
		Week 20	Tezepelumab	1	1 (100.0)	0.80	0.8	0.80	0.80	0.80	0.8	NE
			Placebo	2	2 (100.0)	1.50 (0.14)	1.4	1.40	1.50	1.60	1.6	
		Week 24	Tezepelumab	1	1 (100.0)	-1.00	-1.0	-1.00	-1.00	-1.00	-1.0	NE
			Placebo	2	2 (100.0)	2.00 (0.57)	1.6	1.60	2.00	2.40	2.4	
		Week 28	Tezepelumab	1	1 (100.0)	0.00	0.0	0.00	0.00	0.00	0.0	NE
			Placebo	2	2 (100.0)	2.80 (1.70)	1.6	1.60	2.80	4.00	4.0	
		Week 32	Tezepelumab	1	1 (100.0)	0.60	0.6	0.60	0.60	0.60	0.6	NE
			Placebo	2	2 (100.0)	2.30 (0.99)	1.6	1.60	2.30	3.00	3.0	
		Week 36	Tezepelumab	1	1 (100.0)	1.00	1.0	1.00	1.00	1.00	1.0	NE
			Placebo	2	2 (100.0)	1.50 (0.14)	1.4	1.40	1.50	1.60	1.6	
		Week 40	Tezepelumab	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	NE
			Placebo	2	2 (100.0)	2.60 (1.41)	1.6	1.60	2.60	3.60	3.6	
		Week 44	Tezepelumab	1	1 (100.0)	1.20	1.2	1.20	1.20	1.20	1.2	NE
			Placebo	2	2 (100.0)	2.40 (1.13)	1.6	1.60	2.40	3.20	3.2	
		Week 48	Tezepelumab	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	NE
			Placebo	2	2 (100.0)	1.10 (0.71)	0.6	0.60	1.10	1.60	1.6	
		Week 52	Tezepelumab	1	1 (100.0)	1.40	1.4	1.40	1.40	1.40	1.4	NE
			Placebo	2	2 (100.0)	1.10 (0.71)	0.6	0.60	1.10	1.60	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	40	36 (90.0)	4.47 (1.16)	1.6	3.60	4.30	5.40	6.4	
			Placebo	36	31 (86.1)	4.70 (1.02)	2.8	4.00	4.60	5.40	6.8	
		Week 4	Tezepelumab	40	37 (92.5)	4.85 (1.25)	1.2	4.00	5.00	5.80	7.0	
			Placebo	36	31 (86.1)	5.01 (1.14)	1.6	4.40	5.00	5.80	7.0	
		Week 8	Tezepelumab	40	38 (95.0)	5.22 (1.12)	2.8	4.40	5.30	6.00	7.0	
			Placebo	36	32 (88.9)	4.99 (1.11)	3.0	4.10	5.00	5.90	7.0	
		Week 12	Tezepelumab	40	38 (95.0)	5.48 (1.06)	3.0	4.60	5.50	6.40	7.0	
			Placebo	36	32 (88.9)	5.17 (1.14)	1.8	4.50	5.20	6.00	7.0	
		Week 16	Tezepelumab	40	38 (95.0)	5.33 (1.17)	2.6	4.40	5.20	6.20	7.0	
			Placebo	36	32 (88.9)	5.04 (1.38)	1.0	4.20	5.00	5.90	7.0	
		Week 20	Tezepelumab	40	39 (97.5)	5.44 (1.06)	2.8	4.60	5.60	6.20	7.0	
			Placebo	36	32 (88.9)	5.17 (1.29)	1.0	4.70	5.00	6.30	7.0	
		Week 24	Tezepelumab	40	39 (97.5)	5.42 (1.15)	3.0	4.40	5.60	6.40	7.0	
			Placebo	36	32 (88.9)	4.96 (1.43)	1.0	4.40	5.10	6.10	7.0	
		Week 28	Tezepelumab	40	40 (100.0)	5.39 (1.09)	3.2	4.40	5.50	6.20	7.0	
			Placebo	36	33 (91.7)	5.05 (1.44)	1.0	4.00	5.40	6.00	7.0	
		Week 32	Tezepelumab	40	40 (100.0)	5.41 (1.15)	2.6	4.60	5.50	6.40	7.0	
			Placebo	36	33 (91.7)	5.05 (1.47)	1.0	4.00	5.20	6.20	7.0	
		Week 36	Tezepelumab	40	40 (100.0)	5.57 (1.17)	3.0	4.60	5.80	6.60	7.0	
			Placebo	36	33 (91.7)	5.14 (1.34)	1.6	4.60	5.20	6.00	7.0	
		Week 40	Tezepelumab	40	40 (100.0)	5.47 (1.13)	2.8	4.60	5.40	6.50	7.0	
			Placebo	36	33 (91.7)	5.17 (1.42)	1.6	4.20	5.40	6.40	7.0	
		Week 44	Tezepelumab	40	40 (100.0)	5.50 (1.15)	3.2	4.60	5.60	6.60	7.0	
			Placebo	36	33 (91.7)	5.17 (1.37)	1.8	4.40	5.40	6.60	7.0	
		Week 48	Tezepelumab	40	40 (100.0)	5.41 (1.21)	2.6	4.50	5.60	6.40	7.0	
			Placebo	36	33 (91.7)	5.14 (1.34)	1.4	4.20	5.20	6.00	7.0	
		Week 52	Tezepelumab	40	40 (100.0)	5.43 (1.19)	2.6	4.50	5.60	6.40	7.0	
			Placebo	36	33 (91.7)	5.18 (1.32)	2.0	4.20	5.20	6.20	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	40	35 (87.5)	0.44 (1.40)	-4.2	-0.40	0.40	1.60	3.0	0.09 [-0.40, 0.58]
			Placebo	36	30 (83.3)	0.33 (0.89)	-2.0	-0.20	0.40	1.00	1.8	
		Week 8	Tezepelumab	40	36 (90.0)	0.72 (1.24)	-2.2	-0.20	0.70	1.50	3.4	0.35 [-0.13, 0.84]
			Placebo	36	31 (86.1)	0.32 (0.95)	-1.6	-0.20	0.20	1.00	2.6	
		Week 12	Tezepelumab	40	36 (90.0)	0.96 (1.19)	-2.4	0.10	1.00	1.70	3.6	0.42 [-0.06, 0.91]
			Placebo	36	31 (86.1)	0.48 (1.04)	-1.8	0.00	0.60	1.20	2.6	
		Week 16	Tezepelumab	40	36 (90.0)	0.80 (1.27)	-2.8	-0.20	1.00	1.60	3.4	0.37 [-0.12, 0.85]
			Placebo	36	31 (86.1)	0.35 (1.14)	-3.4	0.00	0.40	1.00	2.6	
		Week 20	Tezepelumab	40	36 (90.0)	0.93 (1.09)	-1.4	0.10	1.00	1.50	3.4	0.41 [-0.07, 0.90]
			Placebo	36	31 (86.1)	0.48 (1.10)	-3.4	0.00	0.60	1.00	2.6	
		Week 24	Tezepelumab	40	36 (90.0)	0.90 (1.22)	-1.4	-0.10	0.80	1.80	3.8	0.52 [0.03, 1.01]
			Placebo	36	31 (86.1)	0.26 (1.21)	-3.4	-0.20	0.20	1.00	2.6	
		Week 28	Tezepelumab	40	36 (90.0)	0.91 (1.15)	-1.4	0.00	0.80	1.70	3.0	0.49 [0.01, 0.98]
			Placebo	36	31 (86.1)	0.31 (1.27)	-3.4	-0.20	0.20	1.20	2.6	
		Week 32	Tezepelumab	40	36 (90.0)	0.91 (1.24)	-1.6	0.10	0.90	1.50	3.2	0.51 [0.02, 1.00]
			Placebo	36	31 (86.1)	0.31 (1.11)	-3.4	-0.20	0.40	1.20	2.6	
		Week 36	Tezepelumab	40	36 (90.0)	1.07 (1.35)	-1.6	0.20	1.00	1.80	3.8	0.57 [0.08, 1.07]
			Placebo	36	31 (86.1)	0.39 (0.95)	-2.0	-0.20	0.40	0.80	2.6	
		Week 40	Tezepelumab	40	36 (90.0)	0.99 (1.23)	-1.4	0.20	1.00	1.60	3.4	0.46 [-0.03, 0.94]
			Placebo	36	31 (86.1)	0.44 (1.20)	-2.0	-0.40	0.40	1.20	2.8	
		Week 44	Tezepelumab	40	36 (90.0)	0.99 (1.26)	-1.4	-0.10	1.00	1.60	3.6	0.51 [0.02, 0.99]
			Placebo	36	31 (86.1)	0.40 (1.04)	-1.8	-0.40	0.60	1.00	2.6	
		Week 48	Tezepelumab	40	36 (90.0)	0.91 (1.24)	-1.4	0.00	1.00	1.60	3.6	0.47 [-0.01, 0.96]
			Placebo	36	31 (86.1)	0.37 (1.03)	-2.2	-0.20	0.40	0.80	2.6	
		Week 52	Tezepelumab	40	36 (90.0)	0.93 (1.27)	-1.6	-0.10	1.00	1.60	3.6	0.44 [-0.05, 0.92]
			Placebo	36	31 (86.1)	0.43 (0.98)	-1.6	-0.20	0.20	1.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	3.56 (1.96)	1.4	1.80	3.80	4.80	6.0	
			Placebo	4	3 (75.0)	3.13 (0.92)	2.6	2.60	2.60	4.20	4.2	
		Week 4	Tezepelumab	6	4 (66.7)	5.70 (0.66)	4.8	5.20	5.90	6.20	6.2	
			Placebo	4	3 (75.0)	5.13 (0.81)	4.2	4.20	5.60	5.60	5.6	
		Week 8	Tezepelumab	6	5 (83.3)	5.52 (1.52)	3.0	5.40	6.00	6.20	7.0	
			Placebo	4	3 (75.0)	6.00 (0.53)	5.6	5.60	5.80	6.60	6.6	
		Week 12	Tezepelumab	6	5 (83.3)	5.44 (1.55)	2.8	5.60	5.80	6.20	6.8	
			Placebo	4	3 (75.0)	5.60 (1.78)	3.6	3.60	6.20	7.00	7.0	
		Week 16	Tezepelumab	6	5 (83.3)	5.32 (1.44)	2.8	5.60	5.80	6.00	6.4	
			Placebo	4	3 (75.0)	6.07 (1.01)	5.0	5.00	6.20	7.00	7.0	
		Week 20	Tezepelumab	6	5 (83.3)	5.68 (1.69)	2.8	5.60	6.40	6.60	7.0	
			Placebo	4	3 (75.0)	6.00 (0.92)	5.0	5.00	6.20	6.80	6.8	
		Week 24	Tezepelumab	6	5 (83.3)	5.08 (1.37)	2.8	5.20	5.20	5.80	6.4	
			Placebo	4	3 (75.0)	5.80 (1.25)	4.4	4.40	6.20	6.80	6.8	
		Week 28	Tezepelumab	6	6 (100.0)	5.67 (1.54)	2.8	5.40	6.00	6.80	7.0	
			Placebo	4	3 (75.0)	5.87 (1.33)	4.4	4.40	6.20	7.00	7.0	
		Week 32	Tezepelumab	6	6 (100.0)	5.10 (1.44)	2.8	4.20	5.30	6.40	6.6	
			Placebo	4	3 (75.0)	5.80 (1.25)	4.4	4.40	6.20	6.80	6.8	
		Week 36	Tezepelumab	6	6 (100.0)	5.27 (1.40)	2.8	4.80	5.60	6.40	6.4	
			Placebo	4	3 (75.0)	5.67 (1.10)	4.4	4.40	6.20	6.40	6.4	
		Week 40	Tezepelumab	6	6 (100.0)	5.23 (1.34)	2.8	4.80	5.50	6.40	6.4	
			Placebo	4	3 (75.0)	5.53 (0.99)	4.4	4.40	6.00	6.20	6.2	
		Week 44	Tezepelumab	6	6 (100.0)	5.37 (1.38)	2.8	5.00	5.80	6.40	6.4	
			Placebo	4	3 (75.0)	6.47 (0.42)	6.0	6.00	6.60	6.80	6.8	
		Week 48	Tezepelumab	6	6 (100.0)	5.33 (1.36)	2.8	5.00	5.70	6.40	6.4	
			Placebo	4	3 (75.0)	6.67 (0.23)	6.4	6.40	6.80	6.80	6.8	
		Week 52	Tezepelumab	6	6 (100.0)	5.47 (1.42)	2.8	5.40	5.70	6.40	6.8	
			Placebo	4	3 (75.0)	6.73 (0.31)	6.4	6.40	6.80	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	6	4 (66.7)	1.60 (2.11)	-1.2	0.10	1.90	3.10	3.8	-0.20 [-1.71, 1.30]
			Placebo	4	3 (75.0)	2.00 (1.73)	0.0	0.00	3.00	3.00	3.0	
		Week 8	Tezepelumab	6	5 (83.3)	1.96 (1.92)	-0.6	1.20	1.60	3.20	4.4	-0.53 [-1.99, 0.93]
			Placebo	4	3 (75.0)	2.87 (1.21)	1.6	1.60	3.00	4.00	4.0	
		Week 12	Tezepelumab	6	5 (83.3)	1.88 (1.56)	-0.2	1.40	1.40	3.00	3.8	-0.36 [-1.81, 1.08]
			Placebo	4	3 (75.0)	2.47 (1.75)	1.0	1.00	2.00	4.40	4.4	
		Week 16	Tezepelumab	6	5 (83.3)	1.76 (1.65)	-0.4	1.20	1.40	2.60	4.0	-0.76 [-2.26, 0.73]
			Placebo	4	3 (75.0)	2.93 (1.29)	2.0	2.00	2.40	4.40	4.4	
		Week 20	Tezepelumab	6	5 (83.3)	2.12 (1.89)	-0.4	1.40	1.80	3.20	4.6	-0.44 [-1.90, 1.01]
			Placebo	4	3 (75.0)	2.87 (1.17)	2.0	2.00	2.40	4.20	4.2	
		Week 24	Tezepelumab	6	5 (83.3)	1.52 (2.02)	-0.8	0.40	1.40	2.00	4.6	-0.63 [-2.10, 0.85]
			Placebo	4	3 (75.0)	2.67 (1.33)	1.8	1.80	2.00	4.20	4.2	
		Week 28	Tezepelumab	6	5 (83.3)	1.88 (2.01)	-0.4	0.60	1.40	3.20	4.6	-0.46 [-1.92, 0.99]
			Placebo	4	3 (75.0)	2.73 (1.45)	1.8	1.80	2.00	4.40	4.4	
		Week 32	Tezepelumab	6	5 (83.3)	1.24 (2.09)	-0.6	-0.40	1.20	1.40	4.6	-0.76 [-2.26, 0.73]
			Placebo	4	3 (75.0)	2.67 (1.33)	1.8	1.80	2.00	4.20	4.2	
		Week 36	Tezepelumab	6	5 (83.3)	1.48 (2.18)	-1.0	0.00	1.40	2.40	4.6	-0.56 [-2.02, 0.91]
			Placebo	4	3 (75.0)	2.53 (1.10)	1.8	1.80	2.00	3.80	3.8	
		Week 40	Tezepelumab	6	5 (83.3)	1.44 (2.09)	-1.2	0.80	1.40	1.60	4.6	-0.54 [-2.00, 0.92]
			Placebo	4	3 (75.0)	2.40 (0.87)	1.8	1.80	2.00	3.40	3.4	
		Week 44	Tezepelumab	6	5 (83.3)	1.60 (1.99)	-1.0	1.40	1.40	1.60	4.6	-1.02 [-2.56, 0.53]
			Placebo	4	3 (75.0)	3.33 (0.90)	2.4	2.40	3.40	4.20	4.2	
		Week 48	Tezepelumab	6	5 (83.3)	1.56 (2.00)	-1.0	1.20	1.40	1.60	4.6	-1.16 [-2.74, 0.41]
			Placebo	4	3 (75.0)	3.53 (0.83)	2.6	2.60	3.80	4.20	4.2	
		Week 52	Tezepelumab	6	5 (83.3)	1.64 (1.87)	-0.6	1.20	1.40	1.60	4.6	-1.21 [-2.80, 0.38]
			Placebo	4	3 (75.0)	3.60 (0.92)	2.6	2.60	3.80	4.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.93 (1.55)	2.2	2.20	4.40	5.20	5.2	
			Placebo	3	3 (100.0)	4.33 (0.12)	4.2	4.20	4.40	4.40	4.4	
		Week 4	Tezepelumab	3	3 (100.0)	5.53 (1.15)	4.2	4.20	6.20	6.20	6.2	
			Placebo	3	3 (100.0)	4.60 (0.53)	4.2	4.20	4.40	5.20	5.2	
		Week 8	Tezepelumab	3	3 (100.0)	5.80 (1.06)	4.6	4.60	6.20	6.60	6.6	
			Placebo	3	3 (100.0)	4.40 (0.92)	3.4	3.40	4.60	5.20	5.2	
		Week 12	Tezepelumab	3	3 (100.0)	6.20 (0.92)	5.2	5.20	6.40	7.00	7.0	
			Placebo	3	3 (100.0)	4.80 (0.53)	4.2	4.20	5.00	5.20	5.2	
		Week 16	Tezepelumab	3	3 (100.0)	6.27 (0.70)	5.6	5.60	6.20	7.00	7.0	
			Placebo	3	3 (100.0)	5.07 (0.70)	4.4	4.40	5.00	5.80	5.8	
		Week 20	Tezepelumab	3	3 (100.0)	6.20 (0.80)	5.4	5.40	6.20	7.00	7.0	
			Placebo	3	3 (100.0)	4.13 (0.90)	3.2	3.20	4.20	5.00	5.0	
		Week 24	Tezepelumab	3	3 (100.0)	6.33 (0.58)	6.0	6.00	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.53 (0.99)	3.4	3.40	5.00	5.20	5.2	
		Week 28	Tezepelumab	3	3 (100.0)	6.27 (0.64)	5.8	5.80	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	5.67 (0.99)	5.0	5.00	5.20	6.80	6.8	
		Week 32	Tezepelumab	3	3 (100.0)	6.27 (0.64)	5.8	5.80	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	5.27 (0.46)	5.0	5.00	5.00	5.80	5.8	
		Week 36	Tezepelumab	3	3 (100.0)	6.33 (0.58)	6.0	6.00	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.27 (1.10)	3.0	3.00	4.80	5.00	5.0	
		Week 40	Tezepelumab	3	3 (100.0)	6.13 (0.81)	5.4	5.40	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.60 (0.35)	4.4	4.40	4.40	5.00	5.0	
		Week 44	Tezepelumab	3	3 (100.0)	6.27 (0.64)	5.8	5.80	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.07 (0.50)	3.6	3.60	4.00	4.60	4.6	
		Week 48	Tezepelumab	3	3 (100.0)	6.33 (0.58)	6.0	6.00	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.27 (0.31)	4.0	4.00	4.20	4.60	4.6	
		Week 52	Tezepelumab	3	3 (100.0)	6.33 (0.58)	6.0	6.00	6.00	7.00	7.0	
			Placebo	3	3 (100.0)	4.27 (0.31)	4.0	4.00	4.20	4.60	4.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.60 (0.53)	1.0	1.00	1.80	2.00	2.0	2.26 [0.02, 4.51]
			Placebo	3	3 (100.0)	0.27 (0.64)	-0.2	-0.20	0.00	1.00	1.0	
		Week 8	Tezepelumab	3	3 (100.0)	1.87 (0.76)	1.0	1.00	2.20	2.40	2.4	2.10 [-0.06, 4.27]
			Placebo	3	3 (100.0)	0.07 (0.95)	-1.0	-1.00	0.40	0.80	0.8	
		Week 12	Tezepelumab	3	3 (100.0)	2.27 (0.95)	1.2	1.20	2.60	3.00	3.0	2.30 [0.04, 4.56]
			Placebo	3	3 (100.0)	0.47 (0.58)	-0.2	-0.20	0.80	0.80	0.8	
		Week 16	Tezepelumab	3	3 (100.0)	2.33 (1.22)	1.0	1.00	2.60	3.40	3.4	1.61 [-0.34, 3.55]
			Placebo	3	3 (100.0)	0.73 (0.70)	0.0	0.00	0.80	1.40	1.4	
		Week 20	Tezepelumab	3	3 (100.0)	2.27 (1.14)	1.0	1.00	2.60	3.20	3.2	2.30 [0.04, 4.56]
			Placebo	3	3 (100.0)	-0.20 (1.00)	-1.2	-1.20	-0.20	0.80	0.8	
		Week 24	Tezepelumab	3	3 (100.0)	2.40 (1.51)	0.8	0.80	2.60	3.80	3.8	1.70 [-0.29, 3.68]
			Placebo	3	3 (100.0)	0.20 (1.04)	-1.0	-1.00	0.80	0.80	0.8	
		Week 28	Tezepelumab	3	3 (100.0)	2.33 (1.42)	0.8	0.80	2.60	3.60	3.6	0.84 [-0.87, 2.54]
			Placebo	3	3 (100.0)	1.33 (0.92)	0.8	0.80	0.80	2.40	2.4	
		Week 32	Tezepelumab	3	3 (100.0)	2.33 (1.42)	0.8	0.80	2.60	3.60	3.6	1.34 [-0.51, 3.19]
			Placebo	3	3 (100.0)	0.93 (0.42)	0.6	0.60	0.80	1.40	1.4	
		Week 36	Tezepelumab	3	3 (100.0)	2.40 (1.51)	0.8	0.80	2.60	3.80	3.8	1.84 [-0.21, 3.88]
			Placebo	3	3 (100.0)	-0.07 (1.15)	-1.4	-1.40	0.60	0.60	0.6	
		Week 40	Tezepelumab	3	3 (100.0)	2.20 (1.25)	0.8	0.80	2.60	3.20	3.2	2.05 [-0.09, 4.19]
			Placebo	3	3 (100.0)	0.27 (0.46)	0.0	0.00	0.00	0.80	0.8	
		Week 44	Tezepelumab	3	3 (100.0)	2.33 (1.62)	0.6	0.60	2.60	3.80	3.8	2.17 [-0.03, 4.37]
			Placebo	3	3 (100.0)	-0.27 (0.50)	-0.8	-0.80	-0.20	0.20	0.2	
		Week 48	Tezepelumab	3	3 (100.0)	2.40 (1.51)	0.8	0.80	2.60	3.80	3.8	2.23 [0.00, 4.45]
			Placebo	3	3 (100.0)	-0.07 (0.42)	-0.4	-0.40	-0.20	0.40	0.4	
		Week 52	Tezepelumab	3	3 (100.0)	2.40 (1.51)	0.8	0.80	2.60	3.80	3.8	2.23 [0.00, 4.45]
			Placebo	3	3 (100.0)	-0.07 (0.42)	-0.4	-0.40	-0.20	0.40	0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Absolute values	Baseline	Tezepelumab	17	14 (82.4)	4.06 (0.61)	2.8	3.60	4.10	4.60	5.0	
			Placebo	22	18 (81.8)	4.06 (1.34)	1.0	3.60	4.10	4.40	7.0	
		Week 4	Tezepelumab	17	16 (94.1)	4.61 (0.99)	3.0	4.00	4.60	5.10	7.0	
			Placebo	22	20 (90.9)	4.75 (1.63)	1.6	3.90	4.60	6.20	7.0	
		Week 8	Tezepelumab	17	16 (94.1)	4.80 (1.33)	3.2	3.70	4.50	6.10	7.0	
			Placebo	22	21 (95.5)	4.87 (1.27)	2.0	4.40	5.00	5.40	7.0	
		Week 12	Tezepelumab	17	16 (94.1)	4.94 (1.31)	3.2	3.90	4.40	6.10	7.0	
			Placebo	22	21 (95.5)	4.99 (1.38)	2.6	4.00	4.60	6.20	7.0	
		Week 16	Tezepelumab	17	16 (94.1)	5.10 (1.30)	3.2	4.10	4.70	6.50	7.0	
			Placebo	22	21 (95.5)	5.01 (1.25)	2.6	4.40	5.00	5.80	7.0	
		Week 20	Tezepelumab	17	16 (94.1)	5.01 (1.25)	2.4	4.10	4.60	5.90	7.0	
			Placebo	22	21 (95.5)	4.80 (1.20)	2.6	4.00	4.60	5.80	7.0	
		Week 24	Tezepelumab	17	16 (94.1)	4.83 (1.38)	2.0	4.00	4.40	6.20	6.8	
			Placebo	22	21 (95.5)	4.99 (1.13)	2.6	4.20	5.00	5.60	7.0	
		Week 28	Tezepelumab	17	16 (94.1)	5.06 (1.08)	4.0	4.00	4.80	6.00	7.0	
			Placebo	22	21 (95.5)	4.92 (1.21)	2.6	4.20	4.60	6.00	7.0	
		Week 32	Tezepelumab	17	16 (94.1)	5.10 (1.18)	3.6	4.00	4.70	6.20	7.0	
			Placebo	22	21 (95.5)	5.01 (1.22)	2.6	4.00	5.20	6.00	7.0	
		Week 36	Tezepelumab	17	16 (94.1)	5.23 (1.38)	3.4	4.00	5.30	6.70	7.0	
			Placebo	22	21 (95.5)	4.95 (1.22)	2.6	4.40	4.60	5.80	7.0	
		Week 40	Tezepelumab	17	16 (94.1)	4.70 (1.62)	1.8	3.90	4.30	6.40	7.0	
			Placebo	22	21 (95.5)	4.96 (1.26)	2.6	4.40	4.80	5.80	7.0	
		Week 44	Tezepelumab	17	16 (94.1)	5.04 (1.14)	3.8	4.00	4.60	6.20	7.0	
			Placebo	22	21 (95.5)	4.86 (1.26)	2.6	4.00	4.60	6.00	7.0	
		Week 48	Tezepelumab	17	16 (94.1)	5.24 (1.08)	4.0	4.50	4.80	6.30	7.0	
			Placebo	22	21 (95.5)	4.82 (1.30)	2.6	3.80	4.60	5.80	7.0	
		Week 52	Tezepelumab	17	16 (94.1)	5.24 (1.14)	4.0	4.40	4.70	6.40	7.0	
			Placebo	22	21 (95.5)	4.68 (1.38)	2.2	3.60	4.40	5.80	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	17	13 (76.5)	0.58 (0.81)	-1.2	0.40	0.60	0.80	2.2	-0.07 [-0.79, 0.64]
			Placebo	22	18 (81.8)	0.66 (1.07)	-2.2	0.20	0.60	1.40	2.8	
		Week 8	Tezepelumab	17	13 (76.5)	0.51 (1.11)	-1.2	-0.20	0.40	1.40	2.2	-0.31 [-1.03, 0.41]
			Placebo	22	18 (81.8)	0.86 (1.14)	-1.2	0.00	1.20	1.80	2.8	
		Week 12	Tezepelumab	17	13 (76.5)	0.69 (1.11)	-1.0	0.20	0.40	1.60	2.4	-0.20 [-0.91, 0.52]
			Placebo	22	18 (81.8)	0.94 (1.38)	-1.2	0.00	0.70	2.00	3.6	
		Week 16	Tezepelumab	17	13 (76.5)	0.92 (0.90)	-0.6	0.20	0.60	1.60	2.2	-0.05 [-0.76, 0.67]
			Placebo	22	18 (81.8)	0.98 (1.32)	-1.0	0.20	0.90	1.80	4.0	
		Week 20	Tezepelumab	17	13 (76.5)	1.08 (0.94)	-0.6	0.40	1.00	1.80	2.4	0.25 [-0.47, 0.97]
			Placebo	22	18 (81.8)	0.80 (1.21)	-2.2	0.20	1.30	1.60	2.4	
		Week 24	Tezepelumab	17	13 (76.5)	0.83 (1.04)	-1.4	0.00	1.20	1.60	2.2	-0.18 [-0.89, 0.54]
			Placebo	22	18 (81.8)	1.02 (1.11)	-1.0	0.40	1.00	1.80	2.8	
		Week 28	Tezepelumab	17	13 (76.5)	0.91 (0.94)	-1.0	0.40	1.00	1.60	2.4	-0.06 [-0.77, 0.66]
			Placebo	22	18 (81.8)	0.98 (1.42)	-2.2	0.00	1.00	1.80	4.0	
		Week 32	Tezepelumab	17	13 (76.5)	1.03 (1.04)	-0.4	0.20	0.80	2.00	2.4	-0.06 [-0.77, 0.65]
			Placebo	22	18 (81.8)	1.10 (1.22)	-1.0	0.40	1.40	1.80	3.0	
		Week 36	Tezepelumab	17	13 (76.5)	1.28 (1.14)	-0.4	0.40	1.20	2.00	3.4	0.28 [-0.44, 1.00]
			Placebo	22	18 (81.8)	0.98 (1.01)	-1.0	0.40	1.00	1.80	2.6	
		Week 40	Tezepelumab	17	13 (76.5)	0.69 (1.47)	-2.4	0.00	0.60	2.00	2.6	-0.25 [-0.96, 0.47]
			Placebo	22	18 (81.8)	1.03 (1.32)	-1.4	0.40	1.20	1.80	3.6	
		Week 44	Tezepelumab	17	13 (76.5)	0.92 (1.01)	-0.6	0.20	0.80	1.60	2.4	0.03 [-0.68, 0.74]
			Placebo	22	18 (81.8)	0.89 (1.19)	-1.0	-0.20	0.80	1.80	3.2	
		Week 48	Tezepelumab	17	13 (76.5)	1.18 (0.96)	-0.2	0.40	1.40	2.20	2.4	0.26 [-0.45, 0.98]
			Placebo	22	18 (81.8)	0.92 (1.03)	-1.0	0.40	0.80	1.60	2.8	
		Week 52	Tezepelumab	17	13 (76.5)	1.15 (1.02)	-0.6	0.40	1.40	2.20	2.4	0.33 [-0.39, 1.05]
			Placebo	22	18 (81.8)	0.72 (1.47)	-2.6	-0.20	0.80	1.80	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	4.04 (1.41)	1.8	3.20	3.90	4.80	6.4	
			Placebo	21	17 (81.0)	4.41 (1.38)	1.0	3.60	4.40	5.00	6.8	
		Week 4	Tezepelumab	15	13 (86.7)	5.37 (1.12)	3.6	4.20	5.60	6.20	7.0	
			Placebo	21	19 (90.5)	4.82 (1.29)	1.6	4.20	4.60	6.00	6.8	
		Week 8	Tezepelumab	15	14 (93.3)	5.61 (1.21)	3.2	4.60	6.00	6.60	7.0	
			Placebo	21	19 (90.5)	5.06 (1.12)	3.2	4.20	5.00	6.00	7.0	
		Week 12	Tezepelumab	15	14 (93.3)	5.89 (1.04)	3.8	5.20	6.20	7.00	7.0	
			Placebo	21	19 (90.5)	5.35 (1.21)	2.8	4.40	5.20	6.40	7.0	
		Week 16	Tezepelumab	15	14 (93.3)	5.86 (0.92)	4.4	4.80	6.00	6.80	7.0	
			Placebo	21	19 (90.5)	5.34 (1.21)	2.6	4.60	5.80	6.00	7.0	
		Week 20	Tezepelumab	15	14 (93.3)	5.96 (0.86)	4.0	5.80	6.00	6.60	7.0	
			Placebo	21	19 (90.5)	5.23 (1.40)	2.6	4.00	5.60	6.40	7.0	
		Week 24	Tezepelumab	15	14 (93.3)	5.96 (0.96)	3.4	5.80	6.10	6.40	7.0	
			Placebo	21	19 (90.5)	5.23 (1.44)	2.6	4.40	5.20	6.40	7.0	
		Week 28	Tezepelumab	15	14 (93.3)	5.93 (0.78)	4.4	5.40	5.90	6.40	7.0	
			Placebo	21	20 (95.2)	5.38 (1.28)	2.6	4.40	5.60	6.40	7.0	
		Week 32	Tezepelumab	15	14 (93.3)	5.80 (1.00)	3.6	5.80	6.00	6.40	7.0	
			Placebo	21	20 (95.2)	5.37 (1.33)	2.6	4.50	5.60	6.40	7.0	
		Week 36	Tezepelumab	15	14 (93.3)	6.26 (0.91)	4.0	6.00	6.50	7.00	7.0	
			Placebo	21	20 (95.2)	5.15 (1.52)	2.2	4.20	4.90	6.70	7.0	
		Week 40	Tezepelumab	15	14 (93.3)	5.99 (0.90)	4.4	5.40	6.10	6.80	7.0	
			Placebo	21	20 (95.2)	5.28 (1.30)	2.6	4.30	5.10	6.60	7.0	
		Week 44	Tezepelumab	15	14 (93.3)	6.07 (0.75)	4.6	5.80	6.20	6.60	7.0	
			Placebo	21	20 (95.2)	5.22 (1.36)	2.6	4.20	5.40	6.50	7.0	
		Week 48	Tezepelumab	15	14 (93.3)	6.04 (0.91)	4.2	6.00	6.10	6.80	7.0	
			Placebo	21	20 (95.2)	5.21 (1.42)	2.6	4.10	5.10	6.70	7.0	
		Week 52	Tezepelumab	15	14 (93.3)	5.99 (0.90)	4.2	5.80	6.00	6.80	7.0	
			Placebo	21	20 (95.2)	5.08 (1.43)	2.6	4.00	4.80	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	15	12 (80.0)	1.68 (1.08)	0.4	0.70	1.60	2.40	3.8	1.50 [0.66, 2.34]
			Placebo	21	17 (81.0)	0.38 (0.70)	-0.6	-0.20	0.40	0.60	1.8	
		Week 8	Tezepelumab	15	13 (86.7)	1.51 (1.38)	-0.4	0.60	1.20	2.20	4.4	0.68 [-0.06, 1.42]
			Placebo	21	17 (81.0)	0.72 (0.97)	-1.0	0.00	0.60	1.20	2.6	
		Week 12	Tezepelumab	15	13 (86.7)	1.77 (1.30)	-0.6	1.00	1.40	3.00	3.8	0.72 [-0.03, 1.46]
			Placebo	21	17 (81.0)	0.94 (1.03)	-0.6	0.00	0.80	1.80	2.6	
		Week 16	Tezepelumab	15	13 (86.7)	1.74 (1.24)	0.2	0.80	1.20	2.60	4.0	0.77 [0.02, 1.52]
			Placebo	21	17 (81.0)	0.93 (0.87)	-1.0	0.40	0.80	1.40	2.6	
		Week 20	Tezepelumab	15	13 (86.7)	1.86 (1.27)	0.4	1.00	1.40	2.40	4.6	0.84 [0.08, 1.59]
			Placebo	21	17 (81.0)	0.81 (1.24)	-2.2	0.00	1.00	1.60	2.6	
		Week 24	Tezepelumab	15	13 (86.7)	1.86 (1.52)	-0.2	0.60	1.60	2.80	4.6	0.73 [-0.02, 1.48]
			Placebo	21	17 (81.0)	0.89 (1.16)	-1.0	0.00	1.00	2.00	2.6	
		Week 28	Tezepelumab	15	13 (86.7)	1.83 (1.34)	0.6	0.80	1.20	2.80	4.6	0.65 [-0.09, 1.40]
			Placebo	21	17 (81.0)	0.99 (1.25)	-2.2	0.20	1.20	1.80	2.6	
		Week 32	Tezepelumab	15	13 (86.7)	1.72 (1.51)	-0.6	0.60	1.60	2.80	4.6	0.60 [-0.14, 1.34]
			Placebo	21	17 (81.0)	0.98 (0.99)	-1.0	0.40	1.20	1.60	2.6	
		Week 36	Tezepelumab	15	13 (86.7)	2.18 (1.61)	0.0	0.60	2.60	3.40	4.6	1.12 [0.34, 1.90]
			Placebo	21	17 (81.0)	0.69 (1.08)	-1.4	0.20	0.60	1.40	2.6	
		Week 40	Tezepelumab	15	13 (86.7)	1.89 (1.42)	0.0	0.80	1.60	3.20	4.6	0.82 [0.07, 1.57]
			Placebo	21	17 (81.0)	0.88 (1.07)	-1.4	0.00	1.00	1.60	2.6	
		Week 44	Tezepelumab	15	13 (86.7)	1.98 (1.38)	0.6	0.80	1.40	3.20	4.6	1.06 [0.29, 1.84]
			Placebo	21	17 (81.0)	0.74 (0.98)	-0.8	0.20	0.60	1.20	2.6	
		Week 48	Tezepelumab	15	13 (86.7)	1.97 (1.46)	0.4	0.60	1.40	3.40	4.6	0.98 [0.22, 1.75]
			Placebo	21	17 (81.0)	0.73 (1.09)	-0.8	-0.20	0.60	1.40	2.6	
		Week 52	Tezepelumab	15	13 (86.7)	1.88 (1.59)	-0.6	0.60	1.40	3.40	4.6	0.86 [0.10, 1.61]
			Placebo	21	17 (81.0)	0.61 (1.39)	-2.6	-0.40	0.60	1.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	24	20 (83.3)	4.47 (1.22)	1.6	3.80	4.60	5.50	6.2	
			Placebo	20	18 (90.0)	4.36 (1.14)	2.6	3.60	4.20	4.80	7.0	
		Week 4	Tezepelumab	24	23 (95.8)	5.22 (1.01)	3.4	4.40	5.40	6.00	7.0	
			Placebo	20	17 (85.0)	4.89 (1.51)	1.6	4.20	5.20	5.60	7.0	
		Week 8	Tezepelumab	24	23 (95.8)	5.48 (1.08)	3.6	4.60	5.60	6.20	7.0	
			Placebo	20	18 (90.0)	4.98 (1.19)	2.6	4.20	5.30	5.80	7.0	
		Week 12	Tezepelumab	24	23 (95.8)	5.71 (1.10)	3.6	4.60	6.00	6.60	7.0	
			Placebo	20	18 (90.0)	4.94 (1.43)	1.8	4.20	4.80	6.00	7.0	
		Week 16	Tezepelumab	24	23 (95.8)	5.74 (1.14)	3.4	4.60	6.20	6.80	7.0	
			Placebo	20	18 (90.0)	4.86 (1.54)	1.0	4.60	5.00	6.00	7.0	
		Week 20	Tezepelumab	24	23 (95.8)	5.68 (1.09)	4.0	4.40	6.00	6.80	7.0	
			Placebo	20	18 (90.0)	4.93 (1.49)	1.0	4.60	5.00	6.00	7.0	
		Week 24	Tezepelumab	24	23 (95.8)	5.57 (1.15)	3.6	4.40	5.60	6.60	7.0	
			Placebo	20	18 (90.0)	4.91 (1.40)	1.0	4.40	5.00	5.60	7.0	
		Week 28	Tezepelumab	24	24 (100.0)	5.69 (1.10)	4.0	4.60	5.90	6.60	7.0	
			Placebo	20	18 (90.0)	4.84 (1.45)	1.0	4.40	4.90	5.80	7.0	
		Week 32	Tezepelumab	24	24 (100.0)	5.72 (1.10)	3.6	4.70	5.80	6.70	7.0	
			Placebo	20	18 (90.0)	4.84 (1.56)	1.0	4.00	5.20	5.80	7.0	
		Week 36	Tezepelumab	24	24 (100.0)	5.82 (1.03)	4.0	5.10	6.20	6.70	7.0	
			Placebo	20	18 (90.0)	4.92 (1.37)	1.6	4.40	5.30	5.80	7.0	
		Week 40	Tezepelumab	24	24 (100.0)	5.70 (1.09)	3.8	4.80	5.70	6.70	7.0	
			Placebo	20	18 (90.0)	4.94 (1.36)	1.6	4.40	5.20	6.00	7.0	
		Week 44	Tezepelumab	24	24 (100.0)	5.75 (1.08)	4.0	4.70	6.10	6.60	7.0	
			Placebo	20	18 (90.0)	5.06 (1.36)	1.8	4.00	5.30	6.00	7.0	
		Week 48	Tezepelumab	24	24 (100.0)	5.68 (1.01)	4.0	4.70	5.60	6.70	7.0	
			Placebo	20	18 (90.0)	5.07 (1.41)	1.4	4.20	5.10	6.00	7.0	
		Week 52	Tezepelumab	24	24 (100.0)	5.77 (1.08)	4.0	4.60	5.80	6.90	7.0	
			Placebo	20	18 (90.0)	5.06 (1.49)	2.0	4.20	5.20	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	24	20 (83.3)	0.77 (0.99)	-1.2	0.10	0.80	1.70	2.2	0.18 [-0.46, 0.83]
			Placebo	20	17 (85.0)	0.54 (1.50)	-2.2	0.00	0.60	1.40	3.0	
		Week 8	Tezepelumab	24	20 (83.3)	0.94 (1.11)	-1.2	0.30	1.00	2.00	2.4	0.25 [-0.39, 0.88]
			Placebo	20	18 (90.0)	0.62 (1.47)	-1.6	-0.60	0.60	1.20	4.0	
		Week 12	Tezepelumab	24	20 (83.3)	1.16 (1.09)	-0.8	0.50	1.50	2.00	2.8	0.44 [-0.20, 1.09]
			Placebo	20	18 (90.0)	0.59 (1.48)	-1.8	-0.20	0.70	1.40	4.4	
		Week 16	Tezepelumab	24	20 (83.3)	1.15 (1.09)	-0.6	0.50	1.30	2.10	2.6	0.46 [-0.19, 1.10]
			Placebo	20	18 (90.0)	0.50 (1.73)	-3.4	-1.00	0.50	1.40	4.4	
		Week 20	Tezepelumab	24	20 (83.3)	1.23 (1.10)	-0.6	0.60	1.30	2.10	2.8	0.47 [-0.18, 1.11]
			Placebo	20	18 (90.0)	0.58 (1.67)	-3.4	-0.60	0.60	1.60	4.2	
		Week 24	Tezepelumab	24	20 (83.3)	1.07 (1.18)	-1.4	0.40	1.30	2.00	2.6	0.37 [-0.27, 1.01]
			Placebo	20	18 (90.0)	0.56 (1.59)	-3.4	-0.20	0.60	1.40	4.2	
		Week 28	Tezepelumab	24	20 (83.3)	1.15 (1.14)	-1.0	0.50	1.30	2.10	2.8	0.47 [-0.18, 1.11]
			Placebo	20	18 (90.0)	0.49 (1.67)	-3.4	-0.20	0.60	1.20	4.4	
		Week 32	Tezepelumab	24	20 (83.3)	1.23 (1.19)	-0.6	0.40	1.40	2.40	3.2	0.51 [-0.14, 1.16]
			Placebo	20	18 (90.0)	0.49 (1.68)	-3.4	-0.80	0.80	1.40	4.2	
		Week 36	Tezepelumab	24	20 (83.3)	1.36 (1.23)	-1.0	0.60	1.40	2.20	3.6	0.60 [-0.05, 1.25]
			Placebo	20	18 (90.0)	0.57 (1.42)	-2.0	-0.60	0.60	1.80	3.8	
		Week 40	Tezepelumab	24	20 (83.3)	1.21 (1.33)	-1.2	0.40	1.40	2.10	3.4	0.45 [-0.19, 1.10]
			Placebo	20	18 (90.0)	0.59 (1.43)	-2.0	-0.60	1.00	1.80	3.4	
		Week 44	Tezepelumab	24	20 (83.3)	1.23 (1.33)	-1.0	-0.10	1.50	2.20	3.6	0.36 [-0.28, 1.00]
			Placebo	20	18 (90.0)	0.70 (1.60)	-1.8	-0.40	0.60	1.80	4.2	
		Week 48	Tezepelumab	24	20 (83.3)	1.20 (1.23)	-1.0	0.10	1.50	2.20	3.0	0.34 [-0.31, 0.98]
			Placebo	20	18 (90.0)	0.71 (1.67)	-2.2	-0.60	0.50	1.80	4.2	
		Week 52	Tezepelumab	24	20 (83.3)	1.28 (1.22)	-0.6	0.20	1.50	2.30	3.0	0.39 [-0.25, 1.03]
			Placebo	20	18 (90.0)	0.70 (1.73)	-1.6	-0.80	0.60	1.80	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	27	24 (88.9)	4.22 (0.96)	1.4	3.70	4.10	4.90	6.2	
			Placebo	24	20 (83.3)	4.39 (1.04)	2.0	3.80	4.20	5.30	6.6	
		Week 4	Tezepelumab	27	24 (88.9)	4.29 (1.12)	1.2	3.80	4.00	5.00	6.2	
			Placebo	24	21 (87.5)	4.98 (1.14)	3.0	4.40	4.80	5.80	7.0	
		Week 8	Tezepelumab	27	25 (92.6)	4.62 (1.13)	2.8	4.00	4.80	5.00	7.0	
			Placebo	24	22 (91.7)	4.88 (1.19)	2.0	4.40	4.90	5.40	7.0	
		Week 12	Tezepelumab	27	25 (92.6)	4.77 (1.07)	2.8	4.20	4.80	5.40	6.8	
			Placebo	24	22 (91.7)	5.04 (1.07)	3.6	4.00	5.10	5.80	6.8	
		Week 16	Tezepelumab	27	25 (92.6)	4.62 (1.09)	2.6	4.00	4.40	5.40	6.8	
			Placebo	24	22 (91.7)	5.05 (1.14)	3.4	4.20	5.00	5.80	7.0	
		Week 20	Tezepelumab	27	26 (96.3)	4.82 (1.14)	2.4	4.20	4.70	5.60	7.0	
			Placebo	24	22 (91.7)	4.93 (0.90)	3.6	4.40	4.90	5.40	6.6	
		Week 24	Tezepelumab	27	26 (96.3)	4.66 (1.19)	2.0	4.00	4.60	5.60	6.8	
			Placebo	24	22 (91.7)	4.85 (1.07)	2.4	4.20	4.70	5.60	7.0	
		Week 28	Tezepelumab	27	27 (100.0)	4.80 (1.07)	2.8	4.00	4.80	5.40	7.0	
			Placebo	24	22 (91.7)	5.00 (1.28)	2.6	4.00	5.00	6.00	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	4.79 (1.11)	2.6	4.00	4.60	5.60	6.6	
			Placebo	24	22 (91.7)	5.03 (1.12)	3.6	4.00	4.80	6.00	7.0	
		Week 36	Tezepelumab	27	27 (100.0)	4.81 (1.20)	2.8	3.80	4.60	6.00	7.0	
			Placebo	24	22 (91.7)	5.08 (0.97)	3.6	4.40	4.90	5.60	7.0	
		Week 40	Tezepelumab	27	27 (100.0)	4.56 (1.32)	1.8	4.00	4.40	5.40	6.6	
			Placebo	24	22 (91.7)	5.03 (1.30)	3.0	3.60	4.90	6.40	7.0	
		Week 44	Tezepelumab	27	27 (100.0)	4.76 (1.11)	2.8	4.00	4.80	5.40	6.8	
			Placebo	24	22 (91.7)	4.95 (1.30)	2.6	4.00	4.60	6.20	7.0	
		Week 48	Tezepelumab	27	27 (100.0)	4.82 (1.18)	2.6	4.00	5.00	5.60	6.8	
			Placebo	24	22 (91.7)	4.92 (1.19)	3.6	4.00	4.70	6.00	7.0	
		Week 52	Tezepelumab	27	27 (100.0)	4.83 (1.14)	2.6	4.00	4.80	5.60	6.8	
			Placebo	24	22 (91.7)	4.97 (1.21)	3.6	4.00	4.70	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	-0.06 (1.35)	-4.2	-0.80	0.00	0.80	2.4	-0.62 [-1.24, -0.01]
			Placebo	24	20 (83.3)	0.65 (0.83)	-1.2	0.20	0.40	1.20	2.8	
		Week 8	Tezepelumab	27	24 (88.9)	0.39 (1.30)	-2.2	-0.60	0.30	1.30	3.2	-0.12 [-0.72, 0.47]
			Placebo	24	20 (83.3)	0.54 (1.06)	-1.6	0.00	0.50	1.20	2.8	
		Week 12	Tezepelumab	27	24 (88.9)	0.57 (1.15)	-2.4	0.00	0.40	1.30	3.0	-0.12 [-0.72, 0.47]
			Placebo	24	20 (83.3)	0.71 (1.21)	-1.6	0.10	0.60	1.20	3.6	
		Week 16	Tezepelumab	27	24 (88.9)	0.46 (1.22)	-2.8	-0.30	0.30	1.30	2.6	-0.23 [-0.83, 0.36]
			Placebo	24	20 (83.3)	0.74 (1.22)	-1.2	0.00	0.40	1.30	4.0	
		Week 20	Tezepelumab	27	24 (88.9)	0.67 (1.04)	-1.4	0.00	0.60	1.40	3.2	0.02 [-0.58, 0.61]
			Placebo	24	20 (83.3)	0.65 (0.77)	-0.6	0.00	0.70	1.20	2.4	
		Week 24	Tezepelumab	27	24 (88.9)	0.52 (1.03)	-1.4	-0.20	0.40	1.50	2.4	0.02 [-0.58, 0.61]
			Placebo	24	20 (83.3)	0.50 (1.13)	-2.2	-0.10	0.30	0.80	2.8	
		Week 28	Tezepelumab	27	24 (88.9)	0.58 (1.08)	-1.4	-0.10	0.50	1.40	3.2	-0.09 [-0.68, 0.50]
			Placebo	24	20 (83.3)	0.69 (1.33)	-2.0	-0.10	0.60	1.20	4.0	
		Week 32	Tezepelumab	27	24 (88.9)	0.52 (1.06)	-1.6	-0.10	0.70	1.30	2.4	-0.22 [-0.81, 0.38]
			Placebo	24	20 (83.3)	0.74 (1.01)	-0.6	-0.10	0.60	1.30	3.0	
		Week 36	Tezepelumab	27	24 (88.9)	0.58 (1.07)	-1.6	-0.30	0.80	1.30	2.4	-0.17 [-0.77, 0.42]
			Placebo	24	20 (83.3)	0.75 (0.82)	-0.6	0.30	0.50	1.40	2.6	
		Week 40	Tezepelumab	27	24 (88.9)	0.41 (1.11)	-2.4	-0.20	0.60	1.40	2.4	-0.26 [-0.86, 0.33]
			Placebo	24	20 (83.3)	0.73 (1.34)	-1.6	-0.30	0.70	1.50	3.6	
		Week 44	Tezepelumab	27	24 (88.9)	0.51 (0.92)	-1.4	-0.20	0.60	1.40	2.4	-0.11 [-0.70, 0.49]
			Placebo	24	20 (83.3)	0.62 (1.20)	-1.6	-0.30	0.70	1.10	3.2	
		Week 48	Tezepelumab	27	24 (88.9)	0.57 (0.99)	-1.4	-0.20	0.80	1.40	2.2	-0.10 [-0.69, 0.50]
			Placebo	24	20 (83.3)	0.66 (0.90)	-0.4	-0.10	0.50	1.20	2.8	
		Week 52	Tezepelumab	27	24 (88.9)	0.58 (0.98)	-1.6	-0.10	0.70	1.40	2.2	-0.12 [-0.72, 0.47]
			Placebo	24	20 (83.3)	0.69 (0.89)	-0.4	0.00	0.50	1.20	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	3.98 (1.24)	1.8	3.40	4.00	5.20	6.2	
			Placebo	14	11 (78.6)	4.38 (0.90)	3.0	3.80	4.20	4.80	6.6	
		Week 4	Tezepelumab	11	11 (100.0)	4.76 (0.92)	3.2	4.00	4.80	5.60	6.0	
			Placebo	14	12 (85.7)	4.52 (1.38)	1.6	3.90	4.60	5.30	7.0	
		Week 8	Tezepelumab	11	11 (100.0)	5.18 (1.07)	3.2	4.60	5.00	6.20	6.4	
			Placebo	14	12 (85.7)	4.88 (1.18)	2.6	4.20	5.10	5.50	7.0	
		Week 12	Tezepelumab	11	11 (100.0)	5.31 (0.86)	3.8	4.60	5.40	6.20	6.4	
			Placebo	14	12 (85.7)	5.12 (1.33)	2.6	4.30	5.10	6.20	7.0	
		Week 16	Tezepelumab	11	11 (100.0)	5.11 (0.90)	4.0	4.40	5.00	5.80	6.8	
			Placebo	14	12 (85.7)	5.18 (1.31)	2.8	4.40	5.00	6.40	7.0	
		Week 20	Tezepelumab	11	11 (100.0)	5.42 (0.92)	4.2	4.60	5.60	6.40	6.6	
			Placebo	14	12 (85.7)	4.73 (1.05)	3.0	4.10	4.60	5.00	7.0	
		Week 24	Tezepelumab	11	11 (100.0)	5.42 (1.04)	4.0	4.40	5.80	6.40	6.8	
			Placebo	14	12 (85.7)	4.95 (0.95)	3.8	4.30	4.80	5.30	7.0	
		Week 28	Tezepelumab	11	11 (100.0)	5.38 (1.02)	4.0	4.60	5.00	6.40	6.8	
			Placebo	14	12 (85.7)	5.08 (1.25)	3.6	4.20	4.70	6.10	7.0	
		Week 32	Tezepelumab	11	11 (100.0)	5.40 (1.12)	3.6	4.60	5.80	6.40	6.6	
			Placebo	14	12 (85.7)	4.98 (1.27)	3.0	4.10	4.70	6.00	7.0	
		Week 36	Tezepelumab	11	11 (100.0)	5.47 (1.28)	3.4	4.60	6.00	6.40	7.0	
			Placebo	14	12 (85.7)	4.98 (1.19)	3.0	4.40	4.90	5.50	7.0	
		Week 40	Tezepelumab	11	11 (100.0)	5.40 (1.10)	4.0	4.00	5.80	6.40	6.6	
			Placebo	14	12 (85.7)	4.77 (1.38)	2.8	3.90	4.40	5.80	7.0	
		Week 44	Tezepelumab	11	11 (100.0)	5.31 (1.18)	3.4	4.00	5.80	6.40	6.6	
			Placebo	14	12 (85.7)	4.78 (1.34)	3.2	3.60	4.50	5.80	7.0	
		Week 48	Tezepelumab	11	11 (100.0)	5.42 (1.04)	3.8	4.40	5.80	6.40	6.8	
			Placebo	14	12 (85.7)	4.75 (1.09)	3.6	4.00	4.30	5.20	7.0	
		Week 52	Tezepelumab	11	11 (100.0)	5.44 (1.02)	4.0	4.40	5.80	6.40	6.8	
			Placebo	14	12 (85.7)	4.47 (1.17)	2.2	3.80	4.30	4.90	6.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	11	11 (100.0)	0.78 (1.32)	-1.0	-0.20	0.60	1.80	3.8	0.51 [-0.34, 1.36]
			Placebo	14	11 (78.6)	0.20 (0.94)	-2.2	0.00	0.20	0.40	1.8	
		Week 8	Tezepelumab	11	11 (100.0)	1.20 (1.55)	-1.2	-0.20	1.20	2.00	4.4	0.47 [-0.38, 1.32]
			Placebo	14	11 (78.6)	0.58 (1.03)	-1.2	0.00	0.60	1.20	2.2	
		Week 12	Tezepelumab	11	11 (100.0)	1.33 (1.15)	0.0	0.40	1.20	2.00	3.8	0.42 [-0.42, 1.27]
			Placebo	14	11 (78.6)	0.78 (1.43)	-1.2	-0.20	0.80	2.00	3.6	
		Week 16	Tezepelumab	11	11 (100.0)	1.13 (1.39)	-1.2	0.40	1.00	2.00	4.0	0.20 [-0.64, 1.04]
			Placebo	14	11 (78.6)	0.85 (1.38)	-1.0	0.00	0.40	2.00	4.0	
		Week 20	Tezepelumab	11	11 (100.0)	1.44 (1.35)	-0.2	0.40	1.20	2.20	4.6	0.96 [0.07, 1.85]
			Placebo	14	11 (78.6)	0.35 (0.86)	-0.8	-0.20	0.20	0.80	2.2	
		Week 24	Tezepelumab	11	11 (100.0)	1.44 (1.31)	0.0	0.60	1.20	2.00	4.6	0.76 [-0.11, 1.63]
			Placebo	14	11 (78.6)	0.58 (0.91)	-0.2	-0.20	0.20	0.80	2.4	
		Week 28	Tezepelumab	11	11 (100.0)	1.40 (1.33)	-0.2	0.60	1.20	2.00	4.6	0.48 [-0.37, 1.33]
			Placebo	14	11 (78.6)	0.76 (1.33)	-0.6	-0.20	0.40	1.00	4.0	
		Week 32	Tezepelumab	11	11 (100.0)	1.42 (1.37)	-0.4	0.20	1.20	2.20	4.6	0.58 [-0.27, 1.44]
			Placebo	14	11 (78.6)	0.65 (1.25)	-0.8	-0.20	0.40	1.80	3.0	
		Week 36	Tezepelumab	11	11 (100.0)	1.49 (1.52)	-0.4	0.00	1.20	2.20	4.6	0.69 [-0.17, 1.55]
			Placebo	14	11 (78.6)	0.62 (0.94)	-0.8	-0.20	0.60	1.40	2.2	
		Week 40	Tezepelumab	11	11 (100.0)	1.42 (1.40)	-0.2	0.60	1.00	2.40	4.6	0.70 [-0.17, 1.56]
			Placebo	14	11 (78.6)	0.44 (1.41)	-1.0	-0.40	0.00	1.20	3.6	
		Week 44	Tezepelumab	11	11 (100.0)	1.33 (1.44)	-0.2	0.00	0.80	2.40	4.6	0.72 [-0.14, 1.59]
			Placebo	14	11 (78.6)	0.35 (1.28)	-1.0	-0.40	-0.20	0.80	3.2	
		Week 48	Tezepelumab	11	11 (100.0)	1.44 (1.37)	-0.4	0.60	1.00	2.20	4.6	1.00 [0.11, 1.90]
			Placebo	14	11 (78.6)	0.31 (0.80)	-0.6	-0.20	0.00	0.60	2.2	
		Week 52	Tezepelumab	11	11 (100.0)	1.45 (1.34)	-0.2	0.60	1.00	2.20	4.6	1.24 [0.32, 2.16]
			Placebo	14	11 (78.6)	0.05 (0.85)	-1.6	-0.40	-0.20	0.60	1.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	54	46 (85.2)	4.31 (1.15)	1.4	3.60	4.30	5.00	6.4	
			Placebo	51	44 (86.3)	4.39 (1.23)	1.0	3.60	4.30	5.30	7.0	
		Week 4	Tezepelumab	54	48 (88.9)	4.91 (1.24)	1.2	4.00	4.90	6.00	7.0	
			Placebo	51	45 (88.2)	5.00 (1.26)	1.6	4.20	5.20	6.00	7.0	
		Week 8	Tezepelumab	54	50 (92.6)	5.18 (1.24)	2.8	4.20	5.30	6.20	7.0	
			Placebo	51	47 (92.2)	4.99 (1.16)	2.0	4.20	5.00	5.80	7.0	
		Week 12	Tezepelumab	54	50 (92.6)	5.41 (1.24)	2.8	4.40	5.50	6.40	7.0	
			Placebo	51	47 (92.2)	5.11 (1.21)	1.8	4.20	5.20	6.20	7.0	
		Week 16	Tezepelumab	54	50 (92.6)	5.38 (1.27)	2.6	4.40	5.60	6.40	7.0	
			Placebo	51	47 (92.2)	5.06 (1.29)	1.0	4.20	5.00	6.00	7.0	
		Week 20	Tezepelumab	54	51 (94.4)	5.40 (1.22)	2.4	4.40	5.60	6.40	7.0	
			Placebo	51	47 (92.2)	5.10 (1.30)	1.0	4.60	5.20	6.00	7.0	
		Week 24	Tezepelumab	54	51 (94.4)	5.29 (1.27)	2.0	4.00	5.40	6.40	7.0	
			Placebo	51	47 (92.2)	5.00 (1.37)	1.0	4.40	5.20	6.00	7.0	
		Week 28	Tezepelumab	54	53 (98.1)	5.40 (1.15)	2.8	4.40	5.60	6.40	7.0	
			Placebo	51	48 (94.1)	5.08 (1.36)	1.0	4.20	5.20	6.00	7.0	
		Week 32	Tezepelumab	54	53 (98.1)	5.35 (1.20)	2.6	4.40	5.60	6.40	7.0	
			Placebo	51	48 (94.1)	5.11 (1.35)	1.0	4.20	5.30	6.10	7.0	
		Week 36	Tezepelumab	54	53 (98.1)	5.49 (1.24)	2.8	4.40	5.60	6.60	7.0	
			Placebo	51	48 (94.1)	5.08 (1.31)	1.6	4.40	5.10	6.00	7.0	
		Week 40	Tezepelumab	54	53 (98.1)	5.29 (1.35)	1.8	4.40	5.40	6.40	7.0	
			Placebo	51	48 (94.1)	5.17 (1.29)	1.6	4.40	5.30	6.30	7.0	
		Week 44	Tezepelumab	54	53 (98.1)	5.45 (1.17)	2.8	4.40	5.40	6.60	7.0	
			Placebo	51	48 (94.1)	5.14 (1.32)	1.8	4.20	5.30	6.30	7.0	
		Week 48	Tezepelumab	54	53 (98.1)	5.41 (1.21)	2.6	4.60	5.40	6.40	7.0	
			Placebo	51	48 (94.1)	5.14 (1.37)	1.4	4.00	5.00	6.30	7.0	
		Week 52	Tezepelumab	54	53 (98.1)	5.44 (1.21)	2.6	4.60	5.40	6.80	7.0	
			Placebo	51	48 (94.1)	5.18 (1.36)	2.0	4.00	5.10	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	54	43 (79.6)	0.60 (1.36)	-4.2	-0.20	0.60	1.60	3.0	-0.01 [-0.43, 0.41]
			Placebo	51	43 (84.3)	0.61 (1.06)	-2.0	0.00	0.60	1.20	3.0	
		Week 8	Tezepelumab	54	45 (83.3)	0.80 (1.23)	-2.2	-0.20	0.80	1.60	3.4	0.13 [-0.28, 0.55]
			Placebo	51	44 (86.3)	0.63 (1.21)	-1.6	-0.10	0.60	1.20	4.0	
		Week 12	Tezepelumab	54	45 (83.3)	1.02 (1.25)	-2.4	0.20	1.00	1.60	3.6	0.24 [-0.18, 0.65]
			Placebo	51	44 (86.3)	0.73 (1.21)	-1.8	0.00	0.70	1.50	4.4	
		Week 16	Tezepelumab	54	45 (83.3)	1.00 (1.24)	-2.8	0.20	1.00	1.80	3.4	0.24 [-0.17, 0.66]
			Placebo	51	44 (86.3)	0.69 (1.31)	-3.4	0.20	0.70	1.40	4.4	
		Week 20	Tezepelumab	54	45 (83.3)	1.10 (1.14)	-1.4	0.40	1.20	1.80	3.4	0.28 [-0.14, 0.70]
			Placebo	51	44 (86.3)	0.76 (1.32)	-3.4	0.10	0.80	1.60	4.2	
		Week 24	Tezepelumab	54	45 (83.3)	0.97 (1.25)	-1.4	0.00	1.00	1.80	3.8	0.24 [-0.18, 0.66]
			Placebo	51	44 (86.3)	0.65 (1.38)	-3.4	0.00	0.70	1.60	4.2	
		Week 28	Tezepelumab	54	45 (83.3)	1.03 (1.20)	-1.4	0.00	0.80	1.80	3.6	0.25 [-0.17, 0.66]
			Placebo	51	44 (86.3)	0.70 (1.45)	-3.4	0.00	0.80	1.70	4.4	
		Week 32	Tezepelumab	54	45 (83.3)	0.98 (1.27)	-1.6	0.20	0.80	1.60	3.6	0.18 [-0.23, 0.60]
			Placebo	51	44 (86.3)	0.75 (1.27)	-3.4	-0.10	0.80	1.40	4.2	
		Week 36	Tezepelumab	54	45 (83.3)	1.17 (1.38)	-1.6	0.40	1.20	2.00	3.8	0.38 [-0.04, 0.80]
			Placebo	51	44 (86.3)	0.69 (1.15)	-2.0	0.10	0.60	1.50	3.8	
		Week 40	Tezepelumab	54	45 (83.3)	0.98 (1.34)	-2.4	0.00	1.00	1.60	3.4	0.14 [-0.28, 0.55]
			Placebo	51	44 (86.3)	0.80 (1.25)	-2.0	-0.10	0.90	1.70	3.4	
		Week 44	Tezepelumab	54	45 (83.3)	1.08 (1.27)	-1.4	0.20	1.20	1.60	3.8	0.25 [-0.17, 0.66]
			Placebo	51	44 (86.3)	0.77 (1.26)	-1.8	-0.10	0.80	1.40	4.2	
		Week 48	Tezepelumab	54	45 (83.3)	1.06 (1.28)	-1.4	0.20	1.20	1.80	3.8	0.20 [-0.21, 0.62]
			Placebo	51	44 (86.3)	0.80 (1.31)	-2.2	-0.10	0.60	1.60	4.2	
		Week 52	Tezepelumab	54	45 (83.3)	1.08 (1.29)	-1.6	0.20	1.20	1.80	3.8	0.19 [-0.23, 0.60]
			Placebo	51	44 (86.3)	0.82 (1.40)	-2.6	0.00	0.80	1.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	33	31 (93.9)	4.25 (1.07)	1.4	3.60	4.20	5.00	6.2	
			Placebo	34	27 (79.4)	4.44 (1.12)	1.0	3.80	4.40	5.20	6.6	
		Week 4	Tezepelumab	33	29 (87.9)	4.76 (1.30)	1.2	4.00	4.80	6.00	7.0	
			Placebo	34	27 (79.4)	4.82 (1.50)	1.6	4.00	4.60	6.00	7.0	
		Week 8	Tezepelumab	33	30 (90.9)	5.11 (1.28)	2.8	4.20	4.90	6.20	7.0	
			Placebo	34	29 (85.3)	5.03 (1.21)	2.6	4.20	5.00	6.00	7.0	
		Week 12	Tezepelumab	33	30 (90.9)	5.32 (1.27)	2.8	4.60	5.30	6.40	7.0	
			Placebo	34	29 (85.3)	5.21 (1.31)	2.6	4.20	5.20	6.60	7.0	
		Week 16	Tezepelumab	33	30 (90.9)	5.17 (1.26)	2.6	4.40	5.00	6.20	7.0	
			Placebo	34	29 (85.3)	5.10 (1.49)	1.0	4.40	5.20	6.00	7.0	
		Week 20	Tezepelumab	33	31 (93.9)	5.42 (1.19)	2.8	4.60	5.60	6.40	7.0	
			Placebo	34	29 (85.3)	4.98 (1.42)	1.0	4.00	5.00	6.20	7.0	
		Week 24	Tezepelumab	33	31 (93.9)	5.26 (1.17)	2.8	4.40	5.40	6.40	7.0	
			Placebo	34	29 (85.3)	5.01 (1.40)	1.0	4.40	5.20	6.20	7.0	
		Week 28	Tezepelumab	33	32 (97.0)	5.29 (1.21)	2.8	4.20	5.00	6.40	7.0	
			Placebo	34	30 (88.2)	5.13 (1.45)	1.0	4.20	5.20	6.20	7.0	
		Week 32	Tezepelumab	33	32 (97.0)	5.34 (1.22)	2.8	4.40	5.30	6.40	7.0	
			Placebo	34	30 (88.2)	5.09 (1.53)	1.0	4.20	5.20	6.20	7.0	
		Week 36	Tezepelumab	33	32 (97.0)	5.42 (1.27)	2.8	4.50	5.80	6.40	7.0	
			Placebo	34	30 (88.2)	5.13 (1.36)	2.2	4.40	5.10	6.20	7.0	
		Week 40	Tezepelumab	33	32 (97.0)	5.31 (1.33)	1.8	4.20	5.40	6.50	7.0	
			Placebo	34	30 (88.2)	5.13 (1.38)	2.6	4.20	4.90	6.60	7.0	
		Week 44	Tezepelumab	33	32 (97.0)	5.33 (1.26)	2.8	4.20	5.50	6.40	7.0	
			Placebo	34	30 (88.2)	5.16 (1.41)	2.6	3.80	5.00	6.60	7.0	
		Week 48	Tezepelumab	33	32 (97.0)	5.41 (1.24)	2.6	4.40	5.50	6.40	7.0	
			Placebo	34	30 (88.2)	5.06 (1.41)	2.6	4.00	4.70	6.60	7.0	
		Week 52	Tezepelumab	33	32 (97.0)	5.42 (1.22)	2.8	4.40	5.50	6.40	7.0	
			Placebo	34	30 (88.2)	4.87 (1.48)	2.2	3.60	4.60	6.60	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	33	29 (87.9)	0.41 (1.55)	-4.2	-0.40	0.40	1.60	3.8	-0.01 [-0.54, 0.52]
			Placebo	34	26 (76.5)	0.42 (0.88)	-2.2	0.00	0.40	0.60	2.8	
		Week 8	Tezepelumab	33	30 (90.9)	0.85 (1.47)	-2.2	-0.20	0.80	2.00	4.4	0.14 [-0.39, 0.66]
			Placebo	34	27 (79.4)	0.68 (1.00)	-1.2	0.00	0.60	1.40	2.8	
		Week 12	Tezepelumab	33	30 (90.9)	1.07 (1.31)	-2.4	0.20	1.10	2.00	3.8	0.17 [-0.35, 0.69]
			Placebo	34	27 (79.4)	0.86 (1.11)	-1.2	0.20	0.80	1.80	3.6	
		Week 16	Tezepelumab	33	30 (90.9)	0.91 (1.38)	-2.8	0.00	1.00	2.00	4.0	0.13 [-0.39, 0.65]
			Placebo	34	27 (79.4)	0.74 (1.37)	-3.4	0.20	0.60	1.60	4.0	
		Week 20	Tezepelumab	33	30 (90.9)	1.16 (1.27)	-1.4	0.40	1.10	2.20	4.6	0.45 [-0.07, 0.98]
			Placebo	34	27 (79.4)	0.59 (1.26)	-3.4	0.00	0.80	1.40	2.4	
		Week 24	Tezepelumab	33	30 (90.9)	1.00 (1.23)	-1.4	0.00	1.00	1.80	4.6	0.31 [-0.22, 0.83]
			Placebo	34	27 (79.4)	0.62 (1.23)	-3.4	0.00	0.60	1.60	2.8	
		Week 28	Tezepelumab	33	30 (90.9)	1.08 (1.28)	-1.4	0.00	1.10	1.80	4.6	0.29 [-0.23, 0.82]
			Placebo	34	27 (79.4)	0.68 (1.43)	-3.4	0.00	0.80	1.40	4.0	
		Week 32	Tezepelumab	33	30 (90.9)	1.07 (1.28)	-1.6	0.20	1.20	2.00	4.6	0.32 [-0.20, 0.85]
			Placebo	34	27 (79.4)	0.65 (1.33)	-3.4	-0.20	0.60	1.60	3.0	
		Week 36	Tezepelumab	33	30 (90.9)	1.16 (1.33)	-1.6	0.00	1.20	2.00	4.6	0.42 [-0.11, 0.94]
			Placebo	34	27 (79.4)	0.67 (0.98)	-1.4	0.00	0.60	1.40	2.6	
		Week 40	Tezepelumab	33	30 (90.9)	1.07 (1.36)	-2.4	0.40	1.30	2.00	4.6	0.28 [-0.25, 0.80]
			Placebo	34	27 (79.4)	0.71 (1.27)	-1.4	-0.40	0.80	1.60	3.6	
		Week 44	Tezepelumab	33	30 (90.9)	1.07 (1.28)	-1.4	0.00	1.30	1.80	4.6	0.33 [-0.19, 0.86]
			Placebo	34	27 (79.4)	0.67 (1.14)	-1.0	-0.40	0.60	1.20	3.2	
		Week 48	Tezepelumab	33	30 (90.9)	1.15 (1.22)	-1.4	0.20	1.30	2.00	4.6	0.50 [-0.03, 1.03]
			Placebo	34	27 (79.4)	0.59 (1.00)	-1.0	-0.20	0.40	1.20	2.8	
		Week 52	Tezepelumab	33	30 (90.9)	1.17 (1.23)	-1.6	0.20	1.30	2.00	4.6	0.62 [0.09, 1.15]
			Placebo	34	27 (79.4)	0.41 (1.22)	-2.6	-0.40	0.40	1.40	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	4.25 (1.29)	1.6	3.60	4.00	5.20	6.4	
			Placebo	31	28 (90.3)	4.34 (1.22)	2.0	3.60	4.20	4.90	7.0	
		Week 4	Tezepelumab	32	30 (93.8)	5.00 (1.06)	3.2	4.00	5.00	5.80	7.0	
			Placebo	31	30 (96.8)	4.97 (1.08)	1.6	4.20	5.20	5.60	6.6	
		Week 8	Tezepelumab	32	31 (96.9)	5.26 (1.13)	3.0	4.20	5.40	6.00	7.0	
			Placebo	31	30 (96.8)	4.91 (1.11)	2.0	4.60	4.90	5.60	7.0	
		Week 12	Tezepelumab	32	31 (96.9)	5.46 (1.09)	3.6	4.40	5.80	6.40	7.0	
			Placebo	31	30 (96.8)	5.01 (1.14)	1.8	4.20	5.10	6.00	7.0	
		Week 16	Tezepelumab	32	31 (96.9)	5.48 (1.16)	3.2	4.40	5.60	6.20	7.0	
			Placebo	31	30 (96.8)	5.07 (1.08)	2.6	4.60	5.00	5.80	7.0	
		Week 20	Tezepelumab	32	31 (96.9)	5.38 (1.16)	2.4	4.40	5.60	6.20	7.0	
			Placebo	31	30 (96.8)	5.07 (1.09)	3.0	4.60	5.00	5.80	7.0	
		Week 24	Tezepelumab	32	31 (96.9)	5.35 (1.30)	2.0	4.00	5.60	6.40	7.0	
			Placebo	31	30 (96.8)	4.97 (1.20)	2.4	4.40	5.00	6.00	7.0	
		Week 28	Tezepelumab	32	32 (100.0)	5.49 (1.02)	3.4	4.50	5.60	6.30	7.0	
			Placebo	31	30 (96.8)	5.03 (1.21)	2.6	4.20	5.20	6.00	7.0	
		Week 32	Tezepelumab	32	32 (100.0)	5.38 (1.15)	2.6	4.40	5.70	6.30	7.0	
			Placebo	31	30 (96.8)	5.08 (1.12)	2.2	4.00	5.10	6.00	7.0	
		Week 36	Tezepelumab	32	32 (100.0)	5.56 (1.22)	3.0	4.40	5.80	6.70	7.0	
			Placebo	31	30 (96.8)	4.98 (1.20)	1.6	4.40	4.90	5.80	7.0	
		Week 40	Tezepelumab	32	32 (100.0)	5.31 (1.29)	2.0	4.40	5.40	6.40	7.0	
			Placebo	31	30 (96.8)	5.05 (1.25)	1.6	4.40	5.10	6.00	7.0	
		Week 44	Tezepelumab	32	32 (100.0)	5.52 (1.07)	3.4	4.70	5.50	6.60	7.0	
			Placebo	31	30 (96.8)	4.98 (1.25)	1.8	4.00	5.10	6.00	7.0	
		Week 48	Tezepelumab	32	32 (100.0)	5.42 (1.12)	2.6	4.60	5.50	6.30	7.0	
			Placebo	31	30 (96.8)	5.06 (1.25)	1.4	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	32	32 (100.0)	5.46 (1.15)	2.6	4.60	5.50	6.50	7.0	
			Placebo	31	30 (96.8)	5.19 (1.20)	2.0	4.20	5.20	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	32	25 (78.1)	0.90 (1.02)	-1.2	0.40	0.80	1.60	3.0	0.25 [-0.29, 0.79]
			Placebo	31	28 (90.3)	0.63 (1.18)	-2.0	0.00	0.60	1.40	3.0	
		Week 8	Tezepelumab	32	26 (81.3)	0.90 (1.08)	-1.0	0.20	1.00	1.40	3.4	0.28 [-0.26, 0.81]
			Placebo	31	28 (90.3)	0.56 (1.32)	-1.6	-0.30	0.50	1.20	4.0	
		Week 12	Tezepelumab	32	26 (81.3)	1.10 (1.14)	-0.6	0.40	1.10	1.60	3.6	0.37 [-0.17, 0.91]
			Placebo	31	28 (90.3)	0.63 (1.36)	-1.8	-0.20	0.60	1.30	4.4	
		Week 16	Tezepelumab	32	26 (81.3)	1.15 (1.12)	-0.6	0.40	1.20	1.60	3.4	0.37 [-0.17, 0.91]
			Placebo	31	28 (90.3)	0.70 (1.27)	-1.6	-0.10	0.60	1.40	4.4	
		Week 20	Tezepelumab	32	26 (81.3)	1.18 (1.09)	-0.6	0.40	1.20	1.80	3.4	0.35 [-0.19, 0.89]
			Placebo	31	28 (90.3)	0.76 (1.24)	-1.4	0.00	0.70	1.60	4.2	
		Week 24	Tezepelumab	32	26 (81.3)	1.13 (1.32)	-0.8	0.00	1.10	2.20	3.8	0.35 [-0.19, 0.89]
			Placebo	31	28 (90.3)	0.66 (1.37)	-2.2	-0.10	0.40	1.50	4.2	
		Week 28	Tezepelumab	32	26 (81.3)	1.13 (1.17)	-0.6	0.60	0.80	2.00	3.6	0.29 [-0.25, 0.83]
			Placebo	31	28 (90.3)	0.75 (1.43)	-2.0	-0.20	0.60	1.80	4.4	
		Week 32	Tezepelumab	32	26 (81.3)	1.06 (1.33)	-1.4	0.00	0.80	2.00	3.6	0.20 [-0.33, 0.74]
			Placebo	31	28 (90.3)	0.81 (1.20)	-1.4	-0.10	0.80	1.40	4.2	
		Week 36	Tezepelumab	32	26 (81.3)	1.32 (1.49)	-1.0	0.40	1.10	2.60	3.8	0.47 [-0.07, 1.01]
			Placebo	31	28 (90.3)	0.68 (1.23)	-2.0	0.00	0.60	1.50	3.8	
		Week 40	Tezepelumab	32	26 (81.3)	1.06 (1.38)	-1.2	0.00	0.80	1.60	3.4	0.23 [-0.30, 0.77]
			Placebo	31	28 (90.3)	0.75 (1.30)	-2.0	-0.10	0.80	1.70	3.4	
		Week 44	Tezepelumab	32	26 (81.3)	1.19 (1.33)	-1.0	0.40	1.20	1.60	3.8	0.36 [-0.18, 0.90]
			Placebo	31	28 (90.3)	0.70 (1.39)	-1.8	-0.30	0.70	1.40	4.2	
		Week 48	Tezepelumab	32	26 (81.3)	1.11 (1.39)	-1.4	0.40	1.00	1.80	3.8	0.22 [-0.32, 0.75]
			Placebo	31	28 (90.3)	0.80 (1.43)	-2.2	-0.20	0.60	1.50	4.2	
		Week 52	Tezepelumab	32	26 (81.3)	1.13 (1.39)	-1.4	0.40	1.20	1.80	3.8	0.15 [-0.39, 0.68]
			Placebo	31	28 (90.3)	0.92 (1.42)	-1.6	0.10	0.70	1.70	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	39	32 (82.1)	4.30 (1.00)	1.8	3.60	4.20	5.20	6.2	
			Placebo	30	23 (76.7)	4.29 (0.94)	2.6	3.80	4.20	4.40	6.2	
		Week 4	Tezepelumab	39	36 (92.3)	4.67 (1.15)	1.2	4.00	4.80	5.60	7.0	
			Placebo	30	25 (83.3)	4.70 (1.19)	1.6	4.00	4.60	5.40	7.0	
		Week 8	Tezepelumab	39	36 (92.3)	5.07 (1.06)	3.0	4.30	4.90	6.00	7.0	
			Placebo	30	25 (83.3)	4.93 (1.04)	2.6	4.20	4.80	5.60	7.0	
		Week 12	Tezepelumab	39	36 (92.3)	5.23 (1.12)	3.0	4.40	5.30	6.30	7.0	
			Placebo	30	25 (83.3)	4.98 (1.11)	2.6	4.20	4.60	5.80	7.0	
		Week 16	Tezepelumab	39	36 (92.3)	5.09 (1.16)	2.6	4.20	5.00	6.20	7.0	
			Placebo	30	25 (83.3)	4.91 (1.06)	2.8	4.40	4.60	5.20	7.0	
		Week 20	Tezepelumab	39	37 (94.9)	5.23 (1.14)	2.4	4.40	5.40	6.20	7.0	
			Placebo	30	25 (83.3)	4.92 (1.02)	3.0	4.00	4.80	5.20	6.8	
		Week 24	Tezepelumab	39	37 (94.9)	5.16 (1.15)	2.0	4.40	5.40	6.00	7.0	
			Placebo	30	25 (83.3)	5.04 (0.98)	2.8	4.40	5.00	5.60	7.0	
		Week 28	Tezepelumab	39	39 (100.0)	5.28 (1.07)	3.2	4.20	5.40	6.20	7.0	
			Placebo	30	26 (86.7)	5.05 (1.10)	3.4	4.00	4.90	6.00	7.0	
		Week 32	Tezepelumab	39	39 (100.0)	5.21 (1.13)	2.6	4.40	5.20	6.20	7.0	
			Placebo	30	26 (86.7)	5.09 (1.19)	2.6	4.20	5.00	6.20	7.0	
		Week 36	Tezepelumab	39	39 (100.0)	5.33 (1.27)	3.0	4.20	5.60	6.40	7.0	
			Placebo	30	26 (86.7)	5.18 (1.17)	2.2	4.60	5.20	6.00	7.0	
		Week 40	Tezepelumab	39	39 (100.0)	5.04 (1.29)	1.8	4.00	5.20	6.20	7.0	
			Placebo	30	26 (86.7)	5.11 (1.14)	2.8	4.40	5.00	6.00	7.0	
		Week 44	Tezepelumab	39	39 (100.0)	5.18 (1.11)	3.2	4.00	5.00	6.20	7.0	
			Placebo	30	26 (86.7)	5.02 (1.26)	3.2	4.00	4.60	6.40	7.0	
		Week 48	Tezepelumab	39	39 (100.0)	5.18 (1.11)	2.6	4.40	5.20	6.20	7.0	
			Placebo	30	26 (86.7)	5.14 (1.29)	2.8	4.00	4.90	6.40	7.0	
		Week 52	Tezepelumab	39	39 (100.0)	5.21 (1.10)	2.6	4.40	5.00	6.20	7.0	
			Placebo	30	26 (86.7)	4.97 (1.39)	2.2	4.00	4.70	6.40	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	39	32 (82.1)	0.34 (1.48)	-4.2	-0.50	0.40	1.30	3.8	-0.12 [-0.65, 0.42]
			Placebo	30	23 (76.7)	0.50 (1.19)	-2.2	0.00	0.40	1.20	3.0	
		Week 8	Tezepelumab	39	32 (82.1)	0.70 (1.31)	-1.2	-0.30	0.50	1.40	4.4	0.02 [-0.51, 0.56]
			Placebo	30	23 (76.7)	0.67 (1.33)	-1.6	-0.20	0.80	1.40	4.0	
		Week 12	Tezepelumab	39	32 (82.1)	0.86 (1.25)	-2.4	0.00	1.00	1.70	3.8	0.12 [-0.42, 0.65]
			Placebo	30	23 (76.7)	0.70 (1.35)	-1.6	0.20	0.60	1.20	4.4	
		Week 16	Tezepelumab	39	32 (82.1)	0.72 (1.30)	-2.8	-0.20	0.80	1.50	4.0	0.06 [-0.47, 0.60]
			Placebo	30	23 (76.7)	0.63 (1.31)	-1.6	0.00	0.40	1.20	4.4	
		Week 20	Tezepelumab	39	32 (82.1)	0.97 (1.24)	-1.4	0.00	1.00	1.50	4.6	0.22 [-0.32, 0.76]
			Placebo	30	23 (76.7)	0.70 (1.30)	-2.2	0.00	0.80	1.20	4.2	
		Week 24	Tezepelumab	39	32 (82.1)	0.88 (1.22)	-1.4	0.00	0.70	1.70	4.6	0.10 [-0.44, 0.63]
			Placebo	30	23 (76.7)	0.77 (1.16)	-1.0	0.20	0.60	1.00	4.2	
		Week 28	Tezepelumab	39	32 (82.1)	0.93 (1.26)	-1.4	0.00	0.70	1.60	4.6	0.14 [-0.40, 0.68]
			Placebo	30	23 (76.7)	0.74 (1.39)	-2.2	0.00	0.80	1.20	4.4	
		Week 32	Tezepelumab	39	32 (82.1)	0.83 (1.29)	-1.6	0.00	0.90	1.50	4.6	0.03 [-0.51, 0.56]
			Placebo	30	23 (76.7)	0.80 (1.18)	-1.0	0.00	0.60	1.40	4.2	
		Week 36	Tezepelumab	39	32 (82.1)	1.03 (1.49)	-1.6	-0.10	1.00	1.90	4.6	0.13 [-0.41, 0.67]
			Placebo	30	23 (76.7)	0.85 (1.10)	-0.8	0.20	0.60	1.80	3.8	
		Week 40	Tezepelumab	39	32 (82.1)	0.74 (1.38)	-2.4	-0.10	0.70	1.60	4.6	-0.04 [-0.58, 0.49]
			Placebo	30	23 (76.7)	0.80 (1.25)	-1.4	0.00	0.80	1.40	3.4	
		Week 44	Tezepelumab	39	32 (82.1)	0.79 (1.27)	-1.4	-0.20	0.60	1.60	4.6	0.10 [-0.44, 0.63]
			Placebo	30	23 (76.7)	0.67 (1.15)	-1.0	-0.40	0.60	1.20	3.4	
		Week 48	Tezepelumab	39	32 (82.1)	0.81 (1.25)	-1.4	0.00	0.90	1.60	4.6	-0.01 [-0.55, 0.52]
			Placebo	30	23 (76.7)	0.83 (1.19)	-0.8	0.00	0.40	1.60	3.8	
		Week 52	Tezepelumab	39	32 (82.1)	0.84 (1.24)	-1.6	0.00	0.90	1.60	4.6	0.15 [-0.39, 0.69]
			Placebo	30	23 (76.7)	0.63 (1.47)	-2.6	-0.20	0.40	1.60	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	27	26 (96.3)	4.22 (1.35)	1.4	3.60	4.30	5.00	6.4	
			Placebo	34	31 (91.2)	4.46 (1.33)	1.0	3.60	4.40	5.20	7.0	
		Week 4	Tezepelumab	27	24 (88.9)	5.19 (1.15)	3.4	4.10	5.30	6.10	7.0	
			Placebo	34	32 (94.1)	5.06 (1.36)	1.6	4.20	5.60	6.00	7.0	
		Week 8	Tezepelumab	27	26 (96.3)	5.28 (1.39)	2.8	4.00	5.60	6.60	7.0	
			Placebo	34	33 (97.1)	5.05 (1.23)	2.0	4.60	5.20	6.00	7.0	
		Week 12	Tezepelumab	27	26 (96.3)	5.57 (1.24)	2.8	4.60	5.80	7.00	7.0	
			Placebo	34	33 (97.1)	5.23 (1.31)	1.8	4.20	5.40	6.20	7.0	
		Week 16	Tezepelumab	27	26 (96.3)	5.62 (1.23)	2.8	4.40	5.80	6.80	7.0	
			Placebo	34	33 (97.1)	5.34 (1.25)	2.6	4.60	5.60	6.00	7.0	
		Week 20	Tezepelumab	27	26 (96.3)	5.61 (1.17)	2.8	4.60	5.80	6.80	7.0	
			Placebo	34	33 (97.1)	5.23 (1.23)	2.6	4.60	5.20	6.00	7.0	
		Week 24	Tezepelumab	27	26 (96.3)	5.46 (1.34)	2.8	4.00	5.80	6.80	7.0	
			Placebo	34	33 (97.1)	5.08 (1.34)	2.4	4.40	5.20	6.20	7.0	
		Week 28	Tezepelumab	27	26 (96.3)	5.52 (1.21)	2.8	4.40	5.60	6.40	7.0	
			Placebo	34	33 (97.1)	5.23 (1.33)	2.6	4.40	5.40	6.00	7.0	
		Week 32	Tezepelumab	27	26 (96.3)	5.56 (1.23)	2.8	4.60	5.80	6.60	7.0	
			Placebo	34	33 (97.1)	5.21 (1.27)	2.2	4.40	5.60	6.00	7.0	
		Week 36	Tezepelumab	27	26 (96.3)	5.73 (1.14)	2.8	5.00	6.00	6.80	7.0	
			Placebo	34	33 (97.1)	5.02 (1.34)	1.6	4.40	4.80	6.00	7.0	
		Week 40	Tezepelumab	27	26 (96.3)	5.65 (1.26)	2.8	4.60	5.80	6.80	7.0	
			Placebo	34	33 (97.1)	5.12 (1.42)	1.6	4.40	5.20	6.60	7.0	
		Week 44	Tezepelumab	27	26 (96.3)	5.75 (1.17)	2.8	5.00	6.20	6.60	7.0	
			Placebo	34	33 (97.1)	5.16 (1.37)	1.8	4.40	5.40	6.20	7.0	
		Week 48	Tezepelumab	27	26 (96.3)	5.74 (1.19)	2.8	4.80	6.00	6.80	7.0	
			Placebo	34	33 (97.1)	5.05 (1.35)	1.4	4.20	5.00	6.00	7.0	
		Week 52	Tezepelumab	27	26 (96.3)	5.75 (1.23)	2.8	4.60	6.00	7.00	7.0	
			Placebo	34	33 (97.1)	5.13 (1.32)	2.0	4.20	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	1.02 (1.01)	-0.6	0.20	1.00	1.80	3.0	0.48 [-0.07, 1.02]
			Placebo	34	31 (91.2)	0.55 (0.94)	-2.0	0.00	0.40	1.20	3.0	
		Week 8	Tezepelumab	27	25 (92.6)	1.02 (1.31)	-2.2	0.60	1.20	2.20	3.4	0.32 [-0.21, 0.85]
			Placebo	34	31 (91.2)	0.64 (1.03)	-1.2	0.00	0.60	1.20	3.0	
		Week 12	Tezepelumab	27	25 (92.6)	1.30 (1.21)	-0.8	0.60	1.40	2.20	3.6	0.41 [-0.12, 0.95]
			Placebo	34	31 (91.2)	0.80 (1.19)	-1.8	0.00	0.80	1.80	3.6	
		Week 16	Tezepelumab	27	25 (92.6)	1.34 (1.16)	-0.6	0.60	1.40	2.20	3.4	0.38 [-0.15, 0.91]
			Placebo	34	31 (91.2)	0.92 (1.11)	-1.2	0.40	0.80	1.60	4.0	
		Week 20	Tezepelumab	27	25 (92.6)	1.34 (1.12)	-0.6	0.60	1.20	2.20	3.4	0.52 [-0.01, 1.06]
			Placebo	34	31 (91.2)	0.79 (0.99)	-1.2	0.00	0.80	1.60	2.6	
		Week 24	Tezepelumab	27	25 (92.6)	1.19 (1.39)	-1.4	0.40	1.40	2.20	3.8	0.40 [-0.13, 0.93]
			Placebo	34	31 (91.2)	0.68 (1.21)	-2.2	-0.20	0.20	1.80	2.6	
		Week 28	Tezepelumab	27	25 (92.6)	1.25 (1.22)	-1.0	0.60	1.20	2.20	3.6	0.33 [-0.20, 0.86]
			Placebo	34	31 (91.2)	0.83 (1.27)	-2.0	-0.20	0.60	1.80	4.0	
		Week 32	Tezepelumab	27	25 (92.6)	1.31 (1.28)	-0.6	0.60	1.40	2.40	3.6	0.42 [-0.11, 0.95]
			Placebo	34	31 (91.2)	0.81 (1.12)	-1.4	-0.20	1.20	1.60	3.0	
		Week 36	Tezepelumab	27	25 (92.6)	1.47 (1.24)	-0.6	0.60	1.20	2.40	3.8	0.76 [0.21, 1.30]
			Placebo	34	31 (91.2)	0.61 (1.07)	-2.0	-0.20	0.60	1.40	2.6	
		Week 40	Tezepelumab	27	25 (92.6)	1.39 (1.30)	-1.2	0.60	1.40	2.40	3.4	0.50 [-0.03, 1.04]
			Placebo	34	31 (91.2)	0.74 (1.30)	-2.0	-0.40	0.80	1.80	3.6	
		Week 44	Tezepelumab	27	25 (92.6)	1.50 (1.26)	-0.6	0.80	1.40	2.40	3.8	0.57 [0.03, 1.11]
			Placebo	34	31 (91.2)	0.75 (1.34)	-1.8	-0.20	0.80	1.60	4.2	
		Week 48	Tezepelumab	27	25 (92.6)	1.49 (1.26)	-0.6	0.60	1.40	2.40	3.8	0.66 [0.12, 1.20]
			Placebo	34	31 (91.2)	0.66 (1.26)	-2.2	-0.20	0.60	1.40	4.2	
		Week 52	Tezepelumab	27	25 (92.6)	1.48 (1.32)	-0.6	0.60	1.40	2.40	3.8	0.57 [0.03, 1.11]
			Placebo	34	31 (91.2)	0.75 (1.24)	-1.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	27	23 (85.2)	4.34 (0.87)	2.6	3.60	4.40	5.00	6.2	
			Placebo	29	23 (79.3)	4.48 (1.25)	1.0	3.80	4.40	4.80	7.0	
		Week 4	Tezepelumab	27	26 (96.3)	4.79 (0.91)	3.2	4.00	4.80	5.20	7.0	
			Placebo	29	25 (86.2)	4.74 (1.56)	1.6	3.80	4.80	6.00	7.0	
		Week 8	Tezepelumab	27	26 (96.3)	5.14 (1.01)	3.4	4.40	4.90	6.20	7.0	
			Placebo	29	27 (93.1)	4.76 (1.19)	2.6	3.60	4.80	5.80	7.0	
		Week 12	Tezepelumab	27	26 (96.3)	5.42 (1.06)	3.8	4.60	5.20	6.40	7.0	
			Placebo	29	27 (93.1)	4.97 (1.35)	1.8	4.00	5.20	6.00	7.0	
		Week 16	Tezepelumab	27	26 (96.3)	5.35 (1.03)	4.0	4.40	5.00	6.20	7.0	
			Placebo	29	27 (93.1)	4.70 (1.50)	1.0	3.60	4.60	5.80	7.0	
		Week 20	Tezepelumab	27	26 (96.3)	5.36 (1.05)	4.0	4.60	5.00	6.20	7.0	
			Placebo	29	27 (93.1)	4.71 (1.50)	1.0	3.60	4.80	6.00	7.0	
		Week 24	Tezepelumab	27	26 (96.3)	5.32 (1.10)	3.4	4.40	5.40	6.20	7.0	
			Placebo	29	27 (93.1)	4.72 (1.51)	1.0	3.80	5.00	6.00	7.0	
		Week 28	Tezepelumab	27	27 (100.0)	5.33 (1.05)	4.0	4.40	5.00	6.20	7.0	
			Placebo	29	27 (93.1)	4.71 (1.53)	1.0	3.80	4.40	6.00	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	5.35 (1.06)	3.6	4.60	5.00	6.40	7.0	
			Placebo	29	27 (93.1)	4.68 (1.48)	1.0	4.00	4.40	6.00	7.0	
		Week 36	Tezepelumab	27	27 (100.0)	5.52 (1.08)	4.0	4.60	5.60	6.60	7.0	
			Placebo	29	27 (93.1)	4.79 (1.41)	1.6	4.00	4.60	6.00	7.0	
		Week 40	Tezepelumab	27	27 (100.0)	5.20 (1.07)	3.8	4.20	5.00	6.20	7.0	
			Placebo	29	27 (93.1)	4.68 (1.40)	1.6	3.60	4.40	5.60	7.0	
		Week 44	Tezepelumab	27	27 (100.0)	5.22 (1.07)	3.4	4.40	5.00	6.20	7.0	
			Placebo	29	27 (93.1)	4.72 (1.31)	1.8	3.80	4.60	6.00	7.0	
		Week 48	Tezepelumab	27	27 (100.0)	5.24 (1.01)	4.0	4.40	5.00	6.20	7.0	
			Placebo	29	27 (93.1)	4.67 (1.42)	1.4	3.80	4.20	6.00	7.0	
		Week 52	Tezepelumab	27	27 (100.0)	5.24 (1.05)	4.0	4.40	5.00	6.20	7.0	
			Placebo	29	27 (93.1)	4.53 (1.36)	2.0	3.60	4.20	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	0.51 (0.76)	-1.0	0.00	0.40	1.20	1.8	0.25 [-0.34, 0.84]
			Placebo	29	22 (75.9)	0.27 (1.14)	-2.2	-0.20	0.30	0.80	2.8	
		Week 8	Tezepelumab	27	23 (85.2)	0.66 (0.98)	-1.2	0.20	0.60	1.20	2.4	0.32 [-0.26, 0.90]
			Placebo	29	23 (79.3)	0.33 (1.08)	-1.2	-0.40	0.20	1.20	2.8	
		Week 12	Tezepelumab	27	23 (85.2)	0.92 (0.89)	-0.8	0.40	1.00	1.60	2.4	0.39 [-0.19, 0.98]
			Placebo	29	23 (79.3)	0.51 (1.17)	-1.8	-0.40	0.60	1.60	2.6	
		Week 16	Tezepelumab	27	23 (85.2)	0.82 (0.92)	-1.2	0.20	1.00	1.60	2.2	0.54 [-0.05, 1.13]
			Placebo	29	23 (79.3)	0.21 (1.31)	-3.4	-1.00	0.40	1.00	2.8	
		Week 20	Tezepelumab	27	23 (85.2)	0.97 (0.87)	-0.6	0.40	1.20	1.40	2.4	0.60 [0.01, 1.19]
			Placebo	29	23 (79.3)	0.26 (1.41)	-3.4	-0.60	0.20	1.40	2.4	
		Week 24	Tezepelumab	27	23 (85.2)	0.89 (0.99)	-1.4	0.00	1.00	1.60	2.6	0.49 [-0.09, 1.08]
			Placebo	29	23 (79.3)	0.27 (1.47)	-3.4	-0.80	0.20	1.00	2.8	
		Week 28	Tezepelumab	27	23 (85.2)	0.97 (0.91)	-1.0	0.40	0.80	1.60	2.6	0.51 [-0.08, 1.10]
			Placebo	29	23 (79.3)	0.30 (1.59)	-3.4	-0.60	0.00	1.60	2.8	
		Week 32	Tezepelumab	27	23 (85.2)	0.99 (0.89)	-0.6	0.40	1.20	1.60	2.4	0.60 [0.01, 1.19]
			Placebo	29	23 (79.3)	0.29 (1.42)	-3.4	-0.80	0.40	1.40	2.8	
		Week 36	Tezepelumab	27	23 (85.2)	1.20 (0.95)	-0.6	0.60	1.20	1.80	3.8	0.79 [0.19, 1.40]
			Placebo	29	23 (79.3)	0.35 (1.19)	-2.0	-0.40	0.40	0.80	2.6	
		Week 40	Tezepelumab	27	23 (85.2)	0.81 (0.87)	-1.2	0.00	1.00	1.40	2.2	0.46 [-0.13, 1.05]
			Placebo	29	23 (79.3)	0.29 (1.35)	-2.0	-1.00	0.00	1.60	2.8	
		Week 44	Tezepelumab	27	23 (85.2)	0.84 (0.88)	-0.6	0.00	0.80	1.60	2.4	0.58 [-0.01, 1.17]
			Placebo	29	23 (79.3)	0.26 (1.12)	-1.8	-0.60	0.20	0.80	2.8	
		Week 48	Tezepelumab	27	23 (85.2)	0.90 (0.75)	-0.6	0.40	1.00	1.40	2.2	0.63 [0.04, 1.22]
			Placebo	29	23 (79.3)	0.27 (1.22)	-2.2	-0.60	0.00	0.80	2.8	
		Week 52	Tezepelumab	27	23 (85.2)	0.89 (0.80)	-0.6	0.40	1.00	1.40	2.4	0.70 [0.10, 1.30]
			Placebo	29	23 (79.3)	0.10 (1.38)	-2.6	-0.80	-0.20	0.80	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	4.19 (1.26)	1.4	3.40	4.20	4.90	6.4	
			Placebo	33	29 (87.9)	4.28 (1.15)	2.0	3.60	4.20	5.20	6.6	
		Week 4	Tezepelumab	34	30 (88.2)	4.91 (1.36)	1.2	4.00	5.30	6.00	7.0	
			Placebo	33	29 (87.9)	4.99 (1.06)	3.0	4.40	4.80	5.60	7.0	
		Week 8	Tezepelumab	34	32 (94.1)	5.12 (1.37)	2.8	4.00	5.50	6.10	7.0	
			Placebo	33	29 (87.9)	5.06 (1.10)	2.0	4.60	5.00	5.60	7.0	
		Week 12	Tezepelumab	34	32 (94.1)	5.34 (1.31)	2.8	4.30	5.70	6.40	7.0	
			Placebo	33	29 (87.9)	5.12 (1.10)	3.6	4.40	4.80	6.00	7.0	
		Week 16	Tezepelumab	34	32 (94.1)	5.29 (1.33)	2.6	4.20	5.60	6.20	7.0	
			Placebo	33	29 (87.9)	5.31 (0.98)	3.6	4.60	5.00	5.80	7.0	
		Week 20	Tezepelumab	34	32 (94.1)	5.43 (1.19)	2.8	4.40	5.70	6.30	7.0	
			Placebo	33	29 (87.9)	5.20 (0.91)	3.6	4.60	5.00	5.80	7.0	
		Week 24	Tezepelumab	34	32 (94.1)	5.26 (1.27)	2.8	4.00	5.40	6.30	7.0	
			Placebo	33	29 (87.9)	5.12 (1.01)	2.8	4.40	5.00	6.00	7.0	
		Week 28	Tezepelumab	34	33 (97.1)	5.35 (1.23)	2.8	4.20	5.60	6.40	7.0	
			Placebo	33	30 (90.9)	5.30 (1.06)	3.6	4.60	5.20	6.00	7.0	
		Week 32	Tezepelumab	34	33 (97.1)	5.31 (1.27)	2.6	4.20	5.60	6.40	7.0	
			Placebo	33	30 (90.9)	5.35 (1.12)	2.6	4.60	5.60	6.20	7.0	
		Week 36	Tezepelumab	34	33 (97.1)	5.46 (1.33)	2.8	4.40	6.00	6.40	7.0	
			Placebo	33	30 (90.9)	5.19 (1.13)	2.2	4.40	5.30	5.80	7.0	
		Week 40	Tezepelumab	34	33 (97.1)	5.38 (1.42)	1.8	4.20	5.60	6.60	7.0	
			Placebo	33	30 (90.9)	5.35 (1.14)	3.2	4.40	5.40	6.40	7.0	
		Week 44	Tezepelumab	34	33 (97.1)	5.50 (1.25)	2.8	4.40	6.00	6.60	7.0	
			Placebo	33	30 (90.9)	5.27 (1.28)	2.6	4.40	5.60	6.60	7.0	
		Week 48	Tezepelumab	34	33 (97.1)	5.44 (1.30)	2.6	4.60	5.60	6.40	7.0	
			Placebo	33	30 (90.9)	5.29 (1.15)	2.8	4.60	5.20	6.20	7.0	
		Week 52	Tezepelumab	34	33 (97.1)	5.49 (1.27)	2.6	4.60	5.80	6.40	7.0	
			Placebo	33	30 (90.9)	5.35 (1.20)	2.8	4.60	5.30	6.60	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	34	29 (85.3)	0.67 (1.55)	-4.2	-0.40	0.60	1.80	3.0	-0.03 [-0.55, 0.48]
			Placebo	33	29 (87.9)	0.71 (0.97)	-1.6	0.40	0.40	1.20	3.0	
		Week 8	Tezepelumab	34	31 (91.2)	0.90 (1.40)	-2.2	-0.40	1.20	2.20	3.4	0.10 [-0.41, 0.60]
			Placebo	33	29 (87.9)	0.78 (1.19)	-1.6	0.20	0.80	1.20	4.0	
		Week 12	Tezepelumab	34	31 (91.2)	1.13 (1.37)	-2.4	0.00	1.40	2.20	3.6	0.22 [-0.29, 0.72]
			Placebo	33	29 (87.9)	0.84 (1.28)	-1.6	0.20	0.80	1.20	4.4	
		Week 16	Tezepelumab	34	31 (91.2)	1.07 (1.40)	-2.8	0.00	1.20	2.40	3.4	0.03 [-0.47, 0.54]
			Placebo	33	29 (87.9)	1.03 (1.21)	-1.6	0.40	0.80	1.40	4.4	
		Week 20	Tezepelumab	34	31 (91.2)	1.21 (1.25)	-1.4	0.40	1.20	2.20	3.4	0.26 [-0.25, 0.77]
			Placebo	33	29 (87.9)	0.92 (1.01)	-1.4	0.60	0.80	1.40	4.2	
		Week 24	Tezepelumab	34	31 (91.2)	1.05 (1.38)	-1.4	-0.20	1.20	2.20	3.8	0.16 [-0.34, 0.67]
			Placebo	33	29 (87.9)	0.84 (1.08)	-1.0	0.00	0.80	1.40	4.2	
		Week 28	Tezepelumab	34	31 (91.2)	1.08 (1.33)	-1.4	0.00	0.80	2.20	3.6	0.09 [-0.41, 0.60]
			Placebo	33	29 (87.9)	0.96 (1.22)	-1.6	0.40	0.80	1.20	4.4	
		Week 32	Tezepelumab	34	31 (91.2)	1.06 (1.37)	-1.4	-0.20	0.80	2.20	3.6	0.04 [-0.46, 0.55]
			Placebo	33	29 (87.9)	1.01 (1.01)	-0.6	0.40	1.20	1.40	4.2	
		Week 36	Tezepelumab	34	31 (91.2)	1.21 (1.55)	-1.6	-0.20	1.20	2.60	3.8	0.28 [-0.23, 0.79]
			Placebo	33	29 (87.9)	0.85 (0.96)	-0.6	0.40	0.80	1.40	3.8	
		Week 40	Tezepelumab	34	31 (91.2)	1.14 (1.56)	-2.4	-0.20	1.40	2.40	3.4	0.09 [-0.42, 0.60]
			Placebo	33	29 (87.9)	1.01 (1.11)	-1.0	0.40	1.20	1.60	3.6	
		Week 44	Tezepelumab	34	31 (91.2)	1.24 (1.42)	-1.4	-0.20	1.40	2.40	3.8	0.23 [-0.28, 0.74]
			Placebo	33	29 (87.9)	0.93 (1.27)	-1.6	0.40	1.00	1.20	4.2	
		Week 48	Tezepelumab	34	31 (91.2)	1.19 (1.48)	-1.4	0.00	1.40	2.40	3.8	0.19 [-0.32, 0.70]
			Placebo	33	29 (87.9)	0.94 (1.11)	-0.8	0.40	0.60	1.40	4.2	
		Week 52	Tezepelumab	34	31 (91.2)	1.23 (1.47)	-1.6	-0.20	1.40	2.40	3.8	0.17 [-0.34, 0.68]
			Placebo	33	29 (87.9)	1.01 (1.14)	-0.8	0.20	0.80	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	4.39 (1.14)	1.8	3.60	4.50	5.30	6.2	
			Placebo	14	11 (78.6)	4.87 (1.21)	3.6	4.00	4.40	6.20	7.0	
		Week 4	Tezepelumab	23	21 (91.3)	5.13 (1.09)	3.8	4.00	5.00	6.00	7.0	
			Placebo	14	10 (71.4)	5.00 (1.61)	1.6	4.20	5.30	6.20	6.8	
		Week 8	Tezepelumab	23	21 (91.3)	5.23 (1.18)	3.4	4.20	5.00	6.20	7.0	
			Placebo	14	11 (78.6)	4.85 (1.15)	3.0	3.80	4.80	5.80	6.4	
		Week 12	Tezepelumab	23	21 (91.3)	5.45 (1.12)	4.0	4.40	5.20	6.40	7.0	
			Placebo	14	11 (78.6)	4.85 (1.52)	1.8	3.80	5.20	6.20	6.8	
		Week 16	Tezepelumab	23	21 (91.3)	5.46 (1.04)	4.0	4.60	5.60	6.40	7.0	
			Placebo	14	11 (78.6)	4.47 (1.72)	1.0	3.40	4.60	6.00	7.0	
		Week 20	Tezepelumab	23	22 (95.7)	5.50 (1.07)	4.0	4.60	5.70	6.40	7.0	
			Placebo	14	11 (78.6)	4.62 (1.65)	1.0	4.00	4.60	6.00	6.8	
		Week 24	Tezepelumab	23	22 (95.7)	5.44 (1.08)	3.6	4.20	5.60	6.40	7.0	
			Placebo	14	11 (78.6)	4.42 (1.81)	1.0	2.80	4.40	6.00	7.0	
		Week 28	Tezepelumab	23	23 (100.0)	5.45 (1.16)	4.0	4.20	5.60	6.40	7.0	
			Placebo	14	11 (78.6)	4.27 (1.72)	1.0	2.60	4.40	6.00	6.6	
		Week 32	Tezepelumab	23	23 (100.0)	5.35 (1.10)	3.8	4.40	5.00	6.40	7.0	
			Placebo	14	11 (78.6)	4.47 (1.72)	1.0	3.80	4.40	6.00	6.8	
		Week 36	Tezepelumab	23	23 (100.0)	5.58 (1.11)	3.8	4.60	5.60	6.60	7.0	
			Placebo	14	11 (78.6)	4.87 (1.52)	1.6	4.40	5.00	6.20	6.6	
		Week 40	Tezepelumab	23	23 (100.0)	5.27 (1.12)	3.8	4.20	5.20	6.40	7.0	
			Placebo	14	11 (78.6)	4.60 (1.56)	1.6	3.40	4.80	6.00	6.6	
		Week 44	Tezepelumab	23	23 (100.0)	5.31 (1.12)	4.0	4.20	5.00	6.40	7.0	
			Placebo	14	11 (78.6)	4.65 (1.49)	1.8	3.60	4.60	6.00	6.6	
		Week 48	Tezepelumab	23	23 (100.0)	5.40 (1.16)	3.8	4.20	5.20	6.80	7.0	
			Placebo	14	11 (78.6)	4.67 (1.60)	1.4	3.80	4.40	6.00	6.8	
		Week 52	Tezepelumab	23	23 (100.0)	5.37 (1.17)	4.0	4.20	5.00	6.80	7.0	
			Placebo	14	11 (78.6)	4.42 (1.40)	2.0	3.60	4.20	6.00	6.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	0.80 (1.28)	-1.8	0.00	0.70	1.70	3.8	0.59 [-0.18, 1.37]
			Placebo	14	10 (71.4)	0.08 (1.06)	-2.0	-0.40	0.00	0.60	1.8	
		Week 8	Tezepelumab	23	20 (87.0)	0.81 (1.44)	-1.2	-0.20	0.80	1.50	4.4	0.65 [-0.11, 1.40]
			Placebo	14	11 (78.6)	-0.02 (0.91)	-1.2	-0.60	-0.20	0.20	1.6	
		Week 12	Tezepelumab	23	20 (87.0)	0.99 (1.22)	-0.8	0.10	1.00	1.60	3.8	0.86 [0.09, 1.63]
			Placebo	14	11 (78.6)	-0.02 (1.08)	-1.8	-0.80	-0.20	0.60	2.0	
		Week 16	Tezepelumab	23	20 (87.0)	1.01 (1.27)	-1.2	0.00	1.10	1.80	4.0	1.08 [0.29, 1.87]
			Placebo	14	11 (78.6)	-0.40 (1.37)	-3.4	-1.00	0.00	0.40	2.0	
		Week 20	Tezepelumab	23	20 (87.0)	1.07 (1.31)	-0.6	0.00	1.10	1.50	4.6	0.94 [0.17, 1.72]
			Placebo	14	11 (78.6)	-0.25 (1.56)	-3.4	-1.00	0.00	1.20	2.0	
		Week 24	Tezepelumab	23	20 (87.0)	0.99 (1.34)	-1.4	0.00	1.00	1.60	4.6	1.04 [0.25, 1.82]
			Placebo	14	11 (78.6)	-0.45 (1.49)	-3.4	-1.00	-0.20	0.60	2.0	
		Week 28	Tezepelumab	23	20 (87.0)	1.09 (1.39)	-1.0	0.00	1.00	1.80	4.6	1.16 [0.37, 1.96]
			Placebo	14	11 (78.6)	-0.60 (1.56)	-3.4	-2.00	-0.20	0.00	2.0	
		Week 32	Tezepelumab	23	20 (87.0)	0.90 (1.33)	-1.6	0.00	1.00	1.50	4.6	0.96 [0.19, 1.74]
			Placebo	14	11 (78.6)	-0.40 (1.39)	-3.4	-1.00	-0.20	0.60	2.0	
		Week 36	Tezepelumab	23	20 (87.0)	1.16 (1.38)	-1.0	0.20	1.10	1.80	4.6	0.89 [0.12, 1.66]
			Placebo	14	11 (78.6)	0.00 (1.14)	-2.0	-1.00	0.20	0.80	2.0	
		Week 40	Tezepelumab	23	20 (87.0)	0.86 (1.28)	-1.2	-0.10	0.70	1.60	4.6	0.87 [0.10, 1.64]
			Placebo	14	11 (78.6)	-0.27 (1.35)	-2.0	-1.40	-0.40	1.00	2.0	
		Week 44	Tezepelumab	23	20 (87.0)	0.87 (1.27)	-0.6	-0.10	1.10	1.60	4.6	0.90 [0.12, 1.67]
			Placebo	14	11 (78.6)	-0.22 (1.11)	-1.8	-1.00	-0.40	0.20	2.4	
		Week 48	Tezepelumab	23	20 (87.0)	0.99 (1.22)	-0.6	0.00	1.30	1.60	4.6	0.98 [0.20, 1.75]
			Placebo	14	11 (78.6)	-0.20 (1.21)	-2.2	-1.00	-0.20	0.40	2.6	
		Week 52	Tezepelumab	23	20 (87.0)	0.96 (1.26)	-0.6	0.00	1.30	1.60	4.6	1.11 [0.32, 1.90]
			Placebo	14	11 (78.6)	-0.45 (1.31)	-2.6	-1.00	-0.60	0.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	4.25 (1.14)	1.4	3.40	4.20	4.80	6.4	
			Placebo	44	37 (84.1)	4.28 (1.18)	1.0	3.60	4.20	5.00	6.6	
		Week 4	Tezepelumab	40	36 (90.0)	4.77 (1.22)	1.2	4.00	4.80	5.80	7.0	
			Placebo	44	40 (90.9)	4.86 (1.25)	1.6	4.20	4.70	5.60	7.0	
		Week 8	Tezepelumab	40	38 (95.0)	5.21 (1.20)	3.0	4.40	5.50	6.20	7.0	
			Placebo	44	41 (93.2)	5.05 (1.17)	2.0	4.60	5.20	5.80	7.0	
		Week 12	Tezepelumab	40	38 (95.0)	5.35 (1.25)	2.8	4.40	5.50	6.40	7.0	
			Placebo	44	41 (93.2)	5.23 (1.18)	2.6	4.40	5.20	6.00	7.0	
		Week 16	Tezepelumab	40	38 (95.0)	5.27 (1.33)	2.6	4.40	5.60	6.20	7.0	
			Placebo	44	41 (93.2)	5.27 (1.17)	2.6	4.60	5.20	6.00	7.0	
		Week 20	Tezepelumab	40	38 (95.0)	5.33 (1.25)	2.4	4.40	5.60	6.40	7.0	
			Placebo	44	41 (93.2)	5.11 (1.19)	2.6	4.40	5.00	6.00	7.0	
		Week 24	Tezepelumab	40	38 (95.0)	5.26 (1.34)	2.0	4.40	5.50	6.20	7.0	
			Placebo	44	41 (93.2)	5.19 (1.13)	2.6	4.40	5.20	6.00	7.0	
		Week 28	Tezepelumab	40	39 (97.5)	5.36 (1.15)	2.8	4.40	5.60	6.20	7.0	
			Placebo	44	42 (95.5)	5.33 (1.21)	2.6	4.40	5.30	6.20	7.0	
		Week 32	Tezepelumab	40	39 (97.5)	5.35 (1.27)	2.6	4.40	5.80	6.40	7.0	
			Placebo	44	42 (95.5)	5.29 (1.19)	2.6	4.40	5.50	6.20	7.0	
		Week 36	Tezepelumab	40	39 (97.5)	5.44 (1.34)	2.8	4.20	6.00	6.60	7.0	
			Placebo	44	42 (95.5)	5.16 (1.20)	2.6	4.40	5.10	6.00	7.0	
		Week 40	Tezepelumab	40	39 (97.5)	5.27 (1.45)	1.8	4.20	5.40	6.60	7.0	
			Placebo	44	42 (95.5)	5.21 (1.25)	2.6	4.40	5.10	6.40	7.0	
		Week 44	Tezepelumab	40	39 (97.5)	5.45 (1.23)	2.8	4.40	5.80	6.60	7.0	
			Placebo	44	42 (95.5)	5.24 (1.25)	2.6	4.40	5.30	6.60	7.0	
		Week 48	Tezepelumab	40	39 (97.5)	5.40 (1.21)	2.6	4.60	5.60	6.40	7.0	
			Placebo	44	42 (95.5)	5.20 (1.25)	2.6	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	40	39 (97.5)	5.45 (1.22)	2.6	4.60	5.80	6.40	7.0	
			Placebo	44	42 (95.5)	5.24 (1.32)	2.2	4.20	5.10	6.60	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	40	32 (80.0)	0.48 (1.39)	-4.2	-0.30	0.60	1.40	3.0	-0.10 [-0.57, 0.38]
			Placebo	44	37 (84.1)	0.60 (1.10)	-2.2	0.20	0.40	1.20	3.0	
		Week 8	Tezepelumab	40	34 (85.0)	0.88 (1.16)	-1.2	-0.20	0.90	2.00	3.4	0.03 [-0.43, 0.50]
			Placebo	44	37 (84.1)	0.84 (1.22)	-1.6	0.20	0.80	1.20	4.0	
		Week 12	Tezepelumab	40	34 (85.0)	1.04 (1.26)	-2.4	0.40	1.00	1.80	3.6	0.04 [-0.43, 0.50]
			Placebo	44	37 (84.1)	0.99 (1.28)	-1.6	0.20	0.80	1.80	4.4	
		Week 16	Tezepelumab	40	34 (85.0)	0.95 (1.29)	-2.8	0.20	0.90	1.80	3.4	-0.07 [-0.54, 0.39]
			Placebo	44	37 (84.1)	1.04 (1.22)	-1.6	0.40	0.80	1.60	4.4	
		Week 20	Tezepelumab	40	34 (85.0)	1.13 (1.15)	-1.4	0.40	1.10	2.20	3.4	0.20 [-0.26, 0.67]
			Placebo	44	37 (84.1)	0.90 (1.13)	-1.4	0.20	0.80	1.60	4.2	
		Week 24	Tezepelumab	40	34 (85.0)	1.04 (1.27)	-1.4	0.40	0.90	2.00	3.8	0.05 [-0.42, 0.51]
			Placebo	44	37 (84.1)	0.98 (1.16)	-1.0	0.20	0.80	1.80	4.2	
		Week 28	Tezepelumab	40	34 (85.0)	1.02 (1.17)	-1.4	0.40	0.80	1.80	3.6	-0.08 [-0.54, 0.39]
			Placebo	44	37 (84.1)	1.12 (1.26)	-1.6	0.20	1.00	1.80	4.4	
		Week 32	Tezepelumab	40	34 (85.0)	1.06 (1.29)	-1.4	0.20	0.90	2.20	3.6	-0.02 [-0.48, 0.45]
			Placebo	44	37 (84.1)	1.09 (1.11)	-0.8	0.40	1.20	1.80	4.2	
		Week 36	Tezepelumab	40	34 (85.0)	1.19 (1.41)	-1.6	0.00	1.20	2.40	3.8	0.23 [-0.24, 0.70]
			Placebo	44	37 (84.1)	0.90 (1.09)	-1.4	0.40	0.60	1.80	3.8	
		Week 40	Tezepelumab	40	34 (85.0)	1.04 (1.44)	-2.4	0.60	1.00	2.20	3.4	0.03 [-0.44, 0.49]
			Placebo	44	37 (84.1)	1.00 (1.20)	-1.0	0.20	0.80	1.80	3.6	
		Week 44	Tezepelumab	40	34 (85.0)	1.15 (1.32)	-1.4	0.60	1.00	2.40	3.8	0.13 [-0.34, 0.59]
			Placebo	44	37 (84.1)	0.98 (1.22)	-1.0	0.40	0.80	1.60	4.2	
		Week 48	Tezepelumab	40	34 (85.0)	1.11 (1.36)	-1.4	0.40	1.00	2.20	3.8	0.10 [-0.37, 0.56]
			Placebo	44	37 (84.1)	0.98 (1.21)	-0.8	0.00	0.60	1.60	4.2	
		Week 52	Tezepelumab	40	34 (85.0)	1.14 (1.36)	-1.6	0.40	1.00	2.20	3.8	0.09 [-0.38, 0.56]
			Placebo	44	37 (84.1)	1.02 (1.27)	-1.6	0.00	0.80	1.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	3.53 (1.75)	1.6	1.60	4.00	5.00	5.0	
			Placebo	7	7 (100.0)	4.20 (0.92)	2.8	3.40	4.20	5.20	5.4	
		Week 4	Tezepelumab	3	3 (100.0)	4.47 (1.10)	3.4	3.40	4.40	5.60	5.6	
			Placebo	7	7 (100.0)	5.00 (1.18)	3.2	3.80	5.20	5.80	6.6	
		Week 8	Tezepelumab	3	3 (100.0)	4.07 (1.30)	2.8	2.80	4.00	5.40	5.4	
			Placebo	7	7 (100.0)	4.66 (1.14)	3.0	4.00	4.60	5.40	6.6	
		Week 12	Tezepelumab	3	3 (100.0)	5.07 (0.70)	4.4	4.40	5.00	5.80	5.8	
			Placebo	7	7 (100.0)	4.80 (0.95)	3.6	4.20	4.60	5.20	6.6	
		Week 16	Tezepelumab	3	3 (100.0)	4.87 (0.61)	4.2	4.20	5.00	5.40	5.4	
			Placebo	7	7 (100.0)	4.97 (1.03)	3.6	4.20	5.00	5.60	6.8	
		Week 20	Tezepelumab	3	3 (100.0)	5.20 (0.72)	4.4	4.40	5.40	5.80	5.8	
			Placebo	7	7 (100.0)	5.17 (0.89)	3.8	4.60	5.00	5.80	6.6	
		Week 24	Tezepelumab	3	3 (100.0)	4.47 (0.81)	4.0	4.00	4.00	5.40	5.4	
			Placebo	7	7 (100.0)	4.74 (1.08)	2.8	4.20	4.80	5.60	6.2	
		Week 28	Tezepelumab	3	3 (100.0)	4.93 (0.50)	4.4	4.40	5.00	5.40	5.4	
			Placebo	7	7 (100.0)	4.86 (0.85)	3.8	4.00	4.80	5.60	6.2	
		Week 32	Tezepelumab	3	3 (100.0)	5.27 (0.42)	4.8	4.80	5.40	5.60	5.6	
			Placebo	7	7 (100.0)	4.83 (1.32)	2.6	3.80	5.00	5.60	6.6	
		Week 36	Tezepelumab	3	3 (100.0)	5.53 (0.42)	5.2	5.20	5.40	6.00	6.0	
			Placebo	7	7 (100.0)	4.74 (1.43)	2.2	4.00	4.80	5.60	6.8	
		Week 40	Tezepelumab	3	3 (100.0)	5.60 (0.72)	5.0	5.00	5.40	6.40	6.4	
			Placebo	7	7 (100.0)	5.09 (1.19)	3.4	4.00	5.00	6.00	6.8	
		Week 44	Tezepelumab	3	3 (100.0)	5.60 (0.53)	5.2	5.20	5.40	6.20	6.2	
			Placebo	7	7 (100.0)	4.71 (1.48)	2.6	3.40	4.60	6.00	6.6	
		Week 48	Tezepelumab	3	3 (100.0)	5.47 (0.90)	4.6	4.60	5.40	6.40	6.4	
			Placebo	7	7 (100.0)	4.80 (1.31)	2.8	4.00	4.60	5.60	7.0	
		Week 52	Tezepelumab	3	3 (100.0)	5.47 (0.90)	4.6	4.60	5.40	6.40	6.4	
			Placebo	7	7 (100.0)	4.77 (1.29)	2.8	4.00	4.60	5.40	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	0.93 (1.33)	-0.6	-0.60	1.60	1.80	1.8	0.17 [-1.18, 1.53]
			Placebo	7	7 (100.0)	0.80 (0.48)	0.4	0.40	0.60	1.20	1.6	
		Week 8	Tezepelumab	3	3 (100.0)	0.53 (2.42)	-2.2	-2.20	1.40	2.40	2.4	0.05 [-1.30, 1.40]
			Placebo	7	7 (100.0)	0.46 (0.96)	-1.2	-0.40	0.60	1.20	1.4	
		Week 12	Tezepelumab	3	3 (100.0)	1.53 (1.42)	0.0	0.00	1.80	2.80	2.8	0.94 [-0.49, 2.36]
			Placebo	7	7 (100.0)	0.60 (0.81)	-0.6	0.00	0.80	1.20	1.6	
		Week 16	Tezepelumab	3	3 (100.0)	1.33 (1.30)	0.0	0.00	1.40	2.60	2.6	0.65 [-0.74, 2.04]
			Placebo	7	7 (100.0)	0.77 (0.65)	-0.2	0.00	0.80	1.40	1.4	
		Week 20	Tezepelumab	3	3 (100.0)	1.67 (1.03)	0.8	0.80	1.40	2.80	2.8	1.09 [-0.37, 2.54]
			Placebo	7	7 (100.0)	0.97 (0.44)	0.2	0.80	1.00	1.20	1.6	
		Week 24	Tezepelumab	3	3 (100.0)	0.93 (1.75)	-1.0	-1.00	1.40	2.40	2.4	0.37 [-0.99, 1.74]
			Placebo	7	7 (100.0)	0.54 (0.68)	-0.4	0.00	0.80	1.20	1.4	
		Week 28	Tezepelumab	3	3 (100.0)	1.40 (1.40)	0.0	0.00	1.40	2.80	2.8	0.88 [-0.54, 2.30]
			Placebo	7	7 (100.0)	0.66 (0.55)	-0.4	0.40	0.80	1.20	1.2	
		Week 32	Tezepelumab	3	3 (100.0)	1.73 (1.33)	0.6	0.60	1.40	3.20	3.2	1.21 [-0.26, 2.69]
			Placebo	7	7 (100.0)	0.63 (0.72)	-0.4	-0.20	0.80	1.20	1.4	
		Week 36	Tezepelumab	3	3 (100.0)	2.00 (1.40)	1.0	1.00	1.40	3.60	3.6	1.54 [-0.01, 3.09]
			Placebo	7	7 (100.0)	0.54 (0.74)	-0.6	-0.20	0.60	1.20	1.4	
		Week 40	Tezepelumab	3	3 (100.0)	2.07 (1.15)	1.4	1.40	1.40	3.40	3.4	1.31 [-0.19, 2.81]
			Placebo	7	7 (100.0)	0.89 (0.80)	-0.8	0.80	1.20	1.40	1.6	
		Week 44	Tezepelumab	3	3 (100.0)	2.07 (1.33)	1.2	1.20	1.40	3.60	3.6	1.32 [-0.18, 2.81]
			Placebo	7	7 (100.0)	0.51 (1.12)	-1.6	-0.20	0.60	1.20	1.8	
		Week 48	Tezepelumab	3	3 (100.0)	1.93 (0.92)	1.4	1.40	1.40	3.00	3.0	1.84 [0.22, 3.47]
			Placebo	7	7 (100.0)	0.60 (0.64)	-0.2	0.00	0.40	1.20	1.6	
		Week 52	Tezepelumab	3	3 (100.0)	1.93 (0.92)	1.4	1.40	1.40	3.00	3.0	1.86 [0.23, 3.49]
			Placebo	7	7 (100.0)	0.57 (0.66)	-0.2	0.00	0.40	1.20	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.08 (1.04)	2.2	3.60	4.10	4.70	5.6	
			Placebo	13	9 (69.2)	4.53 (1.06)	3.4	4.20	4.20	4.60	7.0	
		Week 4	Tezepelumab	9	8 (88.9)	5.00 (0.96)	3.8	4.10	5.00	5.90	6.2	
			Placebo	13	11 (84.6)	5.02 (1.58)	1.6	3.80	4.80	6.40	7.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.50 (1.04)	4.0	4.70	5.60	6.20	7.0	
			Placebo	13	12 (92.3)	4.75 (1.27)	3.0	3.80	4.80	5.60	7.0	
		Week 12	Tezepelumab	9	8 (88.9)	5.55 (1.08)	4.0	4.70	5.60	6.40	7.0	
			Placebo	13	12 (92.3)	4.65 (1.47)	1.8	3.60	4.50	6.10	7.0	
		Week 16	Tezepelumab	9	8 (88.9)	5.85 (1.06)	4.0	5.20	5.90	6.80	7.0	
			Placebo	13	12 (92.3)	4.95 (1.21)	2.6	4.30	4.80	5.90	7.0	
		Week 20	Tezepelumab	9	8 (88.9)	5.35 (1.02)	4.0	4.50	5.20	6.30	6.8	
			Placebo	13	12 (92.3)	5.10 (1.08)	3.0	4.50	4.90	5.90	7.0	
		Week 24	Tezepelumab	9	8 (88.9)	5.48 (1.12)	4.0	4.50	5.60	6.30	7.0	
			Placebo	13	12 (92.3)	4.93 (1.18)	2.8	4.30	4.70	5.80	7.0	
		Week 28	Tezepelumab	9	8 (88.9)	5.33 (0.99)	4.0	4.50	5.30	6.20	6.6	
			Placebo	13	13 (100.0)	4.97 (1.28)	2.6	4.40	4.60	6.00	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.43 (1.04)	4.0	4.60	5.40	6.20	7.0	
			Placebo	13	13 (100.0)	5.05 (1.39)	2.2	4.40	4.60	6.00	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.43 (1.09)	4.0	4.40	5.60	6.20	7.0	
			Placebo	13	13 (100.0)	5.03 (1.48)	1.6	4.40	4.80	6.00	7.0	
		Week 40	Tezepelumab	9	8 (88.9)	5.25 (1.20)	3.8	4.20	5.10	6.30	7.0	
			Placebo	13	13 (100.0)	4.88 (1.57)	1.6	4.20	4.60	6.00	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.45 (1.09)	4.0	4.50	5.50	6.30	7.0	
			Placebo	13	13 (100.0)	4.89 (1.59)	1.8	4.40	4.60	6.00	7.0	
		Week 48	Tezepelumab	9	8 (88.9)	5.25 (0.94)	4.0	4.30	5.50	6.00	6.4	
			Placebo	13	13 (100.0)	4.97 (1.58)	1.4	4.40	4.80	6.00	7.0	
		Week 52	Tezepelumab	9	8 (88.9)	5.43 (1.12)	4.0	4.30	5.70	6.20	7.0	
			Placebo	13	13 (100.0)	4.97 (1.47)	2.0	4.40	4.80	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.89 (0.75)	0.2	0.20	0.60	1.80	2.0	0.41 [-0.59, 1.41]
			Placebo	13	9 (69.2)	0.47 (1.19)	-2.0	0.20	0.40	1.60	1.8	
		Week 8	Tezepelumab	9	7 (77.8)	1.34 (0.67)	0.4	1.00	1.20	2.00	2.4	0.94 [-0.11, 1.98]
			Placebo	13	9 (69.2)	0.40 (1.20)	-1.2	-0.60	0.60	1.20	1.8	
		Week 12	Tezepelumab	9	7 (77.8)	1.43 (0.98)	0.2	0.40	1.40	2.20	3.0	1.15 [0.08, 2.23]
			Placebo	13	9 (69.2)	0.09 (1.28)	-1.8	-0.80	0.00	1.20	1.8	
		Week 16	Tezepelumab	9	7 (77.8)	1.66 (1.02)	0.4	1.00	1.40	2.60	3.4	1.13 [0.06, 2.21]
			Placebo	13	9 (69.2)	0.49 (1.04)	-1.0	0.00	0.40	1.40	1.8	
		Week 20	Tezepelumab	9	7 (77.8)	1.43 (0.98)	0.4	0.60	1.20	2.20	3.2	0.78 [-0.25, 1.81]
			Placebo	13	9 (69.2)	0.64 (1.03)	-1.0	-0.20	0.80	1.60	1.8	
		Week 24	Tezepelumab	9	7 (77.8)	1.49 (1.30)	0.0	0.40	1.40	2.40	3.8	0.75 [-0.28, 1.77]
			Placebo	13	9 (69.2)	0.58 (1.15)	-1.0	-0.20	0.60	1.40	2.2	
		Week 28	Tezepelumab	9	7 (77.8)	1.34 (1.19)	0.4	0.60	0.80	2.40	3.6	0.80 [-0.23, 1.83]
			Placebo	13	9 (69.2)	0.42 (1.11)	-1.0	-0.40	0.60	1.20	1.8	
		Week 32	Tezepelumab	9	7 (77.8)	1.46 (1.14)	0.4	0.40	1.40	2.20	3.6	0.73 [-0.29, 1.75]
			Placebo	13	9 (69.2)	0.56 (1.30)	-1.4	-0.40	1.20	1.80	1.8	
		Week 36	Tezepelumab	9	7 (77.8)	1.54 (1.14)	0.4	0.80	1.20	2.20	3.8	0.85 [-0.19, 1.88]
			Placebo	13	9 (69.2)	0.44 (1.40)	-2.0	-0.20	1.00	1.20	2.4	
		Week 40	Tezepelumab	9	7 (77.8)	1.26 (1.18)	-0.2	0.40	0.80	2.40	3.2	0.66 [-0.36, 1.67]
			Placebo	13	9 (69.2)	0.38 (1.45)	-2.0	-0.80	0.60	1.60	2.2	
		Week 44	Tezepelumab	9	7 (77.8)	1.49 (1.28)	0.2	0.40	1.40	2.40	3.8	0.94 [-0.11, 1.99]
			Placebo	13	9 (69.2)	0.16 (1.51)	-1.8	-1.00	-0.20	1.80	1.8	
		Week 48	Tezepelumab	9	7 (77.8)	1.29 (1.33)	0.0	0.40	0.80	2.20	3.8	0.65 [-0.37, 1.66]
			Placebo	13	9 (69.2)	0.38 (1.46)	-2.2	-0.20	0.60	1.20	2.6	
		Week 52	Tezepelumab	9	7 (77.8)	1.49 (1.20)	0.4	0.40	1.40	2.20	3.8	0.81 [-0.22, 1.84]
			Placebo	13	9 (69.2)	0.44 (1.34)	-1.6	-0.20	0.60	1.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.29 (1.19)	1.4	3.60	4.30	5.00	6.4	
			Placebo	52	46 (88.5)	4.36 (1.19)	1.0	3.80	4.30	5.20	6.8	
		Week 4	Tezepelumab	57	52 (91.2)	4.86 (1.20)	1.2	4.00	4.80	5.90	7.0	
			Placebo	52	46 (88.5)	4.87 (1.23)	1.6	4.20	4.80	5.60	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.11 (1.23)	2.8	4.20	5.10	6.00	7.0	
			Placebo	52	47 (90.4)	5.03 (1.13)	2.0	4.40	5.00	5.80	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.34 (1.19)	2.8	4.40	5.40	6.40	7.0	
			Placebo	52	47 (90.4)	5.23 (1.14)	2.6	4.20	5.20	6.20	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.23 (1.21)	2.6	4.40	5.20	6.20	7.0	
			Placebo	52	47 (90.4)	5.12 (1.32)	1.0	4.40	5.00	6.00	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.39 (1.19)	2.4	4.40	5.60	6.40	7.0	
			Placebo	52	47 (90.4)	5.01 (1.30)	1.0	4.00	5.00	6.20	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.25 (1.26)	2.0	4.20	5.40	6.40	7.0	
			Placebo	52	47 (90.4)	5.01 (1.33)	1.0	4.40	5.20	6.00	7.0	
		Week 28	Tezepelumab	57	57 (100.0)	5.38 (1.15)	2.8	4.40	5.40	6.40	7.0	
			Placebo	52	47 (90.4)	5.11 (1.35)	1.0	4.00	5.20	6.00	7.0	
		Week 32	Tezepelumab	57	57 (100.0)	5.34 (1.20)	2.6	4.40	5.60	6.40	7.0	
			Placebo	52	47 (90.4)	5.10 (1.33)	1.0	4.00	5.20	6.00	7.0	
		Week 36	Tezepelumab	57	57 (100.0)	5.50 (1.25)	2.8	4.60	5.60	6.60	7.0	
			Placebo	52	47 (90.4)	5.06 (1.23)	2.2	4.40	5.00	6.00	7.0	
		Week 40	Tezepelumab	57	57 (100.0)	5.29 (1.33)	1.8	4.20	5.40	6.40	7.0	
			Placebo	52	47 (90.4)	5.14 (1.23)	2.6	4.40	5.20	6.40	7.0	
		Week 44	Tezepelumab	57	57 (100.0)	5.40 (1.18)	2.8	4.40	5.40	6.40	7.0	
			Placebo	52	47 (90.4)	5.12 (1.25)	2.6	4.00	5.20	6.40	7.0	
		Week 48	Tezepelumab	57	57 (100.0)	5.42 (1.20)	2.6	4.60	5.40	6.40	7.0	
			Placebo	52	47 (90.4)	5.09 (1.26)	2.6	4.00	5.00	6.20	7.0	
		Week 52	Tezepelumab	57	57 (100.0)	5.42 (1.19)	2.6	4.60	5.40	6.40	7.0	
			Placebo	52	47 (90.4)	5.05 (1.33)	2.2	4.00	5.00	6.20	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	0.58 (1.40)	-4.2	-0.30	0.60	1.60	3.8	0.03 [-0.37, 0.44]
			Placebo	52	45 (86.5)	0.54 (1.03)	-2.2	0.00	0.40	1.00	3.0	
		Week 8	Tezepelumab	57	50 (87.7)	0.77 (1.37)	-2.2	-0.20	0.70	1.60	4.4	0.08 [-0.32, 0.48]
			Placebo	52	46 (88.5)	0.67 (1.17)	-1.6	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	57	50 (87.7)	1.00 (1.27)	-2.4	0.00	1.00	1.80	3.8	0.10 [-0.30, 0.50]
			Placebo	52	46 (88.5)	0.87 (1.21)	-1.6	0.20	0.80	1.60	4.4	
		Week 16	Tezepelumab	57	50 (87.7)	0.90 (1.28)	-2.8	0.00	1.00	1.80	4.0	0.10 [-0.30, 0.50]
			Placebo	52	46 (88.5)	0.77 (1.36)	-3.4	0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	57	50 (87.7)	1.10 (1.22)	-1.4	0.20	1.10	2.00	4.6	0.33 [-0.07, 0.73]
			Placebo	52	46 (88.5)	0.68 (1.29)	-3.4	0.00	0.80	1.40	4.2	
		Week 24	Tezepelumab	57	50 (87.7)	0.95 (1.29)	-1.4	0.00	1.00	1.80	4.6	0.23 [-0.17, 0.63]
			Placebo	52	46 (88.5)	0.65 (1.33)	-3.4	0.00	0.40	1.60	4.2	
		Week 28	Tezepelumab	57	50 (87.7)	1.03 (1.26)	-1.4	0.00	1.00	1.80	4.6	0.19 [-0.22, 0.59]
			Placebo	52	46 (88.5)	0.77 (1.47)	-3.4	0.00	0.80	1.60	4.4	
		Week 32	Tezepelumab	57	50 (87.7)	0.98 (1.31)	-1.6	0.00	0.90	2.00	4.6	0.17 [-0.23, 0.57]
			Placebo	52	46 (88.5)	0.77 (1.26)	-3.4	0.00	0.70	1.40	4.2	
		Week 36	Tezepelumab	57	50 (87.7)	1.18 (1.42)	-1.6	0.00	1.20	2.00	4.6	0.36 [-0.04, 0.77]
			Placebo	52	46 (88.5)	0.72 (1.05)	-1.4	0.20	0.60	1.40	3.8	
		Week 40	Tezepelumab	57	50 (87.7)	1.00 (1.41)	-2.4	0.00	1.00	2.00	4.6	0.15 [-0.25, 0.55]
			Placebo	52	46 (88.5)	0.80 (1.24)	-1.6	-0.20	0.80	1.60	3.6	
		Week 44	Tezepelumab	57	50 (87.7)	1.04 (1.31)	-1.4	0.00	1.20	1.60	4.6	0.20 [-0.20, 0.61]
			Placebo	52	46 (88.5)	0.79 (1.20)	-1.0	-0.20	0.70	1.20	4.2	
		Week 48	Tezepelumab	57	50 (87.7)	1.08 (1.30)	-1.4	0.20	1.20	1.80	4.6	0.26 [-0.14, 0.66]
			Placebo	52	46 (88.5)	0.76 (1.19)	-1.0	0.00	0.60	1.40	4.2	
		Week 52	Tezepelumab	57	50 (87.7)	1.07 (1.32)	-1.6	0.00	1.20	1.80	4.6	0.27 [-0.14, 0.67]
			Placebo	52	46 (88.5)	0.71 (1.35)	-2.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	4.53 (0.65)	3.6	4.00	4.60	5.20	5.2	
			Placebo	3	2 (66.7)	3.80 (0.28)	3.6	3.60	3.80	4.00	4.0	
		Week 4	Tezepelumab	7	7 (100.0)	5.03 (1.19)	4.0	4.00	4.80	6.20	7.0	
			Placebo	3	3 (100.0)	3.73 (2.10)	1.6	1.60	3.80	5.80	5.8	
		Week 8	Tezepelumab	7	7 (100.0)	5.74 (0.91)	4.4	4.80	5.80	6.40	7.0	
			Placebo	3	3 (100.0)	4.20 (1.31)	3.0	3.00	4.00	5.60	5.6	
		Week 12	Tezepelumab	7	7 (100.0)	5.83 (0.92)	4.6	5.00	5.60	6.80	7.0	
			Placebo	3	3 (100.0)	3.87 (1.81)	1.8	1.80	4.60	5.20	5.2	
		Week 16	Tezepelumab	7	7 (100.0)	5.51 (1.09)	4.0	4.40	5.60	6.60	6.8	
			Placebo	3	3 (100.0)	3.73 (1.03)	2.6	2.60	4.00	4.60	4.6	
		Week 20	Tezepelumab	7	7 (100.0)	5.34 (0.84)	4.0	4.60	5.60	6.20	6.2	
			Placebo	3	3 (100.0)	3.93 (0.90)	3.0	3.00	4.00	4.80	4.8	
		Week 24	Tezepelumab	7	7 (100.0)	5.51 (1.08)	3.4	4.80	5.80	6.40	6.4	
			Placebo	3	3 (100.0)	3.80 (1.00)	2.8	2.80	3.80	4.80	4.8	
		Week 28	Tezepelumab	7	7 (100.0)	5.54 (0.81)	4.4	4.80	5.80	6.40	6.4	
			Placebo	3	3 (100.0)	3.67 (0.95)	2.6	2.60	4.00	4.40	4.4	
		Week 32	Tezepelumab	7	7 (100.0)	5.51 (1.01)	3.6	5.00	6.00	6.40	6.4	
			Placebo	3	3 (100.0)	3.47 (1.14)	2.2	2.20	3.80	4.40	4.4	
		Week 36	Tezepelumab	7	7 (100.0)	5.51 (0.82)	4.0	4.80	6.00	6.00	6.2	
			Placebo	3	3 (100.0)	3.60 (1.74)	1.6	1.60	4.40	4.80	4.8	
		Week 40	Tezepelumab	7	7 (100.0)	5.69 (0.75)	4.6	5.00	5.80	6.20	6.8	
			Placebo	3	3 (100.0)	3.13 (1.36)	1.6	1.60	3.60	4.20	4.2	
		Week 44	Tezepelumab	7	7 (100.0)	5.54 (0.67)	4.8	4.80	5.80	6.20	6.4	
			Placebo	3	3 (100.0)	3.60 (1.80)	1.8	1.80	3.60	5.40	5.4	
		Week 48	Tezepelumab	7	7 (100.0)	5.63 (0.87)	4.2	5.00	5.80	6.00	7.0	
			Placebo	3	3 (100.0)	3.60 (2.03)	1.4	1.40	4.00	5.40	5.4	
		Week 52	Tezepelumab	7	7 (100.0)	5.63 (0.87)	4.2	5.00	5.80	6.00	7.0	
			Placebo	3	3 (100.0)	3.47 (1.40)	2.0	2.00	3.60	4.80	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	0.67 (0.91)	-0.4	0.00	0.60	1.00	2.2	0.56 [-1.07, 2.19]
			Placebo	3	2 (66.7)	-0.10 (2.69)	-2.0	-2.00	-0.10	1.80	1.8	
		Week 8	Tezepelumab	7	6 (85.7)	1.20 (0.89)	0.4	0.40	0.90	2.20	2.4	0.68 [-0.97, 2.33]
			Placebo	3	2 (66.7)	0.50 (1.56)	-0.6	-0.60	0.50	1.60	1.6	
		Week 12	Tezepelumab	7	6 (85.7)	1.13 (0.59)	0.4	1.00	1.00	1.20	2.2	1.41 [-0.38, 3.19]
			Placebo	3	2 (66.7)	-0.30 (2.12)	-1.8	-1.80	-0.30	1.20	1.2	
		Week 16	Tezepelumab	7	6 (85.7)	0.80 (0.79)	-0.4	0.40	0.90	1.00	2.0	1.67 [-0.19, 3.53]
			Placebo	3	2 (66.7)	-0.50 (0.71)	-1.0	-1.00	-0.50	0.00	0.0	
		Week 20	Tezepelumab	7	6 (85.7)	0.67 (0.37)	0.2	0.40	0.70	1.00	1.0	2.53 [0.39, 4.68]
			Placebo	3	2 (66.7)	-0.30 (0.42)	-0.6	-0.60	-0.30	0.00	0.0	
		Week 24	Tezepelumab	7	6 (85.7)	0.83 (0.75)	-0.2	0.40	0.70	1.60	1.8	1.88 [-0.04, 3.80]
			Placebo	3	2 (66.7)	-0.50 (0.42)	-0.8	-0.80	-0.50	-0.20	-0.2	
		Week 28	Tezepelumab	7	6 (85.7)	0.87 (0.41)	0.4	0.60	0.80	1.00	1.6	2.88 [0.59, 5.16]
			Placebo	3	2 (66.7)	-0.50 (0.71)	-1.0	-1.00	-0.50	0.00	0.0	
		Week 32	Tezepelumab	7	6 (85.7)	0.90 (0.53)	0.0	0.80	0.90	1.20	1.6	2.85 [0.58, 5.12]
			Placebo	3	2 (66.7)	-0.80 (0.85)	-1.4	-1.40	-0.80	-0.20	-0.2	
		Week 36	Tezepelumab	7	6 (85.7)	0.87 (0.30)	0.4	0.80	0.80	1.20	1.2	2.24 [0.20, 4.28]
			Placebo	3	2 (66.7)	-0.80 (1.70)	-2.0	-2.00	-0.80	0.40	0.4	
		Week 40	Tezepelumab	7	6 (85.7)	1.07 (0.48)	0.6	0.80	1.00	1.00	2.0	3.54 [0.98, 6.11]
			Placebo	3	2 (66.7)	-1.20 (1.13)	-2.0	-2.00	-1.20	-0.40	-0.4	
		Week 44	Tezepelumab	7	6 (85.7)	0.90 (0.41)	0.6	0.60	0.70	1.20	1.6	3.61 [1.02, 6.21]
			Placebo	3	2 (66.7)	-1.10 (0.99)	-1.8	-1.80	-1.10	-0.40	-0.4	
		Week 48	Tezepelumab	7	6 (85.7)	1.07 (0.60)	0.6	0.60	0.90	1.20	2.2	2.58 [0.41, 4.75]
			Placebo	3	2 (66.7)	-1.10 (1.56)	-2.2	-2.20	-1.10	0.00	0.0	
		Week 52	Tezepelumab	7	6 (85.7)	1.07 (0.60)	0.6	0.60	0.90	1.20	2.2	3.18 [0.77, 5.59]
			Placebo	3	2 (66.7)	-1.00 (0.85)	-1.6	-1.60	-1.00	-0.40	-0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	59	52 (88.1)	4.23 (1.21)	1.4	3.50	4.20	5.00	6.4	
			Placebo	62	53 (85.5)	4.41 (1.18)	1.0	3.80	4.40	5.20	7.0	
		Week 4	Tezepelumab	59	53 (89.8)	4.86 (1.18)	1.2	4.00	4.80	5.80	7.0	
			Placebo	62	54 (87.1)	4.97 (1.23)	1.6	4.20	4.80	5.80	7.0	
		Week 8	Tezepelumab	59	55 (93.2)	5.09 (1.22)	2.8	4.00	5.00	6.20	7.0	
			Placebo	62	56 (90.3)	5.01 (1.14)	2.0	4.30	5.00	5.80	7.0	
		Week 12	Tezepelumab	59	55 (93.2)	5.31 (1.20)	2.8	4.40	5.20	6.40	7.0	
			Placebo	62	56 (90.3)	5.17 (1.17)	2.6	4.20	5.20	6.20	7.0	
		Week 16	Tezepelumab	59	55 (93.2)	5.29 (1.23)	2.6	4.40	5.60	6.20	7.0	
			Placebo	62	56 (90.3)	5.16 (1.27)	1.0	4.50	5.00	6.00	7.0	
		Week 20	Tezepelumab	59	56 (94.9)	5.39 (1.20)	2.4	4.40	5.60	6.40	7.0	
			Placebo	62	56 (90.3)	5.09 (1.25)	1.0	4.40	5.00	6.00	7.0	
		Week 24	Tezepelumab	59	56 (94.9)	5.25 (1.26)	2.0	4.10	5.30	6.30	7.0	
			Placebo	62	56 (90.3)	5.06 (1.28)	1.0	4.40	5.10	6.00	7.0	
		Week 28	Tezepelumab	59	58 (98.3)	5.35 (1.16)	2.8	4.20	5.40	6.40	7.0	
			Placebo	62	57 (91.9)	5.15 (1.31)	1.0	4.40	5.20	6.00	7.0	
		Week 32	Tezepelumab	59	58 (98.3)	5.33 (1.20)	2.6	4.40	5.50	6.40	7.0	
			Placebo	62	57 (91.9)	5.17 (1.29)	1.0	4.40	5.20	6.00	7.0	
		Week 36	Tezepelumab	59	58 (98.3)	5.49 (1.27)	2.8	4.40	5.60	6.60	7.0	
			Placebo	62	57 (91.9)	5.13 (1.22)	2.2	4.40	5.20	6.00	7.0	
		Week 40	Tezepelumab	59	58 (98.3)	5.24 (1.35)	1.8	4.20	5.40	6.40	7.0	
			Placebo	62	57 (91.9)	5.19 (1.23)	2.6	4.40	5.20	6.40	7.0	
		Week 44	Tezepelumab	59	58 (98.3)	5.39 (1.21)	2.8	4.40	5.40	6.60	7.0	
			Placebo	62	57 (91.9)	5.15 (1.27)	2.6	4.40	5.20	6.20	7.0	
		Week 48	Tezepelumab	59	58 (98.3)	5.38 (1.20)	2.6	4.60	5.40	6.40	7.0	
			Placebo	62	57 (91.9)	5.14 (1.25)	2.6	4.00	5.00	6.20	7.0	
		Week 52	Tezepelumab	59	58 (98.3)	5.40 (1.21)	2.6	4.40	5.40	6.40	7.0	
			Placebo	62	57 (91.9)	5.12 (1.31)	2.2	4.00	5.00	6.20	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	59	49 (83.1)	0.62 (1.39)	-4.2	-0.20	0.60	1.60	3.8	0.05 [-0.34, 0.44]
			Placebo	62	52 (83.9)	0.55 (0.99)	-2.2	0.00	0.40	1.10	3.0	
		Week 8	Tezepelumab	59	51 (86.4)	0.80 (1.35)	-2.2	-0.20	1.00	1.60	4.4	0.13 [-0.25, 0.52]
			Placebo	62	53 (85.5)	0.63 (1.17)	-1.6	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	59	51 (86.4)	1.04 (1.30)	-2.4	0.00	1.20	1.80	3.8	0.21 [-0.18, 0.59]
			Placebo	62	53 (85.5)	0.78 (1.21)	-1.6	0.00	0.80	1.60	4.4	
		Week 16	Tezepelumab	59	51 (86.4)	1.02 (1.31)	-2.8	0.00	1.00	2.00	4.0	0.19 [-0.19, 0.58]
			Placebo	62	53 (85.5)	0.77 (1.31)	-3.4	0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	59	51 (86.4)	1.19 (1.24)	-1.4	0.40	1.20	2.20	4.6	0.38 [-0.00, 0.77]
			Placebo	62	53 (85.5)	0.71 (1.25)	-3.4	0.00	0.80	1.60	4.2	
		Week 24	Tezepelumab	59	51 (86.4)	1.04 (1.35)	-1.4	0.00	1.00	2.00	4.6	0.27 [-0.12, 0.66]
			Placebo	62	53 (85.5)	0.68 (1.30)	-3.4	0.00	0.60	1.60	4.2	
		Week 28	Tezepelumab	59	51 (86.4)	1.09 (1.31)	-1.4	0.00	1.00	2.00	4.6	0.24 [-0.15, 0.63]
			Placebo	62	53 (85.5)	0.76 (1.42)	-3.4	0.00	0.80	1.60	4.4	
		Week 32	Tezepelumab	59	51 (86.4)	1.06 (1.36)	-1.6	0.00	1.20	2.20	4.6	0.21 [-0.18, 0.59]
			Placebo	62	53 (85.5)	0.79 (1.24)	-3.4	0.00	0.80	1.40	4.2	
		Week 36	Tezepelumab	59	51 (86.4)	1.26 (1.46)	-1.6	0.00	1.20	2.40	4.6	0.42 [0.03, 0.81]
			Placebo	62	53 (85.5)	0.73 (1.06)	-1.4	0.20	0.60	1.40	3.8	
		Week 40	Tezepelumab	59	51 (86.4)	1.02 (1.45)	-2.4	0.00	1.20	2.00	4.6	0.16 [-0.22, 0.55]
			Placebo	62	53 (85.5)	0.80 (1.23)	-1.6	-0.20	0.80	1.60	3.6	
		Week 44	Tezepelumab	59	51 (86.4)	1.12 (1.37)	-1.4	0.00	1.40	2.00	4.6	0.29 [-0.10, 0.67]
			Placebo	62	53 (85.5)	0.75 (1.23)	-1.6	-0.20	0.80	1.20	4.2	
		Week 48	Tezepelumab	59	51 (86.4)	1.11 (1.35)	-1.4	0.00	1.20	2.00	4.6	0.27 [-0.11, 0.66]
			Placebo	62	53 (85.5)	0.77 (1.18)	-1.0	-0.20	0.60	1.40	4.2	
		Week 52	Tezepelumab	59	51 (86.4)	1.13 (1.37)	-1.6	0.00	1.40	2.00	4.6	0.29 [-0.09, 0.68]
			Placebo	62	53 (85.5)	0.73 (1.32)	-2.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	4.56 (0.73)	3.6	4.00	4.80	5.20	5.2	
			Placebo	2	1 (50.0)	4.00	4.0	4.00	4.00	4.00	4.0	
		Week 4	Tezepelumab	6	6 (100.0)	5.20 (1.21)	4.0	4.00	5.00	6.20	7.0	
			Placebo	2	2 (100.0)	4.80 (1.41)	3.8	3.80	4.80	5.80	5.8	
		Week 8	Tezepelumab	6	6 (100.0)	5.90 (0.88)	4.4	5.60	6.00	6.40	7.0	
			Placebo	2	2 (100.0)	4.80 (1.13)	4.0	4.00	4.80	5.60	5.6	
		Week 12	Tezepelumab	6	6 (100.0)	5.90 (0.99)	4.6	5.00	6.00	6.80	7.0	
			Placebo	2	2 (100.0)	4.90 (0.42)	4.6	4.60	4.90	5.20	5.2	
		Week 16	Tezepelumab	6	6 (100.0)	5.77 (0.94)	4.4	5.00	5.90	6.60	6.8	
			Placebo	2	2 (100.0)	4.30 (0.42)	4.0	4.00	4.30	4.60	4.6	
		Week 20	Tezepelumab	6	6 (100.0)	5.47 (0.85)	4.0	5.00	5.70	6.20	6.2	
			Placebo	2	2 (100.0)	4.40 (0.57)	4.0	4.00	4.40	4.80	4.8	
		Week 24	Tezepelumab	6	6 (100.0)	5.63 (1.13)	3.4	5.80	5.90	6.40	6.4	
			Placebo	2	2 (100.0)	4.30 (0.71)	3.8	3.80	4.30	4.80	4.8	
		Week 28	Tezepelumab	6	6 (100.0)	5.67 (0.81)	4.4	5.00	5.90	6.40	6.4	
			Placebo	2	2 (100.0)	4.20 (0.28)	4.0	4.00	4.20	4.40	4.4	
		Week 32	Tezepelumab	6	6 (100.0)	5.57 (1.09)	3.6	5.00	6.00	6.40	6.4	
			Placebo	2	2 (100.0)	4.10 (0.42)	3.8	3.80	4.10	4.40	4.4	
		Week 36	Tezepelumab	6	6 (100.0)	5.50 (0.89)	4.0	4.80	6.00	6.00	6.2	
			Placebo	2	2 (100.0)	4.60 (0.28)	4.4	4.40	4.60	4.80	4.8	
		Week 40	Tezepelumab	6	6 (100.0)	5.73 (0.81)	4.6	5.00	5.90	6.20	6.8	
			Placebo	2	2 (100.0)	3.90 (0.42)	3.6	3.60	3.90	4.20	4.2	
		Week 44	Tezepelumab	6	6 (100.0)	5.63 (0.69)	4.8	4.80	5.80	6.20	6.4	
			Placebo	2	2 (100.0)	4.50 (1.27)	3.6	3.60	4.50	5.40	5.4	
		Week 48	Tezepelumab	6	6 (100.0)	5.63 (0.95)	4.2	5.00	5.80	6.00	7.0	
			Placebo	2	2 (100.0)	4.70 (0.99)	4.0	4.00	4.70	5.40	5.4	
		Week 52	Tezepelumab	6	6 (100.0)	5.63 (0.95)	4.2	5.00	5.80	6.00	7.0	
			Placebo	2	2 (100.0)	4.20 (0.85)	3.6	3.60	4.20	4.80	4.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	6	5 (83.3)	0.88 (0.83)	0.0	0.40	0.80	1.00	2.2	NE
			Placebo	2	1 (50.0)	1.80	1.8	1.80	1.80	1.80	1.8	
		Week 8	Tezepelumab	6	5 (83.3)	1.36 (0.89)	0.4	0.80	1.00	2.20	2.4	NE
			Placebo	2	1 (50.0)	1.60	1.6	1.60	1.60	1.60	1.6	
		Week 12	Tezepelumab	6	5 (83.3)	1.16 (0.65)	0.4	1.00	1.00	1.20	2.2	NE
			Placebo	2	1 (50.0)	1.20	1.2	1.20	1.20	1.20	1.2	
		Week 16	Tezepelumab	6	5 (83.3)	1.04 (0.59)	0.4	0.80	1.00	1.00	2.0	NE
			Placebo	2	1 (50.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 20	Tezepelumab	6	5 (83.3)	0.76 (0.33)	0.4	0.40	1.00	1.00	1.0	NE
			Placebo	2	1 (50.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 24	Tezepelumab	6	5 (83.3)	0.92 (0.81)	-0.2	0.60	0.80	1.60	1.8	NE
			Placebo	2	1 (50.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	
		Week 28	Tezepelumab	6	5 (83.3)	0.96 (0.38)	0.6	0.80	0.80	1.00	1.6	NE
			Placebo	2	1 (50.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 32	Tezepelumab	6	5 (83.3)	0.92 (0.59)	0.0	0.80	1.00	1.20	1.6	NE
			Placebo	2	1 (50.0)	-0.20	-0.2	-0.20	-0.20	-0.20	-0.2	
		Week 36	Tezepelumab	6	5 (83.3)	0.80 (0.28)	0.4	0.80	0.80	0.80	1.2	NE
			Placebo	2	1 (50.0)	0.40	0.4	0.40	0.40	0.40	0.4	
		Week 40	Tezepelumab	6	5 (83.3)	1.08 (0.54)	0.6	0.80	1.00	1.00	2.0	NE
			Placebo	2	1 (50.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	
		Week 44	Tezepelumab	6	5 (83.3)	0.96 (0.43)	0.6	0.60	0.80	1.20	1.6	NE
			Placebo	2	1 (50.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	
		Week 48	Tezepelumab	6	5 (83.3)	1.04 (0.67)	0.6	0.60	0.80	1.00	2.2	NE
			Placebo	2	1 (50.0)	0.00	0.0	0.00	0.00	0.00	0.0	
		Week 52	Tezepelumab	6	5 (83.3)	1.04 (0.67)	0.6	0.60	0.80	1.00	2.2	NE
			Placebo	2	1 (50.0)	-0.40	-0.4	-0.40	-0.40	-0.40	-0.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	4.23 (1.19)	1.4	3.60	4.20	5.00	6.4	
			Placebo	63	54 (85.7)	4.39 (1.17)	1.0	3.80	4.30	5.20	7.0	
		Week 4	Tezepelumab	60	54 (90.0)	4.84 (1.17)	1.2	4.00	4.80	5.80	7.0	
			Placebo	63	55 (87.3)	4.91 (1.30)	1.6	4.20	4.80	5.80	7.0	
		Week 8	Tezepelumab	60	56 (93.3)	5.08 (1.21)	2.8	4.10	4.90	6.10	7.0	
			Placebo	63	57 (90.5)	4.98 (1.16)	2.0	4.20	5.00	5.80	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.31 (1.19)	2.8	4.40	5.30	6.40	7.0	
			Placebo	63	57 (90.5)	5.12 (1.24)	1.8	4.20	5.20	6.20	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.26 (1.23)	2.6	4.30	5.50	6.20	7.0	
			Placebo	63	57 (90.5)	5.11 (1.30)	1.0	4.40	5.00	6.00	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.38 (1.19)	2.4	4.40	5.60	6.40	7.0	
			Placebo	63	57 (90.5)	5.05 (1.27)	1.0	4.40	5.00	6.00	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.25 (1.25)	2.0	4.20	5.20	6.20	7.0	
			Placebo	63	57 (90.5)	5.02 (1.30)	1.0	4.40	5.00	6.00	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.34 (1.15)	2.8	4.20	5.40	6.40	7.0	
			Placebo	63	58 (92.1)	5.11 (1.34)	1.0	4.20	5.20	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.33 (1.19)	2.6	4.40	5.40	6.40	7.0	
			Placebo	63	58 (92.1)	5.12 (1.34)	1.0	4.20	5.20	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.49 (1.26)	2.8	4.40	5.60	6.60	7.0	
			Placebo	63	58 (92.1)	5.07 (1.29)	1.6	4.40	5.10	6.00	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.24 (1.34)	1.8	4.20	5.40	6.40	7.0	
			Placebo	63	58 (92.1)	5.13 (1.31)	1.6	4.40	5.10	6.40	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.39 (1.20)	2.8	4.40	5.40	6.60	7.0	
			Placebo	63	58 (92.1)	5.09 (1.33)	1.8	4.00	5.10	6.20	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.38 (1.19)	2.6	4.60	5.40	6.40	7.0	
			Placebo	63	58 (92.1)	5.07 (1.34)	1.4	4.00	5.00	6.20	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.40 (1.20)	2.6	4.40	5.40	6.40	7.0	
			Placebo	63	58 (92.1)	5.06 (1.36)	2.0	4.00	4.90	6.20	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	60	50 (83.3)	0.60 (1.38)	-4.2	-0.20	0.60	1.60	3.8	0.07 [-0.31, 0.46]
			Placebo	63	53 (84.1)	0.51 (1.04)	-2.2	0.00	0.40	1.00	3.0	
		Week 8	Tezepelumab	60	52 (86.7)	0.79 (1.34)	-2.2	-0.20	0.90	1.60	4.4	0.15 [-0.23, 0.53]
			Placebo	63	54 (85.7)	0.60 (1.17)	-1.6	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	60	52 (86.7)	1.04 (1.28)	-2.4	0.10	1.10	1.80	3.8	0.24 [-0.14, 0.62]
			Placebo	63	54 (85.7)	0.73 (1.25)	-1.8	0.00	0.70	1.60	4.4	
		Week 16	Tezepelumab	60	52 (86.7)	0.99 (1.32)	-2.8	0.00	1.00	1.90	4.0	0.19 [-0.19, 0.58]
			Placebo	63	54 (85.7)	0.73 (1.32)	-3.4	0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	60	52 (86.7)	1.17 (1.24)	-1.4	0.30	1.20	2.10	4.6	0.39 [0.00, 0.77]
			Placebo	63	54 (85.7)	0.69 (1.25)	-3.4	0.00	0.80	1.60	4.2	
		Week 24	Tezepelumab	60	52 (86.7)	1.03 (1.34)	-1.4	0.00	1.00	2.00	4.6	0.28 [-0.10, 0.66]
			Placebo	63	54 (85.7)	0.66 (1.30)	-3.4	0.00	0.50	1.60	4.2	
		Week 28	Tezepelumab	60	52 (86.7)	1.08 (1.30)	-1.4	0.00	0.90	2.00	4.6	0.25 [-0.13, 0.64]
			Placebo	63	54 (85.7)	0.73 (1.43)	-3.4	0.00	0.80	1.60	4.4	
		Week 32	Tezepelumab	60	52 (86.7)	1.05 (1.34)	-1.6	0.10	1.00	2.10	4.6	0.23 [-0.15, 0.62]
			Placebo	63	54 (85.7)	0.75 (1.26)	-3.4	-0.20	0.80	1.40	4.2	
		Week 36	Tezepelumab	60	52 (86.7)	1.26 (1.45)	-1.6	0.00	1.20	2.30	4.6	0.45 [0.07, 0.84]
			Placebo	63	54 (85.7)	0.68 (1.12)	-2.0	0.00	0.60	1.40	3.8	
		Week 40	Tezepelumab	60	52 (86.7)	1.02 (1.43)	-2.4	0.00	1.10	2.00	4.6	0.20 [-0.18, 0.58]
			Placebo	63	54 (85.7)	0.75 (1.28)	-2.0	-0.20	0.80	1.60	3.6	
		Week 44	Tezepelumab	60	52 (86.7)	1.11 (1.36)	-1.4	0.00	1.30	1.90	4.6	0.31 [-0.07, 0.69]
			Placebo	63	54 (85.7)	0.70 (1.27)	-1.8	-0.20	0.70	1.20	4.2	
		Week 48	Tezepelumab	60	52 (86.7)	1.12 (1.34)	-1.4	0.10	1.20	1.90	4.6	0.31 [-0.07, 0.70]
			Placebo	63	54 (85.7)	0.71 (1.24)	-2.2	-0.20	0.60	1.40	4.2	
		Week 52	Tezepelumab	60	52 (86.7)	1.13 (1.35)	-1.6	0.00	1.30	1.90	4.6	0.32 [-0.06, 0.71]
			Placebo	63	54 (85.7)	0.69 (1.34)	-2.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	17	15 (88.2)	3.71 (1.39)	1.4	2.60	3.60	4.80	6.2	
			Placebo	21	20 (95.2)	4.35 (0.92)	3.0	3.60	4.20	4.80	6.6	
		Week 4	Tezepelumab	17	15 (88.2)	4.68 (1.09)	3.2	3.60	4.20	5.60	6.2	
			Placebo	21	20 (95.2)	4.84 (1.40)	1.6	3.80	4.70	6.00	7.0	
		Week 8	Tezepelumab	17	16 (94.1)	5.08 (1.22)	3.0	4.20	5.50	5.90	7.0	
			Placebo	21	21 (100.0)	4.92 (1.16)	3.0	4.00	4.80	5.40	7.0	
		Week 12	Tezepelumab	17	16 (94.1)	5.36 (1.27)	2.8	4.40	5.40	6.40	7.0	
			Placebo	21	21 (100.0)	5.18 (1.25)	1.8	4.60	5.00	6.00	7.0	
		Week 16	Tezepelumab	17	16 (94.1)	5.26 (1.30)	2.8	4.30	5.60	6.10	7.0	
			Placebo	21	21 (100.0)	5.03 (1.51)	1.0	4.60	5.00	5.80	7.0	
		Week 20	Tezepelumab	17	16 (94.1)	5.20 (1.23)	2.8	4.40	5.50	6.10	6.8	
			Placebo	21	21 (100.0)	4.95 (1.46)	1.0	4.60	5.00	6.00	7.0	
		Week 24	Tezepelumab	17	16 (94.1)	5.25 (1.36)	2.8	4.30	5.50	6.30	7.0	
			Placebo	21	21 (100.0)	4.76 (1.52)	1.0	4.40	5.00	5.60	7.0	
		Week 28	Tezepelumab	17	16 (94.1)	5.14 (1.24)	2.8	4.30	5.60	6.10	6.8	
			Placebo	21	21 (100.0)	5.10 (1.67)	1.0	4.40	5.20	6.40	7.0	
		Week 32	Tezepelumab	17	16 (94.1)	5.20 (1.27)	2.6	4.60	5.70	6.00	7.0	
			Placebo	21	21 (100.0)	5.00 (1.50)	1.0	4.40	5.00	6.00	7.0	
		Week 36	Tezepelumab	17	16 (94.1)	5.31 (1.35)	2.8	4.50	5.80	6.20	7.0	
			Placebo	21	21 (100.0)	4.73 (1.36)	1.6	4.00	4.80	5.20	7.0	
		Week 40	Tezepelumab	17	16 (94.1)	5.19 (1.37)	2.8	4.30	5.40	6.10	7.0	
			Placebo	21	21 (100.0)	4.92 (1.44)	1.6	4.20	5.00	5.80	7.0	
		Week 44	Tezepelumab	17	16 (94.1)	5.36 (1.29)	2.8	4.80	5.70	6.20	7.0	
			Placebo	21	21 (100.0)	4.95 (1.39)	1.8	4.00	4.60	6.00	7.0	
		Week 48	Tezepelumab	17	16 (94.1)	5.04 (1.39)	2.6	4.20	5.60	6.00	6.8	
			Placebo	21	21 (100.0)	4.84 (1.34)	1.4	4.00	4.80	5.40	7.0	
		Week 52	Tezepelumab	17	16 (94.1)	5.20 (1.44)	2.6	4.20	5.70	6.10	7.0	
			Placebo	21	21 (100.0)	4.89 (1.28)	2.0	4.00	4.80	5.80	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	17	13 (76.5)	0.97 (1.32)	-0.8	0.20	1.00	2.00	3.0	0.39 [-0.32, 1.10]
			Placebo	21	19 (90.5)	0.55 (0.89)	-2.0	0.00	0.40	1.20	1.8	
		Week 8	Tezepelumab	17	14 (82.4)	1.24 (1.29)	-1.0	0.20	1.40	2.20	3.4	0.58 [-0.12, 1.28]
			Placebo	21	20 (95.2)	0.62 (0.89)	-1.0	0.10	0.40	1.20	2.6	
		Week 12	Tezepelumab	17	14 (82.4)	1.47 (1.32)	-0.6	0.20	1.50	2.80	3.6	0.50 [-0.20, 1.19]
			Placebo	21	20 (95.2)	0.86 (1.16)	-1.8	0.20	0.70	1.40	3.6	
		Week 16	Tezepelumab	17	14 (82.4)	1.37 (1.39)	-0.6	-0.20	1.40	2.60	3.4	0.46 [-0.23, 1.16]
			Placebo	21	20 (95.2)	0.70 (1.49)	-3.4	0.30	0.80	1.40	4.0	
		Week 20	Tezepelumab	17	14 (82.4)	1.34 (1.36)	-0.6	0.00	1.40	2.40	3.4	0.54 [-0.15, 1.24]
			Placebo	21	20 (95.2)	0.61 (1.33)	-3.4	-0.10	0.80	1.50	2.6	
		Week 24	Tezepelumab	17	14 (82.4)	1.39 (1.52)	-0.8	-0.20	1.40	2.40	3.8	0.64 [-0.06, 1.35]
			Placebo	21	20 (95.2)	0.41 (1.51)	-3.4	-0.20	0.50	1.30	2.6	
		Week 28	Tezepelumab	17	14 (82.4)	1.26 (1.45)	-0.6	-0.20	1.10	2.80	3.6	0.30 [-0.39, 0.99]
			Placebo	21	20 (95.2)	0.78 (1.67)	-3.4	0.10	0.90	1.80	4.0	
		Week 32	Tezepelumab	17	14 (82.4)	1.39 (1.55)	-1.4	0.20	1.40	2.80	3.6	0.48 [-0.22, 1.17]
			Placebo	21	20 (95.2)	0.68 (1.43)	-3.4	0.20	0.70	1.40	3.0	
		Week 36	Tezepelumab	17	14 (82.4)	1.47 (1.66)	-1.0	-0.20	1.40	3.20	3.8	0.80 [0.09, 1.51]
			Placebo	21	20 (95.2)	0.38 (1.13)	-2.0	-0.20	0.40	1.10	2.6	
		Week 40	Tezepelumab	17	14 (82.4)	1.33 (1.61)	-1.2	-0.20	1.40	3.20	3.4	0.48 [-0.22, 1.17]
			Placebo	21	20 (95.2)	0.61 (1.43)	-2.0	-0.50	0.80	1.70	3.6	
		Week 44	Tezepelumab	17	14 (82.4)	1.53 (1.63)	-0.6	-0.20	1.40	3.20	3.8	0.67 [-0.03, 1.38]
			Placebo	21	20 (95.2)	0.58 (1.24)	-1.8	-0.20	0.70	1.10	3.2	
		Week 48	Tezepelumab	17	14 (82.4)	1.20 (1.76)	-1.4	-0.40	1.10	3.00	3.8	0.53 [-0.16, 1.23]
			Placebo	21	20 (95.2)	0.46 (1.05)	-2.2	-0.10	0.50	1.20	2.6	
		Week 52	Tezepelumab	17	14 (82.4)	1.36 (1.69)	-1.4	-0.20	1.40	3.00	3.8	0.61 [-0.09, 1.30]
			Placebo	21	20 (95.2)	0.54 (1.05)	-1.6	-0.10	0.50	1.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	49	43 (87.8)	4.46 (1.02)	1.8	3.80	4.40	5.20	6.4	
			Placebo	44	35 (79.5)	4.41 (1.30)	1.0	3.80	4.40	5.40	7.0	
		Week 4	Tezepelumab	49	45 (91.8)	4.95 (1.20)	1.2	4.00	4.80	6.00	7.0	
			Placebo	44	37 (84.1)	4.94 (1.24)	1.6	4.40	4.80	5.60	7.0	
		Week 8	Tezepelumab	49	46 (93.9)	5.19 (1.21)	2.8	4.20	5.00	6.20	7.0	
			Placebo	44	38 (86.4)	4.99 (1.16)	2.0	4.40	5.20	5.80	7.0	
		Week 12	Tezepelumab	49	46 (93.9)	5.37 (1.15)	3.0	4.40	5.40	6.40	7.0	
			Placebo	44	38 (86.4)	5.07 (1.22)	2.6	4.00	5.20	6.20	7.0	
		Week 16	Tezepelumab	49	46 (93.9)	5.33 (1.19)	2.6	4.40	5.30	6.20	7.0	
			Placebo	44	38 (86.4)	5.12 (1.17)	2.6	4.40	5.00	6.00	7.0	
		Week 20	Tezepelumab	49	47 (95.9)	5.45 (1.14)	2.4	4.60	5.60	6.40	7.0	
			Placebo	44	38 (86.4)	5.07 (1.14)	2.6	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	49	47 (95.9)	5.29 (1.21)	2.0	4.20	5.20	6.40	7.0	
			Placebo	44	38 (86.4)	5.12 (1.14)	2.6	4.40	5.00	6.20	7.0	
		Week 28	Tezepelumab	49	49 (100.0)	5.45 (1.09)	4.0	4.60	5.40	6.40	7.0	
			Placebo	44	39 (88.6)	5.07 (1.13)	2.6	4.20	5.20	6.00	7.0	
		Week 32	Tezepelumab	49	49 (100.0)	5.40 (1.15)	3.6	4.40	5.40	6.40	7.0	
			Placebo	44	39 (88.6)	5.13 (1.24)	2.6	4.00	5.20	6.20	7.0	
		Week 36	Tezepelumab	49	49 (100.0)	5.55 (1.19)	3.4	4.60	5.60	6.60	7.0	
			Placebo	44	39 (88.6)	5.23 (1.21)	2.2	4.40	5.40	6.20	7.0	
		Week 40	Tezepelumab	49	49 (100.0)	5.32 (1.29)	1.8	4.20	5.40	6.40	7.0	
			Placebo	44	39 (88.6)	5.17 (1.24)	2.6	4.40	5.00	6.40	7.0	
		Week 44	Tezepelumab	49	49 (100.0)	5.42 (1.13)	3.4	4.40	5.20	6.60	7.0	
			Placebo	44	39 (88.6)	5.13 (1.29)	2.6	4.00	5.20	6.40	7.0	
		Week 48	Tezepelumab	49	49 (100.0)	5.52 (1.07)	3.8	4.60	5.40	6.40	7.0	
			Placebo	44	39 (88.6)	5.18 (1.31)	2.6	4.00	5.20	6.40	7.0	
		Week 52	Tezepelumab	49	49 (100.0)	5.50 (1.08)	3.8	4.60	5.40	6.40	7.0	
			Placebo	44	39 (88.6)	5.11 (1.39)	2.2	4.00	5.20	6.40	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHK: Change from baseline in AQLQ+12 emotional function score by key subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Change from baseline	Week 4	Tezepelumab	49	42 (85.7)	0.51 (1.34)	-4.2	-0.20	0.60	1.40	3.8	-0.00 [-0.45, 0.44]
			Placebo	44	35 (79.5)	0.52 (1.13)	-2.2	0.00	0.40	1.20	3.0	
		Week 8	Tezepelumab	49	43 (87.8)	0.71 (1.31)	-2.2	-0.20	0.60	1.40	4.4	0.06 [-0.38, 0.51]
			Placebo	44	35 (79.5)	0.62 (1.31)	-1.6	-0.20	0.60	1.40	4.0	
		Week 12	Tezepelumab	49	43 (87.8)	0.91 (1.19)	-2.4	0.20	1.00	1.80	3.8	0.19 [-0.26, 0.64]
			Placebo	44	35 (79.5)	0.67 (1.29)	-1.6	-0.40	0.80	1.60	4.4	
		Week 16	Tezepelumab	49	43 (87.8)	0.87 (1.21)	-2.8	0.20	1.00	1.60	4.0	0.11 [-0.33, 0.56]
			Placebo	44	35 (79.5)	0.73 (1.22)	-1.6	0.00	0.40	1.40	4.4	
		Week 20	Tezepelumab	49	43 (87.8)	1.07 (1.14)	-1.4	0.40	1.00	1.80	4.6	0.30 [-0.15, 0.75]
			Placebo	44	35 (79.5)	0.71 (1.21)	-2.2	0.00	0.80	1.60	4.2	
		Week 24	Tezepelumab	49	43 (87.8)	0.90 (1.21)	-1.4	0.00	0.60	1.80	4.6	0.11 [-0.34, 0.55]
			Placebo	44	35 (79.5)	0.77 (1.16)	-1.0	0.00	0.40	1.60	4.2	
		Week 28	Tezepelumab	49	43 (87.8)	1.00 (1.18)	-1.4	0.00	0.80	1.80	4.6	0.27 [-0.18, 0.71]
			Placebo	44	35 (79.5)	0.68 (1.28)	-2.2	-0.20	0.60	1.60	4.4	
		Week 32	Tezepelumab	49	43 (87.8)	0.93 (1.20)	-1.6	0.00	0.80	1.60	4.6	0.14 [-0.30, 0.59]
			Placebo	44	35 (79.5)	0.76 (1.17)	-1.0	-0.20	0.80	1.60	4.2	
		Week 36	Tezepelumab	49	43 (87.8)	1.14 (1.30)	-1.6	0.40	1.20	2.00	4.6	0.25 [-0.20, 0.70]
			Placebo	44	35 (79.5)	0.84 (1.07)	-1.0	0.20	0.60	1.80	3.8	
		Week 40	Tezepelumab	49	43 (87.8)	0.93 (1.30)	-2.4	0.00	1.00	1.60	4.6	0.10 [-0.34, 0.55]
			Placebo	44	35 (79.5)	0.80 (1.19)	-1.4	-0.20	0.80	1.60	3.4	
		Week 44	Tezepelumab	49	43 (87.8)	0.96 (1.17)	-1.4	0.00	0.80	1.60	4.6	0.18 [-0.27, 0.62]
			Placebo	44	35 (79.5)	0.74 (1.29)	-1.6	-0.40	0.60	1.60	4.2	
		Week 48	Tezepelumab	49	43 (87.8)	1.08 (1.12)	-1.4	0.40	1.20	1.80	4.6	0.20 [-0.25, 0.65]
			Placebo	44	35 (79.5)	0.83 (1.32)	-1.0	-0.20	0.60	1.60	4.2	
		Week 52	Tezepelumab	49	43 (87.8)	1.04 (1.17)	-1.6	0.20	1.20	1.80	4.6	0.23 [-0.22, 0.67]
			Placebo	44	35 (79.5)	0.74 (1.49)	-2.6	-0.20	0.60	1.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	4.32 (1.13)	1.4	3.60	4.20	5.10	6.4	
			Placebo	58	48 (82.8)	4.51 (1.14)	1.0	3.80	4.40	5.30	7.0	
		Week 4	Tezepelumab	60	54 (90.0)	4.81 (1.18)	1.2	4.00	4.80	5.80	7.0	
			Placebo	58	50 (86.2)	4.99 (1.32)	1.6	4.20	4.90	6.00	7.0	
		Week 8	Tezepelumab	60	56 (93.3)	5.12 (1.16)	3.0	4.20	5.00	6.00	7.0	
			Placebo	58	52 (89.7)	5.03 (1.12)	2.6	4.20	5.00	5.90	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.30 (1.19)	2.8	4.40	5.30	6.40	7.0	
			Placebo	58	52 (89.7)	5.13 (1.24)	1.8	4.20	5.20	6.10	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.24 (1.23)	2.6	4.30	5.20	6.20	7.0	
			Placebo	58	52 (89.7)	5.05 (1.32)	1.0	4.30	5.00	5.90	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.29 (1.16)	2.4	4.40	5.60	6.20	7.0	
			Placebo	58	52 (89.7)	5.10 (1.27)	1.0	4.50	5.00	6.00	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.22 (1.25)	2.0	4.20	5.20	6.20	7.0	
			Placebo	58	52 (89.7)	5.03 (1.33)	1.0	4.40	5.00	6.00	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.29 (1.12)	2.8	4.20	5.40	6.20	7.0	
			Placebo	58	53 (91.4)	5.03 (1.34)	1.0	4.20	5.20	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.28 (1.20)	2.6	4.40	5.40	6.40	7.0	
			Placebo	58	53 (91.4)	5.08 (1.38)	1.0	4.00	5.20	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.41 (1.25)	2.8	4.40	5.60	6.60	7.0	
			Placebo	58	53 (91.4)	5.13 (1.29)	1.6	4.40	5.20	6.00	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.20 (1.33)	1.8	4.20	5.20	6.40	7.0	
			Placebo	58	53 (91.4)	5.11 (1.34)	1.6	4.20	5.20	6.40	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.34 (1.18)	2.8	4.40	5.20	6.60	7.0	
			Placebo	58	53 (91.4)	5.07 (1.32)	1.8	4.40	5.20	6.00	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.32 (1.19)	2.6	4.40	5.20	6.40	7.0	
			Placebo	58	53 (91.4)	5.09 (1.32)	1.4	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.35 (1.19)	2.6	4.40	5.40	6.40	7.0	
			Placebo	58	53 (91.4)	5.06 (1.35)	2.0	4.00	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	60	49 (81.7)	0.49 (1.27)	-4.2	-0.20	0.60	1.40	3.0	-0.01 [-0.41, 0.39]
			Placebo	58	47 (81.0)	0.50 (1.03)	-2.2	0.20	0.40	1.20	3.0	
		Week 8	Tezepelumab	60	51 (85.0)	0.72 (1.13)	-1.2	-0.20	0.80	1.40	3.4	0.14 [-0.26, 0.53]
			Placebo	58	48 (82.8)	0.57 (1.14)	-1.6	-0.10	0.60	1.20	4.0	
		Week 12	Tezepelumab	60	51 (85.0)	0.91 (1.15)	-2.4	0.20	1.00	1.60	3.6	0.22 [-0.17, 0.62]
			Placebo	58	48 (82.8)	0.64 (1.22)	-1.8	0.00	0.60	1.30	4.4	
		Week 16	Tezepelumab	60	51 (85.0)	0.84 (1.16)	-2.8	0.00	1.00	1.60	3.4	0.23 [-0.16, 0.63]
			Placebo	58	48 (82.8)	0.56 (1.25)	-3.4	0.10	0.40	1.30	4.4	
		Week 20	Tezepelumab	60	51 (85.0)	0.97 (1.05)	-1.4	0.20	1.00	1.80	3.4	0.29 [-0.11, 0.69]
			Placebo	58	48 (82.8)	0.63 (1.25)	-3.4	0.00	0.80	1.30	4.2	
		Week 24	Tezepelumab	60	51 (85.0)	0.89 (1.14)	-1.4	0.00	1.00	1.60	3.8	0.27 [-0.13, 0.66]
			Placebo	58	48 (82.8)	0.56 (1.31)	-3.4	-0.10	0.40	1.20	4.2	
		Week 28	Tezepelumab	60	51 (85.0)	0.90 (1.08)	-1.4	0.00	0.80	1.60	3.0	0.29 [-0.10, 0.69]
			Placebo	58	48 (82.8)	0.54 (1.38)	-3.4	-0.20	0.50	1.20	4.4	
		Week 32	Tezepelumab	60	51 (85.0)	0.90 (1.19)	-1.6	0.00	0.80	1.60	3.2	0.24 [-0.15, 0.64]
			Placebo	58	48 (82.8)	0.60 (1.27)	-3.4	-0.20	0.60	1.30	4.2	
		Week 36	Tezepelumab	60	51 (85.0)	1.07 (1.31)	-1.6	0.00	1.20	1.80	3.8	0.36 [-0.04, 0.75]
			Placebo	58	48 (82.8)	0.63 (1.10)	-2.0	-0.10	0.50	1.30	3.8	
		Week 40	Tezepelumab	60	51 (85.0)	0.87 (1.30)	-2.4	0.00	0.80	1.60	3.4	0.19 [-0.21, 0.58]
			Placebo	58	48 (82.8)	0.63 (1.26)	-2.0	-0.40	0.80	1.50	3.4	
		Week 44	Tezepelumab	60	51 (85.0)	0.95 (1.20)	-1.4	0.00	0.80	1.60	3.6	0.33 [-0.07, 0.73]
			Placebo	58	48 (82.8)	0.56 (1.13)	-1.8	-0.40	0.60	1.20	3.4	
		Week 48	Tezepelumab	60	51 (85.0)	0.95 (1.18)	-1.4	0.00	1.00	1.80	3.6	0.28 [-0.11, 0.68]
			Placebo	58	48 (82.8)	0.62 (1.16)	-2.2	-0.20	0.60	1.30	3.8	
		Week 52	Tezepelumab	60	51 (85.0)	0.96 (1.20)	-1.6	0.00	1.00	1.80	3.6	0.31 [-0.09, 0.71]
			Placebo	58	48 (82.8)	0.58 (1.27)	-2.6	-0.20	0.60	1.40	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	3.73 (1.43)	1.8	2.20	4.10	5.00	5.2	
			Placebo	7	7 (100.0)	3.54 (0.99)	2.0	2.60	4.20	4.40	4.4	
		Week 4	Tezepelumab	6	6 (100.0)	5.47 (0.94)	4.2	4.40	5.90	6.20	6.2	
			Placebo	7	7 (100.0)	4.29 (0.92)	3.0	3.40	4.20	5.20	5.6	
		Week 8	Tezepelumab	6	6 (100.0)	5.57 (1.58)	2.8	4.60	6.20	6.60	7.0	
			Placebo	7	7 (100.0)	4.54 (1.37)	2.0	3.40	5.20	5.60	5.8	
		Week 12	Tezepelumab	6	6 (100.0)	6.00 (0.85)	5.0	5.20	6.00	6.80	7.0	
			Placebo	7	7 (100.0)	4.97 (1.13)	3.6	4.00	5.00	6.20	6.6	
		Week 16	Tezepelumab	6	6 (100.0)	6.00 (0.69)	5.0	5.60	6.00	6.40	7.0	
			Placebo	7	7 (100.0)	5.34 (1.05)	4.0	4.40	5.00	6.20	7.0	
		Week 20	Tezepelumab	6	6 (100.0)	6.30 (0.64)	5.4	5.80	6.30	7.00	7.0	
			Placebo	7	7 (100.0)	4.51 (1.00)	3.2	3.60	4.40	5.00	6.2	
		Week 24	Tezepelumab	6	6 (100.0)	5.87 (1.01)	4.0	5.80	6.00	6.40	7.0	
			Placebo	7	7 (100.0)	4.74 (1.00)	3.4	3.60	5.00	5.40	6.2	
		Week 28	Tezepelumab	6	6 (100.0)	6.20 (0.77)	5.0	5.80	6.20	7.00	7.0	
			Placebo	7	7 (100.0)	5.46 (1.26)	3.6	4.40	5.20	6.80	7.0	
		Week 32	Tezepelumab	6	6 (100.0)	5.97 (0.69)	5.0	5.60	5.90	6.40	7.0	
			Placebo	7	7 (100.0)	5.14 (0.94)	3.6	4.40	5.00	6.00	6.2	
		Week 36	Tezepelumab	6	6 (100.0)	6.27 (0.39)	6.0	6.00	6.10	6.40	7.0	
			Placebo	7	7 (100.0)	4.49 (1.03)	3.0	3.60	4.40	5.00	6.2	
		Week 40	Tezepelumab	6	6 (100.0)	6.10 (0.63)	5.4	5.40	6.20	6.40	7.0	
			Placebo	7	7 (100.0)	4.94 (1.08)	3.6	4.40	4.40	6.20	6.6	
		Week 44	Tezepelumab	6	6 (100.0)	6.13 (0.55)	5.4	5.80	6.10	6.40	7.0	
			Placebo	7	7 (100.0)	5.06 (1.43)	3.6	3.60	4.60	6.60	6.8	
		Week 48	Tezepelumab	6	6 (100.0)	6.20 (0.54)	5.4	6.00	6.20	6.40	7.0	
			Placebo	7	7 (100.0)	4.80 (1.41)	3.6	3.60	4.20	6.80	6.8	
		Week 52	Tezepelumab	6	6 (100.0)	6.20 (0.54)	5.4	6.00	6.20	6.40	7.0	
			Placebo	7	7 (100.0)	4.83 (1.46)	3.6	3.60	4.20	6.80	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	6	6 (100.0)	1.73 (1.47)	-0.6	1.00	1.90	2.40	3.8	0.76 [-0.38, 1.89]
			Placebo	7	7 (100.0)	0.74 (1.16)	-0.2	0.00	0.00	1.40	3.0	
		Week 8	Tezepelumab	6	6 (100.0)	1.83 (2.27)	-2.2	1.00	2.30	3.20	4.4	0.45 [-0.65, 1.56]
			Placebo	7	7 (100.0)	1.00 (1.37)	-1.0	0.00	0.80	2.20	3.0	
		Week 12	Tezepelumab	6	6 (100.0)	2.27 (1.40)	0.0	1.20	2.80	3.00	3.8	0.64 [-0.48, 1.76]
			Placebo	7	7 (100.0)	1.43 (1.22)	-0.2	0.80	1.00	2.00	3.6	
		Week 16	Tezepelumab	6	6 (100.0)	2.27 (1.50)	0.0	1.00	2.60	3.40	4.0	0.34 [-0.76, 1.44]
			Placebo	7	7 (100.0)	1.80 (1.27)	0.0	0.80	2.00	2.40	4.0	
		Week 20	Tezepelumab	6	6 (100.0)	2.57 (1.45)	0.8	1.00	2.90	3.20	4.6	1.17 [-0.02, 2.37]
			Placebo	7	7 (100.0)	0.97 (1.28)	-1.2	-0.20	1.40	2.00	2.4	
		Week 24	Tezepelumab	6	6 (100.0)	2.13 (2.03)	-1.0	0.80	2.30	3.80	4.6	0.58 [-0.54, 1.70]
			Placebo	7	7 (100.0)	1.20 (1.14)	-1.0	0.80	1.60	2.00	2.4	
		Week 28	Tezepelumab	6	6 (100.0)	2.47 (1.75)	0.0	0.80	2.90	3.60	4.6	0.39 [-0.72, 1.49]
			Placebo	7	7 (100.0)	1.91 (1.09)	0.8	0.80	1.80	2.40	4.0	
		Week 32	Tezepelumab	6	6 (100.0)	2.23 (1.64)	0.6	0.80	1.90	3.60	4.6	0.51 [-0.60, 1.62]
			Placebo	7	7 (100.0)	1.60 (0.80)	0.6	0.80	1.60	2.00	3.0	
		Week 36	Tezepelumab	6	6 (100.0)	2.53 (1.50)	0.8	1.00	2.50	3.80	4.6	1.20 [-0.00, 2.39]
			Placebo	7	7 (100.0)	0.94 (1.17)	-1.4	0.60	1.40	1.80	2.0	
		Week 40	Tezepelumab	6	6 (100.0)	2.37 (1.39)	0.8	1.40	2.10	3.20	4.6	0.73 [-0.40, 1.86]
			Placebo	7	7 (100.0)	1.40 (1.27)	0.0	0.00	1.60	2.00	3.6	
		Week 44	Tezepelumab	6	6 (100.0)	2.40 (1.56)	0.6	1.20	2.10	3.80	4.6	0.51 [-0.60, 1.62]
			Placebo	7	7 (100.0)	1.51 (1.86)	-0.8	-0.20	1.60	3.20	4.2	
		Week 48	Tezepelumab	6	6 (100.0)	2.47 (1.48)	0.8	1.40	2.10	3.80	4.6	0.76 [-0.37, 1.90]
			Placebo	7	7 (100.0)	1.26 (1.66)	-0.4	-0.20	0.60	2.60	4.2	
		Week 52	Tezepelumab	6	6 (100.0)	2.47 (1.48)	0.8	1.40	2.10	3.80	4.6	0.73 [-0.40, 1.86]
			Placebo	7	7 (100.0)	1.29 (1.72)	-0.4	-0.20	0.60	2.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	3.56 (1.96)	1.4	1.80	3.80	4.80	6.0	
			Placebo	4	3 (75.0)	3.13 (0.92)	2.6	2.60	2.60	4.20	4.2	
		Week 4	Tezepelumab	6	4 (66.7)	5.70 (0.66)	4.8	5.20	5.90	6.20	6.2	
			Placebo	4	3 (75.0)	5.13 (0.81)	4.2	4.20	5.60	5.60	5.6	
		Week 8	Tezepelumab	6	5 (83.3)	5.52 (1.52)	3.0	5.40	6.00	6.20	7.0	
			Placebo	4	3 (75.0)	6.00 (0.53)	5.6	5.60	5.80	6.60	6.6	
		Week 12	Tezepelumab	6	5 (83.3)	5.44 (1.55)	2.8	5.60	5.80	6.20	6.8	
			Placebo	4	3 (75.0)	5.60 (1.78)	3.6	3.60	6.20	7.00	7.0	
		Week 16	Tezepelumab	6	5 (83.3)	5.32 (1.44)	2.8	5.60	5.80	6.00	6.4	
			Placebo	4	3 (75.0)	6.07 (1.01)	5.0	5.00	6.20	7.00	7.0	
		Week 20	Tezepelumab	6	5 (83.3)	5.68 (1.69)	2.8	5.60	6.40	6.60	7.0	
			Placebo	4	3 (75.0)	6.00 (0.92)	5.0	5.00	6.20	6.80	6.8	
		Week 24	Tezepelumab	6	5 (83.3)	5.08 (1.37)	2.8	5.20	5.20	5.80	6.4	
			Placebo	4	3 (75.0)	5.80 (1.25)	4.4	4.40	6.20	6.80	6.8	
		Week 28	Tezepelumab	6	6 (100.0)	5.67 (1.54)	2.8	5.40	6.00	6.80	7.0	
			Placebo	4	3 (75.0)	5.87 (1.33)	4.4	4.40	6.20	7.00	7.0	
		Week 32	Tezepelumab	6	6 (100.0)	5.10 (1.44)	2.8	4.20	5.30	6.40	6.6	
			Placebo	4	3 (75.0)	5.80 (1.25)	4.4	4.40	6.20	6.80	6.8	
		Week 36	Tezepelumab	6	6 (100.0)	5.27 (1.40)	2.8	4.80	5.60	6.40	6.4	
			Placebo	4	3 (75.0)	5.67 (1.10)	4.4	4.40	6.20	6.40	6.4	
		Week 40	Tezepelumab	6	6 (100.0)	5.23 (1.34)	2.8	4.80	5.50	6.40	6.4	
			Placebo	4	3 (75.0)	5.53 (0.99)	4.4	4.40	6.00	6.20	6.2	
		Week 44	Tezepelumab	6	6 (100.0)	5.37 (1.38)	2.8	5.00	5.80	6.40	6.4	
			Placebo	4	3 (75.0)	6.47 (0.42)	6.0	6.00	6.60	6.80	6.8	
		Week 48	Tezepelumab	6	6 (100.0)	5.33 (1.36)	2.8	5.00	5.70	6.40	6.4	
			Placebo	4	3 (75.0)	6.67 (0.23)	6.4	6.40	6.80	6.80	6.8	
		Week 52	Tezepelumab	6	6 (100.0)	5.47 (1.42)	2.8	5.40	5.70	6.40	6.8	
			Placebo	4	3 (75.0)	6.73 (0.31)	6.4	6.40	6.80	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	6	4 (66.7)	1.60 (2.11)	-1.2	0.10	1.90	3.10	3.8	-0.20 [-1.71, 1.30]
			Placebo	4	3 (75.0)	2.00 (1.73)	0.0	0.00	3.00	3.00	3.0	
		Week 8	Tezepelumab	6	5 (83.3)	1.96 (1.92)	-0.6	1.20	1.60	3.20	4.4	-0.53 [-1.99, 0.93]
			Placebo	4	3 (75.0)	2.87 (1.21)	1.6	1.60	3.00	4.00	4.0	
		Week 12	Tezepelumab	6	5 (83.3)	1.88 (1.56)	-0.2	1.40	1.40	3.00	3.8	-0.36 [-1.81, 1.08]
			Placebo	4	3 (75.0)	2.47 (1.75)	1.0	1.00	2.00	4.40	4.4	
		Week 16	Tezepelumab	6	5 (83.3)	1.76 (1.65)	-0.4	1.20	1.40	2.60	4.0	-0.76 [-2.26, 0.73]
			Placebo	4	3 (75.0)	2.93 (1.29)	2.0	2.00	2.40	4.40	4.4	
		Week 20	Tezepelumab	6	5 (83.3)	2.12 (1.89)	-0.4	1.40	1.80	3.20	4.6	-0.44 [-1.90, 1.01]
			Placebo	4	3 (75.0)	2.87 (1.17)	2.0	2.00	2.40	4.20	4.2	
		Week 24	Tezepelumab	6	5 (83.3)	1.52 (2.02)	-0.8	0.40	1.40	2.00	4.6	-0.63 [-2.10, 0.85]
			Placebo	4	3 (75.0)	2.67 (1.33)	1.8	1.80	2.00	4.20	4.2	
		Week 28	Tezepelumab	6	5 (83.3)	1.88 (2.01)	-0.4	0.60	1.40	3.20	4.6	-0.46 [-1.92, 0.99]
			Placebo	4	3 (75.0)	2.73 (1.45)	1.8	1.80	2.00	4.40	4.4	
		Week 32	Tezepelumab	6	5 (83.3)	1.24 (2.09)	-0.6	-0.40	1.20	1.40	4.6	-0.76 [-2.26, 0.73]
			Placebo	4	3 (75.0)	2.67 (1.33)	1.8	1.80	2.00	4.20	4.2	
		Week 36	Tezepelumab	6	5 (83.3)	1.48 (2.18)	-1.0	0.00	1.40	2.40	4.6	-0.56 [-2.02, 0.91]
			Placebo	4	3 (75.0)	2.53 (1.10)	1.8	1.80	2.00	3.80	3.8	
		Week 40	Tezepelumab	6	5 (83.3)	1.44 (2.09)	-1.2	0.80	1.40	1.60	4.6	-0.54 [-2.00, 0.92]
			Placebo	4	3 (75.0)	2.40 (0.87)	1.8	1.80	2.00	3.40	3.4	
		Week 44	Tezepelumab	6	5 (83.3)	1.60 (1.99)	-1.0	1.40	1.40	1.60	4.6	-1.02 [-2.56, 0.53]
			Placebo	4	3 (75.0)	3.33 (0.90)	2.4	2.40	3.40	4.20	4.2	
		Week 48	Tezepelumab	6	5 (83.3)	1.56 (2.00)	-1.0	1.20	1.40	1.60	4.6	-1.16 [-2.74, 0.41]
			Placebo	4	3 (75.0)	3.53 (0.83)	2.6	2.60	3.80	4.20	4.2	
		Week 52	Tezepelumab	6	5 (83.3)	1.64 (1.87)	-0.6	1.20	1.40	1.60	4.6	-1.21 [-2.80, 0.38]
			Placebo	4	3 (75.0)	3.60 (0.92)	2.6	2.60	3.80	4.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	4.33 (1.06)	1.6	3.60	4.20	5.00	6.4	
			Placebo	61	52 (85.2)	4.46 (1.14)	1.0	3.80	4.40	5.20	7.0	
		Week 4	Tezepelumab	60	56 (93.3)	4.82 (1.18)	1.2	4.00	4.80	5.80	7.0	
			Placebo	61	54 (88.5)	4.89 (1.31)	1.6	4.20	4.80	5.80	7.0	
		Week 8	Tezepelumab	60	57 (95.0)	5.13 (1.18)	2.8	4.20	5.00	6.20	7.0	
			Placebo	61	56 (91.8)	4.91 (1.15)	2.0	4.20	5.00	5.70	7.0	
		Week 12	Tezepelumab	60	57 (95.0)	5.36 (1.15)	3.0	4.40	5.20	6.40	7.0	
			Placebo	61	56 (91.8)	5.08 (1.20)	1.8	4.20	5.10	6.00	7.0	
		Week 16	Tezepelumab	60	57 (95.0)	5.31 (1.20)	2.6	4.40	5.40	6.20	7.0	
			Placebo	61	56 (91.8)	5.03 (1.29)	1.0	4.30	5.00	5.80	7.0	
		Week 20	Tezepelumab	60	58 (96.7)	5.36 (1.12)	2.4	4.40	5.60	6.20	7.0	
			Placebo	61	56 (91.8)	4.98 (1.25)	1.0	4.10	5.00	5.90	7.0	
		Week 24	Tezepelumab	60	58 (96.7)	5.30 (1.23)	2.0	4.20	5.50	6.40	7.0	
			Placebo	61	56 (91.8)	4.95 (1.29)	1.0	4.30	5.00	6.00	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.34 (1.09)	3.2	4.40	5.40	6.20	7.0	
			Placebo	61	57 (93.4)	5.04 (1.33)	1.0	4.20	5.20	6.00	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.37 (1.15)	2.6	4.40	5.60	6.40	7.0	
			Placebo	61	57 (93.4)	5.05 (1.33)	1.0	4.00	5.20	6.00	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.52 (1.22)	3.0	4.40	5.60	6.60	7.0	
			Placebo	61	57 (93.4)	5.02 (1.28)	1.6	4.40	5.00	5.80	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.29 (1.31)	1.8	4.20	5.40	6.60	7.0	
			Placebo	61	57 (93.4)	5.06 (1.32)	1.6	4.20	5.00	6.40	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.41 (1.15)	3.2	4.40	5.40	6.60	7.0	
			Placebo	61	57 (93.4)	5.00 (1.31)	1.8	4.00	4.60	6.00	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.41 (1.16)	2.6	4.60	5.40	6.40	7.0	
			Placebo	61	57 (93.4)	4.98 (1.30)	1.4	4.00	4.80	6.00	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.42 (1.16)	2.6	4.40	5.40	6.40	7.0	
			Placebo	61	57 (93.4)	4.94 (1.32)	2.0	4.00	4.80	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	60	51 (85.0)	0.55 (1.26)	-4.2	-0.20	0.60	1.60	3.0	0.09 [-0.30, 0.48]
			Placebo	61	51 (83.6)	0.44 (0.95)	-2.2	0.00	0.40	1.00	2.8	
		Week 8	Tezepelumab	60	52 (86.7)	0.73 (1.21)	-2.2	-0.20	0.80	1.50	3.4	0.21 [-0.17, 0.60]
			Placebo	61	52 (85.2)	0.49 (1.03)	-1.6	-0.10	0.60	1.20	2.8	
		Week 12	Tezepelumab	60	52 (86.7)	0.97 (1.19)	-2.4	0.20	1.00	1.80	3.6	0.28 [-0.11, 0.67]
			Placebo	61	52 (85.2)	0.64 (1.15)	-1.8	0.00	0.60	1.30	3.6	
		Week 16	Tezepelumab	60	52 (86.7)	0.92 (1.22)	-2.8	0.10	1.00	1.70	3.4	0.27 [-0.12, 0.66]
			Placebo	61	52 (85.2)	0.59 (1.20)	-3.4	0.10	0.50	1.40	4.0	
		Week 20	Tezepelumab	60	52 (86.7)	1.04 (1.08)	-1.4	0.40	1.00	1.90	3.4	0.44 [0.05, 0.83]
			Placebo	61	52 (85.2)	0.55 (1.14)	-3.4	0.00	0.80	1.30	2.6	
		Week 24	Tezepelumab	60	52 (86.7)	0.97 (1.22)	-1.4	0.00	1.00	1.80	3.8	0.37 [-0.02, 0.76]
			Placebo	61	52 (85.2)	0.52 (1.21)	-3.4	-0.10	0.40	1.20	2.8	
		Week 28	Tezepelumab	60	52 (86.7)	0.99 (1.14)	-1.4	0.00	0.80	1.80	3.6	0.31 [-0.07, 0.70]
			Placebo	61	52 (85.2)	0.60 (1.34)	-3.4	-0.10	0.70	1.30	4.0	
		Week 32	Tezepelumab	60	52 (86.7)	1.02 (1.22)	-1.6	0.20	0.90	2.00	3.6	0.34 [-0.05, 0.72]
			Placebo	61	52 (85.2)	0.62 (1.17)	-3.4	-0.20	0.60	1.40	3.0	
		Week 36	Tezepelumab	60	52 (86.7)	1.20 (1.32)	-1.6	0.40	1.20	2.00	3.8	0.54 [0.14, 0.93]
			Placebo	61	52 (85.2)	0.57 (1.02)	-2.0	-0.10	0.60	1.30	2.6	
		Week 40	Tezepelumab	60	52 (86.7)	0.99 (1.31)	-2.4	0.00	1.00	2.00	3.4	0.28 [-0.11, 0.66]
			Placebo	61	52 (85.2)	0.63 (1.23)	-2.0	-0.40	0.80	1.50	3.6	
		Week 44	Tezepelumab	60	52 (86.7)	1.05 (1.24)	-1.4	0.00	1.00	1.70	3.8	0.44 [0.05, 0.83]
			Placebo	61	52 (85.2)	0.53 (1.10)	-1.8	-0.40	0.60	1.20	3.2	
		Week 48	Tezepelumab	60	52 (86.7)	1.07 (1.22)	-1.4	0.20	1.00	1.90	3.8	0.47 [0.08, 0.86]
			Placebo	61	52 (85.2)	0.53 (1.04)	-2.2	-0.20	0.50	1.20	2.8	
		Week 52	Tezepelumab	60	52 (86.7)	1.07 (1.25)	-1.6	0.10	1.10	1.90	3.8	0.47 [0.08, 0.86]
			Placebo	61	52 (85.2)	0.50 (1.15)	-2.6	-0.20	0.50	1.30	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	30	26 (86.7)	4.35 (1.10)	1.8	3.80	4.30	5.20	6.4	
			Placebo	29	25 (86.2)	4.19 (1.16)	1.0	3.80	4.20	4.60	6.6	
		Week 4	Tezepelumab	30	26 (86.7)	4.76 (1.22)	1.2	4.00	4.70	5.60	7.0	
			Placebo	29	25 (86.2)	4.77 (1.42)	1.6	4.20	4.60	5.80	7.0	
		Week 8	Tezepelumab	30	27 (90.0)	5.13 (1.19)	2.8	4.20	4.80	6.20	7.0	
			Placebo	29	26 (89.7)	4.83 (1.24)	2.0	4.20	4.90	5.60	7.0	
		Week 12	Tezepelumab	30	27 (90.0)	5.22 (1.12)	3.0	4.40	5.00	6.40	7.0	
			Placebo	29	26 (89.7)	4.93 (1.21)	2.6	4.20	4.70	6.00	7.0	
		Week 16	Tezepelumab	30	27 (90.0)	5.17 (1.14)	2.6	4.40	5.00	6.20	7.0	
			Placebo	29	26 (89.7)	4.84 (1.48)	1.0	4.00	4.70	5.80	7.0	
		Week 20	Tezepelumab	30	28 (93.3)	5.34 (1.14)	2.4	4.50	5.50	6.10	7.0	
			Placebo	29	26 (89.7)	4.82 (1.39)	1.0	4.00	4.80	5.80	7.0	
		Week 24	Tezepelumab	30	28 (93.3)	5.16 (1.22)	2.0	4.10	5.40	6.00	7.0	
			Placebo	29	26 (89.7)	4.75 (1.50)	1.0	4.00	4.70	6.00	7.0	
		Week 28	Tezepelumab	30	29 (96.7)	5.30 (1.06)	4.0	4.60	5.00	6.20	7.0	
			Placebo	29	26 (89.7)	4.73 (1.47)	1.0	4.00	4.60	6.00	7.0	
		Week 32	Tezepelumab	30	29 (96.7)	5.28 (1.08)	3.6	4.40	5.00	6.40	7.0	
			Placebo	29	26 (89.7)	4.82 (1.51)	1.0	4.00	5.00	6.00	7.0	
		Week 36	Tezepelumab	30	29 (96.7)	5.48 (1.20)	3.4	4.60	5.60	6.40	7.0	
			Placebo	29	26 (89.7)	4.87 (1.35)	2.2	4.00	5.00	5.60	7.0	
		Week 40	Tezepelumab	30	29 (96.7)	5.15 (1.25)	2.0	4.00	5.20	6.20	7.0	
			Placebo	29	26 (89.7)	4.88 (1.40)	2.6	3.60	4.70	6.20	7.0	
		Week 44	Tezepelumab	30	29 (96.7)	5.30 (1.14)	3.4	4.40	5.20	6.40	7.0	
			Placebo	29	26 (89.7)	4.82 (1.38)	2.6	3.60	4.60	6.00	7.0	
		Week 48	Tezepelumab	30	29 (96.7)	5.42 (1.07)	3.8	4.60	5.20	6.40	7.0	
			Placebo	29	26 (89.7)	4.88 (1.33)	2.6	4.00	4.70	6.00	7.0	
		Week 52	Tezepelumab	30	29 (96.7)	5.39 (1.08)	3.8	4.40	5.00	6.40	7.0	
			Placebo	29	26 (89.7)	4.78 (1.39)	2.2	3.80	4.70	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	30	24 (80.0)	0.46 (1.56)	-4.2	-0.20	0.60	1.20	3.8	-0.04 [-0.61, 0.52]
			Placebo	29	24 (82.8)	0.52 (1.02)	-2.2	0.10	0.40	1.20	2.8	
		Week 8	Tezepelumab	30	25 (83.3)	0.76 (1.50)	-2.2	-0.20	0.60	1.60	4.4	0.10 [-0.46, 0.65]
			Placebo	29	25 (86.2)	0.63 (1.08)	-1.6	0.00	0.80	1.20	2.8	
		Week 12	Tezepelumab	30	25 (83.3)	0.87 (1.39)	-2.4	0.00	0.80	1.80	3.8	0.14 [-0.42, 0.69]
			Placebo	29	25 (86.2)	0.70 (1.12)	-1.6	0.00	0.80	1.60	2.6	
		Week 16	Tezepelumab	30	25 (83.3)	0.86 (1.38)	-2.8	0.20	1.00	1.60	4.0	0.19 [-0.37, 0.74]
			Placebo	29	25 (86.2)	0.60 (1.36)	-3.4	0.20	0.80	1.40	2.8	
		Week 20	Tezepelumab	30	25 (83.3)	1.06 (1.32)	-1.4	0.40	1.00	1.40	4.6	0.37 [-0.19, 0.93]
			Placebo	29	25 (86.2)	0.58 (1.26)	-3.4	0.00	0.80	1.60	2.4	
		Week 24	Tezepelumab	30	25 (83.3)	0.89 (1.41)	-1.4	0.00	0.60	1.60	4.6	0.22 [-0.33, 0.78]
			Placebo	29	25 (86.2)	0.58 (1.39)	-3.4	0.00	0.60	1.60	2.8	
		Week 28	Tezepelumab	30	25 (83.3)	0.97 (1.39)	-1.4	0.00	0.60	1.60	4.6	0.30 [-0.26, 0.86]
			Placebo	29	25 (86.2)	0.55 (1.39)	-3.4	0.00	0.80	1.20	2.8	
		Week 32	Tezepelumab	30	25 (83.3)	0.92 (1.37)	-1.6	0.20	1.00	1.60	4.6	0.21 [-0.34, 0.77]
			Placebo	29	25 (86.2)	0.64 (1.26)	-3.4	-0.20	0.80	1.40	2.8	
		Week 36	Tezepelumab	30	25 (83.3)	1.18 (1.44)	-1.6	0.60	1.20	1.80	4.6	0.38 [-0.18, 0.94]
			Placebo	29	25 (86.2)	0.70 (1.03)	-1.4	0.40	0.60	1.60	2.6	
		Week 40	Tezepelumab	30	25 (83.3)	0.91 (1.36)	-1.4	0.00	0.60	1.60	4.6	0.16 [-0.40, 0.71]
			Placebo	29	25 (86.2)	0.71 (1.21)	-1.6	-0.20	0.80	1.60	2.8	
		Week 44	Tezepelumab	30	25 (83.3)	0.92 (1.38)	-1.4	0.00	0.80	1.60	4.6	0.22 [-0.34, 0.77]
			Placebo	29	25 (86.2)	0.65 (1.11)	-1.0	-0.40	0.60	1.60	2.8	
		Week 48	Tezepelumab	30	25 (83.3)	1.07 (1.32)	-1.4	0.20	1.00	1.60	4.6	0.30 [-0.26, 0.86]
			Placebo	29	25 (86.2)	0.71 (1.07)	-1.0	0.00	0.60	1.60	2.8	
		Week 52	Tezepelumab	30	25 (83.3)	1.04 (1.37)	-1.6	0.00	1.00	1.60	4.6	0.35 [-0.21, 0.91]
			Placebo	29	25 (86.2)	0.60 (1.14)	-1.6	-0.20	0.60	1.40	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	36	32 (88.9)	4.19 (1.22)	1.4	3.50	4.20	4.80	6.4	
			Placebo	36	30 (83.3)	4.55 (1.16)	2.6	3.60	4.40	5.40	7.0	
		Week 4	Tezepelumab	36	34 (94.4)	4.97 (1.14)	3.0	4.00	5.10	6.00	7.0	
			Placebo	36	32 (88.9)	5.01 (1.19)	1.6	4.20	5.20	5.60	7.0	
		Week 8	Tezepelumab	36	35 (97.2)	5.19 (1.23)	3.0	4.00	5.40	6.20	7.0	
			Placebo	36	33 (91.7)	5.08 (1.09)	3.0	4.20	5.20	6.00	7.0	
		Week 12	Tezepelumab	36	35 (97.2)	5.49 (1.22)	2.8	4.60	5.80	6.40	7.0	
			Placebo	36	33 (91.7)	5.25 (1.23)	1.8	4.60	5.20	6.20	7.0	
		Week 16	Tezepelumab	36	35 (97.2)	5.42 (1.26)	2.8	4.20	5.60	6.60	7.0	
			Placebo	36	33 (91.7)	5.28 (1.10)	2.6	4.60	5.20	6.00	7.0	
		Week 20	Tezepelumab	36	35 (97.2)	5.42 (1.19)	2.8	4.40	5.60	6.40	7.0	
			Placebo	36	33 (91.7)	5.19 (1.12)	3.0	4.60	5.00	6.00	7.0	
		Week 24	Tezepelumab	36	35 (97.2)	5.38 (1.25)	2.8	4.20	5.40	6.40	7.0	
			Placebo	36	33 (91.7)	5.18 (1.08)	2.8	4.60	5.00	6.00	7.0	
		Week 28	Tezepelumab	36	36 (100.0)	5.43 (1.19)	2.8	4.40	5.60	6.40	7.0	
			Placebo	36	34 (94.4)	5.35 (1.16)	2.6	4.40	5.40	6.00	7.0	
		Week 32	Tezepelumab	36	36 (100.0)	5.40 (1.25)	2.6	4.40	5.70	6.40	7.0	
			Placebo	36	34 (94.4)	5.29 (1.15)	2.2	4.40	5.50	6.00	7.0	
		Week 36	Tezepelumab	36	36 (100.0)	5.50 (1.26)	2.8	4.40	5.80	6.60	7.0	
			Placebo	36	34 (94.4)	5.20 (1.22)	1.6	4.40	5.00	6.00	7.0	
		Week 40	Tezepelumab	36	36 (100.0)	5.39 (1.35)	1.8	4.70	5.50	6.60	7.0	
			Placebo	36	34 (94.4)	5.24 (1.22)	1.6	4.40	5.20	6.40	7.0	
		Week 44	Tezepelumab	36	36 (100.0)	5.50 (1.19)	2.8	4.80	5.70	6.60	7.0	
			Placebo	36	34 (94.4)	5.26 (1.27)	1.8	4.40	5.40	6.20	7.0	
		Week 48	Tezepelumab	36	36 (100.0)	5.39 (1.26)	2.6	4.60	5.60	6.40	7.0	
			Placebo	36	34 (94.4)	5.19 (1.32)	1.4	4.20	5.10	6.20	7.0	
		Week 52	Tezepelumab	36	36 (100.0)	5.45 (1.25)	2.6	4.60	5.70	6.60	7.0	
			Placebo	36	34 (94.4)	5.23 (1.30)	2.0	4.20	5.20	6.40	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	36	31 (86.1)	0.75 (1.15)	-1.2	-0.20	0.80	1.80	3.0	0.19 [-0.32, 0.69]
			Placebo	36	30 (83.3)	0.54 (1.08)	-2.0	-0.20	0.50	1.00	3.0	
		Week 8	Tezepelumab	36	32 (88.9)	0.90 (1.16)	-1.2	0.00	1.00	1.80	3.4	0.24 [-0.26, 0.74]
			Placebo	36	30 (83.3)	0.61 (1.25)	-1.6	-0.20	0.50	1.20	4.0	
		Week 12	Tezepelumab	36	32 (88.9)	1.19 (1.11)	-1.0	0.40	1.30	1.90	3.6	0.33 [-0.17, 0.83]
			Placebo	36	30 (83.3)	0.78 (1.35)	-1.8	0.00	0.70	1.40	4.4	
		Week 16	Tezepelumab	36	32 (88.9)	1.10 (1.18)	-1.2	0.10	1.20	2.10	3.4	0.23 [-0.27, 0.73]
			Placebo	36	30 (83.3)	0.82 (1.28)	-1.0	0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	36	32 (88.9)	1.19 (1.09)	-0.6	0.40	1.30	2.20	3.4	0.38 [-0.13, 0.88]
			Placebo	36	30 (83.3)	0.75 (1.25)	-2.2	0.00	0.80	1.40	4.2	
		Week 24	Tezepelumab	36	32 (88.9)	1.12 (1.21)	-0.8	0.20	1.30	2.10	3.8	0.35 [-0.15, 0.85]
			Placebo	36	30 (83.3)	0.69 (1.23)	-1.0	0.00	0.30	1.20	4.2	
		Week 28	Tezepelumab	36	32 (88.9)	1.14 (1.13)	-0.6	0.20	1.00	2.20	3.0	0.22 [-0.28, 0.72]
			Placebo	36	30 (83.3)	0.85 (1.45)	-2.2	-0.20	0.70	1.80	4.4	
		Week 32	Tezepelumab	36	32 (88.9)	1.14 (1.25)	-1.4	0.10	1.10	2.40	3.2	0.26 [-0.24, 0.76]
			Placebo	36	30 (83.3)	0.81 (1.27)	-1.4	-0.20	0.70	1.40	4.2	
		Week 36	Tezepelumab	36	32 (88.9)	1.26 (1.37)	-1.0	0.20	1.30	2.30	3.8	0.47 [-0.04, 0.98]
			Placebo	36	30 (83.3)	0.65 (1.18)	-2.0	0.00	0.60	1.40	3.8	
		Week 40	Tezepelumab	36	32 (88.9)	1.12 (1.40)	-2.4	0.50	1.20	2.10	3.4	0.27 [-0.23, 0.77]
			Placebo	36	30 (83.3)	0.75 (1.35)	-2.0	-0.40	0.80	1.80	3.6	
		Week 44	Tezepelumab	36	32 (88.9)	1.24 (1.25)	-1.0	0.50	1.40	2.20	3.6	0.40 [-0.11, 0.90]
			Placebo	36	30 (83.3)	0.71 (1.39)	-1.8	-0.20	0.70	1.20	4.2	
		Week 48	Tezepelumab	36	32 (88.9)	1.14 (1.29)	-1.4	0.30	1.20	2.20	3.6	0.34 [-0.16, 0.84]
			Placebo	36	30 (83.3)	0.69 (1.37)	-2.2	-0.20	0.60	1.40	4.2	
		Week 52	Tezepelumab	36	32 (88.9)	1.18 (1.28)	-1.4	0.30	1.30	2.20	3.6	0.33 [-0.17, 0.83]
			Placebo	36	30 (83.3)	0.73 (1.50)	-2.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	38	31 (81.6)	4.25 (0.96)	1.8	3.60	4.20	5.20	6.2	
			Placebo	30	23 (76.7)	4.29 (0.94)	2.6	3.80	4.20	4.40	6.2	
		Week 4	Tezepelumab	38	35 (92.1)	4.67 (1.17)	1.2	4.00	4.80	5.60	7.0	
			Placebo	30	25 (83.3)	4.70 (1.19)	1.6	4.00	4.60	5.40	7.0	
		Week 8	Tezepelumab	38	35 (92.1)	5.06 (1.07)	3.0	4.20	4.80	6.20	7.0	
			Placebo	30	25 (83.3)	4.93 (1.04)	2.6	4.20	4.80	5.60	7.0	
		Week 12	Tezepelumab	38	35 (92.1)	5.21 (1.13)	3.0	4.40	5.20	6.40	7.0	
			Placebo	30	25 (83.3)	4.98 (1.11)	2.6	4.20	4.60	5.80	7.0	
		Week 16	Tezepelumab	38	35 (92.1)	5.08 (1.17)	2.6	4.20	5.00	6.20	7.0	
			Placebo	30	25 (83.3)	4.91 (1.06)	2.8	4.40	4.60	5.20	7.0	
		Week 20	Tezepelumab	38	36 (94.7)	5.22 (1.16)	2.4	4.40	5.20	6.20	7.0	
			Placebo	30	25 (83.3)	4.92 (1.02)	3.0	4.00	4.80	5.20	6.8	
		Week 24	Tezepelumab	38	36 (94.7)	5.16 (1.17)	2.0	4.30	5.40	6.00	7.0	
			Placebo	30	25 (83.3)	5.04 (0.98)	2.8	4.40	5.00	5.60	7.0	
		Week 28	Tezepelumab	38	38 (100.0)	5.27 (1.08)	3.2	4.20	5.20	6.20	7.0	
			Placebo	30	26 (86.7)	5.05 (1.10)	3.4	4.00	4.90	6.00	7.0	
		Week 32	Tezepelumab	38	38 (100.0)	5.19 (1.14)	2.6	4.40	5.10	6.20	7.0	
			Placebo	30	26 (86.7)	5.09 (1.19)	2.6	4.20	5.00	6.20	7.0	
		Week 36	Tezepelumab	38	38 (100.0)	5.34 (1.28)	3.0	4.20	5.60	6.40	7.0	
			Placebo	30	26 (86.7)	5.18 (1.17)	2.2	4.60	5.20	6.00	7.0	
		Week 40	Tezepelumab	38	38 (100.0)	5.05 (1.30)	1.8	4.00	5.30	6.20	7.0	
			Placebo	30	26 (86.7)	5.11 (1.14)	2.8	4.40	5.00	6.00	7.0	
		Week 44	Tezepelumab	38	38 (100.0)	5.18 (1.13)	3.2	4.00	5.10	6.20	7.0	
			Placebo	30	26 (86.7)	5.02 (1.26)	3.2	4.00	4.60	6.40	7.0	
		Week 48	Tezepelumab	38	38 (100.0)	5.18 (1.13)	2.6	4.40	5.20	6.20	7.0	
			Placebo	30	26 (86.7)	5.14 (1.29)	2.8	4.00	4.90	6.40	7.0	
		Week 52	Tezepelumab	38	38 (100.0)	5.21 (1.11)	2.6	4.40	5.00	6.20	7.0	
			Placebo	30	26 (86.7)	4.97 (1.39)	2.2	4.00	4.70	6.40	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	38	31 (81.6)	0.39 (1.47)	-4.2	-0.40	0.40	1.60	3.8	-0.08 [-0.62, 0.46]
			Placebo	30	23 (76.7)	0.50 (1.19)	-2.2	0.00	0.40	1.20	3.0	
		Week 8	Tezepelumab	38	31 (81.6)	0.74 (1.31)	-1.2	-0.20	0.60	1.40	4.4	0.05 [-0.48, 0.59]
			Placebo	30	23 (76.7)	0.67 (1.33)	-1.6	-0.20	0.80	1.40	4.0	
		Week 12	Tezepelumab	38	31 (81.6)	0.89 (1.25)	-2.4	0.00	1.00	1.80	3.8	0.14 [-0.40, 0.68]
			Placebo	30	23 (76.7)	0.70 (1.35)	-1.6	0.20	0.60	1.20	4.4	
		Week 16	Tezepelumab	38	31 (81.6)	0.75 (1.30)	-2.8	-0.20	1.00	1.60	4.0	0.09 [-0.45, 0.63]
			Placebo	30	23 (76.7)	0.63 (1.31)	-1.6	0.00	0.40	1.20	4.4	
		Week 20	Tezepelumab	38	31 (81.6)	1.02 (1.23)	-1.4	0.00	1.00	1.60	4.6	0.26 [-0.29, 0.80]
			Placebo	30	23 (76.7)	0.70 (1.30)	-2.2	0.00	0.80	1.20	4.2	
		Week 24	Tezepelumab	38	31 (81.6)	0.94 (1.20)	-1.4	0.00	0.80	1.80	4.6	0.14 [-0.40, 0.68]
			Placebo	30	23 (76.7)	0.77 (1.16)	-1.0	0.20	0.60	1.00	4.2	
		Week 28	Tezepelumab	38	31 (81.6)	0.97 (1.26)	-1.4	0.00	0.80	1.60	4.6	0.17 [-0.37, 0.71]
			Placebo	30	23 (76.7)	0.74 (1.39)	-2.2	0.00	0.80	1.20	4.4	
		Week 32	Tezepelumab	38	31 (81.6)	0.87 (1.29)	-1.6	0.00	1.00	1.60	4.6	0.06 [-0.48, 0.60]
			Placebo	30	23 (76.7)	0.80 (1.18)	-1.0	0.00	0.60	1.40	4.2	
		Week 36	Tezepelumab	38	31 (81.6)	1.09 (1.46)	-1.6	0.00	1.20	2.00	4.6	0.18 [-0.36, 0.72]
			Placebo	30	23 (76.7)	0.85 (1.10)	-0.8	0.20	0.60	1.80	3.8	
		Week 40	Tezepelumab	38	31 (81.6)	0.81 (1.36)	-2.4	0.00	0.80	1.60	4.6	0.00 [-0.53, 0.54]
			Placebo	30	23 (76.7)	0.80 (1.25)	-1.4	0.00	0.80	1.40	3.4	
		Week 44	Tezepelumab	38	31 (81.6)	0.85 (1.24)	-1.4	-0.20	0.60	1.60	4.6	0.15 [-0.39, 0.69]
			Placebo	30	23 (76.7)	0.67 (1.15)	-1.0	-0.40	0.60	1.20	3.4	
		Week 48	Tezepelumab	38	31 (81.6)	0.87 (1.23)	-1.4	0.00	1.00	1.60	4.6	0.04 [-0.50, 0.58]
			Placebo	30	23 (76.7)	0.83 (1.19)	-0.8	0.00	0.40	1.60	3.8	
		Week 52	Tezepelumab	38	31 (81.6)	0.88 (1.23)	-1.6	0.00	1.00	1.60	4.6	0.19 [-0.35, 0.73]
			Placebo	30	23 (76.7)	0.63 (1.47)	-2.6	-0.20	0.40	1.60	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	28	27 (96.4)	4.28 (1.37)	1.4	3.60	4.40	5.00	6.4	
			Placebo	34	31 (91.2)	4.46 (1.33)	1.0	3.60	4.40	5.20	7.0	
		Week 4	Tezepelumab	28	25 (89.3)	5.18 (1.12)	3.4	4.20	5.00	6.00	7.0	
			Placebo	34	32 (94.1)	5.06 (1.36)	1.6	4.20	5.60	6.00	7.0	
		Week 8	Tezepelumab	28	27 (96.4)	5.29 (1.37)	2.8	4.00	5.60	6.60	7.0	
			Placebo	34	33 (97.1)	5.05 (1.23)	2.0	4.60	5.20	6.00	7.0	
		Week 12	Tezepelumab	28	27 (96.4)	5.58 (1.22)	2.8	4.60	5.80	7.00	7.0	
			Placebo	34	33 (97.1)	5.23 (1.31)	1.8	4.20	5.40	6.20	7.0	
		Week 16	Tezepelumab	28	27 (96.4)	5.61 (1.21)	2.8	4.40	5.60	6.80	7.0	
			Placebo	34	33 (97.1)	5.34 (1.25)	2.6	4.60	5.60	6.00	7.0	
		Week 20	Tezepelumab	28	27 (96.4)	5.61 (1.15)	2.8	4.60	5.80	6.80	7.0	
			Placebo	34	33 (97.1)	5.23 (1.23)	2.6	4.60	5.20	6.00	7.0	
		Week 24	Tezepelumab	28	27 (96.4)	5.45 (1.32)	2.8	4.00	5.60	6.80	7.0	
			Placebo	34	33 (97.1)	5.08 (1.34)	2.4	4.40	5.20	6.20	7.0	
		Week 28	Tezepelumab	28	27 (96.4)	5.52 (1.18)	2.8	4.40	5.60	6.40	7.0	
			Placebo	34	33 (97.1)	5.23 (1.33)	2.6	4.40	5.40	6.00	7.0	
		Week 32	Tezepelumab	28	27 (96.4)	5.56 (1.21)	2.8	4.60	5.80	6.60	7.0	
			Placebo	34	33 (97.1)	5.21 (1.27)	2.2	4.40	5.60	6.00	7.0	
		Week 36	Tezepelumab	28	27 (96.4)	5.70 (1.13)	2.8	5.00	6.00	6.80	7.0	
			Placebo	34	33 (97.1)	5.02 (1.34)	1.6	4.40	4.80	6.00	7.0	
		Week 40	Tezepelumab	28	27 (96.4)	5.62 (1.25)	2.8	4.60	5.60	6.80	7.0	
			Placebo	34	33 (97.1)	5.12 (1.42)	1.6	4.40	5.20	6.60	7.0	
		Week 44	Tezepelumab	28	27 (96.4)	5.73 (1.15)	2.8	5.00	6.20	6.60	7.0	
			Placebo	34	33 (97.1)	5.16 (1.37)	1.8	4.40	5.40	6.20	7.0	
		Week 48	Tezepelumab	28	27 (96.4)	5.71 (1.17)	2.8	4.80	6.00	6.80	7.0	
			Placebo	34	33 (97.1)	5.05 (1.35)	1.4	4.20	5.00	6.00	7.0	
		Week 52	Tezepelumab	28	27 (96.4)	5.73 (1.21)	2.8	4.60	6.00	7.00	7.0	
			Placebo	34	33 (97.1)	5.13 (1.32)	2.0	4.20	5.00	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	28	24 (85.7)	0.93 (1.09)	-1.2	0.20	0.90	1.80	3.0	0.37 [-0.17, 0.91]
			Placebo	34	31 (91.2)	0.55 (0.94)	-2.0	0.00	0.40	1.20	3.0	
		Week 8	Tezepelumab	28	26 (92.9)	0.95 (1.32)	-2.2	-0.20	1.10	2.20	3.4	0.27 [-0.26, 0.79]
			Placebo	34	31 (91.2)	0.64 (1.03)	-1.2	0.00	0.60	1.20	3.0	
		Week 12	Tezepelumab	28	26 (92.9)	1.24 (1.22)	-0.8	0.40	1.30	2.20	3.6	0.37 [-0.16, 0.89]
			Placebo	34	31 (91.2)	0.80 (1.19)	-1.8	0.00	0.80	1.80	3.6	
		Week 16	Tezepelumab	28	26 (92.9)	1.28 (1.18)	-0.6	0.60	1.30	2.20	3.4	0.32 [-0.21, 0.84]
			Placebo	34	31 (91.2)	0.92 (1.11)	-1.2	0.40	0.80	1.60	4.0	
		Week 20	Tezepelumab	28	26 (92.9)	1.28 (1.15)	-0.6	0.60	1.20	2.20	3.4	0.45 [-0.07, 0.98]
			Placebo	34	31 (91.2)	0.79 (0.99)	-1.2	0.00	0.80	1.60	2.6	
		Week 24	Tezepelumab	28	26 (92.9)	1.12 (1.41)	-1.4	0.00	1.30	2.20	3.8	0.33 [-0.19, 0.86]
			Placebo	34	31 (91.2)	0.68 (1.21)	-2.2	-0.20	0.20	1.80	2.6	
		Week 28	Tezepelumab	28	26 (92.9)	1.18 (1.24)	-1.0	0.60	1.00	2.20	3.6	0.28 [-0.24, 0.80]
			Placebo	34	31 (91.2)	0.83 (1.27)	-2.0	-0.20	0.60	1.80	4.0	
		Week 32	Tezepelumab	28	26 (92.9)	1.25 (1.30)	-0.6	0.40	1.10	2.40	3.6	0.36 [-0.17, 0.89]
			Placebo	34	31 (91.2)	0.81 (1.12)	-1.4	-0.20	1.20	1.60	3.0	
		Week 36	Tezepelumab	28	26 (92.9)	1.38 (1.30)	-1.0	0.60	1.20	2.40	3.8	0.65 [0.12, 1.19]
			Placebo	34	31 (91.2)	0.61 (1.07)	-2.0	-0.20	0.60	1.40	2.6	
		Week 40	Tezepelumab	28	26 (92.9)	1.29 (1.38)	-1.2	0.60	1.40	2.40	3.4	0.42 [-0.11, 0.94]
			Placebo	34	31 (91.2)	0.74 (1.30)	-2.0	-0.40	0.80	1.80	3.6	
		Week 44	Tezepelumab	28	26 (92.9)	1.40 (1.33)	-1.0	0.60	1.40	2.40	3.8	0.49 [-0.04, 1.02]
			Placebo	34	31 (91.2)	0.75 (1.34)	-1.8	-0.20	0.80	1.60	4.2	
		Week 48	Tezepelumab	28	26 (92.9)	1.39 (1.33)	-1.0	0.60	1.40	2.40	3.8	0.57 [0.04, 1.10]
			Placebo	34	31 (91.2)	0.66 (1.26)	-2.2	-0.20	0.60	1.40	4.2	
		Week 52	Tezepelumab	28	26 (92.9)	1.40 (1.36)	-0.6	0.60	1.40	2.40	3.8	0.50 [-0.03, 1.03]
			Placebo	34	31 (91.2)	0.75 (1.24)	-1.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	4.17 (0.97)	1.8	3.40	4.10	5.00	6.2	
			Placebo	27	21 (77.8)	4.44 (0.83)	3.6	3.80	4.20	4.40	6.2	
		Week 4	Tezepelumab	32	30 (93.8)	4.75 (1.18)	1.2	4.00	4.90	5.60	7.0	
			Placebo	27	23 (85.2)	4.73 (1.19)	1.6	4.00	4.60	5.40	7.0	
		Week 8	Tezepelumab	32	30 (93.8)	5.15 (1.01)	3.2	4.40	4.90	6.20	7.0	
			Placebo	27	23 (85.2)	4.89 (1.01)	2.6	4.20	4.80	5.60	7.0	
		Week 12	Tezepelumab	32	30 (93.8)	5.17 (1.15)	3.0	4.40	5.10	6.20	7.0	
			Placebo	27	23 (85.2)	4.92 (1.07)	2.6	4.20	4.60	5.80	6.8	
		Week 16	Tezepelumab	32	30 (93.8)	5.05 (1.19)	2.6	4.20	4.90	6.20	7.0	
			Placebo	27	23 (85.2)	4.88 (0.97)	2.8	4.40	4.60	5.20	7.0	
		Week 20	Tezepelumab	32	31 (96.9)	5.14 (1.15)	2.4	4.40	5.00	6.20	7.0	
			Placebo	27	23 (85.2)	4.89 (0.95)	3.0	4.00	4.80	5.20	6.6	
		Week 24	Tezepelumab	32	31 (96.9)	5.15 (1.17)	2.0	4.20	5.40	6.00	7.0	
			Placebo	27	23 (85.2)	5.06 (0.82)	3.8	4.40	5.00	5.60	7.0	
		Week 28	Tezepelumab	32	32 (100.0)	5.22 (1.04)	3.2	4.20	5.20	6.10	7.0	
			Placebo	27	24 (88.9)	5.01 (1.05)	3.4	4.10	4.90	5.90	7.0	
		Week 32	Tezepelumab	32	32 (100.0)	5.14 (1.01)	3.6	4.40	5.00	6.00	7.0	
			Placebo	27	24 (88.9)	5.12 (1.06)	3.0	4.30	5.00	6.10	7.0	
		Week 36	Tezepelumab	32	32 (100.0)	5.27 (1.23)	3.2	4.10	5.50	6.20	7.0	
			Placebo	27	24 (88.9)	5.25 (1.01)	3.0	4.60	5.20	5.90	7.0	
		Week 40	Tezepelumab	32	32 (100.0)	4.93 (1.24)	1.8	4.00	5.10	5.80	7.0	
			Placebo	27	24 (88.9)	5.12 (1.15)	2.8	4.40	5.00	6.00	7.0	
		Week 44	Tezepelumab	32	32 (100.0)	5.09 (1.10)	3.2	4.00	4.90	6.10	7.0	
			Placebo	27	24 (88.9)	5.04 (1.26)	3.2	4.00	4.60	6.50	7.0	
		Week 48	Tezepelumab	32	32 (100.0)	5.11 (1.04)	2.6	4.40	5.00	5.90	7.0	
			Placebo	27	24 (88.9)	5.18 (1.23)	3.6	4.00	4.90	6.40	7.0	
		Week 52	Tezepelumab	32	32 (100.0)	5.13 (1.01)	3.2	4.40	5.00	5.90	7.0	
			Placebo	27	24 (88.9)	5.00 (1.34)	2.2	4.00	4.70	6.30	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	32	26 (81.3)	0.55 (1.51)	-4.2	-0.20	0.70	1.60	3.8	0.12 [-0.45, 0.70]
			Placebo	27	21 (77.8)	0.38 (1.11)	-2.2	0.00	0.40	1.00	2.8	
		Week 8	Tezepelumab	32	26 (81.3)	0.91 (1.33)	-1.2	0.20	0.80	1.60	4.4	0.34 [-0.23, 0.92]
			Placebo	27	21 (77.8)	0.48 (1.15)	-1.6	-0.20	0.60	1.20	2.8	
		Week 12	Tezepelumab	32	26 (81.3)	0.91 (1.28)	-2.4	0.20	1.00	1.60	3.8	0.35 [-0.23, 0.93]
			Placebo	27	21 (77.8)	0.49 (1.10)	-1.6	0.20	0.60	1.20	2.6	
		Week 16	Tezepelumab	32	26 (81.3)	0.78 (1.36)	-2.8	0.00	0.80	1.60	4.0	0.27 [-0.31, 0.85]
			Placebo	27	21 (77.8)	0.45 (1.06)	-1.6	0.00	0.40	0.80	2.8	
		Week 20	Tezepelumab	32	26 (81.3)	1.01 (1.24)	-1.4	0.20	1.00	1.40	4.6	0.42 [-0.16, 1.00]
			Placebo	27	21 (77.8)	0.51 (1.10)	-2.2	0.00	0.80	1.20	2.4	
		Week 24	Tezepelumab	32	26 (81.3)	1.01 (1.23)	-1.4	0.00	0.70	1.80	4.6	0.34 [-0.24, 0.91]
			Placebo	27	21 (77.8)	0.64 (0.92)	-1.0	0.20	0.60	0.80	2.8	
		Week 28	Tezepelumab	32	26 (81.3)	1.03 (1.29)	-1.4	0.00	0.70	1.60	4.6	0.39 [-0.19, 0.97]
			Placebo	27	21 (77.8)	0.54 (1.19)	-2.2	0.00	0.80	1.00	2.8	
		Week 32	Tezepelumab	32	26 (81.3)	0.92 (1.17)	-1.4	0.20	0.90	1.40	4.6	0.22 [-0.36, 0.80]
			Placebo	27	21 (77.8)	0.69 (0.94)	-1.0	0.00	0.60	1.20	2.8	
		Week 36	Tezepelumab	32	26 (81.3)	1.12 (1.41)	-1.6	0.00	1.00	2.00	4.6	0.28 [-0.29, 0.86]
			Placebo	27	21 (77.8)	0.78 (0.89)	-0.8	0.40	0.60	1.40	2.6	
		Week 40	Tezepelumab	32	26 (81.3)	0.78 (1.33)	-2.4	0.00	0.70	1.60	4.6	0.10 [-0.47, 0.68]
			Placebo	27	21 (77.8)	0.66 (1.16)	-1.4	0.00	0.80	1.20	2.8	
		Week 44	Tezepelumab	32	26 (81.3)	0.84 (1.24)	-1.4	0.00	0.60	1.60	4.6	0.26 [-0.32, 0.83]
			Placebo	27	21 (77.8)	0.54 (1.03)	-1.0	-0.40	0.40	1.00	2.8	
		Week 48	Tezepelumab	32	26 (81.3)	0.89 (1.19)	-1.4	0.20	0.90	1.60	4.6	0.15 [-0.43, 0.73]
			Placebo	27	21 (77.8)	0.72 (1.03)	-0.8	0.00	0.40	1.20	2.8	
		Week 52	Tezepelumab	32	26 (81.3)	0.92 (1.18)	-1.6	0.00	0.90	1.60	4.6	0.32 [-0.26, 0.90]
			Placebo	27	21 (77.8)	0.51 (1.35)	-2.6	-0.20	0.40	1.20	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	4.34 (1.31)	1.4	3.60	4.40	5.30	6.4	
			Placebo	37	33 (89.2)	4.35 (1.36)	1.0	3.40	4.40	5.20	7.0	
		Week 4	Tezepelumab	34	30 (88.2)	5.01 (1.16)	3.2	4.00	4.80	6.00	7.0	
			Placebo	37	34 (91.9)	5.02 (1.36)	1.6	4.20	5.60	6.00	7.0	
		Week 8	Tezepelumab	34	32 (94.1)	5.17 (1.38)	2.8	4.00	5.40	6.40	7.0	
			Placebo	37	35 (94.6)	5.07 (1.23)	2.0	4.20	5.20	6.00	7.0	
		Week 12	Tezepelumab	34	32 (94.1)	5.56 (1.19)	2.8	4.60	5.70	6.50	7.0	
			Placebo	37	35 (94.6)	5.26 (1.32)	1.8	4.20	5.40	6.20	7.0	
		Week 16	Tezepelumab	34	32 (94.1)	5.56 (1.19)	2.8	4.60	5.60	6.70	7.0	
			Placebo	37	35 (94.6)	5.34 (1.28)	2.6	4.60	5.60	6.00	7.0	
		Week 20	Tezepelumab	34	32 (94.1)	5.63 (1.14)	2.8	4.70	5.80	6.70	7.0	
			Placebo	37	35 (94.6)	5.23 (1.24)	2.6	4.40	5.20	6.20	7.0	
		Week 24	Tezepelumab	34	32 (94.1)	5.41 (1.30)	2.8	4.10	5.40	6.60	7.0	
			Placebo	37	35 (94.6)	5.06 (1.38)	2.4	4.20	5.20	6.40	7.0	
		Week 28	Tezepelumab	34	33 (97.1)	5.52 (1.20)	2.8	4.40	5.60	6.40	7.0	
			Placebo	37	35 (94.6)	5.25 (1.34)	2.6	4.40	5.40	6.20	7.0	
		Week 32	Tezepelumab	34	33 (97.1)	5.55 (1.30)	2.6	4.60	5.80	6.60	7.0	
			Placebo	37	35 (94.6)	5.18 (1.34)	2.2	4.00	5.60	6.00	7.0	
		Week 36	Tezepelumab	34	33 (97.1)	5.70 (1.19)	2.8	5.00	6.00	6.80	7.0	
			Placebo	37	35 (94.6)	4.98 (1.40)	1.6	4.40	4.80	6.00	7.0	
		Week 40	Tezepelumab	34	33 (97.1)	5.64 (1.28)	2.8	4.80	6.00	6.80	7.0	
			Placebo	37	35 (94.6)	5.11 (1.40)	1.6	4.20	5.20	6.60	7.0	
		Week 44	Tezepelumab	34	33 (97.1)	5.72 (1.16)	2.8	5.00	6.20	6.60	7.0	
			Placebo	37	35 (94.6)	5.14 (1.37)	1.8	4.40	5.40	6.20	7.0	
		Week 48	Tezepelumab	34	33 (97.1)	5.68 (1.23)	2.6	5.00	6.00	6.80	7.0	
			Placebo	37	35 (94.6)	5.02 (1.39)	1.4	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	34	33 (97.1)	5.71 (1.26)	2.6	4.80	6.00	6.80	7.0	
			Placebo	37	35 (94.6)	5.10 (1.36)	2.0	4.00	5.00	6.20	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	34	29 (85.3)	0.69 (1.18)	-1.8	-0.20	0.60	1.40	3.0	0.06 [-0.44, 0.56]
			Placebo	37	33 (89.2)	0.62 (1.00)	-2.0	0.20	0.40	1.20	3.0	
		Week 8	Tezepelumab	34	31 (91.2)	0.78 (1.31)	-2.2	-0.40	1.00	2.00	3.4	0.01 [-0.48, 0.50]
			Placebo	37	33 (89.2)	0.76 (1.16)	-1.2	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	34	31 (91.2)	1.17 (1.21)	-0.8	0.20	1.20	2.20	3.6	0.19 [-0.31, 0.68]
			Placebo	37	33 (89.2)	0.93 (1.31)	-1.8	0.00	0.80	1.80	4.4	
		Week 16	Tezepelumab	34	31 (91.2)	1.17 (1.17)	-0.6	0.20	1.20	2.00	3.4	0.12 [-0.37, 0.61]
			Placebo	37	33 (89.2)	1.02 (1.23)	-1.2	0.40	0.80	1.60	4.4	
		Week 20	Tezepelumab	34	31 (91.2)	1.25 (1.16)	-0.6	0.60	1.20	2.20	3.4	0.30 [-0.19, 0.79]
			Placebo	37	33 (89.2)	0.90 (1.13)	-1.2	0.00	0.80	1.60	4.2	
		Week 24	Tezepelumab	34	31 (91.2)	1.03 (1.37)	-1.4	-0.20	1.20	2.00	3.8	0.19 [-0.30, 0.69]
			Placebo	37	33 (89.2)	0.76 (1.33)	-2.2	-0.20	0.20	1.80	4.2	
		Week 28	Tezepelumab	34	31 (91.2)	1.10 (1.22)	-1.0	0.00	1.20	2.00	3.6	0.11 [-0.38, 0.60]
			Placebo	37	33 (89.2)	0.95 (1.38)	-2.0	0.00	1.00	1.80	4.4	
		Week 32	Tezepelumab	34	31 (91.2)	1.14 (1.40)	-1.6	0.00	1.40	2.40	3.6	0.19 [-0.30, 0.69]
			Placebo	37	33 (89.2)	0.88 (1.25)	-1.4	-0.20	1.20	1.60	4.2	
		Week 36	Tezepelumab	34	31 (91.2)	1.30 (1.39)	-1.0	0.60	1.20	2.40	3.8	0.49 [-0.01, 0.99]
			Placebo	37	33 (89.2)	0.67 (1.19)	-2.0	-0.20	0.60	1.40	3.8	
		Week 40	Tezepelumab	34	31 (91.2)	1.23 (1.40)	-1.2	0.60	1.40	2.40	3.4	0.29 [-0.20, 0.79]
			Placebo	37	33 (89.2)	0.83 (1.34)	-2.0	-0.20	1.20	1.80	3.6	
		Week 44	Tezepelumab	34	31 (91.2)	1.32 (1.33)	-1.0	0.60	1.40	2.40	3.8	0.36 [-0.13, 0.86]
			Placebo	37	33 (89.2)	0.82 (1.38)	-1.8	-0.20	0.80	1.60	4.2	
		Week 48	Tezepelumab	34	31 (91.2)	1.29 (1.37)	-1.4	0.40	1.40	2.40	3.8	0.41 [-0.08, 0.91]
			Placebo	37	33 (89.2)	0.73 (1.34)	-2.2	-0.20	0.60	1.40	4.2	
		Week 52	Tezepelumab	34	31 (91.2)	1.29 (1.40)	-1.4	0.40	1.40	2.40	3.8	0.35 [-0.15, 0.84]
			Placebo	37	33 (89.2)	0.82 (1.33)	-1.6	0.00	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	25	21 (84.0)	4.25 (0.85)	2.6	3.60	4.00	4.80	6.2	
			Placebo	22	18 (81.8)	4.60 (1.38)	1.0	4.00	4.40	5.00	7.0	
		Week 4	Tezepelumab	25	24 (96.0)	4.74 (0.92)	3.2	4.00	4.80	5.20	7.0	
			Placebo	22	18 (81.8)	4.96 (1.58)	1.6	4.20	5.30	6.00	7.0	
		Week 8	Tezepelumab	25	24 (96.0)	5.15 (0.99)	3.4	4.50	4.90	6.00	7.0	
			Placebo	22	20 (90.9)	4.96 (1.20)	3.0	3.90	4.90	6.00	7.0	
		Week 12	Tezepelumab	25	24 (96.0)	5.43 (1.06)	3.8	4.60	5.20	6.50	7.0	
			Placebo	22	20 (90.9)	5.06 (1.42)	1.8	4.10	5.20	6.20	7.0	
		Week 16	Tezepelumab	25	24 (96.0)	5.33 (1.02)	4.0	4.50	5.00	6.20	7.0	
			Placebo	22	20 (90.9)	4.72 (1.65)	1.0	3.60	4.60	5.90	7.0	
		Week 20	Tezepelumab	25	24 (96.0)	5.33 (1.02)	4.0	4.60	5.00	6.20	7.0	
			Placebo	22	20 (90.9)	4.97 (1.57)	1.0	4.00	5.00	6.00	7.0	
		Week 24	Tezepelumab	25	24 (96.0)	5.34 (1.05)	3.4	4.40	5.40	6.20	7.0	
			Placebo	22	20 (90.9)	4.84 (1.69)	1.0	3.90	5.10	6.10	7.0	
		Week 28	Tezepelumab	25	25 (100.0)	5.32 (1.00)	4.0	4.60	5.00	6.20	7.0	
			Placebo	22	20 (90.9)	4.69 (1.68)	1.0	3.70	4.50	6.00	7.0	
		Week 32	Tezepelumab	25	25 (100.0)	5.31 (1.04)	3.6	4.60	5.00	6.20	7.0	
			Placebo	22	20 (90.9)	4.77 (1.64)	1.0	4.00	4.80	6.00	7.0	
		Week 36	Tezepelumab	25	25 (100.0)	5.46 (1.08)	4.0	4.60	5.40	6.20	7.0	
			Placebo	22	20 (90.9)	5.04 (1.50)	1.6	4.40	4.90	6.50	7.0	
		Week 40	Tezepelumab	25	25 (100.0)	5.18 (1.02)	3.8	4.40	5.00	6.20	7.0	
			Placebo	22	20 (90.9)	4.82 (1.56)	1.6	3.60	4.70	6.30	7.0	
		Week 44	Tezepelumab	25	25 (100.0)	5.18 (1.04)	3.4	4.40	5.00	6.20	7.0	
			Placebo	22	20 (90.9)	4.91 (1.44)	1.8	4.10	4.60	6.10	7.0	
		Week 48	Tezepelumab	25	25 (100.0)	5.19 (0.98)	4.0	4.40	5.00	5.80	7.0	
			Placebo	22	20 (90.9)	4.86 (1.59)	1.4	3.80	4.70	6.30	7.0	
		Week 52	Tezepelumab	25	25 (100.0)	5.21 (1.02)	4.0	4.40	5.00	5.80	7.0	
			Placebo	22	20 (90.9)	4.71 (1.47)	2.0	3.60	4.40	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	25	21 (84.0)	0.55 (0.78)	-1.0	0.00	0.60	1.20	1.8	0.15 [-0.49, 0.79]
			Placebo	22	17 (77.3)	0.41 (1.11)	-2.0	-0.20	0.60	0.80	2.8	
		Week 8	Tezepelumab	25	21 (84.0)	0.75 (0.93)	-1.2	0.20	0.80	1.20	2.4	0.26 [-0.37, 0.89]
			Placebo	22	18 (81.8)	0.49 (1.11)	-1.2	-0.20	0.20	1.20	2.8	
		Week 12	Tezepelumab	25	21 (84.0)	1.01 (0.84)	-0.6	0.40	1.00	1.60	2.4	0.43 [-0.21, 1.06]
			Placebo	22	18 (81.8)	0.57 (1.23)	-1.8	-0.40	0.40	1.80	2.6	
		Week 16	Tezepelumab	25	21 (84.0)	0.88 (0.91)	-1.2	0.40	1.00	1.60	2.2	0.58 [-0.06, 1.23]
			Placebo	22	18 (81.8)	0.19 (1.43)	-3.4	-1.00	0.30	1.00	2.8	
		Week 20	Tezepelumab	25	21 (84.0)	1.02 (0.83)	-0.6	0.40	1.20	1.40	2.4	0.49 [-0.15, 1.13]
			Placebo	22	18 (81.8)	0.43 (1.53)	-3.4	0.00	0.70	1.60	2.4	
		Week 24	Tezepelumab	25	21 (84.0)	0.99 (0.90)	-0.6	0.40	1.00	1.60	2.6	0.55 [-0.10, 1.19]
			Placebo	22	18 (81.8)	0.29 (1.63)	-3.4	-0.80	0.20	1.60	2.8	
		Week 28	Tezepelumab	25	21 (84.0)	1.04 (0.84)	-0.6	0.60	0.80	1.60	2.6	0.69 [0.04, 1.34]
			Placebo	22	18 (81.8)	0.13 (1.71)	-3.4	-1.00	-0.10	1.60	2.8	
		Week 32	Tezepelumab	25	21 (84.0)	1.04 (0.87)	-0.6	0.40	1.20	1.60	2.4	0.65 [0.01, 1.30]
			Placebo	22	18 (81.8)	0.23 (1.56)	-3.4	-0.80	0.00	1.60	2.8	
		Week 36	Tezepelumab	25	21 (84.0)	1.22 (0.98)	-0.6	0.60	1.20	1.80	3.8	0.66 [0.01, 1.31]
			Placebo	22	18 (81.8)	0.49 (1.24)	-2.0	-0.20	0.50	1.00	2.6	
		Week 40	Tezepelumab	25	21 (84.0)	0.88 (0.78)	-0.6	0.40	1.00	1.40	2.2	0.48 [-0.16, 1.12]
			Placebo	22	18 (81.8)	0.32 (1.48)	-2.0	-1.00	0.10	1.80	2.8	
		Week 44	Tezepelumab	25	21 (84.0)	0.89 (0.85)	-0.6	0.20	0.80	1.60	2.4	0.57 [-0.08, 1.21]
			Placebo	22	18 (81.8)	0.30 (1.22)	-1.8	-0.60	0.30	0.80	2.8	
		Week 48	Tezepelumab	25	21 (84.0)	0.93 (0.74)	-0.6	0.40	1.00	1.40	2.2	0.59 [-0.05, 1.24]
			Placebo	22	18 (81.8)	0.30 (1.36)	-2.2	-0.60	0.10	1.40	2.8	
		Week 52	Tezepelumab	25	21 (84.0)	0.93 (0.77)	-0.6	0.40	1.00	1.40	2.4	0.66 [0.01, 1.31]
			Placebo	22	18 (81.8)	0.17 (1.49)	-2.6	-0.80	-0.20	1.40	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	35	33 (94.3)	4.24 (1.27)	1.4	3.40	4.20	5.00	6.4	
			Placebo	41	35 (85.4)	4.25 (1.06)	2.0	3.60	4.20	5.20	6.6	
		Week 4	Tezepelumab	35	31 (88.6)	4.95 (1.36)	1.2	4.00	5.60	6.00	7.0	
			Placebo	41	37 (90.2)	4.88 (1.17)	1.6	4.20	4.80	5.60	7.0	
		Week 8	Tezepelumab	35	33 (94.3)	5.15 (1.36)	2.8	4.00	5.60	6.20	7.0	
			Placebo	41	37 (90.2)	4.95 (1.16)	2.0	4.40	5.00	5.60	7.0	
		Week 12	Tezepelumab	35	33 (94.3)	5.38 (1.31)	2.8	4.40	5.80	6.40	7.0	
			Placebo	41	37 (90.2)	5.10 (1.14)	2.6	4.20	5.00	6.00	7.0	
		Week 16	Tezepelumab	35	33 (94.3)	5.33 (1.33)	2.6	4.20	5.60	6.20	7.0	
			Placebo	41	37 (90.2)	5.23 (1.05)	2.8	4.60	5.00	5.80	7.0	
		Week 20	Tezepelumab	35	33 (94.3)	5.47 (1.20)	2.8	4.40	5.80	6.40	7.0	
			Placebo	41	37 (90.2)	5.02 (1.08)	3.0	4.40	5.00	5.80	7.0	
		Week 24	Tezepelumab	35	33 (94.3)	5.30 (1.27)	2.8	4.00	5.40	6.40	7.0	
			Placebo	41	37 (90.2)	5.03 (1.05)	2.8	4.40	5.00	5.60	7.0	
		Week 28	Tezepelumab	35	34 (97.1)	5.39 (1.24)	2.8	4.20	5.60	6.40	7.0	
			Placebo	41	38 (92.7)	5.25 (1.10)	3.6	4.40	5.20	6.00	7.0	
		Week 32	Tezepelumab	35	34 (97.1)	5.36 (1.28)	2.6	4.20	5.70	6.40	7.0	
			Placebo	41	38 (92.7)	5.22 (1.16)	2.6	4.40	5.20	6.00	7.0	
		Week 36	Tezepelumab	35	34 (97.1)	5.51 (1.34)	2.8	4.40	6.00	6.60	7.0	
			Placebo	41	38 (92.7)	5.03 (1.18)	2.2	4.40	4.90	5.80	7.0	
		Week 40	Tezepelumab	35	34 (97.1)	5.42 (1.43)	1.8	4.20	5.60	6.80	7.0	
			Placebo	41	38 (92.7)	5.20 (1.17)	2.8	4.40	5.10	6.40	7.0	
		Week 44	Tezepelumab	35	34 (97.1)	5.54 (1.25)	2.8	4.40	6.00	6.60	7.0	
			Placebo	41	38 (92.7)	5.12 (1.28)	2.6	4.00	5.20	6.20	7.0	
		Week 48	Tezepelumab	35	34 (97.1)	5.49 (1.31)	2.6	4.60	5.80	6.40	7.0	
			Placebo	41	38 (92.7)	5.12 (1.17)	2.8	4.00	5.00	6.00	7.0	
		Week 52	Tezepelumab	35	34 (97.1)	5.54 (1.28)	2.6	4.60	5.90	6.80	7.0	
			Placebo	41	38 (92.7)	5.14 (1.28)	2.2	4.20	5.00	6.40	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	35	30 (85.7)	0.66 (1.52)	-4.2	-0.40	0.60	1.80	3.0	0.04 [-0.45, 0.53]
			Placebo	41	35 (85.4)	0.61 (1.04)	-2.2	0.20	0.40	1.20	3.0	
		Week 8	Tezepelumab	35	32 (91.4)	0.89 (1.38)	-2.2	-0.30	1.10	2.10	3.4	0.16 [-0.32, 0.64]
			Placebo	41	35 (85.4)	0.69 (1.22)	-1.6	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	35	32 (91.4)	1.12 (1.35)	-2.4	0.10	1.30	2.10	3.6	0.23 [-0.25, 0.71]
			Placebo	41	35 (85.4)	0.82 (1.27)	-1.6	0.20	0.80	1.40	4.4	
		Week 16	Tezepelumab	35	32 (91.4)	1.07 (1.37)	-2.8	0.00	1.10	2.30	3.4	0.08 [-0.40, 0.56]
			Placebo	41	35 (85.4)	0.97 (1.20)	-1.6	0.20	0.80	1.40	4.4	
		Week 20	Tezepelumab	35	32 (91.4)	1.22 (1.23)	-1.4	0.50	1.20	2.20	3.4	0.38 [-0.11, 0.86]
			Placebo	41	35 (85.4)	0.78 (1.09)	-1.4	0.20	0.80	1.40	4.2	
		Week 24	Tezepelumab	35	32 (91.4)	1.04 (1.36)	-1.4	-0.10	1.10	2.10	3.8	0.20 [-0.28, 0.68]
			Placebo	41	35 (85.4)	0.80 (1.09)	-1.0	0.00	0.80	1.40	4.2	
		Week 28	Tezepelumab	35	32 (91.4)	1.09 (1.31)	-1.4	0.00	1.00	2.20	3.6	0.07 [-0.41, 0.55]
			Placebo	41	35 (85.4)	1.00 (1.19)	-1.6	0.20	0.80	1.60	4.4	
		Week 32	Tezepelumab	35	32 (91.4)	1.07 (1.35)	-1.4	0.00	1.00	2.20	3.6	0.08 [-0.40, 0.56]
			Placebo	41	35 (85.4)	0.98 (1.02)	-0.8	0.40	1.20	1.40	4.2	
		Week 36	Tezepelumab	35	32 (91.4)	1.22 (1.52)	-1.6	-0.10	1.30	2.50	3.8	0.36 [-0.12, 0.84]
			Placebo	41	35 (85.4)	0.75 (1.04)	-1.4	0.20	0.60	1.40	3.8	
		Week 40	Tezepelumab	35	32 (91.4)	1.14 (1.53)	-2.4	0.20	1.40	2.40	3.4	0.15 [-0.33, 0.63]
			Placebo	41	35 (85.4)	0.94 (1.13)	-1.0	0.20	0.80	1.60	3.6	
		Week 44	Tezepelumab	35	32 (91.4)	1.24 (1.40)	-1.4	0.20	1.40	2.40	3.8	0.29 [-0.19, 0.77]
			Placebo	41	35 (85.4)	0.86 (1.25)	-1.6	-0.20	0.80	1.20	4.2	
		Week 48	Tezepelumab	35	32 (91.4)	1.20 (1.45)	-1.4	0.10	1.40	2.30	3.8	0.25 [-0.23, 0.73]
			Placebo	41	35 (85.4)	0.88 (1.11)	-0.8	0.00	0.60	1.40	4.2	
		Week 52	Tezepelumab	35	32 (91.4)	1.24 (1.44)	-1.6	0.00	1.40	2.30	3.8	0.27 [-0.21, 0.75]
			Placebo	41	35 (85.4)	0.89 (1.20)	-1.6	0.00	0.80	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	41	36 (87.8)	4.43 (1.04)	1.8	3.90	4.40	5.10	6.4	
			Placebo	30	25 (83.3)	4.30 (1.35)	1.0	3.80	4.20	4.80	7.0	
		Week 4	Tezepelumab	41	37 (90.2)	5.02 (1.02)	3.2	4.00	5.00	6.00	7.0	
			Placebo	30	24 (80.0)	4.50 (1.50)	1.6	3.50	4.70	5.60	6.8	
		Week 8	Tezepelumab	41	38 (92.7)	5.35 (1.19)	2.8	4.60	5.50	6.20	7.0	
			Placebo	30	26 (86.7)	4.72 (1.20)	2.0	3.80	5.00	5.60	6.4	
		Week 12	Tezepelumab	41	38 (92.7)	5.55 (1.09)	3.8	4.60	5.60	6.40	7.0	
			Placebo	30	26 (86.7)	4.83 (1.35)	1.8	4.00	4.90	6.00	7.0	
		Week 16	Tezepelumab	41	38 (92.7)	5.55 (1.07)	3.6	4.60	5.60	6.60	7.0	
			Placebo	30	26 (86.7)	4.68 (1.52)	1.0	3.60	4.70	5.80	7.0	
		Week 20	Tezepelumab	41	39 (95.1)	5.59 (1.02)	4.0	4.60	5.80	6.40	7.0	
			Placebo	30	26 (86.7)	4.69 (1.42)	1.0	4.00	4.70	5.80	7.0	
		Week 24	Tezepelumab	41	39 (95.1)	5.55 (1.09)	3.2	4.60	5.80	6.40	7.0	
			Placebo	30	26 (86.7)	4.58 (1.46)	1.0	3.80	4.70	5.40	7.0	
		Week 28	Tezepelumab	41	40 (97.6)	5.53 (1.10)	3.4	4.60	5.60	6.40	7.0	
			Placebo	30	26 (86.7)	4.63 (1.50)	1.0	3.80	4.50	6.00	7.0	
		Week 32	Tezepelumab	41	40 (97.6)	5.50 (1.14)	2.6	4.60	5.70	6.40	7.0	
			Placebo	30	26 (86.7)	4.58 (1.50)	1.0	3.80	4.50	6.00	7.0	
		Week 36	Tezepelumab	41	40 (97.6)	5.67 (1.16)	3.0	4.60	6.00	6.70	7.0	
			Placebo	30	26 (86.7)	4.68 (1.43)	1.6	3.60	4.70	5.40	7.0	
		Week 40	Tezepelumab	41	40 (97.6)	5.47 (1.17)	2.8	4.40	5.50	6.60	7.0	
			Placebo	30	26 (86.7)	4.68 (1.50)	1.6	3.60	4.60	6.20	7.0	
		Week 44	Tezepelumab	41	40 (97.6)	5.50 (1.10)	3.4	4.50	5.50	6.60	7.0	
			Placebo	30	26 (86.7)	4.65 (1.38)	1.8	3.60	4.60	6.00	7.0	
		Week 48	Tezepelumab	41	40 (97.6)	5.54 (1.16)	2.6	4.60	5.60	6.60	7.0	
			Placebo	30	26 (86.7)	4.56 (1.41)	1.4	3.60	4.30	6.00	7.0	
		Week 52	Tezepelumab	41	40 (97.6)	5.54 (1.18)	2.6	4.60	5.60	6.80	7.0	
			Placebo	30	26 (86.7)	4.38 (1.36)	2.0	3.60	4.20	5.80	6.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	41	34 (82.9)	0.71 (1.23)	-1.8	-0.20	0.60	1.60	3.8	0.44 [-0.09, 0.97]
			Placebo	30	24 (80.0)	0.21 (0.95)	-2.2	-0.20	0.30	0.80	1.8	
		Week 8	Tezepelumab	41	35 (85.4)	0.84 (1.43)	-2.2	-0.20	1.00	2.00	4.4	0.29 [-0.23, 0.81]
			Placebo	30	25 (83.3)	0.47 (1.00)	-1.2	-0.20	0.20	1.20	2.2	
		Week 12	Tezepelumab	41	35 (85.4)	1.03 (1.20)	-0.8	0.00	1.00	2.00	3.8	0.36 [-0.15, 0.88]
			Placebo	30	25 (83.3)	0.58 (1.25)	-1.8	-0.40	0.60	1.40	3.6	
		Week 16	Tezepelumab	41	35 (85.4)	1.01 (1.23)	-1.2	0.00	1.00	2.00	4.0	0.44 [-0.08, 0.96]
			Placebo	30	25 (83.3)	0.43 (1.44)	-3.4	0.00	0.40	1.00	4.0	
		Week 20	Tezepelumab	41	35 (85.4)	1.14 (1.21)	-0.6	0.20	1.00	2.00	4.6	0.58 [0.05, 1.10]
			Placebo	30	25 (83.3)	0.42 (1.30)	-3.4	0.00	0.80	1.40	2.2	
		Week 24	Tezepelumab	41	35 (85.4)	1.07 (1.33)	-1.4	0.00	1.00	2.00	4.6	0.56 [0.04, 1.09]
			Placebo	30	25 (83.3)	0.31 (1.37)	-3.4	-0.20	0.20	1.00	2.4	
		Week 28	Tezepelumab	41	35 (85.4)	1.10 (1.26)	-1.0	0.00	1.00	2.00	4.6	0.53 [0.00, 1.05]
			Placebo	30	25 (83.3)	0.35 (1.61)	-3.4	-0.20	0.00	1.40	4.0	
		Week 32	Tezepelumab	41	35 (85.4)	1.05 (1.29)	-1.6	0.20	1.20	2.00	4.6	0.55 [0.03, 1.07]
			Placebo	30	25 (83.3)	0.31 (1.39)	-3.4	-0.60	0.00	1.40	3.0	
		Week 36	Tezepelumab	41	35 (85.4)	1.23 (1.32)	-1.0	0.40	1.20	2.00	4.6	0.68 [0.15, 1.20]
			Placebo	30	25 (83.3)	0.40 (1.09)	-2.0	-0.40	0.60	1.00	2.2	
		Week 40	Tezepelumab	41	35 (85.4)	1.02 (1.28)	-1.2	0.00	1.00	2.00	4.6	0.43 [-0.09, 0.95]
			Placebo	30	25 (83.3)	0.43 (1.49)	-2.0	-1.00	0.40	1.60	3.6	
		Week 44	Tezepelumab	41	35 (85.4)	1.03 (1.23)	-0.6	0.00	0.80	1.60	4.6	0.55 [0.03, 1.07]
			Placebo	30	25 (83.3)	0.35 (1.25)	-1.8	-0.60	0.20	0.80	3.2	
		Week 48	Tezepelumab	41	35 (85.4)	1.10 (1.24)	-1.4	0.20	1.20	1.80	4.6	0.67 [0.14, 1.19]
			Placebo	30	25 (83.3)	0.30 (1.14)	-2.2	-0.40	0.20	0.60	2.6	
		Week 52	Tezepelumab	41	35 (85.4)	1.09 (1.27)	-1.4	0.00	1.20	1.80	4.6	0.77 [0.24, 1.30]
			Placebo	30	25 (83.3)	0.12 (1.26)	-2.6	-0.60	0.00	0.80	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	25	22 (88.0)	3.99 (1.31)	1.4	3.40	4.00	4.80	6.4	
			Placebo	34	29 (85.3)	4.47 (1.01)	2.6	3.80	4.40	5.40	6.6	
		Week 4	Tezepelumab	25	23 (92.0)	4.65 (1.37)	1.2	3.60	4.60	5.80	7.0	
			Placebo	34	32 (94.1)	5.14 (1.00)	3.8	4.20	5.20	5.90	7.0	
		Week 8	Tezepelumab	25	24 (96.0)	4.87 (1.19)	3.0	4.00	4.60	5.70	7.0	
			Placebo	34	32 (94.1)	5.11 (1.06)	3.0	4.50	5.00	5.90	7.0	
		Week 12	Tezepelumab	25	24 (96.0)	5.08 (1.27)	2.8	4.40	5.10	6.10	7.0	
			Placebo	34	32 (94.1)	5.28 (1.06)	3.6	4.40	5.20	6.10	7.0	
		Week 16	Tezepelumab	25	24 (96.0)	4.93 (1.33)	2.6	4.20	4.70	6.00	7.0	
			Placebo	34	32 (94.1)	5.35 (0.96)	3.6	4.60	5.10	5.90	7.0	
		Week 20	Tezepelumab	25	24 (96.0)	5.04 (1.31)	2.4	4.20	5.10	6.00	7.0	
			Placebo	34	32 (94.1)	5.25 (1.04)	3.2	4.70	5.10	6.10	7.0	
		Week 24	Tezepelumab	25	24 (96.0)	4.85 (1.35)	2.0	4.00	4.70	6.00	7.0	
			Placebo	34	32 (94.1)	5.26 (1.02)	3.2	4.50	5.20	6.10	7.0	
		Week 28	Tezepelumab	25	25 (100.0)	5.13 (1.14)	2.8	4.20	5.00	6.00	7.0	
			Placebo	34	33 (97.1)	5.38 (1.07)	3.4	4.60	5.40	6.20	7.0	
		Week 32	Tezepelumab	25	25 (100.0)	5.10 (1.20)	2.8	4.20	5.00	5.80	7.0	
			Placebo	34	33 (97.1)	5.42 (1.03)	3.8	4.60	5.60	6.20	7.0	
		Week 36	Tezepelumab	25	25 (100.0)	5.21 (1.30)	2.8	4.20	5.20	6.20	7.0	
			Placebo	34	33 (97.1)	5.30 (1.07)	3.0	4.60	5.20	6.00	7.0	
		Week 40	Tezepelumab	25	25 (100.0)	4.99 (1.47)	1.8	4.20	5.20	6.00	7.0	
			Placebo	34	33 (97.1)	5.35 (1.03)	3.4	4.40	5.20	6.00	7.0	
		Week 44	Tezepelumab	25	25 (100.0)	5.26 (1.26)	2.8	4.40	5.40	6.20	7.0	
			Placebo	34	33 (97.1)	5.35 (1.18)	2.6	4.40	5.40	6.60	7.0	
		Week 48	Tezepelumab	25	25 (100.0)	5.18 (1.16)	2.6	4.40	5.00	6.00	7.0	
			Placebo	34	33 (97.1)	5.39 (1.11)	3.6	4.60	5.20	6.40	7.0	
		Week 52	Tezepelumab	25	25 (100.0)	5.24 (1.15)	2.8	4.40	5.40	6.00	7.0	
			Placebo	34	33 (97.1)	5.48 (1.12)	4.0	4.60	5.40	6.60	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	25	21 (84.0)	0.49 (1.52)	-4.2	-0.20	0.60	1.60	2.6	-0.19 [-0.75, 0.38]
			Placebo	34	29 (85.3)	0.72 (1.00)	-1.6	0.20	0.60	1.20	3.0	
		Week 8	Tezepelumab	25	22 (88.0)	0.84 (1.12)	-1.2	-0.20	0.90	1.60	2.4	0.13 [-0.42, 0.69]
			Placebo	34	29 (85.3)	0.68 (1.26)	-1.6	0.20	0.60	1.20	4.0	
		Week 12	Tezepelumab	25	22 (88.0)	1.08 (1.32)	-2.4	0.40	1.30	1.80	3.0	0.21 [-0.34, 0.77]
			Placebo	34	29 (85.3)	0.81 (1.21)	-1.6	0.20	0.80	1.20	4.4	
		Week 16	Tezepelumab	25	22 (88.0)	0.96 (1.34)	-2.8	0.20	1.00	1.40	3.4	0.05 [-0.50, 0.61]
			Placebo	34	29 (85.3)	0.90 (1.13)	-1.6	0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	25	22 (88.0)	1.13 (1.20)	-1.4	0.40	1.20	2.20	3.2	0.25 [-0.31, 0.80]
			Placebo	34	29 (85.3)	0.83 (1.17)	-1.4	0.20	0.80	1.60	4.2	
		Week 24	Tezepelumab	25	22 (88.0)	0.94 (1.27)	-1.4	-0.20	0.90	1.40	3.8	0.07 [-0.48, 0.63]
			Placebo	34	29 (85.3)	0.85 (1.15)	-1.0	0.00	0.80	1.40	4.2	
		Week 28	Tezepelumab	25	22 (88.0)	1.02 (1.24)	-1.4	0.00	0.80	1.60	3.6	0.05 [-0.50, 0.60]
			Placebo	34	29 (85.3)	0.96 (1.15)	-1.6	0.20	0.80	1.80	4.4	
		Week 32	Tezepelumab	25	22 (88.0)	1.04 (1.33)	-1.4	0.00	0.80	2.20	3.6	0.01 [-0.54, 0.57]
			Placebo	34	29 (85.3)	1.02 (1.00)	-0.6	0.40	1.20	1.40	4.2	
		Week 36	Tezepelumab	25	22 (88.0)	1.20 (1.52)	-1.6	0.00	1.20	2.60	3.8	0.28 [-0.28, 0.84]
			Placebo	34	29 (85.3)	0.84 (1.05)	-1.4	0.40	0.60	1.40	3.8	
		Week 40	Tezepelumab	25	22 (88.0)	1.04 (1.54)	-2.4	0.60	1.10	2.00	3.4	0.10 [-0.46, 0.65]
			Placebo	34	29 (85.3)	0.92 (0.98)	-0.8	0.20	0.80	1.40	3.4	
		Week 44	Tezepelumab	25	22 (88.0)	1.20 (1.43)	-1.4	0.00	1.30	2.40	3.8	0.23 [-0.32, 0.79]
			Placebo	34	29 (85.3)	0.90 (1.19)	-1.6	0.40	1.00	1.20	4.2	
		Week 48	Tezepelumab	25	22 (88.0)	1.12 (1.40)	-1.4	0.20	1.00	2.20	3.8	0.12 [-0.44, 0.67]
			Placebo	34	29 (85.3)	0.97 (1.20)	-0.8	0.00	0.80	1.40	4.2	
		Week 52	Tezepelumab	25	22 (88.0)	1.16 (1.40)	-1.6	0.20	1.10	2.40	3.8	0.07 [-0.48, 0.63]
			Placebo	34	29 (85.3)	1.07 (1.22)	-0.8	0.20	0.80	1.60	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	26	23 (88.5)	4.25 (0.94)	2.6	3.40	4.20	5.00	6.2	
			Placebo	31	25 (80.6)	4.42 (1.16)	1.0	3.80	4.40	5.20	6.6	
		Week 4	Tezepelumab	26	23 (88.5)	4.57 (1.35)	1.2	3.80	4.40	5.20	7.0	
			Placebo	31	25 (80.6)	4.82 (1.48)	1.6	4.20	4.60	5.60	7.0	
		Week 8	Tezepelumab	26	23 (88.5)	4.85 (1.25)	2.8	4.00	4.60	6.00	7.0	
			Placebo	31	27 (87.1)	4.95 (1.24)	3.0	3.80	5.00	6.00	7.0	
		Week 12	Tezepelumab	26	23 (88.5)	5.06 (1.21)	3.0	4.20	5.00	6.20	7.0	
			Placebo	31	27 (87.1)	5.02 (1.43)	1.8	4.00	5.00	6.60	7.0	
		Week 16	Tezepelumab	26	23 (88.5)	4.89 (1.16)	2.6	4.00	4.80	6.00	7.0	
			Placebo	31	27 (87.1)	5.12 (1.51)	1.0	4.40	5.00	6.20	7.0	
		Week 20	Tezepelumab	26	24 (92.3)	5.15 (1.04)	2.8	4.60	4.90	5.90	7.0	
			Placebo	31	27 (87.1)	5.05 (1.44)	1.0	4.40	5.00	6.40	7.0	
		Week 24	Tezepelumab	26	24 (92.3)	5.07 (1.05)	3.0	4.10	5.00	5.80	7.0	
			Placebo	31	27 (87.1)	5.04 (1.46)	1.0	4.40	5.20	6.20	7.0	
		Week 28	Tezepelumab	26	26 (100.0)	5.17 (1.09)	3.2	4.20	5.00	6.20	7.0	
			Placebo	31	28 (90.3)	5.14 (1.55)	1.0	4.40	5.40	6.30	7.0	
		Week 32	Tezepelumab	26	26 (100.0)	5.09 (1.09)	3.6	4.00	5.00	6.20	7.0	
			Placebo	31	28 (90.3)	5.14 (1.57)	1.0	4.30	5.40	6.40	7.0	
		Week 36	Tezepelumab	26	26 (100.0)	5.28 (1.20)	3.2	4.40	5.30	6.20	7.0	
			Placebo	31	28 (90.3)	5.14 (1.40)	1.6	4.40	5.10	6.10	7.0	
		Week 40	Tezepelumab	26	26 (100.0)	5.09 (1.24)	1.8	4.20	5.10	6.20	7.0	
			Placebo	31	28 (90.3)	5.21 (1.50)	1.6	4.30	5.50	6.60	7.0	
		Week 44	Tezepelumab	26	26 (100.0)	5.08 (1.14)	3.2	4.00	5.00	6.20	7.0	
			Placebo	31	28 (90.3)	5.34 (1.51)	1.8	4.40	5.60	6.60	7.0	
		Week 48	Tezepelumab	26	26 (100.0)	5.22 (1.14)	2.6	4.40	5.00	6.40	7.0	
			Placebo	31	28 (90.3)	5.15 (1.57)	1.4	4.00	5.30	6.80	7.0	
		Week 52	Tezepelumab	26	26 (100.0)	5.25 (1.13)	3.2	4.40	5.00	6.40	7.0	
			Placebo	31	28 (90.3)	5.16 (1.53)	2.0	4.00	5.00	6.80	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	26	23 (88.5)	0.31 (1.52)	-4.2	-0.40	0.60	1.60	2.4	-0.10 [-0.67, 0.47]
			Placebo	31	24 (77.4)	0.44 (1.05)	-2.0	0.00	0.40	0.70	3.0	
		Week 8	Tezepelumab	26	23 (88.5)	0.60 (1.36)	-2.2	-0.20	0.60	1.60	3.2	-0.02 [-0.59, 0.55]
			Placebo	31	25 (80.6)	0.62 (1.18)	-1.6	0.00	0.60	1.20	3.0	
		Week 12	Tezepelumab	26	23 (88.5)	0.81 (1.19)	-2.4	0.00	1.00	1.60	3.0	0.10 [-0.46, 0.67]
			Placebo	31	25 (80.6)	0.68 (1.26)	-1.8	0.00	0.80	1.20	3.6	
		Week 16	Tezepelumab	26	23 (88.5)	0.63 (1.25)	-2.8	-0.20	0.60	1.60	2.6	-0.11 [-0.68, 0.46]
			Placebo	31	25 (80.6)	0.78 (1.42)	-3.4	0.20	0.60	1.60	4.0	
		Week 20	Tezepelumab	26	23 (88.5)	0.88 (1.03)	-1.4	0.20	1.00	1.40	3.2	0.17 [-0.40, 0.73]
			Placebo	31	25 (80.6)	0.69 (1.25)	-3.4	-0.20	0.80	1.40	2.4	
		Week 24	Tezepelumab	26	23 (88.5)	0.79 (1.08)	-1.4	0.00	0.60	1.60	2.6	0.09 [-0.47, 0.66]
			Placebo	31	25 (80.6)	0.68 (1.31)	-3.4	-0.20	0.80	1.80	2.8	
		Week 28	Tezepelumab	26	23 (88.5)	0.89 (1.13)	-1.4	0.00	0.60	1.60	3.2	0.13 [-0.44, 0.70]
			Placebo	31	25 (80.6)	0.72 (1.42)	-3.4	0.00	0.80	1.60	4.0	
		Week 32	Tezepelumab	26	23 (88.5)	0.73 (1.04)	-1.6	0.20	0.80	1.40	2.4	0.01 [-0.56, 0.57]
			Placebo	31	25 (80.6)	0.72 (1.35)	-3.4	0.40	0.60	1.60	3.0	
		Week 36	Tezepelumab	26	23 (88.5)	0.96 (1.25)	-1.6	0.00	1.20	1.80	3.8	0.23 [-0.34, 0.79]
			Placebo	31	25 (80.6)	0.70 (1.06)	-2.0	0.40	0.60	1.40	2.6	
		Week 40	Tezepelumab	26	23 (88.5)	0.79 (1.17)	-2.4	0.00	1.00	1.60	2.8	-0.03 [-0.60, 0.53]
			Placebo	31	25 (80.6)	0.83 (1.29)	-2.0	0.00	0.80	1.80	3.6	
		Week 44	Tezepelumab	26	23 (88.5)	0.74 (1.00)	-1.4	-0.20	0.80	1.60	2.6	-0.11 [-0.68, 0.45]
			Placebo	31	25 (80.6)	0.88 (1.40)	-1.8	-0.20	0.80	1.60	4.2	
		Week 48	Tezepelumab	26	23 (88.5)	0.90 (1.01)	-1.4	0.20	1.00	1.60	2.6	0.16 [-0.41, 0.73]
			Placebo	31	25 (80.6)	0.71 (1.35)	-2.2	-0.20	0.60	1.60	4.2	
		Week 52	Tezepelumab	26	23 (88.5)	0.91 (1.02)	-1.6	0.00	1.00	1.60	2.8	0.14 [-0.43, 0.70]
			Placebo	31	25 (80.6)	0.75 (1.31)	-1.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	4.27 (1.30)	1.4	3.60	4.40	5.20	6.4	
			Placebo	34	30 (88.2)	4.36 (1.18)	2.0	3.60	4.20	4.60	7.0	
		Week 4	Tezepelumab	40	37 (92.5)	5.08 (1.01)	3.2	4.00	5.20	6.00	7.0	
			Placebo	34	32 (94.1)	4.97 (1.13)	1.6	4.20	5.00	5.80	6.8	
		Week 8	Tezepelumab	40	39 (97.5)	5.34 (1.15)	3.0	4.40	5.60	6.20	7.0	
			Placebo	34	32 (94.1)	4.99 (1.09)	2.0	4.60	5.10	5.60	7.0	
		Week 12	Tezepelumab	40	39 (97.5)	5.55 (1.13)	2.8	4.40	5.80	6.40	7.0	
			Placebo	34	32 (94.1)	5.18 (1.03)	2.6	4.50	5.20	6.00	7.0	
		Week 16	Tezepelumab	40	39 (97.5)	5.56 (1.18)	2.8	4.40	5.80	6.60	7.0	
			Placebo	34	32 (94.1)	5.06 (1.09)	2.8	4.30	5.00	5.80	7.0	
		Week 20	Tezepelumab	40	39 (97.5)	5.53 (1.22)	2.4	4.40	5.80	6.60	7.0	
			Placebo	34	32 (94.1)	5.01 (1.09)	3.0	4.00	5.00	5.80	7.0	
		Week 24	Tezepelumab	40	39 (97.5)	5.42 (1.33)	2.0	4.20	5.80	6.60	7.0	
			Placebo	34	32 (94.1)	4.95 (1.15)	2.4	4.20	5.00	5.80	7.0	
		Week 28	Tezepelumab	40	39 (97.5)	5.51 (1.14)	2.8	4.40	5.60	6.40	7.0	
			Placebo	34	32 (94.1)	5.03 (1.13)	2.6	4.00	5.10	6.00	7.0	
		Week 32	Tezepelumab	40	39 (97.5)	5.52 (1.21)	2.6	4.40	5.80	6.40	7.0	
			Placebo	34	32 (94.1)	5.04 (1.10)	2.6	4.00	5.10	5.90	7.0	
		Week 36	Tezepelumab	40	39 (97.5)	5.63 (1.24)	2.8	4.60	6.00	6.60	7.0	
			Placebo	34	32 (94.1)	4.98 (1.17)	2.2	4.40	4.90	5.70	7.0	
		Week 40	Tezepelumab	40	39 (97.5)	5.42 (1.34)	2.0	4.40	5.60	6.60	7.0	
			Placebo	34	32 (94.1)	4.98 (1.12)	2.8	4.30	4.90	5.90	7.0	
		Week 44	Tezepelumab	40	39 (97.5)	5.63 (1.14)	2.8	4.80	6.00	6.60	7.0	
			Placebo	34	32 (94.1)	4.84 (1.11)	2.6	4.00	4.60	5.80	7.0	
		Week 48	Tezepelumab	40	39 (97.5)	5.52 (1.18)	2.6	4.60	5.80	6.40	7.0	
			Placebo	34	32 (94.1)	4.98 (1.08)	2.8	4.00	4.90	5.90	7.0	
		Week 52	Tezepelumab	40	39 (97.5)	5.54 (1.20)	2.6	4.60	5.80	6.40	7.0	
			Placebo	34	32 (94.1)	4.92 (1.18)	2.2	4.00	4.80	5.90	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	40	32 (80.0)	0.84 (1.16)	-1.2	0.10	0.60	1.70	3.8	0.22 [-0.28, 0.72]
			Placebo	34	30 (88.2)	0.60 (1.05)	-2.2	0.20	0.60	1.40	3.0	
		Week 8	Tezepelumab	40	34 (85.0)	1.00 (1.27)	-1.2	0.20	1.00	2.00	4.4	0.31 [-0.18, 0.80]
			Placebo	34	30 (88.2)	0.62 (1.18)	-1.6	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	40	34 (85.0)	1.21 (1.26)	-0.8	0.40	1.30	2.20	3.8	0.33 [-0.16, 0.83]
			Placebo	34	30 (88.2)	0.79 (1.25)	-1.6	0.00	0.70	1.60	4.4	
		Week 16	Tezepelumab	40	34 (85.0)	1.24 (1.23)	-0.6	0.40	1.20	2.20	4.0	0.46 [-0.04, 0.96]
			Placebo	34	30 (88.2)	0.67 (1.24)	-1.6	0.00	0.70	1.40	4.4	
		Week 20	Tezepelumab	40	34 (85.0)	1.31 (1.27)	-0.6	0.40	1.40	2.20	4.6	0.51 [0.01, 1.01]
			Placebo	34	30 (88.2)	0.67 (1.26)	-2.2	0.00	0.70	1.60	4.2	
		Week 24	Tezepelumab	40	34 (85.0)	1.17 (1.42)	-1.4	0.00	1.10	2.00	4.6	0.41 [-0.08, 0.91]
			Placebo	34	30 (88.2)	0.61 (1.31)	-2.2	0.00	0.40	1.20	4.2	
		Week 28	Tezepelumab	40	34 (85.0)	1.19 (1.32)	-1.0	0.60	0.90	2.20	4.6	0.34 [-0.15, 0.84]
			Placebo	34	30 (88.2)	0.71 (1.44)	-2.2	-0.20	0.90	1.60	4.4	
		Week 32	Tezepelumab	40	34 (85.0)	1.25 (1.42)	-1.4	0.00	1.40	2.40	4.6	0.39 [-0.11, 0.88]
			Placebo	34	30 (88.2)	0.74 (1.20)	-1.0	-0.20	0.80	1.40	4.2	
		Week 36	Tezepelumab	40	34 (85.0)	1.40 (1.47)	-1.0	0.40	1.30	2.60	4.6	0.56 [0.06, 1.06]
			Placebo	34	30 (88.2)	0.65 (1.16)	-1.4	-0.20	0.50	1.40	3.8	
		Week 40	Tezepelumab	40	34 (85.0)	1.19 (1.49)	-1.2	0.00	0.90	2.40	4.6	0.39 [-0.11, 0.88]
			Placebo	34	30 (88.2)	0.65 (1.28)	-1.6	-0.40	0.70	1.60	3.4	
		Week 44	Tezepelumab	40	34 (85.0)	1.34 (1.44)	-1.0	0.40	1.40	2.40	4.6	0.63 [0.13, 1.13]
			Placebo	34	30 (88.2)	0.52 (1.13)	-1.6	-0.40	0.40	1.20	3.4	
		Week 48	Tezepelumab	40	34 (85.0)	1.25 (1.45)	-1.4	0.40	1.20	2.20	4.6	0.43 [-0.07, 0.92]
			Placebo	34	30 (88.2)	0.69 (1.14)	-1.0	-0.20	0.50	1.40	3.8	
		Week 52	Tezepelumab	40	34 (85.0)	1.26 (1.47)	-1.4	0.40	1.30	2.40	4.6	0.46 [-0.04, 0.96]
			Placebo	34	30 (88.2)	0.60 (1.38)	-2.6	-0.40	0.50	1.40	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	57	49 (86.0)	4.13 (1.14)	1.4	3.60	4.20	4.80	6.4	
			Placebo	60	51 (85.0)	4.41 (1.08)	1.0	3.80	4.40	5.20	6.8	
		Week 4	Tezepelumab	57	51 (89.5)	4.70 (1.10)	1.2	4.00	4.80	5.60	7.0	
			Placebo	60	52 (86.7)	4.96 (1.27)	1.6	4.20	4.90	5.80	7.0	
		Week 8	Tezepelumab	57	53 (93.0)	4.99 (1.16)	2.8	4.00	4.80	6.00	7.0	
			Placebo	60	54 (90.0)	5.02 (1.12)	2.6	4.20	5.00	5.80	7.0	
		Week 12	Tezepelumab	57	53 (93.0)	5.22 (1.16)	2.8	4.40	5.20	6.20	7.0	
			Placebo	60	54 (90.0)	5.09 (1.24)	1.8	4.20	5.20	6.00	7.0	
		Week 16	Tezepelumab	57	53 (93.0)	5.15 (1.17)	2.6	4.20	5.00	6.20	7.0	
			Placebo	60	54 (90.0)	5.06 (1.31)	1.0	4.40	5.00	5.80	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.24 (1.14)	2.4	4.40	5.50	6.00	7.0	
			Placebo	60	54 (90.0)	5.05 (1.28)	1.0	4.20	5.00	6.00	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.10 (1.21)	2.0	4.00	5.20	6.20	7.0	
			Placebo	60	54 (90.0)	5.01 (1.32)	1.0	4.40	5.00	6.00	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.23 (1.10)	2.8	4.20	5.20	6.20	7.0	
			Placebo	60	55 (91.7)	5.09 (1.32)	1.0	4.20	5.20	6.00	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.20 (1.14)	2.6	4.30	5.30	6.20	7.0	
			Placebo	60	55 (91.7)	5.11 (1.35)	1.0	4.00	5.20	6.20	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.34 (1.21)	2.8	4.30	5.50	6.30	7.0	
			Placebo	60	55 (91.7)	5.11 (1.29)	1.6	4.40	5.20	6.00	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.15 (1.30)	1.8	4.20	5.30	6.30	7.0	
			Placebo	60	55 (91.7)	5.12 (1.29)	1.6	4.40	5.00	6.40	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.28 (1.15)	2.8	4.30	5.20	6.30	7.0	
			Placebo	60	55 (91.7)	5.09 (1.33)	1.8	4.00	5.00	6.40	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.31 (1.15)	2.6	4.50	5.30	6.30	7.0	
			Placebo	60	55 (91.7)	5.11 (1.34)	1.4	4.00	5.00	6.40	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.33 (1.16)	2.6	4.40	5.40	6.30	7.0	
			Placebo	60	55 (91.7)	5.09 (1.37)	2.0	4.00	5.00	6.40	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	57	46 (80.7)	0.57 (1.43)	-4.2	-0.40	0.60	1.60	3.8	0.02 [-0.38, 0.42]
			Placebo	60	50 (83.3)	0.54 (1.07)	-2.2	0.00	0.40	1.20	3.0	
		Week 8	Tezepelumab	57	48 (84.2)	0.77 (1.40)	-2.2	-0.30	0.70	2.00	4.4	0.11 [-0.29, 0.50]
			Placebo	60	51 (85.0)	0.64 (1.16)	-1.6	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	57	48 (84.2)	1.01 (1.32)	-2.4	0.00	1.00	1.90	3.8	0.25 [-0.14, 0.65]
			Placebo	60	51 (85.0)	0.69 (1.19)	-1.8	0.00	0.60	1.40	4.4	
		Week 16	Tezepelumab	57	48 (84.2)	0.94 (1.35)	-2.8	-0.10	1.00	2.00	4.0	0.21 [-0.18, 0.61]
			Placebo	60	51 (85.0)	0.66 (1.24)	-3.4	0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	57	48 (84.2)	1.12 (1.27)	-1.4	0.10	1.10	2.10	4.6	0.35 [-0.05, 0.75]
			Placebo	60	51 (85.0)	0.67 (1.26)	-3.4	0.00	0.80	1.60	4.2	
		Week 24	Tezepelumab	57	48 (84.2)	0.94 (1.36)	-1.4	-0.10	0.80	1.90	4.6	0.24 [-0.16, 0.63]
			Placebo	60	51 (85.0)	0.63 (1.29)	-3.4	0.00	0.40	1.40	4.2	
		Week 28	Tezepelumab	57	48 (84.2)	1.03 (1.31)	-1.4	0.00	0.90	1.90	4.6	0.25 [-0.15, 0.64]
			Placebo	60	51 (85.0)	0.69 (1.36)	-3.4	0.00	0.80	1.60	4.4	
		Week 32	Tezepelumab	57	48 (84.2)	0.99 (1.39)	-1.6	0.00	0.80	2.10	4.6	0.21 [-0.19, 0.60]
			Placebo	60	51 (85.0)	0.72 (1.23)	-3.4	-0.20	0.80	1.40	4.2	
		Week 36	Tezepelumab	57	48 (84.2)	1.17 (1.45)	-1.6	0.00	1.20	2.10	4.6	0.37 [-0.03, 0.77]
			Placebo	60	51 (85.0)	0.70 (1.10)	-2.0	0.20	0.60	1.40	3.8	
		Week 40	Tezepelumab	57	48 (84.2)	1.00 (1.47)	-2.4	-0.10	1.00	2.00	4.6	0.20 [-0.19, 0.60]
			Placebo	60	51 (85.0)	0.73 (1.21)	-2.0	-0.20	0.80	1.60	3.4	
		Week 44	Tezepelumab	57	48 (84.2)	1.07 (1.39)	-1.4	-0.10	1.20	1.90	4.6	0.30 [-0.10, 0.69]
			Placebo	60	51 (85.0)	0.68 (1.21)	-1.8	-0.20	0.60	1.20	4.2	
		Week 48	Tezepelumab	57	48 (84.2)	1.13 (1.37)	-1.4	0.10	1.20	2.10	4.6	0.30 [-0.10, 0.70]
			Placebo	60	51 (85.0)	0.73 (1.24)	-2.2	-0.20	0.60	1.40	4.2	
		Week 52	Tezepelumab	57	48 (84.2)	1.13 (1.38)	-1.6	0.00	1.20	2.10	4.6	0.32 [-0.08, 0.71]
			Placebo	60	51 (85.0)	0.70 (1.36)	-2.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	4.98 (1.05)	3.2	4.40	5.20	5.60	6.4	
			Placebo	5	4 (80.0)	4.05 (2.16)	2.0	2.50	3.60	5.60	7.0	
		Week 4	Tezepelumab	9	9 (100.0)	5.89 (1.07)	3.8	5.20	6.20	6.80	7.0	
			Placebo	5	5 (100.0)	4.28 (1.43)	3.0	3.40	3.80	4.60	6.6	
		Week 8	Tezepelumab	9	9 (100.0)	6.18 (0.96)	4.6	5.60	6.60	7.00	7.0	
			Placebo	5	5 (100.0)	4.40 (1.49)	2.0	4.00	5.00	5.20	5.8	
		Week 12	Tezepelumab	9	9 (100.0)	6.24 (0.90)	4.6	5.60	6.40	7.00	7.0	
			Placebo	5	5 (100.0)	5.28 (1.09)	4.0	4.60	5.00	6.20	6.6	
		Week 16	Tezepelumab	9	9 (100.0)	6.27 (0.96)	4.8	5.60	7.00	7.00	7.0	
			Placebo	5	5 (100.0)	5.32 (1.19)	4.0	4.60	5.00	6.00	7.0	
		Week 20	Tezepelumab	9	9 (100.0)	6.22 (0.94)	4.6	5.60	6.80	7.00	7.0	
			Placebo	5	5 (100.0)	4.76 (0.88)	3.6	4.40	4.80	5.00	6.0	
		Week 24	Tezepelumab	9	9 (100.0)	6.40 (0.70)	5.2	5.80	6.80	7.00	7.0	
			Placebo	5	5 (100.0)	4.84 (0.92)	3.6	4.40	4.80	5.40	6.0	
		Week 28	Tezepelumab	9	9 (100.0)	6.27 (0.88)	4.4	5.80	6.40	7.00	7.0	
			Placebo	5	5 (100.0)	4.92 (1.52)	3.6	3.60	4.40	6.00	7.0	
		Week 32	Tezepelumab	9	9 (100.0)	6.29 (0.92)	4.6	6.00	6.60	7.00	7.0	
			Placebo	5	5 (100.0)	4.84 (1.10)	3.6	4.20	4.40	6.00	6.0	
		Week 36	Tezepelumab	9	9 (100.0)	6.47 (0.82)	4.6	6.00	7.00	7.00	7.0	
			Placebo	5	5 (100.0)	4.48 (1.00)	3.6	3.60	4.40	4.80	6.0	
		Week 40	Tezepelumab	9	9 (100.0)	6.16 (1.00)	4.4	5.80	6.40	7.00	7.0	
			Placebo	5	5 (100.0)	4.72 (1.50)	3.2	3.60	4.20	6.00	6.6	
		Week 44	Tezepelumab	9	9 (100.0)	6.22 (0.91)	4.6	5.80	6.60	7.00	7.0	
			Placebo	5	5 (100.0)	4.88 (1.39)	3.2	3.60	5.40	6.00	6.2	
		Week 48	Tezepelumab	9	9 (100.0)	6.00 (1.13)	4.0	5.60	6.00	7.00	7.0	
			Placebo	5	5 (100.0)	4.52 (1.11)	3.6	3.60	4.00	5.40	6.0	
		Week 52	Tezepelumab	9	9 (100.0)	6.02 (1.12)	4.0	5.80	6.00	7.00	7.0	
			Placebo	5	5 (100.0)	4.40 (1.02)	3.6	3.60	4.00	4.80	6.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	0.91 (0.71)	0.0	0.20	1.00	1.60	1.8	0.77 [-0.45, 1.99]
			Placebo	5	4 (80.0)	0.35 (0.77)	-0.4	-0.20	0.20	0.90	1.4	
		Week 8	Tezepelumab	9	9 (100.0)	1.20 (0.54)	0.4	1.00	1.20	1.40	2.2	0.86 [-0.37, 2.09]
			Placebo	5	4 (80.0)	0.45 (1.43)	-1.2	-0.60	0.40	1.50	2.2	
		Week 12	Tezepelumab	9	9 (100.0)	1.27 (0.68)	0.4	0.60	1.40	1.60	2.6	-0.12 [-1.30, 1.06]
			Placebo	5	4 (80.0)	1.40 (1.86)	-0.8	0.00	1.40	2.80	3.6	
		Week 16	Tezepelumab	9	9 (100.0)	1.29 (0.64)	0.4	1.00	1.20	1.60	2.6	-0.13 [-1.31, 1.05]
			Placebo	5	4 (80.0)	1.45 (2.10)	-1.0	-0.10	1.40	3.00	4.0	
		Week 20	Tezepelumab	9	9 (100.0)	1.24 (0.64)	0.4	1.00	1.20	1.40	2.6	0.66 [-0.55, 1.87]
			Placebo	5	4 (80.0)	0.70 (1.18)	-1.0	-0.10	1.10	1.50	1.6	
		Week 24	Tezepelumab	9	9 (100.0)	1.42 (0.77)	0.6	0.80	1.40	1.60	2.6	0.61 [-0.60, 1.81]
			Placebo	5	4 (80.0)	0.80 (1.51)	-1.0	-0.40	0.90	2.00	2.4	
		Week 28	Tezepelumab	9	9 (100.0)	1.29 (0.81)	0.6	0.80	0.80	1.60	2.6	0.21 [-0.97, 1.39]
			Placebo	5	4 (80.0)	1.00 (2.30)	-1.0	-0.80	0.50	2.80	4.0	
		Week 32	Tezepelumab	9	9 (100.0)	1.31 (0.59)	0.6	0.80	1.40	1.40	2.6	0.39 [-0.80, 1.58]
			Placebo	5	4 (80.0)	0.90 (1.76)	-1.0	-0.50	0.80	2.30	3.0	
		Week 36	Tezepelumab	9	9 (100.0)	1.49 (1.06)	0.6	0.80	1.00	1.60	3.8	0.99 [-0.25, 2.24]
			Placebo	5	4 (80.0)	0.35 (1.34)	-1.0	-0.80	0.40	1.50	1.6	
		Week 40	Tezepelumab	9	9 (100.0)	1.18 (0.68)	0.6	0.60	0.80	1.60	2.6	0.29 [-0.89, 1.47]
			Placebo	5	4 (80.0)	0.80 (2.23)	-1.0	-1.00	0.30	2.60	3.6	
		Week 44	Tezepelumab	9	9 (100.0)	1.24 (0.67)	0.6	0.60	1.40	1.60	2.6	0.45 [-0.75, 1.64]
			Placebo	5	4 (80.0)	0.70 (2.07)	-1.0	-1.00	0.30	2.40	3.2	
		Week 48	Tezepelumab	9	9 (100.0)	1.02 (0.78)	0.0	0.60	0.80	1.40	2.6	0.88 [-0.36, 2.11]
			Placebo	5	4 (80.0)	0.25 (1.11)	-1.0	-0.60	0.20	1.10	1.6	
		Week 52	Tezepelumab	9	9 (100.0)	1.04 (0.89)	-0.6	0.60	1.20	1.40	2.6	0.83 [-0.40, 2.06]
			Placebo	5	4 (80.0)	0.25 (1.11)	-1.0	-0.60	0.20	1.10	1.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	4.08 (1.04)	2.2	3.60	4.10	4.70	5.6	
			Placebo	14	10 (71.4)	4.38 (1.11)	3.0	3.60	4.20	4.60	7.0	
		Week 4	Tezepelumab	9	8 (88.9)	5.00 (0.96)	3.8	4.10	5.00	5.90	6.2	
			Placebo	14	12 (85.7)	4.85 (1.61)	1.6	3.80	4.80	6.20	7.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.50 (1.04)	4.0	4.70	5.60	6.20	7.0	
			Placebo	14	13 (92.9)	4.78 (1.22)	3.0	4.00	5.00	5.40	7.0	
		Week 12	Tezepelumab	9	8 (88.9)	5.55 (1.08)	4.0	4.70	5.60	6.40	7.0	
			Placebo	14	13 (92.9)	4.80 (1.51)	1.8	3.60	4.60	6.20	7.0	
		Week 16	Tezepelumab	9	8 (88.9)	5.85 (1.06)	4.0	5.20	5.90	6.80	7.0	
			Placebo	14	13 (92.9)	5.11 (1.29)	2.6	4.40	5.00	6.00	7.0	
		Week 20	Tezepelumab	9	8 (88.9)	5.35 (1.02)	4.0	4.50	5.20	6.30	6.8	
			Placebo	14	13 (92.9)	5.05 (1.05)	3.0	4.40	4.80	5.80	7.0	
		Week 24	Tezepelumab	9	8 (88.9)	5.48 (1.12)	4.0	4.50	5.60	6.30	7.0	
			Placebo	14	13 (92.9)	4.97 (1.14)	2.8	4.40	4.80	5.60	7.0	
		Week 28	Tezepelumab	9	8 (88.9)	5.33 (0.99)	4.0	4.50	5.30	6.20	6.6	
			Placebo	14	14 (100.0)	5.11 (1.34)	2.6	4.40	4.70	6.20	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.43 (1.04)	4.0	4.60	5.40	6.20	7.0	
			Placebo	14	14 (100.0)	5.11 (1.36)	2.2	4.40	5.10	6.00	7.0	
		Week 36	Tezepelumab	9	8 (88.9)	5.43 (1.09)	4.0	4.40	5.60	6.20	7.0	
			Placebo	14	14 (100.0)	4.99 (1.43)	1.6	4.40	4.70	6.00	7.0	
		Week 40	Tezepelumab	9	8 (88.9)	5.25 (1.20)	3.8	4.20	5.10	6.30	7.0	
			Placebo	14	14 (100.0)	5.00 (1.58)	1.6	4.20	4.70	6.60	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.45 (1.09)	4.0	4.50	5.50	6.30	7.0	
			Placebo	14	14 (100.0)	4.99 (1.57)	1.8	4.40	5.00	6.20	7.0	
		Week 48	Tezepelumab	9	8 (88.9)	5.25 (0.94)	4.0	4.30	5.50	6.00	6.4	
			Placebo	14	14 (100.0)	4.87 (1.56)	1.4	4.00	4.70	6.00	7.0	
		Week 52	Tezepelumab	9	8 (88.9)	5.43 (1.12)	4.0	4.30	5.70	6.20	7.0	
			Placebo	14	14 (100.0)	4.87 (1.46)	2.0	4.00	4.70	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.89 (0.75)	0.2	0.20	0.60	1.80	2.0	0.47 [-0.51, 1.45]
			Placebo	14	10 (71.4)	0.42 (1.13)	-2.0	0.00	0.40	1.60	1.8	
		Week 8	Tezepelumab	9	7 (77.8)	1.34 (0.67)	0.4	1.00	1.20	2.00	2.4	0.71 [-0.29, 1.71]
			Placebo	14	10 (71.4)	0.58 (1.27)	-1.2	-0.60	0.90	1.80	2.2	
		Week 12	Tezepelumab	9	7 (77.8)	1.43 (0.98)	0.2	0.40	1.40	2.20	3.0	0.70 [-0.30, 1.70]
			Placebo	14	10 (71.4)	0.44 (1.64)	-1.8	-0.80	0.10	1.80	3.6	
		Week 16	Tezepelumab	9	7 (77.8)	1.66 (1.02)	0.4	1.00	1.40	2.60	3.4	0.62 [-0.37, 1.61]
			Placebo	14	10 (71.4)	0.84 (1.48)	-1.0	0.00	0.80	1.40	4.0	
		Week 20	Tezepelumab	9	7 (77.8)	1.43 (0.98)	0.4	0.60	1.20	2.20	3.2	0.72 [-0.28, 1.72]
			Placebo	14	10 (71.4)	0.72 (1.00)	-1.0	-0.20	1.00	1.60	1.8	
		Week 24	Tezepelumab	9	7 (77.8)	1.49 (1.30)	0.0	0.40	1.40	2.40	3.8	0.58 [-0.41, 1.57]
			Placebo	14	10 (71.4)	0.76 (1.22)	-1.0	-0.20	0.90	1.80	2.4	
		Week 28	Tezepelumab	9	7 (77.8)	1.34 (1.19)	0.4	0.60	0.80	2.40	3.6	0.40 [-0.58, 1.37]
			Placebo	14	10 (71.4)	0.78 (1.54)	-1.0	-0.40	0.80	1.80	4.0	
		Week 32	Tezepelumab	9	7 (77.8)	1.46 (1.14)	0.4	0.40	1.40	2.20	3.6	0.49 [-0.49, 1.47]
			Placebo	14	10 (71.4)	0.80 (1.45)	-1.4	-0.40	1.30	1.80	3.0	
		Week 36	Tezepelumab	9	7 (77.8)	1.54 (1.14)	0.4	0.80	1.20	2.20	3.8	0.79 [-0.22, 1.79]
			Placebo	14	10 (71.4)	0.54 (1.36)	-2.0	-0.20	1.00	1.40	2.4	
		Week 40	Tezepelumab	9	7 (77.8)	1.26 (1.18)	-0.2	0.40	0.80	2.40	3.2	0.37 [-0.61, 1.34]
			Placebo	14	10 (71.4)	0.70 (1.71)	-2.0	-0.80	0.90	1.80	3.6	
		Week 44	Tezepelumab	9	7 (77.8)	1.49 (1.28)	0.2	0.40	1.40	2.40	3.8	0.66 [-0.34, 1.65]
			Placebo	14	10 (71.4)	0.46 (1.72)	-1.8	-1.00	0.50	1.80	3.2	
		Week 48	Tezepelumab	9	7 (77.8)	1.29 (1.33)	0.0	0.40	0.80	2.20	3.8	0.65 [-0.34, 1.64]
			Placebo	14	10 (71.4)	0.40 (1.38)	-2.2	-0.20	0.60	1.20	2.6	
		Week 52	Tezepelumab	9	7 (77.8)	1.49 (1.20)	0.4	0.40	1.40	2.20	3.8	0.83 [-0.18, 1.84]
			Placebo	14	10 (71.4)	0.46 (1.26)	-1.6	-0.20	0.60	1.20	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.29 (1.19)	1.4	3.60	4.30	5.00	6.4	
			Placebo	51	45 (88.2)	4.39 (1.19)	1.0	3.80	4.40	5.20	6.8	
		Week 4	Tezepelumab	57	52 (91.2)	4.86 (1.20)	1.2	4.00	4.80	5.90	7.0	
			Placebo	51	45 (88.2)	4.92 (1.21)	1.6	4.20	4.80	5.60	7.0	
		Week 8	Tezepelumab	57	54 (94.7)	5.11 (1.23)	2.8	4.20	5.10	6.00	7.0	
			Placebo	51	46 (90.2)	5.02 (1.14)	2.0	4.40	5.00	5.80	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.34 (1.19)	2.8	4.40	5.40	6.40	7.0	
			Placebo	51	46 (90.2)	5.20 (1.13)	2.6	4.20	5.20	6.00	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.23 (1.21)	2.6	4.40	5.20	6.20	7.0	
			Placebo	51	46 (90.2)	5.08 (1.30)	1.0	4.40	5.00	5.80	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.39 (1.19)	2.4	4.40	5.60	6.40	7.0	
			Placebo	51	46 (90.2)	5.02 (1.31)	1.0	4.00	5.00	6.20	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.25 (1.26)	2.0	4.20	5.40	6.40	7.0	
			Placebo	51	46 (90.2)	5.00 (1.34)	1.0	4.40	5.10	6.00	7.0	
		Week 28	Tezepelumab	57	57 (100.0)	5.38 (1.15)	2.8	4.40	5.40	6.40	7.0	
			Placebo	51	46 (90.2)	5.07 (1.34)	1.0	4.00	5.20	6.00	7.0	
		Week 32	Tezepelumab	57	57 (100.0)	5.34 (1.20)	2.6	4.40	5.60	6.40	7.0	
			Placebo	51	46 (90.2)	5.08 (1.33)	1.0	4.00	5.20	6.00	7.0	
		Week 36	Tezepelumab	57	57 (100.0)	5.50 (1.25)	2.8	4.60	5.60	6.60	7.0	
			Placebo	51	46 (90.2)	5.08 (1.24)	2.2	4.40	5.10	6.00	7.0	
		Week 40	Tezepelumab	57	57 (100.0)	5.29 (1.33)	1.8	4.20	5.40	6.40	7.0	
			Placebo	51	46 (90.2)	5.11 (1.23)	2.6	4.40	5.10	6.20	7.0	
		Week 44	Tezepelumab	57	57 (100.0)	5.40 (1.18)	2.8	4.40	5.40	6.40	7.0	
			Placebo	51	46 (90.2)	5.10 (1.25)	2.6	4.00	5.10	6.40	7.0	
		Week 48	Tezepelumab	57	57 (100.0)	5.42 (1.20)	2.6	4.60	5.40	6.40	7.0	
			Placebo	51	46 (90.2)	5.12 (1.25)	2.6	4.00	5.00	6.20	7.0	
		Week 52	Tezepelumab	57	57 (100.0)	5.42 (1.19)	2.6	4.60	5.40	6.40	7.0	
			Placebo	51	46 (90.2)	5.08 (1.33)	2.2	4.00	5.00	6.20	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	0.58 (1.40)	-4.2	-0.30	0.60	1.60	3.8	0.02 [-0.39, 0.43]
			Placebo	51	44 (86.3)	0.55 (1.04)	-2.2	0.00	0.40	1.10	3.0	
		Week 8	Tezepelumab	57	50 (87.7)	0.77 (1.37)	-2.2	-0.20	0.70	1.60	4.4	0.11 [-0.30, 0.51]
			Placebo	51	45 (88.2)	0.63 (1.16)	-1.6	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	57	50 (87.7)	1.00 (1.27)	-2.4	0.00	1.00	1.80	3.8	0.15 [-0.25, 0.56]
			Placebo	51	45 (88.2)	0.81 (1.15)	-1.6	0.20	0.80	1.40	4.4	
		Week 16	Tezepelumab	57	50 (87.7)	0.90 (1.28)	-2.8	0.00	1.00	1.80	4.0	0.16 [-0.24, 0.56]
			Placebo	51	45 (88.2)	0.69 (1.29)	-3.4	0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	57	50 (87.7)	1.10 (1.22)	-1.4	0.20	1.10	2.00	4.6	0.34 [-0.07, 0.75]
			Placebo	51	45 (88.2)	0.67 (1.30)	-3.4	0.00	0.80	1.40	4.2	
		Week 24	Tezepelumab	57	50 (87.7)	0.95 (1.29)	-1.4	0.00	1.00	1.80	4.6	0.26 [-0.15, 0.66]
			Placebo	51	45 (88.2)	0.61 (1.32)	-3.4	0.00	0.40	1.20	4.2	
		Week 28	Tezepelumab	57	50 (87.7)	1.03 (1.26)	-1.4	0.00	1.00	1.80	4.6	0.24 [-0.16, 0.65]
			Placebo	51	45 (88.2)	0.70 (1.41)	-3.4	0.00	0.80	1.60	4.4	
		Week 32	Tezepelumab	57	50 (87.7)	0.98 (1.31)	-1.6	0.00	0.90	2.00	4.6	0.21 [-0.19, 0.61]
			Placebo	51	45 (88.2)	0.72 (1.23)	-3.4	0.00	0.60	1.40	4.2	
		Week 36	Tezepelumab	57	50 (87.7)	1.18 (1.42)	-1.6	0.00	1.20	2.00	4.6	0.37 [-0.03, 0.78]
			Placebo	51	45 (88.2)	0.70 (1.06)	-1.4	0.20	0.60	1.40	3.8	
		Week 40	Tezepelumab	57	50 (87.7)	1.00 (1.41)	-2.4	0.00	1.00	2.00	4.6	0.20 [-0.21, 0.60]
			Placebo	51	45 (88.2)	0.74 (1.18)	-1.6	-0.20	0.80	1.60	3.4	
		Week 44	Tezepelumab	57	50 (87.7)	1.04 (1.31)	-1.4	0.00	1.20	1.60	4.6	0.25 [-0.15, 0.65]
			Placebo	51	45 (88.2)	0.73 (1.16)	-1.0	-0.20	0.60	1.20	4.2	
		Week 48	Tezepelumab	57	50 (87.7)	1.08 (1.30)	-1.4	0.20	1.20	1.80	4.6	0.25 [-0.15, 0.66]
			Placebo	51	45 (88.2)	0.76 (1.20)	-1.0	0.00	0.60	1.40	4.2	
		Week 52	Tezepelumab	57	50 (87.7)	1.07 (1.32)	-1.6	0.00	1.20	1.80	4.6	0.26 [-0.14, 0.67]
			Placebo	51	45 (88.2)	0.72 (1.36)	-2.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	51	44 (86.3)	4.19 (1.16)	1.4	3.50	4.20	4.90	6.4	
			Placebo	49	43 (87.8)	4.45 (1.16)	1.0	3.80	4.40	5.40	6.8	
		Week 4	Tezepelumab	51	46 (90.2)	4.69 (1.13)	1.2	4.00	4.80	5.60	7.0	
			Placebo	49	43 (87.8)	4.96 (1.21)	1.6	4.20	5.00	5.60	7.0	
		Week 8	Tezepelumab	51	48 (94.1)	4.97 (1.18)	2.8	4.00	4.80	6.00	7.0	
			Placebo	49	44 (89.8)	5.09 (1.07)	2.6	4.50	5.10	5.90	7.0	
		Week 12	Tezepelumab	51	48 (94.1)	5.23 (1.17)	2.8	4.40	5.10	6.20	7.0	
			Placebo	49	44 (89.8)	5.23 (1.14)	2.6	4.30	5.20	6.10	7.0	
		Week 16	Tezepelumab	51	48 (94.1)	5.09 (1.17)	2.6	4.20	5.00	6.10	7.0	
			Placebo	49	44 (89.8)	5.10 (1.32)	1.0	4.50	5.00	5.90	7.0	
		Week 20	Tezepelumab	51	49 (96.1)	5.27 (1.16)	2.4	4.40	5.60	6.00	7.0	
			Placebo	49	44 (89.8)	5.05 (1.33)	1.0	4.10	5.00	6.20	7.0	
		Week 24	Tezepelumab	51	49 (96.1)	5.09 (1.22)	2.0	4.00	5.20	6.20	7.0	
			Placebo	49	44 (89.8)	5.05 (1.35)	1.0	4.40	5.20	6.10	7.0	
		Week 28	Tezepelumab	51	51 (100.0)	5.24 (1.11)	2.8	4.20	5.40	6.20	7.0	
			Placebo	49	44 (89.8)	5.14 (1.33)	1.0	4.30	5.20	6.00	7.0	
		Week 32	Tezepelumab	51	51 (100.0)	5.21 (1.17)	2.6	4.20	5.40	6.20	7.0	
			Placebo	49	44 (89.8)	5.13 (1.34)	1.0	4.20	5.20	6.10	7.0	
		Week 36	Tezepelumab	51	51 (100.0)	5.35 (1.23)	2.8	4.40	5.60	6.40	7.0	
			Placebo	49	44 (89.8)	5.15 (1.23)	2.2	4.50	5.20	6.00	7.0	
		Week 40	Tezepelumab	51	51 (100.0)	5.17 (1.32)	1.8	4.20	5.40	6.40	7.0	
			Placebo	49	44 (89.8)	5.19 (1.20)	2.6	4.40	5.20	6.30	7.0	
		Week 44	Tezepelumab	51	51 (100.0)	5.29 (1.16)	2.8	4.40	5.20	6.40	7.0	
			Placebo	49	44 (89.8)	5.17 (1.23)	2.6	4.20	5.20	6.50	7.0	
		Week 48	Tezepelumab	51	51 (100.0)	5.31 (1.18)	2.6	4.40	5.20	6.40	7.0	
			Placebo	49	44 (89.8)	5.18 (1.25)	2.6	4.10	5.00	6.30	7.0	
		Week 52	Tezepelumab	51	51 (100.0)	5.33 (1.19)	2.6	4.40	5.40	6.40	7.0	
			Placebo	49	44 (89.8)	5.14 (1.33)	2.2	4.10	5.10	6.30	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	51	42 (82.4)	0.50 (1.46)	-4.2	-0.40	0.50	1.40	3.8	-0.03 [-0.45, 0.40]
			Placebo	49	42 (85.7)	0.54 (1.05)	-2.2	0.00	0.40	1.00	3.0	
		Week 8	Tezepelumab	51	44 (86.3)	0.71 (1.43)	-2.2	-0.40	0.60	1.80	4.4	0.05 [-0.37, 0.47]
			Placebo	49	43 (87.8)	0.64 (1.18)	-1.6	0.00	0.60	1.20	4.0	
		Week 12	Tezepelumab	51	44 (86.3)	0.97 (1.32)	-2.4	0.00	1.00	1.80	3.8	0.15 [-0.27, 0.57]
			Placebo	49	43 (87.8)	0.78 (1.16)	-1.6	0.00	0.80	1.40	4.4	
		Week 16	Tezepelumab	51	44 (86.3)	0.84 (1.32)	-2.8	-0.20	0.90	1.90	4.0	0.14 [-0.28, 0.56]
			Placebo	49	43 (87.8)	0.66 (1.30)	-3.4	0.20	0.60	1.40	4.4	
		Week 20	Tezepelumab	51	44 (86.3)	1.07 (1.27)	-1.4	0.00	1.10	2.00	4.6	0.33 [-0.09, 0.75]
			Placebo	49	43 (87.8)	0.64 (1.33)	-3.4	0.00	0.80	1.40	4.2	
		Week 24	Tezepelumab	51	44 (86.3)	0.88 (1.33)	-1.4	-0.20	0.80	1.80	4.6	0.21 [-0.21, 0.63]
			Placebo	49	43 (87.8)	0.60 (1.34)	-3.4	0.00	0.40	1.20	4.2	
		Week 28	Tezepelumab	51	44 (86.3)	0.96 (1.29)	-1.4	0.00	0.90	1.80	4.6	0.18 [-0.24, 0.60]
			Placebo	49	43 (87.8)	0.71 (1.42)	-3.4	0.00	0.80	1.60	4.4	
		Week 32	Tezepelumab	51	44 (86.3)	0.93 (1.37)	-1.6	-0.10	0.80	2.00	4.6	0.17 [-0.25, 0.59]
			Placebo	49	43 (87.8)	0.71 (1.25)	-3.4	-0.20	0.60	1.40	4.2	
		Week 36	Tezepelumab	51	44 (86.3)	1.10 (1.44)	-1.6	0.00	1.20	2.00	4.6	0.31 [-0.11, 0.73]
			Placebo	49	43 (87.8)	0.71 (1.06)	-1.4	0.20	0.60	1.40	3.8	
		Week 40	Tezepelumab	51	44 (86.3)	0.96 (1.47)	-2.4	-0.10	1.00	2.00	4.6	0.15 [-0.27, 0.57]
			Placebo	49	43 (87.8)	0.76 (1.17)	-1.6	-0.20	0.80	1.60	3.4	
		Week 44	Tezepelumab	51	44 (86.3)	1.01 (1.37)	-1.4	-0.20	1.20	1.70	4.6	0.21 [-0.22, 0.63]
			Placebo	49	43 (87.8)	0.75 (1.15)	-1.0	-0.20	0.60	1.20	4.2	
		Week 48	Tezepelumab	51	44 (86.3)	1.05 (1.36)	-1.4	0.00	1.10	1.90	4.6	0.22 [-0.20, 0.64]
			Placebo	49	43 (87.8)	0.77 (1.21)	-1.0	0.00	0.60	1.40	4.2	
		Week 52	Tezepelumab	51	44 (86.3)	1.06 (1.36)	-1.6	0.00	1.10	1.90	4.6	0.25 [-0.17, 0.67]
			Placebo	49	43 (87.8)	0.72 (1.38)	-2.6	-0.20	0.60	1.40	4.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	4.50 (1.15)	2.2	3.60	4.30	5.40	6.4	
			Placebo	16	12 (75.0)	4.17 (1.22)	2.0	3.50	4.20	4.50	7.0	
		Week 4	Tezepelumab	15	14 (93.3)	5.51 (1.09)	3.8	4.60	5.60	6.20	7.0	
			Placebo	16	14 (87.5)	4.73 (1.53)	1.6	3.80	4.70	6.00	7.0	
		Week 8	Tezepelumab	15	14 (93.3)	5.83 (1.05)	4.0	4.80	6.20	6.80	7.0	
			Placebo	16	15 (93.8)	4.61 (1.34)	2.0	3.60	5.00	5.40	7.0	
		Week 12	Tezepelumab	15	14 (93.3)	5.86 (1.07)	4.0	5.20	6.20	7.00	7.0	
			Placebo	16	15 (93.8)	4.76 (1.41)	1.8	3.60	4.60	6.20	7.0	
		Week 16	Tezepelumab	15	14 (93.3)	6.09 (1.02)	4.0	5.60	6.50	7.00	7.0	
			Placebo	16	15 (93.8)	5.03 (1.23)	2.6	4.20	5.00	6.00	7.0	
		Week 20	Tezepelumab	15	14 (93.3)	5.77 (1.10)	4.0	4.60	5.90	6.80	7.0	
			Placebo	16	15 (93.8)	4.95 (1.04)	3.0	4.40	4.80	5.80	7.0	
		Week 24	Tezepelumab	15	14 (93.3)	5.94 (1.06)	4.0	5.20	6.00	7.00	7.0	
			Placebo	16	15 (93.8)	4.84 (1.12)	2.8	4.20	4.60	5.60	7.0	
		Week 28	Tezepelumab	15	14 (93.3)	5.87 (1.05)	4.0	4.80	5.90	7.00	7.0	
			Placebo	16	16 (100.0)	4.93 (1.35)	2.6	4.00	4.50	6.10	7.0	
		Week 32	Tezepelumab	15	14 (93.3)	5.86 (1.09)	4.0	4.80	6.20	7.00	7.0	
			Placebo	16	16 (100.0)	4.96 (1.34)	2.2	4.10	4.50	6.00	7.0	
		Week 36	Tezepelumab	15	14 (93.3)	6.00 (1.09)	4.0	5.20	6.20	7.00	7.0	
			Placebo	16	16 (100.0)	4.81 (1.41)	1.6	4.20	4.50	5.60	7.0	
		Week 40	Tezepelumab	15	14 (93.3)	5.71 (1.18)	3.8	4.80	5.90	7.00	7.0	
			Placebo	16	16 (100.0)	4.80 (1.57)	1.6	3.60	4.50	6.30	7.0	
		Week 44	Tezepelumab	15	14 (93.3)	5.83 (1.10)	4.0	4.80	5.90	7.00	7.0	
			Placebo	16	16 (100.0)	4.79 (1.56)	1.8	3.60	4.60	6.10	7.0	
		Week 48	Tezepelumab	15	14 (93.3)	5.74 (1.10)	4.0	4.60	5.90	7.00	7.0	
			Placebo	16	16 (100.0)	4.74 (1.50)	1.4	3.80	4.50	5.70	7.0	
		Week 52	Tezepelumab	15	14 (93.3)	5.76 (1.10)	4.0	4.60	5.90	7.00	7.0	
			Placebo	16	16 (100.0)	4.74 (1.41)	2.0	3.80	4.50	5.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_ILSHP: Change from baseline in AQLQ+12 emotional function score by study specific subgroups
DITTL

Subgroup	AQLQ+12 emotional function score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	15	13 (86.7)	1.00 (0.72)	0.0	0.40	1.00	1.80	2.0	0.56 [-0.24, 1.36]
			Placebo	16	12 (75.0)	0.50 (1.06)	-2.0	0.10	0.40	1.50	1.8	
		Week 8	Tezepelumab	15	13 (86.7)	1.28 (0.65)	0.4	1.00	1.20	1.60	2.4	0.78 [-0.03, 1.60]
			Placebo	16	12 (75.0)	0.55 (1.16)	-1.2	-0.30	0.70	1.50	2.2	
		Week 12	Tezepelumab	15	13 (86.7)	1.32 (0.89)	0.2	0.60	1.40	1.60	3.0	0.58 [-0.22, 1.38]
			Placebo	16	12 (75.0)	0.60 (1.55)	-1.8	-0.70	0.50	1.80	3.6	
		Week 16	Tezepelumab	15	13 (86.7)	1.51 (0.90)	0.4	1.00	1.40	1.60	3.4	0.50 [-0.30, 1.29]
			Placebo	16	12 (75.0)	0.93 (1.38)	-1.0	0.10	1.00	1.60	4.0	
		Week 20	Tezepelumab	15	13 (86.7)	1.35 (0.86)	0.4	0.60	1.20	1.60	3.2	0.62 [-0.19, 1.42]
			Placebo	16	12 (75.0)	0.80 (0.94)	-1.0	0.20	1.00	1.60	1.8	
		Week 24	Tezepelumab	15	13 (86.7)	1.49 (1.09)	0.0	0.60	1.40	2.40	3.8	0.63 [-0.17, 1.44]
			Placebo	16	12 (75.0)	0.78 (1.15)	-1.0	-0.10	0.90	1.70	2.4	
		Week 28	Tezepelumab	15	13 (86.7)	1.43 (1.03)	0.4	0.60	0.80	2.40	3.6	0.55 [-0.25, 1.35]
			Placebo	16	12 (75.0)	0.73 (1.48)	-1.0	-0.50	0.80	1.70	4.0	
		Week 32	Tezepelumab	15	13 (86.7)	1.42 (0.93)	0.4	0.80	1.40	1.60	3.6	0.53 [-0.27, 1.33]
			Placebo	16	12 (75.0)	0.80 (1.35)	-1.4	-0.30	1.30	1.80	3.0	
		Week 36	Tezepelumab	15	13 (86.7)	1.62 (1.15)	0.4	0.80	1.20	2.20	3.8	0.88 [0.05, 1.70]
			Placebo	16	12 (75.0)	0.53 (1.31)	-2.0	-0.40	1.00	1.50	2.4	
		Week 40	Tezepelumab	15	13 (86.7)	1.26 (0.99)	-0.2	0.60	0.80	1.60	3.2	0.47 [-0.33, 1.26]
			Placebo	16	12 (75.0)	0.63 (1.65)	-2.0	-0.90	0.90	1.70	3.6	
		Week 44	Tezepelumab	15	13 (86.7)	1.38 (1.04)	0.2	0.60	1.40	1.60	3.8	0.70 [-0.11, 1.51]
			Placebo	16	12 (75.0)	0.43 (1.65)	-1.8	-1.00	0.50	1.80	3.2	
		Week 48	Tezepelumab	15	13 (86.7)	1.31 (1.06)	0.0	0.60	1.20	1.60	3.8	0.72 [-0.09, 1.54]
			Placebo	16	12 (75.0)	0.45 (1.31)	-2.2	-0.20	0.60	1.40	2.6	
		Week 52	Tezepelumab	15	13 (86.7)	1.32 (1.11)	-0.6	0.60	1.40	1.60	3.8	0.71 [-0.10, 1.52]
			Placebo	16	12 (75.0)	0.50 (1.21)	-1.6	-0.20	0.60	1.40	2.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILMH0: Course of AQLQ+12 symptom score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	66	58 (87.9)	3.98 (1.01)	1.4	3.42	4.04	4.67	6.7	
		Placebo	65	55 (84.6)	4.12 (0.88)	1.5	3.67	4.25	4.58	6.3	
	Week 4	Tezepelumab	66	60 (90.9)	4.74 (1.11)	1.3	3.92	4.75	5.58	6.8	
		Placebo	65	57 (87.7)	4.71 (0.92)	2.7	4.17	4.67	5.25	6.7	
	Week 8	Tezepelumab	66	62 (93.9)	5.00 (1.16)	2.0	4.08	4.96	5.83	6.8	
		Placebo	65	59 (90.8)	4.74 (1.08)	1.9	4.17	4.67	5.42	7.0	
	Week 12	Tezepelumab	66	62 (93.9)	5.21 (1.08)	3.0	4.33	5.21	6.17	7.0	
		Placebo	65	59 (90.8)	4.88 (1.06)	2.1	4.17	4.83	5.58	7.0	
	Week 16	Tezepelumab	66	62 (93.9)	5.22 (1.11)	2.7	4.33	5.29	6.08	7.0	
		Placebo	65	59 (90.8)	4.86 (1.23)	1.3	4.08	4.75	5.83	7.0	
	Week 20	Tezepelumab	66	63 (95.5)	5.16 (1.10)	2.3	4.25	5.00	6.00	7.0	
		Placebo	65	59 (90.8)	4.76 (1.22)	1.3	4.00	4.75	5.58	7.0	
	Week 24	Tezepelumab	66	63 (95.5)	5.19 (1.08)	3.1	4.33	5.17	6.08	7.0	
		Placebo	65	59 (90.8)	4.74 (1.23)	1.3	3.83	4.67	5.75	7.0	
	Week 28	Tezepelumab	66	65 (98.5)	5.14 (1.11)	3.2	4.17	5.00	6.08	7.0	
		Placebo	65	60 (92.3)	4.84 (1.30)	1.3	3.96	4.88	5.75	7.0	
	Week 32	Tezepelumab	66	65 (98.5)	5.22 (1.12)	2.8	4.33	5.08	6.08	7.0	
		Placebo	65	60 (92.3)	4.90 (1.17)	1.3	4.04	4.92	5.75	7.0	
	Week 36	Tezepelumab	66	65 (98.5)	5.27 (1.13)	2.9	4.33	5.25	6.17	7.0	
		Placebo	65	60 (92.3)	4.81 (1.18)	2.4	4.00	4.71	5.83	7.0	
	Week 40	Tezepelumab	66	65 (98.5)	5.21 (1.16)	2.3	4.33	5.08	6.08	7.0	
		Placebo	65	60 (92.3)	4.91 (1.19)	2.3	4.00	4.96	5.92	7.0	
	Week 44	Tezepelumab	66	65 (98.5)	5.22 (1.10)	3.0	4.33	5.08	6.08	7.0	
		Placebo	65	60 (92.3)	4.90 (1.15)	2.5	4.04	4.79	5.88	7.0	
	Week 48	Tezepelumab	66	65 (98.5)	5.25 (1.14)	2.8	4.33	5.17	6.17	7.0	
		Placebo	65	60 (92.3)	4.93 (1.15)	2.2	4.08	4.79	5.83	7.0	
	Week 52	Tezepelumab	66	65 (98.5)	5.25 (1.14)	2.8	4.33	5.17	6.17	7.0	
		Placebo	65	60 (92.3)	4.99 (1.12)	2.8	4.17	4.79	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILMH0: Course of AQLQ+12 symptom score
DITTL

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	66	55 (83.3)	0.78 (1.10)	-4.3	0.08	0.92	1.50	3.1	0.17 [-0.21, 0.54]
		Placebo	65	54 (83.1)	0.61 (0.88)	-1.3	0.17	0.50	0.92	3.3	
	Week 8	Tezepelumab	66	57 (86.4)	0.95 (1.11)	-1.9	0.25	1.00	1.83	3.3	0.27 [-0.11, 0.64]
		Placebo	65	55 (84.6)	0.67 (1.03)	-1.8	0.08	0.67	1.17	3.6	
	Week 12	Tezepelumab	66	57 (86.4)	1.17 (1.13)	-2.6	0.42	1.08	1.92	3.7	0.33 [-0.04, 0.70]
		Placebo	65	55 (84.6)	0.78 (1.23)	-2.8	0.08	0.75	1.17	4.0	
	Week 16	Tezepelumab	66	57 (86.4)	1.19 (1.12)	-2.9	0.58	1.08	2.08	3.3	0.34 [-0.03, 0.72]
		Placebo	65	55 (84.6)	0.77 (1.32)	-3.5	0.17	0.83	1.33	4.2	
	Week 20	Tezepelumab	66	57 (86.4)	1.16 (1.08)	-1.8	0.42	1.08	2.08	3.3	0.41 [0.04, 0.78]
		Placebo	65	55 (84.6)	0.68 (1.26)	-3.5	0.08	0.83	1.33	3.8	
	Week 24	Tezepelumab	66	57 (86.4)	1.23 (1.08)	-1.6	0.50	1.17	2.00	3.3	0.47 [0.10, 0.85]
		Placebo	65	55 (84.6)	0.67 (1.31)	-3.5	0.00	0.83	1.25	3.9	
	Week 28	Tezepelumab	66	57 (86.4)	1.14 (1.10)	-1.7	0.42	1.00	2.00	3.3	0.33 [-0.04, 0.70]
		Placebo	65	55 (84.6)	0.73 (1.34)	-3.5	0.08	0.83	1.33	4.3	
	Week 32	Tezepelumab	66	57 (86.4)	1.23 (1.14)	-1.6	0.50	1.08	2.17	3.3	0.36 [-0.01, 0.73]
		Placebo	65	55 (84.6)	0.81 (1.19)	-3.5	0.33	0.92	1.25	3.5	
	Week 36	Tezepelumab	66	57 (86.4)	1.26 (1.20)	-1.7	0.33	1.08	2.17	3.4	0.47 [0.10, 0.85]
		Placebo	65	55 (84.6)	0.70 (1.14)	-3.0	0.08	0.83	1.25	3.8	
	Week 40	Tezepelumab	66	57 (86.4)	1.24 (1.19)	-1.7	0.50	1.08	2.25	3.4	0.35 [-0.02, 0.72]
		Placebo	65	55 (84.6)	0.82 (1.21)	-3.0	0.00	0.83	1.58	4.0	
	Week 44	Tezepelumab	66	57 (86.4)	1.23 (1.15)	-1.6	0.50	1.17	2.08	3.3	0.38 [0.00, 0.75]
		Placebo	65	55 (84.6)	0.79 (1.19)	-3.0	0.25	0.83	1.58	3.7	
	Week 48	Tezepelumab	66	57 (86.4)	1.28 (1.16)	-1.6	0.50	1.17	2.17	3.4	0.39 [0.01, 0.76]
		Placebo	65	55 (84.6)	0.83 (1.16)	-3.0	0.25	0.83	1.50	4.2	
	Week 52	Tezepelumab	66	57 (86.4)	1.28 (1.16)	-1.6	0.50	1.08	2.17	3.6	0.34 [-0.04, 0.71]
		Placebo	65	55 (84.6)	0.89 (1.16)	-3.0	0.25	0.83	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
DITTL

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	54 (83.1)					
Week 8	Tezepelumab	66	55 (83.3)	NE		NE		
	Placebo	65	55 (84.6)					
Week 12	Tezepelumab	66	54 (81.8)	NE		NE		
	Placebo	65	52 (80.0)					
Week 16	Tezepelumab	66	53 (80.3)	NE		NE		
	Placebo	65	50 (76.9)					
Week 20	Tezepelumab	66	51 (77.3)	NE		NE		
	Placebo	65	47 (72.3)					
Week 24	Tezepelumab	66	50 (75.8)	NE		NE		
	Placebo	65	45 (69.2)					
Week 28	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 32	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	43 (66.2)					
Week 36	Tezepelumab	66	49 (74.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 40	Tezepelumab	66	48 (72.7)	NE		NE		
	Placebo	65	45 (69.2)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
DITTL

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	66	47 (71.2)	NE		NE		
	Placebo	65	44 (67.7)					
Week 48	Tezepelumab	66	46 (69.7)	NE		NE		
	Placebo	65	44 (67.7)					
Week 52	Tezepelumab	66	18 (27.3)	NE		NE		
	Placebo	65	16 (24.6)					

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QMC_ILMG0: Course of AQLQ+12 symptom score
DITTL



Note: DITTL = Dossier Label Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QMC_ILMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Absolute values	Baseline	Tezepelumab	19	16 (84.2)	3.61 (0.96)	1.9	3.00	3.83	4.21	5.0	
			Placebo	20	17 (85.0)	3.89 (0.76)	1.7	3.67	4.00	4.42	4.8	
		Week 4	Tezepelumab	19	17 (89.5)	4.67 (1.21)	2.6	3.50	4.83	5.58	6.8	
			Placebo	20	17 (85.0)	4.38 (1.06)	2.7	3.67	4.42	5.25	6.1	
		Week 8	Tezepelumab	19	17 (89.5)	4.87 (1.18)	3.3	3.92	4.83	5.67	6.8	
			Placebo	20	18 (90.0)	4.29 (1.05)	2.1	3.50	4.33	5.08	6.5	
		Week 12	Tezepelumab	19	17 (89.5)	5.10 (1.06)	3.6	4.42	4.83	5.50	6.9	
			Placebo	20	18 (90.0)	4.53 (1.10)	2.1	3.92	4.50	5.25	6.8	
		Week 16	Tezepelumab	19	17 (89.5)	4.94 (1.16)	3.0	4.33	4.42	5.58	6.9	
			Placebo	20	18 (90.0)	4.30 (1.27)	1.3	3.75	4.29	5.17	6.6	
		Week 20	Tezepelumab	19	17 (89.5)	5.04 (1.23)	2.3	4.33	5.00	5.67	7.0	
			Placebo	20	18 (90.0)	4.41 (1.32)	1.3	3.67	4.54	5.17	6.8	
		Week 24	Tezepelumab	19	17 (89.5)	4.97 (1.24)	3.1	4.17	4.58	6.08	6.9	
			Placebo	20	18 (90.0)	4.30 (1.37)	1.3	3.33	4.29	5.17	6.8	
		Week 28	Tezepelumab	19	18 (94.7)	5.00 (1.25)	3.2	4.08	5.00	6.08	7.0	
			Placebo	20	19 (95.0)	4.39 (1.45)	1.3	3.17	4.25	5.17	6.8	
		Week 32	Tezepelumab	19	18 (94.7)	5.08 (1.19)	2.9	4.00	5.08	5.92	7.0	
			Placebo	20	19 (95.0)	4.64 (1.38)	1.3	3.67	4.92	5.58	6.8	
		Week 36	Tezepelumab	19	18 (94.7)	5.19 (1.31)	2.9	4.00	5.29	6.33	7.0	
			Placebo	20	19 (95.0)	4.61 (1.29)	2.4	3.58	4.83	5.58	6.9	
		Week 40	Tezepelumab	19	18 (94.7)	5.00 (1.27)	2.9	4.25	4.79	6.08	7.0	
			Placebo	20	19 (95.0)	4.73 (1.26)	2.3	3.75	4.83	5.75	7.0	
		Week 44	Tezepelumab	19	18 (94.7)	4.94 (1.32)	3.0	4.00	4.71	6.08	7.0	
			Placebo	20	19 (95.0)	4.69 (1.18)	2.5	4.00	4.42	5.75	6.9	
		Week 48	Tezepelumab	19	18 (94.7)	5.04 (1.23)	3.1	4.08	4.92	6.08	7.0	
			Placebo	20	19 (95.0)	4.79 (1.23)	2.2	4.00	4.83	5.67	6.9	
		Week 52	Tezepelumab	19	18 (94.7)	4.97 (1.22)	3.0	4.00	4.83	6.08	7.0	
			Placebo	20	19 (95.0)	4.78 (1.21)	2.8	3.92	4.83	5.67	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Change from baseline	Week 4	Tezepelumab	19	15 (78.9)	1.02 (0.73)	-0.2	0.42	0.92	1.58	2.4	0.45 [-0.26, 1.16]
			Placebo	20	16 (80.0)	0.61 (1.03)	-1.2	0.13	0.54	1.08	3.1	
		Week 8	Tezepelumab	19	15 (78.9)	1.22 (0.78)	0.0	0.50	1.42	1.92	2.5	0.84 [0.11, 1.56]
			Placebo	20	17 (85.0)	0.45 (1.04)	-0.8	-0.08	0.42	0.67	3.6	
		Week 12	Tezepelumab	19	15 (78.9)	1.48 (0.74)	0.3	0.92	1.08	2.25	2.8	0.79 [0.07, 1.51]
			Placebo	20	17 (85.0)	0.70 (1.17)	-1.6	0.17	0.75	1.00	3.8	
		Week 16	Tezepelumab	19	15 (78.9)	1.37 (0.79)	0.3	0.58	1.08	2.17	2.7	0.78 [0.06, 1.50]
			Placebo	20	17 (85.0)	0.43 (1.49)	-3.5	-0.08	0.67	0.92	3.7	
		Week 20	Tezepelumab	19	15 (78.9)	1.44 (0.82)	0.3	0.83	1.25	2.25	2.8	0.72 [0.00, 1.44]
			Placebo	20	17 (85.0)	0.56 (1.48)	-3.5	0.00	0.58	1.17	3.8	
		Week 24	Tezepelumab	19	15 (78.9)	1.48 (0.83)	0.2	0.92	1.50	2.25	2.9	0.81 [0.09, 1.54]
			Placebo	20	17 (85.0)	0.45 (1.56)	-3.5	0.00	0.83	1.17	3.9	
		Week 28	Tezepelumab	19	15 (78.9)	1.52 (0.92)	-0.3	0.92	1.50	2.33	3.0	0.87 [0.14, 1.60]
			Placebo	20	17 (85.0)	0.39 (1.56)	-3.5	-0.42	0.67	1.08	3.8	
		Week 32	Tezepelumab	19	15 (78.9)	1.61 (0.84)	0.3	1.00	1.42	2.25	3.0	0.78 [0.05, 1.50]
			Placebo	20	17 (85.0)	0.68 (1.43)	-3.5	0.42	0.83	1.25	3.3	
		Week 36	Tezepelumab	19	15 (78.9)	1.71 (1.03)	-0.2	0.92	2.00	2.42	3.3	0.95 [0.22, 1.69]
			Placebo	20	17 (85.0)	0.64 (1.21)	-2.3	0.00	1.08	1.17	2.6	
		Week 40	Tezepelumab	19	15 (78.9)	1.61 (0.90)	0.1	1.08	1.17	2.33	3.4	0.79 [0.07, 1.51]
			Placebo	20	17 (85.0)	0.76 (1.19)	-1.4	0.00	0.83	1.67	2.8	
		Week 44	Tezepelumab	19	15 (78.9)	1.50 (0.94)	-0.1	0.83	1.17	2.33	3.3	0.80 [0.08, 1.52]
			Placebo	20	17 (85.0)	0.70 (1.06)	-1.2	0.00	0.83	1.58	2.8	
		Week 48	Tezepelumab	19	15 (78.9)	1.59 (0.83)	0.3	0.83	1.50	2.25	3.2	0.78 [0.06, 1.51]
			Placebo	20	17 (85.0)	0.81 (1.12)	-1.5	0.33	0.83	1.58	2.8	
		Week 52	Tezepelumab	19	15 (78.9)	1.51 (0.99)	0.3	0.75	1.08	2.33	3.6	0.65 [-0.06, 1.37]
			Placebo	20	17 (85.0)	0.82 (1.08)	-1.1	0.33	0.83	1.58	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Absolute values	Baseline	Tezepelumab	47	42 (89.4)	4.13 (1.01)	1.4	3.58	4.17	4.83	6.7	
			Placebo	45	38 (84.4)	4.23 (0.92)	1.5	3.50	4.38	4.75	6.3	
		Week 4	Tezepelumab	47	43 (91.5)	4.78 (1.08)	1.3	3.92	4.75	5.67	6.5	
			Placebo	45	40 (88.9)	4.85 (0.82)	3.0	4.29	4.83	5.25	6.7	
		Week 8	Tezepelumab	47	45 (95.7)	5.05 (1.16)	2.0	4.25	5.08	5.83	6.8	
			Placebo	45	41 (91.1)	4.94 (1.05)	1.9	4.25	4.75	5.83	7.0	
		Week 12	Tezepelumab	47	45 (95.7)	5.25 (1.10)	3.0	4.33	5.33	6.25	7.0	
			Placebo	45	41 (91.1)	5.04 (1.02)	3.3	4.17	4.92	5.92	7.0	
		Week 16	Tezepelumab	47	45 (95.7)	5.33 (1.09)	2.7	4.58	5.42	6.08	7.0	
			Placebo	45	41 (91.1)	5.10 (1.14)	2.1	4.42	4.83	5.92	7.0	
		Week 20	Tezepelumab	47	46 (97.9)	5.20 (1.06)	3.5	4.25	5.21	6.00	6.9	
			Placebo	45	41 (91.1)	4.91 (1.16)	2.1	4.33	4.75	5.75	7.0	
		Week 24	Tezepelumab	47	46 (97.9)	5.27 (1.02)	3.6	4.42	5.29	6.17	7.0	
			Placebo	45	41 (91.1)	4.93 (1.12)	2.2	4.25	4.75	5.92	7.0	
		Week 28	Tezepelumab	47	47 (100.0)	5.20 (1.06)	3.6	4.33	5.00	6.17	7.0	
			Placebo	45	41 (91.1)	5.05 (1.18)	1.8	4.25	5.00	5.92	7.0	
		Week 32	Tezepelumab	47	47 (100.0)	5.28 (1.10)	2.8	4.33	5.17	6.17	7.0	
			Placebo	45	41 (91.1)	5.01 (1.06)	2.9	4.25	5.00	5.83	7.0	
		Week 36	Tezepelumab	47	47 (100.0)	5.29 (1.07)	3.3	4.33	5.25	6.17	7.0	
			Placebo	45	41 (91.1)	4.90 (1.14)	2.8	4.17	4.58	5.92	7.0	
		Week 40	Tezepelumab	47	47 (100.0)	5.29 (1.12)	2.3	4.33	5.33	6.08	7.0	
			Placebo	45	41 (91.1)	5.00 (1.16)	2.5	4.08	5.00	6.08	7.0	
		Week 44	Tezepelumab	47	47 (100.0)	5.32 (1.01)	3.6	4.33	5.33	6.08	7.0	
			Placebo	45	41 (91.1)	5.00 (1.14)	3.1	4.25	5.00	5.92	7.0	
		Week 48	Tezepelumab	47	47 (100.0)	5.33 (1.11)	2.8	4.33	5.33	6.25	7.0	
			Placebo	45	41 (91.1)	5.00 (1.12)	2.4	4.25	4.75	6.00	7.0	
		Week 52	Tezepelumab	47	47 (100.0)	5.36 (1.10)	2.8	4.33	5.33	6.25	7.0	
			Placebo	45	41 (91.1)	5.09 (1.07)	3.2	4.25	4.75	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Female	Change from baseline	Week 4	Tezepelumab	47	40 (85.1)	0.69 (1.21)	-4.3	0.00	0.92	1.33	3.1	0.08 [-0.37, 0.52]
			Placebo	45	38 (84.4)	0.61 (0.82)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	47	42 (89.4)	0.86 (1.20)	-1.9	0.17	0.92	1.83	3.3	0.08 [-0.36, 0.52]
			Placebo	45	38 (84.4)	0.77 (1.02)	-1.8	0.17	0.79	1.17	3.3	
		Week 12	Tezepelumab	47	42 (89.4)	1.06 (1.23)	-2.6	0.33	1.08	1.92	3.7	0.19 [-0.25, 0.63]
			Placebo	45	38 (84.4)	0.82 (1.27)	-2.8	0.00	0.75	1.17	4.0	
		Week 16	Tezepelumab	47	42 (89.4)	1.13 (1.22)	-2.9	0.42	1.17	2.08	3.3	0.16 [-0.28, 0.60]
			Placebo	45	38 (84.4)	0.93 (1.23)	-3.0	0.17	0.96	1.42	4.2	
		Week 20	Tezepelumab	47	42 (89.4)	1.06 (1.15)	-1.8	0.25	0.96	2.00	3.3	0.28 [-0.16, 0.73]
			Placebo	45	38 (84.4)	0.73 (1.17)	-3.0	0.08	0.88	1.33	3.3	
		Week 24	Tezepelumab	47	42 (89.4)	1.14 (1.15)	-1.6	0.42	1.08	2.00	3.3	0.32 [-0.12, 0.76]
			Placebo	45	38 (84.4)	0.77 (1.19)	-3.0	0.00	0.83	1.33	3.6	
		Week 28	Tezepelumab	47	42 (89.4)	1.00 (1.14)	-1.7	0.33	0.88	2.00	3.3	0.10 [-0.34, 0.54]
			Placebo	45	38 (84.4)	0.89 (1.23)	-3.0	0.25	0.92	1.42	4.3	
		Week 32	Tezepelumab	47	42 (89.4)	1.10 (1.21)	-1.6	0.33	1.04	2.08	3.3	0.20 [-0.24, 0.64]
			Placebo	45	38 (84.4)	0.87 (1.08)	-3.0	0.33	0.92	1.17	3.5	
		Week 36	Tezepelumab	47	42 (89.4)	1.10 (1.22)	-1.7	0.17	1.08	2.08	3.4	0.31 [-0.14, 0.75]
			Placebo	45	38 (84.4)	0.73 (1.12)	-3.0	0.08	0.79	1.25	3.8	
		Week 40	Tezepelumab	47	42 (89.4)	1.11 (1.26)	-1.7	0.25	1.00	2.17	3.3	0.21 [-0.23, 0.65]
			Placebo	45	38 (84.4)	0.84 (1.23)	-3.0	0.08	0.79	1.42	4.0	
		Week 44	Tezepelumab	47	42 (89.4)	1.14 (1.21)	-1.6	0.33	0.96	2.08	3.3	0.25 [-0.19, 0.69]
			Placebo	45	38 (84.4)	0.84 (1.26)	-3.0	0.33	0.92	1.33	3.7	
		Week 48	Tezepelumab	47	42 (89.4)	1.17 (1.25)	-1.6	0.33	1.08	2.08	3.4	0.27 [-0.17, 0.71]
			Placebo	45	38 (84.4)	0.84 (1.19)	-3.0	0.25	0.83	1.33	4.2	
		Week 52	Tezepelumab	47	42 (89.4)	1.20 (1.22)	-1.6	0.33	1.08	2.08	3.4	0.23 [-0.21, 0.67]
			Placebo	45	38 (84.4)	0.92 (1.20)	-3.0	0.25	0.79	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	4.02 (1.08)	1.4	3.42	4.17	4.83	6.7	
			Placebo	55	48 (87.3)	4.11 (0.93)	1.5	3.58	4.25	4.58	6.3	
		Week 4	Tezepelumab	57	52 (91.2)	4.75 (1.17)	1.3	3.92	4.79	5.67	6.8	
			Placebo	55	49 (89.1)	4.77 (0.93)	2.7	4.25	4.67	5.25	6.7	
		Week 8	Tezepelumab	57	54 (94.7)	5.05 (1.21)	2.0	4.08	5.13	6.08	6.8	
			Placebo	55	51 (92.7)	4.81 (1.10)	1.9	4.25	4.67	5.75	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.28 (1.13)	3.0	4.42	5.33	6.25	7.0	
			Placebo	55	51 (92.7)	4.97 (1.10)	2.1	4.17	5.00	5.92	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.28 (1.16)	2.7	4.33	5.42	6.25	7.0	
			Placebo	55	51 (92.7)	4.95 (1.26)	1.3	4.25	4.83	5.92	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	5.25 (1.14)	2.3	4.33	5.25	6.17	7.0	
			Placebo	55	51 (92.7)	4.84 (1.24)	1.3	4.17	5.00	5.75	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	5.27 (1.12)	3.1	4.42	5.33	6.17	7.0	
			Placebo	55	51 (92.7)	4.84 (1.23)	1.3	3.92	4.75	5.92	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.23 (1.14)	3.2	4.29	5.08	6.21	7.0	
			Placebo	55	51 (92.7)	4.91 (1.28)	1.3	3.92	5.00	5.92	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.27 (1.17)	2.8	4.29	5.25	6.21	7.0	
			Placebo	55	51 (92.7)	4.96 (1.16)	1.3	4.25	5.00	5.75	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.30 (1.17)	2.9	4.33	5.46	6.17	7.0	
			Placebo	55	51 (92.7)	4.87 (1.19)	2.4	4.00	4.83	5.92	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.25 (1.21)	2.3	4.38	5.13	6.08	7.0	
			Placebo	55	51 (92.7)	4.99 (1.17)	2.3	4.00	5.08	6.08	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.25 (1.14)	3.0	4.38	5.21	6.17	7.0	
			Placebo	55	51 (92.7)	4.94 (1.16)	2.5	4.08	5.00	5.92	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.26 (1.19)	2.8	4.25	5.21	6.21	7.0	
			Placebo	55	51 (92.7)	5.00 (1.13)	2.2	4.25	4.92	6.00	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.26 (1.18)	2.8	4.25	5.25	6.17	7.0	
			Placebo	55	51 (92.7)	5.05 (1.13)	2.8	4.25	4.92	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
< 65 years	Change from baseline	Week 4	Tezepelumab	57	47 (82.5)	0.75 (1.15)	-4.3	0.08	0.92	1.50	3.1	0.09 [-0.32, 0.49]
			Placebo	55	47 (85.5)	0.66 (0.89)	-1.3	0.25	0.50	1.00	3.3	
		Week 8	Tezepelumab	57	49 (86.0)	0.96 (1.16)	-1.9	0.25	1.08	1.83	3.3	0.20 [-0.20, 0.60]
			Placebo	55	48 (87.3)	0.74 (1.04)	-1.8	0.17	0.67	1.17	3.6	
		Week 12	Tezepelumab	57	49 (86.0)	1.20 (1.19)	-2.6	0.42	1.25	2.00	3.7	0.27 [-0.13, 0.67]
			Placebo	55	48 (87.3)	0.87 (1.27)	-2.8	0.33	0.79	1.29	4.0	
		Week 16	Tezepelumab	57	49 (86.0)	1.22 (1.16)	-2.9	0.58	1.25	2.08	3.3	0.27 [-0.13, 0.67]
			Placebo	55	48 (87.3)	0.88 (1.36)	-3.5	0.25	0.92	1.42	4.2	
		Week 20	Tezepelumab	57	49 (86.0)	1.21 (1.12)	-1.8	0.42	1.17	2.17	3.3	0.37 [-0.04, 0.77]
			Placebo	55	48 (87.3)	0.77 (1.29)	-3.5	0.17	0.92	1.50	3.8	
		Week 24	Tezepelumab	57	49 (86.0)	1.28 (1.11)	-1.6	0.50	1.33	2.17	3.3	0.41 [0.00, 0.81]
			Placebo	55	48 (87.3)	0.78 (1.34)	-3.5	0.04	0.92	1.42	3.9	
		Week 28	Tezepelumab	57	49 (86.0)	1.18 (1.13)	-1.7	0.42	1.25	2.08	3.3	0.27 [-0.13, 0.67]
			Placebo	55	48 (87.3)	0.85 (1.36)	-3.5	0.29	0.88	1.54	4.3	
		Week 32	Tezepelumab	57	49 (86.0)	1.27 (1.18)	-1.6	0.50	1.08	2.17	3.3	0.29 [-0.11, 0.69]
			Placebo	55	48 (87.3)	0.92 (1.21)	-3.5	0.46	0.96	1.33	3.5	
		Week 36	Tezepelumab	57	49 (86.0)	1.29 (1.24)	-1.7	0.33	1.33	2.33	3.4	0.40 [-0.01, 0.80]
			Placebo	55	48 (87.3)	0.81 (1.17)	-3.0	0.33	0.96	1.29	3.8	
		Week 40	Tezepelumab	57	49 (86.0)	1.25 (1.21)	-1.7	0.50	1.08	2.25	3.3	0.25 [-0.15, 0.65]
			Placebo	55	48 (87.3)	0.94 (1.23)	-3.0	0.42	0.92	1.67	4.0	
		Week 44	Tezepelumab	57	49 (86.0)	1.26 (1.17)	-1.6	0.58	1.17	2.17	3.3	0.32 [-0.08, 0.72]
			Placebo	55	48 (87.3)	0.88 (1.23)	-3.0	0.38	0.96	1.58	3.7	
		Week 48	Tezepelumab	57	49 (86.0)	1.28 (1.18)	-1.6	0.58	1.17	2.17	3.4	0.29 [-0.11, 0.69]
			Placebo	55	48 (87.3)	0.94 (1.16)	-3.0	0.38	1.00	1.63	4.2	
		Week 52	Tezepelumab	57	49 (86.0)	1.28 (1.16)	-1.6	0.58	1.08	2.17	3.4	0.25 [-0.15, 0.65]
			Placebo	55	48 (87.3)	0.99 (1.19)	-3.0	0.38	0.92	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.76 (0.39)	3.2	3.46	3.92	4.00	4.2	
			Placebo	10	7 (70.0)	4.25 (0.41)	3.5	4.00	4.33	4.58	4.8	
		Week 4	Tezepelumab	9	8 (88.9)	4.71 (0.63)	3.9	4.21	4.54	5.33	5.6	
			Placebo	10	8 (80.0)	4.38 (0.82)	3.2	3.71	4.38	5.21	5.3	
		Week 8	Tezepelumab	9	8 (88.9)	4.65 (0.61)	3.9	4.29	4.33	5.17	5.7	
			Placebo	10	8 (80.0)	4.27 (0.87)	3.2	3.50	4.21	5.04	5.5	
		Week 12	Tezepelumab	9	8 (88.9)	4.72 (0.46)	4.3	4.33	4.54	5.17	5.4	
			Placebo	10	8 (80.0)	4.31 (0.52)	3.5	4.00	4.21	4.75	5.1	
		Week 16	Tezepelumab	9	8 (88.9)	4.79 (0.60)	4.0	4.33	4.75	5.29	5.6	
			Placebo	10	8 (80.0)	4.26 (0.82)	3.4	3.71	4.04	4.58	6.0	
		Week 20	Tezepelumab	9	9 (100.0)	4.61 (0.59)	3.8	4.25	4.50	5.00	5.7	
			Placebo	10	8 (80.0)	4.22 (1.02)	2.4	3.79	4.00	5.08	5.6	
		Week 24	Tezepelumab	9	9 (100.0)	4.72 (0.64)	4.0	4.33	4.50	5.08	6.1	
			Placebo	10	8 (80.0)	4.08 (1.05)	2.2	3.58	3.96	5.00	5.4	
		Week 28	Tezepelumab	9	9 (100.0)	4.59 (0.72)	3.8	4.17	4.33	4.92	6.2	
			Placebo	10	9 (90.0)	4.45 (1.41)	1.8	4.00	4.17	5.25	6.8	
		Week 32	Tezepelumab	9	9 (100.0)	4.91 (0.76)	4.0	4.33	4.92	5.17	6.2	
			Placebo	10	9 (90.0)	4.52 (1.22)	2.9	3.75	4.08	5.08	6.8	
		Week 36	Tezepelumab	9	9 (100.0)	5.04 (0.88)	4.1	4.33	4.83	5.08	6.6	
			Placebo	10	9 (90.0)	4.48 (1.16)	2.8	4.00	4.25	4.67	6.9	
		Week 40	Tezepelumab	9	9 (100.0)	4.98 (0.84)	4.0	4.25	5.08	5.42	6.6	
			Placebo	10	9 (90.0)	4.48 (1.28)	2.5	3.75	4.33	5.00	7.0	
		Week 44	Tezepelumab	9	9 (100.0)	4.98 (0.90)	4.0	4.33	4.75	5.58	6.5	
			Placebo	10	9 (90.0)	4.69 (1.17)	3.1	4.00	4.33	5.33	6.9	
		Week 48	Tezepelumab	9	9 (100.0)	5.18 (0.87)	4.0	4.33	5.08	5.75	6.3	
			Placebo	10	9 (90.0)	4.56 (1.28)	2.4	4.00	4.33	5.17	6.9	
		Week 52	Tezepelumab	9	9 (100.0)	5.19 (0.94)	4.0	4.33	5.08	5.75	6.8	
			Placebo	10	9 (90.0)	4.65 (1.04)	3.6	4.00	4.33	5.17	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
>= 65 years	Change from baseline	Week 4	Tezepelumab	9	8 (88.9)	0.95 (0.80)	-0.1	0.29	1.00	1.33	2.4	0.83 [-0.23, 1.90]
			Placebo	10	7 (70.0)	0.30 (0.75)	-1.2	0.00	0.50	0.92	1.0	
		Week 8	Tezepelumab	9	8 (88.9)	0.89 (0.82)	-0.1	0.29	0.54	1.75	2.0	0.94 [-0.14, 2.01]
			Placebo	10	7 (70.0)	0.13 (0.78)	-0.9	-0.67	0.33	0.83	1.2	
		Week 12	Tezepelumab	9	8 (88.9)	0.96 (0.64)	0.3	0.42	1.00	1.17	2.3	1.24 [0.12, 2.36]
			Placebo	10	7 (70.0)	0.18 (0.61)	-0.7	-0.25	0.25	0.75	1.1	
		Week 16	Tezepelumab	9	8 (88.9)	1.03 (0.87)	0.0	0.42	0.79	1.71	2.4	1.21 [0.09, 2.32]
			Placebo	10	7 (70.0)	0.06 (0.73)	-1.2	-0.25	0.00	0.42	1.3	
		Week 20	Tezepelumab	9	8 (88.9)	0.83 (0.76)	0.0	0.38	0.71	1.00	2.5	0.99 [-0.09, 2.08]
			Placebo	10	7 (70.0)	0.05 (0.82)	-1.1	-0.58	0.00	0.83	1.3	
		Week 24	Tezepelumab	9	8 (88.9)	0.96 (0.87)	0.0	0.50	0.79	1.08	2.9	1.23 [0.11, 2.35]
			Placebo	10	7 (70.0)	-0.10 (0.84)	-1.3	-0.75	0.00	0.67	0.9	
		Week 28	Tezepelumab	9	8 (88.9)	0.86 (0.93)	0.0	0.33	0.71	0.92	3.0	0.98 [-0.10, 2.06]
			Placebo	10	7 (70.0)	-0.05 (0.94)	-1.8	-0.42	0.00	0.83	1.1	
		Week 32	Tezepelumab	9	8 (88.9)	0.99 (0.83)	0.0	0.42	1.00	1.17	2.8	1.18 [0.07, 2.29]
			Placebo	10	7 (70.0)	0.06 (0.74)	-0.8	-0.58	0.08	0.92	1.1	
		Week 36	Tezepelumab	9	8 (88.9)	1.08 (0.99)	0.1	0.38	0.88	1.46	3.2	1.39 [0.24, 2.53]
			Placebo	10	7 (70.0)	-0.01 (0.46)	-0.8	-0.42	0.08	0.25	0.7	
		Week 40	Tezepelumab	9	8 (88.9)	1.17 (1.09)	0.0	0.38	1.00	1.58	3.4	1.29 [0.16, 2.42]
			Placebo	10	7 (70.0)	-0.02 (0.68)	-1.0	-0.58	0.00	0.83	0.8	
		Week 44	Tezepelumab	9	8 (88.9)	1.08 (1.05)	0.0	0.42	0.79	1.46	3.3	0.97 [-0.11, 2.05]
			Placebo	10	7 (70.0)	0.19 (0.75)	-0.5	-0.42	0.00	0.58	1.7	
		Week 48	Tezepelumab	9	8 (88.9)	1.27 (1.12)	0.0	0.38	1.08	2.04	3.2	1.23 [0.11, 2.35]
			Placebo	10	7 (70.0)	0.05 (0.83)	-1.1	-0.58	0.00	0.42	1.5	
		Week 52	Tezepelumab	9	8 (88.9)	1.28 (1.23)	0.0	0.38	1.00	1.96	3.6	1.09 [-0.00, 2.19]
			Placebo	10	7 (70.0)	0.21 (0.56)	-0.7	-0.25	0.33	0.83	0.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Absolute values	Baseline	Tezepelumab	44	39 (88.6)	4.05 (0.89)	2.1	3.58	4.08	4.58	6.7	
			Placebo	45	38 (84.4)	4.13 (0.80)	1.7	3.67	4.29	4.58	5.8	
		Week 4	Tezepelumab	44	40 (90.9)	4.75 (0.96)	2.6	4.08	4.79	5.54	6.8	
			Placebo	45	39 (86.7)	4.81 (0.88)	2.7	4.17	4.67	5.25	6.7	
		Week 8	Tezepelumab	44	41 (93.2)	4.98 (1.00)	2.8	4.25	4.83	5.75	6.8	
			Placebo	45	40 (88.9)	4.87 (1.05)	2.1	4.21	4.71	5.46	7.0	
		Week 12	Tezepelumab	44	41 (93.2)	5.20 (0.99)	3.5	4.42	5.17	6.08	7.0	
			Placebo	45	40 (88.9)	4.94 (0.98)	2.9	4.17	4.88	5.42	7.0	
		Week 16	Tezepelumab	44	41 (93.2)	5.16 (1.02)	3.3	4.33	5.17	6.00	6.9	
			Placebo	45	40 (88.9)	4.94 (1.04)	2.8	4.25	4.71	5.75	7.0	
		Week 20	Tezepelumab	44	42 (95.5)	5.18 (1.00)	3.5	4.33	5.00	6.00	6.9	
			Placebo	45	40 (88.9)	4.90 (1.05)	2.4	4.13	4.88	5.50	7.0	
		Week 24	Tezepelumab	44	42 (95.5)	5.16 (1.02)	3.3	4.42	5.00	5.92	7.0	
			Placebo	45	40 (88.9)	4.89 (1.09)	2.2	4.13	4.92	5.63	7.0	
		Week 28	Tezepelumab	44	43 (97.7)	5.08 (1.04)	3.3	4.33	5.00	5.83	7.0	
			Placebo	45	41 (91.1)	4.98 (1.15)	1.8	4.25	5.08	5.67	7.0	
		Week 32	Tezepelumab	44	43 (97.7)	5.21 (1.11)	2.8	4.33	5.08	6.08	7.0	
			Placebo	45	41 (91.1)	5.01 (1.04)	2.8	4.25	4.92	5.75	7.0	
		Week 36	Tezepelumab	44	43 (97.7)	5.22 (1.12)	3.3	4.25	5.17	6.17	7.0	
			Placebo	45	41 (91.1)	5.08 (1.03)	2.8	4.42	5.08	5.92	7.0	
		Week 40	Tezepelumab	44	43 (97.7)	5.19 (1.17)	2.3	4.33	5.08	6.00	7.0	
			Placebo	45	41 (91.1)	5.06 (1.10)	2.5	4.33	5.08	6.08	7.0	
		Week 44	Tezepelumab	44	43 (97.7)	5.18 (1.07)	3.0	4.33	5.08	6.08	7.0	
			Placebo	45	41 (91.1)	5.10 (1.07)	2.8	4.33	5.08	5.83	7.0	
		Week 48	Tezepelumab	44	43 (97.7)	5.20 (1.16)	2.8	4.25	5.08	6.17	7.0	
			Placebo	45	41 (91.1)	5.14 (1.12)	2.4	4.33	5.17	6.00	7.0	
		Week 52	Tezepelumab	44	43 (97.7)	5.20 (1.14)	2.8	4.25	5.17	6.08	7.0	
			Placebo	45	41 (91.1)	5.18 (1.04)	2.8	4.33	5.17	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
<= 2	Change from baseline	Week 4	Tezepelumab	44	37 (84.1)	0.75 (0.84)	-0.5	0.08	0.58	1.25	3.1	0.08 [-0.38, 0.53]
			Placebo	45	38 (84.4)	0.69 (0.91)	-1.3	0.25	0.54	1.00	3.3	
		Week 8	Tezepelumab	44	38 (86.4)	0.90 (0.95)	-0.8	0.25	0.88	1.50	3.3	0.14 [-0.31, 0.59]
			Placebo	45	38 (84.4)	0.77 (1.00)	-1.0	0.33	0.67	1.17	3.6	
		Week 12	Tezepelumab	44	38 (86.4)	1.14 (1.01)	-0.8	0.33	1.04	1.92	3.7	0.30 [-0.15, 0.75]
			Placebo	45	38 (84.4)	0.83 (1.04)	-1.0	0.25	0.75	1.17	3.8	
		Week 16	Tezepelumab	44	38 (86.4)	1.11 (0.96)	-0.8	0.42	0.92	1.75	3.3	0.28 [-0.17, 0.73]
			Placebo	45	38 (84.4)	0.84 (0.97)	-1.2	0.17	0.83	1.17	3.7	
		Week 20	Tezepelumab	44	38 (86.4)	1.17 (0.95)	-0.8	0.42	1.04	2.00	3.3	0.37 [-0.09, 0.82]
			Placebo	45	38 (84.4)	0.81 (1.00)	-1.1	0.08	0.71	1.25	3.8	
		Week 24	Tezepelumab	44	38 (86.4)	1.20 (1.00)	-0.8	0.42	1.13	1.92	3.3	0.39 [-0.06, 0.84]
			Placebo	45	38 (84.4)	0.79 (1.09)	-1.3	0.08	0.88	1.17	3.9	
		Week 28	Tezepelumab	44	38 (86.4)	1.11 (1.05)	-0.8	0.33	0.92	2.08	3.3	0.27 [-0.18, 0.72]
			Placebo	45	38 (84.4)	0.83 (1.03)	-1.8	0.25	0.79	1.25	3.8	
		Week 32	Tezepelumab	44	38 (86.4)	1.23 (1.07)	-0.8	0.33	1.13	2.17	3.3	0.35 [-0.10, 0.81]
			Placebo	45	38 (84.4)	0.88 (0.92)	-0.8	0.33	0.83	1.17	3.5	
		Week 36	Tezepelumab	44	38 (86.4)	1.22 (1.13)	-0.8	0.17	1.08	2.17	3.4	0.28 [-0.17, 0.73]
			Placebo	45	38 (84.4)	0.94 (0.86)	-0.8	0.33	0.92	1.25	3.8	
		Week 40	Tezepelumab	44	38 (86.4)	1.26 (1.16)	-0.9	0.33	1.08	2.25	3.4	0.32 [-0.13, 0.77]
			Placebo	45	38 (84.4)	0.92 (0.94)	-1.0	0.58	0.83	1.33	3.4	
		Week 44	Tezepelumab	44	38 (86.4)	1.21 (1.06)	-0.8	0.50	1.13	2.08	3.3	0.26 [-0.20, 0.71]
			Placebo	45	38 (84.4)	0.96 (0.90)	-0.5	0.42	0.88	1.58	3.7	
		Week 48	Tezepelumab	44	38 (86.4)	1.22 (1.09)	-0.8	0.33	1.08	2.00	3.4	0.21 [-0.24, 0.66]
			Placebo	45	38 (84.4)	1.00 (1.00)	-1.1	0.33	0.88	1.58	4.2	
		Week 52	Tezepelumab	44	38 (86.4)	1.23 (1.09)	-0.8	0.33	1.04	2.00	3.6	0.20 [-0.25, 0.65]
			Placebo	45	38 (84.4)	1.03 (0.95)	-0.7	0.42	0.83	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study												
> 2	Absolute values	Baseline	Tezepelumab	22	19 (86.4)	3.86 (1.24)	1.4	3.17	3.92	4.83	6.2	
			Placebo	20	17 (85.0)	4.10 (1.08)	1.5	3.67	4.25	4.58	6.3	
		Week 4	Tezepelumab	22	20 (90.9)	4.73 (1.39)	1.3	3.83	4.63	6.17	6.5	
			Placebo	20	18 (90.0)	4.50 (0.99)	2.7	3.75	4.58	5.17	6.2	
		Week 8	Tezepelumab	22	21 (95.5)	5.03 (1.44)	2.0	3.58	5.17	6.25	6.8	
			Placebo	20	19 (95.0)	4.47 (1.13)	1.9	3.92	4.50	5.33	6.4	
		Week 12	Tezepelumab	22	21 (95.5)	5.22 (1.26)	3.0	4.17	5.33	6.42	6.8	
			Placebo	20	19 (95.0)	4.77 (1.24)	2.1	3.83	4.58	5.92	6.7	
		Week 16	Tezepelumab	22	21 (95.5)	5.35 (1.29)	2.7	4.42	5.42	6.25	7.0	
			Placebo	20	19 (95.0)	4.68 (1.57)	1.3	3.92	4.75	5.92	7.0	
		Week 20	Tezepelumab	22	21 (95.5)	5.11 (1.31)	2.3	4.00	5.42	6.17	7.0	
			Placebo	20	19 (95.0)	4.45 (1.51)	1.3	3.25	4.50	5.92	6.7	
		Week 24	Tezepelumab	22	21 (95.5)	5.25 (1.21)	3.1	4.17	5.50	6.17	7.0	
			Placebo	20	19 (95.0)	4.40 (1.45)	1.3	3.42	4.25	5.92	6.8	
		Week 28	Tezepelumab	22	22 (100.0)	5.28 (1.25)	3.2	4.08	5.63	6.42	6.9	
			Placebo	20	19 (95.0)	4.54 (1.55)	1.3	3.25	4.58	6.00	7.0	
		Week 32	Tezepelumab	22	22 (100.0)	5.24 (1.18)	2.9	4.25	5.42	6.17	7.0	
			Placebo	20	19 (95.0)	4.66 (1.42)	1.3	3.42	4.92	5.92	6.7	
		Week 36	Tezepelumab	22	22 (100.0)	5.35 (1.18)	2.9	4.42	5.79	6.17	7.0	
			Placebo	20	19 (95.0)	4.23 (1.32)	2.4	3.25	4.00	4.83	6.8	
		Week 40	Tezepelumab	22	22 (100.0)	5.25 (1.17)	3.1	4.33	5.13	6.08	7.0	
			Placebo	20	19 (95.0)	4.60 (1.33)	2.3	3.42	4.17	5.92	6.7	
		Week 44	Tezepelumab	22	22 (100.0)	5.29 (1.19)	3.1	4.17	5.50	6.50	7.0	
			Placebo	20	19 (95.0)	4.47 (1.23)	2.5	3.25	4.25	5.92	6.3	
		Week 48	Tezepelumab	22	22 (100.0)	5.35 (1.14)	3.3	4.42	5.25	6.50	7.0	
			Placebo	20	19 (95.0)	4.48 (1.12)	2.2	3.83	4.25	5.00	6.5	
		Week 52	Tezepelumab	22	22 (100.0)	5.34 (1.17)	3.0	4.42	5.25	6.42	7.0	
			Placebo	20	19 (95.0)	4.58 (1.21)	2.8	3.67	4.25	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Exacerbations in the year before study											
> 2	Change from baseline	Week 4	Tezepelumab	22	18 (81.8)	0.83 (1.53)	-4.3	0.83	1.33	1.58	2.1	0.32 [-0.36, 1.00]
			Placebo	20	16 (80.0)	0.43 (0.79)	-1.1	0.13	0.42	0.71	1.9	
		Week 8	Tezepelumab	22	19 (86.4)	1.05 (1.40)	-1.9	0.50	1.67	2.00	2.5	0.49 [-0.18, 1.15]
			Placebo	20	17 (85.0)	0.44 (1.08)	-1.8	0.00	0.42	0.92	2.7	
		Week 12	Tezepelumab	22	19 (86.4)	1.22 (1.36)	-2.6	0.92	1.58	2.00	3.0	0.37 [-0.29, 1.03]
			Placebo	20	17 (85.0)	0.67 (1.60)	-2.8	-0.17	0.75	1.67	4.0	
		Week 16	Tezepelumab	22	19 (86.4)	1.36 (1.40)	-2.9	1.00	1.75	2.17	3.0	0.44 [-0.22, 1.11]
			Placebo	20	17 (85.0)	0.62 (1.92)	-3.5	0.17	1.17	1.50	4.2	
		Week 20	Tezepelumab	22	19 (86.4)	1.14 (1.32)	-1.8	0.33	1.17	2.17	3.0	0.50 [-0.17, 1.16]
			Placebo	20	17 (85.0)	0.38 (1.70)	-3.5	-0.83	0.92	1.67	2.0	
		Week 24	Tezepelumab	22	19 (86.4)	1.29 (1.25)	-1.6	0.92	1.25	2.33	3.0	0.61 [-0.06, 1.28]
			Placebo	20	17 (85.0)	0.38 (1.71)	-3.5	-0.08	0.83	1.67	2.7	
		Week 28	Tezepelumab	22	19 (86.4)	1.20 (1.22)	-1.7	0.83	1.25	2.00	3.0	0.43 [-0.23, 1.09]
			Placebo	20	17 (85.0)	0.52 (1.88)	-3.5	0.00	0.83	1.67	4.3	
		Week 32	Tezepelumab	22	19 (86.4)	1.23 (1.30)	-1.6	0.50	1.00	2.33	3.0	0.38 [-0.28, 1.04]
			Placebo	20	17 (85.0)	0.66 (1.67)	-3.5	0.83	1.08	1.67	2.9	
		Week 36	Tezepelumab	22	19 (86.4)	1.33 (1.35)	-1.7	0.75	1.58	2.33	3.3	0.80 [0.12, 1.49]
			Placebo	20	17 (85.0)	0.18 (1.50)	-3.0	-0.50	0.25	1.17	2.3	
		Week 40	Tezepelumab	22	19 (86.4)	1.20 (1.27)	-1.7	0.75	1.08	2.25	3.0	0.41 [-0.25, 1.07]
			Placebo	20	17 (85.0)	0.59 (1.68)	-3.0	-0.33	0.33	1.83	4.0	
		Week 44	Tezepelumab	22	19 (86.4)	1.28 (1.33)	-1.6	0.75	1.17	2.33	3.3	0.58 [-0.09, 1.25]
			Placebo	20	17 (85.0)	0.42 (1.64)	-3.0	-0.83	0.58	1.33	3.4	
		Week 48	Tezepelumab	22	19 (86.4)	1.39 (1.31)	-1.6	0.83	1.42	2.42	3.1	0.70 [0.02, 1.37]
			Placebo	20	17 (85.0)	0.44 (1.41)	-3.0	-0.25	0.50	1.17	2.8	
		Week 52	Tezepelumab	22	19 (86.4)	1.37 (1.31)	-1.6	0.75	1.42	2.42	3.1	0.56 [-0.11, 1.23]
			Placebo	20	17 (85.0)	0.58 (1.51)	-3.0	-0.25	0.50	1.17	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	3.97 (1.02)	1.4	3.42	4.00	4.54	6.7	
			Placebo	58	48 (82.8)	4.20 (0.83)	1.7	3.71	4.29	4.63	6.3	
		Week 4	Tezepelumab	60	54 (90.0)	4.65 (1.10)	1.3	3.92	4.75	5.50	6.8	
			Placebo	58	50 (86.2)	4.76 (0.92)	2.7	4.17	4.67	5.25	6.7	
		Week 8	Tezepelumab	60	56 (93.3)	4.93 (1.16)	2.0	4.08	4.83	5.83	6.8	
			Placebo	58	52 (89.7)	4.79 (1.07)	2.1	4.17	4.67	5.46	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.14 (1.07)	3.0	4.33	5.08	6.08	7.0	
			Placebo	58	52 (89.7)	4.86 (1.06)	2.1	4.13	4.67	5.54	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.15 (1.13)	2.7	4.33	5.21	6.08	7.0	
			Placebo	58	52 (89.7)	4.85 (1.20)	1.3	4.13	4.71	5.79	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.08 (1.11)	2.3	4.25	5.00	6.00	7.0	
			Placebo	58	52 (89.7)	4.84 (1.20)	1.3	4.08	4.88	5.67	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.13 (1.09)	3.1	4.33	4.92	6.08	7.0	
			Placebo	58	52 (89.7)	4.76 (1.25)	1.3	3.92	4.71	5.75	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.07 (1.12)	3.2	4.08	4.92	6.08	7.0	
			Placebo	58	53 (91.4)	4.78 (1.27)	1.3	4.00	4.83	5.67	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.18 (1.15)	2.8	4.25	5.08	6.17	7.0	
			Placebo	58	53 (91.4)	4.89 (1.18)	1.3	4.08	4.92	5.75	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.20 (1.15)	2.9	4.25	5.17	6.17	7.0	
			Placebo	58	53 (91.4)	4.87 (1.19)	2.4	4.08	4.75	5.92	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.16 (1.18)	2.3	4.25	5.08	6.08	7.0	
			Placebo	58	53 (91.4)	4.93 (1.18)	2.3	4.00	4.92	5.92	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.17 (1.12)	3.0	4.17	5.08	6.08	7.0	
			Placebo	58	53 (91.4)	4.91 (1.13)	2.5	4.17	4.75	5.83	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.19 (1.17)	2.8	4.17	5.08	6.17	7.0	
			Placebo	58	53 (91.4)	4.95 (1.15)	2.2	4.25	4.75	5.75	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.19 (1.16)	2.8	4.17	5.08	6.17	7.0	
			Placebo	58	53 (91.4)	5.00 (1.09)	2.8	4.25	4.75	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
White	Change from baseline	Week 4	Tezepelumab	60	49 (81.7)	0.69 (1.08)	-4.3	0.08	0.83	1.33	2.4	0.10 [-0.30, 0.50]
			Placebo	58	47 (81.0)	0.59 (0.89)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	60	51 (85.0)	0.88 (1.06)	-1.9	0.25	1.00	1.67	2.8	0.22 [-0.17, 0.62]
			Placebo	58	48 (82.8)	0.65 (1.04)	-1.8	0.08	0.67	1.08	3.6	
		Week 12	Tezepelumab	60	51 (85.0)	1.09 (1.08)	-2.6	0.42	1.08	1.92	3.3	0.36 [-0.03, 0.76]
			Placebo	58	48 (82.8)	0.68 (1.18)	-2.8	0.04	0.75	1.17	3.8	
		Week 16	Tezepelumab	60	51 (85.0)	1.12 (1.11)	-2.9	0.50	1.08	2.08	3.3	0.36 [-0.04, 0.76]
			Placebo	58	48 (82.8)	0.70 (1.25)	-3.5	0.17	0.83	1.21	3.7	
		Week 20	Tezepelumab	60	51 (85.0)	1.09 (1.06)	-1.8	0.42	1.00	2.00	3.3	0.34 [-0.06, 0.73]
			Placebo	58	48 (82.8)	0.70 (1.27)	-3.5	0.08	0.83	1.25	3.8	
		Week 24	Tezepelumab	60	51 (85.0)	1.17 (1.05)	-1.6	0.50	1.17	1.92	3.3	0.46 [0.06, 0.86]
			Placebo	58	48 (82.8)	0.63 (1.34)	-3.5	0.00	0.83	1.17	3.9	
		Week 28	Tezepelumab	60	51 (85.0)	1.07 (1.08)	-1.7	0.33	1.00	2.00	3.3	0.40 [-0.00, 0.79]
			Placebo	58	48 (82.8)	0.60 (1.29)	-3.5	0.08	0.75	1.21	3.8	
		Week 32	Tezepelumab	60	51 (85.0)	1.20 (1.13)	-1.6	0.50	1.08	2.08	3.3	0.39 [-0.01, 0.79]
			Placebo	58	48 (82.8)	0.74 (1.21)	-3.5	0.33	0.92	1.17	3.5	
		Week 36	Tezepelumab	60	51 (85.0)	1.19 (1.21)	-1.7	0.25	1.08	2.17	3.4	0.43 [0.03, 0.82]
			Placebo	58	48 (82.8)	0.69 (1.15)	-3.0	0.08	0.83	1.17	3.8	
		Week 40	Tezepelumab	60	51 (85.0)	1.20 (1.18)	-1.7	0.50	1.08	2.17	3.4	0.37 [-0.03, 0.77]
			Placebo	58	48 (82.8)	0.76 (1.18)	-3.0	0.04	0.83	1.42	3.4	
		Week 44	Tezepelumab	60	51 (85.0)	1.19 (1.12)	-1.6	0.50	1.17	2.08	3.3	0.41 [0.01, 0.81]
			Placebo	58	48 (82.8)	0.73 (1.11)	-3.0	0.29	0.83	1.29	3.7	
		Week 48	Tezepelumab	60	51 (85.0)	1.23 (1.16)	-1.6	0.33	1.17	2.08	3.4	0.39 [-0.01, 0.79]
			Placebo	58	48 (82.8)	0.77 (1.17)	-3.0	0.25	0.79	1.29	4.2	
		Week 52	Tezepelumab	60	51 (85.0)	1.23 (1.16)	-1.6	0.42	1.08	2.08	3.6	0.35 [-0.05, 0.75]
			Placebo	58	48 (82.8)	0.82 (1.13)	-3.0	0.25	0.79	1.42	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Absolute values	Baseline	Tezepelumab	2	2 (100.0)	3.46 (1.24)	2.6	2.58	3.46	4.33	4.3	
			Placebo	2	2 (100.0)	3.83 (0.59)	3.4	3.42	3.83	4.25	4.3	
		Week 4	Tezepelumab	2	2 (100.0)	6.00 (0.47)	5.7	5.67	6.00	6.33	6.3	
			Placebo	2	2 (100.0)	4.71 (0.65)	4.3	4.25	4.71	5.17	5.2	
		Week 8	Tezepelumab	2	2 (100.0)	6.29 (0.53)	5.9	5.92	6.29	6.67	6.7	
			Placebo	2	2 (100.0)	5.04 (1.00)	4.3	4.33	5.04	5.75	5.8	
		Week 12	Tezepelumab	2	2 (100.0)	6.25 (0.00)	6.3	6.25	6.25	6.25	6.3	
			Placebo	2	2 (100.0)	4.58 (1.89)	3.3	3.25	4.58	5.92	5.9	
		Week 16	Tezepelumab	2	2 (100.0)	5.92 (0.24)	5.8	5.75	5.92	6.08	6.1	
			Placebo	2	2 (100.0)	4.00 (2.71)	2.1	2.08	4.00	5.92	5.9	
		Week 20	Tezepelumab	2	2 (100.0)	5.88 (0.53)	5.5	5.50	5.88	6.25	6.3	
			Placebo	2	2 (100.0)	4.08 (2.83)	2.1	2.08	4.08	6.08	6.1	
		Week 24	Tezepelumab	2	2 (100.0)	5.83 (0.47)	5.5	5.50	5.83	6.17	6.2	
			Placebo	2	2 (100.0)	4.75 (1.89)	3.4	3.42	4.75	6.08	6.1	
		Week 28	Tezepelumab	2	2 (100.0)	5.88 (0.53)	5.5	5.50	5.88	6.25	6.3	
			Placebo	2	2 (100.0)	4.75 (1.89)	3.4	3.42	4.75	6.08	6.1	
		Week 32	Tezepelumab	2	2 (100.0)	5.17 (0.47)	4.8	4.83	5.17	5.50	5.5	
			Placebo	2	2 (100.0)	4.75 (1.89)	3.4	3.42	4.75	6.08	6.1	
		Week 36	Tezepelumab	2	2 (100.0)	5.71 (0.29)	5.5	5.50	5.71	5.92	5.9	
			Placebo	2	2 (100.0)	4.75 (1.89)	3.4	3.42	4.75	6.08	6.1	
		Week 40	Tezepelumab	2	2 (100.0)	5.04 (0.65)	4.6	4.58	5.04	5.50	5.5	
			Placebo	2	2 (100.0)	4.75 (1.89)	3.4	3.42	4.75	6.08	6.1	
		Week 44	Tezepelumab	2	2 (100.0)	5.04 (0.65)	4.6	4.58	5.04	5.50	5.5	
			Placebo	2	2 (100.0)	6.21 (0.06)	6.2	6.17	6.21	6.25	6.3	
		Week 48	Tezepelumab	2	2 (100.0)	5.29 (0.29)	5.1	5.08	5.29	5.50	5.5	
			Placebo	2	2 (100.0)	6.33 (0.24)	6.2	6.17	6.33	6.50	6.5	
		Week 52	Tezepelumab	2	2 (100.0)	5.29 (0.29)	5.1	5.08	5.29	5.50	5.5	
			Placebo	2	2 (100.0)	6.75 (0.35)	6.5	6.50	6.75	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Black or African American	Change from baseline	Week 4	Tezepelumab	2	2 (100.0)	2.54 (0.77)	2.0	2.00	2.54	3.08	3.1	1.62 [-0.90, 4.14]
			Placebo	2	2 (100.0)	0.88 (1.24)	0.0	0.00	0.88	1.75	1.8	
		Week 8	Tezepelumab	2	2 (100.0)	2.83 (0.71)	2.3	2.33	2.83	3.33	3.3	2.81 [-0.57, 6.19]
			Placebo	2	2 (100.0)	1.21 (0.41)	0.9	0.92	1.21	1.50	1.5	
		Week 12	Tezepelumab	2	2 (100.0)	2.79 (1.24)	1.9	1.92	2.79	3.67	3.7	1.61 [-0.91, 4.13]
			Placebo	2	2 (100.0)	0.75 (1.30)	-0.2	-0.17	0.75	1.67	1.7	
		Week 16	Tezepelumab	2	2 (100.0)	2.46 (1.00)	1.8	1.75	2.46	3.17	3.2	1.38 [-1.00, 3.76]
			Placebo	2	2 (100.0)	0.17 (2.12)	-1.3	-1.33	0.17	1.67	1.7	
		Week 20	Tezepelumab	2	2 (100.0)	2.42 (0.71)	1.9	1.92	2.42	2.92	2.9	1.30 [-1.04, 3.65]
			Placebo	2	2 (100.0)	0.25 (2.24)	-1.3	-1.33	0.25	1.83	1.8	
		Week 24	Tezepelumab	2	2 (100.0)	2.38 (0.77)	1.8	1.83	2.38	2.92	2.9	1.37 [-1.01, 3.75]
			Placebo	2	2 (100.0)	0.92 (1.30)	0.0	0.00	0.92	1.83	1.8	
		Week 28	Tezepelumab	2	2 (100.0)	2.42 (0.71)	1.9	1.92	2.42	2.92	2.9	1.44 [-0.98, 3.85]
			Placebo	2	2 (100.0)	0.92 (1.30)	0.0	0.00	0.92	1.83	1.8	
		Week 32	Tezepelumab	2	2 (100.0)	1.71 (1.71)	0.5	0.50	1.71	2.92	2.9	0.52 [-1.50, 2.55]
			Placebo	2	2 (100.0)	0.92 (1.30)	0.0	0.00	0.92	1.83	1.8	
		Week 36	Tezepelumab	2	2 (100.0)	2.25 (0.94)	1.6	1.58	2.25	2.92	2.9	1.18 [-1.10, 3.45]
			Placebo	2	2 (100.0)	0.92 (1.30)	0.0	0.00	0.92	1.83	1.8	
		Week 40	Tezepelumab	2	2 (100.0)	1.58 (1.89)	0.3	0.25	1.58	2.92	2.9	0.41 [-1.59, 2.41]
			Placebo	2	2 (100.0)	0.92 (1.30)	0.0	0.00	0.92	1.83	1.8	
		Week 44	Tezepelumab	2	2 (100.0)	1.58 (1.89)	0.3	0.25	1.58	2.92	2.9	-0.57 [-2.61, 1.47]
			Placebo	2	2 (100.0)	2.38 (0.53)	2.0	2.00	2.38	2.75	2.8	
		Week 48	Tezepelumab	2	2 (100.0)	1.83 (1.53)	0.8	0.75	1.83	2.92	2.9	-0.60 [-2.65, 1.45]
			Placebo	2	2 (100.0)	2.50 (0.35)	2.3	2.25	2.50	2.75	2.8	
		Week 52	Tezepelumab	2	2 (100.0)	1.83 (1.53)	0.8	0.75	1.83	2.92	2.9	-0.85 [-2.98, 1.28]
			Placebo	2	2 (100.0)	2.92 (0.94)	2.3	2.25	2.92	3.58	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	4.28 (0.98)	3.2	3.17	4.67	5.00	5.0	
			Placebo	3	3 (100.0)	4.44 (0.05)	4.4	4.42	4.42	4.50	4.5	
		Week 4	Tezepelumab	3	3 (100.0)	5.67 (1.01)	4.5	4.50	6.17	6.33	6.3	
			Placebo	3	3 (100.0)	4.86 (0.38)	4.5	4.50	4.83	5.25	5.3	
		Week 8	Tezepelumab	3	3 (100.0)	5.83 (0.75)	5.1	5.08	5.83	6.58	6.6	
			Placebo	3	3 (100.0)	4.50 (0.25)	4.3	4.25	4.50	4.75	4.8	
		Week 12	Tezepelumab	3	3 (100.0)	6.22 (0.81)	5.3	5.33	6.42	6.92	6.9	
			Placebo	3	3 (100.0)	5.11 (0.27)	4.9	4.92	5.00	5.42	5.4	
		Week 16	Tezepelumab	3	3 (100.0)	6.17 (0.60)	5.7	5.67	6.00	6.83	6.8	
			Placebo	3	3 (100.0)	5.14 (0.64)	4.6	4.58	5.00	5.83	5.8	
		Week 20	Tezepelumab	3	3 (100.0)	6.25 (0.63)	5.7	5.67	6.17	6.92	6.9	
			Placebo	3	3 (100.0)	4.42 (0.74)	3.6	3.58	4.67	5.00	5.0	
		Week 24	Tezepelumab	3	3 (100.0)	6.28 (0.55)	5.9	5.92	6.00	6.92	6.9	
			Placebo	3	3 (100.0)	4.58 (0.79)	3.8	3.75	4.67	5.33	5.3	
		Week 28	Tezepelumab	3	3 (100.0)	6.19 (0.70)	5.8	5.75	5.83	7.00	7.0	
			Placebo	3	3 (100.0)	5.72 (0.77)	5.1	5.08	5.50	6.58	6.6	
		Week 32	Tezepelumab	3	3 (100.0)	6.22 (0.61)	5.8	5.75	6.00	6.92	6.9	
			Placebo	3	3 (100.0)	5.39 (0.64)	4.8	4.83	5.25	6.08	6.1	
		Week 36	Tezepelumab	3	3 (100.0)	6.33 (0.58)	5.9	5.92	6.08	7.00	7.0	
			Placebo	3	3 (100.0)	4.47 (1.17)	3.2	3.17	4.83	5.42	5.4	
		Week 40	Tezepelumab	3	3 (100.0)	6.36 (0.55)	6.0	6.00	6.08	7.00	7.0	
			Placebo	3	3 (100.0)	4.78 (0.53)	4.2	4.17	5.08	5.08	5.1	
		Week 44	Tezepelumab	3	3 (100.0)	6.42 (0.63)	5.8	5.75	6.50	7.00	7.0	
			Placebo	3	3 (100.0)	4.00 (0.83)	3.2	3.17	4.00	4.83	4.8	
		Week 48	Tezepelumab	3	3 (100.0)	6.42 (0.44)	6.1	6.08	6.25	6.92	6.9	
			Placebo	3	3 (100.0)	4.69 (0.61)	4.0	4.00	4.92	5.17	5.2	
		Week 52	Tezepelumab	3	3 (100.0)	6.42 (0.44)	6.1	6.08	6.25	6.92	6.9	
			Placebo	3	3 (100.0)	4.69 (0.61)	4.0	4.00	4.92	5.17	5.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Asian	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.39 (0.10)	1.3	1.33	1.33	1.50	1.5	3.49 [0.59, 6.39]
			Placebo	3	3 (100.0)	0.42 (0.38)	0.1	0.08	0.33	0.83	0.8	
		Week 8	Tezepelumab	3	3 (100.0)	1.56 (0.63)	0.8	0.83	1.92	1.92	1.9	3.07 [0.41, 5.74]
			Placebo	3	3 (100.0)	0.06 (0.29)	-0.3	-0.25	0.08	0.33	0.3	
		Week 12	Tezepelumab	3	3 (100.0)	1.94 (0.46)	1.4	1.42	2.17	2.25	2.3	3.55 [0.61, 6.48]
			Placebo	3	3 (100.0)	0.67 (0.22)	0.5	0.50	0.58	0.92	0.9	
		Week 16	Tezepelumab	3	3 (100.0)	1.89 (0.79)	1.0	1.00	2.17	2.50	2.5	1.63 [-0.33, 3.59]
			Placebo	3	3 (100.0)	0.69 (0.67)	0.1	0.08	0.58	1.42	1.4	
		Week 20	Tezepelumab	3	3 (100.0)	1.97 (0.71)	1.2	1.17	2.25	2.50	2.5	2.78 [0.28, 5.29]
			Placebo	3	3 (100.0)	-0.03 (0.73)	-0.8	-0.83	0.17	0.58	0.6	
		Week 24	Tezepelumab	3	3 (100.0)	2.00 (0.90)	1.0	1.00	2.25	2.75	2.8	2.24 [0.01, 4.47]
			Placebo	3	3 (100.0)	0.14 (0.76)	-0.7	-0.67	0.25	0.83	0.8	
		Week 28	Tezepelumab	3	3 (100.0)	1.92 (0.95)	0.8	0.83	2.33	2.58	2.6	0.73 [-0.95, 2.41]
			Placebo	3	3 (100.0)	1.28 (0.79)	0.7	0.67	1.00	2.17	2.2	
		Week 32	Tezepelumab	3	3 (100.0)	1.94 (0.83)	1.0	1.00	2.25	2.58	2.6	1.32 [-0.52, 3.16]
			Placebo	3	3 (100.0)	0.94 (0.67)	0.3	0.33	0.83	1.67	1.7	
		Week 36	Tezepelumab	3	3 (100.0)	2.06 (0.87)	1.1	1.08	2.33	2.75	2.8	2.01 [-0.11, 4.13]
			Placebo	3	3 (100.0)	0.03 (1.13)	-1.3	-1.25	0.42	0.92	0.9	
		Week 40	Tezepelumab	3	3 (100.0)	2.08 (0.98)	1.0	1.00	2.33	2.92	2.9	2.24 [0.01, 4.47]
			Placebo	3	3 (100.0)	0.33 (0.51)	-0.3	-0.25	0.58	0.67	0.7	
		Week 44	Tezepelumab	3	3 (100.0)	2.14 (1.30)	0.8	0.75	2.33	3.33	3.3	2.40 [0.09, 4.70]
			Placebo	3	3 (100.0)	-0.44 (0.79)	-1.3	-1.25	-0.42	0.33	0.3	
		Week 48	Tezepelumab	3	3 (100.0)	2.14 (1.00)	1.1	1.08	2.25	3.08	3.1	2.30 [0.04, 4.56]
			Placebo	3	3 (100.0)	0.25 (0.58)	-0.4	-0.42	0.50	0.67	0.7	
		Week 52	Tezepelumab	3	3 (100.0)	2.14 (1.00)	1.1	1.08	2.25	3.08	3.1	2.30 [0.04, 4.56]
			Placebo	3	3 (100.0)	0.25 (0.58)	-0.4	-0.42	0.50	0.67	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Absolute values	Baseline	Tezepelumab	1	1 (100.0)	4.83	4.8	4.83	4.83	4.83	4.8	
			Placebo	2	2 (100.0)	2.08 (0.82)	1.5	1.50	2.08	2.67	2.7	
		Week 4	Tezepelumab	1	1 (100.0)	4.58	4.6	4.58	4.58	4.58	4.6	
			Placebo	2	2 (100.0)	3.21 (0.29)	3.0	3.00	3.21	3.42	3.4	
		Week 8	Tezepelumab	1	1 (100.0)	4.00	4.0	4.00	4.00	4.00	4.0	
			Placebo	2	2 (100.0)	3.63 (2.42)	1.9	1.92	3.63	5.33	5.3	
		Week 12	Tezepelumab	1	1 (100.0)	4.17	4.2	4.17	4.17	4.17	4.2	
			Placebo	2	2 (100.0)	5.42 (1.77)	4.2	4.17	5.42	6.67	6.7	
		Week 16	Tezepelumab	1	1 (100.0)	5.08	5.1	5.08	5.08	5.08	5.1	
			Placebo	2	2 (100.0)	5.42 (2.00)	4.0	4.00	5.42	6.83	6.8	
		Week 20	Tezepelumab	1	1 (100.0)	4.58	4.6	4.58	4.58	4.58	4.6	
			Placebo	2	2 (100.0)	3.79 (0.88)	3.2	3.17	3.79	4.42	4.4	
		Week 24	Tezepelumab	1	1 (100.0)	4.33	4.3	4.33	4.33	4.33	4.3	
			Placebo	2	2 (100.0)	4.25 (1.53)	3.2	3.17	4.25	5.33	5.3	
		Week 28	Tezepelumab	1	1 (100.0)	4.58	4.6	4.58	4.58	4.58	4.6	
			Placebo	2	2 (100.0)	5.08 (2.71)	3.2	3.17	5.08	7.00	7.0	
		Week 32	Tezepelumab	1	1 (100.0)	4.75	4.8	4.75	4.75	4.75	4.8	
			Placebo	2	2 (100.0)	4.38 (1.71)	3.2	3.17	4.38	5.58	5.6	
		Week 36	Tezepelumab	1	1 (100.0)	4.92	4.9	4.92	4.92	4.92	4.9	
			Placebo	2	2 (100.0)	3.88 (1.00)	3.2	3.17	3.88	4.58	4.6	
		Week 40	Tezepelumab	1	1 (100.0)	5.00	5.0	5.00	5.00	5.00	5.0	
			Placebo	2	2 (100.0)	4.92 (2.47)	3.2	3.17	4.92	6.67	6.7	
		Week 44	Tezepelumab	1	1 (100.0)	4.92	4.9	4.92	4.92	4.92	4.9	
			Placebo	2	2 (100.0)	4.63 (2.06)	3.2	3.17	4.63	6.08	6.1	
		Week 48	Tezepelumab	1	1 (100.0)	5.17	5.2	5.17	5.17	5.17	5.2	
			Placebo	2	2 (100.0)	3.50 (0.47)	3.2	3.17	3.50	3.83	3.8	
		Week 52	Tezepelumab	1	1 (100.0)	5.17	5.2	5.17	5.17	5.17	5.2	
			Placebo	2	2 (100.0)	3.50 (0.47)	3.2	3.17	3.50	3.83	3.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race												
Other	Change from baseline	Week 4	Tezepelumab	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	NE
			Placebo	2	2 (100.0)	1.13 (1.12)	0.3	0.33	1.13	1.92	1.9	
		Week 8	Tezepelumab	1	1 (100.0)	-0.83	-0.8	-0.83	-0.83	-0.83	-0.8	NE
			Placebo	2	2 (100.0)	1.54 (1.59)	0.4	0.42	1.54	2.67	2.7	
		Week 12	Tezepelumab	1	1 (100.0)	-0.67	-0.7	-0.67	-0.67	-0.67	-0.7	NE
			Placebo	2	2 (100.0)	3.33 (0.94)	2.7	2.67	3.33	4.00	4.0	
		Week 16	Tezepelumab	1	1 (100.0)	0.25	0.3	0.25	0.25	0.25	0.3	NE
			Placebo	2	2 (100.0)	3.33 (1.18)	2.5	2.50	3.33	4.17	4.2	
		Week 20	Tezepelumab	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	NE
			Placebo	2	2 (100.0)	1.71 (0.06)	1.7	1.67	1.71	1.75	1.8	
		Week 24	Tezepelumab	1	1 (100.0)	-0.50	-0.5	-0.50	-0.50	-0.50	-0.5	NE
			Placebo	2	2 (100.0)	2.17 (0.71)	1.7	1.67	2.17	2.67	2.7	
		Week 28	Tezepelumab	1	1 (100.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	NE
			Placebo	2	2 (100.0)	3.00 (1.89)	1.7	1.67	3.00	4.33	4.3	
		Week 32	Tezepelumab	1	1 (100.0)	-0.08	-0.1	-0.08	-0.08	-0.08	-0.1	NE
			Placebo	2	2 (100.0)	2.29 (0.88)	1.7	1.67	2.29	2.92	2.9	
		Week 36	Tezepelumab	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	NE
			Placebo	2	2 (100.0)	1.79 (0.18)	1.7	1.67	1.79	1.92	1.9	
		Week 40	Tezepelumab	1	1 (100.0)	0.17	0.2	0.17	0.17	0.17	0.2	NE
			Placebo	2	2 (100.0)	2.83 (1.65)	1.7	1.67	2.83	4.00	4.0	
		Week 44	Tezepelumab	1	1 (100.0)	0.08	0.1	0.08	0.08	0.08	0.1	NE
			Placebo	2	2 (100.0)	2.54 (1.24)	1.7	1.67	2.54	3.42	3.4	
		Week 48	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	2	2 (100.0)	1.42 (0.35)	1.2	1.17	1.42	1.67	1.7	
		Week 52	Tezepelumab	1	1 (100.0)	0.33	0.3	0.33	0.33	0.33	0.3	NE
			Placebo	2	2 (100.0)	1.42 (0.35)	1.2	1.17	1.42	1.67	1.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Absolute values	Baseline	Tezepelumab	40	36 (90.0)	4.07 (1.04)	1.9	3.50	4.17	4.75	6.7	
			Placebo	36	31 (86.1)	4.29 (0.77)	2.8	3.67	4.42	4.75	5.8	
		Week 4	Tezepelumab	40	37 (92.5)	4.65 (1.14)	1.3	3.92	4.75	5.58	6.8	
			Placebo	36	31 (86.1)	4.71 (0.95)	2.7	3.92	4.58	5.25	6.7	
		Week 8	Tezepelumab	40	38 (95.0)	4.94 (1.19)	2.0	4.08	4.83	5.83	6.8	
			Placebo	36	32 (88.9)	4.79 (1.09)	2.9	4.00	4.63	5.67	7.0	
		Week 12	Tezepelumab	40	38 (95.0)	5.13 (1.10)	3.0	4.17	5.13	6.08	7.0	
			Placebo	36	32 (88.9)	4.91 (1.08)	2.1	4.13	4.83	5.54	7.0	
		Week 16	Tezepelumab	40	38 (95.0)	5.11 (1.17)	2.7	4.33	5.13	6.25	6.9	
			Placebo	36	32 (88.9)	4.82 (1.27)	1.3	4.13	4.63	5.46	7.0	
		Week 20	Tezepelumab	40	39 (97.5)	5.09 (1.16)	2.3	4.25	4.83	6.00	6.9	
			Placebo	36	32 (88.9)	4.86 (1.18)	1.3	4.33	4.88	5.38	7.0	
		Week 24	Tezepelumab	40	39 (97.5)	5.21 (1.10)	3.1	4.42	5.08	6.17	7.0	
			Placebo	36	32 (88.9)	4.71 (1.24)	1.3	3.88	4.67	5.50	7.0	
		Week 28	Tezepelumab	40	40 (100.0)	5.04 (1.14)	3.2	4.08	4.88	6.13	7.0	
			Placebo	36	33 (91.7)	4.81 (1.32)	1.3	3.92	4.83	5.67	7.0	
		Week 32	Tezepelumab	40	40 (100.0)	5.14 (1.20)	2.8	4.08	4.92	6.13	7.0	
			Placebo	36	33 (91.7)	4.95 (1.23)	1.3	4.25	4.92	5.58	7.0	
		Week 36	Tezepelumab	40	40 (100.0)	5.17 (1.19)	2.9	4.21	5.00	6.17	7.0	
			Placebo	36	33 (91.7)	4.95 (1.22)	2.4	4.17	4.83	6.00	7.0	
		Week 40	Tezepelumab	40	40 (100.0)	5.27 (1.16)	2.9	4.38	5.13	6.08	7.0	
			Placebo	36	33 (91.7)	4.97 (1.20)	2.3	4.00	4.83	6.08	7.0	
		Week 44	Tezepelumab	40	40 (100.0)	5.18 (1.14)	3.0	4.25	5.08	6.08	7.0	
			Placebo	36	33 (91.7)	4.98 (1.19)	2.5	4.17	4.67	5.92	7.0	
		Week 48	Tezepelumab	40	40 (100.0)	5.15 (1.21)	2.8	4.13	5.08	6.13	7.0	
			Placebo	36	33 (91.7)	5.05 (1.17)	2.2	4.25	4.75	6.00	7.0	
		Week 52	Tezepelumab	40	40 (100.0)	5.15 (1.20)	2.8	4.08	5.13	6.08	7.0	
			Placebo	36	33 (91.7)	5.07 (1.15)	2.8	4.25	4.83	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Europe	Change from baseline	Week 4	Tezepelumab	40	35 (87.5)	0.65 (1.22)	-4.3	-0.08	0.83	1.50	2.4	0.16 [-0.33, 0.65]
			Placebo	36	30 (83.3)	0.48 (0.85)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	40	36 (90.0)	0.82 (1.15)	-1.9	0.17	1.04	1.67	2.8	0.26 [-0.22, 0.75]
			Placebo	36	31 (86.1)	0.54 (0.96)	-1.0	-0.08	0.67	0.92	3.3	
		Week 12	Tezepelumab	40	36 (90.0)	1.03 (1.22)	-2.6	0.25	1.08	1.96	3.3	0.32 [-0.17, 0.80]
			Placebo	36	31 (86.1)	0.67 (1.02)	-1.6	0.00	0.75	1.00	3.8	
		Week 16	Tezepelumab	40	36 (90.0)	1.01 (1.19)	-2.9	0.42	1.04	1.92	3.3	0.38 [-0.10, 0.86]
			Placebo	36	31 (86.1)	0.56 (1.16)	-3.5	0.17	0.83	1.00	3.6	
		Week 20	Tezepelumab	40	36 (90.0)	1.01 (1.14)	-1.8	0.21	0.92	2.00	3.3	0.35 [-0.13, 0.83]
			Placebo	36	31 (86.1)	0.61 (1.13)	-3.5	0.17	0.75	1.08	3.3	
		Week 24	Tezepelumab	40	36 (90.0)	1.13 (1.15)	-1.6	0.46	1.13	1.96	3.3	0.57 [0.08, 1.06]
			Placebo	36	31 (86.1)	0.46 (1.21)	-3.5	-0.08	0.83	1.08	3.6	
		Week 28	Tezepelumab	40	36 (90.0)	1.00 (1.17)	-1.7	0.21	0.92	2.00	3.3	0.44 [-0.04, 0.93]
			Placebo	36	31 (86.1)	0.48 (1.17)	-3.5	0.00	0.58	1.00	2.8	
		Week 32	Tezepelumab	40	36 (90.0)	1.07 (1.20)	-1.6	0.33	1.04	2.00	3.3	0.37 [-0.12, 0.85]
			Placebo	36	31 (86.1)	0.64 (1.14)	-3.5	0.25	0.75	1.08	3.5	
		Week 36	Tezepelumab	40	36 (90.0)	1.09 (1.21)	-1.7	0.25	1.00	2.08	3.4	0.39 [-0.09, 0.88]
			Placebo	36	31 (86.1)	0.64 (1.05)	-2.3	0.25	0.75	1.17	3.8	
		Week 40	Tezepelumab	40	36 (90.0)	1.25 (1.20)	-1.7	0.46	1.08	2.21	3.4	0.52 [0.03, 1.01]
			Placebo	36	31 (86.1)	0.65 (1.06)	-1.4	0.00	0.67	1.17	3.4	
		Week 44	Tezepelumab	40	36 (90.0)	1.14 (1.18)	-1.6	0.46	1.13	2.08	3.3	0.44 [-0.04, 0.93]
			Placebo	36	31 (86.1)	0.66 (0.98)	-1.2	0.33	0.58	1.08	3.7	
		Week 48	Tezepelumab	40	36 (90.0)	1.12 (1.22)	-1.6	0.33	1.08	2.00	3.4	0.33 [-0.15, 0.82]
			Placebo	36	31 (86.1)	0.74 (1.03)	-1.5	0.25	0.67	1.17	4.2	
		Week 52	Tezepelumab	40	36 (90.0)	1.12 (1.23)	-1.6	0.33	1.04	2.00	3.6	0.31 [-0.17, 0.80]
			Placebo	36	31 (86.1)	0.76 (1.01)	-1.1	0.25	0.75	1.17	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	3.77 (1.72)	1.4	2.58	4.33	5.00	5.5	
			Placebo	4	3 (75.0)	3.53 (0.67)	2.9	2.92	3.42	4.25	4.3	
		Week 4	Tezepelumab	6	4 (66.7)	5.79 (0.55)	5.1	5.38	5.88	6.21	6.3	
			Placebo	4	3 (75.0)	5.14 (0.88)	4.3	4.25	5.17	6.00	6.0	
		Week 8	Tezepelumab	6	5 (83.3)	5.55 (1.16)	3.6	5.75	5.83	5.92	6.7	
			Placebo	4	3 (75.0)	5.53 (1.10)	4.3	4.33	5.75	6.50	6.5	
		Week 12	Tezepelumab	6	5 (83.3)	5.77 (0.77)	4.4	5.83	6.08	6.25	6.3	
			Placebo	4	3 (75.0)	5.31 (1.83)	3.3	3.25	5.92	6.75	6.8	
		Week 16	Tezepelumab	6	5 (83.3)	5.60 (0.67)	4.4	5.75	5.83	5.92	6.1	
			Placebo	4	3 (75.0)	4.86 (2.43)	2.1	2.08	5.92	6.58	6.6	
		Week 20	Tezepelumab	6	5 (83.3)	5.63 (0.73)	4.4	5.50	6.00	6.00	6.3	
			Placebo	4	3 (75.0)	4.97 (2.52)	2.1	2.08	6.08	6.75	6.8	
		Week 24	Tezepelumab	6	5 (83.3)	5.45 (0.65)	4.4	5.42	5.50	5.75	6.2	
			Placebo	4	3 (75.0)	5.44 (1.80)	3.4	3.42	6.08	6.83	6.8	
		Week 28	Tezepelumab	6	6 (100.0)	5.69 (0.80)	4.4	5.42	5.67	6.25	6.8	
			Placebo	4	3 (75.0)	5.39 (1.73)	3.4	3.42	6.08	6.67	6.7	
		Week 32	Tezepelumab	6	6 (100.0)	5.51 (0.80)	4.4	4.83	5.67	5.83	6.7	
			Placebo	4	3 (75.0)	5.22 (1.56)	3.4	3.42	6.08	6.17	6.2	
		Week 36	Tezepelumab	6	6 (100.0)	5.50 (0.79)	4.4	5.17	5.38	5.92	6.8	
			Placebo	4	3 (75.0)	5.00 (1.40)	3.4	3.42	5.50	6.08	6.1	
		Week 40	Tezepelumab	6	6 (100.0)	5.33 (0.88)	4.4	4.58	5.17	6.00	6.7	
			Placebo	4	3 (75.0)	5.08 (1.45)	3.4	3.42	5.75	6.08	6.1	
		Week 44	Tezepelumab	6	6 (100.0)	5.40 (0.79)	4.4	4.58	5.50	5.92	6.5	
			Placebo	4	3 (75.0)	6.06 (0.27)	5.8	5.75	6.17	6.25	6.3	
		Week 48	Tezepelumab	6	6 (100.0)	5.56 (0.75)	4.4	5.08	5.58	6.17	6.5	
			Placebo	4	3 (75.0)	6.11 (0.42)	5.7	5.67	6.17	6.50	6.5	
		Week 52	Tezepelumab	6	6 (100.0)	5.63 (0.82)	4.4	5.08	5.67	6.17	6.8	
			Placebo	4	3 (75.0)	6.39 (0.67)	5.7	5.67	6.50	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
America	Change from baseline	Week 4	Tezepelumab	6	4 (66.7)	1.44 (1.48)	-0.4	0.33	1.54	2.54	3.1	-0.12 [-1.61, 1.38]
			Placebo	4	3 (75.0)	1.61 (1.55)	0.0	0.00	1.75	3.08	3.1	
		Week 8	Tezepelumab	6	5 (83.3)	1.78 (1.24)	0.3	0.83	2.17	2.33	3.3	-0.17 [-1.60, 1.27]
			Placebo	4	3 (75.0)	2.00 (1.40)	0.9	0.92	1.50	3.58	3.6	
		Week 12	Tezepelumab	6	5 (83.3)	2.00 (1.36)	0.3	1.08	1.92	3.00	3.7	0.14 [-1.29, 1.57]
			Placebo	4	3 (75.0)	1.78 (2.00)	-0.2	-0.17	1.67	3.83	3.8	
		Week 16	Tezepelumab	6	5 (83.3)	1.83 (1.24)	0.4	0.83	1.75	3.00	3.2	0.28 [-1.16, 1.72]
			Placebo	4	3 (75.0)	1.33 (2.52)	-1.3	-1.33	1.67	3.67	3.7	
		Week 20	Tezepelumab	6	5 (83.3)	1.87 (1.12)	0.5	1.00	1.92	2.92	3.0	0.24 [-1.20, 1.68]
			Placebo	4	3 (75.0)	1.44 (2.61)	-1.3	-1.33	1.83	3.83	3.8	
		Week 24	Tezepelumab	6	5 (83.3)	1.68 (1.32)	0.3	0.42	1.83	2.92	3.0	-0.15 [-1.58, 1.28]
			Placebo	4	3 (75.0)	1.92 (1.96)	0.0	0.00	1.83	3.92	3.9	
		Week 28	Tezepelumab	6	5 (83.3)	1.72 (1.30)	0.3	0.42	1.92	2.92	3.0	-0.10 [-1.53, 1.34]
			Placebo	4	3 (75.0)	1.86 (1.88)	0.0	0.00	1.83	3.75	3.8	
		Week 32	Tezepelumab	6	5 (83.3)	1.52 (1.33)	0.3	0.50	0.83	2.92	3.0	-0.12 [-1.56, 1.31]
			Placebo	4	3 (75.0)	1.69 (1.63)	0.0	0.00	1.83	3.25	3.3	
		Week 36	Tezepelumab	6	5 (83.3)	1.48 (1.51)	-0.3	0.17	1.58	2.92	3.0	0.01 [-1.42, 1.44]
			Placebo	4	3 (75.0)	1.47 (1.33)	0.0	0.00	1.83	2.58	2.6	
		Week 40	Tezepelumab	6	5 (83.3)	1.30 (1.63)	-0.7	0.25	1.00	2.92	3.0	-0.16 [-1.60, 1.27]
			Placebo	4	3 (75.0)	1.56 (1.44)	0.0	0.00	1.83	2.83	2.8	
		Week 44	Tezepelumab	6	5 (83.3)	1.42 (1.45)	0.0	0.25	0.92	2.92	3.0	-0.92 [-2.44, 0.60]
			Placebo	4	3 (75.0)	2.53 (0.46)	2.0	2.00	2.75	2.83	2.8	
		Week 48	Tezepelumab	6	5 (83.3)	1.60 (1.29)	0.2	0.75	1.17	2.92	3.0	-0.92 [-2.45, 0.60]
			Placebo	4	3 (75.0)	2.58 (0.29)	2.3	2.25	2.75	2.75	2.8	
		Week 52	Tezepelumab	6	5 (83.3)	1.63 (1.25)	0.3	0.75	1.17	2.92	3.0	-1.13 [-2.70, 0.44]
			Placebo	4	3 (75.0)	2.86 (0.67)	2.3	2.25	2.75	3.58	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	4.28 (0.98)	3.2	3.17	4.67	5.00	5.0	
			Placebo	3	3 (100.0)	4.44 (0.05)	4.4	4.42	4.42	4.50	4.5	
		Week 4	Tezepelumab	3	3 (100.0)	5.67 (1.01)	4.5	4.50	6.17	6.33	6.3	
			Placebo	3	3 (100.0)	4.86 (0.38)	4.5	4.50	4.83	5.25	5.3	
		Week 8	Tezepelumab	3	3 (100.0)	5.83 (0.75)	5.1	5.08	5.83	6.58	6.6	
			Placebo	3	3 (100.0)	4.50 (0.25)	4.3	4.25	4.50	4.75	4.8	
		Week 12	Tezepelumab	3	3 (100.0)	6.22 (0.81)	5.3	5.33	6.42	6.92	6.9	
			Placebo	3	3 (100.0)	5.11 (0.27)	4.9	4.92	5.00	5.42	5.4	
		Week 16	Tezepelumab	3	3 (100.0)	6.17 (0.60)	5.7	5.67	6.00	6.83	6.8	
			Placebo	3	3 (100.0)	5.14 (0.64)	4.6	4.58	5.00	5.83	5.8	
		Week 20	Tezepelumab	3	3 (100.0)	6.25 (0.63)	5.7	5.67	6.17	6.92	6.9	
			Placebo	3	3 (100.0)	4.42 (0.74)	3.6	3.58	4.67	5.00	5.0	
		Week 24	Tezepelumab	3	3 (100.0)	6.28 (0.55)	5.9	5.92	6.00	6.92	6.9	
			Placebo	3	3 (100.0)	4.58 (0.79)	3.8	3.75	4.67	5.33	5.3	
		Week 28	Tezepelumab	3	3 (100.0)	6.19 (0.70)	5.8	5.75	5.83	7.00	7.0	
			Placebo	3	3 (100.0)	5.72 (0.77)	5.1	5.08	5.50	6.58	6.6	
		Week 32	Tezepelumab	3	3 (100.0)	6.22 (0.61)	5.8	5.75	6.00	6.92	6.9	
			Placebo	3	3 (100.0)	5.39 (0.64)	4.8	4.83	5.25	6.08	6.1	
		Week 36	Tezepelumab	3	3 (100.0)	6.33 (0.58)	5.9	5.92	6.08	7.00	7.0	
			Placebo	3	3 (100.0)	4.47 (1.17)	3.2	3.17	4.83	5.42	5.4	
		Week 40	Tezepelumab	3	3 (100.0)	6.36 (0.55)	6.0	6.00	6.08	7.00	7.0	
			Placebo	3	3 (100.0)	4.78 (0.53)	4.2	4.17	5.08	5.08	5.1	
		Week 44	Tezepelumab	3	3 (100.0)	6.42 (0.63)	5.8	5.75	6.50	7.00	7.0	
			Placebo	3	3 (100.0)	4.00 (0.83)	3.2	3.17	4.00	4.83	4.8	
		Week 48	Tezepelumab	3	3 (100.0)	6.42 (0.44)	6.1	6.08	6.25	6.92	6.9	
			Placebo	3	3 (100.0)	4.69 (0.61)	4.0	4.00	4.92	5.17	5.2	
		Week 52	Tezepelumab	3	3 (100.0)	6.42 (0.44)	6.1	6.08	6.25	6.92	6.9	
			Placebo	3	3 (100.0)	4.69 (0.61)	4.0	4.00	4.92	5.17	5.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Asia/Pacific	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	1.39 (0.10)	1.3	1.33	1.33	1.50	1.5	3.49 [0.59, 6.39]
			Placebo	3	3 (100.0)	0.42 (0.38)	0.1	0.08	0.33	0.83	0.8	
		Week 8	Tezepelumab	3	3 (100.0)	1.56 (0.63)	0.8	0.83	1.92	1.92	1.9	3.07 [0.41, 5.74]
			Placebo	3	3 (100.0)	0.06 (0.29)	-0.3	-0.25	0.08	0.33	0.3	
		Week 12	Tezepelumab	3	3 (100.0)	1.94 (0.46)	1.4	1.42	2.17	2.25	2.3	3.55 [0.61, 6.48]
			Placebo	3	3 (100.0)	0.67 (0.22)	0.5	0.50	0.58	0.92	0.9	
		Week 16	Tezepelumab	3	3 (100.0)	1.89 (0.79)	1.0	1.00	2.17	2.50	2.5	1.63 [-0.33, 3.59]
			Placebo	3	3 (100.0)	0.69 (0.67)	0.1	0.08	0.58	1.42	1.4	
		Week 20	Tezepelumab	3	3 (100.0)	1.97 (0.71)	1.2	1.17	2.25	2.50	2.5	2.78 [0.28, 5.29]
			Placebo	3	3 (100.0)	-0.03 (0.73)	-0.8	-0.83	0.17	0.58	0.6	
		Week 24	Tezepelumab	3	3 (100.0)	2.00 (0.90)	1.0	1.00	2.25	2.75	2.8	2.24 [0.01, 4.47]
			Placebo	3	3 (100.0)	0.14 (0.76)	-0.7	-0.67	0.25	0.83	0.8	
		Week 28	Tezepelumab	3	3 (100.0)	1.92 (0.95)	0.8	0.83	2.33	2.58	2.6	0.73 [-0.95, 2.41]
			Placebo	3	3 (100.0)	1.28 (0.79)	0.7	0.67	1.00	2.17	2.2	
		Week 32	Tezepelumab	3	3 (100.0)	1.94 (0.83)	1.0	1.00	2.25	2.58	2.6	1.32 [-0.52, 3.16]
			Placebo	3	3 (100.0)	0.94 (0.67)	0.3	0.33	0.83	1.67	1.7	
		Week 36	Tezepelumab	3	3 (100.0)	2.06 (0.87)	1.1	1.08	2.33	2.75	2.8	2.01 [-0.11, 4.13]
			Placebo	3	3 (100.0)	0.03 (1.13)	-1.3	-1.25	0.42	0.92	0.9	
		Week 40	Tezepelumab	3	3 (100.0)	2.08 (0.98)	1.0	1.00	2.33	2.92	2.9	2.24 [0.01, 4.47]
			Placebo	3	3 (100.0)	0.33 (0.51)	-0.3	-0.25	0.58	0.67	0.7	
		Week 44	Tezepelumab	3	3 (100.0)	2.14 (1.30)	0.8	0.75	2.33	3.33	3.3	2.40 [0.09, 4.70]
			Placebo	3	3 (100.0)	-0.44 (0.79)	-1.3	-1.25	-0.42	0.33	0.3	
		Week 48	Tezepelumab	3	3 (100.0)	2.14 (1.00)	1.1	1.08	2.25	3.08	3.1	2.30 [0.04, 4.56]
			Placebo	3	3 (100.0)	0.25 (0.58)	-0.4	-0.42	0.50	0.67	0.7	
		Week 52	Tezepelumab	3	3 (100.0)	2.14 (1.00)	1.1	1.08	2.25	3.08	3.1	2.30 [0.04, 4.56]
			Placebo	3	3 (100.0)	0.25 (0.58)	-0.4	-0.42	0.50	0.67	0.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region											
Rest of the world	Absolute values	Baseline	Tezepelumab	17	14 (82.4)	3.78 (0.67)	2.3	3.25	3.96	4.25	4.9	
			Placebo	22	18 (81.8)	3.88 (1.10)	1.5	3.50	4.04	4.33	6.3	
		Week 4	Tezepelumab	17	16 (94.1)	4.53 (0.98)	2.8	4.00	4.46	5.13	6.5	
			Placebo	22	20 (90.9)	4.63 (0.95)	2.7	4.13	4.67	5.25	6.5	
		Week 8	Tezepelumab	17	16 (94.1)	4.81 (1.11)	3.4	4.00	4.33	5.83	6.8	
			Placebo	22	21 (95.5)	4.59 (1.14)	1.9	4.25	4.67	5.17	6.7	
		Week 12	Tezepelumab	17	16 (94.1)	5.02 (1.07)	3.6	4.33	4.67	5.83	6.8	
			Placebo	22	21 (95.5)	4.74 (1.04)	2.9	4.17	4.58	5.08	6.8	
		Week 16	Tezepelumab	17	16 (94.1)	5.18 (1.10)	3.4	4.33	5.08	6.00	7.0	
			Placebo	22	21 (95.5)	4.87 (1.11)	2.8	4.00	4.75	5.83	6.8	
		Week 20	Tezepelumab	17	16 (94.1)	4.96 (1.04)	3.8	4.08	4.75	5.50	7.0	
			Placebo	22	21 (95.5)	4.61 (1.19)	2.4	4.00	4.42	5.58	6.6	
		Week 24	Tezepelumab	17	16 (94.1)	4.85 (1.09)	3.3	4.00	4.50	5.67	6.9	
			Placebo	22	21 (95.5)	4.69 (1.24)	2.2	3.92	4.75	5.75	6.7	
		Week 28	Tezepelumab	17	16 (94.1)	4.99 (1.10)	3.4	4.17	4.75	5.79	6.8	
			Placebo	22	21 (95.5)	4.69 (1.27)	1.8	4.00	4.75	5.58	7.0	
		Week 32	Tezepelumab	17	16 (94.1)	5.14 (1.04)	3.7	4.25	5.13	6.04	7.0	
			Placebo	22	21 (95.5)	4.70 (1.11)	2.8	3.92	4.92	5.67	6.3	
		Week 36	Tezepelumab	17	16 (94.1)	5.21 (1.13)	3.6	4.21	5.17	6.13	7.0	
			Placebo	22	21 (95.5)	4.61 (1.16)	2.8	3.83	4.58	5.42	6.8	
		Week 40	Tezepelumab	17	16 (94.1)	4.81 (1.24)	2.3	4.04	4.42	5.54	7.0	
			Placebo	22	21 (95.5)	4.83 (1.26)	2.5	4.00	5.00	5.75	6.7	
		Week 44	Tezepelumab	17	16 (94.1)	5.01 (1.09)	3.7	4.13	4.67	5.75	7.0	
			Placebo	22	21 (95.5)	4.74 (1.10)	2.8	4.00	4.75	5.75	6.5	
		Week 48	Tezepelumab	17	16 (94.1)	5.17 (1.12)	3.7	4.25	4.96	6.13	7.0	
			Placebo	22	21 (95.5)	4.61 (1.16)	2.4	3.83	4.50	5.67	6.5	
		Week 52	Tezepelumab	17	16 (94.1)	5.14 (1.10)	3.7	4.25	4.96	6.08	7.0	
			Placebo	22	21 (95.5)	4.71 (1.05)	2.8	4.00	4.50	5.67	6.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region												
Rest of the world	Change from baseline	Week 4	Tezepelumab	17	13 (76.5)	0.76 (0.62)	-0.5	0.42	0.83	1.17	1.8	0.10 [-0.61, 0.81]
			Placebo	22	18 (81.8)	0.69 (0.80)	-1.1	0.25	0.50	1.17	2.4	
		Week 8	Tezepelumab	17	13 (76.5)	0.86 (0.92)	-0.7	0.33	0.75	1.67	2.5	0.09 [-0.62, 0.81]
			Placebo	22	18 (81.8)	0.77 (1.03)	-1.8	0.42	0.58	1.17	2.7	
		Week 12	Tezepelumab	17	13 (76.5)	1.06 (0.68)	0.3	0.50	0.92	1.50	2.5	0.19 [-0.53, 0.90]
			Placebo	22	18 (81.8)	0.83 (1.50)	-2.8	0.17	0.88	1.25	4.0	
		Week 16	Tezepelumab	17	13 (76.5)	1.30 (0.84)	0.0	0.58	1.67	1.75	2.7	0.19 [-0.52, 0.91]
			Placebo	22	18 (81.8)	1.06 (1.46)	-3.0	0.33	1.17	1.75	4.2	
		Week 20	Tezepelumab	17	13 (76.5)	1.12 (0.82)	0.0	0.50	1.00	1.33	2.8	0.30 [-0.42, 1.01]
			Placebo	22	18 (81.8)	0.79 (1.31)	-3.0	0.08	1.17	1.67	2.5	
		Week 24	Tezepelumab	17	13 (76.5)	1.15 (0.77)	0.0	0.50	1.17	1.50	2.7	0.22 [-0.50, 0.93]
			Placebo	22	18 (81.8)	0.90 (1.37)	-3.0	0.42	1.17	1.75	2.7	
		Week 28	Tezepelumab	17	13 (76.5)	1.12 (0.81)	-0.3	0.58	1.25	1.50	2.6	0.17 [-0.54, 0.89]
			Placebo	22	18 (81.8)	0.89 (1.55)	-3.0	0.33	1.08	1.67	4.3	
		Week 32	Tezepelumab	17	13 (76.5)	1.40 (0.93)	0.0	1.00	1.17	1.92	3.0	0.40 [-0.32, 1.12]
			Placebo	22	18 (81.8)	0.94 (1.28)	-3.0	0.92	1.17	1.67	2.9	
		Week 36	Tezepelumab	17	13 (76.5)	1.46 (1.10)	-0.2	0.50	1.58	2.33	3.3	0.54 [-0.18, 1.27]
			Placebo	22	18 (81.8)	0.80 (1.27)	-3.0	0.08	1.13	1.67	2.3	
		Week 40	Tezepelumab	17	13 (76.5)	1.00 (1.03)	-0.9	0.50	1.08	1.33	2.7	-0.05 [-0.77, 0.66]
			Placebo	22	18 (81.8)	1.07 (1.46)	-3.0	0.83	1.25	1.67	4.0	
		Week 44	Tezepelumab	17	13 (76.5)	1.22 (0.90)	-0.1	0.58	1.17	1.58	2.8	0.23 [-0.49, 0.94]
			Placebo	22	18 (81.8)	0.94 (1.37)	-3.0	0.08	1.21	1.67	3.4	
		Week 48	Tezepelumab	17	13 (76.5)	1.41 (0.94)	0.0	0.75	1.50	2.33	2.8	0.53 [-0.20, 1.25]
			Placebo	22	18 (81.8)	0.80 (1.31)	-3.0	0.08	1.17	1.67	2.3	
		Week 52	Tezepelumab	17	13 (76.5)	1.38 (0.94)	0.0	0.75	1.17	2.33	2.8	0.44 [-0.28, 1.16]
			Placebo	22	18 (81.8)	0.89 (1.24)	-3.0	0.33	1.17	1.67	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	4.06 (1.16)	2.3	3.17	3.88	5.00	6.7	
			Placebo	21	17 (81.0)	4.20 (0.96)	1.7	3.67	4.42	4.58	5.6	
		Week 4	Tezepelumab	15	13 (86.7)	5.33 (1.05)	3.3	4.50	5.67	6.08	6.8	
			Placebo	21	19 (90.5)	4.74 (0.92)	2.7	4.50	4.67	5.25	6.2	
		Week 8	Tezepelumab	15	14 (93.3)	5.67 (0.97)	3.4	5.17	5.83	6.33	6.8	
			Placebo	21	19 (90.5)	4.75 (1.24)	2.1	4.08	4.67	5.83	7.0	
		Week 12	Tezepelumab	15	14 (93.3)	5.89 (0.94)	3.8	5.42	6.17	6.67	6.9	
			Placebo	21	19 (90.5)	5.02 (1.14)	2.9	3.92	5.25	6.00	7.0	
		Week 16	Tezepelumab	15	14 (93.3)	5.86 (0.83)	4.3	5.42	5.79	6.67	7.0	
			Placebo	21	19 (90.5)	5.11 (1.21)	2.8	4.17	5.17	5.92	7.0	
		Week 20	Tezepelumab	15	14 (93.3)	5.79 (0.91)	3.8	5.42	5.79	6.58	6.9	
			Placebo	21	19 (90.5)	4.91 (1.37)	2.4	3.67	4.67	6.42	7.0	
		Week 24	Tezepelumab	15	14 (93.3)	5.84 (0.90)	3.8	5.42	5.96	6.33	7.0	
			Placebo	21	19 (90.5)	4.96 (1.43)	2.2	3.75	5.25	6.00	7.0	
		Week 28	Tezepelumab	15	14 (93.3)	5.85 (0.89)	3.8	5.42	5.79	6.83	7.0	
			Placebo	21	20 (95.2)	5.10 (1.39)	1.8	4.04	5.29	6.21	7.0	
		Week 32	Tezepelumab	15	14 (93.3)	5.88 (0.74)	4.3	5.50	5.88	6.25	7.0	
			Placebo	21	20 (95.2)	5.11 (1.27)	2.8	4.04	5.25	6.04	7.0	
		Week 36	Tezepelumab	15	14 (93.3)	6.01 (0.74)	4.6	5.50	6.00	6.42	7.0	
			Placebo	21	20 (95.2)	4.98 (1.47)	2.8	3.79	4.67	6.38	7.0	
		Week 40	Tezepelumab	15	14 (93.3)	5.93 (0.85)	4.5	5.50	6.00	6.58	7.0	
			Placebo	21	20 (95.2)	5.07 (1.38)	2.5	3.83	5.00	6.33	7.0	
		Week 44	Tezepelumab	15	14 (93.3)	5.99 (0.77)	4.7	5.50	5.96	6.58	7.0	
			Placebo	21	20 (95.2)	4.93 (1.30)	2.8	3.96	5.00	5.92	7.0	
		Week 48	Tezepelumab	15	14 (93.3)	6.08 (0.76)	4.7	5.50	6.21	6.58	7.0	
			Placebo	21	20 (95.2)	4.90 (1.30)	2.4	4.00	4.63	6.00	7.0	
		Week 52	Tezepelumab	15	14 (93.3)	5.99 (0.75)	4.7	5.42	6.13	6.50	7.0	
			Placebo	21	20 (95.2)	5.05 (1.25)	2.8	4.13	4.63	6.08	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
18.5 - < 25.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	15	12 (80.0)	1.60 (0.74)	0.3	1.13	1.46	2.08	3.1	1.79 [0.91, 2.67]
			Placebo	21	17 (81.0)	0.56 (0.43)	-0.3	0.25	0.58	0.92	1.3	
		Week 8	Tezepelumab	15	13 (86.7)	1.56 (0.96)	0.0	0.83	1.67	2.00	3.3	1.11 [0.33, 1.89]
			Placebo	21	17 (81.0)	0.65 (0.70)	-0.3	0.33	0.67	0.83	2.4	
		Week 12	Tezepelumab	15	13 (86.7)	1.76 (1.02)	-0.1	1.42	1.75	2.17	3.7	1.01 [0.24, 1.78]
			Placebo	21	17 (81.0)	0.86 (0.78)	-0.7	0.50	0.92	1.25	2.4	
		Week 16	Tezepelumab	15	13 (86.7)	1.70 (1.05)	-0.3	1.00	1.75	2.42	3.3	0.82 [0.07, 1.57]
			Placebo	21	17 (81.0)	1.00 (0.67)	-0.1	0.67	1.08	1.33	2.4	
		Week 20	Tezepelumab	15	13 (86.7)	1.65 (1.08)	0.0	1.00	1.92	2.50	3.3	0.84 [0.09, 1.60]
			Placebo	21	17 (81.0)	0.80 (0.95)	-1.1	0.25	1.08	1.33	2.4	
		Week 24	Tezepelumab	15	13 (86.7)	1.73 (1.08)	0.3	0.92	1.50	2.75	3.3	0.78 [0.03, 1.53]
			Placebo	21	17 (81.0)	0.91 (1.04)	-1.3	0.17	1.17	1.50	2.4	
		Week 28	Tezepelumab	15	13 (86.7)	1.71 (1.00)	0.3	1.00	1.50	2.58	3.3	0.77 [0.02, 1.52]
			Placebo	21	17 (81.0)	0.95 (0.97)	-1.8	0.58	1.00	1.33	2.4	
		Week 32	Tezepelumab	15	13 (86.7)	1.78 (1.05)	0.3	1.00	1.92	2.75	3.3	0.91 [0.15, 1.67]
			Placebo	21	17 (81.0)	0.98 (0.74)	-0.6	0.58	1.08	1.33	2.4	
		Week 36	Tezepelumab	15	13 (86.7)	1.92 (1.22)	0.2	0.75	2.33	2.92	3.4	0.99 [0.22, 1.75]
			Placebo	21	17 (81.0)	0.81 (1.03)	-1.3	0.08	1.17	1.25	2.4	
		Week 40	Tezepelumab	15	13 (86.7)	1.81 (1.11)	0.3	1.00	2.00	2.92	3.4	0.92 [0.16, 1.68]
			Placebo	21	17 (81.0)	0.91 (0.89)	-1.0	0.50	0.75	1.42	2.4	
		Week 44	Tezepelumab	15	13 (86.7)	1.88 (1.12)	0.3	0.83	2.00	2.92	3.3	1.17 [0.38, 1.95]
			Placebo	21	17 (81.0)	0.73 (0.87)	-1.3	0.33	0.83	1.33	2.4	
		Week 48	Tezepelumab	15	13 (86.7)	1.97 (1.00)	0.3	1.17	1.92	2.92	3.4	1.33 [0.53, 2.13]
			Placebo	21	17 (81.0)	0.70 (0.92)	-1.1	0.17	0.67	1.25	2.4	
		Week 52	Tezepelumab	15	13 (86.7)	1.88 (1.14)	0.3	1.08	1.58	2.92	3.6	0.99 [0.22, 1.76]
			Placebo	21	17 (81.0)	0.90 (0.88)	-0.4	0.25	0.83	1.25	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	24	20 (83.3)	4.10 (0.97)	2.3	3.58	4.21	4.67	6.2	
			Placebo	20	18 (90.0)	4.10 (0.69)	2.9	3.83	4.00	4.33	6.3	
		Week 4	Tezepelumab	24	23 (95.8)	4.94 (0.86)	3.3	4.33	4.92	5.58	6.4	
			Placebo	20	17 (85.0)	4.50 (0.84)	2.7	4.00	4.33	5.17	6.0	
		Week 8	Tezepelumab	24	23 (95.8)	5.15 (1.09)	3.6	4.08	5.25	6.08	6.8	
			Placebo	20	18 (90.0)	4.58 (0.90)	2.9	4.17	4.50	5.17	6.5	
		Week 12	Tezepelumab	24	23 (95.8)	5.29 (1.16)	3.5	4.33	5.17	6.42	7.0	
			Placebo	20	18 (90.0)	4.59 (1.05)	2.1	4.17	4.58	5.08	6.8	
		Week 16	Tezepelumab	24	23 (95.8)	5.29 (1.22)	3.3	4.33	5.42	6.25	6.9	
			Placebo	20	18 (90.0)	4.31 (1.38)	1.3	3.42	4.50	5.17	6.6	
		Week 20	Tezepelumab	24	23 (95.8)	5.34 (1.16)	3.5	4.33	5.25	6.58	7.0	
			Placebo	20	18 (90.0)	4.42 (1.40)	1.3	4.00	4.67	5.25	6.8	
		Week 24	Tezepelumab	24	23 (95.8)	5.35 (1.14)	3.6	4.42	5.17	6.58	7.0	
			Placebo	20	18 (90.0)	4.39 (1.30)	1.3	3.67	4.63	5.17	6.8	
		Week 28	Tezepelumab	24	24 (100.0)	5.38 (1.16)	3.6	4.50	5.00	6.50	7.0	
			Placebo	20	18 (90.0)	4.37 (1.30)	1.3	3.42	4.42	5.17	6.7	
		Week 32	Tezepelumab	24	24 (100.0)	5.50 (1.20)	3.6	4.50	5.54	6.75	7.0	
			Placebo	20	18 (90.0)	4.46 (1.22)	1.3	3.83	4.79	5.17	6.2	
		Week 36	Tezepelumab	24	24 (100.0)	5.37 (1.20)	3.6	4.29	5.21	6.63	7.0	
			Placebo	20	18 (90.0)	4.37 (1.06)	2.4	3.42	4.29	5.17	6.1	
		Week 40	Tezepelumab	24	24 (100.0)	5.54 (1.16)	3.6	4.54	5.63	6.71	7.0	
			Placebo	20	18 (90.0)	4.62 (1.03)	2.3	4.00	4.79	5.25	6.1	
		Week 44	Tezepelumab	24	24 (100.0)	5.41 (1.15)	3.6	4.33	5.50	6.46	7.0	
			Placebo	20	18 (90.0)	4.69 (1.06)	2.5	4.00	4.42	5.75	6.3	
		Week 48	Tezepelumab	24	24 (100.0)	5.38 (1.17)	3.6	4.33	5.29	6.58	7.0	
			Placebo	20	18 (90.0)	4.80 (1.11)	2.2	4.00	4.96	5.67	6.5	
		Week 52	Tezepelumab	24	24 (100.0)	5.47 (1.16)	3.6	4.54	5.29	6.71	7.0	
			Placebo	20	18 (90.0)	4.79 (1.12)	2.8	4.00	4.83	5.67	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
25.0 - < 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	24	20 (83.3)	0.87 (0.80)	-1.4	0.46	1.04	1.42	1.9	0.46 [-0.19, 1.12]
			Placebo	20	17 (85.0)	0.44 (1.09)	-1.2	0.00	0.50	0.92	3.1	
		Week 8	Tezepelumab	24	20 (83.3)	0.95 (0.99)	-1.4	0.38	0.96	1.71	2.5	0.43 [-0.22, 1.07]
			Placebo	20	18 (90.0)	0.48 (1.24)	-1.8	-0.58	0.46	1.17	3.6	
		Week 12	Tezepelumab	24	20 (83.3)	1.14 (1.06)	-1.4	0.63	1.08	2.04	2.6	0.53 [-0.12, 1.18]
			Placebo	20	18 (90.0)	0.49 (1.41)	-2.8	-0.17	0.63	1.00	3.8	
		Week 16	Tezepelumab	24	20 (83.3)	1.12 (1.04)	-1.4	0.58	1.13	2.08	2.7	0.66 [0.00, 1.31]
			Placebo	20	18 (90.0)	0.20 (1.72)	-3.5	-0.92	0.50	1.00	3.7	
		Week 20	Tezepelumab	24	20 (83.3)	1.27 (1.07)	-1.4	0.63	1.42	2.13	2.8	0.67 [0.02, 1.33]
			Placebo	20	18 (90.0)	0.32 (1.72)	-3.5	-0.58	0.71	1.25	3.8	
		Week 24	Tezepelumab	24	20 (83.3)	1.28 (1.10)	-1.4	0.58	1.63	2.21	2.7	0.70 [0.04, 1.36]
			Placebo	20	18 (90.0)	0.29 (1.69)	-3.5	-0.17	0.50	1.17	3.9	
		Week 28	Tezepelumab	24	20 (83.3)	1.21 (1.18)	-1.4	0.42	1.54	2.21	2.6	0.66 [0.01, 1.32]
			Placebo	20	18 (90.0)	0.26 (1.65)	-3.5	-0.42	0.58	1.08	3.8	
		Week 32	Tezepelumab	24	20 (83.3)	1.44 (1.21)	-1.4	0.71	1.88	2.33	2.8	0.77 [0.11, 1.43]
			Placebo	20	18 (90.0)	0.36 (1.60)	-3.5	0.00	0.79	1.08	3.3	
		Week 36	Tezepelumab	24	20 (83.3)	1.25 (1.27)	-1.4	0.17	1.58	2.25	2.8	0.74 [0.08, 1.40]
			Placebo	20	18 (90.0)	0.26 (1.40)	-3.0	-0.42	0.38	1.17	2.6	
		Week 40	Tezepelumab	24	20 (83.3)	1.45 (1.29)	-1.4	0.71	1.96	2.38	3.1	0.71 [0.05, 1.36]
			Placebo	20	18 (90.0)	0.51 (1.36)	-3.0	0.00	0.67	1.25	2.8	
		Week 44	Tezepelumab	24	20 (83.3)	1.33 (1.29)	-1.4	0.50	1.83	2.29	3.0	0.54 [-0.11, 1.19]
			Placebo	20	18 (90.0)	0.59 (1.46)	-3.0	-0.25	0.58	1.67	2.8	
		Week 48	Tezepelumab	24	20 (83.3)	1.35 (1.28)	-1.4	0.33	1.63	2.25	3.2	0.48 [-0.17, 1.12]
			Placebo	20	18 (90.0)	0.69 (1.49)	-3.0	0.00	0.79	1.67	2.8	
		Week 52	Tezepelumab	24	20 (83.3)	1.44 (1.22)	-1.4	0.71	1.63	2.46	3.2	0.55 [-0.10, 1.20]
			Placebo	20	18 (90.0)	0.69 (1.53)	-3.0	0.00	0.67	1.67	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Absolute values	Baseline	Tezepelumab	27	24 (88.9)	3.84 (0.98)	1.4	3.33	4.00	4.42	5.6	
			Placebo	24	20 (83.3)	4.08 (1.00)	1.5	3.46	4.38	4.71	5.8	
		Week 4	Tezepelumab	27	24 (88.9)	4.24 (1.16)	1.3	3.54	4.17	4.96	6.4	
			Placebo	24	21 (87.5)	4.86 (0.99)	3.0	4.33	5.00	5.25	6.7	
		Week 8	Tezepelumab	27	25 (92.6)	4.49 (1.12)	2.0	3.92	4.25	5.17	6.8	
			Placebo	24	22 (91.7)	4.87 (1.10)	1.9	4.17	4.71	5.50	6.8	
		Week 12	Tezepelumab	27	25 (92.6)	4.75 (0.86)	3.0	4.17	4.67	5.33	6.7	
			Placebo	24	22 (91.7)	5.00 (1.00)	3.5	4.17	4.75	5.58	6.8	
		Week 16	Tezepelumab	27	25 (92.6)	4.80 (0.98)	2.7	4.33	4.92	5.33	6.9	
			Placebo	24	22 (91.7)	5.09 (1.00)	3.4	4.42	4.79	6.00	6.8	
		Week 20	Tezepelumab	27	26 (96.3)	4.65 (0.94)	2.3	4.08	4.46	5.00	6.8	
			Placebo	24	22 (91.7)	4.89 (0.88)	3.2	4.33	4.92	5.58	6.6	
		Week 24	Tezepelumab	27	26 (96.3)	4.70 (0.90)	3.1	4.17	4.46	5.42	6.8	
			Placebo	24	22 (91.7)	4.82 (0.94)	3.2	4.25	4.67	5.50	6.3	
		Week 28	Tezepelumab	27	27 (100.0)	4.57 (0.89)	3.2	4.00	4.42	5.08	6.8	
			Placebo	24	22 (91.7)	5.00 (1.14)	2.9	4.25	4.79	5.92	7.0	
		Week 32	Tezepelumab	27	27 (100.0)	4.64 (0.95)	2.8	4.00	4.75	5.08	6.7	
			Placebo	24	22 (91.7)	5.05 (0.98)	3.2	4.33	5.00	5.83	6.8	
		Week 36	Tezepelumab	27	27 (100.0)	4.78 (1.03)	2.9	4.08	4.75	5.67	6.9	
			Placebo	24	22 (91.7)	5.02 (0.91)	3.2	4.42	4.79	5.92	6.6	
		Week 40	Tezepelumab	27	27 (100.0)	4.55 (0.96)	2.3	4.00	4.42	5.17	6.9	
			Placebo	24	22 (91.7)	5.02 (1.13)	3.2	4.00	5.21	6.08	6.7	
		Week 44	Tezepelumab	27	27 (100.0)	4.64 (0.91)	3.0	4.00	4.58	5.08	6.9	
			Placebo	24	22 (91.7)	5.05 (1.10)	3.1	4.33	4.92	6.08	6.8	
		Week 48	Tezepelumab	27	27 (100.0)	4.70 (1.01)	2.8	4.00	5.00	5.33	6.9	
			Placebo	24	22 (91.7)	5.08 (1.08)	3.2	4.25	4.79	6.00	6.9	
		Week 52	Tezepelumab	27	27 (100.0)	4.68 (1.03)	2.8	4.00	4.67	5.33	6.9	
			Placebo	24	22 (91.7)	5.10 (1.02)	3.2	4.42	4.88	5.92	6.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: BMI												
>= 30.0 kg/m**2	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	0.26 (1.22)	-4.3	-0.17	0.17	1.17	2.0	-0.48 [-1.09, 0.12]
			Placebo	24	20 (83.3)	0.80 (0.96)	-1.3	0.33	0.58	1.00	3.3	
		Week 8	Tezepelumab	27	24 (88.9)	0.62 (1.17)	-1.9	0.08	0.42	1.46	2.3	-0.21 [-0.80, 0.39]
			Placebo	24	20 (83.3)	0.85 (1.07)	-1.0	0.38	0.75	1.17	3.3	
		Week 12	Tezepelumab	27	24 (88.9)	0.87 (1.16)	-2.6	0.29	0.92	1.58	3.0	-0.09 [-0.68, 0.51]
			Placebo	24	20 (83.3)	0.98 (1.36)	-1.0	0.17	0.79	1.17	4.0	
		Week 16	Tezepelumab	27	24 (88.9)	0.98 (1.17)	-2.9	0.38	1.04	1.71	3.0	-0.10 [-0.69, 0.50]
			Placebo	24	20 (83.3)	1.10 (1.22)	-0.3	0.17	0.92	1.38	4.2	
		Week 20	Tezepelumab	27	24 (88.9)	0.80 (0.99)	-1.8	0.21	0.67	1.21	3.0	-0.10 [-0.70, 0.49]
			Placebo	24	20 (83.3)	0.90 (0.95)	-0.4	0.08	0.75	1.67	3.3	
		Week 24	Tezepelumab	27	24 (88.9)	0.92 (0.99)	-1.6	0.33	0.96	1.38	3.0	0.12 [-0.48, 0.71]
			Placebo	24	20 (83.3)	0.80 (1.11)	-1.2	0.08	0.75	1.08	3.6	
		Week 28	Tezepelumab	27	24 (88.9)	0.77 (0.98)	-1.7	0.17	0.67	1.25	3.0	-0.18 [-0.78, 0.41]
			Placebo	24	20 (83.3)	0.98 (1.25)	-1.6	0.17	0.92	1.54	4.3	
		Week 32	Tezepelumab	27	24 (88.9)	0.76 (0.97)	-1.6	0.25	0.83	1.25	3.0	-0.33 [-0.92, 0.27]
			Placebo	24	20 (83.3)	1.08 (0.99)	-0.6	0.42	0.96	1.42	3.5	
		Week 36	Tezepelumab	27	24 (88.9)	0.90 (1.01)	-1.7	0.17	0.96	1.58	3.0	-0.11 [-0.71, 0.48]
			Placebo	24	20 (83.3)	1.01 (0.87)	0.1	0.33	0.88	1.33	3.8	
		Week 40	Tezepelumab	27	24 (88.9)	0.75 (0.97)	-1.7	0.21	0.96	1.08	3.0	-0.24 [-0.83, 0.36]
			Placebo	24	20 (83.3)	1.02 (1.30)	-1.0	0.04	0.92	1.71	4.0	
		Week 44	Tezepelumab	27	24 (88.9)	0.81 (0.86)	-1.6	0.29	0.88	1.17	3.0	-0.22 [-0.81, 0.38]
			Placebo	24	20 (83.3)	1.03 (1.18)	-0.8	0.33	1.04	1.46	3.7	
		Week 48	Tezepelumab	27	24 (88.9)	0.84 (0.96)	-1.6	0.29	0.88	1.21	3.0	-0.22 [-0.82, 0.37]
			Placebo	24	20 (83.3)	1.06 (1.02)	-0.6	0.38	1.00	1.42	4.2	
		Week 52	Tezepelumab	27	24 (88.9)	0.82 (0.96)	-1.6	0.29	0.79	1.08	3.0	-0.26 [-0.85, 0.34]
			Placebo	24	20 (83.3)	1.07 (0.99)	-0.3	0.38	0.88	1.42	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Absolute values	Baseline	Tezepelumab	11	11 (100.0)	3.48 (0.94)	2.1	2.58	3.75	4.17	4.8	
			Placebo	14	11 (78.6)	4.21 (0.86)	2.7	3.50	4.33	4.75	5.8	
		Week 4	Tezepelumab	11	11 (100.0)	4.44 (1.18)	2.6	3.50	4.33	5.50	6.4	
			Placebo	14	12 (85.7)	4.59 (1.07)	3.0	3.83	4.58	5.25	6.7	
		Week 8	Tezepelumab	11	11 (100.0)	4.54 (1.38)	2.0	3.58	4.25	5.67	6.8	
			Placebo	14	12 (85.7)	5.01 (0.85)	3.5	4.42	5.04	5.42	6.8	
		Week 12	Tezepelumab	11	11 (100.0)	4.86 (1.01)	3.6	3.83	4.83	5.50	6.7	
			Placebo	14	12 (85.7)	5.03 (1.09)	3.5	4.33	4.96	5.96	6.7	
		Week 16	Tezepelumab	11	11 (100.0)	4.91 (0.92)	3.6	4.25	5.00	5.42	6.9	
			Placebo	14	12 (85.7)	5.18 (1.04)	3.9	4.50	4.67	6.25	6.8	
		Week 20	Tezepelumab	11	11 (100.0)	4.77 (0.93)	3.6	4.08	4.50	5.50	6.8	
			Placebo	14	12 (85.7)	4.73 (0.90)	3.6	4.13	4.46	5.50	6.5	
		Week 24	Tezepelumab	11	11 (100.0)	4.77 (0.99)	3.6	3.92	4.42	5.50	6.8	
			Placebo	14	12 (85.7)	4.84 (0.89)	3.6	4.17	4.83	5.38	6.5	
		Week 28	Tezepelumab	11	11 (100.0)	4.66 (1.00)	3.4	3.83	4.58	5.17	6.8	
			Placebo	14	12 (85.7)	5.13 (1.21)	3.8	3.96	5.00	6.04	7.0	
		Week 32	Tezepelumab	11	11 (100.0)	4.79 (0.95)	3.6	4.00	4.92	5.50	6.7	
			Placebo	14	12 (85.7)	4.97 (1.02)	3.7	4.21	4.83	5.71	6.8	
		Week 36	Tezepelumab	11	11 (100.0)	4.91 (1.05)	3.6	4.00	4.83	5.67	6.9	
			Placebo	14	12 (85.7)	4.85 (0.93)	3.8	4.29	4.50	5.42	6.6	
		Week 40	Tezepelumab	11	11 (100.0)	4.80 (0.93)	3.6	4.17	4.50	5.25	6.9	
			Placebo	14	12 (85.7)	4.97 (1.15)	3.4	3.92	4.96	6.04	6.7	
		Week 44	Tezepelumab	11	11 (100.0)	4.70 (1.04)	3.5	3.67	4.67	5.42	6.9	
			Placebo	14	12 (85.7)	4.97 (1.15)	3.1	4.08	4.79	5.96	6.8	
		Week 48	Tezepelumab	11	11 (100.0)	4.80 (1.03)	3.6	4.00	4.67	5.58	6.9	
			Placebo	14	12 (85.7)	4.90 (1.04)	3.8	4.00	4.79	5.46	6.8	
		Week 52	Tezepelumab	11	11 (100.0)	4.79 (1.03)	3.6	4.00	4.67	5.58	6.9	
			Placebo	14	12 (85.7)	4.77 (0.98)	3.6	4.04	4.46	5.21	6.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
< 150 cells/uL	Change from baseline	Week 4	Tezepelumab	11	11 (100.0)	0.96 (0.90)	-0.2	0.25	0.92	1.33	3.1	0.68 [-0.18, 1.55]
			Placebo	14	11 (78.6)	0.51 (0.28)	0.1	0.33	0.50	0.75	0.9	
		Week 8	Tezepelumab	11	11 (100.0)	1.06 (1.34)	-1.9	0.33	1.08	2.00	3.3	0.12 [-0.72, 0.95]
			Placebo	14	11 (78.6)	0.93 (0.79)	-0.3	0.42	0.83	1.17	2.7	
		Week 12	Tezepelumab	11	11 (100.0)	1.38 (1.07)	-0.2	0.92	1.08	1.83	3.7	0.36 [-0.48, 1.21]
			Placebo	14	11 (78.6)	0.96 (1.22)	-0.8	0.33	0.83	1.33	4.0	
		Week 16	Tezepelumab	11	11 (100.0)	1.43 (0.82)	0.6	0.83	1.08	2.08	3.2	0.35 [-0.50, 1.19]
			Placebo	14	11 (78.6)	1.08 (1.17)	-0.3	0.33	1.00	1.33	4.2	
		Week 20	Tezepelumab	11	11 (100.0)	1.29 (0.90)	0.1	0.67	0.92	2.17	2.9	0.85 [-0.03, 1.72]
			Placebo	14	11 (78.6)	0.61 (0.68)	-0.4	0.08	0.75	1.25	1.8	
		Week 24	Tezepelumab	11	11 (100.0)	1.29 (0.84)	0.2	0.92	1.00	2.00	2.9	0.64 [-0.22, 1.49]
			Placebo	14	11 (78.6)	0.74 (0.87)	-0.8	0.08	0.83	1.17	2.7	
		Week 28	Tezepelumab	11	11 (100.0)	1.18 (0.97)	-0.3	0.50	0.92	2.00	2.9	0.14 [-0.70, 0.97]
			Placebo	14	11 (78.6)	1.03 (1.23)	-0.3	0.08	1.00	1.25	4.3	
		Week 32	Tezepelumab	11	11 (100.0)	1.31 (0.96)	0.3	0.75	0.92	1.83	3.0	0.47 [-0.38, 1.32]
			Placebo	14	11 (78.6)	0.88 (0.87)	-0.6	0.33	0.92	1.08	2.9	
		Week 36	Tezepelumab	11	11 (100.0)	1.43 (1.13)	-0.2	0.67	1.00	2.42	3.3	0.77 [-0.10, 1.64]
			Placebo	14	11 (78.6)	0.74 (0.59)	0.1	0.08	0.83	1.08	1.9	
		Week 40	Tezepelumab	11	11 (100.0)	1.32 (0.91)	0.1	0.75	1.00	2.17	2.9	0.42 [-0.43, 1.26]
			Placebo	14	11 (78.6)	0.87 (1.21)	-0.6	0.08	0.75	1.33	4.0	
		Week 44	Tezepelumab	11	11 (100.0)	1.22 (0.91)	-0.1	0.58	0.92	2.08	2.9	0.38 [-0.46, 1.23]
			Placebo	14	11 (78.6)	0.83 (1.13)	-0.7	0.08	0.58	1.33	3.4	
		Week 48	Tezepelumab	11	11 (100.0)	1.32 (0.85)	0.3	0.83	1.08	2.08	2.9	0.71 [-0.15, 1.57]
			Placebo	14	11 (78.6)	0.77 (0.68)	-0.6	0.42	0.67	1.33	1.8	
		Week 52	Tezepelumab	11	11 (100.0)	1.31 (0.85)	0.3	0.75	1.08	2.08	2.9	0.89 [0.01, 1.77]
			Placebo	14	11 (78.6)	0.67 (0.56)	-0.3	0.33	0.58	1.08	1.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low												
>= 150 cells/uL	Absolute values	Baseline	Tezepelumab	54	46 (85.2)	4.11 (1.01)	1.4	3.58	4.17	4.83	6.7	
			Placebo	51	44 (86.3)	4.10 (0.90)	1.5	3.67	4.25	4.58	6.3	
		Week 4	Tezepelumab	54	48 (88.9)	4.81 (1.10)	1.3	4.00	4.79	5.63	6.8	
			Placebo	51	45 (88.2)	4.74 (0.88)	2.7	4.25	4.67	5.25	6.5	
		Week 8	Tezepelumab	54	50 (92.6)	5.12 (1.09)	2.8	4.25	5.17	6.08	6.8	
			Placebo	51	47 (92.2)	4.67 (1.13)	1.9	4.08	4.50	5.42	7.0	
		Week 12	Tezepelumab	54	50 (92.6)	5.29 (1.10)	3.0	4.42	5.33	6.25	7.0	
			Placebo	51	47 (92.2)	4.84 (1.06)	2.1	4.17	4.67	5.58	7.0	
		Week 16	Tezepelumab	54	50 (92.6)	5.29 (1.15)	2.7	4.33	5.42	6.25	7.0	
			Placebo	51	47 (92.2)	4.77 (1.27)	1.3	4.00	4.75	5.83	7.0	
		Week 20	Tezepelumab	54	51 (94.4)	5.24 (1.14)	2.3	4.33	5.25	6.17	7.0	
			Placebo	51	47 (92.2)	4.76 (1.30)	1.3	4.00	5.00	5.75	7.0	
		Week 24	Tezepelumab	54	51 (94.4)	5.28 (1.10)	3.1	4.42	5.17	6.17	7.0	
			Placebo	51	47 (92.2)	4.71 (1.31)	1.3	3.83	4.67	5.92	7.0	
		Week 28	Tezepelumab	54	53 (98.1)	5.25 (1.12)	3.2	4.33	5.00	6.17	7.0	
			Placebo	51	48 (94.1)	4.77 (1.32)	1.3	3.96	4.88	5.75	7.0	
		Week 32	Tezepelumab	54	53 (98.1)	5.31 (1.15)	2.8	4.33	5.17	6.17	7.0	
			Placebo	51	48 (94.1)	4.88 (1.22)	1.3	4.04	4.96	5.75	7.0	
		Week 36	Tezepelumab	54	53 (98.1)	5.34 (1.15)	2.9	4.42	5.25	6.33	7.0	
			Placebo	51	48 (94.1)	4.80 (1.25)	2.4	3.92	4.83	5.92	7.0	
		Week 40	Tezepelumab	54	53 (98.1)	5.30 (1.20)	2.3	4.33	5.33	6.08	7.0	
			Placebo	51	48 (94.1)	4.90 (1.21)	2.3	4.00	5.00	5.92	7.0	
		Week 44	Tezepelumab	54	53 (98.1)	5.32 (1.11)	3.0	4.42	5.08	6.25	7.0	
			Placebo	51	48 (94.1)	4.89 (1.17)	2.5	4.04	4.83	5.88	7.0	
		Week 48	Tezepelumab	54	53 (98.1)	5.34 (1.16)	2.8	4.33	5.25	6.33	7.0	
			Placebo	51	48 (94.1)	4.94 (1.19)	2.2	4.21	4.79	5.96	7.0	
		Week 52	Tezepelumab	54	53 (98.1)	5.35 (1.16)	2.8	4.42	5.25	6.25	7.0	
			Placebo	51	48 (94.1)	5.05 (1.15)	2.8	4.25	4.88	5.96	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - Low											
>= 150 cells/uL	Change from baseline	Week 4	Tezepelumab	54	43 (79.6)	0.72 (1.16)	-4.3	0.08	0.92	1.50	2.4	0.08 [-0.35, 0.50]
			Placebo	51	43 (84.3)	0.64 (0.97)	-1.3	0.17	0.50	1.08	3.3	
		Week 8	Tezepelumab	54	45 (83.3)	0.95 (1.06)	-1.4	0.25	1.00	1.83	2.8	0.32 [-0.09, 0.74]
			Placebo	51	44 (86.3)	0.60 (1.08)	-1.8	-0.04	0.50	1.08	3.6	
		Week 12	Tezepelumab	54	45 (83.3)	1.12 (1.16)	-2.6	0.33	1.08	2.00	3.3	0.32 [-0.10, 0.74]
			Placebo	51	44 (86.3)	0.74 (1.24)	-2.8	0.04	0.67	1.17	3.8	
		Week 16	Tezepelumab	54	45 (83.3)	1.14 (1.19)	-2.9	0.42	1.08	2.08	3.3	0.34 [-0.08, 0.76]
			Placebo	51	44 (86.3)	0.70 (1.36)	-3.5	0.17	0.83	1.38	3.7	
		Week 20	Tezepelumab	54	45 (83.3)	1.13 (1.13)	-1.8	0.42	1.08	2.08	3.3	0.34 [-0.07, 0.76]
			Placebo	51	44 (86.3)	0.70 (1.37)	-3.5	0.13	0.88	1.50	3.8	
		Week 24	Tezepelumab	54	45 (83.3)	1.22 (1.15)	-1.6	0.50	1.25	2.17	3.3	0.44 [0.02, 0.87]
			Placebo	51	44 (86.3)	0.65 (1.41)	-3.5	0.00	0.88	1.38	3.9	
		Week 28	Tezepelumab	54	45 (83.3)	1.13 (1.15)	-1.7	0.33	1.08	2.08	3.3	0.37 [-0.05, 0.79]
			Placebo	51	44 (86.3)	0.66 (1.37)	-3.5	0.17	0.75	1.54	3.8	
		Week 32	Tezepelumab	54	45 (83.3)	1.21 (1.20)	-1.6	0.50	1.08	2.17	3.3	0.34 [-0.08, 0.76]
			Placebo	51	44 (86.3)	0.80 (1.26)	-3.5	0.33	0.92	1.29	3.5	
		Week 36	Tezepelumab	54	45 (83.3)	1.22 (1.24)	-1.7	0.25	1.33	2.17	3.4	0.42 [0.00, 0.84]
			Placebo	51	44 (86.3)	0.70 (1.25)	-3.0	0.04	0.88	1.25	3.8	
		Week 40	Tezepelumab	54	45 (83.3)	1.22 (1.26)	-1.7	0.33	1.08	2.25	3.4	0.33 [-0.09, 0.75]
			Placebo	51	44 (86.3)	0.81 (1.22)	-3.0	0.00	0.83	1.67	3.4	
		Week 44	Tezepelumab	54	45 (83.3)	1.23 (1.22)	-1.6	0.50	1.17	2.17	3.3	0.37 [-0.05, 0.78]
			Placebo	51	44 (86.3)	0.78 (1.22)	-3.0	0.29	0.88	1.58	3.7	
		Week 48	Tezepelumab	54	45 (83.3)	1.26 (1.24)	-1.6	0.33	1.17	2.25	3.4	0.34 [-0.08, 0.75]
			Placebo	51	44 (86.3)	0.84 (1.25)	-3.0	0.25	0.88	1.63	4.2	
		Week 52	Tezepelumab	54	45 (83.3)	1.27 (1.24)	-1.6	0.42	1.08	2.25	3.6	0.26 [-0.16, 0.68]
			Placebo	51	44 (86.3)	0.95 (1.26)	-3.0	0.25	0.83	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
< 300 cells/uL	Absolute values	Baseline	Tezepelumab	33	31 (93.9)	3.86 (1.00)	1.4	3.25	4.17	4.67	5.6	
			Placebo	34	27 (79.4)	4.07 (0.84)	1.7	3.50	4.25	4.58	5.8	
		Week 4	Tezepelumab	33	29 (87.9)	4.60 (1.29)	1.3	3.75	4.58	5.58	6.5	
			Placebo	34	27 (79.4)	4.69 (0.97)	2.7	4.25	4.67	5.25	6.7	
		Week 8	Tezepelumab	33	30 (90.9)	4.83 (1.24)	2.0	4.00	4.63	5.75	6.8	
			Placebo	34	29 (85.3)	4.87 (1.03)	2.1	4.25	5.00	5.50	6.8	
		Week 12	Tezepelumab	33	30 (90.9)	5.05 (1.12)	3.0	4.17	4.79	6.25	6.9	
			Placebo	34	29 (85.3)	5.02 (1.04)	2.9	4.25	5.00	5.92	6.8	
		Week 16	Tezepelumab	33	30 (90.9)	5.10 (1.14)	2.7	4.33	5.00	6.08	6.9	
			Placebo	34	29 (85.3)	4.98 (1.25)	1.3	4.42	5.17	5.92	6.8	
		Week 20	Tezepelumab	33	31 (93.9)	4.99 (1.16)	2.3	4.25	4.67	5.58	7.0	
			Placebo	34	29 (85.3)	4.84 (1.27)	1.3	4.33	5.00	5.75	6.6	
		Week 24	Tezepelumab	33	31 (93.9)	5.06 (1.08)	3.1	4.33	4.92	5.83	7.0	
			Placebo	34	29 (85.3)	4.84 (1.30)	1.3	4.25	5.08	5.75	6.7	
		Week 28	Tezepelumab	33	32 (97.0)	4.97 (1.16)	3.2	4.13	4.58	5.71	7.0	
			Placebo	34	30 (88.2)	4.97 (1.41)	1.3	4.25	5.13	5.92	7.0	
		Week 32	Tezepelumab	33	32 (97.0)	5.07 (1.14)	2.9	4.08	4.92	5.75	7.0	
			Placebo	34	30 (88.2)	4.98 (1.29)	1.3	4.33	4.96	5.92	6.8	
		Week 36	Tezepelumab	33	32 (97.0)	5.16 (1.16)	2.9	4.33	5.04	5.83	7.0	
			Placebo	34	30 (88.2)	5.00 (1.21)	2.5	4.33	4.79	6.00	6.9	
		Week 40	Tezepelumab	33	32 (97.0)	5.01 (1.21)	2.3	4.29	5.04	5.63	7.0	
			Placebo	34	30 (88.2)	5.13 (1.24)	2.5	4.08	5.04	6.25	7.0	
		Week 44	Tezepelumab	33	32 (97.0)	5.01 (1.18)	3.0	4.17	4.83	5.63	7.0	
			Placebo	34	30 (88.2)	5.09 (1.18)	2.8	4.25	5.00	6.25	6.9	
		Week 48	Tezepelumab	33	32 (97.0)	5.13 (1.17)	3.1	4.17	5.08	6.00	7.0	
			Placebo	34	30 (88.2)	5.02 (1.24)	2.4	4.25	4.96	6.00	6.9	
		Week 52	Tezepelumab	33	32 (97.0)	5.14 (1.19)	3.0	4.17	5.08	6.21	7.0	
			Placebo	34	30 (88.2)	5.07 (1.16)	2.8	4.25	4.67	6.17	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High											
< 300 cells/uL	Change from baseline	Week 4	Tezepelumab	33	29 (87.9)	0.66 (1.28)	-4.3	-0.08	0.83	1.50	3.1	-0.04 [-0.57, 0.48]
			Placebo	34	26 (76.5)	0.71 (0.72)	0.0	0.33	0.50	0.92	3.3	
		Week 8	Tezepelumab	33	30 (90.9)	0.97 (1.16)	-1.9	0.25	1.04	1.92	3.3	0.08 [-0.44, 0.60]
			Placebo	34	27 (79.4)	0.88 (0.91)	-0.6	0.42	0.67	1.17	3.3	
		Week 12	Tezepelumab	33	30 (90.9)	1.19 (1.21)	-2.6	0.58	1.04	2.00	3.7	0.12 [-0.40, 0.64]
			Placebo	34	27 (79.4)	1.05 (1.12)	-0.8	0.67	1.00	1.33	4.0	
		Week 16	Tezepelumab	33	30 (90.9)	1.24 (1.15)	-2.9	0.58	1.17	2.08	3.2	0.20 [-0.32, 0.72]
			Placebo	34	27 (79.4)	1.00 (1.32)	-3.5	0.42	0.92	1.33	4.2	
		Week 20	Tezepelumab	33	30 (90.9)	1.13 (1.11)	-1.8	0.33	0.88	2.17	3.0	0.25 [-0.28, 0.77]
			Placebo	34	27 (79.4)	0.84 (1.26)	-3.5	0.17	1.08	1.67	3.3	
		Week 24	Tezepelumab	33	30 (90.9)	1.21 (1.05)	-1.6	0.50	1.08	2.00	3.0	0.30 [-0.22, 0.83]
			Placebo	34	27 (79.4)	0.85 (1.32)	-3.5	0.42	1.00	1.33	3.6	
		Week 28	Tezepelumab	33	30 (90.9)	1.18 (1.11)	-1.7	0.25	1.00	2.17	3.0	0.22 [-0.30, 0.75]
			Placebo	34	27 (79.4)	0.90 (1.39)	-3.5	0.50	1.00	1.42	4.3	
		Week 32	Tezepelumab	33	30 (90.9)	1.22 (1.13)	-1.6	0.50	1.00	2.17	3.0	0.25 [-0.27, 0.77]
			Placebo	34	27 (79.4)	0.92 (1.27)	-3.5	0.58	1.00	1.33	3.5	
		Week 36	Tezepelumab	33	30 (90.9)	1.31 (1.16)	-1.7	0.33	1.33	2.17	3.3	0.35 [-0.18, 0.87]
			Placebo	34	27 (79.4)	0.91 (1.12)	-2.3	0.08	1.08	1.50	3.8	
		Week 40	Tezepelumab	33	30 (90.9)	1.20 (1.14)	-1.7	0.25	1.04	2.25	3.0	0.11 [-0.41, 0.63]
			Placebo	34	27 (79.4)	1.08 (1.19)	-1.1	0.50	1.17	1.75	4.0	
		Week 44	Tezepelumab	33	30 (90.9)	1.18 (1.10)	-1.6	0.58	1.04	2.17	3.0	0.15 [-0.37, 0.68]
			Placebo	34	27 (79.4)	1.00 (1.12)	-1.1	0.33	1.00	1.67	3.7	
		Week 48	Tezepelumab	33	30 (90.9)	1.30 (1.03)	-1.6	0.75	1.21	2.17	3.0	0.32 [-0.20, 0.85]
			Placebo	34	27 (79.4)	0.95 (1.13)	-1.1	0.17	1.17	1.58	4.2	
		Week 52	Tezepelumab	33	30 (90.9)	1.30 (1.04)	-1.6	0.75	1.08	2.17	3.0	0.29 [-0.23, 0.81]
			Placebo	34	27 (79.4)	1.00 (1.05)	-1.1	0.33	1.00	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High												
>= 300 cells/uL	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	4.13 (1.05)	2.3	3.42	4.04	5.00	6.7	
			Placebo	31	28 (90.3)	4.18 (0.94)	1.5	3.75	4.29	4.58	6.3	
		Week 4	Tezepelumab	32	30 (93.8)	4.87 (0.92)	3.3	4.08	4.79	5.58	6.8	
			Placebo	31	30 (96.8)	4.73 (0.88)	2.7	4.08	4.79	5.25	6.2	
		Week 8	Tezepelumab	32	31 (96.9)	5.20 (1.06)	2.8	4.33	5.42	6.08	6.8	
			Placebo	31	30 (96.8)	4.62 (1.13)	1.9	4.08	4.50	5.17	7.0	
		Week 12	Tezepelumab	32	31 (96.9)	5.36 (1.05)	3.5	4.42	5.42	6.17	7.0	
			Placebo	31	30 (96.8)	4.75 (1.08)	2.1	4.17	4.58	5.42	7.0	
		Week 16	Tezepelumab	32	31 (96.9)	5.33 (1.10)	3.3	4.33	5.58	6.08	7.0	
			Placebo	31	30 (96.8)	4.74 (1.22)	2.1	4.00	4.71	5.75	7.0	
		Week 20	Tezepelumab	32	31 (96.9)	5.33 (1.05)	3.5	4.25	5.67	6.08	6.9	
			Placebo	31	30 (96.8)	4.68 (1.18)	2.1	4.00	4.71	5.25	7.0	
		Week 24	Tezepelumab	32	31 (96.9)	5.32 (1.10)	3.3	4.33	5.50	6.17	7.0	
			Placebo	31	30 (96.8)	4.63 (1.16)	2.8	3.75	4.67	5.25	7.0	
		Week 28	Tezepelumab	32	32 (100.0)	5.33 (1.06)	3.8	4.38	5.42	6.17	7.0	
			Placebo	31	30 (96.8)	4.71 (1.18)	2.8	3.83	4.71	5.42	7.0	
		Week 32	Tezepelumab	32	32 (100.0)	5.38 (1.12)	2.8	4.33	5.63	6.21	7.0	
			Placebo	31	30 (96.8)	4.82 (1.05)	3.0	3.92	4.92	5.58	7.0	
		Week 36	Tezepelumab	32	32 (100.0)	5.38 (1.13)	3.3	4.29	5.46	6.25	7.0	
			Placebo	31	30 (96.8)	4.62 (1.15)	2.4	3.83	4.58	5.42	7.0	
		Week 40	Tezepelumab	32	32 (100.0)	5.41 (1.11)	3.8	4.33	5.63	6.33	7.0	
			Placebo	31	30 (96.8)	4.70 (1.11)	2.3	3.83	4.42	5.50	7.0	
		Week 44	Tezepelumab	32	32 (100.0)	5.41 (1.02)	3.8	4.50	5.58	6.38	7.0	
			Placebo	31	30 (96.8)	4.72 (1.11)	2.5	4.00	4.54	5.67	7.0	
		Week 48	Tezepelumab	32	32 (100.0)	5.36 (1.14)	2.8	4.33	5.46	6.21	7.0	
			Placebo	31	30 (96.8)	4.84 (1.08)	2.2	4.00	4.79	5.67	7.0	
		Week 52	Tezepelumab	32	32 (100.0)	5.37 (1.11)	2.8	4.54	5.42	6.17	7.0	
			Placebo	31	30 (96.8)	4.91 (1.09)	2.8	4.00	4.88	5.75	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils - High											
>= 300 cells/uL	Change from baseline	Week 4	Tezepelumab	32	25 (78.1)	0.90 (0.87)	-1.4	0.33	1.08	1.33	2.4	0.40 [-0.15, 0.94]
			Placebo	31	28 (90.3)	0.52 (1.00)	-1.3	0.00	0.58	1.13	3.1	
		Week 8	Tezepelumab	32	26 (81.3)	0.97 (1.07)	-1.4	0.25	1.04	1.83	2.8	0.47 [-0.07, 1.01]
			Placebo	31	28 (90.3)	0.46 (1.11)	-1.8	-0.13	0.42	0.88	3.6	
		Week 12	Tezepelumab	32	26 (81.3)	1.14 (1.07)	-1.4	0.33	1.25	1.92	3.3	0.52 [-0.02, 1.06]
			Placebo	31	28 (90.3)	0.53 (1.29)	-2.8	-0.04	0.50	0.83	3.8	
		Week 16	Tezepelumab	32	26 (81.3)	1.14 (1.12)	-1.4	0.42	1.04	2.08	3.3	0.47 [-0.07, 1.01]
			Placebo	31	28 (90.3)	0.56 (1.31)	-3.0	-0.04	0.46	1.25	3.7	
		Week 20	Tezepelumab	32	26 (81.3)	1.19 (1.08)	-1.4	0.50	1.21	2.08	3.3	0.57 [0.02, 1.11]
			Placebo	31	28 (90.3)	0.52 (1.26)	-3.0	-0.04	0.54	1.17	3.8	
		Week 24	Tezepelumab	32	26 (81.3)	1.25 (1.15)	-1.4	0.42	1.29	2.17	3.3	0.62 [0.08, 1.17]
			Placebo	31	28 (90.3)	0.49 (1.30)	-3.0	-0.08	0.21	1.21	3.9	
		Week 28	Tezepelumab	32	26 (81.3)	1.10 (1.14)	-1.4	0.42	1.04	2.00	3.3	0.43 [-0.11, 0.97]
			Placebo	31	28 (90.3)	0.57 (1.30)	-3.0	0.00	0.63	1.04	3.8	
		Week 32	Tezepelumab	32	26 (81.3)	1.25 (1.19)	-1.4	0.50	1.25	2.08	3.3	0.47 [-0.07, 1.01]
			Placebo	31	28 (90.3)	0.71 (1.12)	-3.0	0.25	0.83	1.13	3.3	
		Week 36	Tezepelumab	32	26 (81.3)	1.21 (1.29)	-1.4	0.17	1.08	2.33	3.4	0.58 [0.03, 1.12]
			Placebo	31	28 (90.3)	0.50 (1.14)	-3.0	0.04	0.50	1.13	2.6	
		Week 40	Tezepelumab	32	26 (81.3)	1.28 (1.28)	-1.4	0.50	1.08	2.25	3.4	0.57 [0.03, 1.12]
			Placebo	31	28 (90.3)	0.57 (1.20)	-3.0	0.00	0.67	1.25	2.8	
		Week 44	Tezepelumab	32	26 (81.3)	1.29 (1.24)	-1.4	0.50	1.13	2.08	3.3	0.56 [0.02, 1.11]
			Placebo	31	28 (90.3)	0.59 (1.24)	-3.0	0.13	0.58	1.25	2.8	
		Week 48	Tezepelumab	32	26 (81.3)	1.25 (1.33)	-1.4	0.33	1.13	2.42	3.4	0.42 [-0.12, 0.96]
			Placebo	31	28 (90.3)	0.72 (1.20)	-3.0	0.29	0.75	1.21	2.8	
		Week 52	Tezepelumab	32	26 (81.3)	1.26 (1.33)	-1.4	0.33	1.08	2.42	3.6	0.36 [-0.17, 0.90]
			Placebo	31	28 (90.3)	0.79 (1.26)	-3.0	0.25	0.75	1.46	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Absolute values	Baseline	Tezepelumab	39	32 (82.1)	3.95 (0.93)	1.9	3.50	4.04	4.58	5.6	
			Placebo	30	23 (76.7)	4.08 (0.65)	2.8	3.50	4.17	4.50	5.2	
		Week 4	Tezepelumab	39	36 (92.3)	4.57 (1.15)	1.3	3.92	4.58	5.46	6.4	
			Placebo	30	25 (83.3)	4.68 (0.82)	3.2	4.25	4.58	5.25	6.5	
		Week 8	Tezepelumab	39	36 (92.3)	4.88 (1.14)	2.0	4.21	4.83	5.75	6.8	
			Placebo	30	25 (83.3)	4.87 (0.92)	3.2	4.25	4.58	5.50	6.7	
		Week 12	Tezepelumab	39	36 (92.3)	5.07 (1.04)	3.0	4.29	5.00	5.96	6.8	
			Placebo	30	25 (83.3)	4.94 (0.93)	3.5	4.17	4.83	5.50	6.8	
		Week 16	Tezepelumab	39	36 (92.3)	5.04 (1.07)	2.7	4.33	5.00	5.96	6.9	
			Placebo	30	25 (83.3)	4.98 (0.98)	3.4	4.25	4.83	5.92	6.6	
		Week 20	Tezepelumab	39	37 (94.9)	5.00 (1.09)	2.3	4.25	4.83	5.92	6.9	
			Placebo	30	25 (83.3)	4.97 (1.08)	2.4	4.08	5.00	5.92	6.8	
		Week 24	Tezepelumab	39	37 (94.9)	4.98 (1.07)	3.1	4.17	4.92	5.75	7.0	
			Placebo	30	25 (83.3)	4.94 (1.13)	2.2	4.25	4.75	5.92	6.8	
		Week 28	Tezepelumab	39	39 (100.0)	5.03 (1.10)	3.2	4.17	5.00	5.83	7.0	
			Placebo	30	26 (86.7)	5.00 (1.14)	1.8	4.17	4.96	5.92	6.8	
		Week 32	Tezepelumab	39	39 (100.0)	5.01 (1.14)	2.8	4.00	4.92	5.83	7.0	
			Placebo	30	26 (86.7)	5.06 (1.03)	2.9	4.25	5.00	5.92	6.8	
		Week 36	Tezepelumab	39	39 (100.0)	5.16 (1.17)	2.9	4.17	5.25	6.08	7.0	
			Placebo	30	26 (86.7)	5.04 (1.06)	2.8	4.17	5.00	5.92	6.9	
		Week 40	Tezepelumab	39	39 (100.0)	4.95 (1.17)	2.3	4.17	4.83	5.67	7.0	
			Placebo	30	26 (86.7)	5.13 (1.10)	2.5	4.33	5.17	6.08	7.0	
		Week 44	Tezepelumab	39	39 (100.0)	4.96 (1.09)	3.0	4.08	4.75	5.67	7.0	
			Placebo	30	26 (86.7)	5.01 (1.08)	3.1	4.25	4.79	5.92	6.9	
		Week 48	Tezepelumab	39	39 (100.0)	5.00 (1.14)	2.8	4.08	5.00	5.67	7.0	
			Placebo	30	26 (86.7)	5.13 (1.13)	2.4	4.25	5.17	6.00	6.9	
		Week 52	Tezepelumab	39	39 (100.0)	5.03 (1.17)	2.8	4.00	5.00	6.08	7.0	
			Placebo	30	26 (86.7)	5.13 (1.02)	3.6	4.25	5.04	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
< 25 ppb	Change from baseline	Week 4	Tezepelumab	39	32 (82.1)	0.60 (1.22)	-4.3	0.00	0.58	1.33	3.1	-0.07 [-0.61, 0.46]
			Placebo	30	23 (76.7)	0.68 (1.08)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	39	32 (82.1)	0.83 (1.10)	-1.9	0.25	0.88	1.42	3.3	-0.03 [-0.56, 0.51]
			Placebo	30	23 (76.7)	0.86 (1.13)	-1.0	0.08	0.83	1.17	3.6	
		Week 12	Tezepelumab	39	32 (82.1)	1.05 (1.14)	-2.6	0.33	0.96	1.67	3.7	0.10 [-0.44, 0.64]
			Placebo	30	23 (76.7)	0.93 (1.22)	-1.0	0.33	0.75	1.17	3.8	
		Week 16	Tezepelumab	39	32 (82.1)	1.05 (1.12)	-2.9	0.46	1.00	1.71	3.3	0.09 [-0.45, 0.63]
			Placebo	30	23 (76.7)	0.95 (1.14)	-1.2	0.08	0.92	1.33	3.7	
		Week 20	Tezepelumab	39	32 (82.1)	1.05 (1.02)	-1.8	0.38	0.88	1.96	3.3	0.06 [-0.48, 0.59]
			Placebo	30	23 (76.7)	0.99 (1.19)	-1.1	0.08	1.00	1.67	3.8	
		Week 24	Tezepelumab	39	32 (82.1)	1.08 (0.99)	-1.6	0.46	0.96	1.75	3.3	0.13 [-0.41, 0.66]
			Placebo	30	23 (76.7)	0.94 (1.23)	-1.3	0.25	0.83	1.17	3.9	
		Week 28	Tezepelumab	39	32 (82.1)	1.08 (1.03)	-1.7	0.42	0.92	1.96	3.3	0.15 [-0.39, 0.68]
			Placebo	30	23 (76.7)	0.92 (1.13)	-1.8	0.33	0.83	1.42	3.8	
		Week 32	Tezepelumab	39	32 (82.1)	1.04 (1.12)	-1.6	0.33	0.96	1.79	3.3	0.03 [-0.51, 0.56]
			Placebo	30	23 (76.7)	1.01 (1.07)	-0.8	0.33	0.92	1.25	3.5	
		Week 36	Tezepelumab	39	32 (82.1)	1.18 (1.18)	-1.7	0.25	1.08	2.13	3.4	0.17 [-0.37, 0.70]
			Placebo	30	23 (76.7)	0.99 (1.03)	-0.8	0.25	0.92	1.50	3.8	
		Week 40	Tezepelumab	39	32 (82.1)	1.00 (1.14)	-1.7	0.25	0.96	2.13	3.3	-0.06 [-0.59, 0.48]
			Placebo	30	23 (76.7)	1.07 (1.10)	-1.0	0.33	1.00	1.83	3.4	
		Week 44	Tezepelumab	39	32 (82.1)	1.00 (1.04)	-1.6	0.38	0.92	1.75	3.2	0.07 [-0.46, 0.61]
			Placebo	30	23 (76.7)	0.92 (1.14)	-0.7	-0.25	1.00	1.67	3.7	
		Week 48	Tezepelumab	39	32 (82.1)	1.07 (1.06)	-1.6	0.38	0.96	1.79	3.4	0.02 [-0.52, 0.55]
			Placebo	30	23 (76.7)	1.05 (1.19)	-1.1	0.42	0.92	1.75	4.2	
		Week 52	Tezepelumab	39	32 (82.1)	1.09 (1.06)	-1.6	0.42	0.96	1.79	3.4	0.02 [-0.51, 0.56]
			Placebo	30	23 (76.7)	1.06 (1.11)	-0.7	0.42	0.75	1.75	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Absolute values	Baseline	Tezepelumab	27	26 (96.3)	4.03 (1.13)	1.4	3.17	4.08	4.67	6.7	
			Placebo	34	31 (91.2)	4.14 (1.04)	1.5	3.67	4.33	4.58	6.3	
		Week 4	Tezepelumab	27	24 (88.9)	5.01 (1.01)	3.3	4.21	5.04	5.92	6.8	
			Placebo	34	32 (94.1)	4.74 (1.00)	2.7	4.13	4.75	5.25	6.7	
		Week 8	Tezepelumab	27	26 (96.3)	5.17 (1.18)	3.6	3.92	5.17	6.08	6.8	
			Placebo	34	33 (97.1)	4.66 (1.21)	1.9	4.08	4.67	5.33	7.0	
		Week 12	Tezepelumab	27	26 (96.3)	5.40 (1.12)	3.5	4.42	5.42	6.58	7.0	
			Placebo	34	33 (97.1)	4.86 (1.18)	2.1	4.17	4.92	5.67	7.0	
		Week 16	Tezepelumab	27	26 (96.3)	5.46 (1.14)	3.3	4.75	5.63	6.42	7.0	
			Placebo	34	33 (97.1)	4.87 (1.27)	2.1	4.17	4.67	5.75	7.0	
		Week 20	Tezepelumab	27	26 (96.3)	5.38 (1.11)	3.5	4.42	5.63	6.25	7.0	
			Placebo	34	33 (97.1)	4.70 (1.19)	2.1	4.08	4.67	5.25	7.0	
		Week 24	Tezepelumab	27	26 (96.3)	5.49 (1.04)	3.7	4.42	5.63	6.33	7.0	
			Placebo	34	33 (97.1)	4.68 (1.17)	2.8	3.75	4.67	5.50	7.0	
		Week 28	Tezepelumab	27	26 (96.3)	5.31 (1.13)	3.8	4.42	5.21	6.17	7.0	
			Placebo	34	33 (97.1)	4.82 (1.29)	2.8	3.83	4.92	5.75	7.0	
		Week 32	Tezepelumab	27	26 (96.3)	5.54 (1.04)	3.8	4.75	5.63	6.25	7.0	
			Placebo	34	33 (97.1)	4.88 (1.12)	2.8	4.00	4.92	5.58	7.0	
		Week 36	Tezepelumab	27	26 (96.3)	5.42 (1.07)	3.8	4.58	5.21	6.33	7.0	
			Placebo	34	33 (97.1)	4.70 (1.22)	2.4	3.83	4.58	5.58	7.0	
		Week 40	Tezepelumab	27	26 (96.3)	5.61 (1.05)	3.8	4.75	5.75	6.58	7.0	
			Placebo	34	33 (97.1)	4.78 (1.24)	2.3	3.83	4.58	5.75	7.0	
		Week 44	Tezepelumab	27	26 (96.3)	5.61 (1.03)	3.8	4.75	5.75	6.50	7.0	
			Placebo	34	33 (97.1)	4.85 (1.21)	2.5	4.00	5.08	5.83	7.0	
		Week 48	Tezepelumab	27	26 (96.3)	5.62 (1.06)	3.8	4.75	5.83	6.50	7.0	
			Placebo	34	33 (97.1)	4.82 (1.16)	2.2	4.00	4.75	5.75	7.0	
		Week 52	Tezepelumab	27	26 (96.3)	5.59 (1.02)	3.8	4.75	5.58	6.42	7.0	
			Placebo	34	33 (97.1)	4.92 (1.19)	2.8	4.00	4.75	5.75	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO												
>= 25 ppb	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	1.03 (0.87)	-1.4	0.42	1.17	1.58	2.4	0.61 [0.05, 1.16]
			Placebo	34	31 (91.2)	0.56 (0.70)	-1.1	0.25	0.50	1.00	1.9	
		Week 8	Tezepelumab	27	25 (92.6)	1.10 (1.13)	-1.4	0.17	1.67	1.92	2.5	0.53 [-0.01, 1.06]
			Placebo	34	31 (91.2)	0.56 (0.94)	-1.8	0.17	0.42	1.00	2.7	
		Week 12	Tezepelumab	27	25 (92.6)	1.32 (1.12)	-1.4	0.83	1.58	2.17	3.0	0.51 [-0.03, 1.05]
			Placebo	34	31 (91.2)	0.71 (1.24)	-2.8	0.00	0.75	1.25	4.0	
		Week 16	Tezepelumab	27	25 (92.6)	1.37 (1.12)	-1.4	0.58	1.67	2.17	3.0	0.50 [-0.04, 1.03]
			Placebo	34	31 (91.2)	0.78 (1.25)	-3.0	0.17	0.83	1.42	4.2	
		Week 20	Tezepelumab	27	25 (92.6)	1.30 (1.15)	-1.4	0.50	1.33	2.25	3.0	0.64 [0.10, 1.19]
			Placebo	34	31 (91.2)	0.59 (1.07)	-3.0	0.08	0.75	1.25	2.4	
		Week 24	Tezepelumab	27	25 (92.6)	1.43 (1.17)	-1.4	0.92	1.58	2.25	3.0	0.71 [0.17, 1.25]
			Placebo	34	31 (91.2)	0.60 (1.17)	-3.0	0.00	0.83	1.33	2.7	
		Week 28	Tezepelumab	27	25 (92.6)	1.22 (1.20)	-1.4	0.42	1.42	2.17	3.0	0.38 [-0.15, 0.92]
			Placebo	34	31 (91.2)	0.74 (1.30)	-3.0	0.08	0.83	1.33	4.3	
		Week 32	Tezepelumab	27	25 (92.6)	1.48 (1.14)	-1.4	1.00	1.67	2.33	3.0	0.63 [0.09, 1.17]
			Placebo	34	31 (91.2)	0.80 (1.03)	-3.0	0.42	0.83	1.33	2.9	
		Week 36	Tezepelumab	27	25 (92.6)	1.36 (1.25)	-1.4	0.33	1.58	2.33	3.2	0.66 [0.12, 1.20]
			Placebo	34	31 (91.2)	0.59 (1.09)	-3.0	0.08	0.83	1.25	2.4	
		Week 40	Tezepelumab	27	25 (92.6)	1.54 (1.20)	-1.4	1.00	1.33	2.50	3.4	0.69 [0.15, 1.23]
			Placebo	34	31 (91.2)	0.70 (1.25)	-3.0	0.00	0.67	1.42	4.0	
		Week 44	Tezepelumab	27	25 (92.6)	1.54 (1.22)	-1.4	0.83	1.50	2.42	3.3	0.64 [0.10, 1.18]
			Placebo	34	31 (91.2)	0.76 (1.22)	-3.0	0.33	0.83	1.58	3.4	
		Week 48	Tezepelumab	27	25 (92.6)	1.55 (1.24)	-1.4	1.00	1.58	2.58	3.2	0.71 [0.16, 1.25]
			Placebo	34	31 (91.2)	0.73 (1.10)	-3.0	0.25	0.83	1.25	2.8	
		Week 52	Tezepelumab	27	25 (92.6)	1.52 (1.25)	-1.4	0.75	1.50	2.58	3.6	0.58 [0.04, 1.12]
			Placebo	34	31 (91.2)	0.83 (1.16)	-3.0	0.25	0.83	1.58	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	27	23 (85.2)	3.96 (0.66)	2.1	3.75	4.08	4.33	4.8	
			Placebo	29	23 (79.3)	4.19 (0.96)	1.7	3.50	4.25	4.58	6.3	
		Week 4	Tezepelumab	27	26 (96.3)	4.72 (0.86)	2.6	4.08	4.67	5.33	6.4	
			Placebo	29	25 (86.2)	4.65 (1.02)	2.7	4.25	4.50	5.25	6.5	
		Week 8	Tezepelumab	27	26 (96.3)	4.92 (1.11)	2.0	4.25	4.83	5.67	6.8	
			Placebo	29	27 (93.1)	4.56 (1.12)	2.1	3.92	4.50	5.33	6.7	
		Week 12	Tezepelumab	27	26 (96.3)	5.23 (0.98)	3.6	4.42	5.17	5.83	6.8	
			Placebo	29	27 (93.1)	4.68 (1.13)	2.1	3.92	4.58	5.42	6.8	
		Week 16	Tezepelumab	27	26 (96.3)	5.37 (1.02)	3.6	4.33	5.38	6.25	7.0	
			Placebo	29	27 (93.1)	4.52 (1.35)	1.3	3.67	4.42	5.83	7.0	
		Week 20	Tezepelumab	27	26 (96.3)	5.15 (1.12)	3.6	4.17	5.04	5.92	7.0	
			Placebo	29	27 (93.1)	4.51 (1.41)	1.3	3.58	4.33	5.50	6.8	
		Week 24	Tezepelumab	27	26 (96.3)	5.21 (1.05)	3.6	4.33	5.13	6.17	7.0	
			Placebo	29	27 (93.1)	4.35 (1.43)	1.3	3.33	4.25	5.33	6.8	
		Week 28	Tezepelumab	27	27 (100.0)	5.10 (1.14)	3.3	4.17	4.92	6.42	7.0	
			Placebo	29	27 (93.1)	4.38 (1.44)	1.3	3.25	4.25	5.50	6.6	
		Week 32	Tezepelumab	27	27 (100.0)	5.10 (1.15)	3.5	4.17	4.92	6.17	7.0	
			Placebo	29	27 (93.1)	4.54 (1.33)	1.3	3.67	4.33	5.67	6.7	
		Week 36	Tezepelumab	27	27 (100.0)	5.21 (1.16)	3.3	4.17	5.08	6.33	7.0	
			Placebo	29	27 (93.1)	4.42 (1.34)	2.4	3.42	4.17	5.58	6.8	
		Week 40	Tezepelumab	27	27 (100.0)	5.13 (1.13)	2.9	4.25	5.08	6.08	7.0	
			Placebo	29	27 (93.1)	4.57 (1.27)	2.3	3.75	4.25	5.75	6.6	
		Week 44	Tezepelumab	27	27 (100.0)	5.07 (1.17)	3.0	4.08	5.08	5.75	7.0	
			Placebo	29	27 (93.1)	4.51 (1.14)	2.5	3.67	4.33	5.58	6.5	
		Week 48	Tezepelumab	27	27 (100.0)	5.11 (1.19)	3.1	4.00	5.08	5.75	7.0	
			Placebo	29	27 (93.1)	4.48 (1.16)	2.2	3.83	4.25	5.17	6.5	
		Week 52	Tezepelumab	27	27 (100.0)	5.10 (1.17)	3.1	4.00	5.08	5.75	7.0	
			Placebo	29	27 (93.1)	4.57 (1.03)	2.8	4.00	4.50	5.17	6.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	27	23 (85.2)	0.83 (0.64)	-0.2	0.17	0.83	1.25	2.1	0.46 [-0.13, 1.05]
			Placebo	29	22 (75.9)	0.51 (0.77)	-1.1	0.17	0.50	1.00	2.4	
		Week 8	Tezepelumab	27	23 (85.2)	0.83 (1.13)	-1.9	0.00	0.92	1.83	2.8	0.35 [-0.23, 0.93]
			Placebo	29	23 (79.3)	0.46 (0.98)	-1.8	-0.25	0.42	0.83	2.6	
		Week 12	Tezepelumab	27	23 (85.2)	1.15 (0.99)	-0.8	0.42	1.00	2.17	3.3	0.59 [-0.00, 1.18]
			Placebo	29	23 (79.3)	0.51 (1.18)	-2.8	-0.08	0.67	1.25	2.7	
		Week 16	Tezepelumab	27	23 (85.2)	1.29 (0.99)	-0.8	0.58	1.25	2.17	3.3	0.76 [0.16, 1.36]
			Placebo	29	23 (79.3)	0.37 (1.38)	-3.5	-0.08	0.67	1.33	2.4	
		Week 20	Tezepelumab	27	23 (85.2)	1.13 (1.03)	-0.8	0.42	0.92	2.17	3.3	0.58 [-0.01, 1.18]
			Placebo	29	23 (79.3)	0.39 (1.48)	-3.5	-0.42	0.92	1.25	2.5	
		Week 24	Tezepelumab	27	23 (85.2)	1.21 (0.99)	-0.8	0.50	1.00	2.33	3.3	0.76 [0.16, 1.36]
			Placebo	29	23 (79.3)	0.23 (1.53)	-3.5	-0.75	0.83	1.25	2.3	
		Week 28	Tezepelumab	27	23 (85.2)	1.10 (0.99)	-0.8	0.50	0.92	2.17	3.3	0.66 [0.07, 1.25]
			Placebo	29	23 (79.3)	0.25 (1.54)	-3.5	-0.67	0.67	1.17	2.3	
		Week 32	Tezepelumab	27	23 (85.2)	1.19 (0.99)	-0.8	0.50	1.08	1.92	3.3	0.60 [0.01, 1.19]
			Placebo	29	23 (79.3)	0.47 (1.39)	-3.5	0.25	0.92	1.17	2.3	
		Week 36	Tezepelumab	27	23 (85.2)	1.31 (1.02)	-0.8	0.67	1.33	2.17	3.4	0.85 [0.24, 1.45]
			Placebo	29	23 (79.3)	0.30 (1.34)	-3.0	-0.50	0.75	1.17	2.3	
		Week 40	Tezepelumab	27	23 (85.2)	1.20 (0.97)	-0.8	0.50	1.00	2.17	3.3	0.61 [0.02, 1.20]
			Placebo	29	23 (79.3)	0.48 (1.36)	-3.0	-0.58	0.67	1.42	2.3	
		Week 44	Tezepelumab	27	23 (85.2)	1.16 (1.00)	-0.8	0.58	1.17	1.58	3.2	0.71 [0.11, 1.30]
			Placebo	29	23 (79.3)	0.37 (1.21)	-3.0	-0.42	0.58	1.17	2.4	
		Week 48	Tezepelumab	27	23 (85.2)	1.24 (1.03)	-0.8	0.50	1.08	2.00	3.4	0.78 [0.18, 1.38]
			Placebo	29	23 (79.3)	0.36 (1.24)	-3.0	-0.42	0.58	1.17	2.3	
		Week 52	Tezepelumab	27	23 (85.2)	1.24 (1.00)	-0.8	0.50	1.08	2.00	3.4	0.73 [0.13, 1.33]
			Placebo	29	23 (79.3)	0.45 (1.16)	-3.0	-0.25	0.58	1.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	4.02 (1.23)	1.4	3.21	3.96	4.96	6.7	
			Placebo	33	29 (87.9)	4.04 (0.87)	1.5	3.67	4.08	4.58	5.8	
		Week 4	Tezepelumab	34	30 (88.2)	4.71 (1.32)	1.3	3.58	4.75	5.67	6.8	
			Placebo	33	29 (87.9)	4.73 (0.85)	3.0	4.08	4.67	5.25	6.7	
		Week 8	Tezepelumab	34	32 (94.1)	5.01 (1.26)	2.8	3.83	4.96	6.08	6.8	
			Placebo	33	29 (87.9)	4.84 (0.97)	1.9	4.33	4.67	5.42	6.8	
		Week 12	Tezepelumab	34	32 (94.1)	5.14 (1.20)	3.0	4.17	4.96	6.21	7.0	
			Placebo	33	29 (87.9)	4.99 (0.94)	3.3	4.25	5.00	5.50	6.8	
		Week 16	Tezepelumab	34	32 (94.1)	5.09 (1.22)	2.7	4.33	5.17	6.08	6.9	
			Placebo	33	29 (87.9)	5.07 (1.03)	2.1	4.58	5.00	5.75	6.8	
		Week 20	Tezepelumab	34	32 (94.1)	5.15 (1.17)	2.3	4.25	5.13	6.04	6.9	
			Placebo	33	29 (87.9)	4.86 (0.95)	2.1	4.42	5.00	5.25	6.8	
		Week 24	Tezepelumab	34	32 (94.1)	5.23 (1.13)	3.1	4.38	5.21	6.13	7.0	
			Placebo	33	29 (87.9)	4.96 (0.89)	3.2	4.58	4.92	5.50	6.8	
		Week 28	Tezepelumab	34	33 (97.1)	5.17 (1.16)	3.2	4.08	5.00	6.08	7.0	
			Placebo	33	30 (90.9)	5.14 (1.02)	3.2	4.42	5.08	5.75	7.0	
		Week 32	Tezepelumab	34	33 (97.1)	5.29 (1.15)	2.8	4.42	5.50	6.00	7.0	
			Placebo	33	30 (90.9)	5.12 (0.92)	3.2	4.42	5.13	5.75	6.8	
		Week 36	Tezepelumab	34	33 (97.1)	5.26 (1.17)	2.9	4.25	5.25	6.08	7.0	
			Placebo	33	30 (90.9)	5.05 (0.91)	3.2	4.42	5.08	5.75	6.9	
		Week 40	Tezepelumab	34	33 (97.1)	5.28 (1.26)	2.3	4.33	5.00	6.08	7.0	
			Placebo	33	30 (90.9)	5.13 (1.02)	3.2	4.42	5.21	5.92	7.0	
		Week 44	Tezepelumab	34	33 (97.1)	5.29 (1.11)	3.1	4.42	4.92	6.08	7.0	
			Placebo	33	30 (90.9)	5.15 (1.06)	3.1	4.33	5.17	6.08	6.9	
		Week 48	Tezepelumab	34	33 (97.1)	5.31 (1.18)	2.8	4.33	5.17	6.25	7.0	
			Placebo	33	30 (90.9)	5.22 (0.99)	3.2	4.33	5.21	6.00	6.9	
		Week 52	Tezepelumab	34	33 (97.1)	5.31 (1.19)	2.8	4.33	5.42	6.17	7.0	
			Placebo	33	30 (90.9)	5.24 (1.07)	3.2	4.33	5.17	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline specific perennial FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	34	29 (85.3)	0.66 (1.31)	-4.3	-0.08	0.92	1.50	2.4	-0.02 [-0.54, 0.49]
			Placebo	33	29 (87.9)	0.68 (0.99)	-1.3	0.25	0.50	0.92	3.3	
		Week 8	Tezepelumab	34	31 (91.2)	0.97 (1.06)	-1.4	0.25	1.08	1.92	2.3	0.16 [-0.34, 0.67]
			Placebo	33	29 (87.9)	0.80 (1.00)	-1.0	0.33	0.67	1.00	3.6	
		Week 12	Tezepelumab	34	31 (91.2)	1.11 (1.17)	-2.6	0.58	1.25	1.92	3.0	0.14 [-0.37, 0.64]
			Placebo	33	29 (87.9)	0.95 (1.25)	-1.0	0.33	0.75	1.17	4.0	
		Week 16	Tezepelumab	34	31 (91.2)	1.06 (1.19)	-2.9	0.42	1.08	1.75	3.0	0.03 [-0.48, 0.53]
			Placebo	33	29 (87.9)	1.03 (1.24)	-1.3	0.33	0.92	1.25	4.2	
		Week 20	Tezepelumab	34	31 (91.2)	1.12 (1.10)	-1.8	0.42	1.17	2.00	3.0	0.28 [-0.23, 0.79]
			Placebo	33	29 (87.9)	0.82 (1.04)	-1.3	0.08	0.75	1.25	3.8	
		Week 24	Tezepelumab	34	31 (91.2)	1.20 (1.15)	-1.6	0.42	1.42	2.00	3.0	0.26 [-0.25, 0.77]
			Placebo	33	29 (87.9)	0.92 (1.05)	-0.7	0.08	0.83	1.17	3.9	
		Week 28	Tezepelumab	34	31 (91.2)	1.09 (1.19)	-1.7	0.33	1.25	2.00	3.0	0.04 [-0.46, 0.55]
			Placebo	33	29 (87.9)	1.04 (1.08)	-0.4	0.25	0.83	1.25	4.3	
		Week 32	Tezepelumab	34	31 (91.2)	1.23 (1.21)	-1.6	0.33	1.08	2.25	3.0	0.20 [-0.31, 0.71]
			Placebo	33	29 (87.9)	1.01 (0.96)	-0.8	0.42	0.92	1.17	3.5	
		Week 36	Tezepelumab	34	31 (91.2)	1.18 (1.32)	-1.7	0.17	1.08	2.33	3.3	0.21 [-0.29, 0.72]
			Placebo	33	29 (87.9)	0.94 (0.86)	-0.4	0.33	0.83	1.25	3.8	
		Week 40	Tezepelumab	34	31 (91.2)	1.22 (1.35)	-1.7	0.25	1.08	2.25	3.4	0.16 [-0.35, 0.67]
			Placebo	33	29 (87.9)	1.03 (1.04)	-0.5	0.50	0.83	1.42	4.0	
		Week 44	Tezepelumab	34	31 (91.2)	1.23 (1.26)	-1.6	0.33	1.08	2.33	3.3	0.16 [-0.35, 0.66]
			Placebo	33	29 (87.9)	1.05 (1.11)	-0.8	0.42	0.92	1.67	3.7	
		Week 48	Tezepelumab	34	31 (91.2)	1.26 (1.27)	-1.6	0.33	1.17	2.25	3.2	0.12 [-0.39, 0.63]
			Placebo	33	29 (87.9)	1.12 (0.97)	-0.3	0.50	1.08	1.67	4.2	
		Week 52	Tezepelumab	34	31 (91.2)	1.25 (1.29)	-1.6	0.33	1.08	2.33	3.6	0.09 [-0.41, 0.60]
			Placebo	33	29 (87.9)	1.14 (1.07)	-0.7	0.42	0.92	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Absolute values	Baseline	Tezepelumab	23	20 (87.0)	3.98 (0.69)	2.6	3.50	4.08	4.54	4.9	
			Placebo	14	11 (78.6)	4.46 (0.85)	3.4	3.67	4.33	4.75	6.3	
		Week 4	Tezepelumab	23	21 (91.3)	4.96 (0.99)	3.5	4.08	5.08	5.67	6.5	
			Placebo	14	10 (71.4)	4.72 (1.05)	2.7	4.25	4.67	5.25	6.2	
		Week 8	Tezepelumab	23	21 (91.3)	4.98 (1.26)	2.0	4.08	4.83	5.92	6.7	
			Placebo	14	11 (78.6)	4.61 (1.06)	2.9	3.92	4.50	5.50	6.4	
		Week 12	Tezepelumab	23	21 (91.3)	5.24 (1.08)	3.6	4.33	5.08	6.25	6.8	
			Placebo	14	11 (78.6)	4.33 (1.21)	2.1	3.50	4.08	5.42	6.3	
		Week 16	Tezepelumab	23	21 (91.3)	5.43 (1.01)	3.6	4.92	5.42	6.25	6.9	
			Placebo	14	11 (78.6)	4.27 (1.61)	1.3	3.25	4.25	5.83	7.0	
		Week 20	Tezepelumab	23	22 (95.7)	5.16 (1.05)	3.6	4.17	5.21	5.92	6.9	
			Placebo	14	11 (78.6)	4.31 (1.75)	1.3	2.83	4.42	6.08	6.7	
		Week 24	Tezepelumab	23	22 (95.7)	5.21 (1.01)	3.6	4.17	5.29	5.92	7.0	
			Placebo	14	11 (78.6)	4.05 (1.83)	1.3	2.75	3.58	6.08	6.8	
		Week 28	Tezepelumab	23	23 (100.0)	5.06 (1.16)	3.3	4.00	4.92	6.17	7.0	
			Placebo	14	11 (78.6)	3.87 (1.65)	1.3	2.83	4.00	4.83	6.4	
		Week 32	Tezepelumab	23	23 (100.0)	5.08 (1.13)	3.5	4.00	4.83	6.17	7.0	
			Placebo	14	11 (78.6)	4.20 (1.59)	1.3	3.00	4.33	5.67	6.7	
		Week 36	Tezepelumab	23	23 (100.0)	5.15 (1.15)	3.3	4.17	5.08	6.17	7.0	
			Placebo	14	11 (78.6)	4.49 (1.65)	2.4	2.75	4.42	6.08	6.8	
		Week 40	Tezepelumab	23	23 (100.0)	5.03 (1.09)	2.9	4.25	5.08	5.67	7.0	
			Placebo	14	11 (78.6)	4.33 (1.51)	2.3	3.25	3.75	5.92	6.6	
		Week 44	Tezepelumab	23	23 (100.0)	5.07 (1.13)	3.0	4.17	5.08	5.75	7.0	
			Placebo	14	11 (78.6)	4.29 (1.19)	2.5	3.25	4.25	5.42	6.3	
		Week 48	Tezepelumab	23	23 (100.0)	5.12 (1.15)	3.1	4.08	5.08	6.17	7.0	
			Placebo	14	11 (78.6)	4.17 (1.33)	2.2	3.25	4.25	4.83	6.5	
		Week 52	Tezepelumab	23	23 (100.0)	5.12 (1.14)	3.1	4.00	5.08	6.17	7.0	
			Placebo	14	11 (78.6)	4.42 (1.09)	2.8	3.67	4.33	4.83	6.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Low	Change from baseline	Week 4	Tezepelumab	23	20 (87.0)	1.03 (0.89)	-0.4	0.21	1.17	1.67	3.1	0.86 [0.06, 1.65]
			Placebo	14	10 (71.4)	0.28 (0.84)	-1.1	0.00	0.33	0.92	1.6	
		Week 8	Tezepelumab	23	20 (87.0)	0.93 (1.27)	-1.9	0.13	0.92	1.83	3.3	0.67 [-0.09, 1.42]
			Placebo	14	11 (78.6)	0.15 (0.95)	-1.8	-0.58	0.42	0.83	1.5	
		Week 12	Tezepelumab	23	20 (87.0)	1.20 (1.12)	-0.8	0.38	1.04	1.92	3.7	1.12 [0.33, 1.91]
			Placebo	14	11 (78.6)	-0.14 (1.31)	-2.8	-0.83	-0.25	0.92	1.7	
		Week 16	Tezepelumab	23	20 (87.0)	1.41 (1.02)	-0.8	0.71	1.33	2.13	3.3	1.23 [0.43, 2.04]
			Placebo	14	11 (78.6)	-0.20 (1.71)	-3.5	-0.92	0.00	1.33	1.7	
		Week 20	Tezepelumab	23	20 (87.0)	1.16 (1.06)	-0.8	0.46	0.92	2.04	3.3	0.95 [0.17, 1.72]
			Placebo	14	11 (78.6)	-0.15 (1.85)	-3.5	-1.08	0.08	1.67	1.9	
		Week 24	Tezepelumab	23	20 (87.0)	1.20 (1.02)	-0.8	0.46	1.08	1.79	3.3	1.18 [0.39, 1.98]
			Placebo	14	11 (78.6)	-0.41 (1.85)	-3.5	-1.33	-0.75	1.25	2.2	
		Week 28	Tezepelumab	23	20 (87.0)	1.13 (1.01)	-0.8	0.54	0.92	1.96	3.3	1.32 [0.51, 2.13]
			Placebo	14	11 (78.6)	-0.59 (1.73)	-3.5	-1.75	-0.33	0.83	1.8	
		Week 32	Tezepelumab	23	20 (87.0)	1.08 (1.11)	-0.8	0.38	0.96	2.00	3.3	1.00 [0.22, 1.78]
			Placebo	14	11 (78.6)	-0.26 (1.69)	-3.5	-0.67	0.08	1.08	1.8	
		Week 36	Tezepelumab	23	20 (87.0)	1.14 (1.08)	-0.8	0.29	1.00	1.83	3.4	0.84 [0.07, 1.60]
			Placebo	14	11 (78.6)	0.03 (1.69)	-3.0	-1.25	0.08	1.17	2.3	
		Week 40	Tezepelumab	23	20 (87.0)	1.08 (1.01)	-0.8	0.38	1.04	1.50	3.3	0.96 [0.19, 1.74]
			Placebo	14	11 (78.6)	-0.14 (1.65)	-3.0	-1.08	-0.58	1.83	2.3	
		Week 44	Tezepelumab	23	20 (87.0)	1.10 (1.08)	-0.8	0.38	0.96	1.83	3.2	1.08 [0.30, 1.87]
			Placebo	14	11 (78.6)	-0.17 (1.34)	-3.0	-1.08	-0.25	0.92	2.0	
		Week 48	Tezepelumab	23	20 (87.0)	1.19 (1.09)	-0.8	0.42	0.96	2.00	3.4	1.23 [0.43, 2.03]
			Placebo	14	11 (78.6)	-0.30 (1.41)	-3.0	-1.08	-0.25	0.42	2.3	
		Week 52	Tezepelumab	23	20 (87.0)	1.19 (1.06)	-0.8	0.42	0.96	2.00	3.4	1.04 [0.26, 1.83]
			Placebo	14	11 (78.6)	-0.04 (1.36)	-3.0	-0.92	0.08	0.83	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	3.98 (1.15)	1.4	3.25	4.00	4.67	6.7	
			Placebo	44	37 (84.1)	4.04 (0.92)	1.5	3.50	4.08	4.58	5.8	
		Week 4	Tezepelumab	40	36 (90.0)	4.63 (1.18)	1.3	3.92	4.75	5.46	6.8	
			Placebo	44	40 (90.9)	4.66 (0.93)	2.7	4.04	4.54	5.25	6.7	
		Week 8	Tezepelumab	40	38 (95.0)	5.04 (1.12)	2.8	4.17	5.13	5.83	6.8	
			Placebo	44	41 (93.2)	4.76 (1.16)	1.9	4.17	4.67	5.42	7.0	
		Week 12	Tezepelumab	40	38 (95.0)	5.24 (1.08)	3.0	4.42	5.29	6.17	7.0	
			Placebo	44	41 (93.2)	4.98 (1.04)	2.9	4.17	4.92	5.67	7.0	
		Week 16	Tezepelumab	40	38 (95.0)	5.14 (1.15)	2.7	4.33	5.13	6.00	7.0	
			Placebo	44	41 (93.2)	4.96 (1.16)	2.1	4.17	4.75	5.92	7.0	
		Week 20	Tezepelumab	40	38 (95.0)	5.19 (1.14)	2.3	4.33	5.00	6.00	7.0	
			Placebo	44	41 (93.2)	4.80 (1.13)	2.1	4.08	4.67	5.58	7.0	
		Week 24	Tezepelumab	40	38 (95.0)	5.22 (1.13)	3.1	4.42	5.13	6.25	7.0	
			Placebo	44	41 (93.2)	4.87 (1.06)	2.8	3.92	4.92	5.75	7.0	
		Week 28	Tezepelumab	40	39 (97.5)	5.22 (1.10)	3.2	4.42	5.00	6.17	7.0	
			Placebo	44	42 (95.5)	5.08 (1.19)	2.8	4.00	5.17	6.00	7.0	
		Week 32	Tezepelumab	40	39 (97.5)	5.33 (1.13)	2.8	4.42	5.33	6.25	7.0	
			Placebo	44	42 (95.5)	5.01 (1.08)	2.8	4.08	4.92	5.83	7.0	
		Week 36	Tezepelumab	40	39 (97.5)	5.35 (1.15)	2.9	4.50	5.42	6.33	7.0	
			Placebo	44	42 (95.5)	4.83 (1.12)	2.8	4.00	4.58	5.92	7.0	
		Week 40	Tezepelumab	40	39 (97.5)	5.32 (1.23)	2.3	4.42	5.25	6.58	7.0	
			Placebo	44	42 (95.5)	5.03 (1.14)	2.8	4.08	4.96	6.08	7.0	
		Week 44	Tezepelumab	40	39 (97.5)	5.31 (1.12)	3.1	4.42	5.08	6.50	7.0	
			Placebo	44	42 (95.5)	5.06 (1.14)	2.8	4.25	5.08	5.92	7.0	
		Week 48	Tezepelumab	40	39 (97.5)	5.34 (1.17)	2.8	4.33	5.25	6.33	7.0	
			Placebo	44	42 (95.5)	5.10 (1.09)	2.8	4.17	5.08	6.00	7.0	
		Week 52	Tezepelumab	40	39 (97.5)	5.34 (1.17)	2.8	4.42	5.33	6.25	7.0	
			Placebo	44	42 (95.5)	5.12 (1.14)	2.8	4.00	5.17	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
Normal	Change from baseline	Week 4	Tezepelumab	40	32 (80.0)	0.64 (1.23)	-4.3	0.00	0.92	1.42	2.4	0.01 [-0.47, 0.48]
			Placebo	44	37 (84.1)	0.63 (0.81)	-1.3	0.25	0.50	0.92	3.1	
		Week 8	Tezepelumab	40	34 (85.0)	1.00 (1.03)	-1.4	0.25	1.04	1.92	2.5	0.20 [-0.27, 0.66]
			Placebo	44	37 (84.1)	0.80 (0.99)	-1.0	0.42	0.75	1.17	3.6	
		Week 12	Tezepelumab	40	34 (85.0)	1.21 (1.16)	-2.6	0.58	1.25	2.00	3.0	0.19 [-0.27, 0.66]
			Placebo	44	37 (84.1)	0.99 (1.08)	-1.0	0.50	0.75	1.25	4.0	
		Week 16	Tezepelumab	40	34 (85.0)	1.11 (1.21)	-2.9	0.42	1.04	2.08	3.0	0.10 [-0.37, 0.56]
			Placebo	44	37 (84.1)	0.99 (1.10)	-1.3	0.33	0.92	1.33	4.2	
		Week 20	Tezepelumab	40	34 (85.0)	1.20 (1.12)	-1.8	0.42	1.13	2.25	3.0	0.34 [-0.13, 0.81]
			Placebo	44	37 (84.1)	0.84 (0.99)	-1.3	0.17	0.92	1.33	3.8	
		Week 24	Tezepelumab	40	34 (85.0)	1.30 (1.13)	-1.6	0.50	1.42	2.25	3.0	0.35 [-0.12, 0.82]
			Placebo	44	37 (84.1)	0.93 (0.97)	-0.7	0.08	0.92	1.33	3.9	
		Week 28	Tezepelumab	40	34 (85.0)	1.18 (1.19)	-1.7	0.33	1.25	2.17	3.0	0.07 [-0.40, 0.54]
			Placebo	44	37 (84.1)	1.10 (1.03)	-0.7	0.50	1.00	1.67	4.3	
		Week 32	Tezepelumab	40	34 (85.0)	1.35 (1.19)	-1.6	0.67	1.29	2.33	3.0	0.30 [-0.17, 0.76]
			Placebo	44	37 (84.1)	1.05 (0.84)	-0.8	0.50	1.00	1.33	3.3	
		Week 36	Tezepelumab	40	34 (85.0)	1.35 (1.30)	-1.7	0.33	1.33	2.33	3.3	0.49 [0.01, 0.96]
			Placebo	44	37 (84.1)	0.82 (0.85)	-1.3	0.25	0.92	1.25	2.6	
		Week 40	Tezepelumab	40	34 (85.0)	1.34 (1.31)	-1.7	0.50	1.17	2.33	3.4	0.26 [-0.21, 0.72]
			Placebo	44	37 (84.1)	1.05 (0.93)	-0.3	0.58	0.83	1.58	4.0	
		Week 44	Tezepelumab	40	34 (85.0)	1.32 (1.21)	-1.6	0.58	1.17	2.33	3.3	0.24 [-0.23, 0.71]
			Placebo	44	37 (84.1)	1.06 (0.95)	-1.3	0.50	1.00	1.58	3.4	
		Week 48	Tezepelumab	40	34 (85.0)	1.35 (1.25)	-1.6	0.75	1.33	2.33	3.2	0.23 [-0.24, 0.70]
			Placebo	44	37 (84.1)	1.11 (0.82)	-0.4	0.50	1.17	1.67	2.8	
		Week 52	Tezepelumab	40	34 (85.0)	1.35 (1.26)	-1.6	0.75	1.13	2.42	3.6	0.20 [-0.27, 0.67]
			Placebo	44	37 (84.1)	1.14 (0.92)	-0.7	0.50	1.08	1.67	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Absolute values	Baseline	Tezepelumab	3	3 (100.0)	4.03 (1.54)	2.3	2.25	4.83	5.00	5.0	
			Placebo	7	7 (100.0)	4.05 (0.66)	2.8	3.67	4.33	4.50	4.7	
		Week 4	Tezepelumab	3	3 (100.0)	4.58 (1.00)	3.6	3.58	4.58	5.58	5.6	
			Placebo	7	7 (100.0)	5.02 (0.70)	3.9	4.58	5.17	5.50	6.1	
		Week 8	Tezepelumab	3	3 (100.0)	4.61 (1.28)	3.8	3.75	4.00	6.08	6.1	
			Placebo	7	7 (100.0)	4.82 (0.68)	4.3	4.33	4.50	5.42	6.1	
		Week 12	Tezepelumab	3	3 (100.0)	4.58 (1.34)	3.5	3.50	4.17	6.08	6.1	
			Placebo	7	7 (100.0)	5.17 (0.74)	4.2	4.67	5.17	5.33	6.6	
		Week 16	Tezepelumab	3	3 (100.0)	4.81 (1.44)	3.3	3.25	5.08	6.08	6.1	
			Placebo	7	7 (100.0)	5.19 (0.64)	4.6	4.67	5.00	5.75	6.3	
		Week 20	Tezepelumab	3	3 (100.0)	4.72 (1.30)	3.5	3.50	4.58	6.08	6.1	
			Placebo	7	7 (100.0)	5.17 (0.42)	4.8	4.75	5.17	5.25	6.0	
		Week 24	Tezepelumab	3	3 (100.0)	4.69 (1.25)	3.7	3.67	4.33	6.08	6.1	
			Placebo	7	7 (100.0)	5.04 (0.62)	4.6	4.67	4.67	5.17	6.3	
		Week 28	Tezepelumab	3	3 (100.0)	4.81 (1.18)	3.8	3.75	4.58	6.08	6.1	
			Placebo	7	7 (100.0)	4.94 (0.41)	4.3	4.58	5.08	5.17	5.5	
		Week 32	Tezepelumab	3	3 (100.0)	4.92 (1.09)	3.9	3.92	4.75	6.08	6.1	
			Placebo	7	7 (100.0)	5.31 (0.43)	4.9	5.08	5.17	5.33	6.3	
		Week 36	Tezepelumab	3	3 (100.0)	5.03 (1.00)	4.1	4.08	4.92	6.08	6.1	
			Placebo	7	7 (100.0)	5.20 (0.59)	4.8	4.83	5.08	5.17	6.5	
		Week 40	Tezepelumab	3	3 (100.0)	5.14 (0.88)	4.3	4.33	5.00	6.08	6.1	
			Placebo	7	7 (100.0)	5.14 (0.66)	4.0	4.83	5.17	5.50	6.2	
		Week 44	Tezepelumab	3	3 (100.0)	5.11 (0.89)	4.3	4.33	4.92	6.08	6.1	
			Placebo	7	7 (100.0)	4.94 (0.95)	3.7	4.00	5.08	5.67	6.4	
		Week 48	Tezepelumab	3	3 (100.0)	5.08 (1.04)	4.0	4.00	5.17	6.08	6.1	
			Placebo	7	7 (100.0)	5.15 (0.83)	4.3	4.75	4.92	5.25	6.9	
		Week 52	Tezepelumab	3	3 (100.0)	5.08 (1.04)	4.0	4.00	5.17	6.08	6.1	
			Placebo	7	7 (100.0)	5.11 (0.84)	4.3	4.75	4.92	5.17	6.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Total serum IgE												
High	Change from baseline	Week 4	Tezepelumab	3	3 (100.0)	0.56 (0.79)	-0.3	-0.25	0.58	1.33	1.3	-0.37 [-1.74, 0.99]
			Placebo	7	7 (100.0)	0.98 (1.21)	-0.4	0.00	0.83	1.50	3.3	
		Week 8	Tezepelumab	3	3 (100.0)	0.58 (1.24)	-0.8	-0.83	1.08	1.50	1.5	-0.15 [-1.51, 1.20]
			Placebo	7	7 (100.0)	0.77 (1.25)	-0.2	-0.08	0.17	1.42	3.3	
		Week 12	Tezepelumab	3	3 (100.0)	0.56 (1.06)	-0.7	-0.67	1.08	1.25	1.3	-0.45 [-1.82, 0.92]
			Placebo	7	7 (100.0)	1.12 (1.30)	0.0	0.17	0.83	1.58	3.8	
		Week 16	Tezepelumab	3	3 (100.0)	0.78 (0.46)	0.3	0.25	1.00	1.08	1.1	-0.34 [-1.70, 1.02]
			Placebo	7	7 (100.0)	1.14 (1.20)	0.2	0.17	0.83	1.75	3.6	
		Week 20	Tezepelumab	3	3 (100.0)	0.69 (0.82)	-0.3	-0.25	1.08	1.25	1.3	-0.44 [-1.81, 0.93]
			Placebo	7	7 (100.0)	1.12 (1.01)	0.1	0.58	0.83	1.25	3.3	
		Week 24	Tezepelumab	3	3 (100.0)	0.67 (1.02)	-0.5	-0.50	1.08	1.42	1.4	-0.27 [-1.63, 1.09]
			Placebo	7	7 (100.0)	0.99 (1.22)	0.0	0.17	0.83	1.17	3.6	
		Week 28	Tezepelumab	3	3 (100.0)	0.78 (0.91)	-0.3	-0.25	1.08	1.50	1.5	-0.13 [-1.48, 1.23]
			Placebo	7	7 (100.0)	0.89 (0.89)	0.1	0.25	0.67	1.08	2.8	
		Week 32	Tezepelumab	3	3 (100.0)	0.89 (0.89)	-0.1	-0.08	1.08	1.67	1.7	-0.38 [-1.74, 0.99]
			Placebo	7	7 (100.0)	1.26 (1.02)	0.4	0.83	0.83	1.25	3.5	
		Week 36	Tezepelumab	3	3 (100.0)	1.00 (0.88)	0.1	0.08	1.08	1.83	1.8	-0.14 [-1.49, 1.22]
			Placebo	7	7 (100.0)	1.15 (1.19)	0.3	0.42	0.83	1.17	3.8	
		Week 40	Tezepelumab	3	3 (100.0)	1.11 (0.96)	0.2	0.17	1.08	2.08	2.1	0.01 [-1.34, 1.37]
			Placebo	7	7 (100.0)	1.10 (1.17)	-0.5	0.67	0.83	1.25	3.4	
		Week 44	Tezepelumab	3	3 (100.0)	1.08 (1.00)	0.1	0.08	1.08	2.08	2.1	0.14 [-1.22, 1.49]
			Placebo	7	7 (100.0)	0.89 (1.48)	-0.8	-0.42	0.83	1.67	3.7	
		Week 48	Tezepelumab	3	3 (100.0)	1.06 (0.71)	0.3	0.33	1.08	1.75	1.8	-0.04 [-1.39, 1.31]
			Placebo	7	7 (100.0)	1.11 (1.36)	0.3	0.50	0.67	0.83	4.2	
		Week 52	Tezepelumab	3	3 (100.0)	1.06 (0.71)	0.3	0.33	1.08	1.75	1.8	-0.00 [-1.36, 1.35]
			Placebo	7	7 (100.0)	1.06 (1.39)	0.3	0.25	0.67	0.83	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.97 (0.72)	3.2	3.29	3.88	4.63	5.0	
			Placebo	13	9 (69.2)	4.46 (0.74)	3.7	4.08	4.33	4.50	6.3	
		Week 4	Tezepelumab	9	8 (88.9)	4.90 (0.98)	3.6	4.42	4.63	5.54	6.4	
			Placebo	13	11 (84.6)	4.66 (1.02)	2.7	3.92	5.17	5.25	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.52 (0.92)	4.3	4.83	5.38	6.29	6.8	
			Placebo	13	12 (92.3)	4.42 (0.71)	2.9	4.08	4.58	4.92	5.4	
		Week 12	Tezepelumab	9	8 (88.9)	5.64 (0.99)	4.3	4.88	5.46	6.54	7.0	
			Placebo	13	12 (92.3)	4.31 (1.08)	2.1	3.50	4.25	5.13	6.0	
		Week 16	Tezepelumab	9	8 (88.9)	5.79 (0.78)	4.3	5.46	5.83	6.25	6.9	
			Placebo	13	12 (92.3)	4.54 (1.03)	2.8	3.79	4.67	5.46	6.0	
		Week 20	Tezepelumab	9	8 (88.9)	5.33 (1.08)	3.8	4.25	5.67	6.08	6.8	
			Placebo	13	12 (92.3)	4.50 (0.94)	2.8	3.83	4.54	5.25	5.8	
		Week 24	Tezepelumab	9	8 (88.9)	5.45 (1.12)	4.0	4.25	5.83	6.29	6.8	
			Placebo	13	12 (92.3)	4.49 (1.04)	2.8	3.71	4.54	5.29	6.0	
		Week 28	Tezepelumab	9	8 (88.9)	4.88 (1.12)	3.8	3.96	4.46	5.79	6.8	
			Placebo	13	13 (100.0)	4.66 (1.09)	2.8	3.83	4.58	5.17	6.8	
		Week 32	Tezepelumab	9	8 (88.9)	5.28 (1.17)	3.7	4.29	5.29	6.33	6.8	
			Placebo	13	13 (100.0)	4.76 (1.15)	3.0	3.83	5.17	5.58	6.8	
		Week 36	Tezepelumab	9	8 (88.9)	5.01 (1.15)	3.7	4.21	4.54	6.00	6.9	
			Placebo	13	13 (100.0)	4.76 (1.24)	2.4	3.83	4.83	5.42	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.40 (1.24)	4.1	4.29	5.25	6.50	7.0	
			Placebo	13	13 (100.0)	4.66 (1.33)	2.3	3.83	4.42	5.58	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.20 (1.08)	4.1	4.25	4.92	6.13	6.9	
			Placebo	13	13 (100.0)	4.69 (1.23)	2.5	3.83	4.50	5.67	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.14 (1.26)	3.7	4.04	5.04	6.17	6.9	
			Placebo	13	13 (100.0)	4.69 (1.28)	2.2	4.00	4.75	5.17	6.9	
		Week 52	Tezepelumab	9	8 (88.9)	5.27 (1.22)	3.7	4.04	5.58	6.17	6.9	
			Placebo	13	13 (100.0)	4.72 (1.23)	2.8	3.83	4.75	5.17	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.94 (0.58)	0.2	0.33	1.33	1.33	1.6	0.94 [-0.11, 1.98]
			Placebo	13	9 (69.2)	0.21 (0.90)	-1.1	-0.42	0.33	0.67	1.5	
		Week 8	Tezepelumab	9	7 (77.8)	1.54 (0.70)	0.5	0.83	1.92	2.00	2.3	1.67 [0.51, 2.84]
			Placebo	13	9 (69.2)	0.13 (0.93)	-1.8	-0.08	0.33	0.42	1.4	
		Week 12	Tezepelumab	9	7 (77.8)	1.70 (0.70)	0.5	1.25	1.83	2.17	2.6	1.80 [0.61, 2.99]
			Placebo	13	9 (69.2)	-0.21 (1.27)	-2.8	-0.83	0.17	0.83	1.0	
		Week 16	Tezepelumab	9	7 (77.8)	1.85 (0.79)	0.5	1.00	2.08	2.50	2.6	1.31 [0.21, 2.42]
			Placebo	13	9 (69.2)	0.22 (1.48)	-3.0	-0.08	0.33	1.25	1.8	
		Week 20	Tezepelumab	9	7 (77.8)	1.52 (0.78)	0.5	0.67	1.58	2.25	2.5	1.15 [0.08, 2.23]
			Placebo	13	9 (69.2)	0.17 (1.40)	-3.0	-0.08	0.75	0.83	1.7	
		Week 24	Tezepelumab	9	7 (77.8)	1.68 (0.84)	0.5	1.00	2.00	2.33	2.8	1.13 [0.06, 2.20]
			Placebo	13	9 (69.2)	0.27 (1.48)	-3.0	0.08	0.67	1.17	1.8	
		Week 28	Tezepelumab	9	7 (77.8)	0.94 (1.03)	-0.5	0.50	0.58	2.00	2.6	0.60 [-0.41, 1.62]
			Placebo	13	9 (69.2)	0.19 (1.40)	-3.0	0.08	0.83	0.92	1.7	
		Week 32	Tezepelumab	9	7 (77.8)	1.54 (0.75)	0.5	1.00	1.42	2.33	2.6	0.97 [-0.08, 2.02]
			Placebo	13	9 (69.2)	0.37 (1.44)	-3.0	0.08	0.83	1.17	1.7	
		Week 36	Tezepelumab	9	7 (77.8)	1.23 (0.99)	-0.2	0.50	1.08	2.08	2.8	0.72 [-0.31, 1.74]
			Placebo	13	9 (69.2)	0.27 (1.55)	-3.0	0.08	0.67	1.08	2.0	
		Week 40	Tezepelumab	9	7 (77.8)	1.61 (0.92)	0.5	1.00	1.08	2.58	2.9	1.03 [-0.03, 2.09]
			Placebo	13	9 (69.2)	0.20 (1.62)	-3.0	-0.50	0.83	1.25	2.1	
		Week 44	Tezepelumab	9	7 (77.8)	1.38 (1.03)	0.5	0.50	1.00	2.08	3.3	0.89 [-0.15, 1.93]
			Placebo	13	9 (69.2)	0.16 (1.58)	-3.0	-0.83	0.58	1.58	1.7	
		Week 48	Tezepelumab	9	7 (77.8)	1.37 (1.22)	-0.1	0.33	1.08	2.58	3.1	0.81 [-0.22, 1.85]
			Placebo	13	9 (69.2)	0.19 (1.59)	-3.0	0.08	0.42	0.83	2.3	
		Week 52	Tezepelumab	9	7 (77.8)	1.52 (1.06)	0.3	0.50	1.08	2.58	3.1	0.94 [-0.11, 1.99]
			Placebo	13	9 (69.2)	0.26 (1.52)	-3.0	0.08	0.42	0.83	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	3.99 (1.06)	1.4	3.42	4.13	4.67	6.7	
			Placebo	52	46 (88.5)	4.06 (0.90)	1.5	3.50	4.21	4.58	5.8	
		Week 4	Tezepelumab	57	52 (91.2)	4.72 (1.13)	1.3	3.92	4.88	5.58	6.8	
			Placebo	52	46 (88.5)	4.72 (0.90)	2.7	4.17	4.63	5.25	6.7	
		Week 8	Tezepelumab	57	54 (94.7)	4.92 (1.17)	2.0	4.00	4.83	5.83	6.8	
			Placebo	52	47 (90.4)	4.82 (1.15)	1.9	4.17	4.67	5.83	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.15 (1.09)	3.0	4.25	5.08	6.08	6.9	
			Placebo	52	47 (90.4)	5.03 (1.02)	2.9	4.17	4.92	5.92	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.14 (1.13)	2.7	4.33	5.13	6.08	7.0	
			Placebo	52	47 (90.4)	4.94 (1.27)	1.3	4.17	4.83	5.92	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.13 (1.11)	2.3	4.25	5.00	6.00	7.0	
			Placebo	52	47 (90.4)	4.82 (1.28)	1.3	4.08	4.75	5.92	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.15 (1.08)	3.1	4.42	5.08	6.08	7.0	
			Placebo	52	47 (90.4)	4.80 (1.27)	1.3	3.92	4.75	5.92	7.0	
		Week 28	Tezepelumab	57	57 (100.0)	5.18 (1.11)	3.2	4.33	5.00	6.17	7.0	
			Placebo	52	47 (90.4)	4.89 (1.35)	1.3	4.00	4.92	6.00	7.0	
		Week 32	Tezepelumab	57	57 (100.0)	5.21 (1.13)	2.8	4.33	5.08	6.08	7.0	
			Placebo	52	47 (90.4)	4.93 (1.19)	1.3	4.25	4.92	5.92	7.0	
		Week 36	Tezepelumab	57	57 (100.0)	5.30 (1.14)	2.9	4.50	5.25	6.17	7.0	
			Placebo	52	47 (90.4)	4.83 (1.18)	2.5	4.00	4.58	5.92	7.0	
		Week 40	Tezepelumab	57	57 (100.0)	5.19 (1.16)	2.3	4.33	5.08	6.00	7.0	
			Placebo	52	47 (90.4)	4.98 (1.15)	2.5	4.08	5.00	6.08	7.0	
		Week 44	Tezepelumab	57	57 (100.0)	5.22 (1.12)	3.0	4.33	5.08	6.08	7.0	
			Placebo	52	47 (90.4)	4.96 (1.14)	2.8	4.08	4.83	5.92	7.0	
		Week 48	Tezepelumab	57	57 (100.0)	5.26 (1.14)	2.8	4.33	5.17	6.17	7.0	
			Placebo	52	47 (90.4)	5.00 (1.12)	2.4	4.17	4.92	6.00	7.0	
		Week 52	Tezepelumab	57	57 (100.0)	5.25 (1.14)	2.8	4.33	5.17	6.17	7.0	
			Placebo	52	47 (90.4)	5.06 (1.09)	2.8	4.25	4.92	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: OCS at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	0.75 (1.16)	-4.3	0.08	0.92	1.50	3.1	0.06 [-0.35, 0.47]
			Placebo	52	45 (86.5)	0.69 (0.86)	-1.3	0.25	0.50	0.92	3.3	
		Week 8	Tezepelumab	57	50 (87.7)	0.87 (1.14)	-1.9	0.17	0.96	1.67	3.3	0.09 [-0.31, 0.49]
			Placebo	52	46 (88.5)	0.77 (1.02)	-1.0	0.17	0.67	1.17	3.6	
		Week 12	Tezepelumab	57	50 (87.7)	1.09 (1.16)	-2.6	0.33	1.08	1.92	3.7	0.10 [-0.30, 0.50]
			Placebo	52	46 (88.5)	0.98 (1.13)	-1.0	0.50	0.75	1.33	4.0	
		Week 16	Tezepelumab	57	50 (87.7)	1.10 (1.13)	-2.9	0.42	1.08	1.75	3.3	0.18 [-0.22, 0.58]
			Placebo	52	46 (88.5)	0.88 (1.28)	-3.5	0.17	0.92	1.33	4.2	
		Week 20	Tezepelumab	57	50 (87.7)	1.11 (1.11)	-1.8	0.33	1.00	2.08	3.3	0.28 [-0.12, 0.69]
			Placebo	52	46 (88.5)	0.78 (1.22)	-3.5	0.17	0.92	1.33	3.8	
		Week 24	Tezepelumab	57	50 (87.7)	1.17 (1.10)	-1.6	0.42	1.17	1.83	3.3	0.36 [-0.05, 0.76]
			Placebo	52	46 (88.5)	0.74 (1.28)	-3.5	0.00	0.88	1.25	3.9	
		Week 28	Tezepelumab	57	50 (87.7)	1.17 (1.12)	-1.7	0.33	1.04	2.08	3.3	0.27 [-0.14, 0.67]
			Placebo	52	46 (88.5)	0.84 (1.32)	-3.5	0.25	0.79	1.42	4.3	
		Week 32	Tezepelumab	57	50 (87.7)	1.19 (1.18)	-1.6	0.33	1.08	2.17	3.3	0.25 [-0.15, 0.65]
			Placebo	52	46 (88.5)	0.90 (1.13)	-3.5	0.42	0.92	1.25	3.5	
		Week 36	Tezepelumab	57	50 (87.7)	1.26 (1.23)	-1.7	0.25	1.21	2.33	3.4	0.41 [0.01, 0.82]
			Placebo	52	46 (88.5)	0.79 (1.04)	-2.3	0.08	0.92	1.25	3.8	
		Week 40	Tezepelumab	57	50 (87.7)	1.19 (1.22)	-1.7	0.25	1.08	2.25	3.4	0.21 [-0.19, 0.61]
			Placebo	52	46 (88.5)	0.94 (1.10)	-1.1	0.33	0.79	1.58	4.0	
		Week 44	Tezepelumab	57	50 (87.7)	1.21 (1.17)	-1.6	0.42	1.17	2.17	3.3	0.26 [-0.14, 0.67]
			Placebo	52	46 (88.5)	0.92 (1.08)	-1.3	0.33	0.92	1.33	3.7	
		Week 48	Tezepelumab	57	50 (87.7)	1.27 (1.16)	-1.6	0.58	1.25	2.17	3.4	0.28 [-0.12, 0.69]
			Placebo	52	46 (88.5)	0.95 (1.03)	-1.1	0.33	1.00	1.50	4.2	
		Week 52	Tezepelumab	57	50 (87.7)	1.25 (1.18)	-1.6	0.42	1.08	2.17	3.6	0.21 [-0.20, 0.61]
			Placebo	52	46 (88.5)	1.01 (1.05)	-1.1	0.33	0.88	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	7	6 (85.7)	4.46 (0.45)	3.8	4.17	4.42	4.92	5.0	
			Placebo	3	2 (66.7)	4.00 (0.47)	3.7	3.67	4.00	4.33	4.3	
		Week 4	Tezepelumab	7	7 (100.0)	5.15 (1.00)	3.9	4.25	5.00	6.33	6.5	
			Placebo	3	3 (100.0)	3.69 (1.37)	2.7	2.67	3.17	5.25	5.3	
		Week 8	Tezepelumab	7	7 (100.0)	5.62 (0.74)	4.5	4.83	5.67	6.25	6.6	
			Placebo	3	3 (100.0)	3.97 (1.35)	2.9	2.92	3.50	5.50	5.5	
		Week 12	Tezepelumab	7	7 (100.0)	5.77 (0.70)	4.9	5.25	5.42	6.42	6.7	
			Placebo	3	3 (100.0)	3.22 (1.03)	2.1	2.08	3.50	4.08	4.1	
		Week 16	Tezepelumab	7	7 (100.0)	5.60 (0.74)	4.6	5.08	5.42	6.25	6.7	
			Placebo	3	3 (100.0)	3.58 (0.73)	2.8	2.75	3.92	4.08	4.1	
		Week 20	Tezepelumab	7	7 (100.0)	5.20 (0.82)	3.8	4.50	5.42	5.92	6.2	
			Placebo	3	3 (100.0)	3.47 (0.57)	2.8	2.83	3.67	3.92	3.9	
		Week 24	Tezepelumab	7	7 (100.0)	5.52 (0.49)	4.9	5.08	5.50	6.00	6.2	
			Placebo	3	3 (100.0)	3.31 (0.48)	2.8	2.75	3.58	3.58	3.6	
		Week 28	Tezepelumab	7	7 (100.0)	5.37 (0.69)	4.5	4.83	5.08	5.92	6.4	
			Placebo	3	3 (100.0)	3.56 (0.63)	2.8	2.83	3.83	4.00	4.0	
		Week 32	Tezepelumab	7	7 (100.0)	5.39 (0.61)	4.3	5.00	5.58	5.92	6.0	
			Placebo	3	3 (100.0)	3.47 (0.41)	3.0	3.00	3.67	3.75	3.8	
		Week 36	Tezepelumab	7	7 (100.0)	5.44 (0.60)	4.6	4.83	5.50	6.08	6.2	
			Placebo	3	3 (100.0)	3.53 (1.02)	2.4	2.42	3.75	4.42	4.4	
		Week 40	Tezepelumab	7	7 (100.0)	5.46 (0.47)	4.8	5.08	5.33	6.00	6.1	
			Placebo	3	3 (100.0)	3.25 (0.87)	2.3	2.25	3.75	3.75	3.8	
		Week 44	Tezepelumab	7	7 (100.0)	5.39 (0.37)	4.8	5.08	5.42	5.75	5.8	
			Placebo	3	3 (100.0)	3.50 (0.88)	2.5	2.50	3.83	4.17	4.2	
		Week 48	Tezepelumab	7	7 (100.0)	5.54 (0.57)	5.0	5.00	5.33	6.08	6.5	
			Placebo	3	3 (100.0)	3.31 (0.99)	2.2	2.17	3.75	4.00	4.0	
		Week 52	Tezepelumab	7	7 (100.0)	5.54 (0.57)	5.0	5.00	5.33	6.08	6.5	
			Placebo	3	3 (100.0)	3.47 (0.67)	2.8	2.75	3.58	4.08	4.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	7	6 (85.7)	0.90 (0.71)	-0.1	0.08	1.25	1.33	1.6	1.10 [-0.61, 2.82]
			Placebo	3	2 (66.7)	-0.04 (1.36)	-1.0	-1.00	-0.04	0.92	0.9	
		Week 8	Tezepelumab	7	6 (85.7)	1.06 (0.71)	0.2	0.33	1.17	1.67	1.8	0.99 [-0.70, 2.69]
			Placebo	3	2 (66.7)	0.21 (1.36)	-0.8	-0.75	0.21	1.17	1.2	
		Week 12	Tezepelumab	7	6 (85.7)	1.21 (0.48)	0.4	1.00	1.25	1.58	1.8	3.63 [1.03, 6.24]
			Placebo	3	2 (66.7)	-0.92 (0.94)	-1.6	-1.58	-0.92	-0.25	-0.3	
		Week 16	Tezepelumab	7	6 (85.7)	1.03 (0.57)	0.3	0.58	1.00	1.58	1.8	2.90 [0.61, 5.19]
			Placebo	3	2 (66.7)	-0.58 (0.47)	-0.9	-0.92	-0.58	-0.25	-0.3	
		Week 20	Tezepelumab	7	6 (85.7)	0.63 (0.48)	0.0	0.17	0.67	1.08	1.2	2.74 [0.51, 4.97]
			Placebo	3	2 (66.7)	-0.63 (0.29)	-0.8	-0.83	-0.63	-0.42	-0.4	
		Week 24	Tezepelumab	7	6 (85.7)	0.96 (0.24)	0.6	0.92	0.96	1.00	1.3	7.98 [3.19, 12.78]
			Placebo	3	2 (66.7)	-0.83 (0.12)	-0.9	-0.92	-0.83	-0.75	-0.8	
		Week 28	Tezepelumab	7	6 (85.7)	0.74 (0.34)	0.2	0.50	0.88	1.00	1.0	3.90 [1.17, 6.63]
			Placebo	3	2 (66.7)	-0.58 (0.35)	-0.8	-0.83	-0.58	-0.33	-0.3	
		Week 32	Tezepelumab	7	6 (85.7)	0.86 (0.23)	0.5	0.67	0.96	1.00	1.1	7.10 [2.78, 11.43]
			Placebo	3	2 (66.7)	-0.63 (0.06)	-0.7	-0.67	-0.63	-0.58	-0.6	
		Week 36	Tezepelumab	7	6 (85.7)	0.86 (0.35)	0.3	0.67	0.88	1.08	1.3	2.88 [0.60, 5.16]
			Placebo	3	2 (66.7)	-0.58 (0.94)	-1.3	-1.25	-0.58	0.08	0.1	
		Week 40	Tezepelumab	7	6 (85.7)	0.90 (0.12)	0.8	0.75	0.96	1.00	1.0	7.17 [2.81, 11.53]
			Placebo	3	2 (66.7)	-1.00 (0.59)	-1.4	-1.42	-1.00	-0.58	-0.6	
		Week 44	Tezepelumab	7	6 (85.7)	0.89 (0.32)	0.6	0.75	0.79	0.92	1.5	4.93 [1.72, 8.15]
			Placebo	3	2 (66.7)	-0.83 (0.47)	-1.2	-1.17	-0.83	-0.50	-0.5	
		Week 48	Tezepelumab	7	6 (85.7)	1.17 (0.28)	0.8	1.00	1.08	1.42	1.6	6.01 [2.25, 9.77]
			Placebo	3	2 (66.7)	-1.04 (0.65)	-1.5	-1.50	-1.04	-0.58	-0.6	
		Week 52	Tezepelumab	7	6 (85.7)	1.17 (0.28)	0.8	1.00	1.08	1.42	1.6	5.48 [1.99, 8.97]
			Placebo	3	2 (66.7)	-0.58 (0.47)	-0.9	-0.92	-0.58	-0.25	-0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Absolute values	Baseline	Tezepelumab	59	52 (88.1)	3.93 (1.05)	1.4	3.25	4.00	4.63	6.7	
			Placebo	62	53 (85.5)	4.13 (0.90)	1.5	3.67	4.25	4.58	6.3	
		Week 4	Tezepelumab	59	53 (89.8)	4.69 (1.12)	1.3	3.92	4.75	5.58	6.8	
			Placebo	62	54 (87.1)	4.77 (0.87)	2.7	4.25	4.67	5.25	6.7	
		Week 8	Tezepelumab	59	55 (93.2)	4.92 (1.18)	2.0	4.00	4.83	5.83	6.8	
			Placebo	62	56 (90.3)	4.78 (1.06)	1.9	4.21	4.67	5.42	7.0	
		Week 12	Tezepelumab	59	55 (93.2)	5.14 (1.10)	3.0	4.25	5.08	6.08	7.0	
			Placebo	62	56 (90.3)	4.97 (1.00)	2.9	4.17	4.92	5.63	7.0	
		Week 16	Tezepelumab	59	55 (93.2)	5.17 (1.14)	2.7	4.33	5.25	6.08	7.0	
			Placebo	62	56 (90.3)	4.92 (1.22)	1.3	4.21	4.79	5.88	7.0	
		Week 20	Tezepelumab	59	56 (94.9)	5.15 (1.14)	2.3	4.25	5.00	6.04	7.0	
			Placebo	62	56 (90.3)	4.82 (1.21)	1.3	4.13	4.88	5.67	7.0	
		Week 24	Tezepelumab	59	56 (94.9)	5.15 (1.13)	3.1	4.25	4.92	6.13	7.0	
			Placebo	62	56 (90.3)	4.81 (1.21)	1.3	3.92	4.75	5.75	7.0	
		Week 28	Tezepelumab	59	58 (98.3)	5.12 (1.15)	3.2	4.08	4.96	6.17	7.0	
			Placebo	62	57 (91.9)	4.91 (1.29)	1.3	4.08	5.00	5.75	7.0	
		Week 32	Tezepelumab	59	58 (98.3)	5.20 (1.17)	2.8	4.25	5.00	6.17	7.0	
			Placebo	62	57 (91.9)	4.97 (1.15)	1.3	4.25	5.00	5.75	7.0	
		Week 36	Tezepelumab	59	58 (98.3)	5.24 (1.18)	2.9	4.25	5.17	6.33	7.0	
			Placebo	62	57 (91.9)	4.88 (1.16)	2.5	4.08	4.83	5.92	7.0	
		Week 40	Tezepelumab	59	58 (98.3)	5.18 (1.22)	2.3	4.25	5.00	6.08	7.0	
			Placebo	62	57 (91.9)	5.00 (1.14)	2.5	4.08	5.08	5.92	7.0	
		Week 44	Tezepelumab	59	58 (98.3)	5.19 (1.16)	3.0	4.17	4.92	6.25	7.0	
			Placebo	62	57 (91.9)	4.98 (1.12)	2.8	4.25	5.00	5.92	7.0	
		Week 48	Tezepelumab	59	58 (98.3)	5.21 (1.19)	2.8	4.17	5.08	6.25	7.0	
			Placebo	62	57 (91.9)	5.02 (1.10)	2.4	4.25	4.92	5.92	7.0	
		Week 52	Tezepelumab	59	58 (98.3)	5.22 (1.19)	2.8	4.17	5.13	6.17	7.0	
			Placebo	62	57 (91.9)	5.07 (1.08)	2.8	4.25	4.92	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: LAMA use at baseline												
No	Change from baseline	Week 4	Tezepelumab	59	49 (83.1)	0.76 (1.14)	-4.3	0.17	0.92	1.50	3.1	0.12 [-0.27, 0.52]
			Placebo	62	52 (83.9)	0.64 (0.86)	-1.3	0.21	0.50	0.96	3.3	
		Week 8	Tezepelumab	59	51 (86.4)	0.94 (1.15)	-1.9	0.25	1.00	1.92	3.3	0.23 [-0.15, 0.62]
			Placebo	62	53 (85.5)	0.68 (1.03)	-1.8	0.17	0.67	1.00	3.6	
		Week 12	Tezepelumab	59	51 (86.4)	1.16 (1.18)	-2.6	0.33	1.08	2.00	3.7	0.27 [-0.12, 0.65]
			Placebo	62	53 (85.5)	0.85 (1.20)	-2.8	0.25	0.75	1.17	4.0	
		Week 16	Tezepelumab	59	51 (86.4)	1.21 (1.17)	-2.9	0.50	1.25	2.08	3.3	0.31 [-0.08, 0.70]
			Placebo	62	53 (85.5)	0.83 (1.32)	-3.5	0.17	0.92	1.33	4.2	
		Week 20	Tezepelumab	59	51 (86.4)	1.22 (1.11)	-1.8	0.42	1.17	2.17	3.3	0.42 [0.03, 0.80]
			Placebo	62	53 (85.5)	0.73 (1.26)	-3.5	0.17	0.83	1.33	3.8	
		Week 24	Tezepelumab	59	51 (86.4)	1.26 (1.13)	-1.6	0.42	1.25	2.25	3.3	0.44 [0.05, 0.83]
			Placebo	62	53 (85.5)	0.72 (1.30)	-3.5	0.00	0.83	1.25	3.9	
		Week 28	Tezepelumab	59	51 (86.4)	1.19 (1.15)	-1.7	0.33	1.25	2.17	3.3	0.32 [-0.07, 0.71]
			Placebo	62	53 (85.5)	0.78 (1.34)	-3.5	0.25	0.83	1.33	4.3	
		Week 32	Tezepelumab	59	51 (86.4)	1.27 (1.19)	-1.6	0.33	1.17	2.25	3.3	0.34 [-0.04, 0.73]
			Placebo	62	53 (85.5)	0.87 (1.18)	-3.5	0.42	0.92	1.25	3.5	
		Week 36	Tezepelumab	59	51 (86.4)	1.30 (1.26)	-1.7	0.25	1.58	2.33	3.4	0.46 [0.07, 0.85]
			Placebo	62	53 (85.5)	0.75 (1.12)	-3.0	0.25	0.92	1.25	3.8	
		Week 40	Tezepelumab	59	51 (86.4)	1.28 (1.25)	-1.7	0.25	1.17	2.33	3.4	0.32 [-0.07, 0.71]
			Placebo	62	53 (85.5)	0.89 (1.18)	-3.0	0.33	0.83	1.58	4.0	
		Week 44	Tezepelumab	59	51 (86.4)	1.27 (1.20)	-1.6	0.42	1.17	2.25	3.3	0.35 [-0.03, 0.74]
			Placebo	62	53 (85.5)	0.85 (1.17)	-3.0	0.33	0.92	1.58	3.7	
		Week 48	Tezepelumab	59	51 (86.4)	1.29 (1.22)	-1.6	0.33	1.33	2.25	3.4	0.33 [-0.05, 0.72]
			Placebo	62	53 (85.5)	0.90 (1.12)	-3.0	0.33	0.92	1.50	4.2	
		Week 52	Tezepelumab	59	51 (86.4)	1.29 (1.22)	-1.6	0.33	1.08	2.33	3.6	0.29 [-0.09, 0.68]
			Placebo	62	53 (85.5)	0.95 (1.14)	-3.0	0.33	0.83	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	4.48 (0.49)	3.8	4.17	4.50	4.92	5.0	
			Placebo	2	1 (50.0)	4.33	4.3	4.33	4.33	4.33	4.3	
		Week 4	Tezepelumab	6	6 (100.0)	5.31 (1.01)	3.9	4.58	5.25	6.33	6.5	
			Placebo	2	2 (100.0)	4.21 (1.47)	3.2	3.17	4.21	5.25	5.3	
		Week 8	Tezepelumab	6	6 (100.0)	5.81 (0.60)	4.8	5.67	5.75	6.25	6.6	
			Placebo	2	2 (100.0)	4.50 (1.41)	3.5	3.50	4.50	5.50	5.5	
		Week 12	Tezepelumab	6	6 (100.0)	5.85 (0.74)	4.9	5.25	5.92	6.42	6.7	
			Placebo	2	2 (100.0)	3.79 (0.41)	3.5	3.50	3.79	4.08	4.1	
		Week 16	Tezepelumab	6	6 (100.0)	5.76 (0.64)	5.1	5.17	5.71	6.25	6.7	
			Placebo	2	2 (100.0)	4.00 (0.12)	3.9	3.92	4.00	4.08	4.1	
		Week 20	Tezepelumab	6	6 (100.0)	5.32 (0.83)	3.8	5.00	5.50	5.92	6.2	
			Placebo	2	2 (100.0)	3.79 (0.18)	3.7	3.67	3.79	3.92	3.9	
		Week 24	Tezepelumab	6	6 (100.0)	5.63 (0.45)	5.1	5.17	5.67	6.00	6.2	
			Placebo	2	2 (100.0)	3.58 (0.00)	3.6	3.58	3.58	3.58	3.6	
		Week 28	Tezepelumab	6	6 (100.0)	5.51 (0.63)	4.8	5.00	5.46	5.92	6.4	
			Placebo	2	2 (100.0)	3.92 (0.12)	3.8	3.83	3.92	4.00	4.0	
		Week 32	Tezepelumab	6	6 (100.0)	5.46 (0.64)	4.3	5.08	5.71	5.92	6.0	
			Placebo	2	2 (100.0)	3.71 (0.06)	3.7	3.67	3.71	3.75	3.8	
		Week 36	Tezepelumab	6	6 (100.0)	5.40 (0.64)	4.6	4.83	5.38	6.08	6.2	
			Placebo	2	2 (100.0)	4.08 (0.47)	3.8	3.75	4.08	4.42	4.4	
		Week 40	Tezepelumab	6	6 (100.0)	5.49 (0.51)	4.8	5.08	5.46	6.00	6.1	
			Placebo	2	2 (100.0)	3.75 (0.00)	3.8	3.75	3.75	3.75	3.8	
		Week 44	Tezepelumab	6	6 (100.0)	5.44 (0.38)	4.8	5.33	5.54	5.75	5.8	
			Placebo	2	2 (100.0)	4.00 (0.24)	3.8	3.83	4.00	4.17	4.2	
		Week 48	Tezepelumab	6	6 (100.0)	5.57 (0.61)	5.0	5.00	5.42	6.08	6.5	
			Placebo	2	2 (100.0)	3.88 (0.18)	3.8	3.75	3.88	4.00	4.0	
		Week 52	Tezepelumab	6	6 (100.0)	5.57 (0.61)	5.0	5.00	5.42	6.08	6.5	
			Placebo	2	2 (100.0)	3.83 (0.35)	3.6	3.58	3.83	4.08	4.1	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	6	5 (83.3)	1.10 (0.59)	0.1	1.17	1.33	1.33	1.6	NE
			Placebo	2	1 (50.0)	0.92	0.9	0.92	0.92	0.92	0.9	
		Week 8	Tezepelumab	6	5 (83.3)	1.23 (0.63)	0.3	0.83	1.50	1.67	1.8	NE
			Placebo	2	1 (50.0)	1.17	1.2	1.17	1.17	1.17	1.2	
		Week 12	Tezepelumab	6	5 (83.3)	1.25 (0.53)	0.4	1.08	1.42	1.58	1.8	NE
			Placebo	2	1 (50.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	
		Week 16	Tezepelumab	6	5 (83.3)	1.18 (0.48)	0.6	1.00	1.00	1.58	1.8	NE
			Placebo	2	1 (50.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	
		Week 20	Tezepelumab	6	5 (83.3)	0.72 (0.48)	0.0	0.50	0.83	1.08	1.2	NE
			Placebo	2	1 (50.0)	-0.42	-0.4	-0.42	-0.42	-0.42	-0.4	
		Week 24	Tezepelumab	6	5 (83.3)	1.03 (0.17)	0.9	0.92	1.00	1.00	1.3	NE
			Placebo	2	1 (50.0)	-0.75	-0.8	-0.75	-0.75	-0.75	-0.8	
		Week 28	Tezepelumab	6	5 (83.3)	0.85 (0.21)	0.5	0.83	0.92	1.00	1.0	NE
			Placebo	2	1 (50.0)	-0.33	-0.3	-0.33	-0.33	-0.33	-0.3	
		Week 32	Tezepelumab	6	5 (83.3)	0.90 (0.23)	0.5	0.92	1.00	1.00	1.1	NE
			Placebo	2	1 (50.0)	-0.58	-0.6	-0.58	-0.58	-0.58	-0.6	
		Week 36	Tezepelumab	6	5 (83.3)	0.77 (0.30)	0.3	0.67	0.75	1.00	1.1	NE
			Placebo	2	1 (50.0)	0.08	0.1	0.08	0.08	0.08	0.1	
		Week 40	Tezepelumab	6	5 (83.3)	0.88 (0.13)	0.8	0.75	0.92	1.00	1.0	NE
			Placebo	2	1 (50.0)	-0.58	-0.6	-0.58	-0.58	-0.58	-0.6	
		Week 44	Tezepelumab	6	5 (83.3)	0.92 (0.35)	0.6	0.75	0.83	0.92	1.5	NE
			Placebo	2	1 (50.0)	-0.50	-0.5	-0.50	-0.50	-0.50	-0.5	
		Week 48	Tezepelumab	6	5 (83.3)	1.20 (0.30)	0.8	1.08	1.08	1.42	1.6	NE
			Placebo	2	1 (50.0)	-0.58	-0.6	-0.58	-0.58	-0.58	-0.6	
		Week 52	Tezepelumab	6	5 (83.3)	1.20 (0.30)	0.8	1.08	1.08	1.42	1.6	NE
			Placebo	2	1 (50.0)	-0.25	-0.3	-0.25	-0.25	-0.25	-0.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	3.94 (1.04)	1.4	3.25	4.00	4.58	6.7	
			Placebo	63	54 (85.7)	4.12 (0.89)	1.5	3.67	4.25	4.58	6.3	
		Week 4	Tezepelumab	60	54 (90.0)	4.68 (1.11)	1.3	3.92	4.75	5.58	6.8	
			Placebo	63	55 (87.3)	4.73 (0.91)	2.7	4.17	4.67	5.25	6.7	
		Week 8	Tezepelumab	60	56 (93.3)	4.91 (1.17)	2.0	4.04	4.79	5.83	6.8	
			Placebo	63	57 (90.5)	4.75 (1.08)	1.9	4.17	4.67	5.42	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.14 (1.09)	3.0	4.29	5.08	6.08	7.0	
			Placebo	63	57 (90.5)	4.92 (1.06)	2.1	4.17	4.92	5.58	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.16 (1.14)	2.7	4.33	5.25	6.08	7.0	
			Placebo	63	57 (90.5)	4.89 (1.24)	1.3	4.17	4.75	5.83	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.14 (1.13)	2.3	4.25	5.00	6.00	7.0	
			Placebo	63	57 (90.5)	4.79 (1.23)	1.3	4.08	4.75	5.58	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.14 (1.12)	3.1	4.33	4.92	6.08	7.0	
			Placebo	63	57 (90.5)	4.78 (1.23)	1.3	3.92	4.75	5.75	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.11 (1.15)	3.2	4.08	4.92	6.17	7.0	
			Placebo	63	58 (92.1)	4.87 (1.31)	1.3	4.00	4.96	5.75	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.20 (1.16)	2.8	4.25	5.00	6.17	7.0	
			Placebo	63	58 (92.1)	4.94 (1.17)	1.3	4.25	4.96	5.75	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.25 (1.17)	2.9	4.25	5.17	6.33	7.0	
			Placebo	63	58 (92.1)	4.84 (1.20)	2.4	4.00	4.79	5.92	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.18 (1.21)	2.3	4.25	5.00	6.08	7.0	
			Placebo	63	58 (92.1)	4.95 (1.19)	2.3	4.00	5.04	5.92	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.19 (1.15)	3.0	4.17	4.92	6.25	7.0	
			Placebo	63	58 (92.1)	4.93 (1.16)	2.5	4.08	4.92	5.92	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.22 (1.18)	2.8	4.17	5.08	6.25	7.0	
			Placebo	63	58 (92.1)	4.97 (1.16)	2.2	4.25	4.88	5.92	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.22 (1.18)	2.8	4.17	5.17	6.17	7.0	
			Placebo	63	58 (92.1)	5.03 (1.12)	2.8	4.25	4.88	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Tiotropium use at baseline												
No	Change from baseline	Week 4	Tezepelumab	60	50 (83.3)	0.74 (1.14)	-4.3	0.08	0.88	1.50	3.1	0.14 [-0.25, 0.52]
			Placebo	63	53 (84.1)	0.61 (0.88)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	60	52 (86.7)	0.92 (1.14)	-1.9	0.21	1.00	1.92	3.3	0.25 [-0.14, 0.63]
			Placebo	63	54 (85.7)	0.66 (1.04)	-1.8	0.08	0.67	1.00	3.6	
		Week 12	Tezepelumab	60	52 (86.7)	1.16 (1.17)	-2.6	0.38	1.08	2.00	3.7	0.30 [-0.08, 0.68]
			Placebo	63	54 (85.7)	0.80 (1.23)	-2.8	0.17	0.75	1.17	4.0	
		Week 16	Tezepelumab	60	52 (86.7)	1.20 (1.16)	-2.9	0.46	1.17	2.08	3.3	0.32 [-0.06, 0.71]
			Placebo	63	54 (85.7)	0.79 (1.33)	-3.5	0.17	0.88	1.33	4.2	
		Week 20	Tezepelumab	60	52 (86.7)	1.20 (1.11)	-1.8	0.42	1.13	2.17	3.3	0.42 [0.04, 0.81]
			Placebo	63	54 (85.7)	0.70 (1.26)	-3.5	0.08	0.83	1.33	3.8	
		Week 24	Tezepelumab	60	52 (86.7)	1.25 (1.13)	-1.6	0.46	1.25	2.21	3.3	0.46 [0.07, 0.84]
			Placebo	63	54 (85.7)	0.69 (1.31)	-3.5	0.00	0.83	1.25	3.9	
		Week 28	Tezepelumab	60	52 (86.7)	1.17 (1.15)	-1.7	0.33	1.17	2.13	3.3	0.33 [-0.06, 0.71]
			Placebo	63	54 (85.7)	0.75 (1.35)	-3.5	0.25	0.83	1.33	4.3	
		Week 32	Tezepelumab	60	52 (86.7)	1.26 (1.19)	-1.6	0.42	1.17	2.21	3.3	0.36 [-0.03, 0.74]
			Placebo	63	54 (85.7)	0.84 (1.19)	-3.5	0.42	0.92	1.25	3.5	
		Week 36	Tezepelumab	60	52 (86.7)	1.30 (1.24)	-1.7	0.25	1.46	2.33	3.4	0.49 [0.11, 0.88]
			Placebo	63	54 (85.7)	0.72 (1.15)	-3.0	0.08	0.88	1.25	3.8	
		Week 40	Tezepelumab	60	52 (86.7)	1.27 (1.24)	-1.7	0.29	1.13	2.29	3.4	0.35 [-0.03, 0.73]
			Placebo	63	54 (85.7)	0.85 (1.21)	-3.0	0.08	0.83	1.58	4.0	
		Week 44	Tezepelumab	60	52 (86.7)	1.26 (1.19)	-1.6	0.46	1.17	2.21	3.3	0.38 [-0.01, 0.76]
			Placebo	63	54 (85.7)	0.82 (1.19)	-3.0	0.33	0.88	1.58	3.7	
		Week 48	Tezepelumab	60	52 (86.7)	1.29 (1.21)	-1.6	0.33	1.25	2.25	3.4	0.36 [-0.02, 0.75]
			Placebo	63	54 (85.7)	0.86 (1.15)	-3.0	0.33	0.88	1.50	4.2	
		Week 52	Tezepelumab	60	52 (86.7)	1.29 (1.21)	-1.6	0.38	1.08	2.29	3.6	0.32 [-0.07, 0.70]
			Placebo	63	54 (85.7)	0.91 (1.16)	-3.0	0.33	0.83	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	17	15 (88.2)	3.63 (1.23)	1.4	3.17	3.58	4.42	6.2	
			Placebo	21	20 (95.2)	4.07 (0.68)	2.7	3.71	4.04	4.50	5.8	
		Week 4	Tezepelumab	17	15 (88.2)	4.53 (0.93)	3.5	3.58	4.50	5.58	6.3	
			Placebo	21	20 (95.2)	4.58 (1.05)	2.7	3.83	4.50	5.25	6.7	
		Week 8	Tezepelumab	17	16 (94.1)	4.94 (1.16)	2.8	4.00	4.96	5.96	6.8	
			Placebo	21	21 (100.0)	4.68 (1.08)	2.9	4.08	4.58	5.33	7.0	
		Week 12	Tezepelumab	17	16 (94.1)	5.23 (1.11)	3.5	4.33	5.38	6.25	7.0	
			Placebo	21	21 (100.0)	4.87 (1.16)	2.1	4.17	4.92	5.50	7.0	
		Week 16	Tezepelumab	17	16 (94.1)	5.18 (1.18)	3.0	4.38	5.46	6.04	7.0	
			Placebo	21	21 (100.0)	4.92 (1.37)	1.3	4.25	5.17	5.75	7.0	
		Week 20	Tezepelumab	17	16 (94.1)	5.13 (1.16)	2.3	4.33	5.67	5.96	6.6	
			Placebo	21	21 (100.0)	4.73 (1.27)	1.3	4.33	5.00	5.50	7.0	
		Week 24	Tezepelumab	17	16 (94.1)	5.29 (1.11)	3.1	4.46	5.83	6.13	6.6	
			Placebo	21	21 (100.0)	4.53 (1.28)	1.3	3.75	4.67	5.33	7.0	
		Week 28	Tezepelumab	17	16 (94.1)	5.03 (1.12)	3.2	4.04	5.13	5.96	6.8	
			Placebo	21	21 (100.0)	4.88 (1.56)	1.3	3.75	5.08	6.00	7.0	
		Week 32	Tezepelumab	17	16 (94.1)	5.10 (1.17)	2.8	4.38	5.54	5.96	6.8	
			Placebo	21	21 (100.0)	4.97 (1.34)	1.3	4.33	5.17	5.75	7.0	
		Week 36	Tezepelumab	17	16 (94.1)	5.03 (1.14)	2.9	4.21	5.13	6.08	6.3	
			Placebo	21	21 (100.0)	4.55 (1.23)	2.4	3.75	4.50	5.17	7.0	
		Week 40	Tezepelumab	17	16 (94.1)	5.31 (1.15)	3.1	4.38	5.75	6.08	7.0	
			Placebo	21	21 (100.0)	4.86 (1.25)	2.3	3.83	5.08	5.75	7.0	
		Week 44	Tezepelumab	17	16 (94.1)	5.21 (1.02)	3.1	4.38	5.21	6.04	6.6	
			Placebo	21	21 (100.0)	4.78 (1.25)	2.5	4.00	4.58	5.67	7.0	
		Week 48	Tezepelumab	17	16 (94.1)	4.97 (1.19)	2.8	4.13	4.88	6.08	6.6	
			Placebo	21	21 (100.0)	4.81 (1.12)	2.2	4.00	4.75	5.17	7.0	
		Week 52	Tezepelumab	17	16 (94.1)	5.07 (1.25)	2.8	4.13	5.21	6.08	6.8	
			Placebo	21	21 (100.0)	4.87 (1.11)	2.8	4.00	4.75	5.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline											
Yes	Change from baseline	Week 4	Tezepelumab	17	13 (76.5)	0.85 (1.05)	-1.4	0.17	1.33	1.50	2.4	0.28 [-0.43, 0.99]
			Placebo	21	19 (90.5)	0.62 (0.64)	-1.0	0.33	0.58	1.17	1.6	
		Week 8	Tezepelumab	17	14 (82.4)	1.15 (1.12)	-1.4	0.83	1.42	2.00	2.3	0.48 [-0.21, 1.17]
			Placebo	21	20 (95.2)	0.67 (0.94)	-0.8	0.13	0.58	1.00	2.7	
		Week 12	Tezepelumab	17	14 (82.4)	1.43 (1.16)	-1.4	1.08	1.71	2.17	3.0	0.49 [-0.20, 1.19]
			Placebo	21	20 (95.2)	0.87 (1.13)	-1.6	0.50	0.75	1.00	4.0	
		Week 16	Tezepelumab	17	14 (82.4)	1.37 (1.17)	-1.4	1.00	1.33	2.42	3.0	0.35 [-0.34, 1.04]
			Placebo	21	20 (95.2)	0.90 (1.46)	-3.5	0.63	0.92	1.58	4.2	
		Week 20	Tezepelumab	17	14 (82.4)	1.36 (1.17)	-1.4	0.67	1.42	2.33	3.0	0.52 [-0.17, 1.22]
			Placebo	21	20 (95.2)	0.71 (1.31)	-3.5	0.42	0.88	1.67	2.4	
		Week 24	Tezepelumab	17	14 (82.4)	1.54 (1.25)	-1.4	1.00	1.63	2.67	3.0	0.77 [0.06, 1.48]
			Placebo	21	20 (95.2)	0.50 (1.41)	-3.5	-0.04	0.83	1.33	2.7	
		Week 28	Tezepelumab	17	14 (82.4)	1.19 (1.29)	-1.4	0.50	1.17	2.08	3.0	0.22 [-0.47, 0.90]
			Placebo	21	20 (95.2)	0.86 (1.65)	-3.5	0.29	1.04	1.79	4.3	
		Week 32	Tezepelumab	17	14 (82.4)	1.36 (1.29)	-1.4	1.00	1.54	2.33	3.0	0.31 [-0.38, 0.99]
			Placebo	21	20 (95.2)	0.96 (1.31)	-3.5	0.79	1.00	1.67	2.9	
		Week 36	Tezepelumab	17	14 (82.4)	1.24 (1.36)	-1.4	0.25	1.08	2.33	3.2	0.58 [-0.12, 1.28]
			Placebo	21	20 (95.2)	0.52 (1.17)	-2.3	-0.17	0.83	1.21	2.4	
		Week 40	Tezepelumab	17	14 (82.4)	1.56 (1.33)	-1.4	1.00	1.63	2.58	3.4	0.54 [-0.15, 1.24]
			Placebo	21	20 (95.2)	0.84 (1.32)	-1.4	-0.13	0.75	1.71	4.0	
		Week 44	Tezepelumab	17	14 (82.4)	1.47 (1.34)	-1.4	0.50	1.33	2.42	3.3	0.58 [-0.12, 1.27]
			Placebo	21	20 (95.2)	0.74 (1.21)	-1.3	-0.04	0.88	1.50	3.4	
		Week 48	Tezepelumab	17	14 (82.4)	1.25 (1.45)	-1.4	0.25	1.21	2.42	3.2	0.39 [-0.30, 1.08]
			Placebo	21	20 (95.2)	0.78 (0.96)	-1.5	0.42	1.00	1.21	2.4	
		Week 52	Tezepelumab	17	14 (82.4)	1.37 (1.48)	-1.4	0.33	1.08	2.67	3.6	0.43 [-0.26, 1.12]
			Placebo	21	20 (95.2)	0.86 (0.94)	-1.1	0.42	1.00	1.42	2.4	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline												
No	Absolute values	Baseline	Tezepelumab	49	43 (87.8)	4.11 (0.91)	2.1	3.75	4.17	4.67	6.7	
			Placebo	44	35 (79.5)	4.15 (0.99)	1.5	3.50	4.33	4.75	6.3	
		Week 4	Tezepelumab	49	45 (91.8)	4.81 (1.16)	1.3	4.08	4.92	5.67	6.8	
			Placebo	44	37 (84.1)	4.78 (0.84)	2.7	4.25	4.67	5.25	6.5	
		Week 8	Tezepelumab	49	46 (93.9)	5.02 (1.17)	2.0	4.08	5.00	5.83	6.8	
			Placebo	44	38 (86.4)	4.77 (1.10)	1.9	4.25	4.67	5.75	6.7	
		Week 12	Tezepelumab	49	46 (93.9)	5.20 (1.08)	3.0	4.33	5.13	6.17	6.9	
			Placebo	44	38 (86.4)	4.89 (1.02)	2.9	4.17	4.75	5.58	6.8	
		Week 16	Tezepelumab	49	46 (93.9)	5.23 (1.10)	2.7	4.33	5.25	6.08	6.9	
			Placebo	44	38 (86.4)	4.82 (1.16)	2.1	4.08	4.67	5.92	7.0	
		Week 20	Tezepelumab	49	47 (95.9)	5.17 (1.10)	3.6	4.17	5.00	6.25	7.0	
			Placebo	44	38 (86.4)	4.77 (1.21)	2.1	4.00	4.71	5.58	6.8	
		Week 24	Tezepelumab	49	47 (95.9)	5.16 (1.08)	3.3	4.33	4.92	5.92	7.0	
			Placebo	44	38 (86.4)	4.85 (1.20)	2.2	3.92	4.71	5.92	6.8	
		Week 28	Tezepelumab	49	49 (100.0)	5.18 (1.12)	3.3	4.33	5.00	6.17	7.0	
			Placebo	44	39 (88.6)	4.82 (1.15)	1.8	4.00	4.75	5.67	6.8	
		Week 32	Tezepelumab	49	49 (100.0)	5.26 (1.12)	3.5	4.25	5.08	6.17	7.0	
			Placebo	44	39 (88.6)	4.86 (1.09)	2.8	4.00	4.92	5.75	6.8	
		Week 36	Tezepelumab	49	49 (100.0)	5.34 (1.13)	3.3	4.50	5.25	6.42	7.0	
			Placebo	44	39 (88.6)	4.95 (1.15)	2.8	4.17	4.83	6.00	6.9	
		Week 40	Tezepelumab	49	49 (100.0)	5.18 (1.17)	2.3	4.33	5.08	5.83	7.0	
			Placebo	44	39 (88.6)	4.94 (1.16)	2.5	4.00	4.92	6.08	7.0	
		Week 44	Tezepelumab	49	49 (100.0)	5.22 (1.14)	3.0	4.17	5.08	6.08	7.0	
			Placebo	44	39 (88.6)	4.97 (1.11)	2.8	4.25	4.83	5.92	6.9	
		Week 48	Tezepelumab	49	49 (100.0)	5.34 (1.13)	3.1	4.33	5.25	6.33	7.0	
			Placebo	44	39 (88.6)	5.00 (1.18)	2.4	4.17	5.17	6.00	6.9	
		Week 52	Tezepelumab	49	49 (100.0)	5.31 (1.11)	3.1	4.33	5.17	6.17	7.0	
			Placebo	44	39 (88.6)	5.06 (1.13)	2.8	4.25	4.92	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHK: Change from baseline in AQLQ+12 symptom score by key subgroups
DITTL

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Montelukast/ Cromoglicic acid use at baseline											
No	Change from baseline	Week 4	Tezepelumab	49	42 (85.7)	0.75 (1.12)	-4.3	0.08	0.92	1.33	3.1	0.14 [-0.31, 0.59]
			Placebo	44	35 (79.5)	0.61 (0.99)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	49	43 (87.8)	0.89 (1.11)	-1.9	0.17	0.92	1.75	3.3	0.20 [-0.25, 0.65]
			Placebo	44	35 (79.5)	0.67 (1.09)	-1.8	0.00	0.67	1.17	3.6	
		Week 12	Tezepelumab	49	43 (87.8)	1.08 (1.12)	-2.6	0.42	1.00	1.83	3.7	0.29 [-0.16, 0.74]
			Placebo	44	35 (79.5)	0.73 (1.29)	-2.8	-0.08	0.75	1.25	3.8	
		Week 16	Tezepelumab	49	43 (87.8)	1.14 (1.11)	-2.9	0.50	1.08	2.08	3.3	0.37 [-0.08, 0.82]
			Placebo	44	35 (79.5)	0.70 (1.25)	-3.0	0.08	0.83	1.25	3.7	
		Week 20	Tezepelumab	49	43 (87.8)	1.09 (1.05)	-1.8	0.42	0.92	2.00	3.3	0.38 [-0.07, 0.83]
			Placebo	44	35 (79.5)	0.66 (1.25)	-3.0	0.08	0.75	1.25	3.8	
		Week 24	Tezepelumab	49	43 (87.8)	1.13 (1.01)	-1.6	0.42	1.00	1.83	3.3	0.33 [-0.12, 0.78]
			Placebo	44	35 (79.5)	0.76 (1.27)	-3.0	0.00	0.92	1.25	3.9	
		Week 28	Tezepelumab	49	43 (87.8)	1.12 (1.05)	-1.7	0.33	1.00	2.00	3.3	0.42 [-0.03, 0.87]
			Placebo	44	35 (79.5)	0.66 (1.15)	-3.0	0.08	0.67	1.17	3.8	
		Week 32	Tezepelumab	49	43 (87.8)	1.19 (1.10)	-1.6	0.50	1.08	2.08	3.3	0.42 [-0.03, 0.87]
			Placebo	44	35 (79.5)	0.73 (1.13)	-3.0	0.17	0.83	1.17	3.5	
		Week 36	Tezepelumab	49	43 (87.8)	1.26 (1.16)	-1.7	0.33	1.33	2.17	3.4	0.39 [-0.06, 0.84]
			Placebo	44	35 (79.5)	0.81 (1.13)	-3.0	0.08	0.92	1.25	3.8	
		Week 40	Tezepelumab	49	43 (87.8)	1.13 (1.13)	-1.7	0.33	1.00	2.17	3.3	0.29 [-0.16, 0.73]
			Placebo	44	35 (79.5)	0.81 (1.16)	-3.0	0.08	0.83	1.42	3.4	
		Week 44	Tezepelumab	49	43 (87.8)	1.16 (1.08)	-1.6	0.50	1.00	2.08	3.2	0.30 [-0.15, 0.74]
			Placebo	44	35 (79.5)	0.82 (1.20)	-3.0	0.25	0.75	1.58	3.7	
		Week 48	Tezepelumab	49	43 (87.8)	1.29 (1.07)	-1.6	0.58	1.17	2.08	3.4	0.37 [-0.08, 0.82]
			Placebo	44	35 (79.5)	0.86 (1.27)	-3.0	0.25	0.67	1.67	4.2	
		Week 52	Tezepelumab	49	43 (87.8)	1.25 (1.06)	-1.6	0.50	1.08	2.08	3.4	0.30 [-0.15, 0.74]
			Placebo	44	35 (79.5)	0.91 (1.28)	-3.0	0.25	0.75	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Absolute values	Baseline	Tezepelumab	60	52 (86.7)	3.97 (1.02)	1.4	3.42	4.00	4.54	6.7	
			Placebo	58	48 (82.8)	4.20 (0.83)	1.7	3.71	4.29	4.63	6.3	
		Week 4	Tezepelumab	60	54 (90.0)	4.65 (1.10)	1.3	3.92	4.75	5.50	6.8	
			Placebo	58	50 (86.2)	4.76 (0.92)	2.7	4.17	4.67	5.25	6.7	
		Week 8	Tezepelumab	60	56 (93.3)	4.93 (1.16)	2.0	4.08	4.83	5.83	6.8	
			Placebo	58	52 (89.7)	4.79 (1.07)	2.1	4.17	4.67	5.46	7.0	
		Week 12	Tezepelumab	60	56 (93.3)	5.14 (1.07)	3.0	4.33	5.08	6.08	7.0	
			Placebo	58	52 (89.7)	4.86 (1.06)	2.1	4.13	4.67	5.54	7.0	
		Week 16	Tezepelumab	60	56 (93.3)	5.15 (1.13)	2.7	4.33	5.21	6.08	7.0	
			Placebo	58	52 (89.7)	4.85 (1.20)	1.3	4.13	4.71	5.79	7.0	
		Week 20	Tezepelumab	60	57 (95.0)	5.08 (1.11)	2.3	4.25	5.00	6.00	7.0	
			Placebo	58	52 (89.7)	4.84 (1.20)	1.3	4.08	4.88	5.67	7.0	
		Week 24	Tezepelumab	60	57 (95.0)	5.13 (1.09)	3.1	4.33	4.92	6.08	7.0	
			Placebo	58	52 (89.7)	4.76 (1.25)	1.3	3.92	4.71	5.75	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.07 (1.12)	3.2	4.08	4.92	6.08	7.0	
			Placebo	58	53 (91.4)	4.78 (1.27)	1.3	4.00	4.83	5.67	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.18 (1.15)	2.8	4.25	5.08	6.17	7.0	
			Placebo	58	53 (91.4)	4.89 (1.18)	1.3	4.08	4.92	5.75	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.20 (1.15)	2.9	4.25	5.17	6.17	7.0	
			Placebo	58	53 (91.4)	4.87 (1.19)	2.4	4.08	4.75	5.92	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.16 (1.18)	2.3	4.25	5.08	6.08	7.0	
			Placebo	58	53 (91.4)	4.93 (1.18)	2.3	4.00	4.92	5.92	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.17 (1.12)	3.0	4.17	5.08	6.08	7.0	
			Placebo	58	53 (91.4)	4.91 (1.13)	2.5	4.17	4.75	5.83	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.19 (1.17)	2.8	4.17	5.08	6.17	7.0	
			Placebo	58	53 (91.4)	4.95 (1.15)	2.2	4.25	4.75	5.75	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.19 (1.16)	2.8	4.17	5.08	6.17	7.0	
			Placebo	58	53 (91.4)	5.00 (1.09)	2.8	4.25	4.75	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
White	Change from baseline	Week 4	Tezepelumab	60	49 (81.7)	0.69 (1.08)	-4.3	0.08	0.83	1.33	2.4	0.10 [-0.30, 0.50]
			Placebo	58	47 (81.0)	0.59 (0.89)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	60	51 (85.0)	0.88 (1.06)	-1.9	0.25	1.00	1.67	2.8	0.22 [-0.17, 0.62]
			Placebo	58	48 (82.8)	0.65 (1.04)	-1.8	0.08	0.67	1.08	3.6	
		Week 12	Tezepelumab	60	51 (85.0)	1.09 (1.08)	-2.6	0.42	1.08	1.92	3.3	0.36 [-0.03, 0.76]
			Placebo	58	48 (82.8)	0.68 (1.18)	-2.8	0.04	0.75	1.17	3.8	
		Week 16	Tezepelumab	60	51 (85.0)	1.12 (1.11)	-2.9	0.50	1.08	2.08	3.3	0.36 [-0.04, 0.76]
			Placebo	58	48 (82.8)	0.70 (1.25)	-3.5	0.17	0.83	1.21	3.7	
		Week 20	Tezepelumab	60	51 (85.0)	1.09 (1.06)	-1.8	0.42	1.00	2.00	3.3	0.34 [-0.06, 0.73]
			Placebo	58	48 (82.8)	0.70 (1.27)	-3.5	0.08	0.83	1.25	3.8	
		Week 24	Tezepelumab	60	51 (85.0)	1.17 (1.05)	-1.6	0.50	1.17	1.92	3.3	0.46 [0.06, 0.86]
			Placebo	58	48 (82.8)	0.63 (1.34)	-3.5	0.00	0.83	1.17	3.9	
		Week 28	Tezepelumab	60	51 (85.0)	1.07 (1.08)	-1.7	0.33	1.00	2.00	3.3	0.40 [-0.00, 0.79]
			Placebo	58	48 (82.8)	0.60 (1.29)	-3.5	0.08	0.75	1.21	3.8	
		Week 32	Tezepelumab	60	51 (85.0)	1.20 (1.13)	-1.6	0.50	1.08	2.08	3.3	0.39 [-0.01, 0.79]
			Placebo	58	48 (82.8)	0.74 (1.21)	-3.5	0.33	0.92	1.17	3.5	
		Week 36	Tezepelumab	60	51 (85.0)	1.19 (1.21)	-1.7	0.25	1.08	2.17	3.4	0.43 [0.03, 0.82]
			Placebo	58	48 (82.8)	0.69 (1.15)	-3.0	0.08	0.83	1.17	3.8	
		Week 40	Tezepelumab	60	51 (85.0)	1.20 (1.18)	-1.7	0.50	1.08	2.17	3.4	0.37 [-0.03, 0.77]
			Placebo	58	48 (82.8)	0.76 (1.18)	-3.0	0.04	0.83	1.42	3.4	
		Week 44	Tezepelumab	60	51 (85.0)	1.19 (1.12)	-1.6	0.50	1.17	2.08	3.3	0.41 [0.01, 0.81]
			Placebo	58	48 (82.8)	0.73 (1.11)	-3.0	0.29	0.83	1.29	3.7	
		Week 48	Tezepelumab	60	51 (85.0)	1.23 (1.16)	-1.6	0.33	1.17	2.08	3.4	0.39 [-0.01, 0.79]
			Placebo	58	48 (82.8)	0.77 (1.17)	-3.0	0.25	0.79	1.29	4.2	
		Week 52	Tezepelumab	60	51 (85.0)	1.23 (1.16)	-1.6	0.42	1.08	2.08	3.6	0.35 [-0.05, 0.75]
			Placebo	58	48 (82.8)	0.82 (1.13)	-3.0	0.25	0.79	1.42	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Absolute values	Baseline	Tezepelumab	6	6 (100.0)	4.10 (0.99)	2.6	3.17	4.50	4.83	5.0	
			Placebo	7	7 (100.0)	3.60 (1.15)	1.5	2.67	4.25	4.42	4.5	
		Week 4	Tezepelumab	6	6 (100.0)	5.60 (0.85)	4.5	4.58	5.92	6.33	6.3	
			Placebo	7	7 (100.0)	4.35 (0.86)	3.0	3.42	4.50	5.17	5.3	
		Week 8	Tezepelumab	6	6 (100.0)	5.68 (1.00)	4.0	5.08	5.88	6.58	6.7	
			Placebo	7	7 (100.0)	4.40 (1.23)	1.9	4.25	4.50	5.33	5.8	
		Week 12	Tezepelumab	6	6 (100.0)	5.89 (0.99)	4.2	5.33	6.25	6.42	6.9	
			Placebo	7	7 (100.0)	5.05 (1.12)	3.3	4.17	5.00	5.92	6.7	
		Week 16	Tezepelumab	6	6 (100.0)	5.90 (0.58)	5.1	5.67	5.88	6.08	6.8	
			Placebo	7	7 (100.0)	4.89 (1.55)	2.1	4.00	5.00	5.92	6.8	
		Week 20	Tezepelumab	6	6 (100.0)	5.85 (0.79)	4.6	5.50	5.92	6.25	6.9	
			Placebo	7	7 (100.0)	4.14 (1.31)	2.1	3.17	4.42	5.00	6.1	
		Week 24	Tezepelumab	6	6 (100.0)	5.81 (0.86)	4.3	5.50	5.96	6.17	6.9	
			Placebo	7	7 (100.0)	4.54 (1.11)	3.2	3.42	4.67	5.33	6.1	
		Week 28	Tezepelumab	6	6 (100.0)	5.82 (0.80)	4.6	5.50	5.79	6.25	7.0	
			Placebo	7	7 (100.0)	5.26 (1.49)	3.2	3.42	5.50	6.58	7.0	
		Week 32	Tezepelumab	6	6 (100.0)	5.63 (0.80)	4.8	4.83	5.63	6.00	6.9	
			Placebo	7	7 (100.0)	4.92 (1.20)	3.2	3.42	5.25	6.08	6.1	
		Week 36	Tezepelumab	6	6 (100.0)	5.89 (0.69)	4.9	5.50	5.92	6.08	7.0	
			Placebo	7	7 (100.0)	4.38 (1.16)	3.2	3.17	4.58	5.42	6.1	
		Week 40	Tezepelumab	6	6 (100.0)	5.69 (0.86)	4.6	5.00	5.75	6.08	7.0	
			Placebo	7	7 (100.0)	4.81 (1.31)	3.2	3.42	5.08	6.08	6.7	
		Week 44	Tezepelumab	6	6 (100.0)	5.71 (0.92)	4.6	4.92	5.63	6.50	7.0	
			Placebo	7	7 (100.0)	4.81 (1.39)	3.2	3.17	4.83	6.17	6.3	
		Week 48	Tezepelumab	6	6 (100.0)	5.83 (0.71)	5.1	5.17	5.79	6.25	6.9	
			Placebo	7	7 (100.0)	4.82 (1.23)	3.2	3.83	4.92	6.17	6.5	
		Week 52	Tezepelumab	6	6 (100.0)	5.83 (0.71)	5.1	5.17	5.79	6.25	6.9	
			Placebo	7	7 (100.0)	4.94 (1.41)	3.2	3.83	4.92	6.50	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Race (cat. P)												
Non-white	Change from baseline	Week 4	Tezepelumab	6	6 (100.0)	1.50 (1.08)	-0.3	1.33	1.42	2.00	3.1	0.80 [-0.34, 1.94]
			Placebo	7	7 (100.0)	0.75 (0.79)	0.0	0.08	0.33	1.75	1.9	
		Week 8	Tezepelumab	6	6 (100.0)	1.58 (1.43)	-0.8	0.83	1.92	2.33	3.3	0.64 [-0.49, 1.76]
			Placebo	7	7 (100.0)	0.81 (1.00)	-0.3	0.08	0.42	1.50	2.7	
		Week 12	Tezepelumab	6	6 (100.0)	1.79 (1.42)	-0.7	1.42	2.04	2.25	3.7	0.24 [-0.86, 1.33]
			Placebo	7	7 (100.0)	1.45 (1.45)	-0.2	0.50	0.92	2.67	4.0	
		Week 16	Tezepelumab	6	6 (100.0)	1.81 (1.05)	0.3	1.00	1.96	2.50	3.2	0.34 [-0.76, 1.44]
			Placebo	7	7 (100.0)	1.30 (1.77)	-1.3	0.08	1.42	2.50	4.2	
		Week 20	Tezepelumab	6	6 (100.0)	1.75 (1.14)	-0.3	1.17	2.08	2.50	2.9	0.98 [-0.18, 2.15]
			Placebo	7	7 (100.0)	0.55 (1.29)	-1.3	-0.83	0.58	1.75	1.8	
		Week 24	Tezepelumab	6	6 (100.0)	1.71 (1.28)	-0.5	1.00	2.04	2.75	2.9	0.63 [-0.49, 1.75]
			Placebo	7	7 (100.0)	0.94 (1.17)	-0.7	0.00	0.83	1.83	2.7	
		Week 28	Tezepelumab	6	6 (100.0)	1.72 (1.20)	-0.3	0.83	2.13	2.58	2.9	0.04 [-1.05, 1.13]
			Placebo	7	7 (100.0)	1.67 (1.39)	0.0	0.67	1.67	2.17	4.3	
		Week 32	Tezepelumab	6	6 (100.0)	1.53 (1.22)	-0.1	0.50	1.63	2.58	2.9	0.19 [-0.91, 1.28]
			Placebo	7	7 (100.0)	1.32 (1.00)	0.0	0.33	1.67	1.83	2.9	
		Week 36	Tezepelumab	6	6 (100.0)	1.79 (1.09)	0.1	1.08	1.96	2.75	2.9	0.89 [-0.26, 2.04]
			Placebo	7	7 (100.0)	0.79 (1.16)	-1.3	0.00	0.92	1.83	1.9	
		Week 40	Tezepelumab	6	6 (100.0)	1.60 (1.28)	0.2	0.25	1.67	2.92	2.9	0.28 [-0.82, 1.37]
			Placebo	7	7 (100.0)	1.21 (1.45)	-0.3	0.00	0.67	1.83	4.0	
		Week 44	Tezepelumab	6	6 (100.0)	1.61 (1.42)	0.1	0.25	1.54	2.92	3.3	0.25 [-0.85, 1.35]
			Placebo	7	7 (100.0)	1.21 (1.71)	-1.3	-0.42	1.67	2.75	3.4	
		Week 48	Tezepelumab	6	6 (100.0)	1.74 (1.17)	0.3	0.75	1.67	2.92	3.1	0.45 [-0.65, 1.56]
			Placebo	7	7 (100.0)	1.23 (1.09)	-0.4	0.50	1.17	2.25	2.8	
		Week 52	Tezepelumab	6	6 (100.0)	1.74 (1.17)	0.3	0.75	1.67	2.92	3.1	0.31 [-0.78, 1.41]
			Placebo	7	7 (100.0)	1.35 (1.31)	-0.4	0.50	1.17	2.25	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Absolute values	Baseline	Tezepelumab	6	5 (83.3)	3.77 (1.72)	1.4	2.58	4.33	5.00	5.5	
			Placebo	4	3 (75.0)	3.53 (0.67)	2.9	2.92	3.42	4.25	4.3	
		Week 4	Tezepelumab	6	4 (66.7)	5.79 (0.55)	5.1	5.38	5.88	6.21	6.3	
			Placebo	4	3 (75.0)	5.14 (0.88)	4.3	4.25	5.17	6.00	6.0	
		Week 8	Tezepelumab	6	5 (83.3)	5.55 (1.16)	3.6	5.75	5.83	5.92	6.7	
			Placebo	4	3 (75.0)	5.53 (1.10)	4.3	4.33	5.75	6.50	6.5	
		Week 12	Tezepelumab	6	5 (83.3)	5.77 (0.77)	4.4	5.83	6.08	6.25	6.3	
			Placebo	4	3 (75.0)	5.31 (1.83)	3.3	3.25	5.92	6.75	6.8	
		Week 16	Tezepelumab	6	5 (83.3)	5.60 (0.67)	4.4	5.75	5.83	5.92	6.1	
			Placebo	4	3 (75.0)	4.86 (2.43)	2.1	2.08	5.92	6.58	6.6	
		Week 20	Tezepelumab	6	5 (83.3)	5.63 (0.73)	4.4	5.50	6.00	6.00	6.3	
			Placebo	4	3 (75.0)	4.97 (2.52)	2.1	2.08	6.08	6.75	6.8	
		Week 24	Tezepelumab	6	5 (83.3)	5.45 (0.65)	4.4	5.42	5.50	5.75	6.2	
			Placebo	4	3 (75.0)	5.44 (1.80)	3.4	3.42	6.08	6.83	6.8	
		Week 28	Tezepelumab	6	6 (100.0)	5.69 (0.80)	4.4	5.42	5.67	6.25	6.8	
			Placebo	4	3 (75.0)	5.39 (1.73)	3.4	3.42	6.08	6.67	6.7	
		Week 32	Tezepelumab	6	6 (100.0)	5.51 (0.80)	4.4	4.83	5.67	5.83	6.7	
			Placebo	4	3 (75.0)	5.22 (1.56)	3.4	3.42	6.08	6.17	6.2	
		Week 36	Tezepelumab	6	6 (100.0)	5.50 (0.79)	4.4	5.17	5.38	5.92	6.8	
			Placebo	4	3 (75.0)	5.00 (1.40)	3.4	3.42	5.50	6.08	6.1	
		Week 40	Tezepelumab	6	6 (100.0)	5.33 (0.88)	4.4	4.58	5.17	6.00	6.7	
			Placebo	4	3 (75.0)	5.08 (1.45)	3.4	3.42	5.75	6.08	6.1	
		Week 44	Tezepelumab	6	6 (100.0)	5.40 (0.79)	4.4	4.58	5.50	5.92	6.5	
			Placebo	4	3 (75.0)	6.06 (0.27)	5.8	5.75	6.17	6.25	6.3	
		Week 48	Tezepelumab	6	6 (100.0)	5.56 (0.75)	4.4	5.08	5.58	6.17	6.5	
			Placebo	4	3 (75.0)	6.11 (0.42)	5.7	5.67	6.17	6.50	6.5	
		Week 52	Tezepelumab	6	6 (100.0)	5.63 (0.82)	4.4	5.08	5.67	6.17	6.8	
			Placebo	4	3 (75.0)	6.39 (0.67)	5.7	5.67	6.50	7.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
North America/Western EU	Change from baseline	Week 4	Tezepelumab	6	4 (66.7)	1.44 (1.48)	-0.4	0.33	1.54	2.54	3.1	-0.12 [-1.61, 1.38]
			Placebo	4	3 (75.0)	1.61 (1.55)	0.0	0.00	1.75	3.08	3.1	
		Week 8	Tezepelumab	6	5 (83.3)	1.78 (1.24)	0.3	0.83	2.17	2.33	3.3	-0.17 [-1.60, 1.27]
			Placebo	4	3 (75.0)	2.00 (1.40)	0.9	0.92	1.50	3.58	3.6	
		Week 12	Tezepelumab	6	5 (83.3)	2.00 (1.36)	0.3	1.08	1.92	3.00	3.7	0.14 [-1.29, 1.57]
			Placebo	4	3 (75.0)	1.78 (2.00)	-0.2	-0.17	1.67	3.83	3.8	
		Week 16	Tezepelumab	6	5 (83.3)	1.83 (1.24)	0.4	0.83	1.75	3.00	3.2	0.28 [-1.16, 1.72]
			Placebo	4	3 (75.0)	1.33 (2.52)	-1.3	-1.33	1.67	3.67	3.7	
		Week 20	Tezepelumab	6	5 (83.3)	1.87 (1.12)	0.5	1.00	1.92	2.92	3.0	0.24 [-1.20, 1.68]
			Placebo	4	3 (75.0)	1.44 (2.61)	-1.3	-1.33	1.83	3.83	3.8	
		Week 24	Tezepelumab	6	5 (83.3)	1.68 (1.32)	0.3	0.42	1.83	2.92	3.0	-0.15 [-1.58, 1.28]
			Placebo	4	3 (75.0)	1.92 (1.96)	0.0	0.00	1.83	3.92	3.9	
		Week 28	Tezepelumab	6	5 (83.3)	1.72 (1.30)	0.3	0.42	1.92	2.92	3.0	-0.10 [-1.53, 1.34]
			Placebo	4	3 (75.0)	1.86 (1.88)	0.0	0.00	1.83	3.75	3.8	
		Week 32	Tezepelumab	6	5 (83.3)	1.52 (1.33)	0.3	0.50	0.83	2.92	3.0	-0.12 [-1.56, 1.31]
			Placebo	4	3 (75.0)	1.69 (1.63)	0.0	0.00	1.83	3.25	3.3	
		Week 36	Tezepelumab	6	5 (83.3)	1.48 (1.51)	-0.3	0.17	1.58	2.92	3.0	0.01 [-1.42, 1.44]
			Placebo	4	3 (75.0)	1.47 (1.33)	0.0	0.00	1.83	2.58	2.6	
		Week 40	Tezepelumab	6	5 (83.3)	1.30 (1.63)	-0.7	0.25	1.00	2.92	3.0	-0.16 [-1.60, 1.27]
			Placebo	4	3 (75.0)	1.56 (1.44)	0.0	0.00	1.83	2.83	2.8	
		Week 44	Tezepelumab	6	5 (83.3)	1.42 (1.45)	0.0	0.25	0.92	2.92	3.0	-0.92 [-2.44, 0.60]
			Placebo	4	3 (75.0)	2.53 (0.46)	2.0	2.00	2.75	2.83	2.8	
		Week 48	Tezepelumab	6	5 (83.3)	1.60 (1.29)	0.2	0.75	1.17	2.92	3.0	-0.92 [-2.45, 0.60]
			Placebo	4	3 (75.0)	2.58 (0.29)	2.3	2.25	2.75	2.75	2.8	
		Week 52	Tezepelumab	6	5 (83.3)	1.63 (1.25)	0.3	0.75	1.17	2.92	3.0	-1.13 [-2.70, 0.44]
			Placebo	4	3 (75.0)	2.86 (0.67)	2.3	2.25	2.75	3.58	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Absolute values	Baseline	Tezepelumab	60	53 (88.3)	4.00 (0.95)	1.9	3.42	4.00	4.58	6.7	
			Placebo	61	52 (85.2)	4.16 (0.89)	1.5	3.71	4.33	4.58	6.3	
		Week 4	Tezepelumab	60	56 (93.3)	4.67 (1.10)	1.3	3.92	4.67	5.54	6.8	
			Placebo	61	54 (88.5)	4.69 (0.92)	2.7	4.08	4.67	5.25	6.7	
		Week 8	Tezepelumab	60	57 (95.0)	4.95 (1.15)	2.0	4.08	4.83	5.83	6.8	
			Placebo	61	56 (91.8)	4.70 (1.07)	1.9	4.17	4.63	5.38	7.0	
		Week 12	Tezepelumab	60	57 (95.0)	5.16 (1.09)	3.0	4.33	5.08	6.08	7.0	
			Placebo	61	56 (91.8)	4.86 (1.03)	2.1	4.17	4.75	5.46	7.0	
		Week 16	Tezepelumab	60	57 (95.0)	5.19 (1.14)	2.7	4.33	5.25	6.08	7.0	
			Placebo	61	56 (91.8)	4.86 (1.17)	1.3	4.13	4.71	5.79	7.0	
		Week 20	Tezepelumab	60	58 (96.7)	5.12 (1.12)	2.3	4.25	5.00	6.00	7.0	
			Placebo	61	56 (91.8)	4.74 (1.16)	1.3	4.04	4.75	5.46	7.0	
		Week 24	Tezepelumab	60	58 (96.7)	5.17 (1.11)	3.1	4.33	5.00	6.08	7.0	
			Placebo	61	56 (91.8)	4.70 (1.20)	1.3	3.88	4.67	5.50	7.0	
		Week 28	Tezepelumab	60	59 (98.3)	5.09 (1.13)	3.2	4.08	4.92	6.08	7.0	
			Placebo	61	57 (93.4)	4.81 (1.28)	1.3	4.00	4.83	5.67	7.0	
		Week 32	Tezepelumab	60	59 (98.3)	5.19 (1.15)	2.8	4.25	5.08	6.17	7.0	
			Placebo	61	57 (93.4)	4.88 (1.16)	1.3	4.08	4.92	5.67	7.0	
		Week 36	Tezepelumab	60	59 (98.3)	5.24 (1.16)	2.9	4.25	5.17	6.17	7.0	
			Placebo	61	57 (93.4)	4.80 (1.19)	2.4	4.00	4.67	5.75	7.0	
		Week 40	Tezepelumab	60	59 (98.3)	5.20 (1.19)	2.3	4.25	5.08	6.08	7.0	
			Placebo	61	57 (93.4)	4.90 (1.19)	2.3	4.00	4.92	5.92	7.0	
		Week 44	Tezepelumab	60	59 (98.3)	5.20 (1.13)	3.0	4.17	5.08	6.08	7.0	
			Placebo	61	57 (93.4)	4.84 (1.15)	2.5	4.00	4.67	5.83	7.0	
		Week 48	Tezepelumab	60	59 (98.3)	5.22 (1.18)	2.8	4.17	5.08	6.25	7.0	
			Placebo	61	57 (93.4)	4.87 (1.15)	2.2	4.00	4.75	5.75	7.0	
		Week 52	Tezepelumab	60	59 (98.3)	5.21 (1.17)	2.8	4.17	5.17	6.17	7.0	
			Placebo	61	57 (93.4)	4.92 (1.09)	2.8	4.08	4.75	5.75	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Region (cat. P)												
Rest of world	Change from baseline	Week 4	Tezepelumab	60	51 (85.0)	0.73 (1.07)	-4.3	0.08	0.92	1.33	2.4	0.18 [-0.21, 0.57]
			Placebo	61	51 (83.6)	0.55 (0.81)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	60	52 (86.7)	0.87 (1.08)	-1.9	0.21	1.00	1.71	2.8	0.28 [-0.11, 0.66]
			Placebo	61	52 (85.2)	0.59 (0.97)	-1.8	0.04	0.58	1.00	3.3	
		Week 12	Tezepelumab	60	52 (86.7)	1.09 (1.09)	-2.6	0.42	1.08	1.92	3.3	0.32 [-0.06, 0.71]
			Placebo	61	52 (85.2)	0.72 (1.17)	-2.8	0.13	0.75	1.17	4.0	
		Week 16	Tezepelumab	60	52 (86.7)	1.13 (1.10)	-2.9	0.54	1.08	2.08	3.3	0.33 [-0.06, 0.72]
			Placebo	61	52 (85.2)	0.74 (1.26)	-3.5	0.17	0.83	1.29	4.2	
		Week 20	Tezepelumab	60	52 (86.7)	1.09 (1.06)	-1.8	0.38	1.04	2.04	3.3	0.41 [0.02, 0.80]
			Placebo	61	52 (85.2)	0.63 (1.17)	-3.5	0.08	0.79	1.25	3.3	
		Week 24	Tezepelumab	60	52 (86.7)	1.19 (1.06)	-1.6	0.50	1.17	1.96	3.3	0.51 [0.12, 0.90]
			Placebo	61	52 (85.2)	0.59 (1.26)	-3.5	0.00	0.83	1.17	3.6	
		Week 28	Tezepelumab	60	52 (86.7)	1.08 (1.08)	-1.7	0.42	1.00	2.00	3.3	0.35 [-0.04, 0.73]
			Placebo	61	52 (85.2)	0.67 (1.30)	-3.5	0.17	0.79	1.25	4.3	
		Week 32	Tezepelumab	60	52 (86.7)	1.20 (1.13)	-1.6	0.50	1.08	2.13	3.3	0.39 [-0.00, 0.77]
			Placebo	61	52 (85.2)	0.76 (1.16)	-3.5	0.38	0.92	1.17	3.5	
		Week 36	Tezepelumab	60	52 (86.7)	1.24 (1.18)	-1.7	0.33	1.08	2.17	3.4	0.50 [0.11, 0.89]
			Placebo	61	52 (85.2)	0.66 (1.13)	-3.0	0.08	0.83	1.17	3.8	
		Week 40	Tezepelumab	60	52 (86.7)	1.23 (1.16)	-1.7	0.50	1.08	2.21	3.4	0.39 [-0.00, 0.77]
			Placebo	61	52 (85.2)	0.78 (1.20)	-3.0	0.04	0.79	1.42	4.0	
		Week 44	Tezepelumab	60	52 (86.7)	1.22 (1.13)	-1.6	0.54	1.17	2.08	3.3	0.46 [0.07, 0.85]
			Placebo	61	52 (85.2)	0.69 (1.15)	-3.0	0.17	0.79	1.29	3.7	
		Week 48	Tezepelumab	60	52 (86.7)	1.25 (1.16)	-1.6	0.42	1.21	2.13	3.4	0.46 [0.07, 0.85]
			Placebo	61	52 (85.2)	0.73 (1.11)	-3.0	0.25	0.75	1.25	4.2	
		Week 52	Tezepelumab	60	52 (86.7)	1.25 (1.16)	-1.6	0.46	1.08	2.13	3.6	0.42 [0.03, 0.81]
			Placebo	61	52 (85.2)	0.78 (1.08)	-3.0	0.25	0.75	1.21	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Absolute values	Baseline	Tezepelumab	30	26 (86.7)	4.03 (1.02)	2.1	3.25	4.04	4.67	6.7	
			Placebo	29	25 (86.2)	4.13 (0.97)	1.5	4.00	4.33	4.58	5.8	
		Week 4	Tezepelumab	30	26 (86.7)	4.61 (1.16)	1.3	4.08	4.58	5.42	6.5	
			Placebo	29	25 (86.2)	4.89 (1.01)	2.7	4.25	4.83	5.50	6.7	
		Week 8	Tezepelumab	30	27 (90.0)	4.93 (1.01)	3.4	4.08	4.83	5.67	6.8	
			Placebo	29	26 (89.7)	4.88 (1.15)	1.9	4.25	5.04	5.75	6.8	
		Week 12	Tezepelumab	30	27 (90.0)	5.01 (0.96)	3.0	4.33	4.92	5.50	6.8	
			Placebo	29	26 (89.7)	5.04 (1.03)	2.9	4.17	5.17	5.92	6.8	
		Week 16	Tezepelumab	30	27 (90.0)	5.01 (0.98)	2.7	4.33	5.08	5.67	6.8	
			Placebo	29	26 (89.7)	4.97 (1.26)	1.3	4.42	5.00	5.92	6.7	
		Week 20	Tezepelumab	30	28 (93.3)	4.99 (0.91)	3.6	4.29	4.92	5.46	6.8	
			Placebo	29	26 (89.7)	4.86 (1.27)	1.3	4.00	4.92	5.92	6.6	
		Week 24	Tezepelumab	30	28 (93.3)	4.93 (0.99)	3.3	4.17	4.83	5.50	7.0	
			Placebo	29	26 (89.7)	4.81 (1.33)	1.3	3.92	5.13	5.92	6.7	
		Week 28	Tezepelumab	30	29 (96.7)	4.91 (1.03)	3.3	4.08	4.92	5.42	7.0	
			Placebo	29	26 (89.7)	4.78 (1.35)	1.3	4.00	4.92	5.92	7.0	
		Week 32	Tezepelumab	30	29 (96.7)	4.97 (0.99)	3.5	4.00	4.92	5.50	7.0	
			Placebo	29	26 (89.7)	4.90 (1.30)	1.3	4.08	4.96	5.92	6.8	
		Week 36	Tezepelumab	30	29 (96.7)	5.14 (1.03)	3.3	4.50	5.08	5.75	7.0	
			Placebo	29	26 (89.7)	4.96 (1.19)	2.5	4.17	4.96	6.00	6.8	
		Week 40	Tezepelumab	30	29 (96.7)	4.95 (0.99)	2.9	4.25	5.00	5.42	7.0	
			Placebo	29	26 (89.7)	4.96 (1.18)	2.8	3.83	4.96	6.08	6.6	
		Week 44	Tezepelumab	30	29 (96.7)	4.93 (1.07)	3.0	4.17	4.75	5.50	7.0	
			Placebo	29	26 (89.7)	4.97 (1.17)	2.8	4.00	5.00	5.92	6.8	
		Week 48	Tezepelumab	30	29 (96.7)	5.09 (1.04)	3.1	4.25	5.08	5.58	7.0	
			Placebo	29	26 (89.7)	4.98 (1.19)	2.8	4.25	4.79	6.00	6.9	
		Week 52	Tezepelumab	30	29 (96.7)	5.09 (1.03)	3.1	4.25	5.08	5.58	7.0	
			Placebo	29	26 (89.7)	4.92 (1.16)	2.8	4.08	4.63	6.00	6.9	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
< 250 cells/uL	Change from baseline	Week 4	Tezepelumab	30	24 (80.0)	0.64 (1.32)	-4.3	0.08	0.79	1.33	3.1	-0.09 [-0.65, 0.48]
			Placebo	29	24 (82.8)	0.74 (0.92)	-1.2	0.17	0.50	0.96	3.3	
		Week 8	Tezepelumab	30	25 (83.3)	0.87 (1.08)	-1.4	0.25	0.58	1.67	3.3	0.09 [-0.47, 0.64]
			Placebo	29	25 (86.2)	0.78 (0.85)	-0.7	0.42	0.67	1.00	3.3	
		Week 12	Tezepelumab	30	25 (83.3)	0.95 (1.20)	-2.6	0.33	0.92	1.50	3.7	0.06 [-0.49, 0.62]
			Placebo	29	25 (86.2)	0.87 (1.10)	-0.8	0.25	0.92	1.25	3.8	
		Week 16	Tezepelumab	30	25 (83.3)	0.99 (1.19)	-2.9	0.42	0.92	1.75	3.2	0.11 [-0.44, 0.67]
			Placebo	29	25 (86.2)	0.85 (1.33)	-3.5	0.33	1.00	1.33	3.6	
		Week 20	Tezepelumab	30	25 (83.3)	0.95 (1.03)	-1.8	0.33	0.83	1.92	2.9	0.18 [-0.37, 0.74]
			Placebo	29	25 (86.2)	0.74 (1.27)	-3.5	0.08	0.83	1.33	3.3	
		Week 24	Tezepelumab	30	25 (83.3)	0.96 (1.01)	-1.6	0.42	0.92	1.50	2.9	0.20 [-0.35, 0.76]
			Placebo	29	25 (86.2)	0.72 (1.34)	-3.5	0.08	0.92	1.17	3.6	
		Week 28	Tezepelumab	30	25 (83.3)	0.95 (1.05)	-1.7	0.33	0.92	1.50	2.9	0.23 [-0.33, 0.78]
			Placebo	29	25 (86.2)	0.69 (1.27)	-3.5	0.08	1.00	1.25	2.8	
		Week 32	Tezepelumab	30	25 (83.3)	0.95 (1.08)	-1.6	0.33	0.92	1.17	3.0	0.11 [-0.44, 0.67]
			Placebo	29	25 (86.2)	0.82 (1.27)	-3.5	0.33	1.08	1.25	3.5	
		Week 36	Tezepelumab	30	25 (83.3)	1.10 (1.19)	-1.7	0.25	1.00	2.17	3.3	0.20 [-0.35, 0.76]
			Placebo	29	25 (86.2)	0.87 (1.11)	-2.3	0.08	1.08	1.33	3.8	
		Week 40	Tezepelumab	30	25 (83.3)	1.00 (1.07)	-1.7	0.25	0.92	1.83	2.9	0.12 [-0.44, 0.67]
			Placebo	29	25 (86.2)	0.88 (1.06)	-1.1	0.08	1.00	1.42	3.4	
		Week 44	Tezepelumab	30	25 (83.3)	0.94 (1.11)	-1.6	0.33	0.92	1.42	3.3	0.05 [-0.51, 0.60]
			Placebo	29	25 (86.2)	0.89 (1.06)	-1.1	0.08	0.92	1.67	3.7	
		Week 48	Tezepelumab	30	25 (83.3)	1.10 (1.07)	-1.6	0.33	0.92	1.58	3.1	0.19 [-0.37, 0.74]
			Placebo	29	25 (86.2)	0.90 (1.12)	-1.1	0.08	0.75	1.50	4.2	
		Week 52	Tezepelumab	30	25 (83.3)	1.10 (1.04)	-1.6	0.33	0.92	1.58	3.1	0.25 [-0.31, 0.81]
			Placebo	29	25 (86.2)	0.83 (1.12)	-1.1	0.08	0.67	1.17	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Absolute values	Baseline	Tezepelumab	36	32 (88.9)	3.95 (1.02)	1.4	3.42	4.04	4.63	6.2	
			Placebo	36	30 (83.3)	4.12 (0.83)	2.7	3.42	4.04	4.58	6.3	
		Week 4	Tezepelumab	36	34 (94.4)	4.85 (1.07)	2.8	3.92	4.96	5.67	6.8	
			Placebo	36	32 (88.9)	4.57 (0.83)	2.7	4.00	4.50	5.17	6.2	
		Week 8	Tezepelumab	36	35 (97.2)	5.05 (1.27)	2.0	3.92	5.25	6.08	6.8	
			Placebo	36	33 (91.7)	4.63 (1.03)	2.9	3.92	4.50	5.17	7.0	
		Week 12	Tezepelumab	36	35 (97.2)	5.36 (1.15)	3.5	4.33	5.42	6.42	7.0	
			Placebo	36	33 (91.7)	4.76 (1.08)	2.1	4.08	4.67	5.33	7.0	
		Week 16	Tezepelumab	36	35 (97.2)	5.38 (1.19)	3.0	4.42	5.58	6.25	7.0	
			Placebo	36	33 (91.7)	4.77 (1.21)	2.1	4.00	4.67	5.50	7.0	
		Week 20	Tezepelumab	36	35 (97.2)	5.30 (1.23)	2.3	4.25	5.67	6.25	7.0	
			Placebo	36	33 (91.7)	4.67 (1.20)	2.1	4.08	4.75	5.17	7.0	
		Week 24	Tezepelumab	36	35 (97.2)	5.40 (1.12)	3.1	4.42	5.50	6.33	6.9	
			Placebo	36	33 (91.7)	4.68 (1.16)	2.2	3.83	4.67	5.25	7.0	
		Week 28	Tezepelumab	36	36 (100.0)	5.34 (1.15)	3.2	4.38	5.46	6.46	7.0	
			Placebo	36	34 (94.4)	4.89 (1.27)	1.8	3.92	4.88	5.75	7.0	
		Week 32	Tezepelumab	36	36 (100.0)	5.42 (1.20)	2.8	4.38	5.71	6.46	7.0	
			Placebo	36	34 (94.4)	4.89 (1.08)	2.9	4.00	4.92	5.58	7.0	
		Week 36	Tezepelumab	36	36 (100.0)	5.37 (1.21)	2.9	4.29	5.50	6.33	7.0	
			Placebo	36	34 (94.4)	4.70 (1.18)	2.4	3.83	4.63	5.50	7.0	
		Week 40	Tezepelumab	36	36 (100.0)	5.43 (1.26)	2.3	4.38	5.75	6.58	7.0	
			Placebo	36	34 (94.4)	4.88 (1.21)	2.3	4.00	4.83	5.75	7.0	
		Week 44	Tezepelumab	36	36 (100.0)	5.45 (1.09)	3.1	4.42	5.58	6.46	7.0	
			Placebo	36	34 (94.4)	4.85 (1.15)	2.5	4.08	4.63	5.83	7.0	
		Week 48	Tezepelumab	36	36 (100.0)	5.37 (1.23)	2.8	4.33	5.50	6.42	7.0	
			Placebo	36	34 (94.4)	4.89 (1.14)	2.2	4.00	4.83	5.75	7.0	
		Week 52	Tezepelumab	36	36 (100.0)	5.38 (1.22)	2.8	4.33	5.42	6.29	7.0	
			Placebo	36	34 (94.4)	5.04 (1.10)	2.8	4.25	4.92	5.75	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eosinophils (cat. P)												
>= 250 cells/uL	Change from baseline	Week 4	Tezepelumab	36	31 (86.1)	0.88 (0.90)	-1.4	0.17	1.08	1.58	2.4	0.43 [-0.08, 0.93]
			Placebo	36	30 (83.3)	0.51 (0.85)	-1.3	0.25	0.50	0.92	3.1	
		Week 8	Tezepelumab	36	32 (88.9)	1.02 (1.15)	-1.9	0.38	1.13	1.88	2.8	0.39 [-0.12, 0.89]
			Placebo	36	30 (83.3)	0.57 (1.16)	-1.8	-0.08	0.42	1.17	3.6	
		Week 12	Tezepelumab	36	32 (88.9)	1.34 (1.05)	-1.4	0.67	1.42	2.08	3.3	0.53 [0.02, 1.04]
			Placebo	36	30 (83.3)	0.71 (1.34)	-2.8	0.00	0.67	1.08	4.0	
		Week 16	Tezepelumab	36	32 (88.9)	1.35 (1.05)	-1.4	0.58	1.58	2.08	3.3	0.54 [0.03, 1.04]
			Placebo	36	30 (83.3)	0.71 (1.34)	-3.0	0.17	0.67	1.08	4.2	
		Week 20	Tezepelumab	36	32 (88.9)	1.32 (1.10)	-1.4	0.50	1.29	2.25	3.3	0.59 [0.08, 1.10]
			Placebo	36	30 (83.3)	0.63 (1.27)	-3.0	0.08	0.79	1.25	3.8	
		Week 24	Tezepelumab	36	32 (88.9)	1.44 (1.10)	-1.4	0.54	1.54	2.25	3.3	0.68 [0.17, 1.19]
			Placebo	36	30 (83.3)	0.62 (1.31)	-3.0	0.00	0.63	1.25	3.9	
		Week 28	Tezepelumab	36	32 (88.9)	1.29 (1.14)	-1.4	0.46	1.33	2.13	3.3	0.40 [-0.10, 0.90]
			Placebo	36	30 (83.3)	0.78 (1.42)	-3.0	0.25	0.71	1.42	4.3	
		Week 32	Tezepelumab	36	32 (88.9)	1.45 (1.15)	-1.4	0.75	1.63	2.29	3.3	0.56 [0.05, 1.07]
			Placebo	36	30 (83.3)	0.81 (1.14)	-3.0	0.42	0.83	1.08	3.3	
		Week 36	Tezepelumab	36	32 (88.9)	1.38 (1.21)	-1.4	0.63	1.50	2.33	3.4	0.68 [0.17, 1.20]
			Placebo	36	30 (83.3)	0.57 (1.16)	-3.0	0.08	0.75	1.17	2.6	
		Week 40	Tezepelumab	36	32 (88.9)	1.42 (1.26)	-1.4	1.00	1.17	2.38	3.4	0.50 [-0.00, 1.01]
			Placebo	36	30 (83.3)	0.77 (1.34)	-3.0	0.00	0.67	1.58	4.0	
		Week 44	Tezepelumab	36	32 (88.9)	1.47 (1.13)	-1.4	0.75	1.50	2.29	3.3	0.62 [0.11, 1.13]
			Placebo	36	30 (83.3)	0.71 (1.30)	-3.0	0.33	0.71	1.33	3.4	
		Week 48	Tezepelumab	36	32 (88.9)	1.42 (1.23)	-1.4	0.71	1.38	2.33	3.4	0.53 [0.02, 1.04]
			Placebo	36	30 (83.3)	0.77 (1.20)	-3.0	0.33	0.88	1.25	2.8	
		Week 52	Tezepelumab	36	32 (88.9)	1.42 (1.24)	-1.4	0.63	1.13	2.54	3.6	0.39 [-0.11, 0.89]
			Placebo	36	30 (83.3)	0.94 (1.21)	-3.0	0.42	0.83	1.67	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Absolute values	Baseline	Tezepelumab	38	31 (81.6)	3.90 (0.90)	1.9	3.42	4.00	4.50	5.6	
			Placebo	30	23 (76.7)	4.08 (0.65)	2.8	3.50	4.17	4.50	5.2	
		Week 4	Tezepelumab	38	35 (92.1)	4.55 (1.16)	1.3	3.92	4.58	5.50	6.4	
			Placebo	30	25 (83.3)	4.68 (0.82)	3.2	4.25	4.58	5.25	6.5	
		Week 8	Tezepelumab	38	35 (92.1)	4.85 (1.14)	2.0	4.17	4.83	5.75	6.8	
			Placebo	30	25 (83.3)	4.87 (0.92)	3.2	4.25	4.58	5.50	6.7	
		Week 12	Tezepelumab	38	35 (92.1)	5.05 (1.05)	3.0	4.25	4.92	6.08	6.8	
			Placebo	30	25 (83.3)	4.94 (0.93)	3.5	4.17	4.83	5.50	6.8	
		Week 16	Tezepelumab	38	35 (92.1)	5.02 (1.08)	2.7	4.33	5.00	6.00	6.9	
			Placebo	30	25 (83.3)	4.98 (0.98)	3.4	4.25	4.83	5.92	6.6	
		Week 20	Tezepelumab	38	36 (94.7)	4.97 (1.09)	2.3	4.21	4.79	5.75	6.9	
			Placebo	30	25 (83.3)	4.97 (1.08)	2.4	4.08	5.00	5.92	6.8	
		Week 24	Tezepelumab	38	36 (94.7)	4.96 (1.07)	3.1	4.08	4.83	5.75	7.0	
			Placebo	30	25 (83.3)	4.94 (1.13)	2.2	4.25	4.75	5.92	6.8	
		Week 28	Tezepelumab	38	38 (100.0)	5.01 (1.10)	3.2	4.17	4.96	5.83	7.0	
			Placebo	30	26 (86.7)	5.00 (1.14)	1.8	4.17	4.96	5.92	6.8	
		Week 32	Tezepelumab	38	38 (100.0)	4.99 (1.15)	2.8	4.00	4.92	5.83	7.0	
			Placebo	30	26 (86.7)	5.06 (1.03)	2.9	4.25	5.00	5.92	6.8	
		Week 36	Tezepelumab	38	38 (100.0)	5.16 (1.19)	2.9	4.17	5.29	6.08	7.0	
			Placebo	30	26 (86.7)	5.04 (1.06)	2.8	4.17	5.00	5.92	6.9	
		Week 40	Tezepelumab	38	38 (100.0)	4.95 (1.19)	2.3	4.17	4.92	5.67	7.0	
			Placebo	30	26 (86.7)	5.13 (1.10)	2.5	4.33	5.17	6.08	7.0	
		Week 44	Tezepelumab	38	38 (100.0)	4.94 (1.10)	3.0	4.08	4.71	5.67	7.0	
			Placebo	30	26 (86.7)	5.01 (1.08)	3.1	4.25	4.79	5.92	6.9	
		Week 48	Tezepelumab	38	38 (100.0)	4.98 (1.15)	2.8	4.08	5.00	5.67	7.0	
			Placebo	30	26 (86.7)	5.13 (1.13)	2.4	4.25	5.17	6.00	6.9	
		Week 52	Tezepelumab	38	38 (100.0)	5.00 (1.18)	2.8	4.00	5.00	6.08	7.0	
			Placebo	30	26 (86.7)	5.13 (1.02)	3.6	4.25	5.04	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
< 24 ppb	Change from baseline	Week 4	Tezepelumab	38	31 (81.6)	0.63 (1.23)	-4.3	0.08	0.58	1.33	3.1	-0.04 [-0.58, 0.49]
			Placebo	30	23 (76.7)	0.68 (1.08)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	38	31 (81.6)	0.85 (1.11)	-1.9	0.25	0.92	1.42	3.3	-0.01 [-0.55, 0.53]
			Placebo	30	23 (76.7)	0.86 (1.13)	-1.0	0.08	0.83	1.17	3.6	
		Week 12	Tezepelumab	38	31 (81.6)	1.07 (1.15)	-2.6	0.33	1.00	1.83	3.7	0.12 [-0.42, 0.66]
			Placebo	30	23 (76.7)	0.93 (1.22)	-1.0	0.33	0.75	1.17	3.8	
		Week 16	Tezepelumab	38	31 (81.6)	1.08 (1.13)	-2.9	0.50	1.00	1.75	3.3	0.11 [-0.43, 0.65]
			Placebo	30	23 (76.7)	0.95 (1.14)	-1.2	0.08	0.92	1.33	3.7	
		Week 20	Tezepelumab	38	31 (81.6)	1.07 (1.03)	-1.8	0.33	0.92	2.00	3.3	0.07 [-0.47, 0.61]
			Placebo	30	23 (76.7)	0.99 (1.19)	-1.1	0.08	1.00	1.67	3.8	
		Week 24	Tezepelumab	38	31 (81.6)	1.10 (0.99)	-1.6	0.50	1.00	1.83	3.3	0.15 [-0.39, 0.69]
			Placebo	30	23 (76.7)	0.94 (1.23)	-1.3	0.25	0.83	1.17	3.9	
		Week 28	Tezepelumab	38	31 (81.6)	1.10 (1.04)	-1.7	0.50	0.92	2.00	3.3	0.17 [-0.37, 0.71]
			Placebo	30	23 (76.7)	0.92 (1.13)	-1.8	0.33	0.83	1.42	3.8	
		Week 32	Tezepelumab	38	31 (81.6)	1.06 (1.13)	-1.6	0.33	1.00	1.83	3.3	0.05 [-0.49, 0.59]
			Placebo	30	23 (76.7)	1.01 (1.07)	-0.8	0.33	0.92	1.25	3.5	
		Week 36	Tezepelumab	38	31 (81.6)	1.23 (1.16)	-1.7	0.25	1.08	2.17	3.4	0.21 [-0.33, 0.75]
			Placebo	30	23 (76.7)	0.99 (1.03)	-0.8	0.25	0.92	1.50	3.8	
		Week 40	Tezepelumab	38	31 (81.6)	1.06 (1.12)	-1.7	0.25	1.00	2.17	3.3	-0.01 [-0.55, 0.53]
			Placebo	30	23 (76.7)	1.07 (1.10)	-1.0	0.33	1.00	1.83	3.4	
		Week 44	Tezepelumab	38	31 (81.6)	1.03 (1.04)	-1.6	0.42	0.92	2.08	3.2	0.10 [-0.44, 0.64]
			Placebo	30	23 (76.7)	0.92 (1.14)	-0.7	-0.25	1.00	1.67	3.7	
		Week 48	Tezepelumab	38	31 (81.6)	1.10 (1.07)	-1.6	0.50	1.00	2.00	3.4	0.04 [-0.50, 0.58]
			Placebo	30	23 (76.7)	1.05 (1.19)	-1.1	0.42	0.92	1.75	4.2	
		Week 52	Tezepelumab	38	31 (81.6)	1.11 (1.07)	-1.6	0.50	1.00	2.00	3.4	0.05 [-0.49, 0.59]
			Placebo	30	23 (76.7)	1.06 (1.11)	-0.7	0.42	0.75	1.75	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Absolute values	Baseline	Tezepelumab	28	27 (96.4)	4.08 (1.14)	1.4	3.17	4.17	4.83	6.7	
			Placebo	34	31 (91.2)	4.14 (1.04)	1.5	3.67	4.33	4.58	6.3	
		Week 4	Tezepelumab	28	25 (89.3)	5.01 (0.99)	3.3	4.50	5.08	5.83	6.8	
			Placebo	34	32 (94.1)	4.74 (1.00)	2.7	4.13	4.75	5.25	6.7	
		Week 8	Tezepelumab	28	27 (96.4)	5.19 (1.17)	3.6	3.92	5.17	6.08	6.8	
			Placebo	34	33 (97.1)	4.66 (1.21)	1.9	4.08	4.67	5.33	7.0	
		Week 12	Tezepelumab	28	27 (96.4)	5.42 (1.10)	3.5	4.42	5.42	6.58	7.0	
			Placebo	34	33 (97.1)	4.86 (1.18)	2.1	4.17	4.92	5.67	7.0	
		Week 16	Tezepelumab	28	27 (96.4)	5.48 (1.12)	3.3	4.75	5.67	6.42	7.0	
			Placebo	34	33 (97.1)	4.87 (1.27)	2.1	4.17	4.67	5.75	7.0	
		Week 20	Tezepelumab	28	27 (96.4)	5.40 (1.09)	3.5	4.42	5.67	6.25	7.0	
			Placebo	34	33 (97.1)	4.70 (1.19)	2.1	4.08	4.67	5.25	7.0	
		Week 24	Tezepelumab	28	27 (96.4)	5.50 (1.02)	3.7	4.42	5.75	6.33	7.0	
			Placebo	34	33 (97.1)	4.68 (1.17)	2.8	3.75	4.67	5.50	7.0	
		Week 28	Tezepelumab	28	27 (96.4)	5.33 (1.11)	3.8	4.42	5.42	6.17	7.0	
			Placebo	34	33 (97.1)	4.82 (1.29)	2.8	3.83	4.92	5.75	7.0	
		Week 32	Tezepelumab	28	27 (96.4)	5.55 (1.02)	3.8	4.75	5.75	6.25	7.0	
			Placebo	34	33 (97.1)	4.88 (1.12)	2.8	4.00	4.92	5.58	7.0	
		Week 36	Tezepelumab	28	27 (96.4)	5.42 (1.05)	3.8	4.58	5.25	6.33	7.0	
			Placebo	34	33 (97.1)	4.70 (1.22)	2.4	3.83	4.58	5.58	7.0	
		Week 40	Tezepelumab	28	27 (96.4)	5.58 (1.04)	3.8	4.75	5.67	6.58	7.0	
			Placebo	34	33 (97.1)	4.78 (1.24)	2.3	3.83	4.58	5.75	7.0	
		Week 44	Tezepelumab	28	27 (96.4)	5.60 (1.01)	3.8	4.75	5.75	6.50	7.0	
			Placebo	34	33 (97.1)	4.85 (1.21)	2.5	4.00	5.08	5.83	7.0	
		Week 48	Tezepelumab	28	27 (96.4)	5.62 (1.04)	3.8	4.75	5.75	6.50	7.0	
			Placebo	34	33 (97.1)	4.82 (1.16)	2.2	4.00	4.75	5.75	7.0	
		Week 52	Tezepelumab	28	27 (96.4)	5.60 (1.00)	3.8	4.75	5.75	6.42	7.0	
			Placebo	34	33 (97.1)	4.92 (1.19)	2.8	4.00	4.75	5.75	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. P)												
>= 24 ppb	Change from baseline	Week 4	Tezepelumab	28	24 (85.7)	0.97 (0.90)	-1.4	0.38	1.17	1.54	2.4	0.52 [-0.02, 1.06]
			Placebo	34	31 (91.2)	0.56 (0.70)	-1.1	0.25	0.50	1.00	1.9	
		Week 8	Tezepelumab	28	26 (92.9)	1.07 (1.12)	-1.4	0.17	1.58	1.92	2.5	0.50 [-0.03, 1.03]
			Placebo	34	31 (91.2)	0.56 (0.94)	-1.8	0.17	0.42	1.00	2.7	
		Week 12	Tezepelumab	28	26 (92.9)	1.28 (1.12)	-1.4	0.75	1.50	2.17	3.0	0.48 [-0.05, 1.01]
			Placebo	34	31 (91.2)	0.71 (1.24)	-2.8	0.00	0.75	1.25	4.0	
		Week 16	Tezepelumab	28	26 (92.9)	1.34 (1.11)	-1.4	0.58	1.67	2.17	3.0	0.47 [-0.06, 1.00]
			Placebo	34	31 (91.2)	0.78 (1.25)	-3.0	0.17	0.83	1.42	4.2	
		Week 20	Tezepelumab	28	26 (92.9)	1.27 (1.14)	-1.4	0.50	1.29	2.25	3.0	0.62 [0.09, 1.15]
			Placebo	34	31 (91.2)	0.59 (1.07)	-3.0	0.08	0.75	1.25	2.4	
		Week 24	Tezepelumab	28	26 (92.9)	1.38 (1.17)	-1.4	0.50	1.50	2.25	3.0	0.67 [0.14, 1.21]
			Placebo	34	31 (91.2)	0.60 (1.17)	-3.0	0.00	0.83	1.33	2.7	
		Week 28	Tezepelumab	28	26 (92.9)	1.19 (1.19)	-1.4	0.33	1.21	2.17	3.0	0.36 [-0.17, 0.88]
			Placebo	34	31 (91.2)	0.74 (1.30)	-3.0	0.08	0.83	1.33	4.3	
		Week 32	Tezepelumab	28	26 (92.9)	1.43 (1.13)	-1.4	0.83	1.54	2.33	3.0	0.58 [0.05, 1.12]
			Placebo	34	31 (91.2)	0.80 (1.03)	-3.0	0.42	0.83	1.33	2.9	
		Week 36	Tezepelumab	28	26 (92.9)	1.29 (1.26)	-1.4	0.33	1.33	2.33	3.2	0.60 [0.07, 1.14]
			Placebo	34	31 (91.2)	0.59 (1.09)	-3.0	0.08	0.83	1.25	2.4	
		Week 40	Tezepelumab	28	26 (92.9)	1.46 (1.25)	-1.4	1.00	1.25	2.50	3.4	0.61 [0.07, 1.14]
			Placebo	34	31 (91.2)	0.70 (1.25)	-3.0	0.00	0.67	1.42	4.0	
		Week 44	Tezepelumab	28	26 (92.9)	1.48 (1.23)	-1.4	0.83	1.50	2.42	3.3	0.59 [0.05, 1.12]
			Placebo	34	31 (91.2)	0.76 (1.22)	-3.0	0.33	0.83	1.58	3.4	
		Week 48	Tezepelumab	28	26 (92.9)	1.50 (1.25)	-1.4	0.33	1.54	2.58	3.2	0.66 [0.12, 1.19]
			Placebo	34	31 (91.2)	0.73 (1.10)	-3.0	0.25	0.83	1.25	2.8	
		Week 52	Tezepelumab	28	26 (92.9)	1.48 (1.25)	-1.4	0.42	1.46	2.58	3.6	0.54 [0.01, 1.07]
			Placebo	34	31 (91.2)	0.83 (1.16)	-3.0	0.25	0.83	1.58	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Absolute values	Baseline	Tezepelumab	32	26 (81.3)	3.90 (0.90)	1.9	3.42	4.00	4.50	5.6	
			Placebo	27	21 (77.8)	4.15 (0.62)	2.8	3.75	4.25	4.50	5.2	
		Week 4	Tezepelumab	32	30 (93.8)	4.59 (1.20)	1.3	3.92	4.58	5.50	6.4	
			Placebo	27	23 (85.2)	4.63 (0.81)	3.2	4.00	4.50	5.25	6.5	
		Week 8	Tezepelumab	32	30 (93.8)	4.93 (1.13)	2.0	4.25	4.83	5.83	6.8	
			Placebo	27	23 (85.2)	4.82 (0.88)	3.2	4.17	4.58	5.50	6.7	
		Week 12	Tezepelumab	32	30 (93.8)	5.07 (1.04)	3.0	4.33	5.00	6.08	6.8	
			Placebo	27	23 (85.2)	4.85 (0.88)	3.5	4.08	4.67	5.50	6.8	
		Week 16	Tezepelumab	32	30 (93.8)	4.99 (1.08)	2.7	4.33	5.00	5.75	6.9	
			Placebo	27	23 (85.2)	4.92 (0.96)	3.4	4.08	4.83	5.92	6.5	
		Week 20	Tezepelumab	32	31 (96.9)	4.91 (1.07)	2.3	4.17	4.83	5.58	6.9	
			Placebo	27	23 (85.2)	4.90 (1.06)	2.4	4.00	5.00	5.92	6.6	
		Week 24	Tezepelumab	32	31 (96.9)	4.93 (1.04)	3.1	4.17	4.75	5.50	7.0	
			Placebo	27	23 (85.2)	4.88 (1.10)	2.2	4.00	4.75	5.92	6.7	
		Week 28	Tezepelumab	32	32 (100.0)	4.91 (1.04)	3.2	4.17	4.75	5.50	6.9	
			Placebo	27	24 (88.9)	4.96 (1.13)	1.8	4.08	4.96	5.79	6.8	
		Week 32	Tezepelumab	32	32 (100.0)	4.91 (1.03)	2.9	4.00	4.92	5.58	7.0	
			Placebo	27	24 (88.9)	5.02 (1.05)	2.9	4.17	5.00	5.88	6.8	
		Week 36	Tezepelumab	32	32 (100.0)	5.07 (1.14)	2.9	4.13	5.13	6.00	7.0	
			Placebo	27	24 (88.9)	5.03 (1.10)	2.8	4.17	5.00	5.96	6.9	
		Week 40	Tezepelumab	32	32 (100.0)	4.83 (1.14)	2.3	4.13	4.71	5.54	7.0	
			Placebo	27	24 (88.9)	5.12 (1.14)	2.5	4.29	5.17	6.08	7.0	
		Week 44	Tezepelumab	32	32 (100.0)	4.82 (1.05)	3.0	4.04	4.67	5.50	7.0	
			Placebo	27	24 (88.9)	5.00 (1.12)	3.1	4.21	4.79	6.08	6.9	
		Week 48	Tezepelumab	32	32 (100.0)	4.89 (1.05)	3.1	4.04	4.92	5.58	7.0	
			Placebo	27	24 (88.9)	5.14 (1.17)	2.4	4.25	5.17	6.13	6.9	
		Week 52	Tezepelumab	32	32 (100.0)	4.91 (1.08)	3.0	4.00	5.00	5.58	7.0	
			Placebo	27	24 (88.9)	5.15 (1.04)	3.6	4.25	5.04	5.96	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
< 22.0 ppb	Change from baseline	Week 4	Tezepelumab	32	26 (81.3)	0.67 (1.32)	-4.3	0.08	0.58	1.50	3.1	0.10 [-0.48, 0.67]
			Placebo	27	21 (77.8)	0.56 (0.99)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	32	26 (81.3)	0.92 (1.16)	-1.9	0.33	0.88	1.50	3.3	0.16 [-0.42, 0.74]
			Placebo	27	21 (77.8)	0.74 (1.00)	-1.0	0.08	0.83	1.17	3.3	
		Week 12	Tezepelumab	32	26 (81.3)	1.08 (1.20)	-2.6	0.42	0.96	1.83	3.7	0.28 [-0.30, 0.86]
			Placebo	27	21 (77.8)	0.76 (1.08)	-1.0	0.33	0.67	1.08	3.8	
		Week 16	Tezepelumab	32	26 (81.3)	1.04 (1.17)	-2.9	0.58	1.00	1.67	3.3	0.19 [-0.39, 0.77]
			Placebo	27	21 (77.8)	0.83 (1.02)	-1.2	0.08	0.83	1.25	3.6	
		Week 20	Tezepelumab	32	26 (81.3)	0.98 (1.03)	-1.8	0.33	0.88	1.58	3.3	0.13 [-0.44, 0.71]
			Placebo	27	21 (77.8)	0.85 (1.07)	-1.1	0.08	0.83	1.67	3.3	
		Week 24	Tezepelumab	32	26 (81.3)	1.08 (1.02)	-1.6	0.50	0.96	1.83	3.3	0.27 [-0.31, 0.84]
			Placebo	27	21 (77.8)	0.80 (1.09)	-1.3	0.25	0.83	1.00	3.6	
		Week 28	Tezepelumab	32	26 (81.3)	1.03 (1.08)	-1.7	0.25	0.92	1.92	3.3	0.23 [-0.35, 0.80]
			Placebo	27	21 (77.8)	0.80 (0.99)	-1.8	0.33	0.83	1.25	2.8	
		Week 32	Tezepelumab	32	26 (81.3)	1.02 (1.00)	-1.6	0.50	0.96	1.58	3.3	0.12 [-0.45, 0.70]
			Placebo	27	21 (77.8)	0.89 (1.00)	-0.8	0.33	0.92	1.17	3.5	
		Week 36	Tezepelumab	32	26 (81.3)	1.17 (1.10)	-1.7	0.50	1.08	2.08	3.4	0.25 [-0.33, 0.83]
			Placebo	27	21 (77.8)	0.91 (1.01)	-0.8	0.25	0.92	1.17	3.8	
		Week 40	Tezepelumab	32	26 (81.3)	0.97 (1.13)	-1.7	0.25	0.96	1.83	3.3	-0.01 [-0.58, 0.57]
			Placebo	27	21 (77.8)	0.98 (1.08)	-1.0	0.33	1.00	1.75	3.4	
		Week 44	Tezepelumab	32	26 (81.3)	0.93 (1.04)	-1.6	0.33	0.92	1.33	3.2	0.10 [-0.48, 0.67]
			Placebo	27	21 (77.8)	0.83 (1.11)	-0.7	-0.25	1.00	1.25	3.7	
		Week 48	Tezepelumab	32	26 (81.3)	1.04 (1.01)	-1.6	0.50	0.96	1.42	3.4	0.05 [-0.53, 0.62]
			Placebo	27	21 (77.8)	0.99 (1.18)	-1.1	0.42	0.92	1.67	4.2	
		Week 52	Tezepelumab	32	26 (81.3)	1.06 (1.01)	-1.6	0.50	0.96	1.42	3.4	0.06 [-0.52, 0.63]
			Placebo	27	21 (77.8)	1.00 (1.09)	-0.7	0.42	0.75	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Absolute values	Baseline	Tezepelumab	34	32 (94.1)	4.05 (1.11)	1.4	3.29	4.17	4.75	6.7	
			Placebo	37	33 (89.2)	4.09 (1.03)	1.5	3.67	4.25	4.58	6.3	
		Week 4	Tezepelumab	34	30 (88.2)	4.89 (1.01)	3.3	3.92	5.04	5.67	6.8	
			Placebo	37	34 (91.9)	4.77 (0.99)	2.7	4.17	4.75	5.25	6.7	
		Week 8	Tezepelumab	34	32 (94.1)	5.07 (1.19)	2.8	3.92	5.17	5.96	6.8	
			Placebo	37	35 (94.6)	4.70 (1.22)	1.9	4.08	4.67	5.42	7.0	
		Week 12	Tezepelumab	34	32 (94.1)	5.34 (1.11)	3.5	4.42	5.42	6.29	7.0	
			Placebo	37	35 (94.6)	4.92 (1.19)	2.1	4.17	5.00	5.92	7.0	
		Week 16	Tezepelumab	34	32 (94.1)	5.43 (1.11)	3.3	4.58	5.63	6.33	7.0	
			Placebo	37	35 (94.6)	4.91 (1.26)	2.1	4.17	4.67	5.83	7.0	
		Week 20	Tezepelumab	34	32 (94.1)	5.40 (1.10)	3.5	4.46	5.63	6.42	7.0	
			Placebo	37	35 (94.6)	4.76 (1.20)	2.1	4.08	4.75	5.50	7.0	
		Week 24	Tezepelumab	34	32 (94.1)	5.44 (1.07)	3.7	4.42	5.63	6.42	7.0	
			Placebo	37	35 (94.6)	4.74 (1.19)	2.8	3.75	4.67	5.75	7.0	
		Week 28	Tezepelumab	34	33 (97.1)	5.37 (1.15)	3.8	4.42	5.42	6.50	7.0	
			Placebo	37	35 (94.6)	4.86 (1.29)	2.8	3.83	4.92	5.75	7.0	
		Week 32	Tezepelumab	34	33 (97.1)	5.53 (1.14)	2.8	4.75	5.75	6.67	7.0	
			Placebo	37	35 (94.6)	4.92 (1.11)	2.8	4.00	4.92	5.75	7.0	
		Week 36	Tezepelumab	34	33 (97.1)	5.45 (1.11)	3.3	4.58	5.25	6.33	7.0	
			Placebo	37	35 (94.6)	4.72 (1.19)	2.4	3.83	4.67	5.58	7.0	
		Week 40	Tezepelumab	34	33 (97.1)	5.58 (1.08)	3.8	4.75	5.67	6.58	7.0	
			Placebo	37	35 (94.6)	4.81 (1.22)	2.3	3.83	4.58	5.75	7.0	
		Week 44	Tezepelumab	34	33 (97.1)	5.60 (1.02)	3.8	4.75	5.75	6.50	7.0	
			Placebo	37	35 (94.6)	4.87 (1.19)	2.5	4.00	5.08	5.83	7.0	
		Week 48	Tezepelumab	34	33 (97.1)	5.60 (1.14)	2.8	4.75	5.75	6.50	7.0	
			Placebo	37	35 (94.6)	4.83 (1.14)	2.2	4.00	4.75	5.75	7.0	
		Week 52	Tezepelumab	34	33 (97.1)	5.58 (1.12)	2.8	4.75	5.75	6.50	7.0	
			Placebo	37	35 (94.6)	4.92 (1.17)	2.8	4.00	4.75	5.75	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline FENO (cat. M)												
>= 22.0 ppb	Change from baseline	Week 4	Tezepelumab	34	29 (85.3)	0.87 (0.87)	-1.4	0.33	1.08	1.33	2.4	0.27 [-0.23, 0.77]
			Placebo	37	33 (89.2)	0.65 (0.81)	-1.1	0.25	0.58	1.00	3.1	
		Week 8	Tezepelumab	34	31 (91.2)	0.98 (1.08)	-1.4	0.17	1.08	1.92	2.5	0.31 [-0.19, 0.80]
			Placebo	37	33 (89.2)	0.66 (1.05)	-1.8	0.17	0.67	1.00	3.6	
		Week 12	Tezepelumab	34	31 (91.2)	1.24 (1.07)	-1.4	0.42	1.42	2.17	3.0	0.34 [-0.16, 0.83]
			Placebo	37	33 (89.2)	0.83 (1.33)	-2.8	0.08	0.75	1.33	4.0	
		Week 16	Tezepelumab	34	31 (91.2)	1.33 (1.07)	-1.4	0.42	1.67	2.17	3.0	0.38 [-0.11, 0.87]
			Placebo	37	33 (89.2)	0.87 (1.31)	-3.0	0.17	0.92	1.42	4.2	
		Week 20	Tezepelumab	34	31 (91.2)	1.31 (1.11)	-1.4	0.50	1.33	2.25	3.0	0.53 [0.03, 1.03]
			Placebo	37	33 (89.2)	0.70 (1.18)	-3.0	0.25	0.83	1.25	3.8	
		Week 24	Tezepelumab	34	31 (91.2)	1.36 (1.12)	-1.4	0.42	1.50	2.25	3.0	0.54 [0.04, 1.04]
			Placebo	37	33 (89.2)	0.71 (1.27)	-3.0	0.00	0.92	1.33	3.9	
		Week 28	Tezepelumab	34	31 (91.2)	1.23 (1.13)	-1.4	0.42	1.42	2.17	3.0	0.32 [-0.17, 0.82]
			Placebo	37	33 (89.2)	0.82 (1.36)	-3.0	0.25	0.83	1.33	4.3	
		Week 32	Tezepelumab	34	31 (91.2)	1.41 (1.22)	-1.4	0.50	1.67	2.50	3.0	0.45 [-0.05, 0.95]
			Placebo	37	33 (89.2)	0.89 (1.08)	-3.0	0.42	0.92	1.33	3.3	
		Week 36	Tezepelumab	34	31 (91.2)	1.33 (1.29)	-1.4	0.17	1.58	2.33	3.3	0.55 [0.05, 1.05]
			Placebo	37	33 (89.2)	0.66 (1.12)	-3.0	0.08	0.83	1.25	2.6	
		Week 40	Tezepelumab	34	31 (91.2)	1.46 (1.20)	-1.4	0.75	1.33	2.42	3.4	0.56 [0.06, 1.06]
			Placebo	37	33 (89.2)	0.78 (1.27)	-3.0	0.08	0.75	1.42	4.0	
		Week 44	Tezepelumab	34	31 (91.2)	1.49 (1.18)	-1.4	0.58	1.50	2.33	3.3	0.55 [0.05, 1.05]
			Placebo	37	33 (89.2)	0.83 (1.23)	-3.0	0.42	0.83	1.58	3.4	
		Week 48	Tezepelumab	34	31 (91.2)	1.48 (1.25)	-1.4	0.33	1.58	2.58	3.2	0.58 [0.08, 1.08]
			Placebo	37	33 (89.2)	0.79 (1.12)	-3.0	0.33	0.83	1.25	2.8	
		Week 52	Tezepelumab	34	31 (91.2)	1.47 (1.26)	-1.4	0.42	1.50	2.58	3.6	0.48 [-0.02, 0.98]
			Placebo	37	33 (89.2)	0.88 (1.18)	-3.0	0.25	0.83	1.58	3.6	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Absolute values	Baseline	Tezepelumab	25	21 (84.0)	3.92 (0.66)	2.1	3.75	4.08	4.25	4.8	
			Placebo	22	18 (81.8)	4.24 (1.05)	1.7	3.50	4.29	4.75	6.3	
		Week 4	Tezepelumab	25	24 (96.0)	4.67 (0.88)	2.6	4.00	4.58	5.21	6.4	
			Placebo	22	18 (81.8)	4.69 (1.14)	2.7	3.92	4.75	5.25	6.5	
		Week 8	Tezepelumab	25	24 (96.0)	4.93 (1.12)	2.0	4.29	4.83	5.67	6.8	
			Placebo	22	20 (90.9)	4.69 (1.22)	2.1	3.92	4.67	5.67	6.7	
		Week 12	Tezepelumab	25	24 (96.0)	5.22 (1.02)	3.6	4.42	5.17	6.00	6.8	
			Placebo	22	20 (90.9)	4.55 (1.22)	2.1	3.88	4.29	5.42	6.8	
		Week 16	Tezepelumab	25	24 (96.0)	5.33 (1.05)	3.6	4.33	5.38	6.13	7.0	
			Placebo	22	20 (90.9)	4.49 (1.54)	1.3	3.46	4.21	5.88	7.0	
		Week 20	Tezepelumab	25	24 (96.0)	5.08 (1.11)	3.6	4.08	4.92	5.79	7.0	
			Placebo	22	20 (90.9)	4.58 (1.60)	1.3	3.46	4.33	6.17	6.8	
		Week 24	Tezepelumab	25	24 (96.0)	5.15 (1.06)	3.6	4.25	5.00	5.96	7.0	
			Placebo	22	20 (90.9)	4.39 (1.61)	1.3	3.29	4.25	6.00	6.8	
		Week 28	Tezepelumab	25	25 (100.0)	5.03 (1.12)	3.3	4.17	4.83	5.67	6.9	
			Placebo	22	20 (90.9)	4.30 (1.53)	1.3	3.08	4.13	5.50	6.5	
		Week 32	Tezepelumab	25	25 (100.0)	5.02 (1.13)	3.5	4.17	4.92	5.83	7.0	
			Placebo	22	20 (90.9)	4.51 (1.47)	1.3	3.46	4.29	5.71	6.7	
		Week 36	Tezepelumab	25	25 (100.0)	5.14 (1.15)	3.3	4.17	4.83	6.17	7.0	
			Placebo	22	20 (90.9)	4.60 (1.47)	2.4	3.50	4.38	6.17	6.8	
		Week 40	Tezepelumab	25	25 (100.0)	5.04 (1.11)	2.9	4.25	4.83	5.58	7.0	
			Placebo	22	20 (90.9)	4.57 (1.43)	2.3	3.58	4.17	6.04	6.6	
		Week 44	Tezepelumab	25	25 (100.0)	4.98 (1.14)	3.0	4.08	4.92	5.67	7.0	
			Placebo	22	20 (90.9)	4.60 (1.22)	2.5	3.75	4.42	5.71	6.5	
		Week 48	Tezepelumab	25	25 (100.0)	5.02 (1.17)	3.1	4.00	5.00	5.58	7.0	
			Placebo	22	20 (90.9)	4.45 (1.30)	2.2	3.71	4.25	5.38	6.5	
		Week 52	Tezepelumab	25	25 (100.0)	5.03 (1.15)	3.1	4.00	5.00	5.58	7.0	
			Placebo	22	20 (90.9)	4.61 (1.17)	2.8	3.83	4.42	5.88	6.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
All negative	Change from baseline	Week 4	Tezepelumab	25	21 (84.0)	0.82 (0.66)	-0.2	0.17	0.83	1.25	2.1	0.34 [-0.31, 0.98]
			Placebo	22	17 (77.3)	0.56 (0.86)	-1.1	0.25	0.58	1.00	2.4	
		Week 8	Tezepelumab	25	21 (84.0)	0.87 (1.16)	-1.9	0.17	0.92	1.83	2.8	0.28 [-0.35, 0.91]
			Placebo	22	18 (81.8)	0.56 (1.05)	-1.8	0.00	0.58	1.17	2.6	
		Week 12	Tezepelumab	25	21 (84.0)	1.16 (1.04)	-0.8	0.42	1.00	2.17	3.3	0.65 [0.00, 1.30]
			Placebo	22	18 (81.8)	0.40 (1.30)	-2.8	-0.25	0.67	1.25	2.7	
		Week 16	Tezepelumab	25	21 (84.0)	1.28 (1.04)	-0.8	0.58	1.08	2.17	3.3	0.74 [0.09, 1.39]
			Placebo	22	18 (81.8)	0.32 (1.55)	-3.5	-0.08	0.88	1.33	2.4	
		Week 20	Tezepelumab	25	21 (84.0)	1.09 (1.07)	-0.8	0.42	0.83	2.17	3.3	0.50 [-0.14, 1.13]
			Placebo	22	18 (81.8)	0.42 (1.64)	-3.5	-0.42	1.00	1.33	2.5	
		Week 24	Tezepelumab	25	21 (84.0)	1.19 (1.03)	-0.8	0.50	1.00	2.33	3.3	0.70 [0.05, 1.34]
			Placebo	22	18 (81.8)	0.22 (1.71)	-3.5	-0.92	0.92	1.33	2.3	
		Week 28	Tezepelumab	25	21 (84.0)	1.06 (1.01)	-0.8	0.50	0.92	1.42	3.3	0.73 [0.08, 1.38]
			Placebo	22	18 (81.8)	0.08 (1.64)	-3.5	-0.83	0.58	1.17	2.3	
		Week 32	Tezepelumab	25	21 (84.0)	1.15 (1.02)	-0.8	0.50	1.08	1.75	3.3	0.63 [-0.02, 1.27]
			Placebo	22	18 (81.8)	0.34 (1.54)	-3.5	-0.58	0.92	1.17	2.3	
		Week 36	Tezepelumab	25	21 (84.0)	1.28 (1.05)	-0.8	0.67	1.33	2.17	3.4	0.71 [0.06, 1.36]
			Placebo	22	18 (81.8)	0.39 (1.46)	-3.0	-0.50	0.92	1.17	2.3	
		Week 40	Tezepelumab	25	21 (84.0)	1.15 (0.99)	-0.8	0.50	1.00	1.83	3.3	0.60 [-0.04, 1.24]
			Placebo	22	18 (81.8)	0.40 (1.49)	-3.0	-1.00	0.67	1.42	2.3	
		Week 44	Tezepelumab	25	21 (84.0)	1.09 (1.02)	-0.8	0.58	1.00	1.50	3.2	0.62 [-0.03, 1.26]
			Placebo	22	18 (81.8)	0.38 (1.27)	-3.0	-0.42	0.75	1.17	2.4	
		Week 48	Tezepelumab	25	21 (84.0)	1.18 (1.06)	-0.8	0.50	1.00	1.58	3.4	0.79 [0.13, 1.44]
			Placebo	22	18 (81.8)	0.24 (1.34)	-3.0	-0.58	0.38	1.17	2.3	
		Week 52	Tezepelumab	25	21 (84.0)	1.20 (1.03)	-0.8	0.50	1.00	1.58	3.4	0.67 [0.02, 1.32]
			Placebo	22	18 (81.8)	0.43 (1.28)	-3.0	-0.25	0.50	1.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Absolute values	Baseline	Tezepelumab	35	33 (94.3)	4.05 (1.22)	1.4	3.25	4.00	4.92	6.7	
			Placebo	41	35 (85.4)	4.05 (0.82)	1.5	3.67	4.17	4.58	5.8	
		Week 4	Tezepelumab	35	31 (88.6)	4.74 (1.31)	1.3	3.58	4.75	5.67	6.8	
			Placebo	41	37 (90.2)	4.73 (0.83)	3.0	4.17	4.67	5.25	6.7	
		Week 8	Tezepelumab	35	33 (94.3)	5.03 (1.25)	2.8	3.92	5.08	6.08	6.8	
			Placebo	41	37 (90.2)	4.77 (1.01)	1.9	4.25	4.58	5.33	7.0	
		Week 12	Tezepelumab	35	33 (94.3)	5.16 (1.18)	3.0	4.17	5.17	6.17	7.0	
			Placebo	41	37 (90.2)	5.05 (0.94)	3.3	4.50	5.00	5.58	7.0	
		Week 16	Tezepelumab	35	33 (94.3)	5.13 (1.21)	2.7	4.33	5.25	6.08	6.9	
			Placebo	41	37 (90.2)	5.03 (1.02)	2.1	4.58	4.83	5.75	7.0	
		Week 20	Tezepelumab	35	33 (94.3)	5.20 (1.19)	2.3	4.25	5.25	6.08	6.9	
			Placebo	41	37 (90.2)	4.82 (0.99)	2.1	4.33	4.75	5.25	7.0	
		Week 24	Tezepelumab	35	33 (94.3)	5.27 (1.14)	3.1	4.42	5.25	6.17	7.0	
			Placebo	41	37 (90.2)	4.88 (0.96)	3.2	4.00	4.75	5.50	7.0	
		Week 28	Tezepelumab	35	34 (97.1)	5.22 (1.18)	3.2	4.08	5.21	6.17	7.0	
			Placebo	41	38 (92.7)	5.10 (1.09)	3.2	4.25	5.08	5.75	7.0	
		Week 32	Tezepelumab	35	34 (97.1)	5.34 (1.17)	2.8	4.42	5.50	6.08	7.0	
			Placebo	41	38 (92.7)	5.07 (0.96)	3.2	4.42	5.04	5.75	7.0	
		Week 36	Tezepelumab	35	34 (97.1)	5.31 (1.19)	2.9	4.25	5.25	6.08	7.0	
			Placebo	41	38 (92.7)	4.89 (1.03)	3.2	4.17	4.83	5.50	7.0	
		Week 40	Tezepelumab	35	34 (97.1)	5.33 (1.28)	2.3	4.33	5.33	6.58	7.0	
			Placebo	41	38 (92.7)	5.08 (1.03)	3.2	4.33	5.08	5.75	7.0	
		Week 44	Tezepelumab	35	34 (97.1)	5.34 (1.13)	3.1	4.42	5.21	6.50	7.0	
			Placebo	41	38 (92.7)	5.03 (1.11)	3.1	4.25	5.04	5.92	7.0	
		Week 48	Tezepelumab	35	34 (97.1)	5.36 (1.20)	2.8	4.33	5.42	6.33	7.0	
			Placebo	41	38 (92.7)	5.15 (1.00)	3.2	4.33	5.17	5.92	7.0	
		Week 52	Tezepelumab	35	34 (97.1)	5.36 (1.20)	2.8	4.33	5.42	6.25	7.0	
			Placebo	41	38 (92.7)	5.14 (1.06)	3.2	4.25	4.96	5.92	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline all FEIA status												
Any positive	Change from baseline	Week 4	Tezepelumab	35	30 (85.7)	0.66 (1.29)	-4.3	-0.08	0.92	1.50	2.4	0.01 [-0.48, 0.50]
			Placebo	41	35 (85.4)	0.65 (0.91)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	35	32 (91.4)	0.97 (1.05)	-1.4	0.29	1.04	1.83	2.3	0.21 [-0.27, 0.70]
			Placebo	41	35 (85.4)	0.75 (1.01)	-1.0	0.17	0.67	1.00	3.6	
		Week 12	Tezepelumab	35	32 (91.4)	1.11 (1.16)	-2.6	0.67	1.17	1.92	3.0	0.11 [-0.37, 0.59]
			Placebo	41	35 (85.4)	0.98 (1.17)	-1.0	0.50	0.75	1.17	4.0	
		Week 16	Tezepelumab	35	32 (91.4)	1.07 (1.17)	-2.9	0.50	1.08	1.75	3.0	0.06 [-0.42, 0.54]
			Placebo	41	35 (85.4)	1.00 (1.18)	-1.3	0.33	0.83	1.42	4.2	
		Week 20	Tezepelumab	35	32 (91.4)	1.15 (1.10)	-1.8	0.46	1.21	2.00	3.0	0.34 [-0.14, 0.82]
			Placebo	41	35 (85.4)	0.79 (1.04)	-1.3	0.08	0.75	1.25	3.8	
		Week 24	Tezepelumab	35	32 (91.4)	1.22 (1.13)	-1.6	0.46	1.46	1.96	3.0	0.32 [-0.16, 0.81]
			Placebo	41	35 (85.4)	0.87 (1.04)	-0.7	0.08	0.83	1.17	3.9	
		Week 28	Tezepelumab	35	32 (91.4)	1.13 (1.18)	-1.7	0.33	1.25	2.04	3.0	0.07 [-0.41, 0.55]
			Placebo	41	35 (85.4)	1.05 (1.07)	-0.7	0.25	0.83	1.67	4.3	
		Week 32	Tezepelumab	35	32 (91.4)	1.26 (1.21)	-1.6	0.42	1.25	2.21	3.0	0.21 [-0.27, 0.69]
			Placebo	41	35 (85.4)	1.04 (0.92)	-0.8	0.42	0.92	1.25	3.5	
		Week 36	Tezepelumab	35	32 (91.4)	1.21 (1.31)	-1.7	0.21	1.08	2.25	3.3	0.32 [-0.16, 0.81]
			Placebo	41	35 (85.4)	0.85 (0.94)	-1.3	0.25	0.83	1.25	3.8	
		Week 40	Tezepelumab	35	32 (91.4)	1.25 (1.34)	-1.7	0.25	1.13	2.25	3.4	0.19 [-0.29, 0.67]
			Placebo	41	35 (85.4)	1.03 (1.01)	-0.5	0.50	0.83	1.58	4.0	
		Week 44	Tezepelumab	35	32 (91.4)	1.26 (1.25)	-1.6	0.38	1.13	2.25	3.3	0.23 [-0.25, 0.71]
			Placebo	41	35 (85.4)	0.98 (1.13)	-1.3	0.33	0.83	1.67	3.7	
		Week 48	Tezepelumab	35	32 (91.4)	1.28 (1.26)	-1.6	0.33	1.25	2.25	3.2	0.16 [-0.32, 0.64]
			Placebo	41	35 (85.4)	1.11 (0.95)	-0.4	0.50	1.08	1.67	4.2	
		Week 52	Tezepelumab	35	32 (91.4)	1.28 (1.27)	-1.6	0.38	1.08	2.29	3.6	0.16 [-0.32, 0.64]
			Placebo	41	35 (85.4)	1.09 (1.05)	-0.7	0.42	0.92	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Absolute values	Baseline	Tezepelumab	41	36 (87.8)	4.16 (0.83)	2.6	3.67	4.17	4.54	6.7	
			Placebo	30	25 (83.3)	4.14 (1.11)	1.5	3.67	4.33	4.75	6.3	
		Week 4	Tezepelumab	41	37 (90.2)	4.90 (0.91)	3.5	4.08	4.75	5.67	6.5	
			Placebo	30	24 (80.0)	4.55 (0.97)	2.7	4.00	4.63	5.25	6.2	
		Week 8	Tezepelumab	41	38 (92.7)	5.06 (1.21)	2.0	4.08	5.00	6.08	6.8	
			Placebo	30	26 (86.7)	4.64 (1.19)	1.9	3.92	4.75	5.50	6.4	
		Week 12	Tezepelumab	41	38 (92.7)	5.31 (1.03)	3.6	4.42	5.29	6.25	6.8	
			Placebo	30	26 (86.7)	4.71 (1.11)	2.1	4.08	4.58	5.42	6.7	
		Week 16	Tezepelumab	41	38 (92.7)	5.40 (1.05)	3.3	4.58	5.38	6.25	7.0	
			Placebo	30	26 (86.7)	4.76 (1.42)	1.3	4.00	4.58	5.92	7.0	
		Week 20	Tezepelumab	41	39 (95.1)	5.29 (1.06)	3.6	4.33	5.17	6.25	7.0	
			Placebo	30	26 (86.7)	4.63 (1.42)	1.3	3.92	4.63	5.58	6.8	
		Week 24	Tezepelumab	41	39 (95.1)	5.30 (1.07)	3.6	4.33	5.17	6.25	7.0	
			Placebo	30	26 (86.7)	4.46 (1.44)	1.3	3.33	4.54	5.42	6.8	
		Week 28	Tezepelumab	41	40 (97.6)	5.22 (1.14)	3.3	4.25	5.04	6.33	7.0	
			Placebo	30	26 (86.7)	4.47 (1.50)	1.3	3.25	4.33	5.58	7.0	
		Week 32	Tezepelumab	41	40 (97.6)	5.23 (1.17)	2.8	4.21	5.13	6.21	7.0	
			Placebo	30	26 (86.7)	4.61 (1.32)	1.3	3.75	4.88	5.67	6.7	
		Week 36	Tezepelumab	41	40 (97.6)	5.33 (1.19)	3.3	4.25	5.50	6.38	7.0	
			Placebo	30	26 (86.7)	4.61 (1.31)	2.4	4.00	4.42	5.58	6.8	
		Week 40	Tezepelumab	41	40 (97.6)	5.25 (1.12)	2.9	4.33	5.21	5.96	7.0	
			Placebo	30	26 (86.7)	4.65 (1.36)	2.3	3.50	4.50	5.92	6.7	
		Week 44	Tezepelumab	41	40 (97.6)	5.26 (1.14)	3.0	4.17	5.21	6.17	7.0	
			Placebo	30	26 (86.7)	4.63 (1.21)	2.5	3.67	4.54	5.83	6.5	
		Week 48	Tezepelumab	41	40 (97.6)	5.31 (1.21)	2.8	4.25	5.29	6.42	7.0	
			Placebo	30	26 (86.7)	4.48 (1.20)	2.2	3.75	4.29	5.67	6.5	
		Week 52	Tezepelumab	41	40 (97.6)	5.30 (1.20)	2.8	4.25	5.21	6.38	7.0	
			Placebo	30	26 (86.7)	4.54 (1.03)	2.8	4.00	4.38	5.17	6.5	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
Low	Change from baseline	Week 4	Tezepelumab	41	34 (82.9)	0.87 (0.92)	-1.4	0.08	0.92	1.58	3.1	0.53 [-0.00, 1.06]
			Placebo	30	24 (80.0)	0.43 (0.67)	-1.1	0.17	0.42	0.83	1.9	
		Week 8	Tezepelumab	41	35 (85.4)	0.82 (1.22)	-1.9	0.00	0.92	1.75	3.3	0.26 [-0.25, 0.78]
			Placebo	30	25 (83.3)	0.53 (0.88)	-1.8	0.17	0.67	0.83	2.7	
		Week 12	Tezepelumab	41	35 (85.4)	1.07 (1.11)	-1.4	0.33	1.00	1.92	3.7	0.39 [-0.13, 0.91]
			Placebo	30	25 (83.3)	0.60 (1.34)	-2.8	-0.08	0.75	1.25	4.0	
		Week 16	Tezepelumab	41	35 (85.4)	1.16 (1.08)	-1.4	0.42	1.08	2.08	3.3	0.39 [-0.13, 0.91]
			Placebo	30	25 (83.3)	0.66 (1.52)	-3.5	0.33	1.00	1.33	4.2	
		Week 20	Tezepelumab	41	35 (85.4)	1.13 (1.10)	-1.4	0.33	0.92	2.08	3.3	0.50 [-0.02, 1.02]
			Placebo	30	25 (83.3)	0.51 (1.38)	-3.5	0.17	0.92	1.25	1.9	
		Week 24	Tezepelumab	41	35 (85.4)	1.13 (1.10)	-1.4	0.33	1.00	2.00	3.3	0.63 [0.10, 1.15]
			Placebo	30	25 (83.3)	0.34 (1.48)	-3.5	-0.25	0.83	1.17	2.7	
		Week 28	Tezepelumab	41	35 (85.4)	1.08 (1.08)	-1.4	0.33	0.92	2.00	3.3	0.56 [0.04, 1.09]
			Placebo	30	25 (83.3)	0.33 (1.60)	-3.5	-0.08	0.58	1.17	4.3	
		Week 32	Tezepelumab	41	35 (85.4)	1.09 (1.17)	-1.4	0.25	1.00	2.08	3.3	0.48 [-0.04, 1.00]
			Placebo	30	25 (83.3)	0.49 (1.38)	-3.5	0.17	0.92	1.17	2.9	
		Week 36	Tezepelumab	41	35 (85.4)	1.19 (1.18)	-1.4	0.25	1.08	2.17	3.4	0.60 [0.07, 1.12]
			Placebo	30	25 (83.3)	0.46 (1.26)	-3.0	0.08	0.75	1.17	2.3	
		Week 40	Tezepelumab	41	35 (85.4)	1.12 (1.11)	-1.4	0.25	1.00	2.17	3.3	0.47 [-0.05, 0.99]
			Placebo	30	25 (83.3)	0.53 (1.43)	-3.0	-0.33	0.67	1.17	4.0	
		Week 44	Tezepelumab	41	35 (85.4)	1.12 (1.15)	-1.4	0.33	0.92	2.17	3.2	0.53 [0.00, 1.05]
			Placebo	30	25 (83.3)	0.49 (1.25)	-3.0	-0.25	0.58	1.17	3.4	
		Week 48	Tezepelumab	41	35 (85.4)	1.20 (1.20)	-1.4	0.33	1.00	2.17	3.4	0.73 [0.20, 1.26]
			Placebo	30	25 (83.3)	0.34 (1.13)	-3.0	0.08	0.42	1.17	2.3	
		Week 52	Tezepelumab	41	35 (85.4)	1.20 (1.19)	-1.4	0.33	1.00	2.17	3.4	0.71 [0.18, 1.24]
			Placebo	30	25 (83.3)	0.40 (1.02)	-3.0	0.17	0.42	1.00	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Absolute values	Baseline	Tezepelumab	25	22 (88.0)	3.70 (1.23)	1.4	2.83	3.79	5.00	5.6	
			Placebo	34	29 (85.3)	4.11 (0.67)	2.8	3.83	4.25	4.50	5.8	
		Week 4	Tezepelumab	25	23 (92.0)	4.50 (1.36)	1.3	3.50	4.75	5.58	6.8	
			Placebo	34	32 (94.1)	4.78 (0.83)	3.2	4.25	4.75	5.25	6.7	
		Week 8	Tezepelumab	25	24 (96.0)	4.90 (1.08)	3.3	4.04	4.96	5.79	6.8	
			Placebo	34	32 (94.1)	4.76 (0.96)	3.0	4.21	4.50	5.29	7.0	
		Week 12	Tezepelumab	25	24 (96.0)	5.05 (1.15)	3.0	4.08	5.00	5.96	7.0	
			Placebo	34	32 (94.1)	4.96 (0.99)	3.3	4.17	4.88	5.58	7.0	
		Week 16	Tezepelumab	25	24 (96.0)	4.93 (1.16)	2.7	4.33	4.96	5.88	6.8	
			Placebo	34	32 (94.1)	4.88 (1.05)	2.1	4.25	4.79	5.58	7.0	
		Week 20	Tezepelumab	25	24 (96.0)	4.93 (1.15)	2.3	4.17	4.75	6.00	6.9	
			Placebo	34	32 (94.1)	4.80 (1.02)	2.1	4.13	4.75	5.25	7.0	
		Week 24	Tezepelumab	25	24 (96.0)	5.02 (1.10)	3.1	4.42	4.96	5.96	6.9	
			Placebo	34	32 (94.1)	4.91 (0.98)	3.3	3.96	4.83	5.63	7.0	
		Week 28	Tezepelumab	25	25 (100.0)	5.02 (1.07)	3.2	4.17	4.83	5.83	7.0	
			Placebo	34	33 (97.1)	5.09 (1.05)	3.2	4.42	5.08	5.75	7.0	
		Week 32	Tezepelumab	25	25 (100.0)	5.21 (1.07)	2.9	4.33	5.08	5.92	6.9	
			Placebo	34	33 (97.1)	5.08 (1.00)	3.4	4.25	5.00	5.75	7.0	
		Week 36	Tezepelumab	25	25 (100.0)	5.16 (1.04)	2.9	4.42	5.17	5.92	7.0	
			Placebo	34	33 (97.1)	4.93 (1.07)	3.2	4.00	4.83	5.75	7.0	
		Week 40	Tezepelumab	25	25 (100.0)	5.15 (1.25)	2.3	4.33	5.00	6.08	7.0	
			Placebo	34	33 (97.1)	5.08 (1.00)	3.4	4.25	5.08	5.75	7.0	
		Week 44	Tezepelumab	25	25 (100.0)	5.15 (1.06)	3.1	4.42	4.92	5.92	7.0	
			Placebo	34	33 (97.1)	5.07 (1.07)	3.2	4.25	5.00	5.83	7.0	
		Week 48	Tezepelumab	25	25 (100.0)	5.16 (1.05)	3.3	4.33	5.08	6.08	6.9	
			Placebo	34	33 (97.1)	5.25 (0.99)	3.8	4.50	5.17	6.00	7.0	
		Week 52	Tezepelumab	25	25 (100.0)	5.17 (1.06)	3.0	4.33	5.08	6.08	6.9	
			Placebo	34	33 (97.1)	5.30 (1.08)	3.6	4.50	5.17	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Th2 status												
High	Change from baseline	Week 4	Tezepelumab	25	21 (84.0)	0.63 (1.35)	-4.3	0.33	0.92	1.33	2.4	-0.06 [-0.62, 0.50]
			Placebo	34	29 (85.3)	0.70 (0.97)	-1.3	0.25	0.58	1.08	3.3	
		Week 8	Tezepelumab	25	22 (88.0)	1.16 (0.89)	-1.4	0.75	1.25	1.92	2.3	0.44 [-0.13, 1.00]
			Placebo	34	29 (85.3)	0.72 (1.11)	-1.0	0.08	0.67	1.17	3.6	
		Week 12	Tezepelumab	25	22 (88.0)	1.32 (1.17)	-2.6	0.83	1.33	2.17	3.0	0.40 [-0.16, 0.96]
			Placebo	34	29 (85.3)	0.87 (1.10)	-1.0	0.25	0.75	1.00	3.8	
		Week 16	Tezepelumab	25	22 (88.0)	1.24 (1.20)	-2.9	0.58	1.33	2.08	3.0	0.37 [-0.19, 0.93]
			Placebo	34	29 (85.3)	0.81 (1.13)	-1.3	0.17	0.67	1.17	3.7	
		Week 20	Tezepelumab	25	22 (88.0)	1.21 (1.07)	-1.8	0.50	1.21	2.17	3.0	0.41 [-0.15, 0.97]
			Placebo	34	29 (85.3)	0.76 (1.13)	-1.3	0.08	0.50	1.25	3.8	
		Week 24	Tezepelumab	25	22 (88.0)	1.39 (1.05)	-1.6	0.67	1.46	2.17	3.0	0.46 [-0.11, 1.02]
			Placebo	34	29 (85.3)	0.90 (1.09)	-0.7	0.08	0.83	1.17	3.9	
		Week 28	Tezepelumab	25	22 (88.0)	1.24 (1.16)	-1.7	0.42	1.25	2.08	3.0	0.20 [-0.35, 0.76]
			Placebo	34	29 (85.3)	1.03 (0.98)	-0.7	0.50	0.83	1.67	3.8	
		Week 32	Tezepelumab	25	22 (88.0)	1.46 (1.07)	-1.6	1.00	1.50	2.25	3.0	0.42 [-0.14, 0.98]
			Placebo	34	29 (85.3)	1.04 (0.94)	-0.8	0.42	0.92	1.33	3.5	
		Week 36	Tezepelumab	25	22 (88.0)	1.37 (1.25)	-1.7	0.75	1.21	2.33	3.3	0.45 [-0.11, 1.01]
			Placebo	34	29 (85.3)	0.87 (1.01)	-1.3	0.25	0.83	1.25	3.8	
		Week 40	Tezepelumab	25	22 (88.0)	1.43 (1.30)	-1.7	1.00	1.50	2.33	3.4	0.37 [-0.19, 0.93]
			Placebo	34	29 (85.3)	1.02 (0.94)	-0.5	0.50	0.83	1.58	3.4	
		Week 44	Tezepelumab	25	22 (88.0)	1.41 (1.14)	-1.6	0.83	1.25	2.08	3.3	0.38 [-0.18, 0.94]
			Placebo	34	29 (85.3)	0.99 (1.09)	-1.3	0.33	1.00	1.58	3.7	
		Week 48	Tezepelumab	25	22 (88.0)	1.41 (1.11)	-1.6	1.08	1.38	2.25	3.2	0.20 [-0.36, 0.75]
			Placebo	34	29 (85.3)	1.20 (1.02)	-0.4	0.58	1.08	1.67	4.2	
		Week 52	Tezepelumab	25	22 (88.0)	1.41 (1.13)	-1.6	0.92	1.25	2.25	3.6	0.13 [-0.43, 0.68]
			Placebo	34	29 (85.3)	1.27 (1.12)	-0.7	0.67	1.08	2.00	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	26	23 (88.5)	3.84 (0.94)	1.9	3.25	3.92	4.50	5.6	
			Placebo	31	25 (80.6)	4.06 (0.91)	1.7	3.42	4.25	4.67	5.8	
		Week 4	Tezepelumab	26	23 (88.5)	4.34 (1.29)	1.3	3.50	4.25	5.33	6.5	
			Placebo	31	25 (80.6)	4.57 (1.08)	2.7	3.92	4.67	5.25	6.7	
		Week 8	Tezepelumab	26	23 (88.5)	4.53 (1.21)	2.0	3.75	4.25	5.58	6.7	
			Placebo	31	27 (87.1)	4.76 (1.11)	2.1	4.17	4.58	5.75	6.8	
		Week 12	Tezepelumab	26	23 (88.5)	4.79 (1.07)	3.0	3.92	4.67	5.33	6.8	
			Placebo	31	27 (87.1)	4.82 (1.28)	2.1	3.83	4.67	5.92	6.8	
		Week 16	Tezepelumab	26	23 (88.5)	4.79 (1.18)	2.7	4.08	4.92	5.42	6.9	
			Placebo	31	27 (87.1)	4.81 (1.43)	1.3	3.92	5.00	5.92	6.8	
		Week 20	Tezepelumab	26	24 (92.3)	4.67 (1.02)	2.3	4.08	4.50	5.13	6.9	
			Placebo	31	27 (87.1)	4.72 (1.37)	1.3	4.00	4.75	5.92	6.6	
		Week 24	Tezepelumab	26	24 (92.3)	4.82 (0.95)	3.1	4.25	4.67	5.25	7.0	
			Placebo	31	27 (87.1)	4.84 (1.34)	1.3	3.92	5.25	5.92	6.7	
		Week 28	Tezepelumab	26	26 (100.0)	4.81 (1.06)	3.2	4.08	4.58	5.25	6.9	
			Placebo	31	28 (90.3)	4.95 (1.41)	1.3	3.88	4.96	6.00	7.0	
		Week 32	Tezepelumab	26	26 (100.0)	4.87 (1.08)	2.9	4.00	4.83	5.50	7.0	
			Placebo	31	28 (90.3)	4.91 (1.36)	1.3	4.00	4.92	6.00	6.8	
		Week 36	Tezepelumab	26	26 (100.0)	4.95 (1.13)	2.9	4.00	4.88	5.75	7.0	
			Placebo	31	28 (90.3)	5.01 (1.32)	2.4	4.17	5.13	6.04	6.9	
		Week 40	Tezepelumab	26	26 (100.0)	4.81 (1.16)	2.3	4.00	5.00	5.42	7.0	
			Placebo	31	28 (90.3)	5.11 (1.33)	2.3	3.92	5.50	6.29	7.0	
		Week 44	Tezepelumab	26	26 (100.0)	4.80 (1.10)	3.0	4.00	4.75	5.75	7.0	
			Placebo	31	28 (90.3)	5.11 (1.30)	2.5	4.21	5.13	6.29	6.9	
		Week 48	Tezepelumab	26	26 (100.0)	4.94 (1.09)	3.1	4.08	5.04	5.58	7.0	
			Placebo	31	28 (90.3)	5.11 (1.31)	2.2	4.13	5.21	6.33	6.9	
		Week 52	Tezepelumab	26	26 (100.0)	4.94 (1.12)	3.0	4.00	5.04	5.58	7.0	
			Placebo	31	28 (90.3)	5.15 (1.32)	2.8	4.13	5.04	6.42	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
Low (< 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	26	23 (88.5)	0.50 (1.31)	-4.3	-0.17	0.58	1.33	2.1	-0.09 [-0.66, 0.48]
			Placebo	31	24 (77.4)	0.60 (0.94)	-1.3	0.25	0.50	0.83	3.3	
		Week 8	Tezepelumab	26	23 (88.5)	0.69 (1.18)	-1.9	0.00	0.75	1.50	2.8	-0.09 [-0.65, 0.48]
			Placebo	31	25 (80.6)	0.79 (1.04)	-1.0	0.42	0.67	1.17	3.3	
		Week 12	Tezepelumab	26	23 (88.5)	0.95 (1.19)	-2.6	0.42	0.92	1.75	3.3	0.08 [-0.49, 0.64]
			Placebo	31	25 (80.6)	0.85 (1.33)	-1.6	0.00	0.92	1.25	4.0	
		Week 16	Tezepelumab	26	23 (88.5)	0.96 (1.13)	-2.9	0.58	0.92	1.67	3.3	0.09 [-0.48, 0.66]
			Placebo	31	25 (80.6)	0.84 (1.48)	-3.5	0.33	0.92	1.33	4.2	
		Week 20	Tezepelumab	26	23 (88.5)	0.83 (1.02)	-1.8	0.33	0.67	1.33	3.3	0.09 [-0.48, 0.65]
			Placebo	31	25 (80.6)	0.73 (1.36)	-3.5	0.08	0.92	1.67	3.3	
		Week 24	Tezepelumab	26	23 (88.5)	0.99 (1.02)	-1.6	0.42	0.92	1.58	3.3	0.10 [-0.47, 0.67]
			Placebo	31	25 (80.6)	0.87 (1.33)	-3.5	0.08	1.00	1.33	3.6	
		Week 28	Tezepelumab	26	23 (88.5)	0.97 (1.07)	-1.7	0.17	0.92	1.58	3.3	0.07 [-0.50, 0.63]
			Placebo	31	25 (80.6)	0.89 (1.38)	-3.5	0.33	1.00	1.42	4.3	
		Week 32	Tezepelumab	26	23 (88.5)	0.95 (1.07)	-1.6	0.25	0.92	1.58	3.3	0.07 [-0.49, 0.64]
			Placebo	31	25 (80.6)	0.87 (1.31)	-3.5	0.42	0.92	1.33	3.5	
		Week 36	Tezepelumab	26	23 (88.5)	1.04 (1.11)	-1.7	0.25	1.00	1.67	3.4	0.09 [-0.48, 0.66]
			Placebo	31	25 (80.6)	0.93 (1.16)	-2.3	0.50	1.00	1.50	3.8	
		Week 40	Tezepelumab	26	23 (88.5)	0.95 (1.14)	-1.7	0.25	1.00	1.17	3.3	-0.10 [-0.67, 0.46]
			Placebo	31	25 (80.6)	1.08 (1.23)	-1.4	0.50	0.83	1.75	4.0	
		Week 44	Tezepelumab	26	23 (88.5)	0.91 (1.06)	-1.6	0.25	0.92	1.33	3.2	-0.12 [-0.68, 0.45]
			Placebo	31	25 (80.6)	1.04 (1.23)	-1.2	0.33	1.17	1.67	3.7	
		Week 48	Tezepelumab	26	23 (88.5)	1.05 (1.02)	-1.6	0.58	1.00	1.50	3.4	-0.01 [-0.57, 0.56]
			Placebo	31	25 (80.6)	1.06 (1.18)	-1.5	0.58	1.17	1.58	4.2	
		Week 52	Tezepelumab	26	23 (88.5)	1.04 (1.00)	-1.6	0.58	0.92	1.50	3.4	-0.06 [-0.62, 0.51]
			Placebo	31	25 (80.6)	1.11 (1.22)	-1.1	0.50	1.08	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Absolute values	Baseline	Tezepelumab	40	35 (87.5)	4.08 (1.06)	1.4	3.42	4.08	4.83	6.7	
			Placebo	34	30 (88.2)	4.18 (0.87)	1.5	3.83	4.29	4.58	6.3	
		Week 4	Tezepelumab	40	37 (92.5)	5.00 (0.91)	3.3	4.42	5.00	5.67	6.8	
			Placebo	34	32 (94.1)	4.82 (0.76)	3.4	4.29	4.88	5.25	6.2	
		Week 8	Tezepelumab	40	39 (97.5)	5.28 (1.04)	2.8	4.33	5.42	6.08	6.8	
			Placebo	34	32 (94.1)	4.72 (1.07)	1.9	4.21	4.67	5.29	7.0	
		Week 12	Tezepelumab	40	39 (97.5)	5.46 (1.02)	3.5	4.42	5.50	6.42	7.0	
			Placebo	34	32 (94.1)	4.93 (0.86)	3.5	4.21	4.88	5.42	7.0	
		Week 16	Tezepelumab	40	39 (97.5)	5.47 (0.99)	3.3	4.42	5.58	6.25	7.0	
			Placebo	34	32 (94.1)	4.89 (1.05)	3.3	4.13	4.67	5.79	7.0	
		Week 20	Tezepelumab	40	39 (97.5)	5.46 (1.05)	3.5	4.42	5.67	6.25	7.0	
			Placebo	34	32 (94.1)	4.79 (1.10)	2.4	4.04	4.75	5.33	7.0	
		Week 24	Tezepelumab	40	39 (97.5)	5.42 (1.10)	3.3	4.42	5.50	6.33	7.0	
			Placebo	34	32 (94.1)	4.65 (1.14)	2.2	3.83	4.63	5.21	7.0	
		Week 28	Tezepelumab	40	39 (97.5)	5.37 (1.10)	3.8	4.33	5.42	6.42	7.0	
			Placebo	34	32 (94.1)	4.75 (1.20)	1.8	4.00	4.75	5.50	7.0	
		Week 32	Tezepelumab	40	39 (97.5)	5.46 (1.10)	2.8	4.42	5.58	6.25	7.0	
			Placebo	34	32 (94.1)	4.88 (1.00)	2.9	4.17	4.92	5.54	7.0	
		Week 36	Tezepelumab	40	39 (97.5)	5.47 (1.10)	3.3	4.42	5.50	6.33	7.0	
			Placebo	34	32 (94.1)	4.64 (1.04)	2.8	4.00	4.54	5.29	7.0	
		Week 40	Tezepelumab	40	39 (97.5)	5.48 (1.10)	3.8	4.42	5.50	6.58	7.0	
			Placebo	34	32 (94.1)	4.74 (1.03)	2.5	4.00	4.71	5.46	7.0	
		Week 44	Tezepelumab	40	39 (97.5)	5.49 (1.03)	3.8	4.67	5.50	6.50	7.0	
			Placebo	34	32 (94.1)	4.72 (0.99)	3.1	4.00	4.63	5.63	7.0	
		Week 48	Tezepelumab	40	39 (97.5)	5.46 (1.15)	2.8	4.42	5.58	6.33	7.0	
			Placebo	34	32 (94.1)	4.78 (0.98)	2.4	4.08	4.75	5.46	7.0	
		Week 52	Tezepelumab	40	39 (97.5)	5.46 (1.12)	2.8	4.67	5.50	6.25	7.0	
			Placebo	34	32 (94.1)	4.85 (0.90)	3.2	4.17	4.75	5.46	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline Periostin												
High (>= 20.9 ng/ml)	Change from baseline	Week 4	Tezepelumab	40	32 (80.0)	0.97 (0.90)	-1.4	0.33	1.13	1.50	3.1	0.41 [-0.09, 0.91]
			Placebo	34	30 (88.2)	0.62 (0.84)	-1.2	0.17	0.63	1.00	3.1	
		Week 8	Tezepelumab	40	34 (85.0)	1.13 (1.04)	-1.4	0.33	1.13	1.92	3.3	0.55 [0.05, 1.05]
			Placebo	34	30 (88.2)	0.56 (1.02)	-1.8	0.08	0.58	0.83	3.6	
		Week 12	Tezepelumab	40	34 (85.0)	1.32 (1.08)	-1.4	0.42	1.33	2.17	3.7	0.53 [0.03, 1.03]
			Placebo	34	30 (88.2)	0.72 (1.16)	-2.8	0.17	0.67	1.08	3.8	
		Week 16	Tezepelumab	40	34 (85.0)	1.36 (1.10)	-1.4	0.50	1.58	2.17	3.2	0.55 [0.05, 1.05]
			Placebo	34	30 (88.2)	0.72 (1.20)	-3.0	0.17	0.83	1.25	3.7	
		Week 20	Tezepelumab	40	34 (85.0)	1.38 (1.07)	-1.4	0.67	1.42	2.25	3.0	0.66 [0.15, 1.16]
			Placebo	34	30 (88.2)	0.64 (1.20)	-3.0	0.08	0.79	1.25	3.8	
		Week 24	Tezepelumab	40	34 (85.0)	1.40 (1.10)	-1.4	0.50	1.46	2.25	3.0	0.75 [0.24, 1.26]
			Placebo	34	30 (88.2)	0.50 (1.29)	-3.0	-0.17	0.58	1.17	3.9	
		Week 28	Tezepelumab	40	34 (85.0)	1.25 (1.13)	-1.4	0.50	1.21	2.17	3.0	0.53 [0.03, 1.03]
			Placebo	34	30 (88.2)	0.61 (1.32)	-3.0	0.00	0.79	1.08	3.8	
		Week 32	Tezepelumab	40	34 (85.0)	1.42 (1.16)	-1.4	0.50	1.54	2.33	3.0	0.58 [0.08, 1.08]
			Placebo	34	30 (88.2)	0.77 (1.10)	-3.0	0.25	0.92	1.17	3.3	
		Week 36	Tezepelumab	40	34 (85.0)	1.41 (1.25)	-1.4	0.33	1.71	2.33	3.3	0.75 [0.25, 1.26]
			Placebo	34	30 (88.2)	0.51 (1.10)	-3.0	0.08	0.54	1.17	2.6	
		Week 40	Tezepelumab	40	34 (85.0)	1.43 (1.19)	-1.4	0.50	1.50	2.33	3.4	0.70 [0.19, 1.21]
			Placebo	34	30 (88.2)	0.61 (1.17)	-3.0	0.00	0.75	1.25	2.8	
		Week 44	Tezepelumab	40	34 (85.0)	1.45 (1.17)	-1.4	0.50	1.54	2.33	3.3	0.76 [0.25, 1.26]
			Placebo	34	30 (88.2)	0.58 (1.14)	-3.0	0.00	0.71	1.25	2.8	
		Week 48	Tezepelumab	40	34 (85.0)	1.43 (1.24)	-1.4	0.33	1.63	2.42	3.2	0.67 [0.17, 1.18]
			Placebo	34	30 (88.2)	0.64 (1.12)	-3.0	0.25	0.58	1.25	2.8	
		Week 52	Tezepelumab	40	34 (85.0)	1.44 (1.25)	-1.4	0.42	1.29	2.58	3.6	0.62 [0.12, 1.12]
			Placebo	34	30 (88.2)	0.71 (1.09)	-3.0	0.25	0.71	1.25	2.8	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	57	49 (86.0)	3.91 (1.06)	1.4	3.25	4.00	4.50	6.7	
			Placebo	60	51 (85.0)	4.17 (0.75)	1.7	3.67	4.33	4.58	5.8	
		Week 4	Tezepelumab	57	51 (89.5)	4.59 (1.06)	1.3	3.92	4.58	5.42	6.5	
			Placebo	60	52 (86.7)	4.79 (0.88)	2.7	4.25	4.75	5.25	6.7	
		Week 8	Tezepelumab	57	53 (93.0)	4.83 (1.12)	2.0	4.00	4.75	5.75	6.8	
			Placebo	60	54 (90.0)	4.81 (1.04)	2.1	4.17	4.67	5.50	7.0	
		Week 12	Tezepelumab	57	53 (93.0)	5.01 (1.00)	3.0	4.25	4.83	5.83	6.8	
			Placebo	60	54 (90.0)	4.92 (1.04)	2.1	4.17	4.92	5.58	7.0	
		Week 16	Tezepelumab	57	53 (93.0)	5.03 (1.07)	2.7	4.33	5.08	5.83	7.0	
			Placebo	60	54 (90.0)	4.87 (1.22)	1.3	4.17	4.75	5.83	7.0	
		Week 20	Tezepelumab	57	54 (94.7)	4.96 (1.04)	2.3	4.17	4.75	5.67	7.0	
			Placebo	60	54 (90.0)	4.84 (1.23)	1.3	4.08	5.00	5.75	7.0	
		Week 24	Tezepelumab	57	54 (94.7)	4.99 (1.01)	3.1	4.17	4.83	5.83	7.0	
			Placebo	60	54 (90.0)	4.81 (1.23)	1.3	3.92	4.75	5.75	7.0	
		Week 28	Tezepelumab	57	56 (98.2)	5.03 (1.05)	3.2	4.17	4.92	5.79	7.0	
			Placebo	60	55 (91.7)	4.90 (1.27)	1.3	4.08	5.00	5.75	7.0	
		Week 32	Tezepelumab	57	56 (98.2)	5.04 (1.07)	2.8	4.21	4.92	5.83	7.0	
			Placebo	60	55 (91.7)	4.97 (1.16)	1.3	4.25	5.00	5.83	7.0	
		Week 36	Tezepelumab	57	56 (98.2)	5.15 (1.09)	2.9	4.29	5.13	5.92	7.0	
			Placebo	60	55 (91.7)	4.91 (1.18)	2.4	4.17	4.83	5.92	7.0	
		Week 40	Tezepelumab	57	56 (98.2)	5.04 (1.11)	2.3	4.25	5.00	5.83	7.0	
			Placebo	60	55 (91.7)	4.99 (1.14)	2.3	4.08	5.08	5.92	7.0	
		Week 44	Tezepelumab	57	56 (98.2)	5.07 (1.07)	3.0	4.17	4.92	5.83	7.0	
			Placebo	60	55 (91.7)	4.99 (1.11)	2.5	4.25	5.00	5.92	7.0	
		Week 48	Tezepelumab	57	56 (98.2)	5.14 (1.11)	2.8	4.21	5.08	6.04	7.0	
			Placebo	60	55 (91.7)	5.05 (1.13)	2.2	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	57	56 (98.2)	5.15 (1.14)	2.8	4.21	5.08	6.08	7.0	
			Placebo	60	55 (91.7)	5.12 (1.08)	2.8	4.25	4.92	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
Yes	Change from baseline	Week 4	Tezepelumab	57	46 (80.7)	0.69 (1.14)	-4.3	0.08	0.88	1.33	3.1	0.07 [-0.33, 0.47]
			Placebo	60	50 (83.3)	0.62 (0.86)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	57	48 (84.2)	0.82 (1.12)	-1.9	0.17	0.92	1.71	3.3	0.14 [-0.25, 0.54]
			Placebo	60	51 (85.0)	0.68 (0.97)	-1.0	0.08	0.67	1.17	3.6	
		Week 12	Tezepelumab	57	48 (84.2)	1.01 (1.12)	-2.6	0.33	1.04	1.79	3.7	0.24 [-0.16, 0.64]
			Placebo	60	51 (85.0)	0.75 (1.05)	-1.6	0.08	0.75	1.17	3.8	
		Week 16	Tezepelumab	57	48 (84.2)	1.05 (1.11)	-2.9	0.42	1.04	1.75	3.2	0.28 [-0.12, 0.68]
			Placebo	60	51 (85.0)	0.73 (1.14)	-3.5	0.17	0.83	1.25	3.7	
		Week 20	Tezepelumab	57	48 (84.2)	1.01 (1.07)	-1.8	0.33	0.88	1.96	3.0	0.26 [-0.13, 0.66]
			Placebo	60	51 (85.0)	0.71 (1.18)	-3.5	0.08	0.83	1.25	3.8	
		Week 24	Tezepelumab	57	48 (84.2)	1.09 (1.08)	-1.6	0.42	1.04	1.83	3.0	0.35 [-0.04, 0.75]
			Placebo	60	51 (85.0)	0.68 (1.22)	-3.5	0.00	0.83	1.17	3.9	
		Week 28	Tezepelumab	57	48 (84.2)	1.08 (1.09)	-1.7	0.33	1.00	2.00	3.0	0.30 [-0.09, 0.70]
			Placebo	60	51 (85.0)	0.73 (1.18)	-3.5	0.25	0.83	1.25	3.8	
		Week 32	Tezepelumab	57	48 (84.2)	1.09 (1.15)	-1.6	0.33	1.00	1.92	3.0	0.24 [-0.15, 0.64]
			Placebo	60	51 (85.0)	0.82 (1.06)	-3.5	0.33	0.92	1.17	3.5	
		Week 36	Tezepelumab	57	48 (84.2)	1.19 (1.22)	-1.7	0.25	1.08	2.25	3.3	0.39 [-0.00, 0.79]
			Placebo	60	51 (85.0)	0.74 (1.04)	-2.3	0.08	0.83	1.17	3.8	
		Week 40	Tezepelumab	57	48 (84.2)	1.11 (1.21)	-1.7	0.25	1.04	2.17	3.4	0.25 [-0.15, 0.64]
			Placebo	60	51 (85.0)	0.84 (1.02)	-1.4	0.08	0.83	1.42	3.4	
		Week 44	Tezepelumab	57	48 (84.2)	1.14 (1.17)	-1.6	0.38	1.04	2.08	3.3	0.29 [-0.11, 0.68]
			Placebo	60	51 (85.0)	0.83 (1.03)	-1.3	0.33	0.83	1.33	3.7	
		Week 48	Tezepelumab	57	48 (84.2)	1.23 (1.18)	-1.6	0.42	1.13	2.21	3.2	0.30 [-0.09, 0.70]
			Placebo	60	51 (85.0)	0.89 (1.06)	-1.5	0.25	0.83	1.50	4.2	
		Week 52	Tezepelumab	57	48 (84.2)	1.24 (1.19)	-1.6	0.42	1.08	2.25	3.6	0.25 [-0.15, 0.65]
			Placebo	60	51 (85.0)	0.95 (1.06)	-1.1	0.25	0.83	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	9	9 (100.0)	4.38 (0.57)	3.4	4.17	4.50	4.67	5.0	
			Placebo	5	4 (80.0)	3.54 (2.03)	1.5	2.08	3.21	5.00	6.3	
		Week 4	Tezepelumab	9	9 (100.0)	5.59 (1.06)	3.6	4.75	6.08	6.33	6.8	
			Placebo	5	5 (100.0)	3.85 (0.94)	3.0	3.17	3.42	4.50	5.2	
		Week 8	Tezepelumab	9	9 (100.0)	6.01 (0.82)	4.6	5.83	6.33	6.67	6.8	
			Placebo	5	5 (100.0)	3.97 (1.32)	1.9	3.50	4.50	4.58	5.3	
		Week 12	Tezepelumab	9	9 (100.0)	6.39 (0.73)	4.9	6.08	6.83	6.92	7.0	
			Placebo	5	5 (100.0)	4.48 (1.30)	3.5	3.50	4.17	4.58	6.7	
		Week 16	Tezepelumab	9	9 (100.0)	6.34 (0.59)	5.1	6.00	6.50	6.83	6.9	
			Placebo	5	5 (100.0)	4.65 (1.42)	3.3	3.92	4.00	5.25	6.8	
		Week 20	Tezepelumab	9	9 (100.0)	6.36 (0.55)	5.6	6.00	6.25	6.92	6.9	
			Placebo	5	5 (100.0)	3.80 (0.63)	3.2	3.25	3.67	4.42	4.5	
		Week 24	Tezepelumab	9	9 (100.0)	6.39 (0.59)	5.5	5.92	6.58	6.92	7.0	
			Placebo	5	5 (100.0)	3.98 (0.94)	3.2	3.25	3.58	4.58	5.3	
		Week 28	Tezepelumab	9	9 (100.0)	5.85 (1.26)	3.9	5.00	6.17	6.92	7.0	
			Placebo	5	5 (100.0)	4.20 (1.59)	3.2	3.25	3.75	3.83	7.0	
		Week 32	Tezepelumab	9	9 (100.0)	6.35 (0.76)	4.8	6.00	6.75	6.92	7.0	
			Placebo	5	5 (100.0)	4.10 (1.06)	3.2	3.25	3.67	4.83	5.6	
		Week 36	Tezepelumab	9	9 (100.0)	6.00 (1.14)	4.2	5.50	6.17	7.00	7.0	
			Placebo	5	5 (100.0)	3.75 (0.58)	3.2	3.25	3.75	4.00	4.6	
		Week 40	Tezepelumab	9	9 (100.0)	6.28 (0.93)	4.5	5.83	6.92	7.00	7.0	
			Placebo	5	5 (100.0)	4.05 (1.48)	3.2	3.25	3.42	3.75	6.7	
		Week 44	Tezepelumab	9	9 (100.0)	6.11 (0.88)	4.9	5.42	6.25	7.00	7.0	
			Placebo	5	5 (100.0)	3.95 (1.27)	3.1	3.17	3.25	4.17	6.1	
		Week 48	Tezepelumab	9	9 (100.0)	5.94 (1.18)	3.8	5.58	6.17	6.92	7.0	
			Placebo	5	5 (100.0)	3.70 (0.47)	3.2	3.25	3.83	4.00	4.3	
		Week 52	Tezepelumab	9	9 (100.0)	5.89 (1.01)	3.8	5.42	6.08	6.67	7.0	
			Placebo	5	5 (100.0)	3.62 (0.44)	3.2	3.25	3.58	3.83	4.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Current post-BD FEV1 reversibility												
No	Change from baseline	Week 4	Tezepelumab	9	9 (100.0)	1.21 (0.80)	0.1	0.33	1.50	1.75	2.1	0.78 [-0.44, 2.00]
			Placebo	5	4 (80.0)	0.48 (1.24)	-1.1	-0.37	0.54	1.33	1.9	
		Week 8	Tezepelumab	9	9 (100.0)	1.63 (0.75)	0.3	1.17	1.67	2.00	2.8	0.95 [-0.29, 2.20]
			Placebo	5	4 (80.0)	0.54 (1.81)	-1.8	-0.67	0.63	1.75	2.7	
		Week 12	Tezepelumab	9	9 (100.0)	2.01 (0.78)	0.4	1.92	2.17	2.25	3.3	0.49 [-0.70, 1.69]
			Placebo	5	4 (80.0)	1.19 (2.93)	-2.8	-0.96	1.75	3.33	4.0	
		Week 16	Tezepelumab	9	9 (100.0)	1.96 (0.81)	0.6	1.67	2.08	2.17	3.3	0.38 [-0.80, 1.57]
			Placebo	5	4 (80.0)	1.29 (3.07)	-3.0	-0.75	2.00	3.33	4.2	
		Week 20	Tezepelumab	9	9 (100.0)	1.98 (0.68)	1.1	1.58	2.08	2.25	3.3	1.30 [-0.00, 2.59]
			Placebo	5	4 (80.0)	0.29 (2.24)	-3.0	-1.13	1.21	1.71	1.8	
		Week 24	Tezepelumab	9	9 (100.0)	2.01 (0.72)	1.0	1.75	2.17	2.33	3.3	1.02 [-0.23, 2.28]
			Placebo	5	4 (80.0)	0.54 (2.48)	-3.0	-1.08	1.25	2.17	2.7	
		Week 28	Tezepelumab	9	9 (100.0)	1.47 (1.18)	-0.5	0.58	2.00	2.25	3.3	0.38 [-0.81, 1.57]
			Placebo	5	4 (80.0)	0.75 (3.07)	-3.0	-1.50	0.83	3.00	4.3	
		Week 32	Tezepelumab	9	9 (100.0)	1.97 (0.73)	1.0	1.42	2.08	2.33	3.3	0.89 [-0.35, 2.12]
			Placebo	5	4 (80.0)	0.67 (2.56)	-3.0	-0.96	1.38	2.29	2.9	
		Week 36	Tezepelumab	9	9 (100.0)	1.62 (1.06)	-0.2	1.00	2.00	2.17	3.4	0.95 [-0.29, 2.19]
			Placebo	5	4 (80.0)	0.21 (2.26)	-3.0	-1.38	0.96	1.79	1.9	
		Week 40	Tezepelumab	9	9 (100.0)	1.90 (0.85)	0.8	1.08	2.00	2.33	3.3	0.77 [-0.45, 1.99]
			Placebo	5	4 (80.0)	0.58 (2.97)	-3.0	-1.67	0.67	2.83	4.0	
		Week 44	Tezepelumab	9	9 (100.0)	1.73 (0.88)	0.5	0.92	2.00	2.33	3.2	0.84 [-0.39, 2.07]
			Placebo	5	4 (80.0)	0.35 (2.79)	-3.0	-1.83	0.50	2.54	3.4	
		Week 48	Tezepelumab	9	9 (100.0)	1.56 (1.07)	-0.1	1.08	1.92	2.00	3.4	1.03 [-0.22, 2.28]
			Placebo	5	4 (80.0)	0.08 (2.11)	-3.0	-1.25	0.83	1.42	1.7	
		Week 52	Tezepelumab	9	9 (100.0)	1.51 (0.99)	0.3	1.00	1.08	2.00	3.4	1.03 [-0.23, 2.28]
			Placebo	5	4 (80.0)	0.08 (2.11)	-3.0	-1.25	0.83	1.42	1.7	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Absolute values	Baseline	Tezepelumab	9	8 (88.9)	3.97 (0.72)	3.2	3.29	3.88	4.63	5.0	
			Placebo	14	10 (71.4)	4.28 (0.90)	2.7	4.00	4.29	4.50	6.3	
		Week 4	Tezepelumab	9	8 (88.9)	4.90 (0.98)	3.6	4.42	4.63	5.54	6.4	
			Placebo	14	12 (85.7)	4.52 (1.09)	2.7	3.54	4.92	5.25	6.0	
		Week 8	Tezepelumab	9	8 (88.9)	5.52 (0.92)	4.3	4.83	5.38	6.29	6.8	
			Placebo	14	13 (92.9)	4.49 (0.72)	2.9	4.25	4.67	5.08	5.4	
		Week 12	Tezepelumab	9	8 (88.9)	5.64 (0.99)	4.3	4.88	5.46	6.54	7.0	
			Placebo	14	13 (92.9)	4.49 (1.23)	2.1	3.50	4.33	5.17	6.7	
		Week 16	Tezepelumab	9	8 (88.9)	5.79 (0.78)	4.3	5.46	5.83	6.25	6.9	
			Placebo	14	13 (92.9)	4.72 (1.17)	2.8	3.92	4.67	5.75	6.8	
		Week 20	Tezepelumab	9	8 (88.9)	5.33 (1.08)	3.8	4.25	5.67	6.08	6.8	
			Placebo	14	13 (92.9)	4.49 (0.90)	2.8	4.00	4.42	5.25	5.8	
		Week 24	Tezepelumab	9	8 (88.9)	5.45 (1.12)	4.0	4.25	5.83	6.29	6.8	
			Placebo	14	13 (92.9)	4.56 (1.02)	2.8	3.83	4.67	5.33	6.0	
		Week 28	Tezepelumab	9	8 (88.9)	4.88 (1.12)	3.8	3.96	4.46	5.79	6.8	
			Placebo	14	14 (100.0)	4.83 (1.22)	2.8	3.83	4.83	5.58	7.0	
		Week 32	Tezepelumab	9	8 (88.9)	5.28 (1.17)	3.7	4.29	5.29	6.33	6.8	
			Placebo	14	14 (100.0)	4.82 (1.13)	3.0	3.83	5.17	5.58	6.8	
		Week 36	Tezepelumab	9	8 (88.9)	5.01 (1.15)	3.7	4.21	4.54	6.00	6.9	
			Placebo	14	14 (100.0)	4.74 (1.19)	2.4	3.83	4.79	5.42	6.9	
		Week 40	Tezepelumab	9	8 (88.9)	5.40 (1.24)	4.1	4.29	5.25	6.50	7.0	
			Placebo	14	14 (100.0)	4.80 (1.38)	2.3	3.83	4.79	5.75	7.0	
		Week 44	Tezepelumab	9	8 (88.9)	5.20 (1.08)	4.1	4.25	4.92	6.13	6.9	
			Placebo	14	14 (100.0)	4.79 (1.23)	2.5	3.83	4.83	5.75	6.9	
		Week 48	Tezepelumab	9	8 (88.9)	5.14 (1.26)	3.7	4.04	5.04	6.17	6.9	
			Placebo	14	14 (100.0)	4.62 (1.25)	2.2	3.83	4.58	5.17	6.9	
		Week 52	Tezepelumab	9	8 (88.9)	5.27 (1.22)	3.7	4.04	5.58	6.17	6.9	
			Placebo	14	14 (100.0)	4.66 (1.20)	2.8	3.83	4.63	5.17	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
Yes	Change from baseline	Week 4	Tezepelumab	9	7 (77.8)	0.94 (0.58)	0.2	0.33	1.33	1.33	1.6	0.95 [-0.07, 1.98]
			Placebo	14	10 (71.4)	0.23 (0.85)	-1.1	-0.42	0.33	0.67	1.5	
		Week 8	Tezepelumab	9	7 (77.8)	1.54 (0.70)	0.5	0.83	1.92	2.00	2.3	1.13 [0.08, 2.17]
			Placebo	14	10 (71.4)	0.38 (1.19)	-1.8	-0.08	0.38	1.00	2.7	
		Week 12	Tezepelumab	9	7 (77.8)	1.70 (0.70)	0.5	1.25	1.83	2.17	2.6	1.03 [-0.01, 2.06]
			Placebo	14	10 (71.4)	0.21 (1.79)	-2.8	-0.83	0.25	0.83	4.0	
		Week 16	Tezepelumab	9	7 (77.8)	1.85 (0.79)	0.5	1.00	2.08	2.50	2.6	0.80 [-0.21, 1.81]
			Placebo	14	10 (71.4)	0.62 (1.88)	-3.0	-0.08	0.58	1.67	4.2	
		Week 20	Tezepelumab	9	7 (77.8)	1.52 (0.78)	0.5	0.67	1.58	2.25	2.5	1.00 [-0.03, 2.03]
			Placebo	14	10 (71.4)	0.33 (1.41)	-3.0	-0.08	0.79	1.25	1.8	
		Week 24	Tezepelumab	9	7 (77.8)	1.68 (0.84)	0.5	1.00	2.00	2.33	2.8	0.87 [-0.14, 1.89]
			Placebo	14	10 (71.4)	0.51 (1.59)	-3.0	0.08	0.75	1.67	2.7	
		Week 28	Tezepelumab	9	7 (77.8)	0.94 (1.03)	-0.5	0.50	0.58	2.00	2.6	0.22 [-0.75, 1.18]
			Placebo	14	10 (71.4)	0.60 (1.86)	-3.0	0.08	0.83	1.08	4.3	
		Week 32	Tezepelumab	9	7 (77.8)	1.54 (0.75)	0.5	1.00	1.42	2.33	2.6	0.69 [-0.30, 1.69]
			Placebo	14	10 (71.4)	0.62 (1.58)	-3.0	0.08	0.96	1.33	2.9	
		Week 36	Tezepelumab	9	7 (77.8)	1.23 (0.99)	-0.2	0.50	1.08	2.08	2.8	0.59 [-0.40, 1.57]
			Placebo	14	10 (71.4)	0.43 (1.55)	-3.0	0.08	0.75	1.67	2.0	
		Week 40	Tezepelumab	9	7 (77.8)	1.61 (0.92)	0.5	1.00	1.08	2.58	2.9	0.64 [-0.36, 1.63]
			Placebo	14	10 (71.4)	0.58 (1.94)	-3.0	-0.50	0.83	1.67	4.0	
		Week 44	Tezepelumab	9	7 (77.8)	1.38 (1.03)	0.5	0.50	1.00	2.08	3.3	0.58 [-0.41, 1.57]
			Placebo	14	10 (71.4)	0.48 (1.81)	-3.0	-0.83	0.71	1.67	3.4	
		Week 48	Tezepelumab	9	7 (77.8)	1.37 (1.22)	-0.1	0.33	1.08	2.58	3.1	0.76 [-0.24, 1.76]
			Placebo	14	10 (71.4)	0.29 (1.53)	-3.0	0.08	0.58	1.17	2.3	
		Week 52	Tezepelumab	9	7 (77.8)	1.52 (1.06)	0.3	0.50	1.08	2.58	3.1	0.89 [-0.13, 1.91]
			Placebo	14	10 (71.4)	0.35 (1.47)	-3.0	0.08	0.58	1.17	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Absolute values	Baseline	Tezepelumab	57	50 (87.7)	3.99 (1.06)	1.4	3.42	4.13	4.67	6.7	
			Placebo	51	45 (88.2)	4.09 (0.89)	1.5	3.50	4.25	4.58	5.8	
		Week 4	Tezepelumab	57	52 (91.2)	4.72 (1.13)	1.3	3.92	4.88	5.58	6.8	
			Placebo	51	45 (88.2)	4.76 (0.87)	2.7	4.25	4.67	5.25	6.7	
		Week 8	Tezepelumab	57	54 (94.7)	4.92 (1.17)	2.0	4.00	4.83	5.83	6.8	
			Placebo	51	46 (90.2)	4.81 (1.16)	1.9	4.17	4.63	5.83	7.0	
		Week 12	Tezepelumab	57	54 (94.7)	5.15 (1.09)	3.0	4.25	5.08	6.08	6.9	
			Placebo	51	46 (90.2)	4.99 (1.00)	2.9	4.17	4.88	5.67	7.0	
		Week 16	Tezepelumab	57	54 (94.7)	5.14 (1.13)	2.7	4.33	5.13	6.08	7.0	
			Placebo	51	46 (90.2)	4.89 (1.25)	1.3	4.17	4.79	5.92	7.0	
		Week 20	Tezepelumab	57	55 (96.5)	5.13 (1.11)	2.3	4.25	5.00	6.00	7.0	
			Placebo	51	46 (90.2)	4.83 (1.30)	1.3	4.08	4.88	5.92	7.0	
		Week 24	Tezepelumab	57	55 (96.5)	5.15 (1.08)	3.1	4.42	5.08	6.08	7.0	
			Placebo	51	46 (90.2)	4.79 (1.29)	1.3	3.92	4.71	5.92	7.0	
		Week 28	Tezepelumab	57	57 (100.0)	5.18 (1.11)	3.2	4.33	5.00	6.17	7.0	
			Placebo	51	46 (90.2)	4.84 (1.33)	1.3	4.00	4.88	5.92	7.0	
		Week 32	Tezepelumab	57	57 (100.0)	5.21 (1.13)	2.8	4.33	5.08	6.08	7.0	
			Placebo	51	46 (90.2)	4.92 (1.20)	1.3	4.25	4.92	5.92	7.0	
		Week 36	Tezepelumab	57	57 (100.0)	5.30 (1.14)	2.9	4.50	5.25	6.17	7.0	
			Placebo	51	46 (90.2)	4.83 (1.20)	2.5	4.00	4.63	5.92	7.0	
		Week 40	Tezepelumab	57	57 (100.0)	5.19 (1.16)	2.3	4.33	5.08	6.00	7.0	
			Placebo	51	46 (90.2)	4.95 (1.13)	2.5	4.08	4.96	5.92	7.0	
		Week 44	Tezepelumab	57	57 (100.0)	5.22 (1.12)	3.0	4.33	5.08	6.08	7.0	
			Placebo	51	46 (90.2)	4.93 (1.14)	2.8	4.08	4.79	5.92	7.0	
		Week 48	Tezepelumab	57	57 (100.0)	5.26 (1.14)	2.8	4.33	5.17	6.17	7.0	
			Placebo	51	46 (90.2)	5.03 (1.12)	2.4	4.25	4.96	6.00	7.0	
		Week 52	Tezepelumab	57	57 (100.0)	5.25 (1.14)	2.8	4.33	5.17	6.17	7.0	
			Placebo	51	46 (90.2)	5.09 (1.09)	2.8	4.25	4.92	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Maintenance OCS use at baseline												
No	Change from baseline	Week 4	Tezepelumab	57	48 (84.2)	0.75 (1.16)	-4.3	0.08	0.92	1.50	3.1	0.05 [-0.36, 0.46]
			Placebo	51	44 (86.3)	0.70 (0.87)	-1.3	0.21	0.54	0.96	3.3	
		Week 8	Tezepelumab	57	50 (87.7)	0.87 (1.14)	-1.9	0.17	0.96	1.67	3.3	0.13 [-0.27, 0.53]
			Placebo	51	45 (88.2)	0.73 (0.99)	-1.0	0.17	0.67	1.17	3.6	
		Week 12	Tezepelumab	57	50 (87.7)	1.09 (1.16)	-2.6	0.33	1.08	1.92	3.7	0.17 [-0.24, 0.57]
			Placebo	51	45 (88.2)	0.91 (1.05)	-1.0	0.50	0.75	1.25	3.8	
		Week 16	Tezepelumab	57	50 (87.7)	1.10 (1.13)	-2.9	0.42	1.08	1.75	3.3	0.25 [-0.15, 0.66]
			Placebo	51	45 (88.2)	0.81 (1.19)	-3.5	0.17	0.92	1.33	3.7	
		Week 20	Tezepelumab	57	50 (87.7)	1.11 (1.11)	-1.8	0.33	1.00	2.08	3.3	0.30 [-0.10, 0.71]
			Placebo	51	45 (88.2)	0.76 (1.23)	-3.5	0.17	0.92	1.33	3.8	
		Week 24	Tezepelumab	57	50 (87.7)	1.17 (1.10)	-1.6	0.42	1.17	1.83	3.3	0.40 [-0.01, 0.80]
			Placebo	51	45 (88.2)	0.70 (1.26)	-3.5	0.00	0.83	1.17	3.9	
		Week 28	Tezepelumab	57	50 (87.7)	1.17 (1.12)	-1.7	0.33	1.04	2.08	3.3	0.34 [-0.06, 0.75]
			Placebo	51	45 (88.2)	0.76 (1.23)	-3.5	0.25	0.75	1.33	3.8	
		Week 32	Tezepelumab	57	50 (87.7)	1.19 (1.18)	-1.6	0.33	1.08	2.17	3.3	0.29 [-0.11, 0.70]
			Placebo	51	45 (88.2)	0.85 (1.10)	-3.5	0.42	0.92	1.17	3.5	
		Week 36	Tezepelumab	57	50 (87.7)	1.26 (1.23)	-1.7	0.25	1.21	2.33	3.4	0.43 [0.03, 0.84]
			Placebo	51	45 (88.2)	0.76 (1.04)	-2.3	0.08	0.92	1.17	3.8	
		Week 40	Tezepelumab	57	50 (87.7)	1.19 (1.22)	-1.7	0.25	1.08	2.25	3.4	0.28 [-0.12, 0.68]
			Placebo	51	45 (88.2)	0.87 (1.01)	-1.1	0.33	0.75	1.42	3.4	
		Week 44	Tezepelumab	57	50 (87.7)	1.21 (1.17)	-1.6	0.42	1.17	2.17	3.3	0.32 [-0.09, 0.72]
			Placebo	51	45 (88.2)	0.86 (1.03)	-1.3	0.33	0.92	1.33	3.7	
		Week 48	Tezepelumab	57	50 (87.7)	1.27 (1.16)	-1.6	0.58	1.25	2.17	3.4	0.29 [-0.12, 0.69]
			Placebo	51	45 (88.2)	0.95 (1.04)	-1.1	0.33	0.92	1.50	4.2	
		Week 52	Tezepelumab	57	50 (87.7)	1.25 (1.18)	-1.6	0.42	1.08	2.17	3.6	0.21 [-0.20, 0.61]
			Placebo	51	45 (88.2)	1.01 (1.06)	-1.1	0.33	0.83	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
Yes	Absolute values	Baseline	Tezepelumab	51	44 (86.3)	3.93 (1.10)	1.4	3.25	4.00	4.54	6.7	
			Placebo	49	43 (87.8)	4.16 (0.81)	1.7	3.50	4.33	4.58	5.8	
		Week 4	Tezepelumab	51	46 (90.2)	4.56 (1.08)	1.3	3.92	4.67	5.42	6.5	
			Placebo	49	43 (87.8)	4.80 (0.87)	2.7	4.25	4.67	5.25	6.7	
		Week 8	Tezepelumab	51	48 (94.1)	4.77 (1.13)	2.0	3.92	4.63	5.75	6.8	
			Placebo	49	44 (89.8)	4.88 (1.10)	2.1	4.17	4.71	5.83	7.0	
		Week 12	Tezepelumab	51	48 (94.1)	4.99 (1.01)	3.0	4.17	4.79	5.83	6.8	
			Placebo	49	44 (89.8)	5.02 (1.01)	2.9	4.21	4.92	5.79	7.0	
		Week 16	Tezepelumab	51	48 (94.1)	4.97 (1.07)	2.7	4.33	5.00	5.88	7.0	
			Placebo	49	44 (89.8)	4.91 (1.27)	1.3	4.21	4.79	5.92	7.0	
		Week 20	Tezepelumab	51	49 (96.1)	4.96 (1.04)	2.3	4.25	4.75	5.67	7.0	
			Placebo	49	44 (89.8)	4.88 (1.30)	1.3	4.08	5.00	5.92	7.0	
		Week 24	Tezepelumab	51	49 (96.1)	4.98 (1.00)	3.1	4.33	4.92	5.75	7.0	
			Placebo	49	44 (89.8)	4.83 (1.29)	1.3	3.92	4.75	5.92	7.0	
		Week 28	Tezepelumab	51	51 (100.0)	5.03 (1.05)	3.2	4.17	4.92	5.83	7.0	
			Placebo	49	44 (89.8)	4.91 (1.32)	1.3	4.04	4.96	5.96	7.0	
		Week 32	Tezepelumab	51	51 (100.0)	5.05 (1.06)	2.8	4.17	4.92	5.83	7.0	
			Placebo	49	44 (89.8)	4.96 (1.19)	1.3	4.25	4.92	5.96	7.0	
		Week 36	Tezepelumab	51	51 (100.0)	5.15 (1.09)	2.9	4.25	5.17	5.92	7.0	
			Placebo	49	44 (89.8)	4.89 (1.19)	2.5	4.13	4.75	5.96	7.0	
		Week 40	Tezepelumab	51	51 (100.0)	5.03 (1.10)	2.3	4.25	5.00	5.83	7.0	
			Placebo	49	44 (89.8)	5.02 (1.10)	2.5	4.21	5.04	6.00	7.0	
		Week 44	Tezepelumab	51	51 (100.0)	5.06 (1.05)	3.0	4.17	4.92	5.75	7.0	
			Placebo	49	44 (89.8)	5.02 (1.09)	2.8	4.25	4.92	5.92	7.0	
		Week 48	Tezepelumab	51	51 (100.0)	5.11 (1.10)	2.8	4.17	5.08	6.00	7.0	
			Placebo	49	44 (89.8)	5.09 (1.10)	2.4	4.25	5.00	6.00	7.0	
		Week 52	Tezepelumab	51	51 (100.0)	5.12 (1.13)	2.8	4.17	5.08	6.08	7.0	
			Placebo	49	44 (89.8)	5.15 (1.06)	2.8	4.25	4.96	6.00	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility											
Yes	Change from baseline	Week 4	Tezepelumab	51	42 (82.4)	0.64 (1.17)	-4.3	-0.08	0.83	1.25	3.1	-0.02 [-0.45, 0.40]
			Placebo	49	42 (85.7)	0.67 (0.87)	-1.3	0.17	0.50	0.92	3.3	
		Week 8	Tezepelumab	51	44 (86.3)	0.75 (1.13)	-1.9	0.08	0.88	1.50	3.3	0.02 [-0.40, 0.44]
			Placebo	49	43 (87.8)	0.73 (1.01)	-1.0	0.08	0.67	1.17	3.6	
		Week 12	Tezepelumab	51	44 (86.3)	0.97 (1.15)	-2.6	0.33	1.00	1.67	3.7	0.09 [-0.33, 0.51]
			Placebo	49	43 (87.8)	0.87 (1.04)	-1.0	0.25	0.75	1.25	3.8	
		Week 16	Tezepelumab	51	44 (86.3)	0.98 (1.12)	-2.9	0.42	1.00	1.71	3.2	0.20 [-0.22, 0.62]
			Placebo	49	43 (87.8)	0.75 (1.19)	-3.5	0.17	0.83	1.17	3.7	
		Week 20	Tezepelumab	51	44 (86.3)	0.97 (1.08)	-1.8	0.29	0.88	1.83	3.0	0.20 [-0.22, 0.62]
			Placebo	49	43 (87.8)	0.74 (1.25)	-3.5	0.08	0.92	1.33	3.8	
		Week 24	Tezepelumab	51	44 (86.3)	1.04 (1.08)	-1.6	0.38	1.00	1.75	3.0	0.31 [-0.11, 0.73]
			Placebo	49	43 (87.8)	0.68 (1.28)	-3.5	0.00	0.83	1.17	3.9	
		Week 28	Tezepelumab	51	44 (86.3)	1.05 (1.10)	-1.7	0.29	1.00	1.96	3.0	0.24 [-0.18, 0.66]
			Placebo	49	43 (87.8)	0.76 (1.24)	-3.5	0.25	0.75	1.33	3.8	
		Week 32	Tezepelumab	51	44 (86.3)	1.05 (1.17)	-1.6	0.33	1.00	1.92	3.0	0.20 [-0.22, 0.62]
			Placebo	49	43 (87.8)	0.83 (1.12)	-3.5	0.33	0.92	1.17	3.5	
		Week 36	Tezepelumab	51	44 (86.3)	1.14 (1.24)	-1.7	0.21	1.04	2.25	3.3	0.33 [-0.09, 0.76]
			Placebo	49	43 (87.8)	0.76 (1.05)	-2.3	0.08	0.92	1.17	3.8	
		Week 40	Tezepelumab	51	44 (86.3)	1.07 (1.22)	-1.7	0.25	1.00	2.17	3.4	0.17 [-0.26, 0.59]
			Placebo	49	43 (87.8)	0.88 (1.00)	-1.1	0.33	0.75	1.42	3.4	
		Week 44	Tezepelumab	51	44 (86.3)	1.09 (1.16)	-1.6	0.33	1.00	2.08	3.3	0.19 [-0.23, 0.61]
			Placebo	49	43 (87.8)	0.88 (1.01)	-1.3	0.33	0.92	1.33	3.7	
		Week 48	Tezepelumab	51	44 (86.3)	1.15 (1.17)	-1.6	0.33	1.08	1.96	3.2	0.19 [-0.23, 0.61]
			Placebo	49	43 (87.8)	0.94 (1.06)	-1.1	0.33	0.92	1.50	4.2	
		Week 52	Tezepelumab	51	44 (86.3)	1.16 (1.18)	-1.6	0.33	1.04	1.96	3.6	0.14 [-0.29, 0.56]
			Placebo	49	43 (87.8)	1.01 (1.08)	-1.1	0.33	0.83	1.67	4.2	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility												
No	Absolute values	Baseline	Tezepelumab	15	14 (93.3)	4.17 (0.66)	3.2	3.58	4.29	4.67	5.0	
			Placebo	16	12 (75.0)	4.01 (1.14)	1.5	3.71	4.17	4.42	6.3	
		Week 4	Tezepelumab	15	14 (93.3)	5.35 (1.02)	3.6	4.50	5.21	6.33	6.8	
			Placebo	16	14 (87.5)	4.44 (1.04)	2.7	3.42	4.58	5.25	6.0	
		Week 8	Tezepelumab	15	14 (93.3)	5.79 (0.87)	4.3	5.08	5.83	6.67	6.8	
			Placebo	16	15 (93.8)	4.32 (0.95)	1.9	3.92	4.58	5.08	5.4	
		Week 12	Tezepelumab	15	14 (93.3)	5.97 (0.97)	4.3	5.33	6.25	6.83	7.0	
			Placebo	16	15 (93.8)	4.47 (1.14)	2.1	3.50	4.33	5.17	6.7	
		Week 16	Tezepelumab	15	14 (93.3)	6.07 (0.79)	4.3	5.58	6.13	6.83	6.9	
			Placebo	16	15 (93.8)	4.71 (1.11)	2.8	3.92	4.67	5.75	6.8	
		Week 20	Tezepelumab	15	14 (93.3)	5.86 (1.07)	3.8	5.58	6.08	6.83	6.9	
			Placebo	16	15 (93.8)	4.41 (0.90)	2.8	3.67	4.42	5.25	5.8	
		Week 24	Tezepelumab	15	14 (93.3)	5.91 (1.07)	4.0	5.50	5.96	6.92	7.0	
			Placebo	16	15 (93.8)	4.47 (1.01)	2.8	3.58	4.58	5.33	6.0	
		Week 28	Tezepelumab	15	14 (93.3)	5.57 (1.27)	3.8	4.33	5.79	6.83	7.0	
			Placebo	16	16 (100.0)	4.66 (1.24)	2.8	3.79	4.50	5.38	7.0	
		Week 32	Tezepelumab	15	14 (93.3)	5.85 (1.15)	3.7	4.83	6.13	6.92	7.0	
			Placebo	16	16 (100.0)	4.71 (1.13)	3.0	3.75	5.00	5.58	6.8	
		Week 36	Tezepelumab	15	14 (93.3)	5.68 (1.23)	3.7	4.33	6.00	6.92	7.0	
			Placebo	16	16 (100.0)	4.60 (1.18)	2.4	3.79	4.67	5.29	6.9	
		Week 40	Tezepelumab	15	14 (93.3)	5.87 (1.17)	4.1	4.50	6.04	7.00	7.0	
			Placebo	16	16 (100.0)	4.61 (1.39)	2.3	3.58	4.21	5.67	7.0	
		Week 44	Tezepelumab	15	14 (93.3)	5.79 (1.13)	4.1	4.92	6.00	6.92	7.0	
			Placebo	16	16 (100.0)	4.58 (1.28)	2.5	3.46	4.46	5.71	6.9	
		Week 48	Tezepelumab	15	14 (93.3)	5.74 (1.22)	3.7	4.33	6.13	6.92	7.0	
			Placebo	16	16 (100.0)	4.51 (1.22)	2.2	3.83	4.33	5.17	6.9	
		Week 52	Tezepelumab	15	14 (93.3)	5.71 (1.12)	3.7	5.42	5.92	6.67	7.0	
			Placebo	16	16 (100.0)	4.54 (1.18)	2.8	3.71	4.46	5.17	7.0	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_ILSHP: Change from baseline in AQLQ+12 symptom score by study specific subgroups
DITTL

Subgroup	AQLQ+12 symptom score	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: No chronic OCS use and current post-BD FEV1 reversibility											
No	Change from baseline	Week 4	Tezepelumab	15	13 (86.7)	1.21 (0.69)	0.1	0.50	1.33	1.75	2.1	0.99 [0.15, 1.82]
			Placebo	16	12 (75.0)	0.41 (0.91)	-1.1	-0.08	0.42	0.96	1.9	
		Week 8	Tezepelumab	15	13 (86.7)	1.62 (0.71)	0.3	1.17	1.92	2.00	2.8	1.32 [0.44, 2.19]
			Placebo	16	12 (75.0)	0.42 (1.09)	-1.8	0.04	0.42	0.92	2.7	
		Week 12	Tezepelumab	15	13 (86.7)	1.83 (0.78)	0.4	1.42	1.92	2.17	3.3	1.01 [0.18, 1.85]
			Placebo	16	12 (75.0)	0.47 (1.77)	-2.8	-0.37	0.58	0.92	4.0	
		Week 16	Tezepelumab	15	13 (86.7)	1.92 (0.80)	0.5	1.67	2.08	2.17	3.3	0.78 [-0.04, 1.60]
			Placebo	16	12 (75.0)	0.85 (1.79)	-3.0	0.04	1.04	1.71	4.2	
		Week 20	Tezepelumab	15	13 (86.7)	1.81 (0.79)	0.5	1.17	2.00	2.25	3.3	1.23 [0.37, 2.09]
			Placebo	16	12 (75.0)	0.47 (1.34)	-3.0	0.00	0.79	1.46	1.8	
		Week 24	Tezepelumab	15	13 (86.7)	1.87 (0.80)	0.5	1.00	2.00	2.33	3.3	1.06 [0.21, 1.90]
			Placebo	16	12 (75.0)	0.63 (1.48)	-3.0	0.13	0.83	1.67	2.7	
		Week 28	Tezepelumab	15	13 (86.7)	1.46 (1.09)	-0.5	0.58	2.00	2.25	3.3	0.57 [-0.23, 1.37]
			Placebo	16	12 (75.0)	0.64 (1.72)	-3.0	0.04	0.83	1.38	4.3	
		Week 32	Tezepelumab	15	13 (86.7)	1.83 (0.78)	0.5	1.08	1.92	2.33	3.3	0.93 [0.10, 1.76]
			Placebo	16	12 (75.0)	0.75 (1.47)	-3.0	0.46	1.08	1.50	2.9	
		Week 36	Tezepelumab	15	13 (86.7)	1.65 (0.99)	-0.2	1.00	2.00	2.17	3.4	0.92 [0.09, 1.75]
			Placebo	16	12 (75.0)	0.52 (1.45)	-3.0	0.17	0.75	1.67	2.0	
		Week 40	Tezepelumab	15	13 (86.7)	1.82 (0.88)	0.5	1.08	2.00	2.33	3.3	0.87 [0.05, 1.70]
			Placebo	16	12 (75.0)	0.60 (1.81)	-3.0	-0.42	0.83	1.67	4.0	
		Week 44	Tezepelumab	15	13 (86.7)	1.73 (0.95)	0.5	0.92	2.00	2.33	3.3	0.91 [0.08, 1.74]
			Placebo	16	12 (75.0)	0.49 (1.71)	-3.0	-0.75	0.71	1.67	3.4	
		Week 48	Tezepelumab	15	13 (86.7)	1.71 (1.06)	-0.1	1.08	2.00	2.25	3.4	1.02 [0.19, 1.86]
			Placebo	16	12 (75.0)	0.42 (1.44)	-3.0	0.17	0.63	1.42	2.3	
		Week 52	Tezepelumab	15	13 (86.7)	1.68 (1.02)	0.3	1.00	2.00	2.25	3.4	1.00 [0.17, 1.84]
			Placebo	16	12 (75.0)	0.47 (1.38)	-3.0	0.17	0.63	1.42	2.3	

Note: DITTL = Dossier Label Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTI_IBMP0: Increase of at least 0.9 points in AQLQ+12 total score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 total score	Week 52	12	10 (83.3)	6 (50.0) [21.1, 78.9]	9	7 (77.8)	3 (33.3) [7.5, 70.1]	1.500 [0.508, 4.432]	2.000 [0.334, 11.969]	16.7 [-34.9, 68.2]	0.660 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAI_IBMP0: Increase of at least 0.9 points in AQLQ+12 activity limitations score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 activity limitations score	Week 52	12	10 (83.3)	7 (58.3) [27.7, 84.8]	9	7 (77.8)	3 (33.3) [7.5, 70.1]	1.750 [0.618, 4.953]	2.800 [0.463, 16.929]	25.0 [-26.3, 76.3]	0.387 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEI_IBMP0: Increase of at least 0.9 points in AQLQ+12 environmental stimuli score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 environmental stimuli score	Week 52	12	10 (83.3)	7 (58.3) [27.7, 84.8]	9	7 (77.8)	4 (44.4) [13.7, 78.8]	1.313 [0.548, 3.142]	1.750 [0.306, 10.022]	13.9 [-38.6, 66.4]	0.670 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGI_IBMP0: Increase of at least 0.9 points in AQLQ+12 emotional function score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 emotional function score	Week 52	12	10 (83.3)	6 (50.0) [21.1, 78.9]	9	7 (77.8)	2 (22.2) [2.8, 60.0]	2.250 [0.585, 8.652]	3.500 [0.505, 24.270]	27.8 [-21.2, 76.7]	0.367 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMI_IBMP0: Increase of at least 0.9 points in AQLQ+12 symptom score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval (%)	n (%) [95 % CI]	N	nval (%)	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Increase of at least 0.9 points in AQLQ+12 symptom score	Week 52	12	10 (83.3)	5 (41.7) [15.2, 72.3]	9	7 (77.8)	3 (33.3) [7.5, 70.1]	1.250 [0.399, 3.912]	1.429 [0.236, 8.637]	8.3 [-42.9, 59.6]	1.000 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTD_IBMP0: Decrease of at least 0.9 points in AQLQ+12 total score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 total score	Week 52	12	10 (83.3)	0 (0.0) [0.0, 26.5]	9	7 (77.8)	0 (0.0) [0.0, 33.6]				

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAD_IBMP0: Decrease of at least 0.9 points in AQLQ+12 activity limitations score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 activity limitations score	Week 52	12	10 (83.3)	0 (0.0) [0.0, 26.5]	9	7 (77.8)	0 (0.0) [0.0, 33.6]				

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QED_IBMP0: Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 environmental stimuli score	Week 52	12	10 (83.3)	0 (0.0) [0.0, 26.5]	9	7 (77.8)	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGD_IBMP0: Decrease of at least 0.9 points in AQLQ+12 emotional function score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 emotional function score	Week 52	12	10 (83.3)	0 (0.0) [0.0, 26.5]	9	7 (77.8)	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429 #

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMD_IBMP0: Decrease of at least 0.9 points in AQLQ+12 symptom score
DITTB

		Tezepelumab			Placebo						
Variable	Time	N	nval	n (%) [95 % CI]	N	nval	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Decrease of at least 0.9 points in AQLQ+12 symptom score	Week 52	12	10 (83.3)	0 (0.0) [0.0, 26.5]	9	7 (77.8)	0 (0.0) [0.0, 33.6]				

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of patients with response. nval = number of patients with non-missing values. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Chi-square test, a # indicates that exact test of Fisher was used instead. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. Last observation carried forward is applied in case of a missing value at Week 52.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IBMH0: Course of AQLQ+12 total score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 total score	Baseline	Tezepelumab	12	10 (83.3)	4.06 (0.94)	2.2	3.59	4.48	4.69	5.0	
		Placebo	9	7 (77.8)	3.85 (0.37)	3.4	3.63	3.72	4.22	4.5	
	Week 4	Tezepelumab	12	10 (83.3)	5.06 (1.07)	3.6	4.13	5.06	5.81	6.6	
		Placebo	9	7 (77.8)	4.50 (0.74)	3.8	3.97	4.38	4.72	6.0	
	Week 8	Tezepelumab	12	10 (83.3)	5.15 (1.17)	3.4	4.09	5.22	5.97	6.7	
		Placebo	9	7 (77.8)	4.74 (1.05)	3.3	3.94	4.63	5.72	6.3	
	Week 12	Tezepelumab	12	10 (83.3)	5.41 (1.05)	4.1	4.34	5.59	6.22	6.9	
		Placebo	9	7 (77.8)	4.74 (1.06)	3.7	4.00	4.22	5.91	6.5	
	Week 16	Tezepelumab	12	10 (83.3)	5.36 (0.87)	4.1	4.84	5.47	5.78	6.8	
		Placebo	9	7 (77.8)	4.84 (1.14)	3.3	4.06	4.56	5.91	6.5	
	Week 20	Tezepelumab	12	11 (91.7)	5.38 (0.96)	4.1	4.47	5.38	6.19	6.9	
		Placebo	9	7 (77.8)	4.79 (1.37)	2.4	4.00	4.72	5.97	6.3	
	Week 24	Tezepelumab	12	11 (91.7)	5.39 (0.98)	4.1	4.69	5.28	6.13	7.0	
		Placebo	9	7 (77.8)	4.63 (1.44)	2.4	3.59	4.53	5.91	6.4	
	Week 28	Tezepelumab	12	12 (100.0)	5.27 (1.10)	3.8	4.42	4.97	6.23	7.0	
		Placebo	9	7 (77.8)	4.62 (1.31)	2.2	3.94	4.75	5.91	6.1	
	Week 32	Tezepelumab	12	12 (100.0)	5.19 (1.14)	3.9	4.06	5.02	5.97	7.0	
		Placebo	9	7 (77.8)	4.69 (1.31)	2.7	3.84	4.41	5.91	6.4	
	Week 36	Tezepelumab	12	12 (100.0)	5.33 (1.18)	3.9	4.30	5.16	6.34	7.0	
		Placebo	9	7 (77.8)	4.92 (1.34)	3.0	3.84	4.69	6.16	6.6	
	Week 40	Tezepelumab	12	12 (100.0)	5.21 (1.05)	3.7	4.41	5.14	5.73	7.0	
		Placebo	9	7 (77.8)	5.01 (1.49)	2.5	3.88	5.63	6.34	6.5	
	Week 44	Tezepelumab	12	12 (100.0)	5.23 (1.13)	3.8	4.08	5.25	5.98	7.0	
		Placebo	9	7 (77.8)	4.68 (1.31)	3.2	3.78	4.19	6.28	6.6	
	Week 48	Tezepelumab	12	12 (100.0)	5.26 (1.09)	3.6	4.30	5.33	6.08	7.0	
		Placebo	9	7 (77.8)	4.74 (1.42)	3.2	3.81	4.19	6.44	7.0	
	Week 52	Tezepelumab	12	12 (100.0)	5.31 (1.07)	3.6	4.39	5.41	6.08	7.0	
		Placebo	9	7 (77.8)	4.87 (1.30)	3.8	3.88	4.19	6.44	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IBMH0: Course of AQLQ+12 total score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 total score	Week 4	Tezepelumab	12	10 (83.3)	1.01 (1.19)	-0.5	0.00	1.20	1.56	3.3	0.34 [-0.63, 1.31]
		Placebo	9	7 (77.8)	0.65 (0.78)	0.0	0.16	0.38	0.88	2.3	
	Week 8	Tezepelumab	12	10 (83.3)	1.10 (1.36)	-1.0	0.00	1.20	1.88	3.8	0.17 [-0.79, 1.14]
		Placebo	9	7 (77.8)	0.88 (1.00)	-0.4	0.16	0.78	1.50	2.6	
	Week 12	Tezepelumab	12	10 (83.3)	1.35 (1.19)	-0.1	0.47	1.34	1.91	4.0	0.40 [-0.58, 1.38]
		Placebo	9	7 (77.8)	0.88 (1.15)	-0.8	0.16	0.53	1.69	2.8	
	Week 16	Tezepelumab	12	10 (83.3)	1.30 (0.91)	0.3	0.59	1.31	1.69	3.4	0.33 [-0.64, 1.30]
		Placebo	9	7 (77.8)	0.99 (1.02)	-0.4	0.22	0.94	1.69	2.8	
	Week 20	Tezepelumab	12	10 (83.3)	1.33 (1.01)	0.1	0.50	1.48	1.69	3.4	0.36 [-0.61, 1.33]
		Placebo	9	7 (77.8)	0.93 (1.21)	-1.3	0.16	1.09	1.69	2.5	
	Week 24	Tezepelumab	12	10 (83.3)	1.34 (1.05)	0.1	0.38	1.48	1.97	3.4	0.49 [-0.49, 1.48]
		Placebo	9	7 (77.8)	0.77 (1.29)	-1.3	-0.25	0.91	1.69	2.7	
	Week 28	Tezepelumab	12	10 (83.3)	1.42 (1.04)	0.1	0.56	1.56	2.16	3.4	0.57 [-0.41, 1.56]
		Placebo	9	7 (77.8)	0.76 (1.26)	-1.5	0.09	0.97	1.69	2.4	
	Week 32	Tezepelumab	12	10 (83.3)	1.15 (1.22)	-0.6	0.28	1.09	2.03	3.4	0.26 [-0.71, 1.23]
		Placebo	9	7 (77.8)	0.83 (1.17)	-1.0	0.00	0.78	1.69	2.7	
	Week 36	Tezepelumab	12	10 (83.3)	1.31 (1.18)	-0.1	0.28	1.52	2.19	3.4	0.21 [-0.76, 1.18]
		Placebo	9	7 (77.8)	1.06 (1.16)	-0.7	0.31	1.06	1.69	2.9	
	Week 40	Tezepelumab	12	10 (83.3)	1.29 (1.06)	0.1	0.44	1.08	2.03	3.4	0.11 [-0.85, 1.08]
		Placebo	9	7 (77.8)	1.16 (1.36)	-1.2	0.03	1.69	2.00	2.8	
	Week 44	Tezepelumab	12	10 (83.3)	1.24 (1.17)	-0.6	0.47	1.08	2.03	3.4	0.34 [-0.63, 1.31]
		Placebo	9	7 (77.8)	0.83 (1.28)	-0.5	-0.28	0.56	2.06	2.9	
	Week 48	Tezepelumab	12	10 (83.3)	1.28 (1.09)	-0.2	0.44	1.30	2.06	3.4	0.33 [-0.64, 1.30]
		Placebo	9	7 (77.8)	0.88 (1.39)	-0.5	-0.28	0.41	2.22	3.3	
	Week 52	Tezepelumab	12	10 (83.3)	1.35 (1.01)	0.3	0.47	1.30	2.06	3.4	0.30 [-0.67, 1.27]
		Placebo	9	7 (77.8)	1.01 (1.28)	-0.3	0.03	0.41	2.22	3.3	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IBMC0: Change from baseline in AQLQ+12 total score - MMRM results
DITTB

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 8	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 12	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 16	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 20	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 24	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 28	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 32	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 36	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 40	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QTC_IBMC0: Change from baseline in AQLQ+12 total score - MMRM results
DITTB

Change from baseline in AQLQ+12 total score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	12	5 (41.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QTC_IBMG0: Course of AQLQ+12 total score
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QTC_IBMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IBMH0: Course of AQLQ+12 activity limitations score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 activity limitations score	Baseline	Tezepelumab	12	10 (83.3)	3.96 (0.99)	2.2	3.36	4.27	4.64	5.2	
		Placebo	9	7 (77.8)	3.87 (0.42)	3.4	3.45	3.91	4.18	4.5	
	Week 4	Tezepelumab	12	10 (83.3)	5.10 (1.12)	3.6	4.27	4.82	6.00	6.9	
		Placebo	9	7 (77.8)	4.19 (0.92)	3.3	3.36	4.09	4.64	5.9	
	Week 8	Tezepelumab	12	10 (83.3)	5.10 (1.19)	3.4	4.27	5.09	6.09	6.5	
		Placebo	9	7 (77.8)	4.49 (1.20)	2.8	3.91	4.09	5.64	6.5	
	Week 12	Tezepelumab	12	10 (83.3)	5.45 (1.14)	3.9	4.27	5.64	6.36	7.0	
		Placebo	9	7 (77.8)	4.51 (1.27)	3.4	3.36	4.18	6.00	6.5	
	Week 16	Tezepelumab	12	10 (83.3)	5.34 (0.88)	4.2	4.55	5.32	5.91	6.7	
		Placebo	9	7 (77.8)	4.88 (1.32)	2.9	3.91	5.27	6.00	6.6	
	Week 20	Tezepelumab	12	11 (91.7)	5.41 (0.99)	4.0	4.27	5.55	6.27	7.0	
		Placebo	9	7 (77.8)	4.68 (1.55)	2.1	4.09	4.09	5.91	6.6	
	Week 24	Tezepelumab	12	11 (91.7)	5.38 (1.07)	3.9	4.27	5.55	6.27	7.0	
		Placebo	9	7 (77.8)	4.58 (1.57)	2.0	3.45	5.00	5.82	6.6	
	Week 28	Tezepelumab	12	12 (100.0)	5.32 (1.10)	4.2	4.36	4.95	6.32	7.0	
		Placebo	9	7 (77.8)	4.70 (1.51)	2.0	3.91	5.09	5.82	6.7	
	Week 32	Tezepelumab	12	12 (100.0)	5.26 (1.17)	3.9	4.32	5.05	6.18	7.0	
		Placebo	9	7 (77.8)	4.64 (1.57)	1.7	4.00	4.55	5.82	6.5	
	Week 36	Tezepelumab	12	12 (100.0)	5.32 (1.20)	3.8	4.27	5.09	6.45	7.0	
		Placebo	9	7 (77.8)	4.88 (1.55)	2.5	3.82	5.09	6.27	6.8	
	Week 40	Tezepelumab	12	12 (100.0)	5.24 (1.05)	4.0	4.36	5.05	5.95	7.0	
		Placebo	9	7 (77.8)	5.05 (1.72)	2.0	4.09	5.64	6.73	6.8	
	Week 44	Tezepelumab	12	12 (100.0)	5.33 (1.09)	4.0	4.36	5.45	6.09	7.0	
		Placebo	9	7 (77.8)	4.74 (1.55)	2.5	3.82	4.55	6.36	6.9	
	Week 48	Tezepelumab	12	12 (100.0)	5.28 (1.11)	3.8	4.27	5.27	6.32	7.0	
		Placebo	9	7 (77.8)	4.75 (1.62)	2.3	3.82	4.55	6.45	7.0	
	Week 52	Tezepelumab	12	12 (100.0)	5.39 (1.05)	3.8	4.36	5.55	6.32	7.0	
		Placebo	9	7 (77.8)	5.00 (1.28)	3.7	4.00	4.55	6.45	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IBMH0: Course of AQLQ+12 activity limitations score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 activity limitations score	Week 4	Tezepelumab	12	10 (83.3)	1.14 (1.12)	-0.3	0.00	1.50	1.91	3.1	0.83 [-0.18, 1.84]
		Placebo	9	7 (77.8)	0.32 (0.71)	-0.4	-0.27	0.18	0.55	1.7	
	Week 8	Tezepelumab	12	10 (83.3)	1.14 (1.45)	-1.3	0.00	1.41	1.64	3.7	0.40 [-0.58, 1.38]
		Placebo	9	7 (77.8)	0.62 (0.98)	-0.7	0.09	0.55	1.45	2.3	
	Week 12	Tezepelumab	12	10 (83.3)	1.49 (1.34)	-0.5	0.45	1.55	1.91	4.2	0.68 [-0.31, 1.68]
		Placebo	9	7 (77.8)	0.64 (1.11)	-0.7	-0.18	0.45	1.82	2.4	
	Week 16	Tezepelumab	12	10 (83.3)	1.37 (1.06)	0.3	0.55	1.18	2.00	3.5	0.35 [-0.63, 1.32]
		Placebo	9	7 (77.8)	1.01 (1.00)	-0.6	0.45	1.00	1.82	2.5	
	Week 20	Tezepelumab	12	10 (83.3)	1.44 (1.15)	-0.4	0.55	1.32	2.55	3.5	0.53 [-0.46, 1.51]
		Placebo	9	7 (77.8)	0.81 (1.25)	-1.5	0.18	0.73	1.64	2.5	
	Week 24	Tezepelumab	12	10 (83.3)	1.40 (1.24)	-0.2	0.27	1.36	2.27	3.5	0.55 [-0.44, 1.54]
		Placebo	9	7 (77.8)	0.71 (1.26)	-1.5	0.09	0.82	1.64	2.5	
	Week 28	Tezepelumab	12	10 (83.3)	1.53 (1.17)	-0.2	0.73	1.55	2.55	3.5	0.58 [-0.41, 1.57]
		Placebo	9	7 (77.8)	0.83 (1.26)	-1.5	0.55	0.82	1.64	2.5	
	Week 32	Tezepelumab	12	10 (83.3)	1.29 (1.36)	-0.4	0.09	1.23	2.55	3.5	0.39 [-0.58, 1.37]
		Placebo	9	7 (77.8)	0.77 (1.30)	-1.8	0.64	0.82	1.64	2.4	
	Week 36	Tezepelumab	12	10 (83.3)	1.41 (1.33)	-0.2	0.18	1.50	2.55	3.5	0.31 [-0.66, 1.28]
		Placebo	9	7 (77.8)	1.01 (1.19)	-1.0	0.36	1.18	1.82	2.6	
	Week 40	Tezepelumab	12	10 (83.3)	1.38 (1.28)	-0.2	0.36	1.18	2.55	3.5	0.15 [-0.82, 1.12]
		Placebo	9	7 (77.8)	1.18 (1.39)	-1.5	0.73	1.64	2.27	2.6	
	Week 44	Tezepelumab	12	10 (83.3)	1.38 (1.29)	-0.3	0.36	1.41	2.55	3.5	0.39 [-0.58, 1.37]
		Placebo	9	7 (77.8)	0.87 (1.30)	-1.1	0.09	0.55	2.18	2.7	
	Week 48	Tezepelumab	12	10 (83.3)	1.42 (1.25)	-0.2	0.45	1.32	2.55	3.5	0.41 [-0.57, 1.39]
		Placebo	9	7 (77.8)	0.88 (1.38)	-1.3	0.09	0.55	2.27	2.8	
	Week 52	Tezepelumab	12	10 (83.3)	1.55 (1.15)	-0.2	0.64	1.32	2.55	3.5	0.38 [-0.60, 1.35]
		Placebo	9	7 (77.8)	1.13 (1.04)	0.1	0.36	0.55	2.27	2.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IBMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
DITTB

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 8	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 12	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 16	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 20	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 24	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 28	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 32	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 36	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 40	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QAC_IBMC0: Change from baseline in AQLQ+12 activity limitations score - MMRM results
DITTB

Change from baseline in AQLQ+12 activity limitations score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	12	5 (41.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QAC_IBMG0: Course of AQLQ+12 activity limitations score
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QAC_IBMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IBMH0: Course of AQLQ+12 environmental stimuli score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 environmental stimuli score	Baseline	Tezepelumab	12	10 (83.3)	3.95 (1.08)	1.8	3.00	4.25	4.75	5.0	
		Placebo	9	7 (77.8)	3.36 (0.97)	1.5	3.25	3.25	4.25	4.5	
	Week 4	Tezepelumab	12	10 (83.3)	5.00 (1.14)	3.5	4.00	5.00	5.75	7.0	
		Placebo	9	7 (77.8)	4.14 (1.38)	2.3	2.50	4.25	5.50	5.5	
	Week 8	Tezepelumab	12	10 (83.3)	5.30 (0.90)	4.0	4.50	5.50	6.00	6.8	
		Placebo	9	7 (77.8)	4.82 (1.78)	1.5	4.00	5.75	6.25	6.5	
	Week 12	Tezepelumab	12	10 (83.3)	5.40 (1.07)	4.0	4.50	5.25	6.50	7.0	
		Placebo	9	7 (77.8)	4.18 (1.30)	2.3	3.25	4.00	5.25	6.3	
	Week 16	Tezepelumab	12	10 (83.3)	5.10 (0.68)	4.0	4.75	5.00	5.50	6.3	
		Placebo	9	7 (77.8)	4.32 (1.48)	1.5	4.00	4.25	5.25	6.3	
	Week 20	Tezepelumab	12	11 (91.7)	5.20 (0.85)	4.0	4.50	5.00	5.75	7.0	
		Placebo	9	7 (77.8)	4.25 (1.41)	1.5	3.50	5.00	5.25	5.5	
	Week 24	Tezepelumab	12	11 (91.7)	5.45 (1.05)	4.0	4.50	5.00	6.50	7.0	
		Placebo	9	7 (77.8)	3.89 (1.73)	1.0	2.50	4.25	5.25	6.3	
	Week 28	Tezepelumab	12	12 (100.0)	5.23 (1.03)	4.0	4.50	5.00	5.88	7.0	
		Placebo	9	7 (77.8)	4.54 (1.38)	2.0	3.75	5.25	5.50	6.0	
	Week 32	Tezepelumab	12	12 (100.0)	5.25 (1.09)	4.0	4.25	5.00	6.00	7.0	
		Placebo	9	7 (77.8)	4.14 (1.59)	1.3	3.25	4.25	5.25	6.0	
	Week 36	Tezepelumab	12	12 (100.0)	5.33 (1.08)	4.0	4.38	5.00	6.38	7.0	
		Placebo	9	7 (77.8)	4.11 (1.71)	1.0	3.00	4.25	5.25	6.3	
	Week 40	Tezepelumab	12	12 (100.0)	5.27 (1.16)	3.8	4.50	5.00	6.38	7.0	
		Placebo	9	7 (77.8)	4.46 (1.88)	1.0	3.25	5.25	5.75	6.5	
	Week 44	Tezepelumab	12	12 (100.0)	5.31 (1.17)	4.0	4.25	5.00	6.50	7.0	
		Placebo	9	7 (77.8)	4.00 (1.73)	1.3	3.25	3.50	5.75	6.5	
	Week 48	Tezepelumab	12	12 (100.0)	5.21 (1.04)	4.0	4.25	5.00	6.00	7.0	
		Placebo	9	7 (77.8)	4.50 (1.39)	3.0	3.50	4.00	5.75	7.0	
	Week 52	Tezepelumab	12	12 (100.0)	5.29 (0.97)	4.0	4.75	5.00	6.00	7.0	
		Placebo	9	7 (77.8)	4.50 (1.39)	3.0	3.50	4.00	5.75	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IBMH0: Course of AQLQ+12 environmental stimuli score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 environmental stimuli score	Week 4	Tezepelumab	12	10 (83.3)	1.05 (1.30)	-0.5	0.00	1.13	1.25	4.0	0.22 [-0.75, 1.19]
		Placebo	9	7 (77.8)	0.79 (1.06)	-0.8	0.00	0.75	2.00	2.3	
	Week 8	Tezepelumab	12	10 (83.3)	1.35 (1.42)	-0.8	0.25	1.38	1.75	4.3	-0.09 [-1.05, 0.88]
		Placebo	9	7 (77.8)	1.46 (1.15)	0.0	0.75	1.25	3.00	3.0	
	Week 12	Tezepelumab	12	10 (83.3)	1.45 (1.37)	0.0	0.25	1.38	1.75	4.8	0.48 [-0.50, 1.46]
		Placebo	9	7 (77.8)	0.82 (1.24)	-1.3	0.50	0.75	1.00	3.0	
	Week 16	Tezepelumab	12	10 (83.3)	1.15 (0.99)	-0.3	0.25	1.38	1.50	3.0	0.19 [-0.78, 1.16]
		Placebo	9	7 (77.8)	0.96 (0.95)	0.0	0.50	0.75	1.00	3.0	
	Week 20	Tezepelumab	12	10 (83.3)	1.20 (1.09)	-0.3	0.25	1.38	1.75	3.3	0.31 [-0.66, 1.28]
		Placebo	9	7 (77.8)	0.89 (0.83)	0.0	0.25	0.50	1.75	2.3	
	Week 24	Tezepelumab	12	10 (83.3)	1.48 (1.15)	-0.5	0.25	1.75	2.25	3.3	0.78 [-0.23, 1.79]
		Placebo	9	7 (77.8)	0.54 (1.29)	-0.8	-0.50	0.25	1.00	3.0	
	Week 28	Tezepelumab	12	10 (83.3)	1.43 (1.09)	-0.5	0.50	1.50	2.00	3.3	0.22 [-0.75, 1.19]
		Placebo	9	7 (77.8)	1.18 (1.19)	-0.5	0.25	1.00	2.25	2.8	
	Week 32	Tezepelumab	12	10 (83.3)	1.35 (1.21)	-0.5	0.25	1.63	2.25	3.3	0.50 [-0.48, 1.48]
		Placebo	9	7 (77.8)	0.79 (0.99)	-0.3	0.00	0.75	1.00	2.8	
	Week 36	Tezepelumab	12	10 (83.3)	1.38 (1.25)	-0.8	0.25	1.63	2.25	3.3	0.52 [-0.47, 1.50]
		Placebo	9	7 (77.8)	0.75 (1.15)	-0.5	-0.25	0.50	1.00	3.0	
	Week 40	Tezepelumab	12	10 (83.3)	1.55 (1.06)	0.0	0.25	1.88	2.25	3.3	0.38 [-0.59, 1.36]
		Placebo	9	7 (77.8)	1.11 (1.30)	-0.5	0.00	1.00	2.25	3.3	
	Week 44	Tezepelumab	12	10 (83.3)	1.50 (1.24)	-1.0	0.50	2.00	2.25	3.3	0.65 [-0.34, 1.65]
		Placebo	9	7 (77.8)	0.64 (1.41)	-1.0	-0.25	0.00	1.50	3.3	
	Week 48	Tezepelumab	12	10 (83.3)	1.38 (1.20)	-1.0	0.50	1.63	2.00	3.3	0.17 [-0.80, 1.14]
		Placebo	9	7 (77.8)	1.14 (1.62)	-1.0	-0.25	1.00	2.50	3.8	
	Week 52	Tezepelumab	12	10 (83.3)	1.48 (1.00)	0.0	0.50	1.63	2.00	3.3	0.26 [-0.71, 1.23]
		Placebo	9	7 (77.8)	1.14 (1.62)	-1.0	-0.25	1.00	2.50	3.8	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IBMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
DITTB

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 8	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 12	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 16	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 20	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 24	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 28	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 32	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 36	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 40	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QEC_IBMC0: Change from baseline in AQLQ+12 environmental stimuli score - MMRM results
DITTB

Change from baseline in AQLQ+12 environmental stimuli score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	12	5 (41.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QEC_IBMG0: Course of AQLQ+12 environmental stimuli score
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QEC_IBMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IBMH0: Course of AQLQ+12 emotional function score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 emotional function score	Baseline	Tezepelumab	12	10 (83.3)	4.54 (1.43)	1.8	3.80	5.10	5.60	6.2	
		Placebo	9	7 (77.8)	4.40 (1.11)	2.8	3.80	4.20	5.40	6.2	
	Week 4	Tezepelumab	12	10 (83.3)	5.30 (1.06)	3.8	4.40	5.40	6.00	7.0	
		Placebo	9	7 (77.8)	4.94 (1.45)	3.2	3.60	4.40	6.60	6.8	
	Week 8	Tezepelumab	12	10 (83.3)	5.64 (1.05)	4.0	4.80	5.70	6.40	7.0	
		Placebo	9	7 (77.8)	5.17 (1.09)	3.8	4.20	5.60	6.00	6.6	
	Week 12	Tezepelumab	12	10 (83.3)	5.86 (1.00)	4.2	4.80	6.30	6.60	7.0	
		Placebo	9	7 (77.8)	5.29 (1.26)	3.8	4.00	5.20	6.60	6.8	
	Week 16	Tezepelumab	12	10 (83.3)	5.66 (0.97)	4.0	5.00	5.90	6.40	7.0	
		Placebo	9	7 (77.8)	4.94 (1.19)	3.6	4.00	4.60	6.20	6.8	
	Week 20	Tezepelumab	12	11 (91.7)	5.96 (1.00)	4.2	5.00	6.20	7.00	7.0	
		Placebo	9	7 (77.8)	5.06 (1.16)	3.8	4.00	5.00	6.20	6.6	
	Week 24	Tezepelumab	12	11 (91.7)	5.82 (0.90)	4.2	5.20	5.80	6.60	7.0	
		Placebo	9	7 (77.8)	4.86 (1.26)	2.8	3.80	5.20	6.20	6.2	
	Week 28	Tezepelumab	12	12 (100.0)	5.75 (1.15)	4.0	4.80	5.90	6.90	7.0	
		Placebo	9	7 (77.8)	4.86 (1.01)	4.0	4.00	4.40	6.20	6.2	
	Week 32	Tezepelumab	12	12 (100.0)	5.60 (1.17)	3.8	4.60	5.80	6.60	7.0	
		Placebo	9	7 (77.8)	4.86 (1.38)	2.6	3.80	5.20	6.20	6.6	
	Week 36	Tezepelumab	12	12 (100.0)	5.80 (1.16)	3.8	4.60	6.20	6.90	7.0	
		Placebo	9	7 (77.8)	5.14 (1.57)	2.2	4.40	5.20	6.40	6.8	
	Week 40	Tezepelumab	12	12 (100.0)	5.65 (1.03)	4.0	4.90	5.60	6.50	7.0	
		Placebo	9	7 (77.8)	5.20 (1.15)	3.6	4.00	5.40	6.20	6.8	
	Week 44	Tezepelumab	12	12 (100.0)	5.62 (1.18)	4.0	4.50	5.80	6.70	7.0	
		Placebo	9	7 (77.8)	5.00 (1.48)	3.4	3.60	4.60	6.60	6.6	
	Week 48	Tezepelumab	12	12 (100.0)	5.70 (1.16)	3.8	4.90	5.80	6.80	7.0	
		Placebo	9	7 (77.8)	5.03 (1.72)	2.8	3.80	4.20	6.80	7.0	
	Week 52	Tezepelumab	12	12 (100.0)	5.68 (1.15)	4.0	4.80	5.80	6.80	7.0	
		Placebo	9	7 (77.8)	4.54 (1.66)	2.8	3.60	3.80	6.80	7.0	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IBMH0: Course of AQLQ+12 emotional function score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 emotional function score	Week 4	Tezepelumab	12	10 (83.3)	0.76 (1.68)	-1.8	-0.40	0.60	1.80	3.8	0.16 [-0.81, 1.12]
		Placebo	9	7 (77.8)	0.54 (0.73)	-0.2	0.00	0.40	1.20	1.8	
	Week 8	Tezepelumab	12	10 (83.3)	1.10 (1.76)	-1.2	-0.20	0.90	2.00	4.4	0.22 [-0.75, 1.19]
		Placebo	9	7 (77.8)	0.77 (0.86)	-0.2	-0.20	1.20	1.60	1.6	
	Week 12	Tezepelumab	12	10 (83.3)	1.32 (1.41)	-0.8	0.00	1.40	2.00	3.8	0.35 [-0.62, 1.33]
		Placebo	9	7 (77.8)	0.89 (0.89)	-0.6	0.20	1.20	1.60	2.0	
	Week 16	Tezepelumab	12	10 (83.3)	1.12 (1.55)	-1.2	-0.20	1.00	2.00	4.0	0.43 [-0.55, 1.41]
		Placebo	9	7 (77.8)	0.54 (0.98)	-1.0	0.00	0.40	1.40	2.0	
	Week 20	Tezepelumab	12	10 (83.3)	1.46 (1.58)	-0.6	0.00	1.40	2.00	4.6	0.53 [-0.45, 1.52]
		Placebo	9	7 (77.8)	0.66 (1.39)	-2.2	0.00	1.20	1.40	2.0	
	Week 24	Tezepelumab	12	10 (83.3)	1.30 (1.45)	-0.4	0.00	1.30	2.00	4.6	0.66 [-0.33, 1.65]
		Placebo	9	7 (77.8)	0.46 (0.96)	-1.0	-0.20	0.60	1.00	2.0	
	Week 28	Tezepelumab	12	10 (83.3)	1.42 (1.60)	-0.6	0.00	1.50	2.00	4.6	0.63 [-0.36, 1.63]
		Placebo	9	7 (77.8)	0.46 (1.38)	-2.2	0.00	0.80	1.40	2.0	
	Week 32	Tezepelumab	12	10 (83.3)	1.06 (1.66)	-1.6	0.00	1.30	1.60	4.6	0.42 [-0.56, 1.40]
		Placebo	9	7 (77.8)	0.46 (1.00)	-1.0	-0.20	0.60	1.20	2.0	
	Week 36	Tezepelumab	12	10 (83.3)	1.30 (1.61)	-1.0	0.00	1.50	2.00	4.6	0.41 [-0.57, 1.39]
		Placebo	9	7 (77.8)	0.74 (0.85)	-0.6	0.20	0.80	1.40	2.0	
	Week 40	Tezepelumab	12	10 (83.3)	1.24 (1.46)	-0.4	0.00	1.40	1.60	4.6	0.32 [-0.65, 1.29]
		Placebo	9	7 (77.8)	0.80 (1.24)	-1.4	-0.40	1.20	1.80	2.0	
	Week 44	Tezepelumab	12	10 (83.3)	1.12 (1.58)	-0.6	-0.20	1.40	1.60	4.6	0.38 [-0.60, 1.35]
		Placebo	9	7 (77.8)	0.60 (1.02)	-0.6	-0.40	0.60	1.20	2.4	
	Week 48	Tezepelumab	12	10 (83.3)	1.22 (1.50)	-0.4	0.00	1.50	1.60	4.6	0.44 [-0.54, 1.42]
		Placebo	9	7 (77.8)	0.63 (1.10)	-0.6	0.00	0.40	1.60	2.6	
	Week 52	Tezepelumab	12	10 (83.3)	1.20 (1.52)	-0.6	0.00	1.50	1.60	4.6	0.67 [-0.33, 1.66]
		Placebo	9	7 (77.8)	0.14 (1.66)	-2.6	-0.60	0.00	1.60	2.6	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IBMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
DITTB

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 8	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 12	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 16	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 20	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 24	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 28	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 32	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 36	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 40	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QGC_IBMC0: Change from baseline in AQLQ+12 emotional function score - MMRM results
DITTB

Change from baseline in AQLQ+12 emotional function score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	12	5 (41.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QGC_IBMG0: Course of AQLQ+12 emotional function score
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QGC_IBMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IBMH0: Course of AQLQ+12 symptom score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
AQLQ+12 symptom score	Baseline	Tezepelumab	12	10 (83.3)	3.98 (0.85)	2.6	3.25	4.25	4.67	4.8	
		Placebo	9	7 (77.8)	3.77 (0.62)	2.8	3.42	3.67	4.33	4.5	
	Week 4	Tezepelumab	12	10 (83.3)	4.95 (1.08)	3.5	3.92	5.13	5.67	6.4	
		Placebo	9	7 (77.8)	4.73 (0.75)	3.8	4.25	4.58	5.25	6.1	
	Week 8	Tezepelumab	12	10 (83.3)	4.95 (1.49)	2.0	3.75	5.21	5.92	6.7	
		Placebo	9	7 (77.8)	4.75 (1.06)	3.2	3.92	4.50	5.75	6.1	
	Week 12	Tezepelumab	12	10 (83.3)	5.18 (1.13)	3.6	4.17	5.29	6.25	6.8	
		Placebo	9	7 (77.8)	4.90 (1.05)	3.8	4.08	4.58	5.92	6.6	
	Week 16	Tezepelumab	12	10 (83.3)	5.33 (0.99)	3.6	4.92	5.42	6.08	6.8	
		Placebo	9	7 (77.8)	4.93 (1.09)	3.5	4.08	4.58	5.92	6.3	
	Week 20	Tezepelumab	12	11 (91.7)	5.15 (1.11)	3.6	4.17	4.83	6.25	6.8	
		Placebo	9	7 (77.8)	4.95 (1.42)	2.4	3.92	5.08	6.08	6.4	
	Week 24	Tezepelumab	12	11 (91.7)	5.19 (1.05)	3.6	4.17	4.92	6.17	7.0	
		Placebo	9	7 (77.8)	4.81 (1.65)	2.2	3.58	4.58	6.33	6.7	
	Week 28	Tezepelumab	12	12 (100.0)	5.04 (1.22)	3.3	4.13	5.04	5.88	7.0	
		Placebo	9	7 (77.8)	4.46 (1.39)	1.8	4.00	4.83	5.50	6.1	
	Week 32	Tezepelumab	12	12 (100.0)	4.94 (1.23)	3.5	4.00	4.75	5.83	7.0	
		Placebo	9	7 (77.8)	4.85 (1.25)	2.9	3.75	4.92	6.08	6.3	
	Week 36	Tezepelumab	12	12 (100.0)	5.15 (1.29)	3.3	4.08	5.04	6.25	7.0	
		Placebo	9	7 (77.8)	5.12 (1.44)	2.8	4.42	4.83	6.50	6.8	
	Week 40	Tezepelumab	12	12 (100.0)	4.97 (1.21)	2.9	4.25	4.96	5.46	7.0	
		Placebo	9	7 (77.8)	5.08 (1.49)	2.5	3.75	5.67	6.17	6.6	
	Week 44	Tezepelumab	12	12 (100.0)	4.96 (1.28)	3.0	4.08	4.83	5.79	7.0	
		Placebo	9	7 (77.8)	4.71 (1.22)	3.1	3.83	4.58	6.25	6.4	
	Week 48	Tezepelumab	12	12 (100.0)	5.06 (1.22)	3.1	4.13	5.08	5.96	7.0	
		Placebo	9	7 (77.8)	4.68 (1.56)	2.4	3.75	4.33	6.50	6.9	
	Week 52	Tezepelumab	12	12 (100.0)	5.09 (1.22)	3.1	4.08	5.08	5.96	7.0	
		Placebo	9	7 (77.8)	5.00 (1.18)	4.1	4.25	4.33	6.50	6.9	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IBMH0: Course of AQLQ+12 symptom score
DITTB

		Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Change from baseline in AQLQ+12 symptom score	Week 4	Tezepelumab	12	10 (83.3)	0.97 (1.10)	-0.4	0.08	0.96	1.75	3.1	0.02 [-0.95, 0.99]
		Placebo	9	7 (77.8)	0.95 (1.12)	0.0	0.17	0.92	1.00	3.3	
	Week 8	Tezepelumab	12	10 (83.3)	0.97 (1.44)	-1.9	0.25	0.92	2.00	3.3	-0.00 [-0.97, 0.97]
		Placebo	9	7 (77.8)	0.98 (1.21)	-0.3	0.00	0.67	1.50	3.3	
	Week 12	Tezepelumab	12	10 (83.3)	1.21 (1.14)	-0.2	0.25	0.96	1.92	3.7	0.06 [-0.91, 1.03]
		Placebo	9	7 (77.8)	1.13 (1.48)	-0.7	-0.25	1.08	1.67	3.8	
	Week 16	Tezepelumab	12	10 (83.3)	1.36 (0.83)	0.4	0.83	1.17	1.75	3.2	0.20 [-0.77, 1.17]
		Placebo	9	7 (77.8)	1.15 (1.27)	-0.3	0.00	0.92	1.67	3.6	
	Week 20	Tezepelumab	12	10 (83.3)	1.22 (0.97)	0.1	0.42	0.92	2.00	2.9	0.03 [-0.93, 1.00]
		Placebo	9	7 (77.8)	1.18 (1.48)	-1.1	-0.42	1.67	1.92	3.3	
	Week 24	Tezepelumab	12	10 (83.3)	1.26 (0.93)	0.1	0.42	1.08	1.83	2.9	0.17 [-0.80, 1.14]
		Placebo	9	7 (77.8)	1.04 (1.70)	-1.3	-0.75	0.92	2.17	3.6	
	Week 28	Tezepelumab	12	10 (83.3)	1.31 (0.94)	0.1	0.75	0.96	2.17	2.9	0.52 [-0.46, 1.50]
		Placebo	9	7 (77.8)	0.69 (1.48)	-1.8	-0.33	0.58	1.83	2.8	
	Week 32	Tezepelumab	12	10 (83.3)	0.99 (1.12)	-0.5	0.25	0.75	2.17	2.9	-0.06 [-1.03, 0.90]
		Placebo	9	7 (77.8)	1.07 (1.42)	-0.6	-0.58	1.17	1.83	3.5	
	Week 36	Tezepelumab	12	10 (83.3)	1.21 (1.05)	-0.3	0.25	1.25	2.17	2.9	-0.11 [-1.08, 0.86]
		Placebo	9	7 (77.8)	1.35 (1.48)	-0.8	0.08	1.17	2.33	3.8	
	Week 40	Tezepelumab	12	10 (83.3)	1.15 (0.99)	0.0	0.25	0.96	2.17	2.9	-0.13 [-1.09, 0.84]
		Placebo	9	7 (77.8)	1.31 (1.59)	-1.0	-0.58	1.83	2.25	3.4	
	Week 44	Tezepelumab	12	10 (83.3)	1.07 (1.13)	-0.8	0.25	0.92	2.17	2.9	0.10 [-0.87, 1.06]
		Placebo	9	7 (77.8)	0.94 (1.52)	-0.5	-0.42	0.92	2.00	3.7	
	Week 48	Tezepelumab	12	10 (83.3)	1.16 (0.96)	-0.3	0.58	0.88	2.00	2.9	0.18 [-0.78, 1.15]
		Placebo	9	7 (77.8)	0.90 (1.83)	-1.1	-0.58	0.67	2.25	4.2	
	Week 52	Tezepelumab	12	10 (83.3)	1.19 (0.91)	0.2	0.58	0.83	2.00	2.9	-0.03 [-0.99, 0.94]
		Placebo	9	7 (77.8)	1.23 (1.56)	-0.3	-0.25	0.83	2.25	4.2	

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Last observation carried forward is applied in case of missing values.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IBMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
DITTB

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 4	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 8	Tezepelumab	12	10 (83.3)	NE		NE		
	Placebo	9	7 (77.8)					
Week 12	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 16	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 20	Tezepelumab	12	9 (75.0)	NE		NE		
	Placebo	9	7 (77.8)					
Week 24	Tezepelumab	12	8 (66.7)	NE		NE		
	Placebo	9	6 (66.7)					
Week 28	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 32	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 36	Tezepelumab	12	7 (58.3)	NE		NE		
	Placebo	9	6 (66.7)					
Week 40	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Table PT2QMC_IBMC0: Change from baseline in AQLQ+12 symptom score - MMRM results
DITTB

Change from baseline in AQLQ+12 symptom score				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (SE)	95% CI	LS-Mean (SE)	95% CI	p-value
Week 44	Tezepelumab	12	5 (41.7)	NE		NE		
	Placebo	9	7 (77.8)					
Week 48	Tezepelumab	12	6 (50.0)	NE		NE		
	Placebo	9	6 (66.7)					
Week 52	Tezepelumab	12	3 (25.0)	NE		NE		
	Placebo	9	2 (22.2)					

Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
N = total number of patients in analysis set. n = number of non-missing values. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. SE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time and baseline as covariate. Only observed values are included into the model. An unstructured covariance structure was used.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source Data: aqlq, created on: 11AUG2022

Figure PF2QMC_IBMG0: Course of AQLQ+12 symptom score
DITTB



Note: DITTB = Dossier Biomarker Intent-to-Treat Set.
SD = standard deviation. BL = Baseline. The number of available values are provided below graph.
AQLQ+12 = Standardised asthma quality of life questionnaire for 12 years and older.
Source table: PT2QMC_IBMH0
Source Data: aqlq, created on: 11AUG2022

Table PT2A_SOMI0: Incidence of TEAEs during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
TEAEs during study period	137	89 (65.0) [56.4, 72.9]	138	91 (65.9) [57.4, 73.8]	0.985 [0.830, 1.170]	0.958 [0.583, 1.574]	-1.0 [-12.9, 11.0]	0.899

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2A_SOMS0: TEAEs during study period by SOC and PT
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Gastrointestinal disorders	137	14 (10.2) [5.7, 16.6]	138	11 (8.0) [4.0, 13.8]	1.282 [0.603, 2.724]	1.314 [0.574, 3.007]	2.2 [-5.3, 9.8]	0.537
SOC: General disorders and administration site conditions	137	9 (6.6) [3.0, 12.1]	138	12 (8.7) [4.6, 14.7]	0.755 [0.329, 1.735]	0.738 [0.301, 1.813]	-2.1 [-9.1, 4.9]	0.651
SOC: Infections and infestations	137	56 (40.9) [32.6, 49.6]	138	56 (40.6) [32.3, 49.3]	1.007 [0.757, 1.340]	1.012 [0.626, 1.638]	0.3 [-12.0, 12.6]	1.000
Nasopharyngitis	137	19 (13.9) [8.6, 20.8]	138	16 (11.6) [6.8, 18.1]	1.196 [0.642, 2.227]	1.228 [0.603, 2.501]	2.3 [-6.3, 10.9]	0.592
SOC: Injury, poisoning and procedural complications	137	9 (6.6) [3.0, 12.1]	138	11 (8.0) [4.0, 13.8]	0.824 [0.353, 1.926]	0.812 [0.325, 2.026]	-1.4 [-8.3, 5.5]	0.817
SOC: Musculoskeletal and connective tissue disorders	137	18 (13.1) [8.0, 20.0]	138	17 (12.3) [7.3, 19.0]	1.067 [0.574, 1.981]	1.077 [0.530, 2.189]	0.8 [-7.8, 9.4]	0.858
SOC: Nervous system disorders	137	19 (13.9) [8.6, 20.8]	138	11 (8.0) [4.0, 13.8]	1.740 [0.861, 3.518]	1.859 [0.849, 4.070]	5.9 [-2.2, 14.0]	0.126
Headache	137	11 (8.0) [4.1, 13.9]	138	6 (4.3) [1.6, 9.2]	1.847 [0.703, 4.853]	1.921 [0.690, 5.349]	3.7 [-2.7, 10.1]	0.222
SOC: Respiratory, thoracic and mediastinal disorders	137	33 (24.1) [17.2, 32.1]	138	54 (39.1) [30.9, 47.8]	0.616 [0.428, 0.885]	0.494 [0.294, 0.830]	-15.0 [-26.6, -3.5]	0.009 *
Asthma	137	27 (19.7) [13.4, 27.4]	138	50 (36.2) [28.2, 44.8]	0.544 [0.363, 0.815]	0.432 [0.250, 0.745]	-16.5 [-27.7, -5.4]	0.003 *

Note: DSAF = Dossier Safety Set. Only events are displayed with an incidence of at least 10 percent in a treatment group or 10 patients with an incidence of at least 1 percent in a treatment group.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2A_SOSIK: Incidence of TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.672
Male	50	34 (68.0) [53.3, 80.5]	44	32 (72.7) [57.2, 85.0]	0.935 [0.719, 1.216]	0.797 [0.327, 1.942]	-4.7 [-25.3, 15.9]	0.657
Female	87	55 (63.2) [52.2, 73.3]	94	59 (62.8) [52.2, 72.5]	1.007 [0.806, 1.259]	1.020 [0.557, 1.865]	0.5 [-14.7, 15.6]	1.000
Age								0.955
< 65 years	114	73 (64.0) [54.5, 72.8]	118	77 (65.3) [55.9, 73.8]	0.981 [0.811, 1.187]	0.948 [0.553, 1.624]	-1.2 [-14.4, 11.9]	0.891
>= 65 years	23	16 (69.6) [47.1, 86.8]	20	14 (70.0) [45.7, 88.1]	0.994 [0.670, 1.474]	0.980 [0.266, 3.613]	-0.4 [-32.6, 31.8]	1.000
Exacerbations in the year before study								0.347
<= 2	105	64 (61.0) [50.9, 70.3]	110	66 (60.0) [50.2, 69.2]	1.016 [0.818, 1.261]	1.041 [0.602, 1.798]	1.0 [-13.1, 15.0]	0.890
> 2	32	25 (78.1) [60.0, 90.7]	28	25 (89.3) [71.8, 97.7]	0.875 [0.700, 1.094]	0.429 [0.099, 1.849]	-11.2 [-32.9, 10.5]	0.312

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSIK: Incidence of TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	128	82 (64.1) [55.1, 72.3]	123	80 (65.0) [55.9, 73.4]				
Black or African American	3	3 (100.0) [29.2, 100.0]	6	5 (83.3) [35.9, 99.6]				
Asian	5	4 (80.0) [28.4, 99.5]	6	3 (50.0) [11.8, 88.2]				
Other	1	0 (0.0) [0.0, 97.5]	3	3 (100.0) [29.2, 100.0]				
Region								0.552
Europe	78	49 (62.8) [51.1, 73.5]	80	53 (66.3) [54.8, 76.4]	0.948 [0.752, 1.195]	0.861 [0.448, 1.653]	-3.4 [-19.6, 12.7]	0.740
America	10	10 (100.0) [69.2, 100.0]	9	9 (100.0) [66.4, 100.0]				NE
Asia/Pacific	5	4 (80.0) [28.4, 99.5]	6	3 (50.0) [11.8, 88.2]	1.600 [0.643, 3.984]	4.000 [0.265, 60.325]	30.0 [-41.5, 100.0]	0.545
Rest of the world	44	26 (59.1) [43.2, 73.7]	43	26 (60.5) [44.4, 75.0]	0.977 [0.692, 1.380]	0.944 [0.401, 2.226]	-1.4 [-24.3, 21.5]	1.000
BMI		N<10 any level						NE
< 18.5 kg/m**2	0		1	1 (100.0) [2.5, 100.0]				
18.5 - < 25.0 kg/m**2	39	24 (61.5) [44.6, 76.6]	43	27 (62.8) [46.7, 77.0]				
25.0 - < 30.0 kg/m**2	45	27 (60.0) [44.3, 74.3]	47	29 (61.7) [46.4, 75.5]				
>= 30.0 kg/m**2	53	38 (71.7) [57.7, 83.2]	47	34 (72.3) [57.4, 84.4]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSIK: Incidence of TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.652
< 150 cells/uL	27	19 (70.4) [49.8, 86.2]	33	22 (66.7) [48.2, 82.0]	1.056 [0.749, 1.488]	1.188 [0.396, 3.561]	3.7 [-23.2, 30.6]	0.788
>= 150 cells/uL	109	69 (63.3) [53.5, 72.3]	105	69 (65.7) [55.8, 74.7]	0.963 [0.790, 1.175]	0.900 [0.514, 1.576]	-2.4 [-16.2, 11.3]	0.776
Baseline eosinophils - High								0.962
< 300 cells/uL	69	44 (63.8) [51.3, 75.0]	72	47 (65.3) [53.1, 76.1]	0.977 [0.765, 1.248]	0.936 [0.469, 1.867]	-1.5 [-18.7, 15.7]	0.862
>= 300 cells/uL	67	44 (65.7) [53.1, 76.8]	66	44 (66.7) [54.0, 77.8]	0.985 [0.773, 1.256]	0.957 [0.466, 1.962]	-1.0 [-18.6, 16.6]	1.000
Baseline FENO								0.393
< 25 ppb	78	52 (66.7) [55.1, 76.9]	74	47 (63.5) [51.5, 74.4]	1.050 [0.831, 1.325]	1.149 [0.589, 2.240]	3.2 [-13.3, 19.6]	0.735
>= 25 ppb	57	35 (61.4) [47.6, 74.0]	63	43 (68.3) [55.3, 79.4]	0.900 [0.690, 1.174]	0.740 [0.349, 1.570]	-6.9 [-25.6, 11.9]	0.450

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSIK: Incidence of TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.526
All negative	57	39 (68.4) [54.8, 80.1]	66	47 (71.2) [58.7, 81.7]	0.961 [0.761, 1.214]	0.876 [0.405, 1.895]	-2.8 [-20.7, 15.1]	0.844
Any positive	71	45 (63.4) [51.1, 74.5]	63	37 (58.7) [45.6, 71.0]	1.079 [0.822, 1.417]	1.216 [0.606, 2.440]	4.7 [-13.4, 22.7]	0.599
Total serum IgE								0.991
Low	35	24 (68.6) [50.7, 83.1]	32	22 (68.8) [50.0, 83.9]	0.997 [0.721, 1.379]	0.992 [0.353, 2.788]	-0.2 [-25.4, 25.0]	1.000
Normal	95	60 (63.2) [52.6, 72.8]	98	63 (64.3) [54.0, 73.7]	0.982 [0.794, 1.216]	0.952 [0.530, 1.713]	-1.1 [-15.7, 13.5]	0.882
High	7	5 (71.4) [29.0, 96.3]	8	6 (75.0) [34.9, 96.8]	0.952 [0.514, 1.764]	0.833 [0.084, 8.240]	-3.6 [-61.9, 54.8]	1.000
OCS at baseline								0.230
Yes	9	8 (88.9) [51.8, 99.7]	13	9 (69.2) [38.6, 90.9]	1.284 [0.835, 1.973]	3.556 [0.326, 38.777]	19.7 [-22.2, 61.5]	0.360
No	128	81 (63.3) [54.3, 71.6]	125	82 (65.6) [56.6, 73.9]	0.965 [0.803, 1.158]	0.904 [0.540, 1.513]	-2.3 [-14.9, 10.3]	0.793

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSIK: Incidence of TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)								0.727
Medium/Low	70	43 (61.4) [49.0, 72.8]	73	47 (64.4) [52.3, 75.3]	0.954 [0.741, 1.228]	0.881 [0.447, 1.737]	-3.0 [-20.2, 14.3]	0.732
High	67	46 (68.7) [56.2, 79.4]	65	44 (67.7) [54.9, 78.8]	1.014 [0.803, 1.281]	1.045 [0.503, 2.175]	1.0 [-16.4, 18.4]	1.000
LAMA use at baseline								0.752
Yes	11	8 (72.7) [39.0, 94.0]	6	4 (66.7) [22.3, 95.7]	1.091 [0.557, 2.135]	1.333 [0.155, 11.498]	6.1 [-52.8, 64.9]	1.000
No	126	81 (64.3) [55.3, 72.6]	132	87 (65.9) [57.2, 73.9]	0.975 [0.816, 1.166]	0.931 [0.558, 1.554]	-1.6 [-14.0, 10.8]	0.795
Tiotropium use at baseline								0.688
Yes	9	7 (77.8) [40.0, 97.2]	3	2 (66.7) [9.4, 99.2]	1.167 [0.487, 2.793]	1.750 [0.099, 30.837]	11.1 [-71.0, 93.2]	1.000
No	128	82 (64.1) [55.1, 72.3]	135	89 (65.9) [57.3, 73.9]	0.972 [0.814, 1.161]	0.921 [0.555, 1.530]	-1.9 [-14.2, 10.4]	0.796

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSIK: Incidence of TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
		n (%)		n (%)	RR	OR	RD	
TEAEs during study period	N	[95 % CI]	N	[95 % CI]	[95 % CI]	[95 % CI]	[95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline								0.234
Yes	29	26 (89.7) [72.6, 97.8]	37	29 (78.4) [61.8, 90.2]	1.144 [0.928, 1.411]	2.391 [0.573, 9.976]	11.3 [-9.1, 31.6]	0.323
No	108	63 (58.3) [48.5, 67.7]	101	62 (61.4) [51.2, 70.9]	0.950 [0.761, 1.187]	0.881 [0.506, 1.532]	-3.1 [-17.3, 11.2]	0.674

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAF

	Tezepelumab		Placebo						
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Respiratory, thoracic and mediastinal disorders									
Sex								0.799	
Male	50	12 (24.0) [13.1, 38.2]	44	16 (36.4) [22.4, 52.2]	0.660 [0.352, 1.238]	0.553 [0.226, 1.351]	-12.4 [-33.0, 8.3]	0.259	
Female	87	21 (24.1) [15.6, 34.5]	94	38 (40.4) [30.4, 51.0]	0.597 [0.382, 0.933]	0.469 [0.247, 0.890]	-16.3 [-30.8, -1.8]	0.026	*
Age								0.014	i
< 65 years	114	24 (21.1) [14.0, 29.7]	118	50 (42.4) [33.3, 51.8]	0.497 [0.329, 0.751]	0.363 [0.203, 0.648]	-21.3 [-33.8, -8.8]	<0.001	*
>= 65 years	23	9 (39.1) [19.7, 61.5]	20	4 (20.0) [5.7, 43.7]	1.957 [0.710, 5.393]	2.571 [0.648, 10.211]	19.1 [-12.1, 50.4]	0.203	
Exacerbations in the year before study								0.849	
<= 2	105	18 (17.1) [10.5, 25.7]	110	31 (28.2) [20.0, 37.6]	0.608 [0.363, 1.019]	0.527 [0.274, 1.016]	-11.0 [-23.0, 1.0]	0.073	
> 2	32	15 (46.9) [29.1, 65.3]	28	23 (82.1) [63.1, 93.9]	0.571 [0.380, 0.858]	0.192 [0.058, 0.631]	-35.3 [-61.0, -9.6]	0.007	*
Race		any N<10						NE	
White	128	29 (22.7) [15.7, 30.9]	123	44 (35.8) [27.3, 44.9]					
Black or African American	3	1 (33.3) [0.8, 90.6]	6	5 (83.3) [35.9, 99.6]					
Asian	5	3 (60.0) [14.7, 94.7]	6	2 (33.3) [4.3, 77.7]					
Other	1	0 (0.0) [0.0, 97.5]	3	3 (100.0) [29.2, 100.0]					

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Region								0.023	i
Europe	78	21 (26.9) [17.5, 38.2]	80	24 (30.0) [20.3, 41.3]	0.897 [0.547, 1.473]	0.860 [0.430, 1.717]	-3.1 [-18.4, 12.3]	0.726	
America	10	4 (40.0) [12.2, 73.8]	9	9 (100.0) [66.4, 100.0]	0.400 [0.187, 0.855]	0.036 + [0.002, 0.799]	-60.0 [-100.0, -19.1]	0.011	*
Asia/Pacific	5	3 (60.0) [14.7, 94.7]	6	2 (33.3) [4.3, 77.7]	1.800 [0.472, 6.867]	3.000 [0.255, 35.334]	26.7 [-48.8, 100.0]	0.567	
Rest of the world	44	5 (11.4) [3.8, 24.6]	43	19 (44.2) [29.1, 60.1]	0.257 [0.106, 0.627]	0.162 [0.053, 0.491]	-32.8 [-52.7, -13.0]	<0.001	*
BMI		any N<10						NE	
< 18.5 kg/m**2	0		1	0 (0.0) [0.0, 97.5]					
18.5 - < 25.0 kg/m**2	39	7 (17.9) [7.5, 33.5]	43	19 (44.2) [29.1, 60.1]					
25.0 - < 30.0 kg/m**2	45	13 (28.9) [16.4, 44.3]	47	17 (36.2) [22.7, 51.5]					
>= 30.0 kg/m**2	53	13 (24.5) [13.8, 38.3]	47	18 (38.3) [24.5, 53.6]					
Baseline eosinophils - Low								0.282	
< 150 cells/uL	27	5 (18.5) [6.3, 38.1]	33	15 (45.5) [28.1, 63.6]	0.407 [0.170, 0.977]	0.273 [0.083, 0.895]	-26.9 [-52.7, -1.1]	0.032	*
>= 150 cells/uL	109	28 (25.7) [17.8, 34.9]	105	39 (37.1) [27.9, 47.1]	0.692 [0.461, 1.037]	0.585 [0.326, 1.049]	-11.5 [-24.7, 1.8]	0.078	
Baseline eosinophils - High								0.949	
< 300 cells/uL	69	15 (21.7) [12.7, 33.3]	72	25 (34.7) [23.9, 46.9]	0.626 [0.362, 1.083]	0.522 [0.247, 1.106]	-13.0 [-29.1, 3.1]	0.096	
>= 300 cells/uL	67	18 (26.9) [16.8, 39.1]	66	29 (43.9) [31.7, 56.7]	0.611 [0.378, 0.988]	0.469 [0.227, 0.969]	-17.1 [-34.6, 0.4]	0.047	*

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO								0.146
< 25 ppb	78	21 (26.9) [17.5, 38.2]	74	25 (33.8) [23.2, 45.7]	0.797 [0.491, 1.295]	0.722 [0.361, 1.446]	-6.9 [-22.8, 9.1]	0.382
>= 25 ppb	57	12 (21.1) [11.4, 33.9]	63	29 (46.0) [33.4, 59.1]	0.457 [0.259, 0.808]	0.313 [0.140, 0.701]	-25.0 [-42.9, -7.1]	0.007 *
Baseline specific perennial FEIA status								0.914
All negative	57	15 (26.3) [15.5, 39.7]	66	27 (40.9) [29.0, 53.7]	0.643 [0.382, 1.084]	0.516 [0.240, 1.111]	-14.6 [-32.7, 3.5]	0.127
Any positive	71	16 (22.5) [13.5, 34.0]	63	23 (36.5) [24.7, 49.6]	0.617 [0.360, 1.060]	0.506 [0.237, 1.079]	-14.0 [-30.8, 2.9]	0.088
Total serum IgE								0.709
Low	35	11 (31.4) [16.9, 49.3]	32	13 (40.6) [23.7, 59.4]	0.774 [0.406, 1.473]	0.670 [0.246, 1.827]	-9.2 [-35.1, 16.7]	0.457
Normal	95	21 (22.1) [14.2, 31.8]	98	39 (39.8) [30.0, 50.2]	0.555 [0.354, 0.870]	0.429 [0.228, 0.807]	-17.7 [-31.5, -3.9]	0.009 *
High	7	1 (14.3) [0.4, 57.9]	8	2 (25.0) [3.2, 65.1]	0.571 [0.065, 5.033]	0.500 [0.035, 7.104]	-10.7 [-63.8, 42.3]	1.000
OCS at baseline								0.738
Yes	9	4 (44.4) [13.7, 78.8]	13	8 (61.5) [31.6, 86.1]	0.722 [0.309, 1.685]	0.500 [0.089, 2.807]	-17.1 [-68.4, 34.2]	0.666
No	128	29 (22.7) [15.7, 30.9]	125	46 (36.8) [28.4, 45.9]	0.616 [0.415, 0.913]	0.503 [0.290, 0.873]	-14.1 [-26.1, -2.2]	0.019 *

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
ICS dose level (at study entry)								0.918	
Medium/Low	70	15 (21.4) [12.5, 32.9]	73	25 (34.2) [23.5, 46.3]	0.626 [0.361, 1.084]	0.524 [0.248, 1.106]	-12.8 [-28.7, 3.1]	0.097	
High	67	18 (26.9) [16.8, 39.1]	65	29 (44.6) [32.3, 57.5]	0.602 [0.373, 0.972]	0.456 [0.220, 0.945]	-17.7 [-35.3, -0.2]	0.045	*
LAMA use at baseline								0.415	
Yes	11	5 (45.5) [16.7, 76.6]	6	3 (50.0) [11.8, 88.2]	0.909 [0.325, 2.544]	0.833 [0.114, 6.111]	-4.5 [-67.1, 58.0]	1.000	
No	126	28 (22.2) [15.3, 30.5]	132	51 (38.6) [30.3, 47.5]	0.575 [0.389, 0.850]	0.454 [0.263, 0.784]	-16.4 [-28.2, -4.6]	0.005	*
Tiotropium use at baseline								0.480	
Yes	9	5 (55.6) [21.2, 86.3]	3	2 (66.7) [9.4, 99.2]	0.833 [0.309, 2.245]	0.625 [0.040, 9.650]	-11.1 [-95.8, 73.6]	1.000	
No	128	28 (21.9) [15.1, 30.0]	135	52 (38.5) [30.3, 47.3]	0.568 [0.384, 0.839]	0.447 [0.259, 0.770]	-16.6 [-28.3, -5.0]	0.005	*
Montelukast/ Cromoglicic acid use at baseline								0.346	
Yes	29	13 (44.8) [26.4, 64.3]	37	21 (56.8) [39.5, 72.9]	0.790 [0.483, 1.292]	0.619 [0.233, 1.648]	-11.9 [-39.1, 15.3]	0.457	
No	108	20 (18.5) [11.7, 27.1]	101	33 (32.7) [23.7, 42.7]	0.567 [0.349, 0.920]	0.468 [0.247, 0.887]	-14.2 [-26.8, -1.5]	0.026	*

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAF

	Tezepelumab		Placebo						
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Asthma									
Sex								0.625	
Male	50	8 (16.0) [7.2, 29.1]	44	15 (34.1) [20.5, 49.9]	0.469 [0.220, 1.000]	0.368 [0.138, 0.981]	-18.1 [-37.5, 1.3]	0.055	
Female	87	19 (21.8) [13.7, 32.0]	94	35 (37.2) [27.5, 47.8]	0.587 [0.364, 0.944]	0.471 [0.244, 0.910]	-15.4 [-29.6, -1.2]	0.034	*
Age								0.097	
< 65 years	114	21 (18.4) [11.8, 26.8]	118	46 (39.0) [30.1, 48.4]	0.473 [0.302, 0.739]	0.353 [0.194, 0.645]	-20.6 [-32.7, -8.4]	<0.001	*
>= 65 years	23	6 (26.1) [10.2, 48.4]	20	4 (20.0) [5.7, 43.7]	1.304 [0.428, 3.975]	1.412 [0.335, 5.944]	6.1 [-23.7, 35.8]	0.728	
Exacerbations in the year before study								0.857	
<= 2	105	14 (13.3) [7.5, 21.4]	110	29 (26.4) [18.4, 35.6]	0.506 [0.283, 0.902]	0.430 [0.212, 0.869]	-13.0 [-24.5, -1.6]	0.018	*
> 2	32	13 (40.6) [23.7, 59.4]	28	21 (75.0) [55.1, 89.3]	0.542 [0.338, 0.867]	0.228 [0.075, 0.691]	-34.4 [-61.1, -7.6]	0.010	*
Race		any N<10						NE	
White	128	24 (18.8) [12.4, 26.6]	123	41 (33.3) [25.1, 42.4]					
Black or African American	3	1 (33.3) [0.8, 90.6]	6	4 (66.7) [22.3, 95.7]					
Asian	5	2 (40.0) [5.3, 85.3]	6	2 (33.3) [4.3, 77.7]					
Other	1	0 (0.0) [0.0, 97.5]	3	3 (100.0) [29.2, 100.0]					

Subgroups presented for PT: Asthma

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAF

	Tezepelumab		Placebo						
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Region								0.052	
Europe	78	18 (23.1) [14.3, 34.0]	80	22 (27.5) [18.1, 38.6]	0.839 [0.489, 1.439]	0.791 [0.385, 1.625]	-4.4 [-19.2, 10.4]	0.585	
America	10	4 (40.0) [12.2, 73.8]	9	8 (88.9) [51.8, 99.7]	0.450 [0.204, 0.995]	0.083 [0.007, 0.950]	-48.9 [-96.1, -1.7]	0.057	
Asia/Pacific	5	2 (40.0) [5.3, 85.3]	6	2 (33.3) [4.3, 77.7]	1.200 [0.252, 5.709]	1.333 [0.113, 15.704]	6.7 [-68.8, 82.2]	1.000	
Rest of the world	44	3 (6.8) [1.4, 18.7]	43	18 (41.9) [27.0, 57.9]	0.163 [0.052, 0.513]	0.102 [0.027, 0.380]	-35.0 [-53.9, -16.2]	<0.001	*
BMI		any N<10						NE	
< 18.5 kg/m**2	0		1	0 (0.0) [0.0, 97.5]					
18.5 - < 25.0 kg/m**2	39	6 (15.4) [5.9, 30.5]	43	17 (39.5) [25.0, 55.6]					
25.0 - < 30.0 kg/m**2	45	10 (22.2) [11.2, 37.1]	47	17 (36.2) [22.7, 51.5]					
>= 30.0 kg/m**2	53	11 (20.8) [10.8, 34.1]	47	16 (34.0) [20.9, 49.3]					
Baseline eosinophils - Low								0.306	
< 150 cells/uL	27	4 (14.8) [4.2, 33.7]	33	14 (42.4) [25.5, 60.8]	0.349 [0.130, 0.938]	0.236 [0.067, 0.837]	-27.6 [-52.5, -2.7]	0.025	*
>= 150 cells/uL	109	23 (21.1) [13.9, 30.0]	105	36 (34.3) [25.3, 44.2]	0.615 [0.393, 0.965]	0.513 [0.278, 0.945]	-13.2 [-26.0, -0.4]	0.033	*
Baseline eosinophils - High								0.990	
< 300 cells/uL	69	12 (17.4) [9.3, 28.4]	72	23 (31.9) [21.4, 44.0]	0.544 [0.294, 1.007]	0.449 [0.202, 0.994]	-14.6 [-30.0, 0.9]	0.053	
>= 300 cells/uL	67	15 (22.4) [13.1, 34.2]	66	27 (40.9) [29.0, 53.7]	0.547 [0.322, 0.931]	0.417 [0.196, 0.887]	-18.5 [-35.5, -1.5]	0.026	*

Subgroups presented for PT: Asthma

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO								0.204
< 25 ppb	78	17 (21.8) [13.2, 32.6]	74	23 (31.1) [20.8, 42.9]	0.701 [0.409, 1.204]	0.618 [0.298, 1.281]	-9.3 [-24.6, 6.0]	0.204
>= 25 ppb	57	10 (17.5) [8.7, 29.9]	63	27 (42.9) [30.5, 56.0]	0.409 [0.218, 0.769]	0.284 [0.122, 0.661]	-25.3 [-42.7, -7.9]	0.003 *
Baseline specific perennial FEIA status								0.846
All negative	57	13 (22.8) [12.7, 35.8]	66	26 (39.4) [27.6, 52.2]	0.579 [0.330, 1.017]	0.455 [0.206, 1.003]	-16.6 [-34.3, 1.1]	0.055
Any positive	71	12 (16.9) [9.0, 27.7]	63	20 (31.7) [20.6, 44.7]	0.532 [0.284, 1.000]	0.437 [0.193, 0.989]	-14.8 [-30.8, 1.1]	0.067
Total serum IgE								0.990
Low	35	8 (22.9) [10.4, 40.1]	32	13 (40.6) [23.7, 59.4]	0.563 [0.269, 1.178]	0.433 [0.150, 1.248]	-17.8 [-42.7, 7.2]	0.187
Normal	95	18 (18.9) [11.6, 28.3]	98	35 (35.7) [26.3, 46.0]	0.531 [0.324, 0.869]	0.421 [0.218, 0.813]	-16.8 [-30.1, -3.4]	0.010 *
High	7	1 (14.3) [0.4, 57.9]	8	2 (25.0) [3.2, 65.1]	0.571 [0.065, 5.033]	0.500 [0.035, 7.104]	-10.7 [-63.8, 42.3]	1.000
OCS at baseline								0.538
Yes	9	4 (44.4) [13.7, 78.8]	13	8 (61.5) [31.6, 86.1]	0.722 [0.309, 1.685]	0.500 [0.089, 2.807]	-17.1 [-68.4, 34.2]	0.666
No	128	23 (18.0) [11.7, 25.7]	125	42 (33.6) [25.4, 42.6]	0.535 [0.343, 0.834]	0.433 [0.241, 0.776]	-15.6 [-27.0, -4.2]	0.006 *

Subgroups presented for PT: Asthma

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAF

	Tezepelumab		Placebo						
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
ICS dose level (at study entry)								0.884	
Medium/Low	70	11 (15.7) [8.1, 26.4]	73	22 (30.1) [19.9, 42.0]	0.521 [0.274, 0.994]	0.432 [0.191, 0.976]	-14.4 [-29.4, 0.5]	0.048	*
High	67	16 (23.9) [14.3, 35.9]	65	28 (43.1) [30.8, 56.0]	0.554 [0.333, 0.924]	0.415 [0.197, 0.874]	-19.2 [-36.5, -1.9]	0.026	*
LAMA use at baseline								0.280	
Yes	11	5 (45.5) [16.7, 76.6]	6	3 (50.0) [11.8, 88.2]	0.909 [0.325, 2.544]	0.833 [0.114, 6.111]	-4.5 [-67.1, 58.0]	1.000	
No	126	22 (17.5) [11.3, 25.2]	132	47 (35.6) [27.5, 44.4]	0.490 [0.315, 0.764]	0.383 [0.214, 0.685]	-18.1 [-29.4, -6.9]	0.001	*
Tiotropium use at baseline								0.325	
Yes	9	5 (55.6) [21.2, 86.3]	3	2 (66.7) [9.4, 99.2]	0.833 [0.309, 2.245]	0.625 [0.040, 9.650]	-11.1 [-95.8, 73.6]	1.000	
No	128	22 (17.2) [11.1, 24.9]	135	48 (35.6) [27.5, 44.2]	0.483 [0.310, 0.753]	0.376 [0.211, 0.671]	-18.4 [-29.5, -7.2]	<0.001	*
Montelukast/ Cromoglicic acid use at baseline								0.093	
Yes	29	12 (41.4) [23.5, 61.1]	37	18 (48.6) [31.9, 65.6]	0.851 [0.493, 1.467]	0.745 [0.279, 1.987]	-7.3 [-34.4, 19.9]	0.623	
No	108	15 (13.9) [8.0, 21.9]	101	32 (31.7) [22.8, 41.7]	0.438 [0.253, 0.760]	0.348 [0.175, 0.692]	-17.8 [-29.9, -5.7]	0.003	*

Subgroups presented for PT: Asthma

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSIP: Incidence of TEAEs during study period by study specific subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.771
White	128	82 (64.1) [55.1, 72.3]	123	80 (65.0) [55.9, 73.4]	0.985 [0.820, 1.183]	0.958 [0.571, 1.607]	-1.0 [-13.6, 11.7]	0.896
Non-white	9	7 (77.8) [40.0, 97.2]	15	11 (73.3) [44.9, 92.2]	1.061 [0.667, 1.686]	1.273 [0.182, 8.892]	4.4 [-39.6, 48.5]	1.000
Region (cat. P)								0.847
North America/Western EU	10	10 (100.0) [69.2, 100.0]	9	9 (100.0) [66.4, 100.0]	1.005 + [0.829, 1.217]	1.105 + [0.020, 61.378]	0.5 + [-27.4, 28.3]	NE
Rest of world	127	79 (62.2) [53.2, 70.7]	129	82 (63.6) [54.6, 71.9]	0.979 [0.811, 1.181]	0.943 [0.568, 1.567]	-1.4 [-14.0, 11.3]	0.897
Baseline eosinophils (cat. P)								0.300
< 250 cells/uL	61	38 (62.3) [49.0, 74.4]	60	42 (70.0) [56.8, 81.2]	0.890 [0.689, 1.150]	0.708 [0.332, 1.509]	-7.7 [-26.2, 10.8]	0.444
>= 250 cells/uL	76	51 (67.1) [55.4, 77.5]	78	49 (62.8) [51.1, 73.5]	1.068 [0.847, 1.347]	1.207 [0.622, 2.343]	4.3 [-12.1, 20.6]	0.615
Baseline FENO (cat. P)								0.315
< 24 ppb	75	50 (66.7) [54.8, 77.1]	72	45 (62.5) [50.3, 73.6]	1.067 [0.839, 1.356]	1.200 [0.610, 2.361]	4.2 [-12.6, 21.0]	0.610
>= 24 ppb	60	37 (61.7) [48.2, 73.9]	65	45 (69.2) [56.6, 80.1]	0.891 [0.689, 1.152]	0.715 [0.341, 1.499]	-7.6 [-25.8, 10.7]	0.452

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSIP: Incidence of TEAEs during study period by study specific subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.146
< 22.0 ppb	65	42 (64.6) [51.8, 76.1]	62	35 (56.5) [43.3, 69.0]	1.145 [0.862, 1.519]	1.409 [0.689, 2.878]	8.2 [-10.4, 26.7]	0.369
>= 22.0 ppb	70	45 (64.3) [51.9, 75.4]	75	55 (73.3) [61.9, 82.9]	0.877 [0.702, 1.094]	0.655 [0.323, 1.328]	-9.0 [-25.5, 7.4]	0.283
Baseline all FEIA status								0.328
All negative	50	36 (72.0) [57.5, 83.8]	50	32 (64.0) [49.2, 77.1]	1.125 [0.858, 1.474]	1.446 [0.621, 3.368]	8.0 [-12.2, 28.2]	0.521
Any positive	77	47 (61.0) [49.2, 72.0]	80	52 (65.0) [53.5, 75.3]	0.939 [0.739, 1.194]	0.844 [0.441, 1.614]	-4.0 [-20.3, 12.4]	0.624
Th2 status								0.688
Low	70	47 (67.1) [54.9, 77.9]	62	41 (66.1) [53.0, 77.7]	1.015 [0.797, 1.293]	1.047 [0.507, 2.161]	1.0 [-16.6, 18.7]	1.000
High	65	41 (63.1) [50.2, 74.7]	75	50 (66.7) [54.8, 77.1]	0.946 [0.740, 1.209]	0.854 [0.426, 1.713]	-3.6 [-20.9, 13.7]	0.724
Baseline Periostin								0.697
Low (< 20.9 ng/ml)	62	39 (62.9) [49.7, 74.8]	67	41 (61.2) [48.5, 72.9]	1.028 [0.785, 1.347]	1.075 [0.528, 2.192]	1.7 [-16.6, 20.0]	0.858
High (>= 20.9 ng/ml)	74	50 (67.6) [55.7, 78.0]	71	50 (70.4) [58.4, 80.7]	0.959 [0.771, 1.193]	0.875 [0.432, 1.770]	-2.9 [-19.3, 13.6]	0.724

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSIP: Incidence of TEAEs during study period by study specific subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.011 i
Yes	114	74 (64.9) [55.4, 73.6]	126	79 (62.7) [53.6, 71.1]	1.035 [0.856, 1.253]	1.101 [0.649, 1.865]	2.2 [-10.8, 15.2]	0.788
No	23	15 (65.2) [42.7, 83.6]	12	12 (100.0) [73.5, 100.0]	0.652 [0.484, 0.879]	0.073 + [0.004, 1.391]	-34.8 [-60.6, -9.0]	0.032 *
Maintenance OCS use at baseline								0.269
Yes	9	8 (88.9) [51.8, 99.7]	14	10 (71.4) [41.9, 91.6]	1.244 [0.831, 1.864]	3.200 [0.296, 34.588]	17.5 [-23.0, 57.9]	0.611
No	128	81 (63.3) [54.3, 71.6]	124	81 (65.3) [56.3, 73.6]	0.969 [0.806, 1.164]	0.915 [0.546, 1.532]	-2.0 [-14.7, 10.6]	0.793
No chronic OCS use and current post-BD FEV1 reversibility								0.284
Yes	108	69 (63.9) [54.1, 72.9]	115	72 (62.6) [53.1, 71.5]	1.020 [0.835, 1.247]	1.057 [0.613, 1.822]	1.3 [-12.3, 14.8]	0.890
No	29	20 (69.0) [49.2, 84.7]	23	19 (82.6) [61.2, 95.0]	0.835 [0.614, 1.136]	0.468 [0.123, 1.777]	-13.6 [-40.4, 13.1]	0.341

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Respiratory, thoracic and mediastinal disorders									
Race (cat. P)								0.912	
White	128	29 (22.7) [15.7, 30.9]	123	44 (35.8) [27.3, 44.9]	0.633 [0.425, 0.943]	0.526 [0.302, 0.915]	-13.1 [-25.1, -1.2]	0.026	*
Non-white	9	4 (44.4) [13.7, 78.8]	15	10 (66.7) [38.4, 88.2]	0.667 [0.296, 1.504]	0.400 [0.073, 2.184]	-22.2 [-71.4, 27.0]	0.403	
Region (cat. P)								0.260	
North America/Western EU	10	4 (40.0) [12.2, 73.8]	9	9 (100.0) [66.4, 100.0]	0.400 [0.187, 0.855]	0.036 + [0.002, 0.799]	-60.0 [-100.0, -19.1]	0.011	*
Rest of world	127	29 (22.8) [15.9, 31.1]	129	45 (34.9) [26.7, 43.8]	0.655 [0.440, 0.974]	0.552 [0.319, 0.958]	-12.0 [-23.8, -0.3]	0.039	*
Baseline eosinophils (cat. P)								0.508	
< 250 cells/uL	61	13 (21.3) [11.9, 33.7]	60	24 (40.0) [27.6, 53.5]	0.533 [0.300, 0.945]	0.406 [0.182, 0.905]	-18.7 [-36.4, -0.9]	0.031	*
>= 250 cells/uL	76	20 (26.3) [16.9, 37.7]	78	30 (38.5) [27.7, 50.2]	0.684 [0.428, 1.094]	0.571 [0.288, 1.133]	-12.1 [-28.1, 3.8]	0.123	
Baseline FENO (cat. P)								0.108	
< 24 ppb	75	20 (26.7) [17.1, 38.1]	72	23 (31.9) [21.4, 44.0]	0.835 [0.504, 1.383]	0.775 [0.380, 1.579]	-5.3 [-21.3, 10.8]	0.587	
>= 24 ppb	60	13 (21.7) [12.1, 34.2]	65	31 (47.7) [35.1, 60.5]	0.454 [0.264, 0.783]	0.303 [0.139, 0.664]	-26.0 [-43.6, -8.4]	0.003	*

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAF

	Tezepelumab		Placebo						
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. M)								0.061	
< 22.0 ppb	65	17 (26.2) [16.0, 38.5]	62	17 (27.4) [16.9, 40.2]	0.954 [0.537, 1.695]	0.938 [0.427, 2.057]	-1.3 [-18.3, 15.7]	1.000	
>= 22.0 ppb	70	16 (22.9) [13.7, 34.4]	75	37 (49.3) [37.6, 61.1]	0.463 [0.285, 0.755]	0.304 [0.148, 0.624]	-26.5 [-42.9, -10.1]	0.001	*
Baseline all FEIA status								0.223	
All negative	50	15 (30.0) [17.9, 44.6]	50	18 (36.0) [22.9, 50.8]	0.833 [0.475, 1.462]	0.762 [0.330, 1.758]	-6.0 [-26.4, 14.4]	0.671	
Any positive	77	16 (20.8) [12.4, 31.5]	80	32 (40.0) [29.2, 51.6]	0.519 [0.311, 0.867]	0.393 [0.194, 0.800]	-19.2 [-34.5, -3.9]	0.010	*
Th2 status								0.757	
Low	70	16 (22.9) [13.7, 34.4]	62	25 (40.3) [28.1, 53.6]	0.567 [0.335, 0.959]	0.439 [0.206, 0.932]	-17.5 [-34.7, -0.3]	0.038	*
High	65	16 (24.6) [14.8, 36.9]	75	29 (38.7) [27.6, 50.6]	0.637 [0.381, 1.062]	0.518 [0.249, 1.076]	-14.1 [-30.7, 2.6]	0.102	
Baseline Periostin								0.668	
Low (< 20.9 ng/ml)	62	15 (24.2) [14.2, 36.7]	67	24 (35.8) [24.5, 48.5]	0.675 [0.392, 1.165]	0.572 [0.266, 1.230]	-11.6 [-28.8, 5.6]	0.181	
High (>= 20.9 ng/ml)	74	18 (24.3) [15.1, 35.7]	71	30 (42.3) [30.6, 54.6]	0.576 [0.354, 0.935]	0.439 [0.216, 0.893]	-17.9 [-34.4, -1.5]	0.034	*

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAF

	Tezepelumab		Placebo						
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility								0.459	
Yes	114	27 (23.7) [16.2, 32.6]	126	47 (37.3) [28.9, 46.4]	0.635 [0.426, 0.947]	0.522 [0.297, 0.916]	-13.6 [-26.0, -1.3]	0.025	*
No	23	6 (26.1) [10.2, 48.4]	12	7 (58.3) [27.7, 84.8]	0.447 [0.193, 1.034]	0.252 [0.058, 1.105]	-32.2 [-71.8, 7.3]	0.079	
Maintenance OCS use at baseline								0.828	
Yes	9	4 (44.4) [13.7, 78.8]	14	9 (64.3) [35.1, 87.2]	0.691 [0.302, 1.583]	0.444 [0.080, 2.457]	-19.8 [-70.0, 30.3]	0.417	
No	128	29 (22.7) [15.7, 30.9]	124	45 (36.3) [27.8, 45.4]	0.624 [0.420, 0.928]	0.514 [0.296, 0.894]	-13.6 [-25.6, -1.7]	0.019	*
No chronic OCS use and current post-BD FEV1 reversibility								0.489	
Yes	108	25 (23.1) [15.6, 32.2]	115	41 (35.7) [26.9, 45.1]	0.649 [0.426, 0.990]	0.544 [0.302, 0.979]	-12.5 [-25.2, 0.2]	0.056	
No	29	8 (27.6) [12.7, 47.2]	23	13 (56.5) [34.5, 76.8]	0.488 [0.245, 0.973]	0.293 [0.092, 0.934]	-28.9 [-58.8, 0.9]	0.048	*

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAF

	Tezepelumab		Placebo						
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Asthma									
Race (cat. P)								0.982	
White	128	24 (18.8) [12.4, 26.6]	123	41 (33.3) [25.1, 42.4]	0.563 [0.363, 0.872]	0.462 [0.258, 0.825]	-14.6 [-26.1, -3.1]	0.010	*
Non-white	9	3 (33.3) [7.5, 70.1]	15	9 (60.0) [32.3, 83.7]	0.556 [0.202, 1.529]	0.333 [0.059, 1.877]	-26.7 [-75.1, 21.8]	0.400	
Region (cat. P)								0.648	
North America/Western EU	10	4 (40.0) [12.2, 73.8]	9	8 (88.9) [51.8, 99.7]	0.450 [0.204, 0.995]	0.083 [0.007, 0.950]	-48.9 [-96.1, -1.7]	0.057	
Rest of world	127	23 (18.1) [11.8, 25.9]	129	42 (32.6) [24.6, 41.4]	0.556 [0.356, 0.868]	0.458 [0.256, 0.820]	-14.4 [-25.7, -3.2]	0.010	*
Baseline eosinophils (cat. P)								0.435	
< 250 cells/uL	61	10 (16.4) [8.2, 28.1]	60	22 (36.7) [24.6, 50.1]	0.447 [0.232, 0.863]	0.339 [0.144, 0.798]	-20.3 [-37.3, -3.3]	0.014	*
>= 250 cells/uL	76	17 (22.4) [13.6, 33.4]	78	28 (35.9) [25.3, 47.6]	0.623 [0.373, 1.041]	0.515 [0.253, 1.047]	-13.5 [-29.0, 2.0]	0.077	
Baseline FENO (cat. P)								0.170	
< 24 ppb	75	16 (21.3) [12.7, 32.3]	72	21 (29.2) [19.0, 41.1]	0.731 [0.416, 1.286]	0.659 [0.311, 1.395]	-7.8 [-23.2, 7.5]	0.342	
>= 24 ppb	60	11 (18.3) [9.5, 30.4]	65	29 (44.6) [32.3, 57.5]	0.411 [0.226, 0.748]	0.279 [0.123, 0.631]	-26.3 [-43.4, -9.1]	0.002	*

Subgroups presented for PT: Asthma

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.126
< 22.0 ppb	65	13 (20.0) [11.1, 31.8]	62	15 (24.2) [14.2, 36.7]	0.827 [0.429, 1.593]	0.783 [0.338, 1.816]	-4.2 [-20.2, 11.8]	0.670
>= 22.0 ppb	70	14 (20.0) [11.4, 31.3]	75	35 (46.7) [35.1, 58.6]	0.429 [0.253, 0.726]	0.286 [0.136, 0.599]	-26.7 [-42.7, -10.6]	<0.001 *
Baseline all FEIA status								0.184
All negative	50	13 (26.0) [14.6, 40.3]	50	17 (34.0) [21.2, 48.8]	0.765 [0.417, 1.402]	0.682 [0.288, 1.614]	-8.0 [-27.9, 11.9]	0.513
Any positive	77	12 (15.6) [8.3, 25.6]	80	29 (36.3) [25.8, 47.8]	0.430 [0.237, 0.780]	0.325 [0.151, 0.699]	-20.7 [-35.2, -6.1]	0.004 *
Th2 status								0.419
Low	70	12 (17.1) [9.2, 28.0]	62	24 (38.7) [26.6, 51.9]	0.443 [0.242, 0.809]	0.328 [0.147, 0.732]	-21.6 [-38.1, -5.0]	0.006 *
High	65	14 (21.5) [12.3, 33.5]	75	26 (34.7) [24.0, 46.5]	0.621 [0.355, 1.086]	0.517 [0.242, 1.105]	-13.1 [-29.3, 3.0]	0.095
Baseline Periostin								0.619
Low (< 20.9 ng/ml)	62	13 (21.0) [11.7, 33.2]	67	23 (34.3) [23.2, 46.9]	0.611 [0.340, 1.097]	0.508 [0.230, 1.121]	-13.4 [-30.1, 3.4]	0.117
High (>= 20.9 ng/ml)	74	14 (18.9) [10.7, 29.7]	71	27 (38.0) [26.8, 50.3]	0.497 [0.285, 0.869]	0.380 [0.179, 0.808]	-19.1 [-34.9, -3.3]	0.016 *

Subgroups presented for PT: Asthma

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SOSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAF

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.983
Yes	114	21 (18.4) [11.8, 26.8]	126	44 (34.9) [26.6, 43.9]	0.528 [0.335, 0.831]	0.421 [0.231, 0.766]	-16.5 [-28.3, -4.7]	0.006 *
No	23	6 (26.1) [10.2, 48.4]	12	6 (50.0) [21.1, 78.9]	0.522 [0.214, 1.271]	0.353 [0.082, 1.528]	-23.9 [-63.8, 15.9]	0.261
Maintenance OCS use at baseline								0.616
Yes	9	4 (44.4) [13.7, 78.8]	14	9 (64.3) [35.1, 87.2]	0.691 [0.302, 1.583]	0.444 [0.080, 2.457]	-19.8 [-70.0, 30.3]	0.417
No	128	23 (18.0) [11.7, 25.7]	124	41 (33.1) [24.9, 42.1]	0.543 [0.348, 0.850]	0.443 [0.247, 0.797]	-15.1 [-26.5, -3.7]	0.006 *
No chronic OCS use and current post-BD FEV1 reversibility								0.987
Yes	108	19 (17.6) [10.9, 26.1]	115	38 (33.0) [24.6, 42.4]	0.532 [0.328, 0.864]	0.433 [0.230, 0.812]	-15.5 [-27.6, -3.4]	0.009 *
No	29	8 (27.6) [12.7, 47.2]	23	12 (52.2) [30.6, 73.2]	0.529 [0.261, 1.073]	0.349 [0.110, 1.108]	-24.6 [-54.6, 5.4]	0.090

Subgroups presented for PT: Asthma

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SOMI0: Incidence of non-severe TEAEs during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-severe TEAEs during study period	137	84 (61.3) [52.6, 69.5]	138	88 (63.8) [55.2, 71.8]	0.962 [0.801, 1.155]	0.901 [0.552, 1.468]	-2.5 [-14.6, 9.7]	0.710

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AN_SOSIK: Incidence of non-severe TEAEs during study period by key subgroups
DSAF

Non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.869
Male	50	32 (64.0) [49.2, 77.1]	44	30 (68.2) [52.4, 81.4]	0.939 [0.703, 1.254]	0.830 [0.352, 1.956]	-4.2 [-25.5, 17.1]	0.828
Female	87	52 (59.8) [48.7, 70.1]	94	58 (61.7) [51.1, 71.5]	0.969 [0.766, 1.225]	0.922 [0.508, 1.675]	-1.9 [-17.3, 13.4]	0.879
Age								0.881
< 65 years	114	69 (60.5) [50.9, 69.6]	118	74 (62.7) [53.3, 71.4]	0.965 [0.788, 1.183]	0.912 [0.537, 1.548]	-2.2 [-15.6, 11.2]	0.788
>= 65 years	23	15 (65.2) [42.7, 83.6]	20	14 (70.0) [45.7, 88.1]	0.932 [0.616, 1.409]	0.804 [0.222, 2.904]	-4.8 [-37.4, 27.9]	1.000
Exacerbations in the year before study								0.732
<= 2	105	59 (56.2) [46.2, 65.9]	110	64 (58.2) [48.4, 67.5]	0.966 [0.766, 1.217]	0.922 [0.537, 1.583]	-2.0 [-16.2, 12.2]	0.784
> 2	32	25 (78.1) [60.0, 90.7]	28	24 (85.7) [67.3, 96.0]	0.911 [0.719, 1.156]	0.595 [0.154, 2.296]	-7.6 [-30.3, 15.1]	0.519

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SOSIK: Incidence of non-severe TEAEs during study period by key subgroups
DSAF

Non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	128	77 (60.2) [51.1, 68.7]	123	77 (62.6) [53.4, 71.2]				
Black or African American	3	3 (100.0) [29.2, 100.0]	6	5 (83.3) [35.9, 99.6]				
Asian	5	4 (80.0) [28.4, 99.5]	6	3 (50.0) [11.8, 88.2]				
Other	1	0 (0.0) [0.0, 97.5]	3	3 (100.0) [29.2, 100.0]				
Region								0.689
Europe	78	47 (60.3) [48.5, 71.2]	80	51 (63.8) [52.2, 74.2]	0.945 [0.740, 1.207]	0.862 [0.453, 1.640]	-3.5 [-19.9, 12.9]	0.743
America	10	9 (90.0) [55.5, 99.7]	9	9 (100.0) [66.4, 100.0]	0.900 [0.732, 1.107]	0.333 + [0.012, 9.262]	-10.0 [-39.1, 19.1]	1.000
Asia/Pacific	5	4 (80.0) [28.4, 99.5]	6	3 (50.0) [11.8, 88.2]	1.600 [0.643, 3.984]	4.000 [0.265, 60.325]	30.0 [-41.5, 100.0]	0.545
Rest of the world	44	24 (54.5) [38.8, 69.6]	43	25 (58.1) [42.1, 73.0]	0.938 [0.648, 1.359]	0.864 [0.370, 2.018]	-3.6 [-26.7, 19.5]	0.830
BMI		N<10 any level						NE
< 18.5 kg/m**2	0		1	1 (100.0) [2.5, 100.0]				
18.5 - < 25.0 kg/m**2	39	23 (59.0) [42.1, 74.4]	43	26 (60.5) [44.4, 75.0]				
25.0 - < 30.0 kg/m**2	45	26 (57.8) [42.2, 72.3]	47	28 (59.6) [44.3, 73.6]				
>= 30.0 kg/m**2	53	35 (66.0) [51.7, 78.5]	47	33 (70.2) [55.1, 82.7]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SOSIK: Incidence of non-severe TEAEs during study period by key subgroups
DSAF

Non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.928
< 150 cells/uL	27	17 (63.0) [42.4, 80.6]	33	22 (66.7) [48.2, 82.0]	0.944 [0.648, 1.376]	0.850 [0.293, 2.465]	-3.7 [-31.4, 24.0]	0.792
>= 150 cells/uL	109	66 (60.6) [50.7, 69.8]	105	66 (62.9) [52.9, 72.1]	0.963 [0.780, 1.190]	0.907 [0.522, 1.575]	-2.3 [-16.3, 11.7]	0.779
Baseline eosinophils - High								0.584
< 300 cells/uL	69	41 (59.4) [46.9, 71.1]	72	47 (65.3) [53.1, 76.1]	0.910 [0.703, 1.178]	0.779 [0.393, 1.542]	-5.9 [-23.3, 11.5]	0.492
>= 300 cells/uL	67	42 (62.7) [50.0, 74.2]	66	41 (62.1) [49.3, 73.8]	1.009 [0.775, 1.314]	1.024 [0.508, 2.067]	0.6 [-17.4, 18.5]	1.000
Baseline FENO								0.246
< 25 ppb	78	50 (64.1) [52.4, 74.7]	74	45 (60.8) [48.8, 72.0]	1.054 [0.823, 1.350]	1.151 [0.596, 2.220]	3.3 [-13.4, 20.0]	0.738
>= 25 ppb	57	32 (56.1) [42.4, 69.3]	63	42 (66.7) [53.7, 78.0]	0.842 [0.631, 1.124]	0.640 [0.305, 1.342]	-10.5 [-29.6, 8.5]	0.263

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SOSIK: Incidence of non-severe TEAEs during study period by key subgroups
DSAF

Non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.728
All negative	57	39 (68.4) [54.8, 80.1]	66	44 (66.7) [54.0, 77.8]	1.026 [0.803, 1.312]	1.083 [0.508, 2.311]	1.8 [-16.5, 20.0]	0.850
Any positive	71	40 (56.3) [44.0, 68.1]	63	37 (58.7) [45.6, 71.0]	0.959 [0.717, 1.283]	0.907 [0.456, 1.802]	-2.4 [-20.6, 15.9]	0.861
Total serum IgE								0.966
Low	35	24 (68.6) [50.7, 83.1]	32	22 (68.8) [50.0, 83.9]	0.997 [0.721, 1.379]	0.992 [0.353, 2.788]	-0.2 [-25.4, 25.0]	1.000
Normal	95	55 (57.9) [47.3, 68.0]	98	60 (61.2) [50.8, 70.9]	0.946 [0.749, 1.194]	0.871 [0.490, 1.548]	-3.3 [-18.2, 11.5]	0.662
High	7	5 (71.4) [29.0, 96.3]	8	6 (75.0) [34.9, 96.8]	0.952 [0.514, 1.764]	0.833 [0.084, 8.240]	-3.6 [-61.9, 54.8]	1.000
OCS at baseline								0.547
Yes	9	7 (77.8) [40.0, 97.2]	13	9 (69.2) [38.6, 90.9]	1.123 [0.679, 1.858]	1.556 [0.218, 11.086]	8.5 [-37.8, 54.9]	1.000
No	128	77 (60.2) [51.1, 68.7]	125	79 (63.2) [54.1, 71.6]	0.952 [0.784, 1.156]	0.879 [0.529, 1.460]	-3.0 [-15.8, 9.7]	0.698

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SOSIK: Incidence of non-severe TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
Non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)								0.714
Medium/Low	70	40 (57.1) [44.7, 68.9]	73	45 (61.6) [49.5, 72.8]	0.927 [0.706, 1.217]	0.830 [0.425, 1.619]	-4.5 [-22.0, 13.0]	0.613
High	67	44 (65.7) [53.1, 76.8]	65	43 (66.2) [53.4, 77.4]	0.993 [0.777, 1.269]	0.979 [0.476, 2.011]	-0.5 [-18.2, 17.2]	1.000
LAMA use at baseline								0.693
Yes	11	8 (72.7) [39.0, 94.0]	6	4 (66.7) [22.3, 95.7]	1.091 [0.557, 2.135]	1.333 [0.155, 11.498]	6.1 [-52.8, 64.9]	1.000
No	126	76 (60.3) [51.2, 68.9]	132	84 (63.6) [54.8, 71.8]	0.948 [0.783, 1.148]	0.869 [0.525, 1.437]	-3.3 [-15.9, 9.3]	0.609
Tiotropium use at baseline								0.643
Yes	9	7 (77.8) [40.0, 97.2]	3	2 (66.7) [9.4, 99.2]	1.167 [0.487, 2.793]	1.750 [0.099, 30.837]	11.1 [-71.0, 93.2]	1.000
No	128	77 (60.2) [51.1, 68.7]	135	86 (63.7) [55.0, 71.8]	0.944 [0.781, 1.142]	0.860 [0.523, 1.416]	-3.5 [-16.0, 8.9]	0.612

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SOSIK: Incidence of non-severe TEAEs during study period by key subgroups
DSAF

Non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline								0.841
Yes	29	22 (75.9) [56.5, 89.7]	37	28 (75.7) [58.8, 88.2]	1.002 [0.762, 1.320]	1.010 [0.325, 3.142]	0.2 [-23.7, 24.1]	1.000
No	108	62 (57.4) [47.5, 66.9]	101	60 (59.4) [49.2, 69.1]	0.966 [0.769, 1.215]	0.921 [0.531, 1.597]	-2.0 [-16.3, 12.3]	0.781

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SOSIP: Incidence of non-severe TEAEs during study period by study specific subgroups
DSAF

Non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.701
White	128	77 (60.2) [51.1, 68.7]	123	77 (62.6) [53.4, 71.2]	0.961 [0.790, 1.169]	0.902 [0.542, 1.500]	-2.4 [-15.3, 10.4]	0.700
Non-white	9	7 (77.8) [40.0, 97.2]	15	11 (73.3) [44.9, 92.2]	1.061 [0.667, 1.686]	1.273 [0.182, 8.892]	4.4 [-39.6, 48.5]	1.000
Region (cat. P)								0.638
North America/Western EU	10	9 (90.0) [55.5, 99.7]	9	9 (100.0) [66.4, 100.0]	0.900 [0.732, 1.107]	0.333 + [0.012, 9.262]	-10.0 [-39.1, 19.1]	1.000
Rest of world	127	75 (59.1) [50.0, 67.7]	129	79 (61.2) [52.3, 69.7]	0.964 [0.790, 1.177]	0.913 [0.553, 1.506]	-2.2 [-15.0, 10.6]	0.799
Baseline eosinophils (cat. P)								0.302
< 250 cells/uL	61	36 (59.0) [45.7, 71.4]	60	41 (68.3) [55.0, 79.7]	0.864 [0.659, 1.132]	0.667 [0.317, 1.407]	-9.3 [-28.0, 9.4]	0.346
>= 250 cells/uL	76	48 (63.2) [51.3, 73.9]	78	47 (60.3) [48.5, 71.2]	1.048 [0.817, 1.344]	1.131 [0.590, 2.167]	2.9 [-13.7, 19.5]	0.742
Baseline FENO (cat. P)								0.296
< 24 ppb	75	48 (64.0) [52.1, 74.8]	72	44 (61.1) [48.9, 72.4]	1.047 [0.815, 1.345]	1.131 [0.580, 2.207]	2.9 [-14.1, 19.9]	0.736
>= 24 ppb	60	34 (56.7) [43.2, 69.4]	65	43 (66.2) [53.4, 77.4]	0.857 [0.646, 1.135]	0.669 [0.324, 1.381]	-9.5 [-28.1, 9.1]	0.358

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SOSIP: Incidence of non-severe TEAEs during study period by study specific subgroups
DSAF

Non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.092
< 22.0 ppb	65	41 (63.1) [50.2, 74.7]	62	34 (54.8) [41.7, 67.5]	1.150 [0.858, 1.541]	1.407 [0.692, 2.861]	8.2 [-10.4, 26.9]	0.371
>= 22.0 ppb	70	41 (58.6) [46.2, 70.2]	75	53 (70.7) [59.0, 80.6]	0.829 [0.649, 1.059]	0.587 [0.295, 1.168]	-12.1 [-28.9, 4.8]	0.164
Baseline all FEIA status								0.087
All negative	50	36 (72.0) [57.5, 83.8]	50	30 (60.0) [45.2, 73.6]	1.200 [0.903, 1.595]	1.714 [0.742, 3.961]	12.0 [-8.4, 32.4]	0.291
Any positive	77	42 (54.5) [42.8, 65.9]	80	51 (63.8) [52.2, 74.2]	0.856 [0.658, 1.112]	0.682 [0.360, 1.293]	-9.2 [-25.8, 7.4]	0.259
Th2 status								0.643
Low	70	45 (64.3) [51.9, 75.4]	62	40 (64.5) [51.3, 76.3]	0.996 [0.773, 1.285]	0.990 [0.485, 2.022]	-0.2 [-18.1, 17.7]	1.000
High	65	38 (58.5) [45.6, 70.6]	75	48 (64.0) [52.1, 74.8]	0.913 [0.700, 1.192]	0.792 [0.400, 1.566]	-5.5 [-23.1, 12.1]	0.602
Baseline Periostin								0.742
Low (< 20.9 ng/ml)	62	37 (59.7) [46.4, 71.9]	67	40 (59.7) [47.0, 71.5]	1.000 [0.753, 1.328]	0.999 [0.494, 2.020]	-0.0 [-18.5, 18.5]	1.000
High (>= 20.9 ng/ml)	74	47 (63.5) [51.5, 74.4]	71	48 (67.6) [55.5, 78.2]	0.939 [0.742, 1.190]	0.834 [0.420, 1.657]	-4.1 [-20.9, 12.7]	0.727

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SOSIP: Incidence of non-severe TEAEs during study period by study specific subgroups
DSAF

	Tezepelumab		Placebo						
Non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility								0.004	i
Yes	114	71 (62.3) [52.7, 71.2]	126	76 (60.3) [51.2, 68.9]	1.033 [0.844, 1.263]	1.086 [0.646, 1.828]	2.0 [-11.2, 15.1]	0.792	
No	23	13 (56.5) [34.5, 76.8]	12	12 (100.0) [73.5, 100.0]	0.565 [0.395, 0.809]	0.051 + [0.003, 0.972]	-43.5 [-70.1, -16.9]	0.007	*
Maintenance OCS use at baseline								0.624	
Yes	9	7 (77.8) [40.0, 97.2]	14	10 (71.4) [41.9, 91.6]	1.089 [0.673, 1.762]	1.400 [0.199, 9.869]	6.3 [-38.8, 51.5]	1.000	
No	128	77 (60.2) [51.1, 68.7]	124	78 (62.9) [53.8, 71.4]	0.956 [0.787, 1.163]	0.890 [0.536, 1.480]	-2.7 [-15.6, 10.1]	0.699	
No chronic OCS use and current post-BD FEV1 reversibility								0.137	
Yes	108	66 (61.1) [51.3, 70.3]	115	69 (60.0) [50.4, 69.0]	1.019 [0.824, 1.259]	1.048 [0.612, 1.793]	1.1 [-12.6, 14.8]	0.892	
No	29	18 (62.1) [42.3, 79.3]	23	19 (82.6) [61.2, 95.0]	0.751 [0.534, 1.056]	0.344 [0.093, 1.281]	-20.5 [-47.9, 6.8]	0.132	

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SOMI0: Incidence of severe TEAEs during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Severe TEAEs during study period	137	28 (20.4) [14.0, 28.2]	138	28 (20.3) [13.9, 28.0]	1.007 [0.631, 1.608]	1.009 [0.561, 1.815]	0.1 [-10.1, 10.4]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AC_SOMS0: Severe TEAEs during study period by SOC and PT
DSAF

	Tezepelumab		Placebo					
Severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Infections and infestations	137	6 (4.4) [1.6, 9.3]	138	11 (8.0) [4.0, 13.8]	0.549 [0.209, 1.444]	0.529 [0.190, 1.473]	-3.6 [-10.0, 2.8]	0.317
SOC: Respiratory, thoracic and mediastinal disorders	137	14 (10.2) [5.7, 16.6]	138	20 (14.5) [9.1, 21.5]	0.705 [0.372, 1.338]	0.672 [0.324, 1.391]	-4.3 [-12.8, 4.2]	0.360
Asthma	137	13 (9.5) [5.1, 15.7]	138	20 (14.5) [9.1, 21.5]	0.655 [0.339, 1.263]	0.619 [0.294, 1.300]	-5.0 [-13.4, 3.4]	0.265

Note: DSAF = Dossier Safety Set. Only events are displayed with an incidence of at least 5 percent in a treatment group.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AC_SOSIK: Incidence of severe TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
Severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.701
Male	50	8 (16.0) [7.2, 29.1]	44	8 (18.2) [8.2, 32.7]	0.880 [0.361, 2.148]	0.857 [0.292, 2.515]	-2.2 [-19.6, 15.2]	0.791
Female	87	20 (23.0) [14.6, 33.2]	94	20 (21.3) [13.5, 30.9]	1.080 [0.625, 1.867]	1.104 [0.547, 2.230]	1.7 [-11.5, 14.9]	0.858
Age								0.555
< 65 years	114	23 (20.2) [13.2, 28.7]	118	25 (21.2) [14.2, 29.7]	0.952 [0.575, 1.577]	0.940 [0.498, 1.776]	-1.0 [-12.3, 10.3]	0.873
>= 65 years	23	5 (21.7) [7.5, 43.7]	20	3 (15.0) [3.2, 37.9]	1.449 [0.395, 5.317]	1.574 [0.325, 7.622]	6.7 [-20.9, 34.4]	0.704
Exacerbations in the year before study								0.301
<= 2	105	18 (17.1) [10.5, 25.7]	110	16 (14.5) [8.5, 22.5]	1.179 [0.635, 2.187]	1.216 [0.584, 2.532]	2.6 [-8.1, 13.3]	0.709
> 2	32	10 (31.3) [16.1, 50.0]	28	12 (42.9) [24.5, 62.8]	0.729 [0.374, 1.423]	0.606 [0.210, 1.745]	-11.6 [-39.3, 16.1]	0.425

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SOSIK: Incidence of severe TEAEs during study period by key subgroups
DSAF

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	128	25 (19.5) [13.1, 27.5]	123	24 (19.5) [12.9, 27.6]				
Black or African American	3	1 (33.3) [0.8, 90.6]	6	2 (33.3) [4.3, 77.7]				
Asian	5	2 (40.0) [5.3, 85.3]	6	0 (0.0) [0.0, 45.9]				
Other	1	0 (0.0) [0.0, 97.5]	3	2 (66.7) [9.4, 99.2]				
Region								0.609
Europe	78	15 (19.2) [11.2, 29.7]	80	17 (21.3) [12.9, 31.8]	0.905 [0.487, 1.683]	0.882 [0.406, 1.919]	-2.0 [-15.8, 11.8]	0.844
America	10	3 (30.0) [6.7, 65.2]	9	2 (22.2) [2.8, 60.0]	1.350 [0.288, 6.335]	1.500 [0.189, 11.927]	7.8 [-42.1, 57.6]	1.000
Asia/Pacific	5	2 (40.0) [5.3, 85.3]	6	0 (0.0) [0.0, 45.9]	5.833 + [0.343, 99.226]	9.286 + [0.342, 252.450]	40.0 [-21.3, 100.0]	0.182
Rest of the world	44	8 (18.2) [8.2, 32.7]	43	9 (20.9) [10.0, 36.0]	0.869 [0.370, 2.042]	0.840 [0.290, 2.427]	-2.7 [-21.7, 16.2]	0.792
BMI		N<10 any level						NE
< 18.5 kg/m**2	0		1	0 (0.0) [0.0, 97.5]				
18.5 - < 25.0 kg/m**2	39	7 (17.9) [7.5, 33.5]	43	9 (20.9) [10.0, 36.0]				
25.0 - < 30.0 kg/m**2	45	7 (15.6) [6.5, 29.5]	47	9 (19.1) [9.1, 33.3]				
>= 30.0 kg/m**2	53	14 (26.4) [15.3, 40.3]	47	10 (21.3) [10.7, 35.7]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SOSIK: Incidence of severe TEAEs during study period by key subgroups
DSAF

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.812
< 150 cells/uL	27	8 (29.6) [13.8, 50.2]	33	9 (27.3) [13.3, 45.5]	1.086 [0.486, 2.430]	1.123 [0.364, 3.464]	2.4 [-24.0, 28.7]	1.000
>= 150 cells/uL	109	19 (17.4) [10.8, 25.9]	105	19 (18.1) [11.3, 26.8]	0.963 [0.541, 1.715]	0.956 [0.474, 1.927]	-0.7 [-11.8, 10.5]	1.000
Baseline eosinophils - High								0.793
< 300 cells/uL	69	13 (18.8) [10.4, 30.1]	72	13 (18.1) [10.0, 28.9]	1.043 [0.521, 2.089]	1.054 [0.450, 2.468]	0.8 [-13.4, 15.0]	1.000
>= 300 cells/uL	67	14 (20.9) [11.9, 32.6]	66	15 (22.7) [13.3, 34.7]	0.919 [0.483, 1.751]	0.898 [0.394, 2.046]	-1.8 [-17.4, 13.7]	0.836
Baseline FENO								0.465
< 25 ppb	78	17 (21.8) [13.2, 32.6]	74	13 (17.6) [9.7, 28.2]	1.241 [0.649, 2.372]	1.308 [0.585, 2.924]	4.2 [-9.7, 18.2]	0.547
>= 25 ppb	57	11 (19.3) [10.0, 31.9]	63	14 (22.2) [12.7, 34.5]	0.868 [0.430, 1.755]	0.837 [0.345, 2.031]	-2.9 [-19.1, 13.3]	0.823

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SOSIK: Incidence of severe TEAEs during study period by key subgroups
DSAF

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.338
All negative	57	13 (22.8) [12.7, 35.8]	66	16 (24.2) [14.5, 36.4]	0.941 [0.496, 1.785]	0.923 [0.400, 2.131]	-1.4 [-18.1, 15.2]	1.000
Any positive	71	14 (19.7) [11.2, 30.9]	63	8 (12.7) [5.6, 23.5]	1.553 [0.698, 3.455]	1.689 [0.657, 4.342]	7.0 [-6.9, 20.9]	0.352
Total serum IgE								0.651
Low	35	9 (25.7) [12.5, 43.3]	32	10 (31.3) [16.1, 50.0]	0.823 [0.384, 1.764]	0.762 [0.263, 2.208]	-5.5 [-30.2, 19.1]	0.787
Normal	95	18 (18.9) [11.6, 28.3]	98	18 (18.4) [11.3, 27.5]	1.032 [0.572, 1.860]	1.039 [0.504, 2.144]	0.6 [-11.5, 12.6]	1.000
High	7	1 (14.3) [0.4, 57.9]	8	0 (0.0) [0.0, 36.9]	3.375 + [0.159, 71.667]	3.923 + [0.136, 112.895]	14.3 [-25.0, 53.6]	0.467
OCS at baseline								0.289
Yes	9	4 (44.4) [13.7, 78.8]	13	3 (23.1) [5.0, 53.8]	1.926 [0.562, 6.604]	2.667 [0.423, 16.826]	21.4 [-27.8, 70.5]	0.376
No	128	24 (18.8) [12.4, 26.6]	125	25 (20.0) [13.4, 28.1]	0.938 [0.567, 1.550]	0.923 [0.495, 1.722]	-1.3 [-11.8, 9.3]	0.874

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SOSIK: Incidence of severe TEAEs during study period by key subgroups
DSAF

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)								0.644
Medium/Low	70	10 (14.3) [7.1, 24.7]	73	12 (16.4) [8.8, 27.0]	0.869 [0.401, 1.882]	0.847 [0.340, 2.108]	-2.2 [-15.4, 11.1]	0.818
High	67	18 (26.9) [16.8, 39.1]	65	16 (24.6) [14.8, 36.9]	1.091 [0.611, 1.950]	1.125 [0.515, 2.457]	2.3 [-14.2, 18.7]	0.843
LAMA use at baseline								0.407
Yes	11	4 (36.4) [10.9, 69.2]	6	1 (16.7) [0.4, 64.1]	2.182 [0.310, 15.374]	2.857 [0.241, 33.902]	19.7 [-34.4, 73.8]	0.600
No	126	24 (19.0) [12.6, 27.0]	132	27 (20.5) [13.9, 28.3]	0.931 [0.569, 1.524]	0.915 [0.495, 1.690]	-1.4 [-11.9, 9.1]	0.876
Tiotropium use at baseline								0.706
Yes	9	4 (44.4) [13.7, 78.8]	3	1 (33.3) [0.8, 90.6]	1.333 [0.230, 7.743]	1.600 [0.104, 24.703]	11.1 [-73.6, 95.8]	1.000
No	128	24 (18.8) [12.4, 26.6]	135	27 (20.0) [13.6, 27.7]	0.938 [0.572, 1.536]	0.923 [0.500, 1.703]	-1.3 [-11.6, 9.1]	0.876

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SOSIK: Incidence of severe TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
Severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline								0.968
Yes	29	11 (37.9) [20.7, 57.7]	37	13 (35.1) [20.2, 52.5]	1.080 [0.570, 2.046]	1.128 [0.411, 3.095]	2.8 [-23.7, 29.3]	1.000
No	108	17 (15.7) [9.4, 24.0]	101	15 (14.9) [8.6, 23.3]	1.060 [0.559, 2.008]	1.071 [0.504, 2.277]	0.9 [-9.8, 11.6]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SOSIP: Incidence of severe TEAEs during study period by study specific subgroups
DSAF

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.746
White	128	25 (19.5) [13.1, 27.5]	123	24 (19.5) [12.9, 27.6]	1.001 [0.606, 1.654]	1.001 [0.536, 1.869]	0.0 [-10.6, 10.6]	1.000
Non-white	9	3 (33.3) [7.5, 70.1]	15	4 (26.7) [7.8, 55.1]	1.250 [0.359, 4.355]	1.375 [0.228, 8.296]	6.7 [-40.3, 53.6]	1.000
Region (cat. P)								0.696
North America/Western EU	10	3 (30.0) [6.7, 65.2]	9	2 (22.2) [2.8, 60.0]	1.350 [0.288, 6.335]	1.500 [0.189, 11.927]	7.8 [-42.1, 57.6]	1.000
Rest of world	127	25 (19.7) [13.2, 27.7]	129	26 (20.2) [13.6, 28.1]	0.977 [0.598, 1.596]	0.971 [0.526, 1.793]	-0.5 [-11.0, 10.1]	1.000
Baseline eosinophils (cat. P)								0.829
< 250 cells/uL	61	12 (19.7) [10.6, 31.8]	60	11 (18.3) [9.5, 30.4]	1.073 [0.514, 2.241]	1.091 [0.440, 2.707]	1.3 [-14.3, 17.0]	1.000
>= 250 cells/uL	76	16 (21.1) [12.5, 31.9]	78	17 (21.8) [13.2, 32.6]	0.966 [0.527, 1.769]	0.957 [0.443, 2.067]	-0.7 [-15.0, 13.5]	1.000
Baseline FENO (cat. P)								0.163
< 24 ppb	75	17 (22.7) [13.8, 33.8]	72	11 (15.3) [7.9, 25.7]	1.484 [0.747, 2.946]	1.625 [0.702, 3.762]	7.4 [-6.6, 21.4]	0.297
>= 24 ppb	60	11 (18.3) [9.5, 30.4]	65	16 (24.6) [14.8, 36.9]	0.745 [0.376, 1.474]	0.688 [0.290, 1.631]	-6.3 [-22.2, 9.7]	0.515

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SOSIP: Incidence of severe TEAEs during study period by study specific subgroups
DSAF

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.151
< 22.0 ppb	65	15 (23.1) [13.5, 35.2]	62	9 (14.5) [6.9, 25.8]	1.590 [0.751, 3.364]	1.767 [0.710, 4.399]	8.6 [-6.5, 23.6]	0.261
>= 22.0 ppb	70	13 (18.6) [10.3, 29.7]	75	18 (24.0) [14.9, 35.3]	0.774 [0.410, 1.460]	0.722 [0.324, 1.611]	-5.4 [-20.1, 9.2]	0.544
Baseline all FEIA status								0.493
All negative	50	11 (22.0) [11.5, 36.0]	50	12 (24.0) [13.1, 38.2]	0.917 [0.447, 1.880]	0.893 [0.352, 2.269]	-2.0 [-20.5, 16.5]	1.000
Any positive	77	15 (19.5) [11.3, 30.1]	80	12 (15.0) [8.0, 24.7]	1.299 [0.650, 2.593]	1.371 [0.596, 3.155]	4.5 [-8.6, 17.6]	0.528
Th2 status								0.148
Low	70	15 (21.4) [12.5, 32.9]	62	18 (29.0) [18.2, 41.9]	0.738 [0.408, 1.337]	0.667 [0.302, 1.471]	-7.6 [-24.0, 8.8]	0.323
High	65	13 (20.0) [11.1, 31.8]	75	10 (13.3) [6.6, 23.2]	1.500 [0.705, 3.190]	1.625 [0.660, 4.003]	6.7 [-7.2, 20.5]	0.362
Baseline Periostin								0.946
Low (< 20.9 ng/ml)	62	10 (16.1) [8.0, 27.7]	67	11 (16.4) [8.5, 27.5]	0.982 [0.449, 2.151]	0.979 [0.384, 2.496]	-0.3 [-14.6, 14.0]	1.000
High (>= 20.9 ng/ml)	74	18 (24.3) [15.1, 35.7]	71	17 (23.9) [14.6, 35.5]	1.016 [0.570, 1.810]	1.021 [0.477, 2.185]	0.4 [-14.9, 15.7]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SOSIP: Incidence of severe TEAEs during study period by study specific subgroups
DSAF

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.348
Yes	114	22 (19.3) [12.5, 27.7]	126	23 (18.3) [11.9, 26.1]	1.057 [0.624, 1.790]	1.071 [0.560, 2.048]	1.0 [-9.7, 11.8]	0.870
No	23	6 (26.1) [10.2, 48.4]	12	5 (41.7) [15.2, 72.3]	0.626 [0.240, 1.635]	0.494 [0.113, 2.165]	-15.6 [-55.1, 23.9]	0.451
Maintenance OCS use at baseline								0.445
Yes	9	4 (44.4) [13.7, 78.8]	14	4 (28.6) [8.4, 58.1]	1.556 [0.516, 4.693]	2.000 [0.346, 11.544]	15.9 [-33.4, 65.2]	0.657
No	128	24 (18.8) [12.4, 26.6]	124	24 (19.4) [12.8, 27.4]	0.969 [0.582, 1.612]	0.962 [0.513, 1.803]	-0.6 [-11.1, 9.9]	1.000
No chronic OCS use and current post-BD FEV1 reversibility								0.870
Yes	108	20 (18.5) [11.7, 27.1]	115	22 (19.1) [12.4, 27.5]	0.968 [0.561, 1.670]	0.961 [0.491, 1.881]	-0.6 [-11.8, 10.5]	1.000
No	29	8 (27.6) [12.7, 47.2]	23	6 (26.1) [10.2, 48.4]	1.057 [0.427, 2.617]	1.079 [0.313, 3.717]	1.5 [-26.6, 29.6]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SOMI0: Incidence of serious TEAEs during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Serious TEAEs during study period	137	13 (9.5) [5.1, 15.7]	138	18 (13.0) [7.9, 19.8]	0.727 [0.371, 1.426]	0.699 [0.328, 1.489]	-3.6 [-11.7, 4.6]	0.446

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AS_SOMS0: Serious TEAEs during study period by SOC and PT
DSAF

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Respiratory, thoracic and mediastinal disorders	137	4 (2.9) [0.8, 7.3]	138	10 (7.2) [3.5, 12.9]	0.403 [0.129, 1.254]	0.385 [0.118, 1.259]	-4.3 [-10.2, 1.6]	0.168
Asthma	137	4 (2.9) [0.8, 7.3]	138	10 (7.2) [3.5, 12.9]	0.403 [0.129, 1.254]	0.385 [0.118, 1.259]	-4.3 [-10.2, 1.6]	0.168

Note: DSAF = Dossier Safety Set. Only events are displayed with an incidence of at least 5 percent in a treatment group.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AS_SOSIK: Incidence of serious TEAEs during study period by key subgroups
DSAF

Serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.438
Male	50	4 (8.0) [2.2, 19.2]	44	7 (15.9) [6.6, 30.1]	0.503 [0.158, 1.604]	0.460 [0.125, 1.691]	-7.9 [-23.2, 7.4]	0.337
Female	87	9 (10.3) [4.8, 18.7]	94	11 (11.7) [6.0, 20.0]	0.884 [0.385, 2.030]	0.871 [0.342, 2.215]	-1.4 [-11.6, 8.9]	0.816
Age								0.484
< 65 years	114	11 (9.6) [4.9, 16.6]	118	14 (11.9) [6.6, 19.1]	0.813 [0.385, 1.716]	0.793 [0.344, 1.829]	-2.2 [-11.0, 6.6]	0.674
>= 65 years	23	2 (8.7) [1.1, 28.0]	20	4 (20.0) [5.7, 43.7]	0.435 [0.089, 2.128]	0.381 [0.062, 2.346]	-11.3 [-37.0, 14.3]	0.393
Exacerbations in the year before study								0.480
<= 2	105	6 (5.7) [2.1, 12.0]	110	7 (6.4) [2.6, 12.7]	0.898 [0.312, 2.584]	0.892 [0.290, 2.746]	-0.6 [-7.9, 6.6]	1.000
> 2	32	7 (21.9) [9.3, 40.0]	28	11 (39.3) [21.5, 59.4]	0.557 [0.250, 1.240]	0.433 [0.140, 1.340]	-17.4 [-43.8, 9.0]	0.167

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SOSIK: Incidence of serious TEAEs during study period by key subgroups
DSAF

Serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Race		N<10 any level						NE	
White	128	12 (9.4) [4.9, 15.8]	123	14 (11.4) [6.4, 18.4]					
Black or African American	3	0 (0.0) [0.0, 70.8]	6	2 (33.3) [4.3, 77.7]					
Asian	5	1 (20.0) [0.5, 71.6]	6	0 (0.0) [0.0, 45.9]					
Other	1	0 (0.0) [0.0, 97.5]	3	2 (66.7) [9.4, 99.2]					
Region								0.234	
Europe	78	10 (12.8) [6.3, 22.3]	80	9 (11.3) [5.3, 20.3]	1.140 [0.490, 2.652]	1.160 [0.444, 3.030]	1.6 [-9.8, 13.0]	0.810	
America	10	2 (20.0) [2.5, 55.6]	9	3 (33.3) [7.5, 70.1]	0.600 [0.128, 2.816]	0.500 [0.063, 3.998]	-13.3 [-63.4, 36.8]	0.628	
Asia/Pacific	5	1 (20.0) [0.5, 71.6]	6	0 (0.0) [0.0, 45.9]	3.500 + [0.173, 70.944]	4.333 + [0.142, 132.315]	20.0 [-33.4, 73.4]	0.455	
Rest of the world	44	0 (0.0) [0.0, 8.0]	43	6 (14.0) [5.3, 27.9]	0.075 + [0.004, 1.295]	0.065 + [0.004, 1.189]	-14.0 [-26.6, -1.3]	0.012	*
BMI		N<10 any level						NE	
< 18.5 kg/m**2	0		1	0 (0.0) [0.0, 97.5]					
18.5 - < 25.0 kg/m**2	39	4 (10.3) [2.9, 24.2]	43	3 (7.0) [1.5, 19.1]					
25.0 - < 30.0 kg/m**2	45	3 (6.7) [1.4, 18.3]	47	7 (14.9) [6.2, 28.3]					
>= 30.0 kg/m**2	53	6 (11.3) [4.3, 23.0]	47	8 (17.0) [7.6, 30.8]					

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SOSIK: Incidence of serious TEAEs during study period by key subgroups
DSAF

Serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.749
< 150 cells/uL	27	5 (18.5) [6.3, 38.1]	33	7 (21.2) [9.0, 38.9]	0.873 [0.312, 2.442]	0.844 [0.235, 3.037]	-2.7 [-26.3, 20.9]	1.000
>= 150 cells/uL	109	8 (7.3) [3.2, 14.0]	105	11 (10.5) [5.3, 18.0]	0.701 [0.293, 1.673]	0.677 [0.261, 1.756]	-3.1 [-11.7, 5.4]	0.477
Baseline eosinophils - High								0.431
< 300 cells/uL	69	6 (8.7) [3.3, 18.0]	72	11 (15.3) [7.9, 25.7]	0.569 [0.223, 1.455]	0.528 [0.184, 1.517]	-6.6 [-18.6, 5.5]	0.303
>= 300 cells/uL	67	7 (10.4) [4.3, 20.3]	66	7 (10.6) [4.4, 20.6]	0.985 [0.366, 2.654]	0.983 [0.325, 2.977]	-0.2 [-12.1, 11.8]	1.000
Baseline FENO								0.276
< 25 ppb	78	8 (10.3) [4.5, 19.2]	74	7 (9.5) [3.9, 18.5]	1.084 [0.414, 2.841]	1.094 [0.376, 3.184]	0.8 [-10.0, 11.6]	1.000
>= 25 ppb	57	5 (8.8) [2.9, 19.3]	63	11 (17.5) [9.1, 29.1]	0.502 [0.186, 1.358]	0.455 [0.148, 1.400]	-8.7 [-22.3, 4.9]	0.188

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SOSIK: Incidence of serious TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.487
All negative	57	6 (10.5) [4.0, 21.5]	66	11 (16.7) [8.6, 27.9]	0.632 [0.249, 1.600]	0.588 [0.203, 1.707]	-6.1 [-19.8, 7.5]	0.434
Any positive	71	7 (9.9) [4.1, 19.3]	63	6 (9.5) [3.6, 19.6]	1.035 [0.367, 2.918]	1.039 [0.330, 3.273]	0.3 [-11.2, 11.9]	1.000
Total serum IgE								0.663
Low	35	4 (11.4) [3.2, 26.7]	32	7 (21.9) [9.3, 40.0]	0.522 [0.169, 1.619]	0.461 [0.121, 1.754]	-10.4 [-31.2, 10.3]	0.329
Normal	95	9 (9.5) [4.4, 17.2]	98	10 (10.2) [5.0, 18.0]	0.928 [0.395, 2.183]	0.921 [0.357, 2.377]	-0.7 [-10.2, 8.7]	1.000
High	7	0 (0.0) [0.0, 41.0]	8	1 (12.5) [0.3, 52.7]	0.375 + [0.018, 7.963]	0.333 + [0.012, 9.566]	-12.5 [-48.8, 23.8]	1.000
OCS at baseline								0.290
Yes	9	1 (11.1) [0.3, 48.2]	13	5 (38.5) [13.9, 68.4]	0.289 [0.040, 2.075]	0.200 [0.019, 2.118]	-27.4 [-70.2, 15.5]	0.333
No	128	12 (9.4) [4.9, 15.8]	125	13 (10.4) [5.7, 17.1]	0.901 [0.428, 1.899]	0.891 [0.390, 2.037]	-1.0 [-9.2, 7.1]	0.835

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SOSIK: Incidence of serious TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)								0.265
Medium/Low	70	5 (7.1) [2.4, 15.9]	73	4 (5.5) [1.5, 13.4]	1.304 [0.365, 4.657]	1.327 [0.341, 5.158]	1.7 [-7.7, 11.0]	0.742
High	67	8 (11.9) [5.3, 22.2]	65	14 (21.5) [12.3, 33.5]	0.554 [0.249, 1.232]	0.494 [0.192, 1.272]	-9.6 [-23.8, 4.6]	0.165
LAMA use at baseline								0.741
Yes	11	3 (27.3) [6.0, 61.0]	6	3 (50.0) [11.8, 88.2]	0.545 [0.156, 1.911]	0.375 [0.047, 2.998]	-22.7 [-83.5, 38.0]	0.600
No	126	10 (7.9) [3.9, 14.1]	132	15 (11.4) [6.5, 18.0]	0.698 [0.326, 1.496]	0.672 [0.290, 1.558]	-3.4 [-11.4, 4.5]	0.404
Tiotropium use at baseline								0.638
Yes	9	3 (33.3) [7.5, 70.1]	3	1 (33.3) [0.8, 90.6]	1.000 [0.158, 6.346]	1.000 [0.063, 15.988]	0.0 [-83.8, 83.8]	1.000
No	128	10 (7.8) [3.8, 13.9]	135	17 (12.6) [7.5, 19.4]	0.620 [0.295, 1.304]	0.588 [0.259, 1.338]	-4.8 [-12.8, 3.3]	0.227

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SOSIK: Incidence of serious TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline								0.573
Yes	29	6 (20.7) [8.0, 39.7]	37	8 (21.6) [9.8, 38.2]	0.957 [0.374, 2.450]	0.946 [0.287, 3.113]	-0.9 [-23.8, 22.0]	1.000
No	108	7 (6.5) [2.6, 12.9]	101	10 (9.9) [4.9, 17.5]	0.655 [0.259, 1.654]	0.631 [0.231, 1.726]	-3.4 [-11.8, 5.0]	0.451

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SOSIP: Incidence of serious TEAEs during study period by study specific subgroups
DSAF

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.536
White	128	12 (9.4) [4.9, 15.8]	123	14 (11.4) [6.4, 18.4]	0.824 [0.397, 1.710]	0.805 [0.357, 1.818]	-2.0 [-10.4, 6.3]	0.681
Non-white	9	1 (11.1) [0.3, 48.2]	15	4 (26.7) [7.8, 55.1]	0.417 [0.055, 3.171]	0.344 [0.032, 3.688]	-15.6 [-54.8, 23.7]	0.615
Region (cat. P)								0.805
North America/Western EU	10	2 (20.0) [2.5, 55.6]	9	3 (33.3) [7.5, 70.1]	0.600 [0.128, 2.816]	0.500 [0.063, 3.998]	-13.3 [-63.4, 36.8]	0.628
Rest of world	127	11 (8.7) [4.4, 15.0]	129	15 (11.6) [6.7, 18.5]	0.745 [0.356, 1.559]	0.721 [0.317, 1.636]	-3.0 [-11.1, 5.2]	0.536
Baseline eosinophils (cat. P)								0.775
< 250 cells/uL	61	6 (9.8) [3.7, 20.2]	60	9 (15.0) [7.1, 26.6]	0.656 [0.249, 1.729]	0.618 [0.206, 1.859]	-5.2 [-18.5, 8.2]	0.422
>= 250 cells/uL	76	7 (9.2) [3.8, 18.1]	78	9 (11.5) [5.4, 20.8]	0.798 [0.313, 2.035]	0.778 [0.274, 2.206]	-2.3 [-13.2, 8.6]	0.793
Baseline FENO (cat. P)								0.257
< 24 ppb	75	8 (10.7) [4.7, 19.9]	72	7 (9.7) [4.0, 19.0]	1.097 [0.419, 2.870]	1.109 [0.380, 3.233]	0.9 [-10.2, 12.1]	1.000
>= 24 ppb	60	5 (8.3) [2.8, 18.4]	65	11 (16.9) [8.8, 28.3]	0.492 [0.182, 1.335]	0.446 [0.145, 1.370]	-8.6 [-21.7, 4.5]	0.186

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SOSIP: Incidence of serious TEAEs during study period by study specific subgroups
DSAF

Serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.550
< 22.0 ppb	65	6 (9.2) [3.5, 19.0]	62	6 (9.7) [3.6, 19.9]	0.954 [0.325, 2.800]	0.949 [0.289, 3.117]	-0.4 [-12.2, 11.3]	1.000
>= 22.0 ppb	70	7 (10.0) [4.1, 19.5]	75	12 (16.0) [8.6, 26.3]	0.625 [0.261, 1.497]	0.583 [0.216, 1.578]	-6.0 [-18.3, 6.3]	0.331
Baseline all FEIA status								0.431
All negative	50	6 (12.0) [4.5, 24.3]	50	10 (20.0) [10.0, 33.7]	0.600 [0.236, 1.525]	0.545 [0.182, 1.637]	-8.0 [-24.3, 8.3]	0.414
Any positive	77	7 (9.1) [3.7, 17.8]	80	7 (8.8) [3.6, 17.2]	1.039 [0.382, 2.824]	1.043 [0.348, 3.126]	0.3 [-9.9, 10.5]	1.000
Th2 status								0.205
Low	70	9 (12.9) [6.1, 23.0]	62	15 (24.2) [14.2, 36.7]	0.531 [0.250, 1.128]	0.462 [0.186, 1.148]	-11.3 [-26.1, 3.4]	0.115
High	65	4 (6.2) [1.7, 15.0]	75	3 (4.0) [0.8, 11.2]	1.538 [0.357, 6.622]	1.574 [0.339, 7.307]	2.2 [-6.6, 10.9]	0.704
Baseline Periostin								0.959
Low (< 20.9 ng/ml)	62	6 (9.7) [3.6, 19.9]	67	9 (13.4) [6.3, 24.0]	0.720 [0.272, 1.907]	0.690 [0.231, 2.067]	-3.8 [-16.3, 8.8]	0.589
High (>= 20.9 ng/ml)	74	7 (9.5) [3.9, 18.5]	71	9 (12.7) [6.0, 22.7]	0.746 [0.294, 1.896]	0.720 [0.253, 2.049]	-3.2 [-14.8, 8.4]	0.603

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SOSIP: Incidence of serious TEAEs during study period by study specific subgroups
DSAF

	Tezepelumab		Placebo						
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility								0.035	i
Yes	114	11 (9.6) [4.9, 16.6]	126	12 (9.5) [5.0, 16.0]	1.013 [0.465, 2.206]	1.015 [0.429, 2.399]	0.1 [-8.2, 8.4]	1.000	
No	23	2 (8.7) [1.1, 28.0]	12	6 (50.0) [21.1, 78.9]	0.174 [0.041, 0.734]	0.095 [0.015, 0.599]	-41.3 [-78.2, -4.4]	0.011	*
Maintenance OCS use at baseline								0.216	
Yes	9	1 (11.1) [0.3, 48.2]	14	6 (42.9) [17.7, 71.1]	0.259 [0.037, 1.812]	0.167 [0.016, 1.718]	-31.7 [-73.9, 10.4]	0.176	
No	128	12 (9.4) [4.9, 15.8]	124	12 (9.7) [5.1, 16.3]	0.969 [0.453, 2.074]	0.966 [0.416, 2.239]	-0.3 [-8.3, 7.7]	1.000	
No chronic OCS use and current post-BD FEV1 reversibility								0.045	i
Yes	108	10 (9.3) [4.5, 16.4]	115	9 (7.8) [3.6, 14.3]	1.183 [0.500, 2.800]	1.202 [0.469, 3.081]	1.4 [-6.8, 9.7]	0.812	
No	29	3 (10.3) [2.2, 27.4]	23	9 (39.1) [19.7, 61.5]	0.264 [0.081, 0.866]	0.179 [0.042, 0.772]	-28.8 [-55.5, -2.1]	0.021	*

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AT_SOMI0: Incidence of TEAEs leading to study drug discontinuation during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
TEAEs leading to study drug discontinuation during study period	137	2 (1.5) [0.2, 5.2]	138	1 (0.7) [0.0, 4.0]	2.015 [0.185, 21.960]	2.030 [0.182, 22.647]	0.7 [-2.4, 3.9]	0.622

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AT_SOMSD: TEAEs leading to study drug discontinuation during study period by SOC and PT
DSAF

TEAEs leading to study drug discontinuation during study period	Tezepelumab N	Tezepelumab n (%)	Placebo N	Placebo n (%)
SOC: Investigations	137	1 (0.7)	138	0 (0.0)
Hepatic enzyme increased	137	1 (0.7)	138	0 (0.0)
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	137	0 (0.0)	138	1 (0.7)
Prostate cancer	137	0 (0.0)	138	1 (0.7)
SOC: Nervous system disorders	137	1 (0.7)	138	0 (0.0)
Guillain-Barre syndrome	137	1 (0.7)	138	0 (0.0)

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
TEAE = treatment emergent adverse event.
Source Data: AAE, created on: 11AUG2022

Table PT2AD_SOMI0: Incidence of fatal TEAEs during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Fatal TEAEs during study period	137	0 (0.0) [0.0, 2.7]	138	0 (0.0) [0.0, 2.6]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AD_SOMSD: Fatal TEAEs during study period by SOC and PT
DSAF

	Tezepelumab		Placebo	
Fatal TEAEs during study period	N	n (%)	N	n (%)

SOC: No events are observed meeting the criteria for tabular output.

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
TEAE = treatment emergent adverse event.
Source Data: AAE, created on: 11AUG2022

Table PT2AEY_SOMI0: Incidence of AESI hypersensitivity reactions during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period	137	2 (1.5) [0.2, 5.2]	138	1 (0.7) [0.0, 4.0]	2.015 [0.185, 21.960]	2.030 [0.182, 22.647]	0.7 [-2.4, 3.9]	0.622

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEYN_SOMI0: Incidence of AESI hypersensitivity reactions during study period - non-severe
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period - non-severe	137	2 (1.5) [0.2, 5.2]	138	1 (0.7) [0.0, 4.0]	2.015 [0.185, 21.960]	2.030 [0.182, 22.647]	0.7 [-2.4, 3.9]	0.622

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEYC_SOMI0: Incidence of AESI hypersensitivity reactions during study period - severe
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period - severe	137	0 (0.0) [0.0, 2.7]	138	0 (0.0) [0.0, 2.6]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEYS_SOMI0: Incidence of AESI hypersensitivity reactions during study period - serious
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period - serious	137	0 (0.0) [0.0, 2.7]	138	0 (0.0) [0.0, 2.6]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEA_SOMI0: Incidence of AESI anaphylactic reactions during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period	137	0 (0.0) [0.0, 2.7]	138	0 (0.0) [0.0, 2.6]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEAN_SOMI0: Incidence of AESI anaphylactic reactions during study period - non-severe
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period - non-severe	137	0 (0.0) [0.0, 2.7]	138	0 (0.0) [0.0, 2.6]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEAC_SOMI0: Incidence of AESI anaphylactic reactions during study period - severe
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period - severe	137	0 (0.0) [0.0, 2.7]	138	0 (0.0) [0.0, 2.6]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEAS_SOMI0: Incidence of AESI anaphylactic reactions during study period - serious
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period - serious	137	0 (0.0) [0.0, 2.7]	138	0 (0.0) [0.0, 2.6]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEI_SOMI0: Incidence of AESI injection site reactions during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period	137	6 (4.4) [1.6, 9.3]	138	7 (5.1) [2.1, 10.2]	0.863 [0.298, 2.503]	0.857 [0.281, 2.619]	-0.7 [-6.4, 5.0]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEI_SOSIK: Incidence of AESI injection site reactions during study period by key subgroups
DSAF

AESI injection site reactions during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex		n<10 all levels						NE
Male	50	1 (2.0) [0.1, 10.6]	44	3 (6.8) [1.4, 18.7]				
Female	87	5 (5.7) [1.9, 12.9]	94	4 (4.3) [1.2, 10.5]				
Age								0.456
< 65 years	114	6 (5.3) [2.0, 11.1]	118	6 (5.1) [1.9, 10.7]	1.035 [0.344, 3.116]	1.037 [0.324, 3.315]	0.2 [-6.4, 6.7]	1.000
>= 65 years	23	0 (0.0) [0.0, 14.8]	20	1 (5.0) [0.1, 24.9]	0.292 + [0.013, 6.783]	0.277 + [0.011, 7.180]	-5.0 [-19.2, 9.2]	0.465
Exacerbations in the year before study		n<10 all levels						NE
<= 2	105	2 (1.9) [0.2, 6.7]	110	3 (2.7) [0.6, 7.8]				
> 2	32	4 (12.5) [3.5, 29.0]	28	4 (14.3) [4.0, 32.7]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEI_SOSIK: Incidence of AESI injection site reactions during study period by key subgroups
DSAF

AESI injection site reactions during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	128	4 (3.1) [0.9, 7.8]	123	4 (3.3) [0.9, 8.1]				
Black or African American	3	2 (66.7) [9.4, 99.2]	6	3 (50.0) [11.8, 88.2]				
Asian	5	0 (0.0) [0.0, 52.2]	6	0 (0.0) [0.0, 45.9]				
Other	1	0 (0.0) [0.0, 97.5]	3	0 (0.0) [0.0, 70.8]				
Region		n<10 all levels						NE
Europe	78	3 (3.8) [0.8, 10.8]	80	3 (3.8) [0.8, 10.6]				
America	10	3 (30.0) [6.7, 65.2]	9	3 (33.3) [7.5, 70.1]				
Asia/Pacific	5	0 (0.0) [0.0, 52.2]	6	0 (0.0) [0.0, 45.9]				
Rest of the world	44	0 (0.0) [0.0, 8.0]	43	1 (2.3) [0.1, 12.3]				
BMI		N<10 any level						NE
< 18.5 kg/m**2	0		1	0 (0.0) [0.0, 97.5]				
18.5 - < 25.0 kg/m**2	39	1 (2.6) [0.1, 13.5]	43	2 (4.7) [0.6, 15.8]				
25.0 - < 30.0 kg/m**2	45	1 (2.2) [0.1, 11.8]	47	2 (4.3) [0.5, 14.5]				
>= 30.0 kg/m**2	53	4 (7.5) [2.1, 18.2]	47	3 (6.4) [1.3, 17.5]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEI_SOSIK: Incidence of AESI injection site reactions during study period by key subgroups
DSAF

AESI injection site reactions during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.323
< 150 cells/uL	27	2 (7.4) [0.9, 24.3]	33	1 (3.0) [0.1, 15.8]	2.444 [0.234, 25.528]	2.560 [0.219, 29.869]	4.4 [-10.5, 19.2]	0.583
>= 150 cells/uL	109	4 (3.7) [1.0, 9.1]	105	6 (5.7) [2.1, 12.0]	0.642 [0.187, 2.211]	0.629 [0.172, 2.294]	-2.0 [-8.7, 4.6]	0.533
Baseline eosinophils - High		n<10 all levels						NE
< 300 cells/uL	69	3 (4.3) [0.9, 12.2]	72	4 (5.6) [1.5, 13.6]				
>= 300 cells/uL	67	3 (4.5) [0.9, 12.5]	66	3 (4.5) [0.9, 12.7]				
Baseline FENO		n<10 all levels						NE
< 25 ppb	78	4 (5.1) [1.4, 12.6]	74	3 (4.1) [0.8, 11.4]				
>= 25 ppb	57	2 (3.5) [0.4, 12.1]	63	4 (6.3) [1.8, 15.5]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEI_SOSIK: Incidence of AESI injection site reactions during study period by key subgroups
DSAF

AESI injection site reactions during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status		n<10 all levels						NE
All negative	57	2 (3.5) [0.4, 12.1]	66	3 (4.5) [0.9, 12.7]				
Any positive	71	3 (4.2) [0.9, 11.9]	63	3 (4.8) [1.0, 13.3]				
Total serum IgE		n<10 all levels						NE
Low	35	2 (5.7) [0.7, 19.2]	32	3 (9.4) [2.0, 25.0]				
Normal	95	4 (4.2) [1.2, 10.4]	98	3 (3.1) [0.6, 8.7]				
High	7	0 (0.0) [0.0, 41.0]	8	1 (12.5) [0.3, 52.7]				
OCS at baseline								0.696
Yes	9	1 (11.1) [0.3, 48.2]	13	1 (7.7) [0.2, 36.0]	1.444 [0.103, 20.207]	1.500 [0.082, 27.607]	3.4 [-31.1, 37.9]	1.000
No	128	5 (3.9) [1.3, 8.9]	125	6 (4.8) [1.8, 10.2]	0.814 [0.255, 2.598]	0.806 [0.240, 2.713]	-0.9 [-6.7, 4.9]	0.767

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEI_SOSIK: Incidence of AESI injection site reactions during study period by key subgroups
DSAF

AESI injection site reactions during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)		n<10 all levels						NE
Medium/Low	70	3 (4.3) [0.9, 12.0]	73	3 (4.1) [0.9, 11.5]				
High	67	3 (4.5) [0.9, 12.5]	65	4 (6.2) [1.7, 15.0]				
LAMA use at baseline								0.311
Yes	11	0 (0.0) [0.0, 28.5]	6	1 (16.7) [0.4, 64.1]	0.194 + [0.009, 4.155]	0.159 + [0.006, 4.581]	-16.7 [-59.4, 26.0]	0.353
No	126	6 (4.8) [1.8, 10.1]	132	6 (4.5) [1.7, 9.6]	1.048 [0.347, 3.163]	1.050 [0.330, 3.346]	0.2 [-5.7, 6.1]	1.000
Tiotropium use at baseline								0.681
Yes	9	0 (0.0) [0.0, 33.6]	3	0 (0.0) [0.0, 70.8]	0.400 + [0.009, 16.915]	0.368 + [0.006, 22.388]	-7.5 + [-60.1, 45.1]	NE
No	128	6 (4.7) [1.7, 9.9]	135	7 (5.2) [2.1, 10.4]	0.904 [0.312, 2.618]	0.899 [0.294, 2.751]	-0.5 [-6.5, 5.5]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEI_SOSIK: Incidence of AESI injection site reactions during study period by key subgroups
DSAF

AESI injection site reactions during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline								0.364
Yes	29	0 (0.0) [0.0, 11.9]	37	2 (5.4) [0.7, 18.2]	0.253 + [0.013, 5.080]	0.241 + [0.011, 5.213]	-5.4 [-15.8, 5.0]	0.500
No	108	6 (5.6) [2.1, 11.7]	101	5 (5.0) [1.6, 11.2]	1.122 [0.353, 3.563]	1.129 [0.334, 3.822]	0.6 [-6.4, 7.6]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEI_SOSIP: Incidence of AESI injection site reactions during study period by study specific subgroups
DSAF

AESI injection site reactions during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)		n<10 all levels						NE
White	128	4 (3.1) [0.9, 7.8]	123	4 (3.3) [0.9, 8.1]				
Non-white	9	2 (22.2) [2.8, 60.0]	15	3 (20.0) [4.3, 48.1]				
Region (cat. P)		n<10 all levels						NE
North America/Western EU	10	3 (30.0) [6.7, 65.2]	9	3 (33.3) [7.5, 70.1]				
Rest of world	127	3 (2.4) [0.5, 6.7]	129	4 (3.1) [0.9, 7.7]				
Baseline eosinophils (cat. P)		n<10 all levels						NE
< 250 cells/uL	61	3 (4.9) [1.0, 13.7]	60	4 (6.7) [1.8, 16.2]				
>= 250 cells/uL	76	3 (3.9) [0.8, 11.1]	78	3 (3.8) [0.8, 10.8]				
Baseline FENO (cat. P)		n<10 all levels						NE
< 24 ppb	75	4 (5.3) [1.5, 13.1]	72	3 (4.2) [0.9, 11.7]				
>= 24 ppb	60	2 (3.3) [0.4, 11.5]	65	4 (6.2) [1.7, 15.0]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEI_SOSIP: Incidence of AESI injection site reactions during study period by study specific subgroups
DSAF

AESI injection site reactions during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)		n<10 all levels						NE
< 22.0 ppb	65	3 (4.6) [1.0, 12.9]	62	2 (3.2) [0.4, 11.2]				
>= 22.0 ppb	70	3 (4.3) [0.9, 12.0]	75	5 (6.7) [2.2, 14.9]				
Baseline all FEIA status		n<10 all levels						NE
All negative	50	2 (4.0) [0.5, 13.7]	50	3 (6.0) [1.3, 16.5]				
Any positive	77	3 (3.9) [0.8, 11.0]	80	3 (3.8) [0.8, 10.6]				
Th2 status		n<10 all levels						NE
Low	70	3 (4.3) [0.9, 12.0]	62	5 (8.1) [2.7, 17.8]				
High	65	3 (4.6) [1.0, 12.9]	75	2 (2.7) [0.3, 9.3]				
Baseline Periostin		n<10 all levels						NE
Low (< 20.9 ng/ml)	62	2 (3.2) [0.4, 11.2]	67	2 (3.0) [0.4, 10.4]				
High (>= 20.9 ng/ml)	74	4 (5.4) [1.5, 13.3]	71	5 (7.0) [2.3, 15.7]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEI_SOSIP: Incidence of AESI injection site reactions during study period by study specific subgroups
DSAF

AESI injection site reactions during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.794
Yes	114	4 (3.5) [1.0, 8.7]	126	6 (4.8) [1.8, 10.1]	0.737 [0.213, 2.545]	0.727 [0.200, 2.646]	-1.3 [-7.1, 4.6]	0.752
No	23	2 (8.7) [1.1, 28.0]	12	1 (8.3) [0.2, 38.5]	1.043 [0.105, 10.374]	1.048 [0.085, 12.876]	0.4 [-25.4, 26.1]	1.000
Maintenance OCS use at baseline								0.656
Yes	9	1 (11.1) [0.3, 48.2]	14	1 (7.1) [0.2, 33.9]	1.556 [0.111, 21.848]	1.625 [0.089, 29.781]	4.0 [-29.7, 37.7]	1.000
No	128	5 (3.9) [1.3, 8.9]	124	6 (4.8) [1.8, 10.2]	0.807 [0.253, 2.577]	0.799 [0.238, 2.690]	-0.9 [-6.8, 4.9]	0.766
No chronic OCS use and current post-BD FEV1 reversibility		n<10 all levels						NE
Yes	108	3 (2.8) [0.6, 7.9]	115	5 (4.3) [1.4, 9.9]				
No	29	3 (10.3) [2.2, 27.4]	23	2 (8.7) [1.1, 28.0]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEIN_SOMI0: Incidence of AESI injection site reactions during study period - non-severe
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period - non-severe	137	6 (4.4) [1.6, 9.3]	138	7 (5.1) [2.1, 10.2]	0.863 [0.298, 2.503]	0.857 [0.281, 2.619]	-0.7 [-6.4, 5.0]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEIN_SOSIK: Incidence of AESI injection site reactions during study period - non-severe by key subgroups
DSAF

AESI injection site reactions during study period - non-severe	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex		n<10 all levels						NE
Male	50	1 (2.0) [0.1, 10.6]	44	3 (6.8) [1.4, 18.7]				
Female	87	5 (5.7) [1.9, 12.9]	94	4 (4.3) [1.2, 10.5]				
Age								0.456
< 65 years	114	6 (5.3) [2.0, 11.1]	118	6 (5.1) [1.9, 10.7]	1.035 [0.344, 3.116]	1.037 [0.324, 3.315]	0.2 [-6.4, 6.7]	1.000
>= 65 years	23	0 (0.0) [0.0, 14.8]	20	1 (5.0) [0.1, 24.9]	0.292 + [0.013, 6.783]	0.277 + [0.011, 7.180]	-5.0 [-19.2, 9.2]	0.465
Exacerbations in the year before study		n<10 all levels						NE
<= 2	105	2 (1.9) [0.2, 6.7]	110	3 (2.7) [0.6, 7.8]				
> 2	32	4 (12.5) [3.5, 29.0]	28	4 (14.3) [4.0, 32.7]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEIN_SOSIK: Incidence of AESI injection site reactions during study period - non-severe by key subgroups
DSAF

AESI injection site reactions during study period - non-severe	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	128	4 (3.1) [0.9, 7.8]	123	4 (3.3) [0.9, 8.1]				
Black or African American	3	2 (66.7) [9.4, 99.2]	6	3 (50.0) [11.8, 88.2]				
Asian	5	0 (0.0) [0.0, 52.2]	6	0 (0.0) [0.0, 45.9]				
Other	1	0 (0.0) [0.0, 97.5]	3	0 (0.0) [0.0, 70.8]				
Region		n<10 all levels						NE
Europe	78	3 (3.8) [0.8, 10.8]	80	3 (3.8) [0.8, 10.6]				
America	10	3 (30.0) [6.7, 65.2]	9	3 (33.3) [7.5, 70.1]				
Asia/Pacific	5	0 (0.0) [0.0, 52.2]	6	0 (0.0) [0.0, 45.9]				
Rest of the world	44	0 (0.0) [0.0, 8.0]	43	1 (2.3) [0.1, 12.3]				
BMI		N<10 any level						NE
< 18.5 kg/m**2	0		1	0 (0.0) [0.0, 97.5]				
18.5 - < 25.0 kg/m**2	39	1 (2.6) [0.1, 13.5]	43	2 (4.7) [0.6, 15.8]				
25.0 - < 30.0 kg/m**2	45	1 (2.2) [0.1, 11.8]	47	2 (4.3) [0.5, 14.5]				
>= 30.0 kg/m**2	53	4 (7.5) [2.1, 18.2]	47	3 (6.4) [1.3, 17.5]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEIN_SOSIK: Incidence of AESI injection site reactions during study period - non-severe by key subgroups
DSAF

AESI injection site reactions during study period - non-severe	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.323
< 150 cells/uL	27	2 (7.4) [0.9, 24.3]	33	1 (3.0) [0.1, 15.8]	2.444 [0.234, 25.528]	2.560 [0.219, 29.869]	4.4 [-10.5, 19.2]	0.583
>= 150 cells/uL	109	4 (3.7) [1.0, 9.1]	105	6 (5.7) [2.1, 12.0]	0.642 [0.187, 2.211]	0.629 [0.172, 2.294]	-2.0 [-8.7, 4.6]	0.533
Baseline eosinophils - High		n<10 all levels						NE
< 300 cells/uL	69	3 (4.3) [0.9, 12.2]	72	4 (5.6) [1.5, 13.6]				
>= 300 cells/uL	67	3 (4.5) [0.9, 12.5]	66	3 (4.5) [0.9, 12.7]				
Baseline FENO		n<10 all levels						NE
< 25 ppb	78	4 (5.1) [1.4, 12.6]	74	3 (4.1) [0.8, 11.4]				
>= 25 ppb	57	2 (3.5) [0.4, 12.1]	63	4 (6.3) [1.8, 15.5]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEIN_SOSIK: Incidence of AESI injection site reactions during study period - non-severe by key subgroups
DSAF

	Tezepelumab		Placebo					
AESI injection site reactions during study period - non-severe	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status		n<10 all levels						NE
All negative	57	2 (3.5) [0.4, 12.1]	66	3 (4.5) [0.9, 12.7]				
Any positive	71	3 (4.2) [0.9, 11.9]	63	3 (4.8) [1.0, 13.3]				
Total serum IgE		n<10 all levels						NE
Low	35	2 (5.7) [0.7, 19.2]	32	3 (9.4) [2.0, 25.0]				
Normal	95	4 (4.2) [1.2, 10.4]	98	3 (3.1) [0.6, 8.7]				
High	7	0 (0.0) [0.0, 41.0]	8	1 (12.5) [0.3, 52.7]				
OCS at baseline								0.696
Yes	9	1 (11.1) [0.3, 48.2]	13	1 (7.7) [0.2, 36.0]	1.444 [0.103, 20.207]	1.500 [0.082, 27.607]	3.4 [-31.1, 37.9]	1.000
No	128	5 (3.9) [1.3, 8.9]	125	6 (4.8) [1.8, 10.2]	0.814 [0.255, 2.598]	0.806 [0.240, 2.713]	-0.9 [-6.7, 4.9]	0.767

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEIN_SOSIK: Incidence of AESI injection site reactions during study period - non-severe by key subgroups
DSAF

	Tezepelumab		Placebo					
AESI injection site reactions during study period - non-severe	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)		n<10 all levels						NE
Medium/Low	70	3 (4.3) [0.9, 12.0]	73	3 (4.1) [0.9, 11.5]				
High	67	3 (4.5) [0.9, 12.5]	65	4 (6.2) [1.7, 15.0]				
LAMA use at baseline								0.311
Yes	11	0 (0.0) [0.0, 28.5]	6	1 (16.7) [0.4, 64.1]	0.194 + [0.009, 4.155]	0.159 + [0.006, 4.581]	-16.7 [-59.4, 26.0]	0.353
No	126	6 (4.8) [1.8, 10.1]	132	6 (4.5) [1.7, 9.6]	1.048 [0.347, 3.163]	1.050 [0.330, 3.346]	0.2 [-5.7, 6.1]	1.000
Tiotropium use at baseline								0.681
Yes	9	0 (0.0) [0.0, 33.6]	3	0 (0.0) [0.0, 70.8]	0.400 + [0.009, 16.915]	0.368 + [0.006, 22.388]	-7.5 + [-60.1, 45.1]	NE
No	128	6 (4.7) [1.7, 9.9]	135	7 (5.2) [2.1, 10.4]	0.904 [0.312, 2.618]	0.899 [0.294, 2.751]	-0.5 [-6.5, 5.5]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEIN_SOSIK: Incidence of AESI injection site reactions during study period - non-severe by key subgroups
DSAF

	Tezepelumab		Placebo					
AESI injection site reactions during study period - non-severe	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline								0.364
Yes	29	0 (0.0) [0.0, 11.9]	37	2 (5.4) [0.7, 18.2]	0.253 + [0.013, 5.080]	0.241 + [0.011, 5.213]	-5.4 [-15.8, 5.0]	0.500
No	108	6 (5.6) [2.1, 11.7]	101	5 (5.0) [1.6, 11.2]	1.122 [0.353, 3.563]	1.129 [0.334, 3.822]	0.6 [-6.4, 7.6]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEIN_SOSIP: Incidence of AESI injection site reactions during study period - non-severe by study specific subgroups
DSAF

AESI injection site reactions during study period - non-severe	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)		n<10 all levels						NE
White	128	4 (3.1) [0.9, 7.8]	123	4 (3.3) [0.9, 8.1]				
Non-white	9	2 (22.2) [2.8, 60.0]	15	3 (20.0) [4.3, 48.1]				
Region (cat. P)		n<10 all levels						NE
North America/Western EU	10	3 (30.0) [6.7, 65.2]	9	3 (33.3) [7.5, 70.1]				
Rest of world	127	3 (2.4) [0.5, 6.7]	129	4 (3.1) [0.9, 7.7]				
Baseline eosinophils (cat. P)		n<10 all levels						NE
< 250 cells/uL	61	3 (4.9) [1.0, 13.7]	60	4 (6.7) [1.8, 16.2]				
>= 250 cells/uL	76	3 (3.9) [0.8, 11.1]	78	3 (3.8) [0.8, 10.8]				
Baseline FENO (cat. P)		n<10 all levels						NE
< 24 ppb	75	4 (5.3) [1.5, 13.1]	72	3 (4.2) [0.9, 11.7]				
>= 24 ppb	60	2 (3.3) [0.4, 11.5]	65	4 (6.2) [1.7, 15.0]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEIN_SOSIP: Incidence of AESI injection site reactions during study period - non-severe by study specific subgroups
DSAF

AESI injection site reactions during study period - non-severe	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)		n<10 all levels						NE
< 22.0 ppb	65	3 (4.6) [1.0, 12.9]	62	2 (3.2) [0.4, 11.2]				
>= 22.0 ppb	70	3 (4.3) [0.9, 12.0]	75	5 (6.7) [2.2, 14.9]				
Baseline all FEIA status		n<10 all levels						NE
All negative	50	2 (4.0) [0.5, 13.7]	50	3 (6.0) [1.3, 16.5]				
Any positive	77	3 (3.9) [0.8, 11.0]	80	3 (3.8) [0.8, 10.6]				
Th2 status		n<10 all levels						NE
Low	70	3 (4.3) [0.9, 12.0]	62	5 (8.1) [2.7, 17.8]				
High	65	3 (4.6) [1.0, 12.9]	75	2 (2.7) [0.3, 9.3]				
Baseline Periostin		n<10 all levels						NE
Low (< 20.9 ng/ml)	62	2 (3.2) [0.4, 11.2]	67	2 (3.0) [0.4, 10.4]				
High (>= 20.9 ng/ml)	74	4 (5.4) [1.5, 13.3]	71	5 (7.0) [2.3, 15.7]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEIN_SOSIP: Incidence of AESI injection site reactions during study period - non-severe by study specific subgroups
DSAF

AESI injection site reactions during study period - non-severe	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.794
Yes	114	4 (3.5) [1.0, 8.7]	126	6 (4.8) [1.8, 10.1]	0.737 [0.213, 2.545]	0.727 [0.200, 2.646]	-1.3 [-7.1, 4.6]	0.752
No	23	2 (8.7) [1.1, 28.0]	12	1 (8.3) [0.2, 38.5]	1.043 [0.105, 10.374]	1.048 [0.085, 12.876]	0.4 [-25.4, 26.1]	1.000
Maintenance OCS use at baseline								0.656
Yes	9	1 (11.1) [0.3, 48.2]	14	1 (7.1) [0.2, 33.9]	1.556 [0.111, 21.848]	1.625 [0.089, 29.781]	4.0 [-29.7, 37.7]	1.000
No	128	5 (3.9) [1.3, 8.9]	124	6 (4.8) [1.8, 10.2]	0.807 [0.253, 2.577]	0.799 [0.238, 2.690]	-0.9 [-6.8, 4.9]	0.766
No chronic OCS use and current post-BD FEV1 reversibility		n<10 all levels						NE
Yes	108	3 (2.8) [0.6, 7.9]	115	5 (4.3) [1.4, 9.9]				
No	29	3 (10.3) [2.2, 27.4]	23	2 (8.7) [1.1, 28.0]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. AESI = adverse event of special interest.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AEIC_SOMI0: Incidence of AESI injection site reactions during study period - severe
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period - severe	137	0 (0.0) [0.0, 2.7]	138	0 (0.0) [0.0, 2.6]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEIS_SOMI0: Incidence of AESI injection site reactions during study period - serious
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period - serious	137	0 (0.0) [0.0, 2.7]	138	0 (0.0) [0.0, 2.6]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEM_SOMI0: Incidence of AESI malignancies during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period	137	2 (1.5) [0.2, 5.2]	138	1 (0.7) [0.0, 4.0]	2.015 [0.185, 21.960]	2.030 [0.182, 22.647]	0.7 [-2.4, 3.9]	0.622

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEMN_SOMI0: Incidence of AESI malignancies during study period - non-severe
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period - non-severe	137	0 (0.0) [0.0, 2.7]	138	1 (0.7) [0.0, 4.0]	0.336 + [0.014, 8.171]	0.333 + [0.013, 8.254]	-0.7 [-2.9, 1.4]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEMC_SOMI0: Incidence of AESI malignancies during study period - severe
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period - severe	137	2 (1.5) [0.2, 5.2]	138	0 (0.0) [0.0, 2.6]	5.036 + [0.244, 103.946]	5.111 + [0.243, 107.439]	1.5 [-1.3, 4.2]	0.247

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEMS_SOMI0: Incidence of AESI malignancies during study period - serious
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period - serious	137	2 (1.5) [0.2, 5.2]	138	1 (0.7) [0.0, 4.0]	2.015 [0.185, 21.960]	2.030 [0.182, 22.647]	0.7 [-2.4, 3.9]	0.622

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEG_SOMI0: Incidence of AESI Giullain Barre syndrome during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period	137	1 (0.7) [0.0, 4.0]	138	0 (0.0) [0.0, 2.6]	3.022 + [0.124, 73.535]	3.044 + [0.123, 75.376]	0.7 [-1.4, 2.9]	0.498

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEGN_SOMI0: Incidence of AESI Giullain Barre syndrome during study period - non-severe
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period - non-severe	137	0 (0.0) [0.0, 2.7]	138	0 (0.0) [0.0, 2.6]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEGC_SOMI0: Incidence of AESI Giullain Barre syndrome during study period - severe
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period - severe	137	1 (0.7) [0.0, 4.0]	138	0 (0.0) [0.0, 2.6]	3.022 + [0.124, 73.535]	3.044 + [0.123, 75.376]	0.7 [-1.4, 2.9]	0.498

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEGS_SOMI0: Incidence of AESI Giullain Barre syndrome during study period - serious
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period - serious	137	1 (0.7) [0.0, 4.0]	138	0 (0.0) [0.0, 2.6]	3.022 + [0.124, 73.535]	3.044 + [0.123, 75.376]	0.7 [-1.4, 2.9]	0.498

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2A_SLMI0: Incidence of TEAEs during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
TEAEs during study period	66	45 (68.2) [55.6, 79.1]	65	44 (67.7) [54.9, 78.8]	1.007 [0.796, 1.274]	1.023 [0.491, 2.130]	0.5 [-17.0, 18.0]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2A_SLMS0: TEAEs during study period by SOC and PT
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: General disorders and administration site conditions	66	5 (7.6) [2.5, 16.8]	65	7 (10.8) [4.4, 20.9]	0.703 [0.235, 2.103]	0.679 [0.204, 2.261]	-3.2 [-14.6, 8.2]	0.561
SOC: Infections and infestations	66	31 (47.0) [34.6, 59.7]	65	29 (44.6) [32.3, 57.5]	1.053 [0.725, 1.529]	1.100 [0.553, 2.187]	2.4 [-16.2, 20.9]	0.861
Nasopharyngitis	66	9 (13.6) [6.4, 24.3]	65	5 (7.7) [2.5, 17.0]	1.773 [0.628, 5.006]	1.895 [0.599, 5.994]	5.9 [-6.1, 18.0]	0.397
SOC: Injury, poisoning and procedural complications	66	5 (7.6) [2.5, 16.8]	65	7 (10.8) [4.4, 20.9]	0.703 [0.235, 2.103]	0.679 [0.204, 2.261]	-3.2 [-14.6, 8.2]	0.561
SOC: Musculoskeletal and connective tissue disorders	66	12 (18.2) [9.8, 29.6]	65	6 (9.2) [3.5, 19.0]	1.970 [0.786, 4.934]	2.185 [0.767, 6.227]	9.0 [-4.2, 22.1]	0.204
SOC: Respiratory, thoracic and mediastinal disorders	66	18 (27.3) [17.0, 39.6]	65	29 (44.6) [32.3, 57.5]	0.611 [0.379, 0.986]	0.466 [0.224, 0.966]	-17.3 [-35.0, 0.4]	0.046 *
Asthma	66	16 (24.2) [14.5, 36.4]	65	28 (43.1) [30.8, 56.0]	0.563 [0.338, 0.937]	0.423 [0.200, 0.892]	-18.8 [-36.2, -1.4]	0.027 *

Note: DSAFL = Dossier Label Safety Set. Only events are displayed with an incidence of at least 10 percent in a treatment group or 10 patients with an incidence of at least 1 percent in a treatment group.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2A_SLSIK: Incidence of TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.326
Male	19	12 (63.2) [38.4, 83.7]	20	15 (75.0) [50.9, 91.3]	0.842 [0.550, 1.290]	0.571 [0.144, 2.262]	-11.8 [-45.8, 22.1]	0.501
Female	47	33 (70.2) [55.1, 82.7]	45	29 (64.4) [48.8, 78.1]	1.090 [0.819, 1.450]	1.300 [0.543, 3.116]	5.8 [-15.6, 27.1]	0.658
Age								0.706
< 65 years	57	38 (66.7) [52.9, 78.6]	55	37 (67.3) [53.3, 79.3]	0.991 [0.764, 1.285]	0.973 [0.443, 2.139]	-0.6 [-19.8, 18.6]	1.000
>= 65 years	9	7 (77.8) [40.0, 97.2]	10	7 (70.0) [34.8, 93.3]	1.111 [0.651, 1.898]	1.500 [0.189, 11.927]	7.8 [-42.1, 57.6]	1.000
Exacerbations in the year before study								0.469
<= 2	44	27 (61.4) [45.5, 75.6]	45	26 (57.8) [42.2, 72.3]	1.062 [0.754, 1.496]	1.161 [0.497, 2.709]	3.6 [-19.0, 26.2]	0.830
> 2	22	18 (81.8) [59.7, 94.8]	20	18 (90.0) [68.3, 98.8]	0.909 [0.711, 1.162]	0.500 [0.081, 3.082]	-8.2 [-33.8, 17.4]	0.665

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSIK: Incidence of TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	60	41 (68.3) [55.0, 79.7]	58	38 (65.5) [51.9, 77.5]				
Black or African American	2	2 (100.0) [15.8, 100.0]	2	2 (100.0) [15.8, 100.0]				
Asian	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Other	1	0 (0.0) [0.0, 97.5]	2	2 (100.0) [15.8, 100.0]				
Region		N<10 any level						NE
Europe	40	26 (65.0) [48.3, 79.4]	36	23 (63.9) [46.2, 79.2]				
America	6	6 (100.0) [54.1, 100.0]	4	4 (100.0) [39.8, 100.0]				
Asia/Pacific	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Rest of the world	17	11 (64.7) [38.3, 85.8]	22	15 (68.2) [45.1, 86.1]				
BMI								0.386
18.5 - < 25.0 kg/m**2	15	10 (66.7) [38.4, 88.2]	21	15 (71.4) [47.8, 88.7]	0.933 [0.596, 1.462]	0.800 [0.191, 3.347]	-4.8 [-41.2, 31.7]	1.000
25.0 - < 30.0 kg/m**2	24	13 (54.2) [32.8, 74.4]	20	13 (65.0) [40.8, 84.6]	0.833 [0.511, 1.359]	0.636 [0.188, 2.156]	-10.8 [-44.3, 22.6]	0.547
>= 30.0 kg/m**2	27	22 (81.5) [61.9, 93.7]	24	16 (66.7) [44.7, 84.4]	1.222 [0.874, 1.709]	2.200 [0.606, 7.989]	14.8 [-13.0, 42.6]	0.336

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSIK: Incidence of TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.531
< 150 cells/uL	11	9 (81.8) [48.2, 97.7]	14	10 (71.4) [41.9, 91.6]	1.145 [0.743, 1.766]	1.800 [0.264, 12.296]	10.4 [-30.6, 51.4]	0.661
>= 150 cells/uL	54	35 (64.8) [50.6, 77.3]	51	34 (66.7) [52.1, 79.2]	0.972 [0.738, 1.281]	0.921 [0.411, 2.064]	-1.9 [-21.9, 18.2]	1.000
Baseline eosinophils - High								0.529
< 300 cells/uL	33	23 (69.7) [51.3, 84.4]	34	22 (64.7) [46.5, 80.3]	1.077 [0.770, 1.506]	1.255 [0.451, 3.488]	5.0 [-20.4, 30.4]	0.796
>= 300 cells/uL	32	21 (65.6) [46.8, 81.4]	31	22 (71.0) [52.0, 85.8]	0.925 [0.660, 1.295]	0.781 [0.269, 2.265]	-5.3 [-31.5, 20.8]	0.788
Baseline FENO								0.191
< 25 ppb	39	29 (74.4) [57.9, 87.0]	30	19 (63.3) [43.9, 80.1]	1.174 [0.845, 1.631]	1.679 [0.597, 4.719]	11.0 [-13.9, 36.0]	0.430
>= 25 ppb	27	16 (59.3) [38.8, 77.6]	34	24 (70.6) [52.5, 84.9]	0.840 [0.574, 1.228]	0.606 [0.209, 1.758]	-11.3 [-38.7, 16.0]	0.422

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSIK: Incidence of TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.826
All negative	27	21 (77.8) [57.7, 91.4]	29	22 (75.9) [56.5, 89.7]	1.025 [0.769, 1.367]	1.114 [0.321, 3.862]	1.9 [-23.8, 27.6]	1.000
Any positive	34	20 (58.8) [40.7, 75.4]	33	20 (60.6) [42.1, 77.1]	0.971 [0.655, 1.438]	0.929 [0.350, 2.466]	-1.8 [-28.3, 24.7]	1.000
Total serum IgE								0.637
Low	23	19 (82.6) [61.2, 95.0]	14	11 (78.6) [49.2, 95.3]	1.051 [0.755, 1.465]	1.295 [0.244, 6.889]	4.0 [-28.2, 36.3]	1.000
Normal	40	25 (62.5) [45.8, 77.3]	44	28 (63.6) [47.8, 77.6]	0.982 [0.708, 1.363]	0.952 [0.392, 2.313]	-1.1 [-24.2, 21.9]	1.000
High	3	1 (33.3) [0.8, 90.6]	7	5 (71.4) [29.0, 96.3]	0.467 [0.088, 2.473]	0.200 [0.011, 3.661]	-38.1 [-100.0, 48.7]	0.500
OCS at baseline								0.269
Yes	9	8 (88.9) [51.8, 99.7]	13	9 (69.2) [38.6, 90.9]	1.284 [0.835, 1.973]	3.556 [0.326, 38.777]	19.7 [-22.2, 61.5]	0.360
No	57	37 (64.9) [51.1, 77.1]	52	35 (67.3) [52.9, 79.7]	0.964 [0.737, 1.262]	0.899 [0.406, 1.989]	-2.4 [-22.0, 17.2]	0.841

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSIK: Incidence of TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline								0.889
Yes	7	5 (71.4) [29.0, 96.3]	3	2 (66.7) [9.4, 99.2]	1.071 [0.424, 2.708]	1.250 [0.068, 22.879]	4.8 [-82.0, 91.5]	1.000
No	59	40 (67.8) [54.4, 79.4]	62	42 (67.7) [54.7, 79.1]	1.001 [0.783, 1.280]	1.003 [0.468, 2.149]	0.1 [-18.3, 18.4]	1.000
Tiotropium use at baseline		N<10 any level						NE
Yes	6	4 (66.7) [22.3, 95.7]	2	1 (50.0) [1.3, 98.7]				
No	60	41 (68.3) [55.0, 79.7]	63	43 (68.3) [55.3, 79.4]				
Montelukast/ Cromoglicic acid use at baseline								0.952
Yes	17	14 (82.4) [56.6, 96.2]	21	17 (81.0) [58.1, 94.6]	1.017 [0.752, 1.377]	1.098 [0.210, 5.750]	1.4 [-28.6, 31.4]	1.000
No	49	31 (63.3) [48.3, 76.6]	44	27 (61.4) [45.5, 75.6]	1.031 [0.751, 1.416]	1.084 [0.468, 2.512]	1.9 [-20.0, 23.8]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Respiratory, thoracic and mediastinal disorders								
Sex								0.850
Male	19	5 (26.3) [9.1, 51.2]	20	8 (40.0) [19.1, 63.9]	0.658 [0.261, 1.658]	0.536 [0.138, 2.082]	-13.7 [-48.0, 20.7]	0.501
Female	47	13 (27.7) [15.6, 42.6]	45	21 (46.7) [31.7, 62.1]	0.593 [0.339, 1.036]	0.437 [0.184, 1.040]	-19.0 [-40.6, 2.6]	0.084
Age								0.117
< 65 years	57	14 (24.6) [14.1, 37.8]	55	26 (47.3) [33.7, 61.2]	0.520 [0.305, 0.886]	0.363 [0.163, 0.810]	-22.7 [-41.8, -3.6]	0.018 *
>= 65 years	9	4 (44.4) [13.7, 78.8]	10	3 (30.0) [6.7, 65.2]	1.481 [0.448, 4.898]	1.867 [0.283, 12.310]	14.4 [-39.2, 68.1]	0.650
Exacerbations in the year before study								0.610
<= 2	44	8 (18.2) [8.2, 32.7]	45	12 (26.7) [14.6, 41.9]	0.682 [0.309, 1.506]	0.611 [0.222, 1.681]	-8.5 [-28.0, 11.0]	0.447
> 2	22	10 (45.5) [24.4, 67.8]	20	17 (85.0) [62.1, 96.8]	0.535 [0.327, 0.876]	0.147 [0.033, 0.650]	-39.5 [-70.4, -8.7]	0.011 *
Race		any N<10						NE
White	60	15 (25.0) [14.7, 37.9]	58	23 (39.7) [27.0, 53.4]				
Black or African American	2	1 (50.0) [1.3, 98.7]	2	2 (100.0) [15.8, 100.0]				
Asian	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Other	1	0 (0.0) [0.0, 97.5]	2	2 (100.0) [15.8, 100.0]				

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Region		any N<10						NE
Europe	40	12 (30.0) [16.6, 46.5]	36	12 (33.3) [18.6, 51.0]				
America	6	2 (33.3) [4.3, 77.7]	4	4 (100.0) [39.8, 100.0]				
Asia/Pacific	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Rest of the world	17	2 (11.8) [1.5, 36.4]	22	11 (50.0) [28.2, 71.8]				
BMI								0.284
18.5 - < 25.0 kg/m**2	15	4 (26.7) [7.8, 55.1]	21	12 (57.1) [34.0, 78.2]	0.467 [0.186, 1.168]	0.273 [0.065, 1.144]	-30.5 [-67.0, 6.0]	0.096
25.0 - < 30.0 kg/m**2	24	4 (16.7) [4.7, 37.4]	20	8 (40.0) [19.1, 63.9]	0.417 [0.147, 1.183]	0.300 [0.074, 1.213]	-23.3 [-54.1, 7.4]	0.102
>= 30.0 kg/m**2	27	10 (37.0) [19.4, 57.6]	24	9 (37.5) [18.8, 59.4]	0.988 [0.484, 2.015]	0.980 [0.314, 3.057]	-0.5 [-31.0, 30.1]	1.000
Baseline eosinophils - Low								0.571
< 150 cells/uL	11	3 (27.3) [6.0, 61.0]	14	8 (57.1) [28.9, 82.3]	0.477 [0.164, 1.386]	0.281 [0.052, 1.536]	-29.9 [-74.9, 15.2]	0.227
>= 150 cells/uL	54	15 (27.8) [16.5, 41.6]	51	21 (41.2) [27.6, 55.8]	0.675 [0.393, 1.159]	0.549 [0.243, 1.242]	-13.4 [-33.3, 6.5]	0.158
Baseline eosinophils - High								0.789
< 300 cells/uL	33	9 (27.3) [13.3, 45.5]	34	14 (41.2) [24.6, 59.3]	0.662 [0.333, 1.316]	0.536 [0.192, 1.495]	-13.9 [-39.4, 11.5]	0.305
>= 300 cells/uL	32	9 (28.1) [13.7, 46.7]	31	15 (48.4) [30.2, 66.9]	0.581 [0.300, 1.127]	0.417 [0.147, 1.186]	-20.3 [-46.9, 6.4]	0.123

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAFL

	Tezepelumab		Placebo						
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO								0.045	i
< 25 ppb	39	13 (33.3) [19.1, 50.2]	30	10 (33.3) [17.3, 52.8]	1.000 [0.510, 1.960]	1.000 [0.364, 2.745]	0.0 [-25.4, 25.4]	1.000	
>= 25 ppb	27	5 (18.5) [6.3, 38.1]	34	19 (55.9) [37.9, 72.8]	0.331 [0.142, 0.772]	0.179 [0.055, 0.586]	-37.4 [-62.9, -11.8]	0.004	*
Baseline specific perennial FEIA status								0.544	
All negative	27	8 (29.6) [13.8, 50.2]	29	16 (55.2) [35.7, 73.6]	0.537 [0.275, 1.047]	0.342 [0.113, 1.031]	-25.5 [-54.1, 3.0]	0.064	
Any positive	34	9 (26.5) [12.9, 44.4]	33	12 (36.4) [20.4, 54.9]	0.728 [0.355, 1.495]	0.630 [0.222, 1.784]	-9.9 [-35.0, 15.2]	0.437	
Total serum IgE								0.946	
Low	23	9 (39.1) [19.7, 61.5]	14	9 (64.3) [35.1, 87.2]	0.609 [0.320, 1.157]	0.357 [0.090, 1.415]	-25.2 [-63.0, 12.6]	0.184	
Normal	40	9 (22.5) [10.8, 38.5]	44	18 (40.9) [26.3, 56.8]	0.550 [0.280, 1.081]	0.419 [0.161, 1.090]	-18.4 [-40.3, 3.4]	0.101	
High	3	0 (0.0) [0.0, 70.8]	7	2 (28.6) [3.7, 71.0]	0.400 + [0.025, 6.506]	0.314 + [0.011, 8.684]	-28.6 [-85.8, 28.7]	1.000	
OCS at baseline								0.740	
Yes	9	4 (44.4) [13.7, 78.8]	13	8 (61.5) [31.6, 86.1]	0.722 [0.309, 1.685]	0.500 [0.089, 2.807]	-17.1 [-68.4, 34.2]	0.666	
No	57	14 (24.6) [14.1, 37.8]	52	21 (40.4) [27.0, 54.9]	0.608 [0.347, 1.067]	0.481 [0.212, 1.090]	-15.8 [-35.1, 3.4]	0.101	

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline								0.443
Yes	7	4 (57.1) [18.4, 90.1]	3	2 (66.7) [9.4, 99.2]	0.857 [0.307, 2.390]	0.667 [0.039, 11.285]	-9.5 [-98.1, 79.0]	1.000
No	59	14 (23.7) [13.6, 36.6]	62	27 (43.5) [31.0, 56.7]	0.545 [0.318, 0.933]	0.403 [0.184, 0.882]	-19.8 [-37.9, -1.7]	0.034 *
Tiotropium use at baseline		any N<10						NE
Yes	6	4 (66.7) [22.3, 95.7]	2	1 (50.0) [1.3, 98.7]				
No	60	14 (23.3) [13.4, 36.0]	63	28 (44.4) [31.9, 57.5]				
Montelukast/ Cromoglicic acid use at baseline								0.875
Yes	17	7 (41.2) [18.4, 67.1]	21	13 (61.9) [38.4, 81.9]	0.665 [0.344, 1.287]	0.431 [0.117, 1.592]	-20.7 [-57.3, 15.9]	0.328
No	49	11 (22.4) [11.8, 36.6]	44	16 (36.4) [22.4, 52.2]	0.617 [0.322, 1.184]	0.507 [0.204, 1.258]	-13.9 [-34.5, 6.6]	0.173

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Asthma								
Sex								0.877
Male	19	4 (21.1) [6.1, 45.6]	20	7 (35.0) [15.4, 59.2]	0.602 [0.209, 1.729]	0.495 [0.118, 2.081]	-13.9 [-46.9, 19.0]	0.480
Female	47	12 (25.5) [13.9, 40.3]	45	21 (46.7) [31.7, 62.1]	0.547 [0.306, 0.977]	0.392 [0.163, 0.944]	-21.1 [-42.5, 0.2]	0.050
Age								0.278
< 65 years	57	13 (22.8) [12.7, 35.8]	55	25 (45.5) [32.0, 59.4]	0.502 [0.287, 0.877]	0.355 [0.157, 0.801]	-22.6 [-41.5, -3.8]	0.016 *
>= 65 years	9	3 (33.3) [7.5, 70.1]	10	3 (30.0) [6.7, 65.2]	1.111 [0.296, 4.171]	1.167 [0.168, 8.090]	3.3 [-49.1, 55.8]	1.000
Exacerbations in the year before study								0.556
<= 2	44	7 (15.9) [6.6, 30.1]	45	11 (24.4) [12.9, 39.5]	0.651 [0.278, 1.525]	0.585 [0.203, 1.681]	-8.5 [-27.3, 10.3]	0.430
> 2	22	9 (40.9) [20.7, 63.6]	20	17 (85.0) [62.1, 96.8]	0.481 [0.282, 0.822]	0.122 [0.027, 0.544]	-44.1 [-74.7, -13.5]	0.005 *
Race		any N<10						NE
White	60	13 (21.7) [12.1, 34.2]	58	22 (37.9) [25.5, 51.6]				
Black or African American	2	1 (50.0) [1.3, 98.7]	2	2 (100.0) [15.8, 100.0]				
Asian	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Other	1	0 (0.0) [0.0, 97.5]	2	2 (100.0) [15.8, 100.0]				

Subgroups presented for PT: Asthma

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Region		any N<10						NE
Europe	40	11 (27.5) [14.6, 43.9]	36	11 (30.6) [16.3, 48.1]				
America	6	2 (33.3) [4.3, 77.7]	4	4 (100.0) [39.8, 100.0]				
Asia/Pacific	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Rest of the world	17	1 (5.9) [0.1, 28.7]	22	11 (50.0) [28.2, 71.8]				
BMI								0.436
18.5 - < 25.0 kg/m**2	15	4 (26.7) [7.8, 55.1]	21	12 (57.1) [34.0, 78.2]	0.467 [0.186, 1.168]	0.273 [0.065, 1.144]	-30.5 [-67.0, 6.0]	0.096
25.0 - < 30.0 kg/m**2	24	4 (16.7) [4.7, 37.4]	20	8 (40.0) [19.1, 63.9]	0.417 [0.147, 1.183]	0.300 [0.074, 1.213]	-23.3 [-54.1, 7.4]	0.102
>= 30.0 kg/m**2	27	8 (29.6) [13.8, 50.2]	24	8 (33.3) [15.6, 55.3]	0.889 [0.395, 2.001]	0.842 [0.258, 2.752]	-3.7 [-33.2, 25.8]	1.000
Baseline eosinophils - Low								0.322
< 150 cells/uL	11	2 (18.2) [2.3, 51.8]	14	8 (57.1) [28.9, 82.3]	0.318 [0.084, 1.207]	0.167 [0.026, 1.073]	-39.0 [-81.6, 3.7]	0.099
>= 150 cells/uL	54	14 (25.9) [15.0, 39.7]	51	20 (39.2) [25.8, 53.9]	0.661 [0.375, 1.164]	0.543 [0.237, 1.242]	-13.3 [-33.0, 6.4]	0.210
Baseline eosinophils - High								0.694
< 300 cells/uL	33	8 (24.2) [11.1, 42.3]	34	13 (38.2) [22.2, 56.4]	0.634 [0.303, 1.328]	0.517 [0.180, 1.484]	-14.0 [-38.9, 10.9]	0.294
>= 300 cells/uL	32	8 (25.0) [11.5, 43.4]	31	15 (48.4) [30.2, 66.9]	0.517 [0.256, 1.042]	0.356 [0.122, 1.032]	-23.4 [-49.7, 2.9]	0.070

Subgroups presented for PT: Asthma

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO								0.069
< 25 ppb	39	11 (28.2) [15.0, 44.9]	30	9 (30.0) [14.7, 49.4]	0.940 [0.448, 1.973]	0.917 [0.322, 2.612]	-1.8 [-26.4, 22.8]	1.000
>= 25 ppb	27	5 (18.5) [6.3, 38.1]	34	19 (55.9) [37.9, 72.8]	0.331 [0.142, 0.772]	0.179 [0.055, 0.586]	-37.4 [-62.9, -11.8]	0.004 *
Baseline specific perennial FEIA status								0.450
All negative	27	7 (25.9) [11.1, 46.3]	29	16 (55.2) [35.7, 73.6]	0.470 [0.229, 0.963]	0.284 [0.092, 0.880]	-29.2 [-57.3, -1.2]	0.033 *
Any positive	34	8 (23.5) [10.7, 41.2]	33	11 (33.3) [18.0, 51.8]	0.706 [0.325, 1.532]	0.615 [0.210, 1.800]	-9.8 [-34.3, 14.7]	0.425
Total serum IgE								0.904
Low	23	7 (30.4) [13.2, 52.9]	14	9 (64.3) [35.1, 87.2]	0.473 [0.228, 0.983]	0.243 [0.059, 0.994]	-33.9 [-71.0, 3.3]	0.086
Normal	40	9 (22.5) [10.8, 38.5]	44	17 (38.6) [24.4, 54.5]	0.582 [0.294, 1.155]	0.461 [0.177, 1.203]	-16.1 [-37.9, 5.6]	0.156
High	3	0 (0.0) [0.0, 70.8]	7	2 (28.6) [3.7, 71.0]	0.400 + [0.025, 6.506]	0.314 + [0.011, 8.684]	-28.6 [-85.8, 28.7]	1.000
OCS at baseline								0.603
Yes	9	4 (44.4) [13.7, 78.8]	13	8 (61.5) [31.6, 86.1]	0.722 [0.309, 1.685]	0.500 [0.089, 2.807]	-17.1 [-68.4, 34.2]	0.666
No	57	12 (21.1) [11.4, 33.9]	52	20 (38.5) [25.3, 53.0]	0.547 [0.298, 1.006]	0.427 [0.183, 0.995]	-17.4 [-36.2, 1.4]	0.059

Subgroups presented for PT: Asthma

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSK: TEAEs during study period by SOC and PT and by key subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline								0.344
Yes	7	4 (57.1) [18.4, 90.1]	3	2 (66.7) [9.4, 99.2]	0.857 [0.307, 2.390]	0.667 [0.039, 11.285]	-9.5 [-98.1, 79.0]	1.000
No	59	12 (20.3) [11.0, 32.8]	62	26 (41.9) [29.5, 55.2]	0.485 [0.271, 0.870]	0.354 [0.157, 0.795]	-21.6 [-39.3, -3.9]	0.012 *
Tiotropium use at baseline		any N<10						NE
Yes	6	4 (66.7) [22.3, 95.7]	2	1 (50.0) [1.3, 98.7]				
No	60	12 (20.0) [10.8, 32.3]	63	27 (42.9) [30.5, 56.0]				
Montelukast/ Cromoglicic acid use at baseline								0.478
Yes	17	7 (41.2) [18.4, 67.1]	21	12 (57.1) [34.0, 78.2]	0.721 [0.366, 1.420]	0.525 [0.144, 1.919]	-16.0 [-52.8, 20.9]	0.515
No	49	9 (18.4) [8.8, 32.0]	44	16 (36.4) [22.4, 52.2]	0.505 [0.249, 1.025]	0.394 [0.152, 1.017]	-18.0 [-38.0, 2.0]	0.063

Subgroups presented for PT: Asthma

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSIP: Incidence of TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.405
White	60	41 (68.3) [55.0, 79.7]	58	38 (65.5) [51.9, 77.5]	1.043 [0.809, 1.345]	1.136 [0.527, 2.447]	2.8 [-15.9, 21.5]	0.845
Non-white	6	4 (66.7) [22.3, 95.7]	7	6 (85.7) [42.1, 99.6]	0.778 [0.409, 1.477]	0.333 [0.022, 5.027]	-19.0 [-80.3, 42.2]	0.559
Region (cat. P)								0.859
North America/Western EU	6	6 (100.0) [54.1, 100.0]	4	4 (100.0) [39.8, 100.0]	1.032 + [0.722, 1.475]	1.444 + [0.024, 87.163]	2.9 + [-46.8, 52.5]	NE
Rest of world	60	39 (65.0) [51.6, 76.9]	61	40 (65.6) [52.3, 77.3]	0.991 [0.764, 1.285]	0.975 [0.461, 2.061]	-0.6 [-19.2, 18.0]	1.000
Baseline eosinophils (cat. P)								0.151
< 250 cells/uL	30	19 (63.3) [43.9, 80.1]	29	22 (75.9) [56.5, 89.7]	0.835 [0.594, 1.174]	0.550 [0.178, 1.700]	-12.5 [-39.2, 14.1]	0.399
>= 250 cells/uL	36	26 (72.2) [54.8, 85.8]	36	22 (61.1) [43.5, 76.9]	1.182 [0.850, 1.644]	1.655 [0.615, 4.455]	11.1 [-13.3, 35.5]	0.454
Baseline FENO (cat. P)								0.233
< 24 ppb	38	28 (73.7) [56.9, 86.6]	30	19 (63.3) [43.9, 80.1]	1.163 [0.835, 1.622]	1.621 [0.575, 4.567]	10.4 [-14.8, 35.5]	0.432
>= 24 ppb	28	17 (60.7) [40.6, 78.5]	34	24 (70.6) [52.5, 84.9]	0.860 [0.595, 1.243]	0.644 [0.224, 1.855]	-9.9 [-36.8, 17.1]	0.434

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSIP: Incidence of TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.112
< 22.0 ppb	32	24 (75.0) [56.6, 88.5]	27	16 (59.3) [38.8, 77.6]	1.266 [0.873, 1.835]	2.063 [0.680, 6.251]	15.7 [-11.5, 43.0]	0.266
>= 22.0 ppb	34	21 (61.8) [43.6, 77.8]	37	27 (73.0) [55.9, 86.2]	0.846 [0.609, 1.176]	0.598 [0.220, 1.630]	-11.2 [-35.7, 13.3]	0.447
Baseline all FEIA status								0.238
All negative	25	20 (80.0) [59.3, 93.2]	22	15 (68.2) [45.1, 86.1]	1.173 [0.830, 1.659]	1.867 [0.494, 7.048]	11.8 [-17.4, 41.1]	0.505
Any positive	35	20 (57.1) [39.4, 73.7]	41	27 (65.9) [49.4, 79.9]	0.868 [0.604, 1.246]	0.691 [0.273, 1.752]	-8.7 [-33.3, 15.8]	0.484
Th2 status								0.171
Low	41	31 (75.6) [59.7, 87.6]	30	20 (66.7) [47.2, 82.7]	1.134 [0.834, 1.542]	1.550 [0.547, 4.391]	8.9 [-15.3, 33.2]	0.435
High	25	14 (56.0) [34.9, 75.6]	34	24 (70.6) [52.5, 84.9]	0.793 [0.527, 1.195]	0.530 [0.180, 1.563]	-14.6 [-42.8, 13.6]	0.282
Baseline Periostin								0.635
Low (< 20.9 ng/ml)	26	18 (69.2) [48.2, 85.7]	31	20 (64.5) [45.4, 80.8]	1.073 [0.744, 1.547]	1.238 [0.407, 3.760]	4.7 [-23.3, 32.7]	0.782
High (>= 20.9 ng/ml)	40	27 (67.5) [50.9, 81.4]	34	24 (70.6) [52.5, 84.9]	0.956 [0.705, 1.298]	0.865 [0.321, 2.331]	-3.1 [-26.9, 20.7]	0.806

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSIP: Incidence of TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.090
Yes	57	39 (68.4) [54.8, 80.1]	60	39 (65.0) [51.6, 76.9]	1.053 [0.815, 1.360]	1.167 [0.540, 2.520]	3.4 [-15.4, 22.2]	0.845
No	9	6 (66.7) [29.9, 92.5]	5	5 (100.0) [47.8, 100.0]	0.667 [0.420, 1.058]	0.169 + [0.007, 4.033]	-33.3 [-79.7, 13.0]	0.258
Maintenance OCS use at baseline								0.323
Yes	9	8 (88.9) [51.8, 99.7]	14	10 (71.4) [41.9, 91.6]	1.244 [0.831, 1.864]	3.200 [0.296, 34.588]	17.5 [-23.0, 57.9]	0.611
No	57	37 (64.9) [51.1, 77.1]	51	34 (66.7) [52.1, 79.2]	0.974 [0.742, 1.278]	0.925 [0.417, 2.052]	-1.8 [-21.5, 18.0]	1.000
No chronic OCS use and current post-BD FEV1 reversibility								0.867
Yes	51	34 (66.7) [52.1, 79.2]	49	32 (65.3) [50.4, 78.3]	1.021 [0.770, 1.353]	1.063 [0.464, 2.431]	1.4 [-19.2, 21.9]	1.000
No	15	11 (73.3) [44.9, 92.2]	16	12 (75.0) [47.6, 92.7]	0.978 [0.645, 1.482]	0.917 [0.183, 4.583]	-1.7 [-39.0, 35.6]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Respiratory, thoracic and mediastinal disorders									
Race (cat. P)								0.880	
White	60	15 (25.0) [14.7, 37.9]	58	23 (39.7) [27.0, 53.4]	0.630 [0.367, 1.083]	0.507 [0.231, 1.114]	-14.7 [-33.0, 3.7]	0.115	
Non-white	6	3 (50.0) [11.8, 88.2]	7	6 (85.7) [42.1, 99.6]	0.583 [0.248, 1.372]	0.167 [0.012, 2.368]	-35.7 [-98.9, 27.4]	0.266	
Region (cat. P)								0.292	
North America/Western EU	6	2 (33.3) [4.3, 77.7]	4	4 (100.0) [39.8, 100.0]	0.333 [0.108, 1.034]	0.062 + [0.002, 1.683]	-66.7 [-100.0, -8.1]	0.076	
Rest of world	60	16 (26.7) [16.1, 39.7]	61	25 (41.0) [28.6, 54.3]	0.651 [0.388, 1.091]	0.524 [0.243, 1.127]	-14.3 [-32.6, 4.0]	0.125	
Baseline eosinophils (cat. P)								0.943	
< 250 cells/uL	30	9 (30.0) [14.7, 49.4]	29	14 (48.3) [29.4, 67.5]	0.621 [0.320, 1.207]	0.459 [0.158, 1.336]	-18.3 [-46.2, 9.6]	0.187	
>= 250 cells/uL	36	9 (25.0) [12.1, 42.2]	36	15 (41.7) [25.5, 59.2]	0.600 [0.302, 1.191]	0.467 [0.171, 1.274]	-16.7 [-40.9, 7.5]	0.211	
Baseline FENO (cat. P)								0.035	i
< 24 ppb	38	13 (34.2) [19.6, 51.4]	30	10 (33.3) [17.3, 52.8]	1.026 [0.525, 2.008]	1.040 [0.378, 2.863]	0.9 [-24.7, 26.5]	1.000	
>= 24 ppb	28	5 (17.9) [6.1, 36.9]	34	19 (55.9) [37.9, 72.8]	0.320 [0.137, 0.747]	0.172 [0.053, 0.559]	-38.0 [-63.2, -12.9]	0.004	*

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAFL

	Tezepelumab		Placebo						
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. M)								0.021	i
< 22.0 ppb	32	12 (37.5) [21.1, 56.3]	27	9 (33.3) [16.5, 54.0]	1.125 [0.561, 2.257]	1.200 [0.410, 3.511]	4.2 [-23.7, 32.0]	0.790	
>= 22.0 ppb	34	6 (17.6) [6.8, 34.5]	37	20 (54.1) [36.9, 70.5]	0.326 [0.149, 0.715]	0.182 [0.061, 0.544]	-36.4 [-59.8, -13.0]	0.003	*
Baseline all FEIA status								0.814	
All negative	25	8 (32.0) [14.9, 53.5]	22	12 (54.5) [32.2, 75.6]	0.587 [0.295, 1.166]	0.392 [0.120, 1.286]	-22.5 [-54.5, 9.4]	0.148	
Any positive	35	9 (25.7) [12.5, 43.3]	41	16 (39.0) [24.2, 55.5]	0.659 [0.334, 1.302]	0.541 [0.202, 1.447]	-13.3 [-36.8, 10.1]	0.234	
Th2 status								0.449	
Low	41	11 (26.8) [14.2, 42.9]	30	16 (53.3) [34.3, 71.7]	0.503 [0.274, 0.922]	0.321 [0.119, 0.869]	-26.5 [-51.8, -1.2]	0.028	*
High	25	7 (28.0) [12.1, 49.4]	34	13 (38.2) [22.2, 56.4]	0.732 [0.342, 1.566]	0.628 [0.206, 1.914]	-10.2 [-37.7, 17.2]	0.579	
Baseline Periostin								0.509	
Low (< 20.9 ng/ml)	26	8 (30.8) [14.3, 51.8]	31	13 (41.9) [24.5, 60.9]	0.734 [0.361, 1.492]	0.615 [0.206, 1.842]	-11.2 [-39.5, 17.2]	0.422	
High (>= 20.9 ng/ml)	40	10 (25.0) [12.7, 41.2]	34	16 (47.1) [29.8, 64.9]	0.531 [0.279, 1.012]	0.375 [0.140, 1.002]	-22.1 [-46.3, 2.1]	0.055	

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.212
Yes	57	15 (26.3) [15.5, 39.7]	60	24 (40.0) [27.6, 53.5]	0.658 [0.386, 1.122]	0.536 [0.245, 1.173]	-13.7 [-32.3, 4.9]	0.169
No	9	3 (33.3) [7.5, 70.1]	5	5 (100.0) [47.8, 100.0]	0.333 [0.132, 0.840]	0.049 + [0.002, 1.169]	-66.7 [-100.0, -20.3]	0.031 *
Maintenance OCS use at baseline								0.847
Yes	9	4 (44.4) [13.7, 78.8]	14	9 (64.3) [35.1, 87.2]	0.691 [0.302, 1.583]	0.444 [0.080, 2.457]	-19.8 [-70.0, 30.3]	0.417
No	57	14 (24.6) [14.1, 37.8]	51	20 (39.2) [25.8, 53.9]	0.626 [0.355, 1.106]	0.505 [0.221, 1.151]	-14.7 [-34.0, 4.7]	0.146
No chronic OCS use and current post-BD FEV1 reversibility								0.477
Yes	51	13 (25.5) [14.3, 39.6]	49	18 (36.7) [23.4, 51.7]	0.694 [0.382, 1.259]	0.589 [0.250, 1.388]	-11.2 [-31.3, 8.8]	0.281
No	15	5 (33.3) [11.8, 61.6]	16	11 (68.8) [41.3, 89.0]	0.485 [0.220, 1.066]	0.227 [0.050, 1.025]	-35.4 [-74.8, 4.0]	0.076

Subgroups presented for SOC: Respiratory, thoracic and mediastinal disorders

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Asthma								
Race (cat. P)								0.968
White	60	13 (21.7) [12.1, 34.2]	58	22 (37.9) [25.5, 51.6]	0.571 [0.319, 1.023]	0.453 [0.201, 1.019]	-16.3 [-34.2, 1.7]	0.070
Non-white	6	3 (50.0) [11.8, 88.2]	7	6 (85.7) [42.1, 99.6]	0.583 [0.248, 1.372]	0.167 [0.012, 2.368]	-35.7 [-98.9, 27.4]	0.266
Region (cat. P)								0.370
North America/Western EU	6	2 (33.3) [4.3, 77.7]	4	4 (100.0) [39.8, 100.0]	0.333 [0.108, 1.034]	0.062 + [0.002, 1.683]	-66.7 [-100.0, -8.1]	0.076
Rest of world	60	14 (23.3) [13.4, 36.0]	61	24 (39.3) [27.1, 52.7]	0.593 [0.341, 1.033]	0.469 [0.213, 1.032]	-16.0 [-33.9, 1.9]	0.078
Baseline eosinophils (cat. P)								0.786
< 250 cells/uL	30	7 (23.3) [9.9, 42.3]	29	13 (44.8) [26.4, 64.3]	0.521 [0.242, 1.118]	0.375 [0.122, 1.146]	-21.5 [-48.5, 5.5]	0.103
>= 250 cells/uL	36	9 (25.0) [12.1, 42.2]	36	15 (41.7) [25.5, 59.2]	0.600 [0.302, 1.191]	0.467 [0.171, 1.274]	-16.7 [-40.9, 7.5]	0.211
Baseline FENO (cat. P)								0.054
< 24 ppb	38	11 (28.9) [15.4, 45.9]	30	9 (30.0) [14.7, 49.4]	0.965 [0.461, 2.021]	0.951 [0.333, 2.715]	-1.1 [-25.9, 23.8]	1.000
>= 24 ppb	28	5 (17.9) [6.1, 36.9]	34	19 (55.9) [37.9, 72.8]	0.320 [0.137, 0.747]	0.172 [0.053, 0.559]	-38.0 [-63.2, -12.9]	0.004 *

Subgroups presented for PT: Asthma

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAFL

	Tezepelumab		Placebo						
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline FENO (cat. M)								0.037	i
< 22.0 ppb	32	10 (31.3) [16.1, 50.0]	27	8 (29.6) [13.8, 50.2]	1.055 [0.485, 2.291]	1.080 [0.354, 3.289]	1.6 [-25.3, 28.6]	1.000	
>= 22.0 ppb	34	6 (17.6) [6.8, 34.5]	37	20 (54.1) [36.9, 70.5]	0.326 [0.149, 0.715]	0.182 [0.061, 0.544]	-36.4 [-59.8, -13.0]	0.003	*
Baseline all FEIA status								0.710	
All negative	25	7 (28.0) [12.1, 49.4]	22	12 (54.5) [32.2, 75.6]	0.513 [0.246, 1.071]	0.324 [0.097, 1.088]	-26.5 [-58.1, 5.0]	0.081	
Any positive	35	8 (22.9) [10.4, 40.1]	41	15 (36.6) [22.1, 53.1]	0.625 [0.301, 1.296]	0.514 [0.186, 1.414]	-13.7 [-36.6, 9.2]	0.220	
Th2 status								0.209	
Low	41	9 (22.0) [10.6, 37.6]	30	16 (53.3) [34.3, 71.7]	0.412 [0.211, 0.802]	0.246 [0.088, 0.689]	-31.4 [-56.2, -6.6]	0.011	*
High	25	7 (28.0) [12.1, 49.4]	34	12 (35.3) [19.7, 53.5]	0.793 [0.365, 1.724]	0.713 [0.232, 2.188]	-7.3 [-34.6, 20.0]	0.587	
Baseline Periostin								0.475	
Low (< 20.9 ng/ml)	26	7 (26.9) [11.6, 47.8]	31	12 (38.7) [21.8, 57.8]	0.696 [0.321, 1.506]	0.583 [0.189, 1.803]	-11.8 [-39.5, 15.9]	0.407	
High (>= 20.9 ng/ml)	40	9 (22.5) [10.8, 38.5]	34	16 (47.1) [29.8, 64.9]	0.478 [0.243, 0.941]	0.327 [0.120, 0.890]	-24.6 [-48.5, -0.6]	0.030	*

Subgroups presented for PT: Asthma

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2A_SLSSP: TEAEs during study period by SOC and PT and by study specific subgroups
DSAFL

	Tezepelumab		Placebo						
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility								0.297	
Yes	57	13 (22.8) [12.7, 35.8]	60	23 (38.3) [26.1, 51.8]	0.595 [0.335, 1.058]	0.475 [0.212, 1.067]	-15.5 [-33.7, 2.6]	0.075	
No	9	3 (33.3) [7.5, 70.1]	5	5 (100.0) [47.8, 100.0]	0.333 [0.132, 0.840]	0.049 + [0.002, 1.169]	-66.7 [-100.0, -20.3]	0.031	*
Maintenance OCS use at baseline								0.702	
Yes	9	4 (44.4) [13.7, 78.8]	14	9 (64.3) [35.1, 87.2]	0.691 [0.302, 1.583]	0.444 [0.080, 2.457]	-19.8 [-70.0, 30.3]	0.417	
No	57	12 (21.1) [11.4, 33.9]	51	19 (37.3) [24.1, 51.9]	0.565 [0.305, 1.046]	0.449 [0.191, 1.054]	-16.2 [-35.0, 2.6]	0.088	
No chronic OCS use and current post-BD FEV1 reversibility								0.633	
Yes	51	11 (21.6) [11.3, 35.3]	49	17 (34.7) [21.7, 49.6]	0.622 [0.325, 1.190]	0.518 [0.213, 1.260]	-13.1 [-32.6, 6.3]	0.183	
No	15	5 (33.3) [11.8, 61.6]	16	11 (68.8) [41.3, 89.0]	0.485 [0.220, 1.066]	0.227 [0.050, 1.025]	-35.4 [-74.8, 4.0]	0.076	

Subgroups presented for PT: Asthma

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. SOC = system organ class. PT = preferred term.
Only significant SOC or PTs were presented. 95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SLMI0: Incidence of non-severe TEAEs during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-severe TEAEs during study period	66	43 (65.2) [52.4, 76.5]	65	43 (66.2) [53.4, 77.4]	0.985 [0.769, 1.262]	0.957 [0.465, 1.968]	-1.0 [-18.8, 16.8]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AN_SLSIK: Incidence of non-severe TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
Non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.213
Male	19	11 (57.9) [33.5, 79.7]	20	15 (75.0) [50.9, 91.3]	0.772 [0.488, 1.222]	0.458 [0.117, 1.789]	-17.1 [-51.4, 17.2]	0.320
Female	47	32 (68.1) [52.9, 80.9]	45	28 (62.2) [46.5, 76.2]	1.094 [0.810, 1.477]	1.295 [0.548, 3.060]	5.9 [-15.8, 27.5]	0.662
Age								0.646
< 65 years	57	36 (63.2) [49.3, 75.6]	55	36 (65.5) [51.4, 77.8]	0.965 [0.732, 1.272]	0.905 [0.417, 1.961]	-2.3 [-21.8, 17.2]	0.845
>= 65 years	9	7 (77.8) [40.0, 97.2]	10	7 (70.0) [34.8, 93.3]	1.111 [0.651, 1.898]	1.500 [0.189, 11.927]	7.8 [-42.1, 57.6]	1.000
Exacerbations in the year before study								0.601
<= 2	44	25 (56.8) [41.0, 71.7]	45	25 (55.6) [40.0, 70.4]	1.023 [0.709, 1.476]	1.053 [0.456, 2.432]	1.3 [-21.6, 24.1]	1.000
> 2	22	18 (81.8) [59.7, 94.8]	20	18 (90.0) [68.3, 98.8]	0.909 [0.711, 1.162]	0.500 [0.081, 3.082]	-8.2 [-33.8, 17.4]	0.665

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SLSIK: Incidence of non-severe TEAEs during study period by key subgroups
DSAFL

Non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	60	39 (65.0) [51.6, 76.9]	58	37 (63.8) [50.1, 76.0]				
Black or African American	2	2 (100.0) [15.8, 100.0]	2	2 (100.0) [15.8, 100.0]				
Asian	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Other	1	0 (0.0) [0.0, 97.5]	2	2 (100.0) [15.8, 100.0]				
Region		N<10 any level						NE
Europe	40	25 (62.5) [45.8, 77.3]	36	22 (61.1) [43.5, 76.9]				
America	6	6 (100.0) [54.1, 100.0]	4	4 (100.0) [39.8, 100.0]				
Asia/Pacific	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Rest of the world	17	10 (58.8) [32.9, 81.6]	22	15 (68.2) [45.1, 86.1]				
BMI								0.419
18.5 - < 25.0 kg/m**2	15	10 (66.7) [38.4, 88.2]	21	14 (66.7) [43.0, 85.4]	1.000 [0.626, 1.598]	1.000 [0.245, 4.078]	0.0 [-36.9, 36.9]	1.000
25.0 - < 30.0 kg/m**2	24	12 (50.0) [29.1, 70.9]	20	13 (65.0) [40.8, 84.6]	0.769 [0.460, 1.285]	0.538 [0.159, 1.821]	-15.0 [-48.5, 18.5]	0.372
>= 30.0 kg/m**2	27	21 (77.8) [57.7, 91.4]	24	16 (66.7) [44.7, 84.4]	1.167 [0.824, 1.651]	1.750 [0.505, 6.062]	11.1 [-17.4, 39.6]	0.531

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SLSIK: Incidence of non-severe TEAEs during study period by key subgroups
DSAFL

Non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.876
< 150 cells/uL	11	8 (72.7) [39.0, 94.0]	14	10 (71.4) [41.9, 91.6]	1.018 [0.623, 1.663]	1.067 [0.183, 6.213]	1.3 [-42.2, 44.8]	1.000
>= 150 cells/uL	54	34 (63.0) [48.7, 75.7]	51	33 (64.7) [50.1, 77.6]	0.973 [0.730, 1.298]	0.927 [0.418, 2.057]	-1.7 [-22.0, 18.5]	1.000
Baseline eosinophils - High								0.666
< 300 cells/uL	33	22 (66.7) [48.2, 82.0]	34	22 (64.7) [46.5, 80.3]	1.030 [0.729, 1.456]	1.091 [0.398, 2.993]	2.0 [-23.8, 27.7]	1.000
>= 300 cells/uL	32	20 (62.5) [43.7, 78.9]	31	21 (67.7) [48.6, 83.3]	0.923 [0.642, 1.325]	0.794 [0.281, 2.243]	-5.2 [-31.9, 21.4]	0.793
Baseline FENO								0.233
< 25 ppb	39	28 (71.8) [55.1, 85.0]	30	19 (63.3) [43.9, 80.1]	1.134 [0.810, 1.586]	1.474 [0.532, 4.082]	8.5 [-16.8, 33.7]	0.603
>= 25 ppb	27	15 (55.6) [35.3, 74.5]	34	23 (67.6) [49.5, 82.6]	0.821 [0.545, 1.237]	0.598 [0.210, 1.700]	-12.1 [-39.9, 15.7]	0.427

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SLSIK: Incidence of non-severe TEAEs during study period by key subgroups
DSAFL

Non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.433
All negative	27	21 (77.8) [57.7, 91.4]	29	21 (72.4) [52.8, 87.3]	1.074 [0.794, 1.453]	1.333 [0.394, 4.512]	5.4 [-20.8, 31.5]	0.761
Any positive	34	18 (52.9) [35.1, 70.2]	33	20 (60.6) [42.1, 77.1]	0.874 [0.574, 1.329]	0.731 [0.277, 1.929]	-7.7 [-34.3, 19.0]	0.624
Total serum IgE								0.608
Low	23	19 (82.6) [61.2, 95.0]	14	11 (78.6) [49.2, 95.3]	1.051 [0.755, 1.465]	1.295 [0.244, 6.889]	4.0 [-28.2, 36.3]	1.000
Normal	40	23 (57.5) [40.9, 73.0]	44	27 (61.4) [45.5, 75.6]	0.937 [0.657, 1.336]	0.852 [0.356, 2.038]	-3.9 [-27.3, 19.5]	0.825
High	3	1 (33.3) [0.8, 90.6]	7	5 (71.4) [29.0, 96.3]	0.467 [0.088, 2.473]	0.200 [0.011, 3.661]	-38.1 [-100.0, 48.7]	0.500
OCS at baseline								0.607
Yes	9	7 (77.8) [40.0, 97.2]	13	9 (69.2) [38.6, 90.9]	1.123 [0.679, 1.858]	1.556 [0.218, 11.086]	8.5 [-37.8, 54.9]	1.000
No	57	36 (63.2) [49.3, 75.6]	52	34 (65.4) [50.9, 78.0]	0.966 [0.730, 1.278]	0.908 [0.414, 1.990]	-2.2 [-22.1, 17.6]	0.844

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SLSIK: Incidence of non-severe TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
Non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline								0.846
Yes	7	5 (71.4) [29.0, 96.3]	3	2 (66.7) [9.4, 99.2]	1.071 [0.424, 2.708]	1.250 [0.068, 22.879]	4.8 [-82.0, 91.5]	1.000
No	59	38 (64.4) [50.9, 76.4]	62	41 (66.1) [53.0, 77.7]	0.974 [0.751, 1.263]	0.927 [0.438, 1.960]	-1.7 [-20.3, 16.9]	0.851
Tiotropium use at baseline	N<10 any level							NE
Yes	6	4 (66.7) [22.3, 95.7]	2	1 (50.0) [1.3, 98.7]				
No	60	39 (65.0) [51.6, 76.9]	63	42 (66.7) [53.7, 78.0]				
Montelukast/ Cromoglicic acid use at baseline								0.701
Yes	17	13 (76.5) [50.1, 93.2]	21	17 (81.0) [58.1, 94.6]	0.945 [0.675, 1.321]	0.765 [0.160, 3.649]	-4.5 [-36.0, 27.1]	1.000
No	49	30 (61.2) [46.2, 74.8]	44	26 (59.1) [43.2, 73.7]	1.036 [0.744, 1.444]	1.093 [0.476, 2.511]	2.1 [-20.0, 24.2]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SLSIP: Incidence of non-severe TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
Non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.447
White	60	39 (65.0) [51.6, 76.9]	58	37 (63.8) [50.1, 76.0]	1.019 [0.779, 1.333]	1.054 [0.496, 2.240]	1.2 [-17.8, 20.2]	1.000
Non-white	6	4 (66.7) [22.3, 95.7]	7	6 (85.7) [42.1, 99.6]	0.778 [0.409, 1.477]	0.333 [0.022, 5.027]	-19.0 [-80.3, 42.2]	0.559
Region (cat. P)								0.769
North America/Western EU	6	6 (100.0) [54.1, 100.0]	4	4 (100.0) [39.8, 100.0]	1.032 + [0.722, 1.475]	1.444 + [0.024, 87.163]	2.9 + [-46.8, 52.5]	NE
Rest of world	60	37 (61.7) [48.2, 73.9]	61	39 (63.9) [50.6, 75.8]	0.965 [0.733, 1.269]	0.907 [0.434, 1.897]	-2.3 [-21.1, 16.6]	0.852
Baseline eosinophils (cat. P)								0.109
< 250 cells/uL	30	18 (60.0) [40.6, 77.3]	29	22 (75.9) [56.5, 89.7]	0.791 [0.553, 1.130]	0.477 [0.156, 1.464]	-15.9 [-42.7, 11.0]	0.267
>= 250 cells/uL	36	25 (69.4) [51.9, 83.7]	36	21 (58.3) [40.8, 74.5]	1.190 [0.838, 1.691]	1.623 [0.615, 4.285]	11.1 [-13.7, 35.9]	0.462
Baseline FENO (cat. P)								0.286
< 24 ppb	38	27 (71.1) [54.1, 84.6]	30	19 (63.3) [43.9, 80.1]	1.122 [0.799, 1.576]	1.421 [0.512, 3.946]	7.7 [-17.7, 33.2]	0.604
>= 24 ppb	28	16 (57.1) [37.2, 75.5]	34	23 (67.6) [49.5, 82.6]	0.845 [0.568, 1.255]	0.638 [0.226, 1.800]	-10.5 [-37.9, 16.9]	0.438

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SLSIP: Incidence of non-severe TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
Non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.160
< 22.0 ppb	32	23 (71.9) [53.3, 86.3]	27	16 (59.3) [38.8, 77.6]	1.213 [0.829, 1.774]	1.757 [0.592, 5.214]	12.6 [-15.0, 40.2]	0.409
>= 22.0 ppb	34	20 (58.8) [40.7, 75.4]	37	26 (70.3) [53.0, 84.1]	0.837 [0.589, 1.189]	0.604 [0.226, 1.613]	-11.4 [-36.4, 13.5]	0.333
Baseline all FEIA status								0.083
All negative	25	20 (80.0) [59.3, 93.2]	22	14 (63.6) [40.7, 82.8]	1.257 [0.867, 1.823]	2.286 [0.617, 8.467]	16.4 [-13.4, 46.1]	0.328
Any positive	35	18 (51.4) [34.0, 68.6]	41	27 (65.9) [49.4, 79.9]	0.781 [0.529, 1.154]	0.549 [0.218, 1.385]	-14.4 [-39.1, 10.2]	0.245
Th2 status								0.106
Low	41	30 (73.2) [57.1, 85.8]	30	19 (63.3) [43.9, 80.1]	1.155 [0.831, 1.606]	1.579 [0.573, 4.354]	9.8 [-15.0, 34.7]	0.441
High	25	13 (52.0) [31.3, 72.2]	34	24 (70.6) [52.5, 84.9]	0.737 [0.477, 1.138]	0.451 [0.154, 1.325]	-18.6 [-46.9, 9.7]	0.179
Baseline Periostin								0.835
Low (< 20.9 ng/ml)	26	17 (65.4) [44.3, 82.8]	31	20 (64.5) [45.4, 80.8]	1.013 [0.691, 1.486]	1.039 [0.348, 3.098]	0.9 [-27.5, 29.3]	1.000
High (>= 20.9 ng/ml)	40	26 (65.0) [48.3, 79.4]	34	23 (67.6) [49.5, 82.6]	0.961 [0.694, 1.330]	0.888 [0.337, 2.340]	-2.6 [-26.9, 21.7]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AN_SLSIP: Incidence of non-severe TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
Non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.051
Yes	57	38 (66.7) [52.9, 78.6]	60	38 (63.3) [49.9, 75.4]	1.053 [0.807, 1.373]	1.158 [0.541, 2.478]	3.3 [-15.7, 22.3]	0.846
No	9	5 (55.6) [21.2, 86.3]	5	5 (100.0) [47.8, 100.0]	0.556 [0.310, 0.997]	0.111 + [0.005, 2.597]	-44.4 [-92.5, 3.6]	0.221
Maintenance OCS use at baseline								0.701
Yes	9	7 (77.8) [40.0, 97.2]	14	10 (71.4) [41.9, 91.6]	1.089 [0.673, 1.762]	1.400 [0.199, 9.869]	6.3 [-38.8, 51.5]	1.000
No	57	36 (63.2) [49.3, 75.6]	51	33 (64.7) [50.1, 77.6]	0.976 [0.735, 1.296]	0.935 [0.426, 2.054]	-1.5 [-21.5, 18.4]	1.000
No chronic OCS use and current post-BD FEV1 reversibility								0.612
Yes	51	33 (64.7) [50.1, 77.6]	49	31 (63.3) [48.3, 76.6]	1.023 [0.762, 1.373]	1.065 [0.470, 2.409]	1.4 [-19.4, 22.3]	1.000
No	15	10 (66.7) [38.4, 88.2]	16	12 (75.0) [47.6, 92.7]	0.889 [0.563, 1.403]	0.667 [0.140, 3.172]	-8.3 [-46.7, 30.1]	0.704

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SLMI0: Incidence of severe TEAEs during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Severe TEAEs during study period	66	18 (27.3) [17.0, 39.6]	65	16 (24.6) [14.8, 36.9]	1.108 [0.620, 1.979]	1.148 [0.525, 2.511]	2.7 [-13.9, 19.2]	0.842

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AC_SLMS0: Severe TEAEs during study period by SOC and PT
DSAFL

	Tezepelumab		Placebo					
Severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Infections and infestations	66	2 (3.0) [0.4, 10.5]	65	8 (12.3) [5.5, 22.8]	0.246 [0.054, 1.116]	0.223 [0.045, 1.092]	-9.3 [-19.8, 1.2]	0.055
SOC: Respiratory, thoracic and mediastinal disorders	66	11 (16.7) [8.6, 27.9]	65	15 (23.1) [13.5, 35.2]	0.722 [0.359, 1.452]	0.667 [0.280, 1.587]	-6.4 [-21.6, 8.7]	0.388
Asthma	66	10 (15.2) [7.5, 26.1]	65	15 (23.1) [13.5, 35.2]	0.657 [0.319, 1.353]	0.595 [0.245, 1.444]	-7.9 [-22.9, 7.0]	0.274

Note: DSAFL = Dossier Label Safety Set. Only events are displayed with an incidence of at least 5 percent in a treatment group.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AC_SLSIK: Incidence of severe TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
Severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.727
Male	19	5 (26.3) [9.1, 51.2]	20	4 (20.0) [5.7, 43.7]	1.316 [0.414, 4.177]	1.429 [0.319, 6.388]	6.3 [-25.3, 37.9]	0.716
Female	47	13 (27.7) [15.6, 42.6]	45	12 (26.7) [14.6, 41.9]	1.037 [0.531, 2.026]	1.051 [0.419, 2.636]	1.0 [-19.4, 21.3]	1.000
Age								0.998
< 65 years	57	15 (26.3) [15.5, 39.7]	55	13 (23.6) [13.2, 37.0]	1.113 [0.585, 2.119]	1.154 [0.490, 2.719]	2.7 [-15.1, 20.5]	0.829
>= 65 years	9	3 (33.3) [7.5, 70.1]	10	3 (30.0) [6.7, 65.2]	1.111 [0.296, 4.171]	1.167 [0.168, 8.090]	3.3 [-49.1, 55.8]	1.000
Exacerbations in the year before study								0.287
<= 2	44	9 (20.5) [9.8, 35.3]	45	6 (13.3) [5.1, 26.8]	1.534 [0.596, 3.950]	1.671 [0.540, 5.171]	7.1 [-10.6, 24.9]	0.409
> 2	22	9 (40.9) [20.7, 63.6]	20	10 (50.0) [27.2, 72.8]	0.818 [0.420, 1.593]	0.692 [0.204, 2.347]	-9.1 [-43.9, 25.7]	0.757

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SLSIK: Incidence of severe TEAEs during study period by key subgroups
DSAFL

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	60	15 (25.0) [14.7, 37.9]	58	13 (22.4) [12.5, 35.3]				
Black or African American	2	1 (50.0) [1.3, 98.7]	2	1 (50.0) [1.3, 98.7]				
Asian	3	2 (66.7) [9.4, 99.2]	3	0 (0.0) [0.0, 70.8]				
Other	1	0 (0.0) [0.0, 97.5]	2	2 (100.0) [15.8, 100.0]				
Region		N<10 any level						NE
Europe	40	11 (27.5) [14.6, 43.9]	36	10 (27.8) [14.2, 45.2]				
America	6	2 (33.3) [4.3, 77.7]	4	1 (25.0) [0.6, 80.6]				
Asia/Pacific	3	2 (66.7) [9.4, 99.2]	3	0 (0.0) [0.0, 70.8]				
Rest of the world	17	3 (17.6) [3.8, 43.4]	22	5 (22.7) [7.8, 45.4]				
BMI								0.833
18.5 - < 25.0 kg/m**2	15	5 (33.3) [11.8, 61.6]	21	6 (28.6) [11.3, 52.2]	1.167 [0.436, 3.123]	1.250 [0.299, 5.230]	4.8 [-31.7, 41.2]	1.000
25.0 - < 30.0 kg/m**2	24	4 (16.7) [4.7, 37.4]	20	4 (20.0) [5.7, 43.7]	0.833 [0.238, 2.916]	0.800 [0.173, 3.709]	-3.3 [-30.9, 24.3]	1.000
>= 30.0 kg/m**2	27	9 (33.3) [16.5, 54.0]	24	6 (25.0) [9.8, 46.7]	1.333 [0.556, 3.197]	1.500 [0.442, 5.092]	8.3 [-20.4, 37.1]	0.554

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SLSIK: Incidence of severe TEAEs during study period by key subgroups
DSAFL

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.415
< 150 cells/uL	11	6 (54.5) [23.4, 83.3]	14	5 (35.7) [12.8, 64.9]	1.527 [0.630, 3.704]	2.160 [0.430, 10.845]	18.8 [-28.0, 65.6]	0.435
>= 150 cells/uL	54	11 (20.4) [10.6, 33.5]	51	11 (21.6) [11.3, 35.3]	0.944 [0.449, 1.985]	0.930 [0.363, 2.382]	-1.2 [-18.7, 16.3]	1.000
Baseline eosinophils - High								0.612
< 300 cells/uL	33	8 (24.2) [11.1, 42.3]	34	9 (26.5) [12.9, 44.4]	0.916 [0.402, 2.086]	0.889 [0.295, 2.676]	-2.2 [-26.0, 21.6]	1.000
>= 300 cells/uL	32	9 (28.1) [13.7, 46.7]	31	7 (22.6) [9.6, 41.1]	1.246 [0.530, 2.930]	1.342 [0.428, 4.201]	5.5 [-19.1, 30.2]	0.774
Baseline FENO								0.085
< 25 ppb	39	13 (33.3) [19.1, 50.2]	30	5 (16.7) [5.6, 34.7]	2.000 [0.801, 4.994]	2.500 [0.777, 8.042]	16.7 [-6.2, 39.5]	0.168
>= 25 ppb	27	5 (18.5) [6.3, 38.1]	34	10 (29.4) [15.1, 47.5]	0.630 [0.244, 1.623]	0.545 [0.161, 1.847]	-10.9 [-35.4, 13.6]	0.382

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SLSIK: Incidence of severe TEAEs during study period by key subgroups
DSAFL

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.290
All negative	27	7 (25.9) [11.1, 46.3]	29	9 (31.0) [15.3, 50.8]	0.835 [0.362, 1.930]	0.778 [0.242, 2.496]	-5.1 [-32.3, 22.1]	0.771
Any positive	34	10 (29.4) [15.1, 47.5]	33	6 (18.2) [7.0, 35.5]	1.618 [0.663, 3.946]	1.875 [0.593, 5.932]	11.2 [-11.9, 34.4]	0.392
Total serum IgE								0.358
Low	23	7 (30.4) [13.2, 52.9]	14	6 (42.9) [17.7, 71.1]	0.710 [0.299, 1.686]	0.583 [0.146, 2.323]	-12.4 [-50.2, 25.3]	0.495
Normal	40	10 (25.0) [12.7, 41.2]	44	10 (22.7) [11.5, 37.8]	1.100 [0.512, 2.363]	1.133 [0.415, 3.095]	2.3 [-18.4, 22.9]	1.000
High	3	1 (33.3) [0.8, 90.6]	7	0 (0.0) [0.0, 41.0]	6.000 + [0.309, 116.606]	9.000 + [0.270, 299.860]	33.3 [-43.8, 100.0]	0.300
OCS at baseline								0.344
Yes	9	4 (44.4) [13.7, 78.8]	13	3 (23.1) [5.0, 53.8]	1.926 [0.562, 6.604]	2.667 [0.423, 16.826]	21.4 [-27.8, 70.5]	0.376
No	57	14 (24.6) [14.1, 37.8]	52	13 (25.0) [14.0, 38.9]	0.982 [0.510, 1.891]	0.977 [0.409, 2.333]	-0.4 [-18.5, 17.6]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SLSIK: Incidence of severe TEAEs during study period by key subgroups
DSAFL

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline								0.551
Yes	7	4 (57.1) [18.4, 90.1]	3	1 (33.3) [0.8, 90.6]	1.714 [0.306, 9.613]	2.667 [0.158, 45.141]	23.8 [-64.7, 100.0]	1.000
No	59	14 (23.7) [13.6, 36.6]	62	15 (24.2) [14.2, 36.7]	0.981 [0.520, 1.851]	0.975 [0.423, 2.247]	-0.5 [-17.3, 16.4]	1.000
Tiotropium use at baseline		N<10 any level						NE
Yes	6	4 (66.7) [22.3, 95.7]	2	1 (50.0) [1.3, 98.7]				
No	60	14 (23.3) [13.4, 36.0]	63	15 (23.8) [14.0, 36.2]				
Montelukast/ Cromoglicic acid use at baseline								0.509
Yes	17	7 (41.2) [18.4, 67.1]	21	9 (42.9) [21.8, 66.0]	0.961 [0.453, 2.040]	0.933 [0.255, 3.411]	-1.7 [-38.6, 35.2]	1.000
No	49	11 (22.4) [11.8, 36.6]	44	7 (15.9) [6.6, 30.1]	1.411 [0.600, 3.320]	1.530 [0.535, 4.373]	6.5 [-11.5, 24.6]	0.446

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SLSIP: Incidence of severe TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
Severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.948
White	60	15 (25.0) [14.7, 37.9]	58	13 (22.4) [12.5, 35.3]	1.115 [0.583, 2.135]	1.154 [0.493, 2.699]	2.6 [-14.4, 19.6]	0.830
Non-white	6	3 (50.0) [11.8, 88.2]	7	3 (42.9) [9.9, 81.6]	1.167 [0.362, 3.764]	1.333 [0.149, 11.929]	7.1 [-62.6, 76.9]	1.000
Region (cat. P)								0.849
North America/Western EU	6	2 (33.3) [4.3, 77.7]	4	1 (25.0) [0.6, 80.6]	1.333 [0.173, 10.254]	1.500 [0.089, 25.392]	8.3 [-69.3, 85.9]	1.000
Rest of world	60	16 (26.7) [16.1, 39.7]	61	15 (24.6) [14.5, 37.3]	1.084 [0.591, 1.991]	1.115 [0.493, 2.524]	2.1 [-15.1, 19.3]	0.837
Baseline eosinophils (cat. P)								0.992
< 250 cells/uL	30	8 (26.7) [12.3, 45.9]	29	7 (24.1) [10.3, 43.5]	1.105 [0.460, 2.654]	1.143 [0.353, 3.697]	2.5 [-23.1, 28.1]	1.000
>= 250 cells/uL	36	10 (27.8) [14.2, 45.2]	36	9 (25.0) [12.1, 42.2]	1.111 [0.513, 2.407]	1.154 [0.404, 3.295]	2.8 [-20.4, 25.9]	1.000
Baseline FENO (cat. P)								0.070
< 24 ppb	38	13 (34.2) [19.6, 51.4]	30	5 (16.7) [5.6, 34.7]	2.053 [0.823, 5.118]	2.600 [0.806, 8.385]	17.5 [-5.6, 40.7]	0.166
>= 24 ppb	28	5 (17.9) [6.1, 36.9]	34	10 (29.4) [15.1, 47.5]	0.607 [0.235, 1.570]	0.522 [0.155, 1.761]	-11.6 [-35.7, 12.6]	0.377

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SLSIP: Incidence of severe TEAEs during study period by study specific subgroups
DSAFL

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.083
< 22.0 ppb	32	12 (37.5) [21.1, 56.3]	27	5 (18.5) [6.3, 38.1]	2.025 [0.816, 5.025]	2.640 [0.790, 8.820]	19.0 [-6.7, 44.7]	0.152
>= 22.0 ppb	34	6 (17.6) [6.8, 34.5]	37	10 (27.0) [13.8, 44.1]	0.653 [0.266, 1.604]	0.579 [0.185, 1.812]	-9.4 [-31.4, 12.7]	0.403
Baseline all FEIA status								0.139
All negative	25	6 (24.0) [9.4, 45.1]	22	8 (36.4) [17.2, 59.3]	0.660 [0.271, 1.607]	0.553 [0.156, 1.956]	-12.4 [-42.8, 18.1]	0.524
Any positive	35	10 (28.6) [14.6, 46.3]	41	7 (17.1) [7.2, 32.1]	1.673 [0.712, 3.931]	1.943 [0.650, 5.809]	11.5 [-10.0, 33.0]	0.276
Th2 status								0.056
Low	41	11 (26.8) [14.2, 42.9]	30	12 (40.0) [22.7, 59.4]	0.671 [0.344, 1.309]	0.550 [0.201, 1.503]	-13.2 [-38.2, 11.9]	0.307
High	25	7 (28.0) [12.1, 49.4]	34	4 (11.8) [3.3, 27.5]	2.380 [0.781, 7.256]	2.917 [0.748, 11.368]	16.2 [-7.9, 40.4]	0.176
Baseline Periostin								0.803
Low (< 20.9 ng/ml)	26	6 (23.1) [9.0, 43.6]	31	6 (19.4) [7.5, 37.5]	1.192 [0.437, 3.255]	1.250 [0.349, 4.474]	3.7 [-21.2, 28.6]	0.755
High (>= 20.9 ng/ml)	40	12 (30.0) [16.6, 46.5]	34	10 (29.4) [15.1, 47.5]	1.020 [0.505, 2.062]	1.029 [0.378, 2.798]	0.6 [-23.0, 24.2]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AC_SLSIP: Incidence of severe TEAEs during study period by study specific subgroups
DSAFL

Severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility								0.013	i
Yes	57	15 (26.3) [15.5, 39.7]	60	11 (18.3) [9.5, 30.4]	1.435 [0.721, 2.857]	1.591 [0.660, 3.837]	8.0 [-8.8, 24.7]	0.375	
No	9	3 (33.3) [7.5, 70.1]	5	5 (100.0) [47.8, 100.0]	0.333 [0.132, 0.840]	0.049 + [0.002, 1.169]	-66.7 [-100.0, -20.3]	0.031	*
Maintenance OCS use at baseline								0.545	
Yes	9	4 (44.4) [13.7, 78.8]	14	4 (28.6) [8.4, 58.1]	1.556 [0.516, 4.693]	2.000 [0.346, 11.544]	15.9 [-33.4, 65.2]	0.657	
No	57	14 (24.6) [14.1, 37.8]	51	12 (23.5) [12.8, 37.5]	1.044 [0.533, 2.044]	1.058 [0.437, 2.563]	1.0 [-17.0, 19.0]	1.000	
No chronic OCS use and current post-BD FEV1 reversibility								0.578	
Yes	51	13 (25.5) [14.3, 39.6]	49	10 (20.4) [10.2, 34.3]	1.249 [0.605, 2.579]	1.334 [0.522, 3.408]	5.1 [-13.4, 23.5]	0.637	
No	15	5 (33.3) [11.8, 61.6]	16	6 (37.5) [15.2, 64.6]	0.889 [0.342, 2.310]	0.833 [0.191, 3.644]	-4.2 [-44.3, 35.9]	1.000	

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SLMI0: Incidence of serious TEAEs during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Serious TEAEs during study period	66	8 (12.1) [5.4, 22.5]	65	14 (21.5) [12.3, 33.5]	0.563 [0.253, 1.250]	0.502 [0.195, 1.295]	-9.4 [-23.7, 4.8]	0.168

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AS_SLMS0: Serious TEAEs during study period by SOC and PT
DSAFL

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Infections and infestations	66	0 (0.0) [0.0, 5.4]	65	4 (6.2) [1.7, 15.0]	0.109 + [0.006, 1.993]	0.103 + [0.005, 1.948]	-6.2 [-13.5, 1.2]	0.058
SOC: Respiratory, thoracic and mediastinal disorders	66	4 (6.1) [1.7, 14.8]	65	9 (13.8) [6.5, 24.7]	0.438 [0.142, 1.351]	0.401 [0.117, 1.376]	-7.8 [-19.5, 3.9]	0.156
Asthma	66	4 (6.1) [1.7, 14.8]	65	9 (13.8) [6.5, 24.7]	0.438 [0.142, 1.351]	0.401 [0.117, 1.376]	-7.8 [-19.5, 3.9]	0.156

Note: DSAFL = Dossier Label Safety Set. Only events are displayed with an incidence of at least 5 percent in a treatment group.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AS_SLSIK: Incidence of serious TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.427
Male	19	2 (10.5) [1.3, 33.1]	20	6 (30.0) [11.9, 54.3]	0.351 [0.081, 1.529]	0.275 [0.048, 1.579]	-19.5 [-49.0, 10.0]	0.235
Female	47	6 (12.8) [4.8, 25.7]	45	8 (17.8) [8.0, 32.1]	0.718 [0.270, 1.906]	0.677 [0.215, 2.133]	-5.0 [-21.9, 11.9]	0.570
Age								0.660
< 65 years	57	7 (12.3) [5.1, 23.7]	55	11 (20.0) [10.4, 33.0]	0.614 [0.257, 1.469]	0.560 [0.200, 1.570]	-7.7 [-23.1, 7.6]	0.311
>= 65 years	9	1 (11.1) [0.3, 48.2]	10	3 (30.0) [6.7, 65.2]	0.370 [0.046, 2.954]	0.292 [0.024, 3.483]	-18.9 [-64.5, 26.7]	0.582
Exacerbations in the year before study								0.668
<= 2	44	2 (4.5) [0.6, 15.5]	45	5 (11.1) [3.7, 24.1]	0.409 [0.084, 1.999]	0.381 [0.070, 2.077]	-6.6 [-19.9, 6.7]	0.434
> 2	22	6 (27.3) [10.7, 50.2]	20	9 (45.0) [23.1, 68.5]	0.606 [0.262, 1.400]	0.458 [0.127, 1.660]	-17.7 [-51.2, 15.7]	0.336

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SLSIK: Incidence of serious TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	60	7 (11.7) [4.8, 22.6]	58	11 (19.0) [9.9, 31.4]				
Black or African American	2	0 (0.0) [0.0, 84.2]	2	1 (50.0) [1.3, 98.7]				
Asian	3	1 (33.3) [0.8, 90.6]	3	0 (0.0) [0.0, 70.8]				
Other	1	0 (0.0) [0.0, 97.5]	2	2 (100.0) [15.8, 100.0]				
Region		N<10 any level						NE
Europe	40	7 (17.5) [7.3, 32.8]	36	6 (16.7) [6.4, 32.8]				
America	6	0 (0.0) [0.0, 45.9]	4	2 (50.0) [6.8, 93.2]				
Asia/Pacific	3	1 (33.3) [0.8, 90.6]	3	0 (0.0) [0.0, 70.8]				
Rest of the world	17	0 (0.0) [0.0, 19.5]	22	6 (27.3) [10.7, 50.2]				
BMI		n<10 all levels						NE
18.5 - < 25.0 kg/m**2	15	3 (20.0) [4.3, 48.1]	21	3 (14.3) [3.0, 36.3]				
25.0 - < 30.0 kg/m**2	24	1 (4.2) [0.1, 21.1]	20	6 (30.0) [11.9, 54.3]				
>= 30.0 kg/m**2	27	4 (14.8) [4.2, 33.7]	24	5 (20.8) [7.1, 42.2]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SLSIK: Incidence of serious TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.640
< 150 cells/uL	11	3 (27.3) [6.0, 61.0]	14	5 (35.7) [12.8, 64.9]	0.764 [0.231, 2.520]	0.675 [0.121, 3.767]	-8.4 [-52.9, 36.0]	1.000
>= 150 cells/uL	54	5 (9.3) [3.1, 20.3]	51	9 (17.6) [8.4, 30.9]	0.525 [0.188, 1.461]	0.476 [0.148, 1.532]	-8.4 [-23.3, 6.5]	0.257
Baseline eosinophils - High								0.379
< 300 cells/uL	33	3 (9.1) [1.9, 24.3]	34	8 (23.5) [10.7, 41.2]	0.386 [0.112, 1.332]	0.325 [0.078, 1.354]	-14.4 [-34.7, 5.9]	0.186
>= 300 cells/uL	32	5 (15.6) [5.3, 32.8]	31	6 (19.4) [7.5, 37.5]	0.807 [0.274, 2.375]	0.772 [0.209, 2.847]	-3.7 [-25.7, 18.2]	0.750
Baseline FENO								0.715
< 25 ppb	39	5 (12.8) [4.3, 27.4]	30	6 (20.0) [7.7, 38.6]	0.641 [0.216, 1.901]	0.588 [0.161, 2.151]	-7.2 [-27.9, 13.5]	0.514
>= 25 ppb	27	3 (11.1) [2.4, 29.2]	34	8 (23.5) [10.7, 41.2]	0.472 [0.138, 1.611]	0.406 [0.096, 1.712]	-12.4 [-34.3, 9.4]	0.317

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SLSIK: Incidence of serious TEAEs during study period by key subgroups
DSAFL

Serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.658
All negative	27	4 (14.8) [4.2, 33.7]	29	8 (27.6) [12.7, 47.2]	0.537 [0.182, 1.581]	0.457 [0.120, 1.740]	-12.8 [-37.4, 11.9]	0.334
Any positive	34	4 (11.8) [3.3, 27.5]	33	5 (15.2) [5.1, 31.9]	0.776 [0.228, 2.642]	0.747 [0.182, 3.065]	-3.4 [-22.7, 15.9]	0.734
Total serum IgE								0.510
Low	23	3 (13.0) [2.8, 33.6]	14	6 (42.9) [17.7, 71.1]	0.304 [0.090, 1.027]	0.200 [0.040, 1.001]	-29.8 [-64.9, 5.3]	0.057
Normal	40	5 (12.5) [4.2, 26.8]	44	7 (15.9) [6.6, 30.1]	0.786 [0.271, 2.279]	0.755 [0.219, 2.602]	-3.4 [-20.7, 13.9]	0.760
High	3	0 (0.0) [0.0, 70.8]	7	1 (14.3) [0.4, 57.9]	0.667 + [0.034, 12.956]	0.619 + [0.020, 19.585]	-14.3 [-64.0, 35.4]	1.000
OCS at baseline								0.418
Yes	9	1 (11.1) [0.3, 48.2]	13	5 (38.5) [13.9, 68.4]	0.289 [0.040, 2.075]	0.200 [0.019, 2.118]	-27.4 [-70.2, 15.5]	0.333
No	57	7 (12.3) [5.1, 23.7]	52	9 (17.3) [8.2, 30.3]	0.710 [0.285, 1.769]	0.669 [0.230, 1.947]	-5.0 [-20.2, 10.2]	0.590

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SLSIK: Incidence of serious TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline								0.622
Yes	7	3 (42.9) [9.9, 81.6]	3	2 (66.7) [9.4, 99.2]	0.643 [0.199, 2.074]	0.375 [0.022, 6.348]	-23.8 [-100.0, 64.7]	1.000
No	59	5 (8.5) [2.8, 18.7]	62	12 (19.4) [10.4, 31.4]	0.438 [0.164, 1.167]	0.386 [0.127, 1.173]	-10.9 [-24.7, 2.9]	0.117
Tiotropium use at baseline		N<10 any level						NE
Yes	6	3 (50.0) [11.8, 88.2]	2	1 (50.0) [1.3, 98.7]				
No	60	5 (8.3) [2.8, 18.4]	63	13 (20.6) [11.5, 32.7]				
Montelukast/ Cromoglicic acid use at baseline								0.689
Yes	17	4 (23.5) [6.8, 49.9]	21	7 (33.3) [14.6, 57.0]	0.706 [0.247, 2.015]	0.615 [0.146, 2.602]	-9.8 [-43.6, 24.0]	0.721
No	49	4 (8.2) [2.3, 19.6]	44	7 (15.9) [6.6, 30.1]	0.513 [0.161, 1.635]	0.470 [0.128, 1.730]	-7.7 [-23.2, 7.7]	0.339

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SLSIP: Incidence of serious TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.678
White	60	7 (11.7) [4.8, 22.6]	58	11 (19.0) [9.9, 31.4]	0.615 [0.256, 1.477]	0.564 [0.202, 1.574]	-7.3 [-21.9, 7.3]	0.313
Non-white	6	1 (16.7) [0.4, 64.1]	7	3 (42.9) [9.9, 81.6]	0.389 [0.054, 2.826]	0.267 [0.019, 3.653]	-26.2 [-88.9, 36.5]	0.559
Region (cat. P)								0.297
North America/Western EU	6	0 (0.0) [0.0, 45.9]	4	2 (50.0) [6.8, 93.2]	0.143 + [0.009, 2.376]	0.077 + [0.003, 2.234]	-50.0 [-100.0, 19.8]	0.133
Rest of world	60	8 (13.3) [5.9, 24.6]	61	12 (19.7) [10.6, 31.8]	0.678 [0.298, 1.540]	0.628 [0.237, 1.667]	-6.3 [-21.2, 8.5]	0.464
Baseline eosinophils (cat. P)								0.514
< 250 cells/uL	30	3 (10.0) [2.1, 26.5]	29	7 (24.1) [10.3, 43.5]	0.414 [0.118, 1.450]	0.349 [0.081, 1.511]	-14.1 [-36.4, 8.2]	0.181
>= 250 cells/uL	36	5 (13.9) [4.7, 29.5]	36	7 (19.4) [8.2, 36.0]	0.714 [0.250, 2.042]	0.668 [0.191, 2.342]	-5.6 [-25.5, 14.4]	0.753
Baseline FENO (cat. P)								0.660
< 24 ppb	38	5 (13.2) [4.4, 28.1]	30	6 (20.0) [7.7, 38.6]	0.658 [0.222, 1.949]	0.606 [0.165, 2.220]	-6.8 [-27.7, 14.0]	0.518
>= 24 ppb	28	3 (10.7) [2.3, 28.2]	34	8 (23.5) [10.7, 41.2]	0.455 [0.133, 1.556]	0.390 [0.093, 1.639]	-12.8 [-34.4, 8.7]	0.317

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SLSIP: Incidence of serious TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.968
< 22.0 ppb	32	4 (12.5) [3.5, 29.0]	27	6 (22.2) [8.6, 42.3]	0.563 [0.177, 1.789]	0.500 [0.125, 1.999]	-9.7 [-32.6, 13.1]	0.488
>= 22.0 ppb	34	4 (11.8) [3.3, 27.5]	37	8 (21.6) [9.8, 38.2]	0.544 [0.180, 1.645]	0.483 [0.131, 1.781]	-9.9 [-29.8, 10.1]	0.349
Baseline all FEIA status								0.591
All negative	25	4 (16.0) [4.5, 36.1]	22	7 (31.8) [13.9, 54.9]	0.503 [0.170, 1.491]	0.408 [0.101, 1.648]	-15.8 [-44.3, 12.6]	0.303
Any positive	35	4 (11.4) [3.2, 26.7]	41	6 (14.6) [5.6, 29.2]	0.781 [0.239, 2.547]	0.753 [0.194, 2.916]	-3.2 [-21.0, 14.5]	0.745
Th2 status								0.403
Low	41	6 (14.6) [5.6, 29.2]	30	11 (36.7) [19.9, 56.1]	0.399 [0.166, 0.959]	0.296 [0.095, 0.927]	-22.0 [-45.3, 1.2]	0.048 *
High	25	2 (8.0) [1.0, 26.0]	34	3 (8.8) [1.9, 23.7]	0.907 [0.163, 5.028]	0.899 [0.139, 5.823]	-0.8 [-18.6, 16.9]	1.000
Baseline Periostin								0.836
Low (< 20.9 ng/ml)	26	3 (11.5) [2.4, 30.2]	31	7 (22.6) [9.6, 41.1]	0.511 [0.147, 1.780]	0.447 [0.103, 1.942]	-11.0 [-33.7, 11.7]	0.319
High (>= 20.9 ng/ml)	40	5 (12.5) [4.2, 26.8]	34	7 (20.6) [8.7, 37.9]	0.607 [0.212, 1.740]	0.551 [0.157, 1.928]	-8.1 [-27.8, 11.7]	0.366

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AS_SLSIP: Incidence of serious TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo						
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility								0.051	
Yes	57	8 (14.0) [6.3, 25.8]	60	9 (15.0) [7.1, 26.6]	0.936 [0.388, 2.257]	0.925 [0.330, 2.591]	-1.0 [-15.4, 13.5]	1.000	
No	9	0 (0.0) [0.0, 33.6]	5	5 (100.0) [47.8, 100.0]	0.055 + [0.004, 0.822]	0.005 + [0.000, 0.277]	-100.0 [-100.0, -84.4]	<0.001	*
Maintenance OCS use at baseline								0.316	
Yes	9	1 (11.1) [0.3, 48.2]	14	6 (42.9) [17.7, 71.1]	0.259 [0.037, 1.812]	0.167 [0.016, 1.718]	-31.7 [-73.9, 10.4]	0.176	
No	57	7 (12.3) [5.1, 23.7]	51	8 (15.7) [7.0, 28.6]	0.783 [0.305, 2.007]	0.753 [0.252, 2.245]	-3.4 [-18.4, 11.6]	0.782	
No chronic OCS use and current post-BD FEV1 reversibility								0.058	
Yes	51	7 (13.7) [5.7, 26.3]	49	6 (12.2) [4.6, 24.8]	1.121 [0.405, 3.101]	1.140 [0.354, 3.668]	1.5 [-13.7, 16.7]	1.000	
No	15	1 (6.7) [0.2, 31.9]	16	8 (50.0) [24.7, 75.3]	0.133 [0.019, 0.943]	0.071 [0.008, 0.680]	-43.3 [-77.4, -9.3]	0.015	*

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AT_SLMI0: Incidence of TEAEs leading to study drug discontinuation during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
TEAEs leading to study drug discontinuation during study period	66	1 (1.5) [0.0, 8.2]	65	0 (0.0) [0.0, 5.5]	2.955 + [0.123, 71.242]	3.000 + [0.120, 75.000]	1.5 [-3.0, 6.0]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AT_SLMSD: TEAEs leading to study drug discontinuation during study period by SOC and PT
DSAFL

TEAEs leading to study drug discontinuation during study period	Tezepelumab N	Tezepelumab n (%)	Placebo N	Placebo n (%)
SOC: Investigations	66	1 (1.5)	65	0 (0.0)
Hepatic enzyme increased	66	1 (1.5)	65	0 (0.0)

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
TEAE = treatment emergent adverse event.
Source Data: AAE, created on: 11AUG2022

Table PT2AD_SLMI0: Incidence of fatal TEAEs during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Fatal TEAEs during study period	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AD_SLMSD: Fatal TEAEs during study period by SOC and PT
DSAFL

	Tezepelumab		Placebo	
Fatal TEAEs during study period	N	n (%)	N	n (%)

SOC: No events are observed meeting the
criteria for tabular output.

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
TEAE = treatment emergent adverse event.
Source Data: AAE, created on: 11AUG2022

Table PT2AEY_SLMI0: Incidence of AESI hypersensitivity reactions during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period	66	1 (1.5) [0.0, 8.2]	65	1 (1.5) [0.0, 8.3]	0.985 [0.063, 15.414]	0.985 [0.060, 16.082]	-0.0 [-5.7, 5.7]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEYN_SLMI0: Incidence of AESI hypersensitivity reactions during study period - non-severe
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period - non-severe	66	1 (1.5) [0.0, 8.2]	65	1 (1.5) [0.0, 8.3]	0.985 [0.063, 15.414]	0.985 [0.060, 16.082]	-0.0 [-5.7, 5.7]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEYC_SLMI0: Incidence of AESI hypersensitivity reactions during study period - severe
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period - severe	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEYS_SLMI0: Incidence of AESI hypersensitivity reactions during study period - serious
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period - serious	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEA_SLMI0: Incidence of AESI anaphylactic reactions during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEAN_SLMI0: Incidence of AESI anaphylactic reactions during study period - non-severe
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period - non-severe	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEAC_SLMI0: Incidence of AESI anaphylactic reactions during study period - severe
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period - severe	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEAS_SLMI0: Incidence of AESI anaphylactic reactions during study period - serious
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period - serious	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEI_SLMI0: Incidence of AESI injection site reactions during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period	66	3 (4.5) [0.9, 12.7]	65	4 (6.2) [1.7, 15.0]	0.739 [0.172, 3.172]	0.726 [0.156, 3.380]	-1.6 [-10.8, 7.6]	0.718

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEIN_SLMI0: Incidence of AESI injection site reactions during study period - non-severe
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period - non-severe	66	3 (4.5) [0.9, 12.7]	65	4 (6.2) [1.7, 15.0]	0.739 [0.172, 3.172]	0.726 [0.156, 3.380]	-1.6 [-10.8, 7.6]	0.718

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEIC_SLMI0: Incidence of AESI injection site reactions during study period - severe
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period - severe	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEIS_SLMI0: Incidence of AESI injection site reactions during study period - serious
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period - serious	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEM_SLMI0: Incidence of AESI malignancies during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period	66	1 (1.5) [0.0, 8.2]	65	0 (0.0) [0.0, 5.5]	2.955 + [0.123, 71.242]	3.000 + [0.120, 75.000]	1.5 [-3.0, 6.0]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEMN_SLMI0: Incidence of AESI malignancies during study period - non-severe
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period - non-severe	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEMC_SLMI0: Incidence of AESI malignancies during study period - severe
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period - severe	66	1 (1.5) [0.0, 8.2]	65	0 (0.0) [0.0, 5.5]	2.955 + [0.123, 71.242]	3.000 + [0.120, 75.000]	1.5 [-3.0, 6.0]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEMS_SLMI0: Incidence of AESI malignancies during study period - serious
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period - serious	66	1 (1.5) [0.0, 8.2]	65	0 (0.0) [0.0, 5.5]	2.955 + [0.123, 71.242]	3.000 + [0.120, 75.000]	1.5 [-3.0, 6.0]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEG_SLMI0: Incidence of AESI Giullain Barre syndrome during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEGN_SLMI0: Incidence of AESI Giullain Barre syndrome during study period - non-severe
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period - non-severe	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEGC_SLMI0: Incidence of AESI Giullain Barre syndrome during study period - severe
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period - severe	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEGS_SLMI0: Incidence of AESI Giullain Barre syndrome during study period - serious
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period - serious	66	0 (0.0) [0.0, 5.4]	65	0 (0.0) [0.0, 5.5]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2A_SBMI0: Incidence of TEAEs during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
TEAEs during study period	12	10 (83.3) [51.6, 97.9]	9	6 (66.7) [29.9, 92.5]	1.250 [0.738, 2.117]	2.500 [0.320, 19.529]	16.7 [-30.4, 63.7]	0.611

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2A_SBMS0: TEAEs during study period by SOC and PT
DSAFB

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Eye disorders	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
Iridocyclitis	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
SOC: Gastrointestinal disorders	12	2 (16.7) [2.1, 48.4]	9	1 (11.1) [0.3, 48.2]	1.500 [0.160, 14.083]	1.600 [0.122, 20.993]	5.6 [-33.6, 44.7]	1.000
Dyspepsia	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
SOC: General disorders and administration site conditions	12	2 (16.7) [2.1, 48.4]	9	4 (44.4) [13.7, 78.8]	0.375 [0.087, 1.616]	0.250 [0.034, 1.863]	-27.8 [-76.2, 20.7]	0.331
Induration	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
Injection site haematoma	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
Injection site pain	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
Non-cardiac chest pain	12	1 (8.3) [0.2, 38.5]	9	1 (11.1) [0.3, 48.2]	0.750 [0.054, 10.443]	0.727 [0.039, 13.452]	-2.8 [-38.3, 32.8]	1.000
Peripheral swelling	12	1 (8.3) [0.2, 38.5]	9	1 (11.1) [0.3, 48.2]	0.750 [0.054, 10.443]	0.727 [0.039, 13.452]	-2.8 [-38.3, 32.8]	1.000
SOC: Infections and infestations	12	3 (25.0) [5.5, 57.2]	9	3 (33.3) [7.5, 70.1]	0.750 [0.195, 2.884]	0.667 [0.099, 4.478]	-8.3 [-57.4, 40.7]	1.000
Ear infection	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
Nasopharyngitis	12	2 (16.7) [2.1, 48.4]	9	1 (11.1) [0.3, 48.2]	1.500 [0.160, 14.083]	1.600 [0.122, 20.993]	5.6 [-33.6, 44.7]	1.000
Sinusitis	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
Urinary tract infection	12	1 (8.3) [0.2, 38.5]	9	1 (11.1) [0.3, 48.2]	0.750 [0.054, 10.443]	0.727 [0.039, 13.452]	-2.8 [-38.3, 32.8]	1.000
Viral upper respiratory tract infection	12	1 (8.3) [0.2, 38.5]	9	1 (11.1) [0.3, 48.2]	0.750 [0.054, 10.443]	0.727 [0.039, 13.452]	-2.8 [-38.3, 32.8]	1.000

Note: DSAFB = Dossier Biomarker Safety Set. Only events are displayed with an incidence of at least 10 percent in a treatment group or 10 patients with an incidence of at least 1 percent in a treatment group.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2A_SBMS0: TEAEs during study period by SOC and PT
DSAFB

	Tezepelumab		Placebo					
TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Musculoskeletal and connective tissue disorders	12	3 (25.0) [5.5, 57.2]	9	1 (11.1) [0.3, 48.2]	2.250 [0.278, 18.221]	2.667 [0.229, 31.069]	13.9 [-27.8, 55.6]	0.603
Arthralgia	12	1 (8.3) [0.2, 38.5]	9	1 (11.1) [0.3, 48.2]	0.750 [0.054, 10.443]	0.727 [0.039, 13.452]	-2.8 [-38.3, 32.8]	1.000
SOC: Nervous system disorders	12	4 (33.3) [9.9, 65.1]	9	0 (0.0) [0.0, 33.6]	6.923 + [0.420, 114.192]	10.059 + [0.469, 215.558]	33.3 [-3.1, 69.7]	0.104
Dizziness	12	2 (16.7) [2.1, 48.4]	9	0 (0.0) [0.0, 33.6]	3.846 + [0.207, 71.477]	4.524 + [0.192, 106.698]	16.7 [-14.1, 47.5]	0.486
Headache	12	3 (25.0) [5.5, 57.2]	9	0 (0.0) [0.0, 33.6]	5.385 + [0.313, 92.735]	7.000 + [0.316, 154.865]	25.0 [-9.2, 59.2]	0.229
Migraine	12	2 (16.7) [2.1, 48.4]	9	0 (0.0) [0.0, 33.6]	3.846 + [0.207, 71.477]	4.524 + [0.192, 106.698]	16.7 [-14.1, 47.5]	0.486
SOC: Renal and urinary disorders	12	2 (16.7) [2.1, 48.4]	9	0 (0.0) [0.0, 33.6]	3.846 + [0.207, 71.477]	4.524 + [0.192, 106.698]	16.7 [-14.1, 47.5]	0.486
SOC: Respiratory, thoracic and mediastinal disorders	12	6 (50.0) [21.1, 78.9]	9	4 (44.4) [13.7, 78.8]	1.125 [0.447, 2.834]	1.250 [0.221, 7.084]	5.6 [-47.2, 58.3]	1.000
Asthma	12	5 (41.7) [15.2, 72.3]	9	4 (44.4) [13.7, 78.8]	0.938 [0.348, 2.525]	0.893 [0.156, 5.113]	-2.8 [-55.3, 49.7]	1.000
SOC: Skin and subcutaneous tissue disorders	12	3 (25.0) [5.5, 57.2]	9	2 (22.2) [2.8, 60.0]	1.125 [0.235, 5.389]	1.167 [0.151, 9.006]	2.8 [-43.5, 49.1]	1.000
Erythema	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
Pruritus	12	0 (0.0) [0.0, 26.5]	9	2 (22.2) [2.8, 60.0]	0.154 + [0.008, 2.859]	0.120 + [0.005, 2.852]	-22.2 [-59.1, 14.7]	0.171
Rash	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
Skin mass	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429

Note: DSAFB = Dossier Biomarker Safety Set. Only events are displayed with an incidence of at least 10 percent in a treatment group or 10 patients with an incidence of at least 1 percent in a treatment group.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AN_SBMI0: Incidence of non-severe TEAEs during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-severe TEAEs during study period	12	10 (83.3) [51.6, 97.9]	9	6 (66.7) [29.9, 92.5]	1.250 [0.738, 2.117]	2.500 [0.320, 19.529]	16.7 [-30.4, 63.7]	0.611

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AC_SBMI0: Incidence of severe TEAEs during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Severe TEAEs during study period	12	4 (33.3) [9.9, 65.1]	9	2 (22.2) [2.8, 60.0]	1.500 [0.348, 6.465]	1.750 [0.242, 12.642]	11.1 [-36.7, 58.9]	0.659

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AC_SBMS0: Severe TEAEs during study period by SOC and PT
DSAFB

	Tezepelumab		Placebo					
Severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Infections and infestations	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
Nasopharyngitis	12	0 (0.0) [0.0, 26.5]	9	1 (11.1) [0.3, 48.2]	0.256 + [0.012, 5.650]	0.227 + [0.008, 6.252]	-11.1 [-41.4, 19.1]	0.429
SOC: Musculoskeletal and connective tissue disorders	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000
Back pain	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000
SOC: Nervous system disorders	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000
Migraine	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000
SOC: Pregnancy, puerperium and perinatal conditions	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000
Abortion threatened	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000
Hyperemesis gravidarum	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000
SOC: Respiratory, thoracic and mediastinal disorders	12	3 (25.0) [5.5, 57.2]	9	2 (22.2) [2.8, 60.0]	1.125 [0.235, 5.389]	1.167 [0.151, 9.006]	2.8 [-43.5, 49.1]	1.000
Asthma	12	2 (16.7) [2.1, 48.4]	9	2 (22.2) [2.8, 60.0]	0.750 [0.129, 4.356]	0.700 [0.079, 6.224]	-5.6 [-49.7, 38.6]	1.000
Dyspnoea	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000

Note: DSAFB = Dossier Biomarker Safety Set. Only events are displayed with an incidence of at least 5 percent in a treatment group.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AS_SBMI0: Incidence of serious TEAEs during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Serious TEAEs during study period	12	2 (16.7) [2.1, 48.4]	9	3 (33.3) [7.5, 70.1]	0.500 [0.104, 2.395]	0.400 [0.051, 3.125]	-16.7 [-63.7, 30.4]	0.611

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AS_SBMS0: Serious TEAEs during study period by SOC and PT
DSAFB

	Tezepelumab		Placebo					
Serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: General disorders and administration site conditions	12	1 (8.3) [0.2, 38.5]	9	1 (11.1) [0.3, 48.2]	0.750 [0.054, 10.443]	0.727 [0.039, 13.452]	-2.8 [-38.3, 32.8]	1.000
Non-cardiac chest pain	12	1 (8.3) [0.2, 38.5]	9	1 (11.1) [0.3, 48.2]	0.750 [0.054, 10.443]	0.727 [0.039, 13.452]	-2.8 [-38.3, 32.8]	1.000
SOC: Pregnancy, puerperium and perinatal conditions	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000
Abortion threatened	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000
Hyperemesis gravidarum	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000
SOC: Respiratory, thoracic and mediastinal disorders	12	0 (0.0) [0.0, 26.5]	9	2 (22.2) [2.8, 60.0]	0.154 + [0.008, 2.859]	0.120 + [0.005, 2.852]	-22.2 [-59.1, 14.7]	0.171
Asthma	12	0 (0.0) [0.0, 26.5]	9	2 (22.2) [2.8, 60.0]	0.154 + [0.008, 2.859]	0.120 + [0.005, 2.852]	-22.2 [-59.1, 14.7]	0.171

Note: DSAFB = Dossier Biomarker Safety Set. Only events are displayed with an incidence of at least 5 percent in a treatment group.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AT_SBMI0: Incidence of TEAEs leading to study drug discontinuation during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
TEAEs leading to study drug discontinuation during study period	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AT_SBMSD: TEAEs leading to study drug discontinuation during study period by SOC and PT
DSAFB

	Tezepelumab		Placebo	
TEAEs leading to study drug discontinuation during study period	N	n (%)	N	n (%)

SOC: No events are observed meeting the criteria for tabular output.

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
TEAE = treatment emergent adverse event.
Source Data: AAE, created on: 11AUG2022

Table PT2AD_SBMI0: Incidence of fatal TEAEs during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Fatal TEAEs during study period	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AD_SBMSD: Fatal TEAEs during study period by SOC and PT
DSAFB

	Tezepelumab		Placebo	
Fatal TEAEs during study period	N	n (%)	N	n (%)

SOC: No events are observed meeting the criteria for tabular output.

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events. SOC = system organ class. PT = preferred term.
TEAE = treatment emergent adverse event.
Source Data: AAE, created on: 11AUG2022

Table PT2AEY_SBMI0: Incidence of AESI hypersensitivity reactions during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEYN_SBMI0: Incidence of AESI hypersensitivity reactions during study period - non-severe
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period - non-severe	12	1 (8.3) [0.2, 38.5]	9	0 (0.0) [0.0, 33.6]	2.308 + [0.105, 50.849]	2.478 + [0.090, 68.136]	8.3 [-17.0, 33.7]	1.000

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEYC_SBMI0: Incidence of AESI hypersensitivity reactions during study period - severe
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period - severe	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEYS_SBMI0: Incidence of AESI hypersensitivity reactions during study period - serious
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypersensitivity reactions during study period - serious	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEA_SBMI0: Incidence of AESI anaphylactic reactions during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEAN_SBMI0: Incidence of AESI anaphylactic reactions during study period - non-severe
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period - non-severe	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEAC_SBMI0: Incidence of AESI anaphylactic reactions during study period - severe
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period - severe	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEAS_SBMI0: Incidence of AESI anaphylactic reactions during study period - serious
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anaphylactic reactions during study period - serious	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEI_SBMI0: Incidence of AESI injection site reactions during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period	12	1 (8.3) [0.2, 38.5]	9	3 (33.3) [7.5, 70.1]	0.250 [0.031, 2.025]	0.182 [0.015, 2.154]	-25.0 [-69.3, 19.3]	0.272

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEIN_SBMI0: Incidence of AESI injection site reactions during study period - non-severe
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period - non-severe	12	1 (8.3) [0.2, 38.5]	9	3 (33.3) [7.5, 70.1]	0.250 [0.031, 2.025]	0.182 [0.015, 2.154]	-25.0 [-69.3, 19.3]	0.272

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEIC_SBMI0: Incidence of AESI injection site reactions during study period - severe
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period - severe	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEIS_SBMI0: Incidence of AESI injection site reactions during study period - serious
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI injection site reactions during study period - serious	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEM_SBMI0: Incidence of AESI malignancies during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEMN_SBMI0: Incidence of AESI malignancies during study period - non-severe
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period - non-severe	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEMC_SBMI0: Incidence of AESI malignancies during study period - severe
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period - severe	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEMS_SBMI0: Incidence of AESI malignancies during study period - serious
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI malignancies during study period - serious	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEG_SBMI0: Incidence of AESI Giullain Barre syndrome during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEGN_SBMI0: Incidence of AESI Giullain Barre syndrome during study period - non-severe
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period - non-severe	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEGC_SBMI0: Incidence of AESI Giullain Barre syndrome during study period - severe
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period - severe	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AEGS_SBMI0: Incidence of AESI Giullain Barre syndrome during study period - serious
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI Giullain Barre syndrome during study period - serious	12	0 (0.0) [0.0, 26.5]	9	0 (0.0) [0.0, 33.6]				

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
AESI = adverse event of special interest. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AA_SOMI0: Incidence of non-disease related TEAEs during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related TEAEs during study period	137	67 (48.9) [40.3, 57.6]	138	63 (45.7) [37.2, 54.3]	1.071 [0.834, 1.375]	1.139 [0.710, 1.830]	3.3 [-9.3, 15.8]	0.630

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AA_SOSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAF

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.551
Male	50	23 (46.0) [31.8, 60.7]	44	21 (47.7) [32.5, 63.3]	0.964 [0.626, 1.483]	0.933 [0.414, 2.101]	-1.7 [-24.1, 20.6]	1.000
Female	87	44 (50.6) [39.6, 61.5]	94	42 (44.7) [34.4, 55.3]	1.132 [0.833, 1.537]	1.267 [0.706, 2.274]	5.9 [-9.8, 21.5]	0.459
Age								0.238
< 65 years	114	55 (48.2) [38.8, 57.8]	118	50 (42.4) [33.3, 51.8]	1.139 [0.857, 1.512]	1.268 [0.755, 2.128]	5.9 [-7.8, 19.5]	0.429
>= 65 years	23	12 (52.2) [30.6, 73.2]	20	13 (65.0) [40.8, 84.6]	0.803 [0.484, 1.332]	0.587 [0.172, 2.010]	-12.8 [-46.7, 21.1]	0.537
Exacerbations in the year before study								0.268
<= 2	105	47 (44.8) [35.0, 54.8]	110	43 (39.1) [29.9, 48.9]	1.145 [0.835, 1.570]	1.263 [0.734, 2.173]	5.7 [-8.4, 19.8]	0.410
> 2	32	20 (62.5) [43.7, 78.9]	28	20 (71.4) [51.3, 86.8]	0.875 [0.613, 1.249]	0.667 [0.225, 1.980]	-8.9 [-36.0, 18.1]	0.585

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SOSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAF

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	128	61 (47.7) [38.8, 56.7]	123	52 (42.3) [33.4, 51.5]				
Black or African American	3	3 (100.0) [29.2, 100.0]	6	5 (83.3) [35.9, 99.6]				
Asian	5	3 (60.0) [14.7, 94.7]	6	3 (50.0) [11.8, 88.2]				
Other	1	0 (0.0) [0.0, 97.5]	3	3 (100.0) [29.2, 100.0]				
Region								0.986
Europe	78	38 (48.7) [37.2, 60.3]	80	37 (46.3) [35.0, 57.8]	1.053 [0.759, 1.462]	1.104 [0.591, 2.062]	2.5 [-14.4, 19.3]	0.873
America	10	9 (90.0) [55.5, 99.7]	9	8 (88.9) [51.8, 99.7]	1.013 [0.743, 1.380]	1.125 [0.060, 21.087]	1.1 [-37.1, 39.4]	1.000
Asia/Pacific	5	3 (60.0) [14.7, 94.7]	6	3 (50.0) [11.8, 88.2]	1.200 [0.410, 3.511]	1.500 [0.136, 16.542]	10.0 [-67.0, 87.0]	1.000
Rest of the world	44	17 (38.6) [24.4, 54.5]	43	15 (34.9) [21.0, 50.9]	1.108 [0.637, 1.925]	1.175 [0.491, 2.813]	3.8 [-18.8, 26.3]	0.825
BMI		N<10 any level						NE
< 18.5 kg/m**2	0		1	0 (0.0) [0.0, 97.5]				
18.5 - < 25.0 kg/m**2	39	19 (48.7) [32.4, 65.2]	43	16 (37.2) [23.0, 53.3]				
25.0 - < 30.0 kg/m**2	45	19 (42.2) [27.7, 57.8]	47	19 (40.4) [26.4, 55.7]				
>= 30.0 kg/m**2	53	29 (54.7) [40.4, 68.4]	47	28 (59.6) [44.3, 73.6]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SOSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAF

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.546
< 150 cells/uL	27	15 (55.6) [35.3, 74.5]	33	19 (57.6) [39.2, 74.5]	0.965 [0.617, 1.508]	0.921 [0.330, 2.570]	-2.0 [-30.6, 26.6]	1.000
>= 150 cells/uL	109	52 (47.7) [38.1, 57.5]	105	44 (41.9) [32.3, 51.9]	1.138 [0.844, 1.535]	1.265 [0.737, 2.170]	5.8 [-8.4, 20.0]	0.412
Baseline eosinophils - High								0.086
< 300 cells/uL	69	31 (44.9) [32.9, 57.4]	72	37 (51.4) [39.3, 63.3]	0.874 [0.619, 1.234]	0.772 [0.398, 1.496]	-6.5 [-24.3, 11.4]	0.501
>= 300 cells/uL	67	36 (53.7) [41.1, 66.0]	66	26 (39.4) [27.6, 52.2]	1.364 [0.940, 1.980]	1.787 [0.897, 3.558]	14.3 [-3.9, 32.6]	0.119
Baseline FENO								0.973
< 25 ppb	78	41 (52.6) [40.9, 64.0]	74	37 (50.0) [38.1, 61.9]	1.051 [0.771, 1.434]	1.108 [0.586, 2.094]	2.6 [-14.6, 19.8]	0.871
>= 25 ppb	57	24 (42.1) [29.1, 55.9]	63	25 (39.7) [27.6, 52.8]	1.061 [0.690, 1.632]	1.105 [0.533, 2.291]	2.4 [-16.9, 21.7]	0.853

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SOSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAF

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.370
All negative	57	29 (50.9) [37.3, 64.4]	66	34 (51.5) [38.9, 64.0]	0.988 [0.699, 1.396]	0.975 [0.480, 1.981]	-0.6 [-20.0, 18.7]	1.000
Any positive	71	34 (47.9) [35.9, 60.1]	63	24 (38.1) [26.1, 51.2]	1.257 [0.845, 1.871]	1.493 [0.749, 2.976]	9.8 [-8.4, 28.0]	0.296
Total serum IgE								0.640
Low	35	18 (51.4) [34.0, 68.6]	32	16 (50.0) [31.9, 68.1]	1.029 [0.641, 1.651]	1.059 [0.406, 2.762]	1.4 [-25.5, 28.4]	1.000
Normal	95	46 (48.4) [38.0, 58.9]	98	42 (42.9) [32.9, 53.3]	1.130 [0.830, 1.539]	1.252 [0.710, 2.208]	5.6 [-9.5, 20.6]	0.472
High	7	3 (42.9) [9.9, 81.6]	8	5 (62.5) [24.5, 91.5]	0.686 [0.250, 1.882]	0.450 [0.057, 3.570]	-19.6 [-82.7, 43.4]	0.619
OCS at baseline								0.871
Yes	9	4 (44.4) [13.7, 78.8]	13	5 (38.5) [13.9, 68.4]	1.156 [0.424, 3.151]	1.280 [0.228, 7.187]	6.0 [-45.3, 57.3]	1.000
No	128	63 (49.2) [40.3, 58.2]	125	58 (46.4) [37.4, 55.5]	1.061 [0.820, 1.373]	1.120 [0.683, 1.834]	2.8 [-10.3, 15.9]	0.706

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SOSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAF

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)								0.145
Medium/Low	70	38 (54.3) [41.9, 66.3]	73	31 (42.5) [31.0, 54.6]	1.278 [0.907, 1.801]	1.609 [0.831, 3.115]	11.8 [-5.9, 29.5]	0.182
High	67	29 (43.3) [31.2, 56.0]	65	32 (49.2) [36.6, 61.9]	0.879 [0.608, 1.271]	0.787 [0.396, 1.562]	-5.9 [-24.4, 12.6]	0.601
LAMA use at baseline								0.296
Yes	11	5 (45.5) [16.7, 76.6]	6	4 (66.7) [22.3, 95.7]	0.682 [0.289, 1.611]	0.417 [0.053, 3.306]	-21.2 [-81.9, 39.5]	0.620
No	126	62 (49.2) [40.2, 58.3]	132	59 (44.7) [36.0, 53.6]	1.101 [0.849, 1.427]	1.199 [0.735, 1.956]	4.5 [-8.4, 17.5]	0.533
Tiotropium use at baseline								0.387
Yes	9	4 (44.4) [13.7, 78.8]	3	2 (66.7) [9.4, 99.2]	0.667 [0.226, 1.970]	0.400 [0.026, 6.176]	-22.2 [-100.0, 62.4]	1.000
No	128	63 (49.2) [40.3, 58.2]	135	61 (45.2) [36.6, 54.0]	1.089 [0.843, 1.407]	1.176 [0.724, 1.909]	4.0 [-8.8, 16.9]	0.538

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SOSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAF

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline								0.749
Yes	29	20 (69.0) [49.2, 84.7]	37	22 (59.5) [42.1, 75.2]	1.160 [0.808, 1.664]	1.515 [0.544, 4.221]	9.5 [-16.7, 35.7]	0.453
No	108	47 (43.5) [34.0, 53.4]	101	41 (40.6) [30.9, 50.8]	1.072 [0.779, 1.475]	1.128 [0.651, 1.954]	2.9 [-11.4, 17.3]	0.677

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SOSIP: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAF

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.495
White	128	61 (47.7) [38.8, 56.7]	123	52 (42.3) [33.4, 51.5]	1.127 [0.856, 1.484]	1.243 [0.755, 2.046]	5.4 [-7.7, 18.5]	0.447
Non-white	9	6 (66.7) [29.9, 92.5]	15	11 (73.3) [44.9, 92.2]	0.909 [0.523, 1.581]	0.727 [0.121, 4.388]	-6.7 [-53.6, 40.3]	1.000
Region (cat. P)								0.790
North America/Western EU	10	9 (90.0) [55.5, 99.7]	9	8 (88.9) [51.8, 99.7]	1.013 [0.743, 1.380]	1.125 [0.060, 21.087]	1.1 [-37.1, 39.4]	1.000
Rest of world	127	58 (45.7) [36.8, 54.7]	129	55 (42.6) [34.0, 51.6]	1.071 [0.813, 1.411]	1.131 [0.690, 1.853]	3.0 [-9.9, 16.0]	0.706
Baseline eosinophils (cat. P)								0.068
< 250 cells/uL	61	28 (45.9) [33.1, 59.2]	60	33 (55.0) [41.6, 67.9]	0.835 [0.585, 1.191]	0.694 [0.339, 1.420]	-9.1 [-28.5, 10.3]	0.365
>= 250 cells/uL	76	39 (51.3) [39.6, 63.0]	78	30 (38.5) [27.7, 50.2]	1.334 [0.935, 1.905]	1.686 [0.889, 3.200]	12.9 [-4.0, 29.7]	0.145
Baseline FENO (cat. P)								0.930
< 24 ppb	75	40 (53.3) [41.4, 64.9]	72	36 (50.0) [38.0, 62.0]	1.067 [0.780, 1.459]	1.143 [0.598, 2.184]	3.3 [-14.2, 20.8]	0.742
>= 24 ppb	60	25 (41.7) [29.1, 55.1]	65	26 (40.0) [28.0, 52.9]	1.042 [0.683, 1.589]	1.071 [0.525, 2.188]	1.7 [-17.2, 20.5]	0.858

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SOSIP: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAF

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.866
< 22.0 ppb	65	33 (50.8) [38.1, 63.4]	62	29 (46.8) [34.0, 59.9]	1.085 [0.759, 1.552]	1.173 [0.585, 2.355]	4.0 [-15.0, 22.9]	0.724
>= 22.0 ppb	70	32 (45.7) [33.7, 58.1]	75	33 (44.0) [32.5, 55.9]	1.039 [0.724, 1.491]	1.072 [0.557, 2.063]	1.7 [-15.9, 19.3]	0.868
Baseline all FEIA status								0.552
All negative	50	28 (56.0) [41.3, 70.0]	50	23 (46.0) [31.8, 60.7]	1.217 [0.826, 1.795]	1.494 [0.679, 3.286]	10.0 [-11.5, 31.5]	0.424
Any positive	77	35 (45.5) [34.1, 57.2]	80	35 (43.8) [32.7, 55.3]	1.039 [0.733, 1.472]	1.071 [0.571, 2.011]	1.7 [-15.1, 18.5]	0.873
Th2 status								0.250
Low	70	32 (45.7) [33.7, 58.1]	62	31 (50.0) [37.0, 63.0]	0.914 [0.640, 1.306]	0.842 [0.425, 1.670]	-4.3 [-22.9, 14.3]	0.727
High	65	34 (52.3) [39.5, 64.9]	75	32 (42.7) [31.3, 54.6]	1.226 [0.864, 1.740]	1.474 [0.756, 2.875]	9.6 [-8.3, 27.6]	0.309
Baseline Periostin								0.324
Low (< 20.9 ng/ml)	62	32 (51.6) [38.6, 64.5]	67	28 (41.8) [29.8, 54.5]	1.235 [0.852, 1.791]	1.486 [0.741, 2.979]	9.8 [-8.9, 28.5]	0.293
High (>= 20.9 ng/ml)	74	35 (47.3) [35.6, 59.3]	71	35 (49.3) [37.2, 61.4]	0.959 [0.685, 1.344]	0.923 [0.481, 1.771]	-2.0 [-19.6, 15.6]	0.869

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SOSIP: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAF

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility								0.006	i
Yes	114	55 (48.2) [38.8, 57.8]	126	52 (41.3) [32.6, 50.4]	1.169 [0.882, 1.550]	1.327 [0.796, 2.211]	7.0 [-6.4, 20.4]	0.300	
No	23	12 (52.2) [30.6, 73.2]	12	11 (91.7) [61.5, 99.8]	0.569 [0.371, 0.872]	0.099 [0.011, 0.899]	-39.5 [-71.5, -7.4]	0.027	*
Maintenance OCS use at baseline								0.949	
Yes	9	4 (44.4) [13.7, 78.8]	14	6 (42.9) [17.7, 71.1]	1.037 [0.402, 2.677]	1.067 [0.197, 5.769]	1.6 [-49.1, 52.3]	1.000	
No	128	63 (49.2) [40.3, 58.2]	124	57 (46.0) [37.0, 55.1]	1.071 [0.826, 1.388]	1.139 [0.695, 1.869]	3.3 [-9.9, 16.4]	0.616	
No chronic OCS use and current post-BD FEV1 reversibility								0.178	
Yes	108	52 (48.1) [38.4, 58.0]	115	48 (41.7) [32.6, 51.3]	1.154 [0.862, 1.544]	1.296 [0.764, 2.200]	6.4 [-7.5, 20.3]	0.349	
No	29	15 (51.7) [32.5, 70.6]	23	15 (65.2) [42.7, 83.6]	0.793 [0.500, 1.258]	0.571 [0.185, 1.761]	-13.5 [-44.0, 17.0]	0.403	

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SOMI0: Incidence of non-disease related non-severe TEAEs during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related non-severe TEAEs during study period	137	62 (45.3) [36.7, 54.0]	138	61 (44.2) [35.8, 52.9]	1.024 [0.787, 1.332]	1.043 [0.649, 1.679]	1.1 [-11.4, 13.5]	0.904

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AAN_SOSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAF

Non-disease related non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.779
Male	50	21 (42.0) [28.2, 56.8]	44	19 (43.2) [28.3, 59.0]	0.973 [0.608, 1.556]	0.953 [0.420, 2.162]	-1.2 [-23.4, 21.0]	1.000
Female	87	41 (47.1) [36.3, 58.1]	94	42 (44.7) [34.4, 55.3]	1.055 [0.769, 1.447]	1.104 [0.615, 1.981]	2.4 [-13.2, 18.1]	0.767
Age								0.198
< 65 years	114	51 (44.7) [35.4, 54.3]	118	48 (40.7) [31.7, 50.1]	1.100 [0.816, 1.482]	1.181 [0.701, 1.987]	4.1 [-9.5, 17.6]	0.596
>= 65 years	23	11 (47.8) [26.8, 69.4]	20	13 (65.0) [40.8, 84.6]	0.736 [0.431, 1.256]	0.494 [0.144, 1.689]	-17.2 [-51.1, 16.7]	0.359
Exacerbations in the year before study								0.431
<= 2	105	43 (41.0) [31.5, 51.0]	110	42 (38.2) [29.1, 47.9]	1.073 [0.771, 1.493]	1.123 [0.650, 1.940]	2.8 [-11.2, 16.8]	0.780
> 2	32	19 (59.4) [40.6, 76.3]	28	19 (67.9) [47.6, 84.1]	0.875 [0.596, 1.284]	0.692 [0.240, 2.001]	-8.5 [-36.1, 19.1]	0.595

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SOSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
Non-disease related non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	128	56 (43.8) [35.0, 52.8]	123	50 (40.7) [31.9, 49.9]				
Black or African American	3	3 (100.0) [29.2, 100.0]	6	5 (83.3) [35.9, 99.6]				
Asian	5	3 (60.0) [14.7, 94.7]	6	3 (50.0) [11.8, 88.2]				
Other	1	0 (0.0) [0.0, 97.5]	3	3 (100.0) [29.2, 100.0]				
Region								0.921
Europe	78	36 (46.2) [34.8, 57.8]	80	35 (43.8) [32.7, 55.3]	1.055 [0.747, 1.490]	1.102 [0.589, 2.063]	2.4 [-14.4, 19.2]	0.873
America	10	8 (80.0) [44.4, 97.5]	9	8 (88.9) [51.8, 99.7]	0.900 [0.611, 1.325]	0.500 [0.037, 6.683]	-8.9 [-51.6, 33.9]	1.000
Asia/Pacific	5	3 (60.0) [14.7, 94.7]	6	3 (50.0) [11.8, 88.2]	1.200 [0.410, 3.511]	1.500 [0.136, 16.542]	10.0 [-67.0, 87.0]	1.000
Rest of the world	44	15 (34.1) [20.5, 49.9]	43	15 (34.9) [21.0, 50.9]	0.977 [0.548, 1.744]	0.966 [0.399, 2.338]	-0.8 [-23.1, 21.5]	1.000
BMI		N<10 any level						NE
< 18.5 kg/m**2	0		1	0 (0.0) [0.0, 97.5]				
18.5 - < 25.0 kg/m**2	39	18 (46.2) [30.1, 62.8]	43	16 (37.2) [23.0, 53.3]				
25.0 - < 30.0 kg/m**2	45	18 (40.0) [25.7, 55.7]	47	18 (38.3) [24.5, 53.6]				
>= 30.0 kg/m**2	53	26 (49.1) [35.1, 63.2]	47	27 (57.4) [42.2, 71.7]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SOSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAF

Non-disease related non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eosinophils - Low								0.318	
< 150 cells/uL	27	13 (48.1) [28.7, 68.1]	33	19 (57.6) [39.2, 74.5]	0.836 [0.513, 1.363]	0.684 [0.246, 1.903]	-9.4 [-38.1, 19.2]	0.604	
>= 150 cells/uL	109	49 (45.0) [35.4, 54.8]	105	42 (40.0) [30.6, 50.0]	1.124 [0.822, 1.537]	1.225 [0.712, 2.108]	5.0 [-9.2, 19.1]	0.491	
Baseline eosinophils - High								0.038	i
< 300 cells/uL	69	28 (40.6) [28.9, 53.1]	72	37 (51.4) [39.3, 63.3]	0.790 [0.549, 1.136]	0.646 [0.332, 1.258]	-10.8 [-28.6, 7.0]	0.238	
>= 300 cells/uL	67	34 (50.7) [38.2, 63.2]	66	24 (36.4) [24.9, 49.1]	1.396 [0.938, 2.075]	1.803 [0.901, 3.607]	14.4 [-3.8, 32.6]	0.116	
Baseline FENO								0.833	
< 25 ppb	78	39 (50.0) [38.5, 61.5]	74	36 (48.6) [36.9, 60.6]	1.028 [0.744, 1.419]	1.056 [0.559, 1.994]	1.4 [-15.9, 18.6]	0.873	
>= 25 ppb	57	21 (36.8) [24.4, 50.7]	63	24 (38.1) [26.1, 51.2]	0.967 [0.609, 1.537]	0.948 [0.452, 1.988]	-1.3 [-20.3, 17.8]	1.000	

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SOSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
Non-disease related non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.748
All negative	57	28 (49.1) [35.6, 62.7]	66	32 (48.5) [36.0, 61.1]	1.013 [0.705, 1.456]	1.026 [0.505, 2.085]	0.6 [-18.7, 20.0]	1.000
Any positive	71	30 (42.3) [30.6, 54.6]	63	24 (38.1) [26.1, 51.2]	1.109 [0.732, 1.681]	1.189 [0.595, 2.378]	4.2 [-13.9, 22.3]	0.725
Total serum IgE								0.684
Low	35	17 (48.6) [31.4, 66.0]	32	16 (50.0) [31.9, 68.1]	0.971 [0.597, 1.579]	0.944 [0.362, 2.464]	-1.4 [-28.4, 25.5]	1.000
Normal	95	42 (44.2) [34.0, 54.8]	98	40 (40.8) [31.0, 51.2]	1.083 [0.780, 1.504]	1.149 [0.649, 2.034]	3.4 [-11.6, 18.4]	0.664
High	7	3 (42.9) [9.9, 81.6]	8	5 (62.5) [24.5, 91.5]	0.686 [0.250, 1.882]	0.450 [0.057, 3.570]	-19.6 [-82.7, 43.4]	0.619
OCS at baseline								0.802
Yes	9	4 (44.4) [13.7, 78.8]	13	5 (38.5) [13.9, 68.4]	1.156 [0.424, 3.151]	1.280 [0.228, 7.187]	6.0 [-45.3, 57.3]	1.000
No	128	58 (45.3) [36.5, 54.3]	125	56 (44.8) [35.9, 54.0]	1.011 [0.770, 1.328]	1.021 [0.622, 1.675]	0.5 [-12.5, 13.6]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SOSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
Non-disease related non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)								0.266
Medium/Low	70	34 (48.6) [36.4, 60.8]	73	30 (41.1) [29.7, 53.2]	1.182 [0.820, 1.703]	1.354 [0.699, 2.622]	7.5 [-10.2, 25.1]	0.403
High	67	28 (41.8) [29.8, 54.5]	65	31 (47.7) [35.1, 60.5]	0.876 [0.599, 1.282]	0.787 [0.396, 1.566]	-5.9 [-24.4, 12.6]	0.600
LAMA use at baseline								0.351
Yes	11	5 (45.5) [16.7, 76.6]	6	4 (66.7) [22.3, 95.7]	0.682 [0.289, 1.611]	0.417 [0.053, 3.306]	-21.2 [-81.9, 39.5]	0.620
No	126	57 (45.2) [36.4, 54.3]	132	57 (43.2) [34.6, 52.1]	1.048 [0.796, 1.378]	1.087 [0.665, 1.777]	2.1 [-10.8, 15.0]	0.802
Tiotropium use at baseline								0.438
Yes	9	4 (44.4) [13.7, 78.8]	3	2 (66.7) [9.4, 99.2]	0.667 [0.226, 1.970]	0.400 [0.026, 6.176]	-22.2 [-100.0, 62.4]	1.000
No	128	58 (45.3) [36.5, 54.3]	135	59 (43.7) [35.2, 52.5]	1.037 [0.792, 1.358]	1.067 [0.656, 1.736]	1.6 [-11.2, 14.4]	0.805

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SOSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAF

	Tezepelumab		Placebo					
Non-disease related non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline								0.841
Yes	29	17 (58.6) [38.9, 76.5]	37	20 (54.1) [36.9, 70.5]	1.084 [0.708, 1.661]	1.204 [0.451, 3.215]	4.6 [-22.6, 31.7]	0.805
No	108	45 (41.7) [32.3, 51.5]	101	41 (40.6) [30.9, 50.8]	1.026 [0.742, 1.420]	1.045 [0.602, 1.814]	1.1 [-13.2, 15.4]	0.889

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SOSIP: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAF

Non-disease related non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.597
White	128	56 (43.8) [35.0, 52.8]	123	50 (40.7) [31.9, 49.9]	1.076 [0.805, 1.439]	1.136 [0.688, 1.875]	3.1 [-9.9, 16.1]	0.702
Non-white	9	6 (66.7) [29.9, 92.5]	15	11 (73.3) [44.9, 92.2]	0.909 [0.523, 1.581]	0.727 [0.121, 4.388]	-6.7 [-53.6, 40.3]	1.000
Region (cat. P)								0.571
North America/Western EU	10	8 (80.0) [44.4, 97.5]	9	8 (88.9) [51.8, 99.7]	0.900 [0.611, 1.325]	0.500 [0.037, 6.683]	-8.9 [-51.6, 33.9]	1.000
Rest of world	127	54 (42.5) [33.8, 51.6]	129	53 (41.1) [32.5, 50.1]	1.035 [0.775, 1.382]	1.061 [0.645, 1.743]	1.4 [-11.4, 14.3]	0.899
Baseline eosinophils (cat. P)								0.083
< 250 cells/uL	61	27 (44.3) [31.5, 57.6]	60	33 (55.0) [41.6, 67.9]	0.805 [0.560, 1.157]	0.650 [0.317, 1.331]	-10.7 [-30.1, 8.6]	0.277
>= 250 cells/uL	76	35 (46.1) [34.5, 57.9]	78	28 (35.9) [25.3, 47.6]	1.283 [0.874, 1.883]	1.524 [0.799, 2.909]	10.2 [-6.6, 26.9]	0.251
Baseline FENO (cat. P)								0.754
< 24 ppb	75	38 (50.7) [38.9, 62.4]	72	35 (48.6) [36.7, 60.7]	1.042 [0.752, 1.444]	1.086 [0.569, 2.073]	2.1 [-15.5, 19.6]	0.869
>= 24 ppb	60	22 (36.7) [24.6, 50.1]	65	25 (38.5) [26.7, 51.4]	0.953 [0.606, 1.500]	0.926 [0.449, 1.912]	-1.8 [-20.4, 16.8]	0.855

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SOSIP: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAF

Non-disease related non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.581
< 22.0 ppb	65	32 (49.2) [36.6, 61.9]	62	28 (45.2) [32.5, 58.3]	1.090 [0.754, 1.577]	1.177 [0.586, 2.365]	4.1 [-14.9, 23.0]	0.723
>= 22.0 ppb	70	28 (40.0) [28.5, 52.4]	75	32 (42.7) [31.3, 54.6]	0.938 [0.636, 1.383]	0.896 [0.462, 1.736]	-2.7 [-20.1, 14.7]	0.866
Baseline all FEIA status								0.356
All negative	50	27 (54.0) [39.3, 68.2]	50	22 (44.0) [30.0, 58.7]	1.227 [0.819, 1.838]	1.494 [0.679, 3.286]	10.0 [-11.5, 31.5]	0.424
Any positive	77	31 (40.3) [29.2, 52.1]	80	34 (42.5) [31.5, 54.1]	0.947 [0.652, 1.375]	0.912 [0.483, 1.721]	-2.2 [-18.9, 14.4]	0.871
Th2 status								0.219
Low	70	30 (42.9) [31.1, 55.3]	62	31 (50.0) [37.0, 63.0]	0.857 [0.593, 1.238]	0.750 [0.377, 1.491]	-7.1 [-25.7, 11.4]	0.485
High	65	31 (47.7) [35.1, 60.5]	75	30 (40.0) [28.9, 52.0]	1.192 [0.818, 1.737]	1.368 [0.699, 2.676]	7.7 [-10.2, 25.6]	0.396
Baseline Periostin								0.414
Low (< 20.9 ng/ml)	62	29 (46.8) [34.0, 59.9]	67	27 (40.3) [28.5, 53.0]	1.161 [0.783, 1.722]	1.302 [0.648, 2.616]	6.5 [-12.2, 25.1]	0.482
High (>= 20.9 ng/ml)	74	33 (44.6) [33.0, 56.6]	71	34 (47.9) [35.9, 60.1]	0.931 [0.655, 1.323]	0.876 [0.456, 1.684]	-3.3 [-20.9, 14.3]	0.740

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SOSIP: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAF

	Tezepelumab		Placebo					
Non-disease related non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.006 i
Yes	114	51 (44.7) [35.4, 54.3]	126	50 (39.7) [31.1, 48.8]	1.127 [0.838, 1.517]	1.230 [0.736, 2.056]	5.1 [-8.3, 18.4]	0.436
No	23	11 (47.8) [26.8, 69.4]	12	11 (91.7) [61.5, 99.8]	0.522 [0.329, 0.826]	0.083 [0.009, 0.756]	-43.8 [-75.9, -11.8]	0.013 *
Maintenance OCS use at baseline								0.976
Yes	9	4 (44.4) [13.7, 78.8]	14	6 (42.9) [17.7, 71.1]	1.037 [0.402, 2.677]	1.067 [0.197, 5.769]	1.6 [-49.1, 52.3]	1.000
No	128	58 (45.3) [36.5, 54.3]	124	55 (44.4) [35.4, 53.5]	1.022 [0.777, 1.344]	1.039 [0.633, 1.708]	1.0 [-12.1, 14.0]	0.900
No chronic OCS use and current post-BD FEV1 reversibility								0.163
Yes	108	48 (44.4) [34.9, 54.3]	115	46 (40.0) [31.0, 49.6]	1.111 [0.817, 1.511]	1.200 [0.705, 2.043]	4.4 [-9.4, 18.3]	0.587
No	29	14 (48.3) [29.4, 67.5]	23	15 (65.2) [42.7, 83.6]	0.740 [0.458, 1.197]	0.498 [0.162, 1.534]	-16.9 [-47.5, 13.6]	0.269

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SOMI0: Incidence of non-disease related severe TEAEs during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related severe TEAEs during study period	137	20 (14.6) [9.2, 21.6]	138	11 (8.0) [4.0, 13.8]	1.831 [0.912, 3.676]	1.974 [0.907, 4.294]	6.6 [-1.5, 14.8]	0.089

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AAC_SOSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAF

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.928
Male	50	6 (12.0) [4.5, 24.3]	44	3 (6.8) [1.4, 18.7]	1.760 [0.468, 6.624]	1.864 [0.437, 7.943]	5.2 [-8.6, 19.0]	0.494
Female	87	14 (16.1) [9.1, 25.5]	94	8 (8.5) [3.7, 16.1]	1.891 [0.834, 4.286]	2.062 [0.819, 5.189]	7.6 [-3.1, 18.3]	0.171
Age								0.515
< 65 years	114	16 (14.0) [8.2, 21.8]	118	10 (8.5) [4.1, 15.0]	1.656 [0.785, 3.495]	1.763 [0.764, 4.068]	5.6 [-3.4, 14.5]	0.214
>= 65 years	23	4 (17.4) [5.0, 38.8]	20	1 (5.0) [0.1, 24.9]	3.478 [0.423, 28.626]	4.000 [0.408, 39.174]	12.4 [-10.5, 35.3]	0.351
Exacerbations in the year before study								0.241
<= 2	105	14 (13.3) [7.5, 21.4]	110	6 (5.5) [2.0, 11.5]	2.444 [0.976, 6.123]	2.667 [0.984, 7.226]	7.9 [-0.8, 16.6]	0.060
> 2	32	6 (18.8) [7.2, 36.4]	28	5 (17.9) [6.1, 36.9]	1.050 [0.359, 3.070]	1.062 [0.286, 3.945]	0.9 [-22.1, 23.8]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SOSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAF

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	128	18 (14.1) [8.6, 21.3]	123	9 (7.3) [3.4, 13.4]				
Black or African American	3	1 (33.3) [0.8, 90.6]	6	1 (16.7) [0.4, 64.1]				
Asian	5	1 (20.0) [0.5, 71.6]	6	0 (0.0) [0.0, 45.9]				
Other	1	0 (0.0) [0.0, 97.5]	3	1 (33.3) [0.8, 90.6]				
Region								0.967
Europe	78	11 (14.1) [7.3, 23.8]	80	7 (8.8) [3.6, 17.2]	1.612 [0.659, 3.944]	1.712 [0.627, 4.673]	5.4 [-5.8, 16.5]	0.325
America	10	2 (20.0) [2.5, 55.6]	9	1 (11.1) [0.3, 48.2]	1.800 [0.194, 16.658]	2.000 [0.150, 26.734]	8.9 [-33.9, 51.6]	1.000
Asia/Pacific	5	1 (20.0) [0.5, 71.6]	6	0 (0.0) [0.0, 45.9]	3.500 + [0.173, 70.944]	4.333 + [0.142, 132.315]	20.0 [-33.4, 73.4]	0.455
Rest of the world	44	6 (13.6) [5.2, 27.4]	43	3 (7.0) [1.5, 19.1]	1.955 [0.522, 7.321]	2.105 [0.491, 9.023]	6.7 [-8.3, 21.6]	0.484
BMI		N<10 any level						NE
< 18.5 kg/m**2	0		1	0 (0.0) [0.0, 97.5]				
18.5 - < 25.0 kg/m**2	39	4 (10.3) [2.9, 24.2]	43	2 (4.7) [0.6, 15.8]				
25.0 - < 30.0 kg/m**2	45	5 (11.1) [3.7, 24.1]	47	2 (4.3) [0.5, 14.5]				
>= 30.0 kg/m**2	53	11 (20.8) [10.8, 34.1]	47	7 (14.9) [6.2, 28.3]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SOSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAF

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.272
< 150 cells/uL	27	6 (22.2) [8.6, 42.3]	33	6 (18.2) [7.0, 35.5]	1.222 [0.445, 3.359]	1.286 [0.362, 4.565]	4.0 [-19.8, 27.9]	0.754
>= 150 cells/uL	109	14 (12.8) [7.2, 20.6]	105	5 (4.8) [1.6, 10.8]	2.697 [1.007, 7.225]	2.947 [1.022, 8.499]	8.1 [-0.3, 16.5]	0.053
Baseline eosinophils - High								0.915
< 300 cells/uL	69	11 (15.9) [8.2, 26.7]	72	6 (8.3) [3.1, 17.3]	1.913 [0.749, 4.889]	2.086 [0.726, 5.994]	7.6 [-4.6, 19.8]	0.201
>= 300 cells/uL	67	9 (13.4) [6.3, 24.0]	66	5 (7.6) [2.5, 16.8]	1.773 [0.627, 5.012]	1.893 [0.599, 5.984]	5.9 [-6.0, 17.7]	0.398
Baseline FENO								0.858
< 25 ppb	78	14 (17.9) [10.2, 28.3]	74	7 (9.5) [3.9, 18.5]	1.897 [0.811, 4.438]	2.094 [0.794, 5.522]	8.5 [-3.6, 20.6]	0.161
>= 25 ppb	57	6 (10.5) [4.0, 21.5]	63	4 (6.3) [1.8, 15.5]	1.658 [0.493, 5.578]	1.735 [0.464, 6.493]	4.2 [-7.5, 15.8]	0.515

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SOSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAF

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.964
All negative	57	10 (17.5) [8.7, 29.9]	66	6 (9.1) [3.4, 18.7]	1.930 [0.748, 4.980]	2.128 [0.721, 6.276]	8.5 [-5.2, 22.2]	0.188
Any positive	71	9 (12.7) [6.0, 22.7]	63	4 (6.3) [1.8, 15.5]	1.996 [0.646, 6.167]	2.141 [0.625, 7.329]	6.3 [-5.0, 17.6]	0.254
Total serum IgE								0.567
Low	35	7 (20.0) [8.4, 36.9]	32	2 (6.3) [0.8, 20.8]	3.200 [0.716, 14.292]	3.750 [0.718, 19.599]	13.8 [-4.9, 32.4]	0.153
Normal	95	12 (12.6) [6.7, 21.0]	98	9 (9.2) [4.3, 16.7]	1.375 [0.608, 3.113]	1.430 [0.573, 3.568]	3.4 [-6.4, 13.3]	0.494
High	7	1 (14.3) [0.4, 57.9]	8	0 (0.0) [0.0, 36.9]	3.375 + [0.159, 71.667]	3.923 + [0.136, 112.895]	14.3 [-25.0, 53.6]	0.467
OCS at baseline								0.680
Yes	9	2 (22.2) [2.8, 60.0]	13	1 (7.7) [0.2, 36.0]	2.889 [0.306, 27.271]	3.429 [0.261, 45.026]	14.5 [-25.7, 54.7]	0.544
No	128	18 (14.1) [8.6, 21.3]	125	10 (8.0) [3.9, 14.2]	1.758 [0.845, 3.657]	1.882 [0.832, 4.256]	6.1 [-2.4, 14.5]	0.161

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SOSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAF

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)								0.664
Medium/Low	70	9 (12.9) [6.1, 23.0]	73	6 (8.2) [3.1, 17.0]	1.564 [0.587, 4.166]	1.648 [0.554, 4.899]	4.6 [-6.8, 16.1]	0.421
High	67	11 (16.4) [8.5, 27.5]	65	5 (7.7) [2.5, 17.0]	2.134 [0.785, 5.805]	2.357 [0.771, 7.211]	8.7 [-3.8, 21.2]	0.182
LAMA use at baseline								0.642
Yes	11	2 (18.2) [2.3, 51.8]	6	1 (16.7) [0.4, 64.1]	1.091 [0.123, 9.696]	1.111 [0.079, 15.534]	1.5 [-48.9, 51.9]	1.000
No	126	18 (14.3) [8.7, 21.6]	132	10 (7.6) [3.7, 13.5]	1.886 [0.906, 3.927]	2.033 [0.900, 4.595]	6.7 [-1.7, 15.1]	0.109
Tiotropium use at baseline								0.339
Yes	9	2 (22.2) [2.8, 60.0]	3	1 (33.3) [0.8, 90.6]	0.667 [0.089, 4.994]	0.571 [0.032, 10.069]	-11.1 [-93.2, 71.0]	1.000
No	128	18 (14.1) [8.6, 21.3]	135	10 (7.4) [3.6, 13.2]	1.898 [0.911, 3.956]	2.045 [0.906, 4.618]	6.7 [-1.6, 14.9]	0.109

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SOSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAF

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline								0.253
Yes	29	9 (31.0) [15.3, 50.8]	37	8 (21.6) [9.8, 38.2]	1.435 [0.633, 3.256]	1.631 [0.538, 4.949]	9.4 [-15.1, 33.9]	0.410
No	108	11 (10.2) [5.2, 17.5]	101	3 (3.0) [0.6, 8.4]	3.429 [0.985, 11.938]	3.704 [1.002, 13.690]	7.2 [-0.3, 14.8]	0.051

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SOSIP: Incidence of non-disease related severe TEAEs during study period by study specific subgroups
DSAF

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.885
White	128	18 (14.1) [8.6, 21.3]	123	9 (7.3) [3.4, 13.4]	1.922 [0.898, 4.113]	2.073 [0.893, 4.811]	6.7 [-1.6, 15.1]	0.104
Non-white	9	2 (22.2) [2.8, 60.0]	15	2 (13.3) [1.7, 40.5]	1.667 [0.282, 9.856]	1.857 [0.213, 16.179]	8.9 [-32.2, 49.9]	0.615
Region (cat. P)								0.990
North America/Western EU	10	2 (20.0) [2.5, 55.6]	9	1 (11.1) [0.3, 48.2]	1.800 [0.194, 16.658]	2.000 [0.150, 26.734]	8.9 [-33.9, 51.6]	1.000
Rest of world	127	18 (14.2) [8.6, 21.5]	129	10 (7.8) [3.8, 13.8]	1.828 [0.878, 3.806]	1.965 [0.869, 4.442]	6.4 [-2.0, 14.8]	0.112
Baseline eosinophils (cat. P)								0.341
< 250 cells/uL	61	9 (14.8) [7.0, 26.2]	60	3 (5.0) [1.0, 13.9]	2.951 [0.839, 10.373]	3.288 [0.844, 12.808]	9.8 [-2.4, 21.9]	0.126
>= 250 cells/uL	76	11 (14.5) [7.5, 24.4]	78	8 (10.3) [4.5, 19.2]	1.411 [0.601, 3.315]	1.481 [0.561, 3.911]	4.2 [-7.5, 15.9]	0.470
Baseline FENO (cat. P)								0.461
< 24 ppb	75	14 (18.7) [10.6, 29.3]	72	6 (8.3) [3.1, 17.3]	2.240 [0.911, 5.510]	2.525 [0.912, 6.985]	10.3 [-1.9, 22.6]	0.092
>= 24 ppb	60	6 (10.0) [3.8, 20.5]	65	5 (7.7) [2.5, 17.0]	1.300 [0.418, 4.040]	1.333 [0.385, 4.619]	2.3 [-9.3, 13.9]	0.757

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SOSIP: Incidence of non-disease related severe TEAEs during study period by study specific subgroups
DSAF

	Tezepelumab		Placebo					
Non-disease related severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.511
< 22.0 ppb	65	12 (18.5) [9.9, 30.0]	62	5 (8.1) [2.7, 17.8]	2.289 [0.856, 6.121]	2.581 [0.852, 7.819]	10.4 [-2.8, 23.6]	0.118
>= 22.0 ppb	70	8 (11.4) [5.1, 21.3]	75	6 (8.0) [3.0, 16.6]	1.429 [0.522, 3.911]	1.484 [0.488, 4.515]	3.4 [-7.6, 14.5]	0.579
Baseline all FEIA status								0.727
All negative	50	9 (18.0) [8.6, 31.4]	50	4 (8.0) [2.2, 19.2]	2.250 [0.741, 6.832]	2.524 [0.723, 8.818]	10.0 [-5.0, 25.0]	0.234
Any positive	77	10 (13.0) [6.4, 22.6]	80	6 (7.5) [2.8, 15.6]	1.732 [0.661, 4.534]	1.841 [0.635, 5.338]	5.5 [-5.3, 16.2]	0.299
Th2 status								0.954
Low	70	12 (17.1) [9.2, 28.0]	62	6 (9.7) [3.6, 19.9]	1.771 [0.707, 4.438]	1.931 [0.678, 5.499]	7.5 [-5.5, 20.5]	0.310
High	65	8 (12.3) [5.5, 22.8]	75	5 (6.7) [2.2, 14.9]	1.846 [0.635, 5.365]	1.965 [0.609, 6.336]	5.6 [-5.6, 16.9]	0.382
Baseline Periostin								0.251
Low (< 20.9 ng/ml)	62	8 (12.9) [5.7, 23.9]	67	7 (10.4) [4.3, 20.3]	1.235 [0.476, 3.205]	1.270 [0.432, 3.735]	2.5 [-10.2, 15.1]	0.786
High (>= 20.9 ng/ml)	74	12 (16.2) [8.7, 26.6]	71	4 (5.6) [1.6, 13.8]	2.878 [0.974, 8.508]	3.242 [0.993, 10.583]	10.6 [-0.8, 21.9]	0.062

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SOSIP: Incidence of non-disease related severe TEAEs during study period by study specific subgroups
DSAF

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility								0.074	
Yes	114	17 (14.9) [8.9, 22.8]	126	8 (6.3) [2.8, 12.1]	2.349 [1.054, 5.234]	2.585 [1.070, 6.246]	8.6 [-0.1, 17.2]	0.035	*
No	23	3 (13.0) [2.8, 33.6]	12	3 (25.0) [5.5, 57.2]	0.522 [0.124, 2.202]	0.450 [0.076, 2.677]	-12.0 [-46.4, 22.5]	0.391	
Maintenance OCS use at baseline								0.823	
Yes	9	2 (22.2) [2.8, 60.0]	14	2 (14.3) [1.8, 42.8]	1.556 [0.264, 9.151]	1.714 [0.196, 15.019]	7.9 [-34.0, 49.8]	1.000	
No	128	18 (14.1) [8.6, 21.3]	124	9 (7.3) [3.4, 13.3]	1.938 [0.905, 4.147]	2.091 [0.901, 4.852]	6.8 [-1.5, 15.2]	0.103	
No chronic OCS use and current post-BD FEV1 reversibility								0.603	
Yes	108	15 (13.9) [8.0, 21.9]	115	8 (7.0) [3.1, 13.2]	1.997 [0.882, 4.519]	2.157 [0.875, 5.316]	6.9 [-2.0, 15.8]	0.122	
No	29	5 (17.2) [5.8, 35.8]	23	3 (13.0) [2.8, 33.6]	1.322 [0.352, 4.961]	1.389 [0.295, 6.540]	4.2 [-19.2, 27.5]	1.000	

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SOMI0: Incidence of non-disease related serious TEAEs during study period
DSAF

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related serious TEAEs during study period	137	12 (8.8) [4.6, 14.8]	138	9 (6.5) [3.0, 12.0]	1.343 [0.585, 3.084]	1.376 [0.560, 3.380]	2.2 [-4.8, 9.2]	0.506

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AAS_SOSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAF

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.439
Male	50	4 (8.0) [2.2, 19.2]	44	4 (9.1) [2.5, 21.7]	0.880 [0.234, 3.312]	0.870 [0.204, 3.704]	-1.1 [-14.6, 12.4]	1.000
Female	87	8 (9.2) [4.1, 17.3]	94	5 (5.3) [1.7, 12.0]	1.729 [0.588, 5.084]	1.803 [0.566, 5.737]	3.9 [-4.8, 12.6]	0.393
Age								0.618
< 65 years	114	10 (8.8) [4.3, 15.5]	118	7 (5.9) [2.4, 11.8]	1.479 [0.583, 3.751]	1.525 [0.560, 4.154]	2.8 [-4.7, 10.4]	0.457
>= 65 years	23	2 (8.7) [1.1, 28.0]	20	2 (10.0) [1.2, 31.7]	0.870 [0.135, 5.620]	0.857 [0.109, 6.716]	-1.3 [-23.5, 20.8]	1.000
Exacerbations in the year before study								0.313
<= 2	105	6 (5.7) [2.1, 12.0]	110	3 (2.7) [0.6, 7.8]	2.095 [0.538, 8.162]	2.162 [0.526, 8.877]	3.0 [-3.3, 9.3]	0.324
> 2	32	6 (18.8) [7.2, 36.4]	28	6 (21.4) [8.3, 41.0]	0.875 [0.318, 2.406]	0.846 [0.239, 3.001]	-2.7 [-26.4, 21.0]	1.000

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SOSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAF

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	128	11 (8.6) [4.4, 14.9]	123	7 (5.7) [2.3, 11.4]				
Black or African American	3	0 (0.0) [0.0, 70.8]	6	1 (16.7) [0.4, 64.1]				
Asian	5	1 (20.0) [0.5, 71.6]	6	0 (0.0) [0.0, 45.9]				
Other	1	0 (0.0) [0.0, 97.5]	3	1 (33.3) [0.8, 90.6]				
Region								0.699
Europe	78	9 (11.5) [5.4, 20.8]	80	6 (7.5) [2.8, 15.6]	1.538 [0.575, 4.119]	1.609 [0.544, 4.755]	4.0 [-6.4, 14.4]	0.427
America	10	2 (20.0) [2.5, 55.6]	9	2 (22.2) [2.8, 60.0]	0.900 [0.158, 5.132]	0.875 [0.096, 7.952]	-2.2 [-49.6, 45.1]	1.000
Asia/Pacific	5	1 (20.0) [0.5, 71.6]	6	0 (0.0) [0.0, 45.9]	3.500 + [0.173, 70.944]	4.333 + [0.142, 132.315]	20.0 [-33.4, 73.4]	0.455
Rest of the world	44	0 (0.0) [0.0, 8.0]	43	1 (2.3) [0.1, 12.3]	0.326 + [0.014, 7.787]	0.318 + [0.013, 8.033]	-2.3 [-9.1, 4.5]	0.494
BMI		N<10 any level						NE
< 18.5 kg/m**2	0		1	0 (0.0) [0.0, 97.5]				
18.5 - < 25.0 kg/m**2	39	3 (7.7) [1.6, 20.9]	43	1 (2.3) [0.1, 12.3]				
25.0 - < 30.0 kg/m**2	45	3 (6.7) [1.4, 18.3]	47	4 (8.5) [2.4, 20.4]				
>= 30.0 kg/m**2	53	6 (11.3) [4.3, 23.0]	47	4 (8.5) [2.4, 20.4]				

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SOSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAF

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.702
< 150 cells/uL	27	5 (18.5) [6.3, 38.1]	33	5 (15.2) [5.1, 31.9]	1.222 [0.395, 3.785]	1.273 [0.327, 4.957]	3.4 [-19.1, 25.8]	0.742
>= 150 cells/uL	109	7 (6.4) [2.6, 12.8]	105	4 (3.8) [1.0, 9.5]	1.686 [0.508, 5.591]	1.733 [0.492, 6.102]	2.6 [-4.2, 9.4]	0.539
Baseline eosinophils - High								0.470
< 300 cells/uL	69	6 (8.7) [3.3, 18.0]	72	6 (8.3) [3.1, 17.3]	1.043 [0.354, 3.080]	1.048 [0.321, 3.420]	0.4 [-10.3, 11.0]	1.000
>= 300 cells/uL	67	6 (9.0) [3.4, 18.5]	66	3 (4.5) [0.9, 12.7]	1.970 [0.514, 7.551]	2.066 [0.494, 8.631]	4.4 [-5.6, 14.4]	0.492
Baseline FENO								0.172
< 25 ppb	78	8 (10.3) [4.5, 19.2]	74	3 (4.1) [0.8, 11.4]	2.530 [0.698, 9.174]	2.705 [0.689, 10.616]	6.2 [-3.2, 15.6]	0.211
>= 25 ppb	57	4 (7.0) [1.9, 17.0]	63	6 (9.5) [3.6, 19.6]	0.737 [0.219, 2.479]	0.717 [0.192, 2.682]	-2.5 [-14.0, 9.0]	0.746

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SOSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAF

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.387
All negative	57	5 (8.8) [2.9, 19.3]	66	6 (9.1) [3.4, 18.7]	0.965 [0.311, 2.995]	0.962 [0.277, 3.335]	-0.3 [-12.1, 11.4]	1.000
Any positive	71	7 (9.9) [4.1, 19.3]	63	3 (4.8) [1.0, 13.3]	2.070 [0.559, 7.668]	2.188 [0.541, 8.850]	5.1 [-5.1, 15.3]	0.334
Total serum IgE								0.661
Low	35	4 (11.4) [3.2, 26.7]	32	3 (9.4) [2.0, 25.0]	1.219 [0.295, 5.034]	1.247 [0.257, 6.057]	2.1 [-15.5, 19.6]	1.000
Normal	95	8 (8.4) [3.7, 15.9]	98	5 (5.1) [1.7, 11.5]	1.651 [0.560, 4.866]	1.710 [0.539, 5.428]	3.3 [-4.8, 11.4]	0.402
High	7	0 (0.0) [0.0, 41.0]	8	1 (12.5) [0.3, 52.7]	0.375 + [0.018, 7.963]	0.333 + [0.012, 9.566]	-12.5 [-48.8, 23.8]	1.000
OCS at baseline								0.265
Yes	9	1 (11.1) [0.3, 48.2]	13	3 (23.1) [5.0, 53.8]	0.481 [0.059, 3.922]	0.417 [0.036, 4.813]	-12.0 [-52.1, 28.2]	0.616
No	128	11 (8.6) [4.4, 14.9]	125	6 (4.8) [1.8, 10.2]	1.790 [0.683, 4.693]	1.865 [0.668, 5.207]	3.8 [-3.1, 10.7]	0.316

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SOSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAF

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
ICS dose level (at study entry)								0.962
Medium/Low	70	5 (7.1) [2.4, 15.9]	73	4 (5.5) [1.5, 13.4]	1.304 [0.365, 4.657]	1.327 [0.341, 5.158]	1.7 [-7.7, 11.0]	0.742
High	67	7 (10.4) [4.3, 20.3]	65	5 (7.7) [2.5, 17.0]	1.358 [0.454, 4.063]	1.400 [0.421, 4.658]	2.8 [-8.5, 14.0]	0.764
LAMA use at baseline								0.084
Yes	11	2 (18.2) [2.3, 51.8]	6	3 (50.0) [11.8, 88.2]	0.364 [0.082, 1.609]	0.222 [0.024, 2.037]	-31.8 [-90.7, 27.1]	0.280
No	126	10 (7.9) [3.9, 14.1]	132	6 (4.5) [1.7, 9.6]	1.746 [0.654, 4.663]	1.810 [0.638, 5.138]	3.4 [-3.3, 10.1]	0.308
Tiotropium use at baseline								0.544
Yes	9	2 (22.2) [2.8, 60.0]	3	1 (33.3) [0.8, 90.6]	0.667 [0.089, 4.994]	0.571 [0.032, 10.069]	-11.1 [-93.2, 71.0]	1.000
No	128	10 (7.8) [3.8, 13.9]	135	8 (5.9) [2.6, 11.3]	1.318 [0.537, 3.235]	1.345 [0.514, 3.524]	1.9 [-5.0, 8.8]	0.629

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SOSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAF

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Montelukast/ Cromoglicic acid use at baseline								0.917
Yes	29	6 (20.7) [8.0, 39.7]	37	5 (13.5) [4.5, 28.8]	1.531 [0.519, 4.521]	1.670 [0.454, 6.139]	7.2 [-14.3, 28.7]	0.515
No	108	6 (5.6) [2.1, 11.7]	101	4 (4.0) [1.1, 9.8]	1.403 [0.408, 4.827]	1.426 [0.391, 5.210]	1.6 [-5.1, 8.3]	0.749

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SOSIP: Incidence of non-disease related serious TEAEs during study period by study specific subgroups
DSAF

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.632
White	128	11 (8.6) [4.4, 14.9]	123	7 (5.7) [2.3, 11.4]	1.510 [0.605, 3.769]	1.558 [0.584, 4.159]	2.9 [-4.2, 10.1]	0.466
Non-white	9	1 (11.1) [0.3, 48.2]	15	2 (13.3) [1.7, 40.5]	0.833 [0.088, 7.936]	0.813 [0.063, 10.478]	-2.2 [-37.9, 33.5]	1.000
Region (cat. P)								0.636
North America/Western EU	10	2 (20.0) [2.5, 55.6]	9	2 (22.2) [2.8, 60.0]	0.900 [0.158, 5.132]	0.875 [0.096, 7.952]	-2.2 [-49.6, 45.1]	1.000
Rest of world	127	10 (7.9) [3.8, 14.0]	129	7 (5.4) [2.2, 10.9]	1.451 [0.570, 3.694]	1.490 [0.549, 4.044]	2.4 [-4.4, 9.3]	0.463
Baseline eosinophils (cat. P)								0.460
< 250 cells/uL	61	6 (9.8) [3.7, 20.2]	60	3 (5.0) [1.0, 13.9]	1.967 [0.515, 7.508]	2.073 [0.494, 8.701]	4.8 [-6.1, 15.8]	0.491
>= 250 cells/uL	76	6 (7.9) [3.0, 16.4]	78	6 (7.7) [2.9, 16.0]	1.026 [0.346, 3.042]	1.029 [0.317, 3.342]	0.2 [-9.6, 10.0]	1.000
Baseline FENO (cat. P)								0.161
< 24 ppb	75	8 (10.7) [4.7, 19.9]	72	3 (4.2) [0.9, 11.7]	2.560 [0.707, 9.271]	2.746 [0.699, 10.795]	6.5 [-3.2, 16.2]	0.210
>= 24 ppb	60	4 (6.7) [1.8, 16.2]	65	6 (9.2) [3.5, 19.0]	0.722 [0.214, 2.435]	0.702 [0.188, 2.621]	-2.6 [-13.6, 8.5]	0.746

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SOSIP: Incidence of non-disease related serious TEAEs during study period by study specific subgroups
DSAF

	Tezepelumab		Placebo					
Non-disease related serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.235
< 22.0 ppb	65	6 (9.2) [3.5, 19.0]	62	2 (3.2) [0.4, 11.2]	2.862 [0.600, 13.645]	3.051 [0.592, 15.730]	6.0 [-3.9, 15.9]	0.274
>= 22.0 ppb	70	6 (8.6) [3.2, 17.7]	75	7 (9.3) [3.8, 18.3]	0.918 [0.324, 2.600]	0.911 [0.291, 2.855]	-0.8 [-11.4, 9.9]	1.000
Baseline all FEIA status								0.226
All negative	50	5 (10.0) [3.3, 21.8]	50	6 (12.0) [4.5, 24.3]	0.833 [0.272, 2.555]	0.815 [0.232, 2.865]	-2.0 [-16.3, 12.3]	1.000
Any positive	77	7 (9.1) [3.7, 17.8]	80	3 (3.8) [0.8, 10.6]	2.424 [0.650, 9.037]	2.567 [0.639, 10.312]	5.3 [-3.6, 14.3]	0.204
Th2 status								0.680
Low	70	9 (12.9) [6.1, 23.0]	62	7 (11.3) [4.7, 21.9]	1.139 [0.451, 2.877]	1.159 [0.405, 3.322]	1.6 [-11.1, 14.2]	1.000
High	65	3 (4.6) [1.0, 12.9]	75	2 (2.7) [0.3, 9.3]	1.731 [0.298, 10.041]	1.766 [0.286, 10.910]	1.9 [-5.8, 9.7]	0.663
Baseline Periostin								0.514
Low (< 20.9 ng/ml)	62	6 (9.7) [3.6, 19.9]	67	6 (9.0) [3.4, 18.5]	1.081 [0.368, 3.174]	1.089 [0.332, 3.574]	0.7 [-10.9, 12.3]	1.000
High (>= 20.9 ng/ml)	74	6 (8.1) [3.0, 16.8]	71	3 (4.2) [0.9, 11.9]	1.919 [0.499, 7.381]	2.000 [0.480, 8.325]	3.9 [-5.3, 13.0]	0.495

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SOSIP: Incidence of non-disease related serious TEAEs during study period by study specific subgroups
DSAF

	Tezepelumab		Placebo					
Non-disease related serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.088
Yes	114	10 (8.8) [4.3, 15.5]	126	6 (4.8) [1.8, 10.1]	1.842 [0.691, 4.908]	1.923 [0.676, 5.472]	4.0 [-3.2, 11.2]	0.301
No	23	2 (8.7) [1.1, 28.0]	12	3 (25.0) [5.5, 57.2]	0.348 [0.067, 1.807]	0.286 [0.041, 2.013]	-16.3 [-49.7, 17.1]	0.313
Maintenance OCS use at baseline								0.142
Yes	9	1 (11.1) [0.3, 48.2]	14	4 (28.6) [8.4, 58.1]	0.389 [0.051, 2.946]	0.313 [0.029, 3.378]	-17.5 [-57.9, 23.0]	0.611
No	128	11 (8.6) [4.4, 14.9]	124	5 (4.0) [1.3, 9.2]	2.131 [0.762, 5.957]	2.238 [0.754, 6.639]	4.6 [-2.2, 11.3]	0.196
No chronic OCS use and current post-BD FEV1 reversibility								0.070
Yes	108	9 (8.3) [3.9, 15.2]	115	4 (3.5) [1.0, 8.7]	2.396 [0.760, 7.552]	2.523 [0.753, 8.448]	4.9 [-2.2, 11.9]	0.156
No	29	3 (10.3) [2.2, 27.4]	23	5 (21.7) [7.5, 43.7]	0.476 [0.127, 1.786]	0.415 [0.088, 1.962]	-11.4 [-35.5, 12.7]	0.441

Note: DSAF = Dossier Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SLMI0: Incidence of non-disease related TEAEs during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related TEAEs during study period	66	29 (43.9) [31.7, 56.7]	65	32 (49.2) [36.6, 61.9]	0.893 [0.618, 1.289]	0.808 [0.406, 1.608]	-5.3 [-23.9, 13.3]	0.601

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AA_SLSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFL

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.087
Male	19	5 (26.3) [9.1, 51.2]	20	11 (55.0) [31.5, 76.9]	0.478 [0.204, 1.120]	0.292 [0.076, 1.126]	-28.7 [-63.3, 5.9]	0.105
Female	47	24 (51.1) [36.1, 65.9]	45	21 (46.7) [31.7, 62.1]	1.094 [0.719, 1.664]	1.193 [0.526, 2.704]	4.4 [-18.2, 27.0]	0.683
Age								0.651
< 65 years	57	25 (43.9) [30.7, 57.6]	55	26 (47.3) [33.7, 61.2]	0.928 [0.619, 1.391]	0.871 [0.414, 1.834]	-3.4 [-23.6, 16.8]	0.850
>= 65 years	9	4 (44.4) [13.7, 78.8]	10	6 (60.0) [26.2, 87.8]	0.741 [0.305, 1.801]	0.533 [0.086, 3.307]	-15.6 [-70.6, 39.5]	0.656
Exacerbations in the year before study								0.855
<= 2	44	15 (34.1) [20.5, 49.9]	45	18 (40.0) [25.7, 55.7]	0.852 [0.494, 1.470]	0.776 [0.327, 1.838]	-5.9 [-28.2, 16.4]	0.662
> 2	22	14 (63.6) [40.7, 82.8]	20	14 (70.0) [45.7, 88.1]	0.909 [0.593, 1.393]	0.750 [0.206, 2.730]	-6.4 [-39.6, 26.8]	0.750

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SLSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFL

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	60	25 (41.7) [29.1, 55.1]	58	26 (44.8) [31.7, 58.5]				
Black or African American	2	2 (100.0) [15.8, 100.0]	2	2 (100.0) [15.8, 100.0]				
Asian	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Other	1	0 (0.0) [0.0, 97.5]	2	2 (100.0) [15.8, 100.0]				
Region		N<10 any level						NE
Europe	40	18 (45.0) [29.3, 61.5]	36	16 (44.4) [27.9, 61.9]				
America	6	5 (83.3) [35.9, 99.6]	4	4 (100.0) [39.8, 100.0]				
Asia/Pacific	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Rest of the world	17	4 (23.5) [6.8, 49.9]	22	10 (45.5) [24.4, 67.8]				
BMI								0.415
18.5 - < 25.0 kg/m**2	15	7 (46.7) [21.3, 73.4]	21	9 (42.9) [21.8, 66.0]	1.089 [0.523, 2.265]	1.167 [0.308, 4.423]	3.8 [-34.8, 42.5]	1.000
25.0 - < 30.0 kg/m**2	24	7 (29.2) [12.6, 51.1]	20	10 (50.0) [27.2, 72.8]	0.583 [0.272, 1.250]	0.412 [0.119, 1.426]	-20.8 [-53.9, 12.2]	0.218
>= 30.0 kg/m**2	27	15 (55.6) [35.3, 74.5]	24	13 (54.2) [32.8, 74.4]	1.026 [0.623, 1.690]	1.058 [0.350, 3.193]	1.4 [-29.9, 32.7]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SLSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFL

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.446
< 150 cells/uL	11	8 (72.7) [39.0, 94.0]	14	9 (64.3) [35.1, 87.2]	1.131 [0.664, 1.927]	1.481 [0.265, 8.267]	8.4 [-36.0, 52.9]	1.000
>= 150 cells/uL	54	21 (38.9) [25.9, 53.1]	51	23 (45.1) [31.1, 59.7]	0.862 [0.549, 1.354]	0.775 [0.356, 1.685]	-6.2 [-27.0, 14.6]	0.557
Baseline eosinophils - High								0.492
< 300 cells/uL	33	14 (42.4) [25.5, 60.8]	34	18 (52.9) [35.1, 70.2]	0.801 [0.482, 1.332]	0.655 [0.250, 1.718]	-10.5 [-37.3, 16.3]	0.466
>= 300 cells/uL	32	15 (46.9) [29.1, 65.3]	31	14 (45.2) [27.3, 64.0]	1.038 [0.608, 1.773]	1.071 [0.398, 2.887]	1.7 [-26.1, 29.5]	1.000
Baseline FENO								0.157
< 25 ppb	39	23 (59.0) [42.1, 74.4]	30	17 (56.7) [37.4, 74.5]	1.041 [0.692, 1.565]	1.099 [0.419, 2.881]	2.3 [-24.2, 28.8]	1.000
>= 25 ppb	27	6 (22.2) [8.6, 42.3]	34	14 (41.2) [24.6, 59.3]	0.540 [0.240, 1.216]	0.408 [0.131, 1.271]	-19.0 [-45.1, 7.2]	0.171

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SLSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFL

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.798
All negative	27	13 (48.1) [28.7, 68.1]	29	15 (51.7) [32.5, 70.6]	0.931 [0.550, 1.575]	0.867 [0.304, 2.474]	-3.6 [-33.3, 26.2]	1.000
Any positive	34	13 (38.2) [22.2, 56.4]	33	15 (45.5) [28.1, 63.6]	0.841 [0.477, 1.484]	0.743 [0.281, 1.967]	-7.2 [-33.8, 19.3]	0.624
Total serum IgE								0.635
Low	23	14 (60.9) [38.5, 80.3]	14	8 (57.1) [28.9, 82.3]	1.065 [0.609, 1.864]	1.167 [0.303, 4.499]	3.7 [-34.7, 42.2]	1.000
Normal	40	14 (35.0) [20.6, 51.7]	44	20 (45.5) [30.4, 61.2]	0.770 [0.452, 1.311]	0.646 [0.268, 1.558]	-10.5 [-33.7, 12.8]	0.378
High	3	1 (33.3) [0.8, 90.6]	7	4 (57.1) [18.4, 90.1]	0.583 [0.104, 3.271]	0.375 [0.022, 6.348]	-23.8 [-100.0, 64.7]	1.000
OCS at baseline								0.569
Yes	9	4 (44.4) [13.7, 78.8]	13	5 (38.5) [13.9, 68.4]	1.156 [0.424, 3.151]	1.280 [0.228, 7.187]	6.0 [-45.3, 57.3]	1.000
No	57	25 (43.9) [30.7, 57.6]	52	27 (51.9) [37.6, 66.0]	0.845 [0.570, 1.252]	0.723 [0.340, 1.539]	-8.1 [-28.6, 12.5]	0.446

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SLSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFL

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline								0.970
Yes	7	4 (57.1) [18.4, 90.1]	3	2 (66.7) [9.4, 99.2]	0.857 [0.307, 2.390]	0.667 [0.039, 11.285]	-9.5 [-98.1, 79.0]	1.000
No	59	25 (42.4) [29.6, 55.9]	62	30 (48.4) [35.5, 61.4]	0.876 [0.591, 1.298]	0.784 [0.383, 1.607]	-6.0 [-25.4, 13.4]	0.585
Tiotropium use at baseline	N<10 any level							NE
Yes	6	3 (50.0) [11.8, 88.2]	2	1 (50.0) [1.3, 98.7]				
No	60	26 (43.3) [30.6, 56.8]	63	31 (49.2) [36.4, 62.1]				
Montelukast/ Cromoglicic acid use at baseline								0.790
Yes	17	9 (52.9) [27.8, 77.0]	21	13 (61.9) [38.4, 81.9]	0.855 [0.489, 1.497]	0.692 [0.189, 2.533]	-9.0 [-45.8, 27.9]	0.743
No	49	20 (40.8) [27.0, 55.8]	44	19 (43.2) [28.3, 59.0]	0.945 [0.586, 1.525]	0.907 [0.398, 2.070]	-2.4 [-24.6, 19.9]	0.836

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SLSIP: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFL

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.647
White	60	25 (41.7) [29.1, 55.1]	58	26 (44.8) [31.7, 58.5]	0.929 [0.615, 1.406]	0.879 [0.424, 1.822]	-3.2 [-22.7, 16.4]	0.853
Non-white	6	4 (66.7) [22.3, 95.7]	7	6 (85.7) [42.1, 99.6]	0.778 [0.409, 1.477]	0.333 [0.022, 5.027]	-19.0 [-80.3, 42.2]	0.559
Region (cat. P)								0.873
North America/Western EU	6	5 (83.3) [35.9, 99.6]	4	4 (100.0) [39.8, 100.0]	0.833 [0.583, 1.192]	0.407 + [0.013, 12.636]	-16.7 [-67.3, 34.0]	1.000
Rest of world	60	24 (40.0) [27.6, 53.5]	61	28 (45.9) [33.1, 59.2]	0.871 [0.577, 1.317]	0.786 [0.382, 1.616]	-5.9 [-25.2, 13.4]	0.583
Baseline eosinophils (cat. P)								0.097
< 250 cells/uL	30	12 (40.0) [22.7, 59.4]	29	18 (62.1) [42.3, 79.3]	0.644 [0.382, 1.087]	0.407 [0.143, 1.161]	-22.1 [-50.3, 6.2]	0.120
>= 250 cells/uL	36	17 (47.2) [30.4, 64.5]	36	14 (38.9) [23.1, 56.5]	1.214 [0.711, 2.075]	1.406 [0.551, 3.587]	8.3 [-17.2, 33.9]	0.634
Baseline FENO (cat. P)								0.237
< 24 ppb	38	22 (57.9) [40.8, 73.7]	30	17 (56.7) [37.4, 74.5]	1.022 [0.675, 1.546]	1.051 [0.400, 2.767]	1.2 [-25.4, 27.9]	1.000
>= 24 ppb	28	7 (25.0) [10.7, 44.9]	34	14 (41.2) [24.6, 59.3]	0.607 [0.285, 1.294]	0.476 [0.159, 1.423]	-16.2 [-42.5, 10.1]	0.281

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SLSIP: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFL

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.144
< 22.0 ppb	32	19 (59.4) [40.6, 76.3]	27	14 (51.9) [31.9, 71.3]	1.145 [0.721, 1.819]	1.357 [0.483, 3.814]	7.5 [-21.3, 36.3]	0.607
>= 22.0 ppb	34	10 (29.4) [15.1, 47.5]	37	17 (45.9) [29.5, 63.1]	0.640 [0.342, 1.199]	0.490 [0.184, 1.307]	-16.5 [-41.5, 8.5]	0.221
Baseline all FEIA status								0.317
All negative	25	13 (52.0) [31.3, 72.2]	22	10 (45.5) [24.4, 67.8]	1.144 [0.632, 2.069]	1.300 [0.412, 4.101]	6.5 [-26.3, 39.4]	0.772
Any positive	35	13 (37.1) [21.5, 55.1]	41	20 (48.8) [32.9, 64.9]	0.761 [0.447, 1.298]	0.620 [0.247, 1.556]	-11.6 [-36.4, 13.2]	0.358
Th2 status								0.284
Low	41	20 (48.8) [32.9, 64.9]	30	14 (46.7) [28.3, 65.7]	1.045 [0.637, 1.714]	1.088 [0.424, 2.795]	2.1 [-24.3, 28.5]	1.000
High	25	9 (36.0) [18.0, 57.5]	34	18 (52.9) [35.1, 70.2]	0.680 [0.369, 1.253]	0.500 [0.173, 1.441]	-16.9 [-45.6, 11.7]	0.290
Baseline Periostin								0.289
Low (< 20.9 ng/ml)	26	14 (53.8) [33.4, 73.4]	31	15 (48.4) [30.2, 66.9]	1.113 [0.669, 1.851]	1.244 [0.438, 3.536]	5.5 [-24.1, 35.0]	0.792
High (>= 20.9 ng/ml)	40	15 (37.5) [22.7, 54.2]	34	17 (50.0) [32.4, 67.6]	0.750 [0.445, 1.265]	0.600 [0.237, 1.518]	-12.5 [-37.7, 12.7]	0.349

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SLSIP: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFL

Non-disease related TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.273
Yes	57	25 (43.9) [30.7, 57.6]	60	28 (46.7) [33.7, 60.0]	0.940 [0.630, 1.401]	0.893 [0.431, 1.850]	-2.8 [-22.6, 16.9]	0.853
No	9	4 (44.4) [13.7, 78.8]	5	4 (80.0) [28.4, 99.5]	0.556 [0.237, 1.302]	0.200 [0.016, 2.575]	-35.6 [-98.9, 27.8]	0.301
Maintenance OCS use at baseline								0.722
Yes	9	4 (44.4) [13.7, 78.8]	14	6 (42.9) [17.7, 71.1]	1.037 [0.402, 2.677]	1.067 [0.197, 5.769]	1.6 [-49.1, 52.3]	1.000
No	57	25 (43.9) [30.7, 57.6]	51	26 (51.0) [36.6, 65.2]	0.860 [0.578, 1.281]	0.751 [0.352, 1.604]	-7.1 [-27.8, 13.6]	0.563
No chronic OCS use and current post-BD FEV1 reversibility								0.893
Yes	51	22 (43.1) [29.3, 57.8]	49	24 (49.0) [34.4, 63.7]	0.881 [0.576, 1.348]	0.790 [0.359, 1.738]	-5.8 [-27.4, 15.7]	0.688
No	15	7 (46.7) [21.3, 73.4]	16	8 (50.0) [24.7, 75.3]	0.933 [0.450, 1.937]	0.875 [0.214, 3.586]	-3.3 [-45.0, 38.3]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SLMI0: Incidence of non-disease related non-severe TEAEs during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related non-severe TEAEs during study period	66	28 (42.4) [30.3, 55.2]	65	31 (47.7) [35.1, 60.5]	0.890 [0.609, 1.300]	0.808 [0.406, 1.610]	-5.3 [-23.8, 13.3]	0.600

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AAN_SLSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFL

Non-disease related non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.164
Male	19	5 (26.3) [9.1, 51.2]	20	10 (50.0) [27.2, 72.8]	0.526 [0.220, 1.257]	0.357 [0.093, 1.372]	-23.7 [-58.3, 11.0]	0.191
Female	47	23 (48.9) [34.1, 63.9]	45	21 (46.7) [31.7, 62.1]	1.049 [0.684, 1.608]	1.095 [0.483, 2.483]	2.3 [-20.3, 24.9]	0.838
Age								0.656
< 65 years	57	24 (42.1) [29.1, 55.9]	55	25 (45.5) [32.0, 59.4]	0.926 [0.609, 1.410]	0.873 [0.413, 1.842]	-3.3 [-23.5, 16.8]	0.849
>= 65 years	9	4 (44.4) [13.7, 78.8]	10	6 (60.0) [26.2, 87.8]	0.741 [0.305, 1.801]	0.533 [0.086, 3.307]	-15.6 [-70.6, 39.5]	0.656
Exacerbations in the year before study								0.861
<= 2	44	15 (34.1) [20.5, 49.9]	45	18 (40.0) [25.7, 55.7]	0.852 [0.494, 1.470]	0.776 [0.327, 1.838]	-5.9 [-28.2, 16.4]	0.662
> 2	22	13 (59.1) [36.4, 79.3]	20	13 (65.0) [40.8, 84.6]	0.909 [0.566, 1.460]	0.778 [0.222, 2.719]	-5.9 [-40.0, 28.2]	0.758

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SLSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
Non-disease related non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	60	24 (40.0) [27.6, 53.5]	58	25 (43.1) [30.2, 56.8]				
Black or African American	2	2 (100.0) [15.8, 100.0]	2	2 (100.0) [15.8, 100.0]				
Asian	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Other	1	0 (0.0) [0.0, 97.5]	2	2 (100.0) [15.8, 100.0]				
Region		N<10 any level						NE
Europe	40	17 (42.5) [27.0, 59.1]	36	15 (41.7) [25.5, 59.2]				
America	6	5 (83.3) [35.9, 99.6]	4	4 (100.0) [39.8, 100.0]				
Asia/Pacific	3	2 (66.7) [9.4, 99.2]	3	2 (66.7) [9.4, 99.2]				
Rest of the world	17	4 (23.5) [6.8, 49.9]	22	10 (45.5) [24.4, 67.8]				
BMI								0.614
18.5 - < 25.0 kg/m**2	15	7 (46.7) [21.3, 73.4]	21	9 (42.9) [21.8, 66.0]	1.089 [0.523, 2.265]	1.167 [0.308, 4.423]	3.8 [-34.8, 42.5]	1.000
25.0 - < 30.0 kg/m**2	24	7 (29.2) [12.6, 51.1]	20	9 (45.0) [23.1, 68.5]	0.648 [0.294, 1.428]	0.503 [0.145, 1.748]	-15.8 [-48.8, 17.1]	0.352
>= 30.0 kg/m**2	27	14 (51.9) [31.9, 71.3]	24	13 (54.2) [32.8, 74.4]	0.957 [0.571, 1.606]	0.911 [0.303, 2.743]	-2.3 [-33.7, 29.1]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SLSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFL

Non-disease related non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low								0.807
< 150 cells/uL	11	7 (63.6) [30.8, 89.1]	14	9 (64.3) [35.1, 87.2]	0.990 [0.547, 1.792]	0.972 [0.188, 5.034]	-0.6 [-46.7, 45.4]	1.000
>= 150 cells/uL	54	21 (38.9) [25.9, 53.1]	51	22 (43.1) [29.3, 57.8]	0.902 [0.569, 1.427]	0.839 [0.385, 1.828]	-4.2 [-25.0, 16.5]	0.695
Baseline eosinophils - High								0.298
< 300 cells/uL	33	13 (39.4) [22.9, 57.9]	34	18 (52.9) [35.1, 70.2]	0.744 [0.439, 1.263]	0.578 [0.219, 1.524]	-13.5 [-40.2, 13.1]	0.330
>= 300 cells/uL	32	15 (46.9) [29.1, 65.3]	31	13 (41.9) [24.5, 60.9]	1.118 [0.642, 1.946]	1.222 [0.451, 3.306]	4.9 [-22.7, 32.6]	0.801
Baseline FENO								0.254
< 25 ppb	39	22 (56.4) [39.6, 72.2]	30	17 (56.7) [37.4, 74.5]	0.995 [0.656, 1.511]	0.990 [0.379, 2.585]	-0.3 [-26.8, 26.3]	1.000
>= 25 ppb	27	6 (22.2) [8.6, 42.3]	34	13 (38.2) [22.2, 56.4]	0.581 [0.255, 1.326]	0.462 [0.147, 1.444]	-16.0 [-42.0, 10.0]	0.266

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SLSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
Non-disease related non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status								0.825
All negative	27	12 (44.4) [25.5, 64.7]	29	14 (48.3) [29.4, 67.5]	0.921 [0.523, 1.621]	0.857 [0.299, 2.454]	-3.8 [-33.5, 25.9]	0.795
Any positive	34	13 (38.2) [22.2, 56.4]	33	15 (45.5) [28.1, 63.6]	0.841 [0.477, 1.484]	0.743 [0.281, 1.967]	-7.2 [-33.8, 19.3]	0.624
Total serum IgE								0.794
Low	23	13 (56.5) [34.5, 76.8]	14	8 (57.1) [28.9, 82.3]	0.989 [0.555, 1.763]	0.975 [0.255, 3.730]	-0.6 [-39.3, 38.0]	1.000
Normal	40	14 (35.0) [20.6, 51.7]	44	19 (43.2) [28.3, 59.0]	0.811 [0.472, 1.393]	0.709 [0.293, 1.712]	-8.2 [-31.4, 15.0]	0.506
High	3	1 (33.3) [0.8, 90.6]	7	4 (57.1) [18.4, 90.1]	0.583 [0.104, 3.271]	0.375 [0.022, 6.348]	-23.8 [-100.0, 64.7]	1.000
OCS at baseline								0.567
Yes	9	4 (44.4) [13.7, 78.8]	13	5 (38.5) [13.9, 68.4]	1.156 [0.424, 3.151]	1.280 [0.228, 7.187]	6.0 [-45.3, 57.3]	1.000
No	57	24 (42.1) [29.1, 55.9]	52	26 (50.0) [35.8, 64.2]	0.842 [0.560, 1.266]	0.727 [0.341, 1.549]	-7.9 [-28.4, 12.6]	0.446

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SLSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFL

	Tezepelumab		Placebo					
Non-disease related non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline								0.979
Yes	7	4 (57.1) [18.4, 90.1]	3	2 (66.7) [9.4, 99.2]	0.857 [0.307, 2.390]	0.667 [0.039, 11.285]	-9.5 [-98.1, 79.0]	1.000
No	59	24 (40.7) [28.1, 54.3]	62	29 (46.8) [34.0, 59.9]	0.870 [0.579, 1.306]	0.780 [0.380, 1.603]	-6.1 [-25.4, 13.2]	0.583
Tiotropium use at baseline		N<10 any level						NE
Yes	6	3 (50.0) [11.8, 88.2]	2	1 (50.0) [1.3, 98.7]				
No	60	25 (41.7) [29.1, 55.1]	63	30 (47.6) [34.9, 60.6]				
Montelukast/ Cromoglicic acid use at baseline								0.936
Yes	17	9 (52.9) [27.8, 77.0]	21	12 (57.1) [34.0, 78.2]	0.926 [0.518, 1.657]	0.844 [0.233, 3.053]	-4.2 [-41.3, 32.9]	1.000
No	49	19 (38.8) [25.2, 53.8]	44	19 (43.2) [28.3, 59.0]	0.898 [0.551, 1.464]	0.833 [0.364, 1.908]	-4.4 [-26.6, 17.8]	0.679

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SLSIP: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFL

Non-disease related non-severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.654
White	60	24 (40.0) [27.6, 53.5]	58	25 (43.1) [30.2, 56.8]	0.928 [0.605, 1.424]	0.880 [0.423, 1.831]	-3.1 [-22.6, 16.4]	0.852
Non-white	6	4 (66.7) [22.3, 95.7]	7	6 (85.7) [42.1, 99.6]	0.778 [0.409, 1.477]	0.333 [0.022, 5.027]	-19.0 [-80.3, 42.2]	0.559
Region (cat. P)								0.892
North America/Western EU	6	5 (83.3) [35.9, 99.6]	4	4 (100.0) [39.8, 100.0]	0.833 [0.583, 1.192]	0.407 + [0.013, 12.636]	-16.7 [-67.3, 34.0]	1.000
Rest of world	60	23 (38.3) [26.1, 51.8]	61	27 (44.3) [31.5, 57.6]	0.866 [0.565, 1.327]	0.783 [0.379, 1.617]	-5.9 [-25.1, 13.2]	0.581
Baseline eosinophils (cat. P)								0.100
< 250 cells/uL	30	12 (40.0) [22.7, 59.4]	29	18 (62.1) [42.3, 79.3]	0.644 [0.382, 1.087]	0.407 [0.143, 1.161]	-22.1 [-50.3, 6.2]	0.120
>= 250 cells/uL	36	16 (44.4) [27.9, 61.9]	36	13 (36.1) [20.8, 53.8]	1.231 [0.698, 2.171]	1.415 [0.550, 3.645]	8.3 [-17.0, 33.7]	0.631
Baseline FENO (cat. P)								0.373
< 24 ppb	38	21 (55.3) [38.3, 71.4]	30	17 (56.7) [37.4, 74.5]	0.975 [0.638, 1.490]	0.945 [0.360, 2.478]	-1.4 [-28.1, 25.3]	1.000
>= 24 ppb	28	7 (25.0) [10.7, 44.9]	34	13 (38.2) [22.2, 56.4]	0.654 [0.303, 1.413]	0.538 [0.179, 1.618]	-13.2 [-39.4, 12.9]	0.291

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SLSIP: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
Non-disease related non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.250
< 22.0 ppb	32	18 (56.3) [37.7, 73.6]	27	14 (51.9) [31.9, 71.3]	1.085 [0.675, 1.744]	1.194 [0.427, 3.339]	4.4 [-24.5, 33.3]	0.797
>= 22.0 ppb	34	10 (29.4) [15.1, 47.5]	37	16 (43.2) [27.1, 60.5]	0.680 [0.359, 1.288]	0.547 [0.205, 1.462]	-13.8 [-38.8, 11.1]	0.324
Baseline all FEIA status								0.509
All negative	25	12 (48.0) [27.8, 68.7]	22	10 (45.5) [24.4, 67.8]	1.056 [0.572, 1.950]	1.108 [0.351, 3.494]	2.5 [-30.3, 35.4]	1.000
Any positive	35	13 (37.1) [21.5, 55.1]	41	19 (46.3) [30.7, 62.6]	0.802 [0.466, 1.379]	0.684 [0.273, 1.717]	-9.2 [-34.0, 15.6]	0.488
Th2 status								0.431
Low	41	19 (46.3) [30.7, 62.6]	30	14 (46.7) [28.3, 65.7]	0.993 [0.599, 1.645]	0.987 [0.384, 2.537]	-0.3 [-26.7, 26.0]	1.000
High	25	9 (36.0) [18.0, 57.5]	34	17 (50.0) [32.4, 67.6]	0.720 [0.387, 1.340]	0.563 [0.195, 1.620]	-14.0 [-42.7, 14.7]	0.305
Baseline Periostin								0.499
Low (< 20.9 ng/ml)	26	13 (50.0) [29.9, 70.1]	31	15 (48.4) [30.2, 66.9]	1.033 [0.609, 1.754]	1.067 [0.376, 3.026]	1.6 [-28.0, 31.2]	1.000
High (>= 20.9 ng/ml)	40	15 (37.5) [22.7, 54.2]	34	16 (47.1) [29.8, 64.9]	0.797 [0.466, 1.362]	0.675 [0.267, 1.709]	-9.6 [-34.8, 15.7]	0.481

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAN_SLSIP: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
Non-disease related non-severe TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.281
Yes	57	24 (42.1) [29.1, 55.9]	60	27 (45.0) [32.1, 58.4]	0.936 [0.619, 1.415]	0.889 [0.428, 1.847]	-2.9 [-22.6, 16.8]	0.852
No	9	4 (44.4) [13.7, 78.8]	5	4 (80.0) [28.4, 99.5]	0.556 [0.237, 1.302]	0.200 [0.016, 2.575]	-35.6 [-98.9, 27.8]	0.301
Maintenance OCS use at baseline								0.721
Yes	9	4 (44.4) [13.7, 78.8]	14	6 (42.9) [17.7, 71.1]	1.037 [0.402, 2.677]	1.067 [0.197, 5.769]	1.6 [-49.1, 52.3]	1.000
No	57	24 (42.1) [29.1, 55.9]	51	25 (49.0) [34.8, 63.4]	0.859 [0.568, 1.299]	0.756 [0.354, 1.618]	-6.9 [-27.5, 13.7]	0.562
No chronic OCS use and current post-BD FEV1 reversibility								0.887
Yes	51	21 (41.2) [27.6, 55.8]	49	23 (46.9) [32.5, 61.7]	0.877 [0.563, 1.366]	0.791 [0.359, 1.745]	-5.8 [-27.2, 15.7]	0.687
No	15	7 (46.7) [21.3, 73.4]	16	8 (50.0) [24.7, 75.3]	0.933 [0.450, 1.937]	0.875 [0.214, 3.586]	-3.3 [-45.0, 38.3]	1.000

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SLMI0: Incidence of non-disease related severe TEAEs during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related severe TEAEs during study period	66	11 (16.7) [8.6, 27.9]	65	5 (7.7) [2.5, 17.0]	2.167 [0.797, 5.890]	2.400 [0.784, 7.346]	9.0 [-3.6, 21.6]	0.181

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AAC_SLSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAFL

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex								0.653
Male	19	3 (15.8) [3.4, 39.6]	20	2 (10.0) [1.2, 31.7]	1.579 [0.296, 8.433]	1.688 [0.249, 11.416]	5.8 [-20.4, 31.9]	0.661
Female	47	8 (17.0) [7.6, 30.8]	45	3 (6.7) [1.4, 18.3]	2.553 [0.723, 9.022]	2.872 [0.711, 11.607]	10.4 [-4.8, 25.5]	0.199
Age								0.985
< 65 years	57	9 (15.8) [7.5, 27.9]	55	4 (7.3) [2.0, 17.6]	2.171 [0.710, 6.641]	2.391 [0.690, 8.278]	8.5 [-5.0, 22.0]	0.238
>= 65 years	9	2 (22.2) [2.8, 60.0]	10	1 (10.0) [0.3, 44.5]	2.222 [0.240, 20.566]	2.571 [0.192, 34.473]	12.2 [-31.2, 55.7]	0.582
Exacerbations in the year before study								0.277
<= 2	44	5 (11.4) [3.8, 24.6]	45	1 (2.2) [0.1, 11.8]	5.114 [0.622, 42.029]	5.641 [0.631, 50.397]	9.1 [-3.4, 21.7]	0.110
> 2	22	6 (27.3) [10.7, 50.2]	20	4 (20.0) [5.7, 43.7]	1.364 [0.449, 4.141]	1.500 [0.355, 6.347]	7.3 [-23.1, 37.6]	0.723

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SLSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAFL

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	60	9 (15.0) [7.1, 26.6]	58	4 (6.9) [1.9, 16.7]				
Black or African American	2	1 (50.0) [1.3, 98.7]	2	0 (0.0) [0.0, 84.2]				
Asian	3	1 (33.3) [0.8, 90.6]	3	0 (0.0) [0.0, 70.8]				
Other	1	0 (0.0) [0.0, 97.5]	2	1 (50.0) [1.3, 98.7]				
Region		N<10 any level						NE
Europe	40	8 (20.0) [9.1, 35.6]	36	4 (11.1) [3.1, 26.1]				
America	6	1 (16.7) [0.4, 64.1]	4	0 (0.0) [0.0, 60.2]				
Asia/Pacific	3	1 (33.3) [0.8, 90.6]	3	0 (0.0) [0.0, 70.8]				
Rest of the world	17	1 (5.9) [0.1, 28.7]	22	1 (4.5) [0.1, 22.8]				
BMI								0.952
18.5 - < 25.0 kg/m**2	15	2 (13.3) [1.7, 40.5]	21	1 (4.8) [0.1, 23.8]	2.800 [0.279, 28.129]	3.077 [0.253, 37.483]	8.6 [-16.6, 33.8]	0.559
25.0 - < 30.0 kg/m**2	24	2 (8.3) [1.0, 27.0]	20	1 (5.0) [0.1, 24.9]	1.667 [0.163, 17.061]	1.727 [0.145, 20.578]	3.3 [-15.9, 22.5]	1.000
>= 30.0 kg/m**2	27	7 (25.9) [11.1, 46.3]	24	3 (12.5) [2.7, 32.4]	2.074 [0.603, 7.136]	2.450 [0.555, 10.813]	13.4 [-11.7, 38.5]	0.300

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SLSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAFL

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low		n<10 all levels						NE
< 150 cells/uL	11	4 (36.4) [10.9, 69.2]	14	4 (28.6) [8.4, 58.1]				
>= 150 cells/uL	54	7 (13.0) [5.4, 24.9]	51	1 (2.0) [0.0, 10.4]				
Baseline eosinophils - High								0.350
< 300 cells/uL	33	6 (18.2) [7.0, 35.5]	34	4 (11.8) [3.3, 27.5]	1.545 [0.479, 4.984]	1.667 [0.424, 6.545]	6.4 [-13.6, 26.4]	0.512
>= 300 cells/uL	32	5 (15.6) [5.3, 32.8]	31	1 (3.2) [0.1, 16.7]	4.844 [0.599, 39.140]	5.556 [0.610, 50.597]	12.4 [-4.8, 29.6]	0.196
Baseline FENO								0.099
< 25 ppb	39	10 (25.6) [13.0, 42.1]	30	2 (6.7) [0.8, 22.1]	3.846 [0.910, 16.260]	4.828 [0.970, 24.020]	19.0 [-0.3, 38.3]	0.055
>= 25 ppb	27	1 (3.7) [0.1, 19.0]	34	3 (8.8) [1.9, 23.7]	0.420 [0.046, 3.811]	0.397 [0.039, 4.054]	-5.1 [-20.3, 10.1]	0.623

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SLSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAFL

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status		n<10 all levels						NE
All negative	27	5 (18.5) [6.3, 38.1]	29	2 (6.9) [0.8, 22.8]				
Any positive	34	5 (14.7) [5.0, 31.1]	33	3 (9.1) [1.9, 24.3]				
Total serum IgE								0.337
Low	23	5 (21.7) [7.5, 43.7]	14	0 (0.0) [0.0, 23.2]	6.875 + [0.409, 115.603]	8.622 + [0.440, 168.988]	21.7 [-0.9, 44.3]	0.135
Normal	40	5 (12.5) [4.2, 26.8]	44	5 (11.4) [3.8, 24.6]	1.100 [0.344, 3.520]	1.114 [0.297, 4.175]	1.1 [-15.1, 17.4]	1.000
High	3	1 (33.3) [0.8, 90.6]	7	0 (0.0) [0.0, 41.0]	6.000 + [0.309, 116.606]	9.000 + [0.270, 299.860]	33.3 [-43.8, 100.0]	0.300
OCS at baseline								0.789
Yes	9	2 (22.2) [2.8, 60.0]	13	1 (7.7) [0.2, 36.0]	2.889 [0.306, 27.271]	3.429 [0.261, 45.026]	14.5 [-25.7, 54.7]	0.544
No	57	9 (15.8) [7.5, 27.9]	52	4 (7.7) [2.1, 18.5]	2.053 [0.672, 6.267]	2.250 [0.649, 7.805]	8.1 [-5.7, 21.9]	0.244

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SLSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAFL

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
LAMA use at baseline								0.383	
Yes	7	2 (28.6) [3.7, 71.0]	3	1 (33.3) [0.8, 90.6]	0.857 [0.118, 6.228]	0.800 [0.044, 14.643]	-4.8 [-91.5, 82.0]	1.000	
No	59	9 (15.3) [7.2, 27.0]	62	4 (6.5) [1.8, 15.7]	2.364 [0.769, 7.265]	2.610 [0.758, 8.992]	8.8 [-3.9, 21.5]	0.148	
Tiotropium use at baseline	N<10 any level							NE	
Yes	6	2 (33.3) [4.3, 77.7]	2	1 (50.0) [1.3, 98.7]					
No	60	9 (15.0) [7.1, 26.6]	63	4 (6.3) [1.8, 15.5]					
Montelukast/ Cromoglicic acid use at baseline								0.147	
Yes	17	5 (29.4) [10.3, 56.0]	21	5 (23.8) [8.2, 47.2]	1.235 [0.427, 3.572]	1.333 [0.313, 5.673]	5.6 [-28.0, 39.2]	0.727	
No	49	6 (12.2) [4.6, 24.8]	44	0 (0.0) [0.0, 8.0]	11.700 + [0.678, 201.885]	13.299 + [0.727, 243.305]	12.2 [0.9, 23.6]	0.028	*

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SLSIP: Incidence of non-disease related severe TEAEs during study period by study specific subgroups
DSAFL

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.955
White	60	9 (15.0) [7.1, 26.6]	58	4 (6.9) [1.9, 16.7]	2.175 [0.709, 6.674]	2.382 [0.691, 8.219]	8.1 [-4.7, 20.9]	0.240
Non-white	6	2 (33.3) [4.3, 77.7]	7	1 (14.3) [0.4, 57.9]	2.333 [0.275, 19.802]	3.000 [0.199, 45.244]	19.0 [-42.2, 80.3]	0.559
Region (cat. P)								0.974
North America/Western EU	6	1 (16.7) [0.4, 64.1]	4	0 (0.0) [0.0, 60.2]	2.143 + [0.108, 42.518]	2.455 + [0.079, 76.132]	16.7 [-34.0, 67.3]	1.000
Rest of world	60	10 (16.7) [8.3, 28.5]	61	5 (8.2) [2.7, 18.1]	2.033 [0.739, 5.597]	2.240 [0.717, 6.999]	8.5 [-4.9, 21.8]	0.179
Baseline eosinophils (cat. P)		n<10 all levels						NE
< 250 cells/uL	30	5 (16.7) [5.6, 34.7]	29	2 (6.9) [0.8, 22.8]				
>= 250 cells/uL	36	6 (16.7) [6.4, 32.8]	36	3 (8.3) [1.8, 22.5]				
Baseline FENO (cat. P)								0.090
< 24 ppb	38	10 (26.3) [13.4, 43.1]	30	2 (6.7) [0.8, 22.1]	3.947 [0.935, 16.673]	5.000 [1.003, 24.914]	19.6 [0.1, 39.2]	0.053
>= 24 ppb	28	1 (3.6) [0.1, 18.3]	34	3 (8.8) [1.9, 23.7]	0.405 [0.045, 3.679]	0.383 [0.038, 3.899]	-5.3 [-20.3, 9.8]	0.620

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SLSIP: Incidence of non-disease related severe TEAEs during study period by study specific subgroups
DSAFL

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)								0.150
< 22.0 ppb	32	9 (28.1) [13.7, 46.7]	27	2 (7.4) [0.9, 24.3]	3.797 [0.896, 16.090]	4.891 [0.955, 25.051]	20.7 [-1.1, 42.6]	0.051
>= 22.0 ppb	34	2 (5.9) [0.7, 19.7]	37	3 (8.1) [1.7, 21.9]	0.725 [0.129, 4.082]	0.708 [0.111, 4.519]	-2.2 [-16.9, 12.4]	1.000
Baseline all FEIA status		n<10 all levels						NE
All negative	25	5 (20.0) [6.8, 40.7]	22	1 (4.5) [0.1, 22.8]				
Any positive	35	5 (14.3) [4.8, 30.3]	41	4 (9.8) [2.7, 23.1]				
Th2 status								0.478
Low	41	8 (19.5) [8.8, 34.9]	30	2 (6.7) [0.8, 22.1]	2.927 [0.669, 12.809]	3.394 [0.665, 17.310]	12.8 [-5.1, 30.8]	0.174
High	25	3 (12.0) [2.5, 31.2]	34	3 (8.8) [1.9, 23.7]	1.360 [0.299, 6.185]	1.409 [0.260, 7.644]	3.2 [-16.2, 22.6]	0.691
Baseline Periostin		n<10 all levels						NE
Low (< 20.9 ng/ml)	26	4 (15.4) [4.4, 34.9]	31	4 (12.9) [3.6, 29.8]				
High (>= 20.9 ng/ml)	40	7 (17.5) [7.3, 32.8]	34	1 (2.9) [0.1, 15.3]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAC_SLSIP: Incidence of non-disease related severe TEAEs during study period by study specific subgroups
DSAFL

Non-disease related severe TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Current post-BD FEV1 reversibility								0.008	i
Yes	57	10 (17.5) [8.7, 29.9]	60	2 (3.3) [0.4, 11.5]	5.263 [1.205, 22.989]	6.170 [1.289, 29.544]	14.2 [1.6, 26.8]	0.014	*
No	9	1 (11.1) [0.3, 48.2]	5	3 (60.0) [14.7, 94.7]	0.185 [0.026, 1.343]	0.083 [0.005, 1.294]	-48.9 [-100.0, 14.3]	0.095	
Maintenance OCS use at baseline								0.622	
Yes	9	2 (22.2) [2.8, 60.0]	14	2 (14.3) [1.8, 42.8]	1.556 [0.264, 9.151]	1.714 [0.196, 15.019]	7.9 [-34.0, 49.8]	1.000	
No	57	9 (15.8) [7.5, 27.9]	51	3 (5.9) [1.2, 16.2]	2.684 [0.768, 9.377]	3.000 [0.765, 11.765]	9.9 [-3.4, 23.2]	0.131	
No chronic OCS use and current post-BD FEV1 reversibility								0.226	
Yes	51	8 (15.7) [7.0, 28.6]	49	2 (4.1) [0.5, 14.0]	3.843 [0.858, 17.208]	4.372 [0.879, 21.736]	11.6 [-1.8, 25.0]	0.092	
No	15	3 (20.0) [4.3, 48.1]	16	3 (18.8) [4.0, 45.6]	1.067 [0.253, 4.488]	1.083 [0.182, 6.439]	1.3 [-33.1, 35.6]	1.000	

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SLMI0: Incidence of non-disease related serious TEAEs during study period
DSAFL

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related serious TEAEs during study period	66	7 (10.6) [4.4, 20.6]	65	5 (7.7) [2.5, 17.0]	1.379 [0.461, 4.123]	1.424 [0.428, 4.739]	2.9 [-8.5, 14.3]	0.763

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AAS_SLSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAFL

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex		n<10 all levels						NE
Male	19	2 (10.5) [1.3, 33.1]	20	3 (15.0) [3.2, 37.9]				
Female	47	5 (10.6) [3.5, 23.1]	45	2 (4.4) [0.5, 15.1]				
Age								0.858
< 65 years	57	6 (10.5) [4.0, 21.5]	55	4 (7.3) [2.0, 17.6]	1.447 [0.432, 4.852]	1.500 [0.399, 5.634]	3.3 [-9.0, 15.6]	0.743
>= 65 years	9	1 (11.1) [0.3, 48.2]	10	1 (10.0) [0.3, 44.5]	1.111 [0.081, 15.284]	1.125 [0.060, 21.087]	1.1 [-37.1, 39.4]	1.000
Exacerbations in the year before study		n<10 all levels						NE
<= 2	44	2 (4.5) [0.6, 15.5]	45	1 (2.2) [0.1, 11.8]				
> 2	22	5 (22.7) [7.8, 45.4]	20	4 (20.0) [5.7, 43.7]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SLSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAFL

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race		N<10 any level						NE
White	60	6 (10.0) [3.8, 20.5]	58	4 (6.9) [1.9, 16.7]				
Black or African American	2	0 (0.0) [0.0, 84.2]	2	0 (0.0) [0.0, 84.2]				
Asian	3	1 (33.3) [0.8, 90.6]	3	0 (0.0) [0.0, 70.8]				
Other	1	0 (0.0) [0.0, 97.5]	2	1 (50.0) [1.3, 98.7]				
Region		N<10 any level						NE
Europe	40	6 (15.0) [5.7, 29.8]	36	3 (8.3) [1.8, 22.5]				
America	6	0 (0.0) [0.0, 45.9]	4	1 (25.0) [0.6, 80.6]				
Asia/Pacific	3	1 (33.3) [0.8, 90.6]	3	0 (0.0) [0.0, 70.8]				
Rest of the world	17	0 (0.0) [0.0, 19.5]	22	1 (4.5) [0.1, 22.8]				
BMI		n<10 all levels						NE
18.5 - < 25.0 kg/m**2	15	2 (13.3) [1.7, 40.5]	21	1 (4.8) [0.1, 23.8]				
25.0 - < 30.0 kg/m**2	24	1 (4.2) [0.1, 21.1]	20	3 (15.0) [3.2, 37.9]				
>= 30.0 kg/m**2	27	4 (14.8) [4.2, 33.7]	24	1 (4.2) [0.1, 21.1]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SLSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAFL

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eosinophils - Low		n<10 all levels						NE
< 150 cells/uL	11	3 (27.3) [6.0, 61.0]	14	3 (21.4) [4.7, 50.8]				
>= 150 cells/uL	54	4 (7.4) [2.1, 17.9]	51	2 (3.9) [0.5, 13.5]				
Baseline eosinophils - High		n<10 all levels						NE
< 300 cells/uL	33	3 (9.1) [1.9, 24.3]	34	3 (8.8) [1.9, 23.7]				
>= 300 cells/uL	32	4 (12.5) [3.5, 29.0]	31	2 (6.5) [0.8, 21.4]				
Baseline FENO		n<10 all levels						NE
< 25 ppb	39	5 (12.8) [4.3, 27.4]	30	2 (6.7) [0.8, 22.1]				
>= 25 ppb	27	2 (7.4) [0.9, 24.3]	34	3 (8.8) [1.9, 23.7]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SLSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAFL

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline specific perennial FEIA status		n<10 all levels						NE
All negative	27	3 (11.1) [2.4, 29.2]	29	3 (10.3) [2.2, 27.4]				
Any positive	34	4 (11.8) [3.3, 27.5]	33	2 (6.1) [0.7, 20.2]				
Total serum IgE		n<10 all levels						NE
Low	23	3 (13.0) [2.8, 33.6]	14	2 (14.3) [1.8, 42.8]				
Normal	40	4 (10.0) [2.8, 23.7]	44	2 (4.5) [0.6, 15.5]				
High	3	0 (0.0) [0.0, 70.8]	7	1 (14.3) [0.4, 57.9]				
OCS at baseline		n<10 all levels						NE
Yes	9	1 (11.1) [0.3, 48.2]	13	3 (23.1) [5.0, 53.8]				
No	57	6 (10.5) [4.0, 21.5]	52	2 (3.8) [0.5, 13.2]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SLSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAFL

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
LAMA use at baseline		n<10 all levels						NE
Yes	7	2 (28.6) [3.7, 71.0]	3	2 (66.7) [9.4, 99.2]				
No	59	5 (8.5) [2.8, 18.7]	62	3 (4.8) [1.0, 13.5]				
Tiotropium use at baseline		N<10 any level						NE
Yes	6	2 (33.3) [4.3, 77.7]	2	1 (50.0) [1.3, 98.7]				
No	60	5 (8.3) [2.8, 18.4]	63	4 (6.3) [1.8, 15.5]				
Montelukast/ Cromoglicic acid use at baseline		n<10 all levels						NE
Yes	17	4 (23.5) [6.8, 49.9]	21	4 (19.0) [5.4, 41.9]				
No	49	3 (6.1) [1.3, 16.9]	44	1 (2.3) [0.1, 12.0]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SLSIP: Incidence of non-disease related serious TEAEs during study period by study specific subgroups
DSAFL

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Race (cat. P)								0.880
White	60	6 (10.0) [3.8, 20.5]	58	4 (6.9) [1.9, 16.7]	1.450 [0.431, 4.875]	1.500 [0.401, 5.616]	3.1 [-8.6, 14.8]	0.743
Non-white	6	1 (16.7) [0.4, 64.1]	7	1 (14.3) [0.4, 57.9]	1.167 [0.091, 14.916]	1.200 [0.059, 24.472]	2.4 [-52.6, 57.4]	1.000
Region (cat. P)								0.220
North America/Western EU	6	0 (0.0) [0.0, 45.9]	4	1 (25.0) [0.6, 80.6]	0.238 + [0.012, 4.724]	0.179 + [0.006, 5.678]	-25.0 [-88.3, 38.3]	0.400
Rest of world	60	7 (11.7) [4.8, 22.6]	61	4 (6.6) [1.8, 15.9]	1.779 [0.549, 5.765]	1.882 [0.521, 6.797]	5.1 [-6.8, 17.0]	0.363
Baseline eosinophils (cat. P)		n<10 all levels						NE
< 250 cells/uL	30	3 (10.0) [2.1, 26.5]	29	1 (3.4) [0.1, 17.8]				
>= 250 cells/uL	36	4 (11.1) [3.1, 26.1]	36	4 (11.1) [3.1, 26.1]				
Baseline FENO (cat. P)		n<10 all levels						NE
< 24 ppb	38	5 (13.2) [4.4, 28.1]	30	2 (6.7) [0.8, 22.1]				
>= 24 ppb	28	2 (7.1) [0.9, 23.5]	34	3 (8.8) [1.9, 23.7]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SLSIP: Incidence of non-disease related serious TEAEs during study period by study specific subgroups
DSAFL

Non-disease related serious TEAEs during study period	Tezepelumab N	Tezepelumab n (%) [95 % CI]	Placebo N	Placebo n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline FENO (cat. M)		n<10 all levels						NE
< 22.0 ppb	32	4 (12.5) [3.5, 29.0]	27	2 (7.4) [0.9, 24.3]				
>= 22.0 ppb	34	3 (8.8) [1.9, 23.7]	37	3 (8.1) [1.7, 21.9]				
Baseline all FEIA status		n<10 all levels						NE
All negative	25	3 (12.0) [2.5, 31.2]	22	3 (13.6) [2.9, 34.9]				
Any positive	35	4 (11.4) [3.2, 26.7]	41	2 (4.9) [0.6, 16.5]				
Th2 status		n<10 all levels						NE
Low	41	6 (14.6) [5.6, 29.2]	30	3 (10.0) [2.1, 26.5]				
High	25	1 (4.0) [0.1, 20.4]	34	2 (5.9) [0.7, 19.7]				
Baseline Periostin		n<10 all levels						NE
Low (< 20.9 ng/ml)	26	3 (11.5) [2.4, 30.2]	31	4 (12.9) [3.6, 29.8]				
High (>= 20.9 ng/ml)	40	4 (10.0) [2.8, 23.7]	34	1 (2.9) [0.1, 15.3]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AAS_SLSIP: Incidence of non-disease related serious TEAEs during study period by study specific subgroups
DSAFL

	Tezepelumab		Placebo					
Non-disease related serious TEAEs during study period	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Current post-BD FEV1 reversibility								0.060
Yes	57	7 (12.3) [5.1, 23.7]	60	3 (5.0) [1.0, 13.9]	2.456 [0.667, 9.040]	2.660 [0.653, 10.839]	7.3 [-4.6, 19.1]	0.197
No	9	0 (0.0) [0.0, 33.6]	5	2 (40.0) [5.3, 85.3]	0.120 + [0.007, 2.101]	0.074 + [0.003, 1.947]	-40.0 [-98.5, 18.5]	0.110
Maintenance OCS use at baseline		n<10 all levels						NE
Yes	9	1 (11.1) [0.3, 48.2]	14	4 (28.6) [8.4, 58.1]				
No	57	6 (10.5) [4.0, 21.5]	51	1 (2.0) [0.0, 10.4]				
No chronic OCS use and current post-BD FEV1 reversibility		n<10 all levels						NE
Yes	51	6 (11.8) [4.4, 23.9]	49	1 (2.0) [0.1, 10.9]				
No	15	1 (6.7) [0.2, 31.9]	16	4 (25.0) [7.3, 52.4]				

Note: DSAFL = Dossier Label Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11AUG2022

Table PT2AA_SBMI0: Incidence of non-disease related TEAEs during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related TEAEs during study period	12	8 (66.7) [34.9, 90.1]	9	6 (66.7) [29.9, 92.5]	1.000 [0.543, 1.843]	1.000 [0.160, 6.255]	0.0 [-50.5, 50.5]	1.000

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AAN_SBMI0: Incidence of non-disease related non-severe TEAEs during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related non-severe TEAEs during study period	12	7 (58.3) [27.7, 84.8]	9	6 (66.7) [29.9, 92.5]	0.875 [0.450, 1.701]	0.700 [0.116, 4.232]	-8.3 [-59.6, 42.9]	1.000

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AAC_SBMI0: Incidence of non-disease related severe TEAEs during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related severe TEAEs during study period	12	3 (25.0) [5.5, 57.2]	9	0 (0.0) [0.0, 33.6]	5.385 + [0.313, 92.735]	7.000 + [0.316, 154.865]	25.0 [-9.2, 59.2]	0.229

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022

Table PT2AAS_SBMI0: Incidence of non-disease related serious TEAEs during study period
DSAFB

	Tezepelumab		Placebo					
	N	n (%) [95 % CI]	N	n (%) [95 % CI]	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related serious TEAEs during study period	12	2 (16.7) [2.1, 48.4]	9	1 (11.1) [0.3, 48.2]	1.500 [0.160, 14.083]	1.600 [0.122, 20.993]	5.6 [-33.6, 44.7]	1.000

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 11AUG2022